From 5545f05eee5790f3cbfd3aff1a5c516c68e67d1f Mon Sep 17 00:00:00 2001 From: "vladimir.buzalka" Date: Mon, 8 Jun 2026 16:06:21 +0200 Subject: [PATCH] Add CentralLogging stack, Covance/EDC sources, email import + IWRS scripts Co-Authored-By: Claude Opus 4.8 --- .gitignore | 1 + CentralLogging/README.md | 158 + CentralLogging/client/central_logging.py | 31 + CentralLogging/client/central_logging_v1.0.md | 56 + CentralLogging/client/central_logging_v1.0.py | 320 ++ CentralLogging/client/example_usage_v1.0.py | 40 + .../docker/dashboards/central-logs.json | 171 ++ CentralLogging/docker/docker-compose.yml | 73 + CentralLogging/docker/grafana-dashboards.yml | 20 + CentralLogging/docker/grafana-datasource.yml | 17 + CentralLogging/docker/loki-config.yml | 62 + CentralLogging/gateway/Dockerfile | 20 + CentralLogging/gateway/log_gateway_v1.0.md | 57 + CentralLogging/gateway/log_gateway_v1.0.py | 162 + CentralLogging/gateway/main.py | 25 + CentralLogging/gateway/requirements.txt | 4 + ...sponsor-study-35472-samples-allSamples.csv | 1215 ++++++++ ...6940-activity-reports-documents-equery.csv | 79 + ...orts-documents-equery_unresponded_only.csv | 9 + ...udy-36940-test-results-930525-standard.csv | 773 +++++ ...udy-36940-test-results-930556-standard.csv | 75 + ...36940-test-results-930556-microbiology.csv | 3 + ...36940-test-results-930525-microbiology.csv | 6 + ...udy-36940-test-results-930549-standard.csv | 242 ++ ...36940-test-results-930549-microbiology.csv | 3 + ...udy-36940-test-results-930555-standard.csv | 422 +++ ...36940-test-results-930555-microbiology.csv | 6 + ...udy-36940-test-results-930547-standard.csv | 570 ++++ ...36940-test-results-930547-microbiology.csv | 5 + ...36940-test-results-930539-microbiology.csv | 5 + ...udy-36940-test-results-930539-standard.csv | 180 ++ ...36940-test-results-930557-microbiology.csv | 7 + ...udy-36940-test-results-930557-standard.csv | 740 +++++ ...36940-test-results-930553-microbiology.csv | 4 + ...udy-36940-test-results-930553-standard.csv | 306 ++ ...36940-test-results-930536-microbiology.csv | 3 + ...udy-36940-test-results-930536-standard.csv | 185 ++ ...36940-test-results-930531-microbiology.csv | 3 + ...udy-36940-test-results-930531-standard.csv | 243 ++ ...udy-35472-test-results-898745-standard.csv | 2615 +++++++++++++++++ ...udy-35472-test-results-898739-standard.csv | 1899 ++++++++++++ ...udy-35472-test-results-898733-standard.csv | 2409 +++++++++++++++ ...udy-35472-test-results-898744-standard.csv | 200 ++ ...udy-35472-test-results-898727-standard.csv | 994 +++++++ ...36940-kit-inventory-on-hand-expiration.csv | 550 ++++ ...35472-kit-inventory-on-hand-expiration.csv | 282 ++ ...sponsor-study-36940-samples-allSamples.csv | 1541 ++++++++++ .../BrowserMetrics-6A26A0E0-6324.pma | Bin 0 -> 4194304 bytes .../Default/Code Cache/js/14f1dc90e99ab10a_0 | Bin 0 -> 29784 bytes .../Default/Code Cache/js/1657d329798c6a39_0 | Bin 0 -> 19000 bytes .../Default/Code Cache/js/19130f2e228b88ac_0 | Bin 0 -> 35088 bytes .../Default/Code Cache/js/19d48a552441b28b_0 | Bin 0 -> 18180 bytes .../Default/Code Cache/js/1c28dc3f08e9fc3e_0 | Bin 0 -> 32648 bytes .../Default/Code Cache/js/2f30f40c84cdbfb7_0 | Bin 0 -> 112808 bytes .../Default/Code Cache/js/3412bc103ca6a5b8_0 | Bin 0 -> 22832 bytes .../Default/Code Cache/js/43fc04b11d310bdf_0 | Bin 0 -> 33960 bytes .../Default/Code Cache/js/4737d527d21bb15d_0 | Bin 0 -> 55368 bytes .../Default/Code Cache/js/5247ebd72642d2af_0 | Bin 0 -> 37936 bytes .../Default/Code Cache/js/5547336dd7f133ce_0 | Bin 0 -> 35308 bytes .../Default/Code Cache/js/61d96a4549a31f3b_0 | Bin 0 -> 552176 bytes .../Default/Code Cache/js/6c52ef606329e72f_0 | Bin 0 -> 37308 bytes .../Default/Code Cache/js/8601c0f8c94fdb8b_0 | Bin 0 -> 29784 bytes .../Default/Code Cache/js/86c21e3cb80dd2e5_0 | Bin 0 -> 39692 bytes .../Default/Code Cache/js/8a62893034c6cb0d_0 | Bin 0 -> 18392 bytes .../Default/Code Cache/js/8b04d9c868176da1_0 | Bin 0 -> 19444 bytes .../Default/Code Cache/js/a5c73b65d5f70c29_0 | Bin 0 -> 31008 bytes .../Default/Code Cache/js/ab5b9839e78357d9_0 | Bin 0 -> 19300 bytes .../Default/Code Cache/js/b3bf963caba959f9_0 | Bin 0 -> 30736 bytes .../Default/Code Cache/js/b94d38b821e43347_0 | Bin 0 -> 18180 bytes .../Default/Code Cache/js/c21d1c91b9e0c424_0 | Bin 0 -> 18828 bytes .../Default/Code Cache/js/c2f2d17b2ee7d838_0 | Bin 0 -> 19020 bytes .../Default/Code Cache/js/e9825c090caa84f9_0 | Bin 0 -> 54504 bytes .../Default/Local Storage/leveldb/000195.ldb | Bin 0 -> 33885 bytes .../Default/Local Storage/leveldb/000198.ldb | Bin 0 -> 26953 bytes .../Default/Local Storage/leveldb/000201.ldb | Bin 0 -> 24913 bytes .../Default/Local Storage/leveldb/000202.log | Bin 0 -> 76349 bytes .../Default/Local Storage/leveldb/000203.ldb | Bin 0 -> 27247 bytes .../Default/Local Storage/leveldb/000204.log | Bin 0 -> 33990 bytes .../Default/Local Storage/leveldb/000205.ldb | Bin 0 -> 9870 bytes .../Sessions/Session_13425389959789404 | Bin 0 -> 36688 bytes .../Sessions/Session_13425390050807468 | Bin 0 -> 128817 bytes .../Default/Sessions/Tabs_13425389960078959 | Bin 0 -> 470388 bytes .../Default/Sessions/Tabs_13425390051090375 | Bin 0 -> 427064 bytes .../BrowserMetrics-spare.pma | Bin 0 -> 4194304 bytes .../BrowserMetrics-6A26A16D-FE0.pma | Bin 0 -> 4194304 bytes .../Default/Code Cache/js/251793a2effe09b5_0 | Bin 0 -> 112176 bytes .../Default/Code Cache/js/74fa76d16c1c4ce0_0 | Bin 0 -> 30120 bytes .../Default/Code Cache/js/7cbb0ac8fc5c2ebb_0 | Bin 0 -> 112808 bytes .../Default/Code Cache/js/d5693db2464dcdc5_0 | Bin 0 -> 112424 bytes .../Default/Code Cache/js/d69123c49689f336_0 | Bin 0 -> 19480 bytes .../Default/Code Cache/js/e5193c0b625471bb_0 | Bin 0 -> 18228 bytes .../Default/Code Cache/js/e6ddf7b7b41aed40_0 | Bin 0 -> 35444 bytes .../Default/Local Storage/leveldb/000004.log | Bin 0 -> 6713 bytes .../Default/Local Storage/leveldb/000005.ldb | Bin 0 -> 27475 bytes .../Network Persistent State~RF12f27d9.TMP | 1 + .../Default/Preferences~RF12f273d.TMP | 1 + .../Default/Sessions/Tabs_13425390192637903 | Bin 0 -> 130584 bytes .../BrowserMetrics-spare.pma | Bin 0 -> 4194304 bytes .../BrowserMetrics-6A26A176-4C38.pma | Bin 0 -> 4194304 bytes .../Default/Code Cache/js/260964320a10260b_0 | Bin 0 -> 18228 bytes .../Default/Code Cache/js/4b8939c9f36bbeb9_0 | Bin 0 -> 206 bytes .../Default/Code Cache/js/65a2ea42c560b83e_0 | Bin 0 -> 30120 bytes .../Default/Code Cache/js/79fced940f0d6da1_0 | Bin 0 -> 249 bytes .../Default/Code Cache/js/8484823b1f8ea286_0 | Bin 0 -> 256 bytes .../Default/Code Cache/js/ec8b27730da46865_0 | Bin 0 -> 35308 bytes .../Default/Code Cache/js/faf61171456283ca_0 | Bin 0 -> 19324 bytes .../Sessions/Session_13425390201372580 | Bin 0 -> 55501 bytes .../Default/Sessions/Tabs_13425390201779235 | Bin 0 -> 59197 bytes .../BrowserMetrics-spare.pma | Bin 0 -> 4194304 bytes .../BrowserMetrics-6A26A181-6610.pma | Bin 0 -> 4194304 bytes .../Default/Code Cache/js/29e52b350ca3c067_0 | Bin 0 -> 112368 bytes .../Default/Code Cache/js/664317935b2662ec_0 | Bin 0 -> 19832 bytes .../Default/Code Cache/js/7f64ac16cc5859d1_0 | Bin 0 -> 18216 bytes .../Default/Code Cache/js/8cfdfc2210e9f894_0 | Bin 0 -> 112688 bytes .../Default/Code Cache/js/def75e7857b5d291_0 | Bin 0 -> 29864 bytes .../Default/Code Cache/js/e8cb31b5b32ed6c3_0 | Bin 0 -> 36440 bytes .../Default/Local Storage/leveldb/000004.log | Bin 0 -> 6589 bytes .../Default/Local Storage/leveldb/000005.ldb | Bin 0 -> 26137 bytes .../Sessions/Session_13425390212704454 | Bin 0 -> 63556 bytes .../Default/Sessions/Tabs_13425390212733961 | Bin 0 -> 81532 bytes .../BrowserMetrics-spare.pma | Bin 0 -> 4194304 bytes .../BrowserMetrics-6A26A187-6974.pma | Bin 0 -> 4194304 bytes .../Default/Code Cache/js/081e526131ff09b7_0 | Bin 0 -> 19712 bytes .../Default/Code Cache/js/137396ab38740fd4_0 | Bin 0 -> 19700 bytes .../Default/Code Cache/js/1bed9b9d0f6c45ea_0 | Bin 0 -> 19700 bytes .../Default/Code Cache/js/1d2d577bdf1b36f7_0 | Bin 0 -> 37032 bytes .../Default/Code Cache/js/1f31cbf2a7b526db_0 | Bin 0 -> 30124 bytes .../Default/Code Cache/js/317926e65137bc45_0 | Bin 0 -> 36892 bytes .../Default/Code Cache/js/31959ccd0255ffc1_0 | Bin 0 -> 19712 bytes .../Default/Code Cache/js/3529c92e41d4b8e0_0 | Bin 0 -> 37040 bytes .../Default/Code Cache/js/3613265f94813995_0 | Bin 0 -> 19712 bytes .../Default/Code Cache/js/36fd152a72b9ff27_0 | Bin 0 -> 19700 bytes .../Default/Code Cache/js/3f53df20ec8881f7_0 | Bin 0 -> 19972 bytes .../Default/Code Cache/js/4b8939c9f36bbeb9_0 | Bin 0 -> 206 bytes .../Default/Code Cache/js/53ff4a9c13781ea9_0 | Bin 0 -> 19388 bytes .../Default/Code Cache/js/573c1d4595418dce_0 | Bin 0 -> 36888 bytes .../Default/Code Cache/js/5d58225d08cb8dc6_0 | Bin 0 -> 37040 bytes .../Default/Code Cache/js/5f665e0d3a0246a8_0 | Bin 0 -> 19972 bytes .../Default/Code Cache/js/69049e160049383c_0 | Bin 0 -> 18228 bytes .../Default/Code Cache/js/70d85b671f14b4a9_0 | Bin 0 -> 35356 bytes .../Default/Code Cache/js/752c11a8a149f7a1_0 | Bin 0 -> 36892 bytes .../Default/Code Cache/js/79fced940f0d6da1_0 | Bin 0 -> 249 bytes .../Default/Code Cache/js/7b34830f1d96af2a_0 | Bin 0 -> 19712 bytes .../Default/Code Cache/js/7ebd481a0516a578_0 | Bin 0 -> 36940 bytes .../Default/Code Cache/js/8484823b1f8ea286_0 | Bin 0 -> 256 bytes .../Default/Code Cache/js/9b059399aa5eba28_0 | Bin 0 -> 37268 bytes .../Default/Code Cache/js/9dad01a1653dc339_0 | Bin 0 -> 36908 bytes .../Default/Code Cache/js/a928e93e1e1b268b_0 | Bin 0 -> 37264 bytes .../Default/Code Cache/js/b3bdf0e5e268fff5_0 | Bin 0 -> 19700 bytes .../Default/Code Cache/js/b4732a7d5dc2223b_0 | Bin 0 -> 19700 bytes .../Default/Code Cache/js/d6658a29d04cbb7e_0 | Bin 0 -> 36912 bytes .../Default/Code Cache/js/f8913d282ad20668_0 | Bin 0 -> 19700 bytes .../Default/Code Cache/js/fd4504246889c125_0 | Bin 0 -> 37044 bytes .../Default/Local Storage/leveldb/000004.log | Bin 0 -> 6378 bytes .../Default/Local Storage/leveldb/000005.ldb | Bin 0 -> 26140 bytes .../Default/Sessions/Tabs_13425390219099891 | Bin 0 -> 118772 bytes EmailsImport/Trash/inbox_full_sync_v1.0.md | 170 ++ EmailsImport/Trash/inbox_full_sync_v1.0.py | 384 +++ EmailsImport/Trash/parse_emails_tower_v1.1.md | 248 ++ EmailsImport/Trash/parse_emails_tower_v1.1.py | 660 +++++ EmailsImport/Trash/parse_emails_tower_v1.2.md | 252 ++ EmailsImport/Trash/parse_emails_tower_v1.2.py | 701 +++++ .../ATTACH__899C0000969E661B0000.msg | Bin 0 -> 680448 bytes .../ENCODING__899C000633B033310000.msg | Bin 0 -> 187904 bytes EmailsImport/create_email_indexes_v1.0.py | 70 + EmailsImport/inbox_full_sync_v1.1.md | 176 ++ EmailsImport/inbox_full_sync_v1.1.py | 389 +++ .../parse_emails_tower_failed_20260608.txt | 126 + EmailsImport/parse_emails_tower_v1.3.md | 289 ++ EmailsImport/parse_emails_tower_v1.3.py | 896 ++++++ .../Trash/janssenpc_file_receive.py | 84 + .../janssenpc_file_receive_v1.1.py | 95 + Soubory/enrich_files_v1.0.md | 2 +- 173 files changed, 21334 insertions(+), 1 deletion(-) create mode 100644 CentralLogging/README.md create mode 100644 CentralLogging/client/central_logging.py create mode 100644 CentralLogging/client/central_logging_v1.0.md create mode 100644 CentralLogging/client/central_logging_v1.0.py create mode 100644 CentralLogging/client/example_usage_v1.0.py create mode 100644 CentralLogging/docker/dashboards/central-logs.json create mode 100644 CentralLogging/docker/docker-compose.yml create mode 100644 CentralLogging/docker/grafana-dashboards.yml create mode 100644 CentralLogging/docker/grafana-datasource.yml create mode 100644 CentralLogging/docker/loki-config.yml create mode 100644 CentralLogging/gateway/Dockerfile create mode 100644 CentralLogging/gateway/log_gateway_v1.0.md create mode 100644 CentralLogging/gateway/log_gateway_v1.0.py create mode 100644 CentralLogging/gateway/main.py create mode 100644 CentralLogging/gateway/requirements.txt create mode 100644 Covance_MDD3003/Source/Zpracovano/2026-06-08_130117 sponsor-study-35472-samples-allSamples.csv create mode 100644 Covance_UCO3001/Source/2026-06-08_125753 sponsor-study-36940-activity-reports-documents-equery.csv create mode 100644 Covance_UCO3001/Source/2026-06-08_125753 sponsor-study-36940-activity-reports-documents-equery_unresponded_only.csv create mode 100644 Covance_UCO3001/Source/2026-06-08_130419 sponsor-study-36940-test-results-930525-standard.csv create mode 100644 Covance_UCO3001/Source/2026-06-08_130421 sponsor-study-36940-test-results-930556-standard.csv create mode 100644 Covance_UCO3001/Source/2026-06-08_130426 sponsor-study-36940-test-results-930556-microbiology.csv create mode 100644 Covance_UCO3001/Source/2026-06-08_130427 sponsor-study-36940-test-results-930525-microbiology.csv create mode 100644 Covance_UCO3001/Source/2026-06-08_130444 sponsor-study-36940-test-results-930549-standard.csv create mode 100644 Covance_UCO3001/Source/2026-06-08_130448 sponsor-study-36940-test-results-930549-microbiology.csv create mode 100644 Covance_UCO3001/Source/2026-06-08_130501 sponsor-study-36940-test-results-930555-standard.csv create mode 100644 Covance_UCO3001/Source/2026-06-08_130505 sponsor-study-36940-test-results-930555-microbiology.csv create mode 100644 Covance_UCO3001/Source/2026-06-08_130509 sponsor-study-36940-test-results-930547-standard.csv create mode 100644 Covance_UCO3001/Source/2026-06-08_130510 sponsor-study-36940-test-results-930547-microbiology.csv create mode 100644 Covance_UCO3001/Source/2026-06-08_130527 sponsor-study-36940-test-results-930539-microbiology.csv create mode 100644 Covance_UCO3001/Source/2026-06-08_130527 sponsor-study-36940-test-results-930539-standard.csv create mode 100644 Covance_UCO3001/Source/2026-06-08_130531 sponsor-study-36940-test-results-930557-microbiology.csv create mode 100644 Covance_UCO3001/Source/2026-06-08_130535 sponsor-study-36940-test-results-930557-standard.csv create mode 100644 Covance_UCO3001/Source/2026-06-08_130548 sponsor-study-36940-test-results-930553-microbiology.csv create mode 100644 Covance_UCO3001/Source/2026-06-08_130550 sponsor-study-36940-test-results-930553-standard.csv create mode 100644 Covance_UCO3001/Source/2026-06-08_130552 sponsor-study-36940-test-results-930536-microbiology.csv create mode 100644 Covance_UCO3001/Source/2026-06-08_130600 sponsor-study-36940-test-results-930536-standard.csv create mode 100644 Covance_UCO3001/Source/2026-06-08_130612 sponsor-study-36940-test-results-930531-microbiology.csv create mode 100644 Covance_UCO3001/Source/2026-06-08_130624 sponsor-study-36940-test-results-930531-standard.csv create mode 100644 Covance_UCO3001/Source/2026-06-08_130625 sponsor-study-35472-test-results-898745-standard.csv create mode 100644 Covance_UCO3001/Source/2026-06-08_130654 sponsor-study-35472-test-results-898739-standard.csv create mode 100644 Covance_UCO3001/Source/2026-06-08_130713 sponsor-study-35472-test-results-898733-standard.csv create mode 100644 Covance_UCO3001/Source/2026-06-08_130717 sponsor-study-35472-test-results-898744-standard.csv create mode 100644 Covance_UCO3001/Source/2026-06-08_130741 sponsor-study-35472-test-results-898727-standard.csv create mode 100644 Covance_UCO3001/Source/Zpracovano/2026-06-08_125953 sponsor-study-36940-kit-inventory-on-hand-expiration.csv create mode 100644 Covance_UCO3001/Source/Zpracovano/2026-06-08_130010 sponsor-study-35472-kit-inventory-on-hand-expiration.csv create mode 100644 Covance_UCO3001/Source/Zpracovano/2026-06-08_130117 sponsor-study-36940-samples-allSamples.csv create mode 100644 Covance_UCO3001/browser_profile/BrowserMetrics/BrowserMetrics-6A26A0E0-6324.pma create mode 100644 Covance_UCO3001/browser_profile/Default/Code Cache/js/14f1dc90e99ab10a_0 create mode 100644 Covance_UCO3001/browser_profile/Default/Code Cache/js/1657d329798c6a39_0 create mode 100644 Covance_UCO3001/browser_profile/Default/Code Cache/js/19130f2e228b88ac_0 create mode 100644 Covance_UCO3001/browser_profile/Default/Code Cache/js/19d48a552441b28b_0 create mode 100644 Covance_UCO3001/browser_profile/Default/Code Cache/js/1c28dc3f08e9fc3e_0 create mode 100644 Covance_UCO3001/browser_profile/Default/Code Cache/js/2f30f40c84cdbfb7_0 create mode 100644 Covance_UCO3001/browser_profile/Default/Code Cache/js/3412bc103ca6a5b8_0 create mode 100644 Covance_UCO3001/browser_profile/Default/Code Cache/js/43fc04b11d310bdf_0 create mode 100644 Covance_UCO3001/browser_profile/Default/Code Cache/js/4737d527d21bb15d_0 create mode 100644 Covance_UCO3001/browser_profile/Default/Code Cache/js/5247ebd72642d2af_0 create mode 100644 Covance_UCO3001/browser_profile/Default/Code Cache/js/5547336dd7f133ce_0 create mode 100644 Covance_UCO3001/browser_profile/Default/Code Cache/js/61d96a4549a31f3b_0 create mode 100644 Covance_UCO3001/browser_profile/Default/Code Cache/js/6c52ef606329e72f_0 create mode 100644 Covance_UCO3001/browser_profile/Default/Code Cache/js/8601c0f8c94fdb8b_0 create mode 100644 Covance_UCO3001/browser_profile/Default/Code Cache/js/86c21e3cb80dd2e5_0 create mode 100644 Covance_UCO3001/browser_profile/Default/Code Cache/js/8a62893034c6cb0d_0 create mode 100644 Covance_UCO3001/browser_profile/Default/Code Cache/js/8b04d9c868176da1_0 create mode 100644 Covance_UCO3001/browser_profile/Default/Code Cache/js/a5c73b65d5f70c29_0 create mode 100644 Covance_UCO3001/browser_profile/Default/Code Cache/js/ab5b9839e78357d9_0 create mode 100644 Covance_UCO3001/browser_profile/Default/Code Cache/js/b3bf963caba959f9_0 create mode 100644 Covance_UCO3001/browser_profile/Default/Code Cache/js/b94d38b821e43347_0 create mode 100644 Covance_UCO3001/browser_profile/Default/Code Cache/js/c21d1c91b9e0c424_0 create mode 100644 Covance_UCO3001/browser_profile/Default/Code Cache/js/c2f2d17b2ee7d838_0 create mode 100644 Covance_UCO3001/browser_profile/Default/Code Cache/js/e9825c090caa84f9_0 create mode 100644 Covance_UCO3001/browser_profile/Default/Local Storage/leveldb/000195.ldb create mode 100644 Covance_UCO3001/browser_profile/Default/Local Storage/leveldb/000198.ldb create mode 100644 Covance_UCO3001/browser_profile/Default/Local Storage/leveldb/000201.ldb create mode 100644 Covance_UCO3001/browser_profile/Default/Local Storage/leveldb/000202.log create mode 100644 Covance_UCO3001/browser_profile/Default/Local Storage/leveldb/000203.ldb create mode 100644 Covance_UCO3001/browser_profile/Default/Local Storage/leveldb/000204.log create mode 100644 Covance_UCO3001/browser_profile/Default/Local Storage/leveldb/000205.ldb create mode 100644 Covance_UCO3001/browser_profile/Default/Sessions/Session_13425389959789404 create mode 100644 Covance_UCO3001/browser_profile/Default/Sessions/Session_13425390050807468 create mode 100644 Covance_UCO3001/browser_profile/Default/Sessions/Tabs_13425389960078959 create mode 100644 Covance_UCO3001/browser_profile/Default/Sessions/Tabs_13425390051090375 create mode 100644 Covance_UCO3001/browser_profile_1/BrowserMetrics-spare.pma create mode 100644 Covance_UCO3001/browser_profile_1/BrowserMetrics/BrowserMetrics-6A26A16D-FE0.pma create mode 100644 Covance_UCO3001/browser_profile_1/Default/Code Cache/js/251793a2effe09b5_0 create mode 100644 Covance_UCO3001/browser_profile_1/Default/Code Cache/js/74fa76d16c1c4ce0_0 create mode 100644 Covance_UCO3001/browser_profile_1/Default/Code Cache/js/7cbb0ac8fc5c2ebb_0 create mode 100644 Covance_UCO3001/browser_profile_1/Default/Code Cache/js/d5693db2464dcdc5_0 create mode 100644 Covance_UCO3001/browser_profile_1/Default/Code Cache/js/d69123c49689f336_0 create mode 100644 Covance_UCO3001/browser_profile_1/Default/Code Cache/js/e5193c0b625471bb_0 create mode 100644 Covance_UCO3001/browser_profile_1/Default/Code Cache/js/e6ddf7b7b41aed40_0 create mode 100644 Covance_UCO3001/browser_profile_1/Default/Local Storage/leveldb/000004.log create mode 100644 Covance_UCO3001/browser_profile_1/Default/Local Storage/leveldb/000005.ldb create mode 100644 Covance_UCO3001/browser_profile_1/Default/Network/Network Persistent State~RF12f27d9.TMP create mode 100644 Covance_UCO3001/browser_profile_1/Default/Preferences~RF12f273d.TMP create mode 100644 Covance_UCO3001/browser_profile_1/Default/Sessions/Tabs_13425390192637903 create mode 100644 Covance_UCO3001/browser_profile_2/BrowserMetrics-spare.pma create mode 100644 Covance_UCO3001/browser_profile_2/BrowserMetrics/BrowserMetrics-6A26A176-4C38.pma create mode 100644 Covance_UCO3001/browser_profile_2/Default/Code Cache/js/260964320a10260b_0 create mode 100644 Covance_UCO3001/browser_profile_2/Default/Code Cache/js/4b8939c9f36bbeb9_0 create mode 100644 Covance_UCO3001/browser_profile_2/Default/Code Cache/js/65a2ea42c560b83e_0 create mode 100644 Covance_UCO3001/browser_profile_2/Default/Code Cache/js/79fced940f0d6da1_0 create mode 100644 Covance_UCO3001/browser_profile_2/Default/Code Cache/js/8484823b1f8ea286_0 create mode 100644 Covance_UCO3001/browser_profile_2/Default/Code Cache/js/ec8b27730da46865_0 create mode 100644 Covance_UCO3001/browser_profile_2/Default/Code Cache/js/faf61171456283ca_0 create mode 100644 Covance_UCO3001/browser_profile_2/Default/Sessions/Session_13425390201372580 create mode 100644 Covance_UCO3001/browser_profile_2/Default/Sessions/Tabs_13425390201779235 create mode 100644 Covance_UCO3001/browser_profile_3/BrowserMetrics-spare.pma create mode 100644 Covance_UCO3001/browser_profile_3/BrowserMetrics/BrowserMetrics-6A26A181-6610.pma create mode 100644 Covance_UCO3001/browser_profile_3/Default/Code Cache/js/29e52b350ca3c067_0 create mode 100644 Covance_UCO3001/browser_profile_3/Default/Code Cache/js/664317935b2662ec_0 create mode 100644 Covance_UCO3001/browser_profile_3/Default/Code Cache/js/7f64ac16cc5859d1_0 create mode 100644 Covance_UCO3001/browser_profile_3/Default/Code Cache/js/8cfdfc2210e9f894_0 create mode 100644 Covance_UCO3001/browser_profile_3/Default/Code Cache/js/def75e7857b5d291_0 create mode 100644 Covance_UCO3001/browser_profile_3/Default/Code Cache/js/e8cb31b5b32ed6c3_0 create mode 100644 Covance_UCO3001/browser_profile_3/Default/Local Storage/leveldb/000004.log create mode 100644 Covance_UCO3001/browser_profile_3/Default/Local Storage/leveldb/000005.ldb create mode 100644 Covance_UCO3001/browser_profile_3/Default/Sessions/Session_13425390212704454 create mode 100644 Covance_UCO3001/browser_profile_3/Default/Sessions/Tabs_13425390212733961 create mode 100644 Covance_UCO3001/browser_profile_4/BrowserMetrics-spare.pma create mode 100644 Covance_UCO3001/browser_profile_4/BrowserMetrics/BrowserMetrics-6A26A187-6974.pma create mode 100644 Covance_UCO3001/browser_profile_4/Default/Code Cache/js/081e526131ff09b7_0 create mode 100644 Covance_UCO3001/browser_profile_4/Default/Code Cache/js/137396ab38740fd4_0 create mode 100644 Covance_UCO3001/browser_profile_4/Default/Code Cache/js/1bed9b9d0f6c45ea_0 create mode 100644 Covance_UCO3001/browser_profile_4/Default/Code Cache/js/1d2d577bdf1b36f7_0 create mode 100644 Covance_UCO3001/browser_profile_4/Default/Code Cache/js/1f31cbf2a7b526db_0 create mode 100644 Covance_UCO3001/browser_profile_4/Default/Code Cache/js/317926e65137bc45_0 create mode 100644 Covance_UCO3001/browser_profile_4/Default/Code Cache/js/31959ccd0255ffc1_0 create mode 100644 Covance_UCO3001/browser_profile_4/Default/Code Cache/js/3529c92e41d4b8e0_0 create mode 100644 Covance_UCO3001/browser_profile_4/Default/Code Cache/js/3613265f94813995_0 create mode 100644 Covance_UCO3001/browser_profile_4/Default/Code Cache/js/36fd152a72b9ff27_0 create mode 100644 Covance_UCO3001/browser_profile_4/Default/Code Cache/js/3f53df20ec8881f7_0 create mode 100644 Covance_UCO3001/browser_profile_4/Default/Code Cache/js/4b8939c9f36bbeb9_0 create mode 100644 Covance_UCO3001/browser_profile_4/Default/Code Cache/js/53ff4a9c13781ea9_0 create mode 100644 Covance_UCO3001/browser_profile_4/Default/Code Cache/js/573c1d4595418dce_0 create mode 100644 Covance_UCO3001/browser_profile_4/Default/Code Cache/js/5d58225d08cb8dc6_0 create mode 100644 Covance_UCO3001/browser_profile_4/Default/Code Cache/js/5f665e0d3a0246a8_0 create mode 100644 Covance_UCO3001/browser_profile_4/Default/Code Cache/js/69049e160049383c_0 create mode 100644 Covance_UCO3001/browser_profile_4/Default/Code Cache/js/70d85b671f14b4a9_0 create mode 100644 Covance_UCO3001/browser_profile_4/Default/Code Cache/js/752c11a8a149f7a1_0 create mode 100644 Covance_UCO3001/browser_profile_4/Default/Code Cache/js/79fced940f0d6da1_0 create mode 100644 Covance_UCO3001/browser_profile_4/Default/Code Cache/js/7b34830f1d96af2a_0 create mode 100644 Covance_UCO3001/browser_profile_4/Default/Code Cache/js/7ebd481a0516a578_0 create mode 100644 Covance_UCO3001/browser_profile_4/Default/Code Cache/js/8484823b1f8ea286_0 create mode 100644 Covance_UCO3001/browser_profile_4/Default/Code Cache/js/9b059399aa5eba28_0 create mode 100644 Covance_UCO3001/browser_profile_4/Default/Code Cache/js/9dad01a1653dc339_0 create mode 100644 Covance_UCO3001/browser_profile_4/Default/Code Cache/js/a928e93e1e1b268b_0 create mode 100644 Covance_UCO3001/browser_profile_4/Default/Code Cache/js/b3bdf0e5e268fff5_0 create mode 100644 Covance_UCO3001/browser_profile_4/Default/Code Cache/js/b4732a7d5dc2223b_0 create mode 100644 Covance_UCO3001/browser_profile_4/Default/Code Cache/js/d6658a29d04cbb7e_0 create mode 100644 Covance_UCO3001/browser_profile_4/Default/Code Cache/js/f8913d282ad20668_0 create mode 100644 Covance_UCO3001/browser_profile_4/Default/Code Cache/js/fd4504246889c125_0 create mode 100644 Covance_UCO3001/browser_profile_4/Default/Local Storage/leveldb/000004.log create mode 100644 Covance_UCO3001/browser_profile_4/Default/Local Storage/leveldb/000005.ldb create mode 100644 Covance_UCO3001/browser_profile_4/Default/Sessions/Tabs_13425390219099891 create mode 100644 EmailsImport/Trash/inbox_full_sync_v1.0.md create mode 100644 EmailsImport/Trash/inbox_full_sync_v1.0.py create mode 100644 EmailsImport/Trash/parse_emails_tower_v1.1.md create mode 100644 EmailsImport/Trash/parse_emails_tower_v1.1.py create mode 100644 EmailsImport/Trash/parse_emails_tower_v1.2.md create mode 100644 EmailsImport/Trash/parse_emails_tower_v1.2.py create mode 100644 EmailsImport/_test_open/ATTACH__899C0000969E661B0000.msg create mode 100644 EmailsImport/_test_open/ENCODING__899C000633B033310000.msg create mode 100644 EmailsImport/create_email_indexes_v1.0.py create mode 100644 EmailsImport/inbox_full_sync_v1.1.md create mode 100644 EmailsImport/inbox_full_sync_v1.1.py create mode 100644 EmailsImport/parse_emails_tower_failed_20260608.txt create mode 100644 EmailsImport/parse_emails_tower_v1.3.md create mode 100644 EmailsImport/parse_emails_tower_v1.3.py create mode 100644 JanssenScripts/FileWatchAndSend/Trash/janssenpc_file_receive.py create mode 100644 JanssenScripts/FileWatchAndSend/janssenpc_file_receive_v1.1.py diff --git a/.gitignore b/.gitignore index dc1a723..bc85a45 100644 --- a/.gitignore +++ b/.gitignore @@ -7,3 +7,4 @@ EmailsImport/SouboryRůznéVelikosti/ IWRS/Patients/Incoming/ Outlook/downloads/ Outlook/outlook_profile/ +/OutlookVBCZ/ diff --git a/CentralLogging/README.md b/CentralLogging/README.md new file mode 100644 index 0000000..b10c0bc --- /dev/null +++ b/CentralLogging/README.md @@ -0,0 +1,158 @@ +# CentralLogging — centrální logování (Loki + Grafana + FastAPI gateway) + +**Verze:** 1.0 · **Datum:** 2026-06-08 · **Autor:** Vladimír Buzalka + +Řešení pro sjednocení logů z rozházených skriptů projektu Janssen do jednoho +centrálního místa na Unraidu, **bez zrušení stávajícího souborového logování**. +Soubory a centrál běží paralelně; po ~měsíci ověřování se souborové logování +vypne jedním přepínačem. + +--- + +## 1. Architektura + +``` + ┌────────────────┐ HTTP POST /log/batch ┌──────────────┐ push ┌────────┐ + │ Python skript │ ── Bearer token, JSON ──────▶ │ Log Gateway │ ───────▶ │ Loki │ + │ (central_ │ (na pozadí, v dávkách) │ (FastAPI) │ /push │ (90 d) │ + │ logging.py) │ └──────────────┘ └────┬───┘ + │ │ │ + │ + soubor .log │ (stávající RotatingFileHandler — zatím zůstává) │ + └────────────────┘ ┌─────▼────┐ + │ Grafana │ + Při výpadku gateway → lokální spool .ndjson, přehraje se po obnovení. │ (dashbrd)│ + └──────────┘ +``` + +**Proč takhle:** +- **Loki** — průmyslový standard pro centrální logy, levné úložiště (chunky na + Unraid share), retence vynucená automaticky, vizualizace v Grafaně. +- **FastAPI gateway** (jako tvůj `msgreceiver`) — skripty neznají interní detaily + Loki ani DB hesla, jen jednoduchý JSON + sdílený token. Backend lze kdykoli + vyměnit beze změny skriptů. +- **Klient jen stdlib** (`urllib`) — žádné `pip install` do desítek skriptů. +- **Neblokující + odolné** — emit jen vloží do fronty, odesílá vlákno na pozadí + v dávkách; při výpadku spool soubor → žádný log se neztratí. + +--- + +## 2. Adresářová struktura + +``` +CentralLogging/ +├── README.md ← tento soubor +├── docker/ +│ ├── docker-compose.yml Loki + Grafana + Gateway +│ ├── loki-config.yml Loki, retence 90 dní +│ └── grafana-datasource.yml auto-přidání Loki do Grafany +├── gateway/ +│ ├── log_gateway_v1.0.py FastAPI brána +│ ├── log_gateway_v1.0.md dokumentace brány +│ ├── requirements.txt +│ └── Dockerfile +└── client/ + ├── central_logging.py stabilní import shim + ├── central_logging_v1.0.py implementace (verze ve jméně) + ├── central_logging_v1.0.md dokumentace knihovny + └── example_usage_v1.0.py ukázka integrace +``` + +--- + +## 3. Nasazení na Unraid + +1. Zkopíruj adresář `CentralLogging/` na Unraid (např. do + `/mnt/user/appdata/central-logging/src`). +2. Uprav cesty volumes v `docker-compose.yml` (výchozí + `/mnt/user/appdata/central-logging/{loki,grafana}`). +3. Nastav tajemství (soubor `.env` vedle compose, NE do gitu): + ```env + LOG_TOKEN=nejaky-dlouhy-nahodny-retezec + GRAFANA_PASSWORD=silne-heslo + ``` +4. Spusť: + ```bash + cd docker + docker compose up -d + docker compose ps + ``` +5. Kontrola: + - Gateway health: `curl http://192.168.1.76:8770/health` + → očekávané `{"status":"ok","loki":"ready",...}` + - Grafana: `http://192.168.1.76:3001` (admin / GRAFANA_PASSWORD) + → Explore → datasource Loki → dotaz `{app="..."}` + +> Porty: Loki 3100 (interní), Grafana 3001 (3000 drží Gitea), Gateway 8770. Uprav, pokud kolidují +> (msgreceiver běží na 8765). + +--- + +## 4. Integrace do stávajících skriptů + +Typický skript dnes obsahuje: +```python +import logging +logging.basicConfig(filename=str(LOG_FILE), level=logging.ERROR, + format="%(asctime)s | %(message)s", + datefmt="%Y-%m-%d %H:%M:%S", encoding="utf-8") +``` + +Nahradíš celý blok `basicConfig(...)` jedním voláním — **zbytek skriptu +(`logging.error(...)`, `log.info(...)`) zůstává beze změny:** +```python +import sys +sys.path.insert(0, r"U:\PythonProject\Janssen\CentralLogging\client") +from central_logging import setup_logging + +log = setup_logging("nazev_skriptu") # label aplikace v Loki +``` + +Konfigurace přes ENV (nebo argumenty `setup_logging`): + +| ENV | Default | Význam | +|-------------------------|-----------------------------|---------------------------------------| +| `CENTRAL_LOG_GATEWAY` | `http://192.168.1.76:8770` | URL brány | +| `CENTRAL_LOG_TOKEN` | `change-this-shared-secret` | sdílené tajemství (musí sedět s bránou)| +| `CENTRAL_LOG_ENV` | `prod` | label prostředí | +| `CENTRAL_LOG_KEEP_FILE` | `1` | psát i do souboru (po měsíci → `0`) | +| `CENTRAL_LOG_LEVEL` | `INFO` | min. úroveň | + +--- + +## 5. Plán migrace (souběh → vypnutí souborů) + +1. **Fáze A — souběh (cca 1 měsíc):** `keep_file=True` (default). Logy jdou do + souboru i do Loki. Ověřuješ úplnost, ladíš dashboardy, labely, úrovně. +2. **Fáze B — ověření:** porovnáš soubor vs. Loki na vybraných skriptech, že + nic nechybí (spool funguje i při výpadcích). +3. **Fáze C — vypnutí souborů:** nastav globálně `CENTRAL_LOG_KEEP_FILE=0` + (nebo `setup_logging(..., keep_file=False)`). Skripty pak píší jen do + centrálu. Staré `.log` soubory přesuň do `TRASH/` (nemazat — konvence). + +--- + +## 6. Dotazy v Grafaně (LogQL) + +```logql +{app="parse_emails_graph"} # vše z jednoho skriptu +{app="parse_emails_graph", level="ERROR"} # jen chyby +{env="prod"} |= "bulk_write" # fulltext napříč skripty +{app="edc_import"} | json | line > 100 # parsování JSON pole z těla +sum by (app) (count_over_time({level="ERROR"}[1h])) # počet chyb / skript / h +``` + +Labely (nízká kardinalita): `app`, `host`, `level`, `env`. +Vše ostatní (`logger`, `func`, `line`, `exc`, `extra`) je v těle řádku jako +JSON → v Grafaně dostupné přes `| json`. + +--- + +## 7. Bezpečnost a poznámky + +- Token je sdílené tajemství; drž ho v `.env` / ENV, ne v gitu. +- Gateway běží v interní docker síti; ven publikuje jen port 8770. Pokud má být + dostupná i mimo LAN, dej před ni reverzní proxy s TLS. +- Loki má `auth_enabled: false` (single-tenant, interní). Pro veřejné vystavení + přidej autentizaci na proxy. +- Spool soubory (`_log_spool/*.ndjson`) vznikají jen při výpadku brány a samy + se po obnovení spojení vyprázdní. diff --git a/CentralLogging/client/central_logging.py b/CentralLogging/client/central_logging.py new file mode 100644 index 0000000..5d42b6b --- /dev/null +++ b/CentralLogging/client/central_logging.py @@ -0,0 +1,31 @@ +# ============================================================================ +# central_logging.py — stabilní import shim +# Verze: 1.0 +# Datum: 2026-06-08 +# Popis: Importovatelný název pro knihovnu centrálního logování. +# Vlastní implementace je ve verzovaném souboru +# central_logging_v1.0.py (konvence: verze ve jméně). Python však +# neumí importovat název s tečkou, takže ho zde načteme přes +# importlib a re-exportujeme veřejné API. +# +# Při vydání nové verze stačí přepnout VERSION_FILE níže. +# +# Použití ve skriptech: +# from central_logging import setup_logging +# log = setup_logging("muj_skript") +# ============================================================================ +import importlib.util +from pathlib import Path + +VERSION_FILE = "central_logging_v1.0.py" # <- při upgrade přepni sem novou verzi + +_path = Path(__file__).resolve().parent / VERSION_FILE +_spec = importlib.util.spec_from_file_location("central_logging_impl", _path) +_mod = importlib.util.module_from_spec(_spec) +_spec.loader.exec_module(_mod) + +# re-export veřejného API +setup_logging = _mod.setup_logging +CentralLogHandler = _mod.CentralLogHandler + +__all__ = ["setup_logging", "CentralLogHandler"] diff --git a/CentralLogging/client/central_logging_v1.0.md b/CentralLogging/client/central_logging_v1.0.md new file mode 100644 index 0000000..faced85 --- /dev/null +++ b/CentralLogging/client/central_logging_v1.0.md @@ -0,0 +1,56 @@ +# central_logging — drop-in klient pro centrální logování + +**Verze:** 1.0 · **Datum:** 2026-06-08 +**Soubory:** `central_logging.py` (import shim) + `central_logging_v1.0.py` (impl) + +Knihovna, která ke stávajícímu souborovému logování přidá odesílání logů do +Loki přes bránu `log_gateway`. Jen standardní knihovna — žádné `pip install`. + +## Rychlý start + +```python +from central_logging import setup_logging +log = setup_logging("nazev_skriptu") +log.info("start") +log.error("chyba: %s", err) +``` + +## `setup_logging(...)` — parametry + +| Argument | Default | Popis | +|-------------|------------------------|---------------------------------------------| +| `app_name` | (povinný) | label aplikace v Loki | +| `log_file` | `.log` | cesta souborového logu | +| `keep_file` | ENV / `True` | psát i do souboru? po měsíci → `False` | +| `level` | ENV / `INFO` | min. úroveň | +| `gateway` | ENV / `192.168.1.76:8770` | URL brány | +| `token` | ENV | sdílené tajemství | +| `env` | ENV / `prod` | label prostředí | + +## Jak to funguje + +1. `emit()` jen vloží záznam do fronty (neblokuje skript). +2. Vlákno na pozadí každé ~2 s pošle dávku (max 200 záznamů) na + `POST /log/batch`. +3. **Výpadek brány** → dávka se zapíše do `_log_spool/central_logging_spool_.ndjson` + a přehraje se při příštím úspěšném spojení. Žádný log se neztratí. +4. `atexit` při ukončení skriptu dolije zbytek fronty. + +Handler je psaný tak, aby **nikdy neshodil aplikaci** — všechny chyby logování +se polykají. + +## Import a konvence verzí + +Konvence projektu = verze ve jméně (`central_logging_v1.0.py`). Python ale neumí +import názvu s tečkou, proto je tu shim `central_logging.py`, který verzovaný +soubor načte přes `importlib` a re-exportuje `setup_logging`. Při vydání v1.1 +stačí v shimu přepnout `VERSION_FILE` a starou verzi přesunout do `TRASH/`. + +## Vypnutí souborů (fáze C migrace) + +Globálně: +```bash +set CENTRAL_LOG_KEEP_FILE=0 # Windows +export CENTRAL_LOG_KEEP_FILE=0 # Linux +``` +nebo v kódu `setup_logging(..., keep_file=False)`. diff --git a/CentralLogging/client/central_logging_v1.0.py b/CentralLogging/client/central_logging_v1.0.py new file mode 100644 index 0000000..2d2bf3c --- /dev/null +++ b/CentralLogging/client/central_logging_v1.0.py @@ -0,0 +1,320 @@ +# ============================================================================ +# central_logging_v1.0.py +# Verze: 1.0 +# Datum: 2026-06-08 +# Autor: Vladimír Buzalka +# Popis: Drop-in knihovna pro centrální logování do Grafana Loki přes +# FastAPI bránu (log_gateway). Přidává se VEDLE stávajícího +# souborového logování — jediným voláním setup_logging(). +# +# Návrh (proč takhle): +# - JEN standardní knihovna (urllib) — nevyžaduje pip install ve všech +# skriptech projektu. +# - Neblokující: emit() jen vloží záznam do fronty, odesílá vlákno na +# pozadí v dávkách (batch). Skript se logováním nezdrží. +# - Odolné proti výpadku: když je gateway nedostupná, dávka spadne do +# lokálního spool souboru (.ndjson) a pošle se při příštím úspěchu. +# => žádné logy se neztratí, i kdyby server byl chvíli dole. +# - keep_file=True ponechá původní souborové logování. Po měsíci, až +# bude centrál ověřený, stačí zavolat s keep_file=False (nebo nastavit +# ENV CENTRAL_LOG_KEEP_FILE=0) a soubory se přestanou psát. +# +# Použití (minimum): +# from central_logging_v1.0 import setup_logging +# log = setup_logging("parse_emails_graph") +# log.info("start") +# log.error("něco selhalo: %s", err) +# +# Konfigurace přes ENV (s rozumnými defaulty): +# CENTRAL_LOG_GATEWAY http://192.168.1.76:8770 +# CENTRAL_LOG_TOKEN sdílené tajemství (musí sedět s gateway) +# CENTRAL_LOG_ENV prod | test | dev (default prod) +# CENTRAL_LOG_KEEP_FILE 1 | 0 (default 1 = piš i soubory) +# CENTRAL_LOG_LEVEL INFO | ERROR | ... (default INFO) +# CENTRAL_LOG_SPOOL_DIR adresář pro spool (default vedle skriptu) +# ============================================================================ +from __future__ import annotations + +import os +import sys +import json +import time +import atexit +import socket +import logging +import threading +import urllib.request +import urllib.error +from collections import deque +from logging.handlers import RotatingFileHandler +from pathlib import Path +from typing import Any, Deque, Dict, List, Optional + +# --------------------------------------------------------------------------- +# Výchozí konfigurace +# --------------------------------------------------------------------------- +DEFAULT_GATEWAY = os.environ.get("CENTRAL_LOG_GATEWAY", "http://192.168.1.76:8770") +DEFAULT_TOKEN = os.environ.get("CENTRAL_LOG_TOKEN", "change-this-shared-secret") +DEFAULT_ENV = os.environ.get("CENTRAL_LOG_ENV", "prod") +DEFAULT_LEVEL = os.environ.get("CENTRAL_LOG_LEVEL", "INFO").upper() + +FLUSH_INTERVAL = 2.0 # s — jak často odeslat nasbíranou dávku +BATCH_MAX = 200 # max záznamů v jedné dávce +QUEUE_MAX = 50_000 # ochrana proti přetečení paměti +HTTP_TIMEOUT = 5.0 # s — timeout odeslání do gateway +SPOOL_REPLAY_MAX = 1000 # max záznamů přehraných ze spoolu na jeden cyklus + + +class _GatewaySender: + """Vlákno na pozadí: sbírá záznamy z fronty a posílá je do gateway + v dávkách. Při neúspěchu zapisuje do spool souboru a později přehraje.""" + + def __init__(self, app_name: str, gateway: str, token: str, env: str, spool_dir: Path): + self.app_name = app_name + self.host = socket.gethostname() + self.gateway = gateway.rstrip("/") + self.token = token + self.env = env + self.spool_file = spool_dir / f"central_logging_spool_{app_name}.ndjson" + spool_dir.mkdir(parents=True, exist_ok=True) + + self._queue: Deque[Dict[str, Any]] = deque(maxlen=QUEUE_MAX) + self._lock = threading.Lock() + self._stop = threading.Event() + self._thread = threading.Thread(target=self._run, name=f"central-log-{app_name}", daemon=True) + self._thread.start() + + # -- veřejné -------------------------------------------------------- + def submit(self, record: Dict[str, Any]) -> None: + with self._lock: + self._queue.append(record) + + def flush_and_stop(self, timeout: float = 5.0) -> None: + self._stop.set() + self._thread.join(timeout=timeout) + # poslední pokus o odeslání toho, co zbylo + self._drain_once(final=True) + + # -- vnitřní -------------------------------------------------------- + def _run(self) -> None: + while not self._stop.is_set(): + time.sleep(FLUSH_INTERVAL) + try: + self._replay_spool() + self._drain_once() + except Exception: # noqa: BLE001 — logování se nikdy nesmí zhroutit + pass + + def _pop_batch(self) -> List[Dict[str, Any]]: + batch: List[Dict[str, Any]] = [] + with self._lock: + while self._queue and len(batch) < BATCH_MAX: + batch.append(self._queue.popleft()) + return batch + + def _drain_once(self, final: bool = False) -> None: + while True: + batch = self._pop_batch() + if not batch: + return + ok = self._send(batch) + if not ok: + self._spool(batch) + if final and not self._queue: + return + + def _send(self, records: List[Dict[str, Any]]) -> bool: + payload = json.dumps({ + "app": self.app_name, + "host": self.host, + "env": self.env, + "records": records, + }, ensure_ascii=False).encode("utf-8") + + req = urllib.request.Request( + f"{self.gateway}/log/batch", + data=payload, + method="POST", + headers={ + "Content-Type": "application/json", + "Authorization": f"Bearer {self.token}", + }, + ) + try: + with urllib.request.urlopen(req, timeout=HTTP_TIMEOUT) as resp: + return 200 <= resp.status < 300 + except Exception: # noqa: BLE001 — síť/timeout/HTTP error -> spool + return False + + # -- spool (fallback při výpadku) ----------------------------------- + def _spool(self, records: List[Dict[str, Any]]) -> None: + try: + with open(self.spool_file, "a", encoding="utf-8") as f: + for r in records: + f.write(json.dumps(r, ensure_ascii=False) + "\n") + except Exception: # noqa: BLE001 + pass + + def _replay_spool(self) -> None: + if not self.spool_file.exists() or self.spool_file.stat().st_size == 0: + return + # načti dávku ze spoolu + try: + with open(self.spool_file, "r", encoding="utf-8") as f: + lines = f.readlines() + except Exception: # noqa: BLE001 + return + if not lines: + return + + chunk = lines[:SPOOL_REPLAY_MAX] + records = [] + for ln in chunk: + ln = ln.strip() + if ln: + try: + records.append(json.loads(ln)) + except Exception: # noqa: BLE001 + pass + if records and self._send(records): + # úspěch -> odeber přehrané řádky ze spoolu + remaining = lines[SPOOL_REPLAY_MAX:] + try: + if remaining: + with open(self.spool_file, "w", encoding="utf-8") as f: + f.writelines(remaining) + else: + self.spool_file.unlink(missing_ok=True) + except Exception: # noqa: BLE001 + pass + + +class CentralLogHandler(logging.Handler): + """logging.Handler, který předává záznamy senderu na pozadí.""" + + def __init__(self, sender: _GatewaySender): + super().__init__() + self._sender = sender + + def emit(self, record: logging.LogRecord) -> None: + try: + # msg = jen samotná zpráva; čas/úroveň/logger jdou do labelů a polí + rec: Dict[str, Any] = { + "ts": record.created, + "level": record.levelname, + "msg": record.getMessage(), + "logger": record.name, + "func": record.funcName, + "line": record.lineno, + } + # POZOR: formatException je metoda Formatteru, ne Handleru — + # proto použij vlastní Formatter, jinak by AttributeError shodil + # celý záznam (a tracebacky by se ztrácely). + if record.exc_info: + rec["exc"] = logging.Formatter().formatException(record.exc_info) + self._sender.submit(rec) + except Exception: # noqa: BLE001 — handler nikdy nesmí shodit aplikaci + pass + + +def setup_logging( + app_name: str, + *, + log_file: Optional[str] = None, + keep_file: Optional[bool] = None, + level: Optional[str] = None, + gateway: Optional[str] = None, + token: Optional[str] = None, + env: Optional[str] = None, + quiet_loggers: Optional[List[str]] = None, + fmt: str = "%(asctime)s | %(levelname)s | %(name)s | %(message)s", + datefmt: str = "%Y-%m-%d %H:%M:%S", + spool_dir: Optional[str] = None, +) -> logging.Logger: + """Nastaví root logger se dvěma cíli: + 1) souborový handler (RotatingFileHandler) — stávající chování, + 2) centrální handler do Loki přes gateway (na pozadí). + + Args: + app_name: label aplikace v Loki (např. "parse_emails_graph"). + log_file: cesta k log souboru. Default .log vedle skriptu. + keep_file: piš i do souboru? Default z ENV CENTRAL_LOG_KEEP_FILE (1). + Po měsíci ověřování nastav False -> jen centrál. + level: min. úroveň, default ENV CENTRAL_LOG_LEVEL nebo INFO. + gateway/token/env: override ENV defaultů. + + Returns: + nakonfigurovaný root logger (lze i logging.getLogger()). + """ + # Konfiguraci čteme z os.environ AŽ TADY (call-time), ne při importu modulu. + # Důvod: skripty často načítají vlastní .env (do os.environ) až po importu + # této knihovny — kdybychom četli při importu, token/gateway bychom minuli. + gw = gateway or os.environ.get("CENTRAL_LOG_GATEWAY", "http://192.168.1.76:8770") + tok = token or os.environ.get("CENTRAL_LOG_TOKEN", "change-this-shared-secret") + ev = env or os.environ.get("CENTRAL_LOG_ENV", "prod") + lvl_name = (level or os.environ.get("CENTRAL_LOG_LEVEL", "INFO")).upper() + lvl = getattr(logging, lvl_name, logging.INFO) + + if keep_file is None: + keep_file = os.environ.get("CENTRAL_LOG_KEEP_FILE", "1") not in ("0", "false", "False") + + root = logging.getLogger() + root.setLevel(lvl) + + # Ztiš upovídané knihovny (jinak root@INFO chytá jejich šum do centrálu). + # Předej quiet_loggers=[] pro vypnutí, nebo vlastní seznam. + _default_quiet = ["httpx", "httpcore", "urllib3", "anthropic", "openai", + "PIL", "asyncio", "fdb", "fontTools", "pdfminer"] + for _name in (_default_quiet if quiet_loggers is None else quiet_loggers): + logging.getLogger(_name).setLevel(logging.WARNING) + + # odstraň případné staré handlery (idempotentní setup) + for h in list(root.handlers): + root.removeHandler(h) + + formatter = logging.Formatter(fmt=fmt, datefmt=datefmt) + + # 1) Souborový handler (stávající způsob) ------------------------------- + if keep_file: + if log_file is None: + base = Path(sys.argv[0]).resolve().parent if sys.argv and sys.argv[0] else Path.cwd() + log_file = str(base / f"{app_name}.log") + fh = RotatingFileHandler(log_file, maxBytes=10 * 1024 * 1024, backupCount=5, encoding="utf-8") + fh.setLevel(lvl) + fh.setFormatter(formatter) + root.addHandler(fh) + + # 2) Centrální handler do Loki (na pozadí) ------------------------------ + spool_base = Path(spool_dir) if spool_dir else ( + Path(sys.argv[0]).resolve().parent if sys.argv and sys.argv[0] else Path.cwd() + ) + sender = _GatewaySender( + app_name=app_name, + gateway=gw, + token=tok, + env=ev, + spool_dir=spool_base / "_log_spool", + ) + ch = CentralLogHandler(sender) + ch.setLevel(lvl) + ch.setFormatter(formatter) + root.addHandler(ch) + + # při ukončení skriptu dolij frontu + atexit.register(sender.flush_and_stop) + + root.info("central_logging v1.0 inicializováno (app=%s, keep_file=%s, gateway=%s)", + app_name, keep_file, gw) + return root + + +if __name__ == "__main__": + # rychlý self-test + log = setup_logging("central_logging_selftest", level="DEBUG") + log.info("ahoj z self-testu") + log.warning("varování %d", 42) + try: + 1 / 0 + except ZeroDivisionError: + log.exception("zachycená výjimka") + print("Self-test odeslán. Zkontroluj Grafanu / spool soubor.") diff --git a/CentralLogging/client/example_usage_v1.0.py b/CentralLogging/client/example_usage_v1.0.py new file mode 100644 index 0000000..267826a --- /dev/null +++ b/CentralLogging/client/example_usage_v1.0.py @@ -0,0 +1,40 @@ +# ============================================================================ +# example_usage_v1.0.py +# Verze: 1.0 +# Datum: 2026-06-08 +# Popis: Ukázka, jak do stávajícího skriptu přidat centrální logování. +# +# PŘED (typický skript v projektu): +# import logging +# logging.basicConfig( +# filename=str(LOG_FILE), level=logging.ERROR, +# format="%(asctime)s | %(message)s", datefmt="%Y-%m-%d %H:%M:%S", +# encoding="utf-8") +# logging.error("něco selhalo: %s", e) +# +# PO (přidáme centrál, soubor zůstává): +# celý blok basicConfig nahradíš jediným řádkem setup_logging(...) +# — zbytek skriptu (logging.error / log.info) zůstává beze změny. +# ============================================================================ +import sys +from pathlib import Path + +# Knihovna leží v tomto adresáři. V praxi přidej CentralLogging/client do +# sys.path (viz níže) nebo zkopíruj central_logging.py + central_logging_v1.0.py +# vedle svého skriptu. +sys.path.insert(0, str(Path(__file__).resolve().parent)) + +from central_logging import setup_logging # stabilní import shim + +log = setup_logging("priklad_skript") # keep_file=True (default) + +log.info("Skript odstartoval") +log.warning("Pozor, %d nezpracovaných položek", 5) + +try: + raise ValueError("ukázková chyba") +except ValueError: + log.exception("Zachycená výjimka při zpracování") + +log.info("Hotovo") +print("Logy odeslány do souboru i do centrálu (Loki).") diff --git a/CentralLogging/docker/dashboards/central-logs.json b/CentralLogging/docker/dashboards/central-logs.json new file mode 100644 index 0000000..a4e4d82 --- /dev/null +++ b/CentralLogging/docker/dashboards/central-logs.json @@ -0,0 +1,171 @@ +{ + "annotations": { "list": [] }, + "editable": true, + "graphTooltip": 1, + "schemaVersion": 39, + "tags": ["central-logging"], + "title": "Central Logs — přehled", + "uid": "central-logs", + "time": { "from": "now-24h", "to": "now" }, + "refresh": "30s", + "templating": { + "list": [ + { + "name": "env", + "label": "Prostředí", + "type": "query", + "datasource": { "type": "loki", "uid": "loki" }, + "query": "label_values(env)", + "refresh": 2, + "includeAll": true, + "allValue": ".+", + "multi": true, + "current": { "text": "All", "value": "$__all" } + }, + { + "name": "app", + "label": "Skript (app)", + "type": "query", + "datasource": { "type": "loki", "uid": "loki" }, + "query": "label_values({env=~\"$env\"}, app)", + "refresh": 2, + "includeAll": true, + "allValue": ".+", + "multi": true, + "current": { "text": "All", "value": "$__all" } + }, + { + "name": "level", + "label": "Úroveň", + "type": "custom", + "query": "DEBUG,INFO,WARNING,ERROR,CRITICAL", + "includeAll": true, + "allValue": ".+", + "multi": true, + "current": { "text": "All", "value": "$__all" } + }, + { + "name": "search", + "label": "Hledat v textu", + "type": "textbox", + "current": { "text": "", "value": "" } + } + ] + }, + "panels": [ + { + "id": 1, + "type": "stat", + "title": "Logů celkem (rozsah)", + "datasource": { "type": "loki", "uid": "loki" }, + "gridPos": { "h": 4, "w": 8, "x": 0, "y": 0 }, + "options": { "colorMode": "value", "graphMode": "area", "reduceOptions": { "calcs": ["lastNotNull"] } }, + "targets": [ + { + "refId": "A", + "datasource": { "type": "loki", "uid": "loki" }, + "expr": "sum(count_over_time({app=~\"$app\", env=~\"$env\", level=~\"$level\"} |~ \"(?i)$search\" [$__range]))", + "queryType": "instant" + } + ] + }, + { + "id": 2, + "type": "stat", + "title": "Chyby (ERROR+CRITICAL, rozsah)", + "datasource": { "type": "loki", "uid": "loki" }, + "gridPos": { "h": 4, "w": 8, "x": 8, "y": 0 }, + "fieldConfig": { + "defaults": { + "color": { "mode": "thresholds" }, + "thresholds": { "mode": "absolute", "steps": [ + { "color": "green", "value": null }, + { "color": "red", "value": 1 } + ] } + } + }, + "options": { "colorMode": "background", "graphMode": "area", "reduceOptions": { "calcs": ["lastNotNull"] } }, + "targets": [ + { + "refId": "A", + "datasource": { "type": "loki", "uid": "loki" }, + "expr": "sum(count_over_time({app=~\"$app\", env=~\"$env\", level=~\"ERROR|CRITICAL\"} |~ \"(?i)$search\" [$__range]))", + "queryType": "instant" + } + ] + }, + { + "id": 3, + "type": "stat", + "title": "Aktivních skriptů", + "datasource": { "type": "loki", "uid": "loki" }, + "gridPos": { "h": 4, "w": 8, "x": 16, "y": 0 }, + "options": { "colorMode": "value", "graphMode": "none", "reduceOptions": { "calcs": ["lastNotNull"] } }, + "targets": [ + { + "refId": "A", + "datasource": { "type": "loki", "uid": "loki" }, + "expr": "count(sum by (app) (count_over_time({env=~\"$env\"} [$__range])))", + "queryType": "instant" + } + ] + }, + { + "id": 4, + "type": "timeseries", + "title": "Tok logů podle úrovně", + "datasource": { "type": "loki", "uid": "loki" }, + "gridPos": { "h": 8, "w": 12, "x": 0, "y": 4 }, + "fieldConfig": { "defaults": { "custom": { "drawStyle": "bars", "fillOpacity": 60, "stacking": { "mode": "normal" } } } }, + "targets": [ + { + "refId": "A", + "datasource": { "type": "loki", "uid": "loki" }, + "expr": "sum by (level) (count_over_time({app=~\"$app\", env=~\"$env\", level=~\"$level\"} |~ \"(?i)$search\" [$__interval]))", + "legendFormat": "{{level}}" + } + ] + }, + { + "id": 5, + "type": "timeseries", + "title": "Chyby podle skriptu", + "datasource": { "type": "loki", "uid": "loki" }, + "gridPos": { "h": 8, "w": 12, "x": 12, "y": 4 }, + "fieldConfig": { "defaults": { "custom": { "drawStyle": "bars", "fillOpacity": 70, "stacking": { "mode": "normal" } } } }, + "targets": [ + { + "refId": "A", + "datasource": { "type": "loki", "uid": "loki" }, + "expr": "sum by (app) (count_over_time({app=~\"$app\", env=~\"$env\", level=~\"ERROR|CRITICAL\"} |~ \"(?i)$search\" [$__interval]))", + "legendFormat": "{{app}}" + } + ] + }, + { + "id": 6, + "type": "logs", + "title": "Poslední logy", + "datasource": { "type": "loki", "uid": "loki" }, + "gridPos": { "h": 14, "w": 24, "x": 0, "y": 12 }, + "options": { + "showTime": true, + "showLabels": false, + "showCommonLabels": false, + "wrapLogMessage": true, + "prettifyLogMessage": true, + "enableLogDetails": true, + "dedupStrategy": "none", + "sortOrder": "Descending" + }, + "targets": [ + { + "refId": "A", + "datasource": { "type": "loki", "uid": "loki" }, + "expr": "{app=~\"$app\", env=~\"$env\", level=~\"$level\"} |~ \"(?i)$search\" | json", + "maxLines": 1000 + } + ] + } + ] +} diff --git a/CentralLogging/docker/docker-compose.yml b/CentralLogging/docker/docker-compose.yml new file mode 100644 index 0000000..9241603 --- /dev/null +++ b/CentralLogging/docker/docker-compose.yml @@ -0,0 +1,73 @@ +# ============================================================================ +# CentralLogging — docker-compose (Loki + Grafana + Log Gateway) +# Verze: 1.0 +# Datum: 2026-06-08 +# Popis: Stack pro centrální logování na Unraidu. +# - loki : úložiště logů (HTTP push API), retence 90 dní +# - grafana : prohlížení a dashboardy nad Loki +# - gateway : FastAPI brána, kam posílají logy klientské skripty +# +# Spuštění na Unraidu: +# docker compose -f docker-compose.yml up -d +# +# Porty (uprav dle potřeby): +# 3100 Loki HTTP (interní, klienti na něj nesahají přímo) +# 3000 Grafana web UI +# 8770 Log Gateway (sem posílají skripty) +# ============================================================================ +services: + + loki: + image: grafana/loki:3.1.1 + container_name: central-loki + restart: unless-stopped + command: -config.file=/etc/loki/loki-config.yml + ports: + - "3100:3100" + volumes: + - ./loki-config.yml:/etc/loki/loki-config.yml:ro + # Persistentní data na Unraid share (desítky TB) — uprav cestu: + - /mnt/user/appdata/central-logging/loki:/loki + networks: + - logging + + grafana: + image: grafana/grafana:11.2.0 + container_name: central-grafana + restart: unless-stopped + ports: + - "3001:3000" # 3000 na Unraidu drží Gitea -> Grafana na 3001 + environment: + - GF_SECURITY_ADMIN_USER=admin + - GF_SECURITY_ADMIN_PASSWORD=${GRAFANA_PASSWORD:-changeme} + - GF_USERS_ALLOW_SIGN_UP=false + volumes: + - /mnt/user/appdata/central-logging/grafana:/var/lib/grafana + - ./grafana-datasource.yml:/etc/grafana/provisioning/datasources/loki.yml:ro + - ./grafana-dashboards.yml:/etc/grafana/provisioning/dashboards/central.yml:ro + - ./dashboards:/etc/grafana/provisioning/dashboards/json:ro + depends_on: + - loki + networks: + - logging + + gateway: + build: + context: ../gateway + image: central-log-gateway:1.0 + container_name: central-log-gateway + restart: unless-stopped + ports: + - "8770:8770" + environment: + - LOKI_URL=http://loki:3100 + - LOG_TOKEN=${LOG_TOKEN:-change-this-shared-secret} + - GATEWAY_ENV=prod + depends_on: + - loki + networks: + - logging + +networks: + logging: + driver: bridge diff --git a/CentralLogging/docker/grafana-dashboards.yml b/CentralLogging/docker/grafana-dashboards.yml new file mode 100644 index 0000000..783ac06 --- /dev/null +++ b/CentralLogging/docker/grafana-dashboards.yml @@ -0,0 +1,20 @@ +# ============================================================================ +# CentralLogging — Grafana dashboard provisioning +# Verze: 1.0 +# Datum: 2026-06-08 +# Popis: Automaticky načte dashboardy z /etc/grafana/provisioning/dashboards/json +# (mountováno z ./dashboards). Soubor .json = jeden dashboard. +# ============================================================================ +apiVersion: 1 + +providers: + - name: CentralLogging + orgId: 1 + folder: CentralLogging + type: file + disableDeletion: false + updateIntervalSeconds: 30 + allowUiUpdates: true + options: + path: /etc/grafana/provisioning/dashboards/json + foldersFromFilesStructure: false diff --git a/CentralLogging/docker/grafana-datasource.yml b/CentralLogging/docker/grafana-datasource.yml new file mode 100644 index 0000000..723f575 --- /dev/null +++ b/CentralLogging/docker/grafana-datasource.yml @@ -0,0 +1,17 @@ +# ============================================================================ +# CentralLogging — Grafana datasource provisioning +# Verze: 1.0 +# Datum: 2026-06-08 +# Popis: Automaticky přidá Loki jako datasource při startu Grafany. +# ============================================================================ +apiVersion: 1 + +datasources: + - name: Loki + type: loki + uid: loki # pevné uid, na které odkazuje dashboard + access: proxy + url: http://loki:3100 + isDefault: true + jsonData: + maxLines: 5000 diff --git a/CentralLogging/docker/loki-config.yml b/CentralLogging/docker/loki-config.yml new file mode 100644 index 0000000..da8a297 --- /dev/null +++ b/CentralLogging/docker/loki-config.yml @@ -0,0 +1,62 @@ +# ============================================================================ +# CentralLogging — Loki konfigurace +# Verze: 1.0 +# Datum: 2026-06-08 +# Popis: Single-binary Loki, filesystem storage, retence 90 dní. +# Retenci vynucuje compactor (delete_request + retention_period). +# ============================================================================ +auth_enabled: false + +server: + http_listen_port: 3100 + grpc_listen_port: 9096 + log_level: info + +common: + instance_addr: 127.0.0.1 + path_prefix: /loki + storage: + filesystem: + chunks_directory: /loki/chunks + rules_directory: /loki/rules + replication_factor: 1 + ring: + kvstore: + store: inmemory + +schema_config: + configs: + - from: 2024-01-01 + store: tsdb + object_store: filesystem + schema: v13 + index: + prefix: index_ + period: 24h + +storage_config: + tsdb_shipper: + active_index_directory: /loki/tsdb-index + cache_location: /loki/tsdb-cache + filesystem: + directory: /loki/chunks + +limits_config: + retention_period: 2160h # 90 dní + reject_old_samples: true + reject_old_samples_max_age: 168h # 7 dní (logy starší se odmítnou) + max_label_names_per_series: 15 + ingestion_rate_mb: 16 + ingestion_burst_size_mb: 32 + allow_structured_metadata: true + +compactor: + working_directory: /loki/compactor + compaction_interval: 10m + retention_enabled: true # zapne mazání dle retention_period + retention_delete_delay: 2h + delete_request_store: filesystem + +# Analytika do Grafana Labs vypnuta +analytics: + reporting_enabled: false diff --git a/CentralLogging/gateway/Dockerfile b/CentralLogging/gateway/Dockerfile new file mode 100644 index 0000000..f09f957 --- /dev/null +++ b/CentralLogging/gateway/Dockerfile @@ -0,0 +1,20 @@ +# ============================================================================ +# CentralLogging — Log Gateway image +# Verze: 1.0 +# Datum: 2026-06-08 +# ============================================================================ +FROM python:3.12-slim + +WORKDIR /app + +COPY requirements.txt . +RUN pip install --no-cache-dir -r requirements.txt + +COPY log_gateway_v1.0.py . +COPY main.py . + +EXPOSE 8770 + +# main.py je shim, který přes importlib načte verzovaný log_gateway_v1.0.py +# (uvicorn neumí import názvu s tečkou). +CMD ["uvicorn", "main:app", "--host", "0.0.0.0", "--port", "8770"] diff --git a/CentralLogging/gateway/log_gateway_v1.0.md b/CentralLogging/gateway/log_gateway_v1.0.md new file mode 100644 index 0000000..3a4686a --- /dev/null +++ b/CentralLogging/gateway/log_gateway_v1.0.md @@ -0,0 +1,57 @@ +# log_gateway — FastAPI brána pro centrální logování + +**Verze:** 1.0 · **Datum:** 2026-06-08 · **Soubor:** `log_gateway_v1.0.py` + +FastAPI služba, která přijímá logy od klientských skriptů a přeposílá je do +Grafana Loki přes jeho HTTP push API. + +## Endpoints + +| Metoda | Cesta | Popis | +|--------|---------------|--------------------------------------------------| +| GET | `/health` | liveness + dostupnost Loki (`/ready`) | +| POST | `/log/batch` | dávka záznamů (klient používá toto) | +| POST | `/log` | jeden záznam (query: `app_name`, `host`, `env`) | + +Autorizace: hlavička `Authorization: Bearer `. + +## Payload `/log/batch` + +```json +{ + "app": "parse_emails_graph", + "host": "PC-VB", + "env": "prod", + "records": [ + {"ts": 1780921433.81, "level": "ERROR", "msg": "bulk_write: ...", + "logger": "root", "func": "save_batch", "line": 542, "exc": "Traceback ..."} + ] +} +``` + +Brána seskupí záznamy podle `(app, host, level, env)` do Loki streamů, převede +`ts` na nanosekundy, tělo řádku uloží jako JSON (kvůli `| json` v Grafaně) a +pošle na `POST {LOKI_URL}/loki/api/v1/push`. + +## ENV + +| ENV | Default | Popis | +|--------------|------------------------|------------------------------------| +| `LOKI_URL` | `http://loki:3100` | adresa Loki (uvnitř docker sítě) | +| `LOG_TOKEN` | `change-this-...` | sdílené tajemství (= klientův token)| +| `GATEWAY_ENV`| `prod` | výchozí label env, když klient neuvede| + +## Lokální běh (mimo docker) + +```bash +pip install -r requirements.txt +LOKI_URL=http://192.168.1.76:3100 LOG_TOKEN=tajne \ + uvicorn log_gateway_v1.0:app --host 0.0.0.0 --port 8770 +``` + +## Návrhové poznámky + +- Labely držíme nízkokardinální (`ALLOWED_LABELS`). Nikdy nedávat do labelů + např. ID zprávy / pacienta — explodovala by kardinalita sérií v Loki. +- Při chybě Loki vrací brána 502; klient si záznam uloží do spoolu a zkusí + znovu → data se neztratí. diff --git a/CentralLogging/gateway/log_gateway_v1.0.py b/CentralLogging/gateway/log_gateway_v1.0.py new file mode 100644 index 0000000..fcd1d85 --- /dev/null +++ b/CentralLogging/gateway/log_gateway_v1.0.py @@ -0,0 +1,162 @@ +# ============================================================================ +# log_gateway_v1.0.py +# Verze: 1.0 +# Datum: 2026-06-08 +# Autor: Vladimír Buzalka +# Popis: FastAPI brána pro centrální logování. Přijímá jednoduchý JSON +# od klientských skriptů (knihovna central_logging) a přeposílá +# do Grafana Loki přes jeho HTTP push API. +# +# Proč brána a ne push přímo do Loki: +# - klient nezná interní detaily Loki (ns timestampy, streamy) +# - jeden sdílený token (Bearer) místo přístupu do DB/Loki +# - lze kdykoli vyměnit backend bez zásahu do skriptů +# - centrální místo pro normalizaci labelů a rate-limit +# +# Endpoints: +# GET /health — liveness + dostupnost Loki +# POST /log — jeden log záznam +# POST /log/batch — dávka záznamů (preferováno klientem) +# +# Autorizace: hlavička Authorization: Bearer +# +# ENV: +# LOKI_URL výchozí http://loki:3100 +# LOG_TOKEN sdílené tajemství (musí sedět s klientem) +# GATEWAY_ENV label env, výchozí "prod" +# ============================================================================ +from __future__ import annotations + +import os +import time +import json +import logging +from typing import Any, Dict, List, Optional + +import httpx +from fastapi import FastAPI, Header, HTTPException +from pydantic import BaseModel, Field + +LOKI_URL = os.environ.get("LOKI_URL", "http://loki:3100").rstrip("/") +LOG_TOKEN = os.environ.get("LOG_TOKEN", "change-this-shared-secret") +DEFAULT_ENV = os.environ.get("GATEWAY_ENV", "prod") + +# Loki: labely držíme s nízkou kardinalitou (jinak exploze sérií). +# Vše ostatní (logger, func, line, exc) jde do těla log řádku jako JSON. +ALLOWED_LABELS = ("app", "host", "level", "env") + +logging.basicConfig(level=logging.INFO, format="%(asctime)s | %(levelname)s | %(message)s") +log = logging.getLogger("log_gateway") + +app = FastAPI(title="Central Log Gateway", version="1.0") + + +class LogRecord(BaseModel): + ts: Optional[float] = Field(None, description="Unix čas v sekundách (float). Když chybí, doplní brána.") + level: str = "INFO" + msg: str = "" + logger: Optional[str] = None + func: Optional[str] = None + line: Optional[int] = None + exc: Optional[str] = None + extra: Optional[Dict[str, Any]] = None + + +class BatchPayload(BaseModel): + app: str + host: str = "unknown" + env: Optional[str] = None + records: List[LogRecord] + + +def _check_token(authorization: Optional[str]) -> None: + expected = f"Bearer {LOG_TOKEN}" + if not authorization or authorization != expected: + raise HTTPException(status_code=401, detail="Neplatný nebo chybějící token.") + + +def _to_loki_streams(payload: BatchPayload) -> Dict[str, Any]: + """Seskupí záznamy podle (app, host, level, env) do Loki streamů. + Hodnota každé položky = [unix_nano_str, json_řádek].""" + env = payload.env or DEFAULT_ENV + streams: Dict[tuple, List[List[str]]] = {} + + for r in payload.records: + ts = r.ts if r.ts is not None else time.time() + ts_nano = str(int(ts * 1_000_000_000)) + + line_obj: Dict[str, Any] = {"msg": r.msg} + if r.logger: + line_obj["logger"] = r.logger + if r.func: + line_obj["func"] = r.func + if r.line is not None: + line_obj["line"] = r.line + if r.exc: + line_obj["exc"] = r.exc + if r.extra: + line_obj["extra"] = r.extra + + key = (payload.app, payload.host, (r.level or "INFO").upper(), env) + streams.setdefault(key, []).append([ts_nano, json.dumps(line_obj, ensure_ascii=False)]) + + out_streams = [] + for (app_name, host, level, env_v), values in streams.items(): + # Loki vyžaduje values seřazené vzestupně dle času v rámci streamu + values.sort(key=lambda v: v[0]) + out_streams.append({ + "stream": {"app": app_name, "host": host, "level": level, "env": env_v}, + "values": values, + }) + return {"streams": out_streams} + + +async def _push_to_loki(body: Dict[str, Any]) -> None: + url = f"{LOKI_URL}/loki/api/v1/push" + async with httpx.AsyncClient(timeout=10.0) as client: + resp = await client.post(url, json=body, headers={"Content-Type": "application/json"}) + if resp.status_code >= 300: + log.error("Loki push selhal %s: %s", resp.status_code, resp.text[:500]) + raise HTTPException(status_code=502, detail=f"Loki push selhal: {resp.status_code}") + + +@app.get("/health") +async def health() -> Dict[str, Any]: + loki_ok = False + try: + async with httpx.AsyncClient(timeout=3.0) as client: + r = await client.get(f"{LOKI_URL}/ready") + loki_ok = r.status_code == 200 + except Exception as e: # noqa: BLE001 + log.warning("Loki nedostupný: %s", e) + return {"status": "ok", "loki": "ready" if loki_ok else "unavailable", "version": "1.0"} + + +@app.post("/log/batch") +async def log_batch(payload: BatchPayload, authorization: Optional[str] = Header(None)) -> Dict[str, Any]: + _check_token(authorization) + if not payload.records: + return {"accepted": 0} + body = _to_loki_streams(payload) + await _push_to_loki(body) + return {"accepted": len(payload.records), "streams": len(body["streams"])} + + +@app.post("/log") +async def log_one( + record: LogRecord, + app_name: str, + host: str = "unknown", + env: Optional[str] = None, + authorization: Optional[str] = Header(None), +) -> Dict[str, Any]: + _check_token(authorization) + payload = BatchPayload(app=app_name, host=host, env=env, records=[record]) + body = _to_loki_streams(payload) + await _push_to_loki(body) + return {"accepted": 1} + + +if __name__ == "__main__": + import uvicorn + uvicorn.run(app, host="0.0.0.0", port=8770) diff --git a/CentralLogging/gateway/main.py b/CentralLogging/gateway/main.py new file mode 100644 index 0000000..cf75bb9 --- /dev/null +++ b/CentralLogging/gateway/main.py @@ -0,0 +1,25 @@ +# ============================================================================ +# main.py — ASGI import shim pro uvicorn +# Verze: 1.0 +# Datum: 2026-06-08 +# Popis: Uvicorn neumí naimportovat modul s tečkou v názvu +# (log_gateway_v1.0 -> čte .0 jako submodul). Tento shim načte +# verzovaný soubor přes importlib a vystaví `app` pro uvicorn. +# Spouštění: uvicorn main:app +# Při upgrade přepni VERSION_FILE. +# ============================================================================ +import sys +import importlib.util +from pathlib import Path + +VERSION_FILE = "log_gateway_v1.0.py" + +_path = Path(__file__).resolve().parent / VERSION_FILE +_spec = importlib.util.spec_from_file_location("log_gateway_impl", _path) +_mod = importlib.util.module_from_spec(_spec) +# Registrace do sys.modules je nutná, aby pydantic uměl dohledat forward-ref +# typy (Optional, ...) při `from __future__ import annotations`. +sys.modules[_spec.name] = _mod +_spec.loader.exec_module(_mod) + +app = _mod.app diff --git a/CentralLogging/gateway/requirements.txt b/CentralLogging/gateway/requirements.txt new file mode 100644 index 0000000..a2834bb --- /dev/null +++ b/CentralLogging/gateway/requirements.txt @@ -0,0 +1,4 @@ +fastapi==0.115.0 +uvicorn[standard]==0.30.6 +httpx==0.27.2 +pydantic==2.9.2 diff --git a/Covance_MDD3003/Source/Zpracovano/2026-06-08_130117 sponsor-study-35472-samples-allSamples.csv b/Covance_MDD3003/Source/Zpracovano/2026-06-08_130117 sponsor-study-35472-samples-allSamples.csv new file mode 100644 index 0000000..3bb4457 --- /dev/null +++ b/Covance_MDD3003/Source/Zpracovano/2026-06-08_130117 sponsor-study-35472-samples-allSamples.csv @@ -0,0 +1,1215 @@ +Protocol Code,Investigator No.,Investigator Name,Patient No.,Collection Date,Protocol Visit Code,Kit Receipt Date,Container Receipt Date,Accession,Container No.,Container Barcode No.,Specimen Type,Sample Status,Expected Receipt Condition,Actual Receipt Condition,Container Label Line 1,Container Label Line 2,SM Sample Status,SMART Specimen Class Description,Aliquot Created Date,Aliquoted Date,Collection Time,Container Receipt Time,Country,Courier,Kit Receipt Time,Parent Barcode Number,Parent Sample Type,Project,Region,Screening No.,Shipped To Organization Name,Site Waybill No.,Site - Scheduled Shipment Date,Site - Shipment Created Date,Site - Shipment Details Entered Date,SMART Specimen Class,Visit Description,Parent Barcode,Children Barcode +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,08-Aug-2025,P1SCR,09-Aug-2025,,6225350971,1,622535097101,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,10:30,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,08-Aug-2025,P1SCR,09-Aug-2025,09-Aug-2025,6225350971,2,622535097102,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,10:30,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,08-Aug-2025,P1SCR,09-Aug-2025,09-Aug-2025,6225350971,3,622535097103,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,"HEMATOLOGY, A1C, &",RETICULOCYTES,,,,,10:30,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,08-Aug-2025,P1SCR,09-Aug-2025,09-Aug-2025,6225350971,4,622535097104,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,10:30,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,08-Aug-2025,P1SCR,09-Aug-2025,09-Aug-2025,6225350971,5,622535097105,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,10:30,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,08-Aug-2025,P1SCR,09-Aug-2025,09-Aug-2025,6225350971,6,622535097106,"Urine, no preservative",Received,Ambient,Default Return Ambient,URINE DRUG SCREEN,,,,,,10:30,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,08-Aug-2025,P1SCR,09-Aug-2025,,6225350971,7,622535097107,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,10:30,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,08-Aug-2025,P1SCR,09-Aug-2025,12-Aug-2025,6225350971,8,622535097108,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,10:30,07:00,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,08-Aug-2025,P1SCR,09-Aug-2025,,6225350971,9,622535097109,"Red Cells, Clot",Not Received,,,TSH,,,,,,10:30,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,08-Aug-2025,P1SCR,09-Aug-2025,09-Aug-2025,6225350971,10,622535097110,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,10:30,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,19-Sep-2025,P1SCR,20-Sep-2025,,6225350972,1,622535097201,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,09:20,,Czech Republic,,22:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,19-Sep-2025,P1SCR,20-Sep-2025,20-Sep-2025,6225350972,3,622535097203,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,"HEMATOLOGY, A1C, &",RETICULOCYTES,,,,,09:20,22:00,Czech Republic,,22:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,19-Sep-2025,P1SCR,20-Sep-2025,20-Sep-2025,6225350972,4,622535097204,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:20,22:00,Czech Republic,,22:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,19-Sep-2025,P1SCR,20-Sep-2025,20-Sep-2025,6225350972,2,622535097202,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,09:20,22:00,Czech Republic,,22:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,19-Sep-2025,P1SCR,20-Sep-2025,20-Sep-2025,6225350972,5,622535097205,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,09:20,22:00,Czech Republic,,22:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,19-Sep-2025,P1SCR,20-Sep-2025,20-Sep-2025,6225350972,6,622535097206,"Urine, no preservative",Received,Ambient,Default Return Ambient,URINE DRUG SCREEN,,,,,,09:20,22:00,Czech Republic,,22:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,19-Sep-2025,P1SCR,20-Sep-2025,,6225350972,7,622535097207,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,09:20,,Czech Republic,,22:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,19-Sep-2025,P1SCR,20-Sep-2025,24-Sep-2025,6225350972,8,622535097208,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,09:20,07:00,Czech Republic,,22:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,19-Sep-2025,P1SCR,20-Sep-2025,,6225350972,9,622535097209,"Red Cells, Clot",Not Received,,,TSH,,,,,,09:20,,Czech Republic,,22:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,19-Sep-2025,P1SCR,20-Sep-2025,20-Sep-2025,6225350972,10,622535097210,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,09:20,22:00,Czech Republic,,22:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,07-Nov-2025,P1SCR,08-Nov-2025,,6225350975,1,622535097501,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,08:10,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,07-Nov-2025,P1SCR,08-Nov-2025,08-Nov-2025,6225350975,2,622535097502,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,08:10,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,07-Nov-2025,P1SCR,08-Nov-2025,08-Nov-2025,6225350975,3,622535097503,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,"HEMATOLOGY, A1C, &",RETICULOCYTES,,,,,08:10,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,07-Nov-2025,P1SCR,08-Nov-2025,08-Nov-2025,6225350975,5,622535097505,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,08:10,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,07-Nov-2025,P1SCR,08-Nov-2025,08-Nov-2025,6225350975,6,622535097506,"Urine, no preservative",Received,Ambient,Default Return Ambient,URINE DRUG SCREEN,,,,,,08:10,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,07-Nov-2025,P1SCR,08-Nov-2025,08-Nov-2025,6225350975,4,622535097504,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,08:10,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,07-Nov-2025,P1SCR,08-Nov-2025,,6225350975,7,622535097507,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,08:10,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,07-Nov-2025,P1SCR,08-Nov-2025,12-Nov-2025,6225350975,8,622535097508,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,08:10,07:00,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,07-Nov-2025,P1SCR,08-Nov-2025,,6225350975,9,622535097509,"Red Cells, Clot",Not Received,,,TSH,,,,,,08:10,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,07-Nov-2025,P1SCR,08-Nov-2025,08-Nov-2025,6225350975,10,622535097510,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,08:10,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,10-Oct-2025,P1SCR,11-Oct-2025,,6225350977,1,622535097701,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,09:20,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,10-Oct-2025,P1SCR,11-Oct-2025,11-Oct-2025,6225350977,2,622535097702,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,09:20,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,10-Oct-2025,P1SCR,11-Oct-2025,11-Oct-2025,6225350977,3,622535097703,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,"HEMATOLOGY, A1C, &",RETICULOCYTES,,,,,09:20,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,10-Oct-2025,P1SCR,11-Oct-2025,11-Oct-2025,6225350977,4,622535097704,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:20,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,10-Oct-2025,P1SCR,11-Oct-2025,11-Oct-2025,6225350977,5,622535097705,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,09:20,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,10-Oct-2025,P1SCR,11-Oct-2025,11-Oct-2025,6225350977,6,622535097706,"Urine, no preservative",Received,Ambient,Default Return Ambient,URINE DRUG SCREEN,,,,,,09:20,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,10-Oct-2025,P1SCR,11-Oct-2025,,6225350977,7,622535097707,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,09:20,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,10-Oct-2025,P1SCR,11-Oct-2025,15-Oct-2025,6225350977,8,622535097708,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,09:20,07:00,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,10-Oct-2025,P1SCR,11-Oct-2025,,6225350977,9,622535097709,"Red Cells, Clot",Not Received,,,TSH,,,,,,09:20,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,10-Oct-2025,P1SCR,11-Oct-2025,11-Oct-2025,6225350977,10,622535097710,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,09:20,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,05-Sep-2025,P1DBBL,06-Sep-2025,06-Sep-2025,6225350981,1,622535098101,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,07:55,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,05-Sep-2025,P1DBBL,06-Sep-2025,,6225350981,2,622535098102,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,07:55,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,05-Sep-2025,P1DBBL,06-Sep-2025,09-Sep-2025,6225350981,3,622535098103,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,07:55,07:00,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,05-Sep-2025,P1DBBL,06-Sep-2025,,6225350981,4,622535098104,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,07:55,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,05-Sep-2025,P1DBBL,06-Sep-2025,06-Sep-2025,6225350981,5,622535098105,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,07:55,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,05-Sep-2025,P1DBBL,06-Sep-2025,06-Sep-2025,6225350981,6,622535098106,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,07:55,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,07-Nov-2025,P1DBBL,08-Nov-2025,,6225350982,2,622535098202,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,09:30,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,07-Nov-2025,P1DBBL,08-Nov-2025,12-Nov-2025,6225350982,3,622535098203,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,09:30,07:00,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,07-Nov-2025,P1DBBL,08-Nov-2025,08-Nov-2025,6225350982,1,622535098201,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,09:30,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,05-Sep-2025,P1DBBL,06-Sep-2025,06-Sep-2025,6225350981,7,622535098107,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,07:55,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,07-Nov-2025,P1DBBL,08-Nov-2025,,6225350982,4,622535098204,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,09:30,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,07-Nov-2025,P1DBBL,08-Nov-2025,08-Nov-2025,6225350982,5,622535098205,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,09:30,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,07-Nov-2025,P1DBBL,08-Nov-2025,08-Nov-2025,6225350982,6,622535098206,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,09:30,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,07-Nov-2025,P1DBBL,08-Nov-2025,08-Nov-2025,6225350982,7,622535098207,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:30,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,17-Oct-2025,P1DBBL,18-Oct-2025,18-Oct-2025,6225350984,1,622535098401,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,10:45,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,17-Oct-2025,P1DBBL,18-Oct-2025,,6225350984,2,622535098402,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,10:45,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,17-Oct-2025,P1DBBL,18-Oct-2025,22-Oct-2025,6225350984,3,622535098403,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,10:45,07:00,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,17-Oct-2025,P1DBBL,18-Oct-2025,,6225350984,4,622535098404,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,10:45,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,17-Oct-2025,P1DBBL,18-Oct-2025,18-Oct-2025,6225350984,5,622535098405,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,10:45,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,17-Oct-2025,P1DBBL,18-Oct-2025,18-Oct-2025,6225350984,6,622535098406,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,10:45,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,17-Oct-2025,P1DBBL,18-Oct-2025,18-Oct-2025,6225350984,7,622535098407,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,10:45,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,17-Oct-2025,P2OLBL,18-Oct-2025,18-Oct-2025,6225350988,5,622535098805,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,09:00,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,17-Oct-2025,P2OLBL,18-Oct-2025,18-Oct-2025,6225350988,6,622535098806,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,09:00,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,17-Oct-2025,P2OLBL,18-Oct-2025,18-Oct-2025,6225350988,7,622535098807,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:00,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,17-Oct-2025,P2OLBL,18-Oct-2025,,6225350988,8,622535098808,"Red Cells, Clot",Not Received,,,TSH,,,,,,09:00,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,17-Oct-2025,P2OLBL,18-Oct-2025,18-Oct-2025,6225350988,1,622535098801,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,09:00,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,17-Oct-2025,P2OLBL,18-Oct-2025,18-Oct-2025,6225350988,9,622535098809,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,09:00,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,17-Oct-2025,P2OLBL,18-Oct-2025,,6225350988,2,622535098802,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,09:00,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,17-Oct-2025,P2OLBL,18-Oct-2025,22-Oct-2025,6225350988,3,622535098803,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,09:00,07:00,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,17-Oct-2025,P2OLBL,18-Oct-2025,,6225350988,4,622535098804,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,09:00,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,19-Aug-2025,P1SCR,21-Aug-2025,,6225351002,1,622535100201,"Whole Blood, EDTA, Dry",Not Received,Ambient,,HEMATOLOGY,,,,,,10:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,19-Aug-2025,P1SCR,21-Aug-2025,,6225351002,2,622535100202,"Slides, Hematology",Not Received,Ambient,,HEMATOLOGY,,,,,,10:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,19-Aug-2025,P1SCR,21-Aug-2025,,6225351002,3,622535100203,"Urine, Cargile Preservative UA",Not Received,Ambient,,URINALYSIS,,,,,,10:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,19-Aug-2025,P1SCR,21-Aug-2025,,6225351002,4,622535100204,"Urine, no preservative",Not Received,Ambient,,URINE DRUG SCREEN,,,,,,10:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,19-Aug-2025,P1SCR,21-Aug-2025,,6225351002,5,622535100205,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,10:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,19-Aug-2025,P1SCR,21-Aug-2025,21-Aug-2025,6225351002,6,622535100206,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,10:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,19-Aug-2025,P1SCR,21-Aug-2025,,6225351002,7,622535100207,"Red Cells, Clot",Not Received,,,TSH,,,,,,10:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,19-Aug-2025,P1SCR,21-Aug-2025,,6225351002,8,622535100208,"Serum, SST",Not Received,Ambient,,TSH,,,,,,10:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,19-Aug-2025,P1SCR,21-Aug-2025,,6225351002,9,622535100209,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,10:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,19-Aug-2025,P1SCR,21-Aug-2025,,6225351002,10,622535100210,"Serum, SST",Not Received,Ambient,,CHEMISTRY,,,,,,10:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10005,Dr.Lubos Janu,CZ100050002,03-Nov-2025,P1SCR,04-Nov-2025,,6225351004,1,622535100401,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,12:08,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10005,Dr.Lubos Janu,CZ100050002,03-Nov-2025,P1SCR,04-Nov-2025,04-Nov-2025,6225351004,2,622535100402,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,12:08,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10005,Dr.Lubos Janu,CZ100050002,03-Nov-2025,P1SCR,04-Nov-2025,04-Nov-2025,6225351004,3,622535100403,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,"HEMATOLOGY, A1C, &",RETICULOCYTES,,,,,12:08,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10005,Dr.Lubos Janu,CZ100050002,03-Nov-2025,P1SCR,04-Nov-2025,04-Nov-2025,6225351004,4,622535100404,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,12:08,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10005,Dr.Lubos Janu,CZ100050002,03-Nov-2025,P1SCR,04-Nov-2025,04-Nov-2025,6225351004,5,622535100405,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,12:08,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10005,Dr.Lubos Janu,CZ100050002,03-Nov-2025,P1SCR,04-Nov-2025,04-Nov-2025,6225351004,6,622535100406,"Urine, no preservative",Received,Ambient,Default Return Ambient,URINE DRUG SCREEN,,,,,,12:08,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10005,Dr.Lubos Janu,CZ100050002,03-Nov-2025,P1SCR,04-Nov-2025,,6225351004,7,622535100407,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,12:08,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10005,Dr.Lubos Janu,CZ100050002,03-Nov-2025,P1SCR,04-Nov-2025,04-Nov-2025,6225351004,8,622535100408,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,12:08,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10005,Dr.Lubos Janu,CZ100050002,03-Nov-2025,P1SCR,04-Nov-2025,,6225351004,9,622535100409,"Red Cells, Clot",Not Received,,,TSH,,,,,,12:08,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10005,Dr.Lubos Janu,CZ100050002,03-Nov-2025,P1SCR,04-Nov-2025,04-Nov-2025,6225351004,10,622535100410,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,12:08,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10005,Dr.Lubos Janu,CZ100050001,09-Sep-2025,P1SCR,10-Sep-2025,10-Sep-2025,6225351006,2,622535100602,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,11:10,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10005,Dr.Lubos Janu,CZ100050001,09-Sep-2025,P1SCR,10-Sep-2025,,6225351006,1,622535100601,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,11:10,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10005,Dr.Lubos Janu,CZ100050001,09-Sep-2025,P1SCR,10-Sep-2025,10-Sep-2025,6225351006,3,622535100603,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,"HEMATOLOGY, A1C, &",RETICULOCYTES,,,,,11:10,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10005,Dr.Lubos Janu,CZ100050001,09-Sep-2025,P1SCR,10-Sep-2025,10-Sep-2025,6225351006,4,622535100604,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,11:10,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10005,Dr.Lubos Janu,CZ100050001,09-Sep-2025,P1SCR,10-Sep-2025,10-Sep-2025,6225351006,5,622535100605,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,11:10,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10005,Dr.Lubos Janu,CZ100050001,09-Sep-2025,P1SCR,10-Sep-2025,10-Sep-2025,6225351006,6,622535100606,"Urine, no preservative",Received,Ambient,Default Return Ambient,URINE DRUG SCREEN,,,,,,11:10,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10005,Dr.Lubos Janu,CZ100050001,09-Sep-2025,P1SCR,10-Sep-2025,,6225351006,7,622535100607,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,11:10,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10005,Dr.Lubos Janu,CZ100050001,09-Sep-2025,P1SCR,10-Sep-2025,10-Sep-2025,6225351006,8,622535100608,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,11:10,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10005,Dr.Lubos Janu,CZ100050001,09-Sep-2025,P1SCR,10-Sep-2025,,6225351006,9,622535100609,"Red Cells, Clot",Not Received,,,TSH,,,,,,11:10,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10005,Dr.Lubos Janu,CZ100050001,09-Sep-2025,P1SCR,10-Sep-2025,10-Sep-2025,6225351006,10,622535100610,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,11:10,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10005,Dr.Lubos Janu,CZ100050001,16-Sep-2025,P1SCR,17-Sep-2025,17-Sep-2025,6225351036,1,622535103601,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,10:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10005,Dr.Lubos Janu,CZ100050001,16-Sep-2025,P1SCR,17-Sep-2025,,6225351036,3,622535103603,"Urine, Cargile Preservative UA",Not Received,Ambient,,URINALYSIS,,,,,,10:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10005,Dr.Lubos Janu,CZ100050001,16-Sep-2025,P1SCR,17-Sep-2025,,6225351036,4,622535103604,"Urine, no preservative",Not Received,Ambient,,URINE DRUG SCREEN,,,,,,10:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10005,Dr.Lubos Janu,CZ100050001,16-Sep-2025,P1SCR,17-Sep-2025,,6225351036,2,622535103602,"Slides, Hematology",Not Received,Ambient,,HEMATOLOGY,,,,,,10:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10005,Dr.Lubos Janu,CZ100050001,16-Sep-2025,P1SCR,17-Sep-2025,,6225351036,5,622535103605,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,10:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10005,Dr.Lubos Janu,CZ100050001,16-Sep-2025,P1SCR,17-Sep-2025,,6225351036,7,622535103607,"Red Cells, Clot",Not Received,,,TSH,,,,,,10:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10005,Dr.Lubos Janu,CZ100050001,16-Sep-2025,P1SCR,17-Sep-2025,,6225351036,8,622535103608,"Serum, SST",Not Received,Ambient,,TSH,,,,,,10:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10005,Dr.Lubos Janu,CZ100050001,16-Sep-2025,P1SCR,17-Sep-2025,,6225351036,6,622535103606,"Plasma, EDTA",Not Received,Frozen,,INSULIN,FROZEN,,,,,10:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10005,Dr.Lubos Janu,CZ100050002,11-Nov-2025,P1SCR,12-Nov-2025,,6225351037,2,622535103702,"Slides, Hematology",Not Received,Ambient,,HEMATOLOGY,,,,,,10:04,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10005,Dr.Lubos Janu,CZ100050001,16-Sep-2025,P1SCR,17-Sep-2025,,6225351036,9,622535103609,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,10:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10005,Dr.Lubos Janu,CZ100050002,11-Nov-2025,P1SCR,12-Nov-2025,,6225351037,3,622535103703,"Urine, Cargile Preservative UA",Not Received,Ambient,,URINALYSIS,,,,,,10:04,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10005,Dr.Lubos Janu,CZ100050001,16-Sep-2025,P1SCR,17-Sep-2025,17-Sep-2025,6225351036,10,622535103610,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,10:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10005,Dr.Lubos Janu,CZ100050002,11-Nov-2025,P1SCR,12-Nov-2025,12-Nov-2025,6225351037,1,622535103701,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,10:04,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10005,Dr.Lubos Janu,CZ100050002,11-Nov-2025,P1SCR,12-Nov-2025,,6225351037,6,622535103706,"Plasma, EDTA",Not Received,Frozen,,INSULIN,FROZEN,,,,,10:04,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10005,Dr.Lubos Janu,CZ100050002,11-Nov-2025,P1SCR,12-Nov-2025,,6225351037,9,622535103709,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,10:04,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10005,Dr.Lubos Janu,CZ100050002,11-Nov-2025,P1SCR,12-Nov-2025,,6225351037,8,622535103708,"Serum, SST",Not Received,Ambient,,TSH,,,,,,10:04,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10005,Dr.Lubos Janu,CZ100050002,11-Nov-2025,P1SCR,12-Nov-2025,12-Nov-2025,6225351037,10,622535103710,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,10:04,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10005,Dr.Lubos Janu,CZ100050002,11-Nov-2025,P1SCR,12-Nov-2025,,6225351037,7,622535103707,"Red Cells, Clot",Not Received,,,TSH,,,,,,10:04,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10005,Dr.Lubos Janu,CZ100050002,11-Nov-2025,P1SCR,12-Nov-2025,,6225351037,4,622535103704,"Urine, no preservative",Not Received,Ambient,,URINE DRUG SCREEN,,,,,,10:04,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10005,Dr.Lubos Janu,CZ100050002,11-Nov-2025,P1SCR,12-Nov-2025,,6225351037,5,622535103705,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,10:04,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,16-Sep-2025,P1SCR,17-Sep-2025,17-Sep-2025,6225351040,2,622535104002,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,09:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,16-Sep-2025,P1SCR,17-Sep-2025,,6225351040,1,622535104001,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,09:45,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,16-Sep-2025,P1SCR,17-Sep-2025,17-Sep-2025,6225351040,5,622535104005,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,09:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,16-Sep-2025,P1SCR,17-Sep-2025,17-Sep-2025,6225351040,4,622535104004,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,16-Sep-2025,P1SCR,17-Sep-2025,17-Sep-2025,6225351040,6,622535104006,"Urine, no preservative",Received,Ambient,Default Return Ambient,URINE DRUG SCREEN,,,,,,09:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,16-Sep-2025,P1SCR,17-Sep-2025,17-Sep-2025,6225351040,8,622535104008,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,09:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,16-Sep-2025,P1SCR,17-Sep-2025,,6225351040,9,622535104009,"Red Cells, Clot",Not Received,,,TSH,,,,,,09:45,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,16-Sep-2025,P1SCR,17-Sep-2025,17-Sep-2025,6225351040,3,622535104003,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,"HEMATOLOGY, A1C, &",RETICULOCYTES,,,,,09:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,16-Sep-2025,P1SCR,17-Sep-2025,,6225351040,7,622535104007,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,09:45,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080003,06-Aug-2025,P1SCR,07-Aug-2025,07-Aug-2025,6225351041,3,622535104103,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,"HEMATOLOGY, A1C, &",RETICULOCYTES,,,,,11:43,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080003,06-Aug-2025,P1SCR,07-Aug-2025,07-Aug-2025,6225351041,5,622535104105,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,11:43,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080003,06-Aug-2025,P1SCR,07-Aug-2025,07-Aug-2025,6225351041,6,622535104106,"Urine, no preservative",Received,Ambient,Default Return Ambient,URINE DRUG SCREEN,,,,,,11:43,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080003,06-Aug-2025,P1SCR,07-Aug-2025,07-Aug-2025,6225351041,4,622535104104,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,11:43,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080003,06-Aug-2025,P1SCR,07-Aug-2025,,6225351041,7,622535104107,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,11:43,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080003,06-Aug-2025,P1SCR,07-Aug-2025,07-Aug-2025,6225351041,8,622535104108,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,11:43,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080003,06-Aug-2025,P1SCR,07-Aug-2025,,6225351041,1,622535104101,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,11:43,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,16-Sep-2025,P1SCR,17-Sep-2025,17-Sep-2025,6225351040,10,622535104010,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,09:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080003,06-Aug-2025,P1SCR,07-Aug-2025,07-Aug-2025,6225351041,2,622535104102,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,11:43,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080003,06-Aug-2025,P1SCR,07-Aug-2025,,6225351041,9,622535104109,"Red Cells, Clot",Not Received,,,TSH,,,,,,11:43,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080003,06-Aug-2025,P1SCR,07-Aug-2025,07-Aug-2025,6225351041,10,622535104110,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,11:43,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080004,26-Aug-2025,P1SCR,27-Aug-2025,,6225351042,1,622535104201,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,11:08,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080004,26-Aug-2025,P1SCR,27-Aug-2025,27-Aug-2025,6225351042,4,622535104204,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,11:08,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080004,26-Aug-2025,P1SCR,27-Aug-2025,27-Aug-2025,6225351042,3,622535104203,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,"HEMATOLOGY, A1C, &",RETICULOCYTES,,,,,11:08,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080004,26-Aug-2025,P1SCR,27-Aug-2025,27-Aug-2025,6225351042,5,622535104205,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,11:08,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080004,26-Aug-2025,P1SCR,27-Aug-2025,27-Aug-2025,6225351042,6,622535104206,"Urine, no preservative",Received,Ambient,Default Return Ambient,URINE DRUG SCREEN,,,,,,11:08,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080004,26-Aug-2025,P1SCR,27-Aug-2025,27-Aug-2025,6225351042,2,622535104202,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,11:08,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080004,26-Aug-2025,P1SCR,27-Aug-2025,27-Aug-2025,6225351042,10,622535104210,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,11:08,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080004,26-Aug-2025,P1SCR,27-Aug-2025,28-Aug-2025,6225351042,8,622535104208,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,11:08,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080004,26-Aug-2025,P1SCR,27-Aug-2025,,6225351042,9,622535104209,"Red Cells, Clot",Not Received,,,TSH,,,,,,11:08,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080004,26-Aug-2025,P1SCR,27-Aug-2025,,6225351042,7,622535104207,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,11:08,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,10-Dec-2025,P1SCR,11-Dec-2025,,6225351044,1,622535104401,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,10:20,,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,10-Dec-2025,P1SCR,11-Dec-2025,11-Dec-2025,6225351044,2,622535104402,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,10:20,07:15,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,10-Dec-2025,P1SCR,11-Dec-2025,11-Dec-2025,6225351044,3,622535104403,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,"HEMATOLOGY, A1C, &",RETICULOCYTES,,,,,10:20,07:15,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,10-Dec-2025,P1SCR,11-Dec-2025,11-Dec-2025,6225351044,4,622535104404,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,10:20,07:15,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,10-Dec-2025,P1SCR,11-Dec-2025,11-Dec-2025,6225351044,5,622535104405,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,10:20,07:15,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,10-Dec-2025,P1SCR,11-Dec-2025,11-Dec-2025,6225351044,6,622535104406,"Urine, no preservative",Received,Ambient,Default Return Ambient,URINE DRUG SCREEN,,,,,,10:20,07:15,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,10-Dec-2025,P1SCR,11-Dec-2025,,6225351044,7,622535104407,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,10:20,,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,10-Dec-2025,P1SCR,11-Dec-2025,,6225351044,9,622535104409,"Red Cells, Clot",Not Received,,,TSH,,,,,,10:20,,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,10-Dec-2025,P1SCR,11-Dec-2025,11-Dec-2025,6225351044,10,622535104410,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,10:20,07:15,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,05-Aug-2025,P1SCR,06-Aug-2025,,6225351045,1,622535104501,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,11:58,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,05-Aug-2025,P1SCR,06-Aug-2025,06-Aug-2025,6225351045,2,622535104502,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,11:58,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,05-Aug-2025,P1SCR,06-Aug-2025,06-Aug-2025,6225351045,3,622535104503,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,"HEMATOLOGY, A1C, &",RETICULOCYTES,,,,,11:58,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,10-Dec-2025,P1SCR,11-Dec-2025,11-Dec-2025,6225351044,8,622535104408,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,10:20,07:15,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,05-Aug-2025,P1SCR,06-Aug-2025,06-Aug-2025,6225351045,4,622535104504,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,11:58,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,05-Aug-2025,P1SCR,06-Aug-2025,06-Aug-2025,6225351045,5,622535104505,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,11:58,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,05-Aug-2025,P1SCR,06-Aug-2025,,6225351045,7,622535104507,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,11:58,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,05-Aug-2025,P1SCR,06-Aug-2025,06-Aug-2025,6225351045,8,622535104508,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,11:58,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,05-Aug-2025,P1SCR,06-Aug-2025,06-Aug-2025,6225351045,6,622535104506,"Urine, no preservative",Received,Ambient,Default Return Ambient,URINE DRUG SCREEN,,,,,,11:58,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,05-Aug-2025,P1SCR,06-Aug-2025,,6225351045,9,622535104509,"Red Cells, Clot",Not Received,,,TSH,,,,,,11:58,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,05-Aug-2025,P1SCR,06-Aug-2025,06-Aug-2025,6225351045,10,622535104510,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,11:58,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080005,10-Sep-2025,P1SCR,11-Sep-2025,,6225351046,1,622535104601,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,13:31,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080005,10-Sep-2025,P1SCR,11-Sep-2025,11-Sep-2025,6225351046,3,622535104603,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,"HEMATOLOGY, A1C, &",RETICULOCYTES,,,,,13:31,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080005,10-Sep-2025,P1SCR,11-Sep-2025,11-Sep-2025,6225351046,4,622535104604,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,13:31,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080005,10-Sep-2025,P1SCR,11-Sep-2025,11-Sep-2025,6225351046,5,622535104605,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,13:31,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080005,10-Sep-2025,P1SCR,11-Sep-2025,11-Sep-2025,6225351046,6,622535104606,"Urine, no preservative",Received,Ambient,Default Return Ambient,URINE DRUG SCREEN,,,,,,13:31,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080005,10-Sep-2025,P1SCR,11-Sep-2025,11-Sep-2025,6225351046,8,622535104608,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,13:31,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080005,10-Sep-2025,P1SCR,11-Sep-2025,11-Sep-2025,6225351046,2,622535104602,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,13:31,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080005,10-Sep-2025,P1SCR,11-Sep-2025,,6225351046,9,622535104609,"Red Cells, Clot",Not Received,,,TSH,,,,,,13:31,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080005,10-Sep-2025,P1SCR,11-Sep-2025,11-Sep-2025,6225351046,10,622535104610,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,13:31,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080005,10-Sep-2025,P1SCR,11-Sep-2025,,6225351046,7,622535104607,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,13:31,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080001,02-Jul-2025,P1SCR,03-Jul-2025,03-Jul-2025,6225351047,2,622535104702,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,11:12,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080001,02-Jul-2025,P1SCR,03-Jul-2025,03-Jul-2025,6225351047,3,622535104703,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,"HEMATOLOGY, A1C, &",RETICULOCYTES,,,,,11:12,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080001,02-Jul-2025,P1SCR,03-Jul-2025,03-Jul-2025,6225351047,4,622535104704,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,11:12,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080001,02-Jul-2025,P1SCR,03-Jul-2025,03-Jul-2025,6225351047,5,622535104705,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,11:12,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080001,02-Jul-2025,P1SCR,03-Jul-2025,03-Jul-2025,6225351047,6,622535104706,"Urine, no preservative",Received,Ambient,Default Return Ambient,URINE DRUG SCREEN,,,,,,11:12,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080001,02-Jul-2025,P1SCR,03-Jul-2025,03-Jul-2025,6225351047,8,622535104708,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,11:12,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080001,02-Jul-2025,P1SCR,03-Jul-2025,,6225351047,1,622535104701,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,11:12,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080001,02-Jul-2025,P1SCR,03-Jul-2025,,6225351047,7,622535104707,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,11:12,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080001,02-Jul-2025,P1SCR,03-Jul-2025,,6225351047,9,622535104709,"Red Cells, Clot",Not Received,,,TSH,,,,,,11:12,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080001,02-Jul-2025,P1SCR,03-Jul-2025,03-Jul-2025,6225351047,10,622535104710,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,11:12,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080001,30-Jul-2025,P1DBBL,31-Jul-2025,31-Jul-2025,6225351049,1,622535104901,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,11:55,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080001,30-Jul-2025,P1DBBL,31-Jul-2025,,6225351049,2,622535104902,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,11:55,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080001,30-Jul-2025,P1DBBL,31-Jul-2025,31-Jul-2025,6225351049,3,622535104903,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,11:55,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080001,30-Jul-2025,P1DBBL,31-Jul-2025,,6225351049,4,622535104904,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,11:55,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080001,30-Jul-2025,P1DBBL,31-Jul-2025,31-Jul-2025,6225351049,5,622535104905,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,11:55,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080001,30-Jul-2025,P1DBBL,31-Jul-2025,31-Jul-2025,6225351049,6,622535104906,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,11:55,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080001,30-Jul-2025,P1DBBL,31-Jul-2025,31-Jul-2025,6225351049,7,622535104907,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,11:55,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080005,08-Oct-2025,P1DBBL,09-Oct-2025,09-Oct-2025,6225351050,1,622535105001,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,11:19,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080005,08-Oct-2025,P1DBBL,09-Oct-2025,,6225351050,2,622535105002,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,11:19,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080005,08-Oct-2025,P1DBBL,09-Oct-2025,,6225351050,4,622535105004,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,11:19,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080005,08-Oct-2025,P1DBBL,09-Oct-2025,09-Oct-2025,6225351050,5,622535105005,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,11:19,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080005,08-Oct-2025,P1DBBL,09-Oct-2025,09-Oct-2025,6225351050,6,622535105006,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,11:19,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080005,08-Oct-2025,P1DBBL,09-Oct-2025,09-Oct-2025,6225351050,3,622535105003,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,11:19,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,26-Aug-2025,P1DBBL,27-Aug-2025,27-Aug-2025,6225351051,1,622535105101,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,12:47,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,26-Aug-2025,P1DBBL,27-Aug-2025,,6225351051,2,622535105102,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,12:47,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,26-Aug-2025,P1DBBL,27-Aug-2025,28-Aug-2025,6225351051,3,622535105103,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,12:47,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080005,08-Oct-2025,P1DBBL,09-Oct-2025,09-Oct-2025,6225351050,7,622535105007,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,11:19,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,26-Aug-2025,P1DBBL,27-Aug-2025,,6225351051,4,622535105104,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,12:47,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,26-Aug-2025,P1DBBL,27-Aug-2025,27-Aug-2025,6225351051,6,622535105106,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,12:47,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,26-Aug-2025,P1DBBL,27-Aug-2025,27-Aug-2025,6225351051,5,622535105105,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,12:47,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,26-Aug-2025,P1DBBL,27-Aug-2025,27-Aug-2025,6225351051,7,622535105107,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,12:47,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080004,16-Sep-2025,P1DBBL,17-Sep-2025,17-Sep-2025,6225351052,3,622535105203,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,12:35,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080004,16-Sep-2025,P1DBBL,17-Sep-2025,17-Sep-2025,6225351052,5,622535105205,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,12:35,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080004,16-Sep-2025,P1DBBL,17-Sep-2025,17-Sep-2025,6225351052,6,622535105206,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,12:35,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080004,16-Sep-2025,P1DBBL,17-Sep-2025,,6225351052,2,622535105202,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,12:35,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080004,16-Sep-2025,P1DBBL,17-Sep-2025,,6225351052,4,622535105204,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,12:35,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080004,16-Sep-2025,P1DBBL,17-Sep-2025,17-Sep-2025,6225351052,1,622535105201,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,12:35,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080004,16-Sep-2025,P1DBBL,17-Sep-2025,17-Sep-2025,6225351052,7,622535105207,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,12:35,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080001,10-Sep-2025,P2OLBL,11-Sep-2025,11-Sep-2025,6225351056,1,622535105601,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,11:35,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080001,10-Sep-2025,P2OLBL,11-Sep-2025,,6225351056,2,622535105602,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,11:35,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080001,10-Sep-2025,P2OLBL,11-Sep-2025,11-Sep-2025,6225351056,3,622535105603,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,11:35,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080001,10-Sep-2025,P2OLBL,11-Sep-2025,,6225351056,4,622535105604,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,11:35,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080001,10-Sep-2025,P2OLBL,11-Sep-2025,11-Sep-2025,6225351056,5,622535105605,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,11:35,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080001,10-Sep-2025,P2OLBL,11-Sep-2025,11-Sep-2025,6225351056,6,622535105606,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,11:35,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080001,10-Sep-2025,P2OLBL,11-Sep-2025,11-Sep-2025,6225351056,7,622535105607,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,11:35,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080001,10-Sep-2025,P2OLBL,11-Sep-2025,,6225351056,8,622535105608,"Red Cells, Clot",Not Received,,,TSH,,,,,,11:35,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080001,10-Sep-2025,P2OLBL,11-Sep-2025,11-Sep-2025,6225351056,9,622535105609,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,11:35,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,07-Oct-2025,P2OLBL,08-Oct-2025,08-Oct-2025,6225351057,1,622535105701,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,12:02,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,07-Oct-2025,P2OLBL,08-Oct-2025,,6225351057,2,622535105702,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,12:02,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,07-Oct-2025,P2OLBL,08-Oct-2025,08-Oct-2025,6225351057,3,622535105703,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,12:02,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,07-Oct-2025,P2OLBL,08-Oct-2025,,6225351057,4,622535105704,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,12:02,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,07-Oct-2025,P2OLBL,08-Oct-2025,08-Oct-2025,6225351057,5,622535105705,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,12:02,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,07-Oct-2025,P2OLBL,08-Oct-2025,08-Oct-2025,6225351057,6,622535105706,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,12:02,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,07-Oct-2025,P2OLBL,08-Oct-2025,08-Oct-2025,6225351057,7,622535105707,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,12:02,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,07-Oct-2025,P2OLBL,08-Oct-2025,,6225351057,8,622535105708,"Red Cells, Clot",Not Received,,,TSH,,,,,,12:02,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,07-Oct-2025,P2OLBL,08-Oct-2025,08-Oct-2025,6225351057,9,622535105709,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,12:02,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080004,14-Oct-2025,EW,15-Oct-2025,15-Oct-2025,6225351066,1,622535106601,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,12:30,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Early Withdrawal,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080004,14-Oct-2025,EW,15-Oct-2025,15-Oct-2025,6225351066,3,622535106603,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,12:30,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Early Withdrawal,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080004,14-Oct-2025,EW,15-Oct-2025,,6225351066,4,622535106604,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,12:30,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Early Withdrawal,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080004,14-Oct-2025,EW,15-Oct-2025,15-Oct-2025,6225351066,7,622535106607,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,12:30,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Early Withdrawal,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080004,14-Oct-2025,EW,15-Oct-2025,,6225351066,8,622535106608,"Red Cells, Clot",Not Received,,,TSH,,,,,,12:30,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Early Withdrawal,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080004,14-Oct-2025,EW,15-Oct-2025,15-Oct-2025,6225351066,9,622535106609,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,12:30,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Early Withdrawal,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080004,14-Oct-2025,EW,15-Oct-2025,,6225351066,6,622535106606,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,12:30,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Early Withdrawal,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080004,14-Oct-2025,EW,15-Oct-2025,15-Oct-2025,6225351066,5,622535106605,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,12:30,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Early Withdrawal,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080004,14-Oct-2025,EW,15-Oct-2025,15-Oct-2025,6225351066,2,622535106602,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,12:30,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Early Withdrawal,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080004,08-Sep-2025,P1SCR,09-Sep-2025,,6225351070,3,622535107003,"Urine, Cargile Preservative UA",Not Received,Ambient,,URINALYSIS,,,,,,10:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080004,08-Sep-2025,P1SCR,09-Sep-2025,09-Sep-2025,6225351070,4,622535107004,"Urine, no preservative",Received,Ambient,Default Return Ambient,URINE DRUG SCREEN,,,,,,10:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080004,08-Sep-2025,P1SCR,09-Sep-2025,,6225351070,2,622535107002,"Slides, Hematology",Not Received,Ambient,,HEMATOLOGY,,,,,,10:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080004,08-Sep-2025,P1SCR,09-Sep-2025,,6225351070,5,622535107005,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,10:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080004,08-Sep-2025,P1SCR,09-Sep-2025,,6225351070,6,622535107006,"Plasma, EDTA",Not Received,Frozen,,INSULIN,FROZEN,,,,,10:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080004,08-Sep-2025,P1SCR,09-Sep-2025,,6225351070,1,622535107001,"Whole Blood, EDTA, Dry",Not Received,Ambient,,HEMATOLOGY,,,,,,10:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080004,08-Sep-2025,P1SCR,09-Sep-2025,,6225351070,9,622535107009,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,10:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080004,08-Sep-2025,P1SCR,09-Sep-2025,,6225351070,8,622535107008,"Serum, SST",Not Received,Ambient,,TSH,,,,,,10:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080004,08-Sep-2025,P1SCR,09-Sep-2025,,6225351070,7,622535107007,"Red Cells, Clot",Not Received,,,TSH,,,,,,10:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080004,08-Sep-2025,P1SCR,09-Sep-2025,,6225351070,10,622535107010,"Serum, SST",Not Received,Ambient,,CHEMISTRY,,,,,,10:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110002,06-Aug-2025,P1SCR,07-Aug-2025,07-Aug-2025,6225351072,2,622535107202,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,09:40,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110002,06-Aug-2025,P1SCR,07-Aug-2025,07-Aug-2025,6225351072,3,622535107203,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,"HEMATOLOGY, A1C, &",RETICULOCYTES,,,,,09:40,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110002,06-Aug-2025,P1SCR,07-Aug-2025,07-Aug-2025,6225351072,4,622535107204,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:40,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110002,06-Aug-2025,P1SCR,07-Aug-2025,07-Aug-2025,6225351072,5,622535107205,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,09:40,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110002,06-Aug-2025,P1SCR,07-Aug-2025,07-Aug-2025,6225351072,6,622535107206,"Urine, no preservative",Received,Ambient,Default Return Ambient,URINE DRUG SCREEN,,,,,,09:40,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110002,06-Aug-2025,P1SCR,07-Aug-2025,,6225351072,7,622535107207,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,09:40,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110002,06-Aug-2025,P1SCR,07-Aug-2025,,6225351072,1,622535107201,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,09:40,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110002,06-Aug-2025,P1SCR,07-Aug-2025,07-Aug-2025,6225351072,10,622535107210,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,09:40,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110002,06-Aug-2025,P1SCR,07-Aug-2025,,6225351072,9,622535107209,"Red Cells, Clot",Not Received,,,TSH,,,,,,09:40,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110002,06-Aug-2025,P1SCR,07-Aug-2025,07-Aug-2025,6225351072,8,622535107208,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,09:40,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110005,03-Nov-2025,P1SCR,04-Nov-2025,04-Nov-2025,6225351074,2,622535107402,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,09:40,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110005,03-Nov-2025,P1SCR,04-Nov-2025,04-Nov-2025,6225351074,3,622535107403,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,"HEMATOLOGY, A1C, &",RETICULOCYTES,,,,,09:40,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110005,03-Nov-2025,P1SCR,04-Nov-2025,04-Nov-2025,6225351074,4,622535107404,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:40,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110005,03-Nov-2025,P1SCR,04-Nov-2025,,6225351074,1,622535107401,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,09:40,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110005,03-Nov-2025,P1SCR,04-Nov-2025,,6225351074,7,622535107407,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,09:40,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110005,03-Nov-2025,P1SCR,04-Nov-2025,04-Nov-2025,6225351074,10,622535107410,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,09:40,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110005,03-Nov-2025,P1SCR,04-Nov-2025,,6225351074,9,622535107409,"Red Cells, Clot",Not Received,,,TSH,,,,,,09:40,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110005,03-Nov-2025,P1SCR,04-Nov-2025,04-Nov-2025,6225351074,6,622535107406,"Urine, no preservative",Received,Ambient,Default Return Ambient,URINE DRUG SCREEN,,,,,,09:40,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110005,03-Nov-2025,P1SCR,04-Nov-2025,04-Nov-2025,6225351074,5,622535107405,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,09:40,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110001,03-Aug-2025,P1SCR,06-Aug-2025,06-Aug-2025,6225351076,2,622535107602,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,09:05,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110001,03-Aug-2025,P1SCR,06-Aug-2025,,6225351076,1,622535107601,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,09:05,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110005,03-Nov-2025,P1SCR,04-Nov-2025,04-Nov-2025,6225351074,8,622535107408,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,09:40,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110001,03-Aug-2025,P1SCR,06-Aug-2025,06-Aug-2025,6225351076,3,622535107603,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,"HEMATOLOGY, A1C, &",RETICULOCYTES,,,,,09:05,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110001,03-Aug-2025,P1SCR,06-Aug-2025,06-Aug-2025,6225351076,5,622535107605,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,09:05,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110001,03-Aug-2025,P1SCR,06-Aug-2025,06-Aug-2025,6225351076,6,622535107606,"Urine, no preservative",Received,Ambient,Default Return Ambient,URINE DRUG SCREEN,,,,,,09:05,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110001,03-Aug-2025,P1SCR,06-Aug-2025,06-Aug-2025,6225351076,4,622535107604,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:05,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110001,03-Aug-2025,P1SCR,06-Aug-2025,,6225351076,7,622535107607,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,09:05,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110001,03-Aug-2025,P1SCR,06-Aug-2025,,6225351076,9,622535107609,"Red Cells, Clot",Not Received,,,TSH,,,,,,09:05,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110001,03-Aug-2025,P1SCR,06-Aug-2025,06-Aug-2025,6225351076,10,622535107610,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,09:05,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110001,03-Aug-2025,P1SCR,06-Aug-2025,07-Aug-2025,6225351076,8,622535107608,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,09:05,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110004,03-Oct-2025,P1SCR,04-Oct-2025,04-Oct-2025,6225351077,3,622535107703,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,"HEMATOLOGY, A1C, &",RETICULOCYTES,,,,,09:33,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110004,03-Oct-2025,P1SCR,04-Oct-2025,,6225351077,1,622535107701,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,09:33,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110004,03-Oct-2025,P1SCR,04-Oct-2025,04-Oct-2025,6225351077,4,622535107704,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:33,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110004,03-Oct-2025,P1SCR,04-Oct-2025,04-Oct-2025,6225351077,5,622535107705,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,09:33,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110004,03-Oct-2025,P1SCR,04-Oct-2025,04-Oct-2025,6225351077,6,622535107706,"Urine, no preservative",Received,Ambient,Default Return Ambient,URINE DRUG SCREEN,,,,,,09:33,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110004,03-Oct-2025,P1SCR,04-Oct-2025,,6225351077,7,622535107707,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,09:33,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110004,03-Oct-2025,P1SCR,04-Oct-2025,04-Oct-2025,6225351077,8,622535107708,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,09:33,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110004,03-Oct-2025,P1SCR,04-Oct-2025,,6225351077,9,622535107709,"Red Cells, Clot",Not Received,,,TSH,,,,,,09:33,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110004,03-Oct-2025,P1SCR,04-Oct-2025,04-Oct-2025,6225351077,10,622535107710,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,09:33,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110004,03-Oct-2025,P1SCR,04-Oct-2025,04-Oct-2025,6225351077,2,622535107702,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,09:33,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,14-Nov-2025,P1SCR,15-Nov-2025,15-Nov-2025,6225351078,5,622535107805,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,10:22,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,14-Nov-2025,P1SCR,15-Nov-2025,15-Nov-2025,6225351078,6,622535107806,"Urine, no preservative",Received,Ambient,Default Return Ambient,URINE DRUG SCREEN,,,,,,10:22,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,14-Nov-2025,P1SCR,15-Nov-2025,,6225351078,7,622535107807,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,10:22,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,14-Nov-2025,P1SCR,15-Nov-2025,15-Nov-2025,6225351078,8,622535107808,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,10:22,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,14-Nov-2025,P1SCR,15-Nov-2025,,6225351078,9,622535107809,"Red Cells, Clot",Not Received,,,TSH,,,,,,10:22,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,14-Nov-2025,P1SCR,15-Nov-2025,15-Nov-2025,6225351078,4,622535107804,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,10:22,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,14-Nov-2025,P1SCR,15-Nov-2025,15-Nov-2025,6225351078,3,622535107803,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,"HEMATOLOGY, A1C, &",RETICULOCYTES,,,,,10:22,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,14-Nov-2025,P1SCR,15-Nov-2025,15-Nov-2025,6225351078,2,622535107802,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,10:22,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,14-Nov-2025,P1SCR,15-Nov-2025,,6225351078,1,622535107801,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,10:22,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,14-Nov-2025,P1SCR,15-Nov-2025,15-Nov-2025,6225351078,10,622535107810,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,10:22,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110006,04-Nov-2025,P1SCR,05-Nov-2025,,6225351080,1,622535108001,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,07:03,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110006,04-Nov-2025,P1SCR,05-Nov-2025,05-Nov-2025,6225351080,2,622535108002,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,07:03,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110006,04-Nov-2025,P1SCR,05-Nov-2025,,6225351080,7,622535108007,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,07:03,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110006,04-Nov-2025,P1SCR,05-Nov-2025,06-Nov-2025,6225351080,8,622535108008,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,07:03,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110006,04-Nov-2025,P1SCR,05-Nov-2025,,6225351080,9,622535108009,"Red Cells, Clot",Not Received,,,TSH,,,,,,07:03,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110006,04-Nov-2025,P1SCR,05-Nov-2025,05-Nov-2025,6225351080,3,622535108003,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,"HEMATOLOGY, A1C, &",RETICULOCYTES,,,,,07:03,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110006,04-Nov-2025,P1SCR,05-Nov-2025,05-Nov-2025,6225351080,10,622535108010,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,07:03,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,26-Sep-2025,P1SCR,27-Sep-2025,,6225351081,1,622535108101,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,09:10,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,26-Sep-2025,P1SCR,27-Sep-2025,27-Sep-2025,6225351081,3,622535108103,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,"HEMATOLOGY, A1C, &",RETICULOCYTES,,,,,09:10,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110006,04-Nov-2025,P1SCR,05-Nov-2025,05-Nov-2025,6225351080,4,622535108004,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,07:03,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,26-Sep-2025,P1SCR,27-Sep-2025,27-Sep-2025,6225351081,4,622535108104,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:10,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,26-Sep-2025,P1SCR,27-Sep-2025,27-Sep-2025,6225351081,2,622535108102,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,09:10,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,26-Sep-2025,P1SCR,27-Sep-2025,27-Sep-2025,6225351081,5,622535108105,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,09:10,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110006,04-Nov-2025,P1SCR,05-Nov-2025,05-Nov-2025,6225351080,5,622535108005,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,07:03,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110006,04-Nov-2025,P1SCR,05-Nov-2025,05-Nov-2025,6225351080,6,622535108006,"Urine, no preservative",Received,Ambient,Default Return Ambient,URINE DRUG SCREEN,,,,,,07:03,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,26-Sep-2025,P1SCR,27-Sep-2025,27-Sep-2025,6225351081,8,622535108108,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,09:10,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,26-Sep-2025,P1SCR,27-Sep-2025,27-Sep-2025,6225351081,10,622535108110,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,09:10,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,26-Sep-2025,P1SCR,27-Sep-2025,,6225351081,9,622535108109,"Red Cells, Clot",Not Received,,,TSH,,,,,,09:10,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110002,28-Aug-2025,P1DBBL,29-Aug-2025,,6225351082,2,622535108202,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,11:45,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,26-Sep-2025,P1SCR,27-Sep-2025,,6225351081,7,622535108107,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,09:10,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110002,28-Aug-2025,P1DBBL,29-Aug-2025,29-Aug-2025,6225351082,3,622535108203,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,11:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110002,28-Aug-2025,P1DBBL,29-Aug-2025,,6225351082,4,622535108204,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,11:45,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,26-Sep-2025,P1SCR,27-Sep-2025,27-Sep-2025,6225351081,6,622535108106,"Urine, no preservative",Received,Ambient,Default Return Ambient,URINE DRUG SCREEN,,,,,,09:10,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110002,28-Aug-2025,P1DBBL,29-Aug-2025,29-Aug-2025,6225351082,5,622535108205,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,11:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110002,28-Aug-2025,P1DBBL,29-Aug-2025,29-Aug-2025,6225351082,6,622535108206,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,11:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110001,28-Aug-2025,P1DBBL,29-Aug-2025,29-Aug-2025,6225351083,1,622535108301,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,07:07,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110001,28-Aug-2025,P1DBBL,29-Aug-2025,,6225351083,2,622535108302,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,07:07,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110001,28-Aug-2025,P1DBBL,29-Aug-2025,29-Aug-2025,6225351083,3,622535108303,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,07:07,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110001,28-Aug-2025,P1DBBL,29-Aug-2025,,6225351083,4,622535108304,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,07:07,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110001,28-Aug-2025,P1DBBL,29-Aug-2025,29-Aug-2025,6225351083,5,622535108305,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,07:07,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110002,28-Aug-2025,P1DBBL,29-Aug-2025,29-Aug-2025,6225351082,1,622535108201,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,11:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110001,28-Aug-2025,P1DBBL,29-Aug-2025,29-Aug-2025,6225351083,6,622535108306,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,07:07,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110002,28-Aug-2025,P1DBBL,29-Aug-2025,29-Aug-2025,6225351082,7,622535108207,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,11:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110001,28-Aug-2025,P1DBBL,29-Aug-2025,29-Aug-2025,6225351083,7,622535108307,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,07:07,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,22-Oct-2025,P1DBBL,23-Oct-2025,23-Oct-2025,6225351084,1,622535108401,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,08:04,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,22-Oct-2025,P1DBBL,23-Oct-2025,,6225351084,4,622535108404,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,08:04,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,22-Oct-2025,P1DBBL,23-Oct-2025,23-Oct-2025,6225351084,3,622535108403,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,08:04,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,22-Oct-2025,P1DBBL,23-Oct-2025,23-Oct-2025,6225351084,5,622535108405,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,08:04,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,22-Oct-2025,P1DBBL,23-Oct-2025,,6225351084,2,622535108402,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,08:04,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,22-Oct-2025,P1DBBL,23-Oct-2025,23-Oct-2025,6225351084,7,622535108407,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,08:04,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,22-Oct-2025,P1DBBL,23-Oct-2025,23-Oct-2025,6225351084,6,622535108406,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,08:04,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,05-Dec-2025,EOT,06-Dec-2025,06-Dec-2025,6225351093,2,622535109302,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:23,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,05-Dec-2025,EOT,06-Dec-2025,06-Dec-2025,6225351093,1,622535109301,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,09:23,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,05-Dec-2025,EOT,06-Dec-2025,06-Dec-2025,6225351093,3,622535109303,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,09:23,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,05-Dec-2025,EOT,06-Dec-2025,06-Dec-2025,6225351093,5,622535109305,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,09:23,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,05-Dec-2025,EOT,06-Dec-2025,,6225351093,4,622535109304,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,09:23,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,05-Dec-2025,EOT,06-Dec-2025,,6225351093,6,622535109306,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,09:23,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,05-Dec-2025,EOT,06-Dec-2025,06-Dec-2025,6225351093,7,622535109307,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,09:23,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,05-Dec-2025,EOT,06-Dec-2025,,6225351093,8,622535109308,"Red Cells, Clot",Not Received,,,TSH,,,,,,09:23,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,05-Dec-2025,EOT,06-Dec-2025,06-Dec-2025,6225351093,9,622535109309,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,09:23,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110001,08-Oct-2025,EOT,09-Oct-2025,09-Oct-2025,6225351094,1,622535109401,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,08:16,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110001,08-Oct-2025,EOT,09-Oct-2025,09-Oct-2025,6225351094,3,622535109403,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,08:16,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110001,08-Oct-2025,EOT,09-Oct-2025,09-Oct-2025,6225351094,2,622535109402,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,08:16,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110001,08-Oct-2025,EOT,09-Oct-2025,,6225351094,4,622535109404,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,08:16,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110001,08-Oct-2025,EOT,09-Oct-2025,09-Oct-2025,6225351094,5,622535109405,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,08:16,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110001,08-Oct-2025,EOT,09-Oct-2025,,6225351094,6,622535109406,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,08:16,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110001,08-Oct-2025,EOT,09-Oct-2025,09-Oct-2025,6225351094,7,622535109407,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,08:16,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110001,08-Oct-2025,EOT,09-Oct-2025,,6225351094,8,622535109408,"Red Cells, Clot",Not Received,,,TSH,,,,,,08:16,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110002,09-Oct-2025,EOT,10-Oct-2025,10-Oct-2025,6225351095,1,622535109501,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,08:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110002,09-Oct-2025,EOT,10-Oct-2025,10-Oct-2025,6225351095,2,622535109502,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,08:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110002,09-Oct-2025,EOT,10-Oct-2025,10-Oct-2025,6225351095,3,622535109503,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,08:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110002,09-Oct-2025,EOT,10-Oct-2025,10-Oct-2025,6225351095,5,622535109505,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,08:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110002,09-Oct-2025,EOT,10-Oct-2025,10-Oct-2025,6225351095,7,622535109507,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,08:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110002,09-Oct-2025,EOT,10-Oct-2025,,6225351095,8,622535109508,"Red Cells, Clot",Not Received,,,TSH,,,,,,08:45,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110002,09-Oct-2025,EOT,10-Oct-2025,,6225351095,4,622535109504,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,08:45,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110002,09-Oct-2025,EOT,10-Oct-2025,,6225351095,6,622535109506,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,08:45,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110001,08-Oct-2025,EOT,09-Oct-2025,09-Oct-2025,6225351094,9,622535109409,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,08:16,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110002,09-Oct-2025,EOT,10-Oct-2025,10-Oct-2025,6225351095,9,622535109509,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,08:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120001,06-Aug-2025,P1SCR,07-Aug-2025,,6225351106,1,622535110601,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,13:35,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120001,06-Aug-2025,P1SCR,07-Aug-2025,07-Aug-2025,6225351106,2,622535110602,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,13:35,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120001,06-Aug-2025,P1SCR,07-Aug-2025,07-Aug-2025,6225351106,4,622535110604,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,13:35,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120001,06-Aug-2025,P1SCR,07-Aug-2025,07-Aug-2025,6225351106,5,622535110605,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,13:35,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120001,06-Aug-2025,P1SCR,07-Aug-2025,07-Aug-2025,6225351106,3,622535110603,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,"HEMATOLOGY, A1C, &",RETICULOCYTES,,,,,13:35,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120001,06-Aug-2025,P1SCR,07-Aug-2025,07-Aug-2025,6225351106,6,622535110606,"Urine, no preservative",Received,Ambient,Default Return Ambient,URINE DRUG SCREEN,,,,,,13:35,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120001,06-Aug-2025,P1SCR,07-Aug-2025,,6225351106,7,622535110607,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,13:35,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120001,06-Aug-2025,P1SCR,07-Aug-2025,08-Aug-2025,6225351106,8,622535110608,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,13:35,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120001,06-Aug-2025,P1SCR,07-Aug-2025,,6225351106,9,622535110609,"Red Cells, Clot",Not Received,,,TSH,,,,,,13:35,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120001,06-Aug-2025,P1SCR,07-Aug-2025,07-Aug-2025,6225351106,10,622535110610,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,13:35,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120002,03-Sep-2025,P1SCR,04-Sep-2025,,6225351109,1,622535110901,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,13:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120002,03-Sep-2025,P1SCR,04-Sep-2025,04-Sep-2025,6225351109,4,622535110904,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,13:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120002,03-Sep-2025,P1SCR,04-Sep-2025,04-Sep-2025,6225351109,5,622535110905,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,13:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120002,03-Sep-2025,P1SCR,04-Sep-2025,04-Sep-2025,6225351109,6,622535110906,"Urine, no preservative",Received,Ambient,Default Return Ambient,URINE DRUG SCREEN,,,,,,13:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120002,03-Sep-2025,P1SCR,04-Sep-2025,,6225351109,7,622535110907,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,13:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120002,03-Sep-2025,P1SCR,04-Sep-2025,05-Sep-2025,6225351109,8,622535110908,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,13:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120002,03-Sep-2025,P1SCR,04-Sep-2025,04-Sep-2025,6225351109,2,622535110902,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,13:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120002,03-Sep-2025,P1SCR,04-Sep-2025,,6225351109,9,622535110909,"Red Cells, Clot",Not Received,,,TSH,,,,,,13:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120002,03-Sep-2025,P1SCR,04-Sep-2025,04-Sep-2025,6225351109,10,622535110910,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,13:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120003,01-Oct-2025,P1SCR,02-Oct-2025,,6225351110,1,622535111001,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,11:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120003,01-Oct-2025,P1SCR,02-Oct-2025,02-Oct-2025,6225351110,2,622535111002,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,11:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120003,01-Oct-2025,P1SCR,02-Oct-2025,02-Oct-2025,6225351110,3,622535111003,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,"HEMATOLOGY, A1C, &",RETICULOCYTES,,,,,11:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120003,01-Oct-2025,P1SCR,02-Oct-2025,02-Oct-2025,6225351110,4,622535111004,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,11:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120003,01-Oct-2025,P1SCR,02-Oct-2025,02-Oct-2025,6225351110,5,622535111005,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,11:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120003,01-Oct-2025,P1SCR,02-Oct-2025,02-Oct-2025,6225351110,6,622535111006,"Urine, no preservative",Received,Ambient,Default Return Ambient,URINE DRUG SCREEN,,,,,,11:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120003,01-Oct-2025,P1SCR,02-Oct-2025,,6225351110,7,622535111007,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,11:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120002,03-Sep-2025,P1SCR,04-Sep-2025,04-Sep-2025,6225351109,3,622535110903,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,"HEMATOLOGY, A1C, &",RETICULOCYTES,,,,,13:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120003,01-Oct-2025,P1SCR,02-Oct-2025,,6225351110,9,622535111009,"Red Cells, Clot",Not Received,,,TSH,,,,,,11:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120003,01-Oct-2025,P1SCR,02-Oct-2025,03-Oct-2025,6225351110,8,622535111008,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,11:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120003,01-Oct-2025,P1SCR,02-Oct-2025,02-Oct-2025,6225351110,10,622535111010,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,11:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120004,01-Oct-2025,P1SCR,02-Oct-2025,,6225351111,1,622535111101,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,13:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120004,01-Oct-2025,P1SCR,02-Oct-2025,02-Oct-2025,6225351111,2,622535111102,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,13:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120004,01-Oct-2025,P1SCR,02-Oct-2025,02-Oct-2025,6225351111,3,622535111103,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,"HEMATOLOGY, A1C, &",RETICULOCYTES,,,,,13:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120004,01-Oct-2025,P1SCR,02-Oct-2025,02-Oct-2025,6225351111,4,622535111104,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,13:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120004,01-Oct-2025,P1SCR,02-Oct-2025,02-Oct-2025,6225351111,5,622535111105,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,13:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120004,01-Oct-2025,P1SCR,02-Oct-2025,02-Oct-2025,6225351111,6,622535111106,"Urine, no preservative",Received,Ambient,Default Return Ambient,URINE DRUG SCREEN,,,,,,13:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120004,01-Oct-2025,P1SCR,02-Oct-2025,03-Oct-2025,6225351111,8,622535111108,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,13:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120004,01-Oct-2025,P1SCR,02-Oct-2025,,6225351111,9,622535111109,"Red Cells, Clot",Not Received,,,TSH,,,,,,13:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120004,01-Oct-2025,P1SCR,02-Oct-2025,,6225351111,7,622535111107,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,13:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120004,01-Oct-2025,P1SCR,02-Oct-2025,02-Oct-2025,6225351111,10,622535111110,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,13:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120004,22-Oct-2025,P1DBBL,23-Oct-2025,23-Oct-2025,6225351120,1,622535112001,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,12:15,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120004,22-Oct-2025,P1DBBL,23-Oct-2025,,6225351120,2,622535112002,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,12:15,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120004,22-Oct-2025,P1DBBL,23-Oct-2025,24-Oct-2025,6225351120,3,622535112003,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,12:15,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120004,22-Oct-2025,P1DBBL,23-Oct-2025,,6225351120,4,622535112004,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,12:15,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120004,22-Oct-2025,P1DBBL,23-Oct-2025,23-Oct-2025,6225351120,5,622535112005,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,12:15,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120004,22-Oct-2025,P1DBBL,23-Oct-2025,23-Oct-2025,6225351120,6,622535112006,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,12:15,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120004,22-Oct-2025,P1DBBL,23-Oct-2025,23-Oct-2025,6225351120,7,622535112007,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,12:15,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120004,05-Dec-2025,EOT,06-Dec-2025,06-Dec-2025,6225351126,2,622535112602,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,15:00,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120004,05-Dec-2025,EOT,06-Dec-2025,06-Dec-2025,6225351126,1,622535112601,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,15:00,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120004,05-Dec-2025,EOT,06-Dec-2025,06-Dec-2025,6225351126,3,622535112603,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,15:00,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120004,05-Dec-2025,EOT,06-Dec-2025,,6225351126,4,622535112604,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,15:00,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120004,05-Dec-2025,EOT,06-Dec-2025,10-Dec-2025,6225351126,5,622535112605,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,15:00,07:00,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120004,05-Dec-2025,EOT,06-Dec-2025,,6225351126,6,622535112606,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,15:00,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120004,05-Dec-2025,EOT,06-Dec-2025,,6225351126,8,622535112608,"Red Cells, Clot",Not Received,,,TSH,,,,,,15:00,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120004,05-Dec-2025,EOT,06-Dec-2025,06-Dec-2025,6225351126,7,622535112607,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,15:00,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120004,05-Dec-2025,EOT,06-Dec-2025,06-Dec-2025,6225351126,9,622535112609,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,15:00,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,01-Apr-2026,P2OLD29,02-Apr-2026,,6226313625,2,622631362502,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,11:10,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,01-Apr-2026,P2OLD29,02-Apr-2026,02-Apr-2026,6226313625,1,622631362501,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,11:10,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,01-Apr-2026,P2OLD29,02-Apr-2026,02-Apr-2026,6226313625,3,622631362503,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,11:10,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,01-Apr-2026,P2OLD29,02-Apr-2026,02-Apr-2026,6226313625,5,622631362505,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,11:10,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,01-Apr-2026,P2OLD29,02-Apr-2026,,6226313625,4,622631362504,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,11:10,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,01-Apr-2026,P2OLD29,02-Apr-2026,02-Apr-2026,6226313625,6,622631362506,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,11:10,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,01-Apr-2026,P2OLD29,02-Apr-2026,02-Apr-2026,6226313625,7,622631362507,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,11:10,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,16-Feb-2026,P2OLD29,17-Feb-2026,,6226550646,2,622655064602,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,09:18,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,16-Feb-2026,P2OLD29,17-Feb-2026,17-Feb-2026,6226550646,1,622655064601,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,09:18,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,16-Feb-2026,P2OLD29,17-Feb-2026,17-Feb-2026,6226550646,7,622655064607,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:18,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,16-Feb-2026,P2OLD29,17-Feb-2026,17-Feb-2026,6226550646,5,622655064605,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,09:18,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,16-Feb-2026,P2OLD29,17-Feb-2026,,6226550646,4,622655064604,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,09:18,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,16-Feb-2026,P2OLD29,17-Feb-2026,17-Feb-2026,6226550646,6,622655064606,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,09:18,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,16-Feb-2026,P2OLD29,17-Feb-2026,17-Feb-2026,6226550646,3,622655064603,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,09:18,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,21-Jan-2026,P1DBBL,22-Jan-2026,,6226551697,4,622655169704,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,11:23,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,21-Jan-2026,P1DBBL,22-Jan-2026,22-Jan-2026,6226551697,5,622655169705,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,11:23,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,21-Jan-2026,P1DBBL,22-Jan-2026,22-Jan-2026,6226551697,1,622655169701,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,11:23,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,21-Jan-2026,P1DBBL,22-Jan-2026,22-Jan-2026,6226551697,6,622655169706,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,11:23,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,21-Jan-2026,P1DBBL,22-Jan-2026,22-Jan-2026,6226551697,7,622655169707,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,11:23,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,29-Oct-2025,P1DBBL,30-Oct-2025,30-Oct-2025,6226551698,1,622655169801,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,10:10,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,21-Jan-2026,P1DBBL,22-Jan-2026,22-Jan-2026,6226551697,3,622655169703,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,11:23,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,29-Oct-2025,P1DBBL,30-Oct-2025,,6226551698,4,622655169804,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,10:10,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,21-Jan-2026,P1DBBL,22-Jan-2026,,6226551697,2,622655169702,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,11:23,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,29-Oct-2025,P1DBBL,30-Oct-2025,,6226551698,2,622655169802,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,10:10,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,29-Oct-2025,P1DBBL,30-Oct-2025,30-Oct-2025,6226551698,6,622655169806,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,10:10,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,29-Oct-2025,P1DBBL,30-Oct-2025,30-Oct-2025,6226551698,3,622655169803,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,10:10,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,29-Oct-2025,P1DBBL,30-Oct-2025,30-Oct-2025,6226551698,5,622655169805,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,10:10,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,29-Oct-2025,P1DBBL,30-Oct-2025,30-Oct-2025,6226551698,7,622655169807,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,10:10,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120005,23-Apr-2026,P2OLD29,25-Apr-2026,,6226560887,4,622656088704,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,16:00,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120005,23-Apr-2026,P2OLD29,25-Apr-2026,20-May-2026,6226560887,3,622656088703,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,16:00,07:00,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120005,23-Apr-2026,P2OLD29,25-Apr-2026,,6226560887,2,622656088702,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,16:00,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120005,23-Apr-2026,P2OLD29,25-Apr-2026,25-Apr-2026,6226560887,1,622656088701,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,16:00,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120005,23-Apr-2026,P2OLD29,25-Apr-2026,25-Apr-2026,6226560887,5,622656088705,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,16:00,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120005,23-Apr-2026,P2OLD29,25-Apr-2026,25-Apr-2026,6226560887,6,622656088706,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,16:00,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120005,25-Mar-2026,EOT,26-Mar-2026,26-Mar-2026,6226560888,1,622656088801,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,17:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120005,23-Apr-2026,P2OLD29,25-Apr-2026,25-Apr-2026,6226560887,7,622656088707,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,16:00,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120005,25-Mar-2026,EOT,26-Mar-2026,26-Mar-2026,6226560888,3,622656088803,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,17:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120005,25-Mar-2026,EOT,26-Mar-2026,26-Mar-2026,6226560888,7,622656088807,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,17:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120005,25-Mar-2026,EOT,26-Mar-2026,26-Mar-2026,6226560888,9,622656088809,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,17:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120005,25-Mar-2026,EOT,26-Mar-2026,20-May-2026,6226560888,5,622656088805,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,17:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120005,25-Mar-2026,EOT,26-Mar-2026,,6226560888,4,622656088804,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,17:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120005,25-Mar-2026,EOT,26-Mar-2026,,6226560888,8,622656088808,"Red Cells, Clot",Not Received,,,TSH,,,,,,17:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120005,25-Mar-2026,EOT,26-Mar-2026,26-Mar-2026,6226560888,2,622656088802,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,17:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120005,25-Mar-2026,EOT,26-Mar-2026,,6226560888,6,622656088806,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,17:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120004,06-Mar-2026,P2DBW25,07-Mar-2026,07-Mar-2026,6226560891,2,622656089102,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,14:00,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 DB Every 12 Weeks,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120004,06-Mar-2026,P2DBW25,07-Mar-2026,07-Mar-2026,6226560891,3,622656089103,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,14:00,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 DB Every 12 Weeks,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120004,06-Mar-2026,P2DBW25,07-Mar-2026,07-Mar-2026,6226560891,1,622656089101,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,14:00,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 DB Every 12 Weeks,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120004,06-Mar-2026,P2DBW25,07-Mar-2026,,6226560891,4,622656089104,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,14:00,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 DB Every 12 Weeks,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120004,06-Mar-2026,P2DBW25,07-Mar-2026,,6226560891,6,622656089106,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,14:00,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 DB Every 12 Weeks,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120004,06-Mar-2026,P2DBW25,07-Mar-2026,,6226560891,8,622656089108,"Red Cells, Clot",Not Received,,,TSH,,,,,,14:00,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 DB Every 12 Weeks,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120004,06-Mar-2026,P2DBW25,07-Mar-2026,20-May-2026,6226560891,5,622656089105,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,14:00,07:00,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 DB Every 12 Weeks,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120004,06-Mar-2026,P2DBW25,07-Mar-2026,07-Mar-2026,6226560891,7,622656089107,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,14:00,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 DB Every 12 Weeks,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120004,06-Mar-2026,P2DBW25,07-Mar-2026,07-Mar-2026,6226560891,9,622656089109,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,14:00,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 DB Every 12 Weeks,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110006,03-Feb-2026,P2OLD29,04-Feb-2026,17-Feb-2026,6226561517,3,622656151703,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,10:23,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110006,03-Feb-2026,P2OLD29,04-Feb-2026,,6226561517,4,622656151704,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,10:23,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110006,03-Feb-2026,P2OLD29,04-Feb-2026,04-Feb-2026,6226561517,5,622656151705,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,10:23,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110006,03-Feb-2026,P2OLD29,04-Feb-2026,,6226561517,2,622656151702,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,10:23,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110006,03-Feb-2026,P2OLD29,04-Feb-2026,04-Feb-2026,6226561517,1,622656151701,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,10:23,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110006,03-Feb-2026,P2OLD29,04-Feb-2026,04-Feb-2026,6226561517,6,622656151706,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,10:23,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110006,03-Feb-2026,P2OLD29,04-Feb-2026,04-Feb-2026,6226561517,7,622656151707,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,10:23,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040009,05-Jun-2026,P2OLD29,06-Jun-2026,06-Jun-2026,6226573502,1,622657350201,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,11:15,07:15,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040009,05-Jun-2026,P2OLD29,06-Jun-2026,,6226573502,2,622657350202,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,11:15,,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040009,05-Jun-2026,P2OLD29,06-Jun-2026,,6226573502,3,622657350203,"Plasma, EDTA",Not Received,Frozen,Specimen not submitted,INSULIN,FROZEN,,,,,11:15,,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040009,05-Jun-2026,P2OLD29,06-Jun-2026,06-Jun-2026,6226573502,5,622657350205,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,11:15,07:15,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040009,05-Jun-2026,P2OLD29,06-Jun-2026,,6226573502,4,622657350204,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,11:15,,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040009,05-Jun-2026,P2OLD29,06-Jun-2026,06-Jun-2026,6226573502,6,622657350206,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,11:15,07:15,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040009,05-Jun-2026,P2OLD29,06-Jun-2026,06-Jun-2026,6226573502,7,622657350207,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,11:15,07:15,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,29-May-2026,P2DBW13,30-May-2026,30-May-2026,6226649754,1,622664975401,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,09:30,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 DB Week 13,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,29-May-2026,P2DBW13,30-May-2026,,6226649754,2,622664975402,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,09:30,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 DB Week 13,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,29-May-2026,P2DBW13,30-May-2026,,6226649754,4,622664975404,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,09:30,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 DB Week 13,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,29-May-2026,P2DBW13,30-May-2026,03-Jun-2026,6226649754,3,622664975403,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,09:30,07:00,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 DB Week 13,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,29-May-2026,P2DBW13,30-May-2026,30-May-2026,6226649754,5,622664975405,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,09:30,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 DB Week 13,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,29-May-2026,P2DBW13,30-May-2026,30-May-2026,6226649754,6,622664975406,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,09:30,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 DB Week 13,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,29-May-2026,P2DBW13,30-May-2026,30-May-2026,6226649754,7,622664975407,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:30,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 DB Week 13,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080001,08-Oct-2025,P2OLD29,09-Oct-2025,09-Oct-2025,6226686952,1,622668695201,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,09:20,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080001,08-Oct-2025,P2OLD29,09-Oct-2025,,6226686952,2,622668695202,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,09:20,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080001,08-Oct-2025,P2OLD29,09-Oct-2025,09-Oct-2025,6226686952,3,622668695203,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,09:20,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080001,08-Oct-2025,P2OLD29,09-Oct-2025,,6226686952,4,622668695204,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,09:20,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080001,08-Oct-2025,P2OLD29,09-Oct-2025,09-Oct-2025,6226686952,5,622668695205,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,09:20,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080001,08-Oct-2025,P2OLD29,09-Oct-2025,09-Oct-2025,6226686952,6,622668695206,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,09:20,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080001,08-Oct-2025,P2OLD29,09-Oct-2025,09-Oct-2025,6226686952,7,622668695207,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:20,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,13-Jan-2026,P2DBBL,14-Jan-2026,14-Jan-2026,6226686953,1,622668695301,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,13:15,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,13-Jan-2026,P2DBBL,14-Jan-2026,14-Jan-2026,6226686953,2,622668695302,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,13:15,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,13-Jan-2026,P2DBBL,14-Jan-2026,14-Jan-2026,6226686953,3,622668695303,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,13:15,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,13-Jan-2026,P2DBBL,14-Jan-2026,,6226686953,4,622668695304,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,13:15,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,13-Jan-2026,P2DBBL,14-Jan-2026,14-Jan-2026,6226686953,5,622668695305,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,13:15,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,13-Jan-2026,P2DBBL,14-Jan-2026,,6226686953,6,622668695306,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,13:15,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,07-Apr-2026,P2DBW13,08-Apr-2026,08-Apr-2026,6226686954,7,622668695407,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,12:01,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 DB Week 13,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,13-Jan-2026,P2DBBL,14-Jan-2026,,6226686953,8,622668695308,"Red Cells, Clot",Not Received,,,TSH,,,,,,13:15,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,13-Jan-2026,P2DBBL,14-Jan-2026,14-Jan-2026,6226686953,9,622668695309,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,13:15,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,13-Jan-2026,P2DBBL,14-Jan-2026,14-Jan-2026,6226686953,7,622668695307,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,13:15,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,07-Apr-2026,P2DBW13,08-Apr-2026,08-Apr-2026,6226686954,1,622668695401,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,12:01,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 DB Week 13,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,07-Apr-2026,P2DBW13,08-Apr-2026,08-Apr-2026,6226686954,3,622668695403,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,12:01,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 DB Week 13,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,07-Apr-2026,P2DBW13,08-Apr-2026,,6226686954,4,622668695404,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,12:01,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 DB Week 13,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,07-Apr-2026,P2DBW13,08-Apr-2026,08-Apr-2026,6226686954,5,622668695405,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,12:01,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 DB Week 13,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,07-Apr-2026,P2DBW13,08-Apr-2026,08-Apr-2026,6226686954,6,622668695406,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,12:01,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 DB Week 13,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,07-Apr-2026,P2DBW13,08-Apr-2026,,6226686954,2,622668695402,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,12:01,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 DB Week 13,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120006,22-Apr-2026,P2OLD29,23-Apr-2026,23-Apr-2026,6226752554,6,622675255406,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,15:30,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120006,25-Mar-2026,EOT,26-Mar-2026,26-Mar-2026,6226752555,2,622675255502,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,15:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120006,22-Apr-2026,P2OLD29,23-Apr-2026,23-Apr-2026,6226752554,5,622675255405,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,15:30,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120006,25-Mar-2026,EOT,26-Mar-2026,26-Mar-2026,6226752555,3,622675255503,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,15:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120006,22-Apr-2026,P2OLD29,23-Apr-2026,,6226752554,4,622675255404,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,15:30,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120006,22-Apr-2026,P2OLD29,23-Apr-2026,23-Apr-2026,6226752554,7,622675255407,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,15:30,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120006,25-Mar-2026,EOT,26-Mar-2026,,6226752555,4,622675255504,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,15:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120006,25-Mar-2026,EOT,26-Mar-2026,20-May-2026,6226752555,5,622675255505,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,15:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120006,22-Apr-2026,P2OLD29,23-Apr-2026,,6226752554,2,622675255402,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,15:30,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120006,22-Apr-2026,P2OLD29,23-Apr-2026,23-Apr-2026,6226752554,3,622675255403,"Plasma, EDTA",Received,Frozen,Default Return Ambient,INSULIN,FROZEN,,,,,15:30,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120006,22-Apr-2026,P2OLD29,23-Apr-2026,23-Apr-2026,6226752554,1,622675255401,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,15:30,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120006,25-Mar-2026,EOT,26-Mar-2026,26-Mar-2026,6226752555,1,622675255501,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,15:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120006,25-Mar-2026,EOT,26-Mar-2026,26-Mar-2026,6226752555,7,622675255507,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,15:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120006,25-Mar-2026,EOT,26-Mar-2026,,6226752555,8,622675255508,"Red Cells, Clot",Not Received,,,TSH,,,,,,15:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120006,25-Mar-2026,EOT,26-Mar-2026,26-Mar-2026,6226752555,9,622675255509,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,15:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120006,25-Mar-2026,EOT,26-Mar-2026,,6226752555,6,622675255506,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,15:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080001,05-Nov-2025,EOT,06-Nov-2025,06-Nov-2025,6226780853,1,622678085301,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,12:50,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080001,05-Nov-2025,EOT,06-Nov-2025,06-Nov-2025,6226780853,5,622678085305,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,12:50,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080001,05-Nov-2025,EOT,06-Nov-2025,06-Nov-2025,6226780853,2,622678085302,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,12:50,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080001,05-Nov-2025,EOT,06-Nov-2025,06-Nov-2025,6226780853,3,622678085303,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,12:50,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080001,05-Nov-2025,EOT,06-Nov-2025,,6226780853,4,622678085304,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,12:50,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080001,05-Nov-2025,EOT,06-Nov-2025,,6226780853,8,622678085308,"Red Cells, Clot",Not Received,,,TSH,,,,,,12:50,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080001,05-Nov-2025,EOT,06-Nov-2025,06-Nov-2025,6226780853,9,622678085309,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,12:50,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080001,05-Nov-2025,EOT,06-Nov-2025,,6226780853,6,622678085306,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,12:50,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080001,05-Nov-2025,EOT,06-Nov-2025,06-Nov-2025,6226780853,7,622678085307,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,12:50,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,09-Dec-2025,EOT,10-Dec-2025,10-Dec-2025,6226780855,1,622678085501,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,11:35,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,09-Dec-2025,EOT,10-Dec-2025,10-Dec-2025,6226780855,2,622678085502,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,11:35,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,09-Dec-2025,EOT,10-Dec-2025,,6226780855,4,622678085504,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,11:35,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,09-Dec-2025,EOT,10-Dec-2025,10-Dec-2025,6226780855,5,622678085505,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,11:35,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,09-Dec-2025,EOT,10-Dec-2025,,6226780855,6,622678085506,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,11:35,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,09-Dec-2025,EOT,10-Dec-2025,10-Dec-2025,6226780855,7,622678085507,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,11:35,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,09-Dec-2025,EOT,10-Dec-2025,,6226780855,8,622678085508,"Red Cells, Clot",Not Received,,,TSH,,,,,,11:35,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,09-Dec-2025,EOT,10-Dec-2025,10-Dec-2025,6226780855,9,622678085509,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,11:35,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,09-Dec-2025,EOT,10-Dec-2025,10-Dec-2025,6226780855,3,622678085503,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,11:35,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080005,18-Nov-2025,EOT,19-Nov-2025,19-Nov-2025,6226780856,1,622678085601,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,11:06,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080005,18-Nov-2025,EOT,19-Nov-2025,19-Nov-2025,6226780856,2,622678085602,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,11:06,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080005,18-Nov-2025,EOT,19-Nov-2025,19-Nov-2025,6226780856,3,622678085603,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,11:06,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080005,18-Nov-2025,EOT,19-Nov-2025,,6226780856,4,622678085604,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,11:06,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080005,18-Nov-2025,EOT,19-Nov-2025,,6226780856,6,622678085606,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,11:06,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080005,18-Nov-2025,EOT,19-Nov-2025,19-Nov-2025,6226780856,7,622678085607,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,11:06,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080005,18-Nov-2025,EOT,19-Nov-2025,,6226780856,8,622678085608,"Red Cells, Clot",Not Received,,,TSH,,,,,,11:06,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080005,18-Nov-2025,EOT,19-Nov-2025,19-Nov-2025,6226780856,9,622678085609,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,11:06,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080005,14-Jan-2026,EOT,15-Jan-2026,15-Jan-2026,6226780857,3,622678085703,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,11:18,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080005,14-Jan-2026,EOT,15-Jan-2026,,6226780857,6,622678085706,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,11:18,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080005,14-Jan-2026,EOT,15-Jan-2026,15-Jan-2026,6226780857,5,622678085705,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,11:18,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080005,14-Jan-2026,EOT,15-Jan-2026,15-Jan-2026,6226780857,7,622678085707,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,11:18,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080005,14-Jan-2026,EOT,15-Jan-2026,,6226780857,8,622678085708,"Red Cells, Clot",Not Received,,,TSH,,,,,,11:18,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080005,14-Jan-2026,EOT,15-Jan-2026,15-Jan-2026,6226780857,9,622678085709,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,11:18,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080005,14-Jan-2026,EOT,15-Jan-2026,15-Jan-2026,6226780857,1,622678085701,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,11:18,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080005,14-Jan-2026,EOT,15-Jan-2026,,6226780857,4,622678085704,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,11:18,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080005,14-Jan-2026,EOT,15-Jan-2026,15-Jan-2026,6226780857,2,622678085702,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,11:18,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080005,18-Nov-2025,EOT,19-Nov-2025,19-Nov-2025,6226780856,5,622678085605,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,11:06,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,18-Feb-2026,P1DBBL,19-Feb-2026,,6226785739,3,622678573903,"Urine, Cargile Preservative UA",Not Received,Ambient,,URINALYSIS,,,,,,10:35,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,18-Feb-2026,P1DBBL,19-Feb-2026,,6226785739,2,622678573902,"Slides, Hematology",Not Received,Ambient,,HEMATOLOGY,,,,,,10:35,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,18-Feb-2026,P1DBBL,19-Feb-2026,,6226785739,4,622678573904,"Urine, no preservative",Not Received,Ambient,,URINE DRUG SCREEN,,,,,,10:35,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,18-Feb-2026,P1DBBL,19-Feb-2026,,6226785739,7,622678573907,"Red Cells, Clot",Not Received,,,TSH,,,,,,10:35,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,18-Feb-2026,P1DBBL,19-Feb-2026,,6226785739,9,622678573909,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,10:35,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,18-Feb-2026,P1DBBL,19-Feb-2026,,6226785739,5,622678573905,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,10:35,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,18-Feb-2026,P1DBBL,19-Feb-2026,,6226785739,6,622678573906,"Plasma, EDTA",Not Received,Frozen,,INSULIN,FROZEN,,,,,10:35,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,18-Feb-2026,P1DBBL,19-Feb-2026,,6226785739,8,622678573908,"Serum, SST",Not Received,Ambient,,TSH,,,,,,10:35,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,18-Feb-2026,P1DBBL,19-Feb-2026,,6226785739,1,622678573901,"Whole Blood, EDTA, Dry",Not Received,Ambient,,HEMATOLOGY,,,,,,10:35,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,18-Feb-2026,P1DBBL,19-Feb-2026,19-Feb-2026,6226785739,10,622678573910,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,10:35,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,15-Dec-2025,P1SCR,16-Dec-2025,,6226785740,1,622678574001,"Whole Blood, EDTA, Dry",Not Received,Ambient,,HEMATOLOGY,,,,,,10:53,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,15-Dec-2025,P1SCR,16-Dec-2025,,6226785740,7,622678574007,"Red Cells, Clot",Not Received,,,TSH,,,,,,10:53,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,15-Dec-2025,P1SCR,16-Dec-2025,,6226785740,5,622678574005,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,10:53,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,15-Dec-2025,P1SCR,16-Dec-2025,16-Dec-2025,6226785740,8,622678574008,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,10:53,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,15-Dec-2025,P1SCR,16-Dec-2025,,6226785740,2,622678574002,"Slides, Hematology",Not Received,Ambient,,HEMATOLOGY,,,,,,10:53,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,15-Dec-2025,P1SCR,16-Dec-2025,,6226785740,6,622678574006,"Plasma, EDTA",Not Received,Frozen,,INSULIN,FROZEN,,,,,10:53,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,15-Dec-2025,P1SCR,16-Dec-2025,,6226785740,3,622678574003,"Urine, Cargile Preservative UA",Not Received,Ambient,,URINALYSIS,,,,,,10:53,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,15-Dec-2025,P1SCR,16-Dec-2025,,6226785740,4,622678574004,"Urine, no preservative",Not Received,Ambient,,URINE DRUG SCREEN,,,,,,10:53,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,15-Dec-2025,P1SCR,16-Dec-2025,,6226785740,9,622678574009,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,10:53,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,15-Dec-2025,P1SCR,16-Dec-2025,16-Dec-2025,6226785740,10,622678574010,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,10:53,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,04-Nov-2025,P2OLD29,05-Nov-2025,,6226804961,2,622680496102,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,12:05,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,04-Nov-2025,P2OLD29,05-Nov-2025,,6226804961,4,622680496104,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,12:05,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,04-Nov-2025,P2OLD29,05-Nov-2025,05-Nov-2025,6226804961,3,622680496103,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,12:05,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,10-Mar-2026,P2DBBL,11-Mar-2026,11-Mar-2026,6226804962,5,622680496205,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,11:10,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,10-Mar-2026,P2DBBL,11-Mar-2026,11-Mar-2026,6226804962,7,622680496207,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,11:10,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,10-Mar-2026,P2DBBL,11-Mar-2026,11-Mar-2026,6226804962,9,622680496209,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,11:10,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,04-Nov-2025,P2OLD29,05-Nov-2025,05-Nov-2025,6226804961,6,622680496106,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,12:05,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,04-Nov-2025,P2OLD29,05-Nov-2025,05-Nov-2025,6226804961,5,622680496105,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,12:05,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,10-Mar-2026,P2DBBL,11-Mar-2026,11-Mar-2026,6226804962,3,622680496203,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,11:10,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,04-Nov-2025,P2OLD29,05-Nov-2025,05-Nov-2025,6226804961,1,622680496101,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,12:05,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,10-Mar-2026,P2DBBL,11-Mar-2026,,6226804962,4,622680496204,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,11:10,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,10-Mar-2026,P2DBBL,11-Mar-2026,,6226804962,8,622680496208,"Red Cells, Clot",Not Received,,,TSH,,,,,,11:10,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,04-Nov-2025,P2OLD29,05-Nov-2025,05-Nov-2025,6226804961,7,622680496107,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,12:05,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,10-Mar-2026,P2DBBL,11-Mar-2026,,6226804962,6,622680496206,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,11:10,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,10-Mar-2026,P2DBBL,11-Mar-2026,11-Mar-2026,6226804962,2,622680496202,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,11:10,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,10-Mar-2026,P2DBBL,11-Mar-2026,11-Mar-2026,6226804962,1,622680496201,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,11:10,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040007,05-Jun-2026,P2OLD29,06-Jun-2026,06-Jun-2026,6226889397,1,622688939701,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,10:35,07:15,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040007,05-Jun-2026,P2OLD29,06-Jun-2026,,6226889397,2,622688939702,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,10:35,,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040007,05-Jun-2026,P2OLD29,06-Jun-2026,,6226889397,3,622688939703,"Plasma, EDTA",Not Received,Frozen,Specimen not submitted,INSULIN,FROZEN,,,,,10:35,,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040007,05-Jun-2026,P2OLD29,06-Jun-2026,,6226889397,4,622688939704,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,10:35,,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040007,05-Jun-2026,P2OLD29,06-Jun-2026,06-Jun-2026,6226889397,5,622688939705,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,10:35,07:15,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040007,05-Jun-2026,P2OLD29,06-Jun-2026,06-Jun-2026,6226889397,6,622688939706,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,10:35,07:15,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040007,05-Jun-2026,P2OLD29,06-Jun-2026,06-Jun-2026,6226889397,7,622688939707,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,10:35,07:15,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,11-Dec-2025,EOT,13-Dec-2025,13-Dec-2025,6226935606,2,622693560602,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:05,21:00,Czech Republic,,21:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,11-Dec-2025,EOT,13-Dec-2025,,6226935606,4,622693560604,"Urine, no preservative",Not Received,Ambient,,URINE DRUG SCREEN,,,,,,09:05,,Czech Republic,,21:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,11-Dec-2025,EOT,13-Dec-2025,13-Dec-2025,6226935606,3,622693560603,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,09:05,21:00,Czech Republic,,21:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,11-Dec-2025,EOT,13-Dec-2025,,6226935606,5,622693560605,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,09:05,,Czech Republic,,21:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,11-Dec-2025,EOT,13-Dec-2025,13-Dec-2025,6226935606,1,622693560601,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,09:05,21:00,Czech Republic,,21:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,11-Dec-2025,EOT,13-Dec-2025,,6226935606,7,622693560607,"Red Cells, Clot",Not Received,,,TSH,,,,,,09:05,,Czech Republic,,21:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,11-Dec-2025,EOT,13-Dec-2025,16-Dec-2025,6226935606,6,622693560606,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,09:05,05:55,Czech Republic,,21:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,11-Dec-2025,EOT,13-Dec-2025,13-Dec-2025,6226935606,8,622693560608,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,09:05,21:00,Czech Republic,,21:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,11-Dec-2025,EOT,13-Dec-2025,,6226935606,9,622693560609,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,09:05,,Czech Republic,,21:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120004,02-Jan-2026,P2OLD29,03-Jan-2026,03-Jan-2026,6226976943,1,622697694301,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,12:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120004,02-Jan-2026,P2OLD29,03-Jan-2026,,6226976943,2,622697694302,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,12:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120004,02-Jan-2026,P2OLD29,03-Jan-2026,31-Jan-2026,6226976943,3,622697694303,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,12:00,07:20,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120004,02-Jan-2026,P2OLD29,03-Jan-2026,,6226976943,4,622697694304,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,12:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120004,02-Jan-2026,P2OLD29,03-Jan-2026,03-Jan-2026,6226976943,6,622697694306,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,12:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120004,02-Jan-2026,P2OLD29,03-Jan-2026,03-Jan-2026,6226976943,7,622697694307,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,12:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120004,02-Jan-2026,P2OLD29,03-Jan-2026,03-Jan-2026,6226976943,5,622697694305,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,12:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110002,06-Nov-2025,P2OLD29,07-Nov-2025,,6226991311,4,622699131104,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,08:14,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110002,06-Nov-2025,P2OLD29,07-Nov-2025,07-Nov-2025,6226991311,5,622699131105,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,08:14,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110002,06-Nov-2025,P2OLD29,07-Nov-2025,07-Nov-2025,6226991311,6,622699131106,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,08:14,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110002,06-Nov-2025,P2OLD29,07-Nov-2025,07-Nov-2025,6226991311,7,622699131107,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,08:14,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110002,06-Nov-2025,P2OLD29,07-Nov-2025,07-Nov-2025,6226991311,3,622699131103,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,08:14,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110002,06-Nov-2025,P2OLD29,07-Nov-2025,07-Nov-2025,6226991311,1,622699131101,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,08:14,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110002,06-Nov-2025,P2OLD29,07-Nov-2025,,6226991311,2,622699131102,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,08:14,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,14-Nov-2025,P2OLD29,15-Nov-2025,15-Nov-2025,6227043302,1,622704330201,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,09:10,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,14-Nov-2025,P2OLD29,15-Nov-2025,,6227043302,4,622704330204,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,09:10,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,14-Nov-2025,P2OLD29,15-Nov-2025,15-Nov-2025,6227043302,5,622704330205,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,09:10,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,14-Nov-2025,P2OLD29,15-Nov-2025,19-Nov-2025,6227043302,3,622704330203,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,09:10,07:00,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,14-Nov-2025,P2OLD29,15-Nov-2025,,6227043302,2,622704330202,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,09:10,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,14-Nov-2025,P2OLD29,15-Nov-2025,15-Nov-2025,6227043302,6,622704330206,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,09:10,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,14-Nov-2025,P2OLD29,15-Nov-2025,15-Nov-2025,6227043302,7,622704330207,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:10,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080005,17-Dec-2025,P2OLD29,18-Dec-2025,18-Dec-2025,6227072419,1,622707241901,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,11:17,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080005,17-Dec-2025,P2OLD29,18-Dec-2025,,6227072419,2,622707241902,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,11:17,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080005,17-Dec-2025,P2OLD29,18-Dec-2025,,6227072419,4,622707241904,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,11:17,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080005,17-Dec-2025,P2OLD29,18-Dec-2025,18-Dec-2025,6227072419,6,622707241906,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,11:17,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080005,17-Dec-2025,P2OLD29,18-Dec-2025,18-Dec-2025,6227072419,3,622707241903,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,11:17,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080005,17-Dec-2025,P2OLD29,18-Dec-2025,18-Dec-2025,6227072419,7,622707241907,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,11:17,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080005,17-Dec-2025,P2OLD29,18-Dec-2025,18-Dec-2025,6227072419,5,622707241905,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,11:17,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,28-Nov-2025,P2OLBL,29-Nov-2025,,6227106905,2,622710690502,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,09:00,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,28-Nov-2025,P2OLBL,29-Nov-2025,29-Nov-2025,6227106905,1,622710690501,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,09:00,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,28-Nov-2025,P2OLBL,29-Nov-2025,03-Dec-2025,6227106905,3,622710690503,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,09:00,07:00,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,28-Nov-2025,P2OLBL,29-Nov-2025,,6227106905,4,622710690504,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,09:00,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,28-Nov-2025,P2OLBL,29-Nov-2025,29-Nov-2025,6227106905,6,622710690506,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,09:00,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,28-Nov-2025,P2OLBL,29-Nov-2025,29-Nov-2025,6227106905,5,622710690505,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,09:00,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,28-Nov-2025,P2OLBL,29-Nov-2025,29-Nov-2025,6227106905,7,622710690507,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:00,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,28-Nov-2025,P2OLBL,29-Nov-2025,,6227106905,8,622710690508,"Red Cells, Clot",Not Received,,,TSH,,,,,,09:00,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,28-Nov-2025,P2OLBL,29-Nov-2025,29-Nov-2025,6227106905,9,622710690509,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,09:00,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,19-Dec-2025,P2OLBL,20-Dec-2025,20-Dec-2025,6227106906,1,622710690601,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,09:25,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,19-Dec-2025,P2OLBL,20-Dec-2025,,6227106906,2,622710690602,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,09:25,,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,19-Dec-2025,P2OLBL,20-Dec-2025,23-Dec-2025,6227106906,3,622710690603,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,09:25,07:00,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,19-Dec-2025,P2OLBL,20-Dec-2025,,6227106906,4,622710690604,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,09:25,,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,19-Dec-2025,P2OLBL,20-Dec-2025,20-Dec-2025,6227106906,5,622710690605,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,09:25,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,19-Dec-2025,P2OLBL,20-Dec-2025,20-Dec-2025,6227106906,6,622710690606,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,09:25,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,19-Dec-2025,P2OLBL,20-Dec-2025,20-Dec-2025,6227106906,9,622710690609,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,09:25,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,19-Dec-2025,P2OLBL,20-Dec-2025,20-Dec-2025,6227106906,7,622710690607,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:25,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,19-Dec-2025,P2OLBL,20-Dec-2025,,6227106906,8,622710690608,"Red Cells, Clot",Not Received,,,TSH,,,,,,09:25,,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110008,27-Jan-2026,P1DBBL,28-Jan-2026,28-Jan-2026,6227144560,6,622714456006,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,08:25,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110008,27-Jan-2026,P1DBBL,28-Jan-2026,28-Jan-2026,6227144560,7,622714456007,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,08:25,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110008,27-Jan-2026,P1DBBL,28-Jan-2026,28-Jan-2026,6227144560,1,622714456001,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,08:25,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110006,25-Nov-2025,P1DBBL,26-Nov-2025,,6227144561,2,622714456102,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,10:04,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110008,27-Jan-2026,P1DBBL,28-Jan-2026,28-Jan-2026,6227144560,5,622714456005,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,08:25,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110006,25-Nov-2025,P1DBBL,26-Nov-2025,26-Nov-2025,6227144561,1,622714456101,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,10:04,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110006,25-Nov-2025,P1DBBL,26-Nov-2025,,6227144561,4,622714456104,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,10:04,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110006,25-Nov-2025,P1DBBL,26-Nov-2025,26-Nov-2025,6227144561,3,622714456103,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,10:04,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110006,25-Nov-2025,P1DBBL,26-Nov-2025,26-Nov-2025,6227144561,5,622714456105,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,10:04,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110008,27-Jan-2026,P1DBBL,28-Jan-2026,28-Jan-2026,6227144560,3,622714456003,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,08:25,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110006,25-Nov-2025,P1DBBL,26-Nov-2025,26-Nov-2025,6227144561,6,622714456106,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,10:04,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110008,27-Jan-2026,P1DBBL,28-Jan-2026,,6227144560,4,622714456004,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,08:25,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110008,27-Jan-2026,P1DBBL,28-Jan-2026,,6227144560,2,622714456002,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,08:25,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,11-Dec-2025,P1DBBL,13-Dec-2025,13-Dec-2025,6227144562,1,622714456201,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,08:13,21:00,Czech Republic,,21:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,11-Dec-2025,P1DBBL,13-Dec-2025,13-Dec-2025,6227144562,5,622714456205,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,08:13,21:00,Czech Republic,,21:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110006,25-Nov-2025,P1DBBL,26-Nov-2025,26-Nov-2025,6227144561,7,622714456107,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,10:04,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,11-Dec-2025,P1DBBL,13-Dec-2025,13-Dec-2025,6227144562,7,622714456207,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,08:13,21:00,Czech Republic,,21:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,11-Dec-2025,P1DBBL,13-Dec-2025,,6227144562,4,622714456204,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,08:13,,Czech Republic,,21:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,11-Dec-2025,P1DBBL,13-Dec-2025,,6227144562,2,622714456202,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,08:13,,Czech Republic,,21:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,11-Dec-2025,P1DBBL,13-Dec-2025,16-Dec-2025,6227144562,3,622714456203,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,08:13,05:55,Czech Republic,,21:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,11-Dec-2025,P1DBBL,13-Dec-2025,13-Dec-2025,6227144562,6,622714456206,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,08:13,21:00,Czech Republic,,21:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,09-Jan-2026,EOT,10-Jan-2026,10-Jan-2026,6227178908,7,622717890807,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,10:20,08:00,Czech Republic,,08:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,09-Jan-2026,EOT,10-Jan-2026,10-Jan-2026,6227178908,9,622717890809,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,10:20,08:00,Czech Republic,,08:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,30-Jan-2026,EOT,31-Jan-2026,31-Jan-2026,6227178909,3,622717890903,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,09:30,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,09-Jan-2026,EOT,10-Jan-2026,,6227178908,6,622717890806,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,10:20,,Czech Republic,,08:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,30-Jan-2026,EOT,31-Jan-2026,,6227178909,4,622717890904,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,09:30,,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,09-Jan-2026,EOT,10-Jan-2026,10-Jan-2026,6227178908,2,622717890802,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,10:20,08:00,Czech Republic,,08:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,30-Jan-2026,EOT,31-Jan-2026,31-Jan-2026,6227178909,1,622717890901,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,09:30,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,09-Jan-2026,EOT,10-Jan-2026,,6227178908,8,622717890808,"Red Cells, Clot",Not Received,,,TSH,,,,,,10:20,,Czech Republic,,08:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,09-Jan-2026,EOT,10-Jan-2026,10-Jan-2026,6227178908,1,622717890801,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,10:20,08:00,Czech Republic,,08:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,30-Jan-2026,EOT,31-Jan-2026,31-Jan-2026,6227178909,2,622717890902,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:30,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,30-Jan-2026,EOT,31-Jan-2026,04-Feb-2026,6227178909,5,622717890905,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,09:30,07:00,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,09-Jan-2026,EOT,10-Jan-2026,,6227178908,4,622717890804,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,10:20,,Czech Republic,,08:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,09-Jan-2026,EOT,10-Jan-2026,10-Jan-2026,6227178908,3,622717890803,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,10:20,08:00,Czech Republic,,08:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,30-Jan-2026,EOT,31-Jan-2026,,6227178909,6,622717890906,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,09:30,,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,30-Jan-2026,EOT,31-Jan-2026,,6227178909,8,622717890908,"Red Cells, Clot",Not Received,,,TSH,,,,,,09:30,,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,30-Jan-2026,EOT,31-Jan-2026,31-Jan-2026,6227178909,9,622717890909,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,09:30,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,30-Jan-2026,EOT,31-Jan-2026,31-Jan-2026,6227178909,7,622717890907,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,09:30,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,05-May-2026,EOT,06-May-2026,06-May-2026,6227178910,1,622717891001,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,07:15,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,05-May-2026,EOT,06-May-2026,06-May-2026,6227178910,3,622717891003,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,07:15,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,05-May-2026,EOT,06-May-2026,,6227178910,4,622717891004,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,07:15,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,05-May-2026,EOT,06-May-2026,06-May-2026,6227178910,2,622717891002,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,07:15,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,05-May-2026,EOT,06-May-2026,20-May-2026,6227178910,5,622717891005,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,07:15,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,09-Jan-2026,EOT,10-Jan-2026,14-Jan-2026,6227178908,5,622717890805,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,10:20,07:00,Czech Republic,,08:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,05-May-2026,EOT,06-May-2026,,6227178910,8,622717891008,"Red Cells, Clot",Not Received,,,TSH,,,,,,07:15,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,05-May-2026,EOT,06-May-2026,06-May-2026,6227178910,9,622717891009,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,07:15,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,06-Mar-2026,EOT,07-Mar-2026,07-Mar-2026,6227178911,2,622717891102,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:50,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,05-May-2026,EOT,06-May-2026,06-May-2026,6227178910,7,622717891007,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,07:15,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,06-Mar-2026,EOT,07-Mar-2026,07-Mar-2026,6227178911,1,622717891101,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,09:50,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,06-Mar-2026,EOT,07-Mar-2026,,6227178911,4,622717891104,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,09:50,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,06-Mar-2026,EOT,07-Mar-2026,11-Mar-2026,6227178911,5,622717891105,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,09:50,07:00,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,06-Mar-2026,EOT,07-Mar-2026,,6227178911,6,622717891106,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,09:50,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,06-Mar-2026,EOT,07-Mar-2026,07-Mar-2026,6227178911,7,622717891107,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,09:50,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,06-Mar-2026,EOT,07-Mar-2026,07-Mar-2026,6227178911,9,622717891109,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,09:50,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,05-May-2026,EOT,06-May-2026,,6227178910,6,622717891006,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,07:15,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,06-Mar-2026,EOT,07-Mar-2026,07-Mar-2026,6227178911,3,622717891103,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,09:50,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,09-Jan-2026,EOT,10-Jan-2026,10-Jan-2026,6227178912,1,622717891201,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,09:10,07:15,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,06-Mar-2026,EOT,07-Mar-2026,,6227178911,8,622717891108,"Red Cells, Clot",Not Received,,,TSH,,,,,,09:50,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,09-Jan-2026,EOT,10-Jan-2026,10-Jan-2026,6227178912,2,622717891202,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:10,07:15,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,09-Jan-2026,EOT,10-Jan-2026,10-Jan-2026,6227178912,3,622717891203,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,09:10,07:15,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,09-Jan-2026,EOT,10-Jan-2026,14-Jan-2026,6227178912,5,622717891205,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,09:10,07:00,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,09-Jan-2026,EOT,10-Jan-2026,,6227178912,4,622717891204,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,09:10,,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,09-Jan-2026,EOT,10-Jan-2026,10-Jan-2026,6227178912,7,622717891207,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,09:10,07:15,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,09-Jan-2026,EOT,10-Jan-2026,,6227178912,8,622717891208,"Red Cells, Clot",Not Received,,,TSH,,,,,,09:10,,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,09-Jan-2026,EOT,10-Jan-2026,,6227178912,6,622717891206,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,09:10,,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,09-Jan-2026,EOT,10-Jan-2026,10-Jan-2026,6227178912,9,622717891209,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,09:10,07:15,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,05-Dec-2025,P1DBBL,06-Dec-2025,06-Dec-2025,6227261230,1,622726123001,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,07:55,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,05-Dec-2025,P1DBBL,06-Dec-2025,,6227261230,2,622726123002,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,07:55,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,05-Dec-2025,P1DBBL,06-Dec-2025,,6227261230,4,622726123004,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,07:55,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,05-Dec-2025,P1DBBL,06-Dec-2025,06-Dec-2025,6227261230,5,622726123005,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,07:55,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,05-Dec-2025,P1DBBL,06-Dec-2025,10-Dec-2025,6227261230,3,622726123003,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,07:55,07:00,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,05-Dec-2025,P1DBBL,06-Dec-2025,06-Dec-2025,6227261230,6,622726123006,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,07:55,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,05-Dec-2025,P1DBBL,06-Dec-2025,06-Dec-2025,6227261230,7,622726123007,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,07:55,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,19-May-2026,P2OLD29,20-May-2026,20-May-2026,6227261835,1,622726183501,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,00:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,19-May-2026,P2OLD29,20-May-2026,,6227261835,2,622726183502,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,00:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,19-May-2026,P2OLD29,20-May-2026,21-May-2026,6227261835,3,622726183503,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,00:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,19-May-2026,P2OLD29,20-May-2026,,6227261835,4,622726183504,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,00:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,19-May-2026,P2OLD29,20-May-2026,20-May-2026,6227261835,5,622726183505,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,00:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,19-May-2026,P2OLD29,20-May-2026,20-May-2026,6227261835,6,622726183506,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,00:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,19-May-2026,P2OLD29,20-May-2026,20-May-2026,6227261835,7,622726183507,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,00:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110006,06-Jan-2026,EOT,08-Jan-2026,08-Jan-2026,6227261836,1,622726183601,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,10:11,07:10,Czech Republic,,07:10,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110006,06-Jan-2026,EOT,08-Jan-2026,08-Jan-2026,6227261836,2,622726183602,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,10:11,07:10,Czech Republic,,07:10,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110006,06-Jan-2026,EOT,08-Jan-2026,08-Jan-2026,6227261836,3,622726183603,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,10:11,07:10,Czech Republic,,07:10,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110006,06-Jan-2026,EOT,08-Jan-2026,,6227261836,4,622726183604,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,10:11,,Czech Republic,,07:10,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110006,06-Jan-2026,EOT,08-Jan-2026,08-Jan-2026,6227261836,5,622726183605,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,10:11,07:10,Czech Republic,,07:10,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110006,06-Jan-2026,EOT,08-Jan-2026,,6227261836,6,622726183606,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,10:11,,Czech Republic,,07:10,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110006,06-Jan-2026,EOT,08-Jan-2026,08-Jan-2026,6227261836,7,622726183607,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,10:11,07:10,Czech Republic,,07:10,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110006,06-Jan-2026,EOT,08-Jan-2026,,6227261836,8,622726183608,"Red Cells, Clot",Not Received,,,TSH,,,,,,10:11,,Czech Republic,,07:10,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110006,06-Jan-2026,EOT,08-Jan-2026,08-Jan-2026,6227261836,9,622726183609,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,10:11,07:10,Czech Republic,,07:10,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110002,02-Jan-2026,EOT,03-Jan-2026,03-Jan-2026,6227498379,3,622749837903,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,09:28,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110002,02-Jan-2026,EOT,03-Jan-2026,03-Jan-2026,6227498379,1,622749837901,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,09:28,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110002,02-Jan-2026,EOT,03-Jan-2026,03-Jan-2026,6227498379,2,622749837902,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:28,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,30-Jan-2026,EOT,31-Jan-2026,,6227498380,8,622749838008,"Red Cells, Clot",Not Received,,,TSH,,,,,,08:36,,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,30-Jan-2026,EOT,31-Jan-2026,31-Jan-2026,6227498380,7,622749838007,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,08:36,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110002,02-Jan-2026,EOT,03-Jan-2026,03-Jan-2026,6227498379,7,622749837907,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,09:28,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,30-Jan-2026,EOT,31-Jan-2026,31-Jan-2026,6227498380,9,622749838009,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,08:36,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110002,02-Jan-2026,EOT,03-Jan-2026,03-Jan-2026,6227498379,9,622749837909,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,09:28,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,30-Jan-2026,EOT,31-Jan-2026,31-Jan-2026,6227498380,1,622749838001,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,08:36,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,30-Jan-2026,EOT,31-Jan-2026,,6227498380,6,622749838006,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,08:36,,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,30-Jan-2026,EOT,31-Jan-2026,31-Jan-2026,6227498380,3,622749838003,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,08:36,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110002,02-Jan-2026,EOT,03-Jan-2026,03-Jan-2026,6227498379,5,622749837905,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,09:28,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,30-Jan-2026,EOT,31-Jan-2026,31-Jan-2026,6227498380,2,622749838002,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,08:36,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,30-Jan-2026,EOT,31-Jan-2026,31-Jan-2026,6227498380,5,622749838005,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,08:36,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110002,02-Jan-2026,EOT,03-Jan-2026,,6227498379,4,622749837904,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,09:28,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,30-Jan-2026,EOT,31-Jan-2026,,6227498380,4,622749838004,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,08:36,,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110002,02-Jan-2026,EOT,03-Jan-2026,,6227498379,8,622749837908,"Red Cells, Clot",Not Received,,,TSH,,,,,,09:28,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110002,02-Jan-2026,EOT,03-Jan-2026,,6227498379,6,622749837906,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,09:28,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,13-Jan-2026,EOT,14-Jan-2026,14-Jan-2026,6227520242,9,622752024209,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,10:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,13-Jan-2026,EOT,14-Jan-2026,14-Jan-2026,6227520242,3,622752024203,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,10:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,29-Apr-2026,EOT,30-Apr-2026,30-Apr-2026,6227520243,7,622752024307,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,11:20,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,29-Apr-2026,EOT,30-Apr-2026,30-Apr-2026,6227520243,5,622752024305,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,11:20,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,13-Jan-2026,EOT,14-Jan-2026,,6227520242,4,622752024204,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,10:45,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,13-Jan-2026,EOT,14-Jan-2026,14-Jan-2026,6227520242,1,622752024201,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,10:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,29-Apr-2026,EOT,30-Apr-2026,30-Apr-2026,6227520243,3,622752024303,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,11:20,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,29-Apr-2026,EOT,30-Apr-2026,,6227520243,6,622752024306,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,11:20,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,29-Apr-2026,EOT,30-Apr-2026,30-Apr-2026,6227520243,1,622752024301,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,11:20,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,29-Apr-2026,EOT,30-Apr-2026,,6227520243,4,622752024304,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,11:20,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,29-Apr-2026,EOT,30-Apr-2026,,6227520243,8,622752024308,"Red Cells, Clot",Not Received,,,TSH,,,,,,11:20,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,13-Jan-2026,EOT,14-Jan-2026,14-Jan-2026,6227520242,2,622752024202,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,10:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,13-Jan-2026,EOT,14-Jan-2026,,6227520242,6,622752024206,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,10:45,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,13-Jan-2026,EOT,14-Jan-2026,14-Jan-2026,6227520242,5,622752024205,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,10:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,29-Apr-2026,EOT,30-Apr-2026,30-Apr-2026,6227520243,2,622752024302,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,11:20,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,13-Jan-2026,EOT,14-Jan-2026,,6227520242,8,622752024208,"Red Cells, Clot",Not Received,,,TSH,,,,,,10:45,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,13-Jan-2026,EOT,14-Jan-2026,14-Jan-2026,6227520242,7,622752024207,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,10:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,29-Apr-2026,EOT,30-Apr-2026,30-Apr-2026,6227520243,9,622752024309,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,11:20,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,04-Mar-2026,EOT,05-Mar-2026,05-Mar-2026,6227520245,2,622752024502,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,12:50,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,04-Mar-2026,EOT,05-Mar-2026,05-Mar-2026,6227520245,3,622752024503,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,12:50,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,04-Mar-2026,EOT,05-Mar-2026,,6227520245,8,622752024508,"Red Cells, Clot",Not Received,,,TSH,,,,,,12:50,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,04-Mar-2026,EOT,05-Mar-2026,05-Mar-2026,6227520245,1,622752024501,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,12:50,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,04-Mar-2026,EOT,05-Mar-2026,05-Mar-2026,6227520245,9,622752024509,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,12:50,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,04-Mar-2026,EOT,05-Mar-2026,,6227520245,4,622752024504,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,12:50,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,04-Mar-2026,EOT,05-Mar-2026,05-Mar-2026,6227520245,5,622752024505,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,12:50,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,04-Mar-2026,EOT,05-Mar-2026,,6227520245,6,622752024506,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,12:50,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,04-Mar-2026,EOT,05-Mar-2026,05-Mar-2026,6227520245,7,622752024507,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,12:50,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040005,27-Jan-2026,P1SCR,28-Jan-2026,,6227541249,1,622754124901,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,09:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040005,27-Jan-2026,P1SCR,28-Jan-2026,28-Jan-2026,6227541249,2,622754124902,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,09:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040005,27-Jan-2026,P1SCR,28-Jan-2026,28-Jan-2026,6227541249,3,622754124903,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,"HEMATOLOGY, A1C, &",RETICULOCYTES,,,,,09:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040005,27-Jan-2026,P1SCR,28-Jan-2026,28-Jan-2026,6227541249,6,622754124906,"Urine, no preservative",Received,Ambient,Default Return Ambient,URINE DRUG SCREEN,,,,,,09:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040005,27-Jan-2026,P1SCR,28-Jan-2026,28-Jan-2026,6227541249,4,622754124904,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040005,27-Jan-2026,P1SCR,28-Jan-2026,,6227541249,7,622754124907,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,09:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040005,27-Jan-2026,P1SCR,28-Jan-2026,28-Jan-2026,6227541249,5,622754124905,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,09:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040007,25-Mar-2026,P1DBBL,26-Mar-2026,26-Mar-2026,6227541251,1,622754125101,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,06:50,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040007,25-Mar-2026,P1DBBL,26-Mar-2026,,6227541251,2,622754125102,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,06:50,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040005,27-Jan-2026,P1SCR,28-Jan-2026,28-Jan-2026,6227541249,10,622754124910,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,09:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040005,27-Jan-2026,P1SCR,28-Jan-2026,30-Jan-2026,6227541249,8,622754124908,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,09:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040005,27-Jan-2026,P1SCR,28-Jan-2026,,6227541249,9,622754124909,"Red Cells, Clot",Not Received,,,TSH,,,,,,09:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040005,20-Feb-2026,P1DBBL,21-Feb-2026,21-Feb-2026,6227541252,6,622754125206,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,10:45,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040005,20-Feb-2026,P1DBBL,21-Feb-2026,21-Feb-2026,6227541252,1,622754125201,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,10:45,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040007,25-Mar-2026,P1DBBL,26-Mar-2026,26-Mar-2026,6227541251,7,622754125107,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,06:50,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040005,20-Feb-2026,P1DBBL,21-Feb-2026,25-Feb-2026,6227541252,3,622754125203,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,10:45,07:00,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040007,25-Mar-2026,P1DBBL,26-Mar-2026,,6227541251,4,622754125104,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,06:50,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040005,20-Feb-2026,P1DBBL,21-Feb-2026,,6227541252,2,622754125202,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,10:45,,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040005,20-Feb-2026,P1DBBL,21-Feb-2026,,6227541252,4,622754125204,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,10:45,,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040007,25-Mar-2026,P1DBBL,26-Mar-2026,26-Mar-2026,6227541251,6,622754125106,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,06:50,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040005,20-Feb-2026,P1DBBL,21-Feb-2026,21-Feb-2026,6227541252,5,622754125205,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,10:45,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040005,20-Feb-2026,P1DBBL,21-Feb-2026,21-Feb-2026,6227541252,7,622754125207,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,10:45,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040007,25-Mar-2026,P1DBBL,26-Mar-2026,26-Mar-2026,6227541251,5,622754125105,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,06:50,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040007,05-May-2026,P2OLBL,06-May-2026,06-May-2026,6227541256,1,622754125601,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,07:50,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040007,05-May-2026,P2OLBL,06-May-2026,06-May-2026,6227541256,5,622754125605,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,07:50,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040007,05-May-2026,P2OLBL,06-May-2026,,6227541256,2,622754125602,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,07:50,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040007,05-May-2026,P2OLBL,06-May-2026,,6227541256,4,622754125604,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,07:50,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040007,05-May-2026,P2OLBL,06-May-2026,06-May-2026,6227541256,7,622754125607,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,07:50,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040007,05-May-2026,P2OLBL,06-May-2026,20-May-2026,6227541256,3,622754125603,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,07:50,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040007,25-Mar-2026,P1DBBL,26-Mar-2026,26-Mar-2026,6227541251,3,622754125103,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,06:50,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040007,05-May-2026,P2OLBL,06-May-2026,06-May-2026,6227541256,6,622754125606,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,07:50,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040007,05-May-2026,P2OLBL,06-May-2026,06-May-2026,6227541256,9,622754125609,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,07:50,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,16-Jan-2026,P2OLBL,17-Jan-2026,21-Jan-2026,6227541257,3,622754125703,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,07:55,07:00,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040007,05-May-2026,P2OLBL,06-May-2026,,6227541256,8,622754125608,"Red Cells, Clot",Not Received,,,TSH,,,,,,07:50,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,16-Jan-2026,P2OLBL,17-Jan-2026,,6227541257,8,622754125708,"Red Cells, Clot",Not Received,,,TSH,,,,,,07:55,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,16-Jan-2026,P2OLBL,17-Jan-2026,17-Jan-2026,6227541257,1,622754125701,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,07:55,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,16-Jan-2026,P2OLBL,17-Jan-2026,17-Jan-2026,6227541257,5,622754125705,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,07:55,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,16-Jan-2026,P2OLBL,17-Jan-2026,17-Jan-2026,6227541257,6,622754125706,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,07:55,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,16-Jan-2026,P2OLBL,17-Jan-2026,,6227541257,4,622754125704,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,07:55,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,16-Jan-2026,P2OLBL,17-Jan-2026,17-Jan-2026,6227541257,7,622754125707,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,07:55,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,16-Jan-2026,P2OLBL,17-Jan-2026,17-Jan-2026,6227541257,9,622754125709,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,07:55,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040005,07-Apr-2026,P2OLBL,08-Apr-2026,,6227541258,2,622754125802,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,09:45,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,13-Feb-2026,P2OLD29,14-Feb-2026,,6227541259,4,622754125904,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,08:45,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,16-Jan-2026,P2OLBL,17-Jan-2026,,6227541257,2,622754125702,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,07:55,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,13-Feb-2026,P2OLD29,14-Feb-2026,18-Feb-2026,6227541259,3,622754125903,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,08:45,07:10,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040005,07-Apr-2026,P2OLBL,08-Apr-2026,08-Apr-2026,6227541258,9,622754125809,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,09:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,13-Feb-2026,P2OLD29,14-Feb-2026,14-Feb-2026,6227541259,6,622754125906,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,08:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,13-Feb-2026,P2OLD29,14-Feb-2026,14-Feb-2026,6227541259,7,622754125907,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,08:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040005,07-Apr-2026,P2OLBL,08-Apr-2026,08-Apr-2026,6227541258,1,622754125801,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,09:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040005,07-Apr-2026,P2OLBL,08-Apr-2026,,6227541258,4,622754125804,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,09:45,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040005,07-Apr-2026,P2OLBL,08-Apr-2026,08-Apr-2026,6227541258,6,622754125806,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,09:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,13-Feb-2026,P2OLD29,14-Feb-2026,14-Feb-2026,6227541259,1,622754125901,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,08:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040005,07-Apr-2026,P2OLBL,08-Apr-2026,08-Apr-2026,6227541258,5,622754125805,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,09:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040005,07-Apr-2026,P2OLBL,08-Apr-2026,08-Apr-2026,6227541258,7,622754125807,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040005,07-Apr-2026,P2OLBL,08-Apr-2026,08-Apr-2026,6227541258,3,622754125803,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,09:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,13-Feb-2026,P2OLD29,14-Feb-2026,14-Feb-2026,6227541259,5,622754125905,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,08:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,16-Jan-2026,P2OLD29,17-Jan-2026,17-Jan-2026,6227541260,1,622754126001,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,10:40,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,16-Jan-2026,P2OLD29,17-Jan-2026,17-Jan-2026,6227541260,5,622754126005,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,10:40,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,16-Jan-2026,P2OLD29,17-Jan-2026,,6227541260,2,622754126002,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,10:40,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,16-Jan-2026,P2OLD29,17-Jan-2026,21-Jan-2026,6227541260,3,622754126003,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,10:40,07:00,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040005,07-Apr-2026,P2OLBL,08-Apr-2026,,6227541258,8,622754125808,"Red Cells, Clot",Not Received,,,TSH,,,,,,09:45,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,13-Feb-2026,P2OLD29,14-Feb-2026,,6227541259,2,622754125902,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,08:45,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,05-May-2026,P2OLD29,06-May-2026,06-May-2026,6227541261,1,622754126101,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,13:15,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,16-Jan-2026,P2OLD29,17-Jan-2026,,6227541260,4,622754126004,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,10:40,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,16-Jan-2026,P2OLD29,17-Jan-2026,17-Jan-2026,6227541260,6,622754126006,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,10:40,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,05-May-2026,P2OLD29,06-May-2026,,6227541261,2,622754126102,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,13:15,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,05-May-2026,P2OLD29,06-May-2026,,6227541261,4,622754126104,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,13:15,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,16-Jan-2026,P2OLD29,17-Jan-2026,17-Jan-2026,6227541260,7,622754126007,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,10:40,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,05-May-2026,P2OLD29,06-May-2026,06-May-2026,6227541261,5,622754126105,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,13:15,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,05-May-2026,P2OLD29,06-May-2026,06-May-2026,6227541261,6,622754126106,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,13:15,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,05-May-2026,P2OLD29,06-May-2026,20-May-2026,6227541261,3,622754126103,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,13:15,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,05-May-2026,P2OLD29,06-May-2026,06-May-2026,6227541261,7,622754126107,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,13:15,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,07-Apr-2026,P2DBW13,08-Apr-2026,,6227541264,2,622754126402,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,08:35,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 DB Week 13,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,07-Apr-2026,P2DBW13,08-Apr-2026,08-Apr-2026,6227541264,1,622754126401,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,08:35,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 DB Week 13,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,07-Apr-2026,P2DBW13,08-Apr-2026,,6227541264,4,622754126404,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,08:35,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 DB Week 13,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,07-Apr-2026,P2DBW13,08-Apr-2026,08-Apr-2026,6227541264,3,622754126403,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,08:35,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 DB Week 13,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,07-Apr-2026,P2DBW13,08-Apr-2026,08-Apr-2026,6227541264,6,622754126406,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,08:35,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 DB Week 13,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,07-Apr-2026,P2DBW13,08-Apr-2026,08-Apr-2026,6227541264,5,622754126405,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,08:35,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 DB Week 13,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,07-Apr-2026,P2DBW13,08-Apr-2026,08-Apr-2026,6227541264,7,622754126407,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,08:35,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 DB Week 13,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110009,21-Jan-2026,P1SCR,22-Jan-2026,22-Jan-2026,6227542160,6,622754216006,"Urine, no preservative",Received,Ambient,Default Return Ambient,URINE DRUG SCREEN,,,,,,10:11,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110009,21-Jan-2026,P1SCR,22-Jan-2026,,6227542160,7,622754216007,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,10:11,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110009,21-Jan-2026,P1SCR,22-Jan-2026,22-Jan-2026,6227542160,5,622754216005,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,10:11,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110009,21-Jan-2026,P1SCR,22-Jan-2026,,6227542160,9,622754216009,"Red Cells, Clot",Not Received,,,TSH,,,,,,10:11,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110009,21-Jan-2026,P1SCR,22-Jan-2026,22-Jan-2026,6227542160,2,622754216002,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,10:11,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110009,21-Jan-2026,P1SCR,22-Jan-2026,22-Jan-2026,6227542160,10,622754216010,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,10:11,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110008,05-Jan-2026,P1SCR,06-Jan-2026,,6227542161,1,622754216101,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,10:58,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110009,21-Jan-2026,P1SCR,22-Jan-2026,22-Jan-2026,6227542160,8,622754216008,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,10:11,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110009,21-Jan-2026,P1SCR,22-Jan-2026,,6227542160,1,622754216001,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,10:11,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110008,05-Jan-2026,P1SCR,06-Jan-2026,06-Jan-2026,6227542161,4,622754216104,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,10:58,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110008,05-Jan-2026,P1SCR,06-Jan-2026,06-Jan-2026,6227542161,2,622754216102,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,10:58,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110008,05-Jan-2026,P1SCR,06-Jan-2026,06-Jan-2026,6227542161,8,622754216108,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,10:58,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110008,05-Jan-2026,P1SCR,06-Jan-2026,06-Jan-2026,6227542161,3,622754216103,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,"HEMATOLOGY, A1C, &",RETICULOCYTES,,,,,10:58,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110008,05-Jan-2026,P1SCR,06-Jan-2026,06-Jan-2026,6227542161,6,622754216106,"Urine, no preservative",Received,Ambient,Default Return Ambient,URINE DRUG SCREEN,,,,,,10:58,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110008,05-Jan-2026,P1SCR,06-Jan-2026,06-Jan-2026,6227542161,10,622754216110,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,10:58,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110009,21-Jan-2026,P1SCR,22-Jan-2026,22-Jan-2026,6227542160,4,622754216004,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,10:11,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110009,21-Jan-2026,P1SCR,22-Jan-2026,22-Jan-2026,6227542160,3,622754216003,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,"HEMATOLOGY, A1C, &",RETICULOCYTES,,,,,10:11,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110008,05-Jan-2026,P1SCR,06-Jan-2026,,6227542161,9,622754216109,"Red Cells, Clot",Not Received,,,TSH,,,,,,10:58,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110008,05-Jan-2026,P1SCR,06-Jan-2026,,6227542161,7,622754216107,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,10:58,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110008,05-Jan-2026,P1SCR,06-Jan-2026,06-Jan-2026,6227542161,5,622754216105,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,10:58,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110008,10-Mar-2026,EOT,11-Mar-2026,11-Mar-2026,6227542170,5,622754217005,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,09:30,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110008,10-Mar-2026,EOT,11-Mar-2026,11-Mar-2026,6227542170,1,622754217001,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,09:30,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110008,10-Mar-2026,EOT,11-Mar-2026,11-Mar-2026,6227542170,7,622754217007,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,09:30,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110008,10-Mar-2026,EOT,11-Mar-2026,11-Mar-2026,6227542170,3,622754217003,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,09:30,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110008,10-Mar-2026,EOT,11-Mar-2026,,6227542170,8,622754217008,"Red Cells, Clot",Not Received,,,TSH,,,,,,09:30,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110008,10-Mar-2026,EOT,11-Mar-2026,11-Mar-2026,6227542170,2,622754217002,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:30,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110008,10-Mar-2026,EOT,11-Mar-2026,,6227542170,6,622754217006,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,09:30,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,16-Mar-2026,EOT,17-Mar-2026,17-Mar-2026,6227542171,1,622754217101,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,09:16,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110008,10-Mar-2026,EOT,11-Mar-2026,11-Mar-2026,6227542170,9,622754217009,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,09:30,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,16-Mar-2026,EOT,17-Mar-2026,17-Mar-2026,6227542171,3,622754217103,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,09:16,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110008,10-Mar-2026,EOT,11-Mar-2026,,6227542170,4,622754217004,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,09:30,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,16-Mar-2026,EOT,17-Mar-2026,17-Mar-2026,6227542171,5,622754217105,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,09:16,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,16-Mar-2026,EOT,17-Mar-2026,17-Mar-2026,6227542171,2,622754217102,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:16,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,16-Mar-2026,EOT,17-Mar-2026,,6227542171,6,622754217106,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,09:16,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,16-Mar-2026,EOT,17-Mar-2026,,6227542171,8,622754217108,"Red Cells, Clot",Not Received,,,TSH,,,,,,09:16,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,16-Mar-2026,EOT,17-Mar-2026,17-Mar-2026,6227542171,7,622754217107,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,09:16,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,16-Mar-2026,EOT,17-Mar-2026,17-Mar-2026,6227542171,9,622754217109,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,09:16,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,30-Mar-2026,EOT,31-Mar-2026,31-Mar-2026,6227542172,2,622754217202,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:31,07:15,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,16-Mar-2026,EOT,17-Mar-2026,,6227542171,4,622754217104,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,09:16,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,30-Mar-2026,EOT,31-Mar-2026,31-Mar-2026,6227542172,3,622754217203,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,09:31,07:15,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,30-Mar-2026,EOT,31-Mar-2026,31-Mar-2026,6227542172,1,622754217201,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,09:31,07:15,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,30-Mar-2026,EOT,31-Mar-2026,31-Mar-2026,6227542172,5,622754217205,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,09:31,07:15,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,30-Mar-2026,EOT,31-Mar-2026,,6227542172,6,622754217206,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,09:31,,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,30-Mar-2026,EOT,31-Mar-2026,31-Mar-2026,6227542172,9,622754217209,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,09:31,07:15,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,30-Mar-2026,EOT,31-Mar-2026,31-Mar-2026,6227542172,7,622754217207,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,09:31,07:15,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,30-Mar-2026,EOT,31-Mar-2026,,6227542172,4,622754217204,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,09:31,,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,30-Mar-2026,EOT,31-Mar-2026,,6227542172,8,622754217208,"Red Cells, Clot",Not Received,,,TSH,,,,,,09:31,,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,16-Jan-2026,EOT,17-Jan-2026,17-Jan-2026,6227542173,1,622754217301,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,08:48,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,16-Jan-2026,EOT,17-Jan-2026,17-Jan-2026,6227542173,5,622754217305,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,08:48,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,16-Jan-2026,EOT,17-Jan-2026,,6227542173,6,622754217306,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,08:48,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,16-Jan-2026,EOT,17-Jan-2026,17-Jan-2026,6227542173,7,622754217307,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,08:48,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,16-Jan-2026,EOT,17-Jan-2026,,6227542173,8,622754217308,"Red Cells, Clot",Not Received,,,TSH,,,,,,08:48,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,16-Jan-2026,EOT,17-Jan-2026,17-Jan-2026,6227542173,2,622754217302,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,08:48,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,16-Jan-2026,EOT,17-Jan-2026,17-Jan-2026,6227542173,9,622754217309,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,08:48,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,16-Jan-2026,EOT,17-Jan-2026,17-Jan-2026,6227542173,3,622754217303,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,08:48,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,16-Jan-2026,EOT,17-Jan-2026,,6227542173,4,622754217304,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,08:48,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,10-Apr-2026,P2OLBL,11-Apr-2026,11-Apr-2026,6227542182,2,622754218202,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,08:16,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,10-Apr-2026,P2OLBL,11-Apr-2026,11-Apr-2026,6227542182,3,622754218203,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,08:16,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,10-Apr-2026,P2OLBL,11-Apr-2026,,6227542182,4,622754218204,"Urine, no preservative",Not Received,Ambient,,URINE DRUG SCREEN,,,,,,08:16,,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,10-Apr-2026,P2OLBL,11-Apr-2026,,6227542182,5,622754218205,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,08:16,,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,10-Apr-2026,P2OLBL,11-Apr-2026,11-Apr-2026,6227542182,8,622754218208,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,08:16,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,10-Apr-2026,P2OLBL,11-Apr-2026,11-Apr-2026,6227542182,1,622754218201,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,08:16,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,10-Apr-2026,P2OLBL,11-Apr-2026,,6227542182,7,622754218207,"Red Cells, Clot",Not Received,,,TSH,,,,,,08:16,,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,10-Apr-2026,P2OLBL,11-Apr-2026,,6227542182,9,622754218209,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,08:16,,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,10-Apr-2026,P2OLBL,11-Apr-2026,11-Apr-2026,6227542182,6,622754218206,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,08:16,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,10-Apr-2026,P2OLBL,11-Apr-2026,11-Apr-2026,6227542182,10,622754218210,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,08:16,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,11-Dec-2025,EOT,13-Dec-2025,13-Dec-2025,6226935606,10,622693560610,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,09:05,21:00,Czech Republic,,21:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,11-Dec-2025,EOT,13-Dec-2025,13-Dec-2025,6226935606,11,622693560611,"Serum, SST",Received,Ambient,Default Return Ambient,,,,,,,09:05,21:00,Czech Republic,,21:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040007,27-Feb-2026,P1SCR,28-Feb-2026,28-Feb-2026,6227547329,2,622754732902,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,08:00,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040007,27-Feb-2026,P1SCR,28-Feb-2026,28-Feb-2026,6227547329,3,622754732903,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,"HEMATOLOGY, A1C, &",RETICULOCYTES,,,,,08:00,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040007,27-Feb-2026,P1SCR,28-Feb-2026,28-Feb-2026,6227547329,4,622754732904,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,08:00,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040007,27-Feb-2026,P1SCR,28-Feb-2026,28-Feb-2026,6227547329,6,622754732906,"Urine, no preservative",Received,Ambient,Default Return Ambient,URINE DRUG SCREEN,,,,,,08:00,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040007,27-Feb-2026,P1SCR,28-Feb-2026,,6227547329,7,622754732907,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,08:00,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040007,27-Feb-2026,P1SCR,28-Feb-2026,28-Feb-2026,6227547329,5,622754732905,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,08:00,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040007,27-Feb-2026,P1SCR,28-Feb-2026,04-Mar-2026,6227547329,8,622754732908,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,08:00,07:00,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040007,27-Feb-2026,P1SCR,28-Feb-2026,28-Feb-2026,6227547329,10,622754732910,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,08:00,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040007,27-Feb-2026,P1SCR,28-Feb-2026,,6227547329,9,622754732909,"Red Cells, Clot",Not Received,,,TSH,,,,,,08:00,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,30-Jan-2026,P1SCR,31-Jan-2026,31-Jan-2026,6227547330,2,622754733002,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,11:40,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,30-Jan-2026,P1SCR,31-Jan-2026,,6227547330,1,622754733001,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,11:40,,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,30-Jan-2026,P1SCR,31-Jan-2026,31-Jan-2026,6227547330,3,622754733003,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,"HEMATOLOGY, A1C, &",RETICULOCYTES,,,,,11:40,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,30-Jan-2026,P1SCR,31-Jan-2026,31-Jan-2026,6227547330,4,622754733004,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,11:40,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,30-Jan-2026,P1SCR,31-Jan-2026,31-Jan-2026,6227547330,5,622754733005,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,11:40,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,30-Jan-2026,P1SCR,31-Jan-2026,31-Jan-2026,6227547330,6,622754733006,"Urine, no preservative",Received,Ambient,Default Return Ambient,URINE DRUG SCREEN,,,,,,11:40,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,30-Jan-2026,P1SCR,31-Jan-2026,,6227547330,7,622754733007,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,11:40,,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,30-Jan-2026,P1SCR,31-Jan-2026,04-Feb-2026,6227547330,8,622754733008,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,11:40,07:00,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,30-Jan-2026,P1SCR,31-Jan-2026,,6227547330,9,622754733009,"Red Cells, Clot",Not Received,,,TSH,,,,,,11:40,,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,30-Jan-2026,P1SCR,31-Jan-2026,31-Jan-2026,6227547330,10,622754733010,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,11:40,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040008,06-Mar-2026,P1SCR,07-Mar-2026,07-Mar-2026,6227547331,2,622754733102,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,09:20,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040007,27-Feb-2026,P1SCR,28-Feb-2026,,6227547329,1,622754732901,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,08:00,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040008,06-Mar-2026,P1SCR,07-Mar-2026,07-Mar-2026,6227547331,3,622754733103,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,"HEMATOLOGY, A1C, &",RETICULOCYTES,,,,,09:20,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040008,06-Mar-2026,P1SCR,07-Mar-2026,07-Mar-2026,6227547331,4,622754733104,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:20,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040008,06-Mar-2026,P1SCR,07-Mar-2026,07-Mar-2026,6227547331,5,622754733105,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,09:20,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040008,06-Mar-2026,P1SCR,07-Mar-2026,07-Mar-2026,6227547331,6,622754733106,"Urine, no preservative",Received,Ambient,Default Return Ambient,URINE DRUG SCREEN,,,,,,09:20,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040008,06-Mar-2026,P1SCR,07-Mar-2026,,6227547331,7,622754733107,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,09:20,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040008,06-Mar-2026,P1SCR,07-Mar-2026,11-Mar-2026,6227547331,8,622754733108,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,09:20,07:00,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,27-Feb-2026,P1DBBL,28-Feb-2026,28-Feb-2026,6227547332,1,622754733201,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,11:35,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,27-Feb-2026,P1DBBL,28-Feb-2026,,6227547332,2,622754733202,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,11:35,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,27-Feb-2026,P1DBBL,28-Feb-2026,04-Mar-2026,6227547332,3,622754733203,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,11:35,07:00,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,27-Feb-2026,P1DBBL,28-Feb-2026,,6227547332,4,622754733204,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,11:35,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,27-Feb-2026,P1DBBL,28-Feb-2026,28-Feb-2026,6227547332,5,622754733205,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,11:35,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,27-Feb-2026,P1DBBL,28-Feb-2026,28-Feb-2026,6227547332,6,622754733206,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,11:35,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,27-Feb-2026,P1DBBL,28-Feb-2026,28-Feb-2026,6227547332,7,622754733207,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,11:35,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040008,06-Mar-2026,P1SCR,07-Mar-2026,,6227547331,1,622754733101,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,09:20,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040008,25-Mar-2026,P1DBBL,26-Mar-2026,26-Mar-2026,6227547333,1,622754733301,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,08:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040008,25-Mar-2026,P1DBBL,26-Mar-2026,,6227547333,2,622754733302,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,08:45,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040008,25-Mar-2026,P1DBBL,26-Mar-2026,26-Mar-2026,6227547333,3,622754733303,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,08:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040008,25-Mar-2026,P1DBBL,26-Mar-2026,,6227547333,4,622754733304,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,08:45,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040008,25-Mar-2026,P1DBBL,26-Mar-2026,26-Mar-2026,6227547333,6,622754733306,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,08:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040008,25-Mar-2026,P1DBBL,26-Mar-2026,26-Mar-2026,6227547333,5,622754733305,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,08:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040008,25-Mar-2026,P1DBBL,26-Mar-2026,26-Mar-2026,6227547333,7,622754733307,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,08:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040008,06-Mar-2026,P1SCR,07-Mar-2026,,6227547331,9,622754733109,"Red Cells, Clot",Not Received,,,TSH,,,,,,09:20,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040008,06-Mar-2026,P1SCR,07-Mar-2026,07-Mar-2026,6227547331,10,622754733110,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,09:20,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040009,10-Apr-2026,P2SCR,11-Apr-2026,,6227547336,1,622754733601,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,08:15,,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 2 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040009,10-Apr-2026,P2SCR,11-Apr-2026,11-Apr-2026,6227547336,2,622754733602,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,08:15,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 2 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040009,10-Apr-2026,P2SCR,11-Apr-2026,11-Apr-2026,6227547336,3,622754733603,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,"HEMATOLOGY, A1C, &",RETICULOCYTES,,,,,08:15,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 2 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040009,10-Apr-2026,P2SCR,11-Apr-2026,11-Apr-2026,6227547336,4,622754733604,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,08:15,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 2 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040009,10-Apr-2026,P2SCR,11-Apr-2026,11-Apr-2026,6227547336,5,622754733605,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,08:15,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 2 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040009,10-Apr-2026,P2SCR,11-Apr-2026,11-Apr-2026,6227547336,6,622754733606,"Urine, no preservative",Received,Ambient,Default Return Ambient,URINE DRUG SCREEN,,,,,,08:15,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 2 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040009,10-Apr-2026,P2SCR,11-Apr-2026,,6227547336,7,622754733607,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,08:15,,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 2 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040009,10-Apr-2026,P2SCR,11-Apr-2026,15-Apr-2026,6227547336,8,622754733608,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,08:15,07:00,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 2 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040009,10-Apr-2026,P2SCR,11-Apr-2026,,6227547336,9,622754733609,"Red Cells, Clot",Not Received,,,TSH,,,,,,08:15,,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 2 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,10-Apr-2026,P2OLBL,11-Apr-2026,,6227547337,2,622754733702,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,11:15,,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,10-Apr-2026,P2OLBL,11-Apr-2026,15-Apr-2026,6227547337,3,622754733703,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,11:15,07:00,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,10-Apr-2026,P2OLBL,11-Apr-2026,,6227547337,4,622754733704,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,11:15,,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,10-Apr-2026,P2OLBL,11-Apr-2026,11-Apr-2026,6227547337,6,622754733706,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,11:15,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,10-Apr-2026,P2OLBL,11-Apr-2026,11-Apr-2026,6227547337,5,622754733705,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,11:15,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,10-Apr-2026,P2OLBL,11-Apr-2026,11-Apr-2026,6227547337,9,622754733709,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,11:15,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040009,05-May-2026,P2OLBL,06-May-2026,,6227547338,2,622754733802,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,09:50,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040009,05-May-2026,P2OLBL,06-May-2026,20-May-2026,6227547338,3,622754733803,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,09:50,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040009,05-May-2026,P2OLBL,06-May-2026,06-May-2026,6227547338,1,622754733801,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,09:50,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040009,05-May-2026,P2OLBL,06-May-2026,,6227547338,4,622754733804,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,09:50,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040009,05-May-2026,P2OLBL,06-May-2026,06-May-2026,6227547338,7,622754733807,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:50,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040009,05-May-2026,P2OLBL,06-May-2026,06-May-2026,6227547338,5,622754733805,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,09:50,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040009,05-May-2026,P2OLBL,06-May-2026,06-May-2026,6227547338,6,622754733806,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,09:50,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,10-Apr-2026,P2OLBL,11-Apr-2026,,6227547337,8,622754733708,"Red Cells, Clot",Not Received,,,TSH,,,,,,11:15,,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,10-Apr-2026,P2OLBL,11-Apr-2026,11-Apr-2026,6227547337,7,622754733707,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,11:15,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040009,05-May-2026,P2OLBL,06-May-2026,,6227547338,8,622754733808,"Red Cells, Clot",Not Received,,,TSH,,,,,,09:50,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040009,05-May-2026,P2OLBL,06-May-2026,06-May-2026,6227547338,9,622754733809,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,09:50,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,10-Apr-2026,P2OLBL,11-Apr-2026,11-Apr-2026,6227547337,1,622754733701,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,11:15,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040009,10-Apr-2026,P2SCR,11-Apr-2026,11-Apr-2026,6227547336,10,622754733610,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,08:15,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 2 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120006,01-Feb-2026,P1SCR,03-Feb-2026,03-Feb-2026,6227767267,3,622776726703,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,"HEMATOLOGY, A1C, &",RETICULOCYTES,,,,,12:25,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120006,01-Feb-2026,P1SCR,03-Feb-2026,03-Feb-2026,6227767267,4,622776726704,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,12:25,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120006,01-Feb-2026,P1SCR,03-Feb-2026,,6227767267,1,622776726701,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,12:25,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120006,01-Feb-2026,P1SCR,03-Feb-2026,03-Feb-2026,6227767267,2,622776726702,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,12:25,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120006,01-Feb-2026,P1SCR,03-Feb-2026,,6227767267,7,622776726707,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,12:25,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120006,01-Feb-2026,P1SCR,03-Feb-2026,03-Feb-2026,6227767267,5,622776726705,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,12:25,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120006,01-Feb-2026,P1SCR,03-Feb-2026,03-Feb-2026,6227767267,6,622776726706,"Urine, no preservative",Received,Ambient,Default Return Ambient,URINE DRUG SCREEN,,,,,,12:25,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120006,01-Feb-2026,P1SCR,03-Feb-2026,,6227767267,9,622776726709,"Red Cells, Clot",Not Received,,,TSH,,,,,,12:25,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120006,01-Feb-2026,P1SCR,03-Feb-2026,04-Feb-2026,6227767267,8,622776726708,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,12:25,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120006,01-Feb-2026,P1SCR,03-Feb-2026,03-Feb-2026,6227767267,10,622776726710,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,12:25,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040008,05-May-2026,EOT,06-May-2026,06-May-2026,6227768458,2,622776845802,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,08:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040008,05-May-2026,EOT,06-May-2026,,6227768458,4,622776845804,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,08:45,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040008,05-May-2026,EOT,06-May-2026,06-May-2026,6227768458,1,622776845801,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,08:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040008,05-May-2026,EOT,06-May-2026,06-May-2026,6227768458,3,622776845803,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,08:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040008,05-May-2026,EOT,06-May-2026,20-May-2026,6227768458,5,622776845805,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,08:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040008,05-May-2026,EOT,06-May-2026,,6227768458,6,622776845806,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,08:45,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040008,05-May-2026,EOT,06-May-2026,,6227768458,8,622776845808,"Red Cells, Clot",Not Received,,,TSH,,,,,,08:45,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040008,05-May-2026,EOT,06-May-2026,06-May-2026,6227768458,7,622776845807,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,08:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,13-Mar-2026,EOT,14-Mar-2026,14-Mar-2026,6227768459,1,622776845901,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,09:00,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,13-Mar-2026,EOT,14-Mar-2026,14-Mar-2026,6227768459,3,622776845903,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,09:00,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,13-Mar-2026,EOT,14-Mar-2026,,6227768459,4,622776845904,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,09:00,,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040008,05-May-2026,EOT,06-May-2026,06-May-2026,6227768458,9,622776845809,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,08:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,27-Mar-2026,EOT,28-Mar-2026,,6227768460,4,622776846004,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,10:00,,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,13-Mar-2026,EOT,14-Mar-2026,,6227768459,6,622776845906,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,09:00,,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,27-Mar-2026,EOT,28-Mar-2026,08-Apr-2026,6227768460,5,622776846005,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,10:00,07:00,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,27-Mar-2026,EOT,28-Mar-2026,28-Mar-2026,6227768460,2,622776846002,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,10:00,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,13-Mar-2026,EOT,14-Mar-2026,14-Mar-2026,6227768459,7,622776845907,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,09:00,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,27-Mar-2026,EOT,28-Mar-2026,28-Mar-2026,6227768460,3,622776846003,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,10:00,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,13-Mar-2026,EOT,14-Mar-2026,,6227768459,8,622776845908,"Red Cells, Clot",Not Received,,,TSH,,,,,,09:00,,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,13-Mar-2026,EOT,14-Mar-2026,18-Mar-2026,6227768459,5,622776845905,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,09:00,07:00,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,13-Mar-2026,EOT,14-Mar-2026,14-Mar-2026,6227768459,9,622776845909,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,09:00,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,27-Mar-2026,EOT,28-Mar-2026,28-Mar-2026,6227768460,7,622776846007,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,10:00,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,27-Mar-2026,EOT,28-Mar-2026,,6227768460,8,622776846008,"Red Cells, Clot",Not Received,,,TSH,,,,,,10:00,,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,27-Mar-2026,EOT,28-Mar-2026,28-Mar-2026,6227768460,1,622776846001,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,10:00,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,27-Mar-2026,EOT,28-Mar-2026,28-Mar-2026,6227768460,9,622776846009,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,10:00,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,13-Mar-2026,EOT,14-Mar-2026,14-Mar-2026,6227768459,2,622776845902,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:00,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,27-Mar-2026,EOT,28-Mar-2026,,6227768460,6,622776846006,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,10:00,,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120005,28-Jan-2026,P1SCR,30-Jan-2026,,6227775505,1,622777550501,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,16:50,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120005,28-Jan-2026,P1SCR,30-Jan-2026,30-Jan-2026,6227775505,5,622777550505,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,16:50,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120005,28-Jan-2026,P1SCR,30-Jan-2026,30-Jan-2026,6227775505,4,622777550504,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,16:50,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120005,28-Jan-2026,P1SCR,30-Jan-2026,30-Jan-2026,6227775505,6,622777550506,"Urine, no preservative",Received,Ambient,Default Return Ambient,URINE DRUG SCREEN,,,,,,16:50,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120005,28-Jan-2026,P1SCR,30-Jan-2026,,6227775505,7,622777550507,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,16:50,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120005,28-Jan-2026,P1SCR,30-Jan-2026,30-Jan-2026,6227775505,2,622777550502,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,16:50,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120005,28-Jan-2026,P1SCR,30-Jan-2026,30-Jan-2026,6227775505,3,622777550503,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,"HEMATOLOGY, A1C, &",RETICULOCYTES,,,,,16:50,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120005,28-Jan-2026,P1SCR,30-Jan-2026,,6227775505,9,622777550509,"Red Cells, Clot",Not Received,,,TSH,,,,,,16:50,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120005,15-Feb-2026,P1DBBL,17-Feb-2026,,6227775508,2,622777550802,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,15:10,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120006,15-Feb-2026,P1DBBL,17-Feb-2026,17-Feb-2026,6227775507,1,622777550701,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,13:30,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120005,15-Feb-2026,P1DBBL,17-Feb-2026,17-Feb-2026,6227775508,5,622777550805,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,15:10,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120006,15-Feb-2026,P1DBBL,17-Feb-2026,18-Feb-2026,6227775507,3,622777550703,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,13:30,07:10,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120006,15-Feb-2026,P1DBBL,17-Feb-2026,,6227775507,4,622777550704,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,13:30,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120005,15-Feb-2026,P1DBBL,17-Feb-2026,18-Feb-2026,6227775508,3,622777550803,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,15:10,07:10,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120006,15-Feb-2026,P1DBBL,17-Feb-2026,17-Feb-2026,6227775507,6,622777550706,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,13:30,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120006,15-Feb-2026,P1DBBL,17-Feb-2026,17-Feb-2026,6227775507,7,622777550707,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,13:30,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120006,15-Feb-2026,P1DBBL,17-Feb-2026,17-Feb-2026,6227775507,5,622777550705,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,13:30,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120005,15-Feb-2026,P1DBBL,17-Feb-2026,17-Feb-2026,6227775508,7,622777550807,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,15:10,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120005,15-Feb-2026,P1DBBL,17-Feb-2026,17-Feb-2026,6227775508,6,622777550806,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,15:10,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120005,15-Feb-2026,P1DBBL,17-Feb-2026,17-Feb-2026,6227775508,1,622777550801,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,15:10,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120006,15-Feb-2026,P1DBBL,17-Feb-2026,,6227775507,2,622777550702,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,13:30,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120005,28-Jan-2026,P1SCR,30-Jan-2026,30-Jan-2026,6227775505,10,622777550510,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,16:50,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120005,15-Feb-2026,P1DBBL,17-Feb-2026,,6227775508,4,622777550804,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,15:10,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120005,28-Jan-2026,P1SCR,30-Jan-2026,31-Jan-2026,6227775505,8,622777550508,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,16:50,07:20,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,17-Feb-2026,P1SCR,18-Feb-2026,18-Feb-2026,6227797406,3,622779740603,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,"HEMATOLOGY, A1C, &",RETICULOCYTES,,,,,11:03,07:10,Czech Republic,,07:10,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,17-Feb-2026,P1SCR,18-Feb-2026,18-Feb-2026,6227797406,6,622779740606,"Urine, no preservative",Received,Ambient,Default Return Ambient,URINE DRUG SCREEN,,,,,,11:03,07:10,Czech Republic,,07:10,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,17-Feb-2026,P1SCR,18-Feb-2026,18-Feb-2026,6227797406,5,622779740605,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,11:03,07:10,Czech Republic,,07:10,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,17-Feb-2026,P1SCR,18-Feb-2026,18-Feb-2026,6227797406,4,622779740604,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,11:03,07:10,Czech Republic,,07:10,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,17-Feb-2026,P1SCR,18-Feb-2026,18-Feb-2026,6227797406,8,622779740608,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,11:03,07:10,Czech Republic,,07:10,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,17-Feb-2026,P1SCR,18-Feb-2026,,6227797406,9,622779740609,"Red Cells, Clot",Not Received,,,TSH,,,,,,11:03,,Czech Republic,,07:10,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,17-Feb-2026,P1SCR,18-Feb-2026,,6227797406,7,622779740607,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,11:03,,Czech Republic,,07:10,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,17-Feb-2026,P1SCR,18-Feb-2026,18-Feb-2026,6227797406,2,622779740602,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,11:03,07:10,Czech Republic,,07:10,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,17-Feb-2026,P1SCR,18-Feb-2026,,6227797406,1,622779740601,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,11:03,,Czech Republic,,07:10,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110012,06-Mar-2026,P1SCR,07-Mar-2026,,6227797407,1,622779740701,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,09:22,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110012,06-Mar-2026,P1SCR,07-Mar-2026,07-Mar-2026,6227797407,3,622779740703,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,"HEMATOLOGY, A1C, &",RETICULOCYTES,,,,,09:22,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110012,06-Mar-2026,P1SCR,07-Mar-2026,07-Mar-2026,6227797407,4,622779740704,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:22,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,17-Feb-2026,P1SCR,18-Feb-2026,18-Feb-2026,6227797406,10,622779740610,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,11:03,07:10,Czech Republic,,07:10,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110012,06-Mar-2026,P1SCR,07-Mar-2026,07-Mar-2026,6227797407,5,622779740705,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,09:22,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110012,06-Mar-2026,P1SCR,07-Mar-2026,07-Mar-2026,6227797407,6,622779740706,"Urine, no preservative",Received,Ambient,Default Return Ambient,URINE DRUG SCREEN,,,,,,09:22,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110012,06-Mar-2026,P1SCR,07-Mar-2026,,6227797407,7,622779740707,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,09:22,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110012,06-Mar-2026,P1SCR,07-Mar-2026,,6227797407,9,622779740709,"Red Cells, Clot",Not Received,,,TSH,,,,,,09:22,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110011,02-Mar-2026,P1SCR,03-Mar-2026,03-Mar-2026,6227797408,5,622779740805,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,09:05,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110011,02-Mar-2026,P1SCR,03-Mar-2026,03-Mar-2026,6227797408,6,622779740806,"Urine, no preservative",Received,Ambient,Default Return Ambient,URINE DRUG SCREEN,,,,,,09:05,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110011,02-Mar-2026,P1SCR,03-Mar-2026,03-Mar-2026,6227797408,4,622779740804,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:05,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110012,06-Mar-2026,P1SCR,07-Mar-2026,07-Mar-2026,6227797407,10,622779740710,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,09:22,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110012,06-Mar-2026,P1SCR,07-Mar-2026,07-Mar-2026,6227797407,2,622779740702,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,09:22,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110012,06-Mar-2026,P1SCR,07-Mar-2026,07-Mar-2026,6227797407,8,622779740708,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,09:22,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110011,02-Mar-2026,P1SCR,03-Mar-2026,,6227797408,1,622779740801,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,09:05,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110011,02-Mar-2026,P1SCR,03-Mar-2026,03-Mar-2026,6227797408,8,622779740808,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,09:05,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110011,02-Mar-2026,P1SCR,03-Mar-2026,03-Mar-2026,6227797408,2,622779740802,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,09:05,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110011,02-Mar-2026,P1SCR,03-Mar-2026,03-Mar-2026,6227797408,3,622779740803,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,"HEMATOLOGY, A1C, &",RETICULOCYTES,,,,,09:05,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110011,02-Mar-2026,P1SCR,03-Mar-2026,,6227797408,7,622779740807,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,09:05,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110011,02-Mar-2026,P1SCR,03-Mar-2026,,6227797408,9,622779740809,"Red Cells, Clot",Not Received,,,TSH,,,,,,09:05,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110011,02-Mar-2026,P1SCR,03-Mar-2026,03-Mar-2026,6227797408,10,622779740810,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,09:05,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,10-Mar-2026,P1DBBL,11-Mar-2026,11-Mar-2026,6227844725,3,622784472503,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,10:21,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,10-Mar-2026,P1DBBL,11-Mar-2026,11-Mar-2026,6227844725,6,622784472506,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,10:21,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,10-Mar-2026,P1DBBL,11-Mar-2026,11-Mar-2026,6227844725,5,622784472505,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,10:21,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,10-Mar-2026,P1DBBL,11-Mar-2026,,6227844725,4,622784472504,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,10:21,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,10-Mar-2026,P1DBBL,11-Mar-2026,11-Mar-2026,6227844725,7,622784472507,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,10:21,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,10-Mar-2026,P1DBBL,11-Mar-2026,11-Mar-2026,6227844725,1,622784472501,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,10:21,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,10-Mar-2026,P1DBBL,11-Mar-2026,,6227844725,2,622784472502,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,10:21,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120005,28-Jan-2026,P1SCR,30-Jan-2026,30-Jan-2026,6227775505,11,622777550511,"Serum, SST",Received,Ambient,Default Return Ambient,,,,,,,16:50,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110008,07-Apr-2026,P2OLD29,08-Apr-2026,08-Apr-2026,6228114460,1,622811446001,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,09:21,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110008,07-Apr-2026,P2OLD29,08-Apr-2026,,6228114460,4,622811446004,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,09:21,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110008,07-Apr-2026,P2OLD29,08-Apr-2026,08-Apr-2026,6228114460,5,622811446005,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,09:21,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110008,07-Apr-2026,P2OLD29,08-Apr-2026,08-Apr-2026,6228114460,6,622811446006,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,09:21,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110008,07-Apr-2026,P2OLD29,08-Apr-2026,,6228114460,2,622811446002,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,09:21,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110008,07-Apr-2026,P2OLD29,08-Apr-2026,08-Apr-2026,6228114460,3,622811446003,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,09:21,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110008,07-Apr-2026,P2OLD29,08-Apr-2026,08-Apr-2026,6228114460,7,622811446007,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:21,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,10-Mar-2026,P2DBBL,11-Mar-2026,,6226804962,10,622680496210,"Urine, no preservative",Not Received,Ambient,,URINE DRUG SCREEN,,,,,,11:10,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110008,07-Apr-2026,P2OLD29,08-Apr-2026,,6228114460,8,622811446008,"Urine, no preservative",Not Received,Ambient,,,,,,,,09:21,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110006,31-Mar-2026,EOT,01-Apr-2026,02-Apr-2026,6228232037,5,622823203705,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,10:10,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110006,31-Mar-2026,EOT,01-Apr-2026,,6228232037,6,622823203706,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,10:10,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110006,31-Mar-2026,EOT,01-Apr-2026,,6228232037,8,622823203708,"Red Cells, Clot",Not Received,,,TSH,,,,,,10:10,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110006,31-Mar-2026,EOT,01-Apr-2026,01-Apr-2026,6228232037,9,622823203709,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,10:10,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110006,31-Mar-2026,EOT,01-Apr-2026,01-Apr-2026,6228232037,7,622823203707,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,10:10,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110006,31-Mar-2026,EOT,01-Apr-2026,01-Apr-2026,6228232037,1,622823203701,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,10:10,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110006,31-Mar-2026,EOT,01-Apr-2026,01-Apr-2026,6228232037,3,622823203703,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,10:10,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110006,31-Mar-2026,EOT,01-Apr-2026,,6228232037,4,622823203704,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,10:10,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110006,31-Mar-2026,EOT,01-Apr-2026,01-Apr-2026,6228232037,2,622823203702,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,10:10,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110008,04-May-2026,EOT,05-May-2026,05-May-2026,6228234297,1,622823429701,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,08:44,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110008,04-May-2026,EOT,05-May-2026,05-May-2026,6228234297,2,622823429702,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,08:44,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110008,04-May-2026,EOT,05-May-2026,05-May-2026,6228234297,3,622823429703,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,08:44,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110008,04-May-2026,EOT,05-May-2026,05-May-2026,6228234297,7,622823429707,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,08:44,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110008,04-May-2026,EOT,05-May-2026,,6228234297,8,622823429708,"Red Cells, Clot",Not Received,,,TSH,,,,,,08:44,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,13-May-2026,EOT,14-May-2026,14-May-2026,6228234298,1,622823429801,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,08:15,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110008,04-May-2026,EOT,05-May-2026,06-May-2026,6228234297,5,622823429705,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,08:44,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110008,04-May-2026,EOT,05-May-2026,,6228234297,6,622823429706,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,08:44,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110008,04-May-2026,EOT,05-May-2026,05-May-2026,6228234297,9,622823429709,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,08:44,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,13-May-2026,EOT,14-May-2026,,6228234298,6,622823429806,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,08:15,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,13-May-2026,EOT,14-May-2026,14-May-2026,6228234298,5,622823429805,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,08:15,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,13-May-2026,EOT,14-May-2026,14-May-2026,6228234298,2,622823429802,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,08:15,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,13-May-2026,EOT,14-May-2026,14-May-2026,6228234298,9,622823429809,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,08:15,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,13-May-2026,EOT,14-May-2026,,6228234298,4,622823429804,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,08:15,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110008,04-May-2026,EOT,05-May-2026,,6228234297,4,622823429704,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,08:44,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,13-May-2026,EOT,14-May-2026,,6228234298,8,622823429808,"Red Cells, Clot",Not Received,,,TSH,,,,,,08:15,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,13-May-2026,EOT,14-May-2026,14-May-2026,6228234298,3,622823429803,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,08:15,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,21-Apr-2026,EOT,23-Apr-2026,23-Apr-2026,6228234300,5,622823430005,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,10:37,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,13-May-2026,EOT,14-May-2026,14-May-2026,6228234298,7,622823429807,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,08:15,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,21-Apr-2026,EOT,23-Apr-2026,23-Apr-2026,6228234300,2,622823430002,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,10:37,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,21-Apr-2026,EOT,23-Apr-2026,23-Apr-2026,6228234300,1,622823430001,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,10:37,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,21-Apr-2026,EOT,23-Apr-2026,23-Apr-2026,6228234300,3,622823430003,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,10:37,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,21-Apr-2026,EOT,23-Apr-2026,,6228234300,6,622823430006,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,10:37,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,21-Apr-2026,EOT,23-Apr-2026,23-Apr-2026,6228234300,9,622823430009,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,10:37,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,21-Apr-2026,EOT,23-Apr-2026,,6228234300,8,622823430008,"Red Cells, Clot",Not Received,,,TSH,,,,,,10:37,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,21-Apr-2026,EOT,23-Apr-2026,,6228234300,4,622823430004,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,10:37,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,21-Apr-2026,EOT,23-Apr-2026,23-Apr-2026,6228234300,7,622823430007,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,10:37,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120005,25-Mar-2026,EOT,26-Mar-2026,,6226560888,10,622656088810,"Urine, no preservative",Not Received,Ambient,,,,,,,,17:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120006,25-Mar-2026,EOT,26-Mar-2026,,6226752555,10,622675255510,"Urine, no preservative",Not Received,Ambient,,,,,,,,15:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,01-Apr-2026,P2OLD29,02-Apr-2026,,6226313625,8,622631362508,"Urine, no preservative",Not Received,Ambient,,URINE DRUG SCREEN,,,,,,11:10,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,07-Apr-2026,P2DBW13,08-Apr-2026,,6226686954,10,622668695410,"Serum, SST",Canceled,Ambient,,TSH,,,,,,12:01,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 DB Week 13,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,07-Apr-2026,P2DBW13,08-Apr-2026,,6226686954,9,622668695409,"Red Cells, Clot",Not Received,,,TSH,,,,,,12:01,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 DB Week 13,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,07-Apr-2026,P2DBW13,08-Apr-2026,,6226686954,8,622668695408,"Urine, no preservative",Not Received,Ambient,,URINE DRUG SCREEN,,,,,,12:01,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 DB Week 13,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,07-Apr-2026,P2DBW13,08-Apr-2026,,6227541264,10,622754126410,"Serum, SST",Canceled,Ambient,,TSH,,,,,,08:35,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 DB Week 13,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,07-Apr-2026,P2DBW13,08-Apr-2026,,6227541264,8,622754126408,"Urine, no preservative",Not Received,Ambient,,URINE DRUG SCREEN,,,,,,08:35,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 DB Week 13,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,07-Apr-2026,P2DBW13,08-Apr-2026,,6227541264,9,622754126409,"Red Cells, Clot",Not Received,,,TSH,,,,,,08:35,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 DB Week 13,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040005,07-Apr-2026,P2OLBL,08-Apr-2026,,6227541258,10,622754125810,"Urine, no preservative",Not Received,Ambient,,URINE DRUG SCREEN,,,,,,09:45,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,10-Apr-2026,P2OLBL,11-Apr-2026,11-Apr-2026,6227542182,11,622754218211,"Serum, SST",Received,Ambient,Default Return Ambient,,,,,,,08:16,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,10-Apr-2026,P2OLBL,11-Apr-2026,,6227547337,10,622754733710,"Urine, no preservative",Not Received,Ambient,,URINE DRUG SCREEN,,,,,,11:15,,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120006,22-Apr-2026,P2OLD29,23-Apr-2026,,6226752554,8,622675255408,"Urine, no preservative",Not Received,Ambient,,URINE DRUG SCREEN,,,,,,15:30,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120005,23-Apr-2026,P2OLD29,25-Apr-2026,,6226560887,8,622656088708,"Urine, no preservative",Not Received,Ambient,,URINE DRUG SCREEN,,,,,,16:00,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,05-May-2026,P2OLD29,06-May-2026,,6227541261,8,622754126108,"Urine, no preservative",Not Received,Ambient,,URINE DRUG SCREEN,,,,,,13:15,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040007,05-May-2026,P2OLBL,06-May-2026,,6227541256,10,622754125610,"Urine, no preservative",Not Received,Ambient,,URINE DRUG SCREEN,,,,,,07:50,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040009,05-May-2026,P2OLBL,06-May-2026,,6227547338,10,622754733810,"Urine, no preservative",Not Received,Ambient,,URINE DRUG SCREEN,,,,,,09:50,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040005,22-May-2026,EOT,23-May-2026,23-May-2026,6228605652,2,622860565202,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:20,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040005,22-May-2026,EOT,23-May-2026,,6228605652,4,622860565204,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,09:20,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,22-May-2026,EOT,23-May-2026,27-May-2026,6228605653,5,622860565305,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,12:00,07:00,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040005,22-May-2026,EOT,23-May-2026,23-May-2026,6228605652,1,622860565201,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,09:20,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040005,22-May-2026,EOT,23-May-2026,23-May-2026,6228605652,9,622860565209,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,09:20,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,22-May-2026,EOT,23-May-2026,23-May-2026,6228605653,1,622860565301,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,12:00,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040005,22-May-2026,EOT,23-May-2026,23-May-2026,6228605652,3,622860565203,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,09:20,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,22-May-2026,EOT,23-May-2026,,6228605653,8,622860565308,"Red Cells, Clot",Not Received,,,TSH,,,,,,12:00,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,22-May-2026,EOT,23-May-2026,23-May-2026,6228605653,9,622860565309,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,12:00,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040005,22-May-2026,EOT,23-May-2026,,6228605652,8,622860565208,"Red Cells, Clot",Not Received,,,TSH,,,,,,09:20,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040005,22-May-2026,EOT,23-May-2026,,6228605652,6,622860565206,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,09:20,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,22-May-2026,EOT,23-May-2026,,6228605653,6,622860565306,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,12:00,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,22-May-2026,EOT,23-May-2026,23-May-2026,6228605653,7,622860565307,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,12:00,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,22-May-2026,EOT,23-May-2026,23-May-2026,6228605653,2,622860565302,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,12:00,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040005,22-May-2026,EOT,23-May-2026,23-May-2026,6228605652,7,622860565207,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,09:20,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,22-May-2026,EOT,23-May-2026,,6228605653,4,622860565304,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,12:00,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040005,22-May-2026,EOT,23-May-2026,27-May-2026,6228605652,5,622860565205,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,09:20,07:00,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,22-May-2026,EOT,23-May-2026,23-May-2026,6228605653,3,622860565303,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,12:00,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,19-May-2026,P2OLD29,20-May-2026,,6227261835,8,622726183508,"Urine, no preservative",Not Received,Ambient,,URINE DRUG SCREEN,,,,,,00:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,29-May-2026,P2DBW13,30-May-2026,,6226649754,10,622664975410,"Serum, SST",Canceled,Ambient,,TSH,,,,,,09:30,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 DB Week 13,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,29-May-2026,P2DBW13,30-May-2026,,6226649754,8,622664975408,"Urine, no preservative",Not Received,Ambient,,URINE DRUG SCREEN,,,,,,09:30,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 DB Week 13,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,29-May-2026,P2DBW13,30-May-2026,,6226649754,9,622664975409,"Red Cells, Clot",Not Received,,,TSH,,,,,,09:30,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 DB Week 13,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040009,05-Jun-2026,P2OLD29,06-Jun-2026,,6226573502,8,622657350208,"Urine, no preservative",Not Received,Ambient,,URINE DRUG SCREEN,,,,,,11:15,,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040007,05-Jun-2026,P2OLD29,06-Jun-2026,,6226889397,8,622688939708,"Urine, no preservative",Not Received,Ambient,,URINE DRUG SCREEN,,,,,,10:35,,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, diff --git a/Covance_UCO3001/Source/2026-06-08_125753 sponsor-study-36940-activity-reports-documents-equery.csv b/Covance_UCO3001/Source/2026-06-08_125753 sponsor-study-36940-activity-reports-documents-equery.csv new file mode 100644 index 0000000..aee3b16 --- /dev/null +++ b/Covance_UCO3001/Source/2026-06-08_125753 sponsor-study-36940-activity-reports-documents-equery.csv @@ -0,0 +1,79 @@ +Site,Country,Visit,Visit Collection Date,Accession,Subject,eQueryId,Create Date,Response Date Time,Issue Type,Status,Time Before Response,User Name,Email,Study Role +CZ10022 - Dr. Petr Hrabak,CZECH REPUBLIC,Unscheduled,"Mar 13, 2026 8:40 AM",6227323295,CZ100222004,2047932,"Mar 17, 2026 3:49 PM","Mar 17, 2026 9:07 PM",VST,Closed,5h 17m,Jana Pomahacova,jana.pomahacova@clinoxus.com,Investigator +CZ10022 - Dr. Petr Hrabak,CZECH REPUBLIC,Unscheduled,"Mar 13, 2026 7:45 AM",6227323297,CZ100222005,2047949,"Mar 17, 2026 3:56 PM","Mar 17, 2026 9:09 PM",VST,Closed,5h 12m,Jana Pomahacova,jana.pomahacova@clinoxus.com,Investigator +CZ10022 - Dr. Petr Hrabak,CZECH REPUBLIC,Induction Week 0,"Mar 9, 2026 8:50 AM",6227323270,CZ100222003,2038559,"Mar 11, 2026 4:39 PM","Mar 11, 2026 8:32 PM","AGE, ADT201, AMT58660, AMT3542",Closed,3h 53m,Jana Pomahacova,jana.pomahacova@clinoxus.com,Investigator +CZ10022 - Dr. Petr Hrabak,CZECH REPUBLIC,Induction Week 2,"Mar 27, 2026 7:10 AM",6227323272,CZ100222003,2073305,"Apr 1, 2026 7:54 PM","Apr 2, 2026 7:37 AM",AMT58660,Closed,11h 43m,Jana Pomahacova,jana.pomahacova@clinoxus.com,Investigator +CZ10022 - Dr. Petr Hrabak,CZECH REPUBLIC,Induction Week 4,"Apr 8, 2026 8:05 AM",6227323274,CZ100222003,2086982,"Apr 10, 2026 1:00 PM","Apr 10, 2026 1:06 PM",AMT58660,Closed,5m,Katerina Havlikova,katerina.havlikova@clinoxus.com,Investigator +CZ10022 - Dr. Petr Hrabak,CZECH REPUBLIC,Screening,"Mar 2, 2026 11:00 AM",6227810899,CZ100222003,2029805,"Mar 5, 2026 6:36 PM","Mar 6, 2026 9:01 AM","AMT58660, AMT3542",Closed,14h 24m,Jana Pomahacova,jana.pomahacova@clinoxus.com,Investigator +CZ10022 - Dr. Petr Hrabak,CZECH REPUBLIC,Screening,"Mar 4, 2026 9:20 AM",6227810900,CZ100222005,2031896,"Mar 6, 2026 6:45 PM","Mar 6, 2026 7:25 PM","AMT58660, AMT3542",Closed,40m,Jana Pomahacova,jana.pomahacova@clinoxus.com,Investigator +CZ10022 - Dr. Petr Hrabak,CZECH REPUBLIC,Screening,"Mar 3, 2026 12:10 PM",6227810901,CZ100222004,2029774,"Mar 5, 2026 6:23 PM","Mar 6, 2026 7:24 PM","AMT58660, AMT3542",Closed,1d,Jana Pomahacova,jana.pomahacova@clinoxus.com,Investigator +CZ10022 - Dr. Petr Hrabak,CZECH REPUBLIC,Induction Week 0,"Apr 9, 2026 10:35 AM",6228173397,CZ100222005,2089669,"Apr 13, 2026 2:06 PM","Apr 23, 2026 12:53 PM",PCFCOM,Closed,9d,Jana Pomahacova,jana.pomahacova@clinoxus.com,Investigator +CZ10021 - Dr.Martin Bortlik,CZECH REPUBLIC,Screening,"Feb 25, 2026 12:15 PM",6227635204,CZ100212001,2019716,"Feb 27, 2026 12:09 PM","Mar 3, 2026 11:11 AM","AMT58660, AMT3542",Closed,3d,Zdenka Dvorakova,dvorakova.zdenka@nemcb.cz,Investigator +CZ10021 - Dr.Martin Bortlik,CZECH REPUBLIC,Induction Week 0,"Apr 7, 2026 10:37 AM",6227635207,CZ100212001,2085089,"Apr 9, 2026 2:54 PM","Apr 15, 2026 7:20 AM","AMT58660, AMT15602",Closed,5d,Tereza Hosnova,hosnova.tereza2@nemcb.cz,Investigator +CZ10021 - Dr.Martin Bortlik,CZECH REPUBLIC,Induction Week 2,"Apr 20, 2026 8:43 AM",6227635208,CZ100212001,2106304,"Apr 22, 2026 7:04 PM","Apr 23, 2026 9:21 AM",AMT58660,Closed,14h 16m,Tereza Hosnova,hosnova.tereza2@nemcb.cz,Investigator +CZ10021 - Dr.Martin Bortlik,CZECH REPUBLIC,Induction Week 4,"May 5, 2026 10:00 AM",6227635211,CZ100212001,2133221,"May 9, 2026 6:24 PM","May 11, 2026 2:34 PM",AMT58660,Closed,1d,Tereza Hosnova,hosnova.tereza2@nemcb.cz,Investigator +CZ10020 - Dr.Lucie Gonsorcikova,CZECH REPUBLIC,Screening,"Apr 13, 2026 12:20 PM",6227993962,CZ100201001,2094721,"Apr 15, 2026 6:02 PM","Apr 21, 2026 12:47 PM","AMT58660, AMT3542",Closed,5d,Zuzana Zahradnikova,zuzana.zahradnikova@ftn.cz,Investigator +CZ10020 - Dr.Lucie Gonsorcikova,CZECH REPUBLIC,Induction Week 0,"May 18, 2026 9:28 AM",6227993966,CZ100201001,2156061,"May 22, 2026 9:37 PM","May 25, 2026 6:43 AM","ADT201, AMT58660, AMT3542",Closed,2d,Zuzana Zahradnikova,zuzana.zahradnikova@ftn.cz,Investigator +CZ10013 - Dr.David Stepek,CZECH REPUBLIC,Biopsy,"May 25, 2026 12:00 AM",6228501732,CZ100132003,2165892,"May 29, 2026 3:13 PM","May 31, 2026 9:26 PM",ADT8471,Closed,2d,David Stepek,dstepek@vnbrno.cz,Investigator +CZ10001 - Dr. Matej Falc,CZECH REPUBLIC,Screening,"Mar 2, 2026 7:00 AM",6227323204,CZ100012002,2032628,"Mar 9, 2026 10:33 AM","Mar 9, 2026 11:58 AM",AMT58660,Closed,1h 24m,Matej Falc,matesfalc@seznam.cz,Investigator +CZ10001 - Dr. Matej Falc,CZECH REPUBLIC,Screening,"Mar 2, 2026 7:00 AM",6227323204,CZ100012002,2026645,"Mar 4, 2026 12:58 PM","Mar 6, 2026 6:01 PM","AMT58660, AMT3542",Closed,2d,Matej Falc,matesfalc@seznam.cz,Investigator +CZ10001 - Dr. Matej Falc,CZECH REPUBLIC,Induction Week 0,,6227323206,,2112374,"Apr 27, 2026 2:17 PM","May 5, 2026 11:24 AM","PCFCOM, ADT201, AMT58660, AMT3542",Closed,7d,Matej Falc,matesfalc@seznam.cz,Investigator +CZ10001 - Dr. Matej Falc,CZECH REPUBLIC,Induction Week 2,"Apr 23, 2026 7:40 AM",6227323207,CZ100012002,2113312,"Apr 27, 2026 6:35 PM","Apr 28, 2026 9:06 PM",AMT58660,Closed,1d,Matej Falc,matesfalc@seznam.cz,Investigator +CZ10001 - Dr. Matej Falc,CZECH REPUBLIC,Induction Week 2,"Mar 4, 2026 7:00 AM",6227323208,CZ100012001,2030545,"Mar 6, 2026 11:02 AM","Mar 6, 2026 11:42 AM","AMT58660, AMT688",Closed,39m,Matej Falc,matesfalc@seznam.cz,Investigator +CZ10001 - Dr. Matej Falc,CZECH REPUBLIC,Induction Week 4,"Mar 18, 2026 7:05 AM",6227323210,CZ100012001,2053955,"Mar 20, 2026 2:50 PM","Mar 25, 2026 3:29 PM","SCD, AMT58660",Closed,5d,Matej Falc,matesfalc@seznam.cz,Investigator +CZ10001 - Dr. Matej Falc,CZECH REPUBLIC,Stool Pathogens,"Jan 28, 2026 6:00 AM",6227323211,CZ100012001,1976585,"Jan 30, 2026 1:21 PM","Feb 6, 2026 2:37 PM","VST, AGE",Closed,7d,Matej Falc,matesfalc@seznam.cz,Investigator +CZ10001 - Dr. Matej Falc,CZECH REPUBLIC,Stool Pathogens,"Jan 28, 2026 6:00 AM",6227323211,CZ100012001,1991148,"Feb 9, 2026 7:43 PM","Feb 13, 2026 8:04 AM",AGE,Closed,3d,Matej Falc,matesfalc@seznam.cz,Investigator +CZ10001 - Dr. Matej Falc,CZECH REPUBLIC,Biopsy,"Feb 5, 2026 12:00 AM",6227323223,CZ100012001,1989998,"Feb 9, 2026 1:42 PM","Feb 10, 2026 6:46 PM",VST,Closed,1d,Matej Falc,matesfalc@seznam.cz,Investigator +CZ10001 - Dr. Matej Falc,CZECH REPUBLIC,Unscheduled,,6227323231,,2053405,"Mar 20, 2026 12:14 PM","Mar 30, 2026 12:54 AM",PCFCOM,Closed,9d,Matej Falc,matesfalc@seznam.cz,Investigator +CZ10001 - Dr. Matej Falc,CZECH REPUBLIC,Unscheduled,"Apr 22, 2026 7:40 AM",6227323232,CZ100012001,2141856,"May 14, 2026 4:23 PM","May 19, 2026 12:54 PM","SCD, AGE",Closed,4d,Matej Falc,matesfalc@seznam.cz,Investigator +CZ10001 - Dr. Matej Falc,CZECH REPUBLIC,Unscheduled,"Apr 22, 2026 7:40 AM",6227323232,CZ100012001,2152157,"May 21, 2026 11:32 AM","May 26, 2026 8:15 AM",AGE,Closed,4d,Matej Falc,matesfalc@seznam.cz,Investigator +CZ10001 - Dr. Matej Falc,CZECH REPUBLIC,Unscheduled,"Apr 22, 2026 7:40 AM",6227323232,CZ100012001,2112413,"Apr 27, 2026 2:24 PM","May 5, 2026 11:25 AM","PSX, SCT, VST, AGE, ADT201",Closed,7d,Matej Falc,matesfalc@seznam.cz,Investigator +CZ10001 - Dr. Matej Falc,CZECH REPUBLIC,Unscheduled,"Apr 22, 2026 7:40 AM",6227323232,CZ100012001,2126904,"May 6, 2026 12:02 PM","May 12, 2026 4:58 PM","SCT, VST, AGE",Closed,6d,Matej Falc,matesfalc@seznam.cz,Investigator +CZ10001 - Dr. Matej Falc,CZECH REPUBLIC,Unscheduled,,6227323233,,2053482,"Mar 20, 2026 12:40 PM","Mar 27, 2026 9:58 AM",PCFCOM,Closed,6d,Matej Falc,matesfalc@seznam.cz,Investigator +CZ10001 - Dr. Matej Falc,CZECH REPUBLIC,Induction Week 0,"Apr 8, 2026 7:10 AM",6228036554,CZ100012002,2089973,"Apr 13, 2026 3:26 PM","Apr 21, 2026 1:32 PM",AMT15602,Closed,7d,Matej Falc,matesfalc@seznam.cz,Investigator +CZ10001 - Dr. Matej Falc,CZECH REPUBLIC,Biopsy,"May 13, 2026 12:00 AM",6228252073,CZ100012003,2147778,"May 19, 2026 10:13 AM","May 21, 2026 4:38 PM",VST,Closed,2d,Matej Falc,matesfalc@seznam.cz,Investigator +CZ10001 - Dr. Matej Falc,CZECH REPUBLIC,Induction Week 4,"May 6, 2026 8:05 AM",6227933142,CZ100012002,2134478,"May 11, 2026 2:54 PM","May 11, 2026 3:11 PM","AMT58660, AMT3542",Closed,16m,Matej Falc,matesfalc@seznam.cz,Investigator +CZ10001 - Dr. Matej Falc,CZECH REPUBLIC,Induction Week 12,"May 13, 2026 8:05 AM",6227933143,CZ100012001,2147202,"May 18, 2026 7:51 PM","May 19, 2026 8:38 AM",AMT58660,Closed,12h 47m,Matej Falc,matesfalc@seznam.cz,Investigator +CZ10003 - Dr. Leksa Vaclav,CZECH REPUBLIC,Screening,"May 13, 2026 8:15 AM",6227323299,CZ100032001,2154732,"May 22, 2026 12:36 PM","May 25, 2026 8:57 AM",AMT58660,Closed,2d,Leksa Vaclav,vaclav.leksa@seznam.cz,Investigator +CZ10016 - Dr.Robert Mudr,CZECH REPUBLIC,Screening,"Apr 21, 2026 10:45 AM",6227635171,CZ100162001,2109874,"Apr 24, 2026 2:00 PM",,AMT58660,Closed,,,, +CZ10016 - Dr.Robert Mudr,CZECH REPUBLIC,Screening,"Apr 21, 2026 10:45 AM",6227635171,CZ100162001,2123465,"May 4, 2026 7:16 PM","May 5, 2026 10:04 AM",AMT58660,Closed,14h 48m,Petr Pekny,petr.pekny@nmskb.cz,Investigator +CZ10016 - Dr.Robert Mudr,CZECH REPUBLIC,Screening,"May 27, 2026 12:35 PM",6227635173,CZ100162002,2168473,"Jun 1, 2026 3:20 PM","Jun 1, 2026 3:50 PM",AMT58660,Closed,29m,Petr Pekny,petr.pekny@nmskb.cz,Investigator +CZ10016 - Dr.Robert Mudr,CZECH REPUBLIC,Induction Week 0,"May 28, 2026 10:45 AM",6227635174,CZ100162001,2173754,"Jun 3, 2026 7:23 PM","Jun 3, 2026 11:14 PM",AMT58660,Closed,3h 50m,Petr Pekny,petr.pekny@nmskb.cz,Investigator +CZ10013 - Dr.David Stepek,CZECH REPUBLIC,Induction Week 0,"Mar 24, 2026 9:40 AM",6227635142,CZ100132001,2064220,"Mar 26, 2026 9:37 PM",,"AMT58660, AMT3542",Closed,,,, +CZ10013 - Dr.David Stepek,CZECH REPUBLIC,Induction Week 0,"Mar 24, 2026 9:40 AM",6227635142,CZ100132001,2066330,"Mar 27, 2026 6:43 PM","Mar 30, 2026 10:41 PM",AMT58660,Closed,3d,David Stepek,dstepek@vnbrno.cz,Investigator +CZ10013 - Dr.David Stepek,CZECH REPUBLIC,Induction Week 2,"Apr 7, 2026 8:50 AM",6227635144,CZ100132001,2087084,"Apr 10, 2026 1:27 PM",,AMT58660,Closed,,,, +CZ10013 - Dr.David Stepek,CZECH REPUBLIC,Induction Week 2,"Apr 7, 2026 8:50 AM",6227635144,CZ100132001,2100086,"Apr 18, 2026 11:15 AM","Apr 22, 2026 7:51 PM",AMT58660,Closed,4d,David Stepek,dstepek@vnbrno.cz,Investigator +CZ10013 - Dr.David Stepek,CZECH REPUBLIC,Induction Week 4,"Apr 21, 2026 8:45 AM",6227635146,CZ100132001,2108501,"Apr 23, 2026 6:55 PM",,AMT58660,Closed,,,, +CZ10013 - Dr.David Stepek,CZECH REPUBLIC,Induction Week 4,"Apr 21, 2026 8:45 AM",6227635146,CZ100132001,2123492,"May 4, 2026 7:24 PM","May 5, 2026 3:30 PM",AMT58660,Closed,20h 6m,David Stepek,dstepek@vnbrno.cz,Investigator +CZ10013 - Dr.David Stepek,CZECH REPUBLIC,Screening,"Apr 1, 2026 8:00 AM",6227635139,CZ100132002,2101883,"Apr 20, 2026 6:49 PM","Apr 22, 2026 7:51 PM",AMT58660,Closed,2d,David Stepek,dstepek@vnbrno.cz,Investigator +CZ10013 - Dr.David Stepek,CZECH REPUBLIC,Screening,"Apr 1, 2026 8:00 AM",6227635139,CZ100132002,2090916,"Apr 13, 2026 9:15 PM",,AMT58660,Closed,,,, +CZ10013 - Dr.David Stepek,CZECH REPUBLIC,Screening,"Apr 1, 2026 8:00 AM",6227635139,CZ100132002,2079289,"Apr 6, 2026 3:21 PM",,AMT58660,Closed,,,, +CZ10013 - Dr.David Stepek,CZECH REPUBLIC,Screening,"Feb 26, 2026 1:20 PM",6227635140,CZ100132001,2033901,"Mar 9, 2026 3:53 PM","Mar 16, 2026 10:08 PM","SCD, AMT58660, AMT3542",Closed,7d,David Stepek,dstepek@vnbrno.cz,Investigator +CZ10013 - Dr.David Stepek,CZECH REPUBLIC,Screening,"Feb 26, 2026 1:20 PM",6227635140,CZ100132001,2023257,"Mar 2, 2026 6:47 PM",,"SCD, AGE, AMT58660, AMT3542",Closed,,,, +CZ10013 - Dr.David Stepek,CZECH REPUBLIC,Screening,"May 6, 2026 10:45 AM",6227635141,CZ100132003,2137874,"May 12, 2026 8:03 PM","May 19, 2026 7:48 AM",AMT58660,Closed,6d,,, +CZ10013 - Dr.David Stepek,CZECH REPUBLIC,Biopsy,"Apr 21, 2026 12:00 AM",6227635159,CZ100132002,2109534,"Apr 24, 2026 12:45 PM",,ADT8471,Closed,,,, +CZ10013 - Dr.David Stepek,CZECH REPUBLIC,Biopsy,"Apr 21, 2026 12:00 AM",6227635159,CZ100132002,2123486,"May 4, 2026 7:23 PM","May 5, 2026 3:30 PM",ADT8471,Closed,20h 7m,David Stepek,dstepek@vnbrno.cz,Investigator +CZ10012 - Dr.Stefan Konecny,CZECH REPUBLIC,Unscheduled,,6227697745,,2140058,"May 13, 2026 7:02 PM","May 26, 2026 9:46 AM",PCFCOM,Response Received,12d,Kristyna Hosova,hosova.kristyna@fnbrno.cz,Investigator +CZ10012 - Dr.Stefan Konecny,CZECH REPUBLIC,Screening,"Mar 18, 2026 9:18 AM",6227697718,CZ100122001,2053959,"Mar 20, 2026 2:52 PM","Mar 23, 2026 12:00 PM","SCT, AMT58660",Closed,2d,Kristyna Hosova,hosova.kristyna@fnbrno.cz,Investigator +CZ10012 - Dr.Stefan Konecny,CZECH REPUBLIC,Induction Week 0,"Apr 7, 2026 11:45 AM",6227697719,CZ100122001,2085069,"Apr 9, 2026 2:48 PM","Apr 9, 2026 6:28 PM",AMT58660,Closed,3h 39m,Kristyna Hosova,hosova.kristyna@fnbrno.cz,Investigator +CZ10012 - Dr.Stefan Konecny,CZECH REPUBLIC,Induction Week 2,"Apr 22, 2026 9:25 AM",6227697722,CZ100122001,2113315,"Apr 27, 2026 6:35 PM","Apr 27, 2026 8:50 PM",AMT58660,Closed,2h 14m,Kristyna Hosova,hosova.kristyna@fnbrno.cz,Investigator +CZ10012 - Dr.Stefan Konecny,CZECH REPUBLIC,Induction Week 4,"May 7, 2026 12:40 PM",6227697723,CZ100122001,2142322,"May 14, 2026 7:10 PM","May 14, 2026 7:42 PM",AMT58660,Closed,31m,Kristyna Hosova,hosova.kristyna@fnbrno.cz,Investigator +CZ10012 - Dr.Stefan Konecny,CZECH REPUBLIC,Biopsy,"Mar 23, 2026 12:00 AM",6227697736,CZ100122001,2060524,"Mar 25, 2026 12:53 PM","Mar 25, 2026 2:09 PM",AMT23260,Closed,1h 15m,Kristyna Hosova,hosova.kristyna@fnbrno.cz,Investigator +CZ10009 - Dr. Jiri Pumprla,CZECH REPUBLIC,Screening,"Mar 31, 2026 8:30 AM",6227323330,CZ100092001,2075611,"Apr 2, 2026 5:37 PM",,AMT58660,Closed,,,, +CZ10009 - Dr. Jiri Pumprla,CZECH REPUBLIC,Screening,"Mar 31, 2026 8:30 AM",6227323330,CZ100092001,2085558,"Apr 9, 2026 5:08 PM","Apr 10, 2026 2:06 PM",AMT58660,Closed,20h 58m,Jiri Pumprla,research@vilazdravi.cz,Investigator +CZ10009 - Dr. Jiri Pumprla,CZECH REPUBLIC,Screening,"Apr 16, 2026 12:00 PM",6227323332,CZ100092002,2101792,"Apr 20, 2026 6:19 PM","Apr 23, 2026 1:22 PM",AMT58660,Closed,2d,Marketa Menyhardova,menyhardova@vilazdravi.cz,Investigator +CZ10009 - Dr. Jiri Pumprla,CZECH REPUBLIC,Induction Week 0,"May 5, 2026 11:30 AM",6227323334,CZ100092001,2133224,"May 9, 2026 6:30 PM","May 13, 2026 10:10 AM","AMT58660, ADT809",Closed,3d,Marketa Menyhardova,menyhardova@vilazdravi.cz,Investigator +CZ10009 - Dr. Jiri Pumprla,CZECH REPUBLIC,Induction Week 2,"May 19, 2026 10:50 AM",6227323335,CZ100092001,2158952,"May 26, 2026 12:21 PM","May 27, 2026 9:03 AM",AMT58660,Closed,20h 42m,Marketa Menyhardova,menyhardova@vilazdravi.cz,Investigator +CZ10006 - Dr. Michal Konecny,CZECH REPUBLIC,Unscheduled,"Mar 17, 2026 8:00 AM",6227323265,CZ100062001,2052144,"Mar 19, 2026 4:08 PM","Mar 24, 2026 9:29 AM","PSX, SCT, AGE",Closed,4d,Michal Konecny,konecnymi@seznam.cz,Investigator +CZ10006 - Dr. Michal Konecny,CZECH REPUBLIC,Screening,"Apr 20, 2026 7:45 AM",6227323234,CZ100062002,2106334,"Apr 22, 2026 7:18 PM","Apr 22, 2026 7:36 PM",AMT58660,Closed,18m,Michal Konecny,konecnymi@seznam.cz,Investigator +CZ10006 - Dr. Michal Konecny,CZECH REPUBLIC,Induction Week 0,"Mar 20, 2026 8:00 AM",6227323237,CZ100062001,2064023,"Mar 26, 2026 7:00 PM","Mar 27, 2026 9:04 AM",PCFCOM,Closed,14h 3m,Michal Konecny,konecnymi@seznam.cz,Investigator +CZ10006 - Dr. Michal Konecny,CZECH REPUBLIC,Induction Week 0,"Mar 20, 2026 8:00 AM",6227323237,CZ100062001,2061456,"Mar 25, 2026 6:16 PM","Mar 26, 2026 8:38 AM",AMT58660,Closed,14h 22m,Michal Konecny,konecnymi@seznam.cz,Investigator +CZ10006 - Dr. Michal Konecny,CZECH REPUBLIC,Induction Week 0,"May 26, 2026 9:20 AM",6227323238,CZ100062002,2168534,"Jun 1, 2026 3:33 PM","Jun 6, 2026 6:19 PM","ADT201, AMT58660",Response Received,5d,Michal Konecny,konecnymi@seznam.cz,Investigator +CZ10006 - Dr. Michal Konecny,CZECH REPUBLIC,Induction Week 2,"Apr 8, 2026 7:10 AM",6227323240,CZ100062001,2086807,"Apr 10, 2026 12:21 PM","Apr 18, 2026 10:40 PM","AMT58660, ADT809",Closed,8d,Michal Konecny,konecnymi@seznam.cz,Investigator +CZ10006 - Dr. Michal Konecny,CZECH REPUBLIC,Induction Week 4,"Apr 15, 2026 8:45 AM",6227323242,CZ100062001,2102704,"Apr 21, 2026 11:22 AM","Apr 22, 2026 7:36 PM",AMT58660,Closed,1d,Michal Konecny,konecnymi@seznam.cz,Investigator +CZ10006 - Dr. Michal Konecny,CZECH REPUBLIC,Biopsy,"Feb 19, 2026 12:00 AM",6227323254,CZ100062001,2014333,"Feb 24, 2026 4:13 PM","Feb 24, 2026 8:20 PM",VST,Closed,4h 6m,Michal Konecny,konecnymi@seznam.cz,Investigator +title,value,,,,,,,,,,,,, +Search,,,,,,,,,,,,,, +Site,"930551, 930556, 930525, 930549, 930543, 930547, 930555, 930557, 930539, 930536, 930553, 930531",,,,,,,,,,,,, +Unresponded Only?,FALSE,,,,,,,,,,,,, +Posted,From - To - ,,,,,,,,,,,,, diff --git a/Covance_UCO3001/Source/2026-06-08_125753 sponsor-study-36940-activity-reports-documents-equery_unresponded_only.csv b/Covance_UCO3001/Source/2026-06-08_125753 sponsor-study-36940-activity-reports-documents-equery_unresponded_only.csv new file mode 100644 index 0000000..652a478 --- /dev/null +++ b/Covance_UCO3001/Source/2026-06-08_125753 sponsor-study-36940-activity-reports-documents-equery_unresponded_only.csv @@ -0,0 +1,9 @@ +Site,Country,Visit,Visit Collection Date,Accession,Subject,eQueryId,Create Date,Response Date Time,Issue Type,Status,Time Before Response,User Name,Email,Study Role +,,,,,,,,,,,,,, +,,,,,,,,,,,,,, +,,,,,,,,,,,,,, +title,value,,,,,,,,,,,,, +Search,,,,,,,,,,,,,, +Site,"930551, 930556, 930525, 930549, 930543, 930547, 930555, 930557, 930539, 930536, 930553, 930531",,,,,,,,,,,,, +Unresponded Only?,TRUE,,,,,,,,,,,,, +Posted,From - To - ,,,,,,,,,,,,, diff --git a/Covance_UCO3001/Source/2026-06-08_130419 sponsor-study-36940-test-results-930525-standard.csv b/Covance_UCO3001/Source/2026-06-08_130419 sponsor-study-36940-test-results-930525-standard.csv new file mode 100644 index 0000000..d9a3620 --- /dev/null +++ b/Covance_UCO3001/Source/2026-06-08_130419 sponsor-study-36940-test-results-930525-standard.csv @@ -0,0 +1,773 @@ +"Disclaimer: The information presented in On-Screen Results is not intended to be a replacement of the official Lab Results, Alerts, Data Revisions and Cancellations found in the Lab Reports section of this software application. On-Screen Results should not be used for patient diagnosis, treatment decisions or submission to regulatory bodies.",,,,,,,,,,,,,,,,,,, +Subject,Subject Data Revision,Screen No.,Age,Age Unit,Gender,Visit,Visit Data Revision,Collected Time,Accession,Test Group,Test,Administrative Question,Value,Result Data Revision,Flags,Cancellation Reason,Comments,Range,Units +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,ALP<2XULN,ALP<2XULN,,Criteria Met,,,,,, +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,ALT>/=3XULN,ALT >/= 3 X ULN,,Criteria not met,,,,,, +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,ALT>/=3XULN & TBIL>/=2XULN,ALT >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,AST>/=3XULN,AST >/= 3 X ULN,,Criteria not met,,,,,, +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,AST>/=3XULN & TBIL>/=2XULN,AST >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,CHEMISTRY PANEL,Total Bilirubin,,5,,,,,3 - 21,umol/L +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,1.7,,,,,0 - 6.2,umol/L +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,CHEMISTRY PANEL,Alkaline Phosphatase,,57,,,,,40 - 129,U/L +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,CHEMISTRY PANEL,ALT (SGPT),,32,,,,,5 - 48,U/L +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,CHEMISTRY PANEL,AST (SGOT),,35,,,,,8 - 40,U/L +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,CHEMISTRY PANEL,GGT,,14,,,,,10 - 61,U/L +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,CHEMISTRY PANEL,LDH,,248,,H,,,53 - 234,U/L +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,CHEMISTRY PANEL,Urea Nitrogen,,8.2,,,,,1.4 - 8.6,mmol/L +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,97,,,,,40 - 110,umol/L +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,CHEMISTRY PANEL,Serum Glucose,,5.0,,,,,3.9 - 5.6,mmol/L +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,CHEMISTRY PANEL,Serum Uric Acid,,395,,,,,125 - 488,umol/L +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,CHEMISTRY PANEL,Calcium (EDTA),,2.44,,,,,2.07 - 2.64,mmol/L +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,CHEMISTRY PANEL,Phosphorus,,1.19,,,,,0.71 - 1.65,mmol/L +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,CHEMISTRY PANEL,Total Protein,,71,,,,,61 - 84,g/L +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,CHEMISTRY PANEL,Albumin-BCG,,44,,,,,33 - 49,g/L +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,CHEMISTRY PANEL,Creatine Kinase,,439,,H,,,39 - 308,U/L +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,CHEMISTRY PANEL,Serum Sodium,,137,,,,,132 - 147,mmol/L +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,CHEMISTRY PANEL,Serum Potassium,,4.6,,,,,3.5 - 5.2,mmol/L +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,CHEMISTRY PANEL,Serum Bicarbonate,,24.4,,,,,19.3 - 29.3,mmol/L +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,CHEMISTRY PANEL,Serum Chloride,,102,,,,,94 - 112,mmol/L +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,CHEMISTRY PANEL,Magnesium,,0.77,,,,,0.66 - 1.07,mmol/L +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,88,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,FECAL COLLECTION D/T,Stool Collection Date,Y,01-Jun-2026,,,,,, +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,FECAL COLLECTION D/T,Stool Collection Time,Y,05:00,,,,,, +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,129,,,,,127 - 181,g/L +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.38,,L,,,0.39 - 0.54, +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.3,,L,,,4.5 - 6.4,TI/L +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,30,,,,,26 - 34,pg +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,88,,,,,79 - 96,fL +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,6.82,,,,,3.8 - 10.7,GI/L +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,4.31,,,,,1.96 - 7.23,GI/L +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.93,,,,,0.91 - 4.28,GI/L +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.22,,,,,0.12 - 0.92,GI/L +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.32,,,,,0 - 0.57,GI/L +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.04,,,,,0 - 0.2,GI/L +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,63.1,,,,,40.5 - 75,% +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,28.4,,,,,15.4 - 48.5,% +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,3.3,,,,,2.6 - 10.1,% +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,4.7,,,,,0 - 6.8,% +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.6,,,,,0 - 2,% +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,251,,,,,140 - 400,GI/L +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,LIPID PANEL,Direct HDL-C 4th Generation,,1.53,,,,Result verified by repeat analysis,1.03 - 1.53,mmol/L +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,LIPID PANEL,Triglycerides (GPO),,0.90,,,,,0.56 - 3.62,mmol/L +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,LIPID PANEL,Cholesterol (High Performance),,5.18,,,,,3.88 - 6.83,mmol/L +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,LIPID PANEL,LDL Chol Friedewald 4th,,3.24,,,,,0 - 3.34,mmol/L +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,SM01/PLASMA PK TROUGH COLL D/T,Collection Date Predose,Y,01-Jun-2026,,,,,, +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,SM01/PLASMA PK TROUGH COLL D/T,Collection Time Predose,Y,14:55,,,,,, +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,SM02/PLASMA PK PEAK COLL D/T,Collection Date Post dose,Y,01-Jun-2026,,,,,, +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,SM02/PLASMA PK PEAK COLL D/T,Post Dose Collection Time,Y,16:05,,,,,, +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,SM04/SERUM ADA PRE COLL D/T,Collection Date Predose,Y,01-Jun-2026,,,,,, +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,SM04/SERUM ADA PRE COLL D/T,Collection Time Predose,Y,14:55,,,,,, +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,SM09/STOOL PK COLL D/T,Stool Collection Date,Y,01-Jun-2026,,,,,, +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,SM09/STOOL PK COLL D/T,Stool Collection Time,Y,05:00,,,,,, +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,SM10/FECAL BMRKS COLL D/T,Stool Collection Date,Y,01-Jun-2026,,,,,, +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,SM10/FECAL BMRKS COLL D/T,Stool Collection Time,Y,05:00,,,,,, +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,SUBJECT HEIGHT (CM),Height (cm),Y,N/A (subject >/= 18 years of age),,,,,cm, +CZ100222003,,,,,Male,Biopsy,,"May 20, 2026 12:00 AM",6228179945,ANATOMICAL SITE,Anatomical Site,Y,15-20cm from anal verge,,,,,, +CZ100222003,,,,,Male,Biopsy,,"May 20, 2026 12:00 AM",6228179945,BIOPSY COLLECTION METHOD,Collection Method,Y,colonoscopy,,,,,, +CZ100222003,,,,,Male,Biopsy,,"May 20, 2026 12:00 AM",6228179945,BIOPSY FIXATIVE USED,Fixative Used,,10% NBF,,,,,, +CZ100222003,,,,,Male,Biopsy,,"May 20, 2026 12:00 AM",6228179945,DATE/TIME PLACED IN FORMALIN,Date Sample placed in Formalin,Y,20-May-2026,,,,,, +CZ100222003,,,,,Male,Biopsy,,"May 20, 2026 12:00 AM",6228179945,DATE/TIME PLACED IN FORMALIN,Time Sample placed in Formalin,Y,11:44,,,,,, +CZ100222003,,,,,Male,Biopsy,,"May 20, 2026 12:00 AM",6228179945,DIAGNOSIS,Diagnosis:,Y,Ulcerative Colitis,,,,,, +CZ100222003,,,,,Male,Biopsy,,"May 20, 2026 12:00 AM",6228179945,INFLAMED AREA,Inflamed area?,,Yes,,,,,, +CZ100222003,,,,,Male,Biopsy,,"May 20, 2026 12:00 AM",6228179945,TISSUE BIOPSY EMBEDDING1,Biopsy technical QC-CL,,Smpl meets HT requirements,,,,,, +CZ100222003,,,,,Male,Biopsy,,"May 20, 2026 12:00 AM",6228179945,TISSUE BIOPSY EMBEDDING1,Biopsy processing Time-CL,,10:00,,,,,, +CZ100222003,,,,,Male,Biopsy,,"May 20, 2026 12:00 AM",6228179945,TISSUE BIOPSY EMBEDDING1,Biopsy processing Date-CL,,22-May-2026,,,,,, +CZ100222003,,,,,Male,Biopsy,,"May 20, 2026 12:00 AM",6228179945,TISSUE BIOPSY EMBEDDING1,Biopsy Comments-CL,,Received in 10% NBF,,,,,, +CZ100222003,,,,,Male,Biopsy,,"May 20, 2026 12:00 AM",6228179945,TISSUE BIOPSY EMBEDDING1,# of Cassettes-(FI)-CL,,1,,,,,, +CZ100222003,,,,,Male,Biopsy,,"May 20, 2026 12:00 AM",6228179945,ULCERATED AREA,Is biopsy site ulcerated?,,Yes,,,,,, +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,ALP<2XULN,ALP<2XULN,,Criteria Met,,,,,, +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,ALT>/=3XULN,ALT >/= 3 X ULN,,Criteria not met,,,,,, +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,ALT>/=3XULN & TBIL>/=2XULN,ALT >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,AST>/=3XULN,AST >/= 3 X ULN,,Criteria not met,,,,,, +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,AST>/=3XULN & TBIL>/=2XULN,AST >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,CHEMISTRY PANEL,Total Bilirubin,,11,,,,,3 - 21,umol/L +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.5,,,,,0 - 6.2,umol/L +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,CHEMISTRY PANEL,Alkaline Phosphatase,,68,,,,,40 - 129,U/L +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,CHEMISTRY PANEL,ALT (SGPT),,10,,,,,5 - 48,U/L +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,CHEMISTRY PANEL,AST (SGOT),,17,,,,,8 - 40,U/L +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,CHEMISTRY PANEL,GGT,,10,,,,,10 - 61,U/L +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,CHEMISTRY PANEL,LDH,,164,,,,,53 - 234,U/L +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,CHEMISTRY PANEL,Urea Nitrogen,,5.1,,,,,1.4 - 8.6,mmol/L +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,101,,,,,40 - 110,umol/L +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,CHEMISTRY PANEL,Serum Glucose,,4.4,,,,,3.9 - 5.6,mmol/L +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,CHEMISTRY PANEL,Serum Uric Acid,,255,,,,,125 - 488,umol/L +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,CHEMISTRY PANEL,Calcium (EDTA),,2.45,,,,,2.07 - 2.64,mmol/L +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,CHEMISTRY PANEL,Phosphorus,,1.10,,,,,0.71 - 1.65,mmol/L +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,CHEMISTRY PANEL,Total Protein,,66,,,,,61 - 84,g/L +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,CHEMISTRY PANEL,Albumin-BCG,,43,,,,,33 - 49,g/L +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,CHEMISTRY PANEL,Creatine Kinase,,131,,,,,39 - 308,U/L +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,CHEMISTRY PANEL,Serum Sodium,,142,,,,,132 - 147,mmol/L +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,CHEMISTRY PANEL,Serum Potassium,,4.5,,,,,3.5 - 5.2,mmol/L +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,CHEMISTRY PANEL,Serum Bicarbonate,,25.4,,,,,19.3 - 29.3,mmol/L +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,CHEMISTRY PANEL,Serum Chloride,,105,,,,,94 - 112,mmol/L +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,CHEMISTRY PANEL,Magnesium,,0.82,,,,,0.66 - 1.07,mmol/L +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,87,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,FECAL COLLECTION D/T,Stool Collection Date,Y,05-May-2026,,,,,, +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,FECAL COLLECTION D/T,Stool Collection Time,Y,06:40,,,,,, +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,145,,,,,127 - 181,g/L +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.42,,,,,0.39 - 0.54, +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.8,,,,,4.5 - 6.4,TI/L +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,30,,,,,26 - 34,pg +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,88,,,,,79 - 96,fL +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,5.72,,,,,3.8 - 10.7,GI/L +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.17,,,,,1.96 - 7.23,GI/L +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.71,,,,,0.91 - 4.28,GI/L +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.36,,,,,0.12 - 0.92,GI/L +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.44,,,,,0 - 0.57,GI/L +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.03,,,,,0 - 0.2,GI/L +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,55.4,,,,,40.5 - 75,% +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,30.0,,,,,15.4 - 48.5,% +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,6.3,,,,,2.6 - 10.1,% +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,7.7,,H,,,0 - 6.8,% +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.6,,,,,0 - 2,% +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,294,,,,,140 - 400,GI/L +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,SM01/PLASMA PK TROUGH COLL D/T,Collection Date Predose,Y,05-May-2026,,,,,, +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,SM01/PLASMA PK TROUGH COLL D/T,Collection Time Predose,Y,07:40,,,,,, +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,SM02/PLASMA PK PEAK COLL D/T,Collection Date Post dose,Y,05-May-2026,,,,,, +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,SM02/PLASMA PK PEAK COLL D/T,Post Dose Collection Time,Y,08:50,,,,,, +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,SM04/SERUM ADA PRE COLL D/T,Collection Date Predose,Y,05-May-2026,,,,,, +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,SM04/SERUM ADA PRE COLL D/T,Collection Time Predose,Y,07:40,,,,,, +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,SM09/STOOL PK COLL D/T,Stool Collection Date,Y,05-May-2026,,,,,, +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,SM09/STOOL PK COLL D/T,Stool Collection Time,Y,06:40,,,,,, +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,SUBJECT HEIGHT (CM),Height (cm),Y,N/A (subject >/= 18 years of age),,,,,cm, +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,ALP<2XULN,ALP<2XULN,,Criteria Met,,,,,, +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,ALT>/=3XULN,ALT >/= 3 X ULN,,Criteria not met,,,,,, +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,ALT>/=3XULN & TBIL>/=2XULN,ALT >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,AST>/=3XULN,AST >/= 3 X ULN,,Criteria not met,,,,,, +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,AST>/=3XULN & TBIL>/=2XULN,AST >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,CHEMISTRY PANEL,Total Bilirubin,,4,,,,,3 - 21,umol/L +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.1,,,,,0 - 6.2,umol/L +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,CHEMISTRY PANEL,Alkaline Phosphatase,,65,,,,,40 - 129,U/L +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,CHEMISTRY PANEL,ALT (SGPT),,7,,,,,5 - 48,U/L +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,CHEMISTRY PANEL,AST (SGOT),,17,,,,,8 - 40,U/L +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,CHEMISTRY PANEL,GGT,,7,,L,,,10 - 61,U/L +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,CHEMISTRY PANEL,LDH,,147,,,,,53 - 234,U/L +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,CHEMISTRY PANEL,Urea Nitrogen,,5.2,,,,,1.4 - 8.6,mmol/L +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,88,,,,,40 - 110,umol/L +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,CHEMISTRY PANEL,Serum Glucose,,4.5,,,,,3.9 - 5.6,mmol/L +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,CHEMISTRY PANEL,Serum Uric Acid,,261,,,,,125 - 488,umol/L +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,CHEMISTRY PANEL,Calcium (EDTA),,2.31,,,,,2.07 - 2.64,mmol/L +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,CHEMISTRY PANEL,Phosphorus,,1.13,,,,,0.71 - 1.65,mmol/L +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,CHEMISTRY PANEL,Total Protein,,65,,,,,61 - 84,g/L +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,CHEMISTRY PANEL,Albumin-BCG,,41,,,,,33 - 49,g/L +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,CHEMISTRY PANEL,Creatine Kinase,,112,,,,,39 - 308,U/L +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,CHEMISTRY PANEL,Serum Sodium,,139,,,,,132 - 147,mmol/L +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,CHEMISTRY PANEL,Serum Potassium,,4.0,,,,,3.5 - 5.2,mmol/L +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,CHEMISTRY PANEL,Serum Bicarbonate,,23.2,,,,,19.3 - 29.3,mmol/L +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,CHEMISTRY PANEL,Serum Chloride,,104,,,,,94 - 112,mmol/L +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,CHEMISTRY PANEL,Magnesium,,0.76,,,,,0.66 - 1.07,mmol/L +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,102,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,FECAL COLLECTION D/T,Stool Collection Date,Y,22-Apr-2026,,,,,, +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,FECAL COLLECTION D/T,Stool Collection Time,Y,05:40,,,,,, +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,143,,,,,127 - 181,g/L +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.41,,,,,0.39 - 0.54, +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.8,,,,,4.5 - 6.4,TI/L +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,30,,,,,26 - 34,pg +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,86,,,,,79 - 96,fL +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,6.68,,,,,3.8 - 10.7,GI/L +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.92,,,,,1.96 - 7.23,GI/L +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.94,,,,,0.91 - 4.28,GI/L +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.39,,,,,0.12 - 0.92,GI/L +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.40,,,,,0 - 0.57,GI/L +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.03,,,,,0 - 0.2,GI/L +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,58.7,,,,,40.5 - 75,% +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,29.0,,,,,15.4 - 48.5,% +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.9,,,,,2.6 - 10.1,% +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,5.9,,,,,0 - 6.8,% +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.5,,,,,0 - 2,% +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,308,,,,,140 - 400,GI/L +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,SM01/PLASMA PK TROUGH COLL D/T,Collection Date Predose,Y,22-Apr-2026,,,,,, +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,SM01/PLASMA PK TROUGH COLL D/T,Collection Time Predose,Y,14:15,,,,,, +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,SM02/PLASMA PK PEAK COLL D/T,Collection Date Post dose,Y,22-Apr-2026,,,,,, +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,SM02/PLASMA PK PEAK COLL D/T,Post Dose Collection Time,Y,15:25,,,,,, +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,SM04/SERUM ADA PRE COLL D/T,Collection Date Predose,Y,22-Apr-2026,,,,,, +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,SM04/SERUM ADA PRE COLL D/T,Collection Time Predose,Y,14:15,,,,,, +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,SM09/STOOL PK COLL D/T,Stool Collection Date,Y,22-Apr-2026,,,,,, +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,SM09/STOOL PK COLL D/T,Stool Collection Time,Y,05:40,,,,,, +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,SUBJECT HEIGHT (CM),Height (cm),Y,N/A (subject >/= 18 years of age),,,,,cm, +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,CHEMISTRY PANEL,Total Bilirubin,,8,,,,,3 - 21,umol/L +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,4.2,,,,,0 - 6.2,umol/L +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,CHEMISTRY PANEL,Alkaline Phosphatase,,71,,,,,40 - 129,U/L +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,CHEMISTRY PANEL,ALT (SGPT),,7,,,,,5 - 48,U/L +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,CHEMISTRY PANEL,AST (SGOT),,16,,,,,8 - 40,U/L +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,CHEMISTRY PANEL,GGT,,7,,L,,,10 - 61,U/L +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,CHEMISTRY PANEL,LDH,,153,,,,,53 - 234,U/L +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,CHEMISTRY PANEL,Urea Nitrogen,,4.9,,,,,1.4 - 8.6,mmol/L +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,86,,,,,40 - 110,umol/L +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,CHEMISTRY PANEL,Serum Glucose,,4.2,,,,,3.9 - 5.6,mmol/L +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,CHEMISTRY PANEL,Serum Uric Acid,,299,,,,,125 - 488,umol/L +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,CHEMISTRY PANEL,Calcium (EDTA),,2.35,,,,,2.07 - 2.64,mmol/L +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,CHEMISTRY PANEL,Phosphorus,,1.05,,,,,0.71 - 1.65,mmol/L +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,CHEMISTRY PANEL,Total Protein,,68,,,,,61 - 84,g/L +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,CHEMISTRY PANEL,Albumin-BCG,,43,,,,,33 - 49,g/L +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,CHEMISTRY PANEL,Creatine Kinase,,116,,,,,39 - 308,U/L +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,CHEMISTRY PANEL,Serum Sodium,,141,,,,,132 - 147,mmol/L +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,CHEMISTRY PANEL,Serum Potassium,,4.1,,,,,3.5 - 5.2,mmol/L +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,CHEMISTRY PANEL,Serum Bicarbonate,,23.9,,,,,19.3 - 29.3,mmol/L +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,CHEMISTRY PANEL,Serum Chloride,,103,,,,,94 - 112,mmol/L +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,CHEMISTRY PANEL,Magnesium,,0.80,,,,,0.66 - 1.07,mmol/L +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,106,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,FECAL COLLECTION D/T,Stool Collection Date,Y,09-Apr-2026,,,,,, +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,FECAL COLLECTION D/T,Stool Collection Time,Y,05:55,,,,,, +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,146,,,,,127 - 181,g/L +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.43,,,,,0.39 - 0.54, +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.9,,,,,4.5 - 6.4,TI/L +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,30,,,,,26 - 34,pg +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,88,,,,,79 - 96,fL +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,6.07,,,,,3.8 - 10.7,GI/L +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.83,,,,,1.96 - 7.23,GI/L +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.67,,,,,0.91 - 4.28,GI/L +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.32,,,,,0.12 - 0.92,GI/L +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.19,,,,,0 - 0.57,GI/L +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.05,,,,,0 - 0.2,GI/L +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,63.1,,,,,40.5 - 75,% +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,27.6,,,,,15.4 - 48.5,% +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.2,,,,,2.6 - 10.1,% +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,3.2,,,,,0 - 6.8,% +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.8,,,,,0 - 2,% +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,314,,,,,140 - 400,GI/L +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,LIPID PANEL,Direct HDL-C 4th Generation,,1.90,,H,,,1.03 - 1.53,mmol/L +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,LIPID PANEL,Triglycerides (GPO),,0.43,,L,,,0.56 - 3.62,mmol/L +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,LIPID PANEL,Cholesterol (High Performance),,3.22,,L,,,3.88 - 6.83,mmol/L +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,LIPID PANEL,LDL Chol Friedewald 4th,,1.12,,,,,0 - 3.34,mmol/L +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,SM01/PLASMA PK TROUGH COLL D/T,Collection Date Predose,Y,09-Apr-2026,,,,,, +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,SM01/PLASMA PK TROUGH COLL D/T,Collection Time Predose,Y,10:35,,,,,, +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,SM02/PLASMA PK PEAK COLL D/T,Collection Date Post dose,Y,09-Apr-2026,,,,,, +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,SM02/PLASMA PK PEAK COLL D/T,Post Dose Collection Time,Y,11:45,,,,,, +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,SM04/SERUM ADA PRE COLL D/T,Collection Date Predose,Y,09-Apr-2026,,,,,, +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,SM04/SERUM ADA PRE COLL D/T,Collection Time Predose,Y,10:35,,,,,, +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,SM10/FECAL BMRKS COLL D/T,Stool Collection Date,Y,09-Apr-2026,,,,,, +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,SM10/FECAL BMRKS COLL D/T,Stool Collection Time,Y,05:55,,,,,, +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,SUBJECT HEIGHT (CM),Height (cm),Y,N/A (subject >/= 18 years of age),,,,,cm, +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,ALP<2XULN,ALP<2XULN,,Criteria Met,,,,,, +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,ALT>/=3XULN,ALT >/= 3 X ULN,,Criteria not met,,,,,, +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,ALT>/=3XULN & TBIL>/=2XULN,ALT >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,AST>/=3XULN,AST >/= 3 X ULN,,Criteria not met,,,,,, +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,AST>/=3XULN & TBIL>/=2XULN,AST >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,CHEMISTRY PANEL,Total Bilirubin,,10,,,,,3 - 21,umol/L +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.9,,,,,0 - 6.2,umol/L +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,CHEMISTRY PANEL,Alkaline Phosphatase,,64,,,,,40 - 129,U/L +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,CHEMISTRY PANEL,ALT (SGPT),,42,,,,,5 - 48,U/L +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,CHEMISTRY PANEL,AST (SGOT),,31,,,,,8 - 40,U/L +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,CHEMISTRY PANEL,GGT,,24,,,,,10 - 61,U/L +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,CHEMISTRY PANEL,LDH,,225,,,,,53 - 234,U/L +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,CHEMISTRY PANEL,Urea Nitrogen,,10.1,,H,,,1.4 - 8.6,mmol/L +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,110,,,,,40 - 110,umol/L +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,CHEMISTRY PANEL,Serum Glucose,,4.6,,,,,3.9 - 5.6,mmol/L +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,CHEMISTRY PANEL,Serum Uric Acid,,455,,,,,125 - 488,umol/L +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,CHEMISTRY PANEL,Calcium (EDTA),,2.42,,,,,2.07 - 2.64,mmol/L +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,CHEMISTRY PANEL,Phosphorus,,1.20,,,,,0.71 - 1.65,mmol/L +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,CHEMISTRY PANEL,Total Protein,,72,,,,,61 - 84,g/L +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,CHEMISTRY PANEL,Albumin-BCG,,44,,,,,33 - 49,g/L +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,CHEMISTRY PANEL,Creatine Kinase,,367,,H,,,39 - 308,U/L +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,CHEMISTRY PANEL,Serum Sodium,,139,,,,,132 - 147,mmol/L +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,CHEMISTRY PANEL,Serum Potassium,,4.2,,,,,3.5 - 5.2,mmol/L +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,CHEMISTRY PANEL,Serum Bicarbonate,,24.7,,,,,19.3 - 29.3,mmol/L +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,CHEMISTRY PANEL,Serum Chloride,,102,,,,,94 - 112,mmol/L +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,CHEMISTRY PANEL,Magnesium,,0.77,,,,,0.66 - 1.07,mmol/L +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,76,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,FECAL COLLECTION D/T,Stool Collection Date,Y,08-Apr-2026,,,,,, +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,FECAL COLLECTION D/T,Stool Collection Time,Y,05:15,,,,,, +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,135,,,,,127 - 181,g/L +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.39,,,,,0.39 - 0.54, +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.6,,,,,4.5 - 6.4,TI/L +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,29,,,,,26 - 34,pg +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,85,,,,,79 - 96,fL +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,5.70,,,,,3.8 - 10.7,GI/L +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.33,,,,,1.96 - 7.23,GI/L +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.26,,,,,0.91 - 4.28,GI/L +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.40,,,,,0.12 - 0.92,GI/L +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.67,R,H,,,0 - 0.57,GI/L +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.05,,,,,0 - 0.2,GI/L +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,40.8,,,,,40.5 - 75,% +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,39.6,,,,,15.4 - 48.5,% +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,7.0,,,,,2.6 - 10.1,% +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,11.7,R,H,,,0 - 6.8,% +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.9,,,,,0 - 2,% +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,282,,,,,140 - 400,GI/L +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,SM01/PLASMA PK TROUGH COLL D/T,Collection Date Predose,Y,08-Apr-2026,,,,,, +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,SM01/PLASMA PK TROUGH COLL D/T,Collection Time Predose,Y,08:05,,,,,, +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,SM02/PLASMA PK PEAK COLL D/T,Collection Date Post dose,Y,08-Apr-2026,,,,,, +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,SM02/PLASMA PK PEAK COLL D/T,Post Dose Collection Time,Y,09:15,,,,,, +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,SM04/SERUM ADA PRE COLL D/T,Collection Date Predose,Y,08-Apr-2026,,,,,, +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,SM04/SERUM ADA PRE COLL D/T,Collection Time Predose,Y,08:05,,,,,, +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,SM09/STOOL PK COLL D/T,Stool Collection Date,Y,08-Apr-2026,,,,,, +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,SM09/STOOL PK COLL D/T,Stool Collection Time,Y,05:15,,,,,, +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,SUBJECT HEIGHT (CM),Height (cm),Y,N/A (subject >/= 18 years of age),,,,,cm, +CZ100222005,,,,,Male,Biopsy,,"Apr 1, 2026 12:00 AM",6228023951,ANATOMICAL SITE,Anatomical Site,Y,15-20cm from anal verge,,,,,, +CZ100222005,,,,,Male,Biopsy,,"Apr 1, 2026 12:00 AM",6228023951,BIOPSY COLLECTION METHOD,Collection Method,Y,colonoscopy,,,,,, +CZ100222005,,,,,Male,Biopsy,,"Apr 1, 2026 12:00 AM",6228023951,BIOPSY FIXATIVE USED,Fixative Used,,10% NBF,,,,,, +CZ100222005,,,,,Male,Biopsy,,"Apr 1, 2026 12:00 AM",6228023951,DATE/TIME PLACED IN FORMALIN,Date Sample placed in Formalin,Y,01-Apr-2026,,,,,, +CZ100222005,,,,,Male,Biopsy,,"Apr 1, 2026 12:00 AM",6228023951,DATE/TIME PLACED IN FORMALIN,Time Sample placed in Formalin,Y,08:46,,,,,, +CZ100222005,,,,,Male,Biopsy,,"Apr 1, 2026 12:00 AM",6228023951,DIAGNOSIS,Diagnosis:,Y,Ulcerative Colitis,,,,,, +CZ100222005,,,,,Male,Biopsy,,"Apr 1, 2026 12:00 AM",6228023951,INFLAMED AREA,Inflamed area?,,Yes,,,,,, +CZ100222005,,,,,Male,Biopsy,,"Apr 1, 2026 12:00 AM",6228023951,TISSUE BIOPSY EMBEDDING1,Biopsy technical QC-CL,,Smpl meets HT requirements,,,,,, +CZ100222005,,,,,Male,Biopsy,,"Apr 1, 2026 12:00 AM",6228023951,TISSUE BIOPSY EMBEDDING1,Biopsy processing Time-CL,,10:00,,,,,, +CZ100222005,,,,,Male,Biopsy,,"Apr 1, 2026 12:00 AM",6228023951,TISSUE BIOPSY EMBEDDING1,Biopsy processing Date-CL,,03-Apr-2026,,,,,, +CZ100222005,,,,,Male,Biopsy,,"Apr 1, 2026 12:00 AM",6228023951,TISSUE BIOPSY EMBEDDING1,Biopsy Comments-CL,,Received in 10% NBF,,,,,, +CZ100222005,,,,,Male,Biopsy,,"Apr 1, 2026 12:00 AM",6228023951,TISSUE BIOPSY EMBEDDING1,# of Cassettes-(FI)-CL,,1,,,,,, +CZ100222005,,,,,Male,Biopsy,,"Apr 1, 2026 12:00 AM",6228023951,ULCERATED AREA,Is biopsy site ulcerated?,,No,,,,,, +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,ALP<2XULN,ALP<2XULN,,Criteria Met,,,,,, +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,ALT>/=3XULN,ALT >/= 3 X ULN,,Criteria not met,,,,,, +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,ALT>/=3XULN & TBIL>/=2XULN,ALT >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,AST>/=3XULN,AST >/= 3 X ULN,,Criteria not met,,,,,, +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,AST>/=3XULN & TBIL>/=2XULN,AST >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,CHEMISTRY PANEL,Total Bilirubin,,4,,,,,3 - 21,umol/L +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,<1.4,,,,,0 - 6.2,umol/L +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,CHEMISTRY PANEL,Alkaline Phosphatase,,58,,,,,40 - 129,U/L +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,CHEMISTRY PANEL,ALT (SGPT),,26,,,,,5 - 48,U/L +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,CHEMISTRY PANEL,AST (SGOT),,24,,,,,8 - 40,U/L +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,CHEMISTRY PANEL,GGT,,14,,,,,10 - 61,U/L +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,CHEMISTRY PANEL,LDH,,170,,,,,53 - 234,U/L +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,CHEMISTRY PANEL,Urea Nitrogen,,9.4,R,H,,,1.4 - 8.6,mmol/L +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,104,,,,,40 - 110,umol/L +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,CHEMISTRY PANEL,Serum Glucose,,4.7,,,,,3.9 - 5.6,mmol/L +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,CHEMISTRY PANEL,Serum Uric Acid,,353,,,,,125 - 488,umol/L +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,CHEMISTRY PANEL,Calcium (EDTA),,2.36,,,,,2.07 - 2.64,mmol/L +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,CHEMISTRY PANEL,Phosphorus,,1.32,,,,,0.71 - 1.65,mmol/L +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,CHEMISTRY PANEL,Total Protein,,68,,,,,61 - 84,g/L +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,CHEMISTRY PANEL,Albumin-BCG,,42,,,,,33 - 49,g/L +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,CHEMISTRY PANEL,Creatine Kinase,,167,,,,,39 - 308,U/L +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,CHEMISTRY PANEL,Serum Sodium,,141,,,,,132 - 147,mmol/L +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,CHEMISTRY PANEL,Serum Potassium,,4.4,,,,,3.5 - 5.2,mmol/L +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,CHEMISTRY PANEL,Serum Bicarbonate,,23.9,,,,,19.3 - 29.3,mmol/L +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,CHEMISTRY PANEL,Serum Chloride,,105,,,,,94 - 112,mmol/L +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,CHEMISTRY PANEL,Magnesium,,0.73,,,,,0.66 - 1.07,mmol/L +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,80,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,FECAL COLLECTION D/T,Stool Collection Date,Y,27-Mar-2026,,,,,, +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,FECAL COLLECTION D/T,Stool Collection Time,Y,05:40,,,,,, +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,133,,,,,127 - 181,g/L +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.39,,,,,0.39 - 0.54, +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.5,,,,,4.5 - 6.4,TI/L +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,29,,,,,26 - 34,pg +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,86,,,,,79 - 96,fL +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,5.92,,,,,3.8 - 10.7,GI/L +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.29,,,,,1.96 - 7.23,GI/L +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.57,,,,,0.91 - 4.28,GI/L +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.41,,,,,0.12 - 0.92,GI/L +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.61,R,H,,,0 - 0.57,GI/L +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.04,,,,,0 - 0.2,GI/L +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,38.7,R,L,,,40.5 - 75,% +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,43.4,,,,,15.4 - 48.5,% +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,6.9,,,,,2.6 - 10.1,% +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,10.3,R,H,,,0 - 6.8,% +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.7,,,,,0 - 2,% +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,252,,,,,140 - 400,GI/L +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,SM01/PLASMA PK TROUGH COLL D/T,Collection Date Predose,Y,27-Mar-2026,,,,,, +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,SM01/PLASMA PK TROUGH COLL D/T,Collection Time Predose,Y,07:10,,,,,, +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,SM02/PLASMA PK PEAK COLL D/T,Collection Date Post dose,Y,27-Mar-2026,,,,,, +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,SM02/PLASMA PK PEAK COLL D/T,Post Dose Collection Time,Y,08:20,,,,,, +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,SM04/SERUM ADA PRE COLL D/T,Collection Date Predose,Y,27-Mar-2026,,,,,, +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,SM04/SERUM ADA PRE COLL D/T,Collection Time Predose,Y,07:10,,,,,, +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,SM09/STOOL PK COLL D/T,Stool Collection Date,Y,27-Mar-2026,,,,,, +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,SM09/STOOL PK COLL D/T,Stool Collection Time,Y,05:40,,,,,, +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,SUBJECT HEIGHT (CM),Height (cm),Y,N/A (subject >/= 18 years of age),,,,,cm, +CZ100222004,,,,,Male,Unscheduled,R,"Mar 13, 2026 8:40 AM",6227323295,CHEMISTRY PANEL,Total Bilirubin,,3,,,,Result verified by repeat analysis,3 - 21,umol/L +CZ100222004,,,,,Male,Unscheduled,R,"Mar 13, 2026 8:40 AM",6227323295,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,<1.4,,,,Result verified by repeat analysis,0 - 6.2,umol/L +CZ100222004,,,,,Male,Unscheduled,R,"Mar 13, 2026 8:40 AM",6227323295,CHEMISTRY PANEL,Alkaline Phosphatase,,85,,,,,40 - 129,U/L +CZ100222004,,,,,Male,Unscheduled,R,"Mar 13, 2026 8:40 AM",6227323295,CHEMISTRY PANEL,ALT (SGPT),,20,,,,,5 - 48,U/L +CZ100222004,,,,,Male,Unscheduled,R,"Mar 13, 2026 8:40 AM",6227323295,CHEMISTRY PANEL,AST (SGOT),,15,,,,,8 - 40,U/L +CZ100222004,,,,,Male,Unscheduled,R,"Mar 13, 2026 8:40 AM",6227323295,CHEMISTRY PANEL,GGT,,19,,,,,10 - 50,U/L +CZ100222004,,,,,Male,Unscheduled,R,"Mar 13, 2026 8:40 AM",6227323295,CHEMISTRY PANEL,LDH,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100222004,,,,,Male,Unscheduled,R,"Mar 13, 2026 8:40 AM",6227323295,CHEMISTRY PANEL,Urea Nitrogen,,5.5,,,,,1.4 - 8.6,mmol/L +CZ100222004,,,,,Male,Unscheduled,R,"Mar 13, 2026 8:40 AM",6227323295,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,108,,,,,40 - 119,umol/L +CZ100222004,,,,,Male,Unscheduled,R,"Mar 13, 2026 8:40 AM",6227323295,CHEMISTRY PANEL,Serum Glucose,,4.9,,,,,3.9 - 5.6,mmol/L +CZ100222004,,,,,Male,Unscheduled,R,"Mar 13, 2026 8:40 AM",6227323295,CHEMISTRY PANEL,Serum Uric Acid,,429,,,,,149 - 494,umol/L +CZ100222004,,,,,Male,Unscheduled,R,"Mar 13, 2026 8:40 AM",6227323295,CHEMISTRY PANEL,Calcium (EDTA),,2.07,,,,,2.07 - 2.64,mmol/L +CZ100222004,,,,,Male,Unscheduled,R,"Mar 13, 2026 8:40 AM",6227323295,CHEMISTRY PANEL,Phosphorus,,1.02,,,,,0.71 - 1.65,mmol/L +CZ100222004,,,,,Male,Unscheduled,R,"Mar 13, 2026 8:40 AM",6227323295,CHEMISTRY PANEL,Total Protein,,55,,L,,,60 - 80,g/L +CZ100222004,,,,,Male,Unscheduled,R,"Mar 13, 2026 8:40 AM",6227323295,CHEMISTRY PANEL,Albumin-BCG,,35,,,,,33 - 49,g/L +CZ100222004,,,,,Male,Unscheduled,R,"Mar 13, 2026 8:40 AM",6227323295,CHEMISTRY PANEL,Creatine Kinase,,49,,,,,39 - 308,U/L +CZ100222004,,,,,Male,Unscheduled,R,"Mar 13, 2026 8:40 AM",6227323295,CHEMISTRY PANEL,Serum Sodium,,148,,H,,,135 - 145,mmol/L +CZ100222004,,,,,Male,Unscheduled,R,"Mar 13, 2026 8:40 AM",6227323295,CHEMISTRY PANEL,Serum Potassium,,4.0,,,,,3.5 - 5.2,mmol/L +CZ100222004,,,,,Male,Unscheduled,R,"Mar 13, 2026 8:40 AM",6227323295,CHEMISTRY PANEL,Serum Bicarbonate,,24.4,,,,,19.3 - 29.3,mmol/L +CZ100222004,,,,,Male,Unscheduled,R,"Mar 13, 2026 8:40 AM",6227323295,CHEMISTRY PANEL,Serum Chloride,,110,,,,,94 - 112,mmol/L +CZ100222004,,,,,Male,Unscheduled,R,"Mar 13, 2026 8:40 AM",6227323295,CHEMISTRY PANEL,Magnesium,,0.82,,,,,0.66 - 0.98,mmol/L +CZ100222005,,,,,Male,Unscheduled,R,"Mar 13, 2026 7:45 AM",6227323297,CHEMISTRY PANEL,Total Bilirubin,,9,,,,,3 - 21,umol/L +CZ100222005,,,,,Male,Unscheduled,R,"Mar 13, 2026 7:45 AM",6227323297,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.2,,,,,0 - 6.2,umol/L +CZ100222005,,,,,Male,Unscheduled,R,"Mar 13, 2026 7:45 AM",6227323297,CHEMISTRY PANEL,Alkaline Phosphatase,,73,,,,,40 - 129,U/L +CZ100222005,,,,,Male,Unscheduled,R,"Mar 13, 2026 7:45 AM",6227323297,CHEMISTRY PANEL,ALT (SGPT),,5,,,,,5 - 48,U/L +CZ100222005,,,,,Male,Unscheduled,R,"Mar 13, 2026 7:45 AM",6227323297,CHEMISTRY PANEL,AST (SGOT),,15,,,,,8 - 40,U/L +CZ100222005,,,,,Male,Unscheduled,R,"Mar 13, 2026 7:45 AM",6227323297,CHEMISTRY PANEL,GGT,,6,R,L,,,10 - 61,U/L +CZ100222005,,,,,Male,Unscheduled,R,"Mar 13, 2026 7:45 AM",6227323297,CHEMISTRY PANEL,LDH,,149,,,,,53 - 234,U/L +CZ100222005,,,,,Male,Unscheduled,R,"Mar 13, 2026 7:45 AM",6227323297,CHEMISTRY PANEL,Urea Nitrogen,,3.8,,,,,1.4 - 8.6,mmol/L +CZ100222005,,,,,Male,Unscheduled,R,"Mar 13, 2026 7:45 AM",6227323297,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,91,,,,,40 - 110,umol/L +CZ100222005,,,,,Male,Unscheduled,R,"Mar 13, 2026 7:45 AM",6227323297,CHEMISTRY PANEL,Serum Glucose,,4.6,,,,,3.9 - 5.6,mmol/L +CZ100222005,,,,,Male,Unscheduled,R,"Mar 13, 2026 7:45 AM",6227323297,CHEMISTRY PANEL,Serum Uric Acid,,277,,,,,125 - 488,umol/L +CZ100222005,,,,,Male,Unscheduled,R,"Mar 13, 2026 7:45 AM",6227323297,CHEMISTRY PANEL,Calcium (EDTA),,2.42,,,,,2.07 - 2.64,mmol/L +CZ100222005,,,,,Male,Unscheduled,R,"Mar 13, 2026 7:45 AM",6227323297,CHEMISTRY PANEL,Phosphorus,,1.23,,,,,0.71 - 1.65,mmol/L +CZ100222005,,,,,Male,Unscheduled,R,"Mar 13, 2026 7:45 AM",6227323297,CHEMISTRY PANEL,Total Protein,,68,,,,,61 - 84,g/L +CZ100222005,,,,,Male,Unscheduled,R,"Mar 13, 2026 7:45 AM",6227323297,CHEMISTRY PANEL,Albumin-BCG,,44,,,,,33 - 49,g/L +CZ100222005,,,,,Male,Unscheduled,R,"Mar 13, 2026 7:45 AM",6227323297,CHEMISTRY PANEL,Creatine Kinase,,119,,,,,39 - 308,U/L +CZ100222005,,,,,Male,Unscheduled,R,"Mar 13, 2026 7:45 AM",6227323297,CHEMISTRY PANEL,Serum Sodium,,140,,,,,132 - 147,mmol/L +CZ100222005,,,,,Male,Unscheduled,R,"Mar 13, 2026 7:45 AM",6227323297,CHEMISTRY PANEL,Serum Potassium,,4.7,,,,,3.5 - 5.2,mmol/L +CZ100222005,,,,,Male,Unscheduled,R,"Mar 13, 2026 7:45 AM",6227323297,CHEMISTRY PANEL,Serum Bicarbonate,,27.4,,,,,19.3 - 29.3,mmol/L +CZ100222005,,,,,Male,Unscheduled,R,"Mar 13, 2026 7:45 AM",6227323297,CHEMISTRY PANEL,Serum Chloride,,103,,,,,94 - 112,mmol/L +CZ100222005,,,,,Male,Unscheduled,R,"Mar 13, 2026 7:45 AM",6227323297,CHEMISTRY PANEL,Magnesium,,0.81,,,,,0.66 - 1.07,mmol/L +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,CHEMISTRY PANEL,Total Bilirubin,,6,,,,,3 - 21,umol/L +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,1.7,,,,,0 - 6.2,umol/L +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,CHEMISTRY PANEL,Alkaline Phosphatase,,91,,,,,40 - 129,U/L +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,CHEMISTRY PANEL,ALT (SGPT),,79,R,H,,,5 - 48,U/L +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,CHEMISTRY PANEL,AST (SGOT),,51,R,H,,,8 - 40,U/L +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,CHEMISTRY PANEL,GGT,,45,,,,,10 - 61,U/L +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,CHEMISTRY PANEL,LDH,,228,,,,,53 - 234,U/L +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,CHEMISTRY PANEL,Urea Nitrogen,,8.3,,,,,1.4 - 8.6,mmol/L +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,106,,,,,40 - 110,umol/L +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,CHEMISTRY PANEL,Serum Glucose,,4.4,,,,,3.9 - 5.6,mmol/L +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,CHEMISTRY PANEL,Serum Uric Acid,,418,,,,,125 - 488,umol/L +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,CHEMISTRY PANEL,Calcium (EDTA),,2.32,,,,,2.07 - 2.64,mmol/L +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,CHEMISTRY PANEL,Phosphorus,,1.10,,,,,0.71 - 1.65,mmol/L +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,CHEMISTRY PANEL,Total Protein,,68,,,,,61 - 84,g/L +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,CHEMISTRY PANEL,Albumin-BCG,,41,,,,,33 - 49,g/L +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,CHEMISTRY PANEL,Creatine Kinase,,250,,,,,39 - 308,U/L +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,CHEMISTRY PANEL,Serum Sodium,,139,,,,,132 - 147,mmol/L +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,CHEMISTRY PANEL,Serum Potassium,,4.5,,,,,3.5 - 5.2,mmol/L +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,CHEMISTRY PANEL,Serum Bicarbonate,,25.4,,,,,19.3 - 29.3,mmol/L +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,CHEMISTRY PANEL,Serum Chloride,,104,,,,,94 - 112,mmol/L +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,CHEMISTRY PANEL,Magnesium,,0.73,,,,,0.66 - 1.07,mmol/L +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,79,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,FECAL COLLECTION D/T,Stool Collection Date,Y,09-Mar-2026,,,,,, +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,FECAL COLLECTION D/T,Stool Collection Time,Y,08:55,,,,,, +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,134,,,,,127 - 181,g/L +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.39,,,,,0.39 - 0.54, +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.5,,,,,4.5 - 6.4,TI/L +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,30,,,,,26 - 34,pg +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,Normocytic,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,87,,,,,79 - 96,fL +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,6.70,,,,,3.8 - 10.7,GI/L +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.17,,,,,1.96 - 7.23,GI/L +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.01,,,,,0.91 - 4.28,GI/L +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.39,,,,,0.12 - 0.92,GI/L +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,1.08,R,H,,,0 - 0.57,GI/L +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.05,,,,,0 - 0.2,GI/L +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,47.4,,,,,40.5 - 75,% +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,29.9,,,,,15.4 - 48.5,% +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.8,,,,,2.6 - 10.1,% +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,16.1,R,H,,,0 - 6.8,% +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.8,,,,,0 - 2,% +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,262,,,,,140 - 400,GI/L +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,LIPID PANEL,Direct HDL-C 4th Generation,,1.13,,,,,1.03 - 1.53,mmol/L +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,LIPID PANEL,Triglycerides (GPO),,0.84,,,,,0.56 - 3.62,mmol/L +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,LIPID PANEL,Cholesterol (High Performance),,5.14,,,,,3.88 - 6.83,mmol/L +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,LIPID PANEL,LDL Chol Friedewald 4th,,3.63,,H,,,0 - 3.34,mmol/L +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,SM01/PLASMA PK TROUGH COLL D/T,Collection Date Predose,Y,09-Mar-2026,,,,,, +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,SM01/PLASMA PK TROUGH COLL D/T,Collection Time Predose,Y,08:50,,,,,, +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,SM02/PLASMA PK PEAK COLL D/T,Collection Date Post dose,Y,09-Mar-2026,,,,,, +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,SM02/PLASMA PK PEAK COLL D/T,Post Dose Collection Time,Y,10:05,,,,,, +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,SM04/SERUM ADA PRE COLL D/T,Collection Date Predose,Y,09-Mar-2026,,,,,, +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,SM04/SERUM ADA PRE COLL D/T,Collection Time Predose,Y,08:50,,,,,, +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,SM10/FECAL BMRKS COLL D/T,Stool Collection Date,Y,09-Mar-2026,,,,,, +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,SM10/FECAL BMRKS COLL D/T,Stool Collection Time,Y,08:55,,,,,, +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,SUBJECT HEIGHT (CM),Height (cm),Y,190,,,,,cm, +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,CHEMISTRY PANEL,Total Bilirubin,,,,,Test group cancelled: No specimen received,,, +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,,,,Test group cancelled: No specimen received,,, +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,CHEMISTRY PANEL,Alkaline Phosphatase,,,,,Test group cancelled: No specimen received,,, +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,CHEMISTRY PANEL,ALT (SGPT),,,,,Test group cancelled: No specimen received,,, +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,CHEMISTRY PANEL,AST (SGOT),,,,,Test group cancelled: No specimen received,,, +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,CHEMISTRY PANEL,GGT,,,,,Test group cancelled: No specimen received,,, +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,CHEMISTRY PANEL,LDH,,,,,Test group cancelled: No specimen received,,, +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,CHEMISTRY PANEL,Urea Nitrogen,,,,,Test group cancelled: No specimen received,,, +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,,,,Test group cancelled: No specimen received,,, +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,CHEMISTRY PANEL,Serum Glucose,,,,,Test group cancelled: No specimen received,,, +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,CHEMISTRY PANEL,Serum Uric Acid,,,,,Test group cancelled: No specimen received,,, +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,CHEMISTRY PANEL,Calcium (EDTA),,,,,Test group cancelled: No specimen received,,, +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,CHEMISTRY PANEL,Phosphorus,,,,,Test group cancelled: No specimen received,,, +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,CHEMISTRY PANEL,Total Protein,,,,,Test group cancelled: No specimen received,,, +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,CHEMISTRY PANEL,Albumin-BCG,,,,,Test group cancelled: No specimen received,,, +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,CHEMISTRY PANEL,Creatine Kinase,,,,,Test group cancelled: No specimen received,,, +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,CHEMISTRY PANEL,Serum Sodium,,,,,Test group cancelled: No specimen received,,, +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,CHEMISTRY PANEL,Serum Potassium,,,,,Test group cancelled: No specimen received,,, +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,CHEMISTRY PANEL,Serum Bicarbonate,,,,,Test group cancelled: No specimen received,,, +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,CHEMISTRY PANEL,Serum Chloride,,,,,Test group cancelled: No specimen received,,, +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,CHEMISTRY PANEL,Magnesium,,,,,Test group cancelled: No specimen received,,, +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,HBV ELIGIBILITY MET?,HBV Eligibility Criteria Met?,,Yes,,,,,, +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,148,,,,,127 - 181,g/L +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.44,,,,,0.39 - 0.54, +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.9,,,,,4.5 - 6.4,TI/L +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,30,,,,,26 - 34,pg +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,89,,,,,79 - 96,fL +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,6.67,,,,,3.8 - 10.7,GI/L +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.96,,,,,1.96 - 7.23,GI/L +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.68,,,,,0.91 - 4.28,GI/L +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.51,,,,,0.12 - 0.92,GI/L +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.42,,,,,0 - 0.57,GI/L +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.10,,,,,0 - 0.2,GI/L +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,59.3,,,,,40.5 - 75,% +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,25.2,,,,,15.4 - 48.5,% +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,7.7,,,,,2.6 - 10.1,% +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,6.3,,,,,0 - 6.8,% +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.5,,,,,0 - 2,% +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,341,,,,,140 - 400,GI/L +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,HEPATITIS B CORE AB NON-US,Hepatitis B Core Total,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,HEPATITIS B SURFACE AB,Anti-HBs II QUAL,,Reactive,,,,,Ref Rng :$Non Reactive, +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,HEPATITIS B SURFACE AG NON-US,Hep B Surface AgII,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,HEPATITIS C VIRUS AB NON-US,Hepatitis C Virus Antibody,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,HIV 1/2 AG/AB SCREEN,anti-HIV-1/2 antibodies,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,HIV 1/2 AG/AB SCREEN,HIV -1 p24 antigen,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,HIV 1/2 AG/AB SCREEN,"HIV 1/2 Ag/Ab Screen, Cobas",,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,QUANTIFERON GOLD MITOGEN/INTER,"QFT,TBGoldPlusInt,pl-4-Tubes",,Negative,,,,,Normal=Negative, +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,SUBJECT HEIGHT (CM),Height (cm),Y,188,,,,,cm, +CZ100222005,,,,,Male,Stool Pathogens,,"Mar 4, 2026 9:10 AM",6227810904,C. DIFF EIA,"C. diff GDH Ag,stool-CL",,Negative,,,,,Ref Rng:Negative, +CZ100222005,,,,,Male,Stool Pathogens,,"Mar 4, 2026 9:10 AM",6227810904,C. DIFF EIA,"C.diff Toxin A&B,stool-CL",,Negative,,,,,Ref Rng:Negative, +CZ100222005,,,,,Male,Stool Pathogens,,"Mar 4, 2026 9:10 AM",6227810904,OVA AND PARASITES 1,Concentrate Exam,,,,,Test group cancelled: No specimen received,,, +CZ100222005,,,,,Male,Stool Pathogens,,"Mar 4, 2026 9:10 AM",6227810904,OVA AND PARASITES 1,Smear for Microsporidia,,,,,Test group cancelled: No specimen received,,, +CZ100222005,,,,,Male,Stool Pathogens,,"Mar 4, 2026 9:10 AM",6227810904,OVA AND PARASITES 1,Modified acid-fast stain,,,,,Test group cancelled: No specimen received,,, +CZ100222005,,,,,Male,Stool Pathogens,,"Mar 4, 2026 9:10 AM",6227810904,OVA AND PARASITES 2,Trichrome Smear,,,,,Test group cancelled: No specimen received,,, +CZ100222004,,,,,Male,Stool Pathogens,,"Mar 3, 2026 12:20 PM",6227810905,C. DIFF EIA,"C. diff GDH Ag,stool-CL",,Negative,,,,,Ref Rng:Negative, +CZ100222004,,,,,Male,Stool Pathogens,,"Mar 3, 2026 12:20 PM",6227810905,C. DIFF EIA,"C.diff Toxin A&B,stool-CL",,Negative,,,,,Ref Rng:Negative, +CZ100222004,,,,,Male,Stool Pathogens,,"Mar 3, 2026 12:20 PM",6227810905,OVA AND PARASITES 1,Concentrate Exam,,,,,Test group cancelled: No specimen received,,, +CZ100222004,,,,,Male,Stool Pathogens,,"Mar 3, 2026 12:20 PM",6227810905,OVA AND PARASITES 1,Smear for Microsporidia,,,,,Test group cancelled: No specimen received,,, +CZ100222004,,,,,Male,Stool Pathogens,,"Mar 3, 2026 12:20 PM",6227810905,OVA AND PARASITES 1,Modified acid-fast stain,,,,,Test group cancelled: No specimen received,,, +CZ100222004,,,,,Male,Stool Pathogens,,"Mar 3, 2026 12:20 PM",6227810905,OVA AND PARASITES 2,Trichrome Smear,,,,,Test group cancelled: No specimen received,,, +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,CHEMISTRY PANEL,Total Bilirubin,,,,,Test group cancelled: No specimen received,,, +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,,,,Test group cancelled: No specimen received,,, +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,CHEMISTRY PANEL,Alkaline Phosphatase,,,,,Test group cancelled: No specimen received,,, +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,CHEMISTRY PANEL,ALT (SGPT),,,,,Test group cancelled: No specimen received,,, +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,CHEMISTRY PANEL,AST (SGOT),,,,,Test group cancelled: No specimen received,,, +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,CHEMISTRY PANEL,GGT,,,,,Test group cancelled: No specimen received,,, +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,CHEMISTRY PANEL,LDH,,,,,Test group cancelled: No specimen received,,, +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,CHEMISTRY PANEL,Urea Nitrogen,,,,,Test group cancelled: No specimen received,,, +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,,,,Test group cancelled: No specimen received,,, +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,CHEMISTRY PANEL,Serum Glucose,,,,,Test group cancelled: No specimen received,,, +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,CHEMISTRY PANEL,Serum Uric Acid,,,,,Test group cancelled: No specimen received,,, +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,CHEMISTRY PANEL,Calcium (EDTA),,,,,Test group cancelled: No specimen received,,, +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,CHEMISTRY PANEL,Phosphorus,,,,,Test group cancelled: No specimen received,,, +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,CHEMISTRY PANEL,Total Protein,,,,,Test group cancelled: No specimen received,,, +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,CHEMISTRY PANEL,Albumin-BCG,,,,,Test group cancelled: No specimen received,,, +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,CHEMISTRY PANEL,Creatine Kinase,,,,,Test group cancelled: No specimen received,,, +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,CHEMISTRY PANEL,Serum Sodium,,,,,Test group cancelled: No specimen received,,, +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,CHEMISTRY PANEL,Serum Potassium,,,,,Test group cancelled: No specimen received,,, +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,CHEMISTRY PANEL,Serum Bicarbonate,,,,,Test group cancelled: No specimen received,,, +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,CHEMISTRY PANEL,Serum Chloride,,,,,Test group cancelled: No specimen received,,, +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,CHEMISTRY PANEL,Magnesium,,,,,Test group cancelled: No specimen received,,, +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,,,,Test group cancelled: No specimen received,,, +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,HBV ELIGIBILITY MET?,HBV Eligibility Criteria Met?,,Yes,,,,,, +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,91,,L,,,125 - 170,g/L +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.31,,L,,,0.37 - 0.51, +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,3.7,,L,,,4 - 5.8,TI/L +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,25,,L,,,26 - 34,pg +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,86,,,,,80 - 100,fL +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,11.98,,H,,,3.8 - 10.7,GI/L +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,9.38,,H,,,1.96 - 7.23,GI/L +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.49,,,,,0.8 - 3,GI/L +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.88,,,,,0.12 - 0.92,GI/L +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.18,,,,,0 - 0.57,GI/L +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.05,,,,,0 - 0.2,GI/L +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,78.4,,H,,,40.5 - 75,% +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,12.4,,L,,,15.4 - 48.5,% +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,7.3,,,,,2.6 - 10.1,% +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.5,,,,,0 - 6.8,% +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.4,,,,,0 - 2,% +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,465,,H,,,130 - 394,GI/L +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,HEPATITIS B CORE AB NON-US,Hepatitis B Core Total,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,HEPATITIS B SURFACE AB,Anti-HBs II QUAL,,Non-Reactive,,,,,Ref Rng :$Non Reactive, +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,HEPATITIS B SURFACE AG NON-US,Hep B Surface AgII,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,HEPATITIS C VIRUS AB NON-US,Hepatitis C Virus Antibody,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,HIV 1/2 AG/AB SCREEN,anti-HIV-1/2 antibodies,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,HIV 1/2 AG/AB SCREEN,HIV -1 p24 antigen,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,HIV 1/2 AG/AB SCREEN,"HIV 1/2 Ag/Ab Screen, Cobas",,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,QUANTIFERON GOLD MITOGEN/INTER,"QFT,TBGoldPlusInt,pl-4-Tubes",,Negative,,,,,Normal=Negative, +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,SUBJECT HEIGHT (CM),Height (cm),Y,158,,,,,cm, +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,CHEMISTRY PANEL,Total Bilirubin,,6,,,,,3 - 21,umol/L +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,1.9,,,,,0 - 6.2,umol/L +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,CHEMISTRY PANEL,Alkaline Phosphatase,,78,,,,,40 - 129,U/L +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,CHEMISTRY PANEL,ALT (SGPT),,69,,H,,,5 - 48,U/L +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,CHEMISTRY PANEL,AST (SGOT),,33,,,,,8 - 40,U/L +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,CHEMISTRY PANEL,GGT,,38,,,,,10 - 61,U/L +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,CHEMISTRY PANEL,LDH,,213,,,,,53 - 234,U/L +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,CHEMISTRY PANEL,Urea Nitrogen,,8.9,,H,,,1.4 - 8.6,mmol/L +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,105,,,,,40 - 110,umol/L +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,CHEMISTRY PANEL,Serum Glucose,,4.4,,,,,3.9 - 5.6,mmol/L +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,CHEMISTRY PANEL,Serum Uric Acid,,414,,,,,125 - 488,umol/L +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,CHEMISTRY PANEL,Calcium (EDTA),,2.40,,,,,2.07 - 2.64,mmol/L +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,CHEMISTRY PANEL,Phosphorus,,1.17,,,,,0.71 - 1.65,mmol/L +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,CHEMISTRY PANEL,Total Protein,,70,,,,,61 - 84,g/L +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,CHEMISTRY PANEL,Albumin-BCG,,43,,,,,33 - 49,g/L +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,CHEMISTRY PANEL,Creatine Kinase,,157,,,,,39 - 308,U/L +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,CHEMISTRY PANEL,Serum Sodium,,139,,,,,132 - 147,mmol/L +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,CHEMISTRY PANEL,Serum Potassium,,4.5,,,,,3.5 - 5.2,mmol/L +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,CHEMISTRY PANEL,Serum Bicarbonate,,25.4,,,,,19.3 - 29.3,mmol/L +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,CHEMISTRY PANEL,Serum Chloride,,102,,,,,94 - 112,mmol/L +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,CHEMISTRY PANEL,Magnesium,,0.74,,,,,0.66 - 1.07,mmol/L +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,80,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,HBV ELIGIBILITY MET?,HBV Eligibility Criteria Met?,,Yes,,,,,, +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,138,,,,,127 - 181,g/L +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.40,,,,,0.39 - 0.54, +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.7,,,,,4.5 - 6.4,TI/L +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,30,,,,,26 - 34,pg +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,86,,,,,79 - 96,fL +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,5.87,,,,,3.8 - 10.7,GI/L +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.24,,,,,1.96 - 7.23,GI/L +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.46,,,,,0.91 - 4.28,GI/L +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.34,,,,,0.12 - 0.92,GI/L +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.79,R,H,,,0 - 0.57,GI/L +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.04,,,,,0 - 0.2,GI/L +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,38.2,R,L,,,40.5 - 75,% +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,41.9,,,,,15.4 - 48.5,% +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.7,,,,,2.6 - 10.1,% +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,13.5,R,H,,,0 - 6.8,% +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.7,,,,,0 - 2,% +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,302,,,,,140 - 400,GI/L +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,HEPATITIS B CORE AB NON-US,Hepatitis B Core Total,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,HEPATITIS B SURFACE AB,Anti-HBs II QUAL,,Reactive,,,,,Ref Rng :$Non Reactive, +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,HEPATITIS B SURFACE AG NON-US,Hep B Surface AgII,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,HEPATITIS C VIRUS AB NON-US,Hepatitis C Virus Antibody,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,HIV 1/2 AG/AB SCREEN,anti-HIV-1/2 antibodies,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,HIV 1/2 AG/AB SCREEN,HIV -1 p24 antigen,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,HIV 1/2 AG/AB SCREEN,"HIV 1/2 Ag/Ab Screen, Cobas",,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,QUANTIFERON GOLD MITOGEN/INTER,"QFT,TBGoldPlusInt,pl-4-Tubes",,,,,Test group cancelled: No specimen received,,, +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,SUBJECT HEIGHT (CM),Height (cm),Y,N/A (subject >/= 18 years of age),,,,,cm, +CZ100222001,,,,,Male,Biopsy,,"Feb 18, 2026 12:00 AM",6227323286,ANATOMICAL SITE,Anatomical Site,Y,15-20cm from anal verge,,,,,, +CZ100222001,,,,,Male,Biopsy,,"Feb 18, 2026 12:00 AM",6227323286,BIOPSY COLLECTION METHOD,Collection Method,Y,colonoscopy,,,,,, +CZ100222001,,,,,Male,Biopsy,,"Feb 18, 2026 12:00 AM",6227323286,BIOPSY FIXATIVE USED,Fixative Used,,10% NBF,,,,,, +CZ100222001,,,,,Male,Biopsy,,"Feb 18, 2026 12:00 AM",6227323286,DATE/TIME PLACED IN FORMALIN,Date Sample placed in Formalin,Y,18-Feb-2026,,,,,, +CZ100222001,,,,,Male,Biopsy,,"Feb 18, 2026 12:00 AM",6227323286,DATE/TIME PLACED IN FORMALIN,Time Sample placed in Formalin,Y,07:39,,,,,, +CZ100222001,,,,,Male,Biopsy,,"Feb 18, 2026 12:00 AM",6227323286,DIAGNOSIS,Diagnosis:,Y,Ulcerative Colitis,,,,,, +CZ100222001,,,,,Male,Biopsy,,"Feb 18, 2026 12:00 AM",6227323286,INFLAMED AREA,Inflamed area?,,No,,,,,, +CZ100222001,,,,,Male,Biopsy,,"Feb 18, 2026 12:00 AM",6227323286,TISSUE BIOPSY EMBEDDING1,Biopsy technical QC-CL,,Smpl meets HT requirements,,,,,, +CZ100222001,,,,,Male,Biopsy,,"Feb 18, 2026 12:00 AM",6227323286,TISSUE BIOPSY EMBEDDING1,Biopsy processing Time-CL,,10:00,,,,,, +CZ100222001,,,,,Male,Biopsy,,"Feb 18, 2026 12:00 AM",6227323286,TISSUE BIOPSY EMBEDDING1,Biopsy processing Date-CL,,20-Feb-2026,,,,,, +CZ100222001,,,,,Male,Biopsy,,"Feb 18, 2026 12:00 AM",6227323286,TISSUE BIOPSY EMBEDDING1,Biopsy Comments-CL,,Received in 10% NBF,,,,,, +CZ100222001,,,,,Male,Biopsy,,"Feb 18, 2026 12:00 AM",6227323286,TISSUE BIOPSY EMBEDDING1,# of Cassettes-(FI)-CL,,1,,,,,, +CZ100222001,,,,,Male,Biopsy,,"Feb 18, 2026 12:00 AM",6227323286,ULCERATED AREA,Is biopsy site ulcerated?,,No,,,,,, +CZ100222003,,,,,Male,Biopsy,,"Feb 11, 2026 12:00 AM",6227323287,ANATOMICAL SITE,Anatomical Site,Y,15-20cm from anal verge,,,,,, +CZ100222003,,,,,Male,Biopsy,,"Feb 11, 2026 12:00 AM",6227323287,BIOPSY COLLECTION METHOD,Collection Method,Y,colonoscopy,,,,,, +CZ100222003,,,,,Male,Biopsy,,"Feb 11, 2026 12:00 AM",6227323287,BIOPSY FIXATIVE USED,Fixative Used,,10% NBF,,,,,, +CZ100222003,,,,,Male,Biopsy,,"Feb 11, 2026 12:00 AM",6227323287,DATE/TIME PLACED IN FORMALIN,Date Sample placed in Formalin,Y,11-Feb-2026,,,,,, +CZ100222003,,,,,Male,Biopsy,,"Feb 11, 2026 12:00 AM",6227323287,DATE/TIME PLACED IN FORMALIN,Time Sample placed in Formalin,Y,14:38,,,,,, +CZ100222003,,,,,Male,Biopsy,,"Feb 11, 2026 12:00 AM",6227323287,DIAGNOSIS,Diagnosis:,Y,Ulcerative Colitis,,,,,, +CZ100222003,,,,,Male,Biopsy,,"Feb 11, 2026 12:00 AM",6227323287,INFLAMED AREA,Inflamed area?,,Yes,,,,,, +CZ100222003,,,,,Male,Biopsy,,"Feb 11, 2026 12:00 AM",6227323287,TISSUE BIOPSY EMBEDDING1,Biopsy technical QC-CL,,Smpl meets HT requirements,,,,,, +CZ100222003,,,,,Male,Biopsy,,"Feb 11, 2026 12:00 AM",6227323287,TISSUE BIOPSY EMBEDDING1,Biopsy processing Time-CL,,10:00,,,,,, +CZ100222003,,,,,Male,Biopsy,,"Feb 11, 2026 12:00 AM",6227323287,TISSUE BIOPSY EMBEDDING1,Biopsy processing Date-CL,,13-Feb-2026,,,,,, +CZ100222003,,,,,Male,Biopsy,,"Feb 11, 2026 12:00 AM",6227323287,TISSUE BIOPSY EMBEDDING1,Biopsy Comments-CL,,Received in 10% NBF,,,,,, +CZ100222003,,,,,Male,Biopsy,,"Feb 11, 2026 12:00 AM",6227323287,TISSUE BIOPSY EMBEDDING1,# of Cassettes-(FI)-CL,,1,,,,,, +CZ100222003,,,,,Male,Biopsy,,"Feb 11, 2026 12:00 AM",6227323287,ULCERATED AREA,Is biopsy site ulcerated?,,Yes,,,,,, +CZ100222002,,,,,Male,Stool Pathogens,,"Jan 23, 2026 10:10 AM",6227323277,C. DIFF EIA,"C. diff GDH Ag,stool-CL",,Negative,,,,,Ref Rng:Negative, +CZ100222002,,,,,Male,Stool Pathogens,,"Jan 23, 2026 10:10 AM",6227323277,C. DIFF EIA,"C.diff Toxin A&B,stool-CL",,Negative,,,,,Ref Rng:Negative, +CZ100222002,,,,,Male,Stool Pathogens,,"Jan 23, 2026 10:10 AM",6227323277,OVA AND PARASITES 1,Concentrate Exam,,,,,Test group cancelled: No specimen received,,, +CZ100222002,,,,,Male,Stool Pathogens,,"Jan 23, 2026 10:10 AM",6227323277,OVA AND PARASITES 1,Smear for Microsporidia,,,,,Test group cancelled: No specimen received,,, +CZ100222002,,,,,Male,Stool Pathogens,,"Jan 23, 2026 10:10 AM",6227323277,OVA AND PARASITES 1,Modified acid-fast stain,,,,,Test group cancelled: No specimen received,,, +CZ100222002,,,,,Male,Stool Pathogens,,"Jan 23, 2026 10:10 AM",6227323277,OVA AND PARASITES 2,Trichrome Smear,,,,,Test group cancelled: No specimen received,,, +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,CHEMISTRY PANEL,Total Bilirubin,,7,,,,,3 - 21,umol/L +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,1.9,,,,,0 - 6.2,umol/L +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,CHEMISTRY PANEL,Alkaline Phosphatase,,55,,,,,40 - 129,U/L +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,CHEMISTRY PANEL,ALT (SGPT),,25,,,,,5 - 48,U/L +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,CHEMISTRY PANEL,AST (SGOT),,24,,,,,8 - 40,U/L +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,CHEMISTRY PANEL,GGT,,12,,,,,10 - 61,U/L +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,CHEMISTRY PANEL,LDH,,190,,,,,53 - 234,U/L +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,CHEMISTRY PANEL,Urea Nitrogen,,8.5,,,,,1.4 - 8.6,mmol/L +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,115,,H,,,40 - 110,umol/L +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,CHEMISTRY PANEL,Serum Glucose,,4.4,,,,,3.9 - 5.6,mmol/L +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,CHEMISTRY PANEL,Serum Uric Acid,,337,,,,,125 - 488,umol/L +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,CHEMISTRY PANEL,Calcium (EDTA),,2.44,,,,,2.07 - 2.64,mmol/L +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,CHEMISTRY PANEL,Phosphorus,,0.86,,,,,0.71 - 1.65,mmol/L +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,CHEMISTRY PANEL,Total Protein,,71,,,,,61 - 84,g/L +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,CHEMISTRY PANEL,Albumin-BCG,,43,,,,,33 - 49,g/L +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,CHEMISTRY PANEL,Creatine Kinase,,144,,,,,39 - 308,U/L +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,CHEMISTRY PANEL,Serum Sodium,,141,,,,,132 - 147,mmol/L +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,CHEMISTRY PANEL,Serum Potassium,,4.1,,,,,3.5 - 5.2,mmol/L +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,CHEMISTRY PANEL,Serum Bicarbonate,,27.5,,,,,19.3 - 29.3,mmol/L +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,CHEMISTRY PANEL,Serum Chloride,,104,,,,,94 - 112,mmol/L +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,CHEMISTRY PANEL,Magnesium,,0.75,,,,,0.66 - 1.07,mmol/L +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,CKD-EPI 2021,CKD-EPI 2021 Without Race,,72,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,HBV ELIGIBILITY MET?,HBV Eligibility Criteria Met?,,Yes,,,,,, +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,136,,,,,127 - 181,g/L +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.39,,,,,0.39 - 0.54, +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.6,,,,,4.5 - 6.4,TI/L +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,30,,,,,26 - 34,pg +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,87,,,,,79 - 96,fL +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,5.82,,,,,3.8 - 10.7,GI/L +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.49,,,,,1.96 - 7.23,GI/L +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.54,,,,,0.91 - 4.28,GI/L +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.41,,,,,0.12 - 0.92,GI/L +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.34,,,,,0 - 0.57,GI/L +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.04,,,,,0 - 0.2,GI/L +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,42.7,,,,,40.5 - 75,% +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,43.7,,,,,15.4 - 48.5,% +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,7.0,,,,,2.6 - 10.1,% +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,5.9,,,,,0 - 6.8,% +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.6,,,,,0 - 2,% +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,224,,,,,140 - 400,GI/L +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,HEPATITIS B CORE AB NON-US,Hepatitis B Core Total,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,HEPATITIS B SURFACE AB NON-US,Anti-HBs II QUAL,,Reactive,,,,,Ref Rng :$Non Reactive, +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,HEPATITIS B SURFACE AG NON-US,Hep B Surface AgII,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,HEPATITIS C VIRUS AB NON-US,Hepatitis C Virus Antibody,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,HIV 1/2 AG/AB SCREEN,anti-HIV-1/2 antibodies,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,HIV 1/2 AG/AB SCREEN,HIV -1 p24 antigen,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,HIV 1/2 AG/AB SCREEN,"HIV 1/2 Ag/Ab Screen, Cobas",,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,QUANTIFERON GOLD MITOGEN/INTER,"QFT,TBGoldPlusInt,pl-4-Tubes",,Negative,,,,,Normal=Negative, +CZ100222001,,,,,Male,Stool Pathogens,R,"Jan 15, 2026 4:55 PM",6227323276,C. DIFF EIA,"C. diff GDH Ag,stool-CL",,,,,Test group cancelled: Specimen received beyond stability,,, +CZ100222001,,,,,Male,Stool Pathogens,R,"Jan 15, 2026 4:55 PM",6227323276,C. DIFF EIA,"C.diff Toxin A&B,stool-CL",,,,,Test group cancelled: Specimen received beyond stability,,, +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,CHEMISTRY PANEL,Total Bilirubin,,<3,,L,,Result verified by repeat analysis,3 - 21,umol/L +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,1.4,,,,,0 - 6.2,umol/L +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,CHEMISTRY PANEL,Alkaline Phosphatase,,140,,H,,,40 - 129,U/L +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,CHEMISTRY PANEL,ALT (SGPT),,23,,,,,5 - 48,U/L +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,CHEMISTRY PANEL,AST (SGOT),,28,,,,,8 - 40,U/L +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,CHEMISTRY PANEL,GGT,,136,,H,,,10 - 61,U/L +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,CHEMISTRY PANEL,LDH,,186,,,,,53 - 234,U/L +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,CHEMISTRY PANEL,Urea Nitrogen,,3.9,,,,,1.4 - 8.6,mmol/L +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,78,,,,,40 - 110,umol/L +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,CHEMISTRY PANEL,Serum Glucose,,4.9,,,,,3.9 - 5.6,mmol/L +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,CHEMISTRY PANEL,Serum Uric Acid,,408,,,,,125 - 488,umol/L +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,CHEMISTRY PANEL,Calcium (EDTA),,2.31,,,,,2.07 - 2.64,mmol/L +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,CHEMISTRY PANEL,Phosphorus,,1.13,,,,,0.71 - 1.65,mmol/L +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,CHEMISTRY PANEL,Total Protein,,77,,,,,61 - 84,g/L +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,CHEMISTRY PANEL,Albumin-BCG,,41,,,,,33 - 49,g/L +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,CHEMISTRY PANEL,Creatine Kinase,,131,,,,,39 - 308,U/L +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,CHEMISTRY PANEL,Serum Sodium,,140,,,,,132 - 147,mmol/L +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,CHEMISTRY PANEL,Serum Potassium,,4.4,,,,,3.5 - 5.2,mmol/L +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,CHEMISTRY PANEL,Serum Bicarbonate,,23.1,,,,,19.3 - 29.3,mmol/L +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,CHEMISTRY PANEL,Serum Chloride,,104,,,,,94 - 112,mmol/L +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,CHEMISTRY PANEL,Magnesium,,0.82,,,,,0.66 - 1.07,mmol/L +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,CKD-EPI 2021,CKD-EPI 2021 Without Race,,111,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,HBV ELIGIBILITY MET?,HBV Eligibility Criteria Met?,,Yes,,,,,, +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,85,,L,,,127 - 181,g/L +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.30,,L,,,0.39 - 0.54, +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.1,,L,,,4.5 - 6.4,TI/L +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,21,,L,,,26 - 34,pg +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,Microcytic,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,Anisocytosis,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,74,,L,,,79 - 96,fL +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,15.03,,H,,,3.8 - 10.7,GI/L +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,11.38,,H,,,1.96 - 7.23,GI/L +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.59,,,,,0.91 - 4.28,GI/L +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.82,,,,,0.12 - 0.92,GI/L +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.13,,,,,0 - 0.57,GI/L +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.11,,,,,0 - 0.2,GI/L +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,75.7,,H,,,40.5 - 75,% +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,17.3,,,,,15.4 - 48.5,% +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.4,,,,,2.6 - 10.1,% +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,0.9,,,,,0 - 6.8,% +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.7,,,,,0 - 2,% +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,529,,H,,,140 - 400,GI/L +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,HEPATITIS B CORE AB NON-US,Hepatitis B Core Total,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,HEPATITIS B SURFACE AB NON-US,Anti-HBs II QUAL,,Non-Reactive,,,,,Ref Rng :$Non Reactive, +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,HEPATITIS B SURFACE AG NON-US,Hep B Surface AgII,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,HEPATITIS C VIRUS AB NON-US,Hepatitis C Virus Antibody,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,HIV 1/2 AG/AB SCREEN,anti-HIV-1/2 antibodies,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,HIV 1/2 AG/AB SCREEN,HIV -1 p24 antigen,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,HIV 1/2 AG/AB SCREEN,"HIV 1/2 Ag/Ab Screen, Cobas",,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,QUANTIFERON GOLD MITOGEN/INTER,"QFT,TBGoldPlusInt,pl-4-Tubes",,Negative,,,,,Normal=Negative, diff --git a/Covance_UCO3001/Source/2026-06-08_130421 sponsor-study-36940-test-results-930556-standard.csv b/Covance_UCO3001/Source/2026-06-08_130421 sponsor-study-36940-test-results-930556-standard.csv new file mode 100644 index 0000000..d10a076 --- /dev/null +++ b/Covance_UCO3001/Source/2026-06-08_130421 sponsor-study-36940-test-results-930556-standard.csv @@ -0,0 +1,75 @@ +"Disclaimer: The information presented in On-Screen Results is not intended to be a replacement of the official Lab Results, Alerts, Data Revisions and Cancellations found in the Lab Reports section of this software application. On-Screen Results should not be used for patient diagnosis, treatment decisions or submission to regulatory bodies.",,,,,,,,,,,,,,,,,,, +Subject,Subject Data Revision,Screen No.,Age,Age Unit,Gender,Visit,Visit Data Revision,Collected Time,Accession,Test Group,Test,Administrative Question,Value,Result Data Revision,Flags,Cancellation Reason,Comments,Range,Units +CZ100032001,,,,,Female,Biopsy,,"May 27, 2026 12:00 AM",6227323320,ANATOMICAL SITE,Anatomical Site,Y,15-20cm from anal verge,,,,,, +CZ100032001,,,,,Female,Biopsy,,"May 27, 2026 12:00 AM",6227323320,BIOPSY COLLECTION METHOD,Collection Method,Y,colonoscopy,,,,,, +CZ100032001,,,,,Female,Biopsy,,"May 27, 2026 12:00 AM",6227323320,BIOPSY FIXATIVE USED,Fixative Used,,10% NBF,,,,,, +CZ100032001,,,,,Female,Biopsy,,"May 27, 2026 12:00 AM",6227323320,DATE/TIME PLACED IN FORMALIN,Date Sample placed in Formalin,Y,27-May-2026,,,,,, +CZ100032001,,,,,Female,Biopsy,,"May 27, 2026 12:00 AM",6227323320,DATE/TIME PLACED IN FORMALIN,Time Sample placed in Formalin,Y,08:10,,,,,, +CZ100032001,,,,,Female,Biopsy,,"May 27, 2026 12:00 AM",6227323320,DIAGNOSIS,Diagnosis:,Y,Ulcerative Colitis,,,,,, +CZ100032001,,,,,Female,Biopsy,,"May 27, 2026 12:00 AM",6227323320,INFLAMED AREA,Inflamed area?,,Yes,,,,,, +CZ100032001,,,,,Female,Biopsy,,"May 27, 2026 12:00 AM",6227323320,TISSUE BIOPSY EMBEDDING1,Biopsy technical QC-CL,,Smpl meets HT requirements,,,,,, +CZ100032001,,,,,Female,Biopsy,,"May 27, 2026 12:00 AM",6227323320,TISSUE BIOPSY EMBEDDING1,Biopsy processing Time-CL,,10:00,,,,,, +CZ100032001,,,,,Female,Biopsy,,"May 27, 2026 12:00 AM",6227323320,TISSUE BIOPSY EMBEDDING1,Biopsy processing Date-CL,,29-May-2026,,,,,, +CZ100032001,,,,,Female,Biopsy,,"May 27, 2026 12:00 AM",6227323320,TISSUE BIOPSY EMBEDDING1,Biopsy Comments-CL,,Received in 10% NBF,,,,,, +CZ100032001,,,,,Female,Biopsy,,"May 27, 2026 12:00 AM",6227323320,TISSUE BIOPSY EMBEDDING1,# of Cassettes-(FI)-CL,,1,,,,,, +CZ100032001,,,,,Female,Biopsy,,"May 27, 2026 12:00 AM",6227323320,ULCERATED AREA,Is biopsy site ulcerated?,,No,,,,,, +CZ100032001,,,,,Female,Stool Pathogens,,"May 13, 2026 9:30 AM",6227323309,C. DIFF EIA,"C. diff GDH Ag,stool-CL",,Negative,,,,,Ref Rng:Negative, +CZ100032001,,,,,Female,Stool Pathogens,,"May 13, 2026 9:30 AM",6227323309,C. DIFF EIA,"C.diff Toxin A&B,stool-CL",,Negative,,,,,Ref Rng:Negative, +CZ100032001,,,,,Female,Stool Pathogens,,"May 13, 2026 9:30 AM",6227323309,OVA AND PARASITES 1,Concentrate Exam,,No ova or parasites found,,,,,, +CZ100032001,,,,,Female,Stool Pathogens,,"May 13, 2026 9:30 AM",6227323309,OVA AND PARASITES 1,Smear for Microsporidia,,No Microsporidia seen.,,,,,, +CZ100032001,,,,,Female,Stool Pathogens,,"May 13, 2026 9:30 AM",6227323309,OVA AND PARASITES 1,Modified acid-fast stain,,No coccidian parasites seen,,,,,, +CZ100032001,,,,,Female,Stool Pathogens,,"May 13, 2026 9:30 AM",6227323309,OVA AND PARASITES 2,Trichrome Smear,,,,,Test group cancelled: Specimen received in expired coll. container; unable to perform test.,,, +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,CHEMISTRY PANEL,Total Bilirubin,,6,,,,,3 - 21,umol/L +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.1,,,,,0 - 6.2,umol/L +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,CHEMISTRY PANEL,Alkaline Phosphatase,,85,,,,,35 - 104,U/L +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,CHEMISTRY PANEL,ALT (SGPT),,9,,,,,4 - 43,U/L +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,CHEMISTRY PANEL,AST (SGOT),,11,,,,,8 - 40,U/L +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,CHEMISTRY PANEL,GGT,,9,,,,,4 - 49,U/L +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,CHEMISTRY PANEL,LDH,,128,,,,,53 - 234,U/L +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,CHEMISTRY PANEL,Urea Nitrogen,,4.0,,,,,1.4 - 8.6,mmol/L +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,75,,,,,31 - 101,umol/L +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,CHEMISTRY PANEL,Serum Glucose,,4.8,,,,,3.9 - 5.6,mmol/L +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,CHEMISTRY PANEL,Serum Uric Acid,,192,,,,,125 - 428,umol/L +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,CHEMISTRY PANEL,Calcium (EDTA),,2.24,,,,,2.07 - 2.64,mmol/L +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,CHEMISTRY PANEL,Phosphorus,,1.00,,,,,0.71 - 1.65,mmol/L +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,CHEMISTRY PANEL,Total Protein,,71,,,,,61 - 84,g/L +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,CHEMISTRY PANEL,Albumin-BCG,,44,,,,,33 - 49,g/L +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,CHEMISTRY PANEL,Creatine Kinase,,85,,,,,26 - 192,U/L +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,CHEMISTRY PANEL,Serum Sodium,,138,,,,,132 - 147,mmol/L +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,CHEMISTRY PANEL,Serum Potassium,,4.1,,,,,3.5 - 5.2,mmol/L +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,CHEMISTRY PANEL,Serum Bicarbonate,,23.8,,,,,19.3 - 29.3,mmol/L +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,CHEMISTRY PANEL,Serum Chloride,,101,,,,,94 - 112,mmol/L +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,CHEMISTRY PANEL,Magnesium,,0.79,,,,,0.66 - 1.07,mmol/L +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,94,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,FEMALE OF CHILDBEARING POT?,Female/of Childbearing pot.?,Y,Yes,,,,,, +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,HBV ELIGIBILITY MET?,HBV Eligibility Criteria Met?,,Yes,,,,,, +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,114,,L,,,116 - 164,g/L +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.36,,,,,0.34 - 0.48, +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.1,,,,,4.1 - 5.6,TI/L +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,28,,,,,26 - 34,pg +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,87,,,,,79 - 98,fL +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,8.80,,,,,3.8 - 10.7,GI/L +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,6.53,,,,,1.96 - 7.23,GI/L +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.32,,,,,0.91 - 4.28,GI/L +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.47,,,,,0.12 - 0.92,GI/L +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.44,,,,,0 - 0.57,GI/L +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.04,,,,,0 - 0.2,GI/L +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,74.2,,,,,40.5 - 75,% +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,15.0,,L,,,15.4 - 48.5,% +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.4,,,,,2.6 - 10.1,% +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,5.0,,,,,0 - 6.8,% +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.5,,,,,0 - 2,% +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,513,,H,,,140 - 400,GI/L +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,HEPATITIS B CORE AB NON-US,Hepatitis B Core Total,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,HEPATITIS B SURFACE AB,Anti-HBs II QUAL,,Reactive,,,,,Ref Rng :$Non Reactive, +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,HEPATITIS B SURFACE AG NON-US,Hep B Surface AgII,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,HEPATITIS C VIRUS AB NON-US,Hepatitis C Virus Antibody,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,HIV 1/2 AG/AB SCREEN,anti-HIV-1/2 antibodies,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,HIV 1/2 AG/AB SCREEN,HIV -1 p24 antigen,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,HIV 1/2 AG/AB SCREEN,"HIV 1/2 Ag/Ab Screen, Cobas",,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,QUANTIFERON GOLD MITOGEN/INTER,"QFT,TBGoldPlusInt,pl-4-Tubes",,Negative,,,,,Normal=Negative, +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,SERUM BETA HCG,"B-hCG, Qualitative",,Negative,,,,,Ref Rng: Negative, +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,SERUM BETA HCG,"B-hCG, Quantitative",,<0.6,,,,,Units: mIU/mL$Pre-menopausal$<5.0: Negative$5.0-24.9:Borderline$>/= 25.0: Positive, +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,SUBJECT HEIGHT (CM),Height (cm),Y,N/A (subject >/= 18 years of age),,,,,cm, diff --git a/Covance_UCO3001/Source/2026-06-08_130426 sponsor-study-36940-test-results-930556-microbiology.csv b/Covance_UCO3001/Source/2026-06-08_130426 sponsor-study-36940-test-results-930556-microbiology.csv new file mode 100644 index 0000000..fba7493 --- /dev/null +++ b/Covance_UCO3001/Source/2026-06-08_130426 sponsor-study-36940-test-results-930556-microbiology.csv @@ -0,0 +1,3 @@ +"Disclaimer: The information presented in On-Screen Results is not intended to be a replacement of the official Lab Results, Alerts, Data Revisions and Cancellations found in the Lab Reports section of this software application. On-Screen Results should not be used for patient diagnosis, treatment decisions or submission to regulatory bodies.",,,,,,,,,,,,,,,,,,,,,,, +Subject,Screening Number,Age,Age Unit,Gender,Visit Description,Collected Time,Accession,Test Group,Specimen,Organism,Growth,Cancellation Reason,Test Description,Test Result,Drug Name/Agent,MIC Result,Units,MIC Interpretation,Disk Diffusion Result,Disk Diffusion Interpretation,Subject Data Revision,Visit Data Revision,Result Data Revision +CZ100032001 - null,,,,Female,SCRNSTOOL Stool Pathogens,"May 13, 2026 9:30 AM",6227323309,STOOL CULTURE,Stool,,,,Final Report,No enteric pathogens isolated,,,,,,,,, diff --git a/Covance_UCO3001/Source/2026-06-08_130427 sponsor-study-36940-test-results-930525-microbiology.csv b/Covance_UCO3001/Source/2026-06-08_130427 sponsor-study-36940-test-results-930525-microbiology.csv new file mode 100644 index 0000000..a4242f9 --- /dev/null +++ b/Covance_UCO3001/Source/2026-06-08_130427 sponsor-study-36940-test-results-930525-microbiology.csv @@ -0,0 +1,6 @@ +"Disclaimer: The information presented in On-Screen Results is not intended to be a replacement of the official Lab Results, Alerts, Data Revisions and Cancellations found in the Lab Reports section of this software application. On-Screen Results should not be used for patient diagnosis, treatment decisions or submission to regulatory bodies.",,,,,,,,,,,,,,,,,,,,,,, +Subject,Screening Number,Age,Age Unit,Gender,Visit Description,Collected Time,Accession,Test Group,Specimen,Organism,Growth,Cancellation Reason,Test Description,Test Result,Drug Name/Agent,MIC Result,Units,MIC Interpretation,Disk Diffusion Result,Disk Diffusion Interpretation,Subject Data Revision,Visit Data Revision,Result Data Revision +CZ100222001 - null,,,,Male,SCRNSTOOL Stool Pathogens,"Jan 15, 2026 4:55 PM",6227323276,STOOL CULTURE,Stool,,,,Final Report,No enteric pathogens isolated,,,,,,,,R, +CZ100222002 - null,,,,Male,SCRNSTOOL Stool Pathogens,"Jan 23, 2026 10:10 AM",6227323277,STOOL CULTURE,Stool,,,,Final Report,No enteric pathogens isolated,,,,,,,,, +CZ100222004 - null,,,,Male,SCRNSTOOL Stool Pathogens,"Mar 3, 2026 12:20 PM",6227810905,STOOL CULTURE,Stool,,,,Final Report,No enteric pathogens isolated,,,,,,,,, +CZ100222005 - null,,,,Male,SCRNSTOOL Stool Pathogens,"Mar 4, 2026 9:10 AM",6227810904,STOOL CULTURE,Stool,,,,Final Report,No enteric pathogens isolated,,,,,,,,, diff --git a/Covance_UCO3001/Source/2026-06-08_130444 sponsor-study-36940-test-results-930549-standard.csv b/Covance_UCO3001/Source/2026-06-08_130444 sponsor-study-36940-test-results-930549-standard.csv new file mode 100644 index 0000000..533a201 --- /dev/null +++ b/Covance_UCO3001/Source/2026-06-08_130444 sponsor-study-36940-test-results-930549-standard.csv @@ -0,0 +1,242 @@ +"Disclaimer: The information presented in On-Screen Results is not intended to be a replacement of the official Lab Results, Alerts, Data Revisions and Cancellations found in the Lab Reports section of this software application. On-Screen Results should not be used for patient diagnosis, treatment decisions or submission to regulatory bodies.",,,,,,,,,,,,,,,,,,, +Subject,Subject Data Revision,Screen No.,Age,Age Unit,Gender,Visit,Visit Data Revision,Collected Time,Accession,Test Group,Test,Administrative Question,Value,Result Data Revision,Flags,Cancellation Reason,Comments,Range,Units +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,ALP<2XULN,ALP<2XULN,,Criteria Met,,,,,, +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,ALT>/=3XULN,ALT >/= 3 X ULN,,Criteria not met,,,,,, +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,ALT>/=3XULN & TBIL>/=2XULN,ALT >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,AST>/=3XULN,AST >/= 3 X ULN,,Criteria not met,,,,,, +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,AST>/=3XULN & TBIL>/=2XULN,AST >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,CHEMISTRY PANEL,Total Bilirubin,,6,,,,,3 - 21,umol/L +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.3,,,,,0 - 6.2,umol/L +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,CHEMISTRY PANEL,Alkaline Phosphatase,,82,,,,,35 - 104,U/L +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,CHEMISTRY PANEL,ALT (SGPT),,18,,,,,4 - 43,U/L +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,CHEMISTRY PANEL,AST (SGOT),,17,,,,,8 - 40,U/L +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,CHEMISTRY PANEL,GGT,,11,,,,,4 - 49,U/L +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,CHEMISTRY PANEL,LDH,,151,,,,,53 - 234,U/L +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,CHEMISTRY PANEL,Urea Nitrogen,,2.1,,,,,1.4 - 8.6,mmol/L +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,55,,,,,31 - 101,umol/L +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,CHEMISTRY PANEL,Serum Glucose,,4.8,,,,,3.9 - 5.6,mmol/L +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,CHEMISTRY PANEL,Serum Uric Acid,,277,,,,,125 - 428,umol/L +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,CHEMISTRY PANEL,Calcium (EDTA),,2.54,,,,,2.07 - 2.64,mmol/L +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,CHEMISTRY PANEL,Phosphorus,,0.81,,,,,0.71 - 1.65,mmol/L +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,CHEMISTRY PANEL,Total Protein,,84,,,,,61 - 84,g/L +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,CHEMISTRY PANEL,Albumin-BCG,,51,,H,,,33 - 49,g/L +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,CHEMISTRY PANEL,Creatine Kinase,,55,,,,,26 - 192,U/L +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,CHEMISTRY PANEL,Serum Sodium,,140,,,,,132 - 147,mmol/L +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,CHEMISTRY PANEL,Serum Potassium,,4.2,,,,,3.5 - 5.2,mmol/L +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,CHEMISTRY PANEL,Serum Bicarbonate,,23.5,,,,,19.3 - 29.3,mmol/L +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,CHEMISTRY PANEL,Serum Chloride,,101,,,,,94 - 112,mmol/L +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,CHEMISTRY PANEL,Magnesium,,0.89,,,,,0.66 - 1.07,mmol/L +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,129,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,FECAL COLLECTION D/T,Stool Collection Date,Y,,,,,,, +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,FECAL COLLECTION D/T,Stool Collection Time,Y,,,,,,, +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,127,,,,Result verified by repeat analysis,116 - 164,g/L +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.39,,,,,0.34 - 0.48, +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.7,,,,Result verified by repeat analysis,4.1 - 5.6,TI/L +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,27,,,,Result verified by repeat analysis,26 - 34,pg +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,Anisocytosis,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,83,,,,Result verified by repeat analysis,79 - 98,fL +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,4.41,,,,Result verified by repeat analysis,3.8 - 10.7,GI/L +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.73,,,,,1.96 - 7.23,GI/L +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.41,,,,,0.91 - 4.28,GI/L +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.22,,,,,0.12 - 0.92,GI/L +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.04,,,,,0 - 0.57,GI/L +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.00,,,,,0 - 0.2,GI/L +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,62.0,,,,,40.5 - 75,% +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,32.0,,,,,15.4 - 48.5,% +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.0,,,,,2.6 - 10.1,% +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.0,,,,,0 - 6.8,% +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.0,,,,,0 - 2,% +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,340,,,,Result verified by repeat analysis,140 - 400,GI/L +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,SM01/PLASMA PK TROUGH COLL D/T,Collection Date Predose,Y,07-May-2026,,,,,, +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,SM01/PLASMA PK TROUGH COLL D/T,Collection Time Predose,Y,12:40,,,,,, +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,SM02/PLASMA PK PEAK COLL D/T,Collection Date Post dose,Y,07-May-2026,,,,,, +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,SM02/PLASMA PK PEAK COLL D/T,Post Dose Collection Time,Y,14:20,,,,,, +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,SM04/SERUM ADA PRE COLL D/T,Collection Date Predose,Y,07-May-2026,,,,,, +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,SM04/SERUM ADA PRE COLL D/T,Collection Time Predose,Y,12:40,,,,,, +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,SM09/STOOL PK COLL D/T,Stool Collection Date,Y,,,,,,, +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,SM09/STOOL PK COLL D/T,Stool Collection Time,Y,,,,,,, +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,SUBJECT HEIGHT (CM),Height (cm),Y,N/A (subject >/= 18 years of age),,,,,cm, +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,ALP<2XULN,ALP<2XULN,,Criteria Met,,,,,, +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,ALT>/=3XULN,ALT >/= 3 X ULN,,Criteria not met,,,,,, +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,ALT>/=3XULN & TBIL>/=2XULN,ALT >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,AST>/=3XULN,AST >/= 3 X ULN,,Criteria not met,,,,,, +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,AST>/=3XULN & TBIL>/=2XULN,AST >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,CHEMISTRY PANEL,Total Bilirubin,,4,,,,,3 - 21,umol/L +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,1.7,,,,,0 - 6.2,umol/L +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,CHEMISTRY PANEL,Alkaline Phosphatase,,71,,,,,35 - 104,U/L +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,CHEMISTRY PANEL,ALT (SGPT),,24,,,,,4 - 43,U/L +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,CHEMISTRY PANEL,AST (SGOT),,19,,,,,8 - 40,U/L +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,CHEMISTRY PANEL,GGT,,12,,,,,4 - 49,U/L +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,CHEMISTRY PANEL,LDH,,138,,,,,53 - 234,U/L +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,CHEMISTRY PANEL,Urea Nitrogen,,3.5,,,,,1.4 - 8.6,mmol/L +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,56,,,,,31 - 101,umol/L +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,CHEMISTRY PANEL,Serum Glucose,,5.1,,,,,3.9 - 5.6,mmol/L +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,CHEMISTRY PANEL,Serum Uric Acid,,296,,,,,125 - 428,umol/L +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,CHEMISTRY PANEL,Calcium (EDTA),,2.55,,,,,2.07 - 2.64,mmol/L +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,CHEMISTRY PANEL,Phosphorus,,0.77,,,,,0.71 - 1.65,mmol/L +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,CHEMISTRY PANEL,Total Protein,,77,,,,,61 - 84,g/L +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,CHEMISTRY PANEL,Albumin-BCG,,46,,,,,33 - 49,g/L +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,CHEMISTRY PANEL,Creatine Kinase,,49,,,,,26 - 192,U/L +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,CHEMISTRY PANEL,Serum Sodium,,138,,,,,132 - 147,mmol/L +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,CHEMISTRY PANEL,Serum Potassium,,4.3,,,,,3.5 - 5.2,mmol/L +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,CHEMISTRY PANEL,Serum Bicarbonate,,25.3,,,,,19.3 - 29.3,mmol/L +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,CHEMISTRY PANEL,Serum Chloride,,100,,,,,94 - 112,mmol/L +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,CHEMISTRY PANEL,Magnesium,,0.83,,,,,0.66 - 1.07,mmol/L +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,129,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,FECAL COLLECTION D/T,Stool Collection Date,Y,22-Apr-2026,,,,,, +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,FECAL COLLECTION D/T,Stool Collection Time,Y,05:30,,,,,, +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,128,,,,Result verified by repeat analysis,116 - 164,g/L +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.40,,,,Result verified by repeat analysis,0.34 - 0.48, +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.9,,,,Result verified by repeat analysis,4.1 - 5.6,TI/L +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,26,,,,Result verified by repeat analysis,26 - 34,pg +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,81,,,,Result verified by repeat analysis,79 - 98,fL +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,6.60,,,,Result verified by repeat analysis,3.8 - 10.7,GI/L +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,4.39,,,,,1.96 - 7.23,GI/L +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.54,,,,,0.91 - 4.28,GI/L +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.47,,,,Result verified by repeat analysis,0.12 - 0.92,GI/L +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.12,,,,Result verified by repeat analysis,0 - 0.57,GI/L +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.07,,,,Result verified by repeat analysis,0 - 0.2,GI/L +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,66.6,,,,Result verified by repeat analysis,40.5 - 75,% +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,23.5,,,,Result verified by repeat analysis,15.4 - 48.5,% +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,7.2,,,,Result verified by repeat analysis,2.6 - 10.1,% +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.8,,,,Result verified by repeat analysis,0 - 6.8,% +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.0,,,,Result verified by repeat analysis,0 - 2,% +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,300,,,,Result verified by repeat analysis,140 - 400,GI/L +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,SM01/PLASMA PK TROUGH COLL D/T,Collection Date Predose,Y,22-Apr-2026,,,,,, +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,SM01/PLASMA PK TROUGH COLL D/T,Collection Time Predose,Y,09:25,,,,,, +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,SM02/PLASMA PK PEAK COLL D/T,Collection Date Post dose,Y,22-Apr-2026,,,,,, +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,SM02/PLASMA PK PEAK COLL D/T,Post Dose Collection Time,Y,10:45,,,,,, +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,SM04/SERUM ADA PRE COLL D/T,Collection Date Predose,Y,22-Apr-2026,,,,,, +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,SM04/SERUM ADA PRE COLL D/T,Collection Time Predose,Y,09:25,,,,,, +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,SM09/STOOL PK COLL D/T,Stool Collection Date,Y,22-Apr-2026,,,,,, +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,SM09/STOOL PK COLL D/T,Stool Collection Time,Y,05:30,,,,,, +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,SUBJECT HEIGHT (CM),Height (cm),Y,N/A (subject >/= 18 years of age),,,,,cm, +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,CHEMISTRY PANEL,Total Bilirubin,,5,,,,,3 - 21,umol/L +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,1.5,,,,,0 - 6.2,umol/L +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,CHEMISTRY PANEL,Alkaline Phosphatase,,66,,,,,35 - 104,U/L +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,CHEMISTRY PANEL,ALT (SGPT),,25,,,,,4 - 43,U/L +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,CHEMISTRY PANEL,AST (SGOT),,24,,,,,8 - 40,U/L +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,CHEMISTRY PANEL,GGT,,12,,,,,4 - 49,U/L +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,CHEMISTRY PANEL,LDH,,157,,,,,53 - 234,U/L +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,CHEMISTRY PANEL,Urea Nitrogen,,3.0,,,,,1.4 - 8.6,mmol/L +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,51,,,,,31 - 101,umol/L +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,CHEMISTRY PANEL,Serum Glucose,,4.4,,,,,3.9 - 5.6,mmol/L +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,CHEMISTRY PANEL,Serum Uric Acid,,258,,,,,125 - 428,umol/L +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,CHEMISTRY PANEL,Calcium (EDTA),,2.35,,,,,2.07 - 2.64,mmol/L +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,CHEMISTRY PANEL,Phosphorus,,0.84,,,,,0.71 - 1.65,mmol/L +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,CHEMISTRY PANEL,Total Protein,,71,,,,,61 - 84,g/L +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,CHEMISTRY PANEL,Albumin-BCG,,46,,,,,33 - 49,g/L +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,CHEMISTRY PANEL,Creatine Kinase,,51,,,,,26 - 192,U/L +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,CHEMISTRY PANEL,Serum Sodium,,139,,,,,132 - 147,mmol/L +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,CHEMISTRY PANEL,Serum Potassium,,4.4,,,,,3.5 - 5.2,mmol/L +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,CHEMISTRY PANEL,Serum Bicarbonate,,23.0,,,,,19.3 - 29.3,mmol/L +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,CHEMISTRY PANEL,Serum Chloride,,103,,,,,94 - 112,mmol/L +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,CHEMISTRY PANEL,Magnesium,,0.82,,,,,0.66 - 1.07,mmol/L +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,131,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,FECAL COLLECTION D/T,Stool Collection Date,Y,07-Apr-2026,,,,,, +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,FECAL COLLECTION D/T,Stool Collection Time,Y,06:00,,,,,, +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,115,R,L,,,116 - 164,g/L +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.36,,,,,0.34 - 0.48, +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.5,,,,,4.1 - 5.6,TI/L +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,25,R,L,,,26 - 34,pg +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,80,,,,,79 - 98,fL +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,9.11,,,,,3.8 - 10.7,GI/L +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,6.31,,,,,1.96 - 7.23,GI/L +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.15,,,,,0.91 - 4.28,GI/L +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.54,,,,,0.12 - 0.92,GI/L +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.05,,,,,0 - 0.57,GI/L +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.06,,,,,0 - 0.2,GI/L +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,69.3,,,,,40.5 - 75,% +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,23.6,,,,,15.4 - 48.5,% +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.9,,,,,2.6 - 10.1,% +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,0.5,,,,,0 - 6.8,% +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.7,,,,,0 - 2,% +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,386,,,,,140 - 400,GI/L +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,LIPID PANEL,Direct HDL-C 4th Generation,,1.35,,,,,1.03 - 1.53,mmol/L +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,LIPID PANEL,Triglycerides (GPO),,1.11,,,,,0.41 - 1.63,mmol/L +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,LIPID PANEL,Cholesterol (High Performance),,4.41,,,,,3.31 - 5.64,mmol/L +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,LIPID PANEL,LDL Chol Friedewald 4th,,2.55,,,,,0 - 3.34,mmol/L +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,SM01/PLASMA PK TROUGH COLL D/T,Collection Date Predose,Y,07-Apr-2026,,,,,, +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,SM01/PLASMA PK TROUGH COLL D/T,Collection Time Predose,Y,11:45,,,,,, +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,SM02/PLASMA PK PEAK COLL D/T,Collection Date Post dose,Y,07-Apr-2026,,,,,, +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,SM02/PLASMA PK PEAK COLL D/T,Post Dose Collection Time,Y,13:35,,,,,, +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,SM04/SERUM ADA PRE COLL D/T,Collection Date Predose,Y,07-Apr-2026,,,,,, +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,SM04/SERUM ADA PRE COLL D/T,Collection Time Predose,Y,11:45,,,,,, +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,SM10/FECAL BMRKS COLL D/T,Stool Collection Date,Y,07-Apr-2026,,,,,, +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,SM10/FECAL BMRKS COLL D/T,Stool Collection Time,Y,06:00,,,,,, +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,SUBJECT HEIGHT (CM),Height (cm),Y,N/A (subject >/= 18 years of age),,,,,cm, +CZ100122001,,,,,Female,Biopsy,,"Mar 23, 2026 12:00 AM",6227697736,ANATOMICAL SITE,Anatomical Site,Y,15 cm,,,,,, +CZ100122001,,,,,Female,Biopsy,,"Mar 23, 2026 12:00 AM",6227697736,BIOPSY COLLECTION METHOD,Collection Method,Y,colonoscopy,,,,,, +CZ100122001,,,,,Female,Biopsy,,"Mar 23, 2026 12:00 AM",6227697736,BIOPSY FIXATIVE USED,Fixative Used,,10% NBF,,,,,, +CZ100122001,,,,,Female,Biopsy,,"Mar 23, 2026 12:00 AM",6227697736,DATE/TIME PLACED IN FORMALIN,Date Sample placed in Formalin,Y,23-Mar-2026,,,,,, +CZ100122001,,,,,Female,Biopsy,,"Mar 23, 2026 12:00 AM",6227697736,DATE/TIME PLACED IN FORMALIN,Time Sample placed in Formalin,Y,09:42,,,,,, +CZ100122001,,,,,Female,Biopsy,,"Mar 23, 2026 12:00 AM",6227697736,DIAGNOSIS,Diagnosis:,Y,Ulcerative Colitis,,,,,, +CZ100122001,,,,,Female,Biopsy,,"Mar 23, 2026 12:00 AM",6227697736,INFLAMED AREA,Inflamed area?,,Yes,,,,,, +CZ100122001,,,,,Female,Biopsy,,"Mar 23, 2026 12:00 AM",6227697736,TISSUE BIOPSY EMBEDDING1,Biopsy technical QC-CL,,Smpl meets HT requirements,,,,,, +CZ100122001,,,,,Female,Biopsy,,"Mar 23, 2026 12:00 AM",6227697736,TISSUE BIOPSY EMBEDDING1,Biopsy processing Time-CL,,10:00,,,,,, +CZ100122001,,,,,Female,Biopsy,,"Mar 23, 2026 12:00 AM",6227697736,TISSUE BIOPSY EMBEDDING1,Biopsy processing Date-CL,,25-Mar-2026,,,,,, +CZ100122001,,,,,Female,Biopsy,,"Mar 23, 2026 12:00 AM",6227697736,TISSUE BIOPSY EMBEDDING1,Biopsy Comments-CL,,Received in 10% NBF,,,,,, +CZ100122001,,,,,Female,Biopsy,,"Mar 23, 2026 12:00 AM",6227697736,TISSUE BIOPSY EMBEDDING1,# of Cassettes-(FI)-CL,,1,,,,,, +CZ100122001,,,,,Female,Biopsy,,"Mar 23, 2026 12:00 AM",6227697736,ULCERATED AREA,Is biopsy site ulcerated?,,Yes,,,,,, +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,CHEMISTRY PANEL,Total Bilirubin,,<3,R,L,,Result verified by repeat analysis,3 - 21,umol/L +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,<1.4,,,,Result verified by repeat analysis,0 - 6.2,umol/L +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,CHEMISTRY PANEL,Alkaline Phosphatase,,74,,,,,35 - 104,U/L +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,CHEMISTRY PANEL,ALT (SGPT),,23,,,,,4 - 43,U/L +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,CHEMISTRY PANEL,AST (SGOT),,23,,,,,8 - 40,U/L +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,CHEMISTRY PANEL,GGT,,9,,,,,4 - 49,U/L +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,CHEMISTRY PANEL,LDH,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,CHEMISTRY PANEL,Urea Nitrogen,,2.5,,,,,1.4 - 8.6,mmol/L +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,55,,,,,31 - 101,umol/L +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,CHEMISTRY PANEL,Serum Glucose,,5.5,,,,,3.9 - 5.6,mmol/L +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,CHEMISTRY PANEL,Serum Uric Acid,,226,,,,,125 - 428,umol/L +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,CHEMISTRY PANEL,Calcium (EDTA),,2.39,,,,,2.07 - 2.64,mmol/L +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,CHEMISTRY PANEL,Phosphorus,,0.90,,,,,0.71 - 1.65,mmol/L +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,CHEMISTRY PANEL,Total Protein,,73,,,,,61 - 84,g/L +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,CHEMISTRY PANEL,Albumin-BCG,,45,,,,,33 - 49,g/L +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,CHEMISTRY PANEL,Creatine Kinase,,84,,,,,26 - 192,U/L +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,CHEMISTRY PANEL,Serum Sodium,,142,,,,,132 - 147,mmol/L +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,CHEMISTRY PANEL,Serum Potassium,,5.1,,,,,3.5 - 5.2,mmol/L +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,CHEMISTRY PANEL,Serum Bicarbonate,,19.2,,L,,,19.3 - 29.3,mmol/L +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,CHEMISTRY PANEL,Serum Chloride,,103,,,,,94 - 112,mmol/L +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,CHEMISTRY PANEL,Magnesium,,0.83,,,,,0.66 - 1.07,mmol/L +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,129,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,FEMALE OF CHILDBEARING POT?,Female/of Childbearing pot.?,Y,Yes,,,,,, +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,HBV ELIGIBILITY MET?,HBV Eligibility Criteria Met?,,Yes,,,,,, +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,111,R,L,,,116 - 164,g/L +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.36,,,,,0.34 - 0.48, +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.6,,,,,4.1 - 5.6,TI/L +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,24,R,L,,,26 - 34,pg +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,78,R,L,,,79 - 98,fL +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,7.66,,,,,3.8 - 10.7,GI/L +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,5.37,,,,,1.96 - 7.23,GI/L +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.63,,,,,0.91 - 4.28,GI/L +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.55,,,,,0.12 - 0.92,GI/L +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.08,,,,,0 - 0.57,GI/L +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.03,,,,,0 - 0.2,GI/L +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,70.2,,,,,40.5 - 75,% +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,21.2,,,,,15.4 - 48.5,% +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,7.2,,,,,2.6 - 10.1,% +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.1,,,,,0 - 6.8,% +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.4,,,,,0 - 2,% +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,412,R,H,,,140 - 400,GI/L +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,HEPATITIS B CORE AB NON-US,Hepatitis B Core Total,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,HEPATITIS B SURFACE AB,Anti-HBs II QUAL,,Non-Reactive,,,,,Ref Rng :$Non Reactive, +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,HEPATITIS B SURFACE AG NON-US,Hep B Surface AgII,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,HEPATITIS C VIRUS AB NON-US,Hepatitis C Virus Antibody,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,HIV 1/2 AG/AB SCREEN,anti-HIV-1/2 antibodies,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,HIV 1/2 AG/AB SCREEN,HIV -1 p24 antigen,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,HIV 1/2 AG/AB SCREEN,"HIV 1/2 Ag/Ab Screen, Cobas",,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,QUANTIFERON GOLD MITOGEN/INTER,"QFT,TBGoldPlusInt,pl-4-Tubes",,Negative,,,,,Normal=Negative, +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,SERUM BETA HCG,"B-hCG, Qualitative",,Negative,,,,,Ref Rng: Negative, +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,SERUM BETA HCG,"B-hCG, Quantitative",,<0.6,,,,,Units: mIU/mL$Pre-menopausal$<5.0: Negative$5.0-24.9:Borderline$>/= 25.0: Positive, +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,SUBJECT HEIGHT (CM),Height (cm),Y,N/A (subject >/= 18 years of age),,,,,cm, +CZ100122001,,,,,Female,Stool Pathogens,,"Mar 17, 2026 5:30 PM",6227697725,C. DIFF EIA,"C. diff GDH Ag,stool-CL",,Negative,,,,,Ref Rng:Negative, +CZ100122001,,,,,Female,Stool Pathogens,,"Mar 17, 2026 5:30 PM",6227697725,C. DIFF EIA,"C.diff Toxin A&B,stool-CL",,Negative,,,,,Ref Rng:Negative, diff --git a/Covance_UCO3001/Source/2026-06-08_130448 sponsor-study-36940-test-results-930549-microbiology.csv b/Covance_UCO3001/Source/2026-06-08_130448 sponsor-study-36940-test-results-930549-microbiology.csv new file mode 100644 index 0000000..a05daf8 --- /dev/null +++ b/Covance_UCO3001/Source/2026-06-08_130448 sponsor-study-36940-test-results-930549-microbiology.csv @@ -0,0 +1,3 @@ +"Disclaimer: The information presented in On-Screen Results is not intended to be a replacement of the official Lab Results, Alerts, Data Revisions and Cancellations found in the Lab Reports section of this software application. On-Screen Results should not be used for patient diagnosis, treatment decisions or submission to regulatory bodies.",,,,,,,,,,,,,,,,,,,,,,, +Subject,Screening Number,Age,Age Unit,Gender,Visit Description,Collected Time,Accession,Test Group,Specimen,Organism,Growth,Cancellation Reason,Test Description,Test Result,Drug Name/Agent,MIC Result,Units,MIC Interpretation,Disk Diffusion Result,Disk Diffusion Interpretation,Subject Data Revision,Visit Data Revision,Result Data Revision +CZ100122001 - null,,,,Female,SCRNSTOOL Stool Pathogens,"Mar 17, 2026 5:30 PM",6227697725,STOOL CULTURE,Stool,,,,Final Report,No enteric pathogens isolated,,,,,,,,, diff --git a/Covance_UCO3001/Source/2026-06-08_130501 sponsor-study-36940-test-results-930555-standard.csv b/Covance_UCO3001/Source/2026-06-08_130501 sponsor-study-36940-test-results-930555-standard.csv new file mode 100644 index 0000000..283d0d8 --- /dev/null +++ b/Covance_UCO3001/Source/2026-06-08_130501 sponsor-study-36940-test-results-930555-standard.csv @@ -0,0 +1,422 @@ +"Disclaimer: The information presented in On-Screen Results is not intended to be a replacement of the official Lab Results, Alerts, Data Revisions and Cancellations found in the Lab Reports section of this software application. On-Screen Results should not be used for patient diagnosis, treatment decisions or submission to regulatory bodies.",,,,,,,,,,,,,,,,,,, +Subject,Subject Data Revision,Screen No.,Age,Age Unit,Gender,Visit,Visit Data Revision,Collected Time,Accession,Test Group,Test,Administrative Question,Value,Result Data Revision,Flags,Cancellation Reason,Comments,Range,Units +CZ100062001,,,,,Male,Biopsy,,"May 29, 2026 12:00 AM",6227323255,ANATOMICAL SITE,Anatomical Site,Y,15-20cm from anal verge,,,,,, +CZ100062001,,,,,Male,Biopsy,,"May 29, 2026 12:00 AM",6227323255,BIOPSY COLLECTION METHOD,Collection Method,Y,sigmoidoscopy,,,,,, +CZ100062001,,,,,Male,Biopsy,,"May 29, 2026 12:00 AM",6227323255,BIOPSY FIXATIVE USED,Fixative Used,,10% NBF,,,,,, +CZ100062001,,,,,Male,Biopsy,,"May 29, 2026 12:00 AM",6227323255,DATE/TIME PLACED IN FORMALIN,Date Sample placed in Formalin,Y,28-May-2026,,,,,, +CZ100062001,,,,,Male,Biopsy,,"May 29, 2026 12:00 AM",6227323255,DATE/TIME PLACED IN FORMALIN,Time Sample placed in Formalin,Y,09:15,,,,,, +CZ100062001,,,,,Male,Biopsy,,"May 29, 2026 12:00 AM",6227323255,DIAGNOSIS,Diagnosis:,Y,Ulcerative Colitis,,,,,, +CZ100062001,,,,,Male,Biopsy,,"May 29, 2026 12:00 AM",6227323255,INFLAMED AREA,Inflamed area?,,Yes,,,,,, +CZ100062001,,,,,Male,Biopsy,,"May 29, 2026 12:00 AM",6227323255,TISSUE BIOPSY EMBEDDING1,Biopsy technical QC-CL,,Smpl meets HT requirements,,,,,, +CZ100062001,,,,,Male,Biopsy,,"May 29, 2026 12:00 AM",6227323255,TISSUE BIOPSY EMBEDDING1,Biopsy processing Time-CL,,10:00,,,,,, +CZ100062001,,,,,Male,Biopsy,,"May 29, 2026 12:00 AM",6227323255,TISSUE BIOPSY EMBEDDING1,Biopsy processing Date-CL,,01-Jun-2026,,,,,, +CZ100062001,,,,,Male,Biopsy,,"May 29, 2026 12:00 AM",6227323255,TISSUE BIOPSY EMBEDDING1,Biopsy Comments-CL,,Received in 10% NBF,,,,,, +CZ100062001,,,,,Male,Biopsy,,"May 29, 2026 12:00 AM",6227323255,TISSUE BIOPSY EMBEDDING1,# of Cassettes-(FI)-CL,,1,,,,,, +CZ100062001,,,,,Male,Biopsy,,"May 29, 2026 12:00 AM",6227323255,ULCERATED AREA,Is biopsy site ulcerated?,,Yes,,,,,, +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,CHEMISTRY PANEL,Total Bilirubin,,18,,,,,3 - 21,umol/L +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,5.8,,,,,0 - 6.2,umol/L +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,CHEMISTRY PANEL,Alkaline Phosphatase,,63,,,,,40 - 129,U/L +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,CHEMISTRY PANEL,ALT (SGPT),,12,,,,,5 - 48,U/L +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,CHEMISTRY PANEL,AST (SGOT),,18,,,,,8 - 40,U/L +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,CHEMISTRY PANEL,GGT,,17,,,,,10 - 61,U/L +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,CHEMISTRY PANEL,LDH,,124,,,,,53 - 234,U/L +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,CHEMISTRY PANEL,Urea Nitrogen,,3.2,,,,,1.4 - 8.6,mmol/L +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,76,,,,,40 - 110,umol/L +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,CHEMISTRY PANEL,Serum Glucose,,5.2,,,,,3.9 - 5.6,mmol/L +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,CHEMISTRY PANEL,Serum Uric Acid,,298,,,,,125 - 488,umol/L +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,CHEMISTRY PANEL,Calcium (EDTA),,2.33,,,,,2.07 - 2.64,mmol/L +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,CHEMISTRY PANEL,Phosphorus,,1.21,,,,,0.71 - 1.65,mmol/L +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,CHEMISTRY PANEL,Total Protein,,69,,,,,61 - 84,g/L +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,CHEMISTRY PANEL,Albumin-BCG,,41,,,,,33 - 49,g/L +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,CHEMISTRY PANEL,Creatine Kinase,,106,,,,,39 - 308,U/L +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,CHEMISTRY PANEL,Serum Sodium,,140,,,,,132 - 147,mmol/L +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,CHEMISTRY PANEL,Serum Potassium,,4.0,,,,,3.5 - 5.2,mmol/L +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,CHEMISTRY PANEL,Serum Bicarbonate,,23.8,,,,,19.3 - 29.3,mmol/L +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,CHEMISTRY PANEL,Serum Chloride,,103,,,,,94 - 112,mmol/L +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,CHEMISTRY PANEL,Magnesium,,0.81,,,,,0.66 - 1.07,mmol/L +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,FECAL COLLECTION D/T,Stool Collection Date,Y,26-May-2026,,,,,, +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,FECAL COLLECTION D/T,Stool Collection Time,Y,06:20,,,,,, +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,129,,,,,127 - 181,g/L +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.40,,,,,0.39 - 0.54, +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.3,,L,,,4.5 - 6.4,TI/L +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,30,,,,,26 - 34,pg +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,92,,,,,79 - 96,fL +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,5.10,,,,,3.8 - 10.7,GI/L +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.34,,,,,1.96 - 7.23,GI/L +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.09,,,,,0.91 - 4.28,GI/L +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.48,,,,,0.12 - 0.92,GI/L +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.16,,,,,0 - 0.57,GI/L +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.02,,,,,0 - 0.2,GI/L +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,65.5,,,,,40.5 - 75,% +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,21.4,,,,,15.4 - 48.5,% +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,9.5,,,,,2.6 - 10.1,% +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,3.2,,,,,0 - 6.8,% +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.4,,,,,0 - 2,% +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,270,,,,,140 - 400,GI/L +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,IS SUBJECT FASTING?,Is Subject Fasting?,Y,,,,,,, +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,LIPID PANEL,Direct HDL-C 4th Generation,,0.90,,L,,,1.03 - 1.53,mmol/L +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,LIPID PANEL,Triglycerides (GPO),,0.88,,,,,0.62 - 3.69,mmol/L +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,LIPID PANEL,Cholesterol (High Performance),,2.48,,L,,Result verified by repeat analysis,4.19 - 7.24,mmol/L +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,LIPID PANEL,LDL Chol Friedewald 4th,,1.18,,,,,0 - 3.34,mmol/L +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,PA1 EEA-2?,Approved to use EEA-2?,,,,,,,, +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,SM01/PLASMA PK TROUGH COLL D/T,Collection Date Predose,Y,26-May-2026,,,,,, +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,SM01/PLASMA PK TROUGH COLL D/T,Collection Time Predose,Y,07:15,,,,,, +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,SM02/PLASMA PK PEAK COLL D/T,Collection Date Post dose,Y,26-May-2026,,,,,, +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,SM02/PLASMA PK PEAK COLL D/T,Post Dose Collection Time,Y,09:05,,,,,, +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,SM04/SERUM ADA PRE COLL D/T,Collection Date Predose,Y,26-May-2026,,,,,, +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,SM04/SERUM ADA PRE COLL D/T,Collection Time Predose,Y,07:15,,,,,, +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,SM10/FECAL BMRKS COLL D/T,Stool Collection Date,Y,26-May-2026,,,,,, +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,SM10/FECAL BMRKS COLL D/T,Stool Collection Time,Y,06:20,,,,,, +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,SUBJECT HEIGHT (CM),Height (cm),Y,N/A (subject >/= 18 years of age),,,,,cm, +CZ100062002,,,,,Male,Biopsy,,"May 14, 2026 12:00 AM",6227323256,ANATOMICAL SITE,Anatomical Site,Y,15-20,,,,,, +CZ100062002,,,,,Male,Biopsy,,"May 14, 2026 12:00 AM",6227323256,BIOPSY COLLECTION METHOD,Collection Method,Y,colonoscopy,,,,,, +CZ100062002,,,,,Male,Biopsy,,"May 14, 2026 12:00 AM",6227323256,BIOPSY FIXATIVE USED,Fixative Used,,10% NBF,,,,,, +CZ100062002,,,,,Male,Biopsy,,"May 14, 2026 12:00 AM",6227323256,DATE/TIME PLACED IN FORMALIN,Date Sample placed in Formalin,Y,14-May-2026,,,,,, +CZ100062002,,,,,Male,Biopsy,,"May 14, 2026 12:00 AM",6227323256,DATE/TIME PLACED IN FORMALIN,Time Sample placed in Formalin,Y,08:15,,,,,, +CZ100062002,,,,,Male,Biopsy,,"May 14, 2026 12:00 AM",6227323256,DIAGNOSIS,Diagnosis:,Y,Ulcerative Colitis,,,,,, +CZ100062002,,,,,Male,Biopsy,,"May 14, 2026 12:00 AM",6227323256,INFLAMED AREA,Inflamed area?,,Yes,,,,,, +CZ100062002,,,,,Male,Biopsy,,"May 14, 2026 12:00 AM",6227323256,TISSUE BIOPSY EMBEDDING1,Biopsy technical QC-CL,,Smpl meets HT requirements,,,,,, +CZ100062002,,,,,Male,Biopsy,,"May 14, 2026 12:00 AM",6227323256,TISSUE BIOPSY EMBEDDING1,Biopsy processing Time-CL,,10:00,,,,,, +CZ100062002,,,,,Male,Biopsy,,"May 14, 2026 12:00 AM",6227323256,TISSUE BIOPSY EMBEDDING1,Biopsy processing Date-CL,,16-May-2026,,,,,, +CZ100062002,,,,,Male,Biopsy,,"May 14, 2026 12:00 AM",6227323256,TISSUE BIOPSY EMBEDDING1,Biopsy Comments-CL,,Received in 10% NBF,,,,,, +CZ100062002,,,,,Male,Biopsy,,"May 14, 2026 12:00 AM",6227323256,TISSUE BIOPSY EMBEDDING1,# of Cassettes-(FI)-CL,,1,,,,,, +CZ100062002,,,,,Male,Biopsy,,"May 14, 2026 12:00 AM",6227323256,ULCERATED AREA,Is biopsy site ulcerated?,,No,,,,,, +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,CHEMISTRY PANEL,Total Bilirubin,,6,,,,,3 - 21,umol/L +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.6,,,,,0 - 6.2,umol/L +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,CHEMISTRY PANEL,Alkaline Phosphatase,,65,,,,,40 - 129,U/L +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,CHEMISTRY PANEL,ALT (SGPT),,13,,,,,5 - 48,U/L +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,CHEMISTRY PANEL,AST (SGOT),,24,,,,,8 - 40,U/L +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,CHEMISTRY PANEL,GGT,,17,,,,,10 - 61,U/L +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,CHEMISTRY PANEL,LDH,,151,,,,,53 - 234,U/L +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,CHEMISTRY PANEL,Urea Nitrogen,,3.7,,,,,1.4 - 8.6,mmol/L +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,71,,,,,40 - 110,umol/L +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,CHEMISTRY PANEL,Serum Glucose,,4.6,,,,,3.9 - 5.6,mmol/L +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,CHEMISTRY PANEL,Serum Uric Acid,,338,,,,,125 - 488,umol/L +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,CHEMISTRY PANEL,Calcium (EDTA),,2.32,,,,,2.07 - 2.64,mmol/L +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,CHEMISTRY PANEL,Phosphorus,,1.19,,,,,0.71 - 1.65,mmol/L +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,CHEMISTRY PANEL,Total Protein,,72,,,,,61 - 84,g/L +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,CHEMISTRY PANEL,Albumin-BCG,,46,,,,,33 - 49,g/L +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,CHEMISTRY PANEL,Creatine Kinase,,281,,,,,39 - 308,U/L +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,CHEMISTRY PANEL,Serum Sodium,,142,,,,,132 - 147,mmol/L +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,CHEMISTRY PANEL,Serum Potassium,,4.0,,,,,3.5 - 5.2,mmol/L +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,CHEMISTRY PANEL,Serum Bicarbonate,,26.0,,,,,19.3 - 29.3,mmol/L +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,CHEMISTRY PANEL,Serum Chloride,,103,,,,,94 - 112,mmol/L +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,CHEMISTRY PANEL,Magnesium,,0.81,,,,,0.66 - 1.07,mmol/L +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,108,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,HBV ELIGIBILITY MET?,HBV Eligibility Criteria Met?,,Yes,,,,,, +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,140,,,,,127 - 181,g/L +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.41,,,,,0.39 - 0.54, +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.6,,,,,4.5 - 6.4,TI/L +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,30,,,,,26 - 34,pg +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,Anisocytosis,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,89,,,,,79 - 96,fL +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,4.17,,,,,3.8 - 10.7,GI/L +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.25,,,,,1.96 - 7.23,GI/L +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.20,,,,,0.91 - 4.28,GI/L +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.38,,,,,0.12 - 0.92,GI/L +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.22,,,,,0 - 0.57,GI/L +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.11,,,,,0 - 0.2,GI/L +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,54.0,,,,,40.5 - 75,% +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,28.9,,,,,15.4 - 48.5,% +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,9.1,,,,,2.6 - 10.1,% +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,5.3,,,,,0 - 6.8,% +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,2.7,,H,,,0 - 2,% +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,306,,,,,140 - 400,GI/L +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,HEPATITIS B CORE AB NON-US,Hepatitis B Core Total,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,HEPATITIS B SURFACE AB,Anti-HBs II QUAL,,Reactive,,,,,Ref Rng :$Non Reactive, +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,HEPATITIS B SURFACE AG NON-US,Hep B Surface AgII,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,HEPATITIS C VIRUS AB NON-US,Hepatitis C Virus Antibody,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,HIV 1/2 AG/AB SCREEN,anti-HIV-1/2 antibodies,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,HIV 1/2 AG/AB SCREEN,HIV -1 p24 antigen,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,HIV 1/2 AG/AB SCREEN,"HIV 1/2 Ag/Ab Screen, Cobas",,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,QUANTIFERON GOLD MITOGEN/INTER,"QFT,TBGoldPlusInt,pl-4-Tubes",,Negative,,,,,Normal=Negative, +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,SUBJECT HEIGHT (CM),Height (cm),Y,N/A (subject >/= 18 years of age),,,,,cm, +CZ100062002,,,,,Male,Stool Pathogens,,"Apr 20, 2026 7:45 AM",6228194341,C. DIFF EIA,"C. diff GDH Ag,stool-CL",,Negative,,,,,Ref Rng:Negative, +CZ100062002,,,,,Male,Stool Pathogens,,"Apr 20, 2026 7:45 AM",6228194341,C. DIFF EIA,"C.diff Toxin A&B,stool-CL",,Negative,,,,,Ref Rng:Negative, +CZ100062002,,,,,Male,Stool Pathogens,,"Apr 20, 2026 7:45 AM",6228194341,OVA AND PARASITES 1,Concentrate Exam,,,,,Test group cancelled: No specimen received,,, +CZ100062002,,,,,Male,Stool Pathogens,,"Apr 20, 2026 7:45 AM",6228194341,OVA AND PARASITES 1,Smear for Microsporidia,,,,,Test group cancelled: No specimen received,,, +CZ100062002,,,,,Male,Stool Pathogens,,"Apr 20, 2026 7:45 AM",6228194341,OVA AND PARASITES 1,Modified acid-fast stain,,,,,Test group cancelled: No specimen received,,, +CZ100062002,,,,,Male,Stool Pathogens,,"Apr 20, 2026 7:45 AM",6228194341,OVA AND PARASITES 2,Trichrome Smear,,,,,Test group cancelled: No specimen received,,, +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,ALP<2XULN,ALP<2XULN,,Criteria Met,,,,,, +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,ALT>/=3XULN,ALT >/= 3 X ULN,,Criteria not met,,,,,, +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,ALT>/=3XULN & TBIL>/=2XULN,ALT >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,AST>/=3XULN,AST >/= 3 X ULN,,Criteria not met,,,,,, +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,AST>/=3XULN & TBIL>/=2XULN,AST >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,CHEMISTRY PANEL,Total Bilirubin,,7,,,,,3 - 21,umol/L +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.3,,,,,0 - 6.2,umol/L +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,CHEMISTRY PANEL,Alkaline Phosphatase,,91,,,,,40 - 129,U/L +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,CHEMISTRY PANEL,ALT (SGPT),,8,,,,,5 - 48,U/L +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,CHEMISTRY PANEL,AST (SGOT),,14,,,,,8 - 40,U/L +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,CHEMISTRY PANEL,GGT,,14,,,,,10 - 61,U/L +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,CHEMISTRY PANEL,LDH,,118,,,,,53 - 234,U/L +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,CHEMISTRY PANEL,Urea Nitrogen,,1.6,,,,,1.4 - 8.6,mmol/L +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,92,,,,,40 - 110,umol/L +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,CHEMISTRY PANEL,Serum Glucose,,4.7,,,,,3.9 - 5.6,mmol/L +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,CHEMISTRY PANEL,Serum Uric Acid,,424,,,,,125 - 488,umol/L +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,CHEMISTRY PANEL,Calcium (EDTA),,2.51,,,,,2.07 - 2.64,mmol/L +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,CHEMISTRY PANEL,Phosphorus,,1.29,,,,,0.71 - 1.65,mmol/L +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,CHEMISTRY PANEL,Total Protein,,78,,,,,61 - 84,g/L +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,CHEMISTRY PANEL,Albumin-BCG,,42,,,,,33 - 49,g/L +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,CHEMISTRY PANEL,Creatine Kinase,,41,,,,,39 - 308,U/L +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,CHEMISTRY PANEL,Serum Sodium,,138,,,,,132 - 147,mmol/L +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,CHEMISTRY PANEL,Serum Potassium,,4.4,,,,,3.5 - 5.2,mmol/L +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,CHEMISTRY PANEL,Serum Bicarbonate,,24.0,,,,,19.3 - 29.3,mmol/L +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,CHEMISTRY PANEL,Serum Chloride,,96,,,,,94 - 112,mmol/L +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,CHEMISTRY PANEL,Magnesium,,0.93,,H,,,0.7 - 0.9,mmol/L +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,106,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,FECAL COLLECTION D/T,Stool Collection Date,Y,14-Apr-2026,,,,,, +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,FECAL COLLECTION D/T,Stool Collection Time,Y,20:30,,,,,, +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,122,R,L,,,127 - 181,g/L +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.42,,,,,0.39 - 0.54, +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.1,,,,,4.5 - 6.4,TI/L +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,24,R,L,,,26 - 34,pg +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,Normocytic,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,83,,,,,79 - 96,fL +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,14.93,R,H,,,3.8 - 10.7,GI/L +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,10.00,R,H,,,1.96 - 7.23,GI/L +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.54,,,,,0.91 - 4.28,GI/L +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,1.79,R,H,,,0.12 - 0.92,GI/L +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.60,R,H,,,0 - 0.57,GI/L +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.00,,,,,0 - 0.2,GI/L +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,67.0,,,,,40.5 - 75,% +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,17.0,,,,,15.4 - 48.5,% +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,12.0,R,H,,,2.6 - 10.1,% +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,4.0,,,,,0 - 6.8,% +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.0,,,,,0 - 2,% +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,647,R,H,,,140 - 400,GI/L +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,SM01/PLASMA PK TROUGH COLL D/T,Collection Date Predose,Y,14-Apr-2026,,,,,, +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,SM01/PLASMA PK TROUGH COLL D/T,Collection Time Predose,Y,07:15,,,,,, +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,SM02/PLASMA PK PEAK COLL D/T,Collection Date Post dose,Y,14-Apr-2026,,,,,, +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,SM02/PLASMA PK PEAK COLL D/T,Post Dose Collection Time,Y,08:40,,,,,, +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,SM04/SERUM ADA PRE COLL D/T,Collection Date Predose,Y,14-Apr-2026,,,,,, +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,SM04/SERUM ADA PRE COLL D/T,Collection Time Predose,Y,07:15,,,,,, +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,SM09/STOOL PK COLL D/T,Stool Collection Date,Y,14-Apr-2026,,,,,, +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,SM09/STOOL PK COLL D/T,Stool Collection Time,Y,20:30,,,,,, +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,SUBJECT HEIGHT (CM),Height (cm),Y,N/A (subject >/= 18 years of age),,,,,cm, +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,ALP<2XULN,ALP<2XULN,,Criteria Met,,,,,, +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,ALT>/=3XULN,ALT >/= 3 X ULN,,Criteria not met,,,,,, +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,ALT>/=3XULN & TBIL>/=2XULN,ALT >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,AST>/=3XULN,AST >/= 3 X ULN,,Criteria not met,,,,,, +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,AST>/=3XULN & TBIL>/=2XULN,AST >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,CHEMISTRY PANEL,Total Bilirubin,,8,,,,,3 - 21,umol/L +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.6,,,,,0 - 6.2,umol/L +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,CHEMISTRY PANEL,Alkaline Phosphatase,,85,,,,,40 - 129,U/L +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,CHEMISTRY PANEL,ALT (SGPT),,9,,,,,5 - 48,U/L +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,CHEMISTRY PANEL,AST (SGOT),,19,,,,,8 - 40,U/L +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,CHEMISTRY PANEL,GGT,,14,,,,,10 - 61,U/L +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,CHEMISTRY PANEL,LDH,,113,,,,,53 - 234,U/L +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,CHEMISTRY PANEL,Urea Nitrogen,,2.0,,,,,1.4 - 8.6,mmol/L +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,86,,,,,40 - 110,umol/L +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,CHEMISTRY PANEL,Serum Glucose,,4.5,,,,,3.9 - 5.6,mmol/L +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,CHEMISTRY PANEL,Serum Uric Acid,,410,,,,,125 - 488,umol/L +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,CHEMISTRY PANEL,Calcium (EDTA),,2.43,,,,,2.07 - 2.64,mmol/L +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,CHEMISTRY PANEL,Phosphorus,,1.28,,,,,0.71 - 1.65,mmol/L +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,CHEMISTRY PANEL,Total Protein,,72,,,,,61 - 84,g/L +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,CHEMISTRY PANEL,Albumin-BCG,,43,,,,,33 - 49,g/L +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,CHEMISTRY PANEL,Creatine Kinase,,64,,,,,39 - 308,U/L +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,CHEMISTRY PANEL,Serum Sodium,,140,,,,,132 - 147,mmol/L +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,CHEMISTRY PANEL,Serum Potassium,,4.6,,,,,3.5 - 5.2,mmol/L +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,CHEMISTRY PANEL,Serum Bicarbonate,,23.2,,,,,19.3 - 29.3,mmol/L +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,CHEMISTRY PANEL,Serum Chloride,,102,,,,,94 - 112,mmol/L +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,CHEMISTRY PANEL,Magnesium,,0.93,R,H,,,0.7 - 0.9,mmol/L +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,115,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,FECAL COLLECTION D/T,Stool Collection Date,Y,08-Apr-2026,,,,,, +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,FECAL COLLECTION D/T,Stool Collection Time,Y,07:10,,,,,, +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,SM01/PLASMA PK TROUGH COLL D/T,Collection Date Predose,Y,08-Apr-2026,,,,,, +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,SM01/PLASMA PK TROUGH COLL D/T,Collection Time Predose,Y,07:10,,,,,, +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,SM02/PLASMA PK PEAK COLL D/T,Collection Date Post dose,Y,08-Apr-2026,,,,,, +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,SM02/PLASMA PK PEAK COLL D/T,Post Dose Collection Time,Y,08:20,,,,,, +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,SM04/SERUM ADA PRE COLL D/T,Collection Date Predose,Y,08-Apr-2026,,,,,, +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,SM04/SERUM ADA PRE COLL D/T,Collection Time Predose,Y,07:10,,,,,, +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,SM09/STOOL PK COLL D/T,Stool Collection Date,Y,08-Apr-2026,,,,,, +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,SM09/STOOL PK COLL D/T,Stool Collection Time,Y,07:10,,,,,, +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,SUBJECT HEIGHT (CM),Height (cm),Y,N/A (subject >/= 18 years of age),,,,,cm, +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,CHEMISTRY PANEL,Total Bilirubin,,7,,,,,3 - 21,umol/L +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.5,,,,,0 - 6.2,umol/L +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,CHEMISTRY PANEL,Alkaline Phosphatase,,89,,,,,40 - 129,U/L +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,CHEMISTRY PANEL,ALT (SGPT),,8,,,,,5 - 48,U/L +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,CHEMISTRY PANEL,AST (SGOT),,17,,,,,8 - 40,U/L +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,CHEMISTRY PANEL,GGT,,18,,,,,10 - 61,U/L +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,CHEMISTRY PANEL,LDH,,141,,,,,53 - 234,U/L +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,CHEMISTRY PANEL,Urea Nitrogen,,2.5,,,,,1.4 - 8.6,mmol/L +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,76,,,,,40 - 110,umol/L +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,CHEMISTRY PANEL,Serum Glucose,,4.0,,,,,3.9 - 5.6,mmol/L +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,CHEMISTRY PANEL,Serum Uric Acid,,415,,,,,125 - 488,umol/L +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,CHEMISTRY PANEL,Calcium (EDTA),,2.41,,,,,2.07 - 2.64,mmol/L +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,CHEMISTRY PANEL,Phosphorus,,1.26,,,,,0.71 - 1.65,mmol/L +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,CHEMISTRY PANEL,Total Protein,,75,,,,,61 - 84,g/L +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,CHEMISTRY PANEL,Albumin-BCG,,44,,,,,33 - 49,g/L +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,CHEMISTRY PANEL,Creatine Kinase,,119,,,,,39 - 308,U/L +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,CHEMISTRY PANEL,Serum Sodium,,138,,,,,132 - 147,mmol/L +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,CHEMISTRY PANEL,Serum Potassium,,4.1,,,,,3.5 - 5.2,mmol/L +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,CHEMISTRY PANEL,Serum Bicarbonate,,23.3,,,,,19.3 - 29.3,mmol/L +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,CHEMISTRY PANEL,Serum Chloride,,101,,,,,94 - 112,mmol/L +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,CHEMISTRY PANEL,Magnesium,,0.90,,,,,0.7 - 0.9,mmol/L +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,128,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,FECAL COLLECTION D/T,Stool Collection Date,Y,20-Mar-2026,,,,,, +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,FECAL COLLECTION D/T,Stool Collection Time,Y,08:00,,,,,, +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,121,,L,,,127 - 181,g/L +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.39,,,,,0.39 - 0.54, +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.8,,,,,4.5 - 6.4,TI/L +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,25,,L,,,26 - 34,pg +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,Normocytic,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,81,,,,,79 - 96,fL +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,13.09,,H,,,3.8 - 10.7,GI/L +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,9.29,,H,,,1.96 - 7.23,GI/L +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.23,,,,,0.91 - 4.28,GI/L +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,1.31,,H,,,0.12 - 0.92,GI/L +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.13,,,,,0 - 0.57,GI/L +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.13,,,,,0 - 0.2,GI/L +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,71.0,,,,,40.5 - 75,% +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,17.0,,,,,15.4 - 48.5,% +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,10.0,,,,,2.6 - 10.1,% +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.0,,,,,0 - 6.8,% +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.0,,,,,0 - 2,% +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,445,,H,,,140 - 400,GI/L +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,IS SUBJECT FASTING?,Is Subject Fasting?,Y,No,,,,,, +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,LIPID PANEL,Direct HDL-C 4th Generation,,1.53,,,,,1.03 - 1.53,mmol/L +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,LIPID PANEL,Triglycerides (GPO),,0.81,,,,,0.42 - 1.67,mmol/L +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,LIPID PANEL,Cholesterol (High Performance),,4.16,,,,,2.95 - 5.12,mmol/L +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,LIPID PANEL,LDL Chol Friedewald 4th,,2.26,,,,,0 - 3.34,mmol/L +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,SM01/PLASMA PK TROUGH COLL D/T,Collection Date Predose,Y,20-Mar-2026,,,,,, +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,SM01/PLASMA PK TROUGH COLL D/T,Collection Time Predose,Y,08:00,,,,,, +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,SM02/PLASMA PK PEAK COLL D/T,Collection Date Post dose,Y,20-Mar-2026,,,,,, +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,SM02/PLASMA PK PEAK COLL D/T,Post Dose Collection Time,Y,09:00,,,,,, +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,SM04/SERUM ADA PRE COLL D/T,Collection Date Predose,Y,20-Mar-2026,,,,,, +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,SM04/SERUM ADA PRE COLL D/T,Collection Time Predose,Y,08:00,,,,,, +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,SM10/FECAL BMRKS COLL D/T,Stool Collection Date,Y,20-Mar-2026,,,,,, +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,SM10/FECAL BMRKS COLL D/T,Stool Collection Time,Y,08:00,,,,,, +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,SUBJECT HEIGHT (CM),Height (cm),Y,N/A (subject >/= 18 years of age),,,,,cm, +CZ100062001,,,,,Male,Stool Pathogens,,"Mar 17, 2026 9:00 AM",6227323243,C. DIFF EIA,"C. diff GDH Ag,stool-CL",,Negative,,,,,Ref Rng:Negative, +CZ100062001,,,,,Male,Stool Pathogens,,"Mar 17, 2026 9:00 AM",6227323243,C. DIFF EIA,"C.diff Toxin A&B,stool-CL",,Negative,,,,,Ref Rng:Negative, +CZ100062001,R,,,,Male,Unscheduled,R,"Mar 17, 2026 8:00 AM",6227323265,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,R,,,,Male,Unscheduled,R,"Mar 17, 2026 8:00 AM",6227323265,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,R,,,,Male,Unscheduled,R,"Mar 17, 2026 8:00 AM",6227323265,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,R,,,,Male,Unscheduled,R,"Mar 17, 2026 8:00 AM",6227323265,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,R,,,,Male,Unscheduled,R,"Mar 17, 2026 8:00 AM",6227323265,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,R,,,,Male,Unscheduled,R,"Mar 17, 2026 8:00 AM",6227323265,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,R,,,,Male,Unscheduled,R,"Mar 17, 2026 8:00 AM",6227323265,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,R,,,,Male,Unscheduled,R,"Mar 17, 2026 8:00 AM",6227323265,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,R,,,,Male,Unscheduled,R,"Mar 17, 2026 8:00 AM",6227323265,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,R,,,,Male,Unscheduled,R,"Mar 17, 2026 8:00 AM",6227323265,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,R,,,,Male,Unscheduled,R,"Mar 17, 2026 8:00 AM",6227323265,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,R,,,,Male,Unscheduled,R,"Mar 17, 2026 8:00 AM",6227323265,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,R,,,,Male,Unscheduled,R,"Mar 17, 2026 8:00 AM",6227323265,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,R,,,,Male,Unscheduled,R,"Mar 17, 2026 8:00 AM",6227323265,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,R,,,,Male,Unscheduled,R,"Mar 17, 2026 8:00 AM",6227323265,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,R,,,,Male,Unscheduled,R,"Mar 17, 2026 8:00 AM",6227323265,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,R,,,,Male,Unscheduled,R,"Mar 17, 2026 8:00 AM",6227323265,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,R,,,,Male,Unscheduled,R,"Mar 17, 2026 8:00 AM",6227323265,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,,,,,Male,Stool Pathogens,,"Mar 11, 2026 9:15 AM",6227323245,C. DIFF EIA,"C. diff GDH Ag,stool-CL",,,,,Test group cancelled: No specimen received,,, +CZ100062001,,,,,Male,Stool Pathogens,,"Mar 11, 2026 9:15 AM",6227323245,C. DIFF EIA,"C.diff Toxin A&B,stool-CL",,,,,Test group cancelled: No specimen received,,, +CZ100062001,,,,,Male,Stool Pathogens,,"Mar 11, 2026 9:15 AM",6227323245,OVA AND PARASITES 1,Concentrate Exam,,,,,Test group cancelled: No specimen received,,, +CZ100062001,,,,,Male,Stool Pathogens,,"Mar 11, 2026 9:15 AM",6227323245,OVA AND PARASITES 1,Smear for Microsporidia,,,,,Test group cancelled: No specimen received,,, +CZ100062001,,,,,Male,Stool Pathogens,,"Mar 11, 2026 9:15 AM",6227323245,OVA AND PARASITES 1,Modified acid-fast stain,,,,,Test group cancelled: No specimen received,,, +CZ100062001,,,,,Male,Stool Pathogens,,"Mar 11, 2026 9:15 AM",6227323245,OVA AND PARASITES 2,Trichrome Smear,,,,,Test group cancelled: No specimen received,,, +CZ100062001,,,,,Male,TB Testing,,"Mar 11, 2026 9:10 AM",6227323253,QUANTIFERON GOLD MITOGEN/INTER,"QFT,TBGoldPlusInt,pl-4-Tubes",,Negative,,,,,Normal=Negative, +CZ100062001,,,,,Male,Unscheduled,,"Mar 11, 2026 9:05 AM",6227323264,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,,,,,Male,Unscheduled,,"Mar 11, 2026 9:05 AM",6227323264,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,,,,,Male,Unscheduled,,"Mar 11, 2026 9:05 AM",6227323264,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,,,,,Male,Unscheduled,,"Mar 11, 2026 9:05 AM",6227323264,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,,,,,Male,Unscheduled,,"Mar 11, 2026 9:05 AM",6227323264,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,,,,,Male,Unscheduled,,"Mar 11, 2026 9:05 AM",6227323264,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,,,,,Male,Unscheduled,,"Mar 11, 2026 9:05 AM",6227323264,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,,,,,Male,Unscheduled,,"Mar 11, 2026 9:05 AM",6227323264,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,,,,,Male,Unscheduled,,"Mar 11, 2026 9:05 AM",6227323264,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,,,,,Male,Unscheduled,,"Mar 11, 2026 9:05 AM",6227323264,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,,,,,Male,Unscheduled,,"Mar 11, 2026 9:05 AM",6227323264,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,,,,,Male,Unscheduled,,"Mar 11, 2026 9:05 AM",6227323264,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,,,,,Male,Unscheduled,,"Mar 11, 2026 9:05 AM",6227323264,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,,,,,Male,Unscheduled,,"Mar 11, 2026 9:05 AM",6227323264,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,,,,,Male,Unscheduled,,"Mar 11, 2026 9:05 AM",6227323264,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,,,,,Male,Unscheduled,,"Mar 11, 2026 9:05 AM",6227323264,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,,,,,Male,Unscheduled,,"Mar 11, 2026 9:05 AM",6227323264,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,,,,,Male,Unscheduled,,"Mar 11, 2026 9:05 AM",6227323264,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,,,,,Male,Biopsy,R,"Feb 19, 2026 12:00 AM",6227323254,ANATOMICAL SITE,Anatomical Site,Y,18,,,,,, +CZ100062001,,,,,Male,Biopsy,R,"Feb 19, 2026 12:00 AM",6227323254,BIOPSY COLLECTION METHOD,Collection Method,Y,sigmoidoscopy,,,,,, +CZ100062001,,,,,Male,Biopsy,R,"Feb 19, 2026 12:00 AM",6227323254,BIOPSY FIXATIVE USED,Fixative Used,,10% NBF,,,,,, +CZ100062001,,,,,Male,Biopsy,R,"Feb 19, 2026 12:00 AM",6227323254,DATE/TIME PLACED IN FORMALIN,Date Sample placed in Formalin,Y,19-Feb-2026,,,,,, +CZ100062001,,,,,Male,Biopsy,R,"Feb 19, 2026 12:00 AM",6227323254,DATE/TIME PLACED IN FORMALIN,Time Sample placed in Formalin,Y,07:20,,,,,, +CZ100062001,,,,,Male,Biopsy,R,"Feb 19, 2026 12:00 AM",6227323254,DIAGNOSIS,Diagnosis:,Y,Ulcerative Colitis,,,,,, +CZ100062001,,,,,Male,Biopsy,R,"Feb 19, 2026 12:00 AM",6227323254,INFLAMED AREA,Inflamed area?,,Yes,,,,,, +CZ100062001,,,,,Male,Biopsy,R,"Feb 19, 2026 12:00 AM",6227323254,TISSUE BIOPSY EMBEDDING1,Biopsy technical QC-CL,,Smpl meets HT requirements,,,,,, +CZ100062001,,,,,Male,Biopsy,R,"Feb 19, 2026 12:00 AM",6227323254,TISSUE BIOPSY EMBEDDING1,Biopsy processing Time-CL,,10:00,,,,,, +CZ100062001,,,,,Male,Biopsy,R,"Feb 19, 2026 12:00 AM",6227323254,TISSUE BIOPSY EMBEDDING1,Biopsy processing Date-CL,,23-Feb-2026,,,,,, +CZ100062001,,,,,Male,Biopsy,R,"Feb 19, 2026 12:00 AM",6227323254,TISSUE BIOPSY EMBEDDING1,Biopsy Comments-CL,,Received in 10% NBF,,,,,, +CZ100062001,,,,,Male,Biopsy,R,"Feb 19, 2026 12:00 AM",6227323254,TISSUE BIOPSY EMBEDDING1,# of Cassettes-(FI)-CL,,1,,,,,, +CZ100062001,,,,,Male,Biopsy,R,"Feb 19, 2026 12:00 AM",6227323254,ULCERATED AREA,Is biopsy site ulcerated?,,Yes,,,,,, +CZ100062001,,,,,Male,Stool Pathogens,,"Feb 16, 2026 7:20 AM",6227323244,C. DIFF EIA,"C. diff GDH Ag,stool-CL",,,,,Test group cancelled: Specimen received beyond stability,,, +CZ100062001,,,,,Male,Stool Pathogens,,"Feb 16, 2026 7:20 AM",6227323244,C. DIFF EIA,"C.diff Toxin A&B,stool-CL",,,,,Test group cancelled: Specimen received beyond stability,,, +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,CHEMISTRY PANEL,Total Bilirubin,,<3,,L,,Result verified by repeat analysis,3 - 21,umol/L +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,<1.4,,,,,0 - 6.2,umol/L +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,CHEMISTRY PANEL,Alkaline Phosphatase,,93,,,,,55 - 149,U/L +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,CHEMISTRY PANEL,ALT (SGPT),,9,,,,,5 - 48,U/L +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,CHEMISTRY PANEL,AST (SGOT),,14,,,,,8 - 40,U/L +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,CHEMISTRY PANEL,GGT,,64,,H,,,10 - 61,U/L +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,CHEMISTRY PANEL,LDH,,105,,,,,53 - 234,U/L +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,CHEMISTRY PANEL,Urea Nitrogen,,1.5,,,,,1.4 - 8.6,mmol/L +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,68,,,,,40 - 110,umol/L +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,CHEMISTRY PANEL,Serum Glucose,,4.2,,,,,3.9 - 5.6,mmol/L +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,CHEMISTRY PANEL,Serum Uric Acid,,288,,,,,125 - 488,umol/L +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,CHEMISTRY PANEL,Calcium (EDTA),,2.32,,,,,2.07 - 2.64,mmol/L +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,CHEMISTRY PANEL,Phosphorus,,0.85,,,,,0.71 - 1.65,mmol/L +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,CHEMISTRY PANEL,Total Protein,,70,,,,,61 - 84,g/L +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,CHEMISTRY PANEL,Albumin-BCG,,39,,,,,33 - 49,g/L +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,CHEMISTRY PANEL,Creatine Kinase,,34,,L,,,39 - 308,U/L +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,CHEMISTRY PANEL,Serum Sodium,,141,,,,,132 - 147,mmol/L +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,CHEMISTRY PANEL,Serum Potassium,,4.2,,,,,3.5 - 5.2,mmol/L +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,CHEMISTRY PANEL,Serum Bicarbonate,,25.5,,,,,19.3 - 29.3,mmol/L +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,CHEMISTRY PANEL,Serum Chloride,,102,,,,,94 - 112,mmol/L +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,CHEMISTRY PANEL,Magnesium,,0.95,,H,,,0.7 - 0.9,mmol/L +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,CKD-EPI 2021,CKD-EPI 2021 Without Race,,133,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,HBV ELIGIBILITY MET?,HBV Eligibility Criteria Met?,,Yes,,,,,, +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,,,,Test cancelled: Clotted Blood Received,,, +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,,,,Test cancelled: Clotted Blood Received,,, +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,,,,Test cancelled: Clotted Blood Received,,, +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,,,,Test cancelled: Clotted Blood Received,,, +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,,,,Test cancelled: Clotted Blood Received,,, +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,,,,Test cancelled: Clotted Blood Received,,, +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,,,,Test cancelled: Clotted Blood Received,,, +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,,,,Test cancelled: Clotted Blood Received,,, +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,,,,Test cancelled: Clotted Blood Received,,, +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,,,,Test cancelled: Clotted Blood Received,,, +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,,,,Test cancelled: Clotted Blood Received,,, +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,,,,Test cancelled: Clotted Blood Received,,, +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,,,,Test cancelled: Clotted Blood Received,,, +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,,,,Test cancelled: Clotted Blood Received,,, +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,,,,Test cancelled: Clotted Blood Received,,, +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,,,,Test cancelled: Clotted Blood Received,,, +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,,,,Test cancelled: Clotted Blood Received,,, +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,,,,Test cancelled: Clotted Blood Received,,, +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,HEPATITIS B CORE AB NON-US,Hepatitis B Core Total,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,HEPATITIS B SURFACE AB NON-US,Anti-HBs II QUAL,,Reactive,,,,,Ref Rng :$Non Reactive, +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,HEPATITIS B SURFACE AG NON-US,Hep B Surface AgII,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,HEPATITIS C VIRUS AB NON-US,Hepatitis C Virus Antibody,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,HIV 1/2 AG/AB SCREEN,anti-HIV-1/2 antibodies,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,HIV 1/2 AG/AB SCREEN,HIV -1 p24 antigen,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,HIV 1/2 AG/AB SCREEN,"HIV 1/2 Ag/Ab Screen, Cobas",,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,QUANTIFERON GOLD MITOGEN/INTER,"QFT,TBGoldPlusInt,pl-4-Tubes",,,,,Test group cancelled: No specimen received,,, +CZ100062001,,,,,Male,TB Testing,,"Feb 16, 2026 7:03 AM",6227323252,QUANTIFERON GOLD MITOGEN/INTER,"QFT,TBGoldPlusInt,pl-4-Tubes",,Indeterminate,,,,,Normal=Negative, diff --git a/Covance_UCO3001/Source/2026-06-08_130505 sponsor-study-36940-test-results-930555-microbiology.csv b/Covance_UCO3001/Source/2026-06-08_130505 sponsor-study-36940-test-results-930555-microbiology.csv new file mode 100644 index 0000000..90a8458 --- /dev/null +++ b/Covance_UCO3001/Source/2026-06-08_130505 sponsor-study-36940-test-results-930555-microbiology.csv @@ -0,0 +1,6 @@ +"Disclaimer: The information presented in On-Screen Results is not intended to be a replacement of the official Lab Results, Alerts, Data Revisions and Cancellations found in the Lab Reports section of this software application. On-Screen Results should not be used for patient diagnosis, treatment decisions or submission to regulatory bodies.",,,,,,,,,,,,,,,,,,,,,,, +Subject,Screening Number,Age,Age Unit,Gender,Visit Description,Collected Time,Accession,Test Group,Specimen,Organism,Growth,Cancellation Reason,Test Description,Test Result,Drug Name/Agent,MIC Result,Units,MIC Interpretation,Disk Diffusion Result,Disk Diffusion Interpretation,Subject Data Revision,Visit Data Revision,Result Data Revision +CZ100062001 - null,,,,Male,SCRNSTOOL Stool Pathogens,"Feb 16, 2026 7:20 AM",6227323244,STOOL CULTURE,Stool,,,,Final Report,No enteric pathogens isolated,,,,,,,,, +CZ100062001 - null,,,,Male,UNSCSTOOL Stool Pathogens,"Mar 11, 2026 9:15 AM",6227323245,STOOL CULTURE,,,,Test group cancelled: Specimen received beyond stability,,,,,,,,,,, +CZ100062001 - null,,,,Male,UNSCSTOOL Stool Pathogens,"Mar 17, 2026 9:00 AM",6227323243,STOOL CULTURE,,,,Test group cancelled: No specimen received,,,,,,,,,,, +CZ100062002 - null,,,,Male,SCRNSTOOL Stool Pathogens,"Apr 20, 2026 7:45 AM",6228194341,STOOL CULTURE,Stool,,,,Final Report,No enteric pathogens isolated,,,,,,,,, diff --git a/Covance_UCO3001/Source/2026-06-08_130509 sponsor-study-36940-test-results-930547-standard.csv b/Covance_UCO3001/Source/2026-06-08_130509 sponsor-study-36940-test-results-930547-standard.csv new file mode 100644 index 0000000..0b57312 --- /dev/null +++ b/Covance_UCO3001/Source/2026-06-08_130509 sponsor-study-36940-test-results-930547-standard.csv @@ -0,0 +1,570 @@ +"Disclaimer: The information presented in On-Screen Results is not intended to be a replacement of the official Lab Results, Alerts, Data Revisions and Cancellations found in the Lab Reports section of this software application. On-Screen Results should not be used for patient diagnosis, treatment decisions or submission to regulatory bodies.",,,,,,,,,,,,,,,,,,, +Subject,Subject Data Revision,Screen No.,Age,Age Unit,Gender,Visit,Visit Data Revision,Collected Time,Accession,Test Group,Test,Administrative Question,Value,Result Data Revision,Flags,Cancellation Reason,Comments,Range,Units +CZ100132001,,,,,Male,Biopsy,,"Jun 4, 2026 12:00 AM",6228501730,ANATOMICAL SITE,Anatomical Site,Y,15-20cm from anal verge,,,,,, +CZ100132001,,,,,Male,Biopsy,,"Jun 4, 2026 12:00 AM",6228501730,BIOPSY COLLECTION METHOD,Collection Method,Y,colonoscopy,,,,,, +CZ100132001,,,,,Male,Biopsy,,"Jun 4, 2026 12:00 AM",6228501730,BIOPSY FIXATIVE USED,Fixative Used,,10% NBF,,,,,, +CZ100132001,,,,,Male,Biopsy,,"Jun 4, 2026 12:00 AM",6228501730,DATE/TIME PLACED IN FORMALIN,Date Sample placed in Formalin,Y,04-Jun-2026,,,,,, +CZ100132001,,,,,Male,Biopsy,,"Jun 4, 2026 12:00 AM",6228501730,DATE/TIME PLACED IN FORMALIN,Time Sample placed in Formalin,Y,12:05,,,,,, +CZ100132001,,,,,Male,Biopsy,,"Jun 4, 2026 12:00 AM",6228501730,DIAGNOSIS,Diagnosis:,Y,Ulcerative Colitis,,,,,, +CZ100132001,,,,,Male,Biopsy,,"Jun 4, 2026 12:00 AM",6228501730,INFLAMED AREA,Inflamed area?,,No,,,,,, +CZ100132001,,,,,Male,Biopsy,,"Jun 4, 2026 12:00 AM",6228501730,TISSUE BIOPSY EMBEDDING1,Biopsy technical QC-CL,,Smpl meets HT requirements,,,,,, +CZ100132001,,,,,Male,Biopsy,,"Jun 4, 2026 12:00 AM",6228501730,TISSUE BIOPSY EMBEDDING1,Biopsy processing Time-CL,,,,,,,, +CZ100132001,,,,,Male,Biopsy,,"Jun 4, 2026 12:00 AM",6228501730,TISSUE BIOPSY EMBEDDING1,Biopsy processing Date-CL,,,,,,,, +CZ100132001,,,,,Male,Biopsy,,"Jun 4, 2026 12:00 AM",6228501730,TISSUE BIOPSY EMBEDDING1,Biopsy Comments-CL,,,,,,,, +CZ100132001,,,,,Male,Biopsy,,"Jun 4, 2026 12:00 AM",6228501730,TISSUE BIOPSY EMBEDDING1,# of Cassettes-(FI)-CL,,,,,,,, +CZ100132001,,,,,Male,Biopsy,,"Jun 4, 2026 12:00 AM",6228501730,ULCERATED AREA,Is biopsy site ulcerated?,,No,,,,,, +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,CHEMISTRY PANEL,Total Bilirubin,,8,,,,,3 - 21,umol/L +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.0,,,,,0 - 6.2,umol/L +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,CHEMISTRY PANEL,Alkaline Phosphatase,,104,,,,,35 - 104,U/L +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,CHEMISTRY PANEL,ALT (SGPT),,47,,H,,,4 - 43,U/L +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,CHEMISTRY PANEL,AST (SGOT),,42,,H,,,8 - 40,U/L +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,CHEMISTRY PANEL,GGT,,45,,,,,4 - 49,U/L +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,CHEMISTRY PANEL,LDH,,180,,,,,53 - 234,U/L +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,CHEMISTRY PANEL,Urea Nitrogen,,2.4,,,,,1.4 - 8.6,mmol/L +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,72,,,,,31 - 101,umol/L +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,CHEMISTRY PANEL,Serum Glucose,,5.1,,,,,3.9 - 5.6,mmol/L +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,CHEMISTRY PANEL,Serum Uric Acid,,378,,,,,125 - 428,umol/L +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,CHEMISTRY PANEL,Calcium (EDTA),,2.48,,,,,2.07 - 2.64,mmol/L +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,CHEMISTRY PANEL,Phosphorus,,1.13,,,,,0.71 - 1.65,mmol/L +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,CHEMISTRY PANEL,Total Protein,,75,,,,,61 - 84,g/L +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,CHEMISTRY PANEL,Albumin-BCG,,46,,,,,33 - 49,g/L +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,CHEMISTRY PANEL,Creatine Kinase,,111,,,,,26 - 192,U/L +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,CHEMISTRY PANEL,Serum Sodium,,143,,,,,132 - 147,mmol/L +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,CHEMISTRY PANEL,Serum Potassium,,4.0,,,,,3.5 - 5.2,mmol/L +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,CHEMISTRY PANEL,Serum Bicarbonate,,21.9,,,,,19.3 - 29.3,mmol/L +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,CHEMISTRY PANEL,Serum Chloride,,105,,,,,94 - 112,mmol/L +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,CHEMISTRY PANEL,Magnesium,,0.83,,,,,0.66 - 1.07,mmol/L +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,89,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,FECAL COLLECTION D/T,Stool Collection Date,Y,02-Jun-2026,,,,,, +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,FECAL COLLECTION D/T,Stool Collection Time,Y,05:40,,,,,, +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,141,,,,,116 - 164,g/L +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.44,,,,,0.34 - 0.48, +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.0,,,,,4.1 - 5.6,TI/L +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,28,,,,,26 - 34,pg +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,87,,,,,79 - 98,fL +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,7.13,,,,,3.8 - 10.7,GI/L +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,4.63,,,,,1.96 - 7.23,GI/L +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.82,,,,,0.91 - 4.28,GI/L +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.51,,,,,0.12 - 0.92,GI/L +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.13,,,,,0 - 0.57,GI/L +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.05,,,,,0 - 0.2,GI/L +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,64.9,,,,,40.5 - 75,% +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,25.4,,,,,15.4 - 48.5,% +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,7.1,,,,,2.6 - 10.1,% +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.8,,,,,0 - 6.8,% +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.7,,,,,0 - 2,% +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,235,,,,,140 - 400,GI/L +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,LIPID PANEL,Direct HDL-C 4th Generation,,1.10,,,,,1.03 - 1.53,mmol/L +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,LIPID PANEL,Triglycerides (GPO),,1.61,,,,,0.51 - 2.42,mmol/L +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,LIPID PANEL,Cholesterol (High Performance),,3.91,,L,,,4.01 - 6.85,mmol/L +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,LIPID PANEL,LDL Chol Friedewald 4th,,2.07,,,,,0 - 3.34,mmol/L +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,SM01/PLASMA PK TROUGH COLL D/T,Collection Date Predose,Y,02-Jun-2026,,,,,, +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,SM01/PLASMA PK TROUGH COLL D/T,Collection Time Predose,Y,09:25,,,,,, +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,SM02/PLASMA PK PEAK COLL D/T,Collection Date Post dose,Y,02-Jun-2026,,,,,, +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,SM02/PLASMA PK PEAK COLL D/T,Post Dose Collection Time,Y,10:30,,,,,, +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,SM04/SERUM ADA PRE COLL D/T,Collection Date Predose,Y,02-Jun-2026,,,,,, +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,SM04/SERUM ADA PRE COLL D/T,Collection Time Predose,Y,09:25,,,,,, +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,SM10/FECAL BMRKS COLL D/T,Stool Collection Date,Y,02-Jun-2026,,,,,, +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,SM10/FECAL BMRKS COLL D/T,Stool Collection Time,Y,05:40,,,,,, +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,SUBJECT HEIGHT (CM),Height (cm),Y,82,,,,,cm, +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,ALP<2XULN,ALP<2XULN,,Criteria Met,,,,,, +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,ALT>/=3XULN,ALT >/= 3 X ULN,,Criteria not met,,,,,, +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,ALT>/=3XULN & TBIL>/=2XULN,ALT >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,AST>/=3XULN,AST >/= 3 X ULN,,Criteria not met,,,,,, +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,AST>/=3XULN & TBIL>/=2XULN,AST >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,CHEMISTRY PANEL,Total Bilirubin,,10,,,,,3 - 21,umol/L +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.8,,,,,0 - 6.2,umol/L +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,CHEMISTRY PANEL,Alkaline Phosphatase,,73,,,,,40 - 129,U/L +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,CHEMISTRY PANEL,ALT (SGPT),,17,,,,,5 - 48,U/L +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,CHEMISTRY PANEL,AST (SGOT),,22,,,,,8 - 40,U/L +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,CHEMISTRY PANEL,GGT,,18,,,,,10 - 61,U/L +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,CHEMISTRY PANEL,LDH,,164,,,,,53 - 234,U/L +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,CHEMISTRY PANEL,Urea Nitrogen,,5.1,,,,,1.4 - 8.6,mmol/L +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,89,,,,,40 - 110,umol/L +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,CHEMISTRY PANEL,Serum Glucose,,5.4,,,,,3.9 - 5.6,mmol/L +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,CHEMISTRY PANEL,Serum Uric Acid,,346,,,,,125 - 488,umol/L +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,CHEMISTRY PANEL,Calcium (EDTA),,2.46,,,,,2.07 - 2.64,mmol/L +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,CHEMISTRY PANEL,Phosphorus,,1.01,,,,,0.71 - 1.65,mmol/L +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,CHEMISTRY PANEL,Total Protein,,75,,,,,61 - 84,g/L +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,CHEMISTRY PANEL,Albumin-BCG,,49,,,,,33 - 49,g/L +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,CHEMISTRY PANEL,Creatine Kinase,,206,,,,,39 - 308,U/L +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,CHEMISTRY PANEL,Serum Sodium,,140,,,,,132 - 147,mmol/L +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,CHEMISTRY PANEL,Serum Potassium,,4.2,,,,,3.5 - 5.2,mmol/L +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,CHEMISTRY PANEL,Serum Bicarbonate,,20.1,,,,,19.3 - 29.3,mmol/L +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,CHEMISTRY PANEL,Serum Chloride,,103,,,,,94 - 112,mmol/L +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,CHEMISTRY PANEL,Magnesium,,0.85,,,,,0.66 - 1.07,mmol/L +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,103,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,FECAL COLLECTION D/T,Stool Collection Date,Y,26-May-2026,,,,,, +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,FECAL COLLECTION D/T,Stool Collection Time,Y,07:00,,,,,, +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,151,,,,,127 - 181,g/L +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.44,,,,,0.39 - 0.54, +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.6,,,,,4.5 - 6.4,TI/L +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,33,,,,,26 - 34,pg +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,97,,H,,,79 - 96,fL +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,5.61,,,,,3.8 - 10.7,GI/L +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.81,,,,,1.96 - 7.23,GI/L +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.03,,,,,0.91 - 4.28,GI/L +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.50,,,,,0.12 - 0.92,GI/L +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.23,,,,,0 - 0.57,GI/L +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.05,,,,,0 - 0.2,GI/L +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,50.0,,,,,40.5 - 75,% +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,36.1,,,,,15.4 - 48.5,% +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,8.9,,,,,2.6 - 10.1,% +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,4.0,,,,,0 - 6.8,% +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.0,,,,,0 - 2,% +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,283,,,,,140 - 400,GI/L +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,SM01/PLASMA PK TROUGH COLL D/T,Collection Date Predose,Y,26-May-2026,,,,,, +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,SM01/PLASMA PK TROUGH COLL D/T,Collection Time Predose,Y,09:05,,,,,, +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,SM02/PLASMA PK PEAK COLL D/T,Collection Date Post dose,Y,26-May-2026,,,,,, +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,SM02/PLASMA PK PEAK COLL D/T,Post Dose Collection Time,Y,10:10,,,,,, +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,SM04/SERUM ADA PRE COLL D/T,Collection Date Predose,Y,26-May-2026,,,,,, +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,SM04/SERUM ADA PRE COLL D/T,Collection Time Predose,Y,09:05,,,,,, +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,SM09/STOOL PK COLL D/T,Stool Collection Date,Y,26-May-2026,,,,,, +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,SM09/STOOL PK COLL D/T,Stool Collection Time,Y,07:00,,,,,, +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,SUBJECT HEIGHT (CM),Height (cm),Y,196,,,,,cm, +CZ100132003,,,,,Female,Biopsy,,"May 25, 2026 12:00 AM",6228501732,ANATOMICAL SITE,Anatomical Site,Y,15-20cm from anal verge,,,,,, +CZ100132003,,,,,Female,Biopsy,,"May 25, 2026 12:00 AM",6228501732,BIOPSY COLLECTION METHOD,Collection Method,Y,colonoscopy,,,,,, +CZ100132003,,,,,Female,Biopsy,,"May 25, 2026 12:00 AM",6228501732,BIOPSY FIXATIVE USED,Fixative Used,,10% NBF,,,,,, +CZ100132003,,,,,Female,Biopsy,,"May 25, 2026 12:00 AM",6228501732,DATE/TIME PLACED IN FORMALIN,Date Sample placed in Formalin,Y,25-May-2026,,,,,, +CZ100132003,,,,,Female,Biopsy,,"May 25, 2026 12:00 AM",6228501732,DATE/TIME PLACED IN FORMALIN,Time Sample placed in Formalin,Y,09:05,,,,,, +CZ100132003,,,,,Female,Biopsy,,"May 25, 2026 12:00 AM",6228501732,DIAGNOSIS,Diagnosis:,Y,Ulcerative Colitis,,,,,, +CZ100132003,,,,,Female,Biopsy,,"May 25, 2026 12:00 AM",6228501732,INFLAMED AREA,Inflamed area?,,Yes,,,,,, +CZ100132003,,,,,Female,Biopsy,,"May 25, 2026 12:00 AM",6228501732,TISSUE BIOPSY EMBEDDING1,Biopsy technical QC-CL,,Smpl meets HT requirements,,,,,, +CZ100132003,,,,,Female,Biopsy,,"May 25, 2026 12:00 AM",6228501732,TISSUE BIOPSY EMBEDDING1,Biopsy processing Time-CL,,12:00,,,,,, +CZ100132003,,,,,Female,Biopsy,,"May 25, 2026 12:00 AM",6228501732,TISSUE BIOPSY EMBEDDING1,Biopsy processing Date-CL,,27-May-2026,,,,,, +CZ100132003,,,,,Female,Biopsy,,"May 25, 2026 12:00 AM",6228501732,TISSUE BIOPSY EMBEDDING1,Biopsy Comments-CL,,Received in 10% NBF,,,,,, +CZ100132003,,,,,Female,Biopsy,,"May 25, 2026 12:00 AM",6228501732,TISSUE BIOPSY EMBEDDING1,# of Cassettes-(FI)-CL,,1,,,,,, +CZ100132003,,,,,Female,Biopsy,,"May 25, 2026 12:00 AM",6228501732,ULCERATED AREA,Is biopsy site ulcerated?,,Yes,,,,,, +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,CHEMISTRY PANEL,Total Bilirubin,,5,,,,,3 - 21,umol/L +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,1.9,,,,,0 - 6.2,umol/L +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,CHEMISTRY PANEL,Alkaline Phosphatase,,77,,,,,40 - 129,U/L +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,CHEMISTRY PANEL,ALT (SGPT),,19,,,,,5 - 48,U/L +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,CHEMISTRY PANEL,AST (SGOT),,21,,,,,8 - 40,U/L +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,CHEMISTRY PANEL,GGT,,16,,,,,10 - 61,U/L +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,CHEMISTRY PANEL,LDH,,159,,,,,53 - 234,U/L +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,CHEMISTRY PANEL,Urea Nitrogen,,5.0,,,,,1.4 - 8.6,mmol/L +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,96,,,,,40 - 110,umol/L +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,CHEMISTRY PANEL,Serum Glucose,,5.0,,,,,3.9 - 5.6,mmol/L +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,CHEMISTRY PANEL,Serum Uric Acid,,342,,,,,125 - 488,umol/L +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,CHEMISTRY PANEL,Calcium (EDTA),,2.48,,,,,2.07 - 2.64,mmol/L +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,CHEMISTRY PANEL,Phosphorus,,1.05,,,,,0.71 - 1.65,mmol/L +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,CHEMISTRY PANEL,Total Protein,,76,,,,,61 - 84,g/L +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,CHEMISTRY PANEL,Albumin-BCG,,49,,,,,33 - 49,g/L +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,CHEMISTRY PANEL,Creatine Kinase,,204,,,,,39 - 308,U/L +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,CHEMISTRY PANEL,Serum Sodium,,141,,,,,132 - 147,mmol/L +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,CHEMISTRY PANEL,Serum Potassium,,4.2,,,,,3.5 - 5.2,mmol/L +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,CHEMISTRY PANEL,Serum Bicarbonate,,21.8,,,,,19.3 - 29.3,mmol/L +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,CHEMISTRY PANEL,Serum Chloride,,104,,,,,94 - 112,mmol/L +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,CHEMISTRY PANEL,Magnesium,,0.85,,,,,0.66 - 1.07,mmol/L +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,94,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,FECAL COLLECTION D/T,Stool Collection Date,Y,12-May-2026,,,,,, +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,FECAL COLLECTION D/T,Stool Collection Time,Y,08:50,,,,,, +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,154,,,,,127 - 181,g/L +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.44,,,,,0.39 - 0.54, +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.6,,,,,4.5 - 6.4,TI/L +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,33,,,,,26 - 34,pg +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,96,,,,,79 - 96,fL +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,5.64,,,,,3.8 - 10.7,GI/L +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.04,,,,,1.96 - 7.23,GI/L +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.81,,,,,0.91 - 4.28,GI/L +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.59,,,,,0.12 - 0.92,GI/L +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.16,,,,,0 - 0.57,GI/L +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.05,,,,,0 - 0.2,GI/L +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,53.9,,,,,40.5 - 75,% +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,32.0,,,,,15.4 - 48.5,% +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,10.4,,H,,,2.6 - 10.1,% +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.8,,,,,0 - 6.8,% +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.9,,,,,0 - 2,% +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,275,,,,,140 - 400,GI/L +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,LIPID PANEL,Direct HDL-C 4th Generation,,1.26,,,,,1.03 - 1.53,mmol/L +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,LIPID PANEL,Triglycerides (GPO),,1.63,,,,,0.5 - 2.81,mmol/L +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,LIPID PANEL,Cholesterol (High Performance),,4.71,,,,,3.31 - 6.1,mmol/L +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,LIPID PANEL,LDL Chol Friedewald 4th,,2.70,,,,,0 - 3.34,mmol/L +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,PA1 EEA-2?,Approved to use EEA-2?,,No,,,,,, +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,SM01/PLASMA PK TROUGH COLL D/T,Collection Date Predose,Y,12-May-2026,,,,,, +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,SM01/PLASMA PK TROUGH COLL D/T,Collection Time Predose,Y,10:25,,,,,, +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,SM02/PLASMA PK PEAK COLL D/T,Collection Date Post dose,Y,12-May-2026,,,,,, +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,SM02/PLASMA PK PEAK COLL D/T,Post Dose Collection Time,Y,11:30,,,,,, +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,SM04/SERUM ADA PRE COLL D/T,Collection Date Predose,Y,12-May-2026,,,,,, +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,SM04/SERUM ADA PRE COLL D/T,Collection Time Predose,Y,10:25,,,,,, +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,SM10/FECAL BMRKS COLL D/T,Stool Collection Date,Y,12-May-2026,,,,,, +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,SM10/FECAL BMRKS COLL D/T,Stool Collection Time,Y,08:50,,,,,, +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,SUBJECT HEIGHT (CM),Height (cm),Y,196,,,,,cm, +CZ100132003,,,,,Female,Stool Pathogens,,"May 7, 2026 5:45 AM",6227635150,C. DIFF EIA,"C. diff GDH Ag,stool-CL",,Negative,,,,,Ref Rng:Negative, +CZ100132003,,,,,Female,Stool Pathogens,,"May 7, 2026 5:45 AM",6227635150,C. DIFF EIA,"C.diff Toxin A&B,stool-CL",,Negative,,,,,Ref Rng:Negative, +CZ100132003,,,,,Female,Stool Pathogens,,"May 7, 2026 5:45 AM",6227635150,OVA AND PARASITES 1,Concentrate Exam,,No ova or parasites found,,,,,, +CZ100132003,,,,,Female,Stool Pathogens,,"May 7, 2026 5:45 AM",6227635150,OVA AND PARASITES 1,Smear for Microsporidia,,No Microsporidia seen.,,,,,, +CZ100132003,,,,,Female,Stool Pathogens,,"May 7, 2026 5:45 AM",6227635150,OVA AND PARASITES 1,Modified acid-fast stain,,No coccidian parasites seen,,,,,, +CZ100132003,,,,,Female,Stool Pathogens,,"May 7, 2026 5:45 AM",6227635150,OVA AND PARASITES 2,Trichrome Smear,,No ova or parasites found,,,,,, +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,CHEMISTRY PANEL,Total Bilirubin,,6,,,,,3 - 21,umol/L +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.1,,,,,0 - 6.2,umol/L +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,CHEMISTRY PANEL,Alkaline Phosphatase,,95,,,,,35 - 104,U/L +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,CHEMISTRY PANEL,ALT (SGPT),,16,,,,,4 - 43,U/L +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,CHEMISTRY PANEL,AST (SGOT),,22,,,,,8 - 40,U/L +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,CHEMISTRY PANEL,GGT,,34,,,,,4 - 49,U/L +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,CHEMISTRY PANEL,LDH,,151,,,,,53 - 234,U/L +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,CHEMISTRY PANEL,Urea Nitrogen,,2.8,,,,,1.4 - 8.6,mmol/L +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,68,,,,,31 - 101,umol/L +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,CHEMISTRY PANEL,Serum Glucose,,5.2,,,,,3.9 - 5.6,mmol/L +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,CHEMISTRY PANEL,Serum Uric Acid,,357,,,,,125 - 428,umol/L +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,CHEMISTRY PANEL,Calcium (EDTA),,2.31,,,,,2.07 - 2.64,mmol/L +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,CHEMISTRY PANEL,Phosphorus,,1.09,,,,,0.71 - 1.65,mmol/L +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,CHEMISTRY PANEL,Total Protein,,71,,,,,61 - 84,g/L +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,CHEMISTRY PANEL,Albumin-BCG,,46,,,,,33 - 49,g/L +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,CHEMISTRY PANEL,Creatine Kinase,,51,,,,,26 - 192,U/L +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,CHEMISTRY PANEL,Serum Sodium,,141,,,,,132 - 147,mmol/L +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,CHEMISTRY PANEL,Serum Potassium,,4.1,,,,,3.5 - 5.2,mmol/L +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,CHEMISTRY PANEL,Serum Bicarbonate,,23.1,,,,,19.3 - 29.3,mmol/L +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,CHEMISTRY PANEL,Serum Chloride,,106,,,,,94 - 112,mmol/L +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,CHEMISTRY PANEL,Magnesium,,0.81,,,,,0.66 - 1.07,mmol/L +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,95,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,FEMALE OF CHILDBEARING POT?,Female/of Childbearing pot.?,Y,Yes,,,,,, +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,HBV ELIGIBILITY MET?,HBV Eligibility Criteria Met?,,Yes,,,,,, +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,133,,,,,116 - 164,g/L +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.40,,,,,0.34 - 0.48, +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.7,,,,,4.1 - 5.6,TI/L +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,28,,,,,26 - 34,pg +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,84,,,,,79 - 98,fL +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,6.91,,,,,3.8 - 10.7,GI/L +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,4.94,,,,,1.96 - 7.23,GI/L +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.35,,,,,0.91 - 4.28,GI/L +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.40,,,,,0.12 - 0.92,GI/L +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.13,,,,,0 - 0.57,GI/L +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.09,,,,,0 - 0.2,GI/L +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,71.5,,,,,40.5 - 75,% +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,19.5,,,,,15.4 - 48.5,% +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.8,,,,,2.6 - 10.1,% +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.9,,,,,0 - 6.8,% +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.3,,,,,0 - 2,% +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,271,,,,,140 - 400,GI/L +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,HEPATITIS B CORE AB NON-US,Hepatitis B Core Total,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,HEPATITIS B SURFACE AB,Anti-HBs II QUAL,,Non-Reactive,,,,,Ref Rng :$Non Reactive, +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,HEPATITIS B SURFACE AG NON-US,Hep B Surface AgII,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,HEPATITIS C VIRUS AB NON-US,Hepatitis C Virus Antibody,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,HIV 1/2 AG/AB SCREEN,anti-HIV-1/2 antibodies,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,HIV 1/2 AG/AB SCREEN,HIV -1 p24 antigen,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,HIV 1/2 AG/AB SCREEN,"HIV 1/2 Ag/Ab Screen, Cobas",,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,QUANTIFERON GOLD MITOGEN/INTER,"QFT,TBGoldPlusInt,pl-4-Tubes",,Negative,,,,,Normal=Negative, +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,SERUM BETA HCG,"B-hCG, Qualitative",,Negative,,,,,Ref Rng: Negative, +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,SERUM BETA HCG,"B-hCG, Quantitative",,<0.6,,,,,Units: mIU/mL$Pre-menopausal$<5.0: Negative$5.0-24.9:Borderline$>/= 25.0: Positive, +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,SUBJECT HEIGHT (CM),Height (cm),Y,N/A (subject >/= 18 years of age),,,,,cm, +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,ALP<2XULN,ALP<2XULN,,Criteria Met,,,,,, +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,ALT>/=3XULN,ALT >/= 3 X ULN,,Criteria not met,,,,,, +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,ALT>/=3XULN & TBIL>/=2XULN,ALT >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,AST>/=3XULN,AST >/= 3 X ULN,,Criteria not met,,,,,, +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,AST>/=3XULN & TBIL>/=2XULN,AST >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,CHEMISTRY PANEL,Total Bilirubin,,7,,,,,3 - 21,umol/L +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.6,,,,,0 - 6.2,umol/L +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,CHEMISTRY PANEL,Alkaline Phosphatase,,88,,,,,40 - 129,U/L +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,CHEMISTRY PANEL,ALT (SGPT),,36,,,,,5 - 48,U/L +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,CHEMISTRY PANEL,AST (SGOT),,30,,,,,8 - 40,U/L +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,CHEMISTRY PANEL,GGT,,21,,,,,10 - 61,U/L +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,CHEMISTRY PANEL,LDH,,172,,,,,53 - 234,U/L +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,CHEMISTRY PANEL,Urea Nitrogen,,6.2,,,,,1.4 - 8.6,mmol/L +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,71,,,,,40 - 110,umol/L +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,CHEMISTRY PANEL,Serum Glucose,,4.6,,,,,3.9 - 5.6,mmol/L +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,CHEMISTRY PANEL,Serum Uric Acid,,297,,,,,125 - 488,umol/L +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,CHEMISTRY PANEL,Calcium (EDTA),,2.45,,,,,2.07 - 2.64,mmol/L +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,CHEMISTRY PANEL,Phosphorus,,1.22,,,,,0.71 - 1.65,mmol/L +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,CHEMISTRY PANEL,Total Protein,,74,,,,,61 - 84,g/L +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,CHEMISTRY PANEL,Albumin-BCG,,48,,,,,33 - 49,g/L +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,CHEMISTRY PANEL,Creatine Kinase,,177,,,,,39 - 308,U/L +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,CHEMISTRY PANEL,Serum Sodium,,140,,,,,132 - 147,mmol/L +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,CHEMISTRY PANEL,Serum Potassium,,4.2,,,,,3.5 - 5.2,mmol/L +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,CHEMISTRY PANEL,Serum Bicarbonate,,26.7,,,,,19.3 - 29.3,mmol/L +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,CHEMISTRY PANEL,Serum Chloride,,100,,,,,94 - 112,mmol/L +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,CHEMISTRY PANEL,Magnesium,,0.83,,,,,0.66 - 1.07,mmol/L +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,123,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,FECAL COLLECTION D/T,Stool Collection Date,Y,21-Apr-2026,,,,,, +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,FECAL COLLECTION D/T,Stool Collection Time,Y,06:20,,,,,, +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,152,,,,,127 - 181,g/L +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.43,,,,,0.39 - 0.54, +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.9,,,,,4.5 - 6.4,TI/L +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,31,,,,,26 - 34,pg +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,Normocytic,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,89,,,,,79 - 96,fL +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,4.31,,,,,3.8 - 10.7,GI/L +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,1.98,,,,,1.96 - 7.23,GI/L +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.64,,,,,0.91 - 4.28,GI/L +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.30,,,,,0.12 - 0.92,GI/L +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.30,,,,,0 - 0.57,GI/L +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.09,,,,,0 - 0.2,GI/L +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,46.0,,,,,40.5 - 75,% +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,38.0,,,,,15.4 - 48.5,% +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,7.0,,,,,2.6 - 10.1,% +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,7.0,,H,,,0 - 6.8,% +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,2.0,,,,,0 - 2,% +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,226,,,,,140 - 400,GI/L +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,SM01/PLASMA PK TROUGH COLL D/T,Collection Date Predose,Y,21-Apr-2026,,,,,, +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,SM01/PLASMA PK TROUGH COLL D/T,Collection Time Predose,Y,08:45,,,,,, +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,SM02/PLASMA PK PEAK COLL D/T,Collection Date Post dose,Y,21-Apr-2026,,,,,, +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,SM02/PLASMA PK PEAK COLL D/T,Post Dose Collection Time,Y,09:50,,,,,, +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,SM04/SERUM ADA PRE COLL D/T,Collection Date Predose,Y,21-Apr-2026,,,,,, +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,SM04/SERUM ADA PRE COLL D/T,Collection Time Predose,Y,08:45,,,,,, +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,SM09/STOOL PK COLL D/T,Stool Collection Date,Y,21-Apr-2026,,,,,, +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,SM09/STOOL PK COLL D/T,Stool Collection Time,Y,06:20,,,,,, +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,SUBJECT HEIGHT (CM),Height (cm),Y,N/A (subject >/= 18 years of age),,,,,cm, +CZ100132002,,,,,Male,Biopsy,,"Apr 21, 2026 12:00 AM",6227635159,ANATOMICAL SITE,Anatomical Site,Y,15-20cm from anal verge,,,,,, +CZ100132002,,,,,Male,Biopsy,,"Apr 21, 2026 12:00 AM",6227635159,BIOPSY COLLECTION METHOD,Collection Method,Y,colonoscopy,,,,,, +CZ100132002,,,,,Male,Biopsy,,"Apr 21, 2026 12:00 AM",6227635159,BIOPSY FIXATIVE USED,Fixative Used,,10% NBF,,,,,, +CZ100132002,,,,,Male,Biopsy,,"Apr 21, 2026 12:00 AM",6227635159,DATE/TIME PLACED IN FORMALIN,Date Sample placed in Formalin,Y,21-Apr-2026,,,,,, +CZ100132002,,,,,Male,Biopsy,,"Apr 21, 2026 12:00 AM",6227635159,DATE/TIME PLACED IN FORMALIN,Time Sample placed in Formalin,Y,08:45,,,,,, +CZ100132002,,,,,Male,Biopsy,,"Apr 21, 2026 12:00 AM",6227635159,DIAGNOSIS,Diagnosis:,Y,Ulcerative Colitis,,,,,, +CZ100132002,,,,,Male,Biopsy,,"Apr 21, 2026 12:00 AM",6227635159,INFLAMED AREA,Inflamed area?,,Yes,,,,,, +CZ100132002,,,,,Male,Biopsy,,"Apr 21, 2026 12:00 AM",6227635159,TISSUE BIOPSY EMBEDDING1,Biopsy technical QC-CL,,Smpl meets HT requirements,,,,,, +CZ100132002,,,,,Male,Biopsy,,"Apr 21, 2026 12:00 AM",6227635159,TISSUE BIOPSY EMBEDDING1,Biopsy processing Time-CL,,12:00,,,,,, +CZ100132002,,,,,Male,Biopsy,,"Apr 21, 2026 12:00 AM",6227635159,TISSUE BIOPSY EMBEDDING1,Biopsy processing Date-CL,,23-Apr-2026,,,,,, +CZ100132002,,,,,Male,Biopsy,,"Apr 21, 2026 12:00 AM",6227635159,TISSUE BIOPSY EMBEDDING1,Biopsy Comments-CL,,Received in 10% NBF,,,,,, +CZ100132002,,,,,Male,Biopsy,,"Apr 21, 2026 12:00 AM",6227635159,TISSUE BIOPSY EMBEDDING1,# of Cassettes-(FI)-CL,,1,,,,,, +CZ100132002,,,,,Male,Biopsy,,"Apr 21, 2026 12:00 AM",6227635159,ULCERATED AREA,Is biopsy site ulcerated?,,Yes,,,,,, +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,ALP<2XULN,ALP<2XULN,,Criteria Met,,,,,, +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,ALT>/=3XULN,ALT >/= 3 X ULN,,Criteria not met,,,,,, +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,ALT>/=3XULN & TBIL>/=2XULN,ALT >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,AST>/=3XULN,AST >/= 3 X ULN,,Criteria not met,,,,,, +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,AST>/=3XULN & TBIL>/=2XULN,AST >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,CHEMISTRY PANEL,Total Bilirubin,,9,,,,,3 - 21,umol/L +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.8,,,,,0 - 6.2,umol/L +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,CHEMISTRY PANEL,Alkaline Phosphatase,,87,,,,,40 - 129,U/L +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,CHEMISTRY PANEL,ALT (SGPT),,27,,,,,5 - 48,U/L +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,CHEMISTRY PANEL,AST (SGOT),,25,,,,,8 - 40,U/L +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,CHEMISTRY PANEL,GGT,,14,,,,,10 - 61,U/L +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,CHEMISTRY PANEL,LDH,,174,,,,,53 - 234,U/L +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,CHEMISTRY PANEL,Urea Nitrogen,,5.5,,,,,1.4 - 8.6,mmol/L +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,87,,,,,40 - 110,umol/L +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,CHEMISTRY PANEL,Serum Glucose,,4.9,,,,,3.9 - 5.6,mmol/L +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,CHEMISTRY PANEL,Serum Uric Acid,,299,,,,,125 - 488,umol/L +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,CHEMISTRY PANEL,Calcium (EDTA),,2.44,,,,,2.07 - 2.64,mmol/L +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,CHEMISTRY PANEL,Phosphorus,,1.17,,,,,0.71 - 1.65,mmol/L +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,CHEMISTRY PANEL,Total Protein,,73,,,,,61 - 84,g/L +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,CHEMISTRY PANEL,Albumin-BCG,,49,,,,,33 - 49,g/L +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,CHEMISTRY PANEL,Creatine Kinase,,177,,,,,39 - 308,U/L +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,CHEMISTRY PANEL,Serum Sodium,,140,,,,,132 - 147,mmol/L +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,CHEMISTRY PANEL,Serum Potassium,,4.2,,,,,3.5 - 5.2,mmol/L +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,CHEMISTRY PANEL,Serum Bicarbonate,,26.5,,,,,19.3 - 29.3,mmol/L +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,CHEMISTRY PANEL,Serum Chloride,,101,,,,,94 - 112,mmol/L +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,CHEMISTRY PANEL,Magnesium,,0.79,,,,,0.66 - 1.07,mmol/L +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,107,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,FECAL COLLECTION D/T,Stool Collection Date,Y,07-Apr-2026,,,,,, +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,FECAL COLLECTION D/T,Stool Collection Time,Y,06:30,,,,,, +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,150,,,,,127 - 181,g/L +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.45,,,,,0.39 - 0.54, +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.9,,,,,4.5 - 6.4,TI/L +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,31,,,,,26 - 34,pg +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,92,,,,,79 - 96,fL +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,4.89,,,,,3.8 - 10.7,GI/L +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.33,,,,,1.96 - 7.23,GI/L +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.84,,,,,0.91 - 4.28,GI/L +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.25,,,,,0.12 - 0.92,GI/L +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.37,,,,,0 - 0.57,GI/L +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.09,,,,,0 - 0.2,GI/L +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,47.7,,,,,40.5 - 75,% +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,37.7,,,,,15.4 - 48.5,% +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.2,,,,,2.6 - 10.1,% +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,7.7,R,H,,,0 - 6.8,% +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.8,,,,,0 - 2,% +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,217,,,,,140 - 400,GI/L +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,SM01/PLASMA PK TROUGH COLL D/T,Collection Date Predose,Y,07-Apr-2026,,,,,, +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,SM01/PLASMA PK TROUGH COLL D/T,Collection Time Predose,Y,08:50,,,,,, +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,SM02/PLASMA PK PEAK COLL D/T,Collection Date Post dose,Y,07-Apr-2026,,,,,, +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,SM02/PLASMA PK PEAK COLL D/T,Post Dose Collection Time,Y,10:00,,,,,, +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,SM04/SERUM ADA PRE COLL D/T,Collection Date Predose,Y,07-Apr-2026,,,,,, +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,SM04/SERUM ADA PRE COLL D/T,Collection Time Predose,Y,08:50,,,,,, +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,SM09/STOOL PK COLL D/T,Stool Collection Date,Y,07-Apr-2026,,,,,, +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,SM09/STOOL PK COLL D/T,Stool Collection Time,Y,06:30,,,,,, +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,SUBJECT HEIGHT (CM),Height (cm),Y,N/A (subject >/= 18 years of age),,,,,cm, +CZ100132002,,,,,Male,Stool Pathogens,,"Apr 1, 2026 8:30 AM",6227635148,C. DIFF EIA,"C. diff GDH Ag,stool-CL",,Negative,,,,,Ref Rng:Negative, +CZ100132002,,,,,Male,Stool Pathogens,,"Apr 1, 2026 8:30 AM",6227635148,C. DIFF EIA,"C.diff Toxin A&B,stool-CL",,Negative,,,,,Ref Rng:Negative, +CZ100132002,,,,,Male,Stool Pathogens,,"Apr 1, 2026 8:30 AM",6227635148,OVA AND PARASITES 1,Concentrate Exam,,No ova or parasites found,,,,,, +CZ100132002,,,,,Male,Stool Pathogens,,"Apr 1, 2026 8:30 AM",6227635148,OVA AND PARASITES 1,Smear for Microsporidia,,No Microsporidia seen.,,,,,, +CZ100132002,,,,,Male,Stool Pathogens,,"Apr 1, 2026 8:30 AM",6227635148,OVA AND PARASITES 1,Modified acid-fast stain,,No coccidian parasites seen,,,,,, +CZ100132002,,,,,Male,Stool Pathogens,,"Apr 1, 2026 8:30 AM",6227635148,OVA AND PARASITES 2,Trichrome Smear,,No ova or parasites found,,,,,, +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,CHEMISTRY PANEL,Total Bilirubin,,7,,,,,3 - 21,umol/L +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.5,,,,,0 - 6.2,umol/L +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,CHEMISTRY PANEL,Alkaline Phosphatase,,69,,,,,40 - 129,U/L +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,CHEMISTRY PANEL,ALT (SGPT),,20,,,,,5 - 48,U/L +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,CHEMISTRY PANEL,AST (SGOT),,18,,,,,8 - 40,U/L +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,CHEMISTRY PANEL,GGT,,15,,,,,10 - 61,U/L +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,CHEMISTRY PANEL,LDH,,130,,,,,53 - 234,U/L +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,CHEMISTRY PANEL,Urea Nitrogen,,6.0,,,,,1.4 - 8.6,mmol/L +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,82,,,,,40 - 110,umol/L +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,CHEMISTRY PANEL,Serum Glucose,,7.1,,H,,,3.9 - 5.6,mmol/L +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,CHEMISTRY PANEL,Serum Uric Acid,,301,,,,,125 - 488,umol/L +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,CHEMISTRY PANEL,Calcium (EDTA),,2.45,,,,,2.07 - 2.64,mmol/L +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,CHEMISTRY PANEL,Phosphorus,,1.42,,,,,0.71 - 1.65,mmol/L +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,CHEMISTRY PANEL,Total Protein,,66,,,,,61 - 84,g/L +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,CHEMISTRY PANEL,Albumin-BCG,,46,,,,,33 - 49,g/L +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,CHEMISTRY PANEL,Creatine Kinase,,91,,,,,39 - 308,U/L +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,CHEMISTRY PANEL,Serum Sodium,,138,,,,,132 - 147,mmol/L +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,CHEMISTRY PANEL,Serum Potassium,,4.4,,,,,3.5 - 5.2,mmol/L +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,CHEMISTRY PANEL,Serum Bicarbonate,,22.2,,,,,19.3 - 29.3,mmol/L +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,CHEMISTRY PANEL,Serum Chloride,,102,,,,,94 - 112,mmol/L +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,CHEMISTRY PANEL,Magnesium,,0.75,,,,,0.66 - 1.07,mmol/L +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,114,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,HBV ELIGIBILITY MET?,HBV Eligibility Criteria Met?,,Yes,,,,,, +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,147,,,,,127 - 181,g/L +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.41,,,,,0.39 - 0.54, +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.3,R,L,,,4.5 - 6.4,TI/L +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,34,,,,,26 - 34,pg +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,96,,,,,79 - 96,fL +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,7.60,,,,,3.8 - 10.7,GI/L +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,4.44,,,,,1.96 - 7.23,GI/L +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.11,,,,,0.91 - 4.28,GI/L +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.65,,,,,0.12 - 0.92,GI/L +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.28,,,,,0 - 0.57,GI/L +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.12,,,,,0 - 0.2,GI/L +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,58.4,,,,,40.5 - 75,% +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,27.8,,,,,15.4 - 48.5,% +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,8.6,,,,,2.6 - 10.1,% +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,3.7,,,,,0 - 6.8,% +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.5,,,,,0 - 2,% +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,256,,,,,140 - 400,GI/L +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,HEPATITIS B CORE AB NON-US,Hepatitis B Core Total,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,HEPATITIS B SURFACE AB,Anti-HBs II QUAL,,Reactive,,,,,Ref Rng :$Non Reactive, +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,HEPATITIS B SURFACE AG NON-US,Hep B Surface AgII,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,HEPATITIS C VIRUS AB NON-US,Hepatitis C Virus Antibody,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,HIV 1/2 AG/AB SCREEN,anti-HIV-1/2 antibodies,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,HIV 1/2 AG/AB SCREEN,HIV -1 p24 antigen,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,HIV 1/2 AG/AB SCREEN,"HIV 1/2 Ag/Ab Screen, Cobas",,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,QUANTIFERON GOLD MITOGEN/INTER,"QFT,TBGoldPlusInt,pl-4-Tubes",,Negative,,,,,Normal=Negative, +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,SUBJECT HEIGHT (CM),Height (cm),Y,N/A (subject >/= 18 years of age),,,,,cm, +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,CHEMISTRY PANEL,Total Bilirubin,,9,,,,,3 - 21,umol/L +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.4,,,,,0 - 6.2,umol/L +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,CHEMISTRY PANEL,Alkaline Phosphatase,,80,,,,,40 - 129,U/L +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,CHEMISTRY PANEL,ALT (SGPT),,24,,,,,5 - 48,U/L +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,CHEMISTRY PANEL,AST (SGOT),,19,,,,,8 - 40,U/L +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,CHEMISTRY PANEL,GGT,,13,,,,,10 - 61,U/L +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,CHEMISTRY PANEL,LDH,,166,,,,,53 - 234,U/L +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,CHEMISTRY PANEL,Urea Nitrogen,,7.7,,,,,1.4 - 8.6,mmol/L +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,89,,,,,40 - 110,umol/L +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,CHEMISTRY PANEL,Serum Glucose,,4.3,,,,,3.9 - 5.6,mmol/L +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,CHEMISTRY PANEL,Serum Uric Acid,,336,,,,,125 - 488,umol/L +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,CHEMISTRY PANEL,Calcium (EDTA),,2.41,,,,,2.07 - 2.64,mmol/L +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,CHEMISTRY PANEL,Phosphorus,,1.04,,,,,0.71 - 1.65,mmol/L +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,CHEMISTRY PANEL,Total Protein,,72,,,,,61 - 84,g/L +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,CHEMISTRY PANEL,Albumin-BCG,,47,,,,,33 - 49,g/L +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,CHEMISTRY PANEL,Creatine Kinase,,135,,,,,39 - 308,U/L +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,CHEMISTRY PANEL,Serum Sodium,,138,,,,,132 - 147,mmol/L +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,CHEMISTRY PANEL,Serum Potassium,,4.3,,,,,3.5 - 5.2,mmol/L +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,CHEMISTRY PANEL,Serum Bicarbonate,,22.2,,,,,19.3 - 29.3,mmol/L +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,CHEMISTRY PANEL,Serum Chloride,,102,,,,,94 - 112,mmol/L +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,CHEMISTRY PANEL,Magnesium,,0.78,,,,,0.66 - 1.07,mmol/L +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,103,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,FECAL COLLECTION D/T,Stool Collection Date,Y,24-Mar-2026,,,,,, +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,FECAL COLLECTION D/T,Stool Collection Time,Y,07:30,,,,,, +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,156,,,,,127 - 181,g/L +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.46,,,,,0.39 - 0.54, +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.1,,,,,4.5 - 6.4,TI/L +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,31,,,,,26 - 34,pg +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,92,,,,,79 - 96,fL +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,5.53,,,,,3.8 - 10.7,GI/L +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.00,,,,,1.96 - 7.23,GI/L +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.61,,,,,0.91 - 4.28,GI/L +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.25,,,,,0.12 - 0.92,GI/L +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.57,,,,,0 - 0.57,GI/L +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.10,,,,,0 - 0.2,GI/L +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,54.3,,,,,40.5 - 75,% +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,29.0,,,,,15.4 - 48.5,% +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,4.6,,,,,2.6 - 10.1,% +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,10.4,R,H,,,0 - 6.8,% +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.8,,,,,0 - 2,% +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,235,,,,,140 - 400,GI/L +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,LIPID PANEL,Direct HDL-C 4th Generation,,1.91,,H,,,1.03 - 1.53,mmol/L +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,LIPID PANEL,Triglycerides (GPO),,0.67,,,,,0.5 - 2.81,mmol/L +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,LIPID PANEL,Cholesterol (High Performance),,4.26,,,,,3.31 - 6.1,mmol/L +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,LIPID PANEL,LDL Chol Friedewald 4th,,2.04,,,,,0 - 3.34,mmol/L +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,SM01/PLASMA PK TROUGH COLL D/T,Collection Date Predose,Y,24-Mar-2026,,,,,, +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,SM01/PLASMA PK TROUGH COLL D/T,Collection Time Predose,Y,09:40,R,,,,, +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,SM02/PLASMA PK PEAK COLL D/T,Collection Date Post dose,Y,24-Mar-2026,,,,,, +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,SM02/PLASMA PK PEAK COLL D/T,Post Dose Collection Time,Y,10:45,,,,,, +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,SM04/SERUM ADA PRE COLL D/T,Collection Date Predose,Y,24-Mar-2026,,,,,, +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,SM04/SERUM ADA PRE COLL D/T,Collection Time Predose,Y,09:40,R,,,,, +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,SM10/FECAL BMRKS COLL D/T,Stool Collection Date,Y,24-Mar-2026,,,,,, +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,SM10/FECAL BMRKS COLL D/T,Stool Collection Time,Y,07:30,,,,,, +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,SUBJECT HEIGHT (CM),Height (cm),Y,N/A (subject >/= 18 years of age),,,,,cm, +CZ100132001,,,,,Male,Biopsy,,"Mar 12, 2026 12:00 AM",6227635161,ANATOMICAL SITE,Anatomical Site,Y,15-20cm from anal verge,,,,,, +CZ100132001,,,,,Male,Biopsy,,"Mar 12, 2026 12:00 AM",6227635161,BIOPSY COLLECTION METHOD,Collection Method,Y,colonoscopy,,,,,, +CZ100132001,,,,,Male,Biopsy,,"Mar 12, 2026 12:00 AM",6227635161,BIOPSY FIXATIVE USED,Fixative Used,,10% NBF,,,,,, +CZ100132001,,,,,Male,Biopsy,,"Mar 12, 2026 12:00 AM",6227635161,DATE/TIME PLACED IN FORMALIN,Date Sample placed in Formalin,Y,12-Mar-2026,,,,,, +CZ100132001,,,,,Male,Biopsy,,"Mar 12, 2026 12:00 AM",6227635161,DATE/TIME PLACED IN FORMALIN,Time Sample placed in Formalin,Y,07:52,,,,,, +CZ100132001,,,,,Male,Biopsy,,"Mar 12, 2026 12:00 AM",6227635161,DIAGNOSIS,Diagnosis:,Y,Ulcerative Colitis,,,,,, +CZ100132001,,,,,Male,Biopsy,,"Mar 12, 2026 12:00 AM",6227635161,INFLAMED AREA,Inflamed area?,,Yes,,,,,, +CZ100132001,,,,,Male,Biopsy,,"Mar 12, 2026 12:00 AM",6227635161,TISSUE BIOPSY EMBEDDING1,Biopsy technical QC-CL,,Smpl meets HT requirements,,,,,, +CZ100132001,,,,,Male,Biopsy,,"Mar 12, 2026 12:00 AM",6227635161,TISSUE BIOPSY EMBEDDING1,Biopsy processing Time-CL,,10:00,,,,,, +CZ100132001,,,,,Male,Biopsy,,"Mar 12, 2026 12:00 AM",6227635161,TISSUE BIOPSY EMBEDDING1,Biopsy processing Date-CL,,14-Mar-2026,,,,,, +CZ100132001,,,,,Male,Biopsy,,"Mar 12, 2026 12:00 AM",6227635161,TISSUE BIOPSY EMBEDDING1,Biopsy Comments-CL,,Received in 10% NBF,,,,,, +CZ100132001,,,,,Male,Biopsy,,"Mar 12, 2026 12:00 AM",6227635161,TISSUE BIOPSY EMBEDDING1,# of Cassettes-(FI)-CL,,1,,,,,, +CZ100132001,,,,,Male,Biopsy,,"Mar 12, 2026 12:00 AM",6227635161,ULCERATED AREA,Is biopsy site ulcerated?,,No,,,,,, +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,CHEMISTRY PANEL,Total Bilirubin,,7,,,,,3 - 21,umol/L +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.7,,,,,0 - 6.2,umol/L +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,CHEMISTRY PANEL,Alkaline Phosphatase,,95,,,,,40 - 129,U/L +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,CHEMISTRY PANEL,ALT (SGPT),,25,,,,,5 - 48,U/L +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,CHEMISTRY PANEL,AST (SGOT),,16,,,,,8 - 40,U/L +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,CHEMISTRY PANEL,GGT,,16,,,,,10 - 61,U/L +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,CHEMISTRY PANEL,LDH,,149,,,,,53 - 234,U/L +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,CHEMISTRY PANEL,Urea Nitrogen,,7.1,,,,,1.4 - 8.6,mmol/L +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,89,,,,,40 - 110,umol/L +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,CHEMISTRY PANEL,Serum Glucose,,6.6,,H,,,3.9 - 5.6,mmol/L +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,CHEMISTRY PANEL,Serum Uric Acid,,358,,,,,125 - 488,umol/L +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,CHEMISTRY PANEL,Calcium (EDTA),,2.32,,,,,2.07 - 2.64,mmol/L +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,CHEMISTRY PANEL,Phosphorus,,1.05,,,,,0.71 - 1.65,mmol/L +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,CHEMISTRY PANEL,Total Protein,,72,,,,,61 - 84,g/L +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,CHEMISTRY PANEL,Albumin-BCG,,47,,,,,33 - 49,g/L +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,CHEMISTRY PANEL,Creatine Kinase,,100,,,,,39 - 308,U/L +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,CHEMISTRY PANEL,Serum Sodium,,140,,,,,132 - 147,mmol/L +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,CHEMISTRY PANEL,Serum Potassium,,3.8,,,,,3.5 - 5.2,mmol/L +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,CHEMISTRY PANEL,Serum Bicarbonate,,23.4,,,,,19.3 - 29.3,mmol/L +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,CHEMISTRY PANEL,Serum Chloride,,103,,,,,94 - 112,mmol/L +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,CHEMISTRY PANEL,Magnesium,,0.75,,,,,0.66 - 1.07,mmol/L +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,103,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,HBV ELIGIBILITY MET?,HBV Eligibility Criteria Met?,,Yes,,,,,, +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,154,,,,,127 - 181,g/L +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.45,,,,,0.39 - 0.54, +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.0,,,,,4.5 - 6.4,TI/L +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,31,,,,,26 - 34,pg +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,90,,,,,79 - 96,fL +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,5.82,,,,,3.8 - 10.7,GI/L +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.88,,,,,1.96 - 7.23,GI/L +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.03,,,,,0.91 - 4.28,GI/L +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.26,,,,,0.12 - 0.92,GI/L +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.57,,,,,0 - 0.57,GI/L +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.08,,,,,0 - 0.2,GI/L +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,49.4,,,,,40.5 - 75,% +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,34.9,,,,,15.4 - 48.5,% +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,4.4,,,,,2.6 - 10.1,% +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,9.9,,H,,,0 - 6.8,% +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.4,,,,,0 - 2,% +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,222,,,,,140 - 400,GI/L +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,HEPATITIS B CORE AB NON-US,Hepatitis B Core Total,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,HEPATITIS B SURFACE AB,Anti-HBs II QUAL,,Non-Reactive,,,,,Ref Rng :$Non Reactive, +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,HEPATITIS B SURFACE AG NON-US,Hep B Surface AgII,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,HEPATITIS C VIRUS AB NON-US,Hepatitis C Virus Antibody,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,HIV 1/2 AG/AB SCREEN,anti-HIV-1/2 antibodies,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,HIV 1/2 AG/AB SCREEN,HIV -1 p24 antigen,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,HIV 1/2 AG/AB SCREEN,"HIV 1/2 Ag/Ab Screen, Cobas",,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,QUANTIFERON GOLD MITOGEN/INTER,"QFT,TBGoldPlusInt,pl-4-Tubes",,Negative,,,,,Normal=Negative, +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,SUBJECT HEIGHT (CM),Height (cm),Y,163,,,,,cm, +CZ100132001,,,,,Male,Stool Pathogens,,"Feb 26, 2026 10:35 AM",6227635149,C. DIFF EIA,"C. diff GDH Ag,stool-CL",,Negative,,,,,Ref Rng:Negative, +CZ100132001,,,,,Male,Stool Pathogens,,"Feb 26, 2026 10:35 AM",6227635149,C. DIFF EIA,"C.diff Toxin A&B,stool-CL",,Negative,,,,,Ref Rng:Negative, +CZ100132001,,,,,Male,Stool Pathogens,,"Feb 26, 2026 10:35 AM",6227635149,OVA AND PARASITES 1,Concentrate Exam,,No ova or parasites found,,,,,, +CZ100132001,,,,,Male,Stool Pathogens,,"Feb 26, 2026 10:35 AM",6227635149,OVA AND PARASITES 1,Smear for Microsporidia,,No Microsporidia seen.,,,,,, +CZ100132001,,,,,Male,Stool Pathogens,,"Feb 26, 2026 10:35 AM",6227635149,OVA AND PARASITES 1,Modified acid-fast stain,,No coccidian parasites seen,,,,,, +CZ100132001,,,,,Male,Stool Pathogens,,"Feb 26, 2026 10:35 AM",6227635149,OVA AND PARASITES 2,Trichrome Smear,,No ova or parasites found,,,,,, diff --git a/Covance_UCO3001/Source/2026-06-08_130510 sponsor-study-36940-test-results-930547-microbiology.csv b/Covance_UCO3001/Source/2026-06-08_130510 sponsor-study-36940-test-results-930547-microbiology.csv new file mode 100644 index 0000000..b9b31df --- /dev/null +++ b/Covance_UCO3001/Source/2026-06-08_130510 sponsor-study-36940-test-results-930547-microbiology.csv @@ -0,0 +1,5 @@ +"Disclaimer: The information presented in On-Screen Results is not intended to be a replacement of the official Lab Results, Alerts, Data Revisions and Cancellations found in the Lab Reports section of this software application. On-Screen Results should not be used for patient diagnosis, treatment decisions or submission to regulatory bodies.",,,,,,,,,,,,,,,,,,,,,,, +Subject,Screening Number,Age,Age Unit,Gender,Visit Description,Collected Time,Accession,Test Group,Specimen,Organism,Growth,Cancellation Reason,Test Description,Test Result,Drug Name/Agent,MIC Result,Units,MIC Interpretation,Disk Diffusion Result,Disk Diffusion Interpretation,Subject Data Revision,Visit Data Revision,Result Data Revision +CZ100132001 - null,,,,Male,SCRNSTOOL Stool Pathogens,"Feb 26, 2026 10:35 AM",6227635149,STOOL CULTURE,Stool,,,,Final Report,No enteric pathogens isolated,,,,,,,,, +CZ100132002 - null,,,,Male,SCRNSTOOL Stool Pathogens,"Apr 1, 2026 8:30 AM",6227635148,STOOL CULTURE,Stool,,,,Final Report,No enteric pathogens isolated,,,,,,,,, +CZ100132003 - null,,,,Female,SCRNSTOOL Stool Pathogens,"May 7, 2026 5:45 AM",6227635150,STOOL CULTURE,Stool,,,,Final Report,No enteric pathogens isolated,,,,,,,,, diff --git a/Covance_UCO3001/Source/2026-06-08_130527 sponsor-study-36940-test-results-930539-microbiology.csv b/Covance_UCO3001/Source/2026-06-08_130527 sponsor-study-36940-test-results-930539-microbiology.csv new file mode 100644 index 0000000..ea00d13 --- /dev/null +++ b/Covance_UCO3001/Source/2026-06-08_130527 sponsor-study-36940-test-results-930539-microbiology.csv @@ -0,0 +1,5 @@ +"Disclaimer: The information presented in On-Screen Results is not intended to be a replacement of the official Lab Results, Alerts, Data Revisions and Cancellations found in the Lab Reports section of this software application. On-Screen Results should not be used for patient diagnosis, treatment decisions or submission to regulatory bodies.",,,,,,,,,,,,,,,,,,,,,,, +Subject,Screening Number,Age,Age Unit,Gender,Visit Description,Collected Time,Accession,Test Group,Specimen,Organism,Growth,Cancellation Reason,Test Description,Test Result,Drug Name/Agent,MIC Result,Units,MIC Interpretation,Disk Diffusion Result,Disk Diffusion Interpretation,Subject Data Revision,Visit Data Revision,Result Data Revision +CZ100162001 - null,,,,Male,SCRNSTOOL Stool Pathogens,"Apr 24, 2026 8:45 AM",6227635182,STOOL CULTURE,Stool,,,,Final Report,No enteric pathogens isolated,,,,,,,,, +CZ100162001 - null,,,,Male,SCRNSTOOL Stool Pathogens,"May 6, 2026 9:30 AM",6228610564,STOOL CULTURE,,,,Test group cancelled: No specimen received,,,,,,,,,,, +CZ100162002 - null,,,,Male,SCRNSTOOL Stool Pathogens,"May 27, 2026 1:15 PM",6227635180,STOOL CULTURE,Stool,,,,Final Report,No enteric pathogens isolated,,,,,,,,, diff --git a/Covance_UCO3001/Source/2026-06-08_130527 sponsor-study-36940-test-results-930539-standard.csv b/Covance_UCO3001/Source/2026-06-08_130527 sponsor-study-36940-test-results-930539-standard.csv new file mode 100644 index 0000000..1f30e6a --- /dev/null +++ b/Covance_UCO3001/Source/2026-06-08_130527 sponsor-study-36940-test-results-930539-standard.csv @@ -0,0 +1,180 @@ +"Disclaimer: The information presented in On-Screen Results is not intended to be a replacement of the official Lab Results, Alerts, Data Revisions and Cancellations found in the Lab Reports section of this software application. On-Screen Results should not be used for patient diagnosis, treatment decisions or submission to regulatory bodies.",,,,,,,,,,,,,,,,,,, +Subject,Subject Data Revision,Screen No.,Age,Age Unit,Gender,Visit,Visit Data Revision,Collected Time,Accession,Test Group,Test,Administrative Question,Value,Result Data Revision,Flags,Cancellation Reason,Comments,Range,Units +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,CHEMISTRY PANEL,Total Bilirubin,,5,,,,,3 - 21,umol/L +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,1.8,,,,,0 - 6.2,umol/L +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,CHEMISTRY PANEL,Alkaline Phosphatase,,50,,,,,40 - 129,U/L +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,CHEMISTRY PANEL,ALT (SGPT),,8,,,,,5 - 48,U/L +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,CHEMISTRY PANEL,AST (SGOT),,10,,,,,8 - 40,U/L +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,CHEMISTRY PANEL,GGT,,15,,,,,10 - 61,U/L +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,CHEMISTRY PANEL,LDH,,167,,,,,53 - 234,U/L +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,CHEMISTRY PANEL,Urea Nitrogen,,4.9,,,,,1.4 - 8.6,mmol/L +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,91,,,,,40 - 110,umol/L +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,CHEMISTRY PANEL,Serum Glucose,,5.7,R,H,,,3.9 - 5.6,mmol/L +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,CHEMISTRY PANEL,Serum Uric Acid,,239,,,,,125 - 488,umol/L +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,CHEMISTRY PANEL,Calcium (EDTA),,2.22,,,,,2.07 - 2.64,mmol/L +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,CHEMISTRY PANEL,Phosphorus,,0.91,,,,,0.71 - 1.65,mmol/L +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,CHEMISTRY PANEL,Total Protein,,60,R,L,,,61 - 84,g/L +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,CHEMISTRY PANEL,Albumin-BCG,,35,,,,,33 - 49,g/L +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,CHEMISTRY PANEL,Creatine Kinase,,<18,R,L,,Result verified by repeat analysis,39 - 308,U/L +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,CHEMISTRY PANEL,Serum Sodium,,140,,,,,132 - 147,mmol/L +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,CHEMISTRY PANEL,Serum Potassium,,3.8,,,,,3.5 - 5.2,mmol/L +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,CHEMISTRY PANEL,Serum Bicarbonate,,26.1,,,,,19.3 - 29.3,mmol/L +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,CHEMISTRY PANEL,Serum Chloride,,102,,,,,94 - 112,mmol/L +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,CHEMISTRY PANEL,Magnesium,,0.88,,,,,0.66 - 1.07,mmol/L +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,90,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,FECAL COLLECTION D/T,Stool Collection Date,Y,28-May-2026,,,,,, +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,FECAL COLLECTION D/T,Stool Collection Time,Y,06:00,,,,,, +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,118,R,L,,,127 - 181,g/L +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.37,R,L,,,0.39 - 0.54, +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.0,R,L,,,4.5 - 6.4,TI/L +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,29,,,,,26 - 34,pg +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,92,,,,,79 - 96,fL +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,12.78,R,H,,,3.8 - 10.7,GI/L +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,9.55,R,H,,,1.96 - 7.23,GI/L +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.58,,,,,0.91 - 4.28,GI/L +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.46,,,,,0.12 - 0.92,GI/L +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.12,,,,,0 - 0.57,GI/L +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.06,,,,,0 - 0.2,GI/L +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,74.8,,,,,40.5 - 75,% +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,20.3,,,,,15.4 - 48.5,% +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,3.6,,,,,2.6 - 10.1,% +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.0,,,,,0 - 6.8,% +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.4,,,,,0 - 2,% +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,371,,,,,140 - 400,GI/L +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,LIPID PANEL,Direct HDL-C 4th Generation,,1.18,,,,,1.03 - 1.53,mmol/L +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,LIPID PANEL,Triglycerides (GPO),,1.61,,,,,0.62 - 3.69,mmol/L +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,LIPID PANEL,Cholesterol (High Performance),,4.55,,,,,4.19 - 7.24,mmol/L +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,LIPID PANEL,LDL Chol Friedewald 4th,,2.63,,,,,0 - 3.34,mmol/L +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,SM01/PLASMA PK TROUGH COLL D/T,Collection Date Predose,Y,28-May-2026,,,,,, +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,SM01/PLASMA PK TROUGH COLL D/T,Collection Time Predose,Y,10:45,,,,,, +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,SM02/PLASMA PK PEAK COLL D/T,Collection Date Post dose,Y,28-May-2026,,,,,, +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,SM02/PLASMA PK PEAK COLL D/T,Post Dose Collection Time,Y,11:53,,,,,, +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,SM04/SERUM ADA PRE COLL D/T,Collection Date Predose,Y,28-May-2026,,,,,, +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,SM04/SERUM ADA PRE COLL D/T,Collection Time Predose,Y,10:45,,,,,, +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,SM10/FECAL BMRKS COLL D/T,Stool Collection Date,Y,28-May-2026,,,,,, +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,SM10/FECAL BMRKS COLL D/T,Stool Collection Time,Y,06:00,,,,,, +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,SUBJECT HEIGHT (CM),Height (cm),Y,N/A (subject >/= 18 years of age),,,,,cm, +CZ100162002,,,,,Male,Stool Pathogens,,"May 27, 2026 1:15 PM",6227635180,C. DIFF EIA,"C. diff GDH Ag,stool-CL",,Negative,,,,,Ref Rng:Negative, +CZ100162002,,,,,Male,Stool Pathogens,,"May 27, 2026 1:15 PM",6227635180,C. DIFF EIA,"C.diff Toxin A&B,stool-CL",,Negative,,,,,Ref Rng:Negative, +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,CHEMISTRY PANEL,Total Bilirubin,,6,,,,,3 - 21,umol/L +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,1.7,,,,,0 - 6.2,umol/L +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,CHEMISTRY PANEL,Alkaline Phosphatase,,105,,,,,40 - 129,U/L +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,CHEMISTRY PANEL,ALT (SGPT),,17,,,,,5 - 48,U/L +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,CHEMISTRY PANEL,AST (SGOT),,18,,,,,8 - 40,U/L +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,CHEMISTRY PANEL,GGT,,14,,,,,10 - 61,U/L +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,CHEMISTRY PANEL,LDH,,194,,,,,53 - 234,U/L +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,CHEMISTRY PANEL,Urea Nitrogen,,5.4,,,,,1.4 - 8.6,mmol/L +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,69,,,,,40 - 110,umol/L +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,CHEMISTRY PANEL,Serum Glucose,,5.9,,H,,,3.9 - 5.6,mmol/L +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,CHEMISTRY PANEL,Serum Uric Acid,,242,,,,,125 - 488,umol/L +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,CHEMISTRY PANEL,Calcium (EDTA),,2.39,,,,,2.07 - 2.64,mmol/L +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,CHEMISTRY PANEL,Phosphorus,,0.82,,,,,0.71 - 1.65,mmol/L +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,CHEMISTRY PANEL,Total Protein,,70,,,,,61 - 84,g/L +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,CHEMISTRY PANEL,Albumin-BCG,,47,,,,,33 - 49,g/L +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,CHEMISTRY PANEL,Creatine Kinase,,67,,,,,39 - 308,U/L +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,CHEMISTRY PANEL,Serum Sodium,,139,,,,,132 - 147,mmol/L +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,CHEMISTRY PANEL,Serum Potassium,,4.7,,,,,3.5 - 5.2,mmol/L +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,CHEMISTRY PANEL,Serum Bicarbonate,,23.9,,,,,19.3 - 29.3,mmol/L +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,CHEMISTRY PANEL,Serum Chloride,,101,,,,,94 - 112,mmol/L +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,CHEMISTRY PANEL,Magnesium,,0.89,,,,,0.66 - 1.07,mmol/L +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,117,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,HBV ELIGIBILITY MET?,HBV Eligibility Criteria Met?,,Yes,,,,,, +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,140,,,,,127 - 181,g/L +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.42,,,,,0.39 - 0.54, +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.6,,,,,4.5 - 6.4,TI/L +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,30,,,,,26 - 34,pg +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,91,,,,,79 - 96,fL +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,6.92,,,,,3.8 - 10.7,GI/L +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,5.54,,,,,1.96 - 7.23,GI/L +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.14,,,,,0.91 - 4.28,GI/L +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.20,,,,,0.12 - 0.92,GI/L +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.03,,,,,0 - 0.57,GI/L +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.02,,,,,0 - 0.2,GI/L +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,80.1,,H,,,40.5 - 75,% +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,16.5,,,,,15.4 - 48.5,% +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,2.8,,,,,2.6 - 10.1,% +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,0.4,,,,,0 - 6.8,% +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.2,,,,,0 - 2,% +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,363,,,,,140 - 400,GI/L +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,HEPATITIS B CORE AB NON-US,Hepatitis B Core Total,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,HEPATITIS B SURFACE AB,Anti-HBs II QUAL,,Non-Reactive,,,,,Ref Rng :$Non Reactive, +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,HEPATITIS B SURFACE AG NON-US,Hep B Surface AgII,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,HEPATITIS C VIRUS AB NON-US,Hepatitis C Virus Antibody,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,HIV 1/2 AG/AB SCREEN,anti-HIV-1/2 antibodies,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,HIV 1/2 AG/AB SCREEN,HIV -1 p24 antigen,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,HIV 1/2 AG/AB SCREEN,"HIV 1/2 Ag/Ab Screen, Cobas",,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,QUANTIFERON GOLD MITOGEN/INTER,"QFT,TBGoldPlusInt,pl-4-Tubes",,Negative,,,,,Normal=Negative, +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,SUBJECT HEIGHT (CM),Height (cm),Y,N/A (subject >/= 18 years of age),,,,,cm, +CZ100162001,,,,,Male,Biopsy,,"May 19, 2026 12:00 AM",6227635193,ANATOMICAL SITE,Anatomical Site,Y,15-20cm from anal verge,,,,,, +CZ100162001,,,,,Male,Biopsy,,"May 19, 2026 12:00 AM",6227635193,BIOPSY COLLECTION METHOD,Collection Method,Y,colonoscopy,,,,,, +CZ100162001,,,,,Male,Biopsy,,"May 19, 2026 12:00 AM",6227635193,BIOPSY FIXATIVE USED,Fixative Used,,10% NBF,,,,,, +CZ100162001,,,,,Male,Biopsy,,"May 19, 2026 12:00 AM",6227635193,DATE/TIME PLACED IN FORMALIN,Date Sample placed in Formalin,Y,19-May-2026,,,,,, +CZ100162001,,,,,Male,Biopsy,,"May 19, 2026 12:00 AM",6227635193,DATE/TIME PLACED IN FORMALIN,Time Sample placed in Formalin,Y,09:40,,,,,, +CZ100162001,,,,,Male,Biopsy,,"May 19, 2026 12:00 AM",6227635193,DIAGNOSIS,Diagnosis:,Y,Ulcerative Colitis,,,,,, +CZ100162001,,,,,Male,Biopsy,,"May 19, 2026 12:00 AM",6227635193,INFLAMED AREA,Inflamed area?,,Yes,,,,,, +CZ100162001,,,,,Male,Biopsy,,"May 19, 2026 12:00 AM",6227635193,TISSUE BIOPSY EMBEDDING1,Biopsy technical QC-CL,,Smpl meets HT requirements,,,,,, +CZ100162001,,,,,Male,Biopsy,,"May 19, 2026 12:00 AM",6227635193,TISSUE BIOPSY EMBEDDING1,Biopsy processing Time-CL,,12:00,,,,,, +CZ100162001,,,,,Male,Biopsy,,"May 19, 2026 12:00 AM",6227635193,TISSUE BIOPSY EMBEDDING1,Biopsy processing Date-CL,,21-May-2026,,,,,, +CZ100162001,,,,,Male,Biopsy,,"May 19, 2026 12:00 AM",6227635193,TISSUE BIOPSY EMBEDDING1,Biopsy Comments-CL,,Received in 10% NBF,,,,,, +CZ100162001,,,,,Male,Biopsy,,"May 19, 2026 12:00 AM",6227635193,TISSUE BIOPSY EMBEDDING1,# of Cassettes-(FI)-CL,,1,,,,,, +CZ100162001,,,,,Male,Biopsy,,"May 19, 2026 12:00 AM",6227635193,ULCERATED AREA,Is biopsy site ulcerated?,,Yes,,,,,, +CZ100162001,,,,,Male,Stool Pathogens,,"May 6, 2026 9:30 AM",6228610564,C. DIFF EIA,"C. diff GDH Ag,stool-CL",,Negative,,,,,Ref Rng:Negative, +CZ100162001,,,,,Male,Stool Pathogens,,"May 6, 2026 9:30 AM",6228610564,C. DIFF EIA,"C.diff Toxin A&B,stool-CL",,Negative,,,,,Ref Rng:Negative, +CZ100162001,,,,,Male,Stool Pathogens,,"Apr 24, 2026 8:45 AM",6227635182,C. DIFF EIA,"C. diff GDH Ag,stool-CL",,,,,,,, +CZ100162001,,,,,Male,Stool Pathogens,,"Apr 24, 2026 8:45 AM",6227635182,C. DIFF EIA,"C.diff Toxin A&B,stool-CL",,,,,,,, +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,CHEMISTRY PANEL,Total Bilirubin,,10,,,,,3 - 21,umol/L +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.8,,,,,0 - 6.2,umol/L +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,CHEMISTRY PANEL,Alkaline Phosphatase,,60,,,,,40 - 129,U/L +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,CHEMISTRY PANEL,ALT (SGPT),,11,,,,,5 - 48,U/L +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,CHEMISTRY PANEL,AST (SGOT),,16,,,,,8 - 40,U/L +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,CHEMISTRY PANEL,GGT,,18,,,,,10 - 61,U/L +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,CHEMISTRY PANEL,LDH,,186,,,,,53 - 234,U/L +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,CHEMISTRY PANEL,Urea Nitrogen,,6.8,,,,,1.4 - 8.6,mmol/L +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,96,,,,,40 - 110,umol/L +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,CHEMISTRY PANEL,Serum Glucose,,5.9,,H,,,3.9 - 5.6,mmol/L +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,CHEMISTRY PANEL,Serum Uric Acid,,233,,,,,125 - 488,umol/L +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,CHEMISTRY PANEL,Calcium (EDTA),,2.34,,,,,2.07 - 2.64,mmol/L +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,CHEMISTRY PANEL,Phosphorus,,0.76,,,,,0.71 - 1.65,mmol/L +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,CHEMISTRY PANEL,Total Protein,,69,,,,,61 - 84,g/L +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,CHEMISTRY PANEL,Albumin-BCG,,43,,,,,33 - 49,g/L +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,CHEMISTRY PANEL,Creatine Kinase,,36,R,L,,,39 - 308,U/L +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,CHEMISTRY PANEL,Serum Sodium,,139,,,,,132 - 147,mmol/L +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,CHEMISTRY PANEL,Serum Potassium,,4.2,,,,,3.5 - 5.2,mmol/L +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,CHEMISTRY PANEL,Serum Bicarbonate,,26.8,,,,,19.3 - 29.3,mmol/L +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,CHEMISTRY PANEL,Serum Chloride,,101,,,,,94 - 112,mmol/L +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,CHEMISTRY PANEL,Magnesium,,0.85,,,,,0.66 - 1.07,mmol/L +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,84,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,HBV ELIGIBILITY MET?,HBV Eligibility Criteria Met?,,Yes,,,,,, +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,154,,,,,127 - 181,g/L +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.45,,,,,0.39 - 0.54, +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.0,,,,,4.5 - 6.4,TI/L +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,31,,,,,26 - 34,pg +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,90,,,,,79 - 96,fL +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,13.56,,H,,,3.8 - 10.7,GI/L +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,11.03,,H,,,1.96 - 7.23,GI/L +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.38,,,,,0.91 - 4.28,GI/L +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.65,,,,,0.12 - 0.92,GI/L +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.36,,,,,0 - 0.57,GI/L +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.14,,,,,0 - 0.2,GI/L +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,81.3,,H,,,40.5 - 75,% +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,10.2,,L,,,15.4 - 48.5,% +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,4.8,,,,,2.6 - 10.1,% +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.7,,,,,0 - 6.8,% +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.0,,,,,0 - 2,% +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,233,,,,,140 - 400,GI/L +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,HEPATITIS B CORE AB NON-US,Hepatitis B Core Total,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,HEPATITIS B SURFACE AB,Anti-HBs II QUAL,,Non-Reactive,,,,,Ref Rng :$Non Reactive, +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,HEPATITIS B SURFACE AG NON-US,Hep B Surface AgII,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,HEPATITIS C VIRUS AB NON-US,Hepatitis C Virus Antibody,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,HIV 1/2 AG/AB SCREEN,anti-HIV-1/2 antibodies,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,HIV 1/2 AG/AB SCREEN,HIV -1 p24 antigen,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,HIV 1/2 AG/AB SCREEN,"HIV 1/2 Ag/Ab Screen, Cobas",,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,QUANTIFERON GOLD MITOGEN/INTER,"QFT,TBGoldPlusInt,pl-4-Tubes",,Negative,,,,,Normal=Negative, +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,SUBJECT HEIGHT (CM),Height (cm),Y,N/A (subject >/= 18 years of age),,,,,cm, diff --git a/Covance_UCO3001/Source/2026-06-08_130531 sponsor-study-36940-test-results-930557-microbiology.csv b/Covance_UCO3001/Source/2026-06-08_130531 sponsor-study-36940-test-results-930557-microbiology.csv new file mode 100644 index 0000000..2a3c953 --- /dev/null +++ b/Covance_UCO3001/Source/2026-06-08_130531 sponsor-study-36940-test-results-930557-microbiology.csv @@ -0,0 +1,7 @@ +"Disclaimer: The information presented in On-Screen Results is not intended to be a replacement of the official Lab Results, Alerts, Data Revisions and Cancellations found in the Lab Reports section of this software application. On-Screen Results should not be used for patient diagnosis, treatment decisions or submission to regulatory bodies.",,,,,,,,,,,,,,,,,,,,,,, +Subject,Screening Number,Age,Age Unit,Gender,Visit Description,Collected Time,Accession,Test Group,Specimen,Organism,Growth,Cancellation Reason,Test Description,Test Result,Drug Name/Agent,MIC Result,Units,MIC Interpretation,Disk Diffusion Result,Disk Diffusion Interpretation,Subject Data Revision,Visit Data Revision,Result Data Revision +CZ100012001 - null,,,,Male,SCRNSTOOL Stool Pathogens,"Jan 28, 2026 6:00 AM",6227323211,STOOL CULTURE,Stool,,,,Final Report,No enteric pathogens isolated,,,,,,,,R, +CZ100012001 - null,,,,Male,UNSCSTOOL Stool Pathogens,"Apr 22, 2026 7:00 AM",6228137359,STOOL CULTURE,Stool,,,,Final Report,No enteric pathogens isolated,,,,,,,,, +CZ100012002 - null,,,,Female,SCRNSTOOL Stool Pathogens,"Mar 3, 2026 1:00 PM",6227323212,STOOL CULTURE,Stool,,,,Final Report,No enteric pathogens isolated,,,,,,,,, +CZ100012003 - null,,,,Male,SCRNSTOOL Stool Pathogens,"Apr 29, 2026 7:55 AM",6227323213,STOOL CULTURE,Stool,,,,Final Report,No enteric pathogens isolated,,,,,,,,, +CZ100012004 - null,,,,Male,SCRNSTOOL Stool Pathogens,"Jun 2, 2026 6:00 PM",6228137357,STOOL CULTURE,,,,,,,,,,,,,,, diff --git a/Covance_UCO3001/Source/2026-06-08_130535 sponsor-study-36940-test-results-930557-standard.csv b/Covance_UCO3001/Source/2026-06-08_130535 sponsor-study-36940-test-results-930557-standard.csv new file mode 100644 index 0000000..d6a0044 --- /dev/null +++ b/Covance_UCO3001/Source/2026-06-08_130535 sponsor-study-36940-test-results-930557-standard.csv @@ -0,0 +1,740 @@ +"Disclaimer: The information presented in On-Screen Results is not intended to be a replacement of the official Lab Results, Alerts, Data Revisions and Cancellations found in the Lab Reports section of this software application. On-Screen Results should not be used for patient diagnosis, treatment decisions or submission to regulatory bodies.",,,,,,,,,,,,,,,,,,, +Subject,Subject Data Revision,Screen No.,Age,Age Unit,Gender,Visit,Visit Data Revision,Collected Time,Accession,Test Group,Test,Administrative Question,Value,Result Data Revision,Flags,Cancellation Reason,Comments,Range,Units +CZ100012004,,,,,Male,Stool Pathogens,,"Jun 2, 2026 6:00 PM",6228137357,C. DIFF EIA,"C. diff GDH Ag,stool-CL",,Negative,,,,,Ref Rng:Negative, +CZ100012004,,,,,Male,Stool Pathogens,,"Jun 2, 2026 6:00 PM",6228137357,C. DIFF EIA,"C.diff Toxin A&B,stool-CL",,Negative,,,,,Ref Rng:Negative, +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,CHEMISTRY PANEL,Total Bilirubin,,13,,,,,3 - 21,umol/L +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,4.0,,,,,0 - 6.2,umol/L +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,CHEMISTRY PANEL,Alkaline Phosphatase,,90,,,,,40 - 129,U/L +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,CHEMISTRY PANEL,ALT (SGPT),,27,,,,,5 - 48,U/L +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,CHEMISTRY PANEL,AST (SGOT),,35,,,,,8 - 40,U/L +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,CHEMISTRY PANEL,GGT,,63,R,H,,,10 - 61,U/L +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,CHEMISTRY PANEL,LDH,,167,,,,,53 - 234,U/L +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,CHEMISTRY PANEL,Urea Nitrogen,,7.1,,,,,1.4 - 8.6,mmol/L +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,95,,,,,40 - 110,umol/L +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,CHEMISTRY PANEL,Serum Glucose,,5.3,,,,,3.9 - 5.6,mmol/L +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,CHEMISTRY PANEL,Serum Uric Acid,,342,,,,,125 - 488,umol/L +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,CHEMISTRY PANEL,Calcium (EDTA),,2.56,,,,,2.07 - 2.64,mmol/L +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,CHEMISTRY PANEL,Phosphorus,,0.97,,,,,0.71 - 1.65,mmol/L +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,CHEMISTRY PANEL,Total Protein,,84,,,,,61 - 84,g/L +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,CHEMISTRY PANEL,Albumin-BCG,,43,,,,,33 - 49,g/L +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,CHEMISTRY PANEL,Creatine Kinase,,217,,,,,39 - 308,U/L +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,CHEMISTRY PANEL,Serum Sodium,,138,,,,,132 - 147,mmol/L +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,CHEMISTRY PANEL,Serum Potassium,,5.2,,,,,3.5 - 5.2,mmol/L +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,CHEMISTRY PANEL,Serum Bicarbonate,,20.1,,,,,19.3 - 29.3,mmol/L +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,CHEMISTRY PANEL,Serum Chloride,,101,,,,,94 - 112,mmol/L +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,CHEMISTRY PANEL,Magnesium,,0.85,,,,,0.66 - 1.07,mmol/L +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,86,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,HBV ELIGIBILITY MET?,HBV Eligibility Criteria Met?,,Yes,,,,,, +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,153,,,,,127 - 181,g/L +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.49,,,,,0.39 - 0.54, +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.4,,,,,4.5 - 6.4,TI/L +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,28,,,,,26 - 34,pg +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,89,,,,,79 - 96,fL +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,10.70,,,,,3.8 - 10.7,GI/L +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,6.42,,,,,1.96 - 7.23,GI/L +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,3.25,,,,,0.91 - 4.28,GI/L +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.75,,,,,0.12 - 0.92,GI/L +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.19,,,,,0 - 0.57,GI/L +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.10,,,,,0 - 0.2,GI/L +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,60.0,,,,,40.5 - 75,% +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,30.4,,,,,15.4 - 48.5,% +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,7.0,,,,,2.6 - 10.1,% +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.7,,,,,0 - 6.8,% +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.9,,,,,0 - 2,% +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,483,R,H,,,140 - 400,GI/L +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,HEPATITIS B CORE AB NON-US,Hepatitis B Core Total,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,HEPATITIS B SURFACE AB,Anti-HBs II QUAL,,Non-Reactive,,,,,Ref Rng :$Non Reactive, +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,HEPATITIS B SURFACE AG NON-US,Hep B Surface AgII,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,HEPATITIS C VIRUS AB NON-US,Hepatitis C Virus Antibody,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,HIV 1/2 AG/AB SCREEN,anti-HIV-1/2 antibodies,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,HIV 1/2 AG/AB SCREEN,HIV -1 p24 antigen,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,HIV 1/2 AG/AB SCREEN,"HIV 1/2 Ag/Ab Screen, Cobas",,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,QUANTIFERON GOLD MITOGEN/INTER,"QFT,TBGoldPlusInt,pl-4-Tubes",,Negative,,,,,Normal=Negative, +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,SUBJECT HEIGHT (CM),Height (cm),Y,178,,,,,cm, +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,CHEMISTRY PANEL,Total Bilirubin,,6,,,,,3 - 21,umol/L +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.0,,,,,0 - 6.2,umol/L +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,CHEMISTRY PANEL,Alkaline Phosphatase,,104,,,,,40 - 129,U/L +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,CHEMISTRY PANEL,ALT (SGPT),,15,,,,,5 - 48,U/L +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,CHEMISTRY PANEL,AST (SGOT),,17,,,,,8 - 40,U/L +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,CHEMISTRY PANEL,GGT,,16,,,,,10 - 61,U/L +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,CHEMISTRY PANEL,LDH,,165,,,,,53 - 234,U/L +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,CHEMISTRY PANEL,Urea Nitrogen,,6.4,,,,,1.4 - 8.6,mmol/L +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,91,,,,,40 - 119,umol/L +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,CHEMISTRY PANEL,Serum Glucose,,5.2,,,,,3.9 - 5.6,mmol/L +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,CHEMISTRY PANEL,Serum Uric Acid,,324,,,,,149 - 494,umol/L +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,CHEMISTRY PANEL,Calcium (EDTA),,2.38,,,,,2.07 - 2.64,mmol/L +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,CHEMISTRY PANEL,Phosphorus,,0.82,,,,,0.71 - 1.65,mmol/L +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,CHEMISTRY PANEL,Total Protein,,75,,,,,61 - 84,g/L +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,CHEMISTRY PANEL,Albumin-BCG,,46,,,,,33 - 49,g/L +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,CHEMISTRY PANEL,Creatine Kinase,,82,,,,,39 - 308,U/L +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,CHEMISTRY PANEL,Serum Sodium,,141,,,,,132 - 147,mmol/L +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,CHEMISTRY PANEL,Serum Potassium,,4.7,,,,,3.5 - 5.2,mmol/L +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,CHEMISTRY PANEL,Serum Bicarbonate,,20.6,,,,,19.3 - 29.3,mmol/L +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,CHEMISTRY PANEL,Serum Chloride,,105,,,,,94 - 112,mmol/L +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,CHEMISTRY PANEL,Magnesium,,0.84,,,,,0.66 - 1.07,mmol/L +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,87,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,FECAL COLLECTION D/T,Stool Collection Date,Y,26-May-2026,,,,,, +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,FECAL COLLECTION D/T,Stool Collection Time,Y,18:00,,,,,, +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,159,,,,,127 - 181,g/L +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.50,,,,,0.39 - 0.54, +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.4,,,,,4.5 - 6.4,TI/L +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,29,,,,,26 - 34,pg +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,92,,,,,79 - 96,fL +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,9.01,,,,,3.8 - 10.7,GI/L +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,7.04,,,,,1.96 - 7.23,GI/L +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.38,,,,,0.91 - 4.28,GI/L +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.44,,,,,0.12 - 0.92,GI/L +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.11,,,,,0 - 0.57,GI/L +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.04,,,,,0 - 0.2,GI/L +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,78.1,,H,,,40.5 - 75,% +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,15.3,,L,,,15.4 - 48.5,% +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,4.9,,,,,2.6 - 10.1,% +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.2,,,,,0 - 6.8,% +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.5,,,,,0 - 2,% +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,265,,,,,140 - 400,GI/L +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,LIPID PANEL,Direct HDL-C 4th Generation,,1.34,,,,,1.03 - 1.53,mmol/L +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,LIPID PANEL,Triglycerides (GPO),,0.65,,,,,0.65 - 3.61,mmol/L +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,LIPID PANEL,Cholesterol (High Performance),,4.32,,L,,,4.4 - 7.53,mmol/L +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,LIPID PANEL,LDL Chol Friedewald 4th,,2.68,,,,,0 - 3.34,mmol/L +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,SM01/PLASMA PK TROUGH COLL D/T,Collection Date Predose,Y,27-May-2026,,,,,, +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,SM01/PLASMA PK TROUGH COLL D/T,Collection Time Predose,Y,07:25,,,,,, +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,SM02/PLASMA PK PEAK COLL D/T,Collection Date Post dose,Y,27-May-2026,,,,,, +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,SM02/PLASMA PK PEAK COLL D/T,Post Dose Collection Time,Y,08:30,,,,,, +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,SM04/SERUM ADA PRE COLL D/T,Collection Date Predose,Y,27-May-2026,,,,,, +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,SM04/SERUM ADA PRE COLL D/T,Collection Time Predose,Y,07:25,,,,,, +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,SM10/FECAL BMRKS COLL D/T,Stool Collection Date,Y,26-May-2026,,,,,, +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,SM10/FECAL BMRKS COLL D/T,Stool Collection Time,Y,18:00,,,,,, +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,SUBJECT HEIGHT (CM),Height (cm),Y,175,,,,,cm, +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,ALP<2XULN,ALP<2XULN,,Criteria Met,,,,,, +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,ALT>/=3XULN,ALT >/= 3 X ULN,,Criteria not met,,,,,, +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,ALT>/=3XULN & TBIL>/=2XULN,ALT >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,AST>/=3XULN,AST >/= 3 X ULN,,Criteria not met,,,,,, +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,AST>/=3XULN & TBIL>/=2XULN,AST >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,CHEMISTRY PANEL,Total Bilirubin,,7,,,,,3 - 21,umol/L +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.8,,,,,0 - 6.2,umol/L +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,CHEMISTRY PANEL,Alkaline Phosphatase,,62,,,,,40 - 129,U/L +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,CHEMISTRY PANEL,ALT (SGPT),,46,,,,,5 - 48,U/L +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,CHEMISTRY PANEL,AST (SGOT),,23,,,,,8 - 40,U/L +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,CHEMISTRY PANEL,GGT,,30,,,,,10 - 61,U/L +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,CHEMISTRY PANEL,LDH,,238,,H,,,53 - 234,U/L +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,CHEMISTRY PANEL,Urea Nitrogen,,4.4,,,,,1.4 - 8.6,mmol/L +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,84,,,,,40 - 110,umol/L +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,CHEMISTRY PANEL,Serum Glucose,,4.6,,,,,3.9 - 5.6,mmol/L +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,CHEMISTRY PANEL,Serum Uric Acid,,328,,,,,125 - 488,umol/L +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,CHEMISTRY PANEL,Calcium (EDTA),,2.43,,,,,2.07 - 2.64,mmol/L +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,CHEMISTRY PANEL,Phosphorus,,1.26,,,,,0.71 - 1.65,mmol/L +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,CHEMISTRY PANEL,Total Protein,,67,,,,,61 - 84,g/L +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,CHEMISTRY PANEL,Albumin-BCG,,42,,,,,33 - 49,g/L +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,CHEMISTRY PANEL,Creatine Kinase,,96,,,,,39 - 308,U/L +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,CHEMISTRY PANEL,Serum Sodium,,140,,,,,132 - 147,mmol/L +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,CHEMISTRY PANEL,Serum Potassium,,4.2,,,,,3.5 - 5.2,mmol/L +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,CHEMISTRY PANEL,Serum Bicarbonate,,25.1,,,,,19.3 - 29.3,mmol/L +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,CHEMISTRY PANEL,Serum Chloride,,102,,,,,94 - 112,mmol/L +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,CHEMISTRY PANEL,Magnesium,,0.87,,,,,0.66 - 1.07,mmol/L +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,99,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,FECAL COLLECTION D/T,Stool Collection Date,Y,12-May-2026,,,,,, +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,FECAL COLLECTION D/T,Stool Collection Time,Y,18:00,,,,,, +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,142,,,,,127 - 181,g/L +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.42,,,,,0.39 - 0.54, +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.8,,,,,4.5 - 6.4,TI/L +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,30,,,,,26 - 34,pg +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,87,,,,,79 - 96,fL +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,8.67,,,,,3.8 - 10.7,GI/L +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,5.93,,,,,1.96 - 7.23,GI/L +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.10,,,,,0.91 - 4.28,GI/L +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.49,,,,,0.12 - 0.92,GI/L +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.11,,,,,0 - 0.57,GI/L +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.04,,,,,0 - 0.2,GI/L +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,68.4,,,,,40.5 - 75,% +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,24.3,,,,,15.4 - 48.5,% +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.7,,,,,2.6 - 10.1,% +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.3,,,,,0 - 6.8,% +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.4,,,,,0 - 2,% +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,343,,,,,140 - 400,GI/L +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,LIPID PANEL,Direct HDL-C 4th Generation,,2.02,,H,,,1.03 - 1.53,mmol/L +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,LIPID PANEL,Triglycerides (GPO),,1.21,,,,,0.62 - 3.69,mmol/L +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,LIPID PANEL,Cholesterol (High Performance),,5.32,,,,,4.19 - 7.24,mmol/L +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,LIPID PANEL,LDL Chol Friedewald 4th,,2.75,,,,,0 - 3.34,mmol/L +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,SM01/PLASMA PK TROUGH COLL D/T,Collection Date Predose,Y,13-May-2026,,,,,, +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,SM01/PLASMA PK TROUGH COLL D/T,Collection Time Predose,Y,08:05,,,,,, +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,SM02/PLASMA PK PEAK COLL D/T,Collection Date Post dose,Y,13-May-2026,,,,,, +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,SM02/PLASMA PK PEAK COLL D/T,Post Dose Collection Time,Y,09:30,,,,,, +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,SM04/SERUM ADA PRE COLL D/T,Collection Date Predose,Y,13-May-2026,,,,,, +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,SM04/SERUM ADA PRE COLL D/T,Collection Time Predose,Y,08:05,,,,,, +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,SM09/STOOL PK COLL D/T,Stool Collection Date,Y,12-May-2026,,,,,, +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,SM09/STOOL PK COLL D/T,Stool Collection Time,Y,18:00,,,,,, +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,SM10/FECAL BMRKS COLL D/T,Stool Collection Date,Y,12-May-2026,,,,,, +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,SM10/FECAL BMRKS COLL D/T,Stool Collection Time,Y,18:00,,,,,, +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,SUBJECT HEIGHT (CM),Height (cm),Y,N/A (subject >/= 18 years of age),,,,,cm, +CZ100012003,,,,,Male,Biopsy,R,"May 13, 2026 12:00 AM",6228252073,ANATOMICAL SITE,Anatomical Site,Y,30,,,,,, +CZ100012003,,,,,Male,Biopsy,R,"May 13, 2026 12:00 AM",6228252073,BIOPSY COLLECTION METHOD,Collection Method,Y,colonoscopy,,,,,, +CZ100012003,,,,,Male,Biopsy,R,"May 13, 2026 12:00 AM",6228252073,BIOPSY FIXATIVE USED,Fixative Used,,10% NBF,,,,,, +CZ100012003,,,,,Male,Biopsy,R,"May 13, 2026 12:00 AM",6228252073,DATE/TIME PLACED IN FORMALIN,Date Sample placed in Formalin,Y,13-May-2026,,,,,, +CZ100012003,,,,,Male,Biopsy,R,"May 13, 2026 12:00 AM",6228252073,DATE/TIME PLACED IN FORMALIN,Time Sample placed in Formalin,Y,09:00,,,,,, +CZ100012003,,,,,Male,Biopsy,R,"May 13, 2026 12:00 AM",6228252073,DIAGNOSIS,Diagnosis:,Y,Ulcerative Colitis,,,,,, +CZ100012003,,,,,Male,Biopsy,R,"May 13, 2026 12:00 AM",6228252073,INFLAMED AREA,Inflamed area?,,Yes,,,,,, +CZ100012003,,,,,Male,Biopsy,R,"May 13, 2026 12:00 AM",6228252073,TISSUE BIOPSY EMBEDDING1,Biopsy technical QC-CL,,Smpl meets HT requirements,,,,,, +CZ100012003,,,,,Male,Biopsy,R,"May 13, 2026 12:00 AM",6228252073,TISSUE BIOPSY EMBEDDING1,Biopsy processing Time-CL,,10:00,,,,,, +CZ100012003,,,,,Male,Biopsy,R,"May 13, 2026 12:00 AM",6228252073,TISSUE BIOPSY EMBEDDING1,Biopsy processing Date-CL,,15-May-2026,,,,,, +CZ100012003,,,,,Male,Biopsy,R,"May 13, 2026 12:00 AM",6228252073,TISSUE BIOPSY EMBEDDING1,Biopsy Comments-CL,,Received in 10% NBF,,,,,, +CZ100012003,,,,,Male,Biopsy,R,"May 13, 2026 12:00 AM",6228252073,TISSUE BIOPSY EMBEDDING1,# of Cassettes-(FI)-CL,,1,,,,,, +CZ100012003,,,,,Male,Biopsy,R,"May 13, 2026 12:00 AM",6228252073,ULCERATED AREA,Is biopsy site ulcerated?,,Yes,,,,,, +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,ALP<2XULN,ALP<2XULN,,Criteria Met,,,,,, +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,ALT>/=3XULN,ALT >/= 3 X ULN,,Criteria not met,,,,,, +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,ALT>/=3XULN & TBIL>/=2XULN,ALT >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,AST>/=3XULN,AST >/= 3 X ULN,,Criteria not met,,,,,, +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,AST>/=3XULN & TBIL>/=2XULN,AST >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,CHEMISTRY PANEL,Total Bilirubin,,11,,,,,3 - 21,umol/L +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.5,,,,,0 - 6.2,umol/L +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,CHEMISTRY PANEL,Alkaline Phosphatase,,99,,,,,35 - 104,U/L +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,CHEMISTRY PANEL,ALT (SGPT),,18,,,,,4 - 43,U/L +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,CHEMISTRY PANEL,AST (SGOT),,29,,,,,8 - 40,U/L +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,CHEMISTRY PANEL,GGT,,23,,,,,5 - 50,U/L +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,CHEMISTRY PANEL,LDH,,181,,,,,53 - 234,U/L +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,CHEMISTRY PANEL,Urea Nitrogen,,5.3,,,,,1.4 - 10.4,mmol/L +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,54,,,,,31 - 110,umol/L +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,CHEMISTRY PANEL,Serum Glucose,,6.0,,H,,,3.9 - 5.6,mmol/L +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,CHEMISTRY PANEL,Serum Uric Acid,,293,,,,,149 - 446,umol/L +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,CHEMISTRY PANEL,Calcium (EDTA),,2.53,,,,,2.07 - 2.64,mmol/L +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,CHEMISTRY PANEL,Phosphorus,,1.19,,,,,0.71 - 1.65,mmol/L +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,CHEMISTRY PANEL,Total Protein,,79,,,,,60 - 80,g/L +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,CHEMISTRY PANEL,Albumin-BCG,,46,,,,,33 - 46,g/L +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,CHEMISTRY PANEL,Creatine Kinase,,143,,,,,26 - 192,U/L +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,CHEMISTRY PANEL,Serum Sodium,,141,,,,,135 - 145,mmol/L +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,CHEMISTRY PANEL,Serum Potassium,,4.6,,,,,3.5 - 5.2,mmol/L +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,CHEMISTRY PANEL,Serum Bicarbonate,,22.3,,,,,19.3 - 29.3,mmol/L +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,CHEMISTRY PANEL,Serum Chloride,,103,,,,,94 - 112,mmol/L +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,CHEMISTRY PANEL,Magnesium,,0.91,,,,,0.66 - 0.98,mmol/L +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,91,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,FECAL COLLECTION D/T,Stool Collection Date,Y,05-May-2026,,,,,, +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,FECAL COLLECTION D/T,Stool Collection Time,Y,18:00,,,,,, +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,145,,,,,115 - 158,g/L +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.44,,,,,0.34 - 0.48, +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.0,,,,,3.9 - 5.5,TI/L +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,29,,,,,26 - 34,pg +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,88,,,,,80 - 100,fL +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,4.54,,,,,3.8 - 10.7,GI/L +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.11,,,,,1.96 - 7.23,GI/L +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.15,,,,,0.8 - 3,GI/L +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.23,,,,,0.12 - 0.92,GI/L +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.02,,,,,0 - 0.57,GI/L +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.02,,,,,0 - 0.2,GI/L +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,46.5,,,,,40.5 - 75,% +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,47.4,,,,,15.4 - 48.5,% +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.1,,,,,2.6 - 10.1,% +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,0.5,,,,,0 - 6.8,% +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.5,,,,,0 - 2,% +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,117,R,L,,,130 - 394,GI/L +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,SM01/PLASMA PK TROUGH COLL D/T,Collection Date Predose,Y,06-May-2026,,,,,, +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,SM01/PLASMA PK TROUGH COLL D/T,Collection Time Predose,Y,08:05,,,,,, +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,SM02/PLASMA PK PEAK COLL D/T,Collection Date Post dose,Y,06-May-2026,,,,,, +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,SM02/PLASMA PK PEAK COLL D/T,Post Dose Collection Time,Y,09:05,,,,,, +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,SM04/SERUM ADA PRE COLL D/T,Collection Date Predose,Y,06-May-2026,,,,,, +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,SM04/SERUM ADA PRE COLL D/T,Collection Time Predose,Y,08:05,,,,,, +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,SM09/STOOL PK COLL D/T,Stool Collection Date,Y,05-May-2026,,,,,, +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,SM09/STOOL PK COLL D/T,Stool Collection Time,Y,18:00,,,,,, +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,SUBJECT HEIGHT (CM),Height (cm),Y,N/A (subject >/= 18 years of age),,,,,cm, +CZ100012001,,,,,Male,Biopsy,,"May 6, 2026 12:00 AM",6228252072,ANATOMICAL SITE,Anatomical Site,Y,15-20cm from anal verge,,,,,, +CZ100012001,,,,,Male,Biopsy,,"May 6, 2026 12:00 AM",6228252072,BIOPSY COLLECTION METHOD,Collection Method,Y,colonoscopy,,,,,, +CZ100012001,,,,,Male,Biopsy,,"May 6, 2026 12:00 AM",6228252072,BIOPSY FIXATIVE USED,Fixative Used,,10% NBF,,,,,, +CZ100012001,,,,,Male,Biopsy,,"May 6, 2026 12:00 AM",6228252072,DATE/TIME PLACED IN FORMALIN,Date Sample placed in Formalin,Y,06-May-2026,,,,,, +CZ100012001,,,,,Male,Biopsy,,"May 6, 2026 12:00 AM",6228252072,DATE/TIME PLACED IN FORMALIN,Time Sample placed in Formalin,Y,07:20,,,,,, +CZ100012001,,,,,Male,Biopsy,,"May 6, 2026 12:00 AM",6228252072,DIAGNOSIS,Diagnosis:,Y,Ulcerative Colitis,,,,,, +CZ100012001,,,,,Male,Biopsy,,"May 6, 2026 12:00 AM",6228252072,INFLAMED AREA,Inflamed area?,,Yes,,,,,, +CZ100012001,,,,,Male,Biopsy,,"May 6, 2026 12:00 AM",6228252072,TISSUE BIOPSY EMBEDDING1,Biopsy technical QC-CL,,Smpl meets HT requirements,,,,,, +CZ100012001,,,,,Male,Biopsy,,"May 6, 2026 12:00 AM",6228252072,TISSUE BIOPSY EMBEDDING1,Biopsy processing Time-CL,,10:00,,,,,, +CZ100012001,,,,,Male,Biopsy,,"May 6, 2026 12:00 AM",6228252072,TISSUE BIOPSY EMBEDDING1,Biopsy processing Date-CL,,08-May-2026,,,,,, +CZ100012001,,,,,Male,Biopsy,,"May 6, 2026 12:00 AM",6228252072,TISSUE BIOPSY EMBEDDING1,Biopsy Comments-CL,,Received in 10% NBF,,,,,, +CZ100012001,,,,,Male,Biopsy,,"May 6, 2026 12:00 AM",6228252072,TISSUE BIOPSY EMBEDDING1,# of Cassettes-(FI)-CL,,1,,,,,, +CZ100012001,,,,,Male,Biopsy,,"May 6, 2026 12:00 AM",6228252072,ULCERATED AREA,Is biopsy site ulcerated?,,No,,,,,, +CZ100012003,,,,,Male,Stool Pathogens,,"Apr 29, 2026 7:55 AM",6227323213,C. DIFF EIA,"C. diff GDH Ag,stool-CL",,Negative,,,,,Ref Rng:Negative, +CZ100012003,,,,,Male,Stool Pathogens,,"Apr 29, 2026 7:55 AM",6227323213,C. DIFF EIA,"C.diff Toxin A&B,stool-CL",,Negative,,,,,Ref Rng:Negative, +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,CHEMISTRY PANEL,Total Bilirubin,,8,,,,,3 - 21,umol/L +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.0,,,,,0 - 6.2,umol/L +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,CHEMISTRY PANEL,Alkaline Phosphatase,,115,,,,,40 - 129,U/L +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,CHEMISTRY PANEL,ALT (SGPT),,22,,,,,5 - 48,U/L +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,CHEMISTRY PANEL,AST (SGOT),,21,,,,,8 - 40,U/L +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,CHEMISTRY PANEL,GGT,,15,,,,,10 - 61,U/L +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,CHEMISTRY PANEL,LDH,,151,,,,,53 - 234,U/L +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,CHEMISTRY PANEL,Urea Nitrogen,,5.4,,,,,1.4 - 8.6,mmol/L +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,88,,,,,40 - 119,umol/L +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,CHEMISTRY PANEL,Serum Glucose,,5.4,,,,,3.9 - 5.6,mmol/L +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,CHEMISTRY PANEL,Serum Uric Acid,,306,,,,,149 - 494,umol/L +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,CHEMISTRY PANEL,Calcium (EDTA),,2.39,,,,,2.07 - 2.64,mmol/L +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,CHEMISTRY PANEL,Phosphorus,,0.90,,,,,0.71 - 1.65,mmol/L +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,CHEMISTRY PANEL,Total Protein,,75,,,,,61 - 84,g/L +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,CHEMISTRY PANEL,Albumin-BCG,,47,,,,,33 - 49,g/L +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,CHEMISTRY PANEL,Creatine Kinase,,100,,,,,39 - 308,U/L +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,CHEMISTRY PANEL,Serum Sodium,,138,,,,,132 - 147,mmol/L +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,CHEMISTRY PANEL,Serum Potassium,,4.8,,,,,3.5 - 5.2,mmol/L +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,CHEMISTRY PANEL,Serum Bicarbonate,,21.5,,,,,19.3 - 29.3,mmol/L +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,CHEMISTRY PANEL,Serum Chloride,,101,,,,,94 - 112,mmol/L +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,CHEMISTRY PANEL,Magnesium,,0.90,,,,,0.66 - 1.07,mmol/L +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,91,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,HBV ELIGIBILITY MET?,HBV Eligibility Criteria Met?,,Yes,,,,,, +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,161,,,,,127 - 181,g/L +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.49,,,,,0.39 - 0.54, +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.5,,,,,4.5 - 6.4,TI/L +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,30,,,,,26 - 34,pg +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,89,,,,,79 - 96,fL +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,7.61,,,,,3.8 - 10.7,GI/L +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,5.63,,,,,1.96 - 7.23,GI/L +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.42,,,,,0.91 - 4.28,GI/L +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.38,,,,,0.12 - 0.92,GI/L +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.13,,,,,0 - 0.57,GI/L +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.04,,,,,0 - 0.2,GI/L +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,74.0,,,,,40.5 - 75,% +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,18.7,,,,,15.4 - 48.5,% +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.0,,,,,2.6 - 10.1,% +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.7,,,,,0 - 6.8,% +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.5,,,,,0 - 2,% +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,242,,,,,140 - 400,GI/L +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,HEPATITIS B CORE AB NON-US,Hepatitis B Core Total,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,HEPATITIS B SURFACE AB,Anti-HBs II QUAL,,Non-Reactive,,,,,Ref Rng :$Non Reactive, +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,HEPATITIS B SURFACE AG NON-US,Hep B Surface AgII,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,HEPATITIS C VIRUS AB NON-US,Hepatitis C Virus Antibody,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,HIV 1/2 AG/AB SCREEN,anti-HIV-1/2 antibodies,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,HIV 1/2 AG/AB SCREEN,HIV -1 p24 antigen,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,HIV 1/2 AG/AB SCREEN,"HIV 1/2 Ag/Ab Screen, Cobas",,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,QUANTIFERON GOLD MITOGEN/INTER,"QFT,TBGoldPlusInt,pl-4-Tubes",,Negative,,,,,Normal=Negative, +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,SUBJECT HEIGHT (CM),Height (cm),Y,175,,,,,cm, +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,ALP<2XULN,ALP<2XULN,,Criteria Met,,,,,, +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,ALT>/=3XULN,ALT >/= 3 X ULN,,Criteria not met,,,,,, +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,ALT>/=3XULN & TBIL>/=2XULN,ALT >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,AST>/=3XULN,AST >/= 3 X ULN,,Criteria not met,,,,,, +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,AST>/=3XULN & TBIL>/=2XULN,AST >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,CHEMISTRY PANEL,Total Bilirubin,,14,,,,,3 - 21,umol/L +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,4.5,,,,,0 - 6.2,umol/L +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,CHEMISTRY PANEL,Alkaline Phosphatase,,102,,,,,35 - 104,U/L +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,CHEMISTRY PANEL,ALT (SGPT),,17,,,,,4 - 43,U/L +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,CHEMISTRY PANEL,AST (SGOT),,25,,,,,8 - 40,U/L +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,CHEMISTRY PANEL,GGT,,23,,,,,5 - 50,U/L +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,CHEMISTRY PANEL,LDH,,154,,,,,53 - 234,U/L +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,CHEMISTRY PANEL,Urea Nitrogen,,4.3,,,,,1.4 - 10.4,mmol/L +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,53,,,,,31 - 110,umol/L +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,CHEMISTRY PANEL,Serum Glucose,,6.3,,H,,,3.9 - 5.6,mmol/L +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,CHEMISTRY PANEL,Serum Uric Acid,,252,,,,,149 - 446,umol/L +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,CHEMISTRY PANEL,Calcium (EDTA),,2.50,,,,,2.07 - 2.64,mmol/L +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,CHEMISTRY PANEL,Phosphorus,,1.16,,,,,0.71 - 1.65,mmol/L +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,CHEMISTRY PANEL,Total Protein,,76,,,,,60 - 80,g/L +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,CHEMISTRY PANEL,Albumin-BCG,,45,,,,,33 - 46,g/L +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,CHEMISTRY PANEL,Creatine Kinase,,83,,,,,26 - 192,U/L +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,CHEMISTRY PANEL,Serum Sodium,,140,,,,,135 - 145,mmol/L +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,CHEMISTRY PANEL,Serum Potassium,,4.1,,,,,3.5 - 5.2,mmol/L +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,CHEMISTRY PANEL,Serum Bicarbonate,,23.8,,,,,19.3 - 29.3,mmol/L +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,CHEMISTRY PANEL,Serum Chloride,,104,,,,,94 - 112,mmol/L +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,CHEMISTRY PANEL,Magnesium,,0.94,,,,,0.66 - 0.98,mmol/L +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,91,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,FECAL COLLECTION D/T,Stool Collection Date,Y,23-Apr-2026,,,,,, +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,FECAL COLLECTION D/T,Stool Collection Time,Y,07:40,,,,,, +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,144,,,,Result verified by repeat analysis,115 - 158,g/L +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.43,,,,,0.34 - 0.48, +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.0,,,,Result verified by repeat analysis,3.9 - 5.5,TI/L +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,29,,,,Result verified by repeat analysis,26 - 34,pg +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,86,,,,,80 - 100,fL +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,3.47,,L,,Result verified by repeat analysis,3.8 - 10.7,GI/L +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,1.78,,L,,Result verified by repeat analysis,1.96 - 7.23,GI/L +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.46,,,,,0.8 - 3,GI/L +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.16,,,,Result verified by repeat analysis,0.12 - 0.92,GI/L +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.04,,,,Result verified by repeat analysis,0 - 0.57,GI/L +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.03,,,,Result verified by repeat analysis,0 - 0.2,GI/L +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,51.4,,,,Result verified by repeat analysis,40.5 - 75,% +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,42.2,,,,Result verified by repeat analysis,15.4 - 48.5,% +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,4.5,,,,Result verified by repeat analysis,2.6 - 10.1,% +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.0,,,,Result verified by repeat analysis,0 - 6.8,% +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.9,,,,Result verified by repeat analysis,0 - 2,% +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,118,,L,,Result verified by repeat analysis,130 - 394,GI/L +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,SM01/PLASMA PK TROUGH COLL D/T,Collection Date Predose,Y,23-Apr-2026,,,,,, +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,SM01/PLASMA PK TROUGH COLL D/T,Collection Time Predose,Y,07:40,,,,,, +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,SM02/PLASMA PK PEAK COLL D/T,Collection Date Post dose,Y,,,,,,, +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,SM02/PLASMA PK PEAK COLL D/T,Post Dose Collection Time,Y,,,,,,, +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,SM04/SERUM ADA PRE COLL D/T,Collection Date Predose,Y,23-Apr-2026,,,,,, +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,SM04/SERUM ADA PRE COLL D/T,Collection Time Predose,Y,07:40,,,,,, +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,SM09/STOOL PK COLL D/T,Stool Collection Date,Y,23-Apr-2026,,,,,, +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,SM09/STOOL PK COLL D/T,Stool Collection Time,Y,07:40,,,,,, +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,SUBJECT HEIGHT (CM),Height (cm),Y,N/A (subject >/= 18 years of age),,,,,cm, +CZ100012001,,,,,Male,Stool Pathogens,,"Apr 22, 2026 7:00 AM",6228137359,C. DIFF EIA,"C. diff GDH Ag,stool-CL",,Negative,,,,,Ref Rng:Negative, +CZ100012001,,,,,Male,Stool Pathogens,,"Apr 22, 2026 7:00 AM",6228137359,C. DIFF EIA,"C.diff Toxin A&B,stool-CL",,Negative,,,,,Ref Rng:Negative, +CZ100012001,,,,,Male,Stool Pathogens,,"Apr 22, 2026 7:00 AM",6228137359,OVA AND PARASITES 1,Concentrate Exam,,No ova or parasites found,,,,,, +CZ100012001,,,,,Male,Stool Pathogens,,"Apr 22, 2026 7:00 AM",6228137359,OVA AND PARASITES 1,Smear for Microsporidia,,No Microsporidia seen.,,,,,, +CZ100012001,,,,,Male,Stool Pathogens,,"Apr 22, 2026 7:00 AM",6228137359,OVA AND PARASITES 1,Modified acid-fast stain,,No coccidian parasites seen,,,,,, +CZ100012001,,,,,Male,Stool Pathogens,,"Apr 22, 2026 7:00 AM",6228137359,OVA AND PARASITES 2,Trichrome Smear,,No ova or parasites found,,,,,, +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,CHEMISTRY PANEL,Total Bilirubin,,12,,,,,3 - 21,umol/L +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.7,,,,,0 - 6.2,umol/L +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,CHEMISTRY PANEL,Alkaline Phosphatase,,96,,,,,35 - 104,U/L +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,CHEMISTRY PANEL,ALT (SGPT),,17,,,,,4 - 43,U/L +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,CHEMISTRY PANEL,AST (SGOT),,28,,,,,8 - 40,U/L +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,CHEMISTRY PANEL,GGT,,19,,,,,5 - 50,U/L +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,CHEMISTRY PANEL,LDH,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,CHEMISTRY PANEL,Urea Nitrogen,,5.3,,,,,1.4 - 10.4,mmol/L +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,56,,,,,31 - 110,umol/L +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,CHEMISTRY PANEL,Serum Glucose,,6.2,R,H,,,3.9 - 5.6,mmol/L +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,CHEMISTRY PANEL,Serum Uric Acid,,284,,,,,149 - 446,umol/L +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,CHEMISTRY PANEL,Calcium (EDTA),,2.50,,,,,2.07 - 2.64,mmol/L +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,CHEMISTRY PANEL,Phosphorus,,1.20,,,,,0.71 - 1.65,mmol/L +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,CHEMISTRY PANEL,Total Protein,,78,,,,,60 - 80,g/L +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,CHEMISTRY PANEL,Albumin-BCG,,46,,,,,33 - 46,g/L +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,CHEMISTRY PANEL,Creatine Kinase,,113,,,,,26 - 192,U/L +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,CHEMISTRY PANEL,Serum Sodium,,140,,,,,135 - 145,mmol/L +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,CHEMISTRY PANEL,Serum Potassium,,4.9,,,,,3.5 - 5.2,mmol/L +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,CHEMISTRY PANEL,Serum Bicarbonate,,24.0,,,,,19.3 - 29.3,mmol/L +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,CHEMISTRY PANEL,Serum Chloride,,103,,,,,94 - 112,mmol/L +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,CHEMISTRY PANEL,Magnesium,,0.97,,,,,0.66 - 0.98,mmol/L +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,90,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,FECAL COLLECTION D/T,Stool Collection Date,Y,07-Apr-2026,,,,,, +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,FECAL COLLECTION D/T,Stool Collection Time,Y,18:00,,,,,, +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,143,,,,,115 - 158,g/L +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.44,,,,,0.34 - 0.48, +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.1,,,,,3.9 - 5.5,TI/L +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,28,,,,,26 - 34,pg +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,87,,,,,80 - 100,fL +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,3.59,R,L,,,3.8 - 10.7,GI/L +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,1.64,R,L,,,1.96 - 7.23,GI/L +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.72,,,,,0.8 - 3,GI/L +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.19,,,,,0.12 - 0.92,GI/L +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.03,,,,,0 - 0.57,GI/L +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.02,,,,,0 - 0.2,GI/L +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,45.6,,,,,40.5 - 75,% +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,47.9,,,,,15.4 - 48.5,% +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.2,,,,,2.6 - 10.1,% +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,0.7,,,,,0 - 6.8,% +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.5,,,,,0 - 2,% +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,126,R,L,,,130 - 394,GI/L +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,LIPID PANEL,Direct HDL-C 4th Generation,,2.07,R,H,,,1.03 - 1.53,mmol/L +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,LIPID PANEL,Triglycerides (GPO),,1.04,,,,,0.63 - 2.71,mmol/L +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,LIPID PANEL,Cholesterol (High Performance),,4.56,R,L,,,5.35 - 9.1,mmol/L +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,LIPID PANEL,LDL Chol Friedewald 4th,,2.01,,,,,0 - 3.34,mmol/L +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,SM01/PLASMA PK TROUGH COLL D/T,Collection Date Predose,Y,08-Apr-2026,,,,,, +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,SM01/PLASMA PK TROUGH COLL D/T,Collection Time Predose,Y,07:10,,,,,, +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,SM02/PLASMA PK PEAK COLL D/T,Collection Date Post dose,Y,08-Apr-2026,,,,,, +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,SM02/PLASMA PK PEAK COLL D/T,Post Dose Collection Time,Y,08:15,,,,,, +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,SM04/SERUM ADA PRE COLL D/T,Collection Date Predose,Y,08-Apr-2026,,,,,, +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,SM04/SERUM ADA PRE COLL D/T,Collection Time Predose,Y,07:10,,,,,, +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,SM10/FECAL BMRKS COLL D/T,Stool Collection Date,Y,07-Apr-2026,,,,,, +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,SM10/FECAL BMRKS COLL D/T,Stool Collection Time,Y,18:00,,,,,, +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,SUBJECT HEIGHT (CM),Height (cm),Y,170,,,,,cm, +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,ALP<2XULN,ALP<2XULN,,Criteria Met,,,,,, +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,ALT>/=3XULN,ALT >/= 3 X ULN,,Criteria not met,,,,,, +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,ALT>/=3XULN & TBIL>/=2XULN,ALT >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,AST>/=3XULN,AST >/= 3 X ULN,,Required testing unavailable,,,,,, +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,AST>/=3XULN & TBIL>/=2XULN,AST >/=3xULN & TBIL >/=2xULN,,Required testing unavailable,,,,,, +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,CHEMISTRY PANEL,Total Bilirubin,,6,,,,,3 - 21,umol/L +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,CHEMISTRY PANEL,Alkaline Phosphatase,,66,,,,,40 - 129,U/L +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,CHEMISTRY PANEL,ALT (SGPT),,50,,H,,,5 - 48,U/L +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,CHEMISTRY PANEL,AST (SGOT),,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,CHEMISTRY PANEL,GGT,,25,,,,,10 - 61,U/L +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,CHEMISTRY PANEL,LDH,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,CHEMISTRY PANEL,Urea Nitrogen,,6.7,,,,,1.4 - 8.6,mmol/L +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,89,,,,,40 - 110,umol/L +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,CHEMISTRY PANEL,Serum Glucose,,5.1,,,,,3.9 - 5.6,mmol/L +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,CHEMISTRY PANEL,Serum Uric Acid,,302,,,,,125 - 488,umol/L +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,CHEMISTRY PANEL,Calcium (EDTA),,2.50,,,,,2.07 - 2.64,mmol/L +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,CHEMISTRY PANEL,Phosphorus,,1.95,R,H,,,0.71 - 1.65,mmol/L +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,CHEMISTRY PANEL,Total Protein,,76,,,,,61 - 84,g/L +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,CHEMISTRY PANEL,Albumin-BCG,,46,,,,,33 - 49,g/L +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,CHEMISTRY PANEL,Creatine Kinase,,66,,,,,39 - 308,U/L +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,CHEMISTRY PANEL,Serum Sodium,,139,,,,,132 - 147,mmol/L +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,CHEMISTRY PANEL,Serum Potassium,,4.9,,,,,3.5 - 5.2,mmol/L +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,CHEMISTRY PANEL,Serum Bicarbonate,,24.8,,,,,19.3 - 29.3,mmol/L +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,CHEMISTRY PANEL,Serum Chloride,,101,,,,,94 - 112,mmol/L +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,CHEMISTRY PANEL,Magnesium,,0.95,,,,,0.66 - 1.07,mmol/L +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,92,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,FECAL COLLECTION D/T,Stool Collection Date,Y,17-Mar-2026,,,,,, +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,FECAL COLLECTION D/T,Stool Collection Time,Y,18:00,,,,,, +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,154,,,,,127 - 181,g/L +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.47,,,,,0.39 - 0.54, +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.2,,,,,4.5 - 6.4,TI/L +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,30,,,,,26 - 34,pg +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,91,,,,,79 - 96,fL +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,6.77,,,,,3.8 - 10.7,GI/L +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,5.03,,,,,1.96 - 7.23,GI/L +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.25,,,,,0.91 - 4.28,GI/L +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.39,,,,,0.12 - 0.92,GI/L +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.07,,,,,0 - 0.57,GI/L +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.03,,,,,0 - 0.2,GI/L +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,74.3,,,,,40.5 - 75,% +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,18.6,,,,,15.4 - 48.5,% +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.8,,,,,2.6 - 10.1,% +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.0,,,,,0 - 6.8,% +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.4,,,,,0 - 2,% +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,327,,,,,140 - 400,GI/L +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,SM01/PLASMA PK TROUGH COLL D/T,Collection Date Predose,Y,18-Mar-2026,R,,,,, +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,SM01/PLASMA PK TROUGH COLL D/T,Collection Time Predose,Y,18:00,,,,,, +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,SM02/PLASMA PK PEAK COLL D/T,Collection Date Post dose,Y,18-Mar-2026,R,,,,, +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,SM02/PLASMA PK PEAK COLL D/T,Post Dose Collection Time,Y,18:00,,,,,, +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,SM04/SERUM ADA PRE COLL D/T,Collection Date Predose,Y,18-Mar-2026,R,,,,, +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,SM04/SERUM ADA PRE COLL D/T,Collection Time Predose,Y,18:00,,,,,, +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,SM09/STOOL PK COLL D/T,Stool Collection Date,Y,17-Mar-2026,,,,,, +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,SM09/STOOL PK COLL D/T,Stool Collection Time,Y,18:00,,,,,, +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,SUBJECT HEIGHT (CM),Height (cm),Y,N/A (subject >/= 18 years of age),,,,,cm, +CZ100012002,,,,,Female,Biopsy,,"Mar 18, 2026 12:00 AM",6227323224,ANATOMICAL SITE,Anatomical Site,Y,25 DISTANCE IN CM FROM ANAL VERGE,,,,,, +CZ100012002,,,,,Female,Biopsy,,"Mar 18, 2026 12:00 AM",6227323224,BIOPSY COLLECTION METHOD,Collection Method,Y,colonoscopy,,,,,, +CZ100012002,,,,,Female,Biopsy,,"Mar 18, 2026 12:00 AM",6227323224,BIOPSY FIXATIVE USED,Fixative Used,,10% NBF,,,,,, +CZ100012002,,,,,Female,Biopsy,,"Mar 18, 2026 12:00 AM",6227323224,DATE/TIME PLACED IN FORMALIN,Date Sample placed in Formalin,Y,18-Mar-2026,,,,,, +CZ100012002,,,,,Female,Biopsy,,"Mar 18, 2026 12:00 AM",6227323224,DATE/TIME PLACED IN FORMALIN,Time Sample placed in Formalin,Y,09:30,,,,,, +CZ100012002,,,,,Female,Biopsy,,"Mar 18, 2026 12:00 AM",6227323224,DIAGNOSIS,Diagnosis:,Y,Ulcerative Colitis,,,,,, +CZ100012002,,,,,Female,Biopsy,,"Mar 18, 2026 12:00 AM",6227323224,INFLAMED AREA,Inflamed area?,,Yes,,,,,, +CZ100012002,,,,,Female,Biopsy,,"Mar 18, 2026 12:00 AM",6227323224,TISSUE BIOPSY EMBEDDING1,Biopsy technical QC-CL,,Smpl meets HT requirements,,,,,, +CZ100012002,,,,,Female,Biopsy,,"Mar 18, 2026 12:00 AM",6227323224,TISSUE BIOPSY EMBEDDING1,Biopsy processing Time-CL,,10:00,,,,,, +CZ100012002,,,,,Female,Biopsy,,"Mar 18, 2026 12:00 AM",6227323224,TISSUE BIOPSY EMBEDDING1,Biopsy processing Date-CL,,20-Mar-2026,,,,,, +CZ100012002,,,,,Female,Biopsy,,"Mar 18, 2026 12:00 AM",6227323224,TISSUE BIOPSY EMBEDDING1,Biopsy Comments-CL,,Received in 10% NBF,,,,,, +CZ100012002,,,,,Female,Biopsy,,"Mar 18, 2026 12:00 AM",6227323224,TISSUE BIOPSY EMBEDDING1,# of Cassettes-(FI)-CL,,1,,,,,, +CZ100012002,,,,,Female,Biopsy,,"Mar 18, 2026 12:00 AM",6227323224,ULCERATED AREA,Is biopsy site ulcerated?,,Yes,,,,,, +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,ALP<2XULN,ALP<2XULN,,Required testing unavailable,,,,,, +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,ALT>/=3XULN,ALT >/= 3 X ULN,,Required testing unavailable,,,,,, +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,ALT>/=3XULN & TBIL>/=2XULN,ALT >/=3xULN & TBIL >/=2xULN,,Required testing unavailable,,,,,, +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,AST>/=3XULN,AST >/= 3 X ULN,,Required testing unavailable,,,,,, +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,AST>/=3XULN & TBIL>/=2XULN,AST >/=3xULN & TBIL >/=2xULN,,Required testing unavailable,,,,,, +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,CHEMISTRY PANEL,Total Bilirubin,,18,,,,,3 - 21,umol/L +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,CHEMISTRY PANEL,Alkaline Phosphatase,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,CHEMISTRY PANEL,ALT (SGPT),,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,CHEMISTRY PANEL,AST (SGOT),,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,CHEMISTRY PANEL,GGT,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,CHEMISTRY PANEL,LDH,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,CHEMISTRY PANEL,Urea Nitrogen,,5.2,,,,,1.4 - 8.6,mmol/L +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,80,,,,,40 - 110,umol/L +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,CHEMISTRY PANEL,Serum Glucose,,5.4,,,,,3.9 - 5.6,mmol/L +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,CHEMISTRY PANEL,Serum Uric Acid,,276,,,,,125 - 488,umol/L +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,CHEMISTRY PANEL,Calcium (EDTA),,2.24,,,,,2.07 - 2.64,mmol/L +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,CHEMISTRY PANEL,Phosphorus,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,CHEMISTRY PANEL,Total Protein,,71,,,,,61 - 84,g/L +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,CHEMISTRY PANEL,Albumin-BCG,,43,,,,,33 - 49,g/L +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,CHEMISTRY PANEL,Creatine Kinase,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,CHEMISTRY PANEL,Serum Sodium,,139,,,,,132 - 147,mmol/L +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,CHEMISTRY PANEL,Serum Potassium,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,CHEMISTRY PANEL,Serum Bicarbonate,,20.3,,,,,19.3 - 29.3,mmol/L +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,CHEMISTRY PANEL,Serum Chloride,,103,,,,,94 - 112,mmol/L +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,CHEMISTRY PANEL,Magnesium,,0.88,,,,,0.66 - 1.07,mmol/L +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,105,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,FECAL COLLECTION D/T,Stool Collection Date,Y,03-Mar-2026,,,,,, +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,FECAL COLLECTION D/T,Stool Collection Time,Y,18:00,R,,,,, +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,155,,,,,127 - 181,g/L +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.48,,,,,0.39 - 0.54, +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.1,,,,,4.5 - 6.4,TI/L +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,30,,,,,26 - 34,pg +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,93,,,,,79 - 96,fL +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,5.57,,,,,3.8 - 10.7,GI/L +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,4.08,,,,,1.96 - 7.23,GI/L +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.16,,,,,0.91 - 4.28,GI/L +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.26,,,,,0.12 - 0.92,GI/L +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.05,,,,,0 - 0.57,GI/L +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.02,,,,,0 - 0.2,GI/L +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,73.3,,,,,40.5 - 75,% +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,20.7,,,,,15.4 - 48.5,% +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,4.7,,,,,2.6 - 10.1,% +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,0.9,,,,,0 - 6.8,% +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.4,,,,,0 - 2,% +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,343,,,,,140 - 400,GI/L +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,SM01/PLASMA PK TROUGH COLL D/T,Collection Date Predose,Y,04-Mar-2026,,,,,, +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,SM01/PLASMA PK TROUGH COLL D/T,Collection Time Predose,Y,07:00,R,,,,, +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,SM02/PLASMA PK PEAK COLL D/T,Collection Date Post dose,Y,04-Mar-2026,,,,,, +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,SM02/PLASMA PK PEAK COLL D/T,Post Dose Collection Time,Y,08:00,,,,,, +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,SM04/SERUM ADA PRE COLL D/T,Collection Date Predose,Y,04-Mar-2026,,,,,, +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,SM04/SERUM ADA PRE COLL D/T,Collection Time Predose,Y,07:00,R,,,,, +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,SM09/STOOL PK COLL D/T,Stool Collection Date,Y,03-Mar-2026,,,,,, +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,SM09/STOOL PK COLL D/T,Stool Collection Time,Y,18:00,R,,,,, +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,SUBJECT HEIGHT (CM),Height (cm),Y,N/A (subject >/= 18 years of age),,,,,cm, +CZ100012002,,,,,Female,Stool Pathogens,,"Mar 3, 2026 1:00 PM",6227323212,C. DIFF EIA,"C. diff GDH Ag,stool-CL",,Negative,,,,,Ref Rng:Negative, +CZ100012002,,,,,Female,Stool Pathogens,,"Mar 3, 2026 1:00 PM",6227323212,C. DIFF EIA,"C.diff Toxin A&B,stool-CL",,Negative,,,,,Ref Rng:Negative, +CZ100012002,,,,,Female,Stool Pathogens,,"Mar 3, 2026 1:00 PM",6227323212,OVA AND PARASITES 1,Concentrate Exam,,No ova or parasites found,,,,,, +CZ100012002,,,,,Female,Stool Pathogens,,"Mar 3, 2026 1:00 PM",6227323212,OVA AND PARASITES 1,Smear for Microsporidia,,No Microsporidia seen.,,,,,, +CZ100012002,,,,,Female,Stool Pathogens,,"Mar 3, 2026 1:00 PM",6227323212,OVA AND PARASITES 1,Modified acid-fast stain,,No coccidian parasites seen,,,,,, +CZ100012002,,,,,Female,Stool Pathogens,,"Mar 3, 2026 1:00 PM",6227323212,OVA AND PARASITES 2,Trichrome Smear,,No ova or parasites found,,,,,, +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,CHEMISTRY PANEL,Total Bilirubin,,10,,,,,3 - 21,umol/L +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.5,,,,,0 - 6.2,umol/L +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,CHEMISTRY PANEL,Alkaline Phosphatase,,100,,,,,35 - 104,U/L +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,CHEMISTRY PANEL,ALT (SGPT),,17,,,,,4 - 43,U/L +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,CHEMISTRY PANEL,AST (SGOT),,24,,,,,8 - 40,U/L +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,CHEMISTRY PANEL,GGT,,27,,,,,5 - 50,U/L +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,CHEMISTRY PANEL,LDH,,120,,,,,53 - 234,U/L +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,CHEMISTRY PANEL,Urea Nitrogen,,4.9,,,,,1.4 - 10.4,mmol/L +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,49,,,,,31 - 110,umol/L +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,CHEMISTRY PANEL,Serum Glucose,,7.0,,H,,,3.9 - 5.6,mmol/L +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,CHEMISTRY PANEL,Serum Uric Acid,,233,,,,,149 - 446,umol/L +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,CHEMISTRY PANEL,Calcium (EDTA),,2.40,,,,,2.07 - 2.64,mmol/L +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,CHEMISTRY PANEL,Phosphorus,,1.05,,,,,0.71 - 1.65,mmol/L +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,CHEMISTRY PANEL,Total Protein,,75,,,,,60 - 80,g/L +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,CHEMISTRY PANEL,Albumin-BCG,,45,,,,,33 - 46,g/L +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,CHEMISTRY PANEL,Creatine Kinase,,101,,,,,26 - 192,U/L +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,CHEMISTRY PANEL,Serum Sodium,,140,,,,,135 - 145,mmol/L +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,CHEMISTRY PANEL,Serum Potassium,,3.9,,,,,3.5 - 5.2,mmol/L +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,CHEMISTRY PANEL,Serum Bicarbonate,,22.1,,,,,19.3 - 29.3,mmol/L +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,CHEMISTRY PANEL,Serum Chloride,,104,,,,,94 - 112,mmol/L +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,CHEMISTRY PANEL,Magnesium,,0.89,,,,,0.66 - 0.98,mmol/L +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,93,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,FEMALE OF CHILDBEARING POT?,Female/of Childbearing pot.?,Y,No,,,,,, +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,HBV ELIGIBILITY MET?,HBV Eligibility Criteria Met?,,Yes,,,,,, +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,145,,,,,115 - 158,g/L +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.43,,,,,0.34 - 0.48, +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.0,,,,,3.9 - 5.5,TI/L +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,29,,,,,26 - 34,pg +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,85,,,,,80 - 100,fL +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,3.95,,,,,3.8 - 10.7,GI/L +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,1.86,,L,,,1.96 - 7.23,GI/L +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.81,,,,,0.8 - 3,GI/L +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.25,,,,,0.12 - 0.92,GI/L +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.02,,,,,0 - 0.57,GI/L +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.02,,,,,0 - 0.2,GI/L +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,47.1,,,,,40.5 - 75,% +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,45.7,,,,,15.4 - 48.5,% +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,6.3,,,,,2.6 - 10.1,% +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,0.4,,,,,0 - 6.8,% +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.5,,,,,0 - 2,% +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,150,,,,,130 - 394,GI/L +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,HEPATITIS B CORE AB NON-US,Hepatitis B Core Total,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,HEPATITIS B SURFACE AB,Anti-HBs II QUAL,,Non-Reactive,,,,,Ref Rng :$Non Reactive, +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,HEPATITIS B SURFACE AG NON-US,Hep B Surface AgII,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,HEPATITIS C VIRUS AB NON-US,Hepatitis C Virus Antibody,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,HIV 1/2 AG/AB SCREEN,anti-HIV-1/2 antibodies,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,HIV 1/2 AG/AB SCREEN,HIV -1 p24 antigen,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,HIV 1/2 AG/AB SCREEN,"HIV 1/2 Ag/Ab Screen, Cobas",,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,QUANTIFERON GOLD MITOGEN/INTER,"QFT,TBGoldPlusInt,pl-4-Tubes",,Negative,,,,,Normal=Negative, +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,SUBJECT HEIGHT (CM),Height (cm),Y,170,,,,,cm, +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,CHEMISTRY PANEL,Total Bilirubin,,,,,Test cancelled: Quantity not sufficient,,, +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,,,,Test cancelled: Quantity not sufficient,,, +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,CHEMISTRY PANEL,Alkaline Phosphatase,,,,,Test cancelled: Quantity not sufficient,,, +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,CHEMISTRY PANEL,ALT (SGPT),,,,,Test cancelled: Quantity not sufficient,,, +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,CHEMISTRY PANEL,AST (SGOT),,,,,Test cancelled: Quantity not sufficient,,, +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,CHEMISTRY PANEL,GGT,,,,,Test cancelled: Quantity not sufficient,,, +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,CHEMISTRY PANEL,LDH,,,,,Test cancelled: Quantity not sufficient,,, +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,CHEMISTRY PANEL,Urea Nitrogen,,,,,Test cancelled: Quantity not sufficient,,, +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,,,,Test cancelled: Quantity not sufficient,,, +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,CHEMISTRY PANEL,Serum Glucose,,,,,Test cancelled: Quantity not sufficient,,, +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,CHEMISTRY PANEL,Serum Uric Acid,,,,,Test cancelled: Quantity not sufficient,,, +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,CHEMISTRY PANEL,Calcium (EDTA),,,,,Test cancelled: Quantity not sufficient,,, +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,CHEMISTRY PANEL,Phosphorus,,,,,Test cancelled: Quantity not sufficient,,, +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,CHEMISTRY PANEL,Total Protein,,,,,Test cancelled: Quantity not sufficient,,, +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,CHEMISTRY PANEL,Albumin-BCG,,,,,Test cancelled: Quantity not sufficient,,, +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,CHEMISTRY PANEL,Creatine Kinase,,,,,Test cancelled: Quantity not sufficient,,, +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,CHEMISTRY PANEL,Serum Sodium,,,,,Test cancelled: Quantity not sufficient,,, +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,CHEMISTRY PANEL,Serum Potassium,,,,,Test cancelled: Quantity not sufficient,,, +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,CHEMISTRY PANEL,Serum Bicarbonate,,,,,Test cancelled: Quantity not sufficient,,, +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,CHEMISTRY PANEL,Serum Chloride,,,,,Test cancelled: Quantity not sufficient,,, +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,CHEMISTRY PANEL,Magnesium,,,,,Test cancelled: Quantity not sufficient,,, +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,CKD-EPI 2021,CKD-EPI 2021 Without Race,,Required testing unavailable,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,FECAL COLLECTION D/T,Stool Collection Date,Y,18-Feb-2026,,,,,, +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,FECAL COLLECTION D/T,Stool Collection Time,Y,18:00,,,,,, +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,140,,,,,127 - 181,g/L +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.42,,,,,0.39 - 0.54, +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.7,,,,,4.5 - 6.4,TI/L +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,30,,,,,26 - 34,pg +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,91,,,,,79 - 96,fL +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,8.88,,,,,3.8 - 10.7,GI/L +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,5.46,,,,,1.96 - 7.23,GI/L +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.78,,,,,0.91 - 4.28,GI/L +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.47,,,,,0.12 - 0.92,GI/L +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.14,,,,,0 - 0.57,GI/L +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.04,,,,,0 - 0.2,GI/L +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,61.4,,,,,40.5 - 75,% +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,31.2,,,,,15.4 - 48.5,% +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.3,,,,,2.6 - 10.1,% +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.6,,,,,0 - 6.8,% +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.4,,,,,0 - 2,% +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,330,,,,,140 - 400,GI/L +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,LIPID PANEL,Direct HDL-C 4th Generation,,,,,Test cancelled: Quantity not sufficient,,, +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,LIPID PANEL,Triglycerides (GPO),,,,,Test cancelled: Quantity not sufficient,,, +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,LIPID PANEL,Cholesterol (High Performance),,,,,Test cancelled: Quantity not sufficient,,, +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,LIPID PANEL,LDL Chol Friedewald 4th,,Required testing unavailable,,,,,0 - 3.34,mmol/L +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,SM01/PLASMA PK TROUGH COLL D/T,Collection Date Predose,Y,19-Feb-2026,,,,,, +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,SM01/PLASMA PK TROUGH COLL D/T,Collection Time Predose,Y,07:20,,,,,, +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,SM02/PLASMA PK PEAK COLL D/T,Collection Date Post dose,Y,19-Feb-2026,,,,,, +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,SM02/PLASMA PK PEAK COLL D/T,Post Dose Collection Time,Y,08:50,,,,,, +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,SM04/SERUM ADA PRE COLL D/T,Collection Date Predose,Y,19-Feb-2026,,,,,, +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,SM04/SERUM ADA PRE COLL D/T,Collection Time Predose,Y,07:20,,,,,, +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,SM10/FECAL BMRKS COLL D/T,Stool Collection Date,Y,18-Feb-2026,,,,,, +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,SM10/FECAL BMRKS COLL D/T,Stool Collection Time,Y,18:00,,,,,, +CZ100012001,,,,,Male,Biopsy,R,"Feb 5, 2026 12:00 AM",6227323223,ANATOMICAL SITE,Anatomical Site,Y,30,,,,,, +CZ100012001,,,,,Male,Biopsy,R,"Feb 5, 2026 12:00 AM",6227323223,BIOPSY COLLECTION METHOD,Collection Method,Y,colonoscopy,,,,,, +CZ100012001,,,,,Male,Biopsy,R,"Feb 5, 2026 12:00 AM",6227323223,BIOPSY FIXATIVE USED,Fixative Used,,10% NBF,,,,,, +CZ100012001,,,,,Male,Biopsy,R,"Feb 5, 2026 12:00 AM",6227323223,DATE/TIME PLACED IN FORMALIN,Date Sample placed in Formalin,Y,05-Feb-2026,,,,,, +CZ100012001,,,,,Male,Biopsy,R,"Feb 5, 2026 12:00 AM",6227323223,DATE/TIME PLACED IN FORMALIN,Time Sample placed in Formalin,Y,08:30,,,,,, +CZ100012001,,,,,Male,Biopsy,R,"Feb 5, 2026 12:00 AM",6227323223,DIAGNOSIS,Diagnosis:,Y,Ulcerative Colitis,,,,,, +CZ100012001,,,,,Male,Biopsy,R,"Feb 5, 2026 12:00 AM",6227323223,INFLAMED AREA,Inflamed area?,,Yes,,,,,, +CZ100012001,,,,,Male,Biopsy,R,"Feb 5, 2026 12:00 AM",6227323223,TISSUE BIOPSY EMBEDDING1,Biopsy technical QC-CL,,Smpl meets HT requirements,,,,,, +CZ100012001,,,,,Male,Biopsy,R,"Feb 5, 2026 12:00 AM",6227323223,TISSUE BIOPSY EMBEDDING1,Biopsy processing Time-CL,,10:00,,,,,, +CZ100012001,,,,,Male,Biopsy,R,"Feb 5, 2026 12:00 AM",6227323223,TISSUE BIOPSY EMBEDDING1,Biopsy processing Date-CL,,07-Feb-2026,,,,,, +CZ100012001,,,,,Male,Biopsy,R,"Feb 5, 2026 12:00 AM",6227323223,TISSUE BIOPSY EMBEDDING1,Biopsy Comments-CL,,Received in 10% NBF,,,,,, +CZ100012001,,,,,Male,Biopsy,R,"Feb 5, 2026 12:00 AM",6227323223,TISSUE BIOPSY EMBEDDING1,# of Cassettes-(FI)-CL,,1,,,,,, +CZ100012001,,,,,Male,Biopsy,R,"Feb 5, 2026 12:00 AM",6227323223,ULCERATED AREA,Is biopsy site ulcerated?,,Yes,,,,,, +CZ100012001,,,,,Male,Stool Pathogens,R,"Jan 28, 2026 6:00 AM",6227323211,C. DIFF EIA,"C. diff GDH Ag,stool-CL",,Negative,,,,,Ref Rng:Negative, +CZ100012001,,,,,Male,Stool Pathogens,R,"Jan 28, 2026 6:00 AM",6227323211,C. DIFF EIA,"C.diff Toxin A&B,stool-CL",,Negative,,,,,Ref Rng:Negative, +CZ100012001,,,,,Male,Stool Pathogens,R,"Jan 28, 2026 6:00 AM",6227323211,OVA AND PARASITES 1,Concentrate Exam,,No ova or parasites found,,,,,, +CZ100012001,,,,,Male,Stool Pathogens,R,"Jan 28, 2026 6:00 AM",6227323211,OVA AND PARASITES 1,Smear for Microsporidia,,No Microsporidia seen.,,,,,, +CZ100012001,,,,,Male,Stool Pathogens,R,"Jan 28, 2026 6:00 AM",6227323211,OVA AND PARASITES 1,Modified acid-fast stain,,No coccidian parasites seen,,,,,, +CZ100012001,,,,,Male,Stool Pathogens,R,"Jan 28, 2026 6:00 AM",6227323211,OVA AND PARASITES 2,Trichrome Smear,,No ova or parasites found,,,,,, +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,CHEMISTRY PANEL,Total Bilirubin,,7,,,,,3 - 21,umol/L +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.4,,,,,0 - 6.2,umol/L +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,CHEMISTRY PANEL,Alkaline Phosphatase,,61,,,,,40 - 129,U/L +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,CHEMISTRY PANEL,ALT (SGPT),,23,,,,,5 - 48,U/L +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,CHEMISTRY PANEL,AST (SGOT),,17,,,,,8 - 40,U/L +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,CHEMISTRY PANEL,GGT,,24,,,,,10 - 61,U/L +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,CHEMISTRY PANEL,LDH,,146,,,,,53 - 234,U/L +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,CHEMISTRY PANEL,Urea Nitrogen,,3.9,,,,,1.4 - 8.6,mmol/L +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,79,,,,,40 - 110,umol/L +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,CHEMISTRY PANEL,Serum Glucose,,5.5,,,,,3.9 - 5.6,mmol/L +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,CHEMISTRY PANEL,Serum Uric Acid,,338,,,,,125 - 488,umol/L +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,CHEMISTRY PANEL,Calcium (EDTA),,2.37,,,,,2.07 - 2.64,mmol/L +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,CHEMISTRY PANEL,Phosphorus,,0.48,,LT,,Result verified by repeat analysis,0.71 - 1.65,mmol/L +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,CHEMISTRY PANEL,Total Protein,,69,,,,,61 - 84,g/L +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,CHEMISTRY PANEL,Albumin-BCG,,43,,,,,33 - 49,g/L +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,CHEMISTRY PANEL,Creatine Kinase,,60,,,,,39 - 308,U/L +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,CHEMISTRY PANEL,Serum Sodium,,139,,,,,132 - 147,mmol/L +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,CHEMISTRY PANEL,Serum Potassium,,4.6,,,,,3.5 - 5.2,mmol/L +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,CHEMISTRY PANEL,Serum Bicarbonate,,25.1,,,,,19.3 - 29.3,mmol/L +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,CHEMISTRY PANEL,Serum Chloride,,103,,,,,94 - 112,mmol/L +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,CHEMISTRY PANEL,Magnesium,,0.92,,,,,0.66 - 1.07,mmol/L +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,CKD-EPI 2021,CKD-EPI 2021 Without Race,,106,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,HBV ELIGIBILITY MET?,HBV Eligibility Criteria Met?,,Yes,,,,,, +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,151,,,,,127 - 181,g/L +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.45,,,,,0.39 - 0.54, +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.0,,,,,4.5 - 6.4,TI/L +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,30,,,,,26 - 34,pg +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,91,,,,,79 - 96,fL +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,4.92,,,,,3.8 - 10.7,GI/L +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.40,,,,,1.96 - 7.23,GI/L +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.00,,,,,0.91 - 4.28,GI/L +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.27,,,,,0.12 - 0.92,GI/L +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.15,,,,,0 - 0.57,GI/L +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.10,,,,,0 - 0.2,GI/L +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,69.1,,,,,40.5 - 75,% +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,20.2,,,,,15.4 - 48.5,% +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.6,,,,,2.6 - 10.1,% +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,3.1,,,,,0 - 6.8,% +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,2.0,,,,,0 - 2,% +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,309,,,,,140 - 400,GI/L +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,HEPATITIS B CORE AB NON-US,Hepatitis B Core Total,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,HEPATITIS B SURFACE AB NON-US,Anti-HBs II QUAL,,Non-Reactive,,,,,Ref Rng :$Non Reactive, +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,HEPATITIS B SURFACE AG NON-US,Hep B Surface AgII,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,HEPATITIS C VIRUS AB NON-US,Hepatitis C Virus Antibody,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,HIV 1/2 AG/AB SCREEN,anti-HIV-1/2 antibodies,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,HIV 1/2 AG/AB SCREEN,HIV -1 p24 antigen,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,HIV 1/2 AG/AB SCREEN,"HIV 1/2 Ag/Ab Screen, Cobas",,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,QUANTIFERON GOLD MITOGEN/INTER,"QFT,TBGoldPlusInt,pl-4-Tubes",,Negative,,,,,Normal=Negative, diff --git a/Covance_UCO3001/Source/2026-06-08_130548 sponsor-study-36940-test-results-930553-microbiology.csv b/Covance_UCO3001/Source/2026-06-08_130548 sponsor-study-36940-test-results-930553-microbiology.csv new file mode 100644 index 0000000..95b16c0 --- /dev/null +++ b/Covance_UCO3001/Source/2026-06-08_130548 sponsor-study-36940-test-results-930553-microbiology.csv @@ -0,0 +1,4 @@ +"Disclaimer: The information presented in On-Screen Results is not intended to be a replacement of the official Lab Results, Alerts, Data Revisions and Cancellations found in the Lab Reports section of this software application. On-Screen Results should not be used for patient diagnosis, treatment decisions or submission to regulatory bodies.",,,,,,,,,,,,,,,,,,,,,,, +Subject,Screening Number,Age,Age Unit,Gender,Visit Description,Collected Time,Accession,Test Group,Specimen,Organism,Growth,Cancellation Reason,Test Description,Test Result,Drug Name/Agent,MIC Result,Units,MIC Interpretation,Disk Diffusion Result,Disk Diffusion Interpretation,Subject Data Revision,Visit Data Revision,Result Data Revision +CZ100092001 - null,,,,Female,SCRNSTOOL Stool Pathogens,"Apr 2, 2026 6:15 AM",6227323340,STOOL CULTURE,Stool,,,,Final Report,No enteric pathogens isolated,,,,,,,,, +CZ100092002 - null,,,,Female,SCRNSTOOL Stool Pathogens,"Apr 20, 2026 6:10 AM",6227323341,STOOL CULTURE,Stool,,,,Final Report,No enteric pathogens isolated,,,,,,,,, diff --git a/Covance_UCO3001/Source/2026-06-08_130550 sponsor-study-36940-test-results-930553-standard.csv b/Covance_UCO3001/Source/2026-06-08_130550 sponsor-study-36940-test-results-930553-standard.csv new file mode 100644 index 0000000..9bfbfde --- /dev/null +++ b/Covance_UCO3001/Source/2026-06-08_130550 sponsor-study-36940-test-results-930553-standard.csv @@ -0,0 +1,306 @@ +"Disclaimer: The information presented in On-Screen Results is not intended to be a replacement of the official Lab Results, Alerts, Data Revisions and Cancellations found in the Lab Reports section of this software application. On-Screen Results should not be used for patient diagnosis, treatment decisions or submission to regulatory bodies.",,,,,,,,,,,,,,,,,,, +Subject,Subject Data Revision,Screen No.,Age,Age Unit,Gender,Visit,Visit Data Revision,Collected Time,Accession,Test Group,Test,Administrative Question,Value,Result Data Revision,Flags,Cancellation Reason,Comments,Range,Units +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,ALP<2XULN,ALP<2XULN,,Criteria Met,,,,,, +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,ALT>/=3XULN,ALT >/= 3 X ULN,,Criteria not met,,,,,, +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,ALT>/=3XULN & TBIL>/=2XULN,ALT >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,AST>/=3XULN,AST >/= 3 X ULN,,Criteria not met,,,,,, +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,AST>/=3XULN & TBIL>/=2XULN,AST >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,CHEMISTRY PANEL,Total Bilirubin,,12,,,,,3 - 21,umol/L +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,4.3,,,,,0 - 6.2,umol/L +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,CHEMISTRY PANEL,Alkaline Phosphatase,,53,,,,,35 - 104,U/L +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,CHEMISTRY PANEL,ALT (SGPT),,20,,,,,4 - 43,U/L +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,CHEMISTRY PANEL,AST (SGOT),,24,,,,,8 - 40,U/L +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,CHEMISTRY PANEL,GGT,,16,,,,,4 - 49,U/L +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,CHEMISTRY PANEL,LDH,,150,,,,,53 - 234,U/L +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,CHEMISTRY PANEL,Urea Nitrogen,,4.0,,,,,1.4 - 8.6,mmol/L +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,67,,,,,31 - 101,umol/L +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,CHEMISTRY PANEL,Serum Glucose,,4.5,,,,,3.9 - 5.6,mmol/L +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,CHEMISTRY PANEL,Serum Uric Acid,,184,,,,,149 - 446,umol/L +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,CHEMISTRY PANEL,Calcium (EDTA),,2.55,,,,,2.07 - 2.64,mmol/L +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,CHEMISTRY PANEL,Phosphorus,,1.17,,,,,0.71 - 1.65,mmol/L +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,CHEMISTRY PANEL,Total Protein,,71,,,,,61 - 84,g/L +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,CHEMISTRY PANEL,Albumin-BCG,,49,,,,,33 - 49,g/L +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,CHEMISTRY PANEL,Creatine Kinase,,98,,,,,26 - 192,U/L +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,CHEMISTRY PANEL,Serum Sodium,,139,,,,,132 - 147,mmol/L +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,CHEMISTRY PANEL,Serum Potassium,,4.5,,,,,3.5 - 5.2,mmol/L +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,CHEMISTRY PANEL,Serum Bicarbonate,,23.5,,,,,19.3 - 29.3,mmol/L +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,CHEMISTRY PANEL,Serum Chloride,,101,,,,,94 - 112,mmol/L +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,CHEMISTRY PANEL,Magnesium,,0.84,,,,,0.66 - 1.07,mmol/L +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,FECAL COLLECTION D/T,Stool Collection Date,Y,04-Jun-2026,,,,,, +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,FECAL COLLECTION D/T,Stool Collection Time,Y,06:30,,,,,, +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,138,,,,,116 - 164,g/L +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.41,,,,,0.34 - 0.48, +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.5,,,,,4.1 - 5.6,TI/L +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,31,,,,,26 - 34,pg +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,92,,,,,79 - 98,fL +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,6.37,,,,,3.8 - 10.7,GI/L +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,4.46,,,,,1.96 - 7.23,GI/L +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.53,,,,,0.91 - 4.28,GI/L +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.25,,,,,0.12 - 0.92,GI/L +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.10,,,,,0 - 0.57,GI/L +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.03,,,,,0 - 0.2,GI/L +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,70.0,,,,,40.5 - 75,% +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,24.1,,,,,15.4 - 48.5,% +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,4.0,,,,,2.6 - 10.1,% +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.6,,,,,0 - 6.8,% +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.4,,,,,0 - 2,% +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,214,,,,,140 - 400,GI/L +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,PA1 EEA-2?,Approved to use EEA-2?,,,,,,,, +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,SM01/PLASMA PK TROUGH COLL D/T,Collection Date Predose,Y,04-Jun-2026,,,,,, +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,SM01/PLASMA PK TROUGH COLL D/T,Collection Time Predose,Y,09:50,,,,,, +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,SM02/PLASMA PK PEAK COLL D/T,Collection Date Post dose,Y,04-Jun-2026,,,,,, +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,SM02/PLASMA PK PEAK COLL D/T,Post Dose Collection Time,Y,11:10,,,,,, +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,SM04/SERUM ADA PRE COLL D/T,Collection Date Predose,Y,04-Jun-2026,,,,,, +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,SM04/SERUM ADA PRE COLL D/T,Collection Time Predose,Y,09:50,,,,,, +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,SM09/STOOL PK COLL D/T,Stool Collection Date,Y,04-Jun-2026,,,,,, +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,SM09/STOOL PK COLL D/T,Stool Collection Time,Y,06:30,,,,,, +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,SUBJECT HEIGHT (CM),Height (cm),Y,,,,,,, +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,ALP<2XULN,ALP<2XULN,,Criteria Met,,,,,, +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,ALT>/=3XULN,ALT >/= 3 X ULN,,Criteria not met,,,,,, +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,ALT>/=3XULN & TBIL>/=2XULN,ALT >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,AST>/=3XULN,AST >/= 3 X ULN,,Criteria not met,,,,,, +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,AST>/=3XULN & TBIL>/=2XULN,AST >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,CHEMISTRY PANEL,Total Bilirubin,,17,,,,,3 - 21,umol/L +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,5.0,,,,,0 - 6.2,umol/L +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,CHEMISTRY PANEL,Alkaline Phosphatase,,60,,,,,35 - 104,U/L +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,CHEMISTRY PANEL,ALT (SGPT),,18,,,,,4 - 43,U/L +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,CHEMISTRY PANEL,AST (SGOT),,21,,,,,8 - 40,U/L +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,CHEMISTRY PANEL,GGT,,15,,,,,4 - 49,U/L +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,CHEMISTRY PANEL,LDH,,154,,,,,53 - 234,U/L +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,CHEMISTRY PANEL,Urea Nitrogen,,3.4,,,,,1.4 - 8.6,mmol/L +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,73,,,,,31 - 101,umol/L +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,CHEMISTRY PANEL,Serum Glucose,,4.6,,,,,3.9 - 5.6,mmol/L +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,CHEMISTRY PANEL,Serum Uric Acid,,196,,,,,149 - 446,umol/L +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,CHEMISTRY PANEL,Calcium (EDTA),,2.47,,,,,2.07 - 2.64,mmol/L +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,CHEMISTRY PANEL,Phosphorus,,1.10,,,,,0.71 - 1.65,mmol/L +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,CHEMISTRY PANEL,Total Protein,,73,,,,,61 - 84,g/L +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,CHEMISTRY PANEL,Albumin-BCG,,48,,,,,33 - 49,g/L +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,CHEMISTRY PANEL,Creatine Kinase,,100,,,,,26 - 192,U/L +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,CHEMISTRY PANEL,Serum Sodium,,136,,,,,132 - 147,mmol/L +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,CHEMISTRY PANEL,Serum Potassium,,4.4,,,,,3.5 - 5.2,mmol/L +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,CHEMISTRY PANEL,Serum Bicarbonate,,22.8,,,,,19.3 - 29.3,mmol/L +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,CHEMISTRY PANEL,Serum Chloride,,100,,,,,94 - 112,mmol/L +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,CHEMISTRY PANEL,Magnesium,,0.81,,,,,0.66 - 1.07,mmol/L +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,86,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,FECAL COLLECTION D/T,Stool Collection Date,Y,19-May-2026,,,,,, +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,FECAL COLLECTION D/T,Stool Collection Time,Y,06:20,,,,,, +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,137,,,,,116 - 164,g/L +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.40,,,,,0.34 - 0.48, +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.4,,,,,4.1 - 5.6,TI/L +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,32,,,,,26 - 34,pg +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,91,,,,,79 - 98,fL +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,6.57,,,,,3.8 - 10.7,GI/L +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,4.33,,,,,1.96 - 7.23,GI/L +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.77,,,,,0.91 - 4.28,GI/L +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.29,,,,,0.12 - 0.92,GI/L +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.12,,,,,0 - 0.57,GI/L +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.06,,,,,0 - 0.2,GI/L +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,65.9,,,,,40.5 - 75,% +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,26.9,,,,,15.4 - 48.5,% +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,4.4,,,,,2.6 - 10.1,% +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.8,,,,,0 - 6.8,% +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.9,,,,,0 - 2,% +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,258,,,,,140 - 400,GI/L +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,SM01/PLASMA PK TROUGH COLL D/T,Collection Date Predose,Y,19-May-2026,,,,,, +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,SM01/PLASMA PK TROUGH COLL D/T,Collection Time Predose,Y,10:50,,,,,, +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,SM02/PLASMA PK PEAK COLL D/T,Collection Date Post dose,Y,19-May-2026,,,,,, +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,SM02/PLASMA PK PEAK COLL D/T,Post Dose Collection Time,Y,11:55,,,,,, +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,SM04/SERUM ADA PRE COLL D/T,Collection Date Predose,Y,19-May-2026,,,,,, +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,SM04/SERUM ADA PRE COLL D/T,Collection Time Predose,Y,10:50,,,,,, +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,SM09/STOOL PK COLL D/T,Stool Collection Date,Y,19-May-2026,,,,,, +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,SM09/STOOL PK COLL D/T,Stool Collection Time,Y,06:20,,,,,, +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,SUBJECT HEIGHT (CM),Height (cm),Y,N/A (subject >/= 18 years of age),,,,,cm, +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,CHEMISTRY PANEL,Total Bilirubin,,12,,,,,3 - 21,umol/L +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,4.5,,,,,0 - 6.2,umol/L +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,CHEMISTRY PANEL,Alkaline Phosphatase,,55,,,,,35 - 104,U/L +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,CHEMISTRY PANEL,ALT (SGPT),,15,,,,,4 - 43,U/L +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,CHEMISTRY PANEL,AST (SGOT),,18,,,,,8 - 40,U/L +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,CHEMISTRY PANEL,GGT,,13,,,,,4 - 49,U/L +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,CHEMISTRY PANEL,LDH,,152,,,,,53 - 234,U/L +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,CHEMISTRY PANEL,Urea Nitrogen,,5.1,,,,,1.4 - 8.6,mmol/L +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,62,,,,,31 - 101,umol/L +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,CHEMISTRY PANEL,Serum Glucose,,4.7,,,,,3.9 - 5.6,mmol/L +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,CHEMISTRY PANEL,Serum Uric Acid,,178,,,,,149 - 446,umol/L +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,CHEMISTRY PANEL,Calcium (EDTA),,2.44,,,,,2.07 - 2.64,mmol/L +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,CHEMISTRY PANEL,Phosphorus,,1.09,,,,,0.71 - 1.65,mmol/L +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,CHEMISTRY PANEL,Total Protein,,71,,,,,61 - 84,g/L +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,CHEMISTRY PANEL,Albumin-BCG,,47,,,,,33 - 49,g/L +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,CHEMISTRY PANEL,Creatine Kinase,,87,,,,,26 - 192,U/L +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,CHEMISTRY PANEL,Serum Sodium,,142,,,,,132 - 147,mmol/L +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,CHEMISTRY PANEL,Serum Potassium,,4.6,,,,,3.5 - 5.2,mmol/L +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,CHEMISTRY PANEL,Serum Bicarbonate,,21.5,,,,,19.3 - 29.3,mmol/L +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,CHEMISTRY PANEL,Serum Chloride,,104,,,,,94 - 112,mmol/L +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,CHEMISTRY PANEL,Magnesium,,0.94,,,,,0.66 - 1.07,mmol/L +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,105,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,FECAL COLLECTION D/T,Stool Collection Date,Y,05-May-2026,,,,,, +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,FECAL COLLECTION D/T,Stool Collection Time,Y,06:30,,,,,, +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,140,,,,,116 - 164,g/L +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.41,,,,,0.34 - 0.48, +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.5,,,,,4.1 - 5.6,TI/L +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,31,,,,,26 - 34,pg +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,92,,,,,79 - 98,fL +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,4.60,,,,,3.8 - 10.7,GI/L +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.94,,,,,1.96 - 7.23,GI/L +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.22,,,,,0.91 - 4.28,GI/L +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.32,,,,,0.12 - 0.92,GI/L +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.10,,,,,0 - 0.57,GI/L +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.02,,,,,0 - 0.2,GI/L +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,63.9,,,,,40.5 - 75,% +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,26.5,,,,,15.4 - 48.5,% +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,6.9,,,,,2.6 - 10.1,% +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.2,,,,,0 - 6.8,% +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.5,,,,,0 - 2,% +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,207,,,,,140 - 400,GI/L +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,LIPID PANEL,Direct HDL-C 4th Generation,,1.70,,H,,,1.03 - 1.53,mmol/L +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,LIPID PANEL,Triglycerides (GPO),,0.59,,,,,0.59 - 2.96,mmol/L +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,LIPID PANEL,Cholesterol (High Performance),,4.49,,,,,4.42 - 7.53,mmol/L +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,LIPID PANEL,LDL Chol Friedewald 4th,,2.52,,,,,0 - 3.34,mmol/L +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,PA1 EEA-2?,Approved to use EEA-2?,,No,,,,,, +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,SM01/PLASMA PK TROUGH COLL D/T,Collection Date Predose,Y,05-May-2026,,,,,, +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,SM01/PLASMA PK TROUGH COLL D/T,Collection Time Predose,Y,11:30,,,,,, +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,SM02/PLASMA PK PEAK COLL D/T,Collection Date Post dose,Y,05-May-2026,,,,,, +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,SM02/PLASMA PK PEAK COLL D/T,Post Dose Collection Time,Y,12:45,,,,,, +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,SM04/SERUM ADA PRE COLL D/T,Collection Date Predose,Y,05-May-2026,,,,,, +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,SM04/SERUM ADA PRE COLL D/T,Collection Time Predose,Y,11:30,,,,,, +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,SM10/FECAL BMRKS COLL D/T,Stool Collection Date,Y,05-May-2026,,,,,, +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,SM10/FECAL BMRKS COLL D/T,Stool Collection Time,Y,06:30,,,,,, +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,SUBJECT HEIGHT (CM),Height (cm),Y,N/A (subject >/= 18 years of age),,,,,cm, +CZ100092002,,,,,Female,TB Testing,,"May 5, 2026 9:00 AM",6227323348,QUANTIFERON GOLD MITOGEN/INTER,"QFT,TBGoldPlusInt,pl-4-Tubes",,Negative,,,,,Normal=Negative, +CZ100092001,,,,,Female,Biopsy,,"Apr 24, 2026 12:00 AM",6227323351,ANATOMICAL SITE,Anatomical Site,Y,15-20cm from anal verge,,,,,, +CZ100092001,,,,,Female,Biopsy,,"Apr 24, 2026 12:00 AM",6227323351,BIOPSY COLLECTION METHOD,Collection Method,Y,colonoscopy,,,,,, +CZ100092001,,,,,Female,Biopsy,,"Apr 24, 2026 12:00 AM",6227323351,BIOPSY FIXATIVE USED,Fixative Used,,10% NBF,,,,,, +CZ100092001,,,,,Female,Biopsy,,"Apr 24, 2026 12:00 AM",6227323351,DATE/TIME PLACED IN FORMALIN,Date Sample placed in Formalin,Y,24-Apr-2026,,,,,, +CZ100092001,,,,,Female,Biopsy,,"Apr 24, 2026 12:00 AM",6227323351,DATE/TIME PLACED IN FORMALIN,Time Sample placed in Formalin,Y,11:09,,,,,, +CZ100092001,,,,,Female,Biopsy,,"Apr 24, 2026 12:00 AM",6227323351,DIAGNOSIS,Diagnosis:,Y,Ulcerative Colitis,,,,,, +CZ100092001,,,,,Female,Biopsy,,"Apr 24, 2026 12:00 AM",6227323351,INFLAMED AREA,Inflamed area?,,Yes,,,,,, +CZ100092001,,,,,Female,Biopsy,,"Apr 24, 2026 12:00 AM",6227323351,TISSUE BIOPSY EMBEDDING1,Biopsy technical QC-CL,,Smpl meets HT requirements,,,,,, +CZ100092001,,,,,Female,Biopsy,,"Apr 24, 2026 12:00 AM",6227323351,TISSUE BIOPSY EMBEDDING1,Biopsy processing Time-CL,,12:00,,,,,, +CZ100092001,,,,,Female,Biopsy,,"Apr 24, 2026 12:00 AM",6227323351,TISSUE BIOPSY EMBEDDING1,Biopsy processing Date-CL,,29-Apr-2026,,,,,, +CZ100092001,,,,,Female,Biopsy,,"Apr 24, 2026 12:00 AM",6227323351,TISSUE BIOPSY EMBEDDING1,Biopsy Comments-CL,,Received in 10% NBF,,,,,, +CZ100092001,,,,,Female,Biopsy,,"Apr 24, 2026 12:00 AM",6227323351,TISSUE BIOPSY EMBEDDING1,# of Cassettes-(FI)-CL,,1,,,,,, +CZ100092001,,,,,Female,Biopsy,,"Apr 24, 2026 12:00 AM",6227323351,ULCERATED AREA,Is biopsy site ulcerated?,,No,,,,,, +CZ100092002,,,,,Female,Stool Pathogens,,"Apr 20, 2026 6:10 AM",6227323341,C. DIFF EIA,"C. diff GDH Ag,stool-CL",,Negative,,,,,Ref Rng:Negative, +CZ100092002,,,,,Female,Stool Pathogens,,"Apr 20, 2026 6:10 AM",6227323341,C. DIFF EIA,"C.diff Toxin A&B,stool-CL",,Negative,,,,,Ref Rng:Negative, +CZ100092002,,,,,Female,Stool Pathogens,,"Apr 20, 2026 6:10 AM",6227323341,OVA AND PARASITES 1,Concentrate Exam,,No ova or parasites found,,,,,, +CZ100092002,,,,,Female,Stool Pathogens,,"Apr 20, 2026 6:10 AM",6227323341,OVA AND PARASITES 1,Smear for Microsporidia,,No Microsporidia seen.,,,,,, +CZ100092002,,,,,Female,Stool Pathogens,,"Apr 20, 2026 6:10 AM",6227323341,OVA AND PARASITES 1,Modified acid-fast stain,,No coccidian parasites seen,,,,,, +CZ100092002,,,,,Female,Stool Pathogens,,"Apr 20, 2026 6:10 AM",6227323341,OVA AND PARASITES 2,Trichrome Smear,,No ova or parasites found,,,,,, +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,CHEMISTRY PANEL,Total Bilirubin,,9,,,,,3 - 21,umol/L +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.3,,,,,0 - 6.2,umol/L +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,CHEMISTRY PANEL,Alkaline Phosphatase,,56,,,,,35 - 104,U/L +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,CHEMISTRY PANEL,ALT (SGPT),,11,,,,,4 - 43,U/L +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,CHEMISTRY PANEL,AST (SGOT),,25,,,,,8 - 40,U/L +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,CHEMISTRY PANEL,GGT,,10,,,,,4 - 49,U/L +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,CHEMISTRY PANEL,LDH,,159,,,,,53 - 234,U/L +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,CHEMISTRY PANEL,Urea Nitrogen,,6.1,,,,,1.4 - 8.6,mmol/L +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,90,,,,,31 - 101,umol/L +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,CHEMISTRY PANEL,Serum Glucose,,4.9,,,,,3.9 - 5.6,mmol/L +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,CHEMISTRY PANEL,Serum Uric Acid,,268,,,,,149 - 446,umol/L +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,CHEMISTRY PANEL,Calcium (EDTA),,2.43,,,,,2.07 - 2.64,mmol/L +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,CHEMISTRY PANEL,Phosphorus,,1.14,,,,,0.71 - 1.65,mmol/L +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,CHEMISTRY PANEL,Total Protein,,70,,,,,61 - 84,g/L +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,CHEMISTRY PANEL,Albumin-BCG,,46,,,,,33 - 49,g/L +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,CHEMISTRY PANEL,Creatine Kinase,,176,,,,,26 - 192,U/L +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,CHEMISTRY PANEL,Serum Sodium,,140,,,,,132 - 147,mmol/L +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,CHEMISTRY PANEL,Serum Potassium,,4.6,,,,,3.5 - 5.2,mmol/L +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,CHEMISTRY PANEL,Serum Bicarbonate,,27.2,,,,,19.3 - 29.3,mmol/L +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,CHEMISTRY PANEL,Serum Chloride,,101,,,,,94 - 112,mmol/L +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,CHEMISTRY PANEL,Magnesium,,0.93,,,,,0.66 - 1.07,mmol/L +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,65,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,FEMALE OF CHILDBEARING POT?,Female/of Childbearing pot.?,Y,Yes,,,,,, +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,HBV ELIGIBILITY MET?,HBV Eligibility Criteria Met?,,Yes,,,,,, +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,138,,,,,116 - 164,g/L +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.39,,,,,0.34 - 0.48, +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.3,,,,,4.1 - 5.6,TI/L +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,32,,,,,26 - 34,pg +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,90,,,,,79 - 98,fL +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,4.05,,,,,3.8 - 10.7,GI/L +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,1.87,,L,,,1.96 - 7.23,GI/L +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.72,,,,,0.91 - 4.28,GI/L +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.29,,,,,0.12 - 0.92,GI/L +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.14,,,,,0 - 0.57,GI/L +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.03,,,,,0 - 0.2,GI/L +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,46.1,,,,,40.5 - 75,% +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,42.6,,,,,15.4 - 48.5,% +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,7.2,,,,,2.6 - 10.1,% +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,3.4,,,,,0 - 6.8,% +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.6,,,,,0 - 2,% +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,216,,,,,140 - 400,GI/L +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,HEPATITIS B CORE AB NON-US,Hepatitis B Core Total,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,HEPATITIS B SURFACE AB,Anti-HBs II QUAL,,Non-Reactive,,,,,Ref Rng :$Non Reactive, +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,HEPATITIS B SURFACE AG NON-US,Hep B Surface AgII,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,HEPATITIS C VIRUS AB NON-US,Hepatitis C Virus Antibody,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,HIV 1/2 AG/AB SCREEN,anti-HIV-1/2 antibodies,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,HIV 1/2 AG/AB SCREEN,HIV -1 p24 antigen,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,HIV 1/2 AG/AB SCREEN,"HIV 1/2 Ag/Ab Screen, Cobas",,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,QUANTIFERON GOLD MITOGEN/INTER,"QFT,TBGoldPlusInt,pl-4-Tubes",,Positive,,RX,,Result verified by repeat analysis,Normal=Negative, +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,SERUM BETA HCG,"B-hCG, Qualitative",,Negative,,,,,Ref Rng: Negative, +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,SERUM BETA HCG,"B-hCG, Quantitative",,0.6,,,,,Units: mIU/mL$Pre-menopausal$<5.0: Negative$5.0-24.9:Borderline$>/= 25.0: Positive, +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,SUBJECT HEIGHT (CM),Height (cm),Y,N/A (subject >/= 18 years of age),,,,,cm, +CZ100092001,,,,,Female,Stool Pathogens,,"Apr 2, 2026 6:15 AM",6227323340,C. DIFF EIA,"C. diff GDH Ag,stool-CL",,Negative,,,,,Ref Rng:Negative, +CZ100092001,,,,,Female,Stool Pathogens,,"Apr 2, 2026 6:15 AM",6227323340,C. DIFF EIA,"C.diff Toxin A&B,stool-CL",,Negative,,,,,Ref Rng:Negative, +CZ100092001,,,,,Female,Stool Pathogens,,"Apr 2, 2026 6:15 AM",6227323340,OVA AND PARASITES 1,Concentrate Exam,,No ova or parasites found,,,,,, +CZ100092001,,,,,Female,Stool Pathogens,,"Apr 2, 2026 6:15 AM",6227323340,OVA AND PARASITES 1,Smear for Microsporidia,,No Microsporidia seen.,,,,,, +CZ100092001,,,,,Female,Stool Pathogens,,"Apr 2, 2026 6:15 AM",6227323340,OVA AND PARASITES 1,Modified acid-fast stain,,No coccidian parasites seen,,,,,, +CZ100092001,,,,,Female,Stool Pathogens,,"Apr 2, 2026 6:15 AM",6227323340,OVA AND PARASITES 2,Trichrome Smear,,No ova or parasites found,,,,,, +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,CHEMISTRY PANEL,Total Bilirubin,,9,,,,,3 - 21,umol/L +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.4,,,,,0 - 6.2,umol/L +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,CHEMISTRY PANEL,Alkaline Phosphatase,,56,,,,,35 - 104,U/L +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,CHEMISTRY PANEL,ALT (SGPT),,15,,,,,4 - 43,U/L +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,CHEMISTRY PANEL,AST (SGOT),,17,,,,,8 - 40,U/L +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,CHEMISTRY PANEL,GGT,,12,,,,,4 - 49,U/L +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,CHEMISTRY PANEL,LDH,,137,,,,,53 - 234,U/L +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,CHEMISTRY PANEL,Urea Nitrogen,,2.7,,,,,1.4 - 8.6,mmol/L +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,58,,,,,31 - 101,umol/L +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,CHEMISTRY PANEL,Serum Glucose,,5.2,,,,,3.9 - 5.6,mmol/L +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,CHEMISTRY PANEL,Serum Uric Acid,,207,,,,,125 - 428,umol/L +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,CHEMISTRY PANEL,Calcium (EDTA),,2.43,,,,,2.07 - 2.64,mmol/L +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,CHEMISTRY PANEL,Phosphorus,,1.15,,,,,0.71 - 1.65,mmol/L +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,CHEMISTRY PANEL,Total Protein,,67,,,,,61 - 84,g/L +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,CHEMISTRY PANEL,Albumin-BCG,,44,,,,,33 - 49,g/L +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,CHEMISTRY PANEL,Creatine Kinase,,81,,,,,26 - 192,U/L +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,CHEMISTRY PANEL,Serum Sodium,,141,,,,,132 - 147,mmol/L +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,CHEMISTRY PANEL,Serum Potassium,,4.3,,,,,3.5 - 5.2,mmol/L +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,CHEMISTRY PANEL,Serum Bicarbonate,,23.7,,,,,19.3 - 29.3,mmol/L +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,CHEMISTRY PANEL,Serum Chloride,,103,,,,,94 - 112,mmol/L +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,CHEMISTRY PANEL,Magnesium,,0.91,,,,,0.66 - 1.07,mmol/L +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,107,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,FEMALE OF CHILDBEARING POT?,Female/of Childbearing pot.?,Y,Yes,,,,,, +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,HBV ELIGIBILITY MET?,HBV Eligibility Criteria Met?,,Yes,,,,,, +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,147,,,,,116 - 164,g/L +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.43,,,,,0.34 - 0.48, +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.7,,,,,4.1 - 5.6,TI/L +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,31,,,,,26 - 34,pg +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,91,,,,,79 - 98,fL +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,5.74,,,,,3.8 - 10.7,GI/L +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.76,,,,,1.96 - 7.23,GI/L +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.18,,,,,0.91 - 4.28,GI/L +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.46,,,,,0.12 - 0.92,GI/L +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.26,,,,,0 - 0.57,GI/L +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.09,,,,,0 - 0.2,GI/L +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,65.5,,,,,40.5 - 75,% +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,20.6,,,,,15.4 - 48.5,% +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,7.9,,,,,2.6 - 10.1,% +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,4.5,,,,,0 - 6.8,% +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.5,,,,,0 - 2,% +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,263,,,,,140 - 400,GI/L +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,HEPATITIS B CORE AB NON-US,Hepatitis B Core Total,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,HEPATITIS B SURFACE AB,Anti-HBs II QUAL,,Non-Reactive,,,,,Ref Rng :$Non Reactive, +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,HEPATITIS B SURFACE AG NON-US,Hep B Surface AgII,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,HEPATITIS C VIRUS AB NON-US,Hepatitis C Virus Antibody,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,HIV 1/2 AG/AB SCREEN,anti-HIV-1/2 antibodies,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,HIV 1/2 AG/AB SCREEN,HIV -1 p24 antigen,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,HIV 1/2 AG/AB SCREEN,"HIV 1/2 Ag/Ab Screen, Cobas",,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,PA1 EEA-2?,Approved to use EEA-2?,,No,,,,,, +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,QUANTIFERON GOLD MITOGEN/INTER,"QFT,TBGoldPlusInt,pl-4-Tubes",,Negative,,,,,Normal=Negative, +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,SERUM BETA HCG,"B-hCG, Qualitative",,Negative,,,,,Ref Rng: Negative, +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,SERUM BETA HCG,"B-hCG, Quantitative",,<0.6,,,,,Units: mIU/mL$Pre-menopausal$<5.0: Negative$5.0-24.9:Borderline$>/= 25.0: Positive, +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,SUBJECT HEIGHT (CM),Height (cm),Y,N/A (subject >/= 18 years of age),,,,,cm, diff --git a/Covance_UCO3001/Source/2026-06-08_130552 sponsor-study-36940-test-results-930536-microbiology.csv b/Covance_UCO3001/Source/2026-06-08_130552 sponsor-study-36940-test-results-930536-microbiology.csv new file mode 100644 index 0000000..4dfdeb2 --- /dev/null +++ b/Covance_UCO3001/Source/2026-06-08_130552 sponsor-study-36940-test-results-930536-microbiology.csv @@ -0,0 +1,3 @@ +"Disclaimer: The information presented in On-Screen Results is not intended to be a replacement of the official Lab Results, Alerts, Data Revisions and Cancellations found in the Lab Reports section of this software application. On-Screen Results should not be used for patient diagnosis, treatment decisions or submission to regulatory bodies.",,,,,,,,,,,,,,,,,,,,,,, +Subject,Screening Number,Age,Age Unit,Gender,Visit Description,Collected Time,Accession,Test Group,Specimen,Organism,Growth,Cancellation Reason,Test Description,Test Result,Drug Name/Agent,MIC Result,Units,MIC Interpretation,Disk Diffusion Result,Disk Diffusion Interpretation,Subject Data Revision,Visit Data Revision,Result Data Revision +CZ100201001 - null,,,,Male,SCRNSTOOL Stool Pathogens,"Apr 13, 2026 6:00 AM",6227993971,STOOL CULTURE,Stool,,,,Final Report,No enteric pathogens isolated,,,,,,,,, diff --git a/Covance_UCO3001/Source/2026-06-08_130600 sponsor-study-36940-test-results-930536-standard.csv b/Covance_UCO3001/Source/2026-06-08_130600 sponsor-study-36940-test-results-930536-standard.csv new file mode 100644 index 0000000..0763d9d --- /dev/null +++ b/Covance_UCO3001/Source/2026-06-08_130600 sponsor-study-36940-test-results-930536-standard.csv @@ -0,0 +1,185 @@ +"Disclaimer: The information presented in On-Screen Results is not intended to be a replacement of the official Lab Results, Alerts, Data Revisions and Cancellations found in the Lab Reports section of this software application. On-Screen Results should not be used for patient diagnosis, treatment decisions or submission to regulatory bodies.",,,,,,,,,,,,,,,,,,, +Subject,Subject Data Revision,Screen No.,Age,Age Unit,Gender,Visit,Visit Data Revision,Collected Time,Accession,Test Group,Test,Administrative Question,Value,Result Data Revision,Flags,Cancellation Reason,Comments,Range,Units +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,ALP<2XULN,ALP<2XULN,,Criteria Met,,,,,, +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,ALT>/=3XULN,ALT >/= 3 X ULN,,Criteria not met,,,,,, +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,ALT>/=3XULN & TBIL>/=2XULN,ALT >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,AST>/=3XULN,AST >/= 3 X ULN,,Criteria not met,,,,,, +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,AST>/=3XULN & TBIL>/=2XULN,AST >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,CHEMISTRY PANEL,Total Bilirubin,,4,,,,,3 - 21,umol/L +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,<1.4,,,,,0 - 6.2,umol/L +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,CHEMISTRY PANEL,Alkaline Phosphatase,,286,,,,,82 - 331,U/L +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,CHEMISTRY PANEL,ALT (SGPT),,32,,,,,6 - 43,U/L +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,CHEMISTRY PANEL,AST (SGOT),,44,,H,,,10 - 40,U/L +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,CHEMISTRY PANEL,GGT,,20,,,,,0 - 51,U/L +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,CHEMISTRY PANEL,LDH,,215,,,,,105 - 235,U/L +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,CHEMISTRY PANEL,Urea Nitrogen,,5.4,,,,,1.4 - 8.6,mmol/L +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,45,,,,,23 - 83,umol/L +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,CHEMISTRY PANEL,Serum Glucose,,4.2,,,,,3.9 - 5.6,mmol/L +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,CHEMISTRY PANEL,Serum Uric Acid,,310,,,,,184 - 416,umol/L +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,CHEMISTRY PANEL,Calcium (EDTA),,2.37,,,,,2.1 - 2.57,mmol/L +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,CHEMISTRY PANEL,Phosphorus,,1.54,,,,,0.71 - 1.65,mmol/L +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,CHEMISTRY PANEL,Total Protein,,79,,,,,61 - 84,g/L +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,CHEMISTRY PANEL,Albumin-BCG,,40,,,,,29 - 47,g/L +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,CHEMISTRY PANEL,Creatine Kinase,,86,,,,,18 - 363,U/L +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,CHEMISTRY PANEL,Serum Sodium,,138,,,,,132 - 147,mmol/L +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,CHEMISTRY PANEL,Serum Potassium,,4.9,,,,,3.5 - 5.2,mmol/L +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,CHEMISTRY PANEL,Serum Bicarbonate,,20.2,,,,,19.3 - 29.3,mmol/L +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,CHEMISTRY PANEL,Serum Chloride,,105,,,,,94 - 112,mmol/L +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,CHEMISTRY PANEL,Magnesium,,0.79,,,,,0.7 - 0.9,mmol/L +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,CRP COPY,C Reactive Protein COPY,,2.3,,H,,,0.4 - 2,mg/L +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,FECAL CALPROTECTIN COPY,Fecal Calprotectin COPY,,4018.5,,H,,,Normal: <80ug/g$Borderline: 80-160$ug/g. Elevated:>160$ug/g, +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,FECAL COLLECTION D/T,Stool Collection Date,Y,31-May-2026,,,,,, +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,FECAL COLLECTION D/T,Stool Collection Time,Y,19:00,,,,,, +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,104,,L,,Result verified by repeat analysis,127 - 181,g/L +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.35,,L,,Result verified by repeat analysis,0.39 - 0.54, +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.0,,L,,Result verified by repeat analysis,4.5 - 6.4,TI/L +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,26,,,,Result verified by repeat analysis,26 - 34,pg +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,87,,,,Result verified by repeat analysis,79 - 96,fL +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,8.73,,,,Result verified by repeat analysis,4.35 - 13.15,GI/L +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,4.46,,,,,1.65 - 8.15,GI/L +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,3.07,,,,,0.95 - 5.25,GI/L +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.81,,,,Result verified by repeat analysis,0.4 - 1.3,GI/L +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.33,,H,,Result verified by repeat analysis,0 - 0.3,GI/L +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.06,,,,Result verified by repeat analysis,0 - 0.2,GI/L +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,51.1,,,,Result verified by repeat analysis,40.5 - 75,% +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,35.2,,,,Result verified by repeat analysis,15.4 - 48.5,% +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,9.3,,H,,Result verified by repeat analysis,4 - 8,% +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,3.7,,H,,Result verified by repeat analysis,0 - 2.8,% +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.7,,,,Result verified by repeat analysis,0 - 1,% +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,444,,H,,Result verified by repeat analysis,140 - 400,GI/L +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,PA1 EEA-2?,Approved to use EEA-2?,,,,,,,, +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,SM01/PLASMA PK TROUGH COLL D/T,Collection Date Predose,Y,01-Jun-2026,,,,,, +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,SM01/PLASMA PK TROUGH COLL D/T,Collection Time Predose,Y,08:35,,,,,, +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,SM02/PLASMA PK PEAK COLL D/T,Collection Date Post dose,Y,01-Jun-2026,,,,,, +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,SM02/PLASMA PK PEAK COLL D/T,Post Dose Collection Time,Y,10:45,,,,,, +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,SM04/SERUM ADA PRE COLL D/T,Collection Date Predose,Y,01-Jun-2026,,,,,, +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,SM04/SERUM ADA PRE COLL D/T,Collection Time Predose,Y,08:35,,,,,, +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,SM09/STOOL PK COLL D/T,Stool Collection Date,Y,31-May-2026,,,,,, +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,SM09/STOOL PK COLL D/T,Stool Collection Time,Y,19:00,,,,,, +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,SUBJECT HEIGHT (CM),Height (cm),Y,,,,,,, +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,2003 SCHWARTZ EGFR,2003 Schwartz eGFR,,191,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,CHEMISTRY PANEL,Total Bilirubin,,9,,,,,3 - 21,umol/L +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.0,,,,,0 - 6.2,umol/L +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,CHEMISTRY PANEL,Alkaline Phosphatase,,282,,,,,82 - 331,U/L +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,CHEMISTRY PANEL,ALT (SGPT),,16,,,,,6 - 43,U/L +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,CHEMISTRY PANEL,AST (SGOT),,26,,,,,10 - 40,U/L +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,CHEMISTRY PANEL,GGT,,15,,,,,0 - 51,U/L +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,CHEMISTRY PANEL,LDH,,214,,,,,105 - 235,U/L +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,CHEMISTRY PANEL,Urea Nitrogen,,4.0,,,,,1.4 - 8.6,mmol/L +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,51,,,,,23 - 83,umol/L +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,CHEMISTRY PANEL,Serum Glucose,,4.3,,,,,3.9 - 5.6,mmol/L +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,CHEMISTRY PANEL,Serum Uric Acid,,336,,,,,184 - 416,umol/L +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,CHEMISTRY PANEL,Calcium (EDTA),,2.47,,,,,2.1 - 2.57,mmol/L +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,CHEMISTRY PANEL,Phosphorus,,1.58,,,,,0.71 - 1.65,mmol/L +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,CHEMISTRY PANEL,Total Protein,,85,,H,,,61 - 84,g/L +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,CHEMISTRY PANEL,Albumin-BCG,,44,,,,,29 - 47,g/L +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,CHEMISTRY PANEL,Creatine Kinase,,65,,,,,18 - 363,U/L +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,CHEMISTRY PANEL,Serum Sodium,,136,,,,,132 - 147,mmol/L +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,CHEMISTRY PANEL,Serum Potassium,,4.7,,,,,3.5 - 5.2,mmol/L +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,CHEMISTRY PANEL,Serum Bicarbonate,,23.4,,,,,19.3 - 29.3,mmol/L +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,CHEMISTRY PANEL,Serum Chloride,,100,,,,,94 - 112,mmol/L +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,CHEMISTRY PANEL,Magnesium,,0.81,,,,,0.7 - 0.9,mmol/L +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,CRP COPY,C Reactive Protein COPY,,1.9,,,,,0.4 - 2,mg/L +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,FECAL CALPROTECTIN COPY,Fecal Calprotectin COPY,,3749.9,,H,,,Normal: <80ug/g$Borderline: 80-160$ug/g. Elevated:>160$ug/g, +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,FECAL COLLECTION D/T,Stool Collection Date,Y,17-May-2026,,,,,, +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,FECAL COLLECTION D/T,Stool Collection Time,Y,18:00,,,,,, +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,114,,L,,,127 - 181,g/L +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.37,,L,,,0.39 - 0.54, +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.2,,L,,,4.5 - 6.4,TI/L +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,27,,,,,26 - 34,pg +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,87,,,,,79 - 96,fL +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,9.73,,,,,4.35 - 13.15,GI/L +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,5.06,,,,,1.65 - 8.15,GI/L +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,3.42,,,,,0.95 - 5.25,GI/L +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.83,,,,,0.4 - 1.3,GI/L +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.34,,H,,,0 - 0.3,GI/L +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.10,,,,,0 - 0.2,GI/L +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,52.0,,,,,40.5 - 75,% +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,35.1,,,,,15.4 - 48.5,% +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,8.5,,H,,,4 - 8,% +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,3.5,,H,,,0 - 2.8,% +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.0,,,,,0 - 1,% +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,607,,H,,,140 - 400,GI/L +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,LIPID PANEL,Direct HDL-C 4th Generation,,1.27,,,,,1.03 - 1.53,mmol/L +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,LIPID PANEL,Triglycerides (GPO),,1.17,,,,,0.42 - 1.67,mmol/L +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,LIPID PANEL,Cholesterol (High Performance),,3.50,,,,,2.95 - 5.12,mmol/L +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,LIPID PANEL,LDL Chol Friedewald 4th,,1.69,,,,,0 - 3.34,mmol/L +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,SM01/PLASMA PK TROUGH COLL D/T,Collection Date Predose,Y,18-May-2026,,,,,, +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,SM01/PLASMA PK TROUGH COLL D/T,Collection Time Predose,Y,09:28,,,,,, +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,SM02/PLASMA PK PEAK COLL D/T,Collection Date Post dose,Y,18-May-2026,,,,,, +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,SM02/PLASMA PK PEAK COLL D/T,Post Dose Collection Time,Y,10:52,,,,,, +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,SM04/SERUM ADA PRE COLL D/T,Collection Date Predose,Y,18-May-2026,,,,,, +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,SM04/SERUM ADA PRE COLL D/T,Collection Time Predose,Y,09:28,,,,,, +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,SM10/FECAL BMRKS COLL D/T,Stool Collection Date,Y,17-May-2026,,,,,, +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,SM10/FECAL BMRKS COLL D/T,Stool Collection Time,Y,18:00,,,,,, +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,SUBJECT HEIGHT (CM),Height (cm),Y,157,,,,,cm, +CZ100201001,,,,,Male,Biopsy,,"Apr 15, 2026 12:00 AM",6227993984,ANATOMICAL SITE,Anatomical Site,Y,20-25,,,,,, +CZ100201001,,,,,Male,Biopsy,,"Apr 15, 2026 12:00 AM",6227993984,BIOPSY COLLECTION METHOD,Collection Method,Y,colonoscopy,,,,,, +CZ100201001,,,,,Male,Biopsy,,"Apr 15, 2026 12:00 AM",6227993984,BIOPSY FIXATIVE USED,Fixative Used,,10% NBF,,,,,, +CZ100201001,,,,,Male,Biopsy,,"Apr 15, 2026 12:00 AM",6227993984,DATE/TIME PLACED IN FORMALIN,Date Sample placed in Formalin,Y,15-Apr-2026,,,,,, +CZ100201001,,,,,Male,Biopsy,,"Apr 15, 2026 12:00 AM",6227993984,DATE/TIME PLACED IN FORMALIN,Time Sample placed in Formalin,Y,13:00,,,,,, +CZ100201001,,,,,Male,Biopsy,,"Apr 15, 2026 12:00 AM",6227993984,DIAGNOSIS,Diagnosis:,Y,Ulcerative Colitis,,,,,, +CZ100201001,,,,,Male,Biopsy,,"Apr 15, 2026 12:00 AM",6227993984,INFLAMED AREA,Inflamed area?,,Yes,,,,,, +CZ100201001,,,,,Male,Biopsy,,"Apr 15, 2026 12:00 AM",6227993984,TISSUE BIOPSY EMBEDDING1,Biopsy technical QC-CL,,Smpl meets HT requirements,,,,,, +CZ100201001,,,,,Male,Biopsy,,"Apr 15, 2026 12:00 AM",6227993984,TISSUE BIOPSY EMBEDDING1,Biopsy processing Time-CL,,10:00,,,,,, +CZ100201001,,,,,Male,Biopsy,,"Apr 15, 2026 12:00 AM",6227993984,TISSUE BIOPSY EMBEDDING1,Biopsy processing Date-CL,,17-Apr-2026,,,,,, +CZ100201001,,,,,Male,Biopsy,,"Apr 15, 2026 12:00 AM",6227993984,TISSUE BIOPSY EMBEDDING1,Biopsy Comments-CL,,Received in 10% NBF,,,,,, +CZ100201001,,,,,Male,Biopsy,,"Apr 15, 2026 12:00 AM",6227993984,TISSUE BIOPSY EMBEDDING1,# of Cassettes-(FI)-CL,,1,,,,,, +CZ100201001,,,,,Male,Biopsy,,"Apr 15, 2026 12:00 AM",6227993984,ULCERATED AREA,Is biopsy site ulcerated?,,No,,,,,, +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,2003 SCHWARTZ EGFR,2003 Schwartz eGFR,,211,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,CHEMISTRY PANEL,Total Bilirubin,,7,,,,,3 - 21,umol/L +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.2,,,,,0 - 6.2,umol/L +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,CHEMISTRY PANEL,Alkaline Phosphatase,,322,,,,,82 - 331,U/L +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,CHEMISTRY PANEL,ALT (SGPT),,20,,,,,6 - 43,U/L +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,CHEMISTRY PANEL,AST (SGOT),,29,,,,,10 - 40,U/L +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,CHEMISTRY PANEL,GGT,,17,,,,,0 - 51,U/L +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,CHEMISTRY PANEL,LDH,,221,,,,,105 - 235,U/L +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,CHEMISTRY PANEL,Urea Nitrogen,,3.6,,,,,1.4 - 8.6,mmol/L +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,46,,,,,23 - 83,umol/L +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,CHEMISTRY PANEL,Serum Glucose,,4.1,,,,,3.9 - 5.6,mmol/L +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,CHEMISTRY PANEL,Serum Uric Acid,,326,,,,,184 - 416,umol/L +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,CHEMISTRY PANEL,Calcium (EDTA),,2.57,,,,,2.1 - 2.57,mmol/L +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,CHEMISTRY PANEL,Phosphorus,,1.72,,H,,,0.71 - 1.65,mmol/L +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,CHEMISTRY PANEL,Total Protein,,87,,H,,,61 - 84,g/L +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,CHEMISTRY PANEL,Albumin-BCG,,45,,,,,29 - 47,g/L +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,CHEMISTRY PANEL,Creatine Kinase,,94,,,,,18 - 363,U/L +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,CHEMISTRY PANEL,Serum Sodium,,136,,,,,132 - 147,mmol/L +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,CHEMISTRY PANEL,Serum Potassium,,4.9,,,,,3.5 - 5.2,mmol/L +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,CHEMISTRY PANEL,Serum Bicarbonate,,20.7,,,,,19.3 - 29.3,mmol/L +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,CHEMISTRY PANEL,Serum Chloride,,100,,,,,94 - 112,mmol/L +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,CHEMISTRY PANEL,Magnesium,,0.77,,,,,0.7 - 0.9,mmol/L +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,HBV ELIGIBILITY MET?,HBV Eligibility Criteria Met?,,Yes,,,,,, +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,118,,L,,Result verified by repeat analysis,127 - 181,g/L +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.37,,L,,,0.39 - 0.54, +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.2,,L,,Result verified by repeat analysis,4.5 - 6.4,TI/L +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,28,,,,Result verified by repeat analysis,26 - 34,pg +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,87,,,,,79 - 96,fL +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,10.04,,,,Result verified by repeat analysis,4.35 - 13.15,GI/L +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,5.19,,,,Result verified by repeat analysis,1.65 - 8.15,GI/L +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,3.73,,,,,0.95 - 5.25,GI/L +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.77,,,,Result verified by repeat analysis,0.4 - 1.3,GI/L +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.29,,,,Result verified by repeat analysis,0 - 0.3,GI/L +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.05,,,,Result verified by repeat analysis,0 - 0.2,GI/L +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,51.7,,,,Result verified by repeat analysis,40.5 - 75,% +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,37.2,,,,Result verified by repeat analysis,15.4 - 48.5,% +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,7.6,,,,Result verified by repeat analysis,4 - 8,% +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.9,,H,,Result verified by repeat analysis,0 - 2.8,% +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.5,,,,Result verified by repeat analysis,0 - 1,% +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,490,,H,,Result verified by repeat analysis,140 - 400,GI/L +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,HEPATITIS B CORE AB NON-US,Hepatitis B Core Total,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,HEPATITIS B SURFACE AB,Anti-HBs II QUAL,,Reactive,,,,,Ref Rng :$Non Reactive, +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,HEPATITIS B SURFACE AG NON-US,Hep B Surface AgII,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,HEPATITIS C VIRUS AB NON-US,Hepatitis C Virus Antibody,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,HIV 1/2 AG/AB SCREEN,anti-HIV-1/2 antibodies,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,HIV 1/2 AG/AB SCREEN,HIV -1 p24 antigen,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,HIV 1/2 AG/AB SCREEN,"HIV 1/2 Ag/Ab Screen, Cobas",,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,QUANTIFERON GOLD MITOGEN/INTER,"QFT,TBGoldPlusInt,pl-4-Tubes",,Negative,,,,,Normal=Negative, +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,SUBJECT HEIGHT (CM),Height (cm),Y,157,,,,,cm, +CZ100201001,,,,,Male,Stool Pathogens,,"Apr 13, 2026 6:00 AM",6227993971,C. DIFF EIA,"C. diff GDH Ag,stool-CL",,Negative,,,,,Ref Rng:Negative, +CZ100201001,,,,,Male,Stool Pathogens,,"Apr 13, 2026 6:00 AM",6227993971,C. DIFF EIA,"C.diff Toxin A&B,stool-CL",,Negative,,,,,Ref Rng:Negative, diff --git a/Covance_UCO3001/Source/2026-06-08_130612 sponsor-study-36940-test-results-930531-microbiology.csv b/Covance_UCO3001/Source/2026-06-08_130612 sponsor-study-36940-test-results-930531-microbiology.csv new file mode 100644 index 0000000..9f10aa5 --- /dev/null +++ b/Covance_UCO3001/Source/2026-06-08_130612 sponsor-study-36940-test-results-930531-microbiology.csv @@ -0,0 +1,3 @@ +"Disclaimer: The information presented in On-Screen Results is not intended to be a replacement of the official Lab Results, Alerts, Data Revisions and Cancellations found in the Lab Reports section of this software application. On-Screen Results should not be used for patient diagnosis, treatment decisions or submission to regulatory bodies.",,,,,,,,,,,,,,,,,,,,,,, +Subject,Screening Number,Age,Age Unit,Gender,Visit Description,Collected Time,Accession,Test Group,Specimen,Organism,Growth,Cancellation Reason,Test Description,Test Result,Drug Name/Agent,MIC Result,Units,MIC Interpretation,Disk Diffusion Result,Disk Diffusion Interpretation,Subject Data Revision,Visit Data Revision,Result Data Revision +CZ100212001 - null,,,,Male,SCRNSTOOL Stool Pathogens,"Mar 1, 2026 2:00 PM",6227635213,STOOL CULTURE,Stool,,,,Final Report,No enteric pathogens isolated,,,,,,,,, diff --git a/Covance_UCO3001/Source/2026-06-08_130624 sponsor-study-36940-test-results-930531-standard.csv b/Covance_UCO3001/Source/2026-06-08_130624 sponsor-study-36940-test-results-930531-standard.csv new file mode 100644 index 0000000..4d4b87b --- /dev/null +++ b/Covance_UCO3001/Source/2026-06-08_130624 sponsor-study-36940-test-results-930531-standard.csv @@ -0,0 +1,243 @@ +"Disclaimer: The information presented in On-Screen Results is not intended to be a replacement of the official Lab Results, Alerts, Data Revisions and Cancellations found in the Lab Reports section of this software application. On-Screen Results should not be used for patient diagnosis, treatment decisions or submission to regulatory bodies.",,,,,,,,,,,,,,,,,,, +Subject,Subject Data Revision,Screen No.,Age,Age Unit,Gender,Visit,Visit Data Revision,Collected Time,Accession,Test Group,Test,Administrative Question,Value,Result Data Revision,Flags,Cancellation Reason,Comments,Range,Units +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,ALP<2XULN,ALP<2XULN,,Criteria Met,,,,,, +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,ALT>/=3XULN,ALT >/= 3 X ULN,,Criteria not met,,,,,, +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,ALT>/=3XULN & TBIL>/=2XULN,ALT >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,AST>/=3XULN,AST >/= 3 X ULN,,Criteria not met,,,,,, +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,AST>/=3XULN & TBIL>/=2XULN,AST >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,CHEMISTRY PANEL,Total Bilirubin,,4,,,,Result verified by repeat analysis,3 - 21,umol/L +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,1.6,,,,,0 - 6.2,umol/L +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,CHEMISTRY PANEL,Alkaline Phosphatase,,113,,,,,40 - 129,U/L +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,CHEMISTRY PANEL,ALT (SGPT),,12,,,,,5 - 48,U/L +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,CHEMISTRY PANEL,AST (SGOT),,18,,,,,8 - 40,U/L +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,CHEMISTRY PANEL,GGT,,23,,,,,10 - 50,U/L +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,CHEMISTRY PANEL,LDH,,195,,,,,53 - 234,U/L +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,CHEMISTRY PANEL,Urea Nitrogen,,2.7,,,,,1.4 - 8.6,mmol/L +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,73,,,,,40 - 119,umol/L +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,CHEMISTRY PANEL,Serum Glucose,,5.7,,H,,,3.9 - 5.6,mmol/L +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,CHEMISTRY PANEL,Serum Uric Acid,,409,,,,,149 - 494,umol/L +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,CHEMISTRY PANEL,Calcium (EDTA),,2.32,,,,,2.07 - 2.64,mmol/L +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,CHEMISTRY PANEL,Phosphorus,,1.01,,,,,0.71 - 1.65,mmol/L +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,CHEMISTRY PANEL,Total Protein,,73,,,,,60 - 80,g/L +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,CHEMISTRY PANEL,Albumin-BCG,,41,,,,,33 - 49,g/L +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,CHEMISTRY PANEL,Creatine Kinase,,159,,,,,39 - 308,U/L +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,CHEMISTRY PANEL,Serum Sodium,,139,,,,,135 - 145,mmol/L +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,CHEMISTRY PANEL,Serum Potassium,,5.1,,,,,3.5 - 5.2,mmol/L +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,CHEMISTRY PANEL,Serum Bicarbonate,,21.3,,,,,19.3 - 29.3,mmol/L +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,CHEMISTRY PANEL,Serum Chloride,,105,,,,,94 - 112,mmol/L +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,CHEMISTRY PANEL,Magnesium,,0.90,,,,,0.66 - 0.98,mmol/L +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,100,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,FECAL COLLECTION D/T,Stool Collection Date,Y,05-May-2026,,,,,, +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,FECAL COLLECTION D/T,Stool Collection Time,Y,06:50,,,,,, +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,98,,L,,,125 - 170,g/L +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.34,,L,,,0.37 - 0.51, +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.5,,,,,4 - 5.8,TI/L +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,22,,L,,Result verified by repeat analysis,26 - 34,pg +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,Microcytic,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,76,,L,,,80 - 100,fL +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,9.13,,,,Result verified by repeat analysis,3.8 - 10.7,GI/L +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,6.41,,,,,1.96 - 7.23,GI/L +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.42,,,,,0.8 - 3,GI/L +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.93,,H,,,0.12 - 0.92,GI/L +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.29,,,,,0 - 0.57,GI/L +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.08,,,,,0 - 0.2,GI/L +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,70.2,,,,,40.5 - 75,% +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,15.6,,,,,15.4 - 48.5,% +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,10.1,,,,,2.6 - 10.1,% +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,3.1,,,,,0 - 6.8,% +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.9,,,,,0 - 2,% +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,812,,HT,,,130 - 394,GI/L +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,SM01/PLASMA PK TROUGH COLL D/T,Collection Date Predose,Y,05-May-2026,,,,,, +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,SM01/PLASMA PK TROUGH COLL D/T,Collection Time Predose,Y,10:00,,,,,, +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,SM02/PLASMA PK PEAK COLL D/T,Collection Date Post dose,Y,05-May-2026,,,,,, +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,SM02/PLASMA PK PEAK COLL D/T,Post Dose Collection Time,Y,13:00,,,,,, +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,SM04/SERUM ADA PRE COLL D/T,Collection Date Predose,Y,05-May-2026,,,,,, +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,SM04/SERUM ADA PRE COLL D/T,Collection Time Predose,Y,10:00,,,,,, +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,SM09/STOOL PK COLL D/T,Stool Collection Date,Y,05-May-2026,,,,,, +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,SM09/STOOL PK COLL D/T,Stool Collection Time,Y,06:50,,,,,, +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,SUBJECT HEIGHT (CM),Height (cm),Y,N/A (subject >/= 18 years of age),,,,,cm, +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,ALP<2XULN,ALP<2XULN,,Criteria Met,,,,,, +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,ALT>/=3XULN,ALT >/= 3 X ULN,,Criteria not met,,,,,, +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,ALT>/=3XULN & TBIL>/=2XULN,ALT >/=3xULN & TBIL >/=2xULN,,Unable to calc due to LOQ,,,,,, +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,AST>/=3XULN,AST >/= 3 X ULN,,Criteria not met,,,,,, +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,AST>/=3XULN & TBIL>/=2XULN,AST >/=3xULN & TBIL >/=2xULN,,Unable to calc due to LOQ,,,,,, +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,CHEMISTRY PANEL,Total Bilirubin,,<3,,L,,Result verified by repeat analysis,3 - 21,umol/L +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,<1.4,,,,Result verified by repeat analysis,0 - 6.2,umol/L +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,CHEMISTRY PANEL,Alkaline Phosphatase,,112,,,,,40 - 129,U/L +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,CHEMISTRY PANEL,ALT (SGPT),,8,,,,,5 - 48,U/L +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,CHEMISTRY PANEL,AST (SGOT),,14,,,,,8 - 40,U/L +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,CHEMISTRY PANEL,GGT,,27,,,,,10 - 50,U/L +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,CHEMISTRY PANEL,LDH,,150,,,,,53 - 234,U/L +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,CHEMISTRY PANEL,Urea Nitrogen,,2.4,,,,,1.4 - 8.6,mmol/L +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,74,,,,,40 - 119,umol/L +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,CHEMISTRY PANEL,Serum Glucose,,6.1,,H,,,3.9 - 5.6,mmol/L +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,CHEMISTRY PANEL,Serum Uric Acid,,378,,,,,149 - 494,umol/L +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,CHEMISTRY PANEL,Calcium (EDTA),,2.36,,,,,2.07 - 2.64,mmol/L +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,CHEMISTRY PANEL,Phosphorus,,1.02,,,,,0.71 - 1.65,mmol/L +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,CHEMISTRY PANEL,Total Protein,,70,,,,,60 - 80,g/L +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,CHEMISTRY PANEL,Albumin-BCG,,40,,,,,33 - 49,g/L +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,CHEMISTRY PANEL,Creatine Kinase,,77,,,,,39 - 308,U/L +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,CHEMISTRY PANEL,Serum Sodium,,139,,,,,135 - 145,mmol/L +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,CHEMISTRY PANEL,Serum Potassium,,5.2,,,,,3.5 - 5.2,mmol/L +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,CHEMISTRY PANEL,Serum Bicarbonate,,22.9,,,,,19.3 - 29.3,mmol/L +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,CHEMISTRY PANEL,Serum Chloride,,104,,,,,94 - 112,mmol/L +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,CHEMISTRY PANEL,Magnesium,,0.87,,,,,0.66 - 0.98,mmol/L +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,99,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,FECAL COLLECTION D/T,Stool Collection Date,Y,20-Apr-2026,,,,,, +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,FECAL COLLECTION D/T,Stool Collection Time,Y,06:00,,,,,, +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,106,,L,,,125 - 170,g/L +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.36,,L,,,0.37 - 0.51, +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.6,,,,,4 - 5.8,TI/L +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,23,,L,,,26 - 34,pg +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,77,,L,,,80 - 100,fL +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,9.30,,,,,3.8 - 10.7,GI/L +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,6.31,,,,,1.96 - 7.23,GI/L +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.61,,,,,0.8 - 3,GI/L +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.94,,H,,,0.12 - 0.92,GI/L +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.35,,,,,0 - 0.57,GI/L +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.09,,,,,0 - 0.2,GI/L +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,67.8,,,,,40.5 - 75,% +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,17.3,,,,,15.4 - 48.5,% +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,10.2,,H,,,2.6 - 10.1,% +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,3.8,,,,,0 - 6.8,% +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.0,,,,,0 - 2,% +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,796,,HT,,,130 - 394,GI/L +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,SM01/PLASMA PK TROUGH COLL D/T,Collection Date Predose,Y,20-Apr-2026,,,,,, +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,SM01/PLASMA PK TROUGH COLL D/T,Collection Time Predose,Y,08:45,,,,,, +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,SM02/PLASMA PK PEAK COLL D/T,Collection Date Post dose,Y,20-Apr-2026,,,,,, +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,SM02/PLASMA PK PEAK COLL D/T,Post Dose Collection Time,Y,10:24,,,,,, +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,SM04/SERUM ADA PRE COLL D/T,Collection Date Predose,Y,20-Apr-2026,,,,,, +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,SM04/SERUM ADA PRE COLL D/T,Collection Time Predose,Y,08:45,,,,,, +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,SM09/STOOL PK COLL D/T,Stool Collection Date,Y,20-Apr-2026,,,,,, +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,SM09/STOOL PK COLL D/T,Stool Collection Time,Y,06:00,,,,,, +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,SUBJECT HEIGHT (CM),Height (cm),Y,N/A (subject >/= 18 years of age),,,,,cm, +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,CHEMISTRY PANEL,Total Bilirubin,,4,,,,,3 - 21,umol/L +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,<1.4,,,,,0 - 6.2,umol/L +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,CHEMISTRY PANEL,Alkaline Phosphatase,,121,,,,,40 - 129,U/L +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,CHEMISTRY PANEL,ALT (SGPT),,13,,,,,5 - 48,U/L +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,CHEMISTRY PANEL,AST (SGOT),,18,,,,,8 - 40,U/L +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,CHEMISTRY PANEL,GGT,,39,,,,,10 - 50,U/L +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,CHEMISTRY PANEL,LDH,,158,,,,,53 - 234,U/L +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,CHEMISTRY PANEL,Urea Nitrogen,,3.0,,,,,1.4 - 8.6,mmol/L +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,80,,,,,40 - 119,umol/L +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,CHEMISTRY PANEL,Serum Glucose,,4.9,,,,,3.9 - 5.6,mmol/L +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,CHEMISTRY PANEL,Serum Uric Acid,,446,,,,,149 - 494,umol/L +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,CHEMISTRY PANEL,Calcium (EDTA),,2.37,,,,,2.07 - 2.64,mmol/L +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,CHEMISTRY PANEL,Phosphorus,,1.20,,,,,0.71 - 1.65,mmol/L +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,CHEMISTRY PANEL,Total Protein,,74,,,,,60 - 80,g/L +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,CHEMISTRY PANEL,Albumin-BCG,,43,,,,,33 - 49,g/L +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,CHEMISTRY PANEL,Creatine Kinase,,64,,,,,39 - 308,U/L +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,CHEMISTRY PANEL,Serum Sodium,,141,,,,,135 - 145,mmol/L +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,CHEMISTRY PANEL,Serum Potassium,,5.2,,,,,3.5 - 5.2,mmol/L +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,CHEMISTRY PANEL,Serum Bicarbonate,,21.0,,,,,19.3 - 29.3,mmol/L +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,CHEMISTRY PANEL,Serum Chloride,,106,,,,,94 - 112,mmol/L +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,CHEMISTRY PANEL,Magnesium,,0.88,,,,,0.66 - 0.98,mmol/L +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,97,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,FECAL COLLECTION D/T,Stool Collection Date,Y,06-Apr-2026,,,,,, +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,FECAL COLLECTION D/T,Stool Collection Time,Y,16:00,,,,,, +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,113,,L,,,125 - 170,g/L +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.39,,,,,0.37 - 0.51, +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.9,,,,,4 - 5.8,TI/L +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,23,,L,,,26 - 34,pg +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,Anisocytosis,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,79,,L,,,80 - 100,fL +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,12.49,,H,,,3.8 - 10.7,GI/L +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,8.91,,H,,,1.96 - 7.23,GI/L +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.02,,,,,0.8 - 3,GI/L +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,1.14,,H,,,0.12 - 0.92,GI/L +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.33,,,,,0 - 0.57,GI/L +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.09,,,,,0 - 0.2,GI/L +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,71.3,,,,,40.5 - 75,% +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,16.2,,,,,15.4 - 48.5,% +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,9.1,,,,,2.6 - 10.1,% +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.6,,,,,0 - 6.8,% +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.7,,,,,0 - 2,% +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,584,,H,,,130 - 394,GI/L +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,LIPID PANEL,Direct HDL-C 4th Generation,,1.01,R,L,,,1.03 - 1.53,mmol/L +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,LIPID PANEL,Triglycerides (GPO),,1.57,,,,,0.65 - 2.94,mmol/L +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,LIPID PANEL,Cholesterol (High Performance),,5.40,,,,,4.53 - 7.71,mmol/L +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,LIPID PANEL,LDL Chol Friedewald 4th,,3.67,,H,,,0 - 3.34,mmol/L +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,SM01/PLASMA PK TROUGH COLL D/T,Collection Date Predose,Y,07-Apr-2026,,,,,, +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,SM01/PLASMA PK TROUGH COLL D/T,Collection Time Predose,Y,10:37,,,,,, +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,SM02/PLASMA PK PEAK COLL D/T,Collection Date Post dose,Y,07-Apr-2026,,,,,, +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,SM02/PLASMA PK PEAK COLL D/T,Post Dose Collection Time,Y,11:55,,,,,, +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,SM04/SERUM ADA PRE COLL D/T,Collection Date Predose,Y,07-Apr-2026,,,,,, +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,SM04/SERUM ADA PRE COLL D/T,Collection Time Predose,Y,10:37,,,,,, +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,SM10/FECAL BMRKS COLL D/T,Stool Collection Date,Y,06-Apr-2026,,,,,, +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,SM10/FECAL BMRKS COLL D/T,Stool Collection Time,Y,16:00,,,,,, +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,SUBJECT HEIGHT (CM),Height (cm),Y,N/A (subject >/= 18 years of age),,,,,cm, +CZ100212001,,,,,Male,Biopsy,,"Mar 16, 2026 12:00 AM",6227635223,ANATOMICAL SITE,Anatomical Site,Y,20,,,,,, +CZ100212001,,,,,Male,Biopsy,,"Mar 16, 2026 12:00 AM",6227635223,BIOPSY COLLECTION METHOD,Collection Method,Y,colonoscopy,,,,,, +CZ100212001,,,,,Male,Biopsy,,"Mar 16, 2026 12:00 AM",6227635223,BIOPSY FIXATIVE USED,Fixative Used,,10% NBF,,,,,, +CZ100212001,,,,,Male,Biopsy,,"Mar 16, 2026 12:00 AM",6227635223,DATE/TIME PLACED IN FORMALIN,Date Sample placed in Formalin,Y,16-Mar-2026,,,,,, +CZ100212001,,,,,Male,Biopsy,,"Mar 16, 2026 12:00 AM",6227635223,DATE/TIME PLACED IN FORMALIN,Time Sample placed in Formalin,Y,13:00,,,,,, +CZ100212001,,,,,Male,Biopsy,,"Mar 16, 2026 12:00 AM",6227635223,DIAGNOSIS,Diagnosis:,Y,Ulcerative Colitis,,,,,, +CZ100212001,,,,,Male,Biopsy,,"Mar 16, 2026 12:00 AM",6227635223,INFLAMED AREA,Inflamed area?,,Yes,,,,,, +CZ100212001,,,,,Male,Biopsy,,"Mar 16, 2026 12:00 AM",6227635223,TISSUE BIOPSY EMBEDDING1,Biopsy technical QC-CL,,Smpl meets HT requirements,,,,,, +CZ100212001,,,,,Male,Biopsy,,"Mar 16, 2026 12:00 AM",6227635223,TISSUE BIOPSY EMBEDDING1,Biopsy processing Time-CL,,10:00,,,,,, +CZ100212001,,,,,Male,Biopsy,,"Mar 16, 2026 12:00 AM",6227635223,TISSUE BIOPSY EMBEDDING1,Biopsy processing Date-CL,,19-Mar-2026,,,,,, +CZ100212001,,,,,Male,Biopsy,,"Mar 16, 2026 12:00 AM",6227635223,TISSUE BIOPSY EMBEDDING1,Biopsy Comments-CL,,Received in 10% NBF,,,,,, +CZ100212001,,,,,Male,Biopsy,,"Mar 16, 2026 12:00 AM",6227635223,TISSUE BIOPSY EMBEDDING1,# of Cassettes-(FI)-CL,,1,,,,,, +CZ100212001,,,,,Male,Biopsy,,"Mar 16, 2026 12:00 AM",6227635223,ULCERATED AREA,Is biopsy site ulcerated?,,Yes,,,,,, +CZ100212001,,,,,Male,Stool Pathogens,,"Mar 1, 2026 2:00 PM",6227635213,C. DIFF EIA,"C. diff GDH Ag,stool-CL",,Negative,,,,,Ref Rng:Negative, +CZ100212001,,,,,Male,Stool Pathogens,,"Mar 1, 2026 2:00 PM",6227635213,C. DIFF EIA,"C.diff Toxin A&B,stool-CL",,Negative,,,,,Ref Rng:Negative, +CZ100212001,,,,,Male,Stool Pathogens,,"Mar 1, 2026 2:00 PM",6227635213,OVA AND PARASITES 1,Concentrate Exam,,No ova or parasites found,,,,,, +CZ100212001,,,,,Male,Stool Pathogens,,"Mar 1, 2026 2:00 PM",6227635213,OVA AND PARASITES 1,Smear for Microsporidia,,No Microsporidia seen.,,,,,, +CZ100212001,,,,,Male,Stool Pathogens,,"Mar 1, 2026 2:00 PM",6227635213,OVA AND PARASITES 1,Modified acid-fast stain,,No coccidian parasites seen,,,,,, +CZ100212001,,,,,Male,Stool Pathogens,,"Mar 1, 2026 2:00 PM",6227635213,OVA AND PARASITES 2,Trichrome Smear,,No ova or parasites found,,,,,, +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,CHEMISTRY PANEL,Total Bilirubin,,<3,,L,,Result verified by repeat analysis,3 - 21,umol/L +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,<1.4,,,,Result verified by repeat analysis,0 - 6.2,umol/L +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,CHEMISTRY PANEL,Alkaline Phosphatase,,120,,,,,40 - 129,U/L +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,CHEMISTRY PANEL,ALT (SGPT),,15,,,,,5 - 48,U/L +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,CHEMISTRY PANEL,AST (SGOT),,19,,,,,8 - 40,U/L +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,CHEMISTRY PANEL,GGT,,39,,,,,10 - 50,U/L +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,CHEMISTRY PANEL,LDH,,174,,,,,53 - 234,U/L +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,CHEMISTRY PANEL,Urea Nitrogen,,3.0,,,,,1.4 - 8.6,mmol/L +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,75,,,,,40 - 119,umol/L +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,CHEMISTRY PANEL,Serum Glucose,,4.8,,,,,3.9 - 5.6,mmol/L +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,CHEMISTRY PANEL,Serum Uric Acid,,357,,,,,149 - 494,umol/L +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,CHEMISTRY PANEL,Calcium (EDTA),,2.34,,,,,2.07 - 2.64,mmol/L +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,CHEMISTRY PANEL,Phosphorus,,1.06,,,,,0.71 - 1.65,mmol/L +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,CHEMISTRY PANEL,Total Protein,,70,,,,,60 - 80,g/L +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,CHEMISTRY PANEL,Albumin-BCG,,43,,,,,33 - 49,g/L +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,CHEMISTRY PANEL,Creatine Kinase,,149,,,,,39 - 308,U/L +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,CHEMISTRY PANEL,Serum Sodium,,141,,,,,135 - 145,mmol/L +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,CHEMISTRY PANEL,Serum Potassium,,4.9,,,,,3.5 - 5.2,mmol/L +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,CHEMISTRY PANEL,Serum Bicarbonate,,18.4,,L,,,19.3 - 29.3,mmol/L +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,CHEMISTRY PANEL,Serum Chloride,,104,,,,,94 - 112,mmol/L +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,CHEMISTRY PANEL,Magnesium,,0.79,,,,,0.66 - 0.98,mmol/L +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,99,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,HBV ELIGIBILITY MET?,HBV Eligibility Criteria Met?,,Yes,,,,,, +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,120,,L,,,125 - 170,g/L +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.40,,,,,0.37 - 0.51, +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.0,,,,,4 - 5.8,TI/L +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,24,,L,,,26 - 34,pg +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,79,,L,,,80 - 100,fL +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,8.50,,,,,3.8 - 10.7,GI/L +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,5.09,,,,,1.96 - 7.23,GI/L +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.97,,,,,0.8 - 3,GI/L +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,1.07,,H,,,0.12 - 0.92,GI/L +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.27,,,,,0 - 0.57,GI/L +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.10,,,,,0 - 0.2,GI/L +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,59.9,,,,,40.5 - 75,% +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,23.3,,,,,15.4 - 48.5,% +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,12.6,,H,,,2.6 - 10.1,% +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,3.1,,,,,0 - 6.8,% +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.2,,,,,0 - 2,% +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,567,,H,,,130 - 394,GI/L +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,HEPATITIS B CORE AB NON-US,Hepatitis B Core Total,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,HEPATITIS B SURFACE AB,Anti-HBs II QUAL,,Non-Reactive,,,,,Ref Rng :$Non Reactive, +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,HEPATITIS B SURFACE AG NON-US,Hep B Surface AgII,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,HEPATITIS C VIRUS AB NON-US,Hepatitis C Virus Antibody,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,HIV 1/2 AG/AB SCREEN,anti-HIV-1/2 antibodies,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,HIV 1/2 AG/AB SCREEN,HIV -1 p24 antigen,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,HIV 1/2 AG/AB SCREEN,"HIV 1/2 Ag/Ab Screen, Cobas",,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,QUANTIFERON GOLD MITOGEN/INTER,"QFT,TBGoldPlusInt,pl-4-Tubes",,Negative,,,,,Normal=Negative, +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,SUBJECT HEIGHT (CM),Height (cm),Y,178,,,,,cm, diff --git a/Covance_UCO3001/Source/2026-06-08_130625 sponsor-study-35472-test-results-898745-standard.csv b/Covance_UCO3001/Source/2026-06-08_130625 sponsor-study-35472-test-results-898745-standard.csv new file mode 100644 index 0000000..1f45987 --- /dev/null +++ b/Covance_UCO3001/Source/2026-06-08_130625 sponsor-study-35472-test-results-898745-standard.csv @@ -0,0 +1,2615 @@ +"Disclaimer: The information presented in On-Screen Results is not intended to be a replacement of the official Lab Results, Alerts, Data Revisions and Cancellations found in the Lab Reports section of this software application. On-Screen Results should not be used for patient diagnosis, treatment decisions or submission to regulatory bodies.",,,,,,,,,,,,,,,,,,, +Subject,Subject Data Revision,Screen No.,Age,Age Unit,Gender,Visit,Visit Data Revision,Collected Time,Accession,Test Group,Test,Administrative Question,Value,Result Data Revision,Flags,Cancellation Reason,Comments,Range,Units +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.3,,,,,0 - 5,mg/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,CHEMISTRY PANEL,Total Bilirubin,,8,,,,,3 - 21,umol/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.2,,,,,0 - 6.2,umol/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,CHEMISTRY PANEL,Alkaline Phosphatase,,71,,,,,35 - 104,U/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,CHEMISTRY PANEL,ALT (SGPT),,26,,,,,4 - 43,U/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,CHEMISTRY PANEL,AST (SGOT),,36,,,,,8 - 40,U/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,CHEMISTRY PANEL,GGT,,55,,H,,,4 - 49,U/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,CHEMISTRY PANEL,LDH,,218,,,,,53 - 234,U/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,CHEMISTRY PANEL,Urea Nitrogen,,7.1,,,,,1.4 - 8.6,mmol/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,68,,,,,31 - 101,umol/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,CHEMISTRY PANEL,Glucose Fasting,,5.2,,,,,3.9 - 5.6,mmol/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,CHEMISTRY PANEL,Serum Uric Acid,,359,,,,,149 - 446,umol/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,CHEMISTRY PANEL,Calcium (EDTA),,2.38,,,,,2.07 - 2.64,mmol/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,CHEMISTRY PANEL,Phosphorus,,1.09,,,,,0.71 - 1.65,mmol/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,CHEMISTRY PANEL,Total Protein,,71,,,,,61 - 84,g/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,CHEMISTRY PANEL,Albumin-BCG,,46,,,,,33 - 49,g/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,CHEMISTRY PANEL,Creatine Kinase,,187,,,,,26 - 192,U/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,CHEMISTRY PANEL,Serum Sodium,,139,,,,,132 - 147,mmol/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,CHEMISTRY PANEL,Serum Potassium,,4.7,,,,,3.5 - 5.2,mmol/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,CHEMISTRY PANEL,Serum Bicarbonate,,25.8,,,,,19.3 - 29.3,mmol/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,CHEMISTRY PANEL,Serum Chloride,,100,,,,,94 - 112,mmol/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,137,,,,,116 - 164,g/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.41,,,,,0.34 - 0.48, +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.4,,,,,4.1 - 5.6,TI/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,95,,,,,79 - 98,fL +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,5.76,,,,,3.8 - 10.7,GI/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.50,,,,,1.96 - 7.23,GI/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.54,,,,,0.91 - 4.28,GI/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.63,,,,,0.12 - 0.92,GI/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.07,,,,,0 - 0.57,GI/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.03,,,,,0 - 0.2,GI/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,60.7,,,,,40.5 - 75,% +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,26.8,,,,,15.4 - 48.5,% +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,10.9,R,H,,,2.6 - 10.1,% +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.1,,,,,0 - 6.8,% +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.5,,,,,0 - 2,% +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,275,,,,,140 - 400,GI/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,,,,,,, +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,IS SUBJECT FASTING?,Is Subject Fasting?,Y,,,,,,, +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,LIPID PANEL,Direct HDL-C 4th Generation,,2.58,,H,,Result verified by repeat analysis,1.03 - 1.53,mmol/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,LIPID PANEL,Triglycerides (GPO),,1.71,,,,,0.59 - 2.96,mmol/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,LIPID PANEL,Cholesterol (High Performance),,4.84,,,,,4.42 - 7.53,mmol/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,LIPID PANEL,LDL Chol Friedewald 4th,,1.48,,,,,0 - 3.34,mmol/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,RETICULOCYTES,Reticulocyte Count %,,1.6,,,,,0.6 - 2.5,% +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,URINE MACRO PANEL,Ur Specific Gravity,,1.013,,,,,1 - 1.04, +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,URINE MACRO PANEL,Ur pH,,5.0,,,,,5 - 8, +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.6,,,,,0 - 5,mg/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,CHEMISTRY PANEL,Total Bilirubin,,6,,,,,3 - 21,umol/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.0,,,,,0 - 6.2,umol/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,CHEMISTRY PANEL,Alkaline Phosphatase,,52,,,,,35 - 104,U/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,CHEMISTRY PANEL,ALT (SGPT),,17,,,,,4 - 43,U/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,CHEMISTRY PANEL,AST (SGOT),,19,,,,,8 - 40,U/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,CHEMISTRY PANEL,GGT,,18,,,,,5 - 50,U/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,CHEMISTRY PANEL,LDH,,176,,,,,53 - 234,U/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,CHEMISTRY PANEL,Urea Nitrogen,,4.4,,,,,1.4 - 8.6,mmol/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,60,,,,,31 - 101,umol/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,CHEMISTRY PANEL,Glucose Fasting,,3.9,,,,,3.9 - 5.6,mmol/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,CHEMISTRY PANEL,Serum Uric Acid,,183,,,,,149 - 446,umol/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,CHEMISTRY PANEL,Calcium (EDTA),,2.36,,,,,2.07 - 2.64,mmol/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,CHEMISTRY PANEL,Phosphorus,,0.78,,,,,0.71 - 1.65,mmol/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,CHEMISTRY PANEL,Total Protein,,61,,,,,60 - 80,g/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,CHEMISTRY PANEL,Albumin-BCG,,41,,,,,33 - 49,g/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,CHEMISTRY PANEL,Creatine Kinase,,98,,,,,26 - 192,U/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,CHEMISTRY PANEL,Serum Sodium,,141,,,,,135 - 145,mmol/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,CHEMISTRY PANEL,Serum Potassium,,3.9,,,,,3.5 - 5.2,mmol/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,CHEMISTRY PANEL,Serum Bicarbonate,,24.4,,,,,19.3 - 29.3,mmol/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,CHEMISTRY PANEL,Serum Chloride,,105,,,,,94 - 112,mmol/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,,,,,,, +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,IS SUBJECT FASTING?,Is Subject Fasting?,Y,,,,,,, +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,LIPID PANEL,Direct HDL-C 4th Generation,,1.35,,,,,1.03 - 1.53,mmol/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,LIPID PANEL,Triglycerides (GPO),,0.82,,,,,0.63 - 2.71,mmol/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,LIPID PANEL,Cholesterol (High Performance),,5.15,,,,,4.86 - 8.28,mmol/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,LIPID PANEL,LDL Chol Friedewald 4th,,3.42,,H,,,0 - 3.34,mmol/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,RETICULOCYTES,Reticulocyte Count %,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,URINE MACRO PANEL,Ur Specific Gravity,,1.019,,,,,1.01 - 1.03, +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,URINE MACRO PANEL,Ur pH,,6.0,,,,,5 - 8, +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,C-REACTIVE PROTEIN,C Reactive Protein HS,,4.2,,,,,0 - 5,mg/L +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,CHEMISTRY PANEL,Total Bilirubin,,6,,,,,3 - 21,umol/L +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,1.6,,,,,0 - 6.2,umol/L +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,CHEMISTRY PANEL,Alkaline Phosphatase,,80,,,,,35 - 104,U/L +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,CHEMISTRY PANEL,ALT (SGPT),,28,,,,,4 - 43,U/L +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,CHEMISTRY PANEL,AST (SGOT),,25,,,,,8 - 40,U/L +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,CHEMISTRY PANEL,GGT,,43,,,,,4 - 49,U/L +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,CHEMISTRY PANEL,LDH,,177,,,,,53 - 234,U/L +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,CHEMISTRY PANEL,Urea Nitrogen,,2.4,,,,,1.4 - 8.6,mmol/L +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,67,,,,,31 - 101,umol/L +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,CHEMISTRY PANEL,Glucose Fasting,,5.3,,,,,3.9 - 5.6,mmol/L +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,CHEMISTRY PANEL,Serum Uric Acid,,277,,,,,125 - 428,umol/L +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,CHEMISTRY PANEL,Calcium (EDTA),,2.40,,,,,2.07 - 2.64,mmol/L +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,CHEMISTRY PANEL,Phosphorus,,1.12,,,,,0.71 - 1.65,mmol/L +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,CHEMISTRY PANEL,Total Protein,,72,,,,,61 - 84,g/L +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,CHEMISTRY PANEL,Albumin-BCG,,45,,,,,33 - 49,g/L +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,CHEMISTRY PANEL,Creatine Kinase,,125,,,,,26 - 192,U/L +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,CHEMISTRY PANEL,Serum Sodium,,137,,,,,132 - 147,mmol/L +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,CHEMISTRY PANEL,Serum Potassium,,4.5,,,,,3.5 - 5.2,mmol/L +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,CHEMISTRY PANEL,Serum Bicarbonate,,23.5,,,,,19.3 - 29.3,mmol/L +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,CHEMISTRY PANEL,Serum Chloride,,101,,,,,94 - 112,mmol/L +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,134,,,,Result verified by repeat analysis,116 - 164,g/L +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.42,,,,,0.34 - 0.48, +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.1,,,,Result verified by repeat analysis,4.1 - 5.6,TI/L +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,102,,H,,,79 - 98,fL +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,6.65,,,,Result verified by repeat analysis,3.8 - 10.7,GI/L +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.18,,,,Result verified by repeat analysis,1.96 - 7.23,GI/L +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.87,,,,,0.91 - 4.28,GI/L +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.44,,,,Result verified by repeat analysis,0.12 - 0.92,GI/L +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.12,,,,Result verified by repeat analysis,0 - 0.57,GI/L +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.05,,,,Result verified by repeat analysis,0 - 0.2,GI/L +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,47.7,,,,Result verified by repeat analysis,40.5 - 75,% +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,43.2,,,,Result verified by repeat analysis,15.4 - 48.5,% +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,6.6,,,,Result verified by repeat analysis,2.6 - 10.1,% +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.7,,,,Result verified by repeat analysis,0 - 6.8,% +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.8,,,,Result verified by repeat analysis,0 - 2,% +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,360,,,,Result verified by repeat analysis,140 - 400,GI/L +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.3,,,,,<6.5 %, +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,5.64,,,,,1.9 - 23,uIU/mL +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,LIPID PANEL,Direct HDL-C 4th Generation,,1.70,,H,,,1.03 - 1.53,mmol/L +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,LIPID PANEL,Triglycerides (GPO),,1.69,,,,,0.51 - 2.42,mmol/L +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,LIPID PANEL,Cholesterol (High Performance),,5.66,,,,,4.01 - 6.85,mmol/L +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,LIPID PANEL,LDL Chol Friedewald 4th,,3.19,,,,,0 - 3.34,mmol/L +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,RETICULOCYTES,Reticulocyte Count %,,1.3,,,,,0.6 - 2.5,% +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,TSH,TSH 3rd IS-QT,,,,,Test group cancelled: No specimen received,,, +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,URINE MACRO PANEL,Ur Specific Gravity,,1.015,,,,,1 - 1.04, +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.1,,,,,0 - 5,mg/L +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,CELLULAR ELEMENTS,Ur WBC/HPF,,2,,,,,0 - 12,/HPF +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,CHEMISTRY PANEL,Total Bilirubin,,5,,,,,3 - 21,umol/L +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,1.6,,,,,0 - 6.2,umol/L +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,CHEMISTRY PANEL,Alkaline Phosphatase,,87,,,,,35 - 104,U/L +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,CHEMISTRY PANEL,ALT (SGPT),,20,,,,,4 - 43,U/L +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,CHEMISTRY PANEL,AST (SGOT),,24,,,,,8 - 40,U/L +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,CHEMISTRY PANEL,GGT,,30,,,,,4 - 49,U/L +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,CHEMISTRY PANEL,LDH,,154,,,,,53 - 234,U/L +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,CHEMISTRY PANEL,Urea Nitrogen,,5.2,,,,,1.4 - 8.6,mmol/L +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,49,,,,,31 - 101,umol/L +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,CHEMISTRY PANEL,Glucose Fasting,,4.9,,,,,3.9 - 5.6,mmol/L +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,CHEMISTRY PANEL,Serum Uric Acid,,314,,,,,125 - 428,umol/L +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,CHEMISTRY PANEL,Calcium (EDTA),,2.51,,,,,2.07 - 2.64,mmol/L +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,CHEMISTRY PANEL,Phosphorus,,1.25,,,,,0.71 - 1.65,mmol/L +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,CHEMISTRY PANEL,Total Protein,,74,,,,,61 - 84,g/L +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,CHEMISTRY PANEL,Albumin-BCG,,47,,,,,33 - 49,g/L +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,CHEMISTRY PANEL,Creatine Kinase,,202,,H,,,26 - 192,U/L +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,CHEMISTRY PANEL,Serum Sodium,,138,,,,,132 - 147,mmol/L +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,CHEMISTRY PANEL,Serum Potassium,,4.8,,,,,3.5 - 5.2,mmol/L +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,CHEMISTRY PANEL,Serum Bicarbonate,,21.2,,,,,19.3 - 29.3,mmol/L +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,CHEMISTRY PANEL,Serum Chloride,,103,,,,,94 - 112,mmol/L +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,144,,,,,116 - 164,g/L +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.44,,,,,0.34 - 0.48, +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.5,,,,,4.1 - 5.6,TI/L +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,97,,,,,79 - 98,fL +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,8.81,,,,,3.8 - 10.7,GI/L +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,4.47,,,,,1.96 - 7.23,GI/L +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,3.67,,,,,0.91 - 4.28,GI/L +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.43,,,,,0.12 - 0.92,GI/L +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.17,,,,,0 - 0.57,GI/L +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.06,,,,,0 - 0.2,GI/L +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,50.7,,,,,40.5 - 75,% +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,41.7,,,,,15.4 - 48.5,% +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,4.8,,,,,2.6 - 10.1,% +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.0,,,,,0 - 6.8,% +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.7,,,,,0 - 2,% +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,504,,H,,,140 - 400,GI/L +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,6.6,,H,,,<6.5 %, +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,23.94,,H,,,1.9 - 23,uIU/mL +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,LIPID PANEL,Direct HDL-C 4th Generation,,1.34,,,,,1.03 - 1.53,mmol/L +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,LIPID PANEL,Triglycerides (GPO),,2.54,,H,,,0.51 - 2.42,mmol/L +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,LIPID PANEL,Cholesterol (High Performance),,6.04,,,,,4.01 - 6.85,mmol/L +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,LIPID PANEL,LDL Chol Friedewald 4th,,3.54,,H,,,0 - 3.34,mmol/L +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,RETICULOCYTES,Reticulocyte Count %,,1.8,,,,,0.6 - 2.5,% +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,TSH,TSH 3rd IS-QT,,3.138,,,,,0.45 - 5.33,mIU/L +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,URINE MACRO PANEL,Ur Specific Gravity,,1.020,,,,,1 - 1.04, +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,URINE MACRO PANEL,Ur Leukocyte Esterase,,Trace,,H,,,Ref Rng:Negative, +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,URINE MICRO PANEL,Ur Microscopic,,Positive,,,,, NEGATIVE$,NEGATIVE +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,C-REACTIVE PROTEIN,C Reactive Protein HS,,10.2,,H,,,0 - 5,mg/L +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,CHEMISTRY PANEL,Total Bilirubin,,6,,,,,3 - 21,umol/L +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,<1.4,,,,,0 - 6.2,umol/L +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,CHEMISTRY PANEL,Alkaline Phosphatase,,90,,,,,35 - 104,U/L +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,CHEMISTRY PANEL,ALT (SGPT),,17,,,,,4 - 43,U/L +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,CHEMISTRY PANEL,AST (SGOT),,20,,,,,8 - 40,U/L +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,CHEMISTRY PANEL,GGT,,22,,,,,5 - 50,U/L +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,CHEMISTRY PANEL,LDH,,185,,,,,53 - 234,U/L +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,CHEMISTRY PANEL,Urea Nitrogen,,6.0,,,,,1.4 - 10.4,mmol/L +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,64,,,,,31 - 110,umol/L +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,CHEMISTRY PANEL,Glucose Fasting,,6.3,R,H,,,3.9 - 5.6,mmol/L +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,CHEMISTRY PANEL,Serum Uric Acid,,316,,,,,149 - 446,umol/L +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,CHEMISTRY PANEL,Calcium (EDTA),,2.38,,,,,2.07 - 2.64,mmol/L +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,CHEMISTRY PANEL,Phosphorus,,1.07,,,,,0.71 - 1.65,mmol/L +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,CHEMISTRY PANEL,Total Protein,,80,,,,,60 - 80,g/L +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,CHEMISTRY PANEL,Albumin-BCG,,47,R,H,,,33 - 46,g/L +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,CHEMISTRY PANEL,Creatine Kinase,,88,,,,,26 - 192,U/L +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,CHEMISTRY PANEL,Serum Sodium,,136,,,,,135 - 145,mmol/L +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,CHEMISTRY PANEL,Serum Potassium,,4.7,,,,,3.5 - 5.2,mmol/L +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,CHEMISTRY PANEL,Serum Bicarbonate,,18.7,R,L,,,19.3 - 29.3,mmol/L +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,CHEMISTRY PANEL,Serum Chloride,,101,,,,,94 - 112,mmol/L +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,163,R,H,,,115 - 158,g/L +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.50,R,H,,,0.34 - 0.48, +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.1,,,,,3.9 - 5.5,TI/L +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,97,,,,,80 - 100,fL +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,11.22,R,H,,,3.8 - 10.7,GI/L +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,6.82,,,,,1.96 - 7.23,GI/L +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,3.47,R,H,,,0.8 - 3,GI/L +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.75,,,,,0.12 - 0.92,GI/L +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.11,,,,,0 - 0.57,GI/L +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.07,,,,,0 - 0.2,GI/L +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,60.8,,,,,40.5 - 75,% +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,30.9,,,,,15.4 - 48.5,% +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,6.7,,,,,2.6 - 10.1,% +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.0,,,,,0 - 6.8,% +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.6,,,,,0 - 2,% +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,285,,,,,130 - 394,GI/L +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.9,,,,,<6.5 %, +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,15.61,,,,,1.9 - 23,uIU/mL +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,LIPID PANEL,Direct HDL-C 4th Generation,,1.36,,,,,1.03 - 1.53,mmol/L +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,LIPID PANEL,Triglycerides (GPO),,2.89,R,H,,,0.63 - 2.71,mmol/L +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,LIPID PANEL,Cholesterol (High Performance),,7.08,,,,,5.35 - 9.1,mmol/L +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,LIPID PANEL,LDL Chol Friedewald 4th,,4.40,,H,,,0 - 3.34,mmol/L +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,RETICULOCYTES,Reticulocyte Count %,,1.1,,,,,0.6 - 2.5,% +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,TSH,TSH 3rd IS-QT,,0.546,,,,,0.45 - 5.33,mIU/L +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,URINE MACRO PANEL,Ur Specific Gravity,,1.016,,,,,1.01 - 1.03, +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,URINE MACRO PANEL,Ur Blood,,Trace,,,,,Ref Rng:$Negative-Trace, +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,URINE MICRO PANEL,Ur Microscopic,,Negative,,,,, NEGATIVE$,NEGATIVE +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,C-REACTIVE PROTEIN,C Reactive Protein HS,,2.3,,,,,0 - 5,mg/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,CELLULAR ELEMENTS,Ur WBC/HPF,,8,,,,,0 - 12,/HPF +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,CHEMISTRY PANEL,Total Bilirubin,,8,,,,,3 - 21,umol/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.2,,,,,0 - 6.2,umol/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,CHEMISTRY PANEL,Alkaline Phosphatase,,83,,,,,35 - 104,U/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,CHEMISTRY PANEL,ALT (SGPT),,22,,,,,4 - 43,U/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,CHEMISTRY PANEL,AST (SGOT),,24,,,,,8 - 40,U/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,CHEMISTRY PANEL,GGT,,32,,,,,4 - 49,U/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,CHEMISTRY PANEL,LDH,,169,,,,,53 - 234,U/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,CHEMISTRY PANEL,Urea Nitrogen,,5.2,,,,,1.4 - 8.6,mmol/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,51,,,,,31 - 101,umol/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,CHEMISTRY PANEL,Glucose Fasting,,5.0,,,,,3.9 - 5.6,mmol/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,CHEMISTRY PANEL,Serum Uric Acid,,383,,,,,125 - 428,umol/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,CHEMISTRY PANEL,Calcium (EDTA),,2.52,,,,,2.07 - 2.64,mmol/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,CHEMISTRY PANEL,Phosphorus,,1.20,,,,,0.71 - 1.65,mmol/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,CHEMISTRY PANEL,Total Protein,,75,,,,,61 - 84,g/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,CHEMISTRY PANEL,Albumin-BCG,,46,,,,,33 - 49,g/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,CHEMISTRY PANEL,Creatine Kinase,,201,,H,,,26 - 192,U/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,CHEMISTRY PANEL,Serum Sodium,,140,,,,,132 - 147,mmol/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,CHEMISTRY PANEL,Serum Potassium,,4.8,,,,,3.5 - 5.2,mmol/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,CHEMISTRY PANEL,Serum Bicarbonate,,21.6,,,,,19.3 - 29.3,mmol/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,CHEMISTRY PANEL,Serum Chloride,,102,,,,,94 - 112,mmol/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,143,,,,,116 - 164,g/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.42,,,,,0.34 - 0.48, +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.4,,,,,4.1 - 5.6,TI/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,95,,,,,79 - 98,fL +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,10.33,,,,,3.8 - 10.7,GI/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,6.06,,,,,1.96 - 7.23,GI/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,3.53,,,,,0.91 - 4.28,GI/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.53,,,,,0.12 - 0.92,GI/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.17,,,,,0 - 0.57,GI/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.05,,,,,0 - 0.2,GI/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,58.6,,,,,40.5 - 75,% +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,34.1,,,,,15.4 - 48.5,% +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.1,,,,,2.6 - 10.1,% +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.6,,,,,0 - 6.8,% +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.5,,,,,0 - 2,% +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,525,R,H,,,140 - 400,GI/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,16.12,,,,,1.9 - 23,uIU/mL +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,LIPID PANEL,Direct HDL-C 4th Generation,,1.37,,,,Result verified by repeat analysis,1.03 - 1.53,mmol/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,LIPID PANEL,Triglycerides (GPO),,2.79,,H,,,0.51 - 2.42,mmol/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,LIPID PANEL,Cholesterol (High Performance),,6.50,,,,,4.01 - 6.85,mmol/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,LIPID PANEL,LDL Chol Friedewald 4th,,3.85,,H,,,0 - 3.34,mmol/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,RETICULOCYTES,Reticulocyte Count %,,1.5,,,,,0.6 - 2.5,% +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,URINE MACRO PANEL,Ur Specific Gravity,,1.029,,,,,1 - 1.04, +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,URINE MACRO PANEL,Ur Protein,,Trace,,H,,,Ref Rng:Negative, +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,URINE MACRO PANEL,Ur Leukocyte Esterase,,Trace,,H,,,Ref Rng:Negative, +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,URINE MICRO PANEL,Ur Microscopic,,Positive,,,,, NEGATIVE$,NEGATIVE +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.1,,,,,0 - 5,mg/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,CHEMISTRY PANEL,Total Bilirubin,,6,,,,,3 - 21,umol/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.3,,,,,0 - 6.2,umol/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,CHEMISTRY PANEL,Alkaline Phosphatase,,66,,,,,35 - 104,U/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,CHEMISTRY PANEL,ALT (SGPT),,18,,,,,4 - 43,U/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,CHEMISTRY PANEL,AST (SGOT),,25,,,,,8 - 40,U/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,CHEMISTRY PANEL,GGT,,36,,,,,4 - 49,U/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,CHEMISTRY PANEL,LDH,,192,,,,,53 - 234,U/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,CHEMISTRY PANEL,Urea Nitrogen,,5.2,,,,,1.4 - 8.6,mmol/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,57,,,,,31 - 101,umol/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,CHEMISTRY PANEL,Glucose Fasting,,4.5,,,,,3.9 - 5.6,mmol/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,CHEMISTRY PANEL,Serum Uric Acid,,277,,,,,149 - 446,umol/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,CHEMISTRY PANEL,Calcium (EDTA),,2.08,,,,,2.07 - 2.64,mmol/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,CHEMISTRY PANEL,Phosphorus,,0.90,,,,,0.71 - 1.65,mmol/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,CHEMISTRY PANEL,Total Protein,,62,,,,,61 - 84,g/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,CHEMISTRY PANEL,Albumin-BCG,,41,,,,,33 - 49,g/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,CHEMISTRY PANEL,Creatine Kinase,,84,,,,,26 - 192,U/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,CHEMISTRY PANEL,Serum Sodium,,144,,,,,132 - 147,mmol/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,CHEMISTRY PANEL,Serum Potassium,,3.5,,,,,3.5 - 5.2,mmol/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,CHEMISTRY PANEL,Serum Bicarbonate,,22.5,,,,,19.3 - 29.3,mmol/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,CHEMISTRY PANEL,Serum Chloride,,109,,,,,94 - 112,mmol/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,132,,,,,116 - 164,g/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.40,,,,,0.34 - 0.48, +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.2,,,,,4.1 - 5.6,TI/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,96,,,,,79 - 98,fL +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,5.40,,,,,3.8 - 10.7,GI/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.63,,,,,1.96 - 7.23,GI/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.90,,,,,0.91 - 4.28,GI/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.78,,,,,0.12 - 0.92,GI/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.05,,,,,0 - 0.57,GI/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.05,,,,,0 - 0.2,GI/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,48.8,,,,,40.5 - 75,% +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,35.1,,,,,15.4 - 48.5,% +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,14.4,R,H,,,2.6 - 10.1,% +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,0.9,,,,,0 - 6.8,% +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.9,,,,,0 - 2,% +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,248,,,,,140 - 400,GI/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.5,,,,,<6.5 %, +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,2.25,,,,,1.9 - 23,uIU/mL +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,LIPID PANEL,Direct HDL-C 4th Generation,,1.92,,H,,,1.03 - 1.53,mmol/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,LIPID PANEL,Triglycerides (GPO),,1.20,,,,,0.59 - 2.96,mmol/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,LIPID PANEL,Cholesterol (High Performance),,3.66,,L,,,4.42 - 7.53,mmol/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,LIPID PANEL,LDL Chol Friedewald 4th,,1.19,,,,,0 - 3.34,mmol/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,RETICULOCYTES,Reticulocyte Count %,,1.1,,,,,0.6 - 2.5,% +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,TSH,TSH 3rd IS-QT,,3.352,,,,,0.45 - 5.33,mIU/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,URINE MACRO PANEL,Ur Specific Gravity,,1.023,,,,,1 - 1.04, +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,URINE MACRO PANEL,Ur pH,,5.0,,,,,5 - 8, +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.3,,,,,0 - 5,mg/L +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,CHEMISTRY PANEL,Total Bilirubin,,10,,,,,3 - 21,umol/L +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.5,,,,,0 - 6.2,umol/L +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,CHEMISTRY PANEL,Alkaline Phosphatase,,137,,H,,,35 - 104,U/L +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,CHEMISTRY PANEL,ALT (SGPT),,11,,,,,4 - 43,U/L +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,CHEMISTRY PANEL,AST (SGOT),,14,,,,,8 - 40,U/L +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,CHEMISTRY PANEL,GGT,,14,,,,,5 - 50,U/L +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,CHEMISTRY PANEL,LDH,,170,,,,,53 - 234,U/L +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,CHEMISTRY PANEL,Urea Nitrogen,,5.3,,,,,1.4 - 8.6,mmol/L +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,61,,,,,31 - 101,umol/L +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,CHEMISTRY PANEL,Glucose Fasting,,5.6,,,,,3.9 - 5.6,mmol/L +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,CHEMISTRY PANEL,Serum Uric Acid,,204,,,,,149 - 446,umol/L +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,CHEMISTRY PANEL,Calcium (EDTA),,2.40,,,,,2.07 - 2.64,mmol/L +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,CHEMISTRY PANEL,Phosphorus,,0.96,,,,,0.71 - 1.65,mmol/L +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,CHEMISTRY PANEL,Total Protein,,73,,,,,60 - 80,g/L +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,CHEMISTRY PANEL,Albumin-BCG,,46,,,,,33 - 49,g/L +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,CHEMISTRY PANEL,Creatine Kinase,,78,,,,,26 - 192,U/L +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,CHEMISTRY PANEL,Serum Sodium,,145,,,,,135 - 145,mmol/L +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,CHEMISTRY PANEL,Serum Potassium,,4.7,,,,,3.5 - 5.2,mmol/L +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,CHEMISTRY PANEL,Serum Bicarbonate,,21.6,,,,,19.3 - 29.3,mmol/L +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,CHEMISTRY PANEL,Serum Chloride,,109,,,,,94 - 112,mmol/L +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,150,,,,,115 - 158,g/L +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.47,,,,,0.34 - 0.48, +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.9,,,,,3.9 - 5.5,TI/L +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,96,,,,,80 - 100,fL +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,7.17,,,,,3.8 - 10.7,GI/L +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.80,,,,,1.96 - 7.23,GI/L +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.79,,,,,0.8 - 3,GI/L +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.41,,,,,0.12 - 0.92,GI/L +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.08,,,,,0 - 0.57,GI/L +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.09,,,,,0 - 0.2,GI/L +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,53.0,,,,,40.5 - 75,% +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,38.9,,,,,15.4 - 48.5,% +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.8,,,,,2.6 - 10.1,% +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.1,,,,,0 - 6.8,% +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.3,,,,,0 - 2,% +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,239,,,,,130 - 394,GI/L +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.5,,,,,<6.5 %, +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,4.88,,,,,1.9 - 23,uIU/mL +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,LIPID PANEL,Direct HDL-C 4th Generation,,1.85,,H,,,1.03 - 1.53,mmol/L +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,LIPID PANEL,Triglycerides (GPO),,0.61,,L,,,0.63 - 2.71,mmol/L +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,LIPID PANEL,Cholesterol (High Performance),,5.06,,,,,4.86 - 8.28,mmol/L +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,LIPID PANEL,LDL Chol Friedewald 4th,,2.93,,,,,0 - 3.34,mmol/L +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,RETICULOCYTES,Reticulocyte Count %,,1.1,,,,,0.6 - 2.5,% +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,TSH,TSH 3rd IS-QT,,0.955,,,,,0.45 - 5.33,mIU/L +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,URINE MACRO PANEL,Ur Specific Gravity,,1.025,,,,,1.01 - 1.03, +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,C-REACTIVE PROTEIN,C Reactive Protein HS,,4.2,,,,,0 - 5,mg/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,CHEMISTRY PANEL,Total Bilirubin,,5,,,,,3 - 21,umol/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.0,,,,,0 - 6.2,umol/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,CHEMISTRY PANEL,Alkaline Phosphatase,,62,,,,,35 - 104,U/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,CHEMISTRY PANEL,ALT (SGPT),,14,,,,,4 - 43,U/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,CHEMISTRY PANEL,AST (SGOT),,19,,,,,8 - 40,U/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,CHEMISTRY PANEL,GGT,,16,,,,,5 - 50,U/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,CHEMISTRY PANEL,LDH,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,CHEMISTRY PANEL,Urea Nitrogen,,4.3,,,,,1.4 - 8.6,mmol/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,64,,,,,31 - 101,umol/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,CHEMISTRY PANEL,Glucose Fasting,,5.8,,H,,,3.9 - 5.6,mmol/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,CHEMISTRY PANEL,Serum Uric Acid,,216,,,,,149 - 446,umol/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,CHEMISTRY PANEL,Calcium (EDTA),,2.38,,,,,2.07 - 2.64,mmol/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,CHEMISTRY PANEL,Phosphorus,,1.09,,,,,0.71 - 1.65,mmol/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,CHEMISTRY PANEL,Total Protein,,63,,,,,60 - 80,g/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,CHEMISTRY PANEL,Albumin-BCG,,42,,,,,33 - 49,g/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,CHEMISTRY PANEL,Creatine Kinase,,151,,,,,26 - 192,U/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,CHEMISTRY PANEL,Serum Sodium,,142,,,,,135 - 145,mmol/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,CHEMISTRY PANEL,Serum Potassium,,4.4,,,,,3.5 - 5.2,mmol/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,CHEMISTRY PANEL,Serum Bicarbonate,,21.4,,,,,19.3 - 29.3,mmol/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,CHEMISTRY PANEL,Serum Chloride,,108,,,,,94 - 112,mmol/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,152,,,,,115 - 158,g/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.46,,,,,0.34 - 0.48, +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.6,,,,,3.9 - 5.5,TI/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,100,,,,,80 - 100,fL +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,7.94,,,,,3.8 - 10.7,GI/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,6.03,,,,,1.96 - 7.23,GI/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.45,,,,,0.8 - 3,GI/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.32,,,,,0.12 - 0.92,GI/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.10,,,,,0 - 0.57,GI/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.04,,,,,0 - 0.2,GI/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,75.9,R,H,,,40.5 - 75,% +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,18.3,,,,,15.4 - 48.5,% +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,4.0,,,,,2.6 - 10.1,% +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.3,,,,,0 - 6.8,% +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.6,,,,,0 - 2,% +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,244,,,,,130 - 394,GI/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.4,,,,,<6.5 %, +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,7.00,,,,,1.9 - 23,uIU/mL +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,LIPID PANEL,Direct HDL-C 4th Generation,,1.24,,,,,1.03 - 1.53,mmol/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,LIPID PANEL,Triglycerides (GPO),,0.74,,,,,0.63 - 2.71,mmol/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,LIPID PANEL,Cholesterol (High Performance),,4.25,,L,,,4.86 - 8.28,mmol/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,LIPID PANEL,LDL Chol Friedewald 4th,,2.67,,,,,0 - 3.34,mmol/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,RETICULOCYTES,Reticulocyte Count %,,1.0,,,,,0.6 - 2.5,% +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,TSH,TSH 3rd IS-QT,,1.798,,,,,0.45 - 5.33,mIU/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,URINE MACRO PANEL,Ur Specific Gravity,,1.016,,,,,1.01 - 1.03, +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,C-REACTIVE PROTEIN,C Reactive Protein HS,,0.9,,,,,0 - 5,mg/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,CHEMISTRY PANEL,Total Bilirubin,,11,,,,,3 - 21,umol/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.4,,,,,0 - 6.2,umol/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,CHEMISTRY PANEL,Alkaline Phosphatase,,81,,,,,35 - 104,U/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,CHEMISTRY PANEL,ALT (SGPT),,23,,,,,4 - 43,U/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,CHEMISTRY PANEL,AST (SGOT),,19,,,,,8 - 40,U/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,CHEMISTRY PANEL,GGT,,19,,,,,4 - 49,U/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,CHEMISTRY PANEL,LDH,,193,,,,,53 - 234,U/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,CHEMISTRY PANEL,Urea Nitrogen,,4.7,,,,,1.4 - 8.6,mmol/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,72,,,,,31 - 101,umol/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,CHEMISTRY PANEL,Glucose Fasting,,5.2,,,,,3.9 - 5.6,mmol/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,CHEMISTRY PANEL,Serum Uric Acid,,206,,,,,149 - 446,umol/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,CHEMISTRY PANEL,Calcium (EDTA),,2.43,,,,,2.07 - 2.64,mmol/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,CHEMISTRY PANEL,Phosphorus,,1.36,,,,,0.71 - 1.65,mmol/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,CHEMISTRY PANEL,Total Protein,,65,,,,,61 - 84,g/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,CHEMISTRY PANEL,Albumin-BCG,,46,,,,,33 - 49,g/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,CHEMISTRY PANEL,Creatine Kinase,,82,,,,,26 - 192,U/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,CHEMISTRY PANEL,Serum Sodium,,145,,,,,132 - 147,mmol/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,CHEMISTRY PANEL,Serum Potassium,,4.3,,,,,3.5 - 5.2,mmol/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,CHEMISTRY PANEL,Serum Bicarbonate,,25.9,,,,,19.3 - 29.3,mmol/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,CHEMISTRY PANEL,Serum Chloride,,105,,,,,94 - 112,mmol/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,139,,,,,116 - 164,g/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.43,,,,,0.34 - 0.48, +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.5,,,,,4.1 - 5.6,TI/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,96,,,,,79 - 98,fL +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,4.84,,,,,3.8 - 10.7,GI/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.66,,,,,1.96 - 7.23,GI/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.78,,,,,0.91 - 4.28,GI/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.27,,,,,0.12 - 0.92,GI/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.08,,,,,0 - 0.57,GI/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.04,,,,,0 - 0.2,GI/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,55.0,,,,,40.5 - 75,% +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,36.8,,,,,15.4 - 48.5,% +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.7,,,,,2.6 - 10.1,% +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.7,,,,,0 - 6.8,% +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.8,,,,,0 - 2,% +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,274,,,,,140 - 400,GI/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.1,,,,,<6.5 %, +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,5.31,,,,,1.9 - 23,uIU/mL +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,LIPID PANEL,Direct HDL-C 4th Generation,,1.64,,H,,,1.03 - 1.53,mmol/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,LIPID PANEL,Triglycerides (GPO),,0.68,,,,,0.59 - 2.96,mmol/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,LIPID PANEL,Cholesterol (High Performance),,5.02,,,,,4.42 - 7.53,mmol/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,LIPID PANEL,LDL Chol Friedewald 4th,,3.07,,,,,0 - 3.34,mmol/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,RETICULOCYTES,Reticulocyte Count %,,0.9,,,,,0.6 - 2.5,% +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,TSH,TSH 3rd IS-QT,,1.896,,,,,0.45 - 5.33,mIU/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,URINE MACRO PANEL,Ur Specific Gravity,,1.022,,,,,1 - 1.04, +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,URINE MACRO PANEL,Ur pH,,6.5,,,,,5 - 8, +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,C-REACTIVE PROTEIN,C Reactive Protein HS,,2.6,,,,,0 - 5,mg/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,CHEMISTRY PANEL,Total Bilirubin,,<3,,L,,Result verified by repeat analysis,3 - 21,umol/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,<1.4,,,,,0 - 6.2,umol/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,CHEMISTRY PANEL,Alkaline Phosphatase,,88,,,,,35 - 104,U/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,CHEMISTRY PANEL,ALT (SGPT),,24,,,,,4 - 43,U/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,CHEMISTRY PANEL,AST (SGOT),,21,,,,,8 - 40,U/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,CHEMISTRY PANEL,GGT,,32,,,,,4 - 49,U/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,CHEMISTRY PANEL,LDH,,156,,,,,53 - 234,U/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,CHEMISTRY PANEL,Urea Nitrogen,,4.0,,,,,1.4 - 8.6,mmol/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,39,,,,,31 - 101,umol/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,CHEMISTRY PANEL,Glucose Fasting,,5.0,,,,,3.9 - 5.6,mmol/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,CHEMISTRY PANEL,Serum Uric Acid,,335,,,,,125 - 428,umol/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,CHEMISTRY PANEL,Calcium (EDTA),,2.12,,,,,2.07 - 2.64,mmol/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,CHEMISTRY PANEL,Phosphorus,,1.07,,,,,0.71 - 1.65,mmol/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,CHEMISTRY PANEL,Total Protein,,66,,,,,61 - 84,g/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,CHEMISTRY PANEL,Albumin-BCG,,39,,,,,33 - 49,g/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,CHEMISTRY PANEL,Creatine Kinase,,135,,,,,26 - 192,U/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,CHEMISTRY PANEL,Serum Sodium,,142,,,,,132 - 147,mmol/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,CHEMISTRY PANEL,Serum Potassium,,4.1,,,,,3.5 - 5.2,mmol/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,CHEMISTRY PANEL,Serum Bicarbonate,,20.2,,,,,19.3 - 29.3,mmol/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,CHEMISTRY PANEL,Serum Chloride,,109,,,,,94 - 112,mmol/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,DIRECT LDL,Direct LDL-C 3rd Gen,,3.40,,H,,,<3.36 mmol/L, +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,145,,,,,116 - 164,g/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.44,,,,,0.34 - 0.48, +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.5,,,,,4.1 - 5.6,TI/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,96,,,,,79 - 98,fL +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,11.75,,H,,,3.8 - 10.7,GI/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,6.71,,,,,1.96 - 7.23,GI/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,4.08,,,,,0.91 - 4.28,GI/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.60,,,,,0.12 - 0.92,GI/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.24,,,,,0 - 0.57,GI/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.11,,,,,0 - 0.2,GI/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,57.1,,,,,40.5 - 75,% +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,34.7,,,,,15.4 - 48.5,% +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.1,,,,,2.6 - 10.1,% +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.1,,,,,0 - 6.8,% +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.9,,,,,0 - 2,% +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,550,,H,,,140 - 400,GI/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,6.7,R,H,,,<6.5 %, +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,73.67,R,H,,,1.9 - 23,uIU/mL +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,LIPID PANEL,Direct HDL-C 4th Generation,,1.00,,L,,Result verified by repeat analysis,1.03 - 1.53,mmol/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,LIPID PANEL,Triglycerides (GPO),,5.91,,H SF,,,0.51 - 2.42,mmol/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,LIPID PANEL,Cholesterol (High Performance),,5.54,,,,,4.01 - 6.85,mmol/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,LIPID PANEL,LDL Chol Friedewald 4th,,,,,Test cancelled: Invalid/High Triglycerides,,, +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,RETICULOCYTES,Reticulocyte Count %,,1.7,,,,,0.6 - 2.5,% +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,TSH,TSH 3rd IS-QT,,2.578,,,,,0.45 - 5.33,mIU/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,URINE MACRO PANEL,Ur Specific Gravity,,1.006,,,,,1 - 1.04, +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.7,,,,,0 - 5,mg/L +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,CHEMISTRY PANEL,Total Bilirubin,,7,,,,,3 - 21,umol/L +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.8,,,,,0 - 6.2,umol/L +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,CHEMISTRY PANEL,Alkaline Phosphatase,,69,,,,,35 - 104,U/L +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,CHEMISTRY PANEL,ALT (SGPT),,25,,,,,4 - 43,U/L +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,CHEMISTRY PANEL,AST (SGOT),,36,,,,,8 - 40,U/L +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,CHEMISTRY PANEL,GGT,,43,,,,,4 - 49,U/L +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,CHEMISTRY PANEL,LDH,,193,,,,,53 - 234,U/L +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,CHEMISTRY PANEL,Urea Nitrogen,,4.6,,,,,1.4 - 8.6,mmol/L +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,65,,,,,31 - 101,umol/L +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,CHEMISTRY PANEL,Glucose Fasting,,4.8,,,,,3.9 - 5.6,mmol/L +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,CHEMISTRY PANEL,Serum Uric Acid,,321,,,,,149 - 446,umol/L +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,CHEMISTRY PANEL,Calcium (EDTA),,2.13,,,,,2.07 - 2.64,mmol/L +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,CHEMISTRY PANEL,Phosphorus,,0.91,,,,,0.71 - 1.65,mmol/L +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,CHEMISTRY PANEL,Total Protein,,65,,,,,61 - 84,g/L +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,CHEMISTRY PANEL,Albumin-BCG,,42,,,,,33 - 49,g/L +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,CHEMISTRY PANEL,Creatine Kinase,,93,,,,,26 - 192,U/L +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,CHEMISTRY PANEL,Serum Sodium,,142,,,,,132 - 147,mmol/L +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,CHEMISTRY PANEL,Serum Potassium,,3.7,,,,,3.5 - 5.2,mmol/L +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,CHEMISTRY PANEL,Serum Bicarbonate,,25.6,,,,,19.3 - 29.3,mmol/L +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,CHEMISTRY PANEL,Serum Chloride,,107,,,,,94 - 112,mmol/L +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,CREATININE CLEARANCE CC&G,CreatininClearancCockcrftGault,,1.65,,,,,1.25 - 1.92,mL/sec +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,CREATININE CLEARANCE CC&G,Creatinine(Rate Blanked)-2dp,,65,,,,,31 - 101,umol/L +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,CREATININE CLEARANCE CC&G,"Weight (kg,1dec place)",Y,75.1,,,,,kg, +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,DRUG SCREEN URINE,Amphetamines/MDMA,,Neg,,,,,Neg;$Cutoff = 1000 ng/mL, +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,DRUG SCREEN URINE,Barbiturates,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,DRUG SCREEN URINE,Cannabinoids,,Neg,,,,,Neg;$Cutoff = 50 ng/mL, +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,DRUG SCREEN URINE,Cocaine,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,DRUG SCREEN URINE,Opiates,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,DRUG SCREEN URINE,Methadone,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,DRUG SCREEN URINE BENZO NON-US,Benzodiazepines Gen 2,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,FEMALE OF CHILDBEARING POT?,Female/of Childbearing pot.?,Y,No,,,,,, +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,GFR,EGFR by MDRD,,81,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,134,,,,,116 - 164,g/L +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.40,,,,,0.34 - 0.48, +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.2,,,,,4.1 - 5.6,TI/L +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,96,,,,,79 - 98,fL +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,5.08,,,,,3.8 - 10.7,GI/L +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.60,,,,,1.96 - 7.23,GI/L +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.79,,,,,0.91 - 4.28,GI/L +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.52,,,,,0.12 - 0.92,GI/L +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.12,,,,,0 - 0.57,GI/L +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.05,,,,,0 - 0.2,GI/L +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,51.1,,,,,40.5 - 75,% +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,35.3,,,,,15.4 - 48.5,% +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,10.2,R,H,,,2.6 - 10.1,% +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.4,,,,,0 - 6.8,% +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.9,,,,,0 - 2,% +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,267,,,,,140 - 400,GI/L +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.5,,,,,<6.5 %, +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,4.13,,,,,1.9 - 23,uIU/mL +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,IS SUBJECT OF BLACK RACE?,Subject of black race?,Y,No,,,,,, +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,LIPID PANEL,Direct HDL-C 4th Generation,,2.21,,H,,,1.03 - 1.53,mmol/L +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,LIPID PANEL,Triglycerides (GPO),,0.81,,,,,0.59 - 2.96,mmol/L +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,LIPID PANEL,Cholesterol (High Performance),,3.95,,L,,,4.42 - 7.53,mmol/L +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,LIPID PANEL,LDL Chol Friedewald 4th,,1.37,,,,,0 - 3.34,mmol/L +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,POSTMENOPAUSAL FEMALE?,<40yrs & amenorrhea >/= 12mo,,No,,,,,, +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,RETICULOCYTES,Reticulocyte Count %,,1.4,,,,,0.6 - 2.5,% +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,TSH,TSH 3rd IS-QT,,3.004,,,,,0.45 - 5.33,mIU/L +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,URINE MACRO PANEL,Ur Specific Gravity,,1.020,,,,,1 - 1.04, +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,C-REACTIVE PROTEIN,C Reactive Protein HS,,3.0,,,,,0 - 5,mg/L +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,CHEMISTRY PANEL,Total Bilirubin,,5,,,,,3 - 21,umol/L +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,<1.4,,,,,0 - 6.2,umol/L +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,CHEMISTRY PANEL,Alkaline Phosphatase,,94,,,,,35 - 104,U/L +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,CHEMISTRY PANEL,ALT (SGPT),,17,,,,,4 - 43,U/L +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,CHEMISTRY PANEL,AST (SGOT),,19,,,,,8 - 40,U/L +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,CHEMISTRY PANEL,GGT,,17,,,,,5 - 50,U/L +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,CHEMISTRY PANEL,LDH,,163,,,,,53 - 234,U/L +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,CHEMISTRY PANEL,Urea Nitrogen,,4.3,,,,,1.4 - 10.4,mmol/L +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,68,,,,,31 - 110,umol/L +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,CHEMISTRY PANEL,Glucose Fasting,,5.4,,,,,3.9 - 5.6,mmol/L +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,CHEMISTRY PANEL,Serum Uric Acid,,265,,,,,149 - 446,umol/L +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,CHEMISTRY PANEL,Calcium (EDTA),,2.38,,,,,2.07 - 2.64,mmol/L +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,CHEMISTRY PANEL,Phosphorus,,1.45,,,,,0.71 - 1.65,mmol/L +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,CHEMISTRY PANEL,Total Protein,,78,,,,,60 - 80,g/L +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,CHEMISTRY PANEL,Albumin-BCG,,47,R,H,,,33 - 46,g/L +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,CHEMISTRY PANEL,Creatine Kinase,,80,,,,,26 - 192,U/L +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,CHEMISTRY PANEL,Serum Sodium,,137,,,,,135 - 145,mmol/L +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,CHEMISTRY PANEL,Serum Potassium,,4.6,,,,,3.5 - 5.2,mmol/L +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,CHEMISTRY PANEL,Serum Bicarbonate,,21.7,,,,,19.3 - 29.3,mmol/L +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,CHEMISTRY PANEL,Serum Chloride,,102,,,,,94 - 112,mmol/L +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,159,R,H,,,115 - 158,g/L +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.47,,,,,0.34 - 0.48, +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.1,,,,,3.9 - 5.5,TI/L +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,93,,,,,80 - 100,fL +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,9.76,,,,,3.8 - 10.7,GI/L +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,5.09,,,,,1.96 - 7.23,GI/L +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,3.77,R,H,,,0.8 - 3,GI/L +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.73,,,,,0.12 - 0.92,GI/L +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.11,,,,,0 - 0.57,GI/L +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.07,,,,,0 - 0.2,GI/L +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,52.1,,,,,40.5 - 75,% +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,38.6,,,,,15.4 - 48.5,% +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,7.5,,,,,2.6 - 10.1,% +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.2,,,,,0 - 6.8,% +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.7,,,,,0 - 2,% +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,307,,,,,130 - 394,GI/L +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.8,,,,,<6.5 %, +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,LIPID PANEL,Direct HDL-C 4th Generation,,1.36,,,,,1.03 - 1.53,mmol/L +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,LIPID PANEL,Triglycerides (GPO),,3.03,,H,,,0.63 - 2.71,mmol/L +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,LIPID PANEL,Cholesterol (High Performance),,7.15,,,,,5.35 - 9.1,mmol/L +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,LIPID PANEL,LDL Chol Friedewald 4th,,4.40,,H,,,0 - 3.34,mmol/L +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,RETICULOCYTES,Reticulocyte Count %,,1.6,,,,,0.6 - 2.5,% +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,TSH,TSH 3rd IS-QT,,1.854,,,,,0.45 - 5.33,mIU/L +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,URINE MACRO PANEL,Ur Specific Gravity,,1.012,,,,,1.01 - 1.03, +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,URINE MACRO PANEL,Ur pH,,5.0,,,,,5 - 8, +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.3,,,,,0 - 5,mg/L +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,CHEMISTRY PANEL,Total Bilirubin,,5,,,,,3 - 21,umol/L +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,1.6,,,,,0 - 6.2,umol/L +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,CHEMISTRY PANEL,Alkaline Phosphatase,,100,,,,,35 - 104,U/L +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,CHEMISTRY PANEL,ALT (SGPT),,30,,,,,4 - 43,U/L +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,CHEMISTRY PANEL,AST (SGOT),,27,,,,,8 - 40,U/L +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,CHEMISTRY PANEL,GGT,,18,,,,,4 - 49,U/L +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,CHEMISTRY PANEL,LDH,,235,,H,,,53 - 234,U/L +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,CHEMISTRY PANEL,Urea Nitrogen,,5.4,,,,,1.4 - 8.6,mmol/L +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,76,,,,,31 - 101,umol/L +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,CHEMISTRY PANEL,Glucose Fasting,,4.7,,,,,3.9 - 5.6,mmol/L +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,CHEMISTRY PANEL,Serum Uric Acid,,308,,,,,149 - 446,umol/L +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,CHEMISTRY PANEL,Calcium (EDTA),,2.33,,,,,2.07 - 2.64,mmol/L +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,CHEMISTRY PANEL,Phosphorus,,1.09,,,,,0.71 - 1.65,mmol/L +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,CHEMISTRY PANEL,Total Protein,,71,,,,,61 - 84,g/L +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,CHEMISTRY PANEL,Albumin-BCG,,46,,,,,33 - 49,g/L +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,CHEMISTRY PANEL,Creatine Kinase,,119,,,,,26 - 192,U/L +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,CHEMISTRY PANEL,Serum Sodium,,139,,,,,132 - 147,mmol/L +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,CHEMISTRY PANEL,Serum Potassium,,4.2,,,,,3.5 - 5.2,mmol/L +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,CHEMISTRY PANEL,Serum Bicarbonate,,24.5,,,,,19.3 - 29.3,mmol/L +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,CHEMISTRY PANEL,Serum Chloride,,101,,,,,94 - 112,mmol/L +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,143,,,,,116 - 164,g/L +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.42,,,,,0.34 - 0.48, +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.8,,,,,4.1 - 5.6,TI/L +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,Normocytic,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,89,,,,,79 - 98,fL +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,5.03,,,,,3.8 - 10.7,GI/L +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.95,,,,,1.96 - 7.23,GI/L +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.62,,,,,0.91 - 4.28,GI/L +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.32,,,,,0.12 - 0.92,GI/L +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.13,,,,,0 - 0.57,GI/L +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.02,,,,,0 - 0.2,GI/L +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,58.6,,,,,40.5 - 75,% +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,32.2,,,,,15.4 - 48.5,% +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,6.3,,,,,2.6 - 10.1,% +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.5,,,,,0 - 6.8,% +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.4,,,,,0 - 2,% +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,,,,Test cancelled: Platelet clumps present,,, +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.6,,,,,<6.5 %, +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,8.28,,,,,1.9 - 23,uIU/mL +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,LIPID PANEL,Direct HDL-C 4th Generation,,1.34,,,,,1.03 - 1.53,mmol/L +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,LIPID PANEL,Triglycerides (GPO),,1.17,,,,,0.59 - 2.96,mmol/L +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,LIPID PANEL,Cholesterol (High Performance),,6.97,,,,,4.42 - 7.53,mmol/L +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,LIPID PANEL,LDL Chol Friedewald 4th,,5.09,,H,,,0 - 3.34,mmol/L +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,RETICULOCYTES,Reticulocyte Count %,,1.7,,,,,0.6 - 2.5,% +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,TSH,TSH 3rd IS-QT,,,,,Test group cancelled: No specimen received,,, +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,URINE MACRO PANEL,Ur Specific Gravity,,1.022,,,,,1 - 1.04, +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,URINE MACRO PANEL,Ur pH,,6.0,,,,,5 - 8, +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.8,,,,,0 - 5,mg/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,CELLULAR ELEMENTS,Ur WBC/HPF,,7,,,,,0 - 12,/HPF +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,CHEMISTRY PANEL,Total Bilirubin,,14,,,,,3 - 21,umol/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,5.1,,,,,0 - 6.2,umol/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,CHEMISTRY PANEL,Alkaline Phosphatase,,86,,,,,35 - 104,U/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,CHEMISTRY PANEL,ALT (SGPT),,61,R,H,,,4 - 43,U/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,CHEMISTRY PANEL,AST (SGOT),,37,,,,,8 - 40,U/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,CHEMISTRY PANEL,GGT,,25,,,,,4 - 49,U/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,CHEMISTRY PANEL,LDH,,181,,,,,53 - 234,U/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,CHEMISTRY PANEL,Urea Nitrogen,,4.3,,,,,1.4 - 8.6,mmol/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,75,,,,,31 - 101,umol/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,CHEMISTRY PANEL,Glucose Fasting,,6.1,R,H,,,3.9 - 5.6,mmol/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,CHEMISTRY PANEL,Serum Uric Acid,,287,,,,,149 - 446,umol/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,CHEMISTRY PANEL,Calcium (EDTA),,2.34,,,,,2.07 - 2.64,mmol/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,CHEMISTRY PANEL,Phosphorus,,1.16,,,,,0.71 - 1.65,mmol/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,CHEMISTRY PANEL,Total Protein,,64,,,,,61 - 84,g/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,CHEMISTRY PANEL,Albumin-BCG,,44,,,,,33 - 49,g/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,CHEMISTRY PANEL,Creatine Kinase,,52,,,,,26 - 192,U/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,CHEMISTRY PANEL,Serum Sodium,,140,,,,,132 - 147,mmol/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,CHEMISTRY PANEL,Serum Potassium,,4.3,,,,,3.5 - 5.2,mmol/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,CHEMISTRY PANEL,Serum Bicarbonate,,25.7,,,,,19.3 - 29.3,mmol/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,CHEMISTRY PANEL,Serum Chloride,,104,,,,,94 - 112,mmol/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,151,,,,,116 - 164,g/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.45,,,,,0.34 - 0.48, +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.0,,,,,4.1 - 5.6,TI/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,91,,,,,79 - 98,fL +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,7.52,,,,,3.8 - 10.7,GI/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,4.64,,,,,1.96 - 7.23,GI/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.27,,,,,0.91 - 4.28,GI/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.38,,,,,0.12 - 0.92,GI/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.15,,,,,0 - 0.57,GI/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.08,,,,,0 - 0.2,GI/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,61.7,,,,,40.5 - 75,% +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,30.2,,,,,15.4 - 48.5,% +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.0,,,,,2.6 - 10.1,% +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.0,,,,,0 - 6.8,% +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.0,,,,,0 - 2,% +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,310,,,,,140 - 400,GI/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,6.4,,,,,<6.5 %, +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,18.47,,,,,1.9 - 23,uIU/mL +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,LIPID PANEL,Direct HDL-C 4th Generation,,0.95,R,L,,,1.03 - 1.53,mmol/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,LIPID PANEL,Triglycerides (GPO),,1.13,,,,,0.59 - 2.96,mmol/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,LIPID PANEL,Cholesterol (High Performance),,2.38,,L,,Result verified by repeat analysis,4.42 - 7.53,mmol/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,LIPID PANEL,LDL Chol Friedewald 4th,,0.91,,,,,0 - 3.34,mmol/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,RETICULOCYTES,Reticulocyte Count %,,2.0,,,,,0.6 - 2.5,% +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,TSH,TSH 3rd IS-QT,,0.827,,,,,0.45 - 5.33,mIU/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,URINE MACRO PANEL,Ur Specific Gravity,,1.019,,,,,1 - 1.04, +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,URINE MACRO PANEL,Ur Leukocyte Esterase,,+2,,H SF,,,Ref Rng:Negative, +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,URINE MICRO PANEL,Ur Microscopic,,Positive,,,,, NEGATIVE$,NEGATIVE +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.7,,,,,0 - 5,mg/L +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,CHEMISTRY PANEL,Total Bilirubin,,19,,,,,3 - 21,umol/L +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,5.6,,,,,0 - 6.2,umol/L +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,CHEMISTRY PANEL,Alkaline Phosphatase,,122,,H,,,35 - 104,U/L +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,CHEMISTRY PANEL,ALT (SGPT),,9,,,,,4 - 43,U/L +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,CHEMISTRY PANEL,AST (SGOT),,15,,,,,8 - 40,U/L +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,CHEMISTRY PANEL,GGT,,12,,,,,5 - 50,U/L +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,CHEMISTRY PANEL,LDH,,154,,,,,53 - 234,U/L +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,CHEMISTRY PANEL,Urea Nitrogen,,6.0,,,,,1.4 - 8.6,mmol/L +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,65,,,,,31 - 101,umol/L +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,CHEMISTRY PANEL,Glucose Fasting,,6.3,,H,,,3.9 - 5.6,mmol/L +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,CHEMISTRY PANEL,Serum Uric Acid,,223,,,,,149 - 446,umol/L +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,CHEMISTRY PANEL,Calcium (EDTA),,2.31,,,,,2.07 - 2.64,mmol/L +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,CHEMISTRY PANEL,Phosphorus,,0.91,,,,,0.71 - 1.65,mmol/L +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,CHEMISTRY PANEL,Total Protein,,68,,,,,60 - 80,g/L +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,CHEMISTRY PANEL,Albumin-BCG,,44,,,,,33 - 49,g/L +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,CHEMISTRY PANEL,Creatine Kinase,,85,,,,,26 - 192,U/L +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,CHEMISTRY PANEL,Serum Sodium,,140,,,,,135 - 145,mmol/L +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,CHEMISTRY PANEL,Serum Potassium,,4.3,,,,,3.5 - 5.2,mmol/L +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,CHEMISTRY PANEL,Serum Bicarbonate,,23.4,,,,,19.3 - 29.3,mmol/L +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,CHEMISTRY PANEL,Serum Chloride,,106,,,,,94 - 112,mmol/L +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,147,,,,,115 - 158,g/L +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.45,,,,,0.34 - 0.48, +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.7,,,,,3.9 - 5.5,TI/L +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,94,,,,,80 - 100,fL +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,6.41,,,,,3.8 - 10.7,GI/L +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.51,,,,,1.96 - 7.23,GI/L +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.33,,,,,0.8 - 3,GI/L +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.35,,,,,0.12 - 0.92,GI/L +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.13,,,,,0 - 0.57,GI/L +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.09,,,,,0 - 0.2,GI/L +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,54.7,,,,,40.5 - 75,% +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,36.2,,,,,15.4 - 48.5,% +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.5,,,,,2.6 - 10.1,% +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.1,,,,,0 - 6.8,% +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.4,,,,,0 - 2,% +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,232,,,,,130 - 394,GI/L +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,4.38,,,,,1.9 - 23,uIU/mL +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,LIPID PANEL,Direct HDL-C 4th Generation,,1.74,R,H,,,1.03 - 1.53,mmol/L +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,LIPID PANEL,Triglycerides (GPO),,0.57,R,L,,,0.63 - 2.71,mmol/L +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,LIPID PANEL,Cholesterol (High Performance),,4.75,R,L,,,4.86 - 8.28,mmol/L +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,LIPID PANEL,LDL Chol Friedewald 4th,,2.75,,,,,0 - 3.34,mmol/L +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,RETICULOCYTES,Reticulocyte Count %,,0.9,,,,,0.6 - 2.5,% +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,URINE MACRO PANEL,Ur Specific Gravity,,1.006,,,,,1.01 - 1.03, +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,C-REACTIVE PROTEIN,C Reactive Protein HS,,8.5,R,H,,,0 - 5,mg/L +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,CHEMISTRY PANEL,Total Bilirubin,,5,,,,,3 - 21,umol/L +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.3,,,,,0 - 6.2,umol/L +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,CHEMISTRY PANEL,Alkaline Phosphatase,,61,,,,,35 - 104,U/L +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,CHEMISTRY PANEL,ALT (SGPT),,15,,,,,4 - 43,U/L +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,CHEMISTRY PANEL,AST (SGOT),,17,,,,,8 - 40,U/L +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,CHEMISTRY PANEL,GGT,,14,,,,,5 - 50,U/L +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,CHEMISTRY PANEL,LDH,,150,,,,,53 - 234,U/L +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,CHEMISTRY PANEL,Urea Nitrogen,,4.4,,,,,1.4 - 8.6,mmol/L +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,56,,,,,31 - 101,umol/L +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,CHEMISTRY PANEL,Glucose Fasting,,5.7,,H,,,3.9 - 5.6,mmol/L +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,CHEMISTRY PANEL,Serum Uric Acid,,207,,,,,149 - 446,umol/L +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,CHEMISTRY PANEL,Calcium (EDTA),,2.32,,,,,2.07 - 2.64,mmol/L +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,CHEMISTRY PANEL,Phosphorus,,0.89,,,,,0.71 - 1.65,mmol/L +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,CHEMISTRY PANEL,Total Protein,,63,,,,,60 - 80,g/L +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,CHEMISTRY PANEL,Albumin-BCG,,41,,,,,33 - 49,g/L +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,CHEMISTRY PANEL,Creatine Kinase,,78,,,,,26 - 192,U/L +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,CHEMISTRY PANEL,Serum Sodium,,142,,,,,135 - 145,mmol/L +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,CHEMISTRY PANEL,Serum Potassium,,4.4,,,,,3.5 - 5.2,mmol/L +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,CHEMISTRY PANEL,Serum Bicarbonate,,23.4,,,,,19.3 - 29.3,mmol/L +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,CHEMISTRY PANEL,Serum Chloride,,107,,,,,94 - 112,mmol/L +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,149,,,,,115 - 158,g/L +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.44,,,,,0.34 - 0.48, +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.5,,,,,3.9 - 5.5,TI/L +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,97,,,,,80 - 100,fL +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,5.75,,,,,3.8 - 10.7,GI/L +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,4.15,,,,,1.96 - 7.23,GI/L +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.07,,,,,0.8 - 3,GI/L +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.38,,,,,0.12 - 0.92,GI/L +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.13,,,,,0 - 0.57,GI/L +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.02,,,,,0 - 0.2,GI/L +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,72.1,,,,,40.5 - 75,% +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,18.6,,,,,15.4 - 48.5,% +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,6.7,,,,,2.6 - 10.1,% +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.2,,,,,0 - 6.8,% +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.4,,,,,0 - 2,% +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,234,,,,,130 - 394,GI/L +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,5.19,,,,,1.9 - 23,uIU/mL +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,LIPID PANEL,Direct HDL-C 4th Generation,,1.30,,,,,1.03 - 1.53,mmol/L +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,LIPID PANEL,Triglycerides (GPO),,0.41,,L,,,0.63 - 2.71,mmol/L +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,LIPID PANEL,Cholesterol (High Performance),,4.53,,L,,,4.86 - 8.28,mmol/L +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,LIPID PANEL,LDL Chol Friedewald 4th,,3.04,,,,,0 - 3.34,mmol/L +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,RETICULOCYTES,Reticulocyte Count %,,1.1,,,,,0.6 - 2.5,% +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,URINE MACRO PANEL,Ur Specific Gravity,,1.019,,,,,1.01 - 1.03, +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,URINE MACRO PANEL,Ur pH,,5.0,,,,,5 - 8, +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,C-REACTIVE PROTEIN,C Reactive Protein HS,,0.9,,,,,0 - 5,mg/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,CHEMISTRY PANEL,Total Bilirubin,,11,,,,,3 - 21,umol/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.0,,,,,0 - 6.2,umol/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,CHEMISTRY PANEL,Alkaline Phosphatase,,78,,,,,35 - 104,U/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,CHEMISTRY PANEL,ALT (SGPT),,29,,,,,4 - 43,U/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,CHEMISTRY PANEL,AST (SGOT),,24,,,,,8 - 40,U/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,CHEMISTRY PANEL,GGT,,23,,,,,4 - 49,U/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,CHEMISTRY PANEL,LDH,,214,,,,,53 - 234,U/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,CHEMISTRY PANEL,Urea Nitrogen,,3.9,,,,,1.4 - 8.6,mmol/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,80,,,,,31 - 101,umol/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,CHEMISTRY PANEL,Glucose Fasting,,5.4,,,,,3.9 - 5.6,mmol/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,CHEMISTRY PANEL,Serum Uric Acid,,248,,,,,149 - 446,umol/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,CHEMISTRY PANEL,Calcium (EDTA),,2.38,,,,,2.07 - 2.64,mmol/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,CHEMISTRY PANEL,Phosphorus,,0.93,,,,,0.71 - 1.65,mmol/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,CHEMISTRY PANEL,Total Protein,,64,,,,,61 - 84,g/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,CHEMISTRY PANEL,Albumin-BCG,,45,,,,,33 - 49,g/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,CHEMISTRY PANEL,Creatine Kinase,,128,,,,,26 - 192,U/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,CHEMISTRY PANEL,Serum Sodium,,142,,,,,132 - 147,mmol/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,CHEMISTRY PANEL,Serum Potassium,,4.5,,,,,3.5 - 5.2,mmol/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,CHEMISTRY PANEL,Serum Bicarbonate,,25.8,,,,,19.3 - 29.3,mmol/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,CHEMISTRY PANEL,Serum Chloride,,105,,,,,94 - 112,mmol/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,138,,,,,116 - 164,g/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.42,,,,,0.34 - 0.48, +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.5,,,,,4.1 - 5.6,TI/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,94,,,,,79 - 98,fL +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,5.44,,,,,3.8 - 10.7,GI/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.15,,,,,1.96 - 7.23,GI/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.79,,,,,0.91 - 4.28,GI/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.33,,,,,0.12 - 0.92,GI/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.15,,,,,0 - 0.57,GI/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.03,,,,,0 - 0.2,GI/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,57.9,,,,,40.5 - 75,% +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,32.9,,,,,15.4 - 48.5,% +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,6.0,,,,,2.6 - 10.1,% +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.7,,,,,0 - 6.8,% +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.6,,,,,0 - 2,% +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,290,,,,,140 - 400,GI/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.1,,,,,<6.5 %, +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,5.23,,,,,1.9 - 23,uIU/mL +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,LIPID PANEL,Direct HDL-C 4th Generation,,1.67,,H,,,1.03 - 1.53,mmol/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,LIPID PANEL,Triglycerides (GPO),,0.88,,,,,0.59 - 2.96,mmol/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,LIPID PANEL,Cholesterol (High Performance),,5.28,,,,,4.42 - 7.53,mmol/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,LIPID PANEL,LDL Chol Friedewald 4th,,3.21,,,,,0 - 3.34,mmol/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,RETICULOCYTES,Reticulocyte Count %,,1.4,,,,,0.6 - 2.5,% +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,TSH,TSH 3rd IS-QT,,1.525,,,,,0.45 - 5.33,mIU/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,URINE MACRO PANEL,Ur Specific Gravity,,1.019,,,,,1 - 1.04, +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,URINE MACRO PANEL,Ur pH,,7.0,,,,,5 - 8, +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,C-REACTIVE PROTEIN,C Reactive Protein HS,,4.4,,,,,0 - 5,mg/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,CHEMISTRY PANEL,Total Bilirubin,,14,,,,,3 - 21,umol/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.8,,,,,0 - 6.2,umol/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,CHEMISTRY PANEL,Alkaline Phosphatase,,81,,,,,35 - 104,U/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,CHEMISTRY PANEL,ALT (SGPT),,25,,,,,4 - 43,U/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,CHEMISTRY PANEL,AST (SGOT),,25,,,,,8 - 40,U/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,CHEMISTRY PANEL,GGT,,52,,H,,,4 - 49,U/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,CHEMISTRY PANEL,LDH,,153,,,,,53 - 234,U/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,CHEMISTRY PANEL,Urea Nitrogen,,3.3,,,,,1.4 - 8.6,mmol/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,66,,,,,31 - 101,umol/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,CHEMISTRY PANEL,Glucose Fasting,,5.4,,,,,3.9 - 5.6,mmol/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,CHEMISTRY PANEL,Serum Uric Acid,,273,,,,,125 - 428,umol/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,CHEMISTRY PANEL,Calcium (EDTA),,2.45,,,,,2.07 - 2.64,mmol/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,CHEMISTRY PANEL,Phosphorus,,1.02,,,,,0.71 - 1.65,mmol/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,CHEMISTRY PANEL,Total Protein,,74,,,,,61 - 84,g/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,CHEMISTRY PANEL,Albumin-BCG,,46,,,,,33 - 49,g/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,CHEMISTRY PANEL,Creatine Kinase,,118,,,,,26 - 192,U/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,CHEMISTRY PANEL,Serum Sodium,,137,,,,,132 - 147,mmol/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,CHEMISTRY PANEL,Serum Potassium,,4.3,,,,,3.5 - 5.2,mmol/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,CHEMISTRY PANEL,Serum Bicarbonate,,23.2,,,,,19.3 - 29.3,mmol/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,CHEMISTRY PANEL,Serum Chloride,,100,,,,,94 - 112,mmol/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,131,,,,,116 - 164,g/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.39,,,,,0.34 - 0.48, +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.1,,,,,4.1 - 5.6,TI/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,96,,,,,79 - 98,fL +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,6.38,,,,,3.8 - 10.7,GI/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.04,,,,,1.96 - 7.23,GI/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.60,,,,,0.91 - 4.28,GI/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.49,,,,,0.12 - 0.92,GI/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.23,,,,,0 - 0.57,GI/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.03,,,,,0 - 0.2,GI/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,47.6,,,,,40.5 - 75,% +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,40.7,,,,,15.4 - 48.5,% +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,7.6,,,,,2.6 - 10.1,% +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,3.6,,,,,0 - 6.8,% +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.5,,,,,0 - 2,% +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,315,,,,,140 - 400,GI/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.2,,,,,<6.5 %, +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,5.83,,,,,1.9 - 23,uIU/mL +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,LIPID PANEL,Direct HDL-C 4th Generation,,1.70,,H,,Result verified by repeat analysis,1.03 - 1.53,mmol/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,LIPID PANEL,Triglycerides (GPO),,2.24,,,,,0.51 - 2.42,mmol/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,LIPID PANEL,Cholesterol (High Performance),,5.71,,,,,4.01 - 6.85,mmol/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,LIPID PANEL,LDL Chol Friedewald 4th,,2.98,,,,,0 - 3.34,mmol/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,RETICULOCYTES,Reticulocyte Count %,,1.9,,,,,0.6 - 2.5,% +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,TSH,TSH 3rd IS-QT,,4.319,,,,,0.45 - 5.33,mIU/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,URINE MACRO PANEL,Ur Specific Gravity,,1.021,,,,,1 - 1.04, +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.0,,,,,0 - 5,mg/L +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,CHEMISTRY PANEL,Total Bilirubin,,11,,,,,3 - 21,umol/L +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.2,,,,,0 - 6.2,umol/L +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,CHEMISTRY PANEL,Alkaline Phosphatase,,130,,H,,,35 - 104,U/L +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,CHEMISTRY PANEL,ALT (SGPT),,10,,,,,4 - 43,U/L +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,CHEMISTRY PANEL,AST (SGOT),,14,,,,,8 - 40,U/L +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,CHEMISTRY PANEL,GGT,,13,,,,,5 - 50,U/L +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,CHEMISTRY PANEL,LDH,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,CHEMISTRY PANEL,Urea Nitrogen,,5.6,,,,,1.4 - 8.6,mmol/L +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,63,,,,,31 - 101,umol/L +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,CHEMISTRY PANEL,Glucose Fasting,,5.4,,,,,3.9 - 5.6,mmol/L +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,CHEMISTRY PANEL,Serum Uric Acid,,232,,,,,149 - 446,umol/L +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,CHEMISTRY PANEL,Calcium (EDTA),,2.49,,,,,2.07 - 2.64,mmol/L +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,CHEMISTRY PANEL,Phosphorus,,0.93,,,,,0.71 - 1.65,mmol/L +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,CHEMISTRY PANEL,Total Protein,,73,,,,,60 - 80,g/L +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,CHEMISTRY PANEL,Albumin-BCG,,45,,,,,33 - 49,g/L +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,CHEMISTRY PANEL,Creatine Kinase,,59,,,,,26 - 192,U/L +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,CHEMISTRY PANEL,Serum Sodium,,141,,,,,135 - 145,mmol/L +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,CHEMISTRY PANEL,Serum Potassium,,4.2,,,,,3.5 - 5.2,mmol/L +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,CHEMISTRY PANEL,Serum Bicarbonate,,25.2,,,,,19.3 - 29.3,mmol/L +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,CHEMISTRY PANEL,Serum Chloride,,104,,,,,94 - 112,mmol/L +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,CREATININE CLEARANCE CC&G,CreatininClearancCockcrftGault,,1.61,,,,,1.25 - 1.92,mL/sec +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,CREATININE CLEARANCE CC&G,Creatinine(Rate Blanked)-2dp,,63,,,,,31 - 101,umol/L +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,CREATININE CLEARANCE CC&G,"Weight (kg,1dec place)",Y,75.5,,,,,kg, +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,DRUG SCREEN URINE,Amphetamines/MDMA,,Neg,,,,,Neg;$Cutoff = 1000 ng/mL, +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,DRUG SCREEN URINE,Barbiturates,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,DRUG SCREEN URINE,Cannabinoids,,Neg,,,,,Neg;$Cutoff = 50 ng/mL, +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,DRUG SCREEN URINE,Cocaine,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,DRUG SCREEN URINE,Opiates,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,DRUG SCREEN URINE,Methadone,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,DRUG SCREEN URINE BENZO NON-US,Benzodiazepines Gen 2,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,FEMALE OF CHILDBEARING POT?,Female/of Childbearing pot.?,Y,No,,,,,, +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,FSH,Follicle Stimulating Hormone,,57.83,,,,,Follicular:$3.90-8.80 IU/L$Midcycle:$4.50-22.50 IU/L$Luteal:$1.80-5.10 IU/L$Postmenopausal:$16.70-113.60 IU/L, +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,GFR,EGFR by MDRD,,83,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,159,R,H,,,115 - 158,g/L +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.49,R,H,,,0.34 - 0.48, +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.2,,,,,3.9 - 5.5,TI/L +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,93,,,,,80 - 100,fL +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,6.19,,,,,3.8 - 10.7,GI/L +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.31,,,,,1.96 - 7.23,GI/L +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.30,,,,,0.8 - 3,GI/L +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.34,,,,,0.12 - 0.92,GI/L +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.18,,,,,0 - 0.57,GI/L +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.06,,,,,0 - 0.2,GI/L +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,53.5,,,,,40.5 - 75,% +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,37.2,,,,,15.4 - 48.5,% +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.5,,,,,2.6 - 10.1,% +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.9,,,,,0 - 6.8,% +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.0,,,,,0 - 2,% +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,255,,,,,130 - 394,GI/L +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.6,,,,,<6.5 %, +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,3.27,,,,,1.9 - 23,uIU/mL +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,IS SUBJECT OF BLACK RACE?,Subject of black race?,Y,No,,,,,, +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,LIPID PANEL,Direct HDL-C 4th Generation,,1.70,,H,,,1.03 - 1.53,mmol/L +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,LIPID PANEL,Triglycerides (GPO),,0.84,,,,,0.63 - 2.71,mmol/L +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,LIPID PANEL,Cholesterol (High Performance),,5.60,,,,,4.86 - 8.28,mmol/L +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,LIPID PANEL,LDL Chol Friedewald 4th,,3.52,,H,,,0 - 3.34,mmol/L +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,MICROORGANISMS,Ur Bacteria,,Present,,,,,Ref Rng:Not present, +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,POSTMENOPAUSAL FEMALE?,<40yrs & amenorrhea >/= 12mo,,Yes,,,,,, +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,RETICULOCYTES,Reticulocyte Count %,,1.0,,,,,0.6 - 2.5,% +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,TSH,TSH 3rd IS-QT,,0.932,,,,,0.45 - 5.33,mIU/L +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,URINE MACRO PANEL,Ur Specific Gravity,,1.006,,,,,1.01 - 1.03, +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,URINE MACRO PANEL,Ur Leukocyte Esterase,,+1,,H,,,Ref Rng:Negative, +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,URINE MICRO PANEL,Ur Microscopic,,Positive,,,,, NEGATIVE$,NEGATIVE +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.3,,,,,0 - 5,mg/L +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,CELLULAR ELEMENTS,Ur WBC/HPF,,48,R,H,,,0 - 12,/HPF +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,CHEMISTRY PANEL,Total Bilirubin,,4,,,,,3 - 21,umol/L +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,1.6,,,,,0 - 6.2,umol/L +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,CHEMISTRY PANEL,Alkaline Phosphatase,,89,,,,,35 - 104,U/L +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,CHEMISTRY PANEL,ALT (SGPT),,16,,,,,4 - 43,U/L +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,CHEMISTRY PANEL,AST (SGOT),,17,,,,,8 - 40,U/L +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,CHEMISTRY PANEL,GGT,,28,,,,,4 - 49,U/L +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,CHEMISTRY PANEL,LDH,,141,,,,,53 - 234,U/L +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,CHEMISTRY PANEL,Urea Nitrogen,,4.6,,,,,1.4 - 8.6,mmol/L +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,52,,,,,31 - 101,umol/L +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,CHEMISTRY PANEL,Glucose Fasting,,6.7,R,H,,,3.9 - 5.6,mmol/L +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,CHEMISTRY PANEL,Serum Uric Acid,,325,,,,,125 - 428,umol/L +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,CHEMISTRY PANEL,Calcium (EDTA),,2.52,,,,,2.07 - 2.64,mmol/L +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,CHEMISTRY PANEL,Phosphorus,,1.23,,,,,0.71 - 1.65,mmol/L +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,CHEMISTRY PANEL,Total Protein,,75,,,,,61 - 84,g/L +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,CHEMISTRY PANEL,Albumin-BCG,,46,,,,,33 - 49,g/L +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,CHEMISTRY PANEL,Creatine Kinase,,205,R,H,,,26 - 192,U/L +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,CHEMISTRY PANEL,Serum Sodium,,137,,,,,132 - 147,mmol/L +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,CHEMISTRY PANEL,Serum Potassium,,4.6,,,,,3.5 - 5.2,mmol/L +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,CHEMISTRY PANEL,Serum Bicarbonate,,24.4,,,,,19.3 - 29.3,mmol/L +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,CHEMISTRY PANEL,Serum Chloride,,100,,,,,94 - 112,mmol/L +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,CRYSTALS,Ur Calcium Oxalate Crystals,,Present,,,,,Ref Rng:Not present, +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,138,,,,,116 - 164,g/L +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.42,,,,,0.34 - 0.48, +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.4,,,,,4.1 - 5.6,TI/L +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,96,,,,,79 - 98,fL +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,9.95,,,,,3.8 - 10.7,GI/L +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,5.30,,,,,1.96 - 7.23,GI/L +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,3.84,R,,,,0.91 - 4.28,GI/L +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.62,,,,,0.12 - 0.92,GI/L +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.14,,,,,0 - 0.57,GI/L +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.05,,,,,0 - 0.2,GI/L +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,53.3,,,,,40.5 - 75,% +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,38.6,,,,,15.4 - 48.5,% +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,6.2,,,,,2.6 - 10.1,% +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.4,,,,,0 - 6.8,% +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.5,,,,,0 - 2,% +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,486,R,H,,,140 - 400,GI/L +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,118.97,R,H,,,1.9 - 23,uIU/mL +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,LIPID PANEL,Direct HDL-C 4th Generation,,1.32,,,,,1.03 - 1.53,mmol/L +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,LIPID PANEL,Triglycerides (GPO),,2.60,R,H,,,0.51 - 2.42,mmol/L +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,LIPID PANEL,Cholesterol (High Performance),,5.47,,,,,4.01 - 6.85,mmol/L +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,LIPID PANEL,LDL Chol Friedewald 4th,,2.96,,,,,0 - 3.34,mmol/L +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,RETICULOCYTES,Reticulocyte Count %,,1.4,,,,,0.6 - 2.5,% +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,URINE MACRO PANEL,Ur Specific Gravity,,1.033,R,,,,1 - 1.04, +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,URINE MACRO PANEL,Ur Protein,,+2,R,H SF,,,Ref Rng:Negative, +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,URINE MACRO PANEL,Ur Ketones,,Trace,R,H,,,Ref Rng:Negative, +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,URINE MACRO PANEL,Ur Leukocyte Esterase,,+3,R,H SF,,,Ref Rng:Negative, +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,URINE MICRO PANEL,Ur Microscopic,,Positive,,,,, NEGATIVE$,NEGATIVE +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,C-REACTIVE PROTEIN,C Reactive Protein HS,,9.0,R,H,,,0 - 5,mg/L +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,CELLULAR ELEMENTS,Ur WBC/HPF,,6,,,,,0 - 12,/HPF +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,CELLULAR ELEMENTS,Ur Squamous Epithelial Cells,,38,,,,,0 - 3,/HPF +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,CHEMISTRY PANEL,Total Bilirubin,,11,,,,,3 - 21,umol/L +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.5,,,,,0 - 6.2,umol/L +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,CHEMISTRY PANEL,Alkaline Phosphatase,,65,,,,,35 - 104,U/L +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,CHEMISTRY PANEL,ALT (SGPT),,16,,,,,4 - 43,U/L +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,CHEMISTRY PANEL,AST (SGOT),,17,,,,,8 - 40,U/L +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,CHEMISTRY PANEL,GGT,,16,,,,,5 - 50,U/L +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,CHEMISTRY PANEL,LDH,,183,,,,,53 - 234,U/L +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,CHEMISTRY PANEL,Urea Nitrogen,,4.2,,,,,1.4 - 8.6,mmol/L +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,58,,,,,31 - 101,umol/L +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,CHEMISTRY PANEL,Glucose Fasting,,5.0,,,,,3.9 - 5.6,mmol/L +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,CHEMISTRY PANEL,Serum Uric Acid,,133,R,L,,,149 - 446,umol/L +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,CHEMISTRY PANEL,Calcium (EDTA),,2.43,,,,,2.07 - 2.64,mmol/L +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,CHEMISTRY PANEL,Phosphorus,,0.91,,,,,0.71 - 1.65,mmol/L +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,CHEMISTRY PANEL,Total Protein,,63,,,,,60 - 80,g/L +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,CHEMISTRY PANEL,Albumin-BCG,,42,,,,,33 - 49,g/L +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,CHEMISTRY PANEL,Creatine Kinase,,87,,,,,26 - 192,U/L +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,CHEMISTRY PANEL,Serum Sodium,,139,,,,,135 - 145,mmol/L +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,CHEMISTRY PANEL,Serum Potassium,,4.2,,,,,3.5 - 5.2,mmol/L +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,CHEMISTRY PANEL,Serum Bicarbonate,,22.0,,,,,19.3 - 29.3,mmol/L +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,CHEMISTRY PANEL,Serum Chloride,,106,,,,,94 - 112,mmol/L +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,CREATININE CLEARANCE CC&G,CreatininClearancCockcrftGault,,1.29,,,,,1.25 - 1.92,mL/sec +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,CREATININE CLEARANCE CC&G,Creatinine(Rate Blanked)-2dp,,58,,,,,31 - 101,umol/L +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,CREATININE CLEARANCE CC&G,"Weight (kg,1dec place)",Y,58.2,,,,,kg, +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,DRUG SCREEN URINE,Amphetamines/MDMA,,Neg,,,,,Neg;$Cutoff = 1000 ng/mL, +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,DRUG SCREEN URINE,Barbiturates,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,DRUG SCREEN URINE,Cannabinoids,,Neg,,,,,Neg;$Cutoff = 50 ng/mL, +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,DRUG SCREEN URINE,Cocaine,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,DRUG SCREEN URINE,Opiates,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,DRUG SCREEN URINE,Methadone,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,DRUG SCREEN URINE BENZO NON-US,Benzodiazepines Gen 2,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,FEMALE OF CHILDBEARING POT?,Female/of Childbearing pot.?,Y,No,,,,,, +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,GFR,EGFR by MDRD,,90,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,148,,,,,115 - 158,g/L +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.45,,,,,0.34 - 0.48, +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.6,,,,,3.9 - 5.5,TI/L +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,99,,,,,80 - 100,fL +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,5.46,,,,,3.8 - 10.7,GI/L +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.63,,,,,1.96 - 7.23,GI/L +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.19,,,,,0.8 - 3,GI/L +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.49,,,,,0.12 - 0.92,GI/L +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.12,,,,,0 - 0.57,GI/L +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.03,,,,,0 - 0.2,GI/L +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,66.4,,,,,40.5 - 75,% +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,21.7,,,,,15.4 - 48.5,% +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,9.0,,,,,2.6 - 10.1,% +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.2,,,,,0 - 6.8,% +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.6,,,,,0 - 2,% +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,247,,,,,130 - 394,GI/L +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.4,,,,,<6.5 %, +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,3.23,,,,,1.9 - 23,uIU/mL +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,IS SUBJECT OF BLACK RACE?,Subject of black race?,Y,No,,,,,, +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,LIPID PANEL,Direct HDL-C 4th Generation,,1.28,,,,,1.03 - 1.53,mmol/L +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,LIPID PANEL,Triglycerides (GPO),,0.70,,,,,0.63 - 2.71,mmol/L +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,LIPID PANEL,Cholesterol (High Performance),,4.86,,,,,4.86 - 8.28,mmol/L +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,LIPID PANEL,LDL Chol Friedewald 4th,,3.26,,,,,0 - 3.34,mmol/L +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,MICROORGANISMS,Ur Bacteria,,Present,,,,,Ref Rng:Not present, +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,MISCELLANEOUS ELEMENTS,Ur Mucous,,Present,,,,,Ref Rng:Not present, +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,POSTMENOPAUSAL FEMALE?,<40yrs & amenorrhea >/= 12mo,,No,,,,,, +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,RETICULOCYTES,Reticulocyte Count %,,1.2,,,,,0.6 - 2.5,% +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,TSH,TSH 3rd IS-QT,,1.723,,,,,0.45 - 5.33,mIU/L +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,URINE MACRO PANEL,Ur Specific Gravity,,1.023,,,,,1.01 - 1.03, +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,URINE MACRO PANEL,Ur Protein,,Trace,R,H,,,Ref Rng:Negative, +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,URINE MACRO PANEL,Ur Glucose,,Trace,R,H,,,Ref Rng:Normal, +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,URINE MICRO PANEL,Ur Microscopic,,Positive,,,,, NEGATIVE$,NEGATIVE +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,C-REACTIVE PROTEIN,C Reactive Protein HS,,3.1,,,,,0 - 5,mg/L +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,CHEMISTRY PANEL,Total Bilirubin,,4,,,,,3 - 21,umol/L +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,1.6,,,,,0 - 6.2,umol/L +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,CHEMISTRY PANEL,Alkaline Phosphatase,,89,,,,,35 - 104,U/L +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,CHEMISTRY PANEL,ALT (SGPT),,14,,,,,4 - 43,U/L +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,CHEMISTRY PANEL,AST (SGOT),,15,,,,,8 - 40,U/L +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,CHEMISTRY PANEL,GGT,,17,,,,,5 - 50,U/L +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,CHEMISTRY PANEL,LDH,,151,,,,,53 - 234,U/L +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,CHEMISTRY PANEL,Urea Nitrogen,,6.7,,,,,1.4 - 10.4,mmol/L +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,70,,,,,31 - 110,umol/L +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,CHEMISTRY PANEL,Glucose Fasting,,5.7,R,H,,,3.9 - 5.6,mmol/L +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,CHEMISTRY PANEL,Serum Uric Acid,,312,,,,,149 - 446,umol/L +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,CHEMISTRY PANEL,Calcium (EDTA),,2.45,,,,,2.07 - 2.64,mmol/L +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,CHEMISTRY PANEL,Phosphorus,,1.48,,,,,0.71 - 1.65,mmol/L +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,CHEMISTRY PANEL,Total Protein,,77,,,,,60 - 80,g/L +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,CHEMISTRY PANEL,Albumin-BCG,,45,,,,,33 - 46,g/L +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,CHEMISTRY PANEL,Creatine Kinase,,66,,,,,26 - 192,U/L +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,CHEMISTRY PANEL,Serum Sodium,,139,,,,,135 - 145,mmol/L +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,CHEMISTRY PANEL,Serum Potassium,,4.7,,,,,3.5 - 5.2,mmol/L +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,CHEMISTRY PANEL,Serum Bicarbonate,,21.8,,,,,19.3 - 29.3,mmol/L +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,CHEMISTRY PANEL,Serum Chloride,,102,,,,,94 - 112,mmol/L +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,161,R,H,,,115 - 158,g/L +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.48,,,,,0.34 - 0.48, +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.3,,,,,3.9 - 5.5,TI/L +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,91,,,,,80 - 100,fL +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,9.57,,,,,3.8 - 10.7,GI/L +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,5.16,,,,,1.96 - 7.23,GI/L +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,3.42,R,H,,,0.8 - 3,GI/L +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.76,,,,,0.12 - 0.92,GI/L +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.15,,,,,0 - 0.57,GI/L +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.06,,,,,0 - 0.2,GI/L +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,54.0,,,,,40.5 - 75,% +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,35.8,,,,,15.4 - 48.5,% +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,8.0,,,,,2.6 - 10.1,% +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.6,,,,,0 - 6.8,% +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.6,,,,,0 - 2,% +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,300,,,,,130 - 394,GI/L +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,7.83,,,,,1.9 - 23,uIU/mL +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,LIPID PANEL,Direct HDL-C 4th Generation,,1.33,,,,,1.03 - 1.53,mmol/L +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,LIPID PANEL,Triglycerides (GPO),,2.03,,,,,0.63 - 2.71,mmol/L +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,LIPID PANEL,Cholesterol (High Performance),,6.94,,,,,5.35 - 9.1,mmol/L +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,LIPID PANEL,LDL Chol Friedewald 4th,,4.68,,H,,,0 - 3.34,mmol/L +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,RETICULOCYTES,Reticulocyte Count %,,1.8,,,,,0.6 - 2.5,% +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,URINE MACRO PANEL,Ur Specific Gravity,,1.009,,,,,1.01 - 1.03, +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.1,,,,,0 - 5,mg/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,CELLULAR ELEMENTS,Ur WBC/HPF,,5,,,,,0 - 12,/HPF +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,CELLULAR ELEMENTS,Ur Transitional Epi Cells,,1,,,,,0 /HPF, +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,CHEMISTRY PANEL,Total Bilirubin,,11,,,,,3 - 21,umol/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.3,,,,,0 - 6.2,umol/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,CHEMISTRY PANEL,Alkaline Phosphatase,,79,,,,,35 - 104,U/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,CHEMISTRY PANEL,ALT (SGPT),,21,,,,,4 - 43,U/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,CHEMISTRY PANEL,AST (SGOT),,21,,,,,8 - 40,U/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,CHEMISTRY PANEL,GGT,,17,,,,,4 - 49,U/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,CHEMISTRY PANEL,LDH,,205,,,,,53 - 234,U/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,CHEMISTRY PANEL,Urea Nitrogen,,3.7,,,,,1.4 - 8.6,mmol/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,73,,,,,31 - 101,umol/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,CHEMISTRY PANEL,Glucose Fasting,,5.2,,,,,3.9 - 5.6,mmol/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,CHEMISTRY PANEL,Serum Uric Acid,,239,,,,,149 - 446,umol/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,CHEMISTRY PANEL,Calcium (EDTA),,2.44,,,,,2.07 - 2.64,mmol/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,CHEMISTRY PANEL,Phosphorus,,1.25,,,,,0.71 - 1.65,mmol/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,CHEMISTRY PANEL,Total Protein,,70,,,,,61 - 84,g/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,CHEMISTRY PANEL,Albumin-BCG,,46,,,,,33 - 49,g/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,CHEMISTRY PANEL,Creatine Kinase,,100,,,,,26 - 192,U/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,CHEMISTRY PANEL,Serum Sodium,,141,,,,,132 - 147,mmol/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,CHEMISTRY PANEL,Serum Potassium,,4.6,,,,,3.5 - 5.2,mmol/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,CHEMISTRY PANEL,Serum Bicarbonate,,25.3,,,,,19.3 - 29.3,mmol/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,CHEMISTRY PANEL,Serum Chloride,,102,,,,,94 - 112,mmol/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,140,,,,,116 - 164,g/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.42,,,,,0.34 - 0.48, +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.6,,,,,4.1 - 5.6,TI/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,93,,,,,79 - 98,fL +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,4.66,,,,,3.8 - 10.7,GI/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.75,,,,,1.96 - 7.23,GI/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.38,,,,,0.91 - 4.28,GI/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.39,,,,,0.12 - 0.92,GI/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.12,,,,,0 - 0.57,GI/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.02,,,,,0 - 0.2,GI/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,58.9,,,,,40.5 - 75,% +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,29.6,,,,,15.4 - 48.5,% +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,8.4,,,,,2.6 - 10.1,% +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.6,,,,,0 - 6.8,% +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.5,,,,,0 - 2,% +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,312,,,,,140 - 400,GI/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,2.82,,,,,1.9 - 23,uIU/mL +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,LIPID PANEL,Direct HDL-C 4th Generation,,1.68,,H,,,1.03 - 1.53,mmol/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,LIPID PANEL,Triglycerides (GPO),,0.71,,,,,0.59 - 2.96,mmol/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,LIPID PANEL,Cholesterol (High Performance),,5.23,,,,,4.42 - 7.53,mmol/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,LIPID PANEL,LDL Chol Friedewald 4th,,3.22,,,,,0 - 3.34,mmol/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,RETICULOCYTES,Reticulocyte Count %,,1.3,,,,,0.6 - 2.5,% +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,URINE MACRO PANEL,Ur Specific Gravity,,1.023,,,,,1 - 1.04, +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,URINE MACRO PANEL,Ur pH,,6.5,,,,,5 - 8, +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,URINE MACRO PANEL,Ur Protein,,Trace,,H,,,Ref Rng:Negative, +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,URINE MACRO PANEL,Ur Leukocyte Esterase,,Trace,,H,,,Ref Rng:Negative, +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,URINE MICRO PANEL,Ur Microscopic,,Positive,,,,, NEGATIVE$,NEGATIVE +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.4,,,,,0 - 5,mg/L +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,CELLULAR ELEMENTS,Ur WBC/HPF,,>150,,HT,,,0 - 12,/HPF +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,CHEMISTRY PANEL,Total Bilirubin,,4,,,,,3 - 21,umol/L +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,1.5,,,,,0 - 6.2,umol/L +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,CHEMISTRY PANEL,Alkaline Phosphatase,,76,,,,,35 - 104,U/L +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,CHEMISTRY PANEL,ALT (SGPT),,16,,,,,4 - 43,U/L +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,CHEMISTRY PANEL,AST (SGOT),,20,,,,,8 - 40,U/L +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,CHEMISTRY PANEL,GGT,,25,,,,,4 - 49,U/L +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,CHEMISTRY PANEL,LDH,,130,,,,,53 - 234,U/L +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,CHEMISTRY PANEL,Urea Nitrogen,,5.1,,,,,1.4 - 8.6,mmol/L +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,53,,,,,31 - 101,umol/L +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,CHEMISTRY PANEL,Glucose Fasting,,5.2,,,,,3.9 - 5.6,mmol/L +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,CHEMISTRY PANEL,Serum Uric Acid,,357,,,,,125 - 428,umol/L +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,CHEMISTRY PANEL,Calcium (EDTA),,2.43,,,,,2.07 - 2.64,mmol/L +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,CHEMISTRY PANEL,Phosphorus,,1.26,,,,,0.71 - 1.65,mmol/L +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,CHEMISTRY PANEL,Total Protein,,69,,,,,61 - 84,g/L +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,CHEMISTRY PANEL,Albumin-BCG,,43,,,,,33 - 49,g/L +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,CHEMISTRY PANEL,Creatine Kinase,,154,,,,,26 - 192,U/L +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,CHEMISTRY PANEL,Serum Sodium,,138,,,,,132 - 147,mmol/L +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,CHEMISTRY PANEL,Serum Potassium,,4.5,,,,,3.5 - 5.2,mmol/L +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,CHEMISTRY PANEL,Serum Bicarbonate,,23.0,,,,,19.3 - 29.3,mmol/L +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,CHEMISTRY PANEL,Serum Chloride,,103,,,,,94 - 112,mmol/L +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,CREATININE CLEARANCE CC&G,CreatininClearancCockcrftGault,,2.63,,H,,,1.25 - 1.92,mL/sec +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,CREATININE CLEARANCE CC&G,Creatinine(Rate Blanked)-2dp,,53,,,,,31 - 101,umol/L +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,CREATININE CLEARANCE CC&G,"Weight (kg,1dec place)",Y,87.2,,,,,kg, +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,DRUG SCREEN URINE,Amphetamines/MDMA,,Neg,,,,,Neg;$Cutoff = 1000 ng/mL, +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,DRUG SCREEN URINE,Barbiturates,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,DRUG SCREEN URINE,Cannabinoids,,Neg,,,,,Neg;$Cutoff = 50 ng/mL, +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,DRUG SCREEN URINE,Cocaine,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,DRUG SCREEN URINE,Opiates,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,DRUG SCREEN URINE,Methadone,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,DRUG SCREEN URINE BENZO NON-US,Benzodiazepines Gen 2,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,FEMALE OF CHILDBEARING POT?,Female/of Childbearing pot.?,Y,Yes,,,,,, +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,GFR,EGFR by MDRD,,107,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,142,,,,,116 - 164,g/L +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.42,,,,,0.34 - 0.48, +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.5,,,,,4.1 - 5.6,TI/L +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,92,,,,,79 - 98,fL +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,11.22,R,H,,,3.8 - 10.7,GI/L +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,6.93,,,,,1.96 - 7.23,GI/L +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,3.51,,,,,0.91 - 4.28,GI/L +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.50,,,,,0.12 - 0.92,GI/L +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.22,,,,,0 - 0.57,GI/L +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.05,,,,,0 - 0.2,GI/L +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,61.8,,,,,40.5 - 75,% +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,31.3,,,,,15.4 - 48.5,% +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,4.4,,,,,2.6 - 10.1,% +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.0,,,,,0 - 6.8,% +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.5,,,,,0 - 2,% +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,509,R,H,,,140 - 400,GI/L +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,6.4,,,,,<6.5 %, +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,39.05,,H,,,1.9 - 23,uIU/mL +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,IS SUBJECT OF BLACK RACE?,Subject of black race?,Y,No,,,,,, +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,LIPID PANEL,Direct HDL-C 4th Generation,,1.21,,,,,1.03 - 1.53,mmol/L +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,LIPID PANEL,Triglycerides (GPO),,3.23,,H,,,0.51 - 2.42,mmol/L +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,LIPID PANEL,Cholesterol (High Performance),,5.80,,,,,4.01 - 6.85,mmol/L +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,LIPID PANEL,LDL Chol Friedewald 4th,,3.11,,,,,0 - 3.34,mmol/L +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,POSTMENOPAUSAL FEMALE?,<40yrs & amenorrhea >/= 12mo,,No,,,,,, +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,RETICULOCYTES,Reticulocyte Count %,,1.9,,,,,0.6 - 2.5,% +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,SERUM BETA HCG,"B-hCG, Qualitative",,Negative,,,,,Ref Rng: Negative, +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,SERUM BETA HCG,"B-hCG, Quantitative",,<0.6,,,,,Units: mIU/mL$Pre-menopausal$<5.0: Negative$5.0-24.9:Borderline$>/= 25.0: Positive, +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,TSH,TSH 3rd IS-QT,,2.280,,,,,0.45 - 5.33,mIU/L +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,URINE MACRO PANEL,Ur Specific Gravity,,1.023,,,,,1 - 1.04, +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,URINE MACRO PANEL,Ur Protein,,Trace,,H,,,Ref Rng:Negative, +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,URINE MACRO PANEL,Ur Leukocyte Esterase,,+3,,H SF,,,Ref Rng:Negative, +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,URINE MICRO PANEL,Ur Microscopic,,Positive,,,,, NEGATIVE$,NEGATIVE +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,C-REACTIVE PROTEIN,C Reactive Protein HS,,7.3,,H,,,0 - 5,mg/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,CELLULAR ELEMENTS,Ur WBC/HPF,,32,,H,,,0 - 12,/HPF +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,CHEMISTRY PANEL,Total Bilirubin,,13,,,,,3 - 21,umol/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,4.9,,,,,0 - 6.2,umol/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,CHEMISTRY PANEL,Alkaline Phosphatase,,94,,,,,35 - 104,U/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,CHEMISTRY PANEL,ALT (SGPT),,55,,H,,,4 - 43,U/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,CHEMISTRY PANEL,AST (SGOT),,30,,,,,8 - 40,U/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,CHEMISTRY PANEL,GGT,,27,,,,,4 - 49,U/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,CHEMISTRY PANEL,LDH,,175,,,,,53 - 234,U/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,CHEMISTRY PANEL,Urea Nitrogen,,4.6,,,,,1.4 - 8.6,mmol/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,75,,,,,31 - 101,umol/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,CHEMISTRY PANEL,Glucose Fasting,,7.2,,H,,,3.9 - 5.6,mmol/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,CHEMISTRY PANEL,Serum Uric Acid,,263,,,,,149 - 446,umol/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,CHEMISTRY PANEL,Calcium (EDTA),,2.41,,,,,2.07 - 2.64,mmol/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,CHEMISTRY PANEL,Phosphorus,,0.95,,,,,0.71 - 1.65,mmol/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,CHEMISTRY PANEL,Total Protein,,69,,,,,61 - 84,g/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,CHEMISTRY PANEL,Albumin-BCG,,47,,,,,33 - 49,g/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,CHEMISTRY PANEL,Creatine Kinase,,38,,,,,26 - 192,U/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,CHEMISTRY PANEL,Serum Sodium,,139,,,,,132 - 147,mmol/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,CHEMISTRY PANEL,Serum Potassium,,4.7,,,,,3.5 - 5.2,mmol/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,CHEMISTRY PANEL,Serum Bicarbonate,,25.0,,,,,19.3 - 29.3,mmol/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,CHEMISTRY PANEL,Serum Chloride,,101,,,,,94 - 112,mmol/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,159,,,,,116 - 164,g/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.47,,,,,0.34 - 0.48, +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.2,,,,,4.1 - 5.6,TI/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,90,,,,,79 - 98,fL +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,7.29,,,,,3.8 - 10.7,GI/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,4.53,,,,,1.96 - 7.23,GI/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.07,,,,,0.91 - 4.28,GI/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.45,,,,,0.12 - 0.92,GI/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.15,,,,,0 - 0.57,GI/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.08,,,,,0 - 0.2,GI/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,62.2,,,,,40.5 - 75,% +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,28.5,,,,,15.4 - 48.5,% +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,6.2,,,,,2.6 - 10.1,% +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.1,,,,,0 - 6.8,% +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.1,,,,,0 - 2,% +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,296,,,,,140 - 400,GI/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,6.4,,,,,<6.5 %, +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,33.25,,H,,,1.9 - 23,uIU/mL +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,LIPID PANEL,Direct HDL-C 4th Generation,,1.02,,L,,,1.03 - 1.53,mmol/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,LIPID PANEL,Triglycerides (GPO),,1.15,,,,,0.59 - 2.96,mmol/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,LIPID PANEL,Cholesterol (High Performance),,2.80,,L,,,4.42 - 7.53,mmol/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,LIPID PANEL,LDL Chol Friedewald 4th,,1.25,,,,,0 - 3.34,mmol/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,MICROORGANISMS,Ur Bacteria,,Present,,,,,Ref Rng:Not present, +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,RETICULOCYTES,Reticulocyte Count %,,1.6,,,,,0.6 - 2.5,% +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,TSH,TSH 3rd IS-QT,,0.595,,,,,0.45 - 5.33,mIU/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,URINE MACRO PANEL,Ur Specific Gravity,,1.015,,,,,1 - 1.04, +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,URINE MACRO PANEL,Ur pH,,6.0,,,,,5 - 8, +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,URINE MACRO PANEL,Ur Leukocyte Esterase,,+3,,H SF,,,Ref Rng:Negative, +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,URINE MICRO PANEL,Ur Microscopic,,Positive,,,,, NEGATIVE$,NEGATIVE +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,C-REACTIVE PROTEIN,C Reactive Protein HS,,2.8,,,,,0 - 5,mg/L +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,CELLULAR ELEMENTS,Ur RBC/HPF,,1,,,,,0 - 8,/HPF +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,CELLULAR ELEMENTS,Ur WBC/HPF,,2,,,,,0 - 12,/HPF +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,CHEMISTRY PANEL,Total Bilirubin,,6,,,,,3 - 21,umol/L +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,1.5,,,,,0 - 6.2,umol/L +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,CHEMISTRY PANEL,Alkaline Phosphatase,,87,,,,,35 - 104,U/L +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,CHEMISTRY PANEL,ALT (SGPT),,14,,,,,4 - 43,U/L +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,CHEMISTRY PANEL,AST (SGOT),,16,,,,,8 - 40,U/L +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,CHEMISTRY PANEL,GGT,,15,,,,,5 - 50,U/L +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,CHEMISTRY PANEL,LDH,,150,,,,,53 - 234,U/L +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,CHEMISTRY PANEL,Urea Nitrogen,,5.0,,,,,1.4 - 10.4,mmol/L +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,63,,,,,31 - 110,umol/L +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,CHEMISTRY PANEL,Glucose Fasting,,7.0,,H,,,3.9 - 5.6,mmol/L +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,CHEMISTRY PANEL,Serum Uric Acid,,320,,,,,149 - 446,umol/L +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,CHEMISTRY PANEL,Calcium (EDTA),,2.39,,,,,2.07 - 2.64,mmol/L +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,CHEMISTRY PANEL,Phosphorus,,1.31,,,,,0.71 - 1.65,mmol/L +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,CHEMISTRY PANEL,Total Protein,,78,,,,,60 - 80,g/L +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,CHEMISTRY PANEL,Albumin-BCG,,45,,,,,33 - 46,g/L +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,CHEMISTRY PANEL,Creatine Kinase,,87,,,,,26 - 192,U/L +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,CHEMISTRY PANEL,Serum Sodium,,139,,,,,135 - 145,mmol/L +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,CHEMISTRY PANEL,Serum Potassium,,4.4,,,,,3.5 - 5.2,mmol/L +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,CHEMISTRY PANEL,Serum Bicarbonate,,23.1,,,,,19.3 - 29.3,mmol/L +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,CHEMISTRY PANEL,Serum Chloride,,102,,,,,94 - 112,mmol/L +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,CREATININE CLEARANCE CC&G,CreatininClearancCockcrftGault,,1.29,,,,,1.25 - 1.92,mL/sec +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,CREATININE CLEARANCE CC&G,Creatinine(Rate Blanked)-2dp,,63,,,,,31 - 110,umol/L +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,CREATININE CLEARANCE CC&G,"Weight (kg,1dec place)",Y,68.5,,,,,kg, +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,CRYSTALS,Ur Calcium Oxalate Crystals,,Present,,,,,Ref Rng:Not present, +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,DRUG SCREEN URINE,Amphetamines/MDMA,,Neg,,,,,Neg;$Cutoff = 1000 ng/mL, +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,DRUG SCREEN URINE,Barbiturates,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,DRUG SCREEN URINE,Cannabinoids,,Neg,,,,,Neg;$Cutoff = 50 ng/mL, +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,DRUG SCREEN URINE,Cocaine,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,DRUG SCREEN URINE,Opiates,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,DRUG SCREEN URINE,Methadone,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,DRUG SCREEN URINE BENZO NON-US,Benzodiazepines Gen 2,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,FEMALE OF CHILDBEARING POT?,Female/of Childbearing pot.?,Y,No,,,,,, +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,FSH,Follicle Stimulating Hormone,,78.10,,,,,Follicular:$3.90-8.80 IU/L$Midcycle:$4.50-22.50 IU/L$Luteal:$1.80-5.10 IU/L$Postmenopausal:$16.70-113.60 IU/L, +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,GFR,EGFR by MDRD,,81,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,165,,H,,,115 - 158,g/L +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.48,,,,,0.34 - 0.48, +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.3,,,,,3.9 - 5.5,TI/L +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,90,,,,,80 - 100,fL +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,10.07,,,,,3.8 - 10.7,GI/L +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,6.15,,,,,1.96 - 7.23,GI/L +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,3.08,,H,,,0.8 - 3,GI/L +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.65,,,,,0.12 - 0.92,GI/L +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.14,,,,,0 - 0.57,GI/L +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.05,,,,,0 - 0.2,GI/L +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,61.0,,,,,40.5 - 75,% +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,30.6,,,,,15.4 - 48.5,% +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,6.5,,,,,2.6 - 10.1,% +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.4,,,,,0 - 6.8,% +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.5,,,,,0 - 2,% +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,269,,,,,130 - 394,GI/L +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.9,,,,,<6.5 %, +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,47.53,,H,,,1.9 - 23,uIU/mL +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,IS SUBJECT OF BLACK RACE?,Subject of black race?,Y,No,,,,,, +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,LIPID PANEL,Direct HDL-C 4th Generation,,1.28,,,,,1.03 - 1.53,mmol/L +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,LIPID PANEL,Triglycerides (GPO),,1.84,,,,,0.63 - 2.71,mmol/L +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,LIPID PANEL,Cholesterol (High Performance),,6.82,,,,,5.35 - 9.1,mmol/L +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,LIPID PANEL,LDL Chol Friedewald 4th,,4.70,,H,,,0 - 3.34,mmol/L +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,MICROORGANISMS,Ur Bacteria,,Present,,,,,Ref Rng:Not present, +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,POSTMENOPAUSAL FEMALE?,<40yrs & amenorrhea >/= 12mo,,Yes,,,,,, +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,RETICULOCYTES,Reticulocyte Count %,,1.4,,,,,0.6 - 2.5,% +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,TSH,TSH 3rd IS-QT,,1.806,,,,,0.45 - 5.33,mIU/L +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,URINE MACRO PANEL,Ur Specific Gravity,,1.025,,,,,1.01 - 1.03, +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,URINE MACRO PANEL,Ur Protein,,Trace,,H,,,Ref Rng:Negative, +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,URINE MACRO PANEL,Ur Blood,,Trace,,,,,Ref Rng:$Negative-Trace, +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,URINE MICRO PANEL,Ur Microscopic,,Positive,,,,, NEGATIVE$,NEGATIVE +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,C-REACTIVE PROTEIN,C Reactive Protein HS,,2.0,,,,,0 - 5,mg/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,CELLULAR ELEMENTS,Ur WBC/HPF,,27,,H,,,0 - 12,/HPF +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,CHEMISTRY PANEL,Total Bilirubin,,13,,,,,3 - 21,umol/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,4.7,,,,,0 - 6.2,umol/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,CHEMISTRY PANEL,Alkaline Phosphatase,,84,,,,,35 - 104,U/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,CHEMISTRY PANEL,ALT (SGPT),,53,,H,,,4 - 43,U/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,CHEMISTRY PANEL,AST (SGOT),,26,,,,,8 - 40,U/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,CHEMISTRY PANEL,GGT,,26,,,,,4 - 49,U/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,CHEMISTRY PANEL,LDH,,172,,,,,53 - 234,U/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,CHEMISTRY PANEL,Urea Nitrogen,,5.2,,,,,1.4 - 8.6,mmol/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,75,,,,,31 - 101,umol/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,CHEMISTRY PANEL,Glucose Fasting,,6.8,,H,,,3.9 - 5.6,mmol/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,CHEMISTRY PANEL,Serum Uric Acid,,279,,,,,149 - 446,umol/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,CHEMISTRY PANEL,Calcium (EDTA),,2.39,,,,,2.07 - 2.64,mmol/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,CHEMISTRY PANEL,Phosphorus,,1.21,,,,,0.71 - 1.65,mmol/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,CHEMISTRY PANEL,Total Protein,,66,,,,,61 - 84,g/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,CHEMISTRY PANEL,Albumin-BCG,,45,,,,,33 - 49,g/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,CHEMISTRY PANEL,Creatine Kinase,,45,,,,,26 - 192,U/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,CHEMISTRY PANEL,Serum Sodium,,140,,,,,132 - 147,mmol/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,CHEMISTRY PANEL,Serum Potassium,,4.7,,,,,3.5 - 5.2,mmol/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,CHEMISTRY PANEL,Serum Bicarbonate,,25.1,,,,,19.3 - 29.3,mmol/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,CHEMISTRY PANEL,Serum Chloride,,102,,,,,94 - 112,mmol/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,CRYSTALS,Ur Calcium Oxalate Crystals,,Present,,,,,Ref Rng:Not present, +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,153,,,,,116 - 164,g/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.46,,,,,0.34 - 0.48, +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.0,,,,,4.1 - 5.6,TI/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,92,,,,,79 - 98,fL +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,8.45,,,,,3.8 - 10.7,GI/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,4.94,,,,,1.96 - 7.23,GI/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.68,,,,,0.91 - 4.28,GI/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.51,,,,,0.12 - 0.92,GI/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.24,,,,,0 - 0.57,GI/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.09,,,,,0 - 0.2,GI/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,58.4,,,,,40.5 - 75,% +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,31.7,,,,,15.4 - 48.5,% +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,6.0,,,,,2.6 - 10.1,% +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.9,,,,,0 - 6.8,% +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.0,,,,,0 - 2,% +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,302,,,,,140 - 400,GI/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,13.07,,,,,1.9 - 23,uIU/mL +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,LIPID PANEL,Direct HDL-C 4th Generation,,0.98,,L,,,1.03 - 1.53,mmol/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,LIPID PANEL,Triglycerides (GPO),,0.95,,,,,0.59 - 2.96,mmol/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,LIPID PANEL,Cholesterol (High Performance),,2.57,,L,,Result verified by repeat analysis,4.42 - 7.53,mmol/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,LIPID PANEL,LDL Chol Friedewald 4th,,1.15,,,,,0 - 3.34,mmol/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,RETICULOCYTES,Reticulocyte Count %,,2.1,,,,,0.6 - 2.5,% +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,URINE MACRO PANEL,Ur Specific Gravity,,1.023,,,,,1 - 1.04, +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,URINE MACRO PANEL,Ur Leukocyte Esterase,,+3,,H SF,,,Ref Rng:Negative, +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,URINE MICRO PANEL,Ur Microscopic,,Positive,,,,, NEGATIVE$,NEGATIVE +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,C-REACTIVE PROTEIN,C Reactive Protein HS,,0.9,,,,,0 - 5,mg/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,CELLULAR ELEMENTS,Ur WBC/HPF,,5,,,,,0 - 12,/HPF +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,CELLULAR ELEMENTS,Ur Transitional Epi Cells,,1,,,,,0 /HPF, +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,CHEMISTRY PANEL,Total Bilirubin,,8,,,,,3 - 21,umol/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.9,,,,,0 - 6.2,umol/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,CHEMISTRY PANEL,Alkaline Phosphatase,,71,,,,,35 - 104,U/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,CHEMISTRY PANEL,ALT (SGPT),,17,,,,,4 - 43,U/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,CHEMISTRY PANEL,AST (SGOT),,20,,,,,8 - 40,U/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,CHEMISTRY PANEL,GGT,,18,,,,,4 - 49,U/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,CHEMISTRY PANEL,LDH,,203,,,,,53 - 234,U/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,CHEMISTRY PANEL,Urea Nitrogen,,3.2,,,,,1.4 - 8.6,mmol/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,70,,,,,31 - 101,umol/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,CHEMISTRY PANEL,Glucose Fasting,,5.1,,,,,3.9 - 5.6,mmol/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,CHEMISTRY PANEL,Serum Uric Acid,,221,,,,,149 - 446,umol/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,CHEMISTRY PANEL,Calcium (EDTA),,2.34,,,,,2.07 - 2.64,mmol/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,CHEMISTRY PANEL,Phosphorus,,1.12,,,,,0.71 - 1.65,mmol/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,CHEMISTRY PANEL,Total Protein,,64,,,,,61 - 84,g/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,CHEMISTRY PANEL,Albumin-BCG,,44,,,,,33 - 49,g/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,CHEMISTRY PANEL,Creatine Kinase,,96,,,,,26 - 192,U/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,CHEMISTRY PANEL,Serum Sodium,,142,,,,,132 - 147,mmol/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,CHEMISTRY PANEL,Serum Potassium,,4.4,,,,,3.5 - 5.2,mmol/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,CHEMISTRY PANEL,Serum Bicarbonate,,27.1,,,,,19.3 - 29.3,mmol/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,CHEMISTRY PANEL,Serum Chloride,,104,,,,,94 - 112,mmol/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,134,,,,,116 - 164,g/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.40,,,,,0.34 - 0.48, +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.3,,,,,4.1 - 5.6,TI/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,93,,,,,79 - 98,fL +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,4.16,,,,,3.8 - 10.7,GI/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.30,,,,,1.96 - 7.23,GI/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.50,,,,,0.91 - 4.28,GI/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.23,,,,,0.12 - 0.92,GI/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.13,,,,,0 - 0.57,GI/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.01,,,,,0 - 0.2,GI/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,55.2,,,,,40.5 - 75,% +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,36.0,,,,,15.4 - 48.5,% +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.5,,,,,2.6 - 10.1,% +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,3.0,,,,,0 - 6.8,% +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.3,,,,,0 - 2,% +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,272,,,,,140 - 400,GI/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.3,,,,,<6.5 %, +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,2.94,,,,,1.9 - 23,uIU/mL +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,LIPID PANEL,Direct HDL-C 4th Generation,,1.49,,,,,1.03 - 1.53,mmol/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,LIPID PANEL,Triglycerides (GPO),,0.80,,,,,0.59 - 2.96,mmol/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,LIPID PANEL,Cholesterol (High Performance),,4.76,,,,,4.42 - 7.53,mmol/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,LIPID PANEL,LDL Chol Friedewald 4th,,2.90,,,,,0 - 3.34,mmol/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,RETICULOCYTES,Reticulocyte Count %,,1.3,,,,,0.6 - 2.5,% +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,TSH,TSH 3rd IS-QT,,1.175,,,,,0.45 - 5.33,mIU/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,URINE MACRO PANEL,Ur Specific Gravity,,1.016,,,,,1 - 1.04, +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,URINE MACRO PANEL,Ur pH,,7.0,,,,,5 - 8, +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,URINE MACRO PANEL,Ur Leukocyte Esterase,,+1,,H,,,Ref Rng:Negative, +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,URINE MICRO PANEL,Ur Microscopic,,Positive,,,,, NEGATIVE$,NEGATIVE +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,C-REACTIVE PROTEIN,C Reactive Protein HS,,2.8,,,,,0 - 5,mg/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,CHEMISTRY PANEL,Total Bilirubin,,4,,,,Result verified by repeat analysis,3 - 21,umol/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,1.5,,,,,0 - 6.2,umol/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,CHEMISTRY PANEL,Alkaline Phosphatase,,78,,,,,35 - 104,U/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,CHEMISTRY PANEL,ALT (SGPT),,40,,,,,4 - 43,U/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,CHEMISTRY PANEL,AST (SGOT),,33,,,,,8 - 40,U/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,CHEMISTRY PANEL,GGT,,49,,,,,4 - 49,U/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,CHEMISTRY PANEL,LDH,,151,,,,,53 - 234,U/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,CHEMISTRY PANEL,Urea Nitrogen,,3.6,,,,,1.4 - 8.6,mmol/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,68,,,,,31 - 101,umol/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,CHEMISTRY PANEL,Glucose Fasting,,5.0,,,,,3.9 - 5.6,mmol/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,CHEMISTRY PANEL,Serum Uric Acid,,300,,,,,125 - 428,umol/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,CHEMISTRY PANEL,Calcium (EDTA),,2.31,,,,,2.07 - 2.64,mmol/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,CHEMISTRY PANEL,Phosphorus,,1.35,,,,,0.71 - 1.65,mmol/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,CHEMISTRY PANEL,Total Protein,,67,,,,,61 - 84,g/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,CHEMISTRY PANEL,Albumin-BCG,,43,,,,,33 - 49,g/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,CHEMISTRY PANEL,Creatine Kinase,,102,,,,,26 - 192,U/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,CHEMISTRY PANEL,Serum Sodium,,139,,,,,132 - 147,mmol/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,CHEMISTRY PANEL,Serum Potassium,,4.5,,,,,3.5 - 5.2,mmol/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,CHEMISTRY PANEL,Serum Bicarbonate,,25.0,,,,,19.3 - 29.3,mmol/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,CHEMISTRY PANEL,Serum Chloride,,103,,,,,94 - 112,mmol/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,126,,,,,116 - 164,g/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.37,,,,,0.34 - 0.48, +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,3.9,,L,,,4.1 - 5.6,TI/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,96,,,,,79 - 98,fL +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,6.94,,,,,3.8 - 10.7,GI/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.95,,,,,1.96 - 7.23,GI/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,3.05,,,,,0.91 - 4.28,GI/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.61,,,,,0.12 - 0.92,GI/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.29,,,,,0 - 0.57,GI/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.04,,,,,0 - 0.2,GI/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,42.5,,,,,40.5 - 75,% +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,43.9,,,,,15.4 - 48.5,% +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,8.7,,,,,2.6 - 10.1,% +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,4.2,,,,,0 - 6.8,% +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.6,,,,,0 - 2,% +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,341,,,,,140 - 400,GI/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.3,,,,,<6.5 %, +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,4.23,,,,,1.9 - 23,uIU/mL +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,LIPID PANEL,Direct HDL-C 4th Generation,,1.37,,,,,1.03 - 1.53,mmol/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,LIPID PANEL,Triglycerides (GPO),,1.49,,,,,0.51 - 2.42,mmol/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,LIPID PANEL,Cholesterol (High Performance),,4.70,,,,,4.01 - 6.85,mmol/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,LIPID PANEL,LDL Chol Friedewald 4th,,2.65,,,,,0 - 3.34,mmol/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,RETICULOCYTES,Reticulocyte Count %,,2.7,,H,,,0.6 - 2.5,% +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,TSH,TSH 3rd IS-QT,,3.282,,,,,0.45 - 5.33,mIU/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,URINE MACRO PANEL,Ur Specific Gravity,,1.009,,,,,1 - 1.04, +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.5,,,,,0 - 5,mg/L +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,CHEMISTRY PANEL,Total Bilirubin,,7,,,,,3 - 21,umol/L +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.2,,,,,0 - 6.2,umol/L +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,CHEMISTRY PANEL,Alkaline Phosphatase,,99,,,,,35 - 104,U/L +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,CHEMISTRY PANEL,ALT (SGPT),,30,,,,,4 - 43,U/L +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,CHEMISTRY PANEL,AST (SGOT),,30,,,,,8 - 40,U/L +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,CHEMISTRY PANEL,GGT,,18,,,,,4 - 49,U/L +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,CHEMISTRY PANEL,LDH,,205,,,,,53 - 234,U/L +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,CHEMISTRY PANEL,Urea Nitrogen,,4.2,,,,,1.4 - 8.6,mmol/L +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,76,,,,,31 - 101,umol/L +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,CHEMISTRY PANEL,Glucose Fasting,,5.1,,,,,3.9 - 5.6,mmol/L +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,CHEMISTRY PANEL,Serum Uric Acid,,323,,,,,149 - 446,umol/L +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,CHEMISTRY PANEL,Calcium (EDTA),,2.27,,,,,2.07 - 2.64,mmol/L +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,CHEMISTRY PANEL,Phosphorus,,1.05,,,,,0.71 - 1.65,mmol/L +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,CHEMISTRY PANEL,Total Protein,,73,,,,,61 - 84,g/L +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,CHEMISTRY PANEL,Albumin-BCG,,47,,,,,33 - 49,g/L +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,CHEMISTRY PANEL,Creatine Kinase,,161,,,,,26 - 192,U/L +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,CHEMISTRY PANEL,Serum Sodium,,139,,,,,132 - 147,mmol/L +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,CHEMISTRY PANEL,Serum Potassium,,3.7,,,,,3.5 - 5.2,mmol/L +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,CHEMISTRY PANEL,Serum Bicarbonate,,24.3,,,,,19.3 - 29.3,mmol/L +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,CHEMISTRY PANEL,Serum Chloride,,100,,,,,94 - 112,mmol/L +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,144,,,,,116 - 164,g/L +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.41,,,,,0.34 - 0.48, +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.8,,,,,4.1 - 5.6,TI/L +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,Normocytic,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,86,,,,,79 - 98,fL +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,4.41,,,,,3.8 - 10.7,GI/L +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.46,,,,,1.96 - 7.23,GI/L +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.53,,,,,0.91 - 4.28,GI/L +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.25,,,,,0.12 - 0.92,GI/L +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.15,,,,,0 - 0.57,GI/L +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.03,,,,,0 - 0.2,GI/L +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,55.7,,,,,40.5 - 75,% +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,34.8,,,,,15.4 - 48.5,% +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.6,,,,,2.6 - 10.1,% +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,3.3,,,,,0 - 6.8,% +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.6,,,,,0 - 2,% +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,,,,Test cancelled: Platelet clumps present,,, +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.7,,,,,<6.5 %, +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,8.57,,,,,1.9 - 23,uIU/mL +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,LIPID PANEL,Direct HDL-C 4th Generation,,1.14,,,,,1.03 - 1.53,mmol/L +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,LIPID PANEL,Triglycerides (GPO),,1.23,,,,,0.59 - 2.96,mmol/L +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,LIPID PANEL,Cholesterol (High Performance),,6.67,,,,,4.42 - 7.53,mmol/L +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,LIPID PANEL,LDL Chol Friedewald 4th,,4.97,,H,,,0 - 3.34,mmol/L +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,RETICULOCYTES,Reticulocyte Count %,,1.5,,,,,0.6 - 2.5,% +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,TSH,TSH 3rd IS-QT,,2.238,,,,,0.45 - 5.33,mIU/L +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,URINE MACRO PANEL,Ur Specific Gravity,,1.019,,,,,1 - 1.04, +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,URINE MACRO PANEL,Ur pH,,6.0,,,,,5 - 8, +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,C-REACTIVE PROTEIN,C Reactive Protein HS,,3.3,,,,,0 - 5,mg/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,CELLULAR ELEMENTS,Ur WBC/HPF,,9,,,,,0 - 12,/HPF +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,CHEMISTRY PANEL,Total Bilirubin,,14,,,,,3 - 21,umol/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,4.8,,,,,0 - 6.2,umol/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,CHEMISTRY PANEL,Alkaline Phosphatase,,94,,,,,35 - 104,U/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,CHEMISTRY PANEL,ALT (SGPT),,50,,H,,,4 - 43,U/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,CHEMISTRY PANEL,AST (SGOT),,27,,,,,8 - 40,U/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,CHEMISTRY PANEL,GGT,,24,,,,,4 - 49,U/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,CHEMISTRY PANEL,LDH,,167,,,,,53 - 234,U/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,CHEMISTRY PANEL,Urea Nitrogen,,4.6,,,,,1.4 - 8.6,mmol/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,72,,,,,31 - 101,umol/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,CHEMISTRY PANEL,Glucose Fasting,,6.3,,H,,,3.9 - 5.6,mmol/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,CHEMISTRY PANEL,Serum Uric Acid,,274,,,,,149 - 446,umol/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,CHEMISTRY PANEL,Calcium (EDTA),,2.43,,,,,2.07 - 2.64,mmol/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,CHEMISTRY PANEL,Phosphorus,,1.21,,,,,0.71 - 1.65,mmol/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,CHEMISTRY PANEL,Total Protein,,67,,,,,61 - 84,g/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,CHEMISTRY PANEL,Albumin-BCG,,45,,,,,33 - 49,g/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,CHEMISTRY PANEL,Creatine Kinase,,45,,,,,26 - 192,U/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,CHEMISTRY PANEL,Serum Sodium,,141,,,,,132 - 147,mmol/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,CHEMISTRY PANEL,Serum Potassium,,5.0,,,,,3.5 - 5.2,mmol/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,CHEMISTRY PANEL,Serum Bicarbonate,,25.7,,,,,19.3 - 29.3,mmol/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,CHEMISTRY PANEL,Serum Chloride,,101,,,,,94 - 112,mmol/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,154,,,,,116 - 164,g/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.46,,,,,0.34 - 0.48, +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.1,,,,,4.1 - 5.6,TI/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,90,,,,,79 - 98,fL +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,8.24,,,,,3.8 - 10.7,GI/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,5.24,,,,,1.96 - 7.23,GI/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.33,,,,,0.91 - 4.28,GI/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.45,,,,,0.12 - 0.92,GI/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.15,,,,,0 - 0.57,GI/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.06,,,,,0 - 0.2,GI/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,63.6,,,,,40.5 - 75,% +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,28.3,,,,,15.4 - 48.5,% +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.4,,,,,2.6 - 10.1,% +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.9,,,,,0 - 6.8,% +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.8,,,,,0 - 2,% +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,330,,,,,140 - 400,GI/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,6.1,,,,,<6.5 %, +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,14.65,,,,,1.9 - 23,uIU/mL +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,LIPID PANEL,Direct HDL-C 4th Generation,,1.03,,,,,1.03 - 1.53,mmol/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,LIPID PANEL,Triglycerides (GPO),,1.18,,,,,0.59 - 2.96,mmol/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,LIPID PANEL,Cholesterol (High Performance),,2.69,,L,,,4.42 - 7.53,mmol/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,LIPID PANEL,LDL Chol Friedewald 4th,,1.12,,,,,0 - 3.34,mmol/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,RETICULOCYTES,Reticulocyte Count %,,2.1,,,,,0.6 - 2.5,% +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,TSH,TSH 3rd IS-QT,,1.264,,,,,0.45 - 5.33,mIU/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,URINE MACRO PANEL,Ur Specific Gravity,,1.021,,,,,1 - 1.04, +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,URINE MACRO PANEL,Ur pH,,6.0,,,,,5 - 8, +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,URINE MACRO PANEL,Ur Leukocyte Esterase,,+3,,H SF,,,Ref Rng:Negative, +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,URINE MICRO PANEL,Ur Microscopic,,Positive,,,,, NEGATIVE$,NEGATIVE +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.8,,,,,0 - 5,mg/L +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,CELLULAR ELEMENTS,Ur WBC/HPF,,2,,,,,0 - 12,/HPF +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,CHEMISTRY PANEL,Total Bilirubin,,10,,,,,3 - 21,umol/L +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.0,,,,,0 - 6.2,umol/L +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,CHEMISTRY PANEL,Alkaline Phosphatase,,85,,,,,35 - 104,U/L +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,CHEMISTRY PANEL,ALT (SGPT),,20,,,,,4 - 43,U/L +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,CHEMISTRY PANEL,AST (SGOT),,18,,,,,8 - 40,U/L +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,CHEMISTRY PANEL,GGT,,22,,,,,4 - 49,U/L +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,CHEMISTRY PANEL,LDH,,199,,,,,53 - 234,U/L +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,CHEMISTRY PANEL,Urea Nitrogen,,3.6,,,,,1.4 - 8.6,mmol/L +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,69,,,,,31 - 101,umol/L +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,CHEMISTRY PANEL,Glucose Fasting,,5.0,,,,,3.9 - 5.6,mmol/L +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,CHEMISTRY PANEL,Serum Uric Acid,,242,,,,,149 - 446,umol/L +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,CHEMISTRY PANEL,Calcium (EDTA),,2.44,,,,,2.07 - 2.64,mmol/L +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,CHEMISTRY PANEL,Phosphorus,,1.18,,,,,0.71 - 1.65,mmol/L +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,CHEMISTRY PANEL,Total Protein,,70,,,,,61 - 84,g/L +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,CHEMISTRY PANEL,Albumin-BCG,,44,,,,,33 - 49,g/L +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,CHEMISTRY PANEL,Creatine Kinase,,113,,,,,26 - 192,U/L +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,CHEMISTRY PANEL,Serum Sodium,,141,,,,,132 - 147,mmol/L +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,CHEMISTRY PANEL,Serum Potassium,,4.5,,,,,3.5 - 5.2,mmol/L +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,CHEMISTRY PANEL,Serum Bicarbonate,,29.7,,H,,,19.3 - 29.3,mmol/L +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,CHEMISTRY PANEL,Serum Chloride,,101,,,,,94 - 112,mmol/L +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,136,,,,,116 - 164,g/L +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.41,,,,,0.34 - 0.48, +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.4,,,,,4.1 - 5.6,TI/L +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,93,,,,,79 - 98,fL +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,4.80,,,,,3.8 - 10.7,GI/L +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.73,,,,,1.96 - 7.23,GI/L +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.58,,,,,0.91 - 4.28,GI/L +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.36,,,,,0.12 - 0.92,GI/L +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.10,,,,,0 - 0.57,GI/L +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.02,,,,,0 - 0.2,GI/L +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,56.9,,,,,40.5 - 75,% +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,32.9,,,,,15.4 - 48.5,% +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,7.6,,,,,2.6 - 10.1,% +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.2,,,,,0 - 6.8,% +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.4,,,,,0 - 2,% +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,308,,,,,140 - 400,GI/L +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,1.74,,L,,,1.9 - 23,uIU/mL +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,LIPID PANEL,Direct HDL-C 4th Generation,,1.50,,,,,1.03 - 1.53,mmol/L +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,LIPID PANEL,Triglycerides (GPO),,0.88,,,,,0.59 - 2.96,mmol/L +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,LIPID PANEL,Cholesterol (High Performance),,5.66,,,,,4.42 - 7.53,mmol/L +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,LIPID PANEL,LDL Chol Friedewald 4th,,3.76,,H,,,0 - 3.34,mmol/L +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,RETICULOCYTES,Reticulocyte Count %,,1.3,,,,,0.6 - 2.5,% +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,URINE MACRO PANEL,Ur Specific Gravity,,1.016,,,,,1 - 1.04, +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,URINE MACRO PANEL,Ur pH,,7.5,,,,,5 - 8, +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,URINE MACRO PANEL,Ur Leukocyte Esterase,,Trace,,H,,,Ref Rng:Negative, +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,URINE MICRO PANEL,Ur Microscopic,,Positive,,,,, NEGATIVE$,NEGATIVE +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,C-REACTIVE PROTEIN,C Reactive Protein HS,,3.0,,,,,0 - 5,mg/L +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,CHEMISTRY PANEL,Total Bilirubin,,7,,,,,3 - 21,umol/L +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.3,,,,,0 - 6.2,umol/L +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,CHEMISTRY PANEL,Alkaline Phosphatase,,72,,,,,35 - 104,U/L +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,CHEMISTRY PANEL,ALT (SGPT),,19,,,,,4 - 43,U/L +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,CHEMISTRY PANEL,AST (SGOT),,18,,,,,8 - 40,U/L +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,CHEMISTRY PANEL,GGT,,45,,,,,4 - 49,U/L +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,CHEMISTRY PANEL,LDH,,135,,,,,53 - 234,U/L +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,CHEMISTRY PANEL,Urea Nitrogen,,4.2,,,,,1.4 - 8.6,mmol/L +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,59,,,,,31 - 101,umol/L +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,CHEMISTRY PANEL,Glucose Fasting,,5.1,,,,,3.9 - 5.6,mmol/L +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,CHEMISTRY PANEL,Serum Uric Acid,,277,,,,,125 - 428,umol/L +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,CHEMISTRY PANEL,Calcium (EDTA),,2.35,,,,,2.07 - 2.64,mmol/L +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,CHEMISTRY PANEL,Phosphorus,,1.06,,,,,0.71 - 1.65,mmol/L +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,CHEMISTRY PANEL,Total Protein,,73,,,,,61 - 84,g/L +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,CHEMISTRY PANEL,Albumin-BCG,,44,,,,,33 - 49,g/L +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,CHEMISTRY PANEL,Creatine Kinase,,94,,,,,26 - 192,U/L +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,CHEMISTRY PANEL,Serum Sodium,,138,,,,,132 - 147,mmol/L +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,CHEMISTRY PANEL,Serum Potassium,,4.8,,,,,3.5 - 5.2,mmol/L +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,CHEMISTRY PANEL,Serum Bicarbonate,,23.2,,,,,19.3 - 29.3,mmol/L +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,CHEMISTRY PANEL,Serum Chloride,,102,,,,,94 - 112,mmol/L +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,125,,,,,116 - 164,g/L +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.38,,,,,0.34 - 0.48, +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.0,R,L,,,4.1 - 5.6,TI/L +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,96,,,,,79 - 98,fL +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,6.92,,,,,3.8 - 10.7,GI/L +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.08,,,,,1.96 - 7.23,GI/L +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.93,,,,,0.91 - 4.28,GI/L +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.56,,,,,0.12 - 0.92,GI/L +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.31,,,,,0 - 0.57,GI/L +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.04,,,,,0 - 0.2,GI/L +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,44.5,,,,,40.5 - 75,% +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,42.3,,,,,15.4 - 48.5,% +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,8.1,,,,,2.6 - 10.1,% +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,4.4,,,,,0 - 6.8,% +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.6,,,,,0 - 2,% +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,304,,,,,140 - 400,GI/L +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,7.03,,,,,1.9 - 23,uIU/mL +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,LIPID PANEL,Direct HDL-C 4th Generation,,1.36,,,,,1.03 - 1.53,mmol/L +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,LIPID PANEL,Triglycerides (GPO),,2.05,,,,,0.51 - 2.42,mmol/L +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,LIPID PANEL,Cholesterol (High Performance),,5.46,,,,,4.01 - 6.85,mmol/L +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,LIPID PANEL,LDL Chol Friedewald 4th,,3.16,,,,,0 - 3.34,mmol/L +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,RETICULOCYTES,Reticulocyte Count %,,1.8,,,,,0.6 - 2.5,% +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,TSH,TSH 3rd IS-QT,,1.135,,,,,0.45 - 5.33,mIU/L +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,URINE MACRO PANEL,Ur Specific Gravity,,1.023,,,,,1 - 1.04, +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.7,,,,,0 - 5,mg/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,CHEMISTRY PANEL,Total Bilirubin,,5,,,,,3 - 21,umol/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,1.8,,,,,0 - 6.2,umol/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,CHEMISTRY PANEL,Alkaline Phosphatase,,100,,,,,35 - 104,U/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,CHEMISTRY PANEL,ALT (SGPT),,29,,,,,4 - 43,U/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,CHEMISTRY PANEL,AST (SGOT),,33,,,,,8 - 40,U/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,CHEMISTRY PANEL,GGT,,17,,,,,4 - 49,U/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,CHEMISTRY PANEL,LDH,,257,,H,,,53 - 234,U/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,CHEMISTRY PANEL,Urea Nitrogen,,5.1,,,,,1.4 - 8.6,mmol/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,72,,,,,31 - 101,umol/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,CHEMISTRY PANEL,Glucose Fasting,,5.1,,,,,3.9 - 5.6,mmol/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,CHEMISTRY PANEL,Serum Uric Acid,,318,,,,,149 - 446,umol/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,CHEMISTRY PANEL,Calcium (EDTA),,2.35,,,,,2.07 - 2.64,mmol/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,CHEMISTRY PANEL,Phosphorus,,1.06,,,,,0.71 - 1.65,mmol/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,CHEMISTRY PANEL,Total Protein,,72,,,,,61 - 84,g/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,CHEMISTRY PANEL,Albumin-BCG,,47,,,,,33 - 49,g/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,CHEMISTRY PANEL,Creatine Kinase,,276,,H,,,26 - 192,U/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,CHEMISTRY PANEL,Serum Sodium,,140,,,,,132 - 147,mmol/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,CHEMISTRY PANEL,Serum Potassium,,4.4,,,,,3.5 - 5.2,mmol/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,CHEMISTRY PANEL,Serum Bicarbonate,,24.3,,,,,19.3 - 29.3,mmol/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,CHEMISTRY PANEL,Serum Chloride,,102,,,,,94 - 112,mmol/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,137,,,,,116 - 164,g/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.40,,,,,0.34 - 0.48, +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.6,,,,,4.1 - 5.6,TI/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,87,,,,,79 - 98,fL +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,4.48,,,,,3.8 - 10.7,GI/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.40,,,,,1.96 - 7.23,GI/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.48,,,,,0.91 - 4.28,GI/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.49,,,,,0.12 - 0.92,GI/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.10,,,,,0 - 0.57,GI/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.01,,,,,0 - 0.2,GI/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,53.5,,,,,40.5 - 75,% +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,33.1,,,,,15.4 - 48.5,% +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,10.9,R,H,,,2.6 - 10.1,% +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.3,,,,,0 - 6.8,% +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.2,,,,,0 - 2,% +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,143,,,,,140 - 400,GI/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,5.90,,,,,1.9 - 23,uIU/mL +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,LIPID PANEL,Direct HDL-C 4th Generation,,1.12,,,,,1.03 - 1.53,mmol/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,LIPID PANEL,Triglycerides (GPO),,1.26,,,,,0.59 - 2.96,mmol/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,LIPID PANEL,Cholesterol (High Performance),,5.71,,,,,4.42 - 7.53,mmol/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,LIPID PANEL,LDL Chol Friedewald 4th,,4.01,,H,,,0 - 3.34,mmol/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,RETICULOCYTES,Reticulocyte Count %,,1.8,,,,,0.6 - 2.5,% +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,URINE MACRO PANEL,Ur Specific Gravity,,1.020,,,,,1 - 1.04, +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,URINE MACRO PANEL,Ur pH,,6.0,,,,,5 - 8, +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.7,,,,,0 - 5,mg/L +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,CELLULAR ELEMENTS,Ur WBC/HPF,,10,,,,,0 - 12,/HPF +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,CHEMISTRY PANEL,Total Bilirubin,,14,,,,,3 - 21,umol/L +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,5.2,,,,,0 - 6.2,umol/L +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,CHEMISTRY PANEL,Alkaline Phosphatase,,91,,,,,35 - 104,U/L +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,CHEMISTRY PANEL,ALT (SGPT),,49,,H,,,4 - 43,U/L +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,CHEMISTRY PANEL,AST (SGOT),,31,,,,,8 - 40,U/L +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,CHEMISTRY PANEL,GGT,,22,,,,,4 - 49,U/L +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,CHEMISTRY PANEL,LDH,,176,,,,,53 - 234,U/L +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,CHEMISTRY PANEL,Urea Nitrogen,,5.0,,,,,1.4 - 8.6,mmol/L +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,75,,,,,31 - 101,umol/L +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,CHEMISTRY PANEL,Glucose Fasting,,6.8,,H,,,3.9 - 5.6,mmol/L +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,CHEMISTRY PANEL,Serum Uric Acid,,282,,,,,149 - 446,umol/L +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,CHEMISTRY PANEL,Calcium (EDTA),,2.46,,,,,2.07 - 2.64,mmol/L +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,CHEMISTRY PANEL,Phosphorus,,1.34,,,,,0.71 - 1.65,mmol/L +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,CHEMISTRY PANEL,Total Protein,,67,,,,,61 - 84,g/L +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,CHEMISTRY PANEL,Albumin-BCG,,46,,,,,33 - 49,g/L +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,CHEMISTRY PANEL,Creatine Kinase,,51,,,,,26 - 192,U/L +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,CHEMISTRY PANEL,Serum Sodium,,139,,,,,132 - 147,mmol/L +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,CHEMISTRY PANEL,Serum Potassium,,5.1,,,,,3.5 - 5.2,mmol/L +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,CHEMISTRY PANEL,Serum Bicarbonate,,22.7,,,,,19.3 - 29.3,mmol/L +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,CHEMISTRY PANEL,Serum Chloride,,102,,,,,94 - 112,mmol/L +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,147,,,,,116 - 164,g/L +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.44,,,,,0.34 - 0.48, +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.9,,,,,4.1 - 5.6,TI/L +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,89,,,,,79 - 98,fL +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,7.87,,,,,3.8 - 10.7,GI/L +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,4.64,,,,,1.96 - 7.23,GI/L +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.53,,,,,0.91 - 4.28,GI/L +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.42,,,,,0.12 - 0.92,GI/L +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.20,,,,,0 - 0.57,GI/L +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.07,,,,,0 - 0.2,GI/L +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,58.9,,,,,40.5 - 75,% +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,32.3,,,,,15.4 - 48.5,% +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.4,,,,,2.6 - 10.1,% +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.5,,,,,0 - 6.8,% +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.9,,,,,0 - 2,% +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,294,,,,,140 - 400,GI/L +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,12.54,,,,,1.9 - 23,uIU/mL +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,LIPID PANEL,Direct HDL-C 4th Generation,,0.96,,L,,,1.03 - 1.53,mmol/L +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,LIPID PANEL,Triglycerides (GPO),,0.90,,,,,0.59 - 2.96,mmol/L +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,LIPID PANEL,Cholesterol (High Performance),,2.39,,L,,Result verified by repeat analysis,4.42 - 7.53,mmol/L +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,LIPID PANEL,LDL Chol Friedewald 4th,,1.02,,,,,0 - 3.34,mmol/L +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,MICROORGANISMS,Ur Bacteria,,Present,,,,,Ref Rng:Not present, +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,RETICULOCYTES,Reticulocyte Count %,,1.6,,,,,0.6 - 2.5,% +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,URINE MACRO PANEL,Ur Specific Gravity,,1.017,,,,,1 - 1.04, +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,URINE MACRO PANEL,Ur Leukocyte Esterase,,+2,,H SF,,,Ref Rng:Negative, +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,URINE MICRO PANEL,Ur Microscopic,,Positive,,,,, NEGATIVE$,NEGATIVE +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.3,,,,,0 - 5,mg/L +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,CELLULAR ELEMENTS,Ur RBC/HPF,,1,,,,,0 - 8,/HPF +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,CELLULAR ELEMENTS,Ur WBC/HPF,,7,,,,,0 - 12,/HPF +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,CHEMISTRY PANEL,Total Bilirubin,,11,,,,,3 - 21,umol/L +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.5,,,,,0 - 6.2,umol/L +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,CHEMISTRY PANEL,Alkaline Phosphatase,,84,,,,,35 - 104,U/L +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,CHEMISTRY PANEL,ALT (SGPT),,18,,,,,4 - 43,U/L +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,CHEMISTRY PANEL,AST (SGOT),,19,,,,,8 - 40,U/L +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,CHEMISTRY PANEL,GGT,,21,,,,,4 - 49,U/L +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,CHEMISTRY PANEL,LDH,,206,,,,,53 - 234,U/L +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,CHEMISTRY PANEL,Urea Nitrogen,,4.0,,,,,1.4 - 8.6,mmol/L +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,78,,,,,31 - 101,umol/L +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,CHEMISTRY PANEL,Glucose Fasting,,5.5,,,,,3.9 - 5.6,mmol/L +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,CHEMISTRY PANEL,Serum Uric Acid,,260,,,,,149 - 446,umol/L +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,CHEMISTRY PANEL,Calcium (EDTA),,2.42,,,,,2.07 - 2.64,mmol/L +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,CHEMISTRY PANEL,Phosphorus,,1.17,,,,,0.71 - 1.65,mmol/L +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,CHEMISTRY PANEL,Total Protein,,68,,,,,61 - 84,g/L +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,CHEMISTRY PANEL,Albumin-BCG,,46,,,,,33 - 49,g/L +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,CHEMISTRY PANEL,Creatine Kinase,,107,,,,,26 - 192,U/L +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,CHEMISTRY PANEL,Serum Sodium,,140,,,,,132 - 147,mmol/L +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,CHEMISTRY PANEL,Serum Potassium,,4.2,,,,,3.5 - 5.2,mmol/L +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,CHEMISTRY PANEL,Serum Bicarbonate,,22.4,,,,,19.3 - 29.3,mmol/L +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,CHEMISTRY PANEL,Serum Chloride,,102,,,,,94 - 112,mmol/L +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,CREATININE CLEARANCE CC&G,CreatininClearancCockcrftGault,,1.58,,,,,1.25 - 1.92,mL/sec +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,CREATININE CLEARANCE CC&G,Creatinine(Rate Blanked)-2dp,,78,,,,,31 - 101,umol/L +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,CREATININE CLEARANCE CC&G,"Weight (kg,1dec place)",Y,81.6,,,,,kg, +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,DRUG SCREEN URINE,Amphetamines/MDMA,,Neg,,,,,Neg;$Cutoff = 1000 ng/mL, +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,DRUG SCREEN URINE,Barbiturates,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,DRUG SCREEN URINE,Cannabinoids,,Neg,,,,,Neg;$Cutoff = 50 ng/mL, +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,DRUG SCREEN URINE,Cocaine,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,DRUG SCREEN URINE,Opiates,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,DRUG SCREEN URINE,Methadone,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,DRUG SCREEN URINE BENZO NON-US,Benzodiazepines Gen 2,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,FEMALE OF CHILDBEARING POT?,Female/of Childbearing pot.?,Y,No,,,,,, +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,GFR,EGFR by MDRD,,67,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,136,,,,,116 - 164,g/L +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.41,,,,,0.34 - 0.48, +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.4,,,,,4.1 - 5.6,TI/L +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,93,,,,,79 - 98,fL +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,5.09,,,,,3.8 - 10.7,GI/L +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.99,,,,,1.96 - 7.23,GI/L +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.48,,,,,0.91 - 4.28,GI/L +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.34,,,,,0.12 - 0.92,GI/L +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.15,,,,,0 - 0.57,GI/L +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.12,,,,,0 - 0.2,GI/L +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,58.8,,,,,40.5 - 75,% +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,29.2,,,,,15.4 - 48.5,% +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,6.7,,,,,2.6 - 10.1,% +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,3.0,,,,,0 - 6.8,% +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,2.3,,H,,,0 - 2,% +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,313,,,,,140 - 400,GI/L +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,HEMOGLOBIN A1C,"Hemoglobin A1c,Variant(-70)-QT",,5.1,,,,,<6.5%, +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,4.19,,,,,1.9 - 23,uIU/mL +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,IS SUBJECT OF BLACK RACE?,Subject of black race?,Y,No,,,,,, +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,LIPID PANEL,Direct HDL-C 4th Generation,,1.52,,,,,1.03 - 1.53,mmol/L +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,LIPID PANEL,Triglycerides (GPO),,1.01,,,,,0.59 - 2.96,mmol/L +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,LIPID PANEL,Cholesterol (High Performance),,5.29,,,,,4.42 - 7.53,mmol/L +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,LIPID PANEL,LDL Chol Friedewald 4th,,3.31,,,,,0 - 3.34,mmol/L +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,POSTMENOPAUSAL FEMALE?,<40yrs & amenorrhea >/= 12mo,,No,,,,,, +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,RETICULOCYTES,Reticulocyte Count %,,1.4,,,,,0.6 - 2.5,% +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,TSH,TSH 3rd IS-QT,,1.461,,,,,0.45 - 5.33,mIU/L +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,URINE MACRO PANEL,Ur Specific Gravity,,1.024,,,,,1 - 1.04, +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,URINE MACRO PANEL,Ur pH,,6.5,,,,,5 - 8, +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,URINE MACRO PANEL,Ur Protein,,Trace,R,H,,,Ref Rng:Negative, +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,URINE MICRO PANEL,Ur Microscopic,,Positive,,,,, NEGATIVE$,NEGATIVE +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,C-REACTIVE PROTEIN,C Reactive Protein HS,,3.5,,,,,0 - 5,mg/L +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,CHEMISTRY PANEL,Total Bilirubin,,9,,,,,3 - 21,umol/L +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.7,,,,,0 - 6.2,umol/L +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,CHEMISTRY PANEL,Alkaline Phosphatase,,77,,,,,35 - 104,U/L +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,CHEMISTRY PANEL,ALT (SGPT),,27,,,,,4 - 43,U/L +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,CHEMISTRY PANEL,AST (SGOT),,25,,,,,8 - 40,U/L +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,CHEMISTRY PANEL,GGT,,45,,,,,4 - 49,U/L +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,CHEMISTRY PANEL,LDH,,161,,,,,53 - 234,U/L +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,CHEMISTRY PANEL,Urea Nitrogen,,3.5,,,,,1.4 - 8.6,mmol/L +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,63,,,,,31 - 101,umol/L +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,CHEMISTRY PANEL,Glucose Fasting,,5.2,,,,,3.9 - 5.6,mmol/L +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,CHEMISTRY PANEL,Serum Uric Acid,,261,,,,,125 - 428,umol/L +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,CHEMISTRY PANEL,Calcium (EDTA),,2.38,,,,,2.07 - 2.64,mmol/L +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,CHEMISTRY PANEL,Phosphorus,,1.12,,,,,0.71 - 1.65,mmol/L +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,CHEMISTRY PANEL,Total Protein,,71,,,,,61 - 84,g/L +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,CHEMISTRY PANEL,Albumin-BCG,,44,,,,,33 - 49,g/L +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,CHEMISTRY PANEL,Creatine Kinase,,99,,,,,26 - 192,U/L +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,CHEMISTRY PANEL,Serum Sodium,,141,,,,,132 - 147,mmol/L +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,CHEMISTRY PANEL,Serum Potassium,,4.7,,,,,3.5 - 5.2,mmol/L +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,CHEMISTRY PANEL,Serum Bicarbonate,,21.9,,,,,19.3 - 29.3,mmol/L +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,CHEMISTRY PANEL,Serum Chloride,,105,,,,,94 - 112,mmol/L +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,126,,,,,116 - 164,g/L +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.39,,,,,0.34 - 0.48, +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.1,,,,,4.1 - 5.6,TI/L +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,96,,,,,79 - 98,fL +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,7.55,,,,,3.8 - 10.7,GI/L +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,4.59,,,,,1.96 - 7.23,GI/L +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.09,,,,,0.91 - 4.28,GI/L +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.63,,,,,0.12 - 0.92,GI/L +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.20,,,,,0 - 0.57,GI/L +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.03,,,,,0 - 0.2,GI/L +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,60.9,,,,,40.5 - 75,% +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,27.7,,,,,15.4 - 48.5,% +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,8.3,,,,,2.6 - 10.1,% +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.6,,,,,0 - 6.8,% +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.5,,,,,0 - 2,% +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,324,,,,,140 - 400,GI/L +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,5.08,,,,,1.9 - 23,uIU/mL +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,LIPID PANEL,Direct HDL-C 4th Generation,,1.54,,H,,Result verified by repeat analysis,1.03 - 1.53,mmol/L +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,LIPID PANEL,Triglycerides (GPO),,2.08,,,,,0.51 - 2.42,mmol/L +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,LIPID PANEL,Cholesterol (High Performance),,5.37,,,,,4.01 - 6.85,mmol/L +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,LIPID PANEL,LDL Chol Friedewald 4th,,2.88,,,,,0 - 3.34,mmol/L +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,RETICULOCYTES,Reticulocyte Count %,,2.1,,,,,0.6 - 2.5,% +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,URINE MACRO PANEL,Ur Specific Gravity,,1.017,,,,,1 - 1.04, +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.5,,,,,0 - 5,mg/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,CELLULAR ELEMENTS,Ur WBC/HPF,,5,,,,,0 - 12,/HPF +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,CHEMISTRY PANEL,Total Bilirubin,,7,,,,,3 - 21,umol/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.0,,,,,0 - 6.2,umol/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,CHEMISTRY PANEL,Alkaline Phosphatase,,99,,,,,35 - 104,U/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,CHEMISTRY PANEL,ALT (SGPT),,32,,,,,4 - 43,U/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,CHEMISTRY PANEL,AST (SGOT),,32,,,,,8 - 40,U/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,CHEMISTRY PANEL,GGT,,18,,,,,4 - 49,U/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,CHEMISTRY PANEL,LDH,,232,,,,,53 - 234,U/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,CHEMISTRY PANEL,Urea Nitrogen,,4.7,,,,,1.4 - 8.6,mmol/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,77,,,,,31 - 101,umol/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,CHEMISTRY PANEL,Glucose Fasting,,5.3,,,,,3.9 - 5.6,mmol/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,CHEMISTRY PANEL,Serum Uric Acid,,392,,,,,149 - 446,umol/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,CHEMISTRY PANEL,Calcium (EDTA),,2.37,,,,,2.07 - 2.64,mmol/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,CHEMISTRY PANEL,Phosphorus,,1.06,,,,,0.71 - 1.65,mmol/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,CHEMISTRY PANEL,Total Protein,,73,,,,,61 - 84,g/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,CHEMISTRY PANEL,Albumin-BCG,,46,,,,,33 - 49,g/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,CHEMISTRY PANEL,Creatine Kinase,,160,,,,,26 - 192,U/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,CHEMISTRY PANEL,Serum Sodium,,140,,,,,132 - 147,mmol/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,CHEMISTRY PANEL,Serum Potassium,,4.4,,,,,3.5 - 5.2,mmol/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,CHEMISTRY PANEL,Serum Bicarbonate,,23.1,,,,,19.3 - 29.3,mmol/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,CHEMISTRY PANEL,Serum Chloride,,102,,,,,94 - 112,mmol/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,143,,,,,116 - 164,g/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.41,,,,,0.34 - 0.48, +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.7,,,,,4.1 - 5.6,TI/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,Normocytic,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,88,,,,,79 - 98,fL +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,4.39,,,,,3.8 - 10.7,GI/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.58,,,,,1.96 - 7.23,GI/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.36,,,,,0.91 - 4.28,GI/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.31,,,,,0.12 - 0.92,GI/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.13,,,,,0 - 0.57,GI/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.02,,,,,0 - 0.2,GI/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,58.8,,,,,40.5 - 75,% +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,30.9,,,,,15.4 - 48.5,% +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,7.1,,,,,2.6 - 10.1,% +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.9,,,,,0 - 6.8,% +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.4,,,,,0 - 2,% +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,,,,Test cancelled: Platelet clumps present,,, +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,HEMOGLOBIN A1C,"Hemoglobin A1c,Variant(-70)-QT",,5.8,,,,,<6.5%, +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,LIPID PANEL,Direct HDL-C 4th Generation,,1.11,,,,,1.03 - 1.53,mmol/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,LIPID PANEL,Triglycerides (GPO),,1.60,,,,,0.59 - 2.96,mmol/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,LIPID PANEL,Cholesterol (High Performance),,6.83,,,,,4.42 - 7.53,mmol/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,LIPID PANEL,LDL Chol Friedewald 4th,,4.99,,H,,,0 - 3.34,mmol/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,MICROORGANISMS,Ur Bacteria,,Present,,,,,Ref Rng:Not present, +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,RETICULOCYTES,Reticulocyte Count %,,1.7,,,,,0.6 - 2.5,% +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,TSH,TSH 3rd IS-QT,,2.025,,,,,0.45 - 5.33,mIU/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,URINE MACRO PANEL,Ur Specific Gravity,,1.018,,,,,1 - 1.04, +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,URINE MACRO PANEL,Ur pH,,7.0,,,,,5 - 8, +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,URINE MACRO PANEL,Ur Leukocyte Esterase,,Trace,R,H,,,Ref Rng:Negative, +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,URINE MICRO PANEL,Ur Microscopic,,Positive,,,,, NEGATIVE$,NEGATIVE +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,C-REACTIVE PROTEIN,C Reactive Protein HS,,3.9,,,,,0 - 5,mg/L +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,CELLULAR ELEMENTS,Ur WBC/HPF,,42,,H,,,0 - 12,/HPF +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,CHEMISTRY PANEL,Total Bilirubin,,13,,,,,3 - 21,umol/L +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,4.7,,,,,0 - 6.2,umol/L +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,CHEMISTRY PANEL,Alkaline Phosphatase,,83,,,,,35 - 104,U/L +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,CHEMISTRY PANEL,ALT (SGPT),,69,,H RX,,,4 - 43,U/L +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,CHEMISTRY PANEL,AST (SGOT),,40,,,,,8 - 40,U/L +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,CHEMISTRY PANEL,GGT,,27,,,,,4 - 49,U/L +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,CHEMISTRY PANEL,LDH,,190,,,,,53 - 234,U/L +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,CHEMISTRY PANEL,Urea Nitrogen,,3.8,,,,,1.4 - 8.6,mmol/L +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,72,,,,,31 - 101,umol/L +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,CHEMISTRY PANEL,Glucose Fasting,,7.5,,H,,,3.9 - 5.6,mmol/L +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,CHEMISTRY PANEL,Serum Uric Acid,,309,,,,,149 - 446,umol/L +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,CHEMISTRY PANEL,Calcium (EDTA),,2.40,,,,,2.07 - 2.64,mmol/L +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,CHEMISTRY PANEL,Phosphorus,,1.28,,,,,0.71 - 1.65,mmol/L +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,CHEMISTRY PANEL,Total Protein,,66,,,,,61 - 84,g/L +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,CHEMISTRY PANEL,Albumin-BCG,,46,,,,,33 - 49,g/L +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,CHEMISTRY PANEL,Creatine Kinase,,48,,,,,26 - 192,U/L +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,CHEMISTRY PANEL,Serum Sodium,,141,,,,,132 - 147,mmol/L +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,CHEMISTRY PANEL,Serum Potassium,,4.2,,,,,3.5 - 5.2,mmol/L +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,CHEMISTRY PANEL,Serum Bicarbonate,,24.7,,,,,19.3 - 29.3,mmol/L +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,CHEMISTRY PANEL,Serum Chloride,,104,,,,,94 - 112,mmol/L +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,CREATININE CLEARANCE CC&G,CreatininClearancCockcrftGault,,1.65,,,,,1.25 - 1.92,mL/sec +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,CREATININE CLEARANCE CC&G,Creatinine(Rate Blanked)-2dp,,72,,,,,31 - 101,umol/L +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,CREATININE CLEARANCE CC&G,"Weight (kg,1dec place)",Y,79.2,,,,,kg, +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,DRUG SCREEN URINE,Amphetamines/MDMA,,Neg,,,,,Neg;$Cutoff = 1000 ng/mL, +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,DRUG SCREEN URINE,Barbiturates,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,DRUG SCREEN URINE,Cannabinoids,,Neg,,,,,Neg;$Cutoff = 50 ng/mL, +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,DRUG SCREEN URINE,Cocaine,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,DRUG SCREEN URINE,Opiates,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,DRUG SCREEN URINE,Methadone,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,DRUG SCREEN URINE BENZO NON-US,Benzodiazepines Gen 2,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,FEMALE OF CHILDBEARING POT?,Female/of Childbearing pot.?,Y,No,,,,,, +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,GFR,EGFR by MDRD,,74,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,151,,,,,116 - 164,g/L +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.45,,,,,0.34 - 0.48, +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.0,,,,,4.1 - 5.6,TI/L +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,91,,,,,79 - 98,fL +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,9.69,,,,,3.8 - 10.7,GI/L +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,6.48,,,,,1.96 - 7.23,GI/L +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.44,,,,,0.91 - 4.28,GI/L +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.48,,,,,0.12 - 0.92,GI/L +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.23,,,,,0 - 0.57,GI/L +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.07,,,,,0 - 0.2,GI/L +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,66.8,,,,,40.5 - 75,% +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,25.1,,,,,15.4 - 48.5,% +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,4.9,,,,,2.6 - 10.1,% +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.3,,,,,0 - 6.8,% +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.8,,,,,0 - 2,% +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,324,,,,,140 - 400,GI/L +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,HEMOGLOBIN A1C,"Hemoglobin A1c,Variant(-70)-QT",,6.6,,H,,,<6.5%, +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,13.86,,,,,1.9 - 23,uIU/mL +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,IS SUBJECT OF BLACK RACE?,Subject of black race?,Y,No,,,,,, +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,LIPID PANEL,Direct HDL-C 4th Generation,,0.89,,L,,,1.03 - 1.53,mmol/L +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,LIPID PANEL,Triglycerides (GPO),,1.13,,,,,0.59 - 2.96,mmol/L +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,LIPID PANEL,Cholesterol (High Performance),,2.44,,L,,Result verified by repeat analysis,4.42 - 7.53,mmol/L +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,LIPID PANEL,LDL Chol Friedewald 4th,,1.03,,,,,0 - 3.34,mmol/L +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,MICROORGANISMS,Ur Bacteria,,Present,,,,,Ref Rng:Not present, +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,MISCELLANEOUS ELEMENTS,Ur Mucous,,Present,,,,,Ref Rng:Not present, +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,POSTMENOPAUSAL FEMALE?,<40yrs & amenorrhea >/= 12mo,,No,,,,,, +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,RETICULOCYTES,Reticulocyte Count %,,2.0,,,,,0.6 - 2.5,% +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,TSH,TSH 3rd IS-QT,,1.524,,,,,0.45 - 5.33,mIU/L +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,URINE MACRO PANEL,Ur Specific Gravity,,1.024,,,,,1 - 1.04, +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,URINE MACRO PANEL,Ur Protein,,Trace,,H,,,Ref Rng:Negative, +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,URINE MACRO PANEL,Ur Leukocyte Esterase,,+3,,H SF,,,Ref Rng:Negative, +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,URINE MICRO PANEL,Ur Microscopic,,Positive,,,,, NEGATIVE$,NEGATIVE +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,C-REACTIVE PROTEIN,C Reactive Protein HS,,2.1,,,,,0 - 5,mg/L +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,CHEMISTRY PANEL,Total Bilirubin,,10,,,,,3 - 21,umol/L +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.9,,,,,0 - 6.2,umol/L +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,CHEMISTRY PANEL,Alkaline Phosphatase,,82,,,,,35 - 104,U/L +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,CHEMISTRY PANEL,ALT (SGPT),,23,,,,,4 - 43,U/L +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,CHEMISTRY PANEL,AST (SGOT),,23,,,,,8 - 40,U/L +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,CHEMISTRY PANEL,GGT,,47,,,,,4 - 49,U/L +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,CHEMISTRY PANEL,LDH,,153,,,,,53 - 234,U/L +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,CHEMISTRY PANEL,Urea Nitrogen,,4.3,,,,,1.4 - 8.6,mmol/L +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,69,,,,,31 - 101,umol/L +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,CHEMISTRY PANEL,Glucose Fasting,,5.2,,,,,3.9 - 5.6,mmol/L +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,CHEMISTRY PANEL,Serum Uric Acid,,322,,,,,125 - 428,umol/L +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,CHEMISTRY PANEL,Calcium (EDTA),,2.47,,,,,2.07 - 2.64,mmol/L +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,CHEMISTRY PANEL,Phosphorus,,1.05,,,,,0.71 - 1.65,mmol/L +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,CHEMISTRY PANEL,Total Protein,,79,,,,,61 - 84,g/L +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,CHEMISTRY PANEL,Albumin-BCG,,48,,,,,33 - 49,g/L +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,CHEMISTRY PANEL,Creatine Kinase,,104,,,,,26 - 192,U/L +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,CHEMISTRY PANEL,Serum Sodium,,139,,,,,132 - 147,mmol/L +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,CHEMISTRY PANEL,Serum Potassium,,4.8,,,,,3.5 - 5.2,mmol/L +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,CHEMISTRY PANEL,Serum Bicarbonate,,22.9,,,,,19.3 - 29.3,mmol/L +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,CHEMISTRY PANEL,Serum Chloride,,102,,,,,94 - 112,mmol/L +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,CREATININE CLEARANCE CC&G,CreatininClearancCockcrftGault,,1.88,,,,,1.25 - 1.92,mL/sec +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,CREATININE CLEARANCE CC&G,Creatinine(Rate Blanked)-2dp,,69,,,,,31 - 101,umol/L +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,CREATININE CLEARANCE CC&G,"Weight (kg,1dec place)",Y,78.6,,,,,kg, +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,DRUG SCREEN URINE,Amphetamines/MDMA,,Neg,,,,,Neg;$Cutoff = 1000 ng/mL, +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,DRUG SCREEN URINE,Barbiturates,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,DRUG SCREEN URINE,Cannabinoids,,Neg,,,,Result verified by repeat analysis,Neg;$Cutoff = 50 ng/mL, +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,DRUG SCREEN URINE,Cocaine,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,DRUG SCREEN URINE,Opiates,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,DRUG SCREEN URINE,Methadone,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,DRUG SCREEN URINE BENZO NON-US,Benzodiazepines Gen 2,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,FEMALE OF CHILDBEARING POT?,Female/of Childbearing pot.?,Y,Yes,,,,,, +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,GFR,EGFR by MDRD,,80,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,137,,,,,116 - 164,g/L +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.46,,,,,0.34 - 0.48, +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.3,,,,,4.1 - 5.6,TI/L +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,106,,H,,,79 - 98,fL +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,5.54,,,,,3.8 - 10.7,GI/L +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.33,,,,,1.96 - 7.23,GI/L +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.64,,,,,0.91 - 4.28,GI/L +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.36,,,,,0.12 - 0.92,GI/L +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.15,,,,,0 - 0.57,GI/L +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.07,,,,,0 - 0.2,GI/L +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,42.0,,,,,40.5 - 75,% +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,47.6,,,,,15.4 - 48.5,% +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,6.5,,,,,2.6 - 10.1,% +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.7,,,,,0 - 6.8,% +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.2,,,,,0 - 2,% +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,301,,,,,140 - 400,GI/L +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,HEMOGLOBIN A1C,"Hemoglobin A1c,Variant(-70)-QT",,5.3,,,,,<6.5%, +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,4.36,,,,,1.9 - 23,uIU/mL +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,IS SUBJECT OF BLACK RACE?,Subject of black race?,Y,No,,,,,, +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,LIPID PANEL,Direct HDL-C 4th Generation,,1.94,,H,,,1.03 - 1.53,mmol/L +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,LIPID PANEL,Triglycerides (GPO),,1.55,,,,,0.51 - 2.42,mmol/L +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,LIPID PANEL,Cholesterol (High Performance),,6.28,,,,,4.01 - 6.85,mmol/L +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,LIPID PANEL,LDL Chol Friedewald 4th,,3.63,,H,,,0 - 3.34,mmol/L +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,POSTMENOPAUSAL FEMALE?,<40yrs & amenorrhea >/= 12mo,,No,,,,,, +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,RETICULOCYTES,Reticulocyte Count %,,1.2,,,,,0.6 - 2.5,% +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,SERUM BETA HCG,"B-hCG, Qualitative",,Negative,,,,,Ref Rng: Negative, +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,SERUM BETA HCG,"B-hCG, Quantitative",,<0.6,,,,,Units: mIU/mL$Pre-menopausal$<5.0: Negative$5.0-24.9:Borderline$>/= 25.0: Positive, +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,TSH,TSH 3rd IS-QT,,1.391,,,,,0.45 - 5.33,mIU/L +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,URINE MACRO PANEL,Ur Specific Gravity,,1.018,,,,,1 - 1.04, +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,URINE MACRO PANEL,Ur pH,,6.0,,,,,5 - 8, +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,C-REACTIVE PROTEIN,C Reactive Protein HS,,2.1,,,,,0 - 5,mg/L +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,CHEMISTRY PANEL,Total Bilirubin,,5,,,,,3 - 21,umol/L +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,1.6,,,,,0 - 6.2,umol/L +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,CHEMISTRY PANEL,Alkaline Phosphatase,,104,,,,,35 - 104,U/L +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,CHEMISTRY PANEL,ALT (SGPT),,30,,,,,4 - 43,U/L +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,CHEMISTRY PANEL,AST (SGOT),,27,,,,,8 - 40,U/L +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,CHEMISTRY PANEL,GGT,,20,,,,,4 - 49,U/L +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,CHEMISTRY PANEL,LDH,,224,,,,,53 - 234,U/L +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,CHEMISTRY PANEL,Urea Nitrogen,,4.6,,,,,1.4 - 8.6,mmol/L +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,75,,,,,31 - 101,umol/L +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,CHEMISTRY PANEL,Glucose Fasting,,5.2,,,,,3.9 - 5.6,mmol/L +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,CHEMISTRY PANEL,Serum Uric Acid,,358,,,,,149 - 446,umol/L +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,CHEMISTRY PANEL,Calcium (EDTA),,2.38,,,,,2.07 - 2.64,mmol/L +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,CHEMISTRY PANEL,Phosphorus,,1.33,,,,,0.71 - 1.65,mmol/L +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,CHEMISTRY PANEL,Total Protein,,72,,,,,61 - 84,g/L +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,CHEMISTRY PANEL,Albumin-BCG,,46,,,,,33 - 49,g/L +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,CHEMISTRY PANEL,Creatine Kinase,,159,,,,,26 - 192,U/L +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,CHEMISTRY PANEL,Serum Sodium,,142,,,,,132 - 147,mmol/L +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,CHEMISTRY PANEL,Serum Potassium,,4.4,,,,,3.5 - 5.2,mmol/L +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,CHEMISTRY PANEL,Serum Bicarbonate,,23.6,,,,,19.3 - 29.3,mmol/L +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,CHEMISTRY PANEL,Serum Chloride,,103,,,,,94 - 112,mmol/L +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,135,,,,,116 - 164,g/L +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.40,,,,,0.34 - 0.48, +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.5,,,,,4.1 - 5.6,TI/L +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,89,,,,,79 - 98,fL +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,4.75,,,,,3.8 - 10.7,GI/L +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.17,,,,,1.96 - 7.23,GI/L +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.12,,,,,0.91 - 4.28,GI/L +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.29,,,,,0.12 - 0.92,GI/L +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.10,,,,,0 - 0.57,GI/L +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.07,,,,,0 - 0.2,GI/L +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,45.7,,,,,40.5 - 75,% +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,44.7,,,,,15.4 - 48.5,% +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,6.1,,,,,2.6 - 10.1,% +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.1,,,,,0 - 6.8,% +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.4,,,,,0 - 2,% +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,157,,,,,140 - 400,GI/L +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,11.38,,,,,1.9 - 23,uIU/mL +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,LIPID PANEL,Direct HDL-C 4th Generation,,1.10,,,,,1.03 - 1.53,mmol/L +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,LIPID PANEL,Triglycerides (GPO),,1.77,,,,,0.59 - 2.96,mmol/L +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,LIPID PANEL,Cholesterol (High Performance),,6.54,,,,,4.42 - 7.53,mmol/L +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,LIPID PANEL,LDL Chol Friedewald 4th,,4.63,,H,,,0 - 3.34,mmol/L +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,RETICULOCYTES,Reticulocyte Count %,,3.5,,H,,,0.6 - 2.5,% +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,URINE MACRO PANEL,Ur Specific Gravity,,1.015,,,,,1 - 1.04, +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,URINE MACRO PANEL,Ur pH,,6.5,,,,,5 - 8, +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100040001,,,56,years,Female,Retest,,"Aug 19, 2025 10:00 AM",6225351002,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100040001,,,56,years,Female,Retest,,"Aug 19, 2025 10:00 AM",6225351002,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.7,,,,,0 - 5,mg/L +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,CELLULAR ELEMENTS,Ur WBC/HPF,,10,,,,,0 - 12,/HPF +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,CHEMISTRY PANEL,Total Bilirubin,,5,,,,,3 - 21,umol/L +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,1.7,,,,,0 - 6.2,umol/L +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,CHEMISTRY PANEL,Alkaline Phosphatase,,106,,H,,,35 - 104,U/L +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,CHEMISTRY PANEL,ALT (SGPT),,28,,,,,4 - 43,U/L +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,CHEMISTRY PANEL,AST (SGOT),,26,,,,,8 - 40,U/L +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,CHEMISTRY PANEL,GGT,,19,,,,,4 - 49,U/L +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,CHEMISTRY PANEL,LDH,,241,,H,,,53 - 234,U/L +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,CHEMISTRY PANEL,Urea Nitrogen,,4.6,,,,,1.4 - 8.6,mmol/L +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,87,,,,,31 - 101,umol/L +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,CHEMISTRY PANEL,Glucose Fasting,,6.5,,H,,,3.9 - 5.6,mmol/L +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,CHEMISTRY PANEL,Serum Uric Acid,,349,,,,,149 - 446,umol/L +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,CHEMISTRY PANEL,Calcium (EDTA),,2.40,,,,,2.07 - 2.64,mmol/L +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,CHEMISTRY PANEL,Phosphorus,,0.95,,,,,0.71 - 1.65,mmol/L +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,CHEMISTRY PANEL,Total Protein,,74,,,,,61 - 84,g/L +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,CHEMISTRY PANEL,Albumin-BCG,,46,,,,,33 - 49,g/L +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,CHEMISTRY PANEL,Creatine Kinase,,140,,,,,26 - 192,U/L +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,CHEMISTRY PANEL,Serum Sodium,,140,,,,,132 - 147,mmol/L +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,CHEMISTRY PANEL,Serum Potassium,,4.2,,,,,3.5 - 5.2,mmol/L +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,CHEMISTRY PANEL,Serum Bicarbonate,,23.9,,,,,19.3 - 29.3,mmol/L +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,CHEMISTRY PANEL,Serum Chloride,,102,,,,,94 - 112,mmol/L +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,CREATININE CLEARANCE CC&G,CreatininClearancCockcrftGault,,1.23,,L,,,1.25 - 1.92,mL/sec +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,CREATININE CLEARANCE CC&G,Creatinine(Rate Blanked)-2dp,,87,,,,,31 - 101,umol/L +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,CREATININE CLEARANCE CC&G,"Weight (kg,1dec place)",Y,72.5,,,,,kg, +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,DRUG SCREEN URINE,Amphetamines/MDMA,,Neg,,,,,Neg;$Cutoff = 1000 ng/mL, +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,DRUG SCREEN URINE,Barbiturates,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,DRUG SCREEN URINE,Cannabinoids,,Neg,,,,,Neg;$Cutoff = 50 ng/mL, +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,DRUG SCREEN URINE,Cocaine,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,DRUG SCREEN URINE,Opiates,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,DRUG SCREEN URINE,Methadone,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,DRUG SCREEN URINE BENZO NON-US,Benzodiazepines Gen 2,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,FEMALE OF CHILDBEARING POT?,Female/of Childbearing pot.?,Y,No,,,,,, +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,FSH,Follicle Stimulating Hormone,,50.25,,,,,Follicular:$3.90-8.80 IU/L$Midcycle:$4.50-22.50 IU/L$Luteal:$1.80-5.10 IU/L$Postmenopausal:$16.70-113.60 IU/L, +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,GFR,EGFR by MDRD,,59,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,139,,,,,116 - 164,g/L +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.42,,,,,0.34 - 0.48, +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.7,,,,,4.1 - 5.6,TI/L +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,90,,,,,79 - 98,fL +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,4.75,,,,,3.8 - 10.7,GI/L +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.40,,,,,1.96 - 7.23,GI/L +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.88,,,,,0.91 - 4.28,GI/L +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.34,,,,,0.12 - 0.92,GI/L +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.08,,,,,0 - 0.57,GI/L +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.06,,,,,0 - 0.2,GI/L +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,50.5,,,,,40.5 - 75,% +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,39.4,,,,,15.4 - 48.5,% +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,7.2,,,,,2.6 - 10.1,% +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.6,,,,,0 - 6.8,% +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.3,,,,,0 - 2,% +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,163,,,,,140 - 400,GI/L +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,HEMOGLOBIN A1C,"Hemoglobin A1c,Variant(-70)-QT",,4.7,,,,,<6.5%, +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,IS SUBJECT OF BLACK RACE?,Subject of black race?,Y,No,,,,,, +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,LIPID PANEL,Direct HDL-C 4th Generation,,0.97,,L,,,1.03 - 1.53,mmol/L +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,LIPID PANEL,Triglycerides (GPO),,3.99,,H,,,0.59 - 2.96,mmol/L +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,LIPID PANEL,Cholesterol (High Performance),,6.69,,,,,4.42 - 7.53,mmol/L +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,LIPID PANEL,LDL Chol Friedewald 4th,,3.89,,H,,,0 - 3.34,mmol/L +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,POSTMENOPAUSAL FEMALE?,<40yrs & amenorrhea >/= 12mo,,Yes,,,,,, +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,RETICULOCYTES,Reticulocyte Count %,,2.9,,H,,,0.6 - 2.5,% +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,TSH,TSH 3rd IS-QT,,2.272,,,,,0.45 - 5.33,mIU/L +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,URINE MACRO PANEL,Ur Specific Gravity,,1.024,,,,,1 - 1.04, +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,URINE MACRO PANEL,Ur Protein,,Trace,R,H,,,Ref Rng:Negative, +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,URINE MACRO PANEL,Ur Leukocyte Esterase,,+1,R,H,,,Ref Rng:Negative, +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,URINE MICRO PANEL,Ur Microscopic,,Positive,,,,, NEGATIVE$,NEGATIVE diff --git a/Covance_UCO3001/Source/2026-06-08_130654 sponsor-study-35472-test-results-898739-standard.csv b/Covance_UCO3001/Source/2026-06-08_130654 sponsor-study-35472-test-results-898739-standard.csv new file mode 100644 index 0000000..777a3b4 --- /dev/null +++ b/Covance_UCO3001/Source/2026-06-08_130654 sponsor-study-35472-test-results-898739-standard.csv @@ -0,0 +1,1899 @@ +"Disclaimer: The information presented in On-Screen Results is not intended to be a replacement of the official Lab Results, Alerts, Data Revisions and Cancellations found in the Lab Reports section of this software application. On-Screen Results should not be used for patient diagnosis, treatment decisions or submission to regulatory bodies.",,,,,,,,,,,,,,,,,,, +Subject,Subject Data Revision,Screen No.,Age,Age Unit,Gender,Visit,Visit Data Revision,Collected Time,Accession,Test Group,Test,Administrative Question,Value,Result Data Revision,Flags,Cancellation Reason,Comments,Range,Units +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,C-REACTIVE PROTEIN,C Reactive Protein HS,,0.2,,,,Result verified by repeat analysis,0 - 5,mg/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,CELLULAR ELEMENTS,Ur WBC/HPF,,1,,,,,0 - 5,/HPF +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,CHEMISTRY PANEL,Total Bilirubin,,9,,,,,3 - 21,umol/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.7,,,,,0 - 6.2,umol/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,CHEMISTRY PANEL,Alkaline Phosphatase,,55,,,,,40 - 129,U/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,CHEMISTRY PANEL,ALT (SGPT),,27,,,,,5 - 48,U/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,CHEMISTRY PANEL,AST (SGOT),,23,,,,,8 - 40,U/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,CHEMISTRY PANEL,GGT,,43,,,,,10 - 61,U/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,CHEMISTRY PANEL,LDH,,168,,,,,53 - 234,U/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,CHEMISTRY PANEL,Urea Nitrogen,,3.5,,,,,1.4 - 8.6,mmol/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,77,,,,,40 - 110,umol/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,CHEMISTRY PANEL,Glucose Fasting,,5.3,,,,,3.9 - 5.6,mmol/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,CHEMISTRY PANEL,Serum Uric Acid,,351,,,,,125 - 488,umol/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,CHEMISTRY PANEL,Calcium (EDTA),,2.44,,,,,2.07 - 2.64,mmol/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,CHEMISTRY PANEL,Phosphorus,,0.86,,,,,0.71 - 1.65,mmol/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,CHEMISTRY PANEL,Total Protein,,76,,,,,61 - 84,g/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,CHEMISTRY PANEL,Albumin-BCG,,50,,H,,,33 - 49,g/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,CHEMISTRY PANEL,Creatine Kinase,,100,,,,,39 - 308,U/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,CHEMISTRY PANEL,Serum Sodium,,141,,,,,132 - 147,mmol/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,CHEMISTRY PANEL,Serum Potassium,,4.0,,,,,3.5 - 5.2,mmol/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,CHEMISTRY PANEL,Serum Bicarbonate,,26.0,,,,,19.3 - 29.3,mmol/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,CHEMISTRY PANEL,Serum Chloride,,101,,,,,94 - 112,mmol/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,149,,,,,127 - 181,g/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.42,,,,,0.39 - 0.54, +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.0,,,,,4.5 - 6.4,TI/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,84,,,,,79 - 96,fL +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,8.24,,,,,3.8 - 10.7,GI/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,5.54,,,,,1.96 - 7.23,GI/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.12,,,,,0.91 - 4.28,GI/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.53,,,,,0.12 - 0.92,GI/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.04,,,,,0 - 0.57,GI/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.03,,,,,0 - 0.2,GI/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,67.2,,,,,40.5 - 75,% +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,25.7,,,,,15.4 - 48.5,% +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,6.4,,,,,2.6 - 10.1,% +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,0.5,,,,,0 - 6.8,% +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.4,,,,,0 - 2,% +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,193,,,,,140 - 400,GI/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.6,,,,,<6.5 %, +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,10.23,,,,,1.9 - 23,uIU/mL +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,LIPID PANEL,Direct HDL-C 4th Generation,,0.92,,L,,,1.03 - 1.53,mmol/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,LIPID PANEL,Triglycerides (GPO),,3.09,,,,,0.62 - 3.69,mmol/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,LIPID PANEL,Cholesterol (High Performance),,5.48,,,,,4.19 - 7.24,mmol/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,LIPID PANEL,LDL Chol Friedewald 4th,,3.14,,,,,0 - 3.34,mmol/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,MISCELLANEOUS ELEMENTS,Ur Mucous,,Present,,,,,Ref Rng:Not present, +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,RETICULOCYTES,Reticulocyte Count %,,1.4,,,,,0.6 - 2.5,% +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,TSH,TSH 3rd IS-QT,,1.690,,,,,0.45 - 5.33,mIU/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,URINE MACRO PANEL,Ur Specific Gravity,,1.026,,,,,1 - 1.04, +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,URINE MACRO PANEL,Ur Protein,,Trace,,H,,,Ref Rng:Negative, +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:Negative, +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,URINE MICRO PANEL,Ur Microscopic,,Positive,,,,, NEGATIVE$,NEGATIVE +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,C-REACTIVE PROTEIN,C Reactive Protein HS,,3.7,,,,,0 - 5,mg/L +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,CELLULAR ELEMENTS,Ur WBC/HPF,,1,,,,,0 - 12,/HPF +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,CHEMISTRY PANEL,Total Bilirubin,,8,,,,,3 - 21,umol/L +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.3,,,,,0 - 6.2,umol/L +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,CHEMISTRY PANEL,Alkaline Phosphatase,,65,,,,,35 - 104,U/L +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,CHEMISTRY PANEL,ALT (SGPT),,53,,H,,,4 - 43,U/L +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,CHEMISTRY PANEL,AST (SGOT),,47,,H,,,8 - 40,U/L +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,CHEMISTRY PANEL,GGT,,101,,H,,,5 - 50,U/L +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,CHEMISTRY PANEL,LDH,,186,,,,,53 - 234,U/L +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,CHEMISTRY PANEL,Urea Nitrogen,,1.4,,,,,1.4 - 8.6,mmol/L +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,52,,,,,31 - 101,umol/L +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,CHEMISTRY PANEL,Glucose Fasting,,5.8,,H,,,3.9 - 5.6,mmol/L +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,CHEMISTRY PANEL,Serum Uric Acid,,426,,,,,149 - 446,umol/L +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,CHEMISTRY PANEL,Calcium (EDTA),,2.60,,,,,2.07 - 2.64,mmol/L +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,CHEMISTRY PANEL,Phosphorus,,1.17,,,,,0.71 - 1.65,mmol/L +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,CHEMISTRY PANEL,Total Protein,,77,,,,,60 - 80,g/L +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,CHEMISTRY PANEL,Albumin-BCG,,49,,,,,33 - 49,g/L +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,CHEMISTRY PANEL,Creatine Kinase,,164,,,,,26 - 192,U/L +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,CHEMISTRY PANEL,Serum Sodium,,135,,,,,135 - 145,mmol/L +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,CHEMISTRY PANEL,Serum Potassium,,3.9,,,,,3.5 - 5.2,mmol/L +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,CHEMISTRY PANEL,Serum Bicarbonate,,21.2,,,,,19.3 - 29.3,mmol/L +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,CHEMISTRY PANEL,Serum Chloride,,94,,,,,94 - 112,mmol/L +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,148,,,,,115 - 158,g/L +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.43,,,,,0.34 - 0.48, +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.3,,,,,3.9 - 5.5,TI/L +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,100,,,,,80 - 100,fL +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,8.45,,,,,3.8 - 10.7,GI/L +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,4.74,,,,,1.96 - 7.23,GI/L +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.85,,,,,0.8 - 3,GI/L +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.49,,,,,0.12 - 0.92,GI/L +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.33,,,,,0 - 0.57,GI/L +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.04,,,,,0 - 0.2,GI/L +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,56.1,,,,,40.5 - 75,% +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,33.8,,,,,15.4 - 48.5,% +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.8,,,,,2.6 - 10.1,% +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,3.9,,,,,0 - 6.8,% +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.5,,,,,0 - 2,% +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,261,,,,,130 - 394,GI/L +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.3,,,,,<6.5 %, +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,5.91,,,,,1.9 - 23,uIU/mL +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,IS SUBJECT FASTING?,Is Subject Fasting?,Y,No,,,,,, +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,LIPID PANEL,Direct HDL-C 4th Generation,,1.71,,H,,,1.03 - 1.53,mmol/L +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,LIPID PANEL,Triglycerides (GPO),,1.73,,,,,0.63 - 2.71,mmol/L +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,LIPID PANEL,Cholesterol (High Performance),,3.78,,L,,,4.86 - 8.28,mmol/L +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,LIPID PANEL,LDL Chol Friedewald 4th,,1.28,,,,,0 - 3.34,mmol/L +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,RETICULOCYTES,Reticulocyte Count %,,1.3,,,,,0.6 - 2.5,% +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,TSH,TSH 3rd IS-QT,,,,,Test group cancelled: No specimen received,,, +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,URINE MACRO PANEL,Ur Specific Gravity,,1.009,,,,,1.01 - 1.03, +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,URINE MACRO PANEL,Ur pH,,5.0,,,,,5 - 8, +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,URINE MACRO PANEL,Ur Ketones,,Trace,,H,,,Ref Rng:Negative, +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,URINE MACRO PANEL,Ur Leukocyte Esterase,,Trace,,H,,,Ref Rng:Negative, +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,URINE MICRO PANEL,Ur Microscopic,,Positive,,,,, NEGATIVE$,NEGATIVE +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,C-REACTIVE PROTEIN,C Reactive Protein HS,,0.3,,,,Result verified by repeat analysis,0 - 5,mg/L +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,CHEMISTRY PANEL,Total Bilirubin,,9,,,,,3 - 21,umol/L +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.8,,,,,0 - 6.2,umol/L +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,CHEMISTRY PANEL,Alkaline Phosphatase,,54,,,,,40 - 129,U/L +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,CHEMISTRY PANEL,ALT (SGPT),,23,,,,,5 - 48,U/L +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,CHEMISTRY PANEL,AST (SGOT),,20,,,,,8 - 40,U/L +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,CHEMISTRY PANEL,GGT,,41,,,,,10 - 61,U/L +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,CHEMISTRY PANEL,LDH,,149,,,,,53 - 234,U/L +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,CHEMISTRY PANEL,Urea Nitrogen,,3.9,,,,,1.4 - 8.6,mmol/L +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,80,,,,,40 - 110,umol/L +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,CHEMISTRY PANEL,Glucose Fasting,,5.0,,,,,3.9 - 5.6,mmol/L +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,CHEMISTRY PANEL,Serum Uric Acid,,379,,,,,125 - 488,umol/L +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,CHEMISTRY PANEL,Calcium (EDTA),,2.53,,,,,2.07 - 2.64,mmol/L +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,CHEMISTRY PANEL,Phosphorus,,0.89,,,,,0.71 - 1.65,mmol/L +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,CHEMISTRY PANEL,Total Protein,,81,,,,,61 - 84,g/L +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,CHEMISTRY PANEL,Albumin-BCG,,50,,H,,,33 - 49,g/L +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,CHEMISTRY PANEL,Creatine Kinase,,88,,,,,39 - 308,U/L +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,CHEMISTRY PANEL,Serum Sodium,,141,,,,,132 - 147,mmol/L +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,CHEMISTRY PANEL,Serum Potassium,,4.0,,,,,3.5 - 5.2,mmol/L +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,CHEMISTRY PANEL,Serum Bicarbonate,,24.1,,,,,19.3 - 29.3,mmol/L +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,CHEMISTRY PANEL,Serum Chloride,,101,,,,,94 - 112,mmol/L +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,152,,,,,127 - 181,g/L +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.45,,,,,0.39 - 0.54, +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.3,,,,,4.5 - 6.4,TI/L +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,84,,,,,79 - 96,fL +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,5.35,,,,,3.8 - 10.7,GI/L +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.03,,,,,1.96 - 7.23,GI/L +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.94,,,,,0.91 - 4.28,GI/L +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.30,,,,,0.12 - 0.92,GI/L +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.06,,,,,0 - 0.57,GI/L +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.02,,,,,0 - 0.2,GI/L +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,56.6,,,,,40.5 - 75,% +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,36.4,,,,,15.4 - 48.5,% +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.6,,,,,2.6 - 10.1,% +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.1,,,,,0 - 6.8,% +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.4,,,,,0 - 2,% +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,202,,,,,140 - 400,GI/L +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,4.79,,,,,1.9 - 23,uIU/mL +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,LIPID PANEL,Direct HDL-C 4th Generation,,0.94,,L,,,1.03 - 1.53,mmol/L +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,LIPID PANEL,Triglycerides (GPO),,2.61,,,,,0.62 - 3.69,mmol/L +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,LIPID PANEL,Cholesterol (High Performance),,5.47,,,,,4.19 - 7.24,mmol/L +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,LIPID PANEL,LDL Chol Friedewald 4th,,3.33,,,,,0 - 3.34,mmol/L +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,RETICULOCYTES,Reticulocyte Count %,,1.1,,,,,0.6 - 2.5,% +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,URINE MACRO PANEL,Ur Specific Gravity,,1.023,,,,,1 - 1.04, +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,URINE MACRO PANEL,Ur pH,,6.5,,,,,5 - 8, +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:Negative, +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.3,,,,,0 - 5,mg/L +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,CELLULAR ELEMENTS,Ur WBC/HPF,,2,,,,,0 - 5,/HPF +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,CHEMISTRY PANEL,Total Bilirubin,,5,,,,,3 - 21,umol/L +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,1.7,,,,,0 - 6.2,umol/L +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,CHEMISTRY PANEL,Alkaline Phosphatase,,61,,,,,40 - 129,U/L +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,CHEMISTRY PANEL,ALT (SGPT),,16,,,,,5 - 48,U/L +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,CHEMISTRY PANEL,AST (SGOT),,19,,,,,8 - 40,U/L +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,CHEMISTRY PANEL,GGT,,34,,,,,10 - 61,U/L +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,CHEMISTRY PANEL,LDH,,164,,,,,53 - 234,U/L +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,CHEMISTRY PANEL,Urea Nitrogen,,5.1,,,,,1.4 - 8.6,mmol/L +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,74,,,,,40 - 119,umol/L +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,CHEMISTRY PANEL,Glucose Fasting,,5.2,,,,,3.9 - 5.6,mmol/L +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,CHEMISTRY PANEL,Serum Uric Acid,,266,,,,,149 - 494,umol/L +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,CHEMISTRY PANEL,Calcium (EDTA),,2.32,,,,,2.07 - 2.64,mmol/L +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,CHEMISTRY PANEL,Phosphorus,,1.13,,,,,0.71 - 1.65,mmol/L +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,CHEMISTRY PANEL,Total Protein,,72,,,,,61 - 84,g/L +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,CHEMISTRY PANEL,Albumin-BCG,,44,,,,,33 - 49,g/L +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,CHEMISTRY PANEL,Creatine Kinase,,77,,,,,39 - 308,U/L +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,CHEMISTRY PANEL,Serum Sodium,,138,,,,,132 - 147,mmol/L +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,CHEMISTRY PANEL,Serum Potassium,,4.4,,,,,3.5 - 5.2,mmol/L +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,CHEMISTRY PANEL,Serum Bicarbonate,,19.7,,,,,19.3 - 29.3,mmol/L +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,CHEMISTRY PANEL,Serum Chloride,,104,,,,,94 - 112,mmol/L +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,161,,,,,127 - 181,g/L +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.47,,,,,0.39 - 0.54, +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.9,,,,,4.5 - 6.4,TI/L +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,96,,,,,79 - 96,fL +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,9.90,,,,,3.8 - 10.7,GI/L +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,6.20,,,,,1.96 - 7.23,GI/L +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.94,,,,,0.91 - 4.28,GI/L +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.58,,,,,0.12 - 0.92,GI/L +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.13,,,,,0 - 0.57,GI/L +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.03,,,,,0 - 0.2,GI/L +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,62.7,,,,,40.5 - 75,% +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,29.8,,,,,15.4 - 48.5,% +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.9,,,,,2.6 - 10.1,% +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.3,,,,,0 - 6.8,% +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.3,,,,,0 - 2,% +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,259,,,,,140 - 400,GI/L +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.5,,,,,<6.5 %, +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,14.04,,,,,1.9 - 23,uIU/mL +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,LIPID PANEL,Direct HDL-C 4th Generation,,1.20,,,,,1.03 - 1.53,mmol/L +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,LIPID PANEL,Triglycerides (GPO),,2.38,,,,,0.65 - 3.61,mmol/L +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,LIPID PANEL,Cholesterol (High Performance),,6.59,,,,,4.4 - 7.53,mmol/L +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,LIPID PANEL,LDL Chol Friedewald 4th,,4.30,,H,,,0 - 3.34,mmol/L +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,RETICULOCYTES,Reticulocyte Count %,,1.1,,,,,0.6 - 2.5,% +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,TSH,TSH 3rd IS-QT,,1.196,,,,,0.45 - 5.33,mIU/L +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,URINE MACRO PANEL,Ur Specific Gravity,,1.019,,,,,1 - 1.04, +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:Negative, +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,URINE MACRO PANEL,Ur Leukocyte Esterase,,Trace,R,H,,,Ref Rng:Negative, +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,URINE MICRO PANEL,Ur Microscopic,,Positive,,,,, NEGATIVE$,NEGATIVE +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,C-REACTIVE PROTEIN,C Reactive Protein HS,,5.2,,H,,,0 - 5,mg/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,CHEMISTRY PANEL,Total Bilirubin,,7,,,,,3 - 21,umol/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.1,,,,,0 - 6.2,umol/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,CHEMISTRY PANEL,Alkaline Phosphatase,,54,,,,,40 - 129,U/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,CHEMISTRY PANEL,ALT (SGPT),,30,,,,,5 - 48,U/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,CHEMISTRY PANEL,AST (SGOT),,25,,,,,8 - 40,U/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,CHEMISTRY PANEL,GGT,,42,,,,,10 - 61,U/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,CHEMISTRY PANEL,LDH,,169,,,,,53 - 234,U/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,CHEMISTRY PANEL,Urea Nitrogen,,2.9,,,,,1.4 - 8.6,mmol/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,72,,,,,40 - 110,umol/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,CHEMISTRY PANEL,Glucose Fasting,,4.9,,,,,3.9 - 5.6,mmol/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,CHEMISTRY PANEL,Serum Uric Acid,,370,,,,,125 - 488,umol/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,CHEMISTRY PANEL,Calcium (EDTA),,2.49,,,,,2.07 - 2.64,mmol/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,CHEMISTRY PANEL,Phosphorus,,0.84,,,,,0.71 - 1.65,mmol/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,CHEMISTRY PANEL,Total Protein,,76,,,,,61 - 84,g/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,CHEMISTRY PANEL,Albumin-BCG,,50,,H,,,33 - 49,g/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,CHEMISTRY PANEL,Creatine Kinase,,127,,,,,39 - 308,U/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,CHEMISTRY PANEL,Serum Sodium,,142,,,,,132 - 147,mmol/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,CHEMISTRY PANEL,Serum Potassium,,4.2,,,,,3.5 - 5.2,mmol/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,CHEMISTRY PANEL,Serum Bicarbonate,,26.2,,,,,19.3 - 29.3,mmol/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,CHEMISTRY PANEL,Serum Chloride,,102,,,,,94 - 112,mmol/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,151,,,,,127 - 181,g/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.43,,,,,0.39 - 0.54, +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.1,,,,,4.5 - 6.4,TI/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,85,,,,,79 - 96,fL +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,4.86,,,,,3.8 - 10.7,GI/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.33,,,,,1.96 - 7.23,GI/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.05,,,,,0.91 - 4.28,GI/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.40,,,,,0.12 - 0.92,GI/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.06,,,,,0 - 0.57,GI/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.02,,,,,0 - 0.2,GI/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,48.0,,,,,40.5 - 75,% +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,42.2,,,,,15.4 - 48.5,% +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,8.2,,,,,2.6 - 10.1,% +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.2,,,,,0 - 6.8,% +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.5,,,,,0 - 2,% +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,189,,,,,140 - 400,GI/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.6,,,,,<6.5 %, +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,8.45,,,,,1.9 - 23,uIU/mL +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,LIPID PANEL,Direct HDL-C 4th Generation,,0.78,,L,,,1.03 - 1.53,mmol/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,LIPID PANEL,Triglycerides (GPO),,3.51,,,,,0.62 - 3.69,mmol/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,LIPID PANEL,Cholesterol (High Performance),,4.45,,,,,4.19 - 7.24,mmol/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,LIPID PANEL,LDL Chol Friedewald 4th,,2.06,,,,,0 - 3.34,mmol/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,RETICULOCYTES,Reticulocyte Count %,,1.1,,,,,0.6 - 2.5,% +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,TSH,TSH 3rd IS-QT,,1.040,,,,,0.45 - 5.33,mIU/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,URINE MACRO PANEL,Ur Specific Gravity,,1.033,,,,,1 - 1.04, +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,URINE MACRO PANEL,Ur pH,,7.0,,,,,5 - 8, +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,URINE MACRO PANEL,Ur Protein,,Trace,,H,,,Ref Rng:Negative, +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,URINE MACRO PANEL,Ur Urobilinogen,,+2,,H,,,Ref Rng:Normal, +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:Negative, +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,URINE MICRO PANEL,Ur Microscopic,,Negative,,,,, NEGATIVE$,NEGATIVE +CZ100080007,,,40,years,Male,Retest,,"Feb 18, 2026 10:35 AM",6226785739,CHEMISTRY PANEL,Total Bilirubin,,4,,,,,3 - 21,umol/L +CZ100080007,,,40,years,Male,Retest,,"Feb 18, 2026 10:35 AM",6226785739,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,1.8,,,,,0 - 6.2,umol/L +CZ100080007,,,40,years,Male,Retest,,"Feb 18, 2026 10:35 AM",6226785739,CHEMISTRY PANEL,Alkaline Phosphatase,,52,,,,,40 - 129,U/L +CZ100080007,,,40,years,Male,Retest,,"Feb 18, 2026 10:35 AM",6226785739,CHEMISTRY PANEL,ALT (SGPT),,26,,,,,5 - 48,U/L +CZ100080007,,,40,years,Male,Retest,,"Feb 18, 2026 10:35 AM",6226785739,CHEMISTRY PANEL,AST (SGOT),,22,,,,,8 - 40,U/L +CZ100080007,,,40,years,Male,Retest,,"Feb 18, 2026 10:35 AM",6226785739,CHEMISTRY PANEL,GGT,,49,,,,,10 - 61,U/L +CZ100080007,,,40,years,Male,Retest,,"Feb 18, 2026 10:35 AM",6226785739,CHEMISTRY PANEL,LDH,,143,,,,,53 - 234,U/L +CZ100080007,,,40,years,Male,Retest,,"Feb 18, 2026 10:35 AM",6226785739,CHEMISTRY PANEL,Urea Nitrogen,,4.2,,,,,1.4 - 8.6,mmol/L +CZ100080007,,,40,years,Male,Retest,,"Feb 18, 2026 10:35 AM",6226785739,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,77,,,,,40 - 110,umol/L +CZ100080007,,,40,years,Male,Retest,,"Feb 18, 2026 10:35 AM",6226785739,CHEMISTRY PANEL,Glucose Fasting,,5.7,,H,,,3.9 - 5.6,mmol/L +CZ100080007,,,40,years,Male,Retest,,"Feb 18, 2026 10:35 AM",6226785739,CHEMISTRY PANEL,Serum Uric Acid,,359,,,,,125 - 488,umol/L +CZ100080007,,,40,years,Male,Retest,,"Feb 18, 2026 10:35 AM",6226785739,CHEMISTRY PANEL,Calcium (EDTA),,2.57,,,,,2.07 - 2.64,mmol/L +CZ100080007,,,40,years,Male,Retest,,"Feb 18, 2026 10:35 AM",6226785739,CHEMISTRY PANEL,Phosphorus,,0.64,,LT,,Result verified by repeat analysis,0.71 - 1.65,mmol/L +CZ100080007,,,40,years,Male,Retest,,"Feb 18, 2026 10:35 AM",6226785739,CHEMISTRY PANEL,Total Protein,,78,,,,,61 - 84,g/L +CZ100080007,,,40,years,Male,Retest,,"Feb 18, 2026 10:35 AM",6226785739,CHEMISTRY PANEL,Albumin-BCG,,51,,H,,,33 - 49,g/L +CZ100080007,,,40,years,Male,Retest,,"Feb 18, 2026 10:35 AM",6226785739,CHEMISTRY PANEL,Creatine Kinase,,102,,,,,39 - 308,U/L +CZ100080007,,,40,years,Male,Retest,,"Feb 18, 2026 10:35 AM",6226785739,CHEMISTRY PANEL,Serum Sodium,,143,,,,,132 - 147,mmol/L +CZ100080007,,,40,years,Male,Retest,,"Feb 18, 2026 10:35 AM",6226785739,CHEMISTRY PANEL,Serum Potassium,,4.3,,,,,3.5 - 5.2,mmol/L +CZ100080007,,,40,years,Male,Retest,,"Feb 18, 2026 10:35 AM",6226785739,CHEMISTRY PANEL,Serum Bicarbonate,,25.8,,,,,19.3 - 29.3,mmol/L +CZ100080007,,,40,years,Male,Retest,,"Feb 18, 2026 10:35 AM",6226785739,CHEMISTRY PANEL,Serum Chloride,,103,,,,,94 - 112,mmol/L +CZ100080007,,,40,years,Male,Retest,,"Feb 18, 2026 10:35 AM",6226785739,CREATININE CLEARANCE CC&G,CreatininClearancCockcrftGault,,2.27,,H,,,1.42 - 2.08,mL/sec +CZ100080007,,,40,years,Male,Retest,,"Feb 18, 2026 10:35 AM",6226785739,CREATININE CLEARANCE CC&G,Creatinine(Rate Blanked)-2dp,,77,,,,,40 - 110,umol/L +CZ100080007,,,40,years,Male,Retest,,"Feb 18, 2026 10:35 AM",6226785739,CREATININE CLEARANCE CC&G,"Weight (kg,1dec place)",Y,85.4,,,,,kg, +CZ100080007,,,40,years,Male,Retest,,"Feb 18, 2026 10:35 AM",6226785739,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,C-REACTIVE PROTEIN,C Reactive Protein HS,,0.2,,,,Result verified by repeat analysis,0 - 5,mg/L +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,CHEMISTRY PANEL,Total Bilirubin,,6,,,,,3 - 21,umol/L +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.1,,,,,0 - 6.2,umol/L +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,CHEMISTRY PANEL,Alkaline Phosphatase,,54,,,,,40 - 129,U/L +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,CHEMISTRY PANEL,ALT (SGPT),,35,,,,,5 - 48,U/L +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,CHEMISTRY PANEL,AST (SGOT),,23,,,,,8 - 40,U/L +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,CHEMISTRY PANEL,GGT,,54,,,,,10 - 61,U/L +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,CHEMISTRY PANEL,LDH,,155,,,,,53 - 234,U/L +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,CHEMISTRY PANEL,Urea Nitrogen,,2.6,,,,,1.4 - 8.6,mmol/L +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,81,,,,,40 - 110,umol/L +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,CHEMISTRY PANEL,Glucose Fasting,,5.2,,,,,3.9 - 5.6,mmol/L +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,CHEMISTRY PANEL,Serum Uric Acid,,385,,,,,125 - 488,umol/L +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,CHEMISTRY PANEL,Calcium (EDTA),,2.59,,,,,2.07 - 2.64,mmol/L +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,CHEMISTRY PANEL,Phosphorus,,0.57,,LT,,Result verified by repeat analysis,0.71 - 1.65,mmol/L +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,CHEMISTRY PANEL,Total Protein,,79,,,,,61 - 84,g/L +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,CHEMISTRY PANEL,Albumin-BCG,,51,,H,,,33 - 49,g/L +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,CHEMISTRY PANEL,Creatine Kinase,,110,,,,,39 - 308,U/L +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,CHEMISTRY PANEL,Serum Sodium,,141,,,,,132 - 147,mmol/L +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,CHEMISTRY PANEL,Serum Potassium,,4.7,,,,,3.5 - 5.2,mmol/L +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,CHEMISTRY PANEL,Serum Bicarbonate,,26.8,,,,,19.3 - 29.3,mmol/L +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,CHEMISTRY PANEL,Serum Chloride,,101,,,,,94 - 112,mmol/L +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,160,,,,,127 - 181,g/L +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.47,,,,,0.39 - 0.54, +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.5,,,,,4.5 - 6.4,TI/L +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,86,,,,,79 - 96,fL +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,6.67,,,,,3.8 - 10.7,GI/L +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.99,,,,,1.96 - 7.23,GI/L +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.20,,,,,0.91 - 4.28,GI/L +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.45,,,,,0.12 - 0.92,GI/L +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.03,,,,,0 - 0.57,GI/L +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.01,,,,,0 - 0.2,GI/L +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,59.8,,,,,40.5 - 75,% +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,32.9,,,,,15.4 - 48.5,% +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,6.7,,,,,2.6 - 10.1,% +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,0.4,,,,,0 - 6.8,% +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.2,,,,,0 - 2,% +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,185,,,,,140 - 400,GI/L +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,9.79,,,,,1.9 - 23,uIU/mL +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,LIPID PANEL,Direct HDL-C 4th Generation,,0.84,,L,,,1.03 - 1.53,mmol/L +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,LIPID PANEL,Triglycerides (GPO),,3.38,,,,,0.62 - 3.69,mmol/L +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,LIPID PANEL,Cholesterol (High Performance),,4.73,,,,,4.19 - 7.24,mmol/L +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,LIPID PANEL,LDL Chol Friedewald 4th,,2.34,,,,,0 - 3.34,mmol/L +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,RETICULOCYTES,Reticulocyte Count %,,1.4,,,,,0.6 - 2.5,% +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,URINE MACRO PANEL,Ur Specific Gravity,,1.029,,,,,1 - 1.04, +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,URINE MACRO PANEL,Ur pH,,6.5,,,,,5 - 8, +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,URINE MACRO PANEL,Ur Protein,,Trace,,H,,,Ref Rng:Negative, +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:Negative, +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,URINE MICRO PANEL,Ur Microscopic,,Negative,,,,, NEGATIVE$,NEGATIVE +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.0,,,,,0 - 5,mg/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,CHEMISTRY PANEL,Total Bilirubin,,12,,,,,3 - 21,umol/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,4.1,,,,,0 - 6.2,umol/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,CHEMISTRY PANEL,Alkaline Phosphatase,,67,,,,,35 - 104,U/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,CHEMISTRY PANEL,ALT (SGPT),,19,,,,,4 - 43,U/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,CHEMISTRY PANEL,AST (SGOT),,25,,,,,8 - 40,U/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,CHEMISTRY PANEL,GGT,,40,,,,,4 - 49,U/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,CHEMISTRY PANEL,LDH,,180,,,,,53 - 234,U/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,CHEMISTRY PANEL,Urea Nitrogen,,2.4,,,,,1.4 - 8.6,mmol/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,57,,,,,31 - 101,umol/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,CHEMISTRY PANEL,Glucose Fasting,,5.3,,,,,3.9 - 5.6,mmol/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,CHEMISTRY PANEL,Serum Uric Acid,,222,,,,,149 - 446,umol/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,CHEMISTRY PANEL,Calcium (EDTA),,2.26,,,,,2.07 - 2.64,mmol/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,CHEMISTRY PANEL,Phosphorus,,0.82,,,,,0.71 - 1.65,mmol/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,CHEMISTRY PANEL,Total Protein,,66,,,,,61 - 84,g/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,CHEMISTRY PANEL,Albumin-BCG,,42,,,,,33 - 49,g/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,CHEMISTRY PANEL,Creatine Kinase,,83,,,,,26 - 192,U/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,CHEMISTRY PANEL,Serum Sodium,,137,,,,,132 - 147,mmol/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,CHEMISTRY PANEL,Serum Potassium,,4.2,,,,,3.5 - 5.2,mmol/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,CHEMISTRY PANEL,Serum Bicarbonate,,24.5,,,,,19.3 - 29.3,mmol/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,CHEMISTRY PANEL,Serum Chloride,,102,,,,,94 - 112,mmol/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,132,,,,,116 - 164,g/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.40,,,,,0.34 - 0.48, +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.1,,,,,4.1 - 5.6,TI/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,99,R,H,,,79 - 98,fL +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,4.87,,,,,3.8 - 10.7,GI/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.00,,,,,1.96 - 7.23,GI/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.51,,,,,0.91 - 4.28,GI/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.22,,,,,0.12 - 0.92,GI/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.12,,,,,0 - 0.57,GI/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.02,,,,,0 - 0.2,GI/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,61.6,,,,,40.5 - 75,% +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,30.9,,,,,15.4 - 48.5,% +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,4.6,,,,,2.6 - 10.1,% +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.4,,,,,0 - 6.8,% +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.5,,,,,0 - 2,% +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,281,,,,,140 - 400,GI/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.1,,,,,<6.5 %, +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,3.73,,,,,1.9 - 23,uIU/mL +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,LIPID PANEL,Direct HDL-C 4th Generation,,2.34,R,H,,,1.03 - 1.53,mmol/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,LIPID PANEL,Triglycerides (GPO),,1.13,,,,,0.59 - 2.96,mmol/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,LIPID PANEL,Cholesterol (High Performance),,5.38,,,,,4.42 - 7.53,mmol/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,LIPID PANEL,LDL Chol Friedewald 4th,,2.52,,,,,0 - 3.34,mmol/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,RETICULOCYTES,Reticulocyte Count %,,2.0,,,,,0.6 - 2.5,% +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,TSH,TSH 3rd IS-QT,,1.897,,,,,0.45 - 5.33,mIU/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,URINE MACRO PANEL,Ur Specific Gravity,,1.026,,,,,1 - 1.04, +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.7,,,,,0 - 5,mg/L +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,CHEMISTRY PANEL,Total Bilirubin,,8,,,,,3 - 21,umol/L +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.9,,,,,0 - 6.2,umol/L +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,CHEMISTRY PANEL,Alkaline Phosphatase,,68,,,,,35 - 104,U/L +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,CHEMISTRY PANEL,ALT (SGPT),,70,,H RX,,,4 - 43,U/L +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,CHEMISTRY PANEL,AST (SGOT),,56,,H,,,8 - 40,U/L +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,CHEMISTRY PANEL,GGT,,98,,H,,,5 - 50,U/L +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,CHEMISTRY PANEL,LDH,,188,,,,,53 - 234,U/L +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,CHEMISTRY PANEL,Urea Nitrogen,,2.1,,,,,1.4 - 8.6,mmol/L +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,52,,,,,31 - 101,umol/L +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,CHEMISTRY PANEL,Glucose Fasting,,4.4,,,,,3.9 - 5.6,mmol/L +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,CHEMISTRY PANEL,Serum Uric Acid,,419,,,,,149 - 446,umol/L +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,CHEMISTRY PANEL,Calcium (EDTA),,2.56,,,,,2.07 - 2.64,mmol/L +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,CHEMISTRY PANEL,Phosphorus,,1.05,,,,,0.71 - 1.65,mmol/L +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,CHEMISTRY PANEL,Total Protein,,77,,,,,60 - 80,g/L +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,CHEMISTRY PANEL,Albumin-BCG,,48,,,,,33 - 49,g/L +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,CHEMISTRY PANEL,Creatine Kinase,,109,,,,,26 - 192,U/L +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,CHEMISTRY PANEL,Serum Sodium,,138,,,,,135 - 145,mmol/L +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,CHEMISTRY PANEL,Serum Potassium,,4.2,,,,,3.5 - 5.2,mmol/L +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,CHEMISTRY PANEL,Serum Bicarbonate,,26.5,,,,,19.3 - 29.3,mmol/L +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,CHEMISTRY PANEL,Serum Chloride,,96,,,,,94 - 112,mmol/L +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,140,,,,,115 - 158,g/L +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.41,,,,,0.34 - 0.48, +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.0,,,,,3.9 - 5.5,TI/L +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,104,,H,,,80 - 100,fL +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,6.88,,,,,3.8 - 10.7,GI/L +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.64,,,,,1.96 - 7.23,GI/L +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.55,,,,,0.8 - 3,GI/L +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.51,,,,,0.12 - 0.92,GI/L +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.13,,,,,0 - 0.57,GI/L +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.04,,,,,0 - 0.2,GI/L +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,53.0,,,,,40.5 - 75,% +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,37.2,,,,,15.4 - 48.5,% +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,7.4,,,,,2.6 - 10.1,% +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.9,,,,,0 - 6.8,% +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.6,,,,,0 - 2,% +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,288,,,,,130 - 394,GI/L +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.6,,,,,<6.5 %, +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,2.19,,,,,1.9 - 23,uIU/mL +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,LIPID PANEL,Direct HDL-C 4th Generation,,1.60,,H,,,1.03 - 1.53,mmol/L +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,LIPID PANEL,Triglycerides (GPO),,1.16,,,,,0.63 - 2.71,mmol/L +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,LIPID PANEL,Cholesterol (High Performance),,3.65,,L,,,4.86 - 8.28,mmol/L +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,LIPID PANEL,LDL Chol Friedewald 4th,,1.52,,,,,0 - 3.34,mmol/L +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,MICROORGANISMS,Ur Bacteria,,Present,,,,,Ref Rng:Not present, +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,RETICULOCYTES,Reticulocyte Count %,,1.4,,,,,0.6 - 2.5,% +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,TSH,TSH 3rd IS-QT,,0.906,,,,,0.45 - 5.33,mIU/L +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,URINE MACRO PANEL,Ur Specific Gravity,,1.012,,,,,1.01 - 1.03, +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,URINE MACRO PANEL,Ur Ketones,,Trace,,H,,,Ref Rng:Negative, +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,URINE MICRO PANEL,Ur Microscopic,,Positive,,,,, NEGATIVE$,NEGATIVE +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,C-REACTIVE PROTEIN,C Reactive Protein HS,,3.0,,,,,0 - 5,mg/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,CELLULAR ELEMENTS,Ur WBC/HPF,,2,,,,,0 - 5,/HPF +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,CHEMISTRY PANEL,Total Bilirubin,,5,,,,,3 - 21,umol/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.1,,,,,0 - 6.2,umol/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,CHEMISTRY PANEL,Alkaline Phosphatase,,67,,,,,40 - 129,U/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,CHEMISTRY PANEL,ALT (SGPT),,15,,,,,5 - 48,U/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,CHEMISTRY PANEL,AST (SGOT),,20,,,,,8 - 40,U/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,CHEMISTRY PANEL,GGT,,30,,,,,10 - 61,U/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,CHEMISTRY PANEL,LDH,,161,,,,,53 - 234,U/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,CHEMISTRY PANEL,Urea Nitrogen,,5.1,,,,,1.4 - 8.6,mmol/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,83,,,,,40 - 119,umol/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,CHEMISTRY PANEL,Glucose Fasting,,6.8,,H,,,3.9 - 5.6,mmol/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,CHEMISTRY PANEL,Serum Uric Acid,,297,,,,,149 - 494,umol/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,CHEMISTRY PANEL,Calcium (EDTA),,2.40,,,,,2.07 - 2.64,mmol/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,CHEMISTRY PANEL,Phosphorus,,1.06,,,,,0.71 - 1.65,mmol/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,CHEMISTRY PANEL,Total Protein,,72,,,,,61 - 84,g/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,CHEMISTRY PANEL,Albumin-BCG,,44,,,,,33 - 49,g/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,CHEMISTRY PANEL,Creatine Kinase,,63,,,,,39 - 308,U/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,CHEMISTRY PANEL,Serum Sodium,,140,,,,,132 - 147,mmol/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,CHEMISTRY PANEL,Serum Potassium,,4.8,,,,,3.5 - 5.2,mmol/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,CHEMISTRY PANEL,Serum Bicarbonate,,21.1,,,,,19.3 - 29.3,mmol/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,CHEMISTRY PANEL,Serum Chloride,,105,,,,,94 - 112,mmol/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,157,,,,,127 - 181,g/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.48,,,,,0.39 - 0.54, +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.8,,,,,4.5 - 6.4,TI/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,100,,H,,,79 - 96,fL +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,8.88,,,,,3.8 - 10.7,GI/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,5.58,,,,,1.96 - 7.23,GI/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.46,,,,,0.91 - 4.28,GI/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.59,,,,,0.12 - 0.92,GI/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.19,,,,,0 - 0.57,GI/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.06,,,,,0 - 0.2,GI/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,62.8,,,,,40.5 - 75,% +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,27.7,,,,,15.4 - 48.5,% +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,6.7,,,,,2.6 - 10.1,% +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.2,,,,,0 - 6.8,% +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.7,,,,,0 - 2,% +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,243,,,,,140 - 400,GI/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.5,,,,,<6.5 %, +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,35.89,,H,,,1.9 - 23,uIU/mL +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,LIPID PANEL,Direct HDL-C 4th Generation,,1.18,,,,,1.03 - 1.53,mmol/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,LIPID PANEL,Triglycerides (GPO),,2.11,,,,,0.65 - 3.61,mmol/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,LIPID PANEL,Cholesterol (High Performance),,5.10,,,,,4.4 - 7.53,mmol/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,LIPID PANEL,LDL Chol Friedewald 4th,,2.95,,,,,0 - 3.34,mmol/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,RETICULOCYTES,Reticulocyte Count %,,1.6,,,,,0.6 - 2.5,% +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,TSH,TSH 3rd IS-QT,,0.729,,,,,0.45 - 5.33,mIU/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,URINE MACRO PANEL,Ur Specific Gravity,,1.030,,,,,1 - 1.04, +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,URINE MACRO PANEL,Ur Protein,,Trace,,H,,,Ref Rng:Negative, +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:Negative, +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,URINE MICRO PANEL,Ur Microscopic,,Positive,,,,, NEGATIVE$,NEGATIVE +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,C-REACTIVE PROTEIN,C Reactive Protein HS,,0.5,,,,,0 - 5,mg/L +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,CHEMISTRY PANEL,Total Bilirubin,,13,,,,,3 - 21,umol/L +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,4.0,,,,,0 - 6.2,umol/L +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,CHEMISTRY PANEL,Alkaline Phosphatase,,72,,,,,35 - 104,U/L +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,CHEMISTRY PANEL,ALT (SGPT),,18,,,,,4 - 43,U/L +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,CHEMISTRY PANEL,AST (SGOT),,24,,,,,8 - 40,U/L +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,CHEMISTRY PANEL,GGT,,40,,,,,4 - 49,U/L +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,CHEMISTRY PANEL,LDH,,177,,,,,53 - 234,U/L +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,CHEMISTRY PANEL,Urea Nitrogen,,3.9,,,,,1.4 - 8.6,mmol/L +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,68,,,,,31 - 101,umol/L +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,CHEMISTRY PANEL,Glucose Fasting,,5.1,,,,,3.9 - 5.6,mmol/L +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,CHEMISTRY PANEL,Serum Uric Acid,,398,,,,,149 - 446,umol/L +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,CHEMISTRY PANEL,Calcium (EDTA),,2.49,,,,,2.07 - 2.64,mmol/L +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,CHEMISTRY PANEL,Phosphorus,,0.96,,,,,0.71 - 1.65,mmol/L +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,CHEMISTRY PANEL,Total Protein,,76,,,,,61 - 84,g/L +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,CHEMISTRY PANEL,Albumin-BCG,,44,,,,,33 - 49,g/L +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,CHEMISTRY PANEL,Creatine Kinase,,73,,,,,26 - 192,U/L +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,CHEMISTRY PANEL,Serum Sodium,,139,,,,,132 - 147,mmol/L +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,CHEMISTRY PANEL,Serum Potassium,,4.5,,,,,3.5 - 5.2,mmol/L +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,CHEMISTRY PANEL,Serum Bicarbonate,,22.1,,,,,19.3 - 29.3,mmol/L +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,CHEMISTRY PANEL,Serum Chloride,,98,,,,,94 - 112,mmol/L +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,149,,,,,116 - 164,g/L +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.45,,,,,0.34 - 0.48, +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.7,,,,,4.1 - 5.6,TI/L +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,97,,,,,79 - 98,fL +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,6.74,,,,,3.8 - 10.7,GI/L +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,4.11,,,,,1.96 - 7.23,GI/L +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.22,,,,,0.91 - 4.28,GI/L +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.27,,,,,0.12 - 0.92,GI/L +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.08,,,,,0 - 0.57,GI/L +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.05,,,,,0 - 0.2,GI/L +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,61.0,,,,,40.5 - 75,% +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,33.1,,,,,15.4 - 48.5,% +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,4.0,,,,,2.6 - 10.1,% +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.2,,,,,0 - 6.8,% +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.8,,,,,0 - 2,% +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,564,,H,,,140 - 400,GI/L +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,2.03,,,,,1.9 - 23,uIU/mL +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,LIPID PANEL,Direct HDL-C 4th Generation,,2.53,,H,,Result verified by repeat analysis,1.03 - 1.53,mmol/L +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,LIPID PANEL,Triglycerides (GPO),,2.65,,,,,0.59 - 2.96,mmol/L +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,LIPID PANEL,Cholesterol (High Performance),,5.29,,,,,4.42 - 7.53,mmol/L +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,LIPID PANEL,LDL Chol Friedewald 4th,,1.55,,,,,0 - 3.34,mmol/L +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,RETICULOCYTES,Reticulocyte Count %,,1.3,,,,,0.6 - 2.5,% +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,URINE MACRO PANEL,Ur Specific Gravity,,1.020,,,,,1 - 1.04, +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,URINE MACRO PANEL,Ur pH,,6.5,,,,,5 - 8, +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100080007,,,40,years,Male,Retest,,"Dec 15, 2025 10:53 AM",6226785740,C-REACTIVE PROTEIN,C Reactive Protein HS,,0.2,,,,Result verified by repeat analysis,0 - 5,mg/L +CZ100080007,,,40,years,Male,Retest,,"Dec 15, 2025 10:53 AM",6226785740,CHEMISTRY PANEL,Total Bilirubin,,7,,,,,3 - 21,umol/L +CZ100080007,,,40,years,Male,Retest,,"Dec 15, 2025 10:53 AM",6226785740,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.3,,,,,0 - 6.2,umol/L +CZ100080007,,,40,years,Male,Retest,,"Dec 15, 2025 10:53 AM",6226785740,CHEMISTRY PANEL,Alkaline Phosphatase,,57,,,,,40 - 129,U/L +CZ100080007,,,40,years,Male,Retest,,"Dec 15, 2025 10:53 AM",6226785740,CHEMISTRY PANEL,ALT (SGPT),,26,,,,,5 - 48,U/L +CZ100080007,,,40,years,Male,Retest,,"Dec 15, 2025 10:53 AM",6226785740,CHEMISTRY PANEL,AST (SGOT),,21,,,,,8 - 40,U/L +CZ100080007,,,40,years,Male,Retest,,"Dec 15, 2025 10:53 AM",6226785740,CHEMISTRY PANEL,GGT,,44,,,,,10 - 61,U/L +CZ100080007,,,40,years,Male,Retest,,"Dec 15, 2025 10:53 AM",6226785740,CHEMISTRY PANEL,LDH,,173,,,,,53 - 234,U/L +CZ100080007,,,40,years,Male,Retest,,"Dec 15, 2025 10:53 AM",6226785740,CHEMISTRY PANEL,Urea Nitrogen,,4.0,,,,,1.4 - 8.6,mmol/L +CZ100080007,,,40,years,Male,Retest,,"Dec 15, 2025 10:53 AM",6226785740,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,78,,,,,40 - 110,umol/L +CZ100080007,,,40,years,Male,Retest,,"Dec 15, 2025 10:53 AM",6226785740,CHEMISTRY PANEL,Glucose Fasting,,5.4,,,,,3.9 - 5.6,mmol/L +CZ100080007,,,40,years,Male,Retest,,"Dec 15, 2025 10:53 AM",6226785740,CHEMISTRY PANEL,Serum Uric Acid,,379,,,,,125 - 488,umol/L +CZ100080007,,,40,years,Male,Retest,,"Dec 15, 2025 10:53 AM",6226785740,CHEMISTRY PANEL,Calcium (EDTA),,2.62,,,,,2.07 - 2.64,mmol/L +CZ100080007,,,40,years,Male,Retest,,"Dec 15, 2025 10:53 AM",6226785740,CHEMISTRY PANEL,Phosphorus,,0.80,,,,,0.71 - 1.65,mmol/L +CZ100080007,,,40,years,Male,Retest,,"Dec 15, 2025 10:53 AM",6226785740,CHEMISTRY PANEL,Total Protein,,84,,,,,61 - 84,g/L +CZ100080007,,,40,years,Male,Retest,,"Dec 15, 2025 10:53 AM",6226785740,CHEMISTRY PANEL,Albumin-BCG,,53,,H,,,33 - 49,g/L +CZ100080007,,,40,years,Male,Retest,,"Dec 15, 2025 10:53 AM",6226785740,CHEMISTRY PANEL,Creatine Kinase,,108,,,,,39 - 308,U/L +CZ100080007,,,40,years,Male,Retest,,"Dec 15, 2025 10:53 AM",6226785740,CHEMISTRY PANEL,Serum Sodium,,145,,,,,132 - 147,mmol/L +CZ100080007,,,40,years,Male,Retest,,"Dec 15, 2025 10:53 AM",6226785740,CHEMISTRY PANEL,Serum Potassium,,4.2,,,,,3.5 - 5.2,mmol/L +CZ100080007,,,40,years,Male,Retest,,"Dec 15, 2025 10:53 AM",6226785740,CHEMISTRY PANEL,Serum Bicarbonate,,23.4,,,,,19.3 - 29.3,mmol/L +CZ100080007,,,40,years,Male,Retest,,"Dec 15, 2025 10:53 AM",6226785740,CHEMISTRY PANEL,Serum Chloride,,102,,,,,94 - 112,mmol/L +CZ100080007,,,40,years,Male,Retest,,"Dec 15, 2025 10:53 AM",6226785740,CREATININE CLEARANCE CC&G,CreatininClearancCockcrftGault,,2.31,,H,,,1.42 - 2.08,mL/sec +CZ100080007,,,40,years,Male,Retest,,"Dec 15, 2025 10:53 AM",6226785740,CREATININE CLEARANCE CC&G,Creatinine(Rate Blanked)-2dp,,78,,,,,40 - 110,umol/L +CZ100080007,,,40,years,Male,Retest,,"Dec 15, 2025 10:53 AM",6226785740,CREATININE CLEARANCE CC&G,"Weight (kg,1dec place)",Y,87.0,,,,,kg, +CZ100080007,,,40,years,Male,Retest,,"Dec 15, 2025 10:53 AM",6226785740,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100080007,,,40,years,Male,Retest,,"Dec 15, 2025 10:53 AM",6226785740,LIPID PANEL,Direct HDL-C 4th Generation,,0.94,,L,,,1.03 - 1.53,mmol/L +CZ100080007,,,40,years,Male,Retest,,"Dec 15, 2025 10:53 AM",6226785740,LIPID PANEL,Triglycerides (GPO),,2.31,,,,,0.56 - 3.62,mmol/L +CZ100080007,,,40,years,Male,Retest,,"Dec 15, 2025 10:53 AM",6226785740,LIPID PANEL,Cholesterol (High Performance),,5.76,,,,,3.88 - 6.83,mmol/L +CZ100080007,,,40,years,Male,Retest,,"Dec 15, 2025 10:53 AM",6226785740,LIPID PANEL,LDL Chol Friedewald 4th,,3.76,,H,,,0 - 3.34,mmol/L +CZ100080007,,,40,years,Male,Retest,,"Dec 15, 2025 10:53 AM",6226785740,TSH,TSH 3rd IS-QT,,1.044,,,,,0.45 - 5.33,mIU/L +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,C-REACTIVE PROTEIN,C Reactive Protein HS,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,CHEMISTRY PANEL,Total Bilirubin,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,CHEMISTRY PANEL,Alkaline Phosphatase,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,CHEMISTRY PANEL,ALT (SGPT),,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,CHEMISTRY PANEL,AST (SGOT),,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,CHEMISTRY PANEL,GGT,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,CHEMISTRY PANEL,LDH,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,CHEMISTRY PANEL,Urea Nitrogen,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,CHEMISTRY PANEL,Glucose Fasting,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,CHEMISTRY PANEL,Serum Uric Acid,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,CHEMISTRY PANEL,Calcium (EDTA),,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,CHEMISTRY PANEL,Phosphorus,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,CHEMISTRY PANEL,Total Protein,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,CHEMISTRY PANEL,Albumin-BCG,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,CHEMISTRY PANEL,Creatine Kinase,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,CHEMISTRY PANEL,Serum Sodium,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,CHEMISTRY PANEL,Serum Potassium,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,CHEMISTRY PANEL,Serum Bicarbonate,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,CHEMISTRY PANEL,Serum Chloride,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,CREATININE CLEARANCE CC&G,CreatininClearancCockcrftGault,,Required testing unavailable,,,,,1.42 - 2.08,mL/sec +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,CREATININE CLEARANCE CC&G,Creatinine(Rate Blanked)-2dp,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,CREATININE CLEARANCE CC&G,"Weight (kg,1dec place)",Y,87.0,,,,,kg, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,DRUG SCREEN URINE,Amphetamines/MDMA,,Neg,,,,,Neg;$Cutoff = 1000 ng/mL, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,DRUG SCREEN URINE,Barbiturates,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,DRUG SCREEN URINE,Cannabinoids,,Neg,,,,,Neg;$Cutoff = 50 ng/mL, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,DRUG SCREEN URINE,Cocaine,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,DRUG SCREEN URINE,Opiates,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,DRUG SCREEN URINE,Methadone,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,DRUG SCREEN URINE BENZO NON-US,Benzodiazepines Gen 2,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,GFR,EGFR by MDRD,,Required testing unavailable,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,151,,,,,127 - 181,g/L +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.44,,,,,0.39 - 0.54, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.2,,,,,4.5 - 6.4,TI/L +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,86,,,,,79 - 96,fL +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,6.79,,,,,3.8 - 10.7,GI/L +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,4.23,,,,,1.96 - 7.23,GI/L +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.09,,,,,0.91 - 4.28,GI/L +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.41,,,,,0.12 - 0.92,GI/L +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.03,,,,,0 - 0.57,GI/L +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.02,,,,,0 - 0.2,GI/L +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,62.4,,,,,40.5 - 75,% +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,30.8,,,,,15.4 - 48.5,% +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,6.0,,,,,2.6 - 10.1,% +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,0.5,,,,,0 - 6.8,% +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.3,,,,,0 - 2,% +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,207,,,,,140 - 400,GI/L +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.5,,,,,<6.5 %, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,15.62,,,,,1.9 - 23,uIU/mL +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,IS SUBJECT OF BLACK RACE?,Subject of black race?,Y,No,,,,,, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,LIPID PANEL,Direct HDL-C 4th Generation,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,LIPID PANEL,Triglycerides (GPO),,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,LIPID PANEL,Cholesterol (High Performance),,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,LIPID PANEL,LDL Chol Friedewald 4th,,Required testing unavailable,,,,,0 - 3.34,mmol/L +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,RETICULOCYTES,Reticulocyte Count %,,1.6,,,,,0.6 - 2.5,% +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,TSH,TSH 3rd IS-QT,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,URINE MACRO PANEL,Ur Specific Gravity,,1.032,,,,,1 - 1.04, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,URINE MACRO PANEL,Ur pH,,7.0,,,,,5 - 8, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,URINE MACRO PANEL,Ur Protein,,Trace,,H,,,Ref Rng:Negative, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:Negative, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,URINE MICRO PANEL,Ur Microscopic,,Negative,,,,, NEGATIVE$,NEGATIVE +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,C-REACTIVE PROTEIN,C Reactive Protein HS,,7.3,,H,,,0 - 5,mg/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,CELLULAR ELEMENTS,Ur RBC/HPF,,2,,,,,0 - 3,/HPF +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,CELLULAR ELEMENTS,Ur WBC/HPF,,7,,H,,,0 - 5,/HPF +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,CHEMISTRY PANEL,Total Bilirubin,,8,,,,,3 - 21,umol/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.0,,,,,0 - 6.2,umol/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,CHEMISTRY PANEL,Alkaline Phosphatase,,58,,,,,40 - 129,U/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,CHEMISTRY PANEL,ALT (SGPT),,15,,,,,5 - 48,U/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,CHEMISTRY PANEL,AST (SGOT),,21,,,,,8 - 40,U/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,CHEMISTRY PANEL,GGT,,26,,,,,10 - 61,U/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,CHEMISTRY PANEL,LDH,,171,,,,,53 - 234,U/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,CHEMISTRY PANEL,Urea Nitrogen,,5.4,,,,,1.4 - 8.6,mmol/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,86,,,,,40 - 119,umol/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,CHEMISTRY PANEL,Glucose Fasting,,6.0,,H,,,3.9 - 5.6,mmol/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,CHEMISTRY PANEL,Serum Uric Acid,,317,,,,,149 - 494,umol/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,CHEMISTRY PANEL,Calcium (EDTA),,2.26,,,,,2.07 - 2.64,mmol/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,CHEMISTRY PANEL,Phosphorus,,0.98,,,,,0.71 - 1.65,mmol/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,CHEMISTRY PANEL,Total Protein,,68,,,,,61 - 84,g/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,CHEMISTRY PANEL,Albumin-BCG,,43,,,,,33 - 49,g/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,CHEMISTRY PANEL,Creatine Kinase,,76,,,,,39 - 308,U/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,CHEMISTRY PANEL,Serum Sodium,,139,,,,,132 - 147,mmol/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,CHEMISTRY PANEL,Serum Potassium,,4.3,,,,,3.5 - 5.2,mmol/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,CHEMISTRY PANEL,Serum Bicarbonate,,25.0,,,,,19.3 - 29.3,mmol/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,CHEMISTRY PANEL,Serum Chloride,,103,,,,,94 - 112,mmol/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,CRYSTALS,Ur Calcium Oxalate Crystals,,Present,,,,,Ref Rng:Not present, +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,154,,,,,127 - 181,g/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.47,,,,,0.39 - 0.54, +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.7,,,,,4.5 - 6.4,TI/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,99,,H,,,79 - 96,fL +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,9.00,,,,,3.8 - 10.7,GI/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,6.16,,,,,1.96 - 7.23,GI/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.99,,,,,0.91 - 4.28,GI/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.71,,,,,0.12 - 0.92,GI/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.11,,,,,0 - 0.57,GI/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.02,,,,,0 - 0.2,GI/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,68.4,,,,,40.5 - 75,% +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,22.2,,,,,15.4 - 48.5,% +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,7.9,,,,,2.6 - 10.1,% +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.3,,,,,0 - 6.8,% +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.2,,,,,0 - 2,% +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,256,,,,,140 - 400,GI/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.5,,,,,<6.5 %, +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,11.88,,,,,1.9 - 23,uIU/mL +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,LIPID PANEL,Direct HDL-C 4th Generation,,1.07,,,,,1.03 - 1.53,mmol/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,LIPID PANEL,Triglycerides (GPO),,1.52,,,,,0.65 - 3.61,mmol/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,LIPID PANEL,Cholesterol (High Performance),,4.74,,,,,4.4 - 7.53,mmol/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,LIPID PANEL,LDL Chol Friedewald 4th,,2.97,,,,,0 - 3.34,mmol/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,MISCELLANEOUS ELEMENTS,Ur Mucous,,Present,,,,,Ref Rng:Not present, +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,MISCELLANEOUS ELEMENTS,Ur Sperm,,Present,,,,,Ref Rng:Not present, +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,RETICULOCYTES,Reticulocyte Count %,,1.3,,,,,0.6 - 2.5,% +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,TSH,TSH 3rd IS-QT,,0.706,,,,,0.45 - 5.33,mIU/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,URINE MACRO PANEL,Ur Specific Gravity,,1.032,,,,,1 - 1.04, +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,URINE MACRO PANEL,Ur Protein,,Trace,,H,,,Ref Rng:Negative, +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:Negative, +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,URINE MACRO PANEL,Ur Leukocyte Esterase,,Trace,,H,,,Ref Rng:Negative, +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,URINE MICRO PANEL,Ur Microscopic,,Positive,,,,, NEGATIVE$,NEGATIVE +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,C-REACTIVE PROTEIN,C Reactive Protein HS,,0.6,,,,,0 - 5,mg/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,CHEMISTRY PANEL,Total Bilirubin,,9,,,,,3 - 21,umol/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.8,,,,,0 - 6.2,umol/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,CHEMISTRY PANEL,Alkaline Phosphatase,,63,,,,,35 - 104,U/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,CHEMISTRY PANEL,ALT (SGPT),,18,,,,,4 - 43,U/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,CHEMISTRY PANEL,AST (SGOT),,19,,,,,8 - 40,U/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,CHEMISTRY PANEL,GGT,,31,,,,,4 - 49,U/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,CHEMISTRY PANEL,LDH,,166,,,,,53 - 234,U/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,CHEMISTRY PANEL,Urea Nitrogen,,2.9,,,,,1.4 - 8.6,mmol/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,58,,,,,31 - 101,umol/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,CHEMISTRY PANEL,Glucose Fasting,,5.2,,,,,3.9 - 5.6,mmol/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,CHEMISTRY PANEL,Serum Uric Acid,,189,,,,,149 - 446,umol/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,CHEMISTRY PANEL,Calcium (EDTA),,2.33,,,,,2.07 - 2.64,mmol/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,CHEMISTRY PANEL,Phosphorus,,0.99,,,,,0.71 - 1.65,mmol/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,CHEMISTRY PANEL,Total Protein,,65,,,,,61 - 84,g/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,CHEMISTRY PANEL,Albumin-BCG,,41,,,,,33 - 49,g/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,CHEMISTRY PANEL,Creatine Kinase,,77,,,,,26 - 192,U/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,CHEMISTRY PANEL,Serum Sodium,,139,,,,,132 - 147,mmol/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,CHEMISTRY PANEL,Serum Potassium,,4.4,,,,,3.5 - 5.2,mmol/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,CHEMISTRY PANEL,Serum Bicarbonate,,23.4,,,,,19.3 - 29.3,mmol/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,CHEMISTRY PANEL,Serum Chloride,,104,,,,,94 - 112,mmol/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,134,,,,,116 - 164,g/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.41,,,,,0.34 - 0.48, +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.2,,,,,4.1 - 5.6,TI/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,97,,,,,79 - 98,fL +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,5.79,,,,,3.8 - 10.7,GI/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.69,,,,,1.96 - 7.23,GI/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.52,,,,,0.91 - 4.28,GI/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.40,,,,,0.12 - 0.92,GI/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.14,,,,,0 - 0.57,GI/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.03,,,,,0 - 0.2,GI/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,63.7,,,,,40.5 - 75,% +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,26.3,,,,,15.4 - 48.5,% +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,6.9,,,,,2.6 - 10.1,% +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.5,,,,,0 - 6.8,% +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.6,,,,,0 - 2,% +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,402,,H,,,140 - 400,GI/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.4,,,,,<6.5 %, +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,3.90,,,,,1.9 - 23,uIU/mL +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,LIPID PANEL,Direct HDL-C 4th Generation,,1.98,,H,,,1.03 - 1.53,mmol/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,LIPID PANEL,Triglycerides (GPO),,1.65,,,,,0.59 - 2.96,mmol/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,LIPID PANEL,Cholesterol (High Performance),,5.40,,,,,4.42 - 7.53,mmol/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,LIPID PANEL,LDL Chol Friedewald 4th,,2.66,,,,,0 - 3.34,mmol/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,RETICULOCYTES,Reticulocyte Count %,,2.3,,,,,0.6 - 2.5,% +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,TSH,TSH 3rd IS-QT,,1.816,,,,,0.45 - 5.33,mIU/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,URINE MACRO PANEL,Ur Specific Gravity,,1.006,,,,,1 - 1.04, +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.6,,,,,0 - 5,mg/L +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,CELLULAR ELEMENTS,Ur RBC/HPF,,1,,,,,0 - 8,/HPF +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,CELLULAR ELEMENTS,Ur WBC/HPF,,2,,,,,0 - 12,/HPF +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,CHEMISTRY PANEL,Total Bilirubin,,6,,,,,3 - 21,umol/L +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.1,,,,,0 - 6.2,umol/L +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,CHEMISTRY PANEL,Alkaline Phosphatase,,36,,,,,35 - 104,U/L +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,CHEMISTRY PANEL,ALT (SGPT),,11,,,,,4 - 43,U/L +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,CHEMISTRY PANEL,AST (SGOT),,17,,,,,8 - 40,U/L +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,CHEMISTRY PANEL,GGT,,6,,,,,4 - 49,U/L +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,CHEMISTRY PANEL,LDH,,153,,,,,53 - 234,U/L +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,CHEMISTRY PANEL,Urea Nitrogen,,3.7,,,,,1.4 - 8.6,mmol/L +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,65,,,,,31 - 101,umol/L +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,CHEMISTRY PANEL,Glucose Fasting,,5.2,,,,,3.9 - 5.6,mmol/L +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,CHEMISTRY PANEL,Serum Uric Acid,,259,,,,,125 - 428,umol/L +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,CHEMISTRY PANEL,Calcium (EDTA),,2.35,,,,,2.07 - 2.64,mmol/L +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,CHEMISTRY PANEL,Phosphorus,,0.98,,,,,0.71 - 1.65,mmol/L +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,CHEMISTRY PANEL,Total Protein,,72,,,,,61 - 84,g/L +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,CHEMISTRY PANEL,Albumin-BCG,,44,,,,,33 - 49,g/L +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,CHEMISTRY PANEL,Creatine Kinase,,105,,,,,26 - 192,U/L +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,CHEMISTRY PANEL,Serum Sodium,,139,,,,,132 - 147,mmol/L +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,CHEMISTRY PANEL,Serum Potassium,,4.4,,,,,3.5 - 5.2,mmol/L +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,CHEMISTRY PANEL,Serum Bicarbonate,,22.1,,,,,19.3 - 29.3,mmol/L +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,CHEMISTRY PANEL,Serum Chloride,,102,,,,,94 - 112,mmol/L +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,131,,,,,116 - 164,g/L +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.39,,,,,0.34 - 0.48, +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.7,,,,,4.1 - 5.6,TI/L +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,82,,,,,79 - 98,fL +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,5.46,,,,,3.8 - 10.7,GI/L +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.81,,,,,1.96 - 7.23,GI/L +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.34,,,,,0.91 - 4.28,GI/L +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.24,,,,,0.12 - 0.92,GI/L +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.05,,,,,0 - 0.57,GI/L +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.02,,,,,0 - 0.2,GI/L +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,69.7,,,,,40.5 - 75,% +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,24.6,,,,,15.4 - 48.5,% +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,4.4,,,,,2.6 - 10.1,% +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.0,,,,,0 - 6.8,% +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.3,,,,,0 - 2,% +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,267,,,,,140 - 400,GI/L +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,HEMOGLOBIN A1C,"Hemoglobin A1c,Variant(-70)-QT",,5.3,,,,,<6.5%, +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,5.64,,,,,1.9 - 23,uIU/mL +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,LIPID PANEL,Direct HDL-C 4th Generation,,1.66,R,H,,,1.03 - 1.53,mmol/L +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,LIPID PANEL,Triglycerides (GPO),,1.43,,,,,0.41 - 1.63,mmol/L +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,LIPID PANEL,Cholesterol (High Performance),,4.82,,,,,3.31 - 5.64,mmol/L +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,LIPID PANEL,LDL Chol Friedewald 4th,,2.51,,,,,0 - 3.34,mmol/L +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,MICROORGANISMS,Ur Bacteria,,Present,,,,,Ref Rng:Not present, +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,MICROORGANISMS,Ur Yeast-Budding,,Present,,,,,Ref Rng:Not present, +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,MICROORGANISMS,Ur Yeast-Hyphae,,Present,,,,,Ref Rng:Not present, +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,RETICULOCYTES,Reticulocyte Count %,,0.6,,,,,0.6 - 2.5,% +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,TSH,TSH 3rd IS-QT,,1.379,,,,,0.45 - 5.33,mIU/L +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,URINE MACRO PANEL,Ur Specific Gravity,,1.024,,,,,1 - 1.04, +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,URINE MACRO PANEL,Ur pH,,6.5,,,,,5 - 8, +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,URINE MACRO PANEL,Ur Protein,,Trace,,H,,,Ref Rng:Negative, +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,URINE MACRO PANEL,Ur Leukocyte Esterase,,+2,,H SF,,,Ref Rng:Negative, +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,URINE MICRO PANEL,Ur Microscopic,,Positive,,,,, NEGATIVE$,NEGATIVE +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.1,,,,,0 - 5,mg/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,CASTS,Ur Hyaline Casts/LPF,,27,,,,,0 /LPF, +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,CELLULAR ELEMENTS,Ur WBC/HPF,,1,,,,,0 - 12,/HPF +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,CHEMISTRY PANEL,Total Bilirubin,,5,,,,,3 - 21,umol/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.5,,,,,0 - 6.2,umol/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,CHEMISTRY PANEL,Alkaline Phosphatase,,61,,,,,35 - 104,U/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,CHEMISTRY PANEL,ALT (SGPT),,64,,H,,,4 - 43,U/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,CHEMISTRY PANEL,AST (SGOT),,63,,H RX,,,8 - 40,U/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,CHEMISTRY PANEL,GGT,,85,,H,,,5 - 50,U/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,CHEMISTRY PANEL,LDH,,207,,,,,53 - 234,U/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,CHEMISTRY PANEL,Urea Nitrogen,,2.8,,,,,1.4 - 8.6,mmol/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,56,,,,,31 - 101,umol/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,CHEMISTRY PANEL,Glucose Fasting,,5.7,,H,,,3.9 - 5.6,mmol/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,CHEMISTRY PANEL,Serum Uric Acid,,423,,,,,149 - 446,umol/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,CHEMISTRY PANEL,Calcium (EDTA),,2.43,,,,,2.07 - 2.64,mmol/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,CHEMISTRY PANEL,Phosphorus,,1.23,,,,,0.71 - 1.65,mmol/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,CHEMISTRY PANEL,Total Protein,,78,,,,,60 - 80,g/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,CHEMISTRY PANEL,Albumin-BCG,,48,,,,,33 - 49,g/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,CHEMISTRY PANEL,Creatine Kinase,,141,,,,,26 - 192,U/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,CHEMISTRY PANEL,Serum Sodium,,140,,,,,135 - 145,mmol/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,CHEMISTRY PANEL,Serum Potassium,,4.5,,,,,3.5 - 5.2,mmol/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,CHEMISTRY PANEL,Serum Bicarbonate,,22.7,,,,,19.3 - 29.3,mmol/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,CHEMISTRY PANEL,Serum Chloride,,99,,,,,94 - 112,mmol/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,138,,,,,115 - 158,g/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.42,,,,,0.34 - 0.48, +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.1,,,,,3.9 - 5.5,TI/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,102,,H,,,80 - 100,fL +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,6.70,,,,,3.8 - 10.7,GI/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.73,,,,,1.96 - 7.23,GI/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.43,,,,,0.8 - 3,GI/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.35,,,,,0.12 - 0.92,GI/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.16,,,,,0 - 0.57,GI/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.03,,,,,0 - 0.2,GI/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,55.7,,,,,40.5 - 75,% +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,36.2,,,,,15.4 - 48.5,% +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.2,,,,,2.6 - 10.1,% +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.3,,,,,0 - 6.8,% +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.5,,,,,0 - 2,% +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,274,,,,,130 - 394,GI/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,5.35,,,,,1.9 - 23,uIU/mL +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,LIPID PANEL,Direct HDL-C 4th Generation,,1.68,,H,,,1.03 - 1.53,mmol/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,LIPID PANEL,Triglycerides (GPO),,1.03,,,,,0.63 - 2.71,mmol/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,LIPID PANEL,Cholesterol (High Performance),,5.23,,,,,4.86 - 8.28,mmol/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,LIPID PANEL,LDL Chol Friedewald 4th,,3.08,,,,,0 - 3.34,mmol/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,RETICULOCYTES,Reticulocyte Count %,,1.3,,,,,0.6 - 2.5,% +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,URINE MACRO PANEL,Ur Specific Gravity,,1.023,,,,,1.01 - 1.03, +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,URINE MACRO PANEL,Ur Protein,,+1,,H,,,Ref Rng:Negative, +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,URINE MACRO PANEL,Ur Ketones,,Trace,,H,,,Ref Rng:Negative, +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,URINE MICRO PANEL,Ur Microscopic,,Positive,,,,, NEGATIVE$,NEGATIVE +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,C-REACTIVE PROTEIN,C Reactive Protein HS,,8.3,,H,,,0 - 5,mg/L +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,CHEMISTRY PANEL,Total Bilirubin,,8,,,,,3 - 21,umol/L +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.9,,,,,0 - 6.2,umol/L +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,CHEMISTRY PANEL,Alkaline Phosphatase,,64,,,,,40 - 129,U/L +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,CHEMISTRY PANEL,ALT (SGPT),,14,,,,,5 - 48,U/L +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,CHEMISTRY PANEL,AST (SGOT),,23,,,,,8 - 40,U/L +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,CHEMISTRY PANEL,GGT,,28,,,,,10 - 61,U/L +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,CHEMISTRY PANEL,LDH,,163,,,,,53 - 234,U/L +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,CHEMISTRY PANEL,Urea Nitrogen,,5.0,,,,,1.4 - 8.6,mmol/L +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,83,,,,,40 - 119,umol/L +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,CHEMISTRY PANEL,Glucose Fasting,,4.7,,,,,3.9 - 5.6,mmol/L +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,CHEMISTRY PANEL,Serum Uric Acid,,311,,,,,149 - 494,umol/L +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,CHEMISTRY PANEL,Calcium (EDTA),,2.30,,,,,2.07 - 2.64,mmol/L +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,CHEMISTRY PANEL,Phosphorus,,1.13,,,,,0.71 - 1.65,mmol/L +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,CHEMISTRY PANEL,Total Protein,,68,,,,,61 - 84,g/L +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,CHEMISTRY PANEL,Albumin-BCG,,45,,,,,33 - 49,g/L +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,CHEMISTRY PANEL,Creatine Kinase,,73,,,,,39 - 308,U/L +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,CHEMISTRY PANEL,Serum Sodium,,137,,,,,132 - 147,mmol/L +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,CHEMISTRY PANEL,Serum Potassium,,4.7,,,,,3.5 - 5.2,mmol/L +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,CHEMISTRY PANEL,Serum Bicarbonate,,21.0,,,,,19.3 - 29.3,mmol/L +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,CHEMISTRY PANEL,Serum Chloride,,102,,,,,94 - 112,mmol/L +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,158,,,,,127 - 181,g/L +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.48,,,,,0.39 - 0.54, +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.8,,,,,4.5 - 6.4,TI/L +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,99,R,H,,,79 - 96,fL +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,10.66,,,,,3.8 - 10.7,GI/L +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,7.67,R,H,,,1.96 - 7.23,GI/L +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.03,,,,,0.91 - 4.28,GI/L +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.77,,,,,0.12 - 0.92,GI/L +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.15,,,,,0 - 0.57,GI/L +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.04,,,,,0 - 0.2,GI/L +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,71.9,,,,,40.5 - 75,% +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,19.1,,,,,15.4 - 48.5,% +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,7.3,,,,,2.6 - 10.1,% +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.4,,,,,0 - 6.8,% +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.4,,,,,0 - 2,% +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,251,,,,,140 - 400,GI/L +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,4.56,,,,,1.9 - 23,uIU/mL +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,LIPID PANEL,Direct HDL-C 4th Generation,,1.04,,,,,1.03 - 1.53,mmol/L +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,LIPID PANEL,Triglycerides (GPO),,1.84,,,,,0.65 - 3.61,mmol/L +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,LIPID PANEL,Cholesterol (High Performance),,5.15,,,,,4.4 - 7.53,mmol/L +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,LIPID PANEL,LDL Chol Friedewald 4th,,3.27,,,,,0 - 3.34,mmol/L +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,RETICULOCYTES,Reticulocyte Count %,,1.4,,,,,0.6 - 2.5,% +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,URINE MACRO PANEL,Ur Specific Gravity,,1.012,,,,,1 - 1.04, +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,URINE MACRO PANEL,Ur pH,,5.0,,,,,5 - 8, +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:Negative, +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,C-REACTIVE PROTEIN,C Reactive Protein HS,,6.1,,H,,,0 - 5,mg/L +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,CHEMISTRY PANEL,Total Bilirubin,,10,,,,,3 - 21,umol/L +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.0,,,,,0 - 6.2,umol/L +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,CHEMISTRY PANEL,Alkaline Phosphatase,,106,,,,,40 - 129,U/L +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,CHEMISTRY PANEL,ALT (SGPT),,32,,,,,5 - 48,U/L +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,CHEMISTRY PANEL,AST (SGOT),,28,,,,,8 - 40,U/L +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,CHEMISTRY PANEL,GGT,,105,,H,,,10 - 61,U/L +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,CHEMISTRY PANEL,LDH,,140,,,,,53 - 234,U/L +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,CHEMISTRY PANEL,Urea Nitrogen,,3.2,,,,,1.4 - 8.6,mmol/L +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,98,,,,,40 - 119,umol/L +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,CHEMISTRY PANEL,Glucose Fasting,,5.3,,,,,3.9 - 5.6,mmol/L +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,CHEMISTRY PANEL,Serum Uric Acid,,378,,,,,149 - 494,umol/L +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,CHEMISTRY PANEL,Calcium (EDTA),,2.42,,,,,2.07 - 2.64,mmol/L +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,CHEMISTRY PANEL,Phosphorus,,0.96,,,,,0.71 - 1.65,mmol/L +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,CHEMISTRY PANEL,Total Protein,,74,,,,,61 - 84,g/L +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,CHEMISTRY PANEL,Albumin-BCG,,46,,,,,33 - 49,g/L +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,CHEMISTRY PANEL,Creatine Kinase,,55,,,,,39 - 308,U/L +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,CHEMISTRY PANEL,Serum Sodium,,142,,,,,132 - 147,mmol/L +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,CHEMISTRY PANEL,Serum Potassium,,4.3,,,,,3.5 - 5.2,mmol/L +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,CHEMISTRY PANEL,Serum Bicarbonate,,26.4,,,,,19.3 - 29.3,mmol/L +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,CHEMISTRY PANEL,Serum Chloride,,102,,,,,94 - 112,mmol/L +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,153,,,,,127 - 181,g/L +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.46,,,,,0.39 - 0.54, +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.9,,,,,4.5 - 6.4,TI/L +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,94,,,,,79 - 96,fL +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,4.05,,,,,3.8 - 10.7,GI/L +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.34,,,,,1.96 - 7.23,GI/L +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.31,,,,,0.91 - 4.28,GI/L +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.30,,,,,0.12 - 0.92,GI/L +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.06,,,,,0 - 0.57,GI/L +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.03,,,,,0 - 0.2,GI/L +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,57.8,,,,,40.5 - 75,% +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,32.3,,,,,15.4 - 48.5,% +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,7.4,,,,,2.6 - 10.1,% +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.6,,,,,0 - 6.8,% +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.8,,,,,0 - 2,% +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,219,,,,,140 - 400,GI/L +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,HEMOGLOBIN A1C,"Hemoglobin A1c,Variant(-70)-QT",,5.3,,,,,<6.5%, +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,6.63,,,,,1.9 - 23,uIU/mL +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,LIPID PANEL,Direct HDL-C 4th Generation,,1.31,,,,,1.03 - 1.53,mmol/L +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,LIPID PANEL,Triglycerides (GPO),,1.15,,,,,0.65 - 3.61,mmol/L +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,LIPID PANEL,Cholesterol (High Performance),,6.10,,,,,4.4 - 7.53,mmol/L +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,LIPID PANEL,LDL Chol Friedewald 4th,,4.26,,H,,,0 - 3.34,mmol/L +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,RETICULOCYTES,Reticulocyte Count %,,0.7,,,,,0.6 - 2.5,% +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,TSH,TSH 3rd IS-QT,,0.733,,,,,0.45 - 5.33,mIU/L +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,URINE MACRO PANEL,Ur Specific Gravity,,1.015,,,,,1 - 1.04, +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:Negative, +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,C-REACTIVE PROTEIN,C Reactive Protein HS,,0.7,,,,,0 - 5,mg/L +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,CHEMISTRY PANEL,Total Bilirubin,,5,,,,,3 - 21,umol/L +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.0,,,,,0 - 6.2,umol/L +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,CHEMISTRY PANEL,Alkaline Phosphatase,,77,,,,,35 - 104,U/L +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,CHEMISTRY PANEL,ALT (SGPT),,22,,,,,4 - 43,U/L +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,CHEMISTRY PANEL,AST (SGOT),,26,,,,,8 - 40,U/L +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,CHEMISTRY PANEL,GGT,,28,,,,,4 - 49,U/L +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,CHEMISTRY PANEL,LDH,,184,,,,,53 - 234,U/L +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,CHEMISTRY PANEL,Urea Nitrogen,,3.5,,,,,1.4 - 8.6,mmol/L +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,62,,,,,31 - 101,umol/L +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,CHEMISTRY PANEL,Glucose Fasting,,5.7,,H,,,3.9 - 5.6,mmol/L +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,CHEMISTRY PANEL,Serum Uric Acid,,259,,,,,149 - 446,umol/L +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,CHEMISTRY PANEL,Calcium (EDTA),,2.46,,,,,2.07 - 2.64,mmol/L +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,CHEMISTRY PANEL,Phosphorus,,1.16,,,,,0.71 - 1.65,mmol/L +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,CHEMISTRY PANEL,Total Protein,,71,,,,,61 - 84,g/L +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,CHEMISTRY PANEL,Albumin-BCG,,44,,,,,33 - 49,g/L +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,CHEMISTRY PANEL,Creatine Kinase,,82,,,,,26 - 192,U/L +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,CHEMISTRY PANEL,Serum Sodium,,139,,,,,132 - 147,mmol/L +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,CHEMISTRY PANEL,Serum Potassium,,4.7,,,,,3.5 - 5.2,mmol/L +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,CHEMISTRY PANEL,Serum Bicarbonate,,21.3,,,,,19.3 - 29.3,mmol/L +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,CHEMISTRY PANEL,Serum Chloride,,101,,,,,94 - 112,mmol/L +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,140,,,,,116 - 164,g/L +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.43,,,,,0.34 - 0.48, +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.4,,,,,4.1 - 5.6,TI/L +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,97,,,,,79 - 98,fL +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,6.32,,,,,3.8 - 10.7,GI/L +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.74,,,,,1.96 - 7.23,GI/L +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.91,,,,,0.91 - 4.28,GI/L +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.45,,,,,0.12 - 0.92,GI/L +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.17,,,,,0 - 0.57,GI/L +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.04,,,,,0 - 0.2,GI/L +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,59.2,,,,,40.5 - 75,% +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,30.3,,,,,15.4 - 48.5,% +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,7.2,,,,,2.6 - 10.1,% +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.7,,,,,0 - 6.8,% +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.6,,,,,0 - 2,% +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,356,,,,,140 - 400,GI/L +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,3.42,,,,,1.9 - 23,uIU/mL +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,LIPID PANEL,Direct HDL-C 4th Generation,,1.90,,H,,,1.03 - 1.53,mmol/L +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,LIPID PANEL,Triglycerides (GPO),,1.05,,,,,0.59 - 2.96,mmol/L +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,LIPID PANEL,Cholesterol (High Performance),,5.04,,,,,4.42 - 7.53,mmol/L +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,LIPID PANEL,LDL Chol Friedewald 4th,,2.66,,,,,0 - 3.34,mmol/L +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,RETICULOCYTES,Reticulocyte Count %,,2.3,,,,,0.6 - 2.5,% +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,URINE MACRO PANEL,Ur Specific Gravity,,1.009,,,,,1 - 1.04, +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.5,,,,,0 - 5,mg/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,CELLULAR ELEMENTS,Ur WBC/HPF,,1,,,,,0 - 12,/HPF +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,CHEMISTRY PANEL,Total Bilirubin,,5,,,,,3 - 21,umol/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.1,,,,,0 - 6.2,umol/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,CHEMISTRY PANEL,Alkaline Phosphatase,,42,,,,,35 - 104,U/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,CHEMISTRY PANEL,ALT (SGPT),,9,,,,,4 - 43,U/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,CHEMISTRY PANEL,AST (SGOT),,17,,,,,8 - 40,U/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,CHEMISTRY PANEL,GGT,,6,,,,,4 - 49,U/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,CHEMISTRY PANEL,LDH,,169,,,,,53 - 234,U/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,CHEMISTRY PANEL,Urea Nitrogen,,3.6,,,,,1.4 - 8.6,mmol/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,67,,,,,31 - 101,umol/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,CHEMISTRY PANEL,Glucose Fasting,,5.1,,,,,3.9 - 5.6,mmol/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,CHEMISTRY PANEL,Serum Uric Acid,,273,,,,,125 - 428,umol/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,CHEMISTRY PANEL,Calcium (EDTA),,2.36,,,,,2.07 - 2.64,mmol/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,CHEMISTRY PANEL,Phosphorus,,0.98,,,,,0.71 - 1.65,mmol/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,CHEMISTRY PANEL,Total Protein,,73,,,,,61 - 84,g/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,CHEMISTRY PANEL,Albumin-BCG,,45,,,,,33 - 49,g/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,CHEMISTRY PANEL,Creatine Kinase,,113,,,,,26 - 192,U/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,CHEMISTRY PANEL,Serum Sodium,,138,,,,,132 - 147,mmol/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,CHEMISTRY PANEL,Serum Potassium,,4.4,,,,,3.5 - 5.2,mmol/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,CHEMISTRY PANEL,Serum Bicarbonate,,20.6,,,,,19.3 - 29.3,mmol/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,CHEMISTRY PANEL,Serum Chloride,,100,,,,,94 - 112,mmol/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,135,,,,,116 - 164,g/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.41,,,,,0.34 - 0.48, +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.0,,,,,4.1 - 5.6,TI/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,82,,,,,79 - 98,fL +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,6.49,,,,,3.8 - 10.7,GI/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,4.33,,,,,1.96 - 7.23,GI/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.72,,,,,0.91 - 4.28,GI/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.35,,,,,0.12 - 0.92,GI/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.06,,,,,0 - 0.57,GI/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.03,,,,,0 - 0.2,GI/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,66.8,,,,,40.5 - 75,% +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,26.5,,,,,15.4 - 48.5,% +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.4,,,,,2.6 - 10.1,% +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.0,,,,,0 - 6.8,% +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.4,,,,,0 - 2,% +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,327,,,,,140 - 400,GI/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,4.98,,,,,1.9 - 23,uIU/mL +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,LIPID PANEL,Direct HDL-C 4th Generation,,1.69,R,H,,,1.03 - 1.53,mmol/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,LIPID PANEL,Triglycerides (GPO),,1.86,R,H,,,0.41 - 1.63,mmol/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,LIPID PANEL,Cholesterol (High Performance),,5.31,,,,,3.31 - 5.64,mmol/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,LIPID PANEL,LDL Chol Friedewald 4th,,2.77,,,,,0 - 3.34,mmol/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,MICROORGANISMS,Ur Bacteria,,Present,,,,,Ref Rng:Not present, +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,RETICULOCYTES,Reticulocyte Count %,,0.8,,,,,0.6 - 2.5,% +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,URINE MACRO PANEL,Ur Specific Gravity,,1.022,,,,,1 - 1.04, +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,URINE MACRO PANEL,Ur pH,,6.5,,,,,5 - 8, +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,URINE MACRO PANEL,Ur Blood,,+3,R,H SF,,,Ref Rng:$Negative-Trace, +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,URINE MICRO PANEL,Ur Microscopic,,Positive,,,,, NEGATIVE$,NEGATIVE +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,C-REACTIVE PROTEIN,C Reactive Protein HS,,2.4,,,,,0 - 5,mg/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,CASTS,Ur Hyaline Casts/LPF,,4,,,,,0 /LPF, +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,CELLULAR ELEMENTS,Ur WBC/HPF,,1,,,,,0 - 12,/HPF +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,CHEMISTRY PANEL,Total Bilirubin,,5,,,,,3 - 21,umol/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.9,,,,,0 - 6.2,umol/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,CHEMISTRY PANEL,Alkaline Phosphatase,,62,,,,,35 - 104,U/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,CHEMISTRY PANEL,ALT (SGPT),,35,,,,,4 - 43,U/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,CHEMISTRY PANEL,AST (SGOT),,29,,,,,8 - 40,U/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,CHEMISTRY PANEL,GGT,,51,,H,,,5 - 50,U/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,CHEMISTRY PANEL,LDH,,178,,,,,53 - 234,U/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,CHEMISTRY PANEL,Urea Nitrogen,,3.3,,,,,1.4 - 8.6,mmol/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,55,,,,,31 - 101,umol/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,CHEMISTRY PANEL,Glucose Fasting,,4.5,,,,,3.9 - 5.6,mmol/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,CHEMISTRY PANEL,Serum Uric Acid,,451,,H,,,149 - 446,umol/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,CHEMISTRY PANEL,Calcium (EDTA),,2.53,,,,,2.07 - 2.64,mmol/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,CHEMISTRY PANEL,Phosphorus,,1.03,,,,,0.71 - 1.65,mmol/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,CHEMISTRY PANEL,Total Protein,,74,,,,,60 - 80,g/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,CHEMISTRY PANEL,Albumin-BCG,,46,,,,,33 - 49,g/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,CHEMISTRY PANEL,Creatine Kinase,,153,,,,,26 - 192,U/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,CHEMISTRY PANEL,Serum Sodium,,138,,,,,135 - 145,mmol/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,CHEMISTRY PANEL,Serum Potassium,,3.9,,,,,3.5 - 5.2,mmol/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,CHEMISTRY PANEL,Serum Bicarbonate,,23.9,,,,,19.3 - 29.3,mmol/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,CHEMISTRY PANEL,Serum Chloride,,97,,,,,94 - 112,mmol/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,133,,,,,115 - 158,g/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.40,,,,,0.34 - 0.48, +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.0,,,,,3.9 - 5.5,TI/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,101,R,H,,,80 - 100,fL +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,5.90,,,,,3.8 - 10.7,GI/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.97,,,,,1.96 - 7.23,GI/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.30,,,,,0.8 - 3,GI/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.40,,,,,0.12 - 0.92,GI/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.20,,,,,0 - 0.57,GI/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.04,,,,,0 - 0.2,GI/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,50.3,,,,,40.5 - 75,% +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,38.9,,,,,15.4 - 48.5,% +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,6.8,,,,,2.6 - 10.1,% +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,3.3,,,,,0 - 6.8,% +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.7,,,,,0 - 2,% +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,244,,,,,130 - 394,GI/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,HEMOGLOBIN A1C,"Hemoglobin A1c,Variant(-70)-QT",,5.6,,,,,<6.5%, +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,2.01,,,,,1.9 - 23,uIU/mL +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,LIPID PANEL,Direct HDL-C 4th Generation,,1.47,,,,,1.03 - 1.53,mmol/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,LIPID PANEL,Triglycerides (GPO),,1.30,,,,,0.63 - 2.71,mmol/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,LIPID PANEL,Cholesterol (High Performance),,3.27,,L,,,4.86 - 8.28,mmol/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,LIPID PANEL,LDL Chol Friedewald 4th,,1.20,,,,,0 - 3.34,mmol/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,RETICULOCYTES,Reticulocyte Count %,,1.2,,,,,0.6 - 2.5,% +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,TSH,TSH 3rd IS-QT,,1.174,,,,,0.45 - 5.33,mIU/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,URINE MACRO PANEL,Ur Specific Gravity,,1.025,,,,,1.01 - 1.03, +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,URINE MACRO PANEL,Ur Protein,,Trace,,H,,,Ref Rng:Negative, +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,URINE MACRO PANEL,Ur Ketones,,Trace,,H,,,Ref Rng:Negative, +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,URINE MICRO PANEL,Ur Microscopic,,Positive,,,,, NEGATIVE$,NEGATIVE +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.1,,,,,0 - 5,mg/L +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,CHEMISTRY PANEL,Total Bilirubin,,12,,,,,3 - 21,umol/L +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.6,,,,,0 - 6.2,umol/L +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,CHEMISTRY PANEL,Alkaline Phosphatase,,80,,,,,40 - 129,U/L +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,CHEMISTRY PANEL,ALT (SGPT),,31,,,,,5 - 48,U/L +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,CHEMISTRY PANEL,AST (SGOT),,30,,,,,8 - 40,U/L +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,CHEMISTRY PANEL,GGT,,68,R,H,,,10 - 61,U/L +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,CHEMISTRY PANEL,LDH,,163,,,,,53 - 234,U/L +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,CHEMISTRY PANEL,Urea Nitrogen,,3.8,,,,,1.4 - 8.6,mmol/L +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,93,,,,,40 - 119,umol/L +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,CHEMISTRY PANEL,Glucose Fasting,,4.8,,,,,3.9 - 5.6,mmol/L +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,CHEMISTRY PANEL,Serum Uric Acid,,448,,,,,149 - 494,umol/L +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,CHEMISTRY PANEL,Calcium (EDTA),,2.38,,,,,2.07 - 2.64,mmol/L +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,CHEMISTRY PANEL,Phosphorus,,0.78,,,,,0.71 - 1.65,mmol/L +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,CHEMISTRY PANEL,Total Protein,,73,,,,,61 - 84,g/L +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,CHEMISTRY PANEL,Albumin-BCG,,45,,,,,33 - 49,g/L +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,CHEMISTRY PANEL,Creatine Kinase,,143,,,,,39 - 308,U/L +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,CHEMISTRY PANEL,Serum Sodium,,140,,,,,132 - 147,mmol/L +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,CHEMISTRY PANEL,Serum Potassium,,3.8,,,,,3.5 - 5.2,mmol/L +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,CHEMISTRY PANEL,Serum Bicarbonate,,24.3,,,,,19.3 - 29.3,mmol/L +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,CHEMISTRY PANEL,Serum Chloride,,98,,,,,94 - 112,mmol/L +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,153,,,,,127 - 181,g/L +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.46,,,,,0.39 - 0.54, +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.9,,,,,4.5 - 6.4,TI/L +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,94,,,,,79 - 96,fL +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,4.18,,,,,3.8 - 10.7,GI/L +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.32,,,,,1.96 - 7.23,GI/L +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.51,,,,,0.91 - 4.28,GI/L +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.23,,,,,0.12 - 0.92,GI/L +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.09,,,,,0 - 0.57,GI/L +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.02,,,,,0 - 0.2,GI/L +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,55.7,,,,,40.5 - 75,% +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,36.1,,,,,15.4 - 48.5,% +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.6,,,,,2.6 - 10.1,% +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.2,,,,,0 - 6.8,% +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.5,,,,,0 - 2,% +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,203,,,,,140 - 400,GI/L +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,8.51,,,,,1.9 - 23,uIU/mL +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,LIPID PANEL,Direct HDL-C 4th Generation,,1.29,,,,,1.03 - 1.53,mmol/L +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,LIPID PANEL,Triglycerides (GPO),,1.22,,,,,0.65 - 3.61,mmol/L +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,LIPID PANEL,Cholesterol (High Performance),,5.80,,,,,4.4 - 7.53,mmol/L +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,LIPID PANEL,LDL Chol Friedewald 4th,,3.95,,H,,,0 - 3.34,mmol/L +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,RETICULOCYTES,Reticulocyte Count %,,0.6,,,,,0.6 - 2.5,% +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,URINE MACRO PANEL,Ur Specific Gravity,,1.014,,,,,1 - 1.04, +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:Negative, +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.5,,,,,0 - 5,mg/L +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,CHEMISTRY PANEL,Total Bilirubin,,7,,,,,3 - 21,umol/L +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.6,,,,,0 - 6.2,umol/L +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,CHEMISTRY PANEL,Alkaline Phosphatase,,60,,,,,40 - 129,U/L +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,CHEMISTRY PANEL,ALT (SGPT),,15,,,,,5 - 48,U/L +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,CHEMISTRY PANEL,AST (SGOT),,23,,,,,8 - 40,U/L +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,CHEMISTRY PANEL,GGT,,29,,,,,10 - 61,U/L +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,CHEMISTRY PANEL,LDH,,173,,,,,53 - 234,U/L +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,CHEMISTRY PANEL,Urea Nitrogen,,3.9,,,,,1.4 - 8.6,mmol/L +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,73,,,,,40 - 119,umol/L +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,CHEMISTRY PANEL,Glucose Fasting,,4.9,,,,,3.9 - 5.6,mmol/L +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,CHEMISTRY PANEL,Serum Uric Acid,,268,,,,,149 - 494,umol/L +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,CHEMISTRY PANEL,Calcium (EDTA),,2.26,,,,,2.07 - 2.64,mmol/L +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,CHEMISTRY PANEL,Phosphorus,,1.02,,,,,0.71 - 1.65,mmol/L +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,CHEMISTRY PANEL,Total Protein,,67,,,,,61 - 84,g/L +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,CHEMISTRY PANEL,Albumin-BCG,,42,,,,,33 - 49,g/L +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,CHEMISTRY PANEL,Creatine Kinase,,93,,,,,39 - 308,U/L +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,CHEMISTRY PANEL,Serum Sodium,,138,,,,,132 - 147,mmol/L +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,CHEMISTRY PANEL,Serum Potassium,,4.0,,,,,3.5 - 5.2,mmol/L +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,CHEMISTRY PANEL,Serum Bicarbonate,,20.0,,,,,19.3 - 29.3,mmol/L +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,CHEMISTRY PANEL,Serum Chloride,,103,,,,,94 - 112,mmol/L +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,CREATININE CLEARANCE CC&G,CreatininClearancCockcrftGault,,2.12,,H,,,1.42 - 2.08,mL/sec +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,CREATININE CLEARANCE CC&G,Creatinine(Rate Blanked)-2dp,,73,,,,,40 - 119,umol/L +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,CREATININE CLEARANCE CC&G,"Weight (kg,1dec place)",Y,85.0,,,,,kg, +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,DRUG SCREEN URINE,Amphetamines/MDMA,,Neg,,,,,Neg;$Cutoff = 1000 ng/mL, +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,DRUG SCREEN URINE,Barbiturates,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,DRUG SCREEN URINE,Cannabinoids,,Neg,,,,,Neg;$Cutoff = 50 ng/mL, +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,DRUG SCREEN URINE,Cocaine,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,DRUG SCREEN URINE,Opiates,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,DRUG SCREEN URINE,Methadone,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,DRUG SCREEN URINE BENZO NON-US,Benzodiazepines Gen 2,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,GFR,EGFR by MDRD,,98,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,153,,,,,127 - 181,g/L +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.47,,,,,0.39 - 0.54, +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.6,,,,,4.5 - 6.4,TI/L +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,101,,H,,,79 - 96,fL +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,8.62,,,,,3.8 - 10.7,GI/L +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,6.14,,,,,1.96 - 7.23,GI/L +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.83,,,,,0.91 - 4.28,GI/L +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.48,,,,,0.12 - 0.92,GI/L +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.14,,,,,0 - 0.57,GI/L +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.03,,,,,0 - 0.2,GI/L +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,71.2,,,,,40.5 - 75,% +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,21.2,,,,,15.4 - 48.5,% +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.6,,,,,2.6 - 10.1,% +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.6,,,,,0 - 6.8,% +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.4,,,,,0 - 2,% +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,218,,,,,140 - 400,GI/L +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,HEMOGLOBIN A1C,"Hemoglobin A1c,Variant(-70)-QT",,5.5,,,,,<6.5%, +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,7.69,,,,,1.9 - 23,uIU/mL +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,IS SUBJECT OF BLACK RACE?,Subject of black race?,Y,No,,,,,, +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,LIPID PANEL,Direct HDL-C 4th Generation,,1.08,,,,,1.03 - 1.53,mmol/L +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,LIPID PANEL,Triglycerides (GPO),,2.26,,,,,0.65 - 3.61,mmol/L +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,LIPID PANEL,Cholesterol (High Performance),,4.47,,,,,4.4 - 7.53,mmol/L +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,LIPID PANEL,LDL Chol Friedewald 4th,,2.35,,,,,0 - 3.34,mmol/L +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,RETICULOCYTES,Reticulocyte Count %,,1.1,,,,,0.6 - 2.5,% +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,TSH,TSH 3rd IS-QT,,0.878,,,,,0.45 - 5.33,mIU/L +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,URINE MACRO PANEL,Ur Specific Gravity,,1.013,,,,,1 - 1.04, +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,URINE MACRO PANEL,Ur pH,,5.0,,,,,5 - 8, +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:Negative, +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,C-REACTIVE PROTEIN,C Reactive Protein HS,,0.5,,,,,0 - 5,mg/L +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,CHEMISTRY PANEL,Total Bilirubin,,10,,,,,3 - 21,umol/L +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.5,,,,,0 - 6.2,umol/L +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,CHEMISTRY PANEL,Alkaline Phosphatase,,63,,,,,35 - 104,U/L +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,CHEMISTRY PANEL,ALT (SGPT),,19,,,,,4 - 43,U/L +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,CHEMISTRY PANEL,AST (SGOT),,20,,,,,8 - 40,U/L +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,CHEMISTRY PANEL,GGT,,22,,,,,4 - 49,U/L +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,CHEMISTRY PANEL,LDH,,182,,,,,53 - 234,U/L +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,CHEMISTRY PANEL,Urea Nitrogen,,3.0,,,,,1.4 - 8.6,mmol/L +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,57,,,,,31 - 101,umol/L +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,CHEMISTRY PANEL,Glucose Fasting,,5.1,,,,,3.9 - 5.6,mmol/L +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,CHEMISTRY PANEL,Serum Uric Acid,,224,,,,,149 - 446,umol/L +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,CHEMISTRY PANEL,Calcium (EDTA),,2.40,,,,,2.07 - 2.64,mmol/L +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,CHEMISTRY PANEL,Phosphorus,,1.06,,,,,0.71 - 1.65,mmol/L +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,CHEMISTRY PANEL,Total Protein,,68,,,,,61 - 84,g/L +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,CHEMISTRY PANEL,Albumin-BCG,,43,,,,,33 - 49,g/L +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,CHEMISTRY PANEL,Creatine Kinase,,71,,,,,26 - 192,U/L +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,CHEMISTRY PANEL,Serum Sodium,,139,,,,,132 - 147,mmol/L +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,CHEMISTRY PANEL,Serum Potassium,,4.7,,,,,3.5 - 5.2,mmol/L +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,CHEMISTRY PANEL,Serum Bicarbonate,,22.7,,,,,19.3 - 29.3,mmol/L +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,CHEMISTRY PANEL,Serum Chloride,,103,,,,,94 - 112,mmol/L +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,CREATININE CLEARANCE CC&G,CreatininClearancCockcrftGault,,1.81,,,,,1.25 - 1.92,mL/sec +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,CREATININE CLEARANCE CC&G,Creatinine(Rate Blanked)-2dp,,57,,,,,31 - 101,umol/L +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,CREATININE CLEARANCE CC&G,"Weight (kg,1dec place)",Y,69.0,,,,,kg, +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,DRUG SCREEN URINE,Amphetamines/MDMA,,Neg,,,,,Neg;$Cutoff = 1000 ng/mL, +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,DRUG SCREEN URINE,Barbiturates,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,DRUG SCREEN URINE,Cannabinoids,,Neg,,,,,Neg;$Cutoff = 50 ng/mL, +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,DRUG SCREEN URINE,Cocaine,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,DRUG SCREEN URINE,Opiates,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,DRUG SCREEN URINE,Methadone,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,DRUG SCREEN URINE BENZO NON-US,Benzodiazepines Gen 2,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,FEMALE OF CHILDBEARING POT?,Female/of Childbearing pot.?,Y,No,,,,,, +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,FSH,Follicle Stimulating Hormone,,6.17,,RX,,,Follicular:$3.90-8.80 IU/L$Midcycle:$4.50-22.50 IU/L$Luteal:$1.80-5.10 IU/L$Postmenopausal:$16.70-113.60 IU/L, +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,GFR,EGFR by MDRD,,97,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,137,,,,,116 - 164,g/L +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.42,,,,,0.34 - 0.48, +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.2,,,,,4.1 - 5.6,TI/L +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,98,,,,,79 - 98,fL +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,7.11,,,,,3.8 - 10.7,GI/L +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,4.39,,,,,1.96 - 7.23,GI/L +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.04,,,,,0.91 - 4.28,GI/L +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.49,,,,,0.12 - 0.92,GI/L +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.14,,,,,0 - 0.57,GI/L +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.05,,,,,0 - 0.2,GI/L +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,61.8,,,,,40.5 - 75,% +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,28.7,,,,,15.4 - 48.5,% +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,6.9,,,,,2.6 - 10.1,% +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.9,,,,,0 - 6.8,% +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.7,,,,,0 - 2,% +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,431,,H,,,140 - 400,GI/L +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,HEMOGLOBIN A1C,"Hemoglobin A1c,Variant(-70)-QT",,5.2,,,,,<6.5%, +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,3.05,,,,,1.9 - 23,uIU/mL +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,IS SUBJECT OF BLACK RACE?,Subject of black race?,Y,No,,,,,, +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,LIPID PANEL,Direct HDL-C 4th Generation,,1.95,,H,,,1.03 - 1.53,mmol/L +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,LIPID PANEL,Triglycerides (GPO),,1.54,,,,,0.59 - 2.96,mmol/L +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,LIPID PANEL,Cholesterol (High Performance),,5.27,,,,,4.42 - 7.53,mmol/L +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,LIPID PANEL,LDL Chol Friedewald 4th,,2.61,,,,,0 - 3.34,mmol/L +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,POSTMENOPAUSAL FEMALE?,<40yrs & amenorrhea >/= 12mo,,Yes,,,,,, +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,RETICULOCYTES,Reticulocyte Count %,,2.9,,H,,,0.6 - 2.5,% +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,TSH,TSH 3rd IS-QT,,1.573,,,,,0.45 - 5.33,mIU/L +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,URINE MACRO PANEL,Ur Specific Gravity,,1.010,,,,,1 - 1.04, +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,URINE MACRO PANEL,Ur pH,,6.0,,,,,5 - 8, +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.3,,,,,0 - 5,mg/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,CHEMISTRY PANEL,Total Bilirubin,,4,,,,,3 - 21,umol/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,1.6,,,,,0 - 6.2,umol/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,CHEMISTRY PANEL,Alkaline Phosphatase,,38,,,,,35 - 104,U/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,CHEMISTRY PANEL,ALT (SGPT),,17,,,,,4 - 43,U/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,CHEMISTRY PANEL,AST (SGOT),,25,,,,,8 - 40,U/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,CHEMISTRY PANEL,GGT,,6,,,,,4 - 49,U/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,CHEMISTRY PANEL,LDH,,162,,,,,53 - 234,U/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,CHEMISTRY PANEL,Urea Nitrogen,,3.5,,,,,1.4 - 8.6,mmol/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,59,,,,,31 - 101,umol/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,CHEMISTRY PANEL,Glucose Fasting,,4.8,,,,,3.9 - 5.6,mmol/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,CHEMISTRY PANEL,Serum Uric Acid,,260,,,,,125 - 428,umol/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,CHEMISTRY PANEL,Calcium (EDTA),,2.26,,,,,2.07 - 2.64,mmol/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,CHEMISTRY PANEL,Phosphorus,,0.56,,LT,,Result verified by repeat analysis,0.71 - 1.65,mmol/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,CHEMISTRY PANEL,Total Protein,,72,,,,,61 - 84,g/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,CHEMISTRY PANEL,Albumin-BCG,,43,,,,,33 - 49,g/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,CHEMISTRY PANEL,Creatine Kinase,,358,R,H,,,26 - 192,U/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,CHEMISTRY PANEL,Serum Sodium,,137,,,,,132 - 147,mmol/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,CHEMISTRY PANEL,Serum Potassium,,4.1,,,,,3.5 - 5.2,mmol/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,CHEMISTRY PANEL,Serum Bicarbonate,,21.1,,,,,19.3 - 29.3,mmol/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,CHEMISTRY PANEL,Serum Chloride,,103,,,,,94 - 112,mmol/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,132,,,,,116 - 164,g/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.39,,,,,0.34 - 0.48, +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.8,,,,,4.1 - 5.6,TI/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,82,,,,,79 - 98,fL +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,4.52,,,,,3.8 - 10.7,GI/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.93,,,,,1.96 - 7.23,GI/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.25,,,,,0.91 - 4.28,GI/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.27,,,,,0.12 - 0.92,GI/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.06,,,,,0 - 0.57,GI/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.01,,,,,0 - 0.2,GI/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,64.8,,,,,40.5 - 75,% +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,27.6,,,,,15.4 - 48.5,% +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,6.0,,,,,2.6 - 10.1,% +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.4,,,,,0 - 6.8,% +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.2,,,,,0 - 2,% +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,262,,,,,140 - 400,GI/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,HEMOGLOBIN A1C,"Hemoglobin A1c,Variant(-70)-QT",,5.2,,,,,<6.5%, +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,7.63,,,,,1.9 - 23,uIU/mL +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,IS SUBJECT FASTING?,Is Subject Fasting?,Y,No,,,,,, +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,LIPID PANEL,Direct HDL-C 4th Generation,,1.42,,,,,1.03 - 1.53,mmol/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,LIPID PANEL,Triglycerides (GPO),,1.42,,,,,0.41 - 1.63,mmol/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,LIPID PANEL,Cholesterol (High Performance),,4.13,,,,,3.31 - 5.64,mmol/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,LIPID PANEL,LDL Chol Friedewald 4th,,2.06,,,,,0 - 3.34,mmol/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,RETICULOCYTES,Reticulocyte Count %,,0.9,,,,,0.6 - 2.5,% +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,TSH,TSH 3rd IS-QT,,1.160,,,,,0.45 - 5.33,mIU/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,URINE MACRO PANEL,Ur Specific Gravity,,1.020,,,,,1 - 1.04, +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100080004,,,54,years,Male,Retest,,"Sep 8, 2025 10:00 AM",6225351070,DRUG SCREEN URINE,Amphetamines/MDMA,,Neg,,,,,Neg;$Cutoff = 1000 ng/mL, +CZ100080004,,,54,years,Male,Retest,,"Sep 8, 2025 10:00 AM",6225351070,DRUG SCREEN URINE,Barbiturates,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100080004,,,54,years,Male,Retest,,"Sep 8, 2025 10:00 AM",6225351070,DRUG SCREEN URINE,Cannabinoids,,Neg,,,,,Neg;$Cutoff = 50 ng/mL, +CZ100080004,,,54,years,Male,Retest,,"Sep 8, 2025 10:00 AM",6225351070,DRUG SCREEN URINE,Cocaine,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100080004,,,54,years,Male,Retest,,"Sep 8, 2025 10:00 AM",6225351070,DRUG SCREEN URINE,Opiates,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100080004,,,54,years,Male,Retest,,"Sep 8, 2025 10:00 AM",6225351070,DRUG SCREEN URINE,Methadone,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100080004,,,54,years,Male,Retest,,"Sep 8, 2025 10:00 AM",6225351070,DRUG SCREEN URINE BENZO NON-US,Benzodiazepines Gen 2,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100080004,,,54,years,Male,Retest,,"Sep 8, 2025 10:00 AM",6225351070,IS SUBJECT FASTING?,Is Subject Fasting?,Y,No,,,,,, +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.3,,,,,0 - 5,mg/L +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,CHEMISTRY PANEL,Total Bilirubin,,7,,,,,3 - 21,umol/L +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.1,,,,,0 - 6.2,umol/L +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,CHEMISTRY PANEL,Alkaline Phosphatase,,70,,,,,35 - 104,U/L +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,CHEMISTRY PANEL,ALT (SGPT),,40,,,,,4 - 43,U/L +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,CHEMISTRY PANEL,AST (SGOT),,35,,,,,8 - 40,U/L +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,CHEMISTRY PANEL,GGT,,54,,H,,,5 - 50,U/L +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,CHEMISTRY PANEL,LDH,,184,,,,,53 - 234,U/L +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,CHEMISTRY PANEL,Urea Nitrogen,,2.1,,,,,1.4 - 8.6,mmol/L +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,58,,,,,31 - 101,umol/L +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,CHEMISTRY PANEL,Glucose Fasting,,4.5,,,,,3.9 - 5.6,mmol/L +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,CHEMISTRY PANEL,Serum Uric Acid,,413,,,,,149 - 446,umol/L +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,CHEMISTRY PANEL,Calcium (EDTA),,2.58,,,,,2.07 - 2.64,mmol/L +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,CHEMISTRY PANEL,Phosphorus,,1.19,,,,,0.71 - 1.65,mmol/L +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,CHEMISTRY PANEL,Total Protein,,77,,,,,60 - 80,g/L +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,CHEMISTRY PANEL,Albumin-BCG,,49,,,,,33 - 49,g/L +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,CHEMISTRY PANEL,Creatine Kinase,,155,,,,,26 - 192,U/L +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,CHEMISTRY PANEL,Serum Sodium,,137,,,,,135 - 145,mmol/L +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,CHEMISTRY PANEL,Serum Potassium,,4.4,,,,,3.5 - 5.2,mmol/L +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,CHEMISTRY PANEL,Serum Bicarbonate,,22.5,,,,,19.3 - 29.3,mmol/L +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,CHEMISTRY PANEL,Serum Chloride,,96,,,,,94 - 112,mmol/L +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,137,,,,,115 - 158,g/L +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.41,,,,,0.34 - 0.48, +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.0,,,,,3.9 - 5.5,TI/L +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,101,R,H,,,80 - 100,fL +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,7.55,,,,,3.8 - 10.7,GI/L +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,4.20,,,,,1.96 - 7.23,GI/L +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.66,,,,,0.8 - 3,GI/L +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.44,,,,,0.12 - 0.92,GI/L +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.21,,,,,0 - 0.57,GI/L +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.05,,,,,0 - 0.2,GI/L +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,55.5,,,,,40.5 - 75,% +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,35.1,,,,,15.4 - 48.5,% +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.9,,,,,2.6 - 10.1,% +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.8,,,,,0 - 6.8,% +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.6,,,,,0 - 2,% +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,275,,,,,130 - 394,GI/L +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,6.10,,,,,1.9 - 23,uIU/mL +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,LIPID PANEL,Direct HDL-C 4th Generation,,1.39,,,,,1.03 - 1.53,mmol/L +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,LIPID PANEL,Triglycerides (GPO),,1.36,,,,,0.63 - 2.71,mmol/L +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,LIPID PANEL,Cholesterol (High Performance),,3.50,,L,,,4.86 - 8.28,mmol/L +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,LIPID PANEL,LDL Chol Friedewald 4th,,1.49,,,,,0 - 3.34,mmol/L +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,RETICULOCYTES,Reticulocyte Count %,,1.2,,,,,0.6 - 2.5,% +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,URINE MACRO PANEL,Ur Specific Gravity,,1.010,,,,,1.01 - 1.03, +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,URINE MACRO PANEL,Ur Ketones,,+1,,H,,,Ref Rng:Negative, +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,URINE MACRO PANEL,Ur Leukocyte Esterase,,Trace,,H,,,Ref Rng:Negative, +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,URINE MICRO PANEL,Ur Microscopic,,Negative,,,,, NEGATIVE$,NEGATIVE +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.5,,,,,0 - 5,mg/L +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,CHEMISTRY PANEL,Total Bilirubin,,13,,,,,3 - 21,umol/L +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.9,,,,,0 - 6.2,umol/L +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,CHEMISTRY PANEL,Alkaline Phosphatase,,76,,,,,40 - 129,U/L +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,CHEMISTRY PANEL,ALT (SGPT),,24,,,,,5 - 48,U/L +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,CHEMISTRY PANEL,AST (SGOT),,26,,,,,8 - 40,U/L +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,CHEMISTRY PANEL,GGT,,61,,,,,10 - 61,U/L +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,CHEMISTRY PANEL,LDH,,160,,,,,53 - 234,U/L +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,CHEMISTRY PANEL,Urea Nitrogen,,4.8,,,,,1.4 - 8.6,mmol/L +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,87,,,,,40 - 119,umol/L +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,CHEMISTRY PANEL,Glucose Fasting,,4.7,,,,,3.9 - 5.6,mmol/L +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,CHEMISTRY PANEL,Serum Uric Acid,,353,,,,,149 - 494,umol/L +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,CHEMISTRY PANEL,Calcium (EDTA),,2.34,,,,,2.07 - 2.64,mmol/L +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,CHEMISTRY PANEL,Phosphorus,,0.79,,,,,0.71 - 1.65,mmol/L +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,CHEMISTRY PANEL,Total Protein,,74,,,,,61 - 84,g/L +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,CHEMISTRY PANEL,Albumin-BCG,,44,,,,,33 - 49,g/L +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,CHEMISTRY PANEL,Creatine Kinase,,153,,,,,39 - 308,U/L +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,CHEMISTRY PANEL,Serum Sodium,,139,,,,,132 - 147,mmol/L +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,CHEMISTRY PANEL,Serum Potassium,,4.4,,,,,3.5 - 5.2,mmol/L +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,CHEMISTRY PANEL,Serum Bicarbonate,,21.7,,,,,19.3 - 29.3,mmol/L +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,CHEMISTRY PANEL,Serum Chloride,,104,,,,,94 - 112,mmol/L +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,CREATININE CLEARANCE CC&G,CreatininClearancCockcrftGault,,1.83,,,,,1.42 - 2.08,mL/sec +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,CREATININE CLEARANCE CC&G,Creatinine(Rate Blanked)-2dp,,87,,,,,40 - 119,umol/L +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,CREATININE CLEARANCE CC&G,"Weight (kg,1dec place)",Y,89.2,,,,,kg, +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,DRUG SCREEN URINE,Amphetamines/MDMA,,Neg,,,,,Neg;$Cutoff = 1000 ng/mL, +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,DRUG SCREEN URINE,Barbiturates,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,DRUG SCREEN URINE,Cannabinoids,,Neg,,,,,Neg;$Cutoff = 50 ng/mL, +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,DRUG SCREEN URINE,Cocaine,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,DRUG SCREEN URINE,Opiates,,Detected (unconfirmed),,,,,Neg;$Cutoff = 300 ng/mL, +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,DRUG SCREEN URINE,Methadone,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,DRUG SCREEN URINE BENZO NON-US,Benzodiazepines Gen 2,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,GFR,EGFR by MDRD,,80,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,152,,,,,127 - 181,g/L +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.46,,,,,0.39 - 0.54, +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.8,,,,,4.5 - 6.4,TI/L +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,96,,,,,79 - 96,fL +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,4.94,,,,,3.8 - 10.7,GI/L +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.25,,,,,1.96 - 7.23,GI/L +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.33,,,,,0.91 - 4.28,GI/L +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.22,,,,,0.12 - 0.92,GI/L +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.10,,,,,0 - 0.57,GI/L +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.03,,,,,0 - 0.2,GI/L +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,65.9,,,,,40.5 - 75,% +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,27.0,,,,,15.4 - 48.5,% +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,4.5,,,,,2.6 - 10.1,% +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.1,,,,,0 - 6.8,% +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.6,,,,,0 - 2,% +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,222,,,,,140 - 400,GI/L +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,HEMOGLOBIN A1C,"Hemoglobin A1c,Variant(-70)-QT",,5.5,,,,,<6.5%, +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,5.22,,,,,1.9 - 23,uIU/mL +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,IS SUBJECT OF BLACK RACE?,Subject of black race?,Y,No,,,,,, +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,LIPID PANEL,Direct HDL-C 4th Generation,,1.15,,,,,1.03 - 1.53,mmol/L +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,LIPID PANEL,Triglycerides (GPO),,0.89,,,,,0.65 - 3.61,mmol/L +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,LIPID PANEL,Cholesterol (High Performance),,5.43,,,,,4.4 - 7.53,mmol/L +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,LIPID PANEL,LDL Chol Friedewald 4th,,3.87,,H,,,0 - 3.34,mmol/L +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,OPIATE CONFIRMATION URINE,Opiates Confirmed-LCMSMS-LDT,,Codeine (Confirmed),,RX,,,No Ref Rng, +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,OPIATE CONFIRMATION URINE,Opiates Confirmed-LCMSMS-LDT,,Morphine (Confirmed),,RX,,,No Ref Rng, +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,OPIATE CONFIRMATION URINE,Opiates Confirmed-LCMSMS-LDT,,6-MAM not present,,,,,No Ref Rng, +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,RETICULOCYTES,Reticulocyte Count %,,0.9,,,,,0.6 - 2.5,% +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,TSH,TSH 3rd IS-QT,,0.914,,,,,0.45 - 5.33,mIU/L +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,URINE MACRO PANEL,Ur Specific Gravity,,1.025,,,,,1 - 1.04, +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,URINE MACRO PANEL,Ur Ketones,,+1,,H,,,Ref Rng:Negative, +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:Negative, +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,URINE MICRO PANEL,Ur Microscopic,,Negative,,,,, NEGATIVE$,NEGATIVE +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,C-REACTIVE PROTEIN,C Reactive Protein HS,,0.3,,,,Result verified by repeat analysis,0 - 5,mg/L +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,CELLULAR ELEMENTS,Ur WBC/HPF,,4,,,,,0 - 12,/HPF +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,CHEMISTRY PANEL,Total Bilirubin,,6,,,,,3 - 21,umol/L +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.5,,,,,0 - 6.2,umol/L +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,CHEMISTRY PANEL,Alkaline Phosphatase,,85,,,,,35 - 104,U/L +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,CHEMISTRY PANEL,ALT (SGPT),,24,,,,,4 - 43,U/L +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,CHEMISTRY PANEL,AST (SGOT),,20,,,,,8 - 40,U/L +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,CHEMISTRY PANEL,GGT,,43,,,,,5 - 50,U/L +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,CHEMISTRY PANEL,LDH,,183,,,,,53 - 234,U/L +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,CHEMISTRY PANEL,Urea Nitrogen,,3.2,,,,,1.4 - 8.6,mmol/L +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,47,,,,,31 - 101,umol/L +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,CHEMISTRY PANEL,Glucose Fasting,,6.0,,H,,,3.9 - 5.6,mmol/L +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,CHEMISTRY PANEL,Serum Uric Acid,,253,,,,,149 - 446,umol/L +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,CHEMISTRY PANEL,Calcium (EDTA),,2.35,,,,,2.07 - 2.64,mmol/L +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,CHEMISTRY PANEL,Phosphorus,,1.22,,,,,0.71 - 1.65,mmol/L +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,CHEMISTRY PANEL,Total Protein,,68,,,,,60 - 80,g/L +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,CHEMISTRY PANEL,Albumin-BCG,,47,,,,,33 - 49,g/L +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,CHEMISTRY PANEL,Creatine Kinase,,89,,,,,26 - 192,U/L +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,CHEMISTRY PANEL,Serum Sodium,,143,,,,,135 - 145,mmol/L +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,CHEMISTRY PANEL,Serum Potassium,,4.9,,,,,3.5 - 5.2,mmol/L +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,CHEMISTRY PANEL,Serum Bicarbonate,,24.4,,,,,19.3 - 29.3,mmol/L +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,CHEMISTRY PANEL,Serum Chloride,,104,,,,,94 - 112,mmol/L +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,CREATININE CLEARANCE CC&G,CreatininClearancCockcrftGault,,2.47,,H,,,1.25 - 1.92,mL/sec +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,CREATININE CLEARANCE CC&G,Creatinine(Rate Blanked)-2dp,,47,,,,,31 - 101,umol/L +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,CREATININE CLEARANCE CC&G,"Weight (kg,1dec place)",Y,89.0,,,,,kg, +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,DRUG SCREEN URINE,Amphetamines/MDMA,,Neg,,,,,Neg;$Cutoff = 1000 ng/mL, +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,DRUG SCREEN URINE,Barbiturates,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,DRUG SCREEN URINE,Cannabinoids,,Neg,,,,,Neg;$Cutoff = 50 ng/mL, +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,DRUG SCREEN URINE,Cocaine,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,DRUG SCREEN URINE,Opiates,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,DRUG SCREEN URINE,Methadone,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,DRUG SCREEN URINE BENZO NON-US,Benzodiazepines Gen 2,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,FEMALE OF CHILDBEARING POT?,Female/of Childbearing pot.?,Y,No,,,,,, +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,FSH,Follicle Stimulating Hormone,,29.08,,RX,,,Follicular:$3.90-8.80 IU/L$Midcycle:$4.50-22.50 IU/L$Luteal:$1.80-5.10 IU/L$Postmenopausal:$16.70-113.60 IU/L, +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,GFR,EGFR by MDRD,,116,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,129,,,,,115 - 158,g/L +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.39,,,,,0.34 - 0.48, +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.2,,,,,3.9 - 5.5,TI/L +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,93,,,,,80 - 100,fL +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,7.29,,,,,3.8 - 10.7,GI/L +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,4.65,,,,,1.96 - 7.23,GI/L +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.23,,,,,0.8 - 3,GI/L +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.31,,,,,0.12 - 0.92,GI/L +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.08,,,,,0 - 0.57,GI/L +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.02,,,,,0 - 0.2,GI/L +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,63.7,,,,,40.5 - 75,% +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,30.6,,,,,15.4 - 48.5,% +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,4.2,,,,,2.6 - 10.1,% +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.1,,,,,0 - 6.8,% +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.3,,,,,0 - 2,% +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,250,,,,,130 - 394,GI/L +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,HEMOGLOBIN A1C,"Hemoglobin A1c,Variant(-70)-QT",,6.4,,,,,<6.5%, +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,15.80,,,,,1.9 - 23,uIU/mL +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,IS SUBJECT OF BLACK RACE?,Subject of black race?,Y,No,,,,,, +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,LIPID PANEL,Direct HDL-C 4th Generation,,1.50,,,,,1.03 - 1.53,mmol/L +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,LIPID PANEL,Triglycerides (GPO),,1.69,,,,,0.63 - 2.71,mmol/L +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,LIPID PANEL,Cholesterol (High Performance),,4.20,,L,,,4.86 - 8.28,mmol/L +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,LIPID PANEL,LDL Chol Friedewald 4th,,1.93,,,,,0 - 3.34,mmol/L +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,MICROORGANISMS,Ur Bacteria,,Present,,,,,Ref Rng:Not present, +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,POSTMENOPAUSAL FEMALE?,<40yrs & amenorrhea >/= 12mo,,Yes,,,,,, +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,RETICULOCYTES,Reticulocyte Count %,,1.5,,,,,0.6 - 2.5,% +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,TSH,TSH 3rd IS-QT,,1.074,,,,,0.45 - 5.33,mIU/L +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,URINE MACRO PANEL,Ur Specific Gravity,,1.024,,,,,1.01 - 1.03, +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,URINE MACRO PANEL,Ur pH,,5.0,,,,,5 - 8, +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,URINE MACRO PANEL,Ur Leukocyte Esterase,,+3,R,H SF,,,Ref Rng:Negative, +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,URINE MICRO PANEL,Ur Microscopic,,Positive,,,,, NEGATIVE$,NEGATIVE +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.3,,,,,0 - 5,mg/L +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,CHEMISTRY PANEL,Total Bilirubin,,8,,,,,3 - 21,umol/L +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.2,,,,,0 - 6.2,umol/L +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,CHEMISTRY PANEL,Alkaline Phosphatase,,73,,,,,35 - 104,U/L +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,CHEMISTRY PANEL,ALT (SGPT),,40,,,,,4 - 43,U/L +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,CHEMISTRY PANEL,AST (SGOT),,26,,,,,8 - 40,U/L +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,CHEMISTRY PANEL,GGT,,56,R,H,,,5 - 50,U/L +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,CHEMISTRY PANEL,LDH,,169,,,,,53 - 234,U/L +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,CHEMISTRY PANEL,Urea Nitrogen,,2.9,,,,,1.4 - 8.6,mmol/L +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,51,,,,,31 - 101,umol/L +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,CHEMISTRY PANEL,Glucose Fasting,,5.0,,,,,3.9 - 5.6,mmol/L +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,CHEMISTRY PANEL,Serum Uric Acid,,479,R,H,,,149 - 446,umol/L +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,CHEMISTRY PANEL,Calcium (EDTA),,2.56,,,,,2.07 - 2.64,mmol/L +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,CHEMISTRY PANEL,Phosphorus,,1.22,,,,,0.71 - 1.65,mmol/L +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,CHEMISTRY PANEL,Total Protein,,74,,,,,60 - 80,g/L +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,CHEMISTRY PANEL,Albumin-BCG,,46,,,,,33 - 49,g/L +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,CHEMISTRY PANEL,Creatine Kinase,,135,,,,,26 - 192,U/L +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,CHEMISTRY PANEL,Serum Sodium,,137,,,,,135 - 145,mmol/L +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,CHEMISTRY PANEL,Serum Potassium,,4.1,,,,,3.5 - 5.2,mmol/L +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,CHEMISTRY PANEL,Serum Bicarbonate,,22.8,,,,,19.3 - 29.3,mmol/L +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,CHEMISTRY PANEL,Serum Chloride,,96,,,,,94 - 112,mmol/L +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,CREATININE CLEARANCE CC&G,CreatininClearancCockcrftGault,,2.51,,H,,,1.25 - 1.92,mL/sec +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,CREATININE CLEARANCE CC&G,Creatinine(Rate Blanked)-2dp,,51,,,,,31 - 101,umol/L +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,CREATININE CLEARANCE CC&G,"Weight (kg,1dec place)",Y,93.1,,,,,kg, +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,DRUG SCREEN URINE,Amphetamines/MDMA,,Neg,,,,,Neg;$Cutoff = 1000 ng/mL, +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,DRUG SCREEN URINE,Barbiturates,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,DRUG SCREEN URINE,Cannabinoids,,Neg,,,,,Neg;$Cutoff = 50 ng/mL, +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,DRUG SCREEN URINE,Cocaine,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,DRUG SCREEN URINE,Opiates,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,DRUG SCREEN URINE,Methadone,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,DRUG SCREEN URINE BENZO NON-US,Benzodiazepines Gen 2,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,FEMALE OF CHILDBEARING POT?,Female/of Childbearing pot.?,Y,No,,,,,, +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,FSH,Follicle Stimulating Hormone,,30.27,,RX,,,Follicular:$3.90-8.80 IU/L$Midcycle:$4.50-22.50 IU/L$Luteal:$1.80-5.10 IU/L$Postmenopausal:$16.70-113.60 IU/L, +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,GFR,EGFR by MDRD,,106,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,134,,,,,115 - 158,g/L +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.40,,,,,0.34 - 0.48, +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,3.9,,,,,3.9 - 5.5,TI/L +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,102,R,H,,,80 - 100,fL +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,5.37,,,,,3.8 - 10.7,GI/L +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.86,,,,,1.96 - 7.23,GI/L +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.96,,,,,0.8 - 3,GI/L +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.39,,,,,0.12 - 0.92,GI/L +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.11,,,,,0 - 0.57,GI/L +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.04,,,,,0 - 0.2,GI/L +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,53.3,,,,,40.5 - 75,% +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,36.6,,,,,15.4 - 48.5,% +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,7.3,,,,,2.6 - 10.1,% +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.0,,,,,0 - 6.8,% +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.8,,,,,0 - 2,% +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,232,,,,,130 - 394,GI/L +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,HEMOGLOBIN A1C,"Hemoglobin A1c,Variant(-70)-QT",,6.2,,,,,<6.5%, +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,7.31,,,,,1.9 - 23,uIU/mL +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,IS SUBJECT OF BLACK RACE?,Subject of black race?,Y,No,,,,,, +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,LIPID PANEL,Direct HDL-C 4th Generation,,1.30,,,,,1.03 - 1.53,mmol/L +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,LIPID PANEL,Triglycerides (GPO),,1.55,,,,,0.63 - 2.71,mmol/L +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,LIPID PANEL,Cholesterol (High Performance),,3.52,R,L,,,4.86 - 8.28,mmol/L +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,LIPID PANEL,LDL Chol Friedewald 4th,,1.51,,,,,0 - 3.34,mmol/L +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,POSTMENOPAUSAL FEMALE?,<40yrs & amenorrhea >/= 12mo,,Yes,,,,,, +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,RETICULOCYTES,Reticulocyte Count %,,1.6,,,,,0.6 - 2.5,% +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,TSH,TSH 3rd IS-QT,,1.889,,,,,0.45 - 5.33,mIU/L +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,URINE MACRO PANEL,Ur Specific Gravity,,1.015,,,,,1.01 - 1.03, +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.0,,,,,0 - 5,mg/L +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,CELLULAR ELEMENTS,Ur WBC/HPF,,3,,,,,0 - 12,/HPF +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,CHEMISTRY PANEL,Total Bilirubin,,4,,,,,3 - 21,umol/L +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,1.7,,,,,0 - 6.2,umol/L +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,CHEMISTRY PANEL,Alkaline Phosphatase,,44,,,,,35 - 104,U/L +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,CHEMISTRY PANEL,ALT (SGPT),,12,,,,,4 - 43,U/L +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,CHEMISTRY PANEL,AST (SGOT),,19,,,,,8 - 40,U/L +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,CHEMISTRY PANEL,GGT,,6,,,,,4 - 49,U/L +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,CHEMISTRY PANEL,LDH,,157,,,,,53 - 234,U/L +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,CHEMISTRY PANEL,Urea Nitrogen,,3.7,,,,,1.4 - 8.6,mmol/L +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,71,,,,,31 - 101,umol/L +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,CHEMISTRY PANEL,Glucose Fasting,,5.1,,,,,3.9 - 5.6,mmol/L +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,CHEMISTRY PANEL,Serum Uric Acid,,263,,,,,125 - 428,umol/L +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,CHEMISTRY PANEL,Calcium (EDTA),,2.39,,,,,2.07 - 2.64,mmol/L +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,CHEMISTRY PANEL,Phosphorus,,0.71,,,,,0.71 - 1.65,mmol/L +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,CHEMISTRY PANEL,Total Protein,,73,,,,,61 - 84,g/L +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,CHEMISTRY PANEL,Albumin-BCG,,45,,,,,33 - 49,g/L +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,CHEMISTRY PANEL,Creatine Kinase,,260,,H,,,26 - 192,U/L +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,CHEMISTRY PANEL,Serum Sodium,,139,,,,,132 - 147,mmol/L +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,CHEMISTRY PANEL,Serum Potassium,,4.8,,,,,3.5 - 5.2,mmol/L +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,CHEMISTRY PANEL,Serum Bicarbonate,,22.8,,,,,19.3 - 29.3,mmol/L +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,CHEMISTRY PANEL,Serum Chloride,,104,,,,,94 - 112,mmol/L +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,CRYSTALS,Ur Calcium Oxalate Crystals,,Present,,,,,Ref Rng:Not present, +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,127,,,,,116 - 164,g/L +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.39,,,,,0.34 - 0.48, +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.8,,,,,4.1 - 5.6,TI/L +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,82,,,,,79 - 98,fL +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,5.54,,,,,3.8 - 10.7,GI/L +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,4.08,,,,,1.96 - 7.23,GI/L +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.06,,,,,0.91 - 4.28,GI/L +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.33,,,,,0.12 - 0.92,GI/L +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.04,,,,,0 - 0.57,GI/L +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.02,,,,,0 - 0.2,GI/L +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,73.7,,,,,40.5 - 75,% +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,19.3,,,,,15.4 - 48.5,% +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,6.0,,,,,2.6 - 10.1,% +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,0.8,,,,,0 - 6.8,% +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.3,,,,,0 - 2,% +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,260,,,,,140 - 400,GI/L +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,16.54,,,,,1.9 - 23,uIU/mL +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,IS SUBJECT FASTING?,Is Subject Fasting?,Y,No,,,,,, +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,LIPID PANEL,Direct HDL-C 4th Generation,,1.52,,,,,1.03 - 1.53,mmol/L +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,LIPID PANEL,Triglycerides (GPO),,1.60,,,,,0.41 - 1.63,mmol/L +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,LIPID PANEL,Cholesterol (High Performance),,4.24,,,,,3.31 - 5.64,mmol/L +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,LIPID PANEL,LDL Chol Friedewald 4th,,1.99,,,,,0 - 3.34,mmol/L +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,MICROORGANISMS,Ur Bacteria,,Present,,,,,Ref Rng:Not present, +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,MISCELLANEOUS ELEMENTS,Ur Fat,,Present,,H,,,Ref Rng:Not present, +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,RETICULOCYTES,Reticulocyte Count %,,0.6,,,,,0.6 - 2.5,% +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,URINE MACRO PANEL,Ur Specific Gravity,,1.031,,,,,1 - 1.04, +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,URINE MACRO PANEL,Ur Protein,,Trace,,H,,,Ref Rng:Negative, +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,URINE MACRO PANEL,Ur Ketones,,Trace,,H,,,Ref Rng:Negative, +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,URINE MICRO PANEL,Ur Microscopic,,Positive,,,,, NEGATIVE$,NEGATIVE +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,C-REACTIVE PROTEIN,C Reactive Protein HS,,0.3,,,,Result verified by repeat analysis,0 - 5,mg/L +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,CHEMISTRY PANEL,Total Bilirubin,,6,,,,,3 - 21,umol/L +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.2,,,,,0 - 6.2,umol/L +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,CHEMISTRY PANEL,Alkaline Phosphatase,,59,,,,,35 - 104,U/L +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,CHEMISTRY PANEL,ALT (SGPT),,12,,,,,4 - 43,U/L +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,CHEMISTRY PANEL,AST (SGOT),,18,,,,,8 - 40,U/L +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,CHEMISTRY PANEL,GGT,,8,,,,,4 - 49,U/L +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,CHEMISTRY PANEL,LDH,,144,,,,,53 - 234,U/L +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,CHEMISTRY PANEL,Urea Nitrogen,,3.6,,,,,1.4 - 8.6,mmol/L +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,63,,,,,31 - 101,umol/L +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,CHEMISTRY PANEL,Glucose Fasting,,4.9,,,,,3.9 - 5.6,mmol/L +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,CHEMISTRY PANEL,Serum Uric Acid,,235,,,,,125 - 428,umol/L +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,CHEMISTRY PANEL,Calcium (EDTA),,2.33,,,,,2.07 - 2.64,mmol/L +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,CHEMISTRY PANEL,Phosphorus,,1.09,,,,,0.71 - 1.65,mmol/L +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,CHEMISTRY PANEL,Total Protein,,69,,,,,61 - 84,g/L +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,CHEMISTRY PANEL,Albumin-BCG,,44,,,,,33 - 49,g/L +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,CHEMISTRY PANEL,Creatine Kinase,,87,,,,,26 - 192,U/L +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,CHEMISTRY PANEL,Serum Sodium,,137,,,,,132 - 147,mmol/L +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,CHEMISTRY PANEL,Serum Potassium,,4.2,,,,,3.5 - 5.2,mmol/L +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,CHEMISTRY PANEL,Serum Bicarbonate,,22.5,,,,,19.3 - 29.3,mmol/L +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,CHEMISTRY PANEL,Serum Chloride,,101,,,,,94 - 112,mmol/L +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,CREATININE CLEARANCE CC&G,CreatininClearancCockcrftGault,,2.06,,H,,,1.25 - 1.92,mL/sec +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,CREATININE CLEARANCE CC&G,Creatinine(Rate Blanked)-2dp,,63,,,,,31 - 101,umol/L +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,CREATININE CLEARANCE CC&G,"Weight (kg,1dec place)",Y,65.0,,,,,kg, +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,DRUG SCREEN URINE,Amphetamines/MDMA,,Neg,,,,,Neg;$Cutoff = 1000 ng/mL, +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,DRUG SCREEN URINE,Barbiturates,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,DRUG SCREEN URINE,Cannabinoids,,Neg,,,,,Neg;$Cutoff = 50 ng/mL, +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,DRUG SCREEN URINE,Cocaine,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,DRUG SCREEN URINE,Opiates,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,DRUG SCREEN URINE,Methadone,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,DRUG SCREEN URINE BENZO NON-US,Benzodiazepines Gen 2,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,FEMALE OF CHILDBEARING POT?,Female/of Childbearing pot.?,Y,Yes,,,,,, +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,GFR,EGFR by MDRD,,100,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,127,,,,,116 - 164,g/L +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.39,,,,,0.34 - 0.48, +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.8,,,,,4.1 - 5.6,TI/L +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,82,,,,,79 - 98,fL +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,4.86,,,,,3.8 - 10.7,GI/L +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.93,,,,,1.96 - 7.23,GI/L +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.59,,,,,0.91 - 4.28,GI/L +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.27,,,,,0.12 - 0.92,GI/L +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.04,,,,,0 - 0.57,GI/L +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.02,,,,,0 - 0.2,GI/L +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,60.3,,,,,40.5 - 75,% +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,32.7,,,,,15.4 - 48.5,% +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.6,,,,,2.6 - 10.1,% +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,0.9,,,,,0 - 6.8,% +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.5,,,,,0 - 2,% +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,261,,,,,140 - 400,GI/L +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,HEMOGLOBIN A1C,"Hemoglobin A1c,Variant(-70)-QT",,5.4,,,,,<6.5%, +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,6.26,,,,,1.9 - 23,uIU/mL +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,IS SUBJECT OF BLACK RACE?,Subject of black race?,Y,No,,,,,, +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,LIPID PANEL,Direct HDL-C 4th Generation,,1.54,,H,,,1.03 - 1.53,mmol/L +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,LIPID PANEL,Triglycerides (GPO),,0.87,,,,,0.41 - 1.63,mmol/L +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,LIPID PANEL,Cholesterol (High Performance),,4.29,,,,,3.31 - 5.64,mmol/L +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,LIPID PANEL,LDL Chol Friedewald 4th,,2.35,,,,,0 - 3.34,mmol/L +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,POSTMENOPAUSAL FEMALE?,<40yrs & amenorrhea >/= 12mo,,No,,,,,, +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,RETICULOCYTES,Reticulocyte Count %,,0.6,,,,,0.6 - 2.5,% +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,SERUM BETA HCG,"B-hCG, Qualitative",,Negative,,,,,Ref Rng: Negative, +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,SERUM BETA HCG,"B-hCG, Quantitative",,<0.6,,,,,Units: mIU/mL$Pre-menopausal$<5.0: Negative$5.0-24.9:Borderline$>/= 25.0: Positive, +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,TSH,TSH 3rd IS-QT,,0.904,,,,,0.45 - 5.33,mIU/L +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,URINE MACRO PANEL,Ur Specific Gravity,,1.009,,,,,1 - 1.04, +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, diff --git a/Covance_UCO3001/Source/2026-06-08_130713 sponsor-study-35472-test-results-898733-standard.csv b/Covance_UCO3001/Source/2026-06-08_130713 sponsor-study-35472-test-results-898733-standard.csv new file mode 100644 index 0000000..c1822ff --- /dev/null +++ b/Covance_UCO3001/Source/2026-06-08_130713 sponsor-study-35472-test-results-898733-standard.csv @@ -0,0 +1,2409 @@ +"Disclaimer: The information presented in On-Screen Results is not intended to be a replacement of the official Lab Results, Alerts, Data Revisions and Cancellations found in the Lab Reports section of this software application. On-Screen Results should not be used for patient diagnosis, treatment decisions or submission to regulatory bodies.",,,,,,,,,,,,,,,,,,, +Subject,Subject Data Revision,Screen No.,Age,Age Unit,Gender,Visit,Visit Data Revision,Collected Time,Accession,Test Group,Test,Administrative Question,Value,Result Data Revision,Flags,Cancellation Reason,Comments,Range,Units +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,C-REACTIVE PROTEIN,C Reactive Protein HS,,2.2,,,,,0 - 5,mg/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,CHEMISTRY PANEL,Total Bilirubin,,5,,,,,3 - 21,umol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.3,,,,,0 - 6.2,umol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,CHEMISTRY PANEL,Alkaline Phosphatase,,59,,,,,35 - 104,U/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,CHEMISTRY PANEL,ALT (SGPT),,20,,,,,4 - 43,U/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,CHEMISTRY PANEL,AST (SGOT),,24,,,,,8 - 40,U/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,CHEMISTRY PANEL,GGT,,27,,,,,4 - 49,U/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,CHEMISTRY PANEL,LDH,,176,,,,,53 - 234,U/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,CHEMISTRY PANEL,Urea Nitrogen,,4.3,,,,,1.4 - 8.6,mmol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,74,,,,,31 - 101,umol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,CHEMISTRY PANEL,Glucose Fasting,,4.7,,,,,3.9 - 5.6,mmol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,CHEMISTRY PANEL,Serum Uric Acid,,289,,,,,149 - 446,umol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,CHEMISTRY PANEL,Calcium (EDTA),,2.38,,,,,2.07 - 2.64,mmol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,CHEMISTRY PANEL,Phosphorus,,1.12,,,,,0.71 - 1.65,mmol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,CHEMISTRY PANEL,Total Protein,,71,,,,,61 - 84,g/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,CHEMISTRY PANEL,Albumin-BCG,,46,,,,,33 - 49,g/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,CHEMISTRY PANEL,Creatine Kinase,,263,,H,,,26 - 192,U/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,CHEMISTRY PANEL,Serum Sodium,,139,,,,,132 - 147,mmol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,CHEMISTRY PANEL,Serum Potassium,,4.5,,,,,3.5 - 5.2,mmol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,CHEMISTRY PANEL,Serum Bicarbonate,,23.3,,,,,19.3 - 29.3,mmol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,CHEMISTRY PANEL,Serum Chloride,,102,,,,,94 - 112,mmol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,139,,,,Result verified by repeat analysis,116 - 164,g/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.40,,,,Result verified by repeat analysis,0.34 - 0.48, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.4,,,,Result verified by repeat analysis,4.1 - 5.6,TI/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,Normocytic,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,92,,,,Result verified by repeat analysis,79 - 98,fL +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,7.14,,,,Result verified by repeat analysis,3.8 - 10.7,GI/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,4.07,,,,,1.96 - 7.23,GI/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.57,,,,,0.91 - 4.28,GI/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.29,,,,,0.12 - 0.92,GI/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.14,,,,,0 - 0.57,GI/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.07,,,,,0 - 0.2,GI/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,57.0,,,,,40.5 - 75,% +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,36.0,,,,,15.4 - 48.5,% +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,4.0,,,,,2.6 - 10.1,% +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.0,,,,,0 - 6.8,% +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.0,,,,,0 - 2,% +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,309,,,,Result verified by repeat analysis,140 - 400,GI/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.1,,,,,<6.5 %, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,4.37,,,,,1.9 - 23,uIU/mL +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,LIPID PANEL,Direct HDL-C 4th Generation,,1.79,,H,,,1.03 - 1.53,mmol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,LIPID PANEL,Triglycerides (GPO),,1.51,,,,,0.59 - 2.96,mmol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,LIPID PANEL,Cholesterol (High Performance),,5.75,,,,,4.42 - 7.53,mmol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,LIPID PANEL,LDL Chol Friedewald 4th,,3.27,,,,,0 - 3.34,mmol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,RETICULOCYTES,Reticulocyte Count %,,1.2,,,,,0.6 - 2.5,% +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,TSH,TSH 3rd IS-QT,,4.824,,,,,0.45 - 5.33,mIU/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,URINE MACRO PANEL,Ur Specific Gravity,,1.029,,,,,1 - 1.04, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,C-REACTIVE PROTEIN,C Reactive Protein HS,,7.3,,H,,,0 - 5,mg/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,CHEMISTRY PANEL,Total Bilirubin,,11,,,,,3 - 21,umol/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,4.9,,,,,0 - 6.2,umol/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,CHEMISTRY PANEL,Alkaline Phosphatase,,80,,,,,40 - 129,U/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,CHEMISTRY PANEL,ALT (SGPT),,163,,H RX,,,5 - 48,U/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,CHEMISTRY PANEL,AST (SGOT),,127,,H RX,,,8 - 40,U/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,CHEMISTRY PANEL,GGT,,350,,HT,,Result verified by repeat analysis,10 - 50,U/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,CHEMISTRY PANEL,LDH,,224,,,,,53 - 234,U/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,CHEMISTRY PANEL,Urea Nitrogen,,4.1,,,,,1.4 - 8.6,mmol/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,106,,,,,40 - 119,umol/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,CHEMISTRY PANEL,Glucose Fasting,,6.1,,H,,,3.9 - 5.6,mmol/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,CHEMISTRY PANEL,Serum Uric Acid,,512,,H,,,149 - 494,umol/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,CHEMISTRY PANEL,Calcium (EDTA),,2.39,,,,,2.07 - 2.64,mmol/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,CHEMISTRY PANEL,Phosphorus,,0.81,,,,,0.71 - 1.65,mmol/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,CHEMISTRY PANEL,Total Protein,,77,,,,,60 - 80,g/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,CHEMISTRY PANEL,Albumin-BCG,,48,,,,,33 - 49,g/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,CHEMISTRY PANEL,Creatine Kinase,,348,,H,,,39 - 308,U/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,CHEMISTRY PANEL,Serum Sodium,,137,,,,,135 - 145,mmol/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,CHEMISTRY PANEL,Serum Potassium,,4.3,,,,,3.5 - 5.2,mmol/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,CHEMISTRY PANEL,Serum Bicarbonate,,21.3,,,,,19.3 - 29.3,mmol/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,CHEMISTRY PANEL,Serum Chloride,,100,,,,,94 - 112,mmol/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,134,,,,,125 - 170,g/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.41,,,,,0.37 - 0.51, +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.1,,,,,4 - 5.8,TI/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,100,,,,,80 - 100,fL +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,3.89,,,,,3.8 - 10.7,GI/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.35,,,,,1.96 - 7.23,GI/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.13,,,,,0.8 - 3,GI/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.34,,,,,0.12 - 0.92,GI/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.03,,,,,0 - 0.57,GI/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.04,,,,,0 - 0.2,GI/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,60.5,,,,,40.5 - 75,% +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,29.0,,,,,15.4 - 48.5,% +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,8.7,,,,,2.6 - 10.1,% +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,0.9,,,,,0 - 6.8,% +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.9,,,,,0 - 2,% +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,137,R,L,,,140 - 400,GI/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,6.3,,,,,<6.5 %, +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,30.61,,H,,,1.9 - 23,uIU/mL +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,LIPID PANEL,Direct HDL-C 4th Generation,,1.03,,,,,1.03 - 1.53,mmol/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,LIPID PANEL,Triglycerides (GPO),,2.89,,,,,0.65 - 3.61,mmol/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,LIPID PANEL,Cholesterol (High Performance),,4.82,,,,,4.4 - 7.53,mmol/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,LIPID PANEL,LDL Chol Friedewald 4th,,2.47,,,,,0 - 3.34,mmol/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,RETICULOCYTES,Reticulocyte Count %,,1.5,,,,,0.6 - 2.5,% +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,TSH,TSH 3rd IS-QT,,1.982,,,,,0.45 - 5.33,mIU/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,URINE MACRO PANEL,Ur Specific Gravity,,1.010,,,,,1.01 - 1.03, +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:Negative, +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,C-REACTIVE PROTEIN,C Reactive Protein HS,,0.9,,,,,0 - 5,mg/L +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,CHEMISTRY PANEL,Total Bilirubin,,8,,,,,3 - 21,umol/L +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.0,,,,,0 - 6.2,umol/L +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,CHEMISTRY PANEL,Alkaline Phosphatase,,92,,,,,40 - 129,U/L +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,CHEMISTRY PANEL,ALT (SGPT),,19,,,,,5 - 48,U/L +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,CHEMISTRY PANEL,AST (SGOT),,14,,,,,8 - 40,U/L +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,CHEMISTRY PANEL,GGT,,13,,,,,10 - 61,U/L +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,CHEMISTRY PANEL,LDH,,144,,,,,53 - 234,U/L +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,CHEMISTRY PANEL,Urea Nitrogen,,4.6,,,,,1.4 - 8.6,mmol/L +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,92,,,,,40 - 110,umol/L +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,CHEMISTRY PANEL,Glucose Fasting,,5.1,,,,,3.9 - 5.6,mmol/L +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,CHEMISTRY PANEL,Serum Uric Acid,,249,,,,,125 - 488,umol/L +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,CHEMISTRY PANEL,Calcium (EDTA),,2.51,,,,,2.07 - 2.64,mmol/L +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,CHEMISTRY PANEL,Phosphorus,,0.97,,,,,0.71 - 1.65,mmol/L +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,CHEMISTRY PANEL,Total Protein,,72,,,,,61 - 84,g/L +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,CHEMISTRY PANEL,Albumin-BCG,,50,R,H,,,33 - 49,g/L +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,CHEMISTRY PANEL,Creatine Kinase,,224,,,,,39 - 308,U/L +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,CHEMISTRY PANEL,Serum Sodium,,138,,,,,132 - 147,mmol/L +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,CHEMISTRY PANEL,Serum Potassium,,4.1,,,,,3.5 - 5.2,mmol/L +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,CHEMISTRY PANEL,Serum Bicarbonate,,27.9,,,,,19.3 - 29.3,mmol/L +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,CHEMISTRY PANEL,Serum Chloride,,98,,,,,94 - 112,mmol/L +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,145,,,,,127 - 181,g/L +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.44,,,,,0.39 - 0.54, +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.9,,,,,4.5 - 6.4,TI/L +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,90,,,,,79 - 96,fL +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,4.75,,,,,3.8 - 10.7,GI/L +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.09,,,,,1.96 - 7.23,GI/L +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.22,,,,,0.91 - 4.28,GI/L +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.35,,,,,0.12 - 0.92,GI/L +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.06,,,,,0 - 0.57,GI/L +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.03,,,,,0 - 0.2,GI/L +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,65.0,,,,,40.5 - 75,% +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,25.8,,,,,15.4 - 48.5,% +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,7.3,,,,,2.6 - 10.1,% +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.4,,,,,0 - 6.8,% +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.6,,,,,0 - 2,% +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,216,,,,,140 - 400,GI/L +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.3,,,,,<6.5 %, +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,4.44,,,,,1.9 - 23,uIU/mL +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,LIPID PANEL,Direct HDL-C 4th Generation,,1.34,,,,,1.03 - 1.53,mmol/L +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,LIPID PANEL,Triglycerides (GPO),,0.59,,,,,0.5 - 2.81,mmol/L +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,LIPID PANEL,Cholesterol (High Performance),,3.92,,,,,3.31 - 6.1,mmol/L +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,LIPID PANEL,LDL Chol Friedewald 4th,,2.31,,,,,0 - 3.34,mmol/L +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,RETICULOCYTES,Reticulocyte Count %,,1.2,,,,,0.6 - 2.5,% +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,TSH,TSH 3rd IS-QT,,1.256,,,,,0.45 - 5.33,mIU/L +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,URINE MACRO PANEL,Ur Specific Gravity,,1.012,,,,,1 - 1.04, +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,URINE MACRO PANEL,Ur pH,,6.0,,,,,5 - 8, +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:Negative, +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.3,,,,,0 - 5,mg/L +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,CHEMISTRY PANEL,Total Bilirubin,,5,,,,,3 - 21,umol/L +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,1.8,,,,,0 - 6.2,umol/L +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,CHEMISTRY PANEL,Alkaline Phosphatase,,104,,,,,40 - 129,U/L +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,CHEMISTRY PANEL,ALT (SGPT),,17,,,,,5 - 48,U/L +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,CHEMISTRY PANEL,AST (SGOT),,18,,,,,8 - 40,U/L +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,CHEMISTRY PANEL,GGT,,13,,,,,10 - 61,U/L +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,CHEMISTRY PANEL,LDH,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,CHEMISTRY PANEL,Urea Nitrogen,,6.2,,,,,1.4 - 8.6,mmol/L +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,95,,,,,40 - 110,umol/L +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,CHEMISTRY PANEL,Glucose Fasting,,4.9,,,,,3.9 - 5.6,mmol/L +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,CHEMISTRY PANEL,Serum Uric Acid,,216,,,,,125 - 488,umol/L +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,CHEMISTRY PANEL,Calcium (EDTA),,2.45,,,,,2.07 - 2.64,mmol/L +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,CHEMISTRY PANEL,Phosphorus,,1.25,,,,,0.71 - 1.65,mmol/L +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,CHEMISTRY PANEL,Total Protein,,75,,,,,61 - 84,g/L +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,CHEMISTRY PANEL,Albumin-BCG,,52,,H,,,33 - 49,g/L +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,CHEMISTRY PANEL,Creatine Kinase,,196,,,,,39 - 308,U/L +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,CHEMISTRY PANEL,Serum Sodium,,142,,,,,132 - 147,mmol/L +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,CHEMISTRY PANEL,Serum Potassium,,4.4,,,,,3.5 - 5.2,mmol/L +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,CHEMISTRY PANEL,Serum Bicarbonate,,22.8,,,,,19.3 - 29.3,mmol/L +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,CHEMISTRY PANEL,Serum Chloride,,101,,,,,94 - 112,mmol/L +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,CREATININE CLEARANCE CC&G,CreatininClearancCockcrftGault,,1.59,,,,,1.42 - 2.08,mL/sec +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,CREATININE CLEARANCE CC&G,Creatinine(Rate Blanked)-2dp,,95,,,,,40 - 110,umol/L +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,CREATININE CLEARANCE CC&G,"Weight (kg,1dec place)",Y,64.0,,,,,kg, +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,FSH,Follicle Stimulating Hormone,,6.14,,RX,,,1.3 - 19.3,IU/L +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,146,,,,,127 - 181,g/L +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.44,,,,,0.39 - 0.54, +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.0,,,,,4.5 - 6.4,TI/L +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,88,,,,,79 - 96,fL +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,6.24,,,,,3.8 - 10.7,GI/L +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.97,,,,,1.96 - 7.23,GI/L +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.72,,,,,0.91 - 4.28,GI/L +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.40,,,,,0.12 - 0.92,GI/L +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.12,,,,,0 - 0.57,GI/L +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.03,,,,,0 - 0.2,GI/L +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,63.6,,,,,40.5 - 75,% +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,27.6,,,,,15.4 - 48.5,% +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,6.5,,,,,2.6 - 10.1,% +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.9,,,,,0 - 6.8,% +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.5,,,,,0 - 2,% +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,223,,,,,140 - 400,GI/L +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.3,,,,,<6.5 %, +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,4.85,,,,,1.9 - 23,uIU/mL +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,LIPID PANEL,Direct HDL-C 4th Generation,,1.40,,,,,1.03 - 1.53,mmol/L +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,LIPID PANEL,Triglycerides (GPO),,0.81,,,,,0.5 - 2.81,mmol/L +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,LIPID PANEL,Cholesterol (High Performance),,4.33,,,,,3.31 - 6.1,mmol/L +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,LIPID PANEL,LDL Chol Friedewald 4th,,2.56,,,,,0 - 3.34,mmol/L +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,RETICULOCYTES,Reticulocyte Count %,,0.9,,,,,0.6 - 2.5,% +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,TSH,TSH 3rd IS-QT,,1.789,,,,,0.45 - 5.33,mIU/L +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,URINE MACRO PANEL,Ur Specific Gravity,,1.028,,,,,1 - 1.04, +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:Negative, +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,C-REACTIVE PROTEIN,C Reactive Protein HS,,4.1,,,,,0 - 5,mg/L +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,CHEMISTRY PANEL,Total Bilirubin,,10,,,,,3 - 21,umol/L +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.6,,,,,0 - 6.2,umol/L +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,CHEMISTRY PANEL,Alkaline Phosphatase,,58,,,,,40 - 129,U/L +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,CHEMISTRY PANEL,ALT (SGPT),,86,,H RX,,,5 - 48,U/L +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,CHEMISTRY PANEL,AST (SGOT),,74,,H RX,,,8 - 40,U/L +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,CHEMISTRY PANEL,GGT,,83,,H,,,10 - 50,U/L +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,CHEMISTRY PANEL,LDH,,187,,,,,53 - 234,U/L +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,CHEMISTRY PANEL,Urea Nitrogen,,5.4,,,,,1.4 - 8.6,mmol/L +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,107,,,,,40 - 119,umol/L +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,CHEMISTRY PANEL,Glucose Fasting,,8.0,,H,,,3.9 - 5.6,mmol/L +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,CHEMISTRY PANEL,Serum Uric Acid,,500,,H,,,149 - 494,umol/L +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,CHEMISTRY PANEL,Calcium (EDTA),,2.36,,,,,2.07 - 2.64,mmol/L +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,CHEMISTRY PANEL,Phosphorus,,0.92,,,,,0.71 - 1.65,mmol/L +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,CHEMISTRY PANEL,Total Protein,,77,,,,,60 - 80,g/L +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,CHEMISTRY PANEL,Albumin-BCG,,48,,,,,33 - 49,g/L +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,CHEMISTRY PANEL,Creatine Kinase,,238,,,,,39 - 308,U/L +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,CHEMISTRY PANEL,Serum Sodium,,137,,,,,135 - 145,mmol/L +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,CHEMISTRY PANEL,Serum Potassium,,3.8,,,,,3.5 - 5.2,mmol/L +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,CHEMISTRY PANEL,Serum Bicarbonate,,21.3,,,,,19.3 - 29.3,mmol/L +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,CHEMISTRY PANEL,Serum Chloride,,99,,,,,94 - 112,mmol/L +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,137,,,,,125 - 170,g/L +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.40,,,,,0.37 - 0.51, +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.2,,,,,4 - 5.8,TI/L +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,Normocytic,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,97,,,,,80 - 100,fL +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,5.57,,,,,3.8 - 10.7,GI/L +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.18,,,,,1.96 - 7.23,GI/L +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.84,,,,,0.8 - 3,GI/L +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.44,,,,,0.12 - 0.92,GI/L +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.06,,,,,0 - 0.57,GI/L +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.05,,,,,0 - 0.2,GI/L +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,57.1,,,,,40.5 - 75,% +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,33.0,,,,,15.4 - 48.5,% +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,7.9,,,,,2.6 - 10.1,% +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.0,,,,,0 - 6.8,% +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.9,,,,,0 - 2,% +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,169,,,,,140 - 400,GI/L +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,33.13,,H,,,1.9 - 23,uIU/mL +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,LIPID PANEL,Direct HDL-C 4th Generation,,0.70,,L,,,1.03 - 1.53,mmol/L +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,LIPID PANEL,Triglycerides (GPO),,2.48,,,,,0.65 - 3.61,mmol/L +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,LIPID PANEL,Cholesterol (High Performance),,4.55,,,,,4.4 - 7.53,mmol/L +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,LIPID PANEL,LDL Chol Friedewald 4th,,2.71,,,,,0 - 3.34,mmol/L +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,RETICULOCYTES,Reticulocyte Count %,,2.1,,,,,0.6 - 2.5,% +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,URINE MACRO PANEL,Ur Specific Gravity,,1.018,,,,,1.01 - 1.03, +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:Negative, +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,C-REACTIVE PROTEIN,C Reactive Protein HS,,3.7,,,,,0 - 5,mg/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,CELLULAR ELEMENTS,Ur WBC/HPF,,1,,,,,0 - 12,/HPF +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,CHEMISTRY PANEL,Total Bilirubin,,15,,,,,3 - 21,umol/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,4.6,,,,,0 - 6.2,umol/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,CHEMISTRY PANEL,Alkaline Phosphatase,,101,,,,,35 - 104,U/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,CHEMISTRY PANEL,ALT (SGPT),,19,,,,,4 - 43,U/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,CHEMISTRY PANEL,AST (SGOT),,21,,,,,8 - 40,U/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,CHEMISTRY PANEL,GGT,,13,,,,,4 - 49,U/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,CHEMISTRY PANEL,LDH,,175,,,,,53 - 234,U/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,CHEMISTRY PANEL,Urea Nitrogen,,3.9,,,,,1.4 - 8.6,mmol/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,54,,,,,31 - 101,umol/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,CHEMISTRY PANEL,Glucose Fasting,,4.6,,,,,3.9 - 5.6,mmol/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,CHEMISTRY PANEL,Serum Uric Acid,,232,,,,,125 - 428,umol/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,CHEMISTRY PANEL,Calcium (EDTA),,2.37,,,,,2.07 - 2.64,mmol/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,CHEMISTRY PANEL,Phosphorus,,1.06,,,,,0.71 - 1.65,mmol/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,CHEMISTRY PANEL,Total Protein,,80,,,,,61 - 84,g/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,CHEMISTRY PANEL,Albumin-BCG,,48,,,,,33 - 49,g/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,CHEMISTRY PANEL,Creatine Kinase,,52,,,,,26 - 192,U/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,CHEMISTRY PANEL,Serum Sodium,,138,,,,,132 - 147,mmol/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,CHEMISTRY PANEL,Serum Potassium,,4.4,,,,,3.5 - 5.2,mmol/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,CHEMISTRY PANEL,Serum Bicarbonate,,22.0,,,,,19.3 - 29.3,mmol/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,CHEMISTRY PANEL,Serum Chloride,,103,,,,,94 - 112,mmol/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,CRYSTALS,Ur Uric Acid Crystals,,Present,,,,,Ref Rng:Not present, +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,FREE T4,Free Thyroxine-QT,,18,,H,,,8 - 14,pmol/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,128,,,,,116 - 164,g/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.39,,,,,0.34 - 0.48, +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.4,,,,,4.1 - 5.6,TI/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,89,,,,,79 - 98,fL +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,5.85,,,,,3.8 - 10.7,GI/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.16,,,,,1.96 - 7.23,GI/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.28,,,,,0.91 - 4.28,GI/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.31,,,,,0.12 - 0.92,GI/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.05,,,,,0 - 0.57,GI/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.06,,,,,0 - 0.2,GI/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,54.0,,,,,40.5 - 75,% +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,38.9,,,,,15.4 - 48.5,% +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.3,,,,,2.6 - 10.1,% +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,0.9,,,,,0 - 6.8,% +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.0,,,,,0 - 2,% +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,312,,,,,140 - 400,GI/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,4.7,,,,,<6.5 %, +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,3.75,,,,,1.9 - 23,uIU/mL +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,LIPID PANEL,Direct HDL-C 4th Generation,,1.07,,,,,1.03 - 1.53,mmol/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,LIPID PANEL,Triglycerides (GPO),,0.77,,,,,0.44 - 1.99,mmol/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,LIPID PANEL,Cholesterol (High Performance),,3.77,,,,,3.65 - 6.21,mmol/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,LIPID PANEL,LDL Chol Friedewald 4th,,2.35,,,,,0 - 3.34,mmol/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,MICROORGANISMS,Ur Bacteria,,Present,,,,,Ref Rng:Not present, +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,RETICULOCYTES,Reticulocyte Count %,,1.5,,,,,0.6 - 2.5,% +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,TSH,TSH 3rd IS-QT,,0.119,,L SF,,,0.45 - 5.33,mIU/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,URINE MACRO PANEL,Ur Specific Gravity,,1.025,,,,,1 - 1.04, +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,URINE MACRO PANEL,Ur pH,,5.0,,,,,5 - 8, +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,URINE MACRO PANEL,Ur Leukocyte Esterase,,Trace,,H,,,Ref Rng:Negative, +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,URINE MICRO PANEL,Ur Microscopic,,Positive,,,,, NEGATIVE$,NEGATIVE +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,C-REACTIVE PROTEIN,C Reactive Protein HS,,0.7,,,,,0 - 5,mg/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,CHEMISTRY PANEL,Total Bilirubin,,5,,,,,3 - 21,umol/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.4,,,,,0 - 6.2,umol/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,CHEMISTRY PANEL,Alkaline Phosphatase,,53,,,,,35 - 104,U/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,CHEMISTRY PANEL,ALT (SGPT),,9,,,,,4 - 43,U/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,CHEMISTRY PANEL,AST (SGOT),,11,,,,,8 - 40,U/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,CHEMISTRY PANEL,GGT,,12,,,,,4 - 49,U/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,CHEMISTRY PANEL,LDH,,134,,,,,53 - 234,U/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,CHEMISTRY PANEL,Urea Nitrogen,,5.0,,,,,1.4 - 8.6,mmol/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,76,,,,,31 - 101,umol/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,CHEMISTRY PANEL,Glucose Fasting,,5.7,,H,,,3.9 - 5.6,mmol/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,CHEMISTRY PANEL,Serum Uric Acid,,216,,,,,125 - 428,umol/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,CHEMISTRY PANEL,Calcium (EDTA),,2.41,,,,,2.07 - 2.64,mmol/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,CHEMISTRY PANEL,Phosphorus,,0.83,,,,,0.71 - 1.65,mmol/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,CHEMISTRY PANEL,Total Protein,,65,,,,,61 - 84,g/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,CHEMISTRY PANEL,Albumin-BCG,,45,,,,,33 - 49,g/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,CHEMISTRY PANEL,Creatine Kinase,,83,,,,,26 - 192,U/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,CHEMISTRY PANEL,Serum Sodium,,141,,,,,132 - 147,mmol/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,CHEMISTRY PANEL,Serum Potassium,,4.2,,,,,3.5 - 5.2,mmol/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,CHEMISTRY PANEL,Serum Bicarbonate,,23.3,,,,,19.3 - 29.3,mmol/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,CHEMISTRY PANEL,Serum Chloride,,106,,,,,94 - 112,mmol/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,121,,,,,116 - 164,g/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.36,,,,,0.34 - 0.48, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.0,,L,,,4.1 - 5.6,TI/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,91,,,,,79 - 98,fL +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,4.63,,,,,3.8 - 10.7,GI/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.66,,,,,1.96 - 7.23,GI/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.64,,,,,0.91 - 4.28,GI/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.20,,,,,0.12 - 0.92,GI/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.11,,,,,0 - 0.57,GI/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.02,,,,,0 - 0.2,GI/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,57.5,,,,,40.5 - 75,% +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,35.3,,,,,15.4 - 48.5,% +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,4.3,,,,,2.6 - 10.1,% +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.4,,,,,0 - 6.8,% +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.5,,,,,0 - 2,% +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,273,,,,,140 - 400,GI/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.4,,,,,<6.5 %, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,5.32,,,,,1.9 - 23,uIU/mL +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,LIPID PANEL,Direct HDL-C 4th Generation,,1.68,,H,,,1.03 - 1.53,mmol/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,LIPID PANEL,Triglycerides (GPO),,0.69,,,,,0.44 - 1.99,mmol/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,LIPID PANEL,Cholesterol (High Performance),,4.75,,,,,3.65 - 6.21,mmol/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,LIPID PANEL,LDL Chol Friedewald 4th,,2.75,,,,,0 - 3.34,mmol/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,RETICULOCYTES,Reticulocyte Count %,,0.7,,,,,0.6 - 2.5,% +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,TSH,TSH 3rd IS-QT,,1.607,,,,,0.45 - 5.33,mIU/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,URINE MACRO PANEL,Ur Specific Gravity,,1.027,,,,,1 - 1.04, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,URINE MACRO PANEL,Ur pH,,6.0,,,,,5 - 8, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.2,,,,,0 - 5,mg/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,CELLULAR ELEMENTS,Ur WBC/HPF,,1,,,,,0 - 12,/HPF +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,CHEMISTRY PANEL,Total Bilirubin,,6,,,,,3 - 21,umol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.3,,,,,0 - 6.2,umol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,CHEMISTRY PANEL,Alkaline Phosphatase,,64,,,,,35 - 104,U/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,CHEMISTRY PANEL,ALT (SGPT),,21,,,,,4 - 43,U/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,CHEMISTRY PANEL,AST (SGOT),,24,,,,,8 - 40,U/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,CHEMISTRY PANEL,GGT,,30,,,,,4 - 49,U/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,CHEMISTRY PANEL,LDH,,164,,,,,53 - 234,U/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,CHEMISTRY PANEL,Urea Nitrogen,,4.5,,,,,1.4 - 8.6,mmol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,76,,,,,31 - 101,umol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,CHEMISTRY PANEL,Glucose Fasting,,4.7,,,,,3.9 - 5.6,mmol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,CHEMISTRY PANEL,Serum Uric Acid,,315,,,,,149 - 446,umol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,CHEMISTRY PANEL,Calcium (EDTA),,2.42,,,,,2.07 - 2.64,mmol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,CHEMISTRY PANEL,Phosphorus,,1.08,,,,,0.71 - 1.65,mmol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,CHEMISTRY PANEL,Total Protein,,71,,,,,61 - 84,g/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,CHEMISTRY PANEL,Albumin-BCG,,45,,,,,33 - 49,g/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,CHEMISTRY PANEL,Creatine Kinase,,151,,,,,26 - 192,U/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,CHEMISTRY PANEL,Serum Sodium,,138,,,,,132 - 147,mmol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,CHEMISTRY PANEL,Serum Potassium,,4.9,,,,,3.5 - 5.2,mmol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,CHEMISTRY PANEL,Serum Bicarbonate,,24.8,,,,,19.3 - 29.3,mmol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,CHEMISTRY PANEL,Serum Chloride,,100,,,,,94 - 112,mmol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,135,,,,,116 - 164,g/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.40,,,,,0.34 - 0.48, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.4,,,,,4.1 - 5.6,TI/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,91,,,,,79 - 98,fL +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,7.44,,,,,3.8 - 10.7,GI/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.89,,,,,1.96 - 7.23,GI/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,3.02,,,,,0.91 - 4.28,GI/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.33,,,,,0.12 - 0.92,GI/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.14,,,,,0 - 0.57,GI/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.06,,,,,0 - 0.2,GI/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,52.3,,,,,40.5 - 75,% +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,40.6,,,,,15.4 - 48.5,% +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,4.5,,,,,2.6 - 10.1,% +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.9,,,,,0 - 6.8,% +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.8,,,,,0 - 2,% +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,307,,,,,140 - 400,GI/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.4,,,,,<6.5 %, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,2.60,,,,,1.9 - 23,uIU/mL +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,LIPID PANEL,Direct HDL-C 4th Generation,,1.98,,H,,,1.03 - 1.53,mmol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,LIPID PANEL,Triglycerides (GPO),,1.32,,,,,0.59 - 2.96,mmol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,LIPID PANEL,Cholesterol (High Performance),,5.66,,,,,4.42 - 7.53,mmol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,LIPID PANEL,LDL Chol Friedewald 4th,,3.08,,,,,0 - 3.34,mmol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,RETICULOCYTES,Reticulocyte Count %,,1.3,,,,,0.6 - 2.5,% +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,TSH,TSH 3rd IS-QT,,3.912,,,,,0.45 - 5.33,mIU/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,URINE MACRO PANEL,Ur Specific Gravity,,1.025,,,,,1 - 1.04, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,URINE MACRO PANEL,Ur Leukocyte Esterase,,Trace,,H,,,Ref Rng:Negative, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,URINE MICRO PANEL,Ur Microscopic,,Positive,,,,, NEGATIVE$,NEGATIVE +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,C-REACTIVE PROTEIN,C Reactive Protein HS,,0.7,,,,,0 - 5,mg/L +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,CELLULAR ELEMENTS,Ur WBC/HPF,,1,,,,,0 - 5,/HPF +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,CHEMISTRY PANEL,Total Bilirubin,,13,,,,,3 - 21,umol/L +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,4.2,,,,,0 - 6.2,umol/L +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,CHEMISTRY PANEL,Alkaline Phosphatase,,91,,,,,40 - 129,U/L +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,CHEMISTRY PANEL,ALT (SGPT),,29,,,,,5 - 48,U/L +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,CHEMISTRY PANEL,AST (SGOT),,39,,,,,8 - 40,U/L +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,CHEMISTRY PANEL,GGT,,13,,,,,10 - 61,U/L +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,CHEMISTRY PANEL,LDH,,206,,,,,53 - 234,U/L +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,CHEMISTRY PANEL,Urea Nitrogen,,5.5,,,,,1.4 - 8.6,mmol/L +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,104,,,,,40 - 110,umol/L +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,CHEMISTRY PANEL,Glucose Fasting,,5.6,,,,,3.9 - 5.6,mmol/L +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,CHEMISTRY PANEL,Serum Uric Acid,,223,,,,,125 - 488,umol/L +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,CHEMISTRY PANEL,Calcium (EDTA),,2.58,,,,,2.07 - 2.64,mmol/L +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,CHEMISTRY PANEL,Phosphorus,,1.09,,,,,0.71 - 1.65,mmol/L +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,CHEMISTRY PANEL,Total Protein,,72,,,,,61 - 84,g/L +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,CHEMISTRY PANEL,Albumin-BCG,,51,R,H,,,33 - 49,g/L +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,CHEMISTRY PANEL,Creatine Kinase,,1857,R,H SF,,Diluted for quantitation,39 - 308,U/L +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,CHEMISTRY PANEL,Serum Sodium,,139,,,,,132 - 147,mmol/L +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,CHEMISTRY PANEL,Serum Potassium,,4.5,,,,,3.5 - 5.2,mmol/L +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,CHEMISTRY PANEL,Serum Bicarbonate,,23.1,,,,,19.3 - 29.3,mmol/L +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,CHEMISTRY PANEL,Serum Chloride,,100,,,,,94 - 112,mmol/L +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,157,,,,,127 - 181,g/L +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.45,,,,,0.39 - 0.54, +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.2,,,,,4.5 - 6.4,TI/L +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,87,,,,,79 - 96,fL +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,6.41,,,,,3.8 - 10.7,GI/L +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,4.57,,,,,1.96 - 7.23,GI/L +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.23,,,,,0.91 - 4.28,GI/L +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.48,,,,,0.12 - 0.92,GI/L +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.08,,,,,0 - 0.57,GI/L +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.06,,,,,0 - 0.2,GI/L +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,71.3,,,,,40.5 - 75,% +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,19.1,,,,,15.4 - 48.5,% +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,7.5,,,,,2.6 - 10.1,% +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.3,,,,,0 - 6.8,% +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.9,,,,,0 - 2,% +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,242,,,,,140 - 400,GI/L +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,6.71,,,,,1.9 - 23,uIU/mL +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,LIPID PANEL,Direct HDL-C 4th Generation,,1.23,,,,,1.03 - 1.53,mmol/L +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,LIPID PANEL,Triglycerides (GPO),,1.12,,,,,0.5 - 2.81,mmol/L +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,LIPID PANEL,Cholesterol (High Performance),,3.95,,,,,3.31 - 6.1,mmol/L +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,LIPID PANEL,LDL Chol Friedewald 4th,,2.21,,,,,0 - 3.34,mmol/L +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,RETICULOCYTES,Reticulocyte Count %,,0.6,,,,,0.6 - 2.5,% +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,URINE MACRO PANEL,Ur Specific Gravity,,1.036,R,H,,,1 - 1.04, +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,URINE MACRO PANEL,Ur Protein,,Trace,R,H,,,Ref Rng:Negative, +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:Negative, +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,URINE MICRO PANEL,Ur Microscopic,,Positive,,,,, NEGATIVE$,NEGATIVE +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,C-REACTIVE PROTEIN,C Reactive Protein HS,,2.7,,,,,0 - 5,mg/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,CHEMISTRY PANEL,Total Bilirubin,,9,,,,,3 - 21,umol/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.1,,,,,0 - 6.2,umol/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,CHEMISTRY PANEL,Alkaline Phosphatase,,53,,,,,40 - 129,U/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,CHEMISTRY PANEL,ALT (SGPT),,79,,H RX,,,5 - 48,U/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,CHEMISTRY PANEL,AST (SGOT),,46,,H,,,8 - 40,U/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,CHEMISTRY PANEL,GGT,,68,,H,,,10 - 50,U/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,CHEMISTRY PANEL,LDH,,161,,,,,53 - 234,U/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,CHEMISTRY PANEL,Urea Nitrogen,,4.8,,,,,1.4 - 8.6,mmol/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,95,,,,,40 - 119,umol/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,CHEMISTRY PANEL,Glucose Fasting,,7.0,,H,,,3.9 - 5.6,mmol/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,CHEMISTRY PANEL,Serum Uric Acid,,393,,,,,149 - 494,umol/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,CHEMISTRY PANEL,Calcium (EDTA),,2.28,,,,,2.07 - 2.64,mmol/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,CHEMISTRY PANEL,Phosphorus,,0.81,,,,,0.71 - 1.65,mmol/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,CHEMISTRY PANEL,Total Protein,,72,,,,,60 - 80,g/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,CHEMISTRY PANEL,Albumin-BCG,,46,,,,,33 - 49,g/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,CHEMISTRY PANEL,Creatine Kinase,,212,,,,,39 - 308,U/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,CHEMISTRY PANEL,Serum Sodium,,139,,,,,135 - 145,mmol/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,CHEMISTRY PANEL,Serum Potassium,,4.0,,,,,3.5 - 5.2,mmol/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,CHEMISTRY PANEL,Serum Bicarbonate,,22.5,,,,,19.3 - 29.3,mmol/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,CHEMISTRY PANEL,Serum Chloride,,102,,,,,94 - 112,mmol/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,132,,,,,125 - 170,g/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.38,,,,,0.37 - 0.51, +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,3.9,,L,,,4 - 5.8,TI/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,98,,,,,80 - 100,fL +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,4.42,,,,,3.8 - 10.7,GI/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.42,,,,,1.96 - 7.23,GI/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.61,,,,,0.8 - 3,GI/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.28,,,,,0.12 - 0.92,GI/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.06,,,,,0 - 0.57,GI/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.05,,,,,0 - 0.2,GI/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,54.8,,,,,40.5 - 75,% +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,36.4,,,,,15.4 - 48.5,% +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,6.4,,,,,2.6 - 10.1,% +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.3,,,,,0 - 6.8,% +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.2,,,,,0 - 2,% +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,149,,,,,140 - 400,GI/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,6.2,,,,,<6.5 %, +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,33.25,R,H,,,1.9 - 23,uIU/mL +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,LIPID PANEL,Direct HDL-C 4th Generation,,0.79,,L,,,1.03 - 1.53,mmol/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,LIPID PANEL,Triglycerides (GPO),,2.48,,,,,0.65 - 3.61,mmol/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,LIPID PANEL,Cholesterol (High Performance),,4.67,,,,,4.4 - 7.53,mmol/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,LIPID PANEL,LDL Chol Friedewald 4th,,2.74,,,,,0 - 3.34,mmol/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,RETICULOCYTES,Reticulocyte Count %,,1.8,,,,,0.6 - 2.5,% +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,TSH,TSH 3rd IS-QT,,1.053,,,,,0.45 - 5.33,mIU/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,URINE MACRO PANEL,Ur Specific Gravity,,1.017,,,,,1.01 - 1.03, +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:Negative, +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,C-REACTIVE PROTEIN,C Reactive Protein HS,,0.7,,,,,0 - 5,mg/L +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,CHEMISTRY PANEL,Total Bilirubin,,10,,,,,3 - 21,umol/L +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.2,,,,,0 - 6.2,umol/L +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,CHEMISTRY PANEL,Alkaline Phosphatase,,60,,,,,40 - 129,U/L +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,CHEMISTRY PANEL,ALT (SGPT),,22,,,,,5 - 48,U/L +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,CHEMISTRY PANEL,AST (SGOT),,17,,,,,8 - 40,U/L +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,CHEMISTRY PANEL,GGT,,26,,,,,10 - 61,U/L +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,CHEMISTRY PANEL,LDH,,161,,,,,53 - 234,U/L +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,CHEMISTRY PANEL,Urea Nitrogen,,5.2,,,,,1.4 - 8.6,mmol/L +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,86,,,,,40 - 110,umol/L +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,CHEMISTRY PANEL,Glucose Fasting,,5.0,,,,,3.9 - 5.6,mmol/L +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,CHEMISTRY PANEL,Serum Uric Acid,,261,,,,,125 - 488,umol/L +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,CHEMISTRY PANEL,Calcium (EDTA),,2.52,,,,,2.07 - 2.64,mmol/L +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,CHEMISTRY PANEL,Phosphorus,,1.20,,,,,0.71 - 1.65,mmol/L +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,CHEMISTRY PANEL,Total Protein,,74,,,,,61 - 84,g/L +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,CHEMISTRY PANEL,Albumin-BCG,,53,,H,,,33 - 49,g/L +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,CHEMISTRY PANEL,Creatine Kinase,,70,,,,,39 - 308,U/L +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,CHEMISTRY PANEL,Serum Sodium,,142,,,,,132 - 147,mmol/L +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,CHEMISTRY PANEL,Serum Potassium,,4.4,,,,,3.5 - 5.2,mmol/L +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,CHEMISTRY PANEL,Serum Bicarbonate,,25.3,,,,,19.3 - 29.3,mmol/L +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,CHEMISTRY PANEL,Serum Chloride,,104,,,,,94 - 112,mmol/L +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,CREATININE CLEARANCE CC&G,CreatininClearancCockcrftGault,,1.99,,,,,1.42 - 2.08,mL/sec +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,CREATININE CLEARANCE CC&G,Creatinine(Rate Blanked)-2dp,,86,,,,,40 - 110,umol/L +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,CREATININE CLEARANCE CC&G,"Weight (kg,1dec place)",Y,81.1,,,,,kg, +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,DRUG SCREEN URINE,Amphetamines/MDMA,,Neg,,,,,Neg;$Cutoff = 1000 ng/mL, +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,DRUG SCREEN URINE,Barbiturates,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,DRUG SCREEN URINE,Cannabinoids,,Neg,,,,,Neg;$Cutoff = 50 ng/mL, +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,DRUG SCREEN URINE,Cocaine,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,DRUG SCREEN URINE,Opiates,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,DRUG SCREEN URINE,Methadone,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,DRUG SCREEN URINE BENZO NON-US,Benzodiazepines Gen 2,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,GFR,EGFR by MDRD,,87,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,,,,Test cancelled: Clotted Blood Received,,, +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,,,,Test cancelled: Clotted Blood Received,,, +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,,,,Test cancelled: Clotted Blood Received,,, +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,,,,Test cancelled: Clotted Blood Received,,, +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,,,,Test cancelled: Clotted Blood Received,,, +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,,,,Test cancelled: Clotted Blood Received,,, +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,,,,Test cancelled: Clotted Blood Received,,, +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,,,,Test cancelled: Clotted Blood Received,,, +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,,,,Test cancelled: Clotted Blood Received,,, +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,,,,Test cancelled: Clotted Blood Received,,, +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,,,,Test cancelled: Clotted Blood Received,,, +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,,,,Test cancelled: Clotted Blood Received,,, +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,,,,Test cancelled: Clotted Blood Received,,, +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,,,,Test cancelled: Clotted Blood Received,,, +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,,,,Test cancelled: Clotted Blood Received,,, +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,,,,Test cancelled: Clotted Blood Received,,, +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,,,,Test cancelled: Clotted Blood Received,,, +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.2,,,,,<6.5 %, +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,5.94,,,,,1.9 - 23,uIU/mL +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,IS SUBJECT OF BLACK RACE?,Subject of black race?,Y,No,,,,,, +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,LIPID PANEL,Direct HDL-C 4th Generation,,0.90,,L,,,1.03 - 1.53,mmol/L +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,LIPID PANEL,Triglycerides (GPO),,1.55,,,,,0.56 - 3.62,mmol/L +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,LIPID PANEL,Cholesterol (High Performance),,4.40,,,,,3.88 - 6.83,mmol/L +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,LIPID PANEL,LDL Chol Friedewald 4th,,2.79,,,,,0 - 3.34,mmol/L +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,RETICULOCYTES,Reticulocyte Count %,,,,,Test cancelled: Clotted Blood Received,,, +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,TSH,TSH 3rd IS-QT,,0.855,,,,,0.45 - 5.33,mIU/L +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,URINE MACRO PANEL,Ur Specific Gravity,,1.017,,,,,1 - 1.04, +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:Negative, +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,C-REACTIVE PROTEIN,C Reactive Protein HS,,12.0,,H,,,0 - 5,mg/L +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,CHEMISTRY PANEL,Total Bilirubin,,8,,,,,3 - 21,umol/L +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.7,,,,,0 - 6.2,umol/L +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,CHEMISTRY PANEL,Alkaline Phosphatase,,120,,,,,40 - 129,U/L +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,CHEMISTRY PANEL,ALT (SGPT),,15,,,,,5 - 48,U/L +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,CHEMISTRY PANEL,AST (SGOT),,20,,,,,8 - 40,U/L +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,CHEMISTRY PANEL,GGT,,15,,,,,10 - 50,U/L +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,CHEMISTRY PANEL,LDH,,165,,,,,53 - 234,U/L +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,CHEMISTRY PANEL,Urea Nitrogen,,6.1,,,,,1.4 - 8.6,mmol/L +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,108,,,,,40 - 119,umol/L +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,CHEMISTRY PANEL,Glucose Fasting,,5.7,,H,,,3.9 - 5.6,mmol/L +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,CHEMISTRY PANEL,Serum Uric Acid,,237,,,,,149 - 494,umol/L +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,CHEMISTRY PANEL,Calcium (EDTA),,2.37,,,,,2.07 - 2.64,mmol/L +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,CHEMISTRY PANEL,Phosphorus,,0.98,,,,,0.71 - 1.65,mmol/L +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,CHEMISTRY PANEL,Total Protein,,84,,H,,,60 - 80,g/L +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,CHEMISTRY PANEL,Albumin-BCG,,46,,,,,33 - 49,g/L +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,CHEMISTRY PANEL,Creatine Kinase,,116,,,,,39 - 308,U/L +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,CHEMISTRY PANEL,Serum Sodium,,138,,,,,135 - 145,mmol/L +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,CHEMISTRY PANEL,Serum Potassium,,4.0,,,,,3.5 - 5.2,mmol/L +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,CHEMISTRY PANEL,Serum Bicarbonate,,17.8,,L,,,19.3 - 29.3,mmol/L +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,CHEMISTRY PANEL,Serum Chloride,,102,,,,,94 - 112,mmol/L +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,CREATININE CLEARANCE CC&G,CreatininClearancCockcrftGault,,1.23,,L,,,1.42 - 2.08,mL/sec +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,CREATININE CLEARANCE CC&G,Creatinine(Rate Blanked)-2dp,,108,,,,,40 - 119,umol/L +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,CREATININE CLEARANCE CC&G,"Weight (kg,1dec place)",Y,82.0,,,,,kg, +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,DRUG SCREEN URINE,Amphetamines/MDMA,,Neg,,,,,Neg;$Cutoff = 1000 ng/mL, +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,DRUG SCREEN URINE,Barbiturates,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,DRUG SCREEN URINE,Cannabinoids,,Neg,,,,,Neg;$Cutoff = 50 ng/mL, +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,DRUG SCREEN URINE,Cocaine,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,DRUG SCREEN URINE,Opiates,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,DRUG SCREEN URINE,Methadone,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,DRUG SCREEN URINE BENZO NON-US,Benzodiazepines Gen 2,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,GFR,EGFR by MDRD,,60,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,140,,,,,125 - 170,g/L +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.42,,,,,0.37 - 0.51, +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.1,,,,,4 - 5.8,TI/L +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,83,,,,,80 - 100,fL +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,9.37,,,,,3.8 - 10.7,GI/L +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,6.83,,,,,1.96 - 7.23,GI/L +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.79,,,,,0.8 - 3,GI/L +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.61,,,,,0.12 - 0.92,GI/L +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.10,,,,,0 - 0.57,GI/L +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.04,,,,,0 - 0.2,GI/L +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,72.9,,,,,40.5 - 75,% +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,19.1,,,,,15.4 - 48.5,% +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,6.5,,,,,2.6 - 10.1,% +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.1,,,,,0 - 6.8,% +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.4,,,,,0 - 2,% +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,509,R,H,,,130 - 394,GI/L +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,6.5,,H,,,<6.5 %, +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,5.10,,,,,1.9 - 23,uIU/mL +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,IS SUBJECT OF BLACK RACE?,Subject of black race?,Y,No,,,,,, +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,LIPID PANEL,Direct HDL-C 4th Generation,,1.24,,,,,1.03 - 1.53,mmol/L +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,LIPID PANEL,Triglycerides (GPO),,1.36,,,,,0.65 - 2.94,mmol/L +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,LIPID PANEL,Cholesterol (High Performance),,3.73,,L,,,4.53 - 7.71,mmol/L +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,LIPID PANEL,LDL Chol Friedewald 4th,,1.87,,,,,0 - 3.34,mmol/L +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,RETICULOCYTES,Reticulocyte Count %,,0.7,,,,,0.6 - 2.5,% +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,TSH,TSH 3rd IS-QT,,1.311,,,,,0.45 - 5.33,mIU/L +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,URINE MACRO PANEL,Ur Specific Gravity,,1.017,,,,,1.01 - 1.03, +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:Negative, +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,C-REACTIVE PROTEIN,C Reactive Protein HS,,0.5,,,,,0 - 5,mg/L +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,CHEMISTRY PANEL,Total Bilirubin,,15,,,,,3 - 21,umol/L +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,4.7,,,,,0 - 6.2,umol/L +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,CHEMISTRY PANEL,Alkaline Phosphatase,,89,,,,,40 - 129,U/L +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,CHEMISTRY PANEL,ALT (SGPT),,23,,,,,5 - 48,U/L +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,CHEMISTRY PANEL,AST (SGOT),,16,,,,,8 - 40,U/L +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,CHEMISTRY PANEL,GGT,,13,,,,,10 - 61,U/L +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,CHEMISTRY PANEL,LDH,,157,,,,,53 - 234,U/L +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,CHEMISTRY PANEL,Urea Nitrogen,,4.9,,,,,1.4 - 8.6,mmol/L +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,90,,,,,40 - 110,umol/L +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,CHEMISTRY PANEL,Glucose Fasting,,4.9,,,,,3.9 - 5.6,mmol/L +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,CHEMISTRY PANEL,Serum Uric Acid,,287,,,,,125 - 488,umol/L +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,CHEMISTRY PANEL,Calcium (EDTA),,2.55,,,,,2.07 - 2.64,mmol/L +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,CHEMISTRY PANEL,Phosphorus,,1.09,,,,,0.71 - 1.65,mmol/L +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,CHEMISTRY PANEL,Total Protein,,76,,,,,61 - 84,g/L +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,CHEMISTRY PANEL,Albumin-BCG,,51,,H,,,33 - 49,g/L +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,CHEMISTRY PANEL,Creatine Kinase,,332,,H,,,39 - 308,U/L +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,CHEMISTRY PANEL,Serum Sodium,,139,,,,,132 - 147,mmol/L +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,CHEMISTRY PANEL,Serum Potassium,,3.9,,,,,3.5 - 5.2,mmol/L +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,CHEMISTRY PANEL,Serum Bicarbonate,,23.8,,,,,19.3 - 29.3,mmol/L +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,CHEMISTRY PANEL,Serum Chloride,,100,,,,,94 - 112,mmol/L +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,CREATININE CLEARANCE CC&G,CreatininClearancCockcrftGault,,1.60,,,,,1.42 - 2.08,mL/sec +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,CREATININE CLEARANCE CC&G,Creatinine(Rate Blanked)-2dp,,90,,,,,40 - 110,umol/L +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,CREATININE CLEARANCE CC&G,"Weight (kg,1dec place)",Y,61.0,,,,,kg, +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,DRUG SCREEN URINE,Amphetamines/MDMA,,Neg,,,,,Neg;$Cutoff = 1000 ng/mL, +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,DRUG SCREEN URINE,Barbiturates,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,DRUG SCREEN URINE,Cannabinoids,,Neg,,,,,Neg;$Cutoff = 50 ng/mL, +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,DRUG SCREEN URINE,Cocaine,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,DRUG SCREEN URINE,Opiates,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,DRUG SCREEN URINE,Methadone,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,DRUG SCREEN URINE BENZO NON-US,Benzodiazepines Gen 2,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,GFR,EGFR by MDRD,,89,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,149,,,,,127 - 181,g/L +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.43,,,,,0.39 - 0.54, +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.9,,,,,4.5 - 6.4,TI/L +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,86,,,,,79 - 96,fL +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,6.69,,,,,3.8 - 10.7,GI/L +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,4.98,,,,,1.96 - 7.23,GI/L +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.11,,,,,0.91 - 4.28,GI/L +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.45,,,,,0.12 - 0.92,GI/L +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.06,,,,,0 - 0.57,GI/L +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.10,,,,,0 - 0.2,GI/L +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,74.5,,,,,40.5 - 75,% +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,16.5,,,,,15.4 - 48.5,% +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,6.8,,,,,2.6 - 10.1,% +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,0.9,,,,,0 - 6.8,% +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.4,,,,,0 - 2,% +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,262,,,,,140 - 400,GI/L +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.1,,,,,<6.5 %, +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,4.81,,,,,1.9 - 23,uIU/mL +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,IS SUBJECT OF BLACK RACE?,Subject of black race?,Y,No,,,,,, +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,LIPID PANEL,Direct HDL-C 4th Generation,,1.32,,,,,1.03 - 1.53,mmol/L +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,LIPID PANEL,Triglycerides (GPO),,0.69,,,,,0.5 - 2.81,mmol/L +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,LIPID PANEL,Cholesterol (High Performance),,4.31,,,,,3.31 - 6.1,mmol/L +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,LIPID PANEL,LDL Chol Friedewald 4th,,2.67,,,,,0 - 3.34,mmol/L +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,RETICULOCYTES,Reticulocyte Count %,,1.2,,,,,0.6 - 2.5,% +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,TSH,TSH 3rd IS-QT,,0.928,,,,,0.45 - 5.33,mIU/L +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,URINE MACRO PANEL,Ur Specific Gravity,,1.009,,,,,1 - 1.04, +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:Negative, +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,C-REACTIVE PROTEIN,C Reactive Protein HS,,4.4,,,,,0 - 5,mg/L +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,CHEMISTRY PANEL,Total Bilirubin,,6,,,,,3 - 21,umol/L +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.3,,,,,0 - 6.2,umol/L +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,CHEMISTRY PANEL,Alkaline Phosphatase,,67,,,,,35 - 104,U/L +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,CHEMISTRY PANEL,ALT (SGPT),,28,,,,,4 - 43,U/L +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,CHEMISTRY PANEL,AST (SGOT),,30,,,,,8 - 40,U/L +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,CHEMISTRY PANEL,GGT,,27,,,,,4 - 49,U/L +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,CHEMISTRY PANEL,LDH,,166,,,,,53 - 234,U/L +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,CHEMISTRY PANEL,Urea Nitrogen,,4.7,,,,,1.4 - 8.6,mmol/L +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,76,,,,,31 - 101,umol/L +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,CHEMISTRY PANEL,Glucose Fasting,,4.8,,,,,3.9 - 5.6,mmol/L +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,CHEMISTRY PANEL,Serum Uric Acid,,337,,,,,149 - 446,umol/L +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,CHEMISTRY PANEL,Calcium (EDTA),,2.51,,,,,2.07 - 2.64,mmol/L +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,CHEMISTRY PANEL,Phosphorus,,1.16,,,,,0.71 - 1.65,mmol/L +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,CHEMISTRY PANEL,Total Protein,,75,,,,,61 - 84,g/L +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,CHEMISTRY PANEL,Albumin-BCG,,46,,,,,33 - 49,g/L +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,CHEMISTRY PANEL,Creatine Kinase,,148,,,,,26 - 192,U/L +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,CHEMISTRY PANEL,Serum Sodium,,138,,,,,132 - 147,mmol/L +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,CHEMISTRY PANEL,Serum Potassium,,4.4,,,,,3.5 - 5.2,mmol/L +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,CHEMISTRY PANEL,Serum Bicarbonate,,21.7,,,,,19.3 - 29.3,mmol/L +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,CHEMISTRY PANEL,Serum Chloride,,102,,,,,94 - 112,mmol/L +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,145,,,,,116 - 164,g/L +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.43,,,,,0.34 - 0.48, +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.7,,,,,4.1 - 5.6,TI/L +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,91,,,,,79 - 98,fL +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,8.09,,,,,3.8 - 10.7,GI/L +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,4.49,,,,,1.96 - 7.23,GI/L +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,3.02,,,,,0.91 - 4.28,GI/L +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.33,,,,,0.12 - 0.92,GI/L +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.16,,,,,0 - 0.57,GI/L +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.08,,,,,0 - 0.2,GI/L +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,55.6,,,,,40.5 - 75,% +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,37.4,,,,,15.4 - 48.5,% +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,4.0,,,,,2.6 - 10.1,% +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.0,,,,,0 - 6.8,% +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.0,,,,,0 - 2,% +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,316,,,,,140 - 400,GI/L +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,3.12,,,,,1.9 - 23,uIU/mL +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,LIPID PANEL,Direct HDL-C 4th Generation,,1.96,,H,,,1.03 - 1.53,mmol/L +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,LIPID PANEL,Triglycerides (GPO),,1.32,,,,,0.59 - 2.96,mmol/L +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,LIPID PANEL,Cholesterol (High Performance),,5.64,,,,,4.42 - 7.53,mmol/L +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,LIPID PANEL,LDL Chol Friedewald 4th,,3.08,,,,,0 - 3.34,mmol/L +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,RETICULOCYTES,Reticulocyte Count %,,0.6,,,,,0.6 - 2.5,% +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,URINE MACRO PANEL,Ur Specific Gravity,,1.021,,,,,1 - 1.04, +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,URINE MACRO PANEL,Ur Leukocyte Esterase,,Trace,,H,,,Ref Rng:Negative, +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,URINE MICRO PANEL,Ur Microscopic,,Negative,,,,, NEGATIVE$,NEGATIVE +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,C-REACTIVE PROTEIN,C Reactive Protein HS,,2.0,,,,,0 - 5,mg/L +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,CELLULAR ELEMENTS,Ur WBC/HPF,,3,,,,,0 - 12,/HPF +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,CHEMISTRY PANEL,Total Bilirubin,,7,,,,,3 - 21,umol/L +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.4,,,,,0 - 6.2,umol/L +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,CHEMISTRY PANEL,Alkaline Phosphatase,,90,,,,,35 - 104,U/L +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,CHEMISTRY PANEL,ALT (SGPT),,9,,,,,4 - 43,U/L +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,CHEMISTRY PANEL,AST (SGOT),,15,,,,,8 - 40,U/L +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,CHEMISTRY PANEL,GGT,,8,,,,,4 - 49,U/L +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,CHEMISTRY PANEL,LDH,,150,,,,,53 - 234,U/L +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,CHEMISTRY PANEL,Urea Nitrogen,,4.1,,,,,1.4 - 8.6,mmol/L +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,61,,,,,31 - 101,umol/L +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,CHEMISTRY PANEL,Glucose Fasting,,4.8,,,,,3.9 - 5.6,mmol/L +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,CHEMISTRY PANEL,Serum Uric Acid,,250,,,,,125 - 428,umol/L +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,CHEMISTRY PANEL,Calcium (EDTA),,2.30,,,,,2.07 - 2.64,mmol/L +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,CHEMISTRY PANEL,Phosphorus,,1.08,,,,,0.71 - 1.65,mmol/L +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,CHEMISTRY PANEL,Total Protein,,77,,,,,61 - 84,g/L +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,CHEMISTRY PANEL,Albumin-BCG,,46,,,,,33 - 49,g/L +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,CHEMISTRY PANEL,Creatine Kinase,,69,,,,,26 - 192,U/L +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,CHEMISTRY PANEL,Serum Sodium,,140,,,,,132 - 147,mmol/L +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,CHEMISTRY PANEL,Serum Potassium,,4.9,,,,,3.5 - 5.2,mmol/L +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,CHEMISTRY PANEL,Serum Bicarbonate,,23.4,,,,,19.3 - 29.3,mmol/L +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,CHEMISTRY PANEL,Serum Chloride,,104,,,,,94 - 112,mmol/L +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,136,,,,,116 - 164,g/L +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.40,,,,,0.34 - 0.48, +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.5,,,,,4.1 - 5.6,TI/L +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,89,,,,,79 - 98,fL +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,7.73,,,,,3.8 - 10.7,GI/L +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,4.57,,,,,1.96 - 7.23,GI/L +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.54,,,,,0.91 - 4.28,GI/L +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.42,,,,,0.12 - 0.92,GI/L +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.14,,,,,0 - 0.57,GI/L +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.06,,,,,0 - 0.2,GI/L +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,59.1,,,,,40.5 - 75,% +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,32.9,,,,,15.4 - 48.5,% +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.4,,,,,2.6 - 10.1,% +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.9,,,,,0 - 6.8,% +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.7,,,,,0 - 2,% +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,348,,,,,140 - 400,GI/L +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,4.60,,,,,1.9 - 23,uIU/mL +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,LIPID PANEL,Direct HDL-C 4th Generation,,1.10,,,,,1.03 - 1.53,mmol/L +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,LIPID PANEL,Triglycerides (GPO),,1.17,,,,,0.44 - 1.99,mmol/L +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,LIPID PANEL,Cholesterol (High Performance),,4.41,,,,,3.65 - 6.21,mmol/L +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,LIPID PANEL,LDL Chol Friedewald 4th,,2.77,,,,,0 - 3.34,mmol/L +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,RETICULOCYTES,Reticulocyte Count %,,1.9,,,,,0.6 - 2.5,% +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,URINE MACRO PANEL,Ur Specific Gravity,,1.026,,,,,1 - 1.04, +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,URINE MACRO PANEL,Ur pH,,6.0,,,,,5 - 8, +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,URINE MACRO PANEL,Ur Leukocyte Esterase,,+1,,H,,,Ref Rng:Negative, +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,URINE MICRO PANEL,Ur Microscopic,,Positive,,,,, NEGATIVE$,NEGATIVE +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.2,,,,,0 - 5,mg/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,CELLULAR ELEMENTS,Ur WBC/HPF,,4,,,,,0 - 12,/HPF +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,CHEMISTRY PANEL,Total Bilirubin,,<3,,L,,Result verified by repeat analysis,3 - 21,umol/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,1.5,,,,,0 - 6.2,umol/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,CHEMISTRY PANEL,Alkaline Phosphatase,,60,,,,,35 - 104,U/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,CHEMISTRY PANEL,ALT (SGPT),,11,,,,,4 - 43,U/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,CHEMISTRY PANEL,AST (SGOT),,13,,,,,8 - 40,U/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,CHEMISTRY PANEL,GGT,,16,,,,,4 - 49,U/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,CHEMISTRY PANEL,LDH,,128,,,,,53 - 234,U/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,CHEMISTRY PANEL,Urea Nitrogen,,7.9,,,,,1.4 - 8.6,mmol/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,84,,,,,31 - 101,umol/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,CHEMISTRY PANEL,Glucose Fasting,,4.9,,,,,3.9 - 5.6,mmol/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,CHEMISTRY PANEL,Serum Uric Acid,,250,,,,,125 - 428,umol/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,CHEMISTRY PANEL,Calcium (EDTA),,2.33,,,,,2.07 - 2.64,mmol/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,CHEMISTRY PANEL,Phosphorus,,0.97,,,,,0.71 - 1.65,mmol/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,CHEMISTRY PANEL,Total Protein,,66,,,,,61 - 84,g/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,CHEMISTRY PANEL,Albumin-BCG,,45,,,,,33 - 49,g/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,CHEMISTRY PANEL,Creatine Kinase,,79,,,,,26 - 192,U/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,CHEMISTRY PANEL,Serum Sodium,,139,,,,,132 - 147,mmol/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,CHEMISTRY PANEL,Serum Potassium,,4.4,,,,,3.5 - 5.2,mmol/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,CHEMISTRY PANEL,Serum Bicarbonate,,22.0,,,,,19.3 - 29.3,mmol/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,CHEMISTRY PANEL,Serum Chloride,,105,,,,,94 - 112,mmol/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,123,,,,,116 - 164,g/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.37,,,,,0.34 - 0.48, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.1,,,,,4.1 - 5.6,TI/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,90,,,,,79 - 98,fL +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,3.99,,,,,3.8 - 10.7,GI/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,1.90,,L,,,1.96 - 7.23,GI/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.74,,,,,0.91 - 4.28,GI/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.18,,,,,0.12 - 0.92,GI/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.15,,,,,0 - 0.57,GI/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.02,,,,,0 - 0.2,GI/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,47.6,,,,,40.5 - 75,% +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,43.6,,,,,15.4 - 48.5,% +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,4.5,,,,,2.6 - 10.1,% +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,3.8,,,,,0 - 6.8,% +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.5,,,,,0 - 2,% +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,301,,,,,140 - 400,GI/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.6,,,,,<6.5 %, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,3.63,,,,,1.9 - 23,uIU/mL +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,LIPID PANEL,Direct HDL-C 4th Generation,,1.75,,H,,,1.03 - 1.53,mmol/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,LIPID PANEL,Triglycerides (GPO),,0.50,,,,,0.44 - 1.99,mmol/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,LIPID PANEL,Cholesterol (High Performance),,4.64,,,,,3.65 - 6.21,mmol/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,LIPID PANEL,LDL Chol Friedewald 4th,,2.66,,,,,0 - 3.34,mmol/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,RETICULOCYTES,Reticulocyte Count %,,0.7,,,,,0.6 - 2.5,% +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,TSH,TSH 3rd IS-QT,,1.963,,,,,0.45 - 5.33,mIU/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,URINE MACRO PANEL,Ur Specific Gravity,,1.024,,,,,1 - 1.04, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,URINE MACRO PANEL,Ur Blood,,+1,,H,,,Ref Rng:$Negative-Trace, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,URINE MACRO PANEL,Ur Leukocyte Esterase,,+1,,H,,,Ref Rng:Negative, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,URINE MICRO PANEL,Ur Microscopic,,Positive,,,,, NEGATIVE$,NEGATIVE +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,C-REACTIVE PROTEIN,C Reactive Protein HS,,3.5,,,,,0 - 5,mg/L +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,CHEMISTRY PANEL,Total Bilirubin,,10,,,,,3 - 21,umol/L +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.3,,,,,0 - 6.2,umol/L +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,CHEMISTRY PANEL,Alkaline Phosphatase,,52,,,,,40 - 129,U/L +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,CHEMISTRY PANEL,ALT (SGPT),,77,,H RX,,,5 - 48,U/L +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,CHEMISTRY PANEL,AST (SGOT),,49,,H,,,8 - 40,U/L +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,CHEMISTRY PANEL,GGT,,53,,H,,,10 - 50,U/L +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,CHEMISTRY PANEL,LDH,,139,,,,,53 - 234,U/L +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,CHEMISTRY PANEL,Urea Nitrogen,,4.0,,,,,1.4 - 8.6,mmol/L +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,91,,,,,40 - 119,umol/L +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,CHEMISTRY PANEL,Glucose Fasting,,6.3,,H,,,3.9 - 5.6,mmol/L +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,CHEMISTRY PANEL,Serum Uric Acid,,507,,H,,,149 - 494,umol/L +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,CHEMISTRY PANEL,Calcium (EDTA),,2.38,,,,,2.07 - 2.64,mmol/L +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,CHEMISTRY PANEL,Phosphorus,,0.92,,,,,0.71 - 1.65,mmol/L +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,CHEMISTRY PANEL,Total Protein,,74,,,,,60 - 80,g/L +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,CHEMISTRY PANEL,Albumin-BCG,,46,,,,,33 - 49,g/L +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,CHEMISTRY PANEL,Creatine Kinase,,201,,,,,39 - 308,U/L +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,CHEMISTRY PANEL,Serum Sodium,,140,,,,,135 - 145,mmol/L +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,CHEMISTRY PANEL,Serum Potassium,,4.0,,,,,3.5 - 5.2,mmol/L +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,CHEMISTRY PANEL,Serum Bicarbonate,,27.8,,,,,19.3 - 29.3,mmol/L +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,CHEMISTRY PANEL,Serum Chloride,,100,,,,,94 - 112,mmol/L +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,128,,,,,125 - 170,g/L +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.37,,,,,0.37 - 0.51, +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,3.9,,L,,,4 - 5.8,TI/L +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,96,,,,,80 - 100,fL +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,4.20,,,,,3.8 - 10.7,GI/L +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.39,,,,,1.96 - 7.23,GI/L +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.38,,,,,0.8 - 3,GI/L +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.33,,,,,0.12 - 0.92,GI/L +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.04,,,,,0 - 0.57,GI/L +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.05,,,,,0 - 0.2,GI/L +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,57.0,,,,,40.5 - 75,% +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,32.9,,,,,15.4 - 48.5,% +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,7.8,,,,,2.6 - 10.1,% +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.1,,,,,0 - 6.8,% +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.2,,,,,0 - 2,% +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,144,,,,,140 - 400,GI/L +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,22.36,,,,,1.9 - 23,uIU/mL +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,LIPID PANEL,Direct HDL-C 4th Generation,,0.75,,L,,,1.03 - 1.53,mmol/L +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,LIPID PANEL,Triglycerides (GPO),,3.00,,,,,0.65 - 3.61,mmol/L +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,LIPID PANEL,Cholesterol (High Performance),,4.63,,,,,4.4 - 7.53,mmol/L +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,LIPID PANEL,LDL Chol Friedewald 4th,,2.51,,,,,0 - 3.34,mmol/L +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,RETICULOCYTES,Reticulocyte Count %,,1.4,,,,,0.6 - 2.5,% +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,URINE MACRO PANEL,Ur Specific Gravity,,1.010,,,,,1.01 - 1.03, +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,URINE MACRO PANEL,Ur pH,,6.0,,,,,5 - 8, +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:Negative, +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,C-REACTIVE PROTEIN,C Reactive Protein HS,,0.2,,,,Result verified by repeat analysis,0 - 5,mg/L +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,CHEMISTRY PANEL,Total Bilirubin,,7,,,,,3 - 21,umol/L +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.4,,,,,0 - 6.2,umol/L +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,CHEMISTRY PANEL,Alkaline Phosphatase,,39,,,,,35 - 104,U/L +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,CHEMISTRY PANEL,ALT (SGPT),,7,,,,,4 - 43,U/L +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,CHEMISTRY PANEL,AST (SGOT),,13,,,,,8 - 40,U/L +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,CHEMISTRY PANEL,GGT,,10,,,,,4 - 49,U/L +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,CHEMISTRY PANEL,LDH,,144,,,,,53 - 234,U/L +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,CHEMISTRY PANEL,Urea Nitrogen,,2.9,,,,,1.4 - 8.6,mmol/L +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,63,,,,,31 - 101,umol/L +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,CHEMISTRY PANEL,Glucose Fasting,,4.9,,,,,3.9 - 5.6,mmol/L +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,CHEMISTRY PANEL,Serum Uric Acid,,162,,,,,125 - 428,umol/L +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,CHEMISTRY PANEL,Calcium (EDTA),,2.41,,,,,2.07 - 2.64,mmol/L +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,CHEMISTRY PANEL,Phosphorus,,0.94,,,,,0.71 - 1.65,mmol/L +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,CHEMISTRY PANEL,Total Protein,,69,,,,,61 - 84,g/L +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,CHEMISTRY PANEL,Albumin-BCG,,44,,,,,33 - 49,g/L +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,CHEMISTRY PANEL,Creatine Kinase,,56,,,,,26 - 192,U/L +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,CHEMISTRY PANEL,Serum Sodium,,142,,,,,132 - 147,mmol/L +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,CHEMISTRY PANEL,Serum Potassium,,4.7,,,,,3.5 - 5.2,mmol/L +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,CHEMISTRY PANEL,Serum Bicarbonate,,26.3,,,,,19.3 - 29.3,mmol/L +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,CHEMISTRY PANEL,Serum Chloride,,104,,,,,94 - 112,mmol/L +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,CREATININE CLEARANCE CC&G,CreatininClearancCockcrftGault,,1.79,,,,,1.25 - 1.92,mL/sec +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,CREATININE CLEARANCE CC&G,Creatinine(Rate Blanked)-2dp,,63,,,,,31 - 101,umol/L +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,CREATININE CLEARANCE CC&G,"Weight (kg,1dec place)",Y,70.3,,,,,kg, +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,DRUG SCREEN URINE,Amphetamines/MDMA,,Neg,,,,,Neg;$Cutoff = 1000 ng/mL, +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,DRUG SCREEN URINE,Barbiturates,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,DRUG SCREEN URINE,Cannabinoids,,Neg,,,,,Neg;$Cutoff = 50 ng/mL, +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,DRUG SCREEN URINE,Cocaine,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,DRUG SCREEN URINE,Opiates,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,DRUG SCREEN URINE,Methadone,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,DRUG SCREEN URINE BENZO NON-US,Benzodiazepines Gen 2,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,FEMALE OF CHILDBEARING POT?,Female/of Childbearing pot.?,Y,Yes,,,,,, +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,GFR,EGFR by MDRD,,88,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,140,,,,Result verified by repeat analysis,116 - 164,g/L +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.41,,,,,0.34 - 0.48, +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.5,,,,Result verified by repeat analysis,4.1 - 5.6,TI/L +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,90,,,,,79 - 98,fL +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,4.80,,,,Result verified by repeat analysis,3.8 - 10.7,GI/L +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.45,,,,Result verified by repeat analysis,1.96 - 7.23,GI/L +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.67,,,,,0.91 - 4.28,GI/L +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.43,,,,Result verified by repeat analysis,0.12 - 0.92,GI/L +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.21,,,,Result verified by repeat analysis,0 - 0.57,GI/L +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.04,,,,Result verified by repeat analysis,0 - 0.2,GI/L +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,51.1,,,,Result verified by repeat analysis,40.5 - 75,% +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,34.7,,,,Result verified by repeat analysis,15.4 - 48.5,% +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,9.0,,,,Result verified by repeat analysis,2.6 - 10.1,% +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,4.4,,,,Result verified by repeat analysis,0 - 6.8,% +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.8,,,,Result verified by repeat analysis,0 - 2,% +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,254,,,,Result verified by repeat analysis,140 - 400,GI/L +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.5,,,,,<6.5 %, +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,6.02,,,,,1.9 - 23,uIU/mL +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,IS SUBJECT OF BLACK RACE?,Subject of black race?,Y,No,,,,,, +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,LIPID PANEL,Direct HDL-C 4th Generation,,1.67,,H,,,1.03 - 1.53,mmol/L +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,LIPID PANEL,Triglycerides (GPO),,0.69,,,,,0.51 - 2.42,mmol/L +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,LIPID PANEL,Cholesterol (High Performance),,5.79,,,,,4.01 - 6.85,mmol/L +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,LIPID PANEL,LDL Chol Friedewald 4th,,3.80,,H,,,0 - 3.34,mmol/L +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,POSTMENOPAUSAL FEMALE?,<40yrs & amenorrhea >/= 12mo,,No,,,,,, +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,RETICULOCYTES,Reticulocyte Count %,,1.2,,,,,0.6 - 2.5,% +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,SERUM BETA HCG,"B-hCG, Qualitative",,Negative,,,,,Ref Rng: Negative, +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,SERUM BETA HCG,"B-hCG, Quantitative",,<0.6,,,,,Units: mIU/mL$Pre-menopausal$<5.0: Negative$5.0-24.9:Borderline$>/= 25.0: Positive, +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,TSH,TSH 3rd IS-QT,,1.837,,,,,0.45 - 5.33,mIU/L +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,URINE MACRO PANEL,Ur Specific Gravity,,1.005,,,,,1 - 1.04, +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,C-REACTIVE PROTEIN,C Reactive Protein HS,,0.9,,,,,0 - 5,mg/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,CELLULAR ELEMENTS,Ur RBC/HPF,,3,,,,,0 - 8,/HPF +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,CELLULAR ELEMENTS,Ur WBC/HPF,,1,,,,,0 - 12,/HPF +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,CHEMISTRY PANEL,Total Bilirubin,,10,,,,,3 - 21,umol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.4,,,,,0 - 6.2,umol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,CHEMISTRY PANEL,Alkaline Phosphatase,,60,,,,,35 - 104,U/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,CHEMISTRY PANEL,ALT (SGPT),,23,,,,,4 - 43,U/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,CHEMISTRY PANEL,AST (SGOT),,27,,,,,8 - 40,U/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,CHEMISTRY PANEL,GGT,,21,,,,,4 - 49,U/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,CHEMISTRY PANEL,LDH,,167,,,,,53 - 234,U/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,CHEMISTRY PANEL,Urea Nitrogen,,3.7,,,,,1.4 - 8.6,mmol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,79,,,,,31 - 101,umol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,CHEMISTRY PANEL,Glucose Fasting,,4.9,,,,,3.9 - 5.6,mmol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,CHEMISTRY PANEL,Serum Uric Acid,,286,,,,,149 - 446,umol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,CHEMISTRY PANEL,Calcium (EDTA),,2.43,,,,,2.07 - 2.64,mmol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,CHEMISTRY PANEL,Phosphorus,,1.01,,,,,0.71 - 1.65,mmol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,CHEMISTRY PANEL,Total Protein,,76,,,,,61 - 84,g/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,CHEMISTRY PANEL,Albumin-BCG,,47,,,,,33 - 49,g/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,CHEMISTRY PANEL,Creatine Kinase,,147,,,,,26 - 192,U/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,CHEMISTRY PANEL,Serum Sodium,,138,,,,,132 - 147,mmol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,CHEMISTRY PANEL,Serum Potassium,,4.4,,,,,3.5 - 5.2,mmol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,CHEMISTRY PANEL,Serum Bicarbonate,,22.4,,,,,19.3 - 29.3,mmol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,CHEMISTRY PANEL,Serum Chloride,,100,,,,,94 - 112,mmol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,FREE T4,Free Thyroxine-QT,,9,,,,,8 - 14,pmol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,143,,,,,116 - 164,g/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.42,,,,,0.34 - 0.48, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.6,,,,,4.1 - 5.6,TI/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,92,,,,,79 - 98,fL +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,7.42,,,,,3.8 - 10.7,GI/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.84,,,,,1.96 - 7.23,GI/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,3.08,,,,,0.91 - 4.28,GI/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.29,,,,,0.12 - 0.92,GI/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.13,,,,,0 - 0.57,GI/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.07,,,,,0 - 0.2,GI/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,51.8,,,,,40.5 - 75,% +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,41.6,,,,,15.4 - 48.5,% +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,3.9,,,,,2.6 - 10.1,% +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.8,,,,,0 - 6.8,% +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.9,,,,,0 - 2,% +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,332,,,,,140 - 400,GI/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.2,,,,,<6.5 %, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,3.98,,,,,1.9 - 23,uIU/mL +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,LIPID PANEL,Direct HDL-C 4th Generation,,2.01,,H,,,1.03 - 1.53,mmol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,LIPID PANEL,Triglycerides (GPO),,1.43,,,,,0.59 - 2.96,mmol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,LIPID PANEL,Cholesterol (High Performance),,5.46,,,,,4.42 - 7.53,mmol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,LIPID PANEL,LDL Chol Friedewald 4th,,2.80,,,,,0 - 3.34,mmol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,RETICULOCYTES,Reticulocyte Count %,,0.9,,,,,0.6 - 2.5,% +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,TSH,TSH 3rd IS-QT,,6.224,,H SF,,,0.45 - 5.33,mIU/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,URINE MACRO PANEL,Ur Specific Gravity,,1.033,,,,,1 - 1.04, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,URINE MACRO PANEL,Ur pH,,6.5,,,,,5 - 8, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,URINE MACRO PANEL,Ur Protein,,Trace,,H,,,Ref Rng:Negative, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,URINE MICRO PANEL,Ur Microscopic,,Positive,,,,, NEGATIVE$,NEGATIVE +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.2,,,,,0 - 5,mg/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,CHEMISTRY PANEL,Total Bilirubin,,10,,,,,3 - 21,umol/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.0,,,,,0 - 6.2,umol/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,CHEMISTRY PANEL,Alkaline Phosphatase,,73,,,,,35 - 104,U/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,CHEMISTRY PANEL,ALT (SGPT),,9,,,,,4 - 43,U/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,CHEMISTRY PANEL,AST (SGOT),,13,,,,,8 - 40,U/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,CHEMISTRY PANEL,GGT,,7,,,,,4 - 49,U/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,CHEMISTRY PANEL,LDH,,145,,,,,53 - 234,U/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,CHEMISTRY PANEL,Urea Nitrogen,,4.2,,,,,1.4 - 8.6,mmol/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,56,,,,,31 - 101,umol/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,CHEMISTRY PANEL,Glucose Fasting,,4.5,,,,,3.9 - 5.6,mmol/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,CHEMISTRY PANEL,Serum Uric Acid,,236,,,,,125 - 428,umol/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,CHEMISTRY PANEL,Calcium (EDTA),,2.35,,,,,2.07 - 2.64,mmol/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,CHEMISTRY PANEL,Phosphorus,,1.19,,,,,0.71 - 1.65,mmol/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,CHEMISTRY PANEL,Total Protein,,73,,,,,61 - 84,g/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,CHEMISTRY PANEL,Albumin-BCG,,45,,,,,33 - 49,g/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,CHEMISTRY PANEL,Creatine Kinase,,72,,,,,26 - 192,U/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,CHEMISTRY PANEL,Serum Sodium,,140,,,,,132 - 147,mmol/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,CHEMISTRY PANEL,Serum Potassium,,4.1,,,,,3.5 - 5.2,mmol/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,CHEMISTRY PANEL,Serum Bicarbonate,,23.8,,,,,19.3 - 29.3,mmol/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,CHEMISTRY PANEL,Serum Chloride,,104,,,,,94 - 112,mmol/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,127,,,,,116 - 164,g/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.38,,,,,0.34 - 0.48, +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.3,,,,,4.1 - 5.6,TI/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,89,,,,,79 - 98,fL +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,6.59,,,,,3.8 - 10.7,GI/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,4.25,,,,,1.96 - 7.23,GI/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.64,,,,,0.91 - 4.28,GI/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.37,,,,,0.12 - 0.92,GI/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.13,,,,,0 - 0.57,GI/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.19,,,,,0 - 0.2,GI/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,64.5,,,,,40.5 - 75,% +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,24.9,,,,,15.4 - 48.5,% +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.6,,,,,2.6 - 10.1,% +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.0,,,,,0 - 6.8,% +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,2.9,,H,,,0 - 2,% +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,300,,,,,140 - 400,GI/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,4.9,,,,,<6.5 %, +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,2.92,,,,,1.9 - 23,uIU/mL +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,LIPID PANEL,Direct HDL-C 4th Generation,,1.01,,L,,,1.03 - 1.53,mmol/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,LIPID PANEL,Triglycerides (GPO),,1.05,,,,,0.44 - 1.99,mmol/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,LIPID PANEL,Cholesterol (High Performance),,3.68,,,,,3.65 - 6.21,mmol/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,LIPID PANEL,LDL Chol Friedewald 4th,,2.19,,,,,0 - 3.34,mmol/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,RETICULOCYTES,Reticulocyte Count %,,1.8,,,,,0.6 - 2.5,% +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,TSH,TSH 3rd IS-QT,,1.385,,,,,0.45 - 5.33,mIU/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,URINE MACRO PANEL,Ur Specific Gravity,,1.024,,,,,1 - 1.04, +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,C-REACTIVE PROTEIN,C Reactive Protein HS,,8.1,,H,,,0 - 5,mg/L +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,CHEMISTRY PANEL,Total Bilirubin,,9,,,,,3 - 21,umol/L +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.3,,,,,0 - 6.2,umol/L +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,CHEMISTRY PANEL,Alkaline Phosphatase,,51,,,,,40 - 129,U/L +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,CHEMISTRY PANEL,ALT (SGPT),,79,,H RX,,,5 - 48,U/L +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,CHEMISTRY PANEL,AST (SGOT),,51,,H,,,8 - 40,U/L +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,CHEMISTRY PANEL,GGT,,52,,H,,,10 - 50,U/L +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,CHEMISTRY PANEL,LDH,,160,,,,,53 - 234,U/L +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,CHEMISTRY PANEL,Urea Nitrogen,,4.5,,,,,1.4 - 8.6,mmol/L +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,92,,,,,40 - 119,umol/L +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,CHEMISTRY PANEL,Glucose Fasting,,6.1,,H,,,3.9 - 5.6,mmol/L +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,CHEMISTRY PANEL,Serum Uric Acid,,521,,H,,,149 - 494,umol/L +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,CHEMISTRY PANEL,Calcium (EDTA),,2.37,,,,,2.07 - 2.64,mmol/L +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,CHEMISTRY PANEL,Phosphorus,,1.00,,,,,0.71 - 1.65,mmol/L +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,CHEMISTRY PANEL,Total Protein,,75,,,,,60 - 80,g/L +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,CHEMISTRY PANEL,Albumin-BCG,,47,,,,,33 - 49,g/L +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,CHEMISTRY PANEL,Creatine Kinase,,206,,,,,39 - 308,U/L +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,CHEMISTRY PANEL,Serum Sodium,,139,,,,,135 - 145,mmol/L +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,CHEMISTRY PANEL,Serum Potassium,,4.3,,,,,3.5 - 5.2,mmol/L +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,CHEMISTRY PANEL,Serum Bicarbonate,,25.6,,,,,19.3 - 29.3,mmol/L +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,CHEMISTRY PANEL,Serum Chloride,,100,,,,,94 - 112,mmol/L +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,CREATININE CLEARANCE CC&G,CreatininClearancCockcrftGault,,1.95,,,,,1.42 - 2.08,mL/sec +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,CREATININE CLEARANCE CC&G,Creatinine(Rate Blanked)-2dp,,92,,,,,40 - 119,umol/L +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,CREATININE CLEARANCE CC&G,"Weight (kg,1dec place)",Y,108.0,,,,,kg, +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,DRUG SCREEN URINE,Amphetamines/MDMA,,Neg,,,,,Neg;$Cutoff = 1000 ng/mL, +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,DRUG SCREEN URINE,Barbiturates,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,DRUG SCREEN URINE,Cannabinoids,,Neg,,,,,Neg;$Cutoff = 50 ng/mL, +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,DRUG SCREEN URINE,Cocaine,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,DRUG SCREEN URINE,Opiates,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,DRUG SCREEN URINE,Methadone,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,DRUG SCREEN URINE BENZO NON-US,Benzodiazepines Gen 2,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,GFR,EGFR by MDRD,,73,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,132,,,,,125 - 170,g/L +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.39,,,,,0.37 - 0.51, +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.0,,,,,4 - 5.8,TI/L +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,97,,,,,80 - 100,fL +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,6.10,,,,,3.8 - 10.7,GI/L +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.77,,,,,1.96 - 7.23,GI/L +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.71,,,,,0.8 - 3,GI/L +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.52,,,,,0.12 - 0.92,GI/L +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.05,,,,,0 - 0.57,GI/L +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.05,,,,,0 - 0.2,GI/L +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,61.7,,,,,40.5 - 75,% +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,28.1,,,,,15.4 - 48.5,% +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,8.5,,,,,2.6 - 10.1,% +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,0.9,,,,,0 - 6.8,% +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.8,,,,,0 - 2,% +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,178,,,,,140 - 400,GI/L +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,6.2,,,,,<6.5 %, +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,15.17,,,,,1.9 - 23,uIU/mL +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,IS SUBJECT OF BLACK RACE?,Subject of black race?,Y,No,,,,,, +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,LIPID PANEL,Direct HDL-C 4th Generation,,0.74,,L,,,1.03 - 1.53,mmol/L +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,LIPID PANEL,Triglycerides (GPO),,2.04,,,,,0.65 - 3.61,mmol/L +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,LIPID PANEL,Cholesterol (High Performance),,4.38,,L,,,4.4 - 7.53,mmol/L +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,LIPID PANEL,LDL Chol Friedewald 4th,,2.71,,,,,0 - 3.34,mmol/L +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,RETICULOCYTES,Reticulocyte Count %,,1.9,,,,,0.6 - 2.5,% +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,TSH,TSH 3rd IS-QT,,1.243,,,,,0.45 - 5.33,mIU/L +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,URINE MACRO PANEL,Ur Specific Gravity,,1.013,,,,,1.01 - 1.03, +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,URINE MACRO PANEL,Ur pH,,5.0,,,,,5 - 8, +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:Negative, +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,C-REACTIVE PROTEIN,C Reactive Protein HS,,0.2,,,,Result verified by repeat analysis,0 - 5,mg/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,CHEMISTRY PANEL,Total Bilirubin,,8,,,,,3 - 21,umol/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.6,,,,,0 - 6.2,umol/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,CHEMISTRY PANEL,Alkaline Phosphatase,,93,,,,,40 - 129,U/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,CHEMISTRY PANEL,ALT (SGPT),,128,,H RX,,,5 - 48,U/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,CHEMISTRY PANEL,AST (SGOT),,54,,H,,,8 - 40,U/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,CHEMISTRY PANEL,GGT,,247,,H,,Result verified by repeat analysis,10 - 61,U/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,CHEMISTRY PANEL,LDH,,161,,,,,53 - 234,U/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,CHEMISTRY PANEL,Urea Nitrogen,,6.0,,,,,1.4 - 8.6,mmol/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,89,,,,,40 - 110,umol/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,CHEMISTRY PANEL,Glucose Fasting,,4.6,,,,,3.9 - 5.6,mmol/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,CHEMISTRY PANEL,Serum Uric Acid,,430,,,,,125 - 488,umol/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,CHEMISTRY PANEL,Calcium (EDTA),,2.56,,,,,2.07 - 2.64,mmol/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,CHEMISTRY PANEL,Phosphorus,,1.25,,,,,0.71 - 1.65,mmol/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,CHEMISTRY PANEL,Total Protein,,77,,,,,61 - 84,g/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,CHEMISTRY PANEL,Albumin-BCG,,48,,,,,33 - 49,g/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,CHEMISTRY PANEL,Creatine Kinase,,127,,,,,39 - 308,U/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,CHEMISTRY PANEL,Serum Sodium,,141,,,,,132 - 147,mmol/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,CHEMISTRY PANEL,Serum Potassium,,4.7,,,,,3.5 - 5.2,mmol/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,CHEMISTRY PANEL,Serum Bicarbonate,,24.5,,,,,19.3 - 29.3,mmol/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,CHEMISTRY PANEL,Serum Chloride,,103,,,,,94 - 112,mmol/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,162,,,,,127 - 181,g/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.47,,,,,0.39 - 0.54, +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.4,,,,,4.5 - 6.4,TI/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,88,,,,,79 - 96,fL +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,4.78,,,,,3.8 - 10.7,GI/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.00,,,,,1.96 - 7.23,GI/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.31,,,,,0.91 - 4.28,GI/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.26,,,,,0.12 - 0.92,GI/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.16,,,,,0 - 0.57,GI/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.04,,,,,0 - 0.2,GI/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,62.8,,,,,40.5 - 75,% +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,27.5,,,,,15.4 - 48.5,% +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.4,,,,,2.6 - 10.1,% +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,3.4,,,,,0 - 6.8,% +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.9,,,,,0 - 2,% +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,271,,,,,140 - 400,GI/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.1,,,,,<6.5 %, +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,8.27,,,,,1.9 - 23,uIU/mL +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,LIPID PANEL,Direct HDL-C 4th Generation,,1.32,,,,Result verified by repeat analysis,1.03 - 1.53,mmol/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,LIPID PANEL,Triglycerides (GPO),,2.24,,,,,0.5 - 2.81,mmol/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,LIPID PANEL,Cholesterol (High Performance),,5.39,,,,,3.31 - 6.1,mmol/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,LIPID PANEL,LDL Chol Friedewald 4th,,3.04,,,,,0 - 3.34,mmol/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,RETICULOCYTES,Reticulocyte Count %,,1.1,,,,,0.6 - 2.5,% +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,TSH,TSH 3rd IS-QT,,1.417,,,,,0.45 - 5.33,mIU/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,URINE MACRO PANEL,Ur Specific Gravity,,1.023,,,,,1 - 1.04, +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:Negative, +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.0,,,,,0 - 5,mg/L +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,CHEMISTRY PANEL,Total Bilirubin,,9,,,,,3 - 21,umol/L +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.4,,,,,0 - 6.2,umol/L +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,CHEMISTRY PANEL,Alkaline Phosphatase,,63,,,,,35 - 104,U/L +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,CHEMISTRY PANEL,ALT (SGPT),,18,,,,,4 - 43,U/L +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,CHEMISTRY PANEL,AST (SGOT),,21,,,,,8 - 40,U/L +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,CHEMISTRY PANEL,GGT,,15,,,,,4 - 49,U/L +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,CHEMISTRY PANEL,LDH,,142,,,,,53 - 234,U/L +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,CHEMISTRY PANEL,Urea Nitrogen,,4.2,,,,,1.4 - 8.6,mmol/L +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,81,,,,,31 - 101,umol/L +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,CHEMISTRY PANEL,Glucose Fasting,,5.2,,,,,3.9 - 5.6,mmol/L +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,CHEMISTRY PANEL,Serum Uric Acid,,291,,,,,125 - 428,umol/L +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,CHEMISTRY PANEL,Calcium (EDTA),,2.40,,,,,2.07 - 2.64,mmol/L +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,CHEMISTRY PANEL,Phosphorus,,1.15,,,,,0.71 - 1.65,mmol/L +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,CHEMISTRY PANEL,Total Protein,,70,,,,,61 - 84,g/L +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,CHEMISTRY PANEL,Albumin-BCG,,45,,,,,33 - 49,g/L +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,CHEMISTRY PANEL,Creatine Kinase,,109,,,,,26 - 192,U/L +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,CHEMISTRY PANEL,Serum Sodium,,140,,,,,132 - 147,mmol/L +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,CHEMISTRY PANEL,Serum Potassium,,4.1,,,,,3.5 - 5.2,mmol/L +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,CHEMISTRY PANEL,Serum Bicarbonate,,21.7,,,,,19.3 - 29.3,mmol/L +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,CHEMISTRY PANEL,Serum Chloride,,102,,,,,94 - 112,mmol/L +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,CREATININE CLEARANCE CC&G,CreatininClearancCockcrftGault,,1.55,,,,,1.25 - 1.92,mL/sec +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,CREATININE CLEARANCE CC&G,Creatinine(Rate Blanked)-2dp,,81,,,,,31 - 101,umol/L +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,CREATININE CLEARANCE CC&G,"Weight (kg,1dec place)",Y,68.0,,,,,kg, +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,FSH,Follicle Stimulating Hormone,,1.95,,RX,,,Follicular:$3.90-8.80 IU/L$Midcycle:$4.50-22.50 IU/L$Luteal:$1.80-5.10 IU/L$Postmenopausal:$16.70-113.60 IU/L, +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,124,,,,,116 - 164,g/L +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.37,,,,,0.34 - 0.48, +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.2,,,,,4.1 - 5.6,TI/L +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,89,,,,,79 - 98,fL +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,5.35,,,,,3.8 - 10.7,GI/L +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.19,,,,,1.96 - 7.23,GI/L +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.57,,,,,0.91 - 4.28,GI/L +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.39,,,,,0.12 - 0.92,GI/L +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.11,,,,,0 - 0.57,GI/L +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.08,,,,,0 - 0.2,GI/L +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,59.6,,,,,40.5 - 75,% +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,29.4,,,,,15.4 - 48.5,% +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,7.3,,,,,2.6 - 10.1,% +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.1,,,,,0 - 6.8,% +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.6,,,,,0 - 2,% +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,340,,,,,140 - 400,GI/L +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.7,,,,,<6.5 %, +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,4.35,,,,,1.9 - 23,uIU/mL +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,LIPID PANEL,Direct HDL-C 4th Generation,,1.82,,H,,,1.03 - 1.53,mmol/L +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,LIPID PANEL,Triglycerides (GPO),,0.63,,,,,0.44 - 1.99,mmol/L +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,LIPID PANEL,Cholesterol (High Performance),,5.11,,,,,3.65 - 6.21,mmol/L +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,LIPID PANEL,LDL Chol Friedewald 4th,,3.00,,,,,0 - 3.34,mmol/L +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,RETICULOCYTES,Reticulocyte Count %,,0.7,,,,,0.6 - 2.5,% +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,SERUM BETA HCG,"B-hCG, Qualitative",,Negative,,,,,Ref Rng: Negative, +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,SERUM BETA HCG,"B-hCG, Quantitative",,<0.6,,,,,Units: mIU/mL$Pre-menopausal$<5.0: Negative$5.0-24.9:Borderline$>/= 25.0: Positive, +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,TSH,TSH 3rd IS-QT,,2.024,,,,,0.45 - 5.33,mIU/L +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,URINE MACRO PANEL,Ur Specific Gravity,,1.017,,,,,1 - 1.04, +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,C-REACTIVE PROTEIN,C Reactive Protein HS,,0.7,,,,,0 - 5,mg/L +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,CHEMISTRY PANEL,Total Bilirubin,,7,,,,,3 - 21,umol/L +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.9,,,,,0 - 6.2,umol/L +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,CHEMISTRY PANEL,Alkaline Phosphatase,,62,,,,,35 - 104,U/L +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,CHEMISTRY PANEL,ALT (SGPT),,21,,,,,4 - 43,U/L +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,CHEMISTRY PANEL,AST (SGOT),,24,,,,,8 - 40,U/L +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,CHEMISTRY PANEL,GGT,,33,,,,,4 - 49,U/L +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,CHEMISTRY PANEL,LDH,,158,,,,,53 - 234,U/L +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,CHEMISTRY PANEL,Urea Nitrogen,,4.1,,,,,1.4 - 8.6,mmol/L +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,73,,,,,31 - 101,umol/L +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,CHEMISTRY PANEL,Glucose Fasting,,4.2,,,,,3.9 - 5.6,mmol/L +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,CHEMISTRY PANEL,Serum Uric Acid,,307,,,,,149 - 446,umol/L +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,CHEMISTRY PANEL,Calcium (EDTA),,2.34,,,,,2.07 - 2.64,mmol/L +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,CHEMISTRY PANEL,Phosphorus,,1.07,,,,,0.71 - 1.65,mmol/L +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,CHEMISTRY PANEL,Total Protein,,71,,,,,61 - 84,g/L +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,CHEMISTRY PANEL,Albumin-BCG,,44,,,,,33 - 49,g/L +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,CHEMISTRY PANEL,Creatine Kinase,,203,,H,,,26 - 192,U/L +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,CHEMISTRY PANEL,Serum Sodium,,139,,,,,132 - 147,mmol/L +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,CHEMISTRY PANEL,Serum Potassium,,4.3,,,,,3.5 - 5.2,mmol/L +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,CHEMISTRY PANEL,Serum Bicarbonate,,22.0,,,,,19.3 - 29.3,mmol/L +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,CHEMISTRY PANEL,Serum Chloride,,103,,,,,94 - 112,mmol/L +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,136,,,,,116 - 164,g/L +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.41,,,,,0.34 - 0.48, +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.5,,,,,4.1 - 5.6,TI/L +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,90,,,,,79 - 98,fL +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,6.49,,,,,3.8 - 10.7,GI/L +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.93,,,,,1.96 - 7.23,GI/L +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.72,,,,,0.91 - 4.28,GI/L +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.34,,,,,0.12 - 0.92,GI/L +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.32,,,,,0 - 0.57,GI/L +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.17,,,,,0 - 0.2,GI/L +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,45.2,,,,,40.5 - 75,% +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,41.9,,,,,15.4 - 48.5,% +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.3,,,,,2.6 - 10.1,% +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,4.9,,,,,0 - 6.8,% +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,2.7,R,H,,,0 - 2,% +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,332,,,,,140 - 400,GI/L +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,3.15,,,,,1.9 - 23,uIU/mL +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,LIPID PANEL,Direct HDL-C 4th Generation,,1.91,,H,,,1.03 - 1.53,mmol/L +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,LIPID PANEL,Triglycerides (GPO),,1.28,,,,,0.59 - 2.96,mmol/L +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,LIPID PANEL,Cholesterol (High Performance),,5.21,,,,,4.42 - 7.53,mmol/L +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,LIPID PANEL,LDL Chol Friedewald 4th,,2.71,,,,,0 - 3.34,mmol/L +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,RETICULOCYTES,Reticulocyte Count %,,1.1,,,,,0.6 - 2.5,% +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,URINE MACRO PANEL,Ur Specific Gravity,,1.024,,,,,1 - 1.04, +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,URINE MACRO PANEL,Ur pH,,6.0,,,,,5 - 8, +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,C-REACTIVE PROTEIN,C Reactive Protein HS,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,CHEMISTRY PANEL,Total Bilirubin,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,CHEMISTRY PANEL,Alkaline Phosphatase,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,CHEMISTRY PANEL,ALT (SGPT),,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,CHEMISTRY PANEL,AST (SGOT),,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,CHEMISTRY PANEL,GGT,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,CHEMISTRY PANEL,LDH,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,CHEMISTRY PANEL,Urea Nitrogen,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,CHEMISTRY PANEL,Glucose Fasting,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,CHEMISTRY PANEL,Serum Uric Acid,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,CHEMISTRY PANEL,Calcium (EDTA),,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,CHEMISTRY PANEL,Phosphorus,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,CHEMISTRY PANEL,Total Protein,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,CHEMISTRY PANEL,Albumin-BCG,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,CHEMISTRY PANEL,Creatine Kinase,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,CHEMISTRY PANEL,Serum Sodium,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,CHEMISTRY PANEL,Serum Potassium,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,CHEMISTRY PANEL,Serum Bicarbonate,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,CHEMISTRY PANEL,Serum Chloride,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,126,,,,,116 - 164,g/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.38,,,,,0.34 - 0.48, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.3,,,,,4.1 - 5.6,TI/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,89,,,,,79 - 98,fL +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,4.49,,,,,3.8 - 10.7,GI/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.37,,,,,1.96 - 7.23,GI/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.74,,,,,0.91 - 4.28,GI/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.29,,,,,0.12 - 0.92,GI/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.07,,,,,0 - 0.57,GI/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.02,,,,,0 - 0.2,GI/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,52.8,,,,,40.5 - 75,% +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,38.7,,,,,15.4 - 48.5,% +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,6.5,,,,,2.6 - 10.1,% +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.6,,,,,0 - 6.8,% +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.5,,,,,0 - 2,% +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,299,,,,,140 - 400,GI/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.5,,,,,<6.5 %, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,2.65,,,,,1.9 - 23,uIU/mL +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,LIPID PANEL,Direct HDL-C 4th Generation,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,LIPID PANEL,Triglycerides (GPO),,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,LIPID PANEL,Cholesterol (High Performance),,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,LIPID PANEL,LDL Chol Friedewald 4th,,Required testing unavailable,,,,,0 - 3.34,mmol/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,RETICULOCYTES,Reticulocyte Count %,,1.0,,,,,0.6 - 2.5,% +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,TSH,TSH 3rd IS-QT,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,URINE MACRO PANEL,Ur Specific Gravity,,1.011,,,,,1 - 1.04, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,URINE MACRO PANEL,Ur pH,,6.5,,,,,5 - 8, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,C-REACTIVE PROTEIN,C Reactive Protein HS,,2.1,,,,,0 - 5,mg/L +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,CELLULAR ELEMENTS,Ur WBC/HPF,,5,,,,,0 - 12,/HPF +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,CELLULAR ELEMENTS,Ur Squamous Epithelial Cells,,80,,,,,0 - 3,/HPF +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,CHEMISTRY PANEL,Total Bilirubin,,6,,,,,3 - 21,umol/L +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.5,,,,,0 - 6.2,umol/L +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,CHEMISTRY PANEL,Alkaline Phosphatase,,98,,,,,35 - 104,U/L +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,CHEMISTRY PANEL,ALT (SGPT),,8,,,,,4 - 43,U/L +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,CHEMISTRY PANEL,AST (SGOT),,10,,,,,8 - 40,U/L +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,CHEMISTRY PANEL,GGT,,8,,,,,4 - 49,U/L +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,CHEMISTRY PANEL,LDH,,142,,,,,53 - 234,U/L +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,CHEMISTRY PANEL,Urea Nitrogen,,4.8,,,,,1.4 - 8.6,mmol/L +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,62,,,,,31 - 101,umol/L +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,CHEMISTRY PANEL,Glucose Fasting,,4.9,,,,,3.9 - 5.6,mmol/L +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,CHEMISTRY PANEL,Serum Uric Acid,,261,,,,,125 - 428,umol/L +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,CHEMISTRY PANEL,Calcium (EDTA),,2.34,,,,,2.07 - 2.64,mmol/L +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,CHEMISTRY PANEL,Phosphorus,,1.10,,,,,0.71 - 1.65,mmol/L +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,CHEMISTRY PANEL,Total Protein,,78,,,,,61 - 84,g/L +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,CHEMISTRY PANEL,Albumin-BCG,,49,,,,,33 - 49,g/L +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,CHEMISTRY PANEL,Creatine Kinase,,42,,,,,26 - 192,U/L +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,CHEMISTRY PANEL,Serum Sodium,,139,,,,,132 - 147,mmol/L +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,CHEMISTRY PANEL,Serum Potassium,,4.4,,,,,3.5 - 5.2,mmol/L +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,CHEMISTRY PANEL,Serum Bicarbonate,,21.8,,,,,19.3 - 29.3,mmol/L +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,CHEMISTRY PANEL,Serum Chloride,,102,,,,,94 - 112,mmol/L +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,CRYSTALS,Ur Calcium Oxalate Crystals,,Present,,,,,Ref Rng:Not present, +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,136,,,,,116 - 164,g/L +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.41,,,,,0.34 - 0.48, +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.5,,,,,4.1 - 5.6,TI/L +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,91,,,,,79 - 98,fL +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,7.82,,,,,3.8 - 10.7,GI/L +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,5.12,,,,,1.96 - 7.23,GI/L +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.07,,,,,0.91 - 4.28,GI/L +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.39,,,,,0.12 - 0.92,GI/L +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.17,,,,,0 - 0.57,GI/L +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.08,,,,,0 - 0.2,GI/L +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,65.4,,,,,40.5 - 75,% +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,26.4,,,,,15.4 - 48.5,% +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.0,,,,,2.6 - 10.1,% +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.1,,,,,0 - 6.8,% +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.0,,,,,0 - 2,% +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,322,,,,,140 - 400,GI/L +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,4.28,,,,,1.9 - 23,uIU/mL +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,LIPID PANEL,Direct HDL-C 4th Generation,,1.25,,,,Result verified by repeat analysis,1.03 - 1.53,mmol/L +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,LIPID PANEL,Triglycerides (GPO),,0.86,,,,,0.44 - 1.99,mmol/L +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,LIPID PANEL,Cholesterol (High Performance),,4.48,,,,,3.65 - 6.21,mmol/L +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,LIPID PANEL,LDL Chol Friedewald 4th,,2.84,,,,,0 - 3.34,mmol/L +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,MICROORGANISMS,Ur Bacteria,,Present,,,,,Ref Rng:Not present, +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,MISCELLANEOUS ELEMENTS,Ur Mucous,,Present,,,,,Ref Rng:Not present, +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,RETICULOCYTES,Reticulocyte Count %,,2.1,,,,,0.6 - 2.5,% +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,URINE MACRO PANEL,Ur Specific Gravity,,1.037,,H,,,1 - 1.04, +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,URINE MACRO PANEL,Ur Protein,,Trace,,H,,,Ref Rng:Negative, +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,URINE MACRO PANEL,Ur Leukocyte Esterase,,+1,,H,,,Ref Rng:Negative, +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,URINE MICRO PANEL,Ur Microscopic,,Positive,,,,, NEGATIVE$,NEGATIVE +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,C-REACTIVE PROTEIN,C Reactive Protein HS,,0.4,,,,,0 - 5,mg/L +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,CHEMISTRY PANEL,Total Bilirubin,,10,,,,,3 - 21,umol/L +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.6,,,,,0 - 6.2,umol/L +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,CHEMISTRY PANEL,Alkaline Phosphatase,,100,,,,,35 - 104,U/L +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,CHEMISTRY PANEL,ALT (SGPT),,20,,,,,4 - 43,U/L +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,CHEMISTRY PANEL,AST (SGOT),,25,,,,,8 - 40,U/L +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,CHEMISTRY PANEL,GGT,,63,,H,,,4 - 49,U/L +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,CHEMISTRY PANEL,LDH,,174,,,,,53 - 234,U/L +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,CHEMISTRY PANEL,Urea Nitrogen,,3.7,,,,,1.4 - 8.6,mmol/L +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,75,,,,,31 - 101,umol/L +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,CHEMISTRY PANEL,Glucose Fasting,,4.6,,,,,3.9 - 5.6,mmol/L +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,CHEMISTRY PANEL,Serum Uric Acid,,291,,,,,149 - 446,umol/L +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,CHEMISTRY PANEL,Calcium (EDTA),,2.42,,,,,2.07 - 2.64,mmol/L +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,CHEMISTRY PANEL,Phosphorus,,1.02,,,,,0.71 - 1.65,mmol/L +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,CHEMISTRY PANEL,Total Protein,,78,,,,,61 - 84,g/L +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,CHEMISTRY PANEL,Albumin-BCG,,47,,,,,33 - 49,g/L +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,CHEMISTRY PANEL,Creatine Kinase,,141,,,,,26 - 192,U/L +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,CHEMISTRY PANEL,Serum Sodium,,140,,,,,132 - 147,mmol/L +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,CHEMISTRY PANEL,Serum Potassium,,4.3,,,,,3.5 - 5.2,mmol/L +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,CHEMISTRY PANEL,Serum Bicarbonate,,21.3,,,,,19.3 - 29.3,mmol/L +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,CHEMISTRY PANEL,Serum Chloride,,102,,,,,94 - 112,mmol/L +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,CREATININE CLEARANCE CC&G,CreatininClearancCockcrftGault,,1.17,,L,,,1.25 - 1.92,mL/sec +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,CREATININE CLEARANCE CC&G,Creatinine(Rate Blanked)-2dp,,75,,,,,31 - 101,umol/L +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,CREATININE CLEARANCE CC&G,"Weight (kg,1dec place)",Y,59.2,,,,,kg, +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,DRUG SCREEN URINE,Amphetamines/MDMA,,Neg,,,,,Neg;$Cutoff = 1000 ng/mL, +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,DRUG SCREEN URINE,Barbiturates,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,DRUG SCREEN URINE,Cannabinoids,,Neg,,,,,Neg;$Cutoff = 50 ng/mL, +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,DRUG SCREEN URINE,Cocaine,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,DRUG SCREEN URINE,Opiates,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,DRUG SCREEN URINE,Methadone,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,DRUG SCREEN URINE BENZO NON-US,Benzodiazepines Gen 2,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,FEMALE OF CHILDBEARING POT?,Female/of Childbearing pot.?,Y,No,,,,,, +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,FREE T4,Free Thyroxine-QT,,9,,,,,8 - 14,pmol/L +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,GFR,EGFR by MDRD,,69,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,140,,,,,116 - 164,g/L +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.41,,,,,0.34 - 0.48, +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.6,,,,,4.1 - 5.6,TI/L +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,88,,,,,79 - 98,fL +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,7.44,,,,,3.8 - 10.7,GI/L +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.83,,,,,1.96 - 7.23,GI/L +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,4.07,,,,,0.91 - 4.28,GI/L +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.29,,,,,0.12 - 0.92,GI/L +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.21,,,,,0 - 0.57,GI/L +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.05,,,,,0 - 0.2,GI/L +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,38.0,R,L,,,40.5 - 75,% +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,54.7,R,H,,,15.4 - 48.5,% +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,3.8,,,,,2.6 - 10.1,% +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.8,,,,,0 - 6.8,% +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.6,,,,,0 - 2,% +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,295,,,,,140 - 400,GI/L +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,HEMOGLOBIN A1C,"Hemoglobin A1c,Variant(-70)-QT",,5.3,,,,,<6.5%, +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,2.96,,,,,1.9 - 23,uIU/mL +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,IS SUBJECT OF BLACK RACE?,Subject of black race?,Y,No,,,,,, +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,LIPID PANEL,Direct HDL-C 4th Generation,,1.84,,H,,,1.03 - 1.53,mmol/L +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,LIPID PANEL,Triglycerides (GPO),,1.42,,,,,0.59 - 2.96,mmol/L +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,LIPID PANEL,Cholesterol (High Performance),,5.78,,,,,4.42 - 7.53,mmol/L +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,LIPID PANEL,LDL Chol Friedewald 4th,,3.29,,,,,0 - 3.34,mmol/L +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,POSTMENOPAUSAL FEMALE?,<40yrs & amenorrhea >/= 12mo,,No,,,,,, +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,RETICULOCYTES,Reticulocyte Count %,,1.1,,,,,0.6 - 2.5,% +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,TSH,TSH 3rd IS-QT,,5.438,R,H SF,,,0.45 - 5.33,mIU/L +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,URINE MACRO PANEL,Ur Specific Gravity,,1.017,,,,,1 - 1.04, +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,URINE MACRO PANEL,Ur pH,,5.0,,,,,5 - 8, +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,C-REACTIVE PROTEIN,C Reactive Protein HS,,0.4,,,,,0 - 5,mg/L +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,CHEMISTRY PANEL,Total Bilirubin,,9,,,,,3 - 21,umol/L +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.9,,,,,0 - 6.2,umol/L +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,CHEMISTRY PANEL,Alkaline Phosphatase,,84,,,,,40 - 129,U/L +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,CHEMISTRY PANEL,ALT (SGPT),,64,,H,,,5 - 48,U/L +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,CHEMISTRY PANEL,AST (SGOT),,27,,,,,8 - 40,U/L +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,CHEMISTRY PANEL,GGT,,123,,H,,,10 - 61,U/L +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,CHEMISTRY PANEL,LDH,,159,,,,,53 - 234,U/L +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,CHEMISTRY PANEL,Urea Nitrogen,,6.3,,,,,1.4 - 8.6,mmol/L +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,91,,,,,40 - 110,umol/L +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,CHEMISTRY PANEL,Glucose Fasting,,4.8,,,,,3.9 - 5.6,mmol/L +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,CHEMISTRY PANEL,Serum Uric Acid,,419,,,,,125 - 488,umol/L +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,CHEMISTRY PANEL,Calcium (EDTA),,2.53,,,,,2.07 - 2.64,mmol/L +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,CHEMISTRY PANEL,Phosphorus,,1.27,,,,,0.71 - 1.65,mmol/L +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,CHEMISTRY PANEL,Total Protein,,73,,,,,61 - 84,g/L +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,CHEMISTRY PANEL,Albumin-BCG,,47,,,,,33 - 49,g/L +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,CHEMISTRY PANEL,Creatine Kinase,,141,,,,,39 - 308,U/L +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,CHEMISTRY PANEL,Serum Sodium,,139,,,,,132 - 147,mmol/L +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,CHEMISTRY PANEL,Serum Potassium,,4.5,,,,,3.5 - 5.2,mmol/L +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,CHEMISTRY PANEL,Serum Bicarbonate,,21.9,,,,,19.3 - 29.3,mmol/L +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,CHEMISTRY PANEL,Serum Chloride,,104,,,,,94 - 112,mmol/L +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,157,,,,,127 - 181,g/L +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.44,,,,,0.39 - 0.54, +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.0,,,,,4.5 - 6.4,TI/L +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,88,,,,,79 - 96,fL +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,4.88,,,,,3.8 - 10.7,GI/L +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.07,,,,,1.96 - 7.23,GI/L +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.32,,,,,0.91 - 4.28,GI/L +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.29,,,,,0.12 - 0.92,GI/L +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.15,,,,,0 - 0.57,GI/L +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.05,,,,,0 - 0.2,GI/L +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,62.9,,,,,40.5 - 75,% +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,27.1,,,,,15.4 - 48.5,% +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.9,,,,,2.6 - 10.1,% +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,3.0,,,,,0 - 6.8,% +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.0,,,,,0 - 2,% +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,266,,,,,140 - 400,GI/L +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,6.45,,,,,1.9 - 23,uIU/mL +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,LIPID PANEL,Direct HDL-C 4th Generation,,0.92,,L,,,1.03 - 1.53,mmol/L +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,LIPID PANEL,Triglycerides (GPO),,1.73,,,,,0.5 - 2.81,mmol/L +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,LIPID PANEL,Cholesterol (High Performance),,4.62,,,,,3.31 - 6.1,mmol/L +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,LIPID PANEL,LDL Chol Friedewald 4th,,2.91,,,,,0 - 3.34,mmol/L +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,RETICULOCYTES,Reticulocyte Count %,,1.4,,,,,0.6 - 2.5,% +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,URINE MACRO PANEL,Ur Specific Gravity,,1.024,,,,,1 - 1.04, +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:Negative, +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,C-REACTIVE PROTEIN,C Reactive Protein HS,,5.3,,H,,,0 - 5,mg/L +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,CELLULAR ELEMENTS,Ur WBC/HPF,,3,,,,,0 - 12,/HPF +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,CHEMISTRY PANEL,Total Bilirubin,,8,,,,,3 - 21,umol/L +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.6,,,,,0 - 6.2,umol/L +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,CHEMISTRY PANEL,Alkaline Phosphatase,,101,,,,,35 - 104,U/L +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,CHEMISTRY PANEL,ALT (SGPT),,9,,,,,4 - 43,U/L +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,CHEMISTRY PANEL,AST (SGOT),,12,,,,,8 - 40,U/L +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,CHEMISTRY PANEL,GGT,,6,,,,,4 - 49,U/L +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,CHEMISTRY PANEL,LDH,,157,,,,,53 - 234,U/L +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,CHEMISTRY PANEL,Urea Nitrogen,,3.7,,,,,1.4 - 8.6,mmol/L +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,57,,,,,31 - 101,umol/L +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,CHEMISTRY PANEL,Glucose Fasting,,4.7,,,,,3.9 - 5.6,mmol/L +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,CHEMISTRY PANEL,Serum Uric Acid,,232,,,,,125 - 428,umol/L +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,CHEMISTRY PANEL,Calcium (EDTA),,2.27,,,,,2.07 - 2.64,mmol/L +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,CHEMISTRY PANEL,Phosphorus,,1.14,,,,,0.71 - 1.65,mmol/L +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,CHEMISTRY PANEL,Total Protein,,75,,,,,61 - 84,g/L +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,CHEMISTRY PANEL,Albumin-BCG,,44,,,,,33 - 49,g/L +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,CHEMISTRY PANEL,Creatine Kinase,,59,,,,,26 - 192,U/L +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,CHEMISTRY PANEL,Serum Sodium,,136,,,,,132 - 147,mmol/L +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,CHEMISTRY PANEL,Serum Potassium,,4.2,,,,,3.5 - 5.2,mmol/L +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,CHEMISTRY PANEL,Serum Bicarbonate,,21.4,,,,,19.3 - 29.3,mmol/L +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,CHEMISTRY PANEL,Serum Chloride,,102,,,,,94 - 112,mmol/L +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,CREATININE CLEARANCE CC&G,CreatininClearancCockcrftGault,,2.50,,H,,,1.25 - 1.92,mL/sec +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,CREATININE CLEARANCE CC&G,Creatinine(Rate Blanked)-2dp,,57,,,,,31 - 101,umol/L +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,CREATININE CLEARANCE CC&G,"Weight (kg,1dec place)",Y,75.2,,,,,kg, +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,DRUG SCREEN URINE,Amphetamines/MDMA,,Neg,,,,,Neg;$Cutoff = 1000 ng/mL, +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,DRUG SCREEN URINE,Barbiturates,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,DRUG SCREEN URINE,Cannabinoids,,Neg,,,,,Neg;$Cutoff = 50 ng/mL, +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,DRUG SCREEN URINE,Cocaine,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,DRUG SCREEN URINE,Opiates,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,DRUG SCREEN URINE,Methadone,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,DRUG SCREEN URINE BENZO NON-US,Benzodiazepines Gen 2,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,FEMALE OF CHILDBEARING POT?,Female/of Childbearing pot.?,Y,Yes,,,,,, +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,GFR,EGFR by MDRD,,108,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,127,,,,,116 - 164,g/L +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.39,,,,,0.34 - 0.48, +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.4,,,,,4.1 - 5.6,TI/L +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,89,,,,,79 - 98,fL +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,7.26,,,,,3.8 - 10.7,GI/L +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,4.66,,,,,1.96 - 7.23,GI/L +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.98,,,,,0.91 - 4.28,GI/L +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.40,,,,,0.12 - 0.92,GI/L +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.17,,,,,0 - 0.57,GI/L +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.06,,,,,0 - 0.2,GI/L +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,64.1,,,,,40.5 - 75,% +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,27.4,,,,,15.4 - 48.5,% +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.4,,,,,2.6 - 10.1,% +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.3,,,,,0 - 6.8,% +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.8,,,,,0 - 2,% +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,335,,,,,140 - 400,GI/L +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,HEMOGLOBIN A1C,"Hemoglobin A1c,Variant(-70)-QT",,4.8,,,,,<6.5%, +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,4.40,,,,,1.9 - 23,uIU/mL +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,IS SUBJECT OF BLACK RACE?,Subject of black race?,Y,No,,,,,, +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,LIPID PANEL,Direct HDL-C 4th Generation,,0.99,,L,,,1.03 - 1.53,mmol/L +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,LIPID PANEL,Triglycerides (GPO),,0.76,,,,,0.44 - 1.99,mmol/L +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,LIPID PANEL,Cholesterol (High Performance),,4.01,,,,,3.65 - 6.21,mmol/L +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,LIPID PANEL,LDL Chol Friedewald 4th,,2.67,,,,,0 - 3.34,mmol/L +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,MICROORGANISMS,Ur Bacteria,,Present,,,,,Ref Rng:Not present, +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,POSTMENOPAUSAL FEMALE?,<40yrs & amenorrhea >/= 12mo,,No,,,,,, +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,RETICULOCYTES,Reticulocyte Count %,,2.4,,,,,0.6 - 2.5,% +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,SERUM BETA HCG,"B-hCG, Qualitative",,Negative,,,,,Ref Rng: Negative, +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,SERUM BETA HCG,"B-hCG, Quantitative",,<0.6,,,,,Units: mIU/mL$Pre-menopausal$<5.0: Negative$5.0-24.9:Borderline$>/= 25.0: Positive, +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,TSH,TSH 3rd IS-QT,,1.593,,,,,0.45 - 5.33,mIU/L +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,URINE MACRO PANEL,Ur Specific Gravity,,1.029,,,,,1 - 1.04, +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,URINE MACRO PANEL,Ur Leukocyte Esterase,,+1,,H,,,Ref Rng:Negative, +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,URINE MICRO PANEL,Ur Microscopic,,Positive,,,,, NEGATIVE$,NEGATIVE +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,BENZODIAZEPINE CONFIRM. UR,BenzodiazepineConf-LCMSMS-LDT,,Oxazepam (Confirmed),R,RX,,,No Ref Rng, +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.2,,,,,0 - 5,mg/L +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,CHEMISTRY PANEL,Total Bilirubin,,4,,,,,3 - 21,umol/L +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,1.6,,,,,0 - 6.2,umol/L +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,CHEMISTRY PANEL,Alkaline Phosphatase,,94,,,,,40 - 129,U/L +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,CHEMISTRY PANEL,ALT (SGPT),,27,,,,,5 - 48,U/L +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,CHEMISTRY PANEL,AST (SGOT),,23,,,,,8 - 40,U/L +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,CHEMISTRY PANEL,GGT,,17,,,,,10 - 61,U/L +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,CHEMISTRY PANEL,LDH,,161,,,,,53 - 234,U/L +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,CHEMISTRY PANEL,Urea Nitrogen,,6.1,,,,,1.4 - 8.6,mmol/L +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,83,,,,,40 - 110,umol/L +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,CHEMISTRY PANEL,Glucose Fasting,,5.4,,,,,3.9 - 5.6,mmol/L +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,CHEMISTRY PANEL,Serum Uric Acid,,344,,,,,125 - 488,umol/L +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,CHEMISTRY PANEL,Calcium (EDTA),,2.46,,,,,2.07 - 2.64,mmol/L +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,CHEMISTRY PANEL,Phosphorus,,1.03,,,,,0.71 - 1.65,mmol/L +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,CHEMISTRY PANEL,Total Protein,,78,,,,,61 - 84,g/L +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,CHEMISTRY PANEL,Albumin-BCG,,47,,,,,33 - 49,g/L +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,CHEMISTRY PANEL,Creatine Kinase,,232,,,,,39 - 308,U/L +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,CHEMISTRY PANEL,Serum Sodium,,139,,,,,132 - 147,mmol/L +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,CHEMISTRY PANEL,Serum Potassium,,4.7,,,,,3.5 - 5.2,mmol/L +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,CHEMISTRY PANEL,Serum Bicarbonate,,21.3,,,,,19.3 - 29.3,mmol/L +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,CHEMISTRY PANEL,Serum Chloride,,101,,,,,94 - 112,mmol/L +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,CREATININE CLEARANCE CC&G,CreatininClearancCockcrftGault,,2.37,,H,,,1.42 - 2.08,mL/sec +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,CREATININE CLEARANCE CC&G,Creatinine(Rate Blanked)-2dp,,83,,,,,40 - 110,umol/L +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,CREATININE CLEARANCE CC&G,"Weight (kg,1dec place)",Y,89.1,,,,,kg, +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,DRUG SCREEN URINE,Amphetamines/MDMA,,Neg,,,,,Neg;$Cutoff = 1000 ng/mL, +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,DRUG SCREEN URINE,Barbiturates,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,DRUG SCREEN URINE,Cannabinoids,,Neg,,,,,Neg;$Cutoff = 50 ng/mL, +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,DRUG SCREEN URINE,Cocaine,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,DRUG SCREEN URINE,Opiates,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,DRUG SCREEN URINE,Methadone,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,DRUG SCREEN URINE BENZO NON-US,Benzodiazepines Gen 2,,Detected (unconfirmed),,,,,Neg;$Cutoff = 200 ng/mL, +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,GFR,EGFR by MDRD,,93,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,141,,,,,127 - 181,g/L +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.40,,,,,0.39 - 0.54, +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.7,,,,,4.5 - 6.4,TI/L +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,86,,,,,79 - 96,fL +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,6.63,,,,,3.8 - 10.7,GI/L +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.10,,,,,1.96 - 7.23,GI/L +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,3.01,,,,,0.91 - 4.28,GI/L +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.37,,,,,0.12 - 0.92,GI/L +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.11,,,,,0 - 0.57,GI/L +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.03,,,,,0 - 0.2,GI/L +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,46.8,,,,,40.5 - 75,% +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,45.4,,,,,15.4 - 48.5,% +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.6,,,,,2.6 - 10.1,% +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.6,,,,,0 - 6.8,% +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.5,,,,,0 - 2,% +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,306,,,,,140 - 400,GI/L +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,HEMOGLOBIN A1C,"Hemoglobin A1c,Variant(-70)-QT",,5.3,,,,,<6.5%, +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,16.63,,,,,1.9 - 23,uIU/mL +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,IS SUBJECT OF BLACK RACE?,Subject of black race?,Y,No,,,,,, +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,LIPID PANEL,Direct HDL-C 4th Generation,,0.95,R,L,,,1.03 - 1.53,mmol/L +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,LIPID PANEL,Triglycerides (GPO),,2.07,,,,,0.56 - 3.62,mmol/L +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,LIPID PANEL,Cholesterol (High Performance),,5.65,,,,,3.88 - 6.83,mmol/L +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,LIPID PANEL,LDL Chol Friedewald 4th,,3.75,,H,,,0 - 3.34,mmol/L +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,RETICULOCYTES,Reticulocyte Count %,,1.1,,,,,0.6 - 2.5,% +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,TSH,TSH 3rd IS-QT,,2.249,,,,,0.45 - 5.33,mIU/L +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,URINE MACRO PANEL,Ur Specific Gravity,,1.006,,,,,1 - 1.04, +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,URINE MACRO PANEL,Ur pH,,5.0,,,,,5 - 8, +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:Negative, +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,C-REACTIVE PROTEIN,C Reactive Protein HS,,0.4,,,,Result verified by repeat analysis,0 - 5,mg/L +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,CHEMISTRY PANEL,Total Bilirubin,,6,,,,,3 - 21,umol/L +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.5,,,,,0 - 6.2,umol/L +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,CHEMISTRY PANEL,Alkaline Phosphatase,,60,,,,,35 - 104,U/L +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,CHEMISTRY PANEL,ALT (SGPT),,9,,,,,4 - 43,U/L +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,CHEMISTRY PANEL,AST (SGOT),,11,,,,,8 - 40,U/L +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,CHEMISTRY PANEL,GGT,,13,,,,,4 - 49,U/L +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,CHEMISTRY PANEL,LDH,,126,,,,,53 - 234,U/L +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,CHEMISTRY PANEL,Urea Nitrogen,,3.6,,,,,1.4 - 8.6,mmol/L +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,77,,,,,31 - 101,umol/L +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,CHEMISTRY PANEL,Glucose Fasting,,5.0,,,,,3.9 - 5.6,mmol/L +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,CHEMISTRY PANEL,Serum Uric Acid,,217,,,,,125 - 428,umol/L +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,CHEMISTRY PANEL,Calcium (EDTA),,2.40,,,,,2.07 - 2.64,mmol/L +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,CHEMISTRY PANEL,Phosphorus,,1.01,,,,,0.71 - 1.65,mmol/L +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,CHEMISTRY PANEL,Total Protein,,66,,,,,61 - 84,g/L +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,CHEMISTRY PANEL,Albumin-BCG,,45,,,,,33 - 49,g/L +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,CHEMISTRY PANEL,Creatine Kinase,,66,,,,,26 - 192,U/L +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,CHEMISTRY PANEL,Serum Sodium,,141,,,,,132 - 147,mmol/L +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,CHEMISTRY PANEL,Serum Potassium,,4.2,,,,,3.5 - 5.2,mmol/L +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,CHEMISTRY PANEL,Serum Bicarbonate,,24.5,,,,,19.3 - 29.3,mmol/L +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,CHEMISTRY PANEL,Serum Chloride,,103,,,,,94 - 112,mmol/L +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,121,,,,,116 - 164,g/L +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.38,,,,,0.34 - 0.48, +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.2,,,,,4.1 - 5.6,TI/L +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,90,,,,,79 - 98,fL +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,5.05,,,,,3.8 - 10.7,GI/L +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.88,,,,,1.96 - 7.23,GI/L +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.73,,,,,0.91 - 4.28,GI/L +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.29,,,,,0.12 - 0.92,GI/L +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.13,,,,,0 - 0.57,GI/L +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.02,,,,,0 - 0.2,GI/L +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,57.1,,,,,40.5 - 75,% +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,34.3,,,,,15.4 - 48.5,% +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.7,,,,,2.6 - 10.1,% +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.6,,,,,0 - 6.8,% +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.4,,,,,0 - 2,% +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,286,,,,,140 - 400,GI/L +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,4.08,,,,,1.9 - 23,uIU/mL +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,LIPID PANEL,Direct HDL-C 4th Generation,,1.85,R,H,,,1.03 - 1.53,mmol/L +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,LIPID PANEL,Triglycerides (GPO),,0.57,,,,,0.44 - 1.99,mmol/L +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,LIPID PANEL,Cholesterol (High Performance),,4.35,,,,,3.65 - 6.21,mmol/L +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,LIPID PANEL,LDL Chol Friedewald 4th,,2.24,,,,,0 - 3.34,mmol/L +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,RETICULOCYTES,Reticulocyte Count %,,0.8,,,,,0.6 - 2.5,% +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,URINE MACRO PANEL,Ur Specific Gravity,,1.015,,,,,1 - 1.04, +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,C-REACTIVE PROTEIN,C Reactive Protein HS,,0.2,,,,Result verified by repeat analysis,0 - 5,mg/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,CHEMISTRY PANEL,Total Bilirubin,,11,,,,,3 - 21,umol/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.8,,,,,0 - 6.2,umol/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,CHEMISTRY PANEL,Alkaline Phosphatase,,88,,,,,40 - 129,U/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,CHEMISTRY PANEL,ALT (SGPT),,46,,,,,5 - 48,U/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,CHEMISTRY PANEL,AST (SGOT),,21,,,,,8 - 40,U/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,CHEMISTRY PANEL,GGT,,129,,H,,,10 - 61,U/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,CHEMISTRY PANEL,LDH,,156,,,,,53 - 234,U/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,CHEMISTRY PANEL,Urea Nitrogen,,5.2,,,,,1.4 - 8.6,mmol/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,91,,,,,40 - 110,umol/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,CHEMISTRY PANEL,Glucose Fasting,,4.6,,,,,3.9 - 5.6,mmol/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,CHEMISTRY PANEL,Serum Uric Acid,,429,,,,,125 - 488,umol/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,CHEMISTRY PANEL,Calcium (EDTA),,2.56,,,,,2.07 - 2.64,mmol/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,CHEMISTRY PANEL,Phosphorus,,1.13,,,,,0.71 - 1.65,mmol/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,CHEMISTRY PANEL,Total Protein,,75,,,,,61 - 84,g/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,CHEMISTRY PANEL,Albumin-BCG,,49,,,,,33 - 49,g/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,CHEMISTRY PANEL,Creatine Kinase,,131,,,,,39 - 308,U/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,CHEMISTRY PANEL,Serum Sodium,,137,,,,,132 - 147,mmol/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,CHEMISTRY PANEL,Serum Potassium,,4.3,,,,,3.5 - 5.2,mmol/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,CHEMISTRY PANEL,Serum Bicarbonate,,21.4,,,,,19.3 - 29.3,mmol/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,CHEMISTRY PANEL,Serum Chloride,,100,,,,,94 - 112,mmol/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,157,,,,,127 - 181,g/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.46,,,,,0.39 - 0.54, +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.2,,,,,4.5 - 6.4,TI/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,88,,,,,79 - 96,fL +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,4.79,,,,,3.8 - 10.7,GI/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.75,,,,,1.96 - 7.23,GI/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.48,,,,,0.91 - 4.28,GI/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.34,,,,,0.12 - 0.92,GI/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.14,,,,,0 - 0.57,GI/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.07,,,,,0 - 0.2,GI/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,57.5,,,,,40.5 - 75,% +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,30.9,,,,,15.4 - 48.5,% +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,7.2,,,,,2.6 - 10.1,% +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.9,,,,,0 - 6.8,% +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.5,,,,,0 - 2,% +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,280,,,,,140 - 400,GI/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,HEMOGLOBIN A1C,"Hemoglobin A1c,Variant(-70)-QT",,4.8,,,,,<6.5%, +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,10.32,,,,,1.9 - 23,uIU/mL +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,LIPID PANEL,Direct HDL-C 4th Generation,,0.92,,L,,,1.03 - 1.53,mmol/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,LIPID PANEL,Triglycerides (GPO),,1.99,,,,,0.5 - 2.81,mmol/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,LIPID PANEL,Cholesterol (High Performance),,4.77,,,,,3.31 - 6.1,mmol/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,LIPID PANEL,LDL Chol Friedewald 4th,,2.94,,,,,0 - 3.34,mmol/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,RETICULOCYTES,Reticulocyte Count %,,1.3,,,,,0.6 - 2.5,% +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,TSH,TSH 3rd IS-QT,,1.125,,,,,0.45 - 5.33,mIU/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,URINE MACRO PANEL,Ur Specific Gravity,,1.023,,,,,1 - 1.04, +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:Negative, +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,C-REACTIVE PROTEIN,C Reactive Protein HS,,2.4,,,,,0 - 5,mg/L +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,CHEMISTRY PANEL,Total Bilirubin,,8,,,,,3 - 21,umol/L +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.2,,,,,0 - 6.2,umol/L +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,CHEMISTRY PANEL,Alkaline Phosphatase,,89,,,,,35 - 104,U/L +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,CHEMISTRY PANEL,ALT (SGPT),,16,,,,,4 - 43,U/L +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,CHEMISTRY PANEL,AST (SGOT),,14,,,,,8 - 40,U/L +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,CHEMISTRY PANEL,GGT,,16,,,,,4 - 49,U/L +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,CHEMISTRY PANEL,LDH,,124,,,,,53 - 234,U/L +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,CHEMISTRY PANEL,Urea Nitrogen,,4.5,,,,,1.4 - 8.6,mmol/L +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,68,,,,,31 - 101,umol/L +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,CHEMISTRY PANEL,Glucose Fasting,,4.3,,,,,3.9 - 5.6,mmol/L +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,CHEMISTRY PANEL,Serum Uric Acid,,303,,,,,125 - 428,umol/L +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,CHEMISTRY PANEL,Calcium (EDTA),,2.40,,,,,2.07 - 2.64,mmol/L +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,CHEMISTRY PANEL,Phosphorus,,1.03,,,,,0.71 - 1.65,mmol/L +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,CHEMISTRY PANEL,Total Protein,,74,,,,,61 - 84,g/L +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,CHEMISTRY PANEL,Albumin-BCG,,47,,,,,33 - 49,g/L +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,CHEMISTRY PANEL,Creatine Kinase,,79,,,,,26 - 192,U/L +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,CHEMISTRY PANEL,Serum Sodium,,138,,,,,132 - 147,mmol/L +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,CHEMISTRY PANEL,Serum Potassium,,4.4,,,,,3.5 - 5.2,mmol/L +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,CHEMISTRY PANEL,Serum Bicarbonate,,23.6,,,,,19.3 - 29.3,mmol/L +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,CHEMISTRY PANEL,Serum Chloride,,102,,,,,94 - 112,mmol/L +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,127,,,,,116 - 164,g/L +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.39,,,,,0.34 - 0.48, +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.7,,,,,4.1 - 5.6,TI/L +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,83,,,,,79 - 98,fL +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,5.69,,,,,3.8 - 10.7,GI/L +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.05,,,,,1.96 - 7.23,GI/L +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.72,,,,,0.91 - 4.28,GI/L +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.49,,,,,0.12 - 0.92,GI/L +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.34,,,,,0 - 0.57,GI/L +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.09,,,,,0 - 0.2,GI/L +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,53.5,,,,,40.5 - 75,% +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,30.1,,,,,15.4 - 48.5,% +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,8.6,,,,,2.6 - 10.1,% +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,6.1,,,,,0 - 6.8,% +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.6,,,,,0 - 2,% +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,274,,,,,140 - 400,GI/L +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,HEMOGLOBIN A1C,"Hemoglobin A1c,Variant(-70)-QT",,5.2,,,,,<6.5%, +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,5.14,,,,,1.9 - 23,uIU/mL +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,LIPID PANEL,Direct HDL-C 4th Generation,,1.48,,,,Result verified by repeat analysis,1.03 - 1.53,mmol/L +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,LIPID PANEL,Triglycerides (GPO),,0.82,,,,,0.44 - 1.99,mmol/L +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,LIPID PANEL,Cholesterol (High Performance),,3.76,,,,,3.65 - 6.21,mmol/L +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,LIPID PANEL,LDL Chol Friedewald 4th,,1.90,,,,,0 - 3.34,mmol/L +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,RETICULOCYTES,Reticulocyte Count %,,0.9,,,,,0.6 - 2.5,% +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,TSH,TSH 3rd IS-QT,,1.582,,,,,0.45 - 5.33,mIU/L +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,URINE MACRO PANEL,Ur Specific Gravity,,1.011,,,,,1 - 1.04, +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,C-REACTIVE PROTEIN,C Reactive Protein HS,,3.4,,,,,0 - 5,mg/L +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,CHEMISTRY PANEL,Total Bilirubin,,9,,,,,3 - 21,umol/L +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.3,,,,,0 - 6.2,umol/L +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,CHEMISTRY PANEL,Alkaline Phosphatase,,80,,,,,35 - 104,U/L +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,CHEMISTRY PANEL,ALT (SGPT),,32,,,,,4 - 43,U/L +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,CHEMISTRY PANEL,AST (SGOT),,34,,,,,8 - 40,U/L +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,CHEMISTRY PANEL,GGT,,25,,,,,5 - 50,U/L +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,CHEMISTRY PANEL,LDH,,167,,,,,53 - 234,U/L +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,CHEMISTRY PANEL,Urea Nitrogen,,4.0,,,,,1.4 - 8.6,mmol/L +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,58,,,,,31 - 101,umol/L +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,CHEMISTRY PANEL,Glucose Fasting,,4.8,,,,,3.9 - 5.6,mmol/L +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,CHEMISTRY PANEL,Serum Uric Acid,,265,,,,,149 - 446,umol/L +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,CHEMISTRY PANEL,Calcium (EDTA),,2.34,,,,,2.07 - 2.64,mmol/L +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,CHEMISTRY PANEL,Phosphorus,,1.18,,,,,0.71 - 1.65,mmol/L +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,CHEMISTRY PANEL,Total Protein,,63,,,,,60 - 80,g/L +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,CHEMISTRY PANEL,Albumin-BCG,,43,,,,,33 - 49,g/L +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,CHEMISTRY PANEL,Creatine Kinase,,46,,,,,26 - 192,U/L +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,CHEMISTRY PANEL,Serum Sodium,,143,,,,,135 - 145,mmol/L +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,CHEMISTRY PANEL,Serum Potassium,,4.2,,,,,3.5 - 5.2,mmol/L +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,CHEMISTRY PANEL,Serum Bicarbonate,,24.9,,,,,19.3 - 29.3,mmol/L +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,CHEMISTRY PANEL,Serum Chloride,,103,,,,,94 - 112,mmol/L +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,CREATININE CLEARANCE CC&G,CreatininClearancCockcrftGault,,1.74,,,,,1.25 - 1.92,mL/sec +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,CREATININE CLEARANCE CC&G,Creatinine(Rate Blanked)-2dp,,58,,,,,31 - 101,umol/L +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,CREATININE CLEARANCE CC&G,"Weight (kg,1dec place)",Y,75.3,,,,,kg, +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,DRUG SCREEN URINE,Amphetamines/MDMA,,Neg,,,,,Neg;$Cutoff = 1000 ng/mL, +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,DRUG SCREEN URINE,Barbiturates,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,DRUG SCREEN URINE,Cannabinoids,,Neg,,,,,Neg;$Cutoff = 50 ng/mL, +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,DRUG SCREEN URINE,Cocaine,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,DRUG SCREEN URINE,Opiates,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,DRUG SCREEN URINE,Methadone,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,DRUG SCREEN URINE BENZO NON-US,Benzodiazepines Gen 2,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,FEMALE OF CHILDBEARING POT?,Female/of Childbearing pot.?,Y,No,,,,,, +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,GFR,EGFR by MDRD,,90,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,146,,,,,115 - 158,g/L +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.42,,,,,0.34 - 0.48, +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.4,,,,,3.9 - 5.5,TI/L +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,95,,,,,80 - 100,fL +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,3.39,R,L,,,3.8 - 10.7,GI/L +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,1.95,R,L,,,1.96 - 7.23,GI/L +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.01,,,,,0.8 - 3,GI/L +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.24,,,,,0.12 - 0.92,GI/L +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.16,,,,,0 - 0.57,GI/L +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.02,,,,,0 - 0.2,GI/L +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,57.5,,,,,40.5 - 75,% +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,29.8,,,,,15.4 - 48.5,% +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,7.1,,,,,2.6 - 10.1,% +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,4.8,,,,,0 - 6.8,% +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.7,,,,,0 - 2,% +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,169,,,,,130 - 394,GI/L +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,HEMOGLOBIN A1C,"Hemoglobin A1c,Variant(-70)-QT",,5.6,,,,,<6.5%, +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,4.01,,,,,1.9 - 23,uIU/mL +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,IS SUBJECT OF BLACK RACE?,Subject of black race?,Y,No,,,,,, +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,LIPID PANEL,Direct HDL-C 4th Generation,,1.49,,,,,1.03 - 1.53,mmol/L +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,LIPID PANEL,Triglycerides (GPO),,0.88,,,,,0.63 - 2.71,mmol/L +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,LIPID PANEL,Cholesterol (High Performance),,4.46,R,L,,,4.86 - 8.28,mmol/L +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,LIPID PANEL,LDL Chol Friedewald 4th,,2.57,,,,,0 - 3.34,mmol/L +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,POSTMENOPAUSAL FEMALE?,<40yrs & amenorrhea >/= 12mo,,No,,,,,, +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,RETICULOCYTES,Reticulocyte Count %,,0.9,,,,,0.6 - 2.5,% +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,TSH,TSH 3rd IS-QT,,2.205,,,,,0.45 - 5.33,mIU/L +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,URINE MACRO PANEL,Ur Specific Gravity,,1.006,,,,,1.01 - 1.03, +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.0,,,,,0 - 5,mg/L +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,CHEMISTRY PANEL,Total Bilirubin,,9,,,,,3 - 21,umol/L +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.5,,,,,0 - 6.2,umol/L +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,CHEMISTRY PANEL,Alkaline Phosphatase,,61,,,,,35 - 104,U/L +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,CHEMISTRY PANEL,ALT (SGPT),,13,,,,,4 - 43,U/L +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,CHEMISTRY PANEL,AST (SGOT),,16,,,,,8 - 40,U/L +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,CHEMISTRY PANEL,GGT,,14,,,,,4 - 49,U/L +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,CHEMISTRY PANEL,LDH,,137,,,,,53 - 234,U/L +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,CHEMISTRY PANEL,Urea Nitrogen,,4.3,,,,,1.4 - 8.6,mmol/L +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,79,,,,,31 - 101,umol/L +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,CHEMISTRY PANEL,Glucose Fasting,,4.5,,,,,3.9 - 5.6,mmol/L +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,CHEMISTRY PANEL,Serum Uric Acid,,273,,,,,125 - 428,umol/L +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,CHEMISTRY PANEL,Calcium (EDTA),,2.34,,,,,2.07 - 2.64,mmol/L +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,CHEMISTRY PANEL,Phosphorus,,1.07,,,,,0.71 - 1.65,mmol/L +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,CHEMISTRY PANEL,Total Protein,,69,,,,,61 - 84,g/L +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,CHEMISTRY PANEL,Albumin-BCG,,45,,,,,33 - 49,g/L +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,CHEMISTRY PANEL,Creatine Kinase,,123,,,,,26 - 192,U/L +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,CHEMISTRY PANEL,Serum Sodium,,139,,,,,132 - 147,mmol/L +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,CHEMISTRY PANEL,Serum Potassium,,4.3,,,,,3.5 - 5.2,mmol/L +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,CHEMISTRY PANEL,Serum Bicarbonate,,22.8,,,,,19.3 - 29.3,mmol/L +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,CHEMISTRY PANEL,Serum Chloride,,101,,,,,94 - 112,mmol/L +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,CREATININE CLEARANCE CC&G,CreatininClearancCockcrftGault,,1.59,,,,,1.25 - 1.92,mL/sec +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,CREATININE CLEARANCE CC&G,Creatinine(Rate Blanked)-2dp,,79,,,,,31 - 101,umol/L +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,CREATININE CLEARANCE CC&G,"Weight (kg,1dec place)",Y,68.1,,,,,kg, +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,DRUG SCREEN URINE,Amphetamines/MDMA,,Neg,,,,,Neg;$Cutoff = 1000 ng/mL, +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,DRUG SCREEN URINE,Barbiturates,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,DRUG SCREEN URINE,Cannabinoids,,Neg,,,,,Neg;$Cutoff = 50 ng/mL, +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,DRUG SCREEN URINE,Cocaine,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,DRUG SCREEN URINE,Opiates,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,DRUG SCREEN URINE,Methadone,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,DRUG SCREEN URINE BENZO NON-US,Benzodiazepines Gen 2,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,FEMALE OF CHILDBEARING POT?,Female/of Childbearing pot.?,Y,Yes,,,,,, +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,GFR,EGFR by MDRD,,73,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,125,,,,,116 - 164,g/L +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.38,,,,,0.34 - 0.48, +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.2,,,,,4.1 - 5.6,TI/L +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,90,,,,,79 - 98,fL +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,4.30,,,,,3.8 - 10.7,GI/L +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.33,,,,,1.96 - 7.23,GI/L +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.57,,,,,0.91 - 4.28,GI/L +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.29,,,,,0.12 - 0.92,GI/L +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.10,,,,,0 - 0.57,GI/L +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.01,,,,,0 - 0.2,GI/L +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,54.1,,,,,40.5 - 75,% +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,36.6,,,,,15.4 - 48.5,% +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,6.7,,,,,2.6 - 10.1,% +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.3,,,,,0 - 6.8,% +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.3,,,,,0 - 2,% +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,250,,,,,140 - 400,GI/L +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,HEMOGLOBIN A1C,"Hemoglobin A1c,Variant(-70)-QT",,5.5,,,,,<6.5%, +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,4.11,,,,,1.9 - 23,uIU/mL +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,IS SUBJECT OF BLACK RACE?,Subject of black race?,Y,No,,,,,, +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,LIPID PANEL,Direct HDL-C 4th Generation,,1.65,,H,,,1.03 - 1.53,mmol/L +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,LIPID PANEL,Triglycerides (GPO),,0.93,,,,,0.44 - 1.99,mmol/L +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,LIPID PANEL,Cholesterol (High Performance),,4.65,,,,,3.65 - 6.21,mmol/L +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,LIPID PANEL,LDL Chol Friedewald 4th,,2.57,,,,,0 - 3.34,mmol/L +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,POSTMENOPAUSAL FEMALE?,<40yrs & amenorrhea >/= 12mo,,No,,,,,, +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,RETICULOCYTES,Reticulocyte Count %,,0.9,,,,,0.6 - 2.5,% +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,SERUM BETA HCG,"B-hCG, Qualitative",,Negative,,,,,Ref Rng: Negative, +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,SERUM BETA HCG,"B-hCG, Quantitative",,<0.6,,,,,Units: mIU/mL$Pre-menopausal$<5.0: Negative$5.0-24.9:Borderline$>/= 25.0: Positive, +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,TSH,TSH 3rd IS-QT,,3.025,,,,,0.45 - 5.33,mIU/L +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,URINE MACRO PANEL,Ur Specific Gravity,,1.014,,,,,1 - 1.04, +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,URINE MACRO PANEL,Ur pH,,6.5,,,,,5 - 8, +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,C-REACTIVE PROTEIN,C Reactive Protein HS,,0.3,,,,Result verified by repeat analysis,0 - 5,mg/L +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,CHEMISTRY PANEL,Total Bilirubin,,10,,,,,3 - 21,umol/L +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.4,,,,,0 - 6.2,umol/L +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,CHEMISTRY PANEL,Alkaline Phosphatase,,94,,,,,40 - 129,U/L +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,CHEMISTRY PANEL,ALT (SGPT),,46,,,,,5 - 48,U/L +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,CHEMISTRY PANEL,AST (SGOT),,18,,,,,8 - 40,U/L +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,CHEMISTRY PANEL,GGT,,93,,H,,,10 - 61,U/L +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,CHEMISTRY PANEL,LDH,,165,,,,,53 - 234,U/L +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,CHEMISTRY PANEL,Urea Nitrogen,,5.7,,,,,1.4 - 8.6,mmol/L +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,94,,,,,40 - 110,umol/L +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,CHEMISTRY PANEL,Glucose Fasting,,4.6,,,,,3.9 - 5.6,mmol/L +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,CHEMISTRY PANEL,Serum Uric Acid,,427,,,,,125 - 488,umol/L +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,CHEMISTRY PANEL,Calcium (EDTA),,2.57,,,,,2.07 - 2.64,mmol/L +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,CHEMISTRY PANEL,Phosphorus,,1.18,,,,,0.71 - 1.65,mmol/L +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,CHEMISTRY PANEL,Total Protein,,77,,,,,61 - 84,g/L +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,CHEMISTRY PANEL,Albumin-BCG,,49,,,,,33 - 49,g/L +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,CHEMISTRY PANEL,Creatine Kinase,,89,,,,,39 - 308,U/L +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,CHEMISTRY PANEL,Serum Sodium,,140,,,,,132 - 147,mmol/L +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,CHEMISTRY PANEL,Serum Potassium,,4.3,,,,,3.5 - 5.2,mmol/L +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,CHEMISTRY PANEL,Serum Bicarbonate,,21.0,,,,,19.3 - 29.3,mmol/L +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,CHEMISTRY PANEL,Serum Chloride,,101,,,,,94 - 112,mmol/L +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,165,,,,,127 - 181,g/L +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.47,,,,,0.39 - 0.54, +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.2,,,,,4.5 - 6.4,TI/L +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,Normocytic,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,89,,,,,79 - 96,fL +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,6.70,,,,,3.8 - 10.7,GI/L +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.28,,,,,1.96 - 7.23,GI/L +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.74,,,,,0.91 - 4.28,GI/L +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.34,,,,,0.12 - 0.92,GI/L +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,1.34,R,H,,,0 - 0.57,GI/L +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.00,,,,,0 - 0.2,GI/L +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,49.0,,,,,40.5 - 75,% +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,26.0,,,,,15.4 - 48.5,% +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.0,,,,,2.6 - 10.1,% +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,20.0,R,H,,,0 - 6.8,% +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.0,,,,,0 - 2,% +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,250,,,,,140 - 400,GI/L +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,LIPID PANEL,Direct HDL-C 4th Generation,,0.77,,L,,Result verified by repeat analysis,1.03 - 1.53,mmol/L +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,LIPID PANEL,Triglycerides (GPO),,1.72,,,,,0.5 - 2.81,mmol/L +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,LIPID PANEL,Cholesterol (High Performance),,4.31,,,,,3.31 - 6.1,mmol/L +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,LIPID PANEL,LDL Chol Friedewald 4th,,2.75,,,,,0 - 3.34,mmol/L +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,RETICULOCYTES,Reticulocyte Count %,,1.1,,,,,0.6 - 2.5,% +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,URINE MACRO PANEL,Ur Specific Gravity,,1.018,,,,,1 - 1.04, +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:Negative, +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,C-REACTIVE PROTEIN,C Reactive Protein HS,,2.1,,,,,0 - 5,mg/L +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,CELLULAR ELEMENTS,Ur WBC/HPF,,3,,,,,0 - 12,/HPF +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,CHEMISTRY PANEL,Total Bilirubin,,12,,,,,3 - 21,umol/L +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.8,,,,,0 - 6.2,umol/L +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,CHEMISTRY PANEL,Alkaline Phosphatase,,83,,,,,35 - 104,U/L +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,CHEMISTRY PANEL,ALT (SGPT),,10,,,,,4 - 43,U/L +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,CHEMISTRY PANEL,AST (SGOT),,11,,,,,8 - 40,U/L +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,CHEMISTRY PANEL,GGT,,14,,,,,4 - 49,U/L +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,CHEMISTRY PANEL,LDH,,133,,,,,53 - 234,U/L +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,CHEMISTRY PANEL,Urea Nitrogen,,4.4,,,,,1.4 - 8.6,mmol/L +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,68,,,,,31 - 101,umol/L +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,CHEMISTRY PANEL,Glucose Fasting,,4.7,,,,,3.9 - 5.6,mmol/L +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,CHEMISTRY PANEL,Serum Uric Acid,,303,,,,,125 - 428,umol/L +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,CHEMISTRY PANEL,Calcium (EDTA),,2.36,,,,,2.07 - 2.64,mmol/L +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,CHEMISTRY PANEL,Phosphorus,,1.06,,,,,0.71 - 1.65,mmol/L +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,CHEMISTRY PANEL,Total Protein,,72,,,,,61 - 84,g/L +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,CHEMISTRY PANEL,Albumin-BCG,,45,,,,,33 - 49,g/L +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,CHEMISTRY PANEL,Creatine Kinase,,79,,,,,26 - 192,U/L +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,CHEMISTRY PANEL,Serum Sodium,,140,,,,,132 - 147,mmol/L +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,CHEMISTRY PANEL,Serum Potassium,,4.2,,,,,3.5 - 5.2,mmol/L +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,CHEMISTRY PANEL,Serum Bicarbonate,,22.2,,,,,19.3 - 29.3,mmol/L +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,CHEMISTRY PANEL,Serum Chloride,,105,,,,,94 - 112,mmol/L +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,129,,,,,116 - 164,g/L +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.40,,,,,0.34 - 0.48, +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.7,,,,,4.1 - 5.6,TI/L +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,85,,,,,79 - 98,fL +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,5.56,,,,,3.8 - 10.7,GI/L +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.30,,,,,1.96 - 7.23,GI/L +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.54,,,,,0.91 - 4.28,GI/L +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.39,,,,,0.12 - 0.92,GI/L +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.20,,,,,0 - 0.57,GI/L +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.11,,,,,0 - 0.2,GI/L +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,59.4,,,,,40.5 - 75,% +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,27.9,,,,,15.4 - 48.5,% +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,7.1,,,,,2.6 - 10.1,% +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,3.6,,,,,0 - 6.8,% +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,2.0,,,,,0 - 2,% +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,255,,,,,140 - 400,GI/L +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,5.14,,,,,1.9 - 23,uIU/mL +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,LIPID PANEL,Direct HDL-C 4th Generation,,1.22,,,,,1.03 - 1.53,mmol/L +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,LIPID PANEL,Triglycerides (GPO),,0.56,,,,,0.44 - 1.99,mmol/L +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,LIPID PANEL,Cholesterol (High Performance),,3.42,,L,,,3.65 - 6.21,mmol/L +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,LIPID PANEL,LDL Chol Friedewald 4th,,1.94,,,,,0 - 3.34,mmol/L +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,RETICULOCYTES,Reticulocyte Count %,,0.8,,,,,0.6 - 2.5,% +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,URINE MACRO PANEL,Ur Specific Gravity,,1.029,,,,,1 - 1.04, +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,URINE MACRO PANEL,Ur Protein,,Trace,,H,,,Ref Rng:Negative, +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,URINE MACRO PANEL,Ur Blood,,Trace,,,,,Ref Rng:$Negative-Trace, +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,URINE MACRO PANEL,Ur Leukocyte Esterase,,Trace,,H,,,Ref Rng:Negative, +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,URINE MICRO PANEL,Ur Microscopic,,Positive,,,,, NEGATIVE$,NEGATIVE +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,C-REACTIVE PROTEIN,C Reactive Protein HS,,0.2,,,,Result verified by repeat analysis,0 - 5,mg/L +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,CHEMISTRY PANEL,Total Bilirubin,,13,,,,,3 - 21,umol/L +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.7,,,,,0 - 6.2,umol/L +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,CHEMISTRY PANEL,Alkaline Phosphatase,,85,,,,,40 - 129,U/L +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,CHEMISTRY PANEL,ALT (SGPT),,73,,H RX,,,5 - 48,U/L +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,CHEMISTRY PANEL,AST (SGOT),,31,,,,,8 - 40,U/L +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,CHEMISTRY PANEL,GGT,,149,,H,,,10 - 61,U/L +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,CHEMISTRY PANEL,LDH,,171,,,,,53 - 234,U/L +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,CHEMISTRY PANEL,Urea Nitrogen,,6.0,,,,,1.4 - 8.6,mmol/L +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,104,,,,,40 - 110,umol/L +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,CHEMISTRY PANEL,Glucose Fasting,,4.9,,,,,3.9 - 5.6,mmol/L +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,CHEMISTRY PANEL,Serum Uric Acid,,469,,,,,125 - 488,umol/L +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,CHEMISTRY PANEL,Calcium (EDTA),,2.57,,,,,2.07 - 2.64,mmol/L +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,CHEMISTRY PANEL,Phosphorus,,1.15,,,,,0.71 - 1.65,mmol/L +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,CHEMISTRY PANEL,Total Protein,,80,,,,,61 - 84,g/L +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,CHEMISTRY PANEL,Albumin-BCG,,50,,H,,,33 - 49,g/L +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,CHEMISTRY PANEL,Creatine Kinase,,138,,,,,39 - 308,U/L +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,CHEMISTRY PANEL,Serum Sodium,,140,,,,,132 - 147,mmol/L +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,CHEMISTRY PANEL,Serum Potassium,,4.5,,,,,3.5 - 5.2,mmol/L +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,CHEMISTRY PANEL,Serum Bicarbonate,,21.5,,,,,19.3 - 29.3,mmol/L +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,CHEMISTRY PANEL,Serum Chloride,,103,,,,,94 - 112,mmol/L +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,CREATININE CLEARANCE CC&G,CreatininClearancCockcrftGault,,2.14,,H,,,1.42 - 2.08,mL/sec +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,CREATININE CLEARANCE CC&G,Creatinine(Rate Blanked)-2dp,,104,,,,,40 - 110,umol/L +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,CREATININE CLEARANCE CC&G,"Weight (kg,1dec place)",Y,93.8,,,,,kg, +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,DRUG SCREEN URINE,Amphetamines/MDMA,,Neg,,,,,Neg;$Cutoff = 1000 ng/mL, +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,DRUG SCREEN URINE,Barbiturates,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,DRUG SCREEN URINE,Cannabinoids,,Neg,,,,,Neg;$Cutoff = 50 ng/mL, +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,DRUG SCREEN URINE,Cocaine,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,DRUG SCREEN URINE,Opiates,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,DRUG SCREEN URINE,Methadone,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,DRUG SCREEN URINE BENZO NON-US,Benzodiazepines Gen 2,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,GFR,EGFR by MDRD,,76,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,169,,,,,127 - 181,g/L +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.49,,,,,0.39 - 0.54, +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.4,,,,,4.5 - 6.4,TI/L +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,91,,,,,79 - 96,fL +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,4.17,,,,,3.8 - 10.7,GI/L +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.44,,,,,1.96 - 7.23,GI/L +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.28,,,,,0.91 - 4.28,GI/L +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.29,,,,,0.12 - 0.92,GI/L +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.10,,,,,0 - 0.57,GI/L +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.06,,,,,0 - 0.2,GI/L +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,58.4,,,,,40.5 - 75,% +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,30.7,,,,,15.4 - 48.5,% +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,6.9,,,,,2.6 - 10.1,% +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.5,,,,,0 - 6.8,% +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.4,,,,,0 - 2,% +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,259,,,,,140 - 400,GI/L +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,HEMOGLOBIN A1C,"Hemoglobin A1c,Variant(-70)-QT",,4.8,,,,,<6.5%, +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,7.13,,,,,1.9 - 23,uIU/mL +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,IS SUBJECT OF BLACK RACE?,Subject of black race?,Y,No,,,,,, +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,LIPID PANEL,Direct HDL-C 4th Generation,,0.96,,L,,,1.03 - 1.53,mmol/L +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,LIPID PANEL,Triglycerides (GPO),,2.37,,,,,0.5 - 2.81,mmol/L +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,LIPID PANEL,Cholesterol (High Performance),,5.50,,,,,3.31 - 6.1,mmol/L +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,LIPID PANEL,LDL Chol Friedewald 4th,,3.45,,H,,,0 - 3.34,mmol/L +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,RETICULOCYTES,Reticulocyte Count %,,1.0,,,,,0.6 - 2.5,% +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,TSH,TSH 3rd IS-QT,,2.030,,,,,0.45 - 5.33,mIU/L +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,URINE MACRO PANEL,Ur Specific Gravity,,1.019,,,,,1 - 1.04, +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,URINE MACRO PANEL,Ur pH,,6.0,,,,,5 - 8, +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:Negative, +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,C-REACTIVE PROTEIN,C Reactive Protein HS,,3.4,,,,,0 - 5,mg/L +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,CHEMISTRY PANEL,Total Bilirubin,,6,,,,,3 - 21,umol/L +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.4,,,,,0 - 6.2,umol/L +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,CHEMISTRY PANEL,Alkaline Phosphatase,,77,,,,,35 - 104,U/L +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,CHEMISTRY PANEL,ALT (SGPT),,10,,,,,4 - 43,U/L +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,CHEMISTRY PANEL,AST (SGOT),,12,,,,,8 - 40,U/L +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,CHEMISTRY PANEL,GGT,,14,,,,,4 - 49,U/L +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,CHEMISTRY PANEL,LDH,,127,,,,,53 - 234,U/L +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,CHEMISTRY PANEL,Urea Nitrogen,,6.1,,,,,1.4 - 8.6,mmol/L +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,65,,,,,31 - 101,umol/L +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,CHEMISTRY PANEL,Glucose Fasting,,4.6,,,,,3.9 - 5.6,mmol/L +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,CHEMISTRY PANEL,Serum Uric Acid,,273,,,,,125 - 428,umol/L +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,CHEMISTRY PANEL,Calcium (EDTA),,2.35,,,,,2.07 - 2.64,mmol/L +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,CHEMISTRY PANEL,Phosphorus,,1.14,,,,,0.71 - 1.65,mmol/L +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,CHEMISTRY PANEL,Total Protein,,72,,,,,61 - 84,g/L +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,CHEMISTRY PANEL,Albumin-BCG,,44,,,,,33 - 49,g/L +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,CHEMISTRY PANEL,Creatine Kinase,,88,,,,,26 - 192,U/L +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,CHEMISTRY PANEL,Serum Sodium,,139,,,,,132 - 147,mmol/L +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,CHEMISTRY PANEL,Serum Potassium,,4.5,,,,,3.5 - 5.2,mmol/L +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,CHEMISTRY PANEL,Serum Bicarbonate,,21.2,,,,,19.3 - 29.3,mmol/L +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,CHEMISTRY PANEL,Serum Chloride,,105,,,,,94 - 112,mmol/L +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,CREATININE CLEARANCE CC&G,CreatininClearancCockcrftGault,,2.33,,H,,,1.25 - 1.92,mL/sec +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,CREATININE CLEARANCE CC&G,Creatinine(Rate Blanked)-2dp,,65,,,,,31 - 101,umol/L +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,CREATININE CLEARANCE CC&G,"Weight (kg,1dec place)",Y,79.2,,,,,kg, +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,DRUG SCREEN URINE,Amphetamines/MDMA,,Neg,,,,,Neg;$Cutoff = 1000 ng/mL, +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,DRUG SCREEN URINE,Barbiturates,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,DRUG SCREEN URINE,Cannabinoids,,Neg,,,,,Neg;$Cutoff = 50 ng/mL, +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,DRUG SCREEN URINE,Cocaine,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,DRUG SCREEN URINE,Opiates,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,DRUG SCREEN URINE,Methadone,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,DRUG SCREEN URINE BENZO NON-US,Benzodiazepines Gen 2,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,FEMALE OF CHILDBEARING POT?,Female/of Childbearing pot.?,Y,Yes,,,,,, +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,FSH,Follicle Stimulating Hormone,,3.55,,RX,,,Follicular:$3.90-8.80 IU/L$Midcycle:$4.50-22.50 IU/L$Luteal:$1.80-5.10 IU/L$Postmenopausal:$16.70-113.60 IU/L, +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,GFR,EGFR by MDRD,,92,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,128,,,,,116 - 164,g/L +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,,,,Test cancelled: Beyond stability,,, +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.5,,,,,4.1 - 5.6,TI/L +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,,,,Test cancelled: Beyond stability,,, +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,5.62,,,,,3.8 - 10.7,GI/L +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.19,,,,,1.96 - 7.23,GI/L +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.85,,,,,0.91 - 4.28,GI/L +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.34,,,,,0.12 - 0.92,GI/L +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.19,,,,,0 - 0.57,GI/L +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.05,,,,,0 - 0.2,GI/L +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,56.7,,,,,40.5 - 75,% +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,33.0,,,,,15.4 - 48.5,% +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,6.0,,,,,2.6 - 10.1,% +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,3.4,,,,,0 - 6.8,% +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.0,,,,,0 - 2,% +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,253,,,,,140 - 400,GI/L +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,HEMOGLOBIN A1C,"Hemoglobin A1c,Variant(-70)-QT",,5.1,,,,,<6.5%, +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,5.61,,,,,1.9 - 23,uIU/mL +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,IS SUBJECT OF BLACK RACE?,Subject of black race?,Y,No,,,,,, +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,LIPID PANEL,Direct HDL-C 4th Generation,,1.23,,,,,1.03 - 1.53,mmol/L +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,LIPID PANEL,Triglycerides (GPO),,0.46,,,,,0.44 - 1.99,mmol/L +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,LIPID PANEL,Cholesterol (High Performance),,3.59,R,L,,,3.65 - 6.21,mmol/L +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,LIPID PANEL,LDL Chol Friedewald 4th,,2.15,,,,,0 - 3.34,mmol/L +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,POSTMENOPAUSAL FEMALE?,<40yrs & amenorrhea >/= 12mo,,Yes,,,,,, +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,RETICULOCYTES,Reticulocyte Count %,,1.0,,,,,0.6 - 2.5,% +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,SERUM BETA HCG,"B-hCG, Qualitative",,Negative,,,,,Ref Rng: Negative, +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,SERUM BETA HCG,"B-hCG, Quantitative",,<0.6,,,,,Units: mIU/mL$Pre-menopausal$<5.0: Negative$5.0-24.9:Borderline$>/= 25.0: Positive, +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,TSH,TSH 3rd IS-QT,,1.803,,,,,0.45 - 5.33,mIU/L +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,URINE MACRO PANEL,Ur Specific Gravity,,1.024,,,,,1 - 1.04, +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, diff --git a/Covance_UCO3001/Source/2026-06-08_130717 sponsor-study-35472-test-results-898744-standard.csv b/Covance_UCO3001/Source/2026-06-08_130717 sponsor-study-35472-test-results-898744-standard.csv new file mode 100644 index 0000000..1cacad6 --- /dev/null +++ b/Covance_UCO3001/Source/2026-06-08_130717 sponsor-study-35472-test-results-898744-standard.csv @@ -0,0 +1,200 @@ +"Disclaimer: The information presented in On-Screen Results is not intended to be a replacement of the official Lab Results, Alerts, Data Revisions and Cancellations found in the Lab Reports section of this software application. On-Screen Results should not be used for patient diagnosis, treatment decisions or submission to regulatory bodies.",,,,,,,,,,,,,,,,,,, +Subject,Subject Data Revision,Screen No.,Age,Age Unit,Gender,Visit,Visit Data Revision,Collected Time,Accession,Test Group,Test,Administrative Question,Value,Result Data Revision,Flags,Cancellation Reason,Comments,Range,Units +CZ100050002,,,62,years,Male,Retest,,"Nov 11, 2025 10:04 AM",6225351037,CHEMISTRY PANEL,Total Bilirubin,,8,,,,,3 - 21,umol/L +CZ100050002,,,62,years,Male,Retest,,"Nov 11, 2025 10:04 AM",6225351037,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,4.6,,,,,0 - 6.2,umol/L +CZ100050002,,,62,years,Male,Retest,,"Nov 11, 2025 10:04 AM",6225351037,CHEMISTRY PANEL,Alkaline Phosphatase,,60,,,,,40 - 129,U/L +CZ100050002,,,62,years,Male,Retest,,"Nov 11, 2025 10:04 AM",6225351037,CHEMISTRY PANEL,ALT (SGPT),,37,,,,,5 - 48,U/L +CZ100050002,,,62,years,Male,Retest,,"Nov 11, 2025 10:04 AM",6225351037,CHEMISTRY PANEL,AST (SGOT),,63,R,H RX,,,8 - 40,U/L +CZ100050002,,,62,years,Male,Retest,,"Nov 11, 2025 10:04 AM",6225351037,CHEMISTRY PANEL,GGT,,143,R,H,,,10 - 50,U/L +CZ100050002,,,62,years,Male,Retest,,"Nov 11, 2025 10:04 AM",6225351037,CHEMISTRY PANEL,LDH,,148,,,,,53 - 234,U/L +CZ100050002,,,62,years,Male,Retest,,"Nov 11, 2025 10:04 AM",6225351037,CHEMISTRY PANEL,Urea Nitrogen,,8.4,,,,,1.4 - 8.6,mmol/L +CZ100050002,,,62,years,Male,Retest,,"Nov 11, 2025 10:04 AM",6225351037,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,93,,,,,40 - 119,umol/L +CZ100050002,,,62,years,Male,Retest,,"Nov 11, 2025 10:04 AM",6225351037,CHEMISTRY PANEL,Glucose Fasting,,8.5,R,H RX,,,3.9 - 5.6,mmol/L +CZ100050002,,,62,years,Male,Retest,,"Nov 11, 2025 10:04 AM",6225351037,CHEMISTRY PANEL,Serum Uric Acid,,397,,,,,149 - 494,umol/L +CZ100050002,,,62,years,Male,Retest,,"Nov 11, 2025 10:04 AM",6225351037,CHEMISTRY PANEL,Calcium (EDTA),,2.51,,,,,2.07 - 2.64,mmol/L +CZ100050002,,,62,years,Male,Retest,,"Nov 11, 2025 10:04 AM",6225351037,CHEMISTRY PANEL,Phosphorus,,1.21,,,,,0.71 - 1.65,mmol/L +CZ100050002,,,62,years,Male,Retest,,"Nov 11, 2025 10:04 AM",6225351037,CHEMISTRY PANEL,Total Protein,,81,R,H,,,60 - 80,g/L +CZ100050002,,,62,years,Male,Retest,,"Nov 11, 2025 10:04 AM",6225351037,CHEMISTRY PANEL,Albumin-BCG,,42,,,,,33 - 49,g/L +CZ100050002,,,62,years,Male,Retest,,"Nov 11, 2025 10:04 AM",6225351037,CHEMISTRY PANEL,Creatine Kinase,,54,,,,,39 - 308,U/L +CZ100050002,,,62,years,Male,Retest,,"Nov 11, 2025 10:04 AM",6225351037,CHEMISTRY PANEL,Serum Sodium,,139,,,,,135 - 145,mmol/L +CZ100050002,,,62,years,Male,Retest,,"Nov 11, 2025 10:04 AM",6225351037,CHEMISTRY PANEL,Serum Potassium,,4.0,,,,,3.5 - 5.2,mmol/L +CZ100050002,,,62,years,Male,Retest,,"Nov 11, 2025 10:04 AM",6225351037,CHEMISTRY PANEL,Serum Bicarbonate,,23.3,,,,,19.3 - 29.3,mmol/L +CZ100050002,,,62,years,Male,Retest,,"Nov 11, 2025 10:04 AM",6225351037,CHEMISTRY PANEL,Serum Chloride,,96,,,,,94 - 112,mmol/L +CZ100050002,,,62,years,Male,Retest,,"Nov 11, 2025 10:04 AM",6225351037,CREATININE CLEARANCE CC&G,CreatininClearancCockcrftGault,,1.85,,,,,1.42 - 2.08,mL/sec +CZ100050002,,,62,years,Male,Retest,,"Nov 11, 2025 10:04 AM",6225351037,CREATININE CLEARANCE CC&G,Creatinine(Rate Blanked)-2dp,,93,,,,,40 - 119,umol/L +CZ100050002,,,62,years,Male,Retest,,"Nov 11, 2025 10:04 AM",6225351037,CREATININE CLEARANCE CC&G,"Weight (kg,1dec place)",Y,106.6,,,,,kg, +CZ100050002,,,62,years,Male,Retest,,"Nov 11, 2025 10:04 AM",6225351037,HEMOGLOBIN A1C,"Hemoglobin A1c,Variant(-70)-QT",,8.7,R,H RX,,,<6.5%, +CZ100050002,,,62,years,Male,Retest,,"Nov 11, 2025 10:04 AM",6225351037,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,C-REACTIVE PROTEIN,C Reactive Protein HS,,11.9,,H,,,0 - 5,mg/L +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,CASTS,Ur Hyaline Casts/LPF,,96,,,,,0 /LPF, +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,CELLULAR ELEMENTS,Ur RBC/HPF,,5,,H,,,0 - 3,/HPF +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,CELLULAR ELEMENTS,Ur WBC/HPF,,2,,,,,0 - 5,/HPF +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,CHEMISTRY PANEL,Total Bilirubin,,12,,,,,3 - 21,umol/L +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,4.9,,,,,0 - 6.2,umol/L +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,CHEMISTRY PANEL,Alkaline Phosphatase,,70,,,,,40 - 129,U/L +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,CHEMISTRY PANEL,ALT (SGPT),,36,,,,,5 - 48,U/L +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,CHEMISTRY PANEL,AST (SGOT),,72,,H RX,,,8 - 40,U/L +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,CHEMISTRY PANEL,GGT,,264,,HT,,Result verified by repeat analysis,10 - 50,U/L +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,CHEMISTRY PANEL,LDH,,171,,,,,53 - 234,U/L +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,CHEMISTRY PANEL,Urea Nitrogen,,7.3,,,,,1.4 - 8.6,mmol/L +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,109,,,,,40 - 119,umol/L +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,CHEMISTRY PANEL,Glucose Fasting,,8.3,,H,,,3.9 - 5.6,mmol/L +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,CHEMISTRY PANEL,Serum Uric Acid,,497,,H,,,149 - 494,umol/L +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,CHEMISTRY PANEL,Calcium (EDTA),,2.55,,,,,2.07 - 2.64,mmol/L +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,CHEMISTRY PANEL,Phosphorus,,1.17,,,,,0.71 - 1.65,mmol/L +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,CHEMISTRY PANEL,Total Protein,,84,,H,,,60 - 80,g/L +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,CHEMISTRY PANEL,Albumin-BCG,,43,,,,,33 - 49,g/L +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,CHEMISTRY PANEL,Creatine Kinase,,37,,L,,,39 - 308,U/L +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,CHEMISTRY PANEL,Serum Sodium,,137,,,,,135 - 145,mmol/L +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,CHEMISTRY PANEL,Serum Potassium,,3.9,,,,,3.5 - 5.2,mmol/L +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,CHEMISTRY PANEL,Serum Bicarbonate,,23.7,,,,,19.3 - 29.3,mmol/L +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,CHEMISTRY PANEL,Serum Chloride,,94,,,,,94 - 112,mmol/L +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,CREATININE CLEARANCE CC&G,CreatininClearancCockcrftGault,,1.60,,,,,1.42 - 2.08,mL/sec +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,CREATININE CLEARANCE CC&G,Creatinine(Rate Blanked)-2dp,,109,,,,,40 - 119,umol/L +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,CREATININE CLEARANCE CC&G,"Weight (kg,1dec place)",Y,108.0,,,,,kg, +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,DIRECT LDL,Direct LDL-C 3rd Gen,,3.83,R,H,,,<3.36 mmol/L, +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,DRUG SCREEN URINE,Amphetamines/MDMA,,Neg,,,,,Neg;$Cutoff = 1000 ng/mL, +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,DRUG SCREEN URINE,Barbiturates,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,DRUG SCREEN URINE,Cannabinoids,,Neg,,,,,Neg;$Cutoff = 50 ng/mL, +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,DRUG SCREEN URINE,Cocaine,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,DRUG SCREEN URINE,Opiates,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,DRUG SCREEN URINE,Methadone,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,DRUG SCREEN URINE BENZO NON-US,Benzodiazepines Gen 2,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,GFR,EGFR by MDRD,,60,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,160,,,,,125 - 170,g/L +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.47,,,,,0.37 - 0.51, +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.1,,,,,4 - 5.8,TI/L +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,92,,,,,80 - 100,fL +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,10.32,,,,,3.8 - 10.7,GI/L +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,6.59,,,,,1.96 - 7.23,GI/L +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.36,,,,,0.8 - 3,GI/L +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,1.06,,H,,,0.12 - 0.92,GI/L +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.17,,,,,0 - 0.57,GI/L +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.12,,,,,0 - 0.2,GI/L +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,63.9,,,,,40.5 - 75,% +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,22.9,,,,,15.4 - 48.5,% +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,10.3,,H,,,2.6 - 10.1,% +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.7,,,,,0 - 6.8,% +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.2,,,,,0 - 2,% +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,311,,,,,130 - 394,GI/L +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,HEMOGLOBIN A1C,"Hemoglobin A1c,Variant(-70)-QT",,8.9,,H RX,,,<6.5%, +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,12.96,,,,,1.9 - 23,uIU/mL +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,IS SUBJECT OF BLACK RACE?,Subject of black race?,Y,No,,,,,, +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,LIPID PANEL,Direct HDL-C 4th Generation,,0.81,,L,,,1.03 - 1.53,mmol/L +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,LIPID PANEL,Triglycerides (GPO),,5.76,,H SF,,,0.65 - 2.94,mmol/L +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,LIPID PANEL,Cholesterol (High Performance),,6.27,,,,,4.53 - 7.71,mmol/L +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,LIPID PANEL,LDL Chol Friedewald 4th,,,,,Test cancelled: Invalid/High Triglycerides,,, +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,MISCELLANEOUS ELEMENTS,Ur Mucous,,Present,,,,,Ref Rng:Not present, +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,RETICULOCYTES,Reticulocyte Count %,,4.6,,H,,,0.6 - 2.5,% +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,TSH,TSH 3rd IS-QT,,3.611,,,,,0.45 - 5.33,mIU/L +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,URINE MACRO PANEL,Ur Specific Gravity,,1.034,,H,,,1.01 - 1.03, +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,URINE MACRO PANEL,Ur Protein,,+1,,H,,,Ref Rng:Negative, +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,URINE MACRO PANEL,Ur Glucose,,+1,,H,,,Ref Rng:Normal, +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,URINE MACRO PANEL,Ur Ketones,,Trace,,H,,,Ref Rng:Negative, +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,URINE MACRO PANEL,Ur Urobilinogen,,+1,,H,,,Ref Rng:Normal, +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:Negative, +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,URINE MICRO PANEL,Ur Microscopic,,Positive,,,,, NEGATIVE$,NEGATIVE +CZ100050001,,,65,years,Female,Retest,R,"Sep 16, 2025 10:00 AM",6225351036,CHEMISTRY PANEL,Total Bilirubin,,5,,,,,3 - 21,umol/L +CZ100050001,,,65,years,Female,Retest,R,"Sep 16, 2025 10:00 AM",6225351036,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.2,,,,,0 - 6.2,umol/L +CZ100050001,,,65,years,Female,Retest,R,"Sep 16, 2025 10:00 AM",6225351036,CHEMISTRY PANEL,Alkaline Phosphatase,,85,,,,,35 - 104,U/L +CZ100050001,,,65,years,Female,Retest,R,"Sep 16, 2025 10:00 AM",6225351036,CHEMISTRY PANEL,ALT (SGPT),,24,,,,,4 - 43,U/L +CZ100050001,,,65,years,Female,Retest,R,"Sep 16, 2025 10:00 AM",6225351036,CHEMISTRY PANEL,AST (SGOT),,17,,,,,8 - 40,U/L +CZ100050001,,,65,years,Female,Retest,R,"Sep 16, 2025 10:00 AM",6225351036,CHEMISTRY PANEL,GGT,,32,,,,,5 - 50,U/L +CZ100050001,,,65,years,Female,Retest,R,"Sep 16, 2025 10:00 AM",6225351036,CHEMISTRY PANEL,LDH,,176,,,,,53 - 234,U/L +CZ100050001,,,65,years,Female,Retest,R,"Sep 16, 2025 10:00 AM",6225351036,CHEMISTRY PANEL,Urea Nitrogen,,3.5,,,,,1.4 - 8.6,mmol/L +CZ100050001,,,65,years,Female,Retest,R,"Sep 16, 2025 10:00 AM",6225351036,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,79,,,,,31 - 101,umol/L +CZ100050001,,,65,years,Female,Retest,R,"Sep 16, 2025 10:00 AM",6225351036,CHEMISTRY PANEL,Glucose Fasting,,9.7,,H RX,,,3.9 - 5.6,mmol/L +CZ100050001,,,65,years,Female,Retest,R,"Sep 16, 2025 10:00 AM",6225351036,CHEMISTRY PANEL,Serum Uric Acid,,289,,,,,149 - 446,umol/L +CZ100050001,,,65,years,Female,Retest,R,"Sep 16, 2025 10:00 AM",6225351036,CHEMISTRY PANEL,Calcium (EDTA),,2.39,,,,,2.07 - 2.64,mmol/L +CZ100050001,,,65,years,Female,Retest,R,"Sep 16, 2025 10:00 AM",6225351036,CHEMISTRY PANEL,Phosphorus,,1.09,,,,,0.71 - 1.65,mmol/L +CZ100050001,,,65,years,Female,Retest,R,"Sep 16, 2025 10:00 AM",6225351036,CHEMISTRY PANEL,Total Protein,,66,,,,,60 - 80,g/L +CZ100050001,,,65,years,Female,Retest,R,"Sep 16, 2025 10:00 AM",6225351036,CHEMISTRY PANEL,Albumin-BCG,,43,,,,,33 - 49,g/L +CZ100050001,,,65,years,Female,Retest,R,"Sep 16, 2025 10:00 AM",6225351036,CHEMISTRY PANEL,Creatine Kinase,,135,,,,,26 - 192,U/L +CZ100050001,,,65,years,Female,Retest,R,"Sep 16, 2025 10:00 AM",6225351036,CHEMISTRY PANEL,Serum Sodium,,143,,,,,135 - 145,mmol/L +CZ100050001,,,65,years,Female,Retest,R,"Sep 16, 2025 10:00 AM",6225351036,CHEMISTRY PANEL,Serum Potassium,,4.3,,,,,3.5 - 5.2,mmol/L +CZ100050001,,,65,years,Female,Retest,R,"Sep 16, 2025 10:00 AM",6225351036,CHEMISTRY PANEL,Serum Bicarbonate,,22.7,,,,,19.3 - 29.3,mmol/L +CZ100050001,,,65,years,Female,Retest,R,"Sep 16, 2025 10:00 AM",6225351036,CHEMISTRY PANEL,Serum Chloride,,104,,,,,94 - 112,mmol/L +CZ100050001,,,65,years,Female,Retest,R,"Sep 16, 2025 10:00 AM",6225351036,CREATININE CLEARANCE CC&G,CreatininClearancCockcrftGault,,1.05,,L,,,1.25 - 1.92,mL/sec +CZ100050001,,,65,years,Female,Retest,R,"Sep 16, 2025 10:00 AM",6225351036,CREATININE CLEARANCE CC&G,Creatinine(Rate Blanked)-2dp,,79,,,,,31 - 101,umol/L +CZ100050001,,,65,years,Female,Retest,R,"Sep 16, 2025 10:00 AM",6225351036,CREATININE CLEARANCE CC&G,"Weight (kg,1dec place)",Y,63.0,,,,,kg, +CZ100050001,,,65,years,Female,Retest,R,"Sep 16, 2025 10:00 AM",6225351036,HEMOGLOBIN A1C,"Hemoglobin A1c,Variant(-70)-QT",,7.8,,H,,,<6.5%, +CZ100050001,,,65,years,Female,Retest,R,"Sep 16, 2025 10:00 AM",6225351036,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,C-REACTIVE PROTEIN,C Reactive Protein HS,,4.9,,,,,0 - 5,mg/L +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,CELLULAR ELEMENTS,Ur WBC/HPF,,3,,,,,0 - 12,/HPF +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,CHEMISTRY PANEL,Total Bilirubin,,6,,,,,3 - 21,umol/L +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.6,,,,,0 - 6.2,umol/L +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,CHEMISTRY PANEL,Alkaline Phosphatase,,85,,,,,35 - 104,U/L +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,CHEMISTRY PANEL,ALT (SGPT),,18,,,,,4 - 43,U/L +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,CHEMISTRY PANEL,AST (SGOT),,16,,,,,8 - 40,U/L +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,CHEMISTRY PANEL,GGT,,31,,,,,5 - 50,U/L +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,CHEMISTRY PANEL,LDH,,192,,,,,53 - 234,U/L +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,CHEMISTRY PANEL,Urea Nitrogen,,5.4,,,,,1.4 - 8.6,mmol/L +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,79,,,,,31 - 101,umol/L +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,CHEMISTRY PANEL,Glucose Fasting,,9.2,,H RX,,,3.9 - 5.6,mmol/L +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,CHEMISTRY PANEL,Serum Uric Acid,,325,,,,,149 - 446,umol/L +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,CHEMISTRY PANEL,Calcium (EDTA),,2.54,,,,,2.07 - 2.64,mmol/L +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,CHEMISTRY PANEL,Phosphorus,,1.09,,,,,0.71 - 1.65,mmol/L +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,CHEMISTRY PANEL,Total Protein,,67,,,,,60 - 80,g/L +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,CHEMISTRY PANEL,Albumin-BCG,,43,,,,,33 - 49,g/L +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,CHEMISTRY PANEL,Creatine Kinase,,143,,,,,26 - 192,U/L +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,CHEMISTRY PANEL,Serum Sodium,,141,,,,,135 - 145,mmol/L +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,CHEMISTRY PANEL,Serum Potassium,,4.4,,,,,3.5 - 5.2,mmol/L +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,CHEMISTRY PANEL,Serum Bicarbonate,,20.8,,,,,19.3 - 29.3,mmol/L +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,CHEMISTRY PANEL,Serum Chloride,,103,,,,,94 - 112,mmol/L +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,CREATININE CLEARANCE CC&G,CreatininClearancCockcrftGault,,1.05,,L,,,1.25 - 1.92,mL/sec +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,CREATININE CLEARANCE CC&G,Creatinine(Rate Blanked)-2dp,,79,,,,,31 - 101,umol/L +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,CREATININE CLEARANCE CC&G,"Weight (kg,1dec place)",Y,63.0,,,,,kg, +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,DRUG SCREEN URINE,Amphetamines/MDMA,,Neg,,,,,Neg;$Cutoff = 1000 ng/mL, +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,DRUG SCREEN URINE,Barbiturates,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,DRUG SCREEN URINE,Cannabinoids,,Neg,,,,,Neg;$Cutoff = 50 ng/mL, +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,DRUG SCREEN URINE,Cocaine,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,DRUG SCREEN URINE,Opiates,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,DRUG SCREEN URINE,Methadone,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,DRUG SCREEN URINE BENZO NON-US,Benzodiazepines Gen 2,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,FEMALE OF CHILDBEARING POT?,Female/of Childbearing pot.?,Y,No,,,,,, +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,GFR,EGFR by MDRD,,64,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,142,,,,,115 - 158,g/L +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.43,,,,,0.34 - 0.48, +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.7,,,,,3.9 - 5.5,TI/L +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,91,,,,,80 - 100,fL +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,10.78,,H,,,3.8 - 10.7,GI/L +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,6.25,,,,,1.96 - 7.23,GI/L +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,3.50,,H,,,0.8 - 3,GI/L +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.52,,,,,0.12 - 0.92,GI/L +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.37,,,,,0 - 0.57,GI/L +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.13,,,,,0 - 0.2,GI/L +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,58.0,,,,,40.5 - 75,% +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,32.5,,,,,15.4 - 48.5,% +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,4.8,,,,,2.6 - 10.1,% +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,3.4,,,,,0 - 6.8,% +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.2,,,,,0 - 2,% +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,284,,,,,130 - 394,GI/L +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,HEMOGLOBIN A1C,"Hemoglobin A1c,Variant(-70)-QT",,7.7,,H,,,<6.5%, +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,14.50,,,,,1.9 - 23,uIU/mL +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,IS SUBJECT OF BLACK RACE?,Subject of black race?,Y,No,,,,,, +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,LIPID PANEL,Direct HDL-C 4th Generation,,1.94,,H,,,1.03 - 1.53,mmol/L +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,LIPID PANEL,Triglycerides (GPO),,1.32,,,,,0.63 - 2.71,mmol/L +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,LIPID PANEL,Cholesterol (High Performance),,4.53,,L,,,4.86 - 8.28,mmol/L +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,LIPID PANEL,LDL Chol Friedewald 4th,,1.99,,,,,0 - 3.34,mmol/L +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,POSTMENOPAUSAL FEMALE?,<40yrs & amenorrhea >/= 12mo,,No,,,,,, +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,RETICULOCYTES,Reticulocyte Count %,,1.6,,,,,0.6 - 2.5,% +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,TSH,TSH 3rd IS-QT,,1.354,,,,,0.45 - 5.33,mIU/L +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,URINE MACRO PANEL,Ur Specific Gravity,,1.011,,,,,1.01 - 1.03, +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,URINE MACRO PANEL,Ur pH,,6.5,,,,,5 - 8, +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,URINE MACRO PANEL,Ur Leukocyte Esterase,,+2,,H SF,,,Ref Rng:Negative, +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,URINE MICRO PANEL,Ur Microscopic,,Positive,,,,, NEGATIVE$,NEGATIVE diff --git a/Covance_UCO3001/Source/2026-06-08_130741 sponsor-study-35472-test-results-898727-standard.csv b/Covance_UCO3001/Source/2026-06-08_130741 sponsor-study-35472-test-results-898727-standard.csv new file mode 100644 index 0000000..e17118e --- /dev/null +++ b/Covance_UCO3001/Source/2026-06-08_130741 sponsor-study-35472-test-results-898727-standard.csv @@ -0,0 +1,994 @@ +"Disclaimer: The information presented in On-Screen Results is not intended to be a replacement of the official Lab Results, Alerts, Data Revisions and Cancellations found in the Lab Reports section of this software application. On-Screen Results should not be used for patient diagnosis, treatment decisions or submission to regulatory bodies.",,,,,,,,,,,,,,,,,,, +Subject,Subject Data Revision,Screen No.,Age,Age Unit,Gender,Visit,Visit Data Revision,Collected Time,Accession,Test Group,Test,Administrative Question,Value,Result Data Revision,Flags,Cancellation Reason,Comments,Range,Units +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.1,,,,,0 - 5,mg/L +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,CELLULAR ELEMENTS,Ur RBC/HPF,,5,,,,,0 - 8,/HPF +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,CELLULAR ELEMENTS,Ur WBC/HPF,,1,,,,,0 - 12,/HPF +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,CHEMISTRY PANEL,Total Bilirubin,,6,,,,,3 - 21,umol/L +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.5,,,,,0 - 6.2,umol/L +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,CHEMISTRY PANEL,Alkaline Phosphatase,,56,,,,,35 - 104,U/L +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,CHEMISTRY PANEL,ALT (SGPT),,13,,,,,4 - 43,U/L +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,CHEMISTRY PANEL,AST (SGOT),,18,,,,,8 - 40,U/L +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,CHEMISTRY PANEL,GGT,,22,,,,,5 - 50,U/L +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,CHEMISTRY PANEL,LDH,,162,,,,,53 - 234,U/L +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,CHEMISTRY PANEL,Urea Nitrogen,,3.9,,,,,1.4 - 8.6,mmol/L +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,71,,,,,31 - 101,umol/L +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,CHEMISTRY PANEL,Glucose Fasting,,4.0,,,,,3.9 - 5.6,mmol/L +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,CHEMISTRY PANEL,Serum Uric Acid,,242,,,,,149 - 446,umol/L +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,CHEMISTRY PANEL,Calcium (EDTA),,2.39,,,,,2.07 - 2.64,mmol/L +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,CHEMISTRY PANEL,Phosphorus,,1.08,,,,,0.71 - 1.65,mmol/L +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,CHEMISTRY PANEL,Total Protein,,64,,,,,60 - 80,g/L +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,CHEMISTRY PANEL,Albumin-BCG,,44,,,,,33 - 49,g/L +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,CHEMISTRY PANEL,Creatine Kinase,,52,,,,,26 - 192,U/L +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,CHEMISTRY PANEL,Serum Sodium,,139,,,,,135 - 145,mmol/L +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,CHEMISTRY PANEL,Serum Potassium,,4.3,,,,,3.5 - 5.2,mmol/L +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,CHEMISTRY PANEL,Serum Bicarbonate,,22.9,,,,,19.3 - 29.3,mmol/L +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,CHEMISTRY PANEL,Serum Chloride,,102,,,,,94 - 112,mmol/L +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,119,,,,Result verified by repeat analysis,115 - 158,g/L +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.36,,,,,0.34 - 0.48, +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,3.8,,L,,Result verified by repeat analysis,3.9 - 5.5,TI/L +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,96,,,,,80 - 100,fL +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,6.80,,,,Result verified by repeat analysis,3.8 - 10.7,GI/L +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,4.34,,,,Result verified by repeat analysis,1.96 - 7.23,GI/L +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.86,,,,,0.8 - 3,GI/L +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.44,,,,Result verified by repeat analysis,0.12 - 0.92,GI/L +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.12,,,,Result verified by repeat analysis,0 - 0.57,GI/L +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.03,,,,Result verified by repeat analysis,0 - 0.2,GI/L +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,63.8,,,,Result verified by repeat analysis,40.5 - 75,% +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,27.3,,,,Result verified by repeat analysis,15.4 - 48.5,% +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,6.5,,,,Result verified by repeat analysis,2.6 - 10.1,% +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.8,,,,Result verified by repeat analysis,0 - 6.8,% +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.5,,,,Result verified by repeat analysis,0 - 2,% +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,459,,H,,Result verified by repeat analysis,130 - 394,GI/L +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,25.80,,H,,,1.9 - 23,uIU/mL +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,LIPID PANEL,Direct HDL-C 4th Generation,,0.97,,L,,,1.03 - 1.53,mmol/L +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,LIPID PANEL,Triglycerides (GPO),,1.49,,,,,0.63 - 2.71,mmol/L +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,LIPID PANEL,Cholesterol (High Performance),,4.00,,L,,,4.86 - 8.28,mmol/L +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,LIPID PANEL,LDL Chol Friedewald 4th,,2.35,,,,,0 - 3.34,mmol/L +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,MICROORGANISMS,Ur Bacteria,,Present,,,,,Ref Rng:Not present, +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,RETICULOCYTES,Reticulocyte Count %,,0.9,,,,,0.6 - 2.5,% +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,URINE MACRO PANEL,Ur Specific Gravity,,1.013,,,,,1.01 - 1.03, +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,URINE MACRO PANEL,Ur Leukocyte Esterase,,Trace,,H,,,Ref Rng:Negative, +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,URINE MICRO PANEL,Ur Microscopic,,Positive,,,,, NEGATIVE$,NEGATIVE +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,C-REACTIVE PROTEIN,C Reactive Protein HS,,<0.2,,,,Result verified by repeat analysis,0 - 5,mg/L +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,CHEMISTRY PANEL,Total Bilirubin,,9,,,,,3 - 21,umol/L +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.0,,,,,0 - 6.2,umol/L +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,CHEMISTRY PANEL,Alkaline Phosphatase,,60,,,,,40 - 129,U/L +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,CHEMISTRY PANEL,ALT (SGPT),,35,,,,,5 - 48,U/L +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,CHEMISTRY PANEL,AST (SGOT),,28,,,,,8 - 40,U/L +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,CHEMISTRY PANEL,GGT,,14,,,,,10 - 61,U/L +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,CHEMISTRY PANEL,LDH,,149,,,,,53 - 234,U/L +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,CHEMISTRY PANEL,Urea Nitrogen,,4.0,,,,,1.4 - 8.6,mmol/L +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,77,,,,,40 - 110,umol/L +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,CHEMISTRY PANEL,Glucose Fasting,,4.7,,,,,3.9 - 5.6,mmol/L +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,CHEMISTRY PANEL,Serum Uric Acid,,285,,,,,125 - 488,umol/L +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,CHEMISTRY PANEL,Calcium (EDTA),,2.41,,,,,2.07 - 2.64,mmol/L +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,CHEMISTRY PANEL,Phosphorus,,1.11,,,,,0.71 - 1.65,mmol/L +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,CHEMISTRY PANEL,Total Protein,,67,,,,,61 - 84,g/L +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,CHEMISTRY PANEL,Albumin-BCG,,48,,,,,33 - 49,g/L +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,CHEMISTRY PANEL,Creatine Kinase,,157,,,,,39 - 308,U/L +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,CHEMISTRY PANEL,Serum Sodium,,139,,,,,132 - 147,mmol/L +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,CHEMISTRY PANEL,Serum Potassium,,3.9,,,,,3.5 - 5.2,mmol/L +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,CHEMISTRY PANEL,Serum Bicarbonate,,24.5,,,,,19.3 - 29.3,mmol/L +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,CHEMISTRY PANEL,Serum Chloride,,103,,,,,94 - 112,mmol/L +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,154,,,,,127 - 181,g/L +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.44,,,,,0.39 - 0.54, +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.0,,,,,4.5 - 6.4,TI/L +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,88,,,,,79 - 96,fL +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,5.52,,,,,3.8 - 10.7,GI/L +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.31,,,,,1.96 - 7.23,GI/L +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.76,,,,,0.91 - 4.28,GI/L +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.32,,,,,0.12 - 0.92,GI/L +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.12,,,,,0 - 0.57,GI/L +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.01,,,,,0 - 0.2,GI/L +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,59.8,,,,,40.5 - 75,% +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,31.9,,,,,15.4 - 48.5,% +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.8,,,,,2.6 - 10.1,% +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.2,,,,,0 - 6.8,% +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.3,,,,,0 - 2,% +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,174,,,,,140 - 400,GI/L +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,2.95,,,,,1.9 - 23,uIU/mL +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,LIPID PANEL,Direct HDL-C 4th Generation,,1.39,,,,Result verified by repeat analysis,1.03 - 1.53,mmol/L +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,LIPID PANEL,Triglycerides (GPO),,0.75,,,,,0.5 - 2.81,mmol/L +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,LIPID PANEL,Cholesterol (High Performance),,3.90,,,,,3.31 - 6.1,mmol/L +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,LIPID PANEL,LDL Chol Friedewald 4th,,2.17,,,,,0 - 3.34,mmol/L +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,RETICULOCYTES,Reticulocyte Count %,,1.4,,,,,0.6 - 2.5,% +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,URINE MACRO PANEL,Ur Specific Gravity,,1.012,,,,,1 - 1.04, +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,URINE MACRO PANEL,Ur pH,,6.5,,,,,5 - 8, +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:Negative, +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.5,,,,,0 - 5,mg/L +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,CHEMISTRY PANEL,Total Bilirubin,,8,,,,,3 - 21,umol/L +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.8,,,,,0 - 6.2,umol/L +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,CHEMISTRY PANEL,Alkaline Phosphatase,,54,,,,,35 - 104,U/L +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,CHEMISTRY PANEL,ALT (SGPT),,14,,,,,4 - 43,U/L +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,CHEMISTRY PANEL,AST (SGOT),,20,,,,,8 - 40,U/L +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,CHEMISTRY PANEL,GGT,,23,,,,,5 - 50,U/L +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,CHEMISTRY PANEL,LDH,,143,,,,,53 - 234,U/L +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,CHEMISTRY PANEL,Urea Nitrogen,,3.8,,,,,1.4 - 8.6,mmol/L +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,72,,,,,31 - 101,umol/L +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,CHEMISTRY PANEL,Glucose Fasting,,5.3,,,,,3.9 - 5.6,mmol/L +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,CHEMISTRY PANEL,Serum Uric Acid,,259,,,,,149 - 446,umol/L +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,CHEMISTRY PANEL,Calcium (EDTA),,2.47,,,,,2.07 - 2.64,mmol/L +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,CHEMISTRY PANEL,Phosphorus,,1.20,,,,,0.71 - 1.65,mmol/L +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,CHEMISTRY PANEL,Total Protein,,69,,,,,60 - 80,g/L +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,CHEMISTRY PANEL,Albumin-BCG,,45,,,,,33 - 49,g/L +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,CHEMISTRY PANEL,Creatine Kinase,,41,,,,,26 - 192,U/L +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,CHEMISTRY PANEL,Serum Sodium,,143,,,,,135 - 145,mmol/L +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,CHEMISTRY PANEL,Serum Potassium,,4.7,,,,,3.5 - 5.2,mmol/L +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,CHEMISTRY PANEL,Serum Bicarbonate,,25.2,,,,,19.3 - 29.3,mmol/L +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,CHEMISTRY PANEL,Serum Chloride,,104,,,,,94 - 112,mmol/L +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,122,,,,,115 - 158,g/L +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.37,,,,,0.34 - 0.48, +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.0,,,,,3.9 - 5.5,TI/L +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,94,,,,,80 - 100,fL +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,7.11,,,,,3.8 - 10.7,GI/L +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,4.82,,,,,1.96 - 7.23,GI/L +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.76,,,,,0.8 - 3,GI/L +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.43,,,,,0.12 - 0.92,GI/L +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.07,,,,,0 - 0.57,GI/L +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.02,,,,,0 - 0.2,GI/L +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,67.8,,,,,40.5 - 75,% +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,24.8,,,,,15.4 - 48.5,% +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,6.1,,,,,2.6 - 10.1,% +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.0,,,,,0 - 6.8,% +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.2,,,,,0 - 2,% +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,466,R,H,,,130 - 394,GI/L +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.4,,,,,<6.5 %, +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,9.83,,,,,1.9 - 23,uIU/mL +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,LIPID PANEL,Direct HDL-C 4th Generation,,1.06,,,,,1.03 - 1.53,mmol/L +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,LIPID PANEL,Triglycerides (GPO),,1.56,,,,,0.63 - 2.71,mmol/L +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,LIPID PANEL,Cholesterol (High Performance),,4.33,,L,,,4.86 - 8.28,mmol/L +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,LIPID PANEL,LDL Chol Friedewald 4th,,2.56,,,,,0 - 3.34,mmol/L +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,RETICULOCYTES,Reticulocyte Count %,,1.1,,,,,0.6 - 2.5,% +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,TSH,TSH 3rd IS-QT,,0.806,,,,,0.45 - 5.33,mIU/L +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,URINE MACRO PANEL,Ur Specific Gravity,,1.010,,,,,1.01 - 1.03, +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,URINE MACRO PANEL,Ur pH,,6.0,,,,,5 - 8, +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,C-REACTIVE PROTEIN,C Reactive Protein HS,,0.2,,,,Result verified by repeat analysis,0 - 5,mg/L +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,CHEMISTRY PANEL,Total Bilirubin,,6,,,,,3 - 21,umol/L +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.3,,,,,0 - 6.2,umol/L +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,CHEMISTRY PANEL,Alkaline Phosphatase,,62,,,,,40 - 129,U/L +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,CHEMISTRY PANEL,ALT (SGPT),,39,,,,,5 - 48,U/L +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,CHEMISTRY PANEL,AST (SGOT),,29,,,,,8 - 40,U/L +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,CHEMISTRY PANEL,GGT,,13,,,,,10 - 61,U/L +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,CHEMISTRY PANEL,LDH,,156,,,,,53 - 234,U/L +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,CHEMISTRY PANEL,Urea Nitrogen,,5.0,,,,,1.4 - 8.6,mmol/L +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,74,,,,,40 - 110,umol/L +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,CHEMISTRY PANEL,Glucose Fasting,,5.5,,,,,3.9 - 5.6,mmol/L +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,CHEMISTRY PANEL,Serum Uric Acid,,330,,,,,125 - 488,umol/L +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,CHEMISTRY PANEL,Calcium (EDTA),,2.29,,,,,2.07 - 2.64,mmol/L +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,CHEMISTRY PANEL,Phosphorus,,1.11,,,,,0.71 - 1.65,mmol/L +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,CHEMISTRY PANEL,Total Protein,,66,,,,,61 - 84,g/L +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,CHEMISTRY PANEL,Albumin-BCG,,45,,,,,33 - 49,g/L +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,CHEMISTRY PANEL,Creatine Kinase,,149,,,,,39 - 308,U/L +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,CHEMISTRY PANEL,Serum Sodium,,140,,,,,132 - 147,mmol/L +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,CHEMISTRY PANEL,Serum Potassium,,4.1,,,,,3.5 - 5.2,mmol/L +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,CHEMISTRY PANEL,Serum Bicarbonate,,23.2,,,,,19.3 - 29.3,mmol/L +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,CHEMISTRY PANEL,Serum Chloride,,103,,,,,94 - 112,mmol/L +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,159,,,,,127 - 181,g/L +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.45,,,,,0.39 - 0.54, +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.1,,,,,4.5 - 6.4,TI/L +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,87,,,,,79 - 96,fL +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,5.94,,,,,3.8 - 10.7,GI/L +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.55,,,,,1.96 - 7.23,GI/L +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.81,,,,,0.91 - 4.28,GI/L +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.40,,,,,0.12 - 0.92,GI/L +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.15,,,,,0 - 0.57,GI/L +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.03,,,,,0 - 0.2,GI/L +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,59.8,,,,,40.5 - 75,% +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,30.5,,,,,15.4 - 48.5,% +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,6.7,,,,,2.6 - 10.1,% +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.5,,,,,0 - 6.8,% +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.5,,,,,0 - 2,% +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,189,,,,,140 - 400,GI/L +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.1,,,,,<6.5 %, +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,19.10,,,,,1.9 - 23,uIU/mL +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,LIPID PANEL,Direct HDL-C 4th Generation,,1.09,,,,,1.03 - 1.53,mmol/L +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,LIPID PANEL,Triglycerides (GPO),,1.96,,,,,0.5 - 2.81,mmol/L +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,LIPID PANEL,Cholesterol (High Performance),,3.72,,,,,3.31 - 6.1,mmol/L +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,LIPID PANEL,LDL Chol Friedewald 4th,,1.73,,,,,0 - 3.34,mmol/L +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,RETICULOCYTES,Reticulocyte Count %,,1.2,,,,,0.6 - 2.5,% +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,TSH,TSH 3rd IS-QT,,1.089,,,,,0.45 - 5.33,mIU/L +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,URINE MACRO PANEL,Ur Specific Gravity,,1.019,,,,,1 - 1.04, +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:Negative, +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,C-REACTIVE PROTEIN,C Reactive Protein HS,,9.2,,H,,,0 - 5,mg/L +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,CHEMISTRY PANEL,Total Bilirubin,,16,,,,,3 - 21,umol/L +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,4.6,,,,,0 - 6.2,umol/L +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,CHEMISTRY PANEL,Alkaline Phosphatase,,77,,,,,40 - 129,U/L +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,CHEMISTRY PANEL,ALT (SGPT),,37,,,,,5 - 48,U/L +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,CHEMISTRY PANEL,AST (SGOT),,29,,,,,8 - 40,U/L +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,CHEMISTRY PANEL,GGT,,79,R,H,,,10 - 61,U/L +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,CHEMISTRY PANEL,LDH,,103,,,,,53 - 234,U/L +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,CHEMISTRY PANEL,Urea Nitrogen,,2.3,,,,,1.4 - 8.6,mmol/L +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,74,,,,,40 - 110,umol/L +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,CHEMISTRY PANEL,Glucose Fasting,,5.2,,,,,3.9 - 5.6,mmol/L +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,CHEMISTRY PANEL,Serum Uric Acid,,427,,,,,125 - 488,umol/L +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,CHEMISTRY PANEL,Calcium (EDTA),,2.40,,,,,2.07 - 2.64,mmol/L +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,CHEMISTRY PANEL,Phosphorus,,0.97,,,,,0.71 - 1.65,mmol/L +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,CHEMISTRY PANEL,Total Protein,,71,,,,,61 - 84,g/L +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,CHEMISTRY PANEL,Albumin-BCG,,47,,,,,33 - 49,g/L +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,CHEMISTRY PANEL,Creatine Kinase,,102,,,,,39 - 308,U/L +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,CHEMISTRY PANEL,Serum Sodium,,138,,,,,132 - 147,mmol/L +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,CHEMISTRY PANEL,Serum Potassium,,3.8,,,,,3.5 - 5.2,mmol/L +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,CHEMISTRY PANEL,Serum Bicarbonate,,25.2,,,,,19.3 - 29.3,mmol/L +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,CHEMISTRY PANEL,Serum Chloride,,97,,,,,94 - 112,mmol/L +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,160,,,,,127 - 181,g/L +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.45,,,,,0.39 - 0.54, +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.2,,,,,4.5 - 6.4,TI/L +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,87,,,,,79 - 96,fL +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,7.04,,,,,3.8 - 10.7,GI/L +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,4.60,,,,,1.96 - 7.23,GI/L +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.86,,,,,0.91 - 4.28,GI/L +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.41,,,,,0.12 - 0.92,GI/L +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.12,,,,,0 - 0.57,GI/L +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.05,,,,,0 - 0.2,GI/L +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,65.3,,,,,40.5 - 75,% +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,26.4,,,,,15.4 - 48.5,% +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.8,,,,,2.6 - 10.1,% +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.7,,,,,0 - 6.8,% +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.7,,,,,0 - 2,% +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,366,,,,,140 - 400,GI/L +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.7,,,,,<6.5 %, +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,R,"Mar 6, 2026 2:00 PM",6226560891,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,16.55,,,,,1.9 - 23,uIU/mL +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,LIPID PANEL,Direct HDL-C 4th Generation,,1.23,,,,,1.03 - 1.53,mmol/L +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,LIPID PANEL,Triglycerides (GPO),,1.94,,,,,0.56 - 3.62,mmol/L +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,LIPID PANEL,Cholesterol (High Performance),,4.72,,,,,3.88 - 6.83,mmol/L +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,LIPID PANEL,LDL Chol Friedewald 4th,,2.60,,,,,0 - 3.34,mmol/L +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,RETICULOCYTES,Reticulocyte Count %,,1.2,,,,,0.6 - 2.5,% +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,TSH,TSH 3rd IS-QT,,0.976,,,,,0.45 - 5.33,mIU/L +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,URINE MACRO PANEL,Ur Specific Gravity,,1.016,,,,,1 - 1.04, +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,URINE MACRO PANEL,Ur pH,,6.0,,,,,5 - 8, +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:Negative, +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.3,,,,,0 - 5,mg/L +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,CHEMISTRY PANEL,Total Bilirubin,,10,,,,,3 - 21,umol/L +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.4,,,,,0 - 6.2,umol/L +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,CHEMISTRY PANEL,Alkaline Phosphatase,,55,,,,,35 - 104,U/L +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,CHEMISTRY PANEL,ALT (SGPT),,14,,,,,4 - 43,U/L +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,CHEMISTRY PANEL,AST (SGOT),,17,,,,,8 - 40,U/L +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,CHEMISTRY PANEL,GGT,,21,,,,,5 - 50,U/L +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,CHEMISTRY PANEL,LDH,,136,,,,,53 - 234,U/L +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,CHEMISTRY PANEL,Urea Nitrogen,,4.1,,,,,1.4 - 8.6,mmol/L +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,80,,,,,31 - 101,umol/L +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,CHEMISTRY PANEL,Glucose Fasting,,5.1,,,,,3.9 - 5.6,mmol/L +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,CHEMISTRY PANEL,Serum Uric Acid,,273,,,,,149 - 446,umol/L +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,CHEMISTRY PANEL,Calcium (EDTA),,2.49,,,,,2.07 - 2.64,mmol/L +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,CHEMISTRY PANEL,Phosphorus,,1.13,,,,,0.71 - 1.65,mmol/L +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,CHEMISTRY PANEL,Total Protein,,69,,,,,60 - 80,g/L +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,CHEMISTRY PANEL,Albumin-BCG,,45,,,,,33 - 49,g/L +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,CHEMISTRY PANEL,Creatine Kinase,,42,,,,,26 - 192,U/L +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,CHEMISTRY PANEL,Serum Sodium,,142,,,,,135 - 145,mmol/L +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,CHEMISTRY PANEL,Serum Potassium,,4.7,,,,,3.5 - 5.2,mmol/L +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,CHEMISTRY PANEL,Serum Bicarbonate,,24.2,,,,,19.3 - 29.3,mmol/L +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,CHEMISTRY PANEL,Serum Chloride,,104,,,,,94 - 112,mmol/L +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,122,,,,,115 - 158,g/L +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.37,,,,,0.34 - 0.48, +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.0,,,,,3.9 - 5.5,TI/L +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,92,,,,,80 - 100,fL +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,4.67,,,,,3.8 - 10.7,GI/L +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.77,,,,,1.96 - 7.23,GI/L +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.32,,,,,0.8 - 3,GI/L +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.33,,,,,0.12 - 0.92,GI/L +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.19,,,,,0 - 0.57,GI/L +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.07,,,,,0 - 0.2,GI/L +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,59.2,,,,,40.5 - 75,% +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,28.3,,,,,15.4 - 48.5,% +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,7.0,,,,,2.6 - 10.1,% +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,4.0,,,,,0 - 6.8,% +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.5,,,,,0 - 2,% +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,453,,H,,,130 - 394,GI/L +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,14.65,,,,,1.9 - 23,uIU/mL +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,LIPID PANEL,Direct HDL-C 4th Generation,,1.00,,L,,,1.03 - 1.53,mmol/L +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,LIPID PANEL,Triglycerides (GPO),,1.31,,,,,0.63 - 2.71,mmol/L +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,LIPID PANEL,Cholesterol (High Performance),,4.11,,L,,,4.86 - 8.28,mmol/L +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,LIPID PANEL,LDL Chol Friedewald 4th,,2.51,,,,,0 - 3.34,mmol/L +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,RETICULOCYTES,Reticulocyte Count %,,0.9,,,,,0.6 - 2.5,% +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,URINE MACRO PANEL,Ur Specific Gravity,,1.019,,,,,1.01 - 1.03, +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,URINE MACRO PANEL,Ur pH,,6.5,,,,,5 - 8, +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,C-REACTIVE PROTEIN,C Reactive Protein HS,,<0.2,,,,Result verified by repeat analysis,0 - 5,mg/L +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,CHEMISTRY PANEL,Total Bilirubin,,5,,,,,3 - 21,umol/L +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.3,,,,,0 - 6.2,umol/L +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,CHEMISTRY PANEL,Alkaline Phosphatase,,55,,,,,40 - 129,U/L +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,CHEMISTRY PANEL,ALT (SGPT),,24,,,,,5 - 48,U/L +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,CHEMISTRY PANEL,AST (SGOT),,21,,,,,8 - 40,U/L +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,CHEMISTRY PANEL,GGT,,12,,,,,10 - 61,U/L +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,CHEMISTRY PANEL,LDH,,133,,,,,53 - 234,U/L +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,CHEMISTRY PANEL,Urea Nitrogen,,3.9,,,,,1.4 - 8.6,mmol/L +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,72,,,,,40 - 110,umol/L +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,CHEMISTRY PANEL,Glucose Fasting,,4.9,,,,,3.9 - 5.6,mmol/L +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,CHEMISTRY PANEL,Serum Uric Acid,,244,,,,,125 - 488,umol/L +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,CHEMISTRY PANEL,Calcium (EDTA),,2.40,,,,,2.07 - 2.64,mmol/L +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,CHEMISTRY PANEL,Phosphorus,,1.06,,,,,0.71 - 1.65,mmol/L +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,CHEMISTRY PANEL,Total Protein,,63,,,,,61 - 84,g/L +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,CHEMISTRY PANEL,Albumin-BCG,,45,,,,,33 - 49,g/L +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,CHEMISTRY PANEL,Creatine Kinase,,139,,,,,39 - 308,U/L +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,CHEMISTRY PANEL,Serum Sodium,,141,,,,,132 - 147,mmol/L +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,CHEMISTRY PANEL,Serum Potassium,,4.4,,,,,3.5 - 5.2,mmol/L +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,CHEMISTRY PANEL,Serum Bicarbonate,,22.9,,,,,19.3 - 29.3,mmol/L +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,CHEMISTRY PANEL,Serum Chloride,,106,,,,,94 - 112,mmol/L +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,156,,,,,127 - 181,g/L +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.45,,,,,0.39 - 0.54, +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.0,,,,,4.5 - 6.4,TI/L +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,89,,,,,79 - 96,fL +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,3.41,,L,,,3.8 - 10.7,GI/L +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,1.63,,L,,,1.96 - 7.23,GI/L +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.42,,,,,0.91 - 4.28,GI/L +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.22,,,,,0.12 - 0.92,GI/L +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.08,,,,,0 - 0.57,GI/L +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.05,,,,,0 - 0.2,GI/L +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,47.9,,,,,40.5 - 75,% +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,41.7,,,,,15.4 - 48.5,% +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,6.6,,,,,2.6 - 10.1,% +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.3,,,,,0 - 6.8,% +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.6,,,,,0 - 2,% +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,160,,,,,140 - 400,GI/L +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,4.99,,,,,1.9 - 23,uIU/mL +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,LIPID PANEL,Direct HDL-C 4th Generation,,1.32,,,,,1.03 - 1.53,mmol/L +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,LIPID PANEL,Triglycerides (GPO),,0.52,,,,,0.5 - 2.81,mmol/L +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,LIPID PANEL,Cholesterol (High Performance),,3.73,,,,,3.31 - 6.1,mmol/L +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,LIPID PANEL,LDL Chol Friedewald 4th,,2.17,,,,,0 - 3.34,mmol/L +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,RETICULOCYTES,Reticulocyte Count %,,0.7,,,,,0.6 - 2.5,% +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,URINE MACRO PANEL,Ur Specific Gravity,,1.006,,,,,1 - 1.04, +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,URINE MACRO PANEL,Ur pH,,6.0,,,,,5 - 8, +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:Negative, +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,C-REACTIVE PROTEIN,C Reactive Protein HS,,<0.2,,,,Result verified by repeat analysis,0 - 5,mg/L +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,CHEMISTRY PANEL,Total Bilirubin,,4,,,,,3 - 21,umol/L +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,1.9,,,,,0 - 6.2,umol/L +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,CHEMISTRY PANEL,Alkaline Phosphatase,,57,,,,,40 - 129,U/L +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,CHEMISTRY PANEL,ALT (SGPT),,22,,,,,5 - 48,U/L +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,CHEMISTRY PANEL,AST (SGOT),,21,,,,,8 - 40,U/L +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,CHEMISTRY PANEL,GGT,,11,,,,,10 - 61,U/L +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,CHEMISTRY PANEL,LDH,,131,,,,,53 - 234,U/L +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,CHEMISTRY PANEL,Urea Nitrogen,,5.8,,,,,1.4 - 8.6,mmol/L +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,76,,,,,40 - 110,umol/L +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,CHEMISTRY PANEL,Glucose Fasting,,4.4,,,,,3.9 - 5.6,mmol/L +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,CHEMISTRY PANEL,Serum Uric Acid,,300,,,,,125 - 488,umol/L +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,CHEMISTRY PANEL,Calcium (EDTA),,2.33,,,,,2.07 - 2.64,mmol/L +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,CHEMISTRY PANEL,Phosphorus,,1.05,,,,,0.71 - 1.65,mmol/L +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,CHEMISTRY PANEL,Total Protein,,62,,,,,61 - 84,g/L +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,CHEMISTRY PANEL,Albumin-BCG,,45,,,,,33 - 49,g/L +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,CHEMISTRY PANEL,Creatine Kinase,,120,,,,,39 - 308,U/L +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,CHEMISTRY PANEL,Serum Sodium,,140,,,,,132 - 147,mmol/L +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,CHEMISTRY PANEL,Serum Potassium,,4.8,,,,,3.5 - 5.2,mmol/L +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,CHEMISTRY PANEL,Serum Bicarbonate,,25.3,,,,,19.3 - 29.3,mmol/L +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,CHEMISTRY PANEL,Serum Chloride,,105,,,,,94 - 112,mmol/L +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,CREATININE CLEARANCE CC&G,CreatininClearancCockcrftGault,,2.28,,H,,,1.42 - 2.08,mL/sec +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,CREATININE CLEARANCE CC&G,Creatinine(Rate Blanked)-2dp,,76,,,,,40 - 110,umol/L +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,CREATININE CLEARANCE CC&G,"Weight (kg,1dec place)",Y,75.0,,,,,kg, +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,DRUG SCREEN URINE,Amphetamines/MDMA,,Neg,,,,,Neg;$Cutoff = 1000 ng/mL, +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,DRUG SCREEN URINE,Barbiturates,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,DRUG SCREEN URINE,Cannabinoids,,Neg,,,,,Neg;$Cutoff = 50 ng/mL, +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,DRUG SCREEN URINE,Cocaine,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,DRUG SCREEN URINE,Opiates,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,DRUG SCREEN URINE,Methadone,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,DRUG SCREEN URINE BENZO NON-US,Benzodiazepines Gen 2,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,GFR,EGFR by MDRD,,107,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,152,,,,,127 - 181,g/L +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.45,,,,,0.39 - 0.54, +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.0,,,,,4.5 - 6.4,TI/L +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,90,,,,,79 - 96,fL +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,5.30,,,,,3.8 - 10.7,GI/L +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.90,,,,,1.96 - 7.23,GI/L +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.77,,,,,0.91 - 4.28,GI/L +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.35,,,,,0.12 - 0.92,GI/L +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.14,,,,,0 - 0.57,GI/L +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.14,,,,,0 - 0.2,GI/L +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,54.7,,,,,40.5 - 75,% +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,33.3,,,,,15.4 - 48.5,% +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,6.6,,,,,2.6 - 10.1,% +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.7,,,,,0 - 6.8,% +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,2.6,,H,,,0 - 2,% +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,189,,,,,140 - 400,GI/L +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,4.9,,,,,<6.5 %, +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,3.16,,,,,1.9 - 23,uIU/mL +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,IS SUBJECT OF BLACK RACE?,Subject of black race?,Y,No,,,,,, +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,LIPID PANEL,Direct HDL-C 4th Generation,,1.43,,,,,1.03 - 1.53,mmol/L +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,LIPID PANEL,Triglycerides (GPO),,0.61,,,,,0.5 - 2.81,mmol/L +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,LIPID PANEL,Cholesterol (High Performance),,3.71,,,,,3.31 - 6.1,mmol/L +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,LIPID PANEL,LDL Chol Friedewald 4th,,2.00,,,,,0 - 3.34,mmol/L +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,RETICULOCYTES,Reticulocyte Count %,,1.1,,,,,0.6 - 2.5,% +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,TSH,TSH 3rd IS-QT,,1.462,,,,,0.45 - 5.33,mIU/L +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,URINE MACRO PANEL,Ur Specific Gravity,,1.009,,,,,1 - 1.04, +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,URINE MACRO PANEL,Ur pH,,6.0,,,,,5 - 8, +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:Negative, +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,BENZODIAZEPINE CONFIRM. UR,BenzodiazepineConf-LCMSMS-LDT,,Temazepam (Confirmed),,RX,,,No Ref Rng, +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,BENZODIAZEPINE CONFIRM. UR,BenzodiazepineConf-LCMSMS-LDT,,Oxazepam (Confirmed),,RX,,,No Ref Rng, +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.3,,,,,0 - 5,mg/L +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,CHEMISTRY PANEL,Total Bilirubin,,4,,,,,3 - 21,umol/L +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.5,,,,,0 - 6.2,umol/L +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,CHEMISTRY PANEL,Alkaline Phosphatase,,55,,,,,35 - 104,U/L +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,CHEMISTRY PANEL,ALT (SGPT),,11,,,,,4 - 43,U/L +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,CHEMISTRY PANEL,AST (SGOT),,17,,,,,8 - 40,U/L +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,CHEMISTRY PANEL,GGT,,21,,,,,5 - 50,U/L +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,CHEMISTRY PANEL,LDH,,136,,,,,53 - 234,U/L +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,CHEMISTRY PANEL,Urea Nitrogen,,4.3,,,,,1.4 - 8.6,mmol/L +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,77,,,,,31 - 101,umol/L +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,CHEMISTRY PANEL,Glucose Fasting,,4.8,,,,,3.9 - 5.6,mmol/L +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,CHEMISTRY PANEL,Serum Uric Acid,,247,,,,,149 - 446,umol/L +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,CHEMISTRY PANEL,Calcium (EDTA),,2.40,,,,,2.07 - 2.64,mmol/L +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,CHEMISTRY PANEL,Phosphorus,,1.20,,,,,0.71 - 1.65,mmol/L +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,CHEMISTRY PANEL,Total Protein,,68,,,,,60 - 80,g/L +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,CHEMISTRY PANEL,Albumin-BCG,,45,,,,,33 - 49,g/L +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,CHEMISTRY PANEL,Creatine Kinase,,44,,,,,26 - 192,U/L +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,CHEMISTRY PANEL,Serum Sodium,,142,,,,,135 - 145,mmol/L +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,CHEMISTRY PANEL,Serum Potassium,,4.5,,,,,3.5 - 5.2,mmol/L +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,CHEMISTRY PANEL,Serum Bicarbonate,,23.5,,,,,19.3 - 29.3,mmol/L +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,CHEMISTRY PANEL,Serum Chloride,,103,,,,,94 - 112,mmol/L +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,CREATININE CLEARANCE CC&G,CreatininClearancCockcrftGault,,1.25,,,,,1.25 - 1.92,mL/sec +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,CREATININE CLEARANCE CC&G,Creatinine(Rate Blanked)-2dp,,77,,,,,31 - 101,umol/L +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,CREATININE CLEARANCE CC&G,"Weight (kg,1dec place)",Y,74.0,,,,,kg, +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,DRUG SCREEN URINE,Amphetamines/MDMA,,Neg,,,,,Neg;$Cutoff = 1000 ng/mL, +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,DRUG SCREEN URINE,Barbiturates,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,DRUG SCREEN URINE,Cannabinoids,,Neg,,,,,Neg;$Cutoff = 50 ng/mL, +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,DRUG SCREEN URINE,Cocaine,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,DRUG SCREEN URINE,Opiates,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,DRUG SCREEN URINE,Methadone,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,DRUG SCREEN URINE BENZO NON-US,Benzodiazepines Gen 2,,Detected (unconfirmed),,,,,Neg;$Cutoff = 200 ng/mL, +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,FEMALE OF CHILDBEARING POT?,Female/of Childbearing pot.?,Y,No,,,,,, +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,FSH,Follicle Stimulating Hormone,,55.96,,,,,Follicular:$3.90-8.80 IU/L$Midcycle:$4.50-22.50 IU/L$Luteal:$1.80-5.10 IU/L$Postmenopausal:$16.70-113.60 IU/L, +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,GFR,EGFR by MDRD,,65,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,119,,,,,115 - 158,g/L +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.36,,,,,0.34 - 0.48, +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,3.9,,,,,3.9 - 5.5,TI/L +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,92,,,,,80 - 100,fL +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,6.94,,,,,3.8 - 10.7,GI/L +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,4.50,,,,,1.96 - 7.23,GI/L +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.91,,,,,0.8 - 3,GI/L +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.40,,,,,0.12 - 0.92,GI/L +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.10,,,,,0 - 0.57,GI/L +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.03,,,,,0 - 0.2,GI/L +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,64.8,,,,,40.5 - 75,% +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,27.5,,,,,15.4 - 48.5,% +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.8,,,,,2.6 - 10.1,% +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.5,,,,,0 - 6.8,% +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.4,,,,,0 - 2,% +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,448,R,H,,,130 - 394,GI/L +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.5,,,,,<6.5 %, +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,5.62,,,,,1.9 - 23,uIU/mL +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,IS SUBJECT OF BLACK RACE?,Subject of black race?,Y,No,,,,,, +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,LIPID PANEL,Direct HDL-C 4th Generation,,1.02,R,L,,,1.03 - 1.53,mmol/L +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,LIPID PANEL,Triglycerides (GPO),,1.44,,,,,0.63 - 2.71,mmol/L +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,LIPID PANEL,Cholesterol (High Performance),,4.25,R,L,,,4.86 - 8.28,mmol/L +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,LIPID PANEL,LDL Chol Friedewald 4th,,2.57,,,,,0 - 3.34,mmol/L +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,POSTMENOPAUSAL FEMALE?,<40yrs & amenorrhea >/= 12mo,,Yes,,,,,, +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,RETICULOCYTES,Reticulocyte Count %,,0.7,,,,,0.6 - 2.5,% +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,TSH,TSH 3rd IS-QT,,0.834,,,,,0.45 - 5.33,mIU/L +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,URINE MACRO PANEL,Ur Specific Gravity,,1.007,,,,,1.01 - 1.03, +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,C-REACTIVE PROTEIN,C Reactive Protein HS,,4.8,,,,,0 - 5,mg/L +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,CHEMISTRY PANEL,Total Bilirubin,,10,,,,,3 - 21,umol/L +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.3,,,,,0 - 6.2,umol/L +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,CHEMISTRY PANEL,Alkaline Phosphatase,,70,,,,,40 - 129,U/L +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,CHEMISTRY PANEL,ALT (SGPT),,41,,,,,5 - 48,U/L +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,CHEMISTRY PANEL,AST (SGOT),,27,,,,,8 - 40,U/L +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,CHEMISTRY PANEL,GGT,,81,,H,,,10 - 61,U/L +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,CHEMISTRY PANEL,LDH,,92,,,,,53 - 234,U/L +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,CHEMISTRY PANEL,Urea Nitrogen,,3.3,,,,,1.4 - 8.6,mmol/L +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,74,,,,,40 - 110,umol/L +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,CHEMISTRY PANEL,Glucose Fasting,,6.1,,H,,,3.9 - 5.6,mmol/L +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,CHEMISTRY PANEL,Serum Uric Acid,,412,,,,,125 - 488,umol/L +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,CHEMISTRY PANEL,Calcium (EDTA),,2.37,,,,,2.07 - 2.64,mmol/L +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,CHEMISTRY PANEL,Phosphorus,,0.94,,,,,0.71 - 1.65,mmol/L +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,CHEMISTRY PANEL,Total Protein,,67,,,,,61 - 84,g/L +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,CHEMISTRY PANEL,Albumin-BCG,,45,,,,,33 - 49,g/L +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,CHEMISTRY PANEL,Creatine Kinase,,148,,,,,39 - 308,U/L +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,CHEMISTRY PANEL,Serum Sodium,,139,,,,,132 - 147,mmol/L +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,CHEMISTRY PANEL,Serum Potassium,,4.4,,,,,3.5 - 5.2,mmol/L +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,CHEMISTRY PANEL,Serum Bicarbonate,,25.4,,,,,19.3 - 29.3,mmol/L +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,CHEMISTRY PANEL,Serum Chloride,,100,,,,,94 - 112,mmol/L +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,153,,,,,127 - 181,g/L +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.43,,,,,0.39 - 0.54, +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.0,,,,,4.5 - 6.4,TI/L +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,86,,,,,79 - 96,fL +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,6.61,,,,,3.8 - 10.7,GI/L +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,4.00,,,,,1.96 - 7.23,GI/L +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.02,,,,,0.91 - 4.28,GI/L +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.40,,,,,0.12 - 0.92,GI/L +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.14,,,,,0 - 0.57,GI/L +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.05,,,,,0 - 0.2,GI/L +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,60.5,,,,,40.5 - 75,% +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,30.5,,,,,15.4 - 48.5,% +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,6.0,,,,,2.6 - 10.1,% +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.2,,,,,0 - 6.8,% +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.7,,,,,0 - 2,% +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,322,,,,,140 - 400,GI/L +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,63.81,,H,,,1.9 - 23,uIU/mL +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,LIPID PANEL,Direct HDL-C 4th Generation,,1.13,,,,,1.03 - 1.53,mmol/L +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,LIPID PANEL,Triglycerides (GPO),,2.66,,,,,0.56 - 3.62,mmol/L +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,LIPID PANEL,Cholesterol (High Performance),,4.84,,,,,3.88 - 6.83,mmol/L +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,LIPID PANEL,LDL Chol Friedewald 4th,,2.49,,,,,0 - 3.34,mmol/L +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,RETICULOCYTES,Reticulocyte Count %,,1.1,,,,,0.6 - 2.5,% +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,URINE MACRO PANEL,Ur Specific Gravity,,1.022,,,,,1 - 1.04, +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:Negative, +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,C-REACTIVE PROTEIN,C Reactive Protein HS,,4.0,,,,,0 - 5,mg/L +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,CHEMISTRY PANEL,Total Bilirubin,,9,,,,,3 - 21,umol/L +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.8,,,,,0 - 6.2,umol/L +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,CHEMISTRY PANEL,Alkaline Phosphatase,,74,,,,,40 - 129,U/L +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,CHEMISTRY PANEL,ALT (SGPT),,42,,,,,5 - 48,U/L +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,CHEMISTRY PANEL,AST (SGOT),,26,,,,,8 - 40,U/L +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,CHEMISTRY PANEL,GGT,,70,,H,,,10 - 61,U/L +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,CHEMISTRY PANEL,LDH,,89,,,,,53 - 234,U/L +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,CHEMISTRY PANEL,Urea Nitrogen,,3.1,,,,,1.4 - 8.6,mmol/L +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,77,,,,,40 - 110,umol/L +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,CHEMISTRY PANEL,Glucose Fasting,,6.6,R,H,,,3.9 - 5.6,mmol/L +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,CHEMISTRY PANEL,Serum Uric Acid,,418,,,,,125 - 488,umol/L +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,CHEMISTRY PANEL,Calcium (EDTA),,2.38,,,,,2.07 - 2.64,mmol/L +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,CHEMISTRY PANEL,Phosphorus,,0.91,,,,,0.71 - 1.65,mmol/L +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,CHEMISTRY PANEL,Total Protein,,72,,,,,61 - 84,g/L +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,CHEMISTRY PANEL,Albumin-BCG,,45,,,,,33 - 49,g/L +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,CHEMISTRY PANEL,Creatine Kinase,,100,,,,,39 - 308,U/L +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,CHEMISTRY PANEL,Serum Sodium,,140,,,,,132 - 147,mmol/L +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,CHEMISTRY PANEL,Serum Potassium,,4.0,,,,,3.5 - 5.2,mmol/L +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,CHEMISTRY PANEL,Serum Bicarbonate,,26.3,,,,,19.3 - 29.3,mmol/L +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,CHEMISTRY PANEL,Serum Chloride,,100,,,,,94 - 112,mmol/L +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,153,,,,,127 - 181,g/L +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.43,,,,,0.39 - 0.54, +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.1,,,,,4.5 - 6.4,TI/L +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,84,,,,,79 - 96,fL +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,6.86,,,,,3.8 - 10.7,GI/L +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,4.10,,,,,1.96 - 7.23,GI/L +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.01,,,,,0.91 - 4.28,GI/L +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.39,,,,,0.12 - 0.92,GI/L +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.30,,,,,0 - 0.57,GI/L +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.07,,,,,0 - 0.2,GI/L +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,59.8,,,,,40.5 - 75,% +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,29.2,,,,,15.4 - 48.5,% +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.7,,,,,2.6 - 10.1,% +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,4.3,,,,,0 - 6.8,% +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.0,,,,,0 - 2,% +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,374,,,,,140 - 400,GI/L +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.7,,,,,<6.5 %, +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,196.11,,H,,,1.9 - 23,uIU/mL +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,LIPID PANEL,Direct HDL-C 4th Generation,,0.97,,L,,,1.03 - 1.53,mmol/L +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,LIPID PANEL,Triglycerides (GPO),,2.92,,,,,0.56 - 3.62,mmol/L +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,LIPID PANEL,Cholesterol (High Performance),,4.31,,,,,3.88 - 6.83,mmol/L +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,LIPID PANEL,LDL Chol Friedewald 4th,,2.00,,,,,0 - 3.34,mmol/L +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,RETICULOCYTES,Reticulocyte Count %,,0.9,,,,,0.6 - 2.5,% +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,TSH,TSH 3rd IS-QT,,0.889,,,,,0.45 - 5.33,mIU/L +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,URINE MACRO PANEL,Ur Specific Gravity,,1.011,,,,,1 - 1.04, +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:Negative, +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,C-REACTIVE PROTEIN,C Reactive Protein HS,,3.6,,,,,0 - 5,mg/L +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,CHEMISTRY PANEL,Total Bilirubin,,8,,,,,3 - 21,umol/L +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.9,,,,,0 - 6.2,umol/L +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,CHEMISTRY PANEL,Alkaline Phosphatase,,67,,,,,40 - 129,U/L +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,CHEMISTRY PANEL,ALT (SGPT),,34,,,,,5 - 48,U/L +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,CHEMISTRY PANEL,AST (SGOT),,20,,,,,8 - 40,U/L +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,CHEMISTRY PANEL,GGT,,69,,H,,,10 - 61,U/L +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,CHEMISTRY PANEL,LDH,,98,,,,,53 - 234,U/L +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,CHEMISTRY PANEL,Urea Nitrogen,,2.2,,,,,1.4 - 8.6,mmol/L +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,75,,,,,40 - 110,umol/L +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,CHEMISTRY PANEL,Glucose Fasting,,5.6,,,,,3.9 - 5.6,mmol/L +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,CHEMISTRY PANEL,Serum Uric Acid,,520,R,H,,,125 - 488,umol/L +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,CHEMISTRY PANEL,Calcium (EDTA),,2.37,,,,,2.07 - 2.64,mmol/L +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,CHEMISTRY PANEL,Phosphorus,,1.19,,,,,0.71 - 1.65,mmol/L +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,CHEMISTRY PANEL,Total Protein,,65,,,,,61 - 84,g/L +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,CHEMISTRY PANEL,Albumin-BCG,,44,,,,,33 - 49,g/L +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,CHEMISTRY PANEL,Creatine Kinase,,126,,,,,39 - 308,U/L +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,CHEMISTRY PANEL,Serum Sodium,,142,,,,,132 - 147,mmol/L +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,CHEMISTRY PANEL,Serum Potassium,,4.0,,,,,3.5 - 5.2,mmol/L +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,CHEMISTRY PANEL,Serum Bicarbonate,,21.4,,,,,19.3 - 29.3,mmol/L +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,CHEMISTRY PANEL,Serum Chloride,,104,,,,,94 - 112,mmol/L +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,146,,,,,127 - 181,g/L +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.42,,,,,0.39 - 0.54, +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.9,,,,,4.5 - 6.4,TI/L +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,86,,,,,79 - 96,fL +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,6.43,,,,,3.8 - 10.7,GI/L +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.49,,,,,1.96 - 7.23,GI/L +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.20,,,,,0.91 - 4.28,GI/L +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.44,,,,,0.12 - 0.92,GI/L +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.24,,,,,0 - 0.57,GI/L +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.04,,,,,0 - 0.2,GI/L +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,54.4,,,,,40.5 - 75,% +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,34.2,,,,,15.4 - 48.5,% +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,6.9,,,,,2.6 - 10.1,% +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,3.8,,,,,0 - 6.8,% +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.7,,,,,0 - 2,% +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,288,,,,,140 - 400,GI/L +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,15.24,,,,,1.9 - 23,uIU/mL +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,LIPID PANEL,Direct HDL-C 4th Generation,,1.15,,,,,1.03 - 1.53,mmol/L +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,LIPID PANEL,Triglycerides (GPO),,1.64,,,,,0.56 - 3.62,mmol/L +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,LIPID PANEL,Cholesterol (High Performance),,4.19,,,,,3.88 - 6.83,mmol/L +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,LIPID PANEL,LDL Chol Friedewald 4th,,2.29,,,,,0 - 3.34,mmol/L +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,RETICULOCYTES,Reticulocyte Count %,,1.3,,,,,0.6 - 2.5,% +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,URINE MACRO PANEL,Ur Specific Gravity,,1.011,,,,,1 - 1.04, +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,URINE MACRO PANEL,Ur pH,,5.0,,,,,5 - 8, +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:Negative, +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,C-REACTIVE PROTEIN,C Reactive Protein HS,,3.6,,,,,0 - 5,mg/L +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,CHEMISTRY PANEL,Total Bilirubin,,8,,,,,3 - 21,umol/L +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.2,,,,,0 - 6.2,umol/L +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,CHEMISTRY PANEL,Alkaline Phosphatase,,65,,,,,40 - 129,U/L +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,CHEMISTRY PANEL,ALT (SGPT),,36,,,,,5 - 48,U/L +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,CHEMISTRY PANEL,AST (SGOT),,26,,,,,8 - 40,U/L +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,CHEMISTRY PANEL,GGT,,62,,H,,,10 - 61,U/L +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,CHEMISTRY PANEL,LDH,,105,,,,,53 - 234,U/L +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,CHEMISTRY PANEL,Urea Nitrogen,,2.2,,,,,1.4 - 8.6,mmol/L +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,77,,,,,40 - 110,umol/L +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,CHEMISTRY PANEL,Glucose Fasting,,5.8,,H,,,3.9 - 5.6,mmol/L +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,CHEMISTRY PANEL,Serum Uric Acid,,472,,,,,125 - 488,umol/L +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,CHEMISTRY PANEL,Calcium (EDTA),,2.36,,,,,2.07 - 2.64,mmol/L +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,CHEMISTRY PANEL,Phosphorus,,1.14,,,,,0.71 - 1.65,mmol/L +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,CHEMISTRY PANEL,Total Protein,,69,,,,,61 - 84,g/L +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,CHEMISTRY PANEL,Albumin-BCG,,47,,,,,33 - 49,g/L +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,CHEMISTRY PANEL,Creatine Kinase,,132,,,,,39 - 308,U/L +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,CHEMISTRY PANEL,Serum Sodium,,141,,,,,132 - 147,mmol/L +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,CHEMISTRY PANEL,Serum Potassium,,4.4,,,,,3.5 - 5.2,mmol/L +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,CHEMISTRY PANEL,Serum Bicarbonate,,21.0,,,,,19.3 - 29.3,mmol/L +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,CHEMISTRY PANEL,Serum Chloride,,102,,,,,94 - 112,mmol/L +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,CREATININE CLEARANCE CC&G,CreatininClearancCockcrftGault,,3.53,,H,,,1.42 - 2.08,mL/sec +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,CREATININE CLEARANCE CC&G,Creatinine(Rate Blanked)-2dp,,77,,,,,40 - 110,umol/L +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,CREATININE CLEARANCE CC&G,"Weight (kg,1dec place)",Y,130.2,,,,,kg, +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,DRUG SCREEN URINE,Amphetamines/MDMA,,Neg,,,,,Neg;$Cutoff = 1000 ng/mL, +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,DRUG SCREEN URINE,Barbiturates,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,DRUG SCREEN URINE,Cannabinoids,,Neg,,,,,Neg;$Cutoff = 50 ng/mL, +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,DRUG SCREEN URINE,Cocaine,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,DRUG SCREEN URINE,Opiates,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,DRUG SCREEN URINE,Methadone,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,DRUG SCREEN URINE BENZO NON-US,Benzodiazepines Gen 2,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,GFR,EGFR by MDRD,,98,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,148,,,,,127 - 181,g/L +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.42,,,,,0.39 - 0.54, +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.0,,,,,4.5 - 6.4,TI/L +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,85,,,,,79 - 96,fL +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,5.89,,,,,3.8 - 10.7,GI/L +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.47,,,,,1.96 - 7.23,GI/L +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.93,,,,,0.91 - 4.28,GI/L +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.30,,,,,0.12 - 0.92,GI/L +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.17,,,,,0 - 0.57,GI/L +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.02,,,,,0 - 0.2,GI/L +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,58.8,,,,,40.5 - 75,% +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,32.7,,,,,15.4 - 48.5,% +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.1,,,,,2.6 - 10.1,% +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.9,,,,,0 - 6.8,% +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.4,,,,,0 - 2,% +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,369,,,,,140 - 400,GI/L +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,HEMOGLOBIN A1C,"Hemoglobin A1c,Variant(-70)-QT",,5.5,,,,,<6.5%, +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,16.15,,,,,1.9 - 23,uIU/mL +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,IS SUBJECT OF BLACK RACE?,Subject of black race?,Y,No,,,,,, +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,LIPID PANEL,Direct HDL-C 4th Generation,,1.24,,,,,1.03 - 1.53,mmol/L +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,LIPID PANEL,Triglycerides (GPO),,1.40,,,,,0.56 - 3.62,mmol/L +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,LIPID PANEL,Cholesterol (High Performance),,4.07,,,,,3.88 - 6.83,mmol/L +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,LIPID PANEL,LDL Chol Friedewald 4th,,2.19,,,,,0 - 3.34,mmol/L +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,RETICULOCYTES,Reticulocyte Count %,,1.0,,,,,0.6 - 2.5,% +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,TSH,TSH 3rd IS-QT,,1.099,,,,,0.45 - 5.33,mIU/L +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,URINE MACRO PANEL,Ur Specific Gravity,,1.017,,,,,1 - 1.04, +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,URINE MACRO PANEL,Ur pH,,5.0,,,,,5 - 8, +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:Negative, +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.4,,,,,0 - 5,mg/L +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,CHEMISTRY PANEL,Total Bilirubin,,7,,,,,3 - 21,umol/L +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.4,,,,,0 - 6.2,umol/L +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,CHEMISTRY PANEL,Alkaline Phosphatase,,84,,,,,35 - 104,U/L +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,CHEMISTRY PANEL,ALT (SGPT),,36,,,,,4 - 43,U/L +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,CHEMISTRY PANEL,AST (SGOT),,24,,,,,8 - 40,U/L +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,CHEMISTRY PANEL,GGT,,44,,,,,4 - 49,U/L +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,CHEMISTRY PANEL,LDH,,220,,,,,53 - 234,U/L +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,CHEMISTRY PANEL,Urea Nitrogen,,3.4,,,,,1.4 - 8.6,mmol/L +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,58,,,,,31 - 101,umol/L +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,CHEMISTRY PANEL,Glucose Fasting,,4.6,,,,,3.9 - 5.6,mmol/L +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,CHEMISTRY PANEL,Serum Uric Acid,,295,,,,,125 - 428,umol/L +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,CHEMISTRY PANEL,Calcium (EDTA),,2.42,,,,,2.07 - 2.64,mmol/L +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,CHEMISTRY PANEL,Phosphorus,,0.89,,,,,0.71 - 1.65,mmol/L +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,CHEMISTRY PANEL,Total Protein,,77,,,,,61 - 84,g/L +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,CHEMISTRY PANEL,Albumin-BCG,,47,,,,,33 - 49,g/L +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,CHEMISTRY PANEL,Creatine Kinase,,92,,,,,26 - 192,U/L +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,CHEMISTRY PANEL,Serum Sodium,,139,,,,,132 - 147,mmol/L +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,CHEMISTRY PANEL,Serum Potassium,,4.2,,,,,3.5 - 5.2,mmol/L +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,CHEMISTRY PANEL,Serum Bicarbonate,,23.7,,,,,19.3 - 29.3,mmol/L +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,CHEMISTRY PANEL,Serum Chloride,,100,,,,,94 - 112,mmol/L +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,CREATININE CLEARANCE CC&G,CreatininClearancCockcrftGault,,3.78,,H,,,1.25 - 1.92,mL/sec +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,CREATININE CLEARANCE CC&G,Creatinine(Rate Blanked)-2dp,,58,,,,,31 - 101,umol/L +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,CREATININE CLEARANCE CC&G,"Weight (kg,1dec place)",Y,105.0,,,,,kg, +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,DRUG SCREEN URINE,Amphetamines/MDMA,,Neg,,,,,Neg;$Cutoff = 1000 ng/mL, +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,DRUG SCREEN URINE,Barbiturates,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,DRUG SCREEN URINE,Cannabinoids,,Neg,,,,,Neg;$Cutoff = 50 ng/mL, +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,DRUG SCREEN URINE,Cocaine,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,DRUG SCREEN URINE,Opiates,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,DRUG SCREEN URINE,Methadone,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,DRUG SCREEN URINE BENZO NON-US,Benzodiazepines Gen 2,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,FEMALE OF CHILDBEARING POT?,Female/of Childbearing pot.?,Y,Yes,,,,,, +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,GFR,EGFR by MDRD,,114,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,137,,,,,116 - 164,g/L +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.40,,,,,0.34 - 0.48, +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.6,,,,,4.1 - 5.6,TI/L +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,88,,,,,79 - 98,fL +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,5.91,,,,,3.8 - 10.7,GI/L +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,4.15,,,,,1.96 - 7.23,GI/L +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.38,,,,,0.91 - 4.28,GI/L +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.33,,,,,0.12 - 0.92,GI/L +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.04,,,,,0 - 0.57,GI/L +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.01,,,,,0 - 0.2,GI/L +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,70.3,,,,,40.5 - 75,% +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,23.3,,,,,15.4 - 48.5,% +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.6,,,,,2.6 - 10.1,% +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,0.7,,,,,0 - 6.8,% +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.1,,,,,0 - 2,% +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,241,,,,,140 - 400,GI/L +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,HEMOGLOBIN A1C,"Hemoglobin A1c,Variant(-70)-QT",,4.9,,,,,<6.5%, +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,15.68,,,,,1.9 - 23,uIU/mL +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,IS SUBJECT OF BLACK RACE?,Subject of black race?,Y,No,,,,,, +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,LIPID PANEL,Direct HDL-C 4th Generation,,1.23,,,,,1.03 - 1.53,mmol/L +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,LIPID PANEL,Triglycerides (GPO),,1.78,R,H,,,0.41 - 1.63,mmol/L +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,LIPID PANEL,Cholesterol (High Performance),,5.53,,,,,3.31 - 5.64,mmol/L +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,LIPID PANEL,LDL Chol Friedewald 4th,,3.48,,H,,,0 - 3.34,mmol/L +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,POSTMENOPAUSAL FEMALE?,<40yrs & amenorrhea >/= 12mo,,No,,,,,, +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,RETICULOCYTES,Reticulocyte Count %,,2.0,,,,,0.6 - 2.5,% +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,SERUM BETA HCG,"B-hCG, Qualitative",,Negative,,,,,Ref Rng: Negative, +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,SERUM BETA HCG,"B-hCG, Quantitative",,<0.6,,,,,Units: mIU/mL$Pre-menopausal$<5.0: Negative$5.0-24.9:Borderline$>/= 25.0: Positive, +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,TSH,TSH 3rd IS-QT,,2.503,,,,,0.45 - 5.33,mIU/L +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,URINE MACRO PANEL,Ur Specific Gravity,,1.014,,,,,1 - 1.04, +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,URINE MACRO PANEL,Ur pH,,6.0,,,,,5 - 8, +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.4,,,,,0 - 5,mg/L +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,CHEMISTRY PANEL,Total Bilirubin,,4,,,,,3 - 21,umol/L +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,1.7,,,,,0 - 6.2,umol/L +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,CHEMISTRY PANEL,Alkaline Phosphatase,,69,,,,,35 - 104,U/L +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,CHEMISTRY PANEL,ALT (SGPT),,5,,,,,4 - 43,U/L +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,CHEMISTRY PANEL,AST (SGOT),,13,,,,,8 - 40,U/L +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,CHEMISTRY PANEL,GGT,,<4,,L,,Result verified by repeat analysis,4 - 49,U/L +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,CHEMISTRY PANEL,LDH,,143,,,,,53 - 234,U/L +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,CHEMISTRY PANEL,Urea Nitrogen,,4.8,,,,,1.4 - 8.6,mmol/L +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,56,,,,,31 - 101,umol/L +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,CHEMISTRY PANEL,Glucose Fasting,,4.4,,,,,3.9 - 5.6,mmol/L +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,CHEMISTRY PANEL,Serum Uric Acid,,193,,,,,125 - 428,umol/L +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,CHEMISTRY PANEL,Calcium (EDTA),,2.29,,,,,2.07 - 2.64,mmol/L +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,CHEMISTRY PANEL,Phosphorus,,1.05,,,,,0.71 - 1.65,mmol/L +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,CHEMISTRY PANEL,Total Protein,,67,,,,,61 - 84,g/L +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,CHEMISTRY PANEL,Albumin-BCG,,43,,,,,33 - 49,g/L +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,CHEMISTRY PANEL,Creatine Kinase,,75,,,,,26 - 192,U/L +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,CHEMISTRY PANEL,Serum Sodium,,137,,,,,132 - 147,mmol/L +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,CHEMISTRY PANEL,Serum Potassium,,4.5,,,,,3.5 - 5.2,mmol/L +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,CHEMISTRY PANEL,Serum Bicarbonate,,21.2,,,,,19.3 - 29.3,mmol/L +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,CHEMISTRY PANEL,Serum Chloride,,102,,,,,94 - 112,mmol/L +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,CREATININE CLEARANCE CC&G,CreatininClearancCockcrftGault,,2.06,,H,,,1.25 - 1.92,mL/sec +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,CREATININE CLEARANCE CC&G,Creatinine(Rate Blanked)-2dp,,56,,,,,31 - 101,umol/L +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,CREATININE CLEARANCE CC&G,"Weight (kg,1dec place)",Y,65.8,,,,,kg, +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,DRUG SCREEN URINE,Amphetamines/MDMA,,Neg,,,,,Neg;$Cutoff = 1000 ng/mL, +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,DRUG SCREEN URINE,Barbiturates,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,DRUG SCREEN URINE,Cannabinoids,,Neg,,,,,Neg;$Cutoff = 50 ng/mL, +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,DRUG SCREEN URINE,Cocaine,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,DRUG SCREEN URINE,Opiates,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,DRUG SCREEN URINE,Methadone,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,DRUG SCREEN URINE BENZO NON-US,Benzodiazepines Gen 2,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,FEMALE OF CHILDBEARING POT?,Female/of Childbearing pot.?,Y,Yes,,,,,, +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,GFR,EGFR by MDRD,,105,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,131,,,,,116 - 164,g/L +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.39,,,,,0.34 - 0.48, +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.3,,,,,4.1 - 5.6,TI/L +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,92,,,,,79 - 98,fL +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,5.06,,,,,3.8 - 10.7,GI/L +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.38,,,,,1.96 - 7.23,GI/L +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.11,,,,,0.91 - 4.28,GI/L +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.35,,,,,0.12 - 0.92,GI/L +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.20,,,,,0 - 0.57,GI/L +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.03,,,,,0 - 0.2,GI/L +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,66.7,,,,,40.5 - 75,% +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,21.9,,,,,15.4 - 48.5,% +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,6.8,,,,,2.6 - 10.1,% +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,3.9,,,,,0 - 6.8,% +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.6,,,,,0 - 2,% +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,182,,,,,140 - 400,GI/L +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,HEMOGLOBIN A1C,"Hemoglobin A1c,Variant(-70)-QT",,5.0,,,,,<6.5%, +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,IS SUBJECT OF BLACK RACE?,Subject of black race?,Y,No,,,,,, +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,LIPID PANEL,Direct HDL-C 4th Generation,,1.77,R,H,,,1.03 - 1.53,mmol/L +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,LIPID PANEL,Triglycerides (GPO),,0.71,,,,,0.44 - 1.99,mmol/L +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,LIPID PANEL,Cholesterol (High Performance),,5.82,,,,,3.65 - 6.21,mmol/L +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,LIPID PANEL,LDL Chol Friedewald 4th,,3.72,,H,,,0 - 3.34,mmol/L +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,POSTMENOPAUSAL FEMALE?,<40yrs & amenorrhea >/= 12mo,,No,,,,,, +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,RETICULOCYTES,Reticulocyte Count %,,1.7,,,,,0.6 - 2.5,% +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,SERUM BETA HCG,"B-hCG, Qualitative",,Negative,,,,,Ref Rng: Negative, +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,SERUM BETA HCG,"B-hCG, Quantitative",,<0.6,,,,,Units: mIU/mL$Pre-menopausal$<5.0: Negative$5.0-24.9:Borderline$>/= 25.0: Positive, +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,TSH,TSH 3rd IS-QT,,1.847,,,,,0.45 - 5.33,mIU/L +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,URINE MACRO PANEL,Ur Specific Gravity,,1.006,,,,,1 - 1.04, +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,C-REACTIVE PROTEIN,C Reactive Protein HS,,4.6,,,,,0 - 5,mg/L +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,CHEMISTRY PANEL,Total Bilirubin,,7,,,,,3 - 21,umol/L +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.5,,,,,0 - 6.2,umol/L +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,CHEMISTRY PANEL,Alkaline Phosphatase,,71,,,,,35 - 104,U/L +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,CHEMISTRY PANEL,ALT (SGPT),,24,,,,,4 - 43,U/L +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,CHEMISTRY PANEL,AST (SGOT),,31,,,,,8 - 40,U/L +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,CHEMISTRY PANEL,GGT,,79,R,H,,,4 - 49,U/L +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,CHEMISTRY PANEL,LDH,,144,,,,,53 - 234,U/L +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,CHEMISTRY PANEL,Urea Nitrogen,,4.3,,,,,1.4 - 8.6,mmol/L +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,93,,,,,31 - 101,umol/L +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,CHEMISTRY PANEL,Glucose Fasting,,4.8,,,,,3.9 - 5.6,mmol/L +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,CHEMISTRY PANEL,Serum Uric Acid,,405,,,,,149 - 446,umol/L +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,CHEMISTRY PANEL,Calcium (EDTA),,2.38,,,,,2.07 - 2.64,mmol/L +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,CHEMISTRY PANEL,Phosphorus,,0.92,,,,,0.71 - 1.65,mmol/L +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,CHEMISTRY PANEL,Total Protein,,72,,,,,61 - 84,g/L +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,CHEMISTRY PANEL,Albumin-BCG,,44,,,,,33 - 49,g/L +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,CHEMISTRY PANEL,Creatine Kinase,,157,,,,,26 - 192,U/L +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,CHEMISTRY PANEL,Serum Sodium,,138,,,,,132 - 147,mmol/L +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,CHEMISTRY PANEL,Serum Potassium,,4.5,,,,,3.5 - 5.2,mmol/L +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,CHEMISTRY PANEL,Serum Bicarbonate,,22.8,,,,,19.3 - 29.3,mmol/L +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,CHEMISTRY PANEL,Serum Chloride,,101,,,,,94 - 112,mmol/L +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,CREATININE CLEARANCE CC&G,CreatininClearancCockcrftGault,,1.33,,,,,1.25 - 1.92,mL/sec +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,CREATININE CLEARANCE CC&G,Creatinine(Rate Blanked)-2dp,,93,,,,,31 - 101,umol/L +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,CREATININE CLEARANCE CC&G,"Weight (kg,1dec place)",Y,83.8,,,,,kg, +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,DRUG SCREEN URINE,Amphetamines/MDMA,,Neg,,,,,Neg;$Cutoff = 1000 ng/mL, +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,DRUG SCREEN URINE,Barbiturates,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,DRUG SCREEN URINE,Cannabinoids,,Neg,,,,,Neg;$Cutoff = 50 ng/mL, +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,DRUG SCREEN URINE,Cocaine,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,DRUG SCREEN URINE,Opiates,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,DRUG SCREEN URINE,Methadone,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,DRUG SCREEN URINE BENZO NON-US,Benzodiazepines Gen 2,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,FEMALE OF CHILDBEARING POT?,Female/of Childbearing pot.?,Y,No,,,,,, +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,FSH,Follicle Stimulating Hormone,,32.96,,RX,,,Follicular:$3.90-8.80 IU/L$Midcycle:$4.50-22.50 IU/L$Luteal:$1.80-5.10 IU/L$Postmenopausal:$16.70-113.60 IU/L, +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,GFR,EGFR by MDRD,,54,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,117,,,,,116 - 164,g/L +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.35,,,,,0.34 - 0.48, +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.3,,,,,4.1 - 5.6,TI/L +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,81,,,,,79 - 98,fL +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,5.93,,,,,3.8 - 10.7,GI/L +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,4.05,,,,,1.96 - 7.23,GI/L +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.14,,,,,0.91 - 4.28,GI/L +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.46,,,,,0.12 - 0.92,GI/L +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.25,,,,,0 - 0.57,GI/L +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.03,,,,,0 - 0.2,GI/L +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,68.3,,,,,40.5 - 75,% +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,19.2,,,,,15.4 - 48.5,% +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,7.8,,,,,2.6 - 10.1,% +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,4.2,,,,,0 - 6.8,% +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.5,,,,,0 - 2,% +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,157,,,,,140 - 400,GI/L +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,HEMOGLOBIN A1C,"Hemoglobin A1c,Variant(-70)-QT",,6.5,,H,,,<6.5%, +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,27.42,,H,,,1.9 - 23,uIU/mL +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,IS SUBJECT OF BLACK RACE?,Subject of black race?,Y,No,,,,,, +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,LIPID PANEL,Direct HDL-C 4th Generation,,0.82,R,L,,,1.03 - 1.53,mmol/L +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,LIPID PANEL,Triglycerides (GPO),,2.78,,,,,0.59 - 2.96,mmol/L +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,LIPID PANEL,Cholesterol (High Performance),,5.73,,,,,4.42 - 7.53,mmol/L +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,LIPID PANEL,LDL Chol Friedewald 4th,,3.64,,H,,,0 - 3.34,mmol/L +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,POSTMENOPAUSAL FEMALE?,<40yrs & amenorrhea >/= 12mo,,Yes,,,,,, +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,RETICULOCYTES,Reticulocyte Count %,,1.4,,,,,0.6 - 2.5,% +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,TSH,TSH 3rd IS-QT,,1.091,,,,,0.45 - 5.33,mIU/L +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,URINE MACRO PANEL,Ur Specific Gravity,,1.019,,,,,1 - 1.04, +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,URINE MACRO PANEL,Ur pH,,6.0,,,,,5 - 8, +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, diff --git a/Covance_UCO3001/Source/Zpracovano/2026-06-08_125953 sponsor-study-36940-kit-inventory-on-hand-expiration.csv b/Covance_UCO3001/Source/Zpracovano/2026-06-08_125953 sponsor-study-36940-kit-inventory-on-hand-expiration.csv new file mode 100644 index 0000000..1a77cba --- /dev/null +++ b/Covance_UCO3001/Source/Zpracovano/2026-06-08_125953 sponsor-study-36940-kit-inventory-on-hand-expiration.csv @@ -0,0 +1,550 @@ +Project No.,Region,Country,Site,Kit Type,Description,Accession,Shipped Date,Expiration Date,Days to Expiration +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,1,Screening,6227323202,"Nov 21, 2025","May 31, 2026",-8 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,1,Screening,6228114609,"Mar 10, 2026","Oct 11, 2026",124 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,2,Induction Week 0,6228036552,"Feb 27, 2026","Oct 11, 2026",124 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,2,Induction Week 0,6228462182,"Apr 28, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,2,Induction Week 0,6228462184,"Apr 28, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,2,Induction Week 0,6228462183,"Apr 28, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,3,Induction Week 2,6227933141,"Feb 18, 2026","Oct 11, 2026",124 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,3,Induction Week 2,6228462185,"Apr 28, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,3,Induction Week 2,6228462186,"Apr 28, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,3,Induction Week 2,6228462187,"Apr 28, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,4,Induction Week 4,6227323209,"Nov 21, 2025","May 31, 2026",-8 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,4,Induction Week 4,6228462189,"Apr 28, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,4,Induction Week 4,6228462188,"Apr 28, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,5,Induction Week 12,6227810906,"Jan 29, 2026","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,5,Induction Week 12,6227933144,"Feb 18, 2026","Oct 11, 2026",124 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,5,Induction Week 12,6228462190,"Apr 28, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,5,Induction Week 12,6228462191,"Apr 28, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,6,Maintenance Week 4,6227933145,"Feb 18, 2026","Oct 11, 2026",124 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,6,Maintenance Week 4,6227933146,"Feb 18, 2026","Oct 11, 2026",124 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,7,Maintenance Week 12,6227933147,"Feb 18, 2026","Oct 11, 2026",124 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,7,Maintenance Week 12,6227933148,"Feb 18, 2026","Oct 11, 2026",124 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,T-1,Stool Pathogens,6228137358,"Mar 12, 2026","Jan 29, 2027",234 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,T-1,Stool Pathogens,6228462192,"Apr 28, 2026","May 25, 2027",350 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,T-1,Stool Pathogens,6228462193,"Apr 28, 2026","May 25, 2027",350 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,T-1,Stool Pathogens,6228462194,"Apr 28, 2026","May 25, 2027",350 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,T-1,Stool Pathogens,6228462196,"Apr 28, 2026","May 25, 2027",350 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,T-1,Stool Pathogens,6228462197,"Apr 28, 2026","May 25, 2027",350 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,T-1,Stool Pathogens,6228462195,"Apr 28, 2026","May 25, 2027",350 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,T-2,TB Testing,6227323220,"Nov 21, 2025","Jun 30, 2026",21 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,T-2,TB Testing,6227323221,"Nov 21, 2025","Jun 30, 2026",21 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,T-3,Biopsy,6227323222,"Nov 21, 2025","Sep 12, 2026",95 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,T-3,Biopsy,6228252071,"Mar 26, 2026","Jul 20, 2027",406 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,T-4,Induction ED,6227323225,"Nov 21, 2025","May 31, 2026",-8 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,T-4,Induction ED,6227323226,"Nov 21, 2025","May 31, 2026",-8 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,T-5,Biologic Drug Level,6227323227,"Nov 21, 2025","Jun 30, 2026",21 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,T-5,Biologic Drug Level,6227323228,"Nov 21, 2025","Jun 30, 2026",21 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,T-6,Maintenance ED,6227810907,"Jan 29, 2026","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,T-6,Maintenance ED,6227810909,"Jan 29, 2026","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,T-6,Maintenance ED,6227810908,"Jan 29, 2026","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,T-8,Liver Function Tests,6227323229,"Nov 21, 2025","Jul 1, 2026",22 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,T-8,Liver Function Tests,6227323230,"Nov 21, 2025","Jul 1, 2026",22 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,T-9,LTE Maintenance ED,6227810910,"Jan 29, 2026","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,T-9,LTE Maintenance ED,6227810911,"Jan 29, 2026","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,T-9,LTE Maintenance ED,6227810912,"Jan 29, 2026","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,T-10,Safety FU,6227323214,"Nov 21, 2025","May 31, 2026",-8 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,T-10,Safety FU,6227323215,"Nov 21, 2025","May 31, 2026",-8 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,T-11,DILI,6227323216,"Nov 21, 2025","May 31, 2026",-8 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,T-12,DNA,6227323218,"Nov 21, 2025","Aug 31, 2026",83 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,T-12,DNA,6228252069,"Mar 26, 2026","Mar 31, 2027",295 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,T-12,DNA,6228252070,"Mar 26, 2026","Mar 31, 2027",295 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,T-12,DNA,6228252068,"Mar 26, 2026","Mar 31, 2027",295 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,U,Unscheduled,6228462198,"Apr 28, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,U,Unscheduled,6228462199,"Apr 28, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,U,Unscheduled,6228462200,"Apr 28, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,U,Unscheduled,6228462202,"Apr 28, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,U,Unscheduled,6228462201,"Apr 28, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,U,Unscheduled,6228462203,"Apr 28, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,U,Unscheduled,6228462206,"Apr 28, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,U,Unscheduled,6228462205,"Apr 28, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,U,Unscheduled,6228462204,"Apr 28, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,U,Unscheduled,6228462207,"Apr 28, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,U,Unscheduled,6228489756,"May 1, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,U,Unscheduled,6228489757,"May 1, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,U,Unscheduled,6228489758,"May 1, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,U,Unscheduled,6228489761,"May 1, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,U,Unscheduled,6228489760,"May 1, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,U,Unscheduled,6228489759,"May 1, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,U,Unscheduled,6228489763,"May 1, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,U,Unscheduled,6228489762,"May 1, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10003 - Dr. Leksa Vaclav,1,Screening,6227323298,"Nov 21, 2025","Jun 30, 2026",21 +213069,EMEA,CZE,CZ10003 - Dr. Leksa Vaclav,1,Screening,6227323300,"Nov 21, 2025","Jun 30, 2026",21 +213069,EMEA,CZE,CZ10003 - Dr. Leksa Vaclav,2,Induction Week 0,6227323301,"Nov 21, 2025","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10003 - Dr. Leksa Vaclav,2,Induction Week 0,6227323302,"Nov 21, 2025","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10003 - Dr. Leksa Vaclav,3,Induction Week 2,6227323303,"Nov 21, 2025","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10003 - Dr. Leksa Vaclav,3,Induction Week 2,6227323304,"Nov 21, 2025","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10003 - Dr. Leksa Vaclav,4,Induction Week 4,6227323306,"Nov 21, 2025","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10003 - Dr. Leksa Vaclav,4,Induction Week 4,6227323305,"Nov 21, 2025","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10003 - Dr. Leksa Vaclav,5,Induction Week 12,6228676757,"May 15, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10003 - Dr. Leksa Vaclav,T-1,Stool Pathogens,6227323307,"Nov 21, 2025","Dec 26, 2026",200 +213069,EMEA,CZE,CZ10003 - Dr. Leksa Vaclav,T-1,Stool Pathogens,6227323308,"Nov 21, 2025","Dec 26, 2026",200 +213069,EMEA,CZE,CZ10003 - Dr. Leksa Vaclav,T-2,TB Testing,6227323316,"Nov 21, 2025","Jun 30, 2026",21 +213069,EMEA,CZE,CZ10003 - Dr. Leksa Vaclav,T-2,TB Testing,6227323317,"Nov 21, 2025","Jun 30, 2026",21 +213069,EMEA,CZE,CZ10003 - Dr. Leksa Vaclav,T-3,Biopsy,6227323319,"Nov 21, 2025","Sep 12, 2026",95 +213069,EMEA,CZE,CZ10003 - Dr. Leksa Vaclav,T-3,Biopsy,6227323318,"Nov 21, 2025","Sep 12, 2026",95 +213069,EMEA,CZE,CZ10003 - Dr. Leksa Vaclav,T-4,Induction ED,6227323321,"Nov 21, 2025","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10003 - Dr. Leksa Vaclav,T-4,Induction ED,6227323322,"Nov 21, 2025","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10003 - Dr. Leksa Vaclav,T-5,Biologic Drug Level,6227323323,"Nov 21, 2025","Jun 30, 2026",21 +213069,EMEA,CZE,CZ10003 - Dr. Leksa Vaclav,T-5,Biologic Drug Level,6227323324,"Nov 21, 2025","Jun 30, 2026",21 +213069,EMEA,CZE,CZ10003 - Dr. Leksa Vaclav,T-6,Maintenance ED,6228676759,"May 15, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10003 - Dr. Leksa Vaclav,T-6,Maintenance ED,6228676760,"May 15, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10003 - Dr. Leksa Vaclav,T-6,Maintenance ED,6228676758,"May 15, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10003 - Dr. Leksa Vaclav,T-8,Liver Function Tests,6227323326,"Nov 21, 2025","Jul 1, 2026",22 +213069,EMEA,CZE,CZ10003 - Dr. Leksa Vaclav,T-8,Liver Function Tests,6227323325,"Nov 21, 2025","Jul 1, 2026",22 +213069,EMEA,CZE,CZ10003 - Dr. Leksa Vaclav,T-9,LTE Maintenance ED,6228676762,"May 15, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10003 - Dr. Leksa Vaclav,T-9,LTE Maintenance ED,6228676763,"May 15, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10003 - Dr. Leksa Vaclav,T-9,LTE Maintenance ED,6228676761,"May 15, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10003 - Dr. Leksa Vaclav,T-10,Safety FU,6227323310,"Nov 21, 2025","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10003 - Dr. Leksa Vaclav,T-10,Safety FU,6227323311,"Nov 21, 2025","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10003 - Dr. Leksa Vaclav,T-11,DILI,6227323312,"Nov 21, 2025","Jun 30, 2026",21 +213069,EMEA,CZE,CZ10003 - Dr. Leksa Vaclav,T-12,DNA,6227323313,"Nov 21, 2025","Aug 31, 2026",83 +213069,EMEA,CZE,CZ10003 - Dr. Leksa Vaclav,T-12,DNA,6227323314,"Nov 21, 2025","Aug 31, 2026",83 +213069,EMEA,CZE,CZ10003 - Dr. Leksa Vaclav,T-12,DNA,6227323315,"Nov 21, 2025","Aug 31, 2026",83 +213069,EMEA,CZE,CZ10003 - Dr. Leksa Vaclav,U,Unscheduled,6227323328,"Nov 21, 2025","Aug 31, 2026",83 +213069,EMEA,CZE,CZ10003 - Dr. Leksa Vaclav,U,Unscheduled,6227323327,"Nov 21, 2025","Aug 31, 2026",83 +213069,EMEA,CZE,CZ10003 - Dr. Leksa Vaclav,U,Unscheduled,6227323329,"Nov 21, 2025","May 31, 2026",-8 +213069,EMEA,CZE,CZ10006 - Dr. Michal Konecny,1,Screening,6227323235,"Nov 21, 2025","Jun 30, 2026",21 +213069,EMEA,CZE,CZ10006 - Dr. Michal Konecny,1,Screening,6228492883,"Apr 23, 2026","Nov 30, 2026",174 +213069,EMEA,CZE,CZ10006 - Dr. Michal Konecny,1,Screening,6228492884,"Apr 23, 2026","Nov 30, 2026",174 +213069,EMEA,CZE,CZ10006 - Dr. Michal Konecny,1,Screening,6228492885,"Apr 23, 2026","Nov 30, 2026",174 +213069,EMEA,CZE,CZ10006 - Dr. Michal Konecny,2,Induction Week 0,6228265099,"Mar 27, 2026","Jan 31, 2027",236 +213069,EMEA,CZE,CZ10006 - Dr. Michal Konecny,2,Induction Week 0,6228265098,"Mar 27, 2026","Jan 31, 2027",236 +213069,EMEA,CZE,CZ10006 - Dr. Michal Konecny,2,Induction Week 0,6228265100,"Mar 27, 2026","Jan 31, 2027",236 +213069,EMEA,CZE,CZ10006 - Dr. Michal Konecny,3,Induction Week 2,6227323239,"Nov 21, 2025","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10006 - Dr. Michal Konecny,3,Induction Week 2,6228407563,"Apr 15, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10006 - Dr. Michal Konecny,3,Induction Week 2,6228407564,"Apr 15, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10006 - Dr. Michal Konecny,3,Induction Week 2,6228407565,"Apr 15, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10006 - Dr. Michal Konecny,4,Induction Week 4,6227323241,"Nov 21, 2025","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10006 - Dr. Michal Konecny,4,Induction Week 4,6228461735,"Apr 21, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10006 - Dr. Michal Konecny,4,Induction Week 4,6228461736,"Apr 21, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10006 - Dr. Michal Konecny,4,Induction Week 4,6228461734,"Apr 21, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10006 - Dr. Michal Konecny,5,Induction Week 12,6228013269,"Feb 25, 2026","Oct 11, 2026",124 +213069,EMEA,CZE,CZ10006 - Dr. Michal Konecny,5,Induction Week 12,6228492886,"Apr 23, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10006 - Dr. Michal Konecny,6,Maintenance Week 4,6228194338,"Mar 23, 2026","Sep 30, 2026",113 +213069,EMEA,CZE,CZ10006 - Dr. Michal Konecny,6,Maintenance Week 4,6228690541,"May 19, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10006 - Dr. Michal Konecny,T-1,Stool Pathogens,6228194340,"Mar 23, 2026","Mar 5, 2027",269 +213069,EMEA,CZE,CZ10006 - Dr. Michal Konecny,T-1,Stool Pathogens,6228194339,"Mar 23, 2026","Mar 5, 2027",269 +213069,EMEA,CZE,CZ10006 - Dr. Michal Konecny,T-3,Biopsy,6228690542,"May 19, 2026","Aug 7, 2027",424 +213069,EMEA,CZE,CZ10006 - Dr. Michal Konecny,T-3,Biopsy,6228690544,"May 19, 2026","Aug 7, 2027",424 +213069,EMEA,CZE,CZ10006 - Dr. Michal Konecny,T-3,Biopsy,6228690543,"May 19, 2026","Aug 7, 2027",424 +213069,EMEA,CZE,CZ10006 - Dr. Michal Konecny,T-4,Induction ED,6227323257,"Nov 21, 2025","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10006 - Dr. Michal Konecny,T-4,Induction ED,6227323258,"Nov 21, 2025","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10006 - Dr. Michal Konecny,T-5,Biologic Drug Level,6227323260,"Nov 21, 2025","Jun 30, 2026",21 +213069,EMEA,CZE,CZ10006 - Dr. Michal Konecny,T-5,Biologic Drug Level,6227323259,"Nov 21, 2025","Jun 30, 2026",21 +213069,EMEA,CZE,CZ10006 - Dr. Michal Konecny,T-6,Maintenance ED,6228013270,"Feb 25, 2026","Oct 11, 2026",124 +213069,EMEA,CZE,CZ10006 - Dr. Michal Konecny,T-6,Maintenance ED,6228013271,"Feb 25, 2026","Oct 11, 2026",124 +213069,EMEA,CZE,CZ10006 - Dr. Michal Konecny,T-6,Maintenance ED,6228013272,"Feb 25, 2026","Oct 11, 2026",124 +213069,EMEA,CZE,CZ10006 - Dr. Michal Konecny,T-8,Liver Function Tests,6227323261,"Nov 21, 2025","Jul 1, 2026",22 +213069,EMEA,CZE,CZ10006 - Dr. Michal Konecny,T-8,Liver Function Tests,6227323262,"Nov 21, 2025","Jul 1, 2026",22 +213069,EMEA,CZE,CZ10006 - Dr. Michal Konecny,T-9,LTE Maintenance ED,6228013275,"Feb 25, 2026","Oct 11, 2026",124 +213069,EMEA,CZE,CZ10006 - Dr. Michal Konecny,T-9,LTE Maintenance ED,6228013273,"Feb 25, 2026","Oct 11, 2026",124 +213069,EMEA,CZE,CZ10006 - Dr. Michal Konecny,T-9,LTE Maintenance ED,6228013274,"Feb 25, 2026","Oct 11, 2026",124 +213069,EMEA,CZE,CZ10006 - Dr. Michal Konecny,T-10,Safety FU,6227323246,"Nov 21, 2025","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10006 - Dr. Michal Konecny,T-10,Safety FU,6227323247,"Nov 21, 2025","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10006 - Dr. Michal Konecny,T-11,DILI,6227323248,"Nov 21, 2025","Jun 30, 2026",21 +213069,EMEA,CZE,CZ10006 - Dr. Michal Konecny,T-12,DNA,6227323250,"Nov 21, 2025","Aug 31, 2026",83 +213069,EMEA,CZE,CZ10006 - Dr. Michal Konecny,T-12,DNA,6227323249,"Nov 21, 2025","Aug 31, 2026",83 +213069,EMEA,CZE,CZ10006 - Dr. Michal Konecny,U,Unscheduled,6227323263,"Nov 21, 2025","Aug 31, 2026",83 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,1,Screening,6227323331,"Nov 23, 2025","Jun 30, 2026",21 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,1,Screening,6227765941,"Jan 29, 2026","Sep 30, 2026",113 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,1,Screening,6227765942,"Jan 29, 2026","Sep 30, 2026",113 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,1,Screening,6227765943,"Jan 29, 2026","Sep 30, 2026",113 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,2,Induction Week 0,6227323333,"Nov 23, 2025","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,2,Induction Week 0,6227765944,"Jan 29, 2026","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,2,Induction Week 0,6227765945,"Jan 29, 2026","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,2,Induction Week 0,6227765946,"Jan 29, 2026","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,3,Induction Week 2,6227323336,"Nov 23, 2025","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,3,Induction Week 2,6227765948,"Jan 29, 2026","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,3,Induction Week 2,6227765947,"Jan 29, 2026","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,3,Induction Week 2,6227765949,"Jan 29, 2026","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,4,Induction Week 4,6227323338,"Nov 23, 2025","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,4,Induction Week 4,6227765950,"Jan 29, 2026","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,4,Induction Week 4,6227765951,"Jan 29, 2026","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,4,Induction Week 4,6227765952,"Jan 29, 2026","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,5,Induction Week 12,6227765953,"Jan 29, 2026","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,5,Induction Week 12,6227765954,"Jan 29, 2026","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,5,Induction Week 12,6227765955,"Jan 29, 2026","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,T-1,Stool Pathogens,6227323339,"Nov 23, 2025","Dec 26, 2026",200 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,T-1,Stool Pathogens,6227765956,"Jan 29, 2026","Jan 15, 2027",220 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,T-1,Stool Pathogens,6227765957,"Jan 29, 2026","Jan 15, 2027",220 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,T-1,Stool Pathogens,6227765958,"Jan 29, 2026","Jan 15, 2027",220 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,T-1,Stool Pathogens,6227765959,"Jan 29, 2026","Jan 15, 2027",220 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,T-2,TB Testing,6227323349,"Nov 23, 2025","Jun 30, 2026",21 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,T-2,TB Testing,6227765963,"Jan 29, 2026","Sep 30, 2026",113 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,T-2,TB Testing,6227765964,"Jan 29, 2026","Sep 30, 2026",113 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,T-2,TB Testing,6227765965,"Jan 29, 2026","Sep 30, 2026",113 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,T-2,TB Testing,6227765966,"Jan 29, 2026","Sep 30, 2026",113 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,T-3,Biopsy,6227323350,"Nov 23, 2025","Sep 12, 2026",95 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,T-3,Biopsy,6227323352,"Nov 23, 2025","Sep 12, 2026",95 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,T-3,Biopsy,6227765967,"Jan 29, 2026","Nov 28, 2026",172 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,T-3,Biopsy,6227765968,"Jan 29, 2026","Nov 28, 2026",172 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,T-3,Biopsy,6227765970,"Jan 29, 2026","Nov 28, 2026",172 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,T-3,Biopsy,6227765969,"Jan 29, 2026","Nov 28, 2026",172 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,T-4,Induction ED,6227323353,"Nov 23, 2025","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,T-4,Induction ED,6227323354,"Nov 23, 2025","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,T-5,Biologic Drug Level,6227323356,"Nov 23, 2025","Jun 30, 2026",21 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,T-5,Biologic Drug Level,6227765973,"Jan 29, 2026","Dec 31, 2026",205 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,T-5,Biologic Drug Level,6227765972,"Jan 29, 2026","Dec 31, 2026",205 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,T-5,Biologic Drug Level,6227765974,"Jan 29, 2026","Dec 31, 2026",205 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,T-5,Biologic Drug Level,6227765971,"Jan 29, 2026","Dec 31, 2026",205 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,T-6,Maintenance ED,6228357528,"Apr 7, 2026","Jan 31, 2027",236 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,T-6,Maintenance ED,6228357529,"Apr 7, 2026","Jan 31, 2027",236 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,T-6,Maintenance ED,6228357530,"Apr 7, 2026","Jan 31, 2027",236 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,T-8,Liver Function Tests,6227323357,"Nov 23, 2025","Jul 1, 2026",22 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,T-8,Liver Function Tests,6227323358,"Nov 23, 2025","Jul 1, 2026",22 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,T-9,LTE Maintenance ED,6228357532,"Apr 7, 2026","Jan 31, 2027",236 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,T-9,LTE Maintenance ED,6228357533,"Apr 7, 2026","Jan 31, 2027",236 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,T-9,LTE Maintenance ED,6228357531,"Apr 7, 2026","Jan 31, 2027",236 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,T-10,Safety FU,6227323342,"Nov 23, 2025","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,T-10,Safety FU,6227323343,"Nov 23, 2025","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,T-11,DILI,6227323344,"Nov 23, 2025","Jun 30, 2026",21 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,T-12,DNA,6227323347,"Nov 23, 2025","Aug 31, 2026",83 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,T-12,DNA,6227323345,"Nov 23, 2025","Aug 31, 2026",83 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,T-12,DNA,6227765961,"Jan 29, 2026","Dec 31, 2026",205 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,T-12,DNA,6227765962,"Jan 29, 2026","Dec 31, 2026",205 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,T-12,DNA,6227765960,"Jan 29, 2026","Dec 31, 2026",205 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,U,Unscheduled,6227323359,"Nov 23, 2025","Aug 31, 2026",83 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,U,Unscheduled,6227323361,"Nov 23, 2025","Aug 31, 2026",83 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,U,Unscheduled,6227323360,"Nov 23, 2025","Aug 31, 2026",83 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,U,Unscheduled,6227765975,"Jan 29, 2026","Oct 31, 2026",144 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,U,Unscheduled,6227765976,"Jan 29, 2026","Oct 31, 2026",144 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,U,Unscheduled,6227765977,"Jan 29, 2026","Oct 31, 2026",144 +213069,EMEA,CZE,CZ10010 - Dr.Nabil El Lababidi,1,Screening,6227993930,"Feb 17, 2026","Oct 31, 2026",144 +213069,EMEA,CZE,CZ10010 - Dr.Nabil El Lababidi,1,Screening,6227993931,"Feb 17, 2026","Oct 31, 2026",144 +213069,EMEA,CZE,CZ10010 - Dr.Nabil El Lababidi,1,Screening,6227993932,"Feb 17, 2026","Oct 31, 2026",144 +213069,EMEA,CZE,CZ10010 - Dr.Nabil El Lababidi,2,Induction Week 0,6227993933,"Feb 17, 2026","Oct 11, 2026",124 +213069,EMEA,CZE,CZ10010 - Dr.Nabil El Lababidi,2,Induction Week 0,6227993934,"Feb 17, 2026","Oct 11, 2026",124 +213069,EMEA,CZE,CZ10010 - Dr.Nabil El Lababidi,3,Induction Week 2,6227993935,"Feb 17, 2026","Oct 11, 2026",124 +213069,EMEA,CZE,CZ10010 - Dr.Nabil El Lababidi,3,Induction Week 2,6227993936,"Feb 17, 2026","Oct 11, 2026",124 +213069,EMEA,CZE,CZ10010 - Dr.Nabil El Lababidi,4,Induction Week 4,6227993937,"Feb 17, 2026","Oct 11, 2026",124 +213069,EMEA,CZE,CZ10010 - Dr.Nabil El Lababidi,4,Induction Week 4,6227993938,"Feb 17, 2026","Oct 11, 2026",124 +213069,EMEA,CZE,CZ10010 - Dr.Nabil El Lababidi,T-1,Stool Pathogens,6227993941,"Feb 17, 2026","Jan 15, 2027",220 +213069,EMEA,CZE,CZ10010 - Dr.Nabil El Lababidi,T-1,Stool Pathogens,6227993940,"Feb 17, 2026","Jan 15, 2027",220 +213069,EMEA,CZE,CZ10010 - Dr.Nabil El Lababidi,T-1,Stool Pathogens,6227993939,"Feb 17, 2026","Jan 15, 2027",220 +213069,EMEA,CZE,CZ10010 - Dr.Nabil El Lababidi,T-2,TB Testing,6227993949,"Feb 17, 2026","Oct 31, 2026",144 +213069,EMEA,CZE,CZ10010 - Dr.Nabil El Lababidi,T-2,TB Testing,6227993948,"Feb 17, 2026","Oct 31, 2026",144 +213069,EMEA,CZE,CZ10010 - Dr.Nabil El Lababidi,T-3,Biopsy,6227993952,"Feb 17, 2026","Nov 28, 2026",172 +213069,EMEA,CZE,CZ10010 - Dr.Nabil El Lababidi,T-3,Biopsy,6227993951,"Feb 17, 2026","Nov 28, 2026",172 +213069,EMEA,CZE,CZ10010 - Dr.Nabil El Lababidi,T-3,Biopsy,6227993950,"Feb 17, 2026","Nov 28, 2026",172 +213069,EMEA,CZE,CZ10010 - Dr.Nabil El Lababidi,T-4,Induction ED,6227993954,"Feb 17, 2026","Oct 11, 2026",124 +213069,EMEA,CZE,CZ10010 - Dr.Nabil El Lababidi,T-4,Induction ED,6227993953,"Feb 17, 2026","Oct 11, 2026",124 +213069,EMEA,CZE,CZ10010 - Dr.Nabil El Lababidi,T-5,Biologic Drug Level,6227993955,"Feb 17, 2026","Dec 31, 2026",205 +213069,EMEA,CZE,CZ10010 - Dr.Nabil El Lababidi,T-5,Biologic Drug Level,6227993956,"Feb 17, 2026","Dec 31, 2026",205 +213069,EMEA,CZE,CZ10010 - Dr.Nabil El Lababidi,T-8,Liver Function Tests,6227993957,"Feb 17, 2026","Oct 11, 2026",124 +213069,EMEA,CZE,CZ10010 - Dr.Nabil El Lababidi,T-8,Liver Function Tests,6227993958,"Feb 17, 2026","Oct 11, 2026",124 +213069,EMEA,CZE,CZ10010 - Dr.Nabil El Lababidi,T-10,Safety FU,6227993943,"Feb 17, 2026","Oct 11, 2026",124 +213069,EMEA,CZE,CZ10010 - Dr.Nabil El Lababidi,T-10,Safety FU,6227993942,"Feb 17, 2026","Oct 11, 2026",124 +213069,EMEA,CZE,CZ10010 - Dr.Nabil El Lababidi,T-11,DILI,6227993944,"Feb 17, 2026","Sep 30, 2026",113 +213069,EMEA,CZE,CZ10010 - Dr.Nabil El Lababidi,T-12,DNA,6227993945,"Feb 17, 2026","Dec 31, 2026",205 +213069,EMEA,CZE,CZ10010 - Dr.Nabil El Lababidi,T-12,DNA,6227993946,"Feb 17, 2026","Dec 31, 2026",205 +213069,EMEA,CZE,CZ10010 - Dr.Nabil El Lababidi,T-12,DNA,6227993947,"Feb 17, 2026","Dec 31, 2026",205 +213069,EMEA,CZE,CZ10010 - Dr.Nabil El Lababidi,U,Unscheduled,6227993959,"Feb 17, 2026","Dec 31, 2026",205 +213069,EMEA,CZE,CZ10010 - Dr.Nabil El Lababidi,U,Unscheduled,6227993960,"Feb 17, 2026","Dec 31, 2026",205 +213069,EMEA,CZE,CZ10010 - Dr.Nabil El Lababidi,U,Unscheduled,6227993961,"Feb 17, 2026","Dec 31, 2026",205 +213069,EMEA,CZE,CZ10012 - Dr.Stefan Konecny,1,Screening,6227697716,"Jan 12, 2026","Aug 31, 2026",83 +213069,EMEA,CZE,CZ10012 - Dr.Stefan Konecny,1,Screening,6227697717,"Jan 12, 2026","Aug 31, 2026",83 +213069,EMEA,CZE,CZ10012 - Dr.Stefan Konecny,2,Induction Week 0,6227697720,"Jan 12, 2026","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10012 - Dr.Stefan Konecny,2,Induction Week 0,6228398468,"Apr 14, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10012 - Dr.Stefan Konecny,2,Induction Week 0,6228398470,"Apr 14, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10012 - Dr.Stefan Konecny,2,Induction Week 0,6228398469,"Apr 14, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10012 - Dr.Stefan Konecny,3,Induction Week 2,6227697721,"Jan 12, 2026","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10012 - Dr.Stefan Konecny,3,Induction Week 2,6228512528,"Apr 28, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10012 - Dr.Stefan Konecny,3,Induction Week 2,6228512526,"Apr 28, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10012 - Dr.Stefan Konecny,3,Induction Week 2,6228512527,"Apr 28, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10012 - Dr.Stefan Konecny,4,Induction Week 4,6227697724,"Jan 12, 2026","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10012 - Dr.Stefan Konecny,4,Induction Week 4,6228628517,"May 11, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10012 - Dr.Stefan Konecny,4,Induction Week 4,6228628515,"May 11, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10012 - Dr.Stefan Konecny,4,Induction Week 4,6228628516,"May 11, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10012 - Dr.Stefan Konecny,5,Induction Week 12,6228251912,"Mar 26, 2026","Jan 31, 2027",236 +213069,EMEA,CZE,CZ10012 - Dr.Stefan Konecny,6,Maintenance Week 4,6228628518,"May 11, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10012 - Dr.Stefan Konecny,T-1,Stool Pathogens,6227697726,"Jan 12, 2026","Jan 14, 2027",219 +213069,EMEA,CZE,CZ10012 - Dr.Stefan Konecny,T-1,Stool Pathogens,6227697727,"Jan 12, 2026","Jan 14, 2027",219 +213069,EMEA,CZE,CZ10012 - Dr.Stefan Konecny,T-2,TB Testing,6227697735,"Jan 12, 2026","Aug 31, 2026",83 +213069,EMEA,CZE,CZ10012 - Dr.Stefan Konecny,T-2,TB Testing,6227697734,"Jan 12, 2026","Aug 31, 2026",83 +213069,EMEA,CZE,CZ10012 - Dr.Stefan Konecny,T-3,Biopsy,6227697737,"Jan 12, 2026","May 11, 2027",336 +213069,EMEA,CZE,CZ10012 - Dr.Stefan Konecny,T-3,Biopsy,6227697738,"Jan 12, 2026","May 11, 2027",336 +213069,EMEA,CZE,CZ10012 - Dr.Stefan Konecny,T-4,Induction ED,6227697740,"Jan 12, 2026","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10012 - Dr.Stefan Konecny,T-4,Induction ED,6227697739,"Jan 12, 2026","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10012 - Dr.Stefan Konecny,T-5,Biologic Drug Level,6227697741,"Jan 12, 2026","Dec 31, 2026",205 +213069,EMEA,CZE,CZ10012 - Dr.Stefan Konecny,T-5,Biologic Drug Level,6227697742,"Jan 12, 2026","Dec 31, 2026",205 +213069,EMEA,CZE,CZ10012 - Dr.Stefan Konecny,T-6,Maintenance ED,6228251914,"Mar 26, 2026","Jan 31, 2027",236 +213069,EMEA,CZE,CZ10012 - Dr.Stefan Konecny,T-6,Maintenance ED,6228251913,"Mar 26, 2026","Jan 31, 2027",236 +213069,EMEA,CZE,CZ10012 - Dr.Stefan Konecny,T-6,Maintenance ED,6228251915,"Mar 26, 2026","Jan 31, 2027",236 +213069,EMEA,CZE,CZ10012 - Dr.Stefan Konecny,T-8,Liver Function Tests,6227697743,"Jan 12, 2026","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10012 - Dr.Stefan Konecny,T-8,Liver Function Tests,6227697744,"Jan 12, 2026","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10012 - Dr.Stefan Konecny,T-9,LTE Maintenance ED,6228251918,"Mar 26, 2026","Jan 31, 2027",236 +213069,EMEA,CZE,CZ10012 - Dr.Stefan Konecny,T-9,LTE Maintenance ED,6228251916,"Mar 26, 2026","Jan 31, 2027",236 +213069,EMEA,CZE,CZ10012 - Dr.Stefan Konecny,T-9,LTE Maintenance ED,6228251917,"Mar 26, 2026","Jan 31, 2027",236 +213069,EMEA,CZE,CZ10012 - Dr.Stefan Konecny,T-10,Safety FU,6227697728,"Jan 12, 2026","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10012 - Dr.Stefan Konecny,T-10,Safety FU,6227697729,"Jan 12, 2026","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10012 - Dr.Stefan Konecny,T-11,DILI,6227697730,"Jan 12, 2026","Jul 31, 2026",52 +213069,EMEA,CZE,CZ10012 - Dr.Stefan Konecny,T-12,DNA,6227697733,"Jan 12, 2026","Dec 31, 2026",205 +213069,EMEA,CZE,CZ10012 - Dr.Stefan Konecny,T-12,DNA,6227697732,"Jan 12, 2026","Dec 31, 2026",205 +213069,EMEA,CZE,CZ10012 - Dr.Stefan Konecny,U,Unscheduled,6227697747,"Jan 12, 2026","Oct 31, 2026",144 +213069,EMEA,CZE,CZ10012 - Dr.Stefan Konecny,U,Unscheduled,6227697746,"Jan 12, 2026","Oct 31, 2026",144 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,1,Screening,6228367755,"Apr 8, 2026","Nov 30, 2026",174 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,1,Screening,6228367756,"Apr 8, 2026","Nov 30, 2026",174 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,1,Screening,6228367757,"Apr 8, 2026","Nov 30, 2026",174 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,2,Induction Week 0,6227635143,"Jan 5, 2026","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,2,Induction Week 0,6228308226,"Apr 1, 2026","Jan 31, 2027",236 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,3,Induction Week 2,6227635145,"Jan 5, 2026","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,3,Induction Week 2,6228398114,"Apr 14, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,3,Induction Week 2,6228398116,"Apr 14, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,4,Induction Week 4,6227635147,"Jan 5, 2026","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,4,Induction Week 4,6228501725,"Apr 26, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,4,Induction Week 4,6228501727,"Apr 26, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,4,Induction Week 4,6228501726,"Apr 26, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,5,Induction Week 12,6228308227,"Apr 1, 2026","Jan 31, 2027",236 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,5,Induction Week 12,6228367758,"Apr 8, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,5,Induction Week 12,6228762734,"Jun 4, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,6,Maintenance Week 4,6228501728,"Apr 26, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,6,Maintenance Week 4,6228501729,"Apr 26, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,T-1,Stool Pathogens,6228367759,"Apr 8, 2026","Mar 5, 2027",269 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,T-1,Stool Pathogens,6228367760,"Apr 8, 2026","Mar 5, 2027",269 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,T-1,Stool Pathogens,6228367761,"Apr 8, 2026","Mar 5, 2027",269 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,T-2,TB Testing,6227635158,"Jan 5, 2026","Aug 31, 2026",83 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,T-2,TB Testing,6227635157,"Jan 5, 2026","Aug 31, 2026",83 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,T-3,Biopsy,6227635160,"Jan 5, 2026","Oct 15, 2026",128 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,T-3,Biopsy,6228501731,"Apr 26, 2026","Aug 7, 2027",424 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,T-4,Induction ED,6227635163,"Jan 5, 2026","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,T-4,Induction ED,6227635162,"Jan 5, 2026","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,T-5,Biologic Drug Level,6227635164,"Jan 5, 2026","Dec 31, 2026",205 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,T-5,Biologic Drug Level,6227635165,"Jan 5, 2026","Dec 31, 2026",205 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,T-6,Maintenance ED,6228095872,"Mar 5, 2026","Oct 11, 2026",124 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,T-6,Maintenance ED,6228095870,"Mar 5, 2026","Oct 11, 2026",124 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,T-6,Maintenance ED,6228095871,"Mar 5, 2026","Oct 11, 2026",124 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,T-8,Liver Function Tests,6227635167,"Jan 5, 2026","Sep 12, 2026",95 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,T-8,Liver Function Tests,6227635166,"Jan 5, 2026","Sep 12, 2026",95 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,T-9,LTE Maintenance ED,6228095874,"Mar 5, 2026","Oct 11, 2026",124 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,T-9,LTE Maintenance ED,6228095873,"Mar 5, 2026","Oct 11, 2026",124 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,T-9,LTE Maintenance ED,6228095875,"Mar 5, 2026","Oct 11, 2026",124 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,T-10,Safety FU,6227635151,"Jan 5, 2026","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,T-10,Safety FU,6227635152,"Jan 5, 2026","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,T-11,DILI,6227635153,"Jan 5, 2026","Jul 31, 2026",52 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,T-12,DNA,6228762735,"Jun 4, 2026","Mar 31, 2027",295 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,T-12,DNA,6228762736,"Jun 4, 2026","Mar 31, 2027",295 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,T-12,DNA,6228762737,"Jun 4, 2026","Mar 31, 2027",295 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,U,Unscheduled,6227635168,"Jan 5, 2026","Oct 31, 2026",144 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,U,Unscheduled,6227635169,"Jan 5, 2026","Oct 31, 2026",144 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,U,Unscheduled,6227635170,"Jan 5, 2026","Oct 31, 2026",144 +213069,EMEA,CZE,CZ10015 - Dr.Jan Matous,1,Screening,6227259263,"Nov 13, 2025","May 31, 2026",-8 +213069,EMEA,CZE,CZ10015 - Dr.Jan Matous,1,Screening,6227259264,"Nov 13, 2025","May 31, 2026",-8 +213069,EMEA,CZE,CZ10015 - Dr.Jan Matous,1,Screening,6227259265,"Nov 13, 2025","May 31, 2026",-8 +213069,EMEA,CZE,CZ10015 - Dr.Jan Matous,1,Screening,6228510217,"Apr 30, 2026","Nov 30, 2026",174 +213069,EMEA,CZE,CZ10015 - Dr.Jan Matous,1,Screening,6228510218,"Apr 30, 2026","Nov 30, 2026",174 +213069,EMEA,CZE,CZ10015 - Dr.Jan Matous,2,Induction Week 0,6227259267,"Nov 13, 2025","May 31, 2026",-8 +213069,EMEA,CZE,CZ10015 - Dr.Jan Matous,2,Induction Week 0,6227259266,"Nov 13, 2025","May 31, 2026",-8 +213069,EMEA,CZE,CZ10015 - Dr.Jan Matous,2,Induction Week 0,6228510219,"Apr 30, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10015 - Dr.Jan Matous,2,Induction Week 0,6228510220,"Apr 30, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10015 - Dr.Jan Matous,3,Induction Week 2,6227259268,"Nov 13, 2025","May 31, 2026",-8 +213069,EMEA,CZE,CZ10015 - Dr.Jan Matous,3,Induction Week 2,6227259269,"Nov 13, 2025","May 31, 2026",-8 +213069,EMEA,CZE,CZ10015 - Dr.Jan Matous,3,Induction Week 2,6228510221,"Apr 30, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10015 - Dr.Jan Matous,3,Induction Week 2,6228510222,"Apr 30, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10015 - Dr.Jan Matous,4,Induction Week 4,6227259270,"Nov 13, 2025","May 31, 2026",-8 +213069,EMEA,CZE,CZ10015 - Dr.Jan Matous,4,Induction Week 4,6227259271,"Nov 13, 2025","May 31, 2026",-8 +213069,EMEA,CZE,CZ10015 - Dr.Jan Matous,T-1,Stool Pathogens,6227259274,"Nov 13, 2025","Dec 26, 2026",200 +213069,EMEA,CZE,CZ10015 - Dr.Jan Matous,T-1,Stool Pathogens,6227259273,"Nov 13, 2025","Dec 26, 2026",200 +213069,EMEA,CZE,CZ10015 - Dr.Jan Matous,T-1,Stool Pathogens,6227259272,"Nov 13, 2025","Dec 26, 2026",200 +213069,EMEA,CZE,CZ10015 - Dr.Jan Matous,T-2,TB Testing,6227259281,"Nov 13, 2025","Jun 30, 2026",21 +213069,EMEA,CZE,CZ10015 - Dr.Jan Matous,T-2,TB Testing,6227259282,"Nov 13, 2025","Jun 30, 2026",21 +213069,EMEA,CZE,CZ10015 - Dr.Jan Matous,T-3,Biopsy,6227259283,"Nov 13, 2025","Sep 12, 2026",95 +213069,EMEA,CZE,CZ10015 - Dr.Jan Matous,T-3,Biopsy,6227259284,"Nov 13, 2025","Sep 12, 2026",95 +213069,EMEA,CZE,CZ10015 - Dr.Jan Matous,T-3,Biopsy,6227259285,"Nov 13, 2025","Sep 12, 2026",95 +213069,EMEA,CZE,CZ10015 - Dr.Jan Matous,T-4,Induction ED,6227259286,"Nov 13, 2025","May 31, 2026",-8 +213069,EMEA,CZE,CZ10015 - Dr.Jan Matous,T-4,Induction ED,6227259287,"Nov 13, 2025","May 31, 2026",-8 +213069,EMEA,CZE,CZ10015 - Dr.Jan Matous,T-5,Biologic Drug Level,6227259289,"Nov 13, 2025","Jun 30, 2026",21 +213069,EMEA,CZE,CZ10015 - Dr.Jan Matous,T-5,Biologic Drug Level,6227259288,"Nov 13, 2025","Jun 30, 2026",21 +213069,EMEA,CZE,CZ10015 - Dr.Jan Matous,T-8,Liver Function Tests,6227259290,"Nov 13, 2025","Jul 1, 2026",22 +213069,EMEA,CZE,CZ10015 - Dr.Jan Matous,T-8,Liver Function Tests,6227259291,"Nov 13, 2025","Jul 1, 2026",22 +213069,EMEA,CZE,CZ10015 - Dr.Jan Matous,T-10,Safety FU,6227259276,"Nov 13, 2025","May 31, 2026",-8 +213069,EMEA,CZE,CZ10015 - Dr.Jan Matous,T-10,Safety FU,6227259275,"Nov 13, 2025","May 31, 2026",-8 +213069,EMEA,CZE,CZ10015 - Dr.Jan Matous,T-11,DILI,6227259277,"Nov 13, 2025","May 31, 2026",-8 +213069,EMEA,CZE,CZ10015 - Dr.Jan Matous,T-12,DNA,6227259280,"Nov 13, 2025","Aug 31, 2026",83 +213069,EMEA,CZE,CZ10015 - Dr.Jan Matous,T-12,DNA,6227259278,"Nov 13, 2025","Aug 31, 2026",83 +213069,EMEA,CZE,CZ10015 - Dr.Jan Matous,U,Unscheduled,6227259294,"Nov 13, 2025","May 31, 2026",-8 +213069,EMEA,CZE,CZ10015 - Dr.Jan Matous,U,Unscheduled,6227259293,"Nov 13, 2025","May 31, 2026",-8 +213069,EMEA,CZE,CZ10015 - Dr.Jan Matous,U,Unscheduled,6227259292,"Nov 13, 2025","May 31, 2026",-8 +213069,EMEA,CZE,CZ10016 - Dr.Robert Mudr,1,Screening,6227635172,"Jan 5, 2026","Aug 31, 2026",83 +213069,EMEA,CZE,CZ10016 - Dr.Robert Mudr,1,Screening,6228772364,"Jun 5, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10016 - Dr.Robert Mudr,1,Screening,6228772365,"Jun 5, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10016 - Dr.Robert Mudr,1,Screening,6228772366,"Jun 5, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10016 - Dr.Robert Mudr,2,Induction Week 0,6227635175,"Jan 5, 2026","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10016 - Dr.Robert Mudr,2,Induction Week 0,6228782900,"Jun 5, 2026","Mar 31, 2027",295 +213069,EMEA,CZE,CZ10016 - Dr.Robert Mudr,2,Induction Week 0,6228782899,"Jun 5, 2026","Mar 31, 2027",295 +213069,EMEA,CZE,CZ10016 - Dr.Robert Mudr,2,Induction Week 0,6228782898,"Jun 5, 2026","Mar 31, 2027",295 +213069,EMEA,CZE,CZ10016 - Dr.Robert Mudr,3,Induction Week 2,6227635176,"Jan 5, 2026","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10016 - Dr.Robert Mudr,3,Induction Week 2,6227635177,"Jan 5, 2026","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10016 - Dr.Robert Mudr,4,Induction Week 4,6227635178,"Jan 5, 2026","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10016 - Dr.Robert Mudr,4,Induction Week 4,6227635179,"Jan 5, 2026","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10016 - Dr.Robert Mudr,5,Induction Week 12,6228501793,"Apr 26, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10016 - Dr.Robert Mudr,5,Induction Week 12,6228772367,"Jun 5, 2026","Mar 31, 2027",295 +213069,EMEA,CZE,CZ10016 - Dr.Robert Mudr,6,Maintenance Week 4,6228772368,"Jun 5, 2026","Mar 31, 2027",295 +213069,EMEA,CZE,CZ10016 - Dr.Robert Mudr,T-1,Stool Pathogens,6227635181,"Jan 5, 2026","Jan 14, 2027",219 +213069,EMEA,CZE,CZ10016 - Dr.Robert Mudr,T-1,Stool Pathogens,6228772369,"Jun 5, 2026","Aug 10, 2027",427 +213069,EMEA,CZE,CZ10016 - Dr.Robert Mudr,T-1,Stool Pathogens,6228772370,"Jun 5, 2026","Aug 10, 2027",427 +213069,EMEA,CZE,CZ10016 - Dr.Robert Mudr,T-1,Stool Pathogens,6228772371,"Jun 5, 2026","Aug 10, 2027",427 +213069,EMEA,CZE,CZ10016 - Dr.Robert Mudr,T-2,TB Testing,6227635189,"Jan 5, 2026","Aug 31, 2026",83 +213069,EMEA,CZE,CZ10016 - Dr.Robert Mudr,T-2,TB Testing,6227635190,"Jan 5, 2026","Aug 31, 2026",83 +213069,EMEA,CZE,CZ10016 - Dr.Robert Mudr,T-3,Biopsy,6227635191,"Jan 5, 2026","Oct 15, 2026",128 +213069,EMEA,CZE,CZ10016 - Dr.Robert Mudr,T-3,Biopsy,6227635192,"Jan 5, 2026","Oct 15, 2026",128 +213069,EMEA,CZE,CZ10016 - Dr.Robert Mudr,T-4,Induction ED,6227635195,"Jan 5, 2026","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10016 - Dr.Robert Mudr,T-4,Induction ED,6227635194,"Jan 5, 2026","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10016 - Dr.Robert Mudr,T-5,Biologic Drug Level,6227635197,"Jan 5, 2026","Dec 31, 2026",205 +213069,EMEA,CZE,CZ10016 - Dr.Robert Mudr,T-5,Biologic Drug Level,6227635196,"Jan 5, 2026","Dec 31, 2026",205 +213069,EMEA,CZE,CZ10016 - Dr.Robert Mudr,T-6,Maintenance ED,6228501795,"Apr 26, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10016 - Dr.Robert Mudr,T-6,Maintenance ED,6228501794,"Apr 26, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10016 - Dr.Robert Mudr,T-6,Maintenance ED,6228501796,"Apr 26, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10016 - Dr.Robert Mudr,T-8,Liver Function Tests,6227635198,"Jan 5, 2026","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10016 - Dr.Robert Mudr,T-8,Liver Function Tests,6227635199,"Jan 5, 2026","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10016 - Dr.Robert Mudr,T-9,LTE Maintenance ED,6228501797,"Apr 26, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10016 - Dr.Robert Mudr,T-9,LTE Maintenance ED,6228501798,"Apr 26, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10016 - Dr.Robert Mudr,T-9,LTE Maintenance ED,6228501799,"Apr 26, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10016 - Dr.Robert Mudr,T-10,Safety FU,6227635183,"Jan 5, 2026","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10016 - Dr.Robert Mudr,T-10,Safety FU,6227635184,"Jan 5, 2026","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10016 - Dr.Robert Mudr,T-11,DILI,6227635185,"Jan 5, 2026","Jul 31, 2026",52 +213069,EMEA,CZE,CZ10016 - Dr.Robert Mudr,T-12,DNA,6227635188,"Jan 5, 2026","Dec 31, 2026",205 +213069,EMEA,CZE,CZ10016 - Dr.Robert Mudr,T-12,DNA,6227635187,"Jan 5, 2026","Dec 31, 2026",205 +213069,EMEA,CZE,CZ10016 - Dr.Robert Mudr,U,Unscheduled,6227635200,"Jan 5, 2026","Oct 31, 2026",144 +213069,EMEA,CZE,CZ10016 - Dr.Robert Mudr,U,Unscheduled,6227635202,"Jan 5, 2026","Oct 31, 2026",144 +213069,EMEA,CZE,CZ10016 - Dr.Robert Mudr,U,Unscheduled,6227635201,"Jan 5, 2026","Oct 31, 2026",144 +213069,EMEA,CZE,CZ10020 - Dr.Lucie Gonsorcikova,1,Screening,6227993964,"Feb 18, 2026","Sep 30, 2026",113 +213069,EMEA,CZE,CZ10020 - Dr.Lucie Gonsorcikova,1,Screening,6227993963,"Feb 18, 2026","Sep 30, 2026",113 +213069,EMEA,CZE,CZ10020 - Dr.Lucie Gonsorcikova,2,Induction Week 0,6227993965,"Feb 18, 2026","Oct 11, 2026",124 +213069,EMEA,CZE,CZ10020 - Dr.Lucie Gonsorcikova,2,Induction Week 0,6228707090,"May 22, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10020 - Dr.Lucie Gonsorcikova,2,Induction Week 0,6228707091,"May 22, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10020 - Dr.Lucie Gonsorcikova,2,Induction Week 0,6228707092,"May 22, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10020 - Dr.Lucie Gonsorcikova,2,Induction Week 0,6228711855,"May 29, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10020 - Dr.Lucie Gonsorcikova,3,Induction Week 2,6227993967,"Feb 18, 2026","Oct 11, 2026",124 +213069,EMEA,CZE,CZ10020 - Dr.Lucie Gonsorcikova,4,Induction Week 4,6227993969,"Feb 18, 2026","Oct 11, 2026",124 +213069,EMEA,CZE,CZ10020 - Dr.Lucie Gonsorcikova,4,Induction Week 4,6227993970,"Feb 18, 2026","Oct 11, 2026",124 +213069,EMEA,CZE,CZ10020 - Dr.Lucie Gonsorcikova,5,Induction Week 12,6228436352,"Apr 19, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10020 - Dr.Lucie Gonsorcikova,T-1,Stool Pathogens,6227993973,"Feb 18, 2026","Jan 15, 2027",220 +213069,EMEA,CZE,CZ10020 - Dr.Lucie Gonsorcikova,T-1,Stool Pathogens,6227993972,"Feb 18, 2026","Jan 15, 2027",220 +213069,EMEA,CZE,CZ10020 - Dr.Lucie Gonsorcikova,T-2,TB Testing,6227993980,"Feb 18, 2026","Oct 31, 2026",144 +213069,EMEA,CZE,CZ10020 - Dr.Lucie Gonsorcikova,T-2,TB Testing,6227993981,"Feb 18, 2026","Oct 31, 2026",144 +213069,EMEA,CZE,CZ10020 - Dr.Lucie Gonsorcikova,T-3,Biopsy,6227993983,"Feb 18, 2026","May 11, 2027",336 +213069,EMEA,CZE,CZ10020 - Dr.Lucie Gonsorcikova,T-3,Biopsy,6227993982,"Feb 18, 2026","May 11, 2027",336 +213069,EMEA,CZE,CZ10020 - Dr.Lucie Gonsorcikova,T-4,Induction ED,6227993985,"Feb 18, 2026","Oct 11, 2026",124 +213069,EMEA,CZE,CZ10020 - Dr.Lucie Gonsorcikova,T-4,Induction ED,6227993986,"Feb 18, 2026","Oct 11, 2026",124 +213069,EMEA,CZE,CZ10020 - Dr.Lucie Gonsorcikova,T-5,Biologic Drug Level,6227993988,"Feb 18, 2026","Dec 31, 2026",205 +213069,EMEA,CZE,CZ10020 - Dr.Lucie Gonsorcikova,T-5,Biologic Drug Level,6228711856,"May 29, 2026","May 31, 2027",356 +213069,EMEA,CZE,CZ10020 - Dr.Lucie Gonsorcikova,T-6,Maintenance ED,6228436354,"Apr 19, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10020 - Dr.Lucie Gonsorcikova,T-6,Maintenance ED,6228436353,"Apr 19, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10020 - Dr.Lucie Gonsorcikova,T-6,Maintenance ED,6228436355,"Apr 19, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10020 - Dr.Lucie Gonsorcikova,T-8,Liver Function Tests,6227993989,"Feb 18, 2026","Oct 11, 2026",124 +213069,EMEA,CZE,CZ10020 - Dr.Lucie Gonsorcikova,T-8,Liver Function Tests,6227993990,"Feb 18, 2026","Oct 11, 2026",124 +213069,EMEA,CZE,CZ10020 - Dr.Lucie Gonsorcikova,T-9,LTE Maintenance ED,6228436356,"Apr 19, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10020 - Dr.Lucie Gonsorcikova,T-9,LTE Maintenance ED,6228436357,"Apr 19, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10020 - Dr.Lucie Gonsorcikova,T-9,LTE Maintenance ED,6228436358,"Apr 19, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10020 - Dr.Lucie Gonsorcikova,T-10,Safety FU,6227993974,"Feb 18, 2026","Oct 11, 2026",124 +213069,EMEA,CZE,CZ10020 - Dr.Lucie Gonsorcikova,T-10,Safety FU,6227993975,"Feb 18, 2026","Oct 11, 2026",124 +213069,EMEA,CZE,CZ10020 - Dr.Lucie Gonsorcikova,T-11,DILI,6227993976,"Feb 18, 2026","Sep 30, 2026",113 +213069,EMEA,CZE,CZ10020 - Dr.Lucie Gonsorcikova,T-12,DNA,6227993978,"Feb 18, 2026","Dec 31, 2026",205 +213069,EMEA,CZE,CZ10020 - Dr.Lucie Gonsorcikova,T-12,DNA,6227993979,"Feb 18, 2026","Dec 31, 2026",205 +213069,EMEA,CZE,CZ10020 - Dr.Lucie Gonsorcikova,U,Unscheduled,6227993991,"Feb 18, 2026","Dec 31, 2026",205 +213069,EMEA,CZE,CZ10020 - Dr.Lucie Gonsorcikova,U,Unscheduled,6227993992,"Feb 18, 2026","Dec 31, 2026",205 +213069,EMEA,CZE,CZ10020 - Dr.Lucie Gonsorcikova,U,Unscheduled,6227993993,"Feb 18, 2026","Dec 31, 2026",205 +213069,EMEA,CZE,CZ10021 - Dr.Martin Bortlik,1,Screening,6227635205,"Jan 5, 2026","Aug 31, 2026",83 +213069,EMEA,CZE,CZ10021 - Dr.Martin Bortlik,1,Screening,6227635203,"Jan 5, 2026","Aug 31, 2026",83 +213069,EMEA,CZE,CZ10021 - Dr.Martin Bortlik,2,Induction Week 0,6227635206,"Jan 5, 2026","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10021 - Dr.Martin Bortlik,2,Induction Week 0,6228398426,"Apr 14, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10021 - Dr.Martin Bortlik,2,Induction Week 0,6228398427,"Apr 14, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10021 - Dr.Martin Bortlik,2,Induction Week 0,6228398428,"Apr 14, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10021 - Dr.Martin Bortlik,3,Induction Week 2,6227635209,"Jan 5, 2026","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10021 - Dr.Martin Bortlik,3,Induction Week 2,6228492827,"Apr 23, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10021 - Dr.Martin Bortlik,3,Induction Week 2,6228492828,"Apr 23, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10021 - Dr.Martin Bortlik,3,Induction Week 2,6228492826,"Apr 23, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10021 - Dr.Martin Bortlik,4,Induction Week 4,6227635210,"Jan 5, 2026","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10021 - Dr.Martin Bortlik,4,Induction Week 4,6228605821,"May 7, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10021 - Dr.Martin Bortlik,4,Induction Week 4,6228605823,"May 7, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10021 - Dr.Martin Bortlik,4,Induction Week 4,6228605822,"May 7, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10021 - Dr.Martin Bortlik,5,Induction Week 12,6228084840,"Mar 4, 2026","Oct 11, 2026",124 +213069,EMEA,CZE,CZ10021 - Dr.Martin Bortlik,6,Maintenance Week 4,6228605824,"May 7, 2026","Feb 28, 2027",264 +213069,EMEA,CZE,CZ10021 - Dr.Martin Bortlik,T-1,Stool Pathogens,6227635214,"Jan 5, 2026","Jan 14, 2027",219 +213069,EMEA,CZE,CZ10021 - Dr.Martin Bortlik,T-1,Stool Pathogens,6227635212,"Jan 5, 2026","Jan 14, 2027",219 +213069,EMEA,CZE,CZ10021 - Dr.Martin Bortlik,T-2,TB Testing,6227635221,"Jan 5, 2026","Aug 31, 2026",83 +213069,EMEA,CZE,CZ10021 - Dr.Martin Bortlik,T-2,TB Testing,6227635222,"Jan 5, 2026","Aug 31, 2026",83 +213069,EMEA,CZE,CZ10021 - Dr.Martin Bortlik,T-3,Biopsy,6227635224,"Jan 5, 2026","Nov 25, 2026",169 +213069,EMEA,CZE,CZ10021 - Dr.Martin Bortlik,T-3,Biopsy,6227635225,"Jan 5, 2026","Nov 25, 2026",169 +213069,EMEA,CZE,CZ10021 - Dr.Martin Bortlik,T-4,Induction ED,6227635226,"Jan 5, 2026","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10021 - Dr.Martin Bortlik,T-4,Induction ED,6227635227,"Jan 5, 2026","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10021 - Dr.Martin Bortlik,T-5,Biologic Drug Level,6227635228,"Jan 5, 2026","Dec 31, 2026",205 +213069,EMEA,CZE,CZ10021 - Dr.Martin Bortlik,T-5,Biologic Drug Level,6227635229,"Jan 5, 2026","Dec 31, 2026",205 +213069,EMEA,CZE,CZ10021 - Dr.Martin Bortlik,T-6,Maintenance ED,6228084843,"Mar 4, 2026","Oct 11, 2026",124 +213069,EMEA,CZE,CZ10021 - Dr.Martin Bortlik,T-6,Maintenance ED,6228084842,"Mar 4, 2026","Oct 11, 2026",124 +213069,EMEA,CZE,CZ10021 - Dr.Martin Bortlik,T-6,Maintenance ED,6228084841,"Mar 4, 2026","Oct 11, 2026",124 +213069,EMEA,CZE,CZ10021 - Dr.Martin Bortlik,T-8,Liver Function Tests,6227635230,"Jan 5, 2026","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10021 - Dr.Martin Bortlik,T-8,Liver Function Tests,6227635231,"Jan 5, 2026","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10021 - Dr.Martin Bortlik,T-9,LTE Maintenance ED,6228084845,"Mar 4, 2026","Oct 11, 2026",124 +213069,EMEA,CZE,CZ10021 - Dr.Martin Bortlik,T-9,LTE Maintenance ED,6228084844,"Mar 4, 2026","Oct 11, 2026",124 +213069,EMEA,CZE,CZ10021 - Dr.Martin Bortlik,T-9,LTE Maintenance ED,6228084846,"Mar 4, 2026","Oct 11, 2026",124 +213069,EMEA,CZE,CZ10021 - Dr.Martin Bortlik,T-10,Safety FU,6227635215,"Jan 5, 2026","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10021 - Dr.Martin Bortlik,T-10,Safety FU,6227635216,"Jan 5, 2026","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10021 - Dr.Martin Bortlik,T-11,DILI,6227635217,"Jan 5, 2026","Jul 31, 2026",52 +213069,EMEA,CZE,CZ10021 - Dr.Martin Bortlik,T-12,DNA,6227635219,"Jan 5, 2026","Dec 31, 2026",205 +213069,EMEA,CZE,CZ10021 - Dr.Martin Bortlik,T-12,DNA,6227635220,"Jan 5, 2026","Dec 31, 2026",205 +213069,EMEA,CZE,CZ10021 - Dr.Martin Bortlik,U,Unscheduled,6227635234,"Jan 5, 2026","Oct 31, 2026",144 +213069,EMEA,CZE,CZ10021 - Dr.Martin Bortlik,U,Unscheduled,6227635233,"Jan 5, 2026","Oct 31, 2026",144 +213069,EMEA,CZE,CZ10021 - Dr.Martin Bortlik,U,Unscheduled,6227635232,"Jan 5, 2026","Oct 31, 2026",144 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,1,Screening,6227323267,"Nov 21, 2025","Jun 30, 2026",21 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,1,Screening,6228137352,"Mar 11, 2026","Oct 11, 2026",124 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,1,Screening,6228137353,"Mar 11, 2026","Oct 11, 2026",124 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,1,Screening,6228137354,"Mar 11, 2026","Oct 11, 2026",124 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,1,Screening,6228179928,"Mar 23, 2026","Oct 11, 2026",124 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,1,Screening,6228179930,"Mar 23, 2026","Oct 11, 2026",124 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,1,Screening,6228179929,"Mar 23, 2026","Oct 11, 2026",124 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,2,Induction Week 0,6227323269,"Nov 21, 2025","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,2,Induction Week 0,6228173395,"Mar 18, 2026","Oct 11, 2026",124 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,2,Induction Week 0,6228173396,"Mar 18, 2026","Oct 11, 2026",124 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,3,Induction Week 2,6227323271,"Nov 21, 2025","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,3,Induction Week 2,6228179931,"Mar 23, 2026","Oct 11, 2026",124 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,3,Induction Week 2,6228179933,"Mar 23, 2026","Oct 11, 2026",124 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,4,Induction Week 4,6227323273,"Nov 21, 2025","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,4,Induction Week 4,6228179934,"Mar 23, 2026","Oct 11, 2026",124 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,4,Induction Week 4,6228179935,"Mar 23, 2026","Oct 11, 2026",124 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,5,Induction Week 12,6227752380,"Jan 20, 2026","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,5,Induction Week 12,6227810902,"Jan 28, 2026","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,5,Induction Week 12,6228137356,"Mar 11, 2026","Oct 11, 2026",124 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,6,Maintenance Week 4,6228023948,"Feb 25, 2026","Oct 11, 2026",124 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,6,Maintenance Week 4,6228023949,"Feb 25, 2026","Oct 11, 2026",124 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,12,LTE Maintenance Wk56,6228179938,"Mar 23, 2026","Oct 11, 2026",124 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,12,LTE Maintenance Wk56,6228179937,"Mar 23, 2026","Oct 11, 2026",124 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,T-1,Stool Pathogens,6227323275,"Nov 21, 2025","Dec 26, 2026",200 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,T-1,Stool Pathogens,6227810903,"Jan 28, 2026","Jan 15, 2027",220 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,T-1,Stool Pathogens,6228179939,"Mar 23, 2026","Jan 29, 2027",234 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,T-1,Stool Pathogens,6228179940,"Mar 23, 2026","Jan 29, 2027",234 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,T-2,TB Testing,6227323284,"Nov 21, 2025","Jun 30, 2026",21 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,T-2,TB Testing,6227323285,"Nov 21, 2025","Jun 30, 2026",21 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,T-3,Biopsy,6227323288,"Nov 21, 2025","Sep 12, 2026",95 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,T-3,Biopsy,6228023950,"Feb 25, 2026","Nov 28, 2026",172 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,T-3,Biopsy,6228023952,"Feb 25, 2026","May 11, 2027",336 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,T-3,Biopsy,6228179946,"Mar 23, 2026","Jul 20, 2027",406 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,T-3,Biopsy,6228179944,"Mar 23, 2026","Jul 20, 2027",406 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,T-4,Induction ED,6227323289,"Nov 21, 2025","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,T-4,Induction ED,6227323290,"Nov 21, 2025","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,T-5,Biologic Drug Level,6227323291,"Nov 21, 2025","Jun 30, 2026",21 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,T-5,Biologic Drug Level,6227323292,"Nov 21, 2025","Jun 30, 2026",21 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,T-6,Maintenance ED,6227752381,"Jan 20, 2026","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,T-6,Maintenance ED,6227752383,"Jan 20, 2026","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,T-6,Maintenance ED,6227752382,"Jan 20, 2026","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,T-8,Liver Function Tests,6227323293,"Nov 21, 2025","Jul 1, 2026",22 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,T-8,Liver Function Tests,6227323294,"Nov 21, 2025","Jul 1, 2026",22 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,T-9,LTE Maintenance ED,6227752385,"Jan 20, 2026","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,T-9,LTE Maintenance ED,6227752386,"Jan 20, 2026","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,T-9,LTE Maintenance ED,6227752384,"Jan 20, 2026","Oct 7, 2026",120 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,T-10,Safety FU,6227323279,"Nov 21, 2025","May 31, 2026",-8 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,T-10,Safety FU,6227323278,"Nov 21, 2025","May 31, 2026",-8 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,T-11,DILI,6227323280,"Nov 21, 2025","May 31, 2026",-8 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,T-12,DNA,6227323281,"Nov 21, 2025","Jul 31, 2026",52 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,T-12,DNA,6227323282,"Nov 21, 2025","Jul 31, 2026",52 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,T-12,DNA,6228179941,"Mar 23, 2026","Mar 31, 2027",295 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,T-12,DNA,6228179943,"Mar 23, 2026","Mar 31, 2027",295 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,U,Unscheduled,6227323296,"Nov 21, 2025","Aug 31, 2026",83 +title,value,,,,,,,, +Search,,,,,,,,, +Site,"CZ10015 Dr.Jan Matous, CZ10013 Dr.David Stepek, CZ10001 Dr. Matej Falc, CZ10010 Dr.Nabil El Lababidi, CZ10022 Dr. Petr Hrabak, CZ10020 Dr.Lucie Gonsorcikova, CZ10012 Dr.Stefan Konecny, CZ10006 Dr. Michal Konecny, CZ10021 Dr.Martin Bortlik, CZ10016 Dr.Robert Mudr, CZ10003 Dr. Leksa Vaclav, CZ10009 Dr. Jiri Pumprla",,,,,,,, +Expiration Date Range,From - To - ,,,,,,,, +Shipped Date Range,From - To - ,,,,,,,, +Kit Type,,,,,,,,, +Ignore Record Limit,TRUE,,,,,,,, diff --git a/Covance_UCO3001/Source/Zpracovano/2026-06-08_130010 sponsor-study-35472-kit-inventory-on-hand-expiration.csv b/Covance_UCO3001/Source/Zpracovano/2026-06-08_130010 sponsor-study-35472-kit-inventory-on-hand-expiration.csv new file mode 100644 index 0000000..e3a3081 --- /dev/null +++ b/Covance_UCO3001/Source/Zpracovano/2026-06-08_130010 sponsor-study-35472-kit-inventory-on-hand-expiration.csv @@ -0,0 +1,282 @@ +Project No.,Region,Country,Site,Kit Type,Description,Accession,Shipped Date,Expiration Date,Days to Expiration +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,1,Part 1 Screening,6225350973,"Feb 24, 2025","Dec 1, 2025",-189 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,1,Part 1 Screening,6225350970,"Feb 24, 2025","Dec 1, 2025",-189 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,1,Part 1 Screening,6225350974,"Feb 24, 2025","Dec 1, 2025",-189 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,1,Part 1 Screening,6225350976,"Feb 24, 2025","Dec 1, 2025",-189 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,1,Part 1 Screening,6225350978,"Feb 24, 2025","Dec 1, 2025",-189 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,1,Part 1 Screening,6225350979,"Feb 24, 2025","Dec 1, 2025",-189 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,1,Part 1 Screening,6227541248,"Dec 25, 2025","Oct 7, 2026",120 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,1,Part 1 Screening,6227541247,"Dec 25, 2025","Oct 7, 2026",120 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,1,Part 1 Screening,6228149461,"Mar 13, 2026","Oct 11, 2026",124 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,1,Part 1 Screening,6228149462,"Mar 13, 2026","Oct 11, 2026",124 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,1,Part 1 Screening,6228149463,"Mar 13, 2026","Oct 11, 2026",124 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,2,Part 1 DB Baseline,6225350980,"Feb 24, 2025","Dec 1, 2025",-189 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,2,Part 1 DB Baseline,6225350983,"Feb 24, 2025","Dec 1, 2025",-189 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,2,Part 1 DB Baseline,6227261232,"Nov 18, 2025","May 31, 2026",-8 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,2,Part 1 DB Baseline,6227261231,"Nov 18, 2025","May 31, 2026",-8 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,2,Part 1 DB Baseline,6227541250,"Dec 25, 2025","Oct 7, 2026",120 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,2,Part 1 DB Baseline,6227541253,"Dec 25, 2025","Oct 7, 2026",120 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,3,Part 2 Screening,6225350985,"Feb 24, 2025","Dec 1, 2025",-189 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,3,Part 2 Screening,6225350986,"Feb 24, 2025","Dec 1, 2025",-189 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,3,Part 2 Screening,6225350987,"Feb 24, 2025","Dec 1, 2025",-189 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,3,Part 2 Screening,6227547334,"Dec 31, 2025","Oct 7, 2026",120 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,3,Part 2 Screening,6227547335,"Dec 31, 2025","Oct 7, 2026",120 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,4,Part 2 OL Induction Baseline,6225350989,"Feb 24, 2025","Dec 1, 2025",-189 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,4,Part 2 OL Induction Baseline,6227541255,"Dec 25, 2025","Oct 7, 2026",120 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,4,Part 2 OL Induction Baseline,6227541254,"Dec 25, 2025","Oct 7, 2026",120 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,4,Part 2 OL Induction Baseline,6227547339,"Dec 31, 2025","Oct 7, 2026",120 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,5,Part 2 OL Induction Day 29,6227261233,"Nov 18, 2025","May 31, 2026",-8 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,5,Part 2 OL Induction Day 29,6227541263,"Dec 25, 2025","Oct 7, 2026",120 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,5,Part 2 OL Induction Day 29,6227541262,"Dec 25, 2025","Oct 7, 2026",120 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,6,Part 2 DB Baseline,6226573503,"Aug 21, 2025","Jul 1, 2026",22 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,6,Part 2 DB Baseline,6226889398,"Oct 7, 2025","May 31, 2026",-8 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,6,Part 2 DB Baseline,6227043303,"Oct 23, 2025","Jul 31, 2026",52 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,6,Part 2 DB Baseline,6227261234,"Nov 18, 2025","May 31, 2026",-8 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,6,Part 2 DB Baseline,6228149464,"Mar 13, 2026","Oct 11, 2026",124 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,6,Part 2 DB Baseline,6228149465,"Mar 13, 2026","Oct 11, 2026",124 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,7,Part 2 DB Week 13,6226889399,"Oct 7, 2025","May 31, 2026",-8 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,7,Part 2 DB Week 13,6227541265,"Dec 25, 2025","Oct 7, 2026",120 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,7,Part 2 DB Week 13,6227541267,"Dec 25, 2025","Oct 7, 2026",120 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,7,Part 2 DB Week 13,6227541268,"Dec 25, 2025","Oct 7, 2026",120 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,7,Part 2 DB Week 13,6227541266,"Dec 25, 2025","Oct 7, 2026",120 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,T-1,Part 2 DB Every 12 Weeks,6226573504,"Aug 21, 2025","Jul 1, 2026",22 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,T-1,Part 2 DB Every 12 Weeks,6226573505,"Aug 21, 2025","Jul 1, 2026",22 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,T-1,Part 2 DB Every 12 Weeks,6226573507,"Aug 21, 2025","Jul 1, 2026",22 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,T-1,Part 2 DB Every 12 Weeks,6226573506,"Aug 21, 2025","Jul 1, 2026",22 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,T-1,Part 2 DB Every 12 Weeks,6226573508,"Aug 21, 2025","Jul 1, 2026",22 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,T-1,Part 2 DB Every 12 Weeks,6227541269,"Dec 25, 2025","Oct 7, 2026",120 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,T-1,Part 2 DB Every 12 Weeks,6227541270,"Dec 25, 2025","Oct 7, 2026",120 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,T-1,Part 2 DB Every 12 Weeks,6227541272,"Dec 25, 2025","Oct 7, 2026",120 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,T-1,Part 2 DB Every 12 Weeks,6227541271,"Dec 25, 2025","Oct 7, 2026",120 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,T-2,End of Phase/Treatment,6225350990,"Feb 24, 2025","Dec 1, 2025",-189 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,T-2,End of Phase/Treatment,6225350991,"Feb 24, 2025","Dec 1, 2025",-189 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,T-2,End of Phase/Treatment,6225350992,"Feb 24, 2025","Dec 1, 2025",-189 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,T-2,End of Phase/Treatment,6225350993,"Feb 24, 2025","Dec 1, 2025",-189 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,T-2,End of Phase/Treatment,6225350994,"Feb 24, 2025","Dec 1, 2025",-189 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,T-2,End of Phase/Treatment,6227768461,"Jan 27, 2026","Oct 7, 2026",120 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,T-2,End of Phase/Treatment,6228605654,"May 7, 2026","Feb 28, 2027",264 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,T-2,End of Phase/Treatment,6228605655,"May 7, 2026","Feb 28, 2027",264 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,T-3,Early Withdrawal,6225350996,"Feb 24, 2025","Dec 1, 2025",-189 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,T-3,Early Withdrawal,6225350995,"Feb 24, 2025","Dec 1, 2025",-189 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,T-3,Early Withdrawal,6225350997,"Feb 24, 2025","Dec 1, 2025",-189 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,T-3,Early Withdrawal,6225350998,"Feb 24, 2025","Dec 1, 2025",-189 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,T-3,Early Withdrawal,6225350999,"Feb 24, 2025","Dec 1, 2025",-189 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,T-3,Early Withdrawal,6227768462,"Jan 27, 2026","Oct 7, 2026",120 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,T-3,Early Withdrawal,6227768463,"Jan 27, 2026","Oct 7, 2026",120 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,T-3,Early Withdrawal,6227768464,"Jan 27, 2026","Oct 7, 2026",120 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,T-3,Early Withdrawal,6227768465,"Jan 27, 2026","Oct 7, 2026",120 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,T-4,Liver Monitoring,6225351000,"Feb 24, 2025","Sep 1, 2025",-280 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,T-4,Liver Monitoring,6227547340,"Dec 31, 2025","Sep 12, 2026",95 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,T-4,Liver Monitoring,6227768466,"Jan 27, 2026","Oct 7, 2026",120 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,T-5,Suspected Liver Event FU,6225351001,"Feb 24, 2025","Jul 31, 2025",-312 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,T-5,Suspected Liver Event FU,6227547341,"Dec 31, 2025","Jul 31, 2026",52 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,T-5,Suspected Liver Event FU,6227768467,"Jan 27, 2026","Jul 31, 2026",52 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,U,Retest,6225351003,"Feb 24, 2025","Dec 1, 2025",-189 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,U,Retest,6226649755,"Aug 29, 2025","May 31, 2026",-8 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,U,Retest,6226649756,"Aug 29, 2025","May 31, 2026",-8 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,U,Retest,6227178914,"Nov 14, 2025","Aug 31, 2026",83 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,U,Retest,6227178913,"Nov 14, 2025","Aug 31, 2026",83 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,U,Retest,6227178915,"Nov 14, 2025","Aug 31, 2026",83 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,U,Retest,6227178916,"Nov 14, 2025","Aug 31, 2026",83 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,U,Retest,6227178917,"Nov 14, 2025","Aug 31, 2026",83 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,U,Retest,6227178919,"Nov 14, 2025","Aug 31, 2026",83 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,U,Retest,6227178918,"Nov 14, 2025","Aug 31, 2026",83 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,1,Part 1 Screening,6225351038,"Feb 24, 2025","Dec 1, 2025",-189 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,1,Part 1 Screening,6225351039,"Feb 24, 2025","Dec 1, 2025",-189 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,1,Part 1 Screening,6225351043,"Feb 24, 2025","Dec 1, 2025",-189 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,1,Part 1 Screening,6227520226,"Dec 26, 2025","Aug 31, 2026",83 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,1,Part 1 Screening,6227520225,"Dec 26, 2025","Aug 31, 2026",83 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,1,Part 1 Screening,6227520227,"Dec 26, 2025","Aug 31, 2026",83 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,2,Part 1 DB Baseline,6225351048,"Feb 24, 2025","Dec 1, 2025",-189 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,2,Part 1 DB Baseline,6226551696,"Aug 22, 2025","Apr 17, 2026",-52 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,2,Part 1 DB Baseline,6226551699,"Aug 22, 2025","Apr 17, 2026",-52 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,2,Part 1 DB Baseline,6226551700,"Aug 22, 2025","Apr 17, 2026",-52 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,2,Part 1 DB Baseline,6226655163,"Sep 5, 2025","May 31, 2026",-8 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,2,Part 1 DB Baseline,6226655166,"Sep 5, 2025","May 31, 2026",-8 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,2,Part 1 DB Baseline,6226655165,"Sep 5, 2025","May 31, 2026",-8 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,2,Part 1 DB Baseline,6226655162,"Sep 5, 2025","May 31, 2026",-8 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,2,Part 1 DB Baseline,6226655164,"Sep 5, 2025","May 31, 2026",-8 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,3,Part 2 Screening,6225351053,"Feb 24, 2025","Dec 1, 2025",-189 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,3,Part 2 Screening,6225351054,"Feb 24, 2025","Dec 1, 2025",-189 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,3,Part 2 Screening,6225351055,"Feb 24, 2025","Dec 1, 2025",-189 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,3,Part 2 Screening,6227520230,"Dec 26, 2025","Aug 31, 2026",83 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,3,Part 2 Screening,6227520228,"Dec 26, 2025","Aug 31, 2026",83 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,3,Part 2 Screening,6227520229,"Dec 26, 2025","Aug 31, 2026",83 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,4,Part 2 OL Induction Baseline,6226780849,"Sep 24, 2025","May 31, 2026",-8 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,4,Part 2 OL Induction Baseline,6226780851,"Sep 24, 2025","May 31, 2026",-8 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,4,Part 2 OL Induction Baseline,6226780848,"Sep 24, 2025","May 31, 2026",-8 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,4,Part 2 OL Induction Baseline,6226780852,"Sep 24, 2025","May 31, 2026",-8 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,4,Part 2 OL Induction Baseline,6226780850,"Sep 24, 2025","May 31, 2026",-8 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,4,Part 2 OL Induction Baseline,6227520231,"Dec 26, 2025","Aug 31, 2026",83 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,4,Part 2 OL Induction Baseline,6227520233,"Dec 26, 2025","Aug 31, 2026",83 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,4,Part 2 OL Induction Baseline,6227520232,"Dec 26, 2025","Aug 31, 2026",83 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,5,Part 2 OL Induction Day 29,6226550654,"Aug 21, 2025","Jul 1, 2026",22 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,5,Part 2 OL Induction Day 29,6226561520,"Aug 21, 2025","Jul 1, 2026",22 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,5,Part 2 OL Induction Day 29,6227072416,"Oct 20, 2025","Jul 31, 2026",52 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,5,Part 2 OL Induction Day 29,6227072415,"Oct 20, 2025","Jul 31, 2026",52 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,5,Part 2 OL Induction Day 29,6227072418,"Oct 20, 2025","Jul 31, 2026",52 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,5,Part 2 OL Induction Day 29,6227072417,"Oct 20, 2025","Jul 31, 2026",52 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,6,Part 2 DB Baseline,6226313626,"Jul 14, 2025","Apr 17, 2026",-52 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,6,Part 2 DB Baseline,6226550655,"Aug 21, 2025","Jul 1, 2026",22 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,6,Part 2 DB Baseline,6226561521,"Aug 21, 2025","Jul 1, 2026",22 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,6,Part 2 DB Baseline,6227520234,"Dec 26, 2025","Aug 31, 2026",83 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,6,Part 2 DB Baseline,6227520235,"Dec 26, 2025","Aug 31, 2026",83 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,6,Part 2 DB Baseline,6227520236,"Dec 26, 2025","Aug 31, 2026",83 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,7,Part 2 DB Week 13,6226313627,"Jul 14, 2025","Apr 17, 2026",-52 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,7,Part 2 DB Week 13,6226550656,"Aug 21, 2025","Jul 1, 2026",22 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,7,Part 2 DB Week 13,6226561522,"Aug 21, 2025","Jul 1, 2026",22 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,7,Part 2 DB Week 13,6226804963,"Sep 25, 2025","May 31, 2026",-8 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,T-1,Part 2 DB Every 12 Weeks,6226313628,"Jul 14, 2025","Apr 17, 2026",-52 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,T-1,Part 2 DB Every 12 Weeks,6226313629,"Jul 14, 2025","Apr 17, 2026",-52 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,T-1,Part 2 DB Every 12 Weeks,6226313630,"Jul 14, 2025","Apr 17, 2026",-52 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,T-1,Part 2 DB Every 12 Weeks,6226313631,"Jul 14, 2025","Apr 17, 2026",-52 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,T-1,Part 2 DB Every 12 Weeks,6226313632,"Jul 14, 2025","Apr 17, 2026",-52 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,T-1,Part 2 DB Every 12 Weeks,6227520237,"Dec 26, 2025","Aug 31, 2026",83 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,T-1,Part 2 DB Every 12 Weeks,6227520239,"Dec 26, 2025","Aug 31, 2026",83 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,T-1,Part 2 DB Every 12 Weeks,6227520240,"Dec 26, 2025","Aug 31, 2026",83 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,T-1,Part 2 DB Every 12 Weeks,6227520241,"Dec 26, 2025","Aug 31, 2026",83 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,T-1,Part 2 DB Every 12 Weeks,6227520238,"Dec 26, 2025","Aug 31, 2026",83 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,T-2,End of Phase/Treatment,6225351058,"Feb 24, 2025","Dec 1, 2025",-189 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,T-2,End of Phase/Treatment,6225351059,"Feb 24, 2025","Dec 1, 2025",-189 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,T-2,End of Phase/Treatment,6225351061,"Feb 24, 2025","Dec 1, 2025",-189 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,T-2,End of Phase/Treatment,6225351062,"Feb 24, 2025","Dec 1, 2025",-189 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,T-2,End of Phase/Treatment,6225351060,"Feb 24, 2025","Dec 1, 2025",-189 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,T-2,End of Phase/Treatment,6226780854,"Sep 24, 2025","May 31, 2026",-8 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,T-2,End of Phase/Treatment,6227520244,"Dec 26, 2025","Aug 31, 2026",83 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,T-2,End of Phase/Treatment,6227520246,"Dec 26, 2025","Aug 31, 2026",83 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,T-3,Early Withdrawal,6225351065,"Feb 24, 2025","Dec 1, 2025",-189 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,T-3,Early Withdrawal,6225351067,"Feb 24, 2025","Dec 1, 2025",-189 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,T-3,Early Withdrawal,6225351064,"Feb 24, 2025","Dec 1, 2025",-189 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,T-3,Early Withdrawal,6225351063,"Feb 24, 2025","Dec 1, 2025",-189 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,T-3,Early Withdrawal,6227520248,"Dec 26, 2025","Aug 31, 2026",83 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,T-3,Early Withdrawal,6227520250,"Dec 26, 2025","Aug 31, 2026",83 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,T-3,Early Withdrawal,6227520247,"Dec 26, 2025","Aug 31, 2026",83 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,T-3,Early Withdrawal,6227520249,"Dec 26, 2025","Aug 31, 2026",83 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,T-3,Early Withdrawal,6227520251,"Dec 26, 2025","Aug 31, 2026",83 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,T-4,Liver Monitoring,6225351068,"Feb 24, 2025","Sep 1, 2025",-280 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,T-5,Suspected Liver Event FU,6225351069,"Feb 24, 2025","Jul 31, 2025",-312 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,U,Retest,6225351071,"Feb 24, 2025","Dec 1, 2025",-189 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,U,Retest,6228023802,"Feb 25, 2026","Oct 11, 2026",124 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,U,Retest,6228023803,"Feb 25, 2026","Oct 11, 2026",124 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,1,Part 1 Screening,6225351073,"Feb 24, 2025","Dec 1, 2025",-189 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,1,Part 1 Screening,6225351075,"Feb 24, 2025","Dec 1, 2025",-189 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,1,Part 1 Screening,6225351079,"Feb 24, 2025","Dec 1, 2025",-189 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,1,Part 1 Screening,6227542163,"Dec 25, 2025","Oct 7, 2026",120 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,1,Part 1 Screening,6227542162,"Dec 25, 2025","Oct 7, 2026",120 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,1,Part 1 Screening,6228149810,"Mar 13, 2026","Oct 11, 2026",124 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,1,Part 1 Screening,6228149812,"Mar 13, 2026","Oct 11, 2026",124 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,1,Part 1 Screening,6228149811,"Mar 13, 2026","Oct 11, 2026",124 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,2,Part 1 DB Baseline,6225351085,"Feb 24, 2025","Dec 1, 2025",-189 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,2,Part 1 DB Baseline,6225351086,"Feb 24, 2025","Dec 1, 2025",-189 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,2,Part 1 DB Baseline,6227542165,"Dec 25, 2025","Oct 7, 2026",120 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,2,Part 1 DB Baseline,6227542164,"Dec 25, 2025","Oct 7, 2026",120 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,2,Part 1 DB Baseline,6227844727,"Feb 1, 2026","Oct 11, 2026",124 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,2,Part 1 DB Baseline,6227844726,"Feb 1, 2026","Oct 11, 2026",124 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,3,Part 2 Screening,6225351087,"Feb 24, 2025","Dec 1, 2025",-189 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,3,Part 2 Screening,6225351088,"Feb 24, 2025","Dec 1, 2025",-189 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,3,Part 2 Screening,6225351089,"Feb 24, 2025","Dec 1, 2025",-189 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,3,Part 2 Screening,6227542167,"Dec 25, 2025","Oct 7, 2026",120 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,3,Part 2 Screening,6227542168,"Dec 25, 2025","Oct 7, 2026",120 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,3,Part 2 Screening,6227542169,"Dec 25, 2025","Oct 7, 2026",120 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,3,Part 2 Screening,6227542166,"Dec 25, 2025","Oct 7, 2026",120 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,4,Part 2 OL Induction Baseline,6225351091,"Feb 24, 2025","Dec 1, 2025",-189 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,4,Part 2 OL Induction Baseline,6225351090,"Feb 24, 2025","Dec 1, 2025",-189 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,5,Part 2 OL Induction Day 29,6226935605,"Oct 14, 2025","May 31, 2026",-8 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,5,Part 2 OL Induction Day 29,6228013045,"Feb 26, 2026","Oct 11, 2026",124 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,6,Part 2 DB Baseline,6226550647,"Aug 18, 2025","Jul 1, 2026",22 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,6,Part 2 DB Baseline,6226561518,"Aug 21, 2025","Jul 1, 2026",22 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,6,Part 2 DB Baseline,6226991312,"Oct 26, 2025","May 31, 2026",-8 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,6,Part 2 DB Baseline,6228013046,"Feb 26, 2026","Oct 11, 2026",124 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,6,Part 2 DB Baseline,6228114461,"Mar 11, 2026","Oct 11, 2026",124 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,6,Part 2 DB Baseline,6228398393,"Apr 15, 2026","Feb 28, 2027",264 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,7,Part 2 DB Week 13,6226550648,"Aug 18, 2025","Jul 1, 2026",22 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,7,Part 2 DB Week 13,6226561519,"Aug 21, 2025","Jul 1, 2026",22 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,7,Part 2 DB Week 13,6226991313,"Oct 26, 2025","May 31, 2026",-8 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,7,Part 2 DB Week 13,6227261837,"Nov 20, 2025","Oct 7, 2026",120 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,7,Part 2 DB Week 13,6227261838,"Nov 20, 2025","Oct 7, 2026",120 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,7,Part 2 DB Week 13,6228114462,"Mar 11, 2026","Oct 11, 2026",124 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,T-1,Part 2 DB Every 12 Weeks,6226550649,"Aug 18, 2025","Jul 1, 2026",22 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,T-1,Part 2 DB Every 12 Weeks,6226550650,"Aug 18, 2025","Jul 1, 2026",22 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,T-1,Part 2 DB Every 12 Weeks,6226550652,"Aug 18, 2025","Jul 1, 2026",22 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,T-1,Part 2 DB Every 12 Weeks,6226550651,"Aug 18, 2025","Jul 1, 2026",22 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,T-1,Part 2 DB Every 12 Weeks,6226550653,"Aug 18, 2025","Jul 1, 2026",22 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,T-2,End of Phase/Treatment,6225351092,"Feb 24, 2025","Dec 1, 2025",-189 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,T-2,End of Phase/Treatment,6225351096,"Feb 24, 2025","Dec 1, 2025",-189 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,T-2,End of Phase/Treatment,6227498378,"Dec 22, 2025","Aug 31, 2026",83 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,T-2,End of Phase/Treatment,6228232036,"Mar 25, 2026","Jan 3, 2027",208 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,T-2,End of Phase/Treatment,6228232038,"Mar 25, 2026","Jan 3, 2027",208 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,T-2,End of Phase/Treatment,6228234299,"Mar 30, 2026","Jan 3, 2027",208 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,T-3,Early Withdrawal,6225351097,"Feb 24, 2025","Dec 1, 2025",-189 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,T-3,Early Withdrawal,6225351099,"Feb 24, 2025","Dec 1, 2025",-189 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,T-3,Early Withdrawal,6225351101,"Feb 24, 2025","Dec 1, 2025",-189 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,T-3,Early Withdrawal,6225351100,"Feb 24, 2025","Dec 1, 2025",-189 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,T-3,Early Withdrawal,6225351098,"Feb 24, 2025","Dec 1, 2025",-189 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,T-3,Early Withdrawal,6227542174,"Dec 25, 2025","Oct 7, 2026",120 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,T-3,Early Withdrawal,6227542176,"Dec 25, 2025","Oct 7, 2026",120 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,T-3,Early Withdrawal,6227542175,"Dec 25, 2025","Oct 7, 2026",120 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,T-3,Early Withdrawal,6227542177,"Dec 25, 2025","Oct 7, 2026",120 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,T-4,Liver Monitoring,6225351102,"Feb 24, 2025","Sep 1, 2025",-280 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,T-4,Liver Monitoring,6227542179,"Dec 25, 2025","Sep 12, 2026",95 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,T-4,Liver Monitoring,6227542178,"Dec 25, 2025","Sep 12, 2026",95 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,T-5,Suspected Liver Event FU,6225351103,"Feb 24, 2025","Jul 31, 2025",-312 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,T-5,Suspected Liver Event FU,6227542180,"Dec 25, 2025","Jun 30, 2026",21 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,T-5,Suspected Liver Event FU,6227542181,"Dec 25, 2025","Jun 30, 2026",21 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,U,Retest,6225351104,"Feb 24, 2025","Dec 1, 2025",-189 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,U,Retest,6225351105,"Feb 24, 2025","Dec 1, 2025",-189 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,U,Retest,6227542183,"Dec 25, 2025","Oct 7, 2026",120 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,U,Retest,6228417882,"Apr 15, 2026","Feb 28, 2027",264 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,U,Retest,6228417883,"Apr 15, 2026","Feb 28, 2027",264 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,1,Part 1 Screening,6225351107,"Feb 24, 2025","Dec 1, 2025",-189 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,1,Part 1 Screening,6225351108,"Feb 24, 2025","Dec 1, 2025",-189 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,1,Part 1 Screening,6225351112,"Feb 24, 2025","Dec 1, 2025",-189 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,1,Part 1 Screening,6225351113,"Feb 24, 2025","Dec 1, 2025",-189 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,1,Part 1 Screening,6225351114,"Feb 24, 2025","Dec 1, 2025",-189 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,1,Part 1 Screening,6225351115,"Feb 24, 2025","Dec 1, 2025",-189 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,1,Part 1 Screening,6227767268,"Jan 27, 2026","Oct 7, 2026",120 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,1,Part 1 Screening,6227775503,"Jan 23, 2026","Oct 7, 2026",120 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,1,Part 1 Screening,6227775504,"Jan 23, 2026","Oct 7, 2026",120 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,2,Part 1 DB Baseline,6225351117,"Feb 24, 2025","Dec 1, 2025",-189 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,2,Part 1 DB Baseline,6225351116,"Feb 24, 2025","Dec 1, 2025",-189 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,2,Part 1 DB Baseline,6225351118,"Feb 24, 2025","Dec 1, 2025",-189 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,2,Part 1 DB Baseline,6225351119,"Feb 24, 2025","Dec 1, 2025",-189 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,2,Part 1 DB Baseline,6227767269,"Jan 27, 2026","Oct 7, 2026",120 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,2,Part 1 DB Baseline,6227767270,"Jan 27, 2026","Oct 7, 2026",120 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,2,Part 1 DB Baseline,6227775506,"Jan 23, 2026","Oct 7, 2026",120 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,3,Part 2 Screening,6225351123,"Feb 24, 2025","Dec 1, 2025",-189 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,3,Part 2 Screening,6225351122,"Feb 24, 2025","Dec 1, 2025",-189 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,3,Part 2 Screening,6225351121,"Feb 24, 2025","Dec 1, 2025",-189 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,3,Part 2 Screening,6228742569,"May 25, 2026","Feb 28, 2027",264 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,3,Part 2 Screening,6228742568,"May 25, 2026","Feb 28, 2027",264 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,4,Part 2 OL Induction Baseline,6225351124,"Feb 24, 2025","Dec 1, 2025",-189 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,4,Part 2 OL Induction Baseline,6225351125,"Feb 24, 2025","Dec 1, 2025",-189 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,6,Part 2 DB Baseline,6226976944,"Oct 26, 2025","May 31, 2026",-8 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,6,Part 2 DB Baseline,6228521304,"Apr 30, 2026","Feb 28, 2027",264 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,7,Part 2 DB Week 13,6226560889,"Aug 20, 2025","Jul 1, 2026",22 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,7,Part 2 DB Week 13,6226752556,"Sep 17, 2025","May 31, 2026",-8 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,7,Part 2 DB Week 13,6226976945,"Oct 26, 2025","May 31, 2026",-8 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,T-1,Part 2 DB Every 12 Weeks,6226560890,"Aug 20, 2025","Jul 1, 2026",22 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,T-1,Part 2 DB Every 12 Weeks,6226560892,"Aug 20, 2025","Jul 1, 2026",22 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,T-1,Part 2 DB Every 12 Weeks,6226560894,"Aug 20, 2025","Jul 1, 2026",22 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,T-1,Part 2 DB Every 12 Weeks,6226560893,"Aug 20, 2025","Jul 1, 2026",22 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,T-1,Part 2 DB Every 12 Weeks,6228389162,"Apr 15, 2026","Feb 28, 2027",264 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,T-1,Part 2 DB Every 12 Weeks,6228389161,"Apr 15, 2026","Feb 28, 2027",264 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,T-2,End of Phase/Treatment,6225351129,"Feb 24, 2025","Dec 1, 2025",-189 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,T-2,End of Phase/Treatment,6225351128,"Feb 24, 2025","Dec 1, 2025",-189 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,T-2,End of Phase/Treatment,6225351130,"Feb 24, 2025","Dec 1, 2025",-189 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,T-2,End of Phase/Treatment,6225351127,"Feb 24, 2025","Dec 1, 2025",-189 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,T-3,Early Withdrawal,6225351131,"Feb 24, 2025","Dec 1, 2025",-189 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,T-3,Early Withdrawal,6225351132,"Feb 24, 2025","Dec 1, 2025",-189 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,T-3,Early Withdrawal,6225351133,"Feb 24, 2025","Dec 1, 2025",-189 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,T-3,Early Withdrawal,6225351134,"Feb 24, 2025","Dec 1, 2025",-189 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,T-3,Early Withdrawal,6225351135,"Feb 24, 2025","Dec 1, 2025",-189 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,T-4,Liver Monitoring,6225351136,"Feb 24, 2025","Sep 1, 2025",-280 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,T-5,Suspected Liver Event FU,6225351137,"Feb 24, 2025","Jul 31, 2025",-312 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,U,Retest,6225351139,"Feb 24, 2025","Dec 1, 2025",-189 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,U,Retest,6225351138,"Feb 24, 2025","Dec 1, 2025",-189 +title,value,,,,,,,, +Search,,,,,,,,, +Site,"CZ10004 Dr. Erik Herman, CZ10012 Dr.Ales Urban, CZ10011 Dr. Marta Lendlova, CZ10008 Dr.Zdenek Solle",,,,,,,, +Expiration Date Range,From - To - ,,,,,,,, +Shipped Date Range,From - To - ,,,,,,,, +Kit Type,,,,,,,,, +Ignore Record Limit,TRUE,,,,,,,, diff --git a/Covance_UCO3001/Source/Zpracovano/2026-06-08_130117 sponsor-study-36940-samples-allSamples.csv b/Covance_UCO3001/Source/Zpracovano/2026-06-08_130117 sponsor-study-36940-samples-allSamples.csv new file mode 100644 index 0000000..6deebb8 --- /dev/null +++ b/Covance_UCO3001/Source/Zpracovano/2026-06-08_130117 sponsor-study-36940-samples-allSamples.csv @@ -0,0 +1,1541 @@ +Protocol Code,Investigator No.,Investigator Name,Patient No.,Collection Date,Protocol Visit Code,Kit Receipt Date,Container Receipt Date,Accession,Container No.,Container Barcode No.,Specimen Type,Sample Status,Expected Receipt Condition,Actual Receipt Condition,Container Label Line 1,Container Label Line 2,SM Sample Status,SMART Specimen Class Description,Aliquot Created Date,Aliquoted Date,Collection Time,Container Receipt Time,Country,Courier,Kit Receipt Time,Parent Barcode Number,Parent Sample Type,Project,Region,Screening No.,Shipped To Organization Name,Site Waybill No.,Site - Scheduled Shipment Date,Site - Shipment Created Date,Site - Shipment Details Entered Date,SMART Specimen Class,Visit Description,Parent Barcode,Children Barcode +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Jan-2026,SCRN,23-Jan-2026,24-Jan-2026,6227323203,1,622732320301,Whole Blood QuantiFERON Nil,Received,,Default Discard/Not Return,QUANTIFERON PLUS,NIL-GRAY,,,,,08:00,12:40,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Jan-2026,SCRN,23-Jan-2026,24-Jan-2026,6227323203,2,622732320302,"Plasma, QuantiFERON Nil",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,NIL-GRAY FRZ,,,,,08:00,12:40,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Jan-2026,SCRN,23-Jan-2026,24-Jan-2026,6227323203,3,622732320303,Whole Blood QuantiFERON TB1,Received,,Default Discard/Not Return,QUANTIFERON PLUS,TB1-GREEN,,,,,08:00,12:40,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Jan-2026,SCRN,23-Jan-2026,24-Jan-2026,6227323203,7,622732320307,Whole Blood QuantiFERON Mitoge,Received,,Default Discard/Not Return,QUANTIFERON PLUS,MITOGEN-PURPLE,,,,,08:00,12:40,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Jan-2026,SCRN,23-Jan-2026,24-Jan-2026,6227323203,8,622732320308,"Plasma, QuantiFERON Mitoge",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,MITOGEN-PURPLE FRZ,,,,,08:00,12:40,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Jan-2026,SCRN,23-Jan-2026,24-Jan-2026,6227323203,5,622732320305,Whole Blood QuantiFERON TB2,Received,,Default Discard/Not Return,QUANTIFERON PLUS,TB2-YELLOW,,,,,08:00,12:40,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Jan-2026,SCRN,23-Jan-2026,24-Jan-2026,6227323203,6,622732320306,"Plasma, QuantiFERON TB2",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB2-YELLOW FRZ,,,,,08:00,12:40,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Jan-2026,SCRN,23-Jan-2026,23-Jan-2026,6227323203,11,622732320311,"Red Cells, Clot",Received,,Default Discard/Not Return,"HIV SCREEN,",HEPATITIS B & C,,,,,08:00,07:10,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Jan-2026,SCRN,23-Jan-2026,24-Jan-2026,6227323203,4,622732320304,"Plasma, QuantiFERON TB1",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB1-GREEN FRZ,,,,,08:00,12:40,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Jan-2026,SCRN,23-Jan-2026,23-Jan-2026,6227323203,14,622732320314,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,BETA HCG,,,,,08:00,07:10,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Jan-2026,SCRN,23-Jan-2026,23-Jan-2026,6227323203,12,622732320312,"Serum, SST",Received,Ambient,Default Return Ambient,"HIV SCREEN,",HEPATITIS B & C,,,,,08:00,07:10,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Jan-2026,SCRN,23-Jan-2026,23-Jan-2026,6227323203,15,622732320315,"Serum, SST",Received,Ambient,Default Return Ambient,FSH,,,,,,08:00,07:10,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,02-Mar-2026,SCRN,03-Mar-2026,04-Mar-2026,6227323204,1,622732320401,Whole Blood QuantiFERON Nil,Received,,Default Discard/Not Return,QUANTIFERON PLUS,NIL-GRAY,,,,,07:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Jan-2026,SCRN,23-Jan-2026,23-Jan-2026,6227323203,9,622732320309,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,08:00,07:10,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,02-Mar-2026,SCRN,03-Mar-2026,04-Mar-2026,6227323204,3,622732320403,Whole Blood QuantiFERON TB1,Received,,Default Discard/Not Return,QUANTIFERON PLUS,TB1-GREEN,,,,,07:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,02-Mar-2026,SCRN,03-Mar-2026,04-Mar-2026,6227323204,4,622732320404,"Plasma, QuantiFERON TB1",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB1-GREEN FRZ,,,,,07:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,02-Mar-2026,SCRN,03-Mar-2026,04-Mar-2026,6227323204,2,622732320402,"Plasma, QuantiFERON Nil",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,NIL-GRAY FRZ,,,,,07:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,02-Mar-2026,SCRN,03-Mar-2026,04-Mar-2026,6227323204,6,622732320406,"Plasma, QuantiFERON TB2",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB2-YELLOW FRZ,,,,,07:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,02-Mar-2026,SCRN,03-Mar-2026,04-Mar-2026,6227323204,7,622732320407,Whole Blood QuantiFERON Mitoge,Received,,Default Discard/Not Return,QUANTIFERON PLUS,MITOGEN-PURPLE,,,,,07:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,02-Mar-2026,SCRN,03-Mar-2026,04-Mar-2026,6227323204,5,622732320405,Whole Blood QuantiFERON TB2,Received,,Default Discard/Not Return,QUANTIFERON PLUS,TB2-YELLOW,,,,,07:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Jan-2026,SCRN,23-Jan-2026,,6227323203,10,622732320310,"Slides, Hematology",Not Received,Ambient,,HEMATOLOGY,,,,,,08:00,,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Jan-2026,SCRN,23-Jan-2026,23-Jan-2026,6227323203,13,622732320313,"Red Cells, Clot",Received,,Default Discard/Not Return,"CHEM PANEL, BETA",HCG & FSH,,,,,08:00,07:10,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,02-Mar-2026,SCRN,03-Mar-2026,03-Mar-2026,6227323204,9,622732320409,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,07:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,02-Mar-2026,SCRN,03-Mar-2026,03-Mar-2026,6227323204,10,622732320410,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,07:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,02-Mar-2026,SCRN,03-Mar-2026,03-Mar-2026,6227323204,11,622732320411,"Red Cells, Clot",Received,,Default Discard/Not Return,"HIV SCREEN,",HEPATITIS B & C,,,,,07:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,02-Mar-2026,SCRN,03-Mar-2026,03-Mar-2026,6227323204,13,622732320413,"Red Cells, Clot",Received,,Default Discard/Not Return,"CHEM PANEL, BETA",HCG & FSH,,,,,07:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,02-Mar-2026,SCRN,03-Mar-2026,03-Mar-2026,6227323204,14,622732320414,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,BETA HCG,,,,,07:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,02-Mar-2026,SCRN,03-Mar-2026,03-Mar-2026,6227323204,15,622732320415,"Serum, SST",Received,Ambient,Default Return Ambient,FSH,,,,,,07:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,02-Mar-2026,SCRN,03-Mar-2026,04-Mar-2026,6227323204,8,622732320408,"Plasma, QuantiFERON Mitoge",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,MITOGEN-PURPLE FRZ,,,,,07:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,19-Feb-2026,I-0,20-Feb-2026,20-Feb-2026,6227323205,1,622732320501,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,07:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,02-Mar-2026,SCRN,03-Mar-2026,03-Mar-2026,6227323204,12,622732320412,"Serum, SST",Received,Ambient,Default Return Ambient,"HIV SCREEN,",HEPATITIS B & C,,,,,07:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,19-Feb-2026,I-0,20-Feb-2026,20-Feb-2026,6227323205,2,622732320502,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,07:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,19-Feb-2026,I-0,20-Feb-2026,20-Feb-2026,6227323205,4,622732320504,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMPK I-0 TROUGH,77242113UCO3001,,,,,07:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,19-Feb-2026,I-0,20-Feb-2026,20-Feb-2026,6227323205,7,622732320507,"Red Cells, Clot",Received,,Default Discard/Not Return,SM04/SERUM ADA PRE,,,,,,07:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,19-Feb-2026,I-0,20-Feb-2026,20-Feb-2026,6227323205,3,622732320503,"Whole Blood, EDTA, Dry",Received,,Default Discard/Not Return,PLASMA PK TROUGH,,,,,,07:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,19-Feb-2026,I-0,20-Feb-2026,20-Feb-2026,6227323205,6,622732320506,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMA PK I-0 PEAK,77242113UCO3001,,,,,07:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,19-Feb-2026,I-0,20-Feb-2026,20-Feb-2026,6227323205,10,622732320510,"Stool, unpreserved",In Inventory,Frozen,Default Return Frozen,SM10/FECAL,BIOMARKERS,,,,,07:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,19-Feb-2026,I-0,20-Feb-2026,20-Feb-2026,6227323205,9,622732320509,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-0 PRE,77242113UCO3001-2,,,,,07:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,19-Feb-2026,I-0,20-Feb-2026,20-Feb-2026,6227323205,8,622732320508,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-0 PRE,77242113UCO3001-1,,,,,07:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,19-Feb-2026,I-0,20-Feb-2026,20-Feb-2026,6227323205,5,622732320505,"Whole Blood, EDTA, Dry",Received,,Default Discard/Not Return,SM02/PLASMAPK PEAK,,,,,,07:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,19-Feb-2026,I-0,20-Feb-2026,20-Feb-2026,6227323205,11,622732320511,Whole Blood PAXgene RNA,Shipped,Frozen,Default Return Frozen,SM07/WB RNA,77242113UCO3001,,,,,07:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,19-Feb-2026,I-0,20-Feb-2026,20-Feb-2026,6227323205,13,622732320513,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-1,,,,,07:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,19-Feb-2026,I-0,20-Feb-2026,20-Feb-2026,6227323205,14,622732320514,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-2,,,,,07:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,19-Feb-2026,I-0,20-Feb-2026,20-Feb-2026,6227323205,15,622732320515,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-3,,,,,07:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,19-Feb-2026,I-0,20-Feb-2026,20-Feb-2026,6227323205,16,622732320516,"Feces, unpreserved",Received,Frozen,Default Return Frozen,FECAL CALPROTECTIN,FROZEN,,,,,07:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,19-Feb-2026,I-0,20-Feb-2026,20-Feb-2026,6227323205,18,622732320518,"Serum, SST",Received,Ambient,Default Return Ambient,"CHEM, LIPID PANEL",& CRP,,,,,07:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,23-Apr-2026,,6227323206,1,622732320601,"Whole Blood, EDTA, Dry",Canceled,Ambient,,HEMATOLOGY,,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,19-Feb-2026,I-0,20-Feb-2026,20-Feb-2026,6227323205,17,622732320517,"Red Cells, Clot",Received,,Default Discard/Not Return,"CHEM, LIPID PANEL",& CRP,,,,,07:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,19-Feb-2026,I-0,20-Feb-2026,20-Feb-2026,6227323205,12,622732320512,"Red Cells, Clot",Received,,Default Discard/Not Return,SM06/SERUM,BIOMARKERS,,,,,07:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,23-Apr-2026,,6227323206,4,622732320604,"Plasma, EDTA",Not Received,Frozen,Specimen not submitted,PLASMPK I-0 TROUGH,77242113UCO3001,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,23-Apr-2026,,6227323206,7,622732320607,"Red Cells, Clot",Not Received,,,SM04/SERUM ADA PRE,,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,23-Apr-2026,,6227323206,8,622732320608,"Serum, SST",Not Received,Frozen,Specimen not submitted,SERUM ADA I-0 PRE,77242113UCO3001-1,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,23-Apr-2026,,6227323206,9,622732320609,"Serum, SST",Not Received,Frozen,Specimen not submitted,SERUM ADA I-0 PRE,77242113UCO3001-2,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,23-Apr-2026,,6227323206,10,622732320610,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,SM10/FECAL,BIOMARKERS,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,23-Apr-2026,,6227323206,11,622732320611,Whole Blood PAXgene RNA,Not Received,Frozen,Specimen not submitted,SM07/WB RNA,77242113UCO3001,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,23-Apr-2026,,6227323206,12,622732320612,"Red Cells, Clot",Not Received,,,SM06/SERUM,BIOMARKERS,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,23-Apr-2026,,6227323206,2,622732320602,"Slides, Hematology",Not Received,Ambient,,HEMATOLOGY,,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,23-Apr-2026,,6227323206,6,622732320606,"Plasma, EDTA",Not Received,Frozen,Specimen not submitted,PLASMA PK I-0 PEAK,77242113UCO3001,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,23-Apr-2026,,6227323206,3,622732320603,"Whole Blood, EDTA, Dry",Not Received,,,PLASMA PK TROUGH,,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,23-Apr-2026,,6227323206,5,622732320605,"Whole Blood, EDTA, Dry",Not Received,,,SM02/PLASMAPK PEAK,,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,23-Apr-2026,23-Apr-2026,6227323206,17,622732320617,"Red Cells, Clot",Received,,Default Discard/Not Return,"CHEM, LIPID PANEL",& CRP,,,,,,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,23-Apr-2026,,6227323206,14,622732320614,"Serum, SST",Not Received,Frozen,Specimen not submitted,SM06/SERUM BIOM,77242113UCO3001-2,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,23-Apr-2026,23-Apr-2026,6227323206,18,622732320618,"Serum, SST",Received,Ambient,Default Return Ambient,"CHEM, LIPID PANEL",& CRP,,,,,,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,23-Apr-2026,I-2,24-Apr-2026,24-Apr-2026,6227323207,2,622732320702,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMPK I-2 TROUGH,77242113UCO3001,,,,,07:40,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,23-Apr-2026,,6227323206,16,622732320616,"Feces, unpreserved",Not Received,Frozen,Specimen not submitted,FECAL CALPROTECTIN,FROZEN,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,23-Apr-2026,I-2,24-Apr-2026,,6227323207,3,622732320703,"Whole Blood, EDTA, Dry",Not Received,,,SM02/PLASMAPK PEAK,,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,23-Apr-2026,I-2,24-Apr-2026,24-Apr-2026,6227323207,1,622732320701,"Whole Blood, EDTA, Dry",Received,,Default Discard/Not Return,PLASMA PK TROUGH,,,,,,07:40,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,23-Apr-2026,,6227323206,15,622732320615,"Serum, SST",Not Received,Frozen,Specimen not submitted,SM06/SERUM BIOM,77242113UCO3001-3,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,23-Apr-2026,,6227323206,13,622732320613,"Serum, SST",Not Received,Frozen,Specimen not submitted,SM06/SERUM BIOM,77242113UCO3001-1,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,23-Apr-2026,I-2,24-Apr-2026,,6227323207,4,622732320704,"Plasma, EDTA",Not Received,Frozen,Specimen not submitted,PLASMA PK I-2 PEAK,77242113UCO3001,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,23-Apr-2026,I-2,24-Apr-2026,24-Apr-2026,6227323207,5,622732320705,"Red Cells, Clot",Received,,Default Discard/Not Return,SM04/SERUM ADA PRE,,,,,,07:40,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,23-Apr-2026,I-2,24-Apr-2026,24-Apr-2026,6227323207,6,622732320706,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-2 PRE,77242113UCO3001-1,,,,,07:40,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,23-Apr-2026,I-2,24-Apr-2026,24-Apr-2026,6227323207,7,622732320707,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-2 PRE,77242113UCO3001-2,,,,,07:40,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,23-Apr-2026,I-2,24-Apr-2026,24-Apr-2026,6227323207,8,622732320708,"Stool, unpreserved",Shipped,Frozen,Default Return Frozen,STOOL I-2,77242113UCO3001-1,,,,,07:40,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,23-Apr-2026,I-2,24-Apr-2026,,6227323207,9,622732320709,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-2,77242113UCO3001-2,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,23-Apr-2026,I-2,24-Apr-2026,,6227323207,10,622732320710,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-2,77242113UCO3001-3,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,23-Apr-2026,I-2,24-Apr-2026,,6227323207,11,622732320711,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-2,77242113UCO3001-4,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,23-Apr-2026,I-2,24-Apr-2026,,6227323207,12,622732320712,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-2,77242113UCO3001-5,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,23-Apr-2026,I-2,24-Apr-2026,24-Apr-2026,6227323207,13,622732320713,"Feces, unpreserved",Received,Frozen,Default Return Frozen,FECAL CALPROTECTIN,FROZEN,,,,,07:40,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,23-Apr-2026,I-2,24-Apr-2026,24-Apr-2026,6227323207,14,622732320714,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,07:40,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,23-Apr-2026,I-2,24-Apr-2026,24-Apr-2026,6227323207,16,622732320716,"Red Cells, Clot",Received,,Default Discard/Not Return,CHEM PANEL &,CRP,,,,,07:40,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,23-Apr-2026,I-2,24-Apr-2026,24-Apr-2026,6227323207,17,622732320717,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,CRP,,,,,07:40,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,04-Mar-2026,I-2,05-Mar-2026,05-Mar-2026,6227323208,1,622732320801,"Whole Blood, EDTA, Dry",Received,,Default Discard/Not Return,PLASMA PK TROUGH,,,,,,07:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,04-Mar-2026,I-2,05-Mar-2026,05-Mar-2026,6227323208,2,622732320802,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMPK I-2 TROUGH,77242113UCO3001,,,,,07:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,04-Mar-2026,I-2,05-Mar-2026,05-Mar-2026,6227323208,3,622732320803,"Whole Blood, EDTA, Dry",Received,,Default Discard/Not Return,SM02/PLASMAPK PEAK,,,,,,07:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,04-Mar-2026,I-2,05-Mar-2026,05-Mar-2026,6227323208,5,622732320805,"Red Cells, Clot",Received,,Default Discard/Not Return,SM04/SERUM ADA PRE,,,,,,07:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,04-Mar-2026,I-2,05-Mar-2026,05-Mar-2026,6227323208,4,622732320804,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMA PK I-2 PEAK,77242113UCO3001,,,,,07:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,04-Mar-2026,I-2,05-Mar-2026,05-Mar-2026,6227323208,7,622732320807,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-2 PRE,77242113UCO3001-2,,,,,07:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,04-Mar-2026,I-2,05-Mar-2026,,6227323208,8,622732320808,"Stool, unpreserved",Canceled,Frozen,,STOOL I-2,77242113UCO3001-1,,,,,07:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,04-Mar-2026,I-2,05-Mar-2026,,6227323208,10,622732320810,"Stool, unpreserved",Canceled,Frozen,,STOOL I-2,77242113UCO3001-3,,,,,07:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,23-Apr-2026,I-2,24-Apr-2026,24-Apr-2026,6227323207,15,622732320715,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,07:40,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,04-Mar-2026,I-2,05-Mar-2026,,6227323208,11,622732320811,"Stool, unpreserved",Canceled,Frozen,,STOOL I-2,77242113UCO3001-4,,,,,07:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,04-Mar-2026,I-2,05-Mar-2026,,6227323208,9,622732320809,"Stool, unpreserved",Canceled,Frozen,,STOOL I-2,77242113UCO3001-2,,,,,07:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,04-Mar-2026,I-2,05-Mar-2026,,6227323208,12,622732320812,"Stool, unpreserved",Canceled,Frozen,,STOOL I-2,77242113UCO3001-5,,,,,07:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,04-Mar-2026,I-2,05-Mar-2026,05-Mar-2026,6227323208,13,622732320813,"Feces, unpreserved",Received,Frozen,Default Return Frozen,FECAL CALPROTECTIN,FROZEN,,,,,07:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,04-Mar-2026,I-2,05-Mar-2026,05-Mar-2026,6227323208,14,622732320814,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,07:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,04-Mar-2026,I-2,05-Mar-2026,05-Mar-2026,6227323208,15,622732320815,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,07:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,04-Mar-2026,I-2,05-Mar-2026,05-Mar-2026,6227323208,16,622732320816,"Red Cells, Clot",Received,,Default Discard/Not Return,CHEM PANEL &,CRP,,,,,07:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,04-Mar-2026,I-2,05-Mar-2026,05-Mar-2026,6227323208,17,622732320817,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,CRP,,,,,07:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,04-Mar-2026,I-2,05-Mar-2026,05-Mar-2026,6227323208,6,622732320806,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-2 PRE,77242113UCO3001-1,,,,,07:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,18-Mar-2026,I-4,19-Mar-2026,19-Mar-2026,6227323210,2,622732321002,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,CRP,,,,,07:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,18-Mar-2026,I-4,19-Mar-2026,19-Mar-2026,6227323210,4,622732321004,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,07:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,18-Mar-2026,I-4,19-Mar-2026,19-Mar-2026,6227323210,1,622732321001,"Red Cells, Clot",Received,,Default Discard/Not Return,CHEM PANEL &,CRP,,,,,07:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,18-Mar-2026,I-4,19-Mar-2026,19-Mar-2026,6227323210,3,622732321003,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,07:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,18-Mar-2026,I-4,19-Mar-2026,,6227323210,6,622732321006,"Stool, unpreserved",Canceled,Frozen,,STOOL I-4,77242113UCO3001-1,,,,,07:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,18-Mar-2026,I-4,19-Mar-2026,19-Mar-2026,6227323210,5,622732321005,"Feces, unpreserved",Received,Frozen,Default Return Frozen,FECAL CALPROTECTIN,FROZEN,,,,,07:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,18-Mar-2026,I-4,19-Mar-2026,,6227323210,7,622732321007,"Stool, unpreserved",Canceled,Frozen,,STOOL I-4,77242113UCO3001-2,,,,,07:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,18-Mar-2026,I-4,19-Mar-2026,,6227323210,8,622732321008,"Stool, unpreserved",Canceled,Frozen,,STOOL I-4,77242113UCO3001-3,,,,,07:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,18-Mar-2026,I-4,19-Mar-2026,,6227323210,9,622732321009,"Stool, unpreserved",Canceled,Frozen,,STOOL I-4,77242113UCO3001-4,,,,,07:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,18-Mar-2026,I-4,19-Mar-2026,19-Mar-2026,6227323210,10,622732321010,"Stool, unpreserved",Shipped,Frozen,Default Return Frozen,STOOL I-4,77242113UCO3001-5,,,,,07:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,18-Mar-2026,I-4,19-Mar-2026,19-Mar-2026,6227323210,12,622732321012,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMPK I-4 TROUGH,77242113UCO3001,,,,,07:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,18-Mar-2026,I-4,19-Mar-2026,19-Mar-2026,6227323210,14,622732321014,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMA PK I-4 PEAK,77242113UCO3001,,,,,07:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,18-Mar-2026,I-4,19-Mar-2026,19-Mar-2026,6227323210,11,622732321011,"Whole Blood, EDTA, Dry",Received,,Default Discard/Not Return,PLASMA PK TROUGH,,,,,,07:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,18-Mar-2026,I-4,19-Mar-2026,19-Mar-2026,6227323210,13,622732321013,"Whole Blood, EDTA, Dry",Received,,Default Discard/Not Return,SM02/PLASMAPK PEAK,,,,,,07:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,18-Mar-2026,I-4,19-Mar-2026,19-Mar-2026,6227323210,15,622732321015,"Red Cells, Clot",Received,,Default Discard/Not Return,SM04/SERUM ADA PRE,,,,,,07:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,18-Mar-2026,I-4,19-Mar-2026,19-Mar-2026,6227323210,16,622732321016,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-4 PRE,77242113UCO3001-1,,,,,07:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,18-Mar-2026,I-4,19-Mar-2026,19-Mar-2026,6227323210,17,622732321017,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-4 PRE,77242113UCO3001-2,,,,,07:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,18-Mar-2026,I-4,19-Mar-2026,19-Mar-2026,6227323210,18,622732321018,"Red Cells, Clot",Received,,Default Discard/Not Return,SM06/SERUM,BIOMARKERS,,,,,07:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,18-Mar-2026,I-4,19-Mar-2026,19-Mar-2026,6227323210,19,622732321019,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-1,,,,,07:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,18-Mar-2026,I-4,19-Mar-2026,19-Mar-2026,6227323210,21,622732321021,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-3,,,,,07:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,18-Mar-2026,I-4,19-Mar-2026,19-Mar-2026,6227323210,20,622732321020,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-2,,,,,07:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,18-Mar-2026,I-4,19-Mar-2026,19-Mar-2026,6227323210,22,622732321022,Whole Blood PAXgene RNA,Shipped,Frozen,Default Return Frozen,SM07/WB RNA,77242113UCO3001,,,,,07:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,28-Jan-2026,SCRNSTOOL,29-Jan-2026,29-Jan-2026,6227323211,1,622732321101,"Stool, ova & parasites(form)",Received,Ambient,Default Return Ambient,OVA & PARASITES 1,FORMALIN,,,,,06:00,07:40,Czech Republic,,07:40,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,28-Jan-2026,SCRNSTOOL,29-Jan-2026,29-Jan-2026,6227323211,2,622732321102,"Stool, unpreserved",Received,Frozen,Default Return Frozen,C-DIFF TOXIN,& PCR FROZEN,,,,,06:00,07:40,Czech Republic,,07:40,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,28-Jan-2026,SCRNSTOOL,29-Jan-2026,29-Jan-2026,6227323211,3,622732321103,"Culture, Stool",Received,Ambient,Default Return Ambient,STOOL CULTURE,,,,,,06:00,07:40,Czech Republic,,07:40,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,28-Jan-2026,SCRNSTOOL,29-Jan-2026,29-Jan-2026,6227323211,4,622732321104,"Stool, ova & parasites(PVA)",Received,Ambient,Default Return Ambient,OVA & PARASITES 2,PVA,,,,,06:00,07:40,Czech Republic,,07:40,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,03-Mar-2026,SCRNSTOOL,05-Mar-2026,05-Mar-2026,6227323212,1,622732321201,"Stool, ova & parasites(form)",Received,Ambient,Default Return Ambient,OVA & PARASITES 1,FORMALIN,,,,,13:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,03-Mar-2026,SCRNSTOOL,05-Mar-2026,05-Mar-2026,6227323212,3,622732321203,"Culture, Stool",Received,Ambient,Default Return Ambient,STOOL CULTURE,,,,,,13:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,03-Mar-2026,SCRNSTOOL,05-Mar-2026,05-Mar-2026,6227323212,4,622732321204,"Stool, ova & parasites(PVA)",Received,Ambient,Default Return Ambient,OVA & PARASITES 2,PVA,,,,,13:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,03-Mar-2026,SCRNSTOOL,05-Mar-2026,05-Mar-2026,6227323212,2,622732321202,"Stool, unpreserved",Received,Frozen,Default Return Frozen,C-DIFF TOXIN,& PCR FROZEN,,,,,13:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,29-Apr-2026,SCRNSTOOL,30-Apr-2026,,6227323213,1,622732321301,"Stool, ova & parasites(form)",Not Received,Ambient,,OVA & PARASITES 1,FORMALIN,,,,,07:55,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,29-Apr-2026,SCRNSTOOL,30-Apr-2026,30-Apr-2026,6227323213,2,622732321302,"Stool, unpreserved",Received,Frozen,Default Return Frozen,C-DIFF TOXIN,& PCR FROZEN,,,,,07:55,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,29-Apr-2026,SCRNSTOOL,30-Apr-2026,30-Apr-2026,6227323213,3,622732321303,"Culture, Stool",Received,Ambient,Default Return Ambient,STOOL CULTURE,,,,,,07:55,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,29-Apr-2026,SCRNSTOOL,30-Apr-2026,,6227323213,4,622732321304,"Stool, ova & parasites(PVA)",Not Received,Ambient,,OVA & PARASITES 2,PVA,,,,,07:55,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,19-Feb-2026,DNA,20-Feb-2026,20-Feb-2026,6227323217,1,622732321701,"Whole Blood, EDTA, Dry",Shipped,Frozen,Default Return Frozen,SM08/WB DNA,77242113UCO3001,,,,,08:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,DNA,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,18-Mar-2026,DNA,19-Mar-2026,19-Mar-2026,6227323219,1,622732321901,"Whole Blood, EDTA, Dry",Shipped,Frozen,Default Return Frozen,SM08/WB DNA,77242113UCO3001,,,,,07:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,DNA,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,05-Feb-2026,BXSCR,06-Feb-2026,06-Feb-2026,6227323223,1,622732322301,Wet Tissue Biopsy,Removed,Ambient,Default Return Ambient,SM11/BIOPSY,HISTOLOGY,,,,,00:00,07:10,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,05-Feb-2026,BXSCR,06-Feb-2026,07-Feb-2026,6227323223,2,622732322302,Biopsy RNA Later,Shipped,Frozen,Default Return Frozen,SM13/BIOPSY RNA,FROZEN,,,,,00:00,07:20,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,05-Feb-2026,BXSCR,06-Feb-2026,07-Feb-2026,6227323223,3,622732322303,"Biopsy, Frozen Tissue",Shipped,Frozen,Default Return Frozen,SM14/BIOPSY CRYO,FROZEN,,,,,00:00,07:20,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,05-Feb-2026,BXSCR,06-Feb-2026,,6227323223,4,622732322304,"Biopsy, Frozen Tissue",Not Received,Frozen,,BIOPSY PK,77242113UCO3001,,,,,00:00,,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,18-Mar-2026,BXSCR,19-Mar-2026,20-Mar-2026,6227323224,2,622732322402,Biopsy RNA Later,Shipped,Frozen,Default Return Frozen,SM13/BIOPSY RNA,FROZEN,,,,,00:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,18-Mar-2026,BXSCR,19-Mar-2026,19-Mar-2026,6227323224,1,622732322401,Wet Tissue Biopsy,Removed,Ambient,Default Return Ambient,SM11/BIOPSY,HISTOLOGY,,,,,00:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,18-Mar-2026,BXSCR,19-Mar-2026,20-Mar-2026,6227323224,3,622732322403,"Biopsy, Frozen Tissue",In Inventory,Frozen,Default Return Frozen,SM14/BIOPSY CRYO,FROZEN,,,,,00:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,18-Mar-2026,BXSCR,19-Mar-2026,,6227323224,4,622732322404,"Biopsy, Frozen Tissue",Not Received,Frozen,,BIOPSY PK,77242113UCO3001,,,,,00:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323231,2,622732323102,"Slides, Hematology",Not Received,Ambient,,HEMATOLOGY,,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323231,3,622732323103,"Red Cells, Clot",Not Received,,,"CHEM, LIPID PANEL,","BHCG, FSH & CRP",,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323231,4,622732323104,"Serum, SST",Not Received,Ambient,,"CHEM, LIPID PANEL",BETA HCG & CRP,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,19-Mar-2026,6227323231,5,622732323105,"Serum, SST",Received,Ambient,Default Return Ambient,FSH,,,,,,,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323231,6,622732323106,"Red Cells, Clot",Not Received,,,"HIV SCREEN,",HEPATITIS B & C,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,23-Apr-2026,6227323231,8,622732323108,"Feces, unpreserved",Received,Frozen,Default Return Frozen,FECAL CALPROTECTIN,FROZEN,,,,,,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323231,7,622732323107,"Serum, SST",Not Received,Ambient,,"HIV SCREEN,",HEPATITIS B & C,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323231,1,622732323101,"Whole Blood, EDTA, Dry",Not Received,Ambient,,HEMATOLOGY,,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323231,9,622732323109,"Whole Blood, EDTA, Dry",Not Received,,,HCV RNA COBAS 6800,,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323231,10,622732323110,"Plasma, EDTA",Not Received,Frozen,,HCV RNA COBAS 6800,FROZEN,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323231,12,622732323112,"Plasma, EDTA",Not Received,Frozen,,HBV DNA COBAS 6800,FROZEN,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323231,14,622732323114,Whole Blood PAXgene RNA,Not Received,Frozen,,SM07/WB RNA,77242113UCO3001,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323231,13,622732323113,"Stool, unpreserved",Not Received,Frozen,,SM10/FECAL,BIOMARKERS,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323231,17,622732323117,"Serum, SST",Not Received,Frozen,,SM06/SERUM BIOM,77242113UCO3001-2,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323231,18,622732323118,"Serum, SST",Not Received,Frozen,,SM06/SERUM BIOM,77242113UCO3001-3,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323231,15,622732323115,"Red Cells, Clot",Not Received,,,SM06/SERUM,BIOMARKERS,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323231,16,622732323116,"Serum, SST",Not Received,Frozen,,SM06/SERUM BIOM,77242113UCO3001-1,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323231,11,622732323111,"Whole Blood, EDTA, Dry",Not Received,,,HBV DNA COBAS 6800,,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323231,19,622732323119,"Stool, unpreserved",Not Received,Frozen,,STOOL,77242113UCO3001,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323231,20,622732323120,"Stool, unpreserved",Not Received,Frozen,,STOOL,77242113UCO3001-2,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323231,22,622732323122,"Stool, unpreserved",Not Received,Frozen,,STOOL,77242113UCO3001-4,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323231,21,622732323121,"Stool, unpreserved",Not Received,Frozen,,STOOL,77242113UCO3001-3,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323231,25,622732323125,"Serum, SST",Not Received,Frozen,,SERUM ADA,77242113UCO3001-1,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323231,26,622732323126,"Serum, SST",Not Received,Frozen,,SERUM ADA,77242113UCO3001-2,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323231,24,622732323124,"Red Cells, Clot",Not Received,,,SM05/SERUM ADA,,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323231,23,622732323123,"Stool, unpreserved",Not Received,Frozen,,STOOL,77242113UCO3001-5,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323231,27,622732323127,"Whole Blood, EDTA, Dry",Not Received,,,SM03/PLASMA PK,,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323231,28,622732323128,"Plasma, EDTA",Not Received,Frozen,,PLASMA PK,77242113UCO3001,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323231,29,622732323129,"Whole Blood, EDTA, Dry",Not Received,,,HIV-1/HIV-2,QUALITATIVE RNA,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323231,30,622732323130,"Plasma, EDTA",Not Received,Frozen,,HIV-1/HIV-2 QUAL,RNA FROZEN,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Apr-2026,UNSCH,23-Apr-2026,,6227323232,3,622732323203,"Red Cells, Clot",Not Received,,,"CHEM, LIPID PANEL,","BHCG, FSH & CRP",,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Apr-2026,UNSCH,23-Apr-2026,,6227323232,4,622732323204,"Serum, SST",Canceled,Ambient,,"CHEM, LIPID PANEL",BETA HCG & CRP,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Apr-2026,UNSCH,23-Apr-2026,,6227323232,5,622732323205,"Serum, SST",Not Received,Ambient,,FSH,,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Apr-2026,UNSCH,23-Apr-2026,,6227323232,6,622732323206,"Red Cells, Clot",Not Received,,,"HIV SCREEN,",HEPATITIS B & C,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Apr-2026,UNSCH,23-Apr-2026,,6227323232,7,622732323207,"Serum, SST",Not Received,Ambient,,"HIV SCREEN,",HEPATITIS B & C,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Apr-2026,UNSCH,23-Apr-2026,,6227323232,8,622732323208,"Feces, unpreserved",Not Received,Frozen,Specimen not submitted,FECAL CALPROTECTIN,FROZEN,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Apr-2026,UNSCH,23-Apr-2026,,6227323232,1,622732323201,"Whole Blood, EDTA, Dry",Not Received,Ambient,,HEMATOLOGY,,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Apr-2026,UNSCH,23-Apr-2026,,6227323232,2,622732323202,"Slides, Hematology",Not Received,Ambient,,HEMATOLOGY,,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Apr-2026,UNSCH,23-Apr-2026,,6227323232,10,622732323210,"Plasma, EDTA",Not Received,Frozen,,HCV RNA COBAS 6800,FROZEN,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Apr-2026,UNSCH,23-Apr-2026,,6227323232,12,622732323212,"Plasma, EDTA",Not Received,Frozen,,HBV DNA COBAS 6800,FROZEN,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Apr-2026,UNSCH,23-Apr-2026,,6227323232,14,622732323214,Whole Blood PAXgene RNA,Not Received,Frozen,,SM07/WB RNA,77242113UCO3001,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Apr-2026,UNSCH,23-Apr-2026,,6227323232,13,622732323213,"Stool, unpreserved",Not Received,Frozen,,SM10/FECAL,BIOMARKERS,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Apr-2026,UNSCH,23-Apr-2026,,6227323232,11,622732323211,"Whole Blood, EDTA, Dry",Not Received,,,HBV DNA COBAS 6800,,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Apr-2026,UNSCH,23-Apr-2026,,6227323232,15,622732323215,"Red Cells, Clot",Not Received,,,SM06/SERUM,BIOMARKERS,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Apr-2026,UNSCH,23-Apr-2026,,6227323232,9,622732323209,"Whole Blood, EDTA, Dry",Not Received,,,HCV RNA COBAS 6800,,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Apr-2026,UNSCH,23-Apr-2026,,6227323232,16,622732323216,"Serum, SST",Not Received,Frozen,,SM06/SERUM BIOM,77242113UCO3001-1,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Apr-2026,UNSCH,23-Apr-2026,,6227323232,17,622732323217,"Serum, SST",Not Received,Frozen,,SM06/SERUM BIOM,77242113UCO3001-2,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Apr-2026,UNSCH,23-Apr-2026,,6227323232,21,622732323221,"Stool, unpreserved",Not Received,Frozen,,STOOL,77242113UCO3001-3,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Apr-2026,UNSCH,23-Apr-2026,,6227323232,23,622732323223,"Stool, unpreserved",Not Received,Frozen,,STOOL,77242113UCO3001-5,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Apr-2026,UNSCH,23-Apr-2026,,6227323232,26,622732323226,"Serum, SST",Not Received,Frozen,,SERUM ADA,77242113UCO3001-2,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Apr-2026,UNSCH,23-Apr-2026,,6227323232,20,622732323220,"Stool, unpreserved",Not Received,Frozen,,STOOL,77242113UCO3001-2,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Apr-2026,UNSCH,23-Apr-2026,,6227323232,24,622732323224,"Red Cells, Clot",Not Received,,,SM05/SERUM ADA,,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Apr-2026,UNSCH,23-Apr-2026,,6227323232,22,622732323222,"Stool, unpreserved",Not Received,Frozen,,STOOL,77242113UCO3001-4,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Apr-2026,UNSCH,23-Apr-2026,,6227323232,27,622732323227,"Whole Blood, EDTA, Dry",Not Received,,,SM03/PLASMA PK,,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Apr-2026,UNSCH,23-Apr-2026,,6227323232,25,622732323225,"Serum, SST",Not Received,Frozen,,SERUM ADA,77242113UCO3001-1,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Apr-2026,UNSCH,23-Apr-2026,,6227323232,19,622732323219,"Stool, unpreserved",Not Received,Frozen,,STOOL,77242113UCO3001,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Apr-2026,UNSCH,23-Apr-2026,,6227323232,28,622732323228,"Plasma, EDTA",Not Received,Frozen,,PLASMA PK,77242113UCO3001,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Apr-2026,UNSCH,23-Apr-2026,,6227323232,18,622732323218,"Serum, SST",Not Received,Frozen,,SM06/SERUM BIOM,77242113UCO3001-3,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Apr-2026,UNSCH,23-Apr-2026,,6227323232,29,622732323229,"Whole Blood, EDTA, Dry",Not Received,,,HIV-1/HIV-2,QUALITATIVE RNA,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323233,2,622732323302,"Slides, Hematology",Not Received,Ambient,,HEMATOLOGY,,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,19-Mar-2026,6227323233,4,622732323304,"Serum, SST",Received,Ambient,Default Return Ambient,"CHEM, LIPID PANEL",BETA HCG & CRP,,,,,,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Apr-2026,UNSCH,23-Apr-2026,,6227323232,30,622732323230,"Plasma, EDTA",Not Received,Frozen,,HIV-1/HIV-2 QUAL,RNA FROZEN,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,19-Mar-2026,6227323233,3,622732323303,"Red Cells, Clot",Received,,Default Discard/Not Return,"CHEM, LIPID PANEL,","BHCG, FSH & CRP",,,,,,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323233,6,622732323306,"Red Cells, Clot",Not Received,,,"HIV SCREEN,",HEPATITIS B & C,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323233,7,622732323307,"Serum, SST",Not Received,Ambient,,"HIV SCREEN,",HEPATITIS B & C,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323233,1,622732323301,"Whole Blood, EDTA, Dry",Not Received,Ambient,,HEMATOLOGY,,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323233,5,622732323305,"Serum, SST",Not Received,Ambient,,FSH,,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323233,8,622732323308,"Feces, unpreserved",Not Received,Frozen,,FECAL CALPROTECTIN,FROZEN,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323233,9,622732323309,"Whole Blood, EDTA, Dry",Not Received,,,HCV RNA COBAS 6800,,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323233,10,622732323310,"Plasma, EDTA",Not Received,Frozen,,HCV RNA COBAS 6800,FROZEN,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323233,13,622732323313,"Stool, unpreserved",Not Received,Frozen,,SM10/FECAL,BIOMARKERS,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323233,12,622732323312,"Plasma, EDTA",Not Received,Frozen,,HBV DNA COBAS 6800,FROZEN,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323233,16,622732323316,"Serum, SST",Not Received,Frozen,,SM06/SERUM BIOM,77242113UCO3001-1,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323233,14,622732323314,Whole Blood PAXgene RNA,Not Received,Frozen,,SM07/WB RNA,77242113UCO3001,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323233,15,622732323315,"Red Cells, Clot",Not Received,,,SM06/SERUM,BIOMARKERS,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323233,11,622732323311,"Whole Blood, EDTA, Dry",Not Received,,,HBV DNA COBAS 6800,,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323233,17,622732323317,"Serum, SST",Not Received,Frozen,,SM06/SERUM BIOM,77242113UCO3001-2,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323233,19,622732323319,"Stool, unpreserved",Not Received,Frozen,,STOOL,77242113UCO3001,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323233,24,622732323324,"Red Cells, Clot",Not Received,,,SM05/SERUM ADA,,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323233,20,622732323320,"Stool, unpreserved",Not Received,Frozen,,STOOL,77242113UCO3001-2,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323233,23,622732323323,"Stool, unpreserved",Not Received,Frozen,,STOOL,77242113UCO3001-5,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323233,26,622732323326,"Serum, SST",Not Received,Frozen,,SERUM ADA,77242113UCO3001-2,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323233,25,622732323325,"Serum, SST",Not Received,Frozen,,SERUM ADA,77242113UCO3001-1,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323233,22,622732323322,"Stool, unpreserved",Not Received,Frozen,,STOOL,77242113UCO3001-4,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323233,27,622732323327,"Whole Blood, EDTA, Dry",Not Received,,,SM03/PLASMA PK,,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323233,21,622732323321,"Stool, unpreserved",Not Received,Frozen,,STOOL,77242113UCO3001-3,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323233,18,622732323318,"Serum, SST",Not Received,Frozen,,SM06/SERUM BIOM,77242113UCO3001-3,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323233,29,622732323329,"Whole Blood, EDTA, Dry",Not Received,,,HIV-1/HIV-2,QUALITATIVE RNA,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323233,30,622732323330,"Plasma, EDTA",Not Received,Frozen,,HIV-1/HIV-2 QUAL,RNA FROZEN,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323233,28,622732323328,"Plasma, EDTA",Not Received,Frozen,,PLASMA PK,77242113UCO3001,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,20-Apr-2026,SCRN,21-Apr-2026,22-Apr-2026,6227323234,2,622732323402,"Plasma, QuantiFERON Nil",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,NIL-GRAY FRZ,,,,,07:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,20-Apr-2026,SCRN,21-Apr-2026,,6227323234,3,622732323403,Whole Blood QuantiFERON TB1,Not Received,,,QUANTIFERON PLUS,TB1-GREEN,,,,,07:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,20-Apr-2026,SCRN,21-Apr-2026,22-Apr-2026,6227323234,4,622732323404,"Plasma, QuantiFERON TB1",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB1-GREEN FRZ,,,,,07:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,20-Apr-2026,SCRN,21-Apr-2026,,6227323234,5,622732323405,Whole Blood QuantiFERON TB2,Not Received,,,QUANTIFERON PLUS,TB2-YELLOW,,,,,07:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,20-Apr-2026,SCRN,21-Apr-2026,,6227323234,1,622732323401,Whole Blood QuantiFERON Nil,Not Received,,,QUANTIFERON PLUS,NIL-GRAY,,,,,07:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,20-Apr-2026,SCRN,21-Apr-2026,22-Apr-2026,6227323234,6,622732323406,"Plasma, QuantiFERON TB2",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB2-YELLOW FRZ,,,,,07:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,20-Apr-2026,SCRN,21-Apr-2026,21-Apr-2026,6227323234,10,622732323410,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,07:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,20-Apr-2026,SCRN,21-Apr-2026,22-Apr-2026,6227323234,8,622732323408,"Plasma, QuantiFERON Mitoge",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,MITOGEN-PURPLE FRZ,,,,,07:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,20-Apr-2026,SCRN,21-Apr-2026,,6227323234,11,622732323411,"Red Cells, Clot",Not Received,,,"HIV SCREEN,",HEPATITIS B & C,,,,,07:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,20-Apr-2026,SCRN,21-Apr-2026,,6227323234,7,622732323407,Whole Blood QuantiFERON Mitoge,Not Received,,,QUANTIFERON PLUS,MITOGEN-PURPLE,,,,,07:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,20-Apr-2026,SCRN,21-Apr-2026,21-Apr-2026,6227323234,9,622732323409,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,07:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,20-Apr-2026,SCRN,21-Apr-2026,,6227323234,15,622732323415,"Serum, SST",Canceled,Ambient,,FSH,FROZEN,,,,,07:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,20-Apr-2026,SCRN,21-Apr-2026,21-Apr-2026,6227323234,14,622732323414,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,BETA HCG,,,,,07:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,20-Apr-2026,SCRN,21-Apr-2026,,6227323234,13,622732323413,"Red Cells, Clot",Not Received,,,CHEM PANEL &,BETA HCG,,,,,07:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,20-Apr-2026,SCRN,21-Apr-2026,21-Apr-2026,6227323234,12,622732323412,"Serum, SST",Received,Ambient,Default Return Ambient,"HIV SCREEN,",HEPATITIS B & C,,,,,07:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,16-Feb-2026,SCRN,18-Feb-2026,,6227323236,2,622732323602,"Plasma, QuantiFERON Nil",Canceled,Frozen,,QUANTIFERON PLUS,NIL-GRAY FRZ,,,,,07:03,,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,16-Feb-2026,SCRN,18-Feb-2026,,6227323236,1,622732323601,Whole Blood QuantiFERON Nil,Not Received,,,QUANTIFERON PLUS,NIL-GRAY,,,,,07:03,,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,16-Feb-2026,SCRN,18-Feb-2026,,6227323236,3,622732323603,Whole Blood QuantiFERON TB1,Not Received,,,QUANTIFERON PLUS,TB1-GREEN,,,,,07:03,,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,16-Feb-2026,SCRN,18-Feb-2026,,6227323236,4,622732323604,"Plasma, QuantiFERON TB1",Canceled,Frozen,,QUANTIFERON PLUS,TB1-GREEN FRZ,,,,,07:03,,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,16-Feb-2026,SCRN,18-Feb-2026,,6227323236,8,622732323608,"Plasma, QuantiFERON Mitoge",Canceled,Frozen,,QUANTIFERON PLUS,MITOGEN-PURPLE FRZ,,,,,07:03,,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,16-Feb-2026,SCRN,18-Feb-2026,,6227323236,5,622732323605,Whole Blood QuantiFERON TB2,Not Received,,,QUANTIFERON PLUS,TB2-YELLOW,,,,,07:03,,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,16-Feb-2026,SCRN,18-Feb-2026,18-Feb-2026,6227323236,9,622732323609,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,07:03,07:10,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,16-Feb-2026,SCRN,18-Feb-2026,,6227323236,7,622732323607,Whole Blood QuantiFERON Mitoge,Not Received,,,QUANTIFERON PLUS,MITOGEN-PURPLE,,,,,07:03,,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,16-Feb-2026,SCRN,18-Feb-2026,,6227323236,6,622732323606,"Plasma, QuantiFERON TB2",Canceled,Frozen,,QUANTIFERON PLUS,TB2-YELLOW FRZ,,,,,07:03,,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,16-Feb-2026,SCRN,18-Feb-2026,,6227323236,11,622732323611,"Red Cells, Clot",Not Received,,,"HIV SCREEN,",HEPATITIS B & C,,,,,07:03,,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,16-Feb-2026,SCRN,18-Feb-2026,18-Feb-2026,6227323236,12,622732323612,"Serum, SST",Received,Ambient,Default Return Ambient,"HIV SCREEN,",HEPATITIS B & C,,,,,07:03,07:10,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,16-Feb-2026,SCRN,18-Feb-2026,18-Feb-2026,6227323236,10,622732323610,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,07:03,07:10,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,16-Feb-2026,SCRN,18-Feb-2026,,6227323236,13,622732323613,"Red Cells, Clot",Not Received,,,"CHEM PANEL, BETA",HCG & FSH,,,,,07:03,,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,16-Feb-2026,SCRN,18-Feb-2026,18-Feb-2026,6227323236,14,622732323614,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,BETA HCG,,,,,07:03,07:10,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,16-Feb-2026,SCRN,18-Feb-2026,18-Feb-2026,6227323236,15,622732323615,"Serum, SST",Received,Ambient,Default Return Ambient,FSH,,,,,,07:03,07:10,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,20-Mar-2026,I-0,21-Mar-2026,21-Mar-2026,6227323237,2,622732323702,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,08:00,07:30,Czech Republic,,07:30,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,20-Mar-2026,I-0,21-Mar-2026,21-Mar-2026,6227323237,4,622732323704,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMPK I-0 TROUGH,77242113UCO3001,,,,,08:00,07:30,Czech Republic,,07:30,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,20-Mar-2026,I-0,21-Mar-2026,21-Mar-2026,6227323237,1,622732323701,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,08:00,07:30,Czech Republic,,07:30,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,20-Mar-2026,I-0,21-Mar-2026,,6227323237,3,622732323703,"Whole Blood, EDTA, Dry",Not Received,,,PLASMA PK TROUGH,,,,,,08:00,,Czech Republic,,07:30,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,20-Mar-2026,I-0,21-Mar-2026,,6227323237,7,622732323707,"Red Cells, Clot",Not Received,,,SM04/SERUM ADA PRE,,,,,,08:00,,Czech Republic,,07:30,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,20-Mar-2026,I-0,21-Mar-2026,21-Mar-2026,6227323237,8,622732323708,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-0 PRE,77242113UCO3001-1,,,,,08:00,07:30,Czech Republic,,07:30,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,20-Mar-2026,I-0,21-Mar-2026,,6227323237,5,622732323705,"Whole Blood, EDTA, Dry",Not Received,,,SM02/PLASMAPK PEAK,,,,,,08:00,,Czech Republic,,07:30,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,20-Mar-2026,I-0,21-Mar-2026,21-Mar-2026,6227323237,6,622732323706,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMA PK I-0 PEAK,77242113UCO3001,,,,,08:00,07:30,Czech Republic,,07:30,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,20-Mar-2026,I-0,21-Mar-2026,21-Mar-2026,6227323237,11,622732323711,Whole Blood PAXgene RNA,Shipped,Frozen,Default Return Frozen,SM07/WB RNA,77242113UCO3001,,,,,08:00,07:30,Czech Republic,,07:30,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,20-Mar-2026,I-0,21-Mar-2026,,6227323237,12,622732323712,"Red Cells, Clot",Not Received,,,SM06/SERUM,BIOMARKERS,,,,,08:00,,Czech Republic,,07:30,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,20-Mar-2026,I-0,21-Mar-2026,21-Mar-2026,6227323237,9,622732323709,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-0 PRE,77242113UCO3001-2,,,,,08:00,07:30,Czech Republic,,07:30,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,20-Mar-2026,I-0,21-Mar-2026,21-Mar-2026,6227323237,13,622732323713,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-1,,,,,08:00,07:30,Czech Republic,,07:30,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,20-Mar-2026,I-0,21-Mar-2026,21-Mar-2026,6227323237,10,622732323710,"Stool, unpreserved",In Inventory,Frozen,Default Return Frozen,SM10/FECAL,BIOMARKERS,,,,,08:00,07:30,Czech Republic,,07:30,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,20-Mar-2026,I-0,21-Mar-2026,21-Mar-2026,6227323237,15,622732323715,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-3,,,,,08:00,07:30,Czech Republic,,07:30,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,20-Mar-2026,I-0,21-Mar-2026,21-Mar-2026,6227323237,14,622732323714,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-2,,,,,08:00,07:30,Czech Republic,,07:30,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,20-Mar-2026,I-0,21-Mar-2026,,6227323237,17,622732323717,"Red Cells, Clot",Not Received,,,"CHEM, LIPID PANEL",& CRP,,,,,08:00,,Czech Republic,,07:30,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,20-Mar-2026,I-0,21-Mar-2026,21-Mar-2026,6227323237,18,622732323718,"Serum, SST",Received,Ambient,Default Return Ambient,"CHEM, LIPID PANEL",& CRP,,,,,08:00,07:30,Czech Republic,,07:30,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,20-Mar-2026,I-0,21-Mar-2026,21-Mar-2026,6227323237,16,622732323716,"Feces, unpreserved",Received,Frozen,Default Return Frozen,FECAL CALPROTECTIN,FROZEN,,,,,08:00,07:30,Czech Republic,,07:30,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,26-May-2026,I-0,27-May-2026,27-May-2026,6227323238,1,622732323801,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,09:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,26-May-2026,I-0,27-May-2026,27-May-2026,6227323238,2,622732323802,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,26-May-2026,I-0,27-May-2026,27-May-2026,6227323238,4,622732323804,"Plasma, EDTA",In Inventory,Frozen,Default Return Frozen,PLASMPK I-0 TROUGH,77242113UCO3001,,,,,09:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,26-May-2026,I-0,27-May-2026,,6227323238,5,622732323805,"Whole Blood, EDTA, Dry",Not Received,,,SM02/PLASMAPK PEAK,,,,,,09:20,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,26-May-2026,I-0,27-May-2026,,6227323238,7,622732323807,"Red Cells, Clot",Not Received,,,SM04/SERUM ADA PRE,,,,,,09:20,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,26-May-2026,I-0,27-May-2026,27-May-2026,6227323238,8,622732323808,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-0 PRE,77242113UCO3001-1,,,,,09:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,26-May-2026,I-0,27-May-2026,27-May-2026,6227323238,6,622732323806,"Plasma, EDTA",In Inventory,Frozen,Default Return Frozen,PLASMA PK I-0 PEAK,77242113UCO3001,,,,,09:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,26-May-2026,I-0,27-May-2026,27-May-2026,6227323238,10,622732323810,"Stool, unpreserved",In Inventory,Frozen,Default Return Frozen,SM10/FECAL,BIOMARKERS,,,,,09:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,26-May-2026,I-0,27-May-2026,27-May-2026,6227323238,11,622732323811,Whole Blood PAXgene RNA,In Inventory,Frozen,Default Return Frozen,SM07/WB RNA,77242113UCO3001,,,,,09:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,26-May-2026,I-0,27-May-2026,27-May-2026,6227323238,13,622732323813,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-1,,,,,09:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,26-May-2026,I-0,27-May-2026,,6227323238,12,622732323812,"Red Cells, Clot",Not Received,,,SM06/SERUM,BIOMARKERS,,,,,09:20,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,26-May-2026,I-0,27-May-2026,27-May-2026,6227323238,9,622732323809,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-0 PRE,77242113UCO3001-2,,,,,09:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,26-May-2026,I-0,27-May-2026,27-May-2026,6227323238,16,622732323816,"Feces, unpreserved",Received,Frozen,Default Return Frozen,FECAL CALPROTECTIN,FROZEN,,,,,09:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,26-May-2026,I-0,27-May-2026,27-May-2026,6227323238,15,622732323815,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-3,,,,,09:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,26-May-2026,I-0,27-May-2026,27-May-2026,6227323238,14,622732323814,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-2,,,,,09:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,26-May-2026,I-0,27-May-2026,27-May-2026,6227323238,18,622732323818,"Serum, SST",Received,Ambient,Default Return Ambient,"CHEM, LIPID PANEL",& CRP,,,,,09:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,26-May-2026,I-0,27-May-2026,,6227323238,17,622732323817,"Red Cells, Clot",Not Received,,,"CHEM, LIPID PANEL",& CRP,,,,,09:20,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,08-Apr-2026,I-2,09-Apr-2026,09-Apr-2026,6227323240,2,622732324002,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMPK I-2 TROUGH,77242113UCO3001,,,,,07:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,08-Apr-2026,I-2,09-Apr-2026,,6227323240,1,622732324001,"Whole Blood, EDTA, Dry",Not Received,,,PLASMA PK TROUGH,,,,,,07:10,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,08-Apr-2026,I-2,09-Apr-2026,09-Apr-2026,6227323240,15,622732324015,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,07:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,08-Apr-2026,I-2,09-Apr-2026,09-Apr-2026,6227323240,13,622732324013,"Feces, unpreserved",Received,Frozen,Default Return Frozen,FECAL CALPROTECTIN,FROZEN,,,,,07:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,08-Apr-2026,I-2,09-Apr-2026,,6227323240,16,622732324016,"Red Cells, Clot",Not Received,,,CHEM PANEL &,CRP,,,,,07:10,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,08-Apr-2026,I-2,09-Apr-2026,09-Apr-2026,6227323240,14,622732324014,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,07:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,08-Apr-2026,I-2,09-Apr-2026,,6227323240,5,622732324005,"Red Cells, Clot",Not Received,,,SM04/SERUM ADA PRE,,,,,,07:10,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,08-Apr-2026,I-2,09-Apr-2026,09-Apr-2026,6227323240,4,622732324004,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMA PK I-2 PEAK,77242113UCO3001,,,,,07:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,08-Apr-2026,I-2,09-Apr-2026,,6227323240,8,622732324008,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-2,77242113UCO3001-1,,,,,07:10,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,08-Apr-2026,I-2,09-Apr-2026,,6227323240,9,622732324009,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-2,77242113UCO3001-2,,,,,07:10,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,08-Apr-2026,I-2,09-Apr-2026,09-Apr-2026,6227323240,6,622732324006,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-2 PRE,77242113UCO3001-1,,,,,07:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,08-Apr-2026,I-2,09-Apr-2026,,6227323240,3,622732324003,"Whole Blood, EDTA, Dry",Not Received,,,SM02/PLASMAPK PEAK,,,,,,07:10,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,08-Apr-2026,I-2,09-Apr-2026,,6227323240,10,622732324010,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-2,77242113UCO3001-3,,,,,07:10,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,08-Apr-2026,I-2,09-Apr-2026,09-Apr-2026,6227323240,7,622732324007,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-2 PRE,77242113UCO3001-2,,,,,07:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,08-Apr-2026,I-2,09-Apr-2026,09-Apr-2026,6227323240,17,622732324017,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,CRP,,,,,07:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,08-Apr-2026,I-2,09-Apr-2026,09-Apr-2026,6227323240,12,622732324012,"Stool, unpreserved",Shipped,Frozen,Default Return Frozen,STOOL I-2,77242113UCO3001-5,,,,,07:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,08-Apr-2026,I-2,09-Apr-2026,,6227323240,11,622732324011,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-2,77242113UCO3001-4,,,,,07:10,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,26-May-2026,I-0,27-May-2026,,6227323238,3,622732323803,"Whole Blood, EDTA, Dry",Not Received,,,PLASMA PK TROUGH,,,,,,09:20,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,15-Apr-2026,I-4,16-Apr-2026,,6227323242,1,622732324201,"Red Cells, Clot",Not Received,,,CHEM PANEL &,CRP,,,,,08:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,15-Apr-2026,I-4,16-Apr-2026,16-Apr-2026,6227323242,2,622732324202,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,CRP,,,,,08:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,15-Apr-2026,I-4,16-Apr-2026,16-Apr-2026,6227323242,3,622732324203,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,08:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,15-Apr-2026,I-4,16-Apr-2026,16-Apr-2026,6227323242,4,622732324204,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,08:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,15-Apr-2026,I-4,16-Apr-2026,16-Apr-2026,6227323242,5,622732324205,"Feces, unpreserved",Received,Frozen,Default Return Frozen,FECAL CALPROTECTIN,FROZEN,,,,,08:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,15-Apr-2026,I-4,16-Apr-2026,,6227323242,9,622732324209,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-4,77242113UCO3001-4,,,,,08:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,15-Apr-2026,I-4,16-Apr-2026,,6227323242,10,622732324210,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-4,77242113UCO3001-5,,,,,08:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,15-Apr-2026,I-4,16-Apr-2026,,6227323242,7,622732324207,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-4,77242113UCO3001-2,,,,,08:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,15-Apr-2026,I-4,16-Apr-2026,,6227323242,8,622732324208,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-4,77242113UCO3001-3,,,,,08:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,15-Apr-2026,I-4,16-Apr-2026,,6227323242,11,622732324211,"Whole Blood, EDTA, Dry",Not Received,,,PLASMA PK TROUGH,,,,,,08:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,15-Apr-2026,I-4,16-Apr-2026,16-Apr-2026,6227323242,6,622732324206,"Stool, unpreserved",Shipped,Frozen,Default Return Frozen,STOOL I-4,77242113UCO3001-1,,,,,08:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,15-Apr-2026,I-4,16-Apr-2026,,6227323242,13,622732324213,"Whole Blood, EDTA, Dry",Not Received,,,SM02/PLASMAPK PEAK,,,,,,08:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,15-Apr-2026,I-4,16-Apr-2026,16-Apr-2026,6227323242,12,622732324212,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMPK I-4 TROUGH,77242113UCO3001,,,,,08:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,15-Apr-2026,I-4,16-Apr-2026,,6227323242,15,622732324215,"Red Cells, Clot",Not Received,,,SM04/SERUM ADA PRE,,,,,,08:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,15-Apr-2026,I-4,16-Apr-2026,16-Apr-2026,6227323242,16,622732324216,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-4 PRE,77242113UCO3001-1,,,,,08:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,15-Apr-2026,I-4,16-Apr-2026,16-Apr-2026,6227323242,17,622732324217,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-4 PRE,77242113UCO3001-2,,,,,08:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,15-Apr-2026,I-4,16-Apr-2026,16-Apr-2026,6227323242,19,622732324219,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-1,,,,,08:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,15-Apr-2026,I-4,16-Apr-2026,16-Apr-2026,6227323242,14,622732324214,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMA PK I-4 PEAK,77242113UCO3001,,,,,08:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,15-Apr-2026,I-4,16-Apr-2026,16-Apr-2026,6227323242,21,622732324221,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-3,,,,,08:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,15-Apr-2026,I-4,16-Apr-2026,,6227323242,18,622732324218,"Red Cells, Clot",Not Received,,,SM06/SERUM,BIOMARKERS,,,,,08:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,15-Apr-2026,I-4,16-Apr-2026,16-Apr-2026,6227323242,20,622732324220,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-2,,,,,08:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,15-Apr-2026,I-4,16-Apr-2026,16-Apr-2026,6227323242,22,622732324222,Whole Blood PAXgene RNA,Shipped,Frozen,Default Return Frozen,SM07/WB RNA,77242113UCO3001,,,,,08:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,17-Mar-2026,UNSCSTOOL,18-Mar-2026,,6227323243,1,622732324301,"Stool, ova & parasites(form)",Not Received,Ambient,,OVA & PARASITES 1,FORMALIN,,,,,09:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,17-Mar-2026,UNSCSTOOL,18-Mar-2026,,6227323243,3,622732324303,"Culture, Stool",Canceled,Ambient,,STOOL CULTURE,,,,,,09:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,16-Feb-2026,SCRNSTOOL,18-Feb-2026,,6227323244,1,622732324401,"Stool, ova & parasites(form)",Not Received,Ambient,,OVA & PARASITES 1,FORMALIN,,,,,07:20,,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,17-Mar-2026,UNSCSTOOL,18-Mar-2026,,6227323243,4,622732324304,"Stool, ova & parasites(PVA)",Not Received,Ambient,,OVA & PARASITES 2,PVA,,,,,09:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,16-Feb-2026,SCRNSTOOL,18-Feb-2026,18-Feb-2026,6227323244,2,622732324402,"Stool, unpreserved",Canceled,Frozen,,C-DIFF TOXIN,& PCR FROZEN,,,,,07:20,07:10,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,17-Mar-2026,UNSCSTOOL,18-Mar-2026,18-Mar-2026,6227323243,2,622732324302,"Stool, unpreserved",Received,Frozen,Default Return Frozen,C-DIFF TOXIN,& PCR FROZEN,,,,,09:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,16-Feb-2026,SCRNSTOOL,18-Feb-2026,18-Feb-2026,6227323244,3,622732324403,"Culture, Stool",Received,Ambient,Default Return Ambient,STOOL CULTURE,,,,,,07:20,07:10,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,16-Feb-2026,SCRNSTOOL,18-Feb-2026,,6227323244,4,622732324404,"Stool, ova & parasites(PVA)",Not Received,Ambient,,OVA & PARASITES 2,PVA,,,,,07:20,,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,11-Mar-2026,UNSCSTOOL,12-Mar-2026,12-Mar-2026,6227323245,3,622732324503,"Culture, Stool",Received,Ambient,Default Return Frozen,STOOL CULTURE,,,,,,09:15,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,11-Mar-2026,UNSCSTOOL,12-Mar-2026,,6227323245,4,622732324504,"Stool, ova & parasites(PVA)",Canceled,Ambient,,OVA & PARASITES 2,PVA,,,,,09:15,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,11-Mar-2026,UNSCSTOOL,12-Mar-2026,,6227323245,1,622732324501,"Stool, ova & parasites(form)",Canceled,Ambient,,OVA & PARASITES 1,FORMALIN,,,,,09:15,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,11-Mar-2026,UNSCSTOOL,12-Mar-2026,,6227323245,2,622732324502,"Stool, unpreserved",Canceled,Frozen,,C-DIFF TOXIN,& PCR FROZEN,,,,,09:15,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,20-Mar-2026,DNA,21-Mar-2026,21-Mar-2026,6227323251,1,622732325101,"Whole Blood, EDTA, Dry",Shipped,Frozen,Default Return Frozen,SM08/WB DNA,77242113UCO3001,,,,,08:00,07:30,Czech Republic,,07:30,,,213069,EMEA,,,,,,,,DNA,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,16-Feb-2026,TB,18-Feb-2026,,6227323252,1,622732325201,Whole Blood QuantiFERON Nil,Not Received,,,QUANTIFERON PLUS,NIL-GRAY,,,,,07:03,,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,TB Testing,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,16-Feb-2026,TB,18-Feb-2026,18-Feb-2026,6227323252,2,622732325202,"Plasma, QuantiFERON Nil",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,NIL-GRAY FRZ,,,,,07:03,07:10,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,TB Testing,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,16-Feb-2026,TB,18-Feb-2026,,6227323252,3,622732325203,Whole Blood QuantiFERON TB1,Not Received,,,QUANTIFERON PLUS,TB1-GREEN,,,,,07:03,,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,TB Testing,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,16-Feb-2026,TB,18-Feb-2026,18-Feb-2026,6227323252,4,622732325204,"Plasma, QuantiFERON TB1",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB1-GREEN FRZ,,,,,07:03,07:10,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,TB Testing,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,16-Feb-2026,TB,18-Feb-2026,,6227323252,5,622732325205,Whole Blood QuantiFERON TB2,Not Received,,,QUANTIFERON PLUS,TB2-YELLOW,,,,,07:03,,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,TB Testing,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,16-Feb-2026,TB,18-Feb-2026,18-Feb-2026,6227323252,6,622732325206,"Plasma, QuantiFERON TB2",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB2-YELLOW FRZ,,,,,07:03,07:10,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,TB Testing,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,16-Feb-2026,TB,18-Feb-2026,,6227323252,7,622732325207,Whole Blood QuantiFERON Mitoge,Not Received,,,QUANTIFERON PLUS,MITOGEN-PURPLE,,,,,07:03,,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,TB Testing,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,16-Feb-2026,TB,18-Feb-2026,18-Feb-2026,6227323252,8,622732325208,"Plasma, QuantiFERON Mitoge",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,MITOGEN-PURPLE FRZ,,,,,07:03,07:10,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,TB Testing,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,11-Mar-2026,TB,12-Mar-2026,12-Mar-2026,6227323253,2,622732325302,"Plasma, QuantiFERON Nil",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,NIL-GRAY FRZ,,,,,09:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,TB Testing,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,11-Mar-2026,TB,12-Mar-2026,,6227323253,1,622732325301,Whole Blood QuantiFERON Nil,Not Received,,,QUANTIFERON PLUS,NIL-GRAY,,,,,09:10,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,TB Testing,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,11-Mar-2026,TB,12-Mar-2026,12-Mar-2026,6227323253,6,622732325306,"Plasma, QuantiFERON TB2",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB2-YELLOW FRZ,,,,,09:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,TB Testing,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,11-Mar-2026,TB,12-Mar-2026,,6227323253,5,622732325305,Whole Blood QuantiFERON TB2,Not Received,,,QUANTIFERON PLUS,TB2-YELLOW,,,,,09:10,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,TB Testing,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,11-Mar-2026,TB,12-Mar-2026,,6227323253,3,622732325303,Whole Blood QuantiFERON TB1,Not Received,,,QUANTIFERON PLUS,TB1-GREEN,,,,,09:10,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,TB Testing,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,11-Mar-2026,TB,12-Mar-2026,12-Mar-2026,6227323253,8,622732325308,"Plasma, QuantiFERON Mitoge",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,MITOGEN-PURPLE FRZ,,,,,09:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,TB Testing,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,11-Mar-2026,TB,12-Mar-2026,,6227323253,7,622732325307,Whole Blood QuantiFERON Mitoge,Not Received,,,QUANTIFERON PLUS,MITOGEN-PURPLE,,,,,09:10,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,TB Testing,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,19-Feb-2026,BXSCR,21-Feb-2026,21-Feb-2026,6227323254,2,622732325402,Biopsy RNA Later,Shipped,Frozen,Default Return Frozen,SM13/BIOPSY RNA,FROZEN,,,,,00:00,07:20,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,19-Feb-2026,BXSCR,21-Feb-2026,21-Feb-2026,6227323254,1,622732325401,Wet Tissue Biopsy,Removed,Ambient,Default Return Ambient,SM11/BIOPSY,HISTOLOGY,,,,,00:00,07:20,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,19-Feb-2026,BXSCR,21-Feb-2026,,6227323254,4,622732325404,"Biopsy, Frozen Tissue",Not Received,Frozen,,BIOPSY PK,77242113UCO3001,,,,,00:00,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,11-Mar-2026,TB,12-Mar-2026,12-Mar-2026,6227323253,4,622732325304,"Plasma, QuantiFERON TB1",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB1-GREEN FRZ,,,,,09:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,TB Testing,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,29-May-2026,BX12,30-May-2026,02-Jun-2026,6227323255,2,622732325502,Biopsy RNA Later,In Inventory,Frozen,Default Return Frozen,SM13/BIOPSY RNA,FROZEN,,,,,00:00,07:00,Czech Republic,,07:30,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,29-May-2026,BX12,30-May-2026,30-May-2026,6227323255,1,622732325501,Wet Tissue Biopsy,Removed,Ambient,Default Return Ambient,SM11/BIOPSY,HISTOLOGY,,,,,00:00,07:30,Czech Republic,,07:30,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,29-May-2026,BX12,30-May-2026,02-Jun-2026,6227323255,3,622732325503,"Biopsy, Frozen Tissue",In Inventory,Frozen,Default Return Frozen,SM14/BIOPSY CRYO,FROZEN,,,,,00:00,07:00,Czech Republic,,07:30,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,19-Feb-2026,BXSCR,21-Feb-2026,21-Feb-2026,6227323254,3,622732325403,"Biopsy, Frozen Tissue",Shipped,Frozen,Default Return Frozen,SM14/BIOPSY CRYO,FROZEN,,,,,00:00,05:55,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,29-May-2026,BX12,30-May-2026,02-Jun-2026,6227323255,4,622732325504,"Biopsy, Frozen Tissue",In Inventory,Frozen,Default Return Frozen,BIOPSY PK,77242113UCO3001,,,,,00:00,07:00,Czech Republic,,07:30,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,14-May-2026,BXSCR,15-May-2026,15-May-2026,6227323256,1,622732325601,Wet Tissue Biopsy,Removed,Ambient,Default Return Ambient,SM11/BIOPSY,HISTOLOGY,,,,,00:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,14-May-2026,BXSCR,15-May-2026,15-May-2026,6227323256,2,622732325602,Biopsy RNA Later,In Inventory,Frozen,Default Return Frozen,SM13/BIOPSY RNA,FROZEN,,,,,00:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,14-May-2026,BXSCR,15-May-2026,15-May-2026,6227323256,3,622732325603,"Biopsy, Frozen Tissue",In Inventory,Frozen,Default Return Frozen,SM14/BIOPSY CRYO,FROZEN,,,,,00:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,14-May-2026,BXSCR,15-May-2026,,6227323256,4,622732325604,"Biopsy, Frozen Tissue",Not Received,Frozen,,BIOPSY PK,77242113UCO3001,,,,,00:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,11-Mar-2026,UNSCH,12-Mar-2026,,6227323264,7,622732326407,"Serum, SST",Not Received,Ambient,,"HIV SCREEN,",HEPATITIS B & C,,,,,09:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,11-Mar-2026,UNSCH,12-Mar-2026,,6227323264,6,622732326406,"Red Cells, Clot",Not Received,,,"HIV SCREEN,",HEPATITIS B & C,,,,,09:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,11-Mar-2026,UNSCH,12-Mar-2026,12-Mar-2026,6227323264,1,622732326401,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,09:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,11-Mar-2026,UNSCH,12-Mar-2026,12-Mar-2026,6227323264,2,622732326402,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,11-Mar-2026,UNSCH,12-Mar-2026,,6227323264,9,622732326409,"Whole Blood, EDTA, Dry",Not Received,,,HCV RNA COBAS 6800,,,,,,09:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,11-Mar-2026,UNSCH,12-Mar-2026,,6227323264,10,622732326410,"Plasma, EDTA",Not Received,Frozen,,HCV RNA COBAS 6800,FROZEN,,,,,09:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,11-Mar-2026,UNSCH,12-Mar-2026,,6227323264,3,622732326403,"Red Cells, Clot",Not Received,,,"CHEM, LIPID PANEL,","BHCG, FSH & CRP",,,,,09:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,11-Mar-2026,UNSCH,12-Mar-2026,,6227323264,8,622732326408,"Feces, unpreserved",Not Received,Frozen,,FECAL CALPROTECTIN,FROZEN,,,,,09:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,11-Mar-2026,UNSCH,12-Mar-2026,,6227323264,11,622732326411,"Whole Blood, EDTA, Dry",Not Received,,,HBV DNA COBAS 6800,,,,,,09:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,11-Mar-2026,UNSCH,12-Mar-2026,,6227323264,4,622732326404,"Serum, SST",Not Received,Ambient,,"CHEM, LIPID PANEL",BETA HCG & CRP,,,,,09:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,11-Mar-2026,UNSCH,12-Mar-2026,,6227323264,13,622732326413,"Stool, unpreserved",Not Received,Frozen,,SM10/FECAL,BIOMARKERS,,,,,09:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,11-Mar-2026,UNSCH,12-Mar-2026,,6227323264,12,622732326412,"Plasma, EDTA",Not Received,Frozen,,HBV DNA COBAS 6800,FROZEN,,,,,09:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,11-Mar-2026,UNSCH,12-Mar-2026,,6227323264,15,622732326415,"Red Cells, Clot",Not Received,,,SM06/SERUM,BIOMARKERS,,,,,09:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,11-Mar-2026,UNSCH,12-Mar-2026,,6227323264,14,622732326414,Whole Blood PAXgene RNA,Not Received,Frozen,,SM07/WB RNA,77242113UCO3001,,,,,09:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,11-Mar-2026,UNSCH,12-Mar-2026,,6227323264,17,622732326417,"Serum, SST",Not Received,Frozen,,SM06/SERUM BIOM,77242113UCO3001-2,,,,,09:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,11-Mar-2026,UNSCH,12-Mar-2026,,6227323264,16,622732326416,"Serum, SST",Not Received,Frozen,,SM06/SERUM BIOM,77242113UCO3001-1,,,,,09:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,11-Mar-2026,UNSCH,12-Mar-2026,,6227323264,18,622732326418,"Serum, SST",Not Received,Frozen,,SM06/SERUM BIOM,77242113UCO3001-3,,,,,09:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,11-Mar-2026,UNSCH,12-Mar-2026,,6227323264,20,622732326420,"Stool, unpreserved",Not Received,Frozen,,STOOL,77242113UCO3001-2,,,,,09:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,11-Mar-2026,UNSCH,12-Mar-2026,,6227323264,5,622732326405,"Serum, SST",Not Received,Ambient,,FSH,,,,,,09:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,11-Mar-2026,UNSCH,12-Mar-2026,,6227323264,22,622732326422,"Stool, unpreserved",Not Received,Frozen,,STOOL,77242113UCO3001-4,,,,,09:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,11-Mar-2026,UNSCH,12-Mar-2026,,6227323264,21,622732326421,"Stool, unpreserved",Not Received,Frozen,,STOOL,77242113UCO3001-3,,,,,09:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,11-Mar-2026,UNSCH,12-Mar-2026,,6227323264,23,622732326423,"Stool, unpreserved",Not Received,Frozen,,STOOL,77242113UCO3001-5,,,,,09:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,11-Mar-2026,UNSCH,12-Mar-2026,,6227323264,24,622732326424,"Red Cells, Clot",Not Received,,,SM05/SERUM ADA,,,,,,09:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,11-Mar-2026,UNSCH,12-Mar-2026,,6227323264,25,622732326425,"Serum, SST",Not Received,Frozen,,SERUM ADA,77242113UCO3001-1,,,,,09:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,11-Mar-2026,UNSCH,12-Mar-2026,,6227323264,19,622732326419,"Stool, unpreserved",Not Received,Frozen,,STOOL,77242113UCO3001,,,,,09:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,11-Mar-2026,UNSCH,12-Mar-2026,,6227323264,26,622732326426,"Serum, SST",Not Received,Frozen,,SERUM ADA,77242113UCO3001-2,,,,,09:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,11-Mar-2026,UNSCH,12-Mar-2026,,6227323264,27,622732326427,"Whole Blood, EDTA, Dry",Not Received,,,SM03/PLASMA PK,,,,,,09:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,11-Mar-2026,UNSCH,12-Mar-2026,,6227323264,28,622732326428,"Plasma, EDTA",Not Received,Frozen,,PLASMA PK,77242113UCO3001,,,,,09:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,11-Mar-2026,UNSCH,12-Mar-2026,,6227323264,29,622732326429,"Whole Blood, EDTA, Dry",Not Received,,,HIV-1/HIV-2,QUALITATIVE RNA,,,,,09:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,11-Mar-2026,UNSCH,12-Mar-2026,,6227323264,30,622732326430,"Plasma, EDTA",Not Received,Frozen,,HIV-1/HIV-2 QUAL,RNA FROZEN,,,,,09:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,17-Mar-2026,UNSCH,18-Mar-2026,18-Mar-2026,6227323265,1,622732326501,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,08:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,17-Mar-2026,UNSCH,18-Mar-2026,,6227323265,3,622732326503,"Red Cells, Clot",Not Received,,,"CHEM, LIPID PANEL,","BHCG, FSH & CRP",,,,,08:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,17-Mar-2026,UNSCH,18-Mar-2026,,6227323265,4,622732326504,"Serum, SST",Not Received,Ambient,,"CHEM, LIPID PANEL",BETA HCG & CRP,,,,,08:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,17-Mar-2026,UNSCH,18-Mar-2026,18-Mar-2026,6227323265,2,622732326502,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,08:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,17-Mar-2026,UNSCH,18-Mar-2026,,6227323265,5,622732326505,"Serum, SST",Not Received,Ambient,,FSH,,,,,,08:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,17-Mar-2026,UNSCH,18-Mar-2026,,6227323265,8,622732326508,"Feces, unpreserved",Not Received,Frozen,,FECAL CALPROTECTIN,FROZEN,,,,,08:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,17-Mar-2026,UNSCH,18-Mar-2026,,6227323265,6,622732326506,"Red Cells, Clot",Not Received,,,"HIV SCREEN,",HEPATITIS B & C,,,,,08:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,17-Mar-2026,UNSCH,18-Mar-2026,,6227323265,7,622732326507,"Serum, SST",Not Received,Ambient,,"HIV SCREEN,",HEPATITIS B & C,,,,,08:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,17-Mar-2026,UNSCH,18-Mar-2026,,6227323265,9,622732326509,"Whole Blood, EDTA, Dry",Not Received,,,HCV RNA COBAS 6800,,,,,,08:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,17-Mar-2026,UNSCH,18-Mar-2026,,6227323265,10,622732326510,"Plasma, EDTA",Not Received,Frozen,,HCV RNA COBAS 6800,FROZEN,,,,,08:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,17-Mar-2026,UNSCH,18-Mar-2026,,6227323265,11,622732326511,"Whole Blood, EDTA, Dry",Not Received,,,HBV DNA COBAS 6800,,,,,,08:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,17-Mar-2026,UNSCH,18-Mar-2026,,6227323265,12,622732326512,"Plasma, EDTA",Not Received,Frozen,,HBV DNA COBAS 6800,FROZEN,,,,,08:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,17-Mar-2026,UNSCH,18-Mar-2026,,6227323265,13,622732326513,"Stool, unpreserved",Not Received,Frozen,,SM10/FECAL,BIOMARKERS,,,,,08:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,17-Mar-2026,UNSCH,18-Mar-2026,,6227323265,14,622732326514,Whole Blood PAXgene RNA,Not Received,Frozen,,SM07/WB RNA,77242113UCO3001,,,,,08:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,17-Mar-2026,UNSCH,18-Mar-2026,,6227323265,15,622732326515,"Red Cells, Clot",Not Received,,,SM06/SERUM,BIOMARKERS,,,,,08:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,17-Mar-2026,UNSCH,18-Mar-2026,,6227323265,21,622732326521,"Stool, unpreserved",Not Received,Frozen,,STOOL,77242113UCO3001-3,,,,,08:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,17-Mar-2026,UNSCH,18-Mar-2026,,6227323265,18,622732326518,"Serum, SST",Not Received,Frozen,,SM06/SERUM BIOM,77242113UCO3001-3,,,,,08:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,17-Mar-2026,UNSCH,18-Mar-2026,,6227323265,17,622732326517,"Serum, SST",Not Received,Frozen,,SM06/SERUM BIOM,77242113UCO3001-2,,,,,08:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,17-Mar-2026,UNSCH,18-Mar-2026,,6227323265,25,622732326525,"Serum, SST",Not Received,Frozen,,SERUM ADA,77242113UCO3001-1,,,,,08:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,17-Mar-2026,UNSCH,18-Mar-2026,,6227323265,22,622732326522,"Stool, unpreserved",Not Received,Frozen,,STOOL,77242113UCO3001-4,,,,,08:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,17-Mar-2026,UNSCH,18-Mar-2026,,6227323265,20,622732326520,"Stool, unpreserved",Not Received,Frozen,,STOOL,77242113UCO3001-2,,,,,08:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,17-Mar-2026,UNSCH,18-Mar-2026,,6227323265,29,622732326529,"Whole Blood, EDTA, Dry",Not Received,,,HIV-1/HIV-2,QUALITATIVE RNA,,,,,08:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,17-Mar-2026,UNSCH,18-Mar-2026,,6227323265,27,622732326527,"Whole Blood, EDTA, Dry",Not Received,,,SM03/PLASMA PK,,,,,,08:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,17-Mar-2026,UNSCH,18-Mar-2026,,6227323265,24,622732326524,"Red Cells, Clot",Not Received,,,SM05/SERUM ADA,,,,,,08:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,17-Mar-2026,UNSCH,18-Mar-2026,,6227323265,16,622732326516,"Serum, SST",Not Received,Frozen,,SM06/SERUM BIOM,77242113UCO3001-1,,,,,08:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,17-Mar-2026,UNSCH,18-Mar-2026,,6227323265,19,622732326519,"Stool, unpreserved",Not Received,Frozen,,STOOL,77242113UCO3001,,,,,08:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,17-Mar-2026,UNSCH,18-Mar-2026,,6227323265,28,622732326528,"Plasma, EDTA",Not Received,Frozen,,PLASMA PK,77242113UCO3001,,,,,08:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,17-Mar-2026,UNSCH,18-Mar-2026,,6227323265,26,622732326526,"Serum, SST",Not Received,Frozen,,SERUM ADA,77242113UCO3001-2,,,,,08:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,17-Mar-2026,UNSCH,18-Mar-2026,,6227323265,30,622732326530,"Plasma, EDTA",Not Received,Frozen,,HIV-1/HIV-2 QUAL,RNA FROZEN,,,,,08:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,17-Mar-2026,UNSCH,18-Mar-2026,,6227323265,23,622732326523,"Stool, unpreserved",Not Received,Frozen,,STOOL,77242113UCO3001-5,,,,,08:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222001,15-Jan-2026,SCRN,16-Jan-2026,,6227323266,1,622732326601,Whole Blood QuantiFERON Nil,Not Received,,,QUANTIFERON PLUS,NIL-GRAY,,,,,16:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222001,15-Jan-2026,SCRN,16-Jan-2026,,6227323266,3,622732326603,Whole Blood QuantiFERON TB1,Not Received,,,QUANTIFERON PLUS,TB1-GREEN,,,,,16:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222001,15-Jan-2026,SCRN,16-Jan-2026,17-Jan-2026,6227323266,2,622732326602,"Plasma, QuantiFERON Nil",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,NIL-GRAY FRZ,,,,,16:45,07:30,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222001,15-Jan-2026,SCRN,16-Jan-2026,,6227323266,5,622732326605,Whole Blood QuantiFERON TB2,Not Received,,,QUANTIFERON PLUS,TB2-YELLOW,,,,,16:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222001,15-Jan-2026,SCRN,16-Jan-2026,,6227323266,7,622732326607,Whole Blood QuantiFERON Mitoge,Not Received,,,QUANTIFERON PLUS,MITOGEN-PURPLE,,,,,16:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222001,15-Jan-2026,SCRN,16-Jan-2026,17-Jan-2026,6227323266,6,622732326606,"Plasma, QuantiFERON TB2",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB2-YELLOW FRZ,,,,,16:45,07:30,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222001,15-Jan-2026,SCRN,16-Jan-2026,16-Jan-2026,6227323266,9,622732326609,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,16:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222001,15-Jan-2026,SCRN,16-Jan-2026,16-Jan-2026,6227323266,10,622732326610,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,16:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222001,15-Jan-2026,SCRN,16-Jan-2026,17-Jan-2026,6227323266,8,622732326608,"Plasma, QuantiFERON Mitoge",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,MITOGEN-PURPLE FRZ,,,,,16:45,07:30,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222001,15-Jan-2026,SCRN,16-Jan-2026,17-Jan-2026,6227323266,4,622732326604,"Plasma, QuantiFERON TB1",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB1-GREEN FRZ,,,,,16:45,07:30,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222001,15-Jan-2026,SCRN,16-Jan-2026,16-Jan-2026,6227323266,12,622732326612,"Serum, SST",Received,Ambient,Default Return Ambient,"HIV SCREEN,",HEPATITIS B & C,,,,,16:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222001,15-Jan-2026,SCRN,16-Jan-2026,,6227323266,13,622732326613,"Red Cells, Clot",Not Received,,,"CHEM PANEL, BETA",HCG & FSH,,,,,16:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222001,15-Jan-2026,SCRN,16-Jan-2026,,6227323266,11,622732326611,"Red Cells, Clot",Not Received,,,"HIV SCREEN,",HEPATITIS B & C,,,,,16:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222001,15-Jan-2026,SCRN,16-Jan-2026,16-Jan-2026,6227323266,14,622732326614,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,BETA HCG,,,,,16:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222001,15-Jan-2026,SCRN,16-Jan-2026,,6227323266,15,622732326615,"Serum, SST",Canceled,Ambient,,FSH,,,,,,16:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222002,23-Jan-2026,SCRN,24-Jan-2026,,6227323268,1,622732326801,Whole Blood QuantiFERON Nil,Not Received,,,QUANTIFERON PLUS,NIL-GRAY,,,,,10:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222002,23-Jan-2026,SCRN,24-Jan-2026,30-Jan-2026,6227323268,2,622732326802,"Plasma, QuantiFERON Nil",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,NIL-GRAY FRZ,,,,,10:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222002,23-Jan-2026,SCRN,24-Jan-2026,,6227323268,3,622732326803,Whole Blood QuantiFERON TB1,Not Received,,,QUANTIFERON PLUS,TB1-GREEN,,,,,10:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222002,23-Jan-2026,SCRN,24-Jan-2026,30-Jan-2026,6227323268,4,622732326804,"Plasma, QuantiFERON TB1",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB1-GREEN FRZ,,,,,10:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222002,23-Jan-2026,SCRN,24-Jan-2026,,6227323268,5,622732326805,Whole Blood QuantiFERON TB2,Not Received,,,QUANTIFERON PLUS,TB2-YELLOW,,,,,10:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222002,23-Jan-2026,SCRN,24-Jan-2026,30-Jan-2026,6227323268,6,622732326806,"Plasma, QuantiFERON TB2",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB2-YELLOW FRZ,,,,,10:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222002,23-Jan-2026,SCRN,24-Jan-2026,,6227323268,7,622732326807,Whole Blood QuantiFERON Mitoge,Not Received,,,QUANTIFERON PLUS,MITOGEN-PURPLE,,,,,10:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222002,23-Jan-2026,SCRN,24-Jan-2026,24-Jan-2026,6227323268,12,622732326812,"Serum, SST",Received,Ambient,Default Return Ambient,"HIV SCREEN,",HEPATITIS B & C,,,,,10:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222002,23-Jan-2026,SCRN,24-Jan-2026,,6227323268,13,622732326813,"Red Cells, Clot",Not Received,,,"CHEM PANEL, BETA",HCG & FSH,,,,,10:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222002,23-Jan-2026,SCRN,24-Jan-2026,24-Jan-2026,6227323268,14,622732326814,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,BETA HCG,,,,,10:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222002,23-Jan-2026,SCRN,24-Jan-2026,,6227323268,15,622732326815,"Serum, SST",Canceled,Ambient,,FSH,,,,,,10:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222002,23-Jan-2026,SCRN,24-Jan-2026,30-Jan-2026,6227323268,8,622732326808,"Plasma, QuantiFERON Mitoge",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,MITOGEN-PURPLE FRZ,,,,,10:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222002,23-Jan-2026,SCRN,24-Jan-2026,24-Jan-2026,6227323268,10,622732326810,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,10:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222002,23-Jan-2026,SCRN,24-Jan-2026,24-Jan-2026,6227323268,9,622732326809,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,10:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222002,23-Jan-2026,SCRN,24-Jan-2026,,6227323268,11,622732326811,"Red Cells, Clot",Not Received,,,"HIV SCREEN,",HEPATITIS B & C,,,,,10:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,09-Mar-2026,I-0,10-Mar-2026,,6227323270,3,622732327003,"Whole Blood, EDTA, Dry",Not Received,,,PLASMA PK TROUGH,,,,,,08:50,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,09-Mar-2026,I-0,10-Mar-2026,10-Mar-2026,6227323270,2,622732327002,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,08:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,09-Mar-2026,I-0,10-Mar-2026,10-Mar-2026,6227323270,4,622732327004,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMPK I-0 TROUGH,77242113UCO3001,,,,,08:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,09-Mar-2026,I-0,10-Mar-2026,,6227323270,5,622732327005,"Whole Blood, EDTA, Dry",Not Received,,,SM02/PLASMAPK PEAK,,,,,,08:50,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,09-Mar-2026,I-0,10-Mar-2026,10-Mar-2026,6227323270,6,622732327006,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMA PK I-0 PEAK,77242113UCO3001,,,,,08:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,09-Mar-2026,I-0,10-Mar-2026,10-Mar-2026,6227323270,1,622732327001,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,08:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,09-Mar-2026,I-0,10-Mar-2026,10-Mar-2026,6227323270,8,622732327008,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-0 PRE,77242113UCO3001-1,,,,,08:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,09-Mar-2026,I-0,10-Mar-2026,,6227323270,7,622732327007,"Red Cells, Clot",Not Received,,,SM04/SERUM ADA PRE,,,,,,08:50,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,09-Mar-2026,I-0,10-Mar-2026,10-Mar-2026,6227323270,10,622732327010,"Stool, unpreserved",In Inventory,Frozen,Default Return Frozen,SM10/FECAL,BIOMARKERS,,,,,08:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,09-Mar-2026,I-0,10-Mar-2026,10-Mar-2026,6227323270,9,622732327009,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-0 PRE,77242113UCO3001-2,,,,,08:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,09-Mar-2026,I-0,10-Mar-2026,10-Mar-2026,6227323270,11,622732327011,Whole Blood PAXgene RNA,Shipped,Frozen,Default Return Frozen,SM07/WB RNA,77242113UCO3001,,,,,08:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,09-Mar-2026,I-0,10-Mar-2026,,6227323270,12,622732327012,"Red Cells, Clot",Not Received,,,SM06/SERUM,BIOMARKERS,,,,,08:50,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,09-Mar-2026,I-0,10-Mar-2026,10-Mar-2026,6227323270,13,622732327013,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-1,,,,,08:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,09-Mar-2026,I-0,10-Mar-2026,10-Mar-2026,6227323270,14,622732327014,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-2,,,,,08:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,09-Mar-2026,I-0,10-Mar-2026,10-Mar-2026,6227323270,15,622732327015,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-3,,,,,08:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,09-Mar-2026,I-0,10-Mar-2026,10-Mar-2026,6227323270,18,622732327018,"Serum, SST",Received,Ambient,Default Return Ambient,"CHEM, LIPID PANEL",& CRP,,,,,08:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,09-Mar-2026,I-0,10-Mar-2026,,6227323270,17,622732327017,"Red Cells, Clot",Not Received,,,"CHEM, LIPID PANEL",& CRP,,,,,08:50,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,09-Mar-2026,I-0,10-Mar-2026,10-Mar-2026,6227323270,16,622732327016,"Feces, unpreserved",Received,Frozen,Default Return Frozen,FECAL CALPROTECTIN,FROZEN,,,,,08:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,27-Mar-2026,I-2,28-Mar-2026,,6227323272,1,622732327201,"Whole Blood, EDTA, Dry",Not Received,,,PLASMA PK TROUGH,,,,,,07:10,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,27-Mar-2026,I-2,28-Mar-2026,28-Mar-2026,6227323272,2,622732327202,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMPK I-2 TROUGH,77242113UCO3001,,,,,07:10,07:20,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,27-Mar-2026,I-2,28-Mar-2026,28-Mar-2026,6227323272,12,622732327212,"Stool, unpreserved",Shipped,Frozen,Default Return Frozen,STOOL I-2,77242113UCO3001-5,,,,,07:10,07:20,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,27-Mar-2026,I-2,28-Mar-2026,28-Mar-2026,6227323272,13,622732327213,"Feces, unpreserved",Received,Frozen,Default Return Frozen,FECAL CALPROTECTIN,FROZEN,,,,,07:10,07:20,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,27-Mar-2026,I-2,28-Mar-2026,,6227323272,3,622732327203,"Whole Blood, EDTA, Dry",Not Received,,,SM02/PLASMAPK PEAK,,,,,,07:10,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,27-Mar-2026,I-2,28-Mar-2026,,6227323272,11,622732327211,"Stool, unpreserved",Canceled,Frozen,,STOOL I-2,77242113UCO3001-4,,,,,07:10,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,27-Mar-2026,I-2,28-Mar-2026,28-Mar-2026,6227323272,14,622732327214,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,07:10,07:20,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,27-Mar-2026,I-2,28-Mar-2026,28-Mar-2026,6227323272,15,622732327215,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,07:10,07:20,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,27-Mar-2026,I-2,28-Mar-2026,28-Mar-2026,6227323272,17,622732327217,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,CRP,,,,,07:10,07:20,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,27-Mar-2026,I-2,28-Mar-2026,,6227323272,10,622732327210,"Stool, unpreserved",Canceled,Frozen,,STOOL I-2,77242113UCO3001-3,,,,,07:10,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,27-Mar-2026,I-2,28-Mar-2026,,6227323272,16,622732327216,"Red Cells, Clot",Not Received,,,CHEM PANEL &,CRP,,,,,07:10,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,27-Mar-2026,I-2,28-Mar-2026,,6227323272,5,622732327205,"Red Cells, Clot",Not Received,,,SM04/SERUM ADA PRE,,,,,,07:10,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,27-Mar-2026,I-2,28-Mar-2026,28-Mar-2026,6227323272,6,622732327206,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-2 PRE,77242113UCO3001-1,,,,,07:10,07:20,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,27-Mar-2026,I-2,28-Mar-2026,28-Mar-2026,6227323272,4,622732327204,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMA PK I-2 PEAK,77242113UCO3001,,,,,07:10,07:20,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,27-Mar-2026,I-2,28-Mar-2026,28-Mar-2026,6227323272,7,622732327207,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-2 PRE,77242113UCO3001-2,,,,,07:10,07:20,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,27-Mar-2026,I-2,28-Mar-2026,,6227323272,8,622732327208,"Stool, unpreserved",Canceled,Frozen,,STOOL I-2,77242113UCO3001-1,,,,,07:10,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,27-Mar-2026,I-2,28-Mar-2026,,6227323272,9,622732327209,"Stool, unpreserved",Canceled,Frozen,,STOOL I-2,77242113UCO3001-2,,,,,07:10,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,08-Apr-2026,I-4,09-Apr-2026,,6227323274,1,622732327401,"Red Cells, Clot",Not Received,,,CHEM PANEL &,CRP,,,,,08:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,08-Apr-2026,I-4,09-Apr-2026,09-Apr-2026,6227323274,2,622732327402,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,CRP,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,08-Apr-2026,I-4,09-Apr-2026,09-Apr-2026,6227323274,3,622732327403,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,08-Apr-2026,I-4,09-Apr-2026,09-Apr-2026,6227323274,5,622732327405,"Feces, unpreserved",Received,Frozen,Default Return Frozen,FECAL CALPROTECTIN,FROZEN,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,08-Apr-2026,I-4,09-Apr-2026,09-Apr-2026,6227323274,4,622732327404,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,08-Apr-2026,I-4,09-Apr-2026,,6227323274,6,622732327406,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-4,77242113UCO3001-1,,,,,08:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,08-Apr-2026,I-4,09-Apr-2026,,6227323274,7,622732327407,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-4,77242113UCO3001-2,,,,,08:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,08-Apr-2026,I-4,09-Apr-2026,,6227323274,8,622732327408,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-4,77242113UCO3001-3,,,,,08:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,08-Apr-2026,I-4,09-Apr-2026,,6227323274,9,622732327409,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-4,77242113UCO3001-4,,,,,08:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,08-Apr-2026,I-4,09-Apr-2026,,6227323274,11,622732327411,"Whole Blood, EDTA, Dry",Not Received,,,PLASMA PK TROUGH,,,,,,08:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,08-Apr-2026,I-4,09-Apr-2026,09-Apr-2026,6227323274,10,622732327410,"Stool, unpreserved",Shipped,Frozen,Default Return Frozen,STOOL I-4,77242113UCO3001-5,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,08-Apr-2026,I-4,09-Apr-2026,09-Apr-2026,6227323274,12,622732327412,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMPK I-4 TROUGH,77242113UCO3001,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,08-Apr-2026,I-4,09-Apr-2026,09-Apr-2026,6227323274,20,622732327420,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-2,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,08-Apr-2026,I-4,09-Apr-2026,09-Apr-2026,6227323274,21,622732327421,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-3,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,08-Apr-2026,I-4,09-Apr-2026,,6227323274,13,622732327413,"Whole Blood, EDTA, Dry",Not Received,,,SM02/PLASMAPK PEAK,,,,,,08:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,08-Apr-2026,I-4,09-Apr-2026,09-Apr-2026,6227323274,22,622732327422,Whole Blood PAXgene RNA,Shipped,Frozen,Default Return Frozen,SM07/WB RNA,77242113UCO3001,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,08-Apr-2026,I-4,09-Apr-2026,,6227323274,15,622732327415,"Red Cells, Clot",Not Received,,,SM04/SERUM ADA PRE,,,,,,08:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,08-Apr-2026,I-4,09-Apr-2026,09-Apr-2026,6227323274,19,622732327419,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-1,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,08-Apr-2026,I-4,09-Apr-2026,09-Apr-2026,6227323274,16,622732327416,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-4 PRE,77242113UCO3001-1,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,08-Apr-2026,I-4,09-Apr-2026,09-Apr-2026,6227323274,14,622732327414,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMA PK I-4 PEAK,77242113UCO3001,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,08-Apr-2026,I-4,09-Apr-2026,09-Apr-2026,6227323274,17,622732327417,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-4 PRE,77242113UCO3001-2,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,08-Apr-2026,I-4,09-Apr-2026,,6227323274,18,622732327418,"Red Cells, Clot",Not Received,,,SM06/SERUM,BIOMARKERS,,,,,08:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222001,15-Jan-2026,SCRNSTOOL,16-Jan-2026,,6227323276,1,622732327601,"Stool, ova & parasites(form)",Not Received,Ambient,,OVA & PARASITES 1,FORMALIN,,,,,16:55,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222001,15-Jan-2026,SCRNSTOOL,16-Jan-2026,16-Jan-2026,6227323276,2,622732327602,"Stool, unpreserved",Canceled,Frozen,,C-DIFF TOXIN,& PCR FROZEN,,,,,16:55,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222001,15-Jan-2026,SCRNSTOOL,16-Jan-2026,,6227323276,4,622732327604,"Stool, ova & parasites(PVA)",Not Received,Ambient,,OVA & PARASITES 2,PVA,,,,,16:55,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222001,15-Jan-2026,SCRNSTOOL,16-Jan-2026,16-Jan-2026,6227323276,3,622732327603,"Culture, Stool",Received,Ambient,Default Return Ambient,STOOL CULTURE,,,,,,16:55,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222002,23-Jan-2026,SCRNSTOOL,24-Jan-2026,,6227323277,1,622732327701,"Stool, ova & parasites(form)",Canceled,Ambient,,OVA & PARASITES 1,FORMALIN,,,,,10:10,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222002,23-Jan-2026,SCRNSTOOL,24-Jan-2026,24-Jan-2026,6227323277,3,622732327703,"Culture, Stool",Received,Ambient,Default Return Ambient,STOOL CULTURE,,,,,,10:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222002,23-Jan-2026,SCRNSTOOL,24-Jan-2026,24-Jan-2026,6227323277,2,622732327702,"Stool, unpreserved",Received,Frozen,Default Return Frozen,C-DIFF TOXIN,& PCR FROZEN,,,,,10:10,12:40,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222002,23-Jan-2026,SCRNSTOOL,24-Jan-2026,,6227323277,4,622732327704,"Stool, ova & parasites(PVA)",Canceled,Ambient,,OVA & PARASITES 2,PVA,,,,,10:10,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,09-Mar-2026,DNA,10-Mar-2026,10-Mar-2026,6227323283,1,622732328301,"Whole Blood, EDTA, Dry",Shipped,Frozen,Default Return Frozen,SM08/WB DNA,77242113UCO3001,,,,,08:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,DNA,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222001,18-Feb-2026,BXSCR,19-Feb-2026,19-Feb-2026,6227323286,1,622732328601,Wet Tissue Biopsy,Removed,Ambient,Default Return Ambient,SM11/BIOPSY,HISTOLOGY,,,,,00:00,10:20,Czech Republic,,10:20,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222001,18-Feb-2026,BXSCR,19-Feb-2026,21-Feb-2026,6227323286,3,622732328603,"Biopsy, Frozen Tissue",Shipped,Frozen,Default Return Frozen,SM14/BIOPSY CRYO,FROZEN,,,,,00:00,05:55,Czech Republic,,10:20,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222001,18-Feb-2026,BXSCR,19-Feb-2026,21-Feb-2026,6227323286,2,622732328602,Biopsy RNA Later,Shipped,Frozen,Default Return Frozen,SM13/BIOPSY RNA,FROZEN,,,,,00:00,05:55,Czech Republic,,10:20,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222001,18-Feb-2026,BXSCR,19-Feb-2026,,6227323286,4,622732328604,"Biopsy, Frozen Tissue",Not Received,Frozen,,BIOPSY PK,77242113UCO3001,,,,,00:00,,Czech Republic,,10:20,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,11-Feb-2026,BXSCR,12-Feb-2026,12-Feb-2026,6227323287,1,622732328701,Wet Tissue Biopsy,Removed,Ambient,Default Return Ambient,SM11/BIOPSY,HISTOLOGY,,,,,00:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,11-Feb-2026,BXSCR,12-Feb-2026,14-Feb-2026,6227323287,3,622732328703,"Biopsy, Frozen Tissue",Shipped,Frozen,Default Return Frozen,SM14/BIOPSY CRYO,FROZEN,,,,,00:00,07:45,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,11-Feb-2026,BXSCR,12-Feb-2026,,6227323287,4,622732328704,"Biopsy, Frozen Tissue",Not Received,Frozen,,BIOPSY PK,77242113UCO3001,,,,,00:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,11-Feb-2026,BXSCR,12-Feb-2026,14-Feb-2026,6227323287,2,622732328702,Biopsy RNA Later,Shipped,Frozen,Default Return Frozen,SM13/BIOPSY RNA,FROZEN,,,,,00:00,05:55,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,13-Mar-2026,SCRN,14-Mar-2026,,6227323295,2,622732329502,"Slides, Hematology",Not Received,Ambient,,HEMATOLOGY,,,,,,08:40,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,13-Mar-2026,SCRN,14-Mar-2026,,6227323295,3,622732329503,"Red Cells, Clot",Not Received,,,"CHEM, LIPID PANEL,","BHCG, FSH & CRP",,,,,08:40,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,13-Mar-2026,SCRN,14-Mar-2026,,6227323295,1,622732329501,"Whole Blood, EDTA, Dry",Not Received,Ambient,,HEMATOLOGY,,,,,,08:40,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,13-Mar-2026,SCRN,14-Mar-2026,,6227323295,6,622732329506,"Red Cells, Clot",Not Received,,,"HIV SCREEN,",HEPATITIS B & C,,,,,08:40,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,13-Mar-2026,SCRN,14-Mar-2026,,6227323295,5,622732329505,"Serum, SST",Not Received,Ambient,,FSH,,,,,,08:40,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,13-Mar-2026,SCRN,14-Mar-2026,,6227323295,7,622732329507,"Serum, SST",Not Received,Ambient,,"HIV SCREEN,",HEPATITIS B & C,,,,,08:40,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,13-Mar-2026,SCRN,14-Mar-2026,,6227323295,8,622732329508,"Feces, unpreserved",Not Received,Frozen,,FECAL CALPROTECTIN,FROZEN,,,,,08:40,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,13-Mar-2026,SCRN,14-Mar-2026,,6227323295,11,622732329511,"Whole Blood, EDTA, Dry",Not Received,,,HBV DNA COBAS 6800,,,,,,08:40,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,13-Mar-2026,SCRN,14-Mar-2026,,6227323295,9,622732329509,"Whole Blood, EDTA, Dry",Not Received,,,HCV RNA COBAS 6800,,,,,,08:40,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,13-Mar-2026,SCRN,14-Mar-2026,,6227323295,10,622732329510,"Plasma, EDTA",Not Received,Frozen,,HCV RNA COBAS 6800,FROZEN,,,,,08:40,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,13-Mar-2026,SCRN,14-Mar-2026,14-Mar-2026,6227323295,4,622732329504,"Serum, SST",Received,Ambient,Default Return Ambient,"CHEM, LIPID PANEL",BETA HCG & CRP,,,,,08:40,07:20,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,13-Mar-2026,SCRN,14-Mar-2026,,6227323295,12,622732329512,"Plasma, EDTA",Not Received,Frozen,,HBV DNA COBAS 6800,FROZEN,,,,,08:40,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,13-Mar-2026,SCRN,14-Mar-2026,,6227323295,13,622732329513,"Stool, unpreserved",Not Received,Frozen,,SM10/FECAL,BIOMARKERS,,,,,08:40,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,13-Mar-2026,SCRN,14-Mar-2026,,6227323295,14,622732329514,Whole Blood PAXgene RNA,Not Received,Frozen,,SM07/WB RNA,77242113UCO3001,,,,,08:40,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,13-Mar-2026,SCRN,14-Mar-2026,,6227323295,16,622732329516,"Serum, SST",Not Received,Frozen,,SM06/SERUM BIOM,77242113UCO3001-1,,,,,08:40,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,13-Mar-2026,SCRN,14-Mar-2026,,6227323295,15,622732329515,"Red Cells, Clot",Not Received,,,SM06/SERUM,BIOMARKERS,,,,,08:40,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,13-Mar-2026,SCRN,14-Mar-2026,,6227323295,17,622732329517,"Serum, SST",Not Received,Frozen,,SM06/SERUM BIOM,77242113UCO3001-2,,,,,08:40,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,13-Mar-2026,SCRN,14-Mar-2026,,6227323295,19,622732329519,"Stool, unpreserved",Not Received,Frozen,,STOOL,77242113UCO3001,,,,,08:40,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,13-Mar-2026,SCRN,14-Mar-2026,,6227323295,18,622732329518,"Serum, SST",Not Received,Frozen,,SM06/SERUM BIOM,77242113UCO3001-3,,,,,08:40,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,13-Mar-2026,SCRN,14-Mar-2026,,6227323295,20,622732329520,"Stool, unpreserved",Not Received,Frozen,,STOOL,77242113UCO3001-2,,,,,08:40,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,13-Mar-2026,SCRN,14-Mar-2026,,6227323295,23,622732329523,"Stool, unpreserved",Not Received,Frozen,,STOOL,77242113UCO3001-5,,,,,08:40,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,13-Mar-2026,SCRN,14-Mar-2026,,6227323295,22,622732329522,"Stool, unpreserved",Not Received,Frozen,,STOOL,77242113UCO3001-4,,,,,08:40,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,13-Mar-2026,SCRN,14-Mar-2026,,6227323295,21,622732329521,"Stool, unpreserved",Not Received,Frozen,,STOOL,77242113UCO3001-3,,,,,08:40,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,13-Mar-2026,SCRN,14-Mar-2026,,6227323295,25,622732329525,"Serum, SST",Not Received,Frozen,,SERUM ADA,77242113UCO3001-1,,,,,08:40,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,13-Mar-2026,SCRN,14-Mar-2026,,6227323295,26,622732329526,"Serum, SST",Not Received,Frozen,,SERUM ADA,77242113UCO3001-2,,,,,08:40,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,13-Mar-2026,SCRN,14-Mar-2026,,6227323295,27,622732329527,"Whole Blood, EDTA, Dry",Not Received,,,SM03/PLASMA PK,,,,,,08:40,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,13-Mar-2026,SCRN,14-Mar-2026,,6227323295,24,622732329524,"Red Cells, Clot",Not Received,,,SM05/SERUM ADA,,,,,,08:40,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,13-Mar-2026,SCRN,14-Mar-2026,,6227323295,29,622732329529,"Whole Blood, EDTA, Dry",Not Received,,,HIV-1/HIV-2,QUALITATIVE RNA,,,,,08:40,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,13-Mar-2026,SCRN,14-Mar-2026,,6227323295,30,622732329530,"Plasma, EDTA",Not Received,Frozen,,HIV-1/HIV-2 QUAL,RNA FROZEN,,,,,08:40,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,13-Mar-2026,SCRN,14-Mar-2026,,6227323295,28,622732329528,"Plasma, EDTA",Not Received,Frozen,,PLASMA PK,77242113UCO3001,,,,,08:40,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,13-Mar-2026,SCRN,14-Mar-2026,,6227323297,2,622732329702,"Slides, Hematology",Not Received,Ambient,,HEMATOLOGY,,,,,,07:45,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,13-Mar-2026,SCRN,14-Mar-2026,14-Mar-2026,6227323297,4,622732329704,"Serum, SST",Received,Ambient,Default Return Ambient,"CHEM, LIPID PANEL",BETA HCG & CRP,,,,,07:45,07:20,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,13-Mar-2026,SCRN,14-Mar-2026,,6227323297,6,622732329706,"Red Cells, Clot",Not Received,,,"HIV SCREEN,",HEPATITIS B & C,,,,,07:45,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,13-Mar-2026,SCRN,14-Mar-2026,,6227323297,5,622732329705,"Serum, SST",Not Received,Ambient,,FSH,,,,,,07:45,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,13-Mar-2026,SCRN,14-Mar-2026,,6227323297,1,622732329701,"Whole Blood, EDTA, Dry",Not Received,Ambient,,HEMATOLOGY,,,,,,07:45,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,13-Mar-2026,SCRN,14-Mar-2026,,6227323297,3,622732329703,"Red Cells, Clot",Not Received,,,"CHEM, LIPID PANEL,","BHCG, FSH & CRP",,,,,07:45,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,13-Mar-2026,SCRN,14-Mar-2026,,6227323297,7,622732329707,"Serum, SST",Not Received,Ambient,,"HIV SCREEN,",HEPATITIS B & C,,,,,07:45,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,13-Mar-2026,SCRN,14-Mar-2026,,6227323297,8,622732329708,"Feces, unpreserved",Not Received,Frozen,,FECAL CALPROTECTIN,FROZEN,,,,,07:45,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,13-Mar-2026,SCRN,14-Mar-2026,,6227323297,10,622732329710,"Plasma, EDTA",Not Received,Frozen,,HCV RNA COBAS 6800,FROZEN,,,,,07:45,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,13-Mar-2026,SCRN,14-Mar-2026,,6227323297,9,622732329709,"Whole Blood, EDTA, Dry",Not Received,,,HCV RNA COBAS 6800,,,,,,07:45,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,13-Mar-2026,SCRN,14-Mar-2026,,6227323297,11,622732329711,"Whole Blood, EDTA, Dry",Not Received,,,HBV DNA COBAS 6800,,,,,,07:45,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,13-Mar-2026,SCRN,14-Mar-2026,,6227323297,12,622732329712,"Plasma, EDTA",Not Received,Frozen,,HBV DNA COBAS 6800,FROZEN,,,,,07:45,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,13-Mar-2026,SCRN,14-Mar-2026,,6227323297,14,622732329714,Whole Blood PAXgene RNA,Not Received,Frozen,,SM07/WB RNA,77242113UCO3001,,,,,07:45,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,13-Mar-2026,SCRN,14-Mar-2026,,6227323297,13,622732329713,"Stool, unpreserved",Not Received,Frozen,,SM10/FECAL,BIOMARKERS,,,,,07:45,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,13-Mar-2026,SCRN,14-Mar-2026,,6227323297,18,622732329718,"Serum, SST",Not Received,Frozen,,SM06/SERUM BIOM,77242113UCO3001-3,,,,,07:45,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,13-Mar-2026,SCRN,14-Mar-2026,,6227323297,16,622732329716,"Serum, SST",Not Received,Frozen,,SM06/SERUM BIOM,77242113UCO3001-1,,,,,07:45,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,13-Mar-2026,SCRN,14-Mar-2026,,6227323297,15,622732329715,"Red Cells, Clot",Not Received,,,SM06/SERUM,BIOMARKERS,,,,,07:45,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,13-Mar-2026,SCRN,14-Mar-2026,,6227323297,20,622732329720,"Stool, unpreserved",Not Received,Frozen,,STOOL,77242113UCO3001-2,,,,,07:45,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,13-Mar-2026,SCRN,14-Mar-2026,,6227323297,19,622732329719,"Stool, unpreserved",Not Received,Frozen,,STOOL,77242113UCO3001,,,,,07:45,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,13-Mar-2026,SCRN,14-Mar-2026,,6227323297,17,622732329717,"Serum, SST",Not Received,Frozen,,SM06/SERUM BIOM,77242113UCO3001-2,,,,,07:45,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,13-Mar-2026,SCRN,14-Mar-2026,,6227323297,21,622732329721,"Stool, unpreserved",Not Received,Frozen,,STOOL,77242113UCO3001-3,,,,,07:45,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,13-Mar-2026,SCRN,14-Mar-2026,,6227323297,23,622732329723,"Stool, unpreserved",Not Received,Frozen,,STOOL,77242113UCO3001-5,,,,,07:45,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,13-Mar-2026,SCRN,14-Mar-2026,,6227323297,25,622732329725,"Serum, SST",Not Received,Frozen,,SERUM ADA,77242113UCO3001-1,,,,,07:45,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,13-Mar-2026,SCRN,14-Mar-2026,,6227323297,27,622732329727,"Whole Blood, EDTA, Dry",Not Received,,,SM03/PLASMA PK,,,,,,07:45,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,13-Mar-2026,SCRN,14-Mar-2026,,6227323297,26,622732329726,"Serum, SST",Not Received,Frozen,,SERUM ADA,77242113UCO3001-2,,,,,07:45,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,13-Mar-2026,SCRN,14-Mar-2026,,6227323297,28,622732329728,"Plasma, EDTA",Not Received,Frozen,,PLASMA PK,77242113UCO3001,,,,,07:45,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,13-Mar-2026,SCRN,14-Mar-2026,,6227323297,29,622732329729,"Whole Blood, EDTA, Dry",Not Received,,,HIV-1/HIV-2,QUALITATIVE RNA,,,,,07:45,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,13-Mar-2026,SCRN,14-Mar-2026,,6227323297,30,622732329730,"Plasma, EDTA",Not Received,Frozen,,HIV-1/HIV-2 QUAL,RNA FROZEN,,,,,07:45,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,13-Mar-2026,SCRN,14-Mar-2026,,6227323297,22,622732329722,"Stool, unpreserved",Not Received,Frozen,,STOOL,77242113UCO3001-4,,,,,07:45,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,13-Mar-2026,SCRN,14-Mar-2026,,6227323297,24,622732329724,"Red Cells, Clot",Not Received,,,SM05/SERUM ADA,,,,,,07:45,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10003,Dr. Leksa Vaclav,CZ100032001,13-May-2026,SCRN,14-May-2026,,6227323299,1,622732329901,Whole Blood QuantiFERON Nil,Not Received,,,QUANTIFERON PLUS,NIL-GRAY,,,,,08:15,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10003,Dr. Leksa Vaclav,CZ100032001,13-May-2026,SCRN,14-May-2026,,6227323299,3,622732329903,Whole Blood QuantiFERON TB1,Not Received,,,QUANTIFERON PLUS,TB1-GREEN,,,,,08:15,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10003,Dr. Leksa Vaclav,CZ100032001,13-May-2026,SCRN,14-May-2026,15-May-2026,6227323299,4,622732329904,"Plasma, QuantiFERON TB1",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB1-GREEN FRZ,,,,,08:15,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10003,Dr. Leksa Vaclav,CZ100032001,13-May-2026,SCRN,14-May-2026,,6227323299,5,622732329905,Whole Blood QuantiFERON TB2,Not Received,,,QUANTIFERON PLUS,TB2-YELLOW,,,,,08:15,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10003,Dr. Leksa Vaclav,CZ100032001,13-May-2026,SCRN,14-May-2026,15-May-2026,6227323299,2,622732329902,"Plasma, QuantiFERON Nil",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,NIL-GRAY FRZ,,,,,08:15,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10003,Dr. Leksa Vaclav,CZ100032001,13-May-2026,SCRN,14-May-2026,,6227323299,7,622732329907,Whole Blood QuantiFERON Mitoge,Not Received,,,QUANTIFERON PLUS,MITOGEN-PURPLE,,,,,08:15,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10003,Dr. Leksa Vaclav,CZ100032001,13-May-2026,SCRN,14-May-2026,15-May-2026,6227323299,8,622732329908,"Plasma, QuantiFERON Mitoge",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,MITOGEN-PURPLE FRZ,,,,,08:15,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10003,Dr. Leksa Vaclav,CZ100032001,13-May-2026,SCRN,14-May-2026,14-May-2026,6227323299,9,622732329909,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,08:15,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10003,Dr. Leksa Vaclav,CZ100032001,13-May-2026,SCRN,14-May-2026,15-May-2026,6227323299,6,622732329906,"Plasma, QuantiFERON TB2",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB2-YELLOW FRZ,,,,,08:15,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10003,Dr. Leksa Vaclav,CZ100032001,13-May-2026,SCRN,14-May-2026,,6227323299,11,622732329911,"Red Cells, Clot",Not Received,,,"HIV SCREEN,",HEPATITIS B & C,,,,,08:15,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10003,Dr. Leksa Vaclav,CZ100032001,13-May-2026,SCRN,14-May-2026,14-May-2026,6227323299,12,622732329912,"Serum, SST",Received,Ambient,Default Return Ambient,"HIV SCREEN,",HEPATITIS B & C,,,,,08:15,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10003,Dr. Leksa Vaclav,CZ100032001,13-May-2026,SCRN,14-May-2026,14-May-2026,6227323299,10,622732329910,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,08:15,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10003,Dr. Leksa Vaclav,CZ100032001,13-May-2026,SCRN,14-May-2026,,6227323299,13,622732329913,"Red Cells, Clot",Not Received,,,CHEM PANEL &,BETA HCG,,,,,08:15,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10003,Dr. Leksa Vaclav,CZ100032001,13-May-2026,SCRN,14-May-2026,14-May-2026,6227323299,15,622732329915,"Serum, SST",Received,Ambient,Default Return Ambient,FSH,,,,,,08:15,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10003,Dr. Leksa Vaclav,CZ100032001,13-May-2026,SCRN,14-May-2026,14-May-2026,6227323299,14,622732329914,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,BETA HCG,,,,,08:15,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10003,Dr. Leksa Vaclav,CZ100032001,13-May-2026,SCRNSTOOL,14-May-2026,14-May-2026,6227323309,1,622732330901,"Stool, ova & parasites(form)",Received,Ambient,Default Return Ambient,OVA & PARASITES 1,FORMALIN,,,,,09:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10003,Dr. Leksa Vaclav,CZ100032001,13-May-2026,SCRNSTOOL,14-May-2026,14-May-2026,6227323309,2,622732330902,"Stool, unpreserved",Received,Frozen,Default Return Frozen,C-DIFF TOXIN,& PCR FROZEN,,,,,09:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10003,Dr. Leksa Vaclav,CZ100032001,13-May-2026,SCRNSTOOL,14-May-2026,14-May-2026,6227323309,4,622732330904,"Stool, ova & parasites(PVA)",Received,Ambient,Default Return Ambient,OVA & PARASITES 2,PVA,,,,,09:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10003,Dr. Leksa Vaclav,CZ100032001,13-May-2026,SCRNSTOOL,14-May-2026,14-May-2026,6227323309,3,622732330903,"Culture, Stool",Received,Ambient,Default Return Ambient,STOOL CULTURE,,,,,,09:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10003,Dr. Leksa Vaclav,CZ100032001,27-May-2026,BXSCR,28-May-2026,28-May-2026,6227323320,1,622732332001,Wet Tissue Biopsy,Removed,Ambient,Default Return Ambient,SM11/BIOPSY,HISTOLOGY,,,,,00:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10003,Dr. Leksa Vaclav,CZ100032001,27-May-2026,BXSCR,28-May-2026,29-May-2026,6227323320,2,622732332002,Biopsy RNA Later,In Inventory,Frozen,Default Return Frozen,SM13/BIOPSY RNA,FROZEN,,,,,00:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10003,Dr. Leksa Vaclav,CZ100032001,27-May-2026,BXSCR,28-May-2026,29-May-2026,6227323320,3,622732332003,"Biopsy, Frozen Tissue",In Inventory,Frozen,Default Return Frozen,SM14/BIOPSY CRYO,FROZEN,,,,,00:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10003,Dr. Leksa Vaclav,CZ100032001,27-May-2026,BXSCR,28-May-2026,,6227323320,4,622732332004,"Biopsy, Frozen Tissue",Not Received,Frozen,,BIOPSY PK,77242113UCO3001,,,,,00:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,31-Mar-2026,SCRN,01-Apr-2026,,6227323330,1,622732333001,Whole Blood QuantiFERON Nil,Not Received,,,QUANTIFERON PLUS,NIL-GRAY,,,,,08:30,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,31-Mar-2026,SCRN,01-Apr-2026,03-Apr-2026,6227323330,2,622732333002,"Plasma, QuantiFERON Nil",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,NIL-GRAY FRZ,,,,,08:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,31-Mar-2026,SCRN,01-Apr-2026,,6227323330,3,622732333003,Whole Blood QuantiFERON TB1,Not Received,,,QUANTIFERON PLUS,TB1-GREEN,,,,,08:30,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,31-Mar-2026,SCRN,01-Apr-2026,,6227323330,5,622732333005,Whole Blood QuantiFERON TB2,Not Received,,,QUANTIFERON PLUS,TB2-YELLOW,,,,,08:30,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,31-Mar-2026,SCRN,01-Apr-2026,03-Apr-2026,6227323330,4,622732333004,"Plasma, QuantiFERON TB1",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB1-GREEN FRZ,,,,,08:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,31-Mar-2026,SCRN,01-Apr-2026,,6227323330,7,622732333007,Whole Blood QuantiFERON Mitoge,Not Received,,,QUANTIFERON PLUS,MITOGEN-PURPLE,,,,,08:30,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,31-Mar-2026,SCRN,01-Apr-2026,03-Apr-2026,6227323330,8,622732333008,"Plasma, QuantiFERON Mitoge",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,MITOGEN-PURPLE FRZ,,,,,08:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,31-Mar-2026,SCRN,01-Apr-2026,01-Apr-2026,6227323330,9,622732333009,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,08:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,31-Mar-2026,SCRN,01-Apr-2026,03-Apr-2026,6227323330,6,622732333006,"Plasma, QuantiFERON TB2",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB2-YELLOW FRZ,,,,,08:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,31-Mar-2026,SCRN,01-Apr-2026,01-Apr-2026,6227323330,10,622732333010,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,08:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,31-Mar-2026,SCRN,01-Apr-2026,,6227323330,11,622732333011,"Red Cells, Clot",Not Received,,,"HIV SCREEN,",HEPATITIS B & C,,,,,08:30,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,31-Mar-2026,SCRN,01-Apr-2026,,6227323330,13,622732333013,"Red Cells, Clot",Not Received,,,CHEM PANEL &,BETA HCG,,,,,08:30,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,31-Mar-2026,SCRN,01-Apr-2026,01-Apr-2026,6227323330,12,622732333012,"Serum, SST",Received,Ambient,Default Return Ambient,"HIV SCREEN,",HEPATITIS B & C,,,,,08:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,31-Mar-2026,SCRN,01-Apr-2026,,6227323330,15,622732333015,"Serum, SST",Canceled,Ambient,,FSH,FROZEN,,,,,08:30,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,31-Mar-2026,SCRN,01-Apr-2026,01-Apr-2026,6227323330,14,622732333014,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,BETA HCG,,,,,08:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092002,16-Apr-2026,SCRN,17-Apr-2026,,6227323332,1,622732333201,Whole Blood QuantiFERON Nil,Not Received,,,QUANTIFERON PLUS,NIL-GRAY,,,,,12:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092002,16-Apr-2026,SCRN,17-Apr-2026,21-Apr-2026,6227323332,2,622732333202,"Plasma, QuantiFERON Nil",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,NIL-GRAY FRZ,,,,,12:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092002,16-Apr-2026,SCRN,17-Apr-2026,,6227323332,3,622732333203,Whole Blood QuantiFERON TB1,Not Received,,,QUANTIFERON PLUS,TB1-GREEN,,,,,12:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092002,16-Apr-2026,SCRN,17-Apr-2026,21-Apr-2026,6227323332,6,622732333206,"Plasma, QuantiFERON TB2",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB2-YELLOW FRZ,,,,,12:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092002,16-Apr-2026,SCRN,17-Apr-2026,21-Apr-2026,6227323332,4,622732333204,"Plasma, QuantiFERON TB1",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB1-GREEN FRZ,,,,,12:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092002,16-Apr-2026,SCRN,17-Apr-2026,21-Apr-2026,6227323332,8,622732333208,"Plasma, QuantiFERON Mitoge",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,MITOGEN-PURPLE FRZ,,,,,12:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092002,16-Apr-2026,SCRN,17-Apr-2026,17-Apr-2026,6227323332,9,622732333209,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,12:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092002,16-Apr-2026,SCRN,17-Apr-2026,,6227323332,5,622732333205,Whole Blood QuantiFERON TB2,Not Received,,,QUANTIFERON PLUS,TB2-YELLOW,,,,,12:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092002,16-Apr-2026,SCRN,17-Apr-2026,17-Apr-2026,6227323332,10,622732333210,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,12:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092002,16-Apr-2026,SCRN,17-Apr-2026,,6227323332,7,622732333207,Whole Blood QuantiFERON Mitoge,Not Received,,,QUANTIFERON PLUS,MITOGEN-PURPLE,,,,,12:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092002,16-Apr-2026,SCRN,17-Apr-2026,,6227323332,11,622732333211,"Red Cells, Clot",Not Received,,,"HIV SCREEN,",HEPATITIS B & C,,,,,12:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092002,16-Apr-2026,SCRN,17-Apr-2026,17-Apr-2026,6227323332,12,622732333212,"Serum, SST",Received,Ambient,Default Return Ambient,"HIV SCREEN,",HEPATITIS B & C,,,,,12:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092002,16-Apr-2026,SCRN,17-Apr-2026,17-Apr-2026,6227323332,14,622732333214,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,BETA HCG,,,,,12:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092002,16-Apr-2026,SCRN,17-Apr-2026,,6227323332,13,622732333213,"Red Cells, Clot",Not Received,,,CHEM PANEL &,BETA HCG,,,,,12:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092002,16-Apr-2026,SCRN,17-Apr-2026,17-Apr-2026,6227323332,15,622732333215,"Serum, SST",Received,Ambient,Default Return Ambient,FSH,,,,,,12:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,05-May-2026,I-0,06-May-2026,06-May-2026,6227323334,1,622732333401,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,11:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,05-May-2026,I-0,06-May-2026,06-May-2026,6227323334,4,622732333404,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMPK I-0 TROUGH,77242113UCO3001,,,,,11:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,05-May-2026,I-0,06-May-2026,06-May-2026,6227323334,2,622732333402,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,11:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,05-May-2026,I-0,06-May-2026,,6227323334,5,622732333405,"Whole Blood, EDTA, Dry",Not Received,,,SM02/PLASMAPK PEAK,,,,,,11:30,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,05-May-2026,I-0,06-May-2026,,6227323334,3,622732333403,"Whole Blood, EDTA, Dry",Not Received,,,PLASMA PK TROUGH,,,,,,11:30,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,05-May-2026,I-0,06-May-2026,06-May-2026,6227323334,6,622732333406,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMA PK I-0 PEAK,77242113UCO3001,,,,,11:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,05-May-2026,I-0,06-May-2026,,6227323334,7,622732333407,"Red Cells, Clot",Not Received,,,SM04/SERUM ADA PRE,,,,,,11:30,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,05-May-2026,I-0,06-May-2026,06-May-2026,6227323334,8,622732333408,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-0 PRE,77242113UCO3001-1,,,,,11:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,05-May-2026,I-0,06-May-2026,06-May-2026,6227323334,9,622732333409,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-0 PRE,77242113UCO3001-2,,,,,11:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,05-May-2026,I-0,06-May-2026,06-May-2026,6227323334,10,622732333410,"Stool, unpreserved",In Inventory,Frozen,Default Return Frozen,SM10/FECAL,BIOMARKERS,,,,,11:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,05-May-2026,I-0,06-May-2026,06-May-2026,6227323334,11,622732333411,Whole Blood PAXgene RNA,Shipped,Frozen,Default Return Frozen,SM07/WB RNA,77242113UCO3001,,,,,11:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,05-May-2026,I-0,06-May-2026,,6227323334,12,622732333412,"Red Cells, Clot",Not Received,,,SM06/SERUM,BIOMARKERS,,,,,11:30,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,05-May-2026,I-0,06-May-2026,06-May-2026,6227323334,13,622732333413,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-1,,,,,11:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,05-May-2026,I-0,06-May-2026,06-May-2026,6227323334,14,622732333414,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-2,,,,,11:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,05-May-2026,I-0,06-May-2026,06-May-2026,6227323334,15,622732333415,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-3,,,,,11:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,05-May-2026,I-0,06-May-2026,06-May-2026,6227323334,16,622732333416,"Feces, unpreserved",Received,Frozen,Default Return Frozen,FECAL CALPROTECTIN,FROZEN,,,,,11:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,05-May-2026,I-0,06-May-2026,,6227323334,17,622732333417,"Red Cells, Clot",Not Received,,,"CHEM, LIPID PANEL",& CRP,,,,,11:30,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,05-May-2026,I-0,06-May-2026,06-May-2026,6227323334,18,622732333418,"Serum, SST",Received,Ambient,Default Return Ambient,"CHEM, LIPID PANEL",& CRP,,,,,11:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,19-May-2026,I-2,20-May-2026,20-May-2026,6227323335,2,622732333502,"Plasma, EDTA",In Inventory,Frozen,Default Return Frozen,PLASMPK I-2 TROUGH,77242113UCO3001,,,,,10:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,19-May-2026,I-2,20-May-2026,,6227323335,3,622732333503,"Whole Blood, EDTA, Dry",Not Received,,,SM02/PLASMAPK PEAK,,,,,,10:50,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,19-May-2026,I-2,20-May-2026,,6227323335,5,622732333505,"Red Cells, Clot",Not Received,,,SM04/SERUM ADA PRE,,,,,,10:50,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,19-May-2026,I-2,20-May-2026,,6227323335,1,622732333501,"Whole Blood, EDTA, Dry",Not Received,,,PLASMA PK TROUGH,,,,,,10:50,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,19-May-2026,I-2,20-May-2026,20-May-2026,6227323335,7,622732333507,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-2 PRE,77242113UCO3001-2,,,,,10:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,19-May-2026,I-2,20-May-2026,20-May-2026,6227323335,6,622732333506,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-2 PRE,77242113UCO3001-1,,,,,10:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,19-May-2026,I-2,20-May-2026,20-May-2026,6227323335,4,622732333504,"Plasma, EDTA",In Inventory,Frozen,Default Return Frozen,PLASMA PK I-2 PEAK,77242113UCO3001,,,,,10:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,19-May-2026,I-2,20-May-2026,20-May-2026,6227323335,8,622732333508,"Stool, unpreserved",Shipped,Frozen,Default Return Frozen,STOOL I-2,77242113UCO3001-1,,,,,10:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,19-May-2026,I-2,20-May-2026,20-May-2026,6227323335,9,622732333509,"Stool, unpreserved",Shipped,Frozen,Default Return Frozen,STOOL I-2,77242113UCO3001-2,,,,,10:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,19-May-2026,I-2,20-May-2026,20-May-2026,6227323335,11,622732333511,"Stool, unpreserved",Shipped,Frozen,Default Return Frozen,STOOL I-2,77242113UCO3001-4,,,,,10:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,19-May-2026,I-2,20-May-2026,20-May-2026,6227323335,10,622732333510,"Stool, unpreserved",Shipped,Frozen,Default Return Frozen,STOOL I-2,77242113UCO3001-3,,,,,10:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,19-May-2026,I-2,20-May-2026,20-May-2026,6227323335,13,622732333513,"Feces, unpreserved",Received,Frozen,Default Return Frozen,FECAL CALPROTECTIN,FROZEN,,,,,10:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,19-May-2026,I-2,20-May-2026,20-May-2026,6227323335,15,622732333515,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,10:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,19-May-2026,I-2,20-May-2026,,6227323335,16,622732333516,"Red Cells, Clot",Not Received,,,CHEM PANEL &,CRP,,,,,10:50,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,19-May-2026,I-2,20-May-2026,20-May-2026,6227323335,17,622732333517,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,CRP,,,,,10:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,19-May-2026,I-2,20-May-2026,20-May-2026,6227323335,14,622732333514,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,10:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,19-May-2026,I-2,20-May-2026,20-May-2026,6227323335,12,622732333512,"Stool, unpreserved",Shipped,Frozen,Default Return Frozen,STOOL I-2,77242113UCO3001-5,,,,,10:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,04-Jun-2026,I-4,05-Jun-2026,,6227323337,1,622732333701,"Red Cells, Clot",Not Received,,,CHEM PANEL &,CRP,,,,,09:50,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,04-Jun-2026,I-4,05-Jun-2026,05-Jun-2026,6227323337,3,622732333703,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,09:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,04-Jun-2026,I-4,05-Jun-2026,05-Jun-2026,6227323337,4,622732333704,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,04-Jun-2026,I-4,05-Jun-2026,05-Jun-2026,6227323337,5,622732333705,"Feces, unpreserved",Received,Frozen,Default Return Frozen,FECAL CALPROTECTIN,FROZEN,,,,,09:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,04-Jun-2026,I-4,05-Jun-2026,05-Jun-2026,6227323337,7,622732333707,"Stool, unpreserved",In Inventory,Frozen,Default Return Frozen,STOOL I-4,77242113UCO3001-2,,,,,09:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,04-Jun-2026,I-4,05-Jun-2026,,6227323337,11,622732333711,"Whole Blood, EDTA, Dry",Not Received,,,PLASMA PK TROUGH,,,,,,09:50,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,04-Jun-2026,I-4,05-Jun-2026,05-Jun-2026,6227323337,8,622732333708,"Stool, unpreserved",In Inventory,Frozen,Default Return Frozen,STOOL I-4,77242113UCO3001-3,,,,,09:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,04-Jun-2026,I-4,05-Jun-2026,05-Jun-2026,6227323337,6,622732333706,"Stool, unpreserved",In Inventory,Frozen,Default Return Frozen,STOOL I-4,77242113UCO3001-1,,,,,09:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,04-Jun-2026,I-4,05-Jun-2026,05-Jun-2026,6227323337,9,622732333709,"Stool, unpreserved",In Inventory,Frozen,Default Return Frozen,STOOL I-4,77242113UCO3001-4,,,,,09:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,04-Jun-2026,I-4,05-Jun-2026,05-Jun-2026,6227323337,2,622732333702,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,CRP,,,,,09:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,04-Jun-2026,I-4,05-Jun-2026,05-Jun-2026,6227323337,12,622732333712,"Plasma, EDTA",In Inventory,Frozen,Default Return Frozen,PLASMPK I-4 TROUGH,77242113UCO3001,,,,,09:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,04-Jun-2026,I-4,05-Jun-2026,,6227323337,13,622732333713,"Whole Blood, EDTA, Dry",Not Received,,,SM02/PLASMAPK PEAK,,,,,,09:50,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,04-Jun-2026,I-4,05-Jun-2026,05-Jun-2026,6227323337,14,622732333714,"Plasma, EDTA",In Inventory,Frozen,Default Return Frozen,PLASMA PK I-4 PEAK,77242113UCO3001,,,,,09:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,04-Jun-2026,I-4,05-Jun-2026,,6227323337,15,622732333715,"Red Cells, Clot",Not Received,,,SM04/SERUM ADA PRE,,,,,,09:50,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,04-Jun-2026,I-4,05-Jun-2026,05-Jun-2026,6227323337,10,622732333710,"Stool, unpreserved",In Inventory,Frozen,Default Return Frozen,STOOL I-4,77242113UCO3001-5,,,,,09:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,04-Jun-2026,I-4,05-Jun-2026,05-Jun-2026,6227323337,16,622732333716,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SERUM ADA I-4 PRE,77242113UCO3001-1,,,,,09:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,04-Jun-2026,I-4,05-Jun-2026,05-Jun-2026,6227323337,19,622732333719,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-1,,,,,09:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,04-Jun-2026,I-4,05-Jun-2026,05-Jun-2026,6227323337,17,622732333717,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SERUM ADA I-4 PRE,77242113UCO3001-2,,,,,09:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,04-Jun-2026,I-4,05-Jun-2026,,6227323337,18,622732333718,"Red Cells, Clot",Not Received,,,SM06/SERUM,BIOMARKERS,,,,,09:50,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,04-Jun-2026,I-4,05-Jun-2026,05-Jun-2026,6227323337,21,622732333721,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-3,,,,,09:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,04-Jun-2026,I-4,05-Jun-2026,05-Jun-2026,6227323337,20,622732333720,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-2,,,,,09:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,04-Jun-2026,I-4,05-Jun-2026,05-Jun-2026,6227323337,22,622732333722,Whole Blood PAXgene RNA,In Inventory,Frozen,Default Return Frozen,SM07/WB RNA,77242113UCO3001,,,,,09:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,02-Apr-2026,SCRNSTOOL,03-Apr-2026,03-Apr-2026,6227323340,2,622732334002,"Stool, unpreserved",Received,Frozen,Default Return Frozen,C-DIFF TOXIN,& PCR FROZEN,,,,,06:15,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,02-Apr-2026,SCRNSTOOL,03-Apr-2026,03-Apr-2026,6227323340,4,622732334004,"Stool, ova & parasites(PVA)",Received,Ambient,Default Return Ambient,OVA & PARASITES 2,PVA,,,,,06:15,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,02-Apr-2026,SCRNSTOOL,03-Apr-2026,03-Apr-2026,6227323340,3,622732334003,"Culture, Stool",Received,Ambient,Default Return Ambient,STOOL CULTURE,,,,,,06:15,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,02-Apr-2026,SCRNSTOOL,03-Apr-2026,03-Apr-2026,6227323340,1,622732334001,"Stool, ova & parasites(form)",Received,Ambient,Default Return Ambient,OVA & PARASITES 1,FORMALIN,,,,,06:15,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092002,20-Apr-2026,SCRNSTOOL,21-Apr-2026,21-Apr-2026,6227323341,1,622732334101,"Stool, ova & parasites(form)",Received,Ambient,Default Return Ambient,OVA & PARASITES 1,FORMALIN,,,,,06:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092002,20-Apr-2026,SCRNSTOOL,21-Apr-2026,21-Apr-2026,6227323341,2,622732334102,"Stool, unpreserved",Received,Frozen,Default Return Frozen,C-DIFF TOXIN,& PCR FROZEN,,,,,06:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092002,20-Apr-2026,SCRNSTOOL,21-Apr-2026,21-Apr-2026,6227323341,3,622732334103,"Culture, Stool",Received,Ambient,Default Return Ambient,STOOL CULTURE,,,,,,06:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092002,20-Apr-2026,SCRNSTOOL,21-Apr-2026,21-Apr-2026,6227323341,4,622732334104,"Stool, ova & parasites(PVA)",Received,Ambient,Default Return Ambient,OVA & PARASITES 2,PVA,,,,,06:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,05-May-2026,DNA,06-May-2026,06-May-2026,6227323346,1,622732334601,"Whole Blood, EDTA, Dry",In Inventory,Frozen,Default Return Frozen,SM08/WB DNA,77242113UCO3001,,,,,11:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,DNA,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092002,05-May-2026,TB,07-May-2026,,6227323348,1,622732334801,Whole Blood QuantiFERON Nil,Not Received,,,QUANTIFERON PLUS,NIL-GRAY,,,,,09:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,TB Testing,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092002,05-May-2026,TB,07-May-2026,07-May-2026,6227323348,2,622732334802,"Plasma, QuantiFERON Nil",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,NIL-GRAY FRZ,,,,,09:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,TB Testing,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092002,05-May-2026,TB,07-May-2026,,6227323348,3,622732334803,Whole Blood QuantiFERON TB1,Not Received,,,QUANTIFERON PLUS,TB1-GREEN,,,,,09:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,TB Testing,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092002,05-May-2026,TB,07-May-2026,07-May-2026,6227323348,4,622732334804,"Plasma, QuantiFERON TB1",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB1-GREEN FRZ,,,,,09:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,TB Testing,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092002,05-May-2026,TB,07-May-2026,,6227323348,5,622732334805,Whole Blood QuantiFERON TB2,Not Received,,,QUANTIFERON PLUS,TB2-YELLOW,,,,,09:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,TB Testing,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092002,05-May-2026,TB,07-May-2026,,6227323348,7,622732334807,Whole Blood QuantiFERON Mitoge,Not Received,,,QUANTIFERON PLUS,MITOGEN-PURPLE,,,,,09:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,TB Testing,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092002,05-May-2026,TB,07-May-2026,07-May-2026,6227323348,6,622732334806,"Plasma, QuantiFERON TB2",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB2-YELLOW FRZ,,,,,09:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,TB Testing,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092002,05-May-2026,TB,07-May-2026,07-May-2026,6227323348,8,622732334808,"Plasma, QuantiFERON Mitoge",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,MITOGEN-PURPLE FRZ,,,,,09:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,TB Testing,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,24-Apr-2026,BXSCR,28-Apr-2026,,6227323351,4,622732335104,"Biopsy, Frozen Tissue",Not Received,Frozen,,BIOPSY PK,77242113UCO3001,,,,,00:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,24-Apr-2026,BXSCR,28-Apr-2026,28-Apr-2026,6227323351,3,622732335103,"Biopsy, Frozen Tissue",In Inventory,Frozen,Default Return Frozen,SM14/BIOPSY CRYO,FROZEN,,,,,00:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,24-Apr-2026,BXSCR,28-Apr-2026,28-Apr-2026,6227323351,2,622732335102,Biopsy RNA Later,Shipped,Frozen,Default Return Frozen,SM13/BIOPSY RNA,FROZEN,,,,,00:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,24-Apr-2026,BXSCR,28-Apr-2026,28-Apr-2026,6227323351,1,622732335101,Wet Tissue Biopsy,Removed,Ambient,Default Return Ambient,SM11/BIOPSY,HISTOLOGY,,,,,00:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,05-May-2026,BDL,06-May-2026,,6227323355,1,622732335501,"Red Cells, Clot",Not Received,,,DRUG LEVEL TESTING,,,,,,11:30,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biologic Drug Level,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,05-May-2026,BDL,06-May-2026,06-May-2026,6227323355,2,622732335502,"Serum, SST",Shipped,Frozen,Default Return Frozen,"ADA, GOL, INF",UST OR VED FROZEN,,,,,11:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biologic Drug Level,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,01-Apr-2026,SCRN,02-Apr-2026,,6227635139,1,622763513901,Whole Blood QuantiFERON Nil,Not Received,,,QUANTIFERON PLUS,NIL-GRAY,,,,,08:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,01-Apr-2026,SCRN,02-Apr-2026,,6227635139,3,622763513903,Whole Blood QuantiFERON TB1,Not Received,,,QUANTIFERON PLUS,TB1-GREEN,,,,,08:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,01-Apr-2026,SCRN,02-Apr-2026,03-Apr-2026,6227635139,8,622763513908,"Plasma, QuantiFERON Mitoge",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,MITOGEN-PURPLE FRZ,,,,,08:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,01-Apr-2026,SCRN,02-Apr-2026,03-Apr-2026,6227635139,4,622763513904,"Plasma, QuantiFERON TB1",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB1-GREEN FRZ,,,,,08:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,01-Apr-2026,SCRN,02-Apr-2026,03-Apr-2026,6227635139,2,622763513902,"Plasma, QuantiFERON Nil",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,NIL-GRAY FRZ,,,,,08:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,26-Feb-2026,SCRN,27-Feb-2026,,6227635140,5,622763514005,Whole Blood QuantiFERON TB2,Not Received,,,QUANTIFERON PLUS,TB2-YELLOW,,,,,13:20,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,26-Feb-2026,SCRN,27-Feb-2026,28-Feb-2026,6227635140,8,622763514008,"Plasma, QuantiFERON Mitoge",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,MITOGEN-PURPLE FRZ,,,,,13:20,07:30,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,01-Apr-2026,SCRN,02-Apr-2026,,6227635139,13,622763513913,"Red Cells, Clot",Not Received,,,CHEM PANEL &,BETA HCG,,,,,08:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,01-Apr-2026,SCRN,02-Apr-2026,03-Apr-2026,6227635139,6,622763513906,"Plasma, QuantiFERON TB2",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB2-YELLOW FRZ,,,,,08:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,26-Feb-2026,SCRN,27-Feb-2026,28-Feb-2026,6227635140,6,622763514006,"Plasma, QuantiFERON TB2",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB2-YELLOW FRZ,,,,,13:20,07:30,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,26-Feb-2026,SCRN,27-Feb-2026,,6227635140,7,622763514007,Whole Blood QuantiFERON Mitoge,Not Received,,,QUANTIFERON PLUS,MITOGEN-PURPLE,,,,,13:20,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,26-Feb-2026,SCRN,27-Feb-2026,27-Feb-2026,6227635140,9,622763514009,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,13:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,01-Apr-2026,SCRN,02-Apr-2026,02-Apr-2026,6227635139,10,622763513910,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,08:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,01-Apr-2026,SCRN,02-Apr-2026,,6227635139,15,622763513915,"Serum, SST",Canceled,Ambient,,FSH,FROZEN,,,,,08:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,01-Apr-2026,SCRN,02-Apr-2026,02-Apr-2026,6227635139,12,622763513912,"Serum, SST",Received,Ambient,Default Return Ambient,"HIV SCREEN,",HEPATITIS B & C,,,,,08:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,01-Apr-2026,SCRN,02-Apr-2026,02-Apr-2026,6227635139,9,622763513909,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,08:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,01-Apr-2026,SCRN,02-Apr-2026,,6227635139,7,622763513907,Whole Blood QuantiFERON Mitoge,Not Received,,,QUANTIFERON PLUS,MITOGEN-PURPLE,,,,,08:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,26-Feb-2026,SCRN,27-Feb-2026,28-Feb-2026,6227635140,4,622763514004,"Plasma, QuantiFERON TB1",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB1-GREEN FRZ,,,,,13:20,07:30,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,01-Apr-2026,SCRN,02-Apr-2026,,6227635139,11,622763513911,"Red Cells, Clot",Not Received,,,"HIV SCREEN,",HEPATITIS B & C,,,,,08:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,26-Feb-2026,SCRN,27-Feb-2026,28-Feb-2026,6227635140,2,622763514002,"Plasma, QuantiFERON Nil",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,NIL-GRAY FRZ,,,,,13:20,07:30,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,26-Feb-2026,SCRN,27-Feb-2026,,6227635140,3,622763514003,Whole Blood QuantiFERON TB1,Not Received,,,QUANTIFERON PLUS,TB1-GREEN,,,,,13:20,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,26-Feb-2026,SCRN,27-Feb-2026,,6227635140,1,622763514001,Whole Blood QuantiFERON Nil,Not Received,,,QUANTIFERON PLUS,NIL-GRAY,,,,,13:20,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,01-Apr-2026,SCRN,02-Apr-2026,,6227635139,5,622763513905,Whole Blood QuantiFERON TB2,Not Received,,,QUANTIFERON PLUS,TB2-YELLOW,,,,,08:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,01-Apr-2026,SCRN,02-Apr-2026,02-Apr-2026,6227635139,14,622763513914,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,BETA HCG,,,,,08:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,26-Feb-2026,SCRN,27-Feb-2026,27-Feb-2026,6227635140,12,622763514012,"Serum, SST",Received,Ambient,Default Return Ambient,"HIV SCREEN,",HEPATITIS B & C,,,,,13:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,26-Feb-2026,SCRN,27-Feb-2026,27-Feb-2026,6227635140,14,622763514014,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,BETA HCG,,,,,13:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132003,06-May-2026,SCRN,07-May-2026,,6227635141,1,622763514101,Whole Blood QuantiFERON Nil,Not Received,,,QUANTIFERON PLUS,NIL-GRAY,,,,,10:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,26-Feb-2026,SCRN,27-Feb-2026,,6227635140,15,622763514015,"Serum, SST",Canceled,Ambient,,FSH,FROZEN,,,,,13:20,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132003,06-May-2026,SCRN,07-May-2026,08-May-2026,6227635141,2,622763514102,"Plasma, QuantiFERON Nil",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,NIL-GRAY FRZ,,,,,10:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,26-Feb-2026,SCRN,27-Feb-2026,,6227635140,11,622763514011,"Red Cells, Clot",Not Received,,,"HIV SCREEN,",HEPATITIS B & C,,,,,13:20,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,26-Feb-2026,SCRN,27-Feb-2026,27-Feb-2026,6227635140,10,622763514010,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,13:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132003,06-May-2026,SCRN,07-May-2026,,6227635141,3,622763514103,Whole Blood QuantiFERON TB1,Not Received,,,QUANTIFERON PLUS,TB1-GREEN,,,,,10:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,26-Feb-2026,SCRN,27-Feb-2026,,6227635140,13,622763514013,"Red Cells, Clot",Not Received,,,CHEM PANEL &,BETA HCG,,,,,13:20,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132003,06-May-2026,SCRN,07-May-2026,08-May-2026,6227635141,8,622763514108,"Plasma, QuantiFERON Mitoge",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,MITOGEN-PURPLE FRZ,,,,,10:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132003,06-May-2026,SCRN,07-May-2026,07-May-2026,6227635141,9,622763514109,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,10:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132003,06-May-2026,SCRN,07-May-2026,,6227635141,11,622763514111,"Red Cells, Clot",Not Received,,,"HIV SCREEN,",HEPATITIS B & C,,,,,10:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132003,06-May-2026,SCRN,07-May-2026,07-May-2026,6227635141,12,622763514112,"Serum, SST",Received,Ambient,Default Return Ambient,"HIV SCREEN,",HEPATITIS B & C,,,,,10:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132003,06-May-2026,SCRN,07-May-2026,07-May-2026,6227635141,10,622763514110,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,10:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132003,06-May-2026,SCRN,07-May-2026,,6227635141,13,622763514113,"Red Cells, Clot",Not Received,,,CHEM PANEL &,BETA HCG,,,,,10:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132003,06-May-2026,SCRN,07-May-2026,,6227635141,7,622763514107,Whole Blood QuantiFERON Mitoge,Not Received,,,QUANTIFERON PLUS,MITOGEN-PURPLE,,,,,10:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132003,06-May-2026,SCRN,07-May-2026,08-May-2026,6227635141,6,622763514106,"Plasma, QuantiFERON TB2",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB2-YELLOW FRZ,,,,,10:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,24-Mar-2026,I-0,26-Mar-2026,,6227635142,3,622763514203,"Whole Blood, EDTA, Dry",Not Received,,,PLASMA PK TROUGH,,,,,,09:40,,Czech Republic,,05:55,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,24-Mar-2026,I-0,26-Mar-2026,26-Mar-2026,6227635142,4,622763514204,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMPK I-0 TROUGH,77242113UCO3001,,,,,09:40,05:55,Czech Republic,,05:55,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,24-Mar-2026,I-0,26-Mar-2026,26-Mar-2026,6227635142,13,622763514213,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-1,,,,,09:40,05:55,Czech Republic,,05:55,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,24-Mar-2026,I-0,26-Mar-2026,,6227635142,5,622763514205,"Whole Blood, EDTA, Dry",Not Received,,,SM02/PLASMAPK PEAK,,,,,,09:40,,Czech Republic,,05:55,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132003,06-May-2026,SCRN,07-May-2026,,6227635141,5,622763514105,Whole Blood QuantiFERON TB2,Not Received,,,QUANTIFERON PLUS,TB2-YELLOW,,,,,10:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132003,06-May-2026,SCRN,07-May-2026,08-May-2026,6227635141,4,622763514104,"Plasma, QuantiFERON TB1",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB1-GREEN FRZ,,,,,10:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,24-Mar-2026,I-0,26-Mar-2026,26-Mar-2026,6227635142,6,622763514206,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMA PK I-0 PEAK,77242113UCO3001,,,,,09:40,05:55,Czech Republic,,05:55,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,24-Mar-2026,I-0,26-Mar-2026,26-Mar-2026,6227635142,14,622763514214,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-2,,,,,09:40,05:55,Czech Republic,,05:55,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,24-Mar-2026,I-0,26-Mar-2026,26-Mar-2026,6227635142,2,622763514202,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:40,05:55,Czech Republic,,05:55,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,24-Mar-2026,I-0,26-Mar-2026,26-Mar-2026,6227635142,10,622763514210,"Stool, unpreserved",In Inventory,Frozen,Default Return Frozen,SM10/FECAL,BIOMARKERS,,,,,09:40,05:55,Czech Republic,,05:55,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,24-Mar-2026,I-0,26-Mar-2026,26-Mar-2026,6227635142,1,622763514201,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,09:40,05:55,Czech Republic,,05:55,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,24-Mar-2026,I-0,26-Mar-2026,26-Mar-2026,6227635142,15,622763514215,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-3,,,,,09:40,05:55,Czech Republic,,05:55,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,24-Mar-2026,I-0,26-Mar-2026,,6227635142,7,622763514207,"Red Cells, Clot",Not Received,,,SM04/SERUM ADA PRE,,,,,,09:40,,Czech Republic,,05:55,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,24-Mar-2026,I-0,26-Mar-2026,26-Mar-2026,6227635142,9,622763514209,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-0 PRE,77242113UCO3001-2,,,,,09:40,05:55,Czech Republic,,05:55,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,24-Mar-2026,I-0,26-Mar-2026,26-Mar-2026,6227635142,16,622763514216,"Feces, unpreserved",Received,Frozen,Default Return Frozen,FECAL CALPROTECTIN,FROZEN,,,,,09:40,05:55,Czech Republic,,05:55,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,24-Mar-2026,I-0,26-Mar-2026,,6227635142,17,622763514217,"Red Cells, Clot",Not Received,,,"CHEM, LIPID PANEL",& CRP,,,,,09:40,,Czech Republic,,05:55,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132003,06-May-2026,SCRN,07-May-2026,07-May-2026,6227635141,14,622763514114,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,BETA HCG,,,,,10:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132003,06-May-2026,SCRN,07-May-2026,,6227635141,15,622763514115,"Serum, SST",Canceled,Ambient,,FSH,FROZEN,,,,,10:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,24-Mar-2026,I-0,26-Mar-2026,,6227635142,12,622763514212,"Red Cells, Clot",Not Received,,,SM06/SERUM,BIOMARKERS,,,,,09:40,,Czech Republic,,05:55,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,24-Mar-2026,I-0,26-Mar-2026,26-Mar-2026,6227635142,11,622763514211,Whole Blood PAXgene RNA,Shipped,Frozen,Default Return Frozen,SM07/WB RNA,77242113UCO3001,,,,,09:40,05:55,Czech Republic,,05:55,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,24-Mar-2026,I-0,26-Mar-2026,26-Mar-2026,6227635142,8,622763514208,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-0 PRE,77242113UCO3001-1,,,,,09:40,05:55,Czech Republic,,05:55,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,24-Mar-2026,I-0,26-Mar-2026,26-Mar-2026,6227635142,18,622763514218,"Serum, SST",Received,Ambient,Default Return Ambient,"CHEM, LIPID PANEL",& CRP,,,,,09:40,05:55,Czech Republic,,05:55,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,07-Apr-2026,I-2,08-Apr-2026,09-Apr-2026,6227635144,7,622763514407,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-2 PRE,77242113UCO3001-2,,,,,08:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,07-Apr-2026,I-2,08-Apr-2026,09-Apr-2026,6227635144,6,622763514406,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-2 PRE,77242113UCO3001-1,,,,,08:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,07-Apr-2026,I-2,08-Apr-2026,,6227635144,3,622763514403,"Whole Blood, EDTA, Dry",Not Received,,,SM02/PLASMAPK PEAK,,,,,,08:50,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,07-Apr-2026,I-2,08-Apr-2026,09-Apr-2026,6227635144,2,622763514402,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMPK I-2 TROUGH,77242113UCO3001,,,,,08:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,07-Apr-2026,I-2,08-Apr-2026,,6227635144,1,622763514401,"Whole Blood, EDTA, Dry",Not Received,,,PLASMA PK TROUGH,,,,,,08:50,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,07-Apr-2026,I-2,08-Apr-2026,08-Apr-2026,6227635144,15,622763514415,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,08:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,07-Apr-2026,I-2,08-Apr-2026,,6227635144,16,622763514416,"Red Cells, Clot",Not Received,,,CHEM PANEL &,CRP,,,,,08:50,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,07-Apr-2026,I-2,08-Apr-2026,09-Apr-2026,6227635144,8,622763514408,"Stool, unpreserved",Shipped,Frozen,Default Return Frozen,STOOL I-2,77242113UCO3001-1,,,,,08:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,07-Apr-2026,I-2,08-Apr-2026,09-Apr-2026,6227635144,10,622763514410,"Stool, unpreserved",Shipped,Frozen,Default Return Frozen,STOOL I-2,77242113UCO3001-3,,,,,08:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,07-Apr-2026,I-2,08-Apr-2026,09-Apr-2026,6227635144,4,622763514404,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMA PK I-2 PEAK,77242113UCO3001,,,,,08:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,07-Apr-2026,I-2,08-Apr-2026,08-Apr-2026,6227635144,17,622763514417,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,CRP,,,,,08:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,07-Apr-2026,I-2,08-Apr-2026,09-Apr-2026,6227635144,12,622763514412,"Stool, unpreserved",Shipped,Frozen,Default Return Frozen,STOOL I-2,77242113UCO3001-5,,,,,08:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,07-Apr-2026,I-2,08-Apr-2026,09-Apr-2026,6227635144,11,622763514411,"Stool, unpreserved",Shipped,Frozen,Default Return Frozen,STOOL I-2,77242113UCO3001-4,,,,,08:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,07-Apr-2026,I-2,08-Apr-2026,08-Apr-2026,6227635144,14,622763514414,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,08:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,07-Apr-2026,I-2,08-Apr-2026,09-Apr-2026,6227635144,13,622763514413,"Feces, unpreserved",Received,Frozen,Default Return Frozen,FECAL CALPROTECTIN,FROZEN,,,,,08:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,07-Apr-2026,I-2,08-Apr-2026,,6227635144,5,622763514405,"Red Cells, Clot",Not Received,,,SM04/SERUM ADA PRE,,,,,,08:50,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,07-Apr-2026,I-2,08-Apr-2026,09-Apr-2026,6227635144,9,622763514409,"Stool, unpreserved",Shipped,Frozen,Default Return Frozen,STOOL I-2,77242113UCO3001-2,,,,,08:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,21-Apr-2026,I-4,22-Apr-2026,22-Apr-2026,6227635146,2,622763514602,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,CRP,,,,,08:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,21-Apr-2026,I-4,22-Apr-2026,22-Apr-2026,6227635146,3,622763514603,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,08:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,21-Apr-2026,I-4,22-Apr-2026,23-Apr-2026,6227635146,8,622763514608,"Stool, unpreserved",Shipped,Frozen,Default Return Frozen,STOOL I-4,77242113UCO3001-3,,,,,08:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,21-Apr-2026,I-4,22-Apr-2026,23-Apr-2026,6227635146,9,622763514609,"Stool, unpreserved",Shipped,Frozen,Default Return Frozen,STOOL I-4,77242113UCO3001-4,,,,,08:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,21-Apr-2026,I-4,22-Apr-2026,23-Apr-2026,6227635146,10,622763514610,"Stool, unpreserved",Shipped,Frozen,Default Return Frozen,STOOL I-4,77242113UCO3001-5,,,,,08:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,21-Apr-2026,I-4,22-Apr-2026,22-Apr-2026,6227635146,16,622763514616,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-4 PRE,77242113UCO3001-1,,,,,08:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,21-Apr-2026,I-4,22-Apr-2026,22-Apr-2026,6227635146,14,622763514614,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMA PK I-4 PEAK,77242113UCO3001,,,,,08:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,21-Apr-2026,I-4,22-Apr-2026,22-Apr-2026,6227635146,21,622763514621,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-3,,,,,08:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,21-Apr-2026,I-4,22-Apr-2026,22-Apr-2026,6227635146,4,622763514604,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,08:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,21-Apr-2026,I-4,22-Apr-2026,22-Apr-2026,6227635146,5,622763514605,"Feces, unpreserved",Received,Frozen,Default Return Frozen,FECAL CALPROTECTIN,FROZEN,,,,,08:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,21-Apr-2026,I-4,22-Apr-2026,,6227635146,15,622763514615,"Red Cells, Clot",Not Received,,,SM04/SERUM ADA PRE,,,,,,08:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,21-Apr-2026,I-4,22-Apr-2026,,6227635146,18,622763514618,"Red Cells, Clot",Not Received,,,SM06/SERUM,BIOMARKERS,,,,,08:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,21-Apr-2026,I-4,22-Apr-2026,,6227635146,11,622763514611,"Whole Blood, EDTA, Dry",Not Received,,,PLASMA PK TROUGH,,,,,,08:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,21-Apr-2026,I-4,22-Apr-2026,,6227635146,13,622763514613,"Whole Blood, EDTA, Dry",Not Received,,,SM02/PLASMAPK PEAK,,,,,,08:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,21-Apr-2026,I-4,22-Apr-2026,23-Apr-2026,6227635146,6,622763514606,"Stool, unpreserved",Shipped,Frozen,Default Return Frozen,STOOL I-4,77242113UCO3001-1,,,,,08:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,21-Apr-2026,I-4,22-Apr-2026,22-Apr-2026,6227635146,22,622763514622,Whole Blood PAXgene RNA,Shipped,Frozen,Default Return Frozen,SM07/WB RNA,77242113UCO3001,,,,,08:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,21-Apr-2026,I-4,22-Apr-2026,23-Apr-2026,6227635146,7,622763514607,"Stool, unpreserved",Shipped,Frozen,Default Return Frozen,STOOL I-4,77242113UCO3001-2,,,,,08:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,21-Apr-2026,I-4,22-Apr-2026,22-Apr-2026,6227635146,19,622763514619,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-1,,,,,08:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,21-Apr-2026,I-4,22-Apr-2026,,6227635146,1,622763514601,"Red Cells, Clot",Not Received,,,CHEM PANEL &,CRP,,,,,08:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,21-Apr-2026,I-4,22-Apr-2026,22-Apr-2026,6227635146,17,622763514617,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-4 PRE,77242113UCO3001-2,,,,,08:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,21-Apr-2026,I-4,22-Apr-2026,22-Apr-2026,6227635146,12,622763514612,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMPK I-4 TROUGH,77242113UCO3001,,,,,08:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,21-Apr-2026,I-4,22-Apr-2026,22-Apr-2026,6227635146,20,622763514620,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-2,,,,,08:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,01-Apr-2026,SCRNSTOOL,02-Apr-2026,02-Apr-2026,6227635148,3,622763514803,"Culture, Stool",Received,Ambient,Default Return Ambient,STOOL CULTURE,,,,,,08:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,01-Apr-2026,SCRNSTOOL,02-Apr-2026,02-Apr-2026,6227635148,4,622763514804,"Stool, ova & parasites(PVA)",Received,Ambient,Default Return Ambient,OVA & PARASITES 2,PVA,,,,,08:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,01-Apr-2026,SCRNSTOOL,02-Apr-2026,02-Apr-2026,6227635148,1,622763514801,"Stool, ova & parasites(form)",Received,Ambient,Default Return Ambient,OVA & PARASITES 1,FORMALIN,,,,,08:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132003,07-May-2026,SCRNSTOOL,08-May-2026,08-May-2026,6227635150,2,622763515002,"Stool, unpreserved",Received,Frozen,Default Return Frozen,C-DIFF TOXIN,& PCR FROZEN,,,,,05:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132003,07-May-2026,SCRNSTOOL,08-May-2026,08-May-2026,6227635150,3,622763515003,"Culture, Stool",Received,Ambient,Default Return Ambient,STOOL CULTURE,,,,,,05:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,26-Feb-2026,SCRNSTOOL,27-Feb-2026,27-Feb-2026,6227635149,2,622763514902,"Stool, unpreserved",Received,Frozen,Default Return Frozen,C-DIFF TOXIN,& PCR FROZEN,,,,,10:35,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132003,07-May-2026,SCRNSTOOL,08-May-2026,08-May-2026,6227635150,4,622763515004,"Stool, ova & parasites(PVA)",Received,Ambient,Default Return Ambient,OVA & PARASITES 2,PVA,,,,,05:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,01-Apr-2026,SCRNSTOOL,02-Apr-2026,02-Apr-2026,6227635148,2,622763514802,"Stool, unpreserved",Received,Frozen,Default Return Frozen,C-DIFF TOXIN,& PCR FROZEN,,,,,08:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,26-Feb-2026,SCRNSTOOL,27-Feb-2026,27-Feb-2026,6227635149,1,622763514901,"Stool, ova & parasites(form)",Received,Ambient,Default Return Ambient,OVA & PARASITES 1,FORMALIN,,,,,10:35,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,26-Feb-2026,SCRNSTOOL,27-Feb-2026,27-Feb-2026,6227635149,4,622763514904,"Stool, ova & parasites(PVA)",Received,Ambient,Default Return Ambient,OVA & PARASITES 2,PVA,,,,,10:35,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,26-Feb-2026,SCRNSTOOL,27-Feb-2026,27-Feb-2026,6227635149,3,622763514903,"Culture, Stool",Received,Ambient,Default Return Ambient,STOOL CULTURE,,,,,,10:35,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132003,07-May-2026,SCRNSTOOL,08-May-2026,08-May-2026,6227635150,1,622763515001,"Stool, ova & parasites(form)",Received,Ambient,Default Return Ambient,OVA & PARASITES 1,FORMALIN,,,,,05:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,24-Mar-2026,DNA,26-Mar-2026,26-Mar-2026,6227635156,1,622763515601,"Whole Blood, EDTA, Dry",Shipped,Frozen,Default Return Frozen,SM08/WB DNA,77242113UCO3001,,,,,09:40,05:55,Czech Republic,,05:55,,,213069,EMEA,,,,,,,,DNA,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132003,02-Jun-2026,DNA,03-Jun-2026,03-Jun-2026,6227635154,1,622763515401,"Whole Blood, EDTA, Dry",In Inventory,Frozen,Default Return Frozen,SM08/WB DNA,77242113UCO3001,,,,,09:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,DNA,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,26-May-2026,DNA,27-May-2026,27-May-2026,6227635155,1,622763515501,"Whole Blood, EDTA, Dry",Shipped,Frozen,Default Return Frozen,SM08/WB DNA,77242113UCO3001,,,,,09:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,DNA,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,21-Apr-2026,BXSCR,22-Apr-2026,,6227635159,4,622763515904,"Biopsy, Frozen Tissue",Not Received,Frozen,,BIOPSY PK,77242113UCO3001,,,,,00:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,21-Apr-2026,BXSCR,22-Apr-2026,22-Apr-2026,6227635159,1,622763515901,Wet Tissue Biopsy,Removed,Ambient,Default Return Ambient,SM11/BIOPSY,HISTOLOGY,,,,,00:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,21-Apr-2026,BXSCR,22-Apr-2026,23-Apr-2026,6227635159,2,622763515902,Biopsy RNA Later,Shipped,Frozen,Default Return Frozen,SM13/BIOPSY RNA,FROZEN,,,,,00:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,21-Apr-2026,BXSCR,22-Apr-2026,23-Apr-2026,6227635159,3,622763515903,"Biopsy, Frozen Tissue",In Inventory,Frozen,Default Return Frozen,SM14/BIOPSY CRYO,FROZEN,,,,,00:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,12-Mar-2026,BXSCR,13-Mar-2026,14-Mar-2026,6227635161,3,622763516103,"Biopsy, Frozen Tissue",In Inventory,Frozen,Default Return Frozen,SM14/BIOPSY CRYO,FROZEN,,,,,00:00,07:20,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,12-Mar-2026,BXSCR,13-Mar-2026,,6227635161,4,622763516104,"Biopsy, Frozen Tissue",Not Received,Frozen,,BIOPSY PK,77242113UCO3001,,,,,00:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,12-Mar-2026,BXSCR,13-Mar-2026,13-Mar-2026,6227635161,1,622763516101,Wet Tissue Biopsy,Removed,Ambient,Default Return Ambient,SM11/BIOPSY,HISTOLOGY,,,,,00:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,12-Mar-2026,BXSCR,13-Mar-2026,14-Mar-2026,6227635161,2,622763516102,Biopsy RNA Later,Shipped,Frozen,Default Return Frozen,SM13/BIOPSY RNA,FROZEN,,,,,00:00,07:20,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,21-Apr-2026,SCRN,22-Apr-2026,,6227635171,1,622763517101,Whole Blood QuantiFERON Nil,Not Received,,,QUANTIFERON PLUS,NIL-GRAY,,,,,10:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,21-Apr-2026,SCRN,22-Apr-2026,23-Apr-2026,6227635171,2,622763517102,"Plasma, QuantiFERON Nil",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,NIL-GRAY FRZ,,,,,10:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,21-Apr-2026,SCRN,22-Apr-2026,,6227635171,5,622763517105,Whole Blood QuantiFERON TB2,Not Received,,,QUANTIFERON PLUS,TB2-YELLOW,,,,,10:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,21-Apr-2026,SCRN,22-Apr-2026,,6227635171,7,622763517107,Whole Blood QuantiFERON Mitoge,Not Received,,,QUANTIFERON PLUS,MITOGEN-PURPLE,,,,,10:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,21-Apr-2026,SCRN,22-Apr-2026,,6227635171,3,622763517103,Whole Blood QuantiFERON TB1,Not Received,,,QUANTIFERON PLUS,TB1-GREEN,,,,,10:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,21-Apr-2026,SCRN,22-Apr-2026,23-Apr-2026,6227635171,6,622763517106,"Plasma, QuantiFERON TB2",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB2-YELLOW FRZ,,,,,10:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,21-Apr-2026,SCRN,22-Apr-2026,23-Apr-2026,6227635171,4,622763517104,"Plasma, QuantiFERON TB1",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB1-GREEN FRZ,,,,,10:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,21-Apr-2026,SCRN,22-Apr-2026,22-Apr-2026,6227635171,10,622763517110,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,10:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,21-Apr-2026,SCRN,22-Apr-2026,22-Apr-2026,6227635171,14,622763517114,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,BETA HCG,,,,,10:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,21-Apr-2026,SCRN,22-Apr-2026,22-Apr-2026,6227635171,15,622763517115,"Serum, SST",Received,Ambient,Default Return Ambient,FSH,,,,,,10:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,21-Apr-2026,SCRN,22-Apr-2026,,6227635171,11,622763517111,"Red Cells, Clot",Not Received,,,"HIV SCREEN,",HEPATITIS B & C,,,,,10:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,21-Apr-2026,SCRN,22-Apr-2026,23-Apr-2026,6227635171,8,622763517108,"Plasma, QuantiFERON Mitoge",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,MITOGEN-PURPLE FRZ,,,,,10:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,21-Apr-2026,SCRN,22-Apr-2026,22-Apr-2026,6227635171,9,622763517109,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,10:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,21-Apr-2026,SCRN,22-Apr-2026,,6227635171,13,622763517113,"Red Cells, Clot",Not Received,,,CHEM PANEL &,BETA HCG,,,,,10:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,21-Apr-2026,SCRN,22-Apr-2026,22-Apr-2026,6227635171,12,622763517112,"Serum, SST",Received,Ambient,Default Return Ambient,"HIV SCREEN,",HEPATITIS B & C,,,,,10:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162002,27-May-2026,SCRN,28-May-2026,30-May-2026,6227635173,2,622763517302,"Plasma, QuantiFERON Nil",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,NIL-GRAY FRZ,,,,,12:35,07:30,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162002,27-May-2026,SCRN,28-May-2026,30-May-2026,6227635173,6,622763517306,"Plasma, QuantiFERON TB2",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB2-YELLOW FRZ,,,,,12:35,07:30,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162002,27-May-2026,SCRN,28-May-2026,,6227635173,7,622763517307,Whole Blood QuantiFERON Mitoge,Not Received,,,QUANTIFERON PLUS,MITOGEN-PURPLE,,,,,12:35,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162002,27-May-2026,SCRN,28-May-2026,30-May-2026,6227635173,8,622763517308,"Plasma, QuantiFERON Mitoge",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,MITOGEN-PURPLE FRZ,,,,,12:35,07:30,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162002,27-May-2026,SCRN,28-May-2026,,6227635173,5,622763517305,Whole Blood QuantiFERON TB2,Not Received,,,QUANTIFERON PLUS,TB2-YELLOW,,,,,12:35,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162002,27-May-2026,SCRN,28-May-2026,28-May-2026,6227635173,10,622763517310,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,12:35,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162002,27-May-2026,SCRN,28-May-2026,30-May-2026,6227635173,4,622763517304,"Plasma, QuantiFERON TB1",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB1-GREEN FRZ,,,,,12:35,07:30,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162002,27-May-2026,SCRN,28-May-2026,28-May-2026,6227635173,9,622763517309,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,12:35,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162002,27-May-2026,SCRN,28-May-2026,,6227635173,1,622763517301,Whole Blood QuantiFERON Nil,Not Received,,,QUANTIFERON PLUS,NIL-GRAY,,,,,12:35,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162002,27-May-2026,SCRN,28-May-2026,,6227635173,3,622763517303,Whole Blood QuantiFERON TB1,Not Received,,,QUANTIFERON PLUS,TB1-GREEN,,,,,12:35,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162002,27-May-2026,SCRN,28-May-2026,28-May-2026,6227635173,14,622763517314,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,BETA HCG,,,,,12:35,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162002,27-May-2026,SCRN,28-May-2026,,6227635173,13,622763517313,"Red Cells, Clot",Not Received,,,CHEM PANEL &,BETA HCG,,,,,12:35,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,28-May-2026,I-0,29-May-2026,29-May-2026,6227635174,1,622763517401,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,10:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162002,27-May-2026,SCRN,28-May-2026,28-May-2026,6227635173,15,622763517315,"Serum, SST",Received,Ambient,Default Return Ambient,FSH,,,,,,12:35,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,28-May-2026,I-0,29-May-2026,30-May-2026,6227635174,3,622763517403,"Whole Blood, EDTA, Dry",Received,,Default Discard/Not Return,PLASMA PK TROUGH,,,,,,10:45,07:30,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162002,27-May-2026,SCRN,28-May-2026,,6227635173,11,622763517311,"Red Cells, Clot",Not Received,,,"HIV SCREEN,",HEPATITIS B & C,,,,,12:35,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,28-May-2026,I-0,29-May-2026,29-May-2026,6227635174,2,622763517402,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,10:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162002,27-May-2026,SCRN,28-May-2026,28-May-2026,6227635173,12,622763517312,"Serum, SST",Received,Ambient,Default Return Ambient,"HIV SCREEN,",HEPATITIS B & C,,,,,12:35,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,28-May-2026,I-0,29-May-2026,30-May-2026,6227635174,9,622763517409,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-0 PRE,77242113UCO3001-2,,,,,10:45,07:30,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,28-May-2026,I-0,29-May-2026,,6227635174,5,622763517405,"Whole Blood, EDTA, Dry",Not Received,,,SM02/PLASMAPK PEAK,,,,,,10:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,28-May-2026,I-0,29-May-2026,30-May-2026,6227635174,11,622763517411,Whole Blood PAXgene RNA,In Inventory,Frozen,Default Return Frozen,SM07/WB RNA,77242113UCO3001,,,,,10:45,07:30,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,28-May-2026,I-0,29-May-2026,30-May-2026,6227635174,6,622763517406,"Plasma, EDTA",In Inventory,Frozen,Default Return Frozen,PLASMA PK I-0 PEAK,77242113UCO3001,,,,,10:45,07:30,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,28-May-2026,I-0,29-May-2026,,6227635174,12,622763517412,"Red Cells, Clot",Not Received,,,SM06/SERUM,BIOMARKERS,,,,,10:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,28-May-2026,I-0,29-May-2026,30-May-2026,6227635174,4,622763517404,"Plasma, EDTA",In Inventory,Frozen,Default Return Frozen,PLASMPK I-0 TROUGH,77242113UCO3001,,,,,10:45,07:30,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,28-May-2026,I-0,29-May-2026,,6227635174,7,622763517407,"Red Cells, Clot",Not Received,,,SM04/SERUM ADA PRE,,,,,,10:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,28-May-2026,I-0,29-May-2026,30-May-2026,6227635174,8,622763517408,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-0 PRE,77242113UCO3001-1,,,,,10:45,07:30,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,28-May-2026,I-0,29-May-2026,30-May-2026,6227635174,13,622763517413,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-1,,,,,10:45,07:30,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,28-May-2026,I-0,29-May-2026,30-May-2026,6227635174,10,622763517410,"Stool, unpreserved",In Inventory,Frozen,Default Return Frozen,SM10/FECAL,BIOMARKERS,,,,,10:45,07:30,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,28-May-2026,I-0,29-May-2026,30-May-2026,6227635174,14,622763517414,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-2,,,,,10:45,07:30,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,28-May-2026,I-0,29-May-2026,29-May-2026,6227635174,18,622763517418,"Serum, SST",Received,Ambient,Default Return Ambient,"CHEM, LIPID PANEL",& CRP,,,,,10:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,28-May-2026,I-0,29-May-2026,,6227635174,17,622763517417,"Red Cells, Clot",Not Received,,,"CHEM, LIPID PANEL",& CRP,,,,,10:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,28-May-2026,I-0,29-May-2026,30-May-2026,6227635174,15,622763517415,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-3,,,,,10:45,07:30,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,28-May-2026,I-0,29-May-2026,30-May-2026,6227635174,16,622763517416,"Feces, unpreserved",Received,Frozen,Default Return Frozen,FECAL CALPROTECTIN,FROZEN,,,,,10:45,07:30,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162002,27-May-2026,SCRNSTOOL,28-May-2026,,6227635180,1,622763518001,"Stool, ova & parasites(form)",Not Received,Ambient,,OVA & PARASITES 1,FORMALIN,,,,,13:15,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162002,27-May-2026,SCRNSTOOL,28-May-2026,28-May-2026,6227635180,3,622763518003,"Culture, Stool",Received,Ambient,Default Return Ambient,STOOL CULTURE,,,,,,13:15,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162002,27-May-2026,SCRNSTOOL,28-May-2026,,6227635180,4,622763518004,"Stool, ova & parasites(PVA)",Not Received,Ambient,,OVA & PARASITES 2,PVA,,,,,13:15,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162002,27-May-2026,SCRNSTOOL,28-May-2026,30-May-2026,6227635180,2,622763518002,"Stool, unpreserved",Received,Frozen,Default Return Frozen,C-DIFF TOXIN,& PCR FROZEN,,,,,13:15,07:30,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,24-Apr-2026,SCRNSTOOL,25-Apr-2026,,6227635182,4,622763518204,"Stool, ova & parasites(PVA)",Not Received,Ambient,,OVA & PARASITES 2,PVA,,,,,08:45,,Czech Republic,,07:30,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,24-Apr-2026,SCRNSTOOL,25-Apr-2026,25-Apr-2026,6227635182,3,622763518203,"Culture, Stool",Received,Ambient,Default Return Ambient,STOOL CULTURE,,,,,,08:45,07:30,Czech Republic,,07:30,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,24-Apr-2026,SCRNSTOOL,25-Apr-2026,,6227635182,1,622763518201,"Stool, ova & parasites(form)",Not Received,Ambient,,OVA & PARASITES 1,FORMALIN,,,,,08:45,,Czech Republic,,07:30,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,24-Apr-2026,SCRNSTOOL,25-Apr-2026,,6227635182,2,622763518202,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,C-DIFF TOXIN,& PCR FROZEN,,,,,08:45,,Czech Republic,,07:30,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,28-May-2026,DNA,30-May-2026,30-May-2026,6227635186,1,622763518601,"Whole Blood, EDTA, Dry",Shipped,Frozen,Default Return Frozen,SM08/WB DNA,77242113UCO3001,,,,,10:45,07:30,Czech Republic,,07:30,,,213069,EMEA,,,,,,,,DNA,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,19-May-2026,BXSCR,20-May-2026,21-May-2026,6227635193,2,622763519302,Biopsy RNA Later,In Inventory,Frozen,Default Return Frozen,SM13/BIOPSY RNA,FROZEN,,,,,00:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,19-May-2026,BXSCR,20-May-2026,20-May-2026,6227635193,1,622763519301,Wet Tissue Biopsy,Removed,Ambient,Default Return Ambient,SM11/BIOPSY,HISTOLOGY,,,,,00:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,19-May-2026,BXSCR,20-May-2026,21-May-2026,6227635193,3,622763519303,"Biopsy, Frozen Tissue",In Inventory,Frozen,Default Return Frozen,SM14/BIOPSY CRYO,FROZEN,,,,,00:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,19-May-2026,BXSCR,20-May-2026,,6227635193,4,622763519304,"Biopsy, Frozen Tissue",Not Received,Frozen,,BIOPSY PK,77242113UCO3001,,,,,00:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,25-Feb-2026,SCRN,26-Feb-2026,,6227635204,1,622763520401,Whole Blood QuantiFERON Nil,Not Received,,,QUANTIFERON PLUS,NIL-GRAY,,,,,12:15,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,25-Feb-2026,SCRN,26-Feb-2026,03-Mar-2026,6227635204,2,622763520402,"Plasma, QuantiFERON Nil",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,NIL-GRAY FRZ,,,,,12:15,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,25-Feb-2026,SCRN,26-Feb-2026,,6227635204,3,622763520403,Whole Blood QuantiFERON TB1,Not Received,,,QUANTIFERON PLUS,TB1-GREEN,,,,,12:15,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,25-Feb-2026,SCRN,26-Feb-2026,26-Feb-2026,6227635204,15,622763520415,"Serum, SST",Received,Ambient,Default Return Ambient,FSH,,,,,,12:15,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,25-Feb-2026,SCRN,26-Feb-2026,26-Feb-2026,6227635204,9,622763520409,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,12:15,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,25-Feb-2026,SCRN,26-Feb-2026,26-Feb-2026,6227635204,10,622763520410,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,12:15,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,25-Feb-2026,SCRN,26-Feb-2026,,6227635204,11,622763520411,"Red Cells, Clot",Not Received,,,"HIV SCREEN,",HEPATITIS B & C,,,,,12:15,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,25-Feb-2026,SCRN,26-Feb-2026,26-Feb-2026,6227635204,12,622763520412,"Serum, SST",Received,Ambient,Default Return Ambient,"HIV SCREEN,",HEPATITIS B & C,,,,,12:15,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,25-Feb-2026,SCRN,26-Feb-2026,,6227635204,13,622763520413,"Red Cells, Clot",Not Received,,,CHEM PANEL &,BETA HCG,,,,,12:15,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,25-Feb-2026,SCRN,26-Feb-2026,,6227635204,5,622763520405,Whole Blood QuantiFERON TB2,Not Received,,,QUANTIFERON PLUS,TB2-YELLOW,,,,,12:15,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,25-Feb-2026,SCRN,26-Feb-2026,03-Mar-2026,6227635204,4,622763520404,"Plasma, QuantiFERON TB1",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB1-GREEN FRZ,,,,,12:15,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,25-Feb-2026,SCRN,26-Feb-2026,26-Feb-2026,6227635204,14,622763520414,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,BETA HCG,,,,,12:15,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,25-Feb-2026,SCRN,26-Feb-2026,,6227635204,7,622763520407,Whole Blood QuantiFERON Mitoge,Not Received,,,QUANTIFERON PLUS,MITOGEN-PURPLE,,,,,12:15,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,25-Feb-2026,SCRN,26-Feb-2026,03-Mar-2026,6227635204,6,622763520406,"Plasma, QuantiFERON TB2",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB2-YELLOW FRZ,,,,,12:15,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,25-Feb-2026,SCRN,26-Feb-2026,03-Mar-2026,6227635204,8,622763520408,"Plasma, QuantiFERON Mitoge",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,MITOGEN-PURPLE FRZ,,,,,12:15,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,07-Apr-2026,I-0,08-Apr-2026,08-Apr-2026,6227635207,2,622763520702,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,10:37,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,07-Apr-2026,I-0,08-Apr-2026,09-Apr-2026,6227635207,8,622763520708,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-0 PRE,77242113UCO3001-1,,,,,10:37,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,07-Apr-2026,I-0,08-Apr-2026,,6227635207,5,622763520705,"Whole Blood, EDTA, Dry",Not Received,,,SM02/PLASMAPK PEAK,,,,,,10:37,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,07-Apr-2026,I-0,08-Apr-2026,09-Apr-2026,6227635207,4,622763520704,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMPK I-0 TROUGH,77242113UCO3001,,,,,10:37,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,07-Apr-2026,I-0,08-Apr-2026,09-Apr-2026,6227635207,9,622763520709,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-0 PRE,77242113UCO3001-2,,,,,10:37,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,07-Apr-2026,I-0,08-Apr-2026,08-Apr-2026,6227635207,1,622763520701,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,10:37,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,07-Apr-2026,I-0,08-Apr-2026,09-Apr-2026,6227635207,11,622763520711,Whole Blood PAXgene RNA,Shipped,Frozen,Default Return Frozen,SM07/WB RNA,77242113UCO3001,,,,,10:37,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,07-Apr-2026,I-0,08-Apr-2026,,6227635207,3,622763520703,"Whole Blood, EDTA, Dry",Not Received,,,PLASMA PK TROUGH,,,,,,10:37,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,07-Apr-2026,I-0,08-Apr-2026,09-Apr-2026,6227635207,6,622763520706,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMA PK I-0 PEAK,77242113UCO3001,,,,,10:37,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,07-Apr-2026,I-0,08-Apr-2026,,6227635207,17,622763520717,"Red Cells, Clot",Not Received,,,"CHEM, LIPID PANEL",& CRP,,,,,10:37,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,07-Apr-2026,I-0,08-Apr-2026,08-Apr-2026,6227635207,18,622763520718,"Serum, SST",Received,Ambient,Default Return Ambient,"CHEM, LIPID PANEL",& CRP,,,,,10:37,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,20-Apr-2026,I-2,21-Apr-2026,28-Apr-2026,6227635208,2,622763520802,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMPK I-2 TROUGH,77242113UCO3001,,,,,08:43,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,20-Apr-2026,I-2,21-Apr-2026,,6227635208,3,622763520803,"Whole Blood, EDTA, Dry",Not Received,,,SM02/PLASMAPK PEAK,,,,,,08:43,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,07-Apr-2026,I-0,08-Apr-2026,09-Apr-2026,6227635207,13,622763520713,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-1,,,,,10:37,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,20-Apr-2026,I-2,21-Apr-2026,,6227635208,1,622763520801,"Whole Blood, EDTA, Dry",Not Received,,,PLASMA PK TROUGH,,,,,,08:43,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,07-Apr-2026,I-0,08-Apr-2026,,6227635207,7,622763520707,"Red Cells, Clot",Not Received,,,SM04/SERUM ADA PRE,,,,,,10:37,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,07-Apr-2026,I-0,08-Apr-2026,09-Apr-2026,6227635207,10,622763520710,"Stool, unpreserved",In Inventory,Frozen,Default Return Frozen,SM10/FECAL,BIOMARKERS,,,,,10:37,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,07-Apr-2026,I-0,08-Apr-2026,,6227635207,12,622763520712,"Red Cells, Clot",Not Received,,,SM06/SERUM,BIOMARKERS,,,,,10:37,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,07-Apr-2026,I-0,08-Apr-2026,09-Apr-2026,6227635207,16,622763520716,"Feces, unpreserved",Received,Frozen,Default Return Frozen,FECAL CALPROTECTIN,FROZEN,,,,,10:37,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,20-Apr-2026,I-2,21-Apr-2026,28-Apr-2026,6227635208,7,622763520807,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-2 PRE,77242113UCO3001-2,,,,,08:43,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,20-Apr-2026,I-2,21-Apr-2026,,6227635208,9,622763520809,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-2,77242113UCO3001-2,,,,,08:43,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,20-Apr-2026,I-2,21-Apr-2026,,6227635208,10,622763520810,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-2,77242113UCO3001-3,,,,,08:43,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,20-Apr-2026,I-2,21-Apr-2026,,6227635208,11,622763520811,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-2,77242113UCO3001-4,,,,,08:43,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,07-Apr-2026,I-0,08-Apr-2026,09-Apr-2026,6227635207,14,622763520714,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-2,,,,,10:37,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,07-Apr-2026,I-0,08-Apr-2026,09-Apr-2026,6227635207,15,622763520715,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-3,,,,,10:37,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,20-Apr-2026,I-2,21-Apr-2026,,6227635208,12,622763520812,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-2,77242113UCO3001-5,,,,,08:43,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,20-Apr-2026,I-2,21-Apr-2026,28-Apr-2026,6227635208,4,622763520804,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMA PK I-2 PEAK,77242113UCO3001,,,,,08:43,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,20-Apr-2026,I-2,21-Apr-2026,28-Apr-2026,6227635208,6,622763520806,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-2 PRE,77242113UCO3001-1,,,,,08:43,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,20-Apr-2026,I-2,21-Apr-2026,28-Apr-2026,6227635208,8,622763520808,"Stool, unpreserved",Shipped,Frozen,Default Return Frozen,STOOL I-2,77242113UCO3001-1,,,,,08:43,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,20-Apr-2026,I-2,21-Apr-2026,21-Apr-2026,6227635208,17,622763520817,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,CRP,,,,,08:43,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,20-Apr-2026,I-2,21-Apr-2026,21-Apr-2026,6227635208,14,622763520814,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,08:43,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,20-Apr-2026,I-2,21-Apr-2026,,6227635208,5,622763520805,"Red Cells, Clot",Not Received,,,SM04/SERUM ADA PRE,,,,,,08:43,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,20-Apr-2026,I-2,21-Apr-2026,28-Apr-2026,6227635208,13,622763520813,"Feces, unpreserved",Received,Frozen,Default Return Frozen,FECAL CALPROTECTIN,FROZEN,,,,,08:43,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,20-Apr-2026,I-2,21-Apr-2026,,6227635208,16,622763520816,"Red Cells, Clot",Not Received,,,CHEM PANEL &,CRP,,,,,08:43,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,20-Apr-2026,I-2,21-Apr-2026,21-Apr-2026,6227635208,15,622763520815,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,08:43,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,05-May-2026,I-4,06-May-2026,06-May-2026,6227635211,2,622763521102,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,CRP,,,,,10:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,05-May-2026,I-4,06-May-2026,06-May-2026,6227635211,3,622763521103,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,10:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,05-May-2026,I-4,06-May-2026,06-May-2026,6227635211,4,622763521104,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,10:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,05-May-2026,I-4,06-May-2026,,6227635211,1,622763521101,"Red Cells, Clot",Not Received,,,CHEM PANEL &,CRP,,,,,10:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,05-May-2026,I-4,06-May-2026,,6227635211,8,622763521108,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-4,77242113UCO3001-3,,,,,10:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,05-May-2026,I-4,06-May-2026,,6227635211,10,622763521110,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-4,77242113UCO3001-5,,,,,10:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,05-May-2026,I-4,06-May-2026,07-May-2026,6227635211,6,622763521106,"Stool, unpreserved",Shipped,Frozen,Default Return Frozen,STOOL I-4,77242113UCO3001-1,,,,,10:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,05-May-2026,I-4,06-May-2026,,6227635211,5,622763521105,"Feces, unpreserved",Not Received,Frozen,Specimen not submitted,FECAL CALPROTECTIN,FROZEN,,,,,10:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,05-May-2026,I-4,06-May-2026,,6227635211,11,622763521111,"Whole Blood, EDTA, Dry",Not Received,,,PLASMA PK TROUGH,,,,,,10:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,05-May-2026,I-4,06-May-2026,,6227635211,13,622763521113,"Whole Blood, EDTA, Dry",Not Received,,,SM02/PLASMAPK PEAK,,,,,,10:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,05-May-2026,I-4,06-May-2026,07-May-2026,6227635211,14,622763521114,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMA PK I-4 PEAK,77242113UCO3001,,,,,10:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,05-May-2026,I-4,06-May-2026,,6227635211,7,622763521107,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-4,77242113UCO3001-2,,,,,10:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,05-May-2026,I-4,06-May-2026,07-May-2026,6227635211,19,622763521119,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-1,,,,,10:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,05-May-2026,I-4,06-May-2026,07-May-2026,6227635211,16,622763521116,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-4 PRE,77242113UCO3001-1,,,,,10:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,05-May-2026,I-4,06-May-2026,07-May-2026,6227635211,20,622763521120,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-2,,,,,10:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,05-May-2026,I-4,06-May-2026,,6227635211,9,622763521109,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-4,77242113UCO3001-4,,,,,10:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,05-May-2026,I-4,06-May-2026,07-May-2026,6227635211,21,622763521121,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-3,,,,,10:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,05-May-2026,I-4,06-May-2026,07-May-2026,6227635211,22,622763521122,Whole Blood PAXgene RNA,Shipped,Frozen,Default Return Frozen,SM07/WB RNA,77242113UCO3001,,,,,10:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,05-May-2026,I-4,06-May-2026,07-May-2026,6227635211,17,622763521117,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-4 PRE,77242113UCO3001-2,,,,,10:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,05-May-2026,I-4,06-May-2026,,6227635211,18,622763521118,"Red Cells, Clot",Not Received,,,SM06/SERUM,BIOMARKERS,,,,,10:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,05-May-2026,I-4,06-May-2026,07-May-2026,6227635211,12,622763521112,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMPK I-4 TROUGH,77242113UCO3001,,,,,10:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,01-Mar-2026,SCRNSTOOL,03-Mar-2026,03-Mar-2026,6227635213,2,622763521302,"Stool, unpreserved",Received,Frozen,Default Return Frozen,C-DIFF TOXIN,& PCR FROZEN,,,,,14:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,01-Mar-2026,SCRNSTOOL,03-Mar-2026,03-Mar-2026,6227635213,3,622763521303,"Culture, Stool",Received,Ambient,Default Return Ambient,STOOL CULTURE,,,,,,14:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,01-Mar-2026,SCRNSTOOL,03-Mar-2026,03-Mar-2026,6227635213,4,622763521304,"Stool, ova & parasites(PVA)",Received,Ambient,Default Return Ambient,OVA & PARASITES 2,PVA,,,,,14:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,05-May-2026,I-4,06-May-2026,,6227635211,15,622763521115,"Red Cells, Clot",Not Received,,,SM04/SERUM ADA PRE,,,,,,10:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,01-Mar-2026,SCRNSTOOL,03-Mar-2026,03-Mar-2026,6227635213,1,622763521301,"Stool, ova & parasites(form)",Received,Ambient,Default Return Ambient,OVA & PARASITES 1,FORMALIN,,,,,14:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,07-Apr-2026,DNA,09-Apr-2026,09-Apr-2026,6227635218,1,622763521801,"Whole Blood, EDTA, Dry",Shipped,Frozen,Default Return Frozen,SM08/WB DNA,77242113UCO3001,,,,,10:37,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,DNA,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,16-Mar-2026,BXSCR,18-Mar-2026,18-Mar-2026,6227635223,2,622763522302,Biopsy RNA Later,Shipped,Frozen,Default Return Frozen,SM13/BIOPSY RNA,FROZEN,,,,,00:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,16-Mar-2026,BXSCR,18-Mar-2026,18-Mar-2026,6227635223,1,622763522301,Wet Tissue Biopsy,Removed,Ambient,Default Return Ambient,SM11/BIOPSY,HISTOLOGY,,,,,00:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,16-Mar-2026,BXSCR,18-Mar-2026,18-Mar-2026,6227635223,3,622763522303,"Biopsy, Frozen Tissue",In Inventory,Frozen,Default Return Frozen,SM14/BIOPSY CRYO,FROZEN,,,,,00:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,16-Mar-2026,BXSCR,18-Mar-2026,,6227635223,4,622763522304,"Biopsy, Frozen Tissue",Not Received,Frozen,,BIOPSY PK,77242113UCO3001,,,,,00:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,18-Mar-2026,SCRN,19-Mar-2026,20-Mar-2026,6227697718,2,622769771802,"Plasma, QuantiFERON Nil",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,NIL-GRAY FRZ,,,,,09:18,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,18-Mar-2026,SCRN,19-Mar-2026,,6227697718,3,622769771803,Whole Blood QuantiFERON TB1,Not Received,,,QUANTIFERON PLUS,TB1-GREEN,,,,,09:18,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,18-Mar-2026,SCRN,19-Mar-2026,,6227697718,5,622769771805,Whole Blood QuantiFERON TB2,Not Received,,,QUANTIFERON PLUS,TB2-YELLOW,,,,,09:18,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,18-Mar-2026,SCRN,19-Mar-2026,,6227697718,1,622769771801,Whole Blood QuantiFERON Nil,Not Received,,,QUANTIFERON PLUS,NIL-GRAY,,,,,09:18,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,18-Mar-2026,SCRN,19-Mar-2026,20-Mar-2026,6227697718,6,622769771806,"Plasma, QuantiFERON TB2",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB2-YELLOW FRZ,,,,,09:18,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,18-Mar-2026,SCRN,19-Mar-2026,20-Mar-2026,6227697718,4,622769771804,"Plasma, QuantiFERON TB1",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB1-GREEN FRZ,,,,,09:18,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,18-Mar-2026,SCRN,19-Mar-2026,,6227697718,7,622769771807,Whole Blood QuantiFERON Mitoge,Not Received,,,QUANTIFERON PLUS,MITOGEN-PURPLE,,,,,09:18,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,18-Mar-2026,SCRN,19-Mar-2026,,6227697718,11,622769771811,"Red Cells, Clot",Not Received,,,"HIV SCREEN,",HEPATITIS B & C,,,,,09:18,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,18-Mar-2026,SCRN,19-Mar-2026,,6227697718,13,622769771813,"Red Cells, Clot",Not Received,,,"CHEM PANEL, BETA",HCG & FSH,,,,,09:18,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,18-Mar-2026,SCRN,19-Mar-2026,19-Mar-2026,6227697718,10,622769771810,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:18,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,18-Mar-2026,SCRN,19-Mar-2026,19-Mar-2026,6227697718,14,622769771814,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,BETA HCG,,,,,09:18,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,18-Mar-2026,SCRN,19-Mar-2026,19-Mar-2026,6227697718,15,622769771815,"Serum, SST",Received,Ambient,Default Return Ambient,FSH,,,,,,09:18,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,18-Mar-2026,SCRN,19-Mar-2026,20-Mar-2026,6227697718,8,622769771808,"Plasma, QuantiFERON Mitoge",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,MITOGEN-PURPLE FRZ,,,,,09:18,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,07-Apr-2026,I-0,08-Apr-2026,08-Apr-2026,6227697719,1,622769771901,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,11:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,07-Apr-2026,I-0,08-Apr-2026,08-Apr-2026,6227697719,2,622769771902,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,11:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,07-Apr-2026,I-0,08-Apr-2026,08-Apr-2026,6227697719,4,622769771904,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMPK I-0 TROUGH,77242113UCO3001,,,,,11:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,07-Apr-2026,I-0,08-Apr-2026,,6227697719,5,622769771905,"Whole Blood, EDTA, Dry",Not Received,,,SM02/PLASMAPK PEAK,,,,,,11:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,07-Apr-2026,I-0,08-Apr-2026,,6227697719,3,622769771903,"Whole Blood, EDTA, Dry",Not Received,,,PLASMA PK TROUGH,,,,,,11:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,07-Apr-2026,I-0,08-Apr-2026,08-Apr-2026,6227697719,8,622769771908,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-0 PRE,77242113UCO3001-1,,,,,11:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,07-Apr-2026,I-0,08-Apr-2026,,6227697719,7,622769771907,"Red Cells, Clot",Not Received,,,SM04/SERUM ADA PRE,,,,,,11:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,07-Apr-2026,I-0,08-Apr-2026,08-Apr-2026,6227697719,6,622769771906,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMA PK I-0 PEAK,77242113UCO3001,,,,,11:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,07-Apr-2026,I-0,08-Apr-2026,08-Apr-2026,6227697719,10,622769771910,"Stool, unpreserved",In Inventory,Frozen,Default Return Frozen,SM10/FECAL,BIOMARKERS,,,,,11:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,18-Mar-2026,SCRN,19-Mar-2026,19-Mar-2026,6227697718,9,622769771809,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,09:18,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,07-Apr-2026,I-0,08-Apr-2026,08-Apr-2026,6227697719,11,622769771911,Whole Blood PAXgene RNA,Shipped,Frozen,Default Return Frozen,SM07/WB RNA,77242113UCO3001,,,,,11:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,18-Mar-2026,SCRN,19-Mar-2026,19-Mar-2026,6227697718,12,622769771812,"Serum, SST",Received,Ambient,Default Return Ambient,"HIV SCREEN,",HEPATITIS B & C,,,,,09:18,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,07-Apr-2026,I-0,08-Apr-2026,08-Apr-2026,6227697719,9,622769771909,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-0 PRE,77242113UCO3001-2,,,,,11:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,07-Apr-2026,I-0,08-Apr-2026,,6227697719,12,622769771912,"Red Cells, Clot",Not Received,,,SM06/SERUM,BIOMARKERS,,,,,11:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,07-Apr-2026,I-0,08-Apr-2026,08-Apr-2026,6227697719,13,622769771913,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-1,,,,,11:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,07-Apr-2026,I-0,08-Apr-2026,08-Apr-2026,6227697719,14,622769771914,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-2,,,,,11:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,07-Apr-2026,I-0,08-Apr-2026,,6227697719,17,622769771917,"Red Cells, Clot",Not Received,,,"CHEM, LIPID PANEL",& CRP,,,,,11:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,07-Apr-2026,I-0,08-Apr-2026,08-Apr-2026,6227697719,15,622769771915,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-3,,,,,11:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,07-Apr-2026,I-0,08-Apr-2026,08-Apr-2026,6227697719,16,622769771916,"Feces, unpreserved",Received,Frozen,Default Return Frozen,FECAL CALPROTECTIN,FROZEN,,,,,11:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,07-Apr-2026,I-0,08-Apr-2026,08-Apr-2026,6227697719,18,622769771918,"Serum, SST",Received,Ambient,Default Return Ambient,"CHEM, LIPID PANEL",& CRP,,,,,11:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,22-Apr-2026,I-2,23-Apr-2026,23-Apr-2026,6227697722,6,622769772206,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-2 PRE,77242113UCO3001-1,,,,,09:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,22-Apr-2026,I-2,23-Apr-2026,23-Apr-2026,6227697722,7,622769772207,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-2 PRE,77242113UCO3001-2,,,,,09:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,22-Apr-2026,I-2,23-Apr-2026,23-Apr-2026,6227697722,13,622769772213,"Feces, unpreserved",Received,Frozen,Default Return Frozen,FECAL CALPROTECTIN,FROZEN,,,,,09:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,22-Apr-2026,I-2,23-Apr-2026,,6227697722,10,622769772210,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-2,77242113UCO3001-3,,,,,09:25,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,22-Apr-2026,I-2,23-Apr-2026,23-Apr-2026,6227697722,12,622769772212,"Stool, unpreserved",Shipped,Frozen,Default Return Frozen,STOOL I-2,77242113UCO3001-5,,,,,09:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,22-Apr-2026,I-2,23-Apr-2026,,6227697722,11,622769772211,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-2,77242113UCO3001-4,,,,,09:25,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,22-Apr-2026,I-2,23-Apr-2026,23-Apr-2026,6227697722,14,622769772214,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,09:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,22-Apr-2026,I-2,23-Apr-2026,,6227697722,8,622769772208,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-2,77242113UCO3001-1,,,,,09:25,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,22-Apr-2026,I-2,23-Apr-2026,23-Apr-2026,6227697722,15,622769772215,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,22-Apr-2026,I-2,23-Apr-2026,,6227697722,9,622769772209,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-2,77242113UCO3001-2,,,,,09:25,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,22-Apr-2026,I-2,23-Apr-2026,23-Apr-2026,6227697722,2,622769772202,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMPK I-2 TROUGH,77242113UCO3001,,,,,09:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,22-Apr-2026,I-2,23-Apr-2026,,6227697722,5,622769772205,"Red Cells, Clot",Not Received,,,SM04/SERUM ADA PRE,,,,,,09:25,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,22-Apr-2026,I-2,23-Apr-2026,,6227697722,3,622769772203,"Whole Blood, EDTA, Dry",Not Received,,,SM02/PLASMAPK PEAK,,,,,,09:25,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,22-Apr-2026,I-2,23-Apr-2026,23-Apr-2026,6227697722,4,622769772204,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMA PK I-2 PEAK,77242113UCO3001,,,,,09:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,22-Apr-2026,I-2,23-Apr-2026,,6227697722,1,622769772201,"Whole Blood, EDTA, Dry",Not Received,,,PLASMA PK TROUGH,,,,,,09:25,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,07-May-2026,I-4,08-May-2026,,6227697723,1,622769772301,"Red Cells, Clot",Not Received,,,CHEM PANEL &,CRP,,,,,12:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,07-May-2026,I-4,08-May-2026,08-May-2026,6227697723,4,622769772304,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,12:40,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,07-May-2026,I-4,08-May-2026,08-May-2026,6227697723,2,622769772302,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,CRP,,,,,12:40,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,07-May-2026,I-4,08-May-2026,08-May-2026,6227697723,3,622769772303,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,12:40,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,07-May-2026,I-4,08-May-2026,,6227697723,5,622769772305,"Feces, unpreserved",Not Received,Frozen,Specimen not submitted,FECAL CALPROTECTIN,FROZEN,,,,,12:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,07-May-2026,I-4,08-May-2026,,6227697723,7,622769772307,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-4,77242113UCO3001-2,,,,,12:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,22-Apr-2026,I-2,23-Apr-2026,,6227697722,16,622769772216,"Red Cells, Clot",Not Received,,,CHEM PANEL &,CRP,,,,,09:25,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,22-Apr-2026,I-2,23-Apr-2026,23-Apr-2026,6227697722,17,622769772217,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,CRP,,,,,09:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,07-May-2026,I-4,08-May-2026,08-May-2026,6227697723,21,622769772321,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-3,,,,,12:40,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,07-May-2026,I-4,08-May-2026,,6227697723,6,622769772306,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-4,77242113UCO3001-1,,,,,12:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,07-May-2026,I-4,08-May-2026,08-May-2026,6227697723,12,622769772312,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMPK I-4 TROUGH,77242113UCO3001,,,,,12:40,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,07-May-2026,I-4,08-May-2026,,6227697723,13,622769772313,"Whole Blood, EDTA, Dry",Not Received,,,SM02/PLASMAPK PEAK,,,,,,12:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,07-May-2026,I-4,08-May-2026,08-May-2026,6227697723,14,622769772314,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMA PK I-4 PEAK,77242113UCO3001,,,,,12:40,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,07-May-2026,I-4,08-May-2026,,6227697723,9,622769772309,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-4,77242113UCO3001-4,,,,,12:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,07-May-2026,I-4,08-May-2026,,6227697723,18,622769772318,"Red Cells, Clot",Not Received,,,SM06/SERUM,BIOMARKERS,,,,,12:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,07-May-2026,I-4,08-May-2026,08-May-2026,6227697723,16,622769772316,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-4 PRE,77242113UCO3001-1,,,,,12:40,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,07-May-2026,I-4,08-May-2026,08-May-2026,6227697723,17,622769772317,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-4 PRE,77242113UCO3001-2,,,,,12:40,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,07-May-2026,I-4,08-May-2026,,6227697723,8,622769772308,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-4,77242113UCO3001-3,,,,,12:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,07-May-2026,I-4,08-May-2026,,6227697723,15,622769772315,"Red Cells, Clot",Not Received,,,SM04/SERUM ADA PRE,,,,,,12:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,07-May-2026,I-4,08-May-2026,08-May-2026,6227697723,19,622769772319,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-1,,,,,12:40,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,07-May-2026,I-4,08-May-2026,,6227697723,10,622769772310,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-4,77242113UCO3001-5,,,,,12:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,07-May-2026,I-4,08-May-2026,08-May-2026,6227697723,20,622769772320,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-2,,,,,12:40,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,07-May-2026,I-4,08-May-2026,08-May-2026,6227697723,22,622769772322,Whole Blood PAXgene RNA,Shipped,Frozen,Default Return Frozen,SM07/WB RNA,77242113UCO3001,,,,,12:40,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,07-May-2026,I-4,08-May-2026,,6227697723,11,622769772311,"Whole Blood, EDTA, Dry",Not Received,,,PLASMA PK TROUGH,,,,,,12:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,17-Mar-2026,SCRNSTOOL,19-Mar-2026,,6227697725,1,622769772501,"Stool, ova & parasites(form)",Not Received,Ambient,,OVA & PARASITES 1,FORMALIN,,,,,17:30,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,17-Mar-2026,SCRNSTOOL,19-Mar-2026,19-Mar-2026,6227697725,3,622769772503,"Culture, Stool",Received,Ambient,Default Return Ambient,STOOL CULTURE,,,,,,17:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,17-Mar-2026,SCRNSTOOL,19-Mar-2026,,6227697725,4,622769772504,"Stool, ova & parasites(PVA)",Not Received,Ambient,,OVA & PARASITES 2,PVA,,,,,17:30,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,17-Mar-2026,SCRNSTOOL,19-Mar-2026,19-Mar-2026,6227697725,2,622769772502,"Stool, unpreserved",Received,Frozen,Default Return Frozen,C-DIFF TOXIN,& PCR FROZEN,,,,,17:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,23-Mar-2026,BXSCR,24-Mar-2026,26-Mar-2026,6227697736,2,622769773602,Biopsy RNA Later,Shipped,Frozen,Default Return Frozen,SM13/BIOPSY RNA,FROZEN,,,,,00:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,07-Apr-2026,DNA,08-Apr-2026,08-Apr-2026,6227697731,1,622769773101,"Whole Blood, EDTA, Dry",Shipped,Frozen,Default Return Frozen,SM08/WB DNA,77242113UCO3001,,,,,11:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,DNA,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,23-Mar-2026,BXSCR,24-Mar-2026,24-Mar-2026,6227697736,1,622769773601,Wet Tissue Biopsy,Removed,Ambient,Default Return Ambient,SM11/BIOPSY,HISTOLOGY,,,,,00:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,23-Mar-2026,BXSCR,24-Mar-2026,,6227697736,4,622769773604,"Biopsy, Frozen Tissue",Not Received,Frozen,,BIOPSY PK,77242113UCO3001,,,,,00:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,23-Mar-2026,BXSCR,24-Mar-2026,26-Mar-2026,6227697736,3,622769773603,"Biopsy, Frozen Tissue",In Inventory,Frozen,Default Return Frozen,SM14/BIOPSY CRYO,FROZEN,,,,,00:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,,,,08-May-2026,,6227697745,5,622769774505,"Serum, SST",Not Received,Ambient,,FSH,,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,,,,08-May-2026,,6227697745,1,622769774501,"Whole Blood, EDTA, Dry",Not Received,Ambient,,HEMATOLOGY,,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,,,,08-May-2026,,6227697745,6,622769774506,"Red Cells, Clot",Not Received,,,"HIV SCREEN,",HEPATITIS B & C,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,,,,08-May-2026,,6227697745,4,622769774504,"Serum, SST",Not Received,Ambient,,"CHEM, LIPID PANEL",BETA HCG & CRP,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,,,,08-May-2026,08-May-2026,6227697745,8,622769774508,"Feces, unpreserved",Received,Frozen,Default Return Frozen,FECAL CALPROTECTIN,FROZEN,,,,,,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,,,,08-May-2026,,6227697745,3,622769774503,"Red Cells, Clot",Not Received,,,"CHEM, LIPID PANEL,","BHCG, FSH & CRP",,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,,,,08-May-2026,,6227697745,2,622769774502,"Slides, Hematology",Not Received,Ambient,,HEMATOLOGY,,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,,,,08-May-2026,,6227697745,7,622769774507,"Serum, SST",Not Received,Ambient,,"HIV SCREEN,",HEPATITIS B & C,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,,,,08-May-2026,,6227697745,9,622769774509,"Whole Blood, EDTA, Dry",Not Received,,,HCV RNA COBAS 6800,,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,,,,08-May-2026,,6227697745,14,622769774514,Whole Blood PAXgene RNA,Not Received,Frozen,,SM07/WB RNA,77242113UCO3001,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,,,,08-May-2026,,6227697745,16,622769774516,"Serum, SST",Not Received,Frozen,,SM06/SERUM BIOM,77242113UCO3001-1,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,,,,08-May-2026,,6227697745,18,622769774518,"Serum, SST",Not Received,Frozen,,SM06/SERUM BIOM,77242113UCO3001-3,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,,,,08-May-2026,,6227697745,17,622769774517,"Serum, SST",Not Received,Frozen,,SM06/SERUM BIOM,77242113UCO3001-2,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,,,,08-May-2026,,6227697745,13,622769774513,"Stool, unpreserved",Not Received,Frozen,,SM10/FECAL,BIOMARKERS,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,,,,08-May-2026,,6227697745,12,622769774512,"Plasma, EDTA",Not Received,Frozen,,HBV DNA COBAS 6800,FROZEN,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,,,,08-May-2026,,6227697745,11,622769774511,"Whole Blood, EDTA, Dry",Not Received,,,HBV DNA COBAS 6800,,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,,,,08-May-2026,,6227697745,15,622769774515,"Red Cells, Clot",Not Received,,,SM06/SERUM,BIOMARKERS,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,,,,08-May-2026,,6227697745,19,622769774519,"Stool, unpreserved",Not Received,Frozen,,STOOL,77242113UCO3001,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,,,,08-May-2026,,6227697745,10,622769774510,"Plasma, EDTA",Not Received,Frozen,,HCV RNA COBAS 6800,FROZEN,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,,,,08-May-2026,,6227697745,30,622769774530,"Plasma, EDTA",Not Received,Frozen,,HIV-1/HIV-2 QUAL,RNA FROZEN,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,,,,08-May-2026,,6227697745,20,622769774520,"Stool, unpreserved",Not Received,Frozen,,STOOL,77242113UCO3001-2,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,,,,08-May-2026,,6227697745,22,622769774522,"Stool, unpreserved",Not Received,Frozen,,STOOL,77242113UCO3001-4,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,,,,08-May-2026,,6227697745,25,622769774525,"Serum, SST",Not Received,Frozen,,SERUM ADA,77242113UCO3001-1,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,,,,08-May-2026,,6227697745,23,622769774523,"Stool, unpreserved",Not Received,Frozen,,STOOL,77242113UCO3001-5,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,,,,08-May-2026,,6227697745,26,622769774526,"Serum, SST",Not Received,Frozen,,SERUM ADA,77242113UCO3001-2,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,,,,08-May-2026,,6227697745,21,622769774521,"Stool, unpreserved",Not Received,Frozen,,STOOL,77242113UCO3001-3,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,,,,08-May-2026,,6227697745,29,622769774529,"Whole Blood, EDTA, Dry",Not Received,,,HIV-1/HIV-2,QUALITATIVE RNA,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,,,,08-May-2026,,6227697745,27,622769774527,"Whole Blood, EDTA, Dry",Not Received,,,SM03/PLASMA PK,,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,,,,08-May-2026,,6227697745,24,622769774524,"Red Cells, Clot",Not Received,,,SM05/SERUM ADA,,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,,,,08-May-2026,,6227697745,28,622769774528,"Plasma, EDTA",Not Received,Frozen,,PLASMA PK,77242113UCO3001,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,02-Mar-2026,SCRN,03-Mar-2026,,6227810899,1,622781089901,Whole Blood QuantiFERON Nil,Not Received,,,QUANTIFERON PLUS,NIL-GRAY,,,,,11:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,02-Mar-2026,SCRN,03-Mar-2026,,6227810899,3,622781089903,Whole Blood QuantiFERON TB1,Not Received,,,QUANTIFERON PLUS,TB1-GREEN,,,,,11:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,02-Mar-2026,SCRN,03-Mar-2026,,6227810899,2,622781089902,"Plasma, QuantiFERON Nil",Canceled,Frozen,,QUANTIFERON PLUS,NIL-GRAY FRZ,,,,,11:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,02-Mar-2026,SCRN,03-Mar-2026,,6227810899,4,622781089904,"Plasma, QuantiFERON TB1",Canceled,Frozen,,QUANTIFERON PLUS,TB1-GREEN FRZ,,,,,11:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,02-Mar-2026,SCRN,03-Mar-2026,,6227810899,5,622781089905,Whole Blood QuantiFERON TB2,Not Received,,,QUANTIFERON PLUS,TB2-YELLOW,,,,,11:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,02-Mar-2026,SCRN,03-Mar-2026,,6227810899,6,622781089906,"Plasma, QuantiFERON TB2",Canceled,Frozen,,QUANTIFERON PLUS,TB2-YELLOW FRZ,,,,,11:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,02-Mar-2026,SCRN,03-Mar-2026,03-Mar-2026,6227810899,10,622781089910,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,11:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,02-Mar-2026,SCRN,03-Mar-2026,,6227810899,11,622781089911,"Red Cells, Clot",Not Received,,,"HIV SCREEN,",HEPATITIS B & C,,,,,11:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,02-Mar-2026,SCRN,03-Mar-2026,03-Mar-2026,6227810899,12,622781089912,"Serum, SST",Received,Ambient,Default Return Ambient,"HIV SCREEN,",HEPATITIS B & C,,,,,11:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,02-Mar-2026,SCRN,03-Mar-2026,,6227810899,13,622781089913,"Red Cells, Clot",Not Received,,,CHEM PANEL &,BETA HCG,,,,,11:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,02-Mar-2026,SCRN,03-Mar-2026,03-Mar-2026,6227810899,14,622781089914,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,BETA HCG,,,,,11:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,02-Mar-2026,SCRN,03-Mar-2026,,6227810899,15,622781089915,"Serum, SST",Canceled,Ambient,,FSH,,,,,,11:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,02-Mar-2026,SCRN,03-Mar-2026,,6227810899,8,622781089908,"Plasma, QuantiFERON Mitoge",Canceled,Frozen,,QUANTIFERON PLUS,MITOGEN-PURPLE FRZ,,,,,11:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,02-Mar-2026,SCRN,03-Mar-2026,03-Mar-2026,6227810899,9,622781089909,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,11:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,04-Mar-2026,SCRN,05-Mar-2026,06-Mar-2026,6227810900,2,622781090002,"Plasma, QuantiFERON Nil",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,NIL-GRAY FRZ,,,,,09:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,04-Mar-2026,SCRN,05-Mar-2026,06-Mar-2026,6227810900,4,622781090004,"Plasma, QuantiFERON TB1",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB1-GREEN FRZ,,,,,09:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,04-Mar-2026,SCRN,05-Mar-2026,06-Mar-2026,6227810900,6,622781090006,"Plasma, QuantiFERON TB2",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB2-YELLOW FRZ,,,,,09:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,04-Mar-2026,SCRN,05-Mar-2026,,6227810900,7,622781090007,Whole Blood QuantiFERON Mitoge,Not Received,,,QUANTIFERON PLUS,MITOGEN-PURPLE,,,,,09:20,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,04-Mar-2026,SCRN,05-Mar-2026,06-Mar-2026,6227810900,8,622781090008,"Plasma, QuantiFERON Mitoge",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,MITOGEN-PURPLE FRZ,,,,,09:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,04-Mar-2026,SCRN,05-Mar-2026,05-Mar-2026,6227810900,9,622781090009,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,09:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,04-Mar-2026,SCRN,05-Mar-2026,05-Mar-2026,6227810900,10,622781090010,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,04-Mar-2026,SCRN,05-Mar-2026,,6227810900,3,622781090003,Whole Blood QuantiFERON TB1,Not Received,,,QUANTIFERON PLUS,TB1-GREEN,,,,,09:20,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,04-Mar-2026,SCRN,05-Mar-2026,,6227810900,5,622781090005,Whole Blood QuantiFERON TB2,Not Received,,,QUANTIFERON PLUS,TB2-YELLOW,,,,,09:20,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,04-Mar-2026,SCRN,05-Mar-2026,05-Mar-2026,6227810900,12,622781090012,"Serum, SST",Received,Ambient,Default Return Ambient,"HIV SCREEN,",HEPATITIS B & C,,,,,09:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,04-Mar-2026,SCRN,05-Mar-2026,,6227810900,14,622781090014,"Serum, SST",Canceled,Ambient,,CHEM PANEL &,BETA HCG,,,,,09:20,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,04-Mar-2026,SCRN,05-Mar-2026,,6227810900,13,622781090013,"Red Cells, Clot",Not Received,,,"CHEM PANEL, BETA",HCG & FSH,,,,,09:20,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,04-Mar-2026,SCRN,05-Mar-2026,,6227810900,15,622781090015,"Serum, SST",Canceled,Ambient,,FSH,FROZEN,,,,,09:20,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,03-Mar-2026,SCRN,04-Mar-2026,,6227810901,1,622781090101,Whole Blood QuantiFERON Nil,Not Received,,,QUANTIFERON PLUS,NIL-GRAY,,,,,12:10,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,03-Mar-2026,SCRN,04-Mar-2026,05-Mar-2026,6227810901,2,622781090102,"Plasma, QuantiFERON Nil",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,NIL-GRAY FRZ,,,,,12:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,03-Mar-2026,SCRN,04-Mar-2026,,6227810901,3,622781090103,Whole Blood QuantiFERON TB1,Not Received,,,QUANTIFERON PLUS,TB1-GREEN,,,,,12:10,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,03-Mar-2026,SCRN,04-Mar-2026,05-Mar-2026,6227810901,4,622781090104,"Plasma, QuantiFERON TB1",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB1-GREEN FRZ,,,,,12:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,04-Mar-2026,SCRN,05-Mar-2026,,6227810900,1,622781090001,Whole Blood QuantiFERON Nil,Not Received,,,QUANTIFERON PLUS,NIL-GRAY,,,,,09:20,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,03-Mar-2026,SCRN,04-Mar-2026,05-Mar-2026,6227810901,6,622781090106,"Plasma, QuantiFERON TB2",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB2-YELLOW FRZ,,,,,12:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,03-Mar-2026,SCRN,04-Mar-2026,,6227810901,7,622781090107,Whole Blood QuantiFERON Mitoge,Not Received,,,QUANTIFERON PLUS,MITOGEN-PURPLE,,,,,12:10,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,03-Mar-2026,SCRN,04-Mar-2026,05-Mar-2026,6227810901,8,622781090108,"Plasma, QuantiFERON Mitoge",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,MITOGEN-PURPLE FRZ,,,,,12:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,03-Mar-2026,SCRN,04-Mar-2026,04-Mar-2026,6227810901,9,622781090109,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,12:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,03-Mar-2026,SCRN,04-Mar-2026,,6227810901,10,622781090110,"Slides, Hematology",Not Received,Ambient,,HEMATOLOGY,,,,,,12:10,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,03-Mar-2026,SCRN,04-Mar-2026,,6227810901,11,622781090111,"Red Cells, Clot",Not Received,,,"HIV SCREEN,",HEPATITIS B & C,,,,,12:10,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,03-Mar-2026,SCRN,04-Mar-2026,04-Mar-2026,6227810901,12,622781090112,"Serum, SST",Received,Ambient,Default Return Ambient,"HIV SCREEN,",HEPATITIS B & C,,,,,12:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,03-Mar-2026,SCRN,04-Mar-2026,,6227810901,14,622781090114,"Serum, SST",Canceled,Ambient,,CHEM PANEL &,BETA HCG,,,,,12:10,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,03-Mar-2026,SCRN,04-Mar-2026,,6227810901,13,622781090113,"Red Cells, Clot",Not Received,,,CHEM PANEL &,BETA HCG,,,,,12:10,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,02-Mar-2026,SCRN,03-Mar-2026,,6227810899,7,622781089907,Whole Blood QuantiFERON Mitoge,Not Received,,,QUANTIFERON PLUS,MITOGEN-PURPLE,,,,,11:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,04-Mar-2026,SCRN,05-Mar-2026,,6227810900,11,622781090011,"Red Cells, Clot",Not Received,,,"HIV SCREEN,",HEPATITIS B & C,,,,,09:20,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,03-Mar-2026,SCRN,04-Mar-2026,,6227810901,5,622781090105,Whole Blood QuantiFERON TB2,Not Received,,,QUANTIFERON PLUS,TB2-YELLOW,,,,,12:10,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,03-Mar-2026,SCRN,04-Mar-2026,,6227810901,15,622781090115,"Serum, SST",Canceled,Ambient,,FSH,,,,,,12:10,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,04-Mar-2026,SCRNSTOOL,05-Mar-2026,05-Mar-2026,6227810904,2,622781090402,"Stool, unpreserved",Received,Frozen,Default Return Frozen,C-DIFF TOXIN,& PCR FROZEN,,,,,09:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,04-Mar-2026,SCRNSTOOL,05-Mar-2026,05-Mar-2026,6227810904,3,622781090403,"Culture, Stool",Received,Ambient,Default Return Ambient,STOOL CULTURE,,,,,,09:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,04-Mar-2026,SCRNSTOOL,05-Mar-2026,,6227810904,4,622781090404,"Stool, ova & parasites(PVA)",Canceled,Ambient,,OVA & PARASITES 2,PVA,,,,,09:10,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,03-Mar-2026,SCRNSTOOL,04-Mar-2026,,6227810905,1,622781090501,"Stool, ova & parasites(form)",Canceled,Ambient,,OVA & PARASITES 1,FORMALIN,,,,,12:20,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,03-Mar-2026,SCRNSTOOL,04-Mar-2026,04-Mar-2026,6227810905,2,622781090502,"Stool, unpreserved",Received,Frozen,Default Return Frozen,C-DIFF TOXIN,& PCR FROZEN,,,,,12:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,03-Mar-2026,SCRNSTOOL,04-Mar-2026,04-Mar-2026,6227810905,3,622781090503,"Culture, Stool",Received,Ambient,Default Return Ambient,STOOL CULTURE,,,,,,12:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,03-Mar-2026,SCRNSTOOL,04-Mar-2026,,6227810905,4,622781090504,"Stool, ova & parasites(PVA)",Canceled,Ambient,,OVA & PARASITES 2,PVA,,,,,12:20,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,04-Mar-2026,SCRNSTOOL,05-Mar-2026,,6227810904,1,622781090401,"Stool, ova & parasites(form)",Canceled,Ambient,,OVA & PARASITES 1,FORMALIN,,,,,09:10,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,05-Feb-2026,BXSCR,06-Feb-2026,06-Feb-2026,6227323223,5,622732322305,"Tissue , Paraffin Block",Shipped,,Default Return Ambient,,,,,,,00:00,13:01,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,06-May-2026,I-4,07-May-2026,07-May-2026,6227933142,3,622793314203,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,06-May-2026,I-4,07-May-2026,07-May-2026,6227933142,5,622793314205,"Feces, unpreserved",Received,Frozen,Default Return Frozen,FECAL CALPROTECTIN,FROZEN,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,06-May-2026,I-4,07-May-2026,07-May-2026,6227933142,2,622793314202,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,CRP,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,06-May-2026,I-4,07-May-2026,07-May-2026,6227933142,4,622793314204,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,06-May-2026,I-4,07-May-2026,07-May-2026,6227933142,6,622793314206,"Stool, unpreserved",Shipped,Frozen,Default Return Frozen,STOOL I-4,77242113UCO3001-1,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,06-May-2026,I-4,07-May-2026,07-May-2026,6227933142,1,622793314201,"Red Cells, Clot",Received,,Default Discard/Not Return,CHEM PANEL &,CRP,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,06-May-2026,I-4,07-May-2026,,6227933142,7,622793314207,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-4,77242113UCO3001-2,,,,,08:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,06-May-2026,I-4,07-May-2026,,6227933142,10,622793314210,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-4,77242113UCO3001-5,,,,,08:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,06-May-2026,I-4,07-May-2026,07-May-2026,6227933142,12,622793314212,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMPK I-4 TROUGH,77242113UCO3001,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,06-May-2026,I-4,07-May-2026,,6227933142,9,622793314209,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-4,77242113UCO3001-4,,,,,08:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,06-May-2026,I-4,07-May-2026,07-May-2026,6227933142,11,622793314211,"Whole Blood, EDTA, Dry",Received,,Default Discard/Not Return,PLASMA PK TROUGH,,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,06-May-2026,I-4,07-May-2026,,6227933142,8,622793314208,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-4,77242113UCO3001-3,,,,,08:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,06-May-2026,I-4,07-May-2026,07-May-2026,6227933142,14,622793314214,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMA PK I-4 PEAK,77242113UCO3001,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,06-May-2026,I-4,07-May-2026,07-May-2026,6227933142,17,622793314217,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-4 PRE,77242113UCO3001-2,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,06-May-2026,I-4,07-May-2026,07-May-2026,6227933142,13,622793314213,"Whole Blood, EDTA, Dry",Received,,Default Discard/Not Return,SM02/PLASMAPK PEAK,,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,06-May-2026,I-4,07-May-2026,07-May-2026,6227933142,18,622793314218,"Red Cells, Clot",Received,,Default Discard/Not Return,SM06/SERUM,BIOMARKERS,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,13-May-2026,I-12,14-May-2026,14-May-2026,6227933143,1,622793314301,"Red Cells, Clot",Received,,Default Discard/Not Return,"CHEM, LIPID PANEL",& CRP,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,06-May-2026,I-4,07-May-2026,07-May-2026,6227933142,15,622793314215,"Red Cells, Clot",Received,,Default Discard/Not Return,SM04/SERUM ADA PRE,,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,06-May-2026,I-4,07-May-2026,07-May-2026,6227933142,19,622793314219,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-1,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,13-May-2026,I-12,14-May-2026,14-May-2026,6227933143,2,622793314302,"Serum, SST",Received,Ambient,Default Return Ambient,"CHEM, LIPID PANEL",& CRP,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,06-May-2026,I-4,07-May-2026,07-May-2026,6227933142,21,622793314221,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-3,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,06-May-2026,I-4,07-May-2026,07-May-2026,6227933142,22,622793314222,Whole Blood PAXgene RNA,Shipped,Frozen,Default Return Frozen,SM07/WB RNA,77242113UCO3001,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,06-May-2026,I-4,07-May-2026,07-May-2026,6227933142,20,622793314220,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-2,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,06-May-2026,I-4,07-May-2026,07-May-2026,6227933142,16,622793314216,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-4 PRE,77242113UCO3001-1,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,13-May-2026,I-12,14-May-2026,14-May-2026,6227933143,4,622793314304,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,13-May-2026,I-12,14-May-2026,,6227933143,8,622793314308,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-12,77242113UCO3001-4,,,,,08:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,13-May-2026,I-12,14-May-2026,,6227933143,7,622793314307,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-12,77242113UCO3001-3,,,,,08:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,13-May-2026,I-12,14-May-2026,14-May-2026,6227933143,3,622793314303,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,13-May-2026,I-12,14-May-2026,14-May-2026,6227933143,20,622793314320,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-3,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,13-May-2026,I-12,14-May-2026,,6227933143,6,622793314306,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-12,77242113UCO3001-2,,,,,08:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,13-May-2026,I-12,14-May-2026,,6227933143,9,622793314309,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-12,77242113UCO3001-5,,,,,08:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,13-May-2026,I-12,14-May-2026,14-May-2026,6227933143,11,622793314311,"Plasma, EDTA",In Inventory,Frozen,Default Return Frozen,PLASMPK I-12TROUGH,77242113UCO3001,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,13-May-2026,I-12,14-May-2026,14-May-2026,6227933143,19,622793314319,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-2,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,13-May-2026,I-12,14-May-2026,14-May-2026,6227933143,17,622793314317,"Red Cells, Clot",Received,,Default Discard/Not Return,SM06/SERUM,BIOMARKERS,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,13-May-2026,I-12,14-May-2026,14-May-2026,6227933143,22,622793314322,"Feces, unpreserved",Received,Frozen,Default Return Frozen,FECAL CALPROTECTIN,EXPEDITED FRZN,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,13-May-2026,I-12,14-May-2026,14-May-2026,6227933143,10,622793314310,"Whole Blood, EDTA, Dry",Received,,Default Discard/Not Return,PLASMA PK TROUGH,,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,13-May-2026,I-12,14-May-2026,14-May-2026,6227933143,16,622793314316,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-12 PRE,77242113UCO3001-2,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,13-May-2026,I-12,14-May-2026,14-May-2026,6227933143,23,622793314323,"Stool, unpreserved",In Inventory,Frozen,Default Return Frozen,SM10/FECAL,BIOMARKERS,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,13-May-2026,I-12,14-May-2026,14-May-2026,6227933143,18,622793314318,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-1,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,13-May-2026,I-12,14-May-2026,14-May-2026,6227933143,12,622793314312,"Whole Blood, EDTA, Dry",Received,,Default Discard/Not Return,SM02/PLASMAPK PEAK,,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,13-May-2026,I-12,14-May-2026,14-May-2026,6227933143,15,622793314315,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-12 PRE,77242113UCO3001-1,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,13-May-2026,I-12,14-May-2026,14-May-2026,6227933143,14,622793314314,"Red Cells, Clot",Received,,Default Discard/Not Return,SM04/SERUM ADA PRE,,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,13-May-2026,I-12,14-May-2026,14-May-2026,6227933143,13,622793314313,"Plasma, EDTA",In Inventory,Frozen,Default Return Frozen,PLASMAPK I-12 PEAK,77242113UCO3001,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,13-May-2026,I-12,14-May-2026,14-May-2026,6227933143,5,622793314305,"Stool, unpreserved",Shipped,Frozen,Default Return Frozen,STOOL I-12,77242113UCO3001-1,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,13-May-2026,I-12,14-May-2026,14-May-2026,6227933143,21,622793314321,Whole Blood PAXgene RNA,Shipped,Frozen,Default Return Frozen,SM07/WB RNA,77242113UCO3001,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,11-Feb-2026,BXSCR,12-Feb-2026,12-Feb-2026,6227323287,5,622732328705,"Tissue , Paraffin Block",Shipped,,Default Return Ambient,,,,,,,00:00,12:52,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,13-Apr-2026,SCRN,14-Apr-2026,16-Apr-2026,6227993962,2,622799396202,"Plasma, QuantiFERON Nil",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,NIL-GRAY FRZ,,,,,12:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,13-Apr-2026,SCRN,14-Apr-2026,,6227993962,15,622799396215,"Serum, SST",Canceled,Ambient,,FSH,FROZEN,,,,,12:20,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,13-Apr-2026,SCRN,14-Apr-2026,16-Apr-2026,6227993962,4,622799396204,"Plasma, QuantiFERON TB1",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB1-GREEN FRZ,,,,,12:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,13-Apr-2026,SCRN,14-Apr-2026,,6227993962,1,622799396201,Whole Blood QuantiFERON Nil,Not Received,,,QUANTIFERON PLUS,NIL-GRAY,,,,,12:20,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,13-Apr-2026,SCRN,14-Apr-2026,14-Apr-2026,6227993962,10,622799396210,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,12:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,13-Apr-2026,SCRN,14-Apr-2026,14-Apr-2026,6227993962,14,622799396214,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,BETA HCG,,,,,12:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,13-Apr-2026,SCRN,14-Apr-2026,,6227993962,3,622799396203,Whole Blood QuantiFERON TB1,Not Received,,,QUANTIFERON PLUS,TB1-GREEN,,,,,12:20,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,13-Apr-2026,SCRN,14-Apr-2026,16-Apr-2026,6227993962,8,622799396208,"Plasma, QuantiFERON Mitoge",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,MITOGEN-PURPLE FRZ,,,,,12:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,13-Apr-2026,SCRN,14-Apr-2026,14-Apr-2026,6227993962,12,622799396212,"Serum, SST",Received,Ambient,Default Return Ambient,"HIV SCREEN,",HEPATITIS B & C,,,,,12:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,13-Apr-2026,SCRN,14-Apr-2026,,6227993962,11,622799396211,"Red Cells, Clot",Not Received,,,"HIV SCREEN,",HEPATITIS B & C,,,,,12:20,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,13-Apr-2026,SCRN,14-Apr-2026,,6227993962,7,622799396207,Whole Blood QuantiFERON Mitoge,Not Received,,,QUANTIFERON PLUS,MITOGEN-PURPLE,,,,,12:20,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,13-Apr-2026,SCRN,14-Apr-2026,14-Apr-2026,6227993962,9,622799396209,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,12:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,13-Apr-2026,SCRN,14-Apr-2026,,6227993962,5,622799396205,Whole Blood QuantiFERON TB2,Not Received,,,QUANTIFERON PLUS,TB2-YELLOW,,,,,12:20,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,13-Apr-2026,SCRN,14-Apr-2026,16-Apr-2026,6227993962,6,622799396206,"Plasma, QuantiFERON TB2",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB2-YELLOW FRZ,,,,,12:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,13-Apr-2026,SCRN,14-Apr-2026,,6227993962,13,622799396213,"Red Cells, Clot",Not Received,,,CHEM PANEL &,BETA HCG,,,,,12:20,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,18-May-2026,I-0,19-May-2026,20-May-2026,6227993966,14,622799396614,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-2,,,,,09:28,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,18-May-2026,I-0,19-May-2026,,6227993966,17,622799396617,"Red Cells, Clot",Not Received,,,"CHEM, LIPID PANEL",& CRP,,,,,09:28,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,18-May-2026,I-0,19-May-2026,19-May-2026,6227993966,2,622799396602,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:28,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,18-May-2026,I-0,19-May-2026,,6227993966,3,622799396603,"Whole Blood, EDTA, Dry",Not Received,,,PLASMA PK TROUGH,,,,,,09:28,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,18-May-2026,I-0,19-May-2026,,6227993966,12,622799396612,"Red Cells, Clot",Not Received,,,SM06/SERUM,BIOMARKERS,,,,,09:28,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,18-May-2026,I-0,19-May-2026,19-May-2026,6227993966,1,622799396601,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,09:28,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,18-May-2026,I-0,19-May-2026,20-May-2026,6227993966,13,622799396613,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-1,,,,,09:28,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,18-May-2026,I-0,19-May-2026,,6227993966,7,622799396607,"Red Cells, Clot",Not Received,,,SM04/SERUM ADA PRE,,,,,,09:28,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,18-May-2026,I-0,19-May-2026,20-May-2026,6227993966,15,622799396615,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-3,,,,,09:28,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,18-May-2026,I-0,19-May-2026,20-May-2026,6227993966,8,622799396608,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-0 PRE,77242113UCO3001-1,,,,,09:28,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,18-May-2026,I-0,19-May-2026,20-May-2026,6227993966,4,622799396604,"Plasma, EDTA",In Inventory,Frozen,Default Return Frozen,PLASMPK I-0 TROUGH,77242113UCO3001,,,,,09:28,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,18-May-2026,I-0,19-May-2026,20-May-2026,6227993966,10,622799396610,"Stool, unpreserved",In Inventory,Frozen,Default Return Frozen,SM10/FECAL,BIOMARKERS,,,,,09:28,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,18-May-2026,I-0,19-May-2026,20-May-2026,6227993966,11,622799396611,Whole Blood PAXgene RNA,In Inventory,Frozen,Default Return Frozen,SM07/WB RNA,77242113UCO3001,,,,,09:28,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,18-May-2026,I-0,19-May-2026,20-May-2026,6227993966,6,622799396606,"Plasma, EDTA",In Inventory,Frozen,Default Return Frozen,PLASMA PK I-0 PEAK,77242113UCO3001,,,,,09:28,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,18-May-2026,I-0,19-May-2026,,6227993966,5,622799396605,"Whole Blood, EDTA, Dry",Not Received,,,SM02/PLASMAPK PEAK,,,,,,09:28,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,18-May-2026,I-0,19-May-2026,20-May-2026,6227993966,16,622799396616,"Feces, unpreserved",Received,Frozen,Default Return Frozen,FECAL CALPROTECTIN,FROZEN,,,,,09:28,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,18-May-2026,I-0,19-May-2026,19-May-2026,6227993966,18,622799396618,"Serum, SST",Received,Ambient,Default Return Ambient,"CHEM, LIPID PANEL",& CRP,,,,,09:28,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,18-May-2026,I-0,19-May-2026,20-May-2026,6227993966,9,622799396609,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-0 PRE,77242113UCO3001-2,,,,,09:28,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,01-Jun-2026,I-2,02-Jun-2026,02-Jun-2026,6227993968,8,622799396808,"Stool, unpreserved",In Inventory,Frozen,Default Return Frozen,STOOL I-2,77242113UCO3001-1,,,,,08:35,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,01-Jun-2026,I-2,02-Jun-2026,,6227993968,1,622799396801,"Whole Blood, EDTA, Dry",Not Received,,,PLASMA PK TROUGH,,,,,,08:35,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,01-Jun-2026,I-2,02-Jun-2026,02-Jun-2026,6227993968,13,622799396813,"Feces, unpreserved",Received,Frozen,Default Return Frozen,FECAL CALPROTECTIN,FROZEN,,,,,08:35,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,01-Jun-2026,I-2,02-Jun-2026,02-Jun-2026,6227993968,2,622799396802,"Plasma, EDTA",In Inventory,Frozen,Default Return Frozen,PLASMPK I-2 TROUGH,77242113UCO3001,,,,,08:35,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,01-Jun-2026,I-2,02-Jun-2026,,6227993968,10,622799396810,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-2,77242113UCO3001-3,,,,,08:35,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,01-Jun-2026,I-2,02-Jun-2026,02-Jun-2026,6227993968,4,622799396804,"Plasma, EDTA",In Inventory,Frozen,Default Return Frozen,PLASMA PK I-2 PEAK,77242113UCO3001,,,,,08:35,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,01-Jun-2026,I-2,02-Jun-2026,02-Jun-2026,6227993968,14,622799396814,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,08:35,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,01-Jun-2026,I-2,02-Jun-2026,,6227993968,12,622799396812,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-2,77242113UCO3001-5,,,,,08:35,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,01-Jun-2026,I-2,02-Jun-2026,,6227993968,5,622799396805,"Red Cells, Clot",Not Received,,,SM04/SERUM ADA PRE,,,,,,08:35,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,01-Jun-2026,I-2,02-Jun-2026,02-Jun-2026,6227993968,7,622799396807,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-2 PRE,77242113UCO3001-2,,,,,08:35,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,01-Jun-2026,I-2,02-Jun-2026,,6227993968,11,622799396811,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-2,77242113UCO3001-4,,,,,08:35,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,01-Jun-2026,I-2,02-Jun-2026,,6227993968,3,622799396803,"Whole Blood, EDTA, Dry",Not Received,,,SM02/PLASMAPK PEAK,,,,,,08:35,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,01-Jun-2026,I-2,02-Jun-2026,,6227993968,9,622799396809,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-2,77242113UCO3001-2,,,,,08:35,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,01-Jun-2026,I-2,02-Jun-2026,02-Jun-2026,6227993968,17,622799396817,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,CRP,,,,,08:35,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,01-Jun-2026,I-2,02-Jun-2026,,6227993968,16,622799396816,"Red Cells, Clot",Not Received,,,CHEM PANEL &,CRP,,,,,08:35,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,01-Jun-2026,I-2,02-Jun-2026,02-Jun-2026,6227993968,6,622799396806,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SERUM ADA I-2 PRE,77242113UCO3001-1,,,,,08:35,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,01-Jun-2026,I-2,02-Jun-2026,02-Jun-2026,6227993968,15,622799396815,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,08:35,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,13-Apr-2026,SCRNSTOOL,14-Apr-2026,,6227993971,4,622799397104,"Stool, ova & parasites(PVA)",Not Received,Ambient,,OVA & PARASITES 2,PVA,,,,,06:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,13-Apr-2026,SCRNSTOOL,14-Apr-2026,14-Apr-2026,6227993971,3,622799397103,"Culture, Stool",Received,Ambient,Default Return Ambient,STOOL CULTURE,,,,,,06:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,13-Apr-2026,SCRNSTOOL,14-Apr-2026,,6227993971,1,622799397101,"Stool, ova & parasites(form)",Not Received,Ambient,,OVA & PARASITES 1,FORMALIN,,,,,06:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,13-Apr-2026,SCRNSTOOL,14-Apr-2026,14-Apr-2026,6227993971,2,622799397102,"Stool, unpreserved",Received,Frozen,Default Return Frozen,C-DIFF TOXIN,& PCR FROZEN,,,,,06:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,18-May-2026,DNA,20-May-2026,20-May-2026,6227993977,1,622799397701,"Whole Blood, EDTA, Dry",In Inventory,Frozen,Default Return Frozen,SM08/WB DNA,77242113UCO3001,,,,,09:28,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,DNA,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,15-Apr-2026,BXSCR,16-Apr-2026,16-Apr-2026,6227993984,1,622799398401,Wet Tissue Biopsy,Removed,Ambient,Default Return Ambient,SM11/BIOPSY,HISTOLOGY,,,,,00:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,15-Apr-2026,BXSCR,16-Apr-2026,17-Apr-2026,6227993984,3,622799398403,"Biopsy, Frozen Tissue",In Inventory,Frozen,Default Return Frozen,SM14/BIOPSY CRYO,FROZEN,,,,,00:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,15-Apr-2026,BXSCR,16-Apr-2026,,6227993984,4,622799398404,"Biopsy, Frozen Tissue",Not Received,Frozen,,BIOPSY PK,77242113UCO3001,,,,,00:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,15-Apr-2026,BXSCR,16-Apr-2026,17-Apr-2026,6227993984,2,622799398402,Biopsy RNA Later,Shipped,Frozen,Default Return Frozen,SM13/BIOPSY RNA,FROZEN,,,,,00:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,18-May-2026,BDL,20-May-2026,20-May-2026,6227993987,2,622799398702,"Serum, SST",Shipped,Frozen,Default Return Frozen,"ADA, GOL, INF",UST OR VED FROZEN,,,,,09:28,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biologic Drug Level,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,18-May-2026,BDL,20-May-2026,,6227993987,1,622799398701,"Red Cells, Clot",Not Received,,,DRUG LEVEL TESTING,,,,,,09:28,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biologic Drug Level,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,16-Feb-2026,SCRNSTOOL,18-Feb-2026,18-Feb-2026,6227323244,5,622732324405,,Canceled,,,,,,,,,07:20,12:28,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,16-Feb-2026,SCRNSTOOL,18-Feb-2026,18-Feb-2026,6227323244,6,622732324406,,Canceled,,,,,,,,,07:20,12:28,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222001,18-Feb-2026,BXSCR,19-Feb-2026,19-Feb-2026,6227323286,5,622732328605,"Tissue , Paraffin Block",In Inventory,,Default Return Ambient,,,,,,,00:00,15:49,Czech Republic,,10:20,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,01-Apr-2026,BXSCR,02-Apr-2026,04-Apr-2026,6228023951,2,622802395102,Biopsy RNA Later,Shipped,Frozen,Default Return Frozen,SM13/BIOPSY RNA,FROZEN,,,,,00:00,07:30,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,01-Apr-2026,BXSCR,02-Apr-2026,02-Apr-2026,6228023951,1,622802395101,Wet Tissue Biopsy,Removed,Ambient,Default Return Ambient,SM11/BIOPSY,HISTOLOGY,,,,,00:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,01-Apr-2026,BXSCR,02-Apr-2026,04-Apr-2026,6228023951,3,622802395103,"Biopsy, Frozen Tissue",In Inventory,Frozen,Default Return Frozen,SM14/BIOPSY CRYO,FROZEN,,,,,00:00,07:30,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,01-Apr-2026,BXSCR,02-Apr-2026,,6228023951,4,622802395104,"Biopsy, Frozen Tissue",Not Received,Frozen,,BIOPSY PK,77242113UCO3001,,,,,00:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,19-Feb-2026,BXSCR,21-Feb-2026,21-Feb-2026,6227323254,5,622732325405,"Tissue , Paraffin Block",Shipped,,Default Return Ambient,,,,,,,00:00,14:49,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,27-May-2026,I-0,28-May-2026,28-May-2026,6228036553,3,622803655303,"Whole Blood, EDTA, Dry",Received,,Default Discard/Not Return,PLASMA PK TROUGH,,,,,,07:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,27-May-2026,I-0,28-May-2026,28-May-2026,6228036553,5,622803655305,"Whole Blood, EDTA, Dry",Received,,Default Discard/Not Return,SM02/PLASMAPK PEAK,,,,,,07:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,27-May-2026,I-0,28-May-2026,28-May-2026,6228036553,7,622803655307,"Red Cells, Clot",Received,,Default Discard/Not Return,SM04/SERUM ADA PRE,,,,,,07:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,27-May-2026,I-0,28-May-2026,28-May-2026,6228036553,8,622803655308,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-0 PRE,77242113UCO3001-1,,,,,07:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,27-May-2026,I-0,28-May-2026,28-May-2026,6228036553,4,622803655304,"Plasma, EDTA",In Inventory,Frozen,Default Return Frozen,PLASMPK I-0 TROUGH,77242113UCO3001,,,,,07:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,27-May-2026,I-0,28-May-2026,28-May-2026,6228036553,1,622803655301,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,07:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,27-May-2026,I-0,28-May-2026,28-May-2026,6228036553,6,622803655306,"Plasma, EDTA",In Inventory,Frozen,Default Return Frozen,PLASMA PK I-0 PEAK,77242113UCO3001,,,,,07:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,27-May-2026,I-0,28-May-2026,28-May-2026,6228036553,2,622803655302,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,07:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,27-May-2026,I-0,28-May-2026,28-May-2026,6228036553,12,622803655312,"Red Cells, Clot",Received,,Default Discard/Not Return,SM06/SERUM,BIOMARKERS,,,,,07:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,27-May-2026,I-0,28-May-2026,28-May-2026,6228036553,13,622803655313,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-1,,,,,07:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,27-May-2026,I-0,28-May-2026,28-May-2026,6228036553,15,622803655315,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-3,,,,,07:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,27-May-2026,I-0,28-May-2026,28-May-2026,6228036553,11,622803655311,Whole Blood PAXgene RNA,In Inventory,Frozen,Default Return Frozen,SM07/WB RNA,77242113UCO3001,,,,,07:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,27-May-2026,I-0,28-May-2026,28-May-2026,6228036553,17,622803655317,"Red Cells, Clot",Received,,Default Discard/Not Return,"CHEM, LIPID PANEL",& CRP,,,,,07:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,27-May-2026,I-0,28-May-2026,28-May-2026,6228036553,18,622803655318,"Serum, SST",Received,Ambient,Default Return Ambient,"CHEM, LIPID PANEL",& CRP,,,,,07:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,27-May-2026,I-0,28-May-2026,28-May-2026,6228036553,14,622803655314,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-2,,,,,07:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,27-May-2026,I-0,28-May-2026,28-May-2026,6228036553,9,622803655309,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-0 PRE,77242113UCO3001-2,,,,,07:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,27-May-2026,I-0,28-May-2026,28-May-2026,6228036553,16,622803655316,"Feces, unpreserved",Received,Frozen,Default Return Frozen,FECAL CALPROTECTIN,FROZEN,,,,,07:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,08-Apr-2026,I-0,09-Apr-2026,09-Apr-2026,6228036554,4,622803655404,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMPK I-0 TROUGH,77242113UCO3001,,,,,07:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,08-Apr-2026,I-0,09-Apr-2026,09-Apr-2026,6228036554,5,622803655405,"Whole Blood, EDTA, Dry",Received,,Default Discard/Not Return,SM02/PLASMAPK PEAK,,,,,,07:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,08-Apr-2026,I-0,09-Apr-2026,09-Apr-2026,6228036554,1,622803655401,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,07:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,08-Apr-2026,I-0,09-Apr-2026,09-Apr-2026,6228036554,6,622803655406,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMA PK I-0 PEAK,77242113UCO3001,,,,,07:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,08-Apr-2026,I-0,09-Apr-2026,09-Apr-2026,6228036554,7,622803655407,"Red Cells, Clot",Received,,Default Discard/Not Return,SM04/SERUM ADA PRE,,,,,,07:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,08-Apr-2026,I-0,09-Apr-2026,09-Apr-2026,6228036554,9,622803655409,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-0 PRE,77242113UCO3001-2,,,,,07:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,08-Apr-2026,I-0,09-Apr-2026,09-Apr-2026,6228036554,10,622803655410,"Stool, unpreserved",In Inventory,Frozen,Default Return Frozen,SM10/FECAL,BIOMARKERS,,,,,07:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,08-Apr-2026,I-0,09-Apr-2026,09-Apr-2026,6228036554,8,622803655408,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-0 PRE,77242113UCO3001-1,,,,,07:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,27-May-2026,I-0,28-May-2026,28-May-2026,6228036553,10,622803655310,"Stool, unpreserved",In Inventory,Frozen,Default Return Frozen,SM10/FECAL,BIOMARKERS,,,,,07:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,08-Apr-2026,I-0,09-Apr-2026,09-Apr-2026,6228036554,3,622803655403,"Whole Blood, EDTA, Dry",Received,,Default Discard/Not Return,PLASMA PK TROUGH,,,,,,07:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,08-Apr-2026,I-0,09-Apr-2026,09-Apr-2026,6228036554,11,622803655411,Whole Blood PAXgene RNA,Shipped,Frozen,Default Return Frozen,SM07/WB RNA,77242113UCO3001,,,,,07:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,08-Apr-2026,I-0,09-Apr-2026,09-Apr-2026,6228036554,2,622803655402,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,07:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,08-Apr-2026,I-0,09-Apr-2026,09-Apr-2026,6228036554,12,622803655412,"Red Cells, Clot",Received,,Default Discard/Not Return,SM06/SERUM,BIOMARKERS,,,,,07:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,08-Apr-2026,I-0,09-Apr-2026,09-Apr-2026,6228036554,13,622803655413,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-1,,,,,07:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,08-Apr-2026,I-0,09-Apr-2026,09-Apr-2026,6228036554,14,622803655414,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-2,,,,,07:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,08-Apr-2026,I-0,09-Apr-2026,09-Apr-2026,6228036554,15,622803655415,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-3,,,,,07:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,08-Apr-2026,I-0,09-Apr-2026,09-Apr-2026,6228036554,16,622803655416,"Feces, unpreserved",Received,Frozen,Default Return Frozen,FECAL CALPROTECTIN,FROZEN,,,,,07:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,08-Apr-2026,I-0,09-Apr-2026,09-Apr-2026,6228036554,17,622803655417,"Red Cells, Clot",Received,,Default Discard/Not Return,"CHEM, LIPID PANEL",& CRP,,,,,07:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,08-Apr-2026,I-0,09-Apr-2026,09-Apr-2026,6228036554,18,622803655418,"Serum, SST",Received,Ambient,Default Return Ambient,"CHEM, LIPID PANEL",& CRP,,,,,07:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012004,28-May-2026,SCRN,29-May-2026,30-May-2026,6228114608,1,622811460801,Whole Blood QuantiFERON Nil,Received,,Default Discard/Not Return,QUANTIFERON PLUS,NIL-GRAY,,,,,07:30,07:30,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012004,28-May-2026,SCRN,29-May-2026,30-May-2026,6228114608,7,622811460807,Whole Blood QuantiFERON Mitoge,Received,,Default Discard/Not Return,QUANTIFERON PLUS,MITOGEN-PURPLE,,,,,07:30,07:30,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012004,28-May-2026,SCRN,29-May-2026,30-May-2026,6228114608,3,622811460803,Whole Blood QuantiFERON TB1,Received,,Default Discard/Not Return,QUANTIFERON PLUS,TB1-GREEN,,,,,07:30,07:30,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012004,28-May-2026,SCRN,29-May-2026,30-May-2026,6228114608,6,622811460806,"Plasma, QuantiFERON TB2",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB2-YELLOW FRZ,,,,,07:30,07:30,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012004,28-May-2026,SCRN,29-May-2026,30-May-2026,6228114608,8,622811460808,"Plasma, QuantiFERON Mitoge",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,MITOGEN-PURPLE FRZ,,,,,07:30,07:30,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012004,28-May-2026,SCRN,29-May-2026,29-May-2026,6228114608,9,622811460809,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,07:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012004,28-May-2026,SCRN,29-May-2026,30-May-2026,6228114608,4,622811460804,"Plasma, QuantiFERON TB1",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB1-GREEN FRZ,,,,,07:30,07:30,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012004,28-May-2026,SCRN,29-May-2026,30-May-2026,6228114608,5,622811460805,Whole Blood QuantiFERON TB2,Received,,Default Discard/Not Return,QUANTIFERON PLUS,TB2-YELLOW,,,,,07:30,07:30,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012004,28-May-2026,SCRN,29-May-2026,29-May-2026,6228114608,11,622811460811,"Red Cells, Clot",Received,,Default Discard/Not Return,"HIV SCREEN,",HEPATITIS B & C,,,,,07:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012004,28-May-2026,SCRN,29-May-2026,29-May-2026,6228114608,10,622811460810,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,07:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012004,28-May-2026,SCRN,29-May-2026,30-May-2026,6228114608,2,622811460802,"Plasma, QuantiFERON Nil",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,NIL-GRAY FRZ,,,,,07:30,07:30,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012004,28-May-2026,SCRN,29-May-2026,29-May-2026,6228114608,12,622811460812,"Serum, SST",Received,Ambient,Default Return Ambient,"HIV SCREEN,",HEPATITIS B & C,,,,,07:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012004,28-May-2026,SCRN,29-May-2026,29-May-2026,6228114608,14,622811460814,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,BETA HCG,,,,,07:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012004,28-May-2026,SCRN,29-May-2026,,6228114608,15,622811460815,"Serum, SST",Canceled,Ambient,,FSH,FROZEN,,,,,07:30,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012004,28-May-2026,SCRN,29-May-2026,29-May-2026,6228114608,13,622811460813,"Red Cells, Clot",Received,,Default Discard/Not Return,CHEM PANEL &,BETA HCG,,,,,07:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,29-Apr-2026,SCRN,30-Apr-2026,01-May-2026,6228114610,1,622811461001,Whole Blood QuantiFERON Nil,Received,,Default Discard/Not Return,QUANTIFERON PLUS,NIL-GRAY,,,,,07:55,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,29-Apr-2026,SCRN,30-Apr-2026,01-May-2026,6228114610,2,622811461002,"Plasma, QuantiFERON Nil",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,NIL-GRAY FRZ,,,,,07:55,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,29-Apr-2026,SCRN,30-Apr-2026,01-May-2026,6228114610,5,622811461005,Whole Blood QuantiFERON TB2,Received,,Default Discard/Not Return,QUANTIFERON PLUS,TB2-YELLOW,,,,,07:55,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,29-Apr-2026,SCRN,30-Apr-2026,01-May-2026,6228114610,3,622811461003,Whole Blood QuantiFERON TB1,Received,,Default Discard/Not Return,QUANTIFERON PLUS,TB1-GREEN,,,,,07:55,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,29-Apr-2026,SCRN,30-Apr-2026,01-May-2026,6228114610,6,622811461006,"Plasma, QuantiFERON TB2",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB2-YELLOW FRZ,,,,,07:55,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,29-Apr-2026,SCRN,30-Apr-2026,01-May-2026,6228114610,4,622811461004,"Plasma, QuantiFERON TB1",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB1-GREEN FRZ,,,,,07:55,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,29-Apr-2026,SCRN,30-Apr-2026,30-Apr-2026,6228114610,10,622811461010,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,07:55,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,29-Apr-2026,SCRN,30-Apr-2026,30-Apr-2026,6228114610,11,622811461011,"Red Cells, Clot",Received,,Default Discard/Not Return,"HIV SCREEN,",HEPATITIS B & C,,,,,07:55,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,29-Apr-2026,SCRN,30-Apr-2026,30-Apr-2026,6228114610,9,622811461009,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,07:55,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,29-Apr-2026,SCRN,30-Apr-2026,01-May-2026,6228114610,7,622811461007,Whole Blood QuantiFERON Mitoge,Received,,Default Discard/Not Return,QUANTIFERON PLUS,MITOGEN-PURPLE,,,,,07:55,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,29-Apr-2026,SCRN,30-Apr-2026,30-Apr-2026,6228114610,12,622811461012,"Serum, SST",Received,Ambient,Default Return Ambient,"HIV SCREEN,",HEPATITIS B & C,,,,,07:55,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,29-Apr-2026,SCRN,30-Apr-2026,30-Apr-2026,6228114610,13,622811461013,"Red Cells, Clot",Received,,Default Discard/Not Return,CHEM PANEL &,BETA HCG,,,,,07:55,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,29-Apr-2026,SCRN,30-Apr-2026,30-Apr-2026,6228114610,14,622811461014,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,BETA HCG,,,,,07:55,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,29-Apr-2026,SCRN,30-Apr-2026,01-May-2026,6228114610,8,622811461008,"Plasma, QuantiFERON Mitoge",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,MITOGEN-PURPLE FRZ,,,,,07:55,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,29-Apr-2026,SCRN,30-Apr-2026,,6228114610,15,622811461015,"Serum, SST",Canceled,Ambient,,FSH,FROZEN,,,,,07:55,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,01-Jun-2026,I-12,02-Jun-2026,02-Jun-2026,6228137355,11,622813735511,"Plasma, EDTA",In Inventory,Frozen,Default Return Frozen,PLASMPK I-12TROUGH,77242113UCO3001,,,,,14:55,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,01-Jun-2026,I-12,02-Jun-2026,,6228137355,12,622813735512,"Whole Blood, EDTA, Dry",Not Received,,,SM02/PLASMAPK PEAK,,,,,,14:55,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,01-Jun-2026,I-12,02-Jun-2026,02-Jun-2026,6228137355,16,622813735516,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SERUM ADA I-12 PRE,77242113UCO3001-2,,,,,14:55,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,01-Jun-2026,I-12,02-Jun-2026,,6228137355,8,622813735508,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-12,77242113UCO3001-4,,,,,14:55,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,01-Jun-2026,I-12,02-Jun-2026,,6228137355,9,622813735509,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-12,77242113UCO3001-5,,,,,14:55,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,01-Jun-2026,I-12,02-Jun-2026,,6228137355,14,622813735514,"Red Cells, Clot",Not Received,,,SM04/SERUM ADA PRE,,,,,,14:55,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,01-Jun-2026,I-12,02-Jun-2026,,6228137355,7,622813735507,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-12,77242113UCO3001-3,,,,,14:55,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,01-Jun-2026,I-12,02-Jun-2026,,6228137355,10,622813735510,"Whole Blood, EDTA, Dry",Not Received,,,PLASMA PK TROUGH,,,,,,14:55,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,01-Jun-2026,I-12,02-Jun-2026,02-Jun-2026,6228137355,15,622813735515,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SERUM ADA I-12 PRE,77242113UCO3001-1,,,,,14:55,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,01-Jun-2026,I-12,02-Jun-2026,,6228137355,17,622813735517,"Red Cells, Clot",Not Received,,,SM06/SERUM,BIOMARKERS,,,,,14:55,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,01-Jun-2026,I-12,02-Jun-2026,02-Jun-2026,6228137355,13,622813735513,"Plasma, EDTA",In Inventory,Frozen,Default Return Frozen,PLASMAPK I-12 PEAK,77242113UCO3001,,,,,14:55,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,01-Jun-2026,I-12,02-Jun-2026,,6228137355,6,622813735506,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-12,77242113UCO3001-2,,,,,14:55,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,01-Jun-2026,I-12,02-Jun-2026,02-Jun-2026,6228137355,21,622813735521,Whole Blood PAXgene RNA,In Inventory,Frozen,Default Return Frozen,SM07/WB RNA,77242113UCO3001,,,,,14:55,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,01-Jun-2026,I-12,02-Jun-2026,02-Jun-2026,6228137355,20,622813735520,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-3,,,,,14:55,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,01-Jun-2026,I-12,02-Jun-2026,02-Jun-2026,6228137355,22,622813735522,"Feces, unpreserved",Received,Frozen,Default Return Frozen,FECAL CALPROTECTIN,EXPEDITED FRZN,,,,,14:55,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,01-Jun-2026,I-12,02-Jun-2026,02-Jun-2026,6228137355,18,622813735518,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-1,,,,,14:55,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,01-Jun-2026,I-12,02-Jun-2026,02-Jun-2026,6228137355,23,622813735523,"Stool, unpreserved",In Inventory,Frozen,Default Return Frozen,SM10/FECAL,BIOMARKERS,,,,,14:55,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,01-Jun-2026,I-12,02-Jun-2026,02-Jun-2026,6228137355,19,622813735519,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-2,,,,,14:55,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012004,02-Jun-2026,SCRNSTOOL,04-Jun-2026,,6228137357,1,622813735701,"Stool, ova & parasites(form)",Not Received,Ambient,,OVA & PARASITES 1,FORMALIN,,,,,18:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012004,02-Jun-2026,SCRNSTOOL,04-Jun-2026,,6228137357,4,622813735704,"Stool, ova & parasites(PVA)",Not Received,Ambient,,OVA & PARASITES 2,PVA,,,,,18:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012004,02-Jun-2026,SCRNSTOOL,04-Jun-2026,04-Jun-2026,6228137357,3,622813735703,"Culture, Stool",Received,Ambient,Default Return Ambient,STOOL CULTURE,,,,,,18:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,01-Jun-2026,I-12,02-Jun-2026,02-Jun-2026,6228137355,2,622813735502,"Serum, SST",Received,Ambient,Default Return Ambient,"CHEM, LIPID PANEL",& CRP,,,,,14:55,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,01-Jun-2026,I-12,02-Jun-2026,02-Jun-2026,6228137355,3,622813735503,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,14:55,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,01-Jun-2026,I-12,02-Jun-2026,02-Jun-2026,6228137355,5,622813735505,"Stool, unpreserved",In Inventory,Frozen,Default Return Frozen,STOOL I-12,77242113UCO3001,,,,,14:55,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,01-Jun-2026,I-12,02-Jun-2026,02-Jun-2026,6228137355,4,622813735504,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,14:55,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Apr-2026,UNSCSTOOL,23-Apr-2026,23-Apr-2026,6228137359,3,622813735903,"Culture, Stool",Received,Ambient,Default Return Ambient,STOOL CULTURE,,,,,,07:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012004,02-Jun-2026,SCRNSTOOL,04-Jun-2026,04-Jun-2026,6228137357,2,622813735702,"Stool, unpreserved",Received,Frozen,Default Return Frozen,C-DIFF TOXIN,& PCR FROZEN,,,,,18:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Apr-2026,UNSCSTOOL,23-Apr-2026,23-Apr-2026,6228137359,1,622813735901,"Stool, ova & parasites(form)",Received,Ambient,Default Return Ambient,OVA & PARASITES 1,FORMALIN,,,,,07:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Apr-2026,UNSCSTOOL,23-Apr-2026,23-Apr-2026,6228137359,4,622813735904,"Stool, ova & parasites(PVA)",Received,Ambient,Default Return Ambient,OVA & PARASITES 2,PVA,,,,,07:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,01-Jun-2026,I-12,02-Jun-2026,,6228137355,1,622813735501,"Red Cells, Clot",Not Received,,,"CHEM, LIPID PANEL",& CRP,,,,,14:55,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Apr-2026,UNSCSTOOL,23-Apr-2026,23-Apr-2026,6228137359,2,622813735902,"Stool, unpreserved",Received,Frozen,Default Return Frozen,C-DIFF TOXIN,& PCR FROZEN,,,,,07:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,09-Apr-2026,I-0,10-Apr-2026,10-Apr-2026,6228173397,1,622817339701,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,10:35,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,09-Apr-2026,I-0,10-Apr-2026,10-Apr-2026,6228173397,4,622817339704,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMPK I-0 TROUGH,77242113UCO3001,,,,,10:35,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,09-Apr-2026,I-0,10-Apr-2026,,6228173397,3,622817339703,"Whole Blood, EDTA, Dry",Not Received,,,PLASMA PK TROUGH,,,,,,10:35,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,09-Apr-2026,I-0,10-Apr-2026,10-Apr-2026,6228173397,2,622817339702,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,10:35,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,09-Apr-2026,I-0,10-Apr-2026,10-Apr-2026,6228173397,6,622817339706,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMA PK I-0 PEAK,77242113UCO3001,,,,,10:35,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,09-Apr-2026,I-0,10-Apr-2026,10-Apr-2026,6228173397,8,622817339708,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-0 PRE,77242113UCO3001-1,,,,,10:35,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,09-Apr-2026,I-0,10-Apr-2026,,6228173397,5,622817339705,"Whole Blood, EDTA, Dry",Not Received,,,SM02/PLASMAPK PEAK,,,,,,10:35,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,09-Apr-2026,I-0,10-Apr-2026,,6228173397,7,622817339707,"Red Cells, Clot",Not Received,,,SM04/SERUM ADA PRE,,,,,,10:35,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,09-Apr-2026,I-0,10-Apr-2026,,6228173397,12,622817339712,"Red Cells, Clot",Not Received,,,SM06/SERUM,BIOMARKERS,,,,,10:35,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,09-Apr-2026,I-0,10-Apr-2026,10-Apr-2026,6228173397,16,622817339716,"Feces, unpreserved",Received,Frozen,Default Return Frozen,FECAL CALPROTECTIN,FROZEN,,,,,10:35,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,09-Apr-2026,I-0,10-Apr-2026,10-Apr-2026,6228173397,18,622817339718,"Serum, SST",Received,Ambient,Default Return Ambient,"CHEM, LIPID PANEL",& CRP,,,,,10:35,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,09-Apr-2026,I-0,10-Apr-2026,,6228173397,17,622817339717,"Red Cells, Clot",Not Received,,,"CHEM, LIPID PANEL",& CRP,,,,,10:35,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,09-Apr-2026,I-0,10-Apr-2026,10-Apr-2026,6228173397,9,622817339709,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-0 PRE,77242113UCO3001-2,,,,,10:35,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,09-Apr-2026,I-0,10-Apr-2026,10-Apr-2026,6228173397,14,622817339714,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-2,,,,,10:35,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,09-Apr-2026,I-0,10-Apr-2026,10-Apr-2026,6228173397,11,622817339711,Whole Blood PAXgene RNA,Shipped,Frozen,Default Return Frozen,SM07/WB RNA,77242113UCO3001,,,,,10:35,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,09-Apr-2026,I-0,10-Apr-2026,10-Apr-2026,6228173397,10,622817339710,"Stool, unpreserved",In Inventory,Frozen,Default Return Frozen,SM10/FECAL,BIOMARKERS,,,,,10:35,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,09-Apr-2026,I-0,10-Apr-2026,10-Apr-2026,6228173397,15,622817339715,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-3,,,,,10:35,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,09-Apr-2026,I-0,10-Apr-2026,10-Apr-2026,6228173397,13,622817339713,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-1,,,,,10:35,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,22-Apr-2026,I-2,23-Apr-2026,23-Apr-2026,6228179932,14,622817993214,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,14:15,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,22-Apr-2026,I-2,23-Apr-2026,,6228179932,9,622817993209,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-2,77242113UCO3001-2,,,,,14:15,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,22-Apr-2026,I-2,23-Apr-2026,23-Apr-2026,6228179932,15,622817993215,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,14:15,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,22-Apr-2026,I-2,23-Apr-2026,,6228179932,16,622817993216,"Red Cells, Clot",Not Received,,,CHEM PANEL &,CRP,,,,,14:15,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,22-Apr-2026,I-2,23-Apr-2026,,6228179932,12,622817993212,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-2,77242113UCO3001-5,,,,,14:15,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,22-Apr-2026,I-2,23-Apr-2026,23-Apr-2026,6228179932,13,622817993213,"Feces, unpreserved",Received,Frozen,Default Return Frozen,FECAL CALPROTECTIN,FROZEN,,,,,14:15,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,22-Apr-2026,I-2,23-Apr-2026,23-Apr-2026,6228179932,17,622817993217,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,CRP,,,,,14:15,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,22-Apr-2026,I-2,23-Apr-2026,,6228179932,10,622817993210,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-2,77242113UCO3001-3,,,,,14:15,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,22-Apr-2026,I-2,23-Apr-2026,,6228179932,11,622817993211,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-2,77242113UCO3001-4,,,,,14:15,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,22-Apr-2026,I-2,23-Apr-2026,,6228179932,1,622817993201,"Whole Blood, EDTA, Dry",Not Received,,,PLASMA PK TROUGH,,,,,,14:15,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,22-Apr-2026,I-2,23-Apr-2026,,6228179932,3,622817993203,"Whole Blood, EDTA, Dry",Not Received,,,SM02/PLASMAPK PEAK,,,,,,14:15,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,22-Apr-2026,I-2,23-Apr-2026,23-Apr-2026,6228179932,4,622817993204,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMA PK I-2 PEAK,77242113UCO3001,,,,,14:15,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,22-Apr-2026,I-2,23-Apr-2026,23-Apr-2026,6228179932,7,622817993207,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-2 PRE,77242113UCO3001-2,,,,,14:15,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,22-Apr-2026,I-2,23-Apr-2026,23-Apr-2026,6228179932,2,622817993202,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMPK I-2 TROUGH,77242113UCO3001,,,,,14:15,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,22-Apr-2026,I-2,23-Apr-2026,23-Apr-2026,6228179932,8,622817993208,"Stool, unpreserved",Shipped,Frozen,Default Return Frozen,STOOL I-2,77242113UCO3001,,,,,14:15,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,05-May-2026,I-4,06-May-2026,,6228179936,1,622817993601,"Red Cells, Clot",Not Received,,,CHEM PANEL &,CRP,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,05-May-2026,I-4,06-May-2026,06-May-2026,6228179936,2,622817993602,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,CRP,,,,,07:40,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,05-May-2026,I-4,06-May-2026,06-May-2026,6228179936,6,622817993606,"Stool, unpreserved",Shipped,Frozen,Default Return Frozen,STOOL I-4,77242113UCO3001,,,,,07:40,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,05-May-2026,I-4,06-May-2026,06-May-2026,6228179936,4,622817993604,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,07:40,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,05-May-2026,I-4,06-May-2026,,6228179936,10,622817993610,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-4,77242113UCO3001-5,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,05-May-2026,I-4,06-May-2026,06-May-2026,6228179936,5,622817993605,"Feces, unpreserved",Received,Frozen,Default Return Frozen,FECAL CALPROTECTIN,FROZEN,,,,,07:40,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,05-May-2026,I-4,06-May-2026,06-May-2026,6228179936,14,622817993614,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMA PK I-4 PEAK,77242113UCO3001,,,,,07:40,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,05-May-2026,I-4,06-May-2026,,6228179936,11,622817993611,"Whole Blood, EDTA, Dry",Not Received,,,PLASMA PK TROUGH,,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,05-May-2026,I-4,06-May-2026,06-May-2026,6228179936,12,622817993612,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMPK I-4 TROUGH,77242113UCO3001,,,,,07:40,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,05-May-2026,I-4,06-May-2026,,6228179936,13,622817993613,"Whole Blood, EDTA, Dry",Not Received,,,SM02/PLASMAPK PEAK,,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,05-May-2026,I-4,06-May-2026,06-May-2026,6228179936,16,622817993616,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-4 PRE,77242113UCO3001-1,,,,,07:40,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,05-May-2026,I-4,06-May-2026,,6228179936,15,622817993615,"Red Cells, Clot",Not Received,,,SM04/SERUM ADA PRE,,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,05-May-2026,I-4,06-May-2026,,6228179936,9,622817993609,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-4,77242113UCO3001-4,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,05-May-2026,I-4,06-May-2026,06-May-2026,6228179936,19,622817993619,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-1,,,,,07:40,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,05-May-2026,I-4,06-May-2026,,6228179936,18,622817993618,"Red Cells, Clot",Not Received,,,SM06/SERUM,BIOMARKERS,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,05-May-2026,I-4,06-May-2026,06-May-2026,6228179936,3,622817993603,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,07:40,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,05-May-2026,I-4,06-May-2026,06-May-2026,6228179936,17,622817993617,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-4 PRE,77242113UCO3001-2,,,,,07:40,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,22-Apr-2026,I-2,23-Apr-2026,23-Apr-2026,6228179932,6,622817993206,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-2 PRE,77242113UCO3001-1,,,,,14:15,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,22-Apr-2026,I-2,23-Apr-2026,,6228179932,5,622817993205,"Red Cells, Clot",Not Received,,,SM04/SERUM ADA PRE,,,,,,14:15,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,05-May-2026,I-4,06-May-2026,06-May-2026,6228179936,20,622817993620,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-2,,,,,07:40,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,05-May-2026,I-4,06-May-2026,06-May-2026,6228179936,21,622817993621,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-3,,,,,07:40,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,05-May-2026,I-4,06-May-2026,,6228179936,8,622817993608,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-4,77242113UCO3001-3,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,05-May-2026,I-4,06-May-2026,,6228179936,7,622817993607,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-4,77242113UCO3001-2,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,05-May-2026,I-4,06-May-2026,06-May-2026,6228179936,22,622817993622,Whole Blood PAXgene RNA,Shipped,Frozen,Default Return Frozen,SM07/WB RNA,77242113UCO3001,,,,,07:40,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,09-Apr-2026,DNA,10-Apr-2026,10-Apr-2026,6228179942,1,622817994201,"Whole Blood, EDTA, Dry",Shipped,Frozen,Default Return Frozen,SM08/WB DNA,77242113UCO3001,,,,,10:35,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,DNA,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,20-May-2026,BX12,21-May-2026,23-May-2026,6228179945,3,622817994503,"Biopsy, Frozen Tissue",In Inventory,Frozen,Default Return Frozen,SM14/BIOPSY CRYO,FROZEN,,,,,00:00,07:30,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,20-May-2026,BX12,21-May-2026,23-May-2026,6228179945,4,622817994504,"Biopsy, Frozen Tissue",In Inventory,Frozen,Default Return Frozen,BIOPSY PK,77242113UCO3001,,,,,00:00,07:30,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,20-May-2026,BX12,21-May-2026,21-May-2026,6228179945,1,622817994501,Wet Tissue Biopsy,Removed,Ambient,Default Return Ambient,SM11/BIOPSY,HISTOLOGY,,,,,00:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,20-May-2026,BX12,21-May-2026,23-May-2026,6228179945,2,622817994502,Biopsy RNA Later,In Inventory,Frozen,Default Return Frozen,SM13/BIOPSY RNA,FROZEN,,,,,00:00,07:30,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,20-Apr-2026,SCRNSTOOL,21-Apr-2026,,6228194341,1,622819434101,"Stool, ova & parasites(form)",Canceled,Ambient,,OVA & PARASITES 1,FORMALIN,,,,,07:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,20-Apr-2026,SCRNSTOOL,21-Apr-2026,,6228194341,4,622819434104,"Stool, ova & parasites(PVA)",Canceled,Ambient,,OVA & PARASITES 2,PVA,,,,,07:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,20-Apr-2026,SCRNSTOOL,21-Apr-2026,21-Apr-2026,6228194341,3,622819434103,"Culture, Stool",Received,Ambient,Default Return Ambient,STOOL CULTURE,,,,,,07:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,20-Apr-2026,SCRNSTOOL,21-Apr-2026,21-Apr-2026,6228194341,2,622819434102,"Stool, unpreserved",Received,Frozen,Default Return Frozen,C-DIFF TOXIN,& PCR FROZEN,,,,,07:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,12-Mar-2026,BXSCR,13-Mar-2026,13-Mar-2026,6227635161,5,622763516105,"Tissue , Paraffin Block",Shipped,,Default Return Ambient,,,,,,,00:00,15:58,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,16-Mar-2026,BXSCR,18-Mar-2026,18-Mar-2026,6227635223,5,622763522305,"Tissue , Paraffin Block",Shipped,,Default Return Ambient,,,,,,,00:00,13:49,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,19-Mar-2026,6227323233,31,622732323331,"Serum, SST",Received,Ambient,Default Return Ambient,,,,,,,,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,18-Mar-2026,BXSCR,19-Mar-2026,19-Mar-2026,6227323224,5,622732322405,"Tissue , Paraffin Block",Shipped,,Default Return Ambient,,,,,,,00:00,15:46,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,06-May-2026,BX12,07-May-2026,09-May-2026,6228252072,3,622825207203,"Biopsy, Frozen Tissue",In Inventory,Frozen,Default Return Frozen,SM14/BIOPSY CRYO,FROZEN,,,,,00:00,07:30,Czech Republic,,08:30,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,06-May-2026,BX12,07-May-2026,07-May-2026,6228252072,1,622825207201,Wet Tissue Biopsy,Removed,Ambient,Default Return Ambient,SM11/BIOPSY,HISTOLOGY,,,,,00:00,08:30,Czech Republic,,08:30,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,13-May-2026,BXSCR,14-May-2026,,6228252073,4,622825207304,"Biopsy, Frozen Tissue",Not Received,Frozen,,BIOPSY PK,77242113UCO3001,,,,,00:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,13-May-2026,BXSCR,14-May-2026,15-May-2026,6228252073,2,622825207302,Biopsy RNA Later,In Inventory,Frozen,Default Return Frozen,SM13/BIOPSY RNA,FROZEN,,,,,00:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,06-May-2026,BX12,07-May-2026,09-May-2026,6228252072,4,622825207204,"Biopsy, Frozen Tissue",In Inventory,Frozen,Default Return Frozen,BIOPSY PK,77242113UCO3001,,,,,00:00,07:30,Czech Republic,,08:30,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,06-May-2026,BX12,07-May-2026,09-May-2026,6228252072,2,622825207202,Biopsy RNA Later,In Inventory,Frozen,Default Return Frozen,SM13/BIOPSY RNA,FROZEN,,,,,00:00,07:30,Czech Republic,,08:30,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,13-May-2026,BXSCR,14-May-2026,15-May-2026,6228252073,3,622825207303,"Biopsy, Frozen Tissue",In Inventory,Frozen,Default Return Frozen,SM14/BIOPSY CRYO,FROZEN,,,,,00:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,13-May-2026,BXSCR,14-May-2026,14-May-2026,6228252073,1,622825207301,Wet Tissue Biopsy,Removed,Ambient,Default Return Ambient,SM11/BIOPSY,HISTOLOGY,,,,,00:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,23-Mar-2026,BXSCR,24-Mar-2026,24-Mar-2026,6227697736,5,622769773605,"Tissue , Paraffin Block",Shipped,,Default Return Ambient,,,,,,,00:00,15:15,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,12-May-2026,I-0,13-May-2026,13-May-2026,6228308224,1,622830822401,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,10:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,12-May-2026,I-0,13-May-2026,13-May-2026,6228308224,2,622830822402,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,10:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,12-May-2026,I-0,13-May-2026,,6228308224,5,622830822405,"Whole Blood, EDTA, Dry",Not Received,,,SM02/PLASMAPK PEAK,,,,,,10:25,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,12-May-2026,I-0,13-May-2026,13-May-2026,6228308224,6,622830822406,"Plasma, EDTA",In Inventory,Frozen,Default Return Frozen,PLASMA PK I-0 PEAK,77242113UCO3001,,,,,10:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,12-May-2026,I-0,13-May-2026,,6228308224,7,622830822407,"Red Cells, Clot",Not Received,,,SM04/SERUM ADA PRE,,,,,,10:25,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,12-May-2026,I-0,13-May-2026,13-May-2026,6228308224,9,622830822409,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-0 PRE,77242113UCO3001-2,,,,,10:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,12-May-2026,I-0,13-May-2026,13-May-2026,6228308224,10,622830822410,"Stool, unpreserved",In Inventory,Frozen,Default Return Frozen,SM10/FECAL,BIOMARKERS,,,,,10:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,12-May-2026,I-0,13-May-2026,13-May-2026,6228308224,8,622830822408,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-0 PRE,77242113UCO3001-1,,,,,10:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,12-May-2026,I-0,13-May-2026,13-May-2026,6228308224,11,622830822411,Whole Blood PAXgene RNA,Shipped,Frozen,Default Return Frozen,SM07/WB RNA,77242113UCO3001,,,,,10:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,12-May-2026,I-0,13-May-2026,13-May-2026,6228308224,13,622830822413,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-1,,,,,10:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,12-May-2026,I-0,13-May-2026,,6228308224,3,622830822403,"Whole Blood, EDTA, Dry",Not Received,,,PLASMA PK TROUGH,,,,,,10:25,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,12-May-2026,I-0,13-May-2026,13-May-2026,6228308224,4,622830822404,"Plasma, EDTA",In Inventory,Frozen,Default Return Frozen,PLASMPK I-0 TROUGH,77242113UCO3001,,,,,10:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,12-May-2026,I-0,13-May-2026,13-May-2026,6228308224,14,622830822414,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-2,,,,,10:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,12-May-2026,I-0,13-May-2026,13-May-2026,6228308224,16,622830822416,"Feces, unpreserved",Received,Frozen,Default Return Frozen,FECAL CALPROTECTIN,FROZEN,,,,,10:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,12-May-2026,I-0,13-May-2026,13-May-2026,6228308224,15,622830822415,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-3,,,,,10:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,12-May-2026,I-0,13-May-2026,,6228308224,12,622830822412,"Red Cells, Clot",Not Received,,,SM06/SERUM,BIOMARKERS,,,,,10:25,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,12-May-2026,I-0,13-May-2026,,6228308224,17,622830822417,"Red Cells, Clot",Not Received,,,"CHEM, LIPID PANEL",& CRP,,,,,10:25,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132003,02-Jun-2026,I-0,03-Jun-2026,03-Jun-2026,6228308225,1,622830822501,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,09:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132003,02-Jun-2026,I-0,03-Jun-2026,03-Jun-2026,6228308225,2,622830822502,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132003,02-Jun-2026,I-0,03-Jun-2026,03-Jun-2026,6228308225,6,622830822506,"Plasma, EDTA",In Inventory,Frozen,Default Return Frozen,PLASMA PK I-0 PEAK,77242113UCO3001,,,,,09:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132003,02-Jun-2026,I-0,03-Jun-2026,,6228308225,3,622830822503,"Whole Blood, EDTA, Dry",Not Received,,,PLASMA PK TROUGH,,,,,,09:25,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,12-May-2026,I-0,13-May-2026,13-May-2026,6228308224,18,622830822418,"Serum, SST",Received,Ambient,Default Return Ambient,"CHEM, LIPID PANEL",& CRP,,,,,10:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132003,02-Jun-2026,I-0,03-Jun-2026,03-Jun-2026,6228308225,8,622830822508,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SERUM ADA I-0 PRE,77242113UCO3001-1,,,,,09:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132003,02-Jun-2026,I-0,03-Jun-2026,,6228308225,5,622830822505,"Whole Blood, EDTA, Dry",Not Received,,,SM02/PLASMAPK PEAK,,,,,,09:25,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132003,02-Jun-2026,I-0,03-Jun-2026,03-Jun-2026,6228308225,11,622830822511,Whole Blood PAXgene RNA,In Inventory,Frozen,Default Return Frozen,SM07/WB RNA,77242113UCO3001,,,,,09:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132003,02-Jun-2026,I-0,03-Jun-2026,03-Jun-2026,6228308225,9,622830822509,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SERUM ADA I-0 PRE,77242113UCO3001-2,,,,,09:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132003,02-Jun-2026,I-0,03-Jun-2026,03-Jun-2026,6228308225,10,622830822510,"Stool, unpreserved",In Inventory,Frozen,Default Return Frozen,SM10/FECAL,BIOMARKERS,,,,,09:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132003,02-Jun-2026,I-0,03-Jun-2026,,6228308225,7,622830822507,"Red Cells, Clot",Not Received,,,SM04/SERUM ADA PRE,,,,,,09:25,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132003,02-Jun-2026,I-0,03-Jun-2026,03-Jun-2026,6228308225,15,622830822515,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-3,,,,,09:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132003,02-Jun-2026,I-0,03-Jun-2026,03-Jun-2026,6228308225,16,622830822516,"Feces, unpreserved",Received,Frozen,Default Return Frozen,FECAL CALPROTECTIN,FROZEN,,,,,09:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132003,02-Jun-2026,I-0,03-Jun-2026,03-Jun-2026,6228308225,13,622830822513,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-1,,,,,09:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132003,02-Jun-2026,I-0,03-Jun-2026,,6228308225,12,622830822512,"Red Cells, Clot",Not Received,,,SM06/SERUM,BIOMARKERS,,,,,09:25,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132003,02-Jun-2026,I-0,03-Jun-2026,03-Jun-2026,6228308225,4,622830822504,"Plasma, EDTA",In Inventory,Frozen,Default Return Frozen,PLASMPK I-0 TROUGH,77242113UCO3001,,,,,09:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132003,02-Jun-2026,I-0,03-Jun-2026,,6228308225,17,622830822517,"Red Cells, Clot",Not Received,,,"CHEM, LIPID PANEL",& CRP,,,,,09:25,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132003,02-Jun-2026,I-0,03-Jun-2026,03-Jun-2026,6228308225,14,622830822514,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-2,,,,,09:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132003,02-Jun-2026,I-0,03-Jun-2026,03-Jun-2026,6228308225,18,622830822518,"Serum, SST",Received,Ambient,Default Return Ambient,"CHEM, LIPID PANEL",& CRP,,,,,09:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,01-Apr-2026,BXSCR,02-Apr-2026,02-Apr-2026,6228023951,5,622802395105,"Tissue , Paraffin Block",Shipped,,Default Return Ambient,,,,,,,00:00,15:31,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,26-May-2026,I-2,27-May-2026,,6228398115,3,622839811503,"Whole Blood, EDTA, Dry",Not Received,,,SM02/PLASMAPK PEAK,,,,,,09:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,26-May-2026,I-2,27-May-2026,27-May-2026,6228398115,2,622839811502,"Plasma, EDTA",In Inventory,Frozen,Default Return Frozen,PLASMPK I-2 TROUGH,77242113UCO3001,,,,,09:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,26-May-2026,I-2,27-May-2026,27-May-2026,6228398115,4,622839811504,"Plasma, EDTA",In Inventory,Frozen,Default Return Frozen,PLASMA PK I-2 PEAK,77242113UCO3001,,,,,09:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,26-May-2026,I-2,27-May-2026,27-May-2026,6228398115,6,622839811506,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-2 PRE,77242113UCO3001-1,,,,,09:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,26-May-2026,I-2,27-May-2026,,6228398115,5,622839811505,"Red Cells, Clot",Not Received,,,SM04/SERUM ADA PRE,,,,,,09:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,26-May-2026,I-2,27-May-2026,27-May-2026,6228398115,7,622839811507,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-2 PRE,77242113UCO3001-2,,,,,09:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,26-May-2026,I-2,27-May-2026,27-May-2026,6228398115,8,622839811508,"Stool, unpreserved",Shipped,Frozen,Default Return Frozen,STOOL I-2,77242113UCO3001,,,,,09:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,26-May-2026,I-2,27-May-2026,,6228398115,10,622839811510,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-2,77242113UCO3001-3,,,,,09:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,26-May-2026,I-2,27-May-2026,,6228398115,9,622839811509,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-2,77242113UCO3001-2,,,,,09:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,26-May-2026,I-2,27-May-2026,,6228398115,11,622839811511,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-2,77242113UCO3001-4,,,,,09:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,26-May-2026,I-2,27-May-2026,,6228398115,12,622839811512,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-2,77242113UCO3001-5,,,,,09:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,26-May-2026,I-2,27-May-2026,27-May-2026,6228398115,13,622839811513,"Feces, unpreserved",Received,Frozen,Default Return Frozen,FECAL CALPROTECTIN,FROZEN,,,,,09:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,26-May-2026,I-2,27-May-2026,27-May-2026,6228398115,14,622839811514,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,09:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,26-May-2026,I-2,27-May-2026,,6228398115,1,622839811501,"Whole Blood, EDTA, Dry",Not Received,,,PLASMA PK TROUGH,,,,,,09:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,26-May-2026,I-2,27-May-2026,27-May-2026,6228398115,17,622839811517,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,CRP,,,,,09:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,26-May-2026,I-2,27-May-2026,27-May-2026,6228398115,15,622839811515,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,26-May-2026,I-2,27-May-2026,,6228398115,16,622839811516,"Red Cells, Clot",Not Received,,,CHEM PANEL &,CRP,,,,,09:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,09-Apr-2026,I-0,10-Apr-2026,10-Apr-2026,6228173397,19,622817339719,,Canceled,,,,,,,,,10:35,13:56,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,15-Apr-2026,BXSCR,16-Apr-2026,16-Apr-2026,6227993984,5,622799398405,"Tissue , Paraffin Block",In Inventory,,Default Return Ambient,,,,,,,00:00,17:04,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,21-Apr-2026,BXSCR,22-Apr-2026,22-Apr-2026,6227635159,5,622763515905,"Tissue , Paraffin Block",In Inventory,,Default Return Ambient,,,,,,,00:00,17:18,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,04-Jun-2026,BX12,05-Jun-2026,06-Jun-2026,6228501730,2,622850173002,Biopsy RNA Later,In Inventory,Frozen,Default Return Frozen,SM13/BIOPSY RNA,FROZEN,,,,,00:00,07:15,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,04-Jun-2026,BX12,05-Jun-2026,05-Jun-2026,6228501730,1,622850173001,Wet Tissue Biopsy,Removed,Ambient,Default Return Ambient,SM11/BIOPSY,HISTOLOGY,,,,,00:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,04-Jun-2026,BX12,05-Jun-2026,06-Jun-2026,6228501730,4,622850173004,"Biopsy, Frozen Tissue",In Inventory,Frozen,Default Return Frozen,BIOPSY PK,77242113UCO3001,,,,,00:00,07:15,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132003,25-May-2026,BXSCR,26-May-2026,26-May-2026,6228501732,1,622850173201,Wet Tissue Biopsy,Removed,Ambient,Default Return Ambient,SM11/BIOPSY,HISTOLOGY,,,,,00:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132003,25-May-2026,BXSCR,26-May-2026,28-May-2026,6228501732,2,622850173202,Biopsy RNA Later,In Inventory,Frozen,Default Return Frozen,SM13/BIOPSY RNA,FROZEN,,,,,00:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,04-Jun-2026,BX12,05-Jun-2026,06-Jun-2026,6228501730,3,622850173003,"Biopsy, Frozen Tissue",In Inventory,Frozen,Default Return Frozen,SM14/BIOPSY CRYO,FROZEN,,,,,00:00,07:15,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132003,25-May-2026,BXSCR,26-May-2026,,6228501732,4,622850173204,"Biopsy, Frozen Tissue",Not Received,Frozen,,BIOPSY PK,77242113UCO3001,,,,,00:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132003,25-May-2026,BXSCR,26-May-2026,28-May-2026,6228501732,3,622850173203,"Biopsy, Frozen Tissue",In Inventory,Frozen,Default Return Frozen,SM14/BIOPSY CRYO,FROZEN,,,,,00:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,24-Apr-2026,BXSCR,28-Apr-2026,28-Apr-2026,6227323351,5,622732335105,"Tissue , Paraffin Block",Shipped,,Default Return Ambient,,,,,,,00:00,14:22,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,06-May-2026,SCRNSTOOL,07-May-2026,,6228610564,1,622861056401,"Stool, ova & parasites(form)",Not Received,Ambient,,,,,,,,09:30,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,06-May-2026,SCRNSTOOL,07-May-2026,,6228610564,3,622861056403,"Culture, Stool",Canceled,Ambient,,,,,,,,09:30,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,06-May-2026,SCRNSTOOL,07-May-2026,,6228610564,4,622861056404,"Stool, ova & parasites(PVA)",Not Received,Ambient,,,,,,,,09:30,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,06-May-2026,SCRNSTOOL,07-May-2026,07-May-2026,6228610564,2,622861056402,"Stool, unpreserved",Received,Frozen,Default Return Frozen,C-DIFF TOXIN,& PCR FROZEN,,,,,09:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,06-May-2026,BX12,07-May-2026,07-May-2026,6228252072,5,622825207205,"Tissue , Paraffin Block",Shipped,,Default Return Ambient,,,,,,,00:00,15:52,Czech Republic,,08:30,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,,,,08-May-2026,08-May-2026,6227697745,31,622769774531,,In Inventory,,Default Return Frozen,,,,,,,,16:05,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,13-May-2026,BXSCR,14-May-2026,14-May-2026,6228252073,5,622825207305,"Tissue , Paraffin Block",In Inventory,,Default Return Ambient,,,,,,,00:00,12:51,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,14-May-2026,BXSCR,15-May-2026,15-May-2026,6227323256,5,622732325605,"Tissue , Paraffin Block",In Inventory,,Default Return Ambient,,,,,,,00:00,13:06,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,19-May-2026,BXSCR,20-May-2026,20-May-2026,6227635193,5,622763519305,"Tissue , Paraffin Block",In Inventory,,Default Return Ambient,,,,,,,00:00,17:34,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,20-May-2026,BX12,21-May-2026,21-May-2026,6228179945,5,622817994505,"Tissue , Paraffin Block",In Inventory,,Default Return Ambient,,,,,,,00:00,14:59,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132003,25-May-2026,BXSCR,26-May-2026,26-May-2026,6228501732,5,622850173205,"Tissue , Paraffin Block",In Inventory,,Default Return Ambient,,,,,,,00:00,13:03,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10003,Dr. Leksa Vaclav,CZ100032001,27-May-2026,BXSCR,28-May-2026,28-May-2026,6227323320,5,622732332005,"Tissue , Paraffin Block",In Inventory,,Default Return Ambient,,,,,,,00:00,14:30,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,29-May-2026,BX12,30-May-2026,30-May-2026,6227323255,5,622732325505,"Tissue , Paraffin Block",In Inventory,,Default Return Ambient,,,,,,,00:00,15:53,Czech Republic,,07:30,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,04-Jun-2026,BX12,05-Jun-2026,05-Jun-2026,6228501730,5,622850173005,"Tissue , Paraffin Block",In Inventory,,Default Return Ambient,,,,,,,00:00,16:17,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, diff --git a/Covance_UCO3001/browser_profile/BrowserMetrics/BrowserMetrics-6A26A0E0-6324.pma b/Covance_UCO3001/browser_profile/BrowserMetrics/BrowserMetrics-6A26A0E0-6324.pma new file mode 100644 index 0000000000000000000000000000000000000000..ad0c12ef0b33c6fc35464968a6874a52c396c826 GIT binary patch literal 4194304 zcmeEv2Ygh;_Wx{X5l|wE22lw`DVk7)0G2EXkRX9b0)h=T$xX77?8eevd%Q_xrd6oWLxH6yo zsAgKOJ1x%$1iitK;S0IT%l$>3kUx+%&J!rF%?8(B8t_yE({x-7h=g#R+WV^~IX+4= z0YuN-7Ss;Z9@GJp2-*kK5!4CP8MH5GKTsDC$z^{~SI_~V13}$D2Z0U-C4;(y4gnns zIvkV&>J91(Iug_$G!T>u8Vni+8UY#wIu?`x$^vDBCV}!m(?F+yW`Rhad-m)(7nZ08 zvD}y8q3GG%AhP*+W`kedaqvB0iD}c1Jn_Z5<{S%_G~_P7ju)&Q@-GS-h zPGdVJB9jk6fgLS!FU@^@?6i-|Umt4-vF?O3lRI{vVEC%MJ|o8$GRl*lTi7`{F~!wi zobM8sxx^}$mE>xdYhuTJEBcH+quZv7Kc0#Es~J!A(34MnT^9(N@I;t?WxWqFwb$Cg7Vd^N) z@DZsc#?WEM3@I^+j~P5{Wx|SmA4pi~Dn5MFn>TLEJ8tC1_bhm!UJP8YVRiY|>xbRh zY0*=IwyaCNfA^`cUot*4eDrr`rk*=+!O<^t@4R)NNe>kqkn=~+Jq0}%{*bkiL1PacOJj6?w7<>pZqpCZT-2g6@O8FOyRCu>IeDXb9=tIprY^e^Y%Gt zLq^u_hm$UO^WF6wSM>O~-S?w9ZM&sk)&)7KPj!LbdWe0|~N zYxYd~ao^LwPYARSr$OC}^Obr^ z4RWOVIn5U|%8jCsfeO(Um5Rbr9khkdH#~u&G72o~`eeV)Xp2gBH2hILwfimeS5|s` zrP8;l7p8>D5HgC7>a;CPX22f|W*ODqB7=gFUYP8+F@YH2tuz~jr#e(&WE-C9S_)6P zD3a!IQ$O_3(=?OIpX&`35xPdQ$T0QD5qh|3QzuRL2F-d~QAwqKs>e4+K3}6avP?ac zqQ{Zv2?po-1I4)>A08|~m`Uc7{h?VgoJ3n>Djq}h)Z@wWggk|wpy96cW|n)Aqrt|{ zVU>wqdRVheP}0!?0Y8nN!AkqEM&bPxmHwcShmz$dDZ~ovQ1;YT;MwzQeMM9ZMOzds z((fdb0#D(DfWNA8mg&lWrCy%q^Uw7mL~Q?Mo`6vt(?6nZHLVh8l|ZWmS|!jbfmR8$ zN}yE&trGaJk-%a+3D0MQF~LIf6K)XM7)HstmUQsjAKm><{1t7_TRHDw@A8p!ubQU# z_W6wHJd%ChC=Fwa;=CeEZImI>So0b*Uqo|5G#5m3KQu<8aSF}v90kH~PtNI#ft>*w z2Rady2jaP$*|?`?!a)CAbsi^?CX`_4xoJ$3vNl1^pY=ZwW8`&j{YY+4?SI1Sa~^W} z>7ES9hpswbvT-qoOlcVM6dA!_J_fnvM#%3=EAUnr1sJayo)AG14Iuq_2?ISV&41DO zR(;+9_&*eM9EhIpG|*X~%RzU6-UKB8+;O0bK-)k$n0$H-bQUJyMzs|pt(_33LZGi; z!s;pvsGjO1L@6fR?uKyhgDh^qWZE4mkTnKY1BYN-g>hkri9&3~gjfwEumQr`a)%H< zzbeGzzhlmAgiBn0woCl;P0T1BmmuXwG6odeeAybr4LFhV1t@YZa54B#4okh7{8!I9 zdcQYPPQHxp$&i1#>U_z@r71aMjOZ1Q5wma;)Ylv^OA&lndOh>RqG&l6)(gl z=PmQVfAiVbX{u4=FZ($8fKe--p?flnSLd6qLQMArymF!?m^Q8kQ>(>BalWU-$n_T+ zX=4pfk>5AoTW;iIGRAO+UyFvr zPrvPf<0;tha)bhYV&@qWN79`7~EiwmG6%7YOF02i775BR{$ zlhd0b1rZRgSnDi=z0Ptcxl&^puN?IGp>XMU-)?>V#qE6t;c4@2Hvk)y6b|m zZOI=QvR$|`Uow@8Qcj!EvnL0*9M$(;L3aVWQT z7{iI=v(9Ho3Z6-RPcfF(Dm*^S!YWEL(_e*xsLYV&PQ-*6kK`!a&HldmzGeiX=q#eb!gGm^m+ZU zKlq+^`+P|e9`S4MjgJpM_X+YxhHTP5%$H2%qNJa17{!$L(M}2c%>ezG{H1>4z93#N zMP|u-rBH;f%e(rLM+A!Ko=l!~)%lW*i<0gnZ-qA$Op9=!dh)&VjI=DH#KX&^|91J( zGmwl`{Z*L~Uw^%qaQeZ&J@U(o{2XTaaS5Hz?)gSh6_itL+Jw24?x4q)=0=gNMz63q zE!RV<@x1bG1yI|m#9s07bUovSltI7Gpl*~jj7R6Qdoy_Q&`I@DeUhU)4VT()TI>K< z&LP7VpCNX1<#ZXB&S!Tlxktfng31I-lL+;IP$;u!Hm;_bng1e0Ry29xDN|UBV-n&*`#VP=;=6ah~5_ zo;D4dmj<1lK<&w%IYw0_3n2~t2%{7$WWHiszbm_sy`FNPJQ@61@4YI=1j`;SxMSzb zJuWAmOosBM4X(_WOyz<;ml3E8c!Ne}nNc(+ZA!k`@fr+2PW7E$&$a*$=_fac(x-dE zqxQebHgDYVY2ii>xsxHA^fU7%Q@Q9kbAskVYw;AUb@C&a>%THo9j@G7&FC8+PydA< z4En9Zz$5XJWPa*KoX=NczH6~5`awtD)^kDI>F zOrQPL;U@C@N5p@A&sobCk6zm!Jv`HxI8c%`KD#%5ek(sLO{MCS1_$Xc&K@fEJhOa} z{`}16blGm4ew0HU8}?_@|3{i!H!MmA+04D2;3$cI`G!<@Fq4U`t9o7;* z^;wGyGeZIxm(nCwev#qBoQB^79O>Jr@>#6mp*q_Zr1tCn89v1~bx|5-+)RV24%0{I zeA5;Egcx|ryye9aI3BsPBqkm)z>J0ElLUNJyizbI+~qxIDYp^(&qc7hflgN{T7 zeFyrWoe=*-gD?&N-i9#l#h~INbT}6zVJweEF$Z%qccFGSq+qWeIk)Q|;!OY)Xa6-UxQd%a+}&IUN%ueaph zYbrkM-s23yONMYzKbZNFsa$j%*6uj7OTv>4@LvaFc`ODFGHwvXAFKQg%n!~!=jr}4 z$(;<@BoF3GrgE8*pBbpF45cA`bbyQGeYCXM(@#1oettaMd)}`n7-b*o=`&wRTHeM= zKT`SNL(PW_YnIUsKE@#82DTho~E%DjSH#%QJ;|J<}p1b z_nxM}?h8V37lS~@fG~9~>tZf!8tWBxL)X%R#Poj?Ag#!IVq7dH$@Kn^(PoXUCg|c`Qbu|%S@5Vg) zJy00kF^{nuV=y1U&Ij0I0rn+;J^nbvGY)GoQ-qjfL?(7 z8lX@1Kri%mi76+#L`JPkEWXDjdVT2N_a?h$Ro_?2zMAp_fr9Z$6t zStaen&Li4GM|BVn?dl-zIba|0>9mgGrRO_|g(dsSa=`kd4zl3-vJT}1j~=NnbPo~O z`hB1F-8V4*umS7AmIh*jaS5F-*|_NSHYYd z$It2Oe0Fal{ajB`89I9Q`nt|R`q{7iI^mSeGb7^_PG9G9`tBkcB6tfiZo(iFO?nkZ zm9^HW37*vYnvL=iPyVkx(Q*E}o665M$4O@0aG{1UpVMVqZNL54+KjE`*`6R~6^m%d zkT;Dd6jmbu=ff`GpyzUf$VTyRw0?ADcFx5+#$FMElQb*`ozLzx`7g(aG<qRvP5RsdOBLh5&KUV!YYu9z( zbe@;epWMihP4lbFmrUhC^Xjt3M7F4#j&-m&-8Dn(`NcZ42K>!aKAKG-5}sfF(Atzs zmz&RR`loh|`Q%46(@xA)-bZ4Hqt#Q zuqiyvS8f4Lp0}R?jm#ub@ zKw*vmQ9H(b$y6?Q4y#Ve>EIxuk|vDn-aZ$a0@-h*whPTci{GoD!5f+k+0VpOqTE}Y z0=pN8o|)vPmirmQ!Gv*xNG{aA({t1e6XLh&>(0Wh7!y9>`ge!iR{_;74f*Q~-^{nz z5sS*3_3}%;5un}QnC!u>wh13e?<53*fipAMVA zUJH62lmL(gpmm_h$j^OHp!R?=+o7+F0+oUY+abbtx(M+;I_GmCxTDd=-Uhw3_ITJ+ zF|H`b+WR6QHa&^9c^CBT1eYkh5B<9I1aZ z6vJN~h~!J_N;A-Bh?jol?p5mpbHD#lPoMcp((<;M^ySi$TFx4fK2eEWzcF&A=~c>+^b+$ecEoDFf1NXhJ))Z!DIbeRnq`u3G-c-2bXYQ= zNBUS*F66hy;_KmT?KN$cplQWvmBr}sr(wJymw3lwg0tLEM;}6@AR^Z5tAR^Rm(o^o zXQ#){**h6$J*WOSVVMmrUiN_S4KaP$FVJ zsmch{lIBfAe=XPW1knefSA}xT{+t;}1FU%ZnA+k*5VccKol+Omu&+M|StZ}e^TNIw zv=MX&9_|v*;i&L5UvU5w-yL|6El}zoqap8(NPd9+?Se>7LL@s7$#uCxteOMe0A+r{ z>q1=G(6yp!;Bo@u-B0ehaChorXFfli6fOw?$ zC^3566yf@eOVdA6k&*GVHOs}#%rh3PGiyg5X$$yH^ zEbKvah74~t%@eETIeCm3T~p_P`U%T`x6P3+o=vU?ZJs-G`B!IpR!|{l=u1#v$h!jc5{O=`eFanpeO3thpN&MeA(5rXgJ+OPH4=Fbi5%Qbh!W&Q zr(W2DH9&|L(HGs6fj;a>LM$}Uw}tc$y9s+qUqs*T7tHUZy9CLLoZD+}uIRbq4x)o2!p+Ah(2T`p^3A+vk2=O@Cla`6fj8CO3L*B-e4lkhcP@nmMn| z!{L~6CJX^Qdlx+Wv!E;S{M8*WZvz?Jg@WvYV!asU(T&dkD9BRs33Guh9A=4Gei>I(ZbPM{> z|3uo!F0mdH%A3!G%x-XrgWh$Ct_LTGeLM+b^uq~aziw?ruk+i8?A>j|^2^(bz|rkQ z{U`0jw-2_L@{1+sb&xZ%I8uJ`n6i({>jrgG62v`=?s$6Zd)GdW?34!3WqZbaiyg7# zzC~In;DzEm8u;hS7XVFBV<*$JO51wvE@ZTd1L{@oBhJeZA~bXKuN3)yZ;Ys)nwoe& z-IF2zbk+HijSKZNEeMmmB?j`^7*~zPGuXKIN$Onu*?CK3zipog)w}&cC<;=?Q5{5) zkn@=+7Pj~5N&g)RLUStLukQ&v1=I`F8-$`G=RJ>reI%$K2t`TGgARm!6zFIWik84s zmYf?M40{M@D2Vco^6eN9bzMh-NY_$#W;6&zQO={1PCykCRQ)nQZqQf|im9Aq9S3_n zXaXo3lmnUwIuV3oEOJ4UK~TeTpUFwEr-Jf91)yo5=^zw$IafOq_9>uKL8pOE2b}?$ z1)2@=fC@oHAj%^u!;4|Fo~S2qFoe?u(&zbCzu^)eF7GsO-%h(bb|;T8lply^5A!8c zx#Z@#@p?68pQ1&0lBddtX`leglVRRx85p{mftJByJSh+q;b1%l?kUgJ{rx{LKK{jX zR|QsqEe+uzR61X>aiRKzzCfdMBBI+E<*pEUc0^>8Kf=|67}rV-7nejfDNJHhMJxUAnEq26evK)^027)2`JXsCW zSIZrxf#yl5`%A)WdT!ltU67U{r6HTf>CCs-5liZE`5t>tvAMC=bV`9m@}v2?Wk{Fj z@7}uX{Cy}+wSSZZWuf9COq8Fq6Qb*ZKfU{G-H;pCKM%GvaDqt?I$yGJp;ynbY99<% zmSJsPj!sF%i8>IM_r+SeZQ#}x#O)ex#c@NP3ilf@_;b1^!|CdL)77kpSpoF@b1(>~ z@K@8Ev^oM-pF0r>Qhn}N>37fl*V5~>G}DdVk~Xkia@|@*i`7{(2vbc#V#DRzPQ{f+x?zRLYr zm(%Ys%bDqq*4>#8uQtOttn~c>$io_nNPqRXa=A#PP5?}E=?}^|v;Uw`FW;fdf%#?( z(QA|Gr@5=~3ItU@=~-=m!wzt?8-B{1>z}^x?stQpYN^% zTN={mq}6r4WaDDJw`O(#&`H1%FLTgQ2^lpZ-d|;L^F6-eLVpdZ926O$dMA0OIzwH(c+&NU3

ZkI^E!0AZ{3h{F1ejN;o9*Xx6QqX?#Yi?hVN9~6=s4q%=-~&N4F2WRo90&D+eFSJA zXb_0TE|^x4V-YI0G@hWwa}KBmbP0%Lbr)zIXbXrc`Th{VFc7AK#D$=TLEnG|A~XG< zr$87wiy9EgllpcDW|R9a2Xfza#`+h34nFr0g(ZU|Sykqm4Q8r6#kQg{ z)YdK~qZd!}5vy^3U+$bYFds=vNVa@i zjr1vAPM_|P#kTtU&F)i6*8TCqLQ0nm*;Id-FPX}var*A!V!1otQw|K~oIRFIg6d)x z!c*Dge9Okbn6PAk%;&Y^+H^&NIIw0@$1MxL$LzUjNGH;`mH8GsVog4297bNyZ@$o! zLhPfhMlZ@za3^8w2{xf%1pzx7N@WGMHdi3D+8(4#wdWVr&n}=%z&m$FCl4jIyX##S zKDOzOzbDck7{X8cHkmJ($|VmgY_zcztI0TFF4t3&>n#fSX^f2pw<6kBVR}YZ{b_x& zFXAA~REHN^@yT^mQWh|75aAV(||&xBZ$|VIG?dsf|!q^0Q%f;XUHKi(b9LSNl50#=O2QkJ zmn0;7;c7$Wf%QIMN9t)qoN`l-$*dn=c)R<%&z;ur*>oy>2n(Wm%6!RGE>v!0SA$ma zaA#CDDk{>qildAMVlZwHvaXSyUo#VV{!2~!;Df!l+}@phMsYCT zadTtS4?8s+dOezfiM)QZ1FNz^eQ(m`!Tcx!^UjWATn%2!qRn89gre%tdYUAJVR`5{ z$nE2teHx}*Go;V$DA#02ZhdiOzGNyF!qKQcQ%&X=CA~gmTCaSLj&wEk zUnyxg%QYFYQN85;5aQEVk^a*?*%XHSph`+ZHW9g#O@8PZm~i`-8%j$zgoXKR>we<> z-`jBU;%#;Rzb}C>GGDJRjGFoyWVn1J;=Zfom~9``0V;pYBY#9x*HojHQI*f}GLOTn z|LLB>|Nm-Q^;yevUN2WIkD)chf2su3aYnK=oA1WMP??A|9>22Jad#wqb|vCstbFX`Dg*SLW+@ znp~I4ufnhs+mUF}3P#1zFx!*|%cURO`xAlxe#+~o*Lbkjo%P_bftU4MaJMCx9&jfd z%*S7w;WfRqf`F%J4!uWUlo$cLm1IoAVy%32K>A;UE44R&W}b@2mDD~Zfk;Nw1|0yR zFc(MW@tTT<{1Oh1x2dok_x}~U zRi6LeoKW@gO4J)F6K)Wf4;o{s^Y>R?v1n}lg3SB5ypS#RvBk$d(@+PhG#fwf>8D#u$%&PVQvLCOpiS zOywfi!|8$wT~(RmE5gzNPC_&y!0@svj>wPfcUJZCIt@>(`Po%hoqF3ffwHzb9_A}h zRpYqyidb-TFC5k`x_W~zjLqVoTez_pcddtk3 zHy&yQtb$2Zv~g-hf0vnXZI%YSO8Wk=_i$$q1>?Oc~QL@ ztuudf))|3I7Y}6kk@R)G858z{c@69tvQCjnn_N|q=`Z)wYZ!7PKrpiKU=(B30n^u0 ze3Mb%sts8K&G!-rh6saLPOCMXvHD?Ms>gSDWaO96QCKo&{<(zCH(hm{)Zxm<R<^ga zj1~m2OC}_RW%>-mVmWQmaKzF_pZ@sb(!SfitmJf9PCB36Cwr>BrBWk8Jr?5?8obJB zezF9gw!oXW;1>Dm03C9`F?^-?=7u6BTRzU1W5&vIs{3w)EN?YuV!!Of^@GXvj%QAL zcEL^lF7?zIgCTr0Z_j+mR4y&T7X=&H@z;R3NPhA9lQbtm`jqDG2^#eW`+x?4GC;Hk zvKkZyy$3oH!08a19#DSogSMei9E%J|MnpGYvalUGp|_#q`8hh7o)nxbdKA_#$6()a z9{QUVSfg2jwYv@2AJxSruJgM@CwzBk{VfS%P&w?|h#^R#DDz0>2d|W--y*m8Kr_Sr6=NI!MfUFy5xbpm!Rh23% zS>Gc1&jGHaxtDx#TY64`j*IzwhYN${fb}vR-k-s1hE_h?>4cg?U=4T>WgLvg^zvBm==34mK`Fc5H{@&r5h<#T1MFDSRhy|wN3Om4c z@!cO>T=VG4U8Kjz5I#C*jro$PT%46NdQ)GXVPNhwM))v@%UQ-*@#QsX$I*|yQFuZZ z9T)QzNb=ShE_q6~b>f08J8k$H9N;_sq3Q=meHuDe$H)A=!E%Wyd7v2Q$ zMe~y4Q00|^4sE>r{B`QRn=%TIo}iaE=IA0A`cetYc zkSXYlS9s@Xt-rlqY_Mj}-AIgZ&^}YV5-QTc|L82Sl`#C{iNP<;u4zMCT%|Gbx*GA> zJ&vA>4inOfSz;rKG~cTgL2pw9>O!m~HE&vy1a1cGsc5G1CY!WWI~@pw_qXXK9z`J=1O zmuy^GEGJClVlvRC*LFF;_0vUX${_4IxXRJ^2Nd^(@qTaHiW zXLP#3ifA=#*1t2(F`0~$CKPF1Zzu47H1;#O>upTZ^YZ+UDwpg9aDY+eLh~1i;3wVu_HE>L zU&5Ag!`}J6H{Fxr{L}fS>)zBy^L*r!@jh-5I+D6@G7xcda%l&5(qTy;+BZ7_q&~0O z&NXPy8%s}@^m}Y$aNDh!h(;QIUY*bG&dUK#BfyxO!>PDx3)g*f4_)wj`MZyrK9%yJ@!8!uu1Yz# z!{Jn1E9*>dbGY{X?52NA?|9>@9G>N+^Vz+nxU6QxCa;Y1;^W%-#y9DA<(zmtr^~o> zKD)OVm)VTiaBXpbYjEkEgQskG$eNLl=A+JUIj&LzD?aA*2?DF_N8R~mY;IU2hgjun zVc#p46plY)py@M;OXst@b9pJaQt@T-vQ&Rl^RCHOt!obFIUU;VcgEu#Z)Y6zJcL%~ zv%7PgKKc?H&+*vgx6T2ss)_rKDLA$lRUc^>m(FK*=eRuRyQi8Tv`;NE@CgeE(y$^@ z>+6gQO=ffQ+t9AM$Oyk~`HbeX&Tl!+3U7^3oXQ$5j0m`2u*(6iE$y?vxhdt&UpZZt zpU!7@=klwdxv^C2y)ir$sTJNLGlnoM#<%Pulh>Tw<~+Y7YxLHmx|=?ua?|f04gD6}!PO496TInJ|d) zZE=9_q&2ArzWPW0Hx!l(=daE;U0c$>q56RXh`dFqI5xvqjt>`6%1g{xo0H#t z-O`SDZQ$-ToIc~z`RwjoeihzgZ)&hMXw*>HFo@-rM1wq-=5QUbd;CFrIt}>1^cj_# z&S!V$xPrlQsZUait(`5h&!n~+YaHNvc2>V@z3w4ra{4ScozL#h@lmo6P3$ouBl;S>4`$?sF@6 z1fR}lcjxk}3KpgomHGX62{aYQc6!Vh!mt?MCI|Rt-*wZ{W2y&S$LX{DbUwQ~$5+S; z1F5C7GGIjzhRygYuP~X-$#3K(IcH7Zc@I^4X&9f*XZIH1i>wVm`}wS9*QS>f7n-p) zhwt4~x4Xxe>uESG4dc`K?Cu;NwHvfHV1^9CV!5q!fa`*Da-Ti&jg?Pwx{OQbv%7O# zUOEmVyPGLX~x=|+&T__>YzoJ7x(1!8K2H)cjx#jaV~~ePF1Cn z2n($ZCsrK^BSMzrP6s%@yI@uEaarS!WgLuC=d-(WoWbbcfK=>#vCbe?+qY$l%vhU~ zHDqY8JjS>+N?tcoW zHTI>rRGix#;GA_}+Iiy+Kd?RHV0r3%cK3_8uYjgN+{n{`NcYpaj@+iPmw&`Eft?b384qA;@a*2SM8Ez$=7~(_eM^a<)ri3-8rtH z;S0t-@1*`3Gq&dBb)U!z-2C#7+c{mvrSsX{Ij%}iE%it3!%3UmQm&1UFDJY_)OPq? ziJU&;)A{V~93S=jqCF~Azin`UD`ooux6T}PW*w)?xO6_dJI96cMPjS;;x(;+YtC}>%VX~u)cYvYXH;%FpWR!A zOUqP55(Y88WNUQT9KO>I$X_JvkOqD62ja8!i^UD`alLi-bLn%hYtxI$r#ZX|%4P^IML`Bk`#Dn0QlsJY$!wIBnu_hxg$0SUx(R z-JQ!v)g$zZsZEX8^zljuIG5efX3pHpSO3B|7^lu>cjq{*`Ot_aHe(3G;`Sn&{=hVs zukUZ(@AfWYeYWW{+Fs~B@0eT0{=DXdT{QJ3jmx^~e9O57`{V5So8}JAp*YlfGWZrVRu$h+ zu+;NOYuEi8IQ*IWdzn6?^3(b3zSr`@QG?d!apVGrigSwtoWD%jSTLmH-Bu4Qic{zR zJ8%~GE6qcl5m^|-`CW6X8M`Xa!@*Mbjkc-S{bb!|&%bZ_jN;V!?CxBi=8|q|rN@^V z!Zc*+JioufjxYJP`1m$n_RjB*-T#!evnq;D=eHc+T=~6$R7`~zDGNnvzkam?eBEa( zSutwjG|OicpU!VNKHAh$o?3!eaH(Il8pQcJ`*t(7=JIv+!Y%*ml9siW({;%km(cm_ z?mS<$dGLTyZSB5MryXs0lUBsXd&wd1Ka|?OUlQYCygHxVo#R#8zjD0HY|bPUV-f+c z5@QXnRz|7Hcbx;gPds__8$REJos5U^>U?(JJG|zoB*t=_ZQf|c9cC)cm51w}|9D={ z7Y?DKBn{)$`Rv{Tyhd?RMQV_~(1XBX5SPKD#@|72S83 zdZw3`fo=Gfky3|gPHx4!cbxg`jy89hKBM(p=d=6X;)~UvNVj_R&EY$(?43)(y|;Jf z^jUs7pWXKwUyOZ!n;hV4|HF&tuex&UAWon0>3nu~j;|~fs!a9p$s1urz~!!Tl^I)e za@*-n9&_vQ6C3ptb$-in(P_odIpx^C5%NS9(A9P&(JD>N;p3nu~j!WH#m`anrIGBsxi8WQ0 zigU)@X6(($@0CYAz1pm~v{C;{=eHauj-{x=hsWhOr81OSjA`_>n4{1G# z`5Z6X&heJWcEnp;iS>W_hPoMpn(uk{n!M)n{ra58_IZ85&}2@Z<*D=8-8sH0Ull%M zU~W!`ijx~u73VGoILD=x&wgOP^Y<_g#;Nn!-8oL|?no`CZ@lmhBio2Nj0icum)&Q^ z-kdz2F`mC{(govl7zg9j`Rwi-r=^EzmoKIzszPNl$5lCIP-TK?4&RvfzWMBmgKz6< z`i!>EI-lL0iS$o??0{dFw)MyQ zKM)^pyEC3U|K_j%IGOP0fPt=Fq@^XI?#jVz(`UlO_nkxs7ENu6~(cgI2 z>H9I6&v@B(j@w#bDWbEaa3qesTV%sI_@VeX7j*xz?fNsOU2V!W+Ws(~@v-e3=djA6 z;?yz&r-b3lu0_FA9L#49y=7FYJhwQ(S<`m=xQpAL#yGefEYSGu?i?p=KBF-#eft9a zB)+vGQp@Y&hfQX4`9ABm^M0zW_gZf-M)jx8Z#hnN+-;Rzd_2kU6{8W2wx1lYs<$#8 ziI4l1&b_x@oqf(m4$tz{`RwjozAH@)u<1;ci{Y4r@Ea@P4R z$6JK+|4)#C8WaKrgK+ZshQC%+57-F^H^f3)&( zGq&dBb^MBx2JRYna}uY^xO6_dJC_%A*>DhLs%_jGRg6{+hY>O7Z?;t{o5S0q-J!jE z%zA~lN6K|$Dup_~<#=%tqIzJF8IgF7AID;qGs;Pp*;cbL|MsuHWgLuC z=d=5t#2G1=YX7Xk0nYc=F2C!FPY2V{5z;VDozL#haoX3B(PQ`Ei@&LU90iNcFh02J zDW^EqcCluinM!kV-So&YeRtE>aViTOt{1z)uYK0Lo>!Gq|%~ag52uG~_QWvidO?%{*1CBO*M)O(cv%7P= z_WgvxB7Y@K$gBe~zW&ddu{MXVZI`UOKJj&FG~cH4&6rx!zs33-h6q879KHUkpsm{x zG}lqeG4jPYqOdjU?&0E>9ai5k>?o zx4iXcY|Y87{mo~u?Ij8#<0QtV^Y;dqzp@b8oHdadgW8Voa)7VrB?Ird@ZY@2*9+aiZlFTd^w(T^_t^*3|Vs{<6t@Je0F!9zg~QJ2#qzm zYqELt1z>lp{*)cNf09A^_cGu124TTpTCbb#}ht45b6 zjGwukaWGDu&+g7~Mu(1Q8|A_&-p!)UQZ2=$>dEj+X6$ZQlzyysa@{L=#SafWzLV)Q zT0V6?yF16(lstoF{<&5+4qdo9M9lR)<>mP2$d4YM`P%ne62~wemaEQZ_pvzDu)-6V zgKtMzcVj*H(f}~XWvIwGhw}R&ub81&Ui3W(ny6R}Tu6*Rh&ygoq5_5{lc=x~61)QTxSd7FvFF??8lZ@&M#4-)GLqD<@z z+84ARs0%0wM4j`lpaVeNK-4I92lW6Q2I>jw4LSnUA9NImI>UX29 zvL!>+;mUZ*UNs|f!=iM;7rSI$?mQOwH#f*p@>##vfAZt#yWTNi*t~r+?JH=Z+p%ar}gnQ0RPikEUOMZ>j|C z>8BAd-;0mB;Unt?!LjvkGB%md$MT>uTLN1A8qOh|d5;|BHZ*({-uioC1*gY&bUwRB z@l3<6SL4l>~sUXr1gFu5pLqL?jB=_N9M!G>7M<<33Jb@YQa5bZHom&S!V$c;q%2TRmI+roEo^M5HO8 zUBEfI-9J8}G#-9qchc>?CoZIWGK@#(o31wbV5~acUyey2t(x(+c&V5;9M22=U#VxY z%F~9oO|))H4o5>6RQ^)l!uKHWckfTGzdkwsi-qr9bUxjaVR`9%)76o@Y;yXm`x}3? zJ|bO2dT0oU^bhGC(mSMcNZ*jIAw5GfCjCOXh4c#P6w)Q6Lr8a!&LCYu6@_$z2Sj;M z3Yr7*gMy&Bp!uM4K^K7PK?^}wgO-AB0No6_19T7QLC|BMwV?H&S3#8RTS1?Iz6SjW z`W@5`nM((dCxd!}s624F3B#T1ec3zs1LFq4i^NHKXcuVK!g-`3M8_U?)=&Ix2Emqw z{E=^+FWI;#^}eZk#$M2Y<|>zimsUwC_U|0+bbxQ;&mEs0v1&sex@*$3!8HLVd@$c) zN32QK_RDEOG^c59yv17?VxHM0Aqm)V)VyoThvn1`?v$ST9mT^kpP0J#^1I$lpujLB zCpw>u`I4zz@WqPACw1Le>82gPKtp|^eD$C&);~0^NZM>hz&K*{54(P`{)|t1j(N!v zoy0-?L*^?GrDU>H+07y=5zXNJ1IXX>$dUnrZ_m(Y=d5XpwI5)oljrkwG!F~HsN4Cr_VOw$PZ!U zOJ}Cw&ZwlmJU#{3xai6tYW~c4-;9OjqJO_}dxH>nub#2`lB)I_NzapEJj^$_(W{0> zhmkftmoNrxa@nro(DSGMVI*H;eI<-+_Z0`ty}V_c0NnT!YskLrtHi zo}{bJXZNP@oC zL+JXG=5er8C%;wI1vZxRBI}G^5J06z980Top7HB!W5{SyJ}9Kk*rmD^M92GFVavxswS2n z)%~x&=k(eBtJ7bz8*H9P3WBT#wC7~4gzTht5_;xs7IjWEYRzR+b)I#@_hx9uk+L>H;@A#+ zit{&$>ADsL;Xc3 z>)oVJsBc7iCJ97qwB11|paG!aps^ql9<6}f5NrcG&WvKaI{=y)iR_dqwIaaaxo zwgnA91r(GY9k4&3xQ<1Gaw-~>Wy#1RYzBC^pAey;*msrz`y{NPmI`s+1<-kSU>){t z?CaXsC7zq^5*Iy)^UDS#2$CndkhIh)>OkBd&i;WoP4|Zze#HKh_ZCd~`OdQaSHC<+ z`b|b7Mg39cOQv$M_lG0nfyfrCI{4-EH)!eW%Hv-3yw&L-yaR!n`DP5!tFv)I6p`MJPDKJoK-LQp zWi}`S)B|)Fh$hebfKVjmK1ph0sm-N&Kz$z+U1`(!f&P;lwYyYDsJ>9WVPZe@pW1FB z>Lam{`NDtxVw=;#V@ty}{UJAYXIpx*F0pv3d+YswmjuGdaH_xRx(YubwF6|ROb}6h zpmI%hVF(CnTGl7}KM_Pz9aMMNANlQN{ipEMcU9{I)g$std`^SPsySnW8yMoVp?gvr zRM*sa*!{oJ*7X_5v;;H-M0r5^i{wW-jHoM!@`Lmf$%^uW+)1~QT*)T+vHm&)_te&t zAIb}IBclHl5Ak>$r^;N-7kK$g4X4F=jBQGk+}NFM6-+Fi>fU<)-z9+>JP!9qX8dl> zPq@LOazN#V%CNd$XY0R$2fuuA^+jAx$fk4cn2*0U!#%NF9P%jN(->ESH#&ksO?MO0 zrFu%~Hf3sVoHwA$iT}K1yybz@ueJDkI8K*0n@u+YL3(jF1s>^n!z(^tv=iy7@lu>> z|E%s0GgiVyZhAkJT#vl&>1&hsTt#X@8ndn?G~%;+p7nLFT#pYM@vs#)m>H<847uqO zh-njyP!7FijE(rT9fZQvfjED}ZW9ON!H__tfOvoK;?onvVN0I4@Q{1Hd~u9b=`mc8 z{buIlug%~sgpeO&A!}DdA&rt~KT%cC^cIH2>95&iPajUM3|zv%b$9!rqyoiry>HlX z-(d@v(7kG!;>!cMk-obUpF69;wz80sYgEXR0vj)7Vc&LIru>AKvJo%H*(%3Vgijy0 z?bEBR*ne!IIHahv=zU?57&^er^JOx&m!&hNc&~+_uy;d_G{im+V3Lm_r=ry`cSM- z{sd`%fwaFC|Cql+d~w5%Nc&$%TMi~%7$V8>-ZBWE^DR%7-loSplusK{f8N=7NcRCW zb|pjQy(_NFmrUgnbDRNYjQ4ADd}dB&jYW91-fuwsln$3?YGbJo)u5r?JmsU=xD`7e zdg1hgyFWaG?#Xcd()p$<#)-=QQYy<+jbK%I$X>5!xG2?Vy88aE#5OMR#I@n@zzNSU z3s~c>W8k00pUjsLC>Q(qPaprEnqNfl3)TL|2 z!0tQfo{XvQT#fjqE8e}8XSw5$1$?|X-#nfeCmIyvr4F3^5ybl(^2B1fhBgK73`9QE z!TmRV{6qZ>>VI&*gzGiUxAS}!^|g7iT(|#aYTTcej z{1@qJS{I--0a_a%8PM26?boh>oCt>-M9l;BL@GI&z+V++!!_&9woo5_9f{^fhGrc#`B8xI>h(CGag-IL+;b-w9}=Qlio zqO!EiGCxX2mQh$$nl{Zh$A@D|WSt4r=E$XJE*>^KWnJueV&zA|j?a=^vv4Mjl_24v z_Z*qeIM}8YaJ(K;p6RLd6ykt`kQaw8;6Q_*JUh(7l?TJoCwqYGUFs-*2?wR(_`HSw znzRC=0$-vF8PfuI?@`uyb8-+bq2hz~A)B5Zd_a60gBJbLx9_O_4V(_+(E02h3&+&* zd7Qj${$c~tCpo)8WXCEWw=aLR;Eiqs@wc zTk(7PbNgL+)a8p=FVb_-JRidJf3>sS@_1D&mVn#+tWH8=G(yF zPYdxxB&Clp^?3iP|CA3zt)^81|49;1+s~a^J&x7iy5{VY-kx4_>e-}o$e8-aC75q= zqt|>R6hcoEBS}-0lUH;C?H?Gt@1^xj7+mo6RHhdjcN zzfQO^Uow>ouggX!{pk!8+2xbIQgEg8X?=FxVJ^|Wlr$B!YOhbPYO`0;n&{p&zdMlfXcz?J!usa%}k;XNU=d`foAtu>O0#{;VLS zrM45vDfa#zx$EQ4Q}e}06lyTA8-&{p_NU?q z0|yy5NZx63+up||#{Js%x||>SK0nd)D(4ZYAIy9ifpW30Uq{x{)vS}gRUG|$*>ULe zTG_o_BJ{7L2L1NVRr9B5IGC?MkhgXmO7f8vbTfpCW3`4u-(Qg2&n4XLCLCMV?t$UD zJec1+4*NQ~g331j%pPc$hmM2N`1-!tFZS;5{rzv&fPg~uK`t^s7LNGq=PDvIhA<+g zavf_uu&tE{rOo%8F7;6G6Ut@Y(UG1po#|8Ge^?H_GIzl7QmH;CE?y4U-y2L@j{`hdp^&fxZg zZ0hYYAAfBo+HWl`#!^5qEhlI#z1n-ODvlXP#mDi)#glh^aOcmMi7*Z0V7?6m{zP!l z>b)0-=mm;nLQ&^!cRIk4_~m`0&nfAaqT^tGlQ{A`wX_tA{r6@5Vw^r-U1Yr!8(Tms zu6i7x8!w;EC|dMz$04V`s^en5V_Xo_Si@(OctgQh$kcpGN;Ok+BXW7CjW<@Nxy0qG zej2eel;qmi>erqCzck)pzK+Y@&yS2Z)S;OSQim(gk1f`4=;MtoLtNteyDpx4=>2^c zjj|@{7zgv4#}P?BGTKn(kc{Uf)07-)hPlKa)7q78PuP5@E(hi}pT2#Z5kZ4M>bQB! zsOE939N`iNO*rDtu~nyB?oBjPq;f_1!TeY_;*T?;h+?(JG;W~mr~L(#EdA#-8nWp> zA!plsil|N^j6}p|H{7NsNdX!|-6?+H)O!v64=-XB5! zZ(20u#hu+kk=Jj`{;;bNpZt=^_hO%(A5vqtV~3P7koos z6XdWfal_-h@EE&%;N;4{MSbu2z*ir<;G_>;col4$X^QXcy=Q+#1$_f84||)9a``b3 z?BQUzG96WZ>Bq*$x&Ox72dy9Fx!nd5f12Vu!-?H-HdOX}-Q)n*&%^I{_qFqO({hi^ zG{tv>E6a<|OXJHj(bvUo-*v4yF220>xvkW7<=muaY@qO`DZV3InO45$R}}_}0$zL! z+3(Zj7e*Rf{*sT6kMmkz*TZrSzGkD2vnjqKoGiZ_Ux{ClA*G?}k1+6&p?WLtwE39y z441f}tmpFF`k6EduudlZzj>GwRKVNhE&X4=KSq_{&^OdCK ztv!AFd`tule5&&?>DhKU=r}0i?$vz*N6)|GofMiFfuRunaAm$^Di^}RMYQSnrlW}T z{unhJy+JgFB%(Hk#)w2Tc2vibgoXaIO(lki|KrxNp)h3FHvj$4T`ArFt+fB=p0YKi zKP!PS3Q1G*F$Y?atL2F1W#~V>e@FLZxIWRnRjui^)%+VIpzAYgJ}6)4yfD&b)N!FX zWg^yRoL^+KK2z^04zo4HjYFfx=`hH@)f=VH82+shw?_6~B>}a6n3QAhzfzr{KEOKk zQ$9{OY5+a>z;`-ry0Uyx)aTlyJs0U*>gOy2|K&~>yn|bjcK@@ty*&5vhv}XSKbOuoT^m0aeaw)~PAkT- z#dM1CIC=>X&z6n=EqyL}h8ioJd@tJCeCP&`>U6B{j4!Fb;L?NE%%)evr7`QiOXz%d z=l%Vh7300-M($Yqxlik~bYs0&aNoiieYY&R|A*yDy88nq^Eo}XIo)YfC&|OZ_>BT} zd_3dC`0Lq~MTh2gSbxL>)^TK0>195r$F}v}b%B45;gbo|A#U#Sa>)py*G$`I<;NMP zd&<4o5m0M}RP$jIaFKC?=q{E#k`L{_`jhLI%sI*|K+<0~T$xYdRm1X_?hSfFibU$* ziN{NMlj5gamF9cATl>);-E2ipAt)c1Z?PkmEnTB{lGis!N!>nf+=BEeJ~xPLY7eRX zRKHictD)bZ@i#vHxb@i5AH8?Ye0aB+M)OWNzG9<>N}5X49NU3|j2lFEvC6@S{L&qV z%>U`2A5E{)AC&{;L5UvF3KN+%)!I@%)_R}GHQMp*3U|_~1 zw11fNx8hQ9?gCCqmvQ#QeF})rGi?aA7k?Y?`CGy(3v%d;88ReGl)*jBmrUgn6KB3r zZXU-n9xovo#pp)`aWqS289oDnmmufjh|vJfSil>R^oV9;%V4oQ7w0#Rb7!c%NcCQH z;k58J5LG!paRJRxJe*Nami(WdbosNt7e+E~X zzp@hR5fWJ#5wW~B#K9G=X)pY%0_&dJlDJ35#r!{kD>L8^2D1$Mp0On~M5f{^!^=O- zmAjgG?M2r4%O3crcYnW*kNJNBA1!}X7}{=`!*IP|zR8VVTTtFi(dEze(%~=`Jez)59S0w!nl*04@t^Fo|MPT~6d8IR z>Nhf9GL=gU@S%$@d$m%Ia_wZQ$A_=Z$k@WTvK;eHZeEUgXQL7Pc36+4DIayw^O^Yy zM0wi+oZ1l8%xe|j&N%oe!M92_8$;gMT%*g8`4W_JX#qYSqPZ)*<{2u~X9Gu_U zdy+0c=93@Qv;?2OqS7BU(Ee5UX$4P4qw41kz(>XnqPtk*>+Vl<`)10jiSx)G88Zad zVKlz!O6Od~XoqQ%z&ar=n1z1xbda}oY>BOZpLa_9{z-NEf_;wfv_ExuZKf%{ zwVpW6SB=xq%8igAM}1>GMRTeuY4pXBgmJ_9w-Y$%d09TVb!Fh9uB#hwj{oer*H4bj zKfqaXhaUWW?SVh_ zb$=i|;)0=yyy|?(#$`fgu5}!|EZit-9@({2^DX1__~pCnwzI}BU%v7o6QNn}NUF@| z^w_puqp%J!!Ydt_9$&6!4z^~<*DEmNa`nhyZo{7oUVz_C3HT!=Nm;;0n93;WrsqQ!SUWeFqBK%ZLD)Wtao4{s$eLGtHTZF z(+s?2LwcL@iSG6B%8<8~95bgO@Fkq2VO%<&-EquQwWp{yEz3XIACfy)EJPLpb==l~ z^i{b~+9Vrw{v|E-lN+AN`G|(b(vVG|m~XKo7N2W^;fYaB=bV^tu}|??I+4cnWYl%@ z%31N{@Ij9+4biU%I|)p~IGAs-BUS_l4d8HC8a73R46{d%0|6s&BKe}qWtRgyyVK7e z`TB-Uyd6r)ktCz@8Bi3Dbyj75rBPmvj$Y9m8=5czaQRp^JHA}J?<^eu#NX!)q`V_T zwhLG0OQv$M%16G(S4_vcp^%`vPPNM$kfSivFnM?xHLUqYfI9Ou{msKjTR$b;6CdAc z_pk4=?1XdqHTMWU<}1+TZATCn6X4Iyf5)pC?k7+*evHsbt`J96zV8^VvO; zKJQA4apo!cwdp_Lpm^ONvT5C#&Y)Gl_t4O0zab|-T#XazOhYz>V!p+WSP>jrh86fL zy+uJjes#P*0DL(0Bhn91?CuPgT|T>jgW`3A z$c`nS3*PAX_;0`eJjG1k^hcqX&*`(>6przj2Prk2$)^qL2p?w!YAm0M3B)72x#AavD|I_2CBKizly7ixzz`an8FJny7@JeR6cw`RtyB zlYXh4k8Dzt+8C#VW|n!p7@Dd1HKR1Xe4fu}cxRY@L!NDbilqTmwt1Dm7g+S=_!~mBTz1plR$%MwBm*SDK?!}`hA$-l%JNe>A$l0 z=`YBdbw_Te9oCzkQN6=_C24sZC;k7&-kZQTRdoI1w~J6z1VIFGp@>Kkj3|pBE=?)W zvQ}C)6=-Nf8wp8F+S0la5LrYK0ktAXaigdxi)dAZiV7$yC@$cF)kgvM0xos`eb3x` zlDX3~H~2o!|Np+vhxzo}xjnO-Z_X@t_ObEES1Ejl^q}C#hZ{AFsM4Kq$MuwiTDO}A z?sW|)yN~h@8A49u_skbe=}{kt-qe!iX3<0oj2%R8k>qYavGfO2 z*H3xPM zrfZ;t(aS@;rt;Zc!e;^!>3sS^x3zx8BzL=S-gRAutNDWYESGIbe&{uvI_CPhPLUs} z9klG5wI`Ouom8jR1I%Z+Y=?x3^XXlaoPi?aO2D)-#(_O5MipuPUe$T@(r!m&^fsp@ z?&XGEIwel4xMV6_kD$GB&yo&PKmYz#d97wk_+~!&k&T2W-BA|EcH!Otard8_W{)8s zf+)ZKPuDHcIx8AHYYw6@&=w%T7k4_ehJ6}{?s1?BhUVYS26Y6bfVzNeAgZ`%6VN3f zn)^-%4FY9>Xu;MvkP|coR00ZuZUfy7S^;_zv=Oue^bzPg5Gj)8ySswYK^Owit_R%* zdLFb7bQ}`*0?;*}J3w1Ne}FDQ2kIu!R#2-%%!7lrf;uBJ-VJJkVg1>lW|-T45M)n+ zOwdZy-acfeL8$0@qN3}8dF_Ev&~;GIdMKzFltXEYX}f7bK;-(O)C({$b`ZTqO8*;H z&F{5OyMB+F{>-QFvWb-bLmYvkk-mJ)mzv8%lFuwZ9}!WS$lt{^UnGoLKR$CO%g{r_ zX)2%HCHdGIC6|YbM0XZ*yG2evMj?#=^zmhVl*fQ)>$a?&CtuxUI?H1`DxcjO#?##r zPs(-H`dRtgn-^E5-%3A27{;UW*}Y*rhJMIH1Ny0o0Z+%{R=yIKlrWR!F&>rA?hWHH z^b-Y7hTmF0pZ<1F{)hcDF+!;uvgs?pe8$0c!*~q+NOdWNk@L@<81Qs`u4n1%#SebN z@>oAApWPeAW9Uc0V`~2fto74uK%cXK@)(cGXZMEj82ZWbx?NZmA>%k01CHJ$ zV=ld`fBVBMhjFNUc5fJmp%(*(oIa&R*7~^ql5=maoYL4>Euq(o^i=uQI1GJ^^!PAY z#MfJx@=H>&HJ*_l)P3p5t3?g28`g`;XLn1zD0s>dkn6t+;Gy{KAhPl4LE99094 z-Opc$S8YmF`p<1%PM~IjFpNj#vwOpMvb;XJ-GRnIeYi(PshDM4y-Tcdji0vkQ15|x zpR!!WrSjQ5c3k8$Tp`N1cEy0}<(k%&6ZUP4*YW6jrC-B*#=~~(xXcA###K1gT3@Bl zc&o12cUOOw%lcCJ>>fKVa|WwG1f0K;O099dc=x_TgC43mkL5BhmCx?6hvu6Bg6PqzV51N5LCt^e*I zJaT@hi$VUi&+b0CPt~lk96!rf`RuO9&+uYvem;8ax^#2@r<5AzFm@2VMf&|utWNmx zg2t!kkv}plU*+qr_0l^FbwAeMg%JedG4%Umkl(4e&BNceuMBYfEMMibyYl;aNn=O@ zvi#B;^w{hOOmC5Xf4fPaxqqHFdNjw+@>M>&EAm7CM$&&>4D#om@b|aBKHH++__E5k zlCS4}^ZZfpM(f|-V)W)_b=|sfcOjJiD&I;zDT2NttOvQ?sfz)}P1g-MWBg;IPh~lr z4l1ABLyFhONplJ@`$)2bAkKfKH(CGwndi+tGjGYh8Uz!D<*IykSLBMT1f71nxHORD z%k4t#W^4IJ4!qv-kBbJRar`V_<+HmYf0#GK2xB0>GLAVh;Q0LJX&Y{M?c#dnP~}I! z!Q-Sf%i{D;afur*14c%W+ox@&S?ipoc?@{^yr1>x{%wxFb%{75~ID!bk z>5($sS|8aHo1`uq{q-j-hjFNUc9(EuVAZ%!%@T6{tcpSY=?V6q96w#~1IN$uRX)2* z^80!H{$gKIh?C!En~fO(q_KJY%r&+=71yG!ziA`3V$>sw$OhVE(!wzwJp z3phpqIbHU|fam!E7re3T;T3f(kMXE{c9-yAO_5lZ=N4D48WSDH=fqTR<=$$om*MWKM!lCfly+IuOl{0`;AOPnNZI<=C&j|%@v>lvyAc^HL4wcXDBQdt?qAOlK zbUh~S=A9f`eTEJm-(Z}E+rgZEEC4fB$xxBfV+g`xe8Cv-`Hv)yIP=?@Z7iShseE>~ z=h5aNzAiFz3Tlrbj)_h;S7dU2Nt$h)PW|tBdfM|{x*IKKy}eGoY38$Bwv8Wb!;Z*_ zxbSt7@qfTxWV{)7Z3hv6^)LrGFbxsv579fOB24?cPWh{)$o_OlKLKed5pz_(hzWn~4LUEb3?nACe%43lK z_Tzh8ztr@2m*Z#oDxcjOmT$vV!59Ej7H|a-koD1Kt~p->zwagHM@p~Nw1PofyOE6h z3w|ry`>zjdz33kp3UMNy%oj}QVJs81iCt_?eUY8Kf-DHXEWaG`DLy-hY)moLTh})8 zj?UAMZ~Jl{&Bu|!v=s7CV~zQODLqX37}Z03+-LzLv=P9?z^3{u`8MnPaEq&OM)xOk zC$I>TPbgGAyGN3bHJJj3*vW2ql=H=!7;wDy=%~Pkd+)1aIixSrn#yN)OB^<=@yW&x zL~)C@xxdnTp0!@4be-~ec8xzYj>dXX`BCwRm8qe%yuz!jm+dj&cy&>~wI5~g?89*d6!o0rs1oz#)#F&>rA?lIvRIW^QTl<^#l0neNJ zXDlflyTQ)#7>~+l_n7cNKWVf$45l2!b$T-3VB z={qM;STc-9 z+kuCS9Yk-`#G+;(HEwx*+aql~nQJbe`H_l;`S5BoLmZxhVl_aH1zw~PgGV$O0Z}D z$d}`%-zt|s?JjG4Nv-$2^yqs952*N>7<@!&GSTqa#OK|tI}V(T7sj0oT(VrkU17M> zc{m*H*M3*|6b~6JulEEn{fD&mVfs&B&L$csHajZ!vOvfK z|3W#{&3YZP&|0tS+EWFciO+M|01l9G59*F@G~U7KE7dC@a7M>Gdv?` zGHljsDR9YhNv511nlI8(*ukf_NP3+$Ipw&uA0*UUAIp3MGno*sSaBO_m2p+Zfa}E{ z9=m7a+ZWfH2UhtEE@oWWF64=D0WU=aT)vYRo9jKwY_xDyK9{O=dDl-jj;Z^Y>O?Z6 z*F-#-FPPF}n6qfA*N^#m?lASEEkovU@(M*R#jV!2%kIBCzxN|K)I=6WPuVz4<+D4t z!!td3-U1vq;l=21o|Cq7`9;kp|L#Jp`ltBpAhM|~N54H69ki0;yRB{m_e%;_Oz1RW z^K9y`k)ggD<#Xl>rt}zH=qL(c7?}6;<&^nEjhF>Lq;I~@QvV%#K>1yYD(Y(mTsi%c z?y>&P4;fsQS3B2V&9ca*U(bA17@y13&s~g}K7YVA$Xo39ILiY4-B_tV(e0$^UXNI( zjLm}7CC7RLRx%>105QHf_v%vZ;L+PID4M=wmB2mpvIAl-=Zf2Y>fGYGt*?PCj2mSieYmMb?~#XiWXR=H=#m9;uw|*|EpF^1H?F^MoMT zaoSpq`4p#YMmTX!mOsZ?T9o1NPf9Dk{(4(>p~L4KQS1o}aJbzQF+ofI<@QWDaFDTs z=q=Lz_R1MOem(Ebp?k?686D4BP37yZIQOVNj-fOYQLz+<9@y!mYWK&@g9%sN6GOFr|kWiAs0oVXd~`mW46Rk*{(r zRW!xn(>(`aak;2aaOA^HZr|mu!~J#p9bdfN=c>{-b;#NmDLM}3>#>HPqg>9ZxXjK| zLZ`#}BC_ zxn#N<@|mx5!%tnlF0LQ)K|0!(g>X&=(eI}ATyMzbd#a~g{cSH~Yg2!7yMl|{k=;$> zWwjfAwRd{A&8dc3M1G=Q!+dx*8QL&9$!HD*Y@=PCd@uBbv-gaRQ>eReYqjz9K*%{D zPN%H<&3cMdekyjJba=?>>?3EXvPH2Yx%XoZfJyHC25ZS1P#F@fbs0`oPvQx}mUbpbu z(I@t6e<`IQ8S+Q_Zp5p96ufHg-m`>cb8DBC+ZQ#u zn(`AF@}Gbw^956SG=RrhB*t(khf__b!=bV(<5{5Kp{j(&^Y|Ro>cXblmG^g?v9ed$ z%DW7i6bIEa%s1E}YpC~HFHWLzcsx$GZ8UcBW1DlHGcrT158>biPiSRIAL?Au%@@_0gu+iQjY!LV09(d#6LexF|yl%0b zw#0?Hk%I>D!sV+Hxa4%Bde8~VO4YQYv6uW-`)-`p>g4ZAwqLm^mGV3p#>IS{8-D7z zOrk@_!I3XHoq8{~Za-Bg?q74ypCfbyBD}uD==wO7&j^%x3J=CZobcOR@j@ zaw8sbzVCzPa;VnlsnZj+zb>4(BJTcsRt+=~;YEa}e8+rM^6)7h7aiDOcTLfI4lb-o zF0)DRn4rKu(||J@9gI9G_QC}5?IY+n#mF*%WP~)GMnl{-yXs zdMBfYh^xofT{VsMg8Ew2i~6ohed!GOp*9oAZ>WDlX+!0VzA3b!tUag)Xas0F=nYUB zK>P_h2bJZ|C`j+2pp8EfZ5!Z6lGW=c^nMtgVeBA!i}X94$2&IKo=+_ye`NF!ahl54 zT^stHhN_`-_BRJFtnX^zpm-Sv)h$$4?7C9Zrj9wmfmhAj)^)+$m!9j%-vjdB2%(ry zeq_V?PWR^FFg;IEHU?p_r;kpf6#5tA!q`m^L?FhI`Uu4u#t}&$d)F>1YO`Z`y>*-_ zUqpll<6yaZx-%+syK{RC^4k?$`=ozPs}>x;ju_`CD13I0EPuEM!_zo21&0jg>ptc5 z$a>UT56}MGq0t}nZp>ymj6>zKdt@AFPvz0(1+Sm|$vF1JfTL>L^vAc(z4Hi%XB;Y@ z-5bE+#csCJqGE@eOJooMIA4reX|0c(JH|aa?3wRRXE}^R<+FQa9BE$f>#oeLG)da=d1dz)GpgJ`R$9<{tolu-DFt)RZhRx zs3Wn~oPm?iwWhheEC3E_t1}LI zr+k^)7UQB1ue+S$zGdRxtezivrqDYX)`!a1UBll~^uYZ^w$Tnxkv%|HU^wV7+5q}7 z@W|!0+iE>FmLI7d>6`J)(#^>Ow{rX}U*)qq=MU+)HjIQ*Znf!sJAM5PrhoH`_4znw z2ph#Ax4*Z?fbWhKe+?;=KX>j~neF!Jsjq0ucSy+d&V5szEiNM)(02 zft(=fjvoN^L58J+WSSt;&I5G-nD;=BpwcY|p!H~9{{=unbZ+~hojn2#*XPhFCVfR} zZ&yOEh%Rb*h+n$?%U{mA>2r7!hJFYA8kH~Dcnr_(=P&aW*+eNouFIqUkRy3aKF3Rk zzbfM&Ys}vf)-8_%Q{0p0tnejze(T3_s7+42ewEMedJSMRKAhrkS6hZ7P$<@d>AO>T z2u}o=gD2-V?P(|*#tx!4wVYN1@0)pd-w_zNY~xt+2t#R3{ZQr$ru2xh9Ml{4pgcu+ z?r4qv3ywC_G5=N?sDNTApYXWU%P0_3{!#QqSz^6Yxr%1~sXN8bGAMrefBD@i{%F|# zFT2U@u>~l{q!YWLC#s`SEt<}YdicDQ%EsS4a2u*kVaR_HLNVW9hb&{HS)cYpwI*I3}r>Y1ROcw(ai=RL7;PqG1w z$^_Mi%s1E}t3lj`7KLJmI?5*EVD8CIeUBdnt^hHv;4@}@Qay=JVW|J%>yw~O8=5op zk{$Owh)&V-^3w*N0Oe^Q;+kXI^RJ;Pk(({ z&TIY1MK_c`DVM5z-Br_uIZ9jw;`@b_)ieb@+J$p5izo}yo{1uVah@2xkZ~-C0mm!- z5B_+1>yA5E4(W+%HkHrr^>EOHM?Dng@uaHfto5;Ma_>+7&U@}JmP73+YE`LxcCUwH zfZu`3DpYmU`>t|$E1T+3G_^#&;`~K1dg1ftd=%-v=%quNytnYy;G!CYB|{mo$lpYc9iv|;=emEu+MTZJ! z^wKIe^ygtC}XBRnrW(Yy} zU(Qr$uI2GirLB_rlOOr(5I{jFF`q_DAsJLX5%fLfoCKB-P4V%@T>hlu`^{mSprLmhKHrh)$( z8j$;4Nw1pwr&MPpfpSr?(fWS+ML+hu{heQ1)m%^SWb`r-SC6l|(*7D+51&8Eflam8 z2jmvFj8H?dIAB~5sgJM9II6dranRT_mPl#~fX{vPdsl04zxM4B5BC4+u9@!`g_0V% z)IMZB%V#^&gTaq{bT%`bZXfn_(A`QlT5{vOLSITla<0Y8<9Gt{o%W<5SX z^@~k|?zVkODiEfP@l^SSvnHKXWb0q*!=gJHxp25~;5u!{8-+EJ-hK`r&7xr&qc|YM znV(+l%<*CjrdSL-h^ST&>KJey zxp&(mqyBy)w4R1>s{9yn;;a?ygEJ1w)`xAPY1Mo$ZsBXzdVO-u1Fx<9E&fx+!+2Fb zyIZ9HKqnT<>cfOllixHBm-M7z&N5sC;&p#&wJ#Iekel>OKHV z=ebNes2&>&atg7awb1L%7rVSL>}s0VtgyhB6->~6dOt9s{|IM$YS)k2u{^ck>&$mTw51tv5vykX?KB&);hyN_>j&7#9Ra7lI? zZXstr`H@ZNa;$)j7J1Q*E*j7XExMGySE+C4A0d{XkBBHu>p;Bkxa-%4$KD#as#}sF zglz0~)tGOvLskU&;p#86OGh*1>l)yoJ_zHWchUu~7s&lAPW$!a{(qm^B;bVRje3&u7f(B}BU`f4L7Kdg2BL-yja|E2G@whq*9J_$y zkwu*!KQE*_Qf_Bl_^BYEE9%l}|rKbk#C3sJ{$UjMaG_7y$PmeEH)<|3V zWxEeQJ@>8kHyasW->m*l7HiC%6f%*Xe)PVQ6lJBt_PjDESw z=lIS02dITY8$NLi6beazwp%*$DU)QEA-_&xJ_1)jp`@2c;|mnGu5Z1*r}D$~Ke-(< z|9K6l>7&p0gymBDu#w-1r~c3Wj@kb{4XEkE1@@Tk|9v|CpTyJ~6_#4RQQ9#5PvSln z_Lv6#TQwlJqt~FlLgmE{BAfbt)E1EU5%+$m!@bWeE~23*VbYAJ$~T+=X&H$pd_1q- z8LB`8+@3rb1FrG*!~1vM(|I1tWn3zs-EnT1(?eRoX86!~w6tCnCnsW@1RV|Bt&9y) z4dIj9o52sQ_4a6C+I^!M{k@LmGd`8i?ve2UDy?&A2owU#`6}rn%1z;XrOwNfTU@6H zI;^~Na3#Hy;q@*mUw73sAi!WNbXOD@J`sCnab%IP5J)V1F_v?gaV)UF(dP3w?Lg~Y zwM#EOcu%Gwhz9DYKg4{N&$iT$#b*7`q8prc6LulLvOZEjF{e|ce#uMaEvLR(v~(xS z;dQ<$pWVaKka;H2aE9Df4X+zZK~kvSNs5Elv2%Q}*m|nQ;#1#e+>lSIWB#`pIlZ^cE@qp7X-ig5OTKbUpbaqwDh&P37yZk@Ii5D_?A%pl%$xbHb~PBWs^Ej)$hM z9pAnA#ZR*wedE`7P35zDq;f>^Q9~DCEHOYw9N>NrQ~up!fuq~>1a0k-bq|fSSKr&h z5JWbWBj&Sww&nb5Rs+sHc6mg>BEJdx#MM*`z1tbG&Su&RHChLo-eRY^3!YmtyMcZQ(f;B$xAZjR@E_{%z2bf5&#< zB-2p-Uvo;L*8HZDC9M|yd}q87Bk7xd2lEYf$cmKjIRA(9g1KE#^{?nSvQACZ4xKpW z?2gM`;AKsr{Rqqt0We--!(q;Y6f^}S>zBS0Iy!O7o_+|8 zAF6yt5-wXdOcr^IZ~=svrZ%rE9F2oxasS#BSCKKXgu`3K;G&=7slW^4)V{RF8Ryyh zXqV5szRuzGyo3>6h0pE{;lwdoV){_50*wMwUJtnd_y}Q0k9eoK^EvIX2O{yLD7} z-FL|>*UIy`twwbi>4*9F*JLC-IDH&)#e^JMHN1Dg@EwHB`6vaO`=a4!^I0S9$eM?K z+keNpsU)8arxWvaZunUbhnT>?1_3&A2j1p@SpFId`86jbX~$hyviF;p&pU(K8e~`x z%-6Z$XH@ypXC;UrjHBDZ=z0j2;Cs96=N6CbD{Mt;L&&fmn6GogPZJJoo7PVRrCmF^ zA6XAo7V^7IP1Ihv=>3Q8T>s8fs(j{$CF^gJeCpA<(6+=@TsjC&98DSm5`=fwL+`K5 z^-A*Qcrkx*L_13EBtu*Lp6vVcw4` zlXS_PKbe2Dcub9N1eV7eYAx{0xjaF8aQw_G3wE9Rx{8PS{}_*=DOpd!Z=&ldB{e~7 zI&;gK#V@ot@sOe?<{vFCs^W~kfe2cGC+FkjZ=>VcZcor&JhJ-EuMa-_iHe8${{uXV zru3NP@?HsigwPHmTODsZi1MDabA0gl?;ZLR0An@ADYkqW z2E3PoLVEfxdc8-npZfP7cl>GJ(VpJP5Dt2(e8I*;!jTymNF!;wi=1E9KrR{n{gK*P z_to~>y0Y)j+)WepKGpszUyt1+Hyiy)y?P0Q5zQC5Y{}&+<9lm73nspJeUGnqhR&<# zCFfYjFHP0QrYTGzi1O)wa{VTnQ`6+%ol$H4-I2x# z9jymDp2@iGM*dy=yH!5BNBrI5?l)@b*Z=9J^ama?Tu#(;gX>C8)_%D7{3VZ!>wgC2 z6EcLE+KJ2;OzD9W2?Dlkr`suR(8StZ%Zn=BvScEy+s4i7Se-v%fnaQarjRfNOb(Le&nXdwvZMItEAGyW&@ z0p)F4m)siE2888i*t4gvSvmtY9rS^&i`E|00YqiL6R0z&3+Q~%1)vK-JwSBU#wDQ3 zK&ha9pn;&lpy8lw5H0k)2IK%u0!;>82bv1H2{aQl53~@p1oR;2F%S)SZUk)w?E-xS z+7CJm`Wtj2lCCYNGpG+J6Lb~G4Vng`qxdU9n?Ub@sOn2X;&lL}g2sbx1}z6|0UZFH zgiJ*TDNO|33EB)g1UeUu@^PShLGOZEVSr^UXa(q7P+xRj=7aWw($Fw^2-GAAXPbh) z1YLtgg?mBc@Bussy8Z-=$eWG583wk?rHsFcn{ z!r752#-X&ZLp@@h(vn`i55Qw_hTW^{0>c2&KW9aCBroC{4(mPJu z*ECM6J3UT&>%2H^@+EQF-a*)hdQF^`NI2nQ$MTCPv&}!#>Ajf)475-OmEZk!kMj4YD(faeJde!I2L)CnzgbKkpW=Xg@5u z#C86vbYx3m$R_m6H`pNyZNN#`jbJm@pHhWd;= z{OeYYoV@XJD$c^_c;Ymb&+d!^tKzU^j4D-Jkc&2I!0;e{XVySI89RvHBDH@yKJdiA zKlY6Miu{p5@e)s!FW7iQYHtkpj6&_IkC%&~8!@+_hgbuP^^yCFbvxsTtM8dNZcTdt zMN1g6KEjKo9D%0&cXpp)BQM>9IXzz;=IE;0AZYJryw>yLb(7>CyBF8C{6%lz@fQO$38;YF&O$z*}(yU2XO zlpbNcH1}XY)2AV@`m)41$UE`MVrQ{)2rf{ggWcuy4Azh6Enw8|;u3D;~5P>8oifXGy)h~DKi_&J$2--1RH!K(xZLAav|n4m#-~RZe5%BJ0o8*_>G||343mvsLDQ$^Sw84$dEy$RDIDJBam0X~N^6c-4-aan)OQ zuV}QJ-pPI^;9oV23Q0Z`ek?CYDE_2GrNr8%z;K{ytVKc+~Pj0nVN`d02e&CWWLY zGK7cD@n^nZN)Oypl23OV+Av5?_ZsL8e%xSd0A#O0yl}dt;_zgvbor{q7vrw#v>}7T z>v$40mCx?=aAX(zd^meAkdZ!u`~*QPzZ&xCcX7Hj!aJ2m`CPW^=P#*xseJla@<)bj z3dMZElpe;df$mARG^YdAJ3dB5#Xcy(xZ^?27g>Mlv9kO~>2Un53vavpwcJH4LJtwA zseE>?Cx3*q$X{m1b;478MFD-UPIhr#Xk1p#7khw*;%7XRHflN9_f)&VySg;pqT>kb zgZYeu?J%CuiX*YO-=<$~M2exNnQ6Qz>u)oTM7UGEDDNw{vhMw%J-RImsQHum6sK&A zY-r1Y9&n8>?f(b{ z3y9h-=z55L;!xPs!7cz%UvMty0njs`cR+_ht$`^GR0LWL!my0i7b;o=`W57X@_z!| zg#_x41Zsr>bQ}s$+a&Y_n`qh&eEf<5&H-@u0bEK;U_w9YR`j2W&xC-pHSLN{nl==T zr$P8wUVSP0p8cVREc6+!K|dJ%o|QLf+Vk_#k9-(?vQ6kCp(8r_PxQskiPL6X8K>QI zYn=8Z`YXpbj@M2b9k0z;AFp*iD?!V=FG0)il&D?1BT;*C&T(3LUL!3yp|SSxj3jN% zJ598^MxCGyIJK#E{OQfKTf8T0f3`bCTXjim?cmO~+JlGB(jKeopmpopSuU=k_ySFr^2}r&(djoV28qDhqw#9d^kow;pm( zxn4_2u+~e`m1F+w=Kt-TK1KwDi|&7BKF7;;JzOdfO!Z*idkRi}t#_XGni%l>w7&4# zr%O-VOXY+N;W+_M<_o6uU_3^-wn_RDTh?joI(e7%lA2gwFKYebIJD!!(vQkJaf6v~ zv<3MMEez{b?;HI$5DLzc^8!dM|WF;)lKL-^&k=iBA8vXD~`h7L|9SH~w zS!dwMe8H3+{cxhX%c)~i|C2@vGt9|E-9>xt4$+o zTnXu&K3MnSTeDRCF`x0U9Ua$DocktW!%}N^kwXNPajl5~SIV1XYg=Eq=0LoZuGHRS zKI36KGOqp}EMhKpqH`!v(W*5%*B=&+OAu*k%KxaN$=E?8Hq!UCY~W`%Tzy50krcKF~LrNET`6+G%ZG)Z};Q&GoT`fmy*NO)QS z5A(xF^tWs*S;j>Vqv>u=j6`5Kf{q;+;Vf`r;~t&dt#fd0uedHLgisU=F)*zcfeJ*& z<#Y}PPD#8SL^g&T#W-=r31~l0o%$pG)efDuec#j9-+<9T-RN-R>halK-|v`?MJz?Q zlgN)13#B>U;=Dr9I13n!W@mm{nZDx?cTiGurP#;egLq+lNlnc7s7|BGFDo@X-qv@C z`)lXw#-mRGpA6Z!eNSV)U`h`j=L*junFrf~@XPYIpJ8p6pB?OD=HIM= zNa=GlBIIe>1-VKaR_9VN>P1pzdd%&`4{(`q2DGzOLB& zo$ghPpV9ao^Hp6%mXgEptcN$M6x2H%@2`E>Yr)y^+RDcsoN{yA+ToZU6Nc(xlFxjD9kPsjtc}m6Z6K~!FUm%H z5OJMW;Ztr$%xM-c${*oq$ONAs)O=NZaMKJ|_Iu>VNEU6n!B@k{31JMM;Ut!k zMPd_xp&dG3pTi~Nh0=x2bFBm(mN((CKC?(SvfjEiH>VqYAL%P!2jcTSy5ya+<&MF- z#J3!5<2w&LaPYaa!;;_3B~-Fr zyR|T8rhS;ab6gF=51BS@VCP2uAy?CngrV;^r7!aZQ+hOvb0p5<7JE?o zd&DIQ*o*>`g?I@se^*ING?GLKfBZj(k^kp+w#iQ>yg>k-Va@$cJMt*R&5xF0UcC(FauQ!N8LPLt+$yE?D7NiWyTHwni-=HHEB zDtlID0Q@#cF#6s9WE}GZgy+0K?|$PHg~aASeTr2^s_%3>pHWvDslDEC&(u$ydT20m=sD zfJTBwfkuPIfX0HZ0$mNlu&FiOK#M_lgYE&{3n~ZQ2cnMe{h+0wWuON@ z%Rv>O6`%(}4}l&AJpy_Zv=USaS_OIx^f>4V&}z_=pr=4+y$;#|dIR((=q=Dr&@Ry1 zpm#vKLGOaz1HBLW0JI0R7xW?MBhbg7PeA)XpMq*YpMgFH{R{L3=u6Ok&;igv&{v?Z zLEnJB1$_tl9`pmK7IX-77<2^mBj_j4&!AsGb)a8Czkz-S{Q>$D^cU!F5Y;tk9!zVK zWd5#`(|?<(!f*Y*WDGs{`;dm7UMAu9Miym zp$01Oo4B9kYacIup&d`EqSbRP3)?1WZR`sDjti2shsVu$^yfeRRZ43*$dEA^Q+V-trlhee};IbNFQ4owDK6z*s8c#RZAy;noD;OmI%d5M{k44?G-Y5Xk(zn{n7 z(zh1TQX13v+nN~k^J(1d5B?tduUz5pl1OijN{(RnK!vB-DaI!e& zyY*4j3WVZx$~wo~4^M>KaUfpTlyOVE_WZUx*MHb)cRrfS!jMh*hxrCOWU<_cIMQfn z(35Y&2}X2(E*7xkSQ9rULuu=}xWQEPe;8k#1->Bg&HQZ09d&Kjk5%z8KLpHpiH?u1 zKhN~U0Mj(@zM!KyzpL}M$$>=eja!cY<%`ORb4Q<`10h|L9+_{2Gos4$Bb{9sWTgZa zQONZ}3ie4*-m`E;u(ik_Y%@L*T>HSeE$`7*hDwnF)2 zz7;-7PsSj2#7#nJaEV!WT+5t>X$Lx*Dbs_q%%_Cs;`&d zm88{YFfPgulq*y|yJzE$MVH5x<3)i@a|tlEG}@IQI2he8aky!8pZy2%!g%HY4{4C| z9lcXOM_%7tdE9HBac_5~F1;{}N9D7-foFshLg|WQ0V9yuK9vn7^ylPdTpA<@)(cGXZMg^tnko`8*bNhV1q2xWU`(P#(?YF)oUL} z-hPCJ*@R(SDxckB#l`;RdNtU^T2Hf2dT!;$^WUT)FJTyu%4c^gJn4Sy@A3zRVEKn9 z;N;ZP#}m2SB^#BI9g&i}Ncq}R(rka@%@4F;xr|HYv-?rvQc}^Jj%#ATSJGs{xcMv3 zzJld5K9$ezM~BahC-r>mbiC}Z@|4am|Js@5F&>rA?pAn4ISXBR*tcgCKT|tmPYigj zKDX$kJ@3C08v0^9D*tHls0k<6m$^1;Jq>#J)~&-PHl?9!VHlUnXZINOWYSMv3^;y2 z_JqA4Y&AzT{%`;nR8bBDvqw?9^ z3eR8buZdUn5s9f6$#+pf|b^mhq|l{|UZ&iHgYN z?@-c3);P0I`S_MWO~0b)9bp)!%4hd~phpo@##Ipmu64nwQ^qgba0AO_Tq>X4t#FNS z=F>5v^-{J15pcSucDL5o#+p}NdhPI=t647NQu*wDbhzrLsNBxk6$8FLo|{{}9_KMe zo5J}{<^Lmm2qdRtVGnD4&0Myu-=Hn$6|y|mm&#{%D}4=cy9x@6u+$38LA~Fje<>>v z0jFb9PitJ67soHS^x-$(WVwt><+J){y} z^G%@ePfWOmI*T0n4zXiF#xv$(v!1B$N@FK{PC`}B6ScQ)edVs>*7nV6VF+#oo5pjP zZ?HpF2G-j{8yMWhxi3!IUNRXsa$()4*Pfq009}2j-{;3ALmWU(w*`I7`CT37tp(nv zDlcgA)8di|dOp|J>k%I2bG&Rv#Dm&18=cpH=~QuC{sv$LX&6JvhYlcs${~-h>gm9- z9<%@d)_~k@Z*xiXd_!2j{9);{XSKSFma7P(=byNGe0C4jlVV_*$}}BAA{KYrhBylx zd1bm!xja?IfaB7|onJj(`#ah;6{((FT3vGdzp{R+_gz!@ z4dBY0=_EM7T$Nu>zLYHDYIE9qVaz~<{+E!+?Xm3& zu1I?6=bNC}G2_X!*3oLj}B1%BXC`RpD#g(t`Bbx(BoX{U@^KGhKS&PdtD)Gn)w z0gvz6E9#a_K4Uk_V>~LK-9vaV^(_EJ!h&^1vR>v4H0veOdZ(Em-2ZaFmu}zFNCyx~ zFXpp+woUi%jOxL;#=JjY+88P4pX3ZPo=E+hKUZw|XzcE>HkQYFQTgoN03I7{s$q-0RuQh|r<4wq3VsFnb;GA{vmE%dq zj>eCib=T<&>g8jVPkzZn!$W7AIQ-b_OXt%d!-rAn`!nc!_20N(3d3R3yPcgLHWxLB0Ez0Cw_a=bFWlnuVXo! zA5}iPN5f&Hzl6qIPP2ws>t#XJ)z9C2WMM7KV>~LK-J{_ly^NfSP9=<-K6_%oaoP8e zKfCRsPt#Zq<52nRZiR!(f{Y_~sI@-Y*KQwHy0EYt%V8WUpWUr+WMd0HUCk$dXKI0i z;qF(UyR|-apE8a$!_9iol=fQfmGPSQ*)(s#H_v>; z3-Blejn6Zm<+DxgH8fFiOd^hfz?;(-xrs&@j_PY3k8gqhX>cwyK*tdpwv4-XmKnF& zZb=>)ucbfbSg_-(U7`PQ*W?OgeLoQw1#V+V=+qNFFet*p82{O5Cq4LFiW|LOkd+(qW= z-0(AE`e16l6K$!jkEW6ikK^df1eFZ=MDlkDTx>G@p8Mg0=yhY{&-oHiz% zgnJ4=h1Qcz0L1}T*nf=4Fgd?bEG$cnJKF#MBuupUj=3Gv!2d=KR3M|P;%p+f+Bg5r(TbrxR{ek9)oZ7*B|7ynUc=0{yC3)A?X>JG%n7NRB-eYyFqkZ+h#m zzq4Jxy_5HQ-e17e$ndhm;Hx2U5+n^!;#{rtEaS-90T|91fi+h}&UEL*;sUHFLZD<2 zeSc_QOf_(@oQr4QK*wjB+Lu|^Sf}TOjraU8=$ErX6DJf0rKrjmY&^u-adiEr3j?{h zfeo!m{RB_hp&$A<0JG;tB-dnfhYI=(p(vyM-HVDH#u9K*ZV6+e!KZiG(0PSv$WfDNz#Chw=zL~z6u5qToR$pFT>era zpW~-ENMFeycF&dEX(5#A9+cc)h~Qo!xoWt{8RkvM*U4 z<5BtS9s`~c4my(Ab-k#ZIGp?)IT!=3w3K}x9l3dMz4TN09KRJV+<#O+YmsCezKPcQ z>3Zbv$x{wpLqn9puzplNyT^nBvB@~bue+2iS z{c9q)Crj=$0I7ygmE50>;GQeF zzYxJaD7n8J!M#Fq-xk5WT5_lRa`30gzpqAe-x3`#x?pdMJ->fJZe+;D zttuhDU`mhSQ#>x5wQR$M1mZXoEC&(GhtkUQ`xB{Kh}OA7+;=J6<|VgtN?p-$CBuEp zLoG6YIg;=q_XDXNMEyYKOOV8COt|!0I3-m2d6-mwcz%ZCrF4lz>~3Y3!UM%i{g7Ja z_tHnVJ4jwXu=3Z-94#ju{@^4dVv>Cl5HR0hhb-myhL+&SdY*HwSd!pm zc5uX;A5}iPN0MtZ+Lig)SgoXArio*m)5@~EZWr%2kZ~nXw#Jou>4&A~FWPuN%Vk_D zpWP$k(y`bJ3UFno1KWG*p)&Uut7E{``>wgW0~hUR%W@f)%4he8xI+387mr58C%30E z+}3*QwRmVw{7XMR$m0`)uMzSQ^BEW05%Gz&cett+$HlNe8ON>|aLk;Na^%}5CqBXT z3gJis4(4;bY)8a_V@!NrU$L8dCx%D4zRjItt&dMHn)~$aJzDi-Ih`CzrPc9&0^qc`9Xp$GhIx z&vF@;%4he8xQx@J>#0ks2xMF-UTa+E-tg19O)Yb&yDSXjQu*wDRJiD}7$cyJt2zc; z*I)R^{O_g>4-MZiE|nh@S9bBl01kgCrY^2hcQP~?*BGC*zWOxUy?5t|E(=*M<5KzT z9#LP&Uslj65dnYSwCk*Kb-(e)rSIpzP|b1~m&#}Nh`2b@ixrHdq2V}l1*5!9MR`(w zlW|tYfOB!muxq}#y=WWbV4NzS-6P_Z%4e)l<@$9&z^ugFEF3{$VM-deBQhMA9f3g+e@g;Mr{K!x%k19uK$he3#rZ314JK#UZ9IX zy+M6Imw@_$E(KBJoHmZoAvdWYJ17m*50nn-4;la(2+9D_VEZ7@V9*fIP|z^Ya8MSA z(hp77X|PP=`N_BkhVmE1Pj;kq?%3wQ)kBIl+^?oH^AXHsEYsOGz~RP1ZvL_d5t_?! zYKisy!lvafo&0mf+v^E08M0}EQT=~q2RvCV)4ZB~4bYw!3W^%4wK z2}6scso%zYog03Ndnssk#Di@GhD}q6S&rfWjt?E_@rf6@N?sTlPwv#{c&Y{_X!BAA z*Zp<>hC(cr6Nd3HU+0FOCOpWz;ft0cBa-pdTHqOznV{KQ?tQlA?VI{zD940{`C%mb zn+Z>S{S0sy2MVQa2B!KYSQ=eFb%PSLL)DLuJn{0lG%VpW;bDGMJdyOHAd=fJZOY7e z)b(+DN)ogg7q?5y%yM^q%)pZb0F-~2ui`Q8aU6kTOVMG`(<{Rpz>-WK7V;YmV=qxd zda492%FmpyBaPc^xc@iTH)Fs2lj{rePxqTMU&RHzpCiQ~m-9WqM;c=N&^zIf&(GX>TkfHCt`1LtEez{N<+HmP zpOQZH(3s~pa&NRwuMh9L^UE2@U8zYU4C7Jx>~6**rIH@|T9 z?LE|VV?N7g+l(W6y6MPhK{l?F%5yvL(ePs#1C5XRcm$zB!n+1|tMw9{qVz(bKbc4E>ztkUj~A%4c^oj!^oULBMkb zh|{Y)XvUEbH|p=zf%rbb{3gX;t;^|5-4|gPhstMnTGQn8=h1!dIPz3nDu`6U$}l7i zUZ`_ULkM|(myg!+i1F#rIq-<262$mYr(37j(;d&eXJ)4*?I^F2Av+FF<_o6uh<@I* zbPjgpbIxtNfK9I7YGc58Ug7Hx4N89F85Jk9u@@Io;Lvde%*e z+Sv2j&wakdn=`5mV1%36Tg*Q?yw-X(uAVcU=UsJ6bey#}Cu)sfFUovr;NIOTPUasS z&Y1PeaK$(Qf%IT}hmjCaKfBs3h3L_lNAB~x5T|PeQ@!h`S$`iFW9QUS!8%=8O5{ zM>g~YkGPJxzu)im+eSDY`6HZpxUfTC4i}o|;qp&$>EFn(EyvGpGLPS*xv`&E?Q(eJ z?`Y{9>vc}|uFid^!z$k}#=v&D!B^#CF_Sp?5T``;bNY*1lW485zVI98$?0cH(s+%& z{uWnJk8q0BPss)@TGw0-T(Vq}DdX-o*Sh|A?DxZsedSXIGhVW3+>!bC*JOtKUAWyM z$M14r4K@~K1+e@R9RrDNz@I447o(35prn>@ZI1!h+TPn{yuJ1wS`H)(<6^$S4q0fw z(IK14cqq4~vK(kqxw$pPhe}Xj8CULY*7|y*d`b64%h%ng;$nUXknzH}=)NALIW3dr z!Pe9?0%W`}F7voI^-JmK!$3qFDYskeXY(iR zh7NgT+GnbMnBNeN2UH4)ok#5K)eK6l(hpfo@z*$U1 zAyo*!$#`;pssj$rPtFMo-y#_)hCA28^nKR9ns||n{Qa17M+|zMch60qeDi3%-?Q1^ zOHqqg{yh=&n(Zv0F$lUFCj8sva*#aV8qeGd+V;9?)W6bH{WAY(@ZhQ#huhdl+|TQo zA?R$Br=l3|}`+uFZ6k&~{u(cNqK3FC*a_~@_ zQLka$uGi;t=G$n^8a`GTjzFQ74BwpZG9aJhpHcb1gc7)w8t&8{uZBD6C!{C5(?S5= z$AnjHTh4d$^V1$fic18M(-5Mi=rCwZ z{8dfQGz5|zr=6)WpK-8F>7j2o!X@c?ei2T|cyd1RK`!T$yWUuPSyQ;l^^UgCtS5E+ zr}X*e+Hbk1U6wU}#cwtdyMEs_^}m^KutOFNW@5wBL|jHyR7MROaRC*MO|#j@3ZJ_emJyLy`j^i#d z16tsu!^d$jd$uzVM|u~PQJdOn1eEi8^4(@!+u?`OJ9TlqR&?d}FO?5T(6%&vr1bL( zu6UjDBpK2h~ zEx;0n%c06=cgQvN<za{Y9+b`C9^f|}R@>M>&o8@P@ zu)csc2b(aE-yn!_RK$Q|%+;TqbIQx_kEXC>7>CN&T{X?5|4ffigp>@X??tzAYdsw7 zIBecUQ+My?_*uTnXLqw6`V|L?yi;%_V1E4+(L>1TQWXQ9){75K`Q*whDuTi=9+l7T zVLbi3xLwqTN#KZ3phQVu`vwbb=sL!-x8fRhJ2bjJd<$uJS-rLVRgQr3^QG&-)j(Ft0wlJx6m zw631~DJ@Wf;rzmUog02Oh|82q%=#&}z)?OHI7XlGRK|@fzpjVF;D-_DZ`L@}6w||1 zz~cPdds%e-^u9Vl`|Min-PH?jo~zE1*Hh{E1g*)59p-m@YxD>e2lM|4jz}q3frvQ$ z>MU@z$xYD4ui4Z6xi!Pus<@c{k8njvLAk!3vpl-qsvHU0g+cAzMFXE)_F1Bige+`_U6`P~Yd`cuyO*vTt>R$*KfzHyHO>9(@&}{qXOAmEJM+`zvu`{& zwWo@U`Tq!4lvI?{FZm(!_zji4<3RGh**@Pse%aJj?}lKs5pQiYmCqie`nA8q?=I8F z97XeqmWO6fb@*uQr78WYfP*x}{e5~@$4AO)JKr$&q$7_f8G^{B{j$tA*dYt8f)ZT1 zWJ}M?%C@ByO`$uw^KbxAk&}k9Y*_lKkLWl9Vu&QP&rPoPvmUm_b@BL={ty4F-A#J? zTW>$ap%uaW5Fq2lgo_4j#KmW!A=(CUB_ll5V>I9611=u_n)?2xcGRYn-4{siKaJ?q zk1Dh{-GJ^2o| z*W>J0LIW!>vR?LB;Hj!@s`Z@reuo9~$2}gW2Nz>J^j&4X!46qb@ff!pk!Kl4?#k$T zsR53!``-2OH*>yxM8(1U5CG#PDh_cA)o_m+ZGE|&QEP#NqCQ;x)7goY+Xk^bP9K%e z?on}=?taok$asR4(e*+hZfrEJMa_Hp_p&_3qw?83DxM+UGF(qsMmMame;H5nRn~Z1 zjSkE{nC0f>Eh4{AIa2u?e^flfJ)-B#YhWmhjHd#4C_mUiWK&&F-yZq=vOT}VSGP`! z53P&j@eP%aV8UQD85ePhbIJy|=ngC!RjxGTg`<{m8Ao|*+gCR;QOlmUuI+-iF6!M~NDKE9nQyQ|R_u6en4G3-L9y<|5x_|jx(UK! zeAU2b^?m%n@t1FJUEwYxxN*+)$(qV%cfRK`GtgtqnBo4OW5$qjiZKtB?<7A#5X(<} zJi7cnZ5wNwh74Z(p5ykPPo%&wG!8`d4f6$4da(TLLT|AaqfU?Z4SL17S4yv5C1~_t>NF9?wT~o>BmQ!3W{h` zQwSMP#_H(lPX0S@Yx@L9;x!#-3kvYCWru>AG4l}u9x84L~U!c!mZbRy(uZl5JcsI$^-KacE}ol zd05)3WXr^pR{&ku%U5dnkoB+!^5y!9+IKV`VmhyGV(tY?76xhBMHtq@j|!jNBk2Ld zA+*w8-llBIAB9g@O z0(<53!&#~!g>lzd;9djV*N)qKPW-+$1L-?ShH*1r=Z2sE5ceo->i70@_=<}CPTceq z0k|Qe8aCsvSQ}mMb-+LJxv6E>q;&mW#n1dOa{cWe;vuHg5*w0wBm^Eb{7{N6^(b+mUXRyn)8)A@>?R6)Uz)gDjg3#RlCgZsrk z+W?n8P$W$b*~|q?c%xu4o`W&q+21>$-FW`Z`y4uSf#+O2nJ+;RuQB4`f^O;$`JOiG zM@_eb_a$mGHzuYBZ~E)J=7wNSH|DE&B$b2)2{1vW%MYiS2}d1p$lnJlbCjofTqpU# zL@l9FyGe(;Pg+84Z!&bw0p%a&3#Rl4i_+&~?D^MXPLulhG?pU9cSJ^((`U|x=s3mz z$NR3T10PRF@5wl*UM3vOmmrAOC^$mxIK79chm^mY&7X;$KDo7xv;pHg?|8akTONNO zIDMEO1y2s{4J#_b_mZwD#*sWuzqIjL#!;@|pfW`5j5?5*_dnc7d;jk4ZJvIv+XmJP z<6!<#;SjU$dI&jvQl5>j4+?Sd1>OIA@8V4>Ssvk_+D7HGyOchW^?_;D>x!{f$_OCi zsZ#LN(+k3^81c-lKio9;9+t;=R6e^$#Uu1$1|+9bYE^XolukzK?0$6mj%DLd`puZ% zr8PB_f0@rX*p~5Nhzxu7=sQaTW$DHGap}6x3RwJot+BvCAs*Duy5fa{`$PSAD(_V4 zRlZ>35ebK=`*OTtCnKpaEM}|_3`49y9E>mcTy#CPnUbI#*Xv#X_a`i$HPisW^We-k z*dZ$n!bYV?=qb!IfaQ48oY-v;=7*J7F5zqQd~|#ybiHl$%G%m3Q+1#E+U7X)x|tsW zX1qu;L--UhJarKUg|Kpdue88b<-z>@!XwjDcQl`{()gZo{$hSCxb$y)j+fTEiM16H zB3VzVFGSbV7$4^A&TDbRcJQ5~bVD%XVSX%l^f>{iKN>DsPrEE|)m@jM_5a(^_Q#yX z*B?-DF+UbuA^qfd_3x{sCmB!f#^`z?SueJluzz{-eXp=w(i5$?Q~B&3DL-Wvc(B+3 zY3BE1*20a+jBxpr)2+?|PkA6gTa+{Xu@~OHZGl=(F`sd;9SM)9r}~%XxzWf*Bi103R7Uh}5F?56Epq@}_MWKW2`jcQS;Jo+@9k@rcwvkcK9BO@Dv4xG*t% zv$ovMNqNZ{S5c3}-;RFm$NN|=eZOfno62YRNVw964>h{QG%l}Cxdst{)2~v&p|0Df zxNkqT{rsO6=7iRLvwl=Q`6XkVnnH_V1Nwy&&iqWV?p$va%X;Xx#d`lsqhQ7@H?6++ z=M+79BYluU2H#+ZEZljKMu%)cdZs6UcAlHY`q9#o#@fkqGKlm*^SfEV!E&e_N2w#@ z+yi$q(ejb2MeBZp-#BlH@Q4Sem&#}Ni0Q@sOkTVU&p{BU*O-^hIMno-b7Eud>UHy% zk6f1;$LqGayfL5Uvn`dkP?@rc?q&V-N`1v#-di9Nnj5GAuJZ5wuU52gtPSe3^MQBU zx7*#;5J2@Mwa=MvutOG7#@ORwn#JbHBz>?3zH>pOhyTR<0N|PKW8RM6NhVr)51Np0 z&)BOk&lVo>(7y|(XeyuG8%S^LR`XG6yxx|^7bd3`RL{W#&SJTekeVdkLXN>6_3(`Nj>bRvx$x3JWXYie-QG?MAOrx zo9}txpG&Ry0gzGPiWiBcp`pp z-un8%bKd!6ud0s`2A^@T&2zeXy-KsJfdCyy9}ug_k!^&6%>A4N3J$fNpt#fD{%Q8a z?u+Z4Yo_uW!ZF(Em~4z_(zqthdt+dF2w5*}wwv`53C|y0pBdU^<$7-JiSIR~lghWo zL&(BlN7ySux)u(AK&v%5!UM_}=Oe4qEe{x5S~pPk(^vopUrb7ppS;v6|A zxqg~>1O<4+kul16td1DZmtdD0<+5024wCbe@u<_~@HpbphNfOmp?p#PzC^?$p36rH zXpT30`CI;|(`7vD_xMSczs2Iu70+GqM5;JI5aTHG!{Mm${4lTnAoyvWQRU?HWqzpB zTJ=3@ddeF{EivVm)m>W&%Ql5FjCG(#-UD^!~ZZ}Xamm2P2M;mrlHKI=y=3es#&t+ zMOs(SC+9EYQ>V+}F~`T1>t_C(2j`elT)b7q5qjKsK0ROJ*5sZ;+sAS~G7fdR93E>N zjeHFvQRYXo6NYib^t;sdMe5WCC*~86>uEa~hdNyj*T>=PrIb8hs@vGB-YDO%aeK=9+&Lu6eNjv&9 zm-o_d#~JE$F|O!-JvXPlQ`Dfb zQ}KAby{^s{j)S<5w6?3K7Z=VIfBy~ca}Fauk#jZ>`61qm^AO7VOH&lB&~#dbq&0N; zr5jJw?;+C}-JnxctYf6U9kC_I+Vu>}nbjHN>vO#Gq9T)59;+p1F4w0zT@L@lxPD%5 zR+h8V#AV6^MSjKBJw9dfsY!?1Ie#v!l9v z{I#BCI+HW#;vcuH2E|=>V>>P3a$VA!TOoUhV;owG;^djQZmXMoBt5zPM4dC-e#AYg zxzL65wyjn!_m-I1ET{Kx2SC*rd%ev{wQ#kiu2f84TedW+_+UY_o{3r_k6vbdop zwuO+tbN>_n!!r`UC{~$~1>&4y$VYvv9lD>x*zzx&naK6;a>01H?U?7m+tsB@{nieFOjpJ%-p4;~v1`?}jvDLA zW_sq3+hGXt%I#3BBaxS)kjmvTzi51Uc1;ahdi!#po$B=<)0vz>_Xo?Pua4;FcF3)+ zetsOQX#Z*`_ZOFmQ_SB6q94Xez6}Horv3%SDCI&RJ{CyxDCp=I$mXYu)J)%JOtg}Qe|4iYj0it z>f#l@zcO7Bs`hRC<5iSzb&yQS9I{+H5vMHIVxJ>oQ7%VxJeH&7;L8i&3{R3wy&N)~ zNg8y2upGaYYi(<4`ajUhavgrfc)9j_e*0oK*N%&1FuHh6H0pFYJpOSSDc8!NnYglC zcerZ2Tt6y!ZT+cSA=bJvb?ZnhtxT8k%Kkry+pt`#;vLU~<$f-TctspG5cwzGtB)&p zkMi90CHhf>JU$YA6ONW-Iv))>etBc4FHye~hE=R-zZb@XWzA~_UX`E-PQ5SbS7!g z{XzWd?Mv4fLen0eROR%u-8AKPmhFb|?QBMc$kdwouD|^sQ>V+I;~#I_+nG9eWj-G! zZqeC5d8*FFlc$NEIznjL(#n3%f4KmqVsANrUbW zmP1{>xebW+=0)WT-aI9$e*!9!smuL|=C<+jeXgBdhdXb-$jf}%Wfn`WPM1N)Ki;^@ zcZ|U^6Xo_9LHwe#fymF8%6Z_LdEI8_s(D78-!ff%U)lYG_zlW=Y;h~gdxty5%So9m zy(}BojS|gnYdg^w$4fF@pZv2I|F{+9J%(V-nW8N3p~NZ6y9MbY24((R-8H@(+nlcF zcAUC;f_gb*I+HZ${$M%O<=xreOZ(8b__O1!ZKa`!s}GL@Xs3Ue*PrG7p7C;jcxle5 zH4>S5%iwhJn`qSOa(MjXj=S8)xe&}O5^^~rSq{lz(IKEBBXv_l=jI9X{XBw|lU1moEQx@r&(1rYl0%zKwtUitQkd zpv{@8+#bdguiPG^x^^KHFMqH+>g~bS-!~vY z_md|6MChlapLQgDS&ouDG`>CLkFva&_E_JwGBjQMCK`3R93KC;Qa{9j^AXuB4q8`_{Xg%|FH$j6wUFo{1dM%|F87rU%5Qi&x|imi9!RX)oHXjiO7G^ ziN5$flj+(-#mgTokGlM;ZV}O)NQz|IvfOK)8!z|!Hn)9uV&NoNY_#!;h}G#b&4q5Jp6R#}yuVX0pRxgb& z&$qUfJ*QgDT&-RnnXXtA?b|pf{pW8L_g30ztlC!$B zorqtw?<&*v$v=DlAbx{#A6wkY|Gh3z#>+|hAG4E>UAr$rm*2n2y-fcZu>MW_<5raW z7=krtda}HS5T`8fA7Uu)MPD0Vj*|K69~%?)X}@|oWcq)w9P09}y96nA?~04ik^1Ek z*UcXjuZY72q90RvcbPfkMS8dL)fueqba9(#)ai0~{PR8T@*ZRG%tTqJ#?{f-0 zx9c=z(r@`K(`DSU{}19fDDSbwt=!K$y)|A=s-MYo&+WBiZ(V->D(^B~#w+{rk6TgR zV+)pvPKVqtJ|#NA~c-09X? zcP(8MVO`w~hW8&0e`h?d7t`joZ24||A>qxo<}Kdolcj@qAsLxYhJ`dkeSJ z-=_34ZkhfoV%@v{AZ~-J%gQ({KN^p7Nblg}H51=Cq>fXj|IIjmU7a($K5;u9arXMq zU{~;_mh;td%Jjb&XADc0}%;A&qcuyBx zVt4n{Ei-kzGW{>c8^>8q!?-n{jmMp(!OKOfdhP$MT*&ml75bKK%k;k(cZ~l6mB%sJz8a6W;d8fr z4brvyq>fjn|HXJ?IC?kC-^1~UH!4&9eMRzDvr)$@)Bj?;F&=$|F#~!0(B+$9{;J!% z5V1VpwD6|u`e75s=?@e|FDt)xGF^|+0&leLaC^A$hWv}NVlOM6r3ueNc;bjCx* z7p;m<{k+@l^whT<-NAQvdO!b7`XGwY7tbHcbba#Ap5l2_Cu(8vo=htznI-bysi8V`K@0qf{Q&o4=Z8AdIGFZ1 zK@M5Pp$*>+V?~I3lI=GZA*~SPbq4+96MFwkIS|TxWjPL~+=%re{@=vb6>>5!`|5tR zT0^t-$@q-&n^U)GY6|Pq)!*YFrkSrVZSvaMIdOpCO$F1nx#2=4Ys~qAn7_C`>NNA0 z(;wY?)~h@WQx1<(4Bwpm>wa<4RXIGJ$*=EExwR;Zdbp)xxJ}QL+tkCI6vI!Y)?8N) z_frgiX}i6Qc$Qc>|M809RTfPjp#FZiVz_88S3Uf+V)*!-mfG4?l+%w=3?JmYbg%mR z=@R`~{)ul(rBn~MR17!$(A-x&+==0`{nfB8(F06azTuGNBh*xPw#&4&O0O|v8Ktc#2vnWN&n@P7)~et&x!q3tE zz3k7Ll*Q=Fn4yT{Z{2S%9wZR=*^B$P#l5cL`oDPQKsVH@fI(QFBq$Telj=3#h% zhHQ|LsL9GY1`jiy8z)nbV|Fr)W+0VD_opCEn4f35q$31wV4|Im2Me_(izmsN^XD5jpjOjpcW`&K=F#dFTu z0F=iC>C6n5-<>Ixg(wfQoxQ>fyC3V_C-npE#CZ|RFJ9H@+GJkz&p+1jplT1%RH}IX zv$ki5u5v_YKO5RF_Kt*8J|N^!~BY=yllz!#C+PW(9Dx`fobE*!>de}amju>;?p&2 zuMJ6m(88C)AoK09Dz2E;qqTF7L{<|%HInm{`KC^n!{ZT`Zj=Tz&`S-j>Wqs}#21z< zvG(3;8`8vl*@f^+$v%a<5}PktFLqm+%M~3q241Qs50ACuiR)!DU5umbVmv<9Cn|5l zw$R_OtvjJ5{^EI2aYgJ;ekuPqIdSzx#2Q!J7rQk`{4K!zxBGBqx-w?*{y&P_;0%^- z%3@zG%RzKJ;(fMsWI*j&H6Q5Kzixeqe3t3Dss4KX&*J@cCQF&G%TgH6*9vWm%-dGy zN(*(IGW}PCx_AFkoH3lqQpW3&(s;ZZR&BSr_I1K>b-XhDuf`k0nJne@mM)d?c-tPm z74d!Zf=B9jW%^%@H;yw|%D4~5Bkr4K_SNTQn!H3Ew@m-5amR5cOBr`)YUBA`KRES( z{;S>lspFREe>Ltn&SWX$wn}3>?&bCl5vHwEv{c6})BkGRs)HBZ9WS~$D7VMQ@re7* zj)yy<*4%igj$5Yx)wp9gqovH}u(ZbW`Cjdzp9guSSfGwqrvKG=V?3j!o5OH=^7o`@ zI>Y0gnCdlO<>R*UtjRj7VDUpqC*l|Nh|6?sqT)qcmoD|1*Yfx6!R10-+ta#Q&Yfs7 zAW)7P!W$V!m?{qSahFxrRGL&bU*1~L{I$NODc$qQ;(wh?m(!JfM{gg`j=mxMhhwI{ z4yz3QPZs68nCNUEmMe7XbnWqRvdS7w)ei4hUe1zO^CI)x$%QfwT3Wspe}3pH(-ZTR z>Dolai*DD=c{^%^(&vFi1J|C^gQq(}k)cfIJ97CWi9^g^#^J$x@xM;iE6H1pUH`Fe z_rq6<({|d zv|lynRm3IEhnQzh{IlM(!VZgb6=GNzfr{bsd>ViKw8whp{F% z|8MHi?%2g-lPYZ$>rZsL^_WZ}({-u8USocK)y}tvw!UJ!T5`_W=D@Lg~wR zB8W%ihm1$;Tg3Sh*`5t=HSG%zS~YCJmoMVI=*0NqRh_O)=EXjQJ6Qrmvm+Mr*WAL< z&%;NYxCr#nXv`T$?)O5n{W_0XxS`t`vCV`r1Lb~?B%_@!Cd2JboR^!=fP}iTZT)oOP|H zdg|*)<*>%ascrzx9R;$%`FZ#U_SE0oW6l?4IWi{>IUl3r0Vqu$=+_r&mo?$2`|ru8H9ROB_63bfZfxKuzrw7Sn?-H7M5vp~ETrB1zG#Ai7j z-fBDbXPKVRk39#>86@{p$@2Z$Pg%2{5Bd|BGM!|UPAwWE(c;;KXSc@ z?Z+B+sDPpn#}{JXC-;BK?MC^YQ4+fUFbB-}zTCcwDz>k3Y+qd3G&m0t&T!G$K&*$D z&ciHvSvzaf9>Yrw(yw4Ko;VL9)A?x7sm{YR^av2`k#jM}Put>LU3V`Idg+w^1FZ8K z9(Rl5Q1O4G1M>_{VYzzQz_gl^NxYksn3X)ZxbEwkitMb#@4QSG(^Ph%ZCUpqnlb8Z zp^w3dhyTS{koq1T95~67B+hkp-%`eN+DJT>x6^7~UCy4d|HpMRr;9-8T!>Y~Bhz)M zzh2`TPhCgdca+C#Aq7X)ayeeI)h8A@!qH=?c6x z-xu-8bUqq%4Sl=%a@|ifIpJl|!rwE{LtotVO*$&eRnbC*tdic1@BJc0(#s(-Fl$BpnmaEgmBRU(1 z)uBHBDTWQ7TjyDZH&^tfQg`2ocvYv1aYd&n=d?#hMZBT~5`SMWFE%-C!{FTQPs0Mi zwAiO_!pOqLr>EQ+W$8EkzhYk0Fivrvz@2%86i%!uz2;6eKNC~U$m846MQ?dht(v`O{X6+k0EHm_+l!O7B_NJ%OQQ_RqY|n>Jk(_kThvB9hzt2mApSG9LVJk3 z_Jj|_iS%9w#W0M;6wJY5tj1>S#u1#uO+3MSi2rA4ksBpZ74^{uJ`guwO~DF8;u2mV z8JlAP)I?kK!5q*ul15Z_A|7ZggVq?1EfD2|BA~rLM_KLC<-w(9cPt$1`_+sS;D=`udq|EF=PvsGD6{Yn`AUWlD|C;YrV zlhRakJ8_>*M@JQ1S56!>(aAVvx-RwC>mSCczeK|!oN70%ET`rrs}GWD>}JdsmrO=P&3UDo2HdQo2(rw_MxJa`6|Fl86%-bmI3yZ0|B%o2Yn+ zcU&=Nn|41h6`L+<%*fvDITqf?jYo?2zEX|>0?;{^gU6WIzKOZN0$@%az zU5upYY&nNXLqBeu4A-`MZ&9m>MFS7lP8RmIc1@X47seIySKj|B=Di4!*n``+1MwU4 z6k=y-f}F^OP>A0ZaqsC&Bq#0^s0y(RBKt!5nq1Dvcr0hp+}kWNCLLj-{d3EAlWQf{ z{7mPwvWsasoA~+$%HOZELBgZd`MEA`WpKwhM8{`G}$7cy+vfxHyj-&2TY$8<4Hq_o4(V z@4svFYT43ho3h;&-xZzcoA4^rwTX%s<8e9$1v+-(T8i$FRvC|_xPh2X#uHg2x%Sv) zxMgBZ*zJ4;%qy5`*5wYKoT1-pYZ0&LMS)i$;#CzX3Fs#oRhH4a1r1lcJf=ZFB#7s zQRu62!Y6`#QD=g7BV?VPVd#mSox-ga%t_G%spuG_DTZ z2i}boDxJ>~4Im#*R%Zy(2@H#C}ApE=HBW45<3(d_AFqPafHMAP)F ziROFSM4B_si8QwtCDOQkPo&xDmRQs8Vq%S#i>YSBGgD2DiAgl;8<}aU7NlmEEXg#Y zJcwrZY=8f`gZp6XyF;y z#m39e$APOGhR@%3(f_HjAzjQ@U9O$1Of_o)dJo!vVCp^@pV%LX-vyb@M}zLq7UD%^u^s?cpDN@=_lxq=}OxGv>?1{JG$>(3pY^|1ydHd;y%lmC)JS1y7 zHvhlcDf7vtV%)zg5!OjHXO4Tk7%+Ns3H@QO_I#lzS2A54oc?dS?)D_Eor?1!;&DQY zrhcyew1eQ|?%~hQ+_f8*=IaKC7IAbxh+#}fmak~y5}gf1eu(p>W$A}>W&c<2pk=n{ zW}2-2Ve?;>v3*-hWFVc$ClQxS*Cr}n{v1w9n3oL2|p4 z=^{z*GF-(Ln<-n!Vvy&Z`0cX`a+@FI7rN^*M?eG^KZOc&!Q zyIAA0524Z(PM6Ej>e4u!{xM(=cN-sf8q2d|tB}*O;*E$??jK~jZvOJq@BJ_`I;QXa zKIX3!v2Fy>$-eHB;j4NWhb=#kNe#zL_!L_XB&?sVrz>nEb`O= za+oqLVf`p`1oeAB)AO~VwKMC8| z_u7F8FMmA;Vp~6dG9zQ_ObiziuDAS2uIk23SU-QBXaCJ_B&?tRW^Vuay#B`eQO;Gl zuaoI=|0etLH%$&t=*OM|3F{~Jy!kf_NmxJshP4oT4FApbBll~vAA3{@Lu3vltRI;Z z|IU8G`uTUR7a7%mbN$G9#&nD)hb8n4b0A^;80N>n?Nh?~`M0eR!+4CXALV~a`Cjgy zlzll&OkJic=M+<#a(Ke~m~$Xu{luIv|CZE*_49986EVjT+xn6FEAd}ayqEXI#b-aI z97p*+rU>MJRe9|}&M&5M|1YMg*N@B}W9vkWC-e6IV!r*imRY@i#C@xxliQ0}2lBmk z055TE6Ut%A_wu{yetgDJf9L=*N^yy$YXJT zi0F&;BglQ3=quNO^1U2~QM8?Mm`qFP|5*;iw0^`CMBWN=eaLMpK6$PjNBLe%SKY~V zns9ue&Kce3*w#H6fKy%^h7w(;`vrG`0LVQK0cY4cI0YZDbOF}8d8vjrPn zn_@J-Slid%xtq5xSGC_()<)GDP-=mYLZb(0-G7hKyhWV$CLwx02&G7Z9oIW3yGZJx#T7uQ-a(G;E_-kuH615`f z>W-7;|Fn@fqI#NYx?cXez0|zp)71GP)8+hSKh`*!`3Aar8O}c>)bROUkt?DYhfxu7 zncmLl#WXLS4ccqp*mqPa@qteCO?Z{*+C;_6uLp`PM01cfomo3g1O2H0M^{^RQN|U^ zFYC7vzq`7%p_mA7BlP2m`VdbKjC*~B&ok4kEjT&*-5XOp9_yco7IBJlBhwA1PMv

2#^cE2m1;}wTRBVT2R z4z51bsO#Uvqcc@jQEi*pcZNd78A_aD{~(SlV(TuYFCMzzymzvvb+VTdTS`?*SDdoPtRIGZrwcCnU}G&v}9y+i1~}(moVlpr{DRycc?fP2-Oc4 z`w72WhWoRzSu~n)FdxG2Qq6ZQ$Gaubi0^eV^E~}EI49p^-$O=<{e(={CMsTP(bPpZ zu`9Fn4H6aX^CROL807B}pdZJnl`cMIJ-XtUOK$HXzr^-0Vimu^Vt*jcMT_&DRPm|Z zpNhI$Mct$#uhJnsL>;9WA?hg=bpf*&an@5$b)ee1>doorLw*!MK@>t^6hToGLvfTq zNr)9?0a3U_o>P^mw*Ea)VP<)VW5kLO_1jyaGOC~|XyQRzPpW7Xo~lPR))3{R7HnY$ zd(=i9IG`@-p*|X*Aw(Ukj&K51mulOpm3$PH2uoz3Q z6w9z2E3gu)uo`Qy7U5Wj_1J)o*o4j4f(UHIHf+ZZ?8GkYMkMxNFZN+S4&WdT;V_Qi zD30McPT(X?;WW12Q5LM4Kg9kQLdG9XTND;TCN^$q8N&!1VmdA zrC@>5utXV@g{aH8JSw0fD!~esQ3X{|4b@QtHDL{^6V}v%E$m>A+NcAXWYJK4jHVvy zqX8PC5gg$JQAukPG(|Hwqd8i@1ufAEts&}KZi{wkj}CA}N4UWq9_WP5=mJl4MK^fC z8={R2U-+Rr{1Jda1R)qb5Q3iQh2H3czUYVk2*m&l#2^gD5DdjI495tJ#3+o$7>va@ zjK>5_#3W3{6imf5OvenOCl9L&W$gke4wU?CP^F_vH{mSH(oU?o;zHP&D)!m$qP zu>l*g37fG65!i}t*p408iCx%@NbJF0?8AN>z(E|sVI09x9K&&(z)76KX`I1XoWprs zz(ribWn95kT*GzTz)jr3ZQQ|K+{1l5z(YL3V?4oAJi~Lmz)QSB6kg*E-r^nJ;{!e- z8lUhPU+@**@Et!Oe)vt02#H~eBrro#i1t=wJ^3klp9-Q9=QN<&ZB06)M+Rg>CS*ny zWJNY)M-JpfF62fYO zSfMhiK-TkLo%b~$+K{n^4Qjy_cCbfn)PV!)q8{p_0UDwa9N~nkJ&ijHuDJ3P<{ozVrJ=!$Oef;W8N3qN#+KLQYlAOxcaLeLYv z&>MZw7yZy5p%{RH7=*zXf}t3O;TVCD7=_UogRvNg@tA;#n1sogf~lB>>6n3;n1$Jx zgSnW8FwDmSEW{!##u6;WGAzdmti&p;#u}_eIM!i3Hee$*VKcTM0$Z^S+pz;Xu?xEq zi9Ohheb|o!IEX_yj3YRTV>pfzIEhm@jWallb2yI+xQI)*j4QZ`Yq*XZxQSc1jXSuD zd$^AWc!)=Mj3;=CXLybmc!^ht!fU+2TfD=2e85LU;}bsP3%=qTzT*eP$qW;4s#W{n z!jygzm?0^WLA0rq0x6LSsgVY0kq+sR0U41AnUMuqK~vVEIb=-^h*Q|&G_g3f*&m@8fPol3~(fsq)6(HMiV7>DtgfQgud$(Vwv zn1<!*o%GGj{`V}LpY2hIErI9juSYEQ#g$?IE!;Qj|;enOSp_HxQc7I zjvKg%TeyuoxQlzZj|X^&M|g}Uc#3Cuju&`|SBS!Eyun+%!+U(dM?~WjKI03%;v2r> z2Q;Q^|44+ypeZp;5}1MJuQbV!94SCEQ<_vr4VrS&q(wT=9FZmiG9nW)BMY)38?qw@ zav~RUBMFr5tTrb7@Eqc z0-B-FR6}*p#DbPAsC8b7>*GbiBTAhF&K++7>@~iFz)GybYOKLpgkv4nV*@r~6EQ~(IEVANfQz_<%eaE8xQ6Svft$F6+qi?fxQF|A zfQNX5$9RILc!uYAftPrND7?lSyu~}b#|L~wG(O=ozThjq;X8gnlZ5RbiI5nkNCGn? zMKUBu3Zz6Tq(&N~MLMKM24qAgWJVTbMK)wd4&+2Gkb<{vjSi=UjU<*6gqc-Zm0d-Li_0a$g z(Fl%kLSr;RQ#6BUBdIxBzy&SQ3a!xwZP5pqpieVUz5g3V47>zL)i*Xo_37CjU zn2afyifNdR8JLM#n2kA@i+Kpcd@R61EW%$riNxP{xegS)tg`*?tdc!bAzf~R5v{7kP(@X8Cj4O*^nJMkQ2F( z8+niy=E#TqD1d?}gu*C-q9}&qD1nkF1q+mhCCZ>I%Aq_epdu>43YAd>RZ$JqQ3Ew$ z4I9*gE$m>A+Nc8u)I~kiM*}nj&53Co;e^I$f~IH&XEa9(xS%Ckp*7l|E!v?yI=~ej z;Rbhjpc6Wy3p~*k-QWdp_`nx_=nj7bAP_+aMh}FbCwieb`k*iRp+7<~00S`ygE0g{ zF$}{o0wXaBqcH|!F%IJ~0TVF^lQ9KTF%8o(12ZuTvoQyAF%Mywj|EtWMOcg_Sc+v> zjulvmRalKRSc`D1!+LDMMr^`nY(WIJVjH$&2XEsqMQh)S?RWmG{`R6}*tKuuV~2DM-dJJ_Q(>c9bYQ4jUe01eRyj&MR_ zG(l4|gEN|=1zgY)ttw7=VEoguxhsp%{kY7=e)(h0z#;u^5N(n1G3xgvpqKshEc8 zn1Pv?h1r;cxtNDA%*O&O#3C%l5-i0sEXNA0#44=D8mvV))?qz1U?VnRGqxZCTd@t> zu>(7?3%e1CJ=lwV*pCA^h(kDxBRGmTh(~ygCwPiyc#ao%iC2iiYrMf*yu*8Zz(+*m6F%b$zTz9c;|IhA zeiI}@VwfTc%#akxkQ^zH5~+|HX^=HB?6p)Pyx`Pz$!O zgFR}a4jfPy^-v!T&=8H_2q!c~6EsCLIHNgQzy&SQ3a!xwZP5pqpieVUz5g3V4 z7>zL)i*Xo_37CjUn2afyifNdR8JLM#n2kA@i+Kpcd@R61EW%$riNxP{xegS)tg`*?tdc!bAzf~Rzr z3$h{`vLgp_A{TNa5Awns`H&w4P!NSs7&OzXDT-n!juI$|Qm{a2SfUKdq8!Sj0xF^s ztWX(MP!-is9W_uB*04b>*uoC>sEs;sKwZ>BeKbHrG=d|X&=^h76wTm_=4b&Iv_vbk zMjNz6JG4g!xS}K6;0_OTLT7Y=C%U2=yxMDhF~a$VK_!$Bt~I0#$YVQVLT>aA|_!nreG?jVLE1DCT3wa=3p-7Aq?}e z01L4Qi?IYtu?)+x0xPi!tFZ=a5sr0Oj}6#}P1uYrh`?5C!*=YzPVB;NL}Cy2VjuS7 z01o014&w-p;uwzO1Ww`%4f~u&7>ZpO5u!aq4!4`I~M{U%B1L~q4>Z1V~q7fY7 zgvMxsrf3FdG)D`#pe0(NHQJyp+Mzu{Jkb^1;015^z!!e#4u1q7 z5J3n=4}_p6dZ9P^pfCENKSD7812G7LF$6;~48t)3BQXl2F$QBX4&yNa6EO*sF$GgG z4bw3LGcgOZF$Z%o4`G;(1z3nhSd1lDie*@i6YQY1riq(DlfLTaQzTBJjIWI#q_LS|$^R%AnVq7VwB2#TT@ilYQdq7*Dp8kQ)7vM7i0sDO&71S?cV6;wqvR7VZegf(nX3%0O> zJ!+#498eeaP#+D@5RKpnCp1PAG(|Hwqd8i@1ufAEtH@L$CozNLw z;EAs21}}KS2fpw_claX!fe1n{dLRTn(F?uN2Yt~G{Sk@*7>Gd_j3F3`VHl1P7>Q9B zjWHODaTt#Yn21T3j47CkX_$@~n2A}KjX9W$c?iRNEWko6!eT7JQY^!AtiVdF!fLF+ zT7+XA)?))UViPuF3nH);+prxwuoJtm8stGI^ixPhCvh1YXkRJt55QR_}MNkyQP#h&t5~W~)(y&Asltnp|M+H`@za;DEZQhx%xMhG+ywIH56`pedTc8O_lGE@+8XXpJ^# zi*{&_4sbKWK6+SOv7}{z)Z}-Y|O!2%tILFV*wUo z5f)A1upS$*5u30XTM&V**oN)cft}ce-H5~@eSYc1De!q|44+yFhvrWAt{m}IZ_}c zQXw_cAT81%Ju)C8G9fdvAS<#VJ8~c=av?YJATP|35BX651yKlvQ3OR%48>6bB~c0% zC=E-LL0ObTc~n3}RDu;MqYA2`8mglPYQh>es0CZt!5+0y2M(x>EXoyB|gcBO0 z37VoAoY5RD;DVNDh1O_;wrGd;=m1xAgd5!9flla*F7QNGbb}YX;R9dzp*#E$fItKx z7(Ebzp6G?%=!3rKhyDn~01U(+48{-)#V`!V2#mxijK&y@#W;+|1Wd#vOvV&U#WYOE z49vtV%*Gtd#XN*zJ{Djh7GW`#U@4YiIaXjLR$(>PU@gM24(qW28?gzSu>}#>if!1A z9oUIo*o{c+!CvgcejLC-9KvB7!BHH;ah$+OoWg0G!C9Qcd0fCnT*75s!Bt$tb=<&B z+`?_#!Cl89p2*uJ|Y^Q@EKq572oh3KOi3D zGeIIGhAEQ33`vm;$&msnkqW7i25FHF>5%~$kqMcR1zC{|*^vV|kqfzz2YF$Re8`Ui zD2PHRj3OwCVknLhD2Y4({R}?&AR-;t?L>37+B^p5p~x;uWIs8gK9x@9-WU z@Db7YgwObbulR=V_yO?{uL%+%F-(yJW=M);NRAXpiBw39G)RkdNRJH2h)l?gEXay% z$c`MyiCoByJje@k8KuMH>1xmvbWl$F7P#zUf5tU$t%BX^> zsD|pOfts*}4Qjy_cCbfn)PV!)q8{p_0UDwa9N~n= zJvzV@9pMIdc%TzHqYFII72V(kZ}`9$e&`N=1RxMW2u2TtpeK5vH~OG2`k_BUF#rQG z2!k;MLop1)F#;no3ZpRwV=)fnF#!`X36n7eQ!x$GF#|I(3$rl?b1@HLn2!Zmh(%b8 zC0L4OSdJA~iB(vQHCT&qtiyV2z(#DsW^6$OwqhH$V+VF(7j`2Od$1S#upb9-5QlIW zM{pF!a2zLa5~pw)XK)tha2^+M5tncoS8x^Aa2+>r6Sr_1cW@W?a32rw5RdQ}Pw*7a z@EkAj60Z=2*LZ`sc!&4+fRBjACw#^ie8o3>#}9}H_)U-qiD8N)Fhf!#Lvo}*N~A(+ zq(NGwLwaODMr1-}WI$q8N&!1WKY5EKnMj zD1)*nhw`X^il_uDR7Mq4MKx4M4b+4+Y)}ifu!B8nqYfNU7xhpd4bTvc;0Px)MiVqe zGdQC;TEGP@(F(2625r#}?a=|Q=mZ#Sju9A%Q5cOe7>jWjj|rHFNtlc&n2Kqbjv1JV zS(uGEn2UJ`!+b2jLM*~!EWuJN!*Z;^O02?atif7@V;$CG12$q4He(ASuoc^|9XqfS zyRaLP*n_>;hy6H!gE)l4ID(@%hT}MalQ@ObID@k|hx53Ai@1c#xPq&=hU>V2o4AGB zxP!a6hx>Sdhj@g?c!H;RhUa*Jmw1IJyv7^6#XG#m2Yf^{KH)RI;48l2JAOb^-eH17 zNDNaXff+B~TKjV1d%GL>ZJtIh02QR753Mp)#tVDypG6YM>^pVS`$*g&pis8+G7- zx~PZxXn=-j1V=cbF`A$$n!y>((E=`LiB@QhHfW1>XpatXMMt>79Uka}&gcS9bVWCK z!5cpCg&(@Z9{~tN5Q5PIA?S%-=#4(;i+<>jPz=C848mXx!B7mtaE!o6jKXM)!B~vL zcuc@VOu}SL!BkAcbj-j^%))HU!CcHk80KRE7Ge<=V+odG8J1%OR$>)aV-40K9P6+i z8?X_Zuo+trfvwnv?bv~x*oEDQ#2)O$KJ3Q<9K<0U#t|IFF&xJUoWv=d#u=Q&Ih@A@ zT*M_@#uZ$}HC)FH+{7*1#vR16wJj5eB#uGfnGd#x&yu>R+;WggiE#BchKHwvw z@d=;t1z+(E-|+*Y;vN$uLSmRA3Cxfb$&ef=kP@ko8flOg>5v{7kP(@X8Cj4O*^nJM zkQ2F(8+niy=E#TqD1d?}gu*C-q9}&qD1nkF1q+mhCCZ>I%Aq_epdu>43YAd>RZ$Jq zQ3Ew$4I9*gE$m>A+Nc8u)I~kiM*}oOBRIkdjnM>6(G1RLjuvo1OSD33v_V_6Lwj_9 zD>}jr?(je-bVe6=qAR+=3*PX7FZ|FQ{s=%If)I=z2tiNuLT~gzU-UzNgkk^&Vh{#n z2!>)9hGPUqViZPW48~#{#$y5|ViG1}3Z`Njreg+XVism&4(4JW!Z05Tun>!|7)!7e z%di|PuoA1V8f&l?;aG?D*no}Lgw5E32yDeRY{w4l#4hYcB=%r0_F+E`;2;j+Fpl6T zj^Q{?;3Q7rG|u2G&fz>R;36*JGOpk%uHiav;3jV2Htygq?%_Tj;2|F2F`nQlp5ZxO z;3Zxm3a{}7Z}ATA@c|zZjZgTDFZhaY_>LbCm3EmR5fZ}`NnnPgNQUG{fs{yv)JTK0 zNQd;ufQ-n5%*cYQ$cF65ft<*N+{lBxFh@S*M*$Q>ArwXt6h$!FdQQ=5~DC0V=xxuFdh>y5tA?(Q!o|NFdZ{66SFWI zb1)b45Qh0!fQ49u#aM!+Scc_Tft6T=)mVeI2**0C#|CV~CTzwQL|`knVLNtUCw5^s zBC!X1u@C!k00(ghhj9c)aSX?C0w-|_r*Q^naSrEk0T*!zmvIGGaShjT12=ICw{Zt| zaS!+L01xp9kMRUg@eI%L0x$6jQFx6vc#C&kb<{vjSi=UjU<*6gqc-Zm0d-Li z_0a$g(Fl%kLSr;RQ#6A!nxh3=&=RfC8g0-P?a&?_;EIlLgF8IX37ydep6H5h@Papd z;0r%=hd%-kh#&-`2SU&jz0ezd&=>vCAE6k4ff$6r7=ob~hT#~2kr;*17=y7Ghw+$z ziI{}Rn1ZR8hUu7rnV5yyn1i{PhcL{?0xZNLEXEQn#WF0%3arE`ti~FwML5=BJvLw? zHeoZiAOc&l4coB;JFyG95s5w6i+$LS12~97IE*7WieosA6F7-eIE^zni*q=S3%H0& zxQr{fifg!z8@P#ExQ+kE-g&@BQG9WHLkXctL=+Iv(4)xF5osm_LZU!o3WO%PB%9>m zau@C{kRV_L#fTzNq}XG}j^(fD--7yAv7p!hv4J)AsHljA|L^VYyPMry?kL|Y;8YL=x`Q5|C+G!wgFc`yhz6&D(?LIQ2IvngU;r2h z27$p~2p9^6f#KjxFan$fMuJgbG#CTMg0n#khy~+792gHKfOs$wB!EP44mcM~0+YcM zkOY#!c_0O(f;5m0rh;i8155`qz)Ua;%m(L!IUo~QK^DjcIY0)vAP?jN8<-2`0XrxF z4&VfZU_NjGH}HTWumCIs#h?T%0vCYAUQXuo*l7o&^5|Pl2bwGvHaU1w03y2QPsC zffvC`;AOBCyaHYYuYuRWHt+^`6Kn@>fw#ds;9c+@*a3EeUEqDN8+-sh1RsHq!6#r3 z*b6=dpMlT87vM|q6{rMXgKxmM;5+a=_yPO~s=!a+XYdQy2Yv;=f#1P?@CP^m{se!4 zzrjD?AfONRhJhxaDQE_ogK*FSM1Yo{6=)6GfVSW`&<;d`<3W3H0_Xrv1Sf%xpcCi} zP6k~-SI`Zd0!{@{pgZURdV*e{H|PWUf@p9WI34r@XMp~|0tSGAU=SD#hJc}97#I%D z1S7y%U?dm?MuRb6EI1p)fLJgN#DVc(0*D6_K>|nw=YVs;Brq9F0ZAYkoCi`sDo6wA zU@DjfGQe~&1Iz@oz-(|nm;*9_6=Z>IkOO3p3-Ulduz|T?9)GPz*}IB5(m%43>bU;6hLeE&|KIa&R%Y1grp;f--O!SP3o%SAbREN`TK$Ul@fV z#NWFv#|N$Wd)M7wTAxd=mzQbb^u6m&djfy&IszZ`q2rE^b+r8OKb>$S>LGon4vyuD zP*_y^-t}aw&7piAU;pLnQXIqI1&_gpwdm8Av4DL3?&t>S_h+^zuT!URX>q@=TE5=* zi$~fH#}06rfb?KF$wXI85B#8Fe1`Ai+w>g+O5gnMHtHP=7X!%t<3Jo34<>+kFcBnx zL~sr`7fb?^!4!}LlEHZ(1*C#BkPfDTX&?hk2Q$D-Fbm8E=Yu&Q6IekO$Obt;2Du;) zpz|~+4xCX2R>%e-j0bC2N1J{Eaz>VN0a5Ja?w}4y0 zZQyor2e=d51vY}a!9Cz!a38oIJOCa9o4`ZhVekle6#NG~1|A2S!4u#~@L%v0cp5wd zo&{ULbKrUK0{98@vPF1@D0!U?lB``~-dmzkq$~fTI3LUbnZOFNKsLw$GROsaARpMkTrdyVK>=_8 zCnyB-feW~S2NZz?U?C_5C14S_04xSez*2A_CKWq_$bd8GY?Mgcl_f+?8Qy62kg~Uy-u=R5ekcH*U7ll z)MS^lPd(G=4Y+zm|&FiFjojf|PlegnScn7!>+yyp*yTLu+UT`0{A3Oja1e?G^;9>9x zcoh5xJO&;Io52&{N$_9r6nGju1D*w2z;obv@B;WBcoDn=UItsiE8tb|8h9OS18;yg z!FKQ#cpJO}-UaW09bhNe1>Og{!3W?&@DcbJd;<1>z2H;u8TcH00loxZflBZ-_y&9n zz60NbAHa{G3j73q2ETxP;8*Y)_#NyAe}DtvPw*G`8~g(f0twxUFwg`v1^ z2+$I=0z)EmAxB{#KSAx}`99#vi25Z1IU@ce&)`Jb;T5uh>9^3$K z1UG@3K?S%4+zM_3w}U&to!~C85!?;#0r!IY!2RF>@F3U(9s&=8N5G@tKj1O&IM@uH z08fJdf~UaK;2H2N*aDsd&x04h|GkS?ya~30x4_%r9q=xA z59|Ot!7lJV*bP1aAA*m-$KVsN2kZr(g3rL`;0y32_zF~lufaFqTkswD9{d1)1XbWC z@H6-Y>;u1o-@xx+KllS20DpqNz~A5>a1cnip9lj@KvU2RGza0J1&9DGK`YQ2v;l3w zaiATD1jmE+-~`YCoCr<=9YH718JrBdfUck$I0c*vqCj`h1M~#FKyT0o^aau2G;liT z2hITffdvcz1Hm9L7z_bJ!7wl!oC!vNv%p9&3XBG0z*ulLhyk%+9Ebzs!2}QwCV~Wz z2+jfLf=OU9m;#bOGB^*UfK-qM(!o?P4P=1nU=_8CnyB-feW~S2NZz?U?C_5C14S_04xSez*2A_C8aG z?}MwN+e&vo8ohOGMsWxF9tOG2fX0hit_X!iwfo>$hphm=0?skq4{yLRtjE?r^m<&4 zur(n6_omV>TZhu{m$cx)Zy&KWp;_R1SChP&9?7z+z~*-2AKC6?r`?uaVwq}l+SNbL zPH^Np@!M>QITLl$9M3lI)0d(w(7;hCxCkr*%fZFq60ibX3aCC^23CU0!4+T?xDu=e z<=`qnWt!?AZF9NLI1s$tKYE;_v}0sT8h+5Zn&csrd-_}a!ogZ>qCS-&=rd?ivnfU4 zt7mu6j&BCPxztQzxlT!JgrH9X{>Cf2G=(Z~4BMyd&*1i%`bgeoWv?wNGNxOTJOq7` zUA6_*?2=U3;kJ2f3uMa#hc(MC(+H7T9$3H1ztE_{#RBTmOIP%^(`iIN{z*mCxAOmP zDpmfJx9_;}KTq48OP0cQ98mkoaz!XC(yUo-OR_ajp5(OVSm-CksWwNp9Ggv=Ao4xf zH&FZ39N`gw(m4Ti1N{Mwt5G4k3p9nYG{#zhw(fbH0)5{Nnbmn$3;R;j=GuDKC)a93JYo$ zZH~NT{1x4n?Qyy+sj_EMTynDSKkErLhsToY!Qa7YTz&))%L}#GYD?ksh3LJjbblir z=MAV~h0d?0GR1QBYEeT3nwa;cO^#D+8#vsb&--%6+W71sci%F}3WEHB`EXG9Io^4V@;(%Ra@=>+G|Px4ExM+brYy&+QHQyiUiP?#Q)( zS%2!DH(dVNr(CE%0x+$EJD~u;Y@5d2XdIp8*wi`Sc)4Yq zoM&_Rwi62q?H2FbhJ28yPh{u7`p_|txtjD{GUuc!KE8#r(xRH2!&8g0T(a9)glQP@ zHoHg0z`iwC9_Ml{bYr;RlIHYS?Q!{X_B?tdii1i4wJ-GkWw}A09E6d5=v}2bs}_}) z-4-tG-0Z>Ij}u84QL^~ zx#y$vtA6fHQ%e=c`NMLKmwh4q6y%Q^7V(K#BR3gCpI4$@TY~6CX`RyRweuG)qc^`) zr`qTHYH|+uDdDxtgkm|n$b*SBiZ;`1b~~QFxI8KH{36-S2BUcroL>oD^!BR2%R!W1 zRija6ckX$H()y_V6Qh@JZ$6UN$*Fb=t0q@NG0%WXitI{VX!B&}qx4KDhQ%CKd#cSN z+hM*`+afA9y7zXshoHywUJSo7b(Q~%p_ z(h5$8^)Sjg+^9#QEEgDULHmm3rOKd(v7Mp)yUg4%t$%EXw`iRl)gxLO<%$>!f8}L? z?C=CDG@@Q*-SqbHr`LCdza__i<+y>e4)Ch`kaQY z7c5sI5Eg=7#u}dHRMk{!y}mV4-?!y@pLuF}#1uIzj~zRs1=P+53I z(b18YB3s=~2epM_ds!T%*9Wf>O6|aQya2Z_qqUV1Imgv%{;5Bv(eFMKM}8QzX1ONz zdZ}o$T{cgN#b*hv!RC-j@&ef|Rp1EDzfRqQ=bvpx+nw*ry;>T}JIlQaXe+v_d_rK;lGU~?kvPV8)J-D4P$~ios zeo48xY58)Bob7bwXa`ilXL}{|2yU;D`%11Io|^7$*I6H<7_jqSKj&o*jC41?X&A9W=K@IaI8F`$N#{tj^^XXFT3%2dB$+ zGRiqTpkCVNHBh{C_9^cb+&-VK8Eu)p>P&idRdK9`QO@B3_0W|kUA2=+5doK@$lm() ziLQZkU8%ri@j(})zl&9A?6TKh`sVS8Lus8H^?zw;lq+H^gzKFp4h@wp8~y);6m%%j zup?Zo_XGRr)2BI)r+^CR)%(hw_h;N0F5T95#wA}p(B>O-F%?I4q3a#XHL=&z*+sjk zaJSo{wUpzbjm@F9MXb-^{tgOGNts6}_6N2Gu@9Z}*lUM8`px#==~J4- zvDd4meJsko8|KiKA_guu34QhX=CA*>^POHhrXByvUQU?rBaLzn*XgAsn(ne&X!@*^ zUftGRSGOa5N|Uei{?hOMWv{H4XJ&n`ri*uTuzwhqET=d{r%NAKvpB0m(PF&SW6iR< z)kYWxlmfQH{%E}&dLpbBNQQj;udV*UsglN<3UmiO0G+?Ta$J5IwJN^+GWKgJEWXp;NA6u+NuK~v zT+8ObSSTzcw1 zb64D5zIN8@)HuS0g{kci%T=jwIo0a2DJ_fJqRx+ZbE`w$f4SHbhbwxX(^aA!BI>ir zpbyn$DleU2*g5ZS>%Sd8s?0mLV&12puibte6?!<c^b4GCRfAhdlP1U!yMMl~H_W0q(wW+4mTO|K=j*mw)VmLL26vj1 zd$Dw#5N<}eyi-EoqFqEFJ6P$`l=&6Nn4{_4aK{1La$J5l+}wHwUW5aq>H?L zvK6-`bQ1z6>J!mFa6Traw~%taX}7kj?B)t8|K!+iELWwzWp#Z>6T16Ov(A$pq*K1w zc9!B$Za2%IPq6m;fAjwSrdtymeeOtcY#*bX!)w;ZSw#H~u^eq55ZE3R=Wlm>-+IB{ ze_p`xbNWU(hwIWe_B)hOP~7xeO9m^3p}R+0F`Gwe&iT`P3J9 z1MSuSw7{$V?PSX8WC5{WWe(JrqtYLSE8nBpg%1U+{lT(;68Nr7=l$;dC2uPOOxULU zi^kF`r=0|s=s=&@YRA|5(i3SmyfPZ1m8WSoM~-u$MHvW5#%BeM{pqR@^qF;2>E*6( z@mVvzo*`}0$14|fp;f>7q{wy*aE&YSc$^NsI=cIwvO&S^bCYM|rC&UHW4KWtue@&h zC>L9YC%4G18A{Bz{e$&-J=eFTGLGE|@-}z1{ik$DGwFogCqLKii>{Bf|Du(m!65WU z=(@&ogIdx=m$fk8mQC+~(R&QYyeUps0WPzP=ZLY-wdlk(>5q4kF?v5{65a#PMmiVaU3D~`&+Nu`1G z3U?D}HzrqfM_+tnUUTW~h!zsr5hhaZW6GcdxA%Ku_4clWE_9hHos4f7Y)w@5|L2i$ z)B60>ekGM@a!?!hf?*QN6``=e`(QK(x4Ip$L8Yk0m9Vh3D~~^5d~^b zg(!8a&6WPAss{&{t*7cD9>14)A7dmXj?o+-1fKc(JV90&!O>AKKG;fyiDCq z3p9oWjP-@?bIkhE7?w8UJQgfqtS|HoP8&Ko7EaGR2h#!#Y5`+?F|RKTYF;z4W6T2L zxI*E$X3F!^*Z}AF?!XUA60d8sXsfml_ubypbqQ%*H2#_;nM59 z6?%#3lHM^uypLzQQTpOKZToXE5Z34T3hj7$4v{}T`1tkv%kplD?0EY=9Hux`$1uq# z=kQwObH3G)CtGapIXvHn;@Al2{7ApZ3BmR2eD;qQZ#Z#14H+qp^)t#jye|3`=H$*P zDx{%8pQ;szkoDXYf}WRM8u4Dmr&Hc%Jy=hpoWpCar(2z#GzVj=a&l?iA*LuwIjg3tO!P7JQ^U$f$uynfZJYW6hB z>!U9|9GEB1$&($jIww<9T5NwdhM;e=U#?yJ;YoX@sCHHBdKhXv%UMtML$|NK22~&e zwqrsjJuUV^`joWdSWlK~Vy{;VJq0_~tZxNk=6sJi zC;0U+;+=6N-xOT2pA}-gTN>mXUJHE%bC5yK;kD48?H%+yqM@g#hw(hNBb@HhV*!QHIvyG5=4Vg&^!)Xe&y7?c z&S?A5-bOis6jzJ$2-xC^<-2rJa6Ny!r7)@g*B_>{9&|pWr%}$~wa}C89Z+Afd_+$U zuJ1KJzST1AjRko6qdL~tDCh86=nFk-zA}h*-4%kKQ%mP;yylADGzCdd#?SS>aMg=O=A1+vqOceY~nscX;$X zk>#q?w~TWZ6gufUmh=*p%`Q*2I&e{SSyHU@N>Q5CJoZyRSJUQB>G zeJ!3xK8`kQFFp}@Vwf~1Jxu!KwlJxnSrcgh9$Jze`FWyf?_IDrSsc;T=voi{_|91q zZyd%uKz+rvF~~W5qSa=##1?t-<7s|B3_S@iAH`;8)4OAC3uc>5aJif=y2qlg(@9bk z;C6XG^bymev`V#b>W>#E>*tw8B8-Yb8A@+Lv*V($Dh)3D;jEPRE2C+hoT@M0uQJHh zP|OFi$8BBhzsYt^r> zS0MebZ|?YV=l*l1(Z4Rp(fL#QELViWqI&vV9WCjFY0e=9Hiz4iT9i#Q%IL6-h}T#@ zDJe>au5FwrbpG_rA5}_urp&gYdQ9(zP+g|7LlgUHE&!^Tgh%(v_hO^q_X1Ri@EBjI z-y`6k4dMaK6QBu}R$vD-2k}y{9^4I{2Je9HKm?TQ3osQ@`M((bw~PMiK?;us7Xtdm ze>W(<2z&~r;v{wf8wyuzoX8fi5+`HF$>ie!`7)f$)5!R)IFUOr5I++YVFKEU{0{h6 z02-&F&PWSw#`CBbB|Y)KgTBbKGw|(pl#}6S;#;<3kj{8~zkd?I74_g8v_13i|AB@0 z@4zM45ADgSCEvRFEaRl5)9;!Dr63Aa&1tcvN1*d0?c2=#1N9Sg7m9@!p1rGt{&jV!xwJ z--bA6GmgV&flWx7uWO|l`u3r8-3Fz7h&T)X&dB`r-u?LA_N*>1zdZERp3j~|jXK<4 zfUYYnSA@a>?Ewu)WvRowXch2>g90nQByPd%zu4qN_h1X=25QsW+?Mpov2!4uGjT%N zoaB_GR7i?aeg>$_)qV0|~tY9`%u&G;+3{IBQsQEEe`{FjgPWx1fL zvRX%dr^HT8oEV!nLHRGO*v?UX<~q&3G0le9PCz7Ly10CK)2&VXWm-JSxG?gYTr42n z{mlox{_D}ZJM8}A^%0aH9PLN*FIlb#g@xX}6CC*DgPiV`l{s(e4v$TJXJ6mn8F9W| z4}b4lY&^9^yPwXs#%bBC=+OjAmJ2EMGCqaEp>T^a zEGNfldr~KtuOG>Cf{z~+#}`e$Cd;loIW{BB zCCllBc)3g+C=vThn}X<5`c=5pZr{^yzk6oECv#q=R!99eI_bl5)`R_;_0e9M(Cwg& zqKzDxa*RTk1;Pu1GH%%N zC(`NlRmEZG0j`5&lq+H^g6V_rA}G6xdKBj9?ZRU?Jl;hIy#Mv5pHBR(+qKHUSg;;O zIfn<(!{aLPed0>YA4%4iUw{3;<7eNwbl|kMKTx?QNBPqpOO`7_VWHP!8s6}iy#rsy zyrIKN0bf5#gXpt)b-2_s`_&mA-qzxkGpXYNM|Pq5&vHd5ECT66c_Z2*GB^13>#lj{ zf7{LR1xBJ(M?O6_Wx0^FvMQdlQd||2Xaj$EQIkGUky_%&=Hp7S!uF_wK2&F7DG(j; zuo$)PRSx-Q!{4OgIO)Bu-~E~#Iaihj(w6#OW=p)C>6NQu?=p^lT%U`tE_md$l0tc~ zWn7A7l5EYjq@*gzWMWTBUwlrWq)j&hP$rBNLa_;>qJs-p7+t&~-~;Nohf(J}5_-7ySH&+@5snn{S_eiqr}5z)|uovGmFnsc+%${1WkEwW|O>mcdE$ zd6wc3w)6fF^w@TD`N0ozI^U$+klGW{=QP`Q%r{}hv@|#I7 zbzPa;cg8~ZgOHP{#rC2C;p8ZT!T`1FIq*01!+%Quc(&z+QQ^`K%kj%+jJvXJQ|g$* zVTeJg7c5tV!eX*>t`o)2>cCfdEJ~TASFEi$lVBr9c1gNh+qVKf+bPDT*TY|X@x$2P zzZh|D2BqayPFy193H}Z`r~Abame&~wRR=s8Eq6t1z`R5KtHk_+es_3y63`= zN%!79eC&)X)vKR+?-GVP7?$I3oeTKhZlYUxH)5f@;cYJ@m80qj5y}Scq?c>H76sg6K&Jm!DI}8dc`%pH0t!l?(aEWwwF=P;l8gRSk5bwi)7`ydPxpE@00OEL$0CvZy?aI zQGo14?OtR-GwI3ERqthY$r)Oix4RWtuT%@C@v?G+2dmFtp0pryMbi<=m=O+DeEJR_ z%Sk3WL2vKpL2y?~-$kW6H(h>4JA&uup5s4Rw(!Fze&#fGC@VW8qnyKq^!f7<)xSzo ztrgMtt2c+BSEtQ?4;$8JsrUId=ciH5dR6~UtM_M>V%1PSQb5N<0nW!=(1-K!<9>Ta zQCecZD&MK^@6xrCnzu}3?t)eW@5idtde{CNf7zI6RrOTcy)e{QmeW3>3!ty^Pfg`X z^LRPiMt=szfucV94f+`GzbPH(8J}4CpV9RtPLu6tlyi7U`p}#K?SKmS+-__r3|`J+ z-<`Ix|7p*ZaC)qdQO@DMa+X?z$KLp$6<)>HZr_xPmRre6_1da@ybbr4zJql0#$x6N z*RSpEukL*}a+HPBXZ?(F4)-M`=$DA^lsM<%UHEx2z7`T#K`o*R_-w~LA?VrZp8;3B zoB!_RtOx69lykUWJu&1o-dTVqBN0EC4y>lAU#Tm&9Zzf4|M#%T<6h_V)qYBA$tdS= zpMJjY_WJ)0tDi;%k%;*v{v~=8EuWY^NTprIL{iuJ!a@LFen)KtFLhtuj z{j2BqIRVGrP(EE_{JEOs{`UR1%EWec;{tv8$$?R5++aW8`4AU=)gyb#A2Vqe$E|7C*G8PBWhlG^j4RwTq`#s{k2vsYNvAVD7pvvi5&=~oC zr0Nxo^QHEa?M3I#_eQEk)Mc5rAN9*J@O5F@FBXvPXr1oM#qT2@tore{CYz(Da9rfm zeHP2HsdGX*L05rnJY>*X1WQ6%T5^($mZ|F8rBL)0%Vqfm!S#LX{cYC_U9jyZqrNQH zDT@t3U-~kc%_ZZ4ieJ~__SvuE`8Y<@+Zdm5yQX|F?q}StK!((m4&@b z3L{L{xE3(;r*Z9D-`K@=BWiK*cH`rS$-^pJbT8y|xj$)?bGXoMB)YX0Zk#oHUY-jx ziF4$f!T8oW#*+$c+Koa54y5`_?e3Nk^m%*2L(h0d+!m$k;k%DwIqSi`_byNUFt3{i zgXdw+#$bGw68gB5X@@lBNPUu+quwy!EVKwjdzF{!um8sJkIf&3OGT6047~B-mu~H; z9sfCe>OZoa^?+OcN-9N9S<1@)-Cq4Bv* zsLwpE^ZMJb71BMQSl>%83R2&1jFg-M`nY;OGhQ3{R_C8neP_AR8p7noq%1c^uW81< zb%71P!@vl}1pFbRgq~XD$vNtgG4PE29ZX-4R;s~4mtwy*VwrxNiuy)$hWxxbV|cjq zOzxLS<3B6D;Z`l?Z1{9OEZ4+dFV#lR2I8!EXT(BphtO*f>S-j>3&j|cS3lq{>QQdc zBLcBepN+pe9DP=}G_=(T)BkAGY5pHtN>2Es2g^0F*Q0;LB)Xk;>YtJxsz&Fe;xAG8 zFfV@4r0!Y@kFPh8%L8BkVor>ZI$!kAvM(o|x8MXVC3@F@^kBIr_Ifqyk)U4jDzGP~ zzbQ!i<<_>+DbQWEcYg?t<;!)vJ(%!=+l~$?L>OrX`!!9PP2LPQ>_JZ z65g+|IS{Vw8iggdBN>@3Ho&LvtIrNxF z{MnkQPw@(UJ3}_7bL97}%6hbr+)HkLxV-myC(`3|a-=IvdM z$Kz3@5Ywas+Hn)0^o{vXb4rbl(=^Ht<#tW_k{yihNYGa-ZW_xB19|+5?qfDyrY~>C>nt78 zbM?r(KF@4VmlMUQ<)U3RIfwhzCoSLR%E1&&4<M0*h`pXlykVZ zCh>im`iC3!w^Noxx8d(s_)pNpX{k6^EC(B|P+NCu2dRE?S5LSa!&FYo=MFGqY=C;#s`k}fpvMr|EU>!Q3C-(l>8 zZF(=6Cgt@2eLz1j5YRv}ed9O|oD1l|I=!oG14UptSOabco5364OF;ichyvq4K3D_r z+Mo0X7={X53|;^oQ8KDCVe&o?=W5* zCM7={Chh+sOnULuCXy?&iS*XSCemwvG?DVsno6%e(Nr4U5AU4c(@YvRqPf&_XLIR~ zvT*6wq!!YRmI$RhAgh)49L4fHa1~A*E*AJJH|1#&(lc!lu zc+rJiZql6Ua7Zdz6hwg2_g=U51kr2Dv$`m&tj6kYxF z_0>#K&w;B0>lt-^g!Dz*<6>v0d~)g#?E=X8&2mvkTCba)a*p`h4~j=Dms^AAxjnIk zbi$NLm3d=gc4X1PaHz6Mxn#K_6c)A6Q_XD6gcXQ`^Etmfu>F#)5z>%Pe>rK}i!ry~ zYRG4n3o0qAwa`ngFWLZEjuue`eAX}Gs=)e{=0Lw~m%nu0=QoVmVbo8PYteeWI_Otu zFVQMBViEJTB8YyQ@*<>*GoL?o*r>!y^R(*}mp_(!71LH~q2G8L?vQx|HVVh{b$<)= z;_LoV`ZWnx2fyx5`Qf@fSH=J3onNk2pXQQLj%XE!$t+G6x>zOZ?bSrw zztgFRU3q1{C@fjeeCWY?zIee{C#6xUg_E9@2*+j4dq3oFKF)`!t9R^cy0(J*;}l0z z^a@#yO`YSvOX5eE>JKQD-k)zUyA*qK`P;KLxSgK(dP>6F;Zx7%MA%M7Ifwi5SIIhh z3I{VKy2ra^yt`B=C1~mM{RS@Qic@QXwh@BoFP_@QLCG{!JQc`DvMZk##f@%@lE0)E zuTy>#blzmky6B9V5xzM5RTmg^kU&Q+0dR#O2^hH-k_5V_>cfRLHEEiNzR{iOLH*<u`O9oY2Ei`W`yOtC($ccotl5) z)#M!R&t8~T<};a3IrWY@hipqY7WNf&$==FKi8d^!Q)L72ld}sj!m7@-|F-0p}w1c9_JDD$iFtQ z9vPXDQrqj>jk)^DuNNEjV7X2SY~XnT{!M4`C5+eO@cz3i(c$)>8;(Ef6c)O%Un$`H zEW1AV^{3;$iC@M4)S9{_iX)rR-H%bOh_TR(zs2U@N$z+|igpeiI8@!E0vSN*b30Af zRVr0fZmEqn-Ql%>SWY8v2wdOGyR?v6o*Li&k%K4Xchc0xZN5@pSZ+KUUsETHmrb@7 z$Gb3e?t48?+KL0YobC#uNAbJ}srdyz?i%*a=NFIF5~TK;>MhGd(nB|%Z%NE^I9)V_ zpMIExp(SDdmGCG|x$jAHj*~IYE1VoXh^Lu&;(1iu7}%bj3L>P+b07Kc&UPQ{6Z@NV z9xQL*^DwBb|J6O81EndRNB&KL&ttPALb@z&$@J3Lt`jhvqBzbEma9_VQZSwOae@B% zO2GUO?m_AOE&axlvC0l55EG@IBH}K4U_~ zNjL7ZD~SFX7(Ds9<74mNweO6VBGps%j%Tx+;uKvy^{=M#W<<{RF0Tk|@BQ;5r1r~3 zKG*l3gDcw@^kuoIE3Ma4U#+O{FKB%wMJ(?bw*=OEgB$OIW&OGCw7rXl@%5U^JIfnY z?*K(!Jdg5Q1E0r;q6q1=Y1hB8V!+lOCu$1wd9b{3&V$Ddd5}}cRV_Gsg)OSL05z-N6nLm#mpD z))l?@Th#l}XY#qSJ}lRw^?D)eLod%{Lrsh-(7{oF^rHUvF6hPMEo)t;v>;noXyG*8 zQha-0I~M;ME|m=&^LdvIr{B%xkMf!9$Z~AzoS-+A6gxiqgsB|5Yq9>K#xGoGu~fik zyLP%GuzsC>$NlH{7o3qT2H$ltJ(z)G{aCI_eM^7(1-w`p^b_-aQxN@j4Q?Yv?Y!-) zXFj;;HYy+FSU;AlQr|MDenN{bswV1{aA#n<^v7oy?8b7RM(UbB zy?m;88$52fy{c8%YuWT>}KjQaMB)HCm*b#k{W8FhP@QLcsx&kdE2csQ(f@0=oB_Ar%0 z9VXLXZ!1I4qxlCnl{8@`78v0kyxpx*N5Bw-X)qwgG)E{6u>&3oTKTLOV)7$v4jc~V~=2YZL zmrFT>GK2Fi>i)p`Y`rK#+IGpvy`yqp_}Hiq%UKWhYoU*Y`UNyzsK4)3V-oe;8br_i z7e`1`WC(Bts_N(bx(>xnPPK)+S=&g=Q*QD3xZ`(>`e@`h(z2W34;dJ!hU6ss^yW#M};IpUgbVN)s;it{!`lGwaKV7 z>C_M|P#QJGPiZ$)`Zc9-IOH^Leyok1bN)6)`E6)hahYPjE@dE8oyab18}{pxo_S2@ z76>J8%)Ic~Q!Jw_B^w5^V`J2FPTTZDx4@B-4}r=GoehTvDpzzaM19(2O6yp5+*b_c z9JyZC=9p08t;;^f_Ezk72Gftjjd6scM_rByCEl9$VO?tqH_FYjZnVg;wJo;K;(C40 zlFBue9d1`^6Cah)x*S)VGy?5QdULrK*XbCpuN)pIoe8N4`K(VFt!-c9P+Q7a54gRlj~>Q2 z{lyi^KK_oYi>xmBPRBH6-qmDhV|gPT>Z8Y@v~#e$q4TIuT?!U|UBg+Yx|EZ;rgxoaR)1lVqE^}c(CIs5Bwd+x*jS&kPc!Pud{!s^s8$+ zWM6{HGp|#g81sel@o<-UsL6&a9{iCt3MroB%Fg-UK-+@ z%s5O7{2MF~sP0l&pzwc#eZ+G-oPCjF^&VWbueokoz_h@zZ2|Loa%|^sL!F)3_h=|f z9$oP?X8TanJtB=S@EC)?K3<@(qszM0we@$t)%P+bN4f>5j8fg9GS20dbT-x}3a_ai z(Efp(F|I)Snqi060(H$}Dm%>KJp(g!u5aX<_y1;jFfCwOz_fsA0n-Ae1xyQ=7BDSf zTEMh`X#vv$rUgt3m=-WCU|PVmfN25K0;UB_3z!x#Enr%}w18;=(*mXiObeJ6FfCwO zz_fsA0n-Ae1xyQ=7BDSfTEMh`X#vv$rUgt3m=-WCU|PVmfN25K0;UB_3z!x#Enr%} zw18;=(*mXiObeJ6FfCwOz_fsA0n-Ae1xyQ=7BDSfTEMh`X#vv$rUgt3m=-WCU|PVm zfN25K0;UB_3z!x-Tox#MRFZ60muwxB-aWOhI`H?l>+`+*`lQX@{`MC~UBB&aj4MzY z#(jDFaM**>4#ltQ|16HhZ{BnMhH4YqFVua-e@ujuFTwWVGR=Ol{r!c9suS6TZNt95 z_)J;DSs;|WG4sM_Z?TNBG*}xIYTf1dOuum~aHQlzu(p)zWT0}z*MwkkHI5~Zj##;` z7>c%BuaAVb&Zq;O2g`z;6NmHup`1JKQQk43#b4KO&WpN~le(sPBpvr} zJ@1Cf17n?~c*S~0!RYvft2o*Vy^;Z;7AEpO{ZIop&hv)O2j1yyx=Ieob+3`s~-V z-{F)uMteg2jryE3+m+(sz6<+@(^g{I^*KK=p1Q76`hm)*F<#Mr;<|CahTf*UJe27* zwEjm^e1XaX*C{$5as5!8Ut_d0tb1+Z4ptV$xct@eV8>G)_&bhuJygCw9Vp)k3ga@s z>;Cp{Y+YFgF&&nXFGBm!HrbaD*C|ho`9k?f`y6XdET6~Pxz+W2$R@S5i@*K-$?B@p zp+1hvf1vi?pFT(P`T9GbV@XEsvDha2Ys-vn-r+uf(y_60YOHtzxA1DnoEc8B}*p?oxcBAXHzjEPE*4XFBX|mtg=^c*vxt<=5wCkE? zW9CO=#$DI*HIF;=7Vvl7I`mqEo?@tNf2jL~p7P<_^JqSo!`;_Enr(OZN}QQ8S%9vQ zNBVX0NFMhIX1ieF{z{=)pZ!_o=#q(fcqEtK`damHU;FB-KOKK0oP$_i8sePHI7|!t z8!Qm0?owEw@PC7S#B;1mUqn21(V{6wc+D!fWG< zan)Gyd}P3KMN))W>jPGfjo^{nf0#`J5u&F39T{?s<^y6)c?w&3#&MJFofOep)) zK6TZ(uE&L{S19|{#x|kEcQox&+j7rsl<^$7Z9JB2c_frgqn*ud(*mXiObeJ6FfGtn z7AQr;biZ`M^qilz_6}E)iN%tx@sWKcX)ye#Xi3^{Te6-4|5-8inv2`dxQ^Dz;dV<| z8s&-@i)nIJoYUcv9Uga5mRoi$kX@EEo5wCsv$|7dk5rC*IQ@)1!P7tJ>Nv6MN1&{Qrxbw@^TcF>QqpRM_ z?vgWfsq}m@r7hYyKRU3TBQ9zuy|rkD>wM{&2ai*uSMEVbf0k=vuNU0T=(*|iaOMAKTtBFPOnvIilO<{D?GKNo#GiNFc-lwS&wJ21IkjKeteRX6 zm89T$Y9%AiE?XUPPI}=uIoIiulTmh1lu$I(a$A84OZMh*530ZQadbRE=SO9l?A{u* z1nmLk7!@V*DV)|Robr~=neQD~57DP}3TGKsk9k*tGvxZ3+%Ir>uN>A!y6ED6lVy*~mOb9; zvBt}u?ELXXE-URKNm~W|I-L=`oKK8@r_=nX_ZE>}l(pXSW5mL$0nY%uTQTrPMJ8=8EA^N8=lwO4vPS^cC2q(vOqU%Qvwj)xSNxfG6`Z|SO zxYvE)!l&PCTcTBLDwYFaU6#{6qDyqxJT|Kxm*4b6Tr2Fjl#DC#cu*SS@~w_MnKCrX zE>Cvm$Z1Y$d6RJ&_9Qw|Jx(%}PQOx1b^WMc!q>M>*F{LNt)6--eZn96$7o7Wn?(7@ za!u^@f?nU^tl9Z;PPMC?JKJR|#5GR5enk)P=||~q>DyAVU)9QH(z1^?&Dym(LRvMp z-|x>}UVPmWYCz#A4@f_jD?(urRKF?K1-3k;@}@cCZ7#PbwJ6IaT$58hR+mA~?LqX6 zSQ8=LF!$>*9a{9g?=wvo)|2IeippwGJ>#4O1vXDA>T$?=77z5Ai?#C(q$q}Q_&7fY%)#eJGe10L8rI{)l&Y2Za&s#^WCa^@q)t1*zCli z4-Rb44dcS4ckXI^=gTWxlUGo|fMa{IT$TEkb=K3bRrU2gYKUH6e|G&~=gK~(3|OYs zdR1Rq8s)5UE%bE+FsrV8+G^0#SWdT22$!BZ@t)J&r*&S^U(I;0U0Kfhv0qm`jb;_g zY2i@)^;$+^xuE+upPNRke)^o(9aOu`TMO`+XGCjtqC(C^rs%v%E(`ZpOKCvIP8Tyjr>$|a>R#df- zX6$_Si@zfiUw>3R+-p~sYhte#NZ-U9yIfO!uRsi3-^+&U^)i;r;-qjXV$6Up*^7I1 z`93b|kyxTFwv=JO!)LlE^-bex11snyKzw#XGl}oWuR<5tlD# z&zq1Gk6u!d9i0uhQo#1;G(xpU3}mDS^^NErv3QUq?M&L6iB;+Se$!8@x^nhtS|_L4 z`Rr11+SJ&sy6jccnb~FKt|e(x>vpawP&`QOyqHZSHxL zAKG97?<(q1dRAaP_Ad*UMx40L+HJ)jE&n0|!Oa4s2g?y$CnnmrEJ*qrE)JJk&b{>AGfr{>*Z*uE_HrL3-1OP}&N z&hB)}`ivI!h#aLa?{up~ZGbpFwDqZ->p$<&DN{{F&1YH~XVYyl4B&vGkxR%tV$hTioEZ^5!0HMM$nded?aFFxhnN7r`i@_C=fklht)n# z&eMiWQ?gyN_~k?pAM;&znUQYyPFC;PIE$>+Gmb%?!= z!%0xnx_4)D#k9a7us{XU;C6IlioP8+j^ig=!=(cW2ll@(BJ->Rr>e?v|Ci-Pm4n`& zqZ!eUZiDGZFJ@1LOrIo`-c)Q$4NfJ$8i{MoBok!ff!ss0^MI74vibL+=y|D>y34u zoCf=xj@Twp7+uGWj_y@WcVt_@tUryLKU{Cv=hV#l!*CjLiEM6T6IXUvfuw=O+ z6c(5cRp`V7Z)GBq4HMw34oo(1VY;KUC@+7qTtJh8rr-VuO z&w2K<(#lBbjrK*qWxe>z>fTzKqz{!JmTO|KSCc-fCh2Y{H!WXwi0UcFR=^;}`w+4b z^?}Jw?9)0yj=~9cWJ|Fh&Ef3xex_f03;4?)iiPrp;OA)cOpWYKJ~=UeR7v1vZTAlx z+rKBYq3%O!WB*|LayZvlF*jJo`;gD;;(lC?L>ceLaZs4J?r&dFCa!Z_qKwzYFkUC0 z*C|b27v(JDcufDuw}5z^9&x_mx`=*N4o;yQ*UJl>S@GpL;nLZ=FCFn(^4KS~(Zmn9 zj)1O$`@lxij`j2qFz;+6YoNKC%7dk6V^AP5YhE;W{+>4;%KN` zQJJG_9MubIcS%!fduiGQO$y~XQ8XWi-eo%u&^4RhvFQM4zDg(11<=H;?w~g~4fF@p ze>@Y=y!Y{d=5f)7Pv|tM?=&AQ0ha@MY42X}40s281DZj}?jRQAfXl&S;7iaI%1;B= zf=|H^oX9Hh6Uf8~eE@QBQh$LvaAKJ_v4J?TjySQ7II$s^%jCp~y@3-;MPH>U=0Jaj z6Z;(}7LN?rf!SvdbcK&j+_avOG^#J+?rUF8htrZaY2oxWQMI)DILV(>0O>q7W~a`z?9CazDgfR6=b`ZS$|TYEm9k{US%} zl>e09W}d?cA-GWUhwBpAm##D9vy6Ok9h*ux`9{a}(#^2xfr_>_FEe>Stx<2ky5-|J+`>_vWaZ_8dHGG4+?pEd|tnXSpI2 z7J=Ra3GlvOk|$qwQ8X2R^^Bn+KC@kur zpZdm%rr}1!#rkbD=;yEB_gh($_`$JFNiD^Z{m6<&xgy3Qbp8Ci-{-ZW{(ZURxqJ2lyg%#i?^kFY1GXc}SwHsctf$VJdOi0W^fcOY>o4u4dHL<0PWsQ#8*r1(5Bb)5{oqj-ov!M__GGzFLv^i|diuur4HgyaQB@EeTC%gG7iZN4V7Vr28H#MeALeJmH?+_k7lR4RtKw&H~gQpt81|5;IGqNl_+tn}Is;IZwSWNtLn6{3K$n*xU?{*4 zi8LJ0_|FJHwj2pCY$A;YG$u3_oDE_?EEoskz<4kL#Dj?-0VINRz`0-&m<*Ymp=URr<*8OR9l}4i?du23JdLtn)(%jN%(Y;XEK>UDg~VG zmJre%wR!S^yWf3s=d{x(Hq>QFcDjX+^jXrJg_EpVvK{Z}7ZetG zv_=+@Mgh{3o;U1T7%qu=kPc?P!U%#B^R=`%c)ou7=P6rfoRhwWqu_k~&LHP-|M{Bl zEG)#cm0IL%6e8q&-Bc1TiF%m%%GUPzV!mc93ZAbczM47r#~bcZuI*xdJxi1OVpiAu z=4+hG>2{Bo7ud4pP_s4)(Q&?(U4ZX02zr?LYP7n3++^V5;Q2bT+tZh|2(h4~F8P|dBwP~pF!PnI?eoRw;E_v%=j&V9!|&+cZ?BVM;Cy}C zAm?zu`I>BXyB9iLIohPiQ1h1Ji~?M53-LV_QJ;p$Up^m7i=96ihaKtup?Y3L_dsMP z_Q@`^PL6!Kr!qPYugShO$&K+Cx9fVGF&=aK-)Dg`oHDg9^t@`5S{F)YWX&Q<%)kMg}C`ka&ggF_Wako4gDVj8QXXAptP zcAzkw61Ch=tx(H@j`7`%`9tHRf$YR>-7#*KBj)ss`4b7vxPGuND$6qRd0h-Q*BjOX z6^M@8+2S&_=EOoqw$IVv=SdY0w8OKKkN(?wZ;w&*?1UVRw^BRHaz!XCYWqA%dle^< zo`H~y0^HBs0R4FW=xt5zJ%ife4O%!|Ck9>?d|dtc$5Q3rHZ9+R!xV?9vT$uBqg)YV zk${h9PqX5?j~IhWbgQp=B^2SS#+stqk0UIJN!n{*Q!sF4wd?fS8iHOQJ$az#xKnes zak{LRQO@C^>g9bsP1CCs5paGdtPF0iwJ%J)@bWfA^vFqZ^o)w0R2k)p7>gS9!q=T? zAMv`rJ%sdUKHm0?)Boy7kJl8(=^N!79w_}de39Rljm&{72W*FmEA{2x*uS9tSMEB! z?OoTsevsD5sojjG)#PeuX!Cd{IibuPd^p@AOEHL$^x=L6$7A|F3y{s}*{^wB@Y%#% zQ!OCY=YgyB&v&WZ(DMrMyTI9}U)Aj0iYw?*yyCb%8|56XpO;TB6Qsz6cDyH`eiqas z)@3?IZ09nr3f#U#zu#VZ_NL<4OFQftbCOoLNgukdvYho`U$4(Jv~0dlK#RImAijod zSE&C?wj`faWuNOL`3zPS$NTU$`+N*<{~LX=|56pCoREEN*2=vd93MT!wo+{vR!z>~ z`f}p`{g+fZyT~QaQND2PqJO)%_1DMJs{@x`O6#KM#)n;AdfyeCF7?gmPT45u@KE#; z6%y^#X-)9@eR>m1*{54yq}xHov7L-^4%h2by?*<%5gjYGI~$=FxmZBy`RhltS@B1~ zhedgR(>x<`wBPYqvRn}g3%y?YdhSmrQJ)dl1h>hX>w#n(Ci;9V#i?GK#L#1Jy%?v&{qbEWCv^U?fP5-7R2(|>#C){(xAn)W z)Z~RTy6?EgdI?=y$f?(uCSJKJ^)1t^S(b?|XAwPiPIFlu^hpS(W3cW%t#Ezt`=MQT zE$bAMS3s&MPR*O9l2Oj#^lPw0w-YlOkQ{!@ROH65MJ9VSgVk70`-o1veN|t()ox-F zFvr4@T4=@J?$qBQPPUe0$!XSkGR@$J`o4c4rO5M(WVfgG^SVSGC~s?W9LD)8?nhx9 zPI7(iDH z%E?8~?TY#FK=WrgRxT$-Ifwho1#Twu=#S(sp9qg2ogR-}b}K)K_m*8cR@5uwuHfbO zt&aypPr3f#8#!Ip%P8k?pAwd7HoIMEaI~AmG$*w@_?H;{A=g)uwIfl1YPvr$mP_L{ zr+qa0V!kA7)ZgdR94307v7&b~srQvT@2B(p@BCBoOR?Q0+H1So*hsinPWy;X_y26| zrk{%mN|16FKOT4THitSwkvh*-ScumtG7yQFFZ7)((fuNB)M8y6pWKD>B^Rh2{rcXS ze>Rn~lQ{`4hekPv3*}HPb!zV@&8eNMu@H*mETwk`*C#)H-8Fmir~JU_u|7sQhYR{> zgDO4==Yv{Zjn#%~O1!tfFJ6Bl?g@UKUX^yR<*QH1r_lSVBqaPUe=daeqVP3^lO$oVE3MrT1b7H%)Y6h&55_Hqzfe+=|TM#mMcPG z5mb-yvfWyeB3s=~2OX9PsGK&$ci`v^*GNF;0Tq?^W%px1O{@n9Qs%tSycfD(BHsx0 z(Kwv;AxGOrCmv^vi?_+=bv|A^PF&}Gjr;R)?DKxK&HJ)U^eJxM7T5V0F>Q*A_Yv25 zUzQnt@fa~JmhwQD4f$~ zpW@-;*k>Kcrz$1NY5zcu_GL%MHE|MF=SjKYp>#K_xFR#=2^1A5PH!bmaz8@21 z{?<8te_^$iQCxL#bv@3QmcMw|*2aBnlGA?v;xQf{$~MQtez0R`KgQp_9LDj9+q~}Y zIFgCS)U;1+<-y|QaAW!`CtqBzOZuFT^@*pp=^FRv^I)IDNjGvvxlvc%R`;&olH=mE z>k^yTc5r-RJpN>2cqr>)8lmiesP>_AYl!nZRQfh_I{)T#Z)jVZ@tGDdEnr%}w18;= z(*mXiObeJ6FfCwOz_fsA0n-Ae1xyRn-U8zD=HjivpNoI^$L#t4S=W)LFDlQb=n0ik z&YIwT4CQqU^-Hnp(`A<7O$Y~GEl`}OhxAHtJ+|$9aO9>wKMmk?)W^Dp^3~w>*l}az zx^a8*Ug30D52KvJIY~{A6#O97gI7S*%&I|;4I$`p_H)nQ^2tl5Z{&1X52KvJIY~_q z^%oK>RP?Y68gDJp%@d4%Ex0`_AHUu6%4cr5nA2fBjB*a=Bz5+vQ5*gHZks~T=ZV)x zES54}-NWgzK1Ml*8}#v~$(csG#JnEdE?ZxE;r^L}ZduRiupUM^ha2=z%Snye=;w`W z4?&-U15;-fKa;tR(_?*%at=4><4=>pBginC6XzjiZVPUotmLgDUg|cCJ_D{e*2gI4 zaDzTI+egz%oCmfa`p|QmSU~B}I?crtzYl&~#grXm=1%DevEtO{P|YQyoWp&yj_?^1 zZ6?w1?q@5JHHi#dZWNsjSJljEEYkL>U$Q>Sw1SW&O?H}rO*9q3)P{b0_jMdf>5 zX(wIuUge)l|9WHreXE-sy{AU=eORstg+*+U$C-->gLucmRRAy*&5~Z2gHK|lxnwyh zmnRKVuw|+ZukGRGWH?c;=r{Fx#f)pG=v6#KlKz~!Wqzl3!=-T#OnYlh&d+P^)*grr zL>#0S%aurlMXmJWKMCUa3PAIP=zBCMyNkh%Tuxiji>E?BG=%LSE`ReyR- zls($CDYBBmW`b@MK`CJU61E2~XDuJ>fAF0)EBEkoPV&Pr>xAXl)H$zyiS7vw`UHQD zB^kd@qynYvCtkm{hmd~iaWAwPI{llD#`IaPOB@>k(zm4A@*HwbQW5nnL_IRz3T}s( z^LFk0>n+P#qaG};QIFW1929CdYMozui0x2i2zvarw{1eH^U}wRda%3>demr_!ncFl zrB!qL@el1=KijAe%WKpJ^D_U>-j~2dRki;gT!IwT(n`|`H508yTr#vQ5JWH#6x>SF z5e68A8JYn_+c3*Cv$WN6iFPzgEi1Aztt_?8tPD%dY_r8u+pN_7-{;)>%$$1|X3%=y zdjCHTpYOfHbIv{Id!KXe*_T{rNuu488&Eas_Z{(GXde9@IIGPauP*si=fU!0<6%*a z^r9SB{(feH7a7i{1FZx2>6|<6%o|zxhjfSw&FQ79E|+3leCZccxM{IQrrqOp&}Z$H zCp%c`J0m{~9)87)NO9enEx$V$e@!->6+)&HK=~farBJzq2;Vle)Rp2W^?cCI1ic zJ*QmVLL|P_yJ>lJ^ z{5FT+7h{hU56++cvE#0Jt#p1Y_cJqo`S>LkIuWYZmgcZegf@F9n>5I^4mD{?4>se< z!Sz=)AyWL&XzOEXD|^1A^J95Pe(9x!B~G-8s3u4S+X!b#!PwZb^87HC9iy%( zZ1sJLKMwvrdx|2(pIcURY&zj(kN!R^Kc@G=>&dQ(u|3ARJ!5+wYucf(s{oFlnC-#e zCw5_TF+Tk5yH<|K|M|m*4CYkc(s#&mL+ZcQNIz&3mbi1=g|?LL-Twk{H9s4<)6bjA z8@+y1-8xcC8`1lmKF`_ir}fTc=n3M@aw$|U{_oE=q|{OBkSpCXTtgi>4qEx_@D{sW zUL5q!YvuLwuNr=lZU|iO(91&oeEeGR2wXSobG)n1J-H&MV)vuj?Z}XTY z)Zamdcs0V6IM8_9BPeSj6Qmv130!e|BhX zKkg=9{XC*yY9Q-(d-kEf_V$%qs!od(tDc-A`piu)onb8W_vOzlw~)X;3J?0kXx*hf zcS^R~*z2l?!o+ye^8JV4GxCf`v8Z>GF|VK1>tvk|%a4_hZLnjqpS!icy8N@?dO8># zDQ0~i`^oO{VUsS@^u+R`;SwgTY#K=kLq`ONPSDR$(XlQMN}zlU``EGIuz z<9~Nsz<5*n=(-|*)N+4?#!oNz$^E6>rl)OPGxbgSO~!bm<7&taTT8mi!v1MSa`Kaw z*}1RK$3tqmO8LU7uRwgJIEOF#{ks$Blaz+}=yJCA2W^wpY;#jLtWI^%R%sb7kSReA zHa3QJ7iUej)1qqXc~p7rsspd8#k&Wrd1#PXtMltgmmf7Rg%dri@+$i>xW4AL4i{Zk zIbOed^!?v+y^Z_%Sn=)TKn19zuN9xwvaxk&CBHtWmB}?nc}S_&uDM%*{n^sATiac4$~)6e*LNyM{{?0ixyzgW&Z_^$9VyBUluSufyKy=(}< zqqaSo>c*?~I8@VnRS13u&y5sQHZS;L^v%8Af59xU=tk{XmaE+8cis5;vw{jd z!}=QeeQBOsSkq%Qe&=g^^?K#OHW8vCX~wrlk~>%P#1nc$ieHwS-ui9|U$dTM z=BwN}j!k>=vCp5!e4-L})?fU-;O$C!WW}~M8^>>I6Kg*1t9R>iwy&L!Gq-=CJ7*#$ zAIM#5sKx^ADef&qqv0X(r2hPhAN~FL?=D!FM0E?jpM&R*a9x7=)ZhOZ4FrlGu4Df* zjOs&GHK3N)aX(q}Q9WOx=Uyou)O6_j5;yx1A%8^Fkh8t=T~k}T5aV@5!#CTl?%SAI zVD~yOeo*R>+lg8G1vb=y*H3qhEqd*h^Izt0nU^kS`#`*c5mL*WgMS3qQ}v_>amGUp zFK$^hsJNFIAn~F6o8`=d?{(vo?e@DfHzt$&l+h;Ze%+Cu`gcb%ZingZEB$|RTW|ie z8VD3WbqVoU<0{Z|B;)ZcYM%#kQx{JEKe`DPKmQ3m1@f~#eriuyf#QesMRg0l)6?{u zK!)$efA!b@qz202Ikzv$4h1hSiO25lNgJ=I7#>Hz$((9lb-5Jd;x7l$u<<%d5(}J# zm@q5%b|g150S;dr4jq2c4L0|tHSNdHvt+1`ldig4ig5|F546$2CR;VKKcD9Fs61wd z;L-ZxaIvjl-`mgsu62?U!#h4XZ4ikl(=P+Pi=p;J`%dU zx5oSD+z(#(autVTXz)0p%h_JxL4ERWOt^P@%qof_*Qi+;EmE5KZ`DirpVs)Hd06DC z0zAi;_8D++c7)hCcIld%*Pk@?G5NHAz6Z-qvF~Q(Q{*g>Ly0CYt~0^)E`ZWWsC_`G z?nGT>)bHH_pmrwBz3&LnT)GQ^!GHsp4lD(B0MW>FCIfqbD^bYyMF!Oqh3;fDUQdIk z{o!d8JY9~6o`BBu+mP_@?127qtcbg#uMqvxgy@rlaHa`yVxyzj4V~B)fXT_w= zeK2@y8jg2e&h}P42ab0dGQ!ycGUCH$s zHK456;X%vCg>7)$JLQJzyv=?GQ zhNYK={ZZ3baRaL!#f`T&L>4Gk3>BhmN7L8nnH6Jt4;$NY#X$Nl$k44Ft}K^A<&t$p zp)JW?Vjqw8A;t)DaL6E*)Ll`Cldt5OOK27oy0FKv`Aj+P9IyLA@R`{tT;#pJW@>ZC z#?3?jGzj6-lkv)O(_7z-_+a3o#6dBNUyfoKc|Ho|aLM5pH?-fy(gmf6R4hdExa@@*BV>^>Uet4v=^Li}jlwe3FGHZ;+%94}qNU5FV^hw*>vC7a zs*C%-+s!{6{@?vR_5S_+8mK@bp?pmJUN{t^PGJ3J$c~CevZJz!41GgvNXBxO)!&a@ z1GVL6YQClVPIA&eefxy^{0vH{H~(ie5GX&RZ$QnX{?91mU-+Vd^0QzxsqUtm`g)D7 zk^2Atf7L*+??wF%)Zew~LUlvG`G3CG_FTQZUIYIt8c^psM4zPfNBl12y5H&s4aLqE zdlto=5GlTH9{KrOyGli@`GVZv$8!C>(=q4TGsQMAbC@j?D{75@6ACfYNls|Ul6`$W ze0!SMa9*07{7`vSX}t9QB62^j{Z}9TQt=W^yOxI5Eep}4hFpqqQTjub;R%{_CC`U6 z#wipVeop0;iSxL~Bmk5r1me~3mT9>!iS=KTJ2FQ3+*s&x!`8wp^g0ME^~OST`Ka2j zRDMcmUMIC$an=KGM4$)KFw9Grv%R9P;Ji#u6?jl>CmZp>zSX=_oihgbZ{@9Oe_#aG zUy!LS9?SZLi!(lGv*nwJoAw+1$3~l;`U6=mJy0%+zKm2f-07H1$;&$YWElsGJvBHF z@;)W2XLx+;4u?4?8h4@57hTTwHF%70=H@#}YB15;0mOvjq`q&0HTlopD-k^RpNqD^ z$2~I74Hu=08%2F`pzC&uLo!hSrB{|qp>k2uNxI$XlB1;5Ti0 z3|IBne@X*txf{_wbUszJKL7O}-L_89! zn%=2=ptMXlS`+9QmhpF7o1YveyXSjt?sfUmy4Rnt|G!=X$D#rCyH4p4{JSpe7%pZ# z=We;>_z82nn}N}HP30QPbq>mRjrD!T=S$1^d21Zi-Z#k_o^W}~<2=NS>Ox$P{kMEC z(cnb+53K_!fc|)2r{}MKt|gVds{LBUzN*8bQS?4>=JWiX^j_rK8p?cPho+mxD`-#ydP2d5NXo5_eIy z6KAt$xUfZ(w`6chF+Cd%us&LM3Kwd)6lMi3YJLroG-O90ozS~;y_aP5=D()_wO&|> z_#=}5P&}01HDAtui|8Z71>=5}Q{J}i{`jRYT1G8cZVp&Pz+H0@Ay|%oEhYtXd8k9e zOi*b~*F>)^#qKRYYAbXM^CH1zxJZh9Mrod+$|vru;Pq|_=z^Y~`i*i>w{j zLNu6q-0Ro1T~omAY07hm7t0k&@+a#lu@GOr!{fC{qGcuK|CpUP}B}Zb1_V;CEHEgvZ;I8(bE+G>#Z^buaUWt;&!+9)?FuMEYo?hocvUck5}k@?R@lPYmO2> z%vyl?6?6%%x7JrgisvqPBD~G!P2cPMSWbSbrUt*ixUZe>CCq&T*CH_HAJa8B|CEwQ zarSQ+le*NOj8>|>|%=XwZzSDQodFMh1KSp4lb_iTvmdPmix22;uw zDc!Q%kovDR_)|-{F8kJLMAdw$4E+yOesaFVWh&37-4!1$e!RwBxoY7xDO}HBo-Fq> zG=9nLm%MK5bV+Uabf*^?<4^~($Bg1)x2L4kg$4iE^BjAx+kE{O^d#kX6#rbmInD4+ zUeUc!XH#3ff%&T*QC7?K2a=mvuj-`!_us6682G2gGv(`n;zmuUo6q;>2NXwoIYksZ zmEYQNRr#&=oP7!XXT)nPVwdHH)PKe16O-&HgOXA+v*gZC$sTu+zYs7QAXF~VE~EXC zUUMAsVLg3u9kf2}_;veF{?g-z>I3z0^H0WzHEcb8>c1bWe*WqI^!Ta&e*Wngv4*e5 z59Mw24biYX))cyB;|Kij|=WR(ooBlKMfYXo@u-uUPud>gewAhxAhu#_U zpKQB#A|}$o@HwBLphHs9nu+4wvsW+tm(F9*&)%?Ss?p zE_5?`YV-{`a#M2)9dvS+xuG3As{mL}8$$3b7#bzUyFdCSc2TR5I!~4}KfWJ3Ps4|D z+?e0K3;lZBLkWBIS&gX|DdmE2v2)7PTXs#25M6KI(ER4gQDc4_Wu$m&r;#36j(;tN z2VQOF=6-3;JZuPCu) ziHjB&cRN!QJ`f{T-hZx0y{MtA1@@Skse>!%{9?6t=kA=CF(b$2T~8 zTxx?}W9Btj&}(;tQx0F)@R1)LX!y#+lNz-@bY~-qe?+ZZZ#@(7#pxs>A$U5WsO|sg zl#U%&-*qL_BMp7;lnb$3{;OPSO((XjVywlaexpeaxUVqN3-<>hiTL^nj4p%7Qp|x{ro=noSRZUDoSkGo;A91`>wO{k_=zSPbxoHuKG>Ct^LNb$JpEl zG6PkqB5Z(xO|r?6?5xXjqIf1pG#F@>IC8?K8+90e$1=)+UGQ5kcZf5kRpLbX3YBmu zZseZNv|kDBjY0j-q?_}BG@t;u6<7~6hXP=3*H+6VX$Za`Ue*NH;h zf{yDB9fe4b#q<4fzYJy7)z}wfnGgf^qI^mY6W6Q_6N?HOh;2~YpyMEeC1 z;*a;6ih`sT!aL?uo#c-fDzB-&h$2tKCWeb4 zDJ$d%*&ms=o;J7V@27*VG&271rLx=<`)3>cmwzf2*-<@0}Kad z051T)0||(qdB9#^7~<(oAPbRBb&f?)f&-DC3bmyp0hA){UIW==)He=+><=K@8S(f8 zW~PQ3!iA>L9-e@oDQY(I`GlEGP^U1^0!C)NNtng0>CBn7jt!*XJ9EYfoz^7T?@Z z#5HXsCM{?r-nzK4X!1v6aXHQno%l+)7+xJAwzg~{(ynYOs#`^g(yy9{lmBQTHjQj4 zK5KHaIPU&U#O?P)i-I#diKHQ2#dE!5WqROr18TlOSyPfN_S*6OYGdXXNQ=K}lEi07*oPKh?TFi(~%6y?uj<;ng8TSvuij^<8$kHzTE z(f=&Nr&n+4HSn*{fd0LpIItK_vm{i1TO29>)WwbBy#8ms2L7isPzAPJPFE@AAJysf z`B?N~1I|vJ|3}-KKj=jNz|i**i7U&cP`T77|9t0p%F@~BqRe(DjJLaTF`)$0P36g% z{*ij_Q1GpNF+5l6#VLdR<#uhnzudIf)}!CxES)#Y70UAG(ebv{clOnR&x+;mKEI^z zg`H5fl!o-!0(xY*DfZoJ=R?aRdgRX79Cq6@s@TI&Sx@aemP?^>shuZBB%&7EMAtQ*=fiL28<%OV#}Xx~%f_J2Zr|GR zYoakWr{RG$U#}WTZ4ol0SE@&{Tnd#-?R?E7iF4k(ZdXEyRgGdT{9s;XL#(`LJ`MfI>YQ6r&SlW}343$fyN0v*Wa;cqHn%!HHP7|(6+%AW)aph5e zJ!m^3EaI>B*OIO%eu*2JPlDQz)DECjg65OlKZ)CVXhO;MUNhV|9;i)$=9KT;C2D6= z8<57vS_7mPyt3?vRO7Y9(BS%uZxJEFPF|nB>Y-O!UJO6T5HHdn%cW4c9E<+w@o0eb zLgP2F;KlR!PrCgwCw;4`eWqgHaqGoJlor+Z+5>yiX9A$=mgnC=EUKSe-R_fHMpuwt z$box5>Qkmx(nSNIt#4GVLTCy8|!&K_^_TId1_VzN_R6& zd+Lvh&bFoxPG|F%9w!>*b^8cT#fjc-e5)$9S9E zZ`F~66Rv4H+9}xj5{Eh)F4g#~0uM4ApZfS%)#ek$>=#eIaPrF0?a_udz@&T9W_A)tAhSsgw4Q4*6#^;{lR$esj(gW_w(=lGMA@$mQKSm1A zrmWPNiw>-#?}iNXV!0vpUnLUU&woJAlHu=L zmm9W$`3!Wp9N0e=T|!`zTxidSW0l9uI`FtTa!XR17o#YPl7@Nca<&ho7YmR6&XOW~ zv8CLI9u-<2gR;B5k?6?dY{sV#U0!D%q>p5Kq1Q3kkWgU2pTRbqcVD;Kq z4wv<#%h^7Veq_3#I5KrZZdD$!mxk8Q-1~q1@Yi>L;Oc@;Kf1h5Jd#n}G99Wss_MYw zik(ltw4@wW>+6uvKTv~zHj zs5EN)j2vx!??CI;vMy>Hmpk{0bB3lrBA=&lyCYnd8@~Fl6s|nk6@w&+g{Xn&%Cfq! zP*Xq!9^v;t2p;5b0zh}V#p6mjRF4}Wst{)TsNzl1DRQ=2@^G09Pw)SvQN zkGsrS1O;GEAGvtW*xP3qc3em(Epg}JEcgT`Rmutz5m}s$)q2g`F`@abYyWPyAHp`R zQn}IZ+T?ZOmsR3%PQ=iG-0Iu#S>+XTd1zkaE^3*#|G0M4)UcS^&nV7us_s z7Gn9Ne0l}0oX(2JT6qO3*T4J2duPXKCvD@P4SHchm$SWZ0b-UN6Mm+ol#aJ0j4$Y#)W{X%S^oZr4!9By&qCs#+UF&6AKzU7)Ofp9eL*`o7zh_Hc3Winhy7 zh+TXj!z4s`2i2!p&OG^U-T&LS|9K77sXWTZS@ovZ>#K9a#ZyZ|t-RK9~o~6$@#{UtxkO?ztRuB`*FxYor>`c3srzp|a(!mE!dhj$iJlh-9U zKE_ellRE5Rq5`}kLCE+VwfMcZb@lVbpLB(vS*yoOXtCI3km$A@W?LkIPAG**p~M% z4E_EWtZ#PFhBl5f^>A5UTez8a4;?~Pm{eFuOiwW!m~L zPiSs4p62u$CUiO5^ZO^{q+y+p$14YY5qLQqu->bRtnF#4vQr1*{M0b9sp<3&#=*Y- zvNpf&__qBoJbudKy)1`wi^=xbU0%%Uci4v7U365J>}jx3k4&i-X>=r9Q~1H^A>^Tv z&MaOB{YQ=0cvt9neaX40!>g`OZ)H!7_ze@fobA&cxlX%HUU|zKZng|4L*v^_)|T&U zLmhamoi;lE$+@FCb2!XHm$N;`Ylh2_ge?smv$aII+N5+xI>K{wDzR-t?O|spG@Lm&{&%cmG~S=cMV5T{q4`wKIPaR7RYMOM>4fu*Fu`)>!S~R7jP6pV zr1Gh#1D^%Ae!p||Clfd6d|1vr_#T>1lGBT%zuWk*{<@?!s~-6#rGer?EzumJ1{2D)G4KR87o(%AG=U%nY~Xxbb_h01tX!es9W4 z8v{J96Ei7Xtm?USK&J<0&*%J<`zu)v=N3ae)RR8tn1xZBknYra)HwK0hQkk}_rZ^R zTzbo)9}ZKvWau7-E6b%&x#;1WM+67lpOfE7dA!EYN=R5=5tFU@((7OJ@Lg+PFP?hM zLtWS-Ba8+$NwZ^%r2<(ylr5L}uw%Wn zC<~phwfrfrder2;H?Wr!9)+sQ+1{MLk~P_h_8dy%!~*R9omw^4>5US%mSq0ch4d<3p9aF96#!Ly$ zXYJH*vHP<{UD8r|zlx=3($G9T8mC~nDfZp0;{(3&5|x5o|$33^jeMy)HNp@;N5vxSes2bicO^WsWeEOgiGqaw$|U#Dg0ezVn1@oEz(B zr1v9|{}hy(H<66MMzv#^eplV=cJ=?)Yv6xX0~JWvl#d1Kk5J1pJ^ge2f!slv#sfJ( zEA>~C4ZsZGMu6Hovw)j`*}%=f9N-qIa&ZWD6y8-$R z?g8!v761!@MZjX2T3{XUGVluUDzF}S4R{^c0Bi&{0dD|r0&f9t z1MdKvfp>u|z^zz4uq;6tDq*amzAd<<*{b^tqpPk>#(r@(IDGvIUJ3*bxOD_{@s zHSi7aE$|(%7x*6d0oVuZ2Mz!~0zUyi1HS;j0tbQLfZu^XfJ4Ax;0W+1KpAfs&;V!% zGy)m}#{sn0Nd#~_&;&rYi--iGfMx*gPtyW80XPw83A6%E0!{`_0k8#$Xak%Iv<2D$ z*!oPI4x9l*1MPthKu3TEJUanr0iA&upbO9yI2)k7SIz}&KsO*3=nnJ%XwEnd)Sd_Q z2F?fKfIdK9-~!-6pdWA%a4`@MBmn(^L?8(m03-tgffNA4l41~W36KWRp!8rM1IPr1 z07HQ+AR8D4(EczZfRVr`;8Nf+U^FlWpz}Az0^SbAfrlZNTlo9l)KyUBKPIeBd77USI*R5Lg5(2JQnYfct?5 zfCqtxfQNxcfJcE!UJ%FA-FW@|&H*h`>2lN5@0v7EFc>g1`G#A03!i9SnE>YGGH_? z2Dls;3ycHoz<3}B$ORlg9*_@U%P!#rCIAzGLZAq60dAlexB~D1UZ4ah1ttNLfihqU zFcr8GxC*!$xCXcuCwz198NiLeOkfsp6EGXN8JGjy0^ADB1?B;_0k;Ep z0Cxg+0e1uQfqQ^^fd#-qU=gqwxDTiR?gt(K9t0i&9tIu(9tA3aCBRbPF<=?+IPe6p z99RLY1fB$*0#*S}1J3}@0#(3sz-r)m;054CU=8pRuohScybQboyb7!bUIShSHUJxe zO~4z#o4{MZ+rT@(X5d|53-BKBKJWps75EUS2DSko0Ura~fgQk3;1ggM@F}nx_zd_Q z_yYJ6_zKtqd<}d9d<%RB>;=9DegO6X`+)<%kHAmB&%iIhufRdzH{f^R58x1R7&rp_ z31A3HgaJ6xTQme30gZvA+wB zTj_~RUr&fg6As zz>UC6U>0x_FdMiTm;>Ab+zQME<^i_>w*z+ocLH|-cLVc*dw_d^1;9dJ5wIAz52yg{ z2Oa<(1Req&1|9((1uB6hz*68bU>Wc@@C2|NSOKgAo&=r(Rsl}~&j8N?Rlsw=YT$X` z1>i+s4e%1M7FY+o47>uo3akfS16~I<02_f#z#G7uz+1rEz&pTZ;9Xz~@E-6!@By$D z_zT*fWxl|7!LpNIg#d0ZBE&<1VAXLW%am+Ivm+bc7Icgs=pZGh2 z^QpcoT#V^mc=`MbF8|@YP3>f;XW~lZf-ILpczo%kjF2bI`sVO?;dsk4b5dRGJTwlE6WY3|4KYUj|=)4 z#Ukxeyzn>&she0e0vZF99?hgF?_|&a<7ZG)S9d`@`7c=#*W&=@On3G7e~CtYF#mE5 zR3K5P--}Au%&KI%QPU2mC46eqF4BC6<$PEDs{eg#8qo7I@`d%T-r0A~&p5tV9_U^d zH-Vn}CuGF6K0o^>H2=R9rdl52c`Vo8-dyD3 zt8n045VLa1wG`T_#26!_XH`B2H9mpr&+oQscvtd(epgX{IvL{A7FU)_p>hdWKY~!L zKhs%|{75-|aJ{vx!m1ygPm2e_Mc(iG53k;FbEl#SRD(kM6`*=6%SomhYrWA|fA&!* zhhq-^pccMfZ;pRBTofF6yn9%yGY(}?W(Py@MB%es3YCjBe0d7y@N}Z#H5{q!hw}S_ zzyGdB!o?{~XEj{V`0TO#{v1Bbm7wKMYxvfBvrh?dsiun-OM~+ukE5%8JmvCFR$cN; zlnh3ui>|n`+>rXO#Di00?eppUjP!Db(%ta@)tO24DmX7z%O7?}<&POvk|Vigcla67 zko#bU?fD+e?cZtl-wyBZ-oRB#64yn>l2zBR7E{0^o0?ndyM*+U&mm{?|01 z=V#;_xBp4^oF|dqInSaJPW{d9IBw`p`2gKnhMz%AsCztQr)9p2waz22+; zfCkk1NQG7((d%Ut{5^TIufJ_pw;`O5QF@|%>sYQ+w46)stC(PdKQ^Ys_F33C*ID9U zZG~|Hc)<0<=*O({*(glZH(uUz_)i&qX*gUOy3_i7mYZVVEg&BvVY(>Cox`s{ z_+%0Q>K~6ry|D*=kGu$d?vpOsg`Z-3^vgN#-oEs+GwB}~gGZQ8Zb<#tfZ_X_4c7Nx z<`19z4HO?QK0kIr)6|AEoF@&rqw^_QZi;=kfZ@}W!YRfHm1;e?vJT-7ESMEud{-(> zW0Hp7Uzf9e!0=NX_QH~abXujA<26#l3OvB^F!FJ0I)GJJJTB^ff=^uce&?q*pLHX| z7E_zNPW$4SXZ;Lt(q*{~Rp(PncwP7TU)<(b}3K7cCm|$C$5pA~fH|uk7i1 z;ThlEY$1z(YLovZz5^zKyFs)JVKC1!jVFCuR95nOM*I|azIoZYq*FiXNx#W({OWSU z7UPK*63wtIO#`^(|#a<eD$CfOB$4~d2DUFZ1S_*w5R<{=E9zIkO0(XM(lp1_@xdTI?tauhnh*I zK9DDva{W18-;4b+5C`VQ(u3_q4s0M&0LRe)^IL)NRsV_KeAAxz?OAEf5A=3BoQm)} zCl{Uj@uERPo6>&2Y@WK}+36p3-FJ_9Cdz406!o{TT-Tem zzr)wxQzNOUJPv9+^ztn8SqYw*57Q#_>Bb7npjTp#v_{!KU$aKn2g`%=u=f90Ss72N-*xm0!THb=Cmd*;a#^=7c}=wOQFp<~b5Z|0f%|$WtlGXalGkPz>^ZXgx0|};KmYc3sOR_hYCtas zRo|)4hm86?Q2m0wDOq_SOPEmKjNz*OdMp~K&(CVtT77<2yKerk+NkxU6;O_R-68dy13+E7}2Q*u~qgJi+RzV`qfyDe=UZ#%a@IQ>;#ETMJJ}ZN*wtf^p9XS z9X$tT@Oe)A^S_Dd*ZVqJ z!YPfxCrs#awl~kA!K@A^okd1Ff!WL*O^uFG)1k^^Lmha;^f-5HE6>g!IUMGp%h^5< z5A2X9w^mh&s5~-X4y}*Jk90W@G4EaO=9ck7F{8_a@j(8Q=gc>gk38K%>z}FvkEE}9 zZJG3Kw;T?K^`XnzK9D{V-5yVAaS2X*@eFgB(S?Z1^C}8b^;3*9=E)=g6kee85`Ep8 z1vts6fZUN`Ub@_{#hMG_{4Yy-F;B)(SXjTGgLU9>_Enb;UcKP->p2|eq08Am5D%YH zvfW6@1|79rpZRKNeS8{KboZ{PlAAaj=Ap~kJ}8eYSpW=m6uBoka%=Kwy*@Ob$J}FE zM7>{5OP!@*KDwOkgYv;4LKZT3NYzhe9r#o_wgTXCb5|XB zJ$Lf2XTOy8As3sz?@E`G-(>2<%k1b6K+nRj{Poa!`*p`x)vhkHcgetUVZG^cwyzUE zAF)(dR)M21&ljuKagc-H7pgqnvu|P8-Phes%lxHbe!86P6J$@H(-@nwVf0~8!U(FH zmjfJcWg9|=J9@(KhuRHqFqQq~aCJG`*9dp8-Gd=sxps%#SjKuMuumDaN*4?n!pTMLBL9 z{=Pbd|Nd{sy)e$!hPqp&;qY}i+t&y`-Jb8lIaLl?GzC)*aQMZWLcjmT_q96s*bA>_ z)3anad|htXqD zZ1;#at@)DPt|mX*-1kS+Q|!A1=8^8OyZr3PvC5;xTULDp;!!cJ z(SyIPoIgY7!Ezq~^G9twu*!SlHldtQEZ&FrTqo8eIWP=5!@>&C;c zi>w^Axn6+T=A|{%=e4`00k%;kljan^Agb4DcLk%E%)C zN?9}>K>w4@sNGEN_&42a(1btgh%mZ>3Q9svU`y?kF9_)5y zyUn3gSjvag@m;YcIG=*#Nb%^`hhp=NjJjdbb4HlVhvj}I#;>~Zp>564+nQHeC~4zS zmDl_byymAyitQPV{u;0N=r0BD`(xq*%+nh!x_hDmxDIWyq zSN&{rvF^FAT6G;5`*!PR4HAuTqwkpI3N`uj*!WRblc`ek2$~J>jd`}%8oEB2(C4j` zg=ZX2VLp`qQz@X!+1|%Ps8#9!yv&V%&pCLpzT*u z;4YQDWCI=El2VVuX3ok}-$ecH*5W`Paw~gY%s~B2w(nZg<6PHw?YJ=`4d0rw^7hPrm#38Y4np zTcXG9^&0hPo6O@iuI7UkxN~|q2wqf1lOCy@rr&x$`H0hhJmegb_a>~Qq5Obq1iD;` zajC(}ua>}hs*UE+BK~_CKB)0rSsh$&8!n9$SD%+~xZ1TaMUQ8eGcUf^;FpDC2#OrG zlzzn_uz!`OmH^>T{k%#-hR=Ua!u3!YX0zW5KpcV>R1 zSop%8)jM+TKB()L<;;`sHTb4E>=W^s_fRS!!Ae*)zgqiIaDA3d#&`3}8*%R+__UAC zkLApZ?=|?PV-~Oz=d+s&XJvLYHg;@A2~MYA+0o<)W<_iXMdFe3#{h)PJoz z-@1K|YC2i5Be;I&mq&_B$EVx7EWT!;o=#ZqXKMVyzz@|4Wk-uE-(0!?y_&5AE#8*dToSLi5sVrkvpyROe#}Iuj+c3TTgl=Iqtc8TN_VvJ26b?a<)$`D#qa}c2@~4 zUq=B~h{~=UiNLTuzF=E_w|iod-7_)W;mLR8W|eyKFiMf(!N%CATT-PBZ%lrvJjEw| zeN*`tsDJCdfjfRJtvqz;7?TLOI|-#F%T2NGX5~2oGYcF^rRExSqL5!n)LA_;OsxVS6K_~c4a>z9!CP{dv*1I-qJab{M_ZwzxeQQvIJ0s7c zb_E%_hvCX{DO4`Q(i3c%IL8x5O`@usP*~{Bq0s}|0K2Dfiae1LNBb3dF`LANwCC`c zUz{aA$9)>Q-u3l2&%85r%VoE5&<4LILYK3BmLsQBPGcE3xj4aVci9q1J2?L{*Orc1 z0`43iBjX8GPY3J3=b@nm*{6CgSjgcqA6?G&LHN)L4Yc~)E~!0@mzwTp?hdV|vDb|E zyfx&i&p2G>rOVkKOSp=Wc=E6&3LPVhTNTowZ~8m_}VrG@qw?7-kQ#ocZt_X`H6K*>RR>y4{7$ z(<7HaI&q@eR2(_zEX*}Em*{qTaICKEU4r(mC`B7i8Anuk7JqKlU!d=C&@(S5Mi#wR z#XLAZbvfG)cRFx7^kBD(S8@$5ElPA3x;>yL&qeSWtw^Gs3zb5#8Lq)#JIRqv75`zy zx%81(>cuU-u<{I4E?jc!pNrq$R{8+*V4k|1?Q8I)EGrA=7V=uFT8PQ)4W1MOTppBz zAC*H10Nn$%+uq)@uy5n52039Z4fE6GY(G5CmW9cB9*; zQ`sAvyQ<+~k4jU{;qcub9tv=W2RRio1X^D@u)lN?jVrw`t%r+7`0RfQ3KDu3HJ?}k zdorw#8vE!x79l$ScEblwF}LZ3=D-a3LEk0Ir3cD|__^%G-U4?C4$?&}LMHs7?yO?e zE7F}g9yfA0w=35eHM5Qr#eHSv6DWSFO80+!?Xo9m$XgnYA6?G&;4{MREiw*8McS67 zpW8*_b{NT}x{={h)yoErhpv~oKSzqPireOOr$hzA`eC^t^&K_Dkv)s?j_{AY}-=uM3 zB^Vj;C<&3va)5cneQT7<@sQP)PtTrxL;I?3v%2v>Kwuf+@=GQg752fIsX z76lch(x~O_E;D@27X#%(1#9|TQ`ECv3e6=ZL-#OTSuTajz_7esi&8H zXH8Ffy^4bWC4SP99v8j$+;+K1w=t%98b&r*u27Ue`EdB*PA}RFxoJ+xTuw5^qBMWYW^9q*UC#zM{8F_h$GYbH(9*plxp zr|J-V%2!5+SC1TbU&WiV?|sk=komCO6#H)d(XN_^!5vbBB_(-`HoB^hf_=gD5&cwz zIOWv17hd^n+=556@LBE)*!-dBBN+{GITlXG3ZMwCAyw(*53}8b`JxUF_G^SEs-EV87n$19 zaf?HdV)FVwpStwLHQmV#8G3@!4a=oaxhQ%Hk`GB0%BL!D<#ZE!Aawhq-@Btuf3sIsytZJ;wNlM1rucCCMq|;2}0cGfKK^`d^mR|G2H+uez$1UkP=0__(eVls* z`0xMzr*l^(%s4&He7-C0q%W46V&Bb3*Vfr{6m`jk_Iz?w29SPuUKEw%YMD-M{u8Dg zo^rfYYVS>HlhQ%!j#zK9?X7dmzBpcNPjKdK-}vSQVUUxd3D5N2ESEy%66n4Am(r>( z!;xC=iv7u|cdA-70@Qxrf^#z8Pj$zna}Y+o1N99}&i3i<32yW3^r4O%2b%33TSBh8 zxFpkAj4oj6`;|^r9#wVV@%602N#||I7|h`?4_(gofq2Ni=1l6AF7z@L^}9{^Irw*5 zbtp>Q`{vcp&AzDWQnNZQ+8{uR50-QId{@3(&R(G&Z?PT6sSk5eSHJ8r;AW|%eX%bD z9}1&=O58P%znD$cNNM_;S6yyetL34Z-v*$R;L1fOZXr&F1o2c?p4%qJ*i4U9y_NqG zTyF=Tj}V@RzS((qOK}0sUm-&cY0?|ZrBJyjdP_r>ZDCSIy0PVrP0~gizr^F7;;%=m z=_%sZ;Cxb|qQscYL3@V89{fUPa|oC6VdBGbg^K*C^N}oUC?)JU1+w{SEc~$6|3dJH zxvIGs)pu&qi`%|@HNp&#@&Mw&@*q6WU@e+TT^j$>!0RSEF69{7u*9)J}eKyM}}`EVMG-z zqO#UEXC4l&k3G$z#0$@!-lbc0<}$8dQ5iz|V0n=66@4Tjp_Ir7sX#%emdoeE1IlZ; z{L}rT|AW~Da$i>&m4)@jssTNI_&cz=s{4N}HK$w$BQd8b&55j|=(4)}Uz>k*dG>$B zjoLnnK4SfT_5R7qH=2vfqWe$2dE_IjPB9fv^(y*)S+2jgZzh6e{vb)wUPO%_8Huqh z-`B62hq=Pm{66+iE3X>u{PoSnhj;HA)o)^Wn_`myr8DBia-CO}69t_k5v8#MjmKOE zRk9|^;rujobh~nR9FFS=>ho0gQyx--2V}K{SDXB3dC)!q@tDa^;l~4XC+$!MU3I6R#n%j?QR zEr&PDxA(W7seP@_14wwa^+ow>qEF>;h&O3Zm$Q9#fzy*qBiU2X3dFdr*O>E);r;@5 z?tok;<^-tAye;#n%EKr&{CxCrnfQ~UMCOUzdQV$?;+D_H8%&15J*8KcOAnNbwPmXG z(sGBj#eq4b+qZ89Mj?zbfW!jyRQQf-x2$`LXketL1cXOyDBq(r#qCP`6zj$fTzJQz zw$B@E4R^F2j^*S=HP#*7{5z}As0}*POG?caj2e&g!Gp?f=0U%yexUB_5Z(IK*DuL_ zVh4w1-U z>W){}eez)!4$sg}n9${HukrB>UdwSBo1FiW?M_5BnEJHLHQ4m5%4-97h0;_1_vT)+ z`1(0l=<&sJ=EL{kyd)taM_c)2l$PYUi;U{9h1a-7q0`ax*?0UnYL}ai2bPBJl#W<# zihVa)=Uj@pnl3D3G<3u}nPO-Zo$0w`V=pulyg5{g*yMal?pF$4WD)=hul)PoG9Jq& z;LOQEuf=XoZy`Jr2K{O)JfZhz9gJEWeFOA8vK;?fj5*iFB zDm=yY^NPlP9yDI2uLmmL5hfA85kZbDV*1SoZ7b6|8oZP6UcE0AsQn1W+ z*EQCy^Uk7Au$E&q=GFp;IUQ%6Z|(SX**DEa$>8fgjb3^8p>s@9tY4O^TUSDaetpyZyXJ8MnHGOT~GPvgO=OcVF{QkN4t@rPY zxIJ#pvWU{R_3&9PJy0$+!#57UDTf;lw{=VFdvh74j(7jj`oWf-ga;}(T#6ssABW{i zkn(4uXG(F2+cw|B1|%kBCHUrN$a)0$kpBq)-ARXy0rfnYM<1>3 zH{sy^AqEe_9rZ)79L_Dq&&P}~S{4o$YC0`A$r^5;^s*uUrtV80TlcgcF3T-};-4Df zQo@Ic0VsaBeM0?U`q&7$n`ycuz3c-&GOQOpA1PZDAwIu+(ca{5x?M%%lw`?nG zLghl8LgwsnOpnVod(;PI*^(WYvEY+f@{`uBtvqNxD1Fn#Cr60$PVX_b^?ebde|7Rt z^Btc>AAH+*VdlYdg@XJUmzQ5q+u zzH=(mX{@6afaWRA#1$eM=meY%5KG!~Itj=CsQYFjKnwP61C|1>0bc>l5HL;9DF&VZ zegOu7$THw`ka-A*N22`&*aT89gA^@IIuC?iLdAGCBIhBDznlU>KSD97AY=of)n|Y+ z2wea|lR)Sz5PBJe5;KKZF$SE9us#yKmJRO|V*lfKw>R*6FSxY|6F>G36Tg>*iKbQ9 zQ!A{2m_MR{*z-IHb#Ew^Ki5!PFshN5(z3DmK{8JCG+oTzI@lhK5`pMv8*N z&4lCH6U4^CR^sLlPZ5v4-&WjpRkZm2+fJfM(m7)LV?9N6=7pkJL9%dn8!D227%P7N z!!4RsT_-61k;G(ws+zA3YCk$GD>Gc z(MB-F)Ino^1#?b6mee_2a=2Sm;8`vYQrcM4tWBx>NuWAz|iMT-#N>rP`UWpPnNDq|JP=YKKlh`ZXkOF z%;~yPWcsP{9d}xAzE#&niDp++%p7z0sg~vzQa-*cSE$OLf03`T{6ZnD@@;W?aK3wP zh!TshsyuYgeZMUIelb8Qla&Egn@7DOT{O{uH{{W40I1A%>-fFZ$PUa+j%uU`m2Y|b;QA#N_q1&}>BUs{LsZ8kV^m)n`{ahye?2q$c88`~i`-|9P~#PAP?y!6~ndy+5E^viNTQ{z{i`O42rt}6HCz=6IvmG7<) ze2KyRk)GuV&Ch>|+cB(Pmj5-rntnl8*KZX9;Ckcyj=}Z2@B8LrSl5I%7Azkyg~qqY zaQbDrA@yI6M!!~W=;idSak74Mfs;CmhTWO)mH>anZ? zI2eLY!F?!?K5Ls+-7q$H(~Cxk%!lR7gYP~*we2L7X2-@nv^9ifr_UZrQ%ZWJe#ez( zS^G;!H56UkuQ>k!@Lb^RJacDwKQkJA-v!H=AK!gE1MXKDn53U028tzpvvUWYRsfvt zQaT5Z=e6K_q%42J){{RzN7pOMnJ3?Ue2-GE{Jfgah?wB~_B|XWs?UD3_s` zXMg#Ato(v(St`A*#Fh108G?88k|?q9z|ZrZtt_6P^JY2o<-1&O=5>_jy8WAB9gB)p zo|#>Or`OD7Xs3L!q)pdLZfmKhSC%tBzWelhH0iZQDz)}QZU9d*wY8_pmPd)?2b&## z(yz@f*>5+P@b}MhL+Zc!cqSH?+T?jI!@QWpYw2Ii>>51W$|s}5`48;14?gg~NIhJZ z`$IH-)e^41o5381oeAfho~kt-G~X*1_OXfKVo1u0rPWVIiAS@44{Or(gO7JLGcsg; zf0ozEg9ve<A}H4F##OeoigdBhIn%(&wSYt&S3>U)g8m)&nc^Ub)!_o0{F!-e$R63hu}2@JCn*& zQp|%&5=)CpvC|2bA!Zdg^RRj!Q7pYu%dK(e`t?^E&l%HC`7v@tyBnDY^VH>R|2OdT z7h~{Lt)J}E`0D-slEdR4S1#S*+Q@w9dyus`P0se_8eLmf0S=VsrTVrJZqG!l%&}pU zCQMPLcVhQy`kQI9>MszV^$)a(n3LL_)GH11(dBF(oKF_k3+0py8=7XLP6w~TO^w&M zZdP7;|1O0!YUtiB-Q%mryw=4CnFw~m_sViZ>c7^AS7qupZ@lHNkDGfX%L;pLDi-0| z{286$X9aHjy;RqMZ_{^Mr8pkwu~g^Faz9h!*I(posfU)whSul2kQ)r_wwgpme0SCm<62n*Dy{ zrp{0NXynJn*l-v|h*?f+ivG%S+&&I=zQJ|N9u;qa0yzda6?1gVGb%FRL*N zC$;`%slmpldSbzmg6yt@qeAzGBY0qIPLgPQ~Hb@)Gg_GWN*J7 zDf~d|W8Q6cPwDS>cuF}C`evzKq08C6h8`1g<@S%1Y_YMEv6|o5CItIL$T3>4(H=2; zQ0p1{>cDTrfiuE?dUHQ#2Vh19``>GF!}kF3O#JFVPOXoXpC4LpXS}p1Ys6*ep2*=c zFI~>|0re);6IfZQo?6FQ+qDjOng`5%8}mm-J^m7faX6;otv`0W7^ZZb0}TWxuE^0V9#G@(RfnjwW1EZQuogJVAGx@nE7BB=B3NoKA@g-UgoLW zDl;|yqWfCoPvE>R%E#mTM2MfS9dJ?1CXBP+l`v`Dr2AJqG|bP7+D|NJK70?(3;UlY zu@eehAw2U;TQSOwgG zPK~?prThjZzmEAR?cr&6c-jq~j)$k6;pxFnLX^PM3GqUF2~P(WVeg+?gvfbLh{^kf znASH;Ja|u-n2r4C`)3-64zn7H@9u3RZu}FTLXS|9oCgw(@VQ)yhrYR7YWd@o))dET zd~Ak2kEQaN+_mt%2vgYZn{2vhh7p`d~Tp;Cl@|{spRhx}Leph4#GbASeaR-u`k>9F)v|>NLD7mR_AFtTwURu{WelhCP`CfZj6~Q0rA?AGQ#u z-|>Y#;qx(9(0h|1KS2Pvi%zlW$`W1q;H1xU2u_=&)P8tpPBt4 z#Q0O3qTsD4;l1Uk7wKphK)mackKmJ+E3GMw(6}1SiK7CF@)Md5*B*!gC{MWnNC8Fw z6M$*JB7h2$JwO}0_b^~FK=a@1_z*q=rXg|0Ba&jEkp7tWHXnhWk3mvfQ^Yy)n$i}? zV=(8fZ)<$#$ZwW*6k-78yItE$h?N%$k(`comC!e$R^}rc5EjQv?8OoI&!0~8c!_u? zN(^7w;L!cchd-gm3(KVk$|X=g^WPjrGBh>4uhrf|Pw(_VyAS3JZ`W+&Vx~&zi&B{` zXZs-OD^TJR6?l;KIxgO-*Fbz`T-@pLeXH7@$>A{{UC#D((`!I#(u-(Zi66CV%E6Dz zk5Q`!=Tg|JK3gP&&L0n55_!ov@#i+t^GBA;K$VM6pO*ZCq_P2)j2+brDZ31`4!#0> z$Rq$19@p!+|GIK>l;}S9#^2+9KH-FYTD_j-^t@^U^N|%We;1R#8(Wm)VUFME{(e6A zR0FO*=(GL9`;rGt_?pAy_|@fXZ|pmVo|;Uoo~E6)Y0%Z5om#@Ls6+U3o?JYv^V$Yx zEz-zO>8i^EgpYmau*JP2HyNdvkHJhhcAs=_{8a5Zf{OmwKU8_m$QBCJkn{)IiEht@c`>1HYv0|=1+2W zX*d)IY@3F8=yJBV@Sw_7koc%V_>>Om`=C3D2l<`wy5ZsvqeR2YHywVuq)~Si5zCQBa#p&dh&v%(xTOeqkDSVmY}{&C&5P`oD&yn&jY-nvTno zt??JAK6={qhbB8OJAFQL;Pj)*+1|&G$De3NXxS_0m~1nKDy7p(Tv<=i1O4$w=}0fP z${My1CFv70et7ZH!BpQN!|90ShSYyG4^7g}V?q||?^rP=-5`Ne&W9Z%ath?9#%DJf zpPX8stOieNCvbYF-=s61Cm}=M*g1Xhdv}|=M)>nTp~d)GRBt9uDKK~6z)KiD zN8?8NrE>QmcyqbyDVyOY-Ibg6)SpEQkdW3)sPm`YGT4zk4q? zx4B#*pV-*B-+yQJ?d;6EH*emQot+JA_oGrn=l|B8Sk?N03oc#X@8)M7@MRGJpLRs( z{+!KFx%oR$($j{zb1xc}Gcm_AHOF^j5q#0dc@}=CbLjGxe!n&CvYM*>#8x9S_AZ^y zJ~y4nL+B>ee=OyP6{L4gruo`vsW<}4BdT9ueUN^K%qPb0i&d*99QFzQl0EaMX(k{Dkf! zmwJ-Du^L4yhjP>+z+SEdKXf7&Yq|9JI99E#(R0-|r_Ad8VlpLYj_;|bLN|!op_HG1 zaw*GA0`8IeTmn9%K9^jQ+=H^8=ey4OoYp^3Zj=e*={L6TTICCaqm*8Hm49p38d=*LO<1O&PyeY5pTcM6nO5$+MYqXq`@5v<;AYF!i&{=uMW)^ZcN#)1(H z!iR6KD|3=a&%dY=`G50G%{DvNem2sYztAg@f9aUZg~+uhTAK71rbz7HPNhSF0ch~LDcy_g}W##ugA6@blKM233{#dw8zzxFZ0q`OD z2%jr`*J&RY3=Z9oTkvVDdTrBP<2xlU=w(`Qe|;Ca@F#u{K2znBXz2mGrsnYL;n=j$ zn5z|eivk3c|B#Byf57G!2j5%&o{R4M;ge5kkEC7>^wEVs@q_Vcd>cM{C>IXr3qKM+ z0RfR~5AY-TZN6#AFU%{T{42q4(Xeqdmp!w%kCoqmQ z5k7Uf?oE#}l4rZb^5uY%?-Lh--mv4V4UkZju+;JL(wFPvbKGY;TLOOv3E1`J?@$Uh5C0Si*!AU~Qc^abe+LOz z>x=Y({w&_g>uZ%q|FihA^RXomOaj*W5-iRiO{=I*%60MWy7NbufSumaO5m@kFT$(T z2RYY$UX$x~ebFUjhyO|m{FU`Z|KCzKgl5+lk%aC4og~18OPo*UbDyo#1LwbkJzrh& z%9GWa?D@8p*nIljKUwJ3|5p0^K3$&Kb024}C*`ZJzCG$a_=u3#lb7dz9kI-JEx3-T zB4@30!QxjYPO$rITA&1qAxP_U2+G#fhrqbD%md}|XPgBqpJSPCurel1=wdI9B@h3k zw1bt;v6hjPg)XOKou{7HKPeone2yjm(!S|sq=%1X-v7k3gOv~ECGC$byT7(ngOv|C z3ROOKnf-ZXW-TACRig`529;?eg577PXdjP80@m_j8Y~Bv6J;&!1%igNbNrRa z#yb9C*;vcv&*7&0ToQ1JeDXb)_{;q3$)tVLATrbLX$U?_yfRnE`TEEqNM!>F#W$SG~BFFe7RK3&dx75>P%#NMBErALpU~T6r zyx|XwVAq#FP?&a7e~JX``tqlU+0Nu&A_2R;{7VYb{u_Ua1d5T1jH5cw_m88vKaF*t ze=^i^(r@SN`Tp9BoxaW#y(XAR5IW=NuFO6w_+)0jC&QDSn9>2S=zH_z;|Tu!PKJ66 zI#wrm^UJJ1(9;eU=2%DidE(pSpJ0;uV`#+?vUUC~SjsF5y&UYa2_~gKo>q(`rGCHV z`#4_`Xq3P8dj*|uj8ZAZ8U0-C9$(D&ZRt2$!g&&*8$|6;TEENeTj%@eNwPB|%Y|)Z z^30dZJ-%3{qQziA`X?iA^^ZSTHrD>h-ny|Wy4|&fSGKNlqWKiZe9p`M ziO{Y8=xF;V?n&5r4vCegKh}JX=G@w+5Ph`Lk0$No%{j_bZ6HaT^fIGIM{gL zXgR2CIUdWkRo1kHC-LRK(Pjuu?1!8)jvlVeIph2uXHEb2+-t}E>m-nXti|4CY4&c* zC0k+|~#uAI-#d?pepZrRDpw!y9IN`pCX#PsgW63`gIgswkoR$fcg~oeJ)y zna91bu^+o9!^n6#DbJacn3RF9+F~EwOe}aJm%@?n23<}q z@2Z%e%i3PO`hl8Ge&)q+!jF|M*F*4wrvv%!d~AtoNYBF8JR~6FiM5sBD?My+MC7lT z+azDE3*#<|R=QkIaXEAG2xB}-2VZhb%|SQ=-_60t@0|GDTxKaZg}6cZXnA+V@@a74 zn(o_{T`kkDKKtcRR=V(Eex(Or6msP!O>w%jnLDo)0g~^^O5~fD`}IfHpWoqY-b-iN zHHWg&&8yhQ+MSc>nacm0k?ow~N=)xNGErxs2oWX!miJWrzqj9iKz-Tnk=G@C$=^zs z>p}AGpfjN7zp@hfUvs$2*;P7Ck)zfExo8?E_#1@G@uaic{wt)7Z@#xDn(j`9a zEw8ixP9sC`x&T2VJ)VnWm}v+yO1Z*jVwj(sGsA5e7TQllRb)dk-z8~gnO zJ+7*$Mi!0SFs--8ePqoUh6vi>$ayKDTje6_i_`gZtRNfv(+@6i6}Zr-$VZhD`+KIQ zdEFkb@xj1i2tJg)Skph+bI~npKU`1GsssA9<2C&Ml#kR|y}pTz#Xnx<`bYim|EGL} z2ijYf2g^yyO0L=d|0e-!`HV$!Y_lkDkvW2;=d3eQ22vipZo6Y6fnen$ZG|p>u~#e~ z-L5f??T(!UtmShNvNFfm{&JAIL@w;|Id)|cEM;r?Q2x??4;EkQ5wGdtU~z5Q|1SZ( zzrSE(V1M8GeV>CE4;FC%}8RgUxUkxRYu_;uxDy)YOn zm=t`TY#>sgt`d}ut+x=uU+8o@Sn_0OJ!$zwl$!psw^_rDT}!T_Lc@uk2;HRmkD8uH zyO~JqhsQ6jMB_8Zi85hk++?+b{*-=SNc2klitd(rD)DH4NwalSBx3r-@Wc*gZ4Iq2 z8=J(bhxff#JuUXku8V!i@DAD)q5H_CUPyfz;ly*poC)~4vhT44zHXa2EkJ?v=bGxN z(EN3F#HyRy9lU+=j-4YKTKE%sDPz7sNdA(&EUR*cF1f%hkAOsGtHpC_=4FZu?zHNjBd@Zyz|Q1qw?;z>46eRz$xn$ zpH~(_Z+6veRrGAajHo^>f9=6~rMGVjrbP$TyX*1s-T6SmoN(2w`*)+Fo{Lhv@6hD0 zX1ut>%!lt$(q0MOr23CN(U48V2j^YJXWY?aOB&}X$nTkrZx#>orh79ovGSr1tU>{v z9P+Mt8%%!7dv54Y*$&wfuq9wiz?Oh50b2sL1Z)Y|60jv;OTd_C16XymVhk*TLQKOYzf#Buq9wi zz?Oh50b2sL1Z)Y|60jxkZ zj=k*h*Wal`Y+h^$*b=ZMU`xQ3fGq)A0=5Kf3D^>_C16XymVhk*TLQKOYzf#Buq9wi zz?Oh50b2sL1Z)Y|60jv;OTd_C16Xy zmVhk*TLQKOYzf#Buq9wiz?Oh50b2sL1Z)Y|60jv;OTd_C16XymVhk*TLQKOYzf#Buq9wiz?Oh50b2sL1Z)Y|60jxk_m#i` zu;yMgt)%v-%tKpeL>r7I;phN*^sJ#ez%M*Qsb7X~ot!W|TCKVC&`qlUIJ|RWdX6(UFUynP%a!Nyx}DkX>8@l?PQI%!e}Fr~>q&QIcycoHe76)M zWAf8}Sfg}*Dt}Cfd-;b05k6Ff9|c4L{J*xVSOP_eBKorT($MZ(oxP6XnB znm{~I9jF2D+R46f41BO;=mdT0f#?Z!g^uT>i<3B{+b&Q7g*X-cIDC0%{TO*!v^sUq zu5F$@kNsGqwVBR6@Muqj9+}b5DQQb>H^deUZ+iv za!1f8d(j6;&#DiMXS>i6D8gmYi_S9x_2L9vV;L-X&Y`kLzcIS7C|Wgttj~{^etK7( z#;mk(VmE|tQvFB2UYK?xG1-}s- z_;mp4%wOg7b~hk}p0K`=Th=MIwbgv*ta}ZBh5*AX2gcz&QokfD^^xbgV;Ry}=_d8~ zJ{IBcOMRO+Cs1FCZd_{g>!P}#%^dsv0|%f_J&&Bd;EOk^W9#+a)N&J_hdM;N4Rq`JyX-X zp2BH~$zGQ;U;6$--IH9n$*L!`7qk&97lx15^1)yKTR6Sl*?U!JJ?SwoTD`b${eP0K zX?L^OY}$6}iO{Wos&`?&D<{wG$;nIX<<2xU#B9NRW5kO_xW=V9Cs0@Dtop+KyX0j= zun&K!1a!L+b!}*U$+|jPEn3{-?fyBJmW=apEp|od);|->uB7I;^UZk$pHab0Rz0DO zXCFhx`t<3jJ7Qyw$9BLF!e4MGLY~t8%(Li8Ca!Vb=`e87b<=5r)GHr8+~|(Q%a<}t z$MFJ>R=PpPL9;8VITyP!^3(I3-u#P_^YW5C1v&Xj*VFjx0`)Xl{;hUZU)^)ZEm4xb zXqT(?%8yr}NQyejp##e%ey-xyiBq`FEe5d}_korUtJ^DzvXcm;A-=neEP* zm^i@c>WIPI4s<%gsa^%zBcT=5_T+PV+^y))%?|_xjTRVjIr-MmaSB*l%E%<1DFz z2pau0o=Y7hO|OS~nAeV1r|Zesg`xFiEA;5Ct`2;4><1U{0ql{@jy$UmG8Vg{BFQmz}W!faVmiAJ$>p7b&dK#Uw5K2 z^d+oc|2K#A{@TF`^yKi7ST(o)=HE`evE}M4uW3(sq@D=fDytBBk~Cq0*EIpwB~!C3 zG}xtfeo<(>UFwKatJPb}uX|&~^0206&cct-gY&~FV^1D>0XY*8oaD~e?OcU?B`glj zSLg6JHE2zPdSmN9AKB52YUm&3B=idTO3leF$j|#-d~K|NueT!N)Rycf7w&BJ{#BQ< zqQHr~glb~(f`q>dif^UgfF4{ zIWj{&zVKMcn}^mK1A;;0@VID-lfeq5rqoJ}KXpTB{+Q#P?d!}vJf~=YnY$@B9<6k_ z9+JOQvYq3ENYSo`W_B$S6gjS~1fSX{F2ckbL%YPI2ZLk5wwc zshOhQ?sUE}v|Q^)#i^&VTVHklvf3wJJlVWo%3bKfr}!qnY3QGX7MyO^N-E%^M@*c$ zV8?SeeDdSGfz$g0@*#A|Uwj`QURTAe7`NzhNxLbuT=rIrQ}d@!k6!UjVz*hn%oa)H zB6Q(He3PH_{At+%eYP^TOqa{v3iv3BjZ?Rzzkk}#A54pV|3DxgLYMr-H~HxAoaQMA zT|mAYbbDX8G_+h2YQ(8CN4(Z=%#M??2l*Omk&DoU5AjWYQk*%N*)GGR_MYO(sf1nC z~0XK4lejI9-? zE*yFF#1YG86gRD9<|+IL-Oq^`GWi+dbm#Y}l!4dnXOCr}<-;62jdpi9r|L>}=L|=F zC?zZ1Amd>2)61Qgo9nZb#M%?vR0E^j5|rt^8A5`0dmQRmFa9*5y1hP799nKEw@0hT{`1|Y;-pJdUrvO;aokF|3Ed!S2a_+@>I_$=(dsAVWR`7p z{R6AtI}VqzvSjINZsoLe4qYEhTjP{QwgVMPK-c4`6WDbrn4I$!ng49yqwoatHm<-lrJaH_^|Vy~=pxo+}hJiE!s@8!uTpj9<1 zTF5%4^R>1DzBb-jQ|+r#l6vp*C!Vi6+s_y4m(YbD@lC!`-1$RYc}L4v%8H8R^=;;| z8lPN|H;Z#ubgVa#dzvr?-D8_k@<)#zxRL zPr)Y#@9nb7+&UWXAZj<%?;lT>{VIJpv8Btgg_4VzN zpXisBF4ui>@{k*>MV*EYnAekorOTOkgyYFJr+PYsG-*asg*b}7Mco%#Zdvz6t0(ei zz2eGmdf!(^Ob)kUghjh1bm32YbB17u3rj6B{7*k&AD|A*H`qFAYDyG9Zn)l&&**93 zIkc<~aN#xiz8she^a9!eST1CM>umWvhv2=e8tmWDnOf)%>-`CnY9A?qB0%(_pJkKi}vK365WmasTV@WX@C>G7+2uV_H`tOdR@kYKO!@54J zcw3yB^W4t8gANvU^mQMNdQJThx>bxrTsfI8FQ#1j;8hGf3dX#ZcbXCI<(cH`zHw&3 zm1*9&6rSj7+NwZ(wen-!QPSX~*$-{HO7f+hF|3V+F4rs1PokmPa-S}zy_MkWls67H zdiLEbJIVdRmz6Hp1NlmymY46E)W?~fJwO@VrYm7dUq6?0=nGwZ>oqfm|0wtPDR#(~Kv@as_V(b0 z(DimJ>h;37J-a5}{`AwEGR(9(!ehM^x;2N&)mvZxmetsJ10Z-kX1h2+AA2MbHSa!t|~pLB7OzW74d{ZQBRcy{>smcUy4eQAGp zYz(Z&T;Ip`H@9w-I`fnc(~BRDR}k1kBG3!JE0h^@zdRX+6KcW0-YYYytTbJ0fBF6*=Bto(omib-SY9UmjhL z!>}GN6c4nq(zmy!VW0nX642}S+Q&oJ@1jl7>ie(13vclD%C}C~oxoR-OY67Lt^Y*o zX`fp;TcTCXp?592@shnWJ7t?3w}Z!i zxX`Wt!&1Lx{A@lktDxU4X^DR6dMq@?k+A5S9*^~tPH5s&SEW8%uQLwQlDaL|gQYKV zB@WLe4?Qf`b)R9YlY6an``ng*E`gOek$!iNXG7Q9_@|=P;%YbE;92rU<{Dpx;QTi0 ztUF!4z;JRV>(c(Vr9rN+VwX3- z{-gTeR=$trIc+WV~ORCLb&XDCQT5$)@Lssy$oH>vLjE2!`F zV`9}pcUXtlMxMU6#L|un-OBtQR^Q7RaO>lT!fk=}Dih3D-*a9)p_cdQNzd|<;b^b; zRM1K{$T*aF&$xF^=0#=RG7fwWs9vm?k9XDeciww-j}elO@L{FP^)h^<;suQ$jOg;1 zXW_&89J!=wta^IV+9lC3g}Li|8HxQCy5ukZK~FLp#NgP zbJ4Z`36zJGkNB6O)fMf2sMqKN_fNBZ8S!~7`-ei8{KfZY<;&ZAkZit$tv#SEhJmAg z2V18jX<2>RM4~*K^=H{kD_{S{^CJ8yu|GRr4y`BcwqyL?_pJT9Q~EU8+y8D9kwO#cbC9cFevuF_|3rjZ5?msz80<8uA5!=@cVnOZ4;JlR0*ly zLbv{3OZ_f)yjgJt4?g1jr;azp)=*x${m{c!S?cFUYmX|MzMj|7gvnnh9*-tX`=0+_ z0$Y)U)b|B%hpz8qcSWn#$=kXt>b~>Ws8*)tNPQQ&m7_nfz6Tv~9?Sa9e<<}seEvU% zsmoRx&jkn`GpFYpER%|^2fN3n9Ul@X!rzqozV_X+^_}xGvQKXOJJIU?ejU3EKmGLC z=kWquCgzzq4OY$A5hWL7XX70m{Y5KZlwv3+^Ox~|EY71z!*#xM!9`##fssH4 z&hzyzY-KRoqR<>)< z2V)Ub{eOW|&V1 z&B!_*TP=LB+_|Pb4IAw3eEOABct^)uN4?~I`Q8pzK7`IVx+}v+>LhHs+I!MCS0>&Q z@w1}yap3*X^(AEw_Lbgy_2)ZpT-f4$ZsG=a3k1jdB6O4LKgzCD6h-N~7kCjK+d`R- zV0-3ETbu643P|cW>zT zV3=E@r(f;X=HlEuc@KuZ18*@2-O7>ZM#sdyxdlUEZ#ft*XP|p9-b@3O9Vs3vjj$ zn{qgsqpmOQJ`B_s>vI97f78OrMR^-a4oY68y^SqHm+RVdl5+OD9+s1ricjJf-lue2YvIu`SMcyz=49 z$#5m6PsP`pK+tHtbMn2@QgiT*JD;^;Lbu8yaOVikSmE7f4>y(Q`5E$Z(c z@5-2#fvp|#jgJdh^@q7~fj-~AY3mE~oH{_qG80|lIrWTnigD;uU#M>c$7Td|kZn4_ z`>A8P3s(MmevB)+qThEsgmt@<`$cH|*#Z5!Y;65|2JGE5D2E*-IME-Wn^ga?eEsR; z#?G$p=@^jE2vwvv?7K|__>DO!e}-vyI2NI9Fs$o<=n}}Kwtsc|Nl!aZdZN28d5#@vcZ6=uH5uE&U@v{{oWK{|2RL(JPP~a| zvIaPFb6uHz@Fl}M+*FJL)!SdDLmNS`-s@o5OZg*cyFWn!#mGbSr1RII^6=gWth#QNkGDDSsV74BkxRYu?Mpg#;z$EvU;-kU8{2YxN*7@N4h8aOZ9jK_|1+Ym zTQFkJwsu1k+4A`9pU@4Wb_mEiZ~!15ZMB*{<8G^7vrXf79-0E&Q;1-jNV@dNsM}V% z#(Kawq|@iQ*iHTewy*rx0@_c;m2m~*GyPy~sL-TN9Z&U3AJ6vqK5+ih1$m7J7QBr0 zfumMGslJI;o0mm>;mMtU_k(Pt;I4(RsMkU_ss5vkAJg%*#ms_im_DI!k=xKLeDW)k zYw&#A)2kjRG~Et1NBW${W_hyQSyn7pf?<}G&?GE$Tq?az8bPOr|} zkxPtky~lbkam5dIk6g3*l}W2I_mr28PS?Z1(qtdSc7I<96oEBqr&|6H*bbE78s`hQ zqMpw?;Bq3U#{c}$8~43^^Cb+^nXN%g8M=AZ_`Ys$uh-+vL)G<6&A~v**k!2Dw>^N$ zLPX|2y76a^%RSU7)*03P2h5dTsH9DeU{x@&D6)3f&-T z2a}H!cV527J1r6W61(yJl>Yc;Q(j_fUb-_ozYqGC{zalJmHhl{S3rMYFZj~sLpw@) zD$j!sqxGzxvHIFEJ=?Dq`LI1DUqaVdGJ^fFXs`fX*9LIa zR^ll7Iqz_2dGUq~tKaWa`<#>SH*Us(yz^+K8)O{P3&wd}dHAAlh6`P5%=-JkZN+9L zaR}NVY-W*~mo&xc&gPSVq?~C<_@IdSC6WHFDXwg$H4hLz<9`a2pXhNh6t?}0VXu#D z5~tp{cHq0;{&?FslRtB8NBIezY3k1S_+>f@mEw~oF$t}qv5yY+q4h=9+vnm6_?QPi z){VLE@jDNlT5RP*=sFJ!3k$wwp>kR-N5!~DK3-9@&8g@#@J939l4B_I>vY zm>C@TqFjV-5Vb>@dNpP8m8hZIGA8bXA0`<^PQQZ=fEw#r z`=-x*ak@pGxzgs--ca@&6L9~M`T*O369M+`xu+!OO!&~6&twyTMnGer3D6X11~dm+ z04;&j0Jb5N4^+))FLXP75OSnT0%#YldYjcUPSxL;`|7Dz&N_IQ4F#OYQRpVse>C+X zJ;Rv;>xWg?*(iG|Y==bB{4!1SeT-7>EJ8raH~vT{UP(0f;d&3?0sZbg` z*gCH}*XX(wBL&ghtgz60t!x#iwhg|l_Mi{Or*-z_{26@mC3GLT)HC@)(`t0}e1LB=kvC*8QWiO=OeSbr0 zvr=o}kw2juMD1YmXXFlv8D>{lGMWX6YOP;F7oX+Gy2K4>djlSTYm~YHY!BH+vh8EL z*$7~@C-@wJG`6XX!gf&DpSu+gi)YnWu;4S$55Nc+vcpsptj>$b$oqkUen1oU>h zC?>Fdl<`h+vk2Af`dzDwqGQywPu$mhxPR%$DZY-mw2wl!=9umr@9K#ex;zX(OXnA4 zc1T*JUKkAE>9v2A7E(dw*ZX@ttqJ42sYV;Gg(b+bn>gB*f0EPfeSEdR`fDAJ#kYx5 z>*wao=s$VjZR~5&v3S@o5V}Fs4w}6;7b^LxavpmHL57JsKgAY)tmD?TZR1qK9*u8$ zb$4Fd8=IM#3O_>ESTTYoKf%VWrJE203|V!4+EouNpS064A2HyKQMKz_KZtD(o$w=c zlj=W~$4?N^7&qzlsKmmLRXzvX#i`Rr=cJ$df~#St1T#jA@t~ z!adT@-D}~)`dm0ZtcJR;$NIueFP!#8oNt19J_JNQgs!n*1c!Gv#*A3SVD|k7xbgX$ zbXSHaCzCVOo@_9pPibz|_$iJHEths3<5bN%S~P$4$K2Q3`7)OB61tCE>X~w}&d*_9 zH6LH@#Yc_2Y4`vFM!Eb3xKZVP=X~5+jsLV7f&5$bZO55$YVnHEm!Gur-B;pnGJ93R zztBq=_XV_xK$A;9VT3zB3;)46DbM5_^Z)ty&aKmHJU|^fE!Sn4J7khNzbZbEU#mUK z?S$`zXV$5CZu7{VSw4P*U!nWRrJkQX>H(x`&K#TT+JC2PnW(O>3oQIv_e(GCODmX^JJf^OW_-%Y+Yxhv zxKHX&R?Wb6nl_E&s->w8^!Bx-IxV=qjcfiaq zt_+=V=|;H587sz3tB{vCC_f9&VvL?DKVXRp$4yS%rS0pHHQkDI`uoI zJ9Pc*d$QDu=lDF3j(k+ZQRoIyI|S!rpa+uyJ|2d+oO!ZJJ@C2Dg4%)nFfTr<+%Xv6 zy&74~8HMX(yUh5hZ*=R`SlVnjDQ}^hRR7V+&+yKuHn}jLDQI}?auKvFunwIJFyXbQ9elkeaeJm7n%3U?FlZ{?|mt*^*LXPyf`O9zJ!j`0B6?A zisrri^If`}(oP7?4>OuL?}TU1?f?DgvZGv)976b-i*ukXH^5m)9_ThAJ<8#q`dpjO{o4YG!0A9c zpgq9naC{!e|9K{G7Qkl*oq;X@yUASvK0i1II2Y&+^Z?j?vV)fl^a6SVeSp3|3Xlr) z1I`2b0|S78z#t$EK(|N@0n&k?z%XDqFaj6}i~`OFMgtt*a!tsEz(v4VzzNWPxBzqw zjXe$~!k+|qfXM(K-xL5-0Ss@|4B%4Wa$qJf3z!3330wtS16&8p2NnX0fg6CEfSZBk zz^%aTz#YH};2z*UU=^?icnEkH*a$oZJOMlfJPW)4ya;Rub^xydZvwl4cY*hTeZa@S zr@)uMA>e!9C*W7W;ecKP+}DBoJJbYD02%-%1AI578Ne-MP6s*yU4V0eWFQ3?01N>} z0Am0rFdoPTyg(sv8892T8dw0_2=IOTJAswJ8sHIN3-B!P60j544eSN>178C_0!M(V zXs~Ml^?*}>7C<|o3&7X;&I5)57Xae{4=@dw1zZQ*1l$2U06YRb1^frt1?&U91bzY{ z!yyykWZ*R5OrR$)2p9vnfhoXjU=dIZJP2$7{sX)NdB znpEEbC&9!f1KGe0z>~nIKpiwhJ%DWBX5ar|8nFfIYQ2V^!<>Hv__7;*uMnqVzcQ`ifjO*6<57}^}V z0nBXyo?GI70^?4@_@fod2N>2GmAege5xA%=_L)coAHdAhVSC#t^ zM_~VeQTXoI`LJc9(Jov78+ak=%vh!FcA^esK!-DN?|7wNod6wj!){H)TFq?y{~X9S z7j|Q^QcLns#sz4nrlMazO{ov3Bi~Dudh{~LrwBIo3dm+Q%4;rc=RDN+t0AN7pf~ej z-xuP4E>`Nd8&J=eBJMKeaVzTE?I_bbP*3hs>X&=)pYKB(xC%DoL6qq_)R7Ia6_3K+ zZo+?h9DF_ro}WgYcn<%o1iJSUZ12m^-<@b<-atKn3+4JQ^zD76KG_G_Cn)bvp-*3; zT|5Mv@tsmnABL>|%l5^grbal_rBM#GxVl4aig&1kbsVY_4E1~%>ccS9dCeVIc;-;I z!%(NeP}hc`{`4G&+S${gUg_&ld;2?7BnoQuO%RAIQKW`Axf<*G+Bb_)g9pT@_$e_e_x2c-w=G7U z{9TOloLWsyI@c+INUVy%oNlrwPMyCpPNnaQQ|(W#p$?C%p&q!Qh8p-<4fS!&c$Ggm zUj4Q(US0WGJZx-Db?>N}s?TjT)psA(RFAZ(r51Q=skx8UQny6bR=d(_t8TZ}RQr>Yjw3F@6I6V&XeMyk~{jno@88mnt>Y^+9}+C(MY-$bQ# zYO1b%zNtDgqM2Ivc{BCE%;xHc1})Sr8(OHl2e(uW54BX$i%(NiJGD}tJ+0I)SGHEo zJGN0j?`xxGE@`WtPf1j-A4yb?Y&u;PPHCr_p4DDGf4IH6_=ygx;gx5o{X;scw;G+P z{`>8j>Y{CDskl2ksk)bSR_)TWxFJRXrBpO`Z2!H#PU`bJUEF&Q)FB>#kne z-9z<%J4rpcr>E+?KUux-Z7+36L?4yaps!lqAw@M$OI0U%`>AV|o~N#SroU?Z?Ep2Y z#UORb*fiz5ZLm81gCXkYmP6GW1;f-EFAP_)r;b#MXN*!a-aB8t(`$?>S$BaN)$}5@ z;+C=Mi4(`Et+!>Utu0+@*T(Ux;h-$F@^iOZeEmfAW2Z^#tNl4@;cdCvLdDAqNQ#eCCGxk!oBJFb3CS|6&wC^mnVc;Bf@PaGVkbhg!bQa8K4QK?OTP}>guq|#sh zRW;e{a1=Zo>9}%hwByEiVjcUc)N-uqS=Z5V{)vt)U!3B&YIGCFo_AU}R8AYmS+&|b zN=nXj{I>9HN28qXj!Q4-<+yNcsv~~tK*xu7q&u2@Fw)WT%nKdo-j?Cm+|cbfv^K}l zd33&G|4GvwBfh=d@xcdk93Skz#<3xCkz-@mrH=kr-{#nP=q|@9?*oqRu@5;8KDE)& zV&RjH{xhC;yjZl|5qszBj#=-&BhE=Wk#I3rJwWkYGd}^{!tw7_Rk*(-K6@Dq2~|WIq04l4&9Z~d6agoV+`d`8jtr35-$66$;FRvh=@0$md;}c-K6@DA^9-gi7+|Q`PgXT!#Y3TaxR3h zJ?x>o5BzuYHNLDO;d35J=zb2&P+2~Vr(=1>!_-Xwgo@5bk2Znwu+GnwTp6c&&7arr z{6X1|p?hdJ;X~*?a;aAVAEgDO^HE~q!zz!gtKw9PE9x!o_Q=#bihMZz!wP3 zN757*U+6*6=zOHL4U~s<-aYD?ICa-WotOPKq(|BU3m-!NeSG*8MCaoz3m?|`zLnR; zsW~skMJ&!9*tMaB5207gN8s8tW8x1t>3od!y>nh(eMz}KPL12MDQbPcZ=72(E}@fh z5xPnBAIp}@D7Py+(`CGb;aAfDJ`Py;V7XveQ~JH-rK{uAt^0=6uD7t{gmW-Pr4v4c zZc_cn(0r7tX#gL&r|1l&Vel-o?<8Tl@ zn4RozdU$=D+OurdJ=cv|G5eJm!_t-VA#^_nW~eM5sX4g?`S|F7*O`IW^JHR}dN1?R z^V$W22fuA6RDk!>s2oZkMl!LNg4ILd=kvC<7P4rTf9>4(8U&uMtm(~Bu$ zhtX!W@RT3+CJ~SK;W6xhM#5 z6y_(M>Wz7t6wDc7J|bZt<~ar{_4!cDL5;+^Qp`21bYk9ayi!+SKH(!T<^(Wr5QaH} zGp_(&b3sSrwR!>OGj0UGw_rZ#PW&&-1I)+xKYTOh=AOZG&+Yj8yYU}C#(Kr?@Vph{ z_Q-k;HKUC~&FPJCb%sN6KeDP1ITVUhMJI--YS)CR9+RDcT`nuGm2(I z0Q?hVgo)t>6s^%8Nq}NdZ{;~X#a~%Ron`rnW05%k@q^K+hrCY5`+3e{*6)*ZkPUh? ze8#H+NS>sjsEua>G2vjXk9wO`18y#39OFHCy#(9QDiPc#B2mZ8gazQ2l> z)%dC{47l&@_uhrBi~_D|HdgqJaC39*Ot%*sZ2J~U2Ch3g48Ev~NdSH7GWA~8k07XG z9INKHYJ6wD)K}JpFw_X4Gmh?tJH2jWVRfEwuYf$VIlT1EDXiQq$j*oDpX8b1!j1C) zkyBBpish8nWL>o$n`ShUJXtSUJFRrNZnl5c^`at{UaoBCG^5EW#tp(pLgyHx?u%Sl zPnpkH6w2_s9y%96)#sXze|Yz%dt1WP8jijLPrrojBbR!i*QKZCC1<%Z@U+-`3o&z0 zj&FB9FmAj<9U!NavqQ^iCHQaOt6A22Q*Yk$2@4jE{IOjYx>P;N;8eQW(bm>a9M?BD$4 zoJHf>F%BKelX@a_gQy*Xt>eoyS2_=Hle~Na*_;WsA z50{s}#IasyTBcO3SN@sjg8vV07E5XolFjV z50DE?1~7aw*39I?=Um$qfbA6ZY#M+Ojj@L268M(_7-ku3X^P;_1g-#P0keTQz+B); zfcEt&;A-F+;93BWZq@a`e1LXuA+QKo3@ia|05D`T*50sRcr&mJSPozqXRO1y4gT#w zF>nWPC$Ivz3%DD&2e=nl3ET(V4?F;@0#*YL0&9S^z&hX|U_Gz_co=vDcof(OYyvg| zj{%PZTYx8kCxNZNQ^3=}Gr+UJbHMY!3qT354R{fF3HT3yA*Xs7cm>!2ybA0DUIShS z-T>YNb^&hz?2Eh&yaT)oya((7-Us#q9{~G+4}p(>kAY8s{lEd>Q{Xe;bKnc$OW-Tu zYv3So2>1s07WfYM9{2(H5jYI|1pEyA0{j>F75EJ}0?yzoJSI2RG}VQVVYsRfGyqNnP68SNc!aJ_0rf1yC0N7XlXnV*xA;P~!khRj5qB1&jwK09k+=xEPoS zWCN3c9KZwQ0+RtRkO$-g1;7+wDo_Ya1K7)$0bBxH3UH0s6nX1KbO&1nvXw2Oa=c0jq%rfi=KdU>)!fupZa|JPbSnJPK?CHUXP~$AHIy zEx;4NlfYKsDd1_~8Q@vqIpBHV1)v1j2D}Ko1pEis4!jJ!0_*@@1$F|j0j~pZ0B-`j zfVY6%z}vt(z`MYEz#iazU@!0iun+hU_z3tI_ypJw8~{EAJ_9}nz5u=iz5>1m4g!aO zZ-8%s?||=tAAlc$!@y6#&%iIhe}P|t-+&_kJ82Fe3 zAQp%NxF#?js0q{pY6EqE6M(t^mZ7NnKm*`J;3R0r~pa-l)EMQilKbl~VNd;cU4)q<`wQ&X3*DspkHPsdcZMjP+(GnW2!L{v`D*s9 zY5>e85}=&uC?|q)BC7Zxbo%8viBsNn$)mjM$1|P%YN>ZEu^x;r37|}^dNL1swEFF5 zTR&CQ^&R%1>8Q8V6QLVK?GRi~{CaE5aH0NL^@M%yc0g6Yr;?@hNK4+}Q$N?kp>#%% zXNN16fZlFwg`R}6ZyWKR^hNLQ?Vg*la;ucVXk5xOOYzjS!wu^ec~{F!5&|3 zaeAkX!2X~Gx&9}qXir?`K45aEUa$6oFS_#T6|YTx@rQONpLXM3hUrf79j$bOjD!BB zXqvYGZ>#2eJ>2^fUzNd53@-DX{XqE?4ho##VHxV}(!9J__5KqN-tgO}XY8--%cuc- zmYdLhpW$AT8w)4r_}4)pVz(K_EXLK z>%b#lLN8^=7YI2|S^6%v?^`O`jx<&~WKCB;r*2bz(v~qS?)SDiQcvW5>$%X6cfSw< zkoIaNKZXb=^@{7@I^ewJkQh~~M%$;N(qq)emp}bPr$;YL8s;mUCr~id8=)HsXb0%c z5Z8p>g}I!|&c~XOiFwA=y*M)8Q1g}SvqS^20P9af;548cFao$7*aXC(a5;`;-@iBb zdKL=wEpBd%zw>+?#Xf^fJoOm^%UVXJDp@}-X^BL;P2m7ghA7`t#U${*zo4sEZEgtOX*!c^` zlnvX%T3k{$LSN@-)qBqCa9mA0#Q(&;nzX~Ld$#*?C7`z_3Bv>JILnB-mi1bgy5Rf= zR<;`!qt4pjuFa4Kd)}7kD>OF5)O(>@xi{NizDL^!A1_UF8e6|$jZ&hq@DgJ;JU!+; z9B1kM`C3R<9IF`TW_71s*2!hU^+1U#L;dRs`nYcIs6cze{&6N)T>B#Cb5g^*u0^@5 zn%w33dq2Bv#a$1?3dj!QeGze)mn{f!?JSbweSqI1v3 zywjXFcQ3u8>3lwypp*J5bd%~oR;vD{V{<3pE!K9H_EOhj)?p4!h`*yf1Y7@Vr|Zj( zivsnRKmQU=kz5k=ky6WD^1RM zjrZwJ?$K%1upUPbTjSa1$FBtRe)58`f&FCaHg$Oc##fJ@(RR^DT)%Q^a^Ig~zWT1U zPh{=kv;GR*M=tfO^Bvqz&AJXN9qX{zC)4|Btgi&^yH)o=Ds@E&@jgCBSUWDz{*;*) zamJ{eZjWY-OZ8rt{1j8ib5;C7@-K9Qs2z-Xk?d?NO-(m;vd8w6ZmwL-^TjDf#nSoK zZZ+%(#~SDRum(Qu<(0r~Ko&3<=m&HM*k#2K*7$BpE%=nZ*dm5m9^&dFKpRH+u-((^ zH{(%eyqE1Fecn%}$1^Ga?qd=Dp6Exrj6nUS4z~g1`#kXxvFfYGr^l}!7(MwH(CJrw??O7`0r`Go3HV#^-pV=4?|$Qh1#D#CW&_M$ z=mt?c$n(Przu$;Y-0E|#J_lW*U zI=r_$C-=&A-YfU(GzkaugWVG>9%I&nFW0-LWxlW()C0ztd>$0A%q$$@WzN9JX@my$( zOQ)anKS><%jYt(77&n;H>3VuPo%e}stZ}UIg5_b;{u&8b>kIoOCj%`2_GPF`)H^9# z1k1R}l&`K6WfIT`*0l6h5lFhe>Z;qDmnaH@(osB^#8{4rXAPY73wV^ z_M2hGBgFnQEOCS;@o>p-a*xC#QNr{kzT`tb=tyUnKAprBU()4$qzPX_=RFdZd+5`V zURhUOTq|A9#h3K;JmngF2}?ZN|NBUw2b4-5&#-+t9-LJt@Oyn8hY~F8*I#e^`&?8P`8jv5pg_ zi=i-j`_l{mn|77@BmFGul=Yl*w;TtFz9AS8=6QKezo)!7HrZtbpXJGUSfQI#|54j7$Xo)8kG5llDV`j7 z6H_y@UGn+I#PlqzQ!zic!@I5he1D3^Hl*7%>XB8Ktmjs4ct4$5=X9C)8u`0dOjw_KK>mf5UjpbWM|2@ zlqbuV;JBIXD&MVqXNA^}v@2rNBL_;ltsGvr_RKV{qVns9 z&<&z?D5D?d-e2YFhjwewAZ<7M%;fYOU=XkZ_#8MLO2v2GmjZm}o9|WgU2eYP&G*jv zPJ9BueHI=EMgm-S!DkTh0MjHy51ALk?0-m~1i|CV72)5Ce#FlWtsl9wW7N`~vDci{ z<*ryS7rVfT{SdlI^&iXVhwl|5QIKMkmu^4q!>xQrp6}ALZ2A5?_X${rg5rDmeD{19 z{KmkGhc1uD@CU{Wxa+{qIM{wAI7>*F7P)aS@lD^HDr)w&pF99z#I3zLbyNBtQs=o&i#;K(Vcl-Yp*3s@b^z7VIgs8TdDCWyMBc#{oL%0BO8D#?Tl zlqbRRpp8RwRN5}me)61p#d4!hTSuRu<2jx9a*g-W$vx(o|302e9Q|I2C)Xq&Ntf5j zXL;%B{K-A^c@JH%yoAnc0?C8dYI9OKY#@Ls0HbE$U-mby@BN&PR4T#10BCw_T(%60L}OPV%-Z4+f` zyT88#^mr_(TrwCGSg>L=Fq3dmbkFQ%)roH_P39%2u zzDg)3IpEYUaZ82)ZHTzoa z3SXRg&{ttZ6c@Gy^(IPafYY60L_5~w7>;2$eqleG;}+Th zj#nB1O#%Exqc6^}NPFN+pbKy=kPM^%1A(CcW?a-b;9`JtPcwiy0Ovw61!U~e{xJM! zf!BeLfggctkWm7_Iqx)JBEV;7+}D|VDsvBG?h~8@cz`>AT>w5UtTUM z?*qwb+}8k2(OI|?XoW_93or%-t13DaTLC^k7>f=_DmoUu(cu_|26YBHA)7GRi^o83 z7CI`mA)serAaBCJWB~?u>oBnU4THMrjj(rEQ^bRSIF_-_7g0VO1G0@~zlP%)$_=*| z<4D>~`~{=`fxlAEau4~Evf?$~$9w1tPY4=ucpqsJUq2^J?m^IS zq!AL&q}s>hK>~Wc?Xl8dZ@IRb-|6fCA&f*Lylcw2dy7%8&pG?M>Vw8#+bVN7ci{Ke zTcKNJR$6aUT+ZBdC%->uR95VaJ;|MqjsJW%6hi@NKV<)OYdV!ZXFZ`FQ=b`T9pk^^ zIh|ftg4HR;Vcf<*0${DHoKK;>;8>5Qs}(>y!FZAfg8w>KgnuOVeeC_A^<*pbsAj>k zC*Fy;W9XOrCL3ZA`z~~=fXdSod_UMwkz%BBH2T5JsSo6sWh7;8C@;==oisY}NfWx< z&osn_vrZ%ce0IS(I6lu{-&B0+2la%Y{xOYzyVLE+yj7v~;{f#Mr8#*?r(AjZ4a!Z) z`Rzz4-6F6c`cXQGs@sxc2wT^arbvfnr$kF}G4&&7s1kPW|q!RW()j%LZOQFZZ$!sULJQo)Nl9^&g=pSbvs0 zEhF27jnJKWo}9!{o`ReS5~C0S$v&pb^`ZoN^VE%JE$?;Oo`xwbBskFvp_^3yQP&GjUYai@`gPN)AJjwk zKiT)7p0M0GSJoQn2yhOP`ap<|*g61V93xkRbW8Q)kwE=Ws)u1W4nS{eJo!S;k_|Cx zQT!$Em3%&|-sOu-1rhxax|K~`KYEWJ@6K@JD=5?a`mxuSe?{veX&cBLb%kvU*V{A! z+5t(xNPsqQ1+WL;I_u>CzX5j`h=D>~4wk1Qp*Be9O(@?^DB?0qfWOul-&#B!-%9L( zx#to14%}3vdndj>_%7zg+c?zOc+q13J}!5`w_&O%JVLE0h*aGsRaIx4h;`;$V%3;+ zwbb}Y4b;LL8>>63BO%qJbe)S;|8cR51Dl2uUn1}vtQ+-!(w4S50b$O&v%ZK-c%5}d z?qMBce9}piv{|QY=a;}d1V#TBYz(dc2T?z+nzVT7$q8d_8g&C_$^7WEQApecrhoGTz^lfKKK-ZI! zO@Vrni6|UfAG`$L>g@UPu==<@u3_B7eTSN^4QIm!Cw5ZkCe?q`^(2|E^Jj4P-yzO? zm)}-0_F91YD)UY(+XNt(V|mh1C+K)i&ROPs{+9*t*%bR(Oy^iQU2bWcL-&jKuCA#D zZ%X`VZsF50)_$?jtvu>-!`zFv^aEFxPI3`$lzN`~cwqTi`^P)LXVssl9UOPvb8W2s zW1&}?4_{}w7{b@f&F&{#CHU8#FVOU(_=(W^p|-@RIdg|O`_6rIv$dZrbnCwMqedz!)+jP6%Y?bU^bFS;lj;(?EV(mA#doo7lK78q%iP=kLSo_UFxBiQA^(9y* z8aG?@#hM<^r9BW|;_%$=XNokAjlUGhO8XP_OlW<{dJ6A1559D5_j?~%XYFSS-O6QU z^d*?7sf^x8URJ#!U3ACpcZ!t$SYNj@DbEJ#jkVvo6ngdX_M(NSojc(MYrj+IR_@Bx zn{qm#|Fr&Rz`W?of%4*bCE%&^2_=Ont`hQ}6sJr5hn45h4c7DH|>-dBo zM1DgHyyHB5oH^~!8|s$NQYu*&R?)l$``w(|hypl1BZnM|u}{wVFu}oN0XkQyJyHhtvqyIA78XXaTVQ$-meZ;EV;IC!GPD1#nEz4dDAYJ%Qdp z%KzBA68I*H?>|M5LJPE_Qt&E*oEj^jR8Z`}(PDu@xkN!i8rn#jlq7|sKPBoZ32A? z+6MX!lnkS?AE*cDC{PZF)(6f6(d_KGpsPT4f!2WD0(}K)jj}ojlnt5)nhUB0EeE|0 z`T^7p10cDe(?C~(o&tRXIuwH^lR@--z-K{8czDhModd!vsUi&pbqeTi5Ea-|&`QvL zD7e!>pMWN!0ABzNMJK-VxCD7$*ST~76Jr0H19fg{X zLhXP;-4BJ@4~04gg?bhW^$84ibv#fA4<6hbFqu%AiSLef7vlCF(EVY!zBkGf1!_Zq z7NJ1TLxFBWfffzI`bZS$r6^GQaro9L3e=Yexkq4}wNQu$QJ~eu&;<(gQWWUsQ}9l& z9phiKvCb0(8mxp)=Lzu&3bf&D;GqUW zd!)RJJT~LnZ}EQc?^s{iK1n#cB#EwvC5h^RN#f$XBr$yg-UFTmKaeD-9@1J$XjT+M zzw&bu)T3b!x2Iv9@CorX{6mFW{eW7vaV`{xHU>ujQ5;%*LUCw36sh(fMXl8_KtcNt z*l4Z|jueM{N{1Z%Cr8&%d=#Y?PXFng(nb+#vQWLHJSjc8o_vA|`4pdgN}GI2iyi&v zFy>jlr2$I=mIf>h{B;e~A_;!(s;(z19eMvs-8X0h`iG+%*3@q)tiOP+BbNoD{vY!- zrgT96nfrgdGaWvFHO^BKz$eNlI4j+FE1h0b=k4l3F!pl$Mz){Y3+lgdd%^7wWy9?Q zom+0_Ye2?J-RrUOlKfhGQTWvCUXx#_?C~e|Ga<)#VZJJHqIlu$>r}j`>9xdv#u)cs zsQ*M5r2m9Tb`*~tU&H_RRDUUMob5})o3Zhd^G17dQ+oe}pBA{X@21Wm9OH%gIyZ7m z6feqlb_tCKQZCfTr81_zER{DAiAHGVekzwW|3{GJ{-OqC+$?>^j2m^ovg)_mi>8h z$p0Wl5ceYYAL!O-jEKgCWQSpdup|ApRNW0CEw**E#mtoGvO;H?;dQeZu=M z8Pd?Y9qLap-(ZJ5;C57gp~vCVdQEos7`tzd%TuP$<|0-Q#QA4$GUu<(<1U4KkK9+c zb$Z(aGcmNHInJN?20QFEkw3a~z5qp1+hb}gS-*tIJr$Rvo87@xLkPx4@q4lHu^jmM z`Pth=YVOq+V5m%Ub8!jbllcZa>@|UpM!1-cbSQVSbyW8l7iv9ZemDc`WT$8#h*TLD zl^>XKp*{!J12_FQEg$^iqF<&wPL&%j69q@OV7|_c9HX?i{K%(8QtbvYsSO_vDg#Xd zEdphO$VO2=jId+j14`HhE{HrBAGHm!@v#l~xu@5wE2r9eZ2B-$Z)q7H%vVK@f)9Sg z)1pShhnhxn{u6EpKh)2naq=FZexMvsF=zmYaF${CeGOhO_%xqHeKYE-S@?qz;DR8= z$MTP3<0I{(_QG|v;~v-2g(AWSuC zHY5!`VKA24ld)9;#V|g$Z;p+Rsh_qN-@cXS-2O-Z9x6VVuj)ApKJaBQN0rZq!Dk66 z7EV;n?Oy+7oMe6;8z;ff+KbYP<@w{AGG#qPqr6OK};v(q~OcgIH?1U z9yw$5hZ_&8`sq%Wo-FrQnXhKn6izU?Dv0_fSazcIPX@#9 z4x+IXxj$l+KNRv8T?p56yHoQ&Gfvd;vMs>T*x#yq<-yxC3jG#`Ey9n_`G89I2Y!z5WLw4&x~6 z2Q!Wkl;p&rcw2k1?EC$1+x`vqTd6DPvc(qK=kn#W+Ew3Ek?aujHKud`jz*UZclj&r z0Y~{n`z*I}1ip*wa`H!5c62{Y8V8|viN;Xqd5A`PsLz6>nA+Yeec;nG5Vc`Bpc6sV zzLkL%fUsOr+zxsQ^j{E`LTdY6y5ZCMRr+>Z0SwsPpzbhkcY#Ku5!@S-upfgyLFZ|o zWFh?R(1t>oAMucHgD}sdL46&@c@{cVmtt+`-0m3P!Nc17M+ouI(OAog2md?K$mUPR zd@htb2J1L4x(My<%@6`>HP8M4>rY!JiC$P>d$Kc0oON@O=<-F9`1<%(A~V!V9MpL) z@!ZvWi3NjOi{9H>i;8t^#ENJ47Gt-z6?YW26BQUEd-1VUaR)x&@csOBv3J$J;r zEw){~2||e^6mO&bG%4Vp=1|m4Itl|MwDDiUoaHPHB%%TNd0%H+ zqco;Ptq(nq(kR`*pdKK4j-k1mY)~$!2t+o2HfTNwW>$nit3ew;zk+(AQcnc^2eckU z`x;k(=)Hsj*!f>xH*brRctNf+Hd-&dSJK0|abI8b!?BvVYw=_T_1b-2iTY@m3e z-*F=8=MiG&%<-b;mKkENG!JevNY53G>^+*Yf1D$m9?wx6z{0dHCf+qx_@1kQAa0%e z(;NOEs})(-Om&OwJ=@t3>~Qa-qi(uC^_7R-p^hgU)ibiQ%-5LGLAJBBaiMBt`TaKD zheEovMNbo{JJB+vyJU(M&ODe|%~4!3z0}{goTY)CrGaWB%=NaWm5#Pt@Cbi29!K?- zzbjGvXM1sC#=^HB-2bp6X}+EukH;}z=SGgGx1;iT;B5?c40JoS!8WzNQoSPVlaFqP zHSP)>SkBUbs(~OFTwjy-id|pn+OMvje}0#@+tTBK=BU0>tyTFN8wa(%j;M6Gy=7IJ z8K5{p5a+*k@7Vd*K)xBN7rgZJ*7L`1rHkR%UNB$hMvjg0pJ#VeVb>{+q1p}RvyaD? zMq~11%gB+>q%m;delGo&<8gRXKF4h;+~Qjr*qt;WxAWO;W7pfP&(cNJ%bO;?ch4z! z+SVP{Tjs0xrq)|D`7VFCz6U1Ti!JSA=erzoP0t(p!|ID?SJ3!1InI~)IyZ7u^QHCq z6sp<@dLp6zG}nLjDQ-(U%Qm#MMy>RAl?H;yi0f;4O6>YdGR@BN-Q8($8-39+{&W9A z0HOKOho1@jGd*i-W_neTK~A~Xo% z`(D~9_I=MxO%b(qW2fIf?5cirEjiAY`8qdp)bf?q9T@Ksl~h&eaa4OnW4>&o*pH+Z zIa6(o`acpg`k5SGK93&T;#wNmy)+PnI9zYn(u6czE=a?2E%y1rc}7}_IQ-3Tw64sj z^R6oVWYN3dr_qA~9F05fizD+jrgT8PonrS_jPR7XJkBxBfW6cnu$Q<_cb@3VqiBC+ zUWcTmdQS8C9YJXzn$ss+LUTMBAWW%f^E}<*9|oei9!#lg?@Lf0iPq5%2b~Bi0i6Px z4Vnu&6Z9X@HK1i6OtXtOKwp6Nf`SeK4Fh4yMO*;7AJhQa7Y{{aL6?Hw0`-Kh&H%j! z8U-yr0m?&X>P^r*4BF5)Ex!T1g88ARVTkcsxpre?abs(7W7BYB-Em`GabpFzv6Z+n z2X1USCa~`8F2s1;*r~X&4{&3fFt9W;8}@h@)*Xz%JQOCg`c6U_&%iyPKiNJY#BD+B zg?=gKqi#T)`|z&PQ@G!EgxH9O%=O7h;xg>(Z;1N7D8;<3nASSh;VC7GF1T6%E9(?{CK&Xem1h><;E zzRrytn}Zh{7C`WovRpY`V&iz-igeNQkFtyG#YJb(+AwnC&>)dq%-6Y*W1@0t{c1_D zY9zt>S_QcXr@0{V(F~ZrN3^YPn)vgyJI+h7=iT=n!pM=mBe|HbF{Ohpm+5;%wC2~e z{-dF*Ss$5eTIt^t*@kA~iu+&B$w(1zzVh&1PZ#7*xa$wSCUL&Zm$KAO<$Nc)Dx4)Q zkHcAH_Xl)QG#MzOTA$T)TH?Phv7Qpy3bGT#BVyaZK3JNgI7Dd5O-@eB6z~uIBja=X z0cM=2_J3-(6p>kS>9UJ&`LH${>s`n(PMEKABS#r0VNf8rrEn3gyqHI2PLBVh`xeFn zpOa6-ad2umXh6nA+QG4LQF&mB*n4vO+gE?KamClvfrn#UFkk0Jjw&v=1JDwF7OYJrY#(GEpOa6HDZ#vfK`8K*q() zp0RPU7Pz^!-vO>s$3M3Q!yuYtTrgi1qY*BqIPG%~NyP<~F|D^DxXI^K##T8)3A@+@ zksr4w!CtX((E!|>*|f)(0As^F)o;|b0bF?7s`8)S|k-8kt-u-WCs`j|0mUxzHz6NBR)c1>xldQfeV&bB&N84BT z^=BX~q?IT|46%6sqFbmtM5{YUK&F+U=K zeilm(qidu^RPieJiR5z&gQ|vi&3_pubw|d=NwO_PZ2t4)&$GV0G;OV6bQrJ9SEY`H zliYx}!sXDfP;sKBL;vMAkIso0H+0T+j(PN7KF43n?Vtu^oYWr`8z)&=DWbIK{!i{5 zp44izkssrP`KlQ4aiVvZRGiRUEx+GD<;`Wz=~MZ~a`D1rU2BCk)_^?UD+a~J$;<&M z;+Ka`IP|WpgI1{hB<8C*B!CmSyVU6UoYEtVuw%@y{UAILkL?TNiTQLLom;peP5gBy z!-Ck{uf-1%p$>l&6-IPVRg5eg_(cqZ`DeX?NzU zQpdt=BI{bHO(Y`6HjK_yyT$k+pX0Hw#--~mw__TR@lt(kY`jnoEBC+sq^<|wa2DrA z{U>@lRQVj9C|=muEyaaA?zMbqYe2h zw!A}a7uD-`_J6_@JHiP6r*qN<{U;*a5eD}(7sL%SKDM0@8z05PQp9aXzA%3JiG{tk z989aTBjaDp*O<~F8a{Go2b?|~9#Q-I(&antlyM+uKo}rLVOajBeLsf&@5wHRn`eBa z<;BKFWloA%H^ueuQ}+M-h+7UZyf z$3 zpCEznk-*1DAQg+;f5Jv}Gtr5fi0;$`>;YFj9`EMhU6{qU;(P3PsbxV?lDK3;lDO^0 zR^rChdx_VJ+K2@;ZN<+kvDfP0PNLsU`-#p^94tP*zrR?~ZJ0P{#8mM>)tO?!_ysw8Eq5Limm91Mzl+Bdn7kMC|aYhPHN!{!@Qm4kO;4=;Y_P>cZIdVFT*R zq*sUjI&posZnstv0weW-`Kk^Rs1N!2$0xW(=qZFyI8-m9y_cot(Gve~51m-_^Kf5u@2V zYBR{r5tiBB?ddj8#_i0pv2n5%ILdtKvPCb=KmE*8uk5F(nsLH>jVT>s;Ut=&+tqks zyGA0*c8>m2`$#w;ERkehwJ)^#d~WU=Cz+pXm>-cqKa=GcQH}8s58jqGo^R-VJvslH z@oN6&al0*$@90@mznIiQ*ByiP#=8 zkN%V6`0_c&m+OWW**YYw0lEEMUJ@H0X%kY!+xNcP=ghp5zPqj;l}M!hWxkrR37-*s zG+Htp4JT?^dX74m&t;#^i3ktW-y>hIejBea6w2){^AX+TWSr!C-EK?(;F)^@b}H0u$#TS| z{Q0>;E>}v3%bL&0=dz?QE@RoJXM~;QUpOhl<9)9QAdiZH)kA5^g z|CMP2^x@8Mzn1x`oYD0)#px<54@9gl^1y|pw?xM&FwCIskrd=NG4sI17b&t*X6Lp-er;+s&Le(GXfU;tr^})KLFgcv!?Mf%(yI^YU{Rg)9 zOA|ddwyiq-{)dX+GlXRQF<+Hk*54$*)0gM=I_9`MW%$0B-H*XI?qJB{Ai-(oa#Z&t zXn>rjd~?$JE4SqN)%^&VpRgRUHYY$LAry#guheu~;=f$xgaxioj2XrV`RphT5!W^5 z%V{z1pX>*5b6o#Jrx!Gk3IFjY~R++h>edv(^JIchWx_u?fqY>`xG!=)niP2NN1Wuxr zE%BI0HjcyXi|kX_&TNY*|NpN}#>uvsv2jv-YKmC+XQ%ROo?6>M-M4`GsvctFB(mf= z8cyW$<#d_HKG%N==W=GdA@lg0d~zIzuCZKv4ahjjaKy$*wLL|==jnZY@seRH)cp&X zujUvVC%pQv>3#{9r<^XAtr|v{A^TwMXCP~rHYM{$QyjBJ)ttE2_R|**xNB_x=$To$r#Q0&Ku*LD%?vStYz_MI3G$7+8DRrfn!zM6HSc;T+CiWe$hYEuXkT-J;g^11)XIFWshk7!|h@wLRWT=O*` zkE?8$6B{qtr(r*6$E!yy3oKf$zR$;eRf2@^66xYBY;`{uT4pyJ;?NxSJKt z-pDqB&WYHra6gLv%RJ_jTx@IT+;V?S12S&v8#Z}CR8pT+#YDi@Drsd$#huH;cRYT}eF5T;<9PbN=tqi^ zNWAD*|FgOBbLq^5W*iA&UdO!_I6Lz9(@yB|cAGqP{{`l&+G-L<(Kchi#XE`@HQycm zPqvgDVTS+HIcbOf6A=yxlY5$z@ltzsY`km(o?h9jcEPH?*Ic0P$H075e{u05Z_a>= z|1P{RE@b%$6XYl?6-4h_?deX&%i42e<0bPPtcUC1xZ}e9HAU+F49r*c85b|6xAAu_ zUgS20Fu?z*Uq}C$M|>unYL5PMIQe^`Z6QU-c-eMdY`hfzJ4I|b?EE|3!@AwC?$^M4 zN>g@C;)P#slJ@qX>s0%aEGPCC c*F&@Y#$G#kg?F(at`$BSj?czP?5W>BN`@uCT zUd;P9)SjOrF6sNb!}GwlFVy`Tn6Ij?NxUSonFA72@uQ}{v;Gq{7*m{wwci12BI1W| z%J`|gC^mlTfv@5hw-&8fnR1A_-vRR@DeGs=#gF<<@UF&>Y;V}k(4COo<93X&wWqdE zqzl=F@Q3k}_Mh1Jq3bSdBbFVt?8IT}z6TLL#frG*;zxc*m{O6)PYW)IEngkv?|e$H zSGEn=J5}8Wf%y^1^t1T#McEVqm+op@v)s|_qO~sqYbWB%xCves8#fKWRq?Ou@4w}? z{>Q8PA}~LavVN8@ZWM#Kt8vqmJ*2y^_D4`l)ogDvYGdPuuAWxAsqMTQpZP-FA0fgw z=aDdO6hkOKSJcIktLE`^ak%sI9?u*Z7_07=z z?*V-_X5S~Kw*ExjKY{s)%M*E7p5Jw(YopaG?mx0m@u)r!u^nX|{U;~K<#UcN*Cjo+ zbxc$PvOP|_GB#c+uSgLG58k~0`$rAlN8L|>`D(sR)~gW_yhK}~9St{X+Jpmkd@lPk zPI#PO=5bs(4aOnyD4g-faV%fgfNW=quQKDN6j9{;6+*z3>y?Gw-kpBTGb4#{Wzu<$PxpAmf7hYF>?Sq0RLh;6P+K|Lt+|@3SUdT-<9} z!PbJT9Ai7MFfN%NH-BScA>&idKjVhj_g{Toib#Le-D_3OXJ{U-P&|fGVk`GT~Cg0qO^OiGq5J247ujy^ z7f=>5zUW-WD>WS)hkdY2PQKn0VEsu*12u@n_{_N}Ha^OqN*5`uvM%fYWbd=47^yQp zn6G9k<5R_lY|3Rh*2R${`I&UF{_Y8%ef-nAb5uLd{N~6Zn{-)@;+tdZqwd*sar%!> z-n;Om;ip}$=!5yqkwZ4^vK$-Y$Wicox;V?Xe#Pfcy!@VOH<;fXIb;(e%Q5qo*!tMA zE?peqt^fSG>@+{Nbk`i?gZa&oLw{vRH)itl(6%^o)V!E3I;4H_MZYTs@#AE;ooD_I z$RWekG>#U$HMU;*yp%33UGic5=sO^H~n|6Oc!Sv1vXk`}WxS zDStIxw0q>+5o_a@$*mrxYCw|;((*ImJ|7l=TyGz7zgB&V_%NL_JlD)|2drFYZvc9ham2i zpIdA1kByUUz|rIrPbqxryX0feH5SKne~$U8>SUZqQ<34J=@1kzk8AKay;>gfe?F(W z&0`x>j!Yy2opU_;Z@C@Qfc(6;c13J_WIm80hWIz#^+MX>H*Yye&yVrJd{v4j@SzTI zga@isys&+zvgYz;pYu|~_&?QuJ}2DKIb(>uo{XMNaF(Hrws*`n)BnwmB=C$Cec)rvlRotO z&%8#4Tz<@NmK;sidUJm!XO&qlb>1`tx$oM3+W-l8?SY*r;AwwdODZ+mRzEaYcjuia+roRwM%8a1RsqpPXpxr zVZ+<+-_hrRMe6)2^P4A6WK>M8Kh`{}s>#3izl@XQ$7188;7!bzy!mHfmZxifb-bDR z>fOYyKartkx&CB75nGO>kn^`ow%zsnqTm{JzLoh2%h5y|q~exrzTAIg+fDhfU8i%h z;rxt3d?pH$oqWB_x6TvOfZT7XkAs&jZ>5Wi`meosYQ>fH>ijG7)m)pzt%{dO6QCs_ z%T>N6HjZoFNf+JA&--QiPfz`zwgb%HVY!qhL6%FbjV)K7jp?Fi|4VLqBlnVf)%jWG z@335vrlFC(md255-KKQ$(wAMXIDW{Fb5;Ap{2i7nVu~8cmGxw7eU-nLE~cGxTlv^` zI(XFiTjuYuT=HZt5($BL{H8vRT*)7#3-A6NJNl;l(vfTzIqt7BU*|@S3FF?7OM$;h zzRIU!>#goX;NM;M^-tIQ_uYUzO<)f%SSmDcUy7B=_ig1n`_b^ zX;I~CY#f>^pHdx6@-2@eU%^M|;?p}zMs&=(@@cg`FrVdOzq#@$)xsoS@iVdYx8-B3 z8=RH$zxQvdo~F(RGoR&RKVkWrm>dovA+8_W;>cI?NxE3H@tPy9{p$T9bzYeHEEoGb zB%f5svK{X8yjg!jnCFLUo=p))m8Z{qGJD9C>ijVCSuXaQlrPp~F)mj7JDlFG^7+}9 z@}tVe|LL5xME{A%j`0{EPWKom_m8K(5F0nEfUC(Xk2!w9dy6a8`C{g)ii?XIW%Bs% z!VBX@;3bW>obiM%uM5^kI! z7h!<^Tl2?MQi(YkFRNaTjhBp-aNm-!!T4aG^Hjt5KiLI7C;ZVlV~Nf!*L)4gxG8_bjGIy< zC(kdh0CX=3Gu z{*`U!q`1}jX6EmJ9ve?SBax7y$Id5}eiMo#SMgD4V&;j5KQ!+BCzh%6&&=O(xuRJI zA*v<$GTt)l?O=o*0t%%hiB|LHe=i24iJu|5X~5< z(m!i%*2^m7OLim|#5RR&&CG7-hu``D_NEeI{O5z-J^1zBx`6o4<5Vi2;*u+{d&;KR z1CDa1&sON4SnhM$OAD&B@2Y!Boj#|p*ynXP{eD~FI6cso=ky2A_Jg&*2Hn zN9F4Ey8>QcR6WY`Z#8k`T>Dx_am@|S)owlESU)}6kYju?U*|@Sd2W|yj%`GBrPJrC zaC!oEydm!O&T%{0YZ=jVT>;IgG3)LX=4Ml(c97QT`_%`o&}PpB&{)->XRn(fBak zYfq33Gz2snGy^mrv;?#k^gZZkRFWFdH=uc_IESFJ`~Yf$MtKGV?Tm+sVMzQB3>KV` zCd6lGM9xKBx~V(%Y40b*0mlH}!!hoJ$)Yk3?)zdPuD>63<|8529F!y~PfHRHtxpme zqgsh2|7|6@+_jf@|F+iRm`~e?;itD1?f%tHJkT~((;HN>5F(k^=WdMX7b1#A>skJn zE`DD;>!`g)g`VVcX8kgs(v)3e{bIvQkJAxwmX33m7P~5)dThDhE;glT_9PcUBnQ-^ zm18lK{rXd{9$fQAN0DZK?ZGcsth_ZtzdVdL<{Rv=7Xxqkc37JtfUl}@g418+4p70% z^3*Ewkd12%3Uw9Ys52(LNtsknYyZU1ZQH*kS;>)~gd_7crgVrQ&q$ZgAJ7pw!8x}I z<_*`$^)ch!*yTjo6g`$YDe!7w5@$(xCDf{X4o9g3Pz_6*fq=_X=C|d#-QM{nunzVz zXRd=RZpi|V!(1P;-;XWFQpkDaxkFDs=7jSfrE(+(h->wc`5IF?6nPzXw~?=HjQ2Dz z)yaw8VzLqxErf)qKJxp=YX3$`$~yfUG!R6dY_GE$%=i$ftW>vF0XM%q9+ zLi1Jofc68SdJ9@Ud?=_7=t$6DP%fwlbP~t~`WNVO(A}UHL0dr?$g~i2F6ens7YIN$ z|5H#o1Zf2W@-XOP2y+39=)Dl8Jp{Q0_W$3o|EoI+F$oQf6Kw$LjqSCHf3ibJzC~SA z=|ObM#nFJ=Zmd)AuePVj1JlI$j}*Q5V)~lLSm&f;>aQ?g&8`vtCHpwi>pLnd>%_c? z-lN9k85h>T=lWRuk-0u*u4$#!$1U5?-d%D3>vT!S{1u)2$GE;VE;qhC(5?}m!^hg^ zxytMTm)Bz(=gD)T8}6LsaeM8h6TRruk#Ks<5ImM+8|0w-%mvYX(>c{m`MF`#!1{63 zPrhphTXXtr9_@t6=Wt1m2~Pbc(8(;68 z7W7-5eaErcWLL=P_NBF8zRryt@tioxQ*QT^x}BvXsvXWsf__6{f2tT zLFrQYH|26tCY|w4?^{me@MPm8SK)K`6z8mbV9z$(>!_mV37fOp>A*8i1w^AbnIO_< z==RN*ZA1QY`joa@Z!j^(+R1Xy5*U4+=20y{PRQ0Q?7cD86GL66scLa#apZOY7 zI^tVZ$@q=_|6&a=KA@N4T9Nx^|Un=g}-^&mDwAf}D}9 z7MJP}IpWc|0ZGm0a|*Xy%V|KaS9Jev9&egiq5nQ=?NCpor*PQB#x z+MM+r#h71Ty}D!P(j>+V^@T_d=Hsu)>2|Bgz5qtkRx){1VFext@TiW=0p4*{0jICR z>km*>AL+BRwKwnIyFrmFc-2x(u4F7q8#?ocWeqQN6hGYO$XY&j@(uqYV++S}F<<9K zj?v``H#$wq7D5u-4pnb4>r0g@_)14%%Qzrw?D<`oG&%Nh5mwx6N|_B=vZP1P$%8j_Bi*IS>I9o(dF93CHpP;=?mj}zAxq*?69Zb zm)yQKQv7gNDcuL2@wIyz>GM`d@r{(^cA(}9b3cIE3F?O|MaTZdlyl#rOS)gXcGB+$ z^nHQbVv@5pP{MqQBfBDuZ&slSP4ZJcq9^Oh0P}J^rBf^11%V1TakLnw`kncuSss!_ zgJl;XJ~;4yA5cD>2VZ%qZ_CGh$i9#xdD`O0e2pm`Ci?6izZ<1(V=0C^0~ns64jpqQ zV~lP#^`5}wOJ)1FWvdydYCpFQa!)z>$ggf6{791CkBf}UF`v_AUxJg?<<*Rf4YFad zrm&*YZ7Z2?uS8_Eoh0+hwvEz~+e!Lwxm~LPwS2h$!cuTqvCn+V-!&QtA{%aRlD~;v zkITPK5o_va&bzwZq36NmXbwXaTK|Fh20QFY^;oXLTzwnWU$zgFKr~DcFB(6bp>@)t z8j$UL)_1Y-Q49Pm9C7e5_0t#pf*~u-QFo5|m&`ZVVXqNB$gXP!euA^Y8*p+&)s7h5 zXbx_K2@5A-)$Ed!AaY?lvK%;}b~hJ9-pqV1dmOdEf{l4(Ffsef<1STJclbQRVBGa{8RV%IEN?`C|mh z7dTauLaryP639ROJ#mix$qUJRYL4?)`5YcK|5B&l;d5z2E*vk26V^la5ApTzsH^&M z*YfnU_5AhzBF$SdpVMVOsvQ1+9eSwpxy|D|s}jh6$cW$5eyyC+2nQ-ZX8xrvf2G^L zfa1vIkn>~w`~P^u&^04_e>;!U=WRS(fBYK1o_zNFoVlx$H;-m%^&*jE5jIWGl!WbwX`P$+&D{S~$Ls3e?kFCp`gF*T3r=`$wJwO5ij1lM$$XZB{gS`} zHx0u_=3?|YE4iN5AYbaoaDPS}cgbkKk685Vfp3*hxc5PdM~>jRGLB) zquv$2d~r|ff(>N!;M_1mt#D+%&W#-PaYmY_^J9F>AE41hUm!OSa8^_X{F6KZ7gn#J zC*T-Eix>x(?0r4tiPtZ_{m+}Xo%Q8`&yXDC$WOwN`8qdpj4sbeyW2g>?wB(Y$zU=ju-g@{`z4X-e`b0;S&*3riw`sLpiz>@8Q$s_fUPr4>eWw1}e|YiC z`#2xH{c9ssK8Ks-C|TeKFt{`fRcKLzIC6P3#F3-AqLUa@di}*`JaI)pU&p0CQ;~gP zKIhLq=0i2@=eg~kITM}Lfs%4e9_hA?;?RQ+=U<(qKZdY8NprJo&lX2A`sIepfH z%IEMX_N}V267vau%oEQ;Z`lu7Fz2B!87Ri|QD7il8v?Oh8LiB6sq?TD|H{(~er{L! z+cY{S$8xEBJrwWFH@3TBxinLZxi%OYzcziN3Wr2wy)92bKKB_vKKDiM851~vmQUq# zcr5vJy+xNSgalY`#e1d3wKI;JKDwmmhFn^`n+GC!n9p*sueTFL`NhRH9E_C))c9kGCoQ4l zcp;oHjk;$wf-$_lPcy-IQhjtAN>BF-wU;<;#_zn2lI7q*m&z7g@MKbH)m|8!0~Dqp(Za?R5~9ilUS8WjAf>mqW#P8YVjFZ^uC z)kCuhH{|An2tUl%n9`wX{FLAUw-^NLV~V6(O!2q4#HaT1CX;ZJ&<#raJx$}>k<@Zt#wlr@+zPHq=tqL>Q zrQ~+08U}NbC}EK>O&xn4M-6?SE_zLI3>;Yhjl<|JhTnH!KBAjk0&ih zOlxnpN9yxmva6H$a$vVrOJBcm{TJ8j*>r|Scw)XObNrF>&qI&7%tu}3;Z6riB+^?l zkC)Uy4k`~W7qS&(GkClt2mQ4kpJgl`e{nl)-5`Rr^~59x^NA-r?yqSmC~)zxmHGKM zB{oho(N3M!`|M-uicdI{@j!A>zRZ{Nq;t-#?(+0GVph_8>M{`10}GxizbR^?#6DhIR?@D9(jk;xq4!O9<} z-zX2;NT)qe<#Uekl%X$83l_14#4*R|Ypg6J8UnHX*ph&pUvK>RzP!-Hn^ZZO-vV-) zlqut?vSWNbUU=FGN8SJQyoXfzn6Jv$2v^#mPh(Zda%@jPj+NaekA5hlz^=-{{KVui zsY1IXh$EL*btkjERoid6VDP`@oLoEn&>QKToGwpNBfcJrcOuk!rY+Ob+h~dt0&)Hs zY4OX$zwwFW6VE9)Pt^nSDNWfiu6c=@W@4HFY1uB;B_Q83Kickm`J>hQ=n~1 zZpj#IY*3DutFTs?qSt}AU929IK)X14U}ommZJ*<;NLG^Aukbk>BQX^;bcdl&^IQ4) zLgmP#5xoYC7pn5yUiA4&hgad{++0VXiU(*^Jnw@HEIhN8|9)RBA9_A)$`Qsbw`(<^ zmQSL&w`5tx>XRiZ&p$O@Q{_YYx9r^CU+PVjPok1FrykK*EX8lmHHpgcPmO1l&+c8a zyRv-9UJ_aLCvi+z<&(Is{*IV`wR}kCMC*gq{xrXYt@3HU&UWP$R{88oZ8tx!U0FU> z|G+Ar=4)X0zQU?MR{5|7tg!>uMB@IgtUp%yBwj8Y(<&d<#O~><<6x+n-`U_m}^{uJ05KCT9L1QE|2i=rY z>qArVnBP>J&=jAqi{{fcmW!Y?zR$F-kF9^9l69+>OOjx|np?haL1n;e zn^-(%9QG8^Rx!|Sb|*R)br4cP1Yu>y`HSV+k`8}Tc5oR1V zs+aq85TCWVGqca@e?E3#xh_%;Ji;OKRYBvnm%N>1xTVxnXzn^#HQ!zJKN^l(GH)Kk zYsoaNwElS-uupZbgfeRMRjIpw_`h_46QVGod)E7VyGn2Po(j$ zwY}SkQuy00YAw$BVEHL^D?5qn-d_3GQGo}CEL*J0NPTMvmcrqPFRUF_se9 z1Ood$&|6a4?)mbz7{aQ@x(=!Sa$SyS)jG2@VAjCjRbO_u_Qk3%W?WeRqHEyqsxQ%{ zX_~vU>z7qun%2D)645|4PSx>V3Z;1@eQt{WwY;%IEO#^PFj(ywFpLZ%1kyS7L)8I`>AN@v!f!FMv;@ z&BHt*zU^duX%e3T^NqrX3$SAjKKZD8nNnEKe}=-Xde6wS{8$>W+DTnITwioM7E5DR z*q*EbtG<})%g*e>@5wm(r`-GBRbO^DJI?KkRbT!o$lf{k@psji=HAWDu3uD7th&6g*|?xQa>CiloL_rjZM%%?cA3$Gi^cf05-=Qizwa}KZDRxrRe z-0P^)KA5PlAdM^?o#-7tZcIKtdx}eFBMIXh>3C;Q{|c-5`#;$Wbpf+D^+wh#2gurBbRQ~Ts{U-dR^%i0P{LDT=Yo>@M1Kd-EZQbmW;o_}r0N1=@e(hb0|e9YImkz@1agtgF%aQ)4bKRUgTxr-|w>Yy;~reRJYeOlRlUqkwiZW%VX$cI6e@M zFY|evVbLZosC4>82<1=Z!rxh?bd4qyt&!OgpLuc|=9yz#|5`!=Atb`}ra{4pTCa1i zN)?{T8#){?cjVb`)5dskHW1;2`5IF?gmFT31%x+@Y@?h3e#3~k{&BPOeBSwZ|A_wC zny%NYE;iSzSCLOWXy%2fV*02%UG)ca5X&y9d2C9>B?~$lGVuO=%$G#dP9^yqReopb zNSD)HicbaONB|a7VIW99Cm;I7V|*>)k?={jgX=cs(-xErqW%16zYf~tk7`~A5XsXC zlmVuGa=AK zh`ykHAlk!_?CudDDyJhsS)ijp)Se6k4FVkvItD~-NjB(M&=Am2&~c#SLBl{NfO0^& zpgd4MXgFvDXe4M9r~p(58Vx!TR0J9W8Vec+Dh7=QO#qdECW2^F)ybeKAhJIvfu?~@ z2Au+$4w?Zv6*LoM2h9RGK&2qEd9y)fpmLB4bQ)+5$PKChc|cxJC1@_l2l9icajOE& z1I-6jgBE~J2b}@>7wAmTS)hfWAn0t+IiPbv{|220Iv;cas0MT)=pxX6Ko^590bL5Z z3{(qR1iBn_1!ytoO3+oHC7`9Ct3lU*t_58Ox*l``=tfWobQ9=i&@G@_LAQZ!2i*ax z1KkO_3$zS$H|QSFy`cL*%R%>p9ssQXtpq&?dI|jH0T-7v!Lfd&x6*1UI4uaS`T^&^fKrb(5oPr3R0t{2evx}m&C5uGY{<``ed)T z>F2T$`*oy?;r0fR-C@4Qln!y~wXFo5n{nvuSBO z;n-26HqB8yimmcBHV!3~PPaS1-07HO(~i#4DPCWxU&9mUn{#RWd}lXw_$}>DtqN;N zbG|A+O1@+8-CUA_v(};nape5hCXoMGo*Um4)hrf5ho?{wkltrTk0Ez4JXKRp{`d=Y;PEYfV*c^F8#z z&E4-icg=5{Hs80(=Wr=s?bPKdD{=bfxg1WLNe;3{EJr=$pmcLVCre9CGFj3Z*FtoRiqno6t5MI%-5LGLCYK+RN#J!%TtPG9{BfpE1X(C*6A;)s;u<- z0t0M$-at97Bm2kllrM@e&yU~U*>}rH>w0sRBo9fY@;N+Vc?zmLeyT0wJZ@?aWVyuU z@#T6U?~$cPm%Z{C=gV@bd=5`ouCdtcd7jgd$}HE?1mt@2wzJa?%AZW8UUMv$%IEOJ zf@c$C*>hGkl%wvlLJSMo^+VeN8Ympay3BNHKU>*l=SQ1-4 zaTCTPYKN?RDc$y_Dj)MD(X>;RhxNt(b@{4X?m(d@0WljrpHt$5p|+r85bKhBaui0y zZ6ovOKM{vpPzyJTAe*uGqa=&v`96TjImMXU9 zjt*8`J-CO8C+15~(oSRG$u=%f?xg2#azPN|I{Vt#xUOB3D(2qbwe0AT=f0uJ!F){3!cdLzX+COOOb>`=zEqFMgr-|Sgj0LPKT)6iAPU4ZS55G~9pLY9V zGQe=1K~(>luQ8=VL{1v=3J>?2%4Y-erQ~u!7iY2u{2AD!{m zFvp_XsIi2jeCfWKuQ8>Ak}rlrC;8k(PEVQk^rMfTQT{w$&X@jx6I~kS#P;hD%=fVt z_d#tlmmjy?@^kH&f^n_CzV6-ojN8!K{v;fkuja=6jp+T4*!?40NtMH4G%(90IV*3B zFXv;=zjf*3@89K9iaB#Wz!ud!Y;(61!NdTsO_4}`sZ<7FQVSdl+Ui-?0R zcXA^>hyNwL7TK{d!$FU$+BhG}nT`G>xma>8IjDbX_14SLgV!C)sq#5Iww#ISRT5Vl zcb0K4moMiT%_n=jBiDtD>$H8@6#dY6AK8MX{V~q>^O|-z6?u=HR(0L?C(w|r=Ex3` zHB|W;8;25_l&f;%!2mn0(RvxImBHiRoLtA;DtfHJ02F4inZ1Ok<8e#iMn_`Q{yUpeJGbS-PGY_Pz5EZ`bRDP_Dz0UF&HQl2#)*>u z6uZCBqkVeL2rqyy*<);q(c>l|1I@=jvvEqAm z8T^O@`dL^GZHlcJ>&9H#q61ra-dL*=rQ6spS6%zmWO1K@iz62`1dn^-F}~@U4PX9`j-$Q_fu`~^;{#zrtZh4*MsO_ z!{wPEmb)5q$@!ApGM+N);>-Qrq*LZkn{@6CY<@?Bi zoU$D1eQZhKKJGfv)xCIze^!U?y0~nAmKl80P2f+w`;hSz>rOI}7T-tmovDK5XxCB4 zfE?aO3U3X=NcUN5Tu=3X6~f8of+$RFr)oxZ5Sxomp7!W}`*flCA98e`)URj0#*_|f ze~23QJZE6O)9KNM&dYN__zlYA`J1kC(l8D-#@a=^K@{)1+GX=F_L=?E<`-(ZJ5 z{Y!|hSuV{QVnlZ~+8etE(@~ff$}KMR53o&f&N9}L`fZcO5nXh81IWZq-OlUm&GuSqQS_Xa8C7&`KnaKSjK2~EU*nPEG{u@c^=j(I-L3C=syp4y6xIykjYN3iz7$Y ze>#bd8|pUSW$SVv*E5!b`7!07uGB1a=xvd2v|@??3*$;KkKw0{mT8yeTy%KmX`gH* zBVi;cw`5v!2Ga6Y07p>+-Dva zYL9U0Pgfr$#5?0Ynu${}_Np@vw9i=cCH1$+k-V*OWWL6f4yJN7N))}OGJH!}H(|Cs zHy)P;7U%011>un$AiExfJmhjgl#hxt3Ol+(^1n~3I<}`CQ;*jkv6)YCWM`5`mq3@w zfS8Q)Uy~_nr7@ZS-y2(Yp3mn1z6ra7a z(plQ*8^v^?EKkAx=5mWRj`GT5-?u(yp68F(426-G0eP5j5(a-F^6;~wEtWVU6W6f* z$|28T#hC-X{^Yp4*=xGqN8_Dxc#RZ(lKaX}K1FyC#5hcTz+5kq5k~#KrG-i2#gud3 zTJ>3~So&sK!Svei@8@Sk%7g43^YPc@OgJE;7k)>s&segc-<7eW8^|=c2us(C=t$MTsVRHBeDZJ;RDKC+& zknLe`MSQ&8achVBZr-Pt8<%QMw>PbY%IEM#{UeOjxSeF4Jy;n=)6Zqz07ug6eWde* zXr)F%ruvU{`J`{wyE;z3ZgdB6@I6~|&e+^-pEToo!UmN)^9^>`V-a|ql_jM0*4l%! zF>)=-QU9=64xY=MiHbh2eHJYT6kmUE+(jL>{EwCiYK~;3k$sh~v2jr4z=ZrfjAMB{ zc6W(=o^vE-R`BJ30a5#9-Elp&3zqx)H4p+osb0$cX0rcnKx6}`-gGejlg*+qa)fKk z?R*W$c6=u0^U1M232r?`dk(8U4Qri8KbMtuVh6Dx^X*eNZ2IQRn?hPttsKdoFkk0J zj^XEVNRc8h}Q|QzAHNDo#^; zWRtLKi8K<<%!+7fU^mf#RS$QQg0RHcqcvdF!#%qAt()IXG+@=k-J~EaG4^N;$j`G` z*mr@(6LLZHoJQyBxO2sS@96gZ9k;!QAkFE|b4fzwb9nf9Hu7Shtpr;k%yH7|NVJR{ zV^p@tigtONZ0ZZ~$ z+Zz!>NJxHertv^MZBEJZ|4t2LB6A-1s0L1WJ<(os-Qx+fGLFQH=5ZQzynT652XWTb z9~Y;-eB?Vko<`$sG)}{O{5811Yq}s4#Bydr4jyMeWl`FAdVf<6 z&ym94nOk<78a`7B-*(2-1tXQ~g9v9mJbU+GAL&6}zmu^(etr7=i=%%$uYPGIT}zJq zBpjKqF{J~|oEG}MZtaF`g?=7~rsZlSRkJEw0lXnrhzVb;Bf~slDaNI>rNwgjgdi8y ztz0cHeXNtlyXE)Q7Ipl7%035V+{sz%<wj59*TRyDmlCv=f)ysLm89p?kZ=o9eVNM9cS78 zE?4sJgha^h^uZf@_P2X{UOcvg$Q^TTyLl;7pWt~Z%Aat`e9o8saQ<|{%k{9C9Ixxk z_qyHMJONohC)RD?Le@v|%VvGh{s8qL-p>Q4;?Hg$?t4<^i%WUFh03uMrOAAXBfEs< zp;rk9@G3Cq%%$fLLSii6wglw+ttfP9X4#CdXsnzZ$=41?=4(vp&`kNlt0Mh2UB)`3 z#quqECBFU!UNE-Zzn@JXr0S3Pl4#m#Gv(7~#>V*?$r+O5%zibteWZ*JTfhJNKc08Y zVmc?sxL5glsD%4mm(3W;#=8_FFo+#kFsafX@Hy=j`F2mKs}!&si5Jep^@A#`dH%Wj zHM1Twkx6&ZI>_B=`hYgO9n}wO40c*hxZLi0hx= ztiYGtOKlUq0Xt^DLr8$_!*a+)`Q(DgCtIHmsyPJj8MW@1iBs|JGg-60J@mdusVyK! z@vyo)%-5LGAuN~Cr8bGDy*`G8I+ad`Yqraw38-LQZkMy)Fv~}M0csONU9m^e8I#_m zY|GCE^uf1uPLAz@%GX0>yAY+`Nj-46{OTbGIo4CO{a#Kuf7GRQ*RGw%`LG-+ zpTom?(pG;`w}jqb*A$c+;6U0B#N2-{^`|N~n)P!W3g>uG`J1W2bz={`$+`TMq0jmU z_U3%4{IpV3_#BRfUEx(~EQY}|UKfXnaz_@h;YEQecL47#p`${$+MVoEcihyWpdO%} zpu<4DK%|U5puV7fp#Gr4K}UdWpd&$9AS_eU=2Hj49|WQePL2T$24#b=+|}9#3p%j& z!D{(^u&AF)FPFRydILnp?k&*Upm#tUKpR1uK<|QRK;(VU2cQo@4WN%eAA|l2`ULbT zXfx%5%d#iJLqT7FQ8vRwDHjI zpg%x=f~cWL0<{9|1!@hV&0F>cwFM=E+JV}GQb4Jo4xo;pPM|bUI%pqIXVAW&{XqMJ zx`3$P(G}DUbO4C<5j_ZWFz66aCa62;P*4w0PtakYUZCEfKA^s!exUxK!$C)YY@j1S zS)ijp13&{ogFr`vjsXn@WrL0d4FL@Wk?p1aklcQ4SL}1N_Unp|`&{+#tL@*=+Y7z@ zNPW86P3B702l)ton+JaAx(xB%;=4(vp5ZfeT91r6?Tbb$$Lt0_Bk{Gp^|!3HUDR5f^TF~{R-Kk6dOvgY zhbMG=YFoj1dhUz^=F2kCc|yX_I(UD;UQszngm4Y_Uj^35lFJ35m^6LLxZF~aCNdYj ze5R+cf2(jIrlIPD(1VHEkO&s5|g_ahB)q@4BBrudB_8VtEVACmMz_o>cH z7tcr&|9xQbj7|s7@X<3hIquIhU*|@S@!kWQ;=_b3_2-RC78e@_2lz>mfQ2%MLWoK#s~k8As-8Oz9xWN$AJMPtM5WB=∓;nCN1rv#;m44)7 z7a?RI<5Nny#ZL*NbU#FvOH2c@9oq){&^SXbh;&Hjq*M9*=`{<^J^g~RD{f^SlTYi$ zn2*0E7kOVf^8WM~*aB>ZT;eLDwqrsG7&&bRUPanj4bU-i(14f9leFkccuJB`TENFS5Y=FVQAt0U_B zrfOQv`Oor2yT(wVR^GAVMZ0!S<%OUq*{%^{qv=lO$>%$wx4(M*j^z3O^_ma_=k~h+ z^_W~Ph;&$LP^M>ZvDf~0KUDl_nwYyjBY0o-l3vtrBgg$6=Ih+ZQQ8M_VmTJ&V2fE# zz=uU)*yFvh)a{h4OsT7?!e(rOIH}M`LbiA1-$mrxLK&aZs}0FmFtn}sV8Mg0ud;U# zQ-}Q7_n`-eS5Ka=C&2PC-$*v>@rS7B`=`|RDss(s2GD>H40pm#9qY|4HQBr6zenUC zJ*oReZeN%#4lEWMKm2XR53^}<8IEiRjY~6MV@iiH-qXDJGDqn|FAm1Wn3McA7Ej+4 z67kjggsBQ`KVB&*>-2BbfLcB~Lli1=a)fQ!*3r5ApW;}~tbvv)AJQ|G1Nl_9xo?0| z%l!onv_$#Pqd1id)emx3ozV5r633P(pJ;N(^@+}9iWcAEMb|)c%7<(g=~-<@qNi+e zTS5bJe>VFMb3alYhYB`y5}QU|`PEz9k_xze!Lk&sAIW@GrpN$OxbLVBFluXU!kt>v z`k!@i;;sue&P^^}iTz=aX zIo0x`3;wmt_43-Pfk&|1Eko^V+?o{Fc=~ z2+4)>O7Iam=s-HWid+6}2*q2;+eHsziC1Nt$CT zao9cBK^%*L-Clj4O|(qlg_|eLHQ}2gcmYV3Clp7X$~hgx)_?yo{DE^;eDkDXI9VR% zH$xtyr3{OrT`J3y)z++^Xzj$Pllxzp{7fY+)zzFX*4{$pb9htwX{;Ij3c22vw=>J5 zmRDLu2VuLS+xX-|+pTjL4Gimt`78(fP02HW-if8cYeF!!J>vA(m)jgVr}m0$9Qj0Y zIR0ub8jr&)zj+#v`+YTOX56SaUhe52QpH;$fv-MqBjM{P(9%(%L>bJS2s0U0ghv?1vn_Rtn#|^}>m2 z`VCTezXwugQrj+HAIylzH@({+7mZhhlFa=9uv)|+S%FvGw0G?2oYukdd{;8g>E4Ja zj2+uc{%`rw%ZGHv<5iZ9{$362X#JrwWcTyDO|DT!UEpVcrXJ8i)Mek@8KeEoQ=r#&^bh7> zUR3*r@VKgg!;4S-a13p?qH&&)UPqNb^8NW;wcib@fVNLSEgA-Se24BOUSGk&vs~iV zxupS11C|CX4YY&?toEoSv}mPaX~5Eer2$I=e^mq94~+hNq>c;y)qME+os}-9zdQLf zUb&;Lx!20itn&Ge=D(}2lX219d*9WvTKQQTur%<`(tu@i{#oT|-HoLIO9Pe$EDcy1 zury$4z|w%F0ZRjx1}qI&8n85AX~5Eer2$I=d#(o5bIIgw`BA? zk5)dGUUwf^eV#YK{GE*71KxE>B6blT6ELw zH#T)lIg$Rrkv#v$-gUr7RpkE(H7Jq<6tM>^#I`g`K-7dlNFX7RgksN{O0LVpPZ)hkLfXBrlpPe4E|LFTj7j?1#9Q~600*S5Ou!pWah z60>F9qe!0Xp(QBiqza))j@5m*(Py(nm!l?mKApa_<=H*Sr?DrU_Te(!pvIrEeYkvY zZlxBi3j`b7{#uRisxB+4tPao)TpYuJs~x1buOqjk}J6#9`W98SiS zJ1sS?mrLGx;I6*EUCH5TuP<(X7b>0IC0w{iBoGe!v~f*ZZG_rrI=9m`&Fk|qJadOH zg^faUxmb|~uG(uxezbqq>J|jk74u7_v%4LxxyaA7z#)<-G~=t8o|3=3=%w&RDd{RyI=PXe>H^#N%??)} zh#poL^+;tLcL}al)Q@J>{mXcAk5A37Yj*8Fwf|TDeM1k72lGp%v->n{2HjAD91K;= z2pPS-v0e{LRveZYAc_bn{}T0=jr2J7jW_M$v!iW%N?S(^%kdgqzE(@}lIVWW*Y_WE zR@Q*f9*-DDkn8et2%bz=xzeiLDbw7uaXQ6t7fH5W`|Agc(@9i?Gu(bpz)!a*R)p)d zU|g8^2x8+DR~%bqsplI{h|75*+zrpI|_*q$#8dtXyE-x9p z+duv@KFdHrvU(W!$#jDne#VrqIqTT| z2pot4B-fYgP`*j73ZcoQB20baJd7FKZ}0s%tm3O#zh&3|^RL5=pI!fVNQLY4mQ#D_XU9+s#(ZNpq0-5XR28l- zE)4~IIR712)p<1Iu)zscu5zs*5NxJn2qlL~94h0dbGLCrgS(bG@p;g4e}K-=<2g=P zV`^jTC3@d<6#HW{oiL6chXb9B1M>KC%`9uVSI=#ao}VLjxp?WTHH$tyv3F17E6h%K zA)4P{y83?H12gZd#2l|a{Ke3OM@lZ-JKJ31omn5dQ<~z4qF~A8U5$5R{-;}Jo$pME zx!jigAwCk%*-RX(0MLsw@%ZMW<%#lrJ z%JV&yjn;bKuD>^@*T`Fc{$V5yQ*~w3ja`IFXLsYij$$obTd!C6e8);ipBUrYzv6eA zv`1bzEy7~pVT#r4NV&GgyzTt6%O9>QxZJjv8_Dvny>V`9;q3B9<$;=CPPtGywCVmw z5jBsm^XFLWTe|0bINX~?2=Uw06?3vj_7M-=|6|>w_YXSexf2Xbbgnh^vzcyCMBf>!>kxR%sriSS)(wC|7Dt(Y&EWL!*d11`S5%K}NpvrfTd*Z%(W)syd3 zEL|D9a*pR)R665I#HaW*Sr#~!dGTeTVY)$$KNI1x zxxdQ-Or7_k^kS1v@#ro1OTyOqHTo347j$&{4AEuYydTy+(O2y9M!#Ou);AC052akb zm@Y-FTlMc(K@GRVQRxcdbmL$MgV-^?K<#WgE_+fSTouOkhIDqeG1X?oumA>^`&Gb2 zst}sWlv?f=J7E;bj#s_hU7DR>PE;cfKYUe$%roZ!M=K z$C3Z{KH|?moIAlapkdv`3J#{r7|0&Sk)r-F1E$knsc9toPrM}gBdAno8D#?&N41*+ zYW{HjOc8Q>(C)~cfE&#LHGeib!Xyz;ezQ*E&2f@A;N*|Qj815E@~0DKiUcVacIr3L zdc7$6E4*HB*}H`eR2RwPjQrEB{XM!5h}Lsp*_-%q_pd%A>wd31HDk(%yLaWj0mab` zwHnjOkF5Ci3SNU*jAd}>+7*UESO!juGjVBJ6$n0U3c6i>cY|hx&V|9amjf5$e(%|D z`cvPe#&qX(O)?%hZM2g6c_n99`I3#;<#m_&f5{U4UtaoZ%UP~DnP$p_k;Y$4R{^Pf z850c50|N}cXr8jbOt0TXYx>QAxiFa@^}xgY=;?l{g7QFiZ@MGyerA{Zo5)@Lo=Y@U z+0j%#?fsu9ZXO%AH(n>4!+}k~0kynriZs+Xj>;M5|CZu_Q(m?d=bd!_ zh#c6`<;9L?+~%<9v@dpCa%fwE15SC_5?puE{G)QfDKCH2oO5t*2@Y(D@?w4x#_Xx{ zEpSWZxszu5Ij|+l3(xTrY96Ds{|%gw4hJ?L2h{Syb^qo=V4spR#<%B-L*23*=q%;M z>6>j?IdD=>j{|CXNiWov^R=n^Z(Ls4+;VT|q}-V~pst6fevnKdvoq(d zgKf)kz$q_IdD(K(_s2`wDKAcW`Qu6LmP4FwzikO1@_xbGJFWZlYQ7NqKH-(`^%h?a zdHT!sE3!r7j5W9YIP&VAhnN#$)EA`n+e}yAICf50DGuWd;%qIPK8qt6Xba=CKrj@h z)$B2+fWHjqb@^+XaV~9>e&!+{+9NFIKc>LB=&5Y+7OpEiG=@JCpnj8nt*$-*@*~s#Kfy{@j{7`XZKA$bLAqNbL9MpZXii7EGz%eP( zAW2%t2)U)(6(g6`x7alQIW2i?!n943q7&=Z#sR0iY;8H}yw9fOz?LpA9r14Iv=Quw z%~a_+-&0d@Xxns`_t{3J{vqwJ<^J-}qMqWIl4Z9qc_CX|+i=>3=Wl)B_@_=XB#+j< zP=A@}Di>q@RI-=@5p1p1j1!7@xZx_S!)T=vmt*LiRzxD>TKz`6-)e^|_q#07@0_Eq znRED_@x3m3Ew|;0VZi<)VX0xqvIR3YO4*b#D<4q;Y zTwd7R`g7iS!}f5%DK7@sxSX)r9$q?Owtfyc<;5v4TfdZd+#CMU%1c|`oZ5;+irv^u zBsCFrVf8PPtL3P)82BR zhNJ&XW3%(T^&ba`lRuq1ueO%{TBzyip z%o6uUF0Zd!dj1B!2ZH2^zGpFAuH^Oxg5Gemt2n65 ziO}l0in_wuaK!Da41~P29?ylvUoy_Tx2)&5(h{;d=!LHcvEbM{pCAnPU3}X)+2^dR zTSDB=!sX}Nwey;l|OH3S?zrzbZ)$OSA zlj(W{(xVMHs{>)TFELZ;Q(gR3Mh>kG3>!L>SgorSc=CHJdpkM57p~6|`#k!W+q>V^ z^%`0SNs8ry=>|3a?6~)+)PnKXaN)`rU9G^A@r!>Z$G_^gEb&3p*UL9N`04MXjNmc+ zOgG6fqYe1u=vv7Ouv>E}#{U|mlxQ3!*Z0(aCneJiO7f@EPTKRwX(#RZvaM62U;x)A zjceoey50H;;#KdWLtpEA)U&-q(tY$Ulv1XXA6doflW|RrxVEMNZKd1iGAf7G%Rj2M zAeN}ReN(+?A@ykTQ4z@XMO*6w8B1rdZ_aYaykfI6yuX8C^Kif^H|^)MQ(oH7yFYr! zt)>5Hmk-J0n%&s63(vI8*@khNj@dam;FOot`I1hVN*#;iV{70*E?$DhGj!io<>&Ex zkS@IB>eHxRU17SX`<GK9=_(v-w3Phz8vlo z7T@%A;GF~evU{Exp5LF|&93|`GyU~D*7I%s7uIp>iow0~{k`ih>?Y3oaG8Fya#Puf z3zqM*;z0e9Ff-2G5i`?4vZ&a&H8#Jixo2Z?cerbkd#-n;JM0bktHSPJxH?em#eV9^ zn#UW|YGH;NaSO9P35*Fmx6d~N_b^-Md9%MvjrX~o?%J(9vTV=yO;p4K!pn3ESp3;o zy!yK!9(g``?boSs?z`W&_Z_hQp;6{^fSy;~@nm{O;nX~nX%;<%+jqhA*7t>}>1@jX zcJj#S$!<jW{T8fZ>6%elkBum$E4OuJ%-45qMQ8WINH|c3yA@ryV7sEa(p6a>@N1R6NXYn4 zwuwd4ibvx+aD;NirCrYOVhZ0O(eD6^d_gRNs+oNz!&O2l$WweE;_Z7O~ig&WZ zffEX5(AO594>dR{cKz0G4OMx>$NSJM=O=ud8rOAu9`owm=adz2x{OPuv%89`!cV*8 zw4#7V!w1Ab1G(1*8XA3CSU*`pZ71oR2Ffc{rRz`LXBSQ9{pO#2>^1kE@dc+zW(I!O znRFFL?EQ)(e!u2(Nhd;>d;WqU%~KenDOJR)^ErJ3UxrZW?5^^wDl&5>T0aP<&Mt|4 zGPkU_>c3CTuVKrN3om~6njxGn<5KDD-UeI}x9|-c5m5a@^~?G+a9#1Xx9Xkg3$EmJ z8J9|D_ZY5;T64J;4ti@tF7qze$(q~a^+TRyPRV!{{E(VYqn186^yG>wTj5dZZNejQ zNX9eZ$JF)jF+cAA(~jr-oj*&PWj{lx^j3JvG;ia4@61-rDZ&XrGXp`0wytD6OMr*! z-a=@~2fKRs#GLm_SMD**uLm~$k#CjG?n&}1e)q1FVKSclpHkyl|J+ZvJ-p=kSo_5C zqte@kC!S$4o|V8u@iTwy+RN=LpY%S`v|Tx;$9PmayT|yW4?svVtD297YH^~MP@X3ahWn2 z)k%Rc`_ep8*6Q&@@#Oj;Z+&WfeNLJ_`K?DL4l?){$H#OFIQ-$1UFqVBXSE(xE}qQa zrr+ZHJ#+HuBdBfP*m*F14?VF257m$QKS8jBWDd_}LXVDv!+{RwfZVUk{$G5afn>4e z>P7mwXqh90IHKmqrE4zC5evMp-?+od-7+e6H-JzZMCtCyweI98mKo2e6#{=^S}ODAfGfoXDsyQ5DljM%b?U z*_QryRQ|}klo%Bi;fSM$e?&uxp*@SP|gqO)#K zyxUqBHGkCiPsC^0ANx^F_QQ1k@0jUxAXWaPACtXL&Kow_7yW0=G{ zE8o-or{)iZBc3u}`M<+o;>6}xYW~RiviZ@pKSjb#V~(v&$?G5*cS$}DTZM62&+DFl z(DQidLgR~{5EO#GmoZ)Ck1-CzN%6Isrz+g+(+d5bGIw(z61E?csq)ej5q6g%b;_~C zj4fc5zxyuPExEi*Uz{T@`zHI!eWz^KpUXYvAIS^T)mJd&WrBOIJ5(F=HipLrY9qAi z+!(;y%M8V#$_=Nd#-HrJTE5#8N3!_0Wj9%F3U*H}H*0s!78iZ+P42D7R$jE&Sa_?i z3nsZ?y2?vKZs^Lnu|XWo<4+^{nS_h! z8-Xk7yi^ZFEX$`;52~Ery#L!%-=tfgusJko%@g*f@$mk)+je0yKlyC=Le_PpNo2a3v0S3H@n6QzeSzAV=o zu*Is#jYa8L{yo?2^I};6_Qq5OeBRpT;k4es7jS!AMO9V$WLH(aW?bJbN)VS^USBce zHkZRoDJ8ec>n55Gw7w_31I?8!+)0Q>M;v?w#nk7W#*hB-ukDtSos=PK8LjAss}RO} z>WATu31CF3pNPxr>#-9r6!7a_2ki2vqv3G_#auzsV$jtjUcO`(=Ly)p@4N0X2UTg(Lp5 zCO?!9j@tAbNH>2r6%w_)IpxgC>GtFg^N>uta>VY|l$?L<;Xr%xC!KWEeB(S*%|vmr zzeMia3SC}rQ*cD;ar5oBe_2p;+)2&628Q@Z=kqaL<(oNv$L5C;9Gin}^K_d{8UBXo z6e@#Ojzg(9ToWujZ<2kq6%XAZK;O5Ua0$#i6(85YD&BtQhL1+v^mu+g{ehzSi!OLF zT_;Kp1J78k7HN9)VLF`V0=U9CR94Rr#COxdj2zt2)LdpDX`WvcDT+s z@0p&_<8FD0(`8&Lo!!&JH5PTE&Eza1k>^!cFHgP>Xch4L#gog<-f8=f`WRmIIYwFs z#B|2Rrh(7G7o1NRh+ti$aatkmO@rr-YQN>WLT$Sl6PdC>|;Bdg>|;Bdg>|;Bdgjdk2rg<5FSLk>;)knE$w1kfp z=ssemt0;{7h)b%=%ZlBhaHTt3U+E5pa9?~?q_$QIh3X-v0~Cx$?|U$xh11ldi4khN}=|ZvV`Pd!{y43v0DuZ@}-WE-v$iweo;R^SP!p zdfZ_Re%w}1x~qOOeH0NfzRVSU^t>+wjp|a836hhA5R^wp9DD_=;?=I-6$Nj6b3Drm znHfOIbn+vscFbP0BuGhm$x+vz8>(?6MDejLY(~W%Lgxl`%|xdKjQMcvv;O) zMrt3J)Lt^(pvIp@c`Mf%0>S1YcWu4qnyk%r`@G;Am{}R{d25@8yGk3tVm*+0Py7>R zRC~ZAw{+Dacx1jeJ!$2;`d$>L@2we6e{$ulUpao`^)gz~**(4Y8mqZI(#s*Rj4S)8 z)VQY9z4TGpX>S}$m`PDP-xW`$>qP019PQUN7MbF>V@ZUE~K^+8tBnM2#UyCwuP13^i0>RlXy^A!~9d=KdT&5Qj(E{I` ze)iMJ(_d87SFAaG*DJdHb;ta(OQ{42!Ra$yCrS@%`g+nqUzz5g8LroT$>kuLBK`bv zeZ{JOJiVsk;0s?+-=FDH(z?}}zWV;IDSnR@95$3xQN24T!~%q3e&juqoFA0Hen;$Z zq_^AtT`x7*q37F9crslFAw8^kEc~zttc+t>8aT#lSM6|PMYmZ4&9q2RZ`kKt3!pLNeA=gaEizT&|-`N22OpL2*USB^tTa5ql_#bYlir&O|K+;Nb z%5*g~qZ}Jeic4xHlrvI)LaI#kO9r5Bhfrn;h^Sj@cL)sy%8{0 zj^D82*b{DhK}WaG5MAcY`+?FZ>N5Aw_uljSq+RF_6yezgPp0cc>0ys!QXm||049Y3 zehv~vgmQVJzG5Opd}4ki^5f7umIHSA{qdjY2;|7se3aeVYNxy; zIY>88)AiR@99xtB0=$fzkCcZzZ=4SQn#}Mt|5@;+wO?;H|M{{1v5y~&qB6ZzzQ6P7Hw}!8&)XHm+fYIe?EMAdfrp-tMEfU(83!8+rUw zGAdhmYaZ^O*Z-1Pqs;`#FOAEXZjxih7x+1_P*G6xX#TL*?F*SPw7_J1C9C87+79%BFovI66?LFfMM`!`>{ zk^C;fyu!mb=G?jd#4DdAKcoT~hI}yHpvIq* zHJTa4_jP^#E95G1hbrc3!8)3d(ma*kCe0948OQW@<8q4VTg_ju{2@nN{z2cB_kCXZ z=9uD(^u!1c$tlz02n?Hw!xjX*%Js`y;7G=gRp7_&SN^y3kR=x`QTf62R5+~sC~`M8 z%3QI|BR9U6oGfAGYTA|MusMTv?{+3H&q7VqV zy(Re|O^WIWsyk>3o#$KlKYa%y&5GTr-f>jNaX_A@9QuK^UqNL_ZVxHdf*YeB{~SGK z0wdU6x9r}E&hAEgqgN(lwOV|{4Tg-W1qG=*;tP8lecE`za?O^2_aD6NL1)sVnBJ0Pd&uufFDj-!fnMx!y>b<_}4Jna+6FL+8vrb zHUcQljGR*^T(m<%R5yO3VSdzFY8da(P(` zc`7*M67MA!_N-Rrh3RTa>BtMoiX$f~=Q`JaxxOp;Bzb=!7w!kWH0XrjQPuzA@^?C3 zhw2rkt8Zu2cg8xEsa|bfV;~qV^@maInaf!wV`)ZM(+4Wl=MEWOMIIuO+sRY$pVO4n zkn2V9ujKew1OHyPUi#sAXC3D^muuCgR|<umPrBG^ac=Nm;k{+@EDb#U?%I83j=N?Bk=yYu(2aULTts~R<*uc%(D zojnDsXAAYERb}1=FP0|JBCC=>*j1(Z3>l?3TA&%<&`(q6*A-VCeZ%hG49v+eJ8EQR zh>UJbr#NL*7zqdJygr})J-f^s3cJS5McdEAV9R&PS<%wR?KkFlEcmHO$>(=k|e8}vml0oH->G*3=F&r3+qs&zX zwOVgTb4jRZ34*IQP#Xzpo^d{{0bG(+B&h41Es<}+KU8jIMgN(`Cb`RY*?%fG)vxp4 z;Xp@lU^yb;^4$29wLH_hJ1WnO{WHa(dk&vp@I@bSz%rM&>W$i*y=v#^C7R1K(^X7L zdDfeLtiMdJK)X0};Y^frtozY;xnQe(4Qjg1|MWPJtUi)sNY@{QF`GO&xMSbK99V|* zxtv#io4lOoe%(jhe&Mxy-t+k7yUcw3cN&iC-&CmGX1e-1TvA;|yWPfeKDMH~D1cFc zADu!s=G|NGTT;_={@Zh)E#;JBXlod!d^6`dk12nLt^eLyzSa3bLcQHZ4>a98^@av> z8Lr+h?L{L5ldis5e7xjxH+o%eTEI_!q7WXcS9sm68m_(nWto)iR2h-Bn+s@fT3d5C zxqnyrb8ESv{vD6ka(}>nHgAs|pMT`mXKt)BxWeC0nXd9msrPxjX3XNyAkz5iD~;bm zg?2s&wbS!vUECEAfZ>cO}1B%egv^8?e5Q7;)>=mmk08v{#O}y8^4*h2V0|bUALa za~W0pckM6e_Jh04RqoaI+uHu8TW`qzWV;d3+7{)2TIc@A=(=_Wa5=;J*sajTu}n&$O;0`o$y zILTbK$xB0Alkm}Ou2$jqHCy(Vmvqb0<156I(o@HwjUr3TeLnog(GnT7$*oPx8m%$?mB3b3o0X4Tx$Xn2Rlsq7rsGf8ii#`tH0R z^!CssGQ@wC_v(Lmanwd~fa@E1o~Ph3A)fPXS#C%1UOetui~5G-p%9u-k)6sa@85-0 zY{+=*g8ff?m$x{W-zvJbqLW`z?N~Qp&SV=E&l1GJ_*P`Lt`Ft;mxbN4#Pj3I{`dP8 zfpae=VTYpc_EaA-T_;KprGLirFVcLA{=M87rj=o}g+4Qn5B#x@=SE~3)BoBS39t(* zmuWk9>GfM#?flC$wzJtP0*BymAPo-4^QudFTg$aN-_q18OYEM1(K$u8KXPdIuRPRr z#mY6))g+a2o$z~Fl7ekJ!Ll*sT*c`8w{n2$Ejz{ZRCNyZKONP%I3Snvh1to=dCd-4 z;-`Ow{(H)CXGY%XGFBhaaQn@4_3b*MoZC&PIOSaBbjSSXvTPTd+;6dSXPQ&anG>DI zYylMRr)TG6>Enk&(5TL)^$wJ0@_Ov+Kh3L{^2zSG_jP<=M-|H>D9P;#+i-523k=O2fb@%#vZZX4; zfl1>8rkmuLQHcW%X>ASC#^QVQ|1n`>ATZF3)qL*e5v{-H)A~L_Lu=TnLZko058?}# zg;ebtygI6bI3TavU*A72C)CcY7~D%=uet8RZsM#Dmz}T@a&+nJVL90k_PXxaUNnPZ z?0Y9UVY*I~9;xI6GJ_-7+zpM86;fM6JCkUxFA?2%^W;yXJ}}A)l^If8mblI^sK%ag zwmat5%>lXmuHM<&&d}U4)v-0GSm$mx^v(rvzkXgcn7J~%H+`ogMePukU#9Cs=@IKs z#!r2S9UWYyADf816TyaRGy$_UobyR@tJLnu^LiAWT&GigpRVG0LOKs5x?8+{qWIMP zA&mpF#9wm1-f#bw*B?L9On~2y>1w*M_cI!=MDtzawXn{BFy^`FeQoP0ZokwtlKq$4 zy=49zH-`g%WDYC?c}4&->ikya?pfmd_h#I^PW^}IF4$!n{k!q`KXj;S57rGxb?PH;j z`ZP|Wxhi@`43o}S4byIX1G24R*|&4#vcM+$;r|;mU%+vtYewOb`)5P&AtPLv+W^4A8#y_Cz-Z{2`5(;M(0_w|2KrynJ%MK!v>Wd4GqQXDCide*tr1qI)I%DU{?UxzS!MT z3fAqkH_k@M1KuGxlkhMh4m=v`2}^}|x*GA#5aO{pLOgl45I3Qsd2t!^OSt3hD?YvD2E0f9?K#|RRS$h_IVOIKM5T4purmIX! z@?E_$7@(V*u`q-_uA2d)5IVxc-{tlNoyNn|_K-ZXDa$6&NXv@cW&f%>`L(0TaX9wY z9FXhzrhKcssQvhoL$k!~Lp~Y4^7}b=zdy}d&of<3p>;h!8OIU2TUGQ0=b5e(rALx_ zo@)2%z$C3HtS<&M0;%=96jeei$uZU0G*?PFoi}^0{!g08OihM63BeDe9C~k|WY`zk=&Xk{7a*ERkZr>~2tDj-HjD=yFl%1j;cNN z5Qim`Wkr<}M~-AJwcoxRL0OL0rjVoMzvqZ^KKb^Z=n1#{nd^L(Bc`iJY~={s>kIwf z27NcZenPu(C^c?r(n&^x79YOox7xa_vW2PC816*{$>o1KzUJMz)9kv_uQ_QJw`u%+ zgz1|OH|kVGF7vsvFgaer(qrC58Lv$rzK(GbpQ+TUbarn)pY;~tn1~k9FF{k-EMz_l zoWo735Sq%P+OHwEJKP@@?lNGHyU9+9_)Jfgu9NZTFx&>4Eqq>{2Hq}%%Xa)Z|48gO zHx%<(rL%im@Wz;09Y`+Bh+O7#eNl2gug~Z!&OH3Fe~b#8TE^`t%QMp%FPj~N+vGC# z1R!FrH&%{IjyG>?me_vvfU7?EPw<7mnH2}u8%$@MY^I4V#HC2n)5tud!#bh+oYhq223*iI%Z^6#j&aX_vwb4!xTS4(l0_&8(QS6R<%&pcqt z7ncX7tEqRee8tLzom{cJuuSlOG99^6b7s^2m*uKyLUOrU4Y`Zn_`{BKUbuGtWhN}H zx0tS?O;fJ)FQQZY?%G7_mN=}GS^c~SKlN}d5Tv_=tWfrj8$X$c&v35r6-}v71cY` z#*r!8i6*yyWOvl2=YU*KH6D{(u2w`G6mlJ?tMkpQPn+q=1yBV(1gVD&-6G_!`1Wx!I$%n2zBW~5 zi7{v0=6T|u&39jA3O@6d>Fva6vJvwaxFpGMTw>Rnsfb*y_to_HKb2cjWK!RiG?!&q zbvv0vr&nSBL~~U8IUvh@&9vn5v;y)rf6D7?jyi3W|3y=tSnipwB1u#36Ur0U_)%my z%`5TxltlT@bTX;$N}B949e*7;A|`a8lKZ90k4-K|1Eyz*m)<_HSMK_oukUJ3ba1`I zbQM~fa-{T2Q&vxD*H4UxWr@U}`V?|qL~it-HOm}Gj%p_doS#Ozf@S*G^83bHGViVxK{8{dC!5y9J(6)*Uc?V{pd47pLx?wz<5jxTs9> z*plpAM!CG2*`U*9cQqd8zdZ-!^18Mzxm?xPWQm@0D{$KsM@Fmnn{J^A|op4hM6 zWPX2`RDPMRre>7i*eY8WCSDr@AupDi#AwBCuP+kRCS&(kz|Y|uOmNanxC;;G>$}rYx$;cmDI1|bNp8W|7ic**@MoFj-3oTsa$9(-%KZ(toS^pLtNt< zBc%=KVohoE;aq*JwFztRsFq6#Yfh<|YwYFN;`W8GGVUmFr^@%+%ARlT=X-^M=_=QJ zs&vCuh@`k(`toetn>c$KR%C0`FKvNlJS#%heye(}Rcm>?|QzOAhnIe zN2Z(Pm{G1Z1cJE0(H)%ap5fDUPP(QA(eSydaEGI9zm>}X)zfnSm?I^gv1XcMZW<0O zK(s6$>mqUa_yL*3=X{rhv&8?M|KcT0C4I#~L&l2%H{ICpE}8&@V)Z)gm}JE zi1KMdOg{ug5_DI77VAvx|6gSQn9fau?APmu!CfOc#;+ zdl&KL5naW-r*{?aKigHT-m#n5%iB#1f2Nzbalh{3mxbNM=UsbpB(G4`yH4I6AD zzA*gDIK;fT+)~{_=UO96MCM4G{Z;eh(h}hC-tyD|$4`7h4=1~vXnf`iuM zOwk)rc$e$@g}_1S7ebSn4Nd*I1(2JPZhdlL6|a4ILjUcuenn0iip&iBm~N6|hW}jf0(WlrH6H2yx;9}RR!w8liYK?GYxE$0^xDSp`lZPzHtqWxZPJ@e6R17 zFT{>RBeE!7oN)3u1Vwj~DO4G)l)-l^nP{@I`>)bu|67xN8D56vX#H7MIf|Z_p_i|9 zI23ThJ8K?aFh5J=?J@e`*9ILj@Gn%bpjeKWZcyXTjhCa!0B&O9V%VymAcG}d1wBy>F{jxbHK@;&Cm0;r0C>NTe!9P{i^vx2&mmjR;ML% z+x%~^b*G4-n5Dl-Z%gA#Qmdgo&^<8jOIOL`kCwBo{Udc=W!?E%q9G^$i^WUdUc>zo z?jJE-O}EP1(CE{O+&C^A^L8GMjtieXHV|mAjGC?EkL+`-IOv^d9JC&qzDrUXg#z3@>w?eM-aM|H6Ew0UqZOUq84u2S2sTTgrc5pi(ZG!T(aUoGHSb(2 zU(|6Bh56sDA5`7m^8TLHrc98rBlyB}@*}HB+PrG_4C=+otZ|LiYQ0spfuQCZ>cTvn z+s9#KJj>I-^WZBRCVuqn=#w)gJpF)&=^QVcDe(+TjHl$h)cm>b&5>oxdf#&VyJms} zt1s{{opG?463_6&cvh!@=ZkM|->tcz>*a$bJiUR3>5PNTlz2uY##4{-OR5l>-rG)o zO3Ox`H)HYj<1u}tEArP1zL{>4V@66mhgk8*<*M;gD;~RYwZ~}>WW75(>q){vicFek zV7g9}9$c=f1C3RfybZbZ0#+OhG?*@C;ff+6dEB0fIJi!eqI0ZUhy!Z=aQ>%)ldiu+ z@oa4PMDcEIbTxnExe14dTRyk#^2f=SEuSxpK<-D0%dGS5v_1--bwtxJA>OI@xQ4>~ z@chiLe?IJy9_F;9puFsXC)3G~tSW<;WXF{&V@oTmTw`!pOf5R$VQnV*z&K|SU(a1* zeE7aPqO!;c6@|h5%qZ}XDukwV)OphSd$Yu2-|TYbNpC-V*b)=a0QjTtAxy_#i!#5T zjcaPug6Q62OR&Fl9B=7n4(?x3gGjqf3$;)t)#>+@+IEElZOY6E`i`s+&O*U*Jl zeo<$+4tn7$_(pN;olj5zcgx#TK5iO$_X_$0MffuDWV%k29?9@g?-;PODPgbAJKq>1 z$o-h*De$biGD{o~J^PuG=x6<}G}B~$F}qE-cOM@p=8Y`N5uIL(r%e7|)Q3-fjt@olx@ab7slos1fQbHq& zib3u_C-j)6gYlk5eM5B)E7?vo`M+#u|EeFEzAf1ckdbQs5Wkqu^p%wUlgTtPNs$aB z;;rt%c{m){$~j-vYo=RT{hWH?v8Reu(>#p zhlJ$zN0xCJ!*bJKzhgb$*4$(rci5d1z37d@n)Akd(PcCx07dehhbPl@qV%9iz|v5_ zXDsTOtlCTuw&?`zZ#3x-2+#gmk z;EPEc-pC$+RicI>lji-IZjxgLU;bR~_G7djL|Lt+u~1#a7rzj^6y+YD_yR$FF`^Mv z#I4oD!>+6RNhR8Tp{l&@;yZOVn zF8}7{^UELlmd1Oe2uF83nXVJ1hl+#wfqMZ%VK-Vy(=V4FUjNEb81KpdSPtUWk zcd1#Nnm;==Ow*=JxcF$5KTKEgrsR(c^Ox8qS%D?aRHCDZfa^c;*VK4|C;htP;RCN3 zr{ZCH+wovQ^Ax(&vCud>ybARoYD$i$MZ(vj;G=N};oyBru!<#j&7Qbn(C1j?Zzz^) zmCo)7_*E5%1a(=G^DFySD}U_LfA6tTM~^;w=dU?_PG6<7yP7_|z81pdp$DtaP2n!} z(*+QRk99YP1j{w`OP8d9=icfS|9XFy(n?N`@u+lmPan_ld>xP(P{vhoo0U&AZ$rF_ zVz0-rQ>MI0LH4<{=E@hU&u`{F8sX}Ka?f<~BP$ix1ovEbRc+AQ7_RX9ny0#b5v>&M zl~hR^q2>B$C2&!Ch0sQN#+;J8Pq5n4XIk|;94EJxFqSjQ7~>kDSr>~hsNpMQK8CuQ)di%{w8UZu^{ zzh2PxzDkTL>H@(A7Xxq=dOTAa+~rz0=&dzE$oaKS!DF}nqVBW*-Y{`x!-cg}i9-?p zXk8Q2b)xi8^Q%mA&mOCVjs1tyJKl@ZvX4 zxRAnUCiEg+vR1^mDZ4m?A~D|Hw7OaXNG5dOgG6fBRRgw znCQple63-|zQ{xoQw-ldsq^>BgT5Qwb5zgyM!p*POZ{!8$AFoZKg%KwqM`{#zs7}@ zP9NKp;V=ejm0h^E(&qdt>i2T}&);3CY_jHbsb4RvWaZb+jnk0haO|x)5Cw_*O_`4* zmm3PbYQI_IcOJcA2-!&)yw7MwH(aS-JX0f)urBVA+R5Oi zz(-}qQ4R+Zao~?qUJ~K&C_0r#(oQ?jQ5@Ym<5`K<;`VRoQ>o|ix?k$vFY6Z<9S@=_ zZvRv|yW6*arT)eUUAjaaC&M0yAH`u@<6RV(tI>otRt<;iY0>9+e3!=rJ33l^j~3K| zrG9VNi@8CMo|IGW}6H8unZ$@15ce%B%Sib|CIv=I_b9k(BWaIv;`Ll7c#Y0m*w?%Qjwl!Q^()c6#b@Hck=bByq z(A*)8QFT-&-~jbEHV-kLQ|zgW@fOCX?!-zR-(q?;*O?4S5e%(e&-iTW9ng8xujJ zuiT>*o&1tAUwfQ?uB)oqUmIHoWqJSCtm#tZR3FLfCePaM<};7%b>%e_CngA}>!QP$^?M5B@8ydW9Q1DTetC*JYiam`oqOJXC#S+(yL`#N;FABX{=VDI1|EYyw2qDGjEBuMaM4u?5nlKw z<5{lYvE$Q}YezgdZpLv3aC*!qmCo)7_@iGfsg>51d$9l?ljIeCI!6zIr9?n&`f1S#KQt6yWF5Lo8Z8sH*T2uX5 z9szwQ^x@Drl3w7N0C6Pr(a?p^W1+`GPk^R_5G$dppsDdV7WxF}8ffBmJv1FE*a%JM z;5S2`4t+K>)rprt{|Wk9=$oMb3cVEiUg(FQS3s|XUIo1xdJXjF(BDD-54s2VoejMk z^nTF8p^t)|06h)b1094u6PofLS$hV8i6zi1C(9H$v6I`Jl7FY&>na_iMG-J2)<4VC&awTH7k%&J8%KB5K>tsCIhm)%UYrV8q!KbdjqBN(Ty<+mw&!1mFc2bN_r5mnx?V7|f zd=oUes_*K>5r7f17>Xz&V7@J&%QBz}p(#B(T*Hg*y0rSY{icvVQjANb8?Noa<-!IO z%{-mOT5k?`H+6mfzX#_3zR$30=@?dBF+P>f?(uxJ^aJ!ODr63FT`spT%YcUz^UF@o zMsE1rdqmk@=Wu$AN2Rm76^~qxCxoO2mD`ts_fqre(1NPq!tH;dszFzbOQo~B6<4gk zG+qniDrYRe4+K4-cq?qpw^hJHDjA?_f6^iy%_gSPN$Yw_!>%ZulvT+U>B+=so5>O4nn8yr}M*W~sw6Z5#F z3Zd=VM{-*-_uW%I>RsD1f+jPeNUp}<$#k74JrcK%ybc{LV09qf<}fx-Zr6{LlGUwt zGEcH?M_0q9`+qq+GXJtSSmzCPfg8;yudnPW{(b&aG~Fvo9^awj_d}2S(*XJdMR6DXgRverc zPr(7Tyrl5nDV^I=zSH&V^sPH(R&Q}oQ3w$ABh%^E64-R*O@6WVgptE<%XTM!I(P0D z;KN5-%1`Hhn?DXZwN6q0|8d@A+eX@+^3&P#y0hckwk2-sdiy1K9i9hVj(I>*h0u2M zr~}^37MY`d{q4;O7hX_uh3-{fcR}A7nQluY|78-e9{)Xa=*otTJ!%Yp0fkKFL$S7YBhPvsxeB}lq8ZCrd*a{R+=bs#Z2 zE&PlEH}R4A*&TNJCS8fm+pjHM>V``S%@ zV!ykw5x`)moX`1Pthm&CUi(qDcsVj8THf=UGBux>&Un~N%}=a`!cFmjC131nvJ*de|Hkw++2Yr`248*B9;;UpUrDk2G2NiXpKZYvD%Fn|)C0@qH-87K{Iz_2 zn7#&kXi-mbOv$p_TY&4)*B;IemcMex^7jp7jEm`UM20Pf%X0olz5O9_O&w@1d{PIW+&$drLkRQ`I?h2ee(xSkMXE< zc5jV`D7ArxMjvkDDGcLApc&YM5JR*80a-rQr@%Ad(QMJ}CI8{`_Pllu?WZM0cxc{& z={iw*w8m4V1#t$0${ZO-OHOjWEPpIpJhW!|g+mVczcoDIXB`6bmF2X11N05ri5r{9z!{pn9+ zi)TIve{|NJ|GI0SSzwqCOxF{Y9yaOwXtSLxmzn*N&mT~9H3#^=J7vy47jro!lg>9_ zI{A?muS#^8b7wf7&l53r85@^pnO6yU%s?`pMZiO<5Sr3a>vM8@XV|N1k0f};YCd;!F^&_Q;;;95G$W8KpDT8<;-UMq2=}4`vG4nrCwi^AI!CYY3b@AkJ=Fm`%5Z$JzqWZw2;6FD3}Bif5Htfs z@nR$&>3+{v(@FH7_?1YJTQc`V;kHG(EGKz;SmmVU>P7mwHkl)FWH`*X0B}X=x z<83qBnm;5LZ7qXs_20HP*t&fW#p}uSEXz5~@!P3H{%IU8GdpTF29S(QB^@)Xz?@jx_+|1e!5m7tKbdHxz?jKgw z)@z=K4>!3pr5tBpyQwkXJvn6XU%D{JO6jg z#2k?2X3@apaOW;hu7Tn6B{CRRJmqxu2rOtNtfh*xV{rnyPzSO9#V1ef2uC2>`>o_`#1AbHs$ca$kC{cJWzg9 z9g|2dxc-q%@+<#0Vvo}}F7o53^f|B$Ugh#i(+Sj$5I?y+p)nfsmuSpmcIW?a+T=>b zOY@i9#u5(3$MV9sH#x8b2{`hffH9qftjd!k{~en#PCIDuQ>_Q6uG*aSX2<60))$+a zKh&2pAyPtG1qqq_L|CR$5G zyUo@^^ZiHt7M*cM!xf*$?%Of?l3j&LM-W{Z>qLypS_4>3ge%E?zGh=HTOfitd6pV-*khL9U0H)hgF4Laj^KWN&t$LC@@^?Fj4Sse55Pac0Hs&7?))aM^< ziOKl0sq@<=$u^O=E^1Stt;n-nPt+7xzdO-5lk#=pPC`67;@~UjwXba%A01Mdc>&o; zUANA7s&w5E4_;u1CDX1#zqi4-yU4uW35zrvwP3h;Qoy5Ot@}8iK0{qf^^+=JE@V_8 zM=F`=`cvhQ@}0D!ItK^Td`y%-YCclSM*TbX&t~U%t8EWO3tpMOcdbEvLaGp&@{<-uYU&w>B84!c{eX zPe`=DE2m#mXiZ;TADjDhU(xG$_f6le`n=y_tgR+RvP9`KT_;Kpq;D)O*NRYS6}ho| zM^8UwroRw=IsJ7=pWd6_->yFW{Mx(z@AtelBRC0TtkOlObaroje~7sf1Ql$Vw@#~V zt_5pwlb>dUXo10a8pp)>L36%*&q^LH8O>ku#`hGW|LG@3cRjLS`3dv~itzWwlj%B9 zdbGwv_tNPLhKm9|k7b|IdMSO1SN;A;(dO=RyszK(EequIcS8D1my*`4t>jkCe1tmNsVWEyv~94G!eOpz=)j zbF6{9v^+c^`)^%Z9)Gm&>PG6T%koq*!7Arm-q)^!zdzmcI>mVFvG@IY^?CPX)_+0& zjQVeX&I zKMTL~YLM>+9fuWH&5g7NRK8d_iijBB8r08}ULiD@cK8mOcWKd;8y3g*=Q2K(j^Mgd z@mcuRMtm#4KT?cuEdY|tHSO0`47uxLeYz(*(xvR&c{?uGJ>tRmR64t>_{KzLK)9+R zjg3KEA`E8Xs%|}}aitmYP2cGps&>PZK8Lsf5i$Qt%B}e9`jZ0&h;NE_iGI%MQ~r|_ zsC0HmN+DNOZ4j_DPbrqog|VI3?Q@j}A|cFa0;Azm#?e@j8pqm_SxEDdmNjR||WmdV`TrxrXicwIS3=bFs0Qwv>b-KBFVH z1Od3*L@TZGO68ggR|_t){>#cz{jS!AFGhO`b3S{Q(_wj4>Fi#vH3WjquBzrxSZgr; zl%ec~T;rPR-4PH`n2e$n!V>f9dM~E^%rU#`I4u|;&lH!8v*eiMI9HvWEq;IZ^sc{u z_|qrMFv3aWccwEwHa7-maZuA3=R!ot{9K&^=Ym~w#L)%+>Hl$kVL^q#NWC2*oJ?nY zY$n91A3Yc2rExcXt;zNB0%o`wau80x_$(N*wc{PyG9Tmx$+F4~fO+ zd@J7jzfl=`ymnni-iteTDSqMMF0)R)tn0++;%>7>_UY05#-}|)pO$TR!H$6)eknUQ zXZM%h?N50GaX3TH$Gqy~`3QE114e!^dqm-H<8!BuqQAOa4abw|I#GHg%ttDOQa&z3 z7?$tlDR8VlAM!N6?(H28x$@Y_Un66nV)A6tb)xi0h@(8<@z!}YkA#JSH9<3;p;N5& zDAkb=gV_0#u!@oI?_PX$){r9&G)8?(^CV0sKeD2Flt!&pbfK!h)|@><-3(8h?sB9{ zX%#|Kymslj7LD$??AwuEHC?77m_<>#)s^L~Yi_s4JkiwfF5@Veni@y%{r~pl-&gH; zEhlE+$q*`?-4o!L;-Bpg%=4FyWq-0F%n!94S@LbRxS;p5mlgleP{{mXxnMfS z%cgmornHwKgcCjJP+aO8PLBBfnCPtV`!T21cNOAjWbZE%U{sd0Un6UppV{*Onf9wbHlA}MFOPLv*1+Dv^n2eG9R2fW}Ku?C%K z_!jSm{JM-&PfF=1QYueDvwn^u4wmO=8n~wa?SzVfACLYT)vK-uS9joIx=D^1DRC9~ zG`By}XuvZ?+{8wa$oZLnY-&00yJz&^8%mqkvV4(A<(%m;V5S9qqi|sC81rBYJ~Y@w zgF&y}lKJbrGkF+ihLg+R3g9AD0IlcKV59$(n};n`jj&iZiK3DbYc#+lIfd@}Ha!-p1}Xe35>sNcbKgBpLv&by7BTO4qEP~@IE z0h!DDLM>k2Np@&H-vcvqayPNhB|qwI+US=a_{V*Phh=StJ}@crcNCsX*NM`@xVGAd z&qPy7F<$hcw2z5|aW$o@sNRismkzN;!9}l3quV~4!g}d1^&4L8=N~9d(wjqVu5>oX zyKIUy>Jcf)4}X85eljUqSKpCpbEOkShTFXl%K@2e@5uLa;!2MLoBIAh&RaIqL*@8# zIM6vckPBE;pV9aHWoX|Y9=-0Z+TA>d^mPB6OLet89xADexBqti{RNm!4&JmwMp56} zXJ?*dyf63nnQl0S00sL))ojBAaAi^^pU))J7PmGAWyUk-Wt z%jI2jM7JBVy%XjJ&N<#JxQvVGaYTkKIWB$v)2$!xDfLPyq>O7pAkHsJb_K>jgloZ( znPSGyUNOCUj__ste)puqcCNaV0z)w_rW@4wGdZrJNCQq*2z%#hW$xxcBwSVRtuyA| z)pmrg_8l z=%tll?Ew}qR5kl+#To=8JjuRa)7%L@Gm9Od`$6vxy+1U4vz`V`ne=z)?ZBk7pogK8 zHw2yeC_a8IN8qOr_@F*QT)m?ZpY4I~)7X2^?`R=zJRa*o&K08gNg*B@kRcwsCPR#> z>>`Gq&{cRo?k4W--%~s{aXWF+4}HYKi$+DpfXua?$`Io^xKtZ!cw zqw@1IPC5FnjPfrVyR2V&QCH$4eOm@3%lhDjY4H1#1D`&;;qw_0mETOKIAxU%zs(h1 zdawm}a{dnpS@Ykn930d8={0*l_Q^~c&p_lq(`77Vx5dL5F9C_dFXLFQ;INa!A9L=Q zcC2+#!6plGLL^NR zzV&I~s~+9Iu>T$7D^z?;XIyOB<|7=V(9D-bbB*t+D?p=qoW`Iu*TDC8!YbbEzw+Pj z%^X41m#)a9@2X5U$uXmn77*ZIL41yO`-{o~+m^lQ`c&o%$r00Iz)XuR3R8~AOD;5}PxCPONT26n-r4JglZijF`*g{D zS>}+rs(X{?EBlERvvHPU!CcgaovlFKpFkvfquk~= zUnn_s9x4CLY;oYfa)0;D95%H(2`m)zh3N)0{!D}?(F~HzpJfUjb^d7eTiIgvJ|8XX z-v9KYo-mVSJWP)xF>HzOB$_$OMKG4j1ub#8%($WdFiI=mbm#9ohvGjgGt2m|#f-v{ z;^lCC;mZEmAz zW87gZoogQJ4b|4WgEO_sT4NvximNn)i#5HTDmUF*$gAlo4omx=2Cjp;JXTQ`xcPfd z-@w;JsC0HWaFw{RNkgmkhBOu7_#jqC;&5)9oTLY7!IRp7e#d&g9eS2^-ShTvqh&rN zn1Hzdh~A&UDh}%s-tYSELx0GmKTw3H8=g$piPFQKPc%bg^d#hd>+&?xAGEOQ;pfL) z{~7g7NKtv~h9}c?qV!0TzGX$NjH3YiJ}BNoXfo~i@b?dk4#+E5{Ibdirb`fXYcd@1 z529B2D7Y{+j!ULQ&MYcf^uEdurne7AoHbD}AXPtsctn~MmmlMw^W4-Ns0YJS<N5r=|X9I+@AbWPgsm^Kf8G%UL>{p#HHVTj_AB^ZJqdZL87#kt&3yeDy%n_nP(4 zbgpFHZaHGsz;TOLy?fKSobS~B(EbCa3Z>&HdY99ZtR)n8=ArS3~wxqFT{x$Bv8=YRXEHf!4Q*}I6_pj@6Vpv{%wRn6J71)I zQt-6~n$l199jiP1(6=mXn-tVfqIm(DkL3Ooec!@oD%^7%->XdDyJ(Nn&d|F+)4p3e zYjYsM@l&DChrSZ}7U+ARpM-t` znmV<=LH7k?h;Lv?tM6FTFGOy;(u!`l3Xzn*=zh_T9DV(n z89?rzu1SGs%~#oCfUoPjpA2g_9j~M-&Tpohma69`pBbL1}MAi0Zo7YJAg7QhNNjDi|_KvYyz z{85PY$AV%(ii#)}>|n*p|9-ps-OUY~y9TfW_$dH0)d>dwxH+4pr=m%Q+~ z^Hm-!*L@9c!}CZl#qVb{i-WNWHzrbW72_xH9-;l;^TYF^&=S6Gz51m~o(}}9^TU5# zikxo<&&&AB0XHuII9)DKc&PKkk>8I^>$fQW=x-*_F*)X;%Jr)>-=$}&3xD4sKfnxi z+Kd*u$cJUWo%qI=Mblb%{Uycv6N%UnA8q_6_?(cP*z1SS2BbXl6sk0J18Gvxh9l0$h7F!LHcEor&<~8F2=}3 ztOAEts7L<`#22EswGnub_pgkt|JRteH&ZsJIZkh?oUcd8179RHdLiGl3T_D13%xt# zW#xlo#A}T%-#}qpc5>yJ&mVWi`IOg@qj;>3Ez32bv@!jUF~e#1mtbjZuP2Y97XQDc zd%Yg7EzLR2mFLWv?!tU(+E>2Nc?_E07|M?dt$cvj^P^zy)eDhnOCCyEla<2qno3|3FXqFer7zE!%t2RRp3c38KCgZ=2Q9V>|?Ue zpEDFAe04|n(cP+Cze?Yg&Hhsj&X{*ZjfnU!^{3@d0xBa;f z9@sf{T?U8G`cvh6y$1U06^UQcEs^y%X38h-i(P}0IDF=(%K3T?`1Ov&Z(9`nvQ{O{ zUGUy~s>*1N`KfZgUITuoMdDYsFtYyE*%sw~HgzUVuc0~Sr^@+y4fvfNiC^Nak@;#U;~zcC+`?;dd7{LM!7OUpMM*s`2?@xBK7>ubhO&aaEh zBj?vuKc?=uw;&(kzN zzw0l|hwV|7^Yy6sI`i$A2PrTu5{=L)@hQ9w51S)E%D?%$IES-8d;J}PKB(uxD~I1v zB`9%uwh8e^^~vNgG@s~n;g~kFhJGy9v*`8}hFpErH2y;CQ?_i6k0OujT%$e3!|aos zh1x{W=mOA^ULrguo>Y(C4W2R&(zpB`6^kOLo6Em#x8binulITWTb(iaLFtC&x-_^o zeUH>a%od2*H}bSu?~RFxF$fopgFqSzeOHkPFZn&Hz>~)zRouC|8P%c7jO+A0C<*m_ z;*|{0p4;xFJ%!kq^+_&7qU5>crJv;Y$f9F%bRTV1xhBTOn3qT2rIi#F8}kG6^+X&n zzeBf0oz@_J3`-6ZTHZ#*SvS(o;lqz5-3k0 zN8!+SFP3XUX%lUGWAuz-)bm62KK`yy`!O4*`sCNsZ#?%bXV1JF^*~8CG_H{45*6(b z;|Qrqp^ciGfjJQAA2Mm!)?VwTbi`Bij(U8mzFFr7TLZ-iknMFX?1SPZ8K8Y4&=FYs zR%6j@_a!?rE1HX`XzS*{7CO&VrlqRAPM>0zF=(0T4l?+G7X z?%mBr%4-{1d^3M-rWzj0rJ%G!B|KY(*Hgr6$kPoNp02$wr*rjrIw$+&^v-*;`&1b} zr#{1Sx?jDf`f;evExnj)z6@ecAKR8T*TzaELq>)7I7H?zu&3Ry;m?h>Gu~K9}l!88jPEEph807%l+XLHuuFKi`V+2UD!_n zrUHdP5#Rn)M;G?%myw4s3ZCc z;7VW)Fc+8yTm@VWTmxJSTnEs<$@2j!6K?>hNVy51{_{0CSCJPSMrtOnKqRlxJW3&4xOOTf#(E5Lt&wZN;uYryNk8^Ai?P2eqHJ@7X0 z4nPg+_kaz+`@lwE6R;WB0(<~`2z&%=1wID00iOV$0^5PlfX{(1fG>d^z*oT6z&F6R zz<0p+zz@JqU>EQs@DuPe@C)!O@Efoj_#OBI_!IaG_#5~K*aJ{u5Cg;laX=lQE>I7s z576424FLLYs1eW@XaY0^ngP@{X#vo;kd{Czpf%72I0~S=rybB9I2t$xI2Pyt90w!< z9f3~3@jz$b1fUB*^J;blx&bEvCj<1or8_`tFP#ctnoQ9X=mqo!P6JK{`T%`_egG{@ zK^4LN0F^Z~0pmd6Y#<3p22y}jAPq1Oak%%2jB$qfyqDt-~y%qQ-MOD2yg=) zpcuFi@B%)-50n7YfayRfFawwgTm)PUTmoDQ%mT`Q*}!GM<-irdmB1WeE-(+c3b-1$ z2Dlcu4!9ne4=ey~0B!_s0&WIw0Tu$c0_DJM!0o^yU@>q9a3^pVPyyTx+ymST+y~qb zJODfhR02zYrNBeLGT>q05#Ui^Iq(?pIPe6p0(cU53V0e=2|NS*2UrC>3p@v`2G#&o z!1KThz>C03z{|iZz<+_Yz^lM(!0W&pz&hYf;4NT1@HX%c@GkHkumN}<*a&O_HUnFL z4}cGWkASVf$G|q=6W~)|JMbCsIq(JWC9nhd3iulM2KW~E4)`AU0oV!b0)7O30)7U5 z0e%I319k(y1AhR20)GL21OEVf0IIaa0I@(EPzR_BVA@$xABYDU01bggKx3c@&=jD? zUvr=ZkN~s^vufib{Xfa(yaK8MVoTkue5y|@9QpdsbM zN5LkJ`HqSO(cU!evdBEn|MKn!PM+`+MXlzT2g?HljDsk7>{V|s!}DAZD^qwS;95&y+l#TH z{Ch7I&0_udMswr)&TgXV4d=wGF19SEdt?{jrG4c@YXx7*-G0)IeizkIIQ+H`hw8;F z{J4$h?D%Kb+N;#?SuTf7$ARz%yRjq}KGvladh({yr@FCNFO0ilY?x8A2!E#04Z06h zw_;wEQSj=L^kviUHfHxzd9hsgHMkA%+Dk9^q>1mZh3Md-g*W&KstYoo9*>0TsXng7 z1G$KdX$^Z&6-``t(TxpH`R4mS>(L1u#Zw%%EZ2n6MtgS*GS-!V18urd8`IQSQqNi$ zo?#x#6&`hQjl#=rgFN|#w>scZR4yEMQ->Q*pz4?AhzGGz<(e294v@Z>d;K{Pt)O`~4eB|X|)+@0U^g5r}~h(4DdwXLA<#1@M$Ds4@-Q25lY zW;w}Z7YIMa?siOfIs64#(=fE7urOtY-$}!a^hxR|7|m_Nmh>UFBaEzFYtz)hb)u;#I#si8Iuw_Eq1~E55#5MI;C!#ga+}XN6I@vDdhjuPS>+lrr?cW)uC+44{MJv)bu#Z;7j zZrT1hKW_v%RHo^>DfZ0(V%`GaJf#(mVWy%j&>o;TA%jf>jt9B`-GEboQ-R(@NZ40yhG8084LcG!3U>P5w< zlg&UK`f}9wu7kfQ2!6Z|^{mHG=UM~ByoEZz$EeHg#Pzrsaa!9Lah45#9B0Ic`!0wP zLobRE$K8hgGcjThDtASwNUcL<RJ?ytGjYum&Bcpx31X_dr6~WUm6*4vjd);ETXFsH_M-U($A~_+ zcR)R+qgZ?U@#31vUBt4&ZsN8_P7&>T^$=tJ>McG>=qDb#Xn+`URc)RW(I*KpZD)0j`R1*&V~+iGd`x*8f6U1fZirdCV|mQ;KfM#vWZ7>q z3kDq*I~6smQLRg3zkGE`?6H$Sj=i^kySQ@}kBfWrv)kiVPv0K*$eNyYE<1Hjoi3@L z)JZQ(t=nY!!*%0cJg(lCjTY5gQZKQ-f7+w)SW}yKmDbuQqJmbnd(!%`!($YQEuwWi67wZr1X#%K5Fv-`u^;ipJj_)!^=R?K-yF zaP&F3bvx95)}DC6o!@o3@Wo{(Z0~(<*TtC|PELD#(5c_e+SBXuF0p-Ioi|2Ha-1I} z!Zavfpzk{CkstB*hIHRTs+x*2<2rp0$$pYjeX!rvf#Y7lZh*$4CZ66xTsHLP$^GwN zwFXH@bL0n=4=gvtfgNX4wiIolB20emrKQftx}4LsoU0Oda{0I$;gf&K0FtqGOyS7? z)yKbLd#&wfL#Sz_Ioi{I^(;5UfgP%u+Hdtfzjp>zro5iQLQD_tDYDaodsux>KTLKz z=;wR7%a%%ul4iR6HvR7=(t_Ui!#vkM6RIb(aXxLY$?AIc&NX!?KO;vx+hWUdO(<9r#P78Z0A0KD?CW+V6nqtX49Zz@WHZCDWw|DlHi3Bx0_y-c?NhNp zK`)yz(iT6((bSvMv-}wH82m%dxT+7hHNMT0w-pGG`11Fn%cQXO<&gLjELS@kP~%6| zt$e(%q1A>T`x^GY;W;&a_?=|E%Ex?tfA*Vkw!h^p4Uh(^%g>@M7c5&kuy$m{ z&w4j}gt>dZZ z|36x?m|7apHBeoBxi<8}>4yDM&slEmtJgqn#t)Z|Ry}AYdm|yF=|nU2kZ7mlopvq{>;#X1z*NVQG%-gyn`funTV|qe|Rv%xRP5E}TJA zrWiIu53Bi0z{3M@zvSy_tGg%o4mXv z|Ct+m=L1Nj*RR3X zkEA{6*eVl_q!_RHyISc**BPf1-q&1{))Pm92G-*xxm~)OCTxRC2C6IfPD?6WS+Vkj z|ET32%QX+A&0gi+Ff2BJCI*(NM|;%o@%FN%mlmU`QH1F{?S+^J3xyvRsGylOgS}9r zJz5z#+-axg373&JTI*h)C)Ga5nBvk(|3T$b+PBhwP#@OO-WoX2?Gm;>-tW!8l7!R1 zfr=k1ZwROL=&#B1G*;Aa5pkZzUcKM{a!iu}9`56!J>W=fT^%)Wng2G-Qk`oo}$rSy9rS@%LRcmeODJt2u z(p+0`7poWBX{N>n0P|Z9eiU9ZKzp8pw_h5LU)|DYUS4bQ-xJUNcJi}-(X{rOqq&i( zf1KrpIIv639*n7=H3jNRV%d@l3q8}FnBMZj5~t7aJ1taSrFfG0WHt!Zm)X3QcV%YU zo?AVB5%DEQd;0#ya!n|0jM=F5Mca(Iis^D0z~Qb{!mXGSqkZ?=iFup%Y}~e*?)Qu9 z7Ah-M1Y4GCLTR&CxT9#YavxR&({GaBJE>vh_kQ!E$=^R3({&LCp}&8O zQ007`!_UN=q8{&zz?+xh27d3VD8h|BId%OrZ@s#K{pD~~IbY{+wMFvOz;ToO-u)Uy ze(ym~oj>5u9jj)t{~W$5=j$B4v1oVTz2$J1M-lFt^gV6nJ=4FC{pD~~IbY{+Q;^ zvo>!Q`o6S)5|xFUV&lZt=Xw{>Go|eopZaW7+xlfRIXfJMI|^HtYeH#btYaC{W=)=E zcNJ0#RKGYp1^3J4Sp|5IzsUgYDXYx~$&(s=-y?3d?GA*WwaxKR`X}4<4#XenD;c0Y zuTzkTIrUfcZ~O)EJUjEdUrxIAw9$3w1di^jgDuN7p|r_HUC3)ovHSf_?~F8;FR#Gv zo$MU$aX3#8`4TMKb!kFm9{sXc=NBh@}cd z+v71$`{s36Spe%U&B?Xx9`xYJDj$~9J+d2=J;s*SJFRE03?~+M_ByrYOmIUPz~xDC z%TPT~-xZwG zTu3IPIp(3t`Fa>0+H~|ZGrguYgO9A2$|(4J7ju1&`|f|}Ne++ssB*rZ>9iN?Wg@k& z2D@>bhlPJ_>24~R95&dKcB{;zN1MoY^Wm)ZXKp%rabt= zw7z(O(MZO^2lhf*1Q|;=Q75#cA$aZtl_8|{vUe~K5hs(TFIbRRUE42_E z+$C6MlvY}Bj4tpxeFdIEO3vEaKCG`D;6*MOp!hJ;*HwMen`d5Aw=LaAj(Mqa{VLWy zll8@o`O%)KPB)sU*mBIt_EX$8GLL2b@?ToFwRxc3z&upBDUZx-jyYSV-B*C_{(M)d z&P3+1I|?3sM!eDU;w8Bka5&6EmGkuweMmeqN(u{!3+qG9X9_w*)4IRn!$SjR@k7k4 zI66GyN6v365<~M_abc|1zTb^}_!v_7x!^nBp%0R>&rERoZbdY zrHR%6mP*sslRFmsM4&U!6`)28RaN={wC-OzFdU$@<8pziz;xhB;AY@{U?s2)_#D^+ z90Sg00h0h)4;V|IX=~Ebnyn7tA>a>S6f)@*K*u^*_ZK+6F4o@#9C(?IXjuIOY{d(G zh8K!QgJ%Rf>Yr(XJzfS)G0_k&GXO91C|+htd#o{tm)VktHG=UnAL3wI=jPL*vakny5}1Wo4rvec=or~(byhg5Bu#VQmpgs+PlU@F>^kHbuc_c8BvHYqaPITIx@8h%&esp~^Ke zHc|2kblU~ndO_PJzbXLcS=uSG-iDs^M*ig^pA6Kqn5QZyzsc2F&A+<-DO3kFNBbC2SFqd=2X@GF{hqWG z+n8bpI%{)E^0eN`G-tlOq>y?9<@j5V@X4{h%=))J_k3_i=e+9z{k8NC#6Xp6Vr+5> zJYIiZiQfkz(_H9Ew`CPN(y{L842(e0))DpDvfQ-1p#DS!c5K&GeIoN2G54+SM=f9Y zu>Q1Rci^MS`TE{`G#*YzmUpn*p6ADajG@jM(>>m5NLJv5<$RI-{eRt4{ONJ{|M~`@ zyqm}WyW%JG?e;#C<4!)_`%X(@X~5Eer2$I=mIjU-4Vcx}{%v)h|L53D1bJ>BZ9{$k zwM*XoXHSmnj}_jkA1R*7jqB7tD(xG&eY9t-?XG{C6;0spoV1U@S5KDXG{jXqZX&}@ zgMUi=4$pM=;QVZl&*#E`4t?A>e5e4pol@E_w4F(!N549= z&gJh=`;#2;qH*&q*M!ohro6QA{20LC^SCu%a z@TNGWZ(zFt9^bYwTWNk>+$g#t2o;*K_a{21B$)VQ8Jl>$Ht=)32oTp$~~` zoEJm5)4g7gmq&Rh>A!!d9?kkEzR&HG{Cdi+F7&?Sh!3SsmTN+3BaLljlS}m!6}k9Z z$2k1bL*qO!%FX4@z|cFV{%{3$Z2xTsgz{473!*1l?)>=k)&sY8qVJ64h*vXgS*{7C zjS;_TB}Fv6Oz%0#@X)U_7+A#;UoTr;-USz6r?zJyEKeR0^boMf^y<>zwS3v>J!ujz}5SLRuv zdMjI4uGv>SCPnU_`^!TVUecc>n;%`=_Z<3mOOE*0!xGyC~1dgyiDSAukqmYzBK{mgECYe*7^Qv zpbU?5x=%_9pRRVoj!Hh*^Tcwo^{8`}teSJPt^-uLrG%dQ@B;`vu!f`8%2@%yk`mj<_H?-NLmxUB-lEtgBdCqs`Y z4Mgjx3PPZCKzSV<*W`KJZaG5(71*`ynWgmeksnvsd@Qv+fZAN(e>6+d` zY#XqB`_t!@wry5Nr$Koc*$>NAa*^#veNz)XvrVR`!q38bspea%V%hgcL?8hvh z9PPqy*LF909lV+sa=%gA;gQqb;wCwpU)>o}Ov%9)+1^XDBHLA$mwLPYdiKpi1GG1*A3S(&?>6mEuD?gMCzj)}5NFCuvL}^~+&;=26{;t* zeCpFbx>Owd%hTC^5n(vmC1A^PO(<>5_yp}J$VQH@Z3+*w_`31s*FN}redpm#jj)IZ z#TUyZ3fiF=53~5f2aT!pEg%Q~w!0_$LgK49CvtpMPTcwT(Qlpggj%k!JStvNe1+p9 zMn{gXiVwfsbN!Z#a-J}Y_GtKN~rnbsZBq-ro4=)#+#Td-g#!-dG+LFOzsPQ8{)vuj8`@G4Zg{mP|eB?WtmV|g@uLhLDo zO{hIpM8Rjk77?Lg_wLRYtj^_F|z|^F+qD0UU2;~ zX+o%;%q}UhBLrCGoj91XUs$&(J z4#l~Vc|F)CYts#rUg*)>AV7MJhjv*W4KFi08)RgJayhd=;bUfBWjCyyc-!mk-Sb}Ky1>}c-b%Vwry>Li92JLKcdhouxe@f9wvOZ~^HPKcgRXer2r`b_tYEI7A z3UWjBW@eB1gPs|gyZYDNRA!MQy-~Vhxh9l0W_(QT(I6$~YdgV*{7(k-aP}Tg^iWFi zoAs7o7x+(&?xTJfmP=H$LsLGoy_xVRwTJ4(EMFV>>d@o9UF5S3Q|yW5(eRM$DG)_+ z{KQX+%;SWa{TneQ+>EsNIj-P;bUemKNVej>zYZ&G~*xn zD1NAak>%0wF|(HtQt(99Q;)pJc606Qmu9c%b@UoJU6I|eJStw2-Gt*)1wQ21j?L_+ z(I4ApIwodxa4Yu1@@V)3?MG!3s-J8}WInIY{&HJZ|IU?(M!*zr^uH?0qv4~o2($wS zXQ!qX*xha?^$5%L;T;MeGdsGyq~SYBf83g@#uv+@;bUe;A*A4mY)7Te$aeIa=c%l} zZjYO(@?v>Zyd*mc$0t5Na=bnMuKS_%)t*0|R_uu7(eMe{k;*2tomCkHpN|@z{XpNg zD>q`OrRKiW$3-FufOv5 zUsO9|IUWmfraUD(s|mja1)+L0%fH_9cRy{>xpxh#YbcW5gX;Ax4^Lw`ZmoqzV`Q?XC4I;#^IryhqBr56bz*a)pnX-5vF2&yFSMC*Q1= z(=3mMkD1*uDY+iiZ%SnQTIl?=%Vis9Kdjmp%cJ5W*_RoQD)1o3c5Y@zOP3tgeL=>@ zFYb}-s5Rn=<(p`}Y&AA{x5@Gy&?vHdX9 zZ=h8eYR5aki|ms1W0nt`)O*_Pg_HWvR_%u6QSp-EDIA~D!caY##n+wg4%1$JdGxah zhT#x@iZ7N&!zUPDDx1*p@}ej*pIy&<@oJwh1}>2MU8ugv@@V)d={#qu%N|lMSfKDQ zv!9%^O8Y%N;e5)*YwisOg*KQSp)N z#*9Y=c#vcJHM5t?9M=sfxpd$wHpO089u1G6y)cW=^xe-Bna88frT0(o-f~wrBZ6p0 zT4Z@NJXAZ85;m6T$(u?;Rx02Tm-CwxUS@W4r9I}OkCJ?wIDDO6j8Nr#-K-onwHq^X z@I=(lEgJpN*Q!}i;H_&vR_uA=T!1$JzA+1{Z3X#8Q-i4C-QGaEv`@t-tzM?99gp@TPr_Jwj~lPx za5%wHt}ktif?v~z9{y+Bis^-4zO8eh_#F;@EDti%kE-Wq{PBt(@Du7Cc%DaC~O^gYijvsG6w%FFEh5crocHmlo`8Lw>&g#l;gH8QPg1pEQ1h<%T%0 z3-B9epW!L-4|e$P#}4H^9Jr?b_nF@Rigm|a*@S<8!yAx`5vp7h zV-w~*qIikW^u3@YsORd^&6vcq@|Hg7f4+WCodNMn0zZ~BFWv|ERksl8Fj|*mujRsf zDcTOPhw;;bJSlv$_1?x_wCT5j@mqh2(-o-c@hEIr&ir^E;JNqWZex5-%wdIfL}(f- zk9!!hB6r>lg`k#K;WuGgp$5j?i_Acq+cT}i3qvyg9uG}-n=T4XcV_k9Ygc>Iu3a&s z%y-UYD}GoLhvz<|{(o_>9I39n zi|g?F#Lm~ygtQCc_Dyr|QCsKk!z32iS4@}jhDR!^9|r&+6keSV$I z;p=$-=JQtMd_6obwF+cbb`s zy)?AECA~U<>?Eu^I^j&LrYFS6u9fZ1X*qrFa5{k_zEtmKxh9l0!Sa^o*lt>?XZp^(DkEU-S>0({j+CT<`F5QjgXKAXOy|$P#CX6aO%9!%FHU@?fGPtgk_?0!AB6I<5`dmi@5W zO1l0dZ7XmC*CWcV4R1GMP7CqGAAMI1y=(4GZ@r=W%yz?aHM}V725W_QQCQRRkCU+$ zn@h5ugKs~w4XN)!=aH_PJ@aptMM~eQzUZ9lG-NlFMrp6!15sEP?fuc-7dEi}^NVKj zL*H=e{{yObQePLv0mX^@Z5OA9jr%vpqgnjaRPp9RI8nW2>D)GdSfULaqlNB=%xzro8@l5D06-bF|60?%isFvg}aZ_W@^>* zTH?WSmB-kAm^`DX7+vNW_{K8Xiv@KZ!(Dk^4;pkHw*!mF?L;9aoQn13Fj(;1bRl-- zK;P&q_;scb@7#>*D^Nyl!5VY*@m=@q7;)KUG2)GPV}z|wtVn)1R$OpaoLKiwocMZm z9pPSGS3LStJ@JPtUi@uqC`E3eD>_ng6TIpET0LeFH(#x%4mS#=Pf%zNf3pVP7aUVPQsTN*e#HK4YSsok(IPPYGj zdER=)Tmy3c+GBBO{%ST3yZps&Ymdq6cRI%h?P(kp%hgb{nHsdFsmF);QfTc-45IQG z>pg1oCu8jre@1Gy{-n%DR7B=eZ*a#Czkl=kH_-gk9Py#~I9P6o13R71V2s?N<}z`j z)f{L+1#?QO{RTX$!GW%$8a!a#8np(@;)iWh_QXskU+3d!@8kQeeRvJX{crQ4NYBfT zo-}7uPQ57|3~wnu=>K7stD))XIoa(h!f;aaB&Q;kZ4>a$OqS>O3$Kw8UPhuVt&PcvLMTGrJA?c3_WG8&}T{Z0P?VzN_(r?#M&t ztoYem^=kZ(jx0Uxt*1jJ$wa{NxDh#S+SY)S8qf47rA67l8hB^jTFV+xJ7#hFFlU>;XqEOO`&W{-$#UL zSTDIB8i+?Ck<$%%MQP_?x`P~?>8n|K(AA=rgJ#N7<4Zj^d&ZL0js~pwsU1BYC|}h0 zsfPiMX7xxb%^av02=A{NKWE`X4zUH^=b-e!?P~!)`4hQnF{rBDSVShEC z#*bA$*k6s-?(=H=SmjUc>UV#AQ{#uqA1YI*3^E%psn+NAH+<{)@ES0SA8wOUJgM=) zvS{iB(cBZBopn`>AFKR1ylg^^AFKR1yyM5}e>=S6$I9Oh@A$F$-wyBivC5yrJASPG zx5GPrtp2ydJASPC!QmZ0R{3*y$B)(jcKFAS)&F+*#F5#5gv73SloZwPsq`3qdo^=r z_nO^zC}isY*fhT~_wVxlQ1G(Cv@~!yYd}pmG&ebaQ?b&`;T&@ow?nA`^}7oH{< z(vYf=gLAIN&r}4x-~l)hn;RbsAQmb~~J2EZjB<3%@(PqwT(_qdk6m zVPO5XEKl))pPyRg7wtLO7~5dDXXrlF9@TSto@Klb=Vx`-_UGB^{Iul%UmBqGYUFu* zXsnc(ovQip{=TJI+f|MU6 zw&R!lR@1p$9?&sE=3yP1Ye23CRsJ1X4>FrazUbntlJmRQzxWm-5@^=~F~V{+6rQae zGsxRgoReMd;dYlh!)q^c+GrAaEV(wqqtCmnKWVMA6VxD=8?rsKt;;es9r884H|V2v z^l#IEJWqR%e?rsm4tyx-g%>UxF2ucS2hS>9mmr>=^vJh=EQ{~T`8L@Ot(V1eRX@ok zeowxuu+TQ5q-c`Uo0XsDbxm`6ec4WLhCL69FwD@Oka?6gq~7n~`t~Z1wr?ef`n?~1 z@6}HlUTb6{TAofkSg!jT-0sCg%R@989&Zt?o#^w^-D-J5-y!&2gT7fuhe`u#{LuGs zjvuy#L&ePscklFbl%W(ZQ!E`FS`Db_ht_nZxS?<2Twge}43F&4)%cOe)6<&YmOHc> zP~#^WHdH=Q`XWbVl$;mRG09XpM4F8DmWy5kk>ZE+tvZSy%KJDjtoTtiRD0*S@Jj9v zBHf$C$-agtum9V;QG%9+l8rDZjZr$x#USLd_dPz4!nnQSZ$)yaIfX8SK;7dCx3C=LCPI$@Y5koIamTUIZS`$-F9~;Pw8C+hW=*NV$~5 zWnQYBuSd;``cHz((~AmtK=ILXf@4=^KmO(`zPdSn{xbglPrRrd&2r|$dox}`?Cz*YxIf9^V} z@wit{95KuYmeV!MRW{M4Yqj#Ame)sWy0+4@YEjmCG#Zf8^}KfB(>3{b&lz(DzEnRI zU)FTT?EzKJ*Ui$kSvw`id0~mujTWf!pv)_=ePmu)|G3ZU_;Jg194_-x<$OH~URqY8 z@~VIb-0rN3g4c-eC(e4y_sxqOF7s05d_4+YBb-i$KBm%yq0BG$=*W6Y9C_W+ehu2~ z;P9EBD(CCb@^j{Sybcq7ayzf ztDVOhwDy(;B5Od-pT+Uv({UBjdCmppbz@$6;s&*y$8t49vvgc-J1Ku(VON$L9v%Qd02i8fvL zwgo@r*@olVMHJSNBIsIyh3^Q;lEiyk;7Z%kAuw!>4cZxk=@xGrnqZikCy7 z^i8Q;mGgD8^u1R{NJBo}+#T?|0c>MHf!m75EO$yi|D&c%2q5%aQd~ zb!vFM%{wJQOeh$?;Kz0w`*OPEe39kMi}z-F)B7W8mJd>R947m1?JW&h8VJ?Ea-4F0 zQ`tLwdM@sfAd;569lNB`6&G)K!~eIlJk)pdaX04u66(MpTTmd?der((b?q9Jhjngg z;7Ha$1zw)hdFE;1(>dvBRFjwl=av_rrDJlG&S|U4H8D13<@R3n9n%!8`yl5-yA^(B z^`2c@y8rUrydkG@_{>k0^YtkBohIct`q)HCAZ0~Fu*I9PI=Z?asM2DfH>^?FcHiQ!19`D8tKO?5A;P88I!b!2Hk)xb&!I9;zD5Sp&l zd}!Vo3F3pCs-Jg#@ZPg(eTe0%|7PjhtUhFt8I7>}@k=enofkX3{uxS!6m5U6%Evml zG+=1}|Fc2~obC(G3QhNFe=q6lvfSU+<=^w4v2;w1>mRCIzZzxzC`<~M>ql(|hVoPM zB?@!S)qiXqyD<5A4xjm{a=vbsFDdo68f8gx|9R!mP`;`@tMERTTsmRao=Gidsr4h4 zGf&=|@vWwQ6h^B;SoI{=?-{ zci=P-P5kU{=yDuVzTMdHu&%MEIx*+xhRE6(8i*!-tn_o}%q3F%P~4Dht9>f;?<3`L zWczfDK*EFaCuXhWUb-(tOr$-H;3=@v>PZ~$Xa!n|00`t8gIQ+w(?RDn4d`??>so#rf z=P=(}QJURvw~Z`udS~#xIVF=PV;VT^Cx0~`k-R>jhqaOK*M=Vl^d&9N|8*LW`^PJ@ zL(?E+}8`+nE{vmAdf?I9nTq#eH!4!67QlQG@RX#1p5&S@^6%Rd@qF)}T>pIm1{uAc?Bm!Zp^RQ?B#bZPDnlyBn zX2)gSnu)v!Uin=zp=)$yrZVmVGjT>3PMNju^*Z-#BCa|Q|~ zpU>&AX-hg7a(duUl|Lb558;Vn4jKcBH>21;gp9194`&U?>2`O7bW87XV}p(5&vt(< z@wX;gHmbt7xc9gTwX*Wr@6?l;IkA4$E^N-xG_4$<7ZfPvOIrYVF%Eu*$ z?9I2Xym;ugrIkj2oPV%f<)PQ7QGOL;Dk^;T)h4VO<8yko5)oBf)Lt=8w^ZXBSRw`) zjW(MV>fK0K#4lX`tQsbtbDE?)nveOKwXYow$n}v0=Z3eRov^RBf8MZV!4nPcA-f?* zeM(gRuv`;L8&ms1VILSapwF$ZnNOUWQGP_o`jV z`L&+HBofx)LDzt6SDEL9w<{u-HQMpmRaM1ROjPf?ue+C=ukX8EX{LsDc!}0CpqQ1A zzi*eHAD;Jayw~}==8c%!Dxs~;H<%t+&U|@a6W#%mVG=`i>45S}E6-%DAG*Dq4tC~- zx2Nn262$e6c8|ULp9L?-->@iuWx4t$QQA|6%j@$iIqGQ7Fs$$v6sEf!!PKDI6@^Rr zs%%%5eW|f=@XlqssZTao~Hzz1`aKA z4Vn~{7z8G^*(08$Ikz?Yk&3V|!w`$~H=SQVa;4 zROlx{$JJi;Z)Q)H-KbhWbmy`?l^2A!r`@o(hu)pKrQ?_vyY?|Cvpum~eUm8d$uJ)@ zg3xp9_6M3pp_wT>H?t=-O!b`dD65U6YURM3%l5QmN_cz9bR~$N2YKo?o&5W?1qL0q zCzh)$qqHZbysO@bK+mz8*#4?PwO;q7P}?CiMg zD^KpWx%-Y;Mv!brELWM-#Et^}eqoBcNcN`*L{6`BJ$z)Sh~b ztE;W+*tR%93_PWE{BG>e@3VM&(e9SLrx+c#Y)>p#83zA0H9lJQ(wAo)TvS}Bbs>-T z zceW4{M+q@{iV$g6332*kLcIJL){HqZMr2$PBl> zbZLeBw(LpO@ZohX+f%>k;q9rsBtZ=S?z))w{-jwC9cUESG+f&nQAvIS3?h4 zL?9muih|`@RJKHZTlS=C`0zTH?Wy^t;q9sT;smjy^C15RQ)ZW{_QZ1a?SjS=u&3(E zwWw^$vL{u;hu68>Pd2_RygjXiz5V(5rTtel`{IYIS5c`DEZ11BzMY9ZnHFU zAAIUylyfTQeK|Lp=h~xGW*%v7Enb-WHL5NPZ%2u<6U6Mk^LpR5%J=t9rGCV6RewQ? z2;@sOwpZds*5ekovmRH5x3dM8Cx{KF zo%h9!7kqQ`7NbL!>)|X{Lkyb4{@9seUyh(}-1kO9G}FBH=^XBXEFUQh&WrTinnR6# z&(BBy#J}s#D!dNc+k&~_?QJLQ@uQ(jZfO1dD}6d2t?Pm9jpeF#f)=tr_NI-sZ%-TwYdP9p1j^iR~kH-s4>I z#@!p+>9Iie)fv54EZ2PvZfnoJU{sMB0SLAV;PjGsUHJDYyCy+AaQelAuIri6QEjiV zJoqO1k;(f6MZx}*n%6yzfNGjvRDK8g{77%dY=eT?zAEO2w=Z#hg1D#du*y|i`?ONq zF)UZ(D`-rC@;)fqANz`;Z9`lRwEaly{&%F?lbL>GnQU+3*6{Y0drN{yyU*!a=3Z5ywtrYI`%T9O zF24&jv_slNHMKXn4J04S@3F6Wne2yktZQH!c3i%0i(qf`#4UZZ{`>AZqgtu$A(qoU zvOBQ$7P*a71v318Nw@{rXQ8x zfj+m|M?w3lS{&ZK5*HJNX^?Sk4cRbh~1mRJWJy zuHSv(?XLWu1mXSs%VRbVJi3$GUShc#&H=VN>pPOF@c)x@x!g^>KfK-1EB*1nPk*0% zs*=^!WdP&OPV_8mq%Fg6H zL#CKK6#1{rFPdX+109KZwfrAI>5}mFu?hB*-)HBT#a+(rpxOt^RehV-M^F^}J``dz znlDWdBTp)v)p&^QdDU)MuD)H+NCMw=s_T~tu^r29R81aU z=L~}uH?M*5>j>Pgq)qicD%l6WId3bv%egrE-ynp8;&ziEM{JRN0PHe%5)-G$5BtnU9CJmrB^vu`}xbIrG=wG8-9{K(-f_tD%Rp z7n+km&uT)7B+ZN3E|=I|XwUUmm8*3gy#^|9E0;_2R)pG3b4)_m3)d67Vh#t_CAaQ? zU9~UCdvCt;l-LeNM9@4EG+!snaT?;r_OlI2wQ1AmVA^b#n~S89!a`ey%WW@o&2-uZ zyYsxxBAWNB&^F5HD8ZTt&LWR@27KCI`;qO1iOJ=ae9YIaee@bwj$7G&Ha!*Ie)>I` zAg1nG)Mvzw?WrXu4(#-d#g=XNPPI=ebPg`U(ksYw z><*jJ-ZJi#dCYqz$b;g42MQj_7t4kVaqrr}vvz>zqLF{U|Nb)>x2!XsCmxh9vfK~{ zcGdGh4(TbGTu@x1Eugc%`ClNweLOI;_kHy0U-?)C-iqzD>wiMm+jinwKCs|TA?8hZ zcnuCkosRc?I{VTeZlq&!Y_FufXF?FVqT2X(b9?C@8hil{a;mCr_I< za{^2mEB55si$P!|JYs&^qTu&&n^WF7CAY;(qYMJXuNzphoO$uS2K>;h@Y8xn8D38j zeiEMM@|5_pJuX^lD$O(9Ewc_?f2r+rq3MtE0ZM}KZxh<`1X`Z|iY5-{>2bLf5 zlz8);$lv1OA=&f3tS2Og8_lti1O)X39BxjIm#UXS)3sV25cfqt3}};nL&chA#{awY zZXFOWELYzT?F{PTa1}ap^1QBM|8Q5H7c(s8c~FwtFq<$nO0~!_9z4+LSmhVZImaK} zD<4Pm?7!`vgB?GzzUAY8n_g?{eJbD)m(%NC4$Ws9;To+6lZnYlSM+cEMJ}!nZJ*-n z{`cdZ+CfeZO)sr|#d1w3ZMeUZ*09tUE5Lf1!&1{mJ4^kjh}sJaJ=2}YXzf0aduX<+ z)LH23WgF(1o|ZjW^Q9PDIp0k+{B9tH!H2aG-=#))Ehjj3Wxf)czp4Fj6z(TktIE12 zl%#}mh}lcd*Y$EIyQHXiv}dZ*jb1k|E!H3^aRbN0P9_;F^6_(bJ$jDe zF}-_ppvZKjJUqn<;{)A zp>!JWm8qmK*c}y9hk@ zX{|O{k8^gmInwM2er;SiZS36wESM;waD*vJG~=0-s@-9_E2b`0+B%W!R=*^6W$*RPF9#f4VcA`S)DrggmrW< zH6Z8rJCMIpewhqV`k`a0KIFE?S`GI-uGNsf&Mt1!cJpV`Al96o&SHcr=j&sJC)kS`{I)3n2##w>sXpO-{UQ!?-Il9ZhRE*+Gw@!(IswbIqLm%IreEz?{JU9neHZ5 z4m^{GzB9KUL1x!}CkA;~Rx{Mi_$gB!0`mFH(Gd zeBRbNC*1M!WDcMCsdB!KuCaV{n%UA^jx?vw@Ab?uBq>hl)tOUJ;&zc24F>hbeNjUU3{Fb`GE*HKV==~He_0m^L$pJln3fNexcQO<>h>0YnLOa1UN zpY`AqNiToA{OrKC=Uq(IRn0LURnFI$LA87`?LL`LB_3ouDt$jPAJ3;>9Gi5^Lj@cj z^HJq|Jt7}8J3KJ+8T55-u-oO&u)7LNyv}48SWz)Pgc%-HV9z|;Zj8*+_et@j>xZZ2 zF%Rac%K3WKJhe<>s!C7D_Fe&gSqH>EAeU{4viaS`|7bNG+&@Kcc_o66l>vZ%=#pk9x48DL$^LtO8U_; zIp(3t^{eO`!^c#Nkg}x~I_=&RuV*?{QPb>xyKS`HH&t6nJ2}7&50wENZ_5=vl&9AL zD$u#s^P(}d#E-bGOZKV_vu~fK^U(RkfECN>9@z!*0X-8yHky^6Kf1t4X61$Pl;UO% zf9;k~eVB#+@gMUqy!C;u%Q%d=+QD3*%K18vr@-XXKA7z==QL+wFI=p^3sAURALRS@ zXU{qzKjdTf(@e(KtbM2kWV=ZGFf_f2k_7F0ZPEt`;_5T2w$PKGJ^jYm`?~ZTq1%J5 zf9ii^d8qF~49XrupKtPD7Q48lW|@P5_X6 zwY+64_FmvtfC`8PFn|kyw}Ao_EInZ0XCQ&yT33k4@NgYG`~x1IijRrUV{NQX9fbJu zMC1jh3GsWn5KGQOzxPZbF1bgDQ#J~*^OzWsGb2Vk^izy@<6dwL(rgTzrnY(3_?t#sIW^!%?rdFk6c z$_L2NeRZ&9xh9l0q*uUD?P#aB2!lEOE{_}CJpK}&renIj4B&L%^`lT8ROV9Jm+O>-VLNA2hh<1x%m}_j34^O87K( zmEyPU@rbX@>$>Am-1z&F9nD9dHXTu=ISRin!e_Z54(x*Ar}a+j*)zk5w>PpM?Vd7h zIsC3$L*Jk5N&TMuahvP@`|~;7munAWqw66C<8MOcd|e5jN^X}ns21OlOA7rV`EG?0 zek*uF_MH7gj9C1H<8<=#%xkyDZhg+XLbU^y(>=1I@Y4qkqhAIJ?K4KtpfN|}$^d@v z#E&D_6Y8At%`dT+U$9h-cb1c%vJ1R-s@YHJJd0PBBw6g)cj>eTF?%V$sIaF~ZG=j-M? zGVNZ+bX36i<|D_)+D}5`qa!@+1ayVGUBk7Mjf&}$`fmKq_QmU}9kQJ6ksa}&pM1bCx^J!TxNuP%5#jKv#|H1p7p4cw;8RAHe;;8|)EZ2n6 zhV(LM7=2;W2iQ{nHK%U^A}BQ^WPu6DXkj`oxz z+GjED8dFKmn<31fV=v96iHFHv;+!AQ3hj+{>EoYJo>x=maYtF_~I>_oroO^>}p?8=jG8*^gO%x8_}f@Z_? z9iQdu8)%~kN{Xq?iD6oH2Yrp@hJA27byWU>Eg&lPh0Loe3SJi%eO=*u@R`k{4FZ(5 zh!@KZabRc4E4jEBKV)!o*y|td*^8K5KhOR)vc4KE&S*Nc`0RVKC0^9;!SVnh%sGdc=r?>iZ8BPyYiJ)WiKVs2^{H( z#*?sI6G|J3Hy{u@nsT&A9E)BLjPHU66uw+fr?8`~ms2~M>f_X&rFuBk!Kv;|b?#0; z7vLm-)-|U}WIupDV5I>=fgAwcF535`3$echxEdh)sRW(@-T*!Ub_28qx(yf(cz|1g zHNba3A~NXlz(QaPZ~`**Qs6y+`hk`Jo$+$ZfE2vom%tq;zw*)eNJC}x3{?CFq49Ac z`iTC60__AeJf3Wha1bqH(cmaXW8?X@LS&(V(Gd-cfgQ2ldS|qmx(adsDJU;{3Nfya z5Ig>5%fo|C=j@l{`UhFUa7dulhZ+zmHf`}oYJ9L9{rb&F65K zhbrgmk$8;FK0~`z=27rVWPM!N;_H_i4LTnwS9i=qmGkvTJd(%iURA&&iWhEwmcj#M zLxDCT`)BPBjRwr(2gL*O3>}Atl@%&$fYJ-+Yulno$9J4}#Si@xJ9YLN9?(7pUx!%E z{_>v68@;rnS}lHy&3Bb%p+ZuI8#vtDUqkz=PzBhl-@aShdt1CdYsxtj=_1?>FrX&b zvRs!2w??=aE1~}aPyJT-f*k0#lJl=^yFypapn)Kgx!u`hssCH@J0!b%SN6G{_Ilm>I%Np zy3Oix>>s3l&C#CfnJhQNfgShu&?qnC?P+ZG=#2=CQ zytnn2*VAYArDlQVm=DVhabOpbPx9o+n9Bs!FJhy#Ya{R}$94CXPH#6$ST>sZ6rxQ* z>67IFBF2HtC#S@lZ_jfw1CN*LgQ=e48KayRmSDVx4};Wr;pMJ)Ubg?K2#3Rz!>BOs zqyL?9|BS59`!7G?itAf!e~JAd{z4QsQ{{X;B7g0lui>6)Fn|nKAx6>3ZxQ;xQT$(# z`H7o8oA~tEWxsLw%uki`^_uXbyxHOP6r1s^fQOt;Dx=`}P!n-Za@GX{mO%nY#yKKA9=M3snEtRocKWB`5{H(u+#ThMWwilLb9!MM6UbwuWBE~kd#O{ERM6wUFJXG>t zJEVG094bUjaWlGq#N7aW+r;M*F$Z?@8?XunqNfH3Ef=*0%5f*#M`c`i`-qQiDJBmd z_|5u;-E!|*rw76I!E!a=YV9K{FR!pf>k&$|7v|AG7wR3-e@22Q;p~QN=6E0-$OYyD zNf53EXg;mYz!2EP?b!c=Yxe>-0OtVIdqBUYQ9YmD7TuBB*axyFs&m7P0(lL*&>Xzc z>gC3%wSxxaa%g3}pxw}1G_$kx@s0iJv=rN%zrWwMZcFjQiifjXKH6@>18~)4STX?49V;eui4#3X#)<4p;18a9z>jhPvX_59^9Kr_>W=W%b0)P4z^}KJ`Vn^7^7= zPkk}4FkZa1HC{{`*Fem9zkwKcUPF=gRYUQ}C5^-%?HY@lS2q^lO>H7B?$lJQ{VZdPTGJa62+adVlKg&!n3S_gcJe-+WGWS9WB}maBaYl)+2R zNBh-pDM-)B0PX494Yk7;yc{D6&)sk?4#kZ{KQtP5%Ael*me84=9vUH4uw0i0xA>56 zOG8IBwUiuk;?T#XhNQ>LhQahmWheh1uok=$ZBJcU8Q)T@zpvoM%Ab$E;>T5b7@Qti z9t>GOl7mds#_0uSpD+f+8AE2#?x4!yHaw=LN8*A{LfY6=n5b5UQ~pb18>rbsw(Otz;+O74l);_0B8y_KjPa|SCCnQ&Xl$2L>bdoh)eOo?Yxe<9;-`_^d4sd zcL84kbr9}6gw+jUorkc8;(RLPxj=Uy5ujKiolx0B4!3BI_5{7guFI@#%`_mFPo<56 z>4EgB)_XT0y=<N7`u)SN-YGezBd+!}D7X{;rL0 zCob*&PyhRdFl|BkJdIZ%NA^v?BbuYK zfE=>NfTLpqU!!{|Z>8tRFUk|Co=)dfZjfVt^)vl>x`#l|^Zj&8_mZP9=$yi#W0LbZ zg~8$DFmR2I>7IRc9Jbl>#8Gz4NtVga^ShlO-yj{+^Yk86mRj!c)qvdoUfU{sx}Mjf zr8w%AbL-E&;Fn4@U9(($(7GS206o!dHm zx+ab6zGco`-ELi;$J(Ltno4a|&ex+%*XgBxuU$^pa=o~?ZD_r??8R4Os6SyR`0mNF zf4#mtWhipNgzl`AfZ@cNfxpYcEj!l z5^Sr2qKJYOd+gYwq92xDu%n`40kOx99Xs~_edpe@J9o0#fZ}J{+2`E3duHy;nKNh3 z^qHe~YC3P|Ye#>89#Om?Cw49b+F!=(K$*EvpG1QqSn)HY`t4KePO>E@mHz z^*#HD+=Ik=Zy&&606*Y-zzcvr_?T-h4@Usy&|!-aKqCS;76D8}0G*KJw%ySm+XZ{x zF_`@I5X_HH!TQ3B(SLi@vL4?r%{qH=nsr7E#(`?vT3dh6&g%QsCRWZX9j$5KZDC!o zJi|J4tL?2-PxQ8qotSG)|E9#c=n%6S%kL-%0- z`4+GLXrq_Yylvg(6l_)en1?}$`}f}CoOHOi&%1TAWkWCTd<4b@Xrx^&cpDpkay8%A@<$^w(vl3cgtxy=JxvbO0U>fynw4Bm8X-qrJ%_*5)IImaM%$~(ALrd41Rfxp{WVq=CnT=D)#u zi-!7~av^wy)E<-zE)9y5u8j5kz2+B@0jY(_J#7}NFe(w@o7S5}V< zYu2kNwCLfy zUU50$oJ-b~9n^gF7<5`*ns!JNLkQhjvc>n_JMNY;KsjNl6TJGXJrc-C|LWlQG93Iq zxIg^q^}v{2;_)-T%y#8s(0As83->r_MaA~p7TS@per9b6*J zQ2QVr+WNhb_VqR5SM2ru?w{^2iUf*Wrtj8VE~utt|NUynO;zqQk2O7d$38mi~_5fLd?EGNymWche-onSN6L|G6B{+ilBGUMUax0NRuv%A>5WUI6#1 zK3n}*xXfjx8%wl;R;KS*-W%azI7pF~zeV&pK4!s(MW5z1&v6=#J zZP;gjk^_tSL+0Xr24mc&39GsUX4iNil4IOSCCgf-ilY!6D@5$32tFNwz1$I=bDM`c27B_P6TfSjV?%1ciK z$b6*{nW0TXxnOx^J`?zVBwl(u|D|rj-9>=$}uj@+W_SJz)VR80%V=D`GS(#3vrNo@qTe>=O%JY~2fw6eB3cBZD? zk#53=EWi4EFlk`fVfmz9X8B~fWqr=F%{gINH_UR~3(yC^wgEQ;4g{0~Dgd>BIe=>c z4+A~`@XVVcz)1jX6R@^Nfr|pZ1)Pk+o{fUaIo6dR@+T?!)p(;4fm zz_KgQxLA(K=?Bo*x_D>AvpeG0$L1eY*@=ki4;v={*=l`p9$r2I6oK~J0odwb-HHD* z0RM#_rk}hapU6A%mHdTsOt0ZJrl&;L5r?2+c>Wio`w`sV)z-_w!rXW{Ab-s9qxAhV ztn0VC!!xzh|7}9v(8zqS;B9RD$#zZ&HW^Q;35NYR>7MsD4Dr@un=UTm@K5l|2{;Xi zP_M@(A+scocxb7&KZ^r;dwBJMZaIlwut4d{^aHThY}_|Do!@ucKHF}QwPSxL z6KS!1BX~0%loNZOg~$rG#})Dq0C%_>_cECBVush!f68@hW_|p$7RJBby#WkhdFHx| zZU-lqm%4r#*3(Da_{^Q>%>N=|md!cQD}p!qnOI(IQNeK!>N*X%kO*7nc&N5Zf?ARv z%IQ?V6R0Fgq3E$B$~qJRaTRb7Zz~JHdIVLWYA3TUHcd)?Opa{$|0q5Y`B|3dmY=-A zL)1Bj(OtK+Dtf>7+ycl~MdNGPyS=patV14WE6HvnQQrt&A+-nhm#L*m7@C>vL2Ipl zZMa^OkUw+$S|jsMebwcd?`$_o+lPHQdDn^5ztQoj_kT7A^mgQmf_QnQ%#=QC_oqtp zGpvsX9{poZ{|syS0f&8E+qLo1_9yuiV?^Hz-sD!SRiK^o!*dsKwI}uwIg^t3s0q+o ze~ROt90QTQ6vs%hL{^>WpAEY&fTMWDfYAUyfSnmEnYHc%yaUL9p!3Yo^8oCBj6lV) z0^moX=!wFC?b22kbT-DJ6Zb_r#$piZE>KNhAkvXw&r}T1O~FQ?x*q65?P^)KqQe=% zg4UUbVc-4{*ylL~bH+0f&y_a+pvwNx{uGjw(2z$X0jmMuAf4|cjmIF3Oz#!={|N9k z0FE(nD`77HzhN(#btHlPSFk_ zaH{~YZ1n_ipB&2`mo8FHP*jwxuzd2JeRYu++Wb#Lw||ORfP_dpC$~7cyexn`&0YG@ z>c>3qesOab47|XI-W0q-YL7(ng0_zgMpfE66zv~%&@?W@gHEM3ZB1^NA5e2DzgX6f z0rW*4Gp`>6Q~=J!|4jgM;T8pq1B?X>1{47b0lfj7bD#`RZ?N^oe5O3{UGy~F2y_$K zpgU!SbkL?7-w6;qW#m7|h{=!R^tZMeK)uLK-C@b)W;NvM%Y&{8r5#hWWQLa`|8cny zyh3V^^^==IUkxrv!L%}tkP8Q^r}-+SCN||~Zxrxqgx?>)vcEHcOWP^MlGn^n$`boj zy#Uk?1lBF69<4kFs6TQ6#Bp4Y-|$=3Ga?_?N?Ebg1$XaL5-F@BicPftLI}P;?pC+DI z8jgRf^#=CV58Q7V4EWUP06bH!tadzxbm&j!uk`V6@*3(RmKWr^fdFcdHhPy#3g3OpBR$6yRt8^*1wm9KZ`052yfC z0(^i8fQf)AfFCdkFd0w{m;wj@f`A&pR6qz21~8Lr0n-4}0d;_Szzo2#fa3ti15N;( z2#5ks0-Ovu1uzpZ3vepnG{9`Y>3}l;a{y-o<^s+FoDG-lfJA4B%$r$WU*jqDlpk?a(Fb&ZwUxPCX8t{`3*<`iuEa z*^qsVD?tB=n=QEY^haO6bM|(2C|w=;1+RzA_ayYksLl_E{SyOIu+=ek+;+2lj1um> zo7=ip{+l-SmgL6*q=zOSKzTIh;plem^xR3WTzATT)EhMP$NOyruaMe<N>*?LM!2%@N7zT#R(IIpVv1N8dZ#-_apN^p4<#KCw4|&Oj0}6Y3vnZS3nLR7myDa0vH3Je&YDm8GtJR9J_f1@CzUt zag71Y13VAd5yCnhz)kg|pikZg%!2S1pi`O!MYdB1gqsc;(P%k%GmKH9FPgh0#)!7U zSX3tNcHG9YKJJb&u`J9f?~K0P?ifGZ8{<~}(1$F-7*Z+DtiqsO*%XW+V$f`B404S? zOKr|F^vgcPSk{(lR`-L_thaEXWsjTFto$$2tk(+KSSzo>x!+s0wSJ!8)@tnC&RVmw zowcx`y>#fCyT6bn2X6-a=l(nj+(mMFvh~@7%+bSD=xi#(3#n#H| zRo2OKzPIk5)FZ9&$Kh#Pjy~OWUX;1c1}sv2S+Fr?<5j&=2M|vq?)E?TQ~bEGsedUB z{QWtg>(@0Clk3;T(7$h;?wuJp{lWv!qr!p_{VI4H8-F&}uio(F_^5B}z6!J4c8Uk_ zyWjqb<@c{h)9+?20wmgz44Q+A32en z4Z3LZ0W4?cz8tz$?|aSJ`^@^Ng6}j!mx;Gs-Sc40=_;z@L0a}1w*}Syni|>8vhv?awpqn4&JlYD-_0A~&<0tpoc9xtKF&N*o|0(!bgw6}&b)Q2q!iPgMRKGI} zKMi0!wG8%ZGXX zhgFkdg?`vO>%CoH`*_+4t~`jJuPJyl=H~KY9_3IH;Jro>pZ#S6GE|orGd$)uWrcbF zTa3ty*px>xf|LKW8PE2PoyeVj{!K=gm(F3gyzuV5y}*o|P=LS^r1psILyApz`zri6m4}nywchGDc7nIII$~K(_?Ggbk83fXL`FD9 zD!K;4OiK5V29AAUsL8cnj%`XxHT5ya!MXu3?4-uRc7ojtkPX1_lUmcZAMAqw{Q-jj z!vRMCIHnf_91CFo^a8+jfW?5P08M~(0PZ{A6Ho#O0WJbO0w5ouaxs#HItw8Bdmi`= zr&xVP*<||kdbTulvDJ9uJtSQj`lpsO@d}NHsyDdWq%t_sUU=XsnueJGagX9f;_n=3 zJ^okTdnxDoYd8H_zL)q-ytua%zh{cq&oy*WfW$w~h+p!r7zK1uzs=ugm|u9den0Zr zzFbnKjIAfyHp7d1g7~SRg1l>&CJK=FJJ-6?pD6y^?4~n1?Xt~7{FX-IH}SS>LjF7P z+Z>?$Nc;=dBmN%`I3jo785I&CSKfIrNa>jUH_y{chixMz*x2y3`(<}-0YN=gbmtJrc z-)Tq>pC(?R@nHTJV)dJ6P+&q37hYFm6&!ZFla8TfaM$^<5b;yL=K~ln-zi^mu039% zcMsgL(3<-M-)SU%6K}g>?WNCKgT-GH{MB57H7J00Hsx`unsI@p%X?O}=A+<-+^Le>83_7}?%3odSaUawh zMHoU?)(m&~ka~{`zu(yY(>Ioa?)M*yQB|`|00kCW<$6t2sW!uPE9Zr@eJ@*SC7Zl^<}jc6cPJNovzYjTc@k{nTJ#y zKI_H3C0<)$x3^5ZxVK1GQJ}Ish(}_wT=iGY@yW~W3ef%KUbmk2(-EKbf3uw(^A4~m z4}uqZ#1^_r0!0Po?6lX~_gsj30~oH$gWy}UDXT2g(nl2kB0ut@2E zQp1L>EyeEjz6(JYO+J9}C2D7Hdh0{&zW?C$ZPw5u4E=S-Q}7C@J?w(y8Q>3vBfNOF zzRVX1gHL{5LF=EP8g#L>$Rm8-%6gnAftH?cc&#sl63Fo#8ol1gnb|u3KHlmk?P0uxPJ>1lyb4r%kblE#{S{?sVe#av0XQ+Z%Ffk6VRb~a?OCT|G3a3WgnrNP(ymw!_0Y3Bmco6Hv)V6<$9b^K_Sc76xa3bVqo=Ft)a2>PhP&t3 zbGLZ=m}ABLq|>C;k{hk*2SF-_gHz&9jaV@`9YD;?pm z{VC%J7TkxOH*>^$AI__P(rJ7&!JX+6JpQ^2<#*(WAtQWKYf-DAYQs6*Az!F8SnaRC zDcvD)C}O&>|dGjA|NbvNdo3g3Z7*~jR$Mbx5r^n_2(jW1aV1*>d7d*IbCWMn7 z(DHz$!7VuaUe_y~Pj|})+cFdb*-uCRg`0ocX3c9ijFmPA>1qSI1W!M@G4;wI92-zK zfOkuw|KuwP@bVz~*XdYb&_NwaTJ-VXEv}yb+MM^^=`S)vI}Ja<(~)(CJD<#XL`INz`>|vDcG{H1NEw@+v}Sm5Pe=#O#w@}vI8-|&0n&uZN2g<< zK}Q4DhLF~pVQJPaW0$ae?!S2T>j51xWoNbRvc<+nUk z8;+C*C;QNf((`5A*~#fy26{JpyxoU&BidJ$aiRwXRkYIUf>%iGL3&gX9m91?-!I z5|m`U{>izx6}m3Wu==+-=KC{$?9sH&iJJR8I36JQI7RlGTd&00je65nc{KHj-bQ2E z`9D#6E>XR+KK0Q0__0%vdZsw=*W-X*ZpU2eF1Kd8aWTqu$CV%NfBG%+PQTMhij-Ty zn<;dcTdlapn~ds{WbH;N!z^o3b|oHXI8ptTvPfIr#b3()eH_r`q;rE?PRw>=6XfX8 zPd{7tqvywOP5mx-lNz_2xZ91I)HK^?B(lNqnCB_|ZgMvD|KH33y}h`wm2yiy9dUnS z{f$MvMt0%>1~4pBd*Ug0h14GF*Iv|1u>ElzEE#vry3(yr%zB4k>^q<_dQfN%k4R9) z>pV@o<7}z?MpoEyjAL)nx)LA^EGMUl!@3^bn z{2KR>y>DRIE1O#%@A>e@49EM}QTb=rFS%dl@tD4jNTuM-xXd{mb^UgH9;2|o^Fae_ z;h%N2n}4z=psp|O8Yp>d96y=S>6%+EExngVq$*=4vrRL+xRZY-Eu6!|0tB_orKqmP zuTM5%Zo^X)3I#(>08!XNUljDwNdB%t-f{jtIuvKIE*qrw2b|ew+w4^ESQ3BE_3rq&ABgiStAEA1;?F$OtZOo?mEFg5 z_-U8C<+6{4dn_nlg2!K%5&0^s$0Yica%`r@!bN{|ZOF%Q^u+sc*=Az8?6k#gSHQ*} z@oS({e^VUzM{yvE)JS=4x-ofqZA5v#{DY3$&AM>=9%gwJyvZCXug-b)uChwM=6D5h zsq#uLq)dtf%{idA8ym2|hV@iFfHv2NvHtAV6KBuA{PZ4U;GVf^@vG-~{ny|qEM;W9 zwcs6e%reSr0Tz=?3}Q)3F?>)@$Uddc_|LfX@rPI-NnWCG6Md6)Gv?v&pY*q6ww*cs zmWxJw*2eF6U^;2GbMW@R_|u?YHH|!F)j^&$Mw10#{0-N=e|8??*TZMnQOBM4ERMT1 zt`FI^%UaS#wV$%F!83R13tuh8_b=anOa9g06-za`|Y2{9IFf((wI{T5v(0 zlX=)WrQ}2KCUq^!M}D|IP|n1KA>V6ksbA1sam_*Se@lktB~h87j^TIuw~5+6iN0+qu0INI(qR7oqvB14`}g2L6l6+y zZM@fAUd?g-&i7h2YJ2 zHM!_t&BZyD@x8kAn@B#)Fk1V+p)#_e{#%RxpX{!;*Jm$FE+1%_@HRI7)a0Y2ChUkvVXY6>0#^sed#g)oY`>YA2fw$?s)?do{fN0V5)s1d^OeH3Rpak z(^FPZo?lyu(`y0~)hBxSu3Da)Kg&Sxbq^f#*f*Cyd+|yqLMh*Z7dpgt(=$4Rd6C$0 zIXW$7`IhfDmMwB7;hFyhpRyBkK$qKfhMcgVah>Hlz}UGn=+*k>q;_}h`E$)0zSG$J zPHTp@U2$#@HjY9#>U9D2;5-Xlw5ZMxs)QIru){p(gXKt<+vwBoa>O#kbsGA4Bawp+ z?bG4l=daqw$#~jn);?*17dph2dB?&)*f|@EZ`FPtBkHa3j>oyD5gvS^(~qf$B-Dk>2iUWT=4n#qcjNhz#J$boZ zhH`!T{I0$8FDe))TFQ-z&mJZb}5WLA(DX+!l<)vk1qY7{$FWUmD35DaYoz^#Y z=i=U(VL=~vO8w)>nJ+^4&ChFJ=Uc$dTY}Z2b8< z}P0;0WIkxx;y0XHKvWuzql76%v--0OamZB-+S)-=U5B(70P{DIdI>sBJ<$zDU1Iv zhj`17~WhcT=X6~RhH-#7%N=R5U;7<)`X{{1%F)&Kp_tw+uEt=-8f;XvfuWya*S7Wh=Q3dL zPw{NySuXlr-O zPw85>UNP5aGtT*gcAk9QwL7*Iy-&K@f-b?EbQv+WbljWkp58SE9cDeqIR0FbboXt?Y8HzpkL0MN?p<2+5gcr!w#L%$ynJjD%T`M&VLiYfG~*Xy0XPM(jeLEr5i7v9$NpSLIM=R_pu3<jOi3 zIf1ccQ62ciHR?uWyum zZ_7uTW#Yx%OplWjgMIZw{bAg~R#D|%X{Yly{oB^%wB)sZi$lk4TQ2db@ehoGn0Rp) zdJ01IHIbmR;LyIDvou&!TaELnDhGsuQwqF+V8CDDt+rPuy5x5O=wiC_0kjk8p~uf# zyY%+Tu2*gDL`*x)+T0SngN|83m)tMuZ1Ncqi4=wX5irWzCM@8`D>5jd&-UA&4d_o<59<6@g7;nW405&?4KKk{}Q$yR-NOI z=eR8fos^+`0By7UN8$eD)xZ4I^{J!J>IHWi+N4wP3aLGW&SG4`8?N$Bw(niUxp45K z%P-4`fcAN_SH0bm_oJI$wploCA?Nz>>w*8)h$D!^BO zOb~M*zz4Vh@HBvTik1Pcafqw}p>F~vw1X@G$UlhGiTJ#ko+EB!8uA1r#l|Ddu<7=D z4da=kppI!g8=0=bI+jzo$G<2l1|w&Va1}OcBo_Wc!(WB6b4o z3}7E62f%jx!GIzFb?g{GB|t9|*WmxXfENIt1Ga=v?F~2za0cK3!1sWD5Rg*=Jmb9| z%ELlHFYu6j{9ly^khj4`muu=1>R}z1EI{)6pJep%u*N74iN+hIo^iuz@9Y=eU3hT4 zdb!>*@#1cl2V3}66=gRQar$LdC>RLVhSeu}Jyp{t(^bDSk04^!I0*NsYwkFNA56Nj zYF>|d%NI+&&}REy@bse_lb(3Jsrvfpag_P0C%F5`R$I58NOa!*8TWj8$9YAMy&`cf zRWC~|6EE&29T*={`-YrKGu+>Y+p&F$PwEprpB952@**FAVyNDAzRZLBP77w9KB(_! zud}|O=>?$P61+lc50joaUk2ciUHprLg4NEpWqy_o(Az`QH4+!y#pra`v`bERG2B;e zefWKzv(CLu!V~>Dv4y8;| zU!=^R&jG!ji*`(|7stT8_W^-t@9#BhAlr5{y#bUL!7HTppuF&&9!P|~KVRW|#r}wR zHT7XtB zX-#09B^(SWPddL=Aby&B0Q1MxQ*`UrdBG9)ygp};q=j}GQYLu%(T&6};{eU{l;b%H zTlf&&(oM(G-W^q+WHu)K8=7|NS-N?q^=5XL(>*ub_b&NELpf!>30@(!hsrnYV2ZKW zkTG@$#wY_7+|J%?9|p&((T!Ior6V0iq^uMN91iGuBfWF-^2$&4IKB4mN4t+$A!Ug+ z=Pd>A1RJxOmDd6OP&i_iT6aCPA|p8+4WP65tE_2lGEaM-`j|%ahTv^%{Hf?jP;aX7 zYR||(1>Ag<>bRSFZ5wtoeZu&hu7J|5@fcEXDGsDKun;Ve`oAtSc{wJx&Md#^)wY|R z@Sdqp1aES5L(6eX?MuDgo7XKlot?X6T9f=se%dX4+^N!*pdMg5MerMm&Sv_C?J|ke zj3f0w#esi22lV#KGL&PMm;5A5sS173*#3Z*V&mL0zU(*f5(M>)zV0gC>8{{btbi*-tx!FbwJ&!8_=fWzty` zsNf15P*@a>U~`i{jOLBjuxWt8CA~5)FZwqYp!One=3I)5A!=SzuN#R2y1cA_yd;|! zSP1t;yAHa0@zEzd)y;{2AZ*Hu;7zhjc_|2bt9{`LEQ?U%>>-?<5?^G1kFx=~yl@^~ z;?l#`>9%%s%egteK5qL=D|FJ((!JNw@VpvK8abx6ZkE^N#+mE|2U(|%RI;n)1MEZ zEo~ot{qcF*ymhLlu;V$>@1vcDl_Y}4UzaiECBLG=R}(3y8bAq`G4@e@F9sjgM5W#? zT$bgQUsF$K|0mOWV(@j{=4~}($xBYGT+2fF6}*cW{4wZ>ud`FjCGEvN>$A?z3|Idz zGDKV6=`Q_NkyHJf)cfz_fG#&y&*XA5Zl_FZ`+lWA&OGCn`ZOnlq<$B?NsS>lYX1Y* z(W3pqGb?zGW_b|PxfA@MDe*bp#QIN{2|XSi&v*Gxd1*~Q>EWc_*PjEk;Z^#}vmrO+ zb3TB)7oO|uBEo}@FPpZe-dOtYe#<%r)unHG%vmECqiRRW*Z+dpboMT^|^vqJ#q+?m9xy`}b z|Kd-|iz6%c-UQV<_u!1z2@`ONeIS7Qxz%cE<9z8X1VKH+{`qXsCGqY%v8f&7)alOJ zwRJsQ(DBRbUMQdXywFQK4H{eU`0Fw)(2e6NlasF355;|wm%oLed*Z^p({6odw*#A; z*rogl-bEDt80F6sTcG5$C1lVbQMoh2lK)cfgg3+!ml`h+4sCo}m*40f$>pR8a#S<$ z%IErKjOhK5LyE|W;7tmf$q5>qs_j{;N?S`})2x0s!`1(b+|btFQ~Fxx(#Cy{A~ee+G@njo@u;{AtR~5x!6mo9;Naq{e4*;MHvZ z@oV;@6PYNGLT}!lZhEywiRRXHddB4>&mYG1VCU*9whJG(x6E;op7x+e@asvBoj(Z(((BJ|eckk!{8lAp=sy`?mmac+$NQ3N98zjUAE^;{$Pw)MP{mHS=O;X7Fe zE#+VECQT+^>=hxUp{3{YcrR+zOasrvCr$IG~rC)vd?}sXFT3C!Rj+ z$C7mF0vhHa&mj@KLTZmzkh|6Ht;?6KJ6Gre!%?P)oE9J_CYuPfnojK22a5&r1of4 zZqRAoPWBRo|zV%U;i@vWNW*sRcaz8uG#|GZU+T$_q z@hy8Gs|?$KaF$E_D5bsZfv*C4pj2ClVuzFki|OHbR~_io=^zb_jyuzleNgM^c;(uH z?JvLV^UnB88A->h2438m55FfJT1v6P-?Fk0u%xFL^y>7GmIlY2>FIoM^6|Sh`2OPe zUheZy&C>I@pPGhYaNbt%3aLFdG(CgDPU=VaYQvah5&4pOi~TQ&TZ_hZp2ISvgYA)g z0B!0Cy+6JH?p+T&F?-SUqx;gGhWomi4#6v=_AtwbL#1|JknK4K7Wpmoeun=NhZbDy zwa)QR{^uRyrkiDlV>tSKNcZ1$^0EsX0)^5p=N_3h*l8+w{B;@9&BOag_@>tSpztGM zdkA4Re34GZyUd7}aWY)}9FCpO{_#K8y?@VxJ)O|$-X6XL@1SFr8E@GT=lrrlUxh!6 zV(0kO+YMt5b*G>07mjDtVb|14C2x)6Cwp{yz27YX3f~~}!fxbu#<@bd>_N`D2_(u4$Am6QL&3T)3p!b3I4nJYeb~|UKI}tki z?pMJ(=$O?KJ>H4Fl0cy!H&zYxMZA^Xh!R&Oh3gV_TkiPP^dgM>nm@&!Dg_LG>j8wR2=- z*r$St;wkj4DRRrVc~943(7)YdXO8;%z*)ZTj$pAOqn;GJ3RHWLzQSQ;awmv!J6H34 zX4TPM`F?t>1K9j%6H_3gaTvHtQYjPk8vZTDu8<1R|RKb0G!}ZlqfAC_E zW1TcoUIlMs<4-BCXe>Hw2z>TsKaLl({l)SmVaG#pw~L#K-Fn6B|K|y3xi}25p z{&3aVy1nW|Hr%gRXV4H~l+4rQK0btw251?Bfz)m$@Qs#Ga zKyRN`4N5NejO?|S&ul#5;x`sc#CDsgT{FD67X*Wo{XUPg+}~G;t2axly*PQ;R~NxW zm}o28K6N^>hPvf?9t45HH15SMt=!kQy<#osy#Dwnz8L#X$B#u8NC)Lw@Djh+4jqNw z`f!;)P=Tej6GFall{#cM67u_|IrnIp=eotXPqN`VUFYR%nSDaWj=E&yz{I()=5k$ z&nx6Q1D;#L@jspi$uSe|yWn^Y&%NRKI@~&v1=tDD1Hit0FTl=#T>!lStp9ff>;~uq z*d4G3zysJ5kOSbMCLBe^;JLLAfagr|T)q7Pxqt%z2LcWP90JG#^am6I1^|iyhXIBF zm>H#j5rA^QD8LxN5rCrr9NZiS7!P2NrV2pj1^`n55x{i748ZY#DBu*psem&8X93Ou zTmZNja5>;Az_kF%1yr?~FVXe>8bf}}aR7W~J-V)@`q2CCVi3x7QUcT|&BTlQu;E1> zoLX!*T!sZB{s|bC@P;DVrR&OT9iGzu8&_)AgL%L)_%;C61Nu7W+iTK8=})zzh$y4T zfNv8o?i?H9IWs=2U<*}pke3{EuWMe7co|MUfVSlIia~9xQ`bB~(X@tqGy0UBKb?OZ z-)SUX6K}gB?=jS2$D8Afyx1;LSd!i`!!s39;!VW&XPRa;wLc*5OSZvi81E){3SJ?# zM?AfpmM#zS9Lg9i@D~M0{HwM2*@n%!vV%(d7zpu8(++8ZSL@?b&OY+hneDn-4g6=v zzXRfr;cay68IKnoT%+TsptQM1G=1K zk4i2lvmr+p-&6C&ZMPMTGv!3^Cef|Ri3jK8qmA5v%x8I#@$QtIn4J7`|3?wM=(BZ@ z6PDF{0Bw%prvt{JBH{U33*mm|NBjTh7!lkGohfZBTD7o<}`dTaAHEUnQ<$z|9PZ69EWaIb+;(wTBz)Cw(60yOYoD zJMW$@wLmK)beVW@Z-K56z5w=PmV^p@-1Xs*g?l-1tg@#p;H?Q)1?_sJ0RahpE7pU) zo6b40_KkC-VG#r%cNnmMV z9-FaGPs6&K@*;SJ)E+JBJ89=D?W1<{tFKIXA(FB}nIX`KZU0L>|Cb!l>!s}R$>nAC zxJ>KN-fgnm?(zCoro0H=qKB@x0O}dRE2Q>_%S}m*Pc2|k{eWh2!LdfEe^Paj#=t-6RUbcC){0z^#IaZ2 zz2mdTUDRLd0K0BTi{Z^=#O1=(k79e9Z4{5}P1ort^(B{2#*y`8+Wbv&w>w|rvt=o* z8D895po2n+MPK&qqx7rm*EI$m=-#Puzjd(3&Yi)k+gf_}4l*m^690Hj@+UX`3bRTDC;6>nTxe&?M(be4R28Q-(~3SQ_DJ5Cp9 z&{~$|!Nld5eRm04!bsVF9tWa`TI3^pQgZp24f#2<{Vi1`AJ&C9w?lI`fbt=Dh14E# z`LIVmI96^;hV99$|1SfYIGN+??1XK@9DKQEeyB>(mH zXl_mNbTuJeN6vcagtwlU>zDawrk&+M@Mcskr^|J1wp#O`r;lweiNg$YL;gqMS@Lbg zRCoIF;Fb?qjC6n8>#do1wHA~uKJCRD^C;cO2cA)(lU- zG|U%(Iesi^SdAh(d*amLVS71eLhyjZSZ594==DYCuv>muud{gT=Z<>6&ncLD`&akq zYX!JZT=4MjGA+1?#y zl(8-5%1XH?N~f=BJ?MLA)aOrq()69``;rEs&&2zR)x zKNrJ&*K=n*^Y~Gp4VF4p_$hdyM{LripZ6X+FE|(~3Hc}bxjv638=%)~Os~X2cQJZ- zPOo$4e`k2&n#b7~R4i`SDXV5W_B{_6_D=p5+g$KpHauW{05JaruaMe9opg&Ov9)IeFtlEmc0QC(Qf5NP9{zl<9rXTCw<;0x-Vz_5- z@$Ac8@14?t^wQ8y!&C4IsXa`2#C@_Hpteg1)}`p>VHx62#y19g)w4(MIcN2KT#l-Y zO~`~mLm!D3nM-rWW;K-VV>nJU2MOFW*`+n>XMg@{(PqaGK$nTqw6pSalA60i1;$tli>=P{`xQ*vZ-{LlHX z*K_HoyX9yZNFqc}%(QOX=8{bopPXskvHy^-8^Z(J`kV?{^pN1qRG4yPYasTB*s_P( z8NsFcN;~1|jEI$sh7097)sKz$WAnk({(u5NA)p8_05A|x3>XAB3@{kLy&hak&ix)G zfKtG4zz9GYpd2s~z>01(fa5)f1Go=_hr%2MI2v#aU@Tx9zzY};r~p&~I8-zNFcDA% z@B=0RxL>3iFa^MNX%J8Y;Qo;i0L=rnkA#aervat|>HzH8abL-?fa3ti15N;(2#5ks z0-Ovu1uzpZ3vepnG{9`Y>3}l;a{y-o<^s4Mx9%&>Ggb(yjBmeDx?q@PLx6jnS6bDiqNO9nw#R1lv(!W@Mc40gG z&rg!XYo=cjJ^a6c6CNA-WD&h}a{ONF;LT6jE_4P3?XlGs?oE*IvhYHBcz)bs&?E89 zKdgnhuo9<&Y z_dxpAo0#F(Y3|nzf4)O|#IN%^eNOA+6=!YU;qG%kYV)!1nRXhuE_nQPnHKn+=)MQ_ zT?3wy|HX6N{Q`4+<3iAT_Xm6XmR>x#Y3govw6DWr|5ETaHvS|%0CW7r?n64O@7?nz z+GH1kX#i76pNt!_tw%nJA)0YED3Kq*n=!N?Kh5W}oDXwh>+-_3 zH4R8m<67!Zf`^`tym`sXK?BlR|LOym`X;}Z!M*`aM*z!#;1yDPw2+R(^G%pGG3B1} zXUeS>yz5o>$9KxMj&pfV{rOECV1H8dX5Bf-G-o>c(47ELp`Rv2;L-O1Leh@ z^g|#ixiLBU*ZQyPnT6*imz(r+Gp$4R9{ND&(byXT$m zr8$xudz@j@W_WRzdaj@fmv8%PrxaBCF^y^uqd3bwa58+5Ti;y!0Cc*>G`j2GM08zp zRgaU~{oiY+NxZDrdCHB67xxXNOIB&G-rC(ym+(?{iUTPQH0Qt_Mq?Dyz$x=5b3n$8 zNrsUaUjKk6bDiqNO2&=ffNT)97u5>#eozD{%8*9^Sf&>-o`nXd;t50 zd}p6g_TA#uT7LbD-B*=vzd+U*(dNE9!PAd!WV|iDMVZG0aMLBWTh;`z$;+MrlT}nv zd@Sn}s%}rdK8NvKnYRB4yS}wAm-Z`T&l$C8h8K6zGs0IB#MZLFL}wt9M;3^?&X09Q z{2W{4{ABE$3%n2Ttt>e4>CbPH@eSH(IJrUa`0Fz9^OaoZq}fcsLC#_4P-ppQHeQ4u z3-3stKT){nw%xtcs69U9RYl5hUXb&Vf_Km{D^8E($AA#-BMKmc28ECCg@TUHY}oob zr9|t}=r!v2Q}^ZG+4}hHwf$~=Z^9WR5A$0Zd);6s%f#ER?t3J(^M^)<{1KIhb?_+s z%DXEbKjk!QNgH*pTQ<`QWHp`aqk#b84#sawZi|Zz`0OZFO0Oljt`%%8cFJ6`5cedO+ zh?Lcg19~}H2Du>L^PBmKBYt`3ruUy5c=6HmPquMyI8MJh__$B|jdD@I4XYE>3Gtrt zP;EGpAE>AbhUCy@*hpXPKsv zbUp0gZEXCx{^_#k*d%FL2tv{|26Rch4B1Rqo#rljros81^49I1*3)(4!JEGw9Q7`@ zoGByey2-$c`}(J=AQ%YPcTGsz7)BOA(w7VR^!ORKULQ2Voq3fHK(?uOvwgE*^o0Fp z-1MeYdupE?cgvZ0e69@dbsAA#Zr^F-iC39=yxI50>mkOQXdZK`n;x$Z-n(6hdWwer zy5T8!h14GIc(J?~+f}Fe-097`KY6?jplgSUfeSx={^-qquCW7eghl-zcr8lx>W(*m zd^lKL%bK?V1nYXi{I0eCOfR7|LqCOpLjkNCDW}xstS_0jV&gSsG!E$XU)2N25o}X9$aOA$Tol^-8%g?l-gBv}os7_#m28q%fwOde<}xb zIa%9^oRH9}YbV}t;a1-c5u)WDJQFYO3FO4sRbvZ^u0PWsOfIigOERswrT&p`ta|Z<#ej}dm1c{%v9v1#8BkuBFzLWodcUzawoQIRk#XQJO zW&K$P_5SINBMx<#wG|jZxe&a`kA!mJ3{LRus31C;^?jSm$;PU8B#&v+NFLk&QqT3} zKolO?9$~w+^wH#U(g->79XITR{i~O}(C2oW^FQKy%8B63c$3Kq{Wc&Ny*)%7!gAb_ z9^p5-k^I+jd?)^o(j&U8{nPb`UcVGCbIV6`?GJ6(;avu~>G{)^=?fprv|f8Cc-W|n z9}dYH$Q-n+wE)V8;1yDP=<>k(KFStX(FzwKn^powd3{2dh_?O|1)SJ6V&^4qS5o4%RW(?q;2keX#Yy zqS2Q3@#C%M#x1h$y`@ds+V4VXmspu?$S<(sM3B==?zbkg1tWE!I8(MMcY>!pk`E_4 zc)ITcAfE3mPbsru9EifZ=*6lhlgs@wl#7?Y>hs3bo?or*yTxd-JSO*oCr&rbz`rFA6Y*hVC@$;G~}D$ua5Xasv@JN9>W=wJt64q6 zytG5sL)q|mhQYiQT_SCj{=n@7F#GYWYxoUigzXi+6GR4S>tW%qGU6`(3uYehqDQh2F5Iic)er%dsU`&d2Xix3vWpKdG#-&R55-P{wObk z$6uEz^hUfR!#Pzs}<9Nt2u@g@Yg1`Um+ouDt!i8-ws);yuH^F%i0ocFP;=L>Ll>1dq2 zS%b4q=cBKDpJhGy1>E;fvo<>?%?fPN#ya`ZHdgvEZLM=hx3iACsJ(SqZU<|0Nk?m7 z+UC|5Gq$vL`8LCf{NJ|LFF89|_buPeIyGm1E4tf2tM-v2t)3&NDZYUv3H$eoX-Efk z84dpn=yEOos2AC`+7lqUk^iYrB@BMYcj9TYj1Z_NX;_y^c>FK%@tykAtUCoyn@0C< zWBxf$U0*JS{4=fjPMUqNCjjPQ>}U4jw=BV{hs^(*o6NV?2(|8rl?wD!E~t)3T+DF|*; z$Q-xnVR;n1LTV3JdE^+IRu<{40TD5Nso%9v6TXrz${%gr@IU3sbfbJm033gyA3`4h z$E`&E`JOU~Ij{g|k&n)=yXC{|C)B)}Y5h>}L-yuRwks}dv~y?`zNdT$-i!tE%Cr2+ ze4%On3ZES9XJ2pOoa5(QpR$)YsvtI0Zp?U-{ikG$Y>3R{0oMZ{ZA zX(nFW6RdMUwdpK%DD;IRp+HJ0 z{rb7fvoMJFHq%iG5vR|!t{+_mtgElB=G31uI-k0I z;MQ9?we~#*d2geC(&34h*SwQyt@`ieichy{zvGbZc8&<21h0{xUgLDwS6h__3xfeH z-(85$ncsT9gdtKtus)(%WLt*yjL03^Eo^g3JwzU%8xk8E-5T#q0q0t}0k#8h9F=uf z55UfVT>*Ol`U1$+yK)^7-NWjqmwoB24QFkqz2Kzj~Re;+84*^~TtO5K2=nBGf z07C)QfU^LL0Ivf!MS}VPrUGsTd;-`D2|N+-0$@)h^gKWtB=%UquYh?-vt#> zTon>N7zr;x!pk5W$06YlBH=rC#$5_qfoAl>veDq{jn2#{3>e?j9X1NhUOT~mFZ9)V zBR(_&FG44$>pqAh7wh^Dv8=p8+`VuZ?o=3#J17nZyPW4 zlnww|!v=SAx6ugd|w9kk{XceyqD z{ly<=TKg?|>&5eKy=2O6PLibD3f@dLwkN311+S3WBavKq3cP^`wii|U zdEcbB8nfxLTZoxp)-d*(6 zedVUdY!~p89WPsPY=>33KRBN|x;d>GUfkE49%sNtua6qOiPOV=t*k$g^8~D~Gp#G{ z4YujH^72>CX9pMtLj$Tl61+lc56-8RSJXJ0Tk|nQH>D=x8G@NiV!UkkFuSJsjIE@d`82lV=A-1l)gVfk3vyQ8|FbT&GP4NW`s%=tFcT6p|Zt4{Gg ze9`5GoCw~ekaAKutZXbs6S?CS_0Cw7sIlb*rDNk8qsKaO1KDkahVn|e&j--v7y#Qk^Dsxld;I3X z{ifaK7QI*RS;cuO8flja-p0nCEU#r{L*n=LVzr{IafyYt?92 zc9NMW9EI-UUs^v;W#=nyeCL^KR*%g;&kmJz)9m8l?SJv7LwA{fV!#{0o|^pXiQKYW zHO29g1)K5n{GlquFX5+wX`J8F-Dhj=ZQ)M7>h23Q_jYJlvQ4ay>&^bvoiB9fTw+~c z%X+Egt#Mg!pSHv9A5VXA;yy*d(@4Gu-p0nCPWp;*l25qGJK0z0i+KIjVf(&!ZJifs z<@}}HZ;OBbd)vRW5tQU#XRP{S8%gAj?`&J?=jDys;)c+oy>D+T`9?bpsT4f^x{Q;) z5x#(LVld*zsV>35pumJ+S#1qh+Q~5*>VA2lW5IgRQMP2|{Kcc6y~dTwzJ?-!m zyh3UZhYtNbtwDu6I}mf~^cDq3{56}Pz{5!V<36(I(-(lQ6&0_q%WK=kdhW=T!H=Kv z1-|A)HVotEIFR5KQhPY@Cun4kRXxOwJ+IEWR7@|c^@N;1<$ff6PJI{r-woga>2{)d?A$LY$%t{ z!1H=c8t;LH1D(*s+6e>ilc12-ZihMa9W3jqETpR!_A2*=p4c67lVe$z?~Azl;e4@t z$Vstf)s|omel+IL$Kjhv=v&po|4EiL=4|-89P!_ZxRzShlowGBKT>&{a9$lr|6K;` zQFRR1ve68ik`f+mus3G(_ZTwulH$N0#DN-wD|$7zLvp>|1iicYq(!$q{M8HphhnIV z=vBcx=$Pf`)lt4s7&RQqFI*U(w5MVowHN9|)+rle^!7+2(!p{BRnnr#e!IcIZ*Kl`m9Q>l{OBWx)&6!*g^@7z4kHm*ClCHZQyp4@NC0&Dk^+k0R zRo=ivpQosxuvpq@S@0_9Yef7KKI<&zlkUDkbBCH&Z6w`&t>*p-DnL{xRumxVtLfN! z`i^_;fG$5bZQ;RZ%1HW-H}K*v>C*@PwmGx)_c_-k6(fmLl7*TCQ@t=hk$&WnH zBk>LF`e+*4q`Lb!&3)7-54UBTTz8LZ?t%2JH+cf?dU|s=OWyA74EF~<-(~-zJ1=P~ z>12C@?JU9LugkQM-ePY!agwv~HPb8lf@MnL(gW7%uG*rDa>~au4PeeEECb!g?7P?d z(ay*1_I^)0lqIl8x8QAT{7Je2++(263AS)gdf#UAgeM~?y>2I6tr^{qv={VmnBN5U zMOha4&Tr^f^k<^);QX&Q3%~)MF8?}ikFM>B2x`Fc2;yvjp zxiLBW=l<9A%!;j&%S}$_F4m6Ews}4J?y?zAQTf8qqMi}FLTZl|fMP zJOTP>dNVzv1+~#%OeK%{=&%egzxmhpqL~s+Y z(0H^UFD>1ZJ~A*l5S)&7xZYllW+s>8CeZyu*MnC~9dhA~wKaCkx51(u3ts3E+kJj; zX)ug6S3I}40YanK=i+~TZOR;>HA6pz0FIfkg-qK(8bg`Cyx3c2+ylak{$U$Y8)d0$c;1yDPP+qYPqAXZ3*%v7d2CIkor}!fyFwBeV zgJ-CwE*rlA%8OcaRqgX)8~(^Zg}0{0S6LpEHz!O}o|x~{MYP$!pe;DcfR3j;P&Rf1 zu)o7LQ$8SNHXa9NBPfxlb=}iB~qM=hSZ^F2Lm8rVFiJPF>UjPk@a zS+4Va&2wD$O{{mM&Z5n>^TsrkEs;CQA@vQ7$fU@qjZHlpzygtz-0sQcWWlywtbMay z89!ytw->$S$O-%EloP?59EF^0=>Bj|@t}dlMP=nGs0L)_@2R&;dRqH0eL2dIUT>x3 zCo$)uK#Tk=hWwCk`2gB1d(`dYQ0Tb77O$4~=xv{PqUWOBF?FE~`Pv4hQ}7NtX2sWi zI{RxqoGKd-@=oy;mk%A{ny1U#zV&wAgNtXMbmOrX+{$=q?0ju+3EsxWpYix(`(h0W zY`;-h!iRA?CND=zL1(|!D~>(z(b3C$IZ@pOo8?IG4mxJV>4@*Q@FY2p?J|5xDwq$1 zM5ZNtBEKoz@8f{pA6bx8FT_XQLr;Nh^y&adelUu)%r_8Gc zOk(#vb|hwGEo*MZjPIfubH9@D0s3hJ?hBrNbVIq}eNJWeSh$B*(v65j$}swkfsSBc zU@$nb+J`w`d?flUw}+dKE#cM~kc|etcU8|17lO`byPR~;JIjX;;Cwp`>7e`yULmzd z3v^)bM;P6aI3Y3)B;(Rr5V2R0DP1mOjvM)<0pST>R)a4z`Tx(}y};Q~*M|Z>0n{jn zK#3r=HWj&zO1HdUz6ePmkw;<@B-9s6b|I0F4Z9mj#K$VADArN+dDx0*wW3_*{(fi9e|OI8W*4|BTEFwz|CzJ@nKSd7@BHUK@0mzB z?&f}5cH3j0A3gDD@7;W1i80$VVh)x3?5Ex|U7okDcjalF_bMI}i}AdH^=pSuSk=F_ z^I)jza8-Nfu6->_@yh#nR_!_cd6auD+~!3~-?U|5VJC>Pp8R1azaCqDZ^jo-j#!uX z0!H=HKHoEMps#=4n$>wLM7x8Iyk7A!vCNq=$2_Id6hn^KPcwUb}vj(<)+J@vWM?LQ~tDdQ{CQ?Cb> z{AqW2Z|+xaiQm8a=+h29^2(F<+~e$OY5Zh_mi0i%ACI*9mhn!zUwOd9^;WeURb?d0 z$#hK>&E$P$x6-|QKQ!|4+-hELmE+3Qa?XRYe3X5K(tlZpX1mOz(vGaIb!`4$ewW|> zD>U`(oh$b4E+;X4kLin#JEQ!(>MM``$@x#6)q270KYG*?Ki%`ZT|ZFCofO@(oRs|d zx2qZ79$v6vUH@PlmR~#EyQY1wV9$cJ!-E^+61Mj1Z`&95+JFV6F_G{w#I)59_Q~6Bncik4xW7%m&Yqz)n?anvNXf6NdjMkq# zbDP%tw`|k8?U~!QF8S`Zt^c!SyVgrDdPM8$uROA~OV7;K>u-K^>#JYizO{MYj;+N{ z-?_EwL%X)Fy=C{-+wb|K*7`?3rFGy*Pj8)n-~p|5H$A)cz6+0T{o*k%Xr16;FEM&i8+@O>foB{Wi_vKG6Rk6FufONNMWp(vp|$dVc+TcFSe6h$Mm;bX}_KE6wzW;s;)R*7G514xS-D%%htv!Bl#>QRV|Fh@pb@5l) za3{rQF25zesX6WP+kOl~S$coB*1vJNd%MYHGwX@6jMkUsl9xS}@AYN4EWg=(xBTcd zmfs?wJ(a*nbS%e#u4pX3&HdsW&Zb}9bnTNi?7cF-XEUe0BRS_0&HSos9A}yM{@>c$ zda8YmGX7f+>aIVU<3IesS*^z{+xD8H-*o3=Z;kzsZ2mY>)*mImomu;sbicg33?}*; zjp5|@%W=8fPtFbcT&{A`>dRvMJE7@>F(LoKX8fv#^I*sO+uncuxXsK%yUR!OeK4yI zp4Ix~?T2oB&UZer!^#&|{g(1k@|)9JFCUY<52jsG@;A+L@<8TSmYq!Xe#`gL&N@B6 zm%2T^j(sovWV@c)i(Dr!`_HEITmAR@_gOz~bNDm5%Sp2y8I5wZ`l31e@AuT7&N!BN$@bv&=4~2?>jK++q*DtwV&Xn~_mW^yrHSg->B6{s=N}1@&+{!;w zjbkf6`Mt;wd7$ zg|~ldj}>uPwB2M~p5>?Hce2M?57JZI|Zx;dunll#AJ=Wl=Y#2cT}8DQMH+n%nH-^m_p zO*LKF)7GXZ-Ex_Gu=UwU{H9FL$o%f*{IWP!-51?A$8_HRn8*C5G%}MBb^iJ^O1fTX>Jtob0ggtX|GtI z^7-vIMLIMNyj>7!r&thQA1R+j@uo;mhyrwJq-D9&9rHfte=LHpj{hbczmK1d?GNN} zycpe-WiLXXwAotzq&>?d@H-+f8gZ6-^@=0A>(%CV_v{6;T9WkB*3-o8r{?f~mH+1yMOD&1-&)pDQ6;sH|7X3CP5z&CO7@#6 z|Ia4dQN6XB($0TM_o~bI@5=wb>+Q`k0j2!RT-05Dn%5z%I%-zyTL*pXN#fM%y<{i z^VavT@2`e98Z#^7EXRqO<7xh%^DyV{)|$z>O_sN{-^=e77>$2RIojMPN6mUDfBEb; zU3LHP_D9~4-?Pbbl%LJ~c6NMBUyib{#MNW%J1r*^pH|oLiRVs#z4w{-eR9hSFS_sQ zGXC72%dNU*e(4?$zB=`U-r*?TQM8AuqP=ka+EaUuA6~s?_3*}cMA^!?RC27?m*3Un zy7>Xb_4DeJ+LXtP0p9Ok+Pl3cy7ZliJhc>zUunirE7iqus1w?uc!Rc z>wld8MDy}U+r($dZ)es%<_!#-wz@x_n4PU$o17jm@;YOEtSqX3O0V@eW*^sGe*2=Q z{UY5P=_P;p^7HdIzubJ?wx9jyU*448vnk7aGr#H@*JD+2yceitYu4i@EuPi-+ehy7g7x3{_@)0^Rp9M?;9TxYeseq- zZ>KJQ0MF&vZ^H4n+`fCLP1z>Mc`#Lz-Rt$(RQ>+GcdM@_4p}yJdD#@@>01M@dHGTfXU#nP;3Hp~ z*VAT`B`xcjlHbm(eQc%NbgIc^1MA~83;Xpf%+)}J&`ZDXtGOntR>a!mA?B`Ei z-ba?l{q}Eq{0=>j`=e)F-KigQxEXiJuMa!FZzb-9`~3!{b z7+gHK`qb5VtT>x`xjp2B>En3wd(L~-+rMzkPpe;7%Ugan^Go-PWBmQ|ohTNz@3&pr zzp_7`CDONeZ62iWEOGUCu6Y3QY(D;3fBeF~IpPtOM-|VEh^OS2I7++eQa$*qT8K`F z=Pp+dwCFr#E>02D*JCHGnBM2&-7mQ0|86+(J!O1lJ~i`8_pL0~TYK)ySjAK?KXYE# zT~GGMz)y)(-a~U|#Qnx=FW>uf2QU1eyEeARN`8r_w2RZiI204le4O|un%+}$G_Av< zLax`3<@dktb}lES$>pUqCBL*w{?^+0+xqWIfBE|dI*jt02h*NxoRj^Xi?OpKMt2e)|OK_1$H$9A`5(QqITban|hi-4j24_DA-4?a%XjHq}1cqbKB7T_>&w z7RO`3JBL=Ps;{rJ0g?B8Mjc#_=g!WxT3d@};frRqc02oti%xjTdH<28?6N7_F(tps z9sex#N?9+};+Y$-XM0(HcQ_OF^KwWtBPr+OrVr=0`ucHp@6_dYF=99^xk)#aqIjiee9sl!Lzdcc~~dE#8KKM zo^l&$-p8KZW=G2L=KbpnW4vX!*F=6^KT_|$s@A*7-8{4N+05^Bt{v};r@JkPcj0Y3E*_=R{d|X3-}K`h`AP2)7w&QG zU1hk3wZ9zJYUY>jo#U*rGONDjNrE_4F;qM7+U~VXe>p#x$5tQcwpSU~LuuEy&u@+cU)yZP;#E?x5BZ}xOXl2WIRW&JTLR`qm8HYa{x_s_Cd##tZ7NT@fO=KyBb6&ZiYuMa!FXZ%@ax}L8$uXpXr{x$7h zN24&*87rz#&)b!!jsH}LV>5W{a^GTWmVjnAAvSw8NWrhMcN-oE7Kk9^}BU;j{9 zVW!n1Vvd&l?5Eyj`H0kfE_$_+>@0M75MWLJaDSdk->>J$c#l)Ou&OhV`ucoi_4Mn{ zT@KlE$%0pY<+0^_N|~2`(8;gImfs&pd}EJPiT#+_@tgF@_3CKEQy*WBs~+z@FYR95 zCfn~iZU3E4``|s#zb$^+ZmM`^w3_*)d&awLRqtSb-~83>*G~5iZalVkZ5%ZjT)Z}K zM2MG|$63l_dpA_~NY>-IBI3#6&yAGr&gGC}@8QaEJpJBt&VAc6Zagx-XH(*7=2u-i z`+<#k;@LWb{XLy45Ei_winFJ!*!6s-g{O7L(_DY$IG#PQ>!uIia&@`Pcr2b~em$Oe zKWb0ZM_DZm#iQpsFVpSss~*x+^;y>6S?+gQGj$wSM4X@fw^!ZtnoHg_Gwa=KO1)U} ztK9L=iR;lLV@qP|*E#3r-b2}b*b=`h%kLF29odxm+pOQS+jR$@xM0!G-n-{HPs{(R z`MYnZmi#Jr{Ijz?bmZ#6q2czW=dooJSCy=dlhD0uIuGP6S4_lN^0=a6!*DqFZCpOk zegIKiB{LXrbsjtKF&cv|@wNu0j`yU~XSF{3rhy+HGw>fjt@^CCadLfB^2Z~szIE!F z9QW##`3UrO)zf~<^kAo+={z2Nzn-!Cc4|-Z9E}2>@s;hm9BP>_+0Ilg6WK-cn--`q zw;Q7Tp)J41EIy$# zppj^o`0k1LrYaw!(S6VR?)~F0eQeWt*L8lM+Z|cIl>AQiSZiYWi2bAGtJiK^bb9;D z#ggc=S%2h@PmWZ|LjM0in|gV_Y;fx7Sry&)`pBufJpS(fXZ)|u2u_W5PEW~ij(6hp zR1>nb>FA3AJe29Em)~25r!F^#56x;V?O%TN6))TOr?aX9(XD)TV@^lOZ%)SpD!;K7 z8jS+coIej`dYa?k+W)zooWpOfH?mx6CJKy3R#|>$pE-3o8CgH8^@js*y!*-@e&gL2 zcR;hA$#PQin`3y$^-JeL-;GO%c6Yk`H@vez4`l> z9-a5hWs}JG1tY^-QM>)vqU<^m>`8o?ra`bA6b3Uz;JnqObM+r19KH z+0Hs8>+y2kY-H<3_rCm|O^2+XbCR@Iq z@!ZG1XWK=K&a0NIs%&i=C9LFELmmI@#M3#Vn8(U9tj+<6=&in9xS=urT()yO_4@=i zFL=TQ$NZnWx0G$e^vM0Uk{|zeHJ$MZ;*m`-fKz^vzup zwc%L78I7Nna$DHq(@;LyL?O#N;CIm(zmGZMC%1^x>oUA;r zfBIwYUi`MRa(A=cl=XTuzjTi>5r;hohkB~VK+Id!zw)#=7r%Z@=f0Sc=&_7{pVv-Z zesh=$zIXd0hn_xseO3Qf+aEI`>XM)R)SL1B_uBhbq7q)+7cWNWYfOKPzdrqwtq0ya zcbCV#=(wH#d)j1Em9uSHCBMoY{~RBGIbU2m7!tkJ>)nNCPe1mUxr{&K z&Er-je|*fS7oxL86|bv4cJ)x4Jzcq~r+n$}J92gZnlQfLXybw4t?Wk{PNjm`JhPd`1Y4p{bywMSleM00vpck*L!UCo1=o}Rdkw{K`w z?`gROb;|0&)5q4wvty`bI!7bU631lIc}1;zna=uhx8e=cPv=RepZBkOJogzp=Cfq7 z=^PGh^>*^B-0{x`H=X6JG2QcLL&R0ao70uc-RwwZx;NFjm+7j{zr)X+e!5=Xd-VmE zz2|G!H>c~YPJWE8t9dBXHQ8L89YZbCaZ6bk^tJ?r-c~{+st{=LF38 z;i4~p?GL|wKz`4rI_|Okg#4;&wVzzC&l}5KKD}Y_y8gA*9`sO8UNX?Pc>QqK{_=|R zy5q_!KewCijgzd0SvaufC6 zl6-(gyt}HshtVt_rCwZUMwJyJBQ*Ed2Fd@I{I&pm&<>T1Zv5}lxs#$@Y8>x){&bM`sf8_3i+A-XG|BTi< z?(TWnWf9*gcbzbDW#4XZ9(YNvoyP06lHbm(eKgDG`1-nB6;$>7tA5W$Erj3MujO8q z`UGrkx!YQP{kOjV*Ab{6hu!e@?&Wr}dZTsyn@`*S=5PJCB2em$W`613TyEol$?@y* zm{HG?{Q7RN}j=5#MC{B|rb(Wp7(@*(Luwf16G5YUWp6C)TsaukGt! znfm~}C$EX?^H-i0mqnHv&vR35e${pC1&kvxpc3C9@0@=B@LS(rvExD8e&oMh(K!K8 z#TU;@?c|rZO1tTo`%ur18?0kB(C%e+eCGJ`_{54Be;NLg$j@Qd%iEpNJ)5$gYHr75 zw-;Xf`Jdcy^6j_e_iTz^Gr#IO(Qod_1A}pZvg@9y&PkK@cJE01uz1bEt(m*DN2^alU1%`}&U^ULQTr zj#QSX%`yHm{M#asEPErJ?zvwu=iSrC_p>Y4JodgFetz;cjre}v$&bNxHO=^{x4ljt z-@+Jw8GgJ%v3E zH>Eyk=9lix_(L^zdr$5!J2v(DX!rL{J^l^vnbkV##$^}W`pk>wcdEd;<0IvU!^Fl2Pt^?X`Pdbja6^DiN3R z+RQKAw_aY3=^Z?^xdqU@K0V}pQD^4pE{0m)UVa`oX^?s?~bE+-`7aQx$4Uw-K}rwEpP7J z_BFPCEcs>prQM9<*wt&7E?+)zxh?(YvRlrjl)TcOQNC#Z+66{p3}w6c@QbG|7o$;b z?%D6#&t9^_tS^-Xx770`zZr0|Tr4|%U|=|&vED8m(Q~t2um3*FLDuh?vdRBTYG?TP zwF}hGbM3ylyL{w+{?QS^%~5U+UU5|R+B)t-J3spN1v@^y1XeBMkDicUx=$z{?fvO? zH9A(s_bpo$JOASwD*4;Pqab9teZiBz7jJ{Fnk*YxujF=imYLi}cx0q<-BQMq`}=uL zIm>NstLzvlFW%ZIQr=U$OQhT>*)>wWD`)pedqjF-q_|_Jv{$68q;o>^nGO3! zIxy0qk>a)W?RVtl#^N!NmPT3;=_Qd)iIhiJUKZ)qk@9%^Uq^axqz^{=M5L=C-4H1c zmfRC*o0za!k)9gqIgw6?v@TM<7iV*%FGad5(qm)d4~X>QNasbmJkk#${b_)#jC5h7 zoM*9F_Ue%sZdvX(#e9vQkL|A&i*x_D)mpgSj;7{-u=ee}$6ipak1D?zp;+>> zpL)}rud%;$>Oh=`TClP@zBCd&m+|lZ!S3;wdA9qWVfOXw{w#<4-*(}? zOaHUyf9-m607jE#E4Ob;emk@F(VYJA(p%1R#0~HLE31v~_?`0|HN4K(GOs6gnV6I1 zSM&QLFcOnm>W>v4nff_9sdCCKhh6#ay_a7V)nU8I_Ka9tl>AQiSgUrgfA7$$Bi82u z`^87+Lv^aV6h@-YGX9%m{8?7#j{SP#mjj01{fGB$x%b(n{>(Zqn*%%f)qmrkS%1`@ zn|sv2+%tPOj_+5@j$U*8d3^rf7=IalPFD_lq|-f*$8Go@)5rJjPd)LjGroCuU)d%v z?e}!@V{lzfGrsm!j`0ZH>Zu*oda}f~DaK!hp99JGW=AUBFROLW+BMTir+dbK^Oo-V zdGA=*^F-5~=k3(m<&0T3A9Bg8)?5Dl(?>k!Klgii)n~PDk@a)QkKVhQvG}Xw_i+-d zb0u)6uhAGs##gSt%IuuS8C!Ik&`g#$p(h!?GJ)J~%K4M!x%|zIl;t76XL%{liI13=11c`)gPVw zuDieg&FlAHcG%-HhI*XmNB3+>oX!3J?6zjb9*6WDy6M3Do=r|mem3*l+3~UH^bDwX z?eLMS*Tnr?@er2@k9%qNIuf5{zU}m}?(M#eGncW^xVUuRvyQ(pzP4`r*)!jG;|tz3 zHs4Ad&HU^)o9;L=n5F&e*7UB7R{JK4k?5z4f1giG?Qnj?H~$S6ANtwzFZjX7bB0Ef zbDQ&HxFtAzoR{Gj<`$txH-y4 zI?aug?JS$Q-Cw`2_qGEcd%&NqdfOW#yWLc-Gg{63(tYldMLpwp`Ne~;;wd22tw24U z8`+N7n9su+%WmIz*L}}j4y(RApY#vi<@m!9WUe2tx$h5Jm*2kh^6dZYZ@;DYw(rh3 zadG|=O~$!Le3txnX6+;Ezxs96aU?NbC7fG9`JAwxeai8hdK`B);+U*n*?YynPj>pu z^;c9*RUCO=Ov$f>(Ei$tqkXH=_|8;b&)x2?ewCvNxpm2cf;m(BFaM$puYUf`SkSL>4X1r__@3EUU^U1kI3?o%}^)5`fvQRx%{-Z)1#*8Z0!zBw!OYE z;wa-O>*NhF$Wo54i0)ZF=SIqQ>8HNlKKms*@7w>=xBl=c(LI}7&bEoqlHbm(ePo>Z z9KMAEL&NPS62|lYdWZVE>bW~V)4lxUahj~>HoP?61O41D?z8anS*?%VvF&#MaPVK8 z^RAUE+M5cwuaV17$*+yF{dFtjZC5ir?a#Q#KKg7fN6q2$99>J(2UfS!SBk`CtA2^J4-_JvQ1XCll7k(eI0I-7@Ri+n?~~ z#igoucbJf0x=&e7qGN7A%v%*NW9@HWw%Ap_&AFnx+)ftH_OE&Ez|l{;|0`vDC7xz} z={{vV?b5q&^>BnzUw*bk99d50M#}bN_506{?>Xju|8n+Ul{zH*%ln8+e*D|jY$cAK z>W<2+^{d|N+i?r8?DlBZ_xXz%kA3o^mp}O{Gaj{fwI<9s=0qGNzZ&ZJ=T_qAuJ0#A z70Y!DqLiCE8*xpxeR<30PF!{NY?GhXt+NA)?GFIcEm*s4}bdFf1Lf~oVVFj@x^nBI{8)Z_-DG+HZptK+Yz0O zi1DL-t=8=LNjl|m$@3$Q`gn32_2qB&7rN)~Waa&Jcg$b;AyK?XS&v#&=!HVS&k_>Mn09{%5z-WN{7r=ubcTh-;p|p&3`n{}sg5b;4>i23VGd zdn3Mdm>VhEDU;=@e%$MyKDpo(H$3{hk7f64vYq>VCBL0n`)ImV^~AFN-obc6L#N!e zU%V0*tXDf>vD4gh{7|{^ygpygzq;Em%h}N}uKIcFzggb*=NrEH$eAUCD$W_LW`613 zjIY`^J|>=;votPBdda-S#~rs|-tt9@k9*02CGzHH`3%JEKC&wcW<-UPU*{M?GGpD%vVr`F!_;~ziu;>d0{ z#jTlNx*s#JvNs;4);{pkGru=((}=x~ymP$M!$`Et_&5Dyw@Y)qbWOzf<7@lQ|J1n$ zo%OjnRSlch9OQmT$?ptytaVKP%lg;MKjMVJ-gWEZe04lTBW@C(-@m3ewkfk2jS0x{ zm;LxE_c!xdZ6Qw_SJ|HI%=(Ev{2t{zT<7nnv!AZ}@6jwWslP=6_3gkp*LByYqpzRQ zKCW}mGo#MD>DJF>*fY;N>KzN-z4?GL301kCF(JQn@2bxi53Y+{u5ws?u)lXGUiUZL zJ2o&gZloN~WZN@qp10GIKiT!>v&!<7?cAOz`SEX8(-lv9zpEZj zRP^yalQ@0eiK_D;^%z1ut`+|@z0>wL{@srbzN_yq%E+tuX0)35rTc@6t7vt{bx*{V zMu$h*n%5JT4etF9UwzSSWxUni+IFpGe(7G1E4G>QH4*V1ll8;%z6 z5Ua|*`p$IxctfPJo?dnR^xFwbzkl;NS1r5x2~|8*{CQnj$uIGgb~&`(4knMW=lPj9 z2su(4@0~H;Z01HvkJ+E!rn+9?p4k6++ok`U-F|-f?N=Ok!)srBVZud|{XHQ*OMW}E z_Ax%*IHkFEI35)o*SF>SZ#w;qM0;$yZ|EL>Uv$gyG)s4?a001z^-+C1L3Lygq3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA gz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*@R1S;4Vpa1{> literal 0 HcmV?d00001 diff --git a/Covance_UCO3001/browser_profile/Default/Code Cache/js/14f1dc90e99ab10a_0 b/Covance_UCO3001/browser_profile/Default/Code Cache/js/14f1dc90e99ab10a_0 new file mode 100644 index 0000000000000000000000000000000000000000..1061957e80dece5020501e195447e7961b045839 GIT binary patch literal 29784 zcmWjL1$a}}8^`fqo3=?CX<8^0Myb0c#cR}X8w}Us?lOGXhP%7F%W!vh8I0lXF2nxc zKhN`dlH7aFd*1V&o08nz#8JP?(x2LY`RXny14VlOi04KniWV>BC|$ZpQmG=vokfb4 zcH|Vx$}EvxsD#r|s8rFM(m9z$orQ}!a*CEJR3xWJ@vJ0Aq0-qorHYqM$}Up6a8e-y zF;3^UO#gqZ|Nkp=G}7h&w*#>lO-f6baKDUHysR`1DkoWS1S#dE`iQC^6|5*Zu@5(} zw34)_vUC8ws?eu~^aVp|O8=rjZK)$3bd{32NuRK7jFfM_)E(>a4<4b{ZmIWGDKNuD z8?Xm=&?wVI!>}*QMGw#++eLlQJI6&HrCsEYKIL3guY!yEV*1Z6`qo;Kof+uanWI1#Oby!N@(Yzbfk85QLkPu`V(dPxafIb7xnMwqEQ(1JF)(7(WGJI z2cO|Ca-ZO$ToYaN604>Y>xPSZ-f_{xXD)h=_Rn3k26bMzXv-@X9Yn@!7ghS=qAzZ) zYU=K)bH1+Hl*?87@FcgZ4*I#OfWNCYU{^j@)y?m!LqEAHHo#Rqa52zTErVROC(Bjm zQ7YS2M@qTsaamWHD!HmrWmmOBQgv6A#9mlyxT-bgqgzd4pj$mxO={|@uFYKazLTq> zJG*KGrlM>YSN)DpUAf=QRr$NSDiU9NxTTKUX!xUwG4>aesGJ zkpZsiJkV9!uzirLyav08j+}u39z6RfXod>JLnSeZH$=7P-oQ zsjF@-bJghO~!>q|kSG_n(Ue{dZ`H!pS;_^Fk z{zwf!yJ`SD|6?4JK@(s%8x#OPyFnqCgpVlaV^BMc#STA%E+Zt5K{t?|*PzLm<8RQ5 zdT?vEYlMNb>Vo;+rgHGdhNrP5ruszeDQJ8_gS>%&# z&}{^kVjluZ8?*~|%P`Nf24$i$>XkF-J|>knXnh3(e>V&oiiAoAMgMG2CDg^ess@#< zMjIUc#h}hL4DzXI&^#Q)Wz?)?(Dd2{Ex|o3tYgrpx(01;V$c(O#KfkI*^K$LG^j}{ zgT}Nr=q-%x4Ei0dI~jDOvq1&AQ+HhJVbJs63>wkXpq70M>NwP(R>KW?gpd&i6&`0$ zhyR;I9>_bH{&+Hl`%?{SKhvPcvkb~V+n{DRJ%|4D4XVD{pko^h8n%&oZX&162Cdp^ zP~3KM+F{UD4Bu@~l|77ggc_bD?ls20Zcx@k#zSA^d&HVy%wyL3i9t!v4E#-Du4wh# zpyDqK>i3f446D%my+PwX7_|JOL55ET%{93x$IDHNvBd1A`!+ZIW_Qy%Wv9AnELx_yX&2Jd-E<_wO@Ebjlc}7W zx?poPH?3*nrUUS5>ZWHH)67ltk*B$vreR!5H!VbBD>s#I^} z$hotd>UVKd!#?EH*G(z?-Bblv2D@q55I1cf>ZYqWJB+v^+!Q>@O&e#?cAlHs%y-ko z1#T*~&`n*j8_QO?X~zaPeZ`55ZaQOjS7D30JZ$dD%ImJZ`P{WN*j<_7?y3~$uA7PO zy5w}1TVZ!CNI|x{vMammRSkFTtLLsE&D?dXySvWxa#zCd?s5!Z+aUVRa#!?1cdcIU zuHk#!Rr|QRE}U~$n+xu8x#F(n_ubX#rMrrKbJr+&XoS&2Yjb&MM;`clsQphK>RZr5 zBZEEU6Xv0QQ66d=?V+ByggZDLT&Zv9n zQl9&8uV~a}9Ka*AsASZN%0_)a*3U-m#cNcoYE(}wM|L&x$4Y#}mS2o2Tb)}ht7+8Y zT1K6!ZPZOPsbf@NeWTjp9+DdvRR)vs43!%)Htseus?e`Sm1t~KjVAQN4dgVX9{37- zGozf%jY`L)mfUY^lv_Kap5haFcQEpz%&1}T?PS!TF4P*aU5$EyJKe~!hf(3b8I`XO zV_<(jYV*5M@dJ#iI?$+w*f5CxgSn5@$TfsI{ArY7s8M-_8P#?KwZJEw7)eb=u@2*m z>M)+;Wg>N-%wsIYE99DLR1i+#(hQ@j&m^Z=MxI+7BeRY2o@dnTMMgy~G0M8ks0u5M zTDXZd*i7BF7&R8la0jEe8s)mpD1V&AoIOT0-e*(~{JP($eFv%WVWawBCw@D^+8t$0 zvG+K~EN)}c38RLd;y5_Xm}iX2ILDkXu(lVC+I5*4|IL0RUNvglKh*0w$IA_lJNVyZ zozMV1u>osu8FdgHZ&QC%xJUh9zE68h#$J3t^#|k(J!WjAp(V!RIevO#R21^Q=6G~9 z$=zU5AR;_WnvL5iZ#3yGyuC~+i}q%dJZ&b;vzzo7-o7SHgja5pa^*GYUw@NY<}>M2 z2=PKq`hia2CKZe{X)}IFG^r=%7Bk6Q+$4WA#<3D66;3v(EqcO`YSJrI%rr@*OtPXG zE}&^?V&VucVp|!LhLY#BvPr#vHmO@Rld4rW>7QCA4Xtg`UYx>5 z)U9vQ8vMY_1}5chXi_j{qd;Smo;NY6Z&Q;Jo0-%Q*YLWlNiN;U0cC$9W>1ssy-cd! z+obEr-7RCy@I@lXl@a9%92J_D?pc18!o-6qCMAGil&- zlg3~r;%1oiHy)wROdii-Jk*|J(k$ekM-1$qZ<6Z*=CIJDRq$MFQYAdcA4^OswA7>w zG{8gbTV~Q}JVm?ZjJLuhzm+DHSYuLYG{qat*vN6ViMU(Hf163gwo`i;c9@iNocf(G zsUNPO$4SPZzzOPo2T+a8Iqk5mb!ulp&V(h{s>3Rm4+^ih622PNQxy zPk9t4XAH;b6i?+&^;9s@aU7L0Jko_^OPTEm-p0_%ATrR z#Zz5=_S8PKuj;9Oc!{DlJ=LKW^{VZu33Z57msr@0`t>|zs_!X(oM=qnCZ3wo!cz;e z7gbw&YD^pQZA-rG$QM1@d+IWZcl1H;Q?_SCMio|-(3nqv=sneM4(Gda2dwZUdoSvGG3})&Px+;1Q+2`!ArxSie8F> zsgjreK>y0j0|lyh={#oq?4@&9Si?)}@vf$qn%DBu5b&t%hqv5+$DH1K={9nG@X{4b|45FQ^T|t}J~QwC zy!7o0wfX9$BKgd!kl(DJpUhfPz${Zivl0W%x`f|C%_VW|jWa7hif5VC z8CQ{#ZB|(n%`q#gteMxHX0@(lR$yhbD&jXR#A(>;m=%ES_2^&UtbKUX%&Z@1+}y0* z2x(HuOW;c4pN;N_(@$qfiI4mUc4hJF0Xx>q}R&{_bX0YIn1`VgOuvnANeS<%`yx!tJh$&hQfV_StU^kiGP@thS&IkVSh62aI^kF>NJ*qUI8_CSxI1Ej8;dN-if4 zR9L|n7>E2TSvNFT#oDZ9zL>MdtXp`2-0O&imDq+C>#5fUv;M$D9NcJ@+a~6U%{YkY z&D0Ft(Q^yO$yT!-AY&VAjA1ywo%!rwKFHb0nqV@T?J{ct)?v_YYK1m?=)2dfqE49G^IbpwFx!+Tb*T{^L1=z3~5HR)MdKgE?6EjprSn<3EIbr(Q7p zpys%NwX*1dt3?kD7Nxpb)D4r|E&A1HQF|=(u_$+5i@FALAGh%W*F(4swJ1EyB3rmc z^)V4?5j>8xXgZeQdo=N4ESisb@fHMaNORutk%x0RI)W=y5TNKA>g^ipUXqn1>Ug&$8 zb|`p;dYrZB9TuLm$Z_7HgV=U~d@fqF;}UCf*`hUAblsx$|5{Y>hD9s!_@+fSZn2hk zEoyX+`8~C08Wtnv8F@dqs2Psp1KeI%)C#+B0>xfhG!SEv=aoe*&<&4J;--fTQv-KQQgC; z#rTK>qm|c8RuwW?H3ZL)?rGIDM0#0O7_Bi6HnUZAumgoHR!xM(YSl`cRRz7Rx{O11 zt73etngzSBRR=LJfc^!o@(8r56t>|5b_ZEiIoPVk=n!Jn15^&R>MZUfD$J_77=j7m zR&B*yl#H+{D3aVU4_%_H%8a(^F+SjS40*;A6UGFqN+(+N1yvl3;k0T|l2z>sTlF8x z7vX*}tC|$2eF>}fCR-JoV%11YPPNJ>&8j!)R+&p$bqQ`6R@Fw)Ok$yPmR0NV83{R7 zy~mDHR{d7ms;9_XhB?7dmT~b7UgfMxLU#w?d) z{X(4TR%O(%suD)yC_2@ozO}4cf!4LHnp?-J)Vfx!K~O!b%GS5)B!U`P^(WThUPG&V z8(XypJ({o|>zcAY&8%wLocvlcH|$34){KSM?W~GuZ`C=ZcCe}(7U60~=HH36>&%?H zF#oQs-3TkMRje9|&+r&Yo;U!FVjVFVSCDTs`*0MIW5^M=kvf*Vkbj(2Uy(E3su@^{ zd=sc2j!vO2Q?058w`o>wgzI#xQf6?B!#Ri8s5;lGDY%7V^N58}m^+_2EwJj>g;q6O zL_Ui-CYD&0YZ+rMx2oL=tNzBml~#qUwki=pYdFSXU(4~2=LlP8)gT;&_j-;Y{JO!a z5*w-WCaX^TMNV7D8OCkY9i6vR*B#`rlUna0_uW>t*vtAK;CXSB{IT%3RW(m>>|o7l z*5Z;?!6*-x%jAQdICF(|fAieA&Y1s_H%i~Ia^B3UaLm9t+`y_^)E6&M_%_E3&Z5#o zY63lCoX3mxq1bcAdOo}r`oH7v%X^NO5A;XNk5>Ki$*Mk|84H*G zV?JM~%Xgjwvgv`VO%>g28gI1en#rbSo;E#13$smr7MuR?wP|#2o5uRt)IX0+ckH}({^DYFPU79~b8oARO++7`EICAQ)o@+K1p4O48Ig?ni> z9Za|Bc}ttVplKVM+PAf-Q9GL~?QN=#2{_onrUP9W8?C$BbOg12v&r0(dG=!b-ps3y zO#}Pc6!<%H8bCjM#+ZRN#SEr~f7sOXPn&)j##l%mX;YC=Y#VJ;zA-kQKQ=9e_gI?} zaB-YXHOAZY7z-xY^ll=#PqwMc6q^=LwW;znn{K1~bepcvB;Q#!Ma;G-c#chL=aT1q zo4ReV$z?P1IAGJxqtyABP4Rerfn5KwY48o3P8al6%}8%W*7sIn_cF8 z+Mp>4_V89LE@9|z-kOA_J-xLQoqKt!KZ1IDD;`5&=;JLroPE930$tIipSRXw7drO$ zR$tWooj5QIq&+&I;Sg_){nJ|?P-m#OUJdhB+;DG|!1R&cT06#DE61{Zg11gj^wz>D z-fB73TZgB4YxxXsZAR)$Z#|pstpanr6^#}+1fO|~wa8l)VO;F3#AV)Ug00xQ+*_w$ zT*=t0y>)Pnw>oX`)=jM6;;l7X*}ubE_jY@$%wBIDIpD3o4|;3$A#XiA;jLfKdF%dV zYVnV^YTx!&u}9vj@xog#-!a!u-Wv7ITQgkjT8e81JFk)LvfAv*kCEPXm9g8k0UzP! zV^;|*Mgw2FCg9OecD={2AiEZ#WUyVckPu?m2zE4I8{T`Sm?TFI`eKiif4i(TET+x4l2U2ALF6`+hx3CR}b{M%eIHq`H@|_9@F=UozKDT zy84tlz2LZcY1iS`cFlOtdZPCy+T$5IezvPG%>UVW|7O=cl>TPdX-xTH*Jt$g^U*dO zhAEGaj^y>xQGXv@!m0c|YFyAqt%H2jG1x~DAwGJ7`=LJC8RnzE!+o?U!bfYPe6%#y zM|7L{bIOdtJ`<)ff%9}R=8l#kZH zT-ry!;s8pQ_0i07J_@cxF37IpqfPjVRn>eH{)>;MV;^4D^3m|RK1%x4M^*d#Xv9b# zRh#0YB@gKv9PRk6ap%BkY3s@PD~SN~P_Rh=5#qGK&z zb*tm626cV)Q$1hV8~f^J6JPCX>Z?c1eYL!WucBJfwzaPcwDnaq&Y?p)U)@8&_P!d8 z8ED(hmt)#jj|ceb>M-Jr_f?C@zIw6RSF_jn>hM}$z1hqd2Yq!3*MHC!elEE*8n@kZ z=_ij|>S@fSFR+_($<;HL-cHMGFJSws7ExzueN+hEw9OAUAC(kqnPl}js8cy}&MK(Rf!R0^~A=2C?N?8DN7xzzM< zE}h5lW4V-cJeQh$$)$P7pEtKkqbCaa=jJs*Zq>?{TQeNFRj_t$O>LfAm+)hMZasOK zThl(|)?avqXcs^IW%kn+o1Z4y{qz#8LjAM^Z%X>?`~bX1Cj8IecR$K}yMc#hAbWpnfB=;Azzxs^wkQ1fjbt@x5hkFYCm zUan`zt6BN-Dqr2aYTY2O3bx6s`yKLXX!pEo|9f7oK9X04(|P6oJ+G#^`m0xnKkudd zRV~zC3$UkzzYb^m>!;HGYLAjj{5ePF&vVybb@S%a$*6qVl9*4Ai{{fGW%6lyoqP)H zolgZ`=aWzO0&-hfK*?(gXxY&M`hKhcpHT*=8rGHwP*QS$%3u%H=LD!wsQ_hQG;YD8 zbbwBm3DAae0SYT0pf%`SAwV~fR4G7}Q6H761*k4kY6PepUgK5M0A;lfP_GUFD&93f z^KcD*-2xPeIjGt*K!Y(JU(uphfL0=?cYxNRdY=FtM?~KM4MUyZX@dbcj)Dm*Wlr9(uR#5T+r0x7(WJ@~0+r{lKy|>Mh}aycQYf?~P!+b)4n4O8YB}zr&~|dd@g0Gxv@=jma2#WI z2ddwmK%K*;edM!0P{R%d>JbJX4%7vN90}BZ96uVUEATnST+jmVQR+DLJHa?716A^L zppIS&)HRH{5~%4Yb(OhX3sfJh$BbL#eJ@b=9|S7rVW3(e_6d1EWi2rhdr<0GAfHPI zYWQo~yrFJy1N9QyJ_IWKW1#YX4%AGKAg=!k(jf$xf>gjWNYSWj4$}I9L8==ar0dB+ zGG_#7C;rX}(tSjf3)1rPLE4P?%0XOrO?$kn6(pD1LF$IIxw|Q3Ly#(L4AMWSu{lWTTZ7bd zXOP++B#+ZU8gq{J@VFYJ7WabG6}J09%6Sx|PI!i5kAt)ji(Ulj6TZI+lHpB|9;5xo zAnn02Jiftd4$*o8A^L!&nIUq^3Xv~H;2!E_hv+QqIU!0$a~#Jv z)GQUEad=)jL>J10D5Z9Yy5oGE5M8YsqE>%~XaRl<4bh-sahg!APgs(+IC<2;g1h448NxttDB3-rM<{Dm(leo)rmLiIN~Wrpe!Jj;Y~ zZZlN#um>v3K2)j_st&(|sz26L57n-&q58Q;sFwd0s?F%sGgN<}ZLd(BMep9BT8s_2 zkMKUBDumfc=o_kB{X#Vr*HO7Yad8Ff2ZXBXpP_0pAyhl3hw`~)sJ7xWGG>PA5KOZ| z6@zBjH#<~5b3-{l7b@5Fp=z`tR5dn+YWki~`R@%?i=(0X1Lu%^EL6v_>v*W1;uBh( zAU+Ob;>l2bz~ob*@;)7^xwwViXXuagv*d{>cm~tCP!+krek?-&i?qjQth*elJMg{2 zxaf(0vEo{&?jiGfsN!yr&+|||!w6O5m*o8_RNcRY>KGa*OnqT<2~%CP#4%KI4O2ao zFobEPTbMq=-91c$Fvf$&kY|`4;2nPV3e$LVnC76XB}_x?JjOkrFkSKu(|uIW6{aRQ zm^VzF{KGT=ukiyx`NMP)*HP&w#>OK2Tp&!p;v8;bML?LgpkZK`+F}9P1%+u67GhmU zn0CQEG)yz_2#I0D#v@D$CocRV!W4>$c#OXy!&EGa@lh!{Oy(HcVm_KBgsDYhm})t~ z)Xy2F;zfv6EKE(4!*n?{jBE76G%cMvU|vabz}1W}{tkrcX=a$bve<^lIG!D*ze|NF zU+FNpRR~ifoJ5I=VOoO!P_q*AMAxQa+TSBg-G8Ijy@=T-OjQR_w?F7RJWNwYhpGA4 zFqNIcIMZpfGE9pxbafb?vxO=BAI5vZ974nOwL!RQHw>4fakzfPIuvXYuG!cI@225u zhmR=OEL=5l2SuBQ>uKk3g?9p;p&6GhY@Q;xU!~&YXAyO4_7vhA!25@ z0%nD4=lpOD{wrL&kbg_K@@^&0!Eo(G*F)?>=dWA}ZBNRO(LVJft=s(mN8KHzx z5o$0wLNif$N`xBX9x|sz=sC*Ij^OV{godq*&<|KvMX1n*2$kGOTdaqDQ-rEv2~OiP zJpPJMItF7rs%(zX7JU8x?Uo4rv^7GTPDE(&=?HB=%$W$S!Ns!?{QnxESxCRgxG-Ic zkpJZfHN6s{&Zu-XLQU|~wFo`Ig@1^DJwp8v@Na~AAoxavR^bY|-i%PuTM;@5kK4q# z6QKwAf@yanxE?1$f1}8MY{M8u>L|ipBjss`lrwLn+Ty5xq~7O`RPTb3+KRS;k?I4N zphz_gj@0y!NO`42DhKn^*;X==>%${;8|gWbGM9?f({hoDE+47uc!n+&B6X%>q!v|* zRH3Sonu;oQBRLlnsR#8UHKBf_cD0~y%Scs#N2^E~T1WD_JyHwXM=HBRr0g9dH5>hV zMJn$1NR2?V0g=i(C{mp;b8w{Ijf&LGwUH{fF;d%6V^gHQACKfS>PWrB4=g+xsb9`U zY8&cZWIm{PDN^;J%aQ7V0@uhNk=GgHex&x{RGuiVEsRo$+fiDMuSmKRrOvp5Cy2fq zrK0!)2XGGM??q_~+TV}TOMJtShf&(|C`$96M(HNvpGB!FR-)bWD9yqZ!W z_1dBRI1M*bv{KL!i*X4ap3zD}AFRZ6*uA2aflgS1#^z{s#z$1QMk~h_t;c@R z3dtX>_d(H0435^QkZ4T}jaIX0Zi_}MSFvbS!iwU|u>^5TMk`N7w7O5ruZA(RK zIqH{=Ry({wm9pegj(JyPj$5MjJCe3WD+@;vzMUAmqBZ17w4U6GR=J1KoPUj0@}p># zhxcQ)zl>JcE5>{sts-xt_3&e~fUG&``Mhj-d=WC1RSpAAzuCWS5 zpdnWA_E>enANU(#KCw!|dJOiB)iuQCid83U#T8V@9jkFD?H8+sIEuGWo>&z}Ka9k8 zRLC2vAE@9Tt2!8wFINAee0Z#CVLz@##Oev^M8>Km&PT<{H#Syp&?b&CunwotI6hXZ zu>)BNv1*zatLrG_h~=DftUkf&j8!tqU@UIo1vVuyUZGf(EF7!d@GKImZdip2s8uvp zvoNH1to)K=)ixzof1!D5tWwj6g$n7hx(Qp!Saro`G|!-3n3Wl;Z&|TQ&nCB0u{d`J%*_~oF5QRI_7snCV zHCDO1G53M7nvMSk#p?DD#-0+Zl&Q=W-?4pKtoF=dJJ!vO)n1gIM?L4qs@H;8o!r6x z-R#G@J?uy6z3kr?t48}{)&6L#R-)mtSam@DygvE?#k57aymocxR5& zF-x5K`o?K9a^;TGS#sGucsPuT$K$m8M4a}XjFaPLoJQftZSuSmrzv;iRPA1zf*;1I9=1M;)7-~# zdi@`9zr=AaAx<^1@mrjReJ2lNys~h}6t8|>@%qCWFL(cVjfO2>ydD;eS8!mw`Uk}; zIXGT3!{c=oqaxxp3w0yo)vQ>&wxVEayz0X{Enb0G4A+wJ+Jfg5;uTpjUPCG|Ugda= zX&kSU_`ONI#=@^@yt*`t*Y@V|d=?z9)$r;cuRXXnEMB>X$E)**cm<4%*T9+a+5!LB z@w$Y6m&a@Qig?{c#;SNdL&e?k8iBMu@v4LiaO{iMb&Na_uVd(Yl6k=QRJ=N#j@M6T z==V>&{>0tu)Zqqs+@%J{xgW2R58}1#MZ7kDi`Oeu`Vr6PW%2THNl-h)yCtZjPl8tC zSKkD6Lhf7%8i9v6nH4P0(e$YL%dz)(QHA8f_A!wh5|^(p`y%)jbn5s2BYwC+H8v&qz>P6r7o$1e{0N zSqb_RC1xk69171N$N340U67zOREO`P1btsj-b)g63qzKY*NOx!UX`HoYZKJ#0BsH? zs0VrVU6D64d`_f<~g~u>`F;PX7}L3OvQ!&L$}QU*g_Okoi`EHlxw)1V!FS z(1OS0@q|3AiAu30sx00j!=A|Za})L0Cs7mgB!QlCWCL{r%MCaQ8j;`UF}$bpG!Fep*& z5j8kb`zDb8#6&Gbi%E$ZG%Zoprzffz^3F(9-C2q1y(m#*FlBY3dag~>A8@Qo)T;G~ zirJ8;wwn@lcz>eC9ZJ+}ls!y-$a5r7Pq6-EqQ+iIRLIRl9l6cp*F1igs97lUK2g(f z25UbiYPyR7m_cIX=-N;vchreueLQXERalr)E0 zr90FUGfFzN?Ef+y`U=l1hc@9g3YK!H3w}pTX@`C*?#hOsp?SeUmQxV z;m}&_M9Z2EW!8463L4`uHr8?IQ9Xx7H*jcdBgXjEp*+|J-^LD=!@OqX*Uq7dn1>4O zsY?gu(#gU9YYxrs=it3JW1{^SYB-iLP;(qPPIvIRt3%acoaxZ#IS!qe>(D?8EUd$c&lobco#wYcKYcP#(gp@vr- zI(~!t-gYSW2Z!3=H-vn2sL3aXE`E0CT#M=eM%C)lvCI65EDu}^`VSYZe^XygFa|g&Z&`=oO*=1 zRh)9K>f}4wY)7tYPSwJ(U!3}<24mM`4lvZBO>L*f)^X}|U8lA+bSk_hJ`3WSzBVaBX$R;5;`*$zIAbGW;Z9l!{St%9!{>~q9*8oe7%@wZ>N0w5@!H$@D0lb zIu$*benXskHq5C;!<}k}yd#+7NT(K#a_Y`#r=E;;>eM)=g2q!1tU!$kPOX~g)U8QQ z1x{f;)7U=4sjst~IzQW~<#U`GFqgT`WB&@L+OKqK$||Sct#(Rlooc(zsY~l=yMfpn zovQK|`!+lE=T4_?>~`{fUh2Nzsh0_TwPk5fIbJN5Zrr(WN3YWqW{?2nvkhB-KeYsh}gW30l@Pn_z4 z(@1;j)MdQKif2wao|D@Pr|x64OOi5Nlk_w8z}+p0?*t_2PoE@BMOEJXzX**_(ggG?l%z2zTR2IzaSYx?lhhxh z(~~p@wM!eM!gYo(Y!YP3(%A9#WC9g_3}vpW*2bCS~VH%4|z(mZ5$Wez=( z^tE@Adi6=twBM7|c>wjpT3p6Y1Cta#m|CM7;)hVDsY!YX*J(*=icUC-`CaW>#;2QEclGPSFVRI&{KGwn|DOpu82$xZ~Tr$7;k*x6Y$tr>! z@UNJx54chzS?y{i>tiFfHA_}@%Vd>qova}!)+SkH@D#J#ChH%JX~+1;YM-o6DB2-e zkMS9Qbxf8|H^zo*_hk8E8s7Iv)`s7bb!cR=45N~@8HZ7Ebh4I@Nmh%o$-28ZSpiFu z)q82Ox-LuB+^xxckBa!)v4i;^Pga2w$vT6ZXnrzT`%fjS&zWTPd%~R1;b}6T?Iz3Z z8FhM|%z5o(eYK>hs5M0sZ7JI2ouab-DH?>E`BL~jj1*0Ersy0J3Z>{RzLiK()#Mb_ zDw(43c#)B!4VfwWy>yB$;8B$n<@}t&|K}<4td^n{zoaO&dWuvpMah_2KSd21r0990 z6h;1;q9Kh_l-VRjwOgfV0$#RG(W*8n8r+V2kiSEUUSVFZ6kS8HJ}L6+nSnCb#H#E*6mAGul=c-cOX@+w^NmYw=mpE z)o?txo2m)-QkDKZReh28B2^`E2qCXhbqjfZq^dgjWd`NNZ2aevrX{Xvit$KOEBs_k zQ!LiQ=9$JM3DyILErpnccQ-e5YP?I=#i=S(gSDiGO z+NJ3%yxOO!Wrs8s=$IyFr!;j$Nar*qVJrN)k`ty3Nz+9P{Uc3Nk^N_yu1=!e)HJ!w zWZT>{?U|pZZ&8NmGTR)c7;=i%eGw%!x|Zcbtt**DbV&N!P2`bd7eTYey2d zh0-+}WecavnVhc0xR{!*dw2)8v~=Z07z!f?)zJ*yFa(pZ2%GR4f0j(wPnqd_#+I&9 zIqAI4OIOD-#44Ar>E+XvP%&KxDy6G-m2@ReVyvnqHQSP*&~X{sHa$Ft$J`7}nV+Hfg&Eo#kf~aMnR*eF$?r5}a(*IHt8phP zQwL%)wLBqH(M2;AUm;U%QLthr<7es_R#nebR*g)}!LYiSI*eZRGBq3}>t`xoGh)N5 zd8YE?Ha4`<=qaxpkl~-ow2k;~=n8rW(NBIa5J6h~zGr{C}IN=Djnu4XgTO@)|Oe z&oVOQ9F(ba+#X8bVVOFQJ6JwEQ(Mq@RHk;}IG&ElRPC{u>N_n{PY^yUQv*?NQKqJ& z;^IuzN9vMHJ_pa#M3ml?shTMHSEf22%jA7SrkWhjR2NJ>k*PwrGBp(a?qq5QI^4}v ze{{N+shpRY8iXRRGF1w$ubIpHOr5~EFPS=xfnPH<9!0)oY9&&?XR3^AmR91LA&cwR zv((cqONa3oRot`qet(wcV-3C`#Uo4QupSx4EX{?(l%@LUis`tVKT8(^Xjd>x9bpN~ zQXne*Ur?5wV^2hu?&IgkEPaT|QoHCZO~5IXiOJGMyhT9=+wlXpox~}W#qU{VsXx{f zXB-qRk)^nlELFqBlH`>^UO0innOS;?ZdqCS8!_2gs*Qa)%opQIWvN5yEQOWLk`rmw zv(yxKYiB8RB6CBdndFCI3$rvCf$JF$b+=}z#I`K)<>`VCiMP__&%*;tE?`&~ zZNjtF853~^?=UAKoAdJAkIYt`DE4C!_TdNoVzQNj-!TeBX@ay|*{fU%M)Ept-$P+&)N2L&J%28FcH0S8sPdN%LkfSz%IhusZaXIRSv_$sf zW>Stk3+1R`ksJ-fq!KxNXC+4-X*qJ>VMdO8GIMmeOpab5f0Z0%U>f%0ebpTOR4qqc zF&ianr`i$g}Ira1ay6=kWg_IZVh=3ffF! zT-Ybm7m?F*R0)f51|GA>0k`Mm$UHYk!x!afEsTrF6H}JvXeU~($kBMrU6-Rn2w0z^ zGB~m^N5}u7o_BJTh|&*o)DG|9@sN7{-=iFz#pS0t@_UxUXW2PwfbLj~U9f*7E=qmM zQK8Q{x`gEam@8KN$dL=H{J)y+13HTG-Q)NV=}4E3fP&HlM3g4QKaicWFf-X~LfwJ_ zQ4s09Dgpu$5CQ^HLI-IgRhqQWo78aW1e795FQIwA-gEz)^Es2*nfICJeP$+y%+9>? zJiAYGi~3ajb)Ou3j-zQ(3PhBy&wNI~xe3}^csdUt*g>8Kb zeBx7<_C8g^;?6#m?c&p_u0A#D?&JPopZ53h=?*&d^{F4`{;Qu)jr;p_Vt`N02Kw|J zPNV!F=5Z3~STWeAd-!b#alZ5^4ONHxly#&}my^hA7PY}P9K%JNp5s%6c|I*!NIU$p z$fvliY#SG_c^m!R;nVB8`3!CM_>^+or(Gy|!lwqOd}@bVXMHMo&ZkN^eV%!|f0g`E(m??)x+b=O6l%`4P*}=&_GyM)?e-GT1lRn#oYE{D!K- zSJ=?!xLnN8W4u`$B@Asxg_4G5mNInyU!@HVE@SBIdj`*18(e>39i-TXe#Y5<`3((h zYAAcGq0|Iow=^^rX~@ym;CHK`#P){9B2y>gI^azi=(JG*w9cMLZ=~y4&yO$4mGsr_Lf;9xek;SyR+GxVPy46eaYQyj*!nTB3VF|=nk^_gQZz6;CdvhF-X4HmH+Z!9+S z5*?Np+!JM}9{yQQEm!c_N<$Noyoz;K8>+h2(D7dkZQf`o9jRNXFEVd4R1)u_DgM|= ztW@T43Kw^g_inb2IXLjIJscN%4ISKX=pJ$&ptktzprPIvcF52bG&^GG4u=0`XbEoP zIUXJ}wDmasIm!B`3{A%i6ihQz|6ivKokQa@#6;=drgKb|klYB0|5*Ig7s*$M@F(%_1n@YhU6tYalJutPRnW@cK@0hCUnfe^-Fh5`_5@+hw zpsC7OhJCn>kK;}C!Xdnqz_#!y4&nxKG$$_JY+Th7?czE*B%1mYl|MDr8oSWxGjc)4j;1Ph zGWDXD$(Y~hV`>jR>T7EB2vY|}nffNl9&?z8Ay3T@`I z&LZ-{M~f|GT4L!1jHQ-7S!Ssl&aJR?aHXZi>n!zOZ)qfIZnpG0oUIo3hg-_N%~Gu$ zmSV6JId{@u)J7NVz)2|8QXVwMa7;w*U6#fn*KYDdc#oy(d#U?AYK}7pE%i8LY29&4 z|D2>2mn^-+kC&-2YNyj@xnD;BUNp&Ek0)OFyICbxX7H z$qm}xw6q&V{-jp7E%koDvWJ$gA@qpca1)&$Q&Z%7VyP<*U}FX`o)RC?XXK3f&*>NT z;l~%`_>$ubW&g1>80#=nwqDO<>q}gJ#n$f3Hs9CSDv#n>ZH>h**=+UBZfh0x=de{L zr>!~2o6A-oTtdRDw)W!v+_qAXJCCh_xC$q)tp#xM*^EJB^WDF#r3Gz8U$fP@kgXrF ztB9?_MTv#c#cVw)ZtF=2TN6s!>ifE_ETwEsLHW|Q)}u`sTRGpbbrHd`wie?q_Ld{w zTjYtD3glkV*22m**ZOU)?c1{I*!rZdtyHXwvH9Dc{#&-X;t;CXw#MNvIDT8pkh`g^ zFK`$uo7t-Fkh^EARjjT1Xc}iL6ts03G4VEkE7~fUU@L&TSk%JShb?Wc7qHz{#B5EQ zHnysUY~=~t8jM@mA0-}&x26Ax`1~%q3@XDCN@m4wLO_*W0K9^Q`BxUwfo-I9@Lq_{+mjz zrg6N^pntP$#)Y6RD3ii5J=<3D99#M3+G>cVnD!&{OE`{kd?~puXWwD}3R^vX;&@z1 ze{kYwTc546brQW+vv1Z?vvr&szfk)Pwu)`EHEJ{c+QRnG?N^)e1IQOAa1C)=$zdmX zr`qbj%hpH?-fgS$Ud}Bn+{eD!&vtO(fURr?ZGDR@hiq*;&N+)$PqJ^*$nA`+nrCgD zJ7??d3mj{BiS-vbPcCr`r_<*v97mXS)z-1!ZPmYK>-+1RLpN;wgQPz>UT%>OYTxB} zdBkyz+>eQcCQmq~GpNlo&NXy=&bgJ_&v;XQmB`~)E40h&*O(%HH7e@Yx0qYfuflKo zRkNI5Ptf5lzg~IUuV@9oTEFYpH#maS>VBo6cn#X%C)`H<_x(ylo|=9cxL?Pw`gQ%P z_94sRukTmc2E@nb7>-9M-q5e|=!rFr{JMvK(5kUt2jFkw*ROalhHayo!Ma$FXJ~Bt zH42CEibZ^Uh6T8eGB&Z0jNee$Pk)evop^x{oBGuqD{uwHn)%ff!?7FBP{(1rSdW+Z z(DgG8reCXZ3za--hFLg+*JAzhFc!O!Dd1N<^uQvVN5MG1VlW76@fXSl{c3?E?7#z5 zi6=H@;ux|g_|*VCFdr9DvbkT)F%G+sf$A-&1yXPvd0P5qVHh^xKB~3ybAOdzOK}5l zwWeMek5oKD^)`O)zoMqNin1ZU!kB_%$Q|~p3Ho6<{y>=sagdC|C={hm9sIJp`BiER z^93CxwstfhE!sH5ck~zhVP4)7adbV=QTb0D{SR)S>t~J*c69h&(b3kfjym;pG-sfr zi}bRgM@d5+rHydZAjwgIagI7*_jpHHzH_u5d*DoPv}B^Ap~;SVPIvS( z+Rt#*3s2Ev7VD%q3U6>U9qvX)5nM&1&5kN;arF0IM^*Nb18$@Den-a+I2w7-(UZfD zY8@eWWMJrTj?Nu*^xZM~chb>^m~zTdFwN1&m)HiLTqf^yN6B{`9mVi_jwYeReMfyC zIO_6{pR>4XiC43_Dv3FGnax$@9IoOjy2?_?Zjwb{=)1Nu2!PfNmt3ITz!=0Do?tr zrg(|GS6ofP-K(w^{_gTju&WjL_=cYCM4Fo&nQc|29f>uE(kPaE=k`sOuHv)=R+sqE?Q zJD#pq@pQ7Pr#;m?&8zO|`}aJJtKsR-nx2l<@|0TJ)22Gatm~;{Jx@2Vy*{xTdHPQi zPd8&cy)-;6GCiePp61w|E@GnJ(_B<+>S;tXkMWK@mBLUI9qcIqIfi&DhFN$v)YFhJ zJtgBI=1eCJCe9!ZD$XR%EZU?H2feX>6Z4zN4+jv~LO*|{k6UT8$I~Sw@1c`AshczBs@rc;M&p0Zx|xL?}SUbr_rExqZf#h>*1wx@rv>W;_w z>7J~+o)+9=yZ1efenMLe$nZ1<`Ja0F;+d!7&zWY5)lx)WiB%UoKp;!3ULb$oSe48d ztLE5_qWNRh7&!~X>JI7_iRGOGu}VR&?XjA0I99h$#A=}es*)+7x(H)W=78?wV3vT2 zWDRIYj(|oL4(J*h7Y!(`SU?kS4P}Z4)UrfCcTl)wfN|9V`t6N?F5uHQ1L{yNphGzG zRzQUk`Me9Ux(2ifkGlm_pl?9sh6R*sbU-tc16naDpn`LVH7}rkxQ3I90xG>WpiWq` zDIjxmKwW-ix;LPKrvrMYVw_T2#_88~aeAvmobvaMQ-j5EO57QzVd%OqPH!BI(@l&z z7N?$Rae9b)`GZO<7*x5qpf-IH)b{p4?dT9xa;KmU;&IQQa`y^q8X|pyitQg%>p?*c zz>~p2r49)yVQf(M#|L$8a!?h&4@y&lYK}Ct{UNBBxj|)`7u4OQ#N8CsZ5-VkRL?Cz zjl?qy{xzuH+kz^zJ*ang2DM-pIqha$G(N!ygqLquOoPh zQ;Xv@ehE|DT^g@W%i^^e#a6~ExGG+std3Xh_3>JV13Tl@AT?fLT-X(_TD#-55VQ8g zYr@`my|yo2kMG1Q_HMkolc1gWY9BEUCaA`h1kF-&waL_6{qeL`b7i-it6rz( zDz>>f?+plPequGd09L)gdjL9@6hKLb|bzIO{_?vLU368$-&qC8S13+8WZ_&AzexjY0Yr?Ye2cE4BtJ=D-hG9I;qR9HNT+Bs|4Ph0Ae{)z1(Q;c@5Aep3 zunyzq`7qzrg%$IV7^wM(KH>(FGQzryr%%Ib`z)-knIl?`wpk+ThC*2*I+rb?64@g< zg!4$w5mAkt5p6|6Za&9@k`V=7k0^q}$WsGj3*e;I_$=vK@pW498oLe z9um>(ID?8KB1%N@kr7qGA!HpD(Z?7)hQ6RdQbYq$ZCpeRk!O5_an~d2kDU`E@+U{Q zpF5(n*f}erOeqnqK`I8!j%fUx2>UXkV{_@>Jl4T+{4hVF=F1|Q1ao;rE%5e=h_bDT z=!0J(j73hp_D0kh3((^h>y?bE&YMvks~1(}`ceL$A62M*RG)T;YCaN1MfD>#<2iDU zj;aC1U@EeWiRuNKej8P9oIvHIsIGq()r1LA)t(sD(d4KqPKxp#x2SHThn`k9X}n_B@FzZsE*(!GM$O4IvQXqo*>)VsA`^zs`dG(PB+Rk#n<)egG{`J z^Ut|!iZc1XfAuqclQypGo~(UJTs|@XmkaX~U(GV8e*d4%QNOe+eQWl%ZU1eT`M(YR GfBL_+0Dipy literal 0 HcmV?d00001 diff --git a/Covance_UCO3001/browser_profile/Default/Code Cache/js/1657d329798c6a39_0 b/Covance_UCO3001/browser_profile/Default/Code Cache/js/1657d329798c6a39_0 new file mode 100644 index 0000000000000000000000000000000000000000..a47cd50ee7b0f56f431dc01b71d75f5659211e25 GIT binary patch literal 19000 zcmY-1cXX817w++IrcbB|nG}!~NXSg4&!o>JNbkJ~DoqijC@LUeML+>jdT#g0k_+NbMn{vIMJT(K=W$WOqrn({Y zd?-*WJ5;AuUX40If1NtvnmILV=4I6k*UqWoukFvPmF=&cl~<=ujX>?^YvtzE@`wC^ zoV=V`wZnA+;aYh$jf$}^q4?DQ#roe@x+Np#f44~z)V&KbzyLdCnh8#dT}fP*Nme*s z0{$os2g<_6F#MbgwtUTz;}OWK1!ZeP_hzuHIh1b!KT6G(klG5eq@KLqR&!)`JNW7q ztVD~>R1?!dDMp!R< zq+k?zYVYZas0S$IR2XXuYX);NE-3_N?;vV=~68Eal2Vsf4 zdIg_3d?Zr=mreb^v-rSJi)d8lJeK7Isa#qe0YljRcs1YVPOCHNF- z$ZFXl)BjVy3^DWQjV`wcqWTZ8Q>C)O3!>e*k3SwhuB$i?^ zB+6$}xnvAMxhhYkPpKGQiqoxR#K({;izPlehAMJeu1Uuf%_|>6O?f6ID#Y-i zPYhKwM~2EcsarLMQ!>RF!&z4hO*3P7QPxOrcMMhiF&xT?At^V8`trG)k_vfxEE8pN zVGMg~#PDU!7&_I8A-Q%8FV|7-608@)0ZD8S!!YUIFotD~VkqA@hMi56U$YqAlM%AD zRSfnvF}y3&Uyk8iN9El)hWERuZ*oDLuf#A_zUvmllhTKZeb_W3cXxVZi^Kh+*T&7`(s5u;=#}%AASe z6X|6(u-amviq$~f;s(AbVc=hRJJG<}Bm-?z41AVuV1G3OMHvPf$tgMJHc-QBpsA$# z4b%!4$O;-5E3eiv@Oy0opVTq%NQ&wiSSIV_p_FQ1;C~q-TLbU5Ghlf^>$f+M(#gQCE(UJPTU`wdebvB-?gonWFwp#U10~)x zP*y&8%RrO&4E#OXfbUBK5qV{dfuykpUK(d$kHn5Q@S5C~=O!39D1XWWNtt3GG}SFrHZX00Vt!-bn}r6hEi%w`rGbTFTV>#^yz+yABO48zlhs=c z%-wDvdxwF+@~wQRZ~ohN83_MkpuUWdoCE65LFISCz)6|*n}LK=TH~~Vz*z&u&l!0B znt{vL)x#Tl{ekj%s2m?@J^5D3KT|IM8mMS8(x$kP86}JqD{16ZDI;H$HZn^}#2INB zZ)B^CEMsK4v`#ScsvMUJi5e?6lZ?b98(Am2C7NPnXjvn7C99&5IzlBQrDcfxQrSpe zs*#;ljGT~hRgKJ*gft@^(iKBe14cq}O`gdcK_hEIM$*GZUdcAnPkcE>ie#lc%r(+I z&&W>^BfrYfsF4X`DKyf!$jAnn|Gbg!<&7FfK9pOMTg%8o`M9p~kVf^4yeRv`(ZI-@ zhDK_(GSW&)wpPtDMvk{JvZ<%s+#Z8{m5*;&2oqB%X(v)2`0uJ<&utCwQ* zF_P3zb$_VGAL;QBBey>>@}JBfXT&|;$XgSPJeg?Zt10TCET3-Fv82Ap32D8^$RfG1 z*vQLEj67Xtq~3Dv#R~OGVpkfO`n`H5p&!&+x%#7#W2co3 z#p_1;+%WRpO(Ruq8Mz~QchnF0Ub5~P8GPT!XX1EZ@g|;^6>`6fNynmziiswMrkFUMYT|r`316m(h8`2?UK7OvCRzkdtO}cG zm1E+WyqaqwInP9fOqSF6CK?r(XfJ(gn%Gp|gr|Xtw;L*+jBR2fyQzs8a=w{~8`814 ziQ+93yQPUOQm>6k--}ED= zE4^MfaZubnO}y31MAJ7-Y>+qmn)pa=NY>jX=F2MS+D|=^&;a#GOz)ZaP`>)eM1_w{ z{3N}Gn0QbAk-$(BPllQFp38*gOVvBZ#5y@3CC8dLJk!LKSticRHqm&Fi7rxXfr@Egd$dFK%8xruRNG}DEZM&(?_ZU-Je0q8n;5>w#DDut^gUqWcS${D z!hXTT38{C{#21%LG`On$ykp{mIPaPGUSjT>sQbV~tw$zyNy#TB-j^5uGjUsTW6YGa znR%y#S;v`~6Y`g|EoEkAX*0#+%v`KyW<-XW{Z2FOGR-vhoB2Ur511Jwe~T|ZSbv5%$ zR=i?nv-n;$)32MEKjpUc?`h_kjOb-%s@Qs)Y0}5c2H7o>-!@b39W$N#nK>YX1}K+z z&5V(n1I@IQpT#yHL$K9&61kUuUMmdd-pf8#I55nZ-Ywc_?kRnVBnpZP()+W?tTDX0<%p zWv2Tt>cL*+w@-EL*Xv?FWTuNOJZvWEh#AXCGwo&0Z)QrJQjgAP{2ykT$ttOI&P=!S zX6jrpbN!l`53idE-Y`=`R?35$X13o_pT&F6%y>C@-%Py+X0ALm<9}>swk(xJ|0Fs32Ki66n=CXmTNrDx=obq|D?6nTClFOuvmJpS6?=(M?YH_DvNhmxVh6p$6e~hZVS!#s4sFNWFMs;p$Th9iCa(W3ckP(aNVL zEBD22wbImPWuvSvVZ~C?N~2O%29~z6SIWd&sU)s4R#wV`1S@CDS$S5)O8cr-=A>CE zm2PEHH9aRQGOTPCpVLY|mz6)|w&b}rR$6+jbd^Jr>{A{xQDOpCx=XpBl}wo?e}t4< z*vd;XGRw*%S(6@!Da$TN_TJ;{sN=~7by0S)|7Fp?8UA0KGzLhC*rh%2l z4Xs>gVr5HHE7hA>*)GLeSlQXu$`Kj*f|aTrtOR6%#J^~z-Aj61c67E$8x?1_T zo0W@_*S^TaQ_b4lGeQxEP+?Tk~R<4b+ zvT1^qJ>O`pMT#qvWcOk#@2pqdQnb-Zwe42^xnSk(Kdt<9(MrZ8)g_UnAw1#(?5B5=+|XA`45|NGfg9@1Qoeh_#H3x(*xTWgDyHm2?~bNFc+;9QjrV+vt#GRf5NCd?h!2v+>d?9S34PZKJmDc6Juwv{3baDJMSCqjFcPF(`09**-kf`oq46~*h|}K8fRyt9G2_yL{7xp$u48( zy#zZWwB4<&duzs z7efo>-Bx2?uya5XJJ`9}S?j%S=af|LWoL|R>}|){$IcsX*f}FZv0~BckSN8_U9av9xR(%e#`_ zE*9GhdMtVEV{vwfWAZ4a3qdf;yfD1 z_Oo%6{v!_Cg*aMD=wciL|BhqXl{g;BFaN|*@>(1(NaFQ4`rnRYi?qEP#|QV6?}IpY zNzaFIj5Ee_S{BB}Go)BNd!=FVc;=Ld=N~y;GG0Gd;^`t=F|X5W(qd;kGiBKU#XqI^vf{6JT3(H3mJGS6d3WL|aW|fu&*GU> zq73Jxe6=z(k&`vbP_h&%|??GkwQGOayhH{h3&`pAi$}n?98UB*0yUOsv(K7rZ zXD*jv&EI8+xl)FK*UK>UNg4Lb_y3k*>3?N-AYDmdqagviF@b+f3H)nLpq(Xwd1AFD z&{>vB8CwEzu?f5=rAldhd;+axkRyRk$q6hGXW0baE0;iKr3CuR@$>|GxDxnI8f7N1 zJD5OXD1lpf2}JS}xLA7^1QA?I#KJ9h$&;nKUecjL#ByTMEY~(0)<^UrUY2 z2^36CV7RoJmcZSa2^7sr;EUM_n7>M(ne>>e8kQuGx>R-lkifVN37nP+n-XZdEkVC4 zsh%AP?A@6_zh4q)vp0dS}-kAt#42gQO8hGaX~E5mafe4Fp!p=>B{&@AepV+{w3WphoLq7-S2RZNzcF^eq2dzJHFh^oPc5w0&2UUkUST55?IJhL|Mmh9Bkz&iC@eW4K zad1p}%y%&G8wVQ~JFqWt&}FFu>lz0w_38+j<9+HY$!Z-sIqi%?=D(wBFAS zUY132PX65Hz_;DOmYoj%-L04hl(&2?b&on2C%?*9zd5)nRZlti{k(%}7u2^u)!XY1 zUX^J#9NfO^pvn^m1B{6}RhP(P$tsb^NAhjSMCK~@j}vJ-G?BT|WVqJ;RQbscd3j_ai)6sKM7DgLNbv=Vu_Td!%M#fp^HwL){JTVE zh;glYvpta#I})k5Cy@$!6X_vWWzv4llX^#0>xD!%NTVx>q~1)Vw=8{-$oeOVSf3{9 zeN+-%jY%w%1alHKW0Uwog2j?pS0)KdLJ||7OQLi6B$mpL6_WHGKZ$Gds8SMnRg&}> zQxcP_Cb2Os343}H&&wiD5_je0U=r_zlXT7~iPQ31B#D7FlGr9oY9(>Mp2pWtg62s) zYn`O?j7dE0ki;9WCb3qwbWfr~?<5w;>^GH9-z1vL2x;42xyUO6lQ=mziK_1$?TbwOwwe{ou=Da$#jvYvy<6ACz;Y;CG*@|J(jxjl4&_V znXT1QD4CIh-UJp zL(E>UZjs6qncX>+b+4sj>7GjEzNxg8FJ$rHRPM>RVX3tKER{Jj zbaX1ej!nfePH|>x&a70j#I`7vma=GlD*jEW43@99rt9ejXSGHCqYg<*e9;-^(CsmnD8s{ZkI*rB&X-tvaN@@I)nnre& zG(1()blyXcWsp0Ks4tBz{xqHh(x?+mW1h?or*TF0Wu>tqSFg#u{4^Rw^te!uB~+9~ zpXzC3KA)zaPigu$kjB6|Y22!x#+`;~Y;2-+ny0a&Wg3-UNTa8$?vO@}m(ujvT^jAW zq~Y$H#sKjQ*6Z)5u|`&WlE$@B%K7s&{vDUbCzF+j)S0Te)6*C&eP^Wc?yNMnif?ur zC6*|j^j?|9+>M$quWe7G!k#pGh<|Sy4UeZWN&5YsM%vjl-jw5irt$M-&HpQnd)Lx< zb}x;3_tQB2P_;ct<0rZOG>uE9bOPpdO2?+-E|$&!X;V6#-f`*tC|lywnVOK!pVHN# zvB~MYCsoU)GfcLXOQ+Ox>2xoj&Xx3ZvZ`sWE1f%1n3>LHY2-_1vLuETCodgeemXS@ z)7eocow&N`oN1X(zjon$%B*WwEQETS+ex9#$QjT;*E5+KT2o) zbJehxug2M&YLv>YMq`;GEu+<#CB2@n#!oL+!}L-$%Jr{C)Bl-UjcM}s_G;8TR!!IK zRO9KzYTUhCjiSG*G4gsfeLkS)WX0WT80{G}k-y_IC`id*xGboWfi;++&lEHGxJ3q6 zUd6q3dz`_>|1vPeIC)z>k{wdg=%kg&$yPa1+{wo!oa`*=B)gQ8HOWq%r8wzb*2#?W zPA*h%(z2qH^fWz}?&P#obvoHA37JlYN|%5WN6<-{OqAb4P8x-sv@LYfT~dpj1ZBSb zQ{732=bijf->H9(PL?!qvQ9h=oxIb?$)9q*rIS1IZ7U}m#MjzM|29r8$*oRK44s{< zmpxM0#mTU)PVULJ9!`$Rm#;gSEpa`awCm;6XYEc(4^%#bRHq#Jz)8wSPDV)IAx?h$ z#7V|bCksDw>KZjC9Y;F(VVskH$2;jW!AbmdC&Oo`=9x~Svz$Df?WE`{C%?{hQg@+~ zFBWO66kF`1fs9${q{S-5k=fF4wUcq*Dev!{l#&C|YmLVIpndq!$@HHzcdhPk(EW|N zze#boI`TDE)pxb7%t;dU7W1qqJC8u)18_l-CQpE%U|Mi zySN^3k(B4+<$M?AtGhT|+eOv7E+)vD`YxU|aM8P=i|?Db=+xB3H_bG@xr>=CT>RP6 zrRy(T^pLgk{R=Lhws+C1gNutVy7=-X7sp<9(Yce0c0FCp?&YFXZx;vqx=4Q8#b>hY zT^E~V;6N86BxA6P%OAOTD62kp@w0@7xETD2i+|*yyfVy1<&-3?s6A@uW+$&jf>H1T^w2GqSku#Yongq_L27S zUl*Us^Z&VME?XrwCX+$(r98G|@^!IH*2tU1GxWs)oN+?o86o5^o7Aup5pl9->#O9h$imGd&}`Aljx z$)vTEYO0trR!%g_q+WB4m0fKzIr35_D>GRy{a0z8Jd~pEGFdL$#J4t+7dNXv zTQVv0v(}RFJ2UxeUnZ-h*Zxf2lk1XoQ2QhGk7qLGL?-Y4mdWJXnVh+ksrQtbJa<2n zt`Ag$lzyB^+b5aql$B32Y5z>il4cxSD z=w`e8Cims77H)oOsd%m26iVd|%Db29>Fs8(oR|7g^(MIaYLc5((rdEj$#uz^>ZZXAH_QdRAjm1N{)x#c}hcdAqK9L^9Jgg}0p;8GCml8a95rYzK30MLK-yiFt(wGm_{D@HSu6?>Y-UP51VCPD-WNx^)N+R zwDZtKj!3!o9!AMknbN_-*%v)L?&#t9&Z@18hrzFT*xKEL^G%Pg#qu!uEe~hjmVU~6 zfQN~)SPBPvXgSowv|%1%hkNM!sYmZEJbW*yBh;Ib9-U|OPtP0*N09tO$Dsp{8s z4`akL+rv9^Jp3tVzfpe|dGxusdbiBO^5q^XuJBN6mGWKf;fcKQz4l>^YF+Ok`m2W~ zV%zN@Sw>3By&hhX3i~{GW$%8CJ?vq)R6nBL$c>}Q>ks91&clm;dbsn{L;k<2Nml=- zUf{(V{6{nX< znOw4iiUYvE?YnK5<9}nAQ?Bx z%gN8Z)F16-%9mcwj!{lywcZ4+G11EdnK{YJpOd}ZlK-ZtCsQ>}I!*I(TAEGwvRi7+ z@G?V2&-8L+mLAXc(s7RJmeF&)beZR6(R?o{UwauWpUJSrUiK`}9xPQ3Qu|vkpD*(= zRmv~-^2!SJYmN5o2QSlQq15@&%aaXW9&OYfZT7N4Hb}KC>fKhw-R5PY6x;5l#SSk& z%YGTUQ~SG1d-#iv134vM?e+54J}>R|tCt78j6LKf=CGGCN4>N^=H*v;{)Crn68_E0 zd>Q$>mxHJE{24Dp&U*Rf4=*pC^U_1^N#uf;rSg;Xy6EMQT)*rk;cqYN<;qnrf$LgZ z@@{+i=#H10@=U7VRWIe8dtTPv*PhCt2VS;3^wQ|Dm&;b4KKJl3OIF1Ccu>s8YsG!U zl=e|C&WAP0$NloUt>9ye9F&?BeT=N+SIk6AHP)fQ99kn{!HEae6;oZ*eRET zKH@_@UI_b0&ev_!$DBfqDf01Obsu$VC}vHc-s}3P)kyOj`6#41l}u^U#YYF(BqzK2nD?rWE8Tpwf6Yhb9zMFi?&E|E z?dfB8FCPWHeUy5`N1Hc&?2uEE+SiBcJs*AF_i;|%8tS9mFdtop`#2;kNBHPA(#N-> z6#EMwfiXV5lFk!+ES#uZCiyr$#Yfd?J|@V2(^cb4^+=}7R$X&c*H^l~#D{IEPuD4{ zpDTR)vC>D;8Xv=dP^}w%^gih0yF-d|SYu9U%xNFx|Mc@4AKg=* z@B7Gkp!y$bPvrT>%2O)hr(2AlW3s{M$7J^Nj=W~|v&`nFg56I@elF>!e}bP+<#~r+ z-+%mUmDnUdgQR0wKMTtFNqo-F?y7#`)BOyQ_uLxi@w3S1=ceCJr+}Y5VL$I?`Pr21 z*R|+=ev`_1e#Xjs&ue@Qty$C07HLt-&$ilr`qoh{broCU>npY_Y~treQ{~y(PsNU^ zqm$~8e`H8EKPCG3Y4wKY%c;J8Qr}j-{rtE-P`nTQJpIVemqRsYm|s74wC+f~{<-Rr zf4=Y&9OGxMn8*2PI>FEJNq$aG_EUALp9ykinxC{8ekMxaS$=+;?I&Z7#z@t<8Y6e- z`zcu9*EKbMYJQ_NrRE|(tEKn~KP^{kUHN;pAOH7$=E$(0{CL)CAJ+N#QzmZo^ZO?4 z$reA}U;Om@)lc|<_TjLf&yM(cC@oI*FXH^pHu#F`I4XM zxBZ;Iqw#nBeE7i6j)z+BUq8Fz1JtV=;LFqi|4H#G0k)rY3Sg`e;Cp#mQ?Y6Xm>{7B0jf4s zyhZ^|$zQU&X@L0V0fxxI76Fo51(?@5K!=V2=62F+odYzJZzZowfUc6`KLEl|zhsGkc1 zm=_0h&LhBr)d3Q}3($8>fFFMdQ1hn%Ej9$0x-o!#Q-I@J0#w)<;0u|&C%~D#0h;Vn zO$Sx);Q-6z#E}3akE&nC0*pAR{kssL&PCNIyDqE$e+T$bn*0-B;#KugjMoD+xDjBj zOunyrAE>^E+EbbPIKbae0=)24&;1u*FF~R)K_bQ=jm2sTk|ZPKfH_EYOOQS#gM27? zrGnI#bz+DM@|KiM4w5Ms<(|Bj5@cD~AQj35DXJ8tnZ#DsIQd)-rv|B6B}m`QAVVbL z4$??AirE{apUe&gxfIsxSwXJn1<5K1^0jm>3bL?zkWdZfP+vJT3^KY=kSEQ9)My!G zl_azY(xGjT-O{CfP}lYb3BRP*x&(RDHK@OP3bMFwkXvsl-rGT13=T5&y&zRTP~D#g zd3kh@ee(YJAloKr?!+L!N#)5w#>#I~bbnfqrPG6yTcS0VYVLCNW_^&4HUxFfN^5Ql za&vo-!8?O|_Dhiczp59zgWQq)y;@&3$^Csn-q;`H-&4x>_aO0SRI}_p7i7@+AX_d3 z3H+%wFKW%pT3^2YE6CNqgS>bpNV|W6ym>vy4>y8TyBXxftsoWeDE?jb@S%G6C`g;f zLAuI9Y4{|_xTosdvmlfH4RZQF?KvSfnL=1BA;wxmlq?pab@32?ln9X=7ouZ)i2YJ0 zA;f4$h-We)Da3)~5Y$5}r-X=t&wjsXk7}EEAt=&09OIh1h zF<%YwdAAS=y+d^96XMbvA?}Fd-4HJh46#Q}O7cu`z*xJ z&qM4U9irfi5L>@gZev3Xl9f|JJe(S$`!v-xBgCIGL$sQuy61#A@>Pghb3>G!AENWu zAr8tVF)UEN--M{LD8zVKC}ozbre9UlZsj8N_l6j=F9iETyniS}v%?{J9trWrKbm(v zM6Vkmif)Eze=9`XgAnZ=hS()PJyzZ^VRjnBlr)F=K*r1Oa?cXRVhyud4oD4Km=X3c z{Yr=VwnCV@6~nwzDa?x0Fm0-YnOQYViL@|j)xz}3Pz+h;3S)4Gc}sTq^?ESO`?4`R zj5$}aq;w=q+h~{tg<-B0g;`oVOp``oCN|cXCSmHd2{XEFSf34t`SgV_``U+j;l(hg zI)+K@9A=!<>KbO$D`A~W3bSxPm>chgc`Bm@hM6I428HP+C#2$gVHUryHHU75 zHHU`vdt{jHQha!r$)AR?jSAEB^Dvv_{ug1QV^p`S9~ai&C5ACh2(v-+>x2cc1D!r~EHy4LKw!7gdwIeksh#%V8pahuL-~ zOtE`mlI3$bd_T;~57mEb7VB+Uxb0ayDV;@)_$->rCb1-BQAQTZ4M!Fo6SMH7Wbsbf zEJBsCuvf{VS=B5y%fHegEsM(%m!8EAIVo4Alq-wpq?gopXEDZ;MIUb#-}|yi^Jh^l zPmlAn7}hvT*G*>;X_|$vMHc;AX3?WvmaaWgoL97Fw=7=oorSee7PDl>_$*3H%pzuP z7WL-o`9;cgsdD``i$Tk?F#V84!ymI)Cl`Lo!nH1oo$IyECatqMi%~n2)8Q;uAIYN1 z(JbbiQ2r;gX!~0hbs)H`nFx!}=U*Y|P=}o*dl!a+o0{ zf6t-y=^VDpg}-ueUCCjZRJxYKYu9r~zneq9D!Ht$nyYhwx%}$QCC;DA$8xJ6m)vMB z3#D(ZTz;&bOGces>Nd>fi$=NhZ<5RMp1IubrSW}o8S#ED2R_K9`iHsP`6!qCA-OD; zO)__6F4w2zk~J-tuVt+`rsrarnM>nYxonU_(sO<;^S;UD%EDaQFUsW&iCvyc;;LL; zTAj;YIWPCt<&v~NmzNLZvQI9^pkum!LUDh~WtbfLBbSu(%1c(=&gIdaTn<0Z)v=bx zac>?4IeEI4IFB*I_4v~~CXLRc*_U}t9+Srh0UhzYLKpEAj}e%Hu0}wkwZXzv{Jvns-U_F6UA2S{@Vb=W*&m9@C!Xaj|$l z?vnZBl**?|LO#_K^Yt?>Uq9pWndi!1B);(3gcNYrS|7U^DKNOI1xj?*21Z8WECg!(T<81r%jI!0LDDZ>5E5xR9z+-?zSbdRt~db}QCMb8M8dPOMe8)5ic z8YiXSjnHX%_dweB#jJ3PX7BQ<|igr1+PS7X$xu@U~3n&Z@y@ev-&n^V=_X%YI* zQOtRYIbSiQ*w+!}FO9I{d+oyy+6Ni-qhkN0*lQzvu_40IjS*^ZiqK$Ngt6Nr#O#PL zba#Z^dm>!gAK`(lJP=`vbUGBF*-`aV${mZ4DZd_%Q0BJ??N8~xjQc&p$vEQ7nci=dDpHBu9BQCCX8$P+s>d=)T;j z6eT+~O1&ykj#Z6PK0V69YEk-!qio2E;>nIuCnw72+$fC-qwK98C81%Iq4H^?DEk^m zDQptO*epte=26y)vsIKgTSxgr*0zuG(u+}EmkuvQnfr2-<#M@G6mOR(vt&fqC2E_!EZ(R`RyqCWym{Ge(9$=q)-1S z-w%lL&ilF@66NV9QS3vb_~oQj8m`)8q#XP-%JZK^X(FFW{KzOTj8ZH)ChpIb-{>ew zUq-1aQu=2 z0fjgR7BW>vPA=r<P}LT1cfig}nAvA;)FaqCy@mE~LkjLY+e{=42KzC|E@0SBvQ0t%wtHrgsr(Zxk_6 z>I^Mn^spkH$)U+bq)aVhgnYZ9h`Sq$_Un$}v z$-Y{|``3!NCM9kb(dt$a+obSL5yS2lF-~UQE8@!sMa+;B&zG27`;EtUWAtDCd{_0< zBHjGouR7s{`)WA`K7LXv`SQ7}hn-f|tabQSi^PkAU!HQbWX`k`|8JiD=Y;?7>;C{; C6oFR& literal 0 HcmV?d00001 diff --git a/Covance_UCO3001/browser_profile/Default/Code Cache/js/19130f2e228b88ac_0 b/Covance_UCO3001/browser_profile/Default/Code Cache/js/19130f2e228b88ac_0 new file mode 100644 index 0000000000000000000000000000000000000000..cb4094814893d421ea1b78487cf8bc2489dba632 GIT binary patch literal 35088 zcmWjL1zej~7sv5G2@oR?NU1|0xF>aY*LADw>hA9D?(Xioy1U!z?do0KUDm$8cb|Pf zkUaM}_ndPtH1Y&b-A>E1wEh0WPf`&qde;0;z9?HRZ=Rev^5*g6DB&qqta$EXo}zj4 zc(Z5Al_OWNVmY&Wi|5T=GF$FErAigcR=iZv>^X`SFPXDcu^c7&-7!&+LnB1D^3hRT!r9h7N^Rq#LMYJLM?HJ`Xc$WO_R-5eKI+%kM`JLkKe2}T zXvzrkL-0r+`AzbXbFzj+4LVlRpr>UFGFLRHK_!FQAX`;~3S&R))eLHhh3Hb980b>RpecfFSj zj~xt3=xER=Oh=hc2KC36&V1j+pv+wjio=g?1~u%#xjhY_Pt#+#YFA?@-uN_?+@~3o3%hUy9cLL7HQS(ka}8QE&!Ft{4H}9`a4a+^afv}0 zmm73vg+XIilK&cm@?h#(gHB`LI)mD+XFg=zV9+_-Lj5fU`5rLnByt>NEPRhL=Cnbt z&Xe;EgDf`<@}fS5U_RDh(mw{xxMNV0yR13#-y@g%28BK{=oI!pHmL41=6Pw*qE`kj zc~31L40?c=kM!oVK|v^nHSqn)+F<}z;4v)U3`&m@-x>46Am@Ju^}#h9{K@|DF>0y7 zsFOyc()%0rhsmh@7-}|Z67E}!a@dRtL-PQmss|d?4xtXC+?ayTC>v~48;r*$T*j_Y zqprZ6-l*Fsl)VmHb%VJc0%*8GY&T7=iFr)f~8+8};Tt=OT zCDN#KZlfkfaX&n9MvYD|s#7xGry2FoW7Hk5QJJzCH7BQ0?{GVpQ6KUem6Fe>0r`z; zP|&EeNGfd9TMR8?)LQ(Dl%htB!7TLQw`kttM%{y}B*zd|%BVefP?|oJF{&skp-x$& z9$`v3qip4k+KBK9Mh!=5MWYgaGpZtLqjeSXM48_ihvR=3)v=mU!PSjgfaAD=>NSj- zS<|Rxc!HpSx zTVhnUl}5F~=~YHmT}%88MxEGX)QHWj*%oTtYSfzTMkVj0hF#Q&>lnG0{j`rfjBWO~Bhz__REt!K>jg5KaWTD&wW&nu()zGly34Vr#5YQiU@R(>|h z_{FICW?zl7_^O1}S4*+X=Br16zUuDq)du7Z_Em<=zDmXp9LegdZ7yFOaQo^W8btdl zDaKds1YhmW=BwJdd{w-Fug0T!L0|1bp+deoR>W6-mGPCitgkxZF}D8ht96ZhbqLnR zzIuUiO?6`j$1|~H3)ncTz@Kw21zS`f0cx@Tq&R2=;eHGDx+&lWJZYN*W?@eBP ze3ieSuPWo}U|+2m;;S3TG|X2!hx_U}&W|AeC|^a6@ztW~)G(9W@d@5pzM6v*aL)GC z<~hD|9AEnCoXt-;0{rA3=qD$NW$;t~jDFgm$xp+x`Y9;PPpi-_+)rC^3YlGgdVyUL ze%c=Cr=l@_s)XsWe##W*r>f|f2Bm)BJXR`qaTsDINXP6306E>26m)o$KkRTgcJNPiN4yx1YXa zTpvG0_4U(Er1tky0eA-ZY05x9Jw*ON%!7%jKbUh-Y>1z>A$h2u79!m+KaIdQd>ZMe z!Q=fDHi>$08apQYY4LPFWtico!$_X(C*vIIL>)Aq>!(5U{j>si5VnAvQFD=>5*GVu z?M6S1+{f*ce){`@pIZIxC!eeI8Rlz#8g;`@_M3j{jbrF|%TI4n`yYCbU$^}0Eqqe^bqdc> zHq~FBFfh$u8?naYue&&!-CqrJ`s*8x=JMC)JjBoIuiE+i6_ejzbqbMFd4IL2NF3Cu z;;)MX$!(;+TA}PH@`7VD=i};lfAyX~PRsq3dxgJJSNbbrmA@vf_gA~k%=4GOif{Lq z-)?_-5BSqtf2~8k+tmHkUkd|FT3|P+Z)TIGVmF>)dRCK`g_*R(Wzyf69brV$sCauqD(#KpTMdc=6d@f?rZ$(WCEN0Sj+(o+LCjEiG zk*|bF`$|#|#*{W`ChnFYU-U0)(nEAA$M;xL-Xy;YCT+zbJVCRHCatPu(kB%A&7}Q! ziwadt>VcIg{yQ~cH9lk8A10Nl%2%wYZqm{kCY`Bi(j7FaWs<9|Np0{D`RbWe8dLEC zmFhD$9yBm1`=2J|ZD>-pMx2M+DAAZ6;RhT|O!780sSu_#=lj+s`L;3XIliD*I}=Zo zOd5fZ4kiuiME{Z0*`!yv--R5znH1CAq)fe;0|)!kpZ+GL3^1w6K$GfY(;&_t%=cIe z=MefZ%p~J*lhThcDQ%QVtQaFsa={_RwV3V=A|?9B<&9Zc+r!;PNb! zs?H{_IVOIeuy^K~v}L|YK?_WpyTqipW%LvF6(*HmZPMZ`tjAV*xXq;TSb_T(yWJ$i z4wEwCJm&2)so?>Wy5Y}*CLK6TzmJ;K8@ti{80&bP^~L^^>}TA=lv5@RKf}H_%be#- zDsq86agiSU&01eFY0njUevL6myUu#xFYLHUA8)ajZnH;`@eb>Udgy^oSbx`~!)Skx zb;0Kc)bxFS#miMhzy(5#n@%<9wFth6R()yEBdX=+y4HfFu; zY?eh&8m(E7~aDyM^Ce=_A=`hGWVgcc-EJ5`kA$%zgf8knAKvSS+DQ| zs|J}>bg)?`aTOoXbqF~PHOq@dc!y@g%sPec!Hk9-PEuY?{K@sb;mq9SoU9jx)>}IMb|gSdHXaW?jP* z)SAuhIpl(x^URuq%nOKty$j7UETY!MX03r`saX~A5<{1nm3_HcMNkiq@c{=`m~|G< z(Pkxct}-ihwOM)BnN#vzNCJdmA?)(^&AW|cTeuTQZ)xQcG4nIAh) z_Y8fYY)dlvWb6SKZE{y*k4TU6CzQA6}Yu+^e)ti&Z`vssir z(4r_5!7+3WvS=_q;aG@8cBe&|ksC+QF`Y#N@g5yQEh>@TqD2`kDwElwvB;a1xeym_ zQ5!fSEUE^p+oH;N5M@z(v_IED(b78#Qmj}-ic8aXXmlFOovIE&i3E%MJp z&KQZa`7KIUz@kVL!bwytVo@uUC~46c%*0kSEoD(B)GA|~Dpj_q zE;{{Y(E+rrVo_hb#t(G)-J%PBSk$YkMY*aIAG2`>?P}2Hnifr}#hkU76I)TYjz#9W z7G=b#hQw`T(X?h3EyjLSX>L({jB7=0t*NaIwV_*Ei>}}SvbM7*PkW0>;u-RGuqdK0 zJ?>}GXyof}QQ!dL;S8Rk&p?YzBQ08noTDw;hq+@c`WutSTC``pMN?<6ZrF!EW?Ix_ zwne??So99_=32B4{pPWb^T~6OMTgOL8~xZxZM!U5x|=oFL#}(-FIa#L`-qM22Q0dE z(4ww~$nCI2D^Tu;MK6(Xj6NdEacajE1fHNbCt1T&^zk(N@do?r9}6$eS`>!Q@V&!2 z-?M1*eQHI}BkK8=HF|8(wf}o!(Uhn3>6u0SU$D<#T9gFmYx;$m?<_k1o_+q2{rj2y zhoCPO)k7;7zgjfnJGuQ}fBs~Qk5!EgR&~SyqgCh7$j_?N{#Fe%Sv3xaQPgf#VvtoX zhgHewjQi*lY}MxUR&C3`I6Ot8j8?VBa+Jwp<#kW1R%W#-GSaFwZmV{nN|aUR7^_0j z3?XsEMmPKwZ`DEMO|WWqqE#ypnM{uOnPOG#RI8f9?y+h${_t9P-N>r3NXc&1(wx+i z%c}U?Rvp6=%*bn1rF>SND_T{ufK`(UTD7o{RU->q^#&h`T9vOjxuIAIt4^YLNvo=3 z04C!QuE12vs>}#0ZB^B>#KJLLLU4JjMnDyqA44lz)vpr0Le|PwUBs;4th#{3)vVfx z57n(|TEnVkc!{F5tQtR$af|37sx4-XmROax%&OeWt@?8Xb*!|i*D9+jtfu#Ct(vge zs=3(r7i)*kTdn#5{~hGE)2a@8ta9(S>UT6i*#lN(J7iVFF{>Wn4XPifk0%(5z6d+X zJSca{s-CBN{+_dH%XxZn$*TI7t!j;X=yHW|_;S^%XVmxYJ8Sa8 zs+^f@DxcY=h%7cO%W9K3+@>^_O_$L<%BJubo4&@{bRy9vd$LWLk*AnV9dRA`i`!HN z{ma_avZ76{N;XwMcPz$PIBMAxhMjddudYo8@UDqXztFI$O}*f5VN-2vLd#a1hcaz! zs)qb+ZJLPe?QB}!!KR<6+|j1*oo%|-#ijyXZR(5x@abk#)4n!!g{z-Up9b1w9As0^ z!8Q$t-w>M$qaxCV+Efs4@e3n{G4Dv5ZX#)vP0g_qFW?!?95{t$V{F=v_Ty}tK7n&! zo@mn^oI>zqn|{YfRGezl$Z3qj?&-`w!=?pThfK4m4~?;JwoQZQP$xX|Z0dl1I69x$ z3v5b{q6?`JX8C?@0ZW}AGsP%F0LFcP-XGjv6dZS0TjHvNkt zJ6L0kz{#D|vx|CAVmE7osc5ptrbXC*L3`;HTJ7W9{WfJgU{i*J^yRQkg)rs_d7q$% zC#m@qdlfBD6YC6lpS9^WCY`gX{&|}=Utn!f=^{1%ZByhW_7F;3X5BI1icKk3=_Te| zvHwsP6Ywu`K42d{WZlvJ5&ig=9^%kr`tpQ5f;LZW zs`89I{M@D^$oYbJDDu*#-(J~t5GP-=R&Q;Z{obYzDE@(S@cT!b=6|y3HA;NuHg>}E zg*^m)Wew2^XA$v@pBd~&#_u*|{lPq#hsFQ#bBCAshUlO43&vmc9JjGv0Xk#|&|_nO z3it-73#Rx5=ucCC+G25VfYN0MQ0GX#$348lEjM4I0u&P+pum^_)x~5KjOBJ*fM#MD zekKqvF+dBkASFOKy#d;jJwPXsCr5y$ViCUO3eeNs0s4gMc>}Z(`SJzm3jW9+p!;ZE zfa6GCFhIZ1v`~OnVRqpFU8)wKTGa#eFUHgeP=}fUvepXFa(t^BpngpQG#X!91gK`m z0BuE)ZUH=J3eYK(>lL8ly#urbK79k!W>A2(4G&Pz)Bt^75TJ~U=+EK+mBk?3!~C@Y zdW|1ww=O{Yk+42MeQ*MC8v@j7V}P!r@#X+^+D4r1^bFnb53277(81mGdJpyN4N(4l z^kqN2KEUyV0h(}#n1=)8e`K0@MO~a0(E4*{Bp`N;G!K#kA=SCI6HSXhcr@cm3*aRh&(;up@tTBLrZHyDn0 zDDo{pw(rEm3_Qk1booJExQx>OaSY2);V1pTBZFNIqg^er3qO7B%HwC(2s}Vlf4i3A zGg3`<9uL};-E7woyg(s~T{948wJQf&VgUkecGbcz=(7z4vNKin>Vmt7^X1D~)r!mdh@b~Qvhw_X3DQj}fi@d)wJcGboZOp38< zJ075LtX&atXUENFB^&A;WQxlA3m>2)STGp;?=!(JEP~NUvxLVOJpGtN`qb^$FIQCazUGNow ze-NjtT}7(dRS{!x9386D-x_wULd%+V&97xwf!cPhLqr|B%G9;%G$QKRH4Gc@u)bX( z4ei>8ZjCsO4UJi!CU!M$N`B3$4SSKUC3E3z8@poL+I0a1+SyeWOK`nC^><+HI#P2d z>hH|jjk5Dt#jf%A3jfjMi9^sB))7;26`96z495{SjvR3h1;&#XGEcDU2TDw|YZjIx z(~T2Ov;XlD(Hra$R5I(pQ5w2ho$+CksZaVLGBw7N4}M`Wf~P)}3W7 zF54A}a`3rAKG=iw0uaQPec ze5Wrz`5924{xt-uf^VQEngVsh9H=IiKs`n?TcAP%0yQ)wP-D{tYJ6y*`lS!l{S1NX zmN8H>@elH63RF|<#B+?#9H{*`18bH*o-YLI2P|0wwGQoFfl@@E4*XwypiUKP6Cky@4u}El?%02kIL3KKn?60C|7@K8o+t@ig5!2l{lCl4h>X~VS)N%1al$Z=s@Kh!+m1|m1$fcKRNG7-OQ#2_(u_deL)V#sx;2}8=L9NtZlEIP z1#10#@?03GE}H`7vz0my1#0(k`g|f#DR}!gx!w%a;M;*Z8y=+UaY2f!8>Ae_&?QLG z7=$f209RMWpfSR`1t|%aF}!<_rl4_;AT3A7o%1T(pc#%JcmZ=Q2~q`^mIf(pMUWa{ zJNB;((ixamGxypc9bOlt4x55>2OGBqY29{??+Vhxy+JCyKS;+81?k%1Agw(Tq{pX% z^yh^jJ-R|KZU(95y&&a&5~OOcg7o?WwSEcGnE!$_%g3SRxM6hg7}+6vphKB4I>@2Y z4u>}3Gkk*`Tp!`kQq&7^XcC@eap)sPL^!kf?NEjohsK~) ztV2^09LkaCP;44==W=LsZtlriw-hmy)U)VaJv1u8mJ*-MTehv*9=+LFX z4&B45p$;Vu=j$kH80}EYF%B8VI`n9qL)FGR)Mx^6CQ;X9heD=0)B?_F4%M3OkY}bt z&CnUEkvf<2@D9V~IpkeL9lPigp5yo3^ka`h6L1bmdmYMyp(wPE`wp{SM;vN`RoI4q zk2=)uIP;!h%}zO#?TkZ}&pK2WGtV>s1&3au<}HVY-*u?XJ%>#99qNXj54i6!eSYH5 zo~NAq%)#|H4qbmvpI)(VUORO3twXauvYzPmh4FZS_Fo<91KT$T&)*z+h*JMKbQaTo zIrJ5MLW8vfM`2DMtYaC1bv$FRF5^t*U^NU6R?CQBwT}!|tUFlG@F*%+yQ713Ehbn? zVuQ6lK3L0>g0(+6ShKPPYi{mf?a33Ye0dp{FIYG82P>ptum%=lE-Wd`Tt$O5v{q2yNeTZJ;#g-6F*&3pE zsJcBwn-R1lM1NolitY^215DZzq9%JoWZWO3IVg1?M5Ez2Og*@aw4)*Fgh|Ijcs(&h zC(+?_h~A$e&e;$hx)h?rSIFyXi2B_K(QyRa3{n1DAzJYdIo%1-zy~4n|2ITapN6RZ zs}Rk=DU5r~?KdI1^^2PDo16;uacV4P;e^4djz*_0`Z|^5=hQu9@pr0+$*J#fn4P)` zgT<*JY{pcpQ?t`K)h4}D8_+b9Q`<5-l`e}@!*LETvpTgV%&8(Sr&1!EY7*(xz-YuU zcbrr2uszb7pDpqrZBj5O1ba zb@3jWBv8y|6QiBrqgF@6K_c5okzJDsY(n{~q*l-=Xh zYCJ@ay-rO+?tM;`#N7Q(l|RIBEI;g2U7aiC6x+QT7^)}{5@1PYlf;VI*ka`Z(~E1eR8M_OG0`4AIfWuq3W?WRKpL4 zY7;)A>*Y`d-wM_9r=iO9EL07jhiVCS;21owL)E@$dQI$;UR8#qSBX*SHFH9G9foCM zdafNyuj5P8EAei6T}Jiy>9y*6dOg9O3>mnND}&}_%AicOGpJ>~3<__RL66#H(D1Gq z)V6;Htv!}O#@Uo1&u9}hG z_Zd|?LnfV$&&1C{COyrSNkdC#(#%?!I+-aM!HzU7c0=)@9X-<5~6dL{_eA z2-ELapEpd|@`b51_Te;E=MPh*0%1Cjngzpj5SONOZk z#^NsgONHrd=`d|78>Z-TVOob?<->Fv*(wqfby4y6Fx5u>YGEpiw|LVyOvPG;sb{+| z<>?%z1-OCGE@6tpJap(9rYb$cG#C@{1I>DpFCuz{X#=YE4%11D=o6+|{W*>SIEjLT z!<1u4m{Nv@DIeaW-moxzM(Yt_>VchTJ~B*Qum#sgh3PS-j}FtVF<}ZBAEwc`kJp$s zAxs}9asT8nt`!Q?W&}*3H&}p2NS+#|rdW!9v2q&cBWyZ7Le3dsYLAuJJ2On*ku)nz z_pop_YlK>J$PF3iavzcxhiU4PFfB&*rC}<$jQsI*b(lUOW-a$)2WD;z)5y)#fKLef zi}l_frW$C96DYGMOpEq~X~ureI}oOGXmgM?Jw$&{|8SUE91Bxd{5TP&@C#x31ApQY zieC;>=9}yXjKy&bz7?iD$b36YbFm3)?@$Ns-3!x~`(aA=FS$Gpu}9)8?O58!j-puxJGpdS7fJfHR~L%GhM=E??wzX>JhFoJ;U`4`+JA$cAs#) zz>j|68reTw<^kdI9TG0v@NlJ#2bx;8IErmnPJ7X>2W*{=+}D zIab%D4)CexQU%PY?^3=$U5aVwlA)1H+0YvPja^y?XA_so!QGT`&0MOOds;OIrx3!#a+BY<#yzTbMSBP(kLwK;L;sT>PQbz zs*_85(V(+SZE*~jF|UhDPf@cQJ?QSzb*$*&lD(%(S#YnHONqT*YJvlO7~j{W)!5VD zrA`AFkIsYX#Sr>B)TK-lTpBio`lq?H8UNzw4C2isPpp|m-l#E~_;XxpKi8$8c`iLd z%0ibS7jX>NVOi|b0K8dB50|<04I@^Q-x~U~$)##&j!Br0D`>cxn7DzTTU<*2mrLz1 z46$2XDv9jdTq?hvvFNeGrImPq>^tcVPVRE4;%=83;Uuo&7xL_JX(-0;b!iSF_PNv- z7qI03^&BL>BQ8C`;G-`64fipZ4&vl-;vo10y+$*9M9GuHImKGz!D*KYpLMDFC6_#x zT{?~%7<1L7nJ9Ukns2Z-u@STGQrkm%_b+?mu}dwG^o-h`v*$4y`%v*A{5ev zI4IsNf@@rf*F8ecUX1S@p)!3UWbDh>ff1@XI6~itM`-Y3;;)X-btJAKzqJuMhvn-c z(i>UgA9{-5YpFbni4p)CgXpSPa$PlRw$nG1dBe)k3smP#6bqtBrzesRJ zs!m*_MkPfmB}b&z6^K;VI*}^fK2lG6M9RD-QgshU>gKsfO}r4P_`f6Nx*Vzd=yN4f zSJ37vW3EN2_mfDic^S#SJ&|hhGg3JXZWY5tOfkB(8aMG1*?ryW3%8$JCH>usGr5&w zcIy>-Tilw60IOT&@E`0pw>Ba!z^yhogs1q|?&c*?VgmRj_cNCjPSZO0|l~?7hYs{t5puSx}#xEw?^i2>joZUOJ27Qpm|~DD&p2BEHCPo zZ!xz*FbWS*r?^|^;V9wex^uUh;w1h<^^$H)z{^r@{axCvyU0++t^76J>WYiC+`3+y zI^b^X*1V=}{c1*!+A>djw^|Hy^Sp)ohPyRr1a+YFNVlq@4~C6$%V#V#PjbsL->u?U zu)xjx0B)^8*dn(UE_SQ+YHD9gymf8`ucv1lnfHKOEl;_5Khv$cr|CN`BHI}^@AFgR zS+|;@H&);;d`G!+Zq>v^bUg3Y?h9@n$B_R;w`$=S9Dmc(ORO0Judtq2hQOz+|Mk6yi^v=p202r<2* zlpS-C+9yiRzEPTvTd35JTyPZ|2SlmLuqZW}L|!waxDF;t+wm1eW=H7=%yXiYh$c8N zH%h_tqZE$x3!+qdWt6Vq_=YGMHb$wzrYKe0Ogs$xzpYV<-xj3_yXfn_C}rFqrDn&Y zG!z$5{6v&aV$aDaJ;xWcI7JRPipi&=^a)eXL@DTOl;-0udY$8Z6gp2Wn1&ZHUx-r9 zzd4R2=y!?n_=*izqI4f2SD6<*@DEnqh|)t8y%nY8+w>f*F!+9ywmpo}gGW&ceL_sc zKO^6lQM|7nrG~Gm^$oS6-`6NL{}!dL|3&Ep>M2@%5a<)F+GvgwsAz~*9pp7e>k?M` zM(Z>D{Gv4oeIL|e4x!5k2+&KQUx4(^8|I9iuOqV)(> zozZH9Ch4QOo-tY-GDd3v-r^S`GDqt)ZlPipa>5e)mNi;`;sWkqRamsP;c0lZ>bs)V z8jFxOB3e_h7#rNt+5^9+Xw5=eG_mmnQ(}mV(Aa22VKScLuefOCj%R*UOo)~(k+E2a zCaKYCmKLoVo@n*;Myq2sYREyn+|g>BFIra$L@R&6Xw4`@U$CGsIpBJcXnyxb>v_>= zS&MNWp5kQjXk9BAtxTn&4EP3C(=9Z@m*Q7=X{>&K`WzT-WAwaZjAA;)Xi#VF?-HY; z!(-GN*G3R)RE*kUE-s_kj2I0-_L(s%juVKT9iy;0F?^OLMiX#zZj4ILi_r)i!tRAJ zI*IO!Vid9@hHLR-v~op^UL$UOj0XP|qdmyHEk+r($0!1!|O3xa3e-_ZZhAk7+pn<+cC1-iP6O;F$#Ff znmnT?&tsH`hA8|ZM%!P-=o41HW=*i_O$^VOV)Yi4TE!~5bu6E!iq+PEv3i4wgJYF2 zBv!f59AAdT>W|^E+CMT@-%w+8tWw9sDnGWO@Yqv)B4_LPGJ+f?%)s|DST6#8Cn~-=eR_k!-d@PUWVl@YaE-^REmt&RjN~{`R zja5gaT#MCmRJWGxAaq1Nwr|oF% zic@d+M8v6nWSnNYDF%O2#Q8 zy5kC-myJ_Gxj5az3v?<^yb5tzQZY`OFsd?nR*BPeEWwScajIN9j`wZi^lzOwO{yEG z`S^fs_2SgCL7et9W1i-5Di8k_aWb}y zVNjepVD@0*jfvBp^>He@IZiuKZA+Yfo{Z!Awm7}UFDyPCr$5feX$R_Dq9>?uIZkz< zD{<k=w`i`OK?eCPJhc;#1uF2c_z zfzKo)=qxrH67&ErV}hz<1kNC%Z-Q!LA?_g9FF{4o0ZVWlX8#1`MJFu971&J)DulL} zhqLfCCn!JKV<|4f-;$t$=#AC51&1|3MbH83(9o8kj`)nK_5_s(OwiNN1bsqy`UJT% zC&+_I_!yC(w8#XFaVKbcRDzl$a4x3jN{};mf+}KF9_r4Upm8{ab_EhN6xj+U=rz(6 zB9FoeN?#;For@+Yu2_O{pmoUvtwh~Y32K9Ps9c8p%hIa~^krLu`Xk%+1Qo+^#Ox%_ zo&*iKnxJQQ6IAwb0`K=GDBqI=l|#_e1cjmcvjly^s^|3eWrBWx#TvZk97Mk%-?s_M z`Hr|a2gCaWJ^q}a$S(;zuA?X45>y3UvE^5SUZK2CqOuzjRRlw^%s)|gQP7+ynZJB6M2s=QN7@kAyF?7kugyt&@*!)pQ~nkmPFOc%6L~IziSe8 zEh15MA`{gCW_O}OQ3*@%H;Tk0s$6U$&r=f>kUdc?b0jJ@C;6cP`s61Uv@MXRzAzR{ z)SrbCm0UPc`LGS&(7Q;YPLxX2o(hTjj&&6iwHKW$B`UB^qAK7Qg6bw}D&Ezjp8Dk4 zB2km^rez|pAtq`QuAsq;M9svfnTc97D^cqaJv&h|@Yk|Lo!_3wwYG_xwkJ`SFnn*K zrXy@0{n<|q2NHGgbfR=7QJZlHJAzx0DpZ^t zOD6HVAW3!0Cg~+UmZx78l2oELJ;xg~tdpb*cz_&rlT-nX>d|l5>QhUDBrR{4Bx~y= zy+ExtNh;nUNdu9iBe8H2ah;Qtt_%Gbn54P*HYiE=hEO*uj7?IV@kz=$DM_`bkl(Z< z<)6+m{KU=~N!mA$`>|nulJ=w20(!qNNj(=O>GUp+@8vi)?Bh5}?dSM`BsDmgq_)SC zv>NqKB&i)TpJYwW^7S0+hJP^ee3F`7VU1AZD(j7xD0e+cZEmm^|6>hc`Ng{66uujh zd48F!7x;lezR9}dm(1tAleHQ-Ov!Rsl2r*l)?_|snyl&gU`y7CfMoRvN!C_4(N-Y9=dFjbzQPo2>7DCM#R(WX*@QO|o*gCFl0Zn$#hg z_jHrByj!wN-IFy2M|vhJf3IY%LYCgix;!9RFHvMrvi=y%oG3mdSzpj-=Q(SeUH%Mae38AX)u!>macYC2JcVnsw^BNP#tEFio2*~=Sg-rZn)V=B zzduaox_*u$@^P~2VEYq#@HAO#@b()yeP&-Nx*g6kW%d z*c8n{?YI;*$(^F@ID*o7Qq&#c1&E8Ff+=!gDGY^E`1d76FUzMWu0o22R3yJjDXNTd z4O4U){TrodJVG0%s8f>^?QELDb&e@o3v0g=?Zau9`lo0)Zj4A#x{)dBI4VV9qf?ZK zfwNPz3mNC8=rZmj%e)j#S(u^>i&8Xb8TVt{iWL2`GDRy_rRV{Qtf3G1iX3ZGv;e!d zrSLd|e&8gWJ5tmTA9to`#xC;QouV$-h|GIZRAFz5Mxo%o6jj9E@El0dEj&Z%gY@%Q zibkJG(Fyc9O)n90CPnSflIOV;C14O-f2XJevRx(a%@hs8gIlcKZN_8m1J(;A9;K-8 zzl_0(S1H>1Uy9zK;xB3ef8|BNKB;Ph6yH>}4^Guu{27v}4oK%r)hIm1`Shs@%#f-B zxPY!1Q}rAZGNtNkM5;PQa!x|3zQdfDs`xso8iM@wQ#BqP8mHCGTaax{D#p$!k@rmaa)vx%H{)d5AHGQ`HTW2x$QJXNES z>qM&7oaFpdsdAm6w)3fq`G>f7Qf0fFs;y{nFI92(Q?=+Rc|0Qzdz$hGrl}0xqlhDo zzrmHJr@?8OoIXu&&?sY?9%M>W?#yW_f!D~Mm9JrG8sbWmZ#4JEq^VYH8vl-`sdr+U zuHXRzQ`2Pjq$w2pk(4b>4YH?cUXC>Vkuyyf3#Dm5(KL-ko?@JXxZ-JQQ!7o)>!k5F z6w~N@+b>O{2d1gspft5b{NOYlm_+`Q)3g}Prle`m zj5Jl9nWiSlFe^>9=cK9Ek~EFOw6$sKu|7>h;n|R;H5=2ExG7Dox1{Ol!8A=clBT&R zbCmp${#crxVdLpEjlY~G_nkByyT|Rf-2RZJIVk-xO*3!~>p!PyrjJK{29FA0ozbJh zejXjiWeo85=%LA@cknfP)DqP#9xV&-D5Kq@7@UVA$fH3Hk9vlBG&4QNQ6+;%OA(#X zqqngh{T=7go&?TI^k`HLkN!h!UXQ-OoX?|({2rxZT0xIm6!NGCW)=2m#s3xc=m#vt zJlcY{2rubTC-g^RDUZ6B_V9N}JepUI*p)pxSH+{6e|VIynn&xg8_lbGRJ5i?mC+DK zvALEVKe6(fNA<6Jbn-U+z2{N7Pad^Gcep=$ z)aZ*xm%e)R`iDnve$peX_(cu!%IV`(O+T+1rT3~~1}~q>_wqWnm(SySwIP#Ncd~eu z-{sXr%tP4-uSP|B`CBwzJ}c$rb!M*?pnRNHBTy~btL$lB6~S|~^msMb>s6)fUJcIe z)zgAr^)5{Ol3v}wV@xXL)u+;4`Ihl2J$j=>S+7P{^y&#}SN6)UikH8?#r<&p?o|z( z_`|E4)tI|FHNaSdF*Us!U(2hrwY}O=->aDB%!`jLyqeX@t2g)$D_Rq~4YAvKmD-WH z@LwmdW_R)OcWk|C)y>Q2Cg=&;AyZH4?B!KRAL0xk4*tW6fnFsH=DZacdv$k;SFUN)GlTnQdG%wCR~P4c zwQ`dSE=b5_1^F*78mfp zn(hM1sq2gP_z#!jEe=JCYw*Z0@!UX?naK<~NuUKvaczqi{&;bxxKpeYErk|$Yw_Y% zoZ@cp%Ukbtt1HEC#Wlcpju zk4Y_Y37IA z)G=hzj|nE-z|16*@`O!_Vja>a6AP}um10trMkeh-rY0u&o3amzG@}m4)0})$P1@PQ zq~k43+VCZDwl?X9Z%iuGjyknBac%b=3+p zaU5A6*Ht`vVg>G^%#*r`U@{IP-P5|Nhpt$RD=6@+u98u`ZarD*)l*YjJw?8(ry_gn z=}Bd?%2hG5PKa4Ea1q6;n$;4saTfWinbjU!kfXX;srUtHOlE~J2&YifFtetoSzq|g zs)fxc(9o>sIGtivhsI{Th_S7eSKm#E#z ztlM~n^_|Vi-Gi}_wx?NnFb&VXHEYdxX6^pbtaPKy{03sy9yAkOtnFl+A_R6d&Z<(Jo7WIQEt%c>JEpnx^s9SoA-e$9?c6N&<=CJ6GoE9B`DVIfm=CR0E zz@kC8RM5g2j27)jx55_9!_?{){f#O$EP4XfwCG(uixSNiHLlMX_%Gg~HFk@(;vNQg zEIN)`A;wQ&U);jcM2oT{S=1(Mku{mVnpE+M=X37By*W(F8pB#-bJNEZT(2_+JNdM4?U=J;Xbd=uF>uj5Iyij=8-o zI*U4eEXv#0qLMJMsUJD_XTRYV)yHF`9bwUM{5z5yMp@K)xkYpEb_Myav}h7Ctg^_m z-lCp3w!xzLzghGPj$`&V=4GdalPO~pw z{bSLzvlf2mvgog?7JYG-Trmfu?pt&ytyRU-S#=?URrxbowIGvKt8w}ht8!v35%rMOimFsy`CQ&F^}RlQ4Dfp9&86qAl$EaKN1PMN?au`;v zOtk7QW+z#-3N^!4jZe0!SqkH}CI*fYnpG37TNQWTs=lcDpH=m-8zmoFbs70SSd|P` zI#hnl!s|3PElz7wg^V_}Md3^~Rm88zk;TTcR5sm3&a5_F$Ys;Byf#(MXVa+sHq|X) zle3~t15vY*O)eZj*(x^Oz*DTLYEy=4HhrjRQwN((%MgjPsUw~sA>O99$ZEIg2r@cs zT8k2Xn_|e*z^0N|iVOkbLfRyote76QDVS_ia|}d>6#7S`5&h!{5}J@lQ=2k(u<0*k z?P$~2oop)7*{1Rcp?VjaI-_J)n@so(dApMXo}y6?o2Cr5=>&!iv1uxtLv8wJ68lfJ zDa{PF&9Q0gJe%HO^?aMQ!Lz`|@$ZbW$floH*mM&=tt3WNTV>PeUu>$k+NOP*$oqGj zHeo+Pn{8UL#io{j5Eu61@Lro5?6au}etbfH&&lHjdAwx)UQv^>acYC^_zSbk#pyl% zDj%oIXj36h4=b__Z7RiSEnef(%5f@z-gu7YRpT_eS{&!R#OY7msvf7!Cbrdx(=7OE z#;Fmio8zQ)jhb*F8LiL*gE0vUu?~+gw0@il+v7OiBu;Ku9G@TJ z)Y(g4Mx3Vm<5Z<#oOTA{)Fc$As*@NivA$+yi&v>}@!B*#UZIKcoWl^WK2zeAds@7f zOpljsM!b&Cj91&)@%k_)UQ_19tMY<)Z7XV5<6?IGSKQ9}-gds5vuh=;ma}VT1-pK( zVpsXvc2#a*S9^Tk(9ZaF-NTAxyBsNY&BpL%cI`p0=5~!h{ZzXOwxVxjZEaT}T)~uKVqL9<}Ss19o-8^g{XZ|pjPfp6^^k6Q2SS`O=byS!-~T8^{n9Gr*j(D&&b+JoB& zWpJ8FN+wZTPm}3y3H?E**5}!eQDRai|ei;`5^pE&JP{ztHiRLqA~6 zN5_fx1pQthN4!U_iw>DTy2PB|=w*kVp~w}7;*fxgD0w_P4!?FN#~X)^y>;j<573e)2RN72sqNXFI*#F`ol5tGQ(Z9; zNAVPiWt^IgJ9t{wsix)F2Me(sACR|#Qx*)sD2%P>RP9PmZ9=umP6g1qic>%0v#L&& zMdC-*oO*<{Ca1>LaB2gN)pY87ZKp2OaVk$;r!rZbDuK30Yok5lK8kbdA~M*WsstB2 z4yQ^xiPPuQ z=;YLIIM~gp$H>~MLrmVb$HdEJ_b4U9`=!p3*Q(gYs)z`W3E$6 z@d5?bJJoQPQ{8aukW)Dh6U#AT!3jJ-!Q(hVJ(24awZ(j_!^MwIJJtV;Q>XrM>Mh(C zoobIkSa;2-v$%JYdfsxX(|xBVA^gy(erWN`siCmEWR6hs9dV+tTympgW|tE2^(QX9 zE9_FKA}+Nn=F%htE4kDIwyHdiOD31H)NmVNQs(bnGNEXHmz?+862kZBcf*O93pxQDmG+47f7erBCL#G-9DkzaY~h;>46C zE^Wcr%Ul|dIjddTjiSH0Cs{)^AAK%GkJwE!)U<*#2jG%W49jQ!ZWwhJ!d=YFWkIuW*dsWV*ao-jYnB?c~lMV zydJg3l>#2UK#77VLkAB6ukNh6>Y2Z<& z1dn#5&~Fourr|U)xA5@y*P}MAJQ{^G?K~=ryInlW-PNPBJv>}w&7%(JkEI`d>tStl zkJjT&FONF*@o*loM|Jyplz_kSqQ6I326(jRe;%Dd{=ptq#Za6>?I9j@9qQ3a+#lvq z^AR2m#AfvVk=s!oy~c(y9(9}OQOl|1g^S2A&7-0SU@o@dGMY~JDE=o8-wk@ScP_cj z^RTWbb(+s(3p}zd@vwfUN5z+V^d7C3c{uLYBMUyPqzj6 z#_``g+VZCH@a|D1vHvY`Wb~>5n!u6CtM}QwGRk<>7~L_woL66!_bOKfueMk8>L~hE@~UKI zuPjw~3~Q@;wI9K1Ud^oT)i#q?w~)Q2SHGf6Ew7UCUmdTi)bnbe%`0CVed7*_+Px~| z@^bAiuRim6S@+J%Iu>57YUtG#Yz%l+IpkG)Y{0@qucAp_eG>Mn0#;x@ZlPteS3PhT z6;l`oU*iyNBXcAAMTy2<#UX<8c!gq3yz*dXQ?E9oK{MK7G}hr%bN(G6UtGtcs8_q- zih0!nL$Lze@vtRz_{z(9N?uiK#rU{|)@{7Hiwa+R)eO7Qt}QX)n{T`-*UqbVJ-l4E z58ryV7xlmMYQzw)4i5Kf*k~`u1b8)Tnpcyyd9`&1dF=FR@d2-eId)KF&?|spJeF*9=;l-Y?mk6(`c(Q`pI-F#DSaQG?jh9Ir&s-aYSrJT z#y|LUW1vq@P~d+)jl?;8G1#Y$xQgaOeA~LT(CLr5xpT;2T9^yk}uTRzXu?=V8-0xEY zrr|bTAk#q}JLFTh!#-^|?$d{p)abHL@A2~$<^XlBQVV3g=2LH6M&;`~j#B^nIFFY4 z-tehE{zKK9KF(YA=~sMp%cr^c@-}Vn__PQ4?oz`CKJ|RcW6ylLiPY!Bj63M?f?6Zz zOP@O9Abx*EAFt^ju{XpF>sxZee*FB77~k_8M9B|6^}_}Xm7yYO49-I|bStf)J?RX7 zZ!}Z}1v3~Lh2Jt7>Y2&V8XU-MsBRWR^N=H}p>J^+DW4eHhZ@-o%|W*8hWg+-0yzvV zLLjHXnxzKEt{7UL$58B3LmfUd^fPwnGn6+!ePKiaL(dBudRfTO_`-(1D`F^pQA1Nv z=5s?E(Y%qdydELHOGBl; zGV~O?TN!*uW+;SC7>(69j>pK|#!yW(#z^cz*{_*L{EbR&4b4WCZw&o`uI;D;a8~VHpbAwYz)6GyrOoyqvp`twutw-9PhVsLY({T1TGy#JL z7`lQy|07nIhEVenhF)ONNap27>V(^!l~f?{)cPR}(oah{=^^9{wJ0jB@V z{bf9laeO(ku4L|TV3nb6zwmrqO+Fa*tDzHUyT;H-^jORMtfy`pczygv{WlpZ@VlYm zTgdGX#zdDt4c43^W}LuHByA;*oy5P(P_NyFhN9mdLlyS%`oiM<%+~?N!Nr4yG9EJY zBhnu>)c+{)zU2A+iaNdFb%$@>@;b}r zXRTtt3T5}JDZa|#*T{T++4KALBjy+OD{l$EYL)WqC0dvEEA1D4#mf4%zr0^{D)_Yz zrz-jtU&*h(ai+3g&8qq}3`eo6nxAV`&=-Ee1LUgVR~uxn<(CIf>iT7^=T{XokHc^E zYXeH!7#r;|7|&5K&aX1)j&*jw9^(U=I{Z2aztgWjQQgJZsN!K?Y{VNlynYSG5v29e zKiXmuZlRb#Uzmu$kk?N>7>%8H2Xh0zx?&Zsp+G~w8elN?;0@{q7#ADy9_FB*>nr%R z7WYs-L_IMZXYpx*Um=Xb9;8Y1%YtrLf(yu#Cjw5>$zkC>kO?ZMTP5m54=+|=GM(JkM3uCbh z&rz+ppW_UvDXybrs$UUI#W7@y_~pd+Scw}b7Ns9d#1VWJqfV{;GP?LxbR_rl1k|Qk zKnu~hd4T={x(|OOAVmYZ)h3`aUkCILZliPCfDU~V;CJMJwssDvUH5?I^$F+_CiD$x zKFakAXh{EnMh^(+^pJpTqXWu4CZN{nhP5a@HlT^vgY@G9+K9afj1Oqpgn$N2q&@z| zJDi*vP_=0Rb)ON?uV^(hpdNUQ#(3Fy100d;y7P+xriob4|Iti>MC z?)N;NKBy-6BtuYzF%R!E22~+*P)X&2N?$(6^%{d(gVvRT>WMdKQYEN!c!>X14Jvcp zpgeemEcJpKi+koE=OYF6$Qe{sS5Q~+7~i{tToXR1E#9CGpp-ADJb|DRkS-Y1rGwwD>Nlbr{(zs6)NE?Hgo`sG#m5XFuBY531ULpswKw zdi@a8sewTa8Why{2|*pjpou|EK!Hi*HaVygQ;2JAP_MCaT~L3(xjv}58-i-MF{odT z2X!BFPXx6ZwNC~$@f7i$4l4WApc>#ka$E~)5*}R-YVp58)^!PL6CNVC$0v@~5vqtb`eIYUU{%pujw z9#YvHA+5?8(xzM?4f`~t*(E}XRtV`)#gML73h89!koHyyX+gD+rc@7Uj47nMwL<#4 zc1XMGgtWOXebx)9uqCA1*lwjSdr0xlknXrbdhZEoi8rLvzL4e_Azi`*e@OFDu0cpc z8iu(3dq_nw0Qvicl!DCtLn?sTcrzfR{y&5?5zjDh2K`{dO!`5&S@biTHgo6)J#k<& z_qPxq4kGan^8Aw=x6)>BNS85jA967>X!(kCikhD7zxoT%Y>6Lk}g{E12` zkf`yviDCs4)ud3O9wKkyMAi#W)L+FDbrD~eNL1@mi8_q4r4#j88@6|%ug;0uj2B%J zmHWFyl^T?&tRoUNYht2SO-fXrdGxg)QQzYxPA*B*=j#*I4(m22%DW{|o&Mx@U!wY) zNmRvhN!ryUNq>Hoq|&XEl&fcwY)g~WW@nNHq4WME75_U)cQE`|lDeNx(lc0ch1Dic zSf!G}+Wci$+gpXTqjgvl+l6%qFS>`7tw&hX5&br-gkE7a>l;>YyzCd&uKr=Aj0)?? z*s#t|4y)XhurxKSMmUWYKZWI*A6A+LVLe(-znjB)fWNnd)%}mKhT;wS{TWuzZDD=3 zJ*=ub!&`*m2I-h`FsZCF7}$CwPsn)gYvuHx5h$!gy!Sx502r@sfgXnC^Q ztw`1u6j+_C@S0@SUrAP-jmg@8gFBOD+m);cF78fN?LEm_jM;mWHGW^RKHZoW&R(jjkLDIL#-*y{_*B)Il&V>i zQ{|eL%DD@vS}`M4|ISR+?G5y^F;z!5rRw+JQcPDB;vMsy8N@NQm2riJv6OX$BSqU_7K zk6UXavaXBBzzw`vA5oPJ5e>pvoI}2i5d|?HnKwn07yc~~Ek=`V5j{omqY)j!oeL3u zYmCVCj6P87IXU7sM!$;a3SPgCsKuLzI;V?jC0eA9stZ2L5Y_pNQ5DJ*)nQz~#LQ8d zvP88NDcRVLr-h?RED}`|N07B>R8AydCQc*Q=TQ|!tYlOt%SKhbTvW>{MwL`K$~p;A zedCO(USd?2lGrC4RqbZ9gMn}~LRmMaWhwNjcTu&^jUf4MyD*wbN=S@U)4m)Q@ zm1a(qYY|7a3%%z?HFjQ<$T=^j`xr1krZ?EMAf^I~VmgNw zi(_iDHm3HcVmf{%rpxH_PfSN~2Wig6R1G#v!%Jj57gMeCF|Pd{(;0jAsqW6NpQe$t zv|1#EoB#V?p*hED25-FRwQA#py)`cXS?EN|nF~iG2bTQ0;_2W))$%X<|LxNK{|5i> G_WuANJ6PQS literal 0 HcmV?d00001 diff --git a/Covance_UCO3001/browser_profile/Default/Code Cache/js/19d48a552441b28b_0 b/Covance_UCO3001/browser_profile/Default/Code Cache/js/19d48a552441b28b_0 new file mode 100644 index 0000000000000000000000000000000000000000..ef62e6d63563a5b7f1f9fe89d22fa27841747897 GIT binary patch literal 18180 zcmY-1cXX5GANTQho1{s~Y-u_`R-vUyvy<+mW$(Qem7yTW5|Qmd1eCq^9wJLXz`+KY zviB5JrXo}J(&zI#&w2iMJm+NWjUvTOKjW@h+T4wx+(l5)tW(abI6d|@_sArkp=HU#~yH3iuDFt zKkes=Tk=wR6pP@k z7~M)*Yy{b|Tw)U=s2~^RwzN&szS0p?lUGutOaz}vR&oTjC9;C{$WWOm7b-^3GbMuQ z`eXK+BZ5Zh5xglsNOxxh6}=H0&x#-+JAyhgS}sVL96gpPGA%!XLscUfS1p2e)gwr( z5y9IvRlE3WM{rc)>qan4I@gO}Rs9G`H;7}(!^wPghTW!Bpf{Lxl* zw~yeH4w{=>5&OFl%#ih+B6#s$1YJ8vaH&fKDP0w-yXH7Kf=N>%Ficf{b0au6Pj$|Z z;KKzGY*-jU%f%6FKM;ZWPz3${=WGO9&qd%qAHl(2BPekxf-j_-DUx+jkyJ28Qmb$z zV~a%cuk?kkigcs=6a-B+1@LCio-iSUr+oYee!z z%}Aa}LG4IZNwK<-d?GvRMdGg?$;&2@^lBDK`R0) zwTon5he-aB58sJoXvauKbdID@mq?ntA4!o9BKd1fB%X1Rgyh}vkt9rr?Rh~#-MkJM`(dyvf!GWSF>NWPWN^n-f$zDR<s$7B z&t)XlZKROTNK?O&wLv4zvy8lwj@d>MbBv_PG`W~-q<)@}9@UI&t7F7f*GTVriX{^o z8p&*AWVT#xY~-%AZDOQwQ^jp&WQWvlY2=m+eA7tMTSj(CbXy|>*e(qr8K}Y3z zPc?Mbt#o_e$T4wtHS%FMBaJ>VvPC}VWn{42m5km-7Rx(*)V~D!X(nR)*vMzHV6c%g zpBvdA-G&(XSpF8@P$Msf8TFpVNYps>Hr~i4IVwdb7&$S=$n?2JF3mI2V7`$KQfP^h z*l&%DkRz*%km7-x>L3tr6QgBW>2J-tUdH{6Wvj-5-r?++?K0W+Qv#wA9#Q zWYkt8&n0z_dXt~_8mY8TbNod$?pKY{>!^`mCHc4!>lGtsrS>%=W3L;jdrRl#fsrd> ze`Mr)iFjVkYJkH&Hmo z#I;H$Mx>cIVmHw`-9!Vgi67;CpNWC;mv{mu=E_Q$m}8=Tu5R;8M1)Ml%k-)y$~RFS z+1S*Cy_pG1YZLv%@w$mzStfViFmd8d6I0(Y@k-XbYht^2I-2Oy$;4IZ+ttKr8PUze z46$@K(XfY!Ei$dQiBcb#Xy3=gQ5o1z`TLs~FVzN^XeK|4Wsq{qnU58Fl8NKeaI%TX zQ%w5%*F>T$on|8NwTb;w{2LQr$+th4NdM8qFvYRx;Wd3;*#V%+zm$d$O6OCo9l>5U(r^_a4UNLd!wu#T~nDE~gBr8nnM z*yNZciX*NlK6FQMU$VSWERjuO@I_H8Gm7omQ54FFqP47$`?*oH%Znm5KZ;>;pdgCe z%2D{LMiEsliu%=~cwLIth+>SKs2N4oT2VwaRBXv@6vde)QFLt@#dpo3n9?GOlkKDU zxI+|wiu>Ite(M-T%6m~*yF~GFp!R>PwK8U?;tkW|;Za=uG786tC}v2D*-^}z6Gimg zD9TEM`BALf5XJM2QJ6PHv0S=uRxbmF0V)xVJZow)@oIfhd|BRIhSMIv$Q9 z`EC?l?nTj8Zi?@pC>F?thkEXD6drl)Nfe!B)zc_SKU04%qPX=kiZ-vJI2dWBiowj6 zMl+AaYBtlzVrHwXD`F<9sG0i3%nT@Q=8%+#HB(L;CCq#$PvXq{R?5t)3TED@Xl8zj znPRDCrdHB1S(9dFyLjwo`Z&y7l^mzmNi&z3cjUMvdQ^i%_{?;cQhqb(GE;sJsHUKq zkr`&5$;wPKn2j&AnFjUDTxn=# zMbZ-Ddv2Vy5?1GaIg%NxQCIPA`^Z?NDpS}2IJFiMV@EnJJX z;45UIUttUJMJ;rYrNt~H6u0R2EekuuT*5*vn}tboF5beS1PkR7Ep$q%|hOE^*=*(O3hgo7Rg_;Rofg3{&^NYm0j~K*cMu7FW)S(@MN)t zj$d0?u|&0eW5FZSR$8dB&caX9b-jf_a#OrNSePg4Wx^H<{dcG)DY4VS5J}mkUgXGb zo!bKz#+|fqOZ=xTERehBExdI>=TpoVE%cRHS2U07+9xNa>sVB#7`JZBA zrALI7L2_QQBCUL4urgBaN>`(m?@U%YS*$E7X2n|EN~0JnTjhk@kr#3{)=FjxD<8*M z86hX+bDNdD@m3lqTDkF>l|X4L1Ik$WQ_hsNQlXrcF6FgX1}7`Ol&ffEoXnQraJ*`}llwPXgBP%bZaUZLG=2-PJ z$I5mI_O~){fO`MT%9PKoJeSH}Xzf>4x{cBri5g?2kJKJ(Wrf@yXQkbED=jBjStrjX zs+Sp7UP-lCR@O?yJS*L0-Fz$47Fy}G$V$<*R))&{byjlLTiN}+l|nx%zij=<%IyuB z@g~I*%RbFP?*3xs?fq6x9yOqhZ@((LdPCiIV3l7qw(iO^NEBCqB$xX zszg({YBY`-(R?bqYDN>N70uGx(KKrnO@GO49gXF6J(ip|qOrG$<|FYhj^Puz`BMxT z8)7)IF@__XVko&eh9X;H_+IqlCPuE|#CgQYw~7{bIQ!Uw*6O-|M)Z{2m^SG-X}UL-IkM`g z;$KjFS@UNs&2GgqSBBivz6Y@sc^J#RSFubjQi4CEbfpqBlyg-}P_bGGYIiR|_kkt& zNj3~AL8)ma=p_DSC783O1b<4!eI@wxR0)2OOE*gJ!(SzcxLJY$cS9vfjI8x#1YDk<62%Er}E?YtVJCA zrS#izZ0Zn4)H`vUlf|9mxGQhvQg4wqmbXmkW3qg zWO$a1Z*y%tl`VNT8i#GPt!iVrY_F!hb!{B1XCtA$jSrgkqVjBa#v9Wcz4eJUU9ah>f|6rr3 z^!`z~HY$!-HrtrGRdJ-jHXA=~w-LER`F^(Xwk(rB7;mC;G@EO{-S`(iI0&#{zvUQ3PVYNdEAo_LzcPJcXO1M!@bQNegBWybTN zOvs9-a;}a^wNN~3^5c0Sk1EI0v|2oKq-gbc%GZylo9t{D&-6FqxgweE;%U(#p39Qb zF`f@(MyGf_em|bQ;^`jGRQW@adc?C*!UN;^N{)RVPphHvER=@BmHSK8Cwt`Wk?|~( zeiP%_@pU|fmng=Hcm}MBXO}Em7f+M*@yr&(M$Kk-JVo}zQ}$pyWe&yDMQ+K|Bibjm zPpQ`{@obU$H{(gZ7f*Lt`6QmrFXA!3jMw|41l}+tV66BHC9tVP0#R`Z zOnEJV_N5b8DL<7-(EIKLZp*WB3FK5r(03dOOskl{)|3RSsR>k(Wv&Ds%G>?~J`N`6 zbCv`y%K1_tFO(5aB1Ukq}8L~csL$djY1YX~oz+x%CJ%M4n6F4es_bA8S1O|(L zpJs3%fy>hFU;^_GC-ArQJ)(8T)SG;DJb^_g6SyNkol@-62_&9Lps_5wpn1vNiwR7B zoWK=XM9$HDg{vkK zT`iIF^%SRZB3Vrm^?6nzuUaKiyLBSN-$>-tdx@0moQSbUBAFj1^0|E0TgUn&(p4VI zdwmmGD^>d?64^hIhf->=Vt%2RLlb#AJdrLV5?L<=BNczF;*Znu35gt>nn=Pl?VYLH zxrua;m-7>!s|(*SzZ!zWp}kC%+-^qEbbaf z43Hf)lQ>W-iTK({^pFNkl9(>bnkEs~Jc$MJt5j-{#P^cdI*H*@sZA0a-c7>TF^S?` zl4#K_iTP5cyYlu>yq-zwQSs#T;3OW6RNhfZ#7;`$&a5PIX6yL8BrYsXB6V33pRGvZ z{q@Qrj-Qg~^>Y%NrNn_G79LFEwp2f?V`4s{T#|4!i4HPTMxROIjJ$SPd#`GptiF-N z_CJ#-^j8uS|4yRb!z89kxtB?N8C{a&(#KYk>nSDirIzGXeo0DID@iB0_(n-ibT3Jn z9woW3vpjR|l_&OjdEOF3p=1WcC9_NZawKE-CG(M-u9D2qs>w8Hn#^>W*FKp|?~QuY0cjFIGi6sgM6)E|m zBGX9WvIL8#&>${_>5^S8g};+i$gGfpt73{ii_l{k=u9E(NnwXKg%`dQYWh=HB=dqP z+?2x^DXhuXbFwHmg}Na<&evlJ6r|9jati5HQuOyzivA3wFra1%_v@tapk4}F8!Ate z6!tVrq1@{!bd_~&QmFb?ioTahp>>B8oV`-$C$2$y{*x4bkTqYVaC?+$9-YF!6I1wN zn(C06GqiVB3S*?#>=gRXO<|{a=A}?%h2lx~?^0N}Rr}?=-6@ngm_irv9!jC!nG~i< zpI=i*`7MPH=v17A zQt2lxi>J~(CY7ILM{FuH;!?RP@7T09F_n*{V#!p7$*xkV6nia|&ZSeinVL#QCGB;j z@<8&_Q@J7aJ*iBS_@LtCq~gghnM$qGsZ5k7 z=Td3*dn$8fq08=@>(Sx-l#;upOqMSr;9EC(gOgPmdT*m)$oy4X1-$)d9ZAaSqaiX1nC)w#S*-q>%JHuzI=Q(!5bL~8xXQyC+o&5{# z)LLq1>@uyD@!#2Ly4Fs;b#^AMSDoK$&Oh0iwZTrIjk>=@_qXc)HtpMK$Fj>#quqA4 zNuh(9>tQ=xkJz~&KOVE|dL=t6PuO|wq#d6Okb={y<&2%jQs}Im>X%gG9XsFO)%@?- z$(1vY>^ysJC;EkEA}6KhOFLs;>D)@Q2nRDG9Yh-(jE;72qL71Xg&nLc=HSiZ4i?2Y z^qqo3*X=ksB}d9Qh%e`0xJ*oTaIS)bIu#wvvTKiYayaNKe~QQH;EvBhLXLyCa~+hf z?BHSz2Ni2Mm@Gfkaqz0HgYNYleBaPPyG9PaX{_~49L#Cz;A%66t`Bg~MK;R!uRD18 zhJ$Wx99(d+EvveN!PUIx`U%~ zO&Z^F(B{78C8_^7$dsjW_krqo=-?yy?U~NkzYe~XD*riXB0D8IBAtOUPM$}l^L3$g zevl6er!!dok({FGER(Hbk4xu5Vmh~ENs`t|zq09+t(cBiZpw4%mXgl8)O0FTN+(+u zIn((iJDu|~IVYXP5}%vSTY2dmlFKrzN;=gWrqe=-HBwBOAZHt=Q@e@Q%D$HAoO~;t zQf<>2B}3jxXOc8{SI^54iSLxoaG51h-O~B+qjbKIa38IcZ4%WloxU@6y>Ueb;KAJe7j=>8zGr;@Ozao7**?9qE+#S-E7=-gFimPG_xjJCe@Faz`?b z>HJ8YGwF;!n@<1p=}h}4ol6hW_5LrN*B+P0$x<-3>Zyzxpg|4k?6 zzjWH-WJ!dR_(&&j8J#RPIf;vMQasj4s}ee%>k26SLFFM3RFN(jh=jE|{*wo2}W{TC^NxqbCqk6lkkM2$m z$z`e2)5)$G>hlc?|2%EiC0xu{Xb#nG}ZegER(bc&0bsV-8|Ty(R$ z_*D)#T*NwE43WDY7nwd6OJtM$<9D$m?7~vuqQAVV?V@NM7yIO_)UE4cLOmA|^?#zpnD zs&}1>7t-^4orfRP>t+|>{Vp1c<$#Ms87a*Uxp-H~9CqQBLr1jsgp1))`J`qecTcIV z-&NNiF5bNA;=xN7x&NvsS@)l2fg5v#n=j>Xq?>$$n{P~R?nJqH+w3M}b<;r1(QXoC zgd8p8rgC97g^RdpR@BW-X%MURl32n`n#`0x;@mW`xtSdA=0bv-dWmj4rQGy=&CPY` zUe?X}a$1w@rduU9>(bm*u)8Uj?&dwGTi2YriLdVFtr~6)$@5xneTL=cJ6YAh&7+2H zIyQ1Mu8Et|P2JRN=4R2GZf?Hi#?aPH-F9wT$>;6ey1vv+_B*OmPIOW3fyzC|t>zI8Ktm75t-dbOK(*SMMW zqnl@2HQViO)<~6|Zob;(W{MQr?WXA-H$O|lKF#_UoiAB%$jzUJ-LyWUevi4CaNJGA z2{$E9xq0KXoBdMdtee{sJnv?)jQrKjv5Pu>$<2`8-2C#pn>YW^JSB9+%}Tj>%Z=}j z;!DmyZU#Sab5A~cp_SLeUb*4-5F7CD zdeB2+u5QB~=I3iofrtMpd#G7eF{^p>-qAz#`r6;X!}OLOerx5SQES!E#>2QbJv8j# zVNpj9H#>QF<2?`MyLjmQzK63iw5x{$-8|%V_fV{-hn63B*drGtxt9mW#~ylp;^7bZ zaHxk;!#s2t?%}w6H^M`wksiJsrPyOV_{Mu!Anhl6SUN>DPxWwdx`&E0JxrGWW~t^m z>RG1GQ=Riw=K|ed;lZ-fqw7sIpEVwS|IS0f4<3g9=wZZG58aP>Sbtn`PH4>qt-0u- z^i>aU-|_JET@SW<9?m@UF!+(?_Si$#6ZQO5GnOjPRi~82OQ#4gr)7)5i_zreBYDs4 zWtGKC8LO9o{9M#a-#9N{N)?+|f0n)Ml;{L61EpK`;F?yll(#>RMti=cRm(mkIK56|JwToYlPSkfznW?5g3VS54JY zOR*)kj$+HwhFdL@$jddpR@J%f)G4D$ejSSuV}=k}})N z6zMhB%TM#Xq|MhFskl&U^tR^zt(y2e(z;3a&~ z%eV5yZ(jEQ?j`pR)h{=$dztl*m&*^d{-Kx8o_N{wRQdk(vM<(0?eadxCHweKcBc4< zuH<8&B&YdU?eOt9-N)xHA89_Ht_%0^n>@|+Q4rGe(mL#8UcQfF1wIT_eS9x3tNHk{ zhL4K%d~~hvk$=L+Dmi=7$H-Ia^R$l<=QP_ZK5Aa`@q_HUp;`Uq z<1=aaw~r~eG`BlG>fZISQKmgsPfvUdf2!Hb!skBzdg0^smpb;Jk3;wgNB9XD{4@}= z(NBVmkfSC)m81OhDC*}k$tmWij%H_5HkP;-_jeKWinfrJpvf{2Y)DZ}?f(#!v7qJ=ej{vv>UZw;+C&_wsZ9 zL&fXur|BR+Gd}iH@l*9Z+Rxi#{2Z1~Ci&SlS$n7WIWOg>`I#W+r|bSqKPzYXDYZg5 zR%-8R&1SQo!CU}SUnKfbHVc}+QQD8GFDr=MGY`FZoEpVoi-`QVP9AMg69bkEP( z`+mwkQ2d9Q;Zx1y@9W|N6Q3pUyP_wiyFNMFp5(4p6jEfEI-V z{9YtLVoZRxu>p=q&A0$#Yyn=$h=c$~69ZIE3NWX1fIejcyjM2Bs&WC!ln?Mis#XXP zVGm$*26UZ&fapMglk2krvP!?1GMQ8;Cjyhw*CR$91!53v>l|F9|ws4BtWCj156#F zUcL%2baa3NV*=!j4X|^ZYMBsVpnNwyz|$E4I?q%evjbe66QKEA^*KMl$przbFAPv} zae($;2RJ6zC31=C`zAnzWdSD1QYo=oJ?vKx2LhavI)?&`KOBG~0X{h%pz(AjTQ10&UW|byQT2(Ak)4KVi^^r(dZ!C6&_y_pb-}?naQ% zUqN;~2vX=#kVF|RCmsiR`>Ez{&S0}81E)2E7sWHE8k<2Q*(OnO8I+Kva@UqY+xQH+ z$ur4K%)phD!AB)C2$ajfS|NkR6*Jf_|4N&b3~oqFY6g4coZOOPjtpLtZc@jY!FX2& zJ=__5@5vy=n?a=i#x^fvYnx{+L0%pEB4aS2kqe*p$KE&C0V)dA4UT zYL99SZ&wel~p@X0y6$Hjle$eUEHLe3H%4PqV4~ zSvC&_XOlZ5o8_`i7LLs3&h%_DW@huXY!ut9Y@+65(_n5kTjaQOU7XFLZ?d_$G@Cb; zWz$olS7#HyHk-HBWphX_%cD)%Bpk`+?W5TomMb#wwC#JBPfi9EuIfVf=7C{xXNDV{&LbE{AF3bNF;(4!bAikTE%jy3$Fi zPR(J&v>cwvyDM^7u`-8J-{#)LlChuXJunEW`0 z3r}*G`6`ENg>!Kh%_XZ?E*;`>sT`lHzu$88_ggND9J!Q8&*ketE=zK9xt*KK$WSh0 zJLGceom|%U&*jB{T)Ga-WyjcDEaP*zF*g_Y{9NWr*EPAU{VtbYKjzYGYc4al31!ct=F~xMlQSVm~ANEPGzh<5q_}0`KPWPnSGS zjm_h=@p+7v&ll#gZ&4oEi?x199z(v-8i`tyM}zP3DEy=HUdUtpl{}7I&ExpBJd$qY zX_m_OS01Zx=CN6_{?6mmTY21(jd${hxR*y!StXC|=h5+>Jf1zvqw)*Im7nClmwEJj zrTQX66fuVQM1C}f_}3Dmhc(2sq9HC73-Py1DIVh2m=N`2LzIaNu~&-5hxk->Cxj@R z6yj;wkbdtE>398*e%B8%SeB(}k3GaBM+ifDh+*y!2R$J|-Vl|7%99adkd({}(LO80 zF=?9@Vo4}Od^p6dsv!c^LoAZ&HA9T572<^ysuQAV-4H*^u=hTt5=xiF|i7#13h9JVfJDnx~XH9U@)!p9xXoe26zL=)O$+ zHN?4#n#H9M9qxqaEv~yE!m?T(-_uO)YlhP7X^5H6LPS3gv5hcMkzp>I!<0!3(=jQ` zDJfH0_si(M+$|R-GdWD{3SmxH3{yHa%+g9>`Ub;n$q3`h3{x{J%$V#j_4C6VsuL!z zUYMcsW&JRR8-&Sk7{<^zOx-47Hj2G@m=9Wn`CT@?5$3Ho!@MtT-U_qu?J%q5M!PWX z4q@iXh%%w23ep5fcEC1y%>tx1l&HRpPxvM(<(TpF2b?thXB2U6Jf2tWuuzWs) zlJm(;%g0eOpI)`{`9q@X<2d{plUl%?N(H=~R>13y0_LX|FwkE>`Hls2?o_~8 zxzxRYl%54lk(xsb7&EMZS8{w>0ZB6o7$M(oDd6GO0)E|Iz=_iZlssENC8>E%>(6Vw zIR7f3_ss$ZOXjTtKDk}MZ7FiEfadoL*d_T73K;gVfQd5aQ32zg6fj%PRw**AM$hLD zBlN#4DSo}F{?Wq!{jX-$q5jKXK5$v{3$^*S@12!(ryc43WZ;r4-zWM?Vg2r$|F=*7 KBK`mS@BaXM4Uu#J literal 0 HcmV?d00001 diff --git a/Covance_UCO3001/browser_profile/Default/Code Cache/js/1c28dc3f08e9fc3e_0 b/Covance_UCO3001/browser_profile/Default/Code Cache/js/1c28dc3f08e9fc3e_0 new file mode 100644 index 0000000000000000000000000000000000000000..d7a4e229678163eb50232e8708edf1ee06372233 GIT binary patch literal 32648 zcmWjL1$0wc7lz@lNz){aG%Xa0l)76|ye;lN%-}k>yA19O?t{C#Gq}s(?(T!T5B9%5 zYdtH;y+`)m=cF{rP2Kf6FU`^J>o=36qA0QW(nW4mFn7s(CG(VUd)x)xsqTWs^063rj0W ziz-V8(6b7Cs!Lxnq=s}8IcrHB@NX9>wX5_Q_U_WQu~N4AQZ%Zd8`j}E9;5mK;=>vA z+%5IGDuopF(gy6oJv1!lrQz6D+)MwWeF-o1Mz4}y@+s}5AoMQhrMeZo)Cbdl@zSRj zUNX1z(smq1NGmTTqB0suigeVF&T6= zz@SZ;4BCgMnGHG^Xi&}|gEnASHiPP9H|S6fgA#%b>W&K`2DJz^Xiss2&Y@HZgASK6 z$h)jTPhhEJP{YawwMA+*gNk4;9MuhKh56`OgK^Ncu0ek_F{n#ZgFbXLD6W%1BQX_a zI~&v=pSy6st3lbj85DzW-3@BggT6ftnu%S=)r1$8}{EfH$n76+{c?THOX`n&d zuziq0zJm>NW9ty|g5ghtieeY~59jd+gL;oN=+zkJLW8lyI^G~nFlZo_P9$#}oMe#m zFXG0>$;3XzpnTYYOXxJipop0UrOh^I)f|Iz&oyW$Cc-t}p!h`w1uZq`_A-OUEGPa| z1{J_eT*isj)Od|S?bk9Va;`JzG;W~5ChEP$Zjc8J zFa&e43KMS{H0`!QP4BSwNWV)w_Y4YrXwY%&ePmF*r_A%hpam}tTK~$RAL#tXphfS< z?Y%+w5%s~KjvuMlCxiS@9IN2}UMEW;yM|1&5HN`9s7H-j>LH>eM;VE+&H zmzPnC4MrU^8a38rR2Cnjelr`j7eg&ZO~gH`Q7)TN!DwMOs)p03_V^QlE~CQn7e1k! zzfo;54jXV0I|7Zmgzzjz-9q84Moq??Afu{eGwLM@W;d!Uz92YQ6qwl z>X*x?JE$LG)EQXAj5-}|)Px9*qkE)LZ=;QJ#~3v#&Zy3b+)pv;f!nCt9-}@YTdGmB z^3o2s@)`BMpixO_Mh!?es$n6cP9dR)QExD`s8Or&FOrHGH5xO}ho9C3OBi(*A*DEn z;L=9z!tydk-A7XtL=A^s|Fl&ykM>yfLXQNxg2$*4+IjGB&zi2H@dsDn0D zi5+Esr4Nq$W>iKsqdHYL%D;wD^Kb;0P@^Ve)G}%b9$;Z@qdwO$YI|d&p5hZGH6fO! zToBca&}`~ajm;iFa9uUWDnM; zCwro|QN8;b^-F)FZVqI=LF}O+M$LzY8r1_Gh8fjzgi((XKGLXzZ>81t z)|$rNIso4$-g=I)O}#ZAS(~!cq_CcId}3_ zz0Tfh(A!(Xv9FJ}())R<3jV^^{@%Jg*jvkncx(GGZ(YTi;mk48TVbQgce=MW&hl2{ zdGtl=`QDnez+3qjdaDa|;|FRk_EtamEb*3c8RM<;){YI{`iA2hsq1FydxlzGpaxgH z6??;5-ER}u3vZpanUu$Fl8@7*Oemh!r2auB?agM=u$(6O1)H=2?Q@y58OM=5#H8og z5o*%bFq00UQn*RG@dd@AOsb5j(I#b!F{v89qf>%O<4`Hlq}wSby}(6}N#1!(T9A$s zCY7jc((CFb?W=3jkftW(Yt6AXw8t-PO`6-@q>mj8r&!2~oIOkWfqV$v2Q4mD{$GXH7P zaQuf!!EY%i*IwxqLJNn-CtteH_H7Fdt3B0i=Y}4qM7%}}K57%^qaL`3 zdpH&Eqw6@5;GECG#dL+r3hoex2TWm;RL+O`ltd%Rq)X=97EQM zKAMG_2(09zmRN~r$X%H+tNN%T4&l;oEj2R^RMqO~y_<#nhZ;EeSSjQ3&lZGnDpWw2d(9A6&r0 zNVDGIMHKy_ITvHr8k~wX>ju8XndKXAR`Ue2x?+5yS#z*8$*fYzW}U%JOiVFrE`D{J z)etU^S;07gt2mr$R+Zdlt<7uJhkRy5GAae<`e#3dBl{9Nl zDe}SSGGI|TPWFtn&2B;P0jK&GpjKEYQglr?yS9>!rWX&3mfR1Jj>P)?n(8a8m zxYw1uyAfM=v!ebmD_d{o!T!D+?{8Mp0JEwNG^+tN3}TGI+{bEU8e-PoKg}`@Gb_t* zvrnCi56e@fw+?niYzZxH!YCYBPy( zmYJWO?3>wUZJKMA-#oKsFET4;3H5|ynOPN9nze8f>#&)6ZZT^dmf;@8Y&Gi~4BN~K z!kPcy?jVNUtj`{^8tpTyJAU6!KG=7VwfM)Z-q?vh4zs35SZC}##@@zV{B_){VJF!i zr-^vvyr#J+9CODOXu5{EcnbsqYQ;)GhWaf^M_6sE;1lfVFqb zI*1N;Su=dPPmT|$IcyKh7x2aFjOy+-pwj8)X4ip4BaDT^Fvit}hvn)z`U7qG32MI*|RS2^OTXyJKl(c4PI zS=pjqzgX1uSBrkFX3_PU77eRq(O#UyC)BBD(Hi{3%=#8(ZeURuW+P`Ki(WLgs817O zZE8^iT*K#Pv~6M0@-`NoMY*=rs)I$xP@p5R;bLct-gL3Zt1FMu7b)GS_a7G3zZ3wXrwa9}7c#GzL zS~L;I@y9Ucz-LSzZc(cd7IlYnBsIqvv>0X43>?P3u@)^H$GkX+2IE;5oWr{b)N&%@ zA@d}QcHtNvVZ&dvoorEi+{Tb87JZv$(ZJ~zjm1hN&amhT9;5b59?v2!)S6?_EM%X@ z7}!1EBEtf5UTD!OSQlGV2`?~oiAA}WT2vJE@d)p+Z<$4>@C26Ju{7hiw++-_AP2xWl57$Ef*n)(Mx<{RH!48|s~;{`iXVrz}c1OWn^| zl#H(DS(ghImAGWlO+3BKzC!VbU)AGa~*4Ryj1 z*xu3qKlV26;s<7YrTus2v{+TmYE>ijgTJp;xv(4;kZQ9ki_@wI6vbh5@v~|$KH_kI zRgO$nWk-G-LZ{4D4a7Ti4793b7ONHnSyeW>Rbx;vCvzbtmsM@y3bm>_e8a7(g8LCx z#YS3n8ndIUT7ko;7;RN;T*7~7A7hm8|_szv#%T8~qxliwa(qcI(u(X6ypoiP)&%UWeBXH_6(mnSA{t6){RidNOHWYy)$ zR#mQIRXue6#j1U1SJkS%c!h81`m0rEf3vDrHEM%=HJB4KaU1PxvKFJSGu zqh4LBEcL7k!tq9o-Po!r&8=F9y{Ov4ssL@*pjGA(RxLr^QC982?9o=8$D}bLA2XKUAB|o4yzXLWNmg4?{4-L=3(6) z#>UruR^8ZdRks7gcF?M2D1XSR7l=DdJ(1%G`Qs9tN2$*-*7i8HJi)%bMy+pJdE?%y zV0?o2ZPx#;RU7Y-EBqdk&%dnIBdf0b-(#!(dP1$9TGjtK&xaRQB_Pu)>V@fVtvd6L z=fel~`6u=%{64b}&>F@sRt^73Y~R?&KWO9St0o3tb;3TQuTG<}$yXixDtxc6enmr++vls)1HKA9 z?5q2DjT%RMmF*~P(HFtTmN*&Up+tRt1qZ?iZwp%t4(L9$pv3Exag}kxQnir zXot_2ef9LJuXf$>RrF)xL8d3v6I<~gia+($1YErM{asNFv{lIw0^wC$B zG5r%Y!ko{H{e_(V^VRpStj#xH<;`YOh3qzk=CCOVOLE#|$z@YYh)oyqM}$qeqHOvS zZPU?sn;eNYWk-(UHWff8Tt#{bo5~_zNt#igg;chwBL2WaoPw*iO~Ke+ zm;Uu^+K0DIZTg8u&1~w0@Rl~!!3MNyO+S=vYg2Wkx3g&ia<{i>X-AuWph_p3zIL(c zN>`gQy4lnP1K`!&re=L@>V}YhHhmmulW~wuJqOz~45lGA6+tDW47I5c-ry&O|H-@~ zY`Ttwkv6r!ay*B76m#G>nvb?=D>{s|Y3g|Tz%s$6T{sT^NjCk852!TRrV&$Uhn-WI zf0|A6um;&?kRO_0&rF*J&mvE_=h)N{{qWCR#-3+W78ILLju`v@+XXi5z)=)hL~U^d zHI~>k84Iy$sZIA$WI1u5!V2cVcw}G6x}p9m)@C*NV$K?y?%*XduVXB%#5TNKPrWwS zG!&C?aHCD$o5&TLaS(BvsTsPV#}@Xx~aT;h3fnOb7j70zF^X$sz5V|}mNl;;*P-?1tBF8dGl zFdqLR?|t^+1J)fK9#W5gsUZ$LqAriwBWU}?rm9cb!_RCwguKrg4@F2fu!>Y3@gxUZLbC9%DP)pV>pu7uFE1aSEaT@tnb41bwwB=QrlT z94!3K^A0cYA0mHHFBpGPbKJsO*>%8R*CV4{8Qykv#a|}7emC3I4h#M5%AD1%E@9lq zUA)ANaBd^)ii)($8D&>JOhTb(9>>@<9ZT>dj`8B{nvZ!&cIEZhwJWz>$50@TU6Zi@ z|K+pmNq)ONqDDcxmLo0Au1okW-L89Rk->RnDP-4AG%IY^3d}5G*M;hK)vjUJzZhN9 zu8y_r@~v&xQv6rXu71tz8ig+{?W)zuuFWXg-Og(zyN;uLFS|7b z+2uFcuCMd#3R*yY7TQ$~gK!sfSKIXp-_U-IU3(F?)~-G{ikNkFwO()6Wi;7nSLZE^ zvz3~mJ8q)JHoNxkq}IF0XSZGHd#KA^YQ2y1`|TQkfH4o+<#WicYuI?iu9Ty8oy0H4 zi0L@>MBx*5g`TvlC;FVC9dezf9%t-&kA-LLa-Xy7Ahw++o(p#ExX7AZvTF?%-LPx@ zO}i@IvTG%t+_vl19oF)`T@4?Q-!r?WVKLI56ZZ?dn&JpP!uzFNEwKy7k^hxl12GO+ zUfb0iUGW$N-`G_Khmq|qb;3-%#t*c8XV-QdLGkx?O~71a`(RgNbi^ejd}J&v#z%O6 zqOLfE^QiQheprp z6?Wi8|pjFwd+LAoyoroYd6xt?HTT!J!#gifj|9AC63+E>j(<3-4(TZG>UEL+LZv#;>W^c4%Ilx-octvti?r#!cZPwmxu>Dar!dtuJGKs!JIdV8>MeKcn{X0D9pfF z+`_6m)E6(2=Pr8&XHe-8HGv*8&lBc>*E5F-A^!{JdPyx_u}5Azl=qE8{oeEQeM4Nw>cGPcWP*W zQ)4naH7?Mpep#Hlm({86K~7D_O{8aYsu{N98OCLIYA;U0H;0qg4^Dl9HK$W+&>_Sr zg*vtG|6-jw5$9Bmc&EIRoO}l3R6&nZg;Sj>ncJx=*ptVpVtI)%A7kWqDl1x|O#!D? zVk;gXYZ~LALAq13@Su=W2Mas(qJ>jm(WJFg?bz4I)PXL{jaJ>9 zI*gisIA!ZWo;{hr7kTw|YG7ZdLi&@_0Q%tz#tw8UelRs0>Qs+Eo%(G!b0KY%Q+Y>o zY>ZRc#yWZaIJFdhbk)xug&Cfz^R=_sPj>$lJMp{v0is-@GYlKUF7(d0- z^HUyV?dqpU48kVtLr6E;pb2ty_frBcV%Q&k`U_2Z_-QFR_4HFeg!b}N5{AIo+fOcd z`uM3ix}bAkKdr+qbm-@&KB&>3abO%sd$dP`A$}V7r=LEe_Ao!a9`2{a5q>I&>7)F# zcC4RPj^p@5Kb@N7r-f7e)MBci{+Z^dbSvAx3PYUpVn;U{0=`o*zKn>d;N6yfS;}$ z^wa7?etLA=Prsk_)5A;D;<}$|-St!c$9}5*(oe76lj~$1rQseQAGm*R|xfC$jrIyGv z#iiO)U2;!%sX4k}C6Z^;4{!1392cK=lgAF~glG75C-vCn(s-Ok!fuxeU?>Xj;n+de z>yS%Lu>xE0?>{cJKf=66S+nCVrJi)D$|;xXVfq>7KkL#9)Vkr)usbfbz3Ya_QhzL*^U9@v-nca51M7)ipJ|Wh=mp8O_gAA_{%RHKuMT1UiVpYJQ#_3D z*Um_PU5WD7qG*4ujrG^k1b^*K^w*43f6dPCuU!TFl~#~;Y5uyN?yrDC{u)@Axv;1R za~1Q~(Bl3IE#a@>aF+7d8rVwv>vtSL>9YQsSM< zuWI^hL>+&n{_d};{roj@l)rwR;;$u-=o=cKonZm09v7gg?f@;qAWwkum08n1X4c<$jX1AB{cQ`>7H6O)xdQbHEh7T81aFH3 z>O`?XC6o?SO2t4;|20sxY6YqtIu8%jFJl6gds3hbivszbE|B++0@Y)8poSd`)CPP) zw~K-DzY(ZsPXd+gX`mWC3)CWP!(q5z1*$`_ESk_Ki>eOEqLL%CX!`gpItc58EL<~{ zMMoBAQT&}Ox`-O@vS`KEEP9MxS+jC|QdZ5%mQ~s6WL2yBS(U4GRy}N=Rl~YvRlELK zwfb;Y8Bb-E=|@&gH3X?=co46tg7j-dkQQK1!65xpEJ!&@2dN#3ED7ShvLK$rL8_BA zn@+@L)0UKMdXg`jhL*{u>9w;dq*pfOe3MQ7-Ezu%Wlp87$*E;Wa_Yy?oP3@gtY5LV zV6altf>j24u)bula+eBLQH;SI_>>OTsWQRZP%c=J<%6{by($Fj7E&t(t1{}L(yzg) zgY@dbDu*|C-6UAWTLr6U`(PF560CW+hQO}DioqOo>=vx5J%TkD6Yveqdj@MILVE>k z9jf&X)-go)3D$7b?oS&Gz%djW9IQM;f|WEhSZR2N`hN!N6WR<9Ru61PixI)Yr&piP1{SqeZe}7 zw)iHpI?ew{snF*t(3H-fbb*>44FHa1}O z?O+X>kV~)OH!+uT&dQ}cXokMnk1VruDRF)-HOGMkx#V7yOS8g5^bO&WAxgnTB*%nk zL0pLX#fNYWZHNLBLv$3gtAyw}#{LqbIcQxqM73LnXbaRTM1}DNUadp47&+U7s2e8Y zGv>Dq(OUSn3sFf-#vQywmG&VTgVXTo5TcQo-!VkDF|iZzpmgUD?MA~cA!>)ixQIDj zL-Yi-x)akMA-alXJwoK@8KNAx+bcxzy+hO#`})wnFEMTiQFXMyM9jq{G};)V4!DLN zn?jW3?+~@epNQTZqEg7cB}5gr(iT0og=jhMBlmXV!m%A8s=zlzh+}A5iL8h(eE3PuxEdq9Uh4RO3R3 z+!sT11lKV7a)_p*)Kzl37NXu*j~RE!;X#NV{!85-g{UPGo|3~e))=F(2c@2ea2-O3 zM!ccTTk7~OM6a;zV~CSGM1xS(XvZ8KLv;@C zJBKQuE90O<_fW1+W4u2?m8lo)dxxrQpHLb5(sp2|Y7Gw6*I}U=ypZu%hUzNfR}tUp zP@TroHKFoe8!F#*p_++h7{5ML_i$uGs48p>)g)X;@}^K#-yEvKTSL`jXQQR2}gg`JaSpAr`$1)o1*8O{{N2^#mW`{1mEo z*n@MZ_Bm8lzEan3q5AztsM_Q5&rr=$m=+kqv<|tw!&DS~a0ut&v4p9EHB4*mVY-W# zIOz;im|vJW1%&Be#D#>ZZcLa)CWI*|PngzZgsEHIFqP>Lrt%%bcpinRNcS*(La{%> z^rT0aKBCKzFufldrUt_pcX*gujS5q#lz|zbA+5B8Gdy zH4Pc5#DV9z!__)ZxJKj)*EMV^7_JsY7^`TwK4NLHaCsLGR{%!h0qT|r*BQ7! zIBI$>T(xl+uJhsg;{vsV^AdH%5;!lD_l#~u;-8*O?<=nQ)G ziqK+gz(Yj!j!O$q4zKiqKr#L9f&FN8vNXi79vv%h?F!J_&tVZxPRn2tGfGP@`AG{W?P3zDMXN>MK%x;Pi@A9kjqv zR5C=WE(#hWbpb2ABlQU;Q=|rAtPhXzhdELmERm8mQvc#T`uj#|f-O>WV6jK43kD*? z!90GE`iuluq=sMuT>g=|7!aw4sFo>GjS-S1QcZC%Yos~`MQQ-v;3ryVi&SX#NS(k9 zRLViDScG44M(TH*#ciwzj?@-B$rY&_A(3i;Hdugyp^^Fv3$ZRdQoCS^h|~jMqqTLA}|S0@OMn4^2ZVbD#b<07EfEuN7Lj;HBX6DO?RaFdLq>+m0a>f@);~+ z=8sg9v`Agbh*Wx^NKGqD-7v2Rao}pvNPdPy>RGW!`4;CGp5R!CNL?uvscfYqHc7*=8ek_XL)uJ>8 z7ZG_PN)wRlWR!*=%Y`VF!a!`oQ)Isw#pe`J>V-}4zZ|98n0+HkmyzdIl&rU-bnbDK z>`$o6Q(}A;rL8Zc^byNnQ46ei9mVhC(Rzc*t)ms$CR&>ZM(Z^y4USgakZA245v~7F zb5yjFM@Osv)AfCnfxEm|*7es(lJlcF_zWwd_6zA9R|H$*(b|Gd6YZeM$ zU~X70Ml0x2w3=LwRwpD~iPln7x*Dy<7>^v+qV*J2uSe@Vs@#ZHKLp>5R(FKmiqs%6BJPC*X6JaqmUzUwp;1`_Wu`6|F1C`ya z_89fb6{D?a6B47|@CuDlgRmG)508;=p%|6K{K6b762tdUVssaUOUB4nDn`%B#VD?P zjBemLI#-C%>54I0R4GQetHx+5s?>?${k9nWTQ^1%>&0kSbNaT3Q3d$4jFGWb46nCh zw6I-_O0nwq#puVe z7_LKz(JTDK!V@w2?M#feq3#9pLB)$Pss~+)QFr9LM*N7m!5j}`v=65cn7O2=wRnONN{%lMUJwGUHk#L7`SR+XA?+cZ{d z5Yn8OTEwbR%UG@>A*NQbx{PA2V|nj9RzYp(kE6)iHdY(DalA*Y3f^Ttd_(HJSarf> zJVo67Smnb|9KczWe-NuJX!kHyukam19>r?U<5N=LeB6e=DNe=E5sPpY7N0m3 zL}x6yeuoxHNV~tZG^u|iufXg>dMbQy!(8w02PWXgsjyRQc z#_365oWirm=|gCoQo`aiIy_EOBjVIFj@x{3%9KA&m9U}!ITmExB5}%6G)`TL#VMwE zoZ6I%({j`+9jCTW|c|aVm}@h}zB=yW%wDa-5#tiBq{paeQVF zr?kg$Di6OW9Dfz3$k)vICQf6m{fyH~RPc&dZbQ75_{8fD z3R&W1v&L(CK)gO5PMR8S&~1W1)EcUN~NfMdG!qV!Xa$O{IA4MwiO*a@LJkMf`+cy?9N= z+xpDgAfESm;x!4cTgCIrYaEyNMLgR&&3 z0QzDSexO3u1pP#Xpaj*%$ZQF^iSkhis)_x$7M-A{s2!7_7C0B1pz84n3P?!MTeMDO z9<0MjG)hX)YV1Jq9BS9I37!MT+C+IeuMH18nU(l>5wZp7p z3Hn|JyNt&B&BFQD@LTC{fE`%ATn0utX=SG`_$Zlc;fc9-F9} z@rf$6FH!w*V}GJn97xomBZ)E|Wjy?YipLVQ{CJ}Fo=BAYcA`e(=Uw8wm#8WC6ZPwZ zM1?&{R9$R+oT#}^67}Xk#{HVedrpa}fsNl2HT(y0n3Gf-hb&3z>zkyZjwG3ak~9X+ zY)N{QD@kD?N$MAxq_nUk&5TOYRg8{K(k#@8NmA4NN!p5B8A+-Kzd}h0!D1MSBxws? zR7g@x#Uu@>#C(;LG`3NaPN09|B#lF0lO%O+nxyT`lDL*3Nvq-8FG+iFZFrJ0k4RFd zkx2?3m85|)le7atvy*fYH_lQa^A_9Uqi&cnSgNjEU+c#@8y z&k6ECz{wP z@0F~!Nb*ir2mfTP#_s{i>WIvlk~I>Ka3)K#oLQ5#4`42S(os-WwJ`PO4esoZ=Ec)NmezK?!tIj-6L6pdeVP# zvW6mQMzY!<*UV%k;~dJ)O4gq!I6GP8kY^4t&QDgtf@Bp!H3Te5){n)+y(C$8Fk~rl ztw`45Rmm#9Hd#Fn(B@#Wx}(>jWO@BV9q{dNvicoK)+ppVnygjF=zly}At%Z0OtPYG zGVbkU+3qB3GaBAaR?NL*EqFp4Pl>~kqI749%Hkc0x>ERiAt`#|pQ1@wQuG>)gHm)q zTZ-~$PfAoe05HAM|` zr)W-|6#bSrMdu2qXh5+PjX{Cp^g&FC6t%6Lq84>i`1?^Qe4jf-ea{3E zV=-lQih8U~(NMV8rD)aq6vb~yQJYOE`e%QN#ve-2Y?S?n_>kprik@Qqi4={yn4<98 zDLQ}~})+={{(xcuB24^AtM1lX>_m$iZWXKLRuweDKiF8?t;coU8dKk`aSfT{cek=& z9|9V=RSxr-5?@=lCSe{bw4*NV$)%&4|JU4_-Pg@~4a|vlW2xad=0J_{#5mo}bpviy zgL$S~U*@=Ve6Cy9F?OC?9~V;ZMQ&X|pT%xPEOqMxOv~I{FGUU3xMknyR*A#(!v{1! zN=|rsfm&R4>j#!!ajU^qw~pPSzIWZq{L!t}_ygge+-m&UtqWh=diBk%*FUHcmi;6L zd6db^qgp198fWpSQC1J%SM%^bnTPMGd9*H@N4Il$lpf;I1k6FXP>)82dHDXfhii{L zynp4R9?k6P;cx$W)VjNe>kz34 z+9O*}^6ceNKp(~#z&QAhWdl8m8%)0;9z7rKQNs})wMEvE@;ZeJl9!**0 z(fidNX{|?X)_HVsJ#9BI_C}AY{LQ(|9{st~qg%T@{H+7(zTcx?4tUh*AnS98H9PE4 zj$^FhamGB!`kwYE_MAtRE>NqB4_NWsBlinpd+E_bjPXiUQA4VJ!5)~rQ~6Fy zs{Zs()l^gsNL3@8Lr~^a4MX0LRF#H8Q{}=y91crWzVK8{h)>l5)JsTJTiirMQmQ7R zZ|+o$McF*5s)eKQ%a^Kt7*jY^b5N^Ds#@YILWVINGV~ zuV9##swU`&Qz$Z>_-8O4{AQ-=k6Ec&kD%G9T7)eaupzJNy)2-4_!rq;6;LINzzGDr zE}#k+f*p8+_%{XA6ti$1zHbYtD7s-4o+0{O0oBK3oP_ax0To0iEWup_eJG%6@DwPh z^nwLdyHG*ZZ(LA04;R$Cq%_4Qr}6#SG|j{loXX`BA)Gnm!|6`!qel7yR8JP5xb(8-{La3cxgc=$@txf28Tqs5BWzr)e|( zLB%m?T0S;S&Bvwb{^B$RFG*9crD^K2EKPH_rtv*M#@~(|Bn=kE!n zYpN$*XOWycUGMO{V7jWNrK@IPq^X_#6sUG?jy>qWzK#r&SGA&t^itZ}+(wM^GUylR!MRjt!CxGnJ@d;4^~ z#=M^Cx`zC{(-qh!U0%b}RRnKg7?G~wcsP^8OrLDp@rrQUAAS&-=3k#K^dA7nxP9A7M7u@2oBFs zuZRqlkIc~S_zblzm7x`=Upj;9(lYc8zm(08vs{K&SIy8f%=tA#Ymn!+3{9w(p*q!> zrx|l1two0ZMY}&Uv=rXMGqfL3Q!~^MJEvu6%=8T2@6XUrY?#A&l%1QQ#q%=sV19g3LLlYllsPKyn^+C$Z3>Cp4gul+v9c1~Lp=#i- z(mLQ2U}NTahBQh}gCDv?k~ z1Cb~3e>L3)loNHd$MGM%2nZ_I<>15fo$xI;0X0uC8K`AP|sArRHXX;%!8T2XbBIlUO<=vrHl>@!vRO85 znPbx{tek7pRv7baT$g53V1Z4Gm)Ue3KQ1RHR9#`ysGn`ByV9mT8*Iw_n@tid+6~q>MIkcc9>ZW$!bslTPX$H(s z;#93(oEG4CgE(EqLu9nY>3x*KCvYJNZO{{gFah(i2KO+eVVnxv+M>UdN`#>x-H3dNV6tljg*$(!6+WEoxWO;&%P_p`AG+?VO*mYdO-&+O@sBU5hK* zRj!s@l^WUA0mT~I8Q-qkSe9g$BiXK*7}mnBUFhA?uHk4HwyR(pVk3K7y9(hlR&}&1 zb0@npc4k{VLZ&W^gW_H7iXeA4yFSDY)a!2N-&?!d_OWXNmi4vsJEWb@Y3!;t(5^UK z9?G`E>^h1xEFNyxdVD(4uFcqoe@5HYY>Zv~rr320A5XXIJG7i{*HkoKU{@Fo7TUR% zz|Qqeb{T8zYJ!Gq?drDI&i@nG6oTf8o$K86Db%n+Rlb zFo%XibFc!hP(QOn7Jfl|7Kdh`YF3BB=z*y?S;(PdMOm+yLtT)gxI@L^d+S4o{>7Hk z4*iXUG7dd1>rlsX4voh_c*;9;91l>eD$DT(m#Yz{hJ(2%9ZJE9I*fz#bshQy73({c zh~o{(EuP%4A6`2(;SPE_94ha0s2R4os2OA34s|vhDrGuU4YnkQTH{JHhf1bWA7azU z5yR#=G!eyrVLY_>)uFl@9Actt<;2DP4xK;9HisN)g5@Z7*r6py9QqTTjym)$R=stM ze2)|NJT>Aqa$j($-dh*hCpdh`p+_ik*`YWj-~x)KIaCuqOvDAGzv563Bhle1y~L`& z9r_FRknNg7rQyOD+`Z}02e;@q^8Q2p@M19L-FB$*zYeX#C9J&1>-Qb<6+wcbY$~#pb127U}DmYcEqEj1CwUSdlw5{ya4|uRc_S&ewJ-Zyl$y)OYG5e1Y^fwnyAsaZX)8Cc9G=;ez3C zs+5yFO{XR%IrU?*Q(IA?iBmRw{#H|BHghVB8ZDjr9amAgl~YN$juow)I*s@*oEqQR zsb8_byHod(y@yjJP!9+31kb;5>cigDgV9)nXDP%O=+tZ2M=&nT(N5;naBA9YrxxJ} z3aoXi@eZfDqvV3)xPyYnaGZW3_epw-xmbe>Z=G@~<+M{L|8nXj+!vhc zfPq+Z#i=v6eVu;ZaH{jaPEA1Qu2cQd>XB1JQ2#0W2qj*TCko3YH!5UxDTvSCap_fI zmr53KseN&mCct0OrJk@=;dNZB?ozfIE=6m)Gz=5!y7&&4OPOshRmJsqm-5(M+U0TS zE(!%)ipLcEfk#1?3MabM12a%J*`*lP<1+FzbE!7cTDX*>rAu>SF73wH&s@w??NYV& zE;U8^PA*l%!R{_){l=y0D4ODu6aRhdQi1PSKG>zoI6Ty)XQ=msORexL(okfyOAh>q z9Y`JL;@?+t81GVjw4cDZ$UTv5QD&-3J}kgtWS&kAxIELPcV@XXe7;LRBg+Ev#H62G z+Jw)SxHJy4R=TtkMSpS0gWaoL+P9W|rnyuF#x<8Z;vq6$r=M@#aOqFjZn`)};8MQZ zEDfX&GLgxGLDb*aWPmrkJGbLz#CH!h`PPruCK*4+GV6)fVG4;?TPD{&N$ zk*}y*4bT$(Fb%)q3^=i9;FWo+YCWi0CGR*BATt?J^I zy_=is-`(2xm0New_G`Dk!Q8jLam&%$t>b;%YTVbYu{e#={dkTONW+T$Zr#V9Da85K zty8Ep$gNC6+`2r9yk^oHY{gMrgm1Q6OBS*X(*5MtuSnd&*tmdATdDUCw~Fjy8Cvaj zYX*w!q4vFQMfbb87K+*qGahCgb89EgA^&mq18gVVYK^~;{SsH=#Zk5C7^E^k5 z%j_47Pa_B9xkBG>xD|JgeSp39-MWMGkKD@enB}lPar0ekmZ9h~_8+#SGn75Ip{j7_ zGt>c>3mAHWj|!rYp>4QU*wBokhR(lL%uxU02J;gbob%yz%(4vqg0pXV4fSngC`*E& z9m&LPW@rjdA!{pxzkdz2Yh!36(zQ2K2LE(5l&71aGd&G%9%85?Qn2W)uMFmbG_)2k zdK>E0*Wf!jhU)Y)lz=06l42;^07JXJH*^~L2N|k@AvlX#gAH{XVrV)39crlMa6{i= zBl`Tn<48l#v2L`X?x}`8olIT0fJ{>i6@?G8u@#rle5#@N9}Ujo7}`CX+U6L{XGEXo z^4dH@wx0~FWZ722)p5r7g?j-MBr?9#yXE(H@&eW*o6`3q|c76>@pFj?1I>O%L;Z zc+|=3(Tc_%ZNhq=N0kB|b-+5z4|)_$^yruJaqu|~;3l#* zAuc{@>QNjbIEQB_-pnHd)0=y=5sg}~EknZQ2uj|T3{#Ie?d<8@=K4(w)f~&PY?H&!B-ybM#HZ?8a~*g z{lh#OI?BUmw;s)y;?aby9&P!9I<|YXaGyt$PLShCVxIP>FiztA;ihI`IWmnh^&WhqP0nSS%;{iq z4-HdC@WWVBxu%#ZjN$m;N9skZY1EGb(@p+9qt+R0i*7Tibr##qXPuwO4-FTYO1H$+ zD;P^neYVV0SDag6>cC1oM)qCw7~L=(i*X*2-KIL=2&(R3U7Ue)uc-t~!A(3tmi@eT zz*P5xrq&%Z_2vYDw7y|#Ha@$_wzo{}!UzA*+dHOuJ><1VrmiFWm>O^k9iOld@a|JnU9ca&JtM|* z;v@EgoYCMVwP7z7zaq!i9G@uh##Dc-!w^|2lFrh%xRKt{t_&8R8Cfcgf|)Fh#IKnx z^~z#t74~JdR41FIImngW(pR{IcCBHY8ClEf=To^X{R_p+82mbdu4!Q%4;OJ*HQpVhUr1M6HC=N72nwA2L$QPHwA z8vnxQwX_U58d>UuLs;3^QdJ+h2P`#Du=D_p5-o*8mQKT!Wbyw@OL>zm1#u5QHMLZ) znZ@}E#%)f_7HrefQl+q^oDoa?aU1($#6!VW)Q`kZ$r)dMW~pRrOAoQLjm7yhO96Do zD6GUW+(({vmOepKjKD6G`JDZTBdGX=rJ1PwrKQd2)}B5fPX}^BhK`Jf#honqJ6oEH ztvK1mQn9Y=8=OSC?v@&3DysLeRJ5n1wMgH~Qhs=G3eFTu<1uJ}rOU|sJ-MR#V0u2> z(i1Eg!G8IHKH(-RjI`7hXYk!9*1^ir^l6Nxxi}AvC`vVVr~`sg5t9{re|A9onz_Uxt8M42vZmHd_hJy)}T*3!3iygz=W{~Ih7_|4L=P1LrTG12vRi+MQ6 z8OL!QiCf5HJNfUh)O)9;A?Ux$Qu#f+zp!vG`)eQL;KF`OnGaa{0T~ZkN;ypa`0W_) zU%YdI{d|f%&seH?*3!9imOj3~afjDff06ghC64Db>c7Guw)0Mnx zQN^pFIE)=tz1(w)Soj%tkh_Lg?U1vkR|X!`@v1>xuPWE$b$A+u2(k5|KR2|)F6lm;KBMibWyg(fv<6=Etqn_W(oU>l7#%+`f&`-?78N8R^ zRRANg3+aMh)kk;yg!9Oo=#>louonNKM98bA7==IZ5EYY%jTtzKEXiKk&>iz}5rvz0 z)dZul6VFh!DZRif97E1#UYQt(4S0ac&AnU;=G9W%M5z|^3uCYYk5RRymuto7DXyYK z*sBO8<0x`OymI0jEXOqzj}ix|IE43O^r@{^R#&fzj^KG-pW3zXX+D~^^by~uf8mXA zbIYhtH`@7B`g5QD!cBDf!lwgY`uGggr!8H4YTv`BIemS)i1Gb=nv1gieHxtN)2IPH zof_?(g?*DxWj6ct-yWYT?j;A@L9cy29o_HKkOMwFJ>*lZ!{m-<81Sc0=Z^R^ z_9*q8@TndqpY$no%BN2+F$SJqChs(#Qt$b61cUDTGy#Pk`1JKdpE^I{=ZtsQ8de(p=-*DAEF=vObiK(oqzoyA>zU&XJib^J2$4B6`XH3qlq z`MLhyuX|3vs<`}0!+m_?_H(aNzczXN%Ioth0U7*$y@#oI9PsOEf?tkyeogGm_GtCB zUu!U;w_gYP@Yv6<3%H-+SJeT2UBLtN{?@OP-}yCgpkL$0`*j!tQ~er`0u#u8qF*0P zV(is^J;(Ajer<+xtzWa(`PF#6Uq2u7>tD=1?$=7xI^kF9NxvGN@+)VWUybk@xvuy% z0r#%@weW90-+A|I1wOs$S2q;B<=6H5e*O5+uR)Lf@;_zSGwOWKb}#&z{?gApwtgLa zPtAai)Cy=v?SMAcA!glx3fB+lCbl&omOY?&XF#`H z0lhW?`pFZ}DKnrsRzMdq-W$+dlx-By;Kl*wI1i{O1|Wa`fRd3lC7=SBi5CL`O8GXR zR6N3*X~eBK?V8N`{%HnWI>Uf8#h=bOk6`w`qsoxfA#7Pi?P&?Thqp)Qo$8_hV0i?eaP+m;Iqsxq$Mjx&Rl<7u*Yr6y51OLr{mfi}e=|9wcC!jZ2bvM9$ zB?2<<1+?Hk<30#z_*1q;pJxG$KnL6@sAh$Nx{G{;gUneN)Sn*)bpfA$6ja-iK^?@IQbE1nj^&++)g`En zc+xefJYNS@a$r!|hX*wyHK-L6g33FGSo4DV2G?=or=W_h4XQoXYz)e?DagHnc-#|I z-_t==D4VDq%@Xx{>qM1mo2cBq5}ETLQSG)TY9PAoP1J`+5_Jp1jwY(dsYE?O{oEn7 z%NtV3#E>?A7SgshA^p)dq}28y9l()CW)dhqNOlq~wty zJs1L02y|#w* z{nIg-?&O_C1dIZiH0(wHSY;@;9E zwO^K`O(?K3NugCq`fPQQYOhbyI_%$`B-@T8MQ~wfl4|Wr(n8GKouqMllJwr*Bt5yC zq=b7(>Y6QC`QJ}g9jrs=e92mfeEE|V#VTYkkgTuKu~@P?l}MJaWU~5~PS$t9WcBKv zEOTVC*3L`T%H7G@j_>vo<3O^iUrE+XHBrlSP1GCDYc)|8tBLBjZ=wR5nsC3Au;#Z5 zYiGx>26heWL9ejd_73Y1zUmw1UXNid?ibdO0bx!2Hq3Wj!m2ikM@$ZW<3b=eU7j;WQfR}F{0X8BD#nnxgu)xZbbj(jwnx_2=7l``#7Rg?udRgA{y_D z=)^Y>)ff;_?r$UVV!+gh&drFZ(9DPq;yhAkMO1!vL|5O{tqn<@{8PA_b)apeLAV|HEUGW zvqiN9$vIe#hlQgG7Kti~L&#nV8crd~LX)gy^DDyAD_V;VOurrP6UI+7Yw*$FZ3jT_S)G@Hn}s6Q#j{TgCg zf)hx?2a{uJinjOz<)*|`Zz{{MXIhMFW@7TAFNWa|iq43s0*cO#X(`^F6VtyKFgKg@==)bphj9z(&csv|HcY`&WIh{H&2us4tcmHg zJ?CV1m*)@DaohUaIVXF0_}@RRJ6xO`+f?<*_woBq4+;($bM4mppB<&Ao!HsUs$;xY QZpi;{m*M|6_`k>h0m!Lzk^lez literal 0 HcmV?d00001 diff --git a/Covance_UCO3001/browser_profile/Default/Code Cache/js/2f30f40c84cdbfb7_0 b/Covance_UCO3001/browser_profile/Default/Code Cache/js/2f30f40c84cdbfb7_0 new file mode 100644 index 0000000000000000000000000000000000000000..968ede31caa158eee3cc4e58552679ce5a9d0224 GIT binary patch literal 112808 zcmeFa33OD&);4^4N@oHB1WW)i3?d*Rvw+A=0s+EhG6Y0aIGv=EG)cNcx)TW3AtEAz z7a4;iDj*690xBpfDk37t6crT(5fufIc}P(4d!8CP9isPr-}Qg%`~LN>zoFB8PSqZ2 z?_Ilg?W$AV>CU1Tnil-_yTdSyM7*O%f0=|2qg$_=lKOS;(LJSqa;KYmbx-Nmt4G(K z-TL?M)h)Smw*kFUdi3nxCF!PaNdr3fOzGL9f4^?Y-MXS?{~k%nJ^OX*+|vdepTtH# zPF#Gg2|M`S>7U~-Z&(s$Bt2r^>3H{C&YlexS%|-uPPbldOLT5&Zno!DxHG=q)pond z@)pkG`Ymj+&Q%sOjAg7jZBBFZHC}|zz1kjY;+xT8ehXXc1!i4*b;MbxMOb1-WFEWM z_C8?>d|Ac$Zd8vQQ9q_Z)GrCVndQ#*czH8sM8>fjkH15fT?JW&(-GxJusCqLe)Pfa z@15fP(Zz0~GzMR6hUB@mVYGBEk8f?Uwsbt-pq0g5F~J_Tw^x-B9#vW1r?oY*W!Un@ zt*p@%U8`($mqqhiUX?wjyhUq!13)-i*<;HiqHIeYtsIS;*e2NH_V%)cHHoUMyTLHb z%YXj)r=_j)7E9KaiIy@u$nv!r?+aGLND<|UChu7ioQJZT@f%*wW~N~eFEqkp6Afn^ zzoWts=Uw%}4NL3c^%M3z^=$OfnUf*6I6MBw#0fQ6dQf98=YfvY*dUWQTG-;8uUoPb@YU78Fb?9~qNBxl zNE98dOHCF!0rPMK+xWvoDbm#-+62PRPN`#98YMXESTe&vpSQ&ettm4saU-(AMx+mp zz^#C%z+E(;*qe#(=6WEpG#lZLob$krI=GSJ4y3sz_4gDFa}_|zhWQ3WN9f2s_x}`y z8y^2il=RE>L$jVN-Lq~yB`+}?m;S|JHb>k&B}6VA10gbHY4s<(t(rk57F zhXR=^N03SbrfG&HVMKQ0_ijjxMOA;UuQ)%ezdO^Hvnk1-hc`rFRw=~i$xJHBNeTptJQ>9Sw_!fT zN|5lBvS-GTKqe%d@0sFGO96pSxB<2yshM+1ZS3#_J z>?au{lAT}d&mEbW>!uqhx>cyeoUIfxd&Dh6h{fX{;48}TWM#R%>8>1LX+n7eOL^hd z-@=5A%px~rA_%cP?#TgE>P9RO;S-5t%Bd76wb1R&8tTjPWP992LtRCA?jqbbDyd%iu$;6c|8T9`=xlZQcBnfKw>ZiC9#}YQ{GY#3Al;^(AjWE-dv1g$QevV-ukeg z9qG2D^nQa<(#H22l9DuR)Cj{|Or4>Lk#kRaDA7V!k>3rCx$}Yk6q*S1fNy;3(xWsC zIZ%X{_#3#19)Kz>>tFY3b(Ma;fN zc~gA%_=T4d=Hv~eWO)LvjC{B3b>`$CCw(mkKW9s%1(J--tSp)NZ8LoUk^g07KAvCa?efsNENRW*- z%(3{wW@fkOx|Qk>NA{viD3nfe z$*n)MBoA4_FC-Nexk?Rl6K=3^%TG^l&o=ln{O%&SPjfvBKy~G<1K%W73=zKk688X4 zen7gBXto|yS9ZQ}HMs{%IrK@X0e69UkUYa2)>)o;k{%09n_POE2c6HIJ<2<&$W;iw zKSM#8z_D@eLyi#6|LHD8@de2_m|K0nt&`N3H=WMTEP-$U2?D$JPWe@I(BgovpZ^NM z^ihJTSlc{}=!5+)8R(x-{O?P;?U3Lf&eB~pGJtNLX~wF;{g%fbA!N3%2>oA<;O2WM z1a;WxVavyZK*K2ZVCX)B+fvdeECn%yg1^EbHloPK*7jH0J~Man9u^j2BuIC`Nz!>Q z!3_z!uXCHn&5;CXQRg{&QGII35wr`@@-ve+pN^Ak#d zY^F^v6JAc3MG&))r5T4x-~{m54OX?GpxE5u^tz1|?7@I#@0 z$uF#ZV}nyiY3)JH$}j_Qp`VeAVfIAD=>kthgCB(Z5<{=_Zhmt!@qqt*Ef>xu|B$l? zWlR%IB=!9bdVEYVQUSgK5fvNeWEO(@!L)aJa(crV0e!S9KTY@+9jlp_(1tQW;E2_8 znVNzFk&Jz!ns=t*%?cjPd3t@gID!LC6PLH836qOY;0#ur;FdXT!WbPp+&}D?iyRLJsN#@J*J!|3J{(q{}eOnJff!k4)dC>ZnEu1NtyI$EI=j{(eG$>=n`t zy`h@b_tV~E*eQZRKSVH@16L2Ff#i`VJ|NGO2g*u3aCPQ!7D9Rhmbyn%dPS~D>AsP< zA`n7km*w;3mk!8x<(T_XNahCnAMeRfNrqf01%-i9;q%NgRbkkxXBv?YIq^yL`U5Wb z8t`F~6qKFz{lc%Q>|k#gnF(EGagJh`m<|g8^?mi`?s6Cu<9rf^u7KH>mVow;e&EFG zkQG8l1kZ0n5=1+$;l2lHg$Uq%MOi7?=%fLG8TZUPi55L*-29STIf;N98|IsYf*Fcl z_6KY46UOB$)T1CmEz~6H30+qgk>kSr;>Z@H}rE4hgW#;vF7s6NKf{@ew4elW1$kd@DhNO%iHau-;(vZ}#Ddz92fX2=A z-*uRBlT+bQ!quwjEe1j|1}w9`f1wTy8i5A_D)=^Ek(}3TMujrLL3yj$Uyy^_Tmf`j z^qXBuwB`OKe^8ZZRM794d&oDa*KPIHUQ*AL6JbBCK)4UwGbcdF>@7>?PpnVNb$dBa zSA*XgvWCL6eiaFny71hoUKwUK03_G~fr_Ge?@;buw>!%}Obx9vbzzuAsD|;P!wAp4 z{RSHe8jDu$2v-p%*l2G`FehOy00;sT5Z>-@{3E%-NZ|4o7eearXiwn=2ty+kukIL2 zd3gL|5Ip4>W*M6dxQbTm2asXNGAZBV@(T-i53KSh1te@FvYk{AbmMZw7DD%IE_{EZnvftYt^HJNrp zrEo^oBdKAof%c>XTXuW&CQ15jhNl;QzbHWal&u*K|z^7>YeuKF(MtWgIlt+oh+dt-q&_tB`nN6Y$PLFvzdeg zw^Qu9lG*ErCXE?CYDE8}^px@ahL0MSZUz7=L$B#S92QFOc$15KlQ1(N>J0p0Yi9cQS&#{1Vw_-Zgg($1AbleCmk%kz zpyMY}hHc$s6`)F+J0eakQcu(3+QD_gI*iMCMS z%5#e;E0d0m$rN<6yxVaRox$y6P|Ft%#+(93Fb1j{ThDk?cGXdsbYYGSFctxFbGOae zR9vB)#Bv61n3WO|#oM#env$xB1ComnhGLkil+8hL#kuuO=pta_2=;_$G|YV5pg8s| zi0Vmk2y zSI+k2fL=N-2yOkmZ7!i@L@wkQoNkyC6m*#T{9A;cO+IQbxDLQjjx=&}`%om{v6oYb?l+|hULXvX-;X{XzeHb4Ns4GOXxC*5F)vKe*!`bS{38e$&H&oRNuH%Q+NMu)VvVcT%v-X3}3G(lX4q z6_&m!RsUc-k20t{Q0*0Ug7I$hLo5qhjivrk&FiOAWZG%8Djb|r@{sTeu0o`@IN<|{ zZm8{iJld>~azUH=K6t(v&4e9l1Oj(RtzQNkJwr9R%jXOJ%?gupJpt)!(^43{o83^M zOz@F$zH1-yfmZv95RV1OM|%`QDu@ z2Lj7+gSwg8{rQo!3Xwkzh{TGXDErOkk_!lb_J_VKnN63jT15)O3pp!ci@u?JA+~vr zHGOCbg4j@ZAlH}WH(w+%bk=!4etd+THB(J=%;icBv%81?PC1CaAjT)D4s!-t;e5D` z8I6jLxa9NU<`Xb03`J=A`r`F<*>q`E)iz}w$4xmPZ!SJ~8><9-IXU_6;UXg?5^ig7 zlQ_0IcHY5W>W6IE8!-QnS-?l662bIl_wqZ*G!n5?Ai^`%)QVBB{y@1_PevdIuj;G& z&Of`gAqwHP*tap4;oMSXL6e1U>>bQISsQE|zV`8dvHj@oAc4%Z9;0WAnv~tKAEP>Q zOjKD4WGCgrzH zC%5CrGlieyHOmPLLvB7gJ(diKv{ZjjiHFNjSX5vHVZNv2+_FtVE(ypPkd76>*i(`* zw7UJ)cZK(mi3X9Z!9)$Lf^QUe$)5JM4m9MT0O+4#5prbiyS1>GHo<{GPSsJINP_{3 zeR~|+&w!ajnQM~r+>(M}?o)ytFul%)?2z=pX>O51<&s&pXEL%jkDx$I`KIq!NMDE< zi7(I1Y^cagi}a4L(UsDCA=9+%P8%6cDCa8{NtnGb*C?5c-umZf>?1M=7l9R5c@VTh zCS-eT}>kzWga$}>rpaeCdXg10Wi>TXAXEjF*pp;AO8+v$(-gBTk8*}35i}2 zbd{*`nv&<@^~*aExxcuO9@{^HhRQs+7dMG~ahtNo=ujX7nF`uZsu0fd?7CaYb)gJc zQnT^hyv%Nj!j%IOy3?|%6P_sSNXY@^>LZz=S9tugIVLqu-L1aR^$qII;}_{cc746} zYM3h(>h*1s`%x(#|82o>$ZQLy;Aeqj`||I;V9&y8!3g+AZ^)pDnUU-nFtm!%zw{?r z4tAr&R5Xi0q~DwaOtNzQ{np? zd>U?c1bQ0Eg~lge=V&DI6sS})m;p|&(&MGD^aIkjVQQ0!rP>5y0JE3N2i{06X1M(B z;LO$!$RUCpiJaMY4*^bZ2^8`N6g3GE@cQz}6t={f;u$(>+$Kwjyh;Y@)#z zd!k7WDzDM)%`aI23T(3Id@32mL`}GUvj=rU)DJyfy(%fhFD9K>lV$~Ir}4lEbE%!6 z(I9_;H8(LVn+8~vGu|#ao0@Wz5F@Ne$zaCYfz*Mci?ii-?7U!4$5mpQ%_S|f5ID$U z?@8{%WKp{Tb2baWV&6sEKbNgf_W3xW)-LUCsabgY0ax957x*8}g_k1UET399c?&8mM^4m?`2fwcOn=AB*RNeHK;d_6~nkQAN%JJ`9;+ zi4}#kRVj{xU%d7y#o;Q2{M}28hTM^o+z8BiRGzVcYH*%qF2*GAu{V1h9}9`b>i{2NrQKr`<8rfhB*xN|(Z? zkp#GJ{N<)dT92P`m&(kU=|Q=-{P|Rrus^KM1w>pXqdRjdVAvDd^ei9Q4By52R1&se zVEIQ!EnExmBc?PjD`M>jeVZU=3h=Hf^2XdzHMZlJ^<(LslZM=ubou*FD-`(`vM z0uKZ}JFe$X>=oHwh=@UI54HwPowu!Ff#|G$mCPsHR{TL?0TNt2xd+o>&*c32zCb$14nz1qlu6Ck1l4nrA^w`mxNS%9fksFkw#3m{X=o&lx}d@5F7Oqp_t9{DS>K@y8?uLfL#SzC*nLAli;^4ttGUO34O%rily42t~bb zkNT9_@%U4+xVO#B#RX8qdXnG#x`ft~IxICkHEGCry~|*9(vVRpxNj~|y?MaV6=IP} zjK#tIe5jB?A%e)@qp3?Ik@O<5+l|bS`@xU*n@$Z$KThGQ?gT40)0KwPQuBW&K)|QM z$wXYRqo#d)&0coY>L4`D$L(omC$t-FfcnP0nKgyd##lzt$c5}k6h9&uySLrHzawf| z2z`Ue5KB7j*%4>2BXSt3nl8&ph8eCJHLukCO|mttxF7@3Tuao3P(gL^$L$)@l9f_0 zVS+GDNu7c3baoo5NDS-VY}0@k@_m``#j@O-Ov->?SG6HVdX8b( z+n8JA@?%;8_hLTA3ZTF7&4)i=2#pjZ=lLkY^44rsxaszLAD0~(y{y0^2ROQQLTqV>&V+w9?q=B0yv~QTy zuK3@|8Cs}OP)%5}suMSr#010G_0>IXIIeoI(t_O*1ALjqevCK>j*(_>hL)5GN$h`f z^)5O{u^}Mn-oSD$@Ia3sdFoCLdGGN zGpWA}mij#>U`i9R=E z>z4VVYHrxZM|X3`P+6URAqznW+erp$4{PsEVq?e4-clU^S{0VMk^WDJMa&UI(47+8 z)n^W1Gr?@w_REdPY`!l?%+k%(fQHe5K=UT;<7k&O`QXeP*JcJf3}IW&Oj^r+%$X|2 z2rM7~sf6t~xLizPC2s>@AIt?Hx;lpXlwik8Y$og?ulIqm<XMPE}OaWg;yE&OWCuM2YEH04$Wi=aWOTtOu(KIM1aItB7 zdI{Cy_WFy9-2Jfj3?luBfrXbMmrK9MG?0kakRp`o0fFtkzdu_&R1I_o(2Ssw|DbT} z+J94lH1a$|o6#aO|KVc`#8yn{x}|$FXHxzU@v*TzUZ?!9r-eIHHE+m85*o}M z-d}Q^=z(zgqHFJ>%m8_2aOaM+KA0sOaGKb3BYgUPpq9(Nkx$ltNlK1`nUWlyVi0WA zo%Oa&_&vQu%l_H}2+IsMt?~5-JZxHq+!hz~;pk6TRS!zPdEQmiD1C?&zBj)Vk&|2- zr48gO^|rjeNpq6I?2Y4n0E=jty5R=f(dPPr%h`@$!^i7@Mg%hE%d7zTwg0EDk?ga& zm7~QF&HRhX%O(YGOiq>WH$JY;SUQlVqa5(quGb51j@m`ti6#GDKY2+Yx_Vs z4-{oj8T(e!V761_F@%f4GCJ}v<|C96Bt9;$g@vLNDMOC%A~%{2Z|%hlO5(w|Iicyp zpE4SfX%9J*5$OPxaWdDVD&_!a$MmKR*U)q6hX~9rxDW+jKmUW2T53u!+%qYJP3&ZZLb91wgv_pHJOFq?u}GznIB1C;yQD*0kmUZGJLk#@fqpWFEq5`Q z;~*%xXm#R_US+HzXY?b}bxdKl297d;<-%KCzNS7r{(ioE?nZzu34MHmn{3a89Vd>k zJ<{7X;oHjJ$~T^icEShE}uaf;ebYCL8NYn9@*?R zH8rZ19vp=Dv4cI>hCbD?M;>sqFpcH;P#DQ)iZ| z2tpXV*@nDBECU{yGn`_PeOWF%x^Zo;#vhqS82kIqkJxtM6=bh7Ok9hIWn7;R51_Ti zc(`2??nbmbVRq8hdBIYn72By^EDGZYAZo4gm8o_{H++xp1?K z60Wydv+pP-#Fg&Jocm2B9>}lg_%Ekez|9!ghk>4p3rc<5H~vvnq?q<|z{YoTqiS!- zkbcwId(g!~7Jg76n>s@Xc5kz7d2A4aQS&gq5aqqUC;m(kh_yDTL(p4Ilqj5f=kyc8 zB`Zh3wwTGlQ6_XW`}fb6abklR7xuU7ppPo&-ce9KL?UR=ybf&{bF2u{Sn|y)&#_~sj2ST`wO>*)cJ_%yTXQsx3KeGGxuJ{fxn2=dAjKl` zOy+b|VdW>k6|e%A2ss~RaP4I(WF~Hs=_MUnucQ5jY`WtbA;ys*kQJuu>s0I3HEX(p zJwh%H2H6d+rJJM4Gy>jrzyJAQb-=5K>nmFLJ1ax58$0~lPr=IQ7~y5QZ+L!IY8LI- zT+K#6y&K=ooXbv}ttKwQ&-bLYKm?nA_h-^eO65YSlSQ@;JIz3%%pj5NpL{r~nn*|@ zgGB1GeW!4?p#NV|EPMzS#Lh4o0I;I?@w;W+c;*a$PJ*?}=0SKy!f-*@?Sf_*VAbkkz$R zZ?=!P#-KI81wJl6_0UZe8YXRWQwoAM^B{^L6NoMB!2M!?Vsrb;hY-0ekEbR`27MuH z)%`Cr27m{_u4%wN3vD2zgw3=((4m{0wX0pbcmOdd2v!}WSZy=Z{Uqc5>bVd1?hO>- zxp^3szzam*@rHIo*lhL(vEBsNDRwQ9XSUEX=%HoA@Az6bd%5!Rkr0dAwq(+|7@ zNivU?Yv$q`rO@%$OI4JD2b<^Q(l}5yM+=mMm46d`|J{F*} zV4e(^aWoSk9Clz;eZA_G^E!be%LTb!d`|ZVfY;ygcj%!K z`e3XO7qRhTshTLrjCbhrZ&>Kc%ybv(-75h?Lc_!Ey4fxa`^xDrrS~j#1))qCI%2F8 zig@$@&&1+6TyMZX#O=)q=KSh|1K5kO=aV6iOvdJ_c8}dzzl3%o>|O+BVr)kr zLDOCBCbHI1PLc)Rpn1N$|M8h zk;veKYr;Ybaf7B)KJ=af4kDR;Jl%*bC1zWagAf+~vE>(bTn&^a(s&rlaL*(P=>%5( zvFEpjxPl!I^NFp1s3PYXSgn?vLEh_Doo*8xWBG(Bv5dnX^04mT13PeJhE;Q0zhUlD z1?%q`Tt?=Y;JyuGg1HqMLR0BTufC(H2sddhL4#z%mP!QDt^b~4=PWeC<;fQ=_)c5^ z7EN1!OW(JoPtx|B!HIu2|B;mN^c?a?XhOcS!!vanWr@tC zTyv2c805}JAmBG!gNBT^!VYGO=X0R~<-;*z&Xf2d`no4h{z9`C`-hMLrh%D>AR(tE z%`boXJ&Uujr#v$t@_2r82HGn1+rIhSS<(!UN%CX~7a=+yK+GnR2-?|Y+`5<8fANg$ z$Xp*E<(IZ@PM0PCf%ZQ5*<>~|%O|%Nnah-8=zF4x*yk18Ji(}K9}9uF@4+<*BHl!V zpX$YKYMF<_gQ`l;12zr2OdH8^mjtj%?>77I1w&<` zc-*kw!&r>m_2j~QPbMD|HpeKXj$8es*k2a(xGE8xidnA+%)qQ_3sVJFJLB@8NQt`TjM}MO2h&3NIvli3BbW#W8`o(t~VONITXN&po5nMpj zFpo`}zHCKUy}>^f&fd-Siyx>ez;2#>GL=>*mqw8(V>18?zPES0d!7&rp3%o%PwenO zzi9$~W!K$zFv&&Ka=#qs1#%alxeusimBZel>)5-4qr9H&%u~WWa_{#$sh}G9R>V?# zSkx?%3PLL`99%n}rYb{hZgUm8T#yh|BD!>M#mgi#i7oDs~gt3?Fo;b}g zR*k%DPoStc6KTodf(X)ksEnq=aKe0F+)lnkf;IT;pvuCwCG+4a(sx2k*Oi+KPU+3# zO15>M`Cz$Dh&nM(0zD-YDKh#1MSrZ%YqT@YTmjVBFaXq<{t8 z#*gl}QO&%or(8szZwEYd+UDfHn$wch#?H=W8l?cl?Qi_;YT5DBqp`GvHmJ#ntNowX zUjzbJLTZYc#hVaBn?F}1a`@8rGql(r808l}5?c(UqCv6mjl0g$iYD`^8Sd!0S2ZQM zUgwRBBm8b8-ozuS=*3&5oWaoG8+%<6Vh|Z9>AK88fGra(O&ea>m1^~fZdL8x%*DYf zV^5xI#43d~kE$@tmTWUxFz%X$+o(z%a|NGUV`$J^2`1y)o5i!3G%)d`2MdR=5RVyU zyu0@KYk;9T?iE{f^jM{5Y3Mqt(Gz?t2eHG8t~g?JtfTiVQNsDgnSWHz0= z>Yr4V$Nv{GLwm^$Fl~M28V|jJUL+rwlAfND28N%a!hmPHZ+{N)AQPmraavcXbTZ1`taix@yWAkmKzA0s-%SyT<0abox7Kjp4r`c4tU^m7#kureZc zYGO|z+Y4cw_($;p+JQ`1bMF$cbRroP9{V#_EOjH|3mTGnH`ynouhRo`EhvQIWpd6O zgu*hT{#_9-{&}DA|JC=;XdB<5?fa{Hy8Ozz`o8{T`F~YM*X8H`q;4qO|MWZQ{GX!r zKjrPeQ~&RH|Ev2~-sAO^_g=)k|Mb={p`Wa;ulfCd=bLzm@5;~rL_^p8Pj&vgW&clc z5kB<&-=+Ki*ZbdVNB>Elq528^{&z5}^LJ&u|99nocmMBj{deoLUg-Pp@crMsPyYUI z($}=f$A9(Kb^lL(YM%a2()@n|Ew=lw_^5G&CeIU%b?&q@PjTfS_Hy4pB21QvGfSPN^$`mi0GF>QTZ?ha z!=h{n<2I->K0CZ z@F^6g#B>)pTa344{#yIOMM6x>T2V}#ivAeNeC!;EsRINt0dEQPjt1hqi9l@Ikx-y3 z&$In7q{X%v9)n6PI^quR4|m=kol9|B4NNQWijUgc70IxQoT^HjwW6V=q$cqP?nW=dP94qc*~aFr*@I{`)c8>;qZh2&NyyO?oYRXQ!Z=sGY#A(Xf?I!yR$+ zE`&QjcMK8+-IMeZh*BQG+ai=+H0cpL&NRFfo=wWy)x=vXx}pc~&4z(>ud;6tq-uAy za-;x{;H_MyJzk<0hDE=?mm{W38&(7j3mYSu0E=bk!>ig+Qmcy1ULkDKQL=6bYf-lD zRsYH0FN38nkk((ZrO^Zt_+wN3?NOu+F1E55ySkpYT6fpmnRDU% zIs0|it~OiP?uK?;+RlYnMDOid<%pbA8NEC{-nu)gvU^pXUG;CiaK2tt>AH7^6BRrF0_H zq*SLIiq624tu)0|7@Z`XHbrJ#PKLq>(-27;X&SeO$lMlU8t^~DG;B%(@p01mUa_~aIb@nuWW8IdupMeo-s)@(1Xk@K4u6C+mbGsT`aBoy1C zkiCh8O-joPXtbg*OG)y|?j_815PMZ`R8{6WH$-$W*9i$I3i@i>UYKj8QL(gPylpQm zBkzLEy8C9xF6zR6@YykF!7jD}jIHZd_Y0bBC66d_Zk_F!?UOU^DW28(JIafn8%2jfA`)QBR=Q#*zz`%+tU6FXd`Wlxkn>7r55%3|9S zb+PDTmBq0)s_H)Hp0Un~sEf%Q|^N5kj_2P97v z7kx*0dC2lm7Kc5)))=;MBiY_80iGJJjGYKxLNqV|#pgmBIED@6inMCrcOeag$$ERD z2x!DB%KlQjvWu@=Tyw#Q{$y42v**@cJbS@dQEzWWRAmqQ*$bANZI!llXBRdx98oqj z<8M5`duYMD&S34RU0JLQS8Et-ti{J`mb?5ly~Lfn!_RPz*``*Pt?Jyc5vt{ z#)TSS3|_Zk82B7-3G|Kyai|U9F~bcSLMwb;3GA$8o@9SHd8B zBwQF_;=<_V;hSP$X&fWB>{Zn=U>~_OhwsH+4H`J6k+*Wk8 zTdYlOl}qi@?Rya1U3C1ddwmKD3+q)q#3|9nIuB(sw&u$b+bM#dO1v253=Y26;g(DJ z0}T9q7%b$q#Z8Vie2Ia77A7{kr(1XBR@yF{x549E9Tg32f+=UU%7y1GlVFC?8a(v} zPt38;oU!FrMq1p>5NtBn*@ZPPFiFS~w=jzw(zQ5-SR>2uNgFH|;ba{7g^JqXjyO3L zpF-ryz1#$cumDQ8B*497bL{48>n%^=A+W@iNz;?Hmr=TZ-?5-v^bzd@*ygHG-77nL z5Ju6YwKkbO_AwGn`=RRrb}1Arj?sSx02*D(Hq8yXy2n%J3`QFa1c-`<;|o>Dq3y2& zihc`47CRrv764Iev|AeO8<>8uZ)?8c91QW39Qc%ukT6@((-OL9n0La|oJ9lOh{}J2 z5*k56A3+q-;}s~|6~Cv^jD}8gb>157ygJg-$r*3Sh`}}OhM&$Kt0Ai5Fu>FVy$?{YHznI%F+A0%@GwgwfA|uv#IT3Q~L#XRi!kGJGlnM06l}S9jbpIKJa0jY%du3X%+CE#3m51#5u&67Lm{ z`Ek|rioHcf`5ZT(ji$iC9(yx!)xbFy26_zG7DH-M%1IFbV)8@-^#PEz7SQ@Zu(ebT z^p#x!QFNpPl!mPq&}jh79HN09wkROo6{tC}QwyK6$z*R=u3=o|(Lk;%fkvaUqZXwO z0C+G6lw!4yk&@7+a~q(-YC**n8b&hSQW6i_7Ac+RR*eOevj&vZ$pg^x1;1Siha67{cKN4B0rkGL$1!20kNeL7f1^wnud{-m%R=^XcC- zR3@OJYCy^6-!lj6^K&)a4VF3cgaOg>lNelv5nTg}ZgCL+4rm|-)0?(UNTi!7QjfSP zEcF!@7_w2P7M8c>;ZgGWn)K~q3P>v~8$fky0l5G$x%@J*7#17pC})SERl8Y+MWIUI4rr z1iD`XX?}eGx~dk?764q-K;-v{W!=QkROHU)ju6eS#sZ&U#MQ!5=V`ZV^r~$ zti4CXlKO$j>>wtsyotaRUkg(@uqBjU9~?^Z z>JS>SHC)M1llP;zX)R1uz;ffW8WY4(_qLqb99WCJ5C}dM7A=kdZZ)fgr9UuCdQM}3 zI1V;Slt-e|`oIl|D@?j&#kh5KC?@3^7Xr_WW!g2eXY#dji}lB?bd7&*wO-mLT%)xN z_oc1gViAdd`njgKNoy^^XY(59Iifrb#J(4RyxTkxU!#)o!^hSYJBa$V9oFAI;g@%J zT7TKeFJ-%|Yj;Uv?W=X&qsf{42ms;?fq<_-$l6#S^R2pZr6|58l)8#z?+5MGFKR(S z+!G%E=ossX?fj6E!ox6~t+*GT388r6*ot?7A$=u9G%rUB=<^EeN1u}CZ$7n_e3`=I5|9e%DV9azwEwXec+-Hy>X^YQHG9>o&V`24sYC9#-~X@kpj|Eoq?h@ zwJ1LK9+FL)K{0NA7Dr*eKDgiZ&r)NE9MFg?CW?fxo8mvgtRWL z^LZ$07m6^JT-bIP#`}9T&|JF$YKh9^VgWwe*8wf%ufK& z;wud_H(UWVR6vLxjE=Q{`T^kbAq}+C2_PDUHtWX$bYm@`4d3C6tM4^XBP)PH^@yR^ z=u`{n4gkD+LIdq}0EiOQy28k7bgl(d0f4Gg8mJU&F9=1b;uut?C@_Q?U21^IP~@@G zhSBqk25e_rB&QTe3SV7%ggcE zy9U@osOu{LxFR&r(*&YvXovO!fNrh@R0@DkarBR*bQBS>vM5apgPPH&7TB)c*U>-^IswF1HA7{#3ZtCSw-(SW0OTMUCmD1^0EqU~Q~_a> zGsG_#;4{=^>;=f?1{&-+O-l>@WrEkB#esH3LyPez-jbGuw8)?aS_Pn_P@p-?48arX z^hTq)CN5M8bOuH63vun0*B9nz^%U2Bd7Yj5={w>Y z;XUgge(Kr>#C1SkZ=RSU;U~)LGhZLyB+4;^VSQ`v89uOLj7MP4>nBFV$okpxy5)n9 zzaq->!8b&0%A{%Lp*an1Av@ReM3>-*xmSY98wf3dvIk=NEu zuRbiwG1p}M)mPOi5!Z!=aX0ufc)?fvzkAv6w_z`v#Ts9~m(6OApWX|rh4Bydvf0Dq z+w`(IBIB>akGe+3Khn$QtQ$Y0mn}Rder7LQM1%NQy=;-O@%?()q8i61_p(LD#n0_! ztJ5TYPA^;CX7TfS+3GcqpWn+ClTa&trpYJbiHh|&lGL6QE|jhpv5)~cl+#kOXhd~b z^B3=6g6L{AhW5J})ssWbL&ZGX8(WM6O|?~h?!01l`wGDN)d1sc{5$~uiKm67Dc)dL z(_7su*8r%0EuaYi*dGMy6`_E1Us(&Flv+T)0bnT>wj`zVHUP1M>7ijAfChvDDSx;b zAkEssABrTQj)ngG$iDXzY|DqwOOOaVBh>?!LX^6rzY3HCYoO$KeG`yP5eVl7L#uE0 z*w60~=pq$=DYp3wYIMrifoxDHG9~pnMAb<*>q9HRLTCCL0G1jGCUVo)0HCrP0DI2O zyACzz;(tD5pY=U?SoXbr`H%ea){pjc;>(63_Fs+)?;nM_$Ywi(v z*SdHE^#+I17m@hhe}7U4&-$#? z#XZ%5y7p=B0_BiUluCS2c0|sao)c4N7h>?> z#EC-J;S6RA#>g6!=v`WaMw@}4(`|vUb5t^pPj|fZkfVW-`1K6O;}7%8@mY@Tk2qlP zYyRz+H=AF$sv#}ntLo@oH|k>`Ne?B}hr?qV+*R5C8|s<3P{U(z-_`&`R9G{ivg|Cz zi=rQPPjP2X=UeOZ*?2#=$Iue%{L$jV$RXAz?Hw#}!?So5iFd~k5ZAA0Wx^n(h!o+9 zXvf6NCBEJGyoIFkqVerpc8~atobmF68bz_ZxyH{9jvq1asLNfczUc`uBAU6%=RaIJ}Z2zzr_`Pze*;;$_w#~L0;Y$HXne?9VA~}%E$wQR| zSmIn0x6uMDV^D}zytz${^mOhQ>cb$l3nimMl_dPmlW2hpkLpR?_6k#hkJjv70FAB% z^Z)=dMrxq$;Q*qux(1a=sREz3g#sxXe*hqjvS53I5J(r^j9PrnSmju=iYB&ymE+lU z4n)n{);WH8onIENckF$GUmktWv3oP?yt&1(W~;Er$X5=RDXv#Y=SJgi4uoXkQ+$pI zWkET&o*+LO{!BLaar->EjHNl>53t*7fH4nS0DuYE8Ym({0cjb14WO~LfMx;Utsu}& zQX+$O6@%a4^Nw0Ty8&S2XiDFOD&f znjU#w(x{S~T zSrmwHG{ZWHPp}!S@e{g~jCugba7LUa!$WtOnvG1&hV1}a89^^18_XzPI zy}y|w_ErEm6V5=Q7aGz&gpdlosNq@w^rbjmwdU}>=L^S*FQww174lC}y;4*D9(csD z#H4~4yTO!=JQ5d;%FdRJn$z48E1N_HCC%(?*E68iy-+vl3ame(X3voJ%q))=KiS*b zje|N!N%&x3RvtIl8ddJP6PPOkA=pFx?Ga$;r9C1)seQhn%#4(x3<@sGRxh&dK-_Vw>jGCtH6#a81X_aPUFw-6v*=#jAIZG{nq{NQ7`#$*Ug zzXFq43)9=ca#xwcWWNPbt(+X{B-9B&xoSa82E?;LsIS5n$pJz~Unc>SQ3FWM|2G0; z_5GS{jP~A=XT*>7_~cPn{XKr1H3IVjzRahK<@XKRs!ai9O z7G@;=z9wwlT7EIY_ap*FTIB21*(g1Ss6=5-C}}lNC4y|96-spW&Nh{2)05cC0L!fb z#^r-C05}i?dfovbcBXh#rbqb`pV;vtUQ%}i`V#fZi+AN6`FFF5siA6uW?5tePFB{i5 zzgxpEPp@?@Sm#7a{q;AThu&l5^3BeTn^`pd1LxYU{Icd_=O-WY%ahxkA8zLt1M%F7 z-;RUjxbk2c=Gb!Q`zuM8O$oVQvDP_joq!6jasT*6=f`j1m)KZex}e(`e1|Tu)Pr;; z)spcz$i;soRK}~aW;2Y$8A0NQvz4Yeu+X)%1eVFQu*?RA3qLC?_Re7dqLFL$wgOOT zEuiqD79-`?5Yk)U@`+U$kNiNw)@;DYdX11%{hXDlE8$4W<7#iM`$Zdo-5m-R$90Mq(ncd$EWK7R2B-PI?p=@l0O1uRiomOOv#dgLQ#eR1`zaNKw;5Wz-uF#yc z`|Ao^Q$ulyCH0&LtFb1E>4xeB?vo3`S1ux(u!kUpU6$=TX&#aS4yf~s+!HD25ekV^ zB*I3Bg5UL0oivmcO$k{O4uiQPxCkl>=OGJI0Kq;V&#D z)^C@FSBWpe#8s=XcXRC7PARlrc?hUD3nqBrh?1XYKQ@ zGTl}E#F`a_d@sAvZcOcJ7cpa+_0Vd@jGVoSlat%xf}z{KZIP|mS>#DTJQu28DSk;@ zavof@5OXtTV$VasZ^tWxNU=K_Trq1+1oJnlST&oUWP~p<596aQv!KZh$`lug2N76I z;nM5NA+O$B5AC45eBK&o&Ts>6=n&iw*k;ticJDP-V=3N2Y=L7p05r1}&_n=awAVmiiT$!}iN>dI6B)1{#a?w>4NKg-;GBQWqKGq3z`s{-NVqFpZz-nOXjh{^ZFVR%)s?RSrRPR!E0blD7wH-(-VPwzu#SRm2hf~aKnbI)Mz1?GPy_}+38jZv9*{LR6e_|( z)90_ZDARxcuT4LgbtEt~wS2wZsK8Obc25KGbJ6ynr9rE7B217wwI5W5$k@C(ML<7q z|HER58J@u&!=BU;hkm)5;Y_v1@D`YmF4Q)zlLU8y&Cj)2ibqE3AMYs;5RLS|l`u+c z{4~h8YwYev^L(uN+lN!>+*Wy9=!;OwsOSn?s_4t$)0%YP8NL9)OOyDrzM-| zEX7>0yv{5=q+!@&5|M3LgQu|Y89PEeJIVWcONks~?!c{ip=!T!xIG%G_2BAK?cuh; zCc82F1F3b6uJ%$eqJk@W=dzqpI_Lg z6#ZY1uybmRux!0_0@zz1M%cS>Ykp|!l@mAu<_2XjT*IU+IPaOeCE|lEH9C4ySh++< zyJbHg4}=Rs5ei>49;kjs9~IVX|4#TK_E_y5T!30w14_Hv_2&>LOsaa3FeGW1 zg%FB?HUezr&OROkFiw5p}LaR)a0NqVqu1Gw*NM z$_27+8kz7z1DLa%_rm^_4sg|)Y~hplF8tP3%>7!6M&lkLg#nWf{+m9pH3+fJxE{@O zINwFC6TeF64oMv7bpj5LBHJnQD2OB4;Vk9#UYKq(m~L<@>u=vgtU4e}*BAr{r6M&Q z)e7=}`R-b#pgwF$2eI_lTH&rggD#Z@$k&XDSzx*sCT%nJ&a!e)w^(P{thi&h&vMu} z$cMEG3x~^cM(*iq3yWA**c>sGn6in=l z`2YZS;uLmEGr2nlm5if5M6CK*#u{iz_3oErKSn(Iv(Ta5`1p=K#6%C`Sb;L02qhwx zp^HIa;bhI(hjwsAC2EJ@1JIM9Kvy2j@P4R62rf4csP^dE7->i}#_>FL72jP)L3P~y zy06sQCNL3{JB1ir$sMI8sCgFr280HQtXsqEbVS{e!@me0wD8sOT+nz&E{T+p5e(&28(JSNsA#*g=6X96G) zoQ&?asSy{e#xpt*hvmv&Y0DuJEC1j{>s%V$727SBhT+j!`v%+-BCPGD#&mZW)*cQV zOHlK8s2ax-I1sTZ#}luDm3z>xWufg-g5SB!YRq1vWq1w`PEv$Ay*U+7&)0xrHsDRv z|7o3usS^Ppim)xXrraL@(DGV9;jdba_g>RL_4WA&+UlnP=!H-qWs9E!WDQP1sksjS z`_ag%WB5hwVD`&?t=u(EKJ+B*L7;pw6s2l%H|)ZF<_*os`!=<3pxxj@09#Q5jLRz7 z+pI>x4h{4+V3+{Wq~-!(Bi`f0vnypP$3e3vi&CaN_!3=s0nXFwbFj<>PyX&IV8+cE=UZpa&zd z6xZRM=nA`3n}}`o%2t;(3Xn?)pP);mVXu6@}P4Ygr5xi0Y`Hk{w~~4 zn?i3S5o5Z+W24aSNtL$c-MUs;?0ax~(y-S~kWA$8l5mDV(m#-C^VvbF)R@ za8+naP3pK1K&qvuLt7fuF)~u(7_ve(GvqV~B%3T&oP@O0rVbgZfR>vZ@z+@PHVxx} z5KSHDJ(U-+MZU$}{K_hO_y)A?il))7`Re$x!)US^O>F1 zOE>FrG;4Kev##_r5sgfOi!&OlkHKQ!p7P@d;>Rn4rC2v!Gpt>d#&o{=Sv2jH z(55|0jU5LerLk*6o7Ral%UBdT-;cJy*{uGl^9Gv5xI0`oOi8+7>|J-+D{KKJ{3KG0iyxxvPC^-j9pmuR%<3oh{`C1N^8gf3yV$U8tctf#Z1ZgqA3? zWDTE0z|nZO?3mE6Miqa8{Cz(_;-|Wb3K9ao1cgdG_?mzT7=LC&;7jm$6LJFu`P~!z zh3-ro{Epul$M08kgtBk7TZRmuNHYJxyT32N>kA|l``roRH(GB1psy$azg!@WoKN6y zY-r5>1eZUAZ%2J9gaT;70x@S=( z@>DqW#1SbDW{h6i#JDQTQqeFBW}jGDcW*;yVr9L(*c=-Z->4$5%GO|M{rC>3A08{} zH(nMi>qm(CajY3nJGr74XqR~>Ol0s@n90N|#-{}5p=@p;;46%A3_7?yaS*aliN+k< zQ)bg#b@b<8Hfuu7rjE!wZo_S5H@E(!-EctNxUBdg&fnA=+8Bf&0~?;`X~`zKpW!@h zPqy?KQ80M7e-tz%t0ojcs|gwI1o=ZI{sjIeHS~m^a!L?C@{oYvI10EX0{|=BHSjHR zKD)>=Vnor(z<1VU;L|1tYbkaoz;+URg|vo*mV&94y%XG%VI_DJHo@gh5I-kG8^Cw@ z^BElyKm$!VeCVHIgMLPFARz}vBW?bGqyDMMprQ}I4qzMezG&_Y>%oFr(<`=H{F`| z>)FP;;_Gb5`{hDh)5>3)oPDTux$;a*)WzEy>{-~>Xjr}=z77Fnm$_gkca)udjia}%8gcT}+OsFm zG+vRkb9dCa9#tpLTm}31Fz@*J_@?K6ZCZI^*;Vl^K77dDRGNpaS^n`~&Nqj_I1<`@ z7-)TIQrY$gm*e*bZVGbzpU)z zPM@YxMS2H=jPU_WbE{ z))gIg?~S_9qw4fI+n)G{kMmAlbS#U1$l`4GQPjoWC#>Q8Ym1CJadTB=^t#gstnu_9f?hS;$oij5vcK}A8Is3=GaAu96y&y?M}S$yB``i4~FY495edXh~ zXtBvZw-BVvY~RvS=b$ZYriKc^?)XfNoG#HV)_g9tEM)84iU~ z(7AR)oAFSn0iCVRbTAszH*Knqv$OTfxU4_q=(ubQ@K9DFqsnxW*jKn-yoU8FrKaxG zd#_WRVXV;UPG%NfMX2^pGL}WO2NxG}`AHMq z+gy!C?yRvgD)*Df`F=5$Rdo?0os~Pke1q(a1#~bY{-=9qemQZ8BxYNJL+bJ?*u8gr zzC1ytR!k0OH1ZpQ=jd|q+ci0^c5TBt5a(!^#=ZxXh_o@s9 zBm*z%F`-Vcbrr8g>-RV=UO0~p_H9?Yx!?1qdvp$#Am_^n82mR@u`g=iCNsTZW^br_ zBMo~7o>v3+MC(7bU%X%lN>tfv#*j^!{;lFG81M=^-N5q!C9$;h09>0!3=OZPF zXk@QrPHbyaKc(xcL}R4-OkDNF7cOqQ(9Qpo=OWIYd-3Ag3*DYJ9b9;+z5DjFO(BXo z((p__{z@EP>BV1(dm2-rZPCidk?Kc|-_NwiZ}b8p0f;!IceIfY&T4g*I(s4{jNEWT z6XRx@@-&781y?H%C9C<96cyEgT0Hmogp0m^3m~s(o0xDe`Crg0UYDewXb{_yKqEN0 z!s{vEUUkEfC$k3-AN?Uw6TPwfK?`~spw~P=QGe={o32XG!v=sz3CP*RtpL5Q1qqK@ z10bgi80@h*omyMCx)#2If%-G@Bt8$&n;sxD05hGSHX}e} zmC2M|0O&0bkOP1XSdYr{b;2Y-vRJkO^tK1+eE@=ShBOCN149CqF3T5zdB+2ji1%Z= zNX%ijfkVsQcA(zXqC~M219JqI`>gTCC;VHVV8tS*ZI(i`Jc5$s{UuP`=|++Kai>9R zR}j%_aV|Ewf4%=(>lrnI`rez=>bEB=z96+KUc{N2KFn_w{9r%am1E(Cg9Fi` zH~Jw$Y&y!uudNlvtnonMr4EDXK)}@{mwdJu{q(Ozn-2u&_Bk%KU-YFAvi^ACvOX}{ z=Kw;d2eCC7n=rYEuLIlEumeSiGmAsF`>eXFZ)V1pMLB-5oi z4#5Yq&47>f4TyLgb?Nw!CuGal8&I5Vt*Ans64PV`#u@yZawsA6v}`(7mar0S)*YfkKIniorbj8Okh@T8Lh@yyIgsn{)6N($jddj6vIA1+c~-CH*F{IbKQ{b@GwjOoY{YNLvPe|-AJEb9wU1?ESV}7H z21{8zqh2(*{8Udt60gjq)W6IQEp_RQH$ZW70NA{ zr`<#}U;W0~hiEPshtpp1KiO!SIg!+8gHni#H&IxHqpn(ZkRAd-r_)az6Di6(98YKl zgI2oj6;_{gB2O?GgDAzVhYvhLDOQMFsPn?rUIBn-zN7^(^>B zT?R+K}Gnjj5ac;jqsBZQeJ>oP;la7t`Bxakxul%^*vI zje!>o{(E6k8+xX<8G7Miv_8GfCy`MyB!ir9%BBzkTt|FF8;CX3G(2EW{rd8!gIrJh zGa|@`|G@M%|3UIsz>xH|fOPpQaCmxK;K+!pDU{(ZqxaXqd9}B&?c#+o2-=T%GD$yp z9MT-#)}ASW2LJT7kn8cw4|xooh%XUWG#B}?(!Y4pxnVf0<6ASQaXK4M+9(KlxWja5w% zIXZpBPSh(Zb-qkn*0#5CH&ZB0G>szqD(gC1|L%`yL`r}zSziM;2BHz6%5$?UITD*f zoeMGi&`A)EQ^%l;8Io^-`fjZ*?0jNEou;W7oVpOY0gaU{!g^Mw;o9e&kx!&h5ym;w+oBDL*!9&r%eu|oG{3O)yacuh;`?<3Q z)AsXC@d|>71Fy9QG!6G6)Sy=eRDb&am?^?=#jm>BUv@$vVthhU{!p9a&TG-1)8^PY z)kit*6)>S92V9ZWN+0qXi`)%%=r++$|b|9KO-XD;tKnFw!*ip&TkY=Y)|QfxU+uex%JIJJ)0s0HVj)ea#$tEo^S^I~3#&|Z-=+p`Hzdqe!J23nQg&vZvIIz_dub`Lfa^E-& za9y!zXo5U#1j&xVi;hy%A4M4?VLcyt0_bDRsm7c#v>LP-c>^#F5VcP6527|DrU0bc z`T)1C7i!C{?Vp`{b|N~kd=y;aI^Ym}z~Hg!{Hi4ThHz^G&Yf~zw(D^$Ekf+RoWfK zsPY0I^@`DDth+XTT%(Pb=F%*=H5c3QtoIK$C?DeDyh0ex0UKxc3$Qyz2!TY}>YMNg zjUhBNz$i|qgBEu61~*Y}a06Zw-Oc0L8s#)08lkr3fIys6!;78HsOy0C4b^2B^oM%t zX|@38Wpu$BnM-XZ%&vHzFCy)sBy3aOflKxyqI8*eniL#;j2Q;sYDCR(W);V_Nt*xR~>BA6?pXW!WNSKp(eQ+8-2pT z`@DUV4=7=mulj-fuuDGJ{1S)%eFKz;%gj|g?2;e0qs+%W|6spM>FoibKt)_$fc-FP zIQyD|uYr;5>j`}Af>Y=Y)&yZeczbXxzGA}{jMFuF$5tmcQE(z;-uqND~ zXL9R>R|mF-CW6KE_K0L+17Gn{Xd?bZrodT#`6|M|Df=Ceaw`4mk6-l8!uCsWPG7z{ z!1cR7{T}H0J&=CW7E|&5AUUtlq#My(JOomt%F6ee(cvy$QLuv}$QG`K4a{s|HeaJ> z1waea$PVT{5-d(*n(H%=->21FLLmoVZ%`hbC>5R+akV&32FCanxczQ8TB*4Oh+8K~ z)Cxl*51kwdHc3r>2hafz&j?bQPs_0=GSvk;-$Uk2R(eELP>y-P3IKV?1=GiNhMfiMTMyXtfE;nbwi{*Mq|I{2P_qknG#0+s0kTMJ|w4dC9l1TC=aTIB%uqS!lohdn|HQU zaZ5nq2`3dagXizNZYk9>7y~om_Ze4Of{DyZY(?XBNtW(KQ2XA4r`JL0f|i>8zRxqs z)Bv>^l}jDA8F{5;FexN8S?KTxDL;5n8=GfPs&5s7QQtNS7Nl4@0Q#>7s0DzR7fMjD zPSg_#`U9XJJwUG%8x&)y1O*uBKs4$(L%=G@?oXgjdZ4-kF|ACZtlmw0y}ZoSUjY5& z0V)AtCe{LS%~)jui0ZL4z^?%Gvlg_PuX}S@xSOMMz?HCY?;#79jg7nM%Ie!e#_ebt%E|UsKC)kBrWwFPM+tR$NxObP67f zsbu%ZzL&X@EGHfjVS4enT+|`F@0)&k9o;Xt6_+lu5deLqE}G_cR(_T_gXVS^1S{w= z9mNw%W@nXC=@ayk-^?-0zQvJ8l{P%Zef1(K;{7pyR8XBEJKX7-B^0Qx`EEokwI*>+ z5|FMps111C8OFv3m?yH8qt+6=Z)3Y&p&HGZA4jX~v8bMNQ7~ZEa5AlMN|3cOuZY=| zl+OHlU(Y7)?Inv!7uv=#9&bRLhzi`JbWT3`#u4i6sa{i+rW~DVc7G3Ozeh5;c}O(4wXJ7`sIP7NxEw7(LXA>=J1(hRJtjWZQvYh57 z zQlJ4QY6-Fpe+?j2StS|SO(5#7B}fm@BrS-AsA&XX2o^|dL)3iuTR{8i09sNY=dN{< z18LS6KF(HiGKx$aE1|8`pHLVfIo7|8TlwuArH{By~7qLr6>lN?$)O4&nqUGdw{4^#-MPlLY-jAgVH?%&4BB7AiA6K%)V;u33Uk6NpY|kp&zG z&@2zoEC9wlBthq7N|L=U0L}IQ%>$tCBNEg`AgxIl1kk_SKwN}319Eb$gmnlJQg$$Px!LMif8`BnUmj z%I>EYQO{7!Vro@jIw2Z+matt(cU{)PMR!d6JrNJB6ms5@=Rj9sp?%%YvzDp0fdtWmmm zZHGfepJ=4LYKdOh?5k}hu zLPPY4Q8i(q`o!p(@GyO1Oie_%J~6f?GD4r&y(TJBpV(tnqG6yR8b`JoV)Tisf1*B; zRui^goeiGhZHZMEU-H^gA8l~mjMNWmGwomLGyGDUuYc>n%d!58I|8@ZB5(-x0h*KT zf>}|H--lN(1`lcrrFAmln`p|??NQ{QwrHf$HJ0JJ?UN7p0(YUupo?+)3b8SzCzb;C zYHcdg^^VlfNler?tyhx#6MaGwyGFE!DF;Hk5%uK6ZZ+Mb#HyM`U5@Gaq7;an>LzW3 z4PNmJEz}Oe6jG3~0+&wpRtg>>3k(g6wniAxuh3>MEOW&_e$RyeY2Bq4{x^~zjXkBp z=PRGODtx2a-;mWWT05K_Eqe1W2IVVUykY)gpe0*GSGE^~(o#-oQKBn94b1j)=tkWR zJAM0`F25XuYRmZLyDl3~&=*8V+ngb&zoM%bqY&Aqx`O(zTI!-#y#mT_wn?s*d)M=0 z31p{*;9AOWZZPV9J_lgZB?-z0hV+u`9nHX;_Q1@?`!BRh%sDKA6#`nJ0;JVBJpnqa1qtb& z1jKHn2oMywMH*6TRt44FAH>WUGcV7H#s)~7^q*uS0Tj<^DGG`20ku241tXND`s?oO z?aC5UKuQB2F-uy#K?_TB*@v5Xv{Ev_M^&arfHzHm#z(gXJ@yQGuMEX!*1W}8BD;rm zAV_5-yMaUyyr3l*M!i%Kh@Fa*GBPsX5miyy4v=VxFF)liAEqu@cmTPzCO&zCc~}K-~hwk51HK8p>16l0xeTP=^QT z3INl($)s-61LTbv7+F630s6xOR1Sc#y97NehW~Qy=>TB<^uWa8{W}sRCfbMG6O@u< zkEVP7azpWM`XOL?CP~~eLz8pO#3kb9th93m0rj^B>f1i5 zvfLt3Rxhz=St`cC0A2L}tpnhpR0#?;0Yvq}jJiVhU-oMRhg77LC4jbx!EjBYdAov2j~_6R!NY_CkUb5kr6geN3s|JkkJFw0>BOlQhmGx zh*TVbMgrvJ0s0I8pJ9@{s?I^>M*(E=0L1}tbhrcsJ5L9fVjm5Zw;PHJ@GLM*BP7m8 zFIIv}rI-Pjj~k4XV#!EVnK@p7n7bu4j_s;|A!u_TUW-_4$*E9?06pcv#vk(LCM%u$tp=TN`Z;*2L%^LlXg&S2_M zb>utZjmFf=r;eM`vQ|z6!C);xq3-KIZlG0W?TTK&l9AKLh-ld~x37$U>DAFDM5)WSTdT?D1C z$|Mgqy#Pr8P6a631M~*~E#(sQqEUck#M>-@B0NB^0WhLcf^LKT$@!D0X+W_vm7Eog zWK_KfYId;q~5)^Kd zHmtNHW&;)DfvUetRch`ND6*$!e>mc}%bsF`IHjIXa!S=P2b5y9ltfKmh9Ij)9_U=t z?`;Tqsv(5xrjMvAbI`MKijucmK(VVEMe>~FV`=G$HAK&KR^I7{LK+_C)G~O@JEv=K zXD=JXx@n1tT7DIzT56?$rkMbv_A4t3EoJGhg|UcWwauz>8kaWm*VgAketHg02bUWz zo!PHMO)4HMsP)iN3nRtj*P<%F;^Le?trv!>tPiw$$?O60e@Ip8adFTaMgfwwAs?VP zEl663fUI~FoLgXf+s&jF@cH4TkQZJi-uJ#7a`Y7vWZNqtyI?r<7>oY3X0xgs#>H8mW)v|XX(EHVVg%q*dTBvIK0g6+<~8te z9ptmHHLO$=5`=< zI8hF9@{R1~76Fs&fqC;IRT=V$OsUNzKr$}cVu1R1fF=U)ganbXu_pKs+X1)$^PaRl z0aPfPvL9LkDk)kjq9p5%phrAPwMje5+`2vV%yuR>Us0>CpjLB7rPO5AplH!j6oOj| zYR3?{kjwivFY4P!aB|#q7jUUsTom=pe*rQ7TjImDLF}csLXW%^O4?7l?8Ck5`1U$U z>~0WC(-LD2k8%*&iHoxk-~|xr7pXDt1*oqF=vx51zmuRhC?x{PM!XWBejcC%0KRsD zf@Ml_0C68c{XIZu04O^yQ+fp&oo7lKhKQ4=3~)p7uI(r=kDQRWIwSQ`#G-8C_X9W3 z4M+Xx`=?aplV2suXsCDJuU8AubsnHo06chFf~HB3)SGnx4e|hO1fb%K1Z_h?R0Cyw zsRw4T2c{nHcl}*r`m2IFS-uSb4eNTfs^@`C$D3qr&?WtazO1^@@6B=vH}XoLsoUjRIsBtT>oPKv#2Ew%c}a%)Ki#s8ssNQ^!NHK~iXg4#$A zYTH0*L$ag>lV(`jUqi_`S!gSvU}*^h@Lfni^7RZTjq;#05c`_er%FoT>r}VO+0?JN z@x`f8HIYM=XF+YW2ens0X=|FK2EIbhzwot|ul}BVJqJn|T1rCYMW!2-Be>jE-m@3N zS}%l=vQb0@Ipj1{Wdqv=ieua;lJDj;XsuZQdgB{P1_DhTR7YFbFOP(yUwY}W@IM|4 z2ica#!%u9)bVkP2jp2K@(Vd^Rg+K6acpy>?-1^t8)fkjC*r->c&zE)KUpBL6SS)m0 zax}=)d5On%a5PrSkx;^K<{FjFc|u<5KJTU$8|h$K|K0#>oEFBWO@9EOxB(e)G%WrX zn7~WQ+E2qT?;&ot91LH3C>$onjzi(E{}67{Wqk8P`1X_Z=!=u#Z=Rwrcb^GAw=yD9 zpHXvP#Mk#nAZzXSNBp>+zTCYbV(%9EqWEsTdJ37V1$cZC}0v9FNy#i=FUyH?njB7jO3W8v)X4&5r=e z^Z@+@fVEkII#dCYtq1WJl?fi8I{?`5kObXJAYxDImrnq?-UIYH03nY_&=|P>-1++y zs2e;`NkF{nLps@g`n~KvO(G=K-kPB0+X@b?I+`MRKtYT3+Jc*91e!j!hhXCOLFOO#nT*MVH}o05~II0iw+ z`-R?vIei$Y=^m(DAWpp{QL~KF6(a{7UjW4xwx9uWuMf|+*V{(rXI!Ec(HZr`qSPo~ z0yfhvF|s|BcfjHy35wHoI-~vwK(jnRqXF=0m7wK%0g_epC_uBdAR%EhAj)T*)%yC) zkzZ|&Bnd0kob_qgKGLb<{|Y4kr6nn}XcWke`&@FOqv*VpXX!os2C$pmU}P_>2jB-M z$R^L|lJ))=Kyy4mR{(en(TO;Vn?yoVaeNEREgqPlFN{i`FC}KVPJm=b`W--XJwP`A z@XApMIwu1T%bIo^pllCN7UJ%#L0lTf9oZN=e!K52vR2E=Z8NoI23VjrBrC-UP@CsL z?P*Z@Q&Llp@ld%WSJ_~{2W-9@j90<(AC1Z{xHua@S;78i=4^G)D)&mP`NSdsN?Q(H ze*lpMZbZn5@CV?fCtW0RC)~H5Ia%$FDT@AP#Aj3sNDUl6ySTR07+f=BS2OU z&|?5x_nS->0-Vz8M#d@3su^tdpD%7xK#e3J%kU(q<$6$?1WHrRN*3aX1p>(i@)JOL z9w0jauU?d(Dmu%I#3g0^GeG$spicqtZkM1Ay+}!B_7{L`9-uS;;x9|kPJ!tOA(K`* z1x$elX5LjuRqrM0|7y4fggTab^*6xS`2irq=OImpbSTh=0a6e|1R?NKb%oSm$ozU^ zWz_d8qtNQl)kJ+)7iH382x+FuNO!I@AXN7~DmI0`vkTi~RyXw`xIbh@1&P zPfSp1hsejCh+4Z&@GhH0?$)(SD<~^i;75x>sF=wsNz%WF`wKlNUk9o;zy=MX1wB*=iZVk-nc=T#qB&YQ_7L7o%)*w)jQtSa53P6|c60}+s zAX%yZ0;og_5?Vh6kPqX)y4x8MFT5S~{=1y{b;!Bk1ujjZ%ptXpvIp1|-dYCm<^mC2X}g3J4xX#0y? z99R>*;y?67(Kk6OQMw6)X)Gl>XCDw=q9rVZSqZX{6J-Y9;FX9pitM5M0bJ?^q!ljL z0n+A#RmsC|Wi|o;y4?d5h^@vSPL^pM^X{~2G!URWv>+kOV}NX(CM%H~dp^G*dfx_~ zZKe@maq`01!V8T#ravmYbOa*8ZTi0-suJ;UHb?iwX-E`J@sMQ+8GWI zixvomxV=lDjR2JVOM)`#5Kl@;R_O?Usy$M=2Y^FP&@l;;Dl8J96jrU0a^vX4^Gfz35o;Pq{6xabgu`{nnii_uKvQ*8Iy>0-l z^Z@Mvz}GH8!LnzOYPmZ=_j!QK0DOI`1RWv}=`>j^Jpfwe2I3w2?|}4jNLVqvv_ct5 zVVD8D-wjBeKn5Up7E9P^15_`y8mW5Y0D8a!^e_Np%OvQ2wUfS%2dKsaR06=J+a%~- zy#OT(vG)Y%K@ZSp0Q6rhL8;yVQLT{bB>|w-9-wgmyuCz#5aO(jVAP0Yzt9V?H6E}d zfZV@SrnQemK_IC(djs?zEr^B8$N>9d53?>V2S3D~A?F@u5v1w1F{qacYa7`Y{FSW0 z0PKq15aol@_^e5IKwBl$aQ8T$a_h6!fb_W?R@HrIeK(*(DH}lv;!}Gy`t#}-sI0oX zVqUn5zHGfG=Hq+l%X9a}?75e|{B&Q;ORMNhM@`IgtLclPr${lpMxQgO0dc4?BwbQa zv?MnPInEbLa&I-`rVOFL51Pb2=bk!>prF?u5|RBA4Opcw7Ly`IgXuUL05@@2On!Xl zL(+JVqPCWZ6l%3H?R*AaFRe`fN0g98$a7d+0Qy-R@_GHKC&_@MfT6T;3HxId7CJt^_WAAR_s&akIUKKBNow$NyBZ6$;}8Zatq~xLhOwZ{2;hU*SZ{9fT6pt-WhU? zO875u(ob;Gz39&gk`o!ciF1N6)%0H9-Aa9!J13$%GSvP&C2iS1g>v_+rOt{54`h1K z=V)!r3w1GYRc>jBX=|Y`n6;}Fba)+`OeL%BMfyYTd7@->9?_5)2yq3@nHt#F#u78q zk%jNv2d0M!)vgfMXKnCyG)@(|D&rrzZuY zfD3UfAfke^D%TIUas^{tN#{0(i z9Ys{4vVy}tTvhNJExQ?!Z(n4#@@G^JSAH;b8u|R~B_+0UI&T2qS-?e_|6I9dKYR+9 zK}~&6|0NxAkG%-mcbh9{UwLAH@>LQV3~J&#FK0hVsu7#A zXB3rIIr7Kb@-PX*W$bJVQ6^W=X==@WbiTlNs5H4Yii>;@L|(5Ix#-~^eZoum&pN4H zI}F0VDm&1jfHi1g!rCZZ@1<025Y`4;R!k-R&<8O;e-K0S==y3}SU`=8KJR=G^VJ72 zU(N;>Q(nIi!HXiCuNHhX=#5i0mqnS<@1XVeT zRzW-+cng2>iKxDWzI);Mk=noWi7}_tn2i4TnlAS$Km_ObxXcqDfF710+QRtc$Tk{w%&h;yX4w1IVv{EQmu{{lE5b2dH0de z-fdp>(=OKEuy-eyR$)&$y}RRyYUW!kraLzNZd%`<2V8V#m4R6sz5D6HhOLwrzHb2U zqWa%*%a~wNf1C%gxmNHu;j4>bBt2}!tt>BH3hJEi+?Kn3qWe~C-CP9P^8T8?yZuEx z=G$CPD2>|(?qMp{R$g9OKF(TJS%v+pL<`U2H)aO1=7*>>wsLH5F0j!)RrYNELs3_V zH!fhfck>oHapfn^rcyJP&+LVTv@2H8JwyipjK`CBT%_^IG$@(Vno8=ZlpP{6*;Za? zn}ONiN?W0wZ8J8lBl&b!M!@|9RRFVsw(O5528Zpq_!lvO_;&eKY_IA}dl`O@Q*GYk zjOMt{##2!aJNBa&iJWEe25U*a!&W|)9!wfk!xrK#ww9NO`^s3N+uA2&FlE4ASc1aO z7vU|ijT{vPx0Si-VSPPLzNx2|)9$!s4oS&gFSSxADU4-JOCtlWkb+Ip%4;|Ao3$I{_CiJ=0XB;K*MeLvc#LohU9lCUB zp2NoXYa{RwMfjN$-`J#9#W%O8OXJn$@#>0r-BVe?n@069oqiN3e!5V0Rlj~?htS_~ z{Zi?_@q^jlq3p*5_G1G3F>uIuJQ+A-0-p4rFkwP=)c}C-1OMU4fPMq%$$);>^`pN- zh}wYuL+Q0~{n(EQnfNiVU%&o%GJXgVn2^q%Oc+0oevF?$uYvM-g^ohP{{6N8e$Y-@ za_)Rm+T!RVl=`S6Z@fsQo|dp6JAWS5Za4WG%{qh8{9-H#?fIeGhf`&*LTeubCpqc` z!T<24hx%Dr$EnzhE9|yqmF4z)JjcT*bTNp&Om!-7T<_&TO|`;pPbY-QfRy%(PYBp)bs z4(An|n0~FOj`Ti#=oGTSx1qyk+8aI5k2))LKh)u%^VWqmvY+S~6dXArf1=M(i0{sk zy>8CI1I072*FfBTL@0Cw_A;8+L6X5?TOV%IQ$bcj)uoDz!xkT@%kQmZ;68P+m|{bd zE5K!X!z+hIb+t?e`6PoScr5z(UoIFH^i>HHwv;Gj$Xv22VFeUfLZKzm2kJXxkD zQ&w#yi&$lNV9;!T;&Jw@%mtZKX0v_#p=2PTPt1 z|J+gHfZ@Is7pp<_%xogYs93yyw=Jm|M4^fcLkr|WOw%YDF zf#6Z+UDr)57VkC08S)!*(g2~x;ybH!12q0!Tb$!O_I%#cZjI7)Zw)iFKjy(u?s z9LE|JLZi@cuP=jhsS(o&BF3ogclnSC{k!pHI5pFA7imWAG=SYe>32usi;AF$bsXgW~ZmI01h`dgD)MlAmw7 zKCBO347cESL|Uf-FG8G>wCQv4UTjHx5PYw{#<^7e_&fYCa?3XUKf*J!!^!1u{0}8Y zTLN*E8`BkN>`I_$IOu)Q#Y|AIgu81EN*{fQX`Shqe!S^~ew<4eU8DP|bMLyom-^kA+H;6nnbQ)-70Jc`bKA#$VkTUZzu89cWi9kk6Emat0;j1m*GQ~Ot zL+=T6o5tYuli9oz9HrJu{&iwWr6r%aI%Z9u==z4X!^ig)TM79==%MqQ>mg$06j`QJ z73bQ@Em&)6v#5;RUF2c9h1ame%&QW7HOf_lPW9R@)2Gy$S< zsunaJpmhRddfZ<(G|N%olhr>3w<{`3%Pd$Pvj|GVQekrxSn?{%9hQnBdqJhe>Zr67 zqt#n%OP~|3W$GbJDL3`7(#yS8Q{d9DdiPq*e^RZ+@I{_rPxfINMjK0(rXk)Fbj{P# zvGr)C$Vx4%+uD(OCf;8!GDF@)bkwBasot?B7wjilqHf>C6g^Zkz1?gXc~qnVKbiKG>mq z`7Is!{{_iL5Tw>gnu65EMEt*55H!u>b{21-59_Tjf!_250?EBj+G4p8*e!0%G;~+* z*IPFLvMz^MX>tY!cx$I_-%iGek&C?n1`}5koROPA>`5&#<|*rqyTVAgEdeB@k>HHO z?ut@Q52;3!?80{H11R_^mD%Jn_$wa(xHNL6bqe~n&v6OsaCw5TTd7+l^KdHu_aQ;y z;~tTh-9g7XVDU?LQO621j*i*DTd;1z8oO&N`gmJentX2k6UimxMQ$^SDNNbW(Vi7w znI5|0+bi!4q-Q){8B4&Gf^#@Tz6gxwr{Y zn6i^^D}xK`pR*&MTg`YW0L6IC?4V66{(?Fz*SXwsWffM-F3AVS_u31VLXLw#?B_zH z>=yrE?H=6=d#Lg}x=;7UKJ10fz=}>#zh<&C@E|}WTS))waM6cNE3nWqI5cClUKfqI z1xBF>ZRR*~0@Di@w_&*hwOLeAc$v{wprn%UNKlep5rTE|%*mU(RU?{L*UcvZtR?2p1xg94zSsl(P$A4}JpDcv!P%7j}G}c^Pc8oGwT!j^Ym@89H z%eFzvjua78loBbVT#|$z)cMfIIbRsjF^l5454wz*zle^$%Atsk*(@M16~TTw1e_hl z!b+eSI{SE@3OE%OjwxsVOQ$iHJ`|(!w2;0rO5Y0qICTWX5b;6(vs#A9tQQmN)z!Ej zPk^%u6_281Q_Exr`}Dz!Lgc}{a_~cpJ6yB4tP%48 z5>f~CDx&<#nq33&)A*jE+am<^WrLnYdM9Cq~VqC z?g1l6qWr$iS^+0A9tjOe#n))P?`_l>Tuh>HS%~>7sc;{}>(7WP#mla_dz1BJ05-fM zKuuyvm4vJYa)4-E0c!wxP7CSm$GA;f4P7mtRYTfEo+_hLI zDq*INpdSXhR0V&=|9Vj~+}i{mu#xTq-#^$RI1^8$G!E$W_7zGNcckG%4{ktogJa1wEhJB~7f!27^vR_Y~ej$SL;0 z06o~h_hZpCW2clB6bQau^gVgTTh@m_`@lcZ{}rT+g1*uG{S{qjo~cbi6-~{fM5!-G zBU>5&Td#m-$iFpwYbEg;-tZE1|6hG7BTng++`sj5)~!AVw8(~Y^+(*JLg~?p3NA0M z5r4v+=S9Ub{RkKH0KE^N&fd_VH=6a`bjGOZaBHxNRNGx0qqjcwnoju?7i$o;o#d}V zpS+;0sN4`-ZLqcjvKFV(F&OuwX$Kod0JljXx)0y4u4fZ#iz&n?cKl|Nwis~XjtXi; z<~%g^Tuj|iM)C5ULmqgCux8lIv^|*ao&R|b^UIm3ahFt;nO6Io0)lu(>bk2r)^!Lc zwiY5`47Fh4nYJETz|M<;9f-k(a?ZLnBq;Zu1SB)JH1}3a4Vx!Z*M>l&Q`z|kwsN?8 zFsX$Jozn7oEc&)-a)8=j=Q-LS-Q%_1@c`33MOI8gfolv3tst%$@V8iRGU%1tPjxYonxwwbR-hr-9Z>l9m%P z6R+R@PmsQVyeuGUuXr^%UQLZx`^T$;;??wcb!5CcCSIKwuTG9vr^Tz8@l-6ckDh8F zb7Mf-khK1T!N4IMb-~ARi&{xPT=d!_kFR5k&oF;iL7`mHBaaDbAeY-0^WM}mMTEYh zL0#?Npsw(0P~S5(s3-9KIb3hxI_wX`djCeX8?FZ%Rijs<8f|P;r{U)ue7Di_L*7m5 zECg-}4`{+cOih@rXj0>Fy@&gQg7HG8PqW%Ts9Bwi>nP$A*@ByKo_w=uH@?4u0i*g$ zV2j#@OV_1EjmCAw*n%@STGY1@i)S}cI2>H7o(ry}0?&Ot!Ji7ev}CMiz7-3asAjMI zc;+Kivr9|ZG%TBvWT-yLm4`?VN)(@Y6{uT`@!dFz-zEc;q5de3Jx|)ri7H`pxjd~? zH|%`Nk3F2lZzDCv#P&DG9^nthIA>uQx#?qju*ufalJS~pSdmum8$Y&^)+;TU;WppO zkXzS3d6qN6V+_j)*IMf2TaSIal{)#-68TWhxPr7gD5O^H-y6lQ4(g3^Mlqw5QOGD` z6fsH|<%{A~A4K7zY*Dl*Srjaa6{U(orGx+Cf>D|%OcW(b5(SBJL@}ZiQHUr*lpqQa z<%i-!>7n3IZYVVrnws8Q9f|aNtC_vkiM`dyz13;G)mgpOIla|+y;W;(aLC$L=f2q9 zI|rHiUvmm8Q*dzcK+zD@V!qaw)=`oisXx8}EvrK|#w=V@wRC&;nWe2X*HNk*Z*=?A8cL z<57Co`Wh11IYg6?wp*Kog#MHo;(oo0Zj+VTa44fH#+{_M*bD@eH7HkD2Ow-%k6{|h zT6J|JDE}oXza7pgbJq>0O&mkCZaniv3X1hbP<;U*znEI(W{H;eO`v^6(!ReJrwy|~ zFshX`nM2m02n4nP!L~TLPCepe5c^vYGnxlHB!oa#2xpW^6;2{P_@>sJW?N)+R6%p& zyLD`aUilBMYto(q+E*o`FD5t{bt|?yHxcCXakX8kPRRF zNXAJerib!zZiXu%esGaz7UY|hg};%^=5ha!R2Gub{eK!hU(8mOYD6d!qf%k`m`%rN z6v0eFECf?%GRgI?vjKEH(tkyW(B1N-Ou-31j-2q^BkvP{VSb&PGmm#{bqukLs0|9v8A!alX6UX+{-`91wRRzpsk?Hn_@>8{A#- zlG6{ws-onOXzvHzj3*@RZi!;^m81;QR(VZOZthH(R+nLgFE@+nC2&kp_Z*& zqKA(akk&{VJ#7B6xv2~0CG%BxEM4v-{lv?<3DE_*??9z;bCMpv;CuCguf|E*;4xBM zg;aNlRC!iNU8#c%)}bKx(wl8}20vVID{(zgVtt`i9U5#_DU zpoewVbpVWgSAgm}fgS|t?arVvMr$qrQ+EnbLnqK`fSBzK!D$3_$Yfm#$ll#jP^8`I zvtpIs)(8B^{ibFy-P7bDs5Kz@t{Wd*ugk?7RF~A#SgpY)251b+7H_zw4XDw5|77)h zG~Tf}NQd!fWNg5d!hcZvZjgGHIX$s_qO5|O;Z{8YC+H9df$K*MmuXXltd_OlaHr%D z*4ylNPh@O9GH zSi|L5wLR8&$=-3vR?w;GiPadmQZ5_9quW?1k=%#yi>z}zlbAINs<>?PDC_-QeX(8_V%77p#&dR@`Rs+qMjTDL zsx>-ppW`Cd9{H)y++BU~g^SxR`1*hH+>*2BUc7krg74Gz{fGS826vpj;CB%Jt7k6+ z9Kbov-J%U2FZ{i|%f_&K^ufJ8_W#JQedO*+H3KC4m3(ZVaG#`#u5R?(D==8n2(D%Kju4c#)1v>)?BLOJ4gzNxSEN~P0OLECDc8Y6}gM)8@20nJ8C6$nz&N29@IBOpD z2(xB1f#d8t>UE@F2?rAF;(<1#dVL(XKh)On&Li&kG;)FBr-73*bw710ltwd@jF_r( zDSZ+ZeFAqHmA7!I`*f_khwYX__xVasZjAA^_5?WjNOCeFt9bvxny&ru=KLhSaAO%? z;IT|B=U66>B3d?MX>o3;V;Nt*k(@x@k9Q)+T?ip;c10g&rw)sg7S3ws1;w&|)3g9n zroU;mkIug(2Po9xNo=z}C48YnNuBQ4NV<$G8#`S!p*y3}d(yz_ZJ0 z)EJQ@KFC38Yd`!<%X1}Utw=E_@1z;H<)a29dw6C)K}GpkR1`6YtHX%jWrnKVlHJ;! z*q32F4ypsN4~db&r-+wv@=lXlMC~ z{V7%(*j$5)6Yd``*0M;;{t(FSbtCIO_Mm$1K8_X5!TKbKcEz?dPWW6>C&H~DyiX8r z_N>wMrgdyP#fGF$6Nr}tdj}Ywe(YltF35#d25YQ5r{(yZs_}>WOR2c$j|Fo7Tb0 zm6iX_p^rWxt}E#1Nq$5SHpONw{OSYm?!9o|UV`4!LYcARgg*-(0nr*W%(!65S!p4r zXe;oZtMX&(h_yAtpnN_?@Yjejs&+>kqm_DP4y&DsK9$c-bGEREX_fWS zu?FScae^m4%+(I;zXDeWC0Fx9p$NweRRpqFl)rk(UiT?|%RalQF{+I8IpIDm#u=v46%ztBz zV!pkCM3IlRjQoGv`BPGgk)<8uHk+l$o{ya=7MxLN!{k*lmWj~9No-xM#PZ2vEL_Aw z%3{8y(NT)kg2iCNUIr=iL`zC(XRL+xDOK2Sx8X}gku{(Gccy?7ddoovn<7iF026y< zuoiiVofbdxr2ujjWIn#oJP~+h>ES<{wb+4bBB~8NC@tq@jQKg7A#B4f6rhcEEftg7 z+_K1CVW$Jkp~JF@2Aj6*q+X+_va)Pg-@c0%FHT!LFs-z_uy6nL^z^<<9QKlh&VpX8 zw|<+6L(e9NlCFiy)_R-1Mu8rZ<;?6U)Q&1|>r?<9mLOU|s0DokP-|z9(P(`efC~~- z-wAXKpwA@8W1BWPMG9UyO_E?V-Ff&r)8MyVQaTX)P|Zpm{j3Shmbsg2U0uOQA(7s&a9aSt{+t zHcORdk+s~i7%4CfXsyb(mx3Uk(r!i6)O=ehQp!ag<`dDhJlR@|I$l+t2ac>Ii>yc~ zuiRc%N$rY%!66-Jo}|5a-t&+>TwGY9ZLqSaWMxx{22z9+ExA>dl@JwW(P6J3@!1^t zm|sRYlq0uHTRW_|pzg3?D;u&-`hfH{CoL3sX;mfZb*aFmLU-zUXc3%D3dLo&I!X&c zq@;@dAuR&Y6hoj;cU)mx&>7Hn1*|uQCRmKlq8Qo`g^}wh&0Ba|73zn@UI3BUEZDDD zT8S$7&D7u{Q~~$nLZ!A?OYEr15SG21YF3`ZUItHmktMIH9IAp;BI(eIJS2rjsHO#W z2W6`O9HbWD2y)84jrLixr2v*fOQBgXyK+es@`uweu14cQ-ttYkF@`VdvYwiuan4${a1ACUL* zt7M$v^jw55v=&q2iQ`lG6u+BBmLaS$=<4<`hH(|#awxBX@oIAjRF#aR;LLZzSr}0@a z7spAYc3AR=W$0oxEfho9pw&N9be98HeDIB6Vzw;Sm%&H=Ae=SA14c3f4_ zxPuej83Bf5K!#&5hGL-lhDKddt=njcIn(OYx5MkyxJ0cfFMJ7PyQ7Cp;{yZO1mD95 z56czh$T!e-p4_UTM&yr4BumCHT&^e!9`2HdOI}e?6qi1bFS}h{SG<_`RL&%LoEq~Z^ zd+(+JIyY14p2n{ur^epH64?%1Oh_%Ab{tNI9KMor@Gu};qUY0lY;c%qeH~}t^jf51 z=s~*%q?_y8Q^Bi$3#P%H-ptbST>Up4seLU|L;klcU-As)e|~BzTb+69wzaoY-rygJ zvty49EVz=&1mw%9?^GX?HF`OYd8!r}YQp5Z*7E-slK4g@;i`MWr$RzIm2nbbahj7%=Qo&8?(K*4bk!hUO+IEBJ`4T&zjOC+3$gte9aX1vc_j)3X@ zha_t$y*0}hJWAC^d1|2qhJ4ngscnY0~pQgpEH_ub<{e?{<|QEyr-PT7}g;Ze?&w7 zVC8NaigFsxXG8)t?)pQAKXUD5V|TTi(K-ny@!XEW}UVPWUzo#Txags`S_+ zxN8>?NgPs{cci2-ksj2+rilhDK&G0oA#r|vt`;=78Z)n<=gU`s9d)n zZhV4d;hcIDYty*Ughxs0F6LW>NZI9pqY+Po)*A;8h-yu-evg!@aAb@&Ugm~pLk~Y2iV5rIpAY^1 zd3Ih4bEb0z%DNJ*##xSZe-P=mcy?b1F2g!6%tB}7)i)n`fpib=pJ-~D3WiHaGoygn z-^FRvgW*-{yEq|5|6j1^77=#WhoKLC#026!7H{!Z(14Cu%i05A?Z2`#SxU`rYnoU( za*0$d(n$V^MA7059ro;=(0le$DxdESeS9BJE<>h97KApn2a(#3+SK?e7LhOJ0it|~ zyj#a2t;4vOSk<}|CRkb$CtJyXK<}iWSLa#xNuFyzx#wOZ_+cj!;(xe@J)oiJ?5?zq?_~LbYeHw zbV(daWDOg5X;IxwMwFF9s!8224j?lYbl!dWXap&;zVNUS!ig`0%pfWm2&W zF|(9CVu)tlqFMBSA)F7;t|pabw-d7r!4_z8f~?UsKkWZ4J!B}ihhW0@;;w!qaGo*F z1+12=f;F$cw~f5I{DB6BdyMStqXjFdli)81ZrDSJd%(=!Q^;b=ufl9Tv`f?Vru%)= zLn-Rv6!mCIt$Hj)J&~gRn41pJS+@#X;0LCFt=-c#V6E+ic6jK zPpPj{M_P14Yjep{Pn=Vhk==SM;;u(->oMh1kLeG-O|_H8rd3y@=If^&A4;8zE7#YP z-vtukD;cQ{r|}3-Y)P~AWt~y^(tzB%*@=(c6Sn`pFj@~J0&#OkskRrwk~Za(%qi=- zxKEx>rm)G`X_jjW{4A0SLjX0dRL&)JS_g*pY|5`%!cnd+LQDW_END4{kOqR2f{~A| z4bA{_FFqEwb3+)-aA0JtIs2vhiLmt>cu5K-`XlC%+eF4%F!7sY!ed`DskJ{|_;D<~ zfNjTXTzHuk_9&RJolg%8914v;zV`&AJp>xe(sDSk6Bc_SVz zz56XpC2I$X>%sbI!TL2+vYKi^UpLKyQ46+ptGWpFm2fpYoN8r#>*Qprl?xWYqmfs% z0K0t^SDTkrh^pr7DqC6tU%akZ?}#-jSdqX*$p;i#ezt(0Gg6cg+!x`^4W!T|o~5vf zR!3Z-^!T31-Ih4R2-7RN;#}O*U;KWWX+)qUwkUL!E-+!R(sQRF#2jKC(6jrp$Rox; zOP`@VUUuGzWt$)Pq8mF31RJmo^CeGg1)SA|_R6BF+%#BUeHT^PZmpodsQ@ves0P+}-OE#hw^90= zam^{MGQ-Vi#zN*2c&Hc)SU09kg?hR)-^td6HZyIIGgp?HY0;S(oWY$Z0+^ZUE%V|c z8)3^FrAvtzG46UL&3A^)hWCgBd}?MaUz1ETPML$funO+YzMKT*F^$~C;4^rY8GlIu z(kI%2y^7ezJ}P>|rkLmv&bXIKbUz(p6kcw>q&CO*Gdi1=odSj+_95d3e_kKztBf7(+j%usSJQDD zsVMpw!!od_r&>|N%Gd@~=aeRNKE?r0B5%LT>WeW-MC@xrNeyM+k$p!J7Nw>w%Pt?C zU6PzKIyrlJ_Hspsch(%aJdies&P`40lQMdK!X3+#l9$cRo`=9)+04)2)R&poerBU` z6&GvIne{y8w=}PwLgHs-;%;$_SmzMu$NOxm(mMYebEp`oA@4Z0<$XSz2NNKVn-*$# zceMMXy85~XT~f2#Fseo8Uz^jJ#`CeOF1u*(b7kx58!#W*>^AR7y6}AItO{zWZc=p{6m1pfvx; z<|xS74|h5DxpT*|m@DA^Z_FKG8f=LLF+Je|*UV+TebCm8&nlhrY|()s z`0n(=(-cJ|O+Rp-c?G5)$PG^}Z03yT?)h@z=vQ>9m^4gglZHLuW4rcj3FqJC7iZ4> zylc$?Q0neZcs6Y!=1ip1-(&JbOvlgw`dX7QG`l0GYWRczB*&(J#B>48w!qoX{QN9x zNavXYE<-+(BBnU_B$1pIa7|crk`$Xn!W0G*yrR1~t8(zS{)Z+)q8x;ZkL{*E3NkH_)z`XtAvEK9`KM0`z5Stc+eM~un=BsqCB6=h}C9ixg{ z0t+NvpckdW;g>ouW!SQeWy6;BOwOJ=cRmssojp&RXrKS@M5*adNnFvDT-kGZoWuq5 z=4Pj6r}axsU%+orFZ9L9A4;jI&g%m{@ms&UC54(FsT2DBz?ZXLq2JlVl1H09G19G= z*UuCXWIhH+)WQdBT=Wuk#7tz_eMcvc;-u!E9g;!N`6IIXQp@aKy`h6z=G^(C=Jla> zFuoXd_N&EYCC?ubH-754nRBu-&Ga}0kD15vE0fn@!r*x}oPO-yBfAYap^@L4OYb48 z@6^;DAuT7Svcw#rSRz30+&~6A&DfH^kQ5f>Wcwbkb;MzBN9Ax+xEI|TeBHx1krTHH zajTmb@jcf2Y#i~>o92y%!)$sE3*xX((eJ-^5F5QQVTZel>20IBI?gni$*4T)maU9T z&-CG@iR}H8clY1T-tRduoxT5_kvPBfuI+9rq}~v?qjFhc8`xOKf|bqBST=tV)-VhMBUJ1wbzSSpgvZTg^laF&`B-$Fb?c?SzO%&Re$w3R zitHKl`k*hWNI~Z8CCf?+*mv#v*4TB31 z*=6bf{p!d!S+&kC&n`iaO0r2SY8XngnQP82$gX4$Qs}<^a<>HP$RGi!R~U`f!BKUT zuLYQ=tX#T)(Rk+-Ujvixl43_m#jq(e5HXYTHX%8Xnbh;y9q{ilBv4a(nAU0igx45C z>ynz>`dzp^S`fmnMV;KErM^Lz)0CS8en=*)u~0o2@opV8b22IODtY+vaquO!z-Vt# zyY*?I4E`}NxSC$FSIjEGd@N=cG3LPX8;nRG#y?_~_9JqbfF5hR$yQJ~6)QLJPA#VU zY7tPjR*mzkZB{!{)hnqD)B!fHpD>v^!1<_5ixU>iOIenUT9S-Pm7Pp#c;u*M^X1A& z)EQJXdJl?sG#+Lrv2rh%HNKcU6fWfOKBy9kt|)8CsnxwK*+icrLPIGoNPvz60n+cN z3!QE*%buIa6#eMLdH5dB^#AC1`i`=p|2iY)CHG12TyjZzCM~`6FES%AgRJBXCU$Uh z`rGD0x{1klg%1^W|DV>r1@+E|ptZB1GCsrIL_BC>5os6iTHiTj~72&%EdC9@YQy`+WX zyfgF8nYUD`Y(+}F-(F>Do{S%Ow>u~eW@{BuV zjYKi0-Y%|k59qh`+71&XxVB{&-esuNJH!V{hIdFiFXHm!z0__XxLgL;K*q}3IM^W5 z*-o{j`lQ6@p2b%jBaMn{T0C>B*x8%GLG7{cD(#jWr68MT0_5U&te3orySHBY9yM++6&Bf4nE^x&YToS}IL!59*%lq;MQ?(AFKVyj=!PG9 z;beqtS~kFg6~R%XXKBdI(q`~zm22&kJieO_`{X8he22n@ygGV^>JT)#4n>4AV`sR503J98 zdA3W}P4!En#3@Mpp1V$ba&nzeB5*_n8;TF~v>x(0jH0Dh*4#0Br#!^s!(vDXKD(%* zPBs5D7`!EZLjKszfGzQ|7hM?;{*0KKaY#@BCAh1ic70dw)fsJLc!a%FF%mZx>7!}yz}!t&3b zb6L^QOYzfq_1zQuXIE}^E?-;yr?uV(>_Y3&WbeaE(yV2IE5H3OLbJXk4H5tB=X9{P zv;Pcw*WrJ6qmZwfTQ639+aNZ)0WmjKJg)dFZ@EFdx;Yid2xLbTe;|arXC4S>VvT!lkNbgKo`lxYo)OFxExv;-+c*=m|b3@0;9ui*0;Lfz) zN|!nkjX~@Ndx!cpN4o{2vil93D4A6oG)byFO(WNAUb+TGmO1~rom+muv^SuY`JVa(DVL#D3vRn413*X%>n=u;m4$LsHGc&PYzotnI z^~Ac?rEalH-HEBzCAHY4UqZi!C-$5457*Rx$)!qM5t}_*=EbP<^J7BItaW_oe2+}| zsMw34ipPh0ypZyRyKReN)Zc)&N%W7SJl7!9Z{gcdGR;458sWXK@Xj!ugFFV}tTzAsvN#$yi4lhgrv% zD2H_^6CK66w26skUB;A(VO`dgF2y?5lqt=+oGDv|b$R2KWnICl%M` z*7Z!l&mWkp0<7zs8dtH_re+P+4NR??tdmUbTCAIzI<;9hGx2p;w=i|%`8`vwF7Gu7 z^;owvi3zN4HuV!(cQm>_>$^+?&AO*aYQVa$X_&;iziHHv^?jysBi8quCXHFAnx;)y z4=~M|@*dN?8S8i|b!@JCN*RmdF z+FZwaxM|yl-!a#><(=k+>sgO5$v1G|jJYwH1E2w?G3Fh`rtRFO;Z)crtx^!m! zkm=fm^~2_luB<1TJMUmU$#lDu^<>k%8|z0*kM69en!9?i&NV&nVm;0D>dAV#>D`O< z40CsH)_LZhyIIdPeePjB%k=HTdbYW@FKc7^-OKt>)4w0^gsm|;U%KW@^8v0iG1r?Y;- zj2O=PNi%W;>!(b{NY=~Ds0`N2&FE3ASC}!QS+6viV>s}Y$;#xwNi#N!11HP_V_B~< z;~wC^muCDp)=!%W<2mq!d2j;j)h7Ev)&=IFY}RYc!w<1uYbHL-`dKq+BJ1^L@+8*J znMWqG-e7VbVZG5z$>G3pGj$3FJ~z2jS#LJea#?RN)2DIZGc#j4>laPl4AzBaW*!HQ znOQSgzhq|5V*Ro)vsu4l9yP4DnfymtziQ^>vwqDyHiz{)X6|FG_nLWgS-)rI&tv_* zSumgVKC^HE>-}cYLJk}?ix;szY?dtMz^CT%B^>y~EPb5yN9Kv89QfEg`2_1D=BXz+ zaKtQoiUS{+<;z%qY*s91{fSw*g7v3n)k@Y!&C{z`e{P<6n)OMu`WX%!G6ky{9}`+r zz=03U+BFrAcV^Q@*58}wH?jV~ zY<`~gIkROm>mSVvTUh^Ow!Xmnym@ge>t9Uai>!Y&FBP)BU|xQS^+of_%dCGh+g@S) zyLojR2i`ERy~_HMdHprkMP~c!tp6}?Z0Eps^X40@|1xjA$@;R{@fPd9&D%Rz2hGm6 zS!qS)ot-d=%&vD}GMU}D-#|NL_UwikL*`xF8lX#&*^8S4bZIj0?S)x}%=_=bEK6qJ z`!Fk$*}o5F6*33*!>mf?g99+DkvaGQ%<5zg9fTPmbNCRV{-addR*iy)x{~6{jWPUjh^Hwsy{sQwhG8cY@*@?_WeCJu;PUg3ZFgugM7pVd-nM=QO zpwJXyN~3#_`J;#fFPcC9;J{Y%*Pk4C!Cd}}16$1BmpQQ61pns1^U5d+Dh_N?hHya) z2R16X`x0b>G7jN!6L?OUC;|3JIsmjX`QW`unJQFS+y=p|Dpe6W7_=Hy6^aFvsZP~|4gvL3b)iE+ z1LPMv4D>1r2u%mAL01VK4qB6H2ps`hi)soT30fPMWrJpb)}h)$M}fvu9igK^>r%YX zF`)IRuFy=-1ga-A3p9}ugpLKRPl-bD6DXspzR-t38;}+{5j2S!2%QAlkdlPrJ{!}B z8VY>`v@tb8DXdVY2@a9KEf;Q0@uCED8fY_WDs(z%b804Z251XvE;J9cCAAPb3$zur z6pG1*xtdxD#RVy*HC-(f*PfVbs5RnRrp&c;jkrAqx9jLyp>sjo&~-xRfwrYKLKlEu zPi=)R1igW-7mAxLOfua7RZl8&BPEO5GPvDDHwwkis!cn(N$3jD_S8=3I?xW(Ug&zz zo2i4)=RiBs%|bVTrcg(rn?P@&6rs<9-b%L!-3)pg-70hoXeYW&=nJ5?QzxNYK|9m! zLSF>!LY;*cf_9}YNbOQ(?x3#X_A=b=q&tMZ0@{u46uJ$xJ9QKKDrgVtF7!3fyQqiI z*Fk&IT|&2m_M)Cb-vI4Ry@b9AdN=hJ`WEOtbhpqQpnd2bp>Kosr9MJ;g5FDgh3*FJ zNB0Wd1KOYZ34IszKI$(Nza2IA(|yQ8zA~wFKggrX44_ny*~$#00U)!K8AJm`{0oQ= zra?l#1WlvCLb17FhEST&BG92UMCc!&!)U0`KS9%Jn9#pKhf})H%b+7@xX`~rN74wP zLC_2uDHJO+Gm0{V0%kOg63U=sXtYoVG?T^%#eI$@i!y~qgN~&vp)sHj&{(0RK*!Mo zLQ8{=r*T5dfKH(CLd$|aNE3v*pxN}G&{)uiC|hVb(1+fC$>%(xJPSeEI z57!wqT__Icn>?B!^eWJqlqa+X=q#EkGy!xr%@T^mt1&cNXnoK}$q3b;`Sd7g;2}gY zhw_DHgFZ%cM4%xA=F($A8-dQFxk4L*&c|70&?cY@Xui;b)3i!xGUzk(w9p$tSJN{>Zvri#)k52WuAu^6-v|eZ@&<*sQ(Az;b(gvZOK{wGxp2U}kVk5FbBfRc{+Ed>1d(Dl7OZZkf|gIH>3L8t#D) z`@c@H=mY-B*6zcA1od%NLISoUCs;MS_Fpl+;kKOxz`)lF2rPw57) zJbd`Ux3mSM`xxO}Gt%vEViVqKbnr832Nz_*hu_!+Mg`R{FEgWp9jv72RasK8q&lKw zE8lU*N%NYR6}$y~S|xlzx8aj$_vu#tR%$g;Qtu18-3yE6_$A>bjnowQ3Bn7Q5I;%X zz@dAH=wy=7LzTWZq&W8srC%XA{0hmDXst2Ie@*|e;4FQtL@oFE21o)xzpQ8scmR8bjq{i0ZLovZ1YV`dpo9&PEkQb@%CuANi zBkyOLsFGA51LM$ndJR3WZAS1HnuPGbp!usbZ=`voxCMA^?pK-;(sKcNMoXW8G6aF1 zP>@{gF5{KI6kUF1@FK*rf)!u1O|J&rY69jrdL2FWdPy<1hC^-4%g*mK9mBm!xI}r< z5Y?KF5V%CMJdGpHqk&&evSQVgl z>-|YfBK(&^9k&0itG-b!#*sGj7j2h82}v5B6?_s;nhN?RWiHbjC9ccxcv0qWdJ{S6 z5FR|yu_WVm@LYi>4c1}&76fj^I*fOK+@=zkS9!^ntTR6ok(2^Fd;Fc$>I@ZDh#66_ z!nJrD`5W6*6^9eMS2Z8dI%opVi{j^`YEg?On%|bH9UY9}4H#CCv@EGuR-15;LWZo( zO68T}7epSJHKlo{$Y%x1@K$da>a6n0a$(rt<##;)U+5*zzY7+9ybC!?!IF=6gLG91 z<@ps=H%6_&u5rEc{3==m9!91D?;(!Wcg%QQ--+cPzYF1RSp4zcl2YA{2d2NfB&LES zuoAziX6(>Cu6*9f6G8V1w{T<%b?%MgSwVlV@Ms_zeOu|?YMPJVQHk%WRzC$R^DY#U zL-ZqL0Ti9y;XUy74`QHONqkwu?(K6?}^iWR9-dS@0E);u2<&+p%LEC z2SY5txR}q5`d9HsUV+_FcvFR-VgEs)~9?x zk|*t0p5k9AJ-!_2oN}zERM1$YH{cISlK%}>UKR8UmGstfgZ1k(zSY}je5c=-so$Kb z->Rf{RMKz9>YcHAm#UY6&mv|;7Gp@lUwNrp@;ef&lRnuDgUPAnQ{rA zXo^K4G~iID8dpr(m7dIuT3KU}kJ}+qXegh5o zz+i;l%A}qVy~VE3`#SbtY<1Yje|3-hFp(dR%0vM#S7<(8hQlC>pW8x>n2ZD{a9D+^ z&@1lixrV2w-VIy}Y)r7)m$pDg$n30+bqP<1>ykd9S{)81bAk=yKVhpV??$dq-Z+R_ zI*iUcI;gQ2y@@|8&NAj#3GFz^W)^Rz>$T%XP$4Z}3b6?au_9VWd;Um5sKwG$I`9!| z@!jmTjS&YR*^C1Fm9JxjOA89@Q@)f4msS*bU-_{3u=*ubYYM!ld{~1NyIf0wy~>BB zNU=*B3ZOM&MN;f?Jq7kC9~LIXF3A+wt$bLY6uaC+fnCanWlFJ2dkVaxd|e}4Zl=Ia z<-_`=SSE$^H_CS>2X+sJ)OSP#CP-0y|m#a+lf zE37BqLH^;wdT}@MX9(-fJ;*&J>~8K!?rCB7aBp(I6V`|CA@^HheYr2WXN29${mA`M zSUSPg$?47wDYUQg~GVN-Ymxx0l;wI zJD1f_bY&-5fG3B|mmfX>Z(boYh7YmKjh19<7YrkC!a|H7GPTteNaZd4&xIn0d7O_6MM$%hzYtm;^a=h_D8^>+rnif)-e(* zrX`_R<&o#wSjFuHF2^d_bF;M%JzE+3ow6=KM_9vgtnyxDAES%F$rSP#6eOfxV(fK> zqzbqyHmqJoCE4Ed3d=6%HvZnT-o~=0`6{Z-`gUa5%zTZ{dDdIF7ObzMBCYRsuEUbm z*O1jWxUNK-6?9*dw7kjn5F_Rf`ud16eifyNeb6iB>E6;7lC~zi3E*plEi!4TzPDf^ z?|C~oNz{)D`ma}QM`5LlebF?jlqiM0(Eou#ye+i~cXCrtA$G9%C&`a!#kOfkE4E7i z&su%ELYj7St5DKV3!{R27*oZN5^S8>T%lBUNZ07j*Kv4d_%4D=yOm6|<-oSE``!q5 zY@6yE&?DYMcj3S*VUhPEM6iddlPT=8FTw}=sQN|(-p}WeJ$+NL(18dcY^&;aq;dbXg2IKH*5c?A)BQYjX8uO6QHt44j@nY(vyZ=K)$)x8fcV%zV z^P)V?j`1DrZWZgfI9Wb~lOJm)w`#jlxcF zKXx|=JIVL4`<$?^IF;S?!oKE#?5-2`4G-qh6Lc$l;ow0QF^|Bl?FyX>cQ zbgb|Al4m{5BVawlMV@s&XV`wWHt26}1BTW$-nR0L(I^S@k>dHdqsE{-dSNU(%UKvz zbZ^w#_dGTftG_RKQ9gjy>G9J%9`XIae}vIgE|U*(kAJ`LS?`<%ddaE=tVfr+Gd~>;nH8F0q9+Im?mei@Z3L=4D=*m#}Nu zX=z%%SxcA5)p0-ivjUFNk``%}>KHwPp2JPSQ5Nf!6m z`fQETScL+`o|AqWrgD^iCS+d?6Tk7(1tIq}Fd6o>81fNj^}{Ii$Xx-)S`5#F^c3_R8)EARa=xBZJA-yJ+FfE zTBrt=dNuGmyOvdS-axa7a|mJ4?JGHWzDd8u?LadFk7K9Hc{{QbJ?(Xxo#9Tjve<6h zj=Q|r?nqm5pDMOTS^E>k_GoK=JZzUvxCD7#f_)Krjv)z{;4eYP+{1yzDzCD$S26&V z&&vFvit`@3i-lEn@Q4|)22J(=2NwBTtJT+`SiH>}uMoX0W+?PkL!wZGrn%iY$vGWiYv`PX&F*nPvXS#cgsrjjV}z}V^K*o)se=)!I9xO5LWHe3 zev(k)*TT6JVQcC95n*fP{1sul+W9-e*4jZ=opz1G4(64aGOt8kgyxVkt#=%ZgVxQa zJ~`xuiV`_H?1$XKGskNkbWk*$`KZ(D@U09q|93EYv~kJ^-Gv%z>y&c5N#J}b*EL+) z!LbsjtXCV`8J!d1=LP-ow#nt);KYhN8cwJvGK0wudRDRRMyG`Tu1!8j){SNR$_ zsdH7{O^(kgEjrw}UPP4@~)sS%3Wbacv# zPi8R1sp*6>Tfnt#Vjn}BxW$PNWow?qcB@m@aUTd9rsaTy`4_B3JvP{Zl`ld zXtpQR#c^kOLU&l9nGm|i>E<;C9QAQ3c}=RX)7|>#1;ew`d%be9v-`W8z>KhazX`RugM)a)rFycczhflvpv3VC8NC)SmAzNU z;JyLyi5znKJArA+hubhilE>(NPmga9Of1*!%jRjpQ9%jmjpfHk{A4U23^S~48djxg zP9Qh(wRRf(y%ZcH{E|?@+fDo2V7g~3o}H2!f&5{wC3lFEVe@ntGxw4gw%xMFoO0ZKlh znMz~xB`?FtMm=l1ug@LjJY?G!HeGT@I}cm_S+OE7F;^&>2u0YHF`14J4MgKDeQuUB z*(LzHF}Y)%M=U=H{(zHX`B&iMoGF%n4L;tPYUB9^e1el}-A{o(=uER5yE3`i&UDMa z1AoYwVdb$cll!ofXWh?$PjqHljy;*&NzN=Q^F8=vXSQ|6{!FX9U|+|0MQYy|`b%FeRv_O>-8?b0@Tm;u>$_ zvB*AiFsqnZY`4AJof5Xo^C1VlY`U`~qjz;R3qJkNQ`MmY&V zW;)A5L2|^as9Ubeh8 zifpd)3WgY62XvmZO=vtOEc2bp(oX8ab%FD$mkZ^GRr--{A*u#FVuU=QU$ZG#*1e~+|k%Y%3JMx7Ag`KXXH=;133H>8QRZ31DP@cLmXW2^sNj0% z8*q$qzUN@#JjBq^7-=$s-+Hb%p0mL@4K8CV+Jl4|DtmFGf@dAoE;IN8+(aWZ!*&e(_vw8ZLlK8qgLa((s#&^%C494V$eEcVCMwA`O2a z4S30wyT$p-4g@K(qo}*0xL$CoN^wDa#DkdJUq;Xg;1hxqgF*1|D5CLb=!C;-Jy@R8 zmGK=PD?Se5PL!-*aGI=V$Pc5Ts1m>EuwO4k^P*EN9E~h{OF>=l;yp5%!Gz}!!tZp- zz#qS}ikRUP`?7+o|X-TspNE2GKPN}H6Pp99R9yZo#iesX=E|JC zDyngFe`?DyDy9opO|8@%;Sq1kw^VF%q(RaG{ZaeUttsh?eh2z&eAz0dBGOSK6?Zv7 zrZP;}7f4)Q91@QQ#1q?GbpC$;$|kByO!d^N?Qnf5%47Q~Vt zX{g&yWlC9r=j61}HeHpZ%)D}ovGUDpqrB=%IO`vhPi>j{@ABAJs=CCDe1+-&@k(5k zLwS;VM_Id#+o`dYLVjJ)HlW{Y1Ga8TOW8yr|EUK$sj&yzXaW4|k8Rn!w#}QQH{71k zwo>80z_u~2?zOd$Y0C?BF6G+pwqkRE)IaKWWlnU}oSbMSzjy!d|Jb`wvOFv?h2i$r zVmDS^c=`3O_g`2PZlR2_p~OwX{QG~{RkVe5iY|$*6hcSg;#4n`*m2>$_46cRV3&(p z<-dazgi|Q;(bg_3#-`0t;V&n9F*-J^_#YHk@-wp_h9J8IDJ^dKx8+7f$jcIg&Jcu3qkhd(xsoG)KXXue?Fd(=Br1QTYIKpKmp-a;D&r`A{lO#;_8*2$Psjlk5{8%xso<4EiJ4soH}VEUfkgnhIM;pNf~;n z4u_X|@ybH+GU9>8(n zJWwQnC)EYq>QQlkJcFx8rGRyH5u^{u03aQhE)LrvdkUBbhq!vxqvC-kKpP+h*a-J+ zKp*gQUcIb_hC-0>|M} z1e^pfmxzJ@5`iF;=U!V#Q4T!kEg?GmR$AV-0dz&W4@h^~O_RDfsA3X8b}6GfbJC$s6R*=kPXZN zmH~woCFwiB_5z21qrgevjBuzr37iKn0w@kq195;KNCcVyZGe=xSOr!6LDPXuU=lDL z$d5zpOF>ov>wqHYELR^ofOud_oK*LA`0N$Yqj57}y$EYuC6pMD2s8oO04YFMAPoV> z0aJi^z$#!1umji+90$$=y&#(jOak(OMU^D70_2IK?lfE~aQ;0)lej-&udKnox)3DE<|K-VNGyL7N@pbdPx0~x?{U@5Q+ z?mK`(z)9c?a2_ax-*#XZupc-A90yJTRT?5j;2d}n5ba0(09AmRKqAltXbmI-DL_}C z7ccs5qeHC(Wm9#=XSUivfv;dNUl&cVRcaZ)<(m^tT zY%4zwE3z-g* z4=e(f0R_TExWEb*BJ4&u6$0CVUBG^zTw@dl5Z_qhPHBt){b9{$EHUJZ^$4Vn1E+v3 z@Y(^K2hPEM5ujSo0{DUWCTLDTVl4!0QA?f=?cv<1)@-o;U}-=GFb^(|~2*1@LK?nt)m76m@UAG?|jhbx?8>q#XS_9-4`k$}bny zaabL=$P`xo;U`7vP(4xyaZ7^wU?eWtw%1X47yMA2Qpq&9U2~NqqTzp|Qp$zyqr!J` zP7K0ckJS}}xMXS^nh0CRiuU6R>hn9)Ar?-q>TQ<9#DMf)Tj<&#Z|9fylzk4 poIh60oc&JJ**jN``JwBRt?o@u$=~qk$Fqyh_6vuT>2~D5{{{E?DVqQQ literal 0 HcmV?d00001 diff --git a/Covance_UCO3001/browser_profile/Default/Code Cache/js/3412bc103ca6a5b8_0 b/Covance_UCO3001/browser_profile/Default/Code Cache/js/3412bc103ca6a5b8_0 new file mode 100644 index 0000000000000000000000000000000000000000..5be0fee6d1ab0a8eca2351bae6a1a3796a0371ff GIT binary patch literal 22832 zcmY-1byQo+_crh+o=^oMP^CbCgm`cQ)RnrsySwYHySux)dvD#{-EWP$+waMD&ilvP zwLWV%CnJ0I%%veYxvqL$R^)B}^Op)hVQN##be92%$%&r$BJQFkN)~gu6Oxj=?t~I0 z6Wp%2B$qedUA#zfZ&Jymk_mC~aV3ivjrX`p6n7`O5=thylRYIp2_BDvW1Q1xpXDFR z|EEa37@0qs$iu(+J*J*=;5f}z0yjy=M6zhQ2DqLBc#s>okO$Zw2mG4^Xj9mSuKR%G z;y|7fK&wi?`pQ85DnMP@NyVxH?J2w(5KpD4O-=Tt)3ty_%{W(kpm_)2E#>M87Wu(eQ^H7K6}=q=G#CxErE+6{T9iB% zC`m2G16`@_1YjinoXGK}09!W$L0bUZR$$9E;2TI3H0=zqjErYl^NYY5YJLgmPR|He zfSfd+;;sTE=r85E1`ML{H19fVdmB*Q0S?>)0`3EO=_);?8V`Vq4}nIM=Mi9~In?hl zFpf$+0cz3-zo*=Hn(_=-Li*=G#0$<%S@efGz65^1VqUM=o^DW?HynfJX8{|i^;@7f zy`-}rfO|CaBe0S}KLOG7;WME40_>x+l>QaSr0w5$25InjU=qoHu#U8Wf_?%msTX;E z0YzyG9iq(NtOfl?W&Z#h$@iCQr4o?gD0P;}aG0XyGBl?is|whsIC| zl?>JC7>(A*Fo&vZ*_W=-6G{z`A(PbEWH8c5DwI_bCoGL?#y;WnKx%P`X-!+om^ z6=P+nN872rO@>I943`pRFeS-QhQ`uuDv->_G>vAYGoPX|oTUdep_mMfipvmELWTw< zxgPSAmf->!%gQi}T9uPweWncg%gb=Q0&}e-Lq8fthpWk;t06-#n$tjrhYh)g#xnG8 z!g|tUvNV%n7Hw@I!_Ss7v~4BBz1A|A+j6Y-tnE}8rc9GTF`a9jFT>3R%y*#-T^7l( zYq1P9mdbGOv<#ZFGW7JjA;bQgGB|F@aORE-!S`hNhuW#+*rJvrLL*11>~f6HA;%x; zYLsKQNsgMKa*T|U<9xIn88LEX(rvnClcT6Zj*1lSlB2j=j(Cq8lc;%dIqsB@a4lh4zy%5rqBD#rjSR85ZM^t!qnb!*7cieA&?nsW52 zC5O5;^Qa?7Xd^jJG?C*2b!jTc(B^WCY9&Xu)^b#CBS(%-a^#_HojGn7&dVR<75d3h ze}Eiw2g(sPNRF3ueXtx^L*%$HOpX`h(Rx?PfXd zQ_2=TzeA2I`{j5@TMo(b<%k?*j>@r^5{}8ym)6lh{)2S%gdA}v`8E%$`Jzhj@T%=;VH z@|`)+I?Df>ZT`qnP^mzT>z9pz;>?!QE>`1OHiOY zITIDgpiT5GiT#ol=s}lK6fmbMu*;{wDH@ulz*JJFD^NZ|fqitE3KUjgX%PjsQOBYR z45aszRGfLy;8M(+GD|B^kIs>ytO5(mDNwAM0@WyIb&f+5>3R(X4%AXW*HD2xbcLQ! zjYbO0Ys^|VVV~BlaT|_LS#1?K(T-zuP{7okbsEUWgZOxe0{v;mKMH)Hztnk{0u#n4 zP=CAv&nGbN$qLw}D9~l90zaoIuxKXtf;P-i@ceRpbc32KXU$e{Pgg0hir%hPpurji zeyvxa^ak$jM%I@CHYqS`8|zKp9o#E=y;FfoyA+tdTLIM`1%jw5?cA$Cr+v(W><4(Z z2>)BWp<8DE_koeZMF$k_=xJSVphD@r?dZpe*J1 zsepx={iZ)`3ng+Wlz2unl}gA|O59T`Q7^j^i*qQkfy_CTc#}(s0f9=mgOn&j8|h21 zlK*WeQP8Nw&`>3=hb!?YMhR!E66NelL^+hm=2oJLM~TgGN>oc!;x{!}8ecT8?wjqzXzTR8(RvJ*uR{ zTWVNYiR@K4Usd*}b5y#964mK7eWy+}mFQDPi7j;*>nRahUx_0W&`^oq)UA;c|29$L zV{_)!k~z0xq;_qTxJb6PN_1(bM8!@@?4wSdl^8^CDZZ-`OKCGL>83=}?yMVmd$N|K z?5D&)S~N(B0)v&e8Y}=Hmv7K$`?G7b& z?@=OnuM)@T8kN|m#F+g`{2=WCu7QqFzC+y4V_ZA!Jg!9a2_@nv;Ux1v#r)|Ty*RDJ z@H0yMJ*PzH3rgIf@JmYQ9xHK!ND&y*(1ByoX`0bhg}mKVXxv?e3)H74^X#Rg{t%~Y5Ouq zy55g-O<^8XVX6vKr>Xe5ON9_xIYR~SG8Ily?iDJGq;=a>h~1&WFiPC1!dz;+ONG|E zRoJjcg#vrohnDVR|3fOQ{#S)>bnLJSHIAsTnEpG;YsXY*a9o8g^!9a?xxg9DUDyAjfAFrqInVDwO`JLUo!=FTbha`k}%CT1%_`Ft5KV{G$F) z<0B=@)mTaU=r0{rs!>j*#w4|xza*+*po>~H&fC@K;!xu~CA!pDPJ2kS8LtRXb%;IX)rko|z7)O^&s!_C*8nOx; zn^G#OalNt{ZL6rUsj3=b)p)JC8q;Vom9NGAwbkfYM~zi=)hJ$1jUP0>ff~CSs!^wr z8s5fgT%m{5uZbG}k)xR!_nWI>ZmEW@wHm+raNd5LgT@VI9>e%}xEfDJs9_zY#w@Bn zSB*LI)CicbMnNjSP>n6SINxqHG<(!oP3`xxMh981f7KXDtBi$;a zj9h~v3JpdmHTXh0jRqC98tkVnIW$n`)F3mL2EB7@aF&9DGzcSWum+pxt6qcqc{TVQ zp+TKU4HlX;$Q7l*^k`nAjWHS=B&S7#?p6(+&<83NtHB{kwy_UYwQJCnE>Vb+`Oq|y zxix4-c|97$(rkL*WsY$g)Thz$8hod<2^#FB*hCFFC$SA>QNA<{U%P3Ln9ezAJN?Sg zplxBUiPFkwFq7_;)u4Pi4IWouUKKScTuFnYl&y*e$7^bEg@)GFAhNCoZdy)3^)#qe zpU=~=#u^lAqCv~18Vqis!BdKD#e6BCg9h;(HR#((gA?5}sMMYH>7jwDrv`awbuSHU zV>IY8R)dH1g#yQE@Mf|G2c~LpW(DV3#c^pmonEa$x4m39W$f4B=V1+^k7^J{ua9d` z^MnQqsOf19CSBH`@f8h@kn5TTWv(-?TN=E2tU=c&8ti(iLCiDOf&QU+FEyz4ig~~0 zS$LyC0jf_cK53BuGspbGJ)-C2`N|x>YtZh82Ah9!{l7Fwph>?qm@m`f4waQ_F;Ss~ zU8zNeT8lAsQKQAv04?0vwCI^#3u8_#n$XHzT9|Tc`Tl?whe#8wMJa<8Q|P8qi?b#z z!a}rY5voN@J}suxo%~u1E}+HYf?E8hVuiHWOwFRSct!3QEf&%`ij39rO&l%i#%r-7 zL5mwyH&Kg$G$cujlc8i;o#v)GnvRdis>9Mbq+HbfOh>rULV*$b2hl zahHZw(c%$ zzR_A#rgkKs#@uM?bS>V_&?0pvYd4E|Qpq`5ETI>3ncF-qJPWiKKt~p8VOXq1V_LC9 zi?2(yXueE~HOraH3N4&8W33h?wrH`F+HTdNFTEt!b}bgrR+_X=i(ZGA69pe;y~%up zYoYT;c`i)DeWEi|Q`<3T{ z27TA!+7F(mpIpx`?(<*H2^~7fbm&XBC{eCMe}xXC=`FQY>aa2(-Imuav;hvP;aDuw9qJf9BU{5te5pu>N3y`T;eVLG%f z#J)5robyvyqz)5kF5RcvX66^ALrAm^QAvr|7UM zQwK+R9lBM}@n@k9jVtM}m*iELcTKjft-}Q}*45#4W6sw`huc)BoemRee|sG)9dzi} zQHOhE?#vvz>F|pxb=UFdo{m5FbT~+Hy>#f)TZb1E-A9L^l&h}}$&^L1emdwWVW1Ah zXfsV4tiul~{13+*sYAOl9E;TBbm&f{$Lp|$-cQh>(L^0;OwwTseV@!V&(h&H6`RAc zNVY(S_OxZ84l@?((0PdtIX5#8I<wW5)}aD*yQ9M{I!XGwIz&>FdpfM6 zDffA1XbY8jpu<#J`%s6k^i3atVuk>e4-3FdI!n(}0^msvK!5UO1mFVgDiVOgMFU_h z5r6@7q+|fRr2??BbO5T>3_veRsTBZiZ9b;tIsvfM4L~>YEDc0|dbu+Y@w)^2N|#F%E3SsJQRpI{{~{r;Xuqd5{Oa912N=8AkI?q$v|{H9f7z1fdBX4h%w1eGvX7ZQdYE=^2E3G-4gEZ{u|e+#Q77q}s#hsLJsm%%k-eIR0&p zPaFRWLe*RG^zhgArLQ7^T|>qkW%X?4(^o zf{}MdFj|mjRWRml490&Hc_J7Ct_I^I-FqI4?Jt5Mdl`)0S-}|kGZ^P-+n->p{Tqz0 z)D(K`m+PTZ=n272si zqKCSv9ye)eD?Q#){qA~1_s}CpPd!|{_2^3vXlWmgHGpFc)MLybJ>)~!me&2FN9Un> z?4{|$^oSX$M^{RpqDP(SdMu-&GxSKErN?lpHd~KR^YqA=ugCZWdZ-rZQHfeF<{H-M z5x$n|-l50jeR|xb0tfV{c|_0O#kihhdYnD3NB5I@)HtihBD!);k6WMgFn`t~u8QL1REKtpSJ0p)=rfP6G<(GGJnE19Ar%P?y4j4167J zKzB;f8!+5pz(p!+G~hagn+(`YYs1(s#(=C?179y2kZLy|kJEr`9s`CX7;u(`CmOIW z#ei?LFV%obX$CYbYQSnbSd4wk8gQnZ0j5j?x=`H;2L66z!0w8CT$z1nV-*7))-b?U z(|~fdm|p_}+R~g329)e*z$B{H$$-$V1~j96-3@ru#{hd@0~!r5p!y&K7E-`q18)9f zK;%#ZHqe|=20WvOV+{OIkYm%ODF%#LXuvgUz0`o-D-77b+5p`e1DdQgK(pO|D%5oc z=i1G2NW0g7>H9ejl|Nv>j)Mls4{^SK4QN2C=pj8hVu16g0f&wo@aHtgyuiF^ES0)y zz+^f_i*6bC{vq?cZNQyJ21Gw*-JY4T_@X3IPp9b_)82R?35kDwChY^El zT}~sGnv8f$V?&Ktp3jK)WXW&DMY9q4qKtSFZG_foL{&QMF=D*eh?_Jf&WPv)Bf8L} zL?a5P@ER5K8L=_lh@bSiun|>?88MG?7B`|$rV;Jva0Me~)-mESB{VXkdJ`iak-51M zooH4IBl@*5;y5|m8!??8QfLPw)>2v@BSzB2!A8^^YQ$oyFr0IbV19Ir8jLn#74@8K z#Gz$IWM9rP))>)yy%9%f$rd9jZ#7~rDR#3qM~%pF%!q<#j3{u{h}QI)rk`g&Dt(n} zeQd-&%6w@=_&X!o)7q~_?EPtk=9iJLrA%n5FkwCERVEY*Fkw7-vYD_a*aWrSglYLq zXq?}KwY0N-)w>|%7h}c%5K6ZYTz-UUz~~WS($K` zZuv~;UDSjlw5GTTUrMum852<1gx}Rod=J!wUv*9B*xZEObf}dHb=#Y;oECIqKAlad zOrxk~59UJ6dYf>wuL+U;OxQq;2QycSAI7mpnNVu935xM1cqf@KfS%Iu1twgi{VPpa zw#I~abbp-*rcEX^q1iNKs|jam?{*Vv?>Av76*_3bu%jkipv}iP$8i$|k>>UKE0Si}{#JEeS!@r6D*R9g3VWp>R1vQ8hIb^XX`@P-u#WqA)p1grYYc zDjAB?r9xpW9f}TAzH%sL(yA(<&{qq^BDzD-)kCq3Qfq}`I7QbD#ja+dP&N-m?$)8G z-YygisYrXy+kxYC4CNX*9$gz0iqE4t@0d^oO$kNToKPgs<@E)jxVte-5H9`|At~O1)mPZ;xnOmL&eYW8fngRE;3yRMH8A$W3PweI^}!BzE9YWHari- z!T&;$?L{aizY0aUPobDjVZTB#A|MYgQFlWgJTvEkJ1P%;r{_W5VtLSl?$*hJ%kA@^ zK!-fIeYgRkylNK}%$DWqq zP`3(4q0Zr`N#kjC-*9}U$-}}?ePlQm($I0?I5jC8hRGaf9{bD>M?7g)g`+C1+8Ykn zfpGMtMTf(&>|{9J(W%SfXni9bTdC2ra8&pdj#+d~69H|u2vntj&AAwQ@B4G7I zz}PARjcIA02xJb3zzixlCIS;DMc_8In;(H5`y#N0jvtCZ(7zn(Vg$&=)+NnvKZ3O6Gm!VG()neT=0G4-*Tk>)hxkjsppZZk@H%veGT z;>>tS=i<%Sn8fF3Ns1X|eSDnG$K=g0qeEdcVvCsh?~|GT4Vclpq#5tanDMck8T%`6 zp2}t%t7=AAZ8O@^mbzvXt#9V%nP${#Vur1=89m9~m(TY%V>@m9$BZ{)nDbaO{!BLG zpBc=9O3q^6IcAKb&U4M^HQ$WGvDp zYZN|GdTbP)Q>HTtGsqanagw9pOo>9#^e7xF8HK=7QMgw%3f*f(;UI0OABF6#qfnDp zb!FQDQRqWaW1`S|BIl#n=}}m|EDG-_$Mz_UIvj;7G~^`nIu(Uo=cAy!5QVN+qEPBu z6eiQxn^CCxAPVzo?Q^!zibBD+Q8@ZN3VZWKLz6!m_YP16YKN@*^M5ChL;%LmKu1BL$>{>MM(Tc{er_uQIJQ^AQMPqbUG(UgfHQM+o8VX$u zD$t9-7^H^AU^p$0h=Ilv!_PruFt|z#UN(0>Pz zDrw@jz|Y{Zz)aKVj@N?BIH6{`1%9n0;TaZqXeqraY(d>3!hIzTmS>ZRKz7^LRSkbtVP^+yK3))$ctG#fsvlSs- ztr#g;-^&WW1Crjotr$fyeTCVa_Pu@!!IB{QCIT@?D1eV$oy zfu2&O*FxR*R`|7(M18O#fmYJnk6gniE4tDB??R71Jd-p+Qsl1{mFX}A$YRllCeRPH zuq<0F{I*LvWsk)m`asD!W3h_%lSMDw4vB@|YsvCZ_NAT$g@Tc>@N-FCGX9`;=2&cr zibX_pERtx6O*okp3%^^EsmZZeO2(8})K87YS$agniU`Fk#KNz-Bv(bwN0aDArC5}% z%zkvDhH#~REb=yt#Tdzurm^swA}QaD?dd!jTf|~G%^`I=p-Z<|`28bE>mG~pbb!=7 zW6^`g(3gI~n^Ccd8zWpE8wN%y(2@Ea~EJTDfN=wH$; zh(&K2Pv4gc``5%mwJsKm*9&Vl#lml|q{n8CMc*i6Yb-X<5pwPp>K)`B9EwHozp;p+ zDaVCH=VIZvS<>!&Ec#Iv#b4xkk(9X}i-|X4(d(8l<3lX&eT?PrGD5yDv1t00HIU@~ z5sR8XV{u%v=~pcL>ip(>e_|2%S7-qK{nJ3=5wJ!QeGSU z%19LXYzU@dbSA$Iz5+tiFdJ4EvLR2n@HD~(o7slBlF(=y8pYUfL2}S)gT`jVWV;X( zZ$rlfp&z3q(S}Y*Hh%UmykUHoVnd?Oh82?h88$R4EOcgkLvclI_*hEFS=NT?NP8|t^W;VeC(G987B|JV>ROfWM>4!5E02peuo{$q?E zWkbKw!YIa%lCfiL@S7*8InIWbbd$m+*sx}zPm=tnZNq>wHncy>d};SN8}eSap~(&I%}t@< z0~?k-wBgbt;XdQ{$2@aSZOHwf4L?Zpl52cz!=yJh$g+eXZ*B04eJA)B{l1X;y$!wS zzy}+gAB7s9S@SPEr{9E*Dm%8T?TFF{XS8+%2iWnCq;)nsHfFaYEQjz+Z-?Dz$2>`) zJa)9oEBwi4M~MP*WrP!qH>hk`J0_L0LzXFYuV9CtuA&{4D%o*RvZR_Fej{oM zGa3D=)Uu-qU7@^n>=+|?&FD9?t{wO52|pUzQKYdQXPO9oTiS8Bm0;;)=e?i8j4pQE z>niDPhqP&tsLcA$Yq@aY`zD=*OmIAEetbRnAq zg|iFUb2v~nrvry2<%8IV8c0Hd9f+aX^ic0WWrHx)=)i501LZ;lXI=+-=zfh{o(L|BBdSO;3#9Q?kCU@Y!H{SpqGmHa5>;CuBBY?7=m@4)8@4m7VQ zOsMR@wJHvjtST(2=fKPQf})`VWg7`K83#9Z@Ovc=BsJyQ=yGeJeIMr7*TMJlg>U~j zkTJ}G4U)qn90(ZYKp)BEF%H}u>p+=t!psQ{+@Hw&CkYd#a{g(;SH^kM9e6TBc+dEE zrjUIW`%$CW4&0?ma~wEL#pgOOm&VO=;L3bHUf@8(g+e>Vaf=;jvc!Q^OC1PZCiG?W z8%e`fJ8)(V_kFEUhOxvt2ga@!W-;d9;6SsD+=J~rH#;1dBU#Bg6HQX&!^-z%$pP7AA^55Tb*?#ZN>bzo=c6|icgumLlF@e@xOkV(-4lk~ci`j$2kJc(S~Gqo z-(v^XN_H`}d+NX?%6jgA{)Gd3>E&w&+*!;`lKjDeK_4A>C;81-_!IYrx_x$F&llkY zW1p`M9Qx)!<`3by#>vltotQ7#7~sU$Y)-VyF355_Q995GjY;^D-w8iW0pSqiMJiU% ziP2$B{E&1EcVc^la5B<~+)+-Pj}>w|ov7(@;<)6w$B7`X6Sd=<2uTrYr#Z1Oo&7R| zzlEJBS(I}X6MmOgYs`PEH)7 z+Z5heu=aDJbAKluO1cbn!Y}VICz=d*;*w<3C@1_{jCNw(7~$o3C)^XASR`pY)rpnU znD=zy?o1~lXFD-f@^=nvG><13Kx_r7rIGWYFt>ab)kUH1uy-ZQ|O_0!Ec15h{465?JgXq0Fw)S zBn|Vpusp8|#(cu*NEd>lTo@whXJa3`u*&JeJC_TM+`^eS7yNp~yKo@E#qVMXw-^g0 zyD&-8uL%1WWq!qkLyUe^iVH_dxZu~hq)?y~*F&c%s0?$FtgPU|+lpLob)jHG)}|3_ zL$7E^3n51b7pisSn3CI_T?p^Wb$1u6131q>7k&*ACJf~m!(3=QLO48{?Z&c3l2_wh z@Jw`Ju|zf51;2_@h3nH@@Vh(1g~(YhOqJZ5?Sgr(3)3W>=ew|TfeSGUg}aQAi`icC zX{igT%U!%TQz*8=1;1bZxXOhslI$B@sJe+YmAu&Ef@_-#3njyLx!`Bt&2zHHg(s3} z`(3zmz=f8F1jk7ix}S0(?t)O{vI`@xxbRI<<)#a>Zn^N~whL)@U05gi=e`T49=MS5 zkn5-C&xAQ2TzK@6d-_Qj_|=7D-Q7h>FQekah4`;u=dZe;k_PEsq)jRom$d!`0S}a_!t$DcR0=q`ez4UAX41 zT(jggOS5L`vf9}f zj`hHAh{R{}Ad~i!%HctG$pWtj&*IoFUdT%JAU@TDWs=4j9;__vfw!ozrwsEh=fSv4 z;b&zJidOYtvqWFRgSs_6I4x;X$HVUcc@S4$*xbZ}?@c}Yp1H8Pvj^|Hc+j}3P^GU2 zv-)`uIY2Ot^`OBx56(&YPx0W$RE{-GxW!m#h6j@*w`TJ3Y!BAX5%R9_@ZL9$wLwVU z>%pLX9)9j4tUBVsyQ3cTJuZwq>B0F^tnq2#BV)>04_4Cw`f^U_c-{lQKexHoJ01kx zWBnwjAMzUYdE~*N#~!$!2)CXxx97}Nvg|((Ucd05-be;<`kV6Ow^rB&q7w07<^%+V#P)PX6 zSTw>5nMF|Ay!7xj93 zaYk~JF`*CZ(3iRN^TOC)s5sb*=|fnrk;2fi9CMr(spEyi6S$^HUi6V{n(4*2Szff7 zEzFzi#glnnRGTl1Tj<4=MP3wNEaX}0MdM{&T%>0tUoPBP;YGwMFQ(8+3f>@upJHuJ zdvQ}z=ByVJ&v}9KLjOx%_*J^>McXT0bbKX5WN|!d_g2Vw=S7|OLf}^~YJKzKgk;wb zFDlC7{^z(N4mnkE7(i3#j^wjC4t{ElaFFo=71hRJlr9e4a|`PV#NkuHI5Z0rHipN+ zuSP^1=0(OKhgmR3$Dv&e$CvD}#zAh2Ll?<07u$K_&|k7YAr7h}&LPR|i$l#cVR?ES z-ekmKZ3&@5W*nxKXZs35$r^DOS2K?H$_XQC$KhO^IMl8u+-?|$@WyeNEGgbJ4r7|d z@iP=*WzRUg?IrwT9MfBv%jj35PaIm%4Jz0#4y*eMHHR=i>h+H>iqWsw&^T13qm+Gk z9A=CVv}3pjW8-i@@@0G+(k8}Xon-IiIQV^-A}FTD!EYa(rHpC9LdNIQIrj`fF_Y~` zFFD6}k1EaLytCt=nIojkjleE*yC(Iu+2UbwYC4u0zn z#Not2q1Q34<9HmLCxjQL<9I(&9QK?Oem!Iz9t)KiFHz`I)<@FjSsXS!kAv@paO7hg zvV9gp7{}7(FL7w_P3W$P$6jqbY&zj*?syap5-KttAhliyW?V^c4e@Ab6zrk#=$0oQ z-Y`KI5syld@i<6-sIEC4&nYk}9>?e=y{24NAs=HqDr1YsM7z+z5sz)oc$i&6baFg8 zq{L%b`FMW+Egrs#g0o6IdQ^=^>smrsgLvLQ&heWumlpA8(_YYYh=<>N$+0Q%$T2M* zvc>Tzy@b!L5>~F|+SbLR&jvxcBOc{;#$%7<@veAS_r&A)USZe)=5sI}V~z>!F2`fb zm3Ty46&Bv$+Hc0A<}IP*y?Ce|3b)h=D5OomTAd)vlYr8B6L2}7P(L97OA`}tBUu<$ zH34U;CBRob0hMWkugmy_l|2{(5#R-_SBmuIe2{2L<$@6t{>&Lv{5 zBZxYcmD-ltjgzgbZ*c+L|&*FqrjwA%Sk}z2EJ~atR zX-QZq>0CSsJ4+-Xrle4+ToT4-CZR_KVME&_d}+u29fVQ+lW<``5(*C#J`PGk%8(?i zrUSHiw2(D33GuU&u#9$-VUD1lmxS{3ldz92QQM`$k`+mKxiSfLRwbb$1#A$Eo0Cv~ zOA^k~Bl^5YFr80Ag9}MGM~|t`HR0S1&T}gX!z7m;Bq8)s5=Kcje@Mdjk4d=vLzrk! z#&t(BQWJ$-eUte;wq#5k&g&zRF@2m+X+kn)OcVx8PR7wG$%vntjIz{1QgnJUM$JgZ zcS*A~$yl>C8F|+w!$m_RFE=K`y*U|+B)?B2qxdPdxhNEU#&Mn}qx2hL>X&5P{+f*0 zzlEpSQ(()Pg2Y@x6MYK&3LAw{rWC$@O2HCq3W8&WW!@AlPfo#`loX8i3FDij;A+zp zZ0(hTpS@GiwvTXVdV~`I5F9Q?Pkc3Oer)s_sw0>;owXI4Fc&NM0*L!sx>6zqS-F`o-Z-lZVhhZOXc%#fwxo;(%vv_jM1RIJvgB9B41 zoR6_UDn?5Rg{7iZp;Q!&5r)=CBGHT!YjsUxqY}3=tE|ZP(bg4-*L)m^kIPHsL6-yp+0;o zD2xvC@jYuFPDc9p{kUVX6Y_2FO1uuRTZo^w?YYE|@M zK_wq@RTfTEVXWrEK*^lyK0KiaOUfe&aXY-r@em&QJ{Xd?V<;X~0@K5Uk> zZsWtowmyWl6EZscFuV)NqE6n zY%=RT#fKk~PP2U2G24e83x$j&oNp=TqioB3Sh`j?wvFdu2hW3K*iO#7i*xQ4#_#jt z>V6+e91zML@nO~DQYqYd=s9qayHIKk*w^_vf~zxxpILpXpm zsO4#Rq!9{)q@j6e8m>wTt}%A#k%nzO)6lKIux&^he*GiphNi(qHz{nm zU}qdn7e}O_$Vj0A;|K~Gorc(qirnLGcFCL2|^^}6vD(bq|#WrJSmN5U#P@b zdrBG>PEAAZX+nO+H#B#88nQ?|GY!gFX(%^44SOUf82irQI_IXrGf$|pAPut?rlHny zVe9%d{M?WR`A(tPkuru9ed9SaQBfI*irQFaRwq{^qYzF#xghI_T(5giSZbxiljK zp|dhDO0sTW20rc2z@3A_q%n zfoktFa72>+F$2Rs36mM;ea^syufkl$8%1)=DADo9C;qR7aq@MsEe!wrGpyIG)>~S2 p9(27xcxQ9bo7Q0|9mby;(YjFGa>k5TvkhVYuOI(UdH>&^{{yRO<4gbm literal 0 HcmV?d00001 diff --git a/Covance_UCO3001/browser_profile/Default/Code Cache/js/43fc04b11d310bdf_0 b/Covance_UCO3001/browser_profile/Default/Code Cache/js/43fc04b11d310bdf_0 new file mode 100644 index 0000000000000000000000000000000000000000..a9cbe5337844ad07d3189e8ce2ecd5603b889eb7 GIT binary patch literal 33960 zcmWjL1$0wc7lz@lN!xguwiItucS(x7yA6Z;;O_434uiY9Gq}s(?lL%o>!1Sz|NFDn zvzpv{Wbb`WN|W5gQ@_iKZ0)~&_mfl=FOX)BWIo*UQda1Z?5#*c}nFrGRD~q z_F4ZQ>;L~2jgIyC|Ifi#h9;$@D|lQ+%3D^N1eKE-LVn3@Dw!`6C2K>_dco5 z4ar^9N1L%9574NXk4E8OaUcDS4kdil7kx_l$iK9YGNW%fAJwbiqkfq6i;q6H^pUBR zk9Of0+^v0-j2dWy=r%t36PIzet&dXM`KT}ocJ)#3-aZnB+ z!+rGoDB?rlXdn4a@lo(pAHBiaS&VhZN4*~S=*deTeMI|LK3b1DuYI)rt&fhN=sO=( z`sSl=z6Le*Gw4E)L0f|jI*8{P3_22GQ1;9QZN}a#2Gz}K(9vuLC50N)1DD+fwG20C ze{q8@qErckj+HX#Sy_Y3l?-ZB*`RhvuWnEg9Dt*SL9MX}-D)xhy45r2_ofDQZD!EN zP6j1(HfRiHplla|2I5OsZg(>%Yj=a<@V$pYjeF6zw?T8T7h!#f4d(s^HN+oyKY)1$ z8kB30L7fL1v=h6A7-Su4kOw=4krNCf3@VDf7&waiqYdgi#-KOjnF|dk5bGp^G})lR zSTTj1ab&7N&fkd}pQaJ}bc1qZH?E@dY=ffa7?gjWL2Kt5lw*NG!!ZS}MFu4M&O@|?@1L|eZP4rU z#C+2r%PoVvXoz80fVG(Nmq9b{8r19_YmNfgZ<-U)G~un zCyhpB^f#)S$*2PuZZ>KP9$1WW*^CNBOS@4uokn#)h|8!*{Ep8k7id&FOvGkf!R`>F zt|Bs{QFl-{lTp(!KeJJ_jCzkd{1*I> AMhz-pRHH&h zokda+quyb7QKQ!3Z=@76Y8+;xUvXkAVbp!NOK}dNrH$H)hh?ZiS)+=fGU}Bx>M?#V zZS@%NUev!g>)h9i3uQFxzRWf$sXm($1cl+vKq_6IyQM9j;Vtf^u z;Hy39zN(wsS0xJiY9d+|^3`4xF6^sgMSb;0SznpU`Kk+^VB4?0THnN1hhc5%tCyJ2 z%vXz$vAM5iVp2Z_H*e0399M)+#iNMGH+`B98N##a&Je6@H6Im{w4PV9I z_EnF&#QMrt=WKq;Y4?-A(@()Dp2<%GGyCa47C(*5?x%oIKdnZGFh6a>DP(o~=_PiD z`)NmnpNhr!sWN87`YB7CpQ@vClAk7`QnH`!rupd=u6X_Ao6}E=3!sFbN>ujK+Zuj4 zSkF(xn)xYr8;-T5J$`BDrv)AS^r@4dQabyoHI8-h)4lF~I@jAzw~@1tpU$9pUq5}r zgnoXC>hGsrNFC^>g76IT)9-`*^aurpFb^i9;ZXXb_%J_hNAhq#EkcG7ej0^;@oBW5 zhEDWT=oIq7Y3!WprzJD|lxe1)jv#rCpNwD|zKjrz)PvhjTF(!X)2=><=_+;=`9Cjc$#9zBJBD25RXY*ITFn^84Rz$kF zjUyNv;jfuEjI>DFVLJk&{nbC-Uu_fo)eBef0A~~ZbqmLn{PhNflKoW$>)?~(uTyw| za;g6Mgu!Y4+Jv+Rbm{} ztLm?dgNbdlzuKVO7~+C!Ed6n9qQCl1BBmAo%Cpj6sjK`IzS>_?Hu$T<7UucGUnO?< z%Wsdrya)ZMt-scz!5#8`=C4I|lNLHm>Yvr5Y1o73n33J2<)J1mb(?evbHYuk6G7W3 zlm5hIJdQT$AH0g8Uo7Y1Oj?h#@h08I_XLxyi6*s3GN~ITC7U!KJ5o$4m1@#?{DmoL zCN03P9+Miu7+1!mS-4l0crmb?NsrK_Jh!p5f=PZAP1=UTc#0O4Oj=#pq)#aRi%AFY z4i&4K)C;Rn;#YFQ8hpm~Y9^Jf&QGkYY0|Pw=thh^Op57gQkK5VfkXYN&p?w>2ANcKut^QEc?kW7avSRq zJd8SwFv&R5q>Q6XN*iNRTlB&goEl4A#<4z=OzJS1Jv5c|n8tmqz*_{*Few~oaAmeh z)#nh`Tob=f*gNw~+Pc7`fQ78bB9k&NF=^gXlj4?BS2$LhRAG%tOSZBu+oIe$Y{rIr zCLKY?`>YQ>KP0C|)EKtM^uaV7z$aAyn;f8L#DYR-iHUfHY|l-KN2Yh|S%X=AMzh?A z^*3uC?xVcPtbY(-HLEPz+sv{!&06R(>lyk7axTcMsjy}+D>#!`Ewh;QC6e)?%=(E= zF=mCunY9ho(#-0G;h5zyYoOPxtm$Tr!?he{eMG&SW-Z8LmMyPYnb8<0@|l%0zgcb3 z3&w(Gy+y@hW~r1}4m86hG%d}XIEKsES;nlh`Ny zzg9QvRxPte);8+^&fqiZ);DWCeqv4ovobU^D+2S7y|G!ZnwZtEsaa{w%xZ|6_|n|0 za_!7|*VQbaZp4EANb61wdzw`f4>7WrS+3q@RqtcgZDj37UGcm>eFm7daiCeb2btAs zuvxG19jk|!RcxqPCvgoQ(0v#&4L8e+#dwbvBg{I5o+FtDUodTyS*=H#)dS8kW*wYh z){=?LgEMG2iTdIq{+Uc|rqCA|rkb@EC-DTEf2ZvKhR-Rp~8;rZnDtVF`pJH8b4LwdX zKX#)28S0I1m~_^xqzlydqFJfvc8U65Hmk%{v;M;KYwQyge@wn;_MEt1u*Y7qrmuL6 zVBl*W3vbQ(1BY-I^WRY?9Ea^6`v1#b#eMw1>~FOHk2%d2Rkv8w7y}S!wI~d$a2e?~ zi!wSbib7EwL)QR{hT;>B1zF?>wkRv|;3zt0uxK#;L8lOlN@lcZab}CkX0>QM@?~c( z#D!VZ4z6&EYQP$4Q58IlvM4^Rj^{H-A?wX8`Ik<}swWxD#i>B0J&brKrZKz+* zB6EF_@d( z7B!n=QQx^1y~q4{7OlsC`K;pt;#_Re5wzbpu1i7GmRm#>TgU z7TrE%QTM~dcEqBUD1X$VS4cQU9g*!gx#KFFC#cOy*6+AK|DIa(`!nkF+@gUm+2^k;N<#1(>V;YFEjs@X`}`yO z_cQws0beX?fHp9GwP@5gV*Aei{6QNZtC||D>WqU%tInZ`pH-**tr~2yY66a+n8T{X z0IS?CtCGz-Dv%5GIegjH)Jt=fsIQC68_ ztO`L31jR8ndf<m=8ty+nQWMagR6szi{TGbK`k5y|>&1>bgBdf+EC5KhZ za*<1JtK#!mbqr52GoMwJ^ILhYXjQ3#R!u2n)uO^yjV@x+pjaMiIX6uautuf9zO@xGZ&Khe0kO??pA%BH&5jMi=F zhqCQ#s(}LSZJLZ69c)_B$)+Eu(%GhOU2VGF&8C9gZR(0a@abVw^Zqt95{s*<80c2juUK} zF^N7fPqt|b2RX;h2geTWs>(O0L+3BS_dr&CngawzEHW z*z`Aw?qrQI3MY4w&u;QT$vvzIrlHwhn-*guhU}wOXtSTb2W(0|Xj7&`)a8gxg)#0Z zai5@uC&~E~dljuuGu9d6K5Nq*OgU#$!}B(6xxm_@@B);|{OzFQR`?FBpGPbKJoO*>%`p z*At^%1%2)6hTr|{`pslldn^gGD?=u`x<+st_wgFHBl#I+S4^~B&KSGuV=4;8azD$3+jSMy3fT1k zEemoU84KC<6U__TwHkAZ*mb#vU3F^O^*6@Vva3^VyR3EWT7iG-+cluMU1RaJm0h(v z+qDfvd)RrdWY;N_?_*bqzIJVePk+1G4Y6zcNV@{2+4XIqU6~hCpCxvc!w}rZf^~Mi z!FP06Z`T1NY_O{zP9SchU2Qhmbq!6o*wtk_m@t2g?cr5(b~QIGR> zeZZ0nc6lz^bp$&v5zl42c3)vluG+O8OK;n?=`Xt~-mz;9p53+U&OO%hp3lu zW?~r%yd>^db~VFse1h+5yINr{P9e`5y9Q$-GQPE|1-juW^1ZXG42~hod+LNac#9us z_m5q>a2&-y*fkjokmaLYP0$Hfk@ShNuneEz`XgF`N(L#?qJKYSg^>*vrYJVbSWhnC?pQcVv2 z9&{*&*`Z;0iNY3#W+Kk&P)@YQLO5*>)xmD$v^z8vc85c2oDPKrICK?9T@ED%Iy4uq zAcu}%a47x59P)QNR0=!s3H!nwsvO}^V|0jg=xU-=YrHM($#ah0ett+Jvu2E$Prl>@MX{ z&(aRPK&CR}1Y=p|#ecAtb0{6%F%%msICLA=Dmmm+*`a9EM{69%fvT(vzQS3JajH91 zw1z{KFdoOzsV4QU<(F|H*K??BeTPmXyn#a_un~_MIuz8{q5bI5 zg!9uduB_b{ z2Y;(LG!b9nKbAOg7#hbqVj8X?%XrS=IN~M{BkrT%MB+l$Ne+ES$;l4Q#tLMaLj7=j zI(3=hP(Aq0bZ83`Nie8xuA1rANeJ>*%)SQv)|i^yrQL%%I?sNquLS;n4N z?ojYb=3M1ayVVX|$H6rYMXqxw4dLtA<8W8aG zsXvHmJ2Atwle(kxF6z3Q81_)>y~MuHp%w>N|HC{kjuStYoOGz>8TJm=pJgqsI23{M z@VQDn*n@M|Xm_2*&TZ!Wi?~txj)T`!9g4whT)-Wyy+?iV8aeN?XK)^so=_9$Df2vI z9{9X)s1WkJVy@TJ;thM`twXuqIW*t{zh6GGUp~ZaMLW)`QOpoPt;5W7>ugPa|{2mdeLsnZEg)l78CH^s^ODNg0{ zI#oE`sggOIx{m!hohp`#7;`g59;Y&)724)?Y7KVa5i;dx95gK8)Lc9&D|4fDcc+e_R!^sFy~wjS^YW1Y%1j$`AU$}+*pWoe zo?-D6r#?(2_GwOaneNoG8BSH6>C}C6pXJo;ImA2Hsn~f=Ma*|(paS-nAv_VsZ^$1WB zu3%)(0R4`py#llXoqGpp0K)qOC>D5#y!`^y0$tIie}Fb(FFFngP(Rch$T%<# zrad~K;jjQr91);Ts53G^Z$||vd31pCVb<6HZI}?CH4`~LB|vAV258Cj0JWSEpg(5@ zXw~chZ9~C10eU$vK-uR9C;=^S6oCtwYiWQg!n7tAUOAVJc)O0DL7O~cLsdPOT z&%s?9(1?DGU3%GsxtqBZ+1#a1EnHgO(xn$D+Qy{=_=$XN$qgHE7xC>}8iu?0(B37V z4lX5kcBxl4mx_0HDZGbEm3q4L4>t62>A&7CvhznW>}5w`1?8shY2-bZ+TC}_^uVPa=>3pmPpI=#m-arR?{gQ|OLY9|Qa{-Kb@BYorAH|JpG#*k{ijP`(Jv%WJMkyX83T1J zQ=pD#4%8K#$r`A}VS#EL9;l8Hfr^a`)N?$J3e=wHKwXas)Y8~MZHN!liljgtNDkEO z^gzwa6R5p;1C>7??eYieR)IhT6$;eg!pw!GMVPBtpoSL@RCtL%je@gOpw`1yI#9pi zFiMvV)SPmGil{^^C{ZO)Tk#!he+^VjwLs0nLAeS#TI@StOw>m*; zP&Y`~>IKQwI7oM!1nFSYAU$m!q*X0~6yJ)rt%H=kZIBXh0Ug=}=@G)(2WdQJqiwe! z_H>Y*4GPkYQH(P=NG+xX>GirG&08O&KQ{#F4PI^y((l`X^d4Jw1Sw!=kgB2Bt{^?c zl)XV3dyrU;5I3$M?av@}!IWb`ylxnzljw9hNJp+R=d~aWxEZA5u-^(&f!je^`4{uu z4btF;LGu4QNYkDLsp0D&&BQ58c*Fg-LAw2uc=3yZ72*@D@tBPhhG2Cz2J514u#)_O zbsyRMgVoCvtZ#6cgLMrCORxg41=Fm-+L$qzzX5`^J!`NsWDC|vyviP|wV}aE2@lrb zXv8p2T(I6Fb3(8>;Z9<(3MA1lEm-fo!J3~Qth*STgX6h^^&oGs2Ik{_{$O1}LV;lA zD;TUncwU(CiU!NCM6iNOGe((U4KEw4a^-?G7VXOit51bsox!Mz!CF))ShXt$t8&#~ zt*aiaPpDKQSY_%4>qfm`6{;VsJq?1D+Avs08wIQ9Z^6pbI9T4M#N0AiBU%M(@rYn0 zjtSOee8fL9=|3x2_3;lhJ6I(#84HkgPO!G3^E_&VFDNpf`}l}+OM|t1J?%FJtJ_YF z!MH0}4fh0V4&I{N-e9f4Bjnr{tSQK|KUk$O??A9B9OgV$90^v_KUq7BJ`t?+lfi28 zEm#YYHB$zaMla;ZoPodJGN@LT44Uo9ps?B*G^2S2UBS;o8T9;32F?7GL4V*a5`04R zhb=_gogtd)3eg+1iVD$kye|@>)5SuRR60ay6+<-Z*AUgN9isN=GAcyBj1N(csUb2f z4dL(Z5MJX8QLlX=8hIo{oADXluY@S@c8Fd)3sIKmA!__0L`$&~$KZJrqK?HfYI47f zsyZyAN{-2>S(7sA2rQE`a?Mso9bcAFiT5(<3Tpn7QLDdY)Kl!ul!@!7GHGs>Ov+L> zlUg^(q_8%b^teMNjqILD?FVMkx?`DSJex^=KQd{CA+vf%X6AWsX8jtKS&OkhUuOMT zEVHte&aCz*vOF`dXJ+R2Y-ZKXltriGv#@`&=vnS88eS%gX4T0ecb_cE{w|9GyJwg0 zn(WHIKD$;P&#oUQvU43lsD8zUe4$FuAF49gkJDIFAXJqLhUz?O7YfxObSV<5>P179 zyLc$qu!m|>$x!7e6{?~bk9+Vh9jdcsLbbVEsG`elA?-W@`fw`-^t;wD16g(?p7(W!f=s`d)iP)x>mwCGK|2=5cBji}x? zR3|a2U#RK~P>sa{yutKIq53$5<5NSqMkiETVE>)kU?CnOd0MENV;TO&s_FDc=nQIv zTr)$}5v#CoR;a!qX?CdYW6>Pe2zBNX8#2%17?PKSYTD9JEkTZDp(?eU`0;E_s6HWP z9mlZ~vo?il^cHf!CxrgNdhZBTEi}gol-(Pu#rs1w^8o!0hUy&J9b!!nQy(-u5~^0m zLe(ALPlPJ$La3_YH(W-EE1}AIi~WG{IF6yWL$w!K?}Ta|He=mg^1%K3#PB3kJD$_# zMW}pUhAQ$6^M7L8uc12jgMILmJi^1&Ix0*l(P0YpgsB6LRtuAPP#EuhglWj+Fug^< zlrUwV8>XCSj{Z1=jPt^jyeLd9aCmW;JWIoP{~=5xa17sY^kNv-BZX-N=0>{p9g)#) zrQr%vT*{u_}ig{Jsx`he9xHTVbs=B$R&8-%{y0sg9tGi{a>E?ZP zw^C}kHL12+gtDq?0sxAOnyR!n2J3{BihM_U9pbE`Zen{&Q} zTbEn9Ri~9(+o9HO6~;UGv~g=0vbS}sJEq_Z7PWJ01FY@cDv4>hhu5gmftYX({vF*K zgGHU(x{E2D$sMJ;xU~?CVxD z9PCH?{=~T1tr}>FDOiB3XuQR(j<|^*Tiwd|hg%&m06M6T#H5?Q7xiuHz``zk~3)p&)SP!{1>Zn^!G4xNjE+O)m zTZeG+IO8Dj1bLzbKBCk~#yLfu@$j@;Mb5fa^Rio>D{dXfO^mzd)-05|LC!bX57>m+ z_sH#$TaW){J)XGL3Q5n&?FIV`W3eBlUb?w<#;wusX!D->{^Qmg?EJ(Y`RrEKuk0=V zaIW7C*HMI;!vsNd*@}j153ZLC*JH$%3)iah;o63j%He!g zjQ03YD_lOc!_^Ii>V~U4N;C{t&GyXEDO?xvp-Z@ex-kw)^a$q~NXF|KuHZhj?;EbN z{laDJPus!asy#GZ-$sUO=n}?X6RsObTuXfG!gUTS)`!b?L%6IP!!-vhF=XsBN4iFE<%$pL@54Jgxpsm^Z@;?M(8TqU8BwQ2=#p$p|!6fH1th` zTK$MnE<>b><05`HMrsXi;RkZ~Myfv|{UTM$KT>g~NTrw~^%{LGk(vy|H>k_rP%v!*C zm36{$IIl%28=9fz?MN*{?Z3zguTkM{q|V|YtoI|88Ml%6fcDQKHRVO5a=&3M-g54J zqz<6Vhe$Q}L{0FUqBO`SN;X53MxvH6O0#^Uly2g_JxaegqVx{6Q=@bpor*>23M^%! zcuylr3$Y(6%Q^JN$Z}D9W+qCn%15bEl_+(n7Nr4LUp-2D(4l6OOtqqP1X=6Qu0a&n zYDejA(FdPJ!KR`rb1HgxJ0r9aTNca+YfPoF3)!)822 zOy4Nwz&xb(i&Aj^D9ylaR31PqxQ0!GqEvN6l$uN-u31rB^AM#S_==))qI4AIxlu|) zGaQ^3rN9MI3PYJyQM!ub8>3{{6s1O+qf}!HV_^j1w^PUcQObNEN-d5@X*e#R#EB@K z#NLxpdVw!!b&7fMC#If`(kDzi6QzK&QCfg|=yQ(#D14syF&!^qz7VBcmpG557;u^P z_==5Jqx1kl*O(W*@E2C!jM5_%yB($EJJcC%F!Vu`wm*u}!^cqydCHiGe@?uwqIlml zN{!!;<6Ck>_y3}F0u2$C|ZwEJvdrT&@5v#*QrITQ|4$5 z!aMv#c-Cm0#%)x}Mod_WU$RH*H(bD7tPYLVc03Dl_#G0Q7Iu>wnW-u5t^k&t3_J0YI&m7-y5yY z>Ew`;@$y8gY5r(kEf}o=g`zdHFm=JgBE*0jMWgwh8Lbz^qGc`4F+9V`64AO|Dq2}e zN6WWDv>M?w@>Pu1a{P;$mBVa&M}JV5~CqqIo>Ts#YV=cFRqVbtT8cak9oL) z;xl732sviOs02j?tTy zF^by|qoIGqXfLvEk5Q%_F^Wc6oY_SVyJIwUPmEsfjZvAszj>PByx*lZ= z#QjN(c!%!Ci3_(*#_)G!jK<>%qEE+YGQ!TpXc#hHj!`KL##TH>)+;f*&ljUU*owew zF}jPFn0Gry*O2p0j4XF!bn$77?9ZtGbMk)?qeL{uj@L2zgjH{-JyySs;rT?Y-l1}v zSVgyubO`Hz%~>aAFF@x zeL}1{PK;I7$+4<1C06^;U|Ou^pz`!sHN+znn;ENDC_gWj->b12wI)_SVP6}o9Ge+$ z3vICpuC1~970YoJU*Z2ptO{c&CZo!>SZ&95ShjN;*>=Qg>#0~RI~%LbNIVy-^|*XK zmcO@RH5Y|1GdIjvVwL%7teRenRcEAJkJSoPx)G};n1pOMWAz+WZ^h~os@#s%0EGS( zs~(8B6RWkjhOT$1-Mv_yhW~xWeGsd^@eMN{5);l~{+C!?N3MT42lKaB9O*+2YhEEKWPn)*Yw5@ClDo!-zP|ij30=e8jof zI30+O)8m9VSqsIfBo-B>T@m_WMe#V@N8yrjvXzQcX7t2WyeJo^gz|B^jhEn#LJWhYti_?_)aaw>6*xn#cy&J`8Zwtn58K(;HZxttF>o}gj z#%W3WIF;xSCs)Tf&BK7+aY`N-r!i~*r#JYCC8y(5?R=beqTXfdfQnb*R3Ew;ryj_DlbjHDn>ilG=^)NzjORN3c;&kv zuT}Vt^at_kjB9v~gop9Ujo~36p8q@J)&6n3-rzqBdlIkxPvf=dMZE4J9O zVh!58iq~9xK=kW)g}#Z`JA}QB*P!?D^7$uTrEmrrKg6pMR^TMQqT?sx{2b49ckz0U z9ADyjuO?oXQTg9^O+m~z?*E8a0VU`n{CpC)E<8bJvBi*}hj1GcR1>3c2AO>mR2PeI z7lD2WDuzy2iW@NdCnz7fU>UB$VM)O<0`ILQDF4$0l}Ercj=xDz^jqeBm!Mql>5FrC z@;N~fUlKInE4lrfpsMJOtv?g=8WnsJmBWyzq8N_l{)xJWLgqx-EQ!jDT|tTZf;GX3 z+Kplv5;Z?0QSCA&stfbSbU zkf`#Pi0M|M9^d8Iy+lp8pQs9t$>j;PN15l$j}3V6B2l?tCTipBM1{RcR1zY-B`WYc z_mS;qqBhT}S-1Cx}FO&A)Kq?_+j_B>AQ#sVQzFhbM{mK9lqX4sVk3qYNhE9$sTa zdXl!{P>v)O$(f{mu;fZoH>|}a)XJTtxfqr=Ng?@@)V4s9{y_7BNh(-~@lc^~lJ3G; zBuQQI70ruMJIpPXr2mR1sc;EmES1FLI7#)(CFvDDR-j%LlT@-UHOE^tu9u_>c!-?! zlT;B+8c=W88j?$+B&}$iBx~Cwy+oaMNh;APNrREIGh^W-;<_d&LpSO%I7##H?~o+j zA4cA&I6g`BCMGHSlqA*to%p6FslW`*;RkljOw#`O9LL55NjiYi3#t90B=ugLq|>`O zzmN0SxS#VVeSq@^lho)?lG-0n(i${8k)#gDdXhCc%g=MH8~(!N^GRxPl{G@GYpge3 zq5O>`wY$k){Esz&%=wv+`o2;=Dl6fB}S=T2etJ(BqWnYl2UW<|yzc^W?4kl|LZXaUY!^zr? zCpdaMS;iC827jXB$z-iMm8=7&lXVseXOi_8e_y8Gm1IR+P3H9;#)s!F@#5!w*5pC5 zraw&9uaAf5{s4BU#g6Hl?UIj+#?+ z5&f+x8tzEZ6!>LM(Retsq^Le#W=+wIY$J*+ zF6zdms9ByA?Lb&T#y~)!6uGesh9W82j#m{@6jw1t!zvL=&=n5Vn+x!&$ zz9>bR7N=;)a*kud$`t*zDn+YSr|2Pyt|eD|Mb338T8Q1-Q}}O5#-Pyt6jj0{cn+rMHlCx*A!>FkMPpB;=mh$mrfvv2lcJ7i ziSt~F5-`>YMZL+DBYFuu&!6ChV-WY zv{Vg8%Is9NMcABFrQ#yW&P~+_zNK7#F1~X>qCwp*n(=rs~Hs;$EJrdlXsUevqz?FgEL8)Jr)n&6pGei(lk`88D)$+3JD;kU zzZmy!s%-aCwGEB#rz-A2sun*Zj_1VTNK*l4n#$rI6m_NXy+dhw7MP}~8PoI@O){tH zVU{%I$(p8;c!M0-`5Bs~VeT~fMsqwSO?6_^_`f(!eG}7k6%XM|O_SM^rVt!JQhJ&i zu2z;`BjWi8QsVlctvS()hl(G`=SzO(T%rFiq;4rkZF9 zXTLO6?$5Xb(lmB(ni>pAQ+vb@P1C_C#6LAnOVHx?G!2=Vrs}iO)C`$sr>XATH1%1U zrU{t7E=|2Qq-i)j8`HFQQ<@Str>X7MH2rxfO_PqMX&%b{Nqoq7EKSd`>2#VVUP)8r z-83D$&;57Y|B$A+DDyE*GjR?ZKBsAxk4Jt6j|yVF(W4@M9v#OO4D$Erk;$X?@HKnX z8Z|8*Ew_7=+2K(P&chYp(GZtMy+b^jm67wPn#rSOh|cWMyI7Ad#d)+hfqsb|jmhcJ ze~8WJ(HEHWdlX*4qf|^U$zhWMJho!hjTk#HIr9A3_fk-UvQO`0S zzI(x=`Q;hAibvB`&#NXGy=t7v%V&_iyteD*v&UX-%;MGEY+e;`do>yJQ7+u8F%e$AZ^O&y zLcF~8>eWJ2i1TU`Y9xD=Bh9O#c!Aa)ujYBZs+_~Cp?SP|R>-TqMHs)7S2ytlQ%ZaF zsf<^?WxdLXzGzj>tFe{5dWyPLyz;B+<-3MBj^JOts)ZBPyt-9`xoeUGjJ0S}+pCFn zygFOgtDOzKifPHb_}I#;*=@Xfi~q2)En~N1><(U~c4jX8*Tt(j-MoBXr&n!yc)3QL znxF%+^d`?fUIq1IoI#9(|FCkfR|!MuH_WS-qr7S~+N*ZRG=?0&an+ve4XJzm|}=jA(PsQV$WemU$_=Oe7oQP%93 zSJ_UohNl?w4C{N&tN4pvRk}>Au8_kua=K2wH@%9*1(dwyRj=D#ef`U;clW&7^~5XJ zQ?Hs~KF;7KN<8B}*5a4vUUk7)6nf#+ReZ$imtJ{Z5!-989%H;uI?uh+^$YgH&o`aV z8>VYSV7g|YYEZfw<03L=NY_Z@a;K{_6rL^@2IE*nx^hRRYjR?`7NdSry4v9{M5Ux_ z3i{_r*94T!nXcM6fq>lU8i4VI(={Kpi=?X+ZoplP_DCq3u8!r>)en#G5gW=AFD6w; z*B6wil&;fwf&-P))xJu)#{QD7zcKgMbOlvQS3_)tZ*^k9eUz+`uGE_8Is#Mebd|3| z8)UCb9S~HHeCwy{@Nen5)Hq$+nhgSQ`>Z|!zO>!XrHd(c#ZNM()Aqk zIx<%0bQQvNjO~)Hg(%UL9D1bdd!Kam?whWe1Jl)c5cR_bTt&9Q=}H+&tH4Y zbiILLX1bc96V9T@EaIQdcnFx2uAXz#wF#N$rE4j+W6J7e9TMN=RWr=RC0O6*RZ(=uTD(B)KY7&v({KjH4|$ajov|GEk@;g@Rfjik zJ{8E9Pjw3AQ-db?l>Jyf{gaYk@u~UwPK5lLgF6UM%df_mkDJKo$*;E91E)8?>SF_Z z((|hdhT!V|YPt_7C(7^t;~#nv5KyEG0@8aYW!bbzCXi&a*#(46f(nTAs?voo(xgZe zkg{};CejfUklvLpy-7!UZ~r&v{QjQvI@wHS?sM;*3GOB{&!DzxVID(^KK5Hw2OChR zu|sN2b+>v)FM zoh{1OgRzmZr$zZO8IQiQXvNnSZU5e)Od~CPUtrM=G#+Kq&!a7BGsdDz^DHVp-=f|N zEb6|{qHnPsm43D;eVv8twHfO-Y#>K$Lf4JdyP2`JSaf^zu+)tY__W3R;&8&wrbaYt3JL- zZb-+-+g9z%Xj92dHl4|0Q^Bk@&BhFJw%%%Z4ctyMifpwZK4hNF_d^O^A;NNNPqMpV*bX zgI#|iXGgof=ww&1&URHm2sOIc)fuI_+Eo+lP@p?C;31myuj^X&S0iCtIm(^7Io^<{RA`o*pW%kA2= zp1OatYdv-&w85?=8}0h^ck;qc?B8iuqg{42!}kxU?=f{ep^m5Qzi0HMT!Px5JO09q z@(Fs4zbYi?Jla%D(A`QbLz~J8T8UBB6SScwkF^ps9lqKLYJwV;1kJ+{TY@g*Au`(& z^gha?M|&peg35WhG>0nM?2cIK3v=kT1JG8Z;LqAt_s6t(bsx)$_Jw9ygV0?#e zVM&TZ&QynHU|4g9cA!@ahlZnJnnQ(K5gR#MJ5&T0u%d%QSvxwExf9#s5wdh<9F*wd zP!xH)I#d$dVCm-I_Yj9#_jYJKmh^G(yS0PwA04VO$e{#W7|OQ896E%H_<6WPYw_tw zhknN%+#KytvoQ|!o$SyJd_2vefoL(;p($uQ&!IHf<~ulN$iexJ4jHQ)YJ!HV9qPK< z!QWF3eYVG;ZkV{&p<3r18j5}w9om3SmmKPkE|(p0-*IRV>fCk6gN*m6<&i^s@xu#; z4q)I*hsL7LD~A@t_SzwDMyD3zWF{xq3_A5qW~X-GIzm~T%opXR%+4bLw${% zThXZ_cz_S9vm9@5p$2hkIhhyOss312pK*|}fm5|n+3Hj>jx;2Vq5f9QkijKm7O(b8b0R^|n)Ma30I=@%nwIg81|y#|YkgUA?J*=$h(hs#OYr8D(h%3t55Y*v>(LR)0Cvpo{tN^t2cvN&9-3^xp?OJ!W->2qmfic3GGy0jUU znz&@g7jHEsW;2)4P^*PYf8a8zwsa{4SF!AKmrfwDtxMxNxwH;@ySa29IlH@53Ks0g z6FmRMrINj<2cxkH&-xQ%kV~)O7{R#kjdn2?luJ`*y0j2aP-wMFjkmef4cGR$lxIJ= z93mGS!5tJnj3e|Dd5_Us%*HC5ee1YO{ZF`b>>rn2!gJQ8_85d!ms~oDTUY7lHJ3Ww zc4-14cU|g-mXBN-0_#)u5lX!xPZX6~9#qQiRv2Hrw+anp`FCzr#lfL&J%i!#KCBXg7gz zk#{27qTCd>0+@$`$U2Q2aAAg9@1(mme6Cx+Alp3h#E%Qy+K4X}xiuE)%iY?J;=j7( z#m<#(?O9DfFS=C?#uc|Z;32YJrJrwIbL%hIuej z)U8_2+&T)&bLz#SH*RHMPruCO(d>dA6)xsc0PQgn%W(*gQJ}a-Hnc!rOvP_F2|jdH zc_g6+CgV@sLaRz1jYiX|9u35^+8&jz<58aa9@WP^yGKP6JnHE6=#tN)c7BgM$sTpa z#O5BoljhO5s7D{hJ(}Orqwr@QWp3qBRV?h_QK?QIt?2BLqpOE&WjxyRl}C5c`fHEA z!R)ub@yOZBqa(dNYTU=8A8-O?`|=z|aS_YyW&Ov2hj~H&gGQ9u?ccGPK<3(R38sMeVyiitY7q4kEQ3 zWIUuF_Gmj!qu>$t1MJ5<`W*it=W+Ua%A@?JJ*t2cXLycU7uYWtcaa>B?-G5#=25~u z_5pU^_vjAJJn|^hW0u45#KZ5!EJN{U>_2SEU?^u^L)GCaV5mJV6f*P#9~DLsLtAjA zsG;e_4V`)GLqq*a7|g3<@Oc=oBi%IgD^9)TH`J$*p=?QpwxtrcnW4!zj_fTB{{1!7 zrj?6Ps}!pG+~7_>;lsTZVSdq_$ZG^YGE9*}OK#kbQx{e0zpUE;RHS ztrr=bXKBcaH%sZmGL|hjG!EleuO{|DhNj{b@*g*3d+UUu({P?7Ham&WG zbA}q8XE|nEqAujWY^VgP{7Vg2$l&G7=_$%QGn9f37>rqH_1w@f?0!ieS-on6W^iWn>UA!! z%(7lJMR!ao@73oOyvkeAt1XqhI*5Liy((43D{EC=!^&!2?MAS=SJP^EwYjEO*O0rm zSHGfc9j{XGUp=p?Ht=ef-78-Lv2g>%9bOf2d%5S1SMU40%vI&(I(M&@HTG&F)&{() z67s4&)?jYft5~vE??k++h$YyKYxp$9s~*^oN~w&4FR%~Sk-Z6V@ljK+5)j2{JVS|Q zUKyD7iB}uYs5#qW6jtF_3x1ALFD_$V%&Tp1$GvKaAy|Sfxce!6_}t6&CSFx<#rU{} z)@{7HiHcu%)g0T=t}Qv?%P+ku-_EO7J-pm&3txG)6Ai!iYWR0v?H%UT&{1B#+xBYu zWUnS{_G;6g)Unm8`Fp(j@hCYSBjyRON}s0pXS~XDo<3mcMfM#IT=A-ZPM>z=@#*){ zK9%~|r(df3l#<|6jfOtH2k^<8=+iY!bNH0%@~N2HCx0`aT%Y(qT^Z=p0~Gq7Pa|*&9}o7aBQB!F zcRp=Gz9Bw+f;o5$$55XJV<*yv`E(5L5BDh@OOa)iPwycx+Q;X-KIS6wX&e5=_docQ zXR=R4F&rQKM6GB!mD*8gnvZ|asB=2oqU#LmOlO<9th0dJ&~Two85a5U3dUleK3n2b z7o1+^)4t_CEnMSMueCl6L7k00{fodRAJ^shlx?$5b^r9qjm5~Zm6}lxo$x1)Lfd@G z4JQU;9CB^#tn3MLa*`eQ=d9xFMfMQjOWBh`~^9~_LADL8$Z7y z$JZQ#DD}pteprJcGF2>t$+cvru4Oc}Ba_MZW~R!ba28V|u`a8rp4m*Tz@F@;>gO;u z3wd&y`U>Zf`i`kxsFll9I&$SU)d!am$YW|A0`Hp4GiY)ShN;E*O~v0c)!}_pKV$m` zrV11!7KRrx^|-L9r$tPSEo$oPVx}?|H#G@mKQy%#ElQZmQPR{oL`s=jherHnwqjSGx=PCaX%qubGB(= zs!E!v+)-2ga0`3l#6#hh)Q{v($r)dMW~%h(rXFH@E0fR4Ooh-1qp%!@aUc2Gn5vDY z7=axq_XYbAf1`3+Q!`NYOH;q2YdiXYeC^2znL02Ye(q>0*vZrsY{s$9ratV#zQHkM z=w_-hrl4kbQ^k9jT8)f7O%;S6$KmR4Y8(a+Fm(a>|3|K<`5iqUZt4lD3gD z*J;!@!({F+`hpVa9MdyRjh|)e-PxuR&*t5)3w_i9Oms1ah z{%Yz7+O9Bl6g^h5e^%4CHM~F8(f{?P3jJnk*hXsmoiWkn50iPK$Qeg)70H{(V=MV@ zGu3OmsUhgM!&JpxyuUDiH~VW3AI;m7?>l_?lJ{9IKl6+FRV24xpWyR6evSCRFGoSYzQ^pM zeiiu0uR5judWzO%{L1*TU-5E&?XKWgy^4PA!m&zzC06$9Z=9&&SMzFq4aGrhtL|rh zd1B!g+(F)2ezigFI(`{=P~R_G1HYGf+E4j`kC_-KoHxP}rYu`nKgp@5%yFbZ4o3YJEG zb;UAVLZQZfHNs%*zzft5FfP{OH7r3tbE5mT61PwxL_aYDC-GjAUm=Xd4rB=XWkokE zz!~IE_REdFSdH5#74fSnM&VC9MCBA>V>%8YTdH4nbi-VnL(wLFHNj|X$1_xKN-vO( z!^qvtFCPYBJszOyCw|U{^J_7#qfB%9g)!KM$Ee=I&-rrn6qivd&95jX;Sh2~{c_j*x8aWlq*y@L+5}Ygi-7*Y zb#!hU(7rDNd}kZbrp^Ji>mJaoJ^`J>xV{0+M)`gLeb+yrQ3C=x{#`)!Q32%}9Z+j@ z!%CDK6VQ0OM7~U(sq>Kt1prO=qxO zdO*?j0Zm2lw}4`}49CWR%KaYDf4c&zyqi362R-)$bZBotL-qwU0VnYEKtOd5QYW5a zz+VBK{yU%_4$+IF0a-BVSU{2E0kuT>3C8&+pdu&91v}3K^yztWz|#xVevuqd_Y$?< zqZSOl&v+>EAfT@w2Gr>hKW7fA8Q#efR8h>r>#RXl%pO#7`Jgga2y#EQpjM!D<)C`v z1)5b2>J;wcf7OD@UOy-U&yb@*P-Ae*66AW9pzgVXs^$*rBJSfGPmudH2er`~)E<=f z1(iP#R1z`;gL)5B@HiCIMl zq|RAFiewL|LGF;sg@`nzsO+vAS`u?#&!haSTAgej%kId;gFMVFq3d2&w?ogtma_+8Y63cEuZvL__>-jMR03n_$*=R?Ym z$#`^uF)z}Gt085%7UI1Bkai(>J*34qLTY-Gy6=Sa1}pA{xYtrhzI!3fyU(}}LK^;* zZPEK#NF$KV$^~XHL>9yptt~b1{=NEo+i0=15YeoJq=? zCrL%$O;QtVfirKCa^y?WT{QTB8U6|;DIN0_R^<#~H9!?-VdnA;>#vewoy8X)h1I%rSo?9ZOjz%?VRPlqUL=g>W!!UBHGqJ zqSTQQJs14_1Q|1ly>il_;WqvcN#xo1a|VNOK%787?vM0fD_#)!KA9?=lIK)*jC z>bW_h_qRk;ZEHmHwv*Ei*2TNKBFeHmq6&K=a_o($!I6kQI37_&tT-Lf|IS1-@q9$9 zu=oPwT#RV+qll(Gi^%glqE0U&%KtK=Af{k+mK4o;Cq)O3Z6wSwsohcf-D@E_^ zPSKOQDN4GRqAod7Rq*{()yEoiDv+xAC{Qp}F|0t&LaF*19X?D|$5N>ZlulK@vZ)#v zPF2rtsq&3X)#^E^TD~(?TQP7qG4`dZ=A~54P!qMt&_uoPylxX^Gn>fTu89h5Y{GrT z(lobCnznaH)1WSCdeAdXt$U^E0KV#zreXNGZ<>Y-NYlh`)3{D7O*KaGh^arMsnpms z)tiu}=@ZlBo}9+H_Gwx&HBJ9cOVjl=#95oBgX`1u+iz*g`Foli7_}))n>MHEo1JMY zdL&KfFQ#e1{WPUNNaNa{G_B7Rl_zsl^|D2E4ny)p)#%-*{>vLxzI;*MpS<>QRL4D0 z{bWQnE)dnxZ=$L-Aga9IM&-wVDN&uC9#xSUQSHYWj8BiM;>@Tn;Q?OFimK*Z;^Q3p z&xFIGoYbxl-*Fb1da!P=;Tn2qe~qbdOZ#;E3_+2*JoqU6D- z4&cU_DBmka<$gpA)Ok#exQ$sTw<71rX zAJZvpoe@)p^ceREjcFTt&x~oztQh+;rbDx-Zw~9=Fn*dFQXp8grL|kdD;`*X>Tyv2+EUuri5igNr zcwBajz+_|{5!Wj;`aZ6nID(ZUi8U&&Yd^#_c5Gbr#>M$vHm>p$;@sOjt~+QpF|L6) z0_%@)?qw9$A{@m6jVUV!S&muG<(eJFXX4 zKPRq2^Wr*%mhh-z O|8JM+|8MYrkN*!;R0wMT literal 0 HcmV?d00001 diff --git a/Covance_UCO3001/browser_profile/Default/Code Cache/js/4737d527d21bb15d_0 b/Covance_UCO3001/browser_profile/Default/Code Cache/js/4737d527d21bb15d_0 new file mode 100644 index 0000000000000000000000000000000000000000..451c88b6856628f1bae055d0cc05288ad1d6b7aa GIT binary patch literal 55368 zcmXWj1z1$u8piP#1{h!%7{I_ly4!9=vFqru_2{v?ySrPD-QC^Y-JQqw*xh~K?|$n( z&+q<^FthhsYp*>j!X(%2xHL}4t6s7TvpZhXMPRmuYcxt}9#d41=Wit5?;e_=qwlE7tpR0_yjn&TjpQFity6)3CfveD&$Y~_Iz z+Hc%umsS84Ra6Jr9+d!lHQ+l9t`7W5S!)9A=)X=t_Rhc;^6IL#j|D`g`6`kXm5eUz zI=X2*VXH0RyyzVD*rR%02SiX&Cu}hGvf@6~PgTQNvA>x5j}>i;t6r?=ndStyl1>Pq zUS*t6r<@ad)AT>o=Vnf@Hh01f<0vbFTBvwdR5Kc~;VqqT#JI$sY2}2()~YZo3U*RG zdN@H0rBc1r%ic~9efy}D(78_NH_r)u7C2!Jow=>L-*1-X*lfJ(%enP)My~$O=rF(;+iAx@XLt^BMzXPOurtJA z!+EGPL{VcmEBX!R$45A$*GOl)9;1G+qTX0_X*}15FhLDq#nOrD0xJ$pQr`bKLwqzo zO?HNenWA#DVyAJ16&+@%u$j&f`Dd$DbDSY^%vD2JG0||$cZP^vqym;Y^e)N1arHO^?emh+&j>zr}cxW$Tko0Q9b?maqTYdM&gs50(m!&>N!s_=8Fim=OfQ|W z;FUAhzjnqi>iE_fi{5knKBxz5#7Aee|HSM1S^2QVXcakq;kpNEjVGZV63YJ8Qd)R(`vy!8se@dvf{pn1rD1E zWJNPC3#xmowyYRxq<2^#LXCge&s4_Og4Q&SHqd3-ncjjc6q><;+f+EC1(Rt`fCZH@ zS@4STWwxL*eWk!G7SyBJw37y9wO~Y`1%0zwaF_lHvfvzfgjjGk)Pf0N{5W+Dx8Pl* z1<6qsjEb?KV?6&m$%2Q;7Tig(;1gxaZow@6j{S~q=eFQOJ_{1^ThPCN1@#MAaE9WF zSn!sH6t!SA{YMF@7K}D#u)T|M%*8FZM?oc20vlLT?PkUDQtAOK(wDX%)u_nUDWe{- z;-9h>*veV3p0bsX4Ga|RpxxDbQKLFLFbkTGu;2-Wju z1y5&Lka@NRjp@uB9%H@*QHw0dzTASAbZUhKRaf))>nu3F!Ghr%xo&A#Z-1B=mwxirr=hV>~91FF(rHVbaK(sY_vm(UnjC{T>$mFNuS&=cbif6YQhqJmsYz4F-$Tu?i=^3UUf0hB(U3r0}!f@&Nqk_x$?8SSRRg+HGVYU>DIFUl}dg^YHAs6Sn8oaF-1a30TR zw4CpPNef(%XQ2x^(H{CmH5R*|FYP6_B`&ZmQ_EJlVCM$)gFU%XZQRUbQ@$-OXnk0% zJIB38TQBjtUUxzCEf;jXL{2Z|=IsjMPsK8-egUo!`!cCvSzRG~0@Vsu zw9V#9oI&8r;|wVgjXWsvfdpOEXvG zZpq`daz!V)Lw~e(#Q>VyR()#kii8fXXhBCiy5epZb+!lBmu^wco~}4eO?tWFJB{t_ zim*Pe*g=W?R6#bmzxrnY&rbyga%{!~w%#Chnk_ci6~3A+CIq@3#Ymw<1|+sqWGDvu*~9m8+F)5vt2Q8t}B+&9SWSsxlzpp zu83KvR@u9vxgpBf#tQ%RYG(#F{9gb|ZL+A|+1wyT7@JrT8l*a#0_GaagY^Bp{h44 zwi>?SZV-K*l&LA*A6j&%F(EDZdgVqC}Vjy%%XoOeFZl(rEt ztGnR`{i@-H!F70z8@l05Q#V`~ppr&#jj5$kW+dlIeaJD2^P#Kb+|X;h8(vOv!Y@TIqNL=oQ;1zDLtaQV~wQdMl=Z1v!s>KF3h;c^SjcyR% zHoKwtHaEELa>Gv}Wj~KkC5;LP+#uqPagOKtyvuI9N8GT6{<_Wm^Hd%B;)Xfy*8jW6 zid>$m7Axj^SuxM9`ee33Or~A*jHYI_Vo9Ldo6U+vLFytaW(KQTAv_+<3$x;gafua= z!qt0Lyo^x0B6%K~7p2y);!L!<#fl#>$}`pq(KJqVX2tk;HHQ`35>$yqE5teDUsg;^ zQghiV$*Mjp94RW0J!M>H#nJ4lQVuJ`+FVwA%xy(j9`=GuRIsUdHUjr+uHB=4R+mzNwRbj;s!_k=6fKr;M!t6iI_}{IpaA|GD zbK?u!v#ph1thHje;n&`ZfgRO&R>XC(;uYQR%ysQzMfR?o6Ge2hqEQbkGWD{eAsy($ z&-b$;p}!TC2dH}NhJjZ24YKn0TPs$R|6nWj4Yk5D%!&-dtw;a;L%#x7QLJF3bbo|>Gszv@ zjUlX_w{NKG%wF;Mwbg%a)%cB3(S(P&iC9iqK)logkZ?WNoyMwC`%%W&@H)j?LgtDt^Y z_{@shb=4YH{5EF(zBJ+Snz>_nD|eiyGOf8E+PUKdg*2D-sr<7 zb>V*NrmC|KXjpgU=;01gwWqqpip;&$JXSpGquTf7v1wgDmAk(?MDqda6)RE)sS~WY zYJ6Ztm%%Dz2-k;Fj0LQCXEYtk{X!Gzq|t4dJH#;K3o9lMS1m@kLv$tYk=&QY7*;eJ z<&GJ~QFi}WwQ!s}#5&_NE9#9`typovct3&nH1(XQhOr{uB(<9rCyd9e*zk|4H<`z! zw#FS+44$HXOml}AFkOvh#Y!W7hC9SH;|VKj%~bKT_<8zb)STlEG0Vt2kJp&$8GGit zLpU!`%@^{T(kjDaF<+;sg7K0SLzbux z&)gw~JXZ%_@HLHYy;M(G(eIUVeZ$|EXtQyE6?cp|Z`~nQ8pl{+d#{Rp*)cJ%~;NgOGb8^2Sf&M6~>C9#!*&u@==3W@yR&q z$Ip}9Uu9-R9^)`8I;2wrSn=LypWXu^ErVJR-~mxOvl_#Sd|6drRzzh}ty$p+R@GSH z8LBF=;z5{-4)=gKYs`-DfLLK1WkvZ&Rf`o@=$p|t$^(`-`iMcq2ey{-pDfN`>c2gLq{ zYD!ZNh=s;JR#a}L>ak*MOI5oSuN%3wRvB2)wT-&MiU&s4wjL09+o=+)cxL2l&wWi# zjNm>V5PkcqQLM<{PkHzEfY@i8X2mn3_W%zF>j<@k6}d*Ky{wo$T3uwtq%msuI1h-) z)6@c1>^1(J?g7zwrs_4z1LB=AXSN5#8l&$V&V!=ns>%zvu5`#~vz2>;Uhhy_cJlhs z;$3RQZr%^nb&ndvih0Jmy&e#|jqm$CAZ{H{T@HFccpp;BSW)({ddZ5Iqv|{>vK&+O zSaHShKF;IN{u8S3N#2iC^^^*`!PifE|F6Pr4~RhHGb>!~sE~WSx2Y9vys!4LK96`^ z{^R}f*aO$Z6A%3JlzZoy2l~C>>-kF+$NIlk!R+*R9ys@&uiqc}I{TTgbL8`d_o~s7 zwS4u!@b8@G555-u;^Uk=(a2eKVE0?pS+=38I_2hx0ai7Z6^AI*?ul3*PXswsJS#fU zeWSOpC&b1KYHLPMh(pFxwqby3$BLy?I*TX2AITHTvw9*V#1pGR)pk}?4)cV2gi6nf zrsNl;f>_a&&e7&*b$}K5V${r7Pl#nkNIcI+9q3nrs-5Tw@gda{`HS=XMzJ(coS@<* zJW-wc(;1BB3NA3x_XZU~e#8qSZXHSSFH0KM)_LXb+%@aSrbNzp)T$yYTrV zM(#8lM09D@uZ)dfJGP-k1sj4Y+EAXl(Ly>yj#?^^4X9(o4(d?XhW+%evHHz6XktT8 z3T zzQl&f#zJ=0QX3u^MV50dsRET-!Lbo8v<9WICjn&8}1sf*mUc79$IN^ zXJ4)7b=jbXuwoJ&+GvBzCgsa+F%GdYTX=npE^PO$+~eESe{9k1+<(S!_QVdZ&rX$r zP20siVoYWm@3vuqv5pk|pAJdp_j%tR)qiJnv&(W4eRJO zt%Vm3I(y-<#R~;pywKVB$JGnsZ>ws?STT_98FN>A;kEIDZM((``zU6u7kbliidyG|mg~K6l^SjI zLdUHG zA?dgmPSYPJIM$QAu2lGx7lKcFp$GLo!^cs!vt0Xg>I1v*ycd!$c;OIjzsT`j^1{x` z+#^@i8g|hwFRcI93*~QnVI@7iUCY=$>pXlit3pHRNHsuX*aGQCq#>`Z!N{9;?b_reb27%Pf> z@WKRRE}QA27aAJv*(((HN#$b~(}X-^WPiEXk=NCZ;q<_$>So7c z`b>#dJO9pRM-F#82Ga{F?4hQyQJyL%+k)nix6O`Pw3Bjr*)fT{>}sXA9oc;BxI%{= zcEtLsS**iP9b(0RKprof9d1E(l%Va#Cw5P;9Th`V16H&Rwc|gk7-q*gdPLFTcGRZ9 zG%>=CZS;VOMA{J?r4reB)G^wQ)EGOS8lTvEv7AeSYRd|1q8%lZ?D$TVl6lS)I~HYE zZF1W2jmqY-qfH(=8s_D5^4YO3za4P})F^gxK|6d4+3~Kh9kwENTqc*IcGRTYsXQii zD5lo4Unw!oj*qmngz8q(j^{?kQk*wgN^>0a)9@@~M|SFB3}V-nv*Q+Btzd^!MLWW& zuF--$M*AxBS{q+k??2U|sysdwt)?olVhkOl_SJd4YS^)YTGX^-ZY?_s*0y5}1=q2o zbX_}68Nq+qF_hNP!+Li3HLznZb#2JU(7Hyv=8f%W)P&=2X2*JC51Xz9&q;4v+Y#Bu zj`LKott!KcMRdI#*R4JGLkBxDcC@2gCslhS_XRaG#<5=ww^5u29VCqAUZKf!l`@Ut z=ja$kjpg|19u*wNF;nL8cKo2U33kjdma>^9+A)ZZP2oCDwWAKXOtWJnIZwBvzzp7R zlro3Mr^<8fm_m0c&pegJiqSN8KIgr_j=vY$QEw5)wwU{Ei5>pSc>d*fv|eGyHQK+@ zj?mRAi49(3$1HNJwPPi{r0{ii45VY^v)+zT^!Elk@@?cb*<{Db%^crWj-RaCd5x&U z4zB-Bj$;?E%WlqNj~z|-aUUJzy?Bgsp@k>xsD7Gzk=C5yHM^`r*s|nw#f~J}MQ5+_ zvDbLd-r{-x<@k+~w|TEoz#SFA&Y<(gZFbdNUIXJ5oAVy`9-X5KkGWn3p78unRS4_! z+>Sz&=OxGSitF{7`|XV#x!&5*_XA%WKXUJV;&G_iXFLAAk!$#LpXJ(s^TCdT;d2;Enqkz0ozm8`J4u zDv-$=O=t%_H^yc5#y;aTD?GD!^Y7x`_+fZt^~M@%7vv2Ddt<+d_Qt6gZ&Z)O`5I7&6T zdBfJ7Yt@5e?#Z?3<&6P-yb;uoYti2u6X~llc7Qix2l09g@kaNd>d)aE59J@_ja;Mo zu`%ArG*(5iOUY-PHxlX6cvWqJH^ft8!9;I}50g~&$y@{KI7Ka<>J3qGn!3k|F4NVm znVjz|6*=3RKfmdXwR1Vg`Kt2jRO~$k^EjBAf=&CSyMv)P>J68nM~BsyOyC4eO@ zFj;yj2btY`yE%QM`+Ggxq?gMd}tSdRb)jl}1#s}>;_}~t$-|B-k+xYpN zK6tpt2c`D;;OIeh?T`<|>ci^sNgs&6&#OmQd?5PXR5kDUK;(I%s=e}oc>O{3{^A2M z`lp)V(F>%cAAlh1+h zLJs6A<-j+JE9*d~at;)%;6UX+94P*$16`^*@THmqYpXjDQiF4-=|IUk4t`zFfxh+m z{08bpLyn`d1EEbE_|(*aCCwaoPDNWfu#bLIzE-LfE7s8+if*k2vv=r28|Bp2f%py% zbnomyu`Uh-cXgmbHwWI++U^eg?BPI;z77l=;J~Fp>K-dr3{kPe*pZy;Czl|0=6(bVX~ij_vhXXdd(3P3#DU#U`TS=N z{_L6q*PnCUUvclgcHqcc?(2_gDJyz@QN!35)b6Y5&Dy>>_;ncv9#YAl4xFJWztvY( z^iJ=K?Zy#SxM%Ri(Tu)07N9P(r!)JaK{j8s2=+z05MM-w`r;Wq3iHLTa9>=D@WrA? zU#yMx#nL!m?2GrsjO@OcoyQlu^ZFuxK0YqLFK!m_g z*ic!0tLleZ)%@_yXjj7zqH`_vS8YFtEOnHlfgkQP^uzu}et6Qv56heSA-XxA-@*@B zTd5fKJhg4@hliA{jUUDsGg#58v+B-@r~TFS;eHTzCa9*9{UBbgRZAL657+2N0RyZkYe-cXs{ z{#Z#5jhuV@F_H4@RVCQj`}|SvARk9d5Ba0f5r14TMjZEt$bLdK{O%7ik1}UW_kSf> z(cQ=qkdA*oRy8uEgP4)5veit7sZG>n_V)qx>~%VbX`j?)_6@~2rT@Rpw)7BNz11W~ zdWhFX^RV;~OXyt@bt*MIL|jRgR6ae#^eU=m&GZm$jE=+8L;NvD<(QNn!g-PUdqaBs zw@r25lOAH&q4d~bd}g~`R=&5=Lp*<)9+{r02G7%Dk+Gc>M~&py=^@&sX86Aey)&Tl zV3js91H|<48F0w(n2>=#-=>Z&&Hxd6S6yaB_4jJU_Y4qEjNKVCLhKAsvod9b$W&Xk z_$wpCm1Y@{t)*(-IwKynRTaBr#4zLU?itahpZa50Myx)X5tcI<;rc5hraA{;X4U|t z1qPr;XaK*)6M!mV0a#${%@+VMt6%_*q^c|>1JH*4X%m1;^p2Xg4Zvy2*e(En&|a$4 zJ^)`j1Ymc^0IcW~fFer*_-{7>{JlZd&X@_}RJ7WflnLT#ZZ)J-CWz^^R8Y@M5Lw@< zN<%Z_@%hZSav?K(yJY=8mz7x|@~=_Lj%CG8I!nKfs~(<#c;OX@)Bb_jl`asuvjoC9 zFc5h|193Mp5ci@35fT%~@9kDqSg|&r%AP+EqLi_h73p6DL9Ccy{9r}X9%>~kf_tiUtf<;conS>|Z#A41wfd>1tmto? zU`3%pD(B!ph=d_3KP%qTUqb`&nOY53-C41NnvGDMS+R+(k5rFYF?CcRZjBCv-?%`G zqB(Tmc+H9_;{)+=A|Ep;kUvwSHnLv-@Ve4GdPMP)1JQ&Q(|^YDDLftpPUSVGT+;&4 zj+RsT>1q%Ao#JM2uhIOOYAsu97Ux0%v-vS2eqkUcFH#Fxkz=tcv4ry{>#{)9q^B#@ zCsstPRykO)ou;o3#E6Y*Dl0xw;AZaWZK?(HZl6J2aF7}vq8kqS54W23$h`3k(w161o6WN4G)4y zqRW&R6@&#bLFgN+wy`38ygJT`*_G5yR*d~a&0$5$%BoiLAc(Dm7OF5S-WpCVgCG_g zSz871&vZfPVoYSk7h`_wAc(c(*(L~S#$@)c@rtd~HV9*kv#eXYAdEETx92hFjxn(V z&p``}k{yE}_89d$1wpi-qsC=+PUj#zrJ7wi-)=#;PRqIn!QMk}Rs!=nVXv}4=P=k%C9eaa*ZBiLF2cfMol#Se?O0YS$s&d=-T47JA)u9>{1O`al#n4CkUd?UUi-ooA#?L2ZA7mA68G;K}Xa@R)ii^ z2iOzG)K%8^IM>l=%6_C0CxQ@sQgvY;oKi*31VL246ollM$z;-BnhPV2Bv1Y*XvA1w+)1QMd93L)eO{U97m4 zrXH~(vW!|@HW*@ykx(%hVv(_)6(4FSr<%bKosB}ZgCWWq#p?w_RBywvw^tWf@u6cd z{5q>gtSH`9ZDmDdw_y19P!T&LJoT!+=c zI7>^{1jA)*Fg(|B9gStI7{6ZKXT`A%s@%q4h)Hyl5;p~-+LmAx-ln?m3WjKPNJXCE z7-{TzHIo%?*HzPp!4RDc??=H9#b^bkJyGph@xsXSG#Fx`vFH`A0evxky$Ob}yi-qE z@yYQ1%=1tiV=pT%7*)RnLsa_CJ@iBU{VN!vt#S2tFvKi`{NDoS5Qud~4wn#!qDF64 z95ybpBE?;`^9X@h>!t3o;+1jQI|L%cM|JQEf%wme2?~Lz6QxGRg+L_aRBH-`Ky<02 zO0^4tDBE7m=^Vn>><|>`sy?%+-9qrRyZXd-8XSTTLqbq*7{@g{1T98|pvjmJET^ck zoEsHd7J~5QA#h)%(zBxQ8Wp!T1OqoJuT3Ekmp6x??jhBJ6&DVxMMpxA?q~?c8JF3z zCqoc%N^L$Jg5awB* zExH-P_a6yCuDc;vL4V)p+C2#Xpu%tTb-2zlej0XL zD8zar%8SRM*2Y0rJf;8aD%d-e|IEg*_=Exum7W#%eAU$CP=0+Z6qk+RDWMS4jDp!i zAubp%a)d&(%&A7?4u!a3Y|0l3(X5DiT9jj=PsY;JPzaY|%8wmsJY?$>55+lhq^bO@ zXkwgT#ZSsqB9z~guEw+CWl43hR47D&nyL$Xp;joa*H+DkhC(bbeh&-9z~O2tD@u(} z9&iqpJ#q5L;()#79*#BQVRsZfYsbiv4eI+Wj!sQk`^LNujbw9MGdey6f$RZaE+ zbvUPXoezb$M4=Z{E%vD4xEP9Vm(+SzcwbQySh2+LzRHhNvs-F0D{B6$nzP~+mAey) zGsXi}c-~Vr6T={`8SPWUATAporNSU88uM7Omrz=@XGMids_ma)5Pgj`Rl^{5cT#_J z4TD(TO>JRC`|fHpD_ZqX=h&V-!?4)cz&@ggUMdGWn-Y76!M{%!rqV5{*q384uCii% ze^q&C7(~N~VdywH3?r!M^f2r)GR+9XHu_3MXNKW0xz7qitkIYi`)4cPxnU5;)+y)p zVG#8O6agJ~dHYTvb;j1qDg+n|ts``gRG&F)Tgrl)>C}TK(9w{8{15|%j zyfuEaqGhIV1ZP&KSaHj!kcI0)b&N%<_#>YP~n^E#4FB==7&Z6-;ci{Aj0cKpr+B372oMlebwUc2#9xvOM?iAWaDpEtTVDT zjDVPJY-fc}qX@J%KC>cQ;|NqY?z19y6ZO191VltfHLz0zMD@-pbyx&MFS<6IV;HH5 zO^bl&Z{(OB0a4sI&PL9RK;SI3Ykma8pv`JGD>83Y8Mj413_PUvv7*yqHHZ~aN7QUq zyfwNUi-0(8+&mEh5qwgOVZ~(%KcyzHBHQT*3^p=cihw9#3}D43;~6V5Ush#V(bL$( z3g4^h4l8EgQde1#^S1K169IAIiSl|H0ny@_3VhD>qiwI$Csr(ft+umb#T&J?c_hCk z7>Tz=#g>r};jPq`0g(`Ij0%GyAz}ureIp_vz8N(}MM5NwR)0;7gqUemoWkQ%J>wxO zQm3hxtSCEM?PtaCmFhPuyjDdb#|BkoV{PtGcoxd}fK4w-uvqeE{Gg<}lvDC|O3XVd(kSI(KRi1^SAkvKag`*(q6;VrzMe%*{qHxbB zoE8OPE1{m3iGqkJt8TI4h0(EG6vWx`YEgwKh#ZyGR8~}~twylozdCAS-6)9NO_i-# z6v~lXb7g4}1(CItTG%EE#oI=~(Jl(JjlMmiAmaO}k*sLkUu7H^h4#kGK~WGNMyoq( zqflmJ6m}TZHbp`FI-v@ljN;FpMB%mZn-vRBsXxy}L2NhbT#AC2Zj`?q1yR?)l_-d= zM%Ejg7sXK2E!FrD$4&cK7|UMn>bBQ7kGN3kcE55*N+)2#Mxt#m4et z(GWo;)L>SGl~hYgMML~sn&Yde_OoJYb!D#=4N;+yvNz_hX^j!ol*gt#%~XTt(GXv$ zL<@D5O>L?6u_BP|rg{zYqz=|`*M&}ra2S$)3hVPvhgX+d`R-85hTw)+<8}nIl z$MAKHfk-vlvtp5PofYnGDjzF48jD$R#jsmrAPO68STV;q!wMI7Re%-kjK!?DY`A&E zKol~1v0|lhixmz}Rg@L&jWw)jU{f7f@!6OHw`Jbq=tnhiN zp1tPdDg2EZ@RswWT<_H5&oK}oUsT_(F%W6r)TZAt5U-4KPO%UMdv*kg367z^QDN0n#A zZ^NfC^OBESRCrZHtANvRhqZ z#jrhUDk}o_s-F8|AtLvy1E*pka9V9-#X+O{nOKNY&(s1|+<&fezleoc_ey1Z9Sadh zA>Wnnk64IoMwZ{P5bcamr#Ohe4S(l2h%h6_635rdI3ze!M|KEZGs1o2AhOeX8sw*L zuyOvXJ-f}g%9cx~#dQMrt9_-&L6;IF9`jm)I}WkuNt zRf81=j2n@05YLQSQG7l%GcH8OK~#%XesOUS?~Io5aS#iQb*wmTG)RbpSZ(ZNizUXv zB}p}6Zy7m~J1u8Re4r4 z{7YSB#fw&|R%`AND&AfVU`5UjDvcEV}UxgGY(?!9`%zI>-MUBtSGrpE!@xN zQ~d*~&9OL$l}5eeaS&~d%qQX?Zk6_tTH@)$3g5dzB|W5&EEF1c+Hi?WhEZ#(C5> zR%9!v>axP8kP2eOV#B#e0>oD1Ww`{1sPbxXg#?IV71h`V2@t1@ehm{K#u@1wC7@&D z1ng*{I`vL~SZ#RrO@P>I+!&q!k#2BZNLCcut17VKA|>xnz%66c$pnbwM(U#zxW#dh>ut6A0oQ;Y8)=Uc`2On&DDt0L_9_8l%TM)&6%~G~udMKOO8mdptVnQC z?R*myhoiPz&zj2-wT>{i|R*cW2z6K{kbO=%HV|Xt5 zZn(!LBD#(m%!&f_)HqhOZ=|lU;!Sgv)*=z&i&3p*A_Q8gs;ns4Nj+!9>h5Y_k3@** z$!Z8I5@x7YtjIP~C9>jzQF>M)#84yO>_mt%M$S2j5Rd1pxCMz2g^a4K-y-#EaU#UI zCF(9K1}|0aD-t0VuS$g5>O_=Xt9l$vgz!6*h_2N0a3Y+J@S4+)qpI(*M2Jz8`?y+l zA`#;5NfmTD5#swf74dH(#IHNbb~h1QjQaNy5p`cJc$x^2^BL!8Px`+C-boOpjrXi5 z>QLQS@zhsM%8&%{#%LIj#P^9z!h=jIPv#_uG~+cZa%5Gn1Nmzj9Hd;rlOWO}RISJ) zzPE1@{|u~p#U?>qF&?nqiOM}W2_il1Gvcx*LDbKo=HyI*_%oNfP&f&qf2tb8<}Ick zuu;WT>sm<=&FZMmY*1Y_loi?QDfCK$sBSc3g?DdNu}>1jzP@VIfFy{&2C6o!h#sW& zPfUWCG)XOFMbm%Oz-dVkRi~@QtjIV+)t;3E(Q}a+%Ze$hRrj??5JM<=om#a%2_klb zYPBf|;>ZCt{%{h+Y@_rM?iqSO8IG!FtXO|ajk}x#5qd`*y_W>B{;eAKfuE;YRO+Le z#)`AX+RsT4)18w4&(%2@qM)(Hk_=JARUKo+Wuw1aGQ>lxddCVEch!Ow)jiY_uVjb- zyNY1NIm6+T3^CB5dZbT=n4Uo`VJl};i&+sKpx#C%LtKnX#_kvu5X$eijYD#gZX58E;vUt%T~xihf3H$z+Ib zrPOv-%qgpWR^qtnY-LsR&t!=F)zn&6>@u2FPliaXsVcFefpLTt8*8a2b&?^*{H4a# zPloXLTV-Iye#5UpGT-wi8D)%ljgujQTdPT|m`CN>sE2KNE!wN7PRaZ`QZi=uQN4yG z^WVTZH>1tiWQZc;R3%naAFn!2=lW6F3{{mC)|u+-oMecTbJa~&jGd=GElh?uwn$xL zMeoHbY-uvYN5gd)?+e;y%vi(gPhJ~U@uSHQCykG+XnI_&WyP~g>g`qT2l{0!zm^P9 z@47m1I~ii+J(ccLGDJ(G8!JLTtA<~aAufGYuYV*%y!oYmvSQh96@U~7eY81>$KT)vE}{T|(Vp#baY)$rOlBrIbtQ z6o?E)FIF@!qefLofp}unu9O1dT3OX$MRUWy3fGuw7{~uifw);sm8;GJ2M?8p~RxKs;%!YPaQ>DY1hZ#fqOD)y&Q* z5MPXzT~i=z-Bkltv^6sINP(EwQ~C8yftb->yqW7zRTY`;A#`-6TJamc9zM-cXXkndEl*N|=6MJ;oUe+kz~iCgN;Q3zhtR9l zO4fP^wO^+$toIN)yFs1&1LKB>P3qNVJPwBMRM-FX5c+wq3g3ry4w3s+*8?6xBM+)N zhjDyC!DDLlaU6e8C$@QTBK@tPEVm3CMuVwP;+w@&G((Bj4;)UcnUd;6!pY) zsyro!8I025A5@KEoIrTk-az%Seg4u{t+8EUzrCTOA)>Eib19bqU42@J+V^5)trce`4p&lkz zQ#>D3k5l`bc?z9tt~USZDU{So4f@Gbs6ab4ygk+r4DFx}qZHdw4MXWa6V?gifk$R; zXHUF71!L-}d{Me=#&p9R!F&knuGaqSDWCdyO7Fg&GIOA(bRC4X1#96V6ddd+6@SGV zg&t6GDAvLZ^$blt(^FcQF6b$!GYj+eoBD)ipY18V=BV{(zPV~Kx&;PpsGcJ3zgj}` z%{`RzKT~d$Mwt^R<$A8_qBPX(Kq=XjORgo<(#%2WoXPy6mXN>ciP9?b7^PA#RXj@5 z%t@5eyi&DM>S~svbj##>T}vp&c+{#b)OMsp2Kn-t0svn}>=+X{|}+=_M3lhM;uORC9R=bu%Tyyo9Qo9Vq3i zr{17+DOPo8=q2Miure6H;+6y>EF*6|jaWd8H_7TOS?20FZj&Y1@h-a^5V>U5Mh{-4%cGSyeDqrHWE zVw5!X7Vx0)#`^Z8762r<{SQ=syt`l`#`GMYQ{W#E$m*PKBKg5q1uCzW06|4*caEo@s)@rYWXT( zq5I~y)xJV2OqDghGH$J})Ly5KZ1WXLzg=xZ>8Od=;VY|l`bzU%>f~Wxp}I%Z()U=G zkh-*AiqUnuTp>b8z4o^R!aaGk^l$_O+hnJtw5_8_iPw1|B zg;H8y^&LtjOf{5(O$ahLha4>^#X({nI|Z%icx{F0YXV;WRn1)L#B7r0HIN)PF#Rc{+6mCN|{@! z0w~=w8#)9CrSGWHb_x&*G_O%g*I6w`sYn+Uk5Z1Vswheaj90e+q4}m&p8%n4W>sHo zC*sT*{FKMN2VVyZt65DGD=lLLgjUaR9MP5h`%p)~lDnuJpI z&uS$~K3`O5>Oi5D=1Q7CTvs>{*A-U3qzx201P@I_xF^z^thiD0I%Gt{o^;%~bFX z6sm8|*THjwzrUJ?(s2_O5GZuWJVU8Rpeh#>DAdU84Gt8#ZzhHW;u;Wv(#fGpI0J<| zjBiY!Pz!UXQJ_%qDXI!eiL+G)ltwO6(@-k1UR6M;$yQZ+TcF5pl@+BM$JMoyfkIVI zsRk&mHs7Dd{KJYf>MxW!o>hZT+VFqp@G;asuR2`ASYfjHf>Ms_$_q_#1BEN*^vyt_ z*QU^|Kp{U9iPCjb_;#RBb>l{9nz@cr>N_e5rLm^{U93a1;a_Y6{0+$_)4f2UQYILs z3Fi63K%qR3R47Wh9;*^4g_&U}EqbCVJq;AvY;K~oE?Jd$fyYC*Y5pou=%M-cb)e9Y zcWN0*CqJlc9|MKXeo~)Miu$VlMk$R1r6`*wNa&z>hSEQo)!wW@Lg&oL5syd zBNc~I)u!rClA?w= z?PQQprL!sqrSs+)O8L*3^C)aHIW7hX)i4WD+Gwt$DK4Qf;Ig{-caYF06LLLBsJ$72 z(#AXL3QAAzt6UGTMxoPFH5H}k=c+$S&0eeFD0#nAtxziVSvgTED8VU0P%58MMWJoJ zQJ)J23l%S<+7$^Fnrgx;1Pk>rzLkT8+L#-j!9tm;s)XvnLL<%8+W21Zr%CS{EL6qZ z_YW4z8K4e@1`9nm1tNll{LM_1_LK?yRUk^gnFAp6;QgBq`sLKEHrAdT8mPKCCUS(>A$O;D79IkCZRNMojQn8;q@vMrNe)y zW1E77GTl~{QF7c<9Z-5@(%;9pq00X~z{l{H@qLK(4;LS++)sjqDw=qddYUCD?J_yu zVjkh333-QO6RN&f7f|y0pqiny;;Tx9Bbh#BPz&>h2<0!N+$gm-V^LaX&Z6|jTZ)0(Jn;zEQb$E)uXLxh$#Q&B&L2&HYQ zDxtKjgDTc3L}){270@+A=+AEI*v}zC&rPddAws{Hg=mUjPzda;&i4rss@GRdMCr0A z)h`6s`^M+Y1(a@^HT^?`UYNfIga{oQq%NUUai~f+JVfZ$I2DqF`GWRl4@zgv4V2vT z)rzGdLVuZ5zhhm(R#Sg>h|n+QI!ZhDsN(yuf1%JJ^$SYP4y(B+6*{7lk7B<=!f`bY zrKP9UC6wl!QwLGHYVw{B5gKcJFNO%UFn^PC6svk;| zZ>y~+<-DWDKfsy?zhu=CrK2y@GnB5qR%zaZ2>F?Sw^(P;##}?G@Ou@B((Y7_6q$24 zgsPa3+zz4k=2kw3&|C9EeutzefWlsLub@L{Zeeu|P4PVn{fnqHP6zJa=)h}9)LxY4 zxzu`;{`tQ!d<=c-stl11p#!lhq!GpoGtDKGGB#6{P-@*$jYTO{J5?H`$6Zv;t`4Cq zJ(Tox2z4+6P+InXKjUL?_EMWr`q*1_?CTIZW@`0w2t}GRD7_t^G7WSH9r{&WMk()5 zRT-t><{y-53{zc)JA_u7rz0FfO-HH0DD5zP#yEs_j8z{{+B{x$o8k~^K11zA>AFcb z(}8=WJEX92qcq>_LFuMxJj)^E|C{PH$AQtM2(vcZA-nd5u@p(<{22t}JdD4pA? zc5ZhF-8Kz&ID|%+1G}*<;ju}x2kRXQnyM((HTU-8xPdGOR8^ENni~flLg@~v@hB}Y z$I%prQD}ceojB$YdSNmh$GU=crtJxbP){@Dq(kVAsdw5T^xO>n%OSMFJVWV|d41L) zwELVIc-|p2_k!wq5zhs)&1aNyT~a=1ipwZmHGx+gLT%0WR~NC435d{Am?#-o(u9o8X~c&}p64rVAy3rx!o4xy3e=qHCz zuJoZP>Y~)h1ZD^o`jSPtN`(qFG~H2}RYtWa8!D8eoZ4GHROmGHub_%m3>EUOq*|c# zM`d*srSK|hjz_4_9#8cErL5ILWj&Ot9x5^LU(HadR9hYK4Ha_wVO;RY6b=ZL0>PoU zZcwOv=M0r!U7^x3Os%OGDzwvVafb?3j8N@S+H4j_g$gCqSKma33YCLZaMV0No5zGo z4>$?sV=*q%20Z}}O~wWo1N_i1RQyaldKKQAB8@P9aF{ubF+Z@w)NK+fZOk}yBV25% z#>I!?eHxf&xC=`X)B%)&6GNq$8IG=kz3{xb+S3C20B)EnEklJ)zys5&b*Masa&1DT z2^=)-+G5+_r=LQlOgr_tN2pNgp5|v14x2i?LWM>RQ^!Y!3XK@2hD{5_dksTn?o2gx zPpHuDeade?<`I@2Q`0Ym3SGRY4qnFip!ij_{uXeRf8=4Mt%5IZ$xKkR#B6tGwD7nY0 zXpVV=Qir!{7fRXRsm>@JH{0Jkg?{{?{zED8 zqq>5U&nGn=rK4u~XUq+Z`l247RP3wjkJ4r{TwFqhQmH{GJxHw%rEv+ROY4$SCVx7Y z&{(rIy-TQP2DJgDV;NPgOfI1XCR=8g(9h;3O0nOlBPdnPqUNELC9CR-(p}@u<`PFX=%yK!&n5IGzj{}|B{Zp^>Q%@k zl(w*%fl{gO)fSYR7Ezgsx`b|+=wdFRWhNP=BgNJ75*QyGGr^@@LR-tIrR7{gd8(+j z9xl8t+$GLh>c`qHp#x@funWJha^d&ms*n@=9y*(oC{=K&@hCkt?l8}yM*GR)n$}|W7IU1a>c4Bl#p(lp>(jN%G}C@ z*E6{!!gNAuoLPs`Ir9RgoUK(glp31RC>=7T+qi_rnlmU>XseP?s`QiEg;LjcYBNeX z+pD@LrRku4LTPzN72e4uGz<2ai=A=2!S`KotiVN+s+&uw9?UYH-CaV3d#Ft)rS9pH zybxwCp%gSgO-5rZ#dVN+`c&XJI1Cf3F* zoFC_4?vq@&pF8$56q$!}>U@_>S>TfF3ti%8>Y_Ajxyrr*pNDyHZYAboHI4;1w#Fsh z*5W+1P7Osztar(IXuH8B7of)hH!l_hVZRxTN<%H5~1K$R*{DsGm_czw4ooQ7fOj4H&lf=^MXxT8SSuRYD zz{T=m;$I<5&cNl0VbY|s8iCSjbD&C?P<~If5T&)|8A>^-s@5oFt*#s>y{x5tYKKWB zFFXdqe8Ob2Ddvl@LwgtsZ%lqaJTH`j?yxaHy+G+JG!6`t;}8}UCVzrQFvbj(9I87? zTg*q40z=hElunt{PRturH*HZ`VjiGW#HAXeG{yXdQtmL-1f_9iKT4mCSKTn7u4WBN zcTB!|VR)}qnA9~xQ95KkqEySRx}&tkd_l=8T=hcf5Ay`2vJt8kN=fDlO5aAR2$aT} zLnx(+Qr;+aGryyB&E%>dCKPP?p|r_7MX6Y{YKYP}vk#?Lrb0}ZP%ASRrL!hOY?zR* z>4wr`a|5M<4O9b^#+!pEy*E`Fh6%Mb^H4fxvNpon2d5c=(l+xFrAm!e2b5NthbWb3 zq8g(#!5l#8jj7TUrKl!Zrsz!Ej`Q!v|$n+J5R-La|_Kj;oIFp z3Fa_f{wRgbR)Cr>>*)Vt}eLFkI-4d5Kc*LE&<7 zaJUQ^q9#oa7dmZ*Ou^s7WRq`dxKPh&;qt?Dwet^bBYZHcH--!CGC`ZdW&Y-HskcR~ zJr^$Y)XYDR&%-)X<3hO5l#8m)rEsCFw^dz~zL;!x!iA=q}LTGGlRnR*^=%Lx`6Ct!MK=}tn2t5i` zUmOuazlW+z&Iq9eE_DN?$zf_CN@eOs$gp}5lF_XSqcqUu?H?f&YcdYN*Fip$gwn@> z5i($qnu5}6vtTyH05{C!IT!;hG-c*u955^i-+P`aj8ac?Y)1s{LygbvR69^QZlZQY z2(9^3jo6L-1`7|XnZdr+sJ_sjEmVnC^@VcuRKCmV<6gt{rS*O_1f|YLRnar`g&vuaXX{J%OX@XB z-Z`REw9XYRRJ^|0@nf{m-j>m_uT`{6X{S!0^tQXo(j!`EmPzKq zKU(O(02MnnTIl5jb#+>_P?_mUW<*N^a|vzsn+jeSEtG0ev?Q;@*mkIAD4p4 z8V(;#|39OJdhSu*?Tr?yyk9Lj7%f!%ka~tv_9H6Y(P*Kv$5g=aXrbEYqb1KJRSu;M zSJkiAqGj4mwGmx;OC{gN_+k8OHRpY_P{;?>>0`9y`lQ0qS!R5?7@-BYOG)XtimUHbJP1`7T|8(AD&+K!yaN zlja&qQ!*;gObJ4}O>C9~p_ArS!33eGLMj101(^#cNRWv{=fEY%@x3aHCKgi{N+$?; zlu;|nCkWNAsBQ%&;2wPm@>7ti9hD$-qrOUv#`l35P1GEeBvFk*X=rbC8Kr}LRGPjC zLYvJYl=}5k1^XumH8xoWBnTBUS5PW5OtnTS|8P|nrIRMz$ONJ0X4Ghm53U*CaS8aj zO@j0_mBuFs`I)Q}5`;2NQoT{yKUsxMNf3(pP5pz?{v?%ZUV_j@a{#42^VNg}2|}OE z*@X#0IToq?D4jFEElv<>uu4ruDRi}Jh*HTlD*eU;p=w*z&OZ}`qK>Ez=o0AmM1>Yi z6sq-uI_sS%RL)2B3Qxq(gA*mLrE1eEQD`y5j#SIho$$$I8kH!%Fxt#S(~nM+&!+B} zMCobHqx8pEJl{C=U}B=sq)Dpg)exmtW*NNTYQe8=uD#jO`3GYn$e-fqo)kJA> zEm1B9WStSx`NOMJA`%gIy&sbD&-&TD$L#sFod5IWEGLgvh~M>M@Yg2idyNcF=R16A QMCn%p|Npo&|9^n>e-1h)lmGw# literal 0 HcmV?d00001 diff --git a/Covance_UCO3001/browser_profile/Default/Code Cache/js/5247ebd72642d2af_0 b/Covance_UCO3001/browser_profile/Default/Code Cache/js/5247ebd72642d2af_0 new file mode 100644 index 0000000000000000000000000000000000000000..62c8623cc03d8f1e14192c6a2636154948dec0fd GIT binary patch literal 37936 zcmXus1yq%3+lJwr4ih9zL_oSb46wz-?vAm$XVkHp4GA+7v zcyvN!neepuwCLEl@Q6~8Q3>I(WfI~dBGckZM>>7!Eq9H^x*u5xAe5&gT_@z0q_qUIgqDsh1Y6B~wBv z5y)Gb+Ef*RwbiIVb&>jNyGqLt>7cx8h{ULJ>aW_=OAG(hr3EcSz@Y=R>?i_RMy_rm z;M$AY^w#@TYx_`KKM~k4fWG`K0Uj4CXwLHBAd3*e(l1oA|H%9 z+eE;57cJebYqghlYvHt!v`+-=4w8o!E*cNDka36(9~OZt#<(LQFwe++R0Jv2rM#Oo{2z_=M=4lH^y%*bb3L*UW!1@S9Dwp*NyV8 zMPTk5TBn7!S=2`hFN`zqMc}S6{euWBH#|Rz!23^R^;rb=7-zIl>BJ zeZOjHT-Cy3#<;H?mqtxWSqONPrbcBf1YQ}D<#Zj?dBd%O?ztLjw5ezz zur{3vRI(5_R+(~C)%8;SjZ7^Zs-gQ-%R+h^vl{8SR1X?cTvJ_FHJ}-d)WRbppoN9N z3}bUE3xOZ4sa+cjfxB%j#J8P}p#$aB!lSNKv%5Y9)TBZ5;$I8#8cykx^}MS|Q^;zn zg+Oj&ofa+|Hq$HwCeEcB^DG3)&!<{i=(@l{b}ZEKFQQtD_3f&;(QSpERTa91W@+Kx zI-0lMLLhb{wcezAxS4KmwGbG-o!ai!{o89HE%wvC0~P`^4$+V!dX|n-onsaP`%jVG z84H14|L?lKtoGiZ(3?6wm1La0Z6SH?TFAdfdmBrEO}13T&Qc)Uc%+50*=cMJOM%}; zH#bXxo$gfI(^8;?F(|L4MCZ4Z4F%}C7Pc0mFsa?i5E!3({544c20qxhqCF7|U zJe!c87J3_L%`63utM^9N=9U6OT2f{kOMz@{Ev4FDmXf10Js+d%sKUlkvKCs5C-(`K z0u3k9X)QQTqSjh?Z{(kBDR9Aftc5Rz=X6Vnnn5MBP-V8I+%*a;uoS4Vi0*5l*Akk! zRL8Z9mMymwc)fy}Z?F`&w~<GssfD=nmNMXiuE}+p`NdM;{#UB7y263Q-v?h!^G7!eHY>VJm?IZ#q`QO5nON(Z@<)q2c0dB~agwPHDkAf}*tW z+W4h~PLZ@V%1Xd5np(tK3G^_+^ebT~ZfwxP*LZ4^U?s34nNDh9ND58Xf^9LXRNP8n zkFmIuty;d#Y$kobo!`;#F;vdSyr;n*sX=4^QqSo zEBzdzXUDj%g_%{^jxZi#yTy$ z+D=t>SP4wsNjAHz1e}cwEo|RSo%dJ?JTpS}SqaQGj?u9ZMncKFan=IAjF$0wKguJ4 z{IxL6xRYotke)>Kw9qk)_La952&q8bDq0IXG$vHG7Kp7vv$gQBDrIS*aW%?b-CCe} z1|87CS)*JnYk``^D=mC8I@h)q=v$9A)wdSt+kiY9S_>Rjj*YFQkI}t}wZOq<^r5A- zz@64qqm8bcx?{Be%Ua-q5!}vNplf@o(%D*IkI}h{j!O+Rva}G>jTUQRqtU#FwZLm5 zs+YCELSvm4tozeHT39fU3J$Us*kQCEtm9Svjh9-87(zdWS_`xqOSa>z1=7dUE-jol za!#-oxHN~R&$Sk~JC7>Ow-#t-WLv7|Q8}-nOf8&SOU2e%3#?dA)iziQoY+XNo2&)u zZ>Hcay56eRR$8HjtZlS&m$g8i-E>q7SB=tptOZ8xrSDqsJ4%(cU5)L>tObf5r)Vw2 zo}m6GbzRj<I`bzF7+#H*)^ay;1{=2LI{jDD~cmx3Ce&X;0mA*a-OMr0ZJvpHVxPjm*hy zBiWtkNl_btOn*8TU?Wf`h$@BK2y8R{im(yrYdqINSQO3G!fIn;f{j3WB27%v*Of&w zxoKf~Diy9~BhcO0S=~k;AcO4d*a-A80_)lcBpNHUkX4T^HL%gIZER#}bNZ!)^(|<> z7Q$Lmk5)DUkBy$~Yy_?vneBC*)C|MEgN{d4?nryIFs&Qq>uw{^vBG)?4SV z#v5sUYy>ilgIfE3I$z^je;a|YNpw*Ql_%5WDK-LDQ^`XM%coJ)5*vY&M($-c0waty zTWth_w$V^6#BHb9T4=h1+U~RwShtG`?zRz#G8XT#5mvd ztLp1f@;YWCjf_oN_;#GyoUjqdIzwq^b?sE}A_0UGjJfb(RZ3O;#Ly=iF0;$FZEqr-PN8Z^8gnpt) zTDb9<%6+jBc=46OzuO4RGgkc8Gq1A#qn}zBAhv&e&_aSGE!V;x<3BANv8IYPwgMAu zN$hO(A7E_7)wp19D{wA^x`x^cyffm$Z3UJZyR={xL1klY1@^~Nwgg*&I>st3yi24e zNwxyc#b~G&P8Fxb61D;nsbrgGE0A7_>S`fpX&R%wRK`|P%aTQ9TY;rUVimofx>k+a zRksz`kU>*w+6pW*D%G(Ss9Tph)w2~?QJ?BHu@#7FYAdzXW#fSs`ZuHhX(6-)-D_zp z;M`STrb^L0BF=mLZz@?#-I!xcM9uKF$Ok05&M$Or_0<-3j<6K*TLPn+e zIxn?p2YugZD`2;aR%)TcZaTML&x3M3NJF%+@+iGMW-HM6IAuGf`>v{;ru|yDVzfMK zE8v|)ZQt4o^fX>*A>utP(88^cRNJkE9kUPfRZJAn>B5j%l;J~ZFgP9T>b<=4X0qV!7(>-}lJ7QzCkN1&a+V0N-1wAFx|LY!A_u3MS4`(PT)WlDpA!=;E0i}x}CtW+H_e9L+X-G zeLH~&W2qLL8&I8wb^^zYqfPAu3OA$H&FusRwW23l2x>z!wcyy1VmjFg^y^H=yW0s= z?Lkv}>N!w0y(q61R`#agQFa1dN7Dl>d^ViM*a^IzNc$$+37lR=&MS0YYLGEi3#V36 z_uX~^-&FCvc2e{Ry?kUR(Csnpcw#5u|CCa+@UJoFg`Gf+mo)R0u7h%TO$D{k&{+1- zPN2XiYW`Wzu)1hG(?aAIdi_o3r`ms~jX&%J3jd^7Ell`Db1m!zZW|RW?FGhLQHZs@ zKyh0drG*Q2^u*C#AR-&}%5E>_+_LOwinoFwD7YRc&Q@%?Pb1Ex1znkTH|B7 zy+HFy)L9G5jMJ6v1^lZ}$ErF%b;lT5-Cp3NQ8~k2V5RZ4hP^=Jn)FXSdx1-aX9IhI z5r$1;dx1K}+$Oq@Do0aV)5>1JqBWImqwA`+8r{3v3+y*+yW0!&F#7bc7pUEn9DCUd ztipFVRY2OreRcbxV?b=2=dUvaN|s-?ypK7N!7H_-msivFHqT-Jk?$x zYZ@g@w-*>RgWhVP%q&`@h3B)W&KzAk6*-Uo*23ZWGe(|6_5yss*tA9dHl&gT^H!d@WOSo=~RYbxJs>Zyg@Zz$!hy@2OCYW!XwC+e*6NDIG>Y#;0e z{65hVE#&(`OSLfY8(sZwFA(vAHviQ1S111?e{m4#XhHq7aMOshbPyO|MI*J4Wwf() z5ZGWtt?V5H7Ud#`+ztX&oM^8WE*WpM@WZ(7>>v=Ehx)rX2xJjPE8MC!;F`AkfjzK|G4m z80{s02T2Ve%WwyQg~qT52Z7U(loaJ4P}K-YbP!mPPN9_?1iDwIM_OoFm3C{vvO4Xp zt!u23>e6{FxYeguO&tWr{YAI5P`Evf*TUWo6wuK@I(2f8yM}KU2Z4^=>8BQ|_MoXf z9rW)s4*GW*+OLJ^-qg2`gTQm6XkQ0`Ax5r#4gv|r8!cG$Cl@Wm{zGY6*l0`{_UO0-KC)6CDH=&Y)jfNSj3) zwO}!iI%r|je44hYb%DK@&V2E*YlY>CQW;(LPK_J^U>Z^sl+v)WV2Z5+vv``E7 z$7zKYvQAK=lMVuxPf^}84g#6RTrFHWOP#Ljc~DD@ds@i4PQ`9H2vjz@-_~=hb{HqL z;Btq2w9xD>tQY9}(f$7E>Ej&x4$RtOB z0Y-9hM}hOkj*^Z7B~mG{w4=b^#^ExK0#RjYc{xXcjM~&&3yF2ezOJJ{hLKRuQ6Qi` zb=N}VVy8a_XyL_nirL{LaA_x<+vOyXcQ@tO<0P=f&`-Gfq-!U6WnA9xBv9x8%{u5L zFzOIZJM1Kod5i`hcM>>bB%E*(=yr1BGSg@7w`heV%{cMWNg(HIs;dRJH`MdJlfVI^_D3gyzdzA{FS@?! zxY6#blfXnP=RfXfVYwp>&gLv|#;BOxSzvw+dZ~pwImtb@vwm&hEX|BVPR;_oTA|DUr!#w(hu zg~4y>;0L`wmE$A5{pBn$HAkL59%!LJQL3zk8>!@zmPepm2kOu_kHB_g$KX5y`KD1T zEkv%MIqUNX{Lk0xUSHKP`ntLZH1VKS zS_sHX{qwm91bI(E&~75q?1}G z(1><5a}ls@PB*l$xD91#pQEN}{}I$p3&kc;y{Rq&ON`WME&@q2XqXmi%%qQVTm*{GrLpr| z1Z);iRV}n#NY_^BJ}B?i)L@(Lx0<+z?r5RlKB|4#MPQ-fc2xIAojFE5PPhovIztPz zaQQ6V{OBU!`-wchy9iABO?S0WMO^2k*)%RW9f_*hQ-mEL|1{Y#-1csfvPFgIMr2PrLjNFRp3np zI$hCKz&)M1YN38*TB?PeRj6wH4X5#;lI60%bbU z1TEC)OrG6b1zH$;dgy(rhkYrepQ}KVzp3UxSAqG4;~-ao8~>8e5Lbb9#;i=efA!RO zFiOX*WE@r0!o^86YQC$$Rio`KuZ#ZH}@T4&hr zb`_YqmmX-L(mvX@-&Mf!068Ai`Kd<63N1V^9v^lU2s=Utj=2i_K1B}ab)2e(F< ztm9GB>(L`E#5SRt&D;bY8on*v1UeftTDb}I|BH@kA*=&U)xrbAv!k29Y9pnuo4^R; z!XRBoReK06)I#N9lr~)Ft;QNhwa{oJtLyU=G!;DKCeYS+rG=^I=z$i>U7@azbZ^xjBmIS&fcIPKpoP_6 zX!j2{0lS~n(ZXH7|Ku*st!S+lTx=-K(OqDy5t+?hU{@Zpb#WJ%lAoFua2Hr@Y%l08 zu&@xl*1|V0N+{wkFvOVV<1Vn*mmK`u1xgw#Lfi#D8jT{|1^P$R!~}PJK8?HFF>WTi z3-n2)!&+EXiawWf7bsbtq?)_HubNb@mb*SD&s~1jr%o;11$G(-+PDkU??6knFt0P& zcG2}w)r?Fn)b2?Owa}su-RS2o;M1ShX`$<CIhcq4YCT$EC`SB&)IR0#Os_Z!J7A zhRt&qxM1vEuIsFptfIGCxVMJfH@FKlGiGXG@Mb!rh22}J?p}9+#YW-%?gB%P(0MIv zJW4UgbRKG;5qVtCmzs8p9%`YZ6f$$6a9hXL_WCP2%y#0v8W~S4NL;4}txLXM~49lNdUt1?O0r zsfF}7dZ>jC3Dh&mL*Rgso~*Z12TD@*R1X2iG%8%tL*P|aimT=!5RgH?YI_Kjt3$); zc?eu-ODbJOsRYP&+MrHd^=e5ZGv>_VN(0>`foFkZ&Np`d7!P z;)c-IVIBf)GikFHijSmUV|Dzh+&KC=L2s{4PbK$h9s;Q|$$hTAu9_J?=XnSmnNPVF zcnIWQNI$hub`fPP_7FH!)bo#={+EKndz!C> zk{u{#N1d;7>qM5lJ#{a2Y{u1ro&ujnQi)MIU*$ZB-puk8NSIAm=jrX$t>xsm!c*X% zRrJ?pPk}8);C4@eE(dA17V?~;g{M6QUK^#(dJ60|?9S;vsQHHbc~606#!M}YzDC!y zkpCfdd93%Vb{p%Sc?#_RA7y*)DKPORRs85FFxBw-=_xSWG4CH2wa~+rp8Dn$i14Fd z#qtW|OQTj=xKocVb;v7Fup`|%R9IlnTXOzhSfHU{mCakAj|&~v!t+21i0~HZZd@(t zEifdNDpmIum~PB#>MgLVHQBcD7AV|>YHMMvv9h1Hz$atkP;Y^nBWS)BhK!+;6TAgn zC(_k9Iv!;^mtwSFzk)Kfuwplb@ADSuXDm46EwJPSz170WOVswdx4>qj$y0BE${%Tl z7OvVA`NKY25rGWD(X)ua&jM7oU=e}9NOEgaM4+j$xNi~tUP}>4|C^?1q0lHAKcR@g zEu;P1A_6`4&?+q)J3!6{iwM|Xpz=402uwDLJ}e^e@)4DOT14Qblg}Tq&OQQDnp5gu zJ_2J5?_NFv>x}POi0n=Gwa|DJt<*xtUG(CRk3h^}I&{@XAny;FCcXj>jp*FI0+n27 zx)$QS=%u%>Kx`2T@$nUy?@uqa&^MS;!h8h|gwu}*Ux6}_v`7o{qUnVe&c@LCcwd1Z z#-c>My{eE*>x=38)ej@8xUWFR5)@R@SD<qbPo~uCw|* zk^Y_LD{$5*Geg%+rOu);TIe#Hde8M0IAny)^A*Ukit1>g!v0sNywWfvHB1+r9$6_o%ZLu05uM&wK@P{Et4p_7(W`iOPNU6}a=2I{wgoQ#*|J zKYazBTKoMGVdE!|+mV8^`3dwgYUTD5=-@=#wQ#_hX1MqXJT{uU`UymMP=77>?-nds{z&+Qy1*ega{CQ(rCkjiNr|{R9phK~wz%mM)=pTF9}L zG7tF)Ts8)u@DuPkNjuK@30R+}ZkPQ8%3h_3TKIBPC{sK!^(>pE9+)G!E_zQR)rEwSi1-4uvx#}-4^CsQ8 z>o4GUk7hsd7f63f6QB7D%rl<;&tD+;1XQ(Sl154beig2y%@K5b!mo zXm3XaNP0BYE*2or#_%p4AP{LR*1jweAoWYq{qg|LA3<4}0s6bh z0;KUs+BPvjeoqRJj+4oGR)D~;*>q-(?w3lLOJC;&2ozsHCl>|?lwD3^R|E+BHpXuV z5U9S9DsBo8n7ElNx9Ga58rx~sjsSsdJE_JVeSNRKypPHr()&^NhpEbu0D*l*w$pk$ z<#U$WoeL1SWo)|;Akgw6t-cf>kpD78XrYf${Ho4V4ZB94wUF&PmAV@s(D4mz$qEqg zeM^a2xb}&@eGd?D{6UAcaM>vHGeBU>FZ!j042!@&W?BXcI9kzY$3THg*(fc0pup-} z)F5}Dz#=Eg;~c0z^AM=Ne)d0s)db%=%5y&2M0>Oe*@*E@l^{ghEm}X zfdVIu>sqLlNx4S`3KTGQXyLEXlxK{d4dr9p)xsO2$yi-$wQL-@kJq(UzQ!;uw4O?9 zr|G;^#ToQ;cA!AWTsk>V$EvO`r9#UC1;!bFt<-TTk5$xob)djGW8u0$f#>UK`PM*z zF*^h0@~%KBwVNjI)$^p5@1x!O0|j;+Aj?C60(VbPm79SAO^m#^0tEt%m-lrK)agfb zM+?&)(=si1KA|R0^;+t@@k9$%Us3&cfdcIfzxROxvBq*OWPPBWd z&KM81Ftj97-xg9JtygPR8lOfo99 z2oh*$oYR6^D;lPSS%z)0d3R^q@*w*k{=G(%Y+^#waa(?oY2Xg9M^S(WTKr z0*{TkV}b$Gs#2-_JX&|p6;I-uuAl{iUbP;`_gPJcowB5{=ow0js1ba z0(QYPF(g>PKZZKR1`7nlQRnzzf&0eW#9)EAWLl<$0>!CCiC}>)#%nD^r_zVA!2&re zP|b?L0!NISTKH^qtsX3}BZC5J=(todqj3FT0k`(L4;_N#jPXzlYQwtxA(W8R}<`}id=sv5~#tkiajiXiLg9XY>rUg@j1vVP( zrv(f2H{NI=W(HN59V{?)3Ef#5EKq3~U0AL2QxA>VYxEqb)keX!!2&JU(G@LNZlpX~ zIAh$=LX}N4b+g{DvfV;Cx9R?=n%n7!7B=prZ@Yp8hU}qp2Z9CM4pF{q!2->$)9V|0 zPSnMRRN! zp%8&_K6KSLM4*fx`TB}P5P{eTTB?Oz#{0++fdeTaVqZK& zdKSOy4N5?;Co{#*)&ApbTjJLIz-@58w%(gBG9=DP3syWaJQS$L#upy z(G)GLG>Y{J(VuG!k&GcUb7+Ww<1lJEJVapm2->0r?@VetQqPH!aa4AEh`^!A*W`qcM&7$#I2$>fm-RFnMW8>a3T?gg2f~IPr&01QwE<~WvdMdRsL}1h=`k{qR zTWIT6J@=}|Zb~^BB2d||Kc(kHc^D(Lka31uXrbU)3f01ybJXLKURMn>N?Z;RsA^GJwXo?w`YxdYb`~^T3ui5n50x?*w5UO-z>9`t)i_k3LKCX3 zg+Wc}c(YLb9ju`e-<&FG;Zj@b&{yZGHuoc+{-OGut5E%Vor(_)62%7%8#Mx<3a`Qji)LTbbZvg$@F51&O?1M=1dJ0csz~XY2m-=lzoPt4Rz0G zGBZ@*j!|`1sK6MS3?C(8YQpmc+_hn`evxWVq@g(P=O0~sN`L}y&8OvPTUU_ zXz+mAYT=WS{7Bbdtu|h~((|Pv-p~RqB)q4AA3_D*8o#tq;v=2XLibO!>vO2Uaii}S zJ^$*!S4#gLD)7uM?2k}~F#S1&FqvztcMKEwl8stt4->G+P34@z1nk`DbAd1cyMlB; z3m1&ELSX_Uz396ZI(gI9B4Gk2d?>eHn83Lp${nV!tJ>joObgEPCkNcqCHY z6n$OIFGjhG>owGWC8$hln81ZJ`c)xJzb_glrPAqKCB1Joy%yc89VSqv4wb8~YoNw8 zpvuj{1QxZV7p=ks>b0iAZNmiG{6*KbFr*!wY9A($)PZt!3KOW+nT~4Vmf_tcOdzm- zm~OwvLq`^T;I~Qk6{7>Khd$zdZtv| z7pnYK_fvg0N`4O$*kBZraDi49bX5y`tjO9XT%fzr+AdsRtvwZV2p5Pl4(1FO=;=bk zwNTQPs%hbn;piSN(AQ|3H(X$8K61++E^x|+oc+QD1{?i@!vzk7(2B5dfw$q*BqChk zbTsvj2^ZKGOJQ;0`um^5<)%?MAzWaB(Z8f#UmZ%Ns5G6cI$%^U6)teNG<7KxE>N&6 zozjAHc^a&R<&`O`O1QwJl#C-HjZ3 z==!R_zp2YVIzIJtAdMRmE^u`yH60$VUkB)1N0Q@c{dm>acsVv)BFBfzLc?ZaxImT3 zbZu(5z@2I2Gb3DJvT=82xPb3$nxcg+b7}j$Z~_1MbVmz53u&?zJ}#!DrQrgrjI?Fp z0zZwk75ci`WMp3-E|9T-4r$@}rf>=05-#(Np*z9_LUvO3UHTYMkBupNb=>OqK5BhH z9~Ub01ob!>E)ad5N?y|QuSQ&^uUe>ngJ#?e7x;XOQtpHctTA?K;op07@_x8L;sdIp zg=bG`*86aQhaaf=N4+2Q&lfuSHC$lmZ#wQAAyBR`jq{EW_|G`x8zJCWl=^DH+n?42 zMhJWkqCp`M0{#&Z`n%X8g8GNuhbgA_Q_3C#%#5fi1?*vFr*1lbbzXyJfi-zP$#x3RHbgna8CA#DfH z*MD?9Ri{DJUkihW(21cD0yT!y{}x3Ege{?YT8LUkeV6OLDw~zmcw>aX(oN*HIYOYz zR@%NTLLhAiRo@dKFk>${?28b%c7O^ViVzrUOgkMRaQ6&VJ{uwMtHW!|9w9_g7?WuDMhEgXMFxt{B}QvVp0U+Vp-DX+-tO@vg)ijbYgw9h&| zRs0JL`x+te*;x2p&x?BggX;c_5E%9!osmd^6bnkWiWI11*jYykxEq<;^EQ!E!j?Mb zj1>6CNXQi_P~O<3wRDPVv-^SmKaToM+z)2 zK~brZ0=vqSWksE@8k0^xsznN0G41?_0X2x5@c#q`+X~)B}CH>idumJc<;EcuY5+ z=p0qyXEZ?zOa4c%o<|BactLeuMhbL(L))?<1&Y3<>+d233VooJA9eg{-dB41P0yaH z^_?pIh!mLklPrJfnNm}K)1Ch!1u99@AN#DM1Z-_-f?bqA&TLdOdz8Ta9OU5?CD7QJ z&S{~H3ypD&68L3gx+I90<8LDadBE&B1#}4mAorP3A9Zo|LRc!Q)<%fT2TV&wP{@A zD1oa@s7zCxx7yj9EL!UL)aX{^(jiKqen)!RDN4Y#H#O)JC2-nk+)u};mi8yN0Z{@~ z2GP{PQ35qb(2&tl0;k4M(%2}0L*vMCg073|YiyVvCGd3ywV4?uFlRPBo)aZdV=j%E zuluPkFQ8HjqXhCUrlw1x1TGj)wP3lFZZFgIQ$<$LBrPmA@~n#z@IFaxPw76W8%Fsv zQ3B)7lAMbY7;urQUWyWEcbPi9j1nmFhT3OE2^4=z_1;AZIDMfyU!w$$8#}&72~@F& z{^OWcv_MW9`dbT=jN4lHWJ|Vo(E|I8^IAx?r%Z=vfgZVOO~Gh^kAm)! zT40V3`4M+>YjO_kH5WlAOe*veF6`4Vdh+VFfUr5{Q|OGs^?i%T1I=caM7r< zHd^53URtwH=cE0%QB^HmG(4X~ z>+{TXkBq;bMhk3sM#;~k1rC3pY@eb9JdDv=xb&GCeT^3AVHfkqZu=O4UdTZIY!6O7}*jQBfjBOG$BTyVM_zYBSzZRp`Kc=MpUACjKHfF6xB-CLjBc&dTGI~Be`f{ zuCYoB+dET8H(gtG#AwwcMj*B~CH9FC_+LLdFf2x(=>%QJNt9zsj6j>I6gneDV3=`p zZj6A%LMpc?Mqs<~SqmA9>7EuGme5`;TreJM!EOb)Xkms?YgLTE^3{~JM%Q08UQ2z~ z#Rv>HmT%PCsT`ZgdRvS@#qG393&)K|J7NR^chO8O9NSHowGgz2Z1%+n3^h*g*Zo$> z2dJ+Wt{Ke_#t4itQV;3lN7XdiXkpY*ny!V!6EXV#!=|^VbRW;s3+?4|)c%s5X|?Gx z6}b{45N;H|79%j!n14M+;MonTeKSU&%w4j1pmS3XwKAF{rApT`8|!g&4?8!Ig1`^r_GL)hjYnmeyl)+g*0JNtboO0a??UH zW9`aVflsTbws# z;$E^p5Gx>uso`;5cUAKw^*N>cb~9GK-Hw&McXTZGsM>v9Qv{i^j>F5^-`Pjl4?731m;FViV#7hEAmCGvfq0@1kwH;{;Oo(v#D10>Ni#wia^U zrkZ!+1dbSw{ud_@_=09?!Rs}(eiJ9)_mO%Oi5J-IL&3iB`rO8NIT=b$;qd~4jCV=# z0`V!dTnk-F(e~2u0{&&FY{htivFX&aa=gI0cJ#S@yuhH2lsOZAq7b>y}&UZCM7I-`Y$#;0BJ0`BLi(fN3Rv&JJW^u0=Fuj~7i>rEP}g^9++`#M(T z`H(WTu<<>8`w%a1={t=NNzlJDB*?W;DjSv{L)AmoF+4%0t4a|G`fpJQ(oIc`rVTL( z0!eXHP767U(}A=E@hwFmoJZVUKnj{FUYDW3nCJ0RH zm>?IsQ0_hn`mQ?w_e44}DM27+GF8w*DWx!1a$ zYVv2g^(8@I<}Z4ZJyC*lCQ4i`YUYwCP{NHe-4pfuGKsP%Fj4XZ(UPb{fu#xbIx$gT zWHOCymMCzgIc@HpDDa~XwdAXlKx#lUoJ=^wNTiL+7wO_NcE>7wUPu*)uyC6N&35GlBB9} zv~H5Xt7a6{B1zzVTe>nfNg)4t8m)yv3+ecxB!T$Fl(bZ@uLdup_gb)BPn9+#31r_! zb8hK;)#gV@a_(`GTzo>F&yoZ(jW*A9UTWP7+O37Sm-P3mB!M@^&NoQ{7H=u17S^gy z?~}XR^TET=Y^4 zQ*zU7r(}V2XDaBDEO5-o>6R?;w{gThSs=S7eJzwMFw%=o_$2FdW|H-}GBi*NEBq-v zK<`IQ3M8wbWPzcfbUG|qAUT|hMkfn&jG=y7$Qw&d$#X1(qh0TS~IPt5k|A zl`OExC{-p|U{qQ9p@nSasd|NEfrG}-bRDNUU5Sz_>o`@NDm1TZvOunCbi8`9K&~3} zj}~Utq=&VV1*+Gk@(q&(#y28qoGh@e34LywEYPYM{b;4*RjF-gqZZo!MeExo3wX7s z;$4yjhIOUSTFBj-YWLB-H--+;xvJAcDS4RARc#(gKSt?&t9GMl%6L6f>h=VBu7$LT zG;)%j5%t~ZJR@0P+f3>?KUtvoA{w?>$EZFV*_P;@sKu-4=oWn}s2tm9fEI>sr_(!h z+$wn|jop(haAhx*-j^&;;V?}&k}P0xl!ly27C3d9o}Nn<_+o50pDb{|XmT-Gpz0NB zs)c-4DM$+^uTh?x$pZCm(Mc^#yqzpJ?&vwVOU>RS3v@F=vXTW-jCET0{FYk1)3c$D z8yR1d1!jID$M4Ak`y}NLTgw!IhjvuZBSoO4CtcA(!2;B>puSyQF|xc;1Y*6ZT#*!k zt3Fh~FGXN^QR*3;BCschLSj<{%EZx__!NQkVsxf_ihxT+8lr{a>2$VIia@c-WK}gq zph7j;sfBg z=}apfzjA3qL$q+D9cAy3BH(Ep)Qzm6oJadaIN!5syix0 z;Dm8i3&Epx&Bl=Xxc{rs{z9UNqBxHKD)FI`Bq}J#KT)lk^&nAH%)N=E4+fc7YGOoY z|0E>@DIbcn&yU?NuATV4t)5&+{-XC z_q>e-w$`vy87jpNDl0d7u3KPnRU(PX((S@^!vYJg7OSbuXE<+KU}HvLEzJW7aEQcP z7FfISoXU!Bi)T)H?A8n zw7F>=InpH>x-GDiFNDowf#vp!K`NW}ioia4K2q8*Yy-5O6d0B7EU?}|k?`IEOELZo z(fJ^8!{QN@IecPhjAn}@eHWQjmNhPdC+Is6*AFo=N%KTf{UT_J?)8giz}OtFP_#y2 zdxVIJS74_T#0M%{m?-w{R$y);dXECjPZA%g>{YT@k)psZ8Fnh$w_i9@71-i5QJAj4 z+y_MQAq6&kMj`T?g2T8{qwu;`A=V+nTnfkTD)bu7_Z6leD4b{z1ymN%Bxb0r`H2W@ zQ(!qpM!Nz#YwYY)^iR9OWw)53vM-;-#t{X!d{hL4Xt2ak;R(}V_tuLsn+7`=A=0BX zTpKhBV?=ni20MOKc&Tjgl*YO|jcOzQqDDoD#;ozCMq{Nzqs(aR&|vb-b)?RyAh~Cz^G%F`y)40F1JJi$iDfe)F5 z?`rbCkDPO!CnfTxzWQBOWNZKRo4=%DcskjC9zRqnS6*MP9Qn$W%vrp6&OEtF4(=KV?Rr@_wpU(NBFb>nA^bZ0RR+ zD?jbRF?d@0DH%1;1kr8$^an2BY+FC2w)0aF6zb}yUcLM@9A*3X=|x{Z_3!7Wu^2pn zv4;6+>PX^4@F+j|Pxh00il1I#?JUN+>8GA|{q*R$pWdVW3qP$#otJ)^_R3G&U;F6@ zioNku<*$DFYBH#)zd?V77_`-G&_O)SV9=3JgR*BfXfyU^F{o}JsW z*JcL2?_^LyXM;v#2Fi6YXaGKS<#soNvUWEp4&Qnh)VL>odl@tbdlBB7*kI{rP(%EV zxBZ!SfI+zj8q|4^K|8T)utByV2KlgKC^^9}+@NCEivc6KKgys!qYZjBj=9iqJh4tR zNRtd2gcXy?8AqlV6gZW*@nIUVPd6wJcH!?bk}9avh>AOn=bk zv_UV=6Z18Ltk(@nM?(z70<6X4e+-&=%b;erS#uP;Lo9a<3VmSEDI9oYQ2nRO^TMFT zFAZAyFS)!k=pJI;Q=5+l1)&7i!t|N7!$7RWBUrx}lo6%A(&n2%?*9zxiz_(vo&Doy z)G~unCyhpB3^3{!vrz{y%wp7J+_f6zvKtkKmJXw81{&1?p)RAmn2L`mA8b@ROu%Mb z#O_d|F2S48sGBH~$*5_VpV_FYS&Vv#{8^3ahR+DgW>iDW!)^@8Zq%qSqxy#%bsG&l zMxBQ>(x`J@qb5ah96h3qdK+t$FV3hj2}X5E=60G<_kBj)N;fJ?4x{GgrVVc9G3s4@ zqf!bOHL##jjS3re7D+{odV^ubj9Q0>NGWdASjH(%!Fv?!hs7(m3WYh?xRyHc(C!;E(F4|TjPL%tZb~yfvQJrfT6(%kqJiSn#ex+zp3PaOw*VHPp5NxhEeV381-bXQCa61 z)eL9nGsYsL;+7hfW0g^DaC)^-)z>lpMx#z_HfrP+)@&;|ZZm4_4x^HHk;88C#8r&i z$G+N69LHFn^UQaRzBi02@rXFk7g-*&H!%JQd+aH5J*PJKh*mF*%J>R&Lb(tq!-8>Z&E9G6HLmTXwnYs$zjs$Tqa#ct=#m@ zW76(?CWYoVX%tEqG-(=27BXo9(h8f@5_?gkh)KtaF*XVnH|bp|lYTE}lBK*!UGNCo zem1E<9h1h?GwDcUlh!ve=`d_fO?nQ$X5@}V$k^PZnV8tpq$NmeWm1JUCLL(UT-F(&8D^ZWgt{2c*w7X)aE{J;$Uib4_ZpkU7z2kxBD0 zWwA+lmzdNQ`|usLmYK940n1G?t|X4N%!}QdP5OpYTgY=OYr2i~-fz-9EIrJ6UN9;C z25b6{Nj+|n;|r5QzOp9rS4TWF`fI4aziuGi?yqymp6Bu_-jX`zlz8Bs|ses`YTJEzpA5ilD{UPa3!=gL>l*$#SdW;R`72Kwj=CYuzS)joQ!slm7bqPk*)f+h2Z{sWU8B{5ATTzns_o)d$DW z`G&vVpzc4^9zSmSYyK_P;I_Y3J@8kfSN_WTpTEW`K%>n8+Tae*9{6PlP#ku^9U7qB z8Id_a?Xv}_Z+L)4VJo~IZsQ2XLfUe_s zQh;8eaB_gEVjcWa0(1(`P(C$4A228_K%21E7ogktBWHjb=MK;p{E;U>AM-JO{s7f2 z5TKZX0jgJom?{RSRb|FOy=npaYY?%G3Q!xAA5C0vjiEm-PY6(-iNv%bKzUaND0NkU zB31`z@`eC)*up%&2dLzZ0Qv6;Q2N0DY8#;SXmFFfp9E-;!>ol)v-)K z6O+xFj~yvyl} zne|g~vjR()wF0-1p`=;A;BOQtW!C=Ef?H>>eMvwGmyLuMU3LcRYms}J_zw_~j1an=_H zPO_hI2UAa(HR25W;w*EXGppF2?1{gq!QZU)1+(^EqUKj(ucEd+8>7 z6q#?aerSN6*o+Og%{qdPcUTvEyhl#=sV(de=!0oEfDfqtkQ|^V#DcmN=EZT-&(k$wUVVLE!Xh6C}S#wx47MF8c^d9wcS+pRpMfQ9a zWkzG1$Zt`u0v5GJPZ$eX^ct0lTcpw!InfM%qiGrD#4%jJ&axJbDn~BmiJ_8($EQVa zD-&B4i+cZLQMaEh`nkGA*K1icqP9f`a0VYyx4uQ|@dI-jSd^imMUj|??2RpY(Zr&@ zO)W}mW>G_2!>8sJm2YR!o30l5bt4w^Lt1xg_?tyFaStPUTIA|wQT5&y-9Xm9)D=(r z(Wk#f8wXgFXP`x`23hnH->`bHMa73$bP|{G4&8?m(=dzDu^4aBVz@=8@Y@LH!6!@` zX;JG@7WF{jXzGb^I5^&-B@>trXV7pWb;e)#cM>(4%oxZp#iG49iAUHxmA2C?>VR7q zI-MA2S~O^uMdPss$+IoGg2$*chx>Dh1-0i}G#6PHG6wc7vdFNQT$fn17S?4JRmKYp zTW(R#6&4jk13bbz99(J9Sv*6#Rm{2CqR=%KQ<{7qd$UeR)u2~E+B{9s*HhFMWGmup=*#;L+}B|LacJSt;&kLIEv00tQv%W(J9ob zQW>pUoY|^!S*;p}{Mnfcap6|AgDb+S8nAh-s)~D2R>enKbq@1ltXhp@s1$3JF^Tp_ z!SAS*+p48`tlEULsGHZSfPBP^Q8-)Bstkp!ibN5dMCD>uwLz)UR*l6hY(w)hR&_z0 za#s15w<;9#Dlk7TSFx%}RjcZw%THDvMEh!1^}{QCL${x;`tuj7dRMn9PffO zTGY9=Rg>#5XIc3JkC+a3JI144$IzAgj!ytXhuTW31Ybd1I~m z8&k$vwReJ5(`K@6*pFXkS=DTgRek1K^%nEzS+ySh=d+Frh;y-3N6>yd_1HyjyRBNb zhc(zstozt6Scr}L85>^@T6N=)RoxF0+Yzf)qQX(DULfHZbwsw~=SJV9+vvWBOq z<7xKeHTKs(R^D*7DhwZCy2U!*v1-d*az)Ss@_EP_J+kV`|2?*9>J#ep)T#l`+2=2; zN`m_p^}?*TR-ONseg2;P`;q;JpifpcKpPl8TQ%}4v3+BIey5F}O-&6pb;d!XP3O?W z-=@<6HVrb{G#*D#+-Xx{kWC(!P08qryXYHi)0T`jZO=qIJVBGpHg&`bl*?x0y zYrHFNQ-PAih7zT0I*F2{ZK{cZn1aK&1aldivLdXkP1VaY7LMTpf-BlI5~{@f7*^S) z{#B?IvRAd~FUJ=p z-7e7%pDx?<^r}sJZ`&06n0VlRLLIRKUr^$yO_Oj9L!aAJ=dDd0{^j;NYWbe=;QnCK zWz70WeK7wMV}B;6FE;)6l{NWhQ|>HwRm^HvL^ivYXSd4|ZdaPeu8a6B%C7JjyFSO- zbt2I&XR=*ck*|bZopBWfOWIWq1IpXgy0TrKDt1-EZ&-q}aMiIZ47=*lufAOe@wS;= zKhU_jUA^ILWmjEnM(Z~8L%DW#)j+}ac1=Rg4tA~RWY>38?QGZAu6AANW>=x^c6G%- z`1P=>c|W_l!_(ic4}?({m_<@nbnRk?3*O4^Zu9jGZ z=kSeT4xB=Zv3Bi1$MJT}m`ER3CfT(Yrw}~FuAlK9m8aP?YC7$(X9n}nv}+;OBg<^^ zLsRUZW7m+msi{#d}+3+>8?;)}=;}STO3Et<#tWO60BWe z*F6+nMI5NOnmI5LS=ZPVj|OX5n|0)i`RnbvjhD!oc0EL~ovblN;^Z#!*-btuwTCsqG&I|5*J5nM;C<8zZT8dm zfL%Eb+Lh@Lbva^J5sW=b+$X5vNpe2LUPbHEjCF>%&)Rhplh4`J@Vs4H{$y=Y>-r8$hu?TCA(5CQ%lUf!uhLqO~=32Sl{b*<+@4Cx9y6(!~R2kOvFRvzQ;bi z&$^@I1M2aR8shLH>hhR9f_6{rs`ivU{LHSS$o-u0Q0#?WKfSc;5Kg{gt=`x*=U=+BDj+@vZhYlMYdSrB{kjbHLnCkD)uV#nZV@a?>88SK4HIm!7gO|AB7iuL!D|nWUJ%Q z3Vf;WQ2*u*jlt(u4%P1L&^8q7;ovosL#I%ow?ifSIJ6ah{TymH*rDws915D|(AR|y zWnN5umN--%gK-B7);aVF-_T*bLkEzs!J)o5fw+whwb|s*Wi;L5P?znDvxAzU2mV3L zoemw^L#_9c&pw9=?x!vXsP#e4A985oVa7b-P{2`#u3^h@htf_sbOt}2B&Ji;6Gcut z6miC(Ug&$4b_hR5JhK<78L;1f6gRNgo&s%kTlFkJJ@M@i!`e zq94{F^)t1>2)sqHFAmwiGA3r?5#FQQH{!xYl>Lu$SdL2HsRteyoN^hRYK`6aZgMK0 zzf&V|57h&lT858EH9L7e=u}RNQ$z6_MXXNEM4Zj3TxgAj2(&v@2fLBW;nWm3oKCF? zbSgZ^sY^KOaw;*{skv~4ICTVr!ss9FRDj2+(%6X)*cahcl}M)=ql4F}ho}rZjL>#eWA-cpnRXo9|C-{IniNu-0m@ub0RVK};uc+!{j&!G% z=5VTgE~mbrLT+y7b*f1|+UIxbKmn(c3OY3g(+W8iT-d3%MVzu1b?PEa#hj{*JjEFc zol7{i37?T#%BlC*UD~PN$~g55naYwAjOCaY|G`$?sT}BzA=p^asT;Ul*(tv&PDP_W zTH`nlRAXK68G*krPIae>)o`jZ#^E?R)ug_)oLY_6wVhf}$EiYfom!8GdQO$A@6>5T zG;nG-HsXFmr$QP#wI4m2a2^|*vOdk6YTBImT9O;~Awz5C!kczZ#kP0qPZa9lRCz4L z)sE!fiM8uY&RxjAD{D8}$#WH_Cg3vy#tenSsHC#$O%h(gkopP^a&Q(seTkX^p99-j+cb!vdh*-}ahie1-A1@HS(W${W zj-XBKA^f`8sr*~0^H!%${Z35Vi5cdd)E%97QP{F99J}xg6S4;C0M5XcEs)m>f%*n(_CT#iM^B&>5vYUz z7ayq834yAa7${RpAfKlMDt~&QisT4Xshokjg8jJyRXjH_=3$Jyfy#tdXqzukYp?_N zk*NUVpkcv4&Bgt~fjUwoP%l~r>MNSI2~_*Gfojw)P>%M2s*cGx(jicXyD~RgcMsGt z)cP$@_MYU~i}`z#SD!!)>K7=_0CE~gKYYgcL4isfLJfxns^{=P{W6ldP+&};a*yTM zxIkqYAIRe;P%98LAyBEfFfmXyCI#vV7Ecb;yD7vzEl^#i2Wr`jKvkI;s5|IBD^NG) z5bxYT#m);<_x}^LF$W|0~iO!L9|B)G#nbF3B!Z*0d+GjAUC65YHe#{yZ zqz&VPv}OXwCkN^5lprmc9;B8tg7nACAg!7mq-`iPCrHod1u6UdASIv$jv{y=b1e;0 zC7725DQ#ttnqUVGtP0W@nAb4(x*#1{AEZv3gLDg_T_gey0A-06mb#N)Uvr9d@xm2RNOA$R>s{ETv|6)T=m;USJ zQqKM^4Ibpug&{88!RlcyC63_dXmS|iQtPoU8OFKvV7yB;Cb-mOBI8UZuPH8tOmnFf z+|ymEGs7j{ESFlKE7l-&9{unZ!{@t{zL-3AQztyb&wHrHUY91~9Fq3Aln=vDWIxA_ zuwF-9YKGO=j)#A^)ZsYuo?y*Rxs>CKOI6RhR3Ed>Gyk71y+G|7E{(YDQoB1YneV#P z1HJBX>=AW-?9$#R^nL2$S|XROKBG=A**C9T`s0mDv){9x=>3WIc#e*rUFr+_7Z8wG)59k}+7vG6m~+=3rgKnXJKT93HIJ5y9#h8LU`uu%6;U zRIv6$2kS~qu$IOKYeRgnRwM=MKyt8V=LpukyusR=FIWZg)2=|Ut``heNa0`&D#Bb? zT9mnp2Wwb~U`3P+)<^`F4%T|u%LMCJ97dUP!J1P(Sdo>91tqHnYb(BC?a#rA`6XDh za1gI*1#48@VCDEVSk?LmYxJ04{X9Kb%OBAzkwl74+10kA=G6zF62CgIIgNsP} zBSc*=`B(_=Cx+-GI-L&Dzh@ZdY={nD2+@&C#C17D{jY`SI2_kQRPaWKR{ldww?Z`N zUWfu7hG^Q85H)-mqM0~_@vpf5Iz%^qkQ08ATcLh#jl*o5Fu2v(=+<8*x03wbx`S*1 zZuK;~^%X9QTbE(5x)p>im}YZpP6oHyWpryJnrCrqdseqHWOHi-&f!INx7LQaRm|g7 zN`za@BHbDkjTq*RbL%a3#JiO_!L3fXndnx*B*sajzt62V>2A%>;npn-%IVfc6wK|` zQrykw)`0wO#TVclE+V0zTlovQH4vdi+DGr*Zq+L7=5>Qx?lNwT!duiV z%X}DC&aLw0-5P_)3U0MW?}~1n!N^K(6|d~pBGj(pmb0o`RjRqUF4L`b)fpR=Yq(Xm zu3J~@xmCEnTYDO~mDnvKdVE&eF4R7Vv;^A&3j&^Gj z-lN+@xBi{Uc(dH9kAI=rZk56$EI`&dZf!;9dDI`DP;@@`@gC=vy0v^g?Kd*sPL9F2 z%dLicSU0>z`Mqwf!F}Y~=hkH8-S1Xu%sb###lxJ(iX(0{{e%61Q77EWanh|OU)@@W zteG;X40Uc;My>vuQID}VQzowC%A~njGAT>lOlsXA zlfv6%(t{3}G@^SZwI7g4>yBlT@oXmff6t^DhRo{a&CKiX%=$Shvle52{>=KLcxGiQ zlUeOiba`gpSIx}t`^>7FDT_|WXW_AsMNjf%(Xg^vG^T zen6Nul?qeN(qSrwak!0uGGRJfHcXq#hbg*3nAW3r#W3AOj>?RQ`l$SKnChZnjWCtR z8@z5BrV_2g)T=|7@^uZ>=w=l(FK00*|Q?;I98iGmqh8Deu7ZJU~v=P<&gy|$k z_6<{=0i4G`oJ8RvVahc$Oew>{Q~>{?!SFDBMB9;J>WN)wIVw!uuoYKFhv^Y!j0w|? zv0)0C5T-G>i&vOFF--3#b9_n|*9wJc3mj9a4Hn`7lBb2KIhNreR!yfr!e&q-ThNwdRr2aD#gMyNBF*pPW1$B?`vOw*QzX$f*J3sdRk#E&Oy!t?<#>o|^` zn6)WPqqdL(J|OIO)_X^oYN0t!pxoXtE#4odnFr{1Fihvr?htEwnEIgMkubG77N+j_ zb|OsSe}?H7{E7=Gc`-~`ud^R84#zR%Mws>@>&-CD!)C0zMIN|wCrqF2hAG2CVtEwC z^+93U@s#$@!sPcnOx{=YN3VCpjcV_S?E`au4Fdh5OKKVhO5#ef%tdZezM}@03 z_97)ZTnX{v3iE}l11=#;<#3&=60RdZh3n`q;WAVYSDqRiuNkghwZpZwQMk%94%bx# zHwjmPrs0Zf7Ow9t!?nF_xE8bzSHlkB%HJ_uqdSEwvP-yHbPd;;ZsBtFU<@?r8Lo1@ z!u16Q`h@Fd-*7$0xBlT8H6UD;f#EU@4VQgHxY9<3^Epzu22TptYXnUWSN6H#%7y0W zheOCXFI>rsmK?H5|wA6{k;<(_i6S=M}CMD10qkbG;sYgE!ivG+ab# zoJWfjJnEn5;d*e7LX$l@flHWI)uZbe|C2}a(WaV*>jXV&@v}#}(Wkmc#+n|kRq!aK zmPZq7do-?&NB`lUx}2-;Q78B{@Td}IHuR{#uO7uT_Q=r0qa0|9fTkX;hr5|a72s`7 zyA~c@Xz5X%RvvAKT6R=DAUEGeQ4CxqxLw4i5;RSN7-SU=22=X)ZE$k8N0s+@)C4DS89$J3 zuSdf$VV_5H5wYK+e)tnx50cLz;ydcmV+{Gjqrc%j=FuUXJkB@>K0&R~0`F1!B;%Z7 zt#R+PM@7$iRP%yIzKb3m$2E+-?9nWgzDmy5*qhjd*|*8#i@u=4}^^`l2wKeNvRBDg*~LPrs1iBNWHgc4BA9-&R) z5vrRIp&JDvWG@z>J-AXTLJtsIK0>Q1L}(jQszmS|N800EtqA$mj!-ugt{b5WDA_PV zHQO^srwILpcU>YB(v5LYvPT5hxH8^v5pwsYeV+)G>l-0sKiUq8Q0*ZR`Z^*)LzXc9 znh0G*;#%Tc7ol@lu|7hk4H2?!jL;mc#KcVzx{KqRBUEuqgr?v+QnyB^#e8T@m;og6qs8v>K%zN2n8?Bkz+4Ex|?{d>Wym&m*)I zpI$^L_e<)4Px$_t9NtFg3EF>*(0=@d>Yu3bw+Q|EJwhFD`A3B2DpHFLk=lryrbr#d z9Y>@hgCf;ABvKEN;E7bdxJZpoid0IjNUbjvsqXb6RkmZKp7e~AWo@MDABoiUbCH_# zXQbl)j+EzOr0$~crAS>uyUVn>5~)6qBenKLB>(qBs@3;MmUpki!xU+uRdT!aj#4zyb8f++(*5VUY&=ll$Yzyy=sn=_zyKpdo>X+%6Rp6S+8y* zQ#r2+*7mA9{;K2E)w<*XZ&R=4H}~pC3u@G!c{+O4YPgrzEgT!+)!>ojfwH5#s*b)G zKH4k4apXMNE9(NUN@C$cFP{T=wH9HEy;`)ytF~*%eI4Vi_bPY;HQU6z2fb>2%FE}O zUe!NM-SHQ4obmEGKRKTDss;LBC4R?OR5<5VZTyAK=e^qVrzp3d3 z)(nA{SWhfR;AO9}p&44<@M;-q|3h4OiHf(pI*WU--SH|jZXoflSG^w5=ZRO7pHZLZ zUgdek+P$XDTdxkF%R8?ce4t+VRZ$w~7bUwPN+VFq7^PXJDCICmaY;4D98vno8KpO< zof@Sp=u|vP7hx?M#phg6T8RBnInJRUMwE}@yIN6tQ6Wl|t468AFH!1`_0^-a2OVlg z$y_T+N07A+?HWXJ{eF~gHI3r)@F+RkMX|O~%HJVMd%F@tk0>?3s^6lt4V`*M>36j4 z6{Yj&-8)Lluo({!(6uclx;mEi!N@Z6?=@O1_jFMqflp1Z0QjIN)hvEOXElTm* zqcm|hb=@DO%m<>>;&_yX;ZKx25v7yZdooJT@CmI>5d;3fl+#iAfN5u<6m&L93ve5~ z&(R-6&XWtK<2fvUMk)8-oX1l1zd(C@#>Pugx{Hv@%!{7*2dl3|={}0zh*I)RYK}G- zayLrb??>t0gD8bQW=zCCCEgcNe6Aj)#;?frHMyey=P0%O5~c3{Md<_@C|Z3H=ohWJ zXo(Z3Y=~Ap>taZ>9-z8AT20U_V>H(@MypfiXbr?0{6Iw3Xr0ClRL(|BSc;#rN9$Mo ziCb757Om}g5+1FFo@lkjV&spA)>JIPMsKwC!apinvym3f*m#VoF^r4Q*l0yz3ZCHi zxM<~#XMR*ph?YH(wpfH_snKeY7Oh&oX!T2vR_7e#kc;v1MyqLoXk984t%8N4HM0nH z!NQ`%fUCu#`Q00>XT_ssE5R{5!O4=*x>7n?S;|DqR54nOa2ok5MQb^}pk`%qMc1a$ zI@BXt-G8I@y%@7kw5koJcEjj9Dq7RWMXULQXqB7JJhN!CCR)odVjVHbFD zjuT>)byBP zU99G!$OYzyLI>j<~?G<8HC*@=0~wyKOU<_Ph<7?d8}@|pe`?| z(VJLx`4G$XwXwQ_++XMq%hy=tLobY1oQ@;L5GSiKP8pHY6sH>IIHhNbQ(GL*9H;kL z<7CJdr_M;p9;e>naoT~lo;dY^UqqZ5M#gEDH%=??9_M1?bRa%X4-(>JD;%d%SX6{| zMd^nXCE|1kMM}lVUOG;h@f$ATS@}36REX0JJV%#`j8`d6ODo4|Ge%b>&T4U*fu*=s zJx*2Y#_`!roF3MT)8zVbT7Y-h-XKoB8pUaE3+8DVr-}$@6(?isI9}t&X-WGymFy5F zSI0QbL;qfJN*=%*Xf`lTnFhzH6XpzIys>e*wINRBx5Q}|YHW?u_mgp4;})k^_<<#- zlRX;$Ez#Wpxujj&BZ%J zzl>Mdt9ZRZ`0IELd>b#nf8$jeXOQt-yc%HzPU15ex!*D_&cX0+f*yTLP~@isp4(BAFA1uK?%4VxK`&9!FHt!S zi7JL+SRRn5+bC>Fl--)B%-9u@s83kqPSkD`&ycA3p^1D>m#E(G%ao|+h{&9%k?55* zk?&U1K3k&dWT(9+k>53mx)PD7dXb6h1dBIOp{RnT_#4Gy5>+8Kk=Lq;a^y@@>s*P7 z%}so0guVrd1?>wZsvnGn6ZLD6L?stZQ~_+q7xXEXs1s!pwYO5DzG8jlMD0V@Dv1iL zm#9kkfuQ<{nufOx$fqH(wo23#yl$Py`-q9!j7w-VGf}hfVOF9R&rZ|^M9)doO#Hq) zQRjCga=mS$rteME1&r92s2K>`Pkj!M!@)!yI-Mw;Nz@h`M$fZ}8jcL-i3ex#$Dic? zH*sB0)Pq|byPc@L3-Iygx=un9v#l5`D8?j&`>4qQgX3`v@ZGNDOY zg5&rX%9x~l=!Y@*j*6L*^aB+$C#eobXGzjOs1TE+S~!Gju}ON0I&n#AiNE5LR3kA- zAxTMki#Ey3gN-(lI7z2>bABJ^ zv2j1=QRV>W4<@P6p(M3Go}@Kscp^z1ko6>Ma+aUxSU3EGN#~Q);u33wT9;XGyg-Gk zNoseEz4#w%0P7Fd1*h=Ukj!h$WIe|>3^pa}mVYwe`A*gvF0$&oHQ9vi^m&3}awu*<>Y^OV-?q$tqSUS^IuYR&0%AzOR|AEVYs~r+%`&{+g^D zZIiVCwsy(N+n$&^CTnu1WIoqT)`}j4V7{ zfE$Mx`*513Tn!kJ_}z{3mlyO^xVOUb;i#rW{u zB4(Vx`P<3*afkJ~o2=>glJ)cbWUlS!JR%<@s~&bdrUp-vwH9x_5Yt!MA^W#v)x?(n zk~Q*svZldePEiRQwWR1T^s}XCm@`F_;h#B0;}Do7MfLGKYl>!MOVOk76h(Sc)ITCc z1tL>a7HyHoo1&YT6O*E=7#o|Sxu_eLqGowhv;#*`HeZT9-V{~Zm!i=q zygx;i@i%-2Q*;AQQT7n^JeHy{r&4qReNR(Mgq%rH$FszFE=36#4A0*w>VzDZ8TWdM zhU4B1*6t?lvF;x0g;EbvRP-Tju<~V!w*8l)*Qor1T)6=+^HIkM>wA`Re_mObr64|d*)OpjlFI7WPuwkku zpi|RSUBc^DsVdbvRi99!O{&y3Rn<|ZE8}5Z&r}WWMgM838ithFscMVxIjKs;Unn;> zRl|{gUaHC?*L-4Jl&Yk~sVa=>2w9q{@5_jLd8%$>=nCRmovLMPQ&nL@s(Kx!&5=~~ zK<}fe^8152;M=iO^*^4fG01ZwRclYu|5U0xXUOe*s$%|O+*_%#-%iywG`f?jxVx!Z z{De535{ENQ1q0Jm4*#N<1uNf6Pw2W<7w)Xn5Ij(hrrY{S$t^<#Q`McNK>PnX_}uaO~2$$(_cl>G_ZJ@ z#vxw``XH`kn%dP#Q_Fg3{B6iI{(elFh9gJAG^tOTYN9Cu`=+T%KgR8!rZI!k)L?L$ z+9Q5Qnhs7T{wZl%f)-QLGWc_{Y>@gd`}G(E+p(`lM;F-_iEX*za?`)|1aE=_Y$_I;XW z;v6=7Ow%kspZpCz6~cO>PeuKGI*yAN7~s==vrlhfviQ^*HLX4^cleaq=~E2O!xiMy zV3$w5LVcQ*k@KjQ$){zA&g|2hSfBom^J#Aa{Sti|oy({H5S!npPp}m5DWafHshD2a zr&dLL>WSG!eOmc{#eMn)YYCsW;tj$}`_u&kkXXj2-^%*<+ax~CufW({EFxY({+Te42uV zsMwymbRd^bKAzL~G_RkJ_Xe30?Z;EY3Cw|-6Nzz_kL%Zbst)rUpFYp`>C^(Bu4DW{ zpFS+1-b;PDg1*aqidx~*d-$*Pag8@MSnrc#i%%tw(GTy@;siP2=>=+W*{APVb;YNK zSA9BplltEADZ>Y!+Tb^MKl;?yKFUX=Yjk8fe~%`e?@OigUURw@qGDXSMxsV? zx^kwas~Dc4wJ%-s($iHXXS#;uP1lpc>FQII@k^)c8XjSCnRI<9n=VtibY(;zv?`yj zF_qKx7|GK1WPPcUaK5x3(^hoEs6VwD9kfj%S_D)ww zU&a~8IQS1M2c;`v2>php>-orZH5!$!cE~iE9LJ<<$=Gz=9ha{E)pQ?FPE}vL$A9!9 zAfOZ}(v;pN^ps)Ja|20cCNtDY0#a0ZRq5rA6s30rhK_WQDuU8`Q@Th8=}7PGeOd24 z*ZQoGn|sdLd!J-Xx%b>#W8!pZY@AAtqaIj-)bVjzHX%+IC&sD7Wb&EH_MhVPdPba% z&WzLI^f(QiMXs}Xd`X--E{)UVWpR4EJWg5}r}nGjbmABGT}|I>;uKoPW9#EIbaR}} z{}IQUOVoXPoDz4$sq0SWXBTs}Cr(B8GlvK0^APiUBu?dz#wl=|TAd(=Q{;4-e9y$G zEdGM)pE!MYHcl_j#p%JtIQ@1#PI+&{sWsAZ2xs8D$$czC;;lG!!(rHN$LS=VV9A|0 zRliGY|HbKFjLKl*v%N`)*n%vXO`L~o($IV+O+iwAlUm{^3V&?UFw`nxk_RejQeF(g zo>C^>N0~IPqDga+R>`CeIEOM-Od5}VHB1@}Urm#mU>`oLZBl=XiZ>}8P3oKU75+vE zJNu)8&!ocW)ugJ8OxlTTO-%APWgir4Mjep9Ir*lUw4;Sd$6A`S{tM!4W75E{O)AokI<+@( zeggR;wWCSj<3IR2nRE*?JJVNJlWaJRAG?_}8_w?J@Qq2Ydz;j&k4aMpnACM3^}|Y> zMA1PeRrw#aMh{dOLY=0VbPpM)n$!wia2WNc5&uv0hYzQl^z96jenH`xCe6nN3|w7H zY5&#LY+S=9_v$Ku5jcqa_v@+whF}vOpyGqNYK<8?bmB?T+D}=!~iJFF)HAKz&+;3JbY(n9NW*kX7&ErtnQ1<8i-w}wAid!znWRc zfU$nVCSt@Eblq%Lj;-X4mB_fwtgGA2s<*?evzV~ctb|?EZogT@4w!WW7trRQS=$ep z)#r#=Bhd3Nv#K36>%eid?*DC8sWWDMk4tB%!8x-&yI^MR0kituqIT$X+syG!W@Wy^ zeB3qjyPsL7G4-BVdmfqf-D9%~Juzz}N<1~I$#XO3mQc4BW=($0{A94GA50l7ER$`K zE0aatGF$XImqoR6TQnh$MZbS&(SDfnTJ%SLi+qJG8jK5{SXhVAqJ8LA)S@|<5@*q0 zs9M9KM^H_R-qf=w$!t;M`iz195-eJ6w`dFQV1UP>W4IAw{6zM}4ID|bC`YnIZNnB> zQ|PO?MP^J%vnUd=s2#@PZp@-`Ei4++(jxm876s715G;yg{kX^o@te(1Y!m-OHjgsME)y0(~ti4Fendk#m3c8*Wj3 zJVeG377fS0Kaj&ni`p!;Xck^CBj4o~O+=Oz7FpI=)DuV7TQv7qi&o+o(zh}%J1iW# zZc&3>7UkS)QU84w?LB0X^Qc7)k6Co-ICF7|eevRNi>98j@H>}9e_poe^V{T#Sr~cO zqJtT&Dw)Zub6Kn^l+~(v*{oWHQy*BBFPBx53R_u|%c{vGtvZfjrL3BQ;-#(XUB)W^ zXI3>vfeKdrQPHXnZmX6c;<0j^x>b*m=(8%1Vb$^^t8ODb*{T(&8MbO%idD^08Mh5F z!2G3E*YF4pzq0cF!^(L$R+a8#)sSzjYWgkx4z=oMWFBtSb{xS|Y#2emKUn!K)2h#> zSQW$OsaB1eX4Oyl1KVa=^$x4kX$#*hs}{_*>gpWw-ey&=?N-g+VO7RURwdvOGF`T6 z1g>4NYW!8J;_q737uEi=sy=q1^nI%?qToBLQow45DukJMnZc%o8EvYV)uyjdG@DJ8 z@C)+fu(33iO}Fu3PMglK3-iS;?kBs9D)27xtrERhzEiF;-Wz zDNA*m-qp0JgUzNTh{W5}5s#3VVAE^lwA*wTSsga5K`FmYG30MxQ)w(hmH=@fW3o+F zObgo-OtGms2BAYL{Ug$d{_zNjO~|9EP1!rx^e1w5wCT%EHWlk^Qw4+&*TtsJDBaa2 z6MjX3?&N^SXw<`|$wO>9j$z;1GzHF~HvK)3{ioQJVLIDp*|cSjO>eMju1#CvnP=k| zc*a;@)8b_|UB^$$i4oOT*feUTP4!mUw09$U|7O!h>_cdiP0Kdh)be-Y!X6yjV^f2@ zHZ{SIkI3&Sc|0SJ=gi*=YEmvO-SH8h6MGQoS=MD6ZG@61lgu1=-7+|eU+Y|ce4^Sc}{|= z%uCSL;&wGIVb^~p?W|93=es$(mg91HyLMExYjIV(D%7^CN&~yvccLwxAWLV)L5VJQMUc0v zT_v#-=5BW0$Jy1Uw_O{ttdE_~CU$;TwkvM1UGcayjJCt=I*Q9!Ji^Z37Q0%GwCi{5 z$L-N}H5p@9->G)p!sj#W8ieNa?V5&$3+zgRb)lVO&g>j#YnNxOU5!wGon2k`+4($b z*BATk>V`=N?5c6mu3_kR*{)6Kbj7az=yKIA*FC!iqt<=9+{pNVT%Oo<0ApX-br^$Q z+cgfg-q^Ji*0*+fGdi>sXEHfB7ulijGCQ;zHxbI>U>!P#=3oWhz>?J=1HT|4n?tiu zJ-b6`=#FVPS;V1Z#o6yuhdLuy35QA`@LoxW?qW+>hyF!kIftH>cc?=JhsNU&ycHcf zjz{>kI@|FMm*VKBhJ*FS9qNx2br}a4>p4^tl`Re><9K~yOCUBJfZt9|xQ8ANhblT9 zYJzPpa>iJd!h zlp7ZgICSn1Z4Nus2+Q&55r>xi<TyW>#RyAG|#MXY+j;}0DQqUB?rANc5rLxZ0?v2s&LVgiofF_OwUm5y6@T+XSc<=F@Gu?_D~ zprTV248TZ?spM4c%1&)W^(syU(59+WKjPzRPL)H_d)1wKfHfwk#@29ZJ&x9N>TGSN z&ed@$e_f}tS)3|`uaMD3d&IvN@6>r@u{%{6E_fVHedZ)ipHq`kocbx%sjaBg$SE7X ze6KNmHgPHqHJUs12d<)O3#U?W9V=Qnbs7m@IW@kMQ@`RsH>VyVXLqMc!;C|ChL_(t zRk9cPU^Ld^MSuDj?9^M>e_&krMmt$w&Z+6MomzxvD7?<8hC7|=h8qW+%5#WVjuH!w z;~qXahU3%|c~4SX%*9%qfA5r2{ZBh}@^7bJ!+qYV_85${SDZS7JJ+e_4W~NYb!sBQ z_nqp87EhcS3d?im2&LZ;CyL4?H!5X!DG6VG;L@9-E|n?fQo9l^O+>J=OFdw##^bnP zaw$g*m!h>?8jgweT&!o{QdXNw)p0$+rF?dmc6(jAk0K$L5-=6p@g&KmqRB3G$4t~q zbt#4oxP*L7T&jc1&0NaW+@(1&m-b-n7cQ=g;!<2Yml`8uN0%z&P&b#df9H}3#rwPD z#D4=_Dm;ko-@8;5M~1od0_GoGYJp#I8O27skMMRrF54*nB~%l`7W(QwgtqA$v?Za8DB1OX&h#)a%mTe|KgGtd)BzL ze;xI_>{2y&uDR3!kCF8{^?dJ!OMk+4)5UjBE)}@r;#eh@BIt<)_#Jtl(Kp=BU8?cI zr4ul}Bws9f=TZh{`gJz9<`#16lVWZK&>kbP3PU zEk`f6j`wz}VIQ}~;xx+kmmN^Pd@|QI)y4j+{!Z4txKbbE1lY4D~{p< z0<+y(vXC~&@UvULB6$mA<2*KRCEx9C72C}=wAka;OcdKo?)%(|9&mH4D!CnDJj^=g z)-Ieyq2tU0Y$x4ng};&W6m|W_t^8-*s({nyxQ`l_m=}z{Obp0(g}UExEB*m4}X6>YTMeQ zk;u@_qjI?2#iM*(Jv!6F!^Pt~>VW=O^xiif)<^ef9bWbFsAC@w=MsBVx35Qu_zTba zdz52V#dbAvOhk4X|ghzw03B7;hcBDryv3|5i-6nX{ zate9jJhDvns5kT2MtnEpi=JMD)k8D4CSi{q!l8Zcg zi#AI<9DD1L1@D$qhZSsF<`JyXtc?rVc5BaS|QU` zkBXuO8sORv`rgTXoWzA)#J!t%Fb49wAM-P$XfJg1{)j^MXV(=l4uAt!& zkM3j0pB^p2J-o(~qaJNJ=Fx!T-+5Wf!mAYxz1oZo z0k5irylRj2n4jcTG})^U!d_LxGVH?*v`q1;2M(c9D&ycw9K=mzZ$!T+)!3_eL~s@_ zP@;)f9?WR!)h0A(Mq7-+TAXaoza!*}t5^{AYA0MVuUcRzmSG$2x1biON_F~F%;l56iBHa^K2>Pr)6K3vJ;l6k zJ{9WjQ?#c~pMB%gv)(>s?&H%Pg!=mQqMuK#`}@>*pikEZ`Sb{d|L4;W_y?a4@u?#& zqxttfZ9%@FJ~hQWJcWIjPeZT=X~TUwiH}G4Gz-g-Wt2}JAu!s<_v1d+HuG`KHlO~& zk7IqxGu5Y}7=eO6ktIn@;J);>*IV{YJAP7{`e2ouKPHDnZD8LhEKEc z#ZB7Y@@Y2;-lmTCeCqj_$Da6f9cfRA8@JHm8TH18&wc8Q1NiL)eY~W9#9k3Itgp!r z`>^;8F}~$_h|=$T>WB3hDnrFG7@Uu2=tf3EyE7U5=4hxaKFMNeB!10msAo1qtFb@3 zp}IK?%|V`=hQ7f?q<&y%FKXm6Gz+Y&YEy4rr zEkl2w5hq;bh`qd_g%u5cuQK?3%8;+Fp)cwg+KKfpgYOW?-)E>Z4xzGPXf*C3;5W1k zxf&Sih{IUb&`|XNv4;#bO*Hff4U!F|g$@dE(@-J!aSG1-p}9B*jpY`%uyLHBZ4(SWXHn-#)DFp$4edeQDa_wg zYBi1L>kRTsH&{=Qx}d}?p3}1pO_*co!?}jy(E!sHbAJiXV;oybtjn1@>|bH1+e)5~ ztH=k#elc_$U#&KD0zK9+KkKO5dR`yDQvZ#H3jbzk_-1nZoiWkn4}-Pmh#ALm9m!jW zV+Zl?G}LRCp`qxv+fc>5yuPq-AM>@Jad7^Cp{xfD{fNwm4D~-k{P^t{uU~v{f_Xkg zoM#Nx`p3}OvxYuD&+`s%vEc%*nTtH1FO&Zjo>NG_YUt>{hOE~OO}@eF>87D~7pHjfFzo1U9c-`Ua*SyYh`B}5ruOhkqT=UYeR(bsTp`c&( zLVo>-xkdddP|B}bW&C=MHlO*G@pHdo<^0-L!LK?M{o0F@mHbMm?AKp7UB$0v)%+TU zBiLEp&owLP3oCICd29I97P)Kr<-w!6ep&1JRn^Sn@LT;_kJ2{AMtcmwQ+yKdS6Ot& zTDxBl@eWNLejR|{>DM2Kb1^omde|2m@CpvEU&C=28GZDRudo0&P{N=uOu(Ng;3pr9 z!VbKFxq)9@u>x06xS?MSFa*2t3UvdFiw$@SbI{Lq7W`U+JE#z%o=C?Te3a-{2qUo@ z8It_6pc{V1Ipk0F%Z0vJhr1{p_Ny^QVLKk9ateK8CXOOos$VvA!+cyo(MEnX!f5Qm z3si4REienmkh_UrJ`Bc2JVMo`evT#dYbkExvu4x_W3UrXQN6jJV-2Y(uA+3BUlB~f zQRIsF<-~Vbj%z3pr5{YdVSF5;PHp@$y7*Q62kz$&sBN===A&`*0R0Da7yd{VcPNoKCx00Yx?jG#$a;0*c})?3)8B_j^G9?G32%KH|hZ^xPlN(E|YuJs8kLoW}FR z0o6W2o_K))e+G2+uYkrLr4}awGGofgfWoH&YJpj&8RzeSiku-9>^T=u%ZtQ-=a@z*E*SEV@lfPZK;J$NsMC{x`r^B%Y=0hLP4<9xz2))DK{de#S%NBxIe42j zsEXNxN-iH%<_bZs+Zfbpw5c3aPrO2tszLpO`}kkApt9Eu%7YikQ7@=5xML1-PEt@0 zoIzD{1$7w@@tr%!_3ne(>Lr%14eEC|*9A3ueNYWI1hw*5Pd# zpmJXhssY|2&y}Di;=$FR7XBM#eV3qCpykb=x}x~4psqg*>Ziv+4S5<=@HyLFko!y8 zy$Wi^>mb*S2Tc!D|8=?CLy&=1Pbq@Q%!%%UIk#Qsg(-%NZsfTZ8a^AB>|LYqAy zUBraF_*QJHckDsP@d75y+#jj#=lyot(@FH!eVuOKUh7E07C zEL4&zXGl^#M6f4Qk{;n;<|Gx&lBE9GlQg_QlCHy1C`rkMlQa(3QR0&%H7Sy$`zTN} ziFL!1^k>N=oyV7@lGLV5k`Cd_XG!|FE!#WMSLY;c!m}<(%J*%O$_!3Y&JjtPIUz|a zCMGHW9QvASfBc1N-Xqw~IGmHaDNw=n!@vbvv2))QFrhSfHISY?vK+Vn+O+ggXUy-ipX z+J$ux&$@?|t4CPV5d9{s#9m=F>l;>YJnt9Q&i-MgjtuM3n6S=H3ak9&urwvCMmU8Q zKZWI*8&-ySVLez%znj9khrc$5)&2LdhT;|a{Sj8rtzmt#%~DhS6D4H0Og9UB)lDQq;b6ijLqVPA*E(m?hle!O|49Tb82DD7-2~;ngXu!;+#p z8&b3$2X>^$wlhT$oZpqA+PhP<5b1kTG;VK-KH8U}XZKT-_#j1Ha-^!z$Em7|_2^U} zRSQv|P^zL>jhuy3^({JlnyQYaQxzzas(xitH7F@nJ-emKH!@Z0=A~-Yo>c9?pnddl zFjb~2sY+KPHP6sUz3{SjBV{uh$66B_$Y}Zcmzu9#7N7%W3-gVVY(=O5=R1G;Pcj zkvnrlb+Sct0Ymdd)ZoL2{>vLtzI+j0pFH+?M5o*l{p5*gd?2C|-$hhoKty>5M&!qU zX%U^B8Bvk+hz{W#Cd`Vc;_Qg7;1S-;iO4jc{&4~Q7ethM3HNbhO+?nU5gE9KSL-6G zx;~=87=wRMa6?2v%tiK%5fy-cb3_Z#WNSo^QSwMchjHs%gx?z@ay_9B)Ot#exQS6O zBD#c^FC%L4Dx%JrqFRm?nWO50kF!K|HfvNxvPE?W=P)6ARHhtJZ9!@-w&QWpsFI3B z6~$rXEFP5;iI{;?$opwj#StqV)roRZ#g&h0Nu{Wgt3+8VA*!#PQPoR|>OwO6grln6 zjJ8lLsu38{E2`7j)jP_1`BAOMZuIRNRndM?HASxeQ5C}(l>a`ew)kXdR26UtS%yc| z5+i;f7uZHc)dy8aM-`9UW1?JFEUI4EF+M8)ged1uMD-7Lq(_xuR+MWJN3|2ZXGb+= zPL#Qf>gZhZo5wylhM(p~)o58%6X9JRRbzakuF*QaTY)6Hu zF`1{a4ST1@xISe}#b;u6OiS_MoS5!nz}%Q#VdK1*3NMK1AGBB)Q`s`21$7u8k~6cfB!qz>dW1k sKWLSvzh_lC*>u{wjh2;FGw*1YakTSZ-zI%5fRBn7!VN=5fPDGBO+y$ zj8)diSeJFl$Xp{MV_nx+mo+li$jHoCV_h;<&CDg2jJ418KKB{&>ATPKd_K?X^ZDz$ zIrp4-pX*$|&ULPHoin2wxup0d^Qv!$^nxJ7(aW^5?ichXL{E=;DDt6)rbo#SJ{TD- z%TZGwN|F`&a#U-=4O{OPF4x`?LP7f#pF3UTP;j#mM>hXqOl}LNjyl$;){6 zsC#s}@!HA8H^de31Zi}}KApAhUr$W<+YD2UBd|YmRF@do@Qn^{_1)sw06`dUTsLOC zHr)6dG1Je(GqE-_GnTRZ**&_T@!F7`%fi8~R&Nj{4vB$B4?p1_;y=!uM8oUGYlD8C z38lnHsi7$OgB#TIV)OhWhdv}gmb#Ir0n6?-V!l!SDarqUZ;R)%eXsOq@ z1naXJsYPp>=6pn|_mMYl71QLB^a|1TwpOY(n)`iB!oLr+=$=>&J?N9U~AKl^R-Maj+it}HdzEI(IEItw#6%P&Zk75A%iL0UyyPPg48IQ zPKl-t(NyhasyCWyMwzO#rVvQin+CL|My*t+15;FLX&eWwd1=%VNi^1Q$AxbTWMSsC(8oin{rj4e0(G(sk_|#}k z;R#hbtJdt^d&YwCGIdL{mEvk+MOKWOta=M>eG=Sziz>g3nP=4tE4t zO;*WgiR=|^^hpf%wfOiX6K&+g3NhH%5iSQzj2s&<*4Lc2Z0uu#Q82~Jf^C#3#t`D? z6C9Qy*eA<6N1Q{j`UF2K`gDkvPc)_hjXgPbj!%tfjdO*_QBy*!)95{NN{}tU;%g6c zM9Kkjko?#q&7$l({DE}wa!1G^?#Xh995yjh_R0_*8T3(-Eon-FCZRzm$H-CE2y2)% z*%=oaM3Xy7sTEy<&9qfKK<`#le!J+7lBezvyG7Y#Zx#!$YBB^@msZ{~)~97G`M*v> zk7^6KE|Ol!^oplf4u3D;?PLkP6fLkukXlBVLadYJ2+J&|4{?y7Okm9 zPvJXR_9A{$V{_!mN5j1)sJyeIh!_L6V4^&|ZStKieDVIkC}H`QrP9Y%AA zO(46QMD|v%HAPTN2jN9(w?p>|jj9LS+3d^O-OM^MSnvt=_6_#&i6Hk?X+wq0`lF&x z<6X9z*}>apOHH$7UnyKVwL)H^OqIzp!4(nw?n}c^$M$PruwCR+qTBTad=n?HPmN@6TMyYC)saG^z7tN;( zroMYjLTH$DRbvm2j*m`>PJ1NA9psp7_mXE+iaCxqSQ*wU$gN&fCo09pJ9&SvRt{JBd*u6;M}rvR zFt1W9att@(31RAdZtPve0@>61^*d#g%xN|7aG7j>rN-@u)_OOdRl05I6 z`g;d?Iz0S;;08{g$$g#1o#}aJGn0O0iZm1%JUT(Jj*_O?yb@|P*2&fg`HF@DQyy&@ zC8fpE5|9OVh%Drqr?zXU8DKL_?Ln6A5Y4R`6YT-L515031u0DS%@8IP_^+4Ru;Z|V zLa~YXOrj`f`_Ta%;vH+KlO+TlEzBkKsf^yk=$$qVT18Ty$uuOIS`3uyv4j29%>nN+%-xxejTEZ5|G+O2Xc)^ArzDRnr7>E^>5*TI~CnZuVhQA`A8WP}; zmL56oDlyh8^zqncO@5U&)=LhE^>T#JD~{S%sS6)M-_^!m)doK`Lh2fkADKSIO5^fl zsIM&6EB!5zJ`RfPGYyV?j6PPVA14#ZXo9wZq(#h+jK$Ejd`e|fqKg>B{)k#RwlG&D zwP!i1MF!48gT}_raL~395&Mv%Bwu|FL7|QGg77F3zEkHI(B((P`lioww2MULt#U03S$;G7TBd4^ouRGEm zCXdTlB5xC?HfrQK@?^^+)+IZ|BwN&eanjUYy{W<5)D>nrr8QTHrbeBqRb#H#n|h7r zPMx_yW14J>kS9uU3B*Ji&?dyl4@texh|v&6j|wk()M)6@Z=^>DupWH8u1~D4KS}Z6f|06_r}8azICv8|hU|JBhsok0Cq;@n|JpmExy6 zMR|&)d6(#pk;5#Lq?iqVd{0AFM&0|!=wY@#jfM8wkKWfv{oR@kChEy!c!$>VrdEDM zlv?#>+PzMVGIeN8)jCs!$t1XQWFIn*CIQ(!B4M&TN$MQMOs=~xAzYTEQvvSLE+IDD zt&0tF>C(f3AD4PWm#@JG%iEmfAiXVGsmhS>JFTmO%$-!{CI3z5h_nf=qtrL4TbJ;u z=pGPlK9l-r8fgVYL`O>JL`VEqF>>l;stvVLpGJOGvt1NqA7_I`s@Bq0)k)i(EJ!I7 z4TED$EuvWpvBsMoEcJ9#MM=G8sarCqncGD3fW~}EXKvA%yND$j7jVZb2*&En z?M8E-#@w$lH;O2b$wBp6b8n!z-J42eGtG2}9ODuk579Cs$yElX?p1&DfVa6pXFjDd zcalqKB5HLBG0_i6O;EBLId%w|me6YuPzN5&3!P|PH_)RBWL zLaSUgC{;Qo2ZYx(o5hb3KG*aulG?O)R#fkaQm+AiYZCEi$lw&VX$K~mYe$<8cp>Z@ zAylm$mP6`G^v<&zrV zgCV%-l$jo#qv&x}PmeNsHH@IbQKu|XYDDK1Q91?Z=Ftm|uha1Iu@O^I1vYKiEKpH) zgRpxfJu1BDv5{VFpz1T?1Yk8vS6M`Y8ZT^06fbCFg9;}~R#|V%2rr)Ih_@zN)2uPp zOlzJs&KgOr7;BWhR%3~9J~u*Y_oh)L<}T5ERA;WD)L}5!(0qyJc7wTdq**X{QFR{x z*LR4{SG9)?2Yh@QANChs&~~s&S&E~o7V7wr!9F$Q2p_B@pH4t&^uoc(SN4sLu$IWr zinLpj^H3wyX=GDufJDbedPc}T(Gjv)is$cC6iD?tbG6it~J+d%yl|*tB7c9 zqPDNO$`6C;eVxKtjo{N8WbW3e&7ON%@HT5R1jz|681p$m15LdFk`NrE)@XEifNziLN#!8g!5Vc~ zNgJL2G)f12Bq20_5_1_sg*aD_php$Ls=;6jQ|dI%*ELf2Xv$=g;O`|(CT%0=6-5MB z5uLOp(t+6?uG9r6JzAybE~Q6Dqm)6>`E9h+951zMr524eAX3;%{lr9$l;UJTnr!RH z4E|%L)RQ?OoX#C|;!-GKXy|cOqz7%XlzR;H7#c+nikmCrrS8e5K8+M&>sTH9$JJ8H zS_%fKLnqZ5CAv^BHS47&qtve>gS@DKuw^={p4V7tjeWUWBMt5)D@ITXlCJs?hZyIO zR(@S44L%}Oc}d7hm;$V!9<4O!D|Hg7P8#x+LTD~gVs?xF-v+@|zEaD037MZXK=I0) z11B|UvEod%G-af;5-;b;C2|qH8b$m`q3qwLaZUvofethP<60JS<&bA=L#- zy$?ujqoh8q)H9a$52=wnI6}HULaGy`qjyQ2cf-zBQR>%AZNAcwkJKL^of|84JSZLT zl6tjLr(SB-N#RO?B|^EbM=BiBD{Ui`qk1IDepkt$pgKj(&VR{ z(m6XvSQc$0YS&1$K2opRrIC&rsI-!As5JX3wLXOvdLpS{lvvm)I&2&Jz&I&{Z+*2|x^|!<3ybbOZR4n@BNXB3wciAd?vc)ormE6>-9VSIQpkQ0l`Px- zaVEqzS43p2hN=*E>DsjECH5tUMY=Yydkw$Qm4V&M{Wk-xKwF5@Og^D8-Tw4w(8^xB zh^JA?p--o#Qxz@MnXp(XJm8W6MoN!gYO1_#9X`Q-^f7h$SbTSg({dk~T8)B(7WcVn zluE-T+AWBsuGq`ryI*ILYV(OfO8`Bpv24%5v9x`Al?t?yo9Hy+4#9t0MZs>)H5Zx* zt@pL1CTlMXF7O8Y~$8NGaQKPnFGwp+}RYv9lRtnMF zcc>m|$GlXbR_hI-XM)8w}um+_SxVK4VW57p=`B| z<=G*W6xUS`sS{~xBQxm6oN!jQwvDDx2$N1h*>hT{eT0OHrw%}W`eYf23rj~7)NalI)=*hYi8 z&lj1YPLEvDt5tfbd^e^(XPq>3|1cFDscGLLR>Z%_pfu}KKOHxzVgmUMr==kOfC(n4 zgz`z9sKlYv>Cieqr45R9$_diZaZ(WN9#O8+GcoBM~a)Siyr zk9NY=iP-MK>1dtg$h4*v$6F$80SU?OII0Sk&?yZkw`rCbIzmS55$QT5vM@QJTC~Jx zBp26G-te=?21w1Qdw@04l}v$`N4)3+=uD*Z zUQBwJHPI5{46>(DZwgI$dJ27U6XPTw6}hiiOf?eONoBE#Hdop#X|H7~! zR3f38Rt?NyW=T@TMCrO8mG($Da))?AJ43FueXBinKMp!l6tN?ZnF{E2bq(E8NmcY! z2Nk>;Izi)OloCgw(n71uTN%(ge|eYGa}VX+A*WJpR<4d!IzkHvMz~rKeC8ioG_eQaN*F1wp_a)Gy8Rz3B%Heb+M2~Lh za6sowv2V2J(0?iN6|FR2GW$BGQQ1o0WYU#2?xk>^>7mR_-$#-O?EzFFN&*F2ywo+8 z6_8go3h{Lj*^thL6V_wB`V8Egv21z@S-%ce)@Y+cED^NqTMf#9FI^ZYOumZPI zjV%4qXUc|MVqt}^jq<&{%D6>r(4mk*?hK(MSb(~Ta%HEeyla@+>E%zSBU^z|XFw%X z;iXiKp{p|axd~GBeb^YO8;L85mqIlLshO_TPSV+3y>MwwH&>6Q=) z^cCbB8YS->E%k;Aay=+DG7^LLa-dN|l##fG$_H@LnhL7A1U2D4kw~9k8H^&N5VgQiJUT8B?BAbc;#}EmmrgNv)bK z^c|b67q0x*}vaPn3oMfxnNRR$U>Cxvk$y2tmTR3(`z3xY5 z*W;RGz#BE4=S2Yf+M*U+?At1~OAetbWF=QE?mrtMXa?Ciii(tWi7lKavPh~%ZxvF= z)w@*!A{_LS&RN)X0=wd3^83AUXsf0wkZ6Z+u1N8yK<`MxCHPF8bW))TzDg(cSfm<% zX&@D6!fJm>P{L`)KrNpibXqe>szBmoh3GkCFPuS`qz2^8b`#1?cbIJ)74d^Cv4V)* z`wSpoU&W&V*manC6?J4Xz3O306FTd09vMW*d%$4vrEnO%DMeW@^{9q|t;KIqo1a9b zwo!SmMa7>N!7rxWAJ%|8k#Fh|zUu?*tr^ZM_=s*`_5%R1fx$4e3aV9b!4&YU%S{(QErSqp6p0XclrDdh442+F3im3_ezL3I^<_v>lz5aZ<;Q#az{q!=k8n7;PP zaYwi&+Oww);rqgnJ6|sPZ2tjvXa9d_`&xaZa3C1Pd!i-<(0ZvB<<&0w)=so)=^B5O z9Q6=Iyh|vi?@#i>9AWgmwIG{*R3nbp2JOrVqaS3wogfHBvjk!KdY!P3e$q8wJ9Em< zGxv<8pK7fd@f`iwYr0?{vOPLMI7>hF%EXVo?g}%G6tfMZRhW7OfqouVA&8@s-M8LL z{}{gvOI=08_4I=`74{Q4=K#)MO>hk{QsKb3H5GteSp**>7%YNE|Liq@#cl#G5es9M zA+v}8bcQC6dmNoJa;P(oT9pj86|KkuoL)lkCQfVX{Z|jbvK0j0=Ac|V`5l0{P_Tly zS2G6A#s^`(khX!~B%LbE)pDT`U?~_};|yFae_jR9T}t4AVGCW2u5TF}NpL1-;O^@A z9N?ln0&h_ZCb%>I{zrgwatVwh1^{z~dtU&!!cAZwftwk;sr_wc?)+?m%Q%C|mhN=W zI@S?5fm*5$wnugffaBo<;?3dRaqrv*I2o2jkz$pCKIqT|uS`3E6->&((bK*Fi5;`E znNP!^TK_?S`50&C1|9DG=R$ymFsPGS(EV`au`2)<0vzDrk?Sii0!#y_<5nI{-ctCUBnKYkF+}i{ZW$PU-*Jvseehdml;)-RY2^I*bO5@-CeA#*Enh1T+#R%YKUc;Yx|t&UM%TNw$#rI@uPTt)i> z&&2|qht+YMKvk@BeC!*5a|;Qs<9uCX{6_;U1_Kw-s(hVm9&QG_8gL5doAK5B{Qzgd z$`)#=>!Vowl+8yD9BLg_t^BpA-+?+C3%8dVFk{nSv)Dp#As+gu8(`)8V;6yPJ)%62 z`~k51tFC-D92%sN25RW-TC@2O;9?k2$+_-+ZPfh$7rF`55Cc`QgJO;ba6Ei=j1&Xk zgYW;n9bhV)bC&q3v?soLSpw{UxT0Y{oc`50wIf_22Xf-yO}=Ka}#vk@5q+&$-i zmAn|>9JuE&wK(l`Lk!?jOzUP&duhDOhcQ454{_Bl%{LYSTn`3&hZ)?MKjk{$B>2}c z?B82o1s(vr46f{;7OcDU)fR-GkPc8YY=*(!I|Hx-UOPe!Rkce`?)d}Yr7$|5tLDEW z`3S%?s1`{rl{Wa|p??Bih3ULX4b^Y922fD|fPmFdZ4Nn43`S??mPiR${T2avjPK&6x|(3B@8gxXE(&5`blJ zJW>>MW#wp=mR&IR7`LnP&~LC03A5Y;3Virh|C5YoB6unUs;hoijs*wTWA`UrtA82yQsBff{Nw9J3T|1-uY^ z5dtvb*rC*k0G*gb8=0Weo~;af8E_gLvx^&Xe(w^vSy&HqTZmRw?4rEkAmBteJdAYM z$~fQNk;;~U10h8t7^wNjTjiiFg$_DuK?lRmW7z-~K!-5ZjbnUoyWV5YEkw{bRn+a5 z-98ee`B?;>Bw4Bow~H?`c&?k^K~5Vyb)1v2g~OVt1zDle8fI@6ls!kBHVejOhRhmj z`KlD@PwimdE5a)6qG75C_a9%o8{F1F^Ki~B_o=Tp08B>u*fH!8_v^o7#a1G`S3}-Y zXS>`avh|M5OTRaguUAhE&&2dB2NvSk(QJLdsSrW2sdaue7;%;3le(~;_gSui?; z(;mq#`VBxQ81!@SxHS3(z{LO!!wgQo{t`<}GvV%A)DI0#zuxK%+ErN3GB@G$j77f! zm<*p)kk3@NpEvcM1)K(R>p1O&*G>Nd=!Dz14-32W!KqHbvk~`A)PS%{+PGAJC18+A z3{^%tK6mhT-fdGzragEP62^fK;WwBzON8q3MlQvT>ZjJ z&HyfkzXpfl;2ghq058Sr4d z9l({aD}j5!**%jb+HkmgH&-d4=`|LIYu6Ik!zoi!zH7wrR7_$m7bM4j^&Y_K0E;=8 zQ8kUF<3yNwn)7tmX-b$%ke*CDE0|LG19}bM)nJgy85B0nL_`Z4+yq|d3gAN>1BOokIzX8~l&Yx8l*jx5FGuklMh$gRcIEt)?P_!3t4xC7 z>Rqk>_%mqB5m|JK=8?58;Jx<&=OGGraN7MT@74oc3dgc`%@y z1^ish>SgLy6+4oW7YAB9XoER}eNn%76yQQQW-B-Mc+_pS#_DgiHo9;dh-x5Af=0GNhERl-Hx((Ps?cR9Fj=Ug=}2E7i-L<~Q{ha28F zFc#n(xV)A?)j57IKC_02f_Kw6t>1^&S)rW+t{I$b;M1qro{$P%+h`1|3ZCivFovgL zb}Oi%at(a(n|lG5zyrvRpq=np)>?o$aO8zyTHDv1Y~kmF1!=*Pb>N3zUI+CoWc+Au zu6U?B_1Qmv4KO8(!2QEc%6((|7{Ez@TL}hj{=%v+0A?ZHM^i%;TD+{#3vez>@1~ZT zG&e2WtFZ(Z2L zv|R}oP3A7z@uHe@*CDxF;JWTw_^&VsnhOW{b8z>)nWF*bK~qctc}`Xhi#!83yM z+Eg~|N(;ocO$b5jMFf@r8D(&Gv{m2M-In?Us8thnB zxESDkFeoDiobS4trGOV9>zv_yPkdIJ1aK8{K5`ngJ$dhAH2~)TjG&gv;LMAY)&X7s za|fvb+Or=%`zFBUSO7VsftsH#-|HR)cmr%hoeJ7(fBIt@z+7m1iD*^6H}#=^1iUJT z;22JOYhlrg0Ow^9c<6iDnVaVVUW2)f*LmW=@6xoB42EspWSbfu!O`EsuLAwOMoQnq zp0EV|k`*#`2t-t<)V755hd`YK7&{SkmZRTG2bhJK^CcF>hYgwZnRP~A+Qllu^;il~ zq$C@0b2CfLiy*X+MyMWf85V|uQM{YrA%a1h8vPd*mHA+h${C~vj%9`2O1QL?gBhh0 zpJjSr)32fyhPwj~NB~Qb*>_Vz6;*n81KV=T!8K*rcbjfb(t>&g=I;zOz+%(QUta>~ zg0K=UY;$V)6@YF8fPq?|+yCXjM*x>Vv5nNKVbq6i{^Lu);h3mI znkcY1yl;?&b~YAw5cL8)QhJlc@N{S!PkdD)PH+B(ZTz#bj(Uj|XwRJ3_cXY!!4x5u zDj0nJtjto5|LEJRpk0dulTLh9)%@0fH6Cz0;HqKRVocr% zI0@@HgBmKe_4C`00bUI1dZGqr+e>FymRbR?c~LI|-`+hRl=CoeWy7-(yZq96z^g&) z$7y3fiaY>t8HB}BLv@eiB`xxkuoyG9om$}QSTvoj(Qw!%kjbiIsbf1H1ntZsg7p%SsKs$s*Py<}u|Lpk;U}+YC_1wF;&uwE1#R0I3gBcU&vN*SA z6PU>b6+ZOZatx2pAu!1UexCdZz(T0MiG!tM=l=oVQbewwhthbMMc5iBe~5#*51nLN z^aiAigJdZ5%wPZEW(>~(xR-+&FP(S_U_8JR9NfD8F9=E@6@I!+E!C&H-i-Ma@CwMk z$!*&8(aJ510pw#QAZquPEXE+o4NBr#As9y*GjGyhbniEMLsOv?{Lk|-2jBcB)43e$ z{g6sI#`oac-5-Fo0HJ%48WoJgkvC6%4tPG+)e^4Cu{X0>x=u%YM5!Fy#~=F5H=s;e zPhbO|$0K9^vIt;0ih>4i^~pDb-(nyvIZ7>6)R`?0&H-GGIj89mjI#~&qqO1fH(z0e z#0HFNBtjT?@udnjQ_C=Y<&2f_SBA{VG>WgtH&?P!q6kbA2*#+}6ORNz(pu>6KPF3_fPTJOO}j{{tQ_-f=1@M~*+3E+%K0t>mV{)0D|s2LcZ!iNX;FIo=D61ep= z2ZIy47Xr+|7S_vohW4*}8{l$G%PvlNYs+&mRhW+n^y2=TkeBphfGH4^$|)yw_Wl`Q z8it>shU!$gEwmW$JjnOuqU6N+#~1@-uW+t@>|pv$fMuBJX+)`hLE<_$1ydxX!R;6Y z2d3uTy8z%^q_jvDc7QXQ16+VtL5F&3FtE)v8{lH_P3Icqo-6(W;CfIta?1SrWvsMb zoK0XUbz`_Y?@N}V3gPNxu4{4gg&i1P1grX}p{|=vX)CdJ2+I*|m86ymZ$0-LBqm`t zmfqoEcvt-rRtT?z7p$D~?&e084;DbNy);O5c-}oMZ>~aU(7&s|)jwGsd;zq}Fp2OSlsaAg;8Ml_u{FrSGZD|S zT4Dw$n>l!P@I`jiEP`J*k|@=$7yEC$3kIuTfQ1_1daSvv8ekH1?ci!%9{h~O%PMe1 zwpSV495jyvZGJYvs7x7yvJaa8mS9?ZX57>#h-A@gO3;pK)s{ofFlul8D)4t=!w!n2TqjA{e z=-)16bG8r~=L~aJ-tk!tChjbPck>um-l=5aJST_1bn1pU`!^erri5i~0xuF@Rh;wV zCzy5NP_3Q%LF;&wgTJ$ z#7Mi+bAk4i3Bv@H%krp$1rZANk8K0M3Lr@`wdMf9p)9+EO=x zH--ZybZcl9Xu}bqJGjx7-5<^X=s*+|Q40(v9GN=?;F>G~Pjku%CqHEs(;R?jIB4@; zz#O>_>n?zXsIwh=dCN>NaDw(Qr&aPNvbk^}OIS%Qh_YX9W>zf)deuYX5 z5-=Bm)KX_TBmKGe0Ox>(KWE`SdEs?{v*4HzE-cq^G7(@Bj4k(o!S7?C2ni5&bXZt% zYzZtE)*#~Br~$=FcWXF>c){@?1D)`JKaDZ|)R39O)jJ>jv;%C)V8{dljc@2Pk$Tj)xVd}m8FZ&Y zpKj8}c)uZ&{KZtbwfpa^Kr4k8{ka!4+a|D5YYyh-D5o^ciM|oQ*&GLT1%(CY^ zcqWlRH3L|;{rX|h=D7*J#?`dF`y9)iGr*vkGmx(&-2=+`n6Lo?)tF28w(L6Ke7H7+ zT5wmwBg@&cSr0oyiE9OeT`x@V1#KCYZXOqwI_FIjV*nFcsaK`V_;xBw)J0$sG|VE` z=eq<@muG_o7nl3V(`?V5i)FrvyQc7wP!vG|{iS|7^^?A;kIPr~j0L<13=mb&xBPb@ z`v9i62^`>xC0serir=N!SdMUT^CMZzUrC62zhSOB9*IG)3X8GOW2m7D+w-lCrLb9u zkYIu#Z0`#%KLOe@ti62h-M!y_{5Zf_P|HoN3c;v1W?K1}LywI6Il2oWw#x%v`Q|df zbufDgH~Zj~Ddzz?z3%+SS%0e*9*y zd%EWDUx0Qk;_N&%)LA}%;M?Z`C%Xy0#aUeFIfj%ZECy)MseCUs-1`*3r3gP4H6ZNL zwBNHdwgFsk41*o)+_4INXdX7M>=2;0F;@V>wL#{f3~baOEH zi;+74mSKkXQA3q)`N;}Qim)Mz;0Dfh!Y_XIBm*HI+bHB)p9yAFSaA-4G6!ux*~j80 z5lU6laMjq@XHLd|K`C6bpSwHu7x(M~=!9Auxmxz$bTR`rK&?I0t1@u@>!Wng7J$LN zVc(|CUGrDKsZh*HEhv`$g%l5P6?DkuCS?3;+i8HMMFcibOI;I%BVS=*mzWJ&f>ke+ zKJ)w}P_J_ne3k24zACI2U^;X-KdeLL$SP!DVI4fSi;LU*j0NWt!45MHP($TgIr6u^ z0lWgMy@Fbmg7HB^=0Sp>`R+$!%h5d(F%d(o)KR-v^&SDd9uoF&36;O!!ZKhI7EBFk zvzdMdXn)Qta~fxM?0$Ac66Rz5B@%&Z@tNQEzYAu`Sbx~#Rrun_8n(8bh`Z4wLxpdw zDr1hAnM3e2qK29`?%)3tuviXX)>BKJBh9hSn}7>o^LDO<=Gf~jdoKk8g){IzIGed) zC4_l%gZz#i8i(P9$V7fRRg{0m85ZQLL3x(*4BS)oFHo*P;JAoVbyMiEDYpR6!%AJk zX)Sv`TMMup@?F$|0T$b~W`G-zKr;FCTK!fn0Jt2(6Zvp!=&J(&ofwX&@`zgg0^mG2 ze-mdA>-;(dpc|g;p%z3bd!DrcOu#J2M5!`JPzE0YoQRoraSu4Qhjs$YMKs^$pfmKw zCjjSS@0vgjaCIK5J_>LdLOg>g)fuo9zBC?i3LI0U^T7EBqdx^)3}F_cR&^+LuDt=c z2=i4-4VB5J(~pG%UWqVo=eAWIe03whgd74L)KXb&RZgyEV`HD^1B2XUYl!tF$V;Lk54hv!2LA%c{`y((Yhc0oP!SPKC7=v=y+QsFc2u<|| zWjdw-lZW9aovVrf+T8@+=9H%u+hu^sn1%{&^ofjLGNTtl&@?XS?4}Q22jz5V+Dr}b zJiqB5ELmn_o4?41U$}N;A}Hr(5!lATv)4XZ127Sxg+->8T(@lRveQEj92w8K-nzE# z9ncnFP6D~6nkl1BF|M#FfLf4$YtI%osdiZ3$tk^`_!zsV;DGyVoTuNH=UHMZ1ZePp zpN?l~pbTI*2Lr#%WRtfN>bG$9HSc}I4pj5tlF8g9p`V_}gP=7~o?c8P%M*JieewOu*b%((npKYkM_tF5nsPejyhnk9+A)0O!NeC#j**#=bS`4B)kJiXZV+ zV?AN@J8T)wKzh+|7LG5|?*pwJ&c-$mUpbcE^BKU!Q0xLRQ2C~QI&wFog=Mj%8YT2+ z==WKCl>3RV*#R>i-7(Y+R=MNuV|i*8%&8_&WmP<7iVm#SLB-MB^wOny>?G+xqS-~D zI`P|IZ5;{PT>j`=pw)5OTkqAgbeakW$(-x0QFp%t zN;g*LHKH8z=!ghykM`@b6p z4E_J^^*`yunE#U(%YQ0eV+F_$NjK>_P^@`_Cx%KnCJ8V%lH2OLT~i_SF$~0 zJv5%ro_FA$_MPv*J$;_`o$vj3jJp&6pSHp8-;D)+XWtJ$|GP2&6U@W+f9IY5-v;O+ zGO2hH#6NiB|9rqG#Nm^WtQQ3Q<}c$v{(V%y?0;TrrKgFEWtD6JPO=xM$JdKhfVTF# zgHWsGqfGW3Fl=${3@lhcAZl~eiqXQql0liBMPL$11Q^@$1S`{vP--40O7&vX*|KX8 zw2lV|#tjN+okjla8aEkrrRS%jslBP}D3l7yJWiS3ew|&2mjT50GZ>x`cZe1AC6NF9 zwO@MCoNkE9!^O}6YE>}m!j@5qfZf>ymkz_FwSQRxxDZSf;!FqVFAVILpOCSsxASpy z7ogio-2gX_PGTkfLP)?p7NZL6;SOGv7qzX8wU2HAeG>9^hHgFcU={9zOnFQLsdGwV;DC zrkY*+Erqs~9JEh&p9SS2c)><)0%ZdIn|=US!v{D80d#!zZ3e(>PW6ke2WB4izPvgVg zYhEz{+>l3L0+*gU{scQCPDku`F6Z)J`-2{o3!waF?kD$?ue=5@7XjtDmM)&3G74ZZ zEV@lCNG~4$Dmx(-x(UP&B>x(h+) z`A+iKlcnt9%7I`$MT1nnC#OHjj@YuaxSu@sMS$V(@kVNZ(%-U^<-b)BhVM7o@Eh)SQ08KbIHB{H5$f7~ zFW^-$qnKKJsqXlO-CZOihCF{uz~;a5PoT|*D?PXL^2I4(02crpO%2sOu@~QGF;of@ zT8Th)kHhuxgP=|Xe34pE%~AO#yE9up6MXg1K_9f^-VyBYeXIIpeD&BIj4K6+ok%b) z|I9GuKWZR2{UoIe1H)RCCBDhWFZaeI{i_Pr}%)tpxd9w2MWKgbg6S!BW4!VSeB=ccTL9)k>k>{G zn|=Ehz=eoDE9a>!xXSL?)3HpesTY%@Og)hT$`nwBc%<*lnE-GWtUJR&dB&9G0B1nZ zAQ$9(J)7nJ^@x`W>Ls3Id|jq5{{Yf#Ec2s$B2w3$F94Vf@ewMiJN>CKth$?tDB4a; zRiC8Jcz82t^D$}XID_2ROW1arh2X+nEA-Fbx%B6tTnnH0aZuK#KMSw~)BF9;2ul|{ ze;n{!#9TMEz@Yrs;Vdc6%O(&@Q`Mk!?RpJpQ;@zkau;ltZtMcM2-en8L#3@WRaXOE z4s*|twko_!dZ-WZ0*J%D2XVWf@@Fxc?Iy5-XaVk7TgHq?!%omeLjdlb+Rb+5wJ`Vm zuxs{cpW6wpiBN1iDW(cLB;970);YNT-Anz(Rfgfe;Cc9ileaNu8Qgi88*@loG8>>9 ztNIc(AoSQ&p%7p(ypc{VfG2jgvv4TH%Z=S1GXQ?Kl#CX+d%1dgObm~&7CG@T z&mkE5A#}C&?PvC{Uq+xG4FYIuHL)cg4o}_SloMK;9st)A*pF2SO1bG#cv7&#s?FR~ zTaM#CfHMG=b1-(m!8XD?ERGKDX#2p-D{MG4wGgG6DWjW&Ujd%AfZ$V{))h5&Ex_U| z0`1)X)bQC;0WL>5zVuQy%}@ZG@rV z!f?;m@#P&Y-T+s?`X*{X(59*xZ0}o;Lm*lJD?4IYK&*sHrwFWI@K)WIEXnMT{tjByd2dvf0sEHxFPLc%yE> z@VzBd-vc-U;dYG=cctvc!WDAd1mYKf>VE0&3tj*?6>u}bs?NviUSK|(4o`T#h&tYs z?F-sc>F`A-5vVb9aiDrNsB;l?#oX-|tMn`q ziy^F^gO}?HJ_2PKwz@zLUaO1g0O&@@7xOm2Y{>Wgwo&u+JWQc52cS%%K$0rY$0k0$`m zgrH;8s!&B${T%C0*Z^-OvHHUJSHtkX@iO6S9gB)Z=ynjDI?8hInu8d%2(zpku1aFR zp3b6uCA0}5ZB#EiJ_}|kU=5bbO&SJ$ociOLU@;q^g>L~X1mhnJ!@uK7eeg*mx^ofF zrQBKRZ&WeI7Q=?U)U9fh`}6Cp{w>1F^L%%iufJCY11B^mRXA<>i;Hpa7ZSlYmQPse z*Y?W*Q;~U(b7AE()87JE4q<)Ng4X3fKVA;d&HTZGtMcbM0bo9+>jX8_C@TF-S_*hB zMEP@3+aL6P6JQ=ZH%NMcYx>Xs$|fNfTw{mbxp!vy4ba-*&Ja$!PoH!XU>Vdx=>Z1& zzZO_NT?tW0;s6i6v4_<`$q2)C8m?ZLoS3=o3>Xw(-Su)~Pkt>iu30EZlennUGlO3M zwojvp8`yVA25H=)jxVi2*5Nqfd{y*!JECh0M3M|{?q_v z=uOS<0Zxa@hsZfgLkjG=#lyoL{ieDLB7N@Xl(~V2kX(fIh(y@Oh8x^h z0nWg(ZsYbBmab%5V-8$>fp}Ih+S1%7W`Q;vzEU`CY2YOjz%>Z^NUr{-+_%}qQ6AI} zWf)a^o1+GPtjTbKNze zy#)+%Feyj4{9T(9b^$EIs@3Q{49ahw{4wAeST##H?Y>g=l6F3XWsoqaweRrmbWkpZ zS8o!iM$3^)`}P2~V}%{$w8svw)dE}yXCJ2q7#yFVXIB(Ou&dVtmafkQWfGj-!5w(= zaHj@f8XOqKl{$X2iY?3%7;v3~XLe~_Y&a$m5e`9T5AR_`WD#=FWHOa+i3VpVXtQ9z zG_L8z(#f>|!=e5O4qi@8tOS?{u$6;?gpWq58xP{Tk8`!I z|1m4hS3=Yt4%%L-Sq}#5FsF^2>x9o=yaBMNh(K@d6zi5LOnx4C;)@r3P%-@zl7+nc zvSEBD#w=ez-FEH=`{(nb0WO8fftrofDt`3n=I3 z5SUCYc+5KSK9;izvk6QkP@RYLEzI5oF)2-LY)47bSNQ0?~e1v3FU z5zUz#)YQKn4{$cj4d9k(@@^akxD**e$0@zNUiAl<4G&{)1y8>;_20Zo0i_pFszwA> zXE57R5aRXR3&EX@e*l9Ga7{losGyr~82Ga!h9| zH6TBs|BXKbT;L`UKloGq>q>l%xqTKi@cdLV)l0)t*c{k*iw3E}GJ>pmV3CRmJvXdF zZrgSiXLGX&MwA+VZ(#pQFT@slrDb4D9;TJpF~5y?{MXD294@+(DZX5Bvh)JPbe0hgbHmVEgup1qAw%eN1|DJIk5{*x`XzBgkO7SJo; z!bt9x+iB`oX-U{7j&QEGI~&-Bz8nrLAxc$)n=wBv0@p0KFn|;TSO5D0S!5Lg>}47l zpEL~rJ=)NhpU=UVd0;mGa0y)0#a$G8_Y*z<6XA9{HNanadG|*EmqNh< z9JK$`#;&-su?&km!(aY=Jt)`UP;}BW{I}aKvEfj!X4sjjA8$(mybudEjGL1B+q=F4 zn1wKHC9r~N;Qsje9e_)a(FUmnwQ^^Fzyfb606S%e%snJZTQaqg>N zkbpdyH_W$kMB_xjMcD-BQ%m*o_TTz_1~@H;V1x|B?YR3D1Hc^6!l3|nt*B$w%v|_u z0`;m4_TKkd6=-LIb|bZnkADBpZtedjm?fI^=q%%m4nF@ebEh3q)TQ+pet7ZSY}qEk z%cBWa=kD~w$2-737p5Pimg=Un5C4c2oU_*wTuY{_e}VSK^TkLl!g2^i_^8ykJ`Q7N zh6GUW=Z?C4w@a-Ap~pTF2rF;@-PHpIIhet4@*Y6L{$jQm;$eCe^#b(1HHDpS)`Mp? z=cx&v#1`W`H-YsuT$LYq>rbrc&%;CoaoXVBbFC1y3I>-GXnfi*{BNIGf|o8s=Xxw3 z2Ujk5_ZKY3=RxCU4qCUq)ep*9$SMO|Ih*&D5dc>rjt_glBi(-jI2&3_;95i<`Q80& zIKT)F##&b~o>`C{!v!h96>LE!U?$Gd7}d5=YZ^-+`Jl}tS~V_WPrif8}}+iuxe;2VU$iSgF;8 z?Yx0ykaTe9;cP4O>$@<1k(8F~FVq3d1J43#f#<;^w^ISGhV&@nY5c}8{I9hfKA9hl&NNtdlaDyE z`^QYR1>n7v^R@*$cY<;S9Gl3sIA(o}d3yyy+@DX^35ULg3B)EqDV1q)!m3_jCLpwq z5=j3rEd9-!0?z&7{x?|}u^71)Sp=G2JYPKlj20{)u#k(qeECCGoUDY6HPp@X{;gTw zpiKZ=&l%jheClI>#R!~z)Tm&5Z|)!R1-t=9w{cp-m9;E~PlwUFNiCJu@3CkHXxC;D zoXEBHeIW(n^e{;9`j|pW#emI|t=#^ndF+5=z zKrSfycTr4`3vVJoo_Wl|j4MTedC_3do_*m#mWN8=^AIlb?6w!YzQ;4bcY-tD z`@Z+yKd<5D-g~O*)TvXaPMtcn+|LP^Nh;)K0i1A0ECDxX12_mzl-2ju+2;u8Az+vQ z{$|xrLOxw3fu{3m&uGdJ`Ms zPp9(#1e{e2!TH}!{~g7xB$1iNTb=WP*S;fQ7LkuO!sEt2u$k$S3L;D8WX1O#w3FiA zNOkswD&i&;O*}^68>opL!2|CfU;ZuA!Yin_giNDi>d-7!3wcB_DPJmE%Y+8T#A2fO zGoIb7B9ocnC3YtPFU6eqa?*4H&L^y7loN1P%nGKGH;e$##7nmH{j_w7xq&kJn#WwR zMPhQZgpyAdz$gCB8ciB;wo%n^F75k=Wt2RNaJB$g#j;xaM0g(pmk_02b4qiowdveS zLQsUbn)Q0y(0f@uEF#&8=dyKM-v^r+0wRkvtA_WUzB4~0@O&z4EFP*P^OGj;8Mu3F zs}54|y6Fg>j1p?8a=+=jlE66xj`f1;=j=Yqkde||;T3?Vez}Zk*c&Ko%8hvU?8LsT z&CMoNegs5nm|yyKIcuNGNmzb~EGX_vMLRkOZzdsl9#2}_WAE>(Ch$`9px%#qoa#I2 zaRTNOa6M<#*)7Xm1e`{q@+uz8?_zB&4}AOEf?FwYCb3phwJgtW8MT^#*Avjhfyd^= zohD!@b?~z|@I%{=pAzr}lFrXK@QW?OSx>iwijj&?D#q7y{xpPQ7L#y)k0%12|F-F4 z0_J7`SnLHp`WFIDp_s9p&X*n-{U!l7l4M9=I!kWb_$LC+BA~@v6Hh&{b{v5h5cy+4 zl-4$a=PqYDZ8-^yjiU%_s7s@`<;0u^@IZJYf6O0F!0QS46bCwQ-L{EI*0U^{Iegw>#4qy`J!@MVz6$IQs%z2+DU)ZmMsf|)ds)qAQh9IV1m8dGPpqX(ql$aNi}jIP zryL*zg@j-kN3iq3?F_-%OaLF^Y zrxL%0as+q?k989KFqfXV=}8 zL%>Z0yoUq7Z|GOYaFS@e=Pj!8YGM$9v$6q>#uM@C{0G~aS0j5mfJ3-!1ttx-j$$sR z{8t03RxOba1>Q#BC6w7&o|!YLRVCmC%Is}kfY_w9OtThJkKf8U6~8)%jfT^S)$vF| z`Ns#Ru*S8P*f)a%V_zN3DV>!hul3rd*z}X}PD|y*gpWnp#id^Ds zDw3NASiR@{O};JsT1rt$EQ;V&v^MFD{R|DI_>^Z@e0Jh`0v1wpz6%e;jpE{q4-;@% z8GvU%MHK_z{OZZK2)v$3m(CF^{jl~v0+tij4>@sLSO3TauZ;3{^8B|2Z?#j*9IDJM zNUn*0olPkxI7$bZ8mA zx4M>kO{t7HF%Mwk+I#0GP9xyLOaS+J<9@OF9i~S!sn~%C*NAI*Du&hcGy)F+m{7DQ zy}`QREE3o-&WrZRiy6I}NHZurvz8B)QH+A=01iaiD7kXwVWt~5QOWl3Wt+5T!2OP)p<#RI5O>b!l+dlYvu@!)=Mx#HKnwTi$cgyLC_ zV&LziHWP4O7J$S#B5TM;pLhs3mk>O~V(dH`GuTB}&xF~gr>dc24_f>hLk zM#I!Uzu}_Tv#CQ3K_+-%N6M=6o1NeEAQOoR}D|h~yzzZp}2Y6;X`+vsFjFLIK+-w3DBd+-a6FaL$8$6!+sF7uxOPy&jQW2`N!#6N(SWXRL8Yi%M z%`T>4r;&;z(b3x7rymvlo$${i1cSWUe*I_D5(3Z41h@_;wAkN=tocs@Cz9A^;DNIH z{>o`a;&LMKexL|_IPd_rBObxE6&F4KcP_%=k4L;;Elj}0UC=`JpS!Ah$?L$spkJRx z(B+>-&_Q>KPvLr)e|+)&@5B*t|Np(Gocy2QNtIvS>FY@UEb=Cpcs`%QT+c2ngpKzDO~?M<@o<;y5-)V7gR4*esbdfPI1KL zpT4(u|G4^hf%}MGp8j|!jX#XuuLkce?$uy=di-%7`7f4LtXt5 z3a9s~tEBHOu7C;L`uo2M6ZwgF{}cCrg_FXoaOvsPKNAi5ckwJ})4z*nx{GjeSJUJX z3;G#WnqQA)-Zj}`c7*g(J>g{3N^$0j&^Uw3{G_a{|BX)1-Zo(2-)Nk;W=&4n+>-2y zB3QuY1-2Q+=-2*cF-Cv-p2gfJu*8KJ3jWd0YN#8U3~RVaIt}fCb(Um<(N?Qk4Tq5?avF|P`-Nb<`0q08c5+yD3ZfaRB$uP+-v ze0WxNankyn;_Q;7f|B8$yqx0l;brBX@`9}4$(}JI$Bex8+F{9A*`tSz9x-mju#|D0 zvBNwguN^UF+=xui*xcOVT2id2!%#;1rDkHZz<%WTPtBl5dBB7lGj{fqq-YiYBcjz2 z(Tx4k<|a8-jxc{Nd%!5kj!QMFazqV#rJ|TWFv@+?b9R2R?vo(ARumMMk6m0c)l-%; zW;EVCzsHEE3+zDIhsoJifarIx+N_#zmltpzsrQA0OX{uRIWlU;LUE885564lc>^enVOK#zncmV9jSxvBlTi0U zBvAw=l3YSV==Cv#cIS%5l$4*dN%Ev1=?xJgS5)O5u&0}R)VH+7H(wGvkrCxvD_$tq z{o;l4lq1r!;-8)W1Ef>(l$O#;Hnae(LWnO!M0P=54owGmDnUeLA3?}&k{3N8)U0mx zC1j763~GY40yB}E#Il=Ok(--S>bVbCmqvOq@Abh;NpJJPyPev{5rDa}O^L|B3s<&@ z)IKOpcl)3~65iK_;zWWZa2oA{jw}+#3JJ9b7erF~r#qg+!)2DXTOG zBI@}C2(I-Ktxk#XX9#ioJa0fy?0>ar2={?0dUTq^dmaU<6JB&RwLS_a6sRt6R8(i9 zZVSE@%|jBcC5=8P3ZbC3CrQ*mJ0h+GDd)oFvxV(#l3Q^owDVUU*KS~ss*FdYYHNup(5<)_N$TbZopMHW$%?h2)B>tR=K4C-av`zZD@fLJ{jIc0{cgRxxm&$#2H4I zpOe?l0!;b%PqNwWoS3vS>6dck=rI!`M-N#Xyl6;v;6Dx4_tju2#%?8j?`KOuh-FuL zuJT@=6I8V3A&F5HFX5oLHmI=Cp=AWH|QMqW|n=HxC#sY~`g;@zOeo9g2TLY4`cCk9h< zxZ3DYUtpF=N4urgL@#bbl%Z*yK@PNbMv;laYOJS)avtrIJ|?an4PY_4jgkoS$5~Vg z`WYi&l-OO8=(DUOgrSlI4JC~|$D;7QbOf=UDvY!Km52-q)|hD{T|weYT>9dkTW1me zq7qN`6mFVjQ(THbKeE9<_|+(X6jZ-Yls{(oquh?3Q6M39`%?|=Cyn!=dNffT4KSzr zT|L#^763GXGxbkLsgr`Ol~;fd$di#X`TRA1qt=pBys@CPq<9@{v3Z_#IZ}?k7Y~=3 zsbV*F*(I$(_pFN+lxFHks*AAyVu_%~r13vnqORUcgnAe=so#6lz2|Hy&nYe|prgE5 z{fuw==OJpJ1;r?9Q4vY{RZ2ARswJX*7vB1%ajsS+ppq+_<~bk9df^OBQ_rZ+e*CI5ajGkeukuG1<4fzcqTUW`a5P2w0+ zH7&YBCV8PnN?cxs^~pdiF6C(?v&YBN7*!Y73QiVk2)KSMXjRY;@lGnS+nLzh*3 z+_X)?fJAMw8u2LO(b#D1dL+blBDq6SDle$@88KaLkynD{rRCA5YWhkJWYj4+D=+k|Z?-ki;~DGa%GQ4MuUlJFI%7}Ao9io* zTa2!{lH?Xsd|ehjgA#M%iEscY#BX2gz^H3rLlQ&y$m0 z&p-d&x8ICBKCZ=>Y(1Y~O*z4mTQ8JeI4@sYYoa%Bq2+YETpvrp;kM(}melj(j)w=O zo*#c)i#UNrLGUdtlj`lsEy0sd32GCtA#@w#bRB&jUYZap9=fmKzCrK)PXG$P8LU}0J{T~Z??Yn3G1sw7Lmfyh*8 z1Qeg9vq%adWsvI_;F;_r*F_|QTLI=WI9D%&5hQ~|q0u$PLZi?7D+dRYpy!vAm6OhT z_3&JGFy6TyTa;6}F^9GfmAL>k;2-_0hJ&VvE8()!u(dwLVQwz$GDuqwUE{DeTh)VB z-U&&HQ%zQ743Z6ssWI|On4Ds;oGZW}Ij|S)%^Dj}r-NfZ5ZB~jKh2=;cU0n#E0u9W zVXa)_1`XD(^Wg^94l6NM{XH&*Q~e~!uPq})O7%&{wZlsY8H#0cFtUcpIb@^IZ^y(( zCL%*gPM4@l<5(Spm5eT-bC6D&!m(EIevsA9c1o*_DeutLj(Kxv*&qa|oXrkP6WVWK zXP0zvti#-d2j$>!hm9W8x`B?srqFXShK?9xTR~?Bdi%O?M=-)vizB3|2vGt<4~O}8 zDMC1lCrZ+wNuUBEaC2eOlT@0;P?$f*b36D=7seZ!9@Kaqhon<|c$ZHScw2WF@6(mh z;M3R7XuXh09IPl_S5RD#Tac3tb%);0%YqnVr^C`nT<8E7MkIGh%E2MlPAYw4*x49E zdyKKQprhTOveGvecBm#tNMlh)mujKX`?k#~-nKazMGu^;6@RI%W;GRmO7F#I6-*RG zQ1Nm1D}Fq}uJNqP^LCUPl(yY^r~Ps$&~O1FY$` zfvkpsXn(=})l21|->K_h1L0Di^V2=%b&9{$lZg1!eF*XQdo=kHl1n*gBOF+ISB&!G z#_hGx2Syp~nw7TOgrTVPYXLDsQbEvwP+t+_1Q9}^(gq;@3?G7+85RjJZ#19y669k~ zkzQ)H8dADoBl-~|xRVM(GI5dczq(=h4+Njnv-a&ebJ2n*{)`(4*bP2(rjp>pa29lS z>FDeheDfUv`Gn8FnMn35jQ3!=H|N2USJ3gmH20%kXvj^es9Rj>yS-V1B9@Vhs$M&~ zk!hL_!R18oy#RB@hDK)Kh1)C9)K?IpM%UIKWiri&+`ac7)E?HXDcig*v!rOv8pgy> zTYTOh-=UmWloaQf-wLc4gl92$fq@$?Hzg`kyz$Ve1Vw4IcBXWwjR^+REghD67a(T= zX$v@)*WT7;O)&&DQBY?{z0ulv*bxRxCB5hA#UAk-2LLDiXMI>)+qL?ri+3@sI5OHT0dRWe#k$Uc|G7@_pM`HOE znR@_P;$!%`6U036CW87{%t3M%ttTch`yqvSq=}v2rZ%W-;}2HUU;{LaP^n5XdrW*^ zj{2R-c9N)XSlNkv+a+~FaK<*o+Q~KvkH!1FXMIGXj%6x-07oI z&*ET!hw!{rQl}W%;kS3e_BQg*TA8Ptn5TvoNkb_j7PXA`GA^@qIX6zt|xOc1mhRct$GSe_`;h zU9Jy6Ujf(#BLA0oK-p6Q*;-olyFP3)^)|F2TgFy|;psaY^9KbJ!#6oO;Qh8*!nm1VN1qNyd%ZYAa=kN9SBJ}%ZwZ! z)j}qzY{jiP$CU9Jr5$Hy-MKnlW!q8InJPP326j|N2EsxAToXTnhCZE>2-tSX{EYUA zcsk%=6d=fPM<2HN4NtJ{Rs&{UZeqKaQA+HqS;=CVgUlJ!3#x4vc18ky)Mg&Vy<}oD zJ9M_-BlK=GvwbjC?Aw-P`9Y>J=3hu*GfixjI2i8;U~AkF>tRzy6~ff#>=}2_{Y87m z)3_tfNtGSu8oERN-#J13zmtYeUH|W-|G$;?{{@}?+MFg$7L!V*8s;i_fnFth2RHIW zp^#OoXk5E)Ko<{f2sMOb);(VWGzb^TD9y~Is*^NC+ALxpHjaNAHV)4wN1u&%8qpZ7 zj0iAB$Bzj}Gta~W%^8jh2<==3%reVXlJ=ZUkfbxomu00PxlJ*ij#8$ysHbhG@>?&r zTrxK&7y{th?Xou6(9czN1l31HDXAU7DQzJWIy*wG9m~TTYoeuyD5b%+5zDm?MFh$0 zj*qjm`_S5%4g=7ueHwsK>5MuoUTrCDj#Dv8OHAj*oYu=~j6R^>sUSI}t^Y|Dd;!76 zxWhzAlrmRNI8)eqIq{sWF-ocI7+4=+?MP{JPiXHL3}UWntmz{SjZ)57J14YX9>%gV z4re*HkMuQIHla)AzpugjS>U~>&s7>TM@yPxn#-hizQ;&TOV4L375UeAO0sD#lc1jAH7&BN^w-TlFuMc(@;1HGNd9qY% zic)T)IWw3i-eKr&xVp1QOi<&})5w7CdzrZ&NSR@rJp_c^Wk>Gc&? zHrXd)(Y6<1qYAQzBEuFv*+YqJ>S{RI_vy&SAR~(?6bP+`xT_5?z5q30v(bRi75OwE z-2g+-FbpU!>uE?M8pzP#G(4uG!O+dR-CC1cORhW2ncy!x921PCn!^22#z_PuR>fh6nM?zd}7@tDbmP?__#$;*aWy z_nOSzlU_suT~8qU(Q`mTn>Oi1UwiN&#TdO1*5Z98CSCp`iMRB*c!$tT<>YI^rST{7 zikT(=*g&Gwpfo$cml0PV2}vMm6fV&;8?8YF zaF}j^b4$p|bRBl+x3v}o31#9?nCH@Ih?nZaY;YQE?o#Rl$osw7@H10m?}LzuAVf5p zNm>>@Qlh?Y@# zFI$F0>0e*mxP-Qf%TsWoXmf+f9!}H9Pv9E^0A!nd@xOi2#P~s9 z{w-t<)C0=P|BSx;Uagmg#d(z@5KFkt9Bx?7DrQeH&PRd!*PE=Js}3i~D!>L)qwSov zv$EY%e~q<0r7Pg9wJk-pHsEhZ(8gA~R3BjN*wPkqNDVt|ZC@UGu4bqd7V2xkV!58^ z89qaCTbH3I@U{5%41KZo0%c@BH6lZTy=s^4P+bl{NN~CPjhT?w1NNi7;JlZ(3r1QK zE`}PT-94I!1`<+8*fiXJ@<~>M#cb~*K{PBYmIy8xp2*4*O~?I;KG6YU@W)c`&-(Q_+1e0j zxy}5B&AcSYJkw_WD!{xufaaBy)X~2SLDZW{GS}v0mAe)(2jVJ;)=sp)Gx6;RUDy;_ z0i`WTS~cC=$8Me*V7@QF{BVHTXisD9z!?3=Czj9wh76=K@{v}|PnR8oZ!t*qSb!;E zY6>r^0WYegI#q}HRPrU+1cAR~u)uIUnS4<;oyxm(Q4J)+k>tSPtV;-2PQxH?vDG^q zF{cY#3_*2v_MnCwq!`yUhZ`t*OjpaHiQ($T7Ni^eru4jQ_s1kDGhITDFEW9lY2;^<*)lOqlZ)$toUVef!Z$%debr<2v7$%M5&JlPPO zir3(&>=m=8q0QE=gUhT2O#E7`YP?xX6EdwSSq+)dXzc(V<KxY2TRLae zhq3pL*>z~Tw{*-s6dfJ{PHbtJS07AI>Xw%DdTP$bgX*@0PNUU?`y!_)*=S#U&f0$a z($g!Jp0l>p#X%n!Z$wH)ObFgg%aNLuzs4=ylxz%L2`(88tCLNk8F(_Onbxkl>yr)k z>~qPgJ$GZfR!HE?KfNNKa3(s2o(3XA!72Pz3kBa=E~)ECZfb@|CAHZOH}PtHLvpLV z^c;Ip%TFh_*f%2S#ukk2iTL*0H=SOwiExevs@BbCnZj1vZmElx(s@ZN1k6`4QY z{7V)`lAfztfniaqv|CbKBc?{jjd;xx$L^6dJ)Npe2qK&<1j3}Ox>y+!kT}9^OjYf! zD8TKQsKs+t)g1P0*T(gu2u|9Sbfk(VOv9}z^d2(-Tm6ofdFWlF?nU!P6&bD=>Jx0x z^(1Gj4@CyiIOBSZGlJwsG=vVhqEo3&XIB3#s|wqHn$=KYFdPcBsuilbx;7pG^A7&gXlJswRNI?*x!_4eePj7(du4}O-w*D)PGgF}+&~Wj6S`Wh z@Z$wF*2GG|)-FHo0E8D26LnRp=I!K8qm5}mz6s|9o zzmyl~OXaOD-o0o3-BM2NL{!=~YPr7~tBJP^@gAm$xBOUaGx`N<*BHa)cI8wdR4y}Z zsi*JkvOwMkOM!6xSsQaZI)koSi6>Chsf8feyXvI3;_i(ng|^FDMMZ<+(xg-K55jjK z8TG}TNYa@ID3{JVdM$2GPxUg8@jWUZtq!w7o=1U!q*r~+;wN4-EPI(UVFyrZt4V6~ znRu-_KIq##1?(i2V$K7ZbW$d8806z!3}ts{>B-g(J&?g7lP;qfN4f7M+H0@}U6w30 zN8(Vpx)99Wo{UmX6kfalM{AH$*=0JE4}a^SEYi$fm7V7L<(S%Su{1_rGDt8fIs(rn zx68J(HW=cSt-Pw(KU{$?C670qOZ1Fh(NO* zB_AvV16?96E#Z@WYJHO}Mly>&ng7834ZVbTbqO=(pWASNRB(Aox~CjMk!#0`Xn&5u zIoFsiu!}C zFEztJfaodpeQ8Xn1|Nn5s)iJU(P@D6n44<)Nfy|1Caa;=5ZtpQg2n?VMOq2k9p;RE zOG2F=t&61}lQJ%0`k~%ZgaztLGlv@LG(dT2x^$(1|D-S)L1N9OW${-eJimypVmkncJgUaod{Da^2#8&Ia*;A@-sfIfyi_YE}>5cYbcp(P;{*% zVWRgC8fgV!mUr+6zqKy>5&7~xUW1j$u4Jicdtgs zveNW|u*Q}H5~OD>o5mOmD6ig`y2Ae)Yw44sM|7;EwG=&B%azp}WUvMoi!ohY;^;0n za<)qn#vqcFm%AVuFGAnw$~{JE0^kGY! zTHynfM(ZvM^o8zA>v;kx&^vof;!mjGM1kKdg&b+K$BzOu2p6p~xN6z|fO4PeE_+3f zveWv9+w{~$?15kB6C{z~+|^jNcOP47X#tGbh2>V#?LCr2Av!HI_9mghhDefuBvn0< z%tG`6eG+1$Na8_~J9v_f$d$1GHy8oBc~ytt_@{k$w%C$Sniq-lcd#-I8#UEYXjtTkw&DpD&zc>Mj#uc73UM zt9ca_^S-DYEF7xY@8dttLb6bOGXI|P6&*9W{m0bBm%i}LY^vpga%}c1&&erq;l;b! zcrdwAF{?UxBRr~y!bF#^&70MRJ0|&ZO%*lRvl}`Co=h%B1Hlp<-v(mWbwlJ=5Ihkz zoehG*^o8R*88RLl!f-KkSdhhbchHhi{4mDCNL32=NwyDdX&e&V>P_O6@FCylf}^#C5~B1hFtXK6e?-5@c`(VDK?$`IdPj|rqYo|SDb}>mFP9xU!1 zs^ml=4%%#I;FY@!uUsG7W>u~aN(M8|rNP=-+2*M4Z|%C>d3w3C+1hq{%*o|3XRQ}g+WSs0wZzuA zFk2T1&u|!`#GPIq*KBPEJl@)lAwgnOO|3M*YU-)Z7&}pP1@iL4?P%YF{rmet=8y9S zA_o1EBU2?4WH?k-u#?9U;F`K!GGveS?%LsQPNw=dAbzyIPW*>yOY~LZ6}q0Yw}D%s z2yl64{$KW!5^5?FN#+xgC9m%SJ#z0D5CWYSO_8`j@4?~`tgpe`RDNfN(xt5OV~}oz z*9cHhj!T%m9xVf(8F4Y_qYQ-EyAj#7aW?$x8S#Cxy(SYWfIz#v)*j<2l(6K`^VGlC zzt9)Eo2S!+Iw!?LJ^L?FlGHmjb^ao0^vo{-&BsNnAXT_bd>f)yk5Bh_rbyCnaIqNE z)!j~Nj9Q729O_~dZa;7${ag=*?lo(A*Tdc(>np@`vcfc6B``Ym#b##YOCZ8NRVc=p z>Tb=T68+_7B#O}|@|V9Sd*@Y;qb|nW1^xO9@ahw7<%uzR>VAJkMf};mKbEa@mo2;c zsYju6$3o{8k@>H@yjwN9A}#%=MM_b9!_*~G}o z?TXa}Ewv{O79QJYFD#eHE7!@GxW?yYooeKj0WwX4E6uh>2Uaku^*D^hZ0(u{EsQmm zotryM^+Pq^)BsXLmUA(kZ83({0=3-`SjV;;V9}B-rn94|X1Ej-bfsJB_pvDek`Vf> zM9Cviav}3Ca+xQ!OkEoNRJ%QHWPJC=J+l6U?B9a$n|T%dYuWc%#z2DVyNm%Hgw$7G zpWJME5+dNZUWmby)IaXya}h{^{&5R#{qzY_NmmR7lVemwS=2lH#6~RVxe2weR(2@$ZdAH)bB6(|1B|s%36e@4ND~Ah)o3}J-+?VB0nN47 zXpyY-4lRO0?{no~7NIkw7PBO&#?ZNPSX1pa4yDd*HP$6y6Iy>9&QOHCXW>qG*!y4# zY9q8I%SeUX(4J2YoX9e^D_BHo#9VKxabS$G z!)dI!Msn+=mutByA-@|@VVh84LVhoC`5lBVjjD`(>g)NKy;I_GxpqlvJX!3aGolkL zM{HipUC1-pRJU+RV%wWYO6j*#(li@3AiE7#V~^u%_GD5l2n)0P#2#x11;q1KKx6gd z$>w~>QsolUCx(u7dQQ$IkyYvrLX`yDRt)X$ik%h{5$FoBk;Y?&4V1=u7hZ(OIOfnm zPpUIH(lOAR?>n}^*44+tgRWpZ>&7n3%wm!{1vU-23pLf=bI8*OR;J$#^wBpd;exZ?N#(&$#Vjz)CD(mb z+a-(3S5Jx&VHM)J^z7M1>^Tc4XU}v!d%WE`t;pZ9jPl?r!f{=_3kB*WLnx*R z!!b?R=Nx*A$X=!iMRU6g%qXu0Lz?^<(icmJqChD9$W=fy7@@Lugp2?1_zuL0(=)@r z-(J-#GkV&M_kfhXJ3!9oe8uSQ-g<4BDd?xsHaV|1^p0K|5o3PI0{ZBB8t9#b9%EsQ zh%qjH(UkQi@Z{tA5)txo3C&ZWAx#VYY!jejoI#_`ix_npp*G-Lg6c3~_UTlR;RM#P zNSiMx%~8gt$SV_-6H)5%DCJm?`bNQp^9Dm>6sg-en3cNFXO8bkrHQZi|M?8>b{)PM%8^eJ0HSftVxUibgnVA!vpu`(j5 zm?zQ{>sCPG^@6mFS{2!2yry^bUei5XqpMNNoxG;`#v1Z^&@M*bc28EI|18ME`b@l< zjZFa;x|7D@C^vbNXn^TccFv@Y=*`hYCkaEMcY!zPvLDsP71h)Zs;?I@-t^ez#XUBYq(&H$BtC#*) zSpAPnz1zR*|2Im{%$)xK@&WqNXH#n|2b8zQ?{uYyA+uo+f{dbLo5S4N@ScpI2TT{* znjH(68LX{lst?3kI5K|?Hm8xF7NKtL`Wc5u;4VqJ9~W&2^=-uw@N1iqIsK@!f{n(S zj^4Sk9k7A=((u7Z;!LcY$Hh=$E3Kb97F~wq)+ghW=rUr8HR2 z0$v?gz|&V|3(g&-kW&&2DRlzR+6UqB|Al!<0=e5d(rsF_f2B$WRY4V!E;8$&XPHrYN) zyW4hW;8nUw_C63b=_D-a6i=HkT&JT3&9KOYAaN!R`X~(aw0R|(RARmegWT*;`JzHL z)70a{4x)m713~->T!PdkoK!m|Ohg=ZV$tnasIxUI>FAYeBj zw{ki0^JwX23-ul?bxL2oaYCijjz)pW&l)W>k93V*^hQuU*Z}4AaJO$gWFv%$8r`i% zeDtPgn-YEfoA)8k{fLhJ{@yl44USm^qU8kuAS?ng0|5z>hU%%}?I?GiB>fhbrh&dw z_iFvR712op{TjDn`ebbGl5`|5%pqN2x~J>X%AyfPR3_#y4{7Iv1j&`yq!fnbtys5e ztiwJVb(^6!QM_Ah7^v3vajd3U2nn8nDVUIoF3i!lYe{ITf$HO6R)QH^0vj1{o**XFqHOwnbdNpTvtsm<6C18)kO zgD|m$k(T;jU_GP(+d_OQGEe0!0p|%FA3I~tzV1H{zoyFQpv)Bi1 z7#as*a-*v)BnD@3cGiwZ+IYuOWYgIidN2}wK{$dtTl;t;M%6~L@UAw8E_n=0s(y_% z+oV`pfXNutt@n;;AF@GA-a76A-Y=6f%vGUgSd_KNmh$FH#ZW@@g`bgLL&XF zY8?`d(kEhD_7?-n<^4N-)p~o}oMuZAc4M*LyBDW-!RM8POl`v$?V21_shTw z@6WqCj2@2b&w#y|u=DM>Lhp8I)XiYX8JonJq@;f~Cr!*MS+~9dCwxx!JP0OyDHt(b z4eCdY1I1(`U>dRg7AbzgSyAG`i%>6YbxY)x!AcV;=5si$s9icY0SghV?HEK597|T! zCg@`sP*bR2rK26gn898RimmZA-mUS}0Z|!zozI5=N#>auU9!o$p65H0PU zYK-3cu0_}LyJoW<1>1{^(P8ge_Oft(`1{t0z{AdVcw|g~d5X>ac>qnN|02-n!tsl) zOpAi^aLuc%Oh{PgM0s%eo}`mN7zwO%5*3dvFQ!9RKgXyqx{*v=nlQqT4u5?HFvE@J zJ+@0!@koG2bFQ0T(MVzPit|=He{f6Er?{Bzn9jEyGu;A0MSANy-mIqEFuhED$MilYE0C`z@`H<4P_ruzS zJnearvOJTSkuAl00hgmKiv6wtP_Xs4Zhg4@MY{roX<(vkn{EwoEO^ z6VVaIHmE@s89&%qZ4=R@bzPhFtn=zOCbn!?vB8D7Vx61AiseXFZA201h+zY`RkZ^h z@${tD^>ZZ9Aj5@cCFG&r!G=}t20u)mkFG`R~3X^JudO4~A^DC&V^sJ@U&u%f| zbs(An77n4(OmsHbv!_i5h~R-mP7--Ds`_3~^9zajB#8WL7-HjTQLz=uqf)v1S$F67`bBLJ2M?aw4?2u2hcU8C+*%m=7nnGw6Wk@^+1 z(45lsB}Me5f?5pMZw{!Xy{2DWdHW*C%ESSKZdzHka?z@5t{XgHGRHs>zFtvhB*~gM zV3JP^H7J&Xw~pKUjut%3Cz$0x5x%cIGMPv!&sn#gGGCNaUJkh_Bi01|a@de~FmHE>i^YKY(7jP|z$ zmC2UK(iHF|Q`Vyh7=%l#gX^J`(zBm!e9%o*2|i}!=ag#tl zLmFoK*58KM%D3Mdu)=Ay)gEk#N(_^thFWcbSUwOL?X-=Lh)*2SH#jdmCh~W3_+5su zYoZp%0v2{{WMTLbd12qEIsV1r$2Vb1aosXtmti{7Z_inH(r|85E7ri^lP@$er1FU& zQ~e|d_6oPBw3xA(c4NyGLrh02T&MM+SYZ@!YI#624nuAWtPSL`Y!g~92VeTWmmLmFeUTa5-vnEdJ8+m1>+<+sN9LCcz%B7e~7h^gu z6yT_)enRoHk(_Q7&gfgfMyi5KnrCH?xXy{-=W|bE~wnR*2@N^Ax3F~zsE>xWPNO# z_1#k>dFivEW9&bq4U zo{&^YI)KaDQEAQ~s#4PXrMOMfC*yA6KOo6BxU_ww)KSo{;STv9cgU2vrAk9sBd7oj z=*n=L?1PTRw5!vwMsg-0+n+5^{b9FUvqvWBGH8qHru(6~8$s6zRCCfd%sBd0&UJv@ zw0dPl_Sg|4hT)c*o4abuP2KOAc&FE_-h(N+rv4&m0rT~9FjI=F*OKf-R;eO;;-~*W zK6S66+NISfd#9aE3J|Lw*ejOp3`v9Aw zr-|2b4GQtBw;;8R5TRN7nG|Ij@S2V6;=O5Gr=KBZG5DlePrLmd;(;H*5=dW^>7?UTK=1e|6N`wgbxf=g{-7Tj_e;D58l!3u2yq z07@55nlF*uPhiq8P}gj2`g{*Gvu7NJw{vkZk*-w-^zSAO$sr9Wp|tmJ_=8{Q_Eh{8 zbw$354y!s?!6qmhJSI(%9S#W#S5RdGBRl4?M-`h;&PCIwbYv5q{$fR3)L%Omc@2*2 zSS+23?3gQ^jaC}M&V-#VXlpfC&n75AYz0;b_Eh2IFkoFJ!Hd)Vc}WpXu7*K?V{E;9~~-4mNZA|PA#_EYC_#5J^5l5gbH+HK^OrL>W)sfea1u%wsOgFJM< z&mi(ktu|@0yrcA&K-Hue)`F@S?9ee29X!vCU=MxkAr{o~2Xk zv8OAtYl&{soPX75UvF-wS|9F$MrnqgyQ4{l!vN*n&CzjpZ;pkLqcOpe(F~tBnhN(vnb?WjYpkHDHZb0a8?7k`4fJgPtU={_cg!c@~$Z$M^YuQ|b{UN)w5?XQmQo zvoo35NjKb67XK-^x9Csi-|^=W`t#bS+UKkmV}Y$ESy*6uH!t~~ICQeuwnA!Mp2&`{ zU>!42o?RzNPaR@1g~scl+R{yx?aRQs#J!+3-jBoC0QB*JE?bDBEO2QhQ)^grMrO<+ zqvre=Qf%d=TNjNN(S3-`WT<}yCWn&J$<|X0X67WOqZFEsg8Q=rt2-EWn3I^0U_}8M zOT-A)3cY?$raT@+$V@LUYcr^zVo=S-()dHZJ@_11qhS+#I@9ktoyh1|=T&<|JYC;| zaqrY?4N}K7;ja64yvGTPusa18=iJdAockT}xs#Wr2%PkCPV*iU*Wfq?*OU zsmpBqUbdt-I|ttf#CIQ9z@F8=nG(QaPc11a%JI-3gav&6AHO=F1xzo>p=?<@FMwbgLizQ#ax(^H+|E323&E| z54*^}RZup)w6vsDi}}30@IIaqJGu(rT}#h-{DFa1Vn{)m?#wDd^O)nGvoDMmlnG}L zGG%USR-_@bOZo(|v@^WcISbg9apP=_JKa1+I{3Bm7cOoVsebnE1JoJ|%IE`3*(`fT z{OTBWBPV{{`tr>h@xkBB+n@pGddjo%HDG(%^#&euLxrbE1CF`tkB4cjR!}zAvtE?s z`)glo)VP0Rj;BxrfPK%#Ef}c9h6_Z*etb-pr8_ncfTy03_u9U-ODR(fPG;w9E+d9a zeH%prvOSrxO9|O}PXT>#Mx*DRmG^wdYONUGp+Od`@L|6`(MCClVU0KTwwN6s5cYLB z<@qJqz)pBaow$-oDA;U%~<`9ecW2L3)4^P$&Yh@+V6 zOH0;+F-VSf_5Dj}6G)^4aDFc5;*2Y=OlEwc+J}dQP=wmg?}+`p8_K!$h^^lnRJ`(n zbvcZ$DEXKGlph{O{DqGVe_QZZ?H9`^aVGW~OOyy_n1=h2SDLONrbAVLf1He#^KVa} zs1?Np8!B>UW^3th*gA;uGv8CdY61RC77*WZ;zc5Fy{ELifaDV&&R_va{l9WiKqiK} zQ=n8B@Tog*TgVENv#x|bHcG%yd;Q?I-zMbQIYsQFnl)xepr)-p969PVBRjveq`bT+ z2OsB5&-&uNFMc3kc1~sq8YO`6=#|EPaftX&hupDPv+{oN8I`R#Cy!|o20Z(l58Ek! znjb7FgFlk+ZTyO^QS;S||L6DZ$ zw18UkNgJXnhze*C{awhON0sB*wXm-ONXy@~jGz5+YX;F&P@Gj%km!)jD0^99*H3QW%>9_Dn8T9 zfb%LI%B6yp!81;uZf3y9SC{|9fT)wHn^|f1ysZ&=?7C0?q7jLTLKurbxu*F)HEvcE zQvy~oUnD+XP8GxCo_lRT&8R|fWmpiCmeuR!2CAa<1zCjz2(_&Z%iF-@XI(*gt$CdR zOlld+m{g<{VyU^GQ_H`AwI+t=r+*w9OR0)HW#tU8bn++T2tYkN1Kiwo+Y>u;wG!R4Xd->wTB75+p>sNHKxAFX+U z_@pTU#;4M?jOF?CSHWMB+Zlh4`!!WpMe)rA)EP1MIRCKzbz)C>si(M%H8l!AE)Tu6 z`U}#*6t@L>ksnGt;gX=ZafYnS?YfAuSl zc)yQ<&Cqf)$75KGWx=>KwBPmLt*zrGB}L}-leo>{C~MS9{nfVqYFB^t$NsA9QjIP( zz@-Mc)KHh&$JMh8q&-+>Gw|^(m_(jGA)~KEX3XN~r4&yg)m)yX>d?@Z)6k2Y3Vi6b zIW7Y)n)?MK&i9!zyMI?HDx zyvwyww1>D++oxio^$LLm_VI-4PA?k>i}piYYCjj_o2WGE8#V4S(?}BbIi40fr*Tr7l1gFsRfey~rMKKia2ofx&YCxf~TaLFfO~!t>JnR)~V) zJd4``o)@Fs-=lI=$N%ni3v9s0J`o|-!C+%PCfFq`;9|>pl{#$3m(=E5tl+J+IYu>a zXATkz7K0hCCS(WD_F8eN%XwY-@{gH^J_1J4M?c#2B$jgO9s7Sk*g{^o-977t^d;(r zEKJE`z7ZREacOE{l?%uJ>iP6X#9hQu)xsQQ*x1Ahrs+f@{i;`9rIor6MI52;7y}2J zinXlpW@1Y%nqy_BTAzp=VJc=l`qB2s4zspT0L$sv5nI?)HbAmjyS5$%9Kw^i)j1Qyum)N z9q#!J*eAnfqOs89;!6~TW_=#h#u;`hPXa(b+o+m;{#xW?IEh%)I(cnQJFI0-eHtnc=Af?PL< zp@Zbvf-L*45(w{hVR?rh*(*S{oFm)Ckg?OP#sJLwqq*@Jc;V9l-YLE5KA*0LN?R_w z)0)C1e7OSO0>IX;u2dWir1s*Dhi+xRl_2?@;7ui$CLM^lSPw;TRj8==a3z%fZ9`8p19fXT~VCsXuOyHgEIzArj zW&+JsZ6^|_w48(;dJ_ES8!*RB9H*-mB;*naFPbv)@eU#w=l7_0Xc)+B++(*t%B(vK zU~&*?I*zuuITa5=`_pNb?d&wm#z<&4nk~R5d6ct}?N}xsL4PrqYcQ}68+G8wy(lHM z4HE-b`YG66)zxV}=!k4LNH_`85O5~{a*NVoJu{)JGst?GcFKlur@DGyJX@_vtAglf zJc0$fRf;78^JV_^eiY&N@yb#kj9-gJDhWC9S;$X|G~FsDowtwcR3t3Z=Zyl+(eBTx z2xe*LMv1w(Bfz=Rn}WlHj zQizk+@%$GM*u{&hwWOL@NR8(cB)WGEPq@o(q1fw4^u1pqS*KxhlCnG)pci?b0fxT{ zEYtn4ya6o#6j&gS_2c&iQTx%-VvJAKOO1+tJEZ`2x{`Ma-sTR7QVwF920P-<9Z1Kf zHRIScd0ZFv%h8#=TA?u*LdQsTO_D-)nf;^VrZw#d7;<_IA*(nwdwZ?#ul~*YZbV%_ ze-!ntTVdf><@x>#E_$u+$9k=A;dJSxzIS=hY@~&_SbgtO+j`XZaTK#%Fr8G)dQvg> z0LoQNKmwBY=mVe{%3S~p)nHZJ0niNQ$SYIj=Cxgt+Z1Iym=t*>($I_#E@P7nCeCOn z1df4-Ml;0XOtm>GpfSpP4(FtGw42E!GBb&Eb;Jt9e|V4;{E1oN#wzjzU>*7rYW7WU;`verS|={8b>ILweakorJe?em`ayh&3-8?vLj0tW zDV)H_&QL56haj@0;zAk~oixJ#Ses2UO~R<6C}i2nc=i>>V}Ps{c|WFgNB(1|kqH@y z?qL*0h+k|ZU&|SdBGxsE9;Du-IokNCL!?1hL!oDX?RYAW!Sf_*qZD$>Zls4-0 zu-hxYy-n#*Vb(-v_MA3$z zXhN=+BxF#IOhpCL6MmM6RLOn^J_-X7>DJaD4NB?^!vDef%nkx2(V-tr6L#)tb}Q^K zD)tFKw}FD! z^aU=>Ru^7@m;NGu{uj2eC|DCb^+gv(D7$@zT@AqF;ThGauej8sF7*uzg5kJjep~e< z4Z1(W3;eUFpN}kRgGLTpe;-fOYbyhGBxK;l+XmRdT;4I+!e+;K-TA=&>PGkBnh#&c zHX?LKYLl;s@xc)JmYM6hI zM>u%Z&*@GjeQla4f~uN&k(?%(v_}Dr-i5IXpiWu30V2{`b`k z!VfKZ8j#&TaIsdYc9BGO_Zq;5mh~oXxg2e+`XiTqu!Q5}RY9`|UGY1B=ko&YQ$yp_K5_85GnYFAuqZ%v#IZ8o zMK;I_h|HU{F);%#{yjw+-)w|ght0&*e|OjCM6v6WZ4I3#eOcaG_Ks{9-0a*!0wpX1ShiM)3?S2~sF|Uq!VH!8EH9>Qbh705!dV%y> zcbIEIpVw|d4HRjDsaY(JEE*F?>|7d!9R{Jov%n66FhNyild7Ttf+mh$$EXn4sZiJV z;{rLn{fXL#@|EyGb{r(*t^M6Xhf{aXX05P=i9X)o73TR{&$Db0p9L#I>Fl=QEgO}v(+Y};_g>%HYsjb zwZ*KQtPZd!C#nMjl;hRbK*c?<+J-@uyE@3GxCd1S2Py8s)gi%(dq}lCL~#$T4z(-p zVbx)w%CYM3FvUHhIwD+oqqI zde~6K`B8P!Fva;{_3$Lcy|8-3aK*i-dgKVjy|{YRNX7Ynb@C|1y`*|{vf_NVI%Txt ze5ZO$isD{ceeD>TzQg_loNA;}rKz)f2`m&bO;4PEgz{t0zrV+^ef6 zPg0zX)z?i{+-s^+uT$Kf>M5y;v!QzG6vdrcef?C$c{*{LgpZ~<5~eB6lgTHism_yl z+;~#L>3?`QI3e;%h=K^%JQBiUOgA}C(lesqWI}p67?m)?;ye+4gY$UdiQ|FJlWR}f z;B9D5NDC&EGwp6AVOAJ_G$hWBh&LVzN|+s~L23;la6d8BbE0V!OyIdrx5;6kr+Izd zX6oeL9jD%gqS6N?6b?8R>9@q`6~oyQ7~AG^kRJn!U* ztJHzvDr4r84)Aw7k%T6V45ny`GF+m^6mf;;FxZkjZhP_LZq zJQ+SuLzlYB9emfSsRP_039F}3;F=lElR=8}cu^xD}c4C&h zPk07Y>BEUBj%XAKM_hMb@R9uKlO zk6DkG9zP~$IgeXUl%6;)=OAL&i9EM6v7mq$8kSH{=tM}Dw2p<8oC;sSaBXPBw+t=S zYo}2j9d4XDb};aNQTOHnRaRU7_}=F{XMn?DdJs6^0E*&BC}N6fIN+4?tYv|MilQK( zhG}7vT9i3r*@QXV@@8{6+*=nj6>|W+O?n&9($utaVDeUeKWjh3dCn2M?|pyoKfj}! zXFq$dwTHFV-p?M^URxd{qVi&!%0NPO=f^fL&PoCQW*uG_);zX_Oo{wbUJx7YiiYpk z@<(D@E}OdqHhIX@rM)krkgtxy7H9ImfjAA48Pl9JYx+v1G^=Ais&#DU2A zLm7w5rRPsLu5Pu@zEbl-iLacA0#}#6REZ!z*IjtIQvM2p9}~fwarlZL>$V`MPy}tO zke3S2Up{kng6HS**JHc5VukOou?Z9w6mcl)=kh~4W4lr{9G7|=e*7)+xqA0FyzHG; zY3~s|iayw4Eq-FKDYoy5<-6LQn0>Kscf^I+m+ST-rHkc%KS2m9R(y;mxoqV>I7=#j zvTWH?pOB|`|FWkKkms3$j`ALdSCvPW|FrB`tVqQ6Te12`yV(BA)*R(5Hf7mb4BBD` z`o#`%1w|Y#UN^*qqz{)Lj~(I~LcHj4czvaa*>Il{b29cm7ib0^e;zwj#FPwGV!n(x zFWxr}Q{KOhIH#lmfduy=&y{B$E;pZ!_>n@XDP1 zio#qYBMwD=e=zgAa`V~PQ52W;U3t}y5#I`gZ_3X{{7WEwQ+^@hw8;6n;Y!YzBEDMo z{AE;cQt_q{6!c~Jm548jUl^(Qe~tLO_{C9*|7yfPi(eWIKk?(s@;>{i54*O-XI ztY{14926|xIuSHrS%+_x-#T>5#FfZxxJHa3w@)%eS~y$r7hDq814Ib|Pj9`(?A#Sh zzSo&AFWxcPME<`rKkkyr_XhLlt`PF=WP!Z+&HF|CTP&Enno#K5EQGs4$@dNm<&GQV zdzXcC$93|($0E4n8u{L5O}Q(Kd>^pp+!ao~4_Op&RU(^ zBvLGA{kh{Zg&u}}x~nt!K4XJa-w`&1ySh-=Q8tvj63BOq4Oe}~*+}l{N?{djG%v19 z6)8?&V|nq3G~qwV#`EHTLd732pR z$ajjRa>sAvJI$tYS2Fqj#nQRs68Roy)48iB`M!Y#%;Ik`XomkgHjBHG$oD~>to#k`8cjYMe^d3@Ijor$`|x>~Ng~3Rzl%moJ_mna z^%bxWxoa$i`SIPV&&l_4$G<4dpZ{I;1@MnmUm!2zj?)wy#6MAe!TeM18b@I=KdAab zcsVj}!gH0(L-}Xiaf(2~_)*mt&X04)*A(XBm8vg-pX9Fb6c))pSA9+Sm#VKB|C&3# zqS)sAG_(COt zcz%Psrcgv@Uc((H$k&C};aW!WCGeZ7uPgsu^(FE@x$8lS?MBPj#dq_Em880JlgafE zMfBj3>PzBQ)z_2T0elZHP=I@JU%d9_i-{eXoUmqT*`ug%(3ui&{BA)$(2eG19-T}ag2Nz%&5LWys61?l)?t{=0F?57b|G@@hH3ws~!19@wO&5`v|@!n0rifO~a=q;V^oSj;7djyp^*A zf{w$Wjjb5X<4qV`vEniOF-q|e;5wVw4CPytU=r9p4&NHf6HSi8%6d-;f6}xu=n2!^ zm~Iwga%T(2?Y!a1Ov2OJG*!99w`mT0kD2`naivIUp~dG0jakqHwi8St^jT++>>x?;9i1z2W}7C z7jWOgokPy&@T`aPi3pdPz%_&G(;Vr*6~H|M*8^cY@%*4U3NQ*U8E{MCHo$F$dmZj0 zxKnUv;Hu$*B2g8%K5&!Z=D!*by+@=_Y_Lu^Hr#U6tyU;Hb<0Zo)>lRrJ;F4H%wTfM#@oFHh zpCS|CzFWi80J4r8LdqKE8vl}bHBbr^P{CW9sR5Rdlf}5qs$wNB?5NGCuaiQBDzLU} z>uGb#7gcPEDoQ<6JG~oIshm7&wb-+ug<-My8j`F(spf0MAxw>xXAv?)W2JOJm8)@q z#Lw|jIzP`D`Po?_hGMM3_)$$c3&{wTJhFH7nwbk_9q8-nnpx02(3G=mUsz%PANJyG zA6aovob8m=_J`HB(+ay?xXm1Q_~vOU3jdSmu)`#04nPkIjT2^LS9?rY1rIS%lebzAy5{ctd;_%;iGBCE5j(e`E&I}{u zy!kmf;?&ic?D@IVGV<0A6irEL(pqx0mYTJuM23GcznBu4pO?{RZh-K^?VT#`FxQ zBHjmC&cbO-a4MO4v_x11GVXba4TAH?`Z-7w{esFz;;(k+U8EU@`gh1huwH)5@2JbS z*Ny8~i9k!i2gXtxX{~YCc35GaR&v;mKh2xoz+D@@JUAF}~>XNS8gB{mnVJH(uUY%h` zr>4hspAbh4C3`f?)bo0MsNd0qYTxjM*CV!5n>RyE(-Ct*OxxY)N+eb2pBP3p z9MsY7E;)ygw8Niu(xecL0|`FQa+mOyPTRVYzbJwP3<5T zN%bbP(8+3KcWG@6V+Y~T*uAP32)z#r5~rVis8yE%ttLMqe1)+l-%w4ax?63Au_kS) z)lx%I+NaIXK7T{@i|SB>!`4*lF{pjwd;*$c%j&7~t-#63&YnF#2e>%WH8rDUFY5GX z;{YVu7%9v&X)P$}eeh$cF@K$stC5W~zqM+3K%pGTg!1`tnRavBaAz`AlJ1^aiZF-X zl1;QjXT?omX59DF2pzwxg%wRyLTgF$l*~P}_!_XVC|c7+ROfA#l0jvI@J6Fy`oZY% z&Zk+^I_$vAlIU1J3QATVO)$|4Wh|3~ZxKv)hnbqCn}Y zUD@sTMK^)nN8H2dx22bwp2fd1!E6o0Esnv*i*3xLK*|x)*2vp)B%J}NiJnRr8fAS6 z_K{3P9h6xm&>CSrMEjhd29FmLk574vSY+6Qr%Afj9a4Xx(MP-4k>-)w=26UCTi3hi8{K`<4&Hd;wdsL3~Q7~?4Y-|AEp4GLRpGDx|CC}TNlvzLnH z3Z03MS-D%}Z;GNbE+t)B(Z8^62D zz75{GFux$|O_dly&kZ67u$g{jp`=cj`>6|HbQ>dvD|I0Zx7SCSYjAi1eHg4Na?^3y zbOg6))nBK}@L(P2cxas;w3TXeVdd6}-ncFpDn7OK7JGyxp&n!S)}l9qNhcft^}~q1 z&I+w$upM^`TdMu(7O#?k&^ilcX+a0)o|bInO;=|Gqhw0YlZ@3SrS~CHX{PB-g2h)5 zQfy?gP|c+7L~UQuM%wFNnt^CwwnXO)z=@84o(^*lr00vTyrfk%92EA~S z2l{md{nwH_a4$I!T+pDPJ1e+A^CVwp7UlgF*iReFD-;w{(*B99+qWMj;l@#|bO)fQ z?$`d!-}r;uP%Jy+F&lLSzoWnNAAhHlTPy$Iul^y9aM7?>>EAIEfRT4fK#Y@uAijut zM$J@cVG31H=zEeD9DSyhStS%O@nQe$xamnsEN^aRP7ch3(CFBI`hb5@nQ}7brf0+2 z#q`V>sJnwyb6~~vrqfaxirBRDbR1UCo|~36a{kn;%xQgcat6by2c`gYfd>FENEo8` zL*m^}HTt94$|cjh-3A<9i!vKh>ywiyjE?{x@n432`CbUcXJutC%t#-Rn>izM?wE{R z7#zvtZAZ>*bKmlxTn)z$O3RxmtYi?}^0;9&ks92v%!gr>B_{`^hWYaBxdU?3$espA z`2cczxl!x$ZE`;mwWe~Y_*706wQ*dUZEVcgOY}^eJ2yKYMk&VSX1U>w6DGhe>bdTq zpuL->ZrJ}sPw;b9*y9ICBGUvFQ5U57*@>SLeJCt1FC%|YHnap0-dJ5Rle+e(Xb$WKd$rDb+;hig=4AqdVD7+!N580vpv53H{eGefqIESQqp0tfwXgh4^;L03QuA#z5AbaC z(rfF9-a344US=LBJB_-N#>xh~??yjfLv1o+E>(R@<_wsK(m18#8F>wv8WK0+PpS{B zs!YS2J9}=yob37kp+1v8+jlqBN8qFn%}9g&VLg5Cwt#ZYz0mDf>Px0ma~`ak?io`s zcN)SP#RH$>2Bz)|_r@EWozp*i;oK2(vkLBnYszYA4g;=cDQHZ7c5d2?jG>v+Gw8VQ z9rIoL(yc%tA6iir+%Yg@lKJqR%8a@$ZxOYg>I&k+P7QT+qhZlQ*hjx(p4YyLJL@Tv zgXhf2NY6yKlvQwtJSCqdw8--EJCDz#t^ut)ElaKI9Z7_uPIu1kOkzej)Z518%+H%S zhC0GKumyPyI5=r3iX^qCklGc7%P z;ppsaGKSU|D)o}bTc+Enm&~DN(@z-xal?B_^N#NyYfjQEUR zAy?bc*CQu4V|qqz-`wo9^l8x6?l%*kgp4c$p0`v3cZl=GaX0R;`5+vKI6|pi?j3MJ zi{6j@+@D%1@?C%)Qz7H%jOjSNJ(GH{BRMvgo?{eEKDFh5rm*3B{_UA(^lNb}O$L!WJBNYmpZ;F%;NUeEe$Q6be2 z2CH%l6dQ9BX2M!Z7OJ3^-Iyop{O(^L=}UFa&6qboGuNy8LU@CCkdL!>e}4~see%+% zJ709iulS=wEhRJ@%ge}`PG1t3&|_5Iy}`deN?%ELxI#6L5rMZ1c+&~#n6{66mt@?X zj-V7JBfdP{9?S1VGLr{cP9e_cO@PUtkthi@Rzn@V^Fp&5y)r$SnjL+m(4UOSAX8G= z7;Pc$m+h^dcOotwhRqC}xcEBn-4T2@(MKJrjfL?xH!Z#M0Uu`NMK7bCGYuoig8a;B zd2tyJ3lmXFfg8ugXs)+oz-Zb9apM|0Bt?vMK6>X(a`RD(b<}$*U$FieQ|Hf6bG-v? zDBscvX*7xyt!boc-OXDrX|x$V^eY;bdcXmvo~G}2rqEYR#TlMGci?<{mHKGpZ8SgNzS*Y9GLn~>`E#=R>NvF@_?Z}75JAn47?$}f^_G@w2YkmkxGZtUs`;z|c>~-)atB&_ zw=LA=<7Q=6kGiPVp0va`^1b%#E?2V#^36}nosl8B^%>OU8?QI|lZbB3&eG`S;hDMa zK8xr)WX~~L@JP$ap;6_CT#S0?yWS`rkd|pjt1Dt;Ohy$1+wU-&f&91m*OiB<|Cr{6 zAB)in*#vXvW9&Cku1oh^e4EOpju!i834X->+^(D_!U!>wIU)p|S#^~_gZ5#X>65RUlBu^R+HG+|O8S~R|flNVG zhWlIOjf*;N-}gqfp^lJZ4CAKFbeFFIoE^t&9}s2C9-f^)HWzJ1VL+p01YJh|>(8+y zw_5+Bkn%RNxbrpA1^hex!mi(le+s_H?{@xqmlb%!!%Ci`es2a5rC(lNADR);p%jEs zJ3iZH@875&5bX6KJ4z~ap2iz$+8K1Jc7#S)gzIH* zfM1iN@108H8x?nk7-^1~mYbQAe@8ifwQSg1)K{x`G!tpOZ8t!tv*Z1_PGeODNIu^E zcHzINZE5Mk4sd>EPFxx+@h%*LF_B&uBfUVMRi^cwsEuUK#gHOHv_pKKrZo%?xft(i zv4G?hR)*308CGf#rsv^JFYx!}Q*p;>46opcA$jBQ$Y;pE=Pw}o>f__|jKRVdrt!Pe z!16wg<>E>=PSJ32m(;Lqd~3DlM6|lp>BIx{9icsDZQ*4=cJ6=fH<9*$E*G{_{qvL= zVVoFKp*kMp1_O<4$1FmOPyX$9L-#cxBO`q(`Xe_93@B8@E>gSusfcPufW^W2p30t6?okhhSQ6Hu|HS zoPpFT)tRL>6V`FPSq}W9MN3~Ke5EVwN2w@_goE?w?kVbl+VuMfb${Dt`F;ag4% zk`a!_TvYCbVy#RJL1$#-j?9{m_06G}h0**=ueXtA-pv(hon3eKT^ep;;bCrm!$~n3 zwrn3VVG(_fg*ag(nvd^y1I24NU*xmBb?9SMW>K$^xtZCyVkXpwswwzJ!@-8+0=Tnc z7L22zGrC+cZcrvZN`3Rx3hTJud}^T1-!;Aa8kI#$PfUP3lVj9O-*p5e>7N*|l~xY# zNMFdXf8Mm&)Q(`q6l-^LXQ-qS)133q9=Mmf#_WtaeWp!=A>#bO>3X@1d_vxv_H6Z| zycg1(bZFYtj4ZA7G(sofw2X)f5mOVgZZ3wiL$hZN6AD>e!rEUh=5Hxt zIq;6dUX=C03w>UpvfhqAMi}cIjddZttln}!DoNg#pe^l?isaPoHn(*$7|`NVX*E}Z zqYezJ2GG)2gMKn7{A}=qxq2t{5TqB~1of?}2a4OYXfuX>D;R5cGUQeh(-ueQElFJb z%1MpG<&#uzwipcTxc6oiMB1u>J`bF-Z)ZFUJl$|jEfg$L2}5jG(>4tK-eXqkJj7-a zqV#Rs8wgwVCB-0=D3MJ2n;q#**{0tN6$6iCWeL?=mxQftE^sNgOehC+m`++#=*)y zQAWBND>UyuxfS!U^0iAJAzBR56<9Zu20uheVlLs8Bua98&F7DiWNVEKw}-;!`The% z6qu)|=rI_&G%fR4D_!m2)|ybXTy3s^W>QecQ~)=&qpqpwxManIFWDN=Ef8rfb50@k z1N7T^3tAI!por(LzK5=zgrS|LFMaUd3G@>~OqJ;3%(QLqvrCmZDY2vI zl4!0(KUMKUr-(n)7>FYEh+C&pM6tNx-8&C9Qbf0a)o8V5w?&FtwZPCKXfIay9f#gY zO*M}+*F{RTxVq15raHPWGrXP2kAt`$!%6jC6!qw7p{XS{%{4{`sMWfOLabM-1+zSg zPzo(_(Y}=4Hq%hE+qKBs;H%-KqBf^c)BU)Cl36)Q$2)rR+n`0Rkr;XhY=c@BgW+Mx z(lPDnLdITz6KRyd%COd%J1RN*9e5>L9d1{#r5%s8?+CLzVPaOG`USPjr-?>?l3cQS#|1+PA6&aj6h0FiTNrp#?#MD*6_^_PA;PGLsEn z69!xxg?0pj*^XtVvSlVk+d|Y>^cnbqx>a9LV+bWaOl+fCa{&|7BQP0Z+RdS>SP1Fy zImvLwNntl5K-kR)6m~O$$ZiHKX^`OzSs2a;A;TH5q{nAMqw!Ic|Hupb8Bj_Tp$;jQ zwErm7&l+n{y-s^9)bT{9zb~0B6y5;8Si2k;>mvun`pUtv4q1-%TN&$=Ln?}z_zQI_ z(y|I5bt}@l3V=eN=~z){Q0pU+H?C*a*I0t(u!`CBH6e01JwjzyMNve!uBYYF^t7OZ z1!!}m99dD+w3!~?T#Ik6#7D`^DvFx7)Z<%a)z?(FmRnR5MaAl+!L@rzY1%5KiEgi# zri0wFqNr6T9Y0P>KaLWLmt!i5T6fW76SUZbU{Sh6xlKh;?A>}s-Gh%&4o8dHCbd37 zmF+3Ft0-#UOHZJ;mOyVxK3VQiQPi=o9@|fg?MJaGa;J)-xPf}?AT4$f#SW40BKi%L z<130f57&W4Xh0*B5{{C)R1_tQ(c{Nz@nb2G@p9LSqQr@M>?AFAl7fA|+^wSM?kRfw zgIfH9gqObuzK5Wxvh(v+hx1y-uBYON|Eq*Z-`cb)mMNvwj9=lYF zT}rXb8>=}6o@#IbSx8-}Ji4N2%&R)Y77b#HQjBf# z*ovZYe-ZJ-m)DepcgW)_iYC0F2k)fPyd_VpD4O(+p4PisTJI`py)RF$D7ybcJ${!K zze|bVBR@b@{+m3dqUgbobg+*#u#Xk6GWns3qSR0Hy!R^&G3|if5D&^zD~hI->nR+j z(jAf0D~d9X>1fB5)GFoa6-6^n>ahPL*e~RnRFbdc%!;B}r}VhfT1ieTS#_RZ2Ez<++sNk8(CW&dWI!Me{D`Ww}Vu)Wuy~{`0Y*qiF5YWjVK^ zDDM|N!C$ome_ei6aPFF%Ur{vwh7M4z0aPnF*2)ViiWb)E@i(>jn^eQ!<%g*tf64_F ztY{HF2?`wRRekFQ4zUYZ?Iq|K%dEdua|@#pE`zjz-0goXSAzOJcs-R%t zoD`Rr0OL^@k1*!oFy`O@hL(eq%a2vC*_2%XmkU*I5SN!CmB*RvkxGa$l@RVOXDFAK z0lo;Q&5XIajPNc4d?c5j0Q_>+%mco;5xzM}DLQ0Uv;u}HS|3r0Y+=z{UJ2wUSt}3Z z7$b6wA+t7IeoC!ZTP_y^^=TNbFqX4}5w!znSwxQNTb;Q444_xByF8%djnMH1T6W>` zvw&X>;}#-ym0O8mZ&|Dl(`kM;m)8JpE$iU{mn70vxte51_Z}{<1N?fJz%ZtJuK}bF zmp1^Ug!S_%YJX!<`y1c~aCsx(pM!-ABOwMG;RhSw@8k0GfZxQ1dB6`h!VlL8H|iEPSRRx7l3Y4*0*YIUewH_2TDn z`85E%4r?981oM!FD&ITUe1m*1;PPJq{|4-L7~u=t@H^Qf2KdEXeiQI-!J3B={xM^L zA2SqqDVN^{{5x!!2YitczKFBs%ehXI6M7sja=RXfW7Q_4}eX^Qf@*iUv!u9B`*IBD1T?K zc%YOTQA&aGsvBhsmp=l^$84K|qBhy>0!0-qywI@&rMKN~AmnRY{)Z}OJGfkiboQ|~ zJhI+t%zCE*^(`)c0{H#x9S`_-x%{b4^!K@Z05At(c*IDeT{?;OaQTp$|KGS=4%ox& zBaeD~%vb8km2vqqfE;0;c!2CTl_oRibu}pK59nh? z=wpV|E4W+<_!I1e2mDDR{7D1+=UhIiR_{wL|5NpT&E?OL$`|akM>YPXiQ<>+TTfB^ zj>}&G;cHgqk?k2nPCsz@6hKb1a~^4)H-KE=^1lG`4ZGw4^0O$sDkwi|W%!m|@hrnH zT>cK&-?QI5u&?U0yw2q+wSv`LJ_FdZtk$EvxYtUh`%NzY0DvFa?;eT$p#$9F@;LyU zXWS$NM-^(5$^F@vO!7|vxxlO*AT|Stk4e4=kW0+r0pe!>@i)mo1LQIbR6tZZ1epxO znIMyUm>`?vD}eunHSvHCHNxY?SC`pv)5=(Xmw%@nMcIQHXCv@ozqA zNK+Bws3^YbtA;c;;T$?ksD(A6C|ntQ-N9Lp+FLgmY^|)QW-%svC7H`YYOJ-XxYiGb zQfhC}ow>#JPT{|a8>ox_?JxYlvkow6PY{2wPNw2N14QU8b{FinKw}?^1&HDtR#sM+ zc!H^2h0BK}Vf4nknq0o*lXy21`VaUlyt~QeM?Nc0!f92)wDEh8kevr93Hk8eIIgQ+ z7P6YZ!);YTJ9#n|aA=j)f@5*Q9ks!vN;1PbQk#Il_!fnQ^=uuSgmX%%z2kjSduwsp zQ-M+98w~@l8W(;$4CMj*Hik6xykNGaMQX6(1e{tXf-PiTWi-U;`Q0AoE{j*%R8P;k zD)sd&msk0TR!ax#^rEsF%VoeNdNQ-$NM;&p4KL)v=_Y3Ah%+q`Dh5r+IEwO53B$4x z;yta*{|K(3&l5k`%7Af*)~#VM0xk`13EWF?AHW@hy8_4Cz_0{dVjD6~vZMp7P{8ej zI|JwJh!o&b;4#EEqZDF&OPqroip zxN1N_=CDj#S8LiLyMl1rg+yzf)-6_7=P<0oaMkt2fPeac$|nN+ds5D zpzXrI&H;{(BLHQ%uR=*nsfsw<7DX}2s^>mqRrCXlQm+7UxJ{`7W3Di|p5vse$!@lw zKJd1y0F?}I{2B#)lM4Gskh%_PG(e%PmePW`cR{gu%7%Ir)Z0k^DPuwPg=br|A8de! z`-s&|5)}F^qdz$F$hj~yVa6)Bc6L@Z+)${MeDj(RAm98PNOFUY;lqwv}}Hj)i(NtLpt#blVOU{7exM~JvEMV*rN-s89_4Njyd zo$_0+nCTb$29PIEiVgRu^wYFsau8)y_8cU2QfWpMe9^7M!)VRXTZMt-W$~U9IoQRwh4Oa9QuawG$!X93La3AQed#NKJqg zCXm7jDdHsU1q&KzTM>P9s^0*`f3$M_1g9o2QMRh-w8uq12#h_oWiqn{#yhA(v?EuI z2bvWoB*T__@F0h1`4rGqT6Q+l(!Kvnn|?jk|3*7>I<36unXhcSAP4;ZH?#_H+DYPj~oj-~x~;j|O28a={oRq50P(a%kfKu&a^?p~tkV*~Wf{hz>b;ai_RFu`w2Q08G!b?;e6pD%F2#gV9dRk9I857!__aaF7gOoyDUCi^ zZ}cHH_Yrwv0tdy?gifmg5ZOqN8i;;2#$AIY4c5RC^-d&h3BB3<-JY~(3?;Z+p`io6 zxLI8hHR{eJ9CgP&BAL0y2ks7^wzVkCH=-um#;qngflw~c_+U{tZb4$b@5Km}jq<2P zXHJa3h*M+4^Tuj)x4}dPb-I?QeK1EqGJVIFcRx+lFq~Wx%0Qod^=1U^TjgftKv^DY zYfxT+`6k;a`pSHcgSJyo*wKNL9@2pFDF=g%N#L@h%zQdPhcci$do?cfck0fJNf|(x zlolje0)m?GK>#9aaP%YU(Op4oYn1M#tAR{gv9YU03F{Ov5}`qMB|*XoZ?pAyE6EOX z6&By4GpcV~_uCqQcSKlxj}tUvaP<$x_~T%IquAC!0TZlYTLZnYLn^m+QM0s#9+&M$ zfHKT=! zBZl>`xTu^#r)MBBUNj6%qzchHV~WF8dh|jQNunkLRBhS^j1r|cZA;XNkEE2~xg=d$ z8^At25qNPeMog`D^C{bWowiC>>xH$Z6I6HH?KEW@DqA_L)=ZW4{?H&q{Jum@M+c#{ zkhYVq2fLB9sm74<=zt)dHltg%m5xHcxq^gFD)8eWYsB3JGG1|Sg7ifvy`!M!r44O- z`YS^lD!tYtV_L_a^q|FRqD3WAQfYC~NDJKnjcu4i$_${pw$BAg(SeqzPu7~isvy5b zbH>3e0d)H^7vKh8`{F40wQf*mCmiPab?m`yPN&ZaSJT~mejR^s>nM^W?7o^zCtT6H z%@wf2R3lZ)pj+SYA&=QDA=EPg4bs`zRB zERm4*to=a3r#wg~Mu(!UD+6zzxKu)nw#^TUHoL`1jD{fIFTWG`5OskxS`s>J8olTv zmjD|FWJ&}!o$T;iTRb>rn;$%Om?c_N@9R-l!+m(K!FEPW6GfnMi@&-_0+pFJ3@VXx z=Fb_NG9E|pg?epc0=2=RfOPlR!oq#c2!`k456#%SfZo}$hNy`PswrAD6N`R#d zM3lVH+}Ntyuv!PE<*tTS44k0LMz6deKkQi#tV!Zq1QX+0YZ+x^wXQ{ki-@}XhEK}b zGxk)hRj{C5;!{AzJL$Ka;Ra|J72yl(%rBc0%pB5RW3IDSGG`%MSZm+zpHOe|L0EmQ zqvR@cGW)_>=k{0;=%}4w4Pax+m_Hf#7yWr~Y{m_9U26)9VFRk8lWU@I#Q@5UgoE3%F~6}`k%?c2 zard^TgxgUj6RdIL?(Iac9oZ4eGoJi+F<395JT0A(W5Nlxp*d*Z)p$*(`;$SR2Kr5p z=4@3f441~qUd=h)Ry8Y80b=hJPGk}+i$(RdM@ygDqXYZeeHi?!negNJoEW#N6F^}L z1f2#O?J)=u0xi8RrCnPC;a#hVH14`KinI*8)gA(~)J)y$+nBJa-RnG~z*N%UB^?Fj ze;2dYoIaw^G59+qky|Z|Lbg@+VzZVH)!qm0IcUo-kG^imF88EbUew8k2>7{n{Ct zA7(t9F-LOpo^U~0ZWP)~?pb@#%6Pz$-CO#R;hhSZA4BW7fsch$>6ch1 zLB1B(ShqFD2gE*QTNphmWb-jZIg)Sq0=D*sGoelj*qW43X9=p9UQ;KZ+!{wATYO!n z1=20^_7GUjt8KEycjd93we?|+8K-e@a5~);EQhA zZi!NT9%Yy$S^^81PY4StEHwGzYhq0;^b_9^>XS5+R_LwSzrGOlWX5^=L+fCRbiFEJ zU^#9bB{T;?24Nftv~N7nRyR*c8v}&TH6#cLkVv43=!6soq;GFS8oUvG5u9i}xMbK1 zDFR5}-G;Op2w~4_NLL9-sg;sbB#^$p4JrRc=(WNrIr-S6C2^i;Er3>KL{s(7n(bih zk#`|2ZEcAfGj6rhXA?k(Ft;R?1OkpeY>>k_MmJ0qqA5wDl;X9}uo+NNC`oo@P!< zL2D1RA5}El0jKRFr){58)m~oToCl5&m!*>k=V!!CP5T*w5>uiUB4r~HO0gIVfIu>U z%h)+BwVkl}i8e2auc^ksgk*2~PineeCeL1KH{33`6#T}bY{RwoR_ntwT^FD+nc z=(fS?9c}3I)$8Agiqqn7JQt@quwKN{5+QKIHK9w{xK0pF8%Q)o20v*TptqSkw)<;T zL^nQIC@O&*)JxQ;0MmqZ3lx7QQtrG-r-$dzp&3%Ypr$Uq=-x@ua2rWw=ir$(1j)>N z!H^V5lvYssrd`yNdi4y<1bdrPrC!mLzx@R9YWRrZDXDle*s)Bdj~>~UEybm`sZ{zk z2E|;%*$eOw=Rww|;(;#KZPY2ak#HgN4Zw?ZFgy9I+xn5h^h)0%>(k{rn9uaps8QqrcnXnN+M>YL=-4-Nu>k?S|sGXL^l7fRHWyvNiIO^ z&8wTImO?9?+t)Oco=^eTMVsr^r#%duavGqyZCk0Q0!`Y$0T8Jt1xQIM{FoppRskg= zz&8y5Sd9SZ8vwwi3HmSfw*~-kje`D5z1aW&t#fFmr4D-_PhB`wF%#!eiJ0l9r7U7L>HZL$+g}14*Wr5iyyv?2M3(R)mjdFG= zF#8B^OJ`Dn*;jaDoP7(-4&iO%99>}c6W+GYsRd@I@V0m67MT5ow`m#)mod4X9LFWs2a#Pw=R?4|A-lZtpq>yu6j9d2&Y ztG+H2yDCNIa4k%7AuNKzEKRjAOEZKur!ZTT7G{k`SW61?iP6Grtr6CS!W?b2Fnc?M zwWly=M=i{!6T;#sEFfMB^X-hVE)*8jRSR<@BCH#Q$=$UuXAguWQCO3Ew6K6)2NP9HfPX4Mx}y3Trl03yU0vu;CQeVx$(poJw&LD+*77MrSt^-M$9R0?aCu7&l>K-hE&>o8Lb z8pdaw)8Hz8c1cFJto=f)`M5!ozy-7FIyPizqm8 zu^zmiEur8?DfsR}J@^NHg%QoIM96 zNNq~0&AVpWsvdrl`T_hp9}I7$yWw?A?j0W;F!cZ8$@E16ta=Fp)GaZF+4QB7Z+<+U zSbY<3%h?I18EZKvUQo-oCl;fps+e6b8F}#kJ?UP_^{WWs({2VTnX&326IGX#8~*mN4eh3>(0@^5MpQgGQa)lM76c0d}JwKOo^ zzV>^w4rYXKls|*ENqV21F}{gccpP074U=Yh2v_o7hY613@3?poPSlvP zGp^lrM0QuS>~J#v<9*{Er7Zwsc5ykm+4llu?urGt+BCk^j2Y;ZqTvH|06>797#gLrHb*`9X{qI3D1 zUf#058K69J@26G@ORQt542TcPFu#olP44KoiUl|QxfpNCDJH8p#bgtwn0&-3CSP%i z$tg}T1&C8jfpq_GY!F=l92@K(YYK`r)(!dx$6Fu!QP6?lL_s6>{7PlHZ zRz$RGw?E90bSbiZzc@MoglRdZxK*HO z|Ex>nJ_8>ES~(}|C+1z{lW-@*)mVRA8(p|UtHuD zaeim?`JdjobpGO^*MrL)zdW`$;>Ssg4>^AA`P+|6-aWse8GFp{P{MEVg$Es17XI@1 z_BL{72lhc?8rV)fJ}CYXG^ttx2s(`ae5jbp>z zYjk&-H9VOGVXZg5pWVjJo1|pM+xQ*DCn6M|g~0ge-=GXgF0gkp3q*V&Guulssl>9K zJvFq9S>i`BKiXle^sz;S1xDMWuq}j6l9bn!Te>tgHd;TSwoWUT%0KE$-P2yB_ay`8 zYfc~nKU_W)2Sqiw*Ws$+_+7ZF3C}%nLGVYzb%NW6_Y6Ge!7YV59ESya=?n4q9OACP zJrj?#;uSqGb*U-!BP`#+iB45I5QHrq?txu@4Qhh)p@XslUS3NB4c( zhcS9y!87^p_R&A!$3@Xx!h7s*oW_&V`329ip5+^>=zYoO zr}xr(Qo+K1;Tg4~WD~_#?ao;w;*tJ)1Q&lP;uM~g&#!nE_S!S_426$)fWJ@S-Co%D zHJ+(&{M3iyOF!nDMLhC9hWEm-{t^GAC(3aN&*ZpYhW<$JGq3UEc$Nhv?mLNR=|A4? zL-DCQ$8V;1D&J@HjNJZ4C7x8ypXt5rD;v+@Svap-)?qx8n|-zL1fErU_HCm0sK3T8 zqIjauemo2P3m1M)@2JN`Jj+`8-TaBdCoei(M(_5kZ+wAg)O(|ADZXm+`(YGM_4|~b zrm6eB!jtNG0nfsiCDG^U+3(|BhbUZ&?BEjL+2YSnZ^E;5{qMCDpSnCEjN*wt#CL}0n|KnP1Ygbnj3z#p&0Thy z_|8y|Qar2HKGTunqY7sq6>MP$ZqIlvD@tysdbvMZY z@k#JCB5Ww}x$FT4C%zY6TeXzrpsILqABvB9{;kbIPQX9G_b;NBk{l2piLYgWMbX6P zWR#ouUU=%0yGahBmY(iN@m1^YIZE-wU*bDE`r~Di1LCvbdua7d;&WL_MHcbBu*^D{ z z$we~wMtm&HS@HB)JV{P=&=c*HPpYM zDL(4fw_k~P&}$dolhF=@TtNPak7e0il8CPi^*M@XA>^FoA_{z^_^QiKeMRww$gcv= zGRQH>1<5Dzu`sjW8NqkFAHh3=oRVCm)-}6K@uipk?MLy2kjHX7lOcyfE>IuA=V_Hs z6JJS=KOs2C8OcQ{hP)g=ID?#!TvXk- zHJRe0&b#&sxqv(z#CtO2faHSYpZHqV|Iw$3&(sb?e=zd7tYvtQf?QI3)uDrF6rT)! zivD2e1AINbqr7MFEbJRFLC694CHjM$ZdtD*JoTTWCR2RrzFm7Mz6|^j{XyT4cm0L% zz%Sx!@}L)!h|koHM1KG}{{!!(kb8pq?ZLQD|2bU-g~I zkK&V2AJHG69wZ0UJ_TRzKawQm0Ob|^0m?~okowt%yD7f(>%6Zhz6|9Nd`CG*4ygSS zUz0~ooIrf0b}ae>!N5}!{A^1L_-P6QpYUiRq0369d z)xm{JDL(4+HE9%IhIi2);CZl*m|BZV(z+mPb)aSGoQfCk4HXO}GHF;vH_y_~rC#dg zSAi>oaHUhEZW@!ckx-yf`7=-% zA1gbLm?h&qoV0)nO^I_(fn%*ec$vC01y&m?EsQX`m#*YE6XXu#U4KzV0z= z za^k>RTzQ5F`()7ICc7Wkq&cL4wNoat2RxM3pjIvxkid@9kd^NWp}3P4qR5N7DNFHb zar1LvjW$DF)$F{v18sj!RL2Eely-Un!9FUCHdp1Y^g14e)9l z=73^8M)x>tOL(0jZ!f9xR?_ftSXx{MIK#F|mR(ftz8C~1Eq^u3S!kY0g1JPuaArZJ9v*Hs_>Igj>T4RH!# z5EfM07JuDKOQxoE#k919tZ z6eiwXa-i~VjTGzPAnRIvw)`z-xV$qCdcpPTtju(Uk_Zk9Y_zA%I*Os-F;FE2iX!@TOgo-8|KoWx z`l+`znLpiRCMKB6@JBFGAYxYRx!<3FT-T|&VxH}m3d!Y@HV!!~h7ER56wUfz0H zC`*xu3|dGMK+6sEbC_Qr;pzgtaiLa=^HI>H#i;`;uJHAbACIPWQR}^gu71|IL z$`Y808+wz)!As)2n@$R6?*^SVc+hDi(P<<=RXVLP(n;5=go&tl9~<`0!q0Z|86@r| zH0aKvp3t3b#Tcp4TcG$=Z9~1xK7Cc~Vn?Fc>D?u1^*WC_4SEsv+Ub2@A>3A#t||Xm zLzqKIEy}Oe3CAyl&R}uwjU$F4uf<-XiXbB(vZ##7-gB%m%NRm5uN$8r`?e6Y9;?XmPudT5QLvtEI zWV#jb1Qasa(dpOgP095VZn{jqVSx(2WIZl(aTLH_36*N|!W!T0E?3uMvv1V;CD%D3 z>#9#UY9{$tY=~e1Vk@E%VR#S(8~YN7b~Qjixb>-tXlM`OX9;A{mcYPhsZ7yHYOYj^l5yb4nUrK)yq(uXHR(RW8+3%I*Q)1P{DSF*sTb8CF}(Rkgb2 zwzd!W%w!Z|0Nif4Dx~7X^9cFjqM-K^fM+y7v8YG9x?N!gf%?zp6KLzJQFmGuLgv+BBxwqY^MVf;_l*#$okqMSOq-lcZB+;Ue~YT@c$7=X1WxP7TbB~9O7dTuMqHeJ@oJMd zLLx4p92a)-ZfRlM-reuA{B2k)JtkBwlUy z*^KM8S6gh2(E_6BI_8>IiPf!-2|z^Oh{gT5H+DH{606%`eC^T9k_(mbIAgP3;cQbW zn%TGB$HM6A+CgQ}b=;&}D%4H!WG4SoW)3W560Rpi|Ae2?Uy&ZE(qHw0I8F2rC(-nz zHTJZ!O598cC(1)MO^x5U-oV@F(da@-u!Z+K;Gwsz;7H#Fs#p*^v8H)1uqJurrYd;$ z2F|x9A$`gCZqMyZ;P{=|VqUYAzS~>2n*XxZ3<=+})%=n0oZD*t$2JQ2Vw?Gt@GwW; zLg0wfN(DanB5lZ^5rvj_GV-3R=Dke&qL(z64oGR2k#paFs<<20Ykj)*Js$wf=RE65 z+odUK!-2Cz!;_x$$5~pXTSGa5U~Un3_j}Yfgmg_;0^_)jwK>QOYY?y=@W6_vucFY< zQ@XRkT~d*O_Y97{37-tBU+;q`x&tNyro!{!PbXNUDSj*I3Qf=N`j0sS3)NV5={3$m zUdPS_1{!a^@pfwfvmpyr!q_Zw=TVRnV@)ZbMfhA&pDaT$UPgfho`oVzpLo7lzPK*73GTn{GIlU5<>uhSN4S z3Y6pw#y}~#`zkrR4;7ZaLhASlz0rm7@M#8c)tg;oO*q=aDshYn>H%AVm&0&?iCZci z^*v$n)lrXLlLp`>AB^ag3#RLDI4b?smYQ4~vzJY9^8SHWpKeO*b;u=bpaH6)b-MlWH zhIU99gXcmFq80kA7u}0f<=b#Xzo-&ET-vGf&HKFaVFOjn`cwl$=tLjTl4coCby+(C zeJpPKn<4H%qOj93r))Iy$ijVCS$IM@j{27cFF&?~3WjT6lpCke!OX%trf$klX1JY~ z1>UStx`u!brpZ*5=5tnj?M`~i{O*eRSHPp@g zxzo_q&>)M-LO(~xx8W4t(9qCn5TaOC&~kx+|s!&ZtWJ5 z>QTUaS;bVPI)rpoegx8=8X{4uOXI%AN|D;_2AJ|<{MNTn)x z9}|S=gBr6*ptO6SNs$NByIy=ZuXJEht|rn<>vD9xvk8VrOtqdDB2#av5%}_(oF%^n zd%96wwkuP%WZrbW2Z8qjB=lVafdkQ(YxtUp31yP5^c!PQwap$?Q@5OVpf#j?tu-`= z&87>(z93f7`RR-lx+VdYYLc)~4C5(+C_WC!z3P#iwn>uXN zzmrt)(Yr z{;k?klV8n_JE}d!WZr#+z!E=dJLHIcvzCqTKp(U53)Mm=yXkEh9ciBuC2tc;`P>|M zKZ;T6QFfK&Z9sqrH6loR0x{n59BMuQ%qbp&#&r4yKa6syU&qacTD!l&WYK6|dt63@ z8^*u2OP1()QG_DsLB4Y|>#4;DBuuWSe*`%#7nI&3Hs<&>H)g>p%E&_Zp>#O%( zVL__m_Z@ne1@EDknWC()tk;K*)SvsQP{O!{+Nh{F+Dh#dRP!|t0(sx4vBy|VeX7s< zt1DQHIy7>tP=@yJW2kZ1ila0ba7=AWX(NVu4QZcKY3zFGXb>q@r-mb1CFwCWFLOBN z+38V;AXyHBn}@XUAM_R?Sp@yo zo{YRzCstn>t8_`nF;J+kH|?r?rk0-weBV*mv^KQX#B{M-lm2NzAAv}J{*EfPMdIp! zW?d=;dR&=6;|gtrE)+)a{t(JtiVqz9#BC$mr+pPOH?7B&1^A>x1sPBXR$j)!CJryGwid*595KF$5We8CH; zi38kFW}(`gE*0rMq^7HWrOQd~lM${m>5to()EQ~6g^R{aiO3vnj;F;BnjJ`UFtohw zFcvzUl7B2TlU67WlMT+#n8R#Bf%MN#r~N4u*Jy}Pap}h1r|diEo0dygS!RfET)Kg; z;LC-@e^A6U+;x^alI|=A&u+uh!Hm}1eR0!${DrigtsIc}l z4fTCRW!ieFNmt3$RchAt_NuJ6m2Ozg;G;uTkIVF{%TdEhLH{W_@rB{M&CLb_AqwF!VG+*5&+stb2?S4FtJXPhZr zQ-SY2X}3gO{Yp$eDP#K4N|dm!qqQt$uuK&a@%VESmFc)kZ`XPk6=?XnP)DQ*iPo~y zk;m&Eou_vhr!-Q=&Zqv{G7d%g9{*pI5fdD?!=sGeU+?*98Qq;O4e)3h7_HJU+HJ58 z(;V7P$u%|5_g0~JY_~Gm6n$@JpIPBZMw>E5-m1r9u(F##J1Nqx6VKF{PD0q~o7M&B zeePNhVS5pYnvke;#ZUQwtWQOfO0P?O8U4t9hPMn&M_JM|84`VhSi=?~sVw?zF!ILz zRl)cBrPvu%ZsSKAi`QtRnmIzftlBn?CR*!ze*a|qM zb6py&9)8z8Fqy!c>cN*B`o26(^j7$C%veu-ZNs(?=6Oa=i}<41VPbpR2N(B@Y6l#I z^>)7g3=LL$wY~qro>SVlBMW&^C%c&Pjlu`X!`^1iWI6DX@`PfCp*XoQ9H*DEh zlLuk>A(=H~+in&Jv-5U>N{Le1uOMgGcWT}nu>!2@wWG=yUd#sGo1S>IZrlp+^E4c( ziLckXaTc(qd9cCT6yqO8Hs}f=MDO9No^jAe`XO<@RV^SITB0*T3PG>v-(!jLROuh7rFZ9jMqQLUxHLCKL)vaDfUA>1&@kJKiW7B zih#mB{K{91KH7?5%WPEt9gpgZmMmSdrj7j`14%d`(j<5m4E3q0k>KS3?_Cc(?`8Eq zMzZNf2yx;koss~$`2B|!^ydHItT&uAPc=Qro0fPiv(%vW%|8Xe|8&Wm<`VCD6kN=C z;;BqZ7c|9KaQ)LjsM!Y| zH4~;Une#zhnY4hvEH`?8_Onrj_hWSHWJ)~+FAE0HJr{aFq-;d)`x4Om0KLWno)>h zg+vO$wm?*&=pJcN)(`u+#HIx(vCqj*qu|j-QSR@`uTEqF-ER?S3X$f`opOFUXRMJr(x`e3ixZH~wsQNpAKVZZ?+7z6gp8MRJ;P3sspZEXhkozn%bLPyMGiT16a|ThssCU>M>KNN%!FUZ;jV-n~xet*~ zoxs=@UmCwuH~!Fqw$_&R%*IhxAR7@QN4Mo}%f|08B8QD@i}wh%r|t%RzHG6(VKNyV z^~m2aO;?XjAx3Vj76>qwh8?9p5qOEm|!?Q8_Etp95H}6pGe+VR8|xTox~zgyxanpa=#`yI90g|WiRS4mzUGBR{v?a1?nosT{@^|L@tq&Bl9OjyPZ*h2%DH zAZjt=4shu<=zOgWjbQ6x6M=%u>>bwbg)K(Ys@5FizBG)h4y$1X2jdQVccjfSMz=V7 zFbElj*uSlRq;sOZ!(oi#;GVF5SAlh1+2QnE;Q;^TC!t82ZBW0Lxd+NUt3CTEH%D6T zo^ZO%5#ALJl^qU?9Qk^;&Uy4WVdW43z`UGj9U`_GXj`q6SawDCk77t$77Rc{B%9@j^_|Tso1KPQiMEayQHPlp@<5Btvl2+5AHZ!~y z5Z>#BP{^Or1cduM5ZbQL><*C9P4VO%S& z>4lT<@$v-|oue^X2ROHR;e44x?N~fjnEXM(nb7;u(CId$7f~F(gC2i4Sq~YFNACwg z`i|x|Bkb$i+QkM;7oiXQDyWS=12ZzaD#Ew#G>sRK7-UVT25&ho_kQ-O)(wX2`<Lt?#%!I{iP9`R_VAQh$ z*Mc;O{yHGL!P`}}?5ev^g6gWi$5*gCY0==y8XDtR`m64tm3x%Z2RcyjVp5!wc|4-q z?X%Xe+pw|__u8s7OCl#^k8Ka+@pzW})KRAC@*N=PhBtvE1ls!%o55v{re4nZ5dg!hkv-kbs^7TN^eO~mm2=pW`2Wv6=vbN>LFJzYt7@ouaIkT9)j5;g~HOxk?hf!8k~Z4w`B&V6qrs?xS5 zMF>wx-8a;b7CZvlN}QIej&{c?c8YjpGN0SxIsC%#+$r|C&mEjtiX425)sQ0`5Hcd2 z$5>5^J8WOD7{@LjZ8a_INN>PuVK^eDJ2C8W@&u2JhLJ^1Q`pB7InXSvz9sNIQ(mwF`hYIlovnbk(2sn=_-yU@`e5JAtW&fZ*s z=3~A?SCj5|39FZ!GK7?`kiWrPDHv(y`U`Z z9OsKZmTd-J#2}kFZ}NvXe?rc9=E|DdSosxmtEwuiDwQeDDJGl`+Wzyej$(Xp`q`J1 zpLNz5XI*mA88a?9^PDqgO}gZ)@<~&smY-x8Q*-YpjcDlr8+_QVvP9%|>^9&)9-IcT z7a^!SIvnsaKSNh{1i`V=#jlLqr?6e;sO>t~EcW+hUDcYi{p`%ho+1k}fIoLtE5;5& zkhR%KPom*~ybp%O7dhcH?|nmVDBh5nv1e2~y$9c4oZy18&-E;}0aNH5z>yNbJUw23 zX7LKM+@Lfk!g} zTZK)}7T8wIOWVSA(lKeHe??{|wty!sUMwD-wb%a;A4*Yf`D*d-v+4V8#LD@&1F9f#!S)XnF71 z22Wu!&Ipha_)Km$d}cay4i_T@4tn^^rX)V|EMC8gv{~?(`rI?ksi@A&XwdiYCkk6{ zme_|&oP$-ZEt1iw=eBt66VC;sQO}(>^L8Q!KTl>fdlt8X(KOL87N6pD3`m-G#$NIr zoIjD(5H0fK2+`rzu29G5!#TSaA!K?XyTHKLq+3@YL?xTY`JA zU)b8SCDP(Ec12no&sBm+{!H|;o1a%ZY}&dHP{*rOW~-2WCV!I3;9h`kPTz`7(V zy!dULEP}LNP~isnten8gL=)i}oI2gfY0dIXYjV2ttLe_~neI3}2E=oJaln1<6Vqc* zJP#HJ-RJ(q^oT<(Xpb1k5aMGN1(+PV9Vbtj!MtL-$j7+nm=^QZT8SIHd(|R`+1$HlPaePtQ7uzlU!~~h1m_5hh+mL@-R>-#v&N`=z2g((@ z-B7`Yh{yKHf?@oHOHZ)+uRGD=C_&PlA04Dw?~S072Nc~2zAD(N;C^xk==S4d|N1w& z@@pjnZ`rW9iqu6mN|t;R3V2WxuCxAlkyUI0Q3ay-=0Qce;?NFvIfR8kB}*Zx@+wN- zk-90!W81_#{4*Omj(JGV=HrDRxlRj`%0WODB=@t{pv*rgsMd80lJA5H7A(c-1W2tZ zAf^2zNY?_KH3aFG5~Phk0n#l1>5mGejkyTRjoP^Y;B|+Q*0Uo=E|X;tJ6i;?^NApK zei6hjAcEKha|Wm73{H=9Ofz-_8ke`n5!}zBeh$PL#Mz>0ez~XU42D1`o~HX7*MQ>< z69)0EEy2NQMQJ#~6bqqH`krvc?#1!emW(m&p{(TZhpO*USy4I;IOX?wd%~IG`+R&K zxjCy4)=Jp{SS#fet<4Qu`fbVB_Pkz2!LjY(K5O&S@VZCeBK#ZazqTM9e+vh$Eehdp z@nD`TDmPg+!A0qlr9*)Vk~vR^5%NNif1_}2w)EMTSh-M8QmQoYnE;T;|LPT00->PF ztAOn1notxj1n@cz0lbiQBh5J;Cs*Qc9H|$6k3qTz=|!Y{$Cn}E7k-#0cx>qcL;bNB z$p2QbSMxhq)8)SWG>Rp8x4&cm;a!^3J^8Nv^t*JN`rEtqw)gquq4(|G|FA=*@$NtD z2S4JECqA;@{)leUAAe-u_lX@ajX!;2|MpWG%=>{)?fTCUfzbHNXZE|FG5f*K?8pDf zkN@YN_D%cjfMaalXK(+~4%o)CU)mq-=aYl`?H3NPoaO^|hxoDP8@u6KKKbBV`@3&h zPW)T@hVS^}zVGat5AuhR{@{c77aKrZDm72}<=^d{{~-7fwBU^-g7x#8zkg^S`cOP) zpuXfhzx&v3{#d+AD>DadnXiStS3kA?@hL0%{8KwFei+sZ%sYIGa2;nYH-BzF`#Ir! z<#YQ6v<|&RbPAZTIuqB!pWA==T$B$tJHV=+@BiGsexH60&nZ4fe&gYNcEgv%Ay|_c z-BLx5Og`WHh28lt;@?PTwnRrC@R~q zF8QPt7!wfc-g7dd5 zKM5~LQ4hD;U$zp6!>x8_D^Y)Io4vV>Keo2nAGZ;#f4A9pxAV#G+wJ!{?0{u#joVMg zML%W#`~D<=cemOfi(*hVsfh~^HukUW_QS}EpS;7ro<`o$VLyZu3Gq}lvOEQ`unjU^ zRE=DdXk>Zpb+qPpKcF*WcSW{zm}M zDkWN-Ng>q9X+;c|T*H8l+^AGWJ{qxNX2(Ie`%G~%RS9y7lh5kKZ4qv9@|l@0Z%Ow~ zuTtF;sMsi7R0_>Dt54ULynt7XULvtwoH+_T5hOx|#% zw@%*>s`c7@7b+aqy1Z&()!bVAjuoTU$-3si8yOpt&&7BHb^a}>PGRvl7Fm@@@~L4fdtkB5(IDz=>+{)I(;ycH-OrYZ@I$8^jPxAX^0N z;4yRZRIpyCNg!L^5(7lGI;(@6LNt3t&Ei#H21({E>u(0lwB<8D)Ixi?2xq9Hc%v83=%D369oBea;ZtQNZuCnZGwDA z6ljqc$!=@hou(mptKb{qg)gap-pEMWXAq91W5AdA!x;l*i7Pm3%S$EeXFqDZ@=l_N%=dy7Cf zDMp}M-iooDAfPVeCXO*PtW%BH@@_^ely}f8pio?@{(6j7SvrXq161Cy-_fW97_i4b zqmr#kCEM5p)L7%zx>0&uk`#zttf-CGl4?xdOOZXAp#cCgn@rm3Y$INY@dzYj|)f+Iq)6{GQX&GI8+G ztk|W~Dh+89aqsGDd-?DN=fL6_9XO!YTe^DI&p7YTTOM0dg~uD5B_ZdPG0q!foZVxD zfN(7L0HEv8JmYN-F!WW%8#G2<*h@86*_}UisQG)QWqgmM*@M~$_xPV{ZO#7xFL%Bx z3s!+)WIg$v6V2v)IFmME_W|x1r|&76vBTV5G!w2DEr-pqZI+$iS!P0C=7XaKwkId? zcN%;&LQvzkWj4W((85W~9oVv!6UT7spArOH2KatNB0ev?=h*p_7GOy?Yk6#L)$(bT zDz>OWNE;1*u#W2}V1%&BGt6k<#Eyne!FW@5wA0i*=V4LKK-9h0$3S1r0Ve?!t?Rp-~1F0Hy; zl1pq13cFYrNGkbrXr9>V(w}Tur&ub$0ds+(#MqrwdIgDQDc-7yrpMR{+^C5#LBTQ# zGfWzYEV7uMknEN@U;wbFc-kN1RP`mSCfE_jJ^rtc*b#z!Qv|K|ki}G4mJuhC zx~S5S+y7Q1J{S%mH2O9g`sR0z=SCM!rw!YC>7_r|-a}EU)miJqnb+C~0plMwG!$?M zJ_Q`^5pPt$;u(4tY8PXV?pbH_*g|K;}_2!1OosxbdJKm8qh|t)PrAk(|+~ab(yM@>5>a$Z5w93K%+G%=>6d zl@iir8-#t~bYxLfy7Gu^=yB{~wgI?g4KSqiw86(V_}B)YY{LSy!AZnK&~wZr*Fx(@ zwBdXo+R-c3SMx~ipcY#@ZT%hXn3vR!SsZP%0GDdV?VfgkMK2-AXjAE;)47-F7|q*y z7oE{mGC~DxnaA zmVA(x*V))BH+=}yu2WN|Y?D}-jYk%R+PA%Ja-}_>VIf96h(*$Q0b_~59ZOKORUiVZ zI`Yo{6Ef7Z0NX)-Z0QDc!3H(x_?s$4eFV_gE70X0jgq2nw@u?wBvB^%3P&A#rKpdQ zZ-Z`f4I6<6;u1^}5+GtrM&hS|O%ApZV{&K{BhrlRa1dh>u_ikhV-i-G9f&cBvui{p z>&>1UsyIi8MFe6$vN&=SB1bMNG%bIC$`)u^cAf^GY(n}<@yZ)GKA%7)h5Wb|`Lnot zG>9*y?H$g<#*L`sHsJ6}9GB;Aj2}!PXwHk*{`<~jxB|HZC$3j6t`dQh1Q`oanL}UI znmeunH);+}knsgUEXIZ6jp*dH0Wo~E`yj~FLY$r?jtuKSeP!Uhz|)bWG=~|{@yS|} zMt^sU=TCvL$CRd?Gbxv+qNf?DCpOJ7jYUYJAIjlI#O@TNgP#2iSs!<^UT2EDYl!1# z0hem+&%CX5<1ZpkC8i`qsr+0XZhd7GIW)CXH}4t3G;x!oRg7K7-!KmAPafDFY~GfI zpEsrR9QRPD4TD{LXk~I($DQn^jLSQ6w`ah9AP?*y?&OD3OzB@nFKc$%0sJ+mX&mAR zdKZU1J+?bys7FTzwi-A!2T0K4MoY{81X7+*NRg3XMSL>y=vB|&@gPaKW@(iX`wy^s zrVk5i;j*q7N&T(Pvz%SAtlTPbo)RJUa}@uiD&Cnf&UrB^uznk{{xY&DtY6SQ)?Jj} z`_JIitK@XV%BW8e7&REtQ)1sD19hB+ksAAc!7Ck}AKy@v(G-fW?nvLBGs?C?O_?SH z8#~^bSzm~k*kAm-UkgL{Xxi&1g1>MOLoeh#(FN;&wZHbp&N3#2MLxu&4v1Zz1U=-F32pB#n=N+@)9Y~0Cb|-_a3B5`K6^@c^Nq5bS5;e2q1s75uLXArZ^x{|L^$Q;$*GfRwOvt5ZaQFAW6^^!Z4jdx}Gs^y;F^}Il6Ac#%o66xgP5I zohO;iRO8T7#$+SSy?n;uY>UR)zOn6Apvzl3O}-5wj7Mgdw~j=Vor~}uVK~ji?H#SfM!VtAGNOrsH*?daZKqnew>wvL!&W%W$qg&Q**qD2l7jISH2A+EJ}~W+oH4O;{q5Z7YU@6a1kKcR@Z6aLEv;< zpRRa~20ocbwKgx`E?Ok}bpn2qa4R_OK_Ia?3Abg$?J#6lxEQ$UjLpt_uY$r2B<9n2oGM{UKbR-)61d`K~s-7r> zER?MpF6>1xEXr`NWg)#BIt&CXNLjc21}ivlPsZ+$J)yNF4N^*IZ-FBumrRIV$dP?S#&uU;$Wp+KW?V}o z_&`8HV)aF#4BHjJ07HMenn(mt24Y Rc!mT%v?#om0ShtU{w6tsn ziJctV0MD6X?Y`NvhQjA*>|xvHBz4#)mPKIXPC&?Iw1)D9v|N@s*j^*er|{UHy?0bR zkh^;=L_^AFEr-Je4lMzDY&$8^eikLbJw^8J#duR75r|CbMdWqX?i)fS1K-TpSzt{# zbg<{BLm9ny6*vf8edu6R7S*qSTgZY=Hk(807Ytw{kq|5?xRo9eb@C*Kt#xssJ7nKV z#l0qHnD`otH90#g$IB`4byCmR1WDiLrJm_r)%RmfS8G>7mYa{X23__U4m}4k({oRp zHwXhz7>{~A3#&=v|0jtHmzxR>Y-aIum#T)k147WbP-rb9Fw(*BIWMFM?&E6XIe3`v z8f+QY4gsXedNqtiHR>Lf1&Jl~XP?UDhEmr!`LN+d5?_`(Z;aP6hLAl#eLn(of71fz zlBiInX~rg0Heg=VoMD4ZDvFD-(t)W%;F00K?tvqLXtK8dCey=ZdTff({fbO-P+W- zN@qPCu-t&8d0?8XCQ1Di%&6?xb{Ni0%JzdGMrrue3*?!LID{66i5C4wDKU(82 zmOvqUD9u0>Rbm-rabLyPsvjbrOrZr^{d}-R$MJ8o*U$n#C^uiy4Qj@CnC4a2pP+uF)dj0&?nxNp6E-d>|1mlFUUPcva?j zx)1Bhb3f_(DwT>$RstD_9opzaB-Jn-ILfwRX^?x4HRUq~jza!=7OHajaPBsi;wcyISM z-xb(7lRbRb+G%8YEXP?rVW|LKj1NfezJ`oZ7@@+)0IQaO2`7Xm?Bm;Xb`V~bVspah z2trC_8EhS|yrV2*0g~KU(I$6nW)06?N9&y>-4K^hz~Unkm)EHTdr!t1MO<>PMU0X2 z@u}+Uhq`U8^UDd&H4~QnUp6pR7pEI{8yePvv`);sUR$A>Qr(Ma!~bCe1@T}r$GAl` zP@4It$`fyR8<^ll?&QG^MIlCHI9MjB8IFFOJoH#r&|v1oDL`LHF+%JGRwj`6p|=j# zlul{#H?#)JYlh%sJ+L#HNhsvT^E-TP*oZTY?L9~N5Q7en;1;?7Pg`*?o-@ww2&(0f z#F%?vl*Z@{0J;N71N*jzHYjB9610J_mP#8zwE8xMx@D3f%EhRdPC&uJ^Vb+^6RJvLXe_HG&b4_7FoJ)u1{BaMV_?K*pBqvP{&{fZs9x;3O9|iGkWY@n`x_g zqJZ;+Af)x?kPQop00}#0<8{Kff@+S!tynV?LWWwQQgdS!gA8gxje9W9duI+Y4i?~h z#Y~DORxr2JBPGV#Ebq)gvit%l{e-Iw&&+|-{3_ka1K+q4h<2^_NCBW2K^Lj@kMP!? zVBKBD`njn4J=Tx-(Cir9y#r-_QTEJ@y(><~J2SYcmorHfT#v}pTPlb(Oj>|KMV00Q zVSdUmvydPBCUjmlWBftm%3oZGT6?M)6yFu1rBj#4iGS7soOh5UD3F_#X*PR_2OWBB zv4ydxw3ja6+ubU-Q!@g5o#GHP5=<}25X*; zu2kY=j1QCFHgSbP{PP)#HTjBm|gL;%yGZWn1taUy5nL~pfP7}}IX z(&?!7ubQO0I2)sr&7As6fk<(Q>2NiK70it=OrKfVFC+6t3M?yDUb+Ht^Dm`jj*a=5 zRljuH-JvdXjZYb%GS@D4;!p9BP=|?j`eX z4AumF;`25v=D+I?GKXl^nux&z(M3)tp8bUtTDnkDTHwZXHt?m-mhbn9+ED_5=YRRb zG!ep2#LAghvvO%AMuc~9by5P_hrG}xm_qmJL{0%$p77~pP65ketKqL-X>6%?o|}lS zP|Gs(7_OV4UTi7?ql9`9?2&P+FzQCN+rGxdc1L@liv>tRr+zG zzdmIh?tc<)s*B=n@DddZ4kx`a0vowKv;gJw1g|`$Uc<3Nn_LH!V4>01q2d7Gv2J;6 zke*nfk}zIS1dWas^pk4h(KL}x=}(#q$=|F$uFLfs$B*pogmXgqSpy1sMvP(kk#NZ_ zGZYLMgDQ)I#b-wf6jT2RYReyB8NCN~rM7DnwRud#S9rxe&*ILtvnY?9i0z3OlAzRb z=hKOao&eAoiQl84x2v8YwSsUS{H61KLUxE6&V3VC|3n}8bRRVgmK`CEVBnEZrh}fa z(Gw5}Wl#8F4AtKbHijM1k?DKGzOuHE>d1^I4GHHaVQ|Z_P3b4dPGV;f%Sg!`1*y+? zQFqie6R;|ER-=& z;Q^fkw-@7j)j7GQITPh@S;Fg1IZ%dLp&#Y$H}P#W7OF_N4dELsXCMyFEVL%Hx8Y1( zNSqx(1O4GQ@TDEVi`_H?g!q;wHrMgg35oaA;b!iMbcBrE{CsDj^+t(vxFmiEu>-j2 z#vw(!8FsPAf(a|qk!I{Jw0625+F|)2_mVV7t;PaO>pR_QQ*aFc{&75gNEo7IH#e>qzww1Jg1od5e3}AgpOP6 zqk}+)<<&O*MolJcc)7?pcK zPlWErLARg%JvjApDqv_*%}Z>_*+#>35wLqze57&l_OeLlS#X!&&(R^fpMCN6Qv3;A zynQfwyB~g<+k0kUlc*;rT^tNd!%~__TYj!*j~H=nL|pGwT^W|h zU1r~GH2UqNMyF~X=Xe|Kt^lyX)*hU?G>RhizzNxN?gQcWGv**b7<#lh10wr05tbXV zc4$&Wwcs?9*l-Cs(a``zTqmO~yV#z6GIah%*OVcr8!6knE1!cR-brf9c+wt4UqyQ> zyKM`DjSu|aLj8BazXI3z9I%c&2Joi&1XJ3Q1g|DvZ4gCPr3H&z!250zyuwJu*=NTF z6e091QnK;T_m4ThdfaO~v}xT2Wxo$-z}WIo;(Mw@Wsf3h|Gq%%uPCkwNdlRYF&`P< zPXYypq&g#fv3OyjbJ&^D3N%@4IS?>hOALth4l<4dK_Md~C*lQM7Ub3os zMK$6_UQ%5N1VI{}XTJOrm$lyKNxo=;z((QNcrmuz6`*z@09fK0bgX4ujpU40d)w

* zw>LI-E=2rV(cTT~o%c^H7a=uq@R`XFSl^bmgi+YErK=FyxH77+5XDani$3Onne!(O zPyZ@{Pfo9is#Ucaro=O!XToA%W{UIliKK^XTZ{fmdQde8yg6w(%yQwd z{pT|a+P$>4dfsZ-&{Xt8H|2h6a^&lkHdi-|MHlW}*k+DxH?g)k*TipOY*f;Y*lg1o zo6SzU7h(r~BChWuoD9^EUvxnuylO)6vbIbS2C=@lXyOj;Rr_)p!~Q*Z(V8a?90->< zJpPpIF3>{+fh%Z;c)ksauZrrQQB}oD8jj=14Z8SVW7^YjgwW|`_Js4wTE~dDV}ZPz!{dk2ePqIzj{Fl9 z3MY-}=rN_}yvC9a2f^*i=isDQ$2tWvTaRh0+JnZniFmiDz2mfozVP^&(cDlRiVy0X zWwL?i?1-R&vrN&pGx8DH2M`sUiGK>uW(zvbNkz9^)_R_R=KO9}qng)l#ekm*+aKqa zKnh2m8u(-x_a%5K=e?kjH`7=LC0(6iMJ=u`^2?-xm%q!V;yW`~CdEo=J77!|v#15q z0w))Iw*Y_sk;Dd-SpP^*(|8d{z~Q82gYAO!A%)?>$S6dc>A5fw8IMlB8F@5~d66FkWI;0lUKv9uRMAfF`gK;BC%(@;m2; z6KkUQsbx(Zgd(Dk+s$k75bOif`~^6KXIl=V95$pEoexGwf3=P#0PCl}i|$;8UM;KB zU7HUe?*fp43CiYRV+Ct83pZ5~zeFYn2ZtGdGiH@Mw1A{sj8ZPsJ?oTvrH}I1yS+@~ zYa}@gCS~Bn6PBTe0nAs8BvG?+X$ELiStEE_}lG>7b7W{Rx64=k4zDNfw5iz(UuB z&U?Vo2NO9>WvAeY6yxOz0#}MFco*@oST$;saHXc5)qN0(Lel5&aVN?@fwb~AEK=?8w>Q=8Cp9NzPy^U}-oP5>L@LE*aV zU;LZX{5Ro!WYme4^K2z~TqgMp7cx+@8y~8%P-jR*f>@Z&#(PBv?<+b;#M!0-uP4%r zsFDD9&es!*itpziBn;fYsaa7~IWtzf!0d9;>5g)A3ljBx+%elkJB8kJqfe2(VHUAq zX(4_9K5;=%1Pu(P4QN0A_C5$y$dw61GCS$;Q`)jUY zJE;OUO8jxhx^@X(BIY9Y%STf!~UD5@euzJ?W%XCO(Iv7`^`8g+@amiWbr<9-1=L>s1Jdz!+o}WGG4fFIj_g*(B-G#X>@e+5+Pa;|*0u zZn+5Y>lcJX-LGF*JNvOaii78{L+Xb~K|ltP91O3NOR?+Z;|j=Vc%1raEX`mzhW%(d zq}e<@!to1h?qEYzk-w?P2kG0Fjt|b~2mTBM^F80j91_Ta;y2!MI0tjEC?%M;cT`7O z{_goL9q|ahnyU<>3-t%-#e3I=Ol#LoJ>M*ew^SjzL$CUyp&~Bwp>e^|EF%t?AeBZn2|O=bnk6G=-%5L#QMdt7H{%6jGZ{^ z7J4u%V-G#=P-@m-{F6QO^46oamv|rL4BxXh*OCWklrk2R#5BkbKFyy9rzTFi4$eLz zqvAHP*c8tnnYLBw<)aZiGvwNwv?|ZPL&tyyU;}5|rTRw<0Yx|!ApggZRJV?pBu{SE zQwG$a#xHd?s9WCo)$Lbh1B@lKWUIn)KZ_COtY*0(B5G)@fUrE)dyK;B14=UPQOQHZ z-6v2q?G58pYY|pMZ$BW$+NMN64M^@JBgq$ObWG1GSYsL=X_?L$GpW$2Mp`)uo@q1q z&vldJ+$Q|>%K)unGMgt=;3jq1C(NIyN-F;6*1u4sR3or_dijj<(`Ug8C5nfMb;0%9 zduDbvb3($><$NxG&|`g#(A|9AkSRcTnf0CJuZQ)RPd#w9tC`S(b4tk~2cCecS_PyV+oXdcpWucWQz{ zovJ`=%TOFEf+T9$jF<&p<~ADnK1t5EskhTBEq3hDrtuJx$W@<`>p0~4v}-PZ>=1IC zH&W%=l9KCqZA5To`&MAlE-rb7_-FE+(p$W1ku7iP)7W z;u&2`If{{rcv%cp1fL(N7}m9_x-_rutCZZ(cMS+6>D!?AcXzDUl=*g)m6H<0Ul zozsbBAX2j=cL0)W7+C5U*K|kjzGF;d(kPJo5J_8_euX; zpdEu^y(=BR{kik6&&8{{I)N7Fp$s9VaZ69jTUa_6*Q$DT1j;9E>W&IALKPDkF}VU| zLke~y>%WX_evFJ4Mq(<&tJiS9AL+$XDYNvo@1{U=Dqi`blN}4k{dSt-*x$!~Wd#P} zC|0)r-tX~|Sa4d)0Wh-Jv;65029x6-=oP*FypBXs9=Fs;+9Pi+> zC>*@h`;o0ae7Rz7%`y-k+C8&!=dbHKC}qIDcv3AqsV{|Tl`Dc=J2MjFO9a7kUrr4? zia?ss6<_tweWb~;sx(vucZ|1vsO?^>D=GbD3Eb9^c(9D39O+#LMhaK3^CweJwrkrhZK5aKq?PhwTD9Ivg+B-7qA- zbD_C&@j-*|JUY!a%Hb);k zz9BEtSu5|y;C|e_eeyf!n+;+93n)Sp1X@n~T~y&54K5020JO|WuaEjRYswq*zWcVE zc(|u;iQNL5g~WGSw#y`boSYA zEIRnzIXL~u0VS+Dj5={jvuJP5dD|w8a&j-&8FpSre|&pUV?*(%_PjYeBb|4euSYu9 znP_wSx8GdSSl?rm6OQq_Natd+aREMVpPSz~hXi3)LGa9<-xTWjdG*cz#1q^>BLGw~JmcTJ##uW@ugf>Y{HBEG_$X*|>w>UAB3G zv0_wfLG8|PAwX&UcGd2j*GoFTDd{}G9(;M!*Z#h*j5=I&Me$ejzdGDT2Mp#P?nOkXLTsU;HZ0j5yG9KYGM^Ik)($#b4WBUE6DaX6G9_>w|A(?96#Wz`m+o zP?=Lw_iEUAdHw+3@YABNJeJ{0=)iO_d{4t)n|pR;|i+p{;ICvR#fD5?TlYR%V5 z?C(kre_IXmUQ>)=a0v*<&b#%ENN1h-T6n;#3%;|zIdB^cQ@$#S#;+PC*$jzauI%M959fYP^IX4O3MFpQB++k$b)uLYqSC$IqC!tI4Ti zy%0OJ>S8iVtkkuou*JWiZ!5-$#srd(L}!|VGg+=~Vz zq&)rEb|9x2$;nMsx#hsNKz~I5DIh4hR=D__gqPQ85QWTl8)w^B@u>pup2>afC`fsF8 z*LJlXzUWIEID6*iEd3$t15)z5>Z-++m=e2Aauv%UFCjU;$$F9#ldms&sE>8k3COEg z2b@iy`^3@!hcm;}q|Iv1*^8rIN;+E>*>UIk#!R!RzUQvn4_mu2$Xj|I&g*qpJPS7R zd<{78+Wv-I{>xKLgIKs8j;Ckz?${m-wLKAP|1-}aP`!|Rw9%Kq|7Qeoj0}2Qwz&de z;c)IFD2KhhKt0*@NxdNU%T_VJB$8J=M3V56!(81K4D<+0rNChoXO18}L+7!4stBS5 z(Pao8XctbQ!4s--8-en0K9oa7>uAyCEr`7-ZC$D*PSr;xEB!Tzh{4&h*i8%h*v1Rs-i? z;*LCK`<3Us#CHR_Hq66gt_OG*!H-%HN4XOhJcgYtcr*qz^k&9uipM0`e7MH)-DJm{B6&+02k%H`l4O%Rr2;pp>+MA3ZkEfm2TlH9 zC7S&}qS?(^FFnY27k1xlwf?;ZP2P``y#Bqb)%ka;SpQ~dg!G!Cd5=a2lwQW`3Ly)G zNGjT@0`<^2Iuf4`wFR)ktt&&j4RJ&fFfv{eB7f`U3x0zhPQ{;_T;vR#lDumd2e_lh zX<|Av)J0c31KDrZ*#%P+`rE~F zO|3bgn-psZv49|9?fiZ56KufLSu>_Di{gi7VjQW^ZAP(1xqqxWrQ@%ZD6lH1IFPQ=Kw z!*BW2kMAt?;}e@!=iyEIi@WVeuypvK0pT@vq-0pn<2Kp&z2D*Ql9z*#KEsAj4ux+> ziwqui?66SyeqXu~E<~y`hfOICmsUoM@avI&M)>pmVSlxU4KE#8x}bD+>8!kWtw>36 zcIkUIKIpI_ImIIf4e4j}J3exB_--@l_AWD0*k?iSo|8+$-v!5_CnMsl@1uS|z9kbF9-kLarU7Gjn^cTJ~X_(u!PNM)i~%t*l;U zOkGKqr-?AXvr5gRwAf^<51cg5>6Q96zcwle!r>p=%A;&Mqo42M?LGLTIqZlq09n)$ z=lld=?q6*g{jSo4nGoGLUvSflmr%7r3F+M%(zG}ewD_jtAkL)80y}~Q4nszToqMKK z;6`D`^|-`t3Px*ge)GlG{3Z>r=Pr(|SaCYWEPgxXlats{*cfA*2Azj+0JCVA!!~I# zK<}9A(RMBx^lCSaqA13G=4Ev=usC_{(vA7>7||GEMRF-JsKz`!r2;oc>gx4YxzJ$X zJnN~#k5qT1;3vB4=wl*x#YJ1dM(m*Ov2^xW#!s~_>uSq*3`y_l=wL!gQ#@OTM1e2C z^wB)bg3v`8yHzVa>K0CN^NqoWEbt0 zLeEBX_o(J_uzxo7xqW23&~aQ02{x(t?{Q#!AD zG4>Tpr=1k*eWGbBL6UL+XFy)B|LE-hQ7HW^EeFWMioAl+EZ}Ib#u28)(r2!KbO(Xy zBs8+{vyVLiSrYgm1_XXK#4uSJNAs5Wk+)o{DE!C=#KI>1mRJBvrOf&jT!s*pf3aPyH25FO$O2tb?!d2$E)IEe(lLGxCX zrINs1b-va*9~s|IkidCBK$8~%LhkRTx8*@GZg0z5PjAZyY%GF2$Q$-Hnj>%6+wL1r zZ_BsrZTGF)+wvWI+kN-H_4X}5!;O=4Z?BiD6)pE(fW|f_HFhITO_8;*&s<=;G((ZJ z{Ir)BATD*>d|Y(9piM(j}lI&kt4fV~jF{!a?9&W9((N|E6{ zHxoo?y_VChya*ZJ(it(Te>1e#6pmC@Ddx76E*^?^VnEB&jY!F2K+9X=MYUc&=z|B? zsFXLf%SVId4e{c>Azl=v%eQoV#!rEe# z6j7LvG) z*%!$IhJEqim%0ErHmt0=8l?M%*vnb^dXGIMk&CJ;uO%Lsy=~dkV);5k6?bxM(furr z9|(CpFeBtln|w++f%~!Fb7^e!MO;s^Ei42Lx$^F#{>6fa@j0KN;HB4pwTlG}LqYf^ zH>dfwOU~nP91BB%xr?eQ`O!Crp8qpHih=p@{^G}HZRPz@!(_qD@uLnfPigFqOJ+DDu%z*IhMG?kZ~y z?tz1IYZ~l3c!$$PowC-D5KA-0bojDH+5ViSa6s(p=Ru|m<~Ly1Xg(JtX_2NdO;4^d z%i0R}hC^j-MPdbvz-r8sA@cNOp5EI=dh%qdJkh=3tg^PgxVsu9^xGTGE^F&AN*EwZ z$iXWB)i!8vIJc~AuqbZ`%Nw>W-&0!yW5~Do39^PlQRY~dIeyzjPnjCViF?CEWo;)ah|Bhdi_6+3sk_Od%~M3}C&}_k zM0qE(ys1er@ky zoqScBce8oS4!*kDWu=tOBsZN+Zi?Y$kdao*%$@z1)6sk;?!ieHEU%h}VU6YY3I^B) z2h_ikS*m`T^jdh}DYXO@8W9Tbt=$8rg2eLJWb1=m1)&VFrbI>ZRG%wy>sKy5K=73|! zTClk+v?sw~!rygxQ|_3Kyi&KATv5zO7IVx`6$8#eV8db*!mmm&K-QEm;5vaGEk{_j zzKkKbXILyD@1#E^r|4?|Ea-gBbjZ+AoPVvMbK)sPb^O$YYX@UYwY z>s1eM^>BIBrHiU-XQWuDfi5629JB1K!4w&m)Lhx+0~#(&z9eTgMzv9s@|Jlo-1umS zqW6*&DKGKNxn)v9JGKE2)ZqUCgMR=9|NLX|%<6azgMZj;jM?n)bRqK0ju^)oeehBa zR#%w|nc?q2Xi`}3#FzTs&w4@1b88@e%te$O0RgL_8tJ9WzMm|n=@orBNsqk(FQm`` z8h^O(HHZw(y;NC2M=Dr6X2?qnhit_LpltQh=Wx53Xqg;VgB0{7vX+D zLzEr?@E2+p&+2J)C&yDT7jnEj?2)3mkmC~vK`J?3J|MZcCqw4r#yvBV>o4~WDMrfi zIcHqTWdu{{(rP32_B0%vda4%LyVy=upb_t@Mo4hs06g^M*sqc09XH#C)YVH2+5VoA zO`l)M7P?TfeJ+%}aP$AJbqmnC&jI4Gh|Mk41~@^+t2W@y?mtq1bS^kKHUSwfpK*jt zls!LCnJ&ExGUT;L%aL+_u!aDBR=^883>nlLatop!L6nx54Afp}uC%R-e{*bR8uusQ zd}kWJ84cB_@807=_8`2*@4z7NzWmPFq-`kM7R5W#<_v;)56cjbR>ngYZ$F1Gsd>vN zwi~8mFC$Ah^O2>F9cBA+7;e^=(;W7L)YqGP^Y)b39aZrTC$Ana0{IQlGzapV!$J94 z_~FC(69cMfLDSka%o*4+DjX9}FLoco%$N^*j)`aVb{}RUR2m*e$HcQBV2bf56olCW zt{)T69^`(PV~g*GjEUzC6AwqlbB8w^#Z6N*BCoW0Z5YQy#PcC>iYGmeX? zsvB}4s>@;(LoxHAy4jq;fUaQ|H$?j%RRLlU6WZ`go5CYRu1aifEsuAY^CbKW#K#Nt z#|sGA@P+#0#p>gwY%(E0$)(G#FSfU3s=K3?19>B}h`gU=TZ3Tl1*#6NJtl`wM&;tk zN@T2rf8!Au=#>@ZK=%0-s!4iywk{ zy)3M5`uQO33Q0DIsTWhMkALyZ%8wf2xDfnZ5dlLM7Upsbj_$ku{4(T2UOq>eTx`kz zX!9+Dq3{>~(|7vpT#R_ksAu5MmrclutI)Y-N}=;hq$iPfBYlNUQfKH%g-+}w{I~}{ z-bVTXDXqNF8H4l?QXHx8$%W1|q%)CLpDeckr7lNlRX7nYEL|dJfBcT!0bcY+mmhVb zE2;!&Uun=Jm!?WgN4CpFA;h+dT}SBvQwk>h*lQ^D@zXV@+oax03^2&GOpVZ762^nMZ(VA&UC;NJU9{z>dePsw+4gVrQY4lg>IqQHxO2 zcU_87T~B4EdjvcK9%3Gr0SyarLxst!TLy^W5K?DTBhQgj-(-6;WT_1Qp5EscLbz;s z)yZNvgU?mZa-fw?nl?YGGI;XHScyw2O~;Wl(K#OA z9{lk$0lxZx_U?&YLgYkIF!(bLCjpqUJr==tf+ehr5gU{ug_J38DMvcMqoQS@@m5<^ zLgRfI!1*2thGwv0XJ%fH{K5C^AAG3!l|T66e^6T%crH5J@pX4l5^TPV76oUWGKWZk zl!PfDmD_OzyiIK6u^og|ZO3t5*{H$h28)7PYNylAHI0vvlK0p?{-f{1hXk~?0(EqE zpu(`pXjPypdzchR1!!cma_2{&II*QhEO~G$c7GIf900Kc0Icx*RN!uS*tg{o0bF{W z#AB~hRDaX%pFEHK4f7+T?I(eA(I^j;cF`zrT{OyDqH%L~XykZ_4F;607wO(-R$l8L z^*#6~A$|N&U&~WIvWMWXt-ALoX{e<~7hVEtnAI5VKi&HxC@XO)_iRKfh*NpXR*2r0 zx2)6Mw_zKwgv9P}cZ13|+cZYZ(QVKa{L0h5wSR$qi?R7Hz6bsyDfknVBQam4+u&V8 zzyibQ=&lXru~Sff&x={dI(LlR`i$@I&-ftFeEy8@*Ut(pSzC1t^m_DiL6`{`@zk<6 z!TV$cN}bJ;3)i_vyS?zN?;p_6rpD-{itlHn+$(Jrazd3X(x$?h<4mZ@W%Y z;ONT-9zKq2b=iulm6bIJvgoCX+SqbTuSU$NFpa55qQ3*TWOl<@Zv?DAC|H&3hBNp) zfVhmG#OX4AjuI?$C4eN&q~O5{s8WWzkDUtu7HA+49)6=1Ly-%E<|Y8}V=@48?$Oeo zJ7lDSz#TI3)*UkPmP5u}eiJU|%&8hRVv3vxk(}b)<$&ld4HYc#aPnf;X$P8Xqca({ zdLTzur6xjo!wz-pCB&E&4L_Nbl(t87c?R3EQ>9tiC(N9z$(+A`J%C+ z6fD67*RcQp1!X~1tP)45#%2PH8V!mdu*m-Xhlxn_MJk%0FNT31-s9>*VE=D=uzD#1 zjH3sy1zh)N*sxQPf~DI5i7y$FWESDFQz`BdIFIzljuY%uzGc^;ALR|Z&ch-^=fN|t zwq~gjdk7HOaOp@4$=<)(vW*y1Uvwv_-T_$s$*^t#%aFAxQkOT1)a4ENDM(1(kZ*19 ziYuC*)?&dF%LPccyI^q><(ms0T+D?BUvHLP#afWM6W|0=!6}dZ7Wx0E%P2=43|3e8 z!X|+c?3(9!eBbEJ;}sjARyNYQ=AlQ-_uf2SArES3BfV>$j7k%mM+)tP&0Eh#SBA@?<6DN%cC|H?0EQ zq;?j5!t3D6ojAMm&4kxMs->aF&ERH0^MVVJb8uSf(&;Wh^~O7_7OMx61@6Vwt((ER zE^Y?vl?aDym?5^{PquEO(>hHuhSYZYPOV@SsnOiJcvrNbjnD5wI}w9s2r~RcJ2U4Y zoCcD_ypwxsYCEBmGj{$Tw{vrscIt5>+xbiWaogGBRN2nd7{3EO?S!k=TsE3s2)w%4 zijyzkRDvddfh24xz8Ux%)MZ>yt;BNI>REZ@vqbF=^J{#$X0I$pv1IAKeJwEaoW_px zWEze+r{K+nF8v?wM!s8;@?Ak|q`UD}?TStEv;^B@*q|n7OhkJj*W(gz-ELUzH3`R% zl*9e1*n!#=&->RoC*{0NU*Ym=(*kKZ*n9R_fhBfg*Qh)eoo^a*kyJO&5Z&w@WJK00 zs+(m-%KVFwfz)@&E=#CL_AG%{4wDOedKdduhtF_y-{kvsvs{fzBssZZ zNUq7TB(|dLwW@5jwigSK^4M?`xD83**Lf~$Glvn^u$olvMb_IiSOUR?8-U=4k;leC zr)G4ch{{7M|Neh`*S+Tp<7fJ_1kLQZv5Hi~>yfv7``;2^VgniYmh~OX*u1XFZv@=h zwxPD$Rc%^df{46&?!(Fzx=S5m2ZF-s0Ac7-x1W=(X1AlTTs>wr=(?yhQ4~XBRm*eB zPed`NuRx22Y;@xm{PsiNzE6Dt+j#sl-ygs5MUcn*d1IMj4&PWE#SO0?KlI)C5m$fP zKJx7lKX!iPTmP|WtNHf3jgoTFPVcn!dw`awK>LMPnv(i4vgL(J+>Xr!Q17nvw2=Xh z_yzgzLntVm)W*~k37__kWY@nz?a|Wv0zv*}c|QGWuVef^07 zSm{hxRyteFto+FEen#ZP@H$gYGcMDjRZY*CxrH}fR9M5&?poFKmnJl@h(Tlpc-^E~ z@a(`@;&%mWqO3x(?jj#!OJZlq;K@~D8%o%jgl%kbIzhbfrPH{CrY0Gy;)twyLaLF5p6q)3|!Y~%ohR3!ZgNa~Sj zTHTc#TfV{8+_zoHk=V`?008p*GO@iTw%k(e8y*Fe1xa{Q*v`EIR=`NzV*4@VDon~H zq#@b?C~WsVt%9|uNJBu5^LF{XLcGzGC){$BOOe&*i2f(LzQai!2fMa22M$GgYSVGp zrTPsZqT3$FpQ0p4Rr|J~ZNAmIeF%r>rKTs4t2jAVf7CTj7lplO zDLz&${hexQA_Av{4$ML_AzZVOeeFu}#!~!L;VPC*k{lgRBCR;%H7-^;4BGgm3Re-h zP9J%!`bAm_WdwZL708uzVmWs*pI@k3@`e$>#}N1r%x0Ad!I85_EME-XHo z=XCqG=Tow~c>G1PFQ0whoTDZVz$OCX7QqLU%)0QHMF?_qY0z>G_L%)$rlmhlY| zj%Sr&79KsVyXy4$UB_~o5kiynivG|;Ay^(&u`AdGyozj?_l%1>Tqh-UcH(T@Q#&l9 z5=jlw^%cw~)@?*NFWsL~)RO)A7yNnUUHRTu_}KMnfol*raruwkdW{KdwCk`PlW-Lg ziX(YTEh>~U@`mk#E?nMlgGCmq9#CbIb{md2T8HWWM;K%|4LxqK{5%vXWaChz0M6X8>i_u*8#P1R!?9rqlMMgdh9NijviKDuJX#o+ z{_H&nt`yJRHJ@kJBV!Md@xfmN3Pi?Wp~zU=Fp3#al0UmKoF=T@dy44l>4;ubz!#xt zKk*8uOV!U;&oc*!5{5LCi&i+pwns7$OF!$V%iBk64`z&ZO6%?HVyC1N@&D_s zy^GsyXC$)s*n4|hb|V6HwD)Yg>6k%nmeH%NK72#YD7T5n3P}Ao9fxQE5`^628w;#G zYxDH6N@IY!kTa$|JPtnukXaMPv}c_-Ab%1)mizb5pMnXbM>!5Bup4oMR`e*}yEbB) zdk_HQlu#>!zKEV&XP&gaW*Rz?^!Oy=>mR=E0>jyb!>5HjyI4V+1sc3oyZn{Vn zX`{*dkGteoM{~5*Tn^uu)2dc4h~fro9sJASG)+aL8#99p_KuTTjWL!fLg9Od;j&3} z;#>T42Uu4l615c%&(0CPDl3;85(NpNpA#o%8(!;Blb%pQtQ9SL7A?C|w@j?g&L_K= zjn7q!#&qAJ5BoR+r>kJZvH_eu&_!?&6rSh}y+&E4GurkyZ_CE7VB?zRadvxp2oa0x z?KMv+NR_;}Y)Kt^i&yY_%XkC{!Bs`m6K&xFhOCwsZJ~qtBVE}X3;vw?Ca7CbOrNBA zLrGJ!uR+{9BvED{EfdEtQJx~NV!r2*FPfB3;Ne2NR(QCedpz9Jk9d$gRO7)iS2^R2 z?OCHxD4d)v+o~^A$Y>C_7;UFFhn&%IM1<^u2R*6g{KqnWgM`rHDR`jdtk)?L4|PJA zW8aeJVulyE_$#XKo75(Si+6yB!PhEWkTAE;dZB@&FT>Co27+L+AU+~;UO++pk_r;b z+o=iUT+=;rTKjOiYu2) z&rQ$&!7@(&5k2*WpRunHX!&XX+%HiM0*)H@qv1o4oNH3`ZPEXawKtECs>s^MZ{NPX zB%Oq8WMQ)b*%T2(RB#Ju6crE^R8$}h2_$U6ghhPSi3_44Nh3QE|X++)%b8-Hw>=^VHIPZ-;q*?;pSG=VJQadrqA?b?VfqQ>RX?6~XJ)k_)U! zwqY

    8@`(F3=rP`~6H_RCI&W>CwuQd@zD9Zg50pWNPN6Z1aH#sWaRpKDUP9T#lE;lk532W7F zc`7kna3a~&+o)ZoZWwFh80Au}gum-FaOD-v87nsxCZ&c2Dl{rnOjc>wz^mbFoh6bcQ&V!F9iz<%PauTNZW zgOU<+n_KUhL#0uy5?hHDh)?wqv6me??EBVpRXPt4k1MPFVUf(l*oE<)t_QdIzwMyd z079E^ORF?4D0OdqP^u1*U~^lC#@M})gXRs=)Em|TNvg1JwO&5n9R35)e5&q{D}u;- zL2is|xnhtA6_8tL4J6Vy;-Vy#9Zj(~kWE`S4ZF!i-k5Ui0aF`bZOcf3+g--FxTPk* zz5>~Qq!!qULI}@rJ`QNSXr8v|ywX|it4-uME9ZLZ;MtGknP9=tmZ^VUg6X;g+tE)^+ZCcqnvw*P~$^ zT#f^xG8=HlWlWCMXROpDKeI2~73&Mb#ufmxGTF{zUtp(pT_`ig$i6_KegOSoAoAB@ z+QqE;8@o}Bcr<*0CqnD|<#j~bV*Pz1*&zIOrNUfhSE9muAh?r5L3x{tM5 zPO$DBV_h;<$>mogA6((bS33BX6ikT>o+D&+4$h`1UtkDQ52sDOn-3*fWtdxGvsK6W zs0pU@B4f6x`RK^8I8V-ZZ(>@SD-Yn>(MU(y9dI(-h_S|G8hdk5n}z;uB0spW_;E}x zJt|^a;;&0i#!$rbC);3B1|pL&!3s}?L9oVb;_<%NQiUU#ambg6a~~t?>aqdc=Eigd zdsK$CrLJ3Lf6$nQNkY1qw_v2hmX%DFpEY^?X`EfncOmEf8k6!k`^e#(owJV~>B9L| zw+4PGrdvHA<-XwJ)?Rfv*tOW3GT(s!32*`+4T308k_iV8`Hm z?d0yQwzbD<9DNisVg_4oqc0e!rqs0sU>a68eEUjH;a|8Y_nf+Tgxu#D++Sd2rUurE z451xI0IXCS)3t7BItv)I+vfqp9n%dk2VQXKhYXeYA11;*Y^0$rZfjVp7ya1}&f648 zhQ+gEj~+>Id>Fuo$r$rIDUCB*BjHpU0qJ$)Y>@2VEk`r^aih5}Yx0KEvaQB!3+4E8 zfN6NEzYAr7?Cpjl2@-qM&o~+m)-Q)`Aj|6&Wn!(Xe`WEBsF}7X{A0}2f-LZeyuyxU zG1bF+oz}w?w(K@=rcYEaj8!^8E$(%{6RS^4F(cziGSPD`UR&nfwam*tYXtd^=;zkL zF|aG0@eetpC(ESnwcwM?wkyW zV^OF{!PR=8=ZubU4S?(KfXm^!tNR|8u>rTMTa8HUO%8ps(py*Q_2EzV@2;GhXh7%B zE4@!tipr^gP8g%BrBMasqLfDbF+i0PT@G9sT@K_(cGDmPxfCHm2aKoCdnmdEx8M`h zAkf)Y-F5-pNe-e>*|-tguw@DmMT0GAi6Pj`7E8adY|cg8&#?#u z+xGD_?SZTF|eKDs4&)c^Fyxy%|4CFdLdCk=@sZt0JW+S zC~(PfG-nl{egZ_({itgHY7u=*QTunTchzbyEYlZPdw+k(>&7#)0?&Drn?Q%ZKV9v8 z`ys&$OA>Dt1>&;Xe~J>TRf#&wyrA@Rl-GHM?o1O?07q_VO1}VHjf2txj`*`kf%Jg( z99MuJYQ&GO1wdNTQd^U{-osvrvrMNKl{0`BDOE1|_!)}OqN1{LA`0r z7PG8$p4f5E%Ja%dS7hg0bgjh`9O)P9*Co_l=o%yrY`eyVA=Hw* z_bn#^Y0omyLiEZ`Q;-{Jyo2$;0Ye;=ITGb_|nGY zWw|y$A|G8kx5!>VKCvu%Y?DPS*yU0LB&S-ppUZ-G{qd4N8IR|bP7g7A(W%Vgf!}Fi zDqp=knbrQ7t6>(-Q$mKDwfu`7r*-_ps>{x5e*(*4IFpnHp}!uBfr){mS?!PVbyD2} zS?$k>)v^@Mm{MWGil1gWe`dnW6+his{D}lO)(&FAnE;-y+i@I0xV3xU;Vzi|cuv?k zG~(^G9Xaz4_1s>3N-_DFX_ z?C8kT?KvpWu{^0k;Wwv&Wo=>F`D^hTfAcquF35X)=i3iSJk24Avh&^Q3hjIldoXc} z&Q}G0taM?3DB$@Da6=t%!i_KpZB2H`JC3J*oaaItyJ|Z%t-$%NSm+6NYwO+?023wUu7Rr^6Pk;FuokzqM)I(#vViy; ztAykvrN!>J`ZvBBc03OL1n%{()Ev}C#3N65*FWK~U9U*2lui=O!S8`_wc?;Mo#Gw) z36~dulz3}^f`q{@EjTZTmoXRLagKHs%N}r0xcyjD|KCmmc%qlv=++zj zNlOteA9Wfyf&fH6Q+byhYM?(NY;bQm?HZRbJiy< zj#wMK8D=f=Xz@8ucXhXTnv)iXeOMG>v=)>8B-Z8xB8$UG;?rdDxEPPa@EQxI#0()> z5Vk@0bsKN@1KSP-;@FmhC6P{o9NGb?2|VGg62G;8Y1Sb$&Uo0t0^u2jL8)0V($0dY z(;rLnZ5Y(S2RP~8-b-%48S*P0ebwqu`)DwV;(>C!0`7H*S?%jZkLlvZ(K*?<|I;|T zRV>IF77j5G?hS7j3+o#RWP}yig&5c5ya=ML+(xISqz15|C6b0XEBwL-;S4%RnB~DO z&UW`?b8Px6&WX2LyLwu>dXJW1y*QU~9KdRsUDtI-YG=&CyW^Y$GdRw50w&#&qrK=z zp|7Mi8zat%C`Z2STVLE3X*t>tD^hup0XSA5ukEB*$JTk1ImGh%6#Tz?0NP+_{2>+t z;jcJZek6wk4iStqly{=Rxp|%$ghY#W;mldL%K@~@pB?QYhlv6H&~Ajf^{-Jvy*e%o z3bAFz84iUpfg*h+iclgQvbSf{x|K&VY{qF(Ro_W3TQQFJzFC0bc<&n(5RUgwtuCOZ zk^s5hvLJp$k7~dhnQYo>GrL$=AGhlI;a_hv*6A%jB5dl?vfBH((CEXgM7pe!n$C`d zQvz_#g2VA*uE&1vuzN44`qQZYyi<0|VsjcnslxWwjM_wcYg zDGR|Co9JWqq%?D9frvCtjk+Ui#0n=H3?v~mfnBpgu2sMYb8cfnsGL!%sFt-A=j*(G zpeNZizjS{2g3y8@YxgNwEK18fZTr~gxXg!z^Wy1n#m}UPC>Dvx9^)aGaT;#XAM>lE z{fMsxdk`dM%vS}a^>O9lF%<(KOkA=`*j~KCh zIO{Cj&)DRp=QaUnOyiWd%=RbEb(?Sm^%%@-xp3@H?nkvk$b?Q!cO|CvX`t^GBMiL0 z>0(7G33H=x8P0$OM14l`&aCiF#tt0*ikT8mhtG)?lG25RbgS!k9I#F?upR;|nBF5Y zWkV`~QMLr_wJs+Hy4b+1?L_fyU!2DIq?y^ifn+B27a>n4El(AjMI;}qT!UB68YsAh z0A2dnF@|9*>nj43vHm3d44n3eZ{ph*F`ve8rIT{3_b$(|_Tc^&cjR)Vqi$mFTnlK` zI}^qi;D<6o9kZFV;G)5J!>ua3aGYOO%yklVsF+V7hqA=23s) zxRfz^_;Td`!5$s$xMlB#-?j-07zIuXQToZAtvM8lZJ=>BIe)mK_; z#)a+$wx>15>Q!VT1S;ylLRgA%o)e?opeu3a*m1J%mDauELfe4vSB;bAmK`I4T#WM_ z7~^LUOYCwS9c8SRldVI2t;osp3}J+Z4o>_@=)$TMNaCN2tN?IS6}1Ls;^I0-Tzsr6=`ya_gqXwBH9 z0)>k!46EoDoFHl~O%h+k=3+Upx9CFRCBzjSA48cCS8_!guZY($9&s42BIK6*RlU2$ z#uXiME1eSvxxE#hQ=@PD)2_Jq>X8*dATC7F8C`H&`{Tkcjys{YlSXC#sDm`&!#o3M z6=@r7q`4i6XJg+IQ3c^cIIiEmXbl)03%}uq(^QS@!DACm{b%E~3 z9CXJYJMxyD?r1ttT2OoXVh^McG;8U2$W~c@*49=F$PiYPl?<8dyx9XcnY-$GNlCJ_ zBzYZ@MC}>b^FAJfwb51dq!|*pX_jC124Jusme2_4;29=Z&u&MBeTQyhv(O_9>fubxGN$G~#D#8Us!8 z+S0`&G^67r6dg@m7lGARp9yy7$FsYeZ(mWS`ig_~3x?SXe#xGx0M$0B7BV+#xz@pU z6(9M^pIye8k0||b^-QT*EwrHaDPgtVc-#rc)!I>jSRRF1lL#nK81?0O0QE#isJ{c^ zv0DCEoI)zmkB&zCtfpP(E3H)*zjzF=ykP-m6-a$?# zGi%U-0|7B53bn8kpzK`j45(*2LX`j_uwIunR`bUWnFYw_9FT%P)(gH+9w1-9?R1MD z-0oevgR94I4~g1W<6stcByA{V17n^tLX_|p(wZ&-&oMEGyLaMrt~c#80qhr{j|Ea+!S^ldvr+jSDNL``p$R58QFSCO*Mb z(vsUO0%9RE7WUfF+PL{Lw{aM^^=!Q6qP5XU6pNbgG4EksuaGG z0{KIl!mb4ptFy-QiYmQQk;(b#3}D{0QHzL+A|f3)8nOoQL09{O*nu!LY-5Rb|_<`1n0 zMAv5&0W0GOI1x}6c7S@zAL<8)hc#4X98@1b<#&J@<_m2A#H$*ra(vBUKT+-N5pa*6MChspr4S3|9g zgMvrfxTFKrNGtRMAWnTwQCS%W1$U@%X$PpD-q6{A2>eY!RRM~Ut7`@as&SbEN~**y zp=^NMkK5@3ed9~-o-c()RIxJEwsA-!h3nE7qmU}ChyWdHi9a;(d6#hrH>19^o$$s! z@3;F!r`9r3yV}7;?z0@*5#4@o=onCyzvx6){gwC7H-bVHL{=Gx4&DS~oD-dL@SCAO z0onY&D>_yIkfx@t)@cB|+`+5Nsvg!Op<4j(lLo2=ke$KwbB}ibsWG_?5SPCc&)*lm z_wM*!FhhsHRd%v*SSu>b5sjCX3eX&;=C}?Bd%p~%-D;zWHrl@T{_ulVnt57lKAtEB zm1%}^;I@?TL1UZ(BAbTTWlS$F%Dd@(PA?XOW{Ri}jIzJsL!R7sA{UmtMjqZu#N+0ZdJK%oWj}4G6PBL~Ofnt~Q;?~p+h(`CNAu{*_Ikm}1 z8W!%1eH#%^cI|NfTX!n|h5OK-TX!O|An+Fq1AkZilhB#2mNrCOBhF5VEjZ#RvEI?JMq! zdh_x!`U}$?#spUwRw9fC`YeOmyC%C75TZFpKnkvMNP)8bXTJ(p@+Kua)__j6PRsFZ zz`g1m0-1y6TtK`Sg(^uEP%#ld2T+^hp{!tl_LDs zZi(gr?rLXg(ggV{VD8u)#L`lrk2w}o1nq1@W*Tv_2;Q{fX%?w)y?CTlV? zbFpDHtMh^NO@%dT&B~^|{w-|Idt0-+Bpz}!Aphy0M@+8<03!Jv4fP&VzB)S>ouOMg z!sP(w-u2=V!YiEDjN{bexRX-5XvsL zV*vF|N2pDJaBtO6om1n=8Vjg*olugKodI)}hNBnjmC(BtG*Ecb9|RYHpS|zeEX{eEvD)s z@WEZQ?Dn6Dt9ZfOIclb*QC|hr*D2K63?c4f;5~o46ZgSYzRlGVcZJjs>o18zHxcNr zKMuOlK=o&$>n2I%*xFj{TT|l`dk91oggD{(@*3aj8quqi0mZSu%j%X(sFp*8g%|MH zZrgN}yuAkH-Vn#z9ML0bo2|0& z>rnXQ;}!1SfsB>7?X})n>pNO2YrVxTMEh%fhil_&ecOcZXR_8C!^pg$18X# z3jH>&;J>f-eZBfP?B2TCw|}*xVAT47-&~7W>jkAVXU-`)ZmkPY_|)SS{sRi`y3;8- zcR%E-ekfinZ|-u(?LcBoM`XNWDSwis)A2`vLaxM81nZv&ycgjX;zzl7Zhx^$$i;m6 zqbHQc$p!SV5mI=Rn}Sj?7AW40BeCTn-~CqG_W^ zOnfE4S9l!SmIK)~+_KAdKNV!qDW%Dn4X`2y8G_Rv1LBef1?35rb=Spdc^;u zUw+Kj_?VQc3Ou(LdGJx+ipP9%yqCfPJvd_G4VO~!@z@rW&(TQh!BUi8tjdpW50N9w z{V3jp=n%=jqOl56v%MUUB@RAhQpEg#=%Jyw5c2wfr>^1{QFLQe68MuXw*V++bwtqz z;I~FmFsNhHlXu)ljujV`%q+&T3`n8*qM5i5cxHFRb0=`@ao{Oy+PA_3Jc~;TMf|-DpSyJ9+wvj6){RrWUPhjrp5f_)C$O<$z1u*}c?OD6ZN0PG zZ7e}y^HgEcbc}47{{iYJqUfPRX3f8)i7YI~Cfd*(ScPjQ$i;L%{20Xi38+dt(2azd zz_Krj3BCU2DUW=?{(({I@@d#&z&$>-5*Hs6*X_VH-@#iUF5d&q?@?4BD*cIfzolYZ zfUtx@qr&9ZSd{eAX`dE z^J>Af*c$(xz*?rTMokpi3;qV27ks39LC+*W+O4^}0r{TOF5@cJI6$o0t)cQ00L8pq zVyK6`y$n$AcZ7Nj5N|}G<|Z7+eR2;VKj;Yg0ieE(LiS8lNyc?~_X28bN2r5r;iEE7l1UwUZwpLRjv{9}D7}m2<=Z;09_~4yV5r zJ~)et4W1EkaFYm-LoO19=s_S_=p=$@&H;);8jUBo7EqK8I(sOqD*?4gLFsN!urNSQ z-lG|V(tB+#@Uy7Wc_NE}0X$T1y7VgGS$rHkLxJNCjmO$NK@qLHN;SZ4a)K#!_5grJ zexcPFdnm7`H~Id#$!-u?EnH`CX5Xy^((OtnRGlIsQ1mgpQ0qoxCl(N&&Hcp=>4)OF z9jqaFJ>A7zeIJZJk(|xy-ji+6Yssjcd^sO`qj*lQ3>L=HISvo$@5^;fBcW7HxWnvFiY7G>uyaoCwHt@rKrTps+9$|fT3x7T^0CL`wZwWz}_dcz|2Dj z-R2Y7UE2?FN8Gl+!Lox$h=yHP*{-cae|2Gp6!Iy)KlFe*@q-NOy_vrp_&Mo=nFoLU zB?X(J+^O3#Jot6wm-HRWyqW%Og!*9UFTT!OXa4%j;p`Cy{kcOACv^QF*#*eMKX=Ew z#1pn=c;3hB13gC^4D{}Lunn2d`hb??e%zP&3`)gs6qqtVf*ttz5`pYR>hqrY) zHSp`uNa_%NJ+y9A5@<^u0-R~Xwq~RYoM$#JIXHYne?ABGDI>N8TF1K15d@!$P&{Ct z{cHGqpvo8-_%+b>>b4aJGq+>^%%N@vyC2N`pKY@bx-S6sl>F_4IFwEF|X1<8|X}9@X#i=ao-!T(1vA*_j$@ud982Xf>HC_rI3?J0tei#zP zP@+x-6J3-?2FYW@I^k{nZgo8$#;Z^rh&n6?tBv{tKL4lh-~SY3nR$||$FGXIeW*03 zMg9!3mK;Yz>Vm1ZaGHjsA_G5=Fj4+U$B$~q$Y+};hkW~7#zfrCCHXhE__l9xko59Z zLcem%&?G$yl5TdAB-b)(JfZ&kUB*9fi~3X}NST9#2K);E#hLG*EIQ+}R`^060AkR$ zAg2GyV#Yl3TJwQ#!w0m7R&DeByiH6Od=&;>c3;H~fq#duUi|UX4&U25`Q-3U-_CkYV)oYi)-(v4Eb)2! z3}!>U@9lc=T&>g9cG$_k4%FPLsJTnkR;=7up@E>}bKIg9E32Fs>8hCb~ z*|%<&WB8qvv`S*sW*jUequ$w#lreM$(4CE2kU}ru!>=cnauygn#T$*SyEPBG_gfr~^(U*Gn@^ty_B%RYSD79t zw!mIkG;QI`&^%yWqA_Fh^sNbTs9pf7I~}Ob;*y)lwk7vvF?jMDv%*idm82!OZCPhW+~VL0#iW6HPZkGbUP&KfyvA**+_kIGq6K{6hz})F@=|@_EAB$d}BLQLEybgcj+w-aDPPCttTC1&e#t^&?l*<)Lt=44I_3?&&1;(!rXjKA8dQCJjn*n*h zqk=*rxyGuj;Kywe8QVJS3Er43gj48Re9dGABEQALh&d&;cBzFEUx@3=&r$jpxQDw$ z^E!nS#E8ptp%hNZHYuEM;^hhlrLu+#y`hv}5Ho;VV5D%`+5JzzJ>Y3zeM3)sBK`MsbF z3E9UF89ANlMP_nc4b%u0#CCOvWb@%RodGSjW+uMFKYx7bHZJ;C#~p&H2&>jg;ds08 z-$p%FIyfWRJ_wYm8b8>p5#2VP?>M3;;GVobkYR{};0GI%X7D!k=e@ zpwOj<5ITxmpc3=2aQ|~T4(Lzfu)hcFs~p%xtM>wgVpr#D3h+a%okrOu_H@l;gU9AS zzpA7uGb7>uJ(JE3h^>hy0c7GdlsI zxHr8{hq&Ub$csi}noPQC z_A{C5u{ZX`WV@S^6C3B?2o&!+cTzuhwuwi>!v1yrvf8uEW_YB`rfj$PAhDk%-Zm|_ zT&_m!cuWekY9%hSwQ|jzec6**U|7LCG%YEGcTiaGTIjapakCa4>xye|VA3_xLVby? zodw;dTKiUeYe#o%bliY?5G_6L-_Z@I#VD3dZM_zsK$mT7?G-78`wsutX*B!9VFQao zbIM6~u-7q{efOB2vt{EY=0kE9RA>AUO(}nJ;$*G3MzO$V=S9h$tliLy(z;=49>Egv7j}mDAD6dj4MJ3i|d5 zmoo<-ugKsM#MV{a)Zmh%sq0a-UD2klRL!h(#oJ&?m!o=Q6-od|+yCu*=zC?$2$mr< z>_aZJOR?9wq7j%sbn1#6uCw<6!fOT6)zQphuYd1rcA&IsQdT0`yHvSm|^VVD-ZIShGgTTou%Z%nc_- zm~tE>wE$yK1W0=IYfe__m#P}G9svSd4ymj`its8N^061kp@T`)9t|$Hc zw_}QRTVkmxzqpMm-0(dMGU5n@D;b?YO(AUO-RV3xpMb_12aV6Ot0%^~dc;PfdoUfQ znV>SCzV0FYtRely=6Fn&Xd5Li|L2rWcspL~hhJPWXHIZl>4Ko>lyEv`-9DODi!p2Q z0>d?7eED~Gzr7+Kzc0OJLa?Mf2=^&c=oSWX_NM@wR>bhYh2=$s1A{X{bLNO(!O-;C z!3Cwkh4Z*xgpcPUNg*BmgMcTkI*5ODc1)z}uriD;mfC8Fj+!AidYgA_D9PQ_JSXh7 z=&TeQ5&70Fda1XrA5xI^&OJ|V5cl&SDrD0@X6y`KUTZ)eN|j!VkLpr$UqzY^e@fHr za9e6^XB$X@_$-|}%B6I~>^^PNZ9$_weNgVot)2K6;m$>CUAlO|<@1^3ifT`_s8)8g zLM)u-r_M5`Qm?W)U#puJLwjt)6rF5VrqNUEawc5dZ1GbxM6ILY#l{Ori`MZ2t}Vb1 zWe-IUrV>8#En|WnynMM1A$se-o4Za-g|r9!lni z9ME{(jq?=@S8tcQxhxzpJi|@Xr+*|2H{F5WRm1$hFB|8Z z`4?AclpmvEb{>M^cCK`PTFISU-6{+13!l&7lb`>mIbOxK^eC(91BN0rDXyB$riF0kc`d zVFmb@t5U*I+_(&cnVYeuBi!47*{$Ko=~3O+dDyl{TTn(}P-yswXfXLR9`1-{4^WuD zDYAvh99R5a!2P)+oEI?DH5?ACjDy0|$ath9R5>8r|52q;bgHI!*HR)%=1qqO6zd^M ze1MKz=PMGA35@Y*M|3`*s*j?Bo_hWL+s-B5<}=iZDA39Z#Xg{TtRsqMfdBEkrU)qR z+fdp<7z%hCiv2+GmyRgB$6Q7pZq?_r?SuAE|t#mKX56}CS~(Ypcwmyt{Iq9wJz^DGKakxD9ByS-|v88ok9`y zg%HV=K(Me~BLOYusZ(B~R2G(nN}v%)3mZxc>JLCv=b&XU2R7DO&T)qd&ChkZjY7TzF>%w-oQH-05Z1?#O=24@}!BVqm);z|d*_B8) ze0imb>T4yEidnx_LbRy#)P`rgP;vZ-YOQxvOKhgT1)r*FB~L2A52dzaA;2xy;xwhN znB;1|zl?L9XyPLj*A#FMYs0?jAxvS4OdSy~GQ`()LH;SG_p-u?`gu}wO^(5{P&xsm zpsj-jom;_%TwuF17IT1hI6)Sa)Q{(<77x$)q&>gsN_E zR8{H7Uijb!+ybwtkUHZ;3(?Pje9{3aW~&V-P%-Hg#iZEY2+j(xz&(TlgsW%F*0Czj zv=$D-5a7u%PfY+D%>>^INo?TPUq7o8TkC&rMN5&xNLe9wL-aNBhy_$)%ILC;hjC-l zDVJbflWsXnypztNp&(Zz5rr}Gx@(gi3u}{+Zehr)FROc4PZV4Os|vrd9nrG| zZS)9;TPa(qx&VaHNwBYoLc)vT+T4?1r9O}O#bUOu4 z+hC%dsCRT9g#~16bV6b^XGLl#4^WFWBz;X1j?^$y(64}dTEQuOB{C`I;k|0$ki8c~ z-4WJ`w2q727yH&CuRr_!Z};AJ1;^Rxr3>d#PjU(4v|Ao~hkCMP9^8Ekl0%6pUw%NUl&NkYPGHTXj{AS=e3tPh?x@5MNw|41QK;Ds5>aNh zk6@M}=$@?hBQlSkx$cDCE+&&Vy?8j-1&Kf6;*J`>NcEGrtCxF2+A?<%I2-|IlLKwF zKA7q_fC{NBJt~zYPoq*}C?uVk`SDv^KZ46!K$NvvWxG?dPJP5l3orUdXgRL}YhtPw z9Du?)4Ay<(m=_AIvK?TG+s__f=#az~o1exF_|l}35sOVTi^@)wf50ftm-8OHBQv2^ zF3l@GlkGIAsNAr&+!Dl}T3oOp%7e@b*bN0I0aC-(oyLDf7K}PLhSZ;QESXF!I9l=; zJQaGq)mxjE`wmh*@XS{;u_>)b8*;1Ec?03vBq)4uh8sy6kOL&jLAd~sSD}mlnEXq? zJs^I|Gv!tL;G;nSuzH28l6-LR2rBidgM%XF%o8Y2aj@Rb!P7a}%;HO?Q2TQ3nVI-| z>h$8G>9fZdmCYzEn;V)py$DIv$lmu~`LU@B-8ZhWOnov_| ze1Q2bBtQQ6smBZHJDNJTC{(_%3{Pz+@LX(Yc>2i=)B{ta&4zi;?PAv3<@c3S=_drr z1s8HDaVBRvlI+`#jN6nR|85lY3v3ECZJM=i&n9$6V{WKyHYa_g^8JRlMv+QMP*M5f zAYUjc!0>A{&j_0)j+L|0G2QXvAB+IQO$*s7gE&Vz&&;^YPE&?KnS!7v!UIwQfl z@nn)P<8%KknspSFtJIV@&bOH#+K8?Cuj3Z9*> zHrFLV#N1FHZtK-tvng$Oo8=Xm**tzI?JedeX_h34XTBt+eM`w~znED3srV-$9VfmZ zh$%5s;LGYA$i>s7uKck3<%Kywk|PrO8I2jqVms#vi`#nQU>SUs(u?`sA}6BU-kth3 zE>AVg23PWyehEhX9OR_yKfEpNq~+FwMr+7*Io7$?saXy4q7C<}3qmgl;d|DW(-z(1$q zV@>imz-0Ip9A)CV6DGb$u@p0IIy}m-ut#sLJ32u_%z*K?j;Oi;%~N(%XN-LHbGpuv zU2?v{q*3uPsrn75p6`h2S)e(lQ6VI;B0-Tr%|y8W0Pcm3aIOTLUyECEVfVGld#f$+ z-vRZaf>M@R1$*?nl{c`7$tho1Zu;tIgvMmNygd&YEe&y&8l@ zOLp$BZ;DJzloL6R!~-Z7Z+^C3>UNa8Fd%&_pS_+zs$O`AL zUlxCP>$=Hb9{%#<&{_fKwH~{z z)I3=FxW(A*GBQo5PBdlvaRwY<1=;he&;lAAVdjCXMrO0}<@!)nl#$yJrX+|+o< zQJHwp{5E@KqRs*9he+TV3G&*J&6hB(nqkfFVavD#dXn%s>WW5)kNs5LM~ zXfl|^UWdt<@v?(Z;l&U%$dIG`$0v0EBp4WWvr&32;s})59zHe@_bv%M<+|e#sK26` zBqwQy&>ukpF>^FtaS%9x{rhTss>C8+kBlT*z-eLySH`QI-B}}{n~1og!2gJ zvVPi)PietMWYeq*Vs?OevgzH0GX#-&e5mP8#BVDJ=dy;~DX|$YjR8s%vGV!`Rl6q} z)$0>qJ=*>(jF+_iF*@J@tH}j$j4+~_aM2jAI;yGWxSs?}q$t$d99pU2#NZj!O3Icj zvdbxATZoje$vZcYZgL`JVE!9GHz8T0RQ@S{qd9b&%*w$(VY5GEz(;?_F#VOTg$Pk$HU9s zpr)8sR=OBFY^E;2a8+Zyc7BcJ%Bx{xUb*9oYtXrP{*h5bOZN4;h08dG;1Hhq)PTsX zJHF_N>dd2@a>-L<@usM30d;aswRP_GuAEhld8c*k{0nMVGxzAo>#h9jtxK-Az8y}~ zcl>QbU!q=6hD9O#pP0KmIqoDgicuBP1U8fUdyObqVD z%yCD{B3(V@9=V`3_Q4o+fg33nOMme5Vidq=b-_6T@Jv;~4)+i5T#JqE;M?j0a&? ztv9p1mDn;)7Z%zX&c4W5xE^25=xQ0k9_Wj6<8#iRjw4FW5-et4%rmSpUWAliVkD(* z!S5|b(qQ8b_ai3B&>AwEH%WUTo8togmD*8>sQ7#frGyUPLray($8%AmJ=xC5pI+MeLPD z=(OBRB)mvtcKjq~qF9mpVNR^rNA1PN*DMq(_A?Yag2loeDFhowJ<{8qXRVMJMho=u z(PS^!&~vSty-Y{6bJFd8d|O_GbzwMWicug+WZ8z1 zy>*lEC!=|i(Qj)YJlySa&9>a`j#`4m@|p)Jc>=f9GyZgtRG4;D`n+&{Y;>g78XyTM zKGzizf-K_v*l?;62ke!I^^i6^cN^j8<|3+9cQ+YiMrlR@{^r?M7)GznqNJMFWe)Y5F<=!7fFgNWP$Thd2aaIZRI(A-9~f2T^vlOKq#;mu~zg*9x>ezz1Y} zq2<9k2I0=VLCxaj*4lHCPIeYYz3ZInm z{t*l*?gfd$UOWnP~)G>keC=jY$G8S0(stxpm!{5ZlPu_+1XH@lM-x29~kE4QH` zx4u5mI?SEQGy2kzea*_;l?;TICu>L7$Wfjvk<);)^;$YL47I#nmb7%+kebvGXkFaW z9p_26zFM0H9848|0?>?g1tlcGdI~U{`)v7o-_+7ae9aI0;t2HSKe>nM_py~7&EWkte4 zhHxzQaBZAqwI7lTQdpxvPyrjBHkm$C&68A{gMGmX?DGNS`?r$mOzxBy_G?uY8~#{h zUWMSxALPyE_@w#lB+y>s5|e^0CKKj~`jaGGe|P|luN?JP6ZrcwOyjIft^Vtiv2DPv z{NXh)zIMVfqwNKNm=J|pkq`%!1E_BtPz$JQYC)#zk$dgjj(I(Cy8F4;dvbdH=to$k zwPdJoX(C-CgFskL61XpCTt)5fTpxZdn<8Fd5DChx_! z34;gVbQ2flmC?vvPU!GN4`RAqa`Et62d7lK>;-oNoprlB9#Gj@>4V~Mg;gfwI|rO_ zjM0y-IP98Sz;ESBQPctxieIGI=?~=3>jLtzWTi=?F68*y4MjAl@wJf8q~6C~EsSQ6 z)p*A66J7&PvW#gbgE8yXrjMEeKJGC7%J@9Z2uzEOf9nca$&(#6${V0FHA^$&-hfK+ zpqbGfu-|J~SwlLKx&mTu6l${0gK8IVOa+Y}9FXyj&>?mNtG$A;7(ZxWUZL=Iym1Re5n{y|}^PU4;qvHMlw{26^fw#_JcNovckGhuDNX=WW z;@k!*e$$j#3zM;aVdqazK>nm5C1(i*gTR=DTh!26!kBeC6l@gZ=Z;Vd0r7kkYIhPi zqv?cvK&UYS7zdni(nkFUpoZn@@*Yi&=BU#Wa3UaoaY8cEJr6L`qHx_aaG<80&OU(p zwIkGAKztX43Z=wBK@S@TJ3<`-#Hn30jrXR-LG=UFAqP~vq}}^}l(Yq>!-_sr%*&*t zJsZEd$|h-JLDAp4MkTGLgQP)&86W-sCTY-##$jDcYmJh$_?m9~Ki2d%)bhs>wwk^i zZ}{43x(l^j&^=nympjxHD#_UWf3E4u4t+`|xs>w-C^_Ruw5G4=KE+VY3Q$q6DY1s9 zAs?(=>Yyl$qZ(55skIy&f2NL9ZU#GlqTxv$bJQ#yoA;)6|*q&y@S=EG{pZQ#v+u)0m=p zGexp4L_8gsET~qSWrp>@JnaNbZ*s7)E}Hq__09gjzUil1&A&xxiF|8shZcdlH0o80 zq}^43kJVuzVgVk$r4P6}Y!^bLB0G%6tVlDGA0ubM04&RAn=nL8vpxq~j_%p9%xxth z3&>CAh(ne~oGk4dU}Bq)Sx=yyS&`kwj#-Bjc4S39HIRqI9oU`~*<)L^g@N1eiD$@;g1_W1K#NZ3S6+UF~9+ck*gL+aJblt&t|P&y(uvwz|+B zU`z4%Ef1gQkd##Tk2E~BCr2K=pv4fB!Kl#dYW2i123MespTRA4K5XLLDKfVhg^TMh zLjd^?1*zB|^2I(6pbs^m2+dzD0r9;69Ev~QI1b<^015_GiNbXh2RICXn~ww72SB%I zKx_ZC3XIcp5(=$iyy*ms&mEp`Z?Az|9!dvrY&R!cjCblt%lP<0^uUN0P7U8i@3dmb z%=dUBY=AX!+x#%&)aP>`R`y%Dt8)%}|J_6{d;cVR*-_J2mW{|s(Pvq9E6T25*$23d z)VJR|?I~3*5Bt=Prz<2jY~+x`w;WKr^fZkSVF71=FLpHeq->cIac{ z(`)7?mvDdM9Hz1`T;u($TnoELU9RC_%fz2)!^1e(PyFBO&D95hRf#Zda)X`4@(1Pr zp%J91!{-b^#pq;wsA`99h-h!R6dp_ab}E}_T2W|v={(prTL%-1z`^4x-H0x7_d|>p z2!)$G+r2I&E4e6n9ZfzvNnwzS5BOg zW0l~(af(zkVmW6Pk;-nc#@-F0t~Socm-d&bzz$jS$yV*1<-#PU((v!<3Bx01BE43Kx#R)psR+AF&uae`Q9NOHCbpPmk*oh@ z#Ci%0{rDm>|5vyE7sPP32m3SUR&{+;Tec%Hd`!y0NR+N z7e+hdpGvhmMz8t3P2;2!m5O2)J!3}2c5-rl2pcT%e{1&?X5NSe=bsN$Tb!eWSW7(z zAFJj&U~j&t!&KU7492AD;C;hrgoESO!I)w!6CBE`F2H;E5T@9*^F<(ZvL-g)iU{q@ zL7EpM7e|4%S)YoZ#w?CBdLdG}zNs$M=6b#GhqLUX&4T272v!CPY2TpfiCNk;)KMHG zF}4_QX+~PdR38=Nc_AoUuc;GTKEOM9svH?g=nDY-wuTlpQ^w-cfNSdmK?}lI6j@>@ za(D0Wzp}&c6W&xK&!}+aR7bZ+Z`k2~X$K6+JbWjG3XS*Oc~=}`Su^G=EHB3Ykt@pH zbm+OpJF0jc0rCY$Sq{#s?FLLO0HCtSMstJ@;%CPl{N6E^@yj^09fsHgwpFmDag#1< zg>1s{EN47XNi}w^y_~3wP>sFUp8+F1c1~d00b~AxxyBrlpocQ3Gq#~!ogp?Z+r21^ zFa#XnxQ-gka@dCU1*jRI`+MBl4j3ls5VIN%O}s>ufr|9e3s4YKW5*}*J(bR2P8Fyf zI2Q8%)}uFI!$_J{3lDg$_4o~P-oUr6;FuX2HNMNkBU~wY;(tbFUJYwq)PMC#ArUu` zQETx|F{fsKKt*;X4e62@RV?W#G)Nc*px{C=!ultBXGImuxlUDnO8 z-Zhifib;ZbnjQu;M=t?KcWRDqOk)nc4)ZT-+Z0T!-kVZYxhic7C0eFcrmbLhYs+f; z+Gw1OsOMc-Z69DF)b^p62$}ud?B4ZRZQo&z)3(jnk=3@{*bd!nZJT}Qpm+N+%b&C@ ztF6fxanO@Mc|t-(Z(wVNPb5@KuEWtXKbf_Ni}}$+y2(yr0(CGUEpQMk>4`3LTS;q+ zH={YL?cc_x01lAJHnAp=)VX0LF(< z*08DAYP7F7C@KSSptF9AH?hL-=2TReeUk>~2}_o%C$TvQ6cPMD7lUJAJ#bpXr{-9p zsZyKAFUT*o3r);B7hTH+B2h}x<(9D(H&d>(pcmtDf4|Jr$=-s6jL&9#%m>+ zYg8ez&2rQ|^ze?PKEeN)WEC33k3W6G)ebnRvZQW(2t~ik;$Kt2G?i1Of4gijK(uDB z!U;d&TtHjF152K6DOeayzKMLO$;D+TaCFqn6%}nx4YPgsK?yO!gp^P z3AFMWg<{{wt)zEV0UwJ2fYkD`#}bhkEw>nhjW0iz-xTv>xy&VHlIyF&$j&zJfV7|r z%2B?`m0CNEK;#Q=eHIs*7V6_tAbnSl3|5V5)-@tLk2$y%%QxHG^(ON6ETDq^;LzRo zrLifTbmAn21rrfx*ReYxUeA;B;a>Vk{?@6X7`N@$#@I zs3&8g)}xk8STer|%SfJJbAX@JR^9g+myw7BXN>v|xI%dT#BR z%6h+l&7uKphm!KC$a_1t$eNt!TN7|0=Nb{Q)d?~DHn_o zcH+N|-bBo(*#*U+c{4eyLg-)UMbxeuciOG4(RfW)6|aDMU8)MagD-kUYm3>%{Y00n z_TL$b=du>L&oLhD%AW|08{X>jCbwhe@C{@3{OiunYTwVl66=O!wSUFGlCZB~pQ~}1 znKGchx4YAhp@*%soimOc&KPmj(>cStvuj%mw2eC(Ycf7gI&vE`66yo)yrW%(h<96- z*keHBiGdS(dDa(lafh0yXG8BmZ|L~sKG+s|^hm$DOVyi{0epip@Ft_v_L)ZxA39ll za>}}XcmdetJ`EY2#G}CtNyA!B!$6yQdIN(0&KTKpsyH5bL~Ht4U0ac+NK|A*U1D0p z@JPlvfflS2<>qb5#PaQV%?t^gfix36@({6zF%GZp%D zjGOw^&qdH96=FofZ>*XJF-3#EH5oPN$9L4lfYo|e_js5K#(TPR+Re7ilVG;tmOeh= zbO-pWANlw17Ct^h>K^M79u&-Oul@2EI*o|ZlD+-#4TMQ;;6n@ zmcuK6=6wezL?p;4AW#}=KtTb1DEl!s@^JikYITo--^G_JyIaH6cU3*z16N5elE_hg zv5`l3p<2GU4sCn`h6ng@w=g{va#W+gpH#B_4C=Y*=&kdL<{+fx?N9vHB=PQncb*cd z(l5-vXyn8(6T}9!+aA9B9QNIjW5yVgWs=nmsO3k|np*hRc;0pe94Y4`U>aeBhZO`Z3MO`Z1}-NLE; zOl-F|_^)ZoAmd1jRhN}*p0J@)R`_RQ6SrSk-hO6n?5D>MH;UOLUtq6W^@1>}$L3{#1c&mtB9YL|Rr zcjfjcrUJ&_7yzz9b=|7EnDBk$S7AW>Qm&!ynvH!;UEI_jScb-NW0~#8Tuq4W=iV}W zqvp^gYh;B4!?q2OHHxw_R+=t(im=S;>9oDss7xpz=^azFZ_4zbtsC7fw)r+ zt_8+F6h^HmxPrG5$U2{@)x?_gI5057Xm=9ATw6gvT!$OucXT58)|dWIzjP2Wl1DAD z$#k`@2R5S#H!elQg|r3F!f(~>H`=>>)aZ*X%@CBl-!%pCe+9ze6kS?R9<&?&xVy_g zJN=>8sG~xKg%>X@DJ=4>jdf#db3te+s?=|=Vn(g?vgpY6UWr1De<_o#wuDxQ?BsGs zV!uYqcn{6H=^cpP33& zi80sU>HzbGhO@RM$DRL3?}xi1)CYh#7KPeFDErD?A)u^yDC>|bbmI`ycoDbgvDIo$Bn3oEe=#6E&f4)1mF0kWKMHp{Pja+Fl>o}?fclwT=57d{>N4F! z1*FY(5XJfUISw}iCaFk!y3eACpTkEmfwSH^mPVp*P*P}m@%U0~>lHh5UK@a8Dmo@x zr~s=D;%4NlS*?`>Plv^Bi{jw`m3Ygi$6kO#>=KXm^VzxdZ3^rw?~o%8Uo&<$3-Ow%aiSMd}YtQ2??6kerKH?a!^V_oRRPyxPG z#%44&(KSJY>|?S|Wyt&Y`Ig}=LsyVXg2LGWpF?3WS_kRw4ZS#7jBn|Dobu&W-{O@q za-pIx8m%OD_lToe;Ls2|anc?cjW1zN;a~ayJl$I01Mp%E%Y!v6E8vAcz}L^L5{@Fw zy67quwmC9!QM5#g_5Z%|hd$bwmB}h)cfKYjG=8 zIJ@UNzmD0ejz!S4%SP%=WKw-r!j2pr5TU#<4CA^guaGkgc z`-t-JPC`5eh%0Xb1g0~BuFWAqf!HTD10Sh@VVj+T=oAX_W-T3F8WhM#0Isa|_JGSm zFi5-U8WuKSEgR-8{S@jJPusY{=khkvd~QW3tumg~rj`nY$k+nf5*2NKw70icT5m}z zg!v3O*Nts;kLo?1r;*O|;udv35Hk>9q}~Ts0qt`$mkVpcBLCU^XWm zLg1t)Se4@9baK>-lOEy}VLsOVN~fX~j%$N{WfY9zSB01&m&}1S$8k>6Iu5%1mmu5` zcXZJGHiRRVSDBum+1GOuKT@Nwa9PcY4uR!23WolI;xgyh2NPC^2< zF7A|O9&(N(NJzJV0QDAc!!oyT031Ohj#_@dTONYO{A0_@Y?uN0j1Tk%j<hphHL80>%@f5@gV;(k+1rMU$U zuOb)@v%-j?Y~|X%Wibf}s@vj4YBhh;axadQpV{VaN$ie&wC(05pTLp?EPjb4!E|Ct zA(m8)C0$}kbW1Fm-J`o$EcE>oSI?wsK?MvyJWX;#V!z`;e7eWM zAo?TD2Wzg1vd7vOaxw@FV|=E7L|lNDF|l(BLlxpdIM-GSqefPw9R(Yk%to@P;cm0O z2tnfTY9onwEWDYywWq^O1(j&rF~mt~rCoq$7{3>w;N&K}#)Ykep&aWy+c&Y{m+Bj z6}NMezVw)X{W0kqSt|!l7>Dzcdp`^81_8y4-9q9*KOS%-ybW&}Rk_*?KnLwJz#SI& ztD~`?A0P9#IKF2zi6}kMe7a%M68vkBH_@pxM_q*1Asvp+y$r zgT-PZ{&Rc6#yb)?N-N>4s*%CTx^?abwvU|5B)ZPt(3wE>Inf2HXV5_4^}wA88}397 zBjay(ChWOW;Pne;uZlx^576#bXmwl#_L68F!QuYqg@dq-u4Kj%{2lU)f~x|zZn?D7 zuNDXHC*As+xB`}=fR7zqAbQ(jRX{Jj_m=`~iAHTLxeSQdO*8}U2cl0Lh}2wd5nvK8 zjFVt~G~JgFz@KJ? zD<^gY-;4JpY`ITVP2~=*QJXb%DU~Q?Ph6vR&>z<>9CX!!qWMPX9u)h>#VC3p0(fT9 z@}z!xe0jom_b2#pSoVs9|2&w07;R92=XU?=NB1XubH5T=K4)keulffQ_C6?iuLK3U z=d-JZR)a2sg@Ru8FikI?f2QcYLruSMz=B;$K&|kfhLT5PpABwCMYAo)sOMHD{Jc_- z=%lZCWx|gu6@6M@r}up%`38>u0v-Mz*FtMR%jfaDi**PV30hQ6yfPzn7ibx98R$7@ z_3VClDR@_z@J%Iq-`!OSk5uuGO;rhBR42F*+g+Wop*F#dM}Z2=%p?rJjGtE}gjey? z+p7~+RP&EVsuMPgKi;oSXb^vJ1gGi6HsbY0O~Sq!*6&bF!tJ%9qGU(3b56hXnH4{i z$(r1_x;}!sexd4mkK%hK&XrLI539Q3ypj?eM^I#h&PF}o!7X@+2%b9=;u`WvAl$1E zs#!FTsgdVQkPxs=qT2;DUf5pIX8G>p*{`x$#B2ON4)asM{ACBsicrq+fVpIz0uE&Z z^Zz65J>a7%wmx@GPMOK|v7#MMbkD3j|Ui1u5zaNHu~< zNRcW^K#HiKAov8qLQ8;vf{LPmqN1SG6czY?&y>6O?#B1~fByf~OLp(Qr_7l%XU@!= zIWtg?{Yb`t#!xRHUkSp#7TCWJ#*PHtK=Fh`1B(Rv!Smq}qtv0S1Kddi96J|eEMRH} zaUG>LL6!2`B75}`Uh#%HoVUdO#uBRTcb3>sFJX0PPQd%z@YH#*4O8D4tp~+OVRq!P z@{FeCL9^n=rEiCOmfBA(wX+d$9>>?k&GuR8XTaYE#;AI2-~^!Ch>L^9xv>37&&oys zMjI_)2|DEu0r9&AWewh-wFyuSLZRva(QvS&)yok?>s>%K426mZM5ctYwW4(`BaiO^ zF2(>?KyxOQ5U}vqPb4Sdhw#@EXpr3mKLgtW=pl7)cfE$a%-i5xZw|9<48!ICcE}S= zPU}PSh4-#*j%SX7=%IFiMgPN8H~RfFRj=6#UZarem6WY z+yqm;X&_THM949*pwO@bU@MTFmdHY)0GSJixq&GU;B=_LDU&X2SwPCmrq%moB71a3 zPN@k|{Vo1`DETHl$nq!qQz!ZRW~M)aG}6gAIP~KFY=p*_28zy5`qqG-zaK~O$D;Vp zJPJ^15cA)#uUt#|zGba_`8xViyxv~9p1vG^)BfSx)b|{F+rHo(x>K^zzHuYT>itdj z74MQt?|j!@`z}42yV?H6W+uk)eJcoeY@yZ>9p7Njdz)TTlmsSX#!x+CM#U;W2+6Q_ zSQ&!%-?mFhB2;W_heRSN^n)2({GHo|MdR|C48(lUEA)v$MYhHT=`u!&z(f)~sOJEi zPr=NOf*EA|#6XbGxJRV;+C5=bIzB0?w+tJIY3@^Yqn`opjDRcSaF}n8Oz}Mkh*c7* z08r$mOQ=17`bj_)utUA5k<*9myugkN6fH2w&c`tC5RJ6$D7if0%QDlVwnA1Q8fV{K zTVr+Bwo&I;ZCH{FGn;$X+QRe0E%1-I@_5nT~2 zn#sP6jG`~46HT09?Fiq$hJ3suWy66Xp_a&r;Z^Xp7sO5rV!~Hsc>#yuv9Kj0bozlh zgDs)5P{+~yZuR!ZSPnp`FErKJ*o6F2nE0e*fSAaMbDECKMP$CpzReCpRK707Qm9V# z{Qx=caq+1GeK(7eF`pX6NCF2uIFNjK`dGd3$|Lw2C?KjE1>BDU{vf3pP&+9x@&-s^ zS$-DBruareS_d?Vi9GmHt15u(MH1xL@oo=( zBDo%IaTu(TI}1{8JS8g#oSUjXyZ1_@(4nCPp)`@Khj z`?kewijMT{@W=KSKC$C{<<(E@+dsA2Pz;*Jq+?y(xJ#eEKe504DL0kuH=|i7Xj0wN zQ1~ct+*HM$E7DPC$Epkh#U;2Hl)BHY4TdG;aX`ijNZuSPsUzmITedh)Q}w96@#IkB zxdVhu&&nKDM3siOLt*AxpF&5B(-u$B{yf^H$0GS@#~ylTERk&tOO-t{{rz88ee-Uj z+dhHcx%>MlzCMfd?R$Q>4o=TzCM6)SmSV&agqQJihv&tG%EKPX+26Ssv zfU-#u+bTgXFWhG@-^UQD@k*Z1BoqpfEOhpZMED&Lo()0xE|4upM1v`|NbB{k?6WVe zUhk07i>scLQKossuU_ z4D=&_&gp@Kcq;%hemrTa9CwngzVL;8(NXIAHy^bxJ;qAG+LC^<uFzTkAD ztO7l^XF&M8B#cR>*<}se*+3!-M`2)}BPK9U9}hQ8rri+TahtM{kRf6bzm^wwQ`;Qn zN8qr3SVlS>pFz*!3yhnrFRGX#B~$XGJ))^q|vi-WSQn2viejC>4yR zut@FU?@KE>`^PU_M?B`T_fkR#78WgJSnoK$upJrnT+W(51>ZxlF6=`%hm218g=FYU znM9`xq}2N!IQ{9!k2?q_jy9)!EdLYdrEYOy#AkL!X6979SszYoeAFZ6`W}#2O6UIk zF&PIgmO)IuA@8ai{*B_IS7@Y6`FEf`dhvn)Is~GazkmPqjxMrn96LIZNvWB+*j@Ke z?>BRG9udIbmkZ#Z@Pqs3SFJi6sMJT85bDF-PuGv?^4le2tF3Pybbm*hwC;#jrBRve zH_k$Le;2xo*?3d`0z>v%wfW=l)VB{UAmLP-TMecDjbhBwGDrE+9!bthosgpxm=H%k zYGLwP>TPj|7_wm*p5p}+CF_<2>@Y0^x3i9CGW49G{e5Nf-P9h?T>9i9{5+kb&1O(r z7BByast<9jDQSMb8pt;Ru?>;4@klsDyZlM`5gh1%GSSu{Q+xGjyt>w(-If4gY3Rc? zx}n#KbFd=^DPuod;Zfyjhhc2jDO5X$n8@lVEIb)vt&sb!&I zRr>?rt|HuWRr{KscW~U_3QYFobjoIm=uD9!*)VYGFm+QDJw-A1q_Ol{ z`eu9y=XY@3NN|niG)NeNWI|R=qt$CS^PNJbI|rvt?LMMkJHYc$Hnd=hWD~Pg@%q*p zKPlB0-)ryyybHI7Z8wc9kH;^F760<^W7@Ba@MGCLkQNJ@d{x$p!d6mX8EZ$lTW1Mp zcOB(Dk*>^DZg{4;*fV!|vu<@(Z+RyH7ZwFLtCu}%K-lgvZM8vc;W3A!`Qf0kIEu%z z)q#7?Mu#a2A|1pM)Dn3UM|(gkOoC5?#?Rg;)LLRo1gSMcfv8w)TLVPR_hj>hX2L*f z!ku9*@beJ(MbWwnb**xP-#0MRtmNWiR7w%R!Qp@e>U9xtmjoQ2x4?c_b)(-m4-m^F zR9O(zB|u#kP<)`xTpD$=-}gRXUYH1msOp$jctzI7TzX24yo#D9pQ)bonc6v;Bw4~aACmiwqaoI ziOBbc<8P!VKgy23(UJKL9QfNXIzPsVzc)3^k9Fa1+)Z(gp0$nQ^uzeOY$wwxbb`85 zYo$3nDJGsy`-;tD7w+Ld8qm{!wDL~XLI0urAwyDF8s!%`#!=7EX#QdfmZ{Wh^wsW< zRU>i5`7z{E7x{5(JANL;bpqFUT=vnp*=}^K+67k+{0QhqqVF}-lY64j4D|%XFiX9X z!{v)i@NYGa&5Q z5-QHY=Jc#u;94!9nuJ1i2gHXO)Sw7Jk)UO{>HyU=6lxD3R^>=qk-<=Z0;-u2iU%UU z1DJbrCEO|;qbww8(J1}}*qaTotjz?b1mYlKb)!|D1WYrGG$nuu$40rmm&D-bsNB@F zlm|0Y{Mr5BWDoVHPe`L>3B`8=q(6HFjV=u%iL5>ZiR-&__Sv%>(RQU`mgCAiN3=;< z`J&^41&(MOUHG!2uEY^-R?e0>zF$mVzFFc}w80S_rhKu%v34W9%s#ZrM2(n!E;(hn{^~<~aHaJv+9@v34Gb1FIca}OXEG5eM%N(1R(L2*$b(C#z zI1%0uUcLh3yRtDvsmgZ_E4D^0|Q?UK3;7nK}F&r)fLhoWD(qr#B7Q9EIMbl;dmpaUgEm(S6b2AXei*{u+ zZ;gR0aft-nPJlE)Ax%JY05&%^NJ;}b7!X%*87Do?ZgI?dpUGX8uEY_%tgsjX8Mj1Z8}+Qs)S!gb7wIio28>Aoi<9u;G}6#fJIrRv`A9>{ImJLDX`Tyj(ImEDCUXLDRV$EsadljLr=}TwNuh z+R5VSA=?15RWPJ_)#g)IW6=v2cTF(YqSutRfI4U7ljwE9`vnq4oo;9QodR*p?Euv} zm{y{12_QPHkz77Zd#?2H>g@s5#sDRhvIoJeg*H$eyk-gW4m;K#p;in#tDkuK>9Awj z5vC;~L!8>nD`t?S*4+w9Z3QJQ-h_7|<3Z;STwKvhB6Y1tLU#gmJ0qVYlRp8qU_EhJ zttdLz)&SAIK!v}nd z+d=WxpsJ0f72&Tyt!^VI-dQ@XIdBt&4^KFXz9$vB_Pt}#Nvfy$ryNB;Fr_lp&{kU` z50xhzm%n2?z+=?K!jzwK6#T&M%e`p!$RJehhz5NVfU!K1ne9t*cig$xbMq*&#b(Sixb{8Mu<}%j(0DJUo=!8BhG0NY2^F~5H2G}safMKO*OIu{iAap z${Lb7W^9f|_8>^sX=IO%LAR-23QPdWOGc7x%}mh2ym5diwX-sseY$_yf9@bHf-{!v z@7;T7W@cJW>I9Ur_h$5xTV)x~5;47f>jh$$jl_y|!lelzCfrhH^jqU63Ag*;@r^1@ z+|vp_Q?q-M*~fsnH>K2KUG@+^TtX~L56w(W^YfF972h^6(PNurX(_t*zi3Ha{u{2l8hXSzEUsf zJ|K71NRA7d)99=x*ohImYjFDL^<(CCB!WJqkzizKz79$C{8^8trsRwTakwiJGBdK7 z09Z9pLNVVKFjDiOWTsUxGkw8KwSgI7Db(#|W%Ev9{I!Lmy?;4s{$hsJlsF9Nxe6b3 z2e}uCz}iW)9cfs}80-YXKR=Po?2=oN^`6On0KH9s@Hh$~9iAMl;yAh7+ZzLdIJ}jwSq@CJ&DGmkH z9idQ*0a0;8LTw}-^-#kA^{-H4pzaKX`U?=R9+kA3OIhm6_9!5G zghH+Z)Zwor+JGRHUW*>by zw9i?)pT4|Y;avW?lh)b85@3`{wUEuz70zD{lGt_}axVRx$&XM8qm){o)9V9Qy#-e@ zh5y3*s`cP#{jX#wN>gdVls?Bkch3BR&@TPL`6>JI_Ex$d8 z%M3vE3x?9iy$tV^%m(Vd5+Lb*ULc}1(2NG{Zy{yn&(VeR89UkkX99DLp${~8derIL zp2Lw~Wy~3&Zl9bHO4Bs^xeuZVZ&8%TyjC*4G?Z?wyz)YAo)-WQ-erO0?BIz zlFU>Y2PaHri=0l7xXdzh4KgO=^mtNFODr_0P;ool1^%TCX&m z2_y#*OF?}770JM1VnFZFPXzeH_l;j5DD87Xl+>1iNsGLq&dgcB!2Q7qM+Cd)cyBdxH%R~AApQhcLEYHd5N(FFw?F3@zdys*2y}N! z+G@nOAe;Og$XG(jNLxj?sZK>h4wQ_75z?mkjso*UYzgFM0z7p6vF#GAWc;Pzl06TS zYA8uQPfR7#CXE?&J_*_Bn|~)0bsSKyX^d|UDF0VdS8u1X>GkzLAY}a~LNw0S2zl`X zrxy(NJG>vT$t~W4X_OS-7a)^RD^+B`xO#e-Jdg`BlH)4EOIAO@4A-Ps>VHPDsS6#! z5g=Be5ga)V1ABehrh}NxNK8L#atlzhw#X+hTF_4j5@}tweDd);njd;5%QrzZ#sL|F zFtn#`byTLVXN8gaFBrIRO_q8hF`;i1Gr&Z+feB$BIaTWDwE2^0{3xT&yxCyevMBs8 zS|RkU*&ukwb+hur4Om6PyxH|@&a2m*G;fCG?loC8^CsN*|(5 z=Vm+qiB$d0&X%)Ff2P(p8s+JgmNs-OCVWsIif<2*u}D(;q-gbXOmjibWgr*SOV(#Z zh>#GYFBkY9Q?X2K@NC|m<2p9iMed|n4IvX3bMD-3s(Bqa`3ZV<=7F6E!H(Y5N%TDj z8e79;SrUWCW=QR?+!yTlCi*@Bgxe;euFACsYK%+=(XL+tWdBgeI6%FqLH6=s@>oAU zo)4%2p-?4&Fo#QeXIx^+S<+ensQW{qA^>q(gBlqT1obkY9tedx4~W5bN$apZ2&w>3 z0}W7OsP+V4?r;Rx*ph{=_los3rp~W#lv)U^g9KJ%1@!{TDY&>Jd%%hApFC?>^o0O? z(7+BGrOpJzbq#7CjW_j^3B`bVC=|+$mD6RoIIS~oKO}+f6_`v^2XPP|)Y_ z3RmGuLVIGRYfm|e_T5#kYpdu>^%~dWwe;n;wXVu_^yTCAuEQJXOYvK-6>rfO#nT+& zTnUn$9!_+SdeOWBR)z>xW=W5VPZ;zBC%?o>@tA1RUaz|=0QrbPJZwOE84w2=OQ`b{ zvY~G$uK{YP0ZIt7&|e$IUwYs5*ZVFE?~As&^0v_z9wW_#J4-H)==pjb z6ov^3(#*4+d-H*PWHZv(zz*8Cwz)+*o|F7OFm<(m(I>fW1; z=+13-ZP>wdz`2v7vwB6ZEz!LJbdT19?tY+JF3_=eQPe+nxR!pzxCWA1^j;sa1rlVGCm1EL|~{E?`VzR*ce$+PlS_A-SkmKGL5~`klQ#H*^kNY+s<3a z9r~cPsU`DH_=%AN#T!um!Ty7L?(0nIpFJfz$Dgh}f`ozcmS^UWx0ajj&yr6PkyWWW z-1fBMoC-2ze0TqB^$gt0SKF zUyzt=XOJrFbrt^tleYgE33K=37nASRYm^eIvjtD^HAxV zbC4;#D#GzhZNzFB=-Zu-!Xo$5|=czo~J=H8eDivA0U zH+vIO@))Fa!a`b$_*W^Wqk1uwlb9YPL?>>>fwJoMC)I|Jkp?bb(kGF83m(S*&;(i_ zV#;feP$Qeuc>$QWIJhQnC(T<-O2rCNW)@-`?q%A0^UAXXI{}M@89BX@lf~Wx+TYsL z4HZQaL^!Lvr`^~bjn@W=qf-Tz_|%k6*x3MmPK48ftqm&PA^XJ2d+pvn)PC+P8$}*4 zbqehEnenz2#S7K5*bx^O~s!n0A|J32P&O~4L zdd?sLs#+6}*gTS3iu^%rF;$Q)t2)L5DN9HU(9D;OO< zoggS*x?em&(IV2+$h62^ma%w5R+&D59L3bIk>3u92a(^d&RibmtShz5W!hZ+05mzQ zJdut7#w(Wa%4l`pSiE(?ak%_8ao6gigfk{2oC$O9k2dXzHt%j+_lN)D1=Y(k&qOt@ zt#j5ju0tj!M#$Ena_;_ab>T6D>EeZ0mR=Ir#eI7te!mGN-Xp5wzM~nxAAcATwk<$% zuxZle&dTaoq*!<1wTPCL(QZbtb+pr06LVuAj+(A^wxv^^+n4+K?^$_ z0?#{_x1?8*iqF%vBId>r)4nm_tb2v)_DgqE^r&^->AX~WOSHG58{iWz^<=LkT>5tf z0VQ0ztD;A>^KR!Q1Ic^KqX~e$(97@wxF;TZmp7yr@GId`--;eJ&O{Jt825O^oXGpy z?H_;XVt;Xyg8aK;vm{RZyT354NkMo89T=_)9ep^}HPZu6_GmC?=ilMd89M@W$^@js|@sA>lHf#fu+e1PEe<~i&MYRNed3S`fR z$~otAt$3MWDj~gbmkN7ab}ppH;AprBH%cmSr;N(b!c;l_a^0eX2U^%x|m_R-|3NbajmoYm0T2kV8%Nn z7)i^womYBZZne>Qwddv5?>a9Bca#ZvWZ38v)jLc%G5}q`GM+-aK~+tyM2#myvxx&t#6xQ*hGBbh9ImrGUec+!zYw z<+00wzm6639lb;X?&DcJ%T5XW6#Go%`OXFkIRMkJWgF1fcny8cVCrh_$E%`8Zl0Dz zfWfK6V31d5-O)W9kE8*`9<($vkC>ex2$o&(4oFy}Bd7BTXrD2Kg`3nPI6B)Brq78N zoKf)tB-#D`Fhy<`kxoYg+sR}iOP_x_aNsQzE7DLbwoCdkfQVw4KZ?O>3GY(v zP`@B+=WP@t%214fY`-dA6~!1I1l*vjjPRUfao0)FaYI^(KV4G4Fu+Xan=?{F~?Tx?nzC z&wSuO%I<_eXIXb;>uB=0Z-bMbk#k#i4x(_9 zZv%I$T2rU&K6tc-dh6R*qRJ;bjmvHcAEj#!KP~evl5Fb$bMy4fX({yh9wqPKNY@8v zmad{6JUc5{8AEMLs(l5_S872}l6Mk)b5i=bd!9)XDzv`?szTm(Vv^QQBb-cD-G19KP zqpios(|f{NP)`MxFs9c|S)?SMlj?3*o}y#PprV|;Koi3q_K6u7rsUyL6S@Ml3 zY=|=NDv^|ed>3VCD9gaYaG4sANCp49>g8W}oX>Ax^8ig-OAC0L{DOO9$P@}g2&>Vb z+Yz#TW=gc62HOj~%|5T7Aiq;#Mz~pRXql7i)e0gZvkt$9!i=cmSj6fNpR1VB+M;a0 z#qgWrZq}9pvgA|CA$U0M&UB9W$rxUI(fuJCR9vdB;t@8{TjwLFcK>m z(N6>hq#VO};cIL(m?@@#kh@jd3}P&Zmj`jQlj55JK2`?`Z>0ENP>eGcy+B)3BO`}` zb7Dl9Et>vWR+UX68J(Jj%?Vo3vwKe&mhH!V-(C>A&I(_sElT|Sx$E!G|5wpJ1S5@% zMUM?|LhCacC$y|uOslBZr?jl0Mb&zW-76zya8~9dq~^~8NA22Mlm)o-NqY8v;d<#P zN0>(+KP$kN%$dLCG89kbQ#};W2yv$NOD`q9I?icI*1P< z?;pFa$bp+8!&zolHrA$#)amIHN#LrmAx>*~w6fDq85X7-$HjY}fKt(n4r@z14wSf{ri*xi)2n`q zx(PqAF*g;%>X6!&{W0`BaFXr2in%r1PezqGGMZqO_ID?Q+Qg`DJQgGn=BmZKMuTtx zsrU7bM;lR7(;JX}bZ!|0=X2d^QAXo3HnnxfT&Iq)sYlU?BqF1k-ni@nBTWS(qNzPg zwYwU0L{G5!pKF&L!_%MjA8Dn{l4dZVvZm^10;I6Hr9n{=NuWP_6skSw;VCS#ByiGp*X_h_rZm24C@=mrfH{$U4x>^s7 z%jkY!mo6P65#ay3;bF=h;Ge50`jpZnVuvOQ zQ+K8FzA-rc`5Arn22N%VaYhG&m8B!NGfIAfTIe$N)2Q5^!g-c7YU`#Z4s zG_SS#o7W@BZ^YEEg5w0~R_Wh&g|k~(sft<>Z;N!Q*V17CFas@)a%VZfP!y?)_KYO_ z;FgARfYBqJ|2f`Ls|5QORQ2@90q@1Qq|bSgmz#MP@*Uz^DuQgPyCKE*gd)gX>->Fk zI_cPP=2ep7DpfPh=2i#E$)qzGEI4)HCNt&{RBJ_?na)hTbkRm?ef5fc#_C5|q6Mpy z>Bqgup-_eF$~6(?H*wP@etV!bVVIbm9ZmD!{4TTzWH`HVBLQFFpj)c1sxwx{(4%{JBeI0CMid@d`Z&Q0`N8*x z{AwNLEo9fge!Jj!s%|>7g$-z}-cpO_$c)wTI4LZuk)^z0DBcE6%Zz{0p-s@Aol^P}e)jg2&NGWG#JcXYngKMbTZ1WKa$OA-Z z4qbFa)$Lb4MEz1AM#8v9(zmjsMR~S6x`DeWR+ft!$FqIw`s0KP`+e4a=i2ohEtswP z-u1>w>h`yvbY1+}WrOD16VQ1C7Qt%2b$xe&t*x08Xu~Oa7^F+*esFF1k#Maz%E_u3qh+zdK~k9bS?XlJ&~az12WK88Y5QrLL4^>Go|H0)d$G%m@Od;ioPhN z*o()l-!~#bVVWM^jZq9@tEl4p3!;d;UGwELwEUZ-r(`2P2l04mBmZYz@Sa&$7ej`= zzJ%%`du--2{WH`3!&CjwJd~A~J|SlcA{BG|zHT6V?2h0rdBJ(t=jWMBL`zktlT3`6 z5xxLh&5hkMi~g7UV5l-Q2Y~|I3P>dVh9~?sLp>hlTGJu`*nyvVL0r4|Ef@|mP%dQ_Tv)Vy|3_6oS-9@z{o3ND8S75JY zz4as8FpCnRHeASp9$Ay-K|{O0vtA}O;;T~+X6B@hM%W>fQ|_oyX>6I*x4x%E*@D9- zIS*fFAOJ&ON5?_GRej>&)M#i>BuSI5ETnOQ``*e0q$@N|cmyg^|Nd%-@8)|f%9psf zFDX5x4cA<|t})Ss3AWBl(db$G2CTLIpQ6#s8y`{WnpFGfc)Mm6?D-D^>P zPmp4E(NI|akDpiGxruS9 z-xEJzOa>O(hUBCvzSZFBM_inKmrU#k)6+f)+U*RYVXd0e;YL*urRphT=48T_tHh8m zWgIe48O6c&ywNjTAB&RTPm)a}vihO?DUfadPh`=~X*kPypqUJ|rE%2hM@P8vBQ=}1 zRn3?$yw9Rk;o>D6AtkIQcN*kwHIm~!iENhSIWz0U%{g&E0><>rrUB3OBOX$-A3;_v z1U$-o17|_9O@B!?JriO5dXhhYWCtV35=DjA|HX@=1%#iS^fIyIc>FcMg!HEU8bpXF$4> zfpn1H5)UG}u7SmUL%1+K3oaLW*%SpG!rdz)1B>d(Y=m9@7O=e37;d>Zjs}7fT{A%2-hnaj1kfKpv{0uFVvi&ZNcu3C!Onm^bXP zk^4KEGjWMMCRCC_VtoJ58SSYYh*0mBnVg%=w|Ul+mBRLbMTs9M<@cGCpMECgSFq68 zAU{LLN<(`lJ-+>eX)0IE;S(PCo-`GS^bn(t*3MVfvwb~5u-_m_^y^IY5_*Eafnb+V zf*e21U1>WbNHvQ{H8*YOu_c<3LW!Bp>y?%28|WK_H`}h*1koLK7A`b%}q&0nFhC4?TGEQ3a_MQQ zfEr_f63YA-VBUj2$dj&8cTP3<)y{|?cT!#dvNPi4Pnelgb}D(Wfd$%f)ZASW^FN_l zW;M(2)Awt;B3}H2)vQ_6Y!A6{R$o6>a5PqMBvS{oZQUP%n{8vj(US!^4-jr#S3Zj< z*-iY++Y_;P4Li{vn|lVHn&tp96dm9)EtOd$6lp(6Rv}vX9wO)6+9cpg^9jT!ExkRDgTKs z;dDq1X$Z)12KgheT%xZDAd)qxLZYXywHQE+4~5DA#1;)|7ttayNm@4nDlHUh7a*>r zNe)|ig31;PsPs^%8-Uo9E}?b>GI<3|SsWlULLs*UYM+FpxwT{WI0sQ33{8W<;TsVp z%Z-2{GZe)a09P_3@kCb;RAWF*FhX(b?gUIb4bJKgf@=b}iAFdw4c!6pfd4!n(@#Ydogz!FF;W+NGJA7i%QZ5=vQxhXRD*Ejq~36E zKOIqVnxV4_^Lsm?(<>lttes>;C+zlPKvtL~OEr?x4(Z!hD*!%YC>4vEUkZr!*%E4z z2T=NoX$`2!p-{I2qDX@p5M56f-v*FVLLrv{s&0~`=ksFMhCUR%Euf}`LaEPKl*_ny zpLBa<5L7!rO$&v(4v4}j5^ACyQ2h8>)E1nO_JDfU2*p)=DPX>xD&d}^E&qC%+zPno zjBrKJkDme2`gsYp$^|I>PJ#}AdOj4Y3m_(GP>1DC0e#JN1mu4VkfL!+2i)=hK!ps> z((BhFPG2V_s=Xeu^#;=>rl4GQ!yLkmljfllu;&Tv(peH3bq2Vz@??puk;31UkX-;d z-M|+M{(lY-$2F+uf;W?N1=NgCs55|QK3&qX*Vml80rG`V$PR$Iph0eJF%x zp-_JTqWcU!1s96RmA@h3ybKwQZygLjMnh12Kc#LAA@?ke_*l9#7Xw7zwY``0-HiVv@=1LU>oxw->SXA7=^ zvMc=so<`1;MuaFpDSr?BM$XYh+$V= zGC*CRrH=xtv2b=s!sdxdR2MuXa40Q(w8l@w#Hd|*s)hejb8inZgxnXX8c0-_5b3#W z==&^Qg;0s4?2Gw^7>eBKO5kxO4 zw+kY23V{4tH}FpnqVZX&`-Y&A$2h0e(y+HTkw>KXIeLkoZV~=L_;N=*_~!ukxk8iy zd0lA=hX!oFmAMbUMqSJMue*O;$)$9Xp6QnJuCH((c#S(@ zkTgt@A^TU6MHzvMbB~Ca7v49iDkPY-@^Q^6uhmFh*P?H^}R|xeZKz*k`EvlV_ zH4!METWGA1FITx=Sj`w!3N&*2pI&?`=>%Uh385x43D7GC=3$V4$n(1aHe8A{L4V(bLUz9lGzE{|^A8u#M0ycl_a z<|M80U00ifq>d;R<=^%2`UnuNDV4m!9`{cAcsUtR(PPMcHBP;rQ zKy`PSL|;_QH=nac^WEkwpjH~p{aAO%1i}l z0aS8Ej|klpKzC0lx>BIptf2#EqoU6IMW&s4Pf{nsB`Sh$6RIbH>Rtn?;7E~;SxIJsbXmmp*dVrI`GKs^gJ>#^eMW{rtHO~?wZKn z2m}In5qT@^E&Zhqn_5D&Fp49=d4hp+;ak^11Px!26@;nSVru-9XdW}#&4b;6uQKtj#d<``W zLUn|jr3nYO5;dzhuBMoS;2cwo1fiv%us)$^R|4fuJ=*qLo4-JRazM*J82g=_xw2g+s{eiLwY@@*CGcz>jaUdccK}j5>Lbs_@ejw{_L`G8~ zBY@^PJ*w&t@2jK6n&TTa5IYf>c>yZwL1h~r4O9a{Q56Es1q~JIYQd7W712PIn#~rA zMD0Vl()`37Z(N+aF+h300i_tE*_U8S8JBTId&L&_iT8PT8P5d`MeeuB*O0m`qnRC$ z@leiKf7VdnD3GN23E8ua1<3~lNjarN68R0(;+6{iP>0HgnU#ZRlYT5R zn}|IQLOoWX`V%llPiv1`WSZB0=w82_+@|-oyZ_ihgY_jJx!?VW6ymRs+>3WI&9MFl zZ;~rjs!cW?{Lp>zL-r6s%DQaGJ9fB#-@#l-(@v&N>LMx@DX1(~25=7+#nKWhQ2Hjh zK274IDirCYYd8S2#R$K7bmzaTemnPiB1C1hYhk62H+at z+Po%VKck$i(#56eux9`_zY0Y05sNxBjouXyA8Jsif}th@YC$N}9zcBix}-JV0a_#& z(ov!{1yC;=phV0488Bb3M%6urs>|wwx2fvp?RKBrO;s>skNb~(ZY%8OqW$jO`{~wq z``w>ZxSeL@`wI8WN~(|5mG0e@^yo;X`>O-=g*IPPzH(9>`mEXO-nx%H2v^Dy*fVYE z<@$d2R^WqWrs@tH^!Iv&drJj_5hDlngk3j6mnEADas{GfLCYAIP%iTuLMDk~URT!I zEWiyh)*AKc9=zXI!l*}Ss#;%XvjJ6Tlp|TAhXC;^Eu7pkcAL>k53@;`ZSG+%LP?NVmAQC-=%du#+LH*L1r5`%i9XIs9H}E> z=qSYVlcN?dc9$uS7%Pv@B)_=EqU>EOs+@{dbo=vIDAH&6j$>gI z>BG;H!;X<;e|9!m>cq*(et!z`2%vxEsOdFAT>#X>4XC?QRZ_Pos&b^hDz%M-sImTj z(s3!=ZV>(v7Y^RV3C@P$)0oh{)WXwjX zn{B?mK-Kt7YG3+QsqepZ|M8`pluHB?mOz1w!LJK}bA-St-G_zE)Ng%lfNc>jR^Wm% z&WW@QC4hR|z{wgC{@)}LK2=$w7k*oss`L^YCtCEk#&5Ekt?`#`HmlFwO`BT|e%*Qv zRU4a08^%t)#1>Md%^$^LC$p$$o!w?tJRxB349v{Lpe%C&<~6bPIr62pL{`>k+$K}i zxEi(xdN_r0cdJ&+RikUFF=G~U<2u{l5%x@7`07^li-o+~F@I%t;zdhD)tH*!#}phM4@R=gQvX|;Ea9lA7N9L zJ`N4q&f|l$9kf^}IXQ*`eCWeAr1w=FD-?752y7^)P37#q79oqegcwR8{wECLXIiC> zF!>(efB?m}MYYip;UpSaZDoLa(g=qm!mVcCpMbExBP%-y>J>nZ41pS^`WgbFy@VfQ+0Lm|?lu)~r&zz8copT!+*iYAMCy(^g?ic#k^O5maep zrDcPDKFOxIeWNPbfG#KXLc*Q(QXP6u4w)QwXVAit1JK7N32`0%nFNSEI zHi$+Tg#rlkH7QWFSB`onhi}D{c6bROlZ=qGV{{E*_G@q*A1vfh(h4sHl+OUgMuOyf zh^jEH9(CHh57~%O*hG^7?vZTWOw{JpvD-W zLb_vpRs8?zj{8A;IV3_&(Ry&)|7Ul+5?qcoa4BTjmrACUZc0v2&sz?-R0EtC9i#zf z=~mdDJJIj5?Ji`6UOnSp`74f6RH}Y;|M)ApxIdqF&-sR63V&Tjh62rd%ezt!=zCfwA#9MpG zz5Oyr+JIwx*o89c10CK3z7l~?`r72I?FFhq9|7IK(g{7m5EXDot^4abLbvr#_klm@ zOYNWT_y3|n%HhAZ~GBmiw&)bx_c{Zhh;-+{U6O6F31z5)! zsuaPniN4o?YrlqX;$!NDTpn*lwt{TV`+yrC3ilOY)SZG4@>qKBxYCI%Y-*4nEB3$A zBSN9dWxQ_W}lCiz*kG7f46Dk&#IwGF7!Ls4}Anm!U04mTAH zNE`YApfU_l!3jA|=o_xVhDPP~z6@|>0`hRtwh@?6>b@sEx`Cn{k-{vO9V3pN_Byw>G%Z%Ufi4*@yB04a>ZPk@^CFh|oE*VZ^==2biGrMH zpKPb}>v%4@@uriK@I!Rt+SbVX)U&z$$%ER6lb%nX3V(*XOI*rMb!B8Xbh0a*-QY1{ zv$I)kq)G=VjAh>mFKDN!;p z=nbq{gw3)kAL1ev`L)OC&&eyrk;kmKOc)6eaT0FQDCT4e%|y|M=QZT(z*KpBI*Sjl zK7vfL>Z^jY5dVNr$Oh7Qh$cPhvv9U&?QBmNszA(`kVm=v&BR!0S^S7}E__|e4HErM zkjXZRUMR`Kps^JfuS^u|NaE*ZRInTjUQ-^*%@HX-=oVr67?^Sl46|w1kAY&qrxFdA z>h#0KP1HjD3xGcwKK=X_N%~#~zKZVXg=whzWMN3=TX4BXNplXk6BCZMGh1$?e zTxGZl@Pi7~+|r!}0n|!~gL}>mY)<6((&&H`^?WXk-J#4jyVuskVLM|cr9RQZ_O&bW z!?6SD6NQ zj{c*rNl722S;UQs%F^%(SEcv8{mv^ZZ)tqvk8ahDo7Xo&^0(^dZ$|G1`tznz=U!K{ z%d4!;KepiS>Tu`9_neou1e?F~Jd}ie=H}a!ESR&hpvKV>BgR|AJ2b>_(l*}))Icae zB0<>(?GAX@yrJwyeN8shmr&q7yDiGoxEKv}N)FDtCP7Li+XJ{M1~@+DaKh=E52%~> zqlvMM=rlJ>p1}(XJj;qb6lKOgl={G(QCcQbvygia0&0Xd2n>#nY*R zo{SU6L{ow9Ay7)g#o+{(66ye;rWv?olT$C_{SW^M<{)66HNf;G4eky;ga&WdThqXx zsN)Rp{WL*M5%FIb$V@$8Iwr{L-^^GUI5~s(h{3eg-f+NMb+x3_2lSN zpEgPE+&%=R%Y-W=X2kil-enXsxGqHb zFuuGylPnzuON#_cTCfLAFmD1oU*lp()IutX^m1sT{wUxU8;X)Z_0|bgM7>?p*PAxb zz!K?rJK6i$Sskpz1SXgGStH2%GB%#TwHl?(`mhs-#ln109l0v1v6+54IZ&J37u%HC zxTw67roLWA<$Va{t*2_iI{R3?@mdRY5>=Gz7#=P$luNYG2M<`3CAc)9X1%p_I1w2L zB5>yPs~BGb$xP1FJK&il{1EPqRHnt;F65kok`wBd2x?ak#C?x8|?~TSi5-lmJY>*!n%d@{HWktihdl|7nby zOm`M*N1)ZM_AGdV4Em>Uc+Rb%FV$;2Yu1wa-?q+ka2>Pt&I$0sinUIlaII(cTJ}J6 z0;-8}@f*X6PXg5np$jss7zcRc;5TrP`z5&OTs*Eh%1NK~>ph>ZCyXc7d#c%&ZEt#t zH!vE?YW@zBo0{$@qdL?F!T$uf*90YLh8U$hP}%ww)kPps`sIzD_ck)T4nB=bt>RDn zpo65+Q=!sje6>~DxL<+%b%9(Csi_p70B`ZvM%S0_Y7Z*H?;uky$Y?7+ z)aR%si?1i>EX2iNivdYmE<5FmfShj7BgBEJCcEzdAXa`WwJ!+j5};-TL)nIf`Hlmk zMnWY9LD4AmgzGjICXm?+HMRl~9!1-6+2rz|9GU(;s&?VnV0nwAAGBzAZrVukS=L z;W|fpixz!PM{O(YIsOJk0n`HZ++ft|1z%qvnSW9sD%2)oq{Qj~HqQVSoOH73kPd0 z)Z524<-$Q;Z!;(%Y&oko?O+0H{E#M?5U^Q2NyMBf_JJf)9yMaJHU9KfM3q1{9TjVP zfi)#NcT{?64ql?0yWj2Hf^H^b1sG{A6g7Ra+Oaw7*Y#4JbIPK;f{Qn3b>w6@&H*Ts z>t-QRc0q>4x;y`Hl=bu%DgWO zncSeUw)0`OQ(?BXVYa$3+vYIa#;~z#U}f9Vh4+7fT;xSbbLAy9Yb2+uPI0N%I>I51 zY|#5+`-9YFOvt1R30Wz~i~`Z&!CUX8%%t8tJ(DKV=r+j|52jXn9-;>VB6k8kAUPiS z*V#EV)MpU5Z5mAJ594tMI>Ih;f#32B`;z>L<~3BDdcFi}H-q8gD{fTWE;g5*9%Zb-ybJXl{Gm)ujh02 zMd2<8RgRIM6$INE;32Yq%Hs~fZA(72Z{qY!KGWZuO6N;VX%~PG$HWnwcGS61p*kW$9 zF>j?&pV?G}^GGo8yJ|U79u|#!pV4ZYa3|J|qpkQJc4W4-jeU*{SwAWHUC$c3E#G0n zU#C6aWyaqKXTIBlzn+MEuZq8sp8O~){zgaUHweSuhSB*kHvGM*p|hrq!>N|%#o0kN z_9krS$uc8(AM*Cag;&No=m3DYipc$`SFfmz8ADC$d6Qm?xEZfCuDeWcHfL|%68dJe zhvW3L5;)tiH`~QIv|govZN9k`BBFW~`9ov#kis4pMJ0sGi^Rw`-O#@@ayBXaWMJ9- zD5!_#q8_aAyE-9K118TJzoMAw&@a>jO@+x6*0|}EB*Mv8pgWK?Cfgh6fvD!Fugj>g zDW6ut8gC0rB5NCDRZT5RurQc_2mJM!c>Q^L9XU8zht+Nh(+FBU(Dl|oLeJ`OiGHQy zl;D2FjnZ_HS``_EWRV=46gB=Qi*gSx4lJVRhym*AJpk+~0oO)ERwm&A6q}y&tl^Zv zk+k3?By;pKT{Op0o<-;(6v9FZp&lS#W}yiq5=&)1wl`IvrY&4atwArV{N-YL*-EE3 zs5reL%vKSD6BGAE?Ty^yzjRTxGXzei01^2%I2NRPhjG@CrHV+Ez-`(ZPUnwUkmoVX zb}-Id840!VL%}=;Q<1eiQd62j7^;(_qfs2HA1Dn|l05vyPo@|=@?I)N1SHZzNF*S{ z@etrDO^E2(B@l3+RYwBo7AZzkTlGv^_3O6Qcym*e&f9Q3kVGu7j_`Ey)7yxFoXp(h zvB=P;ukA;FwkXfw;uTgDT-Q;c)l$%k{LC~MSTLcAe|d$~h)NqxBPI`_T$h)19DYLw-#IMBE+*ks`0BNX{ z#} z0Q_c5oMXbACe7I?S~SOl@9d)Q1EmgIS(61Rh0jw+UA~SEIbZX!C&I^`f@=e=ZMZ(e zbr{!)$rw4S=kcu$9=K|sf`8(s#Hw9z^`IY#_%Z@tn39UQpqWt6zGu<>b$}Z%<|dFP z-9B>2v+OX<%$_~$`Q(TP=|>eu9`2i37HVlu@~b@is;HAZQ{`EDm`%%)vxjauFcp98 zuxHm1Lq~d6ZgAJnCpJJ+SXD*97+))#zjw%TyFgg_(ZX_DVzJPZ5|1~@au31P3xXz@ zHMb;?L1$66eWiO%4GKIe%a33p{7Yt`$+zAYHj2!;beh$O2v&E9xU?tXzM^aH-UpHh z2`!;M^-JV^v;sk4gNPoT;2Xp88A2?B#~gcg)LpUS*?@Gc%B5mEm+qy0h%8gB&DEpa zq`ySP+e>(PAmb{1$E2;PqNC(PT2?E>#+uJ<%8sL~V?sH6vJkR=n$OYnQ#Xj7gU{PX z{%TS3aB)+lZe$&g-j{8H8o1qHElYLL`V@VGu1#iIq+-(E2a)rUl*V?zE`QQO@%b5&r2Zm%`BvBX)*`^D&PqCdOI0t7o{b#-2xYchWd&Q?>WbYtlld)HlUj+YXL40&isd};>%$DoXSbBa0DDGuJj@-l{3 zRQ-e&bQRk?hiwHPy@-a~{WomL#bpf5-FwV)80CY2uka z3ls|%`An12s*R=bjoLVKxs&B{Hk(%Ba2z&)U||`}$(2y8w2-0N+OU;<+_2iK;w%SQ zFT~P8J4 z1k+k|{uEO@Jb(sZjM#e@ry=DbaCJrAKGtiJdnl(x@f_<7jZm=F!m7loufh0j#B|tB#>np z*W{8yu{skd_gzL#U;k)dZW@NmLG8HRIg3(>OSI#NspM4X+i`Q0`Cn2Yndhl*$CNh_ zyvdeImQvS_8{?-MIaNMo?HH}lcO3)=otH#|nrsUYyi*V?L6mV&6IgxRrnDf5$R+@m zc@sd=!RjMbj(89aZ30MWs}sXNs6Y4c#ahS;F!+kE#CpWw+eo- zsYgwC6l)uHecN!LZ8#eoigq2C6A{DPhWjSgHsa7WJm3t%W2%7sm$s8*sRGI4=S~Lf zRyd9rYtT6^5BK=!2}=iJA&)nac!=c2|t1d zPkgvVV=pXig&wAe9Qd{s$ctX0HXT$_Tv~>1aB@7bScQ>sTFM7tT#|?bFnT$|$|K|2 zY{l71btYxxYHL)ZFdS`#uz40otsa@9hP69{LolkXbO=UunB5uHv)bllhY>`ufNK*# z!#$c@0%r-aE(T;zLm78`3x%A;&u|O$_^}8Eg4JLjk{}(a1_Q&E<7g=dxh=e8R$4-4 zYoyHd{{Fb%Ez0}2xVb9vU`1KK1k?&}YmIP-ivQHN8z7JVA;1d6GBjh?i}@u0y(B$9 zMr<-w$_j8P{UUv(1P0b}!}Al3Oo!^=sSwFJz)uw{B-b|ynl-3^}}=sRI} zp6r58LXdfzKoqxYYI#(&^$;5}g@sM3M$g+IrUr{5r-3Gr(-$L=k6Yv zKb*vgv_BbvQBbsC-j#OLB!nAIJGf;a7^(~|H*bY6k*V(j03 zz1P6+$?zkIK1+DqkCHd{^QETY9`aP7psBI=D&uyrBa5E^$OAv(EL(X#qM+Cvh%FCL z?DP5$HsvHPHF6rOCONH5r5x9#6BSH>Xp-n$8G=Zo~&F>6>eI*1YRt)s> z?s!T#X^5)$sv-H9OHw&VazRUkUGVzX0vVGmQ!N(oy9S7a>;~v%r>O_RB1sR>m_iP} zqT%145$l`N;t>lrrV7G$<_VOkBc>I=3&a@4bm!o-BhzX-(p>O>40b|Ryr{?c(a4=m zrv=1g4;G#5l@gCMMe#X66t9TbViF2%!DBrFW-SneqngXx#9@XV$1`F>)*K6+nq}!( zquS`~EGs)TtJdkPDQy;mb5^!e+ACYck?8O$dOe}W!?IT)yqH%L3*w=Qlr3}MkH{u+P3V^-Q7rWMjJgmR%b0QMj`D0C$*qb zkXJ(pxj%@w3WIKS#A}7pQmEExG=nq^vq!iRrx_vv_d}~rNzI}FOCBLcsHs(V1EL~{ zh?}bd%wbzEV@ED7CSEl$A}B%(nLd_ z9RH05w_ASqe0+gsslK`3xpsl3q6#j04qT)!Cog)cFVUA*FMIyJ!e^=e^BEDKo*j5} zaW}7D@NB!l2FoVFVO^AVk_s*Sko$K#cw8@dl>6Kf$s^a4^?*9B-0E1<#7w?N_`#a9aaw!e)u-mmc- ztuc=LjWl|LM)5z=AR`PK@{FTwUrXSxybc=Z$%p}}fF*UF9oN|Gpiz+D{^{BI7o%+r zl#f89TiX}3O9X8h?gJsJ+o$=Cf<_+`r633dbA5Q-vw4OWJKlkSsZOxG?gPHkP<&;+ zfxz^s*@$h%3*IfW7&g&A6E;0}_XAs5eb^2F)0-Ax>rl)xU_t~+?JVzyv%OHlZ)SUI zW_wBZ=6Ki4p)ZQ#@d zrA9~uDh{*w+<=)Z;firYkDgub9xi9I$l8m1J@=2;FftlH1BZ(} z3R|5;nJE-s5y<_^0|CUBX+aU|mw8VvBLU1??p?K<)shH`NPiYeW|ZuBuvH!;0LBBZ3Gf;q4q5#_72)>N) z|4{ZFa8Vsk{O|7G-2q3tLOW2;u2^D36Cp9dLZZeNOM2miQ&0p2G%>#vG}hP<6-_rv zH0GBc6HSjP_5#LqV+YhU3nG`O{J*p1c<=D{|9}3MJbYzmc6N4lc6WAm_9;;E8ZHib zF_ayxOHwa8$0ESKAv#CiHmA@G`x&B+55r%1JQELM7#=WJ-~?})1Gn$2Uf-D(Q!Md! z{S$*^SzfHFvH@h#NMB(Q9ZE`0M3`^4QLhg#_TUyh68`cj8jSHOf|@#w`zJK0^_aOC zE&PRvy$DG)n!@-CmAwd0HL8)=#$%4gAB!W{eOo)hd$cVUM-uUt?lne=X5X1 zD$Ipf4T_nxQa8~X3Aj!-0#442Xo|~+9-tZK3S0C$irV#^z=n0cE@ojn_=~~L^*Rw3 z*3NkjRVj6eiXgi|+0>W%lZHnS-u!|6!Jv;GCpS+Mn@G_da2il;5U2v$mZEpB0-B3j zR1-gS{D#Cz_PC6~!h%9&IrkT(SA^(4xOq)a6QS_~#ow`lB4#%N91SyR&`EHQ18$>$ zlU<&RAkPEp={Nxi6C&UUie`KSR|2@#o98zV5HH3{4q%qJ@3T$|C@b}h)zlDH%TL&k)nwJ69K8bn;?e4_O zo1@olVJaXjhd1OWWYBEwK5gs>Q{EI!Sr(qOfcnAX-kX8+N()(#b9AVI*0p~LK;H@C z8*TB9X{jnbaq(Q=3_d}jl*+GD9;_VNmNr<^(!7I#YGgZ7)hHfYup>>d^2|)S7gP>MZ>4KrOj2fk7)IuPFqb#p}>p4QEm6~UP z?0r3}i14d`$m%SM`&)46F6@X>-VY`r!+Mj#O%^rOAiCk_0l7&J$?Pba zdLF7J|7)Nd-c_J1Llkf=@z~g-Y!bvv?bb|shilPg0oAx}!P2|!=jbE9M3eat+GGt$ zZ_~E8>Yt;3!#9XE_32Gc7O(#j{p&AmSSBPon7B0{?t>uW22sD94o--E`GY4i@epht zqfYt7&ScH$eoMihB>F5eQunN)BHT~(;Eyzm!6yB{$3r9dEb2ax=JGI~}ubuZ7`(8FrE z6t&E4WD@^d!2gNBALwZKKzlrJpTfm^%7jSfJgC*z?*ewSEEKn|k&oyFz@+w)aMwqd zaRHaZ^Y;L?B^XLwpn3-Z=8YQ!+$sSj>3knhpX&HPJFMjU8b{94>o-|(IT^3(kV zVdbouXi3`w&@Tk29NMgGsb(0x7Xj4rHd&$-`eO!ZVeU&^iO`p;r&VtAnQiC(WV$1jK)a3M$R^{mDF1Rz$86i_RJpmqUjS1=SN zUr0anP64A1rXd>7O-jjbz;Ky3|% zQWsmizXIl}gewP>R+1|LwOh|g7)&o3ykTRJ8!lGYv`vo3+>#8f0_OOGAg9kV7S0>Vm7h1;=WHQj{=v~sACsDT_GA05kLk^CAKMRq z!srakQO2fgCb-(_flHoJC0G_P1=0Mx4ms_3NK$!)=I7cm$5Ft28&o_3`wk#Q4@T19wHSJ}58;2>Wr=}5~PGiJ%;MJD-z#b@O^!Ix(gK9*&N z{(Ovb9i2py+jMH`w?Ehq{=jHdDj7DlijGy(*3Nn0+o7*ihRzRERg;0PQ|SaUrPKKO znP2Qne@W6(zp^Y#cmXKhw|4MVhYSyj0t9BtG-f!A z+{Wi4N6m4t&m6L!JVZI-r)BSZhwR4>F#=?RJWb{VZNVCl&rVUWpwaa!$Yp4O6ry`& zQ>H@7ru;9Ucj<(P#=OHqyk5Xfld!9T&H}p(sPFYc3#fh;?@T}}kx-?8qP%34UIEk( zI;byc*46{17L)UzpUNZ-1npW=Kf0A>=3i|JjUw*DO=3z>ckaSM_Hk@C*l1UWd0-xc zQw?QC1I1|icjrTJ#Q63hxMSKYa`3{)0x>B{!uHC91N#&9>~msA&c!-qU&5ZfPQ#u_ zbr+0#6L#-OsM?+I{jQ1U)LjWb?VNPhWZ9YU^NxgHwkI6lmV2o_EaU*ef44v3;J$>N zdlPo;flo!)?nxKUhtvKr1NH-%B6lO9Il3yLc8f}G`Ubd>nH~G*SzMj>+WcvC))-qu zT3rZpay2FFw_Pf{RBuQOwjEHTrC+ZjA4Bp-IXlyjZ?%CpER5~u zq44QMaho(ZaG~qJiYnNxuWr^s&i0O-qAE|~Vi~Ly{tB|@8UgmBuI8|nSj~;}&Id$| zgenIV)i?cUlui}@lYkQ4M6e%vXh|le<`o_YS4NfDhboiS56JSsD)YrQsLWS8tWp<0 zL@NQYi`&3&QW$FRFNw&mqNg^H@y45%SMbP4oKu4P0ra6}kk3gXKc&z&-dD&RpOjU6 zpEZlCN*M_m?5rgzoLnQR8cKCB&Rvama=^vZR5VNJe>=GZY1uFRc!)9{7eDi=sm7w= z|0e5|$d{vLif~>ITf7NO`$xDfqO@>2rotZY8b`+`!{|TWTbK)|)+N{E5Z}&21l+$I z+ybYtV(|JWG4KvR;S2Ke)D|TJR&sBu;DX+TfGXvHqt&o`kbXfq|_jE!rrNISf?liuH=oRbwD+#*{*eMq$>~`}E z#?Jd`N8Tg&npST#(bkzX?CO9^wiyl8VuiDHXbwz!CR^1ce?x@Qfny?!FB8Taf-#0f zh3{V&3iqUXHCl_s!LYapODtg_=!AC;NYdziym+Qh^z2?3rg3;TbS(=+`k-n(c`QWn zoP;XKuygJ%&!pFePAhVf@GlwesqL>(EFmS>FcMDoM6@2hqZqy@VxYsdff2mhQ%UfO z60f!|iC2f=@|6h75p`CH;QJ4f_iBs-qd|!SK+q@_;Mgm1uv*JiNvl7O_o7A3)C!i_ zKuzjN05{+B^+R=t(z1aWSTx%!WPp!jT58*O$^9&^ zAj_MF4Mubp=h*zb0&g~!#n+ITcUdQOWeHX{X({$I3tZXYtjIkAp(m2xnqEbE!aHRO zhw^2UYot~h=NGBUdR&a840UmdY{4in(^Mh2IU`$ew>$=W53%GSd>1U)sAWmOUss)z zs@n7N36WG0DX7r{;l2G7O4OjbO%*LjaBsp^(gPFymIrYHCm!GAk0H`pD78_)5{c&V z+7RU+F6qF!nCH)|ilkua$98~0R%D+cH)V!`p5JA8%;{QQ7>iY9J}%A+1im6klY9un z%^wo(+`|lxS>ta;W`YkpwR{LDTU66Ta^90B_dpqA8{eWGDHzt{JWnIF78Z((W#3e2 zDh&Mwo(@s6aRnDT8Y-BSDgCqtcUfQ?2>(+MPBPW9?f09VNXwQ4_<;(6GbLE5#GLAT zaN?tBG&0pLL;iNg{^9Rz2xtD1^GRqh$)|AK{3Wx445oEBdOeMESawB2A-X=@cI)qv zg)&_-JqTGOko_%@!S}mm=mX19r{bUo_!Wp_207i-!aYE>3YYeng~)uiH+YN^DI z?{EYd4nh143zi`+Rj#vQVVy@TKwzi3#7h?v)$1QlYK?kk*gJxp^5Vz+Nya!5uu29Rlh)ui z`w30cHj==>E^?u&UkOsO&LHy~H28Tm5(Mg?jxk87(b+F(?sM%=eMQbzOn0#J8aYX< z$3!o8(SQ>MwX*DFXp)CemsuqSvOoc{voN82{_|&S|QHT&4$dq z8x8j_yJy$dO(}8sR^-c?R)~F07^3H9&6u8BkS8|WL&R=qcOil%H3jVa9vo(idpegK z?qeZ*LP#HaZ#EARwRy8=$Ut+FDTA6BxdMkDC4Vg;uW`o-LK3ace0nqSTF?fcImj)Pm z4*oF#WqYGq;*)4$ziC@oV2q(|^o^&iXnz3x;!M~g!M9eJDA+J#03TD(#t5Q}euwKr zl;}&>9#c>W=tuG62=@_hBvXXC$Eog`aN+zpOIn>d1lEo)7N#bgQm;qq zEtX15XK7ozH4@DZ0Z^DV!WdntxEdPwQHl`TC8YzuC#W^_j$$l@Ip~}w7mJu9@~3a; zXKb-7lX%)ggoNR4{E0}aTo{RsjuZ;2rT7r#p$}~;7e*WShj!wFy#sydRJqV$RZ; zToKo5JWHB$jig-|RU6ycdZX0r@Q96q%6n{4erExeD2r;uKT& z=@qGh3)ekb>FlwOVk?*))4aN#C4F2XS=cjzv*1Y_w@d6yDZ!s!vsetKI|zHq#on_S z%v@cH`PvjWJi}5f(xt!&n4nPLxUrO_DAT3D*)d@8I$}njee+VwJMU$oAXX7v3*-$- z(w?RE^1OW0(IlkirWY$`-~4j>ec`OTn~KDJFV?MzFtEo$`DkR1Me@G36T|6%A8)@X^tX+6ZR3L)Sa>ENN?5iuFP)HNLUvjUa_DJXULki`C(cJ&MqIo(a zY>i}Z93V z2s_2AxIV-6Ev{oF>GA40++3lX(3$aSZ(RLw4Z}4SmlxMmTnlh5n~6j(;^rel9$~y``(ur`1?)C{V<(OU_K+nx}e$Fd-(wt)Ig2PLMdV*!!Ji_#Nx8+rNr1sK z(w-C<)g_E3Kf^}f7Qn&H0E#k*+tLCXnQ{0XSg}L0BSU>~mXv&8U_+U%U`c`)-ak4B zFSWya+CNWGbPmilbTr~58^6)`NQ1imMz&$zWZvHtm(AAD+izu|+1`Mb+J(qzCLVLm zW^1@NqH1ND61fn&oHjQb!b8Iq)Ake>Z2;T)1o{*KMPMamfl`oIR z7`)%3cuQxJ$wN9+1BG&7mSg_Y4lY9U%!HY5uF|%~?m&K0ATLogY9qt@JaGOxOGuL1 zB0S)?NHak)mR=9oeUT^#XRd<;Lt13u z7RAerH;|E@Kwqtw@jQ~&`S>iPb)!~V|1S}xKedD^Bdw5D5f@UOX=3~cgeF#J+|i^l zGraRb>pEOqb*LW%qy{80+Ir*WVIehY-+PKW;kC5XGuKG&5V^@%(VO~5GHG(xNV4?F zH<%m78Y{^^a)0=~Jd6fZgtRhQ0wJvsjtkq5DN7Oxvh7iI(!D;Gb1x*R2?)qXvqUYD za@mAJ?2!dgebG>6dLM=x0J~pbht?_sAb$kZ<=Ln*iZB=0HtC<|D4kE0HfMoj?E(iT zf_oM?s@aWV{!&z=x-p9Fza=@7vVy%dN~OqWrjVAARGY)8NZfevo3=Ka%*cK3F?$?! zhCGM_3Qxtyk1>@@Ls+(|h;NId9ONrD@sY+!_6LVLi3sDc?D;2=Eoqs0SiM8*SfPPh4|U+ST(&qy)B9(XJLMZkb*mn^TQBsN~6M+{IE zEB+Wlt16Xn&92U})f)rbcQIrMG`27C|;F7F^0x-lKh`(DR9F<$90ANx+85!#wL43b1ITJ9)Y z;h^m=z>ibhCHe!)9i=On7ME?yTnIl&5(%0)(-Lbx}VKCA-Uzc6*Cx+upNk>P2Pq3DZ* zJ9z)WxII`oIL3i68!3-Sc=K+F$;nUWCZ+kp9uzAcdz#|@OP1kl3% zX(`ymh5!#ETE_oCNh1V8c{@=4u0zRq^ES}Exk%5OEvp^to@Kl?uHhws39|gg=f9
      d} zZ;c7s)|u>;@TtSatq)iB&ebq}i+ z<0BG`R$en%Rmf!35IjS=r&ZGs>19=6w8lKx%vROG4ivUnH4zr8RV!^)74)|1G7j0T zit({(7VN%O9mK!@`WLjyBhac+*oF_-9b{GIV5=IVLx@!mP&w49v$&6_Fstff2quJE zwH0?!GQz5$NOH$KbcwPmGuo=h_<-9n}|^;>DHo+57<<^)4o#>F>ym9r`d-7y&JDp++LS1MWMQrW67)JJO^#onr{3qHg4 z3vsGjl~Kd0N*Il!=v0&X*0O2^TGzH}ZXK&q>sqx2LG`RETi>da2x?%}pIC=`4XyHR zY}Fq0Xu^K1Ys&gGv#M!x@@vW5up7BsGZtRAvnry!Rp*e}!K!jtgsUBye<#+iGjs03 z{JXMtBdokuv1%+n!($|Q;s7*?b;M*`LB7%K!%;+zAxGRs>R9qZ{&7})Mb3DuW?(7u zO`v`_I)%DSwW=Q6rdhQSuG6hbnZYp*=Nw|A>RhX);1-I_BNj$s?tJF7z^Y#tTGen7 z`7Gv`SYlPKWsJGps&*@^`WyRJS{1U|szd~>;TVT~Eyq8eBW#^jgK!ky>p6z->jtYz zY^2VctUB=*Ic*_l7`IV(bly%~caXzQYQ2lxcU#qBFYAAR=fzR-$HL=Q)jY+qgEgmF zi%V7oqdZ(LlMi;{%oW=G&2#5EWByCtD1F1qc{8iRF$3pt1FLRPU%Wu!+Z;1Ei%Jiv z3G|3@9y1PHo?4ZLV$T`t1+{p|G4jf)BCoCL|Bk;e?>SyR&>t;7TJ_5(tNMIqEL{4J z`Fx=+-+2zmrU$MzRdlmyywRp>CYzdh+Vl`D%r^O1Z2H63rqQ`=8tZ3M|2#I`$!k*& zf19S`U!>%-sX4aeDaPivX)jK}>n9uU8*KUt&jL2BLB~Lw6lBxB|BJHeWVB5+V{CGZ zw{ia4rV>t@(vxh;DP+^%*i+c1%p&Ailo-Wq%8OQLTim9V*ou3|n@k)uOtEPe?xopu zFx{r-Ep7UOrfqC$-`1u^?QF8Nx2ZZN;9v)v4s>N~wC--x5!Cw4CUZ~b*^BXeGp{~2 z4eV!A;P1?70R8Y8V+Pt3Gng9wVN=gPZTe*xVKESO-^yNTpJ*`_X2Y+5|krpnW7x{dDBZMr^_d}rAdG25o#IX11GOP=#> z>bAiqm(9%MfK5A(Qs-kf#pCq_a{b4q!8dF=UC>)KBfS+_-&=)|x0|=ZFbJEl4}slj zgQh6h!&|YqgrUEAYZ99F^wv^z?&Yoi2a@XIH?e+;x7KWB{|;~6+wH9~d%bn!fVciW=&jX4SemIfJZ;s^&Z25>{^JD!FJ6;LWo@>@DZ~^?aC8oSKe^DMxjlFU6Z2iDjZ{1 zL?UAswQFNBwimbSI(C<^D=f{f*z$IDtzcJbCA+HrY*+R#c6G0A*QXkGt*vQSa4mAJ zZCB}fcHV>A)xQz_8r$`(31c_2E2OzyA6nS8q@`U?kugugZgypLw=1ZJU6p>b>n+yywCh_hy9)KUYtTTuE)KTqHdg#$SIkgu zM=*zxcC{X5m+NS|?vJsn##pQn0Ug5&0;U58)WHRC<&iQb=Rk7wxk*{;4Y|7Yj@n_c%%`kP&+G3AF{pV8OPN84~1 zraV46lGjH^{e5%^r}F!#aX}xo4)RgQU>`+<_~;4lhx%w|n2-Jr_tByVAFYk@(b8BS z?Tz!%j3gh;F6N_M#eI}qf_BM1`X|LlzG*%hn9f*ORFbhWee_3`kAkv&Gz_*EU$D7X^2AiIi>HsLE)Rr68!FFu-%eRx^RN5kv-DCt)pRqgMi5hHz6 zZHkYUJfv@suXYCesz$W0raFAJ2!ouyDqP4{#R~f>r;4wtVnbD5{a4*rb!u>njqLuhYsz0bq@vG`)V|1 zplvr_j%i;#9^k91!-zB9S1l&{>cwhb&0gcH!)tx@W;0_P^wlL?|3O>$x#ZGl+;-2U zpFDD@r!kklz;4PVSI=B}J1v*WOwXnIcni(Qr5udMT;!jbOPkPnb}p^MCzPDSW4yo7V)nRV!a^&2Z#a!P>bswRvt`!jJvA_2gx4 zP5Y2rf8iCPUHtTy*-u++ewt|a(@V4p_0tl(De0$^nSP2b?We?wewtp*Pql0NsXe+3 z^V83x{Zwe8pIjID@mkK0^G1H^x!X@e5Bg~XKBD_2Klxnu)6>U(%J;-iji35y5w_t7 z954OUF*A?G_syfKL-HtRL>^5amq!QTIX;h;&CR2ui}NVvRvukK&9`~9;!7Sq!mhk| zxt<}fX64JPe0B4xb%VSr*e0*;cgU-u-Sevb?|HTQNM0FE=au{SyqfCjuU;YkyqEG< zwNQU8z@8HRI-KdRpGy0yJxVU|=Ny?o&s~4j&6`grqw;A>Vm>`Cnooa}$*1Xc@+q)) zJ{5SKPd?oX$Zcf-C9f%`>_IiMj4=LSX&}MNyz~!gFRTE6QDw+0+fN#xCM{W z0XkhKKpV;hD6D*d)}VKV0Np@Rr2th%eN?Izpt?w@5ukE-jaN+rl+`*wy*dP_c-H{U z!!`JI3s5BHplZ(m4aRtUMT=emT8W_E0a}OZeFAhG5q$$R40V2|4F=#i(gp{p@Q?t- z{}G^Myv4^q1Jrg{fO?|k@BnqgCR`m6pof?`GCdR;KL=_K+EfixomPR`0<{iQI$p!2 zO`sN|K-)ld#{_)B{C0s_3$ONpnv7d`fhrvWbp{?C12qEkI|b?{CUhnbl4LcO5M;LrKP!|w#BvAWt{Ai%Az~>lqK?}S`spHh|1mm0xRLRqU zI(jKk*D&fzpr)hLRpxRnP<^l-Gj5Uhy+GZ65U8Aofog@=C*=K-ofhZ8>|P24h&Yk$Y70# z4OV>NV690FR`+_rD$_Aok9!8ov?^Hj4+iU>Gr<~vE?7|)f)#ivSa;C(a-um-;jR;%y9D&iWVES$$ALx@)5AACn4w-EJ1h}hHWnMK^GG@s!skfjaympU&gOJzTK-$8HltI|Q2m9ry+U;sy?cjhF*e{n z!uy1(5N0ExZ>Vzh3)NIyN9F#+#TBd{5UQ$whN{VgQ0<%^%IB7$+KSJ}m>H@=FwF{8 z44Prz>`?j44dwh?s9e{Fs?ml})z}!S>3c%uzc*AZj)v+FoJ01pP#wpvNO!ZL0 z5T=!GVfqMn_b?5@7!Mvpo?&``clg~aOykXAnuD&EFb%Qu825a_bjdeN_fb7pn3~{V z-Y|9Y57Pj=#t#JL57S9pN2Q+_8;kIBfiV4wbGV5W0b$yLhJj&fiv?&G6sAd7h;<=h z+6DK}FwMXtB!&?ik1#2mxbTYzQz$0lG5(4SQ?V$-$Ff~mM)8*7KuF((Ev~=o#c_qmKS2M!+I}oO)nPKwEVjCXgcy^fnE)}MH zrNiV_Axw>M5+y2zX$k&A%}UG@U7Ln!e~&PA|BYJrB4(d3RUJg#{-E#hFija9rsiYA zRCWsEOsCDtFfGQ=)nRe6m1@^r=7zU-X&avy0X1nxH5-^s}KGjMywIx%9<9g0Vp&*T-i8=h?(IE zm=&&_^TRdxuW;=`{w?9kyOlTx!?hP(53vuChsgu4(fug>@z3#a1)T`jXk0?r$#9KF z!BgQHf;<<)RSE;K2~Uv!QaIH*Lo3pjmm8z6xKFEn+Hbd6)FvmQ1p-p?HwMW|4?gWgc3$Y zsKMk2%|zuX5o(Bg$eb3T=O{lrg1;XT8n!Y*KVVrEp+XxXRB|J2u^#qK5vqnIIE~Nn z_$xx`7>x0#vN=Lq@b&+0o{vrPL2=zz6zY*$z;2RNIg)8WKGeSjgMd&0vZWHHD zgdX4vrrnL;dYlOTjUxZC4Pz9kqX>76l&2w5&b*Ooi=+OLdY?a1y$eQaE7}G|st;U( zBGoWBQqw~s<&_qx9L!H=TggbS50BJsq~}D+Tq;se%S9@>e59`98M;)6)R~HrT2v`g zg{nqsDyr0tMseLnl-{7wrzp<#Md>0c{}-hR2>-(4 z?@>xow9dobC0YY<8XH}sbr*q#Xw}3poPxhwwCZ9$ZoY5p?$gF6!EfuZh zs9!o-?eGRw%92Yt=3S9FZi&|KNZJ~$EF4Anc4F*`){raFdU7jT zqrNG`LHpDg^@AZTM!%-VD6V9Tc2$hg7p$oiquuCQIYzd6F{+3k@U9=D$#~O%aT~_) z{yIhz@v3zU@2O+dXj+V>#uF8gA%|747G zDn=V|06kB~sLT`k;?C0;6@3R?2^SpAFg;jyZP{kRqpt0$-v8LO5!9~CR#*jT+mn>fb6I-Ek|_*kvR z4rC?7s%c`ZuA`76mUGUr`UI;pR>>%XvABg7*p$S0g<@5*aIAL2vq-GEVHGZ*R?%3^ z!jR&z@=K0Y+mu-Sh32WTN=+jcDx}BiCTt~R)fJ!7JcD{+R%WceWyLBzo7_sp^1O&u z{c^E-j`tO)QN>v0)TPdNg~s(_bq;q?xPGiEqDcd4jAw1BN4r>McZ$_O6z)u497kl= zSmo}<+y};LHvStFtJ^~udrGWQrZQK2$M$Kl+B1jkST{FTdr^8G^_(B8UJGJ%atHf& zvmfjBupg!OvVUK!8tso&`=ha1iH65w)dBgBQ|r^*o?$KUFUFsZRg25i9<{Epet3@Z zS7X)g8pqZ*>I=^w)Er-2<9N*-r)T(zL2hxn=^n>-NaAGoj8kQ}c*SvDe4M7@ojFd& zEOF}V8>h|4l{-#n(ZN4X%ix|rPTOIMh*N2NhG%4)#^PC2oc@i8Q>lG%`W@Hz$7#iZ zI2}3~C&Mw~;V>#5kJIuKaoT$_PL7*#8igOX$@5N}rreEFwR>?2ei)~E*!n0=b05d) z^?$_u634lOIMu|)Z*dy-oji>3%EBR2y!v^?>kn(Z-2LM<8n%4#dRQ=C!GZDW9~7_T z;CRgpkJnXe4J;+ndMpS#Z2o!>fP1_TbvEc;y}*ug)Xl6)-Yh182r-2mEKp z>k|H591HK+fQ2(O|8i}IE613_#{ZAw)@Dy`9o1pN2iF-3a=35Ecj7GN;6nQ5> z3m%il6Y{VoD#ezlvUrOOdm`V@P1IwbL`}?-s8?v>pQyX}5>+gJqH^#Og$i&Rkf_u!+q8b%S)SSYJ`lU#s&Zj48KxU#w zqj(m55Sg8*c6AcfvR)#;4Uow95fk+%k{TvTeG*j@O=0VssLK6_+dokw2PUe)phUGt z)Zj$zn?U{(6SWX6CM9anv_w^(o~UNXJ0nqbXCGLH3o-Dx;u0fmoUJ?p?gM$-oVY|P;1ombZCjiA%Ckw;W!Jsw?l*M z4)yYLXnG#@qiSA<79-5xq1O=(U5IpOS2X=%92!yBp>K#N;m{|Tk{t?4aVP;((j01) z?odz6DCy9$|I2jfD?GCt+Jx6ASjwR;_#H8&9r~?|gYU^XG^aeVt2lI~szbGZaVWWl zLu;`UEo(ZIS=*s1XpF9xAk_ zE*+RlCkOwpIW)VUgZJKyiS}ct;aJ8%&2i*7-NEOs4poP7rbD0SICNsJL;qmRJcm9k zq~41h`Wt;0I~2Oqq4#iK=HPl0YOuy3%SMN?kI)bA(c&0$!jp^C;)+AxvHWj`8eVni z_zmiN+o9Ya9BPB#5c1KXCZ8O-_}QVCUmbe&of=`;59T1Ja=AEF+uf-qd7NsT*U9&3 zoSYAG@?9FI*5z~R=1)$g1UfYyb5JhGsS&|WzWeCp+D#|tYn+;g3Xx6?Lyb763MD#~ zfv0HgaB8;Gsmg_%8eGh&$7xRWDM|cNPF=%8OepQthcZsNm31l)`k+-gr$$zC>JjQz zamu}_lka4+9l5GGRSU;{aq6EMj9rsCz)*`ewVfJU$EnkGo!ZvWsqmJJi}$UZn$gCo zSNMiyZHe8E*d3fo=*(F7*2Srr-JJXmi&JfSIJu6CnxF&n^omx1`sXL>cdNS6jQ{$Wp8c#j20yQQ$wQ8bMw)yN+w9bzJDs|*+sXHNsr!DXem>w-=Yy=zA=d1OQ$HPN4NnmB6zhA&si^Z#Rk}#6 zE-{BI%;|6Dd(Ei`oI}n(PW8O*)aQSldVR~O?GK%@KXR%W=HL{rA^S0pu?jywajFYW zBkieEm+>Aeo;l@sPHr!px{uK=Ny>0d($Clfcef80n`s`aTz}iOj7({YK?A)A3~j`Cg~+yrzNQ=I^i@*PAC5v#Dn+D zB>grkN$cT1J4uVM1p_t|QT-RiH4hJv?`3gS!f>2~@2ldffFam{*NAytT+J{G7vS}# zxH8ZktMC*NZ;Pt|CgT(g?~1DgI%5fL!~cD8Rfn^938j=Mp*m?L)SyWT6*y8tZ{w2{ zm5|K${*pBlHxQJVtj3swYslkBR$J_Z&6%wFSPPe=WL3c+Tt?w?$^7O=vck(Js|a?$ zzhbgJ;7W~TwX2n^kB!*YELqttlU2HPvWB2on`D*2Q_OCgtbZ`39pfXbeX>5GXoqAy z#%KK1F+a%Y1uRKc z@1@D=x-409wkMw9`N?GMKb5RLXOh+L33Eb+r^$S_n=H3y z)aiLL=e3jd)smv3))Y;&rD&ITipu(@Xb^7ZOX2r0QZ&_>qH{J&|a`Ssw?JH`B+jl**{fNf>L!6LxWQ_6#*fs>K&S@@?ojk9h0hdrBby54N9kS zeNU?1;^(rdvXx8K>Z+-FiaFI%wFZTMN!9r3sj6FpahfwGl3S+g0ownWs-- zpPH&h*f}j#qo=2G{ySAauwf4SQFd;s7SBu7z4@tHw=Y$__NQvzfmFHPPE`ip!f+>5 z!|~v5swUh^Rr>Q(^+n=~RF%XbguF`CE#&!;s_NjE8I%{Z@t;eYmbj)V#v@Iw@RKo3 zu~-kAXBuB2PSd~kG`;srQ(~Spjmn#*;{IvMj!n}*6pl+%4vr%-Ax#g^E-g(f&>%fc z?eP{rXQb&Xg3G6=5qvA8DFn;lUWxJGS}jefnEp$eDpw~?4dS3dP2%7!ey&Ykb<$*N zm!`AuYM-W-9nw^wW15_u($o?M3N@XX9%9C7a)M(`nntfpQ;BtHI=U@Q9^2Ej z4aZPrN19gcOjF}sX*zWzO%;w(e&Cn{avaW*<#x6mRcU9V!(HQJG`9ZB34 zO4n?ZEu1cAa=I4dVrshX;T_!4(v=%wD2yCbM>BN85KO`%Y{F~&Su$NeWv25PTe?c+ zr1Ls2T^-91t6aLKmrqwh#dIC0l&;!U(v>)gv8tBTY)ghh$7N{S_zYEP1i{ztfb-`H4)e#+|54 z9f--)@`Ox97tK_Bg-o?Y!HSuTpQ&e9RXtN#H8M2^!|G=0FnZO?)NqunpQ(J!hz+mi znaYpb*w8Lh9_=&b)`7lw5BH9YgTPLiY5;rZOa1=YsgGK z%gB^-P^QvxdnkQ}W$HZcVEOP&Z9(Hvnc9WpcseFiwZ~?v@3c%kLHMjp4Me>~nVOD@ zi!)UpsY^2X96VDKQF>FRYNF&{nd*EjllKjoYH~bNT`>7XrV8E4)KK)hlc^o(a5q!^ z(dk~Ma$aU?5Q@CYR4KT=W-jkDbpqqQWa=~qe$CW)6#15^l}P=bsWPrvT8V3hEUsVA zQct%m9mZo+anIuW{aKoiHTZ@Uk1UnLdSn>0G#3t2mg=J`rsHz{EL{koUBN7Mge5Rb zfvEId-I}Em+p@%u7s`s8C$jYKDf*nwQcbKz!82J} zaV|?|(f)jv24KVgT_E3!#Qm4~;XCX%vXuOPH(3vyxs|2&C~!MV>G&BpP~;A`aJ@^M z`&qh**T{L0rLlPRI7_}ynG+U1%TmJgEN#Xutb5J&H(9ET#_w2X%{l9Nnn)N+PRexmZH(Z55*)q6fYayZy**b)m_{S?-`>ffzfMH>@ z3C~t%OvD+y!<>k0&dYN@GFx?`*pEfnhad2Z$yN$}$0!ty%honH;PeYGi9KVrynA4K4q# zRyMEkv$eZkw(cR}*KAeCL#%0xqej?*+wiHKqhh#IH%FFwIhx-nM@KNONe;iUm?LMK9Mytr`y9pLRF@o?dgdqz z0sV87jTZxQSfU5*YRV116t z;K;@t9si4Z-pNrSNvN?!$#ds^?j*fv zPV!`aQICqh?U9Wx7?0IBfu|^3%A@*dgQ1v(%{T`x0;(dS(HAqY3wP1s1CJ)4MKzDU zM*1fnm8rt?I~W>|Or433KYJP~(96)dz6Jv<8|sP#Ed5u1gYnJ` zt;djohB5{j>NdpSc>_arh8l{-aa0^;XgH3bbAq9xc!r$A4ekBL&{-56Y3M_Y#(C5l zWvJI^Lo4yuw}#q`HS{&MVDNWL#~XTq4HFFYPBOFycTr}lp)ar#r%)<^`L93aD{_}&uH5h7&qgXM=&|Ard_RXU{DF)-auxvi-E-=(!3Cr=$QbVuN zahbtAQHJW_pOw^d6`!p(GzCd(Sa+?Vs_PA%{Ke4L&4#WabvyM%<{gGg;$t+$AG?W_ z$~?~C@*eWu%l46iL;u>xak1af;e&=ABIhA$i!Tow>W2|W3|&XFV}|Zy$tbfMPEWAR&G(+|Ob=J@YG(Ja6l)gYaw7UD0ftnyy9Kp)Jk z=vDhlUgfXs)y@yRI)-6YyeeDOt9sQ~hP5AhbpTFvuV#Pb)s7lo-9nyEy!sjCYkC!n zziWF{t*%#QL*n8NN;UGTM3k5DjlD|75fn1LjC_(>InwWY!%9O9AsV1#VRqAN!b}v&;v7oo9qJ2z-`LlWvakvQ?0N7PtoXGQzNkt!7--JpwL)T z$ykZ3iKgCyJ;CIgo5&_A@DMSoFjw#n}<`ZkBQ=rxzV zCDUdh>ntHJe74k7re&sH!B}qU^A)Cg;=(FZhgX|gy1~?-jiyGU=2la`!`^Okf4Hga zJ51HuWhx5Gk#jfwMQwD)E}Vu^P31vjjKmb=-eYP4a_uEQg!Y-LzMr}upyoJt*i`Q$ zrZ${3_0MT)amCbY{CJfbqxLoWj9k}E4aOBzy}@#n``y$s6#Bzd0{+H_H%*?WG4(Ur z-!e51pWmkK9aDQz88t<|=can#5H_b1;|1{%$slLc ze@VY^06)GW$JZQRDEp78Vc3Atvh;Q)OJCvE8Dv*0cON%R8TEwr|O-W9jp{mQt}H%HnT(`fpn5fg`A5S(<>qVEZhs zK<=iNy5T5RH?vgTCU@6Tt7uD)&@{$UFktB{qGB!nROZ%h9X(~g|c>2piv+FN>zJsm8rU0HI`9f??tlX!>% z@s>V83yi~FRQQ7Zh~ud8rKP#3*2&T~^y*9>HdxrrwsCVJ2$yu~e$BrS*8DpQWPkAq`CuEKR}4;g+tV;5X!o8l$NBSWC~aXdL_H zJL-hn_+Y%Ho;ZiE6IlnVCs3z}mgeIkG>IwhVAEtvJCiszrds?xMeU|hyYDUSL!IgD zzZukOCdcb+`Zw2NTnOrdGRYj%^DHH$SjsowQbRPw%paLw#&L|3%gJ>m`wj)9AaFeY2jLZQ$Jah1zejRBW@QFn>QvI8jzQ4seblcKDNc@xI@|`}7p?zMT#uf3YQBj}1!~Bvy z6@J&Jn&o_Yj*jp7^v3%>MJo8z`a_?-#WAE-_bCm{C4Q)bz=~qdGp- zuj^B_PgxFMeV@uUAU?WaB%Y#pL!Zi{57ssE=^_3>tHwSZg0G2Bzv81PwvB2A>tZ7^ z(AewK7#zhLCh_ql7U34kSj0jSenVj&{Xrsj;}t$_>QgVQ!gUmD=2KIQ#9m~ej?H$l z5wG#7<6|65pVs0oD!J4Qb8!xDMf>DpJoX}!-=})$jU~8o531yu2rD>sGw2@?Y5cAKXTdFKr#}Wb?hEt?fN*b?##; zWr(fIm@?GXd{i7}YgB@*#NoEmM%ikRXsf^kTOF}?qOB~GY;D9o*pqE7n__EtlC3_o zZ2gQ5vu*Xo3$&QaI?1*|n{3U3v)NV{H_&LStqR+0{k`8-l>_8}d+2x2)`>&5Mjy8I z{HU#3$H*P&82+2B3&(9uIzj(V+xisK&)5p2*=l!%ZQ%J;^1fy(>4B}|82QlFRFrsR zYrtb$-JkGt7Dp}dW>!Zfk%HIR997QYD5j#LER`JIQ{ZR~I#zMi4;g4#&Cz+>$2T83 z%2CIWfpp}o>u4hGe(G=^yQ2q99DNw&=o%hkpvU1|OpdmC9Tl`4MI*E0=q=2|Q`gar zXh)6X9Zl;_d$b+kXdT84a&&kw)1i(o;bDTK>cbsf$0H2-%F&sx9gP^_Xz~RZ;HntrB4fC# zgs)sB;R#Y^5eHLd69*ON5N9rJl8J+UIJkxRt>lM8@Nc7^ztYF;wAttC3X=BIFH}0< zYV<)@QHNX=xa`Ws8&_Nv#0)&S$~Lc2hnudl-g3EL+SPtIw_Pp2w3t zuOeCfO32~Yn8JSDMB}1<#T4^vGH#+walcxY@asMbm-I8PnqR-Y;3AC zbzA)MZuP7CuT1y*HRP;cA5@G{YRee?+CE0_b&OH|elcpWG)D2eV>ALi4#eo4<1xB} zF(+cwCoM)#P%nQ#@dX1a7ZcEy&jZ@oA)s9y14`-~&|y656HxBH0nJ3Xe?ZZL0%|=p zpuu=PETGhcfa1mn^k`y07p4VN@%w-@J)q`DL)#w$ikcr#rUd~#SWet60o}v#tpWAf z7SL#9VA!t#_1h6pp`8JJxI3Uld&p@o>muL&fU+J4sM5iJ8XXF#?x}!^qy2?@nCtZIY$4tZMCz)nd%u z7puwpWA)a7SUtNRtLO)@>X|c6MGM8L4mO~B;W#Zu;i7R0V-0c@i_-vfEgh$BW#eR* zi_@_3ar)XHr+&TTWR8#1`UP=Xy)RC?@$~^>9F9|s>v5W^=4z9vxd!1yt>(&ZHCMgP z%~fn`bKV;e)WZ0n_H+$uM9-ie^$V)wprDST|B#@@;K!jsjUFD>*vo=)55{%@@+&`9msDAjG-KviCzu z^Mv$+5z-Vpq|*aK`gnLq`M(Ouhv73rx-ciC5_3a3f{RE>4yp3IkgnqqUZsRoVC-Q+Gd2*BXd|Q(Kbt1Jy9rYSQoN|RU&&> zM{p5IIl`)uGpy~1%gyI_Trw>G+hK)q6uC-;)dbO)jWpyh9abqs%7%5iLRcSF3~Sj3 zVZ~Gp^L%MootlJI*B{p97}g1dRjV~^p-5O`F>+8?XR&8+nDGR|+JL5BWM7@YA*N^c3{D^`bBKo3ZL<(X$I|PMR<=yM5X3nUPQ~0FD0VCFnoSQ8Q8QSqGF38I*+!C zBZ^-eQI|6joje=S6%6^Gh>qb7GM$U4IvQXGo+I1&h-zMlsP)B&&Nj+3-P7a6<4nAU zvqkoYiA?_Q-})KPw~y=}KfGO9M*o%F(sN9z(ItD-!1wnyYIth%-`gAH|8Kj@|84O9 G)BgounSM0@ literal 0 HcmV?d00001 diff --git a/Covance_UCO3001/browser_profile/Default/Code Cache/js/86c21e3cb80dd2e5_0 b/Covance_UCO3001/browser_profile/Default/Code Cache/js/86c21e3cb80dd2e5_0 new file mode 100644 index 0000000000000000000000000000000000000000..544bf456c83254cd7c67fa46b4e46b650e2d4c87 GIT binary patch literal 39692 zcmXWj1$dL^*T?Z+leCdGZQ4*M(xy!{72Mrj#)j)~cNy;PGThx61BN?nIAa?Q!x`=_ ze|W!rlU>*6I!T`Ax$kqIb7!UPljdyHeO1;@pTGD^Dv4(~ztttEZ0^!IbC)S!K2NSf z1^O=dm8C{Vsv<>I zm2%-Au47d-X?b<&F#6Wun%dH5jHo01i){6zF8Hs9l)I<&0Xrv2nU_cjsDWPCgsXUf z+Dpj|XVG_`)bFz7D(R=q*pJ(2TFOsjaImzW{zK<7e(H~YW&IRT-cJ$eU&&7mtN3XE z=6vU;_ig-SZtJIAI0{!gKc%8Jnj@~gpZ>r(oax}F>>d4797TKhsc&CDjY5U~etJ5< zPlE>fX#$1~W~`BZ`gsibA#|*t{HOWJIo(gsv3?F?UH4O;+kU$L#7}S0>8YPKqW&{K z&3Nvo?JxXv1SMbksoG~heKr}?!r!33!VKE#H0U56WiaSSxIx(>4BCvnnGI@?#h~A_ z8k7=gP;Z=b8Pq1)p#7x{`WxlS7<9CpK@Te$WT|FQ)9MCwMDAJ!mB0bmYa7%KOVG0p zW1we4gMMydP>+@dz3pm{r<+0JFbfsC8#EXndhocXL0Nhkl!!0A4QkehYx^2B4|@^S zkKAAxXiyXUhF61_cd$YEh8Wass6jiiYnVZ{;RfZzjuEU0hEWEU#9j;@!}GBQ^&e-@ z^NGxbCX>i@ib0xc&`_+J#+q?txHz`>=j8C?m>#=G-p^Isa$S09?YMuk0^BqgEJE;SQtR_!;j}Db%Qrn2gOhkKN%$U4T2IQP)vClTkCUFv6%B znT>jeLRpOJiI0fPYE%;}z-|oBX4Ke7qXtD8brX$UMxBK<#;8BtMoo?7b@Yxi>Q#bK zITMWBE}%|buB~U( zO5DY=`bK?dVAQVWMm@rNOmD&bEm>+@sF_svWxZJ4R zYm91-Q)`W?wSna9^z-Wj##y-~&w zMlG_KG|6gGS(`~Kurko3wLvCX?IzWSJJ_Uq_{m|?CKL)aDRY=fsThh(S$K?{_&u9R z+g&E*cAIn%x6mNgq+@6r$8n^@n=}1` zaS?U%F;;$)Di>g0{13$onzS3?g-jZYaz#vx}CXKQjtL>)xgjAJeYM2p$5ZET0O#~E66;`q+O#~56+HZ&T%HiOkj>lCRLnnQh!XE zN$#_#`yA?tcgQu@r1>}w=RA|P%r~j|V&+BrB_=Jz^ra>hSY}cW?88^oU18E7>_@;# zlZ>m$Wj%9a_hys6;N%w8yOsU1js3IVq&rxCn0S^wan7WImrP2!#@_hXq~15^&m-3T z)TFS_^iTfkg8z*E8sYD+YseMouRoDD$X@}${&J#pCVvf%@YjLN{u-UlUm=nHT8qw6 z{@R9<$l~(X6YP%m*Nzx}m5TRQb<9feSLQ^2)k3!ve@#ZURDa#b;jgDSpUYpSy#88R z1ZDhHrnhG`5m^8p&u><|J3)u(zt0-~~@z>8o{dE^bhA|JOqRDWsMd=a#+K$wb{#t?z zqx>}npD=w4^N;n{@X7v)oW`1P3OlF!YuPM+Wt#1;BS@X+FXMdHiiT*hz+b}_`D-<9 zAaXHzqux?~d6xNW!>|4tyPxML{PoXY{%Ze^zx*yzYgjJ%Yupuo*{}MmKaQf?HGjQC zgMX<%zFqg%!W;DAroYzQBYzaU@2|Lr{#u2kM~sW6&;3>4fBu@F0F5&T=oe>z_P{Sg zfD*9-&hP;3&WMNrb;=r`0Z{=Oi>+|Gc#I<$9}}S2IE)-_&ck+u#sz3#Qh+*m0@MfR zaT{ln19TO~QUdfGp{W5Xh8oxazqA0A#z{OzrR)J(fp-|1BS61mea-;g#P-|)`Xf(( zn&k`7C;X8=K<^7OU!edsC>)^pA_4lRXn-0P56}c0LX8rP2V2PiHNq*}#m!R8U6J)v z3D9bsK&GkznvZ`GUM)avu?~-sr+R?eqhZYeb;a+vS|>nXFrp!KZ62T(tpoJ;Q0g+4 zb5Us=HGyM1x#HsF0QH{|prlCwkVoIu63$Y{3ta91SI*WfXEr(f)@O@6Rn!=IGtVo=~WgN|I zR*gJn{gThDxB1PAEkM3_U(&4aN|_a0+N@Q$i40}T`T_r-a9OkVmt#GcP{FJ@*j$nG z@Dzh9nROT4EAtr3tC;0q)vRqej0b34&8)T6&3cE@-uT1p?(_gDJND7^v>|5I9BNh*Y#zq-!+DGiaE_o3qs%gnHY?*8vvQ0x zs{{Jr15S>oE)(d{6tg-{WgktaCo_1CRd@mCEVH6<8t3PlRcju3%{TM^N%qeIv$ifW zD`c@*3znOexRQFpzS^uR>&$$eqaWL-;dZkoV>NDL;tsP6JI#u~SuEUdR{BE6Ms{Kf9Ul&v-Vz~ z=9f4JIWE%={Dz%ZspB>F(slMJB5u$>G)5n6#xFO`I)W~@=nLN8VNG|bEduXx4QAi~ z-l5iitO0sRE+~dJn2e{$`pC@x)6L5ClD%rM$lqv@3kd-hEx;{QHe2)>HLVtf*et4u zPJtF#gDsjIV$mrqc3AWf14B6{%%bVAWw6MZ$)YxyE&AYQ>{yGwp=-QFQHd69!w)$u z>VuJ(lhdNXxh%?(+oB1$n8%{GXqeZcMFlJhEND>#n&EgMi}Dt>r~~@ISk$5ys9MS* zm9xl>miPxP$}=a9;v9BXuxM;W)>Vlds#<) z^utDi;JkYxaM#iM~-GsvP%gDuKG#GFltt5U5MgWrKC&!k4D4HCkzpxoUuMyISXWq74Noz0rA2vGSyU2@aUXAR zaJ5Be@E9G}Fy~r}!q-_;Xro2t(E_h9cMJP`D`RhG4LdC=u#0}exZ9$#C#d~N`h|<= zeTw<96OB&O2YkkqGZv-%Mcx0lC_8%oLtoBWROW(3|Kia__76(mW4&nkh`b-O_ny$} zr@VJC_!;k!7Z&}7L%4y3FR2rbA@DWVe_{{g7QSNcXU_j0b6TvbWwojq1|igDRTS3X z9C8O*l`+_=Sd_$3^a!zPINsrCm{oSCRasB~zoT0QtA^q=x`tad5M?u3RTGP`G{UNi zS*)6fLfM!XiBVQ{gd^Ij+OWB;s)0MPRwcz*^(Pj@TeTKPQ8mFTV+!XZ4ZopoKC71J zx9V4%L4yKT1r#KIjK!HER%Iw^RSb&b1ge#^sy)hjPMx2ikpSG3B%l2zeY zP?`C0vAR{&Ygp9?-M_QyAUf4#op_Ef==r@>fBj%pzgkx1ufzD5ha2czmzvkJYFd5f zY`~n@hDHsovNWZgZ<H_W{ zTW70|pkNoP%Ha_Tb+zgN26wY6ushe{S`Vv=_OGvYm zvy>dsX*+e>MGbaawPFvw+RIw@vB$6&oAxs{J|86CLss=VOm0W4T8+xTlRG>|sW-A7 zqei%Z;N#Tr1id~sTUKqk%~}z1kM;aVFYjA*Dcu9B zett*|A5pg_yf>a&m4aFriNt4CIiFKI%z0(ieVl!5)w(ylU*7UQc+cKN$Oo$$qdklt zts3*0e7~@_zjBVBO)U&Ib;CiUO@E@fzfGqCY#M5|X%dd0l-;J}5Sv^Mn^MsOw=p2p zrY#w5+MbE?@DR--Z0dqlsF>Bp&*^Pilg*}>7@O9+ZQ6;Nu{K%aZ3;(gge5XIdgHew zn+~Cn$EJD7HmycXs#iDS*EE|NWVfje>^W^(haYm;_}QgR6Ooq3rWN^EPkx({3fOcM z4=}rsP1OtA_0;_ELaW(5$V^hDiHdS3m{WsV&Ws6MUvu zhaTH(`hwW)HU;b?zg;$U-D{KkfKA_{DJmUgjzc!(K5SF;QC`O#yg;2})bu#lU?3t- zFeh%H@=2Tep0er5X`4Qx!5QlPr%h+D^(^%{XH%2&Hg&))^t`~i_;AstN0)8dd()SD?=0r`SM6#RuwRLZFT(2g;rrs4OU0I#Atk z8AZwjsv-tg@@iKtP_F8Ms*0bm3}@h|?-fbh)sX8O1?nJPweCKl-wsHw=)IZ&&*2I?znbPLqy9)Y^lGf+i)1*(V75Tal2K(!hes9tal z3e>xyUdCa8>O0(PG%=n3h(ML_sYc8((yJKprO!9wm{H_4*6S)UWn7@zU=5xi=Xi3! zNwl62s2%7sDNwVfa1AU|1GU%ZBr$Y)puWdjpK3D#m2T`zuUW)Bv&e6DpceaVBxar) zsM{mmHS|z(q%g2mGcOFKygg?o%J90 z+IS*R>5iTBI!|nOig`~{gEN7;j%j}es>#_vZTTxu-%$N;>iAEfV$QMmQT9Ch5<@No zD(xb@!~9DezZ|HUczuO^cQsIXud~LRfl9dLm50~}Q}7@1-QhiSmpzFt_o(TA^aY3S zvo{~Gf6?(_plUwi{r5Ofza!rh#ze`df%@)Qpbp{0bN0l`K+Ss{s5dC{#;Ydr`?rBw z^e#}(QTDyp_rzVu`GI{6eGF6*+T#qOKk>fD0YrQbRJJe7hlN=7KmH$rr#_#EabKw) zjNbya3D@z9f^^srr2EDo6*UE^r_ay+K}z?d*{c(AS*TZrOhHQ5BZlX=<@1bq&F%Fp zHc0VtK?;r!QX@=9u>_tc25FAZO5#@!^CWvMAudh}QodY4+MCDg1hHV=AkFYuO8k^R zNDm8my(88s6r?pMTsTM<@I#Rx-A0?DL3)Rb#e(z=t%?U}E#{T*I#)YL>FU?<`j41y zLS3(}^@5bnR^MwCG2N#|UV~Z%DcyK{Z0l98TaeOi^C{Uoi0^N`P7>2q?&npee~{8` z_3;}Rq;wsJd2JsZq;w%Oygn}uQp8gFw9Km#aTsp-EZPvH=RRMEoi_&Q06f10X#kER zaZ`}m{~Dx=Xt5o?g?cY@UPu2<*BL7MHef>`8< zSDmM<2Q6_7?|e+pg47m!eNGY!JP*=PpUK3GFM`zCrzi0N3cd8IKs<`fue=h8^YFsw zE3xD2Ano!wMlAg%NK<_l5i`FHQgffK#0yAy=T(Tf0`GiG@97VI_xXod?L&|j`D`F& z|46NUMiXD5<|3oa3{SSoJIQ#yx{w4x?S|up3`Z zb`|uuYYgt7R)AeA@E+OCcK-cuS00O9Bk%;pt#-{uqRlHWu^kp8IMA;8*p0kFc1=f+ z-L7@Pc14BQbpgLS>`D%`Yd#!db{+8<8p#+@b_KZXDuT&CG0v6 zQ%Sq(A%7{xLbuX({fdvsUe>O+*j>)9pUT_y7?~=tHW({1FaGCat7KPh^zs=_+*HM` zYq(g=F2Cw_#i5Z;JK`}Ms7c>^J`#g}@LFEWu9CIAsu3sR7`oP>2X*aQi+1(wT2$Yz zq7CfYi0FoPRcvI}DMUB6YZNx&ZWFu0n%T72Wt|(w+MB@M*3|vI! zi5$Z*Bu*l4+(OaGnaleG zxfU`$YA&*CCT^m@Vz08q30Sm*wJx>m$7OakSx#On*heeva;|3XHFkAeYu6^hVw*aQwpi2u~5W$*y5IhLB&`d-!p)U4^#Lhpl#<{EghUlRL~i=?l8;qUO8F zV-LO9%Nq9C)%pPY=NU2YE%qADqS}4x<)a78|IjOj==a#JVkq#G zJf2an=j^c;cIA6%*Pu82zw9mh?H%Kw&3n6k_+VH6kIaqppIGl_>h_iQmV))4Ay`#S z!J29g))h;zT3Um3AFTs}6&@6L|fKizV{5)7awc3U~NPfSFjWvtb^&2f_2IhtUAfTGNlFc`@vup$`!2Q zxr0?UPcZkS1Z#iZV3o>8zWIY?E#Q@j*cKfM25X(q4&q&8D$ICjQY2XOakp5ojua2p z(>7k8i7na(t5b(yHSHLzpiaT6g=sj_Iar5#c%3D->lLh{sQXi}0{c*dzU0%7HTMtJ z(1F2n4Q8D~xE3EVX=t#Lhg08?!Rj+ASU-#j)@KwRAFO;6cx_^^GEeeKB(6fpwZC{LvCAN@0mM3ky;=~BL%kft&S)~iYx1ZNy+i%cA$l<;M5$xF3K8dw z5794^LbPr&$EHz>=^h3JpjAzCxnYa6lXybwKE5Ta}gy*$L$_#L5(nR|JN zs=~Y?L^)Q6s5y4{99R>gbf;lnM?M=ubYx?Qx^5294g9)2L>qT-e0PZM?h8?c10gzk zI7F9@cy0JSMCtCI^!o9y5T(0!!E4af5T&bk%d5bH5T&dA%W< zpX2|nB3?0i-6z_Ey|NI;hd5Nh;m~Hh_c4V!xS!3T6=)ph&@?>A>h+d5CfcE8C=uh( zd}Mb!G!E~vAl9LbaSmmQcW46ICph%8$DzE*4khGpXjOiPwiMv?f(~87zCsSg6>})1 zvO_(pI8?NnLp8s1sLT%z^{VC2huRMPQpcf~y5wBXq4EtK{QSzHK~1@?nL|&SGj~ge z+^rmX*V>_#Z5(=xlIqt^)H4ZP{(<=5Gv)NT&->FH4EUJga~ zcBtA<4!y=NeH{8B7 z^C^rqjdf0UC~Ss9ZQ-2hQ2kjB<(%VCYo8v(b;!PeYkgi3M=f-4?}^vS-K-N^@EG6k zpn1ds^~JI8iU|+q1uSR@}c?> zhf%&_sOD7)RZKN*W2n;A9ON}_e5lfW zKhtaF{ZOSl9Ub=n_QZrKU2Tuotejy=w;aQAg(+_yuL60)l&)+IubRZoHN*6&R+#G7 zCZbE-F!ih-rp67zl(k`)9L>UXqj{JPwg}UMR$*GxI!sAzIk#PyvUTwC5dT8wj$yis zs7_&;=rfntp{G|L;=>_cm&b%D-HoYUt!ISk*@iGJ*chfiehJfaL~aSwldWO;d0UuX zq1KKtZ9&M+F#Uk7D77n0ci`F^rfF!oFHFV*VVaNf2g5WTR}Zs}Bdi(ck>igrb;q=$ zjEg$Q!gK;%Plf6AX~sOm`Dep)_*|HdTnJO2i(wjcB}~TeOibiNtJ9 zJ;nM+r%Jk8voJWy-PA$jnf=&%CvbovP5lsml$WD%QxUJ&m2p z-o&Zjn>zK=k4_b6##&pDe=DcXpml5VY(q{M)z+z{qnt_}=hRfZ#it46G{vc&cs-l3 z=TJAihUPj|7E`eZS>`#l72OulM|?nug*?Yw{JGqzl^Z#K6XWgVH5hj})npI-#|u>2 z>(n~jMc#c*O+$hGPL;!g1FY{b$Fb^&Q!V~ruVL(Qr*fZgs`+Q979&fh3@VR4$PSfTZRvC02-wtKaqvshk`&|b8h8OVoh3mJ#aBU9`*K|j?o}+DS zxK`p-iEy1N6|R)>;mT1pTywq;SG{`S>V)oN!u8$6aOIgEF2nM0zE=#_e>=j}XJ5ER z9|_lHyhpF|;R?MLuE!6VS-@IU=LVj?1VyQ!?rZ ztWz^`e{V(|Tai)8H#6!y>b%aVwVyNU0rqCf#67i{G(U4DWp0p3?HUuCW>RBZZ-Ynbc`;CVjUjlQta9B;%P(^8cDivkVdH>yF^(KoR;r zHbP6Wzfgqc7md&#r6QEIe1tmTT&D=N?i``-x^Nsdx<=?jw+QX+9-+!TB2;2!1ixd6 z;A>xm8f40>Q%RY5&t=xb{5&p@SuG1@R^P&zRlZbaH7k=@@5*J?$O@S?r+#L+`ejzO zmzh;#R2JR;D~m4tokgL&vdOeAn+k8trq#!?X*d4F*W=mr%a?3g@->@2qOUDdPl6(q zKWn56k&!Csj^rM(NPUlA3Pmb+;Yd}$ew@O(B9W?IG*V|#uUMoGp?ir)y+^H*j8i(2 z&%8zI*RqkyQ!Y{^F%dTrP(D&;Dnx2?rAWn9j?_l3ga~zk78};FeXxcunTR*Mye;a;_|pi-N&r)k-9b^ zQel%LH69Cb8_zLwN~GRSQ8h$M2`3@+r z`j!3kjrB)IsTH!sM9CQ&rFPhhw74jFlA;uuGfJIt0l6zhX%g;Kj#ADlQCd+oN|~!g z>Cfs>I`UnVe*Ym#hFVd|Uz^wKM5%ARC~a*TrSi?9bQz(|qg1#>loDG;>1&%PZSN4J zMV+G5q;r%Cb&1lru2G8V9;MbjqI9}vlA`*P?W|F zj*?|aluRR{6gWCcImSfsd-Es_n;NAT2$>e8Z1cVH5?lEUBpyP>1yM>}!kjp~lyxnS z;&;+f8ik|yjG)y~dbJ@+r%tfOzoWPxH%hBe>`IjKy@=9$w@Y8(j&mso&LexGOG`a2 z4N7+L`6idbQ(Zca3s_LYrK_0qol6VRzNU+Ny1Djyms(>t`qy&FSjWXZV=krDb!kdH zmnPPC>3{gQ0mmA-)D?b>U8;)NO- zG|p#9SC?*JS~qHg^4(q9ho(JT>V%^>kA*#5dWd?xsm)I=UB>D@F4_CKlohx7c_sIE zsU;2$;F^Iht;62IE_ENmHRv&%8jWzN#7OFn%u`$%^)t1Z>CzVbhd*XB?i_N)`njwD zb>}h9e3!Z`a4BS=OZTvC5j{rQ5|?6@at34$eoPoi44x9pu?X&2VD3OV#$c z)Ep;p5#La7uS+8_d7n%35xw7~f%pqs53;^P0@>uYZW?+(%tHgcHXY5245D z1zO`R%AH`mlk5rHIYoWXxK!tyOF7TGbPQK8;i5}(Q0_A8zrudTub6w2HQuGB|FLiG zyVMpbk67bl-YXc7{V4au#XYVrjeW^Euc-BFm!4ziJNEc{m$H21y%7-2XNaQpJ0dO7 z%4Ut02Q>qu^=nkL8hE00t#GsgOGaxCE|rbeJtS0$)|$%E+J?01(fs`Y&c~a&(ekSo zt)3{>AX=4Crb)EwbYhOK(fS*2x<@OlC*z<@?`S^9z<57J%h`|f`$wzdfM^*9a_-P* z)f*nI&!eL?d>P}fi`Hc%uP46^(fSjsHb%?zOSEj8qBRezG3D22-Nv!a(Wo(UBNk{WC^W|B6x4KQVHhkI`)mxDcZY=y;KHF2$(-gBY!U8pGGQ7`6QxqkIOp zO5<<*Y;ET3Cr^SgBg_p!B*TL;mmgj)|wy7dmLO1Wh!?N%7Z;Vv4MaqBD`WxWa$ z)3x$BK}`2QWG?6CUP`y7;Awfc{;A;BO=PO*)^zl*=~j_?ZuP?7_1(JMfHk6GBe&L| zbQ8BWGXwIX1c#`U}1K)vaaQS=T|g+MRTBe}!9( zPO)zMjohc*+#f}K&yYL%V>N!mXH@>vt$O$y-OhUL`OB?z=ivU^t3L6lkK-TudyYMX z;0x?8tVHldx3Z!oHlfWmw^pFuzvPQ&sB*)tGq?lWEw>_Y4av9N>U*DS9=bK{F|~a{ zFP^iPUU1GUw+^8D8@C$2qqg`_u^QqRt3X4nMx(AVR&z|T%59G2BR;YEV&nCoSbb-Y z)k_R_#;RWSSY1NbQn5M@YlT>TFCMGK*bi0Y7zSc=rC2^k9jm96V^yt2tUCV?t3lXU zD^`2ZxlXLibz^k|S?Y6M<5)gd7ONXAV!8JxR`!mu?2lL#>Kv=RJ;%U|t&hcOB>qB~!^8Pp(Jtv#i-?Ch>`n5z{UA8FY^8 za1$SWHeHC-ZG>GUFZ98`c!afAVs#g#uEi?#I{ia?48I+#?RR5!=U%MBA20`!9RuKbhmy#S$l36)5SE}g^}tXRwKGphoIW7M5vLKD3P)(1 z&WFY69%?z`)EusiacYSpnc~znB2Gi_65r51bDW~H#OV~Sp;}gQ#d3U?Elxk;FWkV| z$T)4s!>BlAb;YR(I$$XZMaSu9EW;*uoc6*$HcoSqBaZR$06)hwHo_C)6pQJ2h~E<9 zR3M2QP|Xvkz+}$F612=7r`9>*R5xdw2Ih)Wx7@5HZyfgmGG>7|wJ02?3q|8pq*$D0 z7pHDmT!K7sxnvw)f8zAGRGe(3c?}P7qD-7Fm5Wp6@^La%iBnUYLZPa0T8U4nQ;jvF zM~gTe>K&(EKhc}MjM+a**RUQO>lv?7qvO>dm&P#9xOjEK0-Q(b+3^~JJaghz z2FH;wFJ6)J!u_9r21oMV#Kn+IPom`kr__*&DBX`^X)|55#K+ ziXM#D3=BIGuLJ1uJ7Xd757vQ~=yiMFLYDLK+`|&De%Ol8i}AXFCy2Wgue+DywfIWB8eV1YYw@~>yw~Gpy%Dd!AH*x@ zAw7OX{T|0F8O>1QNxXU@;wkHS7O!_$^PHYy?F(MRg4guveY|er(^p>q7O%5PP<2y+ zo(Ci-LvVsRh9u}e1coJOBL2ygpuaOG=v&qVKA)DLI#CH~8J(c1F$vo0PLL}$K^GGf zG$JWMxxY`4?S}-FM}K^-#p|^hqfUbI*G`_Onsg65(6%mg*TU6h)gpr@$3Ac3!234D*r`Vh1}L3uVa<`&MyuW)Ql(Dzu0 zGx&&r-x5?D!!Z@cZ3(J@?f3%gb{-?^4r+8VK`YKAXfu-kOwdN0JDb42?GrQ~#m_N6 zEawvxaUnr1E+(iO(k>-v6{=lMP;*Q{)+-5mgql~WDQaA!Cy4ylt2Z%S%yqBz#B>*Z zdfZ4*y8Ji2P7wocG3RZ1j?b8VhkS7wk#||o{RBSum7u1N67=9nf^IyeX3wbK%LH|Q zm%wLT5_AdqK5;!PpA%FNeKARiI)->dqO8V5WkeoRqH3EHl`B)CI^bADqTXgnlp$-P zx*;uFqWVQ8Y6m*F64f7m(TQpjlc+iFM6JSG{F#ub14)Ux=Sh^USfa{eNpa3A!F8C4 zRizVk3&qPODzIFlBJdL~;Bloyc`7IB8lIqg6~?TZsO8lXwHf1TkZa9E&BAhAsg%* zWs+R2lhmwj68Ewvsa(4xT|}w&Ns8!@q@g&DOdXSSpihzt-Ad9Ld_nHpN$Q4+cm&U# zB<06Q9L8U$d^d@IQzfa>y(B%y|1jcylJ-AH(vrtXx`DJON$TOVj+n0FQ?L2NbZ>m( zo+T+=f(WlG1B&9RH_xhfg?v+oT z4@pWl+UFcGUG-01(}?NfKYN|~%5fBt=l}gpOy}?CHI$g{jL#N>M|a>ddQ=Bva2gRN zj~ZYJZXnd(qf+RK<+uz>fJcSU9V>7FcC$yt(FqH21||!+pbJ*uJOZp96+?fl!!+%7>_2nJ(?BEy6`2=qfPN1{`QsJk;q-lqvyy_oVAtkC}T;+E9FsQX^--vLphJu zpiy~`I^q>-RHP=AsDD+Dt|EI4`cjkr{NPdhTGX%({isXb>wC1mfk&?!a(xrVZ0XT} zRvumI;n99|OsCkVhKl(cnp3hv!r1+f@2A+oSz+J^XDOkFG56 zX#OI4y4a(nrSy1%N5Pxu`*yBF?j0VL#xcb2VoiHJ8gbF1M>jpHbl<~$KOPl+;8A6S zJoG3Mbsl;232Pry->3BN8GGzG*C6f%wR`DNzE_NkKVf+7(f#)x#eDGa{SH0<Ss&Va+Go<^ED<}m!gx^FeX`DVR0ub9M!QL|Da@i zvMMJe^RudC1?5RryS&Lt$VZ-NiUCE)37v{2YaooplJ#TpWTlo!R$*+%C-g6wtmEaA zwYO@rK4W9GWbH$b>d6Xjn5?S!hLA?dnt@l1SyvPCZJVs=c+oDI-$^8EGcKU%>}1Ws zyE(~PIyYIrAZ}i=X5+V&$vV3una|)PYv$f$ox|vT$(n`8{nY6IYdDy!L#L9Z)5+R` z!{~D+S)-8QEcxIJ{`iaa|3h9^lXdR~uiZ@6q+7|Va*s9Mr%$Nxh#c?>Za+>|{wK-W z^ekCX&y$scn9s=y{lar({g$jQaQmg`M>q{BiiOLVqBKW}x??0RAucpUx$!H8ho$HW zQk*I3iXFI!Dj8BV1?9t2v<%1a8p@cWf*6SL_=+l-QuGZ~B2rWz<1(k{UsR4yQC%Fu zm4p;MLjA-PwZY#>DXN{EqOg<{y+Zp`=D{YMMzgdOZNP4n&YmJujuf@PHRQ>e!o683 z`T%>b6ct7VOvX(-!>HUT+KNMYQdA6)UU$lHx^aRP}wQk0=5eHogf1^6^9MYl#!e^i~AqK1=G zlx+Sbw-vG?2R+TKiNO{7gNussPzT*3hG{D-{C1LUrtfSE4(NE zNAF?%#=gKwj8v*7`K9W!A(fv8rRoX3V3;XYH~dri8$_vEhrH%gIjpIw4nJEef8Qik zv+yP`RmX!;H6Sci+u+QQsD);52YE|!4nSV;v1pMANRYm%xYAv$% zPu2M$sd|c%!&3FbaOOps5vlrs_9IjIo5rcCJT_Gi$ERxiq*U(LNY$k&scJbhRoND$ zs?U;CzD}m9+`&{0#sZ^bT=X9#>;lFcS zcRp1y7gG6IH{&Dc4RXeDoV}TzK4UP5-V*)0(wux`UGIsRKSD?}juj#_sKD{CkLc-~^mI)6@)accp3eZt~od zrk?l}S@x!>>b^9ML$Up7s)m1%^I)2;;SnkvqMk?7H2!3oj$^;~cDhmZok0OVbNf`^H+pUoBLq zUv_mwnkl=wgl5+U{1}#9U6H|=UH@0peSkMrzW*Qpu!n$vvO$)z$tXLckew8hw6tZm zDJUQ^Whr}!2*}?O*Uy}q(kK=%H>^G|I^t6IOJu6bCx9~<-pshtf{7lTsZ?M;1H-Or#A{V6})pf6DSYlFJrojC>>a1{Qz28}|ac?Jbg zH>}isl|=Diw{Z~b+wdH4N4p3#vRltODt#9$nr+ze3$L-8P%$a zkeQwl_DfEA;QH#-W zno%QW8I>~IsP-uFwNb6-8Z}^vQ4=s@wNd@n8ubNC>x^3Uol!N`8`Wi_QG0$hYSM0_ z=E1**{-O9@qi*55Lq<(JVN|7yM(w@K<9j@QVANdr9vU?ZN3iy>QM0p|lqnpR4_`MnX?c{x zq!-BNG-)I5;T?}jy)YCtye56-GqGNtNtp@M9X9Dml1VL-O|qn#v=&?OQFD_VElmoe z9rj>DE0b=tF=>3dNfR?@qpeBBu>(chnH0c+_Vll-NmH=^O}jBJ-O1$>6Q6ZVnm5?Q zck;A}ZW9>8iL`;{lj!4Y6XztGl!82SOnRDW(!u#AoyCL&COulrcrP*OGzKj-sq!}_ zJw&eMCa#BK4Az)bV1r4ny_Ca4blgu)xOJSdIAzi+tT=5_(32x(KlUei3W`*jQ z^?3ucZraTn*qHh~W}U%xO!1oa$Y)kgzgfjG5S;>MeHAq823m*B%9Uhh4O+J2t!8Gm z!2V>j&Zg3Kb8HaCNmybiPR}(t(t1qrDr&GR+z`pIjI4{7SRBeQVZ?Rc1X{ZI;%W)n%PoC%$9f_0+w=tnenD+icdTt!7>L z#mt(ZjQg)bvtTG3f!-Ld$nE5?oR<)yM1&=dUC&=LxIh`ioGiFu6 zA8?;FtKT`Zo}M@B-X*hsylz(E8)mgfCJy5aTsL`)RY<&LRxkVp`)#vM;vrW4ZI$}+cEoT7>* z$0?F!BQa-6%wS^Fgx0o-8QU7L1=uUrdE6cndaeO~d zpL)jFiBYGseASEb!2-B?$E^J{PA>+;ssF$@%^Dh~p2L`Dti?%`86KzFpYxhPAJiVn ze9ny19b}&srw{Q7enaEgjMLZDhd1ZM>9e_U`VJ-M#c2t?$FTMFl=g2!Ex=zWb*G_% z7=uG7dbgpPVkCaTJ=D0@Q0*}n$B_TOhH8SoScTiDa=)R{F&&4I<3U3;LQgEiWt4o_ zP$@7sY$R)=Mrvhmr1TFOsqEfHx?kI(Y6c5y;aM~X7f``yQ9ESf42qj9>VmB(WVR>` zYmqI^qA*6_BgMb_Yy3sho4aLeTyF9RH{W?TUhisgKh0Ca(!fx_hXAjqCsbi ze7KEyT`W3_30-L)&TbYxLH+I)-NaLD>S0llKD3SOeJv`AS$O!VMe9GaX!lnZ$k5%p*R`tqh)r$gF z)h}q()IwJM{H9e05Lei$Uy54gFKN{XTr6c}O>?XEqgNTL7GkE^sy|?;W7U1Au2nA^ zS(Rk5szqbkz`sqbTJNxG8~(;nuT{rzBTV~=?28*Xl4MoBW>$4fw#t@5U2UwgU}lFHK=#$^1HVO7<(R*h_DmE!}eLKuh}@O^02#tv3B>u6QWPF799osX?r)!C{oxP;HU zk|RoYx9TolqGAu~#(${Ti~W0BS)Z8av7o z82=&r7^_C(e`CpKoK+pZwQ4?ItRnZ-R!u{$HC9k1b!=@qy zY?@xu#`?B4&8T40aeP_PrkN;L$)*97ZAy68rWPnx-KJk^*wocy(@La!ZCo#9(|siR zZ7LM7X?2oKw~^V*rZuRWY}4cvn_8#RZU_1R%SSf-h5LBFla0?*Hm+Hhtc~*wYwdoRyzqTm_tT?U`n1^TC>{^!Ht{S=R>Vz_R?5c_HP$-|B}UBgkgmYv^o?K*&}2D|>k1FSdNmCIz;>$-MzwcE84 z>G5`T!+j(+vFio$JM8)mxt(@xK*a>RGElUsU6rsLxq|cy*_+vA!|Y_cLMe8&!Ekg< zrGBJ0r+(Z=VoUO9Wmn#=cKwe0-R%0PyIo~_*i{{2m_MBc=hm6S0G-q6XIofKVCb7@!UTsUdCy(mDE`C3N%sW zNlmn6aubE8HsN}=CK@=SiHgi>qHkt5k$p}R9h=)koidx~_53E9v9O71FK(jkPG$!4wc4btncbj?rsj{>`qxcM6MpRgYus^l#aqZ9jbs`u=H~9 zSD*x?go@2tK*yko%59BT(P}6;Vfbn|bsYEcj*0Df zjmu{0spI6HMotaEnufH4?2VkNi&|Evn&Eh3`qqTL;UE$m(sk`r_8XYIQ1c}wsflURPsZ{9QugSi=CQ|^54-OTL0iwqb*KxV@MUm#e+_r zKTMh5oNA8Mc;|>yEB|oncXT`I)G(}%I!1qwQ}20l#48lO;FKlmB6ETxmz;WtvX`BT zM)2ZUO7;hB4P5wy0 z7g+qaQ-*(>+KfwBcaP`)b1H;(4|sjxt%pvHc;eJ@9De3hq32E=ec{v#B)z6xbPS{4bt%VtF7?Dz9Ki!5RdFd3xA35pG}h)&3Er##}L;$6CcTn?9N!40p|rFUJ_;J%rT>t>w@Z~^!C^ecvwkjB=ub|V zfQ@)MggQpJ^a_r#v(XGf zedy9CSf4OYsPvM4qKw?~pk`jTlJLmzIq@}iVd`Wz|HjgXDQ;QOc^d7a@N~+e>TI`y zSc)UaJ(oV0n4>E?Sjw~GDk=G;8D($N=7@iPiPrfztixK-z=TPI+7 zM!s12+O2HN^ou+mEh^zrsj?mg(FNnM4oC3_#maePLmLdj9Q=qg;LCYcLn8WM7JkLw zXkXK#320&PXgHqM^{8?^j|w&Ps3GpzJt`CLQ8%AQSN$G!PVmUn%%dKd-rA!#(ma}y z?$J9L9xZF@QPKw<i=;WVlY;xSI(3f2tv=s)~EgnEW~bPBacdX#IFN0-ObuS~`U+i?^Z5nSNW z%4L*6wr@Q80nN72HZEZ6cJlqzqq2M0hPHb>nuoIc$bG*@k%J!2cPFOLAL38sKgGD7^{D7MkE-MJc^;$AW#$D_uFwY*xyrcT@F@NsbAbK-d2|Qo zA9|GI5!>N-?BVk>+feQ)^M`HOyvkqLD-%4$yy}9>CB1r#iltE6s~z~Oj92r@d38SO z9j^wL_p+X;m+wt^9`gfUeTTDA30@6s>Q$aZuXd$UZ%eOc;S}<=^>Y06s$+Yv#vxm0 zud3qqCtell>D8G&UT&c6RaXqb@~BU}+@Hv+O?cklt8N3mtUcjX!$Dpp;txC?;#Iz( zUhVnZtJ5ek(kmlI;VkNZ;Z@I3UaiJIUwYMMj90_)69#-m9Oq^28Lu`^@T%8TuiDKd zFI+&bSzeVx5DTy!m(XgqS53b5^8KP$dl!(~La!!Z-Xfk`?3Mi+FYC>FRbjbTuh3zo zmviI2vf}k>#$gTH)_FArQ`fWa2Cr&w@+uhvaO?-Kw*KhV6*T|Jt1q!@8)JnW+r27- zI%tZ&c2f5)9^)h~?xx>+=nod+VANjbcb}Ja2fX?Z`3`#38J!M!)fXcUdvz7>AMxrg zM*i;AO5DK+e~ ztHzhuj?Am%gre8HDv#R#qyK-={&laa-16$|NrM@4QH=z zq4Wc<8lX8odq^Kq{tG;`^Xa zwZlGj!DcK;@+s2Hr#F&)s)1G5j~i&0;!__SM$J^(!ACfRo5fwity~*nzw47>5siT%YNasXguE z20C=~={9P7c<4Ni~?NjA*jQx3^3SD9x@Z}Ze4!`~7(~$gr?JMMG zof5w)z310jlV2(EewiEl`K`z=UlYG>V6MZjRF_|6-F_vs^vl)Cuj(EAy4lmOM_Am; zuM)leiuCpC-B0~`JixD<1O56N;X!^q9qd>8A%3+O=GR}t{ko5mpZhfyXYt-hzq;WH z+I->HHWV4GKpYPfIti|f*KGc5w zfv+aT6q@B%R2hsx@vq4nZRao!C^^^9agChk#jGIq%p~vmlv~1n-^6qyHeT*mwv~Rp zg!fy&K3Em=3Gv*Tm_zIQTE5w@{@?pG3iY=7^*;o+`MF-zuRPoRs{gBBZhVV;I~fl& zKzIC#6VNWd3c`tzn1TYk{hEOMd+00D_xfep$2OdSYrkKKn1!2oj64VZ`VMCf#q>Jt zSJdWXF|SYf6}9?O%qwElipw#75u+Mhi5WwT%6~Ox05R%PmfF|+idvDS^8fsbTAAhT zznDV|$?`8T%6L7d6EW($EFa$RD{4WO4{kE%7;r0Q4>79v?U>K*FrVoAAZEcs%Hn#K zv`4&_FgMFBVpP}1F+UTd-h2|%gBW!%%a2d}iu&ML%)i8_jOQ_Dh*7o|F%yVU`?IWg z$=G1btC$yw_{ciqjndMDOMt&s7qPKlnf~9QK^_Gr2~qZ zTqfqTvH`B|2qjPL49MRw=7UB7MeWM6*&X0-{s7+{#gz3k_vn%3FfpoD zAZ7wF>YpsZ1jZMuvJ_~_yr5f_--uD`-j6W_1B%KB$FxceDC&Nerp*G1N=uG8O^kA< z#7rkf6-|vvB1YZI@=c3?qAV?At`ehmwTfBQn!ciGo0!^Z0Yw!|j~Psi`a8>k48|Jw zvy^Jf>m84>G;0@7)Y>c`e-Kbq?;%YVeE zA{}Gu5~EsV8B2`XlcnlM0Y#0=@&_@hR;QRuVwBS@F4_=qkdHtZ-jDYr{;Y{8$ zvv?iM=2$qFan1~|?l*Ia^7A=<>e19?K;w6qRR~VbCF%O7Qnb!h3`oDl| z*JEbf;8=Pypw}3GoA<@vF`bDG?r~gs6jR`FK=ttot|uHzo-(G-Io{&q7aT_mBygXW zn9>Ck6xAxrhlLUpHMV$+qeOzDzQUq12`W}GLG>yp=m|Q!o1pCPB`Bk6%>L>LYEUCV z`*5;mf|}Gy&>uKmJ3+0DF<%m+j%3+oN>Eg(xR^!6sI^({5Tgp$iRnm;Dp)VZON_eT zFhRCP2{KsN9|^VuZAK+K{Y4jy#3Pi7Pf!)~#zsei{=;juawg~?5?l%T1!gyWgTc$b z_#V&U^d)FCenWOY^`jG(;s(kGs0&l^JBlTcJH}%tUc%BeK|QesS5fl)1U1D-?7?$1 z4AL&X$17Mu3EY1$K^yQls)v~aWa13oN=#4~at!V+9WndS*ed;yGFxLOP4P_}my$-i9H0@f7(Qg)|X=TS8nj8qz&iNJe)^SMVSDc|tnj z4QZ<{qywnz52vl~yhoLAjIIL9U9THYaWa9bIu!al^ zYbqXM;T-D0l)2P{YV)WklQQ$E2YqqiCmwI5e>jMwpULwVa@ifeQ zbs#MF!LW*43@eQ6m%=KFS$KGvHm@)a*Tc$nBg{2tVeLccW?0|e3aiC!^1c(+YplN; z<{s-|`R|3b^gr6YAJ&*Bl*NFjVU0!MXJK`F9#*Lr#B7QB7Ln|U>W&9U%9*H_cq3OL z=lLgUZtg_Y$d{-b`4d&RP@>AbnW*O20cYVv%B~!&xFp%}OR|GOnY1sU)>5ous=cRwhaL$|mXe3Q4+v zk18gqL**nL#+i4M^ma$Kcc-o%N%{$oKS@%N&yrMmM3VB4Nz%NjNm?^4Nktb@*Wx7g z!*!haCQ0vXN>XQR{3%Jktx4+s3vpkP2A)n*&1%iGt7S9&@?kT*+o72X_iZNo@@DF| zvzbPq$Npxj@JBP&6xx2BEcc>h zWm}xAd*4#;PszH2Kei^T_s_{1h36RjOS1ZIPuANzl4abPtfjl@(;oK4oBNWLYk#t; zA4rztV6qw=Pge0$$*O_%=aTjL`D9JMl&p>T_A>2UN!Emi$(s8#S)OOf>i#@gMPDQ< zgxQ#oD@6<6NYNF1S0F`Q+NbCUp5f&36ir-7#Jz7*)Ol5kwxZ;^6eX`uVcoeDHTXV7 zn{jYwitM{ml#UC#Q&fLXik2aBZ;B@GOVL~VQ}p<5iW2Xo=#zY@D)Dxz8e%iL7faPL z6f2Rc2-YKi$y9xYuJ5F(TcuP5E2nC3l~fH+N>$%psq&9Y)uzR%TDLbIO1e(j*xw%SiZLWfErD;jWH0|!1rV*c{>3-idb?Bd_-|*?c zG>yiJL1`K_G)>corEy(zn#|*gm@_F&l_saD!L&5Zo1P~3tTe9UO4F)2Y5L#XG~L`x zJ>RG4$d)wy_+y&#|C}ZV#&1j0w(V)^w>M2?j;HC;l{9_xUz+CMPvg4NG;PU|E>F&M zHOP~$ix^cXT}|Ii*T03+RisEd?@yk4FI}fR>H6B6t|`HEo#>aYIz!V{cv!j;Fm!gh z&dp0#>CAK;#(7MgpRO7U(sdR0@p56h;+9Z9E@H^ibQN65W8Bz~F5AX*1@IT1Z%UV8 zbGk-gBF>`t_vs2@5%O+HS1}}PP1iEC+@7unsBk2mdxWR!*7&Ui_O?4 zIimWlDGOypGzKI4M|2vy2Sm6RS45k!2ZIJhRAz8Qtx#Y{L}hUX)xLfM25lw?{bwn-j-kOMVZ;Yt!4-xM9%y{jKs4JGD*Wc_{ zCPNJ?X6UFjLp5v}{N0hEwDuYLs6&R9Aa!(xR$wb$Am5k_*)bNgkb7)~UZUw&8S0DU z*f5T|#%Jipqzp}-oS_C&GWg7!p=#4Iv=4XCa(ae_<2bA{GBgt_aROIRd}fAPpaXtI z^;sFR%w`+*&B@Tfxfv=q4+}E%E#6$1p?@%RQHGvl%i;``T$-V?XuB*!9XDjC%gGEK zJDs6R82D#~j^Gxuoym|1cFe*PfgcdG2v1wDQ^=*cI@%P2%-rc_3o&K*}j{hr=75^WBHCinI literal 0 HcmV?d00001 diff --git a/Covance_UCO3001/browser_profile/Default/Code Cache/js/8a62893034c6cb0d_0 b/Covance_UCO3001/browser_profile/Default/Code Cache/js/8a62893034c6cb0d_0 new file mode 100644 index 0000000000000000000000000000000000000000..863f9650e7719041d0705c1c4780149928c8d3a0 GIT binary patch literal 18392 zcmY-1cXZR`8~5>do1{s~Y-u_`R-vUyvy<+mML_o6ipo$BWQoXjAOgzXdk>K%ASlWP znX>l~0ojV|J@xtgo^zf*9?p54Z}QE3U-xxgcSzIZ3*NUs{;pKl7cWgfWf}U%>Hl;f zqe@P-jI7K|ufJNrm+5^Y@OqW1fj~w^wVdizs^$d!-kdkQ)v8phR=sL=HGdU<#_L(Z ztSULx1Ho#(>_E`xGbqNvxWd!^7wdn2rgpJM{O_0`e%-n(eIjAEOgF+Au_}q%GT97& z7Kg(nVRI0E%?3-Z#>=S?$tFQBjZUqTgGBkdz2=q+AD1eN6n>2Hi+guG#j zpqcEF;pPZtNHa?W?d7E8MMqFqq6$S2FW*S{q7nGzro5DH#UgkoMn_4DjUZc=N^D{T z737@UlGaI@S2}{K@=A)7iQo&#N{*nWL{`uo87$-FY{dws>aWoSM+6PhBY0cZN>^tD z6}=H0&59r)JAzs=QqD@59Nm{mG9^EP163jzQ#FD%)gnlIBZ7CUD{t}FjNq`u*N$L_ zbgUD>inC=ST{d{<_ja(x-SCr zfe8Bi&*=y@pNYWzdj$Lch@iyz2)>dorbyOAMN+{WNsYphj4l$%ztS^4lJyCZv`C8N zo76}SRf?n_Et0x&R!%x2sp5{Lfh2n)8Rw6reYHsbcq5Xpsz>rn3Tj5OLW}eOtefjvk zNCvl$WLU>Y3U!L4(T9-~`6!aVM@8Zp6G=$k9~()+xJcd^AIW}+o)F0ga$jDX7|9X2 zB2Oe~Y9xVakyMrjGb1@KrRPP`bU`G4N}q2dnZ8Idzl-F%#gW`v63Kf%L~>!Z&ix$8 z@y(H3lr`HTnZGlV%w3TTkniOSy*TgO6G`y5NNUM2$vUiF98q4U759nOc&c@uDVBUM zrC%xjzmb$R8faeFz|0~B3KcbQwwQs@#SP4sA~6P<#2VNx!%G;LA z=L7>EPc-mil7V?s)jwG|!=UGedLqr17+4~AmKu0>nSqxp4AfkyJy@k4$+Vx;FA4mt ze#*^X3^ZJ4VDfqcrVR#u*=XRSO$M%uYm4?=_*Hu=hqtSjJGB2hwMV;@+in9{dkoY$ zqWmQLn1Syk_7C+^4Cj@rT)l0e+Z_Wx-ZfC+o`DCF^FTFA#v=m*9vk>ZY)=e)EB`#z z^W(XCT-eC`B1Tq9N>L-XiW&Jl#)vQ0$m_C79+xocxn`tnyph34MouLgxs+zalWwGr z%Sfu*NFkq*#(pEKgGQQW8F?k`vyCL?7)g^UaxT|M-8>`Rsv6l+%ZRJCk)CxFOUBhV zlG(t>Ou5w1$Q^0j$VlPFird7L^`4G;&0oosE3l#YlsXjBJvRdKeifcO;{yk%jVJFV!!BKI(}WKQ;1&%o}K= z%$G*iNtZ!JK9zsOH`vIFAx6EAF%mUKwT(5hK@LmNaYl~KGBS0xk@Itm)SGLhofKMR zB=&nF!{pEkBl#o*uFvC+sbIVo>! zGBRSbk>`@SOSQ=_yNy)Zqdxwo9QP_m>2cV|ACi33i1o6O(^B)Qk1v{WHxrv=N>3A|J~7d@mx;sDzmIb0YhtWa?PsEi{3@0KT3b$is@M}u9F_VL zO-!6*($8fRiL!W#iNLoe_Db>ZOnf8XuQieWvxy;+^^1v_(srGRPU}sq++d>2M$M6h zn>2r$iKV}qcq+|zn3ykr?bQ8UCf?m`VvRi8W1{14s{4TQJE)ot>2Wa~HPKEMA2X3~ z+(gtF6K~1f-%S)dtKOW~_&-fFl+{x1qKOWdOjN&Y;`S{QU)(m~zhk0`{2)*6n%H^I zg!_?+33BGKiJDJL+<0oj``pAFS@N&)_|L>k`HUzYNKRxFi)EAiCp(Q%)G#qiB;CMQnZ)Lu6k; z6uFh7@KuQ-s%jKKwTvnb|E zy_TByW)$7uiegEtDBfxl#qqXLeA+IGzr_816c^e@k@7(l)=p8p?60_=Du#?2taXOy z{?I6{d>w^jSQOKw*~}w9))sJ7J7%WS7 zMR9j`6s`BD?tM`-+OHnS32A>YisU;{bh;ZwZ@D49`%%o3vk&#y<0w4x+LI_c%8I8^ zlzyhVUqo^9WfZMmMX^89%vZjccsG?@-7BkbYxS0b|BGybf zag;FggFJ~dbD@-(R~5{>Rng4c6f?zA%}lPObFwPU%vSN(&Gd4Zxgt4EjguxWGw;b! zN%SZOiSU`}D5d;n(q+2*8Bk6^Gs82?Jd@>_W;RNCmYE*edR$%$oAtiJOjf>`8nRYi z7MST=*-W^WnW=KVwwZc$%v`Q-W?KU@l^dGbDTNxF+1=nz<;CC1#YFTjR}anP_JJcUo(S;>u*%x75rh8&$6qY&KJArVL~A}X)8)CD)h|@fOEZ}= z?v$Zf4<&w=5i!q_-`6 zBc|3CTFUG;7K*gB@O=jh5g#bujuzI+Cm&nbDp8+U=q3GnS!mJQLUbRC_RzvGIn>ue zem{#||FyoX8ET=~*A^__SV)ww<-jltq2U%9Nf(Knq}*iUWD9quSjd~I`ll&RsXoKP z0{MHUa+_trKgYu7vSY3V+k6Xc<+}wIo-DM`{#y&n7AcqSEO=zfatm*)vG9v@{?Wn! zxgp-Q7Usy0GH#QFzT1?Ol-O=zkfiKTEplk5_I96zF~=?36#q#J^W@I&7T!6l{S@;# z3%zB=W%c8l=E-p>d)>lmN&8EEll6aFu-~vy>XydK#@iOcch&oQ+Kc-Z4$5WuR|-9_ zkow5Nw^Hhfg+(&(nT3A`}R4a*d@CzA+iJZJt(=weU960i z&0Ve7yIJYp-O71M>7g7xvGP(H_Oj|V$Ew#HD_bSl*Gm6>R{oYs{jCg^Vgsz?$Zd)E z)JmLWeqp7mtd>b%T6r#&zf#O^taKTnSQ0hLN-wE7+R8GyH^xevu~wRov$95>jaSXn zth|z{GZafA=2+<}Yvx*+GT%y%1y+i#Rvxl=>%Fdsx6#7|t%I06J+*+r-*q~Tq z*`t2Ro!_jyyVuI`eO5{y&>qTcId)KeIB8{(T#!4bt>mAzQeQs#!^%4OP2$d3sVMEv zTlrolT+s7H)<~^CtxS~V7p**zr*Y9#wMA2}Tr^YVfLzaw#-A6>XA&xi=CG`LJ(|i@ zqH(+t&F8YCdNhF=(JZbRO_LVU^p)I}(OBNpeaU$%8hfi~J`w-I7(SC5zr>KSE{0?4 zV>q-ShLRg&D6%PrpF~e$Zp!hkF_hgF!;D{J7_mKuDLY~qwmXJFdtx{sIlslwb6*Ub z<-7ecJUAG`oFg$*J{H5G<1yS5`-vEKUWlRipD|c2$IwIqS7Ye+cML0T#PCdh`zMB? zw_$`+f}Dq{YJ+K7XWqpTw|7IzNqJydjozvN$@HL4{&DAax4IGPg)9|H!$b zvHF=1OFP*f6HA}CSbh~tsaPiTiRHX}{k_irr1KK9K9==j+Mvgz@$Oh=$%?~@e^&8j z)nBnRxf#oB8FW|k9>h}QVJvrF#WJ}_2`){^1Z{Y&tRtQ%B< zQd3IMLHtWfFl$u_{*sD&O7QuK68t9Tua{u$-zA8+QG$NAOECCF2@c6m|CV6+e_ojANPD zOUChOsW{Th#nD?%rN+_85yy{GH$9Gh{y5?Taoo#^Ba|D*)x0=P38GU z&@PUs_u@Ds3p>VfN8afbN2T6z6zLO(w_h9sZ(rLbG zSQba}a@GBF9OE~|aZbu?iKE4iIQ`zDdUnNeV0Rq7ev6~|fjH*L@q=;v{xFV|M{y)R zk7L5Wah#V1*w`z!2pbCwHaePYtdUH!jlLEe+r@3Q@u;Yc%EfGqEpDTDjEz=OF4m^^ zs5W{@Zk&ywHXBEzcD#*KlAK^;wJa~EacMSgr`zAGHo1?p;3K9*MXZTj89#`*@j-$-+0Rbv|$o7-@< zuu-R_@_W}tXPME>M)mGC#!1tUY$Wxx@xE;8W#dwR8?FI1+I()K*+3g}CHhMnXTGvg zaj=b*GGmyHYjSafOoObdmfJ9|wb595{;aju zD~?z;+L*jqaircB8$WNg5xGt4{c7V~St1wZ$_^Wzoi?`Zw(;*i#XPLMWu(+NVPm}P zm3hD0xG5FS+W6y=jY^l*w=3%HZ5!=n`W+khAKIw!!bTrMygurR=ecAQiD#gEUo@VD z3Gv*KkxB6^dM%!NVlN%fk(78|OO5ABrFbl!c$&y|e>|fD@tlzn!FVcV#`Cd^%ZjIR zuFgr-P&}*h<9Q*ED#z2fYCN-~Xtj9C*Nvx(Y_A{B)VJcfESYWMY1S^DOOnz)o{wZ& zhj>2yFrMAw=^D>uxhP59;#n@?{_%VxN4|`w#o&16OZ}l*`)lPVyX4*B@hp)(nJI?#>dnr0itLJ~?EZMl9Ehir+?2_OG*4=tP_38a z*(7yu#FKnCp02X|Njw{0#AALLulG?2yk|&Yg~XW>s2ZKXXz>?HU_*%nqT&*m^jZRK zODC{gekqfn_vZ=Rl4s=-$f=N^?@$t$QZa$eDG69p6L?*gxDt3M@A?z?G?<{zZ4x*q zzlRd&S0#ZRvaDJHk85gttpsS4z^i5n`rIyom#q@$-adi#vaMqRt-2<#NalQ`e0n6% zNQOy^-pWPZ@0Y-t0SQ$6G=Y`U_Dkg|8AB9nSOPVMCtw(zKww+~pUYJlIwyf6vUza= z-!4nwu3Y#&frK9tXeZNU(2ofmkd12-cyn_C3#I(l1cvNP;IORTr8RaZFi`w^)PsEq zT#`2X6PSB2fq$g;A&ont+T@#~2`o6Cz-{^EgkqmeAn{ZJ4Q0t$^-J!YOJM5b1TM=O z5}6m5$W7_xO=PPi`4VZ9k;ra|%}ivv)Xhrdl61{Uq<3B-+oWzt$JY}nTqTj{s)>}Z zqc{x{$!e6S&&LvZ)gqCaEfX2~Rw5@pNTgiHM2y`M$^1BxFXfA#I@c?a&hl73=$*)F zsnREr$i9g@lu`o~^DD(1oXFFmiF6v4$d6JmT=7RM{urGfm&pFfi6l(X-03>bPNbc@ zoRi4Txrr2?m&j}Lbzf>MNTkWaM7CE-qG(zYUQZHD@{*V>JF6yPu9ie)ales7KiO72 ziG4Mah_9JMH>uYsiK()raT0M&lb9!eNTp^;{3LlTlNc(MS|zdW{UnU-lPKOPiDq4r zm@BV$)w6%*0m&Mx|QVY z_VUcSTb|hG<#|U8g_7wPm&^|N+mVdjm&_+}^7Ui}S4pN`<7B4FoVLkq_#m06j>(ko zkxUC2ElUR^^GL=INv7F1$;_3(qmtP>E*aZ+#hIl!vy;gX%aUZ8$dZl8c()`oK;~^v z=G)(rxhs2*CDZA2GCxY2Ysu7qn9MXeX|8~!Pz9PubW#OgmaagJG8J(6D-hqY0&Qhs z{|eOoyaH3C?1&1C9an*~(q(o9dT*-0GTFVY0O12@~5;OQIVz6Z9_$FY_CYhj*4tQS&@=2Dl&x> zE=jO>3iaYrm@3)jQurr1h0F>mxGJXTGYj39{>~J_o)oruQ+VM^p}IeX1u`d?!VNi? zk;1BMJthlsQ>Y!%{e0b*KtT%KDyNYCdWwENrReWK3jM05aIaPh59*|_xxUtEl)|ni zDU^FNh0e03RSH$!NzwOQDYR^tg0n{oeZ)0DkAIfJT3Pi~3b#fm=aDJ=J3fW4rYH}o zK239Hq%cZ)%uJ#0>=d?(XHE)5mMNZe{UL?AlP*qK6^{V8-3?|~HRoJwJ`^!g)( zlnW_*B&V*V@auKW|0{(@w^DfZD21AjQ#kijwY^ATo!oz!!Zl+mK2s{iqf>DfN~Mo9 zFP=)*m{fj|ZLz6Li%aE-yl2zc#8f_&iX~GSB0EZ@QtY)q_Xo_DjQ#`gt>GjE@V}rSav1q$y8|)uEcEV@_HrKyipb`QOtxdp?cS3u(-}nnvAgX^g*~#vHl!R~pV6Y0QxE|D@^qlr(DGO5>7r zy{)l#(r7Io%f$O>`rJB=We?K0FVml=vH8C=j1hKv%0SsAMGbbE8trVCfS;Wrn zqINQi*;$)t=T(xOt|jfvEN$m<89PnN+DT2(xl}vnq@vx<0f|euGg#XB?AZKvQe=|+ z5wKG?Xs1QKosN=RV8<^D<)6xSTD@-P&sui)s$=Jqx^}L}r6zVB$oEa{ zY!Xj1JH4CRxhD78*okawXQS+w{C0MRyl3Z;?C50YgpB#n&K!y9Y^P-xyS|sUQ@o$@ z>90EF=;wBl2HF`WJqFqNuBdr}1h#b=KG!|D*E!$xbopvR3DRR?mO2Gh>~d zLhE&VlWuR;?JbJ2-Hv64od!GYY>`6y)#HP9Iv=ugR(?KW*L72NmLIe8+HpHR=_dsz zmDeddkEPIQJJrrB-`jS6x}&|gYbRGuJ+kxcxt-`2>W>_k>M!k#dZm4qCJ_#%M>>c$ zI2al2;8-CCRSP>ELkCTmBM{)4^?@gM=Ih@8&uvUD?68Hyl)~;b5Yyt>xfVZ3kWJIQXf)gEkEueAiIp z8#$QO*uj-14qcbvpp&eZpWbxv@+}8lS~X!6=C5?{_bLaA*E$%r-ofz=4ytWbe>Usf76%)*I@qwyLF9I={hNaZziVwN zdDekL{`u3v{>$pCOu3?*BTQME4+>qzeB_*9Tsp(XxluouRaHjKHb~?Yy#GG^%N_=iQ@8qR(KrYFU*VCz1 zKb>Y$tbt<6I62)gotlj_R`xVc=lDD6lxm&M2pRNVIuoSc`+8gsNqmQNhRO_y>XOdK zpQQ7ZgnMb6Y>}uw>GYNn^7zwqZVgK(I3k^6Bh$Gevqz<~Lb^{#CvBRJ)6=;iy=E%5 zRGyViL-|##bJFQ2qvhE`^=Vl;rtj04zapJwKcur!dau?zc`5}zrn6FZh-ZB|Z*Nt9 zwxv_zSFI%zcBeD%U^=U%%b|2WmD`eWMEfJPPNg&UbUJ;1PiM;gbk09W*ZakEUVEI* zdrwq@6n~yhix=tamLFcG^VTcH{5PGL|I%rVlSL6u;v=2BV|236a#vz&aC?bP>?PVVM9$qG67PD&RzdB3ug9&$^9Rh&Gi;iPD7C(Y_O z*(txvWBItTlXXoLtErQGDc?#tcTp`}og9!$Qmea@BVRd59O5KJDh_qh`D-UcyolO4L$+<;N z>V2p6mTPU9`Ms0nQf7sd_A8y7kjT~Qqa2WP(qN6|{^%s?C)N0~YWzht%Ift_o^5b4 zc$1Su+f>(fC#6m~X?I$EIpgH$C9QkY$+%liB5pewbjL~hUG0lJmZ*D9`pTC3PCO5s zG=HSp9&7)eY7a~<)<(HVHM`hvaZw`L#aGg)kc(A?U6d>0;#!;wSGby5mDDgulg>m4O}#A=whoZXzJqY7A~erM0Zap7$j&s)2Ay{&3%=VHJIF1B}cVgJabYnEJ0`Pjwzp3+Ns_i-^vmP&p< z7flAcm_Ecs^iUUVzjo<;f{ULdd6;@L+@;S9UDOz>coQ{dvWxz5W}5mn!^K!}&2jO` zTo+g5!guQL5|_T8R_|80Sh>@gQZrSft0M(&(YUVkdDi!R>2;^M(e7rFncCRy{JdVw2rgqyGB zV5FOTgPZS6Zf-}pdDrYFWOY+d%+YQVWSAT-FdlzvkwebS>-V$8s8z?50a4H*3<|RIs}#m+s~Rr(4&; zx{0sm=AAd(9FXTV-1^+h%@4Aoo|{MY-L!AuW=tbDCmXw|-o(vu*EZVHCDSt;AUb`w3!O@A3b!p)hHZfcEk zGj)uc3uBejIITBPYfN(UL}pEPb7hK~d-C5@H=|~`IX>G>>$$2)M$LEAZh@O63*97r z>t=uqS?Xs0GWB-3V#^!fyBWE{%`_>!(#`v;+|2md&0?wki<=jl+&tT?o^N%tN;XNQ zZR*8#H{a}VGf4{Vbklg3n_uOS4BoB%+M_-BP5UZmW!?cde;stw@{sx_mczrHV{VE{M=5c_&08nk?3LF~ySXL7-`y;fAEfbFH%n#sA8wAE)0p#a>dROebivJU zf4X`5qV`Bam)$Iv8#mqfZYvL2AvyQm41D0`u6**y&4$O?C+Yvh&9OOaK-R#l# z5*}vDs%Q^S3VHaTu!o4^9%{yTFei9;Tw2F69=6F5san><@NyoWOZQ|CYb$v8t)hqG zsU8lc>*(>&!s}tTT=#p34S0An=pivz$FPUF`5IH;;lIirs#j6Wsvf;R^-!&@=GXHu zwYi52Ej%=6sT^8)81uG=`t3X{Xz$@h2M=$3;Gujc4;?@Ba9Rd;_OP#uhrF&HigowU z{38#$-?iJaicD;rkJaJ=%kBtcQ8hcA|&H zla%vh59g+Os5srjMEP%qa-OA{W$GN|Iahhk)9qy*EXzH*mR9{)<>AjCJQS?;F!W~+ z!!~>9dc?zzM-}Io#+=oda~?`x@$l|#58vMLV7u$#)I$#gAE|GTJ!Cym%}>>1dHuQa zl(Kl~5aH#dY%+K;n!J1>ADF$Yuy`qB^%9U@i+brD=jCg8-R9M6gqQ6So#3Uvv@Ypo zQ7JF+uX)*5(MxQqmqGHWQ{!A-mUz6}^?GUJ^RhqarEi9pEty_jC++2TDWBtIoP7Ga z##hmrRlRJJ#?`#+c*9GN>dK{tVoPi-#g@hOz1(S_Jezqb+gf$BQ62J+4C>&eNH;G{ zyKBCj?cpW4r}FLP#qqh~ec|QhKrdqkYt9g_el}>`;d*?e>XCm&d-0F;GG9#Ny)>BU z<M>$MLXyj+ndG~Qap62=}2*8(4&Z$kkiL~3_qbd zPx=^kM!mi4qxw}JYh}-M_3CdQUr7Cbd`!BjzTNgw`;L$GGUc&qdg5c~Q}tfvKlkzX z3m9Ob85Q9oZuPBA~VWP?P;`1x2$Ci+R2 ztMW)bNb<9yq@OaS{1lY)(@>(zYn+UfW66H1R`Am!-OnHiIsMd?&0=!<=_PXley#=e zc!r?cq~In+`Pb^MH~>*qxyKUJFeSuJtR{j_S~XP>lt%dhKB z{RH39W9|Grd(W?b^WtY|4?p)lR=l2m8V~R@?NdJ$KUdu&{k%KM&q4WYf}b4|HFuJq z-=+K%KjY;0sk%Mg&+-|5N-fhG%QbhUdb82bz)gOAo})E)__@2&&w$;2zWL41p}p$G zK0gm6_kh-yE%NxFpYDhJ{CigU{^2L~ylR$x7yb0V?% z+t1rK{IvYX&qufY{CvkxrMrGk-}6)Uf#N?@51*=s&-^rh?x)TRKjUAjU$6X3{@2gB z|FqWx*kTM26%}BdIY7}u0h$#K@Mn<#i7^3M#|Ahg)#Cz;vITf0!x91><}QXYk*eW0$l4Jz}7dw z+x-IUm(~Lm^V0zFp9N^}Wq`?pRLeI329FG|Z&ZN1(E+xPQ7+>G^p_u|26#FxK*#B- zV`hLWvjQ}otvcrhI6f~xwfO-`E)3B2+W<%8nnW&Ae%}SCuq40)Su7=1s)oI)VPAkV zQtLo~u?GWiD8Oe&12jAqp!4wn-T%?N+X1@V2~co1z+3kM#5@Vm@@arQvhKO^jtH{b z5TvLn$mcRa{*XseL88n-w#s3tVhJ+L8l+e8Am5h>@~~`>_sa!Yl^mpbg&?yk1}Tyf zB&AZ2E@_G(8yrC*ok2d9U0yxz5AvC8&J1G8RxBwV3eqARWKn*QTLnRuzY(N<-5`_d zX-xef)td(y)gq|xLW6w$W{`t#1$p!BAZJ?#Np2ftyi|KH$cXoY`g|qG;yyv{^bPV- zM)V6ZQ=0b=(m_s3*-wKk{Y+~P3exv0)g)C12lcyFkeyO^Xpkvi2eFI@(qLqeEwW$C zqk=ph9V9$f^~=WbLH&EQAcl!SHpu}gm=t8LT%WA?Q}o!>AaQa~&P&5-ialMiW(3Kd z8RW}ZLGH=)*+DMOQQzjN=Zk{+on0~IsI*)W*Ci%3 zgI#h)Zb~sn2CqpMspZUItSf_V?hJnNWRT*`pi++R=VmaZUWTp_&LGqv15e`&dN;|S zQ_BopbE7!#Yt0TBeAqPubGHm;%dQC-6q%Gk#QY3uF3|ZU%5}MN{XT>KD>E?uoI#ym zGT0!O*Ja??kiqVaT4#&a*_y$KUCQZL25XLIP~k)db5AS(Ga0n_J%j4!GcaAu;Pxr)HBeJ)3W3z1U`C6E!QF zdb6|HBuAz5!fY0Nm(7jE*}SzRo9+_5GMo6-*}StRn*(x59&N}b;ZQd39?s^VT$cVP zb^Em9{+`VcIr?WdNtcwDtiGSkvj^E6d!DW5S`Me&Ipk&K=o;D_#tzl}uXC6@Du;$+ za+oqUhtJ37uyaBV8547;EghuFEv2zbuDk%X298eGXn3BsW&&;9H%;JbASz zhiZHE*b&XUrg_(MsCg@giH~zQ`y_|yuX4CrI2UKpT(XMg(k?ES%JI4S*_NxHZMiIP z zmqPb*86Z<4@;D!v$1F=8@0G}7XsTg_;ZnX_9v#c)Q6(*p!OipZo+nS& zZRF8VcDsAq?puhPXrQ z_k;*}LsSZCos19zq-17@wpk&LNb9^1i$Wpd!y#@~2@$9kVu4hv9%4j|5HF-qtq_fC zhxk>7)K$!SidjEI%LXClGz?L!QHVW_b!-~q3z^X@#HHq%(;`HzcS4MPHw3LitZWnF zaoZ3b+9_^_5LG&cSS_7C46&+nh;m&*6!Zu&^ka>a;(bH3=%@N+$Y8BIMC%R>@#ApK z9}%MSNcC#0dNnS@-%@qFdNLuzbNOhR`a3;D@41S(Krt68rWE=%#KPqvcKxJ%_*wfP zLw-^0b&9<{#OO^SPHYbG#+DGZcZ3+XGepF$5QF!H*tb8#wL>AE$Pb4@Y?C%eLo__0 zeoCp6A<|{KTZhn{pwZg>J2{Tx}t{diHy)gOp!x$Qdsof~dda*YR^HH-ff6Dr| z!o2f#m=C4ZJ7MO(8)l_kZxhDdF3fBh_FkC7?}w?}Uhz99en-WZot?uJ?iwaZc1WS_ zVG?D&{QXgw$1>pKFu(Q;b4Uh#66UvFszbW<4)ar=FrR#;mu!{o_GIW{h==T4Z0^5%pv zb0>x=K1sclTQYNUnA;LHHH>jum^#zLY>+)NV21La8OA>=OyfCWrp*o0a#5HcSA==7 zGEC$zVcy>nX4y{la9@~8Cso_2Fwahh8GA0wsqiuoyb4R({ zSFaz0buE3EB2U6JeX3qcuzWrPlJm(;%g0eYpB^>xxhT&FAZF`8<(pSMzaQ&&T$6KE^Ty)G1rQ$#MmJms-H>N(H=| zR=}H%0_LU{(BEG``St~L>`=gIIp4K_lT!vZ_Pe-3x)ki22<2i2brHP>8vvDmyN ee{S5l@98JYx@M$&?0)FX`+xKFFYf=pKmP}-f7f#W literal 0 HcmV?d00001 diff --git a/Covance_UCO3001/browser_profile/Default/Code Cache/js/8b04d9c868176da1_0 b/Covance_UCO3001/browser_profile/Default/Code Cache/js/8b04d9c868176da1_0 new file mode 100644 index 0000000000000000000000000000000000000000..e66a00d6e5f167669d6b21a0ebf9af9c0f342fb1 GIT binary patch literal 19444 zcmY-1cXZR`8~5>do1{s~Y-u_`R-vUyvy<+mWe?dKL1hVoED_nLhztQymh2@<5M+bw zAye5yh6pHAktuuW^Z7mJJbyf%^Eyesx$o<~uImnM^3At;-~8a)QaxV0Gy#=m-^8eR z-QcfL)1Q@-6Ug*sR;!YeQPu0KQaz_;PE}uKAQ;FAL!P=po6?AVX@)do49rK6wMa zc}MH?fKEN(t`zG7w*HDWK(Piw)?iru5j^=AI)4J)KZP~Jpvq?uKN8*?1zjccb66^O zN5k7=pqtbk3#}yQ3#cibzl1(A_$&BaUW`|~Nw97W#I6PBI#|0NcFOz>@IWs7py#&0 z;;qVaJ8YFhlD7lQKSH9Mkjv6^H|*I1zsOg6VXhS42d^JcKg9MEq{tNc`5>H^uMfc@ zi9f8qABSbq=>+tZ>%u80Dsv?G3)GPRq}XW~DqqU%GwShqF#QHQE<*GrC?&thHEHoX zH2eeFNy*FLkeM>%3XGFlSD~dG_@8Uqdzo|{7D(I;sPLE8mOJvV^tuVJ{#IVMG+xe1 zo!iRs4y=@}cVVF1l*9kPMVa;hmPpb=_~#KA9>X>{Ecs7h!&ANXPb|g z2;${)nIc6BM^L_K1b(?CFQsR(2!_ai@>Yx8DAd?VJl2;P*n(#IA- zY+?izUzI)ZBQN{W<;;1kJ8j-a+gR?r+7E)(T^#Rv|hL@-VNR4+LqXqc|} zvO#({BdF+&;6zpg3E2_UkuT)Dl*!R!`C6vtE0?Mf9G2hZt7;Lns~$mOjR@YZsXE19 zJAz{p|9S)?q)XihR@952bo~hSH&C99)B_nUyPK)b77+}PnQuq%M_c9JK7x-rsONG; z?C(S{UDkDu;KjQUbn6nq#jX*gbW^Mz5tNiGA82nrj9}8I5tJLH{g|x#Uq@h=qT1&~ zaBi+@m={3{`QV!fHqBSu1$w+Nf{xN>X$0=?m4jSb8Nu9D5oE53;N7*VZ(RhxZHQph z#t6D@RejqdcxPt>J9a6r-RkdN^=w}Rt@cN-^I!z#!x8lVpR*BcKc~3A>NO&Vev6>Q z#Rxu=?xslAMnzJ=9En%1NUg$=d|4!tf2B`+B%2c=X_*wsJMwACNLH7Qj#i4KAT5%5a$Zh5BdO|+q@g5xBl*i0$pn8SovKIjTa8FQs~O2NDX1OE z3Muw_Bp=D{x{>(nMe?$7B)ywPQodOvi{)1HNZPcBq>J2=i7g`;&?=IsH?(H!NVdo` zY0)N5$&nnFtMWvWrbQB%9!X_sI4hEiQu>=nnk|Ur zcj><+iT@uOdrIB=89m%CNI`%^(r?xA9S-UHe`FkVD+!x7U`CdNRAIaVW zkpzE=q>hZ1tYhliapiSZai3_7r&{-!V#)VX`jz7U8%bHCffj`g%qn7_P*DTtiy8Q` zxPduRB*s9~SOdFdObG)srFoozPI5-d#A~eFOE3_TXkd#RlyH)P;Ux_`l#H?lY6|5H z6qjN0Q+We9$p-dUFmP5TRx~hQ;!+H>NmUF<_8ADsZFwcV{027YH+yQ(z&n`+`idvZ zK!L25r`ZO&)QTYby7Z}(k3#%AdFTJW7_(bkYc69?wxlJ_SoMhmG$p&70ZQz?}>YuEfX<)1LU!=as zS!ur1z*4#Uoq@NP8F;zEK<$;jav=8zsV07&^NSc+ zDJeyb+%9J1;}|2pSR++rl{_wC)N9a4*?1$vlZ>26HgY-5h$r1hU6+wmw~<0VBTf89 z)&z|-%QEsxI%OM4%rTNCQ{_Ugk$QPXT1(GrMt0OO;(FakpSp@C6B-!FY-nVbTyA9K zuC#4zq;M0(Zfazg9Ff{Bj5L>9@=V@uX=G4qBWv5}_Dv&6ZyDJm(QSh(`LTnM z2c49|yUMSNZl(KsMvjZKn~@K?8)^8yk!|vRZzDtHu4MEvvQXAY$G+;11p2FIvQmsg zjC>;B3^h{bQzM(C`!FLztu20bTte=xFni;)sr zjqH=tQe&HuvD=M2m(+c#Q8w;3Qt5z^pk)4}JbzZ6@>KphXr%WsBfm-V2_x1kM$Ss@ zYev4jZshe_+Q$b*u894Sk@XVs*hsA>MyfwEazKi{F!GVS`Ja)0Bs;=HQHzNWiN?^cTk)CURw|+-+^r?;;aZI+}PTtKKoOQ#_qa z^zCfos`Tq-;aX<&m>4hB2AXIpKZ<3r z)|N9v6nm116VhO^iOFA^^ghHyqAZzeBCyEB&rOQRej;N-i zdR|N?OmvVXCru=rG7)voL~EJ%tBGRg)tieN|GSAsvPR1NVWRV86E&}xxO3aYCwENv z@0zG8tL4c(6MOHQa6d9JNzOesQTvIBn@>%6pPQH~OaE0K|Cx9x9}&d^$%%|&iENYq zWUn!bx~3>5L`CUCP!u*fZi(WkD~b=?QQVg-ZxoAVix_-S)XI!vXLb~Ya-wJ@%jAA; z6z%e&h|P~;gd8l0BDZoBzN%3~Rg0ot^(fwuqBWuzCnsx0QMFbS5e*buavMf*rg0SA znnba>X%t^Kk7B;mZ>4!}MA55t6ieGg(Yjp}f%Z|Hl0RffhbaCO_d8Ks>J&xFyHQxX zM)7ix;tx?Q88=+(jnLzfQCuArg=2IS)1~>WC}z%%B6>~~Wu^YSDAsO@;`!z%%v+-P zPI_!rFLtUgKSnWJzS|eYz5P+NJ)rszM$!0?dLh3^rz24$-;JW{y(s$0P4WE`#W!;P zp`Lpjg-2d{5=9qT@idCk&s6`5C~m!sqRp!)4n>-&VlXqxXy&n4&1M=}%xssnMa)DM zHB+ycnSsU49F`KXX3B}9gqhXyB+ksGQf6LNFw?rCnRzK@ilv%)O{P@RaaomSW~X@U zX8JnJT$LQB#!6F{nT~Qo5~Cr2 zlnj5vOvN^4e6m<#-!#+eEj=&$+M6lg!OXiI&3xL~%r!~xq8uf$$ z8ue8V`k68HH&ar+8(_vc*31WAnE68?@H;afZdJWf zu-#0hy=MNtVy4ekGn=lNNxQDP&wl`2#KbU7+=4?MMsFM_I6ZZXr=d$>Gr!LSrm6mhKYywQ`fm zQ!Lz_Y9Vi$>YuJWrRGcv3*@g^%5Am<|6B_n%bs}_Z1XL&mv0wXc(Tw!r$rW)Emkhy zTJXr!D2yzT-*l$|MlofwlD0N%& zWa}LZ;d|PH``VL#EF6(5@~;$nU?KI9g+)^8iG{^7^qGaz&-EI3q5NNJU;on@Sm_yI zWw87zS&>#gGFTZSccq)r%4(C9&K4^RidnH1x6&}i%62&^cjSefjkS_l!pe|1E2HJ4 zd}_0@Ki*2CL@PI5vl1w6WndXAf6AG%Rw|UU(zU$i%Ftx3FXbv)`ATNVC3z!7`K4M( ztYl@JoJ_M))ovxyYh}KS^jSINw~`moI^xQ;vb3HRcYP}#Hn8gFk(Kt1tZbFYCd#{| z#=c?Yn8dfSa;v@8d(X;wDc{}7c-h{=ioK_mUcIbbl$74e;X^AgrBPq2e)d@Pv&YI# z2@bF_XrPt9q|zWO!=>0@D>-sUB8FIrlgv-7RFgIG^`};zOXbfL^K&cR$10XYjkD5M zYJX{EncV-%O1tq^T1>FAR-R2%&C{*Cl4>&*OCsi4=^<<9S(!TDO78_$imp)}^7C5d zvChig^;Qb~pgd*!Mk}{BX)m@YmRJs`Uvl>+D{ud7<m^ z)8w$+$c@II7tKc!Dv0KoY^oAX<*Ly*YDDv~?5P<|pjI?XYDd$wWi$gMw^cNjH}qI? zT1R7V6U~R>Ul_wja&u!08Jl7_xjBZTTVg1=HHISFVpuPF5pzpU?Tn%9t{7(i7{l1z zF-+YP!|44n3_B3RVafR^hCT;l*e>55is8YL80H?2q4LQX7N3gYzSw_>Veh3FivJ#i z!ET!L$V@roPqB_QLP8N2F;jU#V*93!RK zj5r?7j-y~s9AD0j!}LuYjil>*)vzp%|m zeSeCh#o;)+T7f8)3)4YBdF*dlB!Fxco~vawb&%{B&DZ0r`d z)yAWuHYyjhF}}Es;xRVbNV!;>-mlu|E4gttM%ru~m)GNMoRQ=N8*5~FIgLxRaVOoT z_op`UTsBI2Y!vd_7?x?{u#C*I@qMn1r?M^2Mx(HewpDF>Cp)WY?&~%V)wPjO&&CJR zrh!eLH*9QfsK<>pM^-hl@ka|A&XzXnwo-m?+vp}Ud)lbk%fyI=x>PEsj_&UOGc4+hRXLv<5`#x&t3T|9D;;EdgV^S>?&#L@*UdW@$@ieIx&ul4LJ)ZLQ;^{8C z8^klMbv#!jvt2yRJH&HYQaZ)+zD(~N&ye@x*)N_R@l26FB&laS%OyN0p3mj@r}4BL z9?yJfFj8xeQhu^e-X0UrQt3Z2o?VOLDZE%Qmc=u0MLc_C!P?L^UHX>k4m7UA%PVV zXG)-2bOK+Bzfb~ON+b{!m%!JrCD6Wf0?TD%nFPI0PvEvZE0;h{g#>-il)%)A32aYE zz?zys6>S<_S9Am%z(5 z3H0iez-HOiC4n|Q5?CyA-&a1p6KE`>rDZ?mBJT`L;N0K@Dh^3trL_N4xk|!tbB+y8fo>#x*?u7)VJx<_?tR<0e;u5(feZ7h7lq6pw?J^SCFR_`4%#eCniCmT* zIf?YkOJtYS3+c8>B896a5?w8k@^uxbQ6gE56Lr2UkykAfsog4(k*yQ?<=sTebxFk7 zGm*>>68Tg<>7!$P6X_<8<=uXXtdXky6Nwy<$U`YLR53qO%;AYV9hpei(TS{+f-#E! zrQ(03;}a4&G$oOQshT@Ow{sHdATQ@8vUgr0#lK19wfTB1wH74ObYUX9DtH%?-jENzlRT(cy;k>8|J^CZ?w zUaKTVN~JbQY?l^$BRr{eWWQjLlyr-vr-XpGh!n?&rSB<{>i zB4?J4&rRa|k|a`>Ch^I#B;H%6HN>$oiQYdZu~kYOOk)0_ByLOfBRVGLqgqQ6jwR7S zX2=(3k~kx;UDn*I8Ye4nB(d|)BnthN#KgaosQWO9DN^ob5~HF^azgsrN^(7=B)-&= zyvi?0scI$ZEEigrU|ceL@}+z?IGIN>aYQoBKTl?!3?G-w&l8fdO;nuO znlmSv46!Utrl~C5nv8cxGK1xt-N`KaDVcln^T}koo=s+*w7Z^6gNMmXm(%77SPE63 zsYEAL;AQCw)GAW}hra^xT`JIC77nUFy^kv}RmzU7!1xIjI4|AjRG{Cs3M`ZTyDAX- zqhcMeK%H|Hm@JhpSI~Kr3e>o++n9=E##ZF(juol;UPZ=9a{r1t*I$w6;vZ0v-=*!? zihL(Mw^Zcj?uumWsmSir6)E|mB2!7>vIL8#P(Ln(X_8$og};+i$gGfpt73}IUFfk4 za;6aWq_E4I!V6ytHT@|pkh#GWZpx926jo*HIa!dK!s{VD&evlJ6r|9zati5HQuO;N zMgIm;7+5of`*l)yP&b9`4YW?<6!tYuq1+oObd$AhQmFb?ioQQfp;d!Nny8m=B7|&nc_*0)hW#1 zuKDur-W19lN};QG52sM~ObSz^?{6ujTuR}6Ide6IA8%;>pD8@Lox-a}Db#+P!iA@* z?L`Wk3VWYbq^eX&;UKIF&(?IyRMonZ)p6TRLb5>W$&|8w!T&gbLmQ4%Bn=M z>`K&^Y0@-Yi8<1}N+mYESqbA?l_=G(5)J=nekEo|pS_i+cDj8ZraYn6C-qY?#w zR$|PZN;-e9W3uXDB@EUy8pvNUY2+oPF;W&+NW<(;)AxI6eA*<9o1N0g=$uBw_tIGM zaT*WAwMgTZr*U6qY)|8ty=j!&m&R8o(pdjX8l2YgU(+~$F^$wqY0SEoM!oB4OuUiC zT)F;d8qS+(%#?|Lr|G(%G-};WXe%GcAk`@+KDLuI)Xr$>J#+YMyN;Jjc${xpoS^vGenMJGGYB`Eseo%J|iGnyj%? zcdea?>y+nu^?9S6nVaks+N}HAbbq_<@6f#6b}W1BG~8=vhZH)bz8N_#6!BOJ_#bP#QD@I|zPlZ6~qE9_u-F$ZrJcd#JFq3|k~i2UnXqbd7_9uCiIyzv19zYX{xiIJowvgRkClaQbZr z?b|tM)y=`&?hcCeaB#f0gTy`#K9>~(9PE&R109T(w80K;40Z5S)_m&VM+pvdF!(bE zf6G&OXM}_DpF8+j&Pt2X4vLRa{<2Bl`$9b#r#j@K+>v%)D)+CH`*;T_GE&~1qV=ab zs5{-k^;r&Fa};x~VlH-2c8T(r_r6oE%N(>_uHMT0l@9(|`j$ zoBQgcr2gX|Q82gAe7>GwtKQ4n|3p{~R=y-4Y#<&LH_po=2s#s8Bi^hk&rRp8ymSuBWf@T=o$3wJX)eVYDyB@3vyIZJ-B@GgK#O!vy_HU>w&{$O zVI9+%B=z6X^Kw+;JEt>JW=d4|bUyenozEoPSL0-dMDw zI$NdR8qJfZQm`(am9j@Xo6~u7r~0!iof1E4Et#}Goo|k$vqrifO=pPQk&NToAE|RD zo$+VW8Sra5Q~ycl;)8U(XH4g{$LVx@q8g<5^K@FiNN2ySewj||SBm*>Ix+vH(-tR- zBb>xXI(f_JWTDAPT$GdIu})f+(D5WE*`=J+5yNXvO2`N~RN6_XjFXP#oP1Z_Ny%g< z*D5%1rZ|};NtK+mOLKBeb~>DxolYjYoTOzq>6Pikp5^5IY^T1LbaF4(Nmj_ow^F*m z$vc&u^p@Katm@=JEhj}^chbDBlfCk*JeCidIN8)xv6?x_m-20tZ+F$v!^vT}EOmN0 zIsTcG#1T$Xq~b^?-9|Y%FBzkq3>o8Ov^G!lJ@>rtoI~gE5{&C`Y;H1SP)%I9>_f-8ix!4fpBGv5Tki|ubXcwPJ*Fr8< z6?Rdsh>PoSE?n_0W=r{!F1nO*@$YLcYLszttgK7l?YKCd;-Y4%irq9J<*&_e=UF-_GuoSo$Ag^k>C|bwG0XZwLzwTl}T^AAcT=Z?=!rIV9 zqed=v%7SJtMzwS?O`5cF(Lqj0sn#yW$}O4J#>J&KT|95=qDp(!*1^T#cU|o6;==yE zOV>5InEHW>i+!Z8^6u~AYxz#{2fAoF+{KI$E}}=eXg|uO_X#f6OY&&-W{gYc3|-V3 zuXvL+W{QhJa&Ef%HPgj-am{t{;XD^t<G!V-{7l|@PnjUuXj+8m#!Yzl7YV1iDBc<{w^+xXgqP%`rUVpfF z^QwynFJ0vRtD0o(f9eHp%n@!z$&pAm`35)Nn%vxpa`U#?O~~q|zL=xkB*)1| z!fpx|anrP@o83}BR^uhHgqt*(A%DcVX>4;dIo{3r1UGdP-FQm5>GztO>(ZmFn|0+h zCfQB*N^aJsxv5}xQ!d@jyH2;R$#oN7-OXDy+#HtYwcI-I%-y7{WH zo6}9))NJZz!JBSwzU9Wy*3Ikf+_aQW+q-ogt()wQ%2Q5u)!Ku!_F%Wpf4TL0-%Y^? zH!EfLC^ylg-3*e6W8Iwl!cCoVZl-uG*{57SzBxYW`^!&b_njfbz^^w6M#hXtKH z-0bY3^}8O*clFTaJr8GPcsCCRyL-s%;h|VB4=vvJuuslQa&HfgAs%{vEVQ|9_^v?7!Ti%RqQW4_{MwqM%qvIu;gpyJjKI>X&x%h@Gx2ao2i^8l>z zzT;uhT@SW<9?m@UF!Yi7_Si$#6V?1wJ(eoZm8X=&OXmnLr)8VLi_zreLwVQiWrf8{ z8LO9o{8-dWzc??Wq>9a}pA}wqOLT&lLDIIQm&K*L#J}d{U_~#nsa}T35U0kuye##2 zx##uL&gbP&(93`fFFP{5x(?gRuTnn8%LExxMdPb#&1znDNt5bc_SEpwyQXrfrPvZ% zN3mr|121SEyFr{DbmwRvtF7n=X-le?xTGBdU1TLc%OKAIn>Kn z!!>7wSHB~)?ifA)h3b*Nzx3iC?`6K2CVFW&*~^(JUM@`aQgOPM$#QXqmy}svzLwr| zylkB7C2gL@NX7XYBM%pP$y@Bzbu3=0eXBL4+EOoTrSK{*O;>AO`D?8g?|LuuWW**f zuFcwqEncq5*W11PwnKZe%ZvLbFMWUZ5&4>aeYmrtH}+4ody{_EvHtdH8|eSDSd<3HJ*;v>3} zk3o{0=3}M9$K!M#pSpac`Fy&r-p3_*n(Lz=r01no*vH&_AH@oM7^?bMFE6Y47*)eZ z#kxMa)$?&)4mR`=+t|l2Io`xaVly8Ln)_(e*2nyIKH7Ko;q2lgEKkJT)yF{D`JRs@ z-L?J)TECChmxFzMeAv&&2r20AqoM2)%RnCkWX)h7&xZKu`jK+|MDsrNF+_$9_wmyR zAI(Pj_;Y~|&m!e6fp1mw5+A1Te6(HTWAR!a@#}o_-r!^74?e1G^3i0QkLlZeSa3$fxSR%zy6VuNOYvc&TIm`8bT9aD<c|#}jPdhd;Hwn>u2zOKcD~P=jhMs#X&z0B=@k^mmTu>h@W0Z{rr1g z`Tpi7_M&Q*gMauLblK0YD}H=ewdOUgc|+^VqCfrI`peIoH~qBw+t2%V{QPj&Po;Z) z&ffP^_JQI*R1cr3htK@9cfXTP#v=ZT%8@D*&Nk5FTkm90#u(L zpya{;?H2_&F4rY;vGV&iK!v3NCdm>hu~IestQrmmI45-u2N-`O07nCSbRs~blL5M& z3ef9s&AStz``rKq_X4!OA0XyQfL2cf9FR@Vm3Kst{e~b#O+h}EN%EUKiV6~C4zg2@ zNmWab(bgb+iwF6>Opu3VgS=BN$g1QZEh+?=T`@?JlpraUf^<()4B6rc66p-`f$a0@ zd4G_PWP4^1Q?_DB@lcSK;UJ6igWN6%vb;u+2K9n`U0-7w1gY5~$hek4eK#6p)EhyL zv<~vdn?cUE4U*hG$V92$G050=f;!g{WJ&)ZcLxM{DPso)nI$a-1?enjrRXxk&gZg{7Aco07w#i{B z_&UfuxiLj?r|P+BLE_|yT$D!B6>~-q^UNT*vx0m&JIH;RF(=3$bJeeJ)a%7TeRfw& zIU%i91o?Hl*4z=~z)t15Pr2+5;yDo1--!hEeUAEjM0Nh5{I6&YIUz~cRFk}SJ;>@C zK|+58+4CSsp+`XywM~iHgghge;M}whY?F zXW&Z8;KPy`1j=P#t&l;ZiW%&bf2B=I1~()oHG_R}PHsstM+UD+cd6sdV7x1X+0xUU z!Fo>yDc%e!<>+y42EHm5 z9ks?g%BOP%@Ab%_znFVw5GQkFnQVMtdH2a+uXOI4LFRxAatCJc=im%>jm)6^1m!y^ zgCbvN&}B*n?&%r2ZYqOc=VTBuKZDu}6hj_M(}fva66>N2w##w3D(0nHQ>IIcW$M{- z)$zT0wjzT;D>E1+OV((OwHX+H$e`}V47SJtxw0t($CeCc$o{PvoRaiy8JKpcemS&L z_3u&~IU^l^%wU{U-JL;m=^|tIWiU;0f6CC`pJ#CIplUsm!A&`JRJ}i$!P-+9RQM$W zuN0h7Y?*gfdv-2^mcM3D^P<-LLv=@GQr?oua%(0LB{QjADwC71W%5>LCJVDNiObI9 zY)&TED3dX==c7!0rp@Hv zshRYdo=KINnOv2rvog6nCzEpXGI@P|CKDED{e_vtO9xr;T_%r~WzuPRCPTl^Bzk2g z335o%*JP@{ne<(oN!GedK3|{7=pQm!zbTXUTQWJiHIusAGxZ1js^dT=&4141*>8$* zN%{VsN%8BMgl}kF*>*dV?7NC_FO%0EX7VCBiyMWq2o}r25|f3oL>5isvPiIHajH}n zGs7C&swqU!c6t{uw4c_fQj zQuMbhnqSCbuUz>v3&%~xlybMTc=t{gsSmU0TOpgR6|;42Gn=2?*~ECW`Bd)bWs@Dw zW{LE!p3TM@*`(FXrdHi-zO0u`zXsW??3T^r?i$}So6#R-bL``6Du0qqeR(i6o7`d9 zd?!0({+Mj;Ov@%?MmCFNv)E>46E$1o=VY@@PDrgGoV^?8qg0XD;PVlV zKe-H+sS$ZxjLc)UC6A6J^7t+;kCL`L{fy9UnLNfw`Eq%5DW6Bxv^<8l$kTh`JYDCL zMOy*i5JP2Yn&#L;Omc)Uq=y*c4spm6 zBIFHGDX4WaLJXFYnIYO|g*Yy4^Fk~Rg@_M_xK%Yopn8Y}QoUw~v9&_HkV17rGUH9B883W+6V2nax97ZlO6XL)3XI#Q3*E&^E-%b|D_O z57D`U;&u*EwM&RK()GO%tGb0K*F8i*?+_zD&^ReRAVkZ7s$WJ7*SaIL?#K}9#%TW7 z5Z%5|ug0ra6GHqY)h4PZlR`X~_ou7BGeY#6r-)9}BTd+MNi|=oj@< zN}UdoEoURzAbZVF-mBRE3hS`=8 z#+4bSW>%PS*Y;GOq ztvAEGCvDyeGym-{E9FMJFzyav=E&%dVUE2MrgA66@2vP;6kqms3sbm9m?YUFg?fca zl=<@4`(Yl-;19z5*eA?U8TMhApZcl}>De#L`u<@){7ARM!o2(}jCFVzubh)|BUPJ> zk>jJnRQWti0~sZ;W5T>KRZRP4SyRH?k*H~5jMKx^oe^e>9FV~?mH(_T{@Gy)q{-Yc)8~b0wOD&3>sEw$ zu~L0pA0~2Rm|_yQMeAl3N>0K+IKP0+tK8@?;vrC)}^XbzlpDS{-Nj~w-@);?UqcX0^7+#w-@l+&H_%JE}-Pu0xC((a~l7v#!K}10-S#p(C20WLnZT80UzBi;IWhwMMV!48KBWbs literal 0 HcmV?d00001 diff --git a/Covance_UCO3001/browser_profile/Default/Code Cache/js/a5c73b65d5f70c29_0 b/Covance_UCO3001/browser_profile/Default/Code Cache/js/a5c73b65d5f70c29_0 new file mode 100644 index 0000000000000000000000000000000000000000..e145c19c90456d3e337387df4e03a674a65e5117 GIT binary patch literal 31008 zcmWjL1$dKZ7sm0sN!uiiG%e03b+@E=jkdVUa2@V0!=2$i+})kw4jb+^7{lFNhJF8! z>-t?u-uIDn&hwahc92fBxS&u=V=peRIsSKNLG;|C9+BubY~VU=`K>x zRVu4MsX~Q|l_-+s%5s-3U9wQAB0MTtD63djR;kjN#fp`1mnu;rvqZ_HQkf-;jBz@< zZRY>S`u{)6{AiE=-wwu7G%YP%!u>K*(X!G+sGMZS5u}ut8X&5Il)s|n#sS>G@=DT@ z%F-e9u0o%h(iaS?CH;$hb)-&s&`nC}E`7p|@lu|JQUt1?2R7gzJVMPy#D=rzy;tgU zRSL}T&?fA|9W>7L&`2D}^3VfxEa9QP=u^@|-laX18-2@psD1?x^~21n9{SkIL#Eaq z+KD3wY~!Ig)I?K+we`?nxQNs3Je1JhL+MEE=AqubJ@gyO^!3p5ejXao-$P?DWFTV= z_t5Vni4T6GJmfXmL)oTy=q1+7WULz=>UGCM51)DHJvu!1&^pw8;h}A>JaiZtuRT=h zi-*2=8r00opmY8PZOLZP0X)fW(BT{g<;!i*ChW;$P`$hc{rQtYu>l74#Kk~^S_K)j zFUz3wC{@CsBc%*_T-G3SC4(AQHmE(4Y8X@;`(dwXP#Y{n_gajB?)44&y_rGXnj7@K zvq8~a3>uB;DBIPbf%w#o``r!7+rywpeC=salV0@gZP0A&LH<6(26KOd8sQJT8Nj>) z4JtIqpe}HTh_eFS4)(o}XDW48jULgylbja-!rH+I%%A+c$&y;cp!L&c5+5YN^4f<3^)$ zdK>k#$*BDpZZ>K%?pTa+T8#=oE1OZZ97c6S4yREe_#Gcn&d;d!n1D^Vgk3p|x{Q#V zM%_SqE~BPmUT&jaGXj1xsuAX57l!6DYE*zx1M(Yn3k?H}Itxp%QD;Jo zniR@$^b9lVO@vXdNTbF?8`U+A`-w)~a~XBhZB(8lqvjN%4Q>=R>RmCT;**UUlwwrl zG^0)^6O~cFoKg4j zdwHX*6^z=5{1uHFfrLs%MOQVd66&E{HR43s>a@erpN;BL(^G}!FV>(pYu(qVzWt4=I?$+p2Q$wQ_Qo*&7a49;FLWAVRO?Yj zJwnK6qY6%BU;N+i#Eo2286Qukaeul|9cCN#c#ctd=Ni=Ss-%ynmSUOJQ}-R7 z`qk;F4JhX4sa$zI6^9-8GoPon1$yd0h^KC&ahRuK!#x!e?Wx^Ko~l>aQzcS8H36;C zJhcbu>7F{0;i*5$ddghRQ(dvOx~JAP_0%EwH1pImjBoC#g~-{$Q!_BJm8TXXv9+hl zxAoNi_Kekm_8mPH)5%joor$}Pry6wiRHMGc)X!5X13Xm)SB83O#V}9p9O0>}I6IPY zM|&!GEHTgY)aE&~U*M^>3q3Vuk*A6*_Eb0Qh4(T~8CTGMji+{P^3+$H*i0?9dMfI= zr+VIGzUQ7gWA#!&o0q&DUdqblrTuxlv_05Mnc-fl6z8RziC((o_L65oFD*(z2``nX z?4?&Vy>y_ymxeX>(ybm|I@8-r2?M?48sw$l2YcxrQigCIlMpxDOA9e{f|mj&d#MXf zV#gFOEuQYBTr<3M7;&?`WSqm?sE;A@y|e;1QD>2tq8EEWNbR^Ing`Vftz9{h+glxe@>ak6-Wn6^Ex#~t^^fvayJ&Cq z!X@0n=@@VQgQKzDdWp0+Z&krsc*J|_1fHT?g10_kaH6+1VvWmNxA0d1Z#608t^e>> zVQ+mb%J{{+RWI3F;VIs#pU(Uhyw$oA;Itn^mUDsN3*@2!rTndc90mDuhruif5qAMjR}>)u+2hBv%5rPKlcr)fo?v=Dla>XTv?S1^3z!{bQr%$MhMM#jF5-TeNpJByoPH6Ui!^B+PDhz^ z9bcnO@`*92WvofvF)_}hdDtFrQmF)!&f;H8PBdvgs=G{T45!BuAD>%W(_YOPKUC#+ET@CT^7_J`5~p(mix7&wY4RG-)di z;SpL^GHF$1lRhA;s!6X=v6@LMQKC9=V>Lcv+s`JIt-&o;)G}#lZIc2UnA9HkklfIu zGMI{IsN9HoaJR8Z1%5H9SQC?KHZ`d!ZlGi{a>rLVo15frVNyDNZ^iv~CV93u=_x*; zPe&6kx=k7h|IQ{2=}KJ@+s&jGxYM1udYTmet4VqKG6xR!rw#*6iXUWBwZSGe!lohg zAIg2KMYdrk?f=ar;|P;-jx?#=Xp?&36Hbhw4r8hLM3XvBVqZ+5##4EW<#>f`(@hG( zDO{RmQjOWfG{?mAl>IQ*q%HGJ@?Buk+$APOE~9?1uP~{?YLgakq3&C$-!_vbUWNiu5vN%D z)699sq>OW{{dw}gz}j9kY0qWq{Woopc$KxlAK38^HN4J#xxv0e?whO~8lo3AVf`(W z4x`g;)&w8#lG8ov3hRCPU@G?G18O`V2k0@eAPucB0nhQ%6O*El>ot4QV3wEBtUyF~ zn>81=QQlPWNNj54by9HY%TFy5@i6Br+-&}brc#d*A)L`^2s7ulznwFk%X5SxCd z?NqZm;wFYoGwbUNvj)#JYdlsXZkAbp;}Po4=J6b2K%IGJ%|YG;jDfui%`z+^x5Z|y zfn}*#mGB(Hmzh;yxmg)#h=+KG11rorji+e8k~vqIm1DJ8#nzcs8qM$qvo^CYw=niL za@b*3k)5m;jJwP#d7RpwU_EdJJx?+}cA&v2>WnX#c-pMkbJX{|SqbQVf%;!GtHfoq z{>76k>;m)kv*G5c~Jy^qDyv* z2IDO{=dh?`PKy@hwy11gi^ic?KITGXev8_}8DvpS_=H$g1$RR&iVCyn4CaPgvv=OIKuZTt7Maco9a5}}J?5P$7BOS+4DZ`?+ zC|Sy)v6zXiXi?gtuBcnqBCm25<-pwX#Dgo9Evj6_q6X+%)uIFFP|c$Lc!{s*UfrT| zKU>tNhDC*IF+OJFCOX!p?sY7hT$efPF(MTn`_ZJ44B8d&L_@A z79B>1ZPa5Yx$UxO>2B6w53%lL|6l<&>|<|TW3T*c;mtRT0`L)@H(8_G7Hz&mobbI* zEDxyfLyP|Yzeg7R{+Jw}STyh%d-l0SvB>t4Tru;FMQ7i#XWz3IKeCtL`^ln)XbaVgACADux{FCU%s_R(OIkH+ILGVMN!@%2%l(?@aWhCArz z=cCOzeY7nX?eG{)bNi?hmZR)XKD@W(qm}u56ddfMH6cFQfoh>XGKc#p2U@~ElCjYf ze?R`_VqN+0!E<)ezLsnuE^P2B9Gx!Csy zwMMtCKKcsp9mKZNN1gZhC}h8ns-rQ=9q>`oAs+=D@zGtpLan1d%5#ji=#PNo%!BeL zeAN4-kDi_K(Pz{<&Dx&v(U!B+;-ZflUGh;o+(!4yw8N(>K6-N1M|*DhDB=}nUCte@lnUO+R0t@@5CU99@j&8okyV|NKG+e{l ztR-K}TW8fRyg>F1jD^+MffpO8*CwlmV+sy$w#su0xne60BYG<}Ll5-Y#{SrD)dOVg zV2v>n$9Iy?F7iRi-K+_wqWK=H7GVR1?4?#{yN|y6tx7szRjz~7<*-%h82cx2AESoH z$@v6(6>Uy3)+ypXZPg7-K4Vp*vsP_B$J(Oud2+sBRq#dj5K3NR-7)C0Rq|-*yg|&jtctkJ{zC&y!~+z%%Raovx}(#5>hXXY;?P6t@`ycx_K&Tq z_JlqB)T%#G=o#Z7)~a_X@s2*I{@$wjAFO(bk{@}Dop60( z4?&+-9f8V&Ld}< zO+U~g-KJHTUEHRNHEpU}%cchyTid42b!_sfYtwT4*TAL$Eo>Tt&#i5$)5WH($mnU~ z_Y<2=pnM;jO7yj93q1PU)P9If+eX;rJJqHy3v9~0i25wHsT_vjHs-Ij=_S6R<2sx6 zBYM3}{csGC8*FO3(WWbCw%Mkx+Zbm%HA7GQi&{HuI=Gu!?;)SPHl^&NF8itV0nQ(^ zY2qQqJZzKqpEg~?=A$+x9<%8bsvak%6VwywCv6HkWm9kTJ54*}KSMpv+Vl>K&)MWU zZ_{DyxIjD?ZQ6B-HMwllIxM+v)5d>os(8bu)p&f1uTtb;|oWn9y{7yY^-(Z*1XjdET!go)*ih9{K5_eI<+peYfhy;_J*Kc+eFxxc@ z&ya4hYX%~H>?(*hSOACBuDaNTf;PLRz-G5=wZpFbzII*4pH91C{OpDZw$6XYUuq!B%*s%az zqwLCzw(BuI;C2jg#xo{N33ioEwCfA1xR}Fj*ODZ=Iux|)Ka?-T{UUZXElT@hcI{8L zD>lWhF_@ZamtUG)Z_@3u7PspXJTvU7gTk4Ng)UikZNz6Jl(g$Tc9pX0*V1-9MXoaB z1Y=p|#W(nrvnvTbFccdq*mWIOD%s^x*{(1&KpPyz{%WiXKEv@df2Sefn6sN)X=WqumSfP+2!BFu6^j)l=IlojP+@5 zSF;wx*NWV*7unk|7hbowE24v4=aAabu5ws{tDVTdGi%p{oV${LH`Z>no!2UMO~7Y( zk0DMRg2u9rn2IaNGmdjOipcTAh}%e=KwQW>(XOv3ImxbBSdKiCsUMC`qb}3!st?Z@ zc5Q}Xrd=ts*yC`|V{BBLZ`U;3LXicGg|V2wken9T^~++r8Z9B7rR<4ic4b?^oGa~W zzsjz^abUGwA#3eQM9@0+IGpR*|9FnD4R#H|QTT3T58;AqpP37n{v)3+)a5(R0Xg)*;7~^mK=#YXOI`Dr{4xNm4s8)Y-LbLeooL(f||^aah@I@F<^ zLyg-zWb5Ei4NS)2jt(8_#@uMr!=WRn{i{RPUgX)E`TLMpUxxh1YDfxP|ZmWJ;tKR4!xT~ z>{A`;I?bV_(;ccj!=c;gG1H;zvx#?(LlJWw3ZCcC`uW7U(4p>|9P-#o9)}#-eUv&M zb0{9KFA(cL4h_BG(CPfXsuk(0$OgVDh+N%$6^0?$f&&QbK^rtf{+_;y#U+gR)mOix zSubBLN0;8d8i1fazKX{%82kFl33oqVwL~{`?eD7%*n>_3eAN%N1~LwegK3YBXf(`M z6Mpm62h<(mt5+j^6*tOP#V~V>uhx(E)#?cxpX{sCQ+%~}ny*?-_tjrBe6@0xueKs} zwy&Pe^;N!kzKTXm{0YAW%(cW<6=7QHtHc$)YKraHztUHyU|P-GYkhTiov%7?^3_dj z+~%uw+d03>SNHb%s?2_09XaHyzYqIr?VrASc*0k|ob%QF%hci@U)8zot0IqlRr7_f zUcMvOPre%a%~!KLoLY`+MklY4ow7Te%8N0+PL**wwFw{L>F4BgZKsx^p}$j;@#rU~ z-eY8tQ;ShN*r_>42ytpOK4NaDQ#r$&$`$U^ShS6B>i1};3dT4Uk;vSIo!VT4<3*ji zj=ja43QKb;w!Bl_Dmax|$*F2pohtFOQ$1=p^{J*)>uWg`T$@8Zy|ai$k5dja9>)iW$M}XmS|iRGYC*8OAwv zf4oyQCpgt~BI8UZuPILXPj#v_vQ2ZU?sTVIGo5OQZdi?kx%9&u{5H=i_agGxMV;^z z)pt{mJx)!;8N}{&swjpdeILgTvtEBX)f}s^4G;cus^d}SJ;s`ya4PAPQ&mno)c`Zk zGXFWJo}iQacP_K-S1a%#_G`aW@T&4g1|pHin6?3`hPG>GGDb8G(ej1+Tr=Svk8VN@!Kdpncw4Z*#A(Srbr`hHF z6kLf|P@;;Tw%{w)RQFT(&wiST19(~6PowJjDd`tKRU6=^(PR8neVU(^J*01tzjg=v zt7f#nrn~&L1Vh~ZDpWEFo^!=`Hf`mct+>el2Ioof55dtHAutmm(v>if&t z#9ud?`s+Y5e?4m9uazzR71f%yZTyw5oxh@S4jtS3>mKrV@YguZLc8w%>}h{J9^|j9 zBN=CszgkZ9*Ne6On!CM$&ma&pZ|P90sEQ!%%4>Jnx%^_DLFu8un!wc2B<)(0A*ktZo#{BfKHbQ z(57+$3M(I=b?8$eKsS(7DL|Fc0F|l-s2);k2B;if<5jZ&Wwi-V?~VZ~+ATl}a1A-S z2PhKrP_0*hhGG)FqGj&@twvCv0Bt~xz5zOpk^KTxcOd662*;5&G(ZK11t@-afRgbR z4Sx&JN3}{|J9vp{69e>qGRLO`aBW0@ zHpBKib-@DMN8Ho^wZKw5z{+X#N5FLIgF-U`)CnuGcV>XTAa+)OZe!tW>W;c|hz+^t zatv{c12lC>fEJ^`(g2lOM*MiZIzS%~zLw+IftecvG-@+B-~$5wU=6nis5V;Q7|QMm z(4u_-nz5gL2Lf~k?GLh^ho}!49S%_IBLV7xug3zE|6G86#xJ;t5|;v$_aF8G#^ET2 zUJuY7D~x!8oYHv=?eQhvRH@8tZ-Hz&Ueq6PZnAac&luegQz)e?sm<(F$oe$5F9 z)K`Rr1u7AjkPsQDMbUv85EH2F$PpK)W0+edQ2$_j)j-Wd+iHQT+d5F&pf-U@$7^`B z4b)QPYZs^;K;6XTF2sY>KwKlAf|(X8u@3S9%1NTfx3W@BY`@I<3|H^1%AiK2QBd)rH%(G=mhn| z-IIYTemYRKE(XeVDNsjo4P&naY9>luCAVvV>Wht-b&DMC1?v6->i#fLtr7c#9GIj{sT4YHErHd$G3rci5(vT75*_$c|Qkgws#QM_yy@t1ek-A&l03)RI>(Y zWBwr3iw@HD}w=!Fqt` zz+lyn4A$t_V8s^<*1FVS^{5}LGM$3;xL2^uYl79_aIpS46Rb(+f)#ZkSb>*29^-*Mgtr$M%Qr-FhH$NXh;I9Z@cJ-B zmoU;Dq8Ug{A`Uz&5TdpPLo}*zh^}Evu@JQ?&R7{C`hew`A@a-$kv~S`9_p6}(OEc4 zhA0^=a2(%It5k?4;(6&1T__WxlsX~mf%A1kbhTcHTK^WJMffoyL_iN08YKkxP~m2XPU9|oZgVanRDYv$ zW~eT~QYMu5Q$w`?`=GL%L!~OA>iBc024G!{Q0?g!s;WIhwer_cZAIr^q51>udWY&P z`t%9aQf$I~g!c_q0n9~0zffiCAFAoNj>-cV7gw-xP^hZ?7OJL`L$!NmD4&&vYCAq7 zV|J+ign3S=V$d81=7!2|ekkt=hRU!pRE;-Qr@;x1@`M8BXXXuagv&4yMcn0&iP!+nsc`U(zi?qjQ zY`7e%JMh24yy%60vFci=?jiGfsN!xA&+|||Hwjgfm&E-lR6V|h>KGa-O#R^S2va?@ z!ZB1bgsDD?8N+lDt3AW?5nf(l8iMiOJjSo4Fm*DA@#VBIJ-|B*^a;}>YnbN2YztF2 z48|}g$Kmt~(JCu<9LZM{aq?dc}j=LvqG2}<0Ohz4AV0Fhgy}$72TSJ z>0r+=_4t+A_h!t#VX8KS+6|}gs4z_%7p4{y!c=w|^US2p>M$+Eh_%GDFHGtGFy9OE z2o2ZQhT*EyC|oV^1&14ltIaRrdIQfU;d0>@Y(V~|;hKvb@NE{Z_V|eW&BIj-cTl)R zxSnYeVcsQ?3!Zi+;5Oy+LlaT*ZxP~F;#c-9v zU~It?Nm`|siEgDvp860Vz=dp%rNQ1C{$EH}e-{!zGWkEzQOVtg8|?JvUh0V`ip z3#@t-&g;(zy+-A>5ejP;p{;`>^a_=RMksn%g!Ye$(0`~sCPE2gBh+wegl41ivgmIzhHGMvU|c>fWhbPUBLRM{G# zZTJeyHtyr6?Gf5?B0@_~M`#mb&O~S(E}o6x|K$kHLHb4JhWS#2a$k;6vnvtmg8089 zv>cVLMyM$!;-_m7dV*^IMCbylT#wKI1pFJJo(R4Xp*6UIZZ{)T_*R5Y!uvMk-igoy ze8G&n5nMwQp}$e+KaOF%B6SquhDceAk#gsXR688a9jW(uBh@E=q_(47V5IuOBPddh zf+ICEBvL+Ukt&IW=^QH_$@d5%bsOm=BV{cWsi);46P7NCQluW#kJRJ_k=oOezO5ov0p6`6Wo#44?-!9;+#ymWI!4ObDN=JWpm(I= z21aT$nh%Opt|5`?jM+mY^=@pWZmy41xy_N$w>WtHc~rK z|04OI;-yG6fG$U>C-Pk*enehpj{A{1fKxf6xL!0$#coGwCB7o*PL#Uf3Z5YPZj=gR zI1b?)%HNC9HgvcjrI+}IVGpCU?@^Q%K8?~%#6OEtH>^hc=TVx2cL;kCrGS@FdX4sT58j=esC1#&R6TXLR~NoFAjO<|ImQP~cM(?^8zUA}aqErO62Y!sG8z zN>Q}V!^*w?%6plD0=H3r7*YlQH&0YuJ@&J-HRFau1_Jh?kD^r` zzK=QnGFoA;nDceC3cZQe!;jGl{uHeNpNadwXl?lstrw`^5u*Zz7%lUT(JiEzV`R0& zXs3USK4EpX80|u4_885}5u^4wxgQwAb23JM2gRsIYy59F{+3k@NE#Isd&?nc^k#> zK0u77;8mL#e)o@2;~6oUi4QYlv}jh0&TfyA@n*OqcTtEi#tzaRQOqpHoS;Y{+BU|Mevsx`F-Uve)C1$Hdb%YHja6)0jJO; zK2~e73t0)V@=T0XGh9ajS1j+F$LbU8?pP(G3?|?fUf{Q+SZ%?<0AFsx{-awNy9T}rI}K#SB^rKT|+Dx}BiCLG0M)eWD~B7@ptPG+pWWyLDJ z1TmJ1bfvi zy%)vmI=&cYK||4I9|uc=^4Iah-aK`dd2abqc}M&ajFatpE$l3 z5vS>RXN}V_Tb%m&$7w6FWslQYbj%&674XU%r=2iI#Hlns!x9;%33wJ2r+;JORO&#S z2IBg`IITJqr$3Lz$#{(M@E0l`kJHK%aoT?}POh7A8jBydiStgJrrnKG^?Pv&ei*0v z*#0O^^B>3Q^?!`}C64ze;#3Qpzr|_fcj7R`D+_;`G2^2!~rad6~`*Tekr z3J#3dfS`CK2ghr6c)YG+Y(%`~pk8FWniq-JcH~cuR|EK_#VZg?VJIH2ZFpWGUXc~! zHLMczRgTyAChv3!ee;+J|c+yt<5zSHPHf z4W1pZUC2E*UYGFi%6P3@6|cLjsJJ&?qmi~RUX^eGt^@J9jxi_VbqxJZk_Y@x z#jDflc>Q#Se*eVlH{88W9c~cEU21@m_v2OkLA+MHh}YI{@p^?yKjQh^FJ68g32Kjc z&jfYyOVC>U;-8?-$et}hqwx@Db0)}28dNwY?HFq&NMiCTKX~XC$?qvzOg<;EyYgK}lu1Qe& z^$F^Ih&G24)DwOFOpwQ4)B#_QBxu0V1dT!AV+mSwoc<>g6nKi<&L$}QU&g(eAnUCJ zZAIhT35vXvphb^~;|X!t6P4mfR9U=5hBJ}xq$ldJU!tbuOw=nh&7G*bc@kA5Z=y=# zB?{!@HXu>M0u$vK#_{k(z7Leh&+bI^jY-sH+=U|{QD#@7a$rAVlM>aqK%(XqOw`YX z5_LX3QG+rQH4a6y=!3`-iE3XrQLXAH^7ld#`Ce3=C zyF|@FnfHmBfiqbDF;O!;T=Fuwl!|pmmx_D2bQG5`$lIlRCYRp8)9g|k)Uvp=%;r*V zyG!9X3#YG3L!2)4&f(I`oSa9sTrMp|SZiq0da!r@kV>epWaw)TpOI6SWe_?Z7mmbx3XCNyS_UtG$G1MqL+QaLPW zPJHcMnt}zW(1E&iB$v)E{$F!xZhsfQn=>amjHiYZm;<#Y65~u4pC7wa1E$$7eV*si ziTN)5gYgSo`mmUKFLCK_^jqpu=yI3d!)t|$>t?9II+tvlT`F;eet3_T$H)m!E>ept zE`7(!zg=o{)urP%sPAo;vVU-?Eq+DFN0*v@a_Qn{mtKB#>D6~?gcU!?L2hO9aI21& zTTOGi)g+gj?(X9+TMH`n}bKP!LF5uSCB5plSbE|K0#xLd8H9W-R(r$ey_yK*zFm+qgx4GmEo7Uf13F{I6TDZ@IPepw_MMO?S)(SG0r1N8HOZP#Xfj>Ch^^dB>m=>r0J;U zpQI)@kKEalGy;VJlT;cCN|F%KR?eQ-{%JjxbK zQXL$FZ{Z{jz_|1z%|o5yNotL&2+X8CqRS?!Q@JGd!#%vm`trn!i4~Ic2_-5e=_DRv zf8``~sFI{HRg?4pbE+rF|K}t%!WMYeAQs$4$(l(@sFkF{Fx5#?`MR`0zIxOF{`JYX zL6Q#rlB5ewlC-rcakfa(pf*X$+m<@DOX8X@@<+`MNg9q9DBm$jPcXL=V|7VV8ve$Z zu1Q*e65Yt5XOh15NmB2=Nt!V*NnHj}Kdi@P{4_X8@k6OKx+8uVb()@}moUsoQZsbM zX%wGH{IeJjzO$3`>zpKQMDDpsT7qpDw5gC9yeO&#cz`@Fi>eYv;UxTD6;%Zc!!Eo= z% zn-){PBgOPKK3P!-$$VcjS+j8iL5ay~f_b=xoUUZG!)`d-$!dW0@JLEl6%4^;6fBp_ z-?&Luc===%!Y<^ln5+-DQZrfYYbWbtV~#aXR*6>0D%~bo!%(DcvdZ8o=C(`LKN#Ph z`H|HjS)Wk2W3nFOGydq5EWhr|4MUG)`C|s&_e|ENUz7Fcm}D8pCTlDHLd9{(S~)&h zEhi-F?$TrhEK63O<;m){B3bjdC-Z$U#@~rud zir(T|u@qHHPEqaRDVl^A87bP7nWBNEQ*;53s-&o7)fE0ePm!g1idz1hqSP8GQvDPq zV|s%WHEfuo=Z#Yo`Adq1HAzus(-hTdoubKj*(OD6+NNk|d*VUfjwyPD1-(;r4MqB< zC`Z2(d5la^alCjPdDT<34h4Ts)ubA!s#lYFS}-S)Tczp& zI{cQZ%_j?EF+MU687K3sbe>K&pBlOx1!z zsWRM7RR-R|cqdh(@ZfH$Cf`d{`twxvL*k266~~_ld6lYL$oV5xHNao;P%g~He;#RC zW=KW;a?$5Ay@&gO3VjC^)#ho=Fe%WT!V3HG7cKn zVjR3h)jGsgH%;dDX*vs^4ryxDF-`e8rODknO`QH3Dbt9=^{o9Pt$ai z_$^IWf2ZB_Gs4&J#<|k9D~a0z>6(kO1=HnDPS;XgOikB4yn|<2y0Rk-1yK?;&>Y<{48LOuw%|2> zE1s^OGSm5NE?uQcrt>;4U7gA>R=IS|ET67~is?F3DP47{q$}}v=Bid)b8Q(4otU8= zlQL9gN(R@4WvK784EfE-(DIoXN}HXb3v)8mdR~Tp%+JuYg&B%poT2>znW`O_sTV<+ z{9Uq4-k-?STHJ}s)S;M6txU*Nbm2_JSIAU5Ng`( zPY^yQQ-e`|Nv39^;?hhtK#Lx*W^o_l8V0J)Wtqn0g{p z1#V?(1p42})Gl;b@*B8<(Z|w@EBFRviO?`Sz3s7_=XhkES1AXWSFuvA1-s28lW3y z;&R?BT?n9E{w#HZEig-gsPun9S$d9r5m~yAs*zdx5S69&(OH^|Qz#RYrHgor{4S2; z2X4C=r$82eqb*AVu&yZcz)&np1re8$rRum?oY*pm4JS}OlbrAp-LtY3QzA=saG)eP zV`8Z+bu68wu(DZlBdtc3n&EDpEQL-XKQx|Aj2O8%OH&cJk@-+>dzOmr$P$0lRCe4v zk)?l6(dTrQYGEz%pUKjyb6Glz4(GEp2%G-z0`XpC+<(at-{HKGrR4v+$(rEItt`Dq zzS~(!M^)TFz@01=LM2Sa4H)ibsT#(j-92iFP4}~O6|Z4=kfjKe#00#0oTZ#ks5ktd zl0V90I2J$4Qo{2rZN)8Yc+L4YS*naC@7N#6_C8BPK4s~DHQfi4)Kt93@gKcNm%bnh zNN<947KO=Vl7Y$W?CesfAXSmx>!L`PzMvqzBPb$O1f=&S9bxH66Q!4>zAx{*$2p%f zJ4x>U{_j7T1v1IaQXG2TP&r;S)UlTh^%8+M^ow+IscbrzcHu70Wp!y=c9)K0R7sc8 zedtnmB;yDkAyCSt*|?2IrCn-XhHbDA+wcbY%DGe*LogN-%DYsff=e4vrJ_qdw5#OO zx5!)BrP2tzRmG+ISY6eniPc9=LhXr5uOI1x zslQx$3HJq;zQjV??KtjEQwhO$&M6sc}#6sFWRxR=LJ##lpDaN|=$ zxf>YT?J;x@h5d#;#WZZk|$MXsr|Md|5=d{~4d$T*W6aCx?&cjg!xz0lAv$h3$& z@!b+bo6upIp-Gst($Fpx{nd~MdsZ9Tzm|GlF;p4mbwi!-2pMls&$n(G`V+CY49*c4 z%6G@$yK+Ne^u{7=My{vChWnYJYN>`!qRw;1i)C*NrD0FM%;eVm0&W#5;+79zVk}nT z7@isBQ!?c`SRE^e*r z>Q;m9Zmy4ZYkwcN?x9^@xB6lJTm9T>*x#)a1Kesn(5;C$gHnTdkCV896@%S+fIpLn z^OaktQE`}C8AiBuc^rAorZ(7$W4H+4T(_1jrVY|8aqBn4Z=r8oz^1K?ce`6fcC!qv z_P8|*MfNiGeQre#xVd(Su^pj5%sKAXE~KEq3HAeGPr20we>Uz$tJSlFK#hLTG zN43lB7filF4#<6#y5DrG{(bfV_C0XxF3vx8E8P>8qrp=*_uR4!MN`>-*pkLn)?B8l zz@5+3m$+Qe)Kh#=2!%~;!}S1HZ-cT;D3nN0d_suPm1^sPQ7^YEEk zix>S(bslJPe}<`AgG|NYD4r&n$}+^%?r%(;L4jeWDq{rBp~i4i-A9=E8UKzn)pE3{ zudxvWzU6hSspnWX-c*ldQ=fg$xNrd(rkN@VALe2!E}{8!Q=k4|at_DTp1F)|p2@s6 z)M-BJ7MO}%Vlsb?srQ$fdX09=Os=sqRTpo5rVcAuw$jvOB(GxI)ut-0H5J4F9RJPK zrr%9nL6eQ9Mq=j{YK3%LO~s%Z8sYj5V(;WVPT}G%^4?88n1=&z?P34!HFa>msRzh% zz*I+ke$Z5J3_WD(DjFX#bq~Y-G_?$O@e+@Znc8yP)Q}U5@g!|dnVNxD$aC6My|>Po zNY>zo_T{QK{C6;6MRmOxo*Gv^d#lOk_I{n`;RqD2>Fa9-^iuQL+ zuGKa<*Top_^Ya6fIWg@GsMPrXPVZG0zihhs2#5ybtcod2E=$)WPEac1=8=h+%{|(PMlEQIaae;>E%`ajcySGjA|CC85%s7QM&KuG z!@bX_LmQ7SqDou($4#_r@6kUf*TJI}*oBUtlM}x9!lN=BJ$lv4!?Og?$D=*?q_0P# zhkJBjlt&}SdHC+uqgm5DnzGfSE!!E#4v!Y^_vpKm05QBqb*dvjRYT*6ZE4=w#t#Zp3jOCNn=ah}_f=Tl2JF|&cCM3!7-#8S_{LkD$F#Vw z-_lMT#kUhJ<(OtE2BVSx2gZt4GZ;Gx&b0Vl#yDru7Tsqv&N;MM$TmyJ4WBHvlxCTw zS1^}bYWEKFBOV?TIzuwXaRNrLjZ}_%YT*GcD(^gA0wp%i=99ecSX4FI% zY{yAxr={#@h+&wFY`ZLtN7mishwvUtRrazBXW`msDGt+c3r~^h0P7A~>T$@@y5pAK zoTNsVEWO5$m)QrXd4*aa>s3nwa0wN!u^uJo0jIH z^)1@owzM1h|DlF=E%koHy2qAoAoPTsaT}eUQfuUVW~nO<;P+HwJSRS)FUT47UNSc9 z!;i1X@ioUFiodZm80#=Xwu+>&^%ZWWwY58)&G$mKN}*5&TVwHCMq9lz*;w1#LYkWb0XBTa#jJ^(|s6eNkKAqttu0)}v)HTUp+>brHehwwB^P_Ld-C zN%DkIn%v9ST3pWNI|ZBX5NuhsY_+a!YbVwjHs=o*zh$c{4xxf=Ydrpi&ui-^WNT!r zGY(^AV_Q{xW$s3fejYBf;kXlD6_B+6v%4mNd0hrsKBI36H(ds`o) zDaK$oN_SvC;wUP7ZfiCwePL@ex_6`w$o(ZbAzdf>!;hV9IbCc`$5x!`YU{mj>>Hdy znjW?qV>+t#v{kg1t+hzo+g1U1aT=~9Taz(th^@=W^9{M8>Tqg4+SXGn8pD41mO9}U z%8#|x4QKK7IJUvc@ziO8t@$_)P2?4~v0;*}ZOJzO$D+ClvTLpi&HEI)M+f1M6_J_@!3*?LwxPkaBcj*y=qXvt8Xzs z#;bfEcvZcGSI^L{q*rM_^eS4~t9@m?s#(sfy*O3gt4}L6DC>v^>f#bfCkUt$=Zpiq6UN}(s#H1O&H z-k^CyuMWWL^6C$KWY9M%nQV*oc!7ox07u(4N-Fbuo#0=0bfi}iSoI*yn5MZH>$J1Fa?o|uiZcsI@~KgMD=(geJ! ziyl~l^T-qLm4QK6i+@o(=v7mU!*)DEg#=<_7LFlPqF1r#frYq;m?mB|!FcRKDylT4 z7MO$M$llB=3q!F14^gSPm+QT}T8>*N*@Aju0(RmFsT+i($%MqJ$;%t(5H)-Jjkc{C^Oin;YmJ?8{*UH;XcKV^C|au zpW0#f1fSAR^l3fzz&FXKWs`jxlI&B@89x1rwljU|h39BGn{DR!6yD&|3^>306u~t# z*yK~`%|89N*QW~m$N_iJd%sV|4)`?Upij>Z`&8oyxg!-r{`4v3s817*F}{;N)xr0t zd9b4pfoGS=`-)G=_kB8wVGn$og2E4d>ifv2E|2*+y`yG$CxfFH%){%9j>=_r z6kob~FKZ>Ns3u@94hEQDwu? z6+A#cx5G2!9BuMA%HwkshjfmkcQGAL{En{0IcnJ6(bO)qN2|V$)?iG3M+XP+I>^xl zJVWr(Azc!>UAIXd;VqoG3`O`7cJ2!XLQRAee6-SNm8ab{ynu7b+94-Fa;l5`_EAZJZ zN8M5Mwxb&l9R2Xf(Xc0uoM$XcWt`7x_rlT4mkx85Iy&^m;d&mwW~KFOX*$2gruVCB z2ET%t{i>bauhKdET9MPQ4Y~Xp`L18HKkzG3&aeCB{km4cuag!1+EdA|1y%g|?jyg( zSM}?k>V6%q;n&WZer>Ep%-Vj%)b;BYw$&q61HV3X`E}dy>$U0E5|3Y}Ex+d3eqF?5 zuV3>~rjcL68~b@KoL@yT1O*2Bm59tqeig)QycptF(pP>Z<1yyVAPy$aBo4~VBF=2u z%pneXWB*3pZz4Y&KwvZD{DU!Wq0Jt@E+Kg@<3ibeevR1gmvO+a+!y`wBkd)>@?aVs zU#8D1)ZvC-8E*Qye%r6TaBlgv{I*|B|6$yB{d$8{_x#M~@0WGouSE~&_n}{-pV1Zr zQvDi(T+jXL{KBt7FL_N9r{##GjZ+sqLLhydULjYGIK||QQxj}M!(4I7k~>cKP&
      !*1~dsbP^?fu%?bx} z5BXvO%ug54pYI2B0UbUFs9lMG4&iLcfbzCyc^6`J4QL~tb_*zX-+)RC4JhmAfMz8J zv|>s?dFByoK|uX*11FaR^xoQlI%3VnfIOQ5>hcG#djlGHCZO_V;AIMb~}tdjDv=Ze!H3c=bFTug9pHE2#E)f+`Uo)W+69ZEG9U_I5!f zcMR$vp7snXTd$y|Bhn|Rxc))47!=e1JR2O;&ZM9c#|HIqLQpAFgDUe~Q2IWoCOC~& zKLlmW4=T-qpzbdx?#7_*;^?NJdTtJC1YTh9A3^or8dTnGK~>%n)S_MFw3}^_b8k=? z_61dTe^3n$1XcS)Q29>>RSv6Cg8JrsP*X1jwFb*C)6bQl#y<{fW@=FG=RtLO5mcU+ zK{=R?@fi{{@0|o)!LQj8^kv%w9l>*)TAH8<%Xr28IBtX zpP+R(up>dSI};Sfg(vk-u&3PE&o{f+;qzlWPKCGIV z!n%kNIl^j`Gpzq|g_S#Zn9nEcJ`C%$JFFkfuqOM$I@vF*YD2=x^;KA244EEQ%B-*o z&kpMl&LeqFSmox1brlcsYF=1X7ZM*Ak+dkR?8|tMo2$dBwqUe}1ea79!*5YfeWwh2a5qXliDXhfqi ztbasjuxmhsc^M;Ghus)7D599b5j97)q=<^(EXoXzs67geh^Q=Po)UmsC_?3f&pH#x%fWvdvJ(gJGqPjUT zs!5ZgsyR8TqsdW~nG)qWic#G~v#D&0y5B{an?I^$IEgFB|9w9<`KZn`$o{>%>+?rxc${!P9q7Z$|Ni-A w==cS{W_jbjlRkaM*l?fsPb^BQzNl~Ao1b<|np~)L&XoUem+t=?{NL;U0C%R)h5!Hn literal 0 HcmV?d00001 diff --git a/Covance_UCO3001/browser_profile/Default/Code Cache/js/ab5b9839e78357d9_0 b/Covance_UCO3001/browser_profile/Default/Code Cache/js/ab5b9839e78357d9_0 new file mode 100644 index 0000000000000000000000000000000000000000..2d7639f5062e969628d4fa55c1794c78170086cc GIT binary patch literal 19300 zcmY-1cXX817w++Irer3eCS+1TS|A}anLd*~lhAwb0!mW^DT+wPhJez0uL2@XKv0wp zQk7n$h=6oOdart)-(BneaarrLro89uv-du)WO(O|-gX~+Q>y2Smu8@{)a>xHOAmOn zg1!u2&|9r~PL{W3O<&dQDjD7y)%_V&yw$2?`}M?M&09S)tGYisC(D;zvr5pP<*QPo zMpo6F8r1{Usu&gHP+Z}e|BLm%KlNTqi}>GTg8239vh+8=UYTWrGZLjFZp$R4Jtet0WJqm!x0U9~{?_o- zTUx6pyxj}#NU=U(>#tY?6l)-44TkSNf+rtCmrtO_XRvlCRQVj@M?kwTpqpfV3CrZp zNO*G;beDRgp|#|UQ7@&-IOrpT$HSNMVuIpLhVR!x>^g9M59@w_?Xqw^EZMBww!&sP zAbH!Mj#z$%L^&pxq}fi`wF`ce@w;KZ6yF1N_o)wJ`vp>Dn*6#S&dSsS@U_GrRL_sX z3VHh&^p$JE2`DP_B={TDkpHCEN%&O8$=p-w?O8DY0o%?)^aUs-zsXf;`6o2G2py#4 zC2+`W8FCrMO06rz6OgV?mATXTWia0`B&b%0k8g1UN<#fPD`CziXroE z!)obv2L{RwId~t=%ZvxGRFWP-CAt3yjE`Z99F+VgP+!(R)j24iJ%fp2c&l*e$&yBG@UF3=zC7{lsgGpt5`?+a${r z!5|qeHOvvTkUcWW62WX~VbxqYDOV&fI)eHVStx>d`BKUkjleHA<)!p07Qq`adX%)- z2(o3l{3LyB5yU1&P(jYgEoq;m`K2SMCa!qhNf{NY{Qa|Og*x!m^rhMNef*0>Z(7kH}=etFa(p|B7s<%@jm^?KC<22PeFM>1k zmG6QGKKLqv4GSY^xj2ID`y;R%jG+JjoQ`1YnF!p!M{wYe2uhrf;B)C=Hn1+zKn06| zT7?aaD`MbZ=@V~YV}gNJNd~@5HE_6+fr2yx_2sObbQ-AYHqc0ty#}iL3}pBXOq92) z8~CG!fzN9icqRq44Xlz)@>Gh|HSm$_tY^Sq-@wZz26{I$P`1Fpx0Oz#Eec9FXYA2HuhT^4b&wN9Bq0i?VKqfycWH)Y)xdp=9nc zFj&5oPxJ$3_dWx`UvykXO4bqe>8OF6Q_A(Ufip7ecLQ-}wca@cz6%Dn|7oD`MFTse z$}I!eZ!3p8>a9GxtMN~i>r>_bOu5LnQu>v~{A-}B$wM&=YTQmCkrv&D>zD{f?- z6p1m?EY`?Q8CAl_Y-tf^Rj6*Bm1oLPma-VPPXvBr@Mfg90O4WU+qI{~+&GHS&qvlkDn7mdaZKRzX z5?fs(3+frE*4#*QDcV9c%LF;q(#W>fMxxpqDJdu9inQ!tWNt_Gu9N0;Q_tR2e7W7- z$i5zm(aT6eU)BAIUVp0BLyg@3+{k~@d$@9(WW+hy$Olu5yqId_s~PH}te$Puxu)L8 zX=$;{$TGRJ+{l|NjJ#ZBr1om<#~SrZqQ5gT^9S`$0zaz1a`Pu6jW-yXw$X@rlaW|y zCO>U9^8OYh*TuC>=YsIF_FRtaRF8M*yx6V1+oPQK8p+ycq~1~GE!oG7d?T@csK;VF zuiWJm>2}G;)!RmT-7)h0T_Y9l8F?T%57ZO+K{6g08T{DDmtuQj z78WtFT2hLdxK+%=$1x^+u_mg>8hKp8r1Q~4*?1Gfl1!XRHgPG(-LO>Ep` zqQqtsd*r0l*kWSzRuj*~x=p#uE_rQ-_G^#om7n&SsI<>SP%?i}-oGkuc`ASJH!d#ED$H36}d0{x|=yEBYT*cDb}858ul`?MfS_|K4waN zXr^OdGe=}lf8{d3%mk@6&`dM=S*(MVhnyOsH71)mCJm>UnKIR^&l+YDW$AP?fv?T{ zD#gDs^QC;d-c0(BW`;}FPiE#w#|>t>Z8WoblbJG`HAfb2(fl1|mj7(#skGc>W}*DG zTd((+d2_Fsb@FVVnXbR62M3kkA=PzQ$HjciOea}-+)Tm=Gm&S^w2=kBn<;iyJvy)P zf0}75Yo**pGhHs3sd?GV?OSF(xoyUO$4piEPM+K~v-_ULQW+dCQBPo;m)u`0hvYm7IO3V~->8$ZJm` z=_;$9MpF8j`tl-@n=d12`zn$H1`Ab;7QQf9cq~yC3yrK6w#vF979xvUs9(&&z~UAT zN{Ltt<-}3K!gul{&ccOK7G71b(59k=1t}JarCOL)N$<&;Gz;6sW4F-PVd0A0mmH_Y zN;8**&T>o=J<3C-N`%isS1IMUkS??2&wz3ZT6jZ7WmtG7D>E%@mh>zOy|Xn&Zp&+7 zi$4EY$jY}+OV-QF0t?+Ms}>2@u`ol<*R{}~o`uT|E$nDyp>ksjyQNT53wv8xI3dGc zw@|UI1)nUD*mf3LzoFx@r=x}Poh-c5*}`XCEL@fJuF6-Uds)bM&%)sME$sWyLgT*b zOFs+d{uWBg@&Oi{qb+%cnhK1(;D36=k(_0qG$Q$y_Lkp!JsppT?bGa`5CtCBF zg&xl>tbL(+URubMiLWfoi?H&C)HPU{V6@^gSt*FLGFpyWtXz$@;wxmOe_<=}MXhv_ zrNyiy6u0W%vsQM9rG%AQHY=0mOuUtY30BG_TIrHxCG9mU)8voRRz53ZWnoz>ucTUe zD{JMgR4f08FU`sV`Bn&8X`5l?$4o1yrEQj#Ph@Del_gRu$I5;&gshy%xALIC%Io#4 ztdfWIt#oc+<$d`^4m4B_jg)I+E9Yc*Q!Bqp!)8{N%iZQy+P6^rHdc;HQadYOin+a& z)-tbyl_DLLR~IW0?`Z9=R@TdhA6VHgksn&=D+BvlY1Pk4bbqV%-pWWhJito+K&yV{ zXnk2X!b*!TtXRLak|y_LaoL%i#) z%$M(F;ub3db|@z)u~Yq)lwGPt4)4}EvER!06IO1D|D=_#xe5iie>eqa5sqJ!-i4%yDW;1jicBshNjB9mBzjv#Sw{b8^z6zTJPN` z&Pw?nQB07nJ)^MqisHTZqBt)py_Lg~F zM-&_67l}I;MMdd!K8kN;@&%nQvQFy!8O0P?c`=G7@-!}*YPM(^l#6DD9F*(1(fISC z`A9+q(HxNtRidd}H5x~aXg-!*HKPgCie_o;XqvT(W`N|jj>h`BUQ14!XzXpH`B40e zWB5pJ{1ijRh8T`-jN$O67)oxAp~#jPeh{6++>{gBV<@{LhS@*IFnVVU(|5%%a&HVn z_r-8fa(;=S&;A&;$~OmMcyK6&`A1`@d_0CFCt|oK_TOUIeIbV8f5u?F978h+T#aGi z-!ZJZ5yLb2<)0Xe-iqOMiN75~zxy%lkX8?4`1q0XeGHai^Nyb>t$# zP4~t!S5_TS{IiNLYyOI*+09ty$v{(1@4|6PKJ8zmTcy9C2t zl;E)Z@NWrL{#Sx0(wR868sdmD#_^9Sj(^Q@w2q8pkytEobd;4+!Wu_RbR6xZSTT){ zjib2?vc=IMF^&~tFB!*>QgNi0i=&^MN{yqNBaZK-etI1H{c*$x;<%R+M<_Rrt9fz! zmLJC_E#ml9O1~M$rcQB0c8=qWEbbb|9eJZ~9F_XTQKWwy-hpupmOo|jAjSGvu|A1o z^rvwchH9*Q`*|F_hsCj3rVWoH?aMg&NdDwF+Dwb%YpFUtj=Y(1jF9HD;&?bWj)Hk{ zjGG^a`Kve@OSgrpVMQFtD^>T8aZK70$2lppEsj>Z;`Hw()w3s#gL~uX`%4@x561D8 zoH!K6?+@chc@#(D^Ef8|8^?KRgpFUt7GYzN(MDIZjdhY~u`$4EW2d;IY&6m8vZkqxi!E(9TiK}BTKT1*TCARDg1HadK4 zqs6B-7D)7GHqLx*qv9|dt7Y~`8`tFGXq&#UQfxUk*~aJvHcm>n#Wn_hV`J-b8&NB4 zbXsY{vff5h>GPx3+Nd~U-E3ppR>hG9+id)}-G*U@*8ADUo3czU%9ULR?3IVzrI(tlDsJHC#m@DjyX5zoL?@$8aC>*8theLQo-xKX{?9Z!)x@svFfPnm=9 zbd#Gh?Xc!a?cY@E<#@J8{TuNl-;JlItb7vB<`?l;UdHQlR05ri39OPha{|?(6BsA{ zLJ4dtkw9cz0#jd0pkwI-R?1Ih67(5Afm`ydTmm^267)S)0@Eudur(!tsMG|i$TC*~ z59LjN0z-lcx_*?vIr%-5z`&{r?2;AL6L?%(X0(a%Yw+SSCmp~_(B}2bY;Gk??pTO%|6Id+ewzatES0b4oB=VVj z(ns(0O{BX#mUsFkvR110PsA`Fk%v<1Q^ovTF^47cbVMTEMkeyT6pT{*af&})?@vtR zz_dgXrfcpjJ_@>(Y`LMpXQ zV#8ZWnBGpJc(){4^hjcXROzX8dnw*~Nvcuth|lgOE)_va^Z zc4-o+%aZtHMH26RuQkN+Qxd&@PGYl^*q_A014-PH>WB26SPp9~NjQ>3Cz&NG$uQR^Y7km{);*TPmP~eTq;oGnjT{+k{Mf(shulQ_1%h$mE`^vSuM}SKcFIiO8e0jSuVXcRpiFb zie&7n$j*}$Dfyxz(@Eiy1dFH8ATEU&l3gx^f09$ktdN4MVv4SN=(P-TrV#d|u)~|e z3ttK~{V6Px`N0%!$f1lB)@19LEXqxxZb+~5^;!Z2DfFtGLVA@H{d`K%e*-BDteL{S zIw?G;m%`SDTBk`0dzz(C?)4P9%euBHRDB~w-|MB&x>E|y-YN7K*I*t0D24U1=JOP8 zjaJTMQuudL3ZG9`9#V6r=FU!Gtn{9f!hm@x>=e)Z6pE}+Jn8ve3JbStzPz(Lg)#?H z=qBESDbzca!ZhjoM+zwyQg~lZT}k2R>ze;p3Xg83@ajqzB+|u*BZAn zje9a{YZ|}pPNUqOG{zrGkU;H2LFJ&m*H(@4FL#+<8Z)W4R-r0Z$Smur8e;k=Q? zY?<^=n(i@5qt>l7E=kYZ8ha;=_VR&Dxu2%%;c2XRkj8zP^*oKO|D|Dyu+v9Al|53_ zXs5Z!&Q3W|*v@A~?CdRSC$pHH^@(;~CE4j&($1XHb}pB()2ytW)D*p!YUi9(wA(o- zap`u3NhhBjo8L}~OqD+ZcIpT1w92>BRgw$r_+_#DQ`t`2Dt7*?W7mI=c2?B2vq@a_ z?0i_?&K0@T%+3S(wz-`x;%Q;0UrRgJBh zmzeH$TKBN)dw4s=2P&UIs#A`AY$xecJ0qp{P&+?;ZYOP+ouyyeb-$dQ_M`0lILXex zlkN1HVkdUCoe^_X^ISXOd3K)8w^Q(yonIH)skPM3xMdnEg_hf?E0bixcXsB=Icd69 zF=f8gTc_jStA-!!6q6&;W4*@ws6F|~&g>0}vr*5t==oMX-=;No+Oh7k(`dJyZBpof z_TZ46?uYH1l^>7Vb+4SAmB;P8cEXNN21>z6<$cP|V<~jnPWAJu=eC_6?r5*>+R2qu zkL)~qZYTPM`X?u(=1V(cU+FxMW)Ti%85~3#9gK-~aJ-O%YK0xFEasqHaR-ZH9QvNb zp?kR;{3eIXIEXLjV1!Icc5tSGgE|!*%(iQeba6Q7Cx3~@>EO1{K|+p$H*+17uI%7k z4F?r#IhZ2r>o|B-*Fn#E4t{9pphF`E-!#_vCJyE{b#SGbL-%Po=q4NGhu0mvY~!Fu zTL)L$IT-(jgOhJM=-9zQ>+TNb_i#|Gr-P%t9VGT~@TII8;9#2!9Oz)Aqz!g({Zj`| zW$kAUewN@+2ZKL%@Q*x|w}v|?|D}Up<+QXM>7e*1)>E`-Ri_RPIYo(R7x{RdsdiN?ylmg$^$Bb`$1(-|#8JEt>Q8oZ_Ba#-TKq%%ThOJt99KKL-5&n4Vf<7Ase z_D`pujF!hk(z!J; z17(~%TdY22!Xg8l?F1bXvVg zXRmzsGMzTB6!YJ7V*X2~Jx-QHIEgnndBfynvDrynq?6*YPFj`F`$!kcIGH0!m7H`)b8&5bCl6{lDO%S_i+WCW%kT17K4|J> zLo>x|?j&Ezw^iOfR8LPQ2j!B~dC$qw&z&R=cakC%M>y&Jg_E=Lmt>4oPNSTRlm{|q zjFY+2YOIrYLI%VxfC(kxH8MejA;T@`N zr;`d&>XegCr`4Y`PTK$Jr(BmK)0Lrjv=coJ8DqGW3p< z^t;+ac`T9loD7g{_nmkiIBEGv^*`2LKh=JjU969Ek!o>q!0Mtzw2RNBTOk)~3cDy* z#KpBZ7p{00bESMq7hOxa`1dszHOja+Qr4yKkX)QhaZxkXMM|2B9(EUh$bN^5Sf`7j za>wH$)8}G|Y?Awa7dyf(tOYIx$gA2eiq>(lPfknSx-KTxa}iPBMc;-lq8hnq+}Oo- zS=8Lc7p+{(kfyC&bdnQNs*Q`$a#Losb#bAci|6fKROzVNI=LA9j*FdLUD)4u>0T}u z(?4)=zK`@(-u+!nmF1E@&_%OhE@lmP5k101$1hy^JmTU9Ngk=*jB@GPq>EY;6mN>g zOmi_v&dgN5X1kamuK6xLT;Sr0T=+))UFOnv>FV7o7pqshD7(f*^|i`(or@Rp-VfS` z^{REVi}0^58j5wli$obE%?`SFOUfK_;g*AkHTJlR5mNbtdLws!Q(k{6uZu3)U2*Z? zrHkBuRg(E&-{|HWvzyzIZr-%G2}QYSAeLx12{KZS6mnC!u$#g~ z+%zldW~VfW)p$uP;U-OH$;CJ~O>Aza#Jf40;HF-p8&4@W{a$l(O?sAf^L;suNp{nt zlACpDZYtQ_luLK>j?=CCnBBxzck@OKHwWc;Ew`?(x%p03HE{E&p_{iGxf$QY&B>;2 zYBqDTsGXY|Z@4kGcT=~6n^y8!N4M@xc9Y#%dCKu_T6>Vz9_-e2Hn%=AxG5O!X0`16 z!cFu@H-lu-Xg6oZxT!PN&5ZGGE=*8P6SdwHtufWj6PY{B&6VkH?#X{M)RUPSCmm+F zIVX*0yV)<*=eU_8W9Pa#F;B1OyJ^2bb<5a=ZaOV;vuv@Oq_5o!mM>-aayJK7Xb)B@ z2dVL`n=z~0%#_lr-MqC%{aUX*`_av8St>Pua`R$~n`c|KN88=3ku6ebhkCbDad)|y zDus5tX}ZVF&vICX?bZJ7(;oh!^FYqZR|nnvb;wQY!|LTxHxrM!i8$`2#BXleoOJW6 zR5|VDmIQxyvsgy`;pXT$y?@@#&h(3hfrl9_JzQwz zp;2oO?PR%(d|mmp^)SAj=EE9ug(lZUplP0n=ou;^_MH@bLe^Nxq| z-8^)C*TZQU*4@MY9v<>~dMNguhnDYq*du2pxwi+$5D&dS@^Dc;80MkWa1WhEcsM5C zjr7oEl!tFeEA}`Kz6l<_l8#e6ES;)crg=Cw!$ZYc9;V2DvsL3<^+;ySS6vHK*H?PJ z!h?0CNB2CdpKCn)`JIP?^&Uq2s9Lvr=y}w`_s10HxW=5-m~$RVU-9tfZ4Y1H@nE~_ z;nYJ9pFUEbAA87pqWYg|Po&Co9a}zkj^!l;{L6gQR^)FH1^!iGR(@{)%2=Q@sq8Ax@2Rd0FQ1a@XsngU`!> zpqBv|Ubba=b#J?u-=%zxmx(f@ipE#fn$^7QkfznW?5g3VcTMF|OR*)kj$+HwhF&5Z0;(g-f<)>c857V6CUj5wB zx}$V_jOvkp#(D8i@Ul?Mle{#V;^ovdFXyIvsW{Wi6gfZ3OUfKCQ>FJjFF(!qlD0r& zq~b!2k%x=Dv$ z5~%B=Vm-yH@8hieCHoush;8Cys2pwTBeA)UMJ;@^ZSP}Y2OaC^qp^G|Ih}lTmc-6J z(j{LycJa|mwu`f?kFY!uOE(__W&686yxo1&>)~Umte0IqRl^6Wp^s{io3g*JkJIvD zKOe)TpudksvO}x`eGHHhQf`oswS#>;8{(teN2>o5#re#~5E(km$1lT`=LjFozff+{ zcchQZQ9ka-lF>fejqwpT*2gyKJI;q|ypQWLZ-S41C;C`7Nqw2@W8YjKr{?*1XTBcg z<^uI@p^h!mo_wu7%StgVQD48&o-OrZUhdQN7p=3-NBs9bdaw8K(~mx?ZSc`_i;tOG zeMD_jyd6Hu?DR2CrXTQe{-BSBht#*D>gjPGtK{?vAESQLo}BbC@{G=r%RXveRsUq) zb?x!rK0c9#|M-}CQ+p-G+dk^v@v%{+KUNQ)sAo@g-pIn|KK_2;`?0@e_{l z6EgZ~AQqFK1Q{tu%zi3I`sr2F&nJ>o%ugNJB!(D2A4thWKk0H+9?3gNepZ$AQ>K)k zf^vQuOLTdSlQD8U*-y0!etM_-87d*CpZc;@%x*t@Wq!cVwV;k?__>|qCnL|#*V3`T z&(g|%0#%hm9pzBZ&)E8YUNrGjwV9u_64%mC+g5(|OQ$w|-FNIK_=b*k^7E{-U%$uY zXL)Zw_dZa(K7N`G_A_&cpNb!=?lFGe9P8(hd^Fk5t|^*3)z9xze!8ED^7{-upXF!e zY(J$|XpNPcyIQ^3?B~-heqBG)n!Ehm-R)=aUO!*{;^*+M>cxIP4iCX z4*U7{tn&TCPwaWsEc-9|8Fb0dj>~?0SG49;t$AJR%h!MTx%s!Bb~pUA{>RVzxBdKh z$4{lZeoo)>Q}%)4KU5E&s)x_~w0!QTvn-W*FZ@h;slL7PGwokL=l;{46JVPuKxAZq ziIxCG3k7IVIKZDp0wl%+XdfHku+)qTFxD2}m5fXXa3nE6<)i>}O9$v%Ccryo1FR|+ zpiKDyFQjUP01@^8CTBpuCleq#5MX&mfP0w%)`S$dAi$E!0o`jJAh}+EZuJACH4W(A z@c@6c3{bySfbs1E`njUDI|gVb8#^oJ+X2RO2@uyaK-*pcuDuuFf!GEFXg4sx0XZX? zgS5tAtuZ7({6_&AeHLKaP}TNjfMH_->>nE-Z(M+#Y5Ya z%G?0W=c(=m0Zx1sp!&i9B^L+i_;rAza!m|NlPJn{D0ovRP5c4EJ>!$(s$%g03J0i$lW00ce zARo(Q`9mH>28px;*)B(Ss33id2l=*4kcVZ1yj3p9n&coYD+HNaF-Vb=ASsoC z^hi?-+2jafa0dB6_IP#NALJw1ni<5Ltyoe#6r@!+$dddZw+e!+tP!MP{UB2tXiUQ( zHCqN5+bXEOB-J|y8U0pJ*Rp~v?H}aMfFLhr^uQo< zq~)L>UF5Ws9TH^uM_O}ekO7~oCaE?osDG;l*)4@f1eyLt5bNk5jm8AoCXdGj2~SYn zvUyTazh@c5I3>syIVc5FgDjBi(-e2Qj?D-XCx_&`G@hxLvw~P=2g#iiX!?#Zlq zK`zc$zrIqhmjrb^L^0)hB@dc~SXa z)*5n5lCG*IdG}h7@2&?4{T*c2gCK<-1xb`Ka{O_SH=nBimJBvqGjK*_@S=DIRbw+~ zB-sI=V7vS)ZBsJ1E-|SY?2$8aQ;In< zcujgp9cKm;Tp9FoXYhk3gA{KDm2&htH-q5~GIT$82BAh7c$#L=uUQ7&T4(58PxkJgH3XILk5mb z8SLGxb+&1p?HP>TqnwUsu6}c4H_PNe^Grf5GHD{K<=Fd~Bz=&{M}sn{yD*c9i!^_6 zCh^iqRxQuu(TYr>SIY&>`!kd9^-N}!&EjIYESi+h;!L$H%GJoCaQ!UuCuT8xQWk&D z%HsV^S^T&;i>h0*xOyN9=b_itjBGMyW%IRc6x-}Nd`c~7EOXA{3Rn>W^Fb5JhHqfOZ)9M0y=BiS61%QEPso}X6S-?JGm z$NtPF>5}r2wfD1m_8^<%&$D%|<#5WKLta*n?s3jx!U(Xb7(w1hv^e?_;^wd zyC>(6F(rq((nYFH%VFg79G=NrD{@$|GKW&%=HQi~a$`*nzO^}gC9n47Q2kdOJF0ot zH1B#2wQuDx<#7&YpX4y>RSs7R=i)4yOIER5I>qHuIX+iE<8t*gE|*1)TuP+p@^v7W zB{{j=%FSg|D3@`aa`~-uF5eHx<;B2Ux(~`_$GBXq6LPseFBkWMT;@slHMy+)E|=av z=F)6yF0;1f61_c_a>sIc=XfrsIn_*EIinF1zmLQs{mzgJpU| z9_I~t%(dpxxkMhz8`H&z|K` z`Gw-jPx9Z(Jl=by{0t$Am_mFcKUzZkYYovWD#Y}nAI@sCU`9^#Lf5cOk2l!*(m zSBl1m_*ix)geaU8;%V8Cu78Ad%_F319w9!JWoepY4>8#h!k8XnxI4rFPl%8=M5UnC z$p|r6N@j-Wm=)rvw9gB%Borb(9O7ox5P|9;7D@G*Ax75<@j?pK3DLA}h@WM6eZ_2` zm<>a;ZWLmE;}FG~gxJ?qkIh4TBC}hBxYSZ}T7{_dMu-V-hM;|j)g3}S?iiv=C&ld& zqH5O=Yo*(}A=Y#cQLaabg5DuUe4uesd_ag+1698aAEtGOYuyncz8|IeqeFBbqh3u= zuO^20TdGY`PbPJaoq_Kmeun3u6lA$J(OloL(F;>BKmoVZG?$5 zgt=r1QzkLY+eu-5lQO0Cyo{d9opNC^lf%@m5awjXFr`z&EUgr#Uogy;j4-auFg3Hn zjLi;HKR?XDI$`4Kg&8Ja)DLs0L74o8VT_H#)NK-Gqu85=dA~)NKV@T^FmJRA^RBdg zBh11#!>pF;9m2Rfg_$QKJBK;)R+!3fD}EQn@2dE+yL*_zJ;Nl)E-Cb0m_%79f4?8* zu?+qo%+Gzo9G0OUhWVwh>X2Uj!u-%b%!eQ8acG#ApNEMW7RD=Qq}&MACZpu&7h$S= z8K$9pA+e*vygpj7bv{h33##u=h*)Le%B#P zktboAKUFU!SU#V@$@%1_<>RQCPw!g!T$Jc~`827Y&kk`m%BN4`d@jr3ruoD-&u4_R zXqnHPR{0ceozI}xHMUJYpLWRSQvZDH1M`_Fqo(I`bVfc^X693FK|b$%mCq?zyDXn) z%k$~BB45|3^Z8;&K2PM@)qGsn^RfM%kEu)n^~x4-vRnb*q!w_yQUPzK74W*FfCcFV z4DuIH{_O&~b}8VrobOpc%6kP&m72o}7(2XxS8{B60ZB6p7%AUwDd6GO0{+-u!10p> zlssKPC8>EvPR=2lhAf XKg_xG{q?z>Q~uvP{huEGzd!#6B{JGs literal 0 HcmV?d00001 diff --git a/Covance_UCO3001/browser_profile/Default/Code Cache/js/b3bf963caba959f9_0 b/Covance_UCO3001/browser_profile/Default/Code Cache/js/b3bf963caba959f9_0 new file mode 100644 index 0000000000000000000000000000000000000000..3d4b3c8acab66a3e3eb9684ae50465f3cb0b11bc GIT binary patch literal 30736 zcmWjL1$dKZ7sm0sN!uiiG%XYxrS6s#uR&Yf*?{2;cbDPLa3AjO&XD0U+;uR9ySohg z{vX%%yOO+eo^#Igq@>B4y6SgX_Cx#6U%Vuh#KsEyZgL}cRxwwR;#t|nixnzeylA29 zFo757)7* zvb4C0bO61oa!yU@GltfZ{zd-UQb*kHDkXQ5K4SYgDenR)5>?S1>+ugBqUJ(!!x{A2 zE%m-41(o#BM(n|DG|KeQ2<*%9(0z2s_D~=6F6ANbG9Jo#T+fz>mJb=^ZfZ+qy$QxCmE`)3|ni#pFewDqNj4x;2M z4^{r`q0gQMHT5#+tiM5JyFuH@#sYM!MGSPSXVC9W4eHv= zpm&`Nis@|7C`?1SE(Q(2$FAJ(W>CKF21VgZ4}%)_8`K zG-wc(O`>KToNSQeck;&jDdaxYpd#3TOXxh)ps-m6rOYvC^<0Ar&NFBjCc(MDpxDI* zyJ=ABEylfVP{2Kdj$`iwgX%vf{xgFXJ~wFb8}fc@&>cj) zqYobp@qh*G%A<3Q9qfC z+KXXkqbA|D#VDuMs6e!|8CA<+R0jk&jS9u@_<-_$MzzCuY{W(E2r%jrLUS2)9T~Ze znu57`jC!8esN(sI>V{7U{K2S(n1dY{lHaJ2fkyQ&VAM@C2r}vnEFngn4mE0G7~A2B zGHP^;QC;G>pJdcsmr*y|M&(U5YIb3xUgLTZquv%bDj~(FfvH9{N;m2h;z}6x3d2eo zwFdW*kZIHy%tYTTa?CdB7J^E%4}oQj+J!r1=|MT8GEoKf${TeLzgIA7Lq#J$4~-g* z#L7m+R5PkF>f&y7qsslrF*x#*QJrfVP6nC+xj!_@$8ue!r zqaNb}CO2iwX4KZws3xt98rRyW{dj{1ZH+RuGim_Jbug-RC!-E`HY$I2<_A}M81?K| zqek_l-@TaEK1TKFXH>NTM*Ta8F$S{^hVs9|Fr#{+<8Y%|jWp^ZLPr@@XaZ~C|9&TD z>0 zW>oy2)Um^;D;T-ksH%Gy^DuosL;S0pcg?7*2aJop$or5v$GAtVna4&YKc#kjK&xj) z6?<+}zZa}ytVZ*9MooBc)QS&A89y2|&+MsEKAu{FrB+Yfb9m}kr>E8|xJ z@2Rapp4u1csat3i?y0y4Pld*KYG<;i>K5@-cABTgqh-3Mb|E9fQ-@1>>W^}sGMD#M z7i{^_Q)`=e>HvJ2dg>|0HS^R06p;cQ;U$)%2O5EcxrDuVzuY^4xWnb=&9gN z#5ZKo~nw=Lp-&7sHgrM?x`y{GlICIJQXs=Q=4XU?0iqPS>UP3 z3q4hIk*B(1Ha^8Mg=}8(c6cc(x0m+j_0qNwFJ(q} zsdBuRZX|i>qT5TJg}k&d71>_OuHvPaHNCX2o|lF;^U}@kUOL^&ONj%#Dt4%Ud^bsGzqR7xvbFI8?-2ABqvbxVP%2cq<~+TlF#+zoNHVRVEJVRrl7p zLEcIl>8&;>KZ?BI9L@Q-JlfWO{x>ZF<~Yh!Ufz5 zH|Y(YMR0s1`=U%*i&N1iUBj0clYC-LY7u8rH%y2(X)d-Um{dB^q%-&zlafrDhaX)g zHGk6Cnu82utMadH%N}5zH(H|Z|ARNy|mDw(te2k;OrDx0*jib?O0Rn4Tmc!f&UP3nminERtitMCC^e=@0D z4UkERD>==%hd zI!t6uOs3CMc#LIui5$~R3dTuXoM}>xS*(RQCi%`cY0hGkqL!LuUv5&xRVFRkOs}`l zudODH$8y}p*li{mwwsg(XE1kLzcm^^W;^}I>h7fjl9iQfLrek5HnY5PC)=^E?eI_nF0ZZJP+fS%Zh zbvI2qh>o}DJ1X9#Z?N9ucuc`wyhn}uLe&tjX}nX;zNhX0^;~*2hp{g_-poog&OC z5M|aD{FG!?Ps}T7mbI8!dC(X~i=v4&ay{A||n+Gg#=Nqj)v`ev=gcg$*F zR?dcIgkw)+5d80mmq__Kh=Z(RkwHBpOa&{wC6kNz^yltX(*U2Wa)XSsT%C zidh|S14E~pH4zch=s%X?%XG5_%`j^mRv~_-S%2dp>dYc9#LqUXIHuquyyuwJ1hway zH5)78oJSw#Gahy?Fw3xz92S|i8kQwyRYqMr!?2}h6_}MaDReM*{x9&xI{oT*RUcIEA`JE%Gi#&KQYP zsTSo-vnT`^IEKn4Eoy^Or7aqR8Q6m6Wi0A~I^`_#DsNE$=2T#OT&`kKm8uriN0(|A z?L+(O7WKmmd_lJ#Ejs&?MZIfSRHPR1F$*`);b;0>+oDNz7_%;8Vhifmv&dZEqC7a> zn7BTQuM)Yx9{!amew4Ix*w5MQ7fyHs4v) z;3M-2<0p$od}c1bu#Ud57Cn5_)ZnAe*k|<7X*BWj(Ft!K4Kn#?91bGW?xR>=9|bvm z6pyaBjlO<9+LX&jTXS<99-&DdA9chsl>5Pl_lbP8BEOG9LVUD3)JNMNe^noy!^~8LK5B&W`+Ssqz(>J{eRKz%j{4~7N#^IYk2as7o(n!|c+p2~ zaSPopu^%5V`{?l%AMLv7qsWKEMUF@G0^9H(vL5?rBCcZSQyQkguM`NwB$6J*T#j>pGj4MdZwyGQkl((vNWvha!SXBwXVi8WkS;wkC{8^9l>RYuB zubWx*9gUk?)f=I$tg4HRXx)bMP_CU-HIdrhs);Dr!K!7Qtonwkovr%Z)vCX{S(Vn^ zs;(Faj~-Sv?`Kta1ogM-{UEE1gRSZ{#H!)&8fsMuR7TP;tJ3ib-!bAh#vN(ZKZqM; zRZFbEQ@BPm29Be}7^}9S<2b9PP2e1uCt9@&$Kf~Gsvq$Vm8V!Waw^AR=QPHjZq!>sS~cbR&_#u9GXY$`BvpZ<^pQOxc}cSv}y;AB7HHv#Szq6YSk1h z!s=yK-9d>J;yVk0kc#fRwiG@|zj^`Wb*G8*`VKNSG zvdVKawPFhnB4!IcLwEGt%KF%5)qRxQ&KzR|j{QkJJE#Yxb}}cJf@Zs{T8Q-+yqjL3 z%^uF(YgO_-t8(wBF9)s4z?i?t`zSp;M$N}rt7v_KSSQK*lvUR;>9kc1&seqTEOU!0 z=cxI-RUsExLnw8TdB?y@RwZ1fmze!G`>$9v6>qLGzyDZO=sG#yv?}rz>ksuY0rye( z4(sqP^Nx=9=*N9}hyxGk%R|-(+C8$W`eWAc6RZA0;itqy$!Atodv4W!9DBiBy|QZ7 z8>`+T`z`0-$9GoEdvDbXl={G9{0Y}b))4fGIYb+rLhye)XRsG}K3kRl3*%re7JcP; zhiCW?;os;NjNj=wu4A2SI$*HrfzhTkPn){ocQ2cMG1=4}i~MZLncJqWA>79;Jjb zIyNoCfAwwZ-`u9r_|(d#+MR9Mf|5OK{GMUcaa8DSQ+6MlHp8QzP3;ETv~{>mzEf=a zJm01~3+c}yo62J_ZeiXUn_l1xI;^#6FJji&)E7q)wce&S8*I9arkiZ)vXwa7=oxz8 zU)0)e)Bc_GdKdNVwkdTFec4N|_pyJ!O%o0f^Po-Mf7x^un~vC&bkwGksCJB;j?+(M zoUkeQq)olh_Y}vWz-jt%#-_Jebk-)PGwQ>E)R zt-_-lHeJ8TT;8#%(Ov3$V$*aiLF!ZTer8iM9Km~dKDVhAcHuaRzOZQ!#v|8Dn_8e7 z9-{awo66!a^1h}|n1z@4hIVgk`V&Wx_130|n1{UYY-)l|xP-X(#KIE1hvx_Siob9k zl|OPG)*$f{y}@w2M#=wdvVJBersDzLq1zYo!bOz*%04VbrEl~D_Y8J9jdr!h4t(>p ztC*KvBX9>byzN?o4@flGc@1V)L9<;$@e~;ryQU+`$F4$Xjrnj`?W%(vC}gv1GHiCc zRyph{;A__<{N=PO*3YilaQfSI5Q73azkprdL3WkKcD%>#V7sb>*wq*vLhZVbDq(h= z!97HW+f^4sF)6~XZMcIHk#+?~kvrz2OSD~?F?Kz|d)$g8&jez^lxSC(B)dMNs*5q) zb}de}t9>E6{zHYr+%IZZlVTiS+^)STcEzRIH5yaW?D9*u>ve`*))IDIgl9>+YNJRd zvCuiot_}Ev#8P&>!;aE+{aVJZC&*ovnqVx)xcCa6@^&SoJBDC=MZ2!ya%H!6!I=B2EpvO4hWiGREQvI@O}TKijnut!vvguZ~@5b?sV<;CgnIt8do{ z1UInjH>}6qhIaWkwrdZ1G+{s1H)VdB+10c;`L(1r>_*PkjD=V2?22q}*IA@>u&X>4 z<4Q;B@5J17rsgix-<7!=W#_euUE}cy-lNGA2cR*`Bc|Xo@{VO6jv#6rIpP-5#*-KF zO|a_=N=>wDCYB-ZB>IOVQ|ZezyXwJnx?P)Km|<7yOx8HubBT@W^X!_6ng^TcKVLaf6~_-|B^S#T(|Q+qg@f0iL!c zo}*YP?qvZ#? ze)?!vpHGa1i~mv2XZrGu=YSl#Z*ZuRr$ZA>4qY`n)Xd`01GKO@6ku~`n7>0~b2>CW zz@h%R9J-y`p&of0nt^|jn%AM`_!CbsKA%H-aS}d1IQV_Rp)auHcW5m-205f)hxYwn zv_mIi9I6%TkY|E}&jlPR?sh06*`ZPe9r_!43OSTnm>i1`qo_l<(F$#gIkXDfa2L5# zh=Ycy4$a2hbcYURIP|QgL!Z&KjYI9*I@GA0L$>w~)xabi?BLLWu8fV=-5olNpMQ18 z+LJnaF@A6A>f_L$ehviWl+g|q9>cb=4&@!^ z;Q8awGWd>nC=nMXI8<|@Lyxdb{?V6M;%JQtMlagk3&PQJ9MgmuWCj4DyqJ(3L$ql zUxi~ZHe(-xx^oPgqCgK{#o;1`|LUvX(X^+pmZ5VmU-d_DZ(k)~D2#o4<%GMhuUeoh zy7cqadh9~S{=VvqS_6m!;~OJZV_tnc0zKS2|tKyh3+E?qw`D)d8 zwomfasmZ=tG}Tuvr}^s8bYHEQ>8mYBo8_ygb9|M5uCHRy0)N48K4UHRRVA2~_$q0+ zubN;R_O9^NNtjkK_8MOuThFWTTJx8$ z9vt`8FK2yq?-ITE$5*v)`KstcU)6l>s~2yn^`o!GeD&2#52u#ls?o`7WT)&7r}AO6 zuTy26PHn^oc=|b2981u^->FG>_=8jLFe2EgMJN&C)NCY%IyDL(Fel8ZT;WdTj&N!W z+C)0_dyG?sVx5XiV(cPLZ7Rz4VoqJd?&3~`r#lr_!Ktnlol2|hRP}03W&h+<_Zm)p ztm)LcT26)hOs=(^DpSwN@8C}LZ^U_xoqF1Yv70#++T5x4Eu31~(y1pX*~Y28_>SUj zsSWFK1JUiA8j2fu+ukXU4o<~)cB*GLr?R>`72LzA%D+1G2J3n{^|hB%1^YWSc#u;U zhB$Q#D~CB1JDl55)G*qq)?=J9jCJbXIHzikcdE$*;!L8h$xiuCajF$^Om(WxG^boM zoN9rtScSwnoQK!=ZLU-9h19WwKH&*|+(|!nIW+;N5x3i^Vi<;uJ#0J3eEsEAGpxi` z+&|=0ha-%8lsP-@RPsrus-AMHK4zR@{IgCyL+xu$4ZrDByIW3~ZadWjz3#B>0eybx z)UHRI``F2~22NdhLZ6eMMr z{qEE!^bPRSb{v8^m!A&j_S2C(e!7U0`TW$lfS+0i`>A7ypCUv3^ceTT{IoONPk%@F zX>p{V)>3$lN!B|*ag0V9FG%U+c z!P$Nq0Y_;+t%bFWpMJpslqu(@S>^o{Qkh(kUDZ#U@dc}Y^i#x7ewu-Oc=5BJM%MLH z@-Kd>-rrB7M*HcDf80_{}p@RM@TF76es`{%sHdgo7 ze>MD7rzW@P__M#d)$vz@y8im1p1+)p{dJ>>zxFlt*Td%iTG7H^(XBYPwZHPW^;Zne zqC-1>-9>@+{u+y!Xxq)7HSMoQ1O0Vn1aT(%tHl(5JzwLmIcxoOXq~@aZ()ps{f~wn(4}^0=08$ zTJxN`i0}Jz>hX)5n*Khg{=iGbcm(JVYk;;o0yNnfpciNr7NDhgT_QjyG6NJ>CO}D* z0yN{t0M)J?p!Vo8B0$x~2B_fV02vks@LDc__l*M7b9aD-9}Lh&d_eb$0rI;RpeK(4 zl=pFf8b1lpVr<7@xLyRPV`eT*?3+u~hvrhLQMoi@LM|PIWnwNZpO;HVmgG|G&0M;O zT5ob`<>y>_h+VmJbFD~j&CZ)!dF$p@>jt@1piOSw>yTT+yXRK>0lBs2aBdk-<(AjC z+?r;{qh6tT_+2WGehkZ_h1gR(j}B$#(GO+vs69$7&BJ?Sd3f&TQQh2mbs{>iwkGA( zqat}VtZZJ*sFPPgz4I#ntGx2-o?o7;@+)O+el0(eU*C@A=X2da{fKqN1C^W-sIu6D z4W$BAuymkGVk~aLyG)=?l?~L!@_`Dk5U922T`^GCkz6@YRZt(5e+*Pzq}B{ndA!2Q zrh&?89mus`f$D`~T>~{AR}s)HP*IqR>OBKB1QYQEEqVoN6@q&QYCUT73Dhx+=o_dy z1K5v&IEM5gfhsgKPzl2Vm4Y{D@LQlhpzVl2^~9fOIWkb)uo+iI1?mB&jSkecF@f?Q zAE?o|jTe|YAyDrov3+tN*DnNW6KucJ8_dT_xSb1cDqteDFA2%JWbPZ9_nOkd9(b)gb+Y zan*t}7j3EssZOgPZG~C~DFd(I(I!YskiTt^x?>VPVnMqgt%FbdAWgwdJV(_IK{^fZ zjzJoQ1)YL)1Cu(F2g-B_(rz^B8l?6(jEk7tEl7`0y9c@a8l)>&-ZMz{UP1Z+w|WOD zwoj0nVP9X4??-MMgH#hOF$wc<35_=esUyB^4pOc^g46-OA#zKQN~7S`AXVJPap<`{ zNGos$1^*-`9NQ73$~%M91jjIbcaZw+3DQ|?-bX(BgEZo=AU(v8LqR%^(8EF6k7GxI zbQyj}sRb?Y4yBLLzvGN^B1k1p1*z7BAh|9E=?Jc3%;g}>KF0IB0dBu-=`qW@($*@ zyI}o=Ky$G2TY?pX>egUwC=jf=F~Pc)5-e-UVC}@;rGj-2k>!K6qC&8?AfZYy-vQuw zy!|;?9<_tj4e51*RRP%zgH@|NV{{7EIlS!>EdOrAL3WQ|u8|_%uffXEo8$Wgt6bk; z8T)bUpkUP=60Fa|gEeFk@mB@w3Sw82-~}zpY_3-h2@yAAy~I@WMi-@ zZVJ|9{DZ{J!K%3>SQ*=b)pKXC+8$)wQ^6W{mUH2KC0H%)2CFL^_ky{uAy_L>>S3@t z;VFtf3f3Ylejcok`1X=qUkB?E+J6Yv9-KpskM#0OuzvX#tPZ&RJy^39qJ@SKtw%x6 z5dDQ)wh)E*hN!cDi0&gMC`9$5LNqEaLKP*Q>JZgG7@~hp zhiKy25JjI4QP9N@-A3O_A-aTimpSI|5cPQ&qSenrG~`8yT73&qVMD00a1Os4L$wP3 z;2R2hhN>Szy+T#mJ5*7oP$if{^&EXHp_&MrPpB&3E9}-#Z9tSQRPAs8k8s}}%G(LV z@(q=opn1Ss;k&sJX9@95UXUU-eXy2 zs64Ym<&ROgi+b6iIs<2^P^F+bj^Qh6l@8SeJS!8b^JPPoT02zTajs6NuG9@xtKUMk z5Z{M~YVZj1LfMg_vdjxrHs;R{<^8TuwLTuod-9>Ge}ejP4#_7&`K*duPKBxk`d~T! zz-LrA9je+mht6k0wexH!KjZ1?xlq-?VK~o+>embO4vtIo6-(i`Ox@Q)wFI^QB~Ls@ z#T%hIg*))M#lFNa{f$nUVY&!Q*)ZNe4byz=fy%KDm8*uS!%t!AkF_HQE@anw!EjV^5g! z>VKo(j`E+(hrwoR5q%}e<@72;eVNN(G&k-<<&6VMdr0I#a}0%XJLF!5~jv4$oplO zx_=GRQ8ZAv`oiH6uDWQ6qo`~MS3MLrhU)@Wd4}r)yu89S7~{Noj9*RR>Szv^EaAG3 zw;13Pu8G!g&4t+(uC5q_p-#5L=@+hx{^7cZ8acw%1kG}Va~(*yI^_x1K)k|t1m_Fa z30yc@-b22p)B3{vO zHBAZErL=IRriW{K27ST&66Am@CByj{5w0hh;qu918y?|UcDVj79j?4(!sS^pT#ax7 z#VdttDgHyP%G8RkO~bXnN4UEGO7D9Svro9H52km+ICo^Yrj89)^YP&-H4v$bD{5^tLqau_wJwgLfa7Ki(aTJlWA{00~ zLOT~kXviNC+J$^uBb0j^aSldkFS`E4K13ZN54=M6Bb<+ajzuW=c!b8{BEnBZXd()n zjL=Zzx)7n#7=+DujC>a(c%MB&y|Ed7mm_oobFM|`G74RfkmW{%&OMBf?NNkUKPJZ~ z5!&`VLhrHS1--z^ml3?qjMOVsX%ngNwvpO0C{iy`c}S#UhDK`d$VmN%pGQY3aZIEd zOo`MiRGAv7hPaE&>5+Pd3Uea)Sre%dt0MIsw$+g;xG_>CHgPOAz_~e6KVm6P;S;?7 zh*SoKU?Qq+iPTnn`Ty)#gRNwdY3Osy$eKX z8`=g%sSiAYqtq}YN;5*EsK!6|5emX{cH^iua15biZDdCe@G9t`?lzGD;O;Y#qh#4^djwK1$ggqU7ut zr8(%|D@ySLqBIK421Y6O;3##%tRYc)J0?mu)E=8#a@?Rx)L|tQydr{hllewa~eluFdZ$)bbz99K_v^wK5 z9wX*Xw2ELD4&W>*+>O>&w7(av7x;>y52Cf_VYC)JiPjAyJdIXYtU|kI(VC672!9@} zz!%Yag#s_5HSl$`Jl;gBG)^Md+h{eyG91GvbbL>qAELRYBwDXg@MARZLq_WYs{9wN zNr?E&<8RSQRgBKT%Oi&C3}bW(n+!3!gCJv!YGDLUB9CW`>S6(Iz|Sj2ndpSYxB|0x zjEbWRmf#ZXrWj?QJ?7#RJk2pmMMo^bMR;3cl#V`Fg==v7#Hb`XVJ#Y4W7HWRP{SUh zQjQos3W!l?z8Jj=j!{xbjK+k1b)7^D85$osz-ZT=pk=cwortAd7DE%lDo zO{AM+WwpfWPybkb#Ht*z+JVfRv6>qYt9H4#9~8^;F;;&E$EsdPtUAFQ8q4eDSlJ53 zs&%1QMHY@#-&EqDeOj#g!I&PaUov79Um{k!D#hwE)>e+yZgi~@D@VOpRl;}p){oT` zyl%j_4P*H|KUS0RvUM!K+sCTW^jOWn`x&uXI5Spfw#91du2@~b@ZGVRhQK|s>b;j- z_Qh)diCF1mtTy2QdY+0^*~grV+fQOu^F_#Uf{2=$25 zFUVntQy7AbaY}H;sSAeTZ-o2BDH$6u#6M0~5tk!Qov;m;Q88znCZJ3}oEG5--axtH zR1Ezv8sAVccbvYXVxBnF!Kl1(`WF=<;`B52<7#A_9-~fFoLb^sbew9&#>qb}POs4> zo^h}qC($?|PHV6OS&4CKniQvNDCmmgJ@Ghwgxwvd6qLny+{APImK>+e*k3SCB?`r9 zH!OwY)D5d~9zPd}(`*ba7N>xeIJHfU(;sM_7N@jy;-O+joNmBTB2HcL3C&B=H_XnA z)7PvxWn`0I={TMrajIWFPS5bJBE6~0| znNLp_#HrW9IGxzR{@v`y`aSGNnZ4}a7pF%1?D2YvFBt3@uNz+Rd@m?oPD{M1 zz{4k=?s#A`Xc^2O^H<+3EGANX$h(i-}D3pVF?T+60{Z1 zDkdnZQi6t7X1pp18rL{MCorH%g2p4DX@a^mOVFRq6ZpJ3L2KaCKS6tNbwq-4j!aPJ zQ3(nhouEOp60`$(<|ODM{#}uv6)O{T2PIc0=qW1gPS7Z%?@3T)oQG>)g05lo@dO=3 z-xJgU|C0&ocq&0ZoaVfL67(DHT%!-y$>R<^K&g8PDsewS%bzD`%hv?GMCI=Ze5RKm zKaWJULxN|bI{GDQ4Sw-YR43%jk*HC4fHS!g<;b0=eK?Emc@p&m6Y?hNQ*fd>hj30z zqCUeMo2ck|i5iO3hKU-FPE8Ya2`^hEs#NPleMHSRiBj7{)j*l9#KW4Ni5lFC^QRn1wq1^05{f6Rm5>+0B=91%rM8z#kR61(Fe{rI|Eg|oviMolQ%gAeG zqL!>qRE2ek>UDr)4koGxdjFLuk3;kUUk)d#|B*zEMvPS*Kyg^B465rEK(j&hlP0p31muQkFNq6!l zsc60=mBI@Y%+GCLl7u za|?HMGoTPD> zx+Y0I*ClBfTqTpHhqF@A9=7xuxw zu}kGKzZvqhfpd(t%n!x%hw0r8)gv{65Z@Xg`h~j%N(inm~>-Tzod{QVp19 zx%6qSOULKA^bf|(cj^5i`n}ktztMMzOJU1gdIzuNF0P582WwrjZE`95Fz4YNS{$V& zJib6LF1z#%EB(jq(y}IevpAXz}K6I-Y z=Heu-BKr}Ku^QDLyVV7!kp9H2OL&KsPu+4oBe&;n-NRUqWR)}|s~Yye%QKnpEhOtV zzhq5Ab^l~F#yRB4nXKU`9F(jwP;j!G7=*(i$tn_>tckJ7T8R2_$!dpx5tfjwN$6KF zS>sTyP_k;{D13_~t3SqOBx^2emq=DCTtQGK$0Md(vO1PeR$tu3JFKffzL-!kSs#&I zIaw$00DG$>t9{jEjjoog`viyHaRzqxtXAN?}EtIO6ti)Q$ItWwkWL2ocG00z+ zKES^o_0~_;fnSn!zHzd)G$GIC$r{)?S^3(~r?$yl&qe*H**;mr@EjF7B37>N_`e_2cw zF%&!S3bC(>sTpSDJbYdkQ%Q8kYCJ*Yn__B!DL4t^+hQt?&RB|D$n&n4YQSBrxKfK3 zSDp0YYS5&(@*gg)Hwh_j+LtQDe--RpfG|s4aHF;Z9L~tb<2#imGBT zE}>BQ6#n*0iXtkcs4#XQPo)&S$K{$SYWH)BJ~U!mvlL~wOi`KEDH@8RZBkSgPcWx# zivGd4c8rg#_9^;^A{|on2%qpr#}xT>V{90@r^p}E@vcXTHvXETzecCXI3`6~a0r#g zrf9{u6tx(iqB~1c6u2}+y_cn^>+%%M+m^z2y@>xOc2NJZ6y-mjqSLs6<|k6L|742# zoK8`{$JB%lPg3}dIYpjN>C>|m-uq6`7h9@|*i$vxk*Zz3sVbKzRfBOOZz_MkBvsSg zsXB|qf~k6gufxkc|MOH?eoR%1pHh`p zBUP%GsuWDCpQ;88QuVA+s-k{L)zHSN%50LV+O1MG2`^fwYIU1b4QWR{$k!oNFEPJY zs;;7FpHv0(O_j%pRF%MM7)GXQ1n!Mu%rU8IzA9Do@MSf5tx47I@LHRy)IUB zYT>q2MLc0loG_#**qEk&z0#E1J57sBX}WAplb*EWx|SN!73-a@R`|h`t~hLf!;;QduG96eGhOcj(v_4eU1M^mt5}|NWyhs!5DLYo zs}znQDluL6(Jnn*E72e$UG4D()k>!83qmTSs}cMwrYjW7;Z>ROVE8dzX_)a-x~kM5 zPEF#VK`r9o4XV{9uR7^6w@cR<__R+~%MR(v-!Wb8PU-51(9Y>f#x?|WB_~WBnyw2N zJ}h0+ko{Y_uKdn%)6(TJi*57LwP!)PzGD5tbnQi%Md@6Rl&-2v(zRlBx*lNW8ghbb zZMw#;OIPvr={mAKUEY7DYdemj>W*}+-kGk(yV7;?aJniUp~s)7FDgSVFgH3w-*6@- zLpRYPHbXDtGBnnep&iNG7R=Bblq-}WcS?qq;6hr4?&2*x(=(J4;V6VssDWnahN1W! zi?JE6@LP!t{g9c#=WrP+T`Gguc^T?hmRRL8G^0X>5-VlsK;;b8u9~5w-x;fV3C*#U zRM>=)+CH(Qs!lG+wO=LGXKG3LO)sfsGfFCbR!NRGIb8Ov0`MVwxaQvOzpxkJQaBAINb9veXf_pezNU^8W>A=^6G!X6YWPMP=!Ibe7u1WN8vkqHJuI zF5nFcxY&;GxaB5J!7TosS(f@^Z864yp?H=GAwD%rKjK0Oaw|zp%)@b1$fPd3K)0+c z{f*e{EY-%oQq+zKrL)wbOqRmSWyy{78d++JJGHYEHkmrnXcloXVo{c+AZP>QqVBdV z72lpE{*b5axN$s7|DNQWQ(3BoH7Ia8ODoT2=?vPR%hEt>{J-<$eSx_DQY*f}c|A)h z|96AA!Reb>dWZbCvXp^pxQ@WvSt^Xmn1bst+{sdPj6vJG^b{NKW$6lD!E!%Kktl`n zc=;$xxgOJZ_&=e3RKPGSdYYxgXIa{Un^^yf{jalB1&!abPLShWmIi;!(sG>qFH4Tk zSvvP6OJ7j^JLAHrY{eL}^%q{?AD?XPvuEo(Muca}7?G{cn2ghSi|Uctnv2JH85K^`4`KUDfNFf-3OG^RJ_OWAH7Id>VhaJ(m|A76eg2N1}53r*`-cF zs?wz>by1{C5f&7rcLYVGN)v>ogGfg@3(`dCWvTDWJMVGM=VT|7`@jGDPiBEka^umP z_!t@M(;f|8YT(gXWNGM8MHny}dGwZtJS~qVCwlaKl1E!mp{Ymp(eb5b#BA$K<<=f0;tH0v_2>jX{Me(3-8}jgdwY6x2RVCrR0?&l9}n@kuSak6V>}p#RY*@J z#t@I5qv2@!g*DE@{0SaSo9)qJJVcSz9yLkzs3)%O^C-`LaydjUID(rfdKgEjC-NPm zwwQ}mIQ!CZkCIP#bnGvWp2B<9qs|zDRTn)vi5pj_=T(oo{p-;rgl>5>2(9mXG#qsw zv5!#d8F?a3hPe6xCBGJFax!d48^b(7m&ZXp_)i* zX((4KLvvz=cH)~h2J?Ozdbg9IX2{spP(|$TX()SNL)B0s*^meSePO7`m#iOVs4@Ca#@O`M_FHX+|bV#E8$(0l2Ij-t+E#)~B{3}s+XKh5UV z+`?WJE$&qSoiPT>aR?7ku!L9j&mP8 zxAUqp7I*QgR5!0yboZ*^r(Ujw_G-^(Ufn|b&%Nr4xi9tgs!>0$j`a7c$pEju!3mTZ z$ZH%$8kP<6>JI))Ce9aL9Y>|1US%2X)rGO-HIv$43l8BN0<*npJjbgg3u%W8i@f?3 z37hF3XR&b$W8Ugj@g1x~>z!WBK=ECSf45iByEX_z3#~^^bYg z7Jnh5db>^klO${n(azDDs z`5)fLEZfvCIQ5d>)PTmOvc;Q9O(Je{Q&Vsp*;||Z4mQ=HovAU%(8<(0_@{@d{GXaS z+1q5Yb5mWAjKwc~W-@P{snr^0R1AMZ2O2SfIox`-wROx?oJKTR#cO+3Z@L#8$# zHZ}N&Dd#BTM4w}(rr{Y195+?(r4y!3qtQuX3J@n>@q$zLoZA%>r>lu zKIJR#)9)30I)FhHeJWMSr@EDS4=bzqv>Q%UpQgX-)0S#JT}AHqefkAus{53P|7!YF zxwcQc>ic9hAU3X}L_?p789wIQ_USdt$2<={b@ltStcgz>u{PjSCD*6UScCaNpP~sq zy%O@NJbuJ(T*XI;KJ~_aR7j#9bi_VfL-wY`#hcB1YJdn%BON81`($Ez3!gTiaZB1_ zELP!ID}IhJUR=V0s86XdVm`ITaQukhaqA=M(AKAOsM?PHaTV=5`1B9Tcl4 z{^LoIbh8d?prv>Ew_TWW!Mcz}i@EDgm@ zghyIBhSx?}nuVW`Wvr!F5g2E2ZqwpEeoLu1h_An~lxK>iIE+G}?-?svPh;#TGTq|$ z8RMKmTYNf`an7R6e70FcZunrar3_0fJ%hQ_Qkx$w^}y+6mi8^Tw0MoBerqiaNA-=C z{zhQ4#Wn1fvTdA2rjc19D!p)F0hhYcAF#cUt%8M#g;7OpJt%7HQ88N+;%t3h+*aliw!TA| z*KMsutCF^IykYAcLZxgi#%=5>O}w|r6UIB_Ue?ya@;2Ww*nFp8%c^CoO>JALSYz0n zM_~Mxt?t;5ingtB_!j}ctsjxAv8}H71IwG(sv017*H(*oTX)eo!B#kA>jaEMoBvbV zDv)F=h}&4y%vPP|Hs>bjw*@g<(x#QIN?}{MBen+N2KK~=hoY?+KN3D7XMEDeR_V63 z?qPd7n{#HiTy(=&EXQHoLH-W5-bXWx#tyvGk^P8+sQ9t1nW+4Utxfo}6LmoT&g6tl zUFZ)#bhYJlvo#f4aICwn*L$#Ua10rG+G>KSsMgC?iQcwWBV!+1h2h6>c#>^R#L&UE zE}+0y-hn#%Dyo$<}InKOgBpyVu$>DjhY=Ge+R*H!~G#?&8p zy@cZ!hnJG;PwYGFS!S!}&m51-84pJMV(SP#USaDfdaq>vtfp>j_qYL@fu&`fWV{V*Z1>f|mdTGBNq5WHaWqjMO*gJmhF6URx@_y~Y zu?l{DSkbS8I8n*3mR0;3fdfdb>gSmx#KO`Lz_+@K#Ieh4Dzm z15|D0=h`r8ic2UJ_A7$#a0s~~etFOrKjAV;Mu~$I{DIeE)TzB+b`QTwjOKNLfI74c zXg->?3J^b_f8metu&ro7S33k$rei>V;TpPs9MHZ`0(|Eg(B|#|b?Oz+oB;uy!^D9B z%|+Qk0S!wIXzbvCjt>i{{@8%>j|-?hc8m`w^EUyl#ZCk!1hiygK!Z~P>NPE(U(jxP zK)vx8&1SOAtbiix0-6SAeLzuMLc@&#y|XEx|8@mbaW^^OCi?6N=+NGPhVKjL(H{ZT zI6&@5$KXE$I(;ypZw@iOqXE^ycgF$>9S`WE^Ynp77sxv;pp@GI9mLQ(0Zl@&y8(TE zFQ9Js`8l(r=6EHGqd3gL^Q?}_XLpoP)=}ni4$r@Ev;yrbI_iTbXkOXTDcr(WRUBon z<;X-ja@2M-9yjVZTx;*>w#QKw!%-UUps&~A*=de8`WzJqIEqIm$I+{piU+QvOYx2x zb#OGf8|~5hb4RN%x}T$c{aFrlbQX7#9aSCd=pyc--xrRKed%b(5JwXxIy!(MDUK$h z$RzTg?C8yJ>3gN4$M|WLqfPLvb~Jm9qb6$|{e0NbznFc*(Q?!{>L}%yqYsWd%AMw@ zF`gsOMMslx`;w!De>>do>}VN2y5{Ipl(_Eb${k1F-*Ytdfg|S;>(UwLW7<7&H2tZ= z+@y~7zi_y=$JLCCt`=uYFHDO=b^bOfx##|$W;=uC%Y^TtzXma8t;a=Y3E=bEdf*IhOHhjHI@^#Utyxy-BY z%DU}p!5#X&>uS^^+M<8DtI^2!*j3jju8KZonIT?F5zQE{Zn%eF=6F3rzC7`Y%Nwtz z_#K7w#j6o=!UCg2K677eO-v7m0DU|f(n>4N(6jiAn=e!6 z_8ZGxK@B(&RE4q$N^PE?-`XbVt@a7Z*C#>s7bmF0wge49_uUD4<6wfWW8|R(^*WxQ z`>2~Qqz(l_DxDD0hBhJn-Y%rA?L$iG6w*FC>=jb3-XTpz^s|uS`-RkUU`YM(Xi!M0 z$sr|;3F+?mkWNnysqD8Q9?Te0QyfR@??W=?hLmAmNVk^~cSA@wad2Zuy*7n398WOl zw~+d53F)=pL#nbZqy^i_X$RXP@2-%t><+2io{$>u4XO5#kP00SsXSJk4(Y2iAx%CX z(kd*yKtE|Ajk_Px^z@Ltk3;JAB%}gQLvk<`#ac6*{~>`2r?%-or%3A+;Y z>h456yp^c<+llItBT0o{OHwVYLAQcQT8M&$lN7}Y!@9PHIBUZ?ur93i>%+>qDXfMVyE&}QTf*wQGpx8H zVVzG4YtfysX59^QFGpDGGDYOg98t||5uL;EJP|d{8_|FHBFdjX!snFt-j3+FH=^&& zh$aRiI@&j)_XbCl?~9217(6wi(=#F}HZ!9AID?c~5tW}E(M8Y^h{df>GzQJu~jRk3VQ?Z+9U zWRI#^j;J;xDHrQ;FD|NJ@u;Hs1361X>l> z!nT=FWtbJ!Dx{+S?5M`iiLx)FIy9H@&0`xJ#`p81YWibTli>R)s%Ch5SyWk9MfLu# zQRZ={Ub~{|f(7V#gYDvCs`X|}hw8>uzFv%fMm$B1Q8CrW zXiP!Y(J?(kF|k|&SSt|F&)5lWH=d9Rn*56JVMq}F;zbuQ_C|kooJZ*J8$>L z_cHMK+#=hmOkwfAf36lD6Rk5ee~#eS=Q7srJo{q$`a&mPxO3L6etYh#kMf>A`v2`R K{eOf1TmBEo5ruOA literal 0 HcmV?d00001 diff --git a/Covance_UCO3001/browser_profile/Default/Code Cache/js/b94d38b821e43347_0 b/Covance_UCO3001/browser_profile/Default/Code Cache/js/b94d38b821e43347_0 new file mode 100644 index 0000000000000000000000000000000000000000..9271eaf9e69989181e075b98f008549158453e01 GIT binary patch literal 18180 zcmY-1cXX5GANTQho1{s~Y-u_`R-vUyvy<+mW$(Qek)a^S5|Qmd1eCq^9wG<=f{P6@ zW$z&Z%2Z_Usn6&4ob&wgc+Tr2xpQ6Lb%&BBH+tXv;OkO7Uc58`m8J9N%jRvtos4B$)X?Oft>#drmWZV8{wra-K2SJ zflYEi^0tEc7f6(2a!H!)fSo(xq>SGM^QHK1sJj>1i0xNMk!iATKb(`P2jDA-Kd8AM zg%#5281xlR=scZ-8uFhMI|V~zob)&crr%-f1&F=~rR1bsm6m@%qd%d&l)MBEnJph( zhOtuX3bc~F|8rI6S|(qE#S(WND*Uaya$EkDUN_*?KT!0h*2@{Ga|`C(hSk#b4h)nV za_~M}kQonPnIt`g`;Wlz7&gm6$$tVrKGkbYK6?feCGt7E`vL}t|0PtFb+UIc==Mw7mdI#H|3@DEEYlA z7~M)*Yy{czjl?EKP(jYiEoqmeeWfF)Ca=9gaM9?Tbf;Z(y>EVo^qBnwLSrH^;M^Hz`$T=yKqsKB;rsqd+uxbS3t3}YhdIX6z zB6zE&Y8QX)2#!d6-3W$DmwFMbsvkk=1`+IOsQMa5@R5v^9nB-Kwv1qa%zi6^KijG9 z4iS9ZQFD{aVt*%sneu(-2wuD!LANduT<97>N;k#op*c>8VDi)m4Aa!#ya>+DSDgzY z_+ViK>la1Pa!CZ+_D5ho7(xI4ITOK_vk|y|i{QZT5tO(P!RON56v?`%NGg~ksZ}_V zaYZ8eSNg<9vLPXoR!Nb3nHtIAN|6+#MN(hR$th4lLrUmVFF(*G;P{5q1amql`Gc_eRt z7sbAxjT}<@~wQTAJn_{MiTrrk~%U{vW}?lqpIahB(t6<=2PW*rv37* zlzyd{|3*^QXrN_b19OTPC{)zIxnc&!6*n+Xio_Ub7HeRKj4EMZwzP;d&`C~9nRu<0 zy9ov&5)EvW{Sr2U>NnDD7HmQms z$vy)Cxh1cpm*2pT0RyQ)1Mg%S=qsKq0|oM(Jk2)HCC9+}kb!+NENozkMCBW3P+(xQ zEU9AP2kBMSz^8Igva1_dCZE+(9a6uxfj8xl*y~x#c)Bj%GKKjdfqYc{aphU?iqL>IS`{q!cxBtC*2bVvP7=jZ~2}^0gO5hSsP{BRqQLQ9Rr zersf;9A0H4f3=b2Ym7Ac&d9H8jo8*1Y4g46{lQ4fAN8Ev`N_zJjYdjrGO}AvNsY}$ zMsG3lTvB(dH~D#wkxF|t$6r&3(w`Ab?AGcmWgiNY}^ zu2wQJGR?$cyNTB6CK`B6{3P%BObn90#S<_wPgcsL9250(b(?1*B4i?7W>hs%zKQb4 zhNdR$%}iKYo9Hi&*G=Tga=G({iQ{jYnD(}bSF+|E6Wheo$wc4ICay@oZYEC2$nGX) zilv8%hCNMemg#*=l={#_hrT9`$e{kpKfuHUsW#9=Gxm zYSQ1oCK6@YbQ6KEOze~5Uz_++zWvce`cEc?OV-aO=17P2Cc17gv3jG4GMltVmTcDk z?IynY#l%x-xzofV`D>RR?>6z)9uw>2*6nR*vh28tgcByB z&YE~b7W`(S*g4JSg4X|GqOq)%a(|lWe91)3%O-B$GV$qc6aG6Us>*lrW~qBz|oif&D#_^w$LQ(HuFqC*rP zb&TRKalaGA#ZFPAyc>nJYZNaBY5zxBD`ST#-f%r05yh1+qHv6iVy3j16UFSgQAE#+ zqO3Gn5XHLnQ9R!eg?VEX-$;*5>UEp?{w0cG^3Coj?(T`A-Cp&#KZ+&?)T^A7PKTmM zz7s{)yHWI$8{)ek#X>pvP|rP%!XvLeiK2_FdKyLPXX@`o6gOW+(dJbY2O`Z>F_`(n zXy&n4&1M=|%xsZ$Ma)DMHB-NsnSsU49F!8VX3B}9gqiQ;Nt~IBrOdplVCIdAW)`HF zDVAzxS|uHmHECwHiN|iHufxn0$#H6(G;^7GTaHPhM>R-<&rBC74v@>`sHvGft;|$xV`izuzGbR+McFRl|X)9kpG*kMK z=K5H3mFwbvqMXmnbboGU?F;qu(oCjId}U@{goWRwZlr|?1`95ug@PyxqvfdC!qsRC zzCsrI7q$>z)IvvDR?I>|af^Q6vansuB`nmkS(q$m<1HLauuv}1Lgyq4X|GwBCcl@q z@L3rPi^^JfCDqDXSS#-8+Gl85yzyxqXU`|`CMXsB3?l(Vsg^D?}t zg?-YnnT2oUZgUImT3Gn>4GYI5=}ik?im9E2)-tcXg(4j+eB0SV#Jj4ui-jNM!w)QM zlc*0Z^p$~qEwt)qA-cas=g`7PIXu8Z{y>XHma3MoEqG-5N((jCS@>DHeQ#l~+z{`N7Us+MGI6to0ozrRl-OZmsHE&vFLHR7 z&h35+<4;()DgILy7RsI9EVMnR^C{-@7W&ET%bLeE?UNHy_PT{LlJ=M8CL8{?V83CZ z)Ge)-O}8zC?`rn2-jkybu7SQ#aEq?^&ocP1;HEmjs6vtli7rBRHPEpl9L%L_RZYbCRUm5<`A zjFjW@na#?ccq@$)tz3W2N}#lrfn}`xC8x_;sZh>J*YescLz0zW%2l*7UgpR}c|Aq- zrCLd>WM!-zPqR|hZY9!dWs!{VSvlahk{3`OaphWBUf+tlft3#%TJ^KXN{7Z)Hc4bt z)!j;KU$=5Z;@eoc*+Kc*2%L; z>Sd;tS5j@Zm9-Kv-%1Zzx4_EuMOJz*wo-Jhm0_}Pot2#Lt?c^2N}->WU$*>g<<@%5 zc%x#8Wv}KScYd|<);=pI_FE}=Q0GSG$?-$#@069La#8M_v66qzN<;bZcPs1VSBX1s zrJ{7aVC7qxd{M6hStoV=urftf{%PfjJdKN{nk||J<)WD(2jzNhH2%D3K9*2HG)H88 zm1rtgjmA+UnoneB&1eF(qFGiunr5w{86df>qp`fM$CC3#H1;;pd?@}UF?=jHevTny zeGJDp#Bg|H3?({gBVko;khS|TwFnUJ}(|5)&a!(9H_r`Ega(<1W z&;A&;$kzvAcyK6&`A1`@d_0DwCt|oK_LDK}x)?+8KVq<4j-imX5L`CYJtjvHT*IQn5_#AIk;#;#(d6LB}O#Lo6G_v{BDV(><}wl~qR+ z|D58>n!jRcb~BcFGW4$YJ&2{q!&vUVie*}n68tHpE0v(3oUK}diq%R`yGIFn3@X9T zvVLd@N=+|8XYnsD!Q3?^_)9A8Ex{)zOYo~)xL$%E|1LqqjS>vJU4mgRN^n?y__qWr z|0}^0d7C)4M8;t?#PN?Yj(<&Yw2q2nv6#(qbdZ%&!V*VJbR2I=v0_>u8%J{)WQ(JH zVjL^PUNVl4O2v_0E{=Y3IyH{2jyS%T`ss1(_s0<*h~r*P9HHDeuI9yYGCz(_Tg0(X zO1~Ay#*T4By&cC{S<)qrJJPmq9F_XTQKWwy-hpupmOo_4AjSGbu|ADs^pH3rhia{S z`*|F_hsCi;rVWoH?aMg&NdDwF-k280S5kF)9Cr}VMQFtE7kW;aZK7A$9XBUHI7z0@F!98*G{WXr32jf^MCl1B&+rv0g z9>tOPJdVl##&JO!VPl`zB5W)+*yv)iu}(70HU?O1>=3ur#-pM(Di^acp}39WF*e#r zxmcUtZ`$Z9xp6i|*lZk?y74wnOLBsZwX(9D)}`6Foo>^6OdEMF8znt93i)je&9re) zMr7IeHrK{e*_>yiao9$?sy4onZPm25u8jlrY$VjT@qx5yXw&ZlHa0ZU<0jf8Yns~l zv!xAZD;xD%tG>5vbd%XVZPe^#W1=*F-$qg&8}G>GzBVomvf&zRqx~l~S`4wVK%zgh zarSc?6^GeaEwe}3xF&y&w&}|U#g=1}ZH!)EX{O*W=&Q5UonrUZW$xB zPTH6x`()v7Hf~DAb2fgzWTVn$&FzY2d)r1QnRUm;{f9Oxys**V5U-D>;(0C^MdBGE z-xiH$NkTk#WK2>#OJ9rUp4dyrb2KHM*HYuTQYjvbC!S`q!ynJMKs;wXTR6NV2 z|D<@fe-%&RrHZj4o`I|4*(r1#_Ro20&g1?5;!7jcPq!91cr!z zuV%16flJc9$HDg{vkK zT`iIF^%SRZB3Vrm^?6nzuUaKiyLBQX-bm!+yNQ(Rl8CWqBAFi~@|k?vN5}dm(oG)A zyZsVbD^>d^5;-7|hf->YVt%fe!xDKqB9X2m6Zu{WMk)R{#UHQZ6B9WwEs=!j+B-|P z^AhPOFXtz+Ye6E#7bf!BB0ZK`ixX+KB#|AJk|>&%gx8Zqv%Dnc$*yWin5!pIS==>} z7%1CoCb7R(67jW@=qU}FBr!vlH%%h0c@hidcd67Oi611dbrK__Qkx{!zmtTqQxe6y zCefmM5(}hC59RHtc)gO;qvFY_AxS(MrM#n)h@G6o?b%7>%+c}rNt|1jMC$S+K3$Q- zd*3UEIDSr|_b*9ok`nuqSacwXTT=ayj*0oOa!JCGBs$708FM;`)AHIS?Y*LPvif=w z+x|+T(BDZ+`X`Bc50jWC^{adC6pmWqC5qWcj9KyjznQ zEDLue^VP4(+?9RDlj(XUneV0jwPYGTOlGE>GFQM-r~=I-I;jFLOIM&)nF=`k6^QRr zfex}{PzCCLQi17Gc60?MOsv2;={~Ol{We!%h3wg0f!JRZ>u3e)oUOnVsdTA=J_o5l zjcdA%sYqsQMW()8k*e=iWUM6jugGe7F8%=(`9s=`uE;mib7Mtr?5Ie_&Wh|fRgsb} zDl(lEE=jO>3Ju~?m?7EaQurr1h0F>mxGJXTvj{zwLCzGyo)orwQ+VM^p{75D#WFvb z!VNi;k;0m6JtvEEQ>Yu#<9t1qKtT#UE2ofNB}IQfrRdK<3Il7VaIa1Z59+0`rJ?dP zNnv-h6w1AxLN{60CWWePQ}n%53avY);Ow13e{l`g^B<@1qpbNngd?ngCrb=y=5cTJ_0EbpVW zpQJKKQb(sUaDwtl`m|J*ewE5SDe_|~BX^{7LWcgTy7r~A{%|VBBdPQ`kxH#osZ5e5 zXH#kRM=JAV<#nyUol4m|sqA`|%BI&UVJ=;Xi&>Q@mR*SkGDDh$D=|;HSEuB6Y`bxhVgtc1auMnm~K zCXKwLG)BnM3Tc@AY5G1bjnA5stlUdBpkBN3(CE4jw z($1XHb}pB()2ytW)D#^{wR2u7+U*>axO6+iq@&M{&2J|~rpoUDJN1KhTIJj6BFP1I z{IW#;scffB6+3^_vFp#AofUQMY!p{LJ0I4!b44ySv-3c{ZEk0?cv{%$*V4{4x!2xK zWCuH&ueVcZgYIwE{Vlq`Rr_|>vFx zQs{u@ddN<_RJI|imiGHD($O)$T0A(N6FoUP!XPDKZ^?b;)q9S-`*U*d5(xb1V0kmKO3TnD8q zJ2+p%LB(1QrpS+V9K5RQphrCiKQwgEzLA5k8*6jNBgl@0R4>keMN z;h=jP2Up*8FutvWQ*Sxw(B47oZVu*mcTlW{gQLA2B=&LerK}p@V5{+NN}iw!Jj+$N8TCkp!}B(_DS(k4%W+iV>E-Ys#`9|ZD~JFwT@S<6CAud zO?jp}s5jHWwK)!4^R$1ygELDVlwGDe<-KoI(+UUeR%(W_XtjgC*Em@Aql2*<9Guwb zp!z1wWs8n&b+BohgN@rAMD9?|UmZ01O*y6HIR_5;=MM)5E^D4L{fcUlq^nwU&A}15 zDvfVCXmd~VlGOVSGG&?Ed7wHTI`~j7KGXU7*TEN3!N}{FOiMHvK zYM0Jv8TxiQlcm8sdR`7oeCKpV$ZUz~p3Vm!rt`Uk`)ZwRm8kyd^pnx@_@i`gjZ7yv zI-TQV(zzn@#-_7MdQDCzZKiH#rE^jG&QWZsJU5-j@{3sKr!!E-$+IPz(~5LV-=?!@ zRXQuaOJ|exTdRHYR0_UNXSM7U&xUl~+@|?#Pp8B$$|aNcq_gl)I%}o-;dDNd+mdlq z=SS+CPG`cIbO!vE&h-1~TzHVK_kZcU_BfrlpQr~Z{yd#lFVfi~-@Q!djaQ2KZ#psm zrPB^4OCy}bM>=V1bh5WJYrCnaRK94PH1RL05M<(zy| z-bu-1Cs!*tai%z#BT1EpE#s&&e+NO&-e!O`WW7rdZ9L}#l_LYHtlYlo9kr=4^>qq&@Qa_o}w-gGkY zmXnCvPKMrbl73g`L>^1jJtqTX>wPDl2Toc(Qg4rS?w)G?CKo?Oxkxp;IAC#6BHG30 z(zTF_HHBT2E8^l>oC{aHi@8$1q>C=4T>Sf*iyCEI94YJ4_b)C^rMRe>>LMl0MR&W4 z-(|nUMXb}sP`TrAk?C`>R5r?ezl-f*7nTAS1LRe07e(v1*ehqGZe14>>$!-i@1k!* z7uH5D8aH;aO%^wI@kJ{aGo)#27aiqm z=YKA0O;EfkS~JbXAUQiz^P25qg1F|p_;7)XD{}E`&3Cy=-yv&ut6Z#J?V{`&7uDCQ z-gPcsNUtAs9)47>n_PtVxo9Ys{Voz^lr%f&;vFe-$c0-D9@g69E=EY@6Pk_OIjOq- zP+fnzc=L*j2QOXZ{;Qs3-G7<|Zp;yGzK}zaZt@LozBakJ9p&aNvzw6BO#?AUyGf9d za-@)(%7xt&F5;$HQ8zoJL9EtGVhJ~CGE4r9bJN7;W=g!9a|v$hCA#sHa?|fMH`k;` zSvTL8)0$*A-7C3Sm*%E|-A%c4H}5*#y5`hPe04W%Yq&Wm&uh8$8J3&xWK{znObyKsMo5gRsxzW~*p`Dw$?cKDJ&pNnueW{!5w^gSc@2cE`lzXsSpJlmu z`nj8e;ciyTjxXFqk90FgCXIG;c8r@kW8KUc@8;qJ)ihE0rYOf$H&0~lG&fhKySXR- z&2TezuA39{+_YQZrsHBa%a^!G`pV5<8UBr%11mJsm2PT$>t@U zZc3bV^TsJR`=rVlH@77Co0}yv>UTFs&+GUFH$yMF`SlMsZ~m!yO6anim2%^z8{cik zmz?`>;AKhuSe7 z%n2SIm)30=58LIaR4eOYR5=gNrB||tA1iqHwW5dOsU8le>(=9;mDj@_x$gH68}RUY z&_iObZo?iHpO8g}%s zxRZw)ojttqu7~nnJ#=}`!x7nx|58sYf>~S7^6Fe-G4pTfVo2r_pc{o4AL&aGhrpSM@Rr6f+ zEHmb-&IPJ-q3*BnU|H$W^`@H78V`Sb=b_+74WIq#wL z6%TLS_VCpm54O7=PCxW8+L1EkLvB~#qo*aed^`q z5HI70Y0q%4eugXWC_O(${m4J#y!a=0StO=OUK&mDa(bGV^V7XloatqXT$tr0WsaAr z(tDnlpXYl?Tc9;kago-@!zEtwmU?v!h?i<#E2mUj?q!`6UgM?Ncgib&uk+&l!OH>} zzTS&#gU-W7FIQyh7B9bV)j8Sj#r><7zWclckLWxc_wwZlFHfcESuZnx^YZwdm+*Nn z-^%9~z3ltLOYWblU#?&CGW))lOAoaEp_fmec-j3_`Tq5?H`Yh(@;=5V`}j|Gr1*%g z3-@tRp62=}2tE+||cG+4i1~ zW!;tk1Lg0d{Ib8Vj}QC#7%m0 z{)Laf7W?pgrMe~XwfbG=!}N`hc58hsUFReIdmp`j^zrjgKB}$v(R8zqnOl5VxB57} z-A9=nKE}!P13oSs^wIE;YCh^C|G1A;a^{4OQ76^sDIX)xYPOes)V%8BN7;K_v-;b| zr_%5rA5(8?Znu5Zz2jqpOn8DI7KLzFdG?wV{ zS|?-Vc(R{r75wy0_cK&NPCxZ!iq2Ji9n<*$AY@6#;y`*|R_2bEv8%HuW`` zyPwz#>RI;x>1WU-Kie<+@m*2QtIBy@`Q@v>{M`K8&zm>=wEoA>`?vl4bjMGnyME5x z^HcVL;y=_3pK6BB{Iq=Tr``)clU{0Gul!8=*U$O?bgl`o)fgZuD!@c@fTD#0v?v_l zk0JpQV*<2`4RBa$#swH_3-C%tCImQ=7@%@efVrgu^eq$M-Le5zl?za&e1I2HwL*Xh zdjO*|pzHhtLO8lM<`d!#?$}Kfqb3b1=Y!LjgD(;NxQf8XphP?L>fH z|7hRs0Nw8dD7YKoje7xNo&;$9G{9b2|6FxP1leNnv1Zh}5$kYZ}(=bTQmO;k03hMjEAYZ&5`kkOY0|~OMe~>!^g1nT`1B1+wmV<(HmNQcJqafdWteiuG z4ES6NK`EFT zWPx0trnuAf+>9V`a!4*ny}Bx~iV!y=y_fyB;L; zcaWVAf)sibBvHo5@y9{ldaC)GGuULwz-i6kMez)(#%9n+wn|i71|?*f+_7cQE+`n#SFH|ztScpgX4D>tQ>BZJqZyVP-JFu|2U zPj?1Ccrr-wW>6_dk8?8^-XKHQ+-4AJl!2#d2K}04(6x1ju60qIca*bp2JiLAz}z!~ zd9r(Q21TZ35V0tO+KY93x$0i2y1&g}(CQ3~KV?ww=L|N=<@FgjHfFGAlk#j;o^2V7 z-mRLBXRz)>1{F?bu;7g9Kbt|T-!iCqAp_H&8T=NNNqI{qE3KJCl+2`dsZ5T)mPy;p zOqOJ2awaE};mtBR&^(h+i%goxYB~0PCP^P;^6{Wd>MqJ;;$rPzl1aRDlvUqk@@PdS z(W~X6_WhAb_vODZ_PMi( z@n-Xx+{?=*JDklj>0LdWpKD~3Rx_Jg^|BdPKbw9Hvsv9Oo5$U?zGpTgKhEaJC)rf~ zG@A!QvdJBq%{Q`D7LCg0_Ka*YW@Yo0Y!KV*Y@+67(_mgUo8_2vTawMUIO83tw?r+%)mt%iqlXOXS$=dtb zJbRGM@#ookt>tjqokLz$4#fuNFkyrqf04tqu{kszpTqPCIeaoHhh39%$e5BtUFj@U zr{yqmdJfOzofSE(SeZkqZ*%aY~!nrt$=8{z`myU6{RF2Qp-*374`z@Enj$BHl=kiq`m!&zm+{(>mR4A8m z9dkMPb}ru!$mPYrT)GX)W&5~XEE96MJ}(#df?VcFw>7z}{Vtc@KjqSFOD?mv<`TUv zmvYB)dG~lOr{$~Pa=Cdfmlc2J(*J5MTdryU^;~w|&85)&Tn5YZh&(Pt<}ufj$J-_H z_$DrolD0g(-gR3hk5N*-TpnG@=TS8+k6|tI^u8xg*GuHlSa!dj$IXs;1m4Nxe%Cxs zj?3e<33-f>&lcsecX1xsOSFDz9z(y@8i`tyM}zP3DEyQ1p3CF=%Xu8WlE<;Dc_dxW z(=3(m?>tuD$YYaa{gcNhH}kkH8*b+jaW{{mvPvG^%cIl%Jf1zvqw)*Im7nFmmwEJh zrTQX66fuVQSbj2x_}3Dmr!~a%q9HC63-OOkEgs_cm=N`2LzIaNu}6x=hxkNxC4?xP z6yj;wkbdtE>398*e%B8%M3$#%k3Ga>M+ifDh~e%K2RtD{-Vl|7%99adu$0UU(IG3u zQE8VKVreKud^p6-sv!c^LoAl+HA9T972<^ysuQAV-4MUX@cN3`KrtJJXx%8p{Kg@Q zH3_k|scxHx_*7=M2yv;U_OuF7r)`J{Z-t;;h}G>wJnj&pb4SJP9HMHM5NoCDdm+|z z3sJ6nh=SfBMtq=kQhY#&Rs+?)3?HVv!dr{+4Q!G?U38 zp3D0)HQ!kw`Ylk*#frH^F{RK~A(pHRvHJ&|ho5vFWcbgDyyBEwuVhbfa7rc+Xw zlTxO%?w8Shxl=AoW^$O?6~dgV7^ZY;m}Qm1^b3aBoDs&A8K!1dn6cSm>gR_!SSL(e zy)eV%i~3;>H3*a6FpQybn7U2EY!G|%Fz>er^M`DBBTU;j!@MVL+J;&5R+!aty?q#W z$1w9`GIDqn_aD6yl$ zygpj-|o3FDs|rs@1JGZ%zuy)?}CtHQik9VYVUFz@UPvtpNKw?9m!Q|jq- zm}h6gOgJCr^o20BE~=kDl>btgbu#moW`0|>+)*9(HRA_iUArEp$dfS5pK68@ET7Nd zr?`827Y&vtP(%BN4`d@jr3ruoD-&u4_RXqnHPR{0ceozI}x zwf2pChP2P;QvZDH1M`_Fqo(I`bVfc^X693FK|b#;%;&VMU7pXgZ}RE7B43}a=JUn& ze4fa)tNFOD=VSXjA7hyU>Xj|vRJj7aPA%Yer2^hcE8ulU0SnR#800UYe5V4sbS~hG zT*j3fTWoPjFfLT7w~XP0l#l6;P|NmN}eg8lGHq_^}lJo zIR7r7&y50xNaoD~KE74JEh%!hfadoK*eUrB3K;&dfJrjdo1{s~Y-u_`R-vUyvy+yNq-DsGy%AJ~f*?yowi6k$_uf;MfPjc> zWGZ_v0c9$(_tfX}d(L_OcsS>Ez8Uv@UDtixX`6oYE#7xN`L0CQm#<7fC5c#)I8_G% z)q=k2mA#o&y#DO0sy<(^S|CuZa)viMv$`+4O7%ci<;?6Vfr^>c{JyFcv$C_i8Px)n zeg4dffhw6*g8qsI#W)mKaN7T3{qJA&9DBt7jtSz|tt-+e686e;Bb*hhint?_&G1K2 zI8q$82H}@1u;ggGoDMkEpTLZCc!MP6B{s`M;{(4xvS+#A2&2m6; zw}JT=NR(r8SsL$zUAy3bj-zaz<+1R*iRHm2|ob z{p6+`d;k|^>O)u}Nsr*cV=z2{Epkxup2GTPdcDcl&taTIzJL#3LSON}f-16B+DAsv zTfBw{D#;Jh-x$FNsb-3xsqB&A<_Km;Q%eNx<&@+`M^Hzi3Pcbu-^yeuR4{_Fg(L9G zEqNu~ibU|4{3q|m=)R=IMvx`TWP{`ti(sBu<05!R)=F$*1m)y{+?Li!id!;*s`6S2 zm5Sg?shAu=O^Gb0IWkDb%lYyV>`RGYs=g#IIU=Z^uGq3(x;i5$?~UMC#Rw9zBB&)J z<-C;2)_s{IQ}QA>SS5lnRU>HgW(0}VB6zR5)+YX%5gd{Dw;~uU9cxFhvQ7jg>qfA* zp6Y9$b;~f>*+gq=7C~Q`@m>UfwpQJ3Blx_X`YTt&{y_xOWL<{{UVa!s=Z+Cv>=Z#t zXT|EOeou^G!lVccleNCt5uBZ)I_E~vOg@Y7;LXrF{J>w(Um=HCk+&lG zTz1xu#9t?pR}CZS(KwQ_O(Iz=x0*)Ms#zo*<(7N#$EtT!B%U#mgye&< zktB?Zw(nbT#3L2PM$UuR@2F@2TFuJIL*-|LR zK;u{gJ7st=12d#)oPqXoT1v%htlUd55RqtLlkAspl7T_R4Lp*J(gvyvWegORf%0ov z1KG(2_LehnM#h&nFkj+Q475sB3`zDG2*_=DE#3VF)&~rv1`T|WX`q*Q^b<8-evoHb z20CUN_&H?YHyIQ*Fj1oN4AjjxutgSDHt?f#uVUa!xi4978dxG<*H9f&r>22-dJPD_Xs_kSPW5(|UJtvqXM0rZUIP{P8K`|!^-9)p1K&yP@9M1>E~<99cE>=s zy9UnLjH_oPv%Zm;a=C$#yVAO$k%EmBx3Q5O za!6`6GtyLU$#d!7(#YCYI=*8h>0KkcB)YYce)4G>BfqpW^02*ff2g`T>L^`4GICU$ zosE3b#Yp{+jck#Rdl>mj?n*{aBMasIUh0Vi`lwH0{LILgGVd!RrM@=uvve6~7GfpdjQl0di

      I)I`A;6W1!3 z7?x(@u-!z9bQ5*GCVrBSd?xzK-{J|Fm@O-0e71=?IXdQ=hzOa8m#I}ulx?Uyvayi~ zdt(!p7AE?L<82c;vQ+N2H0fuKiOKJqcrB|xFtJ@c?M?LRVB)Iu?rh?e4C`WInpnD; zsMpQJ7Mar1M2SyLwC!c$i1hEH{C!P~m8$(rG?rh)GC;ZI^k<4a!Nf7CH_^nzNhZA) zFp(%rrkDsUGVz-f{m#U<^8I=f=|7nmEEPAHm?>?4HqmLLiB+3Sl-jI0vT%#$?=Z3K z7ZcB<*)9|F<*(hkzsJOTdrhpB=le`_{8j5dsQM0RO^5Zon2wofCrgf-NH}34>a2;D zGWVQ`BInhciyHrji3YMp%KT}f!(|iIub8-V+r*c5O!)7bs3Jee(|aa%-#6iYY+{0( zePW{KQxi9znee_aF-MmEt2+KO@k%}?iieUN8O0LWBLB&5V-&SbQH+a<(k~cM*yN}s zio>obK5<8JUn+W|SS*{w;ESS0W)$1Aq9~9ZMGILj_j96XlN&{BUKE36e|{7>m7?%f zi6W|M6m{N=;%zBhEs9Zcym}N>YD5uHPq8JZeiWx0M$x%Z6hAbMVp7v6=1bicn)h}T z-CIVnv{e)>+e8s)8^sCvQ$A}K#b4t7Ac{-vqe%HM3Tvk*UiDY}&lF2W4N|_rx<4d} zt3#u342xo#G@Tj6j9F1c&yJ$B)SVl}+MlC%u`vqsrYM$4*Ujq1cJ<|#C--9UT$@xcm?nx9LdE;pm9cAUSC`vxp z`d>zI>s1u3UPo~t(oAK8nW08APsD0AQ{Q4{tE??#CaSQRIz`O%D{AJT6pJ-eMjXY= z{2))`%v>sA=5;wUEz6skn_{L&s+q|Z^q8zpGqYVhb~C*kX0A%MQ{$wu%gp<7OcFh+ zK_Yx+I!Xz@nRJ;he*{!h(9G}*GtXs3rkTx>UeQdCEIlu8gw1*{Vy0rAnHsWQUgewV zT**whmYJz?@hvlTYn!=J&&-bcW-2u>vs(%@GPAe2nG-VTZ8POtneoYDiG9aRi+A}hMJY&$a_zHjF14rZ=NdPmhL(cR2sbT>2LV>A0cHPfJ%deGa9sgIfBvaGKe=Lj>O zj5PD7Jdv1DW^Ru+vu&c81K%mvQpJ_YvVWPGPd975lE2kVh23WUxnid0RWmymF|)=e`_{!tybw12nFl#+MlyGLe9K30#PsK;_c{7;qhxtT66%&d8-^}I5ZDdS$7 znH^!_cX=z)!dQa^m(fCgl!Xy;)NJ8ev;|)Q3w;V&h%aoRoh&J0A)%;6zdu^oA?9Kh zYS=7HkhAd?4klPAlW3tsl7+N4EKHW)OIrB4l!f`FExeYhWi70c4^l1sBfc~XbLH*Y z7FNomIu_oqYvE)0P7c<oq8?z`_L?+{nUjQm?UvWpb~Hh1N|ieA&{%aY=f|!na~- zZJ~wCZeyWPTMOTJun_T~>g{M@y?pwKh3yjcsfAwBua|}9y)8udv1ku143oosE#&pH z=;wg)%i19pnhv#K`PM?B43&e!EQE$zXeeDIa*}G3iIXkdonj$(s@6YEbxQRa78c0g zGgaFx3;sD4zK~sWE!gH;Xe-|>u<&%Dh4zaqEMKfzzO&$wDJv{gTWev1bY5p+fZP=C zdJA)8os8RJq3;gWB*k`G7$_;bv=%wMTYJ0T!k7~lZi)Ytg?V!KoP~GKYd^(&!9s7D zaYg;Ou6c4oO5d<>M$-OL-(=(87VI}IWXj5aER?vdd9wMAh44M?!F}z?0}F@biu@}D z9$H9!Y+;deD&PIsTX<;yj19sOnhWM-; z@LS0ZD37>utSqf##a-9Rr}eD*eq^O>11p;)vXSa;uCZ@hIU@0`tlVm=d>>gkFJ-$} z87o`6TCsPt(!INti;~hqHGFF2l{DyO)%PB&zV}$!F2TN5`uDT)w^ZnFWsnpZU?p4b zNW^DW;w1A+D^+EUO#0f&3#s&tVt#9-%Lv7is8LpWNzKt#mdpJyR@#iU(rlcSweozt z);!J1YpFUzu_R)Sm9DaOu9YeCt@K!6rSKZnA-}Cv9qX*@{?ST-pH!!8-C*VR&)SPk ziY1nP>X+R8)yjLnSvj%aO7Vl*Lzykd52+8QtSpvGa`%jtyz^G-$)~?t`B{FIxC>Uw zOS_9!zLyD?^m>uCQtJ;Z6J^DpR-VeUxM-@{qN!UZnyGS7ZsbJc&yD7D3FSv~M1HOu zO{FT)II2bSh3u*xO`t|JOKL{bxOp^vC8tF+mbZ0ZvRg)DZxzj_;$IlU=W=sH3>iPi zaC~D7hd0Ggd~*ziw#4wG=tayeIk7#4(mP_9@kG=@sYV_1A5hWlba8N=>NF%4E_F&Vdc#jp3ATQ z#8CKl3~x*PofvvQh+&5`e-y(Pk5%u}81_l$XEBU7#BxEFM8`6)Kr9EPcEMQY7K-H` zxllM(KO16cCp%+e=@S>rFJdVX%Y;6$T$G{T>+v7;xWsIXWuurj={ae%HP} z4=hHBDaGg@{-wp3wYnI8N%?)n_~K+SewB+iin0FhVnp05M!!4781%9jhvmnAi?QOr zVmy`iiDPSI99Bad{}|)=*Az#Ks5lmg*&Ih(Ss}$Nal}N&@s1QJqVchDG?D(cINBt} zv0UuM&<-~CV^@+pVFOC87hb-)`SYIgCmvM~vDvrp38Y|y_ z6Gx9hacq{!gX2j1HjbW>HzAIeljB$Kg z*>7x=A7o>d%ot|ly8Jo9rVnQnTaHbzF=DQbQ_^Xnjeg(R*t*Pyb-9gpD{Pq8+h`;` ze^RcEiX)cIHYRUX9I3m_#!uUAMD9?&Uu?W5OXW|wy32-Vw~ZZpZT!1mF^{Nj87VbR z+88gt$-HwmZb|v`Hh#Zsqrw&S?W%fv$3}aZe%Ho>M>fj6w9&^9uhU}jypW7S@q8uU z7mjCPLOge6WKukf--zeF*h|K9G$o!lQscQ=As&k-p2o7%AJ6DOJZEJ@FrEsT@q8lV zD#lYOM~_L>P&}*i;&~~LE5*~OYCN-~@SE|JtrJfd*;y~1sV(EVBAIRCY1%HH%aYPQ zo{wc(hj>2wD4xCI=^D>u`BRd*#j`@f{p0yoj(#0a^Fi^m$im^PNekm@Z8qemJ@t9x5>wQ!L?;8?WDRHI*szxU;TKokP*i`({0+nT{D}hJyo~Ol@;4KBQd8q=B|yUjUN=q9`Mm^QwMw9S`vf-1j*bbm>YBh}ne(yg z>5)J~879qps}}j7Ujk$X6)EL@7zRoNS%<5l@lpgC6VZ= ziIlCaI1Li1*f3G&$`X0qJdv6$5*gAmk&_=LQl?`f#%_sZev-)7@?}pw)+>?D@Yo+KLQCNW!fS53nFW)hXeT`h@z zvZHzu`)ec-Uo(krQnz6eQ)OwRB;uMRF;9M%3Qd#vQF2=(F+?h~O5*1ak}$SUqG+ci zns!NIu2k--yxkP9dy>|ucyj8iBpwe}-VsT}PDtX;j3lyW>hU>AoL`be>e3{>T%N>7 z>y$$r8P8aV z|4O33-${)BCyCmRl9()IUL`R!x;V$Am#sM0Q;OqDEzaw_;*_XboDOoKWpR#oEl#O! z#W}yTEVJ&FCH6&G-W5ZEWctM=vrGPVBxCm_^QoMwoXnsq$<%F>%v71vHknNyCKJ^$ znX)~SX)dE>*??po%lN^`H2pT2xiV-}GQW*W#x`DYW@*msWHQ9EG?~V-baOJ^ZOIIf zc{`I?^lLKrQI4_W%5h%0%q~aoE#+7)dv}y0_7}xET8>(0%P~AQwV!f*x^m#r7wl*{uCC-oL~w! zAnQ=Q|MMHh4jiP`uUWiuYnZ$RZro5trQ;CPGM_3R;) z4yis(b7!P5N_xypq3`Szc8X_C3Wb&{o^<^oh51`GUq0NOLa75ObQ15u6l$MNVY2l4 zJ%yA@DSRxaucq+J4bA^6g~zv3c>Oqqnom-=@JwranZnQV;8hCOjj8xdsT7S)#aSSg zKGLjcDqUkz*&sV&Q<)Z*%2j#arm=~sd?w|Kr!rV}l}M$?8>w_Gnaa)7R5B`Pt|OI) zl9!&!4XNWvWs1ZH6(>6tPfjXT@>1DTJ(ZXmsa$NFO0O2FY?oEFP6__qPcUPe5sS3JQrUI|7Rp8N$3grJ)f#G*5=-j;?lhuzZV6di9PyUWc zBR46HA+oq!8fJf*KFdqv>qcqZY@bF(hcxPcl*W=T(s(GYMH;svjr%fvYZ@nar%`54 z8e@*7@#D!fIHkwWrE&gZ8mX7kn0YOYI@i+}e;o^)AclI)VQ6- zW$AiHWACQXT0W7957Ko0I*sKI(|91$U!<}1zch>yc6!QJvPTLV>@+dj*(oOq+WESW zoxO$aWEQcrKGDwWBs*P;+nHI?&XrPj8ke?{nxe;2?Oc%Zb~^_pF5S)`Y3H+J^V><0 zN%DKZPMx5g=6QBHN^-s(zbur0D%ojO+0Gxe?D~4Nv-~YPo5WSy&Zl+kT$Rg>?L3t4 zo7mYRo~CwsH?wnH?zgcM+1AcxIUsrM>y%?(*h%`z&M@gQ(9VW$?4%8{v*cU5t_!o%dbpjR#@qRKf}L&??ZnQoGi0XL zJj+gaww-5l?Bvh0^V@toHI~>Jy;Ngm><@Mtt+7*kt)21fROgTC^9DOJezsF!qi%1} z?X9}KP4jlzvFx%_f47}&Qs994ddN=a!*$9ZIc?{O z6gXq&&5Nq>j-4Oxs{i-wkrPt=m7P(qwYSnZ!ol=N2hj!xBcmN0 zFW{hRK?f^}IC!V1g9R}TeOBSnHBAmq%HdKD;>$P~BIA=CoGs^|R(S_A?3yDT91eQR zU*d5(xZ`t>knP~T90w&UIk-^GLHQaECd&F+4qm_IplfXhKh|^5roMyk8fbh&2eTSE zxZ2pE>lhq#l8y4?+YVl}bkL=hgKO_N81t@!Q|~!w+r~kQ&JN~uaZseIgQGnhB=&Uh zt*q?pV4L*o=U|wm4RCPdD+kYH&DRcok>EfF1HN(ak35qP20JMGt%Kj>j5HhOpy+Vb zFF(siBh`~pT8CVeJJM#fY9FK8$2v%nA@bp5<)7l9_B03AXF71rR?Inyx!6JJC8}RO zTBcf;J7~Q^y_NZ^9Q?i7!IJe3Ms0L(Vv~b6H>+P;_1HECo3}gIw8KHe zEyd3}aL7M@I5==ceU>R#Rg)xL)0pcHj>t7>aLYlf`|6{lK5&pJOXTiD)$z!|r*i4J z_VHf_L#6V64jRf%iH=C8zl@O=QRyrykj{GfxL`V8$pgtQoX%3&D)zW^&L^gGOBN?- ztn?|JPU-ULc;%+NkS;0dtW8a)T!nP9WPvlCU$fFVClj;NSt#*2>Aahp&Ox~>gDa== zX1#QpN|E}CDdXf!gLG;()L7ZqES(eYrco#2Rcj*m>|s>~jh&PwS%A)T~oI!;gLlJuIX z*iva$It}C(vCc`SpNy903)QFP>6pGxXa34`mj95>X6d~~^W>T2uS;i@>=Mt$bl%yn z{_IGn*e}W@6ZWPv?@&5xq|4!SK9f6=aa8*wwN9rq_Dni`&!scvK{^*7rt3XpI&VBl z=l!QzgA{#{PV<-P?3Ev0rPK1YV*Z;>%zx>$#>wIcC-IR^-ZeT|XmS!4<)mn=ljg5>9G~;SDFnWUw44=_FLj$@^uTEGz4zc(Rjg<(xQEoXnJ@3QpRjIXNQR9Zt+n zC*xgC(lVTM&vat1=;Y%pr#_c-axce8#gLQlq-4I64=Oq7A-5%1#mU1OP71%}q-kv@ zyXBlbkxv>q`MI%THF1(BWm~DLh2RliT@ESr138PALZmjIV)wxI9Wc{NzI8)=1q38M!HPVJh>wo)116D)5+vTPA)8V zQujOMTcO-C^Lr;Nq|{0$?N>QDDUoZ`LpdlHr2bmXUFRg~N3HQEt#O0aC~G!4dA`ZX zpe;@g@6ft-Iw^75NxL)Z%ULJKE-UXXC*y8AiMZor;9V!__p~SSM569H=_}hFIPpAm z((JL;_C$O4O#L^xSRdsg)$HPc#YM4b7vD&y0xnh;bWx^|i|cVNT=6buN!j8qI+k$p z?;9?vm2z>Uv`e4uxHy&KqI#-}lr$Gz>@I$n{SFtgP8S2^uE#~D&&6WdBoF*9c7$D6 z@?G?m*EL-fuH|B%oRPQQaxt#9i-mxvkdL&c%QaUF_`W!v3*K*D|@7@`;O!J*AiG?&D&TER(!` zE*cMVF@3O$=pioJ4t42$f{Py|d6;@L+@*7dE^3Tbyonk!*+qXjJ5BwX;bN?~=D7HD zu8XU3={xmzsY{fUA&a;KWZP=Ypt7Ignx5UPb~XgB+77U ze9*-QQtFTkw;VjIvBzBukxD1j8@YQ@b^W2b{&exqRTmFmxybofYm&A9sTa60N4Oa( zha%nN8Qgqla&srj&3k4yA*-9ZVvcr`Aj9NH0XLNjx+z%5P2<9Dc1qn?jhDn?Zqj7B z{2Aw_q0P<2csJ)0+|*8V<0;{$_Zx1mOV`qF)|JtiWH((ZxLKR#rkvePnRGWFI^DYN z)=m7IZr-it=AgW&;nsOCH$TYAx^5oVbJM=Qn=uXDoNDBzdSf>W-f?sDT{ni-Zr*C+ zrn!9G)~#!0-DJJ5I^}pLfKJo-Q{MI6xi*i(H=LyNWwnt-LKkz znRn35Ux(bZIIR91bu;dmn~39Xik)=R@|2t3r1BXzwdk;4|cxd^dhq9eKbo|J}85z{s!~QNF za=Usc(%nO|k3H;>^OD@dgX1#~JwEsFr+hNVLy5s2+70n=Onw;Vp~G+w-;Yr2(H?wb zJd2`RN`e%6~Id^DM1drp{5Fb5-X&-Cpj&vcjY5an+yI9{%{j zL;iXXLw@owY^#T^M?I`NrZ~qn=DfyS@KExqhxhJySajEe?Vg9zk34+!Sbclqq2g1m z`I&kwm0ze%DUFv75nfKo7K0a~$;+qmq1nqyiyk#ucDk)z3h-iZ+h8P%}bB!s-=cvOKdI0mL>JP+^w%Vn|dkTTI*<|b;v(5 zu!EOE-MlpEuK9AlhnM7@s<)RH#}|tCrI%M-mvdkNh**i+`+_ z`C=OHrT#=Orzd;4FvUyxX1SFKeaXYA=m{P+s|atrzc)UgpZ+pS`#?Y9BUvxhj*kdii~u_GE___pe@h z{pKZjMEh{u%eN=IJd;Ley-Yjj<;i(3;R{~Amv1h4`RxxcIe)5txpCdgj0avWKh*d~ zUcP+lWzRF^``639SRXaZ`WTb!<3HJ%;v>3(kN%RJ=3|w^$CGp)U%Pyy`Fy%=-p3_* zmg6Hor01nY*vFhaA4T$g7^?XAQC?N`F|?YG^0j?*uH)mp?62=5wxN%Kas{i*w9H5AH9i)v z^%1|$N00SBHvHtH>d!tJZSgT}s}JioAE$TtD7DkaXqj@r$Hjv_>K#(eM}6cS_pwsW zobWOHq}F-L$FQ^N?G+!@ulZOn`);ULfBX1S>iy$m(k=Dvj*qwQ`q(H_o@h-^eGGY~ z-pl+KKK_2`^~m|@e_{l6EgUzD`umg1Q{krOnxdw`RP{J&zF*2#7`~RB#|+G zK9S;ye$wTdJeCiW{H!eQr&I|)`DOexkm#}+CnM!}vY)Eu{PaloGf+ZKKXqiQnB0DP z$((?n>p?xA;pa}apNw2Ti==J7pCy(21gfZpTB@P8pHX%Eylm*FN@G83B(9mCR?YqF zmv$}vx*pX}@LfIE&d>Ar{rbBZKg)Xfx&Mjc_4LzdfS+lf`6>T});-eCd!zgulFujj z*)>sfC;2%iWvBQVC+DW>_H;ihX80+wTsc-~?ke?Wv!AcF_;rp)Id}QFx7*Kvy?(y^ z)z9JI)QkOo9!kzZ<(F;p<-DQ% zvgj{AxBm9?&P_ip{_*qi9X~(a^;6-VpELLUlzyoAkJQ6w>fv)g&0hGa{nF3)SL)Ym zKa>CUbKyVjH37C614Kmy7-tSpxIloW1q1w1C_rLNfYz}A4omg80HbUHUdynA07nu7 zR7wgkt7L#)r2>3dI>5>@0ZNq(@KUOj3lL!sU~~rbcMk!g0|Az01h}6WV0B1w^8+ld z6wo!t0g`J6=u{^_TBCrjB@Xa=vjBCP2N=^jpzp!T-8R6+_Z6>wfRP;n#B~kOs#}2T z-2>SA26(4mfCJKcfMR|YApY|J^}h}z|~m+n#|TZ=LR@2FTk7g0~B8vpzWdnN9DRiE>?Zt1t_;Pzyw($#a3wz zziAEo1Dusw2Lp^f6oA74K0g+q!SMi{PXy@xkLKM8(B*D`{Cfdf-VYG-G(d}I0rtty zFI0C#kiCW=g-t=ekO}g;JdO$yWe&1kjz|?tkYUy!y^03;zEqG$rGtD>CdlgKAkE4J znN>bWp_Cvg6@qk0Qw-VU2omWG@`>#6>Un>V&t+?75L1?7NzqV{=HVcV^Mc&Y53-_K zka~53OscCf^@3Dy7GzZOpgt1~GW6{rhgt@C`<)=?TL(#Q8)Uq^`F@ZQ9|U!dCCHLK zLGJbq@=8YZ3o=uh^$*fP&PeIcf-L)7IR^&m`;FElRR;z2J6Dk1QgBF+DMN!;Mg*xp zGRQW0GCD|jtkx}?#|QPdY(WeYgKUw5l0PZPT)8n>ai{3HsX^l8kX)1o(-d=h5c7;6 zIWvQNJuAq4nLaznpL5i&dFu7zpnhjpOgSbkRt7n@RXMi>*|%M_?olm!gLw7@^|v8G zeU7949@0AhRQ*?!Lyk$(HLXcLx*p_*8$m*U2if&7NP)*e5@ngUyx< zoYo9p7R{haYzFmZn?%KBP)wG{U0VjN<1=t2W$I#YW-!*3!7SG8hd82TRQa0pzS!- zG9iOPlQQTyIRp2!3|$MA!MWKPM9j~i<^s);C(?Lf2A9OTD1)tXRIZA7X$EmJO_r=s zecxx$e^mxUWyzWhj6Y>idqW1BWS?C5IRnS045rK8%^94K^eq{fwrM?bV7u0{LowvE zy#GrEqom5t44O(u8L=mWsgm<+hWBkLX3+dx2GuVr-=A7%R3>FDnXIs85>Y&pnk6zh{zfM6W@fUmVkT#@Ga1}ClLJjM z2{p~6p{$Z)A7_&ENhY87&*ZK7nT%VY`3p0Nmv*vpStgH{XA-?iE@|E$nS^g-GQD&~ z{w!0GhGi>qwrWMnRI5nAIu*$qSCPTvEAsdBihR7OB0p`eNR_P>xptr;&O;TMDTRNp zNYe`y*)3Q8s)*xeMW#!c+ZFlnPDN55RiszBEH;pVI9!ihC}L!7^Ts{gFk|Wz{EZ9%S+SVHU?Z zJe%b!vMKR>HeMMhH&2H-FP}M>X%d=H1Aq=Iv}IKFQ|%(`=@{&gNRd z9Gr!7s8}S2c5yjWiqFx{<{bTO&S8NghhphDEDGeXI6H^iIXMgu4vn|wFnwDN(c5zE?EmTesL}Xztb3rTAfSXA95-9lk%R=W!;rr4qwgX*tJ}eZse+$%J+9Jt8V79 zSt|aM%NMtDxg#6z7taM1{EJ8X@ z5z={z5MRmCG|jPxnBWLuNDndC9pZo|M93SWLQr`!LJW}NnIYO%3~^Li=Z07u3K1U; zajQy*z?&f!$eYzejHnUfr4*z-XS5@4cGh;Av%v#ug0oZ<3ju`RmZC*6GFU@kEf}>(?j&0 ztC$NEbD?5Nfkhz}t_ZQ`NA1H;+6NiDL9u^U?2REtZwYa7Ylv#wLcFyr#JJrdBKCwB zv_HiD10k*-4)IieI1*xqv^f@{!AbQ~N}LLjF29`)QS4lZmgjX_#{VAT>;?7WVu*Hk zLi7~Z-4J0}B~R|DC->DuY5Xk2^yeX>Uxe63n5f7wm(5{HC5CCA6y~IqDyiG0bX)G0 z36q%|re?V?r^<&ZnHpwEg)qH?VYXz1abCa!jvK{B*Xm_v2L zCD4pXpem?YUH1-gexl=<@a$6=nxfKS5w(lg9q8Te_KUwdgC(ye!x zANz#)^m82thI#c(80(-gUO6jehG=avT#gP6Q~BF4^<=2T4iEG82*r|9;vA{^MukZj z6Q;aO5XOedm639MTv)H2Fb(AG31Q|=3{!NHdMUSM=HxJUBx-6H$x|LyGt_l;mAxshZU{{#syVcMAVJe)`I!}jrenzp+ zh8cSy%;}3^YFrA_L|*-&x-N%VE7NXkKklf;yQ=Sj`u{MjzY_>k=&8m&Q-38`Hje?x zdE}(!;i#TRj~aRWDbcm_XjmtY9pbE?N6!X%T#>_#@`!Je#}JtyO`GL0vw0o`TjbII zZH;f4$5(CgxZEcXd%rxU$?z$89G#j+ zU1~meD&+HCT0U<(@|l~SPk(lm2GlS<#=8l)X3le16w+J%2o0*UPN?KIh!${?deRzSZ0IgKtaqeDTr*RF+Skd}P%P z)vNmhzJNEYdQNqJm5l0H-fFMEo)HXYRSo7;tyZN*cEIn=tX@6Gn^CPsFe_L+Gt-;t zubx>wE8AB?!+c(YVjPMqJpF&M{`Y78h}4Mx-6n`%_byBSNZ2bgjBr-0D&n?GF~jL1 zFtDiR6^B3MNJ&_q0!sq0H3&avgC$on(6te)Yz(EFKpXiN^-u28q#G9^pQbh;VXGDPVpwfx-}5H7M$x~?GLbB z=C6mvn^oIZ*enMmZyVH>Q_^HRY!UO%kSNFGk~G~3yLQ1z8M_=9gaM9?rjg0`|=dO9Ph=#Ai5Rs;#z z5!9Bi<(!ns(PNn`Q}ZJ@SS5n7RU>F$ErP`A5xiAHwTr)21V<#kP6WfGYuyM|){CHY z{Rs9pP<@Re_*h2B&Snu9Vd%1TWr+pnKN{ zE_90^rMqJFR39frFmZAOhACR#oCwa&Rh{!9_~4reHq4Kp#li@-?~lNIFoOR7b0&hV zXCrX`7QunvBPekpf-j_pDU!8OkyJ28QnPR*V~Rxbuk?wJWMe`kEt4YoDm9YBl_Duf zi=>{MlT*$}s<+Q6rLPQcx?Bm9j~mO0hbTd?GvR zM&hp*$;-x(^llnS`DT$UmYdBZY11N-u5wc*w2b7VR*^)#q5Q2QNopU-zK)UHmk&Bc zGPH9fBf3UXs9PkB-;Jcm`;nBCPd|vH!N-yOGddE_*hoV1_P9tA#z*qzgh&oZ^u$Qs zk^A!6q)3j+U-CqfrbQB%9!X_sI4hD1Qu>=nnk|Ur59z-sk{OE?^V>+iT@uNyrIB>{ zK9VJ3Srf^0xhQY{7|DsPk^CuZcSJIOcO;p6A{iv#$!B_V*u5{3;4hKXmJyP5L_IpH z8qX-l6XkoV8lEYZd?%$}Dc8S|lr%|;|z3`(^4j0W94pwfrvx{n`FO)lMDO8C}*I!43S^T8^}pEu(yJN zGcuu~f%y`bVxUc`Vo0*jKtOKED|ydvV12+qYS6&jnFjibC(A&Ad@oP44Rp;hupwmN zR~Z^MFiE2F4b(3%utgTWZr}%buZn@sntCX!W*T&?s4sFxnlCl5RPHP@@YZqz zFIO6vi2FMdsH<`_HhH>O6>3IuNW?wL20b?LmDrvbSR^-|>X>=1z85w!zlf1ll2X*jtzt$#jWObjHS)Tw zmd7QGI{u85jW;qh$;jzsBbU;Qc+!p3bs0%@8!6;7(!_6MP0&cQEF-U^bGDJh93yEm zRnF%csh4M@we+fLWLs?`t~y5g)Kxqg-@r&_LnE`~QX?aGq+Mepg_|gLQzJX1Rtuwk zz8D$U)=1KuMs`VbJ0k<+!}dmg?r7veXXScFb#&FO^my0EQE_%R@<9(H4c|AiMc(gi zWU$aE!OKbx$~oujhl>=*lc8voRaEWjEvf9 zs#BiIKl_agKVam)Lq>WZG4i`4A2VXTY~+m8x?*I^RU>t7YR?`Rxh(caMt+cp$3|*C zF;eZBk$qD1g^^FB?SDq@OLl~bq81Y$7BT5qGI2)!mX^g#%r0)CaEys7l}wCCGjZ5% zqE)(y`d$-1%DX-j1LYs_1We446*3{mM7>>yse2pWlAR#uVnSxCbo;Gvx&Z4O#CJHrC)awr({GA6Vt`g(?o+_ zCbr0ancBxhsSizb=xgGL4D7F3J~A;*stz#GRDKrAAk`tKKUR*3CXPviNhT&uHtBue zM4~L2Y9g@6#II8PTN7W&ck4~0|7c>EWc_4fmUP%)qT5Cjt2UV^vsrUw;TFx`VPe_O zCZ0-*T_)zs-@EmAkBPVTnpi8(_L=DVi+XTS^&Qf>4(oL>9W&8UmK-;caKc2?Sre^g z-ft#~ol}o4X#5{08p#?d_os<2mrT^SY~uDU6QA8S;lE>|ihM6m?wZ(rPkk2mBNG$l z>|+zPo|w4))P(oBiMg^umj0`H{xk7XJ|T(+k`o!l64@gE$!=p5bxl!>kBZVi9-^?x zQA-quT~U1Cj^dtVd81e?o5bLYqGo0k+q0u6loLfOSuXc-qiCNOMQnZ)!(@L!6uFh7 z@KuQ-s%jMVszvdJ6s;b`XgOXZiYhguh-jeLlG`wf(~YC(-Xx0en?^CYc@*=dek;v; zBZ~K0N3pa`6xG^B@m$j0ieiqmZXZRULlh_EPx-iG6n~5R?IGAL={`xWs$A~DVOY>P#%$yxX^qeTlO8t3Jtlgk|8>299iej1c+^pVg zSD${4VyG+_45tb8*yWxc#CFw?!V)*|8BW~Rx7I%ewEHFLRvnH>$yRBmKuw-jn(W^YR~ zCuHawW-7KZ0qXOM>FqqGV^&CGglkznPM<>?1SIQD#2)+RUHwSYk$-xi!Jewn=6Ve5+hb6<4On{$*x9+^ls= z!B#VscAL3z*-W3m%xt(~Che-$C11$w>t>qWP#rh5r?XyCL8~;V83o5Q&!%vQ0kWE$>!S@ev$B9?ZZ9o%Y6%n(Gv zx~!E7<*alouemZfS^1@0MJr=vmRyuKQdD26mBdO`M$7RuD^=`PBE44T%W$8S1AZ%c z0p$@_u9c0jg^}nlCbR^EHh$^}X3tr|YG@=_Z0wd&`URX?w+Y?q);*A5(D;BB~hcT^p#p;tSpy%W399wXQjn>D{JN11g&|x zl~+=AreaCNTq`|g?K~?}=UeH$z)I0IszZKVt2)+M+5Ll+LO-fb+4_@}TN|_&n-ohd z`_wPF^NW?YezkI9zm<{)wTCiCjvrDVPFYzj7v;_wEBWWFG>{K}x3WQgk+}0#DoV!- zR=$&o7j?YITB-eql}WPVPb*L4X;YL_hZ;0Eg#14=_A$qB!+#`{b>vn46&S-CDE}ADHO{=sarUfc|~HmA?J(6 z>ir~^jRvuCObBZsk z|Bj{U%~hMi1fQNP!7p;*S_#(wQ-X-=B^YqK1Vdkx;IRDgZwXfXSAr+f zi8!`K#$h$Yal;tLzos}^Ma8i|%;q>c$ONbK@|56GtQIHeYL4 z9!K&Dt^3C~CTxl0yp-7%N6TGt`gfAnvnP&&d*kT)OB^i@#_^4uI26Zk593IA6i4Fo zI41rZ#|3GKjbFtUVPk>8Mpu)KwUTMJ@sY*GPH|gpJSu9Vaxoj@irXk2W223fi?!)9 zuZ_Nv8)sv<&Bjrw6K~_RBq!KdBP+^jT$+vB={9}FwUOttQPN|hkl)6TOdAJfc$SUt za&0`7EqOK?g>AH}Vq=+Xud2CqY#gX-BcYy+52Q^4oBj=BV`D=-Zmc=7x`~ZHTi9^6 zv{AQ}>U+yZcbVDCMveDujF)Eb+eqqT<89f}*T$uRHe7>jwExsb^T9UeN%ZG7&VFH| z;!qo_WabDPSLM%9HhrO^*m7*5jZyP#oRV$}Z4CI<#@1yvtjle5Tw%k!-bNGY^P_TY zR2;EvwlQU^;z<2%Hh$c0BXWoG{cPhcSt@_ZU%PC0cH7vo*T%p574wMdmanDeNgEU7 zSNY~Q8#krmIUB!UvQg=>`u3N4d)r25nQ_O){f9Oxys**V5U+vMtji;xqcoNU%7x9>1#_Mxb0-X#AtduxY0#&0E7$g2d32Z8nKvY};lV3}q zL+J!o$WLVw^w~avTk@=20yz~D^u165Q!6I0H6;OSY67pzQda^G?i@0aX&%CCjTN@VJ)7*G_=O3A}2ap!0|cylj)edz};5C_B0)(57bsi)HTns;74X zjb((i?5A4f?Ewj#9h5-Dj}urW9X?mBk}*uNMkG*kWCDgU2?WL`@Tpvp;d2u>DqEK% zuxNP#cje-D2_$@uK;r2H8p+ag>X+O(pTM-o30#)7 zB=SvMA~&V4H<9g<qJhzlSsL)i5Pn&lKDX*pUY=`^jzOWy31pEr(Ys# zq)PupB0oyxp_Ce|m|rO7&_tdNPo&$3MAk{cNW~wc_+$0__(Tp&NhD#a=FZUVoJ2ax z%ejf{o|j1RZxVTJz8*`>1&K6Wn8?mbNfb>>!s|(*XpEbi(_43Hf) zlGtA}iTGMc^pg6Glb9w;n&aC^qiOvE0-i3Nus07kgrcCaavxxq`7}-oUFQ*#P+|F zDD+Pf6K*6?_hAxKq}sS_)<&qD!(M9s+OdSoNrx{<2_4KrdLVM z?JUpiyXA>}UY<9_P$-!JamnnGe;mo!eaU<%r(REHXq9B@H%Vri%Y7aX z-pRC-F|uq>GLK}!uw8Sl1a2FW)& zlUejjGI!Y8lgv74e>Ir~50jZLr_2?w6skZ|iB77(%hDC7S*8LGe+A;ZR-l6{ z99V&RpH^V1lpR%papNm+PI}C#K))>&ST1{aR3P?e#X4Gn+Gi^;Nh)2cpmQx1sD4$q zF%`*-t;pm~6{+%WMMg_<|B9@V=i>jUB7aD`Q59Jxy*5?k`p$}E?5fDlQxz%sq9RjC z;gST4r%*pGg=vyqE`=M(DP&ei!BsIu=R5RR20Bv+ds5ipP2q(vg&O`87RcOS3fJXO zMhdI5^_ncmO`%RmkMs3d0tG4bs+>al>nVDFO3~ke6b95t;a=?&9@I@?YXjwJoWh=_ zDU^F7h3>MpO$t@sOwspoDYWXCg0puD{lzs%uYZ!ldRhHN3b#h7=C4!ucR~tZOjR9H zW4h+fOkuS2o|VE!b5htTp1CO$S+01}^ZOL$Z`FKxXLkx^4y4dcya!XLdpdl`l%AOjj#MDgXLeo_Gwn}BYta>w*!rfA7DNFlk?5C*= zl+;nF3>c?;l0GGs#fwt8Cq>q$GGb>cCuGPks_WNOHXKgHcqElRCsL_-DwPTH{9TEWw=3zp0X-+HA6CL(O{0PQ6O%?> zQX0c$afLL@{xp4On8xQ#(zxC^jf^g7G<-LWC7-78KwOJ7ZbcgRWX9GsPVP>l+@3VX z9!ukglWDrpNYDS4#<>e=q+U#8)|E8sT}@-cwKV3+)xXnlUQc7DOt_JzYjD!2c`J=e z((|^)-btgKd?1tVr|CR+8p|J~abIRUPh;zUX&58y^pU}`M~WKkG&9=SDJKfs`Mijo zy+!S07PGTH(ax(RJ3UL_pBiYr>&Pf^juAR9O)7?(19(H|yZm0MF z)iY4*lw+UTNg8Ztg!CR_=ch01qz$#RiQg^ML3F}n*4|a;l z5$UmBV}8_L{A6e52F>57`&)E>tL|@8?45QjyX-XFZD*SlI-uSkveW&ropbWzQM;}o zv$Nv3o!3s-@yP%wIHh_|+j%U7&e*ATLF>3}=Z8Dmqq}x;<@6&v&z{?fexbg}390eY z&gfU#e`y-wU`C{aXoG{Vqa7SCXj|ODf*6Os7jfuXDF-Lza2W^j?RKWYUIk-01!BbiDxr3i2IK;uAFC5&E zr}FkN2j#zV@T;7W79$)KAF29fgS`8-dNNw;kPC8K+K*A~V^#Y&2PraK-kGBOQytWu z?%?Vy2d+7aIae_kJ1DzE^~<}(@kbQTp#XT7{%IGw?A zUvi43vsAW~wyU zNjd2(l=$3q-potqpj?t+ucuS3K|0N)SVP5>@p7h7I<*>Wtn6!%&WShEDb+5WQ8J`c zIuoV-+j?CNOMI7fhRaNe>XFU|AExt#g!^ioY?G+|>GYFP^7!L)ZjDGMI4YgvU#Ihz z%o&}|N_lT$I%(5&J0qQo(s!0(OXb<=G?JgiIyapGGDe;)RG*foWBM+g`76^|{(U-| zrQaIOlc!R!E}d1fOFSFXX}ewh*^y3(pOs4{?oH>LL+PxM9*5KUSZ+(kQSFb^KAq0E zGwFQvTRKzkr*q*!x;|H?^V;KdIz7=Er1th|$w$xg0R zaNpIyjzsY0ypoxSx%-ba&msLlltE(=L*##v%Yh(LdvXk(s`AW zlM=Z`y_JJA%PA8>KJLz~veLCyp z*d-?yrOr(!<8L{Mxb0-f9Vh8`wO{gBqV75QNVeT~;(4IHJkt6eYhRygZ%i)MN4ZEf zyEtHRQ6k#K7t*bei`9i)lq=%mYMcvKyo=dVzNCw;rCj{`nv3dXTpTIu(sx5HPNlf0 zk?JBP%|#Epi{E9x!$qvq#SppUagphBu~;_AeZPwxVHcJH7az&1S}uy#cCk;+NS!(^ z#@BTbQO`x+1}>}(T{LRsV!JG8=HkniE~ZJ7RxUcq2`Sau#VENc)7rSW*w)4Kb}nA; zptW^$G3Xr^JG;8DzwgpDST3f1;Nn6b>8rZ?yO=D?B!7U5rbAuK80I2+xQh;7y7W22 z#SfA^LcJO3(m6*LHODF5B#oKkVxXLzu71sQF-}}_U3@st#b0vqTlIITOW%#FcPm}2 zTIHhbY8TbksNS_MUdVetXdl*Vt(#qhe|6D7Ec;y~%1CK?(8b$Q=8y}w96YSC$6XAU z$|uwtxpPu={h_-4bkX)N7Y|;#$o*GqlC}S-7q~G;xcO2JMY_p1xcS!P=5~~ux6E!r zRyXy<9PK7SM#zyuZYmdcQ@DtmrbXTCl=`t6FNr1Gq{$5VGtNz8o101TZq6mRshjA= zQ_4-h*W6r{o@L#vE2lBZZhBO5vo_651-qMa>2BU}x^-=^oA_#O-mLECpggbX)_F5G z-^v~@|*_~9U9Pg&w z1C@J_Tj$T*`b^-aV3?a#vhzzf(IeaplnJBUoc-EO?a^+gjdgQzoN5}ce3O)8vYRI| zdy1RCrn7KlwRfL?bYhndhOYdZf437sqvGW7hBvs z+p0a9bCTTKgX3cly+85rr+hHfL#bgNIu7@6OuirC zq02}Q-;Gl2F&=#5JbWV^CV5ygS@loxaDJMHiZeV+lK*C^{@Gf;Oq;8k=c(pzbbq-A z%LtcGtt{ zhaLt$QV$<{$aZMWZ&CC9ZUSdSc#Cspe%@buYbZsFs?FEwQx~Tb4BNa;Kr{ zZ0@COJFTO=)*&}!NEa_fdUXXsNTL_9G@!QXI@?o_A+*;<_z=dJwh-U+9=S2bi+`M#`C^*jrQswmr>A&1Kh;ac>0Tzug&AH_W_g(`z2|uOX|9*Fc^V@X z=WC2ST<9flu~*m5c&YlWa!S>uUe-$C)n1x@ue|clS})!oyv&nf8@#wSY9BUv`Aa5m z_44~R?a2-=?q9t0{nbnGi1y*Qm#Dp z<=Ry*Gw*x3^g!budim^$mpxCF?_V$bVtv#q?_+GTkN>1_1s^+8d_-6BF;Kpg2CM2%HiX2x{uFYKGJ+X{f>Z-i}EzrM?pxhORKPtx%obd75Fez@$rMatg2YmeN2)- z9Um3zDqcMw=j3nM-_S>FV;@80XcHfa&3r6q?xRgRAM@MmwGKWS$#;^|(MKmq?BpX| z@})x;AH8I|IJ^1?%M&qo^D#iSzw2X341T>4fL^QkdJ2{`{?$G*87>}f3A9m`uJs-k7i%02KjrUEKt7|sRyz`jElAA zZ`IEwK1|DeIwNTH@8hQ*eN^4xqsbN@)3^GtZu4<^hmSHleTsV7^-FbPe#}CGeaWl`>89xH_*Bo`dQt`&x^)>sx(zhiEH7fO-n!frDJQq zuKo2Bd{eJ=^z*EfU%$`fXIXDQ_dZbGK7N`E@-zKoKNUY!zrObK)@VP6Bhcm*1x8{tQ1WX8I|$Tsc-~?ke?kv!B6R{5q$loV)zo-R)=4UO!*`;^*+M z>fwGr4%6U!sWzpY$ zZvNw^?R7t`Zuoiswx1vG_^EW)&zXCE%05u9W!XbLFZCX2AD(I-p809<+)pQ2B6VN* znebBmeC21#zkbgDr{jhI+l&FCq5_OJ2Pj%7K=Z-@{wNY4F(yE}*Z_y6MqGf=wg9hW zL_&Zgi2*7n1(;nrK;JR}-YFYkWw`)l$_IEMRVoCCum>GZRf$}z`o0ZNVQGMgvP4R((mH?DI`?axQu|PJn{D0b1V+5c4EJtEU0>$%f~uJ0i$lLy)4TAfL)a`CT4G1&J~T*)B(< ziY3ShYmmOhgM3#e$iuQh-Yyqpb#jmv6@tvJ7^Fx_kd#V6dZa0aY;pvNbO!lA_IUNW zKgcJtH8Y4QTd|~gC`ik2kj42yZWRPsQ9Ve5dO;@F*O&%DYP1M4x@Az`F9-SZjUb0w z2YI7ykaO*VBzFihL8^5MGV1N1&P4@T(m%+ZkAl3EQ3Ha^k`@DlbdfVs_TwPSK2gpg zK|cCIYm%x%gZlSpklj*vc#x@I2C<9^((vmb+vM?>AmMRZw``se)bAq(F-!`wMGi{A zLEzpNZ`Op>l>P4e#5Am3jL z68a~|t_ML1JqnU2U(4~wLEd_*{+lz{Y{|fB&EQ4x464Lt&``EXR9prnWQp9dWza4@ z16NW8AC}A@P%Z;&g$x>1%wW6xD{WFTxF#{F8SIg>a#M;qGI&jTNNr~Z<6If^a%b>^ zCxaAk29vtIpT$O?G#|-NJl))ysydeX}rVRFOR-SFjvps`RdsNf$ z4A!2=pu))v=ABXfXESK|TLv{QWMKL;gWsYuDR0SSg*B6il9|*hmC5nfGI=vIlZ9EC zoXN>#Skp`nG|ME^Jd?(1;Wz(-gHmka4^SFn`_sV9(C)phNG@HtwW%FQg zHn~HxSti?L{>W@@Ps=7_MmCFNqu6F<6E!=V`g5|`BFCir!fY0No6Yql*|c7o&3h8P zDx3H<*}S1E+*gY|aj7d4vkuFkYN)98Y z=I~73UY^796*-jpE(fm+k?X5-@U6+=8+o-ahibp-wWFGMRr9XpQ0rC>lOE@A?nw?a zUgdD5a4ycGxnvc~rDI$!mE&{uzL%@_y<8SJaw(CX%c4Loi*s_hm7B}RP%dLS=5n%A zF6%zZ<;8$px)01{$Cz9!<8rw+Cl~j;T;@pk)w!(sK9}A<=F)U)E;F{}61_c_a>sIc z=XfrsWzlcB+&q`d@;`Iwem~F|UQ;9s5#pO}b zmZ#%gw`KAeDdo%M(Y1UYRnqbp+9FS%k@9p6OdgG7&l`E%?3hR3?L6*x%j4vjJYE}@ z$Jg@t{54C6hV&4_+#wElLWH~_Dg~7%Bg7ynnHi!(R*0k0E-%F5 zP>A?&h?`YH1geEtAk}Jw7*#XG3n^4PM3XupewJbN6tli!HVDzGVTienLKJHpVqX*8 zHVg5Y%xoUwQVY##8KU-^A;!HGf_5QRwGZ*QLx?UN6}L->DqTaYk#6sXSlvBDxgH@3 zdWRVPfyPPkk3zH@p!LhJp~^ct8Vs8vFW=n{ZTSHXe7NX9s5aV}; zh}aWi=>8D<4}`dSIK&hA{z!-&(*9V8Mkm!zDRnADy8L=NM2X)*v_7Z%GU4|SXV0q_ z7eaKr9ior8?t}=-DtUZYJ-MeIO4FwyW;_cK{XE1r!bC-exnvGgCNWIsq%bF?OljRO zqx*8FT$s${FtsX#IaM)C>C`YwDuwA646`L8j4LxtjjS-Ev%}QO4|A|~n7F!OhRT=q z!W^m}Cci-#L!&Tt8i&~^_GV$;Zyx3k+1NVFn{C6qD{bBkGyknHtK?eyFz$|F=E#Un zVUD~VrgCS+@1po!6<>CD4^y~jm?YUHh29I3DD&l?_rpAvK_7(qxlfqGGUUTBzx35Q zq*uQ%KlBgt;U~Hs66WO>VXQ;Lc;&2=8?LpLZPvd&|>=0+eeEKxX=dv7bl23fIe1=Q&7WvF-nNQ(X`3!tRV_WAl zxP3mC`sZUGkk51(IW?c7)AD(JdOqdm<@3%r`J9$DOY?cQET3-6^L6eypD%ah^F*#* z$;WjqAKO3q7|Rq;w`>8Y$`$Z!Y5}(^74TMC0dF`8n3rC_Kz{+{I~UNkO95x(LeBzH z-Ya0T)EHX8=wSuCl4DZ~NSa>22>EVH0S~tp@cZ@xj-M)^`lUoJck|K8tXm+oFU6TKxfME{{m>{zs6)^Tm0kh=H>qVwkfA9Ij2>tJU zMi=wyzyJ5oksE`jw>j8-_qrAv7A-h;XvCSfzdO)w=CK>&?qv7skrMgz|IO3?QQ`ml G^M3#(IfC>6 literal 0 HcmV?d00001 diff --git a/Covance_UCO3001/browser_profile/Default/Code Cache/js/e9825c090caa84f9_0 b/Covance_UCO3001/browser_profile/Default/Code Cache/js/e9825c090caa84f9_0 new file mode 100644 index 0000000000000000000000000000000000000000..cad4519ebef8a3900206972d63298e8144d83a26 GIT binary patch literal 54504 zcmXWj1$0wM8^-acP1~eR)21y_q}1JUch`l*VPSE1S=`;--QC^Y-EDCeclYmkzjyYW z-}%!fxp!vnBrKJr)a|%5Q=9KU+yNA(*2hb4U{EwQd#<86OBBhSy=a~yDJ8NM&6T@E zwv_BSN~Wad&XuP~&LUY$JHEWTgB}(MZQ=(X&9NBV|%vLgMv6NgTb7#w*%fe%v zN#i|TjwSy!?-1uA?Qbk*MfEH|!;-*ddQ=L?T^bliD5D(gQOZ|V)n#MK0a?leskGm? z%`U9~EUKsuvfV2Ij%vVn8dM$lmonD`+R=ZVfUKQ?FXY`7*gi&Om=B03qY^8+&^o$l zJYlOX;C$#Db>E|UTn9vOVHa#L_OjwW)i0ukv0{Hw^&czR7E?W0(WAHvJW9GCkb0JJ zL7j3g=ta~2P@kK*z}nmeJB*{O2yUSgSW(Sr$VRku!4cyUd#05Ol3J^RtjOOR4;qEK=kRYMzLZ*Uv+da$3T;YaSaT=;VuwaD0Qq0+$XpoV4@3N)2iueJL@~c z1&3yGj!Y~Xvka_^quE|-V0nXhtAwq-R`?UJbs}*vTa_vU=7uJ<$}qtU9k0y zI>Z)!t15hVf%xv`ibn3PIPdR@O#x~@`z(zs4yAQP=0I0$pxqf6-*m|patk`V4>%+PAbw!STuISL;729dY09SYobVZ7>ZICO(VZ(KZ zD@0*qH!J!MH;ecO;kRUTp>OhpC-FP z#7$6(W`D(IA>@tYRnp>xyZ2T+#S0pEH#29_Mu56=@&2;w0^R?25Y2IHs4bSn$df z>tDO#7j=B=ibe0aejn5WHu9q@+JEA8{j7Z1qO^)!zHnX0?JM`T(T^3&=rMVIQ|Z{^ z-}$&7t_b+)ie7Y$4*cTt)Ww3ut`?lISTM%jf^;4h{Asmd9}Tvt39Pv9X@S$Of>_ba z+k)yosx2#qP+F%7W5p!;OlABmXiZ~j16`(_X)U-yVd*TmO$F0iFq!5AT2Lv21+OSi zMhiOAR|?8xK|PvHJ858M3x)?-&?k!pcj>QS3(k>es0C-kEEpfo&r{b33*JRpkP>ad z$XE+HCh*V67CcO`;7+OqpD06C3ufiu{pfa13qItrATh56{qk8*zkmg2D87&dZ)tF0 z3s%#Alvu=qQN|3mS5c0+m<9JJxP(e%gG#F1tXN*kf(J(0(iRjkDzbITs7I`rRMrA} zISbZPmhu)1HIgb=P@$3q)9De#{=tup+H9-JoFkR4!pG9FKUMy!7Idhl{Hj|pkB%8v z*y=TS%$jNm`;ZpavfxW?wWFa0;+gT86%!k&I*qx8%~ZqY++Qs$I6&{|aVra~tu5$F zK5Z?Cq|$VmTC}&|Xa@^2ci}#v8(l4U`Hux7y78KK=br0nLC@Y6{L$BffBWj~hz+x}h=s z<5VNqbw(aPH)Qa4LjtAGs1n%i#^KCv5L<)Q{xCO)dsII{9cJSr)k`)o#tqFWEY=M< z;@q%}c4bvFvb&*14mZ@!sRDAjp+BX~EWaAdisS-rXhyrKU_mz=E$oKPrIoFW z8#>aFvOHErH`J`;h8?t}iW~CQazoYnZdlV$9b|=9BlUt6E{)wV#+c8hYoeyHVq7z| zkQK?zRoRwq5c^uIf^9fH@@lK%+POi5v{%JD@cK~Qj;dZyHw>fwy?DRgZphb1Rbs^? z`rg+KZTq|7>OeOv8^pN{RoB^b!_?N{9PbDfI?4^A{&cl*mK#LFc|4ENa=sfTE^tGx zg>L9Xd*~O{SnP&Aw3j@VxWTeaEnDS=og35-_T)yjakCrpY;i;D!`w^fxHm5GdR=!z z%q=%`z2k;@FWqp~?*4z-z1<-^d{h8iG`;E@=#G6E)X>cC@C|au3Tm6h9b4!mWej%5 z3)>j%}gpFk2za9ee026^T?8*{M(OcpmzrwL9jvb;qan z?nvz5juv#ZqdV?)QD?hzo#+;2@8OQq)TF07zSEdq?g;PgjvbWLSLJ6@`l(6%c|OWF zfMYPmv-Jk@I8=0yJGN57V0X-?G(+4mjK0ytVI0$NcMKfsj-Ux#CptyjC%R+dRClDG z=8i*@Fw-5DSzJ4#4%=w9I|j^k$1=J@LGw5ls=2@&u?yAe_3jYE_o|vFcspG@uUcMo zhj6*7d|BHycRZrc*WEGVhC3WL-O-bdQiogacuTea<-VZbx7{)44)@1hcPxLTwz9b& zyCdSMJC;(+GoFj;zgD?^xc!9 zfdWP)b~U*qdY~wsq~}y7$pee&6ZKE_zxzFj80Jc@*bE)|5Dlt9%xQ0 z>A8`uq6b=1oyw{`dzh~L$$3`yzz-T!hu5c}2i`RGz=i%Qc{taTS{h|WaDLRAoFh30 zx;oYaJ;!@+yfyiJYZSrfeC9p5V+0* ziR(SkVuJ_9QrnH{+hz|G+vWlHT^{&Jsryw)w!#4q#2@4M&-1>QJ-Amru!jD+?SW}e z)uAsQm}9fzBIWS1q882fwql+`_0DL8m`uCq8BNV>#gZVkH;WaEg4IP<%nVVrLU}xz z7jDH7;}R<#MX2|zcp0g7Me#f|FIuf(#hDm&ixod&l~=|uE%dy-ad(pC6V#iQ(i;kxszO+C+PFN!3Q={Yil4=K zQ3d17Y%5&mTCvISooB`DMOH*F;dLa(GF5J+6$>|UUu@xZ+-k*GV;L*%8>6>bAuf>X zb`{8qbJCrh%O38dy;gjnsQp$nFuJnh?*nQzyZ?~NdxU$2dK$Y}@y}6J{uuWutuXeT z;OmERj}?5KbM4^NY!eKOKFB*+X+928+M_F;n*j~y8F}$=YTZVHhuMV=}T?O^KBG-U= z{GmEmu|ZU+s&3Y>K@6>__Oar$@tGC1>#8-Z_-)Mm%Lb9Ao(g5fY$J068^p_os#hZ$ zL~>(Qj}AbS0k=+>bPxnvJw!1|6mS zW7NX2Hi&h`X;#!5r&_TW=>2%rV*>XL4W%>_)oxatFdnmF!z5L2GLJ=VjXSIuG)4WG zW`pQIU5#PIN+V&04dR;dgcY@Bs)Sj*oxT_~=hz@-85!sCT2eh@&wLw%>jKq$A+H^+ zGCUXawT3DfFIh2oiOROr22t4fixrQJ5A6PB>I^HM8?BeyAjYgvX;<1H@~lxMS<%RN z$BG#n)xAx8&7|gARhsR*29#@un#~H!PF4Jb4Wj)?)tePpjjpG-PiU2~ofUOYt5>Y} zZj3u)L;QIadVzbFl8nw5`C39nE~#QyY!Lq%&#v-0M4yeKk8BXvjKyAvO1Zz`-z~J+IKYZK#+cfiYEUGmtoFS?jE4;!~C00BLS1}Qu z5ND0qk)9AMjH9e5AEj!s;tG8;+D3cA60e-BNHjLHqDBt2D5odHdgBZ$YUffOxjiA$ z8N*p|CZ9@^-xDI#D9DNvMuozj5G{@3CAf|>%9zfIEk=`)o)8^rCeHT2WQ3IMH(Vh^y$EwNGJRuesds*@4 zbk%sKCq&O#>K!ZQ%vNhy(Pxf|p3CPYRbHSDv7*gZ^?C>Q18v!<7Vq+e7`|I|-NUt| zfyO*mtlO)0v)}i7;?@CAbUDa1I^>CERQ9kZUQ+B)?k~!8jMtK`kk4^m{}X)PoaBBw z#n-nR>ixgmgM`~Eh!vj=w>zE?q4!iPcH@1ukM(`Tb^VWf{IMsli6@?z^pw~9nJ4cH-|sIzQCcXi6c3;nHX3@Z*%5r-Gze7z9tR0*u;ME8weeqIn8)2XfLy&w)5PuYfn zsvRqqQt3=y{23K5EYIwP&`>X|3RBxzQ90ZTwn&wh6-~)MS_QMBE1jdwG3o#-^2Dl{ zab6J1jL-z0k2=t=L{&S<3*ti&FXS!8^BYBrd*K8XE8&Ie)Q=|8LApZLl3vJ2L8VmH zGF}i9jH9f$WcZcyf*59?yca}_VXNSU!A75oUJ&;wb0sfaFlPMW1##Y3Sj`J!z44(s z=Rr+ss3q)6V?#||(^_im9509&3)E7!+CuJ=MP5i=;)PsGz3}%kFDzK@g&r%sP<|z^ z>uNP_qZh<%+PhhuVmoc|!VmJ;&Ux?fLi^ob2;1j{Dn@;_%ziIqJ?Mpyqh5GmykV;! z^FoH>e2meX4LZT|Q`wVV=zhuzFHWnkZ0$4L$7j{1b6ybEORC;wFNjujk2+uBQ{&ki#-JBo5VhW^w(q?l27OSMKJwbrJtN?g z7p@x9KYKwep*deTwy#{XZ(jKMo%`#D%8|hiQ7)qj$z+E}q$Qb^EsGr@Iapn0#XsRH zOQap*Ym_=3XNPbksEn-0RMd{#Mh8}0H}Vy;LzFgh7Plj&w4Gm1RV^ym5nR!Z^7Ica zq%-8KrGnVNI(F=!4t4F=PwyJ5-)w^>cJ!dI=62Mk4b-9~k3pqdt7>e%Hg=4sY;EmW z+TM;|RH=g<-#giHt+O5ZyV%jm=*PNrwWCRIJGxMCA3HwvSC#>GbRVdOvci3k9fgbv zZ1P}LfPHKHW`_+?XNGfpbd%yo*wKuZ(+f%&sXDPIsp%*?wo$t=c1#_|$B}Kk9lMQ_ ztlvaCs?bNH!el$d@F{94yK5@PIn9oF#u_%m3_GeBjo7_2?HD*qjb~Hl*wNnT!ycK- zbI()hSW#rY>c@&P(gk+xG>)?c7V-KS$Jpvi?3ipUWLGV<cH7Fmy-oec7T(VNXAEOc?BM$BRO#5_ySPV;$!z1@b}TT~u> zQ(5=hA<`dEDTjDXs346x%r!W!)|{|I96PBlvn@{Xyr;PiXVh(W!dW}&owH-(c{_en z#S2`|i*|%w;&XzEU*>+LepmQ9ah2DQW?kd$*X@`>?{9D)-n1k8ZO-$q9Z~mGHnuK} zqyH$!16AoE_o>nD5!d%WUMD*En0xjK_cgVCYDeW~e11N+<1poT!DCb5m+FsKb{wD+ zuend&+A;IJ9UrLJ2UVG^^3jgDpX_)|#XqYm><&u#!aYy;%GVugNoOeJ8($k}9|eB5 zBl8cQkLJ+ApM0I6m&P|%MEv5KlI6D@>*zMEg*OhmdgHOh8~NS5(b<^f?hWy`RkdLk z`l&SOy&*b<@?*MZykfMj)*k7?cSDc#9&P()0 zj#O{#&ZbVVxwCs?vax{umeU(gbE!{k^*r8KPI>cs;|l$m&l~rtS$=PPqI3nk@tZOi z^hOg}K{E@fOVzv~YE@VNv0_vW)xM@TgjX%Kloj9Vsye*LY(e#jf>6FFH=q>%7r&y*I8>qmAC^xRuA0 z`S$YK?BhPz&-)xu;|}uphrHo&*c&%!<1ud}ANR&-`r`!0dXm?b3ZC*t$Z2nMr(S1x zKgx2JYky9CU>BbEM#=?m9HQ+PIlfEY*m;?I7 z%JWv0VvkaWcPg5lNpFl_Z0q;l*kK%FMbQu57;nsFGko+$L!&)=h2lS{JnUlnWVn6i zHKW7EMYh5hZ_G7Tvq@jM?#58|9Tonj?BBg1GSD=7Y0u;qVo z{ppdb15S$rEsUM)FEKzrh^HW^-T=y`X}gY8o5urLwav zXde049jHY+DZ94=6Up15R{A)Q#n*u=blB-YoS&M-I{nolR`d_z@v=DJ5$r$-+HQPe z_k=i5F;q2RMcXh3{-cWF4xFP$6cgb%ddv z6MHX?b4gTfSz%3bpk%TG->Fgx&zb7LqO7V-b_c#u*&GhE$>l)9+ZO z$xhDifL{Rz-W7DfUdVyVhDJU$h!rYf*v zG##V%)p@;YIIx0R)O28OEeG<~c3=&K)N!D6T?bAXA%8hAgx1l+dJgzEa9}TWZOHr3 zx<D#MCJbiEzdtv&Zc2M5x3bl{&( zs`d!(3uKq=QD$jLb3f-k#^HgzGjH0>oIqwAy z{JqeDdW$%=#oTX890*v(^DlRx^$G{B(f*YVgsoP|Y{(i1W|4EP11sqzMXYmR039RW z^$v`rzc)CLXCtr4CI?P#=J>X9{AAtEYeXG(aQ%039J_d3c5@zk9B8_a`{*E_i^n(@ zT6n^N>ZiFEY0Vj4v&$-!ElVy}97v{JboMImdyUW8TRiW-9KTWWHlJ%0ct=IDGw8f= zn_YF6*T8tiX1~Y1N9U-*W3HEhCp`aC70S9icc1{}ddYFT;(ER2etY9Uj<*i<`M}r4 zkKB8ocpPf>*?~X5IMDMe&rO%ValYTVZol}PgAe|5^+9Z)G(H%c)(3sk`QUzfA9M}$!F2kU@@4Qr6WT$~jjU(c%<6;U*?e$~_Gb4%ksPXg zP9J#YQt4UIoLc4f!AfHr`;gM-<#DNAJ|E1YhXs6asGxe;%m?DT(WoWoN{^^bD<2G@ zmsG#C54_v>psF!}J=E3*2Ro^AY>O^FI7&7C@qxV?*Qz_m+=FY=(+B-~`yjY4*P@>f zCeT-7On)E54dnG0?1OGY)StsR9?Cn?2RTOZbEAEbVT_7qmy+*TA0*MGajM#QABd;M zf(bqlA112mleq@eaf(_z)d!;DGO~!sUxC1_|yXwP+^iYZHAhPsSPByidFPa*i*p9t@vCi1dw(FyM zvDN#kMy#d3a=AY?{7qfkld5(%@MN>LVe)Bk%MZPFc*2TU^UgnF2w9VMJ z+!x|BSyys=t9@~3jW617@WmZkzttCOw(<6zzIeFD7p3<3;^;wj?T|0T>ci^sNneP+ z&#OmQd?EVWR5kDULgad)s=e}sc>O{3`r->Q>Zh9F;)Gag+^{$y9vcoHCqzbLq^}dD zoK9?@&xV_y6M1Mc{pIh(1bUK5ePqS35GNK=p-?AgQBs%_Bj_{D4tFA5gcIo_oft(e zqnwx&>qPcAC!&%$wwz9E%*D^=cH$Q8$>T&s0Vi^la^f4smvy33IVbX0aH8@bP89po zi7r*0_)^V@wbh*nt-(3ebfRP(C%>-eM4$S6d;|5OA;;0!iLfS4d}`{%l4edkr@}3r z*hjx9Pb*c573=5@#k5v~*gN#0jdE%0L_!BAx^;GK-dr3|4VN*%6%UNGDp1a>8}A6OYC?QEjXf4af1A6FBdQPWVrDqB#Xj zaiZ2#l``E4(bVX~ij_vvY_2~>yOb$Q&nsMp-S{$+e)3#&fpHF0SovC&tlPBYqFZ zLAhx#72M0)4msg=ST$x>7+YEK-w`L;9^<%=b8nnq?)&! z7<$)<*7uyS-glxab$`ImJ?6E1;>7N!eEc&fe~-zD>(9CFuef(#J8|SK_w`4$lodU` zsG;l&YWG$3V(s6Y{JM-252@r&C(h86-|8zXdZqQlcH;;uZ0Y=PG`$~=1**&J>5P78 zki`!zLj2G!)DKZ%et1TY!u_x-!VlLX{jey?4{Kxmur%He`x5*xBdZ@~=kmku+>FAIqEiBc?eY-@+f6Td7#~Jhg4@kB5|{jXy>kGg#58v+Bl* zr~TCRVg3+z#;c~2{UKhhR7I64W}&t!qro~pB4a7YI*?b(t86l0#KaB8*|x=GXt>6=rB6~VjX=k3eDl?jE}51 zyGSir696%Oo$9|%q>>G-8N&A1B?P(#l`lyM{v=Fb2=HY1}me9LG>Qs@m5b-5da{06n z)2pbOHPb@0F**)Q3-QNjm2F~L2-ijG?+t13-!|24Pg;nfhtgt$@tN&%S^3>c3-SDE zT4Z>p8az*nMaFhk95qs2r-f)&B;Egw@0AXf2dUyC(m_lgmkx&v&++N_dsgb$;&c#k zchzN9RDZ8ld`}1Q#MqraJ;csHH7i4Uhzzw=i@(xCTxpgbSz4;*t<&RCTUD`3dJHxG z?v@^H`l>&6rN`={>0vpO9`3)=W2$Q)W@ZjV@t{C-4-4eicmh!+JP-?vy?Fv5X5|mW zks>Nn$w0KBNo@jgiQZAuwt+ZJ>DvY3586wW+6UrGhd}J^7>E^}0#Rs5AisAL$iEv@ z?erNSPQ|FL$r&J?=2U}AWq_DoO9l7H0Fn8vsx%}c9-q&MD;F}tuS@3tb6c4iBJUct z>{w>(q_gzvxa#f|gcsgHI2{m#U1@@lGgA;;gMyGdEC_d_f^aV;2%)h-{8?#Lg%xY_ zsH}N|AW9i~S+Tyj%2px>qA-o7yW~+a2xm$KVMCc9M3fD}8tPFl2)B)_6@pOFsLP59 zRa9+OJ@}xMyte7$`2p=c#J`;oZJ11%* z>ph9rl;+VRN|+pkCbXFTGnP-`@hE62uP^187KC=RoXSrR!XElg@iVx`X#PyKmaR35 z^Ps@l{G5@nFbIN$)7J-K_(nCA6`v?* zGxzc~Rf82xjN@$S-9cEeS54a&1d(mOI?IaI2b9M_?sfWX)H@Ue(fp|D!ipcqRhIKX z5Puqfv*MCb>~au9#+#}zJK8wLih;M(ZZ_lXAj~#4uwwNcHDG)eh&P7sge=HBOJ!%9 z7`@p8M!MNqAQI-QrtHB5S&*_w%?b;K_+f-a1Vbd#WlD+;#)8;j^odj3SdlhC9cRVt zO6n#n#{8k?u%cyURjYY0#8yHJRge{L4VRX|5Q~k>t%CXga>3|gOkl+qV}9#kh_&R^ zCK$zy$?RR@6gBBPiI|f7SG3s{;hG;`ajmzwu z&cS#}HM?@Y{{-VYE$bExM|YKpz1Ks<^$dn+Z0zq9%-_rBF?uVP4O|DRM$Kq~F_*nU z4K}KF><#+0Nu}EyjJC!QHfoD1!Did4%5CFgsoVBoET;!XwjI2k+88Hx218WXr5dv0 zgfVtcFhuXY>O3np?N^x&1Vaovte&s~kEn~R2s^3{uqTeGtE}H~uA|YE{YWKF1S8}m z_X0gQr3#%1hNyli7%7*7am={Eicwe9bXJtOuBzSO+EPzrJu7D1Rc#+~9qG}3s`z8> zEoyGWKMRH^_gwX1#Ykf>D@wdj2U#)vt!n;`$D-@+)oWI4|D+;62Sa51s%CnGK#Z`e z!>kChsmz`s5V2I*uGVJ>fv6p;ZsiSuuoqUlSaGemdc=yTGHQ9*5Qr^CV#N@MMaFto ze5j#ZYKA~`HVV`ZfhcPfs}}-My$#3SUR_|thmIle@2noNqF7h8l@(F{gdm^?kJmE< zrF(_I(wmR%AA*_#L-2iQ2nH@x>sN;0I>oKxI;;-CSz5X#1a50X;I)qHXe?vJxb^Bj zD~@eY&==#^n-B=gJN1+mpUCHP2-+BXS#iOr`XvOS(s%Bi zAL{R4ArNhitG`1aW+C+d7Py8&tTVE?g+dgjUUb;F$fnvt(atjzYrR8p&v?b2_6bF( zuj=3*3h|#28ypHzCt8h&4~0m~uGZuah3Ha8m1-9XQMP?3Uw=bUsB0)bQ;~l{@wA)z z#C94KiVuTBQEzA{UJVOHi; z-V}<(Cqof=DioVfha%-{C~g{0*kg17MO|S<>#NFkjpsF5u#0Yn@_i{nk>hSCR?y$~xdsnI(esH~^)eJ<;A=IG z?f#B)d>;zW524ujITY!>g`)W{mBTd*qNs6!6_YGsSZUm3e;L`_!qD3Ya}Pra4;5_< zgGjWgS8PvDHJ%mTUaBlBei{yY7{q!b+MCCs*2Y0rJf;5}D#Ry@-`?U_e8T{zO3R9S zerjq;7{4wRhRepV)G&x?M*gf}5EqOW*}@=NW>>>=hC$pgHsuL}XjVu)EzB{|Cu3=m zFbKDz%AXx!JY?$>3&S~b7FT&$(Zo2xil3CBL>PazTa9DI%aZD1sW6CqHB}e(Lai`d zudSL734>T*{2m&H0mIZ(R+Jj9Jm-c%6r*|b!uY*p)#79r#BQVRsW6D1biv4aI*dOD zsQk}_K{TbFw9MGdey6f$RZaE+bvUPXoezV!L}3?HE%vD4ycmXmE~)jb@VTPKvto(i zbCsW`X1CO0R@D4gHD|>uDt9LgXN(7|@VcjJCWS*>Gujskhq!EbmI{ZcXv|~9UP5Wr zo)r};skVQHL-aA$R1JsN-AVn?H5_93KWYmr+ILf%S<$MyI>+|t5st;i2KEs}_Eg!} z*_6~P909$D!9!XX+?2uH`s;TTSZr-x&gkzqzSw$WEAJTn}J z$u=t-aYkcS?4Pat=7vKYTc=#theOogpsH;QhnT)s1?~%nXnITyX3rbNj)y~>pxr0J z@!a^rHb2R68AsTOr^4}xCZ7(6@0oDSrMuMQtUAvYJjZn~rm!yz+j-83a$HnBSh2|H zbBT|myY$sqcO@L+zTtm09HN-fjTQeID{h2CJT!{j3WrFztxmk;Jjv~qYVbN7qS_nP z83uj!reUr189r~Kc;`I5ol+N z06Zh`pYeh1>!rrqBOvA&Htz_CPDX!L8CFHM?gF>ss=Kmt6k*B;`!isN3^$HOXD~wK!xHsuQSJma82ncjn*L!koRC$2vH#h>qZMd2; zIs&4}SXFvT1jO^{3M(V9n1-%a`Sx;6sNhX?;uYsb^TQ+m@5f(}5E1nvQPXJ3itlu& zzH0GzB*Z(ztwAJ2it#rq))`qEMncRswzI;wQ6yR$pIMQmaU`l6_gRs%iF)245+bsr z8qg^cqIzdlWN0KrPr5dYV;G@|PK$)-XJnfm2~o^A&PL6QM9?g?Yknlez|CqmD>80X z>9<8f3^=6rv7*yqHINn2N7QUqyfwNUi-b6C+&mEp5pq(EX2oTSIHkt3BFpJW3^LMP zii9X(^k>B;;~6V5URGsU(Zkrp3csuB4l8EgQde1#{kHPF6A5wQiSm9L3DM%23VP1< zqiwI$Csr(ft+umb#T&J?c@)1U7lpS*#gwxOicC{4Sy6Vj+Rut%E7fmSc&~~=whgM##wdt-wBB%T zib54*344aV8XlXYP>=>10A{5ji+X@qTnUYgKU?h5O_s3x*7%1ffBE&rEG=kQD{ixDANt~j1`q{s*9|sbSnyd z=qm;NtGcox^tM{XimOJaJ5dlh@2XR*@VKWM-RHRIKjS+qrae$|zC`hN1EX-w$nh-- z;=3^h(GbUsNY`k1T2yNKXoyzEu|VFBK4w%svP45{Gg<}nzSPrj35iC%&}d8#Q(gt4 zA&MLG3r0iKE2Nedjplo_MdO}Puy{0ty@YyRCK@8Pth&XD7e>c&(GX|Lt3?%}A+l9g zQ&~}|wi?cg|LUj-b)zA6H&ym#(I`hA&6TA^G(_fBYGIpb6l)s|XS-<3Hu`jrhDhkE zMzErBKb3w!G};?82S!7D7^Uv4jYgS`(b!>B+Y}A)>x9aGGMc~h5slZzZ&oZkrT#n@ z4YA#*b152Px>5deG(=qkSE3=h8kui!UKC5ww^ZXt95?MZ&ag4*VsP5H!RAUIgW4Hl zuq|T@N@R*b$;>hQ9e^0D&Ju$+R4yzAv%+KeyVo)JMI)kOaE*#a$6x^=CWh~6p`2{- zgcvj=pX@PMOv{VL@O`&qFo?oS#$ZXQ82nqB=cpKi{WP_D3>>v$P@xgqI0kDdxGBfg zECvml$MAQEIIb2kxJpG@#_;FIVi4GhkEi35zI6;Xbm8Z_#URf;)qq`Y{9v=*k3k1x zI(yZ4#){YnDkm!j8wXi&-YEMp23x7kBlVgUKWWh880>u#gZaAP~#FSDt=QFSP}VMUHZk_DIa40?*c2_T~vQooG~`K#zH(Wf-SLpAGKIiH-@p| zv=QhQ3sKvc&x$*SpL;As5u-gT78%!BVe?RVSkci~%!(_9!x{@w&}hSoImQ`QxY<-b zRT6`(77J0-IL3;|9V*>!j)MkWRnP9mLX>%| zhO#2>6IGTKzE9P&*StSPyixt%a-NjqoqGH^79#YE>hm=gqWCwp>31x|E2ErC97Hx( zwZtP1;;vD^76)PXR6G3RAifwY1L7cd8b#8?LCi_3TBnPHC=#rCvf^4u9O{Is_N=gl zsS8=-_;uGfcxO{Bvd2M0jt)kanvG`gLMgDCY(Envm{=PKum zIEZzxRF>Cq5b+fHUHScpgUDiJ`W*++&IogfhxpqFaE*ruH-atke65T}qEmHb2h%kp z!Y>{oE3K!2{^|xBAE4T^+l;Ghxio4VD@vwS3)y4z-axu|C}JX4H!2vPgbm(tM;*?}nJQnqW6+estZV3=~+|_K41io)> z0-T6BU zA!Zr1qZ1(-=Th5PktM&X%L?BDDwq|E4c9`65L=CxLYy-C zHcW&VYou+Ih>ndDv7?FV)GHBUwc*t#5n``#V^|_Yn&GO$h(w5>k*fd9M2MY6;Os>H z9A_df8~-j(gjl{pJzz!QRq6#R%I{GlSW#fFs=$hil(Ih&w~Ub|6CsWpy-p=Uj57RB zC!*b%L}WUv%HQPiX^8RQ7RN#Ex7F$gTmyP+6n~V+_ux)Mq5ssfSBVf?eyTUDsPJ2T zWrd$h(*Lz)MWUN(=a&Sr+W6Z)38KA`CLjr7gz=aa=h7*k^hpr=jq|MN5~!ZDVq6CG zH6#h5L#S#W%X86p!xoo>m^x|@EArJ-V_DI@k-EZ)H_cV?7D*6ajA|{DAka!xWktzO z>NzV`cT)qpCqcwaR)blQI778!MV6T=i4_-&(zB8vh8THfCqa}kvd>9^csyUlFGzwY zU{q!O7pY&1lOWD5QFmD}XsNQTNP<|rDhVE|lTdc8>V7Z@!v9bbx>AqBNpLyBYfe9o zsy@e(AVyNo<7(B3B#65wRq*K~i0|iAfcL3^nJD9X%a;CXPl!W z`Tz3yBtw)o-m{{xQ~kq=r+#W;x@3qqM#I2lzK>xt9%N9tGA2V5H(s+MTW0k-h#%9S zVC5E(3{gB%)rv~y`@<&l|9@4_xMYYc#sk(TN!e18A=1)5BR*>~MEz`PPWEJoKXa%H z1(PBA6;Y$v+(p#`HoBNC#r?4XgWy^n3fDtb-HTIiu5y7?ODkXJr=1kteCP|bz7SZ zF_==;sa5NfA>uZuR-2L`jvP?q4kts*HcB7io}mYn?x=dkiuI?|*vrWfVRzKgd&v;% z->R`6cstFaQXkbcR-84~eols%?vnCKH378~r>|ARb!PJ65>a zR0~#A_f$)~Qy>BzDv}lF45x1j!~m!2o;C$ydOEd)t(;yhW<^AxdK;AjaWOgtyJJ;g z9M3}|va6r0h{~hBu)>yCh2%?tNHV4rNP%cxP<3O)j6!M|`+r4P`eAq$O@Y{Cyk$j} z5~?FB`WkU1Qy~5+rM9zTPFeM{630zvE32A+radl zl)`@_rC@e%)pKYHzqib}8EwX-KolCQDzT#aIMs1F*N=+NP*quBovFUgNr5;ySKVaA zn0e~c!W4*Oi_|q%^jfUKm!?2`G~Ac*c|qHZ8Ebg`$$O(Jb~FXzr16mzO^>U!tax@w zy}io)K);OT*HR$rT~{Y=r$CIjr_y{%foN&`!-}xas^OOuh)ZA9>mMl)Z+@wttXTG2 z1tJw9z(v(`PlafhPBloM3bEBV#EN!-YF&m@h&!27zTi}d@x~lhlnGHILQ^4rhpR$S zseE6iRQ?=`n#YQA(P|hgswJpw$*B;9jpwXrk)md&rb1NArUvFpg?L&(^(@43mryrY z@z|J9G8N)eDdko=6(XI{lNHU&sF4*?A)XkuE2ToXS5|dc(cB2A!ZoHE#_>N>A#PSv z<*IYeRFf<luSk|B8q1b_H z<{+MrUJO(9ho?fcHqwtsg=jZYEgY2!aeuUWHZ~RF^f(nVJ{4lNv4R!VCa6^tQz7n7 zQo&PFA&yT|D`xQi^kbH~Fgq1u`5e`6ZYo5Lc`A4XA5U#oswt~dAwH~DSepvbYMr{g zJ{97^26cKP$4!+ss}EcFI2y7`{ja9G0FUD8!Z?0#DNvxrp|rR|g2#w%b_2U{Gy+A7 zYbjnRUR(+k2u|@*ic4{~;uN>y6oNb7`{tal&+~i!fn+mx@7$TT$?nXRzr2LL->E#i zu+AZBx9YaXOK9X?Rc}9zFDPomA`?Qx(=`-r#IqU~ma$Xg> zfc*<)%n6i2FRC9dc?rF_tWvLe32nZka^Lk5Y6U59)LcMA?&0su3N-4zmvo0?;Qzo& z&YBnKvWKeLBh15pUh=OQo6Z~Wz4w;D^ePIa?T{&>H?FOzhUf7Xnr5Q&dJDBMC((jm zddmn?v$(gA!^qd(xbBj-h$=eLugPI9ycXMx{Q!Ui`Z@q<5TB{$w^A;-HUJdVn^#emYs{JU% zcT&Sp`p-mk#(3bqncc-3ulvB5x+#B@&YPdRV~$`hg!E9qfA1~t`+7^Ce%>;DkhgUE z5o-&6hqF**u(wqH32PL3Lgk@Y3)9qNH2rjMX=%Em$DrN}%-65#J^J}fZ|OZt{ec#o ztrnsi;KwyJ(sxC_1%wm+Tn}RRu2*nw%I(3D7>#8RHb%heYRYmvL z6?#_LCr!C3K0-~+Oq8yeudDh9wJ<3tT`>8p`3Q9|TT#m8r4ms3-K6vO5sEZJP zxO{}Vo6-?JLN(16lnORbFHt%duR1pJ5qg!Z3bw-6K}cKW_|8XYsHxrFM=0DpKxuXd zbrGd;9aRcS!JX7=lxlTW_fUFc)^+g_%F|OtqLjXu%8Sx;^Wu9Sp*6kL-k*JhGK^8{ zQQBu3jP(&(I!?72?;~_`kt(*>NBaKeBR!U=IU9Y1{xP*SW87QRl|$I?Q1q}mj?z`r z`iPIvuA@HE@3HNS)XrRgX5Nqd=4_<4m-skWYs+Chs&gCn#?Q`WU=qohD zTrK1)w6(CB=H)AN!c?j5EA-5KsOu{f?V}pi^A(zC{tNUKS`(xOIedjqnY)p`LZMOW zc(gD6pVn8h#i%y1zCwO+N}Bl!`Iu=57#}1isz=GbLS>t)p)Gucg1%La+xZGjGLOIW z64v3^1m<5bglKcNM!)n(MDt)JXBorYt3@SDjv(oblY zDLu_kDA{bC?k6;MhT1vX53fh|lTT(%il5LfIiJ#CllmC;SP@KVCM}-QQ*(kkD zrxvI87pjn1wL_^$7F7|YKOk2&f826NUC!+<^dg_Cn%`f>6!4ci1yx8zf1$yqMkRlt zP;&^SvQ^Y=lsfvWWhf;Es7@$7Gf{#5LhsEt5&lBSCU1Rzp%P{ZN}1g150ui!C_j{D z#41mmzfi|`wG5@ihN=@v&mgKX=BA0t+R;(kuzjBTfYR#uY6nV= z1!}=Ue_YqaUm_Q&r7Qe}?wDU!`U@>H)mHh-*x&u7?rL>llfO{r&1w@$2TkM_e_65B zUs`NaNB8>+)jyyXzrnhM^koCmv_UDQocf5;-{sXcl-g8KPbvlojjg7(cn1iLt*&OH zNq;!tX3dZIMcOhIX(S&LFC46hd;MS=qG z-lzZx3k|@}r~;%*IJWBwkQosHQl&wF>~;r8-B@gYlsR!ua8j0M`D|B(%e94=_s`Ur50n< zHk1yT2jhZ-8jn}~rw0k$H>GC<2@N*Q76u8;Fbx(32_+c6#X&;xf2zqSIo7I%DAil1 zx*ZG>`rUkcC`hQgnR+-#sQNWE0;K^r)E1OF-&6xp>Uv9sJ`NHZVro7K5(+cvQ-g$j zUZ}$;O?an{p)~ltnut=(4{A9|ejinM`e32u=0b*GTqide*U42sWDFMC2lq^5reNH+ zE?DN7Rp48#kKf zYZM-t?PY?6{xwl$gN0s}Qyt3(3r#XdQ3|i1PNVe9d{r%2Xp;Ga(seIYygJ4N8EXW~ zK(ne&u+S-!zHYEk4O7WCSSZGvu7_Oaj;Oy$*LMk$um_)ltwO4Q&B4ZhpL29(~YX` zreKlnDkn-;539>ZgN3RcQw>pCX}&s+`G;jE)ZZv|I;nm{Y0dwg!p9JET6MgPvBD(t z5vAN$lnQq(g zDIO0V)8cus&^`0Ti(sK4uhkNij=oj7-USPte6QZ46#Ys4gHi?wNmD*Uh|pg17^REZ z)y|wDLZ{5gQXxVaN~>-tO@`yS{eoCu^unwL*k0 z*H(G!ga~EvRo|f0&ZPGb5&F^uplJe7xMDH|g$PwLp(r_mRjH5=q4lAdPp6t17b5g) zyxM_M#fHisrMCaq2p>b1#wr1&>dn+&DBUtunuiF*nL8-0YN^hn6xdEp>Kr1p(H!m` zBJ|W`?-3$Y!uX(c)VxCJ?GNhfJ|RNUW*kau&6|NCLg$C5k0=F=R&7yoj#FJwnmJc3 zLFtt#xGqGf!5-BerMpK|uA?DBRZglnlunz+C>1(oPNT5N&*ZEiFT70S^}%}Wjy+HWR&8!EKfc(o4|YGl%P3Kgnkj&=_f%KC%y zMyc396@t=#KdOR*Lxr*qQ&mtpK0>`g$>(R)9Hous21-T8sbG|THG5E+JW*{zDbFP3 zi&Fb3Y642Rrz#(m%Fa-3lopxeC}p0dDxq{eMSV6WRA|&f^*c&g7AY^3e)&ypMXBvF zH4&vbtJPkViv6L&QQH5fI;=^U3?6G8~=M)|8Vw! z%J(o-sIo~!sh3%V(l(R(73LB4ny}Y6Hlg|(bp|D$x2icx%RZ@eIFjjo7B#;>m{6gj z%8gP7GX|yA<|IllO}=7bLVl(hO8w1Dls20SDB*={Y09A#WqP7C-Rwf?p=nhyOlX{G zR3%Jkuz6D>OsHf{m8(veP#u%%ABLZmgh`PA)hRqo=%!P(j|dYAi&0%rn%Y!-mJlX1 zDN%iu94555xr+WaOekY3RRyIb9aV|WVM1%VsGx3PLVtBvhrSOJdSY7l4ioyp%tzDw zfI@H|b-HhuP=kJI0!rsinf_t8el6+sUJ{k zzF*BosptWfdJy{^k`Ak}C@ns&&Y?8tl-i5ZB~##Zn9vyGe>P00rTGV??B~?Oi&(Re z_mV1)()r8kAxhP+tNtiWx}i3rl;@@zcNc3O0#a2glny>sk5Rh(LS=XvCKOg&dNmFbX@(?II4L*~QdlG|g8i z3@ENLI32hjp#!faQ9DtZ<5GX1bn*Wp@G0KYysh>mWkg3z(Arxg! zp!8~>$~MR$wC^W%9;E_9RaKORn~Nyb8m77pcL=RCk489znvGI}QQBhq{_GIiGDf{c zY5h3WeX>KS#Wb}Or7I@WbO-MF?T})|jnZ7R1Ep)G$qa{3;IFFpEC*gs;*kAwRn~b9 z+}~Txo{zNzO%^Es-yA|K%-2gCLLZ^^GL>V61J?#}h_Csy(jio3m1?~jUk8)Sc}C7&{LD`FxC~cH|>r%gnF4FM;$^pO@reO zp(keO-wvT=<}pg|&5M%`q3x&CpwkYa*=JO*v)C5QG#^mPdrtYGY0jf?$pl|;2(>d` zU2+J$H!ZI?gnF4dXqu}i)VrqMqm*(}?LqV2QpHiK{I5ED8}koO?x-^N9YWtdQg6^U zkJV2or9Q#Dr>dWx;_qPdGl$$ag`YcwYMX{A^?sqYqg4E*@Wzv+ zJDQ;=%`>guI)p}=gYO+ec{7KnsgF`)6PzVn=wlA$Dibc$$n-#IMmg28e7I2V3TkJ? zaG~Qcppq(4Ib6uMifW0{pH zE;M4S8a6c??==jU+0)gO9pOUTcd3Bgm`7NANd0mqTfiVIL)^_)VDO?aSF=&qR+LE&z{hjjj0H?fx zRs)^V=trmA9;}|B1%GnNXt)TahdQMb+<<1ooU+~I8Sa!OumD~{&Md~!rCX*xppND0+Z9fsuIADzr_hnrYRP)1 zP@fHII7&6Qs((>(Z&x!=%CbY%+T|1qHOo=Twp*1(skZ5i(k?gyvPb1agJGzdgyz`m zlyQ)KpGrcz!7Q^By$p%_RR{D0R6C#=qvOm4ltK=wD3qp~dnmm!Sq|gtkErfPokHtR zsZVE|LMyMSk0>p@u5P1L`-U2YQudpwFG|-;(bIrH+um+&-eYFpz{0~&`$5?;R>$#fy0*{3|CgCNH5twD}qtx-0+J@5S zuT>Y64x7zyoI>BeRsW%s{7zj!$?v@yhtff_^aJJwMtxLwQ7Z9C4M1tV87?lNqUqF+ zDBVr3_GNGhWysRJlg z&!Og^lq09=hte(M&gBwXWZa+Q&v4cR=62!z)-G9|S0#Vp66*M+T8h%%{3>4om(Vpc zs-R2gWg+#tuuEuS5!Jh>ODJP8H4UXQU#Sf!H7l;NeeDvuYGO;cgqE08ln#_sOG{yV zaL9y~bqQ@OrxsUm3FWV*e)n?W_24dX)=}TqbqVb;>qA}mJ(UZ;7gt4{*!R%I97U;; zON~S6k#R?0eqn{lQ6KvSI+kN zRH>axL8;1jY8y)3+N<>_<>{d6qm-ee`VOU~os_4uOK1k{FlW2qc!RIH;#h&RCS7-z zPy?7@ynDEWiuF|MP)gs+B?TbDoI@#Opqhlz&_U`tn)fGl3MKDhs>>*>XLw~6jmG%_ zoIk7IP`YO-j&TWfH5X7CJXXCzY4tcYU_90g%r}=&nc$Mk<~~ZBCaRs2UHF{}*5_39 z5{>!ACHqaCX*fqhj_Ft%GjM*Kg}G00;lAY9&rp00&Z%=_}LfJ3WX(*1Xwr&g<>=!idDavIvLamg9z`6t%vI_%r^I9G2}qc^#v z;AS;)E9PvQ+J|=i%Z2+y|3N zL+Q$4mt;Poenu(dQ8n}D@I6Qr3g6z=PO4@)2eC&O2^HfY7s((yw!Y^em9R% z%3WQxK`CcVTGgNV?9w==v?@$U3S0hn6X3{$`Z&1^;Lurw@i&AlyYJ$>a^EXQQ zB2-h9#+uzIeK0=tBZRt{RVdvw1sg=*JysD?-wZ`*pLvH;9k=R%(gyPpB_EIKjnbdy zAxh;VRcn+|%mtLbh*FU#jWPRBN*AqsQR;4fL+P@~8xtWEYWkzJ&OAb?M67Cr(pa+# zrRSznT!c_-GaIFoCQE#TkiY4U(n50;r6LVgLzKpuy(qmg)fz2I%RS;#@Yv` z8G_O#^9-dbO;ksemYaJhm1?S*pfuj>LFuKb)(qo;wq_AZw@iry%p)Y4X(*jEIT9m; zLd*{+tu(h$DxRd8pfuSWL+Q(8^{{n>xVlD2vC;T*UU!-{P2EBZO`~RRp|<7`8jNHllr@b=9_W@+(N?! zs}?MCtW)%z{az@Ybwc z>k-;!Le_a??s|_j*r0wt*h=AOpqVYR7s#v?TOtg3g;Bb4)os*ln~lk28OXo^X_ zg}H*o|EjKcJ-8pIM^>2@_dG(~OtJeOp*v62ug^U~LtiS-YmZQ|H|mSG*l#f9otpLD zBUI|6I{L{YG&Wsin%U_ig_dMcV=_hxb;+b+vqlQl&8f=fiWFM)x!ROFQfR~%D&?C< zp`;2bwPK{utxD=lO=~SsjG_kMhe|C zJN+VsHU+7`kVv8Xq3WX}Qs}pEbv%O6Xyg=W3)-q)C4* zQYf#Pj?#Qbj(G z5^4xLAvkxGWXlsJPoQr8DEXp5l+1y}5}l?}x@e)gCK09m8PqeBj$~B%Gervx%&JD_ ziik!=pi zjNM5nE`*r3iaBdzT6orRCTvnv^Q3$QRp)oHlJ~vxpfk+4 zOmRZT1^o3|*PU82S>Lm_o}oU~t|wxR`B$4Ts(IQjO^IH|ostw#^< zR{ne9BoVIcRkilT2`x4$`{RTr9#CH#j1zkGL`9{>33bgDpQgZ<@j`XXdXzfnQ;Si` zS3o79w8msF7%$Y@bo?q_s8b2$E*UR0po|(E9WTAQE9aPap>+$?>izLTyJ7G_wfG3O z58gLbiZm2zmQM9S>1{2Q#nn)J+pB_G8w%z8A|cJfHVHy|JE|dF6XaPh)w)lD&@uCU zzXYL?u(ZD#J}5zG>W`}B-~?RfK0&<3s+K6toS;ffOc1I)Ma`a?AQU=X75Fs)*H}%E z6*JYpvl4{vtyjl3U_5YqliIvFK`8q+6@=2*?P~ju1o>gVDsnnO=-LhS+tUQ0InPw; z+XP(0JV7>PNK6x!F;Qw~QCHF7xm5kn6NUcEt@7ka#J^iq?b3;IE=>LENEDjnR%d=l z6skT*<^C~IC;|q}P?u&W3KdRKM^U?Ff>OMcCCPUos%~_W(A5}~9EO4w&`>G86l7!ZqeJJ(suZj#v5^7>{3``O#YA&EuZkTF=Qla6hJW5ARrjbcP zEzGFV7$00V{$rEybDJdTXR3@#5(+Rm$0rG8ov8Ytw0n|@n4BaO_p7>y((V+MZcdWW zTC)eGzH`<1c}YSa%*pvlLb(^H-6)+hzb;G?YPdp8K`DHtYJ^hhRVwq^B%vA`)z-g~ zgrX0qj_4xj{!oP%NfxT}jXLR@EL6cy_4Xv==fTO6&`Py!oh-Bv;zz2b=vH`dvW-d> ze;941qnSr1%Lh~c=Va++PNVea7;JB>x;r6RXyQawds4E{iOH(mlw>&ok4=H8$D)@Bz<<)OEu$< zPKVbf^TlMTc_~?%UQU+tK{=;|b$Rs}l&F8({m+E)9!cx5f0<^PY%@c#!`{|C1gQw{(C literal 0 HcmV?d00001 diff --git a/Covance_UCO3001/browser_profile/Default/Local Storage/leveldb/000195.ldb b/Covance_UCO3001/browser_profile/Default/Local Storage/leveldb/000195.ldb new file mode 100644 index 0000000000000000000000000000000000000000..e4b7d9d56957c740837088b27d8fa2acca864bbb GIT binary patch literal 33885 zcma&O3$!E&c^=l6ojJ^CXYbCw*wM1EI~OFt%-yZ`V}ypSSHG*ftE;>Ef!J2PpSP;I zUfor|+E|Ju64_XeUO|$DFyP5r&cQm8f)hf>S`f)cQm`x~NFfL!$-&36wTd_aovg?C z`>q!4@$nF5YVORf>Av0l*Z=tb@BjY#XQy9ieRoTiX53A$DAN4q(@#f<>&H(;x?v_+ z`jnZRwT>^g4!`bu^uB$5I8*7dX&*gy;Rw0>*gGzL_HX}-&wu2f|H-3Qf9?|(A9(1# zH+=7fqqp7nrpX_E>ZktZ?HAzmr~aGQTzG4X69h?BgA#tsW#-C5k6zy2gnvJM`LRdJ zOOHNu`KfKI^~U?2xbgWv_``qs58+uYvbAx(*cu)sVWFQEc3zz3MUv^R-MVs_yL9<& zt(#5jO6zE|x$nDLnW23~lQvT&GY9rRh`L zw1`szVUbgk)tOTrr4fon44rYDqx&yjfA)6k=shPz5uMybX$GN48pSY_#c!NcdQ{pc zH&2k0_gzQdc4im)Q-4ouwXROTjvlxTX7|KxSBian337o+&3@6`ro%){K&T~JB zdms8_tM$Mm#v|+=eh7sxvx+#2_%!e&o#Rh#oD}{Ud`$f;z3=~M5to1Hapry3kw?nn z>?gkasP*6@ab$XW9NX}|PDDSm%>v#AMOJ?9gI)gqr&_It9vPtp`o;?+OTO`$lgcO? zJqq<_{33rUhy(6x*2()GdwnZ*v7Qy#Po3#-k?nozXLakwW%bJS`&+8qYn@(x@XBM4 zed@a<=c=ijo~^hSj{e%^H(mvsc*VN8=kre|dRchb)0XY%WmG)<)Xt8g(=bkU@zV)d z-nUN8BzAna%=7|2_Q}onoY+Ty=Zc+k#dn>hD1u-VMc+8d>^x2491QxN6F<*OJ3G1g zk-BvW3~}^Ep_m${w! zv6Fo1M_Ug((>l3+{i^HdMfSNbw!Vxf$CjI- zPQgd=GEI}Lu&tAu?>aFP>pFeOw>A&_`=bY2Pu{xPdf*KYTzljJ?5Wm$uWP;g=pt^URL9*FNqf+1Vyd@}n!E#<2cNfAUP+J!gE!6)v^3yd9eo%2 zZ;(yyyRjd;8$EJ2pQUdKuemx^F_OZt)|>6v%sqcxp$GkLXLenec!1nrFC4PXIfZhV`_)FEZWy%118g zMXA3HjFpt>(dD5B*C#7|co4Y%(`lACe#EV=f53a{tmaHJDdXZPJxw`qNx00usY5J$ z?4MpL?D)Z7zjWzLkGcP$b>kPw)}_qWxu5=9Uh6~O*IG|nPyKSMl{?S3sJFDVVe6_5 z!4Mfj>+&15o2_TBA07Ss3tXzdVE=9_U%wN~nYnuWn>W{QYF$aaB>u`sJ3WGj{!Hui z&yA0^9(Yo_1)hQA5G__2fw@lgl#@U3&Vwu8cmDOeu7Bn7Rm*})%)R&GPjd8|9S0s~ zZ*zxTU8-`ZUNg=^q5g_l@2f9{@NZ^I?9&CD(~hMvQxYkl_n z9(dh9eh>9X>q4;mdG4)g=2v=QZ@{1Ld+<`6#2@>yt7fG8XE)DUE&t*_yIMh5-FUxq z^n0!H=+7?r`qA)$y?_6m3qf)H%Ef*$SF;3t?z4_}D&i?6>D z`(}9Gy>CvzH|;F5t<6`y|Gq~acKynZH}~E5@R@Hx8hPOOVMjmnqxykk)W3M?@eRD7 z@A&r7PqROArAcD@D__^Yekn0^`~SZAQ%6@fad~E3{L;gzZx&^C^!&p++kpIa^c`1R zi1dqZxMuiS;aU2{M=l&L{{?IFU9Y*O7aLE{z3cD4eEGt=Z~U?F<_%=RD6(VM);@dm z%jV;8ktKO*n;(1k?<1GLQ~Jt{>9loc@|xe8yyi+~SBd}UU;4e)5#I{0f8gly%|YwV zZ?}Hyw_8`>1vig<_R5$3W$P+byrjH-`|-?%fX<7}ga7!_6}zyrr+)47l_D$cCap!i;E9^_L0^Gz5n;`x#vQvzdyTT=w|rX*Y9g> z{_Dx(mK}kSvwHN&@3@jCQFQdDPf@L-AOE-i;rQQOdf+GSyyxiS?>V}ZCh6adTd({1 z%h!MJL;vFFnrG{lo#n^Bd*AEceSE=8-v8alkKb>d>HAYiKHtkw1cKan@~ng^3Kr2L z|NZ~!{a1`1LDK2YGV*?0paZ-tkY_Ih>o7_KhbI_Q`%3KZ!xs zeiB7)lJrfSc(NnUPTu#v_uY8#?e|XK`QWY39$%=?*Zt`g{uhp~AvDIK7^*+=9I$lT5Bl zdMMAM!6`#JTYYD86K<4}jkY4hz8+a#mp0b9P$6#6RYO}y+8o90)OFuw3^q46yzgh2 zzSs`?F0xSv3Ek;A^r|kUwh&ose!H13knTP>r9^7XtFc{8(`;dp(O^rMQ(<(csH*X)u0}BlC`irRm8kE8;*3j?K!gKtx7uLy9*}njnyVv;9k~A z>8<6Y^lC8*8*h6`#S?U^QK$V{LA8KypXS^3&}mOdtlu8k4|tBuf2CEWIVrQ|58n(Vg&eIWZ`v0L?;c-NeXgZhk2i;;+WQ=?NR9B)kna)Hj+yn_maIa%nr z=o-~r7;Z%JbP%{S!qbHA&ZN#pN$I)Tn}u}7r`2$~*kog*H_W9?n%_-(~k{qex9NOdDK4rLf2F6${ZI&bzy5<%A@*^(=y$I%iRP=x(O~KnP(J z&NIj0W@e?AXJIqw4o(+zIq2B&sf7&1W*#r19lxQBfEFun8^`;~VpK-M=JwER^8IQy z-QvaRYE>+#sU&5i4b9u4jO%ny#OG(bd?}95Q$>n2)}HOSCdUToM(&STYbWTde%IR= zJx^QO^{`wI>!#P`ddXs_%(t;lp043~y!*zHqBF<`t;_DmZ@*^j}8X zkfb2rpF%;7bKN|Y_*by^(c53{1ON>VunyHuC7+0YcjIEPB3r89F}lJx4!q?Ju$7=i03Y zZaxkVF91o#pW|B>>BD!2Y7zePUu#`vo`mntt3vU)_rte8454uHGL-Bc@)nZlD48KS z8k*Rd(jINmg1PvyC#`c_KF|E`O>TbpHLa&FzU>_^gWMUw7z2@N?C+C&ka0~#yluw=mg9y4gK&x@(r5j88#PHlw~u~)36L(yY!&_jsFlG>IC_-Z zH!l9~4{PVOTl$Mn*eGo{G-=Var4xYmEDSEDPC{4X7_?~<7^VZjb5O@7PHtTMUP5@K z9?J*ha{YZ*4j}Q?8(J@x@B!w|I8&h|PAm*rq$E#B%$s z2}K34w4-u7IoqKL!zGACo4wMjDwVTMm*-7-D>b9(!rbSJiM(e_qUgoL08=I+yU2N2 zDRA%^=cRitLBsa5&6hrN&z+b4(}(fWJ^$`guaQ1gzx1Nu>_%}?1opmZtH^fF=x)OF z)tyoH9LC)Xv0Gr1#WtoURlHpJE;q*qo;6@BT=$1s6gP0?{GWK~o*#w|&^BxnGobx5 z4GR3(Kxm3&2#O#rhF}O*KYHSdO<~5ZKe*?)m+pD-{gt7MZDFC4`^+lM|uO*4$-+) zj=Rp*$;(xT-tLud=2Y_NV4VLb>i+l}*Kh5n>6O=*r(y)`|X*0x>&omL2BbL+9ya@dOJE% zh~=2XY((D+?R*URY9QG!z1T~8INnYta=(}{WrsDjv^(!E#L>X6nt>P@6++H%WQ8r} zy{;oAJ#XK`dB5Lj?>a_*JqE1uik153AN(#Z^s-@I@uFu|HC`GxJqcNh6{w-L9c{_o zN|Ei|Oblpuz8|~tjIQUJr!4wOj~Xkst00~$=-PBEM99g& zg4fWx$s#&#S-N8zCPCSjNjv=ic5h2=zIN~Jem0Gb(R77x7jvG?DseB6-n3@N1kHD+ z(Wp$4Z9kd>am9gco{^<}#%7CRv>Z>@fQs~Sig@*GX*xZ*2<=ErbYfqQy!E)fmGpY+ zR10+)Oq3Z@(8%6IPo910o~smt(-?gGyB**!=Vo~yykHx1aD9za^g>xXfw!x;!7@WN z-B-{pIzf4C-Hx@8o1)d!ldExt=F`v*aTMqJj@e00ZhYj$`)?D3&46tg6K8OfrA!pZ z9g79Ng*7SE&?$#R3Ef~Y3q5(=>D9wC)&TzM-AFUTv`?FSY2qnFP)^V6c~CXhz6gZX{?>DjR#7j>5d#+nS6ubv?$H z#F;KwF1Jr?nP1q0C|J9_tX$!|nPNWc@dNYZBj0%KZ4@&s(!p_)0Pip{8~81U(QU`T z835r9ZrLQ^IGBwh^ryj3+|&K0PFCCA%n|kJ*z8OtyiaXHQ5pv;Z10~Lg9*7o7uY^O z_zBx1_u_u*3ND*)4KhvR##=JovF7qz4A;yZyZf!)Q2aI#C9Mo-lkQB!sGi25EKSD! zll3=V`!J3ZIF5V^lf2?6hr~i~iCtTvsC96v!4{1jE{924T2-+a47gcHc!X9J_}W`x z;ll1_f{%oWQyG)0m^=7NK2I!^4TXzlA$m*#a~#955Sw-gi=Ze9$1TIw!Dnm(!%XMX zkXS+|w1S1N@n@5|>`eh^mm8L!Rmg04CN0*2NJ}#dQ_fT+IT*#!cC)oZmmPPyt=YWv z#xf~k+a=k{LoaUf!AueGO0p+&$?3Xz?yQoMNj+oGvuD&a-k!vePl#{R9{CcR*|D-7 zO7RqJjC8LBLu$`+FqrNm*Tdq%_1$^?Wxh;!kJzWcrvlX%l2;0G99}; zE`}WM)#{$?tR^SgOZPksNEX4qm6Jf+ypm*Z=~bzb=ZHjV3 zk*jWQM%{^lb;c{iQ%xIVf!Y;}b}5fnz3ljhPCoSICvHPfV6^2xy`~J4q--0bbW~>$ zoFNIQg|tDj42jVwO<4!4#PfPtv={5TqfHfMnxzsi`h&_-NWxY~Mf7IC{Ky-co}Z^! zTYzqA8A^79EHl%^2YMO|=3y49%x(~eTu&&iqOWSK$cnQt7E2Oo_p&sSF+G%KX>;(B zJ70bDZb$RgM_);!6=Pmh^`4BGB&bRSsF9}j)R*RX*w2#&?Jjvy3Jw~iX)I;ZJO0l2O571Cl3xHQ7Q+QZa^;QG<03vAOxe_5}b_Cw;Dbko3^y>PO%k0!bLlYnqkaRTz4<8 z`K-Ve%0Nq5$W~^jaAO)<#Jicfw8>|`@D~52yLktkf5kx#N!6NEYn%{Db}UiUu*c`U zfG+%j)uW{WTQy_D>rCriU+7SBjSP6-LI^+8Fl3L-Za4_* z&^j1_q)n974c#$N2g9M+AkBj{`duCknZ6sroZ!spyY<*j;Ug`&MaKH`db=V`1M9lk zDl-o*vPHYyoKxq^Hn#I;d##vt$B-fL$$AXcY@5_01o3yC=X2~#4Ab^<;g1nD_H)Wh zYpfHVR~nQ=5r(|;ClB52sQ%=kS6t*4hiIXdhUL2GRiqOYNQa zKm<3i*Il721~wwDW5Me?IMZ>}^7${m={9Sc4ggn^A#5D-2mmt!(;XCJ3DzM@5}|e7 zK%rMME#y3dY`B_8iIgdvxrkvw(~OfrqBg-i z9b_zV4n=4P50*p-+o5!aMJW?zYz%Zl5Hu_l0TXb$&4Q(98a-HpWM>nv7okL)sD#@& zW3c6Fv&v>9H}DyBrBsE}#Zzu1aq__$i(ovpd`%O0VLlq}P+u*#(paK#w1zfzBrgQa zYtL)F>Lqh~lv&$#ccGCZIoL0i917>j8Xzmok`>kJ2qI$+pjQ zS43#cb`uud8^$8MB#2;RT+(=X?)Utn-fMecBoi!|E37c{m+Og&J^%TqZxbZ^MoFKcv$YVh;_aJ1?MaIK9f0NOMaKJGdgVCDNznq-U>`-f83>{Da^3lmbn~u$=^z zpQKaL*ljDqoYv(`8wf_Jtckw6R8n2CDN%Gr-9ER^^E!;Nu~l-x!9T7*0YvUrUf}$5 ze^p^_*=R*{@fkLpuV?%a&AaGURou+Xv#G%f(;}C5DK8aU)gg+4Z3n=zZuz1ox)QfE z^7ivkbPeccY}!D8F(ph)r!mtqEcj{y8qo<0T3||t5HfWPdjSkWZ@4p^JzcC=ZfD4+ zX3vhWXuZUGAuZ#mG20`o(Lc=^%RM>%%sXFvhL&OS=4We0&h`U-=dU}qgYPEe^(qlO zhe!51o8s`Lx5uk=VXd4@TFf$grx#AC(2Kk{_m8{h(&p8R zE3U$NVUKduQ1gh1i*{hjBPYBXxaa|iwcCEjn2q|gwprc`-g`ioJFf9B$R+hY=h4e^Q6&YP`i>`pzXTGt_(oMi|I=L}<3Qfjm zi~dIX<8Qq93{H`(E%x%l#42`*4{3$4=VdKMEgld@W4$T}Bt%qiajCZoKUF~(( zqzNsLt2#P($HRb*01keOnp^!PC_B_#sskan+$NZc@$2mZ64^j-B64fH1EOjAy^$?i zNx$$qD=in6R*1%u&AX5~=Hoo|8u1)~I0&X&xNYkW$szz$jl<*|cM!)hA@UguF=@yw zGy^d95Hj{`D?2t?RD*Qg6`2i9nB~-rmM(r~oyE@1)B|a_!6q z5T>2ku<2<%YV8F`(hXNucd7eM-A^XoN*yIt)l_!J>Fy+Cl|o|*ra2E8K#t7aQV5)X z?p0aDSxIZgH^#ftufjRhxx!2$b+PI%$t^7!1Cr`-eSzjuGh}I5ZcIl@)&3UUui1&u zE_w$T@?L;k42C$+%3&k}*b62dCba%EO)~~Y+T`*7d+#-!Fj0#+N2*+$lRJSIqu3f3 zggP6zSk+(E-ab`3!e+1|?fy#T3vsqMuQDDn?4p{bkL$$7hy5s~wi9>9D`LD`m*aKV zLnfJrmI)&YI)d`}l+FmWOYRy8?XMF_J|NW#6n^~UH}3q=>+g0nfAsoqX4YY7ttDKY zlS?g|EO2$iuA{i?8lj5>%h8aF%6uTWM7$b|#YkySJJX2}xg}NAF6o9^c@E7m7Ke`4 z0#HWLfJ7)DN^CF_;C2)TPR(EmN{6NfH!0%aCJ5)P-Q^xdR#UgAkX1KC#M6iX#~ZTi zPJx;-HgQLs8&A&b%-ra(^3;;+-0Q8zfjLyO@yK!cjxN)ElCD*!%*Bu%AoV2SF_?~I z>+xzVkP6+cIy_7X51AF(arDk7#&~~Gp zNtB^7mGUOGQ(2;6nl3lmey64wLod;|B6Nj3Hwg(Dm4v>ZWh@kBZId)?7%V{7&(M%v z44T0S1~n0uMVW(1mi3sCDkmR~>CXI2MZzhOulxHo5474qHKd+8*KD#QO`1bYnBdf5&kWGD~VDWp(e_&p&;Q z0wNtcio2mRIA6UApe2@C(#)_;DC=kujbx%&r885HdvHk-QyRQNIFXTxRSyPmo&Q#;&sSE3LZ-+1j67G;q;Uw-0l$8%qP;+swq zb1tEbrgo=?(mfTW^&x|`6*)3BFDo5(%LH{CxU>1#tE<>cL%DAx3n^y?I~Mddl>f4m zP`INLHijam4WtNb(+q0awvAIJAVmkIC^~^91*#VHv1r5rLK@*V|6M{QB6+J)R6m> zqlJ`&b;W7a;is8m&nD&QMElyk*JzYvp$+{OprraMQ1T2H?7q&=`UwL~==g_5~ zqx02(;#c+_9g%cD26Bq-R8y;=?GYw5>=0KhcGUwWa&fRqK|r;!q4`G$$7T=&VIb35 ztZuOY*D&MwpNt=;py445-FV>_)Z6^bb(YGIPDz-A=7Ky)Ql>4;CcRK{Yof10+pzLW z0U56kjN+|m#RY2^hFct!7dbPYF6Tjnb%C+yMuXv?(&`$Zbd5(&2ASB|=HA#@^`gbr z%(QfdKl^L+RnX%hmy(mK=Ntn&}~YORAUHQu6k5NVn3D$WEci|weAF7g5eReJ`bLO zg=Nmp=q=XP9<8)Jq?2abcr4qKvs~XV<`DD+LTKJvrdI74IixeB=1e5p%Je2Meg3)yj1q71vkh=`UXTW4Gl zovI{BV4p{zS1g<|$9RJ}%7R9;=IRo$oES z&88d7@~V2skH<)ColUw2()m`RTca(bMhVY%wiL?Jo%S#KBW9^` zUCO5&q0ciYyDs@SU|h-$L|b31PmGlQ+yo-JP#DCg93jD z4GoPUG_50;1zisbnp)B!fqp%w1WY1JhXUuTd?*jGX#ov*du@kFxZmT^#uZd$Le~?s z>&WK}8aGQPf+qLT?NmdiUNBeDKwEdlmWj`s0a|F}0xNuUurPN#!E8q(ybpfwcV`6^ zXJ+>7N8fc7ga$ZqH&6oSUyVx$OU(O-*dLjCt*?8j8pXswYBWiama|Ybkbxm|2g+b* zFnuN?myRK-wPRM(LS}mzvpfXO1puhO?7Y>~L5WP`hK1^1`G1Bs!5T1L2RPv1CZZdJ zjZzQ(Z1IcWC7p7It!5lq&tR@o7pq{Kjn3SB;1Q`k3h`;cH(_Yc+7c8Q2%TgxmANFs z3rn$RHx)|KRJ-uM{BY6Pmicg(=nUh`hi$%D4+uOjhr)V>^o?zs%X3LKPu5?%_X>zM zsBdi&P_(@~!m@?D!_p-0Wo@e2Axk3YU@NZ(XMtm^c0#ol%cQRHK@xkIuj~8Hn#MZH zAi#twu#-?Z1kM!{KKt>f-~PiaLBhb-L=b|;E#TrAibil6NEawIr0(blZhRUhUPPA> zxpKK->Qv2{eVJkX$(U{Hyi9OgO@+dvvgCHUw%yesaC9M9>{gS7s_po|E2qFOc!@Le zXQFtSi_hKS5S48XYtuVQSi01BJmjZCB<=S(b-NDf_GAwO&D896I1=$#(KoTx z>R^@Q-)&z-C|k#l|JQrp%vco0QicW9_gb8JpRvjcf)FMzIqj0D@bZ!vXQt8 zz$N<1a*?%{ow`yWbBm+JkfNu$nDYpYZzp|}kCo17I>|jG6QR3pPmB3^hJ|GW1cZfv zLud!LF^qxaLJ`pEvA`NQ6oS|ondg=xotfSCwxOJ9AB>7Vl29DMd&_t1zr~ zZBQ8-8NFueFco_;dg-2PECKnS!oEc*e(qK1BrIaB&2a!wS7nTj*pBG2d&A4|MaS1= zvwsJA_p4YR4vptwj!5fYAHr+mD9PZM1q_J^OcF+$$NyBg z!5RSDFd$M896!`yZc{j}1;Thi&og+aD@Y64#rTemao8Lw>GpW7?#L-SIxuRtI=;AU z#^y{QV`ZA|rbbuB)X9J+DwyFZJCsTz+hj$fKgDJvslpl-wgPsjOqxC-iLCZx;p4y! zpcKrE?$!yz`Byc=w`2sRlXO|DvbVNu+?vXnDa+ytG>iaqa3Z7z9ftJ=)3i71+52HJ zn6h~nNDNf6M%~?kl80d&YXND7;-qenjtM0ONNAb_x&p`of;J3;#4HD;9s1xSS#QA^ z;<_SdNVscITh}B#NOQ4E_fUUkCA$qlXlmOU`{$!yWwK0T(nJ9^am`v?ILX+kd!3RJ zL3iR1ql!;U65kV%<2o*I8e_+6LVh)gl&-(EBJvP853?vr;Ow0*zUgj9^Tjv4l1py+ zdMzk<*_psl!jJWM=9ENT28qxuNMk?Z0oDRHqzEHnlEM_LGi(R3!w*V33dLpMJ^#bI zy}?2Oc60*+!WHx*Fb4-tz$Ot=H-Td#j(`8zYp7{4HbxxHfAOo2-nKP!!kLS4A9Q%9 z9UV>Ca?n2|wwkYuL|=*Xu=3g~Z_DxLZB90sj`%jtJ4`QfKpu(j7yNdPiIeRv*QOq) z6LjF%?PRd@&DvN7L%U*xY%Utm=jN#D<9`dHmo* zd!W)x#s*4FXGsi&ah8tRG;JFwXxvbTIF>K{B6P!ZcQQG1>v+-$C%v2|IF9xD>3r7n zCPs{QLV2?cWS`w|1LP1qT3Q1vjTYFlgD(n(iW_s@>`Fr@_bG>lro zdv-pSB0Q%ns5Hl69Qx%a&R%NWm751*?bY;rZ`B^)%Ux4d-b#|zeyZ}&$aL6Ix^IJV zf;^IT!|}kj8=OnK6H4h(9WFC91z$~UOYEO~1lVWEkhN|NY|nCxWM7|UZ0Xr&x#lZLSPSf z5?NY^(Y`$2P2Hu`_VbWovZxl&)!vcwq26p^Tpzb#PYYp(Qw)V}q8$gd66_kR(tbg` zz>*JoKMC5JkG|_}NAuBleKT;vWshl7?P(y>s_B`*uruKV$Z{*U&cx-c&yLmhL=hOj zt1Quxyeel?K3HPe7v}Wrt{Dc;mCT$9` z;K_|&fox)$>vVWFh*ljEnT!IUkx$ijDJ2~q@`oD*_L-HhmHtE-ABeSELznDu`ee<@ z5@k+pxnFiW17fdhbKKFAHSUduovM%J(Rvs2+In63Q){7SzQwHReP@~P=ylU8W;+k8uYxtD>+V5?^CTzrA4R z(tbRvrYPH038F_Zc`nasX}Q`rV8wWHz$9@y~4{ zgaok_V>nQfZO1|xs6jTW17QGaTHw?eZnSi;iPntpi8`Kf#pYRB20+EJ^cH@Z4Z0VkGA_MYPT)wVp+CHR}hvE?WtR8Vx|& zU~~eBo)m+Hf1>@#LqH7t|Cbuj=-mqE7Fy)_wBJ!_Ox|nWVm^lM(;D}&wJjT!MU)KN zA5S#f8G!5(p@Y?|Pb9_IHXBrRKK?iUx(AsP#+`;VU+u+3S);I>TdNBWN5%> zfhgyFZSI&;b=8|^^FU%jEe!(p21#fiup;Ui<~pB|`JULXP_(DQd@DC6OjxC!rL|Am zFWvKI;Is%7_yGd{_R7sO+)hGkWng9*B$EkfkwJx(>zRzt2U}_#aaqByi@E2|n4vj> zv2IPn4sE|DMr$!{=&XAlJ|JR-4N?Nk0X!oM4KFk~4hYl$Akj8P!>H@P#v0HlQwLz8 z&dZ2L)uPnc%(OP6dgCr6O>LS~5=U`K^~b{~pwzSB>O6ev%;1x)!LmNy+pT26SPb+^ z?@9Z1zh7#*t(bIOYo{b$!NxG$!}-vhS8P7t0aRkO=)r&c{LRllt-tgzT&RPB;`2}6 z?Pxy#^f%Lrgzrd?B}Y?O_N4}(?!r4Y=ZA+;jV=&(?1p#A_c0K2oK4nWSq4Ui<6p96GPx2d!3bhY95 z4jM*6ZjAy-4Ne_lSfkM-BN(ObPlkdL5xYZz9g(BP-0k|Eg*js zb$NBv6@qQB_35n5X8Rt7%(b1#^bMU8+vD-*H*ouh6ShtVBTK%rNN6OTJHJTQs+-W4830Ia>HsIF#*TQ zsTH>bb-K+*n-sA^0(M70TCYe0%CQ5$amy|s7!I;@&Q9ti9n)4b6p~~tBU(AKrd)`N zilL};q>W<+l~Y4GS!4dox@c_nkMx(Wk^r=cJGU2iJD$6}Xelpq1-Iz-DnX}~v6Lpd zUw}p(76BZzGak`$?9YepqTgXWvvJD{*X`Wjs4k)wwrFFjM4!cEJwWEGG~NU( zzfAd+KgIAxn@mBN0`d*J$8Te4Fe- z9>GF0(ETb)*}{XlbURz(R8F?V2&dQ1^PlW|<)Id)-#M9iIe`{JA4ThSw>$0XFMzn@WS zRO4dPNzjNJ>m}}u^WymL{-75IQW4P;pU#&+I_5*gZ$vTe?*uA%_N$M6+j70Vf;FHK zqC~St#>uz}s>+;!SVO2WzTab62RcoBxs9kLxPn{-UOzKnKuIw2GPkiRI|1qYhk*@2 z5g2r$pkD-49OO-9>jWANnpvzJ3siIyB*CBzUMD1&G!#twIefjZiEpl%A#LP z3ce#U+Wh#7&JVZ4U>ep))nV{#Fsx?&ii0AgNL!|iqjVJyhtkKt{KPv@P=NzG19BV7 zp&X1n);~C*DH_wE=8&WbIvf~wQ4Gy|4q`>v_{K)+k!_->^K~`prE4dS+3m25!8HC%Z{(88bhliZ{*vxTv#g+d&;MBX3^<1ka0Kq(K%p40&cyLAy>kNP1$+wu zd}8U0Zi0RuV@)VBx4SzN&k8oQrDnMl#?zjID%2davRQpnS{g}#dASF-^Yi3k6< z!a{MmTXO^FU)A5-LX+9t+~v}&jP&WiN9_?5;Ckk4f1{ z2a9x$z{)n#hUE}*vWmwcX{bBsew8kt4t!q@^c@K#hCj%AlI%^p&qx0y0;&l@$DwX8 zFt|GYzwT{0$NzA1m{fp(0tG(6r0nB+uU*1)^o37$Zs#7;Xdu216$i1GrwO_#`csK( z_Ju%=G@2JNbnS$;-wn^Z8nd_ci2!$DrB0B7!qNNtBH3on04eolv&Xq5Y^K337)JU# z$7uL*ml}>El!vV#=!OT?xp#b9y7*gGBzwzhkdJ9o5KY`K_^t)plz3f=@_a8VKGR7( zSl+=RSbz@bQHt&D9?ll73<`y1@A>qD0L@|afS@)63I)D%-2MkkSd?HK8|3c>z%YWL zEF1(Glzw2&V9%l~nsiz--R|n_6z5q-Q#B#83U1?W#_iaSqdnuMc;fWsgMZv&33Q~4 zW!Qg=lVQ2ixW&qf9msU30R%;pHu1=!wsP5BG#cG85P_?Ro{Vb|tZ5BcY4n5dc`I~y zur~+F2?o2H5**IIS`1#4ov`kW+GUr(Ntd7696-H7s&q-IW7(L9+-?F(l9f<|4(4V}P2@r#~lci}00zc}8mZ z{+h`GVQNU-B{z+fD8cJf^xQ2q?3<) z`3VH(f{-E%U=blIj+rNK7$%Iv8OF9qggX8;;Ypm*VYG*l#$ke$niKXzTGqVq;l@s8;_P@6hIim4v6 zmeFuUXah#jQnOf~ORY9%XxLjLrF*VP1FuED1vY)|RgAL$^Hf}%xNKl0RJWJykcd;o$*fNL%sPtSYtM4#;#gbQf^y1?u%;SLf7 zhK$Yim!D{n;2(F#AFr0ivlX#2CUt)+bP;Y647-HEQ!+6vdRwGq-H}(BW6%#y3#OmV z%o0=kku+WyTQ9WQFgpOG{{5ha2e*J(1Wp@p(=7(}C|C+kQOCdk=p`WXj^FkN57SV9 zE#rmTi`#>6UXUK_5XbDi$E0+3X7ncWc6KTd)YRqp;hJ5dS{)7Y^T}1#?b9&5;iD=U zOZ`+xa(BkCp}d_}qxN>HG$3E^){Zu%dkVT+@H@rBMzcgyi|IhD{PnMX&ovT*b$1s3 z7U|=!^v@UY{P>R_`>McVzNtcsN$(kI68CXSLDtLRj<50|-m9#vWVeWt#>0x*HbvK} z7K&k1dbQNfwZ52v!@@i)`2zBQ?%x7IC!|#P0@`N>G)J&)kD(yIBAD~ZRi9Dq>AWl9 z`aW{DEQPH)eTKsMenz?pUD9Vlz70sWY3~nA;w`zb*5RBH>C7DU1;kfEKNf-L@P?^H zg=~imY-@#1#3Zg)$}npi;k@hbb+o<+c&XEo=+?Tsp9Hg`y%-KEg{9%ds$JNIX*eaPV)-0Q$oofB@-+B8D z;Drd-28XpY3}jW~OB7`sf8n9y-+L4YGuUDz2@22&$T^)CKqet-x^=d$M`boH`a?Dr?yi}yc_!Da{aw(tFcyB*DYf8dpjdP^T!^Sl5l zfHI={DH$+yy2?BI(w*DUN?CSbLj_%Aq8V}M3?Iv`FIlV9*&$Ni>la)JI~$5usHfkmKNkmk`E0{^AoNg|i6Ybp&q7fMEbR80v-JdHZeTRO-S+-6yC;m@2~x zkCeSXaL1b@UrmjbN5mnD2Ya0c(h;~-JY`4axZc8UC;|6m0O<-UO&HANGI1Zn?P`j3 zg-&N_Hmcw<&GZ$jw97@gTh8}%C5~$RB!F==dgqr0cRQM28hq0p8OaRuAv%r3kXNf9 z6V|RUO$9z#3GBpbPqh)*4#pvYSKFjN+*ha(+lw(c6b6%`-QxJ6pZpLA^5HHh3~3zy zWO&KZ?c>w`@%usOYy(izX^?eN2vi#fHjZe3tuK7$ows`(eHqJ>$zm6^fuiPle!n7z zSsaej$ZCV88kACJr(K^rJ?GxHH7rrhmmN_2<~RzsGpazF!~-w8LI(J1Xc+3@o+h=~ zR)SGq3ucs@bGchG4z^!{3QRa(8DMd^tswR74J2+=Wg?(3`etCr?xc;$I6;Q7XZ0Kl9PusMu@ywRu2~Pkc^{R!R!T}vLdYiZ=!fY?d@z2 zVD-Sh8&IV4{r}hAw@1lQUUybCH9L(oYK@wa7>xvK4HD8w8m0PG-93nj`u&)GKWAEK zL{)dybXE6sbyvR|FcQaL?UWM{Z$XNB|{YAtk3Qr*16ItjcQs|-+bTw?sxC~{eGsDrD0Xt4pVK(zLE?t z$D__t%N5I8t*w+PA$kG~s3}~_{%AUq>lBeCXxbwoy6zO-1(XP{U-hF8=9qjxlM4$@ zxA!<)KqI13)_iJVgUW?mB4qN0i^=~!fY3#ya2XQ1@J}AUl+nfcp&4EFjTl{K9WvEz z?ET#2ko$7~zxzOHm!De5e;K*Uzj|0Vh+$No7AE>#T+5i_4j))SDyA^4a+rKDGmJ`G!*6iIs3eWEAcjG| ztF0iIie_|a+0|4MlEh{~Mf{;*nZ+pqd2B$=1$?Ob&6o1Ss02DHLCnwo@ycs1Jd7`f zE5$Wep$ph(jtMm5#d$8z^MyYR&u-?NpEObUUqk~DpFv@o{G|3BH?4P^>TII{WF@65e1QYd@v)h zVrYv>K{O&jQg3~arE>POcU{5uCP6ebyYSs(MC)r$zO7Noh29@e;Hl-)(a&xdZ*n4zK-^;k`Uh4`JG< zBe+8$5d=ccPQBif7`|*zBb>^h1~Xf(w|ZoljO}*+;n`t?r$d55Y#7h&^NGBNeMAAi`C!^^~8SJEO?n} zDHLhjaCk5x)JpfO?MkSY>en5zN6xLp>V2!Ev;`*h?zp+oF9hZWfWHR+^Z~zp5dt8U zt;9?LAze>~%gE%ZNw;pkin25l4M(dbG?jZ$4nt)f6i1DKkM?Gkd+~mhGpAP+_mX*S z*l1VaIE%#$@B;<}2RJimGf-RM06GIFf>l6EFK~+hvzjbsH35_o=~SQ;;RBs+kFy8Y zC0E;*T+W8lZckjU%zM~)Lr8{E>j(^)5z;AhE*WqN3Az%Dw;SfPSaRD_CPuWn+ZNCj z&?{`9mNTu1VF&8CevuQiQYfyl;kwo7#abrQ2hT{P`1i@}+1oTgV zWd(s2=Rj4^hD1780kF={0s;uD$;NIVn}abtYRilk&urT`FLUkAS~_WOaRAZ8Ipe(9 zJ|AB%%x8m=Wr$pD`D{Udv&sad9_LzenM7x=(5hHVo@`%fnfuKs4FTL;$Q&ymKby$Ae7Wv0P3ZN-i~fkW zh?z*&0ttJ736&$xKJu=m&}RJElO%A>_oUk*yc2%a)~H z-NG$fy^=ds$*?gG?=3Utn5S;DR+V5@5E9{5y-FLqktMlVs0^ow{rxjz^p*EU1LxY8 zc3oIhYQ?Y@^igy+TdSok-W9>`wiJ!&0?J;Ing{W@G0wAYOG)etDU{W##$qaztad7` zeyZ81>dqL>zO?HhP=fPFP2!+6MD!Zb_kc_)D*PbbM3*Mk5sol`)mYy}^)?FWb+2{B z=Qa5SkzO{1>b6cQWMsRnFWQf%3P~wf3tGKEE~(3g7t(Epj`)4Om0U-(8Uucd6trPe zv?P1WS+|_=32jd+(hrylsQyR$RY$DHXHzzbH7*xwMQ}EOC;`H@6G;pk<}UQ0dZ>Dxozh;Qg%k(>gL6>T(s$c?yCtAJ#yVTypxP>Z+^8H>gO{HtIF zITHG)5T2k6flgVo9UF83NkmYL&?soq$SGr7XmcR3;`XPcLfmca&X}0klmpYJ1FaRuKDHdf8hqg&9{b8>x%kkjOieF)%n$Wu1OoBVnQO+0GY|XOV;)GZMCnh*YK3ws3 zmog}lY%Cn4=qw*@;T(5H+)k&zmhPlhV&O*LoK8lHmQ2mPl$XU~%-%?*ByZVG^IdzR z9PcZf16WFPzG$lot(9~-;ZygVkK;g(u4N!H)utd07!g!(0S8C#KW)MOYXi7Sw|Qa$ zThDM0j#T6I!kSdixoCt_OBOe}ggha1zFI6!6NrVxc-oAD*m(N0fE1ck8A ziE~)IBXkqta5D&E1lpg9(S=OIltU8J%mjxiAt+6tyX`Vlqa>QfiYHU3f=eMUWyLVitu-_6t{aDgVh0020jM&D z#o62e1UP8m0F$AMRu=m)8WC*($pcM9(?c(^4pJrB%apoVn@=dFGG?=wYh~DI%30}G zs#eiylw#IKFh1{A!;;02kp|v8FZB~Ektov=g*+YfGmaGRwc|(|U{!DLnYf&`jFXi_wy z>lj}_0u8+Y$S^z95(QYWZNn``%39_H!I)on^ZBedQ_AwOd0_rZr<8WT;Le%?CMCrO z!X*JvN4VA+)0fN9a?j}U`eN9y%K!klKo%fc%07gD&Q28^HgR9lMK1;TaHE!WmDlnn zuafo45@YhDXQTgf8~_03GRztm0{}o-p2;R1wyv=l@-0V1z{O~{q=+F(L5=r2=1HcStw--SnVFGHE!**QI z{p7$TNWN_JlP~T1o*=T0ba1`VrMqdj-Av2NZHptq`j)z;Xk;Fg$hI|WBhhbn!yV)i ze#Sv9z4g)W{M(OfE-Vse;-6ulzC`ck=)3AOv-J&48qye8C&(fs0XUgeiXOJflKaNS z_TLLuY5<%{ysG!|9<8xTsoa!7HsUMKE}%kfGacD})yLgPN+IEdAGTV?H$^-iaNwGe z9vIR!quT(I2!?w@NdGkWsv!~*%lw^V@%Lo^E=m8n0tOH+Z&NLJ)KW1k@QZ~w#; zlqnz?KyC+}{)t=eY7*NXva4Lt*jG?3z!}YE8T(oQ8XL_hG!TY~G!xoy91Qs&)#4Vc zMA7U(8$0%TBq^$G$PkEYs+vVgZ1P*OyUlPZjK#(>=jHCp^kg z=ic$~5_Cd};P&U+!^|3_F_a#8iZYqEZzZBvnhe<1*H}elXUCq{f7fJI6^@zfPE=c! z%EC_Kh=*?!6mcl%F}uZZ_BY5$HGR6K5@VzP+zA5gL4$-b4U%GP3u)5$&AA5Q;2Pv{ zLqNe$$c81kUut2j)7XH+e+hNN6n#I+XRXI|4# z472!}W-?WSFwNi<&4#`CipKkj`u#?wPTqgh(X-Si4^HEKy^w#{Tie$#xLbvmf>+ph zxQ#zQ+aL+c>Nm!`FHz`@d`YwHLn7~}A!JCjASHu#6@&k1@u>6Ypi7SIfiAfqjDPu= zx$cYiXU}Vnh4@CRVelR`M2;HbyuuD%(~RsMJf_;DXUdzW z#sgq;5&1^H%o<#x#FphwqpW*t;?T?%txhP>5!5lG?C0 zPf~ZD)SAJWc9PPYHVIAA5RzGp0u**!S&Fdwo*tV}nyoeclbf&o)K!C*^&9rg%lZk> z1zS1y_+DB1`WTTqlbMWTBFM}SG^kq1t}IIK5$SesNm=#p%6uf^OIGJVKo;M#K`!SMcAk#kC&W zFr=Co-&O@0B@54u4Q?k#CfrVH;Zs(fS9>o|XhON2Oviv>6x3lb{^XNB*IRY=t= z5|e{l$&szzO6p$IQzlFP`7tWxJyQ`hlSlAos;Gz|+-f$M*EN)hc9p5gREIC}gCjE= z_U4fp{gIgoBkGW=;qm=)^()$gORR(^M0bxYjD{8$56C2CvakN#Rw}jRe4+Z7HqIff zY>3Duc72^K8d4>(+F_N&JViO|i<$8$P#(0|@*q3DVQ*%~-^glBR(kcZX)2xEdz)~A zI^u>5jMz6g%VoB=;Mhc&jIM__Po`T+nIC+4dSnnJG70Bq=W4<^{cdNYg7K^xbf4c& zHD@!==>K+hP$Nes)kxiM>P>I%zV^S*?ypJHTaHBd5;S=XZm2GmFMgv3Ws>{po;g|g zp56oR3I!sAhi@z5I-aM%o;f<>n;N{V8QDi()^M{kb8X?RJ+vW$mA-Cp<1td~;x#ja z95u3Pj^e&JJ*NnRtw;Q=NR0b(LgD(iXnwh?qQDJ|6c}=YDf0qqgw9Ad+eg zv;Y;&tbS{3$J<+lA82Sps=~J6j65w)topt+J2<~}WZe0!`&+B`?3!x{_ieT$(Rwa6 za5r`qg-5#A1~zacNYt{Lo_8JVJapgY-GHZBtY+F8qHS7U;RZWrHtfxvGc!A9 zC>!cp`{r&Dj&AZ~D{N6*7Zrm?tcY0hjq<{8?Hb%hj_eb+Vc@pU-6q&J8N85gGNj>s z7Jj_v;&J;F#_h$~J1fG+uAL64a(`u3x44N=24!kw&y*?dOZK_GkQtwdh>E1Ye#_oF zpiVThXKo?6o%49AM>oI9YQt=EAW5twnPcvKva=r^&fTa_>OieA{S+a zT?{P@-qwtads}m7nY-qyGiB)udne#cntIkYX#js(W3W6vvImyO_cj4UnrljH6y+@5 zeX|xZ=)$kvIC4$65MD;Gg5C9FQ#-zA7dBm``$yB1!W-gp)%A*1cY4drmK`&nUnJs# z!#9rX(BT_b&rM^3O9ymc)k09}$QEddRTn-oHBiWrwH1=va@~GK`s=Zo`5UL)SS?L< z6yo9H(N{FO|K&@5blY4@LMWALHFS4un{rmxd9k>7Xw%>XH8SM{Mc7uqq=p-JY@2je z;6u*bq(8gs-#@0?PLEtTE~+)`HV*Fj?fNMAmZm1)LmK*12MmU#4%@(v?U|X+nJ`;# z2#rj*A%qz-dEH!3cvUlL@GC5*duVA|L^M-wam-f^4<1<>8TZK21Sla*tAD25@mI?d zIXRi-8+=7~K|jG(*#6*&<&i!3#IhE*a(})HKLF3T?x|@lsIpxD^&kqH51$wr_wb1c z97r6>4}KPFYy=&?a~j>Q$m&yLJ9b5c$EFX0A)(5bG2;-rAD+?OyyXo)5#900Rl+^E zCNeVSnh0Ui-*j{KzRkLyBqig_v|B8c0N5FH5+nP|PJ+9`Iaeoa!uP$FFeD!_HJ5Ot zQu;mLe^?sq+cYv^-zK=pE6jL_8^`Ubes3MIq{!kqdX9>5@x{@+TS8* z=~c}XLg-eZtbgc)R%|sEI_%(gH;;__-OUKl5GW1y%r&HK*I4q1xteUDZ-|R>QyFaD zGP1Lq5wwDQ>N9J?ua8SN9->M7sHvSZFsU{_2%EI}r`@F>#PShA2esOBkV4WP9uugJ24(wl-{$k96Q(J?@Jr$f9TKrRA1?as9p1(v4HQ5uP>- z8HHQ?ySc$V(<8g%o@ojkpSP>)=ea$)@5}hSF!cL$-DTz}{m60R;;tTvl+x;lB0okwx;5gbWzn6|DKDE;$$qynY;-xJe4xCHE*y2%?CE@-eY&+Qo* zcW#ds_j8*L!Rwsgs{1!v2vK*>!O11I3<46rf6yUErgTW|jpY6gK?|6x9=@r&Vc%{R z&S$+L_FSKiZafFmCXc8ZPuS%O5WkAg+;UpGZ+2mD_VnXtPw%{w@aaE(8b?Ncy`jJR z^lqd*hO)2Qeh+d>vqjD=S6b_;?A^8hse&iDPucd@lUY@qmRxilK6A|*RIo_S9(wfj z*zQS4u@+gK;WT+o^w)_U2hQyL93d{gbDC(Aw`CtZqlM_H?sJD+IfANDEME=8gWc#Uo&IwF;C(#|(UI(99XD^Eww9eDU zdHtCQa;MgdN$`a`rlC$aPc!rSl%7yXhZb^Md!Hn)yE3@%qV!Ykz~BGjqX#Y|39Igs z?9)b4X+!9k`~Y=a^7?l*&xUfqNalcE&d#WExdmmnV}@g@X6{g`c&M5?-?;Kx zE%`b%hCgqa-PTeSCLy=mA$~#m-20{=9on2-An&c%KzC|I_slPT`0flbU)de{vZ+EZ=QH*&(GH`FNq$90pKOI%Yz%SBP4i-I=n>e>rXv1`pZ|} zy8n;=fxMSEc*P|FX+cf675Iw;d5h#b@4Q25ridS2O*qH;M~UX;C3;D6`ux@J{3%IX z#{`L~jYlMJpFq`geVa1<9VVCu2*aB{A^&2ExRSbgn{(oi@6s%i&G1n? sVF$k-z;E?w)psDbpS?nP`!0?4^v5(0sglB%`<460)4#E=<^P-i19_$Da{vGU literal 0 HcmV?d00001 diff --git a/Covance_UCO3001/browser_profile/Default/Local Storage/leveldb/000198.ldb b/Covance_UCO3001/browser_profile/Default/Local Storage/leveldb/000198.ldb new file mode 100644 index 0000000000000000000000000000000000000000..20fa3eb3561f619424ef23667775e1c78e52a201 GIT binary patch literal 26953 zcmbTedyFjkbslzCOM**~94@u%EI~@ZOJn@~NNx+AsaB zU;F)UKKJy`fBD@XdgcQ^@FVYf;^7BA_VhpeAAj>tKKI1OKK#%ANEmWqE}i7sf1TPNPU{wA3jkkr)|-V7R$ynoDhU*etOq_v7Q1Ur?PeQcHS&{nBTy zL$8g5I)b<1^-CyCvnYZw6hSk{3)k>vKlBQ6`K+XAx~RT>>Dqty6XuJh*R@CN#W0G! zE^n`2xbEt_`5!*{;EC1umvu5lyE=chfAIbnd-TP>^4FjE=?^ziofL8T)!Bm&z4ZO? z>1~-s#aHz{bxI>?i#XczF!T_dH3 zk~PwxS%BT?v-JsWnRoxjN5iC!f_7IYKT^K*pMTGT7vKF?KiO1e(M0B0MexspGJN9K zzR(0^6*bo{{pdCPStKERsp!s2a`>~V%Q(rS>%aNJb<=_&u3!4!zW6zQ-j-}8$+{QOPSIY(`6n>#^_QjWwIEloR6Yn$#UFk=@W5V=ANmHr+g|? zdiKPB;3S8ltRn;d@Y=41FA;lr6TR^6fA*{e#)%W@Uwt7$X+NgPkfuYApfD`N;N|m3 zn!sb94k7}>Je(n7G>(Yt7vB9NgmCooJSq;68nwsrU;l~s8yHDF{DB9rjqpS7;(ZnE zZ{#SI4;7MEl<9?`LEq%Dxn}D#F3xBfl~`^#1=l|TW{zWn<4N<3mJC-SAssBbW8WKG z6dZUypik1Y-rB*?*qS;p0nsjsRf_4F$l49B>Mi~qSF&Dz@?H1~Z@m8G<4*nhlVDuw zi{tCB3GsPdlx-Rf)676lJH|VdjAESqZV@wwK`0I_rrD>0()z-2lLNQIm&b6)gt(Wi zth|`urAz+)>rZ|bqp`@30?a3HCh#e6VIQF>k|8L93>ktUSnrAF-ycz!|L~tb`O520 zzBcy0C(Z=hBfA@laYNDa)jlfY9d#$jH~Rv+S(;INgNt{@x2?lamE{f{Vdb-(Fp>VHI@Dth#Sj5A_(2FBKAgCw|=$QZS-uFPA{_K5^lzLnE z>#d8Q>>bb6y*LQuaXYdbg68MjeBG7hNy)Xe=(&qgRB5Q$+HTj*X1kx$zPG86<7hfT zyinUL%Ei(nhHib_Z)PXS8&7d>8{1UVO{S%hAwaJ`{rZznQw&aH@4zfS0bg*2#kjY} zDcaWeae6%W+|sF0%S&|hglZ^{?PrCRaa*+C9@TzRqs=x;G91M@B@X2B`i0NE_Q6L4 z5iwv}CcqgyV5tDb@i=5Llwku3^*t&kQNr^XEJUyWwVS6e|6)&0)_7i9K~^c`K9k-3 zF+5})szK+$nkwRvE3u?C!o{Mtj^jwz$^6Wr zqiY^UtVH@`U_>Pz*wm4QZ9i_P=IY;iM)~G55Af*q2lU(6Wdcw7_VqCdb{E&=s zJRrb70xY6XDrUSW_Hl;B*ccBZl89q0LJ|5);3a z)WwG6&R=TeEox&!bMX{*K@Q?@ItT~0Q@9 zln!WF6Z3IfWU8cXltWM$m@THo$s+*R*m3Kc=NqFJ~<0fEJ_ABRXp$3#d_6ouoV zA9>(4k&j_P{3VDfS)7Hboml*xHg=2csH5F2%bPu7I(L%27erbzLrlLj^zveq*gBj0 znC|4m_B66hcigC?gq<96(PYPBYL=!h;Jp-SJ1L$YnkIJ3j;W6RauJ!-wm4lE5JQP~ zXphFh%&5@!E2-F`lV1(qBBldIr6R@Z6L;3CQ9mrp&3q~Fy}OdK(eAxnIxgm3BPQMI z-W~)_;|#?FEWwa5hI(*~LMDs?1S9Dv#KA-%+#HgH;Cr!0z=u^Q=T2Kx-fEjQhl*y; zd7i4W&Mi|est~`!i_~Dp-NhbxOJ`eTKnUIuX2;&zIO1t$nYmS;2WmZpII~F8qe?h< zH#_fGMvi8icE$0>(HKbC)vm4ApL~{JX#{&aCxLtOW|)2G^_@kM!(@5B6FN&p_KdF9 z6QUafQJpB#oi{-~*L+OgxX956B8>GtM(}5yx^Wlv)!)AU#jijA2rdOihcV=6$`42? ziZIGUJqE!Ul7KWw`xMKN7>&|Yc(F>c8=ZD$??>6%>iV{>BwkFG{ZS{0NGEmiXhvbD z-qQ5$KFCJGaW``^DasM24i5OztJ38zt22W+FN=&@2wm7JhQ*4kXl8}jk;rUOSGkIL znPgVe#Y^7!#&eH5(>I>GHwT2*hsb%N+6^xn-a^HK&CFB1dc_c}LvGG^x3(Nn^aNXS zHft}Xxq90qjj51IIp3Za0=xVCH=lV#vv5ZV0+KBqv$4mb5ru>pi!r{3Kx}0wKO!Om z^-26b3$GU%o(2uIQ|=T;>y!L8+*CKt7~!nah5-@?v_R`*x62k64{;NcUGNUAN9$=_ zn;lKq{CX~N!;y)IY|2&rU`g1_*b&@(oX=VzR@W+4FJeGmOFd@pJ%mIsoTlIS)_Wdz zrf)Qs4r-eSt z_WRjpHQ!!;4uYjm6W};_fRRBQQV315IOatxMxi(Y@in4Z4~@Nm4sr70ASy)#xfTj8 zd7P;h9&|dYESPv2>sYzF<+&y4?C9HLJ5Mt(%0nTp3GZa#n@tc&`}r1g0S4N$GM`oj zOL6l--Sc&e+4|C|Scq1E+#U)Vvx~DCI1%~jKm2&|`s2IwWvLWD?a3qzKkR~wyeemkf#IHX%PVmyTQ zaX&`bnD)R3Bpslv=X6vW#*<41 zJ~ltpZXH})Aqy2wKgv9hqrx_!Io$vAKIl9D2Iy%wVJB(-*8 z2r|(k!Xb_Jb73x~5hCsj;i$woBOi?J)j$5&BQ^+Pz^nm7L^#9|fM!1C#VE!SY)k|s zLVKQ%LV*;7$bAI4jJWLCL03Ub^!2C#L~uHEXBG3PD}J24P%^620s+LdCK!^TMBBwY(xx8r)g6zOJhoR z)v{)ZdniJ~^PjiyS42(jX4< z9fLXUty`NUw@et+)%!M{;}y4-IQ8NncDmVyiDe1Auv@RrXkv6HX(Q1%IzsKbR&4=0 z&UT~MFUnoCuEW!QZd>G9O$SGBAaP#r0kmQ?0oBbPe*AG~`ooXEX_JTex;oL48YRr! zB{JVUYb?08pC`N|h+tz}vUqiuERuE{tf5H`C06cqRxlH1uNl~@UwiQpLBekYC6I{3 zW7a1EHiYuVLn#6QoQj}OI)@}q`51MNLq^h4z}4GvcAB4$ks_KJxt$8S$byVC3D4Ot zEtdC8QNPc-Zm=zoh&r)OXoV6n*-hx}cJy|)5v}Z?FO$tCIqT=h_v)RRndd%E&!s8~ z4d?L4inQ+i;}7sR9&@HYz~8jR%QJr;uknP+sr^#Y_MH-q$61s5$|&k=h2>jrf}gL$ zd(_z!R!kTto7(Y9A2XVhq}tiNe^6kEI0)I01|$zi)sNW_OcLNEJO)?>ScJj-h{OWw z;vdqDi$p75pYK}88}XtKBr-TrD;d{SwnG$ZM;;?rU)800eNQL{N3T37qC_!X&lPTHnlUS|P1tei#XsH;2@rW)dV%M!{CS3X z7@<8e$4zXt+nf9fZRY67&<}Oc)LWkwwr!)HD_&|(MohFVJ4@9{Kk@BCJV>15H?vnE z>H1L5M6{2PKnMhwM`J>?>dp`j)%%*c;nrxwEg{1dAxg z^1XvCGFrt^-y9IuS8nPlJX~LW`BSgGOsgb{CH0tV^Clf4|p_*vWR-BLKlJTjak zio>1bfcKRhx^XSpW*wcqHtuxVZrXeQczi6K-Wp34h85;(mo?g8D1&h-5B;bgboQ7n zsMyG?BcUBoxk*~JF8s1$?|qe5bB%Q;ze<+kmIga&u=Zx6;4( z)@v{06v;;7qGHCxMFX=t1oS$)2gb4VVLfi@pQ!vf_l>y|)JT8R5^H<&yMPgUl zGl{=BcS)b^AkVcynH#pNIOK^I{Uu2)I7OhjD#%z`Ri_}fDnmJ;!=BX=)?Qp-$d3c$ zVlX6zQVt^-z+N#z2T=UeG|l)J8If22*ZV%~5dj)9_ehm18uBdgVqS!smN3la0qYfa zJPws13%AQN87Z#8x1wp^XPG0hnxj_eZN@UfS4v(`C+%?Nb+I__yUjjZAXa4+G;j&!VAvvFh1 z?(<@P@UsJwI_njecg<2b5QV$kh`B!7%3Dpy4;|Hy2l9|v-90qJSR5+e5I`A40}`Qt zDv7{MfZI_V=ro@tC=ZGnJfMh+n;_hAe{cpAakq!IN8EXah&MR_j<;g>a*GBkrXAMY zq0sL0%+8ltbsMTv}8Zo1n$f%V(R@iyH-?$rr)aiLI z^Qw98CQy!}Z+v0%xbw;vHs3XgPoRmG?1Va5sf&16HdK3r4#PB@r&=!cmA;jlsfa37 zqQg2;Cu=wx6~@pGTJ(gcllLYeA)=B{_p?lhqHGk9egypksQMWiqKi*6IKiL+!m=oH zF^My77^#n&)rOXLcLtJeiDs`1dmf0jrQu5pV`oLAENRoFxO-R{6ko3iRX}~k${1+QPtF`CA!a%173&>8{k0cAOaXfi6~*Jw89eXb z0?^9P=xAm&BlLZ4=WCT{?Z!p~(cznvZ7Y*FAJq~!D@WH$%{DW7jvwL6=XS};gF+wg zZ34y!Vk!vnfT7^dcoZA3SmXs>0EwA_>Ix%6%BM)+*)BFYMyJ`9>NdR2F7Ec)QqJ*w zh7RtsVEn9T1}R>RkhfR!^#!gzw7XzN$-SI6#w_YqEK`OX+bv`7G?mD*oh>kPcOW3c zZ>XeRIcah@8mF#`vh&;(h1~zvd*08YEb_+JpMTtWQ{t7UJEBS7g9&*K^*aeQiyo7i3C_9>{X%EUkYd-T%`LLuba+?!Ya z{N6lV&W?wjC7=C+y;%joj168Ox$9o2k!Zn=9lZW0c}sVdvzg7?86E{@AfbV5=j?Qx z4p;xq^Z))Agh*g$J(d`rBm4Wyvkb91KKl!M9}Z}54G>PI({yCn zg<3b>VDI44w+LY!_bTPiOmaonNGtQnXo*Y}8lV39^FRhXrqF}uZ>{wl+i8NsuG{9> z7?2ylzb8L)%S4(JS|V}BnXSeLgXpsPDkpM>WXGCI3%nXEhqa}gyI}ce5qSM^;_82T zCWJl~+!oveAc8W0=Yc(=;iEJXUVQ_9K!5cQ@JGhN0gHPswFFSBqz!AezNu`7p;|Gi z2M&hDwSL+*r%=DZ66_GDY#GnO$!`HQ8Zv5Noh_Q2x$<1Z#t$f7ZCV`cdiL4%xDy+d zI0~+3xZEbt8|-p#o@H>7C5Sh^C_L^=UlhI@On6(^YbX6IrFKjnWYlZ=(_}6LCTmHc zts+igS?37cS)PngJ|Ur~bEB{6HsuVEa4FfiT zhh7vx#YaT+m!LV3?2fxls6tOU+_KTeu(N$LgzSv1Zn5y#k1Kw&L5lEBn_o!hhou*; zPmGb5JTIRpl%?g_s%b-MJq@UGXq_29`pKGc3~o*(bS%j75-m~81&nR7Ir`}@Y@THZ zf~4@r*#n-x#Uu}ot-ZVn z1AI3v(bghutWD6R9h`ZBIjz^Y0)C&&&6XkB6nxZH92xLp|3NxZhETM zcZX(qB&ukg;oFp-vMe%Z5+oV8I;Fi;xiZJwP!H)tC3Iw9%;BT_%9c-EvpSa^!^FGQ zjGy*P0&lvNus0FKKh3zNk<{RN|7Y)eKWHQay@;fc8NN8l1Ci!DMqoy>;@SCFpn&b4KJk=av~OqhW@w#uRPC&OBZvxRYf-;xSnA zwB1Js_i}MOA+^u0W*gR-PmkRe_=RH`uM-oMl(lk*DH#k~a{Lsvz?IwiuqMs8G^xcd zUn9!qd)?0{zi@cKUcnpUjb9EPccxzsz8g+XtD|YTY{)l<_Hrv{95$oRl;9kw&1S`K zS4gEOoN?M`^h_I|rC9}YnIn-SD<%Qvx)-Zl{nOdg2o-tQ)qnfGA7nxbV<|s`?E5~0 zK?y*uz(I!$5N!0mzM%$g)g7py<=lniFM217ZQ`NF4Wi8p%R_B3zo-oYS3c_qK*G8s7*zE)$dyV2-kwr2)FEudQ#r z=P4jLum0`xq6+zgW^E}#T7|72&PJcA+1y`D+nDLu>-FnTewZa7{!`f7q~cfJf=;rw zux1D}K7@y)5xk~`Pdx~dO&>5` zjxY|}Ass#2?2R+IW!D!*?V+5A&a??kfh_cGb>8}O6*IIYPxR2k)6XbXp)dS zcYWRi%)yC_TFMN2TyCp{xrl~UyWFzP97qgQ3fJ@Vg_4J692){@hT^2>lW_nk21sa{ z1iAvq0)qB^pTxo#rDOWyBlW`Od~x5CCX$^eH1aITORGkl(+e~)!}5Gf5SB3uH_3hL zSJ#}XAOjR&6F2P*J1#f=xR5(a1j$KEtb4xdNPHmj_z)j})7ZqvDdSx&*XPM8%*o5e zd6q>{0%za&~bH)F}e#2W>@>0}L>5=r3|X50~DmzKi3CH-N|1FQvZNEgk(0_b9RgjSK9J0&=?>*+VO~TPioi$x8IKnCL~5^~afeJaPPenNw@qH9y1o zm|5hpIPLJk=1)6J)K2Hd+8#NNpwl>-l}jfHM&C(SQO^kVPV}M988q3x-om|s?}lR8 zx6_lnwf`&a-E_803^_}8$NC`A$!0}X{p1(A>RPUs>~R*8{JBpU{hW}TBR43Nx#I@l z?;-U8_xfQEiJ+rNUVZN~15jxJ69J{>u_T5bJbj<^aUkzbzteZt3{!xTz?MOXaqz@6cS^= zH`5G(g$&TiPzxh*1Xg1S4+~izdjqSKtl-ZanSP6$}l=ncjxWFk!DGgF-)D00_qO2+N`|k1nv4_7Gx2^uC^Eo z)x@kwM?F1HSa1CUp%M4i<3DEW=74nsY)BcF-TXk#t9JR z+{0Llj;XL4W2Wf>lgxDoU8`J8L-$RdG@^98sp7)B9(3_Y3%_fUj|?jCTh zB%rm(gXSlcz%&_A5CyMa_#KEQL9nk@cgx(BNkm(xKqKE6vrZ~y9^%I#PoulA+3Sj? zZ!W~z!_|S5IZxZOsze3bNL9MIyd(zC+TpQP?(yS#CHD%}HG(LMSQO^Vj5*@>?Hj0XK;FZG6qEqhz);}SpymZ$5dr#$qL>(P8v*PrO5T$t ziHK{3K88!^pYFNbg*>pI?~zk2va`0V5N3Jfdbhhy_3mLBEgq;diTGlXQ%eZjc*$zJ z5~>Ra-(!d}v)P?AY|MU(vU7tV76j8Y>W-EicaWAF!uo~7M_G88NGQJWcZf+UZM})K zaEpj-IFpyTh;ORW=BHVI+KYn3OzByb&btwDq0QCmTdO8^^Nid(B*oyIENXbzgq73Aq2=#z400}K{Y7Dn_VobB9HLe-EalHDkKmIpt zWKNJaQkW=H9H!#TwF&g+g!|YkuLlj&S6h81Nvb66I^lRoμ0hpEl?wKjTnuJ)#q zp66^YAV$6fX@f7P60NmMJGr*L`3w*Pe|f68$VjqXh_+3$Rb+$4)WJI1yA4#I;YPvs zk?Qv$(J`#D(X1$5g5naPQ`c08vfV_%gc|YZ|JF|)A#y^y)AufFD-R?kpzH)N59&=6 zzxr=J{s|BZL{I`^fyZ3k{rYb~(AnNP3#+^d-Lbxvn(f45<+ATUFksq#H*5`PJDkzO z$y-B&28@=9YNJ@YIM^EQVps1{i3N!?DCZ}nq!Yl3=+O`MjY&2GF}NtYFrdHH1R9g| z)iJbY*R$83{6XNf2o(4M0)ON2s?N8ho0qw>gpT?$sA~u&8VHawEGD|1-(Me4E@LQA5;P7xBMSvD6ge>n)BqsS5k^C+ z>%zwRP$*LuU}EgLoJWnev)DQaZ`b4P!Imsznkq?L7agT+R(VPpcPsb)`i!;DmnWZP z6MS)YRl>KIUhgfWVWudZbv}vZ{1Be?^4PKkH1}{m3wAx*?9Kp{SS$bD|Mk_EzV@Q` z`m^vtT@(~wd+~8+`r3=%4J#6UCXXz+-g11{=vYJVg;sUx%A^tF3_)nRsf|C%%>r=B2ehCkZd6T05O1J80i6!i*X+$Nx@eE z-HkKq?zDApIbKGyTxh~|DjDfbEUZQ}*J^^%M@3r+dQO}#0d`HUr{H{6WINC%6qGqp zX(qBr@>)yihXZe{=R$f)PYGSm*m_uC$j&+kjN*HoINNO2e*j|6r*Y^-VsF#*d#lh! zQ)OdqP|E|#p$AYla04MEa$NbX$Y5*G`}As+Kx?-L)ub44>T$(cI|JKFd9M?-Ra`9c zNl-tNBpUmO2f!Wr6<7K%nKT2^D$fH|Kd4HeU;*j?n76O|_VTq3?FQa-JpKlB(0kWY zC)VN!4IHbXT+RVSdc^0q6%uBIey^w3r6mV^rIvdv`L>=OGyfy+^`}Vy+Qb`=?8lu~9@!7{Z*v6?>6u%i z+t7C;%}ZL)rGxrEM&-?#R*Ph}I@pTL9MLwLm#e(Di-VM?h+Fcbx`ZC__X98Q zk+>ILz3@9%KWF?H@I27Uz!?@q(H;&!pYS7a9yI*wum9+yCb=~Zh|xx3gc%ZjSCHcp z*|}A5o3gx9@ouukaC=5pAWQ*Qaby|E1L@?q4tGq)cF(s^2vwnvqr=Y1+VZ$-qftL8 zT0glTu9WgTCM-|`{4Fa2*_;dcjhY(R~v0Ml2TLYRLYT4kH@Y3M9O4L;1*wTh2{ZL3xwSx_5xMJ>>MHk&jwFN|=i3;D*Mh?*`f7xoeB_Tm_TxRh))!1k zxyoQtd(`5JATH6I+jt#*+%)ag-~E|mmP&0-YYE*rKsq)nJ()zYQqBUEe)=2Fy<@rF zpkotggeWmskVU!a)4mT(5Nik{#w!b!jiJ)Sol{OZ;0kJ=9+ldM1|`9$P7`5$eGTIG zUj;SEZ0&M6FE%z%D8nWfgfnwdQzYACHPN^z?~x>=n_$f>EsZtUVs7VWYDbmkwr{an zq0g%%lFDIeCXwK5nL}{4xI^h&#ClJYz><@1{LE(_cc!2D%y%-)k1Y#BR+*^rvz!%G zF=@4ymqo_fUHx(V*;$ruvk~cK2CtW^-b`E$l8`Q)n6Ahxw^*&D&wu^-Pokg#2X+SJ zHepP~70q}Bc`$0_u8V`$3?-OR$Y-5 ztPb)wf|&6(CT{P^c`TbTt8A>MIyzG8({bPSjou6eIa9eT%_)5J4*7|NkRJ=jq2022 z5beR;hs_3Euln`x%HR9i2Vri2c$_W`p7(E&rcDkdB^@X?71RLPIno_f%Z~o+2hyp|juRvft>k9i(u-IBUiLCLM+9&L=Hw_81J;?i`t46?kY2#I z5Wpv)$9Mtg=P@>bB=cx~4)D5Vvq+j8N7!r^F{)ELEUeA(#=o0xj6iC&q+Oh&dw%h- z#{B$zZdWDLhwh2C>9e?F!lbi`VaJxc<}`%UV6!Q+Q~cmOBOTM-LS4o3uDQf=@!}s) z?t!r69o07v(bC)n=SDKS+}kdX9JZRTR@R!;&HZerfo5TeNKOV)2jB=OV}X%su{fN@ zz}C|y;P6-f^!uKMK>_Gk{nX)Q5-L5Cgd81t2nz!7`08)|3W9;4#1DMXPk`9-O8`Xb zHC6;jt|K?wsj><@Kcy+!)3&%ngfWizew`k8cV#=w{Tv16X;TEyH3p0kDf>?9Ohegh zj^`3z9L!=b`DZNqZ`k_>w2&jx_liUo)mrAUIz`9cY(QS?^ZF{9MBvfX#H=(PvX0L0$y{2s9&r zJ3zq-+X;ESz+J!HAibU9}%6X&u*~gu!`q}TA#4`5vB^l^I79WT&-rSZBx>rNNgy$jWwVgf<97aP{_i57njkzJ@&*HqtE>O{eGlTR z-@LtaDnLMi0v`}i(bfAt{1oP)U-@16QFCM_3&i)C9wU)+Q=+%6vX!`LXa#C*(Y%PE z`#6h|d3Imb1dCHbr1$}*=>#clV^0~{@>Iu5r1P9NGEK6awI8&o}E{rj?a0jM?%fT}v$17ZLLIi;?csJaE21JFm_vn^v7%o5;~`6+Yki}_%wtimI@jWC zH!Na^bf^ym#Z*njI;2i&H@7E?mVHFvdSapCRt|$&OIBL{%x69U6&_5^fpUVu9;XC{ z=Wi8*x1F4gi}kFV6F7O`w-EO_oz-#CnvganGjAx%;sX!JbX_Xr#mzi0q;-i1G-05i>v=)ll?Ir%g8 ztO7^Hk;+0oxV>{WqH#Ih?6L7^-HX9pmei2|?;*aEKu{$!UcdM`o|0nM+tpMzE@&wNb|! z0~5^_d!#$uYtq1L(YL{-ue@dANPvDSE@}rh4NGdis1j&>lVZp1q~>gi{d!uqD9o=% z#*Ru*Ojez=rf01|ti8C~?qN=PJrec`YBjN8z1o#WWDTEK)gZ2Rk8Ue0B zzv4mw-0?i_#A3i2s(b^OQpkpCN`wV*1PRSHDf4_O+9ga9!+ZhUno64vPVXB!L8SGT z5

      N4>29@Rc#ad14b4Jy;~HTXPy~^%V+?)!0b8`sk9if3HD!q{s9U8@y?|2Y)`np zHYz7!j&NGKniD=xsl>KjoRE$^tdD)L0sY{%Wt7?sI?PaVX=D4RV;0V!cK}HJ$3P7a zZUMaroc5VGW?+tjrQi{D^+(S=1w`J}U;XFL(vW~d|0|E|N6T#2l1CUHF4*0Ispz@s zFSOmPz7Ys&d*Jxho^?=b%$Lo5=c=A7G<0wHye~JBQVC^qFc~&ePrH6SJ8ks|Y> zwzl*_N6$8Y){ofQEG?tmF2z3C|CfLL!z2bX?kxT`;p5Ns&+o#UtAFv4ZwM@w1O}9t z^uSPBq2Qs8?48w_@0%6A=)<~WPl#R>tDZVd?L6#l-S>O1cdUD@FXrPgB@bi1fIOi3 z4?)lgAr;<$_BjU45scVlCwGH>#juGiPSStdO=vh*TKy(~eRY+y5Or}xjqMBG1qpPp#nV;?E$>5^b;2n=ox37FB-9C8X`sx4ucb8}a<2^WXT#Akt8&!wut>$rLOst0PT!_nx zR?{6j0MDOwNOIMG9)YP6)84aejmrK0^Z(?BUI1Q*fI)B=OT$1`wRwu7{Hs5F=IXzH z4hS=tVk8L)&DofCl7h?kh7M|GBy5nFrz1yc^RGrn$nOiVqsSm@o z_1XuY#bB}nYTFBpVv$A9|Gi2Bf5hr6Z)DS*DFm5NLmx^f$N=nlImcXdaG2^G|? z#USTU6W^$ZL<-$1J|j}IP+G179ojGc_)jBHywL>ABSNV{AXn+nK7}yB)gM1EQaFnM zUPoXL1BLiis3!zvXO+I{@mwF0K0MZpy(ikk@YH=vk*|FXC=+><2bq_C->A9#r>+J6A>;}3Q*CT$N zLOU9L}`-8Bp1io|yRtslaYfaA5O-A7TsZ>@& zkNQPqZ@{52=oFppt7m@x7eSC8c_BmkS3jRU6?@Uu%|HGz5IRQylsp<_ofHDuCWeV4 z8er>JzWk|23)yoDRnzQqJ_CxH=lQ`US9OtXsyv*5rW%w|cQ^BdySeAyPa_Ob?Hm~t zzYUI}7}|q2i3eWRMV7d`@_pm7x?~Jydb(Du)TGpgYYrU~V}k=KFyVe=fW;|Lg}t+e z#KXQT1r%D}3^du}Y6{rcEUG=@p^c>5M_Tp0%JF1-CJTxV(@3^UZ$Qt##0njD9$?|C z^MCXdbR%9{5HKmhpkxS8BVwWb3QAT6X5>A9Y&5iKK-CFrD8PeYO9gBofkD-`ZtJ+L zGr6qmxc}e}{J@{R`w4ge(NJBPjF2DAdR*G-iY)R`$0D1rSP?b_+~$Qw4N*PB**(XY z`jF0>0W*k(ta}!#mW;byIog^#cKl{flAVF+i8!ZVaRu+lYg4t)A@B(;qbkUWi~oZ4 zFBeP)I(IN9d%ynW&8;*4j~y_N-Lvx-FNXR5@^63mlMjf?a+x>R$XvhlxtHEtB=ZR{ zR`>sNmCPsJvPy>g$<<%JN#>JpSrl|xAp~1xKKk9QGTcAn{`3p*-MsUiGEb2Am-5Y( zGD{dtou76gXB{YdM<#Ts6(sizr9iBeq9f&lL5gj9mH6OgUpM$a8bZA#T!_0bo z{oWq|Ui`IRS>@q@4+fYhwW)clg*U#{qPN`E*l7U_Q!_V=OW_19Q@VQZg&U~_INcm4 zQuU-ETTdKbR-AZ-RRJzPRk9#%CB-Qn;cQ)o2wcWkBfhTBJjlxaDH0yzg*ad?3L*aA zUikZ8e)3&i{WwGk6GRU--{Hblei@&Ii8u}={p8|cqu(# zhsxti)c(&k?1G{suoZ|qpH5?1W|~IFGO^Q9-7Rr$Fi*{Sr&fmG*G&)Ng~+h6&X;HV z7+b0|slfIM@c!iQ1AqoG7;v8q&`1IFPG}ewq9{NO(BOhODlicN3J?4;Z0Ox(k+;w-tdoZDpgTuvFUR0;1iVMZWy0I7vSbbyh$u@R!$j{DZ^ul zDvpZU(@-3s0Hw^S=yRnqrW0F=rR{D`6Peb1Od0pt0d_LLSl8nm2A=nSUV^-ASosE< z$L49f%7CN0&}qZIfQB=*UagBG$i+oybV1J?78W)086xeRQJdC2Zo0Lw#1Hopy1@4d z0*A2%Fa?xmI4s0~u89xhWU%dkj6tjm6NxaUiV^siz+a36G3G}#nxBW!XBKxU-_N#= zrI>=KmHCb6X-&LcK^J3wzw^K}aC4M&LUmf~5Jw^Q6<@72G$_-1d%&WDm|>_Glu@uh1t65qLcfm&iX7(s;r@WQ z1BO#E+WYp*@?rzuYKMb()9TTi((lg)bIWu-jK^p`dV@1J+FfvCEmGp%NxB)mklTWq zr=!m=c`V_^pv%dlXias8PwhGaiT_EcQJ%BUsVY!vD4sBF%J=&Xaiq2vN#RFv5L++| z3{Ag7KiNj5>aEAIT=hA+px2`y42z~?MS35eWiQCpeHJ7nw3OxpX+?yf_IP5LteYL0-sZYWJQ3v`OJ0-$X}AIk&f3 znF*~Erb0kSiZz_7l{p?jle(gm9gNih)YK@b3kg&}E`rKNoRE_laOf~w30oaTzEfkZ zgJM`O7MfPK*?B#c13himpiHu7#|?S7_Y?9R+GB=7z1r%XwF*O=)T)fXG z4^|22FyKinWC9=CPT2LxO7t5#JX$cO?;H63+kOIp6;O8!Jf8=$C|IWgTM$_2*;B9; zEs7YRHAp%RVZPyh`N4i~INj7Xm1Og~O_#-DeV4CK;tDBlO$FZsz`W{ver6B%1fVq2 zLRpnU@I>UKohsQ2%f-T5f+7WNUHmW}{RBkj38AOZm|6K%x?Aihrf^FhDdX+^Am+0; zNiodZNgCdAc^(F0xQMq2aWuuyW;qY~hX zI-4052WvE1)`nunJ33SeAjr9bX1yp``+Y?l8;@qC*zM1TX<`A4;~-U73!y zne-w)?ki%(9eIhkJ-a?-+-YF~`VmY1&-yx+` zF!G(Z5hE$1@Qrw)$)a9ZajdVpQ-Pp^x-8ouzvo2%^7ScDuYUdc*B;hYxRPKo6k=Ib zWe}1Z%K{OiW&rIhwGsh$qgvz%#4(v-1KQ;U8XC&BIOpADv`umKQy=}sKmEQ(7!C^# zE^~As^?*rT6!Z+hkV5C4!eA)Ehg$@t35?5--~f7@@#bNb3&qXnMfBjBtv35I+jrGW^pfe>NLj!=<2Vh zg58XfWzeaIIzbh}E+$xj09_7P#q^F?z=x~g3}e+vguC%Z-}e$53X67L4VYrFBX6FF z!w!v<)7+GhrEwMoSS(`GNN?8ux>+{*t3Yys5D1O@%LWm_nQlo@q3*c-MBQn1&bL5$3P-3m5azx@i|2@i zF6N4NFgw|%TV!knX*5OOG0*Oa6JajTWw2re&7OjXaV?e|EnFf_8*yS3NuAw?S0J5W zKNW)FZ)27IE!=2c<*+=fp*MRuq$TLG(AZ&R0Ky0l`p|KSxZ0jj#t(%kw5Vgwp3ev> zub})lPpbwPiA!_#5gMWaMAsOHrAMHT0$2j=1yI1^45a4($U#^gfA0f!(Na&zpd=Bu z-6VS&;kz6L+$F1Dw$UL7_XRv7fpHy zu;^d_6y}&I27&(z0irO9K@tR$b}-+38S4JktSi-7Xe|hRSHOmc$S;eXD8)P;&6*r9 z7VP|1NrgLo`p7q*0due}kg8h1^OBtHw*85P%>e0PKrxV{wp-YP$Y%S%vns;r{CE>U z5d)zyTIJHP+(Gl>|8DH;W7|0IJAUU;Flke=$H({g_ZNv- z%pUKBJl^r{crSd*y3PSw%-Gg8ZL($U{+NrU=(==h2NVc`4M@7W*swKdvIbbP&6o=$ zKu~N++5p+G#o3oqvKd+7RR9H%I*G^U?s=Zy^ZR|jpXZ?CAob?E#VvAk`kc;3X*#LZ z#?`%I&X{>?l|1LGYtd{=6}e)_s8suLDN6B^kRg?3dM6Bzq_@Qd6~Wr8)yj$ajPqMq zrbCSkr{!Gi(}DK`m08%lq3Nf5n0V*!g-PN><_QM6dU4#(wv4(x#LUtr@5>t^+s}fQYwTdvyrbK zWs+QWEUG1*vi9XyH79_5Jxb=$_{Sp_iLm$9R~=JdDrhW&`uW z8$=EihuA>i@!Y>}=hh45y`l(;8OQi57VP<59y+o#?}tD`;XAJ4OsyqYDw8_kQ*l+F zN|zG}1$C2XLaAt4yq+l63gf9>P7ApNjn!3YEKJI|oS6pjfJ#=26k9huO(ZA1f%JYb zAEe+#3E$!txp@?Ew<^Fbg=ZycDr!otmJamXVl)G&proliiwT!SSygC%&acPntO7;ObWPfWUDfLM-Vuq0-wT0bF-#KLq-zrj@-L%4i zT8?$72+ii8%rgl{){s9<~{Y2r@9wvz!6c76g#LW3lfgl zZxjkz29JNP_YtTL0u#;+H8Ec4fU$yz#gAD4BZ>$7%>5~+-|)Ev!QC1}`Bo!d?=|?M z3tqlnTOZBXXv358=v6+I>j|(hVrbO@GgT@`Q+FhuC}P5vAncC-0wDUN1cE<$tbk2Z zN>n0LHpS-*tr3yBEl*r;B-MVv6RT|&{{1k7{efE$Gj1044|AD%qY@5I+*~HHn-^gN zqoRFU-c_w=H!zCHeF2pgf$cF;3UcL15>nM(-Jk=JS^zN(3JV}+KpO{@%N!7a#SV-x zoluAa8o~oNY6sIXyY%+QmjUkzQa?ZpBZy46mL3=rYEp}ayp*~-@`dwEB0KRE@-Fa= zgI&K-o{c8C{i#N-6<}!JV{)TiCD{^+)o>``Z|rh(*3{KX3aMA{my+dKY?dAhh;n9u zxSVcDHIzj>Q#r@XdyW%e(BLoUn7TkIRW(6XCrY447c#wCJ`2?EbT2XSR;6YRwa;#` zTIl8*RNicqDihhFnJQf=nRzNps|_W(e~UoW5rQ`e9hRLl5#eRWD@Yi7prRAtc)*Gn z_5LtQar>2)JnPn)vuuhrp|l$FUAg4~_9y5nPkS}mDu?~4LOEF%M&f8+>w&Dn#DFwd zNyYskI!u@A(NbYL>q`@>3CUBfOx5#UUMLz_-LyJIs*yGNLUQCuWs)6Z7?bw%=>A(I zOK#%ao!1fq`~+O4BaT8fg;!-gOKY>He>a`uqNc)*_1<_UHVrdBWjj-kr5cS?Ut?x+ z(QwB@yWfN>4ApwZ4UieKNtkQHP;5hF3GM+BOW=y4E6tI`=trpDV(wjK^je+KmOgXe zx5u*JcGF4+K&YV(aGK9m%#@hfAfyDc?M9!bkc9j69Bxj|A1{d96MuI0tqX*g00Zv; zhyIaFCh-eUfhGRoOHt&)k?RfyJ@Eawz4d4jIAr%c znL1~7Lw&*w=D*JXcy92@dWAQ5MrV8LjKZzQ_z^Fw+5kZCt@T_ky7}qb?^ybPoW2d1 zx3bMoG*O?D_Z@s5(v5WyycB>MV#Tn1c*&2~?_4_r%_1078^?&MdDcnX?|9vL_An82 z9C6-$`(NC9k9QTUjvnuF`D|psahDyR*)6Vp0F@8ZZ(aOIn)}@Ln3rXjq^M)%+yPwN z#j1)Rb}gNmBirW*y8RR54ceST)bPy)$iI z;WSlL@V8%!9c05-;-`2VGY6^vBuy+laC2__+GE7Zh12-0&clUh>Oc4wq68BA0Z84z z>;180v@KnH_BPTk@l*1=P3O-(_ns^*cR`Le3(pbm|2oT%pP!$qH~=q%70JSy&I@Ri-id3cG{!K-U^;BP9@3Q^ zkvD}MjnSEbvBRGvb{6`CYvU7ZI~+d($Zw@io)hm{ao_n#Co6WC#VYyS%4VcWEUTur zxfTCs+s?W8Gfrxr$$yMEcUx)s+(2Mlj;)2UO)~pc!lrh)? zM8}f%xPN+~4PJ&KD&00CciSUIw$A^ET&~PZI35pinpaqTs?D!;-%qU3t|A>TxybwN zTbq@YV|FaSwvQ2ZaKbLO2s@6gd;tgHPm|F+8MLE{5PAF11-g`uq9xc4caEQcyw5(b z+QEuv&Jx|{?;{<#9hvHe|wFobUsfsYf79I?F5#P382 z$6bvb;^GELzGtH~=6n3hgwc8s&8dTC^~0Uk-NdriQxW9#=12Y^;rh97Kau`e>pZbo zqYU&OB(l+3E=HsCmmefHkAK#luiUe7-LcGpCS=gRzVQ2W@U$S{Aij-km*ckI{es;v zRQjKu`qIl+i1xPAP8~cua-xsg=}3C$X5u9eA^~6WX{G^wqj^s|J34%)vh?=mGOkbMYs1RYs=y3HdAhRX78mTN+IT}S{dw}MuD@Nw1)HIzuD{E?Ygbu@|Jlxy>{AcFN;z(eU*D=!h#RFtFO&{B=bJ2uKfm@0 zK}HB^<1*>k$r3kSB3^ijIE6Pv^BTr=$E#11%lrE;Y<%OC&Z9>gX8ZWJ>`va~_3giQ zI8EK+mn?_lZbE(I+HX8_m`KIz&aKT<^$p9Gs$N&F|IXWwJJyKG;u;bE@UgIlbA9X& zn3sSv_`9Q*Upsz>gUoIG(5YG2+v0-FG8aB}^#sv&AA7Y)+BD{pzSUt^2_H;Rc)9&2 zrBfU)qqX&E;h7^&4T2o<&Fug|KJl;bZ@jkhdp8~-zy1hm*HrCMg*bV|vGK}RUL@Cg zC|UEmvGnrd$%mJ0ta|BQQ^uS!U?wgMKo0;%K~Y=l0}GpRpj{YQy!85|e<0MQLynV? zqfQ*j{Kwxo&-D#;>EhyX$FV2p`$lZmEPiX93a@7@W!;0}d)-a#_(MCCcRdOE7AE1X z**yFGk^8u<4*GKzL#retDshNaIOdHzpra(BU* ze*ZZMTT$$6Ca84HH46h7S7;7;I-N{L_Tm-*z_Z#1m1OYek0bI;?b)zAF$5 z6eCrIA5}EH$@!u64CX=UWim8lO&Yb7yCg_Sq!LE{cCMzt;MW{wK_pUJ(Op+LW~6Jm z0t3B+kdMQbACx1hW=KgFt24Rj?deG^IOGH^xYsO5v)<4ZP)hD$BjCz_8s6wf5-wxd z$_a^*-;p zsUbpnR%3!aZ>gostUuYC!qT&KaP5@uli!GB!>;sf ztkvXNxuxx;M0KwnO=)p2FQ#2wCz34kp+cCA0601NKKaf?ax%;^*}N#3&u%TAY?rlQ zy_&|NQIBY&+_2f!i&Q$Nr^J-tD;4wZ_-;Qkq*`?!;LbeMlvUp(6^5#<9G}f{+RPhu z$E9>AG76(J#OkSWWh6*`&#=e&=!!6q6S*!RK^7_&1*xtJ9Vk>sj5UxDnrB_jpp{MX zii<<~epUyBZX9U`I{jd5)Po{>4a;_>$#YxlZa?~|eA!x~ygTmjj^_z${eOdG z;k|z&J{ln3yj##O2#_B*2q?D>6QP5jK8(1DHf;~zC%^SQKluI+tv>X^Ghh6l z{@Q=|)C({Di{JX5_kHpK$Md3Lq<{Uv1MvgQGta&7f#DVSyZM2S{+Yl2^b5~@;7305 z;DP+17r*!P%meblZTxQ^te+^e*1Kt=roCy}vi1(q1K|VQ(;xW6gIA^pKlI><;(#r~ zJTgA?=N@c7@aLZW=qG;bH=cTGAv8y?j>4O^_KL;}+N3PL*LvR*`UhTmBYNT|uUD8v z$@_CRlcY6vTpIJBIgJ9LYN=C90x>cO!Eg)HG*{aCpsuhe_v7Pswxl|Kq*nC)`jwx& z4!t(w>j>V4*RP;7&7ug#Pz22&FI~fz{odD*%V#A`(?#|5E7$&0Pna*4Ue_M6m%}Lb zy1c!9>AI`)=70XwgD2KMP}a#5?dtsX{=qXZ_vp)i=FdOzvma@qIw|7v%ku}{`^pc% zr?+Jm6Mg_yF@Ucn@B_vTMKmGw|+bu7CQa>mW~}qFur_ca4-D zO4dk&W&w7m&o?KuWuE$tkA+Dc1?{d*ezbh$AAQe*m!JBxpK7YIXd-j0BKT)P89woA zpKF4$ikj*RT942J&!VVUu^hKv`9$27xo67bDWA%e zo&SpVytb?1OT=E@L@zz{FP^u+IB_EWyU#@^?Z-43(sbw%6o!QuynG%> z6L{>?K}2AfhciTs#u0J-(o;W5@JBDtqv8-LQF|=^{hxluz)0%h4?cKfgdchr@2hBk zBSoonsF1v(OfL)#`X-Of4O^daVNOe^$a2Fexc+G{a~vDoj5N<^$#5kS(!sJj_PxPH z!C^KF=#w~YwstTywx$eBK(xzZonpEsuy!+3^cMfND_L(o`9A!mx88j6ai@OsNieSX z`SHy+`1rgj$~KLLX>K5=9pfEJMmElVw~U#?z!!%W)9h10X?@|i$${J9t7EugLflK% zR$ff-(j|ZE%_l#D(OBe10p=4p6ZjOku#eCb$q*Dlh77?FtoOu=&qNgFKm3+)%K5rH{&ZN8Rz#&Az~HR%R66;KH5pE$c8;Ww}E~SowVCczBtI zDod`%NDhloSW+G~Aj_2zW#}&K)J1%Xo6eQ!)1WWvxK}oBTL&&0_RaTy1V<2(VX4QN z2%h(EKKX!o>+|0OR(f?R4#%WFkjr?A>5Vfad?e3HWAx9=YK@qKWb8I8Fxcjd=K5(V zGmAhyQ!L>EFVfF>yBr-)Cor=u?X=7e%`1MlvZK{-(t1I@p+{wa%(c3#0FNi z*ez^fvx@p@CFFjOkS30}n7vyrVzFEvhb2BsWNChue0i^q*VZ3@FnJSx;>Y_9SmbTL zdDR{9&c|sjV?&mw*5PS$BG0a_L}yb->BDYN4~j{TJL{<1a=D~bJv!*f@xXi5_QdDN z^>4oUuG@T$` zDs2|!Lg^7hw>j?B`APJ~Q{3CeHq~^KX=!8#(CbgX`Q)<{gVWf1Fw0NF7o1};?(K1k zw)K6S9?w0ua%$A_5*9cQq_z^)w z4A_{>pRmH=cWdM{ho$-^DHyc+$77k4Y#CZo^xU5vS-> zZL(&uJOxa+Jsg=t6ikl~58O~j%FK>ddAdI=>(0ezL4_skakdJsKl{!1KSD7-Bx4*8 z2=I>pizt+e883=`oS`u`#>0pt;uwoig#H3}%Hd|X9ZUDLG-JWrs)4i>ahbZ!1W`?0 zY)J0>l}6s8Ha0XDPhpqjAPlDie_%^)Lbg>g9UW$&T89}|z^isp55viusM)C$M5{~b zfR;2NAGbxOh?**2@4xx}=W(3CapYZ0^3EGXaAh=xnP5pcHDUG?WzM>+y0CBU)rvDS z;z(G1i|>yvmf6vw<`X0<34=+UW^i3XLBFZ zopjiqMz-mWszQp`$sw0bb}Xi5W$HZMi;=bygcbQkx6Zf({%wclz5N! zXdKLp3Vpv8i!D0&)!;2-I$#tklC3^*=dBX;!>UvlD}L6yYcU(`-rJ?)a^W>X(yj09 zLEtpbP)xuQ3>jmn2iGWM!YDv6l8!NyCF?0C&vA0x5IL$3Hx9amiZH5qMmT7ua2nX-x z=N-#P(OhlU-0V0S11Y)Mwe{wc&l4<-VDIK6aBtoYvk$$#vq*B7EYEjBXC+IX(balF zbYmbW6Gggk4dVF9E~8tSl?rKf8HsoyR5JN>h&*v?ZroMDKI*WAxBewKvGeJ zQ6B0s2+oiMq(R!JScb%Cl%~RqRf^r{v~znuO4e4_w{<1Xgk;qpb&`m5QWuV96n4rj zP4Di5Y{VaTb0-s{9C7O4fUmqNUG1_uGnn(L$halng{^E@tiTFpRtO!5%$IeQE0~vw zW;I>B%WRasiS!#G1G}KPMlO3&3^4n0YZk#c~S-A}ZB;aYD*2!*{EiWG8CM3I@IkX;arcG^j zG-1y+3y~X+OhjZ;uIL9##OB71;1=Uz-tw`sQLuU$1M*twF>~)BB!b~I{nj_%|F|=K z^Zjpo$g9)BHL8V)YMX#ho;B zpR4P|_WH9BEPa{)$H4=P4C0VNXp+S-FJdtY#Sw_F5zTsN>;-g)lNSe3C@RRckax-B zT(R(=(@}ZJ#M4;E^4;x>TanI=zCE^!Gy|hNz)vv2*6wIWY&TH5V#G2wdB%kj+lzxIvKQd^{!`YYJI4ckDz(j3Q~M zV>Mz@cAsfb5=9vDt#3T{xYK{*xwl>9A%|F5SY_S5UG`+0w|Ys5k+RwF(RdPDJ27~P zXc7L9M*9W75Yh+{_62{GW1Nu=M)&$3e*6&|1TkRNfFU9r;s`)9AM;`qV+l4U0urG; z&qtv^3PR*Qg4}W=Q4tmCqgmwd`ZHb%({Wh&CyaB2Gzhy`=o^w7lY5g$h~FT^V$H=T zY<@;u_UxeRpe6cx)Bqwl9lEoMMbs61%ra(xIcv6N^n|Z=Mw*Rt_dbHW@!_`~bEY>w z{I)G#l?_|YWw5v8>HXep7HhFdx|7Nnr;{-oirpfe%{I0e)PC6r7?w_xTCPfCN_W+& zW{GC5qA@4$>Wi zIqt1nn7a-*b!qc@N^ulE32F`9tt=BuB0+?l@miMMU?5Z_cMT2!KhS-3>z zn`ey$_xAH-Ch`K<7#FRXvP+gpI}X;+B!?0!cRI_PiL=)X?Dem_{D>goH-ZvKMB*{) z69F4SdE=oJfdEcLP$->45~qBOy2l|SY02Q~?KnRz&c{d=OpV-51zlu8Mw*1@>{k{$ z^Grd%&%180Es%&hu})}(A~D%b=k@!619CNN8@qcq`o`~I$L4+mYd+`>+l|R z)WV7h<7892*~-U^<|Hb1cJCh)7$OcrHlzW`15)*4HUyIdI0=sdmH`%Fa6clkfV%jH zc;h0`+SeDm7V<{C>;sVuPSje$b%pH^nc9)Z$kmrO`QhRpvtg;XXeDIxGVPPH+LHeH z)DyvW>`ZIL`<=cgPC z6ARqL*1NqqTcgbaJsJ9;4w`!Fv;4Mglyfx`+mjI!ZOhJ6rP5Ecb}1Z0&heZ1>yUJP zsAnSDM@S$90?ebaAoN3c8vq*dh!Cn@%7ZHuco_C2FbI9i-FfVd?Xuk2S8jr3lwA&yH9IGJDT?v4rtaO6KgKg;I7bwR zJI4X9pOn_x|ztSUSBkmdXsvFE%b~w82mY<5V8{Q9tPHFM7yrpTJBmybMh1&R>U;P%S|MNrQ9AR*J^kt z%+NxNW(NozJGH5flW>nfVg&O-Jc_)SWDx+WK8gSeijg=D;N~+S63`G?Xa->H<;q0n zNr@x0?N`-)AuzWz5p>%icMkYncvr;dz)QvTEv7~D3j%pnJ9vdW58K_WB>1gluBWB7 zr1r-YDHoX=E*vk3N4eCFuCXcme(EDBUYte5t)MUk)7)PfK#t7gLI^y6?Hy4hcEvrD z`0BY!`fLYzt_{lEuwB_9Pqg5#NNUN+Jk3=>#?p#11+i5b@(CUGtd_9$@&ZGC3LqDQ zAu*J47|8(kiV-@1;-98z#>dEry!yXB_z{l?(2%)Ds$9{KXMQH+MX0ufVXh8XFT3M$ zs0@j}U7g8Dc8yspnD%{^ITGsyYK5LUmJz;|^MX2Qhx1Gqiu1lx_t_HB>Lc2fjKF&c zI>WbgO`r?%Jc+2hFGb~oRNqJ8SAX-RxBlq+A9tod`u^`k)^!%{Mcmktj#X+`L&)%g6-QT=!z51G~7Lo0Yj!WSXrN%)VZ$8? z?LN=!e2G=Ip)xkdrK_gF+Njk{e3(g|LdzsQ8gbVM8NEVAt(;+no!5KSRe4gU7riu7 z%zHP1avXi@bL!*HYoAlUV-lZ06D`^Cb+T5L@vv&B_6Qw@X*f@{RO)MeD>hRRRfGo4-D?X{JZj3{~4LWA8MT$f}($F>`kyAj7Lv zQm>sfIUJ2sS4G)*;R<~2fAjs%uqcbX^|cotcV7G2i{EjQf;$lUW*bRMlwKMr?X4MX zt}A(99qTS;PfR)%>A~Eo$FVPtRi?;(X^RcBI;|fkrPdXPD5I`)qyWD)z}JK)KW^c@)enit&9?}g|N+~*|ydrQ|mSt z?)f7$O0rOfz6&VnzY9uU<%&Vm!h}B|%b9x|LXSfo-a~ipiki96fNn@yE`Xe(rG6Vu zbhN?5iCyD*$hu2lBJGP+S^~071jRo>#1Vra2m_HeWWA6DxQ6*x|AqPk6cjv!@A+T) z`^KZ0d59f-O;==53=OYnWyQ>SQ(I=@VI*V&$_6*-ctqV_7{!OV%cc8qErlG_v<;(f zon4w^3t%i3`D(rDt#Je>J>q#>LnMw*%~6frWp1B>+Nw@4Z*A8d6U05djtf#_~}zDA-YJ9hB;pQJ6_RgOAev~xTP%s@l~$43#Oms$a+mD7f`THlnn!%(f6)B^`Y z<61v$n^UM?UGS+|g2~M0_u5H6i>V!x2MP6>{xq3Op2=DgXsd{m zS=KoMca|q3lut+~=-lXQx=lI5YHghEg9+RZ1kx{!p%B(d-)DjVDq;_VRKtKx;Gq{q zQ1KBF{RL=FB)j8I4Hf7qhg&vM4LjR6L&(nA>J|%+{kWc~DpG`Z+TubwKP2_5s2v_eZ1a{*(UY>s~VbL#U9L68*w zID5eJcbMd%n9*$2?_4cQaAmZ6_(G%a)w( z_z-B<+0~C_zX%K(1Wbb2n7v|AvEnFSO`@QiLy8ulR&@TQvv}|S8JY2 zj9I3vv26Y)DgumAY7peMkI$AJ=f{!Uy%ghC@Dg1ia5 z(c3R8BQJ=RI9Z}DI%a10$javzD}A;08JVd`C-wznjDvpLD(tdmoXf>|9{|+i<|r1nWaj9pFHW2Z-kr5lVgEf71Roc!|`VG1uhC(S*Lv*t+Sd-rOCU z)sd*8O@?pN*_36GITsaThC|H zensF-x90aIBKxN~*EFIMT<`z*gU^6AgL-$9JSe~2!ixAtVrg=Atmo8pMjRrQF!$JI zW*YnMneX>PSB@jTDvKkQc-|oGX-v{rDaQ9{RA&0+;yi=G&wllVAN~wWkkIQ55QL!d z5V&}Tq7j@1(gjit>BSy``(J>L7qMUju5)ggu`(KF=xR*XRCeyo6oNZh1|%MXB~ROZ zbZ{>h$KzA`>}s}QooDH>+XBCEEaOdLqN2Q!4>2WyVM}f{MJ;gUc0O!KGcHYPxyv_* ztbU*Slk(p=JYcWj4e{152ah|`F9+WVC#Ut%v|KivHHY?cE9V?Gr_U7c94J*?&$er% zl4Z^~?K66=4bal8f`!D9$dMJ20CU}oRj&To{8@yGJnZVf|KJZXA%(G&A42y1puwO7 zpjP0ZLk5U82Kf>YO>4 z)iKS9GNJ*ofOsU1dp(ULK0gsIO{nK|XWPB4A&fR__#Kz=@(3_TUe411UDemtH{bs> zkepZl(fM&$4W9S!fNL#DtpYX|&MCNrtUGo+ccih`A#w{Fdri?>PiSTcjh{3bofW#Y z*=o%ZsRgKR=i7F7A7Mc_gR7h%of`_=`55R3|I#+N*;AlV(LnPt)SD&PCL@*QPY+U zw@*Ui9PEiIoESECKPK!rmnnzxEDvlC_03 z=QseUZdafiRuYcv;2#^@mJ&}v7l7gnvg7i!u4D4(681jbr<^?uZsD!h{_D_3q`m)h z4PO&SNe0J4U`PUBk}x{B`mgwxSRY^;21E*in{|{&{i{|haR4OMyV=~0#@+lEoN@S z9-CNDU!75f3=%{XSnC(E9{_FurJ!f@xJnqFzoQs_s30g^R?cWB$9)*#;Z~^wMG@T1 zc@HoLCo*a!G3;@*t(N988rJP<%Qg!jF;FqwEY2579-47%2&5T`lb%n;0i+lpp=lE6 z3Lpyz+V_1D3uBay>5GrlOPlkBeNUQ5cAn74vqUeg8eu^%(ZmeP^DRMG#ynJ$`_`|n zIaNUhD8MFe+8cIUs{Xi?I!XY^Nla||S=EvFK;-cuJ^-ho#>Xj}xmvC-l2e$Imy7c} zi=qV1zV(M6f83e=@Z)dCl81>m@_N%r8Z;%6!YjY_Xoob>qmXU>DqLIRFG9|OV_6eQ3G2TmX&5z-5QV04eGutHU6WNm`Gu~ymg^;ZoW(?c;S)x`AVlZL4Kii!xB>Wk zNPWP)e#Ao}=xCBx-}l@AR9e79K&g2wiJ{QW^00`eBOe7}8yXW=%G19M)$s11X?KUQ z(4`|_E=JKfd1uA9At&=JVd&{km%jL1E5nyR_3J zv=({L{DcyiCL;=>;Pp%Y0HR3{?5p+NDt9Fk(Kad2$T!Bk6H93Z@#B!E(OuZ=by?HZ z3$gZaeIO;y)Ap<)Qo%M-{J2?5y^J;a{#?wg{k}`Kp>5Pj$n5Ds zGC{ETR`^SgJFkVm^tLTtUGZ8h?FIoc>RO-Y2I8lF+Nq4?E;MQ3xEg|w+?t#fOD~#J zX{GNPUXTPV3iDOQ9P#`14b(Rv?_og-N`Px%C~#^}^8&Ak0DVMJObob<0CpB7@5z!x zz_mgj!xi*T_gwBm9@sDT$f*|Cd0SQpv$}D;+g+!4_b`nX4%C@Me4)sx6@+cPWVKxh z)rEuaF+`r*>`ok1v)`iZ!XStx!8DDsqeaIZ#Fa`|f9LQq7G5S2iZA>yxmtZ|)x>U*&A61sC#+Sq3nuv_&Vq0T zxHKA}uYTn=M@SG`F@6jwIf_G+fgBW}9uNi~p#@Hj;Wkc;Y1XvCHDfo9SO4S_f5Ao; z1Zg9Mi894uD$ZP+K!1+EkFC;X&@g?y)#sw9h~lo}kB9UuU?g{#+I(MYqgUrjZ_4R; z!S+02}hB|@jJDHCO@M!|#{@o)a+zjTDi3GGhbyQr-^kd%P36Tm#EH&OiR zzx%`|K`anK35W$Ab9MLYzYRfWd+RK%@+Nf0`c`bV6N{Crz5~I4Y5U!Z_oxA(&_&Kn4|7i~`hap7LxGZ@ao`zQD0rdBi9w(S0Evz;8d_Z! zHr9tinYsWIW7p*~)Mz`4t%LA(Gu|F-(K4o~5`|6CQL?(uQ_8qoyZ6^;to>Pe@>w>) zmuFWYe0$~f-clUqvfNqclTa=W;aM+_En7fy51(bhu4kLw8K4qt<=^+ezW&NrUiRL6 z9$u)6g5oPLKkiIldHFkGMa0kKktH`#fo;XS*NNIHE*AL| zsGms^jeW!e;12zYEB%*DngMB*=YgspR3%Wb0CfP&+n0W4^+tzw!_0KN*$wER_pYZ* zti=%;I95ZsoCAvVXqMkrNSG1&y`EkdS5zFOfa9D6AQ%p!bi-<6S*dh5t@*N46~yW` z;g-vALHBiIhs<%zry6RllzS}smYyCn|DN~evm^j*;;l#a<9X{xPpiD+%3^< z=sTk3B`xUELH!@2lDeUlBH67Ewk$D6w9OXfI`8e`AZBTig|PzSmi(x!phx@zz{`6i z?uAz`{e!E&Y5WB6JkZL(85Ts*9u7dC@FQ>@H2m_f|M;UOxit=m(MCdq86tgGkmCy3 zxm9tSvNNZexycs8?KxS2Fa=!2kt8G!#FO7T+%X;7{j7yTs0w`?9d=gMmd9NijrvK} z8p4n!0za{|K%a=?Qly6Udh)c+BUIk%{Ti+QDY!AJXnM&8L~A})=)MRlh1aU%5M)$ zvlrTav$&+5=P81LX6<_mvk!URY9$&4uXi>R-kZn@GPGWeVM}$&5}0#feaWd#iDe+q zTpHmTstp1obi@={67uVRqkKB_(5u(7A0lzmXK0YkdsqMV!&(3!1@)jpjv>IJA+SxL z)B4iaU-(r> zV-skEC?QyqMXB~_-v=g$HTV&m$xD`vq0+>iQ%*VH3QC_I<=Te^CBZ086JdRQ4dVA- z1vUglpwWqfei2l8z`8OK1^Oc&2~jA8DI&a(^br<*`Im!72ha9Y+-sdK+={)F0j(+nMGkR)rxcOw{;U&I*c< zv|2lp1jgE3{bBr>d6sUo5$PocuUG5dOk56uE;C5Sg*z3{Mw73LO}%%>0qAg`*+nrl^JTaz{B7djic4}%Ok=a}wPm%Bi-J9^yCN%C z9prBWF`wC(u)Qbev24z)v$2}$=tyl&$9>y3dNUN{T;Z}br|{7`r7nz&W~x3Uck2y zz$c-{cme3=F*blC^JsAn@VaHQNSqvpSGUU;)u|m8*5-KQ-%U40Ahuf4F3-_Dzj)YS zettf;>k{fi_e9(DS=cdQ(pkl@W6NE08p3I?*_7GIesG?Xj_Gcpu3~4dxx#Yc;vZ1% zfw1H~)i)2((%c2-Ml`$J+pdlrwqC5))`r#1{d}i^W?_YhP6kp3;0P#ViIGaNJeM#BZf`OpK4}8#1fY|d307U8y zRs=|{BRAWrvI;yur77Cewy;C^F^*>aCOypDwe2wXa}=1TO%XuX7%)a8?>n(G4Ovx> z=MrBY%wjM3m|b^`d(h=oL+)1R++Rq^(1IQbb?QdHmtuYK$KHC(nZEdAZ-cUjYj+4J zyPFCp?Ws_ll`}%>NOM->8^$yW1fSJV2im1r*1I*aIM*--U^5+e^x1TVAg==f1ey`R z9iU(Z?mdhcBJ@F5OX1MPA#vOTfJ$Nr;FDsi>4s~wWBPRJaF zLjuh$)Qt3vGgQC&Vpgq^L`l6f2_#0cYL=pM+%8_v|6>GH6NHCD-e90{b@jh|@Iid_ zcW*D93J_4Bzy}0WboIfHJdJtimws1z)Et?~0`YyO$4KPdl;~|MZ$)kzTAtci^i06e zeVj$fBD=3@g5@b8Qv3kZbiA0hu_q60d8*?T(s|A_;G6?PX)q0jk;yssr{{i2w{X0A3H(W4T_#HQgwvk9W3X}Af-1I zHbhIDZ4U}46rAPj)z1Soht>mvMsQIm@SUsquQ@O%!Nd{B-+h2#1Ve>52r?+|!kodJ zMb}Q%c4QU{_wELtv9V=Xd>yvj?cr9P7g3Q9%%Q@|SXM6n@sK6Zjjk#%^H`MY&b2t( z4T~5e9qI!?F;!Es38|CPE$qpnB_H9ro>(flmBXOciWN6M_miK53J)gdKsmu+k5huf z^LL8D+fK^H;;`xMMMDl!WY^&?#gftz z&j3yzkuaPG>O_oz-#CnvganGjAx%;sX!JbX_Xr#mzi0q;-i1G-05dI&=)lmka`NZw zSpklUBju%ZaC_%$MB{3@*<<6;x)+1H>`W`CLk1+ha%PW3A}~#X3T8qKy5U#GQQ8T* zp~pE)v4!*Xz!VxcCy&{tX#Knu!VB{Z0OXH9__zaegl}J%SH)>2@0mK~x4yV=xNWZI z6|Qa;43WC0MFZ*)X)yCraJf-}f?s9MXRWMD&ISdgx!1+(&wlMi1p0yyB79&G;Z|HR zAA89UpdHRIQAi@x)$j2i!zmA1dl>0oI#>;U9?5LJ&G~jGi^X19E8yyuwRO5-lcFK6 zHj6uJj`7a@M9G|8Iwe|^hkB+S4slO6lW5>laEKu{Noj={M`o{}nM+tJhPSGqwNb|! z0~5`bd!#$uYtq1L(Rab7uf1d9h=+bEE@%ff4NGdVtP*H_lS0Ss#O7=X{bpLVD9o=% z#*Ru*Oj4Y*rsu6eY`nPJ?&iQIJ_42q>N=PJrec`YBjN8z1o#WWDTEK)gZ2Rk8Ue0B zzv4mw+|6dV6AJ-rDAEmJN*c|&n1^wW*W#rlnI?RxBQMLWkF$?F=I{>8q6QG6% zw}4&*PWwz8GcZTNQt*hn`sXh^4Mg76pZ%B5(~y8e|4WbTN2_etl1CUHF4*0Yspy62 zFSXsgzTpXKd*Ej4J?o&>n6H}q&Q-mTY3Sa}^1f6>x#G*_U@~l`oOb4BlNLdHWK**oj=tZ&x%vJdNyJt2Bktb6J-wTrN~b>Hv3-m&hrzL<~0lst_20`h?B zKLkN1gj9F~+UFQFM=)ZKp&-B_nETF^%ox#jw-9k}$m0`BVXh=I6h4z{@=($peaAPa zlw_y*aA6W3Ds8yWc8oyR!A9nhM9-2!0HWi#u0kqfB{Gdd7uAHa7+rl`&;4w-NCpp` zJ10{t^8Hs{2Jd)$x_#~2>Gr`(*U$d%zq>*c81KQ6<4SP6*r+;GZ#9o2V`4pY=R#Oj zw36=F0eJqbLz1ihHxZaBG3`Ce)~M9)fAgRI@Jql85ikf2V`&)3s??_`%D?*Rb65Z4 z3qY8`6eCGcfKEWp8Gi|65`yK0cl&YEjb?qc4O1}girGmNMtsfPFEmvg9(3RUrLwDFkxvM)8OsJrC zEd)7-nz*VQ5;1hE_>73nQf|2pbZEc$Q$LG9@kSFcj|im-fn23O|1`n`SAY1TK;bL` zcpZT~3>XHGgQ33kPk;Ckaw9IFqn;3yomKj}$8&v1RtNRAY}~Ey9*H7D@pSNLARU2Q z#VdBxspAP|LkU>K0MZpy)EF$_YGEjp`LW&i=+><2O%E@V>A9#r@9ggE>;}3QHY0wW zLOU9L>vvX7e#=oFpptLOgqFM=RH@`r?m0T1uW%D4J%U^Ept|v)OEL$#q?1YL$m`&{Ts`>h5Nda5wkd`)PzBs+}W& z;W&l;hICo#Mt0~3XH!W8DMb=RAKL} zA@Q*9N*;yQHv>)fxS9esHj8S{cxWT)_K{Y6uW~%eo=d!}!!(lZ(kkfrS6HFL&I2rb zeen;UhHk_gO9Cb(7?cbFYD6rwUqQ*rz>K^Hkd1~m4X8R{4Fz}*Y^i_^BrvG@&TSo+ zbtac}9rqvn!5{qNr=EZZ5Dk^J$?*BntjCqDtjQuDbu6-H6)V7|fZM##s3EF{IJ@T< zQyu)rxVqYe(B~$8M(XNwPCAJrNcZEUuV2(#BNma|nDw%P2B(;^IGH z{mTW@fzBPw$=3|6>QtV>j*m$%|qBzx>-D`P2jAvRvlvH8R()eD;;M7s-4Q zjMe@BTqX0#cdU}({?htS-z4*?cdQD!ED?gOG9UZSRvGRea)0zW_-@|&PMIgj`%C%u zN|_Z5rY=sqkh2aHy(1I4)Cw(C_P*Pc^K!RFbyKYE<;t}aJ3^KQf}C(2J?wCeox?hj z99w&T*Zh-L$|V2ztKZrvbHARyxHdPWYY(?2A9sX=xh6r57*dV^H&ppV>{wd-g`-}piQ0cx!_Lcc0$YK&^XW9EWu|F#ED<{$)!h>32J_UMcS>dOe%wIax zkFk|PlQL|t0Pj!!7651vg8}!+0F4wt?}Ub7A&LUj01YmfqXH8Vpzy#i!-n3y_7utV z5N730i;No0vOXPddRyk1(^fKS3QNUZ&Li5*Nou$EN{;P!UG#X6ENwZ6g4E>C%NpTHd$xsD7W=*DXbZDyapr{N z$xsPeS_P^Uh03(tA&yM!t68^af{cw7cNOTBgLklXP=>DYXT) zNJoFRnqdhy23<}b1#7B1d}=olNc>NHjm|jxoGLt}gu)5arhLCwi6gbWND4oOgV=&$ zU}*Y1`pGsb6>l?+<+{(&CA}GWepoggE71G!EO|k$?6V*tp{2AKNGl?ErN&CZ*t9O!Ag0cDasKdR*6-cQK)XpcD(wp|Kgc79p`7f^($#nfo1x_F;Y z9;_13VZf7EN(4T(9lz_5wcs~&c(hQecs>tgQLs)0wji+3v!`Gy zS`;xrYmjst!hFO1@`L@}aJs2&D$$Q)sgP70b zB*ifACTV!b<#`wg;WFMP#L+Cb#lH3DJ-MX>Se&&)%gS(od}E9xwbolSt-CGVk8*&^ z%6x8EkPBwc>rit6UjfwtgjHCQ!mFbabFR0?l=>P+q2svbIrV+TQ`B7YYc*EAy(sw@EuZ2 zc_ZI>st}18g{#7eCX0G$#j(EbP6dJv%BpOG{GJp2)7Pg!z52Bm-*{M8;aY^nP>5w! zl|hJZEb&B$ngO)4lu7{HjcSp{6UStV4QQ7aXlTgW;+%Jr(Kf}^&wT6`|LFT4VK^)} zxXjUk)B`4UQP490LkgXH3WK2tA8rwpCNM5TetTNC3Cuf@bmt-_#R=kI@`*khGU^T9 zd^2fAuubi1Ns2I$bh$K9Z1xnQNb}LP&k2bxBqCkXkPM0K=vaKYo5#J-DboTApsT-` z3RWE>%b-&ab%H8{T}-e50lFNpis?PEfDhNf8OExU2zO&u-}fRL^2>Hn4VY}P0HRO|xqB*MZ~&ArKn*mklzoH3QnNFu)DnHrO!(I&Kgq z!*Vl>fRVsB^w~?gAy+W8wv5isyjl;kJl&FlOxQm%)lPG<%8}jBBy%XyGDpQiX|;MP+^;UV(Ii z{Zt5wzl&A+cW|S5mBaF^hF14dNQ=;Ap|Qi-0E7`9^r7PtVZA+}j34q*Xi>+UJ)aR& zT0{A7p4JU85|`%eBQ!(kzW=&L5yd3G;eae zSh9;-Ipy#4>7(Cx4$Q&2K&ooNY$i(CZrh(&*bI;!1{4EHYP*F!h-|hGJgXv{&X3gq ziWmru(K;80)&Jet*}S@rmvQ`5u3W{-Q3f}TvluUe4tRznZPG?@oHT9Pw0UWoG<^}g zrg>@JPSWP3O#_1iZZ7yAxN|$J85DGNaW>+gAh>lq3tb5#=r=ugDwvCkIX4|HZ>^Mb%W$-W$K&ML zhQ|3l9n)MD>8tI62wYVDH|@TW7u(Tv3bpb{$-agyqhe~ zY!Poe0)3XIMdTl2v6?Bpsy=o?-Woa6Q;^PFqFl>ipz0?%Gng_O#`4M9voezPOZ@GU zO)U_5xyCx?!Zb!%oepU;P2&wB2f{&a;JMhRFLv%s(bj4JikV~4^Ah&_oeLeA=+Y2q zB<}V`ty4p=iOKkmPvz*Hl+y$uLEnTIlKFl=TnL(>oX(jhdXm6lbu~MAl_p7r2;c!R z(pAD<C31fjAvbg2me_h0or8U17$W170Y3p$FxsbnX|Y-m zrwK<(bT(Mn2^a~R&;~Qq_7}pTEkt7o47)JD z!zDxzms#W%uq0y0_?6ieJV#%&+rhG2Sc=ZYb)3)vM}{h$i?bWPNlMo3Pf_ zvci;sw;{w4!|Lv^hh?hbBFmMa3@wquS5#QIT(php%`r+A72hvdlt>@32yJYpZp z)arXH9H`}7rV0)twG4MBX*33tsYIPT<-OsIvIpZ4PfwC_Tc#E>N?-R(I3l#ZxL;}KgVCJqTTF-EpvtRQ2d5d|=#P~c}?LQZIQZak0N-16?m94>s* zRd3+s^PgqM+U8AaOl7(|mV6HuMog`HrcNUzI+OjOpdw&L5cc;00SG#gfaH%mC1BIc zgn6Hsj$J9=oBe3Fp@x|`N<)Sk7*CbIKZdZMd4QO4U)X<;CJS@Ub}Q1E2rD^&4UFJJ zE?%W2zhjPrIP}nI@oe9U#*iylBS=;KMb0sOgF#M%#sY{L(8fXK(f}f`*ntsd+v_<% zLr`#|ZV`^{>%V^IYk+rki9aBR@dArA#M`_gDueH}iF9@Bu(BmgD@u`Xz&Gyh=v=Fh zm2?R;v7x}wzP6;}Dj97&RcCtwZLS<{T4d>bjM6LkOCzlw)Z)QImQypsSlmPg+9K3B zmaOK^c>*wK_thLz?-Gfg3WQ!IjL#_(-;k$3{hrrC)z+h>gx=>))s>xW5^`bA=2cvB zmd?#*g-lGj)J*uxB?3`L58fc$uy(^lgqIy7C>T>v(Rpw@U`336KZ{n}rPCtY9L}X7Tz&9UbG&l8dN!?!O3_?_c)f*7W_;(*I`tZ zOGus!jabM#*HiOpR+L+nFsFIwjgHiKGTP>cL3F93(+?C&?s4wk*$W>01kPj|9D7FM zrg1jq_VtopiIT$?iG9laQynbxLO$EuGgYR!IS%($9jiGx?5#e4D-7Lwiv-9F)g;7P z7K&|%EWtfMVF_GO+)53y821snw}`!8w=!d4?XQ3KgZEFdN0MB!1rX|x0i4#kQ71F2 zzU?K<^qCoQ7at5&mIjXuNu)%dr;W~GJ&lL6q@S-6idyWV#W7V3?KH35(?I6pN+Yr^ zSQFVKHP{KwnSboQ0kdNV_#5UGWb6%i$8~CVxC_#?h<7gYQrH|1-Ar-~GZHkRGf&Uq z4yLZmtLUw7X55muyVKZ*KWtZ3f&-!o%#Cm*zxLus&!IiVPsRe!Ow-WYg3UyMi`bM1 zkjXMw`B|6X+h%t+Nx)eUnpmrJ=$%G~^K!XbJgav%Yn4sbg|$+4z21Iuk&ESXNCtZ_ zLg?cTM=U+(=ub(OR5etmOkyca_u?Kj=x5tw~A~F&z^zDg#blYMP5+{0OlQqlM1KSBxz?dd|MYx`6 zzeIB$vN%|AQ5}MX4286Y35nh{i%SE7ODMJ*gcp1=7;MtBKZ&@K3BixSh>GVt;`u%h1HVoUIi|FUX;#xl%?gq;kN%6Ty?l1eHW%9?B0RT8|ZqG zf=nbtPrna2OP9KE*e^po+9ha*AdWQ3A4(n!K+JA8_4Wqq4uO(&+Z>;OiJ!a4n=>%- zZ!Oy`3;c?2D(2JoUjOFxOP>DQK)fe!yVX9(&Mo=n7bLM-hQkK+IZ!6wetbRp&v6>s z5{CKKSFiM!pnm1<_*;*!#&=toc_;q|3CZNfR^_1-GBX}b@k;h{|(0B zr6m{R9CObtXJ2v(lC%GVJvhiQ_nZPFw;%`t1Nl{#s2R5OTCJ8HEH<^6-JOvrPV@Jw z-skVV_Xoc?`}hBOu_k`|Me>jN-`e^Y<0zVio1cFAWjNdLd4HhvY-6CNFV=!lDlQuT+zWuSX(`)47+17n22F%^OF0acv+fh z6{&&pcPFLIYNK5%fA~^Y4Ml0Q)NEF270;`_?!Ky)%Uk5=Fg?g z&%e5RO7fAGAL9U@tm@Tj<+}N|m3){hF^Ep%X;x9?hQ*Xp%Kqq6#fySLuj@yZsUkAMCarER@&0(97}(3%I4z!MBq z97K9<-rQ^7{qgqoTf!g7c#4-TpYn|iWn=*eV&6}FV_Sp+EoYHbL21)|zlfM#mb4fp z?@`)0+3A$tzx)P)-)J;zjZE+>!0Tb~*&7)QBo72TiT%)_e|zokPIj)NU$3R$UEV5t z^s6NLXHwugLo3|KAadXr0>1`rwsN*t!LO0vvwg0)KV)aZ2*I8Gr9yq$*{@}*{W=N% z&QQfL!R%PY(t%$9e53Zg%(LGh!N1VZ`5f5yVao&dN=IVEodPPPfT}6aDCPJxNg=RT zzPy&V`roPl0#^WTXEj^@v`F-i1uj6BBO)4%rE+J#(AlqKpM4Whtk`B78o}w`;<^v> z%ic=gM_}Yme}U5v15mA|0A6u^JQI~Zj6XZ$k(PrA+fsWD9IKzHAy9cT%h%8AcIcBJFkB<1>;Y|m{L;x_Hj zyOGgCXrrnir{!63sRttf$^csd5W(-6R+k&B7m3-J2W$(u9|P=1sUIf;ld#K^du!B@ z&&|99bPRkP57?FzL!qZU2%H28WZqEmc>Q-SQF0ULpo|?#E!kN-ox#&_GI*8@sK7Y630@iR zy&|H!!1$E+rO$SJcFgDi^>vRBV^jy&2l zZ}V$8OriuaarfXk_n?+(6Fj<10~&*IQB|Bu5jpqtDRr{4SIbsJv}<&(z|e?Lo*!y= z1)g;UG6RGPZITfrOC;$Ma?e0c)V1@Cp1~9sx4Gl9t_JY{511mjD5~}LV{K9&|fOmr^EuSDp@Q@PJc!)#twp! z@-G>VzZ92~6kFPz{ygQfdaFtX!xn#9`>^gB z{6|~~r}%R!eve84S-nGNLD``KPbCl`%J0&to?<;>txAPzl(G0{7~VrA^vL)-^RU|w>QI(4ZLXitgbzvUTKq+7Apc;_oLV=IXl>32Ym$@u&(meR0gR| zJtu`66ACKrGF9)gQpm6YCp?I870|DTf{S+O+p#cD$@f=UZOQ~#^l1}t2>u)TgU^H( z3$`ai!vu0#C>hN2Gzqk*0KiHhqeuHp`dp(qKns+;E;Pq@qg3|Ish~V6sMVlSpH>8h zNwJa{y<YIhkW&+P&$FAh z|H8&)XwC4GjL%24_$CzFDg`kSnW&}5boPV~*h60U|D3FC1 zq2k2wUK?wLW(t%a4B9i>^*M$lrt0tR@aH)EjdIh=hCd_Z{V3l91K)*kzcDxta}1;qPr_*H(^TWkJ2gRNVBTN6~Dxvhq5>60#uz;$SpXZYS8s z3)yh^&4jiGoqa0-+TT2s)9IWY%V~P}q|szf0y)QWLjq)t%SwPYyBBf_mK*d>%H47J z+dYPPS}%Y>|$XIS1d<)1Jx54fd9! z11!Cy&B@?tG9V{EBr?c|fqP)wq6rd|E2ofvK*2`HcC}6Meyjj!gYXvHVy5hnUvljv z@GJ>Xv=b`<+9Y%);h4|a5uYjLWMFC}g>L~F5L+40QQ5g!5`dMF=P@=b`z|~vE(PrU zE@uX49&M1B6T@B2_L*z5;iHl*s(X)c5Rn#AdL+=9H@(*e(7M-~YF3O5jP+hd^R79y z<~2Ri8YJM;A@YI3G$6zVN63t76=M``IzISKiQxDC@r&kv|MhP@bcGuV$2MyQIRF&l#-RD6l4piT%& zCHtiCtkKNA19Ws?8F3d26<_o8;-24>9{P6OfQsj3-vBx==*^@rarn_F4?Q$dGZp(P zl`L{X$W^atkYkCh6`&&n)|<_>5dtCvCxN1|8SHQ)+at<|3XBBg5XXg*2zg}Dom z;{srxbA>Vi`>(UBW^89FLV@#-EqbY*7(=;Rt=jCz!H6f^>7}7^(SQM;iij=vbTq&^ z6X>1;|6UyCpwCmO0rcctTnjzz{@-p#!icf}>$FoTAqRh6_^INIg`al+J0mj_w+F9t zn&xIX@NTaq&3csDe&nFf2|dY$w$Rf~zD+co@!4#(3h9u~i+r}BrCX289Ab=OJ>r*W zf^pzKorv3jmq`)gl4GCId&CaH=o&j;PWi}TzYH0lklO_IkcqwU5I;=LINJe!j(@ z_VasvAtUTP0`tv5|8&J)^XlZV&jk9cF^Ah)Y1SJj1w{vbA@Ip1gBJV@y|Z(vdBnD~ zlEW0=)+wEQN~d0<2Ao*%GZLCZi4|*O9<9GqsrA+l{9NEy%5{q6d~lKN@^moOHZ=R~ z%#_<{yjY~h8hU1S%4#X=AhPu?=kk1*tyd=poLB+S4*xFiYq^k$Z7B#Mt@s`I^+#7L zH|ykVVGBO3dV12o2K3t;C6#-6-(mkK_BF58rXpR7JzYw{bQ$z|DYnPMzL{_yIL%YU z>8Z6zXFpN>bV22W$I$vGSg(MlJ8=9R{sr(a*XmS$Ik^B?1AZiGDkmyHlU>}$)-UKF zCxWMopx&&It9GmiXup5Y7+-Ca;CF|pVmOwDxNGDQRr`3 zEKu1^4fc1=XATM*1W=`jv{nFgz6Tpduyie{>`E|co%i|VNk8>kgCtU&Ch2C{^~ac{ zYYdk>6lT^{YQmdW2Q6_m?m89GSZE)?nyJbxuc}Kp8xc^$maGWq0ANpGy%*d5@jl0{ z-_-GU64=Z+cLNeAQ(=IW038N^-*BaTc@?njSYBO=Fv7NXCy9cszO`nPGzMpnRKE@} zSUdFj4Tk#&J&DuT;r;+DOzeO%a=J*|xl1*JKNXKz{AqJwnLbB8nkfd8v@Le%=W&Ia zO>*9bMW40=82)n!hT$$ci&9K0&tabvd&&*9*k{^+0j7Pvo5sV148ln|40Zy@DFBN2 zUqQdnY#eReV+=Ii?b4-S+)p- zv1{|K6zFBV2`7C0NG<&2cPUrY-GzL2!BC|h>~6P`pjo$=LaFBy)|(kt8|Vz33y0zADa0}Vv(f45SgBe5;D5V!(oT4Az- zjNL6LriEIWzK};pV_-wXxCXCo1`Do*gTEO3O^O3;k3SuYZDZ3>94^?AF9wT=@j+cU zTu=nrc7Tq@woF-44+U<)uAYa1GXVt!keQFjn0NTDFGuJCxM6SSz8Kvbu;emwxoDxy zMkCV(ROlA4SAd;e%)`Y*It5fX2&-oX!4*0XI7tTVU9lrX1K9fLj6mU(P@_sQqZ2z^ zq1_-e*9rxJBdta;OtG`V1*73g_9dXL@ChFcxo<)N(}}$hSHfiGTr^fF8mnYhB`c3* zMz_=e?Ra9sPS6^x2aCB23ktbJ^>(I3uF~pgXE=vDdc<$Ip9BT&A`}roxkjs_M>=J& zkRe82>Mdna+@nVz*jVLjohco~a9$lj;$wnDxkj>e&k_mH2H`@2q>IgX!GQZ93Z*T9 z6F{!0pj>T}b;?8lbZurIRB4#wbBQ)#o#yJAQ6KICJl-->21kgfjh(+T&3bfZ6#Gz> zS&Mo*hW;cDd6c>ZE!g>0DVRONfi&h~sW2U76rAZMRiv>(p!0KGKE;Mk&bng>O_ZL0 z=s5x8(?T_}Q$7(uMupO}>#+lcBsJR`3l)g8E969wQv|h4MU>IHv=fg+AY<0md?4dA zU&!H~3;$-lLDdL)JK0^^X9A>Y3`)Vq$Y6M>(o5PZW&p^l73kfFVKPs}8G&Wjb{*Ry zsoBp~0Ca+`i={}u!hSrqFNSHpx`RLG`6u(E7Jk|hf(0-$f>5U!39PP74XbhZ=fU3` ze<~2L_|wUVeGzCmVf$AIal;#)ZeDT%$RmJSvtFYLWL5xlD10b_V9xepuoiU~rsqIA z{Bz=8&AtG1B>dXHWIMP54*P<|F?0=68R?5hwy>R|9vraOL6TX!^>PeBuj1XyKwQLn zl5CTAUeD6&G3~_F!v38BOFaL6J*PC0Cy&GRR8( ze})-ZQ}zlC0&qk5c*y%s1jR&^R2oD~zj5s~%VH%HjO9D|OQQv^94+^V7wK@dzU-*#%|;p+9U@0e#C!51;-1X07q3 zpPa_iK330dmMUJg+%S$};oN6~$~#-~39X1aLv5sBcn^9s78n{W2O{lyty3 z+{$LC>Dej0-cPrO3Abet1Fe>Oz18_EstSF zI<8Em<18PSPRAW84)8CO){cx@*c5nFG+@!ERgmRCphHyvf2q?XI7i3Ld;U%4?7@7f zl>qG&ZRt2LYcsUEa_Gm!+QaIGEch_`W?W^JPKdt6rYds>{0SO`6 zLHpZmkQ5->A57~X`2A=~g#&bS13JXLZWu&(s|;K>EjLoSC!>#>!J3U4X?%_PsnE{n zt@=6UK;Ml>DQJBgbt(~IPe1K_F5y?h`Mt=?%_+-~jl+bjMs{aBt^DnbzMUbmQFmI# z)F7PM&1rUWeU}yaw4~VWFoz z9CnUH7*^qo)unTC3OM&bpK7YM=+h}3^z#N+;8}sK}mJ z%sSVBT;IZkALr&5&_77)km2qAYa}&2`UZ4E-sh&R-Hd)tjeTxIrmGp{{WutLZSKhO zG2LVzpih#kEc$d#^S~cs?kcGL(Kw}ezPZ@{1S~X6)90XE#gB zC&k||?01zPPXl~)`83k36kL9&H{6fGF4_G2-qU^b$q%p*b@Ov9tE`pLQeUpOlJ5;v zFvRt+-+buDFH?_)zu0WNT)xT6(zW@^9|i`44@}1O-rK(a$@`ZdK4@3P0oK{9e$LxV zOnl7l0y~HR@htB9a!|VWDeLtIKHU8udg!y&5dkkhQtBrF`0^9o`wk|5+JhA7Sm5)0 z^hmvkM_3eT&Ktl0lV$n#9p7gdm^kwjW{~N@-Yjw7|L~=26fJL$6}}$Ym#+I@nVRo> ze2BI|uRF(x2?*k=(hz^x66iw4`&G)7`g+;JFM}_>v4drl$(I}JW&AS14WgKlxR}q3 z6wOQQ8@+$Ow*JL9ie};Fr=NZq&Ngr`2TIR225S0ZEf`e}hQ8RC!Uf+DU(TeSe}Bzu rw#sb}H>8bSr)xht*}3R!67TT6@BaPI|K?wQ_Vq7+_=ErWuTTCLbSA4F literal 0 HcmV?d00001 diff --git a/Covance_UCO3001/browser_profile/Default/Local Storage/leveldb/000203.ldb b/Covance_UCO3001/browser_profile/Default/Local Storage/leveldb/000203.ldb new file mode 100644 index 0000000000000000000000000000000000000000..e50b2f1dee57bb1e94ae7334899c886c47a0cab6 GIT binary patch literal 27247 zcma&O3$!E$c^=po%^YT|(bY&uFa}{s7ce-?mFoQ%<3aW6cXfAlbyq(CHT8bps_J@m zR|#Zm?UNX9HpE%K7QZkCc2;rDIvkvkge9!juuhKcWgWANy&M9&c1(_)SdKYse0DO~ zzppH;le5F3skx(DxBGVYU;pF#zyJH|kFS5J^}Q`wnsGP0qDb=_Pd*tXt{*=U>4uqP z=@Vvh)>>X{9saxTb@%P_!L-8W;)S=h zI6;t9HJG+qi_6TF7TMZ3yVme12@CzSu=CZ%&8DSazW(CPH*hDZ9b3u9Eq%+*H%640p=~{Z>l8|%G<}Mj7I8`-EOJV+I&-R{ zG(xe6p)-ziw7Piom$zC+&zuxRbaDfw8HB|VhNdW#y?#>ZQE8vtI6+R{|2X=#GrQ2A z_&m;dG?#QPsd9xjWspL)wt>)j8>k?HAi zY{T0+5&g_I3wRe4S^2pScKL-*w_5Lcc!cJsZ@hr9KajtpGRj7eLj5Vf$e#$}fcrbv z$@^dbhU3`9dRAmVai+tyviGT<)kja?r@rN%Uq@+*CJBsr{Qj0IYc1pQV^?1P`cHqa zlwUP<)3cT0!qMjP_gn$ncu$|)^Mxl9y(~QJNy~QhGAf>YVrNIuX&5KF_{jt=fN!0e zN$mJ;ndt?5{F58coY+S{cg4=R;w{glD1u-VMPEP3>^x249PIkciJ#}Cot@nHNZq;w z208k`l_c|&lZA`s4#r%jVv6DGBZWv)8)#18;*zm${w!v6Fn| z$6F6P)jE0n@vE+%7un~(+M2)<%*eOnB8SHXyD;CBng36}`{+_=*GD(ek1aPvor0_6 zWtt{gVOu9R-gROo*5mXg-`YIzACDevJ$CbI>wz~uaP8p-uqRsgy|(q9qrd1~yR1X*3`?akb z7lYR6Qu!@3d34&wqrA^)59eW$ksLPbj(SU)1!A>x_&Z!;QmWE zLp*VR>k^4#Pp?~-;IY#W!h_(c9YH>#FXd*!|Jkda;wC)->|h$!llH#Ibn|Qf{UyC9 z_3r~?C1rYadFa6f%1R#|1aa_Wnk9}OajVBa;5~6xbEcV;aq)znrX2VrTxZ|ZAt*lf zKVK^B_`&U^OJ{n_{SU3{pCDV8GF#_<_HTNv552p!p0u9$wN@*4o^MfaZE3^SRU5)0 zGKALU@6m3wo__r3=s#ZIQvC({i>-Y9PB3TY>hW*gSih-tCH0c{Ywy-hkKmy{*E;=k z^JToqS<)PF!i!wWU{-K?1Kq5Q(t}8Bt z`o%Y1GyJUZEdAoc7Y>*Ig0*?etFGzA#?y1}@#ijIzVM#we<-|p11T|z?AW!n&mH}m z`AA%3NuJu~$KLb%$mQ>rzIJ^&ZQYr?>bEDax{}#d;{W+qey?@Jx5CFiaCG^`pmpbW zTEG1}tt;??o7exVD_{9nt*cPNlJfCek7PCkbY5&8{0En=*oB=vF~5AJ$V&UTynOjh zt>oW+<=IcYy498DSFWFQ)qh)F=&E0fzxKEP>?bZ?YfbOF){tW^|L@;(&xKTfF1uprX88Jx$F0qO zH+jUeBQSDSk3RKXSJEVkj{fuss&({}|L#8>|NBc1{M4Oijz0d((WNv=|BJZw+F!c- z`0st_e?7Y9*}7$C`SBO;d+mFUFPO=5-+TNw?zhhL{V61$A7Cf~L9Rb`Rzf)ii|CR6 z+`oD5ORePiRhM7O-+Kj0i~g7Y;>wdjo*X}Y--Ca2{4;hA=VqmS{V{}ntY5~DVUV^T zLy;RKeFG;R>&UZ{_rL%B*B^ZQz0*H>;O6I!FI4Dj|MbfASB@_+G^s!O+Ml>`^ri=2 zf8S#_-u28$Skxysj(_mG{>Q(6A#yKX>HVkAhCXE4lQz&8Nt>Tz!Frs9$E_>J-*x|$6G%s2`~7eDNAPS;;dqEIs4pj(T$l7vo=1aI zhIF?2&g3TCC?y+hMTmVpvb-*BtaG74+@Pz5wvevs*87}Z?zLGLoj75~ zaHxvh3}^9fUN5RaJ?tcFVR@>Ed2cox>2lk1WXW5Vbi{WTOxzo*O|-zhtdr7P%Sq|g zViY#s_LPbz=vJdn`?Z2<0pC8&x9g$Po{(6-X~@2-{kBd*Nue#&`PoRLmEal(~I@M7G@~FjJlO@Y$@&6**N(TJzdm+ncv1PR;Jv#TkWJ zCfV_7<>dX>;o3F7esqf;u&2Fdm(HS@vQAfBKUr;rZYtrn-#fJozB9I&5o_`!$yC37 z^o^&F_S=Czko~aOt$IzoYtF<$eMY9mNJPD<(J2#-x26HPKxb^;K?TB`Ec9G-jcP6o zHzIjD2wWQBX+n2rQfH&2^jz)DLOSEqYPel&vN6&dW?jGQ5R zv(n46uo-j*rwh6qbnN)lLWW{9j~CI7-%v(Ciurplr!DPz zSgwb4)9Z4*WHD6c+gK-0*Kk4JbN%EH=S_a$8o|;mi;;KA3vXN4*7e6w62dh4K=}xQ z-$2jUhwpmGUNm(PJ0AaoW*FvwH@z5x_x4?l~%5*wa8@XxNl zveP*F-16){!=jK5$}Gyi@{ZQg@R0+8wC7p$eDxA?eE9p1e)!s7LB-FvTMyiL1Rh=h zkc>aiw=U9$?+&#h{FlGcy39NV-<{Wl;`7hJw?7K8aPkt8>>V-}lISRzAvqeF*qPEE zZP9|c__4>Vb9g?_{2xeeeE3zZCog{AJ6^)LGXOF0G(eU|zx*kHK7ct7Nb@DQ3@>#K zKj7b&;EjC(*BKgu;_#fooln2&AxLwFy8J^g-ZY#k8K~SC9jlYYO6xblkSRl*Bpq}x zNjhX)QxR|5@qp#H;lLoAB8l`_zurbo6433VUs?j7OEO!9e*kD@@Dh$5<@WW9|Hnhx zdF7V=@>gw?HXNF?Xxh>VzhEj1(39( zay&WPp$Wq!h((*d(yJh?W9iqV*D*d}HWIAa2Z&M7XQsV^Cap;B$NF9|Jb&zCx$MAn!khqc|eVoU5%I<`l81Jw@ExmAw4&eqAx zRfpd0m2T!#^5|fk|19eM@SE45btM^=x|^loe0BSt76Xn5#(JuWUC*yvvgb4oJzDO4 z!S1&cwKjIlV2I529d$k$fZawrG*Y&`KGQYFJE~9kl!>#|Oh5U^?R#$72%=*SYU4Ob z=wKI92ZyswhO|+Fwr!Ro;n60IIXd!yxmzi+y_<;v z?audOSDw-JT=SGgKj~3p#da0Ma|KO zpeH`{4!Kn1kzUoT3-X+6lZ}#SNAjs_DLhZqW(K zW9xRTh1?Xark-4lGc=!ueu$$u*LTcLa&rA6FW!HPAZ!L~%a}NWn=ECbIPO?1hBB;4 zp@vR5BueN8gIVawYfrBpp0Nh>SMNre8K!-59d=f0&vHYN#;dg^XWM)n#EZQf80Km2 z-+uAtcA3xfG)KGUh>D$>OEAAstzIwFyt<|{zq{kmdNp%vEI}%N&xn0z&j!nmFsVgt>13ZcQXl`Z@^$L#n6n9yWB|7pj0;YHXVg|x3@JJYwCK8FNrfRTvgSfqpFCIQ}IVm7c`4x`(SfipD5I=E$% zgyUc~iqM|{KXFg@n>tx-doxGWr(?4-mGC~b2}NlftgyX*W(+3e23=tL{NN{SkKBv< ztt+@}!ZpY=jT>*tbjO;@b1_^qckJ%BdPDKsM3l5LpiR0n5uk2PRp4uHg@p^dn+ZM= zCQfBcs$%ZoEBQRJP&O1UnuX{w3CwW}$3kq{AuNKTC>*y8TL+)94Gc4#&p=`cozMyv zzQ&(T>asTlq+M=UepVr~<(aft3nDGeEKE65mE>R)N88QT4qbNK>9%I`(i_X9gl(5( zFAu%A$pC1(|CIlLp~wCLwn>)Y-Y#GdML$Hv@z1X z4o!*4$dujJDu2~3WV_lAl5uw+@YQN4h0ty2^Pui^0ZaSk@Z25*PU8&4m@EOE5r*mz zL>6P&CW4W)ZQ)=d3*v@kAp;-mVe(d5cA{kwr}}Uj=59)}yC@3ej=~KB&Q1}d#N$9^ z>-oVRQ9*}OWRDR1QfPaXHeQO`wl<5jY`3RIdkbfJLEy>65-;1kIm>kH_P7{wyjQDx zva_0;Xt(cq2#_p-eLE+CxOq9r-qfp7BguWE>BiDp4*DHkEi=U@%Gwm=h9Xzp+>E*t z1M7@eh^Lx1#sa}B80}IXuX@?>-#YowS0B9vL4nbh1NE9ROp>x~jM7n^L2!m7pcc{w z#WEyD12bwJtP;=bWzk-&>y9>6lxdbqyyy=qPaz3gAr;Y^0q-MkXnKC0Vr>E1sbwhH z5wgro7a!R?MOE*~m^p6ivYrhYqF9pS9bS&Kr6}scLRyYTdO&m8H23papX?{y z>8>ZR^N;_@Yi`jj#3(^P#ibqA(OJ}{5DQ~5#?XNqrx?nx37bF-Ahi#+fc6{@%$%C{ z&-%+r{TXHas^Vmvb7ru5J*5QEm!OM(A4&ACFC2T6d?|3LxR4okYzrW+|?_m)Cq&U<+lS zr7UDCvs1V+jV!(_eb4fBSCU0q0+KkV8_nCe<1zgpwUg6gBMec`u*~e_-`! zX~0&^*zh{jde;{^lw2bN-nS6K&om4f=z6A>i`h#_mBFFdvNoe5w1FEA!aB4LMj&Yu zWpzV$4AjAJXf{amV2ys4M?>pM8panTJ* z>Y^X@!QLHRsn)Z+JCt(2+>RM_yH)vpJnsfPKUzp;W+b_YVL{W3lR=_3!8{#gEO8D+ zXb2CML7OXSypQG-kUA z3+@d=5nd8RurV%aygc`Neo^nWJ#dlJR0M@C+9Gkvz^HQ^Qj=OAT)n8<+wRV@`{HauPMesHLo+02guYx4G?v$A zqHVV&ItFZh*}S%$-3;@wb#xAqhE^(n_|(FYvA*hc!e&< zvE~r!c0tYgfq|*{R+1Otxqnb#2*fj&J z=?bxjhSHrEP&b@jWlE&ErG_0`k=YXIQ*+X@S4!_Rau5E&?|VvtrefGmg33?QDQWDs z6=6>6a;6Ogqg2*J-(4!HF4>eQI-_o%+vj;5#@N^@x!~X*SD*kQcPlS&{@K5-FgIbgL?EX6D({V1;Rs%e$19immDpMZvZMpjo$k(Gy*XTN-)$c__LD zbTc+>Ai$UsCZ^MvX&DxLH35z2gas`yr9%jrI)=Rf2BA0Hna-XrRxGzOp(imFaoU;y z?F@7@EVK|bYZ8WqpU29Q7qpNb>8c{5>uu2$@cPU*mRY(9I8G-wCQqTs_-xVNNPqav z7oWl@lC{NNUYJbL7h+yv)!SYW1{uY43Y6pR<^6X?wT~A<#AO< z2k&?Y&=J7FZ&P!tzXD~4noD&cdGaEKN ztw*iB07<&x%IYq4->Lh_#9OJOq^g?A?l|3@gsf6%Ou;ngAp^*fxmyZ>^UuB_i#RK3 z&G^Q6SNc^rhdNi7Nu(}T{Uy1jMPooxJ+3d%Txy0aEz6DRXsO!YqWd*F@!3W107Kpf zkc+_(2USAYDd@%cBI{3seB>M7UxyQBZgg6v-EMD*!Zv?#ng7E@U6@`46U_cNkzhF*a#5KN1eb_cgRvMX?P+H^5hAyws@f&pP%F=&8OGw!@mc`NC>oFm z1w@GrW&+%f;=rjHEJ5ke)ZivX9NYxqytTXBqsVIN78SDUhKP6?5#V@3cHJpZQ^qFl zh;!q~d7YUX9af%Na-Dm<)i^MRYBnA@F5l5*x=+%z>Xf+{(gUQPBs>Pwk!(F)jRjJn zyH$sW8Q~$bLOYJ$`PK2=j%R;${4J9h1nN)xxsdrox##Q$IaPQtfoS%-ChH{1P?<`3 z6WggQ(J)Jw8*RT+Q;eaPXj~DxLY|w1gp5i;-_J4@in6vz8a50TpzCL7$SwxW-~@x3 z2+N|(!6eIi%t)1!565(8ex@Sfl*rfp{h9|_ZJ-)bPn~Nv*^wsAp}D)6s1%=#2w6ZX z9Qf$LcsLJ6ZO6;&Kuv@_!_8!?aq^W}&Qo00wUV;B_w*N@yhZ_$4jska z&>5VsUIEY&OD$<;*d~;9w1`GBQ7rNWB8W>q57;7|5j#&#@L9T4lw`7iDOnfy;N_!5 z!glt3+B>%i7{hcZ)51-Lf|$`M)?{H;1_B=_%nWo_7->-kMFPuqu!(1H+f%9>^9tKL zTTcd^2#?z6el>_0BaHLC>innDVpXGVonb-Il2x?z$^ch>UN(`U;D($eph~dbi`*uRi)MCy6vGlLxqY8%Rb$w?^O(Fq$v z5z_`zgtch~wQSqQDHD*QgHjX%EuM`U);TXiWpz~wCf=L(cTERn1$(hP6MfJ1k!hf& zA(!p9-IAxLqw`#{mTEU#_MHR($1skF+(w&ykgif!NU*Uw6{n~sCunNOeag{7O2WG0 zH0tovOtEK^a&)47X)RW_Sb%Go zar_U*k5JI?5Qc8N@GI&qe&#w$Wk{zaOhR)(o+K&L7G{%PD7iJ!SD|fK`K5r2*9S)N zX0+mhHB7@Tj>?Oi8Bdq}+#y?5ujxVrynvI>Vp- z4f-mBPzd>L;^x`Ej+>i3hR-;PD5WC0LC0ze)XG)jpa@_6~ zZQM3zri7ZEMZ`8<;~xK)kN(1^g%3Lfff$s7Q#Q;cX`D4}grXb^N-aX^a6q*oaFnu% z;}2QKpR_&#W&tFhmJZ#f^hh;^pyaAYMI`oPi9m*7pjYco;3XIyA?x$t8CY26?2O)G zZSB!Y+e12OwvETKJvqzu{bCM5Um%3$tz~M}o{>X3Ly8XX*P6(rmiqKp9|bbtE{z_X ze`T+?Tr6|botM)ntW9zZ_;+iBtHhVO#Kf04uf32RS0&1@JB)~ENwRgu1u>rPwI#cd zBJP0YA41^zZL2W~K#gh#Rk3m*&bZl7Um*+J zMe%f8;9%FC!H(*=n9GDGtaNq7jZG!T4sr7kgOe;l-1)R{x1;&A@U3LRFNF1EtL&s; z;gD_z)$?lG%z6S779`MCHrHp_r3c(u5g_wnO^t-r}VXcFc&PKUHRj8h93e3je;q@jsl(s3f4h^KZJ&c#t@p; z5zK>aRI(Gj-4-)3{-w`q%#Np-r#`jMo7UIJk-E24SPrgFjz< z0=%SC?y%L2BkLK=b?RajY_rjsn-4r9wMQX74frMu?O9ubA_Jk5ET%G-M0jB-7VV}& zNt$XGe##FQoo$&9cZtq0&V1PBoArRe^KvMxXGq`Jwz)i)Wb$U7`e@?O@anjNwvf)2Lwif|S<#%d>2Yq3n~8XqLFhxxj`@2qL8qYMH}r~*3) zl|$fMLE*C>f9CB!$`T-=HcbQ}XxsuWo}p+2r-5{VQbX#Fj^M^;VB$q|8IdcO8>UXx zoY|Kd)}M^ow$950x7AcAJSt0Wr)%3?9Rf!eg2iq%S*Y5M54>^;{DPM_BY%cU{ZZd_ zs16twq)3fj09U?<_9JrUBr~cvk48v;{NQ_b{hx7L>@j>H?);p2x1;$v^IPd;JM?DS zinaLMEe=uH=CC%sqlBePjmJZNIz-ZbpHsK%kZw=*FwjiRZigcgj}?6rTdfXOIsRh% zDni*hcKpBH`)0`4<^pM#s&jLVJ{Y_haNA_w7s9N2XI23}|7~{Zq0QC=!!d0NeNV`}+DdydB#T(UW+s1H7CqleddSQ2Z*4c^4 z2m{suj1t+U?avfB#s)BHWt%yvR_JWeS67v95j%5Dq!#Z^v?)bML#r^Xc5P4@8yUT3 z>M#|1GP-@wHI{(sH-wYM{Gy**uCN9_@d+MGTH?cr;;TX z1zF~h-ilbPgLS|y_WM<=4~NF{Fh`{IzZk-6;wZ`Bm<0@p2}}}3o5%k|xXu~?+b|$f z5F9_$VQy16t_8YyLC-UIs4GYd+Qs;ejd9o)HEZF_^M>7f1|L zvPRwAfs%(|9BTn-hT^1dkd6r@21sa{1iAvq0)jRSgTyQcr5*affpa2jLBYeIfCiIlFtwIcEmI1jNXO5p6BFTd$-NAu-3y_`#K`g$!WdD)r3 zP{NP(c;=KuT?UEJEl6WO;sMqIH>3z7VUofWt21l|vBM8aI|{{R;64ANyS>3e0d{l) z1Hu*bBQOUCPQWG+Qa6EPBaVOn>1(KIF*ZgV%|G$=*WI!;bHbU6aUXPeryU(l*>cc7 zCAONcj6`3F^RV*TD{ss3=WR|lnU452&O1ymazGx5?-%@bj){})F4v|WrxSGG*zIJn z^v&8>21C1IglsMv(C6$YoyEx%;s)Lg1xm&{cUO}%ubBTz>s8Pm_-ZE%=3eGXv_Bq_ zY1J69BCoWS?yqqclZ>uGs8yGcmL9k7Q?og@2mT&PA8@bNbi{^LX0Zmy zCuk6B9h4-|88O+(tTF0!(>q{psT$j=R>{O!ni(e!?qT}4yPCj-9$SMY9-h;Sf%}ndVwV$^nMz& zH6MM~-Hzs?@A_8Ygv%b&rrOg$rd883gJEaF36SMhZk>tCS)U!N?TI2VepgwdBY9QM zrhKr(vN7~}NY97B`BexO45J9cffnOs)bPu>z6408h!|)SYV4Ack$bu)={}E&p z(_E*+vq7}#kjP{d0F8XAwo57L@Q^>;D6r40e692+%J@L6-5k1Phtnr(R+cDpYRmny z+ZhmhU7O>MmaK7aH0)G;ERWW^nAg_p(w|xjHS;ZIP47Fi41&e_*}EOjT0i@;EuI<( z6Q?uZi-?+KN;^^!BQSz;%xJ6bq|;rlCJ0`0Lz0hsy4|LNRGH_3*by?}&2lO?{0PhzFE1~5NebI}Uwz`DCe zwwcJbizG#u!Rboh%u886hiSCvQachc#5ke`khbxJoy-&HE|&NjL;CFnJD2w3Sv5u3 zu1XL+g2{7vPD{(xUK)%E?PuJ_Sh!3iG++34h)L4PXlzfcDIykDyEBMHe4Hi=zG+w6 zwJ1nT6YOLO!1q8W3;u*@sF6iXB!iV{s zaGqN`qx}R^hEt_2NwOr(OTlx4orsZ~+Z53{o78$1$D;Y9J{|K+W31F?V&Eg)v< z%<@$LdfGit--QB-rKEY!dMLSO7BVgcE4Y0 zyRDdXU2CT#UctsN+{5|MoL6i<-vLx&wdlcr_xz17JgMJ)2rkq?LGgtr?{+j_c=B6m zMZ$Na$C9HdEOO)umeXsYkXN+7?VI)v&(vCGXi-C=DNG0AMjis;jF&VE;C&k@mC`u` z(1$@QfKmu%(2!aYXmnU8Hc)?n7{D-$)B(sjxB-$R^Yei2>Na(@ovt<<-$BDj$gNQz zslllu3~Mx+WCWws{mD>JB4T$)up@HRn7duSvoI$O3d$TinfV=&vk{j$3vC!ElhJb9PcE>6o^fp^zkF8PUp-HRVEFR18I(BW)Zr zsGJ(g$r|%t(nVvlzpvlEN&?U(?%Z13?RfUqqNTjV72KrTs|1}|#!{N-egPVFSOjp; z&Ui%2u|FTWi++dk&?4+6!>C%st`r7wXgM;7TOv;$z>N42;N^7^*RA90|LFK9)%OC= z1EUO_VL=kD;{fyt!v^O;tM%*rJW85`7kv^#GZ#(s&cF{4(WN{uIL( zZ88O63b@L$(?KFr+8V`@^Mblq^93|Qsb%2key)W@;>`=YR<`{~PNG@a)0$HuTiXi&$u#x3IbFMsgr zVL)mg|JL6+q}oDGL9!s{?2ziA>#*HS&?r`|CW||#+QeH^oi@Iu>|vpvv#{K1!L?Ou zm-Ksq(CB$l_={{}%&KmjVIVbhHDcCL`&vzD`y_9eh@XdJVd^sZS}dwj_fUEsq6h|t zwclBqy(tJ<(Vs~IwY3azBIRZyke1Lho9U$V&pqG$H`6^(E?RhXt~Eu{eI z5&h@?ZgR=e(c@>sHpsj(PU%6> zb55NlD3C@KIS4|k(u`G5od#pv6=&!`nNDlr^G7Kq?}7;?wyONXLAr_>Cy0{hdGsPk;S&-?3b8uV4*mgecMMk#RDv zf~qoSAl49SjPLhY)`3nFUv49639cYlf!EIr7*G<7yv%K^%1%J~{$XH4Py_~@DCieK zl?SXVV^g3%G7t-eR+u8J14(aV*5`lDyyfZ(eT?hHvb3gBr7%0JGO2tIxBnUg^pr-JrUfR&O*jXdKMd#*-8E6w$W#cZa#!+)BnN6z#YsX4A^=&EH4`#kC zET@cX?ljI#mItxkRT5Zo^3IPubGM`Uk!Sv@(!6&Ns~wrKb0dscQ5OATQt%y-(dNfr zc7C)S2Gg)cst$u^gJCuER~!@}McOiD9HpyxIFvsA)koiff(jhi8Iapp4&`9vvHrmc z-17j_q2`dJ2|64Yc2Nw?d>&#&*!adq>XB`tsq=L;>7{EYj@j+7jKi2!K>kJ$ZGM4? z({pkj3){>vtkWj5J!-V|)&=ZU=KGjz%Ul>l6kh9Yv}GaXJA$__rmSMxYjF4dc#MvQ z)#y{52VcD3z6}K9-KA;OE2L@7l9K!ql$(821=%@LdNQ^s(NGFaGA4TZgiU*rhV;|j zq&ITOWx87~O@B%Eqghtaz2|=-dw@Z=g^NSZCt+lkc2Bc>&)-0H0Voqnn_g z$5<1J%&qRu#Iu48ZK+uX zaJ8iu^iG^JmS1Y|e$FQIe7m=r{elgcdEYR1ZE`tVO`)%1`PFQIMdHCfuCP#C?$+GE z`B(HeH_>D^H+Q)-DyCjfvNB(}N`H`(^T94Mx*dOCfF225X1Q`M#ro_!@7(2RKKss>LD|jWYHw1D zvWb^LMOhM`@IkPy{bvAy%k?I@JAf zZZ5=)y23Vcv6|D(Mme8REW6~S#P=n`EV^in&%6X*5Ol*^fwkPv>7`tULA?5pK;Mx-V)%o+C&}Kl`+W3YBcPffbR6mi1B0vMKf1T& z9RIhQ!=wTP6e#ckCS@Prd+idYqc41_b1V0lMg#GEs5pqdJWbF|(Vt3Ovo8c{q|v;H zp=&3!{cd>P)tJ4lPXxFND|Lbt6pr5C7s)nr21uzdn?24gVKWVO!7$R_IYz^eyVP(T zp*(B_K{q_8&b{M1(#7AjBH3G3gM3Vzf@tD?!FMg#ro`(~l;?X{@tIEQ!SW6k!2)zZ zk5X)J_i(mwWl$(Ad(WpI1ZWPU2L!btP$=-7>Yj0K*7|vTzV&Q2K#6 zgFTC~XwqrTbi1pwQ=DfVP1S_VD!7fi8Mk9Qj`ob3;)&Cj5B_nJCD4&FmSO)fPKM=5 z;}$C`b|BNC1`rfY+QcJ^+R9~j(P(tXKm@KLdNQs>u%bFROymZ$FeaIx!nYo%G-0t%Bw{;C-)tDky-Nq z^Ak=8vZe}+f9-z;TE8voUIk<iHlG+YtdfDyFR zEEecetIZi2_SQ)0o@>&;Yte6mO`m-Q<1D~D6&EKi8(0a|?WI19zDcp<=2E`X#A?(G z3b?5OZ>w|4N3o8)3^KZ1sKiKj%IUlfY~n3oiJ-58ZD7iQT|E;1AF%;{K{|!>f$K0n z06`^H=e>BM&vp#Lg){(NV0M>q3yA_l#^(B~kG4qg zkGtcKS4!jAidY$wy1x~=2sa6aUBcignV1&6EmE@X$g9jT=m)0-)6ZsRiK+ca8ZV5k z7g}wY9RN~)FR0{KAAsmt-hHM>N$IvV8XldG)Tr(t@-M^!SG`l*oQ?u=nW zc{{I0?d?=)K)&9s9c@bY6m+-XcZ!FNW{IX2(}7s|>tFx=Ya|Bi?kxUo(#K!xpD*C~ z@gKha>jI1UrV1@4y=SON+{Y~iSuck>zRHJqud=d|-6BdF4=ZZh6kV%YD27q#)lxgx z`eFtS3-hq#3&;bye+vYikW%3bXrCR>9Kp6dhJpZ#V9qC3eMYsX^R9&J`^ed{6t?R0 z84Bn78R;f;NuLS%HXzxiy+1ICH|4@whjT`xGjr4z5MK%XSOlWO8>SW&vK=z8tra>E zlek_f!>nzD^RB@oCU+!XYkkWE6XZOJKhb7`4S06`Ut7NuVvuuWTs`bZz_wCn#7b0LA9M;k> zkX4N@QIv7~rPmz)-s^xcgDpmqpa7kKoYQ#$WD=sLTW9NfRMxZ1Tc|TpJ&XCRB-Z$l zJ7cE$CR>cQmX8VXdG=6NVwfSE2D+rI@$LCcn!}bhv77Y=peK*(92P8ev7nXZ5?j#o zbs*a5P9E>L9z!O|et)99c>hBfY<56z`@SE(+tIx5hhNU9H}#P<&kK+OC?mR`k^w`f ztGu%>-MJmDlw}7tRM15xnh}T2@UiUrlC?^m9U|que!-QXL;KMCei(t~jV53p5n2@j zISxK}31Q6RFFz_$IEw&YN8pwW7zU7op!`cu-9oI9f4cLQ+8C2>n-et5^zrjkglN8guzTM6ZbLPucla6=yaB5qY5t5 zOkbf&yIhpJ<$O<9;;65L2ZIk|RU!g{9FUH_d7)*+Gi{sb)^oKx@4|hRfNaOgY!%L2CAD{m7 z_kz&b2B4(VAnT+Ms5TC49MJ$j+%qQ{`;A7HTpH$K3u=ez${glPl;dlC#vS^zX`Rws_NUmP;9AFl&oqhUw` znohVO1w*_5$Q_cLJe)B?R%4NG;AD6+ORd%`kQJ*ef2$xkPB(9(w_&BlJ6G*@TqzHtx;!Gq2LgJJIha48d z0SSraarN%(tY(=VL`yAodwOcR|6~9E@B6&Z^XnDM9vy0$_6Ho$6upHucFp-Yf=X}@ zOr5But`b)pC`HaAi90bZ~;c7L)QGxw;xb0x1*c#_B+qA|2_lg(ji=~ zK$rOa$Dby;NH0xvdHX5RHY!DlrbAy8w-38u(d?MM-%nFg17Vd;4M>D*}P0g#E zJy8y*nfIHPHGQSoj$4T?E2)154`A7AD^2d(ioPfp^4aT>0!zUe6Tx(<`Z#)nI+j1d zd^|-Eb?pO_1r(fvcLeJNe zXjiY>9*~H|eRmS~M#))jnN7n|r5BSWy9bc$GB98qQeD;HW4)(Pgj}R)l`VKa3!7mO z6MSFfY`&aGZ{Kv7nRg=u=3$YESvYS)7M>Rl!=wb!(-8R}A)?3--Z>KPvkmf;PjL-ZOKhibfer9-Ra6y2PsWh?XINFKB=TwdW*%ll$Z&kgl3 zN04l+>KJJ1DxpRu&+4FC zboY3-fG~?e8xXUSExNVGuA3jqn2&1PvSw zYzAg40YYbBBCrW8y~r&h%t|qICjdDq;S4rrJUBO(Kp5U?tq!zM6M5QHeJiWNi55p@ zJDd>XC-U(>sxOWpFyLU0XN?2+>#pc}EL()_r*A4KwDNTs^A%P&*XdAiD&;QIATcOL)xL zP2X#GN4hFP70%l2M{!Z|CiwYzwu=;y-|tK7ABhJR_UZYJ#ddY`aQfBNS?cy>KhB03y1Y{+Uof?`lanJ4VXXtJbFdFul> zFhvZM8EOoDIUMEL2_(Q^&qo^%VgA6OR}c3IHel4|3DiIz<|#l|z)BD?+2?>!i(>)e z2g@fBQV>@}!fNF#j_qMzDf8ZJa@;2U-F-f;`vy@wadmnULZ6+kdg{En%7lt)MVhHZ zxD$!msw>Tp%Hhx-!M8#lmh}3v2~t?mQ)ZfBd}9PvHXF`3p;(qZqD<^-T=NZ@qs^Z#dPwW0syZHy zi{9crbY@UB&_iHz1xiH}1=I&g7o)}C1#x&po?%VAGPZ$T`60FvJH9Wo%iK**efqMh z7**Qz6z0i!c_LKHeWH4I;XJix=j_1`GH%b*U?V2;bWHknR4ka$rDlQ!t7Nj1&-_V0 zR<;~H>DN44?1o;FOpRk*5M*PH%0rl6ZxP}7JLBnbI?T^3y!J}Oj84B=Ggy&V2 z!zjx{lbMKgLyW!5s*n1dv|?XoHfftU7^@d#v_Xn+v9 zyd5kdNc58MJwQptgdfyRxHRz`p@l)LhW#kjyAR!ag>3a}EVHhIgpd-zIu7U9^g5H?QfkgwqHw?@`pivB> zgGm&K-Ce?t5N;dB=Y?7sjjp#(*uKu)ORJWd_yYr{dM5v`}qQA+!UU6Vo($#LXyn_N7f2~sm46S%dphjP&k zao;5)GQ|Fx(10VsM}_hPV+c59X#odx2oVv85ds5E0-7?`g`fx1rK~wwXvt)Aw@LQV zT@E|xfk4eGKe@jnHNqOeHoW#tmE}mJZjh@DmJxNypuO4#*;T7*R zI>hTRS``d?jv_1WJF7%b<~20G>(lc&#K4a`{>RZUs+P2`i{2y`0Gss^mQqhk#8`a* z*^&${(k(x?8+FBO>``XWW7{M&uCFy&J3F=yU@sA5BD?`EOh9eN0+7f%a{__aA|NQn z39Lg%g@`lWGR)7Q%2W2tqD@l)z)qPGELvip#&*b}Q`-?yMDwacB zLVUHtUQf}sGy7DFAP8jZhNNI!J=kC;irZD_dlj=d2FWBu$Arx>HgcsI%`hZ+cyJ)m zF)#PvJeEvZlC;V_JIjf&Z)w*yBW6~~qg9zk6Jc*VnX;9MxDobStK9`6vXt~H;)~?C zbls`iojKn}Ll4(75}BPTC_qL86I{f>;r%BVoWDH6Rj>ctYp>zxxt_shVb$R}tLHre z<fi@b!)qEcBvU4={3s0Q(yb%%_2G!jnFQuV=@VJ;?#6uo1Dtj?ThwbK+4;yPN zH0_DWWM7L$=d`q9;@-98>bi(ojBpv{GYlDW z-GB~e2qHptki__$y~e(G{>;$?KvBAOM6&m2p0La}fz}VBipwAtKhtc?=^WkB~glLwo$U_`9DTyU%~{jQ#&HTy-(m zq_s9VX6v(|4Zv?6GxgBpWWKU5iIIy<}0Q3M0NSUpQ@=rP!VAxoy-6KYW*w|NI zZ@XSm%FffujHCMQTjT%ySp)#M7mzic4FG^yKJ#pmZ^%ej7iNmM7$Ij;z9^6KnmhIL zEWt!30Wg0H`1iTdU}@dV_7c}~In*>5K!B_P4;|bv9Y_N04gxcQAVfe&P)Mx?IF7^D z|Ls@549FKxypI|tNqx~B-tQZtabjO$U8yJH03 zm%edY6xu48IHI7k-XfAlfcD!1NVMQIY16jf4(kL}PRl9zaJ6+YKA|qT;df8YYru!{ zFPE%(OcYM35>8Wa8)>X>Tyq3E@MWnsw6mQXn31k0&UkHlgn95RyUCA|??|?FFo}^= zdWC$wMPU9AkRieY8+PnOWZrQF!ZHQ7U4mo;dSdtjM2zgN6B#okt2ub#;Q@}UbG*)1 zcfbSjchk$pm5x)99gL^iEIFm8t0x5NL9>U2xELs`Ac@j+CR^i6n{Aup9M&jzO3ci4 zoJ{tk-QgHa2ye8{6756{bS>D|{q0q6XJ1f_Jj26#RH+Ga2az76C&4Y^GT)7)s-3fo zp%KZ4B0TRl=Qf@159TEdF4VEydxNa<+kCPo6=Crn(qowF`y_y8(4BDBig0$rj0rvh zBq;Dl@hEkeV?0Ng^5X1$!{50xzk2;Qzw^Cwo{*$e1OP|XI{?<0yNPc3?Y&TNqbFV_ zUGp;3@#xB^kcQN7BeO13FGsmz6}|nUps3k;J3EzQcY3zl_}n+8yqOX^9!!dzUb>>r zO5We`-#{pm0Vaog3A=j-=!v5?R@R`{5An*!{ZU<=YJO+LuD4aEDr1+IY>n{OE@{|c zUjE7tzx#c7RPkRX0_x1N@a2NxM1h~!i3F%*IrM&h zcliDzEw1m1RPtd+@fW3%oVEHgpD$)l+V$OXA{NVozZkCtq0&3??GteOcdLK;$_;(< zImGr){hFlkfzkdk`~Btv<(+?d`pIAa`yc(u@8162&9A-kIWHOAe)!>sw_kYU=Fh)& zBmGSKt((J(vGBLIZ~o=i{_L-AZ@%>EZ~Xk?wV(d|?W5aY_~y6p51;Y=3f^zu`6h4t b#gA^k__sg0?XJD>ZT?^1`|Y=n+CTpf4VWc6 literal 0 HcmV?d00001 diff --git a/Covance_UCO3001/browser_profile/Default/Local Storage/leveldb/000204.log b/Covance_UCO3001/browser_profile/Default/Local Storage/leveldb/000204.log new file mode 100644 index 0000000000000000000000000000000000000000..bc988fe09e335522059540e718396ff19fded591 GIT binary patch literal 33990 zcmeHQO>Y}p8E&pFhz*DpY*-vw2#`oq&x{>^>=MV#O;fifE{E~D_|8XC zyNcK#*8Blhh!qmQ0Es<6ffYM8`~h}6XHMM4W53hs4v}+J-QLDycjobP-}AiRe|XpZ z^M8KxS@exZ`9I&pzxRIp)ig~PN%zTOl`3C_PiM8R*KD-h4?pUuK-9XmhTCqmI<7l7Iq~XsueM)H z7Ai_q{DRN*>(6+UBqCzNDUave7g;KO&R$&BZufpf-&!b>^iql&eP@6A-DkMBD;cID z)_<;bzkK)p#>l%^-}xCH#&a5ty5rS5tww(TZ-k$|$mU}a;|5*F^*V?8zO!-RO%PQ6}t@!9v^e+SG-e87$(&W38C zt~svpRTic3Qh&6IPrUo%-POlgIN`C>*R5~zQYJDr&mU!BSa{(?Bz`OxsZ>#|YhJJT z#q8H&G0ERn>ks-zwcGvwA-L;@jn-iS&-FKH;BJ#}A88(*^Oy%bl;YY#4(3*1I3Pc4 zl|tSjA!lF2_&-^(bG4dgumH-U4r5di^(L(ChT+&Cx>I6Th9X^Zb|U981?1MaRK(nA zb?R*b^WJN1%bO(ApJ!v0Fr0STrd??^i>AD{68@B3h($IIrH`v0v_W@T?G7N?$@3g@ z$00Fi10JWGJr_|BZqeKVUoKoU@RWfuz|#iiC=?0%c|7KkC42Z@3w~TI)*Ehz1^Nc4u=poEKo zyhTE;(dO(@h9R_zD2hePaf;&&$_>o{FHtQ|V;&u_XY6O0j1baL?DQZwI6AOIuSj$% z+G23mk(}MO<(Wvbg!K>D;D8N9%&lpu;)go${wbMw_DV|@I^e=iC1iON$y}(*NTsRV zq`6av9NH8uXDJVtxavWR7NFjw47x$RB<6A|c@$<)i6gN5N=6p*N)Z>0Ii*{2%$+)E zTQtFag@_A#ArUSwL|iP(cgN0wxJ$W1260-NGkuKu2y!cUL~*J@%kru$*EVt$BGEI&6| zE$1_JBl(PtmLYz(pjQRGO}YPu=q0x0IrpboiUNR?$E&3!dex+;+c_-9oOVT_%*Uv= z&}mVBC2k;JEYYhHy;*vQx^$w5oyL5u0Ja3~vutc3uMByqL3c}>(Q}COT%Dia@B|r* zle=22d+9l=UMThAd1Qias3VLeahD;_LhX*mDc~;>eXH_fsNyu6-)+h?eSoF=)~DTSO)isogaPf=7W{H^oT0!{#qvR*QRe(_RAUCIDQ zzMn_z7=f`uIhWJM8L=5?xlpJQc<`0EUb{j2{RZ%oFxNm%xd=IX%7e+0Cv22LF=nAi zi!nwEKh1Zt1i-*wlBeszC(`De^-!)`Eb6k9Cu;w_Hp0JD#wf?UECz7F^Bmoo;=p~N z0)>2rH8vHUQdsu}CDsk{C1G7H8rew2GJ=j7Y9muTR;`uUZDlm$4=EXw<6h>M>KrK$ z?}a=IWX483URd*9k?=ZIO64&|eJy870s==-AmW5Q&(eaAKHoY7&!p^A(Q+;of)mK^GvJ%fK_0oSdLm2%RD zxQcK`bHK}#%Q=4ofi9v@U0Hrtgd0J03hwiA>wUr}a}IkFi&dl&pU<{BU7QX|#WsD? zk?x0?J$R?I;T*bclIJ<_v>iv0s5ayS75ZB)kwu*FiE_lLbkQhBye#fA4j|13YRczx z9*(l`K zsOdV%#(Db461|#!@!D>)P6@_W7v%?PPec>BVn?$XUltsH*V&4vzslm7ch$ZYe%(>7LS}emqI@=D|{|)MNfNO+||B}6o@^p`-_(v(OV_W1TG~?>iN9P4c>LY=>k6CCair%ER4QWv! zEwA0GdsHX%MLsfzHY)>(7P!2YNWDQ!D<8IXkLR5xl&4p3?wD~Q;_-tIp6Ae07TrKk z)BQ5!0mje8Xo(KxM4&dh5XH6NmyYMs;FE&UfKP{V`*Vo`U6dsj()||mk7G{ObLF;% z_C%lQNf!v^B58z?i`LX&3PSZDdd_w#Yh>6?%b0?^Lfpm27QzAlMM89 zWsx~xpQC!zTAEMeyVq$^@pMy1NAq0|jW$)IBY}E4QS_B;y)KcP*42wms)){1jnY{R zOi1%F{F|Llg~A~7f`4i;FTuP`o~gPI!=d#%yW~3Fh(L@!RR#LIQc;kR7WgvYsU|N& zc3RB9zC>u1?#YGegW*0rse;RDYow{bBWk3}8BYfu*~@FGYoq%ad?to5yKhk!;7={- ztJVcz&jVFxmy^D18-q4789Tc|X`=S-30n+as&Ha=1&zU*2^}_fVORc1Fwb zd=XEj>U7T|I`H^RaZCghNmA4+)}#dm z1{U+m4H&?jN^2O3(`NiAM75}%da*q>${w4$MLF7w^5tKHAl;02r6;7Vr@LNa=w(45 z+A-Zb*8qUyq`PU*roA7`(2eB^!*qvgzCe=HB3?-vVjMl?Z{~>CKgMsIoZ8XHybDY6 zDkVl>c%x0pLjyUj#&Zu}k9EO9NemdVB(H=xHt4t%$@482E*&$6|AUej6=JvP`w)uG z2JR?wvD=|K4M6QtQE~${?fdkD49jzo7!t+v(t^GFxWs-%DmrWSE7BtTHKtMsjLTJF zSO^x{MSrDLEe&k7bSNcmP^U!->&F;A|ApAjcv{rUQO8MK3C*h;AUK6K`6mVB{Z1cj64cZFfN1mE2VL5U`WIp=KpFtyWGjVj&+q zcdq7%Ty71Bwy0C6WAD6MtRVXRFTeNezkUAsdYy{_|Nq0z{A#}jn<)HL1jAV6HEutw zb>G!w(who@CZKSyc$kO}d&8d25Hx8vbYy!y?6;=^QR~(ku+6QG>kdv%u&Y9w;begv zjf(G5jTnKD=vDDUEG(aMUu3DoGOZVvwc8Ij@l=Kw4sw=?c~a|s`K}i7F&dh?we`*6 zLxXWoh1op9PuDjf^*)yMbD+2-6Z+j-H+1h|&jNh~l2u4-dv(Mx^VfWZwWRUVytwP_ zSB2ZdU#zX@`a||>*ZMEtjRl4zYlmU$V{d_){j(p2LN9`(bg;enmb7R3q0SwTfzj=Gz0da7{EY1$NJ-sLJSY& z^95EQX%vmp%?cPh*wLD(Cg-xm=C(W-Fy7iG))&t_sNsD z$>IRS^i{k#@YVd$UNmvff>0dHu^0G2yj{q6`JFv1g06R*R;%rz1Lo0BKKkwv%Ha4! xJo+hprJAMuaf(p<Qh3)S4Y`?E(yWi>dJKfW4NoltAmeAw?OW7rb1mfT% zlYN!IRLy?7=ks~ua}{0Rd*|N!zVGus?>uuF`z=yy8Sb9w@J}X_Q?mc=yLZV`tvp4C zMQN%vEGE!|0m=U0-}=G+H(vPZe{8T`Si?3NEt~-@D@X9xuK(E&UO+cApZcy2tIzM~ z?Cc&Nr-u<_(lT7+F(Y@+KeRKA+=HMIN}i-eN{Vz*NeYeS|H(7xObsV@PBP&*6RGjD z6fZN)HB*w96vHCl6R+{NdD>m}=F;K=onnNk@z;30PM6c+XxrAgwaspK)HK(~Q=%Y? z(g>A6$)68Uf-ExvImXBgC50zRN{EnMOp4*fsRSb=o5`V}&YHQ(lAr!F#&dFVJI73S zp-&_6(x*#Uj!!ZY`W|=lvB(a~C6rC2lIoi9(HqJoOZ6ZLX1+sG+N>rhB-%qh_vIokIa%p0j#9 zUYAFjLosKKe>2j5^d6X;+|CJMjuIGhSm9-L9@TJa9<{=v-7fz_=p)4^KhY5Rj1*!s>|+bTbqF9Ar4|Mv3&vck)u>n;=*w(RUEOdADVj-6!hVvy62q|S5~ktQ5@vQe+TEdb0_*G}rmgG}+C0L= zc}gY+C1on^zlvindtlmHK0eJQGmNzOZFR<~!8v2CUJNZ78y9z8C%Q%@k!>Z%lg!j4 zC6Gb5Y}NNST`f}gq8eV@i<&)dhc|>3HtuDyLf4QICW9OkVWb2l2%bH#HdMolOQ_jx zcX&eid06Mp#r?5IjkUv6l8KQ$6d(5NMlrWLu#DL|GYnYb7&E2NJcqV!`ioLk|2Zz` zOUv}7)l2jNtZr%N0gTX>HV-jznIgASVV+89D}%=RUKDZcJW>EFd)(?Hhq>@1#gl`g zz=Vagx)0TGc^}N&F6~3vr!39n04H(esFIkHczL5mQZ}*)=~SOB&>%fq0LJnt z#@>%WK4C0}=@k{nzEQA+ZhT9l_@y(kZ9lfG?%Zobk6FyEv^_DQfI>K;_X#XTtQb2&qQ zQ;c+FoOjiZQ89|_NJ>mPa1cX00hbNwwXGHt_ZF%xHVsWJHux(?NYypY#8jQHlak~l zcgn${)Gfwz<_5Smk_>JH5_q-^tQ&`;6+y|?Bsw5HZ3qRSQ)3zU>eTPV3^YxYHVv49fG*;Je%;}ZpQKXICRlMn?I&&{GDXE_j8qR(~U|u)7g*9lEHqBfqnNKfq|a-dXZ3m50A(Y;1Xd?88M2p?iGo^nAEx2d zJ`D5uLa4cMDfW#o_l@7xmh;MqkxUfieNKtrF9`0fXY?FUwi+UK-aQrZaIHjY;Sed<#?5Cn4IVMIV z4*nw3GDJl+PYI1P;4JN_C6wJ@E-SX%gNpo!!X#w~*fJIP{*Y?WYgjSpF|RMQyW!D8 ztiPMsS5q!=5#R_Bbpg|GW&y*z-p~`pbu+O;t$kz<1i&yS!-@x5$>CNq(n=g_K&Jfl z9#yB;@Kv22hY(DA?!|h>h|M&I11SVzthb_4`;6&E$LdPoL0#uax$PU;La1$f2nLMR< z9<$!om-Y-o&+E9A>`Y4>aoyx2d&vj`ksaKC4AEWPk7`)mkA_NZjr-ZsQZmR0OoR(3 znRByWqInvAnx!wH-32gmX=zzSxpjmJPbz`@yEK9YjT4I)ZLNlScq5f4pn}^N=nZAZRXs+1?=}Cq*F*A%l};HEGnanlxt3sO8@7_1Juw zeN0SH5Z*fYZAR(s24i6Ihvak%;Z> zAui#yiUdRT@Kk~dyhLeU3L3|*>&zaz*OA(d#x4;}9~B{!n&*MW*((NmZ^NTA><5Is zhvB(hWUr_|PC%=da1E=MaQedyu$tcyR&rdNnj|tk7?bv+O==3$a4dzvJ@nBRosBc> z`$TOQ!%t0eK-z~?x=h0=U6!@>j}2IFF!ex%br6=!6VHYMAKy*&RZ3ZgAr0BL36PUS z$Uz9X5m7DSHF!$+>?Fj=;W6G1$1+s_>?x5*lS5o0FgK8stGOu zeuNVOk`eI+9;nic2O24zo_?ikHT=V2G_=&( zc$i%)vB{k!2sWdrAO^IUegg`qxzQ_Jq zL2Lz#9ylk_CY6jSkY)0Ll0tQ3zJ~8^%s00?ymsk%i*Tb+v%p)8_Wd`H?*%{7o7vmY zK=v}C6lEYDB!Wge;tPJ=PlS1Oxj{p4xdHP!XdaO>Dx>a3HJsgzcD%Ixu#wTR&r}QndzO=s zb#el99TydrhfuwYYB;+Lv?_(^vrgD_SII<1R8myn^=S2~=k8J!%hND|<>8Q*hf1nB z9cwd}j8AbqClXI@ZV+G{adApic+vm3R~s1`E6XV6@X(Ln*SO67MFm{`skBtRjKd!1 z-n5HLDB?+(^4aH#>y}6^0@>eo2_C=5qp>h(97FYH$itivN3p(bsk`rJCc6_L0zjGo zS%TlvM(}reba~c3MTk;1cZ+)1rJ???t9mYEDg+xenybi;IP66~A6&GkGpL4>GbmlO z1B~y6sd59CWugK_2exd|HWnH$?nXl^6^*;057rSSEIX{@6nKrmQ+2t7@FZl&_K>*+ zrdu=Jdkx_Nx`(xCpmAab9+-Z#0_OVEgpX4EIUZy9ph~N=sD>A3(NL@aT=9RHh#PU@ zTWLfJeEUG|FxdqgT40cOO=XzP8GY)CF7_(|pP&-NBQ9Lzg}@^}d-ODe1?q+7s#7)09UN<9rW+?BHM2Q@qwB1{kyJ*lq z=+IQ-Tx=KC(9KFz5^`*ji}<-M>bg$D$#sxFLT~m$zc)&-2xnXEFeh7fivC|^atAw} z6>04Br~9z}iPR+=0vRLAHN5i$uJ$G1mkB4R}C%$OxPt{1apnQcUEzm_T+ZT#R_{b%Y80`XTios^R5>DDLul zX-gh5x_pFP+vpmgBvIz6X^8oZ6c2Dqh@)qH02>w6l@~Phth|7Gy=|en3b2L3ys{7O zEExpZR162oznS~+C+AU`>ja`$kkR;PIBv5$?=59s|9)u9~9`>w>scXrnl6Naw4c9y`X@qdkZw2-CK|iy#-lj ztTUGng19YZ(u)UiF%}L?{<%7fX*e;9VIE)Tur<5Ix4Wo)xtt{&ILF0aSIY8K3-^$A`A@L zBc)|QHJCN58q6@Y;o-(b%va+-^c)6W{gr>Z2c+elG#3TGJ5BCL^Gq~I^{dO6hLg(} zUG_bYPA+_{c`JNPPNd~boSRl3FV=AW@nXb7ynKW;6oMR;Z^ni>g4#;PK>f_5GoZj3 z@-$p9c^D;5o_E0(P4c(N>3 zywcDeNyAnRQqvS~D>bY6dJSjt_27=!BUq-X4F>{C961WPbCnr~bUe^nOMGxoWuUh5 z{}z;wf-DdJ~d^_4me^{>?7;3nzsZh?zll!r}lg#KW8uPB5mKBX?A8s1xkq>?Uu z0xaw66<8nh?h#l&D!2RfMO^twtb03CyL(i50g?p~p)k!5F%>hLO^mHL?yWY|Ah|SZa ztqB?@7g4(DPvO*0RuQjy?PR|QHoRQv2>vKpD`w48|~I^ z3^aaiz}=8lIfAfF&llS}Apzw@NIF0vi3I+#HP>!dc4xh+n47SSXn?jZiHTI04uL5^?^(#adEOQ1}7>{Q-S~O%H5HbMbr%Ax}>z3-g2`#cjRw>SbI*{bl^-y*lY?%&^ez7NTW`4&YGY35b!~ zz5l_iRB@ug+L4YcNn)X_WD>|uClfsIliaYivV`KEb~~N1wk#p7>?~#{?^k4nh1>@$ zllNN><~|y1+06wUI{=TjX0nnKloTiKIE_%mN0a_(Ywl4%C?I}4Ft)o4PU5nu0V+*E zjmY~sJ`s50)m&=x;v5>9E(2OKU50g}iC5pQ?SoDntToOBK;68KYgoCC$C^jr1TLAr zL~e~JPzQ)gKtW_UiN%AS$7*tO!sB~kpWBG93BV|Xs~gDs85wfmtr>=}Jz=FLBNUx` zlh5u!r2|;(>ITT#1ug@pmSp}5LusS+wT~{bhw6Y8r-^j}84NU^Q+Ht+PVU0!iy1f_ zu^8{?Cy4{g`29*eSn&6`4-CZl=7nDVk&Q2oeQGEx@6H-QlpIoo2=VGz0JLG?iC^H@ zN0oTH(@oD8lzqIBT`xj9H_iR5WCBP6CHU6~_2NbiCoXQxUac+v2DS?{>iSCbN%xmbdD+pVurKa%z@EAlv{TG$cO{a3qtV}(Q7!4=&?3uNHtIhgzyCniiW_+u`9@(;iS$i^4tl&8Tq9J)sNtAm1j{2%6+0<( z)2Ak+-zHl@pg_9WK5#tOzNxKt!W86hYb)yp~!Coby{U+5iET?Vm3x7r|;1h%k) z;p6~k%+0q!ya+vPg&8?xZ8tb0awn9CD0K?cusQ{M?eNc4)xU!;PQh^ZTWcr86m?UH zdLC+G0+#G zUI(dDHi;nqm#Ol!$u_ZBT{CDnzGlEY+1DA^Uv6;qL%<+AQUcc!j z%i{^XSps(ZW=TUo9|4UIqEm9RdfT6;Zyg3Zi#9(9z6>&9(D@^ym8*55wKe|#`j(9? zP-pwBj?`YUsVJro)t&mJ4wk7j`c^-nx^J@LzOiw3K5EUtPb5c@}~&G`kzHW z?RumhNuhH{&B!VXt!9o$eO9qs3NJk5&LviV$TD<#wm1#qMdby=6uuv>l&FPgVaTdS`xr z?c7}U%_%hdFL?UmUn6efq5tMBD+Cpy&VHy_w`OY>t;{ZXGbN4kw_d$M9bTUuD!nf6h$T$=js3?Q5x4y5eK*V^GYDvNyNi9$xy!l=9)^}el4Eg(( z(jWif!^P+S61h|V->))(-njLH{B8ir#~%LT$6fIz&E#QY1Re+*Mfh~|ew8%?aJ?ulUXaNUE z>we$N{MONklxfNG4IF#;&;54hpZWiP{uzyqjE+9zIL=OI=Ql^5I|P^W4d=xj04v_t zS9@Oxdv`h!Nx0K_;YCx#PG`F~_c*VLlZ7`kJ9TAD<~iSb3rXmF1JDl&LEt5G2_j(350Yb+(Tv;cH@EBY;0n>j7bkWZ3bn+_!(Httpg1+3|_21~Pc$=Zxhlrnt-GjoafLo1f z`#<|!q1u}U?q)AwTm!YwarPVk6)Rlg1=>?{YfbkA)C*8T3}qx$O>vZ{(KTlfup8y&P&dn_iwi*#u6$dl`Q0Tw zvt=j*H6>gyRQyb5uz<5Cga!0+hEFvb)%x4f=zP6;AYYlwmh%DNOcYU00a!3$Fk);I z7;%e*h0IdOP3JA+|GvS59~h`sdc+B4m}Jf_g9%d>Mp)i8UyL(W^%*m*;Z&VEHlHZ| z&BIl74&WP9oH=}#GF*Z2&mi9Z@-hPivRu~fng-I}j*)UDt?iFUL<=bOOFr>uke)L? zk2%LpiJQ|TeBJ0(Qf&s@G&m!e|(AdcAw;_{k zbMAx?;dh?t`Vf>Jw*!7SH7Qyk!nY9rE~dmBI$OuIDLUuTod%{#&51Y}1sez{Aswl? zTLxinJ^+OI6lK!vU?YtofvRR3fQ>M!GYB6u=>=Aee<@T>s2Dnxu|G5?vKpHQgfMpb zBET* zB3eMH|8>N_0^4HoY>6;ijgT4@CxKj~Ik~~5F*ALIhH-^#no1-M%B?PiIZYas2+1ue zKx)#c7+dLTTL}5};XA7kQq56}k07cbr1&|!1{;a*|NKnXKN@VL_Xn^oMmAcioG+FS z)`G@tt$eyx>fP%PIQN60KSu@2uzOI)=YX8uG%^zeO82iKj+^Wv6NSvOao;vDOti80 zLbM&QwlvwYuBiF!I08R1{x1xasx0r_c1rtxh=gjq?h`{xShvn&Eh{?*v5p1EJquWN zPUE-a^g4Sn9|lmiJswi89o{x3Kl^lGavB&zf-NZYAp_YHr<|&igYb2SzS>jnuw;r4Wqgr?RC|P(B~@ zW^1QTXRCAZ*^x`7Nzdym=lV0}F4m5ZjKsT79Lr=c&!o!9q46^p`dlmP_)LH*3%#R$ zBDt?z0Y%(f9hf|MEK@j^E6$}(m4iyDHq=+Wd^R!m?r`Bqqny7~o4Rzlc(&d+zL3u? z__LMznZXOy?B&vly4Rl?dw*XoC=_c!zA-*qEB31H?~V0g@xp(L@RZ3Mk%j~$t>$4(EG2m2GLzI5No(?>ER3zsiU&(EGsq!Xu3x~Gqy4<=94 zhiZ-4+zI#0Q2oN>J9GZvv3GLyi$|yT)$4as(kO$e!Cgn*X|?OlI47~vjyM+)(f~&9Q|(|~<8V!({1X1L ztn>Kog}>&U!aAKrOXq;+v&ef1DM+Y$P9M_coPN-y=TKtJIgZ#7r0RA~IL8p0MGI$8 zOBrj*5NbH%TtFW89<`1m5BG>E^nraD#dsu8!akH!fhD`ti}nnl6(?0a1^njF^EuRY z3Mm4lE1^9@sI7`NoJIaI(AC2z?+8j}8J7@0h2P7_cUIBb$DIX)=kV*JpB03iaR$-i zs_I7xed0LwqmD7>eYA!8opV{B^F1J4Wr_<=N$tJSD zb(BAj@)qD{&pC7W#rCOIlRIGOS&YFE#azbly@rr)5N+j-(1*3X4 z=EFRC$&sPZ;S}Osq&Tj=`=sjY5PHL%ItQPNu^2*q7cl1UV4QuFehjW0!Y(>TQ5svr zmgzQXSjK1+RPQPHn87#}@m<(Q7wKw9J*h&1HFzXDzd+L5q)uFedGxnqWXF@Vwm%{f zEuhrDQ5u{(qmO=5HkwjwZx3cN>1FP$E=HaroD`soe-svFF=IT83)x(~0#J}7?Uwdr z&|dD`%o$U8NK=#TB?C;kFUzNtmy9y$Y?eo+n{;;!X_$-bGbbX`CZHG}>5rc^M zLm(%&5rY6Dotc-qre5kWN>2i#^vn2M_R4z%*-012nOw*^FFEF(-vJ^%54-kYmFlOJm2&cWPF0v-HeQ z`4z`(9=~>ZQlHDrF#OJ}KkR4ty^NGA>1=;QB3eN1PbA1C-)%#kUqu+_-6Cw*EQdXC z%lu<7_oWOw0rTg-_+2IJ`>BCfP53nnw&DtODJ#FyKH*v>5XGa2_2yLtbDQ&4pZ8PD zN0E^hmFQW#fH2OG8d6d4bwHID)=iQ6%BYJ%_Fu!!-i?0+h;qs*R}qZrx4c%*pGjVaUrnr5z+_W5!e{Q4+DA-9(ZuE>|aMcQtzXh7gGNowB=RUmV$i5 z(b(T7gD?t7C}yGZ8xJ0NDB6wDP9sDgZ}8}YVOgYOsMe^_>Tk@)BN2{Ku4VZYu236? z>Tn)vpcscoDm?UzqfF}FP%uML8;?&|6IJopCg$rwN*^g(&G#KGgzT#G`yFesYbmzefh2 ziTIXAS=4W1NikR|pz;t>3neLHPa}-jLLD7lCxxTLB8H|A$~yO;tj*y4RtsMX=piwe zGoIt7$B{x?_DL(-67M-$97nDpJhr8Nl!x9@b%JX{*l_Ek^s41r*EzJDdDMrNZ~py` zrovYd$_fliUS?nDs)Ft9oJ&9c=hF8pZuv{lDK}ubTwMbsIZGqUqd*~Nt|G1(S$i*W z%NIucVvAekta^~NKFp!7X*glvO#^jkN8Hj8w{*lUkF&T%)`>^Oc5%HThal}}wO%dD zf?{BY4ezkwoC@}SmqFN*#D;g+j;Pjr?&wOcx~23avK{8Ymz3eZKHK#(Kyo1Ta#a^5 z(^3kJ9;6azZ_oR#J3hLQpDqlaPF6FiY^~OJX6WqU+NpEHM+;NXPIb%Y5|gff!hJvr zqiB-Dn=r*;d(KrI?3qy{a2DK4f)e-i1m2z#xjWCrcx?wVJnP^*tZ zZe5nX{>JhtXrlOy0w{*+JK;&RhB*?L5n4|%>4cd@PW35Tb6ah#2E7W2HY(FWIVxJ` z2bK2tDTejB{()lQz=cvKcKPUdYI1TkI9>6N^~_JF=jvzDv7>H$dhngpxl>;1()m6g zRXP85DA`oFVr#UCpLsss*>$a>^#4RC{ok)}<>$~bS%xM0eGa(M?O>zAl?m>ZF!L7t z$oRi7P^an$S31I#j&SA47p^>h8nK%tKRRb&oeO+hae;3mXJLjZ#cuArxufe1P}pQj z=`Da+5@M4~Y520Hx};dCMeB{(!a_8bOvl~mbg|K0EYIPhW~H_et(3c`vgJZ|Fkda! z)MfsI^&;*u?oAxt>-$H}d9Lev-M$xdlW7FJC4rvXB+&Pp1vX3RHBH&HqGXdY-B`20 zbdx|Y(JZiO_E1H86Gw5y6L($h>F%!K8a z_@Dgol47*~)WDBSx*JydYvR98%IZ^aD{B6ZrddZocW zxo}T|jc$N(qDBfex2TuG985A|-XYsQ<_KgD9CL@Uq@suv~}L zMK~W?Cg;GAk-ew(5Os$<)XPg;X_MluH7S|Cy_EW4hIY!N&Qg12YMqhx%51+!WQ5x( zlPqhyDXC}DPMN$Y+iuGCYj55oe*2^5`l!AHOkqwDx__J}jT5L5kluG-wv-ijzx%GR`^?O!hc!$z%pWI?pr^iTd$FmF?JDh%sm?)81?{;LX+nBA&Z595Y z>RX>cWKWwL>A%F<{)j}hfYPsKZ*zp?v}?vWgYw>h-D_ zIp%VQe6>zB+^rSkY?gfe5D$~gn@38jn|P$;UgYZ{_evO>e7$YLcbUgX1nxKfD+cP^ z_m+Qj$kz_}x|($7b@Fx(6`q{q2O%4T9JpWdH3Bm8dqAq)hTL2<@S1_Q4E)r%$V@c%(3CJ93L9?bhm-~4NMuBF>uPjMFT%F@P>g)1}+={=uHNF&9@K*G6!Z zSHqJX5j@4EAE&th_W;}_95THHcQ}0ven~$JvU3_o!dZl!!7pF&&EjC$&XWw~ISyfv zywXe25Jg8kGArW{+Rm2_`@?izmwmOe~L`S!81hLc`FCkCA`W;pw zI+RbC*m?cC^^Gc)if zvrVjt$^v}mh&dY=$KskEanF!k{62j7n4-Wz{BpFj$niAe6-6IhO5a0I^}`>kyAN$0 zdDQi{S|3}5KWXcx^kaRo#p8Fb)e&>7{GEi3>fM7?z1xVG!zfLXO8kT8y7+e!DDj~8 zZ(!S0noPud{0%5g#-VrU$I{7FN|V%jToXvGM?26>tpv7GMto4(5OP~j?;$JPg7_u= z&x{h{bpr)8TQ+vZm_H3`(3w~M&8qB3mL8dR zlEC&yB%%eBb#J45=2lY*d~<*gR+8S-e^8eXSIXZ6lp}W11bh&bS6(!g$d?2t*W+Iw z;@`)58YzX7{YU*Ur69-DLO}?nAbw7P;DxRU94U6l1AS*|80*X+EXjjIfLlc#EE+ts z$%7>m{<#Hj8-E7xNrX*@JXkr%c#;@CS(eRbg~#cZPsp2xUBOzi@GA#R{WxCYVH6LVcqlf5O}=a$Xpv-> z9Ou+_&f`Yr8O4E?{zIXwkHE+dNDh4@%407caq_s6cVqcCH`X4VaYd1QeMrN1;Ujq9 zss@6C?OI_QWxNF1b^WczwN?0L$GcUzt->Eved`~8VS=|X dtUqjQe zMM@MoOH$g|y>l|>IEmsI#sKjF^EfX7^l*m9{|*D#4`aj$6yN}l4L>js4(7oQ2*e2{ zNSuu0IGf+M`%}`WsgWp(I#GL7WY4Fos=K@%^jH;9e*|$bUyfW@PqDIM}O## z$G`O3!@)DbXJq@i;FH3S{LP0Se%;(nJre|PTd)=KiQu!LLDmP2Upsa@b7boHvGK#F zP97UQJpRh5iNjOjsgc8DBd?5%9+}LHO-&sCMMc=nfZxUOXM>M9AN_|X2ma{EIB52m z;QQ>Do>{%J@zTul^vWd}1+Sa^X*&+sdDb`-nVNSK)C-WR*fC(oHEDX(^`3K`)_e52 z-r4`ko3H)V@1Gk8{uSJE*FE7*Vs_Ey66UvGb<3ZFSp0}F3TH4AtOi$tjo>9aTMnj! zl|UhO;d0j}nXzm1$j}Zc>35=>yYAYgKJ6^}(D}pN=kz(dUdeJH7_~4g1e4~oxnL?d zY@7{_nEr4uZV75OGMloq(5{m0oY~HsooqwQryZa=J5>&7BlEU6+y5b*d;0Cq~8=#-^su&tyg{r)S0{&Sw_J=g-eh zjn7VI7Q!R5nFVsXo@F`RJ*)cre-;J6vYIpcnjycOfv-YQ~nX!yJ5@nciJBu^c zq-C)&GhMJl8EDKh+ssXWCEY(__f14s=}Nh^V9%Q->&p#g$c+6?MeZN5r_R`wdhWda zE|^bd?0T2Y6b4Ivcg&i9`loTq)-_V@9%t@ysMG5ja)DA$PcD#FDSUBbqqzRk@Nj9p z_~Pv9)#;VldE@0_vkK|Zg`<=8qdX(~`cXXF@dGh!E)6EL%Mo-+h)Ssj-c_R3*CnJ30se!LsOHb8-UfkUt_ycBt z#*)NU^ZL3ao2B4_1#!cY%36>PauGMoWZAA$YpzL#Y3xCUX_=c+gYqOw4b&*L8Il<$ z3XGZOx!$pe{zi{GJHXYJ@yc=pXO4?9Du z1vz7xOh?8t)?v$N6PBq}>8YKWv23T7bs5s>bsf3Ua!K$fPYryB+$ilow4+bV4ll1>SXy~`ZGPj*+R9hf zmXE$LdMdb|9Qs%GfGs-?*fZKjrEV#g5*%IdD`uxk_L?s0QCpmMVQ-^Np?8h8zfDwW zuF5J$={X1-tLQt>Ju0ES=}+gsU$6_K_`1&=x@_gv1uM%|f|sovo432K7*~R?*za<1 zGIa$3bRg=?JO)7uQSRR^*@|<${nAxa0TrjFPC|flX zC!%U^+RT*O=C{Rf&f;8Ex2ooOa_?l+s0<@lkC|@* zjt!*%iSzKHie`E3eua1sy%wK#pKb2X1W8>UAXO3Nb zcjffkC%=65>KkVgx1PT|Z;zZidTw;$$ibCWYY`uPGd%T`lkY7rUKu&_c4lOLr1*ON z;^OS-S5K^*Ir940^0~2BXRpqWo!Ph;zBlnRvm+l&O?_};cJAWpNI3WE@w2B^4zA75 zEv?PZZk)fewsbTK{tIKrtnjk`M9bSu?CSO6>dN~3`HlCB^G6l1gXfGt^W8pgsb5|E%8<`q;^R4kCBX5WAyngKDm5KS0<>NCKCtvyM((LrP%;?BU zerO z$fjO)kGj#L*Qv7~{4f7K>IOdxqrRZo52;Vs!w~&77~9@#3OVhz9F?($MQJWkLf$F? zUyS5WGnQx6rgI$uHT+jC7fD97XgO}!a@xG*DVZ#r*|4<;N9@;Kp?jBt5A2$k&81~K zpSSXKBRFqob5^2;k!vHC@7L^n-R`|)*Ns}2_bn@F&j#Y-a8GuLdXV&NJr9>sD$lo10^1HXF6G$IN`g zt_;nkiQs3; zU6=0#d(JWHx44$Od-pHCCU#rhM1^ z1U6~~OO~qodOV8jQ9D!38cSCtWu3B6s)H-p?SlPEY~=jy{F5{Ps^*@sD`w4p(p;4^ zSl!-{C|AbrOE@I=CH0lCNRr{HC_m}_jhKyuK_j zeO;%irSxK|3w5s3mUY;qlAWrQigHtjVCK14pNDlAoBB?b?^O9t)pxT~m2BPouw}%L z+p&FMt*W(rmdSP(S;`Cq@!-G zy3Z0p#G;KkGhMJY<(hRJWv_uRb#~KHw|&h_mdsYAo;v60$lasX5lue#*X^07?6}n} zk4Iu3o=_$o{G9nsopcFhmMjz!&}azn=k53cF`4wI-oX=gxb9fe-o2+gxoo#>3%Bl< z{7P|Fvfre8?s=hZHl_Eh=lAMmelO+Rb=M{JX=l-gs-M&#clUK^omb3E>F$~xy=tph zW9KgY$yoJLPJuA>Z$J3!NZ9vBu!8yZ1pD<0VpnecI{&#|OTnx(6mhq7wQ6Zw={6qk zmzYl?qgYg;LEbeJ>kLOJL_!q_zFv&n>z$k8p0{Gp8nff4tY$xKe{**4N_3Y*G^fn1 z*oAQu1)MNJz^I9IPFO2J6S*V`e8v7`9@_bF6Dy2FCK@?^#qK^CQKAC5{nPdw_uNO7 zF5L4Em|s3;M_)m{*-0hePtMFFB+Qu&W>1o zYIcHV5@-_Kl$lKRbzhN9JSoCaa!zRoloK|(pr&Cy+& zBh)Xw50YLLMyXPdUg^Dv{yBu&pMZ7DUHW$1!aNcKL@wU>CmEj~*kx08+%3Ipa^)=v z!L3y91lPlq^H(j+OOU%B<%oGJ(PO-?bQz4 zFK*e-;ucpDbij zrFZkom)19CS6ALT`{u>7vnMZIUCq4l!5eSw(S%X+QlKwoN_Hq07LB`YO*`S2+>~ml zN<*n3?d*T|4-WoUeS`dau)}qO2%#Mhp)W({R*$ohQL^+qWEVtnZDOqZ`3y|+I^%hM zM@?jK)kIVh7>=8Wc+Es5b2gLjqzUyen0Q$NEs2@mwV8R#Mh%qc-W8kUch+Y5U9{g> zyZVy3vT8z!H*8+x8)mn^<_{+0&9y!pA609}J^z5c-3JjyNsug&kml*>J8TJtBm|B> z4Ar;U@t4#R%S)6rYbLSSZPbKE5+X}v)L-bP4?Z;$P=YxL>?CT_ocwsEp*}2)1%3Kj zKw>G)_}Bbm`A5QViLUg$KyPPJNqtcVpT}*VK_8h6Z>(OLUm13@&R>pZkAGQaN5jz< zm*!r)w7hV3_VRllgsaDki?9Cd*|$c+-9b8yf&@#DAk2JSLfArQj?w6kk0Ap1Pkc3Ohm8haW*necEWt;RU+McfBcq= zH`i%QnrpV$j+UT!@}u(M`orz?>f^e2c7;|^Qdd_qPc*Y4o@t^Ev%0!kmqy*|csACE zU7?v*>QL*x$w%Jl{k4;qkKAcV3)dOG(~N@oj}2&qcRv@Mf6tQpIh)26f5p0e4V(Dm zg%kFY)=kc!HTtGax-}R4nN;47{L~FFEGW6RJA9Sg*jM&C0Kz;e=pj-p&j4t ziS81PD9+AWPDhU#W?9dH}QMau9ZsK%MGcdx%5i<_nJ`NZvuNicl((?=<|NU z{A%C0nG9T|N<0C7#wJbc!&QBKu64B}DPOj0q#m`5dH0_^`f7G3vgLbKv#z@Bow!G5 z#cHA8%u@p=to5xLSK8#tQN1h6tWRGqF3)eQP0wChTDdU1xO#bB2`uXNBzrRjV6GF6={O`nT*a8O52-8oIr)P%aY zTc+>o_5JJYo^-PQ_Q9ImxKg|p7 zc@e`2sYa|_A09h0H69Mzs;(QWv#XM&X`bZW3;(n&M39vF+uUEP1WHs0#RsSmQd9tG zm`_v)H-|z0^X<|Rx9~)Yg5U8F`tp5N2*2dw(_|cXn)|yu=}52aM4!*cpA>6=YnW9v zlXA^u1>rJ&(tO7i2kUBQEqt0UsscpndW@U$^)~tr98A2I4v^LA*((@DEiI|^v1S1#x?d#!k?SkQNzex?$EWECi-V3knwpjjEYs_D> zOsWl|sY9k8q8fA6S{8jCF2ZDg=sM;NxCuLOP-UFlhZ&e0PFEE#RfSG6c?10>>_Y99 zD0K*CU>+9XHCTlWsHp@}Td)g#1PED99)DYScP?X z18%}DOp&n;!3@m9BD@BxumM|e3wGg?w%?GW{_xgE?YpI>Ot8!dn)WZK-p!||mg{$^aS@M1- zaqZVUQSqxHK+Cx=7?bz+i%0)_AOAl6`TXb0A7B3Z`sbrl|9UZnHG)jJc2CaEpSRcazke+KcYy-HYYU%aNz<@Z-93&Z<}c9WzWji#~M4 z;BJTcy!80~rN_)#mH_F`pBdORftLiy(!OKI1C8$u+un^E^J|CQ=$~zYc`lmmydFpp zaLQ)!YR5v&wm*E^DBybVElbAN?T{e3W|ROx%B3hrmtrbrC)wIHUDTtpNO*Jb8q_5c zL~J4Od@>AI zXCrqSuhXL6GtnrZ76aD=3XRffd3Mch*SvYnZPzm4`lM6y+O=SQGQH-^!_V6h&!gAO zdbt@d^FI}dI5i$9vv|h5)=SbDq2|(STLg(O^#tvws3p#Om5P*yS$67K=~sp_cbnwl z#s?jBk1yVDHo$%HuKg5z@t(F!9a5Rbd@A;U?@r*E~#7J|BWvn1hS33@fk(8?Xi2unSY4j{TK}Av_HWun4cg8mz-6 z+=Lw%tr%mE7}Clyrb3v7Ik*VRumZ2cCTzhr?81~*Ix>}p8JL3wScKPL4c6fe*oGY# zXa{LiLokF{n1@AJh81`nHem~H!QcmD_fs$pGcX4Wummfx2J7$!Y{L#5)Ebti(lCTs zn1@AJhE-UHP1u54F!*fjehMCfS(t+bSb`N;gALe%ZP6yRwX!qcz-i?9r7{V;f!9`ex6?h#sVGFil7pAnoqp38^z#J^VBD@A`unup)HtfLQAH?nt!4PI) z9u{F4R^WBmge|xQgCB|APr)?Iz#J^V60E=)tiv0y4Lfj9Vh2-c7{V;f!y+uhDy+jM zY{4yPJ%>o8;31fWIaq)tSb;UzfGyaD9XNO(h*TPe@H8yIA}qrytivYUgdG_CXzYFp z9)ekzgNv{XE3gI|um#(&3sYYp9595ZVF4E5HCTgn*o2#~10#`+JtF;l{G1HT!2&G9 zDy+jMY{M>0y@0=A7Up3QmSGJxU<8Ko3H}|E#qS<4KpwY z3$P5UunwEB4ZAR<#V+J7%)&e@!ZNJE25iALjP`;x_l6`kHxR0n9X4Sbc46v8+=W?~hecS1HQ0bH*oOA`QKW`o2(z#NORxfKun9L| z2S#&<&E<3$yPttMSb$|%g>~43ZPp3xdbNAa zN&of>M?dqOhA&j)nA+*{cIvJVM;x!c?`J3J&A*Qa`+9M&)3JXa{(U@*^3kU&pRRnm z+Su0a__#&N6L$Fg;q!;jA3lF1+jG+Iq#f=1AId$qJ`dSxy!mq1m%BSBe3ju5M2UuAk}i$L;Z=bh4B7br|2~(-raH+DATJ#SxM$ zZ+yCndXw?BOQ%eOy$``h0zES^HAra3sZ=k1|X$zc{(K`>dp&eLwl7yFZMxtxpG^dlj>9JKCA6*i^rT@`@9`~b*y+f!M#{M zW#oy0FWQ{d{jm6TG*hn7k9FJiX=l-gu26ICIK3;h=B(JtSY@P*>8GM4{j~M`Y_yP{ zwxgGg7V;ah#rd>lim*!ex^@x?nnW$veVz2s0JY#<<%_q%Nb;Pul`3t5$Y&C@T*ww#17C?W2;VZ&IJ`bDuMQ(9(F; z(&x0bU*n~#wVbs~7OVtSX&KtP(jwMs8_!tTDKjm4J!#a|3A1LamiR>9wsqVBSE(D9 z$J*yytGC8&Yn97#b;?}Og4wdwwc1WsTli`b?~Fak)#-7l)w|t`vQVx)_0n(LwS;yh zv!m|$%jX8#Ho-t0|3_Ucf9Lyx;D#Ls%v(*P?K#-5CERyD)mSR#-gDT@M~rvD~ouJz`<36VGX-Wm8$0 zhl{WbtMEE(z!r47Qn+ezh?YhOPs2P+cABnZ-hi9XZ@(MApJYB-G~>{Y{n{CF^Pfgc zNFkN|=f(y6_OpKb-36cieEzdEAmz#($7H$m zQ7wNSSD};d=G=cb$4j3AH`3>t)hU|Aj&4_=GUjpN;JZ0li-?ceq2fa7dJMl=8}ZOv zZR|yJ`|ic^?xv%B$NZYczy09CvD>i#Uo78$vCQ~@1S>ro_(;2(86UTe58P$OhdM%c z+kW%Ay@AhX65|7p>jpmk1yTEJ`%S-rPh1B24SeEw@EiEV@!&V`iQ~a<;1kD#-@qr1 z2fu+&91ng2pEw@UUm$-#zkyF2AASR$I3D~4K5;zw4SeEw@EiEV@!&V`iQ~aZn)d4e z^>=%A@cj;m@7H+q;qVJjD~Bt6O1XUQm^9yMI`-+xrz@qWWcu;x>h=$p_d0%jJ*ZT7 zs~q#?)%N()f3MCe&vmO?N6;wp+$H`Y*|M6CD|@^{(Ss5@X>1J z6IQE_M(dUzj@HN>i&oK%_rlQ1x>{jZS7;{-?S(OF%RnyJ`GUpIgxx=~Eq-zqXV2TA z)zK&I$k=rmYd^?^IlEtH~YhJ;W?=J~cpYCQkB8|+CC|GppYkn}>0h_wfL&KJsv9TelCh)f z_EpU8PV4w)Sy$F=?r;sg+*0;%>%=CPPjL%bWp$A$N4H*V9rM`s-V0oP+b)da^O3FN zyT6uC$y$8)1+nfezEC>1IXb~_GOqG=i*R`EXgn{ld47VoDq zFC+l9_!wwvLA$C6vLzsnmScGL*g>~43Ew}}PgR%Q5cnG>xEOO`z zummfx1{<&i+pq%%e~fUz5T1qwScGL*g>~43o3I0eLxck!f?1e@i?9qUum&5j1>3L- zQ$J2PU+l9_!ww9-7`s0NLzsnmScGL*f!ARZw%``DE=#0RFby*>2Me$SE3gLZ z@CIzd4jg#zx1a0}WtLUB0YA((|ZSb!y%Tuq~ac?-5-2M&gW z1BUQ4EWjcx!z!%9CftM_XkElO9Pkj#!W>+LWmthV*nlnAhFzGVBbtUGJPix52(Q5! zOs>AMiFpUIyFxI8SRsU2n1hS33@h+DY{C|7!!AsX^FCk(=3oI9;Wb!;b$A1|VFy~b zJyJt3gjtw}MOcOvcpWxj3vR(^&l7t>N_(G}O2Z7y!2&G73ar68yaC&=0|zH@ABHds z^RNiZunOz230rUrx_(58{=^}eg*jM&C0Kzq*nlnAh8;LKML1vxPs0K%!ZNJFI&8u= z?84MbxDT^14~wu2Yp?-ZunmKsjNKc8A0qEW;XXz!q%7;8+l;AsE6eEWi@1z#44AP1u3K@z~uo%)lHh zz%s1DI&8u=?84M5xC^r|4~wu2Yp?-ZunmI~gdc`53k$FWE3gKea1(Z5a1wvQ49vj- zEW;|S!zOIQE=--mU6_S=ScGL*gALe%Z5aFv;fEp2!U8P83ar5<+=Lw%oW`Fp19Pwd z%diUTunF6+3sYxs7iM7|7GW9IU<0;b8wRfuei*_mEWi@1z#44AP1u3KYxompU=9{w z8CGE(HenlfVd{0Pxr_voH^funcRk0b8&QZPV~b4Z#p*VF8w41=e5_Zo&=>zKlO%2IgP^ zmSGjvVH37t7pA^~yD$s$un5br1{<&i+c0>W@WT*hVF8w41=e5_Zo&?X#!$@Z^gFTp z8JL3wScX+thfUaqU6{%fewc-MScGL*gALe%Z5aG4;fEp2!U8P83ar5<+=Lw%d=-Df z49vj-EW;|S!zOIQE=>I#?!qk0!y+uh8f?H8Y{TFm5q=oLEG)nhtiT#{F?MeVhA;~Yummfx2Agmb zcA#yN9fu!gU=9{w8CGE(HenlfVd^68!Ys_gA}qriY`_+5Lz`wAsUaA`EG)nhtiT#< z!cEwL!7~1Y8JL3wScX+thfUaqU6{IzyD$s$un5br1{<&i+b~!m{4j)BSb!y1fi>8K zo3I0I>TaacFavY20L!on>#zyiunSW~+=W?~hecS1HQ0bH*oMKogdc`53k$FWE3gKe za1(Z*Z4@7eA7)?<7GN1xVI4MM8+Ku89d}_C=3x<*VGTB53$~%nREX3N3}F@)U?7-j({)8Erg9TWIRal2j*oIx0x{A9n3-hoD%diF;um#&Nc#rVI5N2TkmS6?e zU=wb_4z!8ukxIi1%)tUI!z!%9CTznlOudi0Fbngr2+Obr8?Xi2F!+G*!w_a+0hV9| z)?gEE!VV0+hCg8j=3oJqVHMV46SiR&roN85Fbngr2+Obr8?Xi2F!)8n4?~!R1z3U= zSc6Tt2|FHVn#yABHds3$O$$ zum+oO6Lw(mjUZBKn1MN1fMr;Pb=ZV$*oCQI!d;k!d02#HSc47Nf^8W5)7ZTs7{V+p zz!I#$8f?N%*nz<><4>4@Iaq*YScP@igl*V`segvMFbngr2+Obr8?Xi2F!<+$ABHds z3$O$$um+oO6Lw(mFYqVKz#J^VGOWTnY{E9|!qhd~g;|(~MOcP4*nlnAhQYri{4j)B zxCqOz3hS^5w_xxqxCc|Q_U2dii>43l_;~P%;N{?jARQbJmV>2WCAehg>%n}mX1eLf z>;u!yndw5XYNnSX`wg?(F!OY9HM(})uGW_h=|J?&J2nP?2QHha-*$_x?U^ z+9&K#nv&XS{J8s**Gs>X^cF@>+xhc$>aGt*9I?Ic$G?xquYC0RV}I3G{(boOp^{bg zkd!N59h2tL`*QbIJnc4qe0?4zx0~tBr>pJpA(P&GxRZS6)7AEP+)2EJ@ojrv4*K`u z--lu#Sx@xlYuWeecamOxx>Bs&f4up8?%TUcH+!8QeY*1L%BQRT%Mked;q!;jA3lF1 z>s{%6d-wKstn!KL4>;~N-o97MT{r&hS9kTRyZY5#{pz-Ubzi@_v0vTUuWp@eN8M|l z&~w%nd(sZSx^MiUMKb>SwNHKfD{jO4_NQ-u`u3-9fBN>PZ-4ssr*D5I+fTmzdG~qx zzWwd{AHM(P`=7r5?fc&v7faTkUjCq1*&Z)m{^I2?${Sw(vzI@4`P1Fj$?)qnE#W z`LmZld-=1MKYRJJmp^;?vzI?7`w3qD?B&m1{@j0^YA=8H@^>$P_wsiyfA{kDJIR^7 z{5=xCZ<`nF<G9%iq2H z-OJzm?I+^LAN=@(AAj)U4}Sc?k3abFhwbzHT{}A2ukhm!e*D3YKlt$nKmOpyAN=@( zAAj)U4}Sc?k3W3(#vgvzIxCWGuLtwNvK_O*MsPUV#bG`YfG6AQP7XdA*=}#=JNtfe zGG`z5xxZgOVXyu9NqhcNc8mm}{q+yW82-!{CI5B)mj0INynO5Y_A?iM&NQh{JBvPa z@$q@H|EwL08ym&-mxhN+>%|wBr)OqY*NQLBu3p|YuPbNQK5xfFFc(bQ?@TZnogKCi z%mrh?q`l?wV9MV3l$~YFR974}{Ym$B3% z7v}7KosHY?i2WY6XM}d9XU^K+oLw8*b@O)JgxQZ6dzIv9@7U2Nti$Wmmy65u8*9_E zmzGv8pj{sxn;4%Q9WJh|ZmiC(E)Op(EpN=P9gZ(vAD&)bJ{R4$9zE*7H(vY6Fa7p# zbbiBrl@_G7zWtk1GEY)=BTo!`(bB+QoP8#%Wc)C_sN{JnSh6g+VbQc^5qHjB!{wkD PWzskZ@{&{gHOl@!hJu0o literal 0 HcmV?d00001 diff --git a/Covance_UCO3001/browser_profile/Default/Sessions/Tabs_13425389960078959 b/Covance_UCO3001/browser_profile/Default/Sessions/Tabs_13425389960078959 new file mode 100644 index 0000000000000000000000000000000000000000..c979ae891d040bba74362b669b7a7234e3c90ec8 GIT binary patch literal 470388 zcmeFae~esNcHj4Uc4n9RL%X&5wY|!Ew`Mg%Q$Kq8^-orh+~OlS>}d`;WX*6mEXvlh zs=KS%P4!g6hK?8A& z`a?nJKnO}e;FJ(qlkd6jbIIZ(o6|$iYG<8yi?2TK-gn=5_uY5zx#ynynsx5XxpSWg zg5Vc}PZxwAIrB_3AU>tdhp+zW`|rQ2NamR!cvE>T`$28*96gqsoH}-Nd}!vx(b1vt z<1-UOQ{l|W(AdcFkhhe{@mX!pDi(=@@tHv;!2`tW;wQDeN8IC<-+|4(xaIf9Cp+C||K#;g28ZDt zpUFvq-eLPq*H>@@u~{?6ciH=lwl`WmN0_F}3b~@xSzmfp^tWEZK5c z%U#;qs%*YEJY3zZyfD9hqqH_(7FUOVM8{651>8`1H`OMVgUc%GmRiV0kPY&VTS{3` zKI<_pdc@8X^oW*ZS!l-y4)nET>))=K3E%!Zf9iU~e+r#)P*3V()ASUi`HjKqVlt1FGP z>)68vsyptiAn3u+3QmyN;1KcuEYU5uNpB|TyJOb0U0>)E>r#{D`-W0oeSOGoxpKEg zj!1cxb@p{}EjX|5m0&t}Ud?AlvXj^I^^#2AclUkz!*t*75#OEjeRX2H{`x+7uXulX zpH}82-RY|CFquE=1?@pE=W)CHVRh_zZE@GK4n3t7JE87v18+&2b^JNi`eAKDN}pF3 zk30ONj+gX|%KG-@_T|Z|yz#(p!+2TSoRc=B^G6hq2lhp!S$DVVOzDVS{jj@+m7?tS za!Mb&@9wQBe%QWf0{+K~k5&P`>wDTc*FQH<`CL2-+hwhrcopEf{0l3kx%u@C8;@6q z*Gt#8mPUsc%8RAzD_g@iMush6ePj7%`N;gra(Qj*((=M|xLz8W*a$aAuFj9HzBY5_ z+Q?S!;QabR`O^GSX=SCncDX#g@OE`%X64j+<>=|FFO3$)#>dZH$-jB(wb}6ti_0so zoS2#`&A;*L>ao$6lBZr;E$fmC)8|GfCJ(Ny%S4#I^6D$6Prb6VHge`#;ndmu&GFgt z)y4B?&tAK*v32g^_3`nO>!+_>JNDAt`O`07*f_J4KYw##<>oIOd*h9(D-*Npmk(}~ z7nV25^IMm$Z!Ax{+kbxSs5G4ZB}@^eDEDS%eQmRRY3uDudD?F5;O16ot318=b}4s0 zw=tPt8kw0rlRJKH;{0nTFPy(ITix7RUfephayHD5E{ibwnZmu{D7KEw8d_I(v)ROwI{C1=cUhg>QdX2U zEc)9D)+MTzY?54<;(|f==rY($8^?9A9&SE%4vhnk}KJ?m{ki^NPLfa-EUHyy7=?-4%WRf^xi}&sD`HB-advgOXNO{VY4qySlewa#^)z14(QL zKd(AE%77UUn~%1M<2uca{Jgde)mC1m zu;(_bddUUHb>9;@_L}bcf_OveRuY@1Eb9A|?(D2uN?vunsJgkTGu~Fs998P1YIR(- zd{MPzR^^n=xvVn|2d@WjsWcO=4y-g*vbc;f*K}mT-Mv|ht16$h3%kcq`8Je0ZYkvl z`jH>Pl0({8)bl>0?ZKJAJFZXq^UO3D&=$JXzqmQJmDjH8%Td?kwaMIAEp>|TqFXKwxaYF(|t+Sxr#WvxDb+BVzW zP)iwB%A)p4uJ69!0wdr5gTMZ>D$AF(?P<5@n1$r? z$t%rFxOw$9^U2s1snS+*Q@@-aWSDKP+^Z$5b)N)Qpw#^sKYc%P`@h7=YGeNBsrpe-RSQ$oi z|5gsWKP!d|J?^X^J^ z#7uCTY1`G!5VrF5htwwhc-y4*tp4?_7ar<)X#dxTT)JofwBuW!8mPJN4>~E2THj&n=YBT${gkeEHgH`O>vh7msb8 zUtWLpBeKSSLS;I4*GzcO)fk)HFRAfvN+p}Sx+E355Ik*Tk~ULIJuL`4uG#H96)lFN z9+X%&jAbyZ|DQYms~g68utxfJf=%KFRHpvWC)On=ySI5%-1E^u^vKs)%A$so!>X$h89-|?c3zdqbVarIri`aK)nLh)oAWY}j%(<<=7zmX;wecv zrrJKQ)ODTp@iNkq_2!4CWct26Hc!PKo1&h|XSEgF(+Psx@D6k~k@hn@NPAuuBIwPX zBJnEp=1#JFOFB2y_L<;^Gy!@($g0k55@ZW7S=GK7CChq7mS&Tr1*IP_+ zXZ2Jq@1}cNHYv5?FYDw^>)9o*YyHIP?2Ke(wY{Y)+WEBZD&;nHet1;jyaih=3_PU-j+YChpkv) z6&`Jd{k!AQi;bu;8AP_|W#*JQ<;{FBGsBj;%y_Y7E;F;ty>H&XoQ}jUeKR>0m709M zdDY=_+RQI!zB)7P=Jhd;p7{Y|kDi$-<~uY!HKA{F@0)+oOeM;&o)r8g{XIvjmrdEtd?^CN}x=UzT@YUSq5w=SNaSiG1& ze(F;0rH$o z*}6*73EA%p+$^nDR?1r&rTMGNYnO+Y)>q5H7j(`!Rn@A7P4jeQHLtgM%e+*FDUi!L z{znqr(e|wNcg4pY9`ERU3%wXYIKYlzCPmi16mHGz{G@rM{tH+ny_#U1_#GIZ{lQ+T z4_XMYwd;p@q&EBNX)94n!)h$+ZrIzu8cK(iACmtj9ai=`j6Hg|@U8zrdbR0~B;#3s zU=RA?@?i@)efnij^=xxWQ|#8K>}`o5r-tLVCdQR!-bYi zHX!(N`|^18Z|3KsbeGLxb2`sv>o)6+-=r`lZypfy0mScdnE%w~)aE;|`R|;hTYjk{ zFWRl&epp><)z|uyfAvrm{)@l&^Df=5>H4^x^Q~tF>Zout^ryA?QO9OheN{Z1P~mZO zb9iiWYCIg)qQlnu{JL2e=5%(~S>U#BD%fmjv(?Rh z9@WQk#4oa$Rc(2ExqW%^D(`dJ#+(gpue_O~(j?fcaHg1J`L^I;Dt^*g+h&2AHE#Li zC6oo_H)n2tFjeqT=t7hE`p$E!53{Vj8cx#A`M2L5=zTl3tj#}kLE96l>1hHwzg^0#-aO^_h#_j-;xtS+q25o5(h;K{&9Hv$5Pj^hpn?j z1MalD>nZOMw^Y-t2O74gHRyy|o^80~pqOBlcpJvKKG*{PU1fCj`F&H%!|D$G^_^7d z@yc)i5W1-{C+peQcQSq7YW$NpjIweVNk0`t3%9cl!5!!xypl5302B_v2n|n!B58WGw=|MU>+7>71m(`?!Y$ez%D#s zI!Pf5LpTeIumWpv8#ZAJ?!qpVkIjV)JOm?{hfA;q>#zZLU>kN|4`vR=*U7>V&cY(B z!1rJSHen0y!Y&N{ax8xkhA@J8xCCpk4sXF0Y{L%h!OS7<1Lj~J7GVXx2OF>nZ^I7k z!r-U44;aD-7GMR|U>)9qE!c*4U|^m-g$&HX9L&Qatin2Mz$Uy6JFp86*px#d3qu&e z0<6Fq+=flqf^B#Qy2WkD&zOQzI0Pe@hecS0b=ZJAunjw~3l9v%^0P36v#_RQRyO4p0U*VF+ho5mw-PumPK}1$SW=%2IM+ z5QZ>_S;@@qNG$Mz8=Yummc*k5Js>FtFR6mumyKv7ivc1LKfy=9u{E@Zo?*Q!4B-f%!|l{5iGz8ticA{ zfo<4#zY^a2Ix=)`4Bf!W_)QBCNq}*n}Y{6aFg?b&%g)Gd$JS@T*+=flqf*sg{ znHl852o_)k)?fqfz&7kay=CFTAPivyi?9moumM|e7j~guYjq(Db1)B!um-nb6SiOn z_F(2Da$y7uumWqa0e4^~3~Ew~H2Q173(kcByzhecR}+pq~+ zumgKAa~ioYf(2NCHQ0bVunjvVFU}X0&B1VcVHWKpxz^MVGxEef<;(`b=ZI{xC^_`IT_RQ^xR8Z8n1@AJgWIqPTd)IrFmnaDFoFeGfi>8GJFpEqP%qoLFbG2! z!6K}}I&8oe+=X4}-!#px#PV}64~wt{w_y{uUCTzhD?7>V0xiEqSSb;UzfIF}aJ5X=R zyD$ht7{MZ}!a8ig7TkqhsHJ2VvM>kpun22#8#ZAJc3=-?HjxV>Sb!B+gAKR?+pq(* z4D7-n3}FO|unOz20b6hvcA@^X)rBm~!8|O&8r+6W*n%C{gP9x1g%K>k3ar5f+<|S_ zfqHY^g+Um?2o_-#)?ov-;4bV!y*2Mb7Up0c7GVu;!zOIO4(!3q+sK6xEWiq^!3Nxc zZPGOE9 z*DjOwo<5Jb9jEOoZC9qs(*6-Ebgvh@o=^Kn+CS3%vG*TNr~M=CA8G$c`$y7#u=sxF zHR(L+e!FA8^_J@0RPUyGH`TkT-i`HVvL5_AZolc4Z$INz7+>xqpD(B5U|g~N&nVHiAk4gK{`x}$# zssAzcKc@c2)c>0LpHu&H>VHoC&#C`8^*^Wn=hXk4oF}CI=hXk4`k(jye=1Y|d+L8r z{qL#&J@vn*{`b`Xp8DUD_H*igw_fpJyGYj`()EXQ{UKd{NY@|I^@nu*Azgn+*B{dL zhjjfRU4KZksMrL%RNuu0MQ#)*rqiwQRnfP5tlhEAD@Q-wKA@|KeVD3VSa<&}gjAANYUX zKgdtykB57lzt=eVQJ3@cy1xCM`iOq@-O94peU4GioM`?JUv7)v3*964_V3^Ga(!wt zp7jUzps$aw>G+qlEp2U8HeVbbu5MOdSSiiTuWwXdm|tIgp!|8|eNNkm`@Q%%{cik} z_UH9%r*scv+J=I0aZ2AqK}rAXzpefZ1&hixrfoz==9O;sGoch;ZeJcRzoeswCF8Kp zpVGC4bVgZmlQph$7bV%`&%4i%j#()d^%>XxsLMSf8U4ZLQ5UrBaj(OhrPazxd26FI ze|357GSSW9vB|0NaJaIuzO_ETzB0VHys}l^7>YA*4wqI|&bjk8-KGBXzxRi$zxF%B zZvVEvtu0vi#ozn+6-!Uj9Sc5P5P$s4Gm$j~E9QUy`TyfrE&Esh^!@kWRXp=d5WFc_ zChnlNca9#*O->yr#x{Oc$tddJ}>({qloLecaU3HmG>-em;XBCS?GpH>12j=M?TwTXLsqH<> z)E92`?b~j%FK+q$@kaT(KldlEe=_(jc*p0nD(MS7_VbDKzASDxS-!6-)!nE2A&Tq4 zR`8>@%;o}4xcv}&-w#<(3iuX=i_;t`X0UeT$A#x8(OCt)n{HZhP2JA zZDT3+M8F`v(CHV&elC9mA6hEwEF%axRGLz}g38<-Ycd!JK_HyJi8+3;h1AgBEaw--v3j?A7{P%7b_5&d zvJ9Oiy3CyKLZnv{tP{Tjy|g~DF3C4J|7fjgyLwWS+){mPYG4@Fr>eb5@PZ!idT>Mc zzUCBM9ADM(q#Q3Vnf|kq|HIne|FJ)J*XQf~FRXw4b8Dp=%a==A%j;_=7fwF)jw@Gieuf+KDkCE92gV}tDy+j~`IaOr)b^R+hk_%)^FcN^rl-H`hQ+M2 z-!~Mq7O@=MRHI%{jz!l_R<*aOIxA@_YyXD6H;1IK`bBMLT`#km z$g0=9t?#_{*L4T$t}U)8j|FSD1KL81C|GM2t4Fls_K7l zed2F=hY|=I-JeK>6bn+@UHruC0q1SUG_(G{G^5)8?@LOaF-CXa9N|M)Ncs_PN|1V;3PLV^|Iw-Y@j5q;nZ+fd=^M)&)DHF*YN zlgGDgE0>i$q<$>EpWu6l&zp>A{eeB`um8A1n$3O9`DLyr8`i9^9d>QsdW!W6nd*C_cRbK1qmTOL*F`aKNFLS3^&$@pOZh34bV{?3)$(Rm^ z=RP*9nV&#)>u+^mL)vHmJ^ek`b?jl2_&e^bAn3u+3QmyNz+2e=G|?@$$=6KKcgL*F?D|5VSeKeC-#3)% z>gz*x%ayw|azr&&*4fv^wcxzISAuET^rOLyWGAoZ>m`}K?-|R}AEx_${G14n+udzI zomUr&JGl+F)+x<0weD`7?%4Nj)~X#{6m39UP(HIWt;1U^S?_s0BkS(-I^W!Ci|Vwo zBhP%_=0=F+$4-VRsRMJ#nfyt&7w0j9z^+k}qwk|C% zOo!{Gk%^6PbL8s$=;~`TXReKGQSQyk`r2ms z($?FR^0eL9!OgAGR(bm3TPqV+SHi<j*WW(z>e%9iS0@VR!;@3v)sc&H zufKMtGFu&6Jav9!@#^N{xyAD<3pd`nzPvX13x^MG&aX?NwzcJj=SRcxYH4{z)N+Ov zGRi-$=aW>o$7L5C4PFgm2hcfZ8QFB+tffDebLoz@XLVl398IDH-;_PQYN_kk!&Gj| z^r}J|_MoNNZkPD4|D)k!HaGYUSbW-Y$akCIHt{Zub3HJHxLZzNzMQV(+Gj%L-czYB zNQK(S>W8Cy4j^-g**e0KI^VFmv-#gGWkqSjvMWdQ?Q_^r7Q0W5NRqiy%Bsz+;F9(h zq@qKqa9b3cP`*(1=!n)N<|TJEculJNOmIypTT&(mT{-Mpm$bK}b5`^*S(o)aturo2 zWy~mkPEx9J9UNDlik{smDTx_f#jbc$Pq(7sVNK8ZO_g{-SFxGEmEaYnTnuJ)+*HVz zu6tbPJo>7aR7x9kmXy=(<(!i>sk7FU61&Z&CFhDta6|b{$-#6}3T{GIKCbO`-O1}J z=_%dkh`z4{Cv-QnYM0ksJKT`GGfFwB_!ZsVt2+Cp>S<1?=H)%EE6<9{D)}|#JF9!E z1TX8pZz}(q&VEHX4(be3y33C9uI_D^TvmzA8y(xh&+DF#GGNBT=A+$!ah_PVxeM)n zZOQwR=R2;8 z`t!`v*D#^$#KGeC!pF~aF#Y#sZF`Pu6h2uWd8I$6&F0=V7nl;w0c9%@_vY?qwVQ2k z>jpNDk5@5l{%%9Rtv{GSU`EJZ@@*!vAi0*uwAYaK%mj%|6g%J2Y*oUHhxkfn#7wyI zjJR`calb#LWBJE>EVpO%d;enRp)bkBZs?OUH3sDCOp*KE|SYxB)IVW|us zG0SB7wJVe5%Tvq8=jP9jUYK1zQ60^{boS!%%deb1bGmYEu{<+#;>y*9Ya?&Jy8aPa zF^{`e^|aX@+N`_wp1@r3GrX4RD3b+k-|8%b+3}kL^UhrP`>;m3H%~m9q#sb3`a_>s zmz?b0HWPKv=k9>DzqKkeI^scSTEm46#AOYXQ&Q%~r3mIVWSZeHtM~~GBcmFKUQ*gc z#b4Iod0GR^X$=6^ocfv3;B-PVu1ZOmS@O1qCNmN4tpt7l2e)Ls`C%rRzVDfCx;Cd4 zldjEuG;4DoKXc}BJs~-@3VYSZJRRnqG?T(SA@LG~891?VVaMY=TYfOlg*ijbS!pYP zd#~l0U&CbBa>JZ6UTj(tzx!ts2s2>Jc!^gK%@bm;K-sc|`B3c5L;Fkx8s6>(Gh>!) zz(y&YQlMG?OnbF0HSYgD>cubF%$brMPW|m<`@g2R0k;s?@s87lV)NRgOE7 zWnnJ|YL@#w@^6kEx7mCIi==;4uX22l19h*N{AOQ0Z6#`HSdC@f&2aB|Is9I3 z8q*o}4(g)5?TD>*%WC$w>ejtJtS+_c`{Ks@uRlzMua~~#RJ&gb^Km=pTh9#CQQ>Cj zPiym|PU1cLqzd)68_ zw;9!?g)A&UOEYb5%i|VKBvgHmbX%vh;CYC64aP@5*m3*I%INBIkD1WpsrvqbU{mf} zvpuZIhT4xEV9B?zlJ(~6FPXmYnFecWk?zl|7VikVrF{#xV+0-8g$EMPC3*cNZyasCR|QW=A=;aA_Ac9))SbP6Z)=S4 z+jO={X?ymXkXh=serPWy#4r8Zn{~F%IHqIC_L5hjpVMYeNn4f}*SFd2W@FpyJ+@~S zxV>s^7PwjJrl3txTRAM{uv5kM(t@?Td%;w}N1+Q%;*0P8gGZ`muZ}(KoPYc6f!?=c z%i2`j_wrAI?9ahwWN+J=kWHY6?o-~I!FPX4U0U0-%GVMfS1m^a5}=TW??Fp5&3d3= zdqMDWLM_iWTyjuMuu8lQ<6IxCmVZ|nU44Gv)bg+zXn%btReHQ))<1;WA8sX^zwegG z^nI)GPx3N%Rxfi)KNUm^x3dnx9q1msk}}W6>4#th^RNi3unrrr32(y=?7{#zZLU>kN|7alO3q>zOnoP|YLfi<`d zo3I6UVHaw#%Y_U)1S6P-ORxs(umN{q8+Kq1W)8;J$-)rM!Xm7|_h17yVGHiUE)4#1 zEPoJ&FoJow1Z%JkZ^0I9!w&4h%pvXr=3pKcVFkVi8?Xs)!w&4i;HS6`7{Uk^U+7>71m(`HsNj9fn9jOrW^`c7{Uk^U#zZLU>kN|4`$-O&<(OMgtM>+EATzofKAwfyRZwr#WRTI6T%4Q;S#LDI=ls2 zunjw~2Q%2qS(t-)ScDb$9&ErSybU|B3uV>0FbG2!!2+zn8mz-xum#)j4wS7JKW~_Y zIhcnAC7>}=$g&~Y!0ajoQZo?*Q!8W`DWeLak0T00l=3x<5VI4N$ z4s62??7{<++y@NdEG)tbtif&Age};CJ(xL+d>Fw3tiT#v)U=23l4s62?)XQWp z48jmbun4QL4jZrqcVQRm6*?EPFbDIn2y1W~Hem~PU=L=FBNs-n04uNt8*m4CTzhD?7_@Q_ELe;=&*dVFZh?3hS@|TW}Y4pkOz-i>i#5QZ>G~ZP+7>4Q|6GY{3rf!OVH&!Uz^% z1=e5#?!Y$eK)qh>!XOM`1dFf=>#zY^a2Ix=b23VD_ChQ_2lKE9Yj7JjVGDL(4`vFn zyey1h0ajoQHsB6y!w%FtbS@0S5Js>FtFR6mumyKv7wQ#m7qT!1^RNhOa2qyZ3wB@+ zX8tO2VFU}X0&B1VcVHWKVDQ&sd4n*75iG(gtiuLu!Clye`pfzF{$UR0VG-8gHf+Kc z?7$w(d;_^Kf(2NCHQ0bVunjvZTF4Q823t5}%$b}IszzVFv2Hb&d*nxV{(1k%5!Uz^&71m(`w%{)8LcNmb zLKfy=9u{E@Zo?*Q!4B-fOa-|xf(2NCHQ0bVunjv#zY^a2Ix= z{*=vyEX=_?EW#SxhE3Rl9oU1J8_0zbEWiq^!3NxcZPAMJ|kB0ajoQHsB6y!ww9-$^F9+MsNw%;5KZ+ z7Q6$4zm7bZiKBO4Z?xet)b??G&Fk|j+b6WyOG}5vWcd#$%|bHW;!kUP($~C_a(~dS z7h2^gr1ufmgMWUXQFK7tNSwUy`tj!{>(k=aNCc(T_nll7iHkNf`){-ds+w1313 zqQ9M`{rujaMmDND9{q*-UJKi5p+tvN`(O*CP_0*rf-~JfdNeb!n zi0i@EXKE+L^^t5BX}h|=ojh*+q~qX&^|&8BAI7Jp`igo;_0@yz$Wna0r26Wksh?C| zJy?&azPi7kJx;$%+f~}GtOk;HRKNaC+tvQ-=Sk}=wXae?_4lGbrtKoRozg@i=*bl~5ADI7r(E7{gG=@K=&3;G0!hYwE z>G+e5Kk4|Bjz8)6la4>>_>+#msr`}KU#b0>+TY3fLpuL>^xsLO^RIONna;mc|3m73 zN&Qc$|1I@DChe!a-a|?Kuc`kv^}nY6*VO--`d?H3YwCYZ{jaJ2HTA!y{@3LEA@#qe z{?|wSKRv1cIrTrM{^!*HocfCP-&6m4>VHrD z@2USi^}nb7_tgKM`rlLkdvgAi`rlLkd+LAR`*#A;^@nu*Azgn+*B{dLhjjhnVSd)s z|Lok)5B$FzssB0kKd1iZ)c>6NpHu&H>VHoC&#C`8^*^Wn=hXk4`k&+ZlAkxG{`b`X zp8DTY|NCCQkCLuGJl^`lSEOc5w{8aIU`5-!ekpv&{V%d*r-1hwhel)d{D42}gY>jN z9`13z*Z0Zme$?gsysmG*r#_-zeYdhCujk7-Mmck$=^tNii{A^~Blq_2-}7>PYBHYn z2lk+^kFV+Ym$WTyZB;g393HN2R$f>s&CRcGR9={0UwxqbdF6dh+muSYp#M|&u%2yM zcRLhJC~aQbP%tje2PN&5^sDj{?&x9dh00lS=Zpk7rOqqOm)n=e%U@LP3FV(s&IL&v z3dVG1PN^n;OlMDMZ%SNLs-;cn_<~|n+8`U-uM96PuWXe!hT_bd!=;s#bMCxNccIodr*(W*+p~&AqB)c;_y^|cA6#9>KB?_J%hVTc_3hhk zvoCJ>{qe!qe&y(&y#C4H%kYlRXI0V{dhF*D>3vz;ZnAt|RjRvBHIwz=y42B&+FMbB zT+@G!eeb>wASg-en0CpK;}+jf@a6D%lku!Sum^oP{CPf}SAOe=*6ed?_SPkG`nIkx zr&7k9B1c+DU13t`Lt>~s%W3CLx$ZM6DSOGER99M1&T)69bwBI4hv|sc*{pL~caE<< zFUg~-RXZ}L4jgKKR3CfRKBzgx&m!68-uUd_@}0->`g7jjBUm1_?ystK`>dAqOP?5c zR~^NYEov>dzst|B-zcrkmrcD5|A>yAR13JFl5VO^EC-iW-YvC|jUXH39k-OSqI}k4 zTJ(sWC+HC^$+FOn5gh1i$xdAm|HpsnS6z?zC(tPeom1erXNCCfJ~<{j5q;nZTMKq| zqx;SSWt(9&pUoLGeudkh4I63f+E2@`c<+6m3Q!Kup;IHrVCgWLuU=RB1KWs?sYcmhr ze_ryeCr+xKLbd*J)s_u>*4GZZwjU3PV@kE25-QdD>8SEq|0}DXlpI5)&Fv}Qa?R;8 zrt?d>){xGzo;9jHyXLr)Z+UF!w83#s9M=^Wl*eQr)@R)6*59fdYg`-X8~*$5)s17H z{g=Oew^!cQeY!R(UMYRarTfn5<2n=!JU#GdbU}NRKcj80F1WIOd3o)~MtSS{#@hLf zmFee4XM!J9{?qPutr2dhIo{tHvpTx2uDYzo`4wGfP}{RQCu94f1^@Ux{XN%p%(TUO zmZ>k?VZR4MD>y-7gG0psX`)+hlip0wcgL)0yS~sT)}-ZM)<@V*ttGuR8=5@Yx=|y$gDdn?)x2$~|#7(}PZ=KwR+gKS)y1h7$83cBX(tUSt zP4UC_MHBFMyN^}@zUzD1Iluksfm@%BM`63HbrY`wT$k^kW(=>Fu5T@k4lk4!OV?Mn zhHs1vTf+Lr^3C#*`IY7J+SaAzh3Rm;G%~RfZjM}?A6Cp>QGi&EItNG)l%E?ocGwYX@Z@yYNzjpM^>kF@qPF#8A=*8JrCl<%99bZqJ zdTF(+OD;^G8=aUuxVA16Vfy%$$s1dzj@=xexPJWl>+`SYPn{V#b?wCE+0)mKzPd4b z=JLsFSEgRQd2?g#%;Cx7OS6;97q4ADTdBNUx_M=7^p&N98|8)Njq?1~rRy8Z)9&`4 zA3G`yr++rn>Ql8!QSQyk`r2ms($?FR^0eL9!OgAGR(bm3TPqV+SHi<j z*WW(z>e%9iS0@VR!;@3v)sc&HufKMtGFu&6Jav9!@#^N{xyAD<3pd`nzPvX13x^MG z&aX?NwzcJj=SRcxYH4{z)TBn!nevb8`6SitaoI&jgI9yB8d)|t=PaW&?U}Xo$C{1Y z(e|v)>xhr5a$BZX722=|EzNej#DD!C4Ii_)!EeB#^?QYCg4@KqFwV6POGwvo?K7cr z@2S)m+)QCk9W5S??pZ_Y>S8vVSW@R3RyQrXPIq1Tw-mpjPCI-zhn>3|+*F<;lC+}z zvTAcHxTL)WspwGBOFCmh`9fJ?Bbu4aOYUm$npF3h;F?mlG@c)H<*;jA(%zEJS<%O2 zUDo%s&bT1OFr)Z6NvX)Gs zF__hHQz2uz?s1*-=&N2*DQ(bMQck;Xj;RDTZNIM6 z>%r@~lh;+!Q@YO)eP0Vs=x%1!F0Z+ExFLCGlyXw>E4sT^b@olw)0|Sxxo})po)wo> z@@vX>R`*s3UeyjkCt++iCYdQAB4(f=_D7IYc#o#SHxd}bz6+Q98I`53?psIRV)-#;Z z9bK1%6S~_mJ&6nMi4^qALe+!Ku&S!7i>iay_3X~*O0!C_oTuEdzbLtzik;JTURPL9 z&A%myW;RU*zo6?`X{=;%8Dp;L_=3B8bJ(n^tjjvr?lDxp4dq^RDdh)-ELe9HWx4_*N8Zz*uA;C zS?y-q&$;7fV3@IC^LHEiOKLS{5SS6NmwcNQEJ&{9v3bFe_RIu{O%yxd(qbo?%~$M7 zX2eXm@{G81=TwINkdEaa@3GvT)$jd_orliYe(CGK>(V{@&9!fRYM}n9*j%$wx30}M z>x88;e8eo1>DR7ImM>2&AD^2)J9=Su`9yUz|I*ou%P+rj`poIdwZ-zx%!w;k7p{%G z{p$KhWX1f1%5+XDC|0izx@clkr;bG>nXDAbLq@7Zrb5gXd`tFsD`f*PQy9(cpAKGOntA z%`ACaLz9^ZAE&`BS#N%rNv7|6ru$Sp(=F<$d{$e*J)I!94evlVhG{>;gY=$*h9rT@Ix{jpAWJ!oy>SN$8}aUUUmkI8G*5JxuDcVJ&g?w-gexZ8(9ti zmUmP6tPf@N+(Lbu+-W_#mqc+*xgJ=^Q&hna{6j`GF#N++NV5Xe8i09Pu%{OIck-3enhnch3!Vj7`^SGXn zoa(~X+RW2o?nyH#%o7qXL70IP8y9vw-m|3w^IVuS)SQ(I%D?wop!qdS#<Q5jP!w!_ub1(HE8%Ubyzg;_=t=b1z?B*qFI^@$Bf?#m$x1FRWfU@$!{7mkX;a z^K)yb<#kxK3m^Vxzvk8eZU445X1BrDe)C_uVcD~PSpI`&27X_|gRNy)S4lc=`j%>w z%a=>*tL5MeI_I1!WmSsXW{BC~4K-D>@vb@ra#_d!NP;`sp4I-YXx-j|?~b0nTh(>! zaU7^w?)S*QIdr*dtLYf7K^RgIie-j-(TU8bJRoo%YzoZ2?)jfaJ?J>}b=V(QzZjyP3c zmMj}!O#M$ustqdfYa*6rYg}VGKCirs`nDss+AY1|i|*FFKCCXa>igox{IB~J>f4HY z)#P96@M~c{Zs&aKnSnYg+zkC`ZGO~AylsRD*?EG49SdI>fv1 z0MEfcm*n-AlrPlwai2+iSc~88Q_Wdz;K^nZk5<8t_cq>lRj#bIM+M(r9#;iVNg+-; zb!V#2)(TBwnq_P%(pD*L&t4NUOWo4!#RPjDprnr}%#zM~(4m`Gp`X)cPDxvq7}vMi z?Pg=!>piw-7P!3$Xco9x>Sl|ZqPB8a%3)pKh6sCQs6Uu0_$YLt$$atMfAC1P?A5WS zo%3(MJ<$7hY+0K%`@MWI&|V6ik-cqeLN;w2x=(p;2H*WHO$f9-t9&i-aV_v@KmruJ zgW)~mmS&puK*RQe;N^r`o^80~pqOBlcpJvKKG*{PU1fCj`F&H%!)l=Y^_^7d@rqgh z5NfY)ni{d-yQ60^ecx*QlQ@jBau`WJ6+{cSvkt)>=pMY1GS&bT4#5cKVG&kg9X4PS z-i966g$KSK%g@3PMz8=Yum-nb6SiO*-hshS#_}`p5R70R7GV|EVFT{KHtfJIJYYIW zAqzt|3yZJ+7>1-=IxunBL&4(!6< zr??Lo!Uz^%1=e64-hwUIhIe3Ko;`&O%)%VZ!y>H0I&8ouybU|B3lG?oLm>-87{LOp zz#80!P1u5Mcn1cim=rSb5R70R7GV|EVFT{KHtfJIJTMerCksP33yZJ#7{NSTf;Cu&4Y&i_umgKA6Thb)WMK$rVG&l~d$0kUumyKv7kZ0l5X&co z5zNCSSc7$V3$|bzc3=-?u$Qwi2lKE9EATzofK7NCc3>CEs&iowhA@H!Sb;TIhqqu0 zw&5Kp>o9)aFbi`q4~wu0>#zZv@HXtgE<7+EUndJg7{LOpz#80!P1u5Mcn8W7j_(5= zf)UKaBCNtXY``7Zh8@_22PU}>7{XatgcVqW+pq~+umgKAa~SzBf(2NCHQ0bVunjxV z&tC_b$A&P1MOcM(*nlm#3%gMB3>UI62lKE9Yj7JjVGDL(4`yCOE{tFSR$vV_;0|oV z4h()SmNy7P7{MZ}!a8ig7Tkqh82lB=33D(Hi?9Z_VH37s2limb=4A?57{LOpz#448 z9oU8)82o%JZxDtsf<;(`b=ZI{xC^^btD!DrVGibD5!T=~Y{C}oz#hy*$b}IszzVFv z2Hb&d*nxVP%!NT1!Uz^&71m(`w%{)8LahV4kcByzhecR}+pq~+umgKAa~!!af(2NC zHQ0bVunjvk z3ar5f+<|S_fqH+!g+Um?2o_-#)?ov-;4bV!y{q9u7Up0c7GVu;!zOIO4(!3qN#w!^ z7GMR|U<2;JHtayXJ>tS33}FO|unOz20b6hvcA;K#bRi3KFb|8c2Df1owqOVLVCFP( zVFU}X0&B1VcVHWKpx%vfVGxEef<;(`b=ZI{xC^^bZ)UiVg*ljqMOcH|unAkR1A8!Y z7P&Bj1z3SK*nm5*4LeZpN4PKuLm0s#tin2Mz!uzvU8uL1T*$&4%)=tA!EM-tE!crQ zn0Xz!FoFeGfi>8GJFpEqQ0_h#24M&zScFwrhYi?*yRZwjnD0Us=3pKcVGVA>CTzhD z?7_@=_ELr}ya`r+jKL_)$2y1W~ zHem~PU=L;rvAisdU;$QO4L0BoY{L%JJ9I7#!VpHV2&=FT8?Xg;VHfHZZWppJ2lKE9 zYj7JjVGDL(4`%)Y{6aFh5F0+`2JxI z=3x=m;5KZ+7VN+t%zOj6FoFeGfi>8GJFpEqP=5&E!XOM`1dFf=>#zY^a2IxAP^6qN z2lKE9Yj7JjVGDL(4`xb%3t1S!0<6FqY``7Zh8?JNAQuK<2qRd8Ral1&*n+#T3$?Bk zmlNh-9u{E@Zo?*Q!4B-f%mQ*@1PibNYp?-#U>kOz7JXb8gdvPz5msRxHed_x!YTo{BQj9?K~VI4ML z3+}=$^lzGGS7P}&n1@AJgWIqPTd)IrFtf`2!w42&1=e5#?!Y$eK)p8{-#-jt1dFf= z>#zY^a2Ix=UdeMI3v)0Ji?9Z_VH37s2lim5f?OEE0<6FqY``7Zh8?IkZTF4R)83t5eT5iGz8ticA{fo<4< zMOcM(*nlm#3%gK%%H~2A=3pKcVGVA>CTzhD?7_?p_ELa@4_Gq zVFZh?3hS@|TW}Y4q28KzAq#Ub4~wt{w_y{uU+7>4Q|6GY{3rf!OXkJg%K>k3ar5f+<|S_fx$Pq ze;C3DF2NeyhE3RlcVO_>kq0wz^zM5LHav#fKCZ8MeO_hzgf@F=>9CkA{{f|0NTyr- zX>CvXnpaZp58CxYs~m;&KH_@t&+jve4rm*RllNUe{`_QpT6{n4EqxwO_S$8#-qYuC z|KGuX)b*40k61zUx3jdL-+S*d+1@O^pZZDLRobqs29oWkzn|Ih{&?E1?yryj`suHy z{`CF!$IwnvNS{Ys557KAJ29@0WV=Y))&1?{aqA}?2Oq4*{pk5HJ}uQ()I+MT9&AUJ z;_D^VS07FNr26W?dQA1z{r&85`d!+t(spGvkhG)v^>^B?_Fq3wT5qX+mHMf_7yU79 zS82QYIJB!l6~c66`lHwBk6x!gdY%60b^4>%>5pEgKYE@1=yh`b`9bSHpOX#ols5ZM zk}V|9-)kP0+8?R?mD-=F{hiJ~()mX^|48Q_>HH&|f28w|bpDZ?Kcw@INB^BhI{!-N zpXvNN^*^Nkm(>51`rlIjW72*~{jbg~{eWLO^*^Wn=hXk4`kzz(bLxLi{m-fYIrTrM z{^!*Hocf=W^QYARocf<1_5UQL{`b`Xp8DTY|9k3xPyO$y|2_4;C+)}7|DO8aAEp=5 z^@nu*Azgn+*B{dLhjjfRU4KZ|AJX-Qbp0V+e@NFKlJm!O{UKd{NY@|s{+)_+{Uu$0 zN!MS}^_O)0C0&1cn4dNEzo-89hqa5;|DO8aQ~!JFe^34IssBCozo-89)c>CP-&6m4 z>VHrD@9})m&zsZrhkrNMAHJf;Y|nNxCocNfJE63BZ9~DhI3JX>SJJP_Pq?FpwHGR9$(=J2=%Pi7lf~!c_y-^V8y)hXMg;gmi?=L`u_XxDxP^J2;P(| z6L(PCJ4cV@CZ~=a9Uq!GaddQO{P@ho&{Q}xGBh@Fd}MU;aBggB;@CHpQQ?ch(^-jj z`+R-psewP#Wqk5ym0X%zzrOY2+)8Qfs>^g*$7i)Yt5_tOL(77HV4nWL)phKX+TOEF zec@K$zU?;q;+EeZ|8Kwh+}S^Q{gc5zhIf2EtCGIZV?Uor@5|zLljZxWQr&&3nXCub zrH)?I-ijLJT3~ma%zprZp4Kt#k|F69-%s#zecog|>ksTfe|>+RkLQ)&I$}vB8c~BE zQNy<`W}VK|?WF4zb9By<>kQU8=XA`v-n`Bk)AxdMSm)VG{+N!9s5@CVTy#<=+||aM ze3N9Izog^yk~gGWbCNfy{RM5-Rjpf&y0+nOQOzlS7Kt|Z8$b46{zty^SYB%%7JT~q z1Ru9!YTeJOb^ENA^uIkbu&e%J$riPi+u!Bq*Kd^8=F6tuhJQlG&IJ`WFm394Bgh7M z$1UB{ief|BUef+%u%tU#*WQNi=SL;q`sA}Z|A1)Mu;6Ra(?6}cjyc8uV_ z06T*9^(^{h{trf7?^u9!(r+c$B0gxpnb#Nk#JbdE`K&d&dQ!jGQhjWycMR)O)m|ld zLCtFxeTIt5}<#YSc-iCLe>x$aXaASvH1if}B60gEKOqOp+vO;a234SOz5}4LA3=7HgEN)G~%2w5P^0=4#7ya{qdtL9RRn{+RJL`Ix z)kIdk?rnYNwZE=ASa)r4MR_b(yB*LLT13I(_d@rGkLT|tx;xBB$aUAaELmD{xZr0y)#wkS;;YvDy{R@1F!`b_HSE@;mTB-7=w zmS0etG=r<8HfTD2PWgSglkyj(p(m9ur(B_vIoY=<2rD__q~DeFbNZ|8qAIc#ZGlcFrF>Gw}PUcYE|d zqpklEeb#HzqFY*DEeBsv{&T97RVg-`nPh`E)U--!R##nzzpUebq-WjH_N?}IMY|0P zzWO}_>{h*c|M9=^sk|9KUxG#Ip_-sq`*(ajA*)ZUOG%dR z8%lNcq~`lD^=@X683r~0dUbE=eY3Bgwi2~8tj@5mS}aR;@_N2rlIiI%@Iyg548)!R zYqNU|1HS#3`nG(bHVYQtPw?%|=S{}5{=gpe*MFG0?$a+1wEMi|nYvz7zcF(;l!_eH z{*aVqSuwA!%}5^7-ApN0nWKwJ8+ZA0I%3K`+*7{Ii%rqnY7Iv(*FL1G|7Bgn)#pd5>iY+RO$`iVYDm@uL+w`{YMJ>i=ev?;GJW4e!qf50 zAkzJPN}E>&x3q8Jc8s6{yU@?5{BucOe@Xd5Z69~b|ASOz^1dvt=B!rmWS0M-)%`8;*fKT;Wm!_p$*DXrB2=jW}lZFK7g`QEy&jkNI(IoHD;n?7_Fu$vpVx%dwGiROc+Z zQP9$SxqW%^D(`dJ%*SL?ojK)Qbw||E2xTfATODe)w8*Xe#y}zTSGITK4ML)6VIejF@Zvag6`_it>mTH~yj~Bl|6n-Tt3nF8;ko zjby&6JnbA_B>B4LZ{~f%vt&m;suxLqk~MWFQ(wGD;*&qCr0@5OB!jR0%28WO`7*rY z%W7597kcdH6X|_f+-|bZ{k!@iiTQu$-`r6t*xYyy_l-ICgpTCG+~ zZkd57|7@JykZ3>I?0S=3P}mH-8JJx$Nr;T#aqn^c*tpM!*?jx^vf*^SKTrex z^{WYN6@BKuc1)>01S&+PxO#t!`Vw<9v<7#Z2q*=*U|xr3XxDy&^05aYPBG(yapld` zte;YdgUvc0QLsVhP`j%iR{`p$3_h4BF%j6{BT$=CH-cQteF9t12P*tXE1orQi2U+j z`piA5yrJjxmW@lZUl-(is`P1^_sIK>{H~E8uQDtXR$gLxbs?8OQOuS$iutp}<<2(~ z1F^5wIm5xDc;j~1ziU_|x)2!tze(3Qs^2l4gB6CyVe_xwqkp|SI#!J=ZwF`9Hu`&C zrJoLw&y_)B;Tp5{797wO zAC(q4^Dp0d@DSih-y`RI<^xCG`GA{+xh!PjXW@Y4EB)0QS7$d$i;2cec7AqaxzxDX z)JVo^F?S_4lne4^%q8z%j`Gss} zVya^xKe=8`_0ATCPPYxLUd&w?DV)uBpWDccCt5F^>OMa>(mLO~*1H-y_2Noam&|ld zCR*E$=U3%x+Sz-lZL@T`=SoZKM(@T%dLngtwCVI(|H9z#TK7mXF}g6ccBy0J%9Y~W zXnR}l;$U0u{My1;p>T5c%B6hb)Z+1CHj^u6)1`|W#aw6b_-{6MYlPE(T=px*LFK6Q zdSNxcp1oMwDr7r(u;c5c*;2Oi{N?4=rR8{gel%5X$xRImZfy0BG|x|sv`(Lm4|TMZ zo6gTojE@!u%gytr&lcyG*5@bZ&n{;+FK^`XZ5P^)ucud4qkj2Z=FLPryE2jWkUVzp zSo+WYt;QZ?gYPq(!Dgck2Y^bvX6ZYI?x-7%{5}{axumWW^v@6{bU38Gts%6!uNAJv zxTPo~*?{Oa0t;EA_{t{b`Vw%J&Jp#5NEWBmtXi`ayQsa4hUmD4a5M(3Di;?& z+9cmL9KKg#;~Kh0V{6JOX)rmi+|}S(7qz#jbC&gwx)$`eQ)f(RU>Hz(Qni%jgxRYy z1--k|8ngy3@Lp{PdB2ouc)2oluMLKudX~O%<0b8RBlYqR*0R{b6-*Uyv{zQ632B0 zLvSuYqMI)2+Psxc9rb+hn|kJMn=sw9`Cx}?SH{(i<2BDq1l2{=xTQ4j#J{oQft=y= zeVw}3%X)LIde6&xb%-u zLho)=R~l3fB~J&_{=Dj4S87tfv${e?Eq_@x;vn4?yP)fFH{6-KM~8VG&je3To>`-=xYlpW-w}@{Ud(Ozi)K6##3;|3?xV?S-NFs!DP{uh^U{FF*fQ8_E zm^m407N0mE&} z_w0$sJHubSQE^!CV({!|5;5<11fb%6HG=qO`4=eRQJm@xrN)!Pcz~C zhn94sC?~!7D9R~{a&n_pO7KzrlIj%%ZKLTxJqb&JDioFlgC-1!b8E-+z#gUoG#4mC zQC4PDzIISKdJXEp+<>z^W?1}BoF;?-c4Aq%a+BB>G%eoy1sw`ewfyS{{Eyw8J0sho z5`K=mUnLRbG?rGEviU|Y#-9kp@iXLg#uIPnGH&7EAx6bH_qA4`nQuP;wb ztz7CqdFfnkdSy91mmikaVTJ3q|HD5W1e3FWLqC&lW8eJ!p9`jCkCoH1IVv(OGh2j} zHx*G0uT0d`iQnq!MVjw2oUwL@qNbwYSxCcA(>}=6%OBxs+m{RHlZIBF)P+7=@3X$% zgQZ_uruydZ(;p3|>-~Wm=%1^a-K%1JsVQYTi!bhqiC`di5mKx)!tjrEnJEE8YDLC% z4*n>$k$RZ|Sa`tSx4)m1?w9F>NrmB?xGSVmLIO~EdkZu&F!i(E2zl7J@YiwPGU?z5 z)^2glzUs$zRQ#%9`pL9-n(7Y?^{=XdoaZ2@xHgP|Cwg*c<(y$wa;(-;e>@Drc> z^aF=wKOB4HoG<*~k-I-DfVON-XFGt0n|0@y*^gE{e*cU#oJ+12q4;G7g z-?*!mCXbowja~L)v6G=;d2lz#j?ILyZ0VbZuGD+m(|%k9gZ8YUpsHm{s|;7Yf8B!0 zqwf{W+Ncg%8Ko9J*ICRa)$RRy62z{BIS|h-g!3O-Vf3Z8EKa>Rd$FX`LbexMTC4-D@b)*W}(sW*%p4jRrF77VW% z?i%hH?i=1Ryki*qqptp=hH=9#!<6Bo;kMz9;X8)=hBpll4DTA&y=Bi~m^4fo&KMR9 zuNv+e?it=NJTSat82e-P9ENejF2iZVg5kE|j^R6o`-V3SZyUx~zero1VZC9}Fl9Jn zST@`-+%?=YykU4?c*pP!)HmAd4daGghSP=x!)?QBhI@wlhBpmw8^#!zwAC5DW!Pny zGMq6i8}1nH8eTWNX?S3G$MB5?cb$5}xZ$ATjA6lW+whvI~m9 z>@rLlE*fqd?ilVGUN^jHcwl(fu+A;`7^^po8x9)I7#0k#8txkI8SWe2GQ4BxIi91& z`NR#o3{!@ShTDcahVK~e8{RZLFuZG6XZ&)#VbU;VIAd5aylS{>xMz67@WAknp}4wW zJ8Bp=>@u7-EEsMZ?ijvfxNmsV@V22iO834E>kX5JDZ?4Vvf+;5uHl~H4Z{P&JBDwx zxa-s##tpj+rwt2++lJQ+_YC(9ZyMe<6esMS!|*M`F2j`JjA7Yu$8gv1y5UX31H(Ip zZ&=7ryI3h zFmBjoIAd5g+%eoW+&8>sc*jt(NU+r#CJj@DGltuS*9`Xz_YDsW?;6&9!s<2bGMqLn z7;YQx8eTWNX?S25`{S;@qlR(AF2fnavf+;5uHnAnEyFv8v2U~cG)x+%3}+0t4X+vQ z8SWb%7~VCkLoU-+Z`frxZCEheHrzG5Zg|u1z%cghuD+v&alhtX{(|!)e2U;kMzf;dR5Ch6jdnCJVNs zhH=9#!x_V};f~?1;lAN5!#jp@p$oQp!=z!#aK>=k@S5SC;lAO4;a$VJUaQxz%W> zV7P6#Yk1x8rs091{0M^WsA1f&%W%f9Y`9~%Yq)QC%kYk&JP?Ad-Y{vHGMq8oHoRuI zXSi>8V0hQCZouj_>@u7-EEsMZ?iyY@u7&EF10^?i%hJ-ZH#n zC|`|Wt2ay4R0DA7|MGj*p3>; z4Z93y49kW)hP#IQhPMpw7|P8t*y;_FhAG1t!)?QBhI@wlh6jds4eN%jUc)ZKX~Tly zw&AYfb;Fy62Zr*E3AUq#al8V0hQC?yS{o*kw3vSTNi+ z+%>#zc+>E}Q10cycGNI#*kw3lST@`-+%?=cyk&UDFi4R0DA7%H?T*p3>;4Z93y49kW)hP#IQhPMpw7|O&GZ1sjo!<6BS;kMy5!#%@& z!vn*+hIN;$Uc)ZKX~Tlyw&AYfb;Fy62Zr*J4z{C)alj;hy2X;ep{@ z!@5sey@p+e(}o4ZZNpu|>xMTC4-8}9W6y6GH|#Q8G~714X1Hg#Z+P1<_Pti0VVz6f zb8lpNjO+KZE{^?`y0<@|A5Kf{!tnjSp**&5KI!-A_o{jJhM(g}pD#}1XnWfAHo0ma zy58tH-o4aG^gdh%^8Mn2N*>WK>R0b>7y8M=jAIdE9y#TbO^0^ly>=?Ll#wk^V8#KSuh; zNdFk=A0z!^q<@U`k754N>l?%Qk^V8#KSuh;NdFq?pCkQqq<@a|&yoH)(mzM~=Scq? zmJ=fVbEJQc^v|`|MU3?Ck^Vi>zeoD_NdF$`-y{8dq<;_d&yoHes<^*jMD~Zs{t($8 zBKt#Re~9c4k^LdEKScJ2$o>%7A0qohSbmD^50U*LvOh%jhiLu3>UxyO{uJ4tBKuQh ze~Ro+k^QNfo;|WZRG&8^`$J@Zi0luM{UNeHycqk#H)&W#x3jL*--~Wm=-cC)b^Pn}TP&3d>z`dUY?yxuNDh$r&m|*yZ@BR zepJ5>-El^1`nT)dX7#iUu~y}!^=pW=2-C4y?ak_|@~y$qcJ0MgayB@pDV9`jT6zAy z{r&j*=T*8@TN(!XyAus9y#uWc9r1ythUTW;rbJtNvbm$R z=X+F8+gHWjcU)Bm`}XJOzU0Wy=rTV0%auJlx4KdK#N6_1ekmw4tmA|F9aE}H2t&o@ zUzkV#;&ycGOZB@-p^ELDihXwXD$ z!EX5eKCIl}In_;8V;iwj>=W8sR)@^%;}nO_^@ddxMhKHj#_c%ihuQpn__E=2y+2R` z{eAfJd^)A_5MrykdP1GPU0uITgaIM8sPnf6L@}phkW7dE#g*G2lE^9#0!(NR(uF`X z_ugx`{x*?mM*rG%Mn^!@nV`HUbjXwXTde-HO7csp?l%2P>Yk{BckMTIC-*KweeUZg zzxS_r;-RcR$LD|1HlL=9diNhS!Xe4_J703-KkE`?ldRUeKdIwo{pj5V;j`}DAD;f5 zpm%?>;Zf_o@lY>*%hKDSe4e9n3-^X++q>_a@V%X0SGoE7@Oib;zE^Ra&-5&c{#HbN z;qvvqq8eCP4@G=BrG2O&9!v-G>W%cjtkD4d(M=J_pa;(eeY#C~?fN&X{>(&@)VW!m zNniH&6|Ud){T7{-P_K5Bl~iqRT5^=wpmC)||F|Yo5ER<3bhEAi1u^ycp3O6;`&I3u ze`sO5DmD0gPYpgzU7vaXk#{szc#5D~SI&0n)y>&_I?K%7_zgNX87l-l*}DD~WA(9A zfF<4JvQiED^=W@yuZux*R%J4=U(x$J(C?Veza@NJ(%IMfY&RXm-Z)}A0;aion>y=_ zWR4lmSbjN#JC?p}=xeK}HpmLUTDo@7PU?~+wa2<9hDQA>Yp)P{TQ7Gtwy9^&YcFf* z6&(-PI_2}*Af@!fn z;NOc%(IaxPD{6s^O3VlSWJP=HYO`7WvfAI&-=cDII+|A+9=JZJw^K|@_`0+?Z8oaX z_4-}bIh-FZ=Q;aYk^yzFh0i0c?it)$S%1UFeZ93TPqpf;mH(vI`&QlSSLrtvP#G;z zFRI(p-<0-O^#rRyUtCrhHu~)m{o*9Fk$#xXw}USmPS^VbHPAnQHOZl3e7Uc^Q>yQy z`oWxZs23p(B=m#~mrdG(jbPa3c!Mx4gtMPjZ$o-WXfF{A?=T~Yn)NfdGx)aYDzHTi z@>~yj1j%4l12WfSkE2Ks3FT#VM=&Z(9LO1JTmPuR5KVurHI~v;-`Do`4|?Y1hSGi* z`i{>3IvB?NaP8BaW1Rn66`cQXe*544Yfq8$|6|oTf1h2AH+tTj|8E}u&F_Ts|IdcE zX&E+pcg1$s_Wb}?ap+yUzC-)B_iTBicU}5j34b3xGn}sX2Wp_de}A4&r&Qh(5?p+f zIx?NziO88i20#RdtEZ#G+dyWNo!5S=uvy3Gm=QHFvN2VMU{CI^&PD5l(G1uF!9&$PnCg$&^Oe|`;ANn417cq~}@hM`sKtMSQu z_v!C1sUtz#=y_i#w|~TO`<3^_qr~mbxzC5$eEa*d;dH$}Py_w-AD5e(7YQIVqXu%s zz*N+%JjjA0PDp0Lfdgw-8WKXxZdMMWdO`%^@7v!`O84s~If$8ws!cer8qf)+buH>g z+Y66~NX-?P0uiwxXSlu&)t%7McKU^{`k}bFp`ZT95Bmw}hVI34bDulA6Og7SL7%31 zkG${5?-~h0*&oxd7Q?u_x{%ACC}v9=#r)aga_5_gf!Noo{IG6*PLBsE7Ghz6d|3Gl zBG-KEn{=I{`W@3bb?gh-d^39V&%C2!)yVR8a8@jK*Dy{Wv`y8OXKx7ev9tQS9P5-gn}`jl?(p?|yM*%} zT3CPIqmb{*r$2jKa) zs}vk3f*3^3km2-eXp@;+lls@HIvZ3Y`a1@Kd7Xjq2Jydp@O&Ivq?3O9Uq5&V@TBjN zb3XHdBkz2`&BBlmWa5W_faEJ}YmKY38>PiWV|wHRM-T1qEY#s@~%no7yz>D5g3VtP@=r)+*9+qp11H9OWkTbka;O!RM# zCod;9({1Z#+S3zLtEUI^V^gc8v*oen-rmdMQ!lP$b;(TUWTLh0cz#vN!Orq{;!0Cn zOIu%hs5QSjws~oDGkxZAwyk$7(Q|63qho%)Wwd#EZMki_Z@GD7^U~s};@r^W*_PzU z^m;b2Sv+3MW^%=Bx^!`)nClE4|IOxZjd1#pd9gxCpd6K6FRbR*vlmNSg={Aec6_}w zTgrBBwvUbvC0EGk39+?Bq*!l}!>ZI=d)ucud4qkj2Z=FLPryE2-~g>+g|ZS-La9F z(|t|`oDrHVxTRm0UiG$q$8_F-@NtLSeL9A=n}&A{$z%79rGMtH{x9E!Sp4@5XHaHo zD~Ir!rSBNJQuj&E_YHwbT_@baIK5lTU7na`bS+0`r8@suv5w%)9?W|JFWZ4#3o|>x}R~Ke_3^I>dZD>7Fj>$DN(g6&W0RrS(fl3wuhX;9(ftTGSHFdZsnqTbr;? z*sPw)*^4S!)bKZ?>z`H0r1Gcrl<3zsb>z5y2rIb&(?Q!aP3F{U7-AeB{HE&bwh7Zs zn-A82yE3kBH03-m*Sx6uwv^_b_&0W3N4%c6Q}@)ary1A%CUsU@?7Z&3tfy~_T~HgH z(_PSV=$M=Il-+tC^rdFq>sV0FsA^wR9ZP!le$~6I{gj@jT}P+&KBsi{x@db`c~{g@ zeJX!SZQH9WTvDInZn!gdj}G%Hn+cvCv28_H%&A_UF|KmxU+06I?0s}piaz|I3Kb zs$5tHw9Z@$fxdEsg^1?zmv=7bUCn&Fp{m4o?C7@!`5r6TwWjwU`M9QXlqSrcJNo%< z9pY3PPr#XUZVi^p*~Cz;*p^>eU7k*+E@b8>+FFMSrPHTRjZH64tS^pV$t?~x^bI{F zF6L2`H9x8;{T=-v(Ou!=vM64vQ#HYMo$<*wRU7li-yZzMfJJFE^ip5aq(6_-mfkb; zbyZXwWQB(eq|e};XpnytWetpmV--3z6%A@~DU0Y6nsAr`+cdqb==icGi=-xw3mPcq z#SAbE3~8`0X$m>531dvhmz9tCdt4JqPB^Fmqfez?t_dyNZhmU<`1@^&af}u$o>ved zS7P;G3P4^&cAQfh-zJn&^Frsdfue~i0fsc(t||3WrZ6lUsJ+l6yNL@^xAXYG5fSN? z`kgmQgAf}GaxJVfEFKc`TX7O4 zs|}g|w(iJ*+JzxgBWEll67{zn@*Qmqj<9cZ$vt@3SOSw`*F25<+cD1YO7Lbyt!ItN0rQ`)@qqmPp`Ppo2`A4isgcv8P2WbN}Z+RMiwLHdwc7g)*w}i zIe8WBK5`cF*H-M4Um?j+zhkPWAbi}ZVVdz@+oB=UjNjP3ip@>iKT6&SriPz4yleS& z1hi`N_?D%&4c*cAmR@g)UV^@-C#*I#)RJ5eB^BDGQG+`w!;D&}QRIp48XmDxvIQ;K zpuf&ea@dkczj+-&0?h}*M^@8IK_!dI!J5MH6RMdSkb>USkkAvz5(&v5$T)DJ&K(o; zZL{{dGSWsO_VN2lQXW3|y-RZb!eZi!ci(3cI7|s1bi?WyD?#t*R1Ybt|2@1^`Ope#^Cqj;`1~y*s-r@-tA_6w z?i=1TyloiFM=D=uEL)hhOIbc1fNZx7V@wL#jvBsYm^4foE*f4nyk@v(c*F3v;a$Tz zGxxt`m^2(ToG~mLUNyXCxMz67Fg(RG1;_P!*}dVsmLPopp5+VYljapMBE1UUaJXrF zLVfYw<0by6MfqUXOT*>74likcK>N#L+CHxR%JR)h`|`tj?j?=Mv&uWCzi1+7rHKlk z(^hfLh-lPn8tWwzFs`$fSzfb6_`Hsa^G@kJv}>5}Hbm*@kGR^q&tX*e_cyAeb2?*L zIsL)k;ULH5qPYv7o49xGWbjVWzoMyr&|NZr_$%VqyQzBd=5#fn4O_bJI<5E4IAvFG zEl&u=`hBGjTW>|Safs-K5!o>ZJCiWpC4^ge(=j?;N)ew(9^S-g zk`ek51`{ z0iYkVs2#ZCbGQEFXP#mJ=*LwxSMr-J{o=DR%f0BOU;f0WJ~oG^>vtO7_V=n@Qn}r= zL@JbDS%!U2be@=A*8os#hBz_ch=9`q+6U*shMogw14IOZL-Cn|*qQK&yTQ*6Z3%jk zj{Dln6FYWE94N4fBGx#KiVOCnez)ueB#!o(fIBoXxLq(j;7-B4JzU6J;TJypX)mMm z4$V9h^ZA~5e3~)}0Btb&oFtnCfRatJTJL_|0iZwp%MC&Ae#g*T;^LuRjI$FPqUnRS z=i9qqKL6A3^ZVXPzz8A88U1yO9x*YIrr)Cd^8uiQClmMItiH-hV)&yH3d%w)@tV{? zdBR%oL&YB(%HoPnt4OaW4+a>a+|}Q#l1!KQtGX$-^!Sl-{x_>qgU|QW z;M3G)0ibk!dJr0#N{v-T)J5Z?_!K_x0MNf?Wb$dl;9>ME(?%8^3zohSB9~C|zSjw7 z7qm?c%@0O;B%Wu!+{o5T1*yh6o@#&k+)@#YzNjy#V6FS_5(;R*RUh zx%=LeCu=4u)-52Y1LA`0P}zHqlL?SKCMoJCSOS8B*TmD0d*iSAh35wXvU?DHsEfpY zN^7eY^t^`_vZ zS=io-ETaHW*G_(RbE*4zS&pM*BH9 ziaNw&vp69nOnJzd^0lKkT=a#TjhQ(aPT*}_0BDm^ZV*8PWxl06iz_hDV5wtZAyT|@ zdmLKi{O|hy2M+0U6GQV& z<85aXnc|tPhPjn14U_5qQYu#(x|}^9iXE*I0D5J*tv|QXv3ccG)8usPP<&%?Br&zo zwA8EwK#ZvoF?r8;pCYA=0!%JI* zE5+<$+vwWjh0^Bw_j&w$jT(ImbD%T(_c{&IuB$TkE(gb6km+PjFC8-v6`fvfD+(nz} z&dJHCL)_&RMVB<`dea)LhBUNoXgD9yJxytk@YjC*5J&PF;)XO_rgT<8d;M}DG`2>?y#`35v(4+{wuy`p=~stwwL zaNk9_NSD+~>x#Nrm$PDC&p4p==~n4WdNS7Q*;1=4Xn##DGb<|zDu`ayfNSG~^2XH` zS=B=r?>Xg;>0gs-A6C5t#I6T#6_>Y8@%vyD09w!d^?=Q@&&O2eNdiC-xKS(3s@0JK zoQeup87HVCNgyY{G{En}Y_N(Fh`{cI?%E3g!X)5ck5bAlI)fq#set+kFy%^Ik04Z( zX2j#TwOL^vSPvGLoyrXsBAUyeAOQ3k&*i+UyFa^9Rbu=6XD(V>aE< z&$DaQ13*V+M^4Xa#hwcz<#=h~{K?^o!S=QbWAo*$-o>e=p}utf;^5Rs`ij=BumI2} zeey?9);#Y3(EsP-Uz0|2{|km*>hpo09$#bt=!gh)2K>l}u?E7}C^&zxPFzn9_M^O;v8~f_DdizUT?fOO1Yr4kJo0 zB=ER?Y@`pjmruw0q*Dy52jGl_ags$W-5~GmA#MsFk15E>s|0(xb;X#JkR(xR)m{vc zDa0*ugt?WvGD0jNOfl>sui`I?(UWDs-E>1fQxbY=>?hA60JJ+h-q)RKnkt;mmhzK5 z&8Kn`>Gk%t>E*Sp^P4OEO{s=*;@os=j`#o1|Ka~wb;$Jj)rQQ@uRM~}S56o*aU}oG z`c)2@6;8WV13+ifrQBw&wAE0|7FLU;^~TIyt~}CSk!YqIt;oA`#QKDu_vv|79tLI-x>MPr z4T0=%*rF^)#6sBw-nanRb@^jvB`FYQM<{Hq&`gwAd~}BIVZ7Uy^6*I5%hDe~-BtY@ z2BBIv>w$7PZdtt>b(>!~N6u({TQy1}+|`!+oQE zx2)q0s$a1!8g3iz7`|h;Z+Kuxe`NEX$DT!r8+~*cdKRT%>9;K4uvXw=*^c`F#$8Ka zH@s!&0~o#C@8~NYc-ZEe^WOO6-?zu`dnXNR{kWcyjEB^nl}zs_m>{wB=XU*C&s8h` zNuT#e)&C~cXDdBH@zQi3<9M{-$I5daB>=MWyhja!tUUKo0wE92d%R%C!}A|CAoB3c zM+u5NJnLZtBM;Ab_~6LHa~?N9@~{R3p+^alJUlZBlw^rPw}r>IXEhG^dJ)x_!s2#) z(udp2C%RQLELO+__l?^rJdfjG z+zKDtS#o*LL4FV97>jVkAfJ!oQjrtitbC z`G-FE*5JaAR`Zc~>%aXQfmrE%Bz&54R=)DcqKS`iLLX3j{(cl6k8kAN!nc`hW-PzF z6)f_j_Bf{B%OqC5W9;yC!#jq$%|NWYZDQrWHgWRbJR`C48+6^EuS8;HFyOuJV&!o$ z`}sh$_bWCL(3FveHZQZ^mdtj37yJmN%LR1{7se8s*+wEp1F zV&>x%vr_M3i-cBuB9_;-l(ft8i0ypGeW%;~zB;DaZcchnp@~i*$XP#n!WuvNAt@kzyu=Lq7 z>Amm(%Z-0>V+)(#rr~XWvouM?cGvb(q5O&>!LBD_-(z3b082gzKrkc0kGPgIcn~&; z!Jmbsh(m$63A#k1gwL9DAi#eN!ba2dpv9%!YS4UloMDOK0apZE=y6lPGmToYelm;@ zxJDQmt_Qd$FpP0uK3I~MLl3Xk=RWn3)K7a|4dwhfKHn3MPg6z#mT@!llVr01OR`B; zyVCOxu>7&l|HGhnf7bA*_1<`>7r$lc?NC0?QMo&%HC?S_n8}+zP zM6+^%qcc`x$7>U(oY{Lln|E4^8Zy5!UX>brzNZGCrY;Mxr0dgzkO(U^mle@7FLi+B zUpF%O8-~Hd=vk(XEIbx0eIrCJq2zt96HYN`n;M$BD8RB*SpP(0W5~bszIOCvhyNOb zJd*&9(2j$JgM{oLDyAOzOeQI!{Be9{4Me=ySenCq&Y%|A;V6xX0}^s;BtpoXOa0VI zlo!PBzQ=IUNYLVcp7GU|eLS%`zIonRx;A+ZZ1Vl%WOSBMq5G9Jb+AH|D4;(yLB?xH=7$Qn$oi@I@=zjs>cU3<#+k`eV`Gb#SDS|x&g3tgoJ&jk4-leuy!xqP8%y11?ghgbRwn}6x=l&&Ba|7F7{!16(%j-3j>D=X}%sSEU^}T}tqP3n(cL#I7%-{*NtNXZ$m`SIr0#cB z=is1yROHy@oYjR*Qi%U9-K(o1*Fu;N#~?0n>GOiy!J&)cjL3(C!_#7R99;i!C@WL<5$pf`0&F*NIHzq7*2vcb-& zWq8+wTqc#~yEfB0gRspgz;Z<`;#mu(Ew=jLZ|y&x1v#c7PZD6s+UDq_kpmphj%Z9= z3sXD_Ca04o{F2EYS%P&GU?rdhxO+r0hUk5#XL%YMbmnfLKT~r>U`F9 zb$!3V*81b^|K^>5MM)aov2s3|!Q)#d4Q@Z8RESPAcqfmjtf~CMWOi*X^_oOBzjAC<|Kr%WS4zPT& z6I%Ga`uFP*r5CRzZZDDa!)(4@UpAbs_XldAzy2{Df08MKp&4T(I##!K7gi5v5_Mm+ zbh=%p2WRtOO2PiXN?gwT$$9?%{e7i$UrZUU3``S?PP+JhVyB!E3pEx~5|acvUDQqO zs^2XwiC(x#IjFLpMZjcV%Sd`)zBQL0&abpD7xL%lx6X7-7TX7hH>TEBiiPaisnPDf z#Q|QynNK(VJ#R(1p)|D0=JTr!ft?>Xl9ZPuLm)9hXZ5Qb0xO)Os|HM#vg;)UORjG$ zD?~Dgfo#_oHTBiZ*2P=ata5|)*V8?V;6#F)Xh#>6c-W4O>cT#_uwCJZl&O3J4N6x(GkA>q$jXyf`1zi< zcVnRF)h*W9wBx6tKs&4a8O!%UbyqFDYq)2)Z+Oe_o|m!FSDm5%{6e7mQT_h&3o~}y ze|}-dpXZwIo??1Y>9~F``{xdxcaR;^6}0`RL1*FqSF2xA4)%{;{y1MB_>`S~>GmKYePqTpsAs`skbT7)}Czc zXzlqP71SmlmxQVg_U(^(aQW69)Z0~DKoVIFgCCd{(f; zIYQ)0AZ z$*Ojx=k39@+V*Wh?=Bb~wO$<$^=`BkY}=uHmwWj4`S$Kt$AgRB&hSsKWK|HRAS}wx z_KRBB^;SF#*@GI;$RM?Ij7co3ej9FIPYv{EOfL9`IgdrC!C92uI^0koo?5u1pm;_t zja?a~G%9DNw1@j(#MR{At4a+%-&2E6(>u(Ai>^-(V$iOX#9tK;t~Dc*qG9kbdX{M; z3y%d$dzTRv3AQlxgkL9ISI{=%v8zeRkq6hKd2r!R1-}Jv=e)ICRDvTr{I(p2=_H!5J9kom=e;62zLrB**#Gk4KlAgdj82c91j{BIo{*iK$<_ zVO=C(vmQhrl$-hXKe6X0q#H_`&>dU**8ejgO;3V8%{k`51qm|Gy-prn8zHj1W^}d} zLQjtMG(g4nUSt`0aJk0v!^QB%#^w> zE?gWN$Y=A*<>W%4d3FBO$U}H=WtK-4r#DZpkF}?J`_j$1QqN$feXYNFYol-EYs!SH7_hI=6d@tmF8zp zl}oE@#rf0mjoIld<>v0`q2``UayHSLyF5R4rDtrgZFp?CsV94Sxv69D^yVw>!S$h! z{mVdb_zJ@r=w6#&8sB5IL_P}`bxPA#k{PxjE6K%kRj<%P1&TTl(n($me$pgSV7?bBEyA4BnohU{sXgz+;P({Pp6 zo%HE%bD-_*(cSXV$+f^xyrpO9(-~)VMb@3rr%TF7sJ?F5wbJs^V#VHq za>{ChA=TEQR#;FOo_9%CWR>6JdS=ACR`>_Gr>qRjR1;X$|um%AMBxEeChWbMao8C@{^o>io+pIj0gmYTrRk0>i>(O$9x= zlheUohw@MB9Yh{nFVcexnE5TpqFwO~%#A?&#;)wdx*R>G^EwY~u3daQ{SdDZVw^duFAj zXRUkc;+6Kk>ABg_)`rBn_RR3c;9S}~xSo`Yc@z(>=e33xHI*J*5PVi=pVbg>SuDV?rkM#10ZStMEe#{Rnn+hf z_&u6zy5$ypQBz2}Ce3LL1hbl4(VQnVnKG!bPUWET)4>#in*&B)rnwh8p@oM+FD-gR z=|x+|X>@I*54V?3$9qgS_aq))1pK+x6P-MX915%Dlv3DAoJST?Bzr^{Vb5@ZhJ5;z z*xTBc5u{n9Qx_3Wttgz_a`-5moK~3H+!V&d!UV_FkZ+y!rS+M3d=**-)sdVMb=%*k37B{p+Hnvx7->+sLoie0HT2q zSrEk$BC2G_2-_Jhlx_h){9CZ3)h0w%h$lt`8=8xSLAC1EV!+t$?0opl5F3Nsgf|$n z5G3qO_1vTP-s1Jq!>jeVuTPHrtS27I`Ez`}Cmx@sj6A;DOzt4bW*%Q;ldN{7=k4+J z`ER@t^zPp>JZil<^7!Hn9d7l9yH)r6SYB(|pg-bF!q=gY^XZRB<<2UNikUp7AgtBy zn+r(h=x>-x@N2|zq*nc`4uWe6(z>%iqeP~^Lv4g0`xWe1Oq2TEHyg-Dos5GE=lh<` zL)M~(FTFcjl^T4$rv{&(j&Fcxx#yA4Q4yGrGrp{f?==>q6>f^UdVZzn&c( z;}Ne?sAAi<{hNkwR1EHcH;tu#+sNduVel|I$9sBtj6A+vL;Ci&X1(`be7fH6)Ik5< zs`>v{cnRLC*OyPJKDaeFKR7}7LBD_<92k5dYA#2BxPUm9OZ>YaLF_J&9%PAa$3I87 zepGk(bwRW!j{$Jf_=emcnaB<1yxMHE2NkUN@fW?2Xu5zd)YSvtebt(=J+rFOUv@dB7)DZ_k8t&lKt z>!EN-fRPg};eOGzQ!{5G5;E^sZjVEYoc|Zz|8E~S1bEW-$T{Zm#Srj3J-*hPFK@Lj z4NNTemd>8)&tDiB9+3~!xpNcK8|BeUO_}Dg^}&^M1Bu@0q4!?1tN%*RsSC;CrQV6T z{=w<)iRJO-Li5<@V6x@X`L)6I_LG|@%V(BX`_6Z7oy^9Y#*&vWr&f!r-Ba`BEcE)_XHnOKi|=lTD`Kcw9!5=a=BwMpX*Dm=bQS@M z%lgNMZ=J{2y2$^sjJT~b<_^fHyDW__hTc;$@v_p>hzz!PLg5v3PX8uk)ZLHH72(_=c7BB$H~jg8nY* z+0W_-IpccPWwq3_%4bx|aPZ`L)!waCtI95^P4nsrb1GNTS((V=OMU#st=UDiFM=@q zJmNGC+$gKO{un`?Jh*oD@ZLhn%k{A%YU9>UlfMJez5hhMhM-m~A$Pi=~ z1a+s8hDpH>4GlB*SGmDL!18*D`dNB!M|1h3&*i+UfB$#>Q&o2DpY;5CkngdQT{Dj_ z*tLiA_-fxeJtt!F&jZysMy z%Edg2vgUbve0}ay-yg6jziLxO@pk9$Y?%Z1%CW<2Y z4W&mkWp-<_T+z|8rhlA=2bEvYbjl)`W15cR%3ss8HLhuwDb+1(gAue-6Y`6l(85EZ z*K~M%)uhv7>O)WB@r8P*O>f491Tu+W`#?#A6p59@O#x0#gn6G;>45gQ3n>rFM4 zQYf38{}xMA5P5_I%EUwcxFnN@M;J?8aCPi4Xn{G4bD5aho{7g-VRde0Xsoo5omd{p z&7Qx|u+Y~&+?{AyUf=4U7-~3k`bxRHSZ>*bPXFbJH~)dRx>PE;e15ed(>%TyG9!;K z8nN~oUtj&19}kAduQ7}~zFd3N8m_|mk;j*7ugK%ewS%9|B9E`g0}Exl59|$(8@``B zY(C|l#G~yaI{$U{_`+z;ay}Tm-C7HTcDrSSoO<4w)+qtAg?x@H2u|+UeDHhPVCA(j*nzUE7a5zMQeWRT2tPj9b7Sn;3+`2Vb4sff*jT167$*oneS~0g{;8 zi9f+JD?Bi!)Xo_5@n^v+jCC1sszgoJpA0ScXO^2H4i^JriolwTE!wS8g8K;aIErSboLcqM zo1qv~!j1-@ChXTx15PQ>7B4y%W0;@d<;X1-sS+EGP z`U4XhoS##!vDz$T$3%v;hO4`Y2c;ek(b#jC7DW^OQ3JAj5Pi^8@BhWm-y^{rN_&s5 zuTC!p`JM!QnsdzK3lfB~Unh^Rc!(@9f3Za#U#=ZqHJ$q7k~_Q|j-1S*?u!-hd+y5? z3Hu;5%gYky)1<1ZvlIcNH1#)c1dvnI;NY>Z7rW(UwChiua3=@^K+@KQ)|70@$S^6;lY-f7b_RZjV zMs>zQa6GA6ih7>3$|Q8vQ@Y=NJ@J(4Sqr?J@P69V-hfQhFPq0#LC=k^7i*r)1zuY$ zA%00uG@&-=Rg0WdYfj1d&Tu}j_cEe0#N}wZvt;WmX#-8oGeqnccXgj1R<^O_t-HAGBlio{7AMMS$MpkWJg6phquhN?8r2kdg+FQZT{4=n2g$fxLzzjIWw>dQ5%jNj$!g5|JSpY{c&Q-p`1lY6n)V9MmqDD!2i%Wsg*BEOPbWdHstCdg?ltuAHrjXtR6guaMa%AO&w zGoE-mmw9_6*^)eacC9VlGERoekr%qH`lV3Ul>{(O`XimUL2B?beij~{eyVb zA=Bqq8#2w~iy<@e_@WVOdwhN6zyFzFc>IHgk;j*7uP|Bp;VPUTd3?F{iafqtJNSMQ zd3-&Yhmvo{Fum2vr`(fxMAfRdR{pDYy^pAUUT2Rl$J)R?;Sz$4k2M>RsbP1>aUb^J zlUA@(7zZfpzWnICvL3`v;hK-5Jr4KC`qa-q$F8{rQ;^ubVc!`SoYOtNWzJ~OcAt&! zS$ll_?GL_jr<%n1#?0w}t@1WPpJo&@kFQUNeZqtW*OwXnDMVPu{hi$m8qKRF ztyf1LU%a8it^RPg>Rv7OAf?hs;Y=*f#|w85`a7Y%#9q;F@wswRKHgdMV5TYT#<++u zW#Es6&tjMj^7S)`;Sok@=SRl6ch1cOT>)}D)aE`y!8HjTW{D$c(R~S$HBfxd<{=sH ztM$>hK9;IV4L;vfgHKbJd3@3J>0w9p^U8x)$>ZyXjZEG#3?4?$;yt}QMjl^k6m7n{ zy43yYdVin>da`UT`%)UhvQ^UdhdKl6@`G4focP{nrJ z_C0S^IV6MBy%mZC4`JVytacUOf7>*Sl`003j{aXIPLx3lJkGwPU_+kivd>|7)1l+H}U!C13 zEhZW>+4zk2jc#n6DK1V;p6Q!h$@i@F_iZ%~cdsNTW-k_}M%OaAL~s5f*7!Qzlsn&= zZjLXW?wg*SpDb)Njh9lh-L3O2!{v?3`M%SI_K{0xJIWoy6H6QM+|v2X;Cf%;%+!UB zj$+fv%?nS<<7=dpxv+FL+1Fl7kDls{=f;Fb;>AvP6I$jK3ErI z;2o7O)RsJfiW(}XMR}9)*(msuNlo(`IzFyR9^a*ImBPD)wW>Dc$COve(}Bm@ zh>Xx@HT0GB8`d4OHdb8qE~(~>yvEj5GNI?33Ov_Xz@$l@Q=3Y?Y#v`Dde)5Y3lF`d z?z&y~npVr7Qk(Nc<2nM9)2AGqc^CD(1)b5R{0==+t6Bns>3Kb2N~Q3v+fr&=<%%-k z&jmFPs*bYGZc@&)-s+ja%)hKuVi)y`B!YB+CK|EbNer0u9g6~`v4_|XBZ0W?{-NBe z+~8)Tx%>&%>wLy@Iq&Kx?)+L+iS5tt-460SRW~=JD04XGBs(@?_x0O&pn$DZoYFqN_z#WP-p83pZpJGlU%jo5y_3DF#<^WLdnv zkUXiM$;nBnsJxiCh>LPln44f&^NYAAOqZP9{!Bc+*2-)7OyYdUna$Sx`OS%qq4C!B zc*m9GSVv;A-^}H9yWP7y_I&A$y;V?^%0%{oS2^ zQI&ma{9sd%?`?!W%?mP*uTHT~bYT<=f9}({qkrbd8e<>+oiBdzlS27Hl=W686A3i6XuJ;FOpuZ1)o=>M#9zsEN#r)D(VL3Cfu+et%Ovg&YV6MAiBxI|*xRRBPFVi`hXl*;5U(Khp zoyFGV@cMAm#B$$K&*bK%V(*28-ibnQ&+7T!j#Oq~;@oKKz@@RJmgdd1)lLJBpKA^G*G!WFp;N>?`L-1{O;fHk&5S z6pEvpGWDIAJ>N7wural9dHQU*eY0g}2y}FZBaBmaR1dghP z0hJxoc^D-&Wk6b$HW0Jirs|y2^JMkJV;b);=Ouz`&8h{a^jt5S!L3=(*%6pT$7Cp5 z)AR5t?iS@>CY)3r<9@%M-+gkiTe*FDQr_%w85^y)9>i_ zV1wJm;>oGR!s7XhskZgZQfqqS;>8OqZK?8BZfblvKh}F`p=ETqzin}#J#GfKC*@)u z#o+cyJ#$&VV|tE)@Tic@GuR$IBhT|zbHns*l)=gRbG<^~p;`U$w=SOwSd>3zc*n}U z0ljGR_?D%&4c$>^1oHb}`2KMBDCeT4j}_&nRP&am{wW#OmR0MRrr}FE zkEv-`6H=RM7|`Gl4;kEE^n?~}H~)S;zGwlG{`e#YG+ZtbCs{|6sQ{Nt%xO;JgAt2i z9+Q{z)}S=Y>pCHjiH1p~_LPC(h|q`|sq^5*+XKTKQwGc%f~H@@7mX4O3g$MJ9CR!B z5F7YqbYk1+>WloIaLI(;wXx*DLSbTjVx?`aw3_Q*7?_Ut49>?V`?C#`V@+)x4IL9> z{eh3^XTJO&R~-UZa`~f!va?4Myq-tu^vJd&pY%$YN%C46hirIC!ldh|7 zv`09Y;UKlHzr|SCqr5>meEABJW~Jhy{??1D%c^`ydlSLlhKRGIoNrS9KC0g_)mz8D zkj;~WM;!__hLUQ-T`>0RnAhus4QOw93IB2?819Z3UbFnY5Z)V=z2y)5f5!Hq>%k8Va!o6NC`gKI_5Ijty#8_Ix`w zssxUJXib__jxv>RprPiO?peam;oCc$|GW)obvE6E{XkNdUoiC3(ltx(8SWe2G`wx- zSqmZ^*y;_FhAG1tL#AT3tA@LV;r3ZnnYex*RKWI$*qiF_J?iPW9xiErUGJ=@6tNdM zEgXlUxn2ViyxWMY=ZDLA zLsy&1vW1V=dhe9OpNV@b>u>lxUvDh~N}tX}hl-rclQ8J=Jd757y3eTS>3O1&q;ac)Qh575Rmced0oHObJfa!()UxV-dg#u+Vwu7zVqZu zD7<`rO^<7U!|nQwg;j4^aSOWua@<>Ht8uWwY7K=FFRl`!4;`f)W!FUB%a7!z6X9S;_mIaodX zUSPYpCO$G4CNYKLwZb`Q$XHnF$RX$dbhKR$;A!ab-~PLQ>Z_`;U4P*({(QiWdA7@^ zIj4f{dMeR+Egi2d+x1anx88hh*)F0tBDO2icD-E2#&6d!^^N)+vRw@1m24Ld3Qn%Z zw0b%)u@ct6sxJ}S^{m*ETJ_e-e^NH6R=u_IpY(bW+a==B=Gh{&O=zv0UJ1quCtcVe z*dmrJfEmK<=k#9qeBrx=YcS?X=kqmJlkI}B!rRLkCed-hsJW0O>UYc>k%KU2=-Rjw z9F=iDKRQ8OC07`xSK`1&o9K>Wz-!*&Itj`~KOX}#Vu>@u7&EErxj z+%?=Y+&8>sc*ij2jfIA98Fm?leZ9(-zhlU>z~-loMeWD+i;Rr4%3-_UQ}%WGRkB^J z?_#@7X|RXk8WEPnbZyAo7_nQvUxoV_=_m2It5t8U{8#OIA5r@}xt2?n)Y$y{@Q1_c zdVin>`gVR?A1&A;_f3v@9cP-yL)B9p!40o*8b&&)ojUbgkE+}=;C!kV>P>^YmX!tOQ`z#Knh(kdF z;T%>Yfvm#qbx4R#>LD{4+Z@>KHn3MPg6#VB=o3v`=Vr-7MN_3PcDwMKR0pYdHX!3|K!-eg6cAc zubS&XcSiI>u`WDok&eWY z+H1u<9kJx~2{l2CAUc=z(49s$D=PCJU_tYX!5lwCXD~;I;S*;pnTu$HvI_%yxF34% z3GYUDrFoThQN#!*=!N0V(EPfka}kW#Bd~;JulPV4*T&NsbNrFRE+2z?dX_v5^tJT| zIvPADc0*~?HpR~WmB09L@;xW!)0|VmcIkGX{1#hZU!TXz#%`5gTeb_SJz~2e9R`f6xX*NQB@FTSQ^Mf!ksMYPed=u219%!*=*wcu zZ&zcxCT{;^z>ayg%cnVK#1;tt!j@pL>;wwWPE?MLrs!;htPH<+tnoI>TrP- zZ+6dWJ+ykQfd=z+zfIyDeK^S-{exho3R# z%L0z|!RL`Naw|5Kj}*f7s-`84NLuv;j_ zo>&pr{QN>po;SPoDPyyK=(T0Ha3Owuv|JIp^?Dc=?`OA&{%MEB{H~XT)x~_n8u)-C~&%1U3wX7z|;k zaI|vlkXtGRc8jG=2n?B3NxnM6LcbUV(MDnV3-=3OKP#!SN*zoVPF7x%<+NwiMXg*1 zMvJ3v2^E4$2r0oU6C>kOXSW`}%g{nU@YA1wc-zn$ z>+8&DUvHQ+42P5yEdQ$Eu3>oiS=2qo^@~DFcw2|l_ki|sqd(McVMeHAw}!=FrDaxR z>Ex3^Jg-}x{Qqz7UBD~LuKG?Xv7rsNX$+Xc2BWgO`)k{+*410`P;~2AD!uCJt&$z8 zB;Bjh^IqxRE9pvZlZH%4eF=}6v5NfGYLz-ZOWb{kqqt z^uOuZuHW+T;WMSj*XrS6zfMi*9}aC-sqn$g+t{xP?PNG7{nngvlVZh|w4X^X2p|lK zi=z4CBGac@FM4~6ZI1Rk=~K2V=%V0{^^fJmrNiTu{<~k{gVAsi?gTq3r}aVuMI1TU zB0Pd&yNE6ai-gw8*?h6zA`6Zz9dft5r@dEF?*!Y0c|O))EJ(tlv28lbl`LJd$jJ6w z)QS%>SJ9!-A`I}kj)o20TKU!x3>G|&tWw&Ar{UXupypd@OR-%;zfcI+F=M+d%{?7& zDSy`6bYY5g|EQ7CjgtM9~Ne!kI7 zvnser$6tDO>#sb#;`56UXzbW6pYQJ8;a+^Foz}klZ_|amaLRU_n$n*vQ~I58>_D_( ztyiCrF$;`rFveD6Y$R3?+l9_+3m@1#GZ@7Wq>sWDoU&aG(;Zj;#?>2_f7I`JceGuG z{dYnee|9CBuCNO+(BAv7fmMhXhpq~C3L|$I8FWT&@esQyJQ5wd1e=3K3tKHTR@ihA zZ2<eA&ZW zR*o(S9k=~&W4J<>w*8C_tcNwQ3Txy@FF5Hk0a(RnRURn=9~BHDnLK!kFj1Ub!_;dC zCKQvF8lwGW6Va8!?*xUhZGwWF;_7E2BQFs=1vPS`o`edSc-;hU0Zm|-8Rlmh;ibl0 zUF#2Ynhe6nw0kVyCXb~lqrfU18r@cutnxRN{};_WvPphWr)@u6%r8GZon4#EOs55x zsur_X=Q7Xa(uLJrW+bYhHuq#&gf*8 zu#kD!Sz@EzMt34K>Q!wSTYz(nee)y1EE)Fj1)qN-0&n_s1zjCFeDr4dym{VeKdHbNBkQ#36hZr zrTtHV2V?OlG(KZzB|AN$OK|g^dFS*8Zq|bdT&y#P9k@yWB=7>k0vOwvQO9ou?gA!3 z(g{3(#SX!jh<3)T2ZunCCk0)EGe|pEA^6OHo{<(V2p4(&8mm7QEI%+^$;(le9VqPuFXx{8c! zZf-OE%=F@1I#akjmpYfoPFC0F68Y+d>6)d1&i<9^Lemq|*;M-S^z7u~Vmfm*eJ-&u zkjhOot#mCkYz${}D_1Mm#=6^@RtC=xrS-_vxuKf+ zh9@#v;iq%m-E)b><(Bo8m5urALNeJnbG~k5pnBj^wzj1>ypmrZ>02IZo66u^Gc`SZjrH9<$@(X9>C{{g zsHQkNw%mPjZN8zSyKihRyV=&*+|$;z`9yv?s~UA?=2DN>B+^ThbBlt@x$Ml`V)~u> zK2dbrrY(b8Wbo~C|tATWOL4W^PD}1+fp4EM?3mz8bzT(Hxs~+CAaix0s`G!xg zyywRQl$-PL3Syp)Vg$b6({Fg_O6{$=!QLeppAnS1g;Jjm76G=%(bksdSxvK5-8ZXA zTBYgd;<398&8uXufkwtkK)~FF+0ST#BHyOfn}xE=`jrxjP6&lFdFxd!p`fDGl7Aul zOJxH>-Th@N$|(rtJfYld@T|-FTCk!o zS*ezdX|ba%xIQRblObJ!f1lU3)gx+Kn`%j_+={LhwB7yHJ)U}5t%T^z1}!_M`e20` zbXP_>8MTv^bq5P93Dv)>(Y3DHSJbX~l~~Zzl0sKAdS0DcFrarGD7&O9wJKRu+gH>h z>$=jXdxzA%DYZDS_qe3{Fqs_E8`bDrOsR%Wy*VhjN2PHD?$)oQ;1jxs-RoH70iDwK zkjXi<4RyF9xQ_?VbOh7=E$T_j+TOb~@pWZf-IU{f^Q!-{>f2D7H@7eLgs#~3=;zeJ zqRI}c<@E8g(ihbm*c~u}Ms@9y-gr!?J*VDq)(ZS?3%(DGA(CHFUy+#q^m$Qtjj5(? z)wCAW)uG>g%3~34Q}-d)^$2z;MQdo8Yomi~5}pd!1=!6cjYzgL=N%I&ms9DPASb

      #`pW(stj2#yWui*cdC8t_5$mljSnT9=G;d{eyI~ zfi>Px?5OA#Di8~h;E|!7b32g|oAff{);sW zM!#(HgV=(wfNp?#X%7n{v@m?YLY&g_lS|9_R`33$r%SSHRWE)p$Tw(g8~0Sdx%?@S za@aLK@pYXxtRtLC)iZD==hm8sGsAP!YstyZ#+v5AMCaJpg^ij1vCc&Q+RDUI<#>B> zy0&$5wtYH#m$;a3P@7;s)-;SkqOc?`0yq24h2_JtvQLVnzoe5X`l8@rSrn7%R84Ta zTyDP{i(=P5bN)927Uf@hXi}e<>KYvP(x92iBo^m|PIE{KrKh}jrZIw80w!aE@{P+2x!)-LigErif2 z(lM(Pb)PJP7VS49Ee5~RNQ~Pk#E}im7?DHWzHLa6g!)AzMGj;F6*8oNF;OG3KvZqC zSMf?>r&}Uy9X=y?m>}1>@V`i@&ae?(7=h~`Ktylh#F?1q627iZ@l3W3rpPR3p|G6) zP?ggVZ4(y*0kW!)T}WrDOvHL75S50>JC~?=dM@?!*k&#@(mHaXuW4nXvwEp^xM6(h za{Xpca{^ZgY=&V=<$|^r}0$u zL3PBTt7!hdm2rQ~DdS#O-RvFqnof=`PhVy|eBQ(B9=_z^D;}14GWDp3PkI>e2CDCh zPcM6T&BGTxH1hU}Prv5j8y*JYz3M?>%W=AyiR*{xcPEW9=DsW zV40B9k{-h^NDTu>`?V zB(gqbS;-gLw;@;tiat(WM%9=7>BrvNRcb-u-`(B_*f3jWv^4kp$FDBGB{mUu3zXQa z(>TP#vRg}Y)4A-_Tvq(##oO$;1!>K*+W-qZ>9K) zDj4)}jKsO9VN^;XzNG*~+3d^_i5jt?-zcIPQlM))pD=il-$m{+>5 z!m~gL53%szxZ~DIGLU{WFVn)1=r~Z)yVxGA`J;KkR)~#} zTqrg4GHkpAL53ONI;;0!O8T9{zKhk5O#n;+WZXpz;dyQoCp0z|?}KGHo{n+&jPhYR zFx>+agJ<xv&kh1S~%qsDrACTQioYbT-zeK4fOoeE)6 zR`?5IxugAYT>TVRZ(ROSze`-barqD0^WLj(d8%dE(z3u_u>^(trqivseVSN~f^xtX zp&4=Jml#N62SIrtHd|;+YIn?sr1}|Fju2|FSq=K<>TeF1C-f~WqEQR=V+sm;$CJ>p zVCsnuhX^B3JJDGif&r^_oIH)1UG_(pKipl4?fQ;y`d+6pICC)wT*jP#cG#GK1F7*LCeMS{9S)zjnqgT)ox9m-G!eUWvfh zeA=XXS88w8>O~d2`&yQRvsU+7%VOVWcWKaiaVNCzY*(V`3cC;k?fHjwzQWT2j}Et5 zj*^u%ZWm9{nRPkEE>arE2hA5g8AxH6e1R-LQr2#3Pg3m#ohRYv z0V*Po^?N)*@G>Fvw%cRd8GfZyi-x6DeNgFcU-Oyneb4W-2cA;=zNyo5k!6?v(?93| z{TQ0DH08X*Rj1GlGY7`C`;*`QF^b|_>DjRO@A(j zt6%c)mNnKR6HDIqKTPFl`B4}hOb@HW71IbK5>`JjJYn)NA($qtq!3KPt*Rhjl1Ev$ zs)AK869e@}w7?1Lj2y1IJbfm~;k6}XlRN-t5o3$;@P^;YRR7*PnRQtY9}I2D z!4^(V!*5CJ<+UNF+7d9r79W5mJ_P1oYfDbUZ}AnJCj|Xp9i+BI7vs|mMyXR=KIM+0 z#fqypF8@J$-l?|44K(9!FaTx|9v4!UkMICNhvBw7M1+9jaf?HUE-V-k)dBGa%?3gV zep=D-Y4yWtVc?5K#+m;j=(qs$ZeJl5zQ}QLBb=i;dJ>|eqOZX?_&ByyjOS_Sp?~?K z<7>u=-BjAdn2K9Jvl8s1%&|(T~7gPEG+LBnd>uzdGJ|k|DEeg-7ZP=z9 zm$u|4_(#W!o~8Q79yWQKlVk+W`t&Ovy1Va}w&dWf)xFl1yr>R3icQK*2B!|wQoZ5R zk9Zd8Ne`PmOnNx$VbQ~D9=_@cR3QsNzw7WL);jv9& zR~WX{!_1WB5w~Pvj-hVX81e{)&LWB<+RJ^>SH|Ka|9W}76xo0I!#@|W1Ezqn zH1~wGEnvbUYg=}SX!V5Z-`gy8Nb9+*E90`2)87g?`8o5-3c2=$%`5M9u=8K_tiZ25 zwAvP?$f<40OA(gfrcb}_;cX93ZBsxXTX@azTa<+&eH5wwJ9R%EU|XI)r%^Z69Xq7f zxc-mJKk9dht2ZwHL3`eN)yJo{DOhd{Xwx5+cn*PD`3Zr?XooYgtRRvXO66G5!>}3Yg@ji#w}!ht%nbv zw#Bhlr`i?PG2e778WyHOclsE zMk?q;Sb~8WAmA5d8v>1aDJ%dBERbwxQZf~2PwIEDuEqkei!e1iqf`t~UBEAA{t7dJ z1_px^oPBXYCMGZ%8Mh1s3xT#K$^zVN`pRg$GV|DGDYE~rsqftgFS1ygdqUb4B%%Xw zCb1@LiWQSdP3BUS;UFxk`$5;Xw0c&c&BF)7w&mdFsxF4&mcFYp)}5FEw127ZDV2SP z&Yh78-}~0gZK)qiJE0iYM?amabeJ6<9gP<~ePP+cAYWD=d}q zJpRrI(!waKb(}m6^YY0TDnD9^?Rxu_zZbA$rfsn__k^@9m}wk<8;oVU9%OCHbDpL8 z*aM|)IXG)|s%>HLpK4p8q;W4T!YK>n#?4;+6vqn0lxG!>1UaRknL_?7T6Bw zqsKM_iJ(O;t_!BKY}giM0q!<^Wi-C+*JlEkI)2~OX(p||^5*~gxv;jy(v&;0eErLwH`f)@DY>cXzDxLZESDO%F`oj&uIemCt-vZX1dqkHhj!GO#q)yz}k_Z}qO( zSoZ0)ihuXHyXU;y?fn>e8i#k@wd_)kl=s?sw>a^RAAEY~tI9S!yyaTD!-)O1&p&nE zbrX?5q)Y;5?dc{RLbVH~LBJ>0D6kO4e$;JQ;(}=)th0u}>P389H0U~$3*UUV-a&b` zIDtO1LmJZ?9)T&2f`G_tIPGGBLC_AK(0s=cm(RxtFE!@g_kX?c1xCFcaw%eTp6 zX)elnw@0Jfijwu0f35s4^a!#^mU_~2x{ea~tgbH$9+v#Q!~;UdjnHqJWY_2ak8cb{ z_kxFKJUvT9=-QJ$ZR9aj-L{`mw0XR)=_k)pJNo`f^$ui-@y2F5#PY-aiM2r#QZ7oM ziw4MSAYLCf(@u><{66mEE>uztJJ<`WA99pZNkZ75>Y{!Zj+og%z#Ql7UTa-ayD4L%?3*|K)&a%mp>=2l%dZ^VpxZR`i3@QtU3s{ z_&K%l6+c~ABRTAJc}4Bvc-4VB!C*-S%(Nf=i+-9cc^JHm%8dK#2A6%>9CCcMQ2lL3 zbhtF>YS1@Y=Q_ytFVT98wTR~Ld)=%2Ae((|d!=m&d%k5x(-n3h2HJa+3f~eMGqKYG zo{J@L1T%Or7R6a8che5y;37t`Hy6_m9WKU5aBK*D&UGT52r=cTotl`QZb`l&AU#<9 zAw)uYAUTjDI6vZ1G4b)UbY=ndj0=0!fC%k2Kj^CexxeGrjUe4r+62DOyz$9kYT6XE zH23(udYOXE><{XUn}QG8UcJkaX=%dS4L{!u+H|a-1474M)AGAiHt4SdPRp&0B~SP2 zrMoNmv&&&~;PBI(P;4x{FyY*EBr=oJ+2H!@0>&_D9iIqgL=Z$ggZiSeiI3LAL?`e* z+vPcH9_LW)cv?^kCKo)9zgI6P z0F1#jF%)o|d-YCC42`dD7V^s-W33|>R~Kg5b4!c;EA73B%;n+k+Kbb@bzK7!t({}V z=r+G4_Ui3SqzbF^HQCY5m7boawoGb%v?*7ex_GH}ZEU4HV^Zy2R_OtiTGPf4b&5O7uD-SUO?_>8yEWC`t9P5yJHzqJ zsxEk~YMnzWIiYvR1!(c4?A4nTdhb@7hV>@ZdIxy6R&D-~)El(xtrO~w#-EX1MV?`QVk~6jv}C)PN$&?F!_qM^Kfqq~-D&^E z?=jPIzSXN=PL`C|{`e<*gM5QwcFphA3%dq&y{^;PwbFa_UhYZO*44JGbrnZ8R{Ap& z^OK_!O>4#3`pkG|<#0!RVZCx-EK}LBGL`px^&a)j52CEO*L(GT@cYVs2+jRd9-7qG zY`B8Urw2?-Vn7u{~OUz6%I zbj?VasIl<-K+B8Li{(ux@v;bsWQ^AdYcG&B$epVfJu<2ZeX-8q;Vvz$lVtG9ai z!pcHT>(pxFNNu9Ia(JS;wx@pLd{19tpt(6QInQYiEH zA1!}f{Q}Cwm@%bsWli4C=5Y&ih03|iS~^q6<~FLbnaWvNG*qUG%X7KFBjB0*Tp@k# z@%q-sYiimisuPJsb!AO;ZK9!B8BbYeb)rOOO--rHQYEWPmMr<8h7xrqYD;A{m&mNH zFO^yH_RxbKuWy$OJ)O;^dgqqr3g-&B)ildIdq*$n3HGC?5J&7bch3lYv3cA^*>f^( zF6v}zEeoRm>DSJjlg1te~W#`Hs*OYJ7Ul7t(6bUroAPzj#F>z}4C7#+*5^eeZO7evLmfUZh z&gpGG?WD~9p6+Zo_ERTI$os3)S%~bXPT~jbuTH+r{z~!%OO@o?w|fa3nUk18y&4%9 z2NyIp3d&j4D2dKLn}^Z-eXlQhzp4u1=l5w+oe|`?=HW{ozT)Al9^UdWSR_&TM?K3H zW$lta|240by5(V+4@7vz!zVqAy3||X!fXEe3m)F^@TP~iJiP7UqkjGLNe`Pm?DFu6 zheZ#sdH8~d1aIWH>0z{gA;AfqC*1|ySh#5WDMO3@<;D!2;I}CIXWHS`92rgSBG zZ_S;1iCBgK4%BG(R)Wp!iR~)Crh18R=4x0DdMNsw`a5@Y`zQ1X!d0xQH>0JudT&rA zumMCX$Jb)x+FYbO?76k4S0$#^p0sk#2R)tF-&~NlpkHfx>h`CB>FsXX#FL=b6{5A= zSx`T+Us&|6t)Aoiq*X4bd%EFn&xG7+^hG!-_MWx zj&b=98s4<`c+f=tQVY`i*&LSr!LUJLK^O}WEI{xMgu`Ru8NM0~F#2S;Q_Q@u4snKx zSgx>fY1)CPx0?I;uYg(`q0ae{K9A|N2=&dp&@lvg^@&(tL`; zir2rad#81V#aA{!Hu1Ie=EvJb8|I|lF(D=-Ee0Q<7XdFTVQ5jQ?RUTu*&R-#Mr=Yv zMqI`)1^ddKq8B*F?rRC^%_}`35efl{O_`(pb6ouvS8rVYQNPpu7GLi7^W*w8F8`?g z9anE${@r@s?&6aMc+6qr-Y!Se6?P#8+It;V9AZ%cfdk_jC$3-)Gp&D!L(pr)A!eyF z%t!RW6b3O0!yK$1fLb=oa+6cp)xw9S7AG@K_jRuwK=VKQ&3_*=l7fe~tgUoO=(z2F zCnNcxBEiq-;5}X!x#-ik($)^kiKZ*;LJYLYXZKk;sq#!l;w!PmhznBbY~|2-INbyh zlH6o;CiMsl&K8n8n8t){U{c1{k46P+IP@v3Z=p@$iA?sU08yavz=;$y2cAQDw`VJU zIQZq%2J6W7ipYJX#@t7~;~xcX&sNSa&y-odO&&{AP7a{`UOu>h#UTEE-r!F#>cs)5E<86V_OTocT_)1L#>lP2THa@G^Rr zaX&2#F8lP&$aIM$cYIDbyP$7kG(RlTBk^SPsnS|HB)z2Y9?@Z8$T*t6?*;mY!~qn7 zfO97sCpZ%fOtf8W0Mz90ls4^{l(;xRun6+OeO#wpv>%iDP7pbW6nDToVw#N#ABRv# z8;X9S3|ak-++og*4IXCW*xK>Cu1w>?K3OpBcAFo1Y}w!YyTiX(iknOS(N70c)25)M zxyL(zG6k90AJiE)1s^mA(8nXw@&!N7ZbYC>#|p3DrCT`mnwF;ypst^68o1O>MGDtZ zG|dWq;mZ^)Utu@KK$`=l1k4bLxKpo{x9JF1i3bMs)Y(z7uZjx~#zb>Qu#Pf91*bJZ zF|I{0#q1SM5`P?PceH*`0*IH;U_5~h@7#(V(;YhPDDSjVO#HOkLyP!}_XuXYxTc1W z!^}nQ|C68H9R=9bH^@ES0TdK~ikE3(DBw69K-2l@;iZoHOPw7x=V#^;<2BtYjq5|* z)sw}^&i>8h(DdN^*z$$?j^XK!C#JKh^yTT<$;HKV=4!fx188nJ)!WhDSeqCfU0xol z>$o&?zO61*Jv_a*-q5$)KDj(zolH-*)y>Xr&I}FYn={p^q3*%V`r_*5P$8dLyju>S z{hRAGU9-(IV{`r0lPjsrcwNuNO5N0WeaC#;(BjDC#rAZ^LPPDv_Lau^Ozy(y%*;UV z>PjY2UF_@07N!>;a0k#|yY_2=;P3?xqiX?0@Bm}X!#6y1xqG8r)-Zzc8R3MseCnST zg25=p87?k|xS_1_S9Ra4CTW!>t201aRr!L_Ynr%KcS>N4Gbd-fw2WdgyTZr^!{p2Q zm68c$LL8P`K+oxSUiU7jT#eA%fc!A}<#AE1(tEjLo>Q%P-8ZcJ@Y}egdplIic_D{6 z)jO`=-Kwim{v1R4g`TXalP7G-5NJsE4$2#3Oy*h_bbm+Sg4l6a96)ob6SL0_>GMIB z37MdcDsNd&tyAtLweh@k|L{T8!E+bY$_ANDE$fa+{T)|6#!8bxso9`EXLR>~-nm)5 z30K8i4eIy0`WPoz%)0VQFP=CDPM^dXVJ9wma@ zhu=E~SpiNS?-=I23)+II3?$wWaJ*+IfnJ#a;Yb-oT|$6HpG@gE76LW{xdS!=p_^Dt zFd$AXW@bXTpgNBr+JY7wT{Y3tCWHHG{nu~+7UGnaAHf0im}xm*>8buJB_+1x*L)<% zHyCEuyaOog8r1W;PGi?fJAl?NR}L1t+Qx>bI+whNY} z;zDX5JyA0-?Hxdm`sOFu0rY=sedHgYx&PliG^x)VKMmeb2he(<`AQMSqR35~NX@XO zc&8Bjm4|0ousQdbm<-K#T6k%RY8kqzX6D3ql_QLJSi^J_9Pb-2wD| z6SOEQG}2=5D~-gkI)N-o8~~(4)J`rKB_sxoFL@9JG_z=JiAjbVD0iWpLWdl`S15!6 z)f0vgw%aI*CVZ-pOIduSez$Eqi=?Qa&>y2QW(gD`mOd5-(AKpJ>D=gIZfs#}d2p@n z>f+*N@6y$kwU)k(T=Pn5vbDQ$d?{a_0%cbJ+7FgQnU-G)WuAL`dDGj=%0QVIlK({n zWrmD)tMbd)Og@`a*y`2PMpbRFll@Ri0;qCR|2efUakxPsd7bLzvj)zTc9 zSf15;@9mJ;qR)+60=IxY^+f8|Rvd9R!O*=!~7S zrnzEnU5Q#*+7$v@m%az3SlpG`*ei`OS7=@7+E~;reFa`Q?n>PIU^NnVkM)kT^^A^B z8>i9yeXon$r48X;*Er;0JaU-jv9Tx#KR=%J&{&jZpMKIi9L6~=7X5W|V0_W1U-s}d z56ywm*8R@-^}lHU%&LtEohRKA(^RX`_Q!p9%E4M6)-n=&NZo0%U2X=WKg!?1kM>-H z(RLm6`Em8ei44X-FC}Pn4RtS9K-=~ z`?C(_1R1{fAdZk*_Z`j|a_jzsIz(>Wc@U?_t-JQ?7`b)F{+%PY?m4W3!gnu9n= zZryq6D0%N4B@MqkXrf!Gg~gCeumf)=h1(y~$<6|po1uS2f5*}urez3Hh)!m{gRTy1 zR*ZL83`CcRUJxxF_6Je?Z}m^=8Y>z2=s0^-_#&1ush?;;2yf^B-LfOCK)}Ps06ip6 zqK@*29l=+s{G(4+_SE#1-zsGz@hjJVG7u}xM#9qE^S9qxPOKNiM>wIks6WFRx6n{| zsKv)8Rx`OY@^LDix|mtq2!i~mKhEmB8)D_>B<{VUlll<-4l7o^jZN#Pl(xPIS*DJ;T~rstU@m8*P?{@t;jiU*hI&RkRsRwR1GsH5TY=yY^k z_wYpz&C&2xpMJx`Kn7F!Gst2(5*|kTXO?R^PsLDrX^Yl>rHP@R)4OAn7glf~Vpv~aST#jly>aL?7P_2Xu85K#6auU!-^Z24I>7yU!W5*SoX)l5ODzi0e(6E6}Qm@ zJ~M~|c+OzO$O=&Pj`5XLdmqz@_&|_P;#Omo$Z8NNS3lussTF~Q`VeQDC3xU7gK;!b zM=)ca+97V7^2^)#WroKO{Y-n{F~{$lI*sK0`FH=rKs+%q#L|@Wj&~O&hQNBl)&9r- z>V^Ms7ai}Cs#>+)IlSYYWoxPDzB}H%Ywh)qvwZ(<4{upxBi#6HpP!86TXBOniEVNo zuWOP$btklT*p+Cy!Y;%>YroxR>7>dtxv@>+gh*M~9~ZhF)DuI$Iv=)*sB z^|wuir#tK(%eTp6Y0Aj)Zotd$Bso6*)#cX}&X{bH*L8-)`jBaP)iW3%pW8?+*R*c7 z)by_=mxgo0`KyWHn%=I()uF-qk@WeI-pRF0ZA+pvH~PQ3uCBV_{KR0fXRUd?_%5|+ zZ_yeZa9(zaQxZDRm!`_zM3?A1D{xz@I)@dd%~j$RKZ|aMW)mpuQTPuX|Ics!;tw+` zZ+rN>&o?_?gBJVa5x>&p?%rFJ#?dhNJ~5(noCj1ms``fdWm%)MRpv1*g8dTLl3H;c zR*wy<|E_8b4lBP`MmJca4#}LRUbdTQ*}0A=m*9gLjZh45I&}}RBe1p2t4(fgqQT*dl+rstnNwZJn14`jeq}W`{VkZa!ic}g=PPM+WPf6 zF9uizTZ9UYN^C;dyawB3>=uaB;*Q-}>yzi0TZ$DA;r$)+DXG_ln!4>G(f>o^oFh4o zxG>02GhBh7rch5-0~~XV4KS+$=;onzGqLr<#KTHs7Yt>Dnx>V4Dd%~P)yH+6+Q?%i z0()RgyrA-|Ff<>Fu~u^UYRmk_a$9{%^+Io3%V^uBp@pldvHHT~N^Q+xYId-9YO%Yk zGC&o7f9dw`7^Mbh7@Pa1PYeb520!}E8+R!BXWv}@8IcFbGT7mRI>Tgno3?#&X?ZbS z$W2Z!%w?`t&1RR(TCmOL8z zyRCXS5;WK!ylRDi-^Ne>5C1LXvB|?LKED`&rWv~vYRlIZsy4`pqMN-u5#wB9@}Yhr zrfj&EsziivBTnmy(dWgXw^Oq6HfedE*wJ5%FZ!%sJzAl2UE>gB8tqr?*7(*BJ6W;u z)8yYbA;>{`KZo_3m5rt=>_QB*=a)kNA^fuA`y^E#=pUO~mUIzaSbil=30t(dkV1$y zAbn!IvZEc&B9IB^35ux2(kzC1)^2N$)z4<3ZlRZrLRs!b$Kqn6AZ9rM4sTPCJ@pf@ z0YZTh4V#rBf;BLftm;5ra8O)I_kHiJ*IqA$!e?8ngM1UVEX_S1e{=bDkHXPXoYT2a z6rK+-dfpq}F6Xj^>~t3Hg6-RON9))cMdhHfvgd@}iyqZ49|6@HXItTM@wkU-RzTHk zvGH64)!+7ukB@p(Z}3TE=g4T z_ldSYu3ssq;e2FCVs{k$#xuTIJAk#*E`-y+sLTqx5CiSK4vT`F!##eFpkC}?7_n}X z7NW-CMga;YjvH4&jPS*dV`e!TReJoEj40Ws0z`{O3nWfN59i&7h71&rJ`3~=f9~cB zE*w+3)45X+G$4H3EnG;QPyR^7@9u_{4ILZgp6c@Qr!-yQtid{CI*){wt7hgF3+Y^? zA#J(m4>|l@CT|O=Ja9fm)Xk}b!pIvZg6#)gbDZtrX{+!2+=06+B#bcI4oW~zqA+s7 zQ>gA!VPr0wxsbZxt@p3!`=08!wm8O9VMGIBA4iz-Q9PQi*rSf4Qo=eR*tBR422n1S zDO*IaT4TB*g4#fpTtGw&v7lN|DQ71NEsJ*?bX!BP3WW0^l#r!ngbeCO93iL;cC9YZ z4bF&;F1i3ZXt4=eC(2{5dT3$f#ov0*7fVsS|M!p5zem0aBbKJ?L&6BF4u=s&g8dO5 zKw;!!1l2#N!pPPp1*gIY{8WV&eBi3suMs=L3NgM3{YA*R8~UeHVWhB}|4>y`WOvv* zsNL{bQuyRCouEim{)o&(`EoJ7&<=qjS>$#on8==pCCRs<{PKaj%o_j=`jrvB;FE9vmh?M*_O3+sk{>R^@93O+cnyHuo?z&mS)hcC zBgl|jK4fXp;SkJr&?#eCXmNm9h=d03rZB;FklIj_uvkg7V%R?C48^^uNpO$Cp~-Cn z1XGE9A%XqferQv7jCuGrjPO!p?hEgKYKl>BhZz7_zOjLprko6bhBdmaC|N%8HrXUg zJ?UOY-u}+F{zNdkpYiaFAHCs~McQfx7SErk(S7n3_@lGiC^kwvMz}LQW8DVRG}MVu zZ0uMWw}?~Dbq^|z)hkq#5es!?7RA+1U2p;{!@Er_m|qqGnCSD&Hpel*5fBW|jOXAN zXbm(wJY3^u!yo=hWy#rK`8FFY&G_+=w;B43pfftds=$y9#EFi){j8rREgl9hqj#~@ z8H3Ayn%s;`mq>EQ=R`Xm^i9laOPt+VbXXWe7tP=I>c~S9c{`&#WAv& zsJp4ysOiNowD9OMAQ=!AAgO3SCiR_Q#L;IE9t%yq3-!yBi0#d^#@m)(u*uFsC!w5% zV4|{)z@jUbG&ArL_Q?VwwA=j9W6OT}Grw_X3f@%O7WHm@`a6Ssn}U|+9v^v|Dag$J zpw74{_@G7JZjVgM7yLZC5rH-xE9ijGvDdWR%ibk!T5g4jeMZtV`zWspW&%^rMM=(h z8g{B3(cxudA)3GM>FXCatsc+{@0jrKOnU1$c~rF2B3+0??C39>j>x%A!evUr_2IXI zDw65AC9Se}<|JfH=1?O#FBG&IILb%+-Rj5E0;>ynPiV3Wyvc;7eoW!`g>;P940*`R zaJ6o_gK!9{8$J#*7rFmOer0zQU{l{9_k8RvCXIOZRSFA*X8c{wxxm1V${=yPHQZE;e z+mkbMo1=;Gj+NQohSrVIzLmLR_guPV@Z#J=W1@9+aUpTBV|1;jkiI&dn#k1EucuPU zbo|;~U5>ns2_tcp&g#3~5QKto*ibfTDB-%U!R%e5Q0REYlag0GyltdK zW%&7qPk-CZiFY9uzsEy!mbG0u4bHNRspAz7U22E)e5ak(zK1RH_JUAf6wLyg6hWub}Nd6~s^`7W=4LJg%>?qE_^(<*mAJRP9~S)uQ@|7+Zuuy{KOk zdi#V*5Z!%2zb@*&QT11ko|cvgFoa_w_}cX{#)L;qD!*M{WI|8t);Xqn@v@i-T0_fR z8y!5Uk+*F&?}UbL>`F9UVHaYc;Q{a&ws^60%HMDG+kHvp!=aEc z&k$#)hQe7DHUXtJ0yF|L>y8NC#K4ZL-ZwcV>w_AoCJW%-PH=qK^|97TQR?p z31}S=xWfl5!6|J%LL}{DrpJrDs+zG|sQ2=M&xm@ThNok|Sxq zeC>sR<@mIRCdD;*Y0ludPv7v6&&45bciR!2(&#vYZ*qs|d`PCLRYLZ=5t^!C%MM3K zAg0}#Lm^fhsD%x*`at%Ic(&kY~46CuAe7D~cYq026F^_Rlr?aDn6u1qAYxGr-Q(?E9 zB|UOtymda3E3psI7CYk?{$fr;{mwVQ>67sgz%;ZmsNZc9LHuo$Q?0E0XxX?OP%v|iO>1u0jscrAA+iV+2URv$Gnwhzf&oc3T`0KxY+E!6+Ds7U5<(ER4 zK9V*l6JwgM)JSp+(Y^h$TQp2gRwV7`R(~cy*&p-pG?I3!4=-jxf=~z{tJEk|kAquR z;v!Frl?X-V<%cmD6jAm3~rEX_SjZ!e#fYarqyi(RLY0k=m6JgYuANn+(*k+g4V z@tWiNyg2!Hj!CRMjikL@6b0p#7E-aZjk|IhN&8d`b@TOfLnqe{#y;*PmSMa>+0zZ3 zPB(O#k_ran2qJrLZFq%NKP<4FZs-I%k085!Bd|U(;HMip?HBJn7-FcyrKSFwIA+(P z=?c3L1FfG**`Mx5tVD2Qoe$3qypf#eWupW;#6E(>V0Pk6%!#t)JT=u9qE7hH1<*8h>T`ppH{O;#(rAn<< z4klZId=ob<%{|^>azx^0xsuo)d}8s@`Mc;aIjX8v>z%_pOj>p+m$F_pqe~~k-m`*- zwG4gf&O_ag8=*A9wOzmZQ@6ei%g|X5Z&^9IBy`;Nzmt*tP?6xLO=6pz53j={8Y3JQ zu|9Lt7l$!3B*!HTofKLtv{OuEEXZ(V1Y#n9wkg_QN%bN+DcsNSQ^B6iMMo!xSkNFR zjMza~)JO0@e!0!Qot+w2okojqZ3iQ~)R=qEuV!a#@=(_9v3#36mZppxCda&3O^Qx`LkJT#|HL(3e(c^GmU@43aM^u$UgoF@OA12V+a)z56gsD?SlRg8789ED8N zGUo_Ve`jR#rg5|3pa18TlC#0`Z8lh%y1c_AL!Xfa(vGtgJc!NS=hVhmbe>gxFAE-) z7`&qUIbL<3?2*v$5A1q;`s@5OdDO$;WpvNDzix2Zr_DplSBnCC+YucuO}ZNNjTS#k zZKWRPnH8-kZaD5+gY%F$Ov1Nv;&tpyqv0PR0Za=f7G6*ApJpzNH@$O}WKjgtf=gty zf0O!75Fwl$o!7n*9E{=J6k}RrM$NQl%HxoUy8^ar5Iyz?g8acrYh2hT3#Q#}^Me7@ z@ORH#HG*_gX|p~1%txLJrlw6nOLLERm}CkvvmYjh$!~~EORUW~ZbYC>#|k&H@pZrxfk_UB$Zi9U z3S!2}bcFVi=c4_?iK1+A;fJ`-+HLJgs=Z8i)KoZS5_kZr30Fy^RHim2tjvGmz(=) z6ODJvVRCH#{Mh`+*!s-$@IcFK)6jZDUvXh*d}<^ym!4?KP1Lpy=L=KkdwLf7M%Vju z^XsYp$;@c;KL;@3R9!o1f(u<$Un zt&869`R?l8-U|<#!(>iwg9CCd#Jvvp#8v%;{}|LSoai>?R_E;6XXGt`!Nk0r?g}zt zbjB4IRe}wSIs*jKE$6xgm3u-d=c{p9zh+hAqW-0I7q#urVKO7{jtwEGg6;%?cIw$1 z^5wwUZ$WjgDgT1Z@sfIjCc#bR)TwoCdfIutMUPrf96ekB6MCCVaw?ox&PA=ouj@D4 zLp3OWLGQDu^t$d_*7N!TKB!UefS1V0ahM!a>(8rC=H=2krq-gK7}mFIQC~C#@6@2S z7xg|v@`;&Jsf6A(E!W2;y~%{$s#WDNDxFe2J^Htx@}sJ$U)SdaQ~EWjZ#1f27*Od^ zm4VM>^Q@W&%3<>4nNXb-f;ozVC9c7+14LAC4wlFU@c58;1aW8T#0*8}4KI(;J6joX z7cv9)#<376sc^s~HWGKRl^+ons1=C;dB8~|7*@ex;82Mig6fRWFEAj}hDHMj3vo)z zkKkZ=%(R@3^u_OfUrCAWecw_MpG2HEA3#Jn7PoGT)Ui} zDfSQMr)vk(Z3`1^tC`Wkn#=Qbb(Qt23&Rb)YpLbMWSw`gJnEYtL|OBkcuux#Vu~&c z9#&anQk|*^j+aB?o2tDd^)0;e`G7@P^zaQ|?h!Bj8GO>GpZCyLyQi`SooMh)gz68X ztO@U`h$7&E$U{;@^|B`Xj0g+y1@fBWwSsAp*#!}mHW5$=#-OJEWf2iH>8KMRtB}`T z-49!_sG8~`4wmdhuxzzT-*n=dgOMY&2bA7h<42|E#Vbg=Apq3R-8i z!YP>uTjwlckqX`7C5RmKjc%9k3^BoR64Z`V86Tzxl7eF;_n>fM85R$Hr^IsP0o|_i z^GE7*Ve@!4$|#5v+TpJb^#enFmb2hO_3jk^f}E;Cb|Iaq%B53tx%715nS5cgkRB%Q zT%zXbxzy8_hZ7yEeVdhQ>5b0wOZndAmFnK=q2b0tuBLTnxOFN~JKMgrIX%dupZG|! zBnq_rQYi5EA1!}f-xU;y!(>Y1#F`w5E?kvg&Svu2TvfiXn%eL?AT7)lD(5n5=}aM; z+o;NBDrYA%smgS5c`i3u(Dnt-uR$gQSX zl-%2rwnuz#p{zm(3}0}h4z@YUNqTthZ9?@rnOe(&heh?{;By_b9=_-ydHlS_8k&y5 zH~(IM>W4hM?eiaftGjOSNuPe+Lw9v=Y4laimtgG0p!)c2qn6bp8KHCfr7DmLko-0x zn?$jFpmqdm|NzSg%u|J zE@~_sD?I9UJJ+p}SRU=KBxq~DCHGq=Dzp98x&JqEwkuBazT3NlqWAZ7c>VpAbb%DH z4J6m*>N@JSDwJWP5x z>)|yIU+|F7VjMR;yyf9-4Jn7r3 z8A}#zzm1beq}JFeci{JZtM-9`A5rzI}6z`P%eXasLUBNFx2866^E*9N>b zdR@mAvNX)XGfT}FSYZ*34GIyD5aHt;Z86|Ng+Oe40`?)+qe^gQVrZQC#cnoiAx8K; z7MIabV`Pb?3%{pPr`RVCSgTXH+2s44H=UMf` zvx0|JADD*sj29nFj8L^sec&g_N4(nLZ+Ljq=f56-w|zS49e1gRL(^^B5hdr(t3dEg zMgB`^iVvqg*xJ_ZUZ@YyHzUM?&OlP}>H`zt_bzDy{9YvqYF_H;54*T)yPRVT!IAXP z)M2cqa9s1y)MGFE^lKj8@-UFeRQ`+?pPM|i=+;pqj%)t98FAe3>6;$zC5}hu!K|L0 z(0MBEsuOg0baDqq`^&CJ^GWjw4l7>&vhJPM85Vcz%1k`0kf8Q0L2Vt`yJK79(IQl>=4%wkr9_sZnD9|nsTD|;T-COsFtAK zywW3T7Xnm9?-A{vX~X&`&ZVr*mT#fjKpc9| z`D;Gs`+xGqxl&@rziIiiK>RQ5|ZK+y72R@lhZk{loZ z>hkNdsvw)>b)8|cJ>;@b^~`iOl|I+dIx{!D+B=m<){V*(VXWiQ`cmq$rc`g^=5Wi! zOMS_a-jUh9+1&V5Z=f|$)3VbDa7NBjz%stArywLv;M%I=1- z7MrH9naZ@*7kYychq2YDUz;Bj+k8pZy-Vu7%YhYjrAjr*UV2!z!xsa)=%m=zUY)aA zqnK4ckIPPb`*tk@8o_!mIgS%J67W3>*m0wp({-pjjh<#6pfo{>25v{VF zmmNmC*yH}dZoE@}CZ5`CS7*NSp)v~U0TrDJ?!-z%(8~AkSs~6S64%HFuH^XYt z{DZCxU(r_q`;P}-M=P!#MzQas{zLM;I08Z?Xju4)&o6p--NR`6W_3?O=SdeeYt%-L zX#3;(opMJJ{o?A4%RlP#KA`q~z0QjPRzaAo(9GG;-=uzLH7c{3PY8_e*qs%AFjf*m zcz?%tP3kpaZPDZtlEC?aLQQe+HdivtLY?(Ds|B#m==E{hhW@egfFl`p=h1Ov_2YRu zqkk^sCzP{V_<&sgP9W`igalnvwCo z<)&iw`h|v$e13c;UtHSkpKV?0)7Ew?-HeDYoS)q=N_|slXa+~szx`K5@(upL%pcvM z=%0OaIs3;!mcb4m)EOqrp@p8R{N&Q|V!DufS5{b*I7t?xT^m%dU=9H|wO(uL# z?C3AX7k$>R9<9*19%$QgJIZOXq>OLAv51wr#T%3V%oQKMYX230s!t zo{zt|{JKZstlgc{xla`CFnZn_fG_8=h3s?|?gA74-O)Nq=BON0R`#6Gd(or%jyN z2xdNF-Hb)rPEId6bZrPn^Y={>{4UYY>iytaKn)x(IdDhfc-^Pp@bD4;9qhYApFgW| z37schl8DCVd#dBwT5CHMMl>MyafB%!#iQwpJ?c0r zC7clrLLeb3feV&IxFY9bTo=$fe4X5e(5$>TdsAFdUC=>983Yt-x3wp!c0Z=GS^u2= zip5{&0*k#Wt3+%V&#DcSb|!c#ln_eGIuHK{w}f!gj9_b32WyuH#iexPSH1A+$4a5_ z?Du_RkZ;0>rMV|0jIio(7-1wZ(|iDhkxxZX{evouY}rbl3M24S$Gy|xsW9UF>LX6- zu_zLTpFOj%Wg%u9dvvjY&M$-!RQD`?qmx0Ik4+2$14x(+k_bsMjsMvwTS48?g?~rq+{0=BgwqqtiCFrfJYmTa zqZ_xRh-Mlbf||rx=z)`nJOYbHP%SL-hWggqIp~7yhFC{fv4$%mB#pjSaLklJ?UOYbpQE({@Gx3|AL2S{HPAEEYempuy{T)>bVv^qF?KHNB7BF;E%q)jaJ5- zTU{X(9OKb#mVzh)wI*s0q6{M+idv)b&*D9QS(j;24qK_j)sJA4Ra=dGx|pV;233FF2xYsY-!jU0jp9MqY?cBOm6(NgAr$vQa=O@_LrD3 zOluZPonJ50mkCIFnAB(~Acip7SlMV?Y|~ZjHa|2(%0BZi-ueL}NH>+XMZLN|{BSTe zZ3zQ1-u$s$^2-F9e<-RLpW2Mp^vA zD`!!uUZt)EHZR|*_MFjqR`;*~$?I@fHyX5ezOHLvo@*2e9k=}N+a89g60dAj>D9=z zd_n!maU%k4I#$pDp~DxulM`*-dK z{xBGA$3Yi2t)3=5gLh2$Hzd7voIEO8YLPB9KJSbpd%vV!2Gt=3Z*D>&p*sE&UeL*{ zaF|HLZjWgwBSCbbhe)xEYj{>Be6-)Ke&?R=OvsU>k*t~Ij;D3YfKYLQH-TdCMj?z7 zw3t?aW`N=2FmsXn|Mcf~M*%kV4RVi<=ne{C`Y=t53hxZ*mz`WK%+^$;(le8*i-oGS z>MAm_xw*~sGt-N6ijsGEE_E)Eovg0UCGyn^(=|&2o&77-g{DYY_H#3Hlg+~ymh#0! zak#CiHjy1)t84C??CdGl^!HWj&c>_t`GL)~V()t7*2_z2Ju-D}sHVQ*iA**#oj$kH z+dVQm*xXpGPIY&V_suobG$-2TTNcN&t8G^s*4h{6XQnUq&rHuwE_7|quNTj^tar?g z^v)P(htDUP`=&VaMwybCRnpcyZ zgRP04u5@pHd9-!m>O@UPZuES1zM-al_yLdTK0EaTzl&Hr=iwEWD|KM|5{71p|AxLi}q^$ zwGt4pIa$A_%Luf(sNXI!;br|w2}LJ@+F0?(>33fDE~s3MtXBqvy8Fvklv5B|**&)U zIkjL;&uo@)=mp)Imj!)7=di5uQReZKakUIlwNK?b7161vr}Qg@u@}#56e+3Kodas^ zny&WBtZ(Ng`YMmUifCjHvZ3x{HYC4eHNjJ!e$!aIzx0FRN`t z&tK5{EXek}TJ7ynZ(LMAbnAOB=z2yaTGc0O`gU{rY74p!f7uwkYexOntUgLAcQ7c| z6SzkA>iw7X#;q!URbhH-RBuk{^LpC6YOPUk4y!*1=bKeY;xjs!2}UFA0;1xQdKgm& zmv&1Oj4#ZOqom77WHkRl?B=noceX%Ibw%{FXnz|E!OE%aV@gyYBnBh`=cI~cz%#j0 ztG_6!&&&liosB@y6W~1gUp}}#=M2KjA*|m zH5MP!iJq7>5mtX$?WKMK%(*xV$heR&^6W`?2=IJXks)3Xn)+jL=1R@h_pYbg+b8N8 z(~GO)7wSiv*R%Od!)CFj6O)VZX+B5zPUD0UtjHG zq6G;HkVc}WK6ItdBE)m0t~Pw7F_fqe-%}sHQX8(IHvF9WaBa0TM={pU>b>{&<8IMM zCnh+tRttfb<)8)uG00KsVKn(Cllop1JS@sCdenN&!&gG67L@(650N&T{Xd;l z>EV;Gs5+jFz;U0x;h`(Fw^aFtPQi+ zk$0V(iT6WVQU!6giG?2*o83i9VA@wlf~jp?iH2FTD=aD@E7T}dl7n^yc{A=xZS0lC zm@BldbZzxQHl?qCsN$}~y$?REarap7xL|Kl6lo+Un!j(ws<+*JT?6jjI$!exuS?^K zW7fmxJ-qJWOCG-B;p-kU9yu)Zps^?kKR=%J&{&jZpMDbLrXwzLdC_0L=HZJTzU<*^ z9$Ex*TlYKT*Z-pZGplDMbe?ptmIgXSN3{KM-<@)>)`#_K0UuI#TFjZ7!RU|j_w4y` z?-iGS)c5_Q#^0dEY&aAgVcIHnTHNYBu@>~_yz)Brdr|mqdx$oa;@j^bq}zTYpl^TH z!J?pt?>$H)^sW027Y%*u{)0wD-?|fT!~I4@-@0qRk5dv zQKyK2!9pRzmGgOE2@uZ%XD-XKBBnK11z;vinrPcmx@7gUH0f*<5boU4AyGG+$i^=O zL3E55$+04U;Tv2Wx_Y=cQ~?PVc@6cK!76;E%0GJbvLAi=@eh`=k@({8%m!km*+^KL zd;a!Y%h~J+@exkwE$Yv&MDg*7)l4qU4r!@$>SAVbBiQ9j{c%?3-4H83Cvoo;oz#cu zcUZCVCC?7O?BN?8s#<3f<0nJTi<5Z|pY{3U5xDHr7SWq}I5Z5l9noq0E?b2Rnj5;Ew2c@xyEf zIe5^-(7=jBub4!Kqhr>?=RLgcA=-Y9mpy#d!#6w(WH4PngDj>a;bFAjX1S*GR1Bq; zwrKrVni%>yy*oB}rp7|Sg@|cs*rM&}hDf@3TNvl;6-GZ2h$kk7 zSekO>WncEbcb6rJzEA;0Z%?}UBz$sNGvvCYrp^-kLH_&XWa4$Fw9E9^oHwD#M5mQJetV>$_M z?SgDGgIVpx9=TpKm-&rv5$XiIhcPq4hzYYIaES{rijo2Ir?~oAA;zzczzeKmvqp`= z!v#YED}kwScEI!4*+F9!O(0>yZ=*tC4cxCb1aHX*FE!>q@pI`a6XPjp_gKEoA4^k4 zzIT&egg^7MZghL!JF+QJ>Ph$7_wLEpUJpk1`#n74M|C1Hy0J6ics`Qva<~3Qzt-`N z?vv*=5Pkox*?=VkRu}Mf7~0|F<93K}zITjZ>?QD!$K;N&%u+745>QzeoGY$=9EP|T zD(oyO@Ik<)g4u@8J@pf&i!qPta7rzpZhkTMu(p`KGqU-jakJsQH?NkQ4VG`S!P3dwwY zL4=$oEl#G83)n~uj9m0OeC1$i9b@aX+w6D=xuOK5g%mn>Yqzz>>W2x2?BK-e_Lj#u z%I!7bjH?_Gg2Xu%8rNGq@vzcmhX~l@2Kv^j4yIi&1_~wp3I`>WfG7J7?yB6r|G z3q{5-Ao~4nx??ntD=s1KtAo0j&Rd4_)JOez*|~`ig>{@TOK&XGp{EHShnb7q|F;%* zM*%kV4RVk7y#ob+F_8XvH)ogyWYkqlhbMa!nx}$0Q(%tgC8|!W>=4(fKGF=_@O)bqW10!w8{*BG~ zh2rX1eRKWrKw_ltYI^2kz9&~$ow}G9?a9y2oL{Ty>OMb}Uuj=>z{jL3wXQO77nsjygeE#!oCWRZxj(y+uy%yRNHqx}H~VpO&96A>R;kT~!Tv zwYN(xUe?=hs=kZLsn**zsjf>W&i8Iieb6RHhP)8Wd!Ljlbe~jf5K2-mPC#%3G2B z+QO;toksfN9TM!Y%Kll0v%29ZzITvlg4!Xhv)KS@B?3ZOkQ_qXITiv1G-5oyaO`A{ zB;dS!5%J?#2)1}c?1wFY?ZAB>7R0H&o$?Ds0E#P^6>NE6VUS-4dWWn5YZE?TAx>%e z5q$5CnU?dd-v6&3Ntg;TEU|r{>8pZ#gJE{f``*E>L0zxwG@V#pk0R)j;mQ52xb3s#`?e-c(ER#Y3unjp89f-!5Oj2PYCRCzb<=FfX z$C-pk)Pzt1;rD9-60_a+?tT-rC@M55&*1LLrIV-QJt~O-eM4qI=}z0rsw(Rk$g2<@ zWJf1M!U94lkUCw&Ra~`MCE3l8lUi`y#-!8Lg}mxW805pPw;%;0uR857axX1|7`dpf zY)N7VQ)ZUaE2Vadi$P9RA-j;yROQmCxm@JzliSx66)cP>%$^jzxc`Nd@IX8Yx) znVF&VNVcZCvAEE@mLF}dZBNuKbe(US7_M$wzuFRP2KDcsZ77K{Ex#1X{QXDEU)Oj8 zW#V3v3Q4$;z_wM`7Ur|Ls(fKJwc$74S(qzS&Slo*Y?sY#RAn=j+VV72nJzBRw%lV#RW4}@M+}k8M>SSsy z3!?wzFw|ktP{ws#V-fBeg+j-;SA?1om>GRhgiF_0bJOvUf8=IB8vZ*EZ~Od5Wq8YB z@JXM>AUAwySZzC^?R!=8B^Y~p-{UaGWLv+2rY@ce+k2A8GZ|e$0?i1Opz$t>n9Ql4 z@rjuWuE%-!ZTG2h`z2%2ft~ku!^o|YEIIA3q|=b2_ui{cOg#2ir$cM|tJ5vJ?frD8 z+S^Z^AkF=?lRcvMSJExe?dR#d$^Po(3zjPRxDbB3m%v$DVjtyRjgcjtg^&qpbbQ-9 zjOOoqeaZVUR%jxEgZLiWJ;cQ_O=E?`1Moh+ zIT_JY3_ZhbYYw&TAU=ogS%>pCboU2AQ=dX11s(SakDL^v;d}MIarihc|8C*w2TkNJwIID8pH0lT(Du45Z4u`2twcOW z)JO0}Ja-Gk@P~-?Xqa7CoN1M6g3B& z;%9W4W@ZmHN3dVZ!POjf(iGIxHe1jir{+LUu_F^bMKm+fw3T@r>VsZ|;OWwNR{cPj zp2MmSECk9KFFu$Up=zD_z~jY#>eU9H^w4}YU-#Dy-uCIF4=qGJ9OVw&`5Q&|&#OT2 zO~nx3J@o-vM-1Dlq-8#S^#RBZA=d5T6b+-Z#hh*l@Ozgu0e-KN_=l8w`ok{n+6LPM zF6M~(L>7JiH4jZaWysJ={wikIsWx zJv*WERNPf3=?+?GG-uz*ixW; zj0&MmckY-F3xfKWfIAgZ9Ajic;Nb0dU>LLY3=^Uzm4~>DaufT?H9aeOAHi9i5Jj+P zf+1CCO)V#O2c_t}6DQ)nM_m3PS8rVY-Fn{c;*$n=%)#@+ zM>Jg#zF6Y7z1LyIAw0V4 h`D;GqKu3GvxykRFI*r7Se)A7iW0+!MhNUU@{{w3r=j8wZ literal 0 HcmV?d00001 diff --git a/Covance_UCO3001/browser_profile/Default/Sessions/Tabs_13425390051090375 b/Covance_UCO3001/browser_profile/Default/Sessions/Tabs_13425390051090375 new file mode 100644 index 0000000000000000000000000000000000000000..72d8b529747ecb3837439f1055d84b4a4b65c087 GIT binary patch literal 427064 zcmeFae~g^TdEfcYYFDCuSZX=8H8K>bSJ`D~$FuX!@1AvNzT6RKhs$5Rq;}b~W3hW? zdN@PQkLJvf+sj?~+J<8-Z0pd#!MI7B$SqwixA8@X_CL;CkaOCBfunr7Lj!j?3~)Z6 z|M20MgK=mhL9PWj-upiFernl#$>Gj&SJoBKzvNc|MbcK``5nqd&9x!zxUQ#ugjl#A_!hqT#J5K$7{!*%S}!{ zcYJ(k_Qdhgq4Am7iJ|Fmc4TO5WM*V^aw<1AJ@MRE6;bZf!Q+2lNxO4CzVq0?AL%hZ z_~QyL&2QY;es+Gfw0_M+I<4z-I-Zm-5(l|8li(rzb@9VG-oWqiraytrKEK8H*Bj;U z{_LNh|8Ve4c*n=HD(Q1Q&hv@zz9{b0=kpL3J} zNLLoz^&ypVQ8}Mf*tE`bE@nyPFX{S}K1c5>zfXTc*O!#isQwm|#*mJMU`#$szpSI= zQk_(2S!WBuh(adxJWF>$&l*#ldDk|45!IaHcadmw&wlm7uUf13&f14LAO053`|X-q z_ixj2%xms@j}81gJ;H*``=HkSx~^AsSnIBc-|yCax%|Jl)?I{ywB9h$ijUy0CBm&7 z{Vv%WzQ3)zd(5|XYZd*@=fj8X=l8AFu0O70S^aNKy)PL*>l50C{pnZ~@6YSpdV{q~ zYwPoBeUtJH>CF0uwOebc);Fv-gt|VhvngGjmTy9TlZrc`);pq@K3~c7$CakF?s0dg zwfA|oaZAI}U(%n2<#ayb&O)U&r8v{#w9dxdb4Cu-8~&e(mmb&~e7Nro-f#8s?I#A_ z)KKAjgf;8s?d{6ev%|yHt;#bC8#hbq3uSR__$PJkLQs(~To1PNxfx`GyyLctxGLX} zjxXtaORvj>W=U}tgFn^#>*#n=_wR|1+I3pG-&{LJaA<%N!G^i4eaMyQGV{I*5nfHO zj{gpf?~aAGKQ|^{tu<{|Pim6es*f!V48!`X>Z}qxqu09;+*H}ubymi|rt8Ucd{aq= z|BTZAQ5|pn_+RStZTHrvHoo|Y_0r9iE2Zs~jrEg@Cm(yw)j&~EOk@>^dK=z>ZWPja zhWhd%Bf{?o#v=YItixpfmX%hh<72^(1jmA>gKY4e-u{Xk7PG2@vflcNYY{8KE%_D| zW68CXHJxp#&PqDUI=|`SZYj34sjQlOs837xsFarEbFI#;&dw@!R>v#4$DWmp_c6s8 z&@rmRT=Kf5VJ;bNel<^*x2isq*L}JpcC%da`hMx|7ye$K_tVP5r*)ijz07JNt6ul2 zKJz-?Pzg3%TU@ow%2~U$dI`-VXa0jYUrrx4>CgHL`_PyF3%dRp9s9_a`|2~VxKHU= zQhS+J$x0Hqiz?BOgrcbou?QV=*Gz;?I+1C@+C+7%)PyRniP;fd_4)Ss@#&lBom9NC z?wV9OLoS^~otuarb>i64pHMpE?y5a=TK@RzwC*e^PpVs=v{T8gz3x+1r?LEBtq=WO zue{t=TrY;c`Db5oV%&>s?^hJB`Tv7H&HtPK>#zOi@1y4b4+|<{e_rve zBTc9inI>=D$Fyu~-t%hs*5t?a8HbrRWSY&8Xfpr{wfn3~<MDzhGw$v* z4QfQ)bxNsN`qMhB`{dq!dORzzj%@iTE1u0OMh~Rxoc{91f8BQ;s}8UE`*7cRyx-zT z^Z$lgw~uN;zx<(r*VXSV*t`$xvVTq2Pin}qLCXfQmEelPqBVsbL5=j*bHDu zS8Q;yxq=OY#!zAN_r0gQ@@qZaV$JJsO!wQII-cWO-?H@m9NgmAOvdK;Hj^ed(aKttNc|K!_m_sZMKhab|emOkUceXsO>tKNaf2mXRCXs_~b>DX`7T-~^` zvVLr{ynSPH{iV&-qfd{{20y0wr(JPP@7|OKo}87OR`?aCpMFly8PxHl?#bA>XwJWW zPhaM`u9>uW!y@&$JDm4mXc@;T*}!Yq|0>ZfcZkrOV$M^^Y;~ny83#T z-E#Hq8abvKE9>qX;(G9sK3AoCKdpu`tF)8P^YxMpKk$s@@psdGKX^ujNA2!5pf0G3 z#hu)STkDjjnOb)=?bOc9$Pf?4OQH>kiwZM6(>lEQlJ%a~JF@P+p!;KEg=xNK$Qx07 zGb6<5$3})}i32mqnJ}1iXK@@;2<#aprF7R>Q+&65(eD23?!!fZ@A{s0&$mB1@a9M3 zQP>`9-NcIk*X5sCEzK`%Y??V@ZFr+}V|#gYc(J@xy0N-Fd~;;j0yZ{RZk3NMtge*T zw=b_O9t}52BNLn9*2uMm(X|(6&t4zd&K+LZSS(*&ST3!ume;S8kB(lPo?XANRn5@xpk)U()#h2Z!EqzI&t-d&s^M=l<{Fgh`Lczr__ zlA|+MCvR?_dhXWv#EqF7=NHcBPn{h(b^XMZxzpE=pV=Hed*$TytJ7z0-P)W#J2g48 zJU6*=>H3v(mCEy_TUXadUsyi8SzcV(EH7+dzOlJ-)D{2fvE!0(`j@c8C`7ThDjVxt z<;&ZzR?0`MV28K1OWWn6mtI+&xV9Qjt)IAY!6ej=y0e8cLdW`DPkRfP>puN={*k6}YuY(6=rl+3(RR&8zvmvy!%5goeJM$~aP zb-ty0uPNTBY@{zrbe|2bD`Z>a`C*q2d)8&0Ei3(1{aIR9^m$ZwT$IR|mH&cLsmgRP zqc|14yHgSpvwDg>@s{3hMZ?3o-t)`K@uHq$Gl8qY3ktau%;~y`kTE@XM)y4Ysh5>Y z8+4Wx)5>zer8TL$))f+)&5kOatIEMm#XBVf(=7?O2|am6$9a|HymER<K}>KH5+y7I()NEXez_UOfxz9;?>FWmFbn4`Gs?% z7w1+^R7dk)I(KR1`4>)~JzcrJRGytZarN5b^^sT4Y`jle%%iSVJ#N!I9oAiY??GMh zGrX3`C`$|4xz$+)wc{HD3r=169atmWt0$gK!Vf7={jM)r7o6iLUnS5G{D_2req+Ummm z`e|7m*6hJkfBd!I@XH&wo4p>|NIAu|33M$?<_N3@y$u5j5?8PYh1RKB3>c3)nywJj5cev zIj&hQEXJY)_m~?3Y?q$Tx6e;r`F%=<4JszSEmhl>H>7m@E>ug$=D?QzqEfYI+8WoG z?yxH9 z!;d;Pv+Aqj;e-f}y<5X$lhfnju#C0a8w(q@^T&)14;SkX+Orn~uWJl3qv?~nzakEb z=6uzA`g*GC+Jn~0GO9~+Sy+G;X42f2$IYEci25GkwoYfx^9cSLjIX}4;r3S)(beZZ zGoeQl_5B0Emdv-NdsveVbsihQlDn{y_2%m@8GhiI25V}O%4b@OH-x>Zb91+21RdCg zhZ654`TS+Y3w3FWZ>Joo&FkHO6>1ovl*ZnQap?P2JWHZDT^b>ECwN**fExuK9fX z{N$D2r*xQ6(v~I0^=W#$>Dact$IeUxx2@Kuft#jo0@?(%<-+1G#fp<>yKV^6#1KYVMT_pMm7HW7DG$9odX!&*t(E^iKbp{)hU3r-{73O=c{ zXQgl3nvhMPhwc&HTfuj~sV=SKNyTf4k1Cd<0VN=phi^a&Gs$|WVP`?`d_pYGHC%8| zOt6Z-4dYnvES7&?5nX-$z{K*f8fbrgCq;U^V%9%|ZYj^n=I^^fGW@_|{KIVK&T2Ea z~3~yRZ#AunP~FOp?pO5YE9OtiT%Fflb(gd$0?&*yUUX z9)S_e!(~{5b=ZKrunjw~2Q!D`=VW0B=U@?5;2W?3o3I762|GfsaHhA@J8xD0Es z4&Q_=*oGb0gP9|g1Lj~J7GVXx0UNLhZ^I7k!r-SU2Ml2Z3$OxfunymZE!c*4U|_rM z-2l1CPK6=HW7|!8&ZfUD$>l z*n=6qWSE5^oP$MJfp5SDY{C}YgI(w~o+pq(>P+FaHgD`{%#pw;g5Js>FtFR6mum$&E z7wVge&ShZ^=3x=m;0|oU7VN+t%tWLMBUpeHSc46?3)`>*wVBMhK^Vda7GV|EVFR|{ z9_&JGp>r+^b1)B!um*Qv6SiOn_F!g)bYTPwumWqa0e4{=cA)kVI5!AG7{MZ}!a8ig z7Tkkfs2vE-Wnm8HVG-8g4s5~}?7$w(%#tpQU;$QO4L0B|Y{L%J{t4#>VF)8wgjHCF z4cLNvunV8GyRZ#AP&s=3x=m;0|oU7VN+t%oO7EvM_=LSb;UzfV;2_ zJ5YP*oEwB8j9?K~VI4ML3+}-#)D~{%vM>kpun22#2R2~~c3=-?et~ph1PibNYp?-# zVHv) zU=23lE^NaN)H;xJgD`{S&H)sb1)B!um*Qv6SiOn_F!g_bYTPw zumWqa0e4{=cAyr0oEwB8j9?K~VI4ML3+}-#)FOv-S(t-)ScEmW1Dmh~JFo{cS4bB| zumCHt1{-h}wqXalopwrca5+vlgb^&lDy+i>Y{5O)g<9fqE(>!o4~wt{cVH8?Uv)U=23lE^NaN)H1MhgD`{|YNf$=204uNt8*mr4VF&6FtFR6mum$&E7izDIb6J>!d02!s zxC5K81v{_@Gp~{^j9>v)U=23lE^NaN)K@T_8-yW@U=dbf9X4PK?!hh$UL&6{2lKE9 zYj6iPVGDL(4`yB`T^PXvtiT#D-C zwBa$-@j>0@^-1OJLpp5J(v+CY{~?8$ONN{OaUJhC`%P^7*|%$f{fBkc z`^KMlvj2QSX*{OGe#hC|LC3H3`Dy*9?Jw@<8P{er21E?f2R6(a{iFc zKOVkMGo62>^Urkto!TE#`%7wnO6_l{{V}OO?Y9n=+Fw)qYifT@?XRi*HMPH{_Se+@ zn%ZAe`)g`{P3^DA`9o@dP3^A_`<;N){+!yMQ~Psje@^Yssr@;%Kd1KRr2d%NpRHHi z-!4-7duo4A?eD4mJ+;55_V?8Op4#72`+I7CPwnri{XIEH0&u z{*bOer0Wmq`a`<@@E|*DYJYa-=lgz_Beg%L_UF|8oZ6pL`*Ui4PVLXB{W-Nir}pR6 z{+!yMQ~Pr~U-I+D)c&5@-&6a0YJcDF_u13+hjjfRU4KZ|AJX-Qbp0V+f4G02yVs+W z^NMu+;Rn0^@HsVBo7-&Z*WXv&FTigHL+)4H%WeXcd|!SZH0rM2|DOHz{q!V%J>2L1 z{o2XFbQUUR$=x#&5u8|37t)gOA58H30+^5Z(8T0%9q7hR8H?Y)1xlx*r%++Tcx$iYI%FJv~X=@{R-Z# z;jzi-@o>1Zxv{;mu(3M4w6eNg-W-Y}Zw;4LS1-8xw%mjEK5_EvU;DjbcYa%+))vfd zl)m#D7M`SC`^Dg+1>twjJ`q_{uxxtw`R~2;*6Z?Qo(O`Mm6j!USjTI}pUX{7KX-h5 zX!gYM(V_8~*@>a)aCT&9Y-DC+baE;;Ha+p&SL0MZ9X#Gp(y=H0{LW(of27Cw;EyY` zG{13U``P)`()u+Q=d`ZR>3CAUNHl?J&c85E|KjSp_F)}wSfoDpX5YD;Hv9Y*-(Mem z@mG)k`S}kApM`gPJgbsE*W)~&2=9yHPLuijyh2?$)l4>m8^Lz)tj<=|AlLPuQ`{}r zAreZ`I;K4`NqBZ-Rn!R<2oIb59%qy31r^pdj zQdgK%_>dUt%wpPo)2{oBDwX}xpHx>`RLpUAr*%K;xKngQ>ulCJtvkn0Ur@@Us#Uu( zuMQmQd{lq-uDw%pir+=D&3*afzwSGa#r5~RwU4tnYTe&d>-JGC=$Ah<@VYvR1)JAe zZhx0w*tl6*UnrY+8~$s$c2X_irgFNaHn9?1QGU18LN~(cHcvf zXeljo?HIwKzLxC71^z$y>%ZoD#J_}2IOv`N*F7uvZ}+8RNhiGbyZ{tiP}i{qr9*B=)tL`^ukJde##s zRZpQ>|F~+)20rU+Q?BjDL*kf1t*3+vwSGFPc-H^Q>L(?~P+{}?rf;$4^*5&bOM2Fj z?y;UVsxy1$xJ%#S*wAT%yZHjfz)GpK;;7b9%on1p|){`~_XmUgh7?v0oQl-MF%{er&V6ePeU|rOnl&Pmj(9 zKc@JnU2&}uZmK!n+ZnUEx}mPRqQ?0-J!eqIle#Bk=b}0P`aOM_>$+yr;th+`=k9Rc zgP~;{r(}a8`2SU+Tka6vOwf17tVz2**O#mdP3G?_3U&4MF1zLG+ck1bHCEQ$H^lYe zC4H_2M}w!;0A`hT@_D{qlHmvLzK_3~?%O@)yK}y;PVCe_-v{sK@6Ye!ioC3nuBn8{ z_*tLOKJ@84YInB*bwOP$?&LPyTBi)v!K^zjX+X5Il0xFa*fd%j5Em6Tt&V9O-+Vsb zK0kTo*Tl(!?zb+zq)t1ncsB5sb#8;WrEm9JC%54?76y~%~W;zfY#^8M3{;f>Ob?d8$o#qv_=#_IO)&5>aX z*w|dTRX(<`x>8=>zPz${G~6hSOl*c*Bi9y2*It}Gdwpa(cX(lAv3z-9S$cSR{Yv@h z=*8*T^$T0o{7k8G^3>$)#^se;XDTnPAAkAA;)|mbS6?`OY3|I#(%AKxjl`{&*UEb2 z;?WDE6O)J6H>4sQow+)BbNkeDx5g)K%-lG?a6W(P?8vF>C$7w$zJC17=IGfgC$C?f zK6C5V=KR^I$(iN3$(2jjubit?o-f_Hx<2~C^5M<$;>u=uVf*rp&6T6B_)m`=mxR+l zn`!llT7@X~R%K&-t9*I;)k^uO73}cVc4@nO^wKM<6W3P5sr9q@>iEjV*|{69o;WkM zbn(nY;id58^mujT(){@s&sOHDV@s!A+FZJ}wRBRu9 z%Hq?bVR@~zvMOp)qv=ffC-i=j;&w)Q(edC+kX0kg1{a)Ww5~JLmi|n$kvlq`)O{WC zQAKXcd7_MnB?X&3)*{rsMJfkV?yylX<;LpnJg&XwctgG?z6#lg=}j)KkV{h&$_I$W!9J-@6nEb1vX6Sx|@ppZ+!oUWS) z8PjuTbkD<|dRe)&L1$Sptt=N@T9dkKT_Ld!c~t3KRSs?{-l^a@<-n%xHxzm!IIohN zS58leudRfssoK=Z#D1{R$ z?U>%gMfXMudS{{P!Dd)h)zu}{!Fj#AvwG5;LM-MfH|#Gd-7Wbp=y*v_SX9lwq7+SS znhbtk&$HZE&f+}AT-WtQS9&wptSPT6y4T7WD&D4IFS(HNeM6TY!jeOpH?rM76L`&a zQGcJQ1_L@mI<8k0V($k}bujt&SsnY1Ym_5dAAX28)0NEy%*Zt&4#{_S?rvJU>Gt#P zx+xf@Y}owWhW?UTjVT1CgzT5T%?cKkuEnu=!H~{O1&LJ@yWhfMBbv=u>`A7?Ot}1v zxO?Z7hkloi4eg_rusFtGxg5Wm11Kk*=^9(Q2TMi=pd02#1Scl2{ zEi0{1$H#&nk>dDtkd^9W%A*;sv#Rm3Q(#O9jFrnpg)ZrBY-;ef>t5Z+YWTOfTZ(6W zD697t>eJFas&|)suBr7_XJ-{VtK${jWA`WH`L#DcP$aKg8s?JW=C>|js!&y*$?HDd z{nq^UOLxEU_xik_R$f1?#d&#UE|ZOYUlGaFkEGh?y2A2xO7Q7s`k)rGCK znWe+blcrLbB_v*gFa;-8F6?@IW=jQTxiDj>87mhRfB&^Wvujuy^AtqH~x(qmOcB29Ar=^q|Ao!-tDRqwn+jcIShV{;a>S4}JT6kofPDFK^2OA3v}3p3)Jo z_~yh>Cvt6#Yg&KtR*jq!-WF!-T_&E*oNc1qjM_HqjfaJ?ebcu=#l*LzI^slqS!vk- zW8!~WsoJ0tZxgXFTjLtj^##RU(x+Xq)o#fRpLMtH^=@UURo|yK7k<;PP~Vo{izdIV z!>@&Tzuog&PYl!%;il*x)!|2-#BQ6U2={wT?%jc+`_1U^aIv11?w*_n1;OhQ?^Q&7 z0S?-2|b#q z?;i-ZWWF`s!DqmS04|Be~JgNwumOz|z;?6{$ ztreQUG|kvVq^(lgnQap?P2Iw5V}fl5DCy4xW=Z$mZ_v#v(@*IzqogfMjO)|%cGIzK zdyk!&25vh6O#?Sg-E?si)RqqmnbPxZh_Ed~{mw+e`ymT0&1YZ#-G_>0FOEI!p8xQz zf!?=b&Dylt@8`xq+Y~x0ecRTAY}z<F~KVSHjHDvvj+bAis)j<2}J1NrR6|?>!)V6P$ z7%}I&qh~Vwz+(Kv7>u$q7)d@AM02;Z4#6GhUc7=b)&S&=zzF7H5msRxHeeIph8@_2 zhrSr6pM@ceU;$QO4er1uY{53X1B1U2r=NjGU!n1{=-2J7%m*n(}?fjyWxLOEa#=3x<5;2W?3oA5U5z%C4aigLgZ zMz8=Yum@Q_V87Tkkf=rx`}G@lSgFb|hu z4c6hCum#(&1A8!ozMO?Qn1@AJfp5SDY{J{H1G`XKopXaQgb^&j3ar68d=s`{8{UD^ z4&(O?voHtqun4QL4jZruZ^I7k!b9WnbFwgm5iGz8tic`Fge};Hcc3)kxE$~Zj9?xX zVHMV41Mb2$?7%KOG)XyN2_W{moXf%-%)=tA!5!FyE!crQn0c0TVFU}X0&B1VcVQcLVDPhX zdV?^85iG(gtiuLu!9Cc8!QUpIFbDIn2y1W$Hem~PU=L<&UM81?5iGz8ticA{g>Be@ z!Oz9%4Z;vcun4QL4jZrq_h1)lHPpE*%)vY?!W!IxP1u4R*n^pfbYTPwumWqa0e4{= zcAz$sIX4JH7{MZ}!a8ig7TkkfsC8iHvM>kpun22#2R2~~c3=-?W=I!CumCHt1{-h} zwqXa#7U|p|3}FO|unOz20b6hncA<74IG2Svn1@AJgFCPZTd)IrFf&WKFoFeGfi>8G zyRZ#AQ2QsG8-yW@U=dbf9X4PK?!hk9UJd86FbDIn2y1W$Hem~PU=L*wKvAOK^Vda7GV|EVFR|{9_&Kx%y2FXb1)B!um*Qv6SiOn_F(25>B0yW zU_F|0aBdKWFoH!`g>~3~Ew~4}P`j9%%fcMY!y>G~9oU2|*nvHmIZwJU zf(2NCHQ0c=unjv<=04{JVF)8wgjHCF4cLNvunV=A?_3t+7>4er1uY{3rf!OTmf z3nN&76u8!hA@IfScP@ifGxNOyHH!Woy)=;%)=tA!5!Fy zE!crQnE3_Lg%K>k3ar5f+=Xq}fx+L2(;I{#j9?K~VI4ML3+}-#)Hmnj^1~d=!y>G~ z9oU2|*nvHm`3mX62o_)k)?fqf!Zz$ceG$O9K^Vda7GV|EVFR|{9_+%PNIqc>=3x=m z;0|oU7VN+t%#;G>vM_=LSb;UzfV;2_J5cLD&JDs4Mz9F0unrrr1@~YVYF#PLC(OY- zEW#Sxflb(g9oU1JMbd>4EWiq^!3NxgZPQ|7{LOpz#448UD$>l=yuvE$-(6~-4I5w2&=FT8?XiUU>9nM z$GI%b!8|O&8r*?R*n%C{gPE(O3nN&763}FO|unOz2 z0b6hncA>t?=3Ex$U>+7>4er1uY{3rf!OTt4g%K>k3ar5f+=Xq}f!aCm+#n2L1dFf= z>#zY^a1VB&cFjANg*ljqMOcG7unAkR1A8#@D(S)q7GMR|U<2;LHtaxs1=G1f7{Uk^ zVHMV41GeBE?84wR@(FV=4~wt{cVH8?UBe@!B;6i3}FP9 zVGZuUCTzhwF!&|XgPGX-_Pzxh9zz`;)NNj$RNg+M!!|8ViOKvQQkc19xcMK~@m{xi zCDZ+3dtPXjBbSyVt_T1AJ|^#gj*&R{!1d$rPu8dT57OS!_wnAgT_)>2eINIJ5B~kG zpR|9(0;0d2rTzTwzQ<&HGyg&ACv8`0yRsTcwx9lfX4m`uX}h|&KKkpYzn=QT5859? zyGbs6A8|eS`b_o2xIU8YB5haqwv$J#pL86&za9@F=fn86R9;aJsl2+s9a)I4msDQ8 zKlPK!tNZIQl~?!nvq$N7X}e0>mDNB}kLs7-X}daj{k+$DOZBVNPW}Dpk7>I~+tml5 zT@5M|CL`@PvF&Hy(*JZm{ZHr9|8ze6Pv?{R=R4VdKOq_Nm=61qRCCGu_tV2t`IE}u zbo@!j-&Frd^{-U_O!e<{{*lf<()mX^|47as()q{3_i3l|uXO&I&c9RpLu!9X?N6!w zEww);^{3SS>deyj*`-tab83H1?a!(GIki8h_UF|8oZ6pL`*Ui4PVLXB{W&>*O6||7 z{rO?PlakusQ~P^re^2f2sr@~*zo+*1)c&5-A5;5#YJY!_Tu9d+()EXQ{UKd{NY@|I z^@nu*Azgn+*B{dLhjjfRU4KZeKa?bp0h=e@WM0()E{g{pCS+ z*3|x<+TS14E>in@YJX4d@2UMgwZEtK_tgHL+TTzPS+pO z^@nu*Azgpi@Bb%B*I#}(*Izy-F>kVcOTYfU>V5%!I~a1m;#_tEz<%T4XgoaJ_j?-e zG*0;I;Xe2K@h17)_dB1T)bs8CQyF-`1zK1#=sv@BD^^Cu!GyG5Baf_}1AcB5Mkk&8vU$XWy{spa0%lZ@n&m=7}J9 zS!r2vhjqMm{JGrZ^mE6@hh|S49~~N>nVlG#4rfP(#ztmFMkl9oW78AQeN_?VJ{>&% zUnyyK&c}Bi8~7tV#s_~~!KL|)8{5y$ua?%Yxk#sVeNM-d@dL8R zvJu<}wu5JNwyFlXuK%3kZn+MTP?FX$?U5nZ&3_Q*^Wozr{aJruANqXw`@BD|_|_3i z%F&1#{D>O9busI7W^kHxonoHOS#q7hI_JEuS=U?8J!AS@R1E7p`=vjoYa{AT)(w|j zsuS*MV=jG5$vS^Y*B6xDkYdd%y-A%f>aebA-E!2m4PQhxr}$kY+T7QF{Ga}pzVldI zYaix(_**#dw`*$M|46OdN422;^NE2y^%n~^ueIF%F2AsGv$VcYHt{z6le%^xsJMY? zOP`xTHpn|}t4yo%4e9uj&bRa*nOMsyDb8Z>V@lup?XN(jNs4!CxZ3$Eb?RF4@X_^ScG-L-%PNDf6)HVygt{LtP4%%&swvqC-sYM)yI~4 z$FTmYI;#ZF=-qAvH&ym^ot5#g>3T99U*2T+&nW#L)$!Jk|D}6AA8&nX9g2ikVI3y(x2$_Y9UlvR zBsdm49b|*&^!8VrY{)t#W>Y?E5i7wh)xe@+EV*{Frn4>8SxHA(=Qs7asgM<2U6^XJ-{VtK${jWA`WHd9`6b^~lmNm%PvX))XvnRedI}`*inHzxPXb zzwr0^yq{KHKds}O>t$9GS@pVC^_kcChDxyE+TyC>n6q{}pd&PoocZs%?lJGr-wkwU zz8-w=e*XS)T0Jf+2Wx5t$@p2H&_49(JV@Q@lSgl->*HI#P0CNIWTB2FN#a-vFG;eR zY&F$qQg3%rXQm*TERUu9qS~Y>TqU(ZlkxM4@AI8Ze@PO0Qt@(%6}nUx^rQ)eS^74L zOp)r8{6mT}t&nli6txkhyeKZ(yYNXnJ;vJiezMo9>VG_PZO2Re+wvp6g0nOKvl|J# z#P@!?=MSG4_!o$Gd-Z=yNB<-GwAZ9Yx4f}d4nC#$7gQ;05^Odz$p&9m(<-T1U2`4& zimv~u-gQUElRDoMtr+Hf^?CZT)^+Vc;{A@hD+qcpv<%~{s9wDP#DDgYyeU7Qfko<} znxGf^cYHmOR$sC%B$>ajDAd)Hn(u?eyQx8@7}x;l#l4C5t-gBNPSnz{I>Ux)v8=R{ z&-3+?3{QuF9|_W7Ahrxxn|-HY$HceA3w4+?|3RE@cRp^?pY<2^p>Mwr64!n5<-T^G zS9&I{m(*`eT@EE8M|D0VVOf^Xi)&Mohg6zr#VT`kNnztIeoj|R*oXV3Z}Vak^fuca zA=NSWJQLUUR1@4L%5zR|+dwd{n3MXmd2-o3d-OhW{cdHcRp0;im!p60K_dLy|L@nG zX!j!A`|Y0JdSalC2)DVwQ5^>q;eOhE@1$J!e^$rC#rlKv_#k*);=PKfue=9QpFsv^ zVF4;zZdBW~g35g^A?kaCXAtS0NATC)rKtZEJ;T-K`zq@D2ZAjP3}b3Y)&xVHS01RD z`7Y$x@PP*sB#>iMRHUni@sl?Bmmd|3_Q_OH` zPnf)?3f?bSXo=qZlfa! zE!DE*omI{EGe7p6i&sDQ_a8Qr`Kt1?d-^6L*4y6g0Qy0kj2vNv`l)m>lG>y+#rsd) zCgn$>hmV9N3?A(K$n38s{aJruANuD%>PTpo`ALm9ruHvt1hi3aL1T~EacrD2yG?At zx6#Qg_-4zok#bb`EV)t8!hF7ce)7uiQ##DXWK*4a#f;N33zbbxEd5D6%ceM%(v+Kw zm_5lXOG^qjYu1v|wsBV@k5Ag!j^3>-wd(ud+pqnD2Z`{hzx&6(ZQ*`0;{A3{-(*B{ zl1G}1OpH&BzP&=IG=5knBhMs6{SWJ8WI_$i6smMG@>jDAkxoY5-EIk+0@&ok#GFkt zY`Wq1O^hov-q&D;`gtcdO+3cai+CS{iP#af@%==wiBX$g%qw1Os<-}NJ`=&VD6ph6 zTcnLeye-@6Ti;DGN=+{&(kF4;9N^9DCY5eUlM0tv`zLe@|8(vT@_D zYBF-r{8;h-@=Ea^K5QiORpn{-u#x1y*8I(^Pgs`h%KNpE``mx58%fMA97`x$28_3N#1`aOhQwj9 zoG^2WDTyZ2;(b|WGRbKK-hU&>q$HB5pJse9rE^F!$QBvxEH=}aLTdZM;wRa560@C~ z0moF=Q0Jri>)+{NE&PFP?#mzlb>DgHCHi~3`j@1|(MFR0My=aNwV+@A(7@|5gjle7 z2X*wDsrwdghyR+coz&vJE&tngfR*5i@@vc0$t@*8U|X+RI-b-$W)`+|&H0w*>9ygy zu35I;utS^I)tHw32Y>z7T#xvd&f&G7=8=KeMBJY*%X_H9oaOT%&ey+>oAhV>g?;Fs|DXw5Uz@qF9`j1iCR8?M z3f20@)s}2*w!UWC?WpT1)-P;aH=SWh=R*p&^&p#0*@$lp6*j+b`WDNkgJZhirh-Gd z$5M~ex2*z}zQwUUm}bPZ37hE=W;V67Z6Y^*--OMzfxdmDePwkUB0v5o-+sGS-c~vN z%Er~wXI!}NmELdFJMj3xU(f~ZRVL?z{f}7PxU#Z-Y_q(5V{`qb&DEn%kIn`^rh87i zqWHz_SH>Y`WN!vE*=oIxE=>Kn45_c3r-Izxwb->Bjc*=y5P3!`f<&YrzKvYk7;u(4Rays)ed z-R1Qw<)fn)r)SqMY*q6!rOL@uld~I_S8koDytID&ye8`FN{u19$w$jUelv9S0`_7pL*`r_{5Ew8|N3!=TDs-Id%QSmATW`kDu8b zJ$vQk^{dloZr$3PKRY!!vphGsa_Rb&bCt^TrCV3mM_*Vzyjfmc*(@(?U%s)qa?}<7 z>9OOIaQbIk_WR_ZLKJ(eva!BZzP$ZvrF_&1c6e*Mv|T=W>6O)qYpdbZ`q_MSeC6Wo z+>KXHoEclXcxIyTQh0KDygG7e{``w)D|6McrBg3$E?wJNy0G-p>f+5;Zmg_N{`}P8 zt%VJxsAGL)@#)d9yjEIS6}3BF`{K(#q4$#%w=>d6If2^)XDVj5nelQX-(>`b%n$mkdG>zs|vfRQk>FO-CGir z6MFKDj`J$XdFAw!$~mIX>%j??W=`$$x@(7gT<6>8s7nbDKy z#1-ZIy5gNv*($;FD)%kLU)S9)D8^ykVIp|NalzHS4U;R%v27BK_28#f=Hm>Q@v!;u z4b^d+IBnZ_ZRNFZP+eAfugY)l#J{n_Zk`d_`;IEFujtK9=smCMjZf*mv#Nut>Saam za8@O{p%hN2w6;&^qI)9+y|YmDU^A?$>gtl};Jn`5Sv_e^Ar|wL8}^r!?v{KPbiAY| zEUM;TQHr)fdNTNVJ?~g7v7z6-8e$58DIv-F_UYS9#Jx8Br3U?*%Mc7EYjuD$o5uJ{>VYd{HETF}m|&N8SS-xyeM>dNoH8sT0&@oW-q z-$d$neaX7uWcRk2sCz$e4_F8L){iM2vD$D{!-WmRWet?m66P}!1PdB6O>vl$|AdB- zQ4K_2QrIQ=pV#1dS_8~!4FK0A{>vJgW)By;7*q64=(qZOFQz^_8YATB@Xqo~NZ)>-u2RpN+0<&D0 zG1QEei;BPhm&(nqVQJWMgKf6AWmwyP5?ey-3+(n?R(tY@)EBd~_}wpNL$Pnw+TXO> ze;nsLUSwOA$B%LMnF^7^o!#vgOj@h@B0(Qx#cmBnYSe|c%<#r*v9R~9#C zFI_q}dTwcJ_58)Pt0$hn`tnL)ZFOOO{j{tOYxdl!KmMBgGP#}K*1_yH_`)~-jT@Fd z`-f#VD%!AYqeaqq)Ay~0ADVAX9sBps&Dd-{f<@{f{nk|an^%wS`FV}rJ zg?YbKIU5yCgqx!OpVGIcP9#MA59>z7^jlMZwZE5;Zd81C8x^M|5N+$>k`sNlR%im# zG-DINwn}MdwoS-1^;j#9w*%Pk44A+yNo3w{(DfqNjFPr2F|JS3+fB!gf0@A2GX33j z@p#@GehG0Aqy?RXJ7x_hl*t{jy>(3|M0DW-nU|d zm)VCNWuxLje_`sKHY$Gio0<^lcvAUjiI2LT77bXz?*5F*8~82EMyf*%I}3v66JmL; z;evx=f>r!&7{_|&^|aqtL|32t7^wDJOY8r->ixf4(0}!vzRWtT2HO8EwdB3=irED< zd;fb9_T9Cl2IAF)WcYy%Mjz&9akA3vrIHpzbGNe&!5!#cyn-^;0OXFq2!E#E^NaN?7__8_&He^!Z}!k z75D~hz$R?LJ=lf8-;C2AgdvPz9xlTgtiv~93$|eg_F(1+<$yVuhecR{Z@>m@!rQO| zyD<1E$^kAut8;D;hA@H!Sb;TI zhi}3bY{NTH8fE;xVHW0K9u{F0)?ouS;ceJ~U3h3beohvKFoFeGfi<`To3I7j@D7wF z9G3$gff3BZBCNtXY`|UEh8@_2hxp1*7KU&R7GVX};0|oU7VN+t%uG>FFoFeGfi>8G zyRZ#AP%{tb24M&zScFwrhYi?*d$0>N7jZ5Nb1)B!um*Qv6SiOn_F(2&(uEN$zzVFv z2Hb^h*nz>%#_0{h5Js>FtFR6mum$&E7Y2Wue8L>e!y>G~9oU2|*nvHmv3Z$X7DliD zE3gI|a2K{=2L?YEr#A>g7{MZ}!a8ig7TkkfsNZ~aE(>!o4~wt{cVH8?U9l&opV{3gLznlHMj$tumwA?2QxFI z3nN&76lsNEyZ4Z;vcun4QL4jZrq_h1)lo1=4Cn1gv(gf+MWo3I5t zum>}zNf$=204uNt8*mr4VFzk&jB|r9gb^&lDy+i>Y{5O)h1!whTo&eF9u{E@?!YE& z!4B-f%sJA95iGz8ticA{g>Be@+DYWxAPivyi?9moumM|e4|bt;F*%ooIhcn!o4~wt{ zcVH8?UBe@+FtJ5APivyi?9moumM|e4|bt5GAiZl#W?*O z%)=tA!5!FyE!crQm?^~RWnlyhumWqa0e4{=cA)mqIX4JH7{MZ}!a8ig7Tkkfs4d*i zWnm8HVG-8g4s5~}?7$w(`~vC12o_)k)?fqf!Zz%{;P1rg4Z;vcun4QL4jZrq_h1+5 zoAYt`VGibD5!T=iY{C}oz#hzeg>+#A3$OxfumN{r8+M?+2;kfx3}FO|unOz20b6hn zc41H?pD+jWun22#2R2~~c3=-?N`Z4(7{LOpz#448UD$>lsC6Lc24M&zScFwrhYi?* zd$0?&vJ~eN=3pKcVGZuUCTzhD?7_?;>B0yWU_DxoIX4JH7{MZ}!a8ig z7Tkkfs6`IvvM>kpun22#2R2~~c3=-?u8=N_U;$QO4L0B|Y{L%JS8JRbgdvPz5msRx zHed_x!7kJik8@d=gLznlHMj$tumwA?2Qybm7e=rEE3gI|a2K{=2WpqJbAvF15iG(g ztiuLu!9Cc8`dW^2S(t-)ScEmW1Dmh~JFo{cYorS!Sb!B+gAKR~+pq)mbtC5nVF)8w zgjHCF4cLNvunV>0+_@~w!8|O&8r*?R*n%C{gP98H!Uz^%1=e5#?!q?gK<$usZV-kr zf<;(`b=ZI{xCgsXd$FC%!W_)QBCNq3*n}v)U=23lE^NaN)R*p@ z8-yW@U=dbf9X4PK?!hk9w=|r~!W_)QBCNq3*n}W^c8QhEE34%@UeB_{KKNMYuZ z;pTr_#}C`i-efu6YxzQ}9J%*9-H|xi1E-so?pn7)tneOOOU+tt1D%**+-f292*?H~L9cb#efNc%_HKhpk@)E~@$ zkoiD5kGfayIB314ayON`soYKFZYpG+e5zp4I_)SpuQ z>*4#NQvEa4ztj0gI{!-NpXvNNwLhfxm!$sGZ-2D*;r*%oDYZXYTS)D1sr@arzoquK z)c%&*-%|TqYJW@WkE#7FwZA>=dzq>IF||LY_Q%xznA#sx`(tWyXW_w`E-3~(x3Gg z_MxwjFX;MbbS!UgSGJxV9?u;FKld9o>|yfyD$HF#eGW0v~s+t-}Il-yDh7< zL&1c?7IX{+&1`~3LymlS(K@uwAYQ7H}u zW4be^P)mPIcTebST3k}7g-z)CqI}ajA633A#-eh1*V#PkqK<7)gSO;&o+?cbZ=RAT3hz{N~RyT{c+tj zs#YEMtejGdho!hD4oR+z>(8EPLy+~*Df!3r1nWUI^!b);Wl-~bU>p7ME42sq1|RNw zgZEon-+p4?O$`;kM_9A&AMF-4ZkE;;$~LkO|D>*62r5n|+tTM|kPY&V+sfpsd_y|E zr1LGkE)$w1#aRsgRPV2&<4N7WCq8P|Y3Y7*?HIwK0Zs%P=CTZ(S-Q-Vut<0{!8-ms z(5KdytP4uMT5H;_p423_RUca#7>4y%)mbHYMlW|GxT&(Q>#U4_P1lp@_@=i{wUZG7<)>!q73S4!I}8|x<*Pd@gV%W6>(Ok@>^cpKh|?Z^~yaVkNkx8dy|}CD%^Y zbhf2BE9off{H8uP6|$nM>++ipoOS6QmC}-YuGP8K*;&QT>Uc%>*!{_PUbEkCW?*TU zOWtRGHBXnfsy>s~eY*RtJnfh6e&O%+c|WbZep<&l*UPLXvg&oO>NBtN4V7TSwZ&D% zF=y>|Ku2gEIrAUH`Fikilm4u~un&FtA2f65lP~wxcV6i|rNfkyX|*Do4UDRUCN4*G zW@?0qZM!}sE{LYtm(<#9_AsimQ77I_85!L-eG~2`d?)o3Q;ST<+w*KbVl#u11hPHT z&g`nqAVw8dR*p7G;Hp#9tX{^~~eJo+Aw&xa38`m_GRKJ@wb_j!L_@qI@!Eq+7|*&2I1MP77s z0GooFR&Nd6bQ|kt7I#VK6XKYzStHM>3+$J^O}9;}H;rZ9bsFm^K7D(t%{FXavEb6T zPB!o2o0eo9%sTe`fpnb{Yq$Qf?>tr=UO)2TzVmp$#gXR!|Ficl@Ns2#ou>>5>4X41 zArJ#0$W82zH{EL0LyuBE2uDxrteNhPHN&3^W?>-p>qcs}gx z_5ce#vm5Y)WX1`vW=X(=5X^IX7>4xn>>a}306R2~fEn`G-}jz#tnyV|S+X8}q^@21 z-*fK0=iYnn`Jey$e?Fwq?M|i2a{g3PtTeihoAdAJ{;W5;J1wko{zt?4LpI>&s6(E0V*|XWrb6T79jK z_lnzsUxR9BQJAO*>>ITzht4G z+joJcG`dv5nUaXqggav(E=s!4EOEua%l=w7sswig}|k(xU|0uix6XSlu=wH?vXX2ykU zdQaS3@5i6`5l4`2=vf>$_nC<+9%?!ibY;5t#A{A`&Y~cg{iJ?D4CB(uLMD4IpDM29 zvlIEH*3*&hnm6nG0X_VjUJq2v)%XSS0o5-EU9&ZB)qPItcS_eh&b}a<>qZCNJ73YU zN@#i0yQ-${H5W@{$&cd4dT;%ua*TW$OA=laE8zh`0nHTyx|2Ty-?ujmfWWQN`Z7n zv+T?=hJr!`n>^HH4?YvrPpU4VtI;|Kn|Vj{9U(mk{qF2>Fz zR+6ciL|VqDRCXcNx-dIAI~<)YPOT+JyVgfy8=@-;*7lTq#bJhL<`z zHvE^)ET?qKWb0U@vFS{9Masd}(nw@0+|Uw*E4Y@#7HI8{hR*7IlbsbnUfN)%_-@|jle^-o9JG{fmX z=EX84fogPiA-9q(q-Khnxl}7JcBW9AEv8!6n}g)A={L^iR_@cI&!5X9c9P>CMG+A&p46b;`ZYz|i)R zg|{rEj@?&n`4j)=|M4Eg;$O7z8I)PtNL>G(+EiH7c7ivS9saaB8z4*$o{<RW(Vcp3sPD^v)U9GhNb;CmYutnH)Q$ z^@~Ug+o!YOVVK++)Duy?)2g1WNw8Bes*%doX`PwZ^w+EVPw32;>ZkOU=-1YD|#m?x6(-XJq znVR)BBYNJLu4<~esOK-~?VD<*)khcf6!aWA=CIzfP2YpD6xFj1d+iLV^;Na8sCVyD zyGz=S>us8KbV}cIQdbv*+as#mQcrd2{66(kvnAN#S@9h!WmUYLB z+T|TXIuHHpyjPRjfk#2Cg!3%fsrP@chobH}h?U5M?qjw)iPwY2IxzozgMNW@&Ax}9 zwTi3$?fStsAP6(FFe)M9Fb*&iNDRhwjbs2DP^T||VGjNtvY*md=Bnt9@8H^xdS}84 zAb8U%j7PKXM*FZ5uoZ?`K>y2((5PBi2ei)I3xU3TgN3Nl@&}ie^R1qFs;;8McIxCi zym|-A*|qR%Pdp`3j?x6`c||`rtbLqH{W&<3*3F($DHZ9>MR8J{n(?+5nV;;YW^3H> zr+Yr-u_*NxI;k&ar9TI!Z26jnuC20Wy(<5df%NHp6HW5_QP#j{7*?TGq^L*4r6i<} zh~Pj1n?zogb$m(0A|}Eyt%+h@%mC9suO|DVNJzg3#;}ersUGw9hzLnWutyU{r_Oq? z2%5j&9BFazOO3=BMhh0tDTt6Ov3fuPkQb31=TyeG38mD$pz+y2(F93=A@%obT%!~c zhGhe_7n)>4xG;4aj}IIXkzQ%vc%#$_VuL}hg;j>dLt>t*d7VQ9K~N*j&pKl66c@dk z`r^uBDqHVFtaF~IG)`S>DDreB`E+||cs3gAZ!Tu%;{A>5D}~v7Jl&X_YD&c-g^}Tj zY%CJbB`>aX>#zFEKdCrny822}<{v+P;uZA^Q>JFlnxs(FJ+jYtwBD2JR`T_Q;#zXk zx=}7>iglUnx@6mx{AT@1wk|!JP1dDKxlG>kgE&{nNc211*nT<^>6i|OLZNV7BpeMj zwW#7LR~ZgfsEkA^RaQDPT=C3`H)^WTW++;zvZX?0xUo`Y#mmcXbh@!qQn6fclLMLM zOtH0?UrS-cyt}tfzb2_-jgeQ;?jvU*e{I%0`&E)0^*g0@a)S3t8m5^4wWTeD%(#u+ z%h=qs{c7x0k2L(6g|}?|;{>#7bMUM!KWCvidUxsdCE<%V_Vk98NJEh1x-F^DFZG(- zQ5h!HL-j&Wbl32R^^z^<$vXWtc9QL$MEcF@2oh-4n?6z^FFBo=R}Iz_j-OM@w15?XrbeExc~wOBUX=(4$8>|8dK*`B}TTt;Yk9?WTn_5Cv@~Ej(*s z%)+>ZX$vn~_`HSJEWBaiO$%>X__#IqpS3V%VULB+SXi>~vW3rEc+J8a7Wzp%Bsiqs zgYFIIv;_X=cPyX3o-&_^8R=p0hQm$cof?aG&X@S3=H-J~D-DyCLcIOZ1y%#kn&#LZ%{-TMTl_tu6O;g!5gThg#X{?n-uyZ z+BM8~Yr=H&N8IhsYnavD^9||foUT|>O_%p~z^gH}Xzu*iMs8m_=6zH2uV|`wdrIhs zyCZ(R>uMKoPSXO~u*DtsX}ozjy;1cR`klOPEc$7SD9zg3v#Xhs_mZR`=GtW>!C+~ z>Frrv!RE)GM+L9&L}n@-)teg4Id6M>?|Z-RAM_oA>L0dw)4j*TCh}J@Nbe;M5#2B% zJLX_x62`lPa0_QTM#sxp#3xdRH!+%Ignk5hG{M0JY4papHKH=$+&V$Rp^P>eao)I< z8C3(KKH6#G9Pv>`2aUkru*3hPDmOd%{%GZ9=C;4MUVF8YFV7EMUH8-<&X>oPxhD0- z6VFH_Ma==H_)-1#sOD&FXpYqHU(L}VO+h5u(sYNK13kr#O7s-|%1~^(@+i~?1B#aD z(eIS{;a!6Fsy=wkiVY_%bYg^>^^D(_?fmthtlHqWExcjtU-7|Pwj7t!MfrB3yr6wQ zIe$(kc;8gy|M1iYL|%gS$D=-Aih~J4uZhE3u=>CW@OMAc3GjD26LVRmyFcpU?pdqu z!g+!%ZlP0$m2CO4g-$*8qAkB{;Y|xYnN01RwBmEj!X69#P9K+Ty>t4wX3IA$yqh@g z$Ah%)9n!BV?y3{C+3Dmq^!JxL?yslJC%9Mf`ZsiKLcenHwLxNu6JNU|o*>L1s324= zi^0hHL>q9@U4cyt^)DhF0v^^boMrA5hOk|@D~w2u*o26TxQucWXP}*;7jurguFY$= zpfWy}2v8*I^7qeC^;=N8LG=gyPWM}Ux!?B>>erz9gZ6h&yFvAbb-&%kCk^m`&5e6^ z*k7)72LhmbuX`1TFe(`9B=J`X(P)Gn=Z=q~4Ru7Z5Y2+~3rZU7pom1+Fu8hu2mZ$O zyl>YJbv&V%M8ME8{=Z~-FwQ$h7(+xt7(+xd!Iazu0g3njd!ln$Owx zTgzVLCi^$^b0q%bAO5%}emF71l{wD_fc`rhwF6gt;pOlA&>;qZ{(Cjeo!n+qzqo45 za`!v+%RheqlXG~w{u2vtx@XlWDc^3{Lfltheh&K%=^QdWssW(b3~^$>5do(Kv=7FE z4Lt|W28aj*hvG8_vP1BRyTQ*6Z3%jkmL2`&kR7`u4iwl#5o?S_#RPlOzDaulilcod z;0{d;ZWl}sxKr?KdkcBX{nkf5;AC{Zp*7FcxO#^?uFN?K0KI1AbBb&>0F-Kql}7h* z2Y~*_AJloH`>KV`5*PA~Vw|1W5KVX6j(2oFc>bsU_jjX}fDuBFllp6t9zmEWGj7rT zxd2eYlZpF}YOIn;41ZKYK}pmS3d9D^C#(fORQ$2QEbeHuii~>dV1N5q8bU?h0)jd~F3=8@z2i6`fYd>xXrEvS z5Ds1wPd}cGzZw^gAMns_H~i2Lsrk|GN&KiINaftzC;s+lJ=An4=*nDU13*DRF#AdU zf>7{b3jqC)4=ta!cy`SP9Xi%p1uxygb~m)F27sD=a@5U~cJi_uN6~c91ZtH8%rX)Y zh>lpz_y@g&`$WJ5`HX8VZnP#I+ho)s9-HKZpfKly#+)Asx){v8l%1&{}#hGPxFB>{?7TW*d5E<1M+~t_z{Q+(x{2XrXZ`w=p%9$V@f& zEsf`k&Apk!3IL5PcE<)5H*;J0RJv(sH9cKiFN_pQ*~ad{w#7?JP0`KSg{9S&+0N8_ zN4iuTZ5c_VraL+=l!k}HLjwv#eYgWa|M1&B?FkOASm?I}l&sF**#f@Q13-He;zxuz zI_wtdy;E|f+ENV1l(g!@a(L zQ(Uj6%ebz}X|GGJYav~m)3e1@9#YV2qgtWNd*UoLrRlIwI{9(0ADVSm#=4(AI02v$ zy;XYSMYr^=s31Dj0!ycbkEtbbv(KA?69h%IYG@%zAP0B9}rYnRQj z&!=?GK>|P#xKS(3s@IVMjEV|Z86&78NgyY{G{En}Y>-6>h`?@y?%)J~FbTNVqm(j9 zXHY~T70^Bbrre495rm4;jCdTAn-%7Pe6YCely9&QRa$<40MH|*<$SAKpIojev3>R< zm%Mrh%h@#>01CSXHNB#rW7jGNfDXnqo(%VP zCbBa>7u*>D zdcO&plN#L=?T0A6kibLwu~FXM9y}fIK}ihR18~N|I7t#qGszo!h#>*gL4u6DO0cKN zD+WN$oD2{WVv-zTZl$fHAeInF4136{_={rnBn`MBH`GIt&{JbSIf?+#w$w;x zTRc3O>rWN4W9`wt%xI#}ygIeCx_NPZxhov6D@86$HD>t!zw;~qs^XOC>MKo|tzUg2 zrd3XuGI1pT8~w_s%rd9liUFXriDG6wQ{1e}r*bR#Vxc~{l2}_-JZPalwYrwdZGYYyxjg0Bk}2m?=pLgxL`a8x)#}5{pG=SP$b)U&`$x zelJUR1a(*CYnX(Bjzj~GGzT2v=_mB3k=^vkNocinc z8@Tw22HZF4_p%*$JsMYRX$zmT@QQ_3Exc~wD;6>y*_`LGV^KmDKi*}bV^MOpeAWgW z1_dsb>~R;s_<}9JXyMBix&TIJ_dEHJ2Oc(=?z}xex$o_u|GQI$wZ2!+NajP@PD!RW z7)+2@;n?mU^j<;r2YufUYW$6A%$9qC;-zU8%AoL^ViQ$ljmw_V(b3Zj}s+Wir8zc{{F`dAok3-5|LesoHSEA#Iymy^LeV?F=)Y z(dm)gjjTGeItI7Gq8;R>^?#r3_DKkBd{A3-Hik>em=p0yHLY$3_i=BtwgD*{jfs&O zeGB(#YG4(&_s zN^in@)Wym(V)nD1XzwyM5zv&BhBhm+-=@rVE^`heaa&#D=4J=|mS+<$cw*>nanqJL&jwh2Sk_9&JJQQ<{^=io;t&HYKcc49 z>g~-2Sh{MN^zM6r<=SuF*u>_yZsAS$uyje;cFXR^ef4Fhc)JdX-H3fu11wn*fM7;~ zA8{>b@*r#ygFlI+h(iIn3A#k1gwL9BAi#eN#75J!TXHFr4VrbwnUxA~v{shYhYwTQ=7SC$Yw3Wp?QUpU4X`ww<qD$0mm6& zxmb#Ko=@eqnr1i@Ev{y>9h>JfowJ$YLSnLWX6#~QX0Uj1qIqj(r0ebhmID_{iKfZ5 zt?bmL^`>N3`$~Jm`L)LJ_Iz|GHa?aOMceb8p|Q!8u9f`6Kts<)KAB2P#@5=>b1j$J zL!r4t3$UDxZ>0tceeNUCpot!r(3tZ#TYy|EJQT^P?!pP!3N=GO`r7e@N}3yl-~ z8%uLN=QE{ZY-u_?l`km5;h|n(^ZS0LxP@5!{T5aOEO!faY*qMONnwYbikZNX)~uX~ zjyEb!Z&h}=ten<1bu^=MSU-`~8WW0}=v4f~m|`s=f`dBuq9QSx6-hB8m%gq;39uYc znEPco%Y!F5emN!@{b@a>w|&g)pC0wde?^ic%^#mI<+^Z=Uve? zIA~8OHl#t39~;`o`pCP))JB_#1Ia8d=_&%v<{rQROM*tX^vr|$27Q{sONwQIQ|wce z%bMPA&3ktiIUCm7Z0LQXI%7e#S)FlS??gB%Ym*ezw+s4GeTtzesQ)GeH)MmIQ_t|N z3Av1^%(^yHx`MFHYJlakdc?67kS(@a?{DxQ$AX;FDF+F#B)2&_Y2*OIvm+W4*8+)0 z!DMvOgkM7JktN8Z04o75z}+L-yXSY$71wj22q1WqB!LL$Zb5GDXI!aFb_k~kKuSSk zVAW3(yvY?t=Uv_tun@4kj-5ZsWC>MTzJFTIxB8tw`+P--?bqJ<4_>{4`gAMXBy_W`noSpkHr>Bo9lyx@xk+5 z(a>BWx!?jU56H#rC&2Pq@tov%21Rp%2)S$yRUC9E!~3FXz065vo0IBX)r%VXZiB6L z$D9A?s>hWa2XBPp)&%@185J=YnLIb6}cCI%(qjiJdY^EYw(#B!~n$UDQp@YTu-mL@yjx z4XUi82$<|_7)*4}H)gT}+2!V?T=wGp=6K6kzPV>$ZE|%vpG!?l4z+cryZHp;AE^HY zXGOW8GPug->MKowt*<{3lb0k@ATdD``jt)$SSn?(RK`X9@}KaCwHatrgM|Qo~A3geMln^)0DXsQEqh_sjY*yj~K# z*XhpbnBynZkhaSfvQHN}Z?xrwpZBJ_tc6q7N|p0Lx2oGKww`v_%9{1c{^9r$)q4G} zw>yg9M1q{?M-!B|-H-Je!Y;V5S>cGBQ~m|&RIYrb_ZmCU%AuG4{f^ta(Npy55g)f? z$B`jVJFEIlVIj;cYKti(ijh=$2pbR6lCpEx+)LJ?@rYxZZ3h^iWyZ?(PcQ zxNs-=%eC%60CfF)uU=;a48gF#;E*8#)&^G+V^hPb2IE7vY*-(Yq@N5D_>LisBP&BO z+;h9spV*!_%z-=H2uiH|ZL6~D>jjd2|o4AzPz$z$}bYr2N1 z_b7Q2y85%<@r8=)Q|#6AUcIyVxiZ&S53U~<`@~S-F|*yT`SHsiuCIC9-+%Fo&#L^m z_^Jz<@|pEvf!^EJ9&2i8Z)>RQ?rMwFHFR`0*0qGX!*$VcM>x{d9E-Lzw!cp&YLk!4 zPpD~c-~O>4T&}v3kIR4_qes6}y5wDgOi*m@gE{DW_ll0et6b)!vh8ZwKD*b-%AD_x ze@DkV7ye4B>hHAhraO-=Dcf$@eaC2(9lB%J|9p?C2Ul1_9@zn}6%u%ZYGnNaJy3QL zZwT_BkOEO~{lw&rZx`2@sKTAgGso4NAR>ziqA-J%#&dWnH3 z1Sh$vQMQ5b<$Nq7ywaF^cj4#%J)_=j?iyF`kjIrdPow)Mt=!=*vmRVjQ&s6s$L+zj z()4ZK=+0Sq(vIqoZ*-%rV0+G2Z)&&y9`ERWcs#fm?M(lSO0t4Lg0LtX+b?QiGg|R5 zWDjgWBZJh=F^E`74VVxpa1MFtXG( zp19OJl#7&7z0sE9!r=Uc#i`!T!}8!t^sZ(aE=3m>(wUB~OU3!wzEW{zH9y}UTAQ8P zDn;9-dZX>h*leURvoSxn)jr(QG%&mrZcp_ugE>n79hBMjFjC}WC?3?5JtdPcen!KZt`d5ZPW_E~+TM0OEsIXB zdWPany-TOAn9vgq%Ht@b=Q^+FO6y4%RTEKrZL(`6Vsaj)}mfm&^f&C zqV7nR-!pn=#Q2N{NijL2JFw_(t4Bx-AADL@w|R*XyY1hSo;6qVwC+=B*(g#dcH6dH z9*ctRGo$uNe9t#=K6iH-yc2q=Ro%To&mYy(F6b#T>W?m!i+b`|^*x&O6`hq=xnI-# znrf%?eM{a`@?Lyb2nD9uMqR(5Gv{F%BEL$@_fN~Ai=UpDuPCv7>ir3?-obKq z&8EnQU4yz_(a*7Kl|8r;^Qq!QWMgcgYc#eP+MMkeUv6k$ZJV6gYVMqxn;mMbi(F_< z4y^UeC9DV6LAjXycyJweiu`Y!`bTLr_upipllo#-`g3r~mYqqQ&&75(sSus0_f13$ z_M@yR_uvBIQ@VOWQ^1B;fB})2QB47hLi|llBOM~7%R>Bi5t}x-1<#0tG>d3XX(E^v zaYb_;5iw;_Ax~wG>JuIb!Oa1qFJ$ii5;Xr*=%hslQF_tWAv#?fF`lF z8Lcp_84?CzfxvM$Lr0G-XREkeV1i-+5ze!nNw zH;=N%7eUe}+KmDqnHj4bninK?7-Q%0Wn_2Q94*587BeEpQzC%6U#qtipb^s9&H@%5sbR;#x+>+$8PEBVA6x5wAJ{=+Z654o|; z!kg}4%NQxDZrS>($Cp7AkP7RT$svU5jBEuU4TwlW6oZJUl0hSEXSh(B1c3OrU`Y!` zL^8w^qk;|1#KNFjHMtltwi`PiJ~PC|AUEL+hAadM8&f^c=)AZ1e2nl)W9}PbgP(NB z!+Gu+SMQL=l{rTqUq5Z-4vK8nNb|llJeY0i*^{A6^aN&A4vU$lMZ1{>>Llv>X)jMo(W!kbHUkrUl z7#weq@^U{)#82oMuj_Y8?Y$^SyKJtT9CV-OijMJ$mpQ3yyKeVivhcC8$=&m&vE{$B zXmZO!?`3q2^Yn7C>hWbd()GXX*4y93m22Hj0CeB2lK+31m*DMo-T85~2e$_22PX(W z=n~k$fx#D|<}wI~3y5*K#J>v^#O?y>ftJ{I+Kp1iVgpg@?xu!j|+YLYHs-JxI)3;IZhRV+4>n)$1^6DK5x-!>Tk1tRV z%zl(SzW%|7mbkL8RXx5;Kg0y+l8`BCK$dS0o=*K<(VgtCg!B;hgAiyU3P5Sl9nCgW z7Q{w`Gv-uMXBgVbmDo{&!+nSsz!b|l&`Vkcg`ut6!X*JlM!1CgMb}QtT!}~s-7nwn z1sA#gdtdv+!`DaGV}rh3Lj+<6`&dQb%#3uPZw}I4~$5s0$ZHr`AeC zm%_>DaG_`ULU*KNs`u_WySld8`=(?0OC6(gT|HB6qe~-8x#;jvPpsk6#nqld^ZE7j zrSYYe&WmlE=To8ZaBO2EzLH;Qo18Dj#;27PET2kd@~K2|W-XsNz(VR5TiW9*TMLV8 z&E10=E$M8gGgiokJI6B(rIE3@+*tbjMCZuZ$o$gkR3X_tP>N;aZQYIO#i49*ZmHOr ze8@e%e()Dk-+@^CLl#y&zMTKij8Hr+q+ilM7QQteUj?E6hK#t4GUj&6sJkSMFNWSe znRvpu4PN-I`E3Jb$Uf@c8QT{E)~; z6_W?kCAB=Nr|8nXretL1Nk{a<(`;Bz)1$NSg}NvcbdR2>S>9gj`jupwUXmA7r;fDg zJ;_Z5M>MSSH}o&AW5k$Zwk8V}IlrdWGG1#BmdDpcP2TO^^KR+eE$S;YtH%fR4lSNn z8(Gz2dh@K_u2XM;Z&*ohGNxY3>2F%^KA|JjjObmL)KgPBKdDv*yf@FP^){6nb?&12 zG^>#?r}K)sDp~dT(ip#gIlGAVMG%IcN1Voi8)cQ#A0x<92iMLX-diY{4F3-+V7UGu zi2=deL>rR_40F7RFfoEUk_dG~h9J8js2hzmObUKzXqb7v@(mUOme)ztN9ny?rRDpl z<$S9@`I*0}$gcfn`=5LD4wkcP*5eCyZEqf5&71w*(T1^NN8NniW=no{t!{9#ZF;$* zbYWw@r!KcLxiWkybYZo9B-Ld-z7ER8>_=I1+#X+_dH)Z3EXto+SPPzLbDmxf-cOIO zW|7K%kphChNC(s*l*gTWQ`1CVD8Huiph#w$h~=`5mPGz>9_~?nPUMs%nZqK-A=R&n zY>kNQLQ+j)8;qc>BFOibp!uglr|EF;VUtczX$&32;|ujrlfH}z351AX`#?#A6p59@ zkN~45!oY~ciKL12h>e7(^>Cn43T2b=-y$^ykw-|N5FXmcC7C)r!bo+&-Lc1@1?DQQ zg)lW8iN{xNWp255xVVrST^h{HUYxF5=xiQni!>}1HoHc9>&E-HN~LtEVI4gE{d1>( z$yr^>m0YgA(v)dEzL+wr9$$1~aE`Axeds5>>G5kVta^Nz{tB9|{Pk6jFVkODk1x{? zj+|9JzN#KrDBE3NuYcZf<7BV(oOck9wkLG`qwMj8(VTQX7`#oc1wy+`8X=>eH>P#Y zfZ0Mm#}x!8ckFRS-Vav#8=0J?L4x zuSV{`43FG_s?4a)FvObxNzCoUpWvD0pBUrnXN>vyv)~m*UIv^hQIoZ(785&YhLImx z2kRfQ4$=&*f}nVcnIO%*`MCU-|N8F#>SPZ-v-68_^$vMlnRDdv^-(K#P-L?nUsO}9 zG`f%5gV*+{&3a(C=rj_dw7ORp5I8>LX32_(5DC!3SXDqo6YdBJg7?E;3y&;p zIUp&70|FLIgm4{URTeBlWPgC5!TA~G8rfz+I|v!p8t!fg4@x~8qOs>d7KIb;RXw!Z z4L|6r*M91=w^8th%Fg5KO^LKu?@-W{xyE{Yfr4Q6qvY`w@}VW>FSe@3m+6OxO{adZ z=nij(BPUeUtXKiRXI8dgDlls&LJdun0ST9(mYmD9U|c+dmsrC13rcgIG5tcZ;X@6T z<=*h2h8n|jLgAsp=O06tupVDb0mtd_)xS7VY)tnghO;db zy|G+#&-h$#e4;yF*U`{4y3p1>Fx@g0zOcE}Us$-i$5+dG!^OGyX5VT@PpB<^X`rWJ zuDxlnVYJx08d_^v7)q}vhKJe~MvJk&{CHw5GS;`$H9R@DnqEwHucy054$I>!7vEZ# zTAv#mX=u2VA8qOwIG>y>%{R|a55|Y*=Sq>rY^HglHyfWF--w0U7MmBF)uyT{dXpA5$xdYX{#8kZ?~K>H+yXxDXv+8b4Sqzoai zRg0crNUg7X?=z$;7QEvzwUXESBy>(hckR>jcIk~L)y}Ht<%IXsy7szdqJGdkzH)kR ze7(qdHs^V5kwW~E-e^>P(4ihVuil)L@tx^>Uf*RtHl{-xlAlS@pz* zzA`MN7!uDnGv;yv1tIY$nv5Wg zZ+uD5x}9Jm)xiXA|YUKB}L@kmHf6G+h`@b{abIVF(OaQNZFCY_$r7&?f@7g8cJ zB$K=$Cs;jTA0RPA2N@E8jEOE7bre!39$CZ-6KjMX*Wa&kJr|Y{oRE{cg7ZzZJ4z|+ zB(#t9163ETvrG{lhDPqiVuLA@C*z#gsV%pGI%$4IlVpDYzyT0@biGs&k1V-2y1iPfe=c&x9v&{-G@UCJzW&NZxN7kbk}@$;G4nO;dr{oHr; zmqHb%OjloN%CsI|Oqo@WFFG;Uhe< z2RBZt9$yFZP;&j~$G4z*&O3-lR8YG?^$*+qo>2ch${t^awSj%YB?KEEIUA6vVRxu8 z3wyAn73>to0nRlmKN_#B-PkEy^KrDt;T~C^_W5VnHIpy}iQO6Yjd8&^-Q!zkj0R0R zYg~;X ze7WjM{szbG@%8)P_sNf-+WrFzZ@P!IRz+95Wp}C`U)vsEMlFUEgS26kTo}IbVIkJU z_@H1DL$QW5LS_aOVn{hC&l&>d8iRsJOlF-OTBT&#N9F<1N%4Xjjk|-kWJJd05)(Zs zUS{{?<8t~7ga6==htKT%VqCpL9#`fZd3^nxl{+Z1S&uKODOMWY$L;a;{=c~4jqV?| z@T48pRgW*e(Dqily<2fFh&_nwY@~1qi}CTo9fa{ts4uZsj9YxJjFgXe79$ukh20nz z5l9C9SokdZ*&x?GL=2BG&NhBz*Wb=~D z_m#%z*(c)_vBA|lY;a}TvL0UyeMZWGuJo<^5C)^RM4M};}H_9)98*#LRY~UPXqWn?G!PB|- zaL==ib~ssre5CpzNE6ZmXK2U~wi-~KTJDLP2xt#S3YUpb862x{!Zq!o-ER0nSB($- zzqe8FhRV+4>!1GiMX%nWpeu8Y_4on>!R#mX3qnCpdv`9MDz4?T6Zxgq(~<6)H|zWX z?^Q7}=cR3~l{u3=bjwRB4XCsrjdZr=t$Lo5`km4>kFzhx=DN{A_s&;zjG5;$CzWkC z?Y`r!%Bd2s%(@zEKk7qE%wKHReDH=X*U|xHo2|ZGT)()Ea%J}&DIp!VL-@&}3#waxK-dU9;Mb8I==zS`Bf869X_j*ZUF?w3c#wVv+TJquZ z>(htj@ikaXPA^WxI-B!}p}vk#W@Isw?d+SIO%LRfO^Yq(8!x4j7sK(+mF(ulk%4^o z+~Pz}rZgMwo?0F6$}V+3}LzHl2lc3%RP+8YFbtO@me zpZc6P8qpD$oKDr?%$wHx=5$4q>Ra?qjp_*urWf^wah-*4-KI(-IxjB+{+!oxkJ>2d z>ac32^i{__GyjrGRgbUx>G1`Qq9umwH!38^Hr`f{c;YjN=D-^auHM9mz|&)*hB1xkw9EG|4?p~Z*a3!T7H0h zokvW|`Boo$_0K9wY~OS3rdRJ^IlE>(zF^njs;}th*fqb>Wasr+_KO~ zea_R%!Tag)h1Q#8lna^)&Wn^lQkO+oG9nwK`fL(0VhQ4L?ZXC4iGVKY>^_m*Dg7N4 ziEbBJSrd8b)vrz@r{MGWy59uNKNUJ@(ZQI;H4=D8KQ_wS+k=;Z`jj5-U>;wMdPgKx zBu^%O+{BS7Aps`(7F{i}A_M|2EZmSy%n)`AY##H0BnDSy6oq>!WMEBaMYn%T{c-B{J49lgT&C zg^L@7r{G^3dk1x|- zLDQALzUuL1`m5^kW%|L9v#Q5e)dLH5rkdl+;6<$gfqxy|RI>3c&CVrO^0}uIE6cmE zJ9v7r^fl5q26Y@fNCN~rg&Dx8;#tLqJuGiHq#&~!FEQf;@1Nh}dSWDYu7a5&GXty= z5<7`fFxbPcnY>?|gW&-OdZXsYc?Cm&(I%vJ*!YgxJHaM!yVyBQ*$iZ(%Ak!ov2MdF+Z=Sy?y(~dVIO+O8y4N?eR5`$owp- z?LiA~y62@!$~I?}jQi@#PVsjA1M6+7_1;qhYekY>HNpyaVhC~&(BU}2jlU{jiv6n*;IRbd+B21Kt8)T zoLfqEFRV44A8%Q%>&dj$4f!$-k;bMo*_CV})tYaN4HO2#qf4EO?PKeg z@*UF)9izF9_LYkrE%9Xc=!K!i?n}dq4bk=0mA-+}dU!6InjDsWE>akn-I#1TEQ4D# z*D|y=ytx`}PBsj+~7_|-T69JA7oSXecu`UDBinM{4<<`~a zoZcs;Hy+k}hdD3e-D_4oFsb)?&&RLX1$W`u&y?SJTq(6 z;C4R^ZiG{?7A?N3_{CVIf;AMEalni`@g@=ad0w9n6Q7f%4R#Hl{)&FP8{B5{=O-fz>5DV*rb2SDF|jr? zGrimtFKuQfN0zd~9hVjwh6cKt(%sD=Yj8U#7qcIO+p~J-l76T39y!62f^3e#cF-~M zyl*8pOy@@FU93MZmI*v`t2=&nqt9be{yPg_wdXwszG!pstSvuhp*d=dKyDxCe?Htj zc}Avu%wh!zPWAd%(q69SX`$+hrgg+9kk*u!b^M%n1Z#e)=SOp1q#z;^n-+1H5m{-{ z^+}OZJYd#TGb8e`tlGF*-W2Jdlwoa2tqzL}U($7urU4P8CbiJ5$sy!3xZQ7p=I=N6 zeI2~t0wm+{AOwoAkOy2!zl;RDwwcf+IpB zZluP88*dK`bC3*}Hv~XhANtDwP;m-$^_8Z;_r3l^>Gfs` zn@`piQ-xw(K2?xAX+dqHJ;K2Z2dRSo=4<>O<#noI&Ml zPwTzDT2s$$YAVDYOb|jy`{aY6AM4bw?74od*BLkhqBRNYJkBZq0(F5`ns@QPhwE>D z{c#)69=GJi?*|gM^*IY2S$f`I3+`?xpgcP$~w(tcD z{r!{HIU)Vtpn&ajHK#S++cna0JzUg&LEkK|60sKW5DX*Za?NhOQ=^%jQ2G^xZiReH(}D{eV8pe^_)-Z$-#__dZt!n+Qg<%V`_1rW%J+nsGisL=a@Wn zYK74x1Z2KCuKNeQS5W;yzfVxRLG=&Y{hrX+Id}?%2hXqRUJY>gG8w5ER@g8}uxKX3 z6sgpa>W#+}j1#_0BrPP!&Per8n%#ozVBLw=hI-Me$<1sGaIkW;N+2D&0T?sRhV?^w zCrcKVfhhFW4Z#|w?xW;wm|teT?B6|BNdmq0*q?c9nX@6dGS{rV{zT5QUr>dEKVs9d zv0rai=fZZK(sMs1cvS3Ht!1a)VA-y(wD5|pzv_e6ZTaLw$bL0FLhP55{!d!ADP&=f zg=q^*7GAONs)a9Fc*DY1EWBmmW0s8~@RTiNVULAV7N#wH&cf#{^poQ>ZRl5Jzv#{F zx%1n!|Bd=>vtK0bC}+P21x|@cEod69mAQh68DYg+x%JrCo+{hLSKIz>{_$O9yG;MM zzpj7oRu*aVHrIbg5$wDdzb6Df^jdfsH3;7@U68EPtTuzU5_LrJ8CDFRCs;0ONFZyB zF2N~9I8L$>j3&hV!C2uQZWuhWV&i0iW(-{%M>!uY9N7&BqsE}qd<1M)Fi*pWdG49{ z$1Aa2Z~NrOzJ_|ocDXXwl(Ah%rUz!bB8`tM+x7L9-FnL-%XVQ2d~~#4k6HGp%62{6 zTCaC%UczXy&30kazLV{WYsxK316C`KmAs~HG+uZVvN`hR$d`ludPmmoRXbN@yG(x{ zRsROH8&rSL@A-sYr>gCeHAwyNcKt{jMW%F&eXRdQju{NcW=RnAOlYX^Ndfze!H}i> zFbKke!6MSDJKCb5I#Yhu{F_Db#c(B0C!Rq1n0^7ws@sYtWi76DX6|O-;Mq;TG z+noR5XuEddX&CX}{<-h^N0r#F@BNp*=CNar?Q&(VDPy}1C0ehc<&kB(-fr2g(~m6M zMf66M?W$_K9xP+yw`-dECjGYAE++DFwhIRZBUfWu?e|Qqgf)=$rOI|46-4@HF(#Uw`_S z-&Be1`uzX$EndB2yIh%TY?1^QtaM;)S3~sJ*skA`5$|RFPU$sX5 z%R;}eSIO32u@JJr=Ez1``yu_RMn-yNyI=4rdy9VMY**tQY*(Kqdl;@k!J?S1HJKZ$ z?3No>{&7b6AU=0N?FQ99Z1;OY{c~_Fml_G!-1l&Y{pDJBAOO04zE>YD*dw#5AkOia z2uVNg*c%g11^dJj#u)R6oW^$wQz6DYqNj=GcF*meC$8s3D~A6Ti`$?JgKaV`AO;!s z3#wcEK3(|J0k7V%Pp-^0Hc7%S*eD?= z!}opcV+}NONJ$btVdKTQ8=Fm%;Hn>lBnj;=%>4o3$Q>5mG*7z2tNoU(ch2M-ZYk@m8gRU#EgCHEE5zc8Ats38%(YM7qKh>gK6-$D1#T|}V^5}$`AVv_KOFnd? zkxdE9+yX3UeleKihiDAu2r(>iM#@}78e_^m!g-?PegneQ1FK)cJ@1SpJ* z=Oc!8w81E(V2enIg3=0=lktPZSWli#m?S6*0b-cf{dnivCyk5IN23BmKWscIO(+XS zb{H`3VwUOTP8j0xr-Z>{ksPv$9y;5#3r|B2y{=~I=}K(Z=*^$?*fGa;xiZ%*zy3s8 z5x!`<4uvypJU(sL8-;H~_MYNB1drPI{?9GD_1zX;wpzm%eDFnEeq0U#<(r1X9h-mn zJqQU_9wlv;C+eujtH$?-JJckmZwPLevt3~^SKA3zoY_64d}y`Gfd=!n(^T;vSEm$4`P)LmiYlMj( zZ5W{`T;Zp8u6?Y0CZiqK5w1eo7Bp$FbFf+HwtyzU1>-+=HvuoKeqa_&7JYR?;&8NF zyYMpf&`xUm%b_*Bc zM@P$5Ww#y;?6PMK;Hs`S{#i?4R~2AA~$t*)0gkHmy7C z{tfzWLG=gyo>g|se9yQ5+AY$QAh2O5#9#QU{ZTla1MCqv0JXpH8y=P+AXG>gR@(~xn9nw{f9Yy@XuK`>$-)HUix6tH9k7* zmeXq0qPEo*voLO9&cf#`eBQ!q7GAgTB@1s_=#2G`Tcdrgg)s~LAtgCmf7!wpEc8!5 zX+2{|ziMa+Uu&CucWWOv`fcqNW`uHfYd{QELS{u$C!hD?c};q9>K0XA*OXihH90Ew zB&gk>ddB@h*xR6XgX#}@zbEv(2M;xQbbPuHcF-+hFm#?)c%;J$;q?xi1^bl}JA@gK zr1XTOu<8N}MX?G5dFK4{UtIkRdq>7Q;)2a$K4`W`6^v1l_R(n>k9g94p-nT1gYo1d z5ept;_{29I0s9rq+vu@t-cEE6SQ}5U>SLT{BpRPkmsL~i5J#*OX*Kxbj z|E^`be$T>3&y}87t4D|Zs=CrY8rrT(>4RJDV83d$l3_;rt&D2pV#SuVo=M(IAj}l! zpXQH>OjosD^!7H}?C*EVRkq9PBJYpuA6FApE+4P--~CD-jE0MJC-_krtrr?7^2os! z5fKdAMRqw@B(z?}=Zp0gF*ss6ffMtgX$0ZJr76Q zhyGcv|Q{HBOVH0%;=4jL_dwa{4M z(?zxg7$EoD?s?*RUf3vdI2Z?bA`NLDXqYpMkF0xYm@~|hXs<9*8h3r3ZBBPWhbHpu znm!yhY8M`buKxLV$Gwaw?BCGO8YyZffAj}E_R6tQuFQEhvC1c9JcOITKJwEWLj!PQ zhm=_5mu!v+?#5;ltGMb)NiGKT7(M!((&_IKyjKS4s&~WfKi9T*J%-91|H5y+_6wwV z_@ae3-Fb9L*>=nBJBF+5&>g$}f%T{+R>4M&^g@s>2!ItIt2|N$F)BDjf;>cufG9?; z0ri?ZgaT=4!QWpF5zTqTouDvwi=ZH8^404tZRebCg)+hDNtLm8ui3Iq^B+9n}<{)XyzHTq@+APOPlY zW)msF<@%+Sg-rHbK2==HXD9MYt*0a1HE-7W1L{Hi8_XKB=wl39V502?R9f&DhPUcI zC-nnMFl62aK>zN5mt}`<`aFhf{%nKw7U~J#11DXSP!35=)s>wm6eXwuV+_!;Se+A-tG~ERS>#t%i%SGl`XCY9^7MU0OyEAImpIE_F>Tb%f$|tLKZO3%*NdmQ%WAvUM!d z*mNelqWP({uP+l?%C&8*u5MmhS&YY<=g&7xjD$xnu0-2P@iNV}h$6UU!elea( zjZH?@=FWFd&qw+Pn;ZN3Q&MxFuvW3)4 zaWj`{<;Biu1@mI6HB!osP8LUVk>N{C$+e{m*^3jCE%}kAM5ra-(GiL@MH8i1c5^IJ zx-gmR8(zQE)YUgQnOWKDXm086=-E0`NUW$u{j!qysO*v;&yW-tzMtddzeaUNUL4RpyQCHxoJFT-Pyz? z$tGp&=HWedsimD<{Z;D=kdM;wLhcwHdW@$-4{EfBW`*0Ry|=! z=Z@;h>EoQr!|DzE4j4ffbnK$ucv4e)UcF(w71;0az7LEcl3z(*k(~eZc}Z7Is--@) zwC=UlrTszGVZ__gb;x!7f;}qnG(4GkMgv(SJn69uu$#*okt}D z(Xjx2mWD(MEUo^+qfqD+7nNS zl*6v^iLdDAhP97VsXqs2(z@OXSM>u$Ul6=k7R5<*YR21M zJmK~Xi{g%d^!)F7EXv0$bW)#l)pc;nN`uZd*R@vGtXJiqLXkebZ=(0!k5mYwVOWJ$ z^;?U`XjVV+)~u_?W<@BOLRv(8LfW6yzg`iNc`+N4Du)EuMR=!02I^|2YC1(;5}FX& zMLNTSv?Y5hlpBCjBo`s&Q;Y7e?Yb2oTv@_z_IZeMw)}pnN9V8z_?IS1jfV z@2oc(qC3PzPk^j1t}Ldq^-jb(=ZQ+=)U}2pPiK-(Pj2Ot6YUedgR#}=?(lMSylHBA zrg5u3zSdC~>u=0tho_q+8ruiC^My~(R-7_jeWfYW2KX{%YK9S?w*AOVndS1WC)cgy zl^u93xmh1=YH0}77gL2|okTtfyoLIfXsB_Q800f*`!FL;jyu5jPf~yFO^-J%tmaeE z2h|odUHR+xtc?3Iql|k+ZL@aR%lfhPSo)H-@Hq>wSa{XK>lW5nGWEEHXD#%21GV>z zE$1w}Y~c$QI`VeimS48;RSP}wUhSZ;Wveb`V*0`V-6^BYxYs3dA$PDo+Yu*ZU?{h} zSM#Z;d-jZn2mKz74e@{Hp!$dHeov?`s}UyhMN>b#T|Xj5a75%EtF#&R%PfNedqg%A zSSI9jf zIS%n&*{$VFBEK@1SrI?E`ORwY?ktwc`H2#2PEyp06l2&SS#I;kW&gaU-zn{16=d3F zbExj1>*p&vrqgz~Ga~7+#VpKONFCJjx>aufrDdi5%EFMOceWlMe8!evw9uS&ccu6X zI??On0Eu%+!>E!%d|LsEve~#Jk~Lye`zW-qQ-`z2pm3cu&T67+f>&PMX zl01=CclNlyKV852>-Wn#@!n_}p4X4)Mch4|=d|123t~|NKGUjq|Fk&-T3R@3({Y zPf))H)gRXVU`auVkbZ2Gx3`DGKcGys-!Y!!dKpMRnwNxTNOT-1=}m4AZ2o9o@D*ZV zB$G-Fy$lO4L6BhvIF9w6nUa2IbKk|ak52$h0%Y7|4B>ue5hpY@F5d@cIPQ*f_`K?2 zI&j@%CT5=1w{T5+Q`BM8Ri6ECzA@2TiQE@{=;u5(z>#}b<{BGN3b}`J?Sms}Y-o<$ zsa=V+#F`r(-9-XEZ&`pZSm+`cU_;m(yl%@U%e8Gf?kJRZvi|so+|fifG-|M-Xxxnz zU>Fmw!?3PKHe9u=z>5~%u<#WNZ&~=5)vDkY#}=}%$HFNK(-uBw;qw;yzkixG^n1`* z43=(X^FP0v-~9EI55i*XT$>3w>`v`UmsnTg7;0s2Cyg5R^sM)k$M>9wBJ{zSj61cO zNwM%3#d7=mPo>c#~pC>Yj6IQ zuls8ST>ZL*H{HY9$;1_J*&U~HboGAdA54#Gz!hkO6A9K298W+#5CSy8l0q^GV^u-E zq>giqRRynL5CipxzrV_nkM>Q#hG_xhVSBI zW&@#wI4%G9bnU}w;oyr##<>3?=$HiaW?dl+U(}eq5hhR_Jqg)S(bwP{d=yJ62JSH&k|FOzq7Nua%22uFN%`ecg#yWlVwX0;Tt%EeT}14pUq5QE`(jQFuzv zhHuJIX-jS}|7d%`vQ+=t!kG0riThyMmakiAuD)N|lKrz*$E_`SK^=4upOhO6PHj$0 z^{OpDW?7`O7RD@$TbQ=6WZ`8CU$D@zR{p6Vt$T&^d(aI=$L*6+Wq}xl4=xL|yEgLC z@l9b>7?#z;%@p&9FH<6c>-(7tl_%HvLU{#%w6 z_)m|lwgnWa`lej?14`4tOqSy=T=VFKBn*WCQ(XQ3z`M5_OGT~7qqcH~br>!!M6 zhtwL>|3UQ!{VqZ62Gu`o_j^KpT=h-a_Dvxb7v^5#?$DxOL2`N*G$5oqhZVv=jL8_r zi6CsuzW9|GAIY67oX6GA7>dc+0V9Wgg@pv`bS(yBb03tultiyCAKRubkk$U9NXo}TvMiPK{<0^ZHw5hhgsY5hKMm_eWitu zp0>rXR#j~agI}6F%R)gC*c{17Yd@r4Rog3K8Dv|wfocr%L%Z)6q%r#}&79^s5 za3+B+Y|0grP0r?%b>&G|)b_)!ZE3fxK!=47hi}XN-BnEv#ch38U0^sd18DD3-%~pG zP5SN3RQSXjv$N}&h1p_eCEJ_qJ)}GMec7y5wzh?Y6xcxU`$f+J+k=;| zSrf&jyCcNfcnjm>i;e`p6ceWd%N6VyjHU%66?foXn66A76<9gL<{52^Suuq?E11f- zAAjcsc|t#{b(A~}czO2uy7yLMyT1CF|Jh^5oVLZ4xu#6pf}6%ZxWPcS>tWWmJZo91 z_dQhFmi@C(9ryy1!sQ#cVf@}9nMccwMXQZl!>|^L4 zHVzGnSzQ+6iiy_aJoYe)%z2s?{8~5{Q%XaiwuSH^SOD5g=pM8W>Br1M%679Z3v7pp z(PNo`koQC;uM4iTEZF8}0S=qKG8(_?Q}bR(9s4)*b1tpF`P%>C*>Y`*D|6nd*PM8( zSYQ`mbYRXT+M=wtm9;JVN$CA)Nw`S2r}T&~3*M_M>$}wN471WG}=eM%AX{NmA@7#Cf#?|`EweCOwboY1HxpG|RV<$CH zd#tp8A{3`Hli1pLy@T>h5KIKDdO@Z{A`9WwiRvTAqFH$%sC}jb0&|l(7h5mW0(+)? z+~Bw;Spkflmz*}7N4uzQX`L(t8aM9IJ(stm#6P<7+~>3FL?LYZ5$(aW3$1#uDVhn<#7k^mZsnI-A|8wMa`y#H_emoaALn@ z>#M=L1`$a_3KAG^PlI#_)h3w+37@c0;310ts9CbaB-21x$A*FRA~-J^bRFa(Hs9Dg zIG-g>pwFz3271FIfZ`|!$h=0-E-n}(?cfeAw*ztce2nl)WA0l&^Zai!>fNRg3vYAv z4tZReg9_gL4UKMhDph~~Wheedx1gG0r8_;V<0yeo>3B}?Udi88Zcw&eE8FLh-0@5Q z@y*`oUbOI}rDq`@T{~;bjy#q%cgL=O+C19O^asyV+yDM?^$ui-@y231?NeOj6jO>Y{ynpVU7v*G8rSt zQE0efo&`H0IEa<7e7I`(RUD%q`or(9hz+jZVS_6(K)&nCPdqEGl%dZ^Vpx|a^(|Y7 zv3@_?;wSWs*DbnWBe_>}xvuA7d&z*?$zUmZ%(NZ;OBPL*E%aVS=S4djy7T+9n=vYe!lx=rI%lGJ9ufO(*mfH(U zR@dsKyKDKg%jR(4-qD>@Y?xj^ID?L4W->Y(LZ3~-7?9TRiBLuaLBuntFB+TRY)v3K ziT7D9&v^5gfNI0jGPN+pFd4wZLeCL6nMk1H+zY|cMI)MyxEEaH%3q${eF|`>?;zLM zwR)KXm@z;THw7H!TD{ZLV^eEe#X_!YvVCHBZE?Oczq~ZG+Bp!)&W!g(hZ6%0JtNcY z-IFE%GQSnp>g^6Ci))u6D;K&~`}<=Z+2o}Qv3xi=d@;Jdv^Be!>mJFjZ#MLvZ-{Od z*E%NFLj#?2h2~`XLgQR`ZY(-|SZnphoBHzO4dISZvV9?5=-djejwjl}rS5@_(UEAb z?b6uL$VxUnlI@Mh^ToxDp{}r;(CKly>&>vGp_H^rlTdj z{eaFHRUbsv7j5dRF@3=i^WeL1HKcxp$7B)4wEDKu zTYtHry6RfJWg3(x)Z?F(mT7H1F zdXJcv^Q~U`V!Wcn_UHe0z^iw#oL#eP^}?<}U9afp*tN=Q_0IIiqYcrv^`6qi=IT&( z`qJ!$>DYQH-I$%~t{d-aEN;||OlIr4R_6+Kt=@ya`F@l&$GukXlmBDQ_n^6d%0egg z#jNz_;FK+2vyjilb~mXIov8Os_9+#Xuhl!_Em)6GH1>dqV59}xk`3U=u_2<@F~_1k>+>6wR*$j zy{n6n_PMp@iD;;$ZhSf%?Qfhu-#=I!X=w?~jy2~?ZJh(XUEKH$-||0IoHAW~r781| zA3yPm`h_VIXU3$)m3!p9EFQO*Db{7O>#1yUCBIp}lC4Y2qoFQU%4PCiM8LU1rkH9y z-PnFQ66u%@heDxnT_hY0HMOYXDOVW|Rj7Ms*Imm$A8N`~H9N7LPRifQ7eg{o`*m z#~nOt%g94;h>pjV%PRMHV#9&x0NispYn$^>= zm|?c&oQMQ#gQRL&YfcO0+x3?TX*-Jq8gM2KBGhqlYO!ZLwc|{*<$F7mJM8t$y|!tB z-uCjGoU^yP8y}9nw229MZ*3Y6k-fA@{(!x;$+y|tnS8-YXY%bktptwDNlu{wjSQTF ziy9k6)vRfh`0>x-p}&65_9YuvRjc{=TZL371=%iJc-6w|7QSTRO$$9EiOzrAvTT0V zE^g~zwpyv17S`BAgeNULYoR}+-X$))Y>z*0;WZ0ySa{RITNXZU?Wbogj9J)Y;WHMN zEWB*t^A?i4k?n?s{{DpohxB{UL%uQ$_XQqXm*F*mMG~T|V&)#8B5UyfPz3D%DyZ1(Q z20nmj<@j1GT$}fu4}0#OXFz8p^gJomocDUVpuc&qZc%&dy6c^HW2Sdk^Gw_cYF#T@ z%auj-BkP6vuiEZ8zE4W$<#kPu{?glMT-p5i@u=VxF}X~oqk7YH|A} zz2B-0e%Qhrw*D0#yk*Pr*VDrGc4B+i+w+sR=X8SiO-24IxdGmr`d~Xo^f=T9=rv)2 zj3%;a7xjTt3f%onC&1tBOp_pQ=iMK5ahDYn*j|XYpJEUJ#+*K!Nv(w3K=66fgns4XD+?ey@wM{e$9IZ0;H0}^T1-ev3_e0H0^W**p(T~>yaJZUU13CO z#3n>!#AO^)@UPq{dNJp?>)O0_3o1`YghGH~QD%St996#swHs7_(C>7=#h3ei|Db*i zsy}Fd2elhie^~e1U3}6257^wecZdDuT6Z7-y7#(QaR{RV0te1DMqI%iCZT_bL(pr) zA+Xdq<|F#x3WFGhV-DW4D5l(VyXT4PdEc%d!Vl5fDBBTnOiVbbTWB9UCnAz_)nSh? zP{bh=R78=RZY8D@$)33EEjm%9s9kO{vXz9^S_-|k zrBN)|Q+DEI5?6K-Z$hJryd>hpUn&wBH zzvgrP^ZqaXW+^e_*+28WLB5F@mZpq%0R2}IGt?zPSA6(K7Ji3n9?VaXWQTVE zwQQE+N;`E&Ss5{VmK$iXPszw$de`18WpVJ(5JAzg*JsJGT9pgM1jTwCsNEDcn<86V_OTocT_*1Ly@mP5zRH!OQ4f#{9G}xa`xnBhw|4 z-1Rx(?1H|D(fqJTkHnMJr^;yQko1zmdqjtYA>(NNffwlCAr7Dr1e`nBIKi1ld{Z7BMQGGz5Ta)&uL zHh7qgV{6Cn+A@s``((ki+iQO4v1Nbb$A^Ba6gQXo!(RxdrcFUhQ^q@hG6k90pU@dM z1s^pB&?h6)@+CjdZbhI?#|p3DrCT`mo0ew|pst^68o1PMMGDtZG|dWq;mZ`gzrqT} zK$`=l1k4bLxL>c`Z_^R35)TaMsk5VEUlkV~jEUxqU>#+I3QlQ)VqA-0irFiiB>p(o z?r8m>1Q0Kw!FU22-nkV!raN@nQQj$~nD`mBhZgZ4?-9&)aZL>$N12P1|D#{r8wJ?Z zH%J-p0165~#mh7?6mXIbpqawd&{BKd)sFV+OVe|SvFgs1hV{YD+pkVvYOPHtho%wA{lCYHyNsmw%c?d;sv^k9FXDVt0Wb`E6M7gx6ii-qjsgK_}v-CD1{JlixqI@g<= zSV?EcYP&X9YA46)+UHvb7l$YM+A{46^)-EMD-Cto{FRaE>HhB3m24up(bJVHPAxv- z4xnGX@zp?Z_?m~&wSW!q0AtL)&Y`=eaeFoN+J;e@t*>Yo*Y!6?QVE-r_-p`7wp zRc=<3v`UlJ86d6d{-V-rnz&W>@4y&mPR@848O36Dg^>@2$=CENEfdIuI4rk-p4ab! z$}Z@>YN5A&`C;_R<07fM_jAR(s9FmuH>7g-ZCq8^cGYr8$YDS~Zb$Dn?p zC)?1;6SiasG^nxz@&*}|xz-hxZx37$+aHJnXkK+<_Sr6dKFBg56SNWKE$gYZ%Dt*K zUXtz~J}4PHcTugZm)X>^N=)egnDQ}Jnh5Ti4f=ChrTg{HP3ld!D&A^9zt`2rIKg7p zRZx2I)H#6CrqW8f6rdH;5_~;OWYApB~^Lq0^z00urpijM$ zQNJyyk8s^>3%)C!J9&M(5!E=Yp24JSMR|~(4fQ1ke8pe{;=RL|UREs^JG?hj}pVph3(3xrPxQ`ATw5((^4BFKH`d*>i4z{%qs!@PGv zTQHS@#5)3x_Y8NSS0+F>QU+0%5TMZ~b9WpI0h@u`0ULqPO)MrD5T_P1Ga+11oktLD zK?{zqnrLYgLAe_LH5`D2IHTpqZ~#4FTFzH`ruTYDi7oYKJ{9B}46|$A0Tgx(>UmSA zv1_FrKKTubGA^FU!{Xe&E@CEcGHukN4n4xq<< z^V94A`oFh4{y(6(|35r5sm~lg4L(c<&^n>{N)g5lk(*YLnjuZ`4k7qa5r}4?1$1=X zVp-M#w2_nbaHZIQW|b(&K6Xf?3OCU!LLdD?4C6vR{kn6f1L(shXi-#Xq{ZO7jl{4z zfhxVY85G_$hS+_RZ) zT1ii|bT*7F73$KU%;Z;pq9n?+{8A|M;s?qbKTuW%%EXZTk0U5EWVBmVSk7e&xxB(w zuckMvYJ#2QC#H&XYjefT%6w)ymoFBo(z&VCCHaFEsxm99nfzwh1GK3oQCFArCXqqH z>?283*M+Xsnu91;YHPw*8bXP>aGARBm6~t`HR0#fg=?#!IWn=lp!eS2A+uSZ8@B{p zEsEl3-6rzO;wG`QDX5OmX^rX?oz(ZTAbLp-o6-htDnp`JLb$T_xr*C=auI?{Yz9m*R7!!KG2WMHy!XuLgsd8tJ zR;nj6Lh;t4NTWI3gX4{pGYcw}ktBed9j>r(u9?_DusDRy*g0#OE9Ulq^(gqHgIc@XB#l;@$_Vk+?F}JI>ZKIzDZjM)ME6F7kjjguA10 z$iaBzFw0|OQ4)TBJnx~gD9b+mw0Ag+b6ni;*Uf?PWuJc4!#6!N2S!`>JMY*3qWv?g zHYRkQc1uiCtw!4)_uaV<*7~THk>Eq>&WP=DGZ_6*;XZz}=NgQ*>$uO4t2ZwHxX=5X z#@~R(Y}gVME6qxsW)0dSEJ%OOE3ZSp7lrS3T6V(h>@0H_2gsezI-C<^xa?sZA-BsN z%^7mL{9zp;w@V(zDRR5iK^-HvOB~!ea=Xk?9VEAFVALGONpid7nWN;}?c~tHKwtj7j}O3qp892k4d^X$1lvHU{V+c@lM$N9+jRt@4jPS=lpF z*MGZ|jl@@O{#+ndnvH~|Df8FfS5B-K#78)x?^1t;HEyAy@{SfCpIXi4Gsws3Ou8?- zxETcbQGZ;}`5?r~*Cp<~rjz;*{f;VDzT(;8S3P{oLsc7ym1b0P$%~VhJ$&BdudxVR z_GxqIqaF?ogB?e78h=R74aUluSSdsW5{nb+Fsmvpx?!nN`pW4OE1wdx&vG8DKEgfD zNLYpR>DQu!`0dC!ZrDV}i;>T0{-Y*_2390`#i*m`mpa} zSEK0)yAT7dUymwoU^a{xz^ zAqHCet(>J(x}V97Z4xI$%EJD*(Dfh>jH8+6EG0wsKqH`&1|bE?VFc~85pnf{X0T4e zRtYTxhysL#_X8*jZ3hSiLucwoUy@NvSk{KHf_%7g5Lcrg{>hoIn+#8PSQ*Q=$zy5m zk>lNOc=??q$7kPLepBI$$tHPIXIQKcnU+^QhXL}%&Gd40%T{xB?`mpkC_hw~NeoqY zUtU}t9H<-4TpI44Sj*NlCpz-O`F3we({(x3ae1Vt(O`xoE@EjM5(JZ*73F31oRn5V24oFNphVmavYLB^;B3}>nALsb%Ae2*(uVFEQC(yDx5rjqOW6`h@i1)}+f6)CUlLxKIr{0F=3;av|+7jn*z4|5C+2$k+J zEPUNx-|+CJhtc-Us!T%XX&33L{rgATAJ^~P$JBUKSoV*rt>3M)FTg6;B2;KpViUsV zHP|L&w?L#8ckIntpFYRjQml9g@9&yVDZM7t)NL1u{vR6W9LaISg+Ydz;R*ybg?h3Y z;Fx1*aKtY1(j!oq3J}7 zwNgVf&GVbft#!@Gh3?kok=Cn&3p44_y5hu2P4z%}cA$H5vGa0efGYmh(!FmOr3Pmh zoBN)h84U6be){`1?^EJFR_I*UI0TtS`xU!2zV$nutl0Qz^zWMxJ!}`tc zjixK?LJYL$mqPy`{Icu&q*Nd1ADdg2bP-)xekD!`TeP^4LWnjXePX<_qaDs7kO}7r zim1iXEQWj5ZflR#&t{=+p_h$9S?)#0;$ov9W;p>4Z&Q#x^%JoHLV*zto0TGh)iai? z>Ofs^SX@f?{n*_%@03E}vn|OW--InoQ|7aemEZIz94*B~od-nWg#e=$yy5L~K3B|5 z<=`&ZzHM)`j;&Et4k{~qLFj$Mqx$7zpnBtMD?Bb9^H9wSsG2P{UW}mndw%ipoJaKr zpZ4h&J)|CvP_;oiIz)a;nSpm6kAplA4VH(zk!m{dvUPC?Ls@bRE< zA$30e(-q&`3oRQuHb|LddHFM%E^yXhol%{~Ld#XtbBo1HzS5Ak-17$={w|ZZg;X9m zpCan!)j?t8jT6DngRVKr_VBdT?|uEyT^15Xm~Dq8pr=t7x#B5Q=b11vm&;yBU-8!a z*Y$nRbX?mUGyny%QVj^k3oS|QksXbuKZE|w`PH+Qs10_lF3=6mh>kA006J)~30f!0 zW3PH-VdUlC{>ZmVQN2I;!_4oJZ^DSB>H3f`!m7hjgppu>ghx;q>5HKHM^zZv-lX76 z7=fRv(1H(K75g<}XILS|H=+LsIS)erbS8`xmkXb)s*3CmdmptM9!m+IJfRa5iOL_5 znJ8Z_#uwTlP$Y}o4h0k06S2hkSR-IyRpazF2o**;qV;3Q@0JZ*@N3XH!j411pmG)- zK>3I@`~p?G$hL$lB!Ca-KYScj7>VLS>iogqzP2Y?Hgs%|G9h7v#p{Gsn0y34!)&{zG+2w(8&4}5>-dw%hOMc)3Jw}qgE9NqxPvSE)OcI5468~)z+ zzo500Di7}l4b?yK7vbZcPoyIG;d}TUopbM810c627A-nx=-H%e{^;m#YSnz2zRDutlMCkhB^_7jU6lF7IDhC?m@+| zdWDKIVxg|gqPY603r>J#c(TW7FXnOGrEj+pm zNCt!jNGjToDSamxar7C4$3j!@LjCe2VtX^K@wVj`Y_hY^Nhqg2n5e8Hu;_{<%{07( zeX@WE?KMC2*s@>v!f)Q6g142nMZLSf@}3No`lp)+m@K5CJ-+alBQ zB|pz@MW9W`3OXQk>^CjfVh~^)7 z`ufF9s|U2gJ0|=)liof~9~CXNNEadzyZXzfBXX{jaG8>DefX`Qiex%&ORFrNISCn) zIn;>G3k9tPj`GodxB9WP!0H0t6PoM-Z!)2&A5%DfAsyp2Lmo0ST&79 z3vCV4^H(=l7aB$fHaf;@X9v3GyK8y}dJ>oF+b(U)Zw;?*^*pG^+Y{4sTO*0F_LbT0 z`j*X+o|U*;hV(>6Fh-8ntFa=CW$ z0Y~1(gps&P7xZ0k2|__QY$zKvlyFnmVD@fsQ|Nfjlae<)yl13E_we&ApZ*KC$3KKv z{1Fe$S=M&tG&svLrjFMz5JK!G

      9=j zk~lHg>SZvP4W5Qba#2?Z+_|g>+lT?3deVsOuNPH&hkOb;lmcx*sMd7PsM<8D`xewv zkmkJdHuY``N{t5I0Uh!Zz@uP5eggCILa31$;(*>fA-{%tmAa&s&#V2zDz&BjrvlQ5 zUjihO$aU8OGC8NVv4w++koTnOY4!xukO8IU2BI9~mr_NE;iC9i+UVeEjl6BMc{enC zV^^Z-3cC;k4G)0Nu*Hj|Q@*^_Z{A>$8x|LI0*oiyQ>wJgFLRFwqkxG6VN&$aEA|Af-~BD zj7ZuiOq=;uf8{^@en|=J=TqMd@(qUBFCR%8_6urwQ>P8<(vh^&ot4){YsR`}=V#}) zlG(MbhL*-F3-jFreU&4VBYjKx%=GG&hWVAue8M{b9{0^pb0qCoZ@d(+9KYhBNpX!{ znlm`&)3-e2b8(2<-El;xG&;`Uo7^WlpOk58m5}{jgr+LkvcnM)h-s%L`8A>Q8WE2! zk&gM`+|oqPiXd!hvbSiuUlEyrI6^)uMJgtB_K93W0;feruIRpbkpu!5CQccFiuRkK zT!W9Aw0T?-!)h!j-|e@=8Z5e1%wwF?>Fnqs1#Uy(YJFAYRM;(NNspWuZ=H|iO6&u) z#m@MJ|CrNIzw-@n`eZx=Fb!=8>UY~j5PuuxRLzMvXU(K1+KSC99czvKS6U`FvV9%Z zms?w!YudVNw_1l&S64e{veQ=zIVRpuefM9SvQ?DZN}FV1`K3^%kE9LC#F*yY8cB{J zy1!p`vxdp(ilqI*>OTrl_Gdgii=^G+!;4vvAQVE#D%A?rtsn z11n0;B58|#d9tiRObNS=WyO|Mh~2^1Yfi+5Ja#2ZD|cElXtv$E-XD~X?jyn$@ zjZk%u#zNu29I6qCSnOkI4nfUrRb*N_miI7vCC)YaJ47l(Jj`qm$I#$$B{~jL8Z&4e z@kBrfBU-l$Xh-yH9I_GF5X_v}EIH)iY>jY;;E3^?i&T}^Wf$;nm4BFvfB%R7eM#~0 z8~;y3kZ(2*mZr?o2g+yV8i@GFV%J$@z@3o+FQ`vWlUTW5B<;Ieyyp1pUYz{zPDrdg zi=@3%6b0p#7E-aZjk|IdN&8F;b@TOXLnqe{#y;*RmSMcXy=NOboo(neDHROH5k&Uh z-tY>oepp~T+t3Mi9zk~JMqoW+z|S^xIw;=u9qE7jd%<(XWxQ!Zk7eDh0p)1_7`2U5*JzKNTbri^!( zd{g3Pxsuo){LJFH`3LAQ`J1X*wcbCx!=z=Gaw+RpGcM~y*n3{^sFtCx+<&P1aVwNY zxVGyvKY#ZxU>Q2=;a$6rE(sm?{O?pGKXgm*(Iw{=G@KeE_%|%Bihgi@cCydxZSky=GKz_N+ zzMY*KSDi+SZ*2!7ywsTc$ZzDPZSruhm9c!AJeKAjIZXcFUQa`k!#hlpO|sOJ-foA< z_t*SkFuFhB;dwuL6OmDT<}k?@i$82O$BkB8bx|(hBUK-aM;8|c0~fb7JbF_XGmtzq zr%pr59Kv}RavJZs#isPcN+z5pf6f6JV(RK=Hepo59OEj+I#`ZErfHdT1gX0}vU$_E z+3=75(@M$NVEHy1EKObBVUnTG$O37{*$N)UX76>i@imPFmx_K3OpB_L?6Ip!y#_KVt;xw$f&M z_JvQq5KK**f|jO?cbH@fGPB=F4wHW_GA*$-=eQMtHXSSIfY7nuv^;Z|be(0>z`D-T zHg-v4zk#32lB{j)y4_!4KVqQOQ%Ybxh{L1{6OFF}o(N2GI7D_Ea8wX8R;DAgk31Lc zA5Iiyiwi$QIcvAIC#Ci>-BDBFlu6(Ls3u$`ky4r3n6Nq{S?UJO5S9RBLQGSXS$;!U1+)&3`d+>%^sW*ZN#8l}W5#?U|qJ8(i3`ksx2!LiBV#9U^)F+X0@GE^u|Uh3*v=owk>&Cjo=dnd9ZP5mt+ zT{W5N?&=5ZF!^s~Pkh%qOx}4L947zu|N7G(K`egL!|Tj@9Rv#xL)*IOEuZhM?(ev)wrm?j7m}4!5k*D^6uCaf-0&c2(&}b-jpu~&VCE3b4~eI zWR9288#D@TDW_JgYt_>(=`Fg{dgAEe0+`U-T$NMdymI=q7Qe3FY!6kh`~|(wqSEUs zx2)&&1bk3~-T^O>)8jBXs@7jppUlgpb5yNGJu#$j*Q~y14Bn|;ZQs!Q49X{FQgHZQntFA8UNEg+6Z%FY>V`Y#;spiXh)$m|ZJ>to;8I*@Rt#dfwD&>{@9D%f$4Rp48g4%=AX@Kw+w8Ak(@q z-nyC{8K}NCUt3#Qx4JM?-@TSzUQE?`2g~EW`C*hbFNo)4%OS+YhMajltmBU^7lRNr9XpD`}B(*`fB%8)}Rv&zKKx%VU#uDT@_ITToHLl ziKt%Fgr62+A-+ICQ@lnnBQm=nqS7h?3c(oA^uHz|f+ihx0%R5P+O6`i6^p8=HsWCU zunAfe6`E9K5TzHNCgD4t^g#}**Y1s`E9^oHwC7*Y_2ZBXEL}nCtX4QB6JhI|B`i{* zTf793gTB%2@|__jI8K7vkt*ZE^gvQ@tfUMICzfIH(058KM;_4aIzNA;P8T+hXQPaQ zIH4VWZ>S#_>a(0h7pix+_!s0<6>|%jY*jv!p37&Ziq92_6UEFBc^4Da&(5Wvy*89+ zU+vkdT+3{BTv{r0FRvuKlY>JI#e8+k^ia!WqGq;jX=`eLM?dwcR7n(Q`K3_cx6hT| z(RT#};xL)kII$*2q6=3QmUG!cE?-qBuBJEr4oC}g#mc$tS|(e}W((p>RkF~6E&QF4Dv+Ai_E#j*+^ zFnqz0I@snYFX`ch_Y2kQWNIx79u?J(fzNf!dib)3uOosLT#p=fU5|*{(Rv`(E!3iayxW;q?!8rwgQrCD;BvfAFW5ej~np zo0q834CFOpx-~MEg3)nNBP1`DVR!f!BZWpnEq&niBJX%wA^iMNO{(*P95+0C#lzP; ze8a=L9tMjZy8oPK!AwDKF)&g-pWQ||?wU3UqM+lvhfjOh=wZskSr2b`_>zZ&7UQ_> z;av~!d3esR^gr!kqlcG0yzb$Khc`TY$-`S7-u5uszmVXB&eOiVnz3Zj_S-m#=9A_V zfsu~l$Qf5}T>f#NhuOs^H5RwAAo%j|*1Bz)U(c#sx88d}IC(<9NA!P6j5!;i@3eXa z4~L&Ir~8}^uRN+@JmMY$@BE%B{IT{b9B_mZnVRedX6BlA`8-Q~ZL?1FAWK zO>+*f=BSmXpt`21eutU^J;km}^c2y|MB{emNvIFHW1K(iu{+-6dz4}u)VF@ z+o3){-;59oIs-|?s}D?o-~Ub%;P<ql7%p~Q~Y91T8VKnE2w`F z=@9U85|rIGV28Mdh>W<5a+3`v)|3-1hjXYCqMCzx3rY{GT?kNFy+^cv zPO9JH>W#}k?st0F;>*K+eq6uCd#|I4 zLwHc(*@87JM)Mf1V4Q+-8bQY`Iv@lg#vra>Ba487ISbb@m8st~e^YAj6FS+)2%|D; z#qb4V8O-M38}Nw16b5k!%UYI3CW1Phrw!|)IG3_ITfU8I199k4=dbykAN#qN=Sqng z|E&2x1mcH@8J4Ducj){ri5cpWpetHG)A}OSeB?iW=Q}Sb@0>K>BVrfe7@pGk>E@Qk z`lgoV+RBdh=IYAY){eT$rbI`wvL@M@tgdfptZAxi`HXJVA(yw`R@K38|Ia&gS~kma z4|@m9U;nkyDlAvO;^AFuFI^Hk?)l%TNPg&+;HOPGn@sOihfeex>`{r;Dh#`0$kB!{ z8O?^xg?nXMI{y~T-&q0Mb~B6imrZtjbhrzo08+ttAAJj25PW3tMMtB8*aHG^o3LZC zI;}ggrDKnz>I1p3{ntPE`npXXKB8ZqDYJZ=JeKAjjqcy^@;OP4&%U?(rmQN+CV5k5 zSZoiuEL1%=l}l$X*0)U0O|5oMCQ`K{GDR3|zq-DZzNRVF-LN&(+;_DnHQYTs+cTRV zoACx({nb5NS0|eLlS9obYc10qGwYqHRDElr*xWL_ap_9iVsCq~W2?4lW_6&hzu2<2 zzBZPwsUIHfNVn%U`r0pjNNw7GB_I8KL2D0e+d_niblH385}g+WSPeU>2!6}Yp4U9Q z7n)7rm~&o~7`)h+U{(%!_@d7@(ZisLAdmYMI#m%Ip=yJ4bd)^^V=XpKVKbE}tuJ&3 zBMxJ$5x+J+Dz^Emtb3Q#d)ERh>Pp?!AbaT{*$(#wcF`%Zt=&3jwMH?kejbyZ_Rj5E z`Za=kROYI_L$j=dlR@bfvBf;QL-(&MCVxtQ^VxXIKWmv0hmt=?0Cib{Dup94C z9axOcsI3E<7yY`kMYXK!98(L4=P<01!3I9<`sy2MVY}*x_M2g~X#QbWhOg_Zfc?jU zucH-L52M)kod1w~FOGmv2^to@?(;W1yy;=IeX}Z)(0STL&1$ugBijDBe&@d9h<QR9^*^QGIgQGk<`V*=JN9OUAB~lS5Z>SQT~m5ZSX(st zgd}i&piooXyUmphvruRK&1wOxGkSfTwxNHlJm5%%-FbA}Sp9gOPV3Kw{Dg8Qg%8-( z0cz^XyYLHXrJ>etw_f)A^-Lp}fs2(2cS#I1&u3xEdFBHb6 z3mZ#Yy|XP#J=)rCrIQiywM(;`MyYQr4b9-F`t^UhLB7GiIsJ$CDf$;5D`)>W$THaB z6FS3WIkeDIRhU>>Ud$Bp6H^Ow*_o=@+)}3OgSvlE-N8~iT8s*zV3upAq}{+kYev_< zr8#&<=LP*n3wBiUcvs~)?m1AFpuzs&RV)1ae)je6O+p@j%ERkE-!y;*Z~FZE8b4oG zsM;VWI&AjyaE;ecZ}$^R+u>fS5{b*H7c+Wd^m%dU=8UYoUnYD{?dmVa7k$>N9<9*1 z9%$S0yYACsNg3bzolaJ4{OnCG)DbaBN0JJ@%LK7UsCC3K#4Ng{4jjJST~ zJvE#)299T=xi<=a>p4B55#Jv z8|Kv5aK?nQZ_+il;~7XY-j)Xr8vYw@8$=HZ2El`P$wRvZ2aekgzo^UYs>UXplto=W zvE%I@6fUIF$v^n-_e9Hvjtx>KSzi8(rVE@kSZ7q{vCwkW^xR@Gldm+SJ+Zhr7;xl; zGR3)TdsAFdUC=>983Yt-x3wpwc0ZxBNqLX6-u_zLTpFOj%Wg%u9 zdvvjY&M$-!RQD`?qmx0Ik4+2$14x(+kOdggz z)a#bsSw1B24a*Yfi)dH)II1ub#f8-Q#V>#FkL-n(4ILY#Oh_1EvHB>?|Bj}d0%7E! z?cw!jzWPgt?lNxx^mV^7!WVq~XFvALz=JaY`i8fKpoJXX0LZdoj~})HP|M|idgq^L zEv41NyFo+sPy9vrxaSkL^c=nx{vDlj?^FXIoSs-t#L^Gt2}_n3-MA%1G}GV^)FjSA z51d5g5m-EeYGIK_Fti_{;U7^ zi^1srH4o4GQ5{}cq^)LP@nU4ub1i&Czt+i)?$fuxAANrtt&BOhxr5PVSqB}#M5p-T>SQQwufv7r6kg&HqqWhQq zH2D`E1}~#`vDF!a%YK^Nj!c(Ga@XfXJ0A2+%xcS7ME7k*IW%T=^`lKYrz4-zFlPcd zqi^&Nj#0MdQVhY(mWHhnuqt&i8qq(%k^+V8Le~B5xv}Uo?`Smh=nSiv1 zNsX2QVhE#+m5s*54qe4w^Fu?V>X1-(Rt3?#p37&7tNHA3e(~ay)g5JjUS+!VLf{EP#VnU$l*KQ+au${9R%#}&dHDgg z=e*7fD#HRKuft*8XwcsIrmlf`Zg5lRxa)u4^Ds=6cx9tXZ$zf$OX^RKTM=l}v4Rc= z9saiaInnm*XYUd>E%8utJ@TCTiEs|9f?1hT5_E&$OVwJn*zOnW4};Nm9CmTj>S@$7 zc*lf)L(<#F>7$~h7U@Fc^Zq!p_e<$zP#t3M<|ZT(s^c%=1)baqhlw=o_Lzn;5=0kz zh!o4XhG%8MNBiCCckcPlgd9m4$(l*-cv`m%2o)!I6DS666v8+`i)jUD1{gk$G8ZZT z?|*e~6kt=|AZ2_+cTfP+hiPI|cy~y@+{9{ewz?{vnVwi(ELN>0tH{XZ=e9D>O)btT zO5U}(^uVDQ?nBbm$&BEH!d}=x6ck2n(JGJ>hsI#kp~sg zeYt)sx6r$=nQUqA=&SBrS*Xu$wItSR=4ux@YSRtP>)D>B)l|noOQP#?rn|5_(y}l! zUfrG_xs;o)uWlQ9#3Q=TPX5hrA{Nhic%9`+9oW8vp;_X;<@4RuUDETeDc7h08jQ~f zC$x=HpA`xXlcQ$?!n7o761);tRc=;Ov`Ui>F_Ih>hpS}Kp45N40|GWD>-S63HO)?I>qOt{9 z&?j^b$toXZ9#0ul%Mew2bYF)eI&J7Fy-H#1#WNd3O6pXyU#(r!)oz*f?fuk)MRZ?L zO`Rf1go`CI$cCPmR!)an)T36TV#F!0Re@x2s2x*VSCyL4m9@Z!U|w%GC7bQu01}gG zL9W1CLG*Gw4Vu-`c72UuwZ2)Uh4g1K3UVZo6}cY&~^CBhTvVZ>bEBKQA)W3!F^qUYjn5Xe_3zbqWfnQ zrng%4=9Rvrr_HO@YW3!j`h#%3Io(NoMhCOOXoOurR9sRIW9s12Zi#~Nh52!mbQy_^ z=Kp{uA}g-n`EUNKO-bN)KA8J-khXG<8tZUDtv^n9URVUTk_bEC1a*4d3F~1P3mj( z(x1UGpT6ax)fK8X$cnZP>613He^n{d*f^;$9MK(Dx&@(n$U&uu%~cVKl!(Bb2nlla zfUXs^SXCn;(Jv%$O~?bcz7hQm3f-f4Xjb05N^b=BXGK(YIte~(f)?#J`@RO>Z6t;m z>sT1z(uI=9NsKP;JF6eg!XH))hJw{qw|^L925m6rEv#ik`!%Jp_=HaM#H@+1`parB z^%G#u#aTecg@lo3Pr^fh=d+3o@q*CQorp76dbX~6J=4}UUfYmaTphboH{7(ID`e}p zHmaMi=BK7N)2qd+19KBhxNqkBOQKB6FNHEMexSTjwxFO)jBox}XBcJfaONrz0e)ht zIJY)e+^o!JmUH=Hp(>r5T3wQ;Td2yctY-3?;SlgmHHo^qq>qUfBrHH0iR!x0m0F7s z&z0Jm@Rf#8qApyfE_|gXTtQ9vId$RMYG{sPtXkSWI3!z$2_NzWb+HCIMIH}UZr(scbJRgB$K7GqW zch~+>r>V#}cUjb3Y zU5R@id|KnmSns%CZ&4I!Bqy4GV8yDp-Mym$_hFrH`hj;@ESCLzUJW_ z4;haf7JATFl!Tuj&wFSr%Cb*C4RX^F7rA`HU%%nu%O1Y!;hP>>1an*WJMY*3qWv?g zXC-u=cCVItIz>mc{c+!&`(Uk)>eT{1r0$HEGdF|L9~IuV=f}NQT>f$2_j4M50~)j8 zP;i84tJG<6t9!&+(4X_l>(K8-;k%t7+E9w`EJH}QgGNB#`K-f5K@XQbOeFN}az~4X zzFq#X5z)6x;%#`)sOa0J4jLJKyTrkxqi>fvYJ~Ld8W=Tj9k|R_NJHj$5cILpxbM)h zouenE(Q_6lU1;cS$2*Uj=vHcBF(ec0>c5ow6p;#nh=oG@3Wz#I1Pm4m5w4ui151E- z9yoJZmK8Cr!72bVS<*z?j?yKopQTA>qkwSdmJW%!;Y2omAqb*l#7K@60Sw>Z;?UK@ z#i0sFu*hquzYJF4-75d+)yw{;XP^8;DI1AzePcEdE6qm2(vV-dLQ(-zU2dN?!;b{x@Z{2@Iz7%L(}XJRF~tvI0$%~Wa84cD#G zS5BW;`IMObY#`d3Vt_^Fw3Z07Vs|&SYzI4nK;Vw(c=5w*7dd#;#L&QsM6Z}ahofWG z!xufg=^@&Fj#oW=!^5{c3}i4}KaVV?BjI7R-)6a{^Gpn-m$qsByG;yzUGI)fo~f}= za3Nw^8n$R>x;~O_+K~n;h3^L!?M&~yAI2_x9fj1+^v?Fc$nCt|z~|dF|Ksoi^MEOF zR5e9hy>a=+ecow_1irU;!WSrg7~Zj~(R77fh=JCxM-?|<>Dkf;2!jvn&o3+*p{*{G zHLF0*pN2IX{PpkwfD$=d!}t{<7r%)WAk0ZHI3U6{LJIXGxDfdXK_o4KgQv3^g{>o| z5ST8r@%+RtapR0%-pMaBJf3cQPv9}f@7p?!O= zo~&z5X zESRt<0+G1rqG%YfeTu7}dL-3Z2@KR&$Xa0Gn%4B$Mv@(`&lgHBBBgebn_3}GO4)1tJHpx;?db=I(o__OA zFuFhH;dwuL6OmDjkqO6(k$jiC{XhD(PIh#kK9_;$`)|(%%pfqifT_dE4i6uPmC_cJbJ@PwSc<$ z#oWWxV(R|L=8MM7hQD-srsQm}e47oHrmi3TQ{^v+L1&{V63c9D_L z$wB%chdtl!jixK?LJYL$m*QYUV`f)Brc@t9$eGdNVG6l`hs3(bg|5R<4t~~gwNACo zc9)PV?trwALg8-hw)R;4aKMlqJXqbv@>oW>jV7FBl_NrsILANZcZ(YyCc1170gqfy z-&)ndvSv80n>;Qsw*yT5aP3f|Ux8aMaCFRujoHU%wB_j<=WrXVx>6FTFj;G^bv z_iSWZzU1fGtq8Q~SV0Gb4u9MIoapC9$PfDKkkfM8OXSS)j?S&%-yVm}ful}$f&oKe z@ppx?LHiIz-7myPRc_>-O?)V<nQYEZwx`Bd@;$x1wUvFHsfn$n#%z7pwUPPe#Qu(V%N^7GovC!^QB2*8IZ8>S$e4-B5pGxMwCa-B;+!7gs0y5+hxO z`RPk*)t5UjO%_(#79MfOyL(^yE5DCe{GUC%j$%;9nd99xAt9X4+-{QWynq80W+g*% zJ)4jTCk}S2a_d^xJ#ZJ;&S!-t+GTS;E+fpm9JhM)2XE3BY@9P8N3SIzmaLFYm#ptc zWY&be{ey74Tb6m$v<%1Cpa+M$$-or1QLSZfOg1^m>zU1J_m(^W>g0HLMXq{j8DAB3 z$CTb8ulHTo)j3@+D7QyzPuP!d3c0SThJxCASuI}H+i$79KIJ6!wvDRm>Zxw@`)ulM=4BYPp|_-G5YvWqJ)t{#g6}>Zyla^O?6AtgS%(WMa2&@wNHh`c z5Z2jg0JRd)pe#ZT@$DQ7f%X|O9!EH~u}2bcF20EPaV!M;J0kYO7QlAkyAKQEbly(+ zg(3jO70e2TJg_jxFGRdU)_}DMAFvQ-wEP&3cPC8C`BoqMKOaw+3Nb9PeZ28c2l)oW z?3#DHgI$BV-qdOAT4~3-hO3FhwZYA)g>?6D{c@^tBA;&_=^Aax4~=)XrDw%5C9>mn z(~0W7gm=6hHj)sZmBhg)w!3PxUa+F#^eS_Uz4Azj&z#15v+ET>mW?G_hgPGx6b!WrILepAdq^YJYQM+*YQsekg zvT=Q;IoJv6cb=~=i83v}6w3Vex$-+2Z=g(kOVS|;Hxkvh3d6!eE?-qBuBJEr&N~Zp z#mc$tnmp}t`OT_awo?0@rYkcW%X9gOqQd5f{q9=FlZiwkSy`Q|Nz|KPT#%Vel*p{E zE|pp8&Sc3uOFpQ+M4gG6QkhL9GLvW((p)hx%4C^me~Zj6 zp{rt9h2)2<(3W#N!@z#C?1lGBa@5JxS{6kA$ziC&prMSLy2c{h4Q>h@V_p$z7GP%a z#VuUA!J3$y&6i;8>3vVa5|cgs zikiB(DeUY?!p>xM1qn1ORD#BPL&RiG{ftA*TyQF*OjoU04dk&1ecUnbm-^r5G z!R~Y#a`fK&)roz_!RmBq?O=7fWw-sG?o@jRsS~7muy(RR^ug|Q3v>s0I&X5YI{AX7 z?tD@Rzs*bFtSzyLa<|6FlFnktel$A1Z5~GR54^tQ9T+P#kv^)Kbly*>8y>#m;cFhg z;o)5mgGCaRJLg%sC~KGU`EPoy)LjqDyu;yn5BGCmG{?o4{Qb8)yzQYmF5dI$bKWxG zX%8DcyzJq14>vr#;o(aj-tzFahtd9p1SfQ!cFR*+AB?s?ZrpGmpXgDsEW}LXlNyWL zSddVihj%_SXT`%f9$FcKVwt9~LgE2;a!O-1(aOXmI|4|(aUFpL*6}nQyH9d1E6jIRfcHxoJVln)7y>A>oj>~^g zc=}Nj`AaQGAH-o3GcL5fZa-Uuc^oSd&k^+zyb;gc0x|p{Vm%sW7ZYbn_tq$#-ZlPH zniEgxWJ%eXZ{dpR>cZ&Dw8<8ImS;L!>Wpf{o*PIBmZNvupPb3f)zwbEKUujM-1a|z z=|7ZIbA0Z@eL=q2@>rTOnfH}nmq?1515WV^I!!aPkD4RctmW`(j#_C7s%x4o;*V2v zpr_cCiJl^wnP}Y3JPGwdx8m8jIo%+Dz#eeA42A}iL z95wIw>jv-nbjrsSq8^TN2k!rmqWc$hL-0+-5I;Ee0a`~4+p45xK6&*4$POXaZQvA* zp|j1LZVT}H-)RE;es|&=QtIjNbaB^q*CuK)N7Ny5!{^`d(9~n*5c#Ihzw2Qjlc^qa zh-~y?^komDMjtnP{!1R-^6<8Y`-$Vxc`&PICv={PyXpiT9-Z8W(f+dQ(R|W;f}@Jp z|59bAbZ*aDd^@(qUE&85A*Djb48#vx3Y3pgA++&+iE*(YsDFvJQz6AMMkYiJ-dO^} znC)kn5H+DZ#ATG5*jKLUSG{9pHo*zD<>5A~h62I-ejw%k}*@X!Uo30Uw2GIvY zc(-u{f(U{OLJQt5nBHK=>%3O*o#9SgMXlY|o|M}9gwA?h$6y97hXAE)Foi#i6Squ6 zV$~Dl9+pNBf^a9zC=cgT7eJwW8`TDy=0}~s=2P~!w*{V?{JyQzNc_n6{bUlu6caNn z&3)x%-|;@6-^;*a-r{acJ( z|AvQmX)gy|5<2er->FD`=$7DTbo`#Imt6Ge+i7cuNSyP;juz6b?AfG9Lv8#%{RXFk88c9lf3NH+C^>PZz)492+g7Fu_IKJlvd58}&QY z3HSty2No1jr|^7m33XE%Wr$yG3EmRXuhf|PlUKh|YX)50Xk{$l=8vVhM?Rpx??v>A zUvi`Sv+pgxDZ>h~;mB_43`_1Ir>3gsrgG`b#rn18$?4jqd_%gcePd>!xhc1>GPbx- zC{E?F{k?tjy;JQAYq`drt)6~w(^VK)t(k4iw>1r3u5C_?PN&yqyOK@GzW&~q4x;d|&3 zofiaH5Id?AZeBaD`B`)?G@HO$=jb>czx0Kt{vEUOmpy#Z=bQ9l(4>&Z{UV(!y=(IB zqAE}8xxx2|k;3Dg@xp=C*_)(UBM@)SCG`@)w7Xc$m7rna>pp+O z!Nfw{^IJ5%Rlb(KCZTYx6Zx*s~}HSXiRSE ze@ee|dJke(BQv^VZ*KVX*$*c`t&M@=b<={p{FJPD(C4CV2M!{?lK zLF-S#Zg637x_4@6eJhb`S)T2@+S^~9Xla=5%Vrm6u3hbEna+(Q+VaD-D~yPrXkV%~ zN_|^t<8=So(C6#OH`xBmU%yY$zxY`B7epQ)%TS3==nRwP&{|JbVPa`{F;mP>OfAf1 zXR2m%OPR6{>i$7>#*!?pP&ib`Oczv%K`%C1GrImQ&A~f5FX%Ulu%nX4yDHCd&w;W; zx&I-+t5*2;{V(5s?;k-P|HQ-VKHrpp1}!?;eWjnTE>vxh6Gb=sImN~YvES||;?sqD zsY-+@r(VqHiP7i9p_?OQHV|e%bYXQmPO1526P>!;%r=mmnUj6SL4ltO5iX%*I(^ z#?+hb@<7dy0mLW^3vBJS_E`O}gp@`-ArvU9}^9wPBzMRh$b5l9E z3mnPzM(gOAqjFGL*$YDN8y?j!9|P4JXItTM@mL5agUw&{>y%}`w-eRh^ZDmI$~S21 zLofP#RS_JaYJ+rii2RsxgZ>onb-4A&y-9;(5+;^CLm+13nbzef~X_q9D{(YkDkLy?N z({MhvB(XONe(O2ktX;s`X&1ujFDtXcF2q24ucM-1_+3yPu9)bMh|>gW#LON88_aw_ zj0Bm%;2Iwv?nc*5)G@B0t+IAods1re6FSjw<8F#8DO@%+FejY;ny2D?N-dB9ki9b< z;vSGSTsufSe1Hlb1TLh`%v)=FqGdzJ1}T#)FMmeU17Zn2ojR~piu zSX>+oIPyZ7cHELLI~$M|)kS%AP#Af$k<`wEt~tr}@U)87^No8^GV3aXlnDtVjF7_; z(9Ea3OX5sZV}>Pqb|4*dS#>!U&wkQJDW7 bX!#TfBL{5{uYci3yZ-WCl+3!yAZ7l4h@sru literal 0 HcmV?d00001 diff --git a/Covance_UCO3001/browser_profile_1/BrowserMetrics-spare.pma b/Covance_UCO3001/browser_profile_1/BrowserMetrics-spare.pma new file mode 100644 index 0000000000000000000000000000000000000000..98fc2c0bd7fa41623709dbf737993f8b9e26311d GIT binary patch literal 4194304 zcmeIufdBvi0K=g9Qy=7oP+`D;0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj G_#PMozyJXN literal 0 HcmV?d00001 diff --git a/Covance_UCO3001/browser_profile_1/BrowserMetrics/BrowserMetrics-6A26A16D-FE0.pma b/Covance_UCO3001/browser_profile_1/BrowserMetrics/BrowserMetrics-6A26A16D-FE0.pma new file mode 100644 index 0000000000000000000000000000000000000000..0d5e6dace927c55878453da4f119ccb6e1153f2d GIT binary patch literal 4194304 zcmeFa33yY**FSz+D3nF0ELudQAjl#OWiO!8(1I;esFbp}AZe4ffi?+Ax`9GPQCv{m zLH%mo5Em48P!tqJ6ctn=idNNaL6Yfx%8Kh)7ES}PD{e?IKk1hnebCU?(1td!xL__ z-&+-M`Ey-Czq=@)Y0JQ+@b=T4Kkm>Y+QFlrPS8Nm0ni0Y<}QV&omq3uu+~?$?4sW) z?u)~f`E-xb73A7&c`kpz9SFKSL3>%5x5yFn`fXzz{<4~EaJ?mdM|r@e;;Kg?gzMby z->&2INM<~Up1CO~0n`lC9Fz!Z0cr_q1!@gC2Gj=B7DReE7Ss;Z9@GKU5p*2rcu+E^ z6X*ociJ+4}DWLA49-vb|y+M6Jsh~8_Aka|IaL{R>3{Vy*8#Er22Py!a1G)f2`aFF2 z@B(<+Vi4Z<^=?pf zj>jFGdb&N{#<1PD@<(#cf-fwd*)w@DN*?ZP?I3 z18qZ7hYn74x++~|$*VvAa$B?R2`*1+L4M!lmMy2cJx-LxlnImDwH%O!2m^+v4IVsj ze#>Un=|e9VIyh<5-*L&cwR=9j_i)$lowD;%&KWo;EoHK|%H>a)>h;eK1RX)Q*VDU6 zT5X5)x>loGCL)thK!F{hbSUZEsrTbdBlv4+b;WTI(}dO%+x13escV{QTUzEX8$i8 zYnNQ~dY(2bk%Xlq$7|!nb1jS04#d6Et~MU}kuGj=ymozjk70v`IEr1x&eQ>g!-l60 z9x{AzYT>Z-qSV2Kg9?WZA6A?;bbxbZ{KrX;$FGcYo;3WOJGSJVKJ2qq^Iuu4^_{wxhJ~lXb#1FGl7xbOq@0CuiceNP*NFj`q>b5CPrr#R~WVtHcMJ|d)?ZX7Gi3#M0KUmiJ2JxvbmAkTCj>;N} z-{AT5c%4r8^p_yZAwoyUcsdCQ``Yrhs%9b1132`;c>}IIlq@ejd8D`&^-X=n1aC0E##2PaP-}`pNbNh7!^w`qGyUEQ-vu(1 z{}t_WfyZ0rL5#@vmpc3|XTL#02L9E+zZ&>g1OIB^Uk&^}qk*M( z61Hd5!N5ZH2|I{f3>C;ubg|ld-*W>ZFG(C&GwA29m#ArvSDuF z%qt3NS}78ZWY-{j5!r^w7DTomnwQZ$h3q@0f-oHwHl301GeBcNXMyrSY|EL6-}FqF z=r1tZaT3X(1V_(JbDEU(@xp%Ay94IP8{Yky!k#~N)YjQg#(C*CInobZRlZ>3BBx9? zOnHi2fj~Ycw`H!N*JGRPE_Y4FJk{k05)`c-q&_cUpl2of7tL#p&)Wz84+NbKqUSpg zGzWAQ=poQMpm=~g9kd9v8oB2uzLlnxz~J^U zl=~=jaXXA@_oqPDm{|24fO!?>h0Vul+IASks-c0+P~MLFHSO0oHSO8IU~?N9r(Jbn zoc7y0uqd7$FZ4$`1{9OMYz@)|oKX1!6k!Wo3jVr5sn^r}l^67D^LEPAE9o~mx}UBp zU$Aj$OwX7jx{GVV1~WWL13gpPP)o=zNtl=E_mN$-7K%6Gh1!JOG7tQBUfN2gMlFBY zXUXk{uY8eylViLpUxsSh6o=m}3@riMm};0-oi1lS3{AOSr^`0l_K?`V1BNWc#3Ld z3>5hgo@vQw2k}4QY0RBBq2({F7bOuy;UpeSJ73{*cqBX$icP?B1>~J6@JKIpE55q6 z8aRw{NQO~wi7>Rq!nypCvA4Z-*`l{(>Rf&`?N)`);Zbmob-^Sy*5NLz@H1LXOF=}& z+Z%X{@(6FW9!~kZ8R5jUgUILgf;#XA%qw^gEbaaCp74BG`FAFTlOvzjF_#NE4R``otlWTm`@WyHnxEwCSy<84!(JoSZ!T7lCmETFb(XQp!O1@r-txouySA3ie{(POt)wGzJ#@bOFMQ4OyNUz0ars_PK9+@CwtQD` zileN;b(X6}+?0YV=X(kgpLF2}}tmIwoFtn$!m`?dDH zx0gJC_`=C@3_a+4ByDnr=Oa6DW~syDag}MIa!T!0Z^$*KOKH}ExPGlfIPvTt^7;9U z^?&^vLnln!(X)ZxRX(B%XTX)`Epr!&#|!E0d9H$hY?e&*x*m%VMtvqB1scCE20y!Ln-oeg?y7d4 zM) zXZ-oc|M~R6SNS<)`H9n1K8NSKiYm}J)!5Fg^4S9pkIjxETZvJj)0XR?)p%Zc*CQDF zsl;xv@wA(9drJSmrqM7;IL4#$IXnuUJPcCZRG-A`PQhgyH!Zb*E9ZnkOJ`{N+Ob^5 zrSdr(3wSs$6G3Uw7vZO;!2Kk15|H<@0^D_z`-33-TRvmM94eo~W8)Z@ zE`aC}jQP0P0-gmoR}Xym=09I#d5lNpb9h8NdXM3FG!vBP)1+L7edyFpJ z`pEvkJ{Q&udlq#EWR$B22sT-9WvqI5R{PiHxHl0*SZLf%V|Ho>s1hcFF#Qqx7Af1) zK*K@Qew_`P38KdEa!?)U1<+@p)_9;ZKyyJaf;yt{sR8W=%}2#Q1r`4X&_@ZH_8SHo zV*ud27Mk`5CWoJ5;xIo6HW}FWb6{h82)#yq3iez=k35f93>n=2a~hXwgI}^1ytS%l^dtOn;3pXoLPSkt-6v!?n#Ue+T4K{<3`ft@gW5b)Wmk zC|Bvns(j|NT=pZ$4|Qs|$yg2(sglC6{EX3U#aLvfP1AllxW2`KXPRj*jrgfgi!&cQ z=kt;BURujR-8#&C$qip~y|cWSyf`O&aT$;P9v0|=@HT6VOy#{R@jyq~?x5O>wukIO zsQO}kiP|4jf3d~{GppD`odUlHh?@KUpdlbE0g1LK7e3i6oFHnC7J_aBtpu$H?F9V} z>I8flpfb=MpzWY!WKbdK8PM^_s70W7v`tGv1JOQx3tERZ>LFC<=MpvTM*yA#uwS6D zd<2cZ?SwQr$)QP5I*?d4Y5lHy}DDhJ$t z)x=F}%zt4lKu2By z>p+b@`$f31ye18ZE&r|OTF(1mTiF6C7v#u~!PWPgKoz-zK|F55Ty>L7xIV?C&R4yQ#NG1n(EfZgYVsZT7k z*`1X%hIXPM4`S;wtQ4{v&vMbfKuea&5*P}w;v*~udV)s1VM-G--+o%Y{M3$TKKTdZ zVZ17z!}W2PJue4lt6T?dCJv0n_#UH;i3E|?{i+cmq&FQ$26&Wyr1CT8z^!{*&rRt~ zVdTgsJ2~?O({Q2n5z)hhUNw+`weVPO?I3f0v28g6{OuDzok=m`Uta#?`jjh{%jcH& zQ#;Rmy2t1W&dN2sUozfXGRcK*uFNKLN7FKJGs%y%zCm?{%M6-}Q2)>E8`ZrOJwDAp z>VT8yA5-2;!AiAx-D%BWi8m8`3hNF!8I%nE=}*>mO@p=f`U$gAgZr;seNcZubUmUS zXFmQlIXs76Cxux*fUFa)4%ef7E^4>Y6q@Y4Xc9#oZ3iDsW7PL!$S8m&Q;aiV62@## z(^5d)K=jO{H)FX^844zx9Yl{!?HWBt2HMy^r)-#mpW4W}QMY|C;L&n)dBV|st#LQ= zb#}<3@}|GUl<)G>?tK{TU_Eq{k?A(v)7K-06+O||kMf=LLb^cLAfB-&d^9rx`xN*D z_9oEFpm>0s4B7yi5RdpMP=`U82^cG*K&2qT1SI%=TTT10gQitMasAN8+>8EY{Tc8l zVO~*&Jrvh!+O~D*n+~9zJu^-#d=%rF^my&;z46+zolUgP?Gm)7S2fe#+mfhlzo}KD z{X!k|OnS3}$mgkqS`gRolwq;u`wl(0$zS#3&#HXp8$^qrQRIsy!W3OT)z1vb=lVJ0tXs#E4vg*I z8ibQ${X`mP_TKv28BJGQcmlFhI7)-Y`^?wbArG7V1L!WR$FJUe zP41F+iaQkGKKIpihPqIO!;pC$EL3PZcja- zcMr;Ua^zG0!+gOsTo{L5PD2`~#XYS5^bs;bwC5ku)p4k-eLUVHlaA#wUuTEBh;j{2 zZq)w<3-V8TwpsQY7vA$d3y?VCG?mZcw6VqEchV>+3tKg6^#A29C0imM5SHcG~hh9hBZ&A7_bifLFV9P2^l zb9iHVP>QR`ZoJe2j-fC0m~qX9E|{rH$2e3zhc||!vEphhr^y*|Uc`E#z6--Y(|XO$ z%Z~Zsqlf$XBo0|lsXt*p<6!^HyaG&o{mv@9Nl0_@GM8V>KWSrUcs6ccH(Hqy8^;vS z(2pnGyL60-gZV6<{d{a_$_aSOgm7C9R;z+8^z$etWG9&D$DTrLehIIu8TFDz3V~z2 zsP?RsoMW}8KWzK@sO4`DJ52{f^DoRB4l`dQV7NrLXXU^`Bb~8*+YA6r!PepMEhfLJ zy7>)#I;W4;Vd(7}#*I4PbTj@j*#~HgEiI21_?)n?*$s=TX$|7tT8fQvmCO!qWtiS0`%PwV22C!sPh$6Ey96ObXw|Tx%ps-6FrHU3Q;U`TmkChZJl9EUJD{g_+lxcA_aD#Ie#rG{ z>nGicGejL)uc`DvzRXoA+C+9MzCPrzIm zll0GEH0p#ze!_gZEfP5!iR?onx8`cvgR{~0VsbuetEOGiHBS2hyEo?biPye99Iv^M znI~^b&^E^>YGb>!(ypD|R{PZ1QG582E?SkXkM?x;;o68X6ScTM%Qey~>)%)}lg9!a zTx0rA!|cV~MfMn~D<+b;j z(8>1t7bx_;x10R@Le|Pf0u=rypX`jxr+bX9L3<#~Vpwm)O|i-$ijdeNMP-p}kJKKJ ztp`O(>jWY@7UdV&duZrK z1wvkgkV**I2_eU$&=;faXw?mS_xotttFR?*%Ye-c4bT!7>H}(fmpkze(yOo~9fU0| zJx(KiaXDNJxvW=T4*r3&gZ4mf%3aNcUYA1O+bhqgr?B`NdtdOw_Z$CMP5;12{ljNuYy=S|C4RaJ&rdryXlA z!=Z~Rw4+U-kG;pE-9lr07)C_eBi5(4rahgCwVA=V4|6qlCUlNWD42@(ii)sjb`Er2 zt7$i*q1d?sdGS2nE7}2@-EWYcj5#_Mu(!{G&Tfy>j{6`^Yj=FS*1{35jd&_vYtylb z)@@-EE&EUtZTVGAHGjVZZSm&`+V@X16Z&I4FNI22&)PVtH_|h*TIdjuY8u}?>sg+* z{7~_%*T5%7ejKjM7fi!taw&G-IP<*TGFt(5Hq&6r;jfwMnC+_Y@g_qX_UXGyZ~}$L zX&Q$w1|Gt}cnAyB9@>wSHzZzLb?yBx?Am$LvrwaO{c)xChxs}? zKx05-L1%){G-%Xppa_Zg{g8!PE@%R1A}9}prbwFv$_Gsb6@aFIQ2oSO?R5C(fX)S- z2Ra`#14M1)OppUq2r2?mnV>pltWS9)5RPzCc~I@I84&dG@>YG1X?3XOf11*ra!rED zFY_fge9g_XKs`5FU>J$3T2IrlHU&j%Dmat;Q~<=#qKlQ+)DjnBQ!g8WXozu&U)q0!XT3CHqPK8G9R7vzr)OHRQJoFDrk zm-C}lubPuc2gdLuG{zi$QODYjYIvF(BfR==ZdW%ecrY|=@c#1CmruXFS621{ z6%X@6K=dCfo-rP=*9-;}TYiPl=k*82)9Ht%e95NH70wPKIZhB&iUS~i5BagXuCuRg zd;a~hoXPuW9g_LD)#Mn5F5l~iKJ=-PxX;+XY_lN0f6lDl{fEDPzp4l3n}p+^M&;Y= zl~^C5>L;Qs!mgF;$;!@DRnEd>#{-C7A8+%7eJV1EJWz^K3aX;LoZ zjMTr{zngr+ieDeDMO5LM>Q|Mo2lM$1a)5wA1dcD9je$(iRUPE_8gy>H!{aRUR#TIN zB3B1+gnK|iHyYN8`c8O>$nkIfUvi^gkL2FyDTQ&wy6^wh@TGV#ZV!BzU{HH!2a%5H zH;o01@4uv0ezmRgjg6I@2jo+K!F>E{a+zN5Y_|(mV~mFAEu0z*E(1K%bUDX(f^NTy zhQMB`g649(hbB94jEC$T)J`XYf6wNe1r#>*%$vrx++DSZev^~9@V=|Um!X)OMZ^;V zKuD6YUZOhm2+k)ER2xw(JkexCa`m|sHg2_)fnJ5UGE@t_kxT|nJH zJwY@-?GK{4C(SW4L73Ky`5+B`W`n9hmxHLzKLpwU+5w_Q`dBDn5D2Dl?NZQFpuM2J z$V@Njc@Ru7S~ZCDNn>+FGqoSJG{JsjNk9|2lR+_@VR`Z(4-fRaYbr>@4RB)=0EoN_R2fMxKuueN5*Ath_fo> z8Xzq54yUQ83^a`^>VS{*!1!oRNO^DEUwKk~uZ@rV^d&6f($W1iu3)~-4tWjdYvK)F z7uI8FNz#;W=`aXTx-6f5Ba2P-ckiKdi#PoJ$`X=Gj(n=W%oj|bKm&B2Io?9W%ictUvWAoAOQ+JdHm zUp1|j13$Gx?H;;x?Y8^>lSu!-(S3=yGG8zamprW4(hGms4T+Pku`w;zUF7$YjRXt0 zMYJtg-i)cTrsl9?dg113!-sF2;0`FxTqgv`(0<&!X($QJ52?j(;B* zp72+d^Q#8!Jo6F7I(Y3af+if{B(y4DuyIl4 z>#xEw4BG&GXP~jan>ka)j;4qB!um~9n|=Eh%V8WUpTijkMwNKMGlo1j8=CgeERUArr4dJLo z1nzHp>wQc#eYAe@*emA$*0+S^us&2ihpRZ0@@gs9WuIU>xT1Y3}dS^<0johs&S*;FJpn{ydk{=loFl9InbYmrHXyu|biq zj@z>z!(NfI?|7^#`}=V_no0>YPonW3^I0zYjoRJwD=-|ywg{R`!qtK}A2Ldb6CUrW z`yrBRnrYiVT>siJA1pd+*#@bBS-78YFkd8KxQKmm`YBm9aST~5Eh(3{v^EKTctG&fHM z(Y(Ans5dALG#r!#!m@!j6XXX`dviDFMbK9unt#(K&xN2ZpzfH2T>)y^1p6jHSt#G_ z6R;ny8P=bhBYq<0{Q!^z0Mh`VEdb;IKvw{G^hCS^1prF{;4}a@4*-S$z=;45n5k)x z0YDJ|^ap^CHozA0rKYV(iqj@!#cB6l9H-s#I=)ZTEnb_4PvP`v0^v6`(E_8JYELF5 zXa^ITX?OQ&u2o)|sC|*rQk&eWwYGRt8?ANXvD)()9kkgUleJs!IT7cEb=RB=dTZzQ zPSZwa4cGd0%F=HCBTw6K)=X{bLcdmU>SFEFy?1FhVknq@@C)tk?4-C3uVu#NH@`Tp z-LBW-MpmT6zwNs`KK|>tCR84{+yHi{Ue?DbH;c<*+j!-@P9JPMum0R~D7Ucx4@C8n z`GRSl&;NuJIwy4^}q|Jkfo}Gsq`$>p+Bq z`GRSak+OObH>(Mmid#{=P2eX1b?qq#14(1ymh@WO0W2$j18NEc? zKqhI2zPvs>ysXW&=bravF*+ zwc~6@CONG@Ng!%R={MD3R4q}5>Hl`1L=f5GP~F6D`XAL!Lp2n9^67t6QNg2hAxivD zzyG%#$&5sd>3-+3*Wy zmxsnGv?N4h6Ftsi_>5;-l}w-U^g>u~P#ti7n6mZ!{Rr=t^~9jQS9YEMFad$<45D!( z^99pz;XQb^$$m%CY_d?gid}x3BIGK-=1OtYiMV?Wu7u;CtV{Adl-53|t)X^?#!l@) zG#8>hna6>s-=KL>ClIY$(lbzhLGz@OKwUv8pl%@QJ5C1m0QCf&0wTTOk;S~xIL=%O zs{^UU4kBOGUq%furRMq)PRl4z^~ZcfGdT&EAyX`*Pem(hz8HIl(^vzyl^ zRs#>E&vP z_#A8KeMw`xoPMDh4~=1I>||VzfAG3<@4eAq+Em5E{6_Ii_R6E58Ua#`h}=J{1`f&_ z)=Q*(T6gcTD-IX-=&RyjeghoxTvUmHwzOBtJTaD!jEiE+&3xVc;?{|8ou|rWzAD#z zPT6>D@Xd6Hui)DBQ?K-W00Z@iweVRF8!X^?`I<9cyl7#`LY6CW#c3*^!yCn;16XO0 zUpimL;(T!8U%Kr8i1&T&oioFK#nQeEUzBGmMJivWg!ePtF6`mgPba6vytMG zV?C*S8LHx>flNM(EAIW1qQkz3|6ytvJdp`a7#J|hikCL&a zt%a^CpTo`hh<78h-6f^8!2`S2gF;#I&N_Ikr?gr#4z;~WT6L`U#m}$a(qs2GKB{x% z$ft1^^99pznc%2&mxvY*&7Tvm*yCt9`6+CCG8rdlf?MRJ7sn_7pLfCG9)5$GO!>I_ zVwo`OsrHAVqP%UZ#rt&QHl^hO-~BJ1_tN}3y>0i>U<;1%F<)}S*CWCg1{-< z{$h<6X%5MAeu75hJsQu^-n0zRR1gir>p(j}r=UR4VeOsq03U*OqfnfN3`s^px5EIJ zfI;TH7+8LVL8K!E?-`wn{b(ccUSb}`ljV39^9Jk@+l==W+Qw|WHfN-r7q{fgg(@!Q zA04i7c<&*<$nW+ASz$(82Q1*a?BS0ttA1wX0W`0|5kC5!2=jGz$g@_?=;TmwrmB4N z53%b&T+WtV9$R1I_w`%*cHyYDDlX=S0O>!h;Syhe)K7plWv2;WItC}C2Rn%T1duxK zIRDAYCx(9!JWa*Nd_*xhYxr_8L~w}D`;}v#C+8_8R0m@H?XZCFm#;6XJiYL6m5Pt~ zl%~-gF}_SkIgT<4K{S>--xaa-H}~Mkwe|m4jDG##D!J)gdnH zE$PbGxNe>Na<^aNzWi9l#eBkIbk=Z9brp`rNAQC9T1e@c6*vwmBEHoY@YU>H`1yA) z^+};}NsfH#ub3~GhKn_PqhS-22NdX2V|rg#q+-n1?5kqy@9?YXD{|*{YcT(1z5$x} zX$_yfBIu>#N<(Th^{4d~aIG2k#hG6|e=Ki<3F(dbM~4e<27AJJNog4MReg1Aef=@% zk!=};{mxX&8}pA2S3#iAT+B@ENAi-`xNeAjQ+m}?@e+>prt&%b$n_@jGi+|q6Iu-8B&bmm*=pdo=Zy)+1>R zl59}jKz%@iKpCJs5Iry3e~fymyAc6!M!k?tYbN+fcfEHng*_U-W6YrUf9y`b$+2Ek zz6?DYy~ytXPR02+bYQcpoD3u!O)m)ur#37JMD5m4knwqq{apG@2!!M3ja1Kzd#&9P z*nLl?yfgf~DxbrxmsgxthB-IKGveB20oM)lbAEj6!@-wue9i}z&*9c_&BB};AA!f5 zo8lUAmEJ59wft4^H1wd{juST5sI`5bN?mrvMsIGz!gc1vtr$9#F`CsSJ9@g~P- zTq>W#j}({QjhOVc%mS`mZ|_ZiDCev*ST5sI`5b=4xMVkC!j(qKgNv4rX(bP&P2BwC zY2SWP z{3FNZz}P)CfCHe5f~iF=d>UDRbm<8h>+5O@I5#I$7P;!SUdlLFe=48Dt?RGcUF~wF zatl|71bAGKcbiNtTE6aRmc94Rln4G`xr|HYbNCV9BHLIh_SU!@<*DWFBAG%RJjS=* z0>0TV-;gz8*QuRYKI2pQ9DbDeiiC9xiPV7@-_qMN{7&n9100B;6@fjh3%3UC`?$w|&4Y zmd|=q`5bN?AC)__d1zD0MGeLQV>qOx*ey$-F@INDz!}Q zhl*1R9axGNHKPs*aQ-mX!sT;JwB)7ha11rqlfURd=9scuOd*GT2$)w;!uxN9P96pDb&GZ{q??E@}l9J z`OuxW45{p+_sn7aseGBzk?60G7Y0&GXk|c8pbkFc+iU^fu*-AiOxeGRs=aV=`c>uY z!AFq4g`u?pw0<7F+cmYzGw+e9M$_L1sdjtkZ#L0%S~$k1@;Tgk{!+g|YXdT79X!^X zCT8T(>%}D(<-T;v+bh?xT*jsHIovufHyuwGba;ZPq6WJ?#a<+0Y?oJBz}Ir{^T%C# zm9s0$XM8H3!>!}<;hZ|RFjb|J3JdiOCwd*JLxQZw?E7Tu(en3)OCEHdo;9|Cy;kKP zInF?MZ$K*czUbd5G3s%@1$`5bOtj}7thT$j=^;#{^urXEd? zoARO!buK>rX~w}gRX&GX$LYf%xHz@YnW_(P9ZV8W5^i(e##6w>;Q%@I#3#pYf@D4!4ev#(m)tm9c$Gc{nz%ls)b5nLcP% zEz4zGDxbrx<3jl&wfWq54a+aO-c+aj7%Qb!2jcpFnY%-6I>WvbEe-8td9S=V(Q`WwqY_oJ2_Jkxemnny3GQv1>b*j z+N%EDPi47`OXYL;k>OG@6^Yb=7@tp{-9*#ddF``rdF;{~u3`C%PvvvCb$n&65^N+- zmD?Lq9Yu6fk9k~|{FqEN8os-iw|sHeis`8=pYf@D4!4ev_N|ls3?GC@t@4vmBiuTh z%in4XIJ@kanO9dbtS#eUoGPEgt>g3*!vg7|FOZWV&Dd{Ddt9a#O@Hq`yfMA%)+XIp zF5^=99Bv&~xZXA_g=YQjw}5lN(}nTp?%g_#aWGDm&*9c_VjSfw^s*(xsJ~@T$kd|g zZ~HoLW=sEWeIytjN2&ZH#}#lCyHX4Bt=a&ZywnOmtfr-|qS^Z7!ZOzxb=B&FjDvBid=9scQ@4kP zT4I?(9X#$Y>MY>z{WN3mitAX=`KSJUDU7e}Z$e z*C#)+g2d`TTwk_Dz^U#VZBl+{UG0}If5p10-ZmQ4WNe#jbnL5|&EjQ!y zJu6eS!y~zo_DgNK^8LToKKA^4me2T9K8IV!hi|ZB;WQPd@FK%Pk#Ss~_?%2N8oo}` zZdfsVT!C(x4)?z*|H$#trk1kQV!VP&<0={|bH1*zfNSQG9ly7=WvyqqtT&a<;nwx0 z*unj-N`3c@(d=l#TdJ=XMAPHtCw%y1YO`KRjEC{6d=9sc*VzA+;bmrNNpQl5fLDpJ z23I4JH0n3`c_}3t-sjf!d)wnVb3fx@yegl=j}EV#l|)#MGtEC&TflqU%b(5d`pOAZ zl!RlvDxbrT0I$ngRGu23FJ>Zg9f-?m-U~9dXnOql>BUVh|M9qC^3HJmQTZHh9anhY zVd^Y5F9VzK?YDr>d1&9Pm-aQ$EpuUfD*vD2i!`2Cs@L9V`a7@m{mbjR?`h5QIbT&i zhaau}Y!UYT_1+*;jfSt;Pp>X~@S0uySw7=a`5bN?UuiJtOLg$c8+Ay4%iZP;GPP*9 z_S=(3-gCyd2IEAPFH<^_^=bP01lpW3Y~KhvLJR1|er4v1vGH}TegFCCU7!Ax<+I*Y zK8IV^Ta~L279)pGPQ{Gln#7l4XjY6&;QAC8JEiEaO=2?`w&yf=!=85=$%;E zWEpX;wt(}EXB^#{thu7W_)Fy#%nL^tdG>f?TgCSlRtue2qt|RI&E~=I5UOQtHTejH`>dR8x8MqkNiC6 z&8|a>WWGzhw4TI#PM3Y_`Clyh5x3Ka_5Tu>S!D{wd|zn+-)%W-TWp;_Fq!2`oN=1U z=Wy%zD#Vv6>$RrXEd?V{BzJA8)hpFymmHDxbrx90v{ zG<+Y?-TW4x4hV&L}?rAQN0D+ zPcKRMso!4rhIkzq;imnV%-7i=&pK{>fu)GflERTV=3$Wu=i=98^3n7=zthi6H_a%x zo`JA_RX&GX$2rJX zZXG9WKBGA-eaj5vB>t%!S?s=uaWGDm&*9c_8t2`5*~Q07@o@}{ zox=Smr)zAtmc1dl(aOQyt-J5KKKmm53B%(imCxz_BiuM^2ZjQd5w@{BWV{(0Z+efP zCJ);8&LfP6^{nza+&bPOod1WSfLBl|{Kc?kVMSBaG?`KzJZ``0E#TaJdHau7d^=CK zFopH1@{b%Rm0S6~0(}xtwq0g>LG4>I)oA%X?6L*ZKic?L1N*tkKXQBlpUXizOyny^ za(9{;U&_|l`2O;g<}@8y{RGSBd{+4!Zatr+y(%?;bI$OQRE}>Phpe%H@6zuNo$=b( z(cf@<#;5W*+&aG5t{Sn7nMxaDP4=n0Z8EiJ`P#JR?6(&CW`_D*#-;L)9GA~4CX*7D zX?!F;VuA#t;W}f**?kX;xhsj~GA@F>qHIq8}SKV?0Ynaem>pDLfjt>?SJ&P#9D z;xH9jurunh-U7a}zuvX^!zW8>Sw7=a`5gYw@P!Me5$EFfW$MxLd&utUE&2C-_dVla zoGPEg{~^v$!8DG~(m#le^TYMaAG-RBG&(v$IL4{+Iovu<^F9HL*d0#v+Fl$5i@|V^ z_Bc|S#(r^|1-#py9`bkM+#hX>hw-X>4!4e%ULOT6*?5}fyT0u*wP^W$?n{?$pHcGk z5SGihR6d7W#|8TftiV1@Ap-d5H$IyzhCIf6PT3I~-|kP=Ou2jTre9e;<5T$@ZXKU_ zyn|i`2ftzyoW~W!TLiP&s8xrAxgFYI0q zYydI7+MP1hX!+f=ZPr7dd)hXzx2b%Y(vhr7V0{i#gaBraZf`}vH0%h-b(Av9d@+wG ztVxA232i93IuPSe(RT?%!~goMVE%(2>}+6nSNW7SIqUi@lGBSSs+6F-WLZ&Z`lE?76zJ%;6TeNy=xZe5=ye5P`^(gLn#cU`!?n>IN# zPhwmu|7dV|ee{kew?r}pV?Um^Tk@jiYuC&BuDbNIowu`m#;5W*+`8Vpu&~f>+|bHY zAappqsLN7H9U zUDNc>zxm-d#=$sMK8IV!*+`q2>UI)TBhKtkV&gn`-H5XIvD5c34#uhSIovwVuuTnp zqgXh_yIC|?s-d)u?c@OqI5)hJ=X|Q~8Lb!x<5c+^ZXIW1`V5p}H`=ta;UpmbO}=7BbXj%^Cr zpbemt6Yxz0P#mVm^FayCHSHGAkVKr93AzOengIn3fr3tgf=+;f`a(f@P|!6{&{t5< zIZ)2t4w`o7ahg_8sRhDpFI-$uNAH$IYPcf!mMIOg%hSMvE-A5=z) zLDRm#xu4TlttT1v_21U*`m2zNj&O`e<#Tu#PXTtB>IbPRsPbG`(enhcNuwaZD|@Sv zFy)ig^AJ&7#5sUg>l2F1fAzar3U!P)qtU>FIyEfB&CukEku8c8J;_YJaHhp>~Jb9BOZ*ce09AqJffj%+0WAhC0bLKe z1#~;;F3|m;RiGz8YeDNln?P@Z-UICdeGd8#^fTx$Py#ZS4*X6Abq7&-;Br%kaBhdv zC=#3pZ>*m2Ef}zJmCM0PqNEk` zcZJqiz_;bsmM;u_aC2TW5nFx>DIOl8^?>I5PH1 z{ji=A5Ki)p-zDsl`P`)SS3UGjJVk~hJ<0Foj|^kng|Sie-n#9|tgxtw~K z%pW73nctiB(iDl3ZkBe$_;^q%6=kjej%$2t2X^1D>V^4qkJ0IP^6a_cPv6<_aVpGp zYIGp z`ETf(jp7rq^a%|U4&M(lHsgr&{k`?;>gFuoUbCO&Fb~M-2(TUH2?JJPs#d7SsyRT?b3ZHD>pp$4y8Twnd>*szpg(G=Y(S%Dxbs6ICSa2 z<8bQbhH4jmpf_u@P!`9l#}BLhc_Qwm@$xaCBoOsMoj@rd8p{p_jRukOsBNdRxC-bh&eL)LN`@0p!vTe~{phPZ9#yA#(ou_(fS`Zbx za|V12N*AE>xcCyxZ_yb{d=K-)W8$=pQ{uEmPsC|6`^0OcPj26h^;7#1K;Y~kz=-&r z>uH<5czABxKWSJj9NkBEt9-%6rSWn&!8-+YRDSC)R2)s?x@8vdjJoB$*(LwE=tP#s zcvL=zH;yNt-so{=VWSxqhGgp@tB8ndY&TMVlBq@0)6c1cyWa48tM^$hwJp@zsC*7@ z92XVLuzrj82e^+G z^*K_z(V|;Z?by+Y+6hIiweFWDX?^eOpbgxVtd0EoL@hJ1n|4;8o?8C6KH7P+Q#I$+ z1GKVLL$u&q!?la{ovtlP8m%oEFjl*1(m3sozyxi@jgz!To|>XP{lPif`rl`0uO=61 zTZflu+s~P;)z9;4du|VC`=77U4tzWh<)l_?(d|;mUaWO0x?1aY=~BqP5we$QBfh>} z8=ZI;WZwtb4`}DkUZoXX{TO6F1=(x03->**U7GX~WN(7(*R}ry-qP;7@g2zi0J1;S zUikfEZBz2+ko`4ef2VyiZ=d${?LR~I?~wf`sXLC_8)Nw`{neark;VfD>U;Gcd&jfS z>cvKscN!-#-NpO9R)c+36FWGm(ykCy%sY|2!+#32|z6k{W ziHrkZ#~g!AlWtdFqK7aIG~q};C{tk^b?9$MXWH-RuP#{sIsLq)=l+QwuU&X6>53fT zpmXV%FPMf)1014>k#=8+K;HbnIWI)_DZcSRoySR_6i|0i4-mRkVS7r2p9UHPqWRrO z&?rzQC>xXungp5#qWPN(R0g7EisoyVf|h`2j&>L5VbB`TE1-8lpMj`5X#xe3J-9dM zG|(iF8?+Ea-vfFUv=j6Ps0%8?XwWRsO`wgSUqHQ)88bn*gFXVKG({SqXFx46hA0BP z1nPy!$PJ+8%`uk*HBUr3pnm8j-U7|TAZ9RH&4Zvf(5b9Kr*cOd)CZIUuE)l4!v>|i zL>j-Ia_b8>B_F;H)@11b7cO2?`7#u9CH?foT!#k}FPL5enf@AI&`w9p+Rk(Zb7&U_ z46kH?r8vfVwDN#V#SRbZ61bhjGL+x8m8-rx{KSgU8FT|2d8gybe8Dta8kAq0mk_B4 z8*ya+AroL6k@RxUuWLu_d-smFbr=E%yWVf)UGPuW0G`{uKP6{-XQvh9;!1)ox9z-rZ_bDF&ubjholbL1EMF_3C&~xb6a7ZDH_cyf2@F{9_r0|p^v4P5N#%36 zt|ttGU4~gJy&@$4<@E&C3(eQk|Bj6#H*x;VH~K&NA6w z@u++bk3O&0O!CtY$yh8uQoYyqCuUxCZOIN!pXIB34j)6WlF)a<0yfzs(%G69OmY?D zU5!%QWXzAvkWcBce6l^Enb#I~hn;Tco7AOgwOhK3?(6EV&-lajN9EJKF2*V!SD zED4yVm1R17jzTPi1u>SfVc|>6Rh&AeTt~17=e3p~mQg=@EZ|AM|CO?;Ex%E>DjeyP z@GxIzhrEb*#=0Qi6#QO5^oEHBCNW_?5|zZZ9YY1l1On$Yl0IEg1tQ~4Yo3r8lM zJvXr;SmbRuzNrJASbFJfFZ%7T)4rD30->}{L06S8*tkqA_qYqa)#9sq*qG!h@Ry-e zboh%(B^4lFRrDa*+&d{$aUk{F`2h^ns=meAgP%EtK1{N$gOsa@n2jc!`8oq8E zOD}`Q{;|Jy#!N5Er_-dsAA1(OA z!k4orY2JjPE`4M#^-EWk|6jppLj&LsR``&ZvED5OPGkP6^)BzirrKZW8{1rS>Qzg* zU8LutaVhf|AN!W|sJBVRacS>n(eW$=o+WP|{_2^nyI)Z8FrRU-e}s5KnliSNs})?4 z`i~ngJo~*V)#qMFIwVJWO~94;f@!$u-w(#fSY}NgW?|HQFn^$aZwh>#XKVuwo@exU zwfiv23uE|xL-@;!=L9I+_#D;E&HANqwY@(#Upr;xrS}g;kZ@dYR6d9ETA9u6w&B~u zIUaf-SP}WT_&#I(NJ%u~z&&vpxESq;9o~H6lCwX02suu*p*-ZLBZT z@Ihl^{lyIp^my!+`}%Jh?zoR}vELZq6245dCMK5};QDp&{U5w_@gb^8Cf69> z5-!%8L1(7&-!gW)+#&EcVmktaV-AnmZ&U07M9FA7FhkP%l}>)864QFQH7EeD+crizRCmT^H*qg@_X zu{#)ugv{7(?Eo&4X9wwW8`QTJ_m;$6QhVZLA*E)j9&i?5C%)5bcm zP~ya@cmSrA%u+0eqtma#QkNfdB#Z#)5oKb=`jF8!I?n7Tn`x=;MVH<**`7XJ$3p!& z;bgu6qWF0PIOQ~jKq96Q*NzytQl4(6eem5o(-*xqCm~%2z_^(IPjHobeLnQx0$Cjr z;__de6kT7-9%-g|AM|h7xFhkfii`RG09U5p8wg~HcV={@Au%Jq*4$suS%xo83ebkxtbO{;kbW`^u9)?=Q{44_~5v?;znF#j5tl@b9iKYSTxjE zcmg);;Rpy5sGT;H=w=5~z9t`M&Q}tffs1ke=Xz)Cmm9ZE#fqreHO99zj?%%?w2BKK zr*72SY76+*4*Fr$tS?R`lZweT#z1{OBQ23`Y z{t@8P$M4v%RO~iSnvuTIuC&Jj&X+Ul-yh`NOiTVI*BIXt&Mf`I)mfvpYNX2T$V}S& z2gmgw(s=avA8R`N(!>6dxDgk!$J15i3pOriX6EYKlSCoUa_L_{HI}0TkQ-|p-fs7t zvCEgQd{QEm^^bCy`7DopeOjd(BQeFxba--c&Xmr#%kzsz*U+Y1;|$b@YiTEQIihDx z02%iQFIl~Q%e_~v9m{gLT~PTPp6@EcNq4~-TQ(hgIM(eC1aoP7n{Ln2=ft5VVIaq= z#ShM>q!VK6YrwlV44GZ;|Ayl;E|t&WFxOV%vrM)u?*y;hPOT%-5iB;yUk3SgTt=nDZ%ZArX#zip6}L9rD2N~%V${oO3wREtUpQ>*=4}n^ zhAN+Nh4JWX&iOu9Ss4a=MYHi5P#8@eB5?W0J2AFi-0v?L``mx#_NBZdM}8cx%oj|< zMK2%uI8=p}XHZD6{z|pW?H98#)G)CKK^<(q-0V%8nt3{D>eu#Lz<1tbo7yfLwcutI zAM*{+#Lpwar!PE?Dfb0K_-c^~>(2*k5|tM_i2O+9`{ZLg9;^-o^c8k_A6->Gq6-(w zM^WWrSPf#!aZs3l@s_dK{(J!PW3`9l>*l@tT5;ct_2dOklCSbPJS3m3xe@j*(7mSi z?Qj{%;Ymk6#bUnB4tXIQN`~Q$8XW$~+bG6* z{lG^jS#m^UJxlHyTR$^w_kH#Ho}C9czQh-&seBH%hRdv<)xbgN+Ck(;($6Jtw|w@` zzkZ!4<;(jh7V}v?`;Flk3wsD&{L%Y|==w=diLIZm^QU=6x_-Kuj|s-L1#*^?PoT^27RJKFepnF&uVhF04g3kCRM85!7VtH)eK=t)It! zef6Wjed`}%xe{NTrt&%bh;SiN9f;c-dfAQAw}W&&#AV>Oah#vN;*Qbf1s8_)IUrcL z#`u=TfxJ(}6PzfH@tRDhc+u?AJWgGz;G?#Q+C<~~N&BBVXz%qN%~+%(pPq{OIy>Z1 z2U6@V5_ZafZL0VtP=Gd6>WY;8zuvzgmZ|=qY}Qw#aarBgHa~6IIxd|BN?dW8%IEON zc=XdEBp7k4u^g>ba75bQblUG5MvM=R*~oGjhsx*h$T*-Etl8j`Nj3DwQuyryO{+yj zE=Rq4$kgrN(XUARz1qIk{+N_2_TDb<4A(d2Bbv#Db{Yh1wCsv;GmPv$uLreEYMV!8BYN;*di?que?RayPe5@8V2O#_ne6B+@ud<#V_}E=qvdV<-gI z;s$=+lv89XcJSy|qGsxBRow9piM13!Ve3HxZX^epF z+FCX?v_Cnr^;eYOm1k|})N||~mnP6ZaCASd`!ioK4Htuay!tX;|J2n$Q+ZGB6#b)E z5yEki^&wtU`5bP*X95y&|10FjDi_mI(w1K}=hTU6xnMraW#1q_^fR10=6)-?k6C`C z@yCC@d#rV3T$=;(xx?)M^I0zYA)#XbtGn102u`8ho?g%B8peTl)$}IP+&*W^CA?66 zEN(B~x8Dq$bt9@el8l#czV+m)&wg0M4Fu`01+>U~#=*V;PnM%5AP#{M?#Azy@!wvGWeqyW-1I08O zYtQ(i6s)y+1mpN=j|DuNUd`Kj?71y2W_gT9<#TxBcm~D9Q=KYPw<9t76-ht$|MBLq zHCc=3F@$40Dxbp}$D`|qZfHb5iMH5ydM4cea$I7QOIaS{QTZI+I38U;QSdCYfajAx zZgze+Cg*&KL+X)QVdgUq_8Z5e>&MWRQXFIX>D@oJe)_E)QvG_x-QTf1){n~P@W%1z z`cd$h#=jQuv>iJ`76tt>$^E*d7-PykBvjuM}fzOLqd7`ys5lQ8xUJB z1=|mN=_uNd7F;^ki^}Kln0it0EJH-@5B38OrEdq3kFEz}QO>c!R8+hXlBMO&c6rU(et4@sH!~sqf2j8JEiEaO=3Zkk%HgpVw#MNHPmv~>A&j3-k4>stJ2 z*>6`(oyr1b46G9q*7-gUr7Rb}s&1R?f_1*}8?1=NwIqF6G4 zK#&$mfM6p-G9)7*6K5unSVu&~3JNNs=wJm=7duuE8;S)xuC7Mcf<1QDRr!D4eecZN zcQcs@mR;R{?l0%vn{(SY=l0IrUbIIn5peDB=$$6|=46y5W@q3|7cTx&rd{)k$Q z9E1lKc!#(>he}LQkjSITnUxeg$>ed~mK#6&*L@wEtqYiZ0TdU2J%1Yi*RCDh^V&_V zh`;0b729s;y{`C@WO@6xg352bzq>ElZRvk(yC(p`;26HKzR6w<6w|z0TXce8Jm|60XE+^2OeWR~_Z{hrH_0Hsja(@3jNd z|L$)-dS?5d`VPsL@FjkeFZM?Kqk?fp0t4OZI5xBb$9t!ranC7FAKa{-GWkhx$UHI^ z5&fa50d?a**vSZb`JCnK-tZz2{?26iV87>29rNMkKYb(dh&)Wb*vEf<7<&jfzslWG z{!#wv*bc|DU2+sx@I>KJ%4hcBcIc__9P(PxO&>lrWeZ&0 zSqpBy`NlP0OZXDM$rpPqetVaReF)eTgDZb@J|evwO1IA%arQp91tcE9Ve-XZ$B{T` z7jA|l3J;PV^IL(Vc+%#13&(%*4~a)`n0&F(Kf32A%^!(Z5$n*@4ExO zl<*~flP~sK{DXoaJ}eUFsB4Iw!Xw$!)qX5)1)d`xd3nw*k8jT@PNf8o$rt;0?ARMI z4U2BoIKrU}EG$3~g+ob?9(n2I@zojAmVWhghe;B?#BcJ&UW=doTC6vy0;?`QHS5o1 zt%(2N-H+e%wr>3|knkmblP~sK{HQFP?R@HWESzXiGkSK#6@>?pLvL?-IlOw(3HLNc zjvXQK2o94k_DOMQ@$30=Wh>&Z8$INL73;5gO~RM>O}^M`@sC6n@ZqL_O3x?^=cnO5 zIOl%_$MK-oTZQ@Q0uiF}f^`vsTZeZ~X(_B+LPX~)mr zyznJn(VgvF9^Cjg2^VfmcK#20BaVq@)ZjP@5;<%Dj&$j?)wfsdKd@x$TTL9om-t0@ z-RGk={|?2e#!!5HLXW?`AbtEht?u;It$*uPCE?pRGAxrX_RZrjsKHBh@t4o_dL(;D z`uJa5x-RfTWB*qqe2L%Wi+#)S;}Tk4FJWxF)A7s)9)|A)QD>QH2h#Wbp1wN;5az@?I(-3c%a$6Qzl=+ZwZIa=LP`#&{BnKo;$BF zy{JN>-p_n5egnNGqN9HQ&->T;38QzP(*b4jqWQg&=EhDRyK>w$;L3!*7meUkUY z($8)ken9-3gY6^3GWiUL%7w>HqWp$hT-K)=L9T%I9l!-~?(MIsz~N<7GjdlKS}WCs z;^1jHNN~o6rN?>OFR{w?^M8t;w-KBspBSl<;FKc(#k@$14frNPR^jI2OWeFyZzXWc zeHW#BO|K=UsAJE2(ejRRms>1dH`~WM^P-+-Zn4W_1*=EJ}nLpZZImw$!m4{mwTMw*a|#T_nW%3xG@x;pBK59 z{FHdq+*kaxfO4wKrFKMmxjZp<&>e3Uzi^1eBXTkMV&5vcjPzAc$7R>_69q{*YyuuC zFNmh-7YC_*3TvZykK(8&dxK?NRrzDp8~=RW6XQQnbeDs#@D)@0s2S0^T8}#I?zcDL z>pRSKc|=F1m&aCj=S*vwKDoO@VI$74OupE+N*-gU$LDi&JUOG%<9Y7G84Kzs+(VHm zC3sA}*tZG~(kDMqqrA+=SJG#3EAYI2(ziSRe8oN7vZIvXG5KPj9*=#@6z#BKtPjDBJuk<+?X;Q8CSzMVGT^@Yjw zOC@+rzHMu?Cr-WVs`psm3<_7s5x@Az%n3lRm&=OM%WK+z(>Fh2%kARrvfyZm@9aA- zsF{Y_GI@4NT~(fsIrq9+-hM6q_59rg9Q@s05cPJT%|QA(_}JS9&fT!Ic9kt3+Z}xg zAI@D0n-fcdLENY+26a~?N6nmh=h4x@fsnlnp#14_sXy9|MewjK;V^OoNcIokxJ%8j zWk<|>)5Ifu6{z-+w^~|$zr}VOg(mrD18`6l#L<#^e^mG9@A=2gztlLA6+9m}eA8bl z9CVutV*Kn^bjIb+diV@muLqXFJ{`X7PH#VY)2o%&nD{n#_z2RaQsMKcYMUe3+K9Ll z&$%!N?zOvB$A0^^z*y z=BeeAEA~bU&ZOea`RVA0#vKT9>=MP*RpMWlYj#O`x!$>FY}&xXr(gBJ74!bh`%7$m z*njBoC0xe&@lpdSi@p@LX z^9RDGe_h3KwHCJ{RvlOA*z~v_{_>W~C%t%Zvwb!uU$C_rS21py){?p&0Z94I9_Oz2 znAy1Rb1m>bv*lT@GOqe-_j~7|(hYC1oKf+Yw8K~Uim82^_dC?x#5_NT+jDSK)P9GM z@ovgKU~~WKECVkwnf3I-tB$A`aAOIF7)sfa&#+9s*h{}`SWS7b5>r4ytV&@rM6u~c zmsinvx4hUFrp(IF=&So_VSi}VqKW%VTyd_f7qdUW@*#Zu>r&&Ze33AgpEyqB9SkK6 z>iKxJCziqS>H=~kw zZ3k7?VFyMi>^Tb8>el!h!uHLa)qZZnvG1tH;d0Cva~~LgvJ+4Yy5OswV8`kOkEXQ{ zG~2&9r5V=9!#`4I{}-MAUC)juJ^3`)O4&X#ER!$x&G6yHrRl*?h5f<{mll*M%%_hy z?Sf@u*L_rt2xwFDFUyjQb+JWTy}!%*MYacV;hKBaxnF%x(B7c^K>VE?;W*}Cu}L`_^azNR@li`7uR~s@YnBs(CS#R zHOna#^$dK4ubA3r>`1RVt7h-AuxABn9Ro>vMo(aDiFgl#nN*M6>$4a9@(k@ZX3slh z?m_3OI*<2)WGDRV%q^E!f9@9h9$5n=t;3Dg<|F%W;Llge z_L0$yFZRDCo%;4?LWNZj^AW*+E1j4|OrKm3(}iim^k7;r9Vmawo${ufDPPJq4>TB5 z2pR!88pQUEo!&CgWKcDTd9eW$1we44LZ0T z-k=3N2+Be};K4!Whh+JtRMkX@@|`T-G}S-kDJ%GK#@Wow{0*Rq_zGV!wNLVVGpwSz z#nP?k8uxf_0Us2hm+lzEiDmF52kPyuKpi21P$gdvN1 zYxr#F^FTL(mV=%Hy$|{Yv@3)$5QJ*LIu~>|=tB_m)UhD;za(EUA4`2wTJCN~JHRd* zR0j9*&PBuQSx0XlI*Hj?DeCkke1{#^lFNOJ9~1u(yY}a5l)Hb`Xy70Q_F47u-&dsr zs!sdIL)V))gdYds7?R^q+ki{3*)M7TYJR01x))(6lkx6S@AVnhHS2EL>gp~f^F8d8 zKtWWhUn6|Q)IP0wcL^JMtllWoOcxnvX+iucj3W2n0_OJ!c?hE2j2gxy8Hy-Zkeors9adw%HSD%5@Z9 zsZV1D4)gwrU4XWlN^l6@<|e*w9J0$G>=`$bn8L1cY7c}@#W0o0 zsJ~{_WLQ6s-K=tb=IgteauB`>K>N7kFQ~`0eLOnXOc?ANi5!-nlp06>QUhQi)?lwzD)f%rd@gJXsEAW=?MQUB5` z{;2Ej#C@CIdI=I-reiPe&G>36w+ED&>PD$|1^r0Vd1Eb5#|JziX1pcZLXe%#& z)s$<){ojy)-apI>xyQL%0}$K#wN;pZ$=sLIc2=)fw_JO1^=uBim9pEG%w~MCm!6n& zSw1d>!=4JciCcR>TgS25z`=IT9OruOSariQ(;v7;;t?DsU+hgB#kg7>Z|L|ihwkHc zw*o$*hzW-I@F4xOvasDsdcjjBqo2sIJAU-!3Ga6q_;gK_|Jm*ihHK&5+{8C&{|rq1 zePP~*>kkd`hny=9{qU~$8=KPLiq+x0yF0u7(z)r83l~0M$4&XMA20j_BHQHdzsCFV z$)G3?dV1AI+;TGe^K0uftXr3rE<3lb{hHBE#DYioY4Dg5iTCSuxn$#aQ?-;{wI^p- zU-r1D_`y#v?q$kF_^ENY`}N6$qvxO4X{qrrt|xjtv*^>E2UT5irX4eVF#ibO<|e*L z^G~z>eRE{V+C}!yZG?&NrLSo66E6NbrvHWC@Yj*{{}$31GEYn6V!e!*dCZxv_}>!7 zpYYeT)n|XgL}`QcrVNIwyK^Q0B_Y2bOT1xh zI$?sT+g7k93J7{TNJNK&&Ic8P27tJ?pfiYTw>yKlXQU&DbH*G$5?L;Y>$}{GKzCa@ zx~!#AXPUB4O5*r{Jkt!8OWFC-p7&(i%m4pBsbuZo|KjgwzSEWYzi!uNZj(Su642)h z25yj(e z;K@D@_a*$;Zo#mxyFEVODmzZryR7eppFm=pTA0_-At;CXd`{sxZn>EKgDPyEiTtqd z0snsWl2dT>Kqpls1`cz*dccJlmUpwEhgEHMXMa;3!cQQu zO>P|S`5XBSX}NI&Rf*Z`lZjLMHyFJzT_pR!fy|q{Z8SVagUx_6X3(2-oRA* zL?L>-c*RyT*3l{blYvY{H z*b~$rGzN4gh-Vz~0pe#+H#F?uqa*ezI$tMXGDO~ZffHB1e|al@r+*9IL!JlnrqM4I zf>&RYuh{q`|DDdM%CTcch`U)Zh`jSIb>{=l-Ef~-=?U0dU%I7_euBFM4mj`8`wx`) zH{xgyG{UDFT?vlC!SXt85iPE(#66S|%zWAMSNBcenye^1367P(LFEO}lq}ufxMOal z^O|eN(;b!VBf~QJwrxxD5LE8;D4d%<{w|d#-X5B@Bd58PlK4%&*oz$GciZ`HbPcYX zz{9wO*nwcX)YD^aD{$QReb@FsU2rO=;*=5`CSUB6u@V znMB#N9uglQX-@9Ao*flD{z!tbo@=D?)`#C)07e%CSUB6 zyh4||N)e&`*j-C#Ut%(2K zz{?{xHXef#Yb%N0#<=(+&!0-%b5L=I&zSt*^U#`Pb|2f=(SNRfXPYy4sB<;Gpt?XiAn2)91Xq zSEu8?ynybgY#$kx$+vA=swXv6jzfJOEy}}T$rc&`3>rT2xmyB#C(2_BO#_Q~-$P=?@mJP$xZ={V-J0!P=A zvj%*%^d2suC?z;dzSt+nF~pBIUPHJBBi@gR!h@8ToCWFEwa%LKM$v(9)=ZUn1c%8N zd%>aZgz${_;nZ4~Tk3ofyfq)jx{((DGQ>~i1<_=#W6`d5#=Tds$Q}A5%~TS<$+vA2 z`P5q%36|seL|h#u$1Uu&H2YpbT<26#XWy@bt1lgF48zs`y(&Gvix&Nq>pl91Be=dr zMIT$>D}2S&J|drV_=@q~2Cmu|ROh_ESdTCy-C|d}aj|^&h5bt4op;h#JR)fY-g{(= z`}f{s7|m27H$JzmIc?*&wdbaUG9+VfGW*8DgK9 zG9oy3(0hOm0I?#@0}Th2f+|7$trvoB0IdWyf;g_|3-W^&fj$Bqg0T%B-rXFP=>?#! z0P`y7MpU}<0q8CO`UQZZI2bVq{p>O5xZa;**M}IQG`laODuzIzydav){Mch*hV@+e zWfz5qE_{e*ovC&Lal9jZ#ne8nOz&pvsgxb%X(Q4COk>@;Nb1L;~?U}B6+Uo!7=5*nw!uD6T)B7D8kXV$7*O3|PA{2kuJJL7w>an=P z=hvLi`ihF~v+)(aVrm~}2aA2}3_2fNm*FE-czvX}7I%+2J2tRoJRGb+WxO1IrM_N< z3M(C+1K)n@i_n3wOC?IWCn}RK_UZ80KyfDx2hz?ha%w^afFl$95&Qnq3Uw3S2wz=| zJ^E9K}C78J`}!UYM&NyJ5p4F9qDVBgbN?1`0ZO) z=sgA!d9F8bNgE{n?7V}rtTRTIj68JBmDkz3UlO>4&oFh>GA``ER}Ud$FN`boy||L4 zvW9aP3}+Td@YOn}>?Qx1>!ftQ>oaGRJUxguw&K}6_8d&UZEIPheA5Dz_I)olit&Mp zN`Hh|kZ%PNtQE;04R^s&5RRmgva~T2@ zd2VP0&Tp=G>c(*!pN-Fh3r>^YN}RZ21^3aacCgxh{5Pdk-ExiHl3uR2FT3XHJATZ3 zNAL(0;Ph zpYggWBsf^+AjStGRk*0HqzW5b6ym>F0wa-PfhT*EB85`tG&x#DX#YJ?;L4 z-S1_8O!$IJ^i=pT%UM@lfd`OkIYW}~$ChCK*qUnGvFXNDi&t~l26{oPvuS3#sqc?& z=y~M@Z~oLZKF=rp43iIUO10b{vwPdBpICr35(sj1q{<&s{YUqFa1(G5kKiIEw%;*K zMD#gj>?=9wCw4vevMn}0ZtmBURIK)0XOx%l9d=wB=fgH=PAP>wT%6$zshlc_FILWi zOG&T#+ZcNyeuz!Y(`SQ{!N#37-y_pTY~S}rIS60JK(m%_a6h}R0Z&%dg+i!;ov{&fd47XE zvOrU+Qb!FooPcyW#eh#wC-$#8fM)FlIlb}R{xRVD$LS*;J1p4lxvq}?1ECY2@Evws z)9_&ggo(&7G763!sO2o&p*Utp;UHhw@7h=2`){dntOt(mHb3>v7gjAUHgO0)4!|*J zI566AOY4z;Z~mam-{0B$`Md6RItG** zr%W%dRRE<)Zz9hklPFWe6OiK;14?!f1HDpeB67PTP`d^m|}CSYkYpsz{v4G zOg@hJjEZ>q-mvf$Q~M07sjb6mZ!my`y$~-;4kMXh9|cLg%Zzx<^2^}n1p4hg>D@Jh z&3J`RH@a#TZxMP9zK}CZ@2=O@-Xds(E} zIX4uNFt0E6S1^+lHz2=G6+S%2AW+Ih=AR@y(J5~dWkkg?#Q&*GUFRtWzr#o3_#J}! zO9r90)6u(ZX?XEVc-L|6q7JIu&MCC4*QXuP$RBv0b>+14pPJQ)dqk*g9~p7J%}spG zdkVB2!13+EVvsXT^sU#kdH1=?G3yGpJ7vhda$n)M2VVHnzjkaqnSQARm&vznEvqEN zd%`Qm`Rb}8cvqnsb0j|Ax*n+uacOGC473jFuxV} zZmP<^a$Nh3cS`(%&*Y1Ja(s{*=Ve<01bpPo5?WaExx!O6^W8Zns zugRxdszhwqdN7&8RedOuSm)@01Tfo4`d5qkG;D&hQ?+#-Qq3!}j`_1GJ-r%{UQ}KX zP08|aw+ElB{Bg^}?xH&?Tb{dHCf~NTtYrCjaDY9VP=wudbk~(r9Y@u}>2X{?{f-m* z?bUDicRgx#Ue%;A0z!X%Ec$#@WvF!x(>E*zcW&CwG05)DCkALYGtN3O7EpJ?#wpZfC5x zaMf<5FQ4NCK%H_DzJx2f>z%(bC0tPmV}o;O9A=8pmfGvXaGVFy%lRND0MVU)Th#R5 z(FmMWE#?2*tG2dsPMfx1$GP9nW*SiK1LE%xzG7;hWcg0=eaDG> zwkqAL`@#on1&8E2;cF0-v2{4yd5|7^fOPq?ov_i-HldjRb$7(WMF_eTj4-BEzgIXh zM6BbHazQ-F@RKK#526!nGPmTnsoy4n#qiGb;ks7+W44sN;L((<-T84;=6)BwS;IU3Mc@&axVlW8K&X1?Z znNjoPP5ZvL-!tN0aGHFvZwaToO2cVHPYRg&ex1d@M}%=X!pwaev$|lnbpC;Hw3J8Z~u~6%F5{YI|?Y=uiL`PljFd zzyqF0ji+#4JFDaMi|2ShIb~-PkMQF_97C({6r*=)19G+JD}jgUA@ZS_eNtIpY1}Ty zD!TgZL(d7^yuS?mxXw)Z2p|8tl!gbdT_aw#;DTO_>~(QmN1;nT%6l?3j=TvStZ$ZG z|Ko=j-8r3gD3zp>@NI75+YE=ApvHz4-aP|nvp^F6>NN3Jz1zXstk1MJK7Fj$Zd`Mx z5;+Lp<|e)=yF_Bd8tk+|;Pp6j0hQqR~*RN`-IpCBFzI}-q z6H4-@@NI75n}|%UGn(?ya;WV`pKr*1CN-Y(#!iw;3GmWh`Kr7R(N?kEBl2LqFa1^%i{I6 z_jtW4e1{#^G<;HhO+pjd-c#_nZB!S&MV5E1L#AdGo;UN7ybCOR zpp*HB7y^*=v7S#Yr`lt;v6fz&drjlULr%TJiI^L1SgwTcu;W@Wj_p*`@l|^EM^P7Z zRxcE+R^2D{8lieX1kX-N&(GtnY4E5m84M%_5`2Yg-T1gRRzWwweZcMS9yVZXrnToq zUtajqVRt@vU@0u1UIG!H@D)@0{0e;P@SY&V)-;9hkKWhEeTtnxok2VY!*ao@jr*oK z7lp2_Iy2rCdUp^93_U^nf;a}`S(!ed{ve*2ITUm_C=bLrgCU@!K%+ooK;uBnd=o*G zaR5{UV(~f|6a}3Nx)^jBXd&oE&}|^jNv!}q4SE^$Ht1u}cc4tjYg^Fnp#4C6er7lb zPj6Z^pff={j*2Z`)=JRppf5q$=(KhP9SJ%fbSh{e2wev2pCF#$!FF=%SkNrceIVu! zB>fqP*0oQs$;d}$eUNkfHrDsEGKci_X4PX!LaBG~Wj+$V!;WjM&qt#tPaafTmpr$- zan64cKOD*nqRGtfrT1)U&DiJ47jB!h-{c4=9T<^x2=WLc0oTfaN zov@8HrE1%UN8i)`>QfvrB2VG#7-`-FoHZ%L=}PzY22N9+vr03qy?>m3OP3iZo?mse zjY#Av{ND?wAx;<0IWN20YmQ?kgG%2=-kxyVisg7z@aZ1?KJ{JIci?@)ZA2nZ;r~XQ z*dECj1GyE}RUNx<4tOOs&J8DIT4!$fZouAiCXERXwGoLth5!5EbW2okZ`T4RRZIDE zz@$v;xChn`n|)ViVW~6l6L|`MQ*iPX&X&rzjw^?in}&<^EUD_%3@dA=Tkl=J?bg=% zqJmqx-}28bhdJfD9`>w04=#;iX}JGKXYO&3ruXiv~ypst{9 zAhv6JgV?t90I_}R1!5bwABgRo2gJ6nH;Cf!JoU2(o`R62$g%G^hx~Dr5|(7*qlp3u3#< zP1U8K2_Uwy$AXRn9S=GIG!aw=@_{CSm?x0rXFzj}7qi#7%ij*L-w_l;zPkFZ3jSQ{ zz&l@zc73cJf3{NgIjh~8@x{IfMc!Ub)H-UT>ZVTehirBjz1 zyWXFlZ~SgF^Uc;*eVvB;?kzm&RAQu(-)-`3TclUA-%VziGo;ObI?JK-OLN}HP{A<2 z(8P9y`7RrYd;RKRXXN~}o%Q9x`!Bfh_=4Rsl}mg6jpbPQ4m+;l9CaAi2UYvgN9N`V z*_xXR7mSzZU3w#4Iq%YW@vSOs-M&b(&slfZevEs*OWh{GD~# zbY@ShzVMZT$JSoIf@Ufke`YhjZ3{UjZhn@hdGJ%l;5M3YAW{yOMwEE_w4{>Xkb>ju^btOHo?S=L#$eIT~sQ$Qzyrh`rc%>-Qlx)ihkbRFmx&|RR1 zKu?0!g5Csu2>Ked5wsPOZWmBb&>^5MqbC&}X25?J*7jeF)0$ zfIJV{JR4&L&+`x_3L& z@g4E|w#QfpmD=7&I4=@z3KH&y&iE}D01ev}{!yq8LWA*47t0Foi89v}@piYY4SS;; zqH*ZHFJz8J;R!SdgOSbNMc^shl>|5_eoHyHkrXy*^dm;#A*JrXSwmGf0d zw2;rT&YO(iFa`ZCB-(T&+C50Lp)=9GT!1}~NVMINXuYn3KP1}4NVFy-+6zwt%Zq5k z-hzxi!W-e=FugOZx3|u)Htd>VJ>M(CnsO-alsXFK7XzOX41D+|=hYbaJdc6Tu8(F| zm!ggv^i_s+>Y>Fb&q(HYKL;XhcF)!+ zXLdfY&&*ES>;gL~gob+-7_QA%Oznet1z&BgCozLCNF9pecs?=71NTvo;OOx-Q6zAf z_vOJeHY|K4TEdsGV6ux3=ANT#b@pq&E&vq1rCh;#e;y1@5>)*?; z4ju6I!jG@GIKLk|98gF~6~FKmQ~S8%N3_QM!cn-D_-`MN=ZR*m zd?0hU{CmRg9XGv{6eN17;FMH{wpL&Hsf@UANQC zx|{!mneuH@Z4zin0x@Jx)*s2vXRw@5F%O|>RON?d2F;~~CNiGKY0o@Po%SqqG_#D+ zOr52jgeE%9w`*W9p#Ga>#76Mv{F?U(Q)b;j=!&THV7;~_h;k>P+Y^^1(;%6mtc7&@ zRB52w>1N&kf5P0-Z~9Nf-4@56Ujq90xa?DRzZ63NRaW%<{!Mp3aeSwp??KPoR(Af% zv`oI(qo*Oql{`EvDxFcYoQnHDqyAgU?{D$@XOu-7rvHuv^l?KI$|;o>q)f)Rg?8_J z9oVDumn*ORC;x$>yIt@VzG7;hq~iuK^>>M#+b)%_D84d|s{JfAo@`8N9Q4NNqrY2H zwOw9QSosg4v&3_3y(w_|GaH`=N0lo$N3E808ah_l6gobf9R443^+v)@iW72}Y2be^(o`~1IM)vFUv&i04bzwMX8K7Q)1LDHQlBw?rW=Wh|C@@uw))JJO56Yc2?^9A66u#k(H~(x z^@1edGGCUVkso)%o$Ll!Z~hSO^vpTa&X#;koug3U(~YjACpOX_@nOLdr)KH{;YirE ze{}=mWt+=*TT=DcoZNHU;oo03#Bm_;H#mILpTsMJS?8Rel?#XbyP?WD(_zIrY z1|G9N-}J8x>)5+b>biUGIsNu>8Ysadd<}{+y74%vnSc@R+3RvCMLbkqkTMzRwept? zt7FORM|M4C+c!m*zmvCWBs_3RowMpR5EP=N2@@Gz+Hf(=32}A)%`fIhB zYylGeB=bEL+C3k6JwEp-10ET z5k;G4S~Jgz&g*!{HqTz@M8x?p#xHz_9oO9POSJLfgXjJYvV-j^90g5HxhE=ZoBJ+;T8+(0!j(ujE{HUQ^K+9@>JEd?9?r)IP+K ze%z2iWVWvipE2nq!PCxE!V{hLy4iI9SNQ+0j{mP9=K$h|8riy zCDoSST9VAB^OMzQ3`OcQUDmo;ViKO{CSU&lE9vHM`72>>!}`ZcK<|$%Gx{TDzl=z_ zUvulwpVm$ISWvMa&EB-h7klh8YjzLm=$dgj&1ByTsII6|cPQFEmO+z#V%fHts@!_P zV;*K1X1`otr}!o?aQ9Q6%)f?feN@yl@D;vdYM;bG3|v`=`*rYWm-EVeK@BdV;yZHX z!I~Nz8-oR2E(ryvi@u-@Aig(I zv`dyX?AyPO%Q@@8hmQh}>RgcOS37*g)IJHkykpUUW?#36R|KZ{j|xsYy3SwcAK|a5 zj8wVtM04DD%=F9&XIpa~9C3_i;FsNH{5QPdA9&yw{cc?<{)vw$O}^O6JGeuF<#l0uv#-BmSWTihI}W4JMGnh= zgTKoQqRygV&fg4NQ2mMjwhrT^e@i_Bxm5W0*QI3MWGrh{bvD;Md84;Sc{@__iTIO^ zk5{dl|G~~n4!IIf&?!Z24EZt<=b2I}YP;bpe8tp0k}n+HX>Zi^+-QL8_j??s@}=jK(w$PvXG7;q>*}g5SB~tw z*~%^*xm(3P7t4A~_=>50-18WTc^pk7%5@Z9$tUX!9Hv});AHj4Rk^>sJhJKb_D)7Q z7ygMu_$pBCAaSzy5j-CyjS(5hc zKx|tnHO5af?I}AU7~_gOTf%XcG9=?A^Y8Zc$N%?d!0^Za%C;DOjRa!I94xQN=Cx$+ z2lJ08mLLA#9VBCi9GF>-$d`RmFt(}RK>}ud#`=l<{_R1OJL@U#0L!;M6q zd|c&Y&m&>GtOr-{c}8;Lpwb=|#uwCeoK<_J$2sca%lZt+ZjdTDj??7-2ApGXC-n&2 zfQp-`<1no#0+jyVdf=pdM4oIDSntStqA*$~U%X)Xqw~+4V9U{#C&$miryE__Z`l=8 zPxj>deV7Krq+O)07M)H!bVql3KfJzcdO2-z_NC_^@pRc-i9^!UedRpULJ z_#mYK@@T+w2$*;a)VSlfy1UaQ*?ttySr1P;;KsNepVGR&hlyf(6b?}cG$2kD;UA>q@FuAE_yrv&-H zj~B`C-np{Y(|_?k?%y5#;viMWSbJw$mwn-xMi0k#nSPP)u`iB!#CEE1?t`!J^*Cvk zc%8Wcr|uXL#Fh^}k)-Bc>F&4OOUOPRraj|lVR-)+=PBi!O?Q|%H_18fLqUT;BS8~D zm7wXM^FY^t?ghOB`Wn;;Ld^$7KzyQ^_tOr<@16_#7pMlp{|B23DY(b#6w7+xV%+a_1I}zcg1f8U#9d=Q znbywOlQZM4Ol!YAFn@n#mQ}G&JL|+X?W~7qZDtKFZ*N5>cCc=kk!>w|X>;q6aa&qL zcG}w7V%Kf0vx3`MKX=)|T5@P7YyAtmSl4~Mhjq*Hu2%1XJ*~nk4zQRHFa>f35L;1@ zl+zwPAOt8c2%=H$DC4zJ$n~fvd&6iwH22%9DnDIzYRGn~-0gs`@aaZZMt&I|sHq4} zcgFB^r|)N9*^2n5T)HZ<>j4w{GTo_&b1Qs>ubA3L;^!+V>T+*P1hTTUAEGM>Vuhue zuN|OiR8GaKUauGROfQ%0qf3A89s2R5fldH|OZXD5=*@7MK=AZ|dPbF(k;9W-uGh5! z&v$oKop^WsR&VU5;n@;$629ONUGO;N+M~%!J?+XTUg=hsOI5Gta;cyrt$y)+wWd$~ zoAdYigaU!0)(v0bE2j1l99VSXFW2gqF?BV=rq<%Q8)t>b_Ouw9FCW z{g*!szOu2xxoS({>4LBD?NAfnLBZgZfFCd1hQg5|RB#Pw|JkDoL;}9*z{&QzGIe|s z5`6={S-~6SaasEatm(lii;q%zK407loU4Yc-{IB9ZJ%(8nZn6dMEDY}=*e+PYC2D~ zW5q6nr@j-tCwKYFQ#VZ}%6~HXWewiv^*bMa{v1<&!WTTEr^Yoh$QLx#GxEfSr$?(J zKIK)H*Sc2V>hau!rcQm9eKc0fXS+jQ!WTTEC&yJ#gGW8<{8&U(sQ8Lo#9tqQHaSqK z($bax_jl*FWbJFi(05Nc_Q;N7`#A|oc-?_Z_<~1t$^X*6q6{G8NOYVgC!PlqzTgnO7$b*3xqo~x#0x-+u{w>R0y26fPTAo_ zK0J)5IK%x7gM4^0Adb*35Ug?SA`nA>QcjlvC!_a*sB?`GS3z2HusE4HefqaBT3_wF z`t7?zV3Z`N4S9DH1ptNJskWOM-RfRjP9ub|z{475NSJ3+vv9 zBWUp-g+cJu_I2Z;DUnx~|Ny9_0&TU^^eB&pvH=bkRg5ns1>w>~pOzor1tH}MxSj`UB;ktd*a;d(h zeV%rt-xo&lo{9+#2;b%=zC(+~dO$7+@j)S+>HXLk;%BfDKgWG){(dz2^iTi&pj^n|=3B0t zdV0nkqjzRZj!gttlZInMU9c`7*cC3ILqn&3eVVxdX(0YP9e5rh>u(tm@b?* zi~^6uH}RH3&Y_HYJND8(Fh6k54k?+6fhp;ndyreslp%kwehy{kVGDl#qUky3g%zoL zGA!Z4xl0Z82djhjxXEKTsT!wPl?#mZq@#?|Gc^$AL%3-3)XZ57p$Wc~t-!a(glpyu z$ls=vvY?{Q_Ez|cseLpwsqmS=WZRY%MOcC_@8IVTbuwO1y&0F<}2(uO4(U>D+E zwmYW1by&jx%p~@?n*H-h?DI7H_mbF`Y4(iVj6bT`ACSa8rrC4h$MnBavp+V8eWPYy zmBijUJn{R(N$hhqdp73yvvNTq-#pF!{3P~en*GH|?4z3fRY~k)n*G&D>{n{`*CerT z)a-9aVs9Oh`2Cz$$DgJDzFf_ISrYp^&Hm0L_GOy=-AU}Dn*D=G>|>fepYFz=rQ=(v z+2e`bX7-JmJ)Y!jX3xj%r2M>)#6DNEX9o*^mL7keX3r z-{$1G>pRvttn>8sr@B3(Z=CQ-Ij_x8ig7R|ldstLu%5A-<Jwbbcx`Miax`Xxx?E~ro>Iv!v;+h_tIV_+3Pre6Mj^9-Q@`EOWkUi~p zxS*d1!t$WSKGReX*L;E?&JLag!W4qV^o@Yfjj*_Q%XLoXGdAicgH8dR3OWsRI*1E= zQP7#78KAR3GeKvA&HW2!tg{Yc`1W$R(glL32U#K$n3o2QjO1 zoNy(G6SY@?t_CdxT?4un6ay^+T?e`zbOY!{&`qG5L5o34K(~OFf^G%f2D%;eH_$TB z9iTfwcY*E(-2=K8bRTFr=zb8#JsjI`{PHm95zq?IO3Nm@ z=o!!&(6gZDKB|T)LOMmYaRZ{-F0*D<^IWW z{#D^^^;ZSnhPzDyZ4&s8N+5>VWPDUODpSSHb`;%)X6t6_@tEXu)24QQHvIHvu@1_q zItRdUituf2;_Du#Xsc)*XUx*q!z0X|u_L_`F@%{o$~$h@P;W_rguwo#;A=GSnfo|v z$F{S2Ui#i~J^poB@5|BOp~?jjpYX}kRa$&4Ae)6i1XtB)x7;dV*B8XT8PDHCv-U0T zw(6qcYuSBM%Jz}jj4$@sJH!d*u*ZIT6>EC_$=GjEQ;ywOVQxWkHu2=b195QOXclnD zyRxHlpDSY=I?kM;^!so#ufFSpANDxyJ;AZBGVE)ae6b&0JSfyq8}WF<4K?N1-%!r~ zFyJ5JtFE4et>z`cVpzEMjWr$Z9uMz>z}OdxO+!CA_l4tQz&YZKruJ!BUSn&@)jbat1vLtsy}(k0a49$G4>Ounq(!CN$^YU<|6k0a(@ip^^CcY7 z>0UP{^Z#e!>G`aFOrkvSP37E09aMRkQ;0Fsv?Cgcd;CWoZ~O4JmzMW;euOQHj5yz6 z$F&hyY^;{;M{+QAbPaZrPASHQpW*qAOC5)W^I+T5BhSuWD6Vdo1i4=_zNrX>KNo(aTvnAP%4Lu8n@(pO^^U#d zKm6OGa-b=D`xmw7G_6Gpf$8}^od?Fp_>qh)D%uN1Q#UcBRB>pe{Xx;)O?qO7Z7#~UaG)tbK9};;I zp17wQiAVf{rQFjGm0%KgjDuz>Jxs9|JNlaxgcNu zr&&lZ7Yu>25_i<;jy#ri;j>(lN53?)%_gxv;s2y(kOPsS=t;?7=!`_;~a@G>J7=|LA(UB^iu5joU$9YjwmH~OupF1@pv3S$*|x@ z>*>^F;7B&lIrH_a9vk%Nh3k&90Vw%#o>TY|zv#uj$$oVPl_hapf0=Q0pYPNT_UQG( ztSYx$%yk;Z@$;fpZ%%l5f=A*LxtM&hZvl^olfNEb`w^~?D?#uyN^m-lRnV`VUO9pE zxF+2_=YpxHRCSej1((Se`*gVS1J$g|THpi~ASR?46JT8PP_l{Sn-__kKi!*V&97N*U-4j>2lzqN+p*$%a48F z^lvV0lK2FV$rt-ncqo^#)5FTCo<4a~)8jb&i>3EH)%TrziAQjle6df5LrSQQV|6QV z?Af$>RQ;t@y(J#OVe-X39gbogA?5idJ)e};q|YaBJ$gyEhv!F+m3Rb)$rt-nIGlO{ zsUv7CD+-U&{;mTaDldrfBr8A1$BsBM`>1Pgr#mXaWAbg=)a8e6^mHi;rkBSRMZr_8 zpU&b|O{FA$lP~t^7##5r_D`y-tW-U;TzHK4Cu=h;iRa*RPvP}SuKY6}_DnJ2 zq#ex|GPv$lxOUd@50ox>?s3{vQD?tg_=>50xVu2z0ansbi`&QWNCGdo^Vi^xas7&x z_!Vh-yVv_9clzZZT+SEF>S9@i?Y7BXeLn7Q_Vq5@_|~D}U7a{7XO3Tl@37+FC{5T-TP~;1TaWJ|<4zJ7qN@VJouHBi7!M&8PQe5&x`3nyIc8-X-6yO@pftxOSZJNiECHzgp)jVAd zcfm%$KCU&W zz_4Oi&E#MRa}m6J%AMAFyPY%5jW>ovi0tF{7>cxfz44LKZL+M!0V^JE$eCSv;~_S( z@z9vg!Z-0c_Y*nOHJF?kJItQ1@s#+&Q%2X|Vo{l@QC@XCu{3x#Y@21x$PCTC`M@*p z=6XnI6j&TDt#Yq!GzmZ%-=4{>iXX7J#)XGE}{^kv?me8+`~bEHf!;VY*085uk= zh!K|$S4mZi&Pt)kR~N?irLi@&%D|^{l+y7O)u+Z2E6B1g=rMf5FIU}Db&!Ea_!<;t zbm4K`7Lpv1j;ApVp1h%1mUsI%?rVJUv;tE;!cU3Ek&`B$A=P!^Ds8&Mm0qyO#V8}=KDe)wekAX<9*9V;D#$)y$a&gP(jDx$h8&*`k-(W73Ky3zM z{t>=nY9FV(k3r8$y?M*imW8;-%2Qm62?YnBbD@V?x8Q;aZP zec=T?>h7v>xZkoO5NWVO(Cgo_)7|YQ$C9i@X6=Rj?r%J|KYdJ|wWzjT&5wgKUkz7(hq)?&)g3JU;0EsUaz4JzQRhT-)T}7HO8>C-jP&XD zR`kU+GuP%dNsM;-WmqO(?A>@coU||8u28YN=S7+jKb7PguFJ8%mwgP*;I1Ba2JNmL zwO^sF2@C4SM} zI8vvZjg0r^VOxKBwGW-q5S9gbM5h)dPX!snSMY8CUP?~nMl*5g_jHarr+mjHhrWC* z*h-1qOupE=@#^W=8g%Y;l{sgnPuGXf?Ko@TXAd~FY@!^R{N(uJ>6#W?3;~GTde2Os z&i}kEvodS*ncd8E7QWyS-7UA&>5LhP%4+r*S;IO3xaPlrFI~Fs))adr^Mxhc_Mw!d ztH~F8H$FXG-Dq?iMdzeXzwakU?ml-uEg&4gc>dd2TW8^-=)z#V7^JhPP$!2#9ERy*lW)zNZ zgpYq+O5Ste3&E&su=Ict7gLs7R0)u~&;u%#pwb)l33F9r`!~>dP%(DPrKIX7cMaB?;o^KeR z#A(LS_Wyrg0#QUM_3(V;8|DKqh-pN#*?!&e%}2XzJ!1y13sQd-K21ND4>pss#C1-b8`qpFXv?!xXXF6aYm1ed+glx zV($!D&!V1z-GRavT%xn)Pr6=I5DMYpQ{Lb|2G3oGD(vOpcsZAPnBnMYA>oQHcJjZj zr?S)CwZ^;{jwBtkFHE10?(V+(}N9OJAjz!2L|2Lb*Prgp$ zkp;J92vcw_Zw1a?RnJ_1RPM9)nmC28K~zS;l^kdDdHpnSUF%C_7rD!axo%Umu$?ub z*PiD+(DAt$dpn6s+^pAyziD{wrOOoSU${y*f8rTf7}L z>k;9bxKhhUOGjD6u@A^gv2f+H)vdsH{E?HsT~T9Yn)rmjY51C#ixyzI+KZ|=sq38SIc*;=)cED(Xrpc(V5Nw_Cbel`WriZB%ZEQ*KgzA z++b}jZfVbNAg4iH&z=hpf`2{Ym+)sSzGh-R?CKqR)-z>u-Tf7gtMvUO_}6->kieGW5@s@=`#!QO8Q*#>>Y>mzBFAiMa*uZ`@m5ygI@DP!t8_j0_zj4Sz6K3CX z#K-hYCG+Se-?qj3cBnEjJj5aoFr3i}-ZP6qH%OMf|r*m(L&9=C*NJ--i_ z@5Z$n_Dt{6D>ALf(O*0oJu1suwe^kl?;UXDGqR72a$~*{KK^wntbkzt!G}r~s|?sF zU_YGq$M28c5hz$m>S1_iMNRXpY@p+2x0F z6+Xk%l}oPP@(6B97ttzbdb;+$GIhGH9GPX6Z@cAv7d+D?Vy3I`^|)zv#gBC5y)ooR zLGrto8S&BqWxW9;05=!J))IV1fI0 zCyReo`12PZZhZ4S318wj`C{*mzbJrxC|u=pVW8V6NN_A~1&-2V|IuxS$6n)h9Hj(@ z$rpQ<{D;*jL1@X~s-Fw5N-u}?-A7%}clygOOZXDM$rpRK90t{eBf+US!cx&ZMQk5> zx~y#lo=)?=n);8Ui&zAe5=Sqf;gFrL7K?gGq3G>a+0|~jB&&yi{9vyI+0ic> zB_64VO}^MCtA`VP5Y->!)KUNsA2U0;(y1v8o@Lj!vz|Qv^+_*3vu6KeoCqlw))T^a z*l{fpx6`flhtMoITt9cX;EB0F%@DR!^b`e2zO7y8mXA3eFB_d@tyr+zd)q#r|K^W& zM@+R-#3Ou$sVfZ+njt*28??nCZuESzAx-?&(OK5sKU_2B=68PRV8$XWto{asBQ!k73(PsD`_xHLI<(CP74V&`>@Jb#4=$RJy7 z+ovv{&ex{Kl~ZNDHwxqNxz)yQsXK+F3UP$*}8uBFB`RsiA(su3Rj90 z)Z33(8hq9XSyrE@^~&6#w=ax13wS)V&GZxgufnI5#TWt*dF5T7T3)eu*Rc&&Elp z*S7s~Ugv4c8pBS;jMXr7wxarUw_xN;|FS-ZcJyVt4frypqI68^8kl_C}O^c!%Kd;X>!B4aYi zxgW-T$Y)CrpT6W38kO3|`I>yk+S2N^0$-@Q!JaEr-6w7%E}rhIUhoD628PQI(h}ueB}+E!NZD*J^7KT`RFl}<3L-)dA zw({9CI{vVlB5`&dx${-k&FOI+d_s?c8~)klG`s(8&y!?ewnX@XM|2l1PS~i82=S@a z7IEbw0M=vb{$Jpd`LF4(J<^3`O1EFE*?%|YknT*=#g2c@{}e4w|GQRX`+mCUm@D3e zH>LVJUz6`xTNqn8FF%Go1@*Ofr;byJzG__kz=x#uTOaVOdRRS)hzZ6zoJqjwyiV=> zWLSFsT-OSm7iLUbbJQ(!&lVi^JmdbB$rpP$Z{``o*S4#%-WkGB$Qx#+^bEqS9)ZXp z%&ED?9aT%x%WLC#AMWtNCFgXPcm#*Z7yFbr(BrMC@KpzE{DY=(Vg*WTgLcmpQ=k$-qnA`gGO@H<~zv z9|zzVQsO9>iVY5h{<;p29JTZ#dzxdX2zwJH-P5OnUx4H3b4m))j1|~?~-tF_Z=ik)M zD!$;(UFJOBcYp|3#)-nWLrr{JkH>>eu-vqR{V2XLUQn}D6q?{$2Yl(;$Jc$o)V{Hy zYOUivJ|AxK#a{NE4GZ@#Egc;?u(TAF4qogXgnM!5CJK`HOK(pdf9ILm)*~Z^&wJH( z;rEBFJ=4xn|wb>c(Oh4UA; zv(7C&XyC3-Jh$}`;8RKb!ne7JuhvhAj}~~yajIW+FYWib(BA%0_miM1R`cL`xmcU# zcNQ*bXN`>>x%ZG0J-)r2pCb8C_=#U=n_B*zg9DS*O9MC>Sn2#|c+v5cElZv5jG^a4 zUA}sG==iJc*b?hRCSUB6;lYB{n355LgQ(qc(YqU!-rlTl1)f2L8^&L>+t1fZe9Q;T z4JKdg)8VmmgS-8$y~CX!H$z}tuXnwZJgMw}1(!y-?4gw4_}1WyeKH)*9%6P)1cobp ztUJ@=IPTi1J70Th$uSa-)T1U}?9<>dlgCw0M1dz&J(ar@^RwGlJ$ce6k7RS4PsM&b z`z69xOzktoH!Z+3Ii6woI=gB-eGaPS`VG}`kkk_c?sCh6X`-K3%D$(awb|ltu3F;l z{{iobq>}O@e4Cs2w%D&lN1o?{Sa~F5h7H7lFfO*k&aT9>=_SEhb$eSOHcQ}4Ww1Jc zeO)UNh2Y+h26qu~pLqO=Zkca)9x8GZ+`>;FwoShh_qafXKRC!&8>tKVad<2Va3`Xb z&;|eUyHm@3KJbsde|p1lJ@)&;#4mg&*tqs9@q6nk0vUxbY_|&+BJg{mJ@W z`+qF}r5u@jv3EAj#GflE3f8L2La;{wd${=^yg$T_39`2GqR%%r0uPn+kIZ$KM#%HU z;>Dj82X|{a_PfvV>ubA4Wm3X9}yT)a+3_NDKt$nba zHS?i%gQKVY(yNyfr=*+kH7Lrci6lNrfCVZ${)Bv7IC7S|^E3O_%+oTjll^!*E318% z$zS)Iyg>DHVaIiC<{#nXUzbWmWv|D0D^A3kCdc@kOHuPXDkJOZ6H9|54>(>6EdS`O ziGvRm9MT>L-vt8yq`(pH$Jrx9+o#@t=yAV0znJN>esTwE$O%2y++F!pIrleEN%{!i z<|e)x9^8u&j6|w2qk+NUU_Rrd9gx>?EHiL$Ou+_z1BmPXv#L5+uU*!!^WFFNc4~qI z4&f&d*rt>?)atwKPEVh_2U5#}J`O&h-_Nfe{K(C=ZyN`{CSUAR;!w+}WBe!8VXu_q zLC3S!z+=jVUKWkH_v|lEJMVIdkLg1^CSUAR;!$$Jx~~REPp8rcQ_E*%B`TGdZ#r|$ z!V|Xnz$wssBVv{#;R_DYbv&3N!&wQovz#b%U87>f;6d8g4QX&N?CY#Oj(l+ahw<^d zy_~XDGd|r?CBvcWzLH?V%8?AF#q6tRG>9>TA^7G$lv++@fh=pYgI)=JvE{YroX5za zWPB!ko16G1K&T6El$;Vg2Utlk-;cY668wY^_4c&)!>RFEQ?jhPJh$E4)U;~4(@dy- zEYnf=31qfOi<7xp;WNO<(nSIkyz2RVWg1+uYOLR1`pubnYjP(3-2o=~OZct9Ww-Gq zLGE``&Ao<5ms9B@spXU#>0tHg)$tq8`j@ibb|Mx$!fy>8driO}N`*_8)A}^H@@lfI zf{ngizAc$|^5;&!LvRVdHMrvPDGA!`t0pHMPyLG2a$;N$?>O7CvrpD74%(CW|oO#QGFP=Z=eWRWdzTgl& z86H(n71WnkqmzwJtba1ljjgHX99taOVgw-d!tyk@q9<$DKOawbYK|v`g#l-F|Y;5fA!p6pK#qREYe`j|O3?mBO*L6MD{k#vu=es+c znVtFXInz6Hj!ch^P~R6@oQCqWrILxCN;HIz$$WblM?5CSjFksIk22Moai(QW!;EFV z$#g?<)LT5``DK2om$#sOF^@0BsX`aXdbA#nOr})aaJ|UKBA2@F)2xp&Jt{CmPdww} zv@p6ZE%DJ1$b2*1|NFRXil$TU4Y}B*{k)>B(}@q$$$XRP`qb#xc*Yeo-&9em^KC2f ziOv!tTeQcYVwk<@?!z{3ZRKL7i%&$UO&8;eF1GUn)ujn}Pk$YEU0pBHPl&3Ib7~!k zJ1)O+Q=Yaw@^*%PuKN3i#j7@54v#G^>n4p1r^VvBy#6QGAU+_=FH94M_P%{F?J-&M zje9q#S=4>ssYRla`lobVGB5h)1)assu)gMoUmb0A_nqqxiq-jGb1?4bPLc-M4DPpT z`g{4qgns^9XELPA`O0_N5vVOHV`J{Np1vIC=^oJKNK19CU5slAkq_ecU033e^AYE5 zqIA@8zGS%QezzRCWyosP;CQi_x)FKNUzg9WXw&8JSj$VEXX@@8){hy)n=CKyLowsf zmY3=7bV}Rx!oBmQ30c0V9Z~!<&R1Fi#3et z2$2u}#P0)y7o-00NWQ1&eplZ0I~q-E-L{5_wAsJw z$28?lE|*Gp^nC{v_q3@Xww*zS;o`o6Acl+Wnv7Fh9xofFQ3`gxZ3F4^15UiT1_o%eO|>jNgMa*2M? ziFn1UHeHv@i@F{yDpVI4V=nF`an@C&MQhCgPVS<$W;uQkJ#zh+Ks=)4WPXT#aTxE& z$xn+#>vca>g(f-T+5U9V7bNRC8ILwy4mZSO@4`$)6U_Shylg$KJL$(T5g;x`8ui%4)yW&!+6AT|M}hrecr#WBj+RI(5B1bQE^zh8D`JD=hP(a zqK`oL9K5$^c}CYDam?fGpks08%a9NC>{nLUt^18n%u~jrP5j9<_ap%vMTno*fCNEw>&PT?fO_#&tileda3Zav`Esvx6ILE%;g~cPTVY^;G z8aUr!iJY&DOPel-|6yF(;)}8Uv^yPlzMY@3G{dWKv#N6bGCpm(9R6qV#oSK4j7K~( zhW98Dx%tpzIX@YXHeC*nE1m|PUOhdj&WBdesFcs&qZ4;h8FqoXNrdt$k8gs{#GPNw zSIt}CZroK~?vL6|Y198od_NT`6H{+5EY8Lqr$eS|gX^b$bV$Y_^HG~FhyMrpsQaio zuJCxowLYk)M~69^`pEgpxU}hVcwBMWyXbD^{HbI^n1C!-*K={_*UrcTdyl+6u}aQY z#-&Y{!~ZO+aUo)sLn{I2_dfIHO-nLzsXpM~e$_$7NeF@q}uNPMnbQm2qj) z_WuJ%8dO_g>82k|%TZ zsOu{--?ZsJ#ic*jG2Ggv{{gb0OIIFM(2uEJ&LiUyN3|(M52jEaZ%UU?2i3Sam08=z_7Y=^-#S&g=yl7 z?S2QpLyF1kum)r0d}UnPbUFNYap~HZ5%

      vd0LZsu-5zAU-Jf7qza%%%|9{_iVGt zm%P-Fw$0@HWIWn*Ib0J@^blX_rXu+DcbZuiNjo1F^*g3?w*Fq2KaCYWcesJ;*RTbjpPxB7n;i3 zm!gh)wCR5wm#rsPI=O*>vpfC4qkanN^?gJ<;v3w$dWyiRr*+pp#S~=uY188wpZ?&2 zk=5mAdNb~P3jA1hLH665emXDFrvFhKu@qnk6OiQ>7LT~nF1YA(!`pnEoUhCuZMqyD z$MUVuA6;B6+&RrCss-0+czO{;sJKx$YeKRc3Dr)hHDnD)dpT{Qxv-I(^_26-Y zn7=Dr(!>?pc5-%DK#Dtd?|#~^Y14lZmu)8}Ps0{TKZZJAyl=&wFLx_Ex_h_!gP*SJ zXw!e1zp7Ytk4lO<*9=#rqyAS#rrv)jw`0Z?TfSI%cR73V@uUrMzH)ierpw_`%TsMn zZ+9Nl^!4Xzs;Ep?+=s%!q5keqe{VUyI-i1xM@-)m;@t$v5z#!6ax~@O^YkhMUzNI? z;nJ78VwmW}dm>(Cx-L=m(!|5lt&>+T*BAD0EgTP@6B`{9kzE?K{m{9Q_>t3uNC#w#w}lV>ifsJKUhPmAq=tRGcQ zSL9c0Lq3uP=(<@I)u(orYJLu1i$CXufaM z5~;Y)lam(n6?507%i*!j*Ss$GBl3WPvjbJQ>l>8eKKt5%hDR%O zA63U?aWC%ts8#Jsuac8@&XV($acR@#@L1#0$70#FD^=7u@tf99QN`S!N5mtpN)tz( z^(}LZUkvq~j7ys?hsPRMRDS6i-}!BP>iv1E`*G)6g(;1iCEojXfmmNeC*n)Wt4!A= zs$OD^Pq)_cXbg24%2CyEM8+eIAs%LLp04h+Qf^m7945pe)8%yKd#rKrbFMefX}F8J zFAXEAx3}I8;?9qoWkzlsQ!aCPIUiYG+H^TQ);RRbk$wZGTZU*nou9LKSR}@F&E#R+ z@woPyzGL>$Yd_@tWIWn*IXu>QI0KJbgnqHgsn@rVc*M1DjoJM|6OZ4Q^ObRF)8+73 zP1~mEU`hhn6w{eLY`T3FC-;cW(G}}%YnmR7m$8qOZ<)mjXpPFBMlAN#1FKxOU z9&3KFe8m-7C=-zTw{%b9j;n0nx3e!e?+BCgm2qj)BoJ$r!)GG7cH1HeC*nHBQy~8Q)OV+t-k1G4r!2GqXpnr-_xt zQ!I7Ijzy<=Iq*h$j8p>6W05Z=<{XnZDUs#muKXD&bMuN!% zaqpRU-jm1qm243A!igQKIMx$40*QO2@*povkq`M%00mJ9g(03bF+)*^+o;9KhWG)s zB+O9?7AOsQ%vFwlu`{TEil~IjsDi4fhUyR}#Nx;NTChZISiu_Nrk1*>2OEg9uli^J zaUWtMG)5EHL6o1khm5xv*PAS!$6d~avOQ?q&~MW$Z8^(yF->(BXE~eKe@-Vhc7vrcqS~iSs z5=A~QOd>066K|SA6csu;xYCrVv$z1RJJr;ET)jTnz4(1x6J8}&ytdT#>iT5!)zpTW zi%*FA*krmoCebhA5_f&-Zo{R|#XI&;)Nx$W#G$=kIP7g=#d?j?gk#I!Ur1}1p^QVO z#}S7*C(K(k5^?$JKB7MEaeevw{BV4qSXt*@{NTiv?w7UsA=7^!N1a|&y(}JvjXhKN zuzI;s$bZrOZn;?+IjZFLW{vB1PpTVLw|o`mRi^7xqhDiPZp0EJ?>qcOWa@mH@F`|o z+VT=}%Q@%DlQfp?*C#Q|S}fK{h)bp$lB3=XOKHqyHhKvsDse}mE>I6|ceX#=V5mL6 zG^{#N(~PYrKI6ppxrDTY9Qfay10gK<+Vw^IeYER__J8g83IG3nIgqeD`}^`TVM_o1 z=Yab7G27?3pFh~Yq~_#X`3FYIoY8OF5-HkrIXp%^B2?UD<>l4g%_XX3KXKZl>wBn|l)TRHlx%=O|bT>Snsv9pouQFYHUfnfz@iVt_@$qXxO_N>RxJgkQ zpXn-z)m0lCK4{bB@So=2)ZfKl)ZwP9 zOTf3KtBa>T5W@$8c$fJRs)4xN}w^)`B{rX|pVg)g#oWBjz7v1mH zk1q{V55Bs^ZHIRGl`eEVIbWkk9pPX?fW~?5lzd!^Lx$CW(K){FoRSDT~WC zEL=Eek*eDDN2W8m7+oyOkAD3T7dYvHAlIJ}am-(gzrw!4jh=_gZz-lBj&8N-ayZXhQx$-$13=zPQ#(-p?xwzu zcqtz9H?4jz;BmdthNC;f^>gO0O^?s~shnN+@PK=up^5^2{Z^kxI3|rdKk}b%P_Tu) z)lxY>nIGD8IoyyR)^34hi*M9?_4gP>XNwZT2jq4|Nfvh;k^4H%j-28bCg&sL(5B1b zzbltm^2J=-3MDIS7SmAY(};M)SF)K&@*-`k=aci7@oCfL@Yv(y#H*PP_3ybji)vBD z6?=6Y=}h9zr>9Fg+uyNi|4`0H#-UA@!+#k^W3L#IsN)FM#1Y$hSNmtFQy-d?@2BUH zwdtBTntQtGYtx`*0Z&mTqEa0$fYZK%{?;V*?*$gg8ZMqyT zPVTt!-q6k0&%C*(5C2h>rno<@iKn9m zIvJNXT@F{rCHmtRRm|U498<)dUm*+5mtDJP?{GO^8J9L)4p+zZoBT37f)br$>iqf` zkGPUww4M24RmwARzA`Rtx*V>K>zDcUQ&chU;|fk`#FjVuc-@8mE|B#hiFp+ma=Sym zycau&e$mOewCVbxy7nV=?eqESTc~j0flSekqApF`A}U(Sqp|}1(7H5>!2NKlYKLNM z4@^_VEYH}kzu2FAyrAHj>zDHx0ub?~B}$ntPZhw9KI-<6HU*DcyRN$bCQ2Zt( zF380E{duh>j@Yg{Sf743yi?gJKjo7){a10cbaCo#sM%K3Z|mY56`1}L>g`jd)G_lV zws^jl*xac2(hcI)09_}`O`9%<%h}0%iH=9~$)Ub6u1|%>BaZSR<@Vjh#c!!1O++n-esNwSVp6Az|7E%ySNt!?&&kh_WLQTP}oI6zO8R@^jjG$YJ7hvS0fd z`B|AR#ufeQPRv_;UJ(6aJrM6Qo!*4*zcdGeh)bS#w#sazTb?X`6Kf$m(=spaR;wLu z{=V@Qu0y{yEDVJW>DrH4y96}z@^bezx3abq_2AOrS6v@351Fi(8s;yq_w{1_a{6QX z%z7d2WmFFjRt?{r{42Gp#~i*@HGJyLMOn1NFR6xG2BzGu9sW@@{8Vb?ns#`$EYa~j zx7tx!?3dN?RZ@JtI$S%vmumQgT^2jV`lOzIuxj|==1cc!KfhHq zeA1heDYe5dsfHWBZ{ejK{*mEF`U1dEYQW-1uyNw*be@Xu()UW{)_sNOhD`dKE0;-orE*@S!f#&t>nw#5k;Hdvs z_vBL_DaR8hjg&}^UHHWzPR0%a; z4RJrJ1KObrdY~UhL7c~hVjGU*7Cs^a@s~mqhzjav-~isB2nFqkdEikQr3~3T9QV+O zLJC7o^79y6*tn)+<9-~oSpWy|;Mo8UK&Ep5ay%9H^m0%#lba-~@CB0?zMutPa3)`{ z4qvb$U$AF>j$QbIN%(>;e8DPw!3lgpKfd5QzFv8M@O$c>Aih6lMkY^fmmK- zx-L=mqN+EOr&zcs`!93GTz<9j)XHn5EPb_i z>VYmXbiHxLV`aE4Soga*=ZpH&MJ0sktB+giF*R}TG)0-v{TJkbDKUuh z5&NZdxuUP5Z|d7Ii&!+&=aC@{7o8=yY(as8UxvrX{X_)^+P8?ydImYwm67#~s$*e)?;G;xj>z`*Bm&E78e#w9B~| z_H|&ViSN!;=*^}@*NJ$HiASazlB3?V=e5!2`}zesh%x2-BTeI;|Dd%!pI0eTzNmKo zGCgX>h92$wRpwF|s@!7L#KWsyj9n^Ja6a>(@sdeQYbz^<_j) zLid+*KwCbhOi`4BAo7`AnXc0>htcN~;(t*#vOHv&i2oD1zb^+&nUvh#Dfx_|+FdSe zvpAP0!`SUdt>3{67o8oQ%JsCsd5>8fi; zSv(wJ$AhV~x!@6f`@g>3%;rAswD{e;yN83W{ZrkiNAN1QJEr+##uZz;T`N61uQ-!v zU8OmO6<)+I+R2jXs*rTOh6nARE_M_Q{Rf09Zll-$?<#9BjX6x#G%cf z&?Y8IsvFO5E^qPbkk~GXPCT0>@<*oY5>+qqc{trn4aX2-aE$L?K=b{l1?%=hA=W&D z<@j#JR)#;z{ANm_jDweYkI0~#dH~0aV!kq6HA`JD=WO0yzEl`2>Vwwjfq6rxKq^bn zmx&BTy?nGP6!-50)&s_MzPol+Q8_;k;!qTiRN8boT(+fB&b*$tzpm~KYmWYSLQy7A?#2@^9Fh74~$~8+BeS^4`oaTwWg+`Dj>m z>5J~v$72yiVy*|;-#aV{8!5NGuI`e`^5nSH74#+3!>}I6^yn$;`(j%UWSWo(MfP2Pn)n6^5n?uQ13iQgNN^BR@T|LRWM zGtLd;o!L6-9z!;-ZExPt#i@&V9V=@GX5`Aq;`^(wr-*qkLKyZU61VUOk0HKvBIHCa z1VLOR64x?jA~|uVfVkOCdQ1wNZsg+YtGjCC<*jRJ)7IJDMK`*7`_QU*%<>jxEwqVwLy!q{_)89`?m& zB@Y+JRWNtv!oRK18cwVnNG9<8gnAqG2t58bn`4P0Ejxo_XF^K5Rb|41#nAiB3L;d)Sb!PmO++&kY!sL37>BGnSs6UA=tFbc>@=O9ab@ z$ZZjac-NLoxKBFe#ii^S2YgsJvk2F+L|2)D6UQ$yU7s5L8sBoU6%UounL_T5OiCCj z@_UP6;t)k0Z!p6}cF1@|zgTS5?OwEd5xR8xrfiYA!yAT)_e8wPbpDOe#hq_W{Qa7A z;ns+sm+J`gnCn+qk>t8-5oRTgl#s}L1+uvrE9-IxOv%uHRV~Bn71b`aOpg%^|Hycv zo(Dc5EtQXI}CQog56tekG1SczPeSn15O1iLyLDg7@PDekR|m61=3l^m0jDC-+1 zRjL+DrXG+2^GHt5E4=3Oo~^eWXxO-_+^+OZX4xah=t zBK~B$E>ZRJ2g{9lJuk1W?k@UTJH0(^xEdYveA7fc97*@9_(u2{E319`3_fsh+J60* z`s=7-yCBnb6HvYUd3^d0$5{X4h|9*^SeaeerT)jz5vj#8EjqE?6miLPU83qm#MOwp ze%$oy6*thTAO12tb`{kMVa#%@RQmV%BxX~whvlr?UZg_*?Pkh)Eay#$H4=(a|ucTI$mWjOa zHVjvvcaRj-iG9=G*{SpCBk`~aidx=9zbIL`UkRO>OgVkr<=Mb7n~Sq)(sd#pkxw$+ zkR0`9IQ-C`MpHpeXAYFa&n4y#-c%AI&#s#}b>|S()>qsisNX?{Fa^1t2re6Q`4Y!( zWf&e2#P+ZLA&ZE#$&{=t83X8KTryps8vXhwafzLbgBw*e%7%KGj5^;e z%Kbh*@AS!(>W_!^_P%4YsFEf=nI0XPzVG+(88WhwQ(z|-k#|wM!5G`uh&bX(mob@= zIiOD;uYD8GYvYpXe?2aJN$W~jlW(r&V;*;jbx*8!V#j+U*RvZz8`3M+mp6LU&U@^3 zc7wW(-JfoGlj(-!sJGwen_S+w!`$1+ud^$^-?7aT9}b0F-g;U6emxN5?{=BH;aTof z73KOU-V?FZ$#gM}y8C5Zb$W4&Gl%aoG+S=g=du@d0rz%sw)Ax7CV6Yt3OOxt>>=Wm z+Xs;@*2PkyCzh@fY1;9{X!>|#`G6rQgpE;bpOc>u+bSWxog82N9^cO`X|aqeiyO7RIfiGU2Z4kI0^5+&w+&U`F;NU+e81!@`-K#Bi1K*PWW$s z_x}y^Pbi=N?ot{-c=CKO%rEA7syGJ~=c?*<7e2k|P@(vnLu^tTzV;>a>LZxO3o7%17k;ug=9}nZ#B;31t&^Is9sjKPewE4Uzu|>(8%p^Y2gplk!Pe zfBydbk86stm5(R~Sr2twpHCS6&*s3d$|qr;@z3Uae5d}a@<~{K;+up2?0B)2&tILR z*gncm97~AvWwAbr^W%i;v}D2`bP4722buLRjG9nB|3aq!!7Tsj@)6rLu}u@(Jb8Sc zaO@HP0!k>K_~+HXF=j&f{2RF*|9Sq?h%R#JlL!|BHSxp6Fz{{=eAQD>)50j{KbZ z|Ac;h4rt3qq>Amo`Z+QAETGK$*tTuzVX{p1b4YmoD>)Eb`KYHS@?EY=vRveTNj+X% z{pxi_^owbTa+K2&{jyvWjt|HTLl;;1$npN_ySjYDv}E~+bS*I~q0{HU|77`S%Se{X z@5(~^nct23|Kl)IzLYqA6ZIKK@*IV%XK(J;)NRDEg8DfNSAYG{wI%5y--0ytNUoh` ztawbhH!1Vx=5O{HGFH?BA?lxy>HHg`vvPOiu?ib%%;eDu7asXH)YILOTD-f6>Lv_h ztK)bXM;vy+#>&~6YuBf;`+Qtpmy&VF^cX?#&+p>!aq)C^@e#FR@SPb~K6m0B@caCD zIm1}#cIoSmlJkyFKdi|QnI7*rntAy-xyPJ;ww^JcdlAuyeMAU#x|iNNElO_Ht??}@0@UZxw8qux~YmW!qtExS@W4m7nz1?7R>EnOzef@#>(PxOzEj)hlM)+WK0>2U_|)35+=T z$XZ6G&x;g4rOV;bG0;+8Z5OJurPX$KFDK_F0WLnS(KTj;@&TEDN?_b^E>dp_R;-%VQ96ises~^RK##>5By&FzsV9 zY+J4VqI^Z&U81{WNZ0=t{iu{OnbB4tNFHduc1j4@j2I|ZV|OsR^gM>U&Fzc zh*PHP5>+p?soJl*Ijf4U%601VtLx(AM_Y8VzE8V0`uNoKDT+;jSa0O|Dz;JLm`)t$ zn?TmHBIDsBt#Ji{ylCPnw4=o$-VjZW7F(oHNb$B9= zscuZyhJ`8b`H&w4P!NSs7)4-)q9}&qplULuB+MZeE|KR{Ri>-oM^wmF4&_k+qApxf zpGjqi+^dRe5cRN$HZrK%OsNI2eAI>&tWgJbQ4cn-MSV0tLo`BTG=Uwc8cnf>SYw-^ zIa;74TA?+_cBL(-LQQFp4(JF+IH40d!x?PWbnSI?<=qu-=!WiKldE_@JnQELZ}fl< zL>c?R9|7ozUI;{Q^g&PU@g{RJvLw?HeoZi zU@Nv^J9c0vc40U6APjr45BqTd2XP385so7`ieosA6F7-eh`?!_!C9Qcd0fCnT*75s z!Bt$tb=<&BMB)~1;|}iP9`54-9^w%m;|ZSP8J^<>Ug8yA;|<>89p2*uKH?KT;|spx z8@}TQ#DP;HB!&@;kpxMR3?@j96iA6wNR2cQ^%JH;dWd#oG9nW)Lo_~-71@v-IUws} z%}u|kmpU&@kq`M%00mJ9g;4}%D2iezjuI#dbBK0oL}TlvQ3j%}#BwMPQC)IHR6=D` zK~+>kb<{vj)B@ENDz#w+Yt%tq)Prb@+7|WE01eRyjUn2|v4g03)gGcPmS$*<7HEl9 zXpJ^#3sIM2dvriYIKl~?&>7BfK^Js|E8Nfx-Qf-oc)|FdQQ=5~DC0V=xxuFdh>y5tA?(Q!o|NFde~|fti?v*_ea5 zn1>L|#{w+GA}q!dEJY}mVL4V{C01cI)?h8xVLdirBQ{|(wqPr^VLNtUCw5^s_8<&< zu@C!k00(ghhY^k=IErI9juSYEQ;5K6oWWU~!+Bi5MO?yVT)|ab!*$%iO+?}rZsQK_ z;vVkf0UqKJ9^(m~;u)Uf1zzG6UgHhk;vL@O13uytKI03%;v2r>2gHs)5fZ})#z=ys zNCp$g`jS)9p9-mw22|^*q(gdSKt^OjW@JHDWJ7l3Ku+XBZsb8;m?9tYqW}t`5DG)I zH)V#RD2C!Ffs!ysDTsQ0OQQ_Rq8!Sj0xF^sDx(Tyeb3eDuYsDV1xwV16|7MQbx{vC zutj||KtnV_V>E#sn!+9qXa=e}Ra&4WTA?-Cpe@>=JvyKx9N~mc=nQALpbNUf6>jK; z?r?_(JmCdz^nee1;Rk;NpeK4E5WUd{ebEp7F#tgrh(Q>PAsC8b7>*GbiBTAhF&K++ z7>@~MCL(bQw{Zt|aS!+L01xp9kMRUg@eI%L0x$6juki+N@ec3t z0Uz-RpYa7>@eSYc1LB}R5fZ})#z=ysNCp##X3<4c-!!YOh$f>&^T=tC7U_^48ITc~ zK=XtOP4p==x2I%-XkIM`M6+h12`bU-Qy$QanPLjjOp9oWqyP$n<`op0K2SvS2vjYv zQ0=%Ps${47Z-uI?6{?9=L>1DaI$%+?t*EY5v_&VX{VWHniBu|}A}XOWs-P;Wp*m_n z)SX-lmZ%M?aa62P2X#>oHn2r~G(bZ%LSr<69h$-(4rqqvXn~e!h1O_;wrGd;=zxxJ zgcCZUGo0aqF6atZxS<=m!yO**gcrQg13vJDAH?M-aVbb#<`9<*I1N=erBwQ$FZ!WB z1|SFnF$jY(1Vb?l!!ZIQF$$wG24gV}<1qmfF$t3~1yeB%(-Djrn2A}KjX9W$c?iLL zEWko6!eT7JQiNg|mSY80Vii_n4c1~E)?))UViPuF3$|h#wqpl&Vi$H}55lk)`>-De za1e)Z7~wdAqd11+IDwNmg$SI+8JxvAoW})R#3fwD6t^6oDB; z-R8w0DiJP$k}yXpSfDh@pe)LvJSw0fDxor}pem}NI%=RMYQYk# z4bTvxt;@z}0y{K?Jsi*s&CvoaK^5mpYqUXIv_pGzKu0*j37yax&Tv5&bcHM2&<))| zRo#jQJRurJ^+pf)z!y|8uJ|JWR8y_=LLfu~dVSCr{m>r+5QKpkguxhsp%{kY7=e)( zh0z#;u^5N(n1G3xgvpqKshEc82*wP|#4OCl9L&W$gkU}vU?CP^F_vH{La_|Xu>vcx z3ahaOYq1XNu>l*g37fG6Td@t>u>(7?3%jugVc3g(*pCA^h(kDxa2&x=9K&&(z)74! z1Ww}&&f*--;{q^~NstuDV1ndGfs{yv)JTK0NQd;ufQ-n5 z%*cYQ$cF65ft<*N+{lBxFhxG(M*$Q>ArwXtn4u_&p*TvQB+O9?7ATD}D2s9^j|!-W zN~nw~sETT+jv5ec)z*R~YQqZFsDrww2OHR;J{q7Q8lf?ozz$7e4+k`ZXoH~zTA~$N zqYc`k9onMHf7=!DL2h6}o&D_r4*Zs-noc)$~0@J0{#z!!e-M*w=F7Xr~6eb5*E z&>sU3gn<}@!5D&}7>3~(fsq)6(HMiV7>DtgfQgud$(Vwvn1<;H#th8FEX>9n%*8x} zU_KULAr@gVmS8DDu?)+x0xPi!tFZ=au@3980UNOio3RC3u?^d?13R$`yRiph*o%GG zj{`V}LpY3Z9Klf>!*QIzNt{9iPU8&D;vCN70xsebF5?QW;u@~w25uq}w{RPGa2NM* z9}n;lkMI~z@D$JR953(^ukadg@D}gz9v|=#pYR!9@D<nOKMJ5A3ZXEHzzjuE z48>6bC1H+Ius~^)L0ObTc~n3}R6=D`K~+>kb<{vj)Pf~y!wS}@gSw~(8`z>g8lWK> zf#yn-Ca^nV#$p`CV*(~( z5+-8`reYeVBN#I<6SFWIb1)b45Q6zwfQ49u#aM!+2*oli#|o^(Dy+sDti?L4#|CV~ zCTzwQY{fQg#}4eoF6_o0gkdlCVLuMwAP(U$!f^ygaSX?C0w-|_5jc%AIE!;Qj|;en zOSp_HxQc7IjvKg%NZi70+`(Pk!+ku!Lp;J`Ji${u!*jgAOT5Bsyun+%!+U(dM|{F( ze8E?I!*~3El8p5qiD3j|BtcRng9(x&1yUjvQX>s$Mnl)eJIz%n89?(8N+$60xsnB0 zkqz0A138fkxseBXVTydnj{=|xAf*rrqX^7U6va>+B~TLPCnAhdVsr2`_k~2YlcQKlmd6J<$t+=#4(;i+<>j z0SLlC48mXx!B7mtaE!o6jKXM)!B~vLcuc@VOu}SL!BkAcbOd7tW?~j*V-DtG9zrl5 z3$PH2uoz3Q6ros#9UcX*Ev_=r#Vj4$|#Z}^TM5I^uILSh)f7)g*6$zX!y zNP(0{h15ucv`B~a$bgKimZfG51* zjUMoUFZ|$-0Q5vJ1fn)aV-40~9oAz5HewSt zV+*!o8@6Kyc48NHV-Lcx7yGau2XGLFa2Vk@f}=Qw<2ZqnIE4tD#u=Q&Ih@A@T*M_@ z#uZ$}HC)FH+(aa9;WqBzF7Dwz9^fG!;W3`zDW2guUf?BO;WggiE#BchKHwuh;WNJA zE56}7en8yZlL(1n1Y;yYQY3>3k|PCDA{A024bmbV(jx;hA`>zr3$h{`vLgp_A{TNa z5Awnk`H&w4P!NSs7&HT@n4u_&p*TvQB+O9?7ATD}D2s9^j|!-WN~nw~sETT+jvA7BfK^Js|E8Nfx-Qf-oc)| zFdQQ=5~DC0V=xxuFdh>y5tA?(Q!o|NFde~|fti?v*_ea5n1>L|#{w+GA}q!dEJY}m zVL4V{C01cI)?h8xVLdirBQ{|(wqPr^VLNtUCw5^s_8<&2gJ>?iI5mZFh&w2MKYKmIZ_}cQXw_cAT81% zJu)C8G9fdvAS<#VJ8~c=av?YJATLaj5BX651yKlvQ3Pfviee~^5-16Cl!66HqYTQT z9Ll2tDxwl9qYA2`8mglPYN8e_Q5#mUMjg~eJ=nk&_0a$g(Fl#v1a@c&dpMvOnxh3; zq7_<0+`Qfv?a&?_&=HPsLML>FGhEOGUEvBhbVGNz!vmi1f;W1=2fpxwKLXGby%31r z=!3rKhyECVAPmGH48{-)#V`!V2#mxijK&y@#W;+|1Wd#vOvV&U#WYMuFlJyTW??qw zU@qn%1oN=~3$X}`u>?yIie*@i6?rvPT~|Ia2jWD7Uyst7jO}ma2Z!{71wYbH*gb?xP{xe zgS)tg`*?tdc!bAzf~Rw>E3`%%v_(6#M+bC-Bb?9)o#6}@bU|0R!VTTf9q#ae zC%oW|9`J!L{NRrO^h7TNqBr`WFZ!WB1|SFnF$jY(1Vb?l!!ZIQF$$wG24gV}<1qmf zF$t3~1yeB%(-Djrn2A}KjX9W$c?iLLEWko6!eT7JQiNg|mSY80Vii_n4c1~E)?))U zViPuF3$|h#wqpl&Vi$H}55lk)`>-Dea1e)Z7~wdAqd11+IDwNmg$SI+8JxvAoW})R z#3fwD6APkRJt55QR_}MPP=aD2C!Ffs!ysDOjL1%AhRDp*$*}A}XOWs-P;Wp*m`y zCThVFwP6Ko)InX;gAHs^9}UnDjnEiPV27r#hXb0SIa;74TA?-Cpe@>=JvyKx9N~mc z=nQALpbNUf6>jK;?r?_(JmCdz^nee1;Rk;NpeK4E5WUd{ebEp7F#tgrh(Q>PAsC8b z7>*GbiBTAhF&K++7>@~MCL(bQw{Zt|aS!+L01xp9kMRUg@eI%L z0x$6juki+N@ec3t0Uz-RpYa7>@eSYc1L9$xL`V!H7$XUiA{k7O94U|zsgN3JkQV8X z9vP4knUEP-kQLdG9XXH_xsV%qkQb)Nhx{mjf+&Q-C;~GSMKKgd36z96O2Go9Q3hpE z4&_k+6;TP5Q3X{|4b@QtHBk$es0}MvqYmn#9&BKX`e=ZLXoSXS0y{K?Jsi*s&Cvoa z(F(2625r#}?a=`p;Rq*mLT5O`1zpe;u5d#)bcZ`U;0Z5yqX&H83qSZH06ozQf#{7s z=!<^nj{yk6Kn%iQ48c$g!*GniNQ}a0jKNrp!+1=3?3if{OiA5hY;{v$DrV2mV4 ziexZBa-={?q(W+>L0Y6kdSpOGWI|?SK~`i#cH}@#+B~TLPC=HB?6p)I=>Z1V~ zq7fRS3GC1m_HaNmG)D`xL@TsL8?;3`v_}VYgd?2L37z2#7j!{axWWzH&>imZfG51* zjUMoUFZ|$-0Q5vJ1fn)aV-40~9oAz5HewSt zV+*!o8@6Kyc48NHV-Lcx7yGau2XGLFa2Vk@f}=Qw<2ZqnIE4tD#u=Q&Ih@A@T*M_@ z#uZ$}HC)FH+(aa9;WqBzF7Dwz9^fG!;W3`zDW2guUf?BO;WggiE#BchKHwuh;WNJA zE56}7en33Ln+S3k|PCDA{A024bmbV(jx;hA`>zr3$h{`vLgp_A{TNa z5Awnk`H&w4P!NSs7)4-)q9}&qD1nkNM=4mKG|HeX%Aq_epdu=vGOC~|s-Ze+peAa; z618CkYt%tq)PoIdQ6CM^5RK3nO<;$nu!jShp*dQhC0e01+Mq4kp*=dFBOKv`PUsA0 zxS$KV!WC}lhVF2O2Rz{gZ}flGd_j3F3`VHl1P z7>Q9BjWHODaTt#Yn21T3j47CkX_$^+%)m^{!fedJT+BlV=3@aCVi6W&36>%h%di|P zuoA1V8f&l?>#!ahuo0WE8C$Rw+prxwuoJtm8+#Cjz1WBSIDmsVgu@8O5gf%a9LEWq z#3@AJG|u2G&fz>R;36*JGOpk%uHiav;3gt*3%79xcX1E*@c<9;2#@guPw@=T@d7XL z3a{}7Z}ATA@c|$437_!=U-1p!@dM%k{zOO&BN!tIk|G&QkQ^zH5~+|HX^MwXaYMlg*_b549(F3Ezt_C z(FSeN4(-ta9pMNkbV6r1!v$T?6|QhYH*|+PJm3j0c%uh=;0r(aBLF?o3xVj3KIn^n z=#K#i!axkdU<|=f48w4Yz(|b3XpF&FjKg?Lz(h>KWK6+SOv7{pV+Lko7G`4(=3*W~ zFdqxB5R0%FORyB7Scc_Tft6T=)mVeIScmo4fQ{IM&Desi*oN)cft}ce-PnUL?8QFp z#{nF~Asj|Hj^HSc;W$p4_=<1%jvo+}cO*h$7{M4xkQB*a zg5*enlt_itNQ1OUhxEvRjL3w{$bziMhV00JoXCaT$b-BvMLy(50Te_b6h;x4p(u)> zI7*--%uxy!D2*~Gi*hKB3aE%msEjJ8ifX8i8mNg{utaTG!5Vc?7xiERThvDbG(;mb zMibbfDeU2ZW@wHUXo*&6jW%eDc4&_d=m#0!5cl` z17G;T9|7ozUI;{Q^g&=dVjRX}0w!V-CSwYw zVj89+7&9;vvoITTFcg85j0g;<2eSc0Vp#WF0%3arE`ti~Fw#X79V25iJ8Y{nLB z#Wrlm4(!A(?8Y91VK4S!KMvp^4&gAuaRf(k499T-Cvgf9IE^zni*q=S3%H0&xQr{f zifg!z8@P!`+`?_#!Cl34 zcl>~;xF-=3!wAMmf}}_W6C_6pq(myDMjE6=I;2MiWJD%pMiyj6He^Q*kLS*O<@lQG(&T=KufejYqUXIv_pGzKu0*j37yax&Tv5& zbcHM2&<)+;4i9+33*P7fANax#{s=%%^gxVVK??5412K;`*8pVaR`SIjw3jVV>pfzIEhn; zz-gSpS)9XpT);(K!ev~+Rb0b$+`vsl;udb>4({R}?&AR-;t?L>37+B^p5p~x;uT)w z4c_7%-s1y4;uAjO3%=qTzT*c(rCo`T7)CHg5+p@3m>@Y)ASF^EHPRq0(jh%EAR{s% zGqNBnvLQQiASZGmH}W7aOpy=yQ2+%|2!&AuW+;kcD2@^+33HT!1xlj~%Ay>~qXH_T z5-Ot#s-haIqXufC7A#R4RlXbO8cpc$H@1zMsNTB8lx zq8-|!13JPHPUwWraE1%IpetPAhHmH%cX+@PUhqZ__`nx_@J9f8q89?u8-36h{m>r+ z5QKpkguxhsp%{kY7=e)(h0z#;u^5N(n1G3xgvpqKshEc82*wP|#4OCl9L&W$gkU}v zU?CP^F_vH{La_|Xu>vcx3ahaOYq1XNu>l*g37fG6Td@t>u>(7?3%jugVc3g(*pCA^ zh(kDxa2&x=9K&&(z)74!1Ww}&&f*--;{q^~NstuDV1ndG zfs{yv)JTK0NQd;ufQ-n5%*cYQ$cF65ft<*N+{lBxFhxG(M*$Q>ArwXtn4u_&p*TvQ zB+O9?7ATD}D2s9^j|!-WN~nw~sETT+jvAnV#$p`CV*(~(5+-8`reYeV zBN#I<6SFWIb1)b45Q6zwfQ49u#aM!+2*oli#|o^(Dy+sDti?L4#|CV~CTzwQY{fQg z#}4eoF6_o0gkdlCVLuMwAP(U$!f^ygaSX?C0w-|_5jc%AIE!;Qj|;enOSp_HxQc7I zjvKg%NZi70+`(Pk!+ku!Lp;J`Ji${u!*jgAOT5Bsyun+%!+U(dM|{F(e8E?I!*~3E zsH`&)62l0_NP?tD1`{Ml3Zz6Tq(&N~MLMKM24qAgWJVTbMK)wd4&+2GnO zKMJ5A3ZXEHzzjuE48>6bC1H+Iu=s!Mod~ zlTa1NCD|kgm%DIxfdoV&D8zzBRER#*SRP`>@)UiF*s){BjvYHHD&kY$@4vhMyV=dP zgizhd=exW4@9xZR|1&!?JG-|FP6h+OKrjdl21CFpU??~h3q0^vOx|w1LT4{kPjw+iC_|#45omo;7o89moC|8e zd0-(}1kMK+fW=@5s09~-i@?R;60j6p3N8b6;Bv4GTmh~GSApeV1*ivCgKNOQz)El} zxDH$o8o&+UMsO3j8T=cp0=IzG;8t)OxE%e1RJ$M{E0iFa;fv3SU;90N%JO`c!FMt=pOW#4fqy(2fhbCfUV$1 z@DunMYy-c5U%_u+JNO;!0Dpl0fj_}t;BP=L>Wu-dKx@zjv<2-zEQkZ`K?iUE=m`<6!Dx^IQb8I>2V+16 z$ONZ@u^3C;r3z;rMJ6aYIY1Vx}2D4+zC zf->L$Gr=t21m(a5+@J!?1|HxAK2QnffVrRwRD*e7J~$gJ0Ox>nK@B($ECh?d`QQSu z7%Ty`;6iW_xENdlmV!$GUPFCu0*Vm7@45~zzvA~@ANkCR5_-I(R$ou=yY7Y;W6>)o zlL5^sj>`bQ?|Lgl*CC z?=MfnOSohm{NB-e==-C{S4uC7IQxVz+rQZN^ZRa|rzQ3>W~77dnl&(Oq+^m&m^wM| z@@;yL0i|!fcN^y&+?E8W9E=7jAQhy6bT9^FfJ|^Y7z?t%I4~Y$gB)-M$OU;IA4~uf z!6YylOaW8Dncyri4NM0!Kmo9WLQn*XfdWcEDJTODFcZuIPEZb9zzr(EY~TT2-~*Ll z4wwt7KsBJ^GasA{7JzfWxu6D|2Nr@w;CyfaSPYf`I&Urn7lDhxC15GI6kG=Cz~x{W zxB^@Wt^&)!3Q!NO2G@XpftBD|a2>cFG=Lkxjo>D5Gx#@H1#SVW!L8sna67mI+zIXi zcY`(H9&j(X58My_10Dbmg0sdhj@S0z3(x0#Acyz_VZjcn&-d zUH~tGm%z*56|fP!3SI-RgEzpN;4Sbr*aY4I?}GQh```ocA@~Sv1|Ne@z^C9d@HzMb zdpcv2! zv<7WJThI=~f;i9~bN~l{j-V4b5F7;J!NK4Va40wobOv2OSI`X{4vqlbK@V^wI0_sM z5Rr$ARO)3E)J~AK1W2AQ7Al27rNJ5Eu-GfK$Lwa4HxEhJz7c zBp3xw14$qmj0Pzn6{LZ5Fa~6ROmI3F3$nmCFdk%s9B>B61$iJJOaK$XBrq9F0aL-5 z;4Cl=Ob0VS0kDHYPy~vB0!lzBC<6{K6U+imP!3$c4JyEF-~nFX1C?M7mUdqTnVlM%fSjz z53UB+fPaCN;977UxE?fs8^Dd=CV-~xTq>3|fZNFoyl@h$L^7cH%GQVjtVjEq)%oDW z47|YR^E3Y*cf!FB4t$4RXoW!UnxJ-)?W$3lG-@YP^73*#?h3`@b0}UM_kmVBITHRF z1x^D=fc!riq<~bA2GYS8kO4Bm>0m6#0^`7VkPULc86X$rfqXClOazm_WH1Fx1!sb@ zz%(!&%m4+z4hlgLC|8MfP2Ax;C}EQ@BnxatOXB&hrxfrBj8c6 z4m<|dgU7)W;7RZlcp5wdo&_7gbKrUK0(cR;1YQQOfQ{f)@EUj>yaC<>Z-KYLCh!h; z7rY1F2OoeB!AD>-_!xWwJ_VnF&%qbqORxoe1-=H~fN#Nf;Ct``*b06GKY^dYHt-Ah z75oOagWtgp@CW!G_!ImE{sy8I`W~PaXbswcwxAt|1#zG~=l~7?9YH5>AUFubgM+~# z;81WF=nT4muAmz@92^0M)pa>KL1(bkNPzD@eCYS}B zpd7e>8&rVVzyrL%2P(lFFc(yTYA_GX2WNu?;2dx+r~&7Jg(+y(9iYrs9=UT`0{AN&VA03HNu!9(C-@L%u0Qfxz`f3}^*fgEpWoXa{0J9B2wZ9C7=|P0SA}~W&tNC2QJ_S6<{{- z059-?N-zh^1y!IL%meem*FPzMQa3|s-O1XqFOUwyQ>I(&#!k+2ts=`;=nS^>97*VI3R3H|ki1bytA0Z(EC>Hw>cTFEQut zZ|-xnqNl)(A(Xw5jvU2P?(ljYZkIR5?Q|4X+a@~PPP-2VTbc{s2Q8w@Keb)3#cHiI$~2vS^goyT$v;Fc z_xB&@s_7cvo`xR`A(TCea-ZyUy5|niW0Uo4i9*lGS#8Eww!3WFDf<2gVBS_7AlPmY ziGQNdlYy`CDjr=>1NLG6)NYOJpNaRCURe9Wyh?Mrq3luU$?-Vm*o&(36qncGbIegt zJ=hDK3XKpM#}T*uh)NY98BmvATyl()4kHfsj~ZIPTJ}?GvE|3oZ3oupVCi(V4uPw)3s$}6?#Wwn~a-PFgq$C%S5=6ck+lH&3+G2ei=m-u4M}q!< z#?`10-2z%eERC_2qaX4F4uRh9->yCSDV?-u5-#hBvN{lDHwWv^Mm_vE`hX|Ih-_SR zm7()>>(n;l5WHmkCvOLF?0|T2M7P65{l~|Ok)uY4ib>PN_t)3q`Hs!v*#T$9jM{d1 ztA&e_TPIZ>(Dq}zQMh|ykB)txee#g?9S%M6x2YZbk5yhwBfrtP0cq;_#`(Ycm+=0L z+tyl4d)~Kl?kiv2{6K7P+THJ8wyQ>I62iaQhpUSRsN=_!{>c-1=1IE+U4#o8gHP&bfigJlMbRtVvN1~@p{{4qyi&KvXp^7dB#$li#4IRTqe{xq!m;<61me|!H_ zxZ?Zo-h1WDhgSFw!8*CUsr%Jfzf<|A`iq{udSqb#Ws|Y~l3C|=`O4LA^kJ}5pgN7} zPqwQ@X+qVe!&RDtuckYSd~S~|Pw{1?a9&_nw?;Az!&!Hh0jd4JrVLO8IIo!9487UE;;?n-o% z(;ZHHmEM+TFHuH&+;hEfH$EEgvpZADl%iSGWMQWoKz^m?V-mL;{Zou}Q=D*L zo?{*r8^d!|6+4Xn38rI8pST-e`}&#-I32C{#0ayU*N4(E#-mh+(y=`X9asE!z{LOd z$fC;vHLwn|o!6UnWGYIz*%!2}Twdz_F#01{dFg)UTa)@HANDGzL+25lO=df<4_030 zC@x>5LL=+y_rJ)xzODE*C;dy;N=}z`neDtjl&;iDk9y4>sw~U8)44X$ZSkhK zT|ST7=~O(aic=}Y;0Gd*bxr;=yuUVH9V_nnzQpxV(vZ2-523*I5!*FuU@GY{pW*p# zO{RL*8*3x&c_^-@>EoG^{FTu6+97vlep95CZ_TeU@Gjc}inOIX#WTlIq)c*qX2DU} zE-v>}165Yo@@6?I44Y)T(j6YJFK{?|gmU{<2c48Y=PO<7kbmgGfR4|-JA@XW>Nhhv zdGTA<98dosQ2W*zQ?{!{X_8&;aum9&&|R>5iptP^C{a*R*?2+K=qk-s>|VEv>O#4` z?Dn@&52bYwn2d)F=1xAqPRX3^=`j1~AM&3-(NhD>V{o;?cHQis<)O~@IDFN%fG6|{ zo7ZG1a}=j&z#g1`YoQ}j{yC<0dix!vPkVEDXS-j3zF=tOGjekCZJ91q*rg6!5lf5d zZcm<~j;>{UvfM@LDXPXG=UWD@a3bl;xM29T6Ke1Kh;?v1VYc)7u==t~O7hE;T&2kE zp*{zN2EhK>5`~^&+p4b~k~hI$ud^Pro#LhtR!_in zPRGlWs9UTC)@Qc!dO1~_IX}m{ed^$lQarj^8zeQ&d_H=A= zcpgE|7`M9=Jv;R9%F)@hyQpuk?kb;u^-<_L_3*le6CdnGk5Q_D{baWD`mnn6$DdKW z4E{-M9oavhTrt8nZRsfvPKR}v?Yus$4nuh|oOXu(_ZsMu>q}~V+JFWme)9YYZ%|sJ z7QXPz*AI>vM9UP^`V>>MU0aKLHi7oemV%1PQH1_~MlL#(sMxWQeBN(tV@#jMq>chf zupe{j+jmyWoqEBScXj-FzMcU2h5G+&*UkQ!!7qBF!rgA0UQ?z*jl-qYMXYB} zKc|jEQpdUE{yqnEWVEw1JU+?qQq=TRPm=osfNVA>S8+56OPVhKwG`#6{(KhmVUC}P``PB1^K84So zSxB!AR0GXp(9W}6H~VLX^wFB7*j=iMRJ+e!X!mNBFt)A%?1%bTWB&BUx;|hl^rimN z;V&$T`fvWbe8`XQ|K}3=2Z3~Sz?AK(QJNTZ`27H13G~Z?U7w_P`}n@wFWW+oXsTglEX`KNn(f+J-0xLnYsAZx~tB*q^*{66?UNdhwYj* zFr8@kIMkZOYt!yuc)8Z0?!QvyOF@fX>h@IYyU2QS+8gyyAD`S%3+K*w=cWFu@gb|y zu?@36`RuBV^vnPS*28wq8kh#r1Gi1II~~QUOw`PkPMemPX6T`i49HK7 z@~xqh$VyY<-u>y0V{|!c`#}C-JMAxrK)2PVU43XH?D=l)#Zo&VU5s#fr~Inz5MECM zUaWj-{X?Ie(`oylcs)_RK4QD9g_b2fcr3dJebs=4iO>X9B0R+30;IB$a+>o4~0Bnfr z5Lwf;wfOMSf#o&$5cCa`bGse%!Kx?do;L*=Bck?-?W$3lj8n?dSlhjRhXhVg}rgN^l%S?3zG`gv*jD?TV+bI~JoQHH=e z*{)dw)8^^SEXNZCdA`a*Lwm8wq_5`tA*vtgA>gaNx6PqczwLPVc5m5&*E;I`BC0b^ zKreyq0cF}!rVH1Cb|-!%JRy_rvZ={f7V znu|T(;4>yBJ#3FkPp;y`!0qTtpAQdz8RQtQ=f$Cs^<3v$z2x)zuWe`6!}ezCQ45yK zS5oQJ9VNH(6^9vhJ>IvydVi)4dOP0I>96&(+lWKoJ>u~rKksp0-KV$-iBO1wMdhFE zW?f@E_KGq`5j}fC_eYU=I5AC1y5oF4;m*mIHZM_uF$?Ufcsaq&_(TaGJu=ZWw^<3e`DSC zk01PN!>jZY4K>i5#_QRxoBcC%j(zUb(Y6T{xNcDLDvPMAY#XQe?D*eqypNI4rHwj{ zl5CC&JFjn|F8yx0aXf83bVVxn_0wPYW$nflnPz{no%QgX%a^gf zNI|>rFG}jBa=uMIBC?KqhCaLS)q9rHPrTJYb2|UnuABX{5IXcCo`aiuiZkD1FPeoL z2(q$T#K86G<|uTn7_#hwD~GR|V%EiWzaV`fxUN)(x5! zBTp$UN0ph0hw=SxF`VypJtF(%!jp~|GIipoqs@L{dsFl{O6dU=G(G4%qp>b=NF}EM z5plUmJkof+7h@fr@7n=A--MZX>Y62OY>SKRv`j(M7t_eDt;MbE$nA-?i8r~p829TG z{DMJAEu`#Kqma+H4JLiT`Y#Xm_$pz=x|+^6PzM5m^!3J+?W$3lM4?Y>u2o4iUZm~Z zfEoL(?5N0oOPVmZ)zHg-r!Jxz*l%V#ua82Pwn>)TJ*%?9Yj&LMH*s|2{>_$`-tTUb-#fjk~Jn4-~QQWpx zu%u+bs9o3Fzmhxk_<1(Rr>#y&f|z4+%Yu1`N!**FSEl00A&pro_il}!1_IGyc%du`M`GF?4LE^c=YDfe;($QxhpEr{h`y)P+!FLiG1FT{^q)jFMqnLQ9W$7 zv(V^uhClBNq7k`VUe-c4g=9c}3s%k_ee>*s`Nur+l(wa|9UU#(X@5C1L${%voAt`& zq2QRv<)QMk2Zya#`(wGeJg{BXO3TsfmCCnSB;u(9TyD2Uq4Tke9qazs{v~~eNDVZP z!3YoAb+doQ{XXM$g09}!Uz4c$SJO-NF54xk>SFYI}R&q{&HxBZbP{?>y_)dh7%%}i^Y#;9zUe# zv}4SA*)D6P<>>WF<=QL~@gxAQuh&B-mv0QmH!9y1Cq_PwLFwy1c)riispjKgJEAp& zCLD*kd}AE6!tGViLY2GuF*LCrv2%Tr*gtaletmjs!N))Ufx8e|&~(QLvz^yRuQz=8 z4k{jr$mi!4=%7Ev8k^NtGQsm=!IOqK%vzOmV zKg(7F`=9N)**|N-ahS_H9^ko-C5-y#+Fkf{h8p(<-za7*{) zqgu5qXJMND7-6>a`sj6sFZW>&0*S2$d>mVG92AlP=?hl=4;}UElZ&5S_5nS2Oo6sL z7*n>ZMrqQF<1m!}Nc!b=s^R3w<>wLCUvEtR{C0Z1ni^#|6|t zb1MIA*UkP}^tz?;A4)7@O#uG#54~Le@d_iTFqQwok&ox7my)`E^W!#~`FPllC=Hd!H-E%`kbQ?}Foa%hHrL%9#7TP`Q{!y=cH z!qIb2+41HR^h#MZ(45K%+jX;l7QJq%+=mj2SQ7x3`?b)^<(^&*MOx(JDH|U7c>bJr zs$==kYwk2358Dx?AvEE5%;lbMvL{zKv|sblGdAl1m-~JrBA5Gv-u?E?zU_aCV^Ny! z7-6>a`snqBFZV&kBN4gWZ-#yf$$)ePtM9Ly+4;sR)7rL2cBz53qhE8gT{rt@&CqWs z_n~yl*S)nPBbSpwf3IwR>D^DR)%>j;AC-Hy`vvO@(d(AVeGst;h>y$rYUt$hj#u?G zD({m=MLv!bdyai!X~XaI`e!xJoQ{L-y4gQ#!f}|(yLMNPs(0xo^m@e1<-OZ!k<0t! zYp(w8;G#hzS&*hXMwsoqK6<_3%X?7qNJK908=;>S%KNp)e4AQw)fJ8W&34*f z4$aVSDDRhd1t$rNM2i(`YyJsR;8gW*ZO*>slLyuJ2Y{KV{0c zOU^LsV!Nz~mYbq012WyE9(#G3tC9zV8W0ETn>;$Q-zIN$E^V{p?)%O9*iM?{&@6p; z!lP1u9!Wlb;!`5)JAXvOMQsn7d^tVSPJzl}draA`8l_24ee?*hO?}!&yB%6g&qt*? zN=g)uf|osJ;xXLn2+z&P?Zw(Cbl=)~YW=n+j-6uG&2~w$y0{a%4R@Diodv0p{d>Xu zIqgqt{qeJAoosJOoq@Y^#(r9ST4bH`e$84p=RZ?!FzaM{3+fDVx5cP;eH41zeSga% zr&jjuWY){}7StPLwA|QERi#Jv@5Vl>Qa^d+BYG{V8u&b8dkg9fGpcFSoj4}4?k-v1 z-+afsry7+Dwzr_}Fr!gM-CLs2-B7tz+;sEoe6zpV-h#Trj3OAzb$v!;fB$jAfv=6a zul@|PZnn3e?x0tJaz7>`GqT=s-xfWY6+iuVvtG8hpxz+8ccXu|N1=D?VZEO0+iOI! zSufjLP;b!QR|68@{zLugM*k+@LlX3yb=?o(ihI;&3%>o&O&{9tU2^#<{eq6_jqYfl z*^Yk=A#^*ZzOaDan&{Sl)99F|KDC>L-y^w-_`MEt{~>2=0;vLfq#YgSh4KfMX3@bf)1 zkHJ$mZ1)S+7j{awp$DNwDEA{)N1^wdTQ2gZk3Nk)>7fSJ%XZ!DpY5F9Ku<#U>*R5f z{W^GB-|HV9^Ufr5d0@L=puVtEI)n5iWW90YBkR5Ij{hdV_rJ^Ob4+UB^2>JJ?4RwF z-XJ{*`FvX+h2Ck;f3)_m2X3TKI;ny6vfVFKU)U+VVR{m>?yBs_e*Ums+Q{nAX-MoFW`U7r9p~Fcp6U7@C zl5;Y>wlRti0_o$l)%sXS0(K;S(DSJ^(81}X;>#NJ+kLrQCgvOaVKvL^)qYq*D!%np z@XPISQ`(5Lxa-+CXGHw)tfXJ-@KT(e)j6AZNzCA zDKCw6KJvr?dcTqUN_yF@N9&(O)Ehx!17c!*@sq;)Gvll_;<_tSFYW$R?~P7f0li;< z^s!wx`)3jL1^4IpKiMJ$u5%-8XRQx-AOVYf zzHUYN;qx^K=j(x3SEa9)-!CQCxmdkRLIz?bU7RkJ4^Fo!3Ci_i)nwE85#&8J|N3gg zyNA8|`HL&GP1Q8%JvD4Mr)@kxa6`!9QZTNrzS(So%jeMEk#GE6OzjM#j$pr|U43-y zK|h{mPvJ66$4=3(Hdi*ZGweR_F&su zw(uSZmOs1)=Mm)(eFua}6F)E#EDyL0$@}xNHE*5=Lgf$nn(~12ga4;gINxa53cJ<= zq4I}P<$T~ah5n~}qW7no&lQ-0hG@47y0c|8yq`I~!1%lb*Ju3wCUV!I%W`VAb-(s> zcAa+p)T5D|*K3z-wsgEim##MRw9iN2l}~frv+yReoD_Y-)tGbtc`bBMNCs3U%-18E z?QO)U?Ux!fAUA%Bmg zD!p>tzkm609E+jvNYK|L%ywQM!e9D(!+d4gE?n#3i%m)fUY_q%49_vt6h+o^eV^g6 z7i`JBm(ycCW;?GBp(mgq$L=f3#n&~|JKbKqm`8gRM5ObcfJ}(|b_XVm$>u-^|zj-8#mK()7OXcU`?=)gMEs=D>I70O@4AYLq6S z>xFTOr&LLvobOQ-?Iw)+$})M}q)Z8~XZz{x#6jC0eeI1?%0Ei@f_~|aZ(&0g>0!Gh zMO_T7M}O(2VFUdU=V8OLT?Ts^ee%hx-b+KQT(537=?!+j?e!0)Fa7I;DU%P;g^?FK zpcZDkZuZX%$=cL(F%m^D8N}mF^cc)QyweXA7QO+b?jz@CZAp0l)n~O6pWl-<@yPFT z$G){$^WQy)h5W~MzYu-Fs7J2nwF)zNa=l{$^7PqZ-2>&pQ(rh`cJ#|XfN6X?3&p>m0rG>UtOULu#L{e3k>Zgw%j~5 znF4G{>C5lEQPb8NwHOiv_r#EkP(j2{B@u@?paI1gx=@YB9FV3MAd)Z#$S%Wo%B#vE zAK$>6vu}LmwbPCg-4G7~CEp%Xzg@KkCc%y`liod9jt@uT4lf^P4R&EaZ;wL9OV`)^ z{a*3m*NJ{wT68_p9#<89yJq%JgXze1yM3H~0=A^|XVwr+rI)YohgC-H1!9I@qf39 zHlokcUtXkj=YH(naqgq9bjpsQ|InU;<1uBsYLq7WvsK#r;tlU*PbsszN)>uj0X{WI z4@>8}$K$&?>dUY*UFa26P&BKNfVm$+Y0|l@cR|!KJ-$Yv?gu@~M%M~74omGN-AkkE zT6(GAp`bIM-Xp!tgT7Uk0QvxG(&>7J`pHAVX&@cYOVK6)J8%MeHf#x40d57<0ec;M z3+M$@eF42N)eWuz>Pr|Qcmy~XJP(e9_<7(HFcEIw1RUs09DoB^4=zH*<;201;b0cx zU>?Q6^uU4q8#jN>M4u`R9r7}~lk$ZwLR8|V25ww{J#jR&^%mm#zR1H9g>aoL#E?^j zxE;S{`6N|{AG5#&^uK1{ee1J?czUi78!o_hSK)n@s}RS-_zu}dXx<{kE3IS1z+N%p z7`&n7pqVkkaV6dr`eck)x;;iL8`w&mQ`t&T`JlcW4m;?53$lj_YX1-`aoB2roBa8x zoBT6ccdY&&kKg)NVuA9Sx|tMcTM9ha{tG?j?T{sEpgC*OP5Z^H4oAV~`Bt3gbeze6 zj-QrM3=QK{y^sB>`pjd`zKq^?LV@Nnn6h0pN)zo-E_@q;J{FGQDE&&*mgaI-mX_&X zwa_nFX}5a7dbZ5dJkEL=aIzNDM!yMh=Zwcbtr{IGUOuGq*TScNzN`xgMIb$N-N$y- zC{04?(UeT^;`ZC5GQ}m!Q}+(mf6$YZVz(A84_F=`517vvI+F>iR|qRu9K1SVw z$o;W*7M5NY-}UBg*i8-EF~kV7o!2+Puj+M}&EcKF-+iYzRs-&z4Lv8azQa%Z;r#l} zD;9D3tj}!c_07>&QCu>kvVuNk5s=y->D&~B&I^~sz1i@|_;*+b>onVWeUo*1=~jo^ zH3Q#5Q>u*5)z+RH*^liO5BXb}FgusiXMJWnuWzzG$&e~J-oXFWV`f-e3_pWzIb&+l#v zBkMcq_DfH?t@rzl-bccA*2VKC=!33cXSNoTTpl+>p>tF9+{cbfJ{KbuTA;c5`#asP zoBgvU=#=~zT5khl=6o+(6uG^Odwq2E*X5UNXF;sHy~)n&o1oWJ6KOFdU`G0=U8;pX zIeki7E*FXCN7kSC$XW3-JzL7P*aL0r$tF9mZ-RdIcf{k!flgV6`8c*?eWdY@@t;gz zvE}h$G?b(UEgxcp+0N^ma2#Q4T)BL&z96#BUvH?$?*G;M7{${9>onVWeG_!Dzr*U4 z%SX=Q$a=5*;nnu}FVDfqqfxKf&g+|?7dk_?46|&oS0jZDh>P`YhCT|R{MYZpSkY(E zZT+YA%xTpJmfgqH_dilA6BRQeRWwBc9#2jYopLL@YgmkU3g2cd`_3o53`-uM{#}xJu_roITuIv zS4!(83CEx9{f^URf0^yP9={QBl&Za6+ZmNgrJ|mx*)IL#VSI+##^I~J>3A~}uIROp zfEl;*70~tYh^=oHbuS*YrS#nnbYHASUr*PcTd_V;`}jqdIR%Sb4;8r8qz0PD;6JwO zX8%mm?XPz5lrQO|CqxbTS$j!jzimGFqlI(df9NMp;4QV`dn?9l=k-$h!E3vqxoLd9 zu-nqey1K3XbMW9}&l$|=a(Jc?y&VEd)i>$NTUngDuM%fz|vkum2w)6U+I`L?G zs=FLjhWaLyuzr;FZH_|Uac%nl7Bg=2i=4jJPw6Jic3vOQXY!SgzdW7KMSQVwNe{1QQM8s@|t}A-k)$Y7O1T; zhhR4IHvi=R<$5*lDr5O6hGXcNmF%}-t@`}8@)BN zc#Pd)=M@=tZ<+dfN=hlvALH?LvQfVxT+lRVTTp$lEApKCV|$yfemGvLKUo(YyH@9D z{@`h?zMcB}2IMns$L$p@o1fG8d+QIswp!b7JjX?Iy3S%d{xt-to}gBs2tT^gFH>w8 z`T0579-8K9&q76`S1y-z|B9^l)puUHa?qTYel+W4yFo1ek@V&&vnw6wJf-3Z?jk(G z9aMN3_K|g)<1_ysDj&?-ng4GRNqp&xIPL!uch6y&NuX?1WiZaI+yLNgXi=<4jLS_ z>7PoVA4AQ8Z2-R04m}>lql?sju~@8K(BUZb2xNcNH5mJ6=IhMWxv`>hT*t&~?|tUR z<$8lK84U#W@7d0}cph|o3O+Io1W`9%-6h!h)lzLwOU1*-_D`H!`LlQDdIIE8eM9$2 z*Wi5Sakm#=d!Yi4+#ANZYHkRBzSEJqPde6f%(~Q>v`payeQLI=W=y1)p=B51djNAV zQW&T+(_B7Jwe|xFy7)s#0_OhcFxdP999Rw)!>s7h(m1j+m4MBV#MKkuG}UyM0p4iC%?#r~v&?OLpX zX-FLzT8r0!O*#FXe}_+h%iW#CbHip&D{Q#wt^_>^PM__%**^=JevTWjKlVB7PVGr~ zYLg{T>FQ7xf?WS_yFk}E6sXK-XNGqDqZ%=x^}G$+ta;0NpaIcw`Pmww{7}j}Zhvpy z#Y67>%G_UKJ8dHe!+ks|Oz0l@6xME6w#Yr(iLA(nR;hb zjYdAtt5$_C-?YQ36V8broKl_08nklNrjec3WLhEj8*6Wg?1x1MzIOfW zr2~%Ws>eg~82p-z?WX93`pp(kwN3pZuu`1maLw{+|75vwzoM9Kv&uIQWj)+h{Q=8Vn>dcvfK>OHpWX8$Z2J^3EH%Zr~9(G8^jSj z{5wDTG2e$hzWXrY%}(OkI|h%sw$mvGaXwIE-iU*0VS0mCIZ0ZN~gH-!ClK7Aw*_|M;ipjA1qW zpbqCR+vVe<<-qwLxJPcI`YP~^uq3!L-TRtl|#Q$A* ztz2|#Was#U>d7y2c#83=Bwuw3?#nrp(M}A^;yz)T%Z}g17Sq1{fLspgT%<7)b4Y-J zwxjy24Enh~OFDV@*yFKIK0a|rTzK$N_c9%Mp zJoRZ~Tc%fi^Gm=9>2A-MNf>T6^rwg3MMtNNdw0Nmec$%#?*Z$ecj1R?&f0KqtXQ%r zcD`%tjFo58k9rY00Xomwt{SCDBVGRM`+%50>lFNV$E1aPPGyeLqw!t&H^r3q^v&p_ zKrcYQS*3n{BA^>FBR~om3+Ta=>A(Rh!6I-4xEZVkFM}^Y3>=;SMuReN1)zspe+Pqc z0#|`2L01&cO7J0|*CEsIiJhpd55`IKJh&PU1Js}cy$F@&zi}X6;Xv|n5MQH_TN5wD z9ft_<`C<5tGwRagP@2>6!|2Bo(C+p@n|7QKpJD)Y@<1WHrwWmgB*b@PgqWX$chOE2 z;;CZfQ3dup2fqbhD#W&Hg;=)+_NRq7{R1IZ{sv!ljuEZ#4yI41;y1XwH6~zXd_NUeK2@vThaUNw&M5NcH)=pSaGc_ zPAw0}YV~)=a(Uhuq1>!LAx^C8wB_Deg)=UBnHqNlu0PnWSp(Ck%T2yp8?MSj?-{$} z@cs2j&E3chgk%t`Ja5G@&6{!Sfd?*Ma>{ikU2In)kS0ygHQtR;qGH@RDf032LfT`1 zDR!r`5dC|Kb~WI7uiu*RdJ_i32_?2e`?K$vb4RsFFWV)l>f+An4V;;>&W#at<_wM# zpLaSid0OsAM>pUcpuqXfcFh`?HczKgOgE?S^oL)lTrSJ*3GdJC|A`fcj?dasIx^|4 zWx5oqU#LD~dqAPK)C8ScX6wotusi2-+`Zv-)eMaj13&q>%S%ru-Awfa1@<4?HEUqn z1YO$sq7Pse>rpgd&iYnI(6?qd^u2WPGiQ9Za^&q)86)`h>2}Q;m^MRSg|k{esS%Bw zuSxfX_uuAGapL@fCypLGJab8Vy`5rxY!4{YmYSe1)qxQV9wAS_?%eJdKo__BZzgw( zr!;Hz^)!CI1?$mdguSmk{`+e-U!MLyYRc3=agcY-cGZjt9=>vW(8a3OF0aO5e1#50 z?#ip1CSb}sFXduP2?gSdV7TuQS;5Z13k?_SUx6S2gs(b`&U%)|j$g zHA<5_Jn>8yrZ!$sdw+qO4K>)7%U{idk^S`0SK~8g4w-lwC&7L)+j)H;f7Ps`yV!73 zrZ?4#K9Z+GWa#Ph^#+=AHK4g}QV14LQ{$inTPmIgWF+~OkBj1_GD!JLXAv*c{{$U3 zL+k0fld5p`2Ntc+f*z3Thq$$o&$}D0KkTw)Z>`%z?Gy!?$6(5K)hJE)bi;#1C5o>) z-%;TWEaH1$b6wiT4Vdxyw>kfWe<#_{MaS!TOx#>6m=mt2fH_Nn-Bf_qTnAZ?2V6hPVEona4eSaTX)>qd^;~Z2@*{+-Yvp|(8jk}Gr zSE)ZzQJ*8#Hr;?3m(%s@!s}Q)I!?5m|HG!iuYY!auAUOr`=o>Iy4gPqs>5(!z?NC+ za(fh98lzrSFhnIi2PxfhRj;4&-J=zZ7fX>+MK=Jc$;VOqSoq_}NR1O)#@_ess)OF! z)<;*$$H8|00q6@-lK$a(qE9{u?D6)c^s1Le7EV@7sGL^N0MBw;vWxx9HegeTQ6rPO&Q+kcOPauZA+mg zk0WqvEN}?&_|f_Z`fJC;iLbgo@XjsUPJAYlI?4!Kp4hHg1Jj+<-$?RWM9u!LdLq2P z`(?(7LlzEuyzgIsUvyWTrit~kJ)l%u+DW~7QOQu~=da#?n+@eX>B;cAH=G_PrWXFO z{J4+j4aTDoYGB=L*UkP}i|P(jZ$O@QI-`aUYPW+mlvP3q1TDJQa%p0`wu{0 zXqn^S@kbskm15N^(xFIC?l;h|3HQ~^n&kh@`_X9-&3<**j>~P_(-HjECtl2&^~%hd z-@S4@U+_~J)c&wt)=@c&W244DeA44+z?}Umo(-?Bp*&XHkou%MK6bz@r}fq%V0~=YqxH{% z=?mLfne@r|ULQdpC7ST|O<%5i@4A~<0O=zyn(e$kqCTlcm!-+N5;uhRTar6gy!65^ z*Pr;&@elsoOG}yk#&*`j^I*CHQv4MjSKNMS4TymAb7KTun=4|)(?|X_=hS{ze>PN4 zn02w8_3%8HE@LC&*T$8a%`Xm-$bMV>VtBvRcw)u7YtD1M|HfN~EjQ_7JL}?k7=5gV zD_Mgs^K}^wn^Rp$3TaM(#@MLdp=&dmGg!33F7|*qf3%XLCCX!;e9dg-&o0i4Ako*t z#`R9(OUCw@u8HY8Nc9PA#I&imucqB!>zwe-iFv2oLdz7ks+qU7mD#SX6~cdiK>b*W z%kK0)n}lW$kA!H$ZN~O?V-z~tzIR=9+oe}L$mz^b7iI{vo!3XF!;I2kJlSpO~NL$T%ZT4EkU1nX4*u5+5<$$74I|;<;ZR9-HyfTQT4p>1sXS zt=iQtm%0mO2IpJcE8+E2<;RJaE*SRl@RBD#H0xnI>)?44^w_9hK;x3e>vt_CS?8Jv zI#*AM6Rp3gel|V#rLAV2Y-fEu_v_^6bMo*+HeUXt{_GQFEh=XsGP!-r*cjfQo2JHz zUMrt+C5#z2&#aT}tdHl7bcT9f$CT5u{}RV&H~o_lX|Qs)KJ!3P`{(%Dyp`X5@P>XP zgT|xPeyDC|Jv?uui=KOR7rC9bjFV4pg8ypo*UF=OKaA6ec237cf%@OnMso-?rp@bH zV(x$TGDKvgsU<>l?pe}4&DpOd^zQ07$nX18;4&c9IXa`wKk^IvhUd*m z&)TPDJz(WUz@Ks%Wh=Ek;o6^l;XLPK*`McoOFp!O4vK?lsXoX4nD5cHJ9O;SzR|he zlznKwT@lRnEoov~Bz?S|w{MERooVBnk`8a%RE@h^AM3Q{yT=1^y(lm5Z0c0bnp<}G zeA-zJ&E21Lvvzrz;^Xs&*EctfU9sPu_FGFI6Z@Fw=J=@{-rtVde2lx|e=ftjB5o_r z{l^2`-)-&@#Wi=w-L#*%UNQgQ92wD^ThVOOoU~hNAF5MZ!WW_RM0@>2yf?Hcfsnnf1)2E<&Wi) z&>pgU6WTZCHRk%Ksq4+#TmSD_56ERdQr_-arT^U2DPQD#3gwAtwh6UwG=2X_<%8Se zozW3WUrX7eInJi0MSZZHIcD}N#l!tMo;Ov?uG)TQj;|#&QTptsXyTLoCoe~{@6K+s zyVKiQz5D9^)_8RIoFo54DvPoYgPr4%_K&u03a@nM*9OzhvC8XsncFJfW^bL7|M|L~ zd`*xoSiUr+enb>j*hf7O>3OVu^st&Fo6cjo?rPG`|B#LOH%0rx;ZlBb-5g49usSc) zw!6d5b@8r9Yi~Q&U2%;2OPp4_8~&X?R1Y!cJZInW+`QiUzj+?mSNgZ%j?O9*;k?uG z>*zXTSB#IfywX67Rv8KS!dluj9@v-q(M|C{r2ckO;@Z>O?#surr?p#k=$OC zLfP4y$B82OFVgybx8zvL!+Aiye%qhR!2U4KwKp7tTwcPJD{GzQ0m}mc4}?2+XR0e;_SQ}(g8{pWeW>U;e2@|=!%SB?dTiktd% z;re#Gj_3PR&g_rJv_IufQ;vn|Omi7GU%$~fNpr_a%yCDnjmDo_>bK8(^H_GY{@5Mc zH8-!QJ|G`k^}_DRrSNHR9@5+@_u+kIt+hO0dBF03dPw1J~+*J6z`Sh-Qeh)Xr)l%=V52uUX_08!A+pf9q?>EOK zAD4MusQ+o7=Ij?LzLvJ{%zNwiw|A^_8H&~?v|Y5@wsgL6nc{hK;*U1}$S>?0o;N2w zYoC_&fRz^kf68T)t^93p<|{z z33hJp34fUDTe;sE>6m!EIgV(Kqb15^H0kg*P1U%&^|4NCzI!|%*U$3u&ZbV~thr@} z&!?T$(A@n=H*1%dDLy`bcztuz*cJQjX}`7fF|m(%ZjPVY;r;EH&BwSa{^v5hE8@1| z+lO3=&5;q!xfRVe%}KkZ_MtkpC43P|Pqf!hRDO1*47Fr` zCe*P+YbSs1O?p`OuFPjnV{e{^8$;Tgb?+_O==?O7Yq@^=Czh{Z_1izu50T2K<&)4J zvV0TTH|90w`p0}tXkKsLe_#B6e>^762f6I;&&SEfyD!cuU*voWbqvvL6KdaR`u>s1 z2e-vLqa&2Qma<24oJ~!O`d~YA%CpZ>pAEwf)WJI5pKPrePd-|qHTFb$-Q^>G>C zdW74m-Kmo`$Z4{T<}$Pm{ZIbq>waEOwqW@}>#eZ=dmz&DSo^;Rv^qzwyP`Sff7TY4u95d<$3C&^pGvFZ+(? z=JnS9&GW#X=-)O^Y3RK|m5EUH&@t`&8cvhvJ0IiT7Xw{q?27TRU3sLtGCy`@+`G~z zR@^P?fpBeG%cj&au|?`fb1Knp$J_7C^L_bP_O$jro&Mfjt}JcgJwR>b-ri0&b(|>t z5x4BxNWP1-KA0Nod=BQ7eaj|azcr@}>?=pRKa6wj4aXptmwhGgEuEGJ_Ou7Wox8Ly z-1<2^BZl zxo;P28@BN_d%!KbEXn=xn0A@7_VS3S&g8PnQq9+IG)~gou@ZCKoJOQMjX$^4Z=d(( zvFu2G*q!T}n^#mHkdLi;VRzOJK;6AdfmIo{kSRSxEV0pmufaL+p1C|FY z4_F?sJYadi@_^+5%LA4NEDu;7usmRS!193Q0m}oH2P_X*9fPYYf3rW9X{Kc?~ApRZ+6FVT4`7wusmRS!193Qft~e04I-fHr9-C_ z|F~vMJ2kpwOsS2J?<>Rr%(omT#CFGm6`TGWFaBCQ>dNyEnR*TP0lHxQ-w15SzlJbL zDNJ#@e2UBG%`WsRo;ixgmhbR6l}UDQp5haA*qYN%$_Sr6Mf|s?>zE$nu6~*mq4b65 z(#X#1Bcz}1_KdSTT)n$M;<|Ap5{1POq!F&{df2ygtL>^|?LO zwiIWj*Qa>AHq|>-KK*}qXQIRF@a1^iMT*z!aFu4+;k=@1+XRnOU85AMQ8i%7I%_kH zeoJ_)m6~sLKL}BG#XYa}n-wPxAOG+tOG|F-bidvKrWxfM+to;=Nshf#$#UC^ZD~~% zipNoo4759KWX*S!LzXR9@wzKLMe0T{DYjyFQ6+7rMUsFS>1$Z^#bv9Z@8Je$X=YISY;uV&cvBj>4jN!gK9$AJ{+ZMavX4cXw=L*VYOV zS*KnyQk;t2r4&!77_F4JJxUJB4vG?rhE{GHa6*#5dEA5J4>oUOGSV?n4p1MM*3tje zw?7gb4!VH^kf_fO!JO7(s715|R2R^`v>*LXanYROqIDd|U-Un3NArJ5XuyF7%OBZ4 zP4NZqN8eVYd^ia70F*cJfbxT&u@3SxLEBQ^P`+?JQJ!%4N9PZm!1d`SoaYph0r}Zn zAJx0!#Chje%)F`BfmLhujNtl|?X^whegfntwyQ>Ik~iCFn^WSoZOAL`Hzl<>LP;bC$5jE{*l`Zu8;JrSIY|7{>j0dKfQxEgZ&j`Rn#Wg z_Y_|!zqdqMQH$CKHf(@KuBQ_w7|&aCzr12@oJj8Q$g305e&3#~JCe>DI&ax-KIDk~ z@)UbfnNr-SckV6nI4aOLUoGj|AnBv?a(&?T_vOS3#&5$(Q!S#9y+-mALy;Drv4c9na%CW zsjy{&V4)U9EDVj+8Q`XjWQwI!bS)Q@fC?!4B+?oXMI$l3*hp+!iMd6yojd zj|*TD@0>8@xUH8?8$rtyG(TrHvTJL@_(Rtq`(YE(r;rRNeRIFC+p1V`#Hm*uTXK;y zVmNJpK3^r@4U>P_9!ObRYLq_ZbBfdLRg4)e>&Q6MSl+2>qvYiAh7FIrz2dW8-3qi+w0x$i z+0N@5>7WjvszW;Iu(7OTqppL?J>?Gd-D-OYG2@+=`e%6BiCLLDm5NMpI$Vlg31Ra(z~v%ty0Kg|ERIpztAexIiTUor z^rTDLiPPR)GW3OG>ZlHFFuGbF)@qqfphXL|eH$eSm zs!&PyG2l4R9}EDefRP{-j0IH3o&`$4Y_I@a46XsUgLU9_@HJ=ykv#$RGm62*-~sRj z=mGJQz}4UrFc5`oDfkf-;DFu(#i;cE2mXx%D?sKa;=sD%z`Ek(ABYPgHxBG&99SL( zB3h%b@F@=LHyl_xE(YF0t8f<@!?%t`I=zJ$-WTzoAjA|jj&}?e;;P{|*3m+^P+6XT zh7jjW6{50Ohzs08yfhziUns=o^+HU)6~_UuuiYrbeP0SOBql~&cw~&&F(O8MJR?R> zc|ca5i^DaPo2nUsazk}hQm59cKkHGRPE7b?a6>^m(bfG?rwdnmYtDU&_7d0?zI_HbGaccR32#ThROkz0m}cL;5a~ePJ@bBU^<`{ z@iMRmYyusScVoaZ@I5F%-hB(|k#A1qSq1WI4Gw)6^6Drg=0RfFNbC(H)(`nIA9)go z{OE$b_-l|5wqzkr$U*tR!H=mH;`pnCnEN2g{KrCE(m6)Vm=GgAx+zAKw`nC#n%_$G zBm27ndiXr;27gjObZR?k?)T=@wG%rsc5HugXu+x5Qq)ZaB&hyoyJihcBlg!&eHq82 zxyP%;A=hU~g~omrikeVBx3Tc?lwmt)kHemczvJ$qlUm2q$%#PcO+2P-*Q|l*M8`Y~ zm80Tt*`1@6QvH@fo+`axSncm$kr#2QssGa)S*vmY=IsI1 zBgkUa$FvUFt_E7BcxX<6=VW8ZE-&-{H2)_DI=8qSZ$&wwkPOII=Kdb7ORybV_T;+5 zuBT-Rv>i>&cGZkYCYn8u&+hW2qtdYD;ns@X>6oW>vbesmjdr_dmD@eD#wngsr8uwB zQ(`YtvOQ?0&|2o<_7Q3tj!!PvRYl?TCcM^8e6YopdBmh|W@|dNF@CD&*v|3tJQ}^p zPNzt~4&*l)&#H$Gz7AU6<=s-M=j!zJG@jM3xSe_(lMGv^aKL~MSDiKHTC@&YV7(np zc3wZm?y%dED}80^xG5^)EDTd77ZtfHap%!CUh$=QJZ=wN@p#o;5-?@G8PFrAM`_jQ z>q+khtS1}krFlG{%i&tIXBlk{Ou(WTQ1Sh#x$kW0N6QpwJDQs9su`0!N2$x7-CknM*P4MJ$55S>qqGy>uR8lrigRM?FE1W3FuV7;kK zvyEtTYFqLCiS0!Hak1ji8{@<=gFA?a5AG<2r5z~F{U}~!{Cucbx4f(9{8@LAu_Hn3 z`14pX{|K9iSu{i(;Y$)T24{(??o-8ri)M-q+ZTv2KV2!@J=Ta%hHVr-4Ej}c?$JBu z{(+NYj@_|5hROlAzjAq5UurBbbp8=Fu#fCsn1e;}!6ylure&-vpk)ehsX8^=RWl}y z%L@vyQk>~Zp))K{W|FWiomWliACopd4!NGlDT{m@>mD2X?bIU=MDA;WkHc)|^&yTU zyV7Sm5Pb*PubZOK^F&tFi`^2I{lMw59{z2Q|{49kd{8Rb8N@vhM*t6lzzU)QA$1f@ou{Clgs56q)&m5pZd4O_`h34 z8_{R!FE4IF`d?k&_1VMw&zSTj>LChr{FFZ1RiiX%oW8$1FrgyfJrK`a;ATx_5j_<` zyUFD;&TZ5~TIkwgJD9O_9!VD`Ot^Q`qWjX)X_*4&huN;JMcd+WmrxI7d}Vo|;>j-I zrWB2XzDnD&3^U3Xxj#!~LJsEt<#o|6C!&s*(`kt~qfL8HZ}(3+);;a({Uv?5zN$z4 zKxHTy&>W|dT4&4m5l-?h9X~uK4I?dD(8^qlFxz>(@w$L6W^$DZC$3YpVMJTLhn{aM zo@mzx^5yy}p(3)LUi8oe>Mp9Gr#>~?_0^{9s>XWg8ij(aW3@?#xgDYH-}&m3 zPsaRup|g$kcd+ZsgQu-JCvj4z?@!VbqWn1+ zxyg1;pXbK>nS^Ic6n}$a&KugN25|ejHiDilue1}ri=LnQ{!OvZT}A^|2;>)P-`K7i zrAatFlsB?J>M)*6?Nc(KzleRwb;TKN z^w@E!qWYEX=0x+fv2z+m&o9H>nqqpM)Z=zi4=Ndt7tK+4@X4S3$*yW1?4FRx@yR+j zn{;l$0aKr%;bqhZcYQo!?Ywp(@x1O^JN$LgnJ>_V9Rgk3QU0@CHA<6a=*%m_NQqgg zth3e^-k+5GC3odk9I@4r$Wq9k^rW2G&g-MsnO#znQc)Sot7{OUKi?~jI?evvS`{l^ zzvX~c&o1_i`;ZD30{fHgnl&(Ow$7klH9i-x*`(K8A61-tuz2t7i;g|&q=oHux$3ir zl>clGDAkslpw|_~t%m0pYUhOa>y`!W#3P+=JKlTT;S0W_0UHGNE88_|VA@=rX1B`a zG;yx6y`v$X5-|BQv`16!e5~7f?Zm32w=c<>J>%z_XkZtC&wI9O*1)uhI?-(}!lMir zIJ6m0f4Q7)j-Ye$`R&AwCs%e~bJUci2jVm>>`%4_6lzP&*J<{s79VZ{`OmAWDr5ee z%W1*m@nY)RkA41UeCCTwbYbjQw(Dm9ES%oVVrQTcHM&tWAO=3)H(X@YWj^2Qm$Vac zBTwpHbatQar^ahZ(~Qm^wrkeFG-_SJ-4^k_Lm;KdOVrj<`$Y3e(&p4oYwfVsW^31& z(gtA`X+Luy8^>v0x4->wzP@dV)CzfNJ5p}Q2Lv?J;&3O{mkcw ze9mw@G-o@_=~{{BoF?5jF~`O0toh#KfqnV>X{r~gj5a4UWj}M7r+wMR@z9*@H0Se& zwo{_ytnzZLdQ543cDt)-4K+Oi{WCoeZe2kpmYnD>**vK+6x%-hnO?L3#)nU^DN z6KTCUKI{M8=Yc9D#p6jy7aPZuYL?fl_xBr8@ho-0FSnDb87FN0YySV)yAt>)ilyHP zM>ZTG2x1V#C?XMX4WJNIG#4QtA%TQL0bxld$wIOlcQ=rrXb_KhfT*abfa~!zC~CYT zDxf?O@aY2-jEIUp)Oa9>$A{waRrO5m_H<^C1Q68e{q^*0_4S|X>SKDktFM3hjepx< zQ5u**U{8iC(K%7LWGSUw4F%ujGzwHYc(PK_y9zAjyEa6=b%SHsd39O8tax|Td#_GW zzm8zOIFChi_^UIzd{bt@k~ds-rsj7qAVv+kYjZF@hv@Zbg7JR0Rs zbWBq;y8QjKqT}3}UX5e5of4m+DfiUAU|mOxrG(Oi^LJ#)&!{~xqCr&Cm>l37$bqZ; zUipIdtp)cbOauX3dA|DnFdUXG($d3qxBG6@*MD43iu-0Z7vnyazGqalYtP2q+w1B_ z230;%rU_~(_+$G+boi??SuU;19LV@DE@ zxxw|6xT;d7b241AbJJXvWgcsa8y1m(a+G}h2bxtZ19OhX4Z}LN5GBxm*+F7>@=TM84PF6-J$vU&AO-? z&+5M7QW+=F4+&?E&F!A;bQNfuSP?6wC$?7&Vc=XG_wkFj|30L%jFae;F1bzOXRcy% z*1^5RH)|Udf5}gx;iy=PTHeWKVLdh@Zdc`hLT+Z>fl5$iQh^v2s z)f*9SLl}6k8GP60FT~G&OU6rd0V=<37TzHBN5s2iX=wiDcO5#RbMe);$aslkP0U!@VKP-5K`XsiSyTZWtX!ZV+r+ssNUzwjo zKRoyv*Q+{#k4u(^9zUHq^Wqb3f9ru>ghw5dL@=37{^7`}Z_OvKZvkqRxLF4h7x|lf zU+D6mao5eCMx59CM;b$+i|d<-PI$=;2e-B~KQRDeo|MSn1Ar4v3RukFXndOAy5%{~ zE!)#Ud{>Et&_u`hq6r75kH35`TmZBZe?{E2UOj(}#wTyTJLzHX>jxUig-j>xVc}K^ zak~QyS7w3EL%yZfQw|z_1CLhpaxwA#(C;O4x1G0O`-p~pvRn|I@RA!2?p)g}+O`o8 ztH|Hj2SUrmZ?_IlOL*bm+GrG)`YHK_x{$c+t$*hIPJm>x>&!6u91CCICzEnWrz_I6XmrY zaH0t&2iH}!nlN{l%}-n_RX+U;ak*>Z9{s{B`o` z=RuQ}Y6z!HC;xD8`s$S*p^krXkA~*oq`941e0pE|Pvm+;bizY!IJkWLQ|pl*oxne_ zoYw+QVj(K0%^Wt$?xLHv{HZ4bu?$XjvJ$yd&7!37$SXzN7q!k20P7!@=h(Z>_!vZ;8GV z_dJTxD>WzTX$43$80l+Ep(Wu^J9~U#T^NJBm2nX>|rjvhII0Muh z0k5v!)I1rw-u$;p`EhQy{hzA%{Pl+Dgpb^CaEkRt#D-}c>h}b~K`!CO|8!3-g*ld8 zQLb`8NnuL>n-T|OdO|5l6NYw1~sXmmNMVR=b!x7Hk|TR3UQn&&JVWt$G` z0#LbQIcP6{MB~9?JA!)6$^fT`12KsHUeGqvbN}?azTNY|e_KC0FRK;!AMSF8Bpa1C z@dEvhbt9I0=F_3e{oIpYxpqOxL2RR$v!Tm%Oa7pLoznLcC#6E=x>cf+zhSu=jOxQFTTC+^EY<6Y&$VVE9P-y^#I>h{iDxti&a;yi7&KfB90?buJl~^JakX4 z{EWxqf3aNafnTBe;ja(&*l@|nakta6(6fFc(aGPi-ohSr-}llmOEw-7r23lhQfnsS zKn#Dzx?Or!d^V%?c}OFJ<8-vhPa3nMAEiMq(gK-q!WhMEZaky3OxoX*1M%=!RG%`T zK9RoO2O}TrhaYXKG=HxD7W~nqfJND=`gRcCf3UfVv7(Xd6M@9?ayDJs?$pdH@g9vT zgAtABsxP+paJnU&ea2rsg%{Cs?F5o)2#EMF|D2aY=dbj*ZE@}i6V_4sl)p?T{{Z>p zW&{sTD^R#a0*=y9;gr?r`TEU(awnE3kY{XMC3~_{i=u(%MjN~cLIw#PjDg_mSJ;!9au;& zfJOcBSA*>j4b)lCczL0*s)NX{LF9h0(E3i$m;3oijFt9Y}_i`uYDe~4j=>W*jgZ$6oA+j=IudtoZu^Vl?Y znf+!qyk$k<*;7DV^j~uv|G2U=PREUiFmp}`4e5lg7=1asNe-4UI*&_4nUzEc~|e`_EnzaUtJ`9u_X*o5rUs z_w?x$&kHwHj>)fv=F`?Y<|lpf^iRu0Jjf@aQ@Z3zuSB2&E+2IcYFgv@Dnt*gUH7%P zsCQN=0QJY(+BN(TNBHW(z?XM^my|9mhiA+9h)%f3H7rN)^n#^)C%&f6->n52wx2kD z!m*XOKKtD+8+Pv~8i>soH|XN`BBE<#pOZ5#D+SIhE`mPCR+45bvrUI1H$AWb8g%d* z^+c!$7&Pt|Py$tOL-^_eADR@fJb#0JV9VnVJyQFw^)rz#C`Ux+2?!TM6q+1iFtHt) zwl4JiW?n(eguM5%M&bAq4Z0C;I>>LICWj2dvLT$cPh zG@k0^!@oXm|NGgLUmt$chskvE52kl3w0^}AzI;TS$*=2i%KE{o3!~YM|5+7#;Ds;G zudt{{5GTGz6P@sp+YFpKO<{yo#MvO>G%DYy;m`bM#~1hdzB3X(WqQ+b2G*~LSZg6c zU%9Uj&d)k~G;=nj+`W2J$)(ru3JYi3Kz!sU(Fq^9;qz0%X~a+`}& zW~+#E(FXl@DIB~Pf~EDGM6LI=?5{vp3fuo|F zCT|RmbD}$%ZHw8H{dCt;icNZ4vRp2i70s@C;Of`Dod5BCDcXA&yvFeQ zPIMn2?Ivto#%$B|&kXjZqanT}r*=@!se`jd_W!&lI`Nb!w%yus{w1jk+ut!x1%Tr& zY>$YpQvKJ)`&RRuxRpygJ#ZX96aa#Y{qyFx^*D^$nH%f-w14ED|NKEYQU5H{$zQL> z+4%gTQOe}$3MT%tu5d6-aMT6LiJgulfS+`>-5$0MU-M)#yHhr zsU5D~61;txwx$zXv%DhZ`p&zCg6eQ?5D&Ic1455`HJ^w z5hL-IXy{^{L>CQ(q5nw3dW%M+sg!@-RUAjGeJ8k_Ab0GxhEF;>K75&Yhc3R)6J6$@ zUQUerpEz`+A9Jvt%Mw}1Z0C-SVQoy2%=x{$Nor4UwEOK4HQ?@U*T}y2Nx)IPa z5FNvaCeJqAI^5+f$L*teE}H|7M0Pp`=;l+WZPVvVZIjsU_ldMtf4brIJW5-Y=?Es% z$zRWh#_hgQ-NCqG`RoH+Xow$1#nUoL7k4z_jkXtUcFn@{)FZgFX zqWMp`(eop&J~%%x?YG{0^4!|fzdMWaAsjND{3%Zj2OJvbAd(0}S1#T#aD0_>`2(G(W5#ZSA>m_5IgS zK7>Q2lRsst<3~U=dU@Rt2A&uHlXL}}xM>&VM|fm9`Ac|=kPMdjGVz1ZeA%#m-Q$z` z-w!92s)lgLbn=&QsB#hzjlSJ)2m{X_iMf+1R!_T=@*_Mlo%|&{Mo0!EA!9Tnw)+)3 zL-S{P&W5D*C!M36Rz+jJ2qx1heF;xs{%EMMV$ge0Jm{Iiem?~)J~!TDpDljBa*rGs zAHO$hJ&?KSqFrUW<_%~4x=QW*LzNrO87~9fJzULCiFF)mEwiSAilHJHMmP$1b3DSG zTH?%~sT8D_D|t>}W;s7$8WI!RpX6Wl{iOx`aovEZ$7RxxJ0E;z)aa^zYe3M2uc3_S z8rkRM!a-vr+)mIuq`*;B1xlI?4ydwDNXgBzrYgm@S#~%P9RquTG2%EJwN{dD4t2~# zW#mhm->7nAOf&MMkmwi8pTe20%7FtgLK4ddsW?Qz`KLCTi}#|1zdnBqg9iO&BgT=_ zqW|d9J;fK}iT4y%4o~sOrEvJ4!V*n%F>U%U-cuYgZ%m8Ai1!qhXtFED5%VHC#TWCU zd-6k9H0Y1UC_Rcx{^Sx}jDvnem%~vWNEb~odMH22n_Ntn@+TMl@E%>P$08m61~nL# z48}iPCQw>Pm;H!FbaD?BiB#ZJ`A_MP8!8TlBWo0v{3t!~KiwO}Lz);TP?)CDL#0Xna{fd|SG;dd{#1^Kl1@|e zmBZ6>kW2oE4UJ5fvC@Av^r2lTEz0}QQuCLOm=5J3(*7>@_-udY=L=O%|Kw*6#T(P# z}nAe64%$gcUnHnx#Dfg_XK`(0+Z?F4=ZT#IF$)b*G$k{o?&+s;AUC3$HlQ`I9+Ka zb^tWaRRXxv;7}u_0Eqslp>&$6hXv;YLw%PIA^UG|Lw$*g0EsXWDI;hPbYdwbJ8~ z^`B&3Wnq)2p7!cjub1x~`Kt^4vQJk$xF!&^caSm-M`arq! z*3L5Dh>mHB#)nHCXSuDTK>DDR2MC;l9knh`WA^c6yl^FaOSIGMQh;W}w~^R7 zmR-kZuax;lbe^biX#zeU`#4@rh010DU$G^4xgJ<=VFz1oe{9rK1J}s>Bf0>M-!{UR z1xG;GVHGc;K>?$KWESG-|i%fjGySu!rz4Qknz_E{4Z-89RGniv21$O+jl-Sq3FlS zQEIz~^&I;(qKCxK75?NqORSmw`yYbfi0`F!?Stb^xH6V4|N5)DHzf91-0wI&ZlWJH z+!BMm(9NQJlO6&aWYks8O#6?>a7O{I*~j(p5Y@LYUq$U-(~o zwJH1v#Z&S(%cm(^)rU39N6(LA?Vs2`WF8;7f0%pM9an!gcj`0r9BSQ&WHO!n_5DK@ zY#~(CP9VFi%<1x!JM5lHYX)u{gd=~Z7rJbv3XfU^S9%{PK0)7~%KQ9_?*zTSS1w-h zUE8-$JWtCQ`v>e#iLQ}-j=!mg^HJfLcO|zBv~|D)haJu$&B$!DKhPJki8t7W;JAy% zanz>B$%t(X`qBSD;pO=MwExxcz$730LdZvTYBY;l-THw-_S+vc7RK=f$_LS9{t5Dt zZZF_72{^LCH+h|$iuI>DE_D6*;l!&l*4(jTG3AFkwNSH`OecQxb+EKkPfMzKHTw)j_mtL?{0V z3cULBZ-nmb=`hfm1z+umQ37Tkuf+07?iLzP;eoCT_b&GAr2GhvOecRK&s6wu=1`BfG!BHo0X>)@$K= zkK-f1blJ(Ci_hIrNs5ZFT%v$8M8`0q$+Z`F$)TyH*RQAcARTe_=J$}i_!SN(tV`0VP?p(a9c=We89zuh7upcHmCkhtYW3%U_(C?mQ6k>3WKZ%8XqY>x6W zRYQ?pk4Y@(Va0Nz^6Loq$APT{d@T#l+L3g16zd&1WqE14H5Q7`u13!htAB4Vhi3#7=G>Q^4(WrM+v4kSZrU2&WXaM>GRO`QkbM>nUIFqABtlW z^&LpaB*<;NmJYTjHN*Vt3!-fQ7mxKfklq;TZ-OM|J zd=lG1@xHnFAI*4&!ndP|+sxbKfXRWsCI_0@-u^Y8(nM`?z~q3*0h0qJ2TTr_956Xx za=_$($pMoCCI?Iom>e)UU~<6ZfXRWsKL-wF9YrASoEgC5ul_wQz+;)@e-H=6b#zG? z`gIcQ`rBI+0559oj8%Ntc0IDCcFLe}Q+w79U!pAv!a8sYtP~uBb zPs7s_;^VpvqHD?e9K-`__dE*fM1VV`jIVL^L8yX|lz-B2JwN1ig;f_tvHR~?HDTBM zi>w!Ejlro9AM+==FJtXSpFhvmIz9_=xOoV1ecoCrf4My3v!dA4w55@&##P-+&rkUi zJ$U}ZDqyn*Zu!$Q0V0WVk&~n6gNy_7@c#06%!2Fh9XS>kn1Mld^nxqVIZ?P6$^}Zq z2v|(-a@a~FL~^^1>0^;&b{gyXf284mTmwUE+0Z2mw})gXuR}`2jBIk?2y?&-f-0^v z6SKp*fku{PJo^sUh?0^0iEg@w&VfMf8I}$49ow>C?HTzU3L47mP|`5tnjARN9H@m1 zXk5m|=*J_;sU5gpiR5z_J2-yrWjV8>Sk7^04Vt(7xUCP2R3-c-h>znkqRV(w_{h{g z-3}wuN>DlGf<1(#HaM%EHoNEoWZ4|BnAdggx!I0Unntp;V$cVMC)=w=96v1*@ZuUs zS-;n=a;6HCt$5s_Y@#rqI05f@vT43vDpokdx1V4w}*T3SR$VIv3mZ= z<64X`Z^EE{LteDrPg&A_8JSN0{@o}roLAtqQykc5JH{&c3hpFU++|J&e*@6=HjCrj zhH?7+AF+@q?wzQH!$>n*#>8VDKh1b&aP`7VKc9?$z@S=>NVpQ66NL-c8wQ86DlUG6 zt-2{G&t)%yVgrS#xgLA|OgzL^?k5L>xFC0Me+NFZ*goPtS-1^o#5e&18F(}|ou6=RAG>~DttJGnMV~~m8@^5a z_|xeTv)X72*-;L#T_So@aizJOZqj#;alK$^T%9>N1fTvF#XijMmpNzc(0|Ezh>mHB z#{cYA!*Ubx$h^XIM7gS$@X76X*)_53lC$QI+P-?uf2b`YxgxrV4etefxu7FW6(>KD zH|KsS*Y_)BQ}q0j@nHIu_VLSp`KBXQNp7(GaMn_$b241~S>rUd%cCiggWbvs&eLW) z0F1|_fcjylvn+SE4L8|mmwR;k9W9rJ##Oic(_yP08u<|AOSoh@`G<{5z=Uzddgu*- zt6_c=JL6g9jk%NW|CaVbYI~^vAUfe8SHLB)Dy>+_p9$qz2Al&P5#zLo72uNG$4w2+ zuj1$0voR~b%er>VkiBY1b>124A<+pBxdJXt6OHO4%5zPKd@)Av-&fa-JLRU!Dc!#O zrf(xU`3w1`6u~Es-27stpu7aMHVk(;%geaxzp+ZG6W+<3zmlc}=L6<((!P<~ zist@sE9Hmv3*VGvI{6EDNN*3Q$I+{36I>5OpJ_XJx=~$h2@2ZKl)f3 zz)*cBI^iH!z{Beo^&oNwB9>E*P0tq@$AK2ntU7PcTX83yUM}MxI^|DpNE}jQ=!J+R zulqvaS<)(+6?;x8e%?KDf{cgggoE7Bc;KyBDFPXC6lg=+9GBhcg4q(Dgg6eVm>!&8 z)4q;k`{tyv)z4M69jgsQs9z&G;UYI6KCuIVz+!t7n;#qp+Y`l>pE|_)$$*+P83)lR ze{#dZA(b7*^@64Hs||t6`)w3^|NPO;*ojZ}lyMOq(-cj3xB{1(QMC_<-a+~s;`jo5M6-6 zZ<~gvae>wf_!cR_`BedfrR!g1pZ#8V!-q0Hq8}o@zy+%%ES7J4p&qY1Zi(L?#k}d) zef@hz@A~1|K#J-o(SzXC`eAh_Wu-$AP|XzR6?AD4Yrv)Q-2ixky|-YL+V@v)oW7}R zq81%SP-t2;qLaT+z7igLK`NXgF>|=$;aYL9M+EK(;dMacAwk56dKMC9`1LGoxp!$g z>V1*lqk9p6X1FwFCAS$#m{BAS7?lsonrV&=4v78rTBu)W@MQ_>fZQ&{wTou!%0{*w z`?|-ebvs<&681Yp$M~WV>NUR0!9W<6A*ttghQD4hDwU#9fmbeqqCDu_z& z=gG5zk2f)wPy45Dyv#d33GdOU@4>wq(N$mFcMkYOu6WXl?Ii^+#Xrt52Ci@jLUI&P=A0zmeW{b%L7D3h?hOcx0Z4BmRoue5iW>=Iw@_d;8#TPN_Rf z%LsAcxSQydKe_(#G)$1-89ly93Dl5a*+7p;jAZUMM}}h!B^AU|Ssv7MIa< z1KSg<73}$7M}t+s&IkJ_*bl+R1K!zS8^B%;j6N3{rGWr`HoWNJaSm`q3~LXGJ_#S- zXF%t5+lh?baVnGvtVUaWF6dn!#n_O1$Y&ntXs>~C*}>RT-6Pm_t_XJir?B749m#e; zV|YsMmaL|z725)5%p(7QHCzw6Snf5z=TPOYeB_Ql{?W@s{bnB(XurzcrQeu@lHjR9*6wB zIVm@q?M=RX;0LSrjNhUTbhr+Bls}^T5vX@fUq@*#^c@-iNkCC^d~|LnjvGL9xcq^0 z%(U0yd~)nOJs;)yWW+t~lrMJtt9lQ{MLlK0%SV*3%EkB8-gRtZTZDKs#qWE;hY6DDPU2&jretZ=i1XB zc+)Z#!=WKuGF|o6@hdnk4U-olVm%-^)0Vwaa*bSUKl+2!s$(Pn!%Yy|i)pZ42~8k= z#oZspPTtma>sOW=zoX}{KzOXDMCS!LF4{DrlYb)|6YK>=il-40FECy#FGPYC%LB{CG)I>M)NbQ``r_+?_qUcM zQLKD<%l04d@3Rxzb~LyS59O8UoG4rbImv>ZNc`bmIWBnRcX(1f zyh-4x;lzO`M<_oyw$YXc@i0agvAt*4!+9|f2TIkTbAhEG48Wp&&1;726=-VlIffbmtnY# zzRYEZJy)oH0hVle6!mc5abrh~S6l`5d`~VvC|Qjm*JGr{f<^ulkC0}Xqr(AF&Jz}d zZtsgfeR=jnG55SmXh~jVI{6FrSpH6)Tj|JG`yxd<%3Ao=n+(D#)?1VrlwJI8bfo2m z(nl99_BUdmL;gT+goWau-{CT1eupbfGo8OT2gG{4HblLSTLk+-UUYWa8a-ptaE&ck zud#n7y38%1UcI(@_y`!g;8wqtL{E8^m^{rpS22F0BIm@qQhUE(GFG3RXlK{V3FGj%k|Qn z&Y5;aqmY^yp(*0=y#P*ZkC2FKPM|C0eHp&5;JYifQMe`s{qP?9T!cn-m|P&4<}h-= zsC>lak?-{WfcIp@Fy{S{5QE>?Z?Lu#rvOru;#N)?eCqY zRT!*O(NMF9E+fsf!+_aUY1IbOqwJ2EZfmB^T@0h_5@nnl2HK!g0jMbj1^E3<#8VG= zu#TpH#q97N>#aCXeBKqFE8AT6>}x>g2Jv7`m+71g7ehRdHykbPbfnqJ;h6T+%Ci&C zrtn_4!S)5;r{eC=^GBX9skj~R&T0L|)!kMX_tg@>_6OTNqHAQILwM3k;LSpDxvjh* ztng_6@pS3wqd zQ^2B&V`owCMR9sGi=TGlqM0|{e&Y?@P}&*$x;)V@VzE)Tr8pT6U%pd1FW0yuTF@2N~ zvETE8KN`e`epTNN;^WHARg4vlT%QOe_T7EozA|UoIa@p6hioty?qs+UofCx%pGk(} z#ZwAl)TI5%v$<#TW4@JwaSo52s}!XuRd7T6ieIM3Bah=S&d*tK1G{|s)NpE#5KkoF zAv%T;O&~mJ(1l^=ixat&{{|_4`FpQ-T`Wufq4)haU3$*Yj#`U|-;=OECAye5-uu4y zrj=lK?-o^>Y1+%I{&)X8CqLxAU_?QQ0=+D4^o4Z1UvQ{t4ma0aJmtSj z)frLZBhewa&d|iCRonDD%3cVH7)q6aS}0uqf%%K;H8AgdsDOLGRzpWN2s*M~z-|Y4 zZ$ZQPDP-CeUIbLdHJ65AuD6v85ZKK7GpAg}=iZ zkdt6-Msfs;DUM*{7K6J!f_?T|1iR<_NY-k8BWgoUVj(wWinZ35Q z3+uF?E4$*U?rdvPJiG9$(^$y^3GAu+&txMm7|3qEX$U*#zGSxI)=ZXtxFDiv75bh_dK@$hFjTA=YuTyh8LK<+uJO`^9B3ls}>Q@ebO_ce*N%>wq431GA~&c zvHYyf5!u6{Bl}Jp5qb8MTO;p1`_sr1emlR#!+RfSv2Nz^El>INj+R*dP(}E;mfyDZbtq{@qU*Qr^POQ0Qpko=wwX+lm@73gm zzHejlXw~%nu8_2O`zLZhE+3pfz&0PthuZ$8z@c(&N*pt6U=AdJ7uI8{KgeILis~ZO zY2k35=D?%=`p(Pa!%}rU-@l^R-i2po)<4poZQYqWxn}3C)7xr#L@-V4Ux}_u9RBFv zSNWT&w$D6U`$z_#i7^mYdz5PjO`;eGC%LqqgfHlDR>H?*-%twL_g#>-+@Fx_AtvZj z_>gE!&_k zx)%DNJC9>*Axx5=+LN&?7=ab1f;$QNpt-Q_ZzX(B-UIzkMg+TZZ3J6Z9LZkIZozI` z(2}`QTeDN{wXlQlwq?cXvCKWC3#(bvgV{3ru>L2X%U)=JP73%F2H3Q+`~yE)M6d;MJQ=d@_oS$*g@8!ynAK<)lRef9Zj9*JxC^jquS`s{iVn|G*nq zc?F9dgb5hZsbL+hDLQ3F^9_gvzbnEpj<46mZ%C+D8HcjC?g6F}SUgy4W6l737T7^x zF916n>=>|!AfV~0iQm{{heG}{#V58tc`hgt}_ByaHgZ%|;3bY}&g53jl98~K6 zfX#&t3FkhR!N5)dMvMTqWkG{e4r9&r05${WJ$?nSdtva}8^)babOt`d2E=;YYtjSU zQyF`vH+*A06Xr2sqUCwmcd|PbFvGz1-SLq2bfCd}$BZgipLrYXKY19wi@m~_tsdq= zeq!vCxCquVIfC6=62Xe^i(n((k6`D)_p>R5k?j9oiey)v)PgO)xdlsV+mg+?w)P{|^ye+Hm+@6(x5yQG1jAff9c4Gf)(}kUOQdjo< z((df`yW?5$X}wtbm_F>qL5W-*Xq*eseEmQb$PKW{FVAoU~?6IT;yU%Euwgk%% z4Z0CFNVf> zukBIGOLa>tWt>F!0n~1qi<8nZ+Sf^bhw37agBkRX1dDwog(a8bQ5gI$`%xIvH97ES zaX_vw*f#|-qP&XtM&U#G8^tkcCI^mn4%7ia>i>2L{U6pF`J5npmSKHIEIHWi=4}J; z4;ZW$9pFlIP82SU`oB?%Z6*vg2Y>=`8>pM$-zoE)DbsC^0#M=x+g-9f#fqQ~lRj){ zJ9yO5g??OIw#wgc2g3dNrajgHLr3SzxQQ-6=C@75tsn2iy%ZWx?UP$xT5<0Ay|T27 zk&m5#k3*E8uXY#!c^WHLg1`;tUb&Ac-2cEz7}!Yw=hmdgX005 zA0Rp>3YWlqqk@E&9#G>KZaFW3voUrSGDh+_3y zXFn77`YVaJM;;B1sgRFE=S1NW7}qG9+mnSGzC2EcqAC(-a_xb4N5~8Di{FirS2W&( z*C#$Fj_;8u&G7of_xof0!goD*h2rlB_)D6ab-E4GK!fFr{3ALi3YX^a52MF}MZVxVl8Jze_8lC5 z`y{(d@~;s5dv3q5v={h`&lS5S_&P-h&g!3D)&1jzlfB3zH0VaamFS!(TyhoHEPK8( z!ReX_YjJaD+RM^xC8%CM!|s3ui$$=!Sydqlt0>f0qj9bhh`$J|PhP{owQ|5`3+FF7 z{yNH9txxTlOeg;w=WJXXY;(=b!dbx)4mgVl&ip|F7Dbw~1P(oeNyAcgT0_t0wSGQ7 z{LBrJC|@EUt6%fCrzoTHe9XS*JF%Ny>2m(;rzUqtIYk4n`dmJU&WXZB|NSi0<(%yX zCXS$kWwLA)e5DK=#HW2O)8dMJTnl_elL8iT;kWz&;94$$^%5IKT-8tz&0L#uM^rD{ z|0>oaG=z)jD%F4GNEFZ%g1VTrtofk{fC$dnP+X<33)J_)&TaTTpHic`j4m0(NtS4) zd*nDE%1a!~?Vurfk>z;v+>UJK*ei!G99tjV3kwMhwmI0&5uFo-ORiFc+o<@mrjtL+O{J8TSx4li9+^)5MtFuR4h0%(6-h>ktq1~(IFerv&6k_oZB6g` zN_&{;R1M*f>Es_0N2=XZYAe&Vzx83@7@2q0n`ufRHgDVz4w+8=A#or-GHfMoWwcU6 zi$e(HJL-S|a^5HqftJWq`zJyDrlfMxzE;lGG8gDSHh@&A49EJ(0*dt&5nppVz#n;+$)ZPjEd~D~4PWhAT8_xwjZ#E6iUWC@Lu)Ks$o)vL< zL*T0amxb-jzU6}6doR89$y7Zqq7xo+4RPhzTy8~sv*k(|8sn;k1gIU(*%+K(mK7HE z;6=|Dp53$C5yp~P+ zeuLfxST?*DY}_#@X(gOzx4(P0O9xf|i^jE7zC zYs@R)t^wR=QotI?Wi8-NsdLPp@xG-&<}=ZG0>Z_IyGd|IJF%a{I$Q(RCkJl^$2VI}4I=hhuM~U$fhxUyJp$~_bWB4XTM`w#qBG$VN z@Em9Y$wN)8g>_6>*KOqL*%7il5S{Ro>wAtS$pg-Xxd z*Zs2Ft{r=679TbF=NX7jILYcjlI4#@l^ItM9S8sYWL8~X(zSPv_Lq3()v&BYat~=*SM6$gwIzH)O@;XlmkAKATOnri%p=pJUOM;Cyb_ZeflO zM{L{t?!;;Ga}d2*&jF9cXG5kAnCf&*9oP)<*44-4t-+sT(e1J9#km`)UG7G>wgY>Pm%SyV2oR)Op2Oa+qUOS`~wEV;rA$_bE0q=mz9FL zT(V#RBOJvvqJUO7QIHC_q5Nwhe@qYi4RmQvd=V^oe|g}Uw*iTrx?^f5`-3eH;(R_D z4A%m#MCU}|g8BP0hXxFeK;@AlFkpj%SGqRaa2ZS@t8kNM*IGoo{% zaKU`}iL`uP7`_}7@VU;C5{Us`h(kE)0SBg=0v26#lHs!9d&X9_9>BZse|^0F{uX!b zya+u-6No-anWdDZr{bK9%UNMB1qNg(rCj+2xG+fs<2P$cxyM-uXV|CMaWc7tuQt^Z z7so?ou%Rs!zE@A#a@O96P0xzh@IDYdEPS~j{WD?76Q7D#QxHrrSDo>+%wr>u)@8~)2`1jS=RPGT>rjx%wkG;^Iug*-uyfsc5I2~h^Sx%LPQ-t|5OW=bAmrHG9>LN&( zhCmLOjHvvA| zz_$lzNj>?+ypYup@!%jI@H^Bl$X84k)2!0`aoy~+_e0}KiYr?&bdGEO<=t&MTthTE zB&Rctab2Xi97@SRoR|d@50>y%LH=U;h)-D4=hz@^s zhVX&vo=kgDF-$ExOUhAa4*wi(&!6d5gNx-?6$XwQ?_WP9@4Aj>%Q%Rx0|9>o9C^hq z1zzLSymin2LFnf{@Aa4qHgr`^lk+8dpnPF;0N?+hNi8YSMw!DLxXBCaHX7aYhk@g% z%z3YW-m!yk+l-1Qg2{9>b^r6H+Gdfo(Ydf=1Xbv%4KG)2#il_F zY)5E6rSAg*&^ZQQit3HZ2ZJGFVY|2y-l)4sSE`wTB6DCQp|sl(!heHiA8 zR(uw`7cKlX4RF9LpJQ7L5&)i9e^9>FxjjAZBTd$ z%T_eRd{JEV!SVPe=%42!IwuO3z_>!L+cjdm4sZ1r!TE?VuA1Lr!=m^hujdU>K_NF& zKn{qmQvKJ!c(s*jOo|G->R5-?jnewvxJP1{XY|#d#6NY{uj<>kpT9)+ zBUSGL2W4n*zRiewd{i_(DTd}#+ z<2d11PFOSTbi1`hY<|sLx^Yz5clvf-#ATZT?%(^{&&NSD zZq#y$WHO!n=^O+&t!%7wHa`p^1->-Fp%4xpBonS;|4QYG>56mMlwKfLtTz*X^w%4s z_xhae?b+^IrdD+xb4AY$t<)58?Jc%5M3?jNy&vh;Rr;&0wz$$y5EoTx=M{63mavG| z@>6iURqwZFF_(F(r~LLzrybgcOu|d_!;IHm=5%OFuho=AymcY)*6wW2mS0ixYrp$` zUfL2jHi99%L|3W)>ml)%e=Kw12EOU=xr8Sw;w}Ea;QZb7aeFqQ*QRy*|F~p#rG%I0 zex&MM^YJ=tCGeFs7=Pmq1jifuzxM3vsEe%yo!kDfT*6EA!-_Wqe>a4{oBVluc1gyQ ze|XO9{>R%AUZNi^y#5NPosk9G7%**79x8qg&fl^x+p}I|`3?>Ft)`1i)FdGW@E3~h;>uYDl852$t%HeO!6E-QzX>%JD)sK$wSs}F|e@BQsu zPo{Jj{0!=6MML~0x=Qt5n}%27F94SLTL(#FKZ*Tx@~^@1)}I*5#`Q^g^WGi}Tg>A#h{(Wd$=D?92Kb#CtTv zXPK`0iu2X#nj@_r7VBBMvlLFW9R;7v%ggvN0vLA@SmI~#Z^8L#c`BBTnUk6M)zFoD zp4SE_#809V9&&yB)Yd{7;L?0lNFtsCA@C$U8_R~DJbL5T2S3X=L&8IJ!a;5rcyiq( zKKAJL(|CUm&Y#VDp+EXxw^8*i5(};$r;Z5m+a->th)y`j_2CJ$(sh*0RRon-+VM3& zc$MQxiS;<=j}Y^Q-viEj?Y*l%iW*Auu|Av{o$!(C!)dsm${3^{BP`V58|iRQikhMq z9Fn_zfEP^)Sfg=j0^t3i$ z`^|AH}zi>hwNC-IN>iOz|_#fLMktlXOC^w>)H znSr`>W(Pv#8`~m=4SrycZS?*JCd&B|UC5H(2FTYx&7m!MtA@}dPgO1S&oAo>O>P~- z9?AP9qD`M|AIwg`w`%|M6P*))m?9+wZ9xPAXqg>G%7BF#4vJs>XHsUhz3Gwu#}5;brodD2=*IF`}PX4}fG{#j4`$PCfh3WPZJb^E*yi_~OB)8aJ z=*i7jchTzKlf13{{0oHhy7?!3-)=(p>j?+pl3cFfv%PXBl@eA z6%rvlGM&;V1jcxBl@eHY4|8o+oD6Xb*u-&Cg+PuX7aJ=5mF|6&D&Y8*s z10I#}5}k08dx&^-mr zwTXxzy@UQas{tqRAv3#AK0c=xER|ydOiJNcF&Qj29P+pkNNi}#FTdZ|`-$(dpGAXi z1YC*EiNdAPbL5s!cfn?ma#udznTT6)VUGyxF`Q+0mb>|R#d%J3e>*1Q1xxrgXp?5i zKr`w$ygg#s?T>DLHhI+W7;QR`f4f!PF(l&64$i(uS z)=4i{4D>(XdrH-D7WU&+!!AfZJ%)XAXUeQsXWd`B@F_KC#D(>a=!A#d;JBayq!fs# z*e-~O?LavCRS_-r>-dQjb?~9iRGhEJy;l9fCWFldTLN|g*gCNLzz%^*y##D0=t!Rh zdo8>K-U&73=T?lNDzH-^(f*L=S&-;-NVGR3dY~6$9!PXXGGm`ZqQgt!+>C{AUg(RA z&Hj$DdFMv32k(wxHyt0zzI{HDoq9tH_RT#l+4X-wqQFOB5!c@u5BXESR0aH|eyP*< zm2t>Ru{>fshnC-KM*Ut>J%5T9qH;rWBGbv=xI9!K()0FSSOx-nnWy`lBKFAi7HRUmM}cE4I4|V0R|Gw5p>Gx3>EY6bcs% zU{w&6`ic1C_58tid2H~+ea^*`J|5+{DeBxfprb)Nk#HqCCkhuI9++h)(B{c-r4i{H zh=;ILe#wwOm0!~S^cYNA^q(g9PcO}AEBjXo{sotm_C|k^-?3fv{4M~0dETJM;?Ha; zyQf?RUff_B_>?l8li}ifKHa*8TxX%j-$NqD)zgmEIz#-fIYEzS?GzQy2EaM}1Usub zBZj#bzPEMqy6tVx#KHiBc(8pSIwuMjA0F5SE6rJ;E?I+V3u~^zcf_kZH?6~MW&INq z6HDDNO;B+Tze67F0*koAX-A;S^O^!i`z+z|80JbX#{y4B$0dPvr2JOrLz|I4HB!h4!Kyv^`FR~?&>0ns!VugYFB4}&M zW1)@d#25;y0`1MCJyB;o>_a#k&dIqD&fdv_{VKq3YDYFeUQ{k+aTfUJua|PU#P^M1 znqXWug>`RscS!w%3r`ho3^b4o6B--+#}-I z1$fY;fW^8-<9a%WYi++6)_>9Uza;(GvEvSDTu*e2FB)S!d;sR38=Cs*!TG4-| zOzU{Puum%qxJmRw!=;Wu#*NUxL1NWlNq%YopIClIVPJTEr@FshsO1Jov0I#9^f8w*L2ytpChD6Z3a1nZp|+@FIQ?9fOO;hX*UjFg&sW zj~DT=LsuS2r|9bg^)obol$0F99xvLrf61Ej&aRf)Gop)m_u3wxwtDh3EhBvX7Qh9fYh<6}%b#wz&Le9!F2RC>W$E=q z-~XSg$03&kCO#o*ROXd+rF;5mIiXy%gxOi5Yh<58+4EHqLOBEw3tf9z4|vd|fJOeu zhp#x(vmTcYRw<( zb5&10-&%qn4BHv$ud6#XmQA?zgp~TT6EGMp3CNN!#M+re>urmn*+}x zNmue=4$!GpBoT+@Gz*l4$}fLP`n$eM-N&tr`~qK9xIr9f`bl(^%2;3=<3S6N4+e{e z2*j@hz#-;?d5Ab`!C#d3l}y?;X-NirXL@M=U{~we_US-JL;NDTO7&k2 zaOQz>-6F-M=T{X(p>`*+mmY^)@Ag5tz1X*^Ws6U;E9G({x*vghXMjUhi_Ay4imu(M z4UvCx&ses9f5(1XYrmQ(=TG!7^7oCgv5yhUA?b7rk52W==zI7I<&yO&KVS7e<)g|= zJ0{b~-{AS-BREk(UbJz(h+}OSIC`!8_?vC*Zg`IJAsjND{3%DF{s0cpil<7ghC<&j z=JXC-e;$h+aKeeJXT&^_{I5xvmx=@QG-`CppIieRBoFGhGtiA!4xIyqkB1woM`eJA z@{9Z9i_SQv75R1`47?*Bx^JEHy}rlEcrViElrOmkcvbn4(8faq!WoxfVU!QytkL|j zeOwFvICdjBlgDvOhR3jXUVNxxeoo3JY2x)Av_c>9&U)Q zWq^nBTXomsgL1!fAPl@!=`YiwVA zJA-35)N57)@w%VA95u$|HIRMmf`mUJ;hM7}m< zeh=TTk>@xTr8z$AtGa@Pqwx4S+kL>r=K)dR^Y!9$d*Qjoeh#^SX>NuIzfEoDZ;L%G zmR&GsW#ZR2)^6GCT{W1eEwNJ$JL+H zk-Ni@8nyvw$fbI(Qq?QcL@WB4_a+C91_zEteZeukSPzWq3i3j%OM${14W5~K{&P8C z)|Y>7*_%(^bPmY%MN@Oqq=e+QU;ZB|F)=*d%WkMNOn;LDe+CES`toPwX}-Vw8C*8= zI1(H<8ubOA1K&-^2I@c>I=s8gSgdE zoeGB|e^vF4{_SUt&bPpCY2g^ETcN^+8!l8j|5Sf3Fc9U2&Zi+h;QKGOfyiI71i(&qW z_j36hX&zv^iDi!Uh>Te-#EHhPQTgB+KI9>Ne`_4er2JVNFe)F+8_NdENtA86Cl|w+ z=E!nDE+1Uyf`-aKY==~z&{v8ZI;0sQ6bIz;p?w|VI3ZLTrvH)Sz|op#!ty6e^^IJ5 zTKq3sqMNSCfuqF%v%VZH&YSuE6**wmm%n1EnV63j2h93%v^a0(`&ZZ_aPfUN+F_32zxh$1tL4q~`#R8}m5xoh8=H0kB2Z^87@2vHbH(7#_>Ps4R?V;ihkf zQ#s%Thw69r41fJb-pcx+8;UI~)0;n1NqqTsP(j5F&eP(4Nuq0HpX00Fjr0U*%J0)` z`NayTaqz30<=Qyip2`y3JbSeIYkUCY0X`oZqxm%SCyQb5-ZUl$jwS~})t6xXoG8C| zFUmaCgQNLuX5JXn%^jcEOI76_!Q{u6Ni%O~tp~{zxkhbxGqd>HM@xh! z6zeyBuO{6dMh`ESC-R#5L7DGV9^_IuqjXK$;o*Q>KH;Q_B1LuyxM8f1!-~(vcX>kW*-#rexdESKkJ%Fuq1p7WUg8fnfC)m_QuoV%J zY{`U3*6feGr`CSZPNR(osSJ<^*QIWnBolPJZmh=*gKW|a?r_Q z>aJ#3{vcvp|Bu}6WCFiJ8DO7j{v-~F`k9i;_4T*_Fkn460CwtvIT(};|7F=}(`N0v zUk$1D54fv^=om&cnRYj9KdH24Ikh8(l!82aiGl|rmD}L_+=BA55_>*B44Fr(hAXuz z8zek(`-Tx7opHmL4fhYr;*sH^%1%ThI{6cxG3AP@QUC>Kz`1b(jlzk1nK(<&m*mtA zoG;1eFm`bK+RHG`uMdBi`)Jk99uu_$5Jv|IHe2mKJ zq`A*^czy-nqdv@E*gW zB}4zoMOnkJvOzk9k^Rj7p*aw0J~wm<{t)s0+n{$xvfYr=CYd6afQjLZOZ9$ zjw`1XP8>7LvB3dxd=YztzCV}S>74P=Y*5aGP4Q2@>U}a!#ZP)Vi7r1?N`5{bJER?_ zJZu&m7yv64IL%RnefdCZhTY}%P&~PPCHmoT!9jGojh!(_7&jW5e<&_EF_?TjM6guzv43Z@Hme zMgD8rw+(!U#_ttGhrc>AR&f+4E;t588%>U~!%13vIGJU$JNQAzJiLe_{zm=yR-Uig z)h?E0z5PT?YdG4C7u<{&Ko%6%ts%N-;L)IpdnmDSE>H15w78i zC)MSg4X0!vmn5DE*f5nUu!OJd=HTagVEE`K&-~+^b~o;#aV@$LaB3jYF^p(@_(r&g zIc#v!Ih+;;lg6W*Hk20W{F5;9&y88v?(B=dIzi5#=wjY@A0&S`TCK>T6l9m6{D~pZvlcgWXZ2ZjHcd z?M`u5I`Vbry(KRSo`3x37IyV%oxVAcd}ZEES_bfmmbb@5r+mo`k-v3pxg%47lM3A) zdp@?rqWo?Sfd}(QTQjI_Reb$y%C9HC>Dh=*{-N-weFgvO&!fb{70U3$5PpuSpIwti1Ti{p7f8~ab8W<1CqEP zmMz`>?92T<&z(E?By|LX;qd)|=<*ZLWH3x@*&QBjl1tS2!B^Fcz+HDd1jRS&F>ykz zyI5zYx;?{vv1MMh565z1An#pawPf| z;*42mh!dt8hy#DM`hw4KBg8s1(Fbx zE^@%EFJ^ra<-xoU&Vj#LeK`{EF2o_Tk0DN&ZXgbr^~KK_v%dIwVcr>Ypbp5iZgexO z8%2`>)@UCf`sHqUu}@r^mFFzMO=)0I#?F8%(K%7L_|}c4mDoYIwj1>!`pyGScjlLu z0@Yx9V0v~|n$zI{PgE(V6mZSluxAk0h@zz?lI2CAt8S-v-4Qbnm6c-oo+{aRa7^H}ij? z@t(8qq(xVi=D&9{3IZ5(PJt`YIZ?QTjn{uBe4dl<6*b0dw)cMKBJa_f`$hdcG4J#o z@PdFC?dQ>lYTmzeh;}AeJhu+@!NSpTydP-^F3BdkrU}e}Q00TXB#XMU;J7~D`94~g z(I|0~=Z#p>Y=ReJ(zv5R=pT{CvR=^Q6Qf!0WpNiI)~(rnoR%Y~nm2Fw;SC zv*H>HJ7z$Mbe_vzRHUl?9aiCS+44Phr(;+}zEb9~a$VACpwpS3QR0P^2w(MXfB%j6 zWW8{f?$NCMj5oI2^@;cWcuhzMAJKilw40{m(<>&ff^-O<%9n+G`~FX%-i6WJ-hL`g5p&N z2BIGt{4Nv;KcaJ@aPjenpOWWSp=!-Sy?IJOipS%!PlrO);#7l6{8;-%aDG($U||(s zSqE-j_^waSE1vI#dN_zKK;gGOJQ_dJ6_6*;IIH-eeBxMt$)LP7nwHE_L7`bJ-`{tKCH2D=MzPZ_?#K5=e)_Sk~zmnW1isKob7Gzb&% z5uFo-i-0e`+^rO3*p-q3IGPErD8OtYG!V$2rk=Zt`J+xuZ1=D(;h3cZ*jTW54llOb zaP%!dj~DAi7qB?KL4M*nDLBr-GkUv&MV-$*z@qNuc(A8{Jr!(Eu&04Vo$sfE?F}{o z>=|JDfb9zw_2}c+3C|x!-I$4B`-2?-b|BcZ!JY$l5ZJ+BlfVuEi|1&b2ljlhL&09~ z|Lk1{d=$kOUKBI|13@fc4OobxCsGu}LI@>6QXrw&fFn7QlgnMayMzQ=6iXCK#D-vr z9TWu%iVYD_V@DK0MVc*k?AZU`x4Z9dc5}H4ihtYA@AvJ@zG-jYyeT^~I}02O3;;5K zfj}lO2p9|u0fquuKsGQ8I1U&N2`B+d0WWY0Fd6UxWq=XE)yr;&_tpcb7rT|p{ z|6DK?I1M-*I0HBnI18u&&IZl_rUB;y=K<#f7XY=ug}_C?bl_s(65vwcGN2B)9GC%I z0bB`O1zZhW1Iz@j1!e)Wf$M11|tC0xtnC1Frz6iWH-zzidcQuN$YOXzBg#zv+jP!8^BQWSDIL)@z~bMCFp8 zUb_n1Wu82Ye!Nr+7?!)Vg9AQG(rFpEwgT+!AU(hGwr*H|#88S&Hw?$ncDhc+rJ&s7 z^JSKLiYB}CtEYHOAXpsI^-1zw(t>;^txx$mb*^58^`s?VJ3U6eIo?o+Tu9b>kQ!Vi z{{f#Te(p2gYA* zzwQLToq_sQt+eazFYe2<3)=e5{-DhsSF`@nkdJL}6}nDTE_&t|phEA*c>Trr%Lw!z ze>KJ*J@B_@PpF`xygU#L_i_ykgi8^R?Vs?|*aCjO`)ck1jmI~1mn=mtcDnetn4hc) ze~7gu&+lV@pz>AoWnwu!H}K(^eM?^cQ1TVN>~!&OF<-g(cX*}8Ea({BBJk6lASM`jxh~YZjCMAZ_`7=_MRKM zsYLP@{_J$|k22E&{uEtP+lfWrTjkaUiEjtw@1kidmcFtV^SYtvJYP!JpO(-~W3(6B zG@%>5i0cl8rl3d6ar<$oM^OKr(`au9ze2|kfILC0?%*#^9(_ozN2$kyvK-|<9NU5_ zx+7_dO}gqwH~DqUpCDTmLbc9pqoa*7s) z`8)5`|NQrAsKHt4c(yKqKCSPXtbLv_tfu1H!}qc4lh74a(w%Yi$(0u__3(Y3rUnqb zPW>sqUYG8dtetvqmy*6iroCq8L+DIXHL>^@T;}%5I8l|u%mn#wN>A20`Ig^a-tM~d z?D-2_&71DH`74r0Ls-gz|FK#GJ{~!0)5@aVi~IC_=%ifM-73?c|EcWxa}w^N^VR%U zCErq#FbQ)@L-twgXQyfpcX{Zw+RW73h0k{IXZ;sC{xU)mnb7;m5I{taCKBO4csxR@?g2&$ID|QNz$?`3c=5 zM=bj|Q0@!Dm^&WmE}D%0pJIB}=hN3c@K!rKfH@rV=XOYC4j}yX`z=0yY1?2OsP4!I zUhL?4-OiuTBaE32;YY@)a&Pcg;q`^H{VibA!smMM$uW@V1Kk||OxO+cqPO06471M3 z%4_|_b#I#|s-td#)(TglGmL74uh@LXm!qqoqNoV}oMd_n0Fh@M{>+_-&&Qr!dFkWt z+!-`9Jj$ogRUYY%&u5F|sj_R4Yd`28jmS0aiEZ?HR`&&T^on~|(C?)iFI(H|{!G+7 z!x(%gHKB`te0~$ibvS-Y>o4MTf<>-lJ0#}wnmv2$Q1$r?ykQwe__Wi-KR%x=ldHn6 zzAm7)A8PqZp0RB97r!T7J=!HTUaYkL2o1^WhBoUO!S>5BEt7y#J}r~eUlqzJpTA1- zEz9@ME+64S+Bx2x#{{w^gEn-6>WsPC9gI}}@H|4*vDeC&Di zJ&z_{S;g}+VmsI0D}gjbAxL$m~W(ME`RN^6s_c_g`XTVrg9g3krQDhf1&FMD3{pz zhqC>{-Jx)f*DpJEYY>NWq8w6pOgzu>LTF9qx;9;UOIAjCwbSf$@wf3Y#tjxS-Po96 z2FNn=m-#`aCy+f?ER#e=mFLU^&yjXxs@CeEXLma4(l%jqRk|QHn@20g-3VPKouubbRlPyUdv2NyZ!(jXbN@r0YcG65&JNDw>b)2fg~{ zc~@lrGyZ6f{iJz*hAaw{mHV(m+FBp-!IzpZ^GpMzzLdjX=IxKW_r#u*(HzsCdeV8P z#Lwl+dg0m$bzi)SXu6T-DznkWzq#icQQ`J^!_}^gl9HgO1oK!49yARJ%5(GspDG{Z zL7i7@Y{7F}oVoh={-@pCN8d<``0^Z=2pu%lBzlg4)sa2E37*7AH4Ti8QB$5UQ-%G%knlJfQ z^{I51#C(4}>ZBZg~jYBzg{2pW;198q$*I$OoUoM{;{Zma2cb;@`TH;a_LQ zXZ_bY$M3J|>r%82hM#!Cqwl8g8ZsY{7S~^dj$4bd&l}_O4$nYOc#6m4*Oxdl{KdxO znXy!U>JsoXU`C48uEzID?&X19Kw7m_DaeI~S+@kLbz>kcZ_Pu<} zi}v<&Y?s9S>>anJ%)fcZ{e8lhF-P25v(v@D3BOpP@_G1kB0qK~a3$5bU&`om05*B2ANI2woJbFiF zu3V~o%-Pe*2bU(9&jbjzvTe`1nfMoLkGd$O@iT5e*A00k$9B3-#>LJDHhNWJ+gHHv z_7%7*Jwvdvjz2o}YVsYCk*XmJNz1YSItkQ6G1;!k_%RkItbYV`SRgcec=|hL>q$Uu zr~6?)7fl90IoEuCn7%H$yawOU411<$`jshKb=n)_SHJb;8HaLV42I>z_C)A9QMp9= zNBj4Yqx@m7FB>Orm|vF~+uyY`#Fc)q>Y(U2_n5kMW64u3@>TVTv_z)4FwM~urKkFD zjWpEs9JeEZe}V*@diYN$C5OjJYy6vgH z5v)IIJ@4GxI*(@Guh4K+igxC;8}oN~>5x^%x)+m}>(M>?B<_!X`MB?Q=PjREZcg{=`p^njp(9I+ zDL@aD9SZn#g>+?yWF3dwFA6FqmU+YYazEQYi2EY2Tc8;0I{GI?YW-ORzNn8G0B!bF zTrX135xBhlH)D3(z4Kg!|(uTKQmIB`@+F z8=P9{LBm=-GVJ{cbkhhQcDmtOeX+8M)us=cCeVQnZYmX~~uC#xCB`%z*iGK3?c1Ibucfr$e@%;E-(Dr;-`)`Sf)* zjvlZtr5-Uw9;Js_<-v2CmIHFm8l2j1yRF;l__XI|%6cWsuNb8$bcRt)i}~RZ54~hp z17zkka;QgQ!e7$iiTV3^c>SemCF4FdT4+PR7)$6XZ**@Vf0122A(z499EHCHE#R;B z1-Z%RKHag8U4BCUgZvpQ%Xz^jeAX*`=JzwCBlXYTf02j%UfAWG@6J1n$CT+t^xjSv z|EL_jE^{de-=Yr2B2c(`RCy>I^tj71-Tq>4G1P7d4g!kQ4`bt&S}*F3w3c%kGU*De z2j3kwpV3%#M6&kUp%Vv>==^P`XH5pMjY6*%LO00~E6QJSF-P&{!6MmZJcWq61922Q zkB*n|w6vptr*jHW?a%6r3di~&>#eMRG-9i6q0v^|vBHohMh&aF#h)y}hjGq_4Wof0TUz4a0T7Rp>fV zxkUIf581G=r+J}?3p2^0W@z$joeFa{V4 z91q}V4Cj1O$lyBQ-*i6day$<=ORoT41K8ND1l|Bv0jq&GfwzFS0Zu5s1FQws0qcPc zz((L*;631d-~-@8pb_{8_!#&E_!RgI_#F5G*aUnDuwnfg_y+hE_zw6U*bMvt{0RI6 z{0#g8{0jUAu%l=NYy)fyv<7&n-gdzDKoXD)v<2D$I{+y_d!Pf53UmZ^1Udmb0XqY` z0J{PlcXR=E19k`Y0QLm-0`>;dfUZC{U>{&#U_W4gpgWKb8~_{$^Z*V54hCGnAwW;y zP@osk8|VY{1r7ra2l@d=07nA-0k*vy57om~$3tv{*>5@K?;(LSu)*@-_e@#nKV`mR z>YQi0Zv#KozkW#6|AcG1_NV_$Gro*>ajWHEP;vv6_%Aeez1tF2&~@wkXOp%hk`s1| zBv6mgGVUHQl&wN^JQ?dem~CFWXy2kxU3-pMXsBH&xC&h-DwoKArv_JHXok)5ehl|r zq?&KP`bSp97_J2>f<-v>)?Lgk^)BzEAohb}%!ssvza`+0x}E_rU%J_bsq0vy=T4u0 z&A>jlgRC1v`&(&ty7?V^!C8+;gY<2stq zg%7b4^OJ)Yw_vrfr1Ddqomf7zFZ+D$BkLwVZ|6to!iU(2`5EL5O%`sf<)sZv%ujvx zqnD<)F2S3nVWhn5bn#Ej4}O|f#zHiBQsqaoX{~JfIUAkQo5~W%mv6A^OXmw!{Akw#T~+GP)8Ooq&v9Kt>&Q!Mn}w z7^il{Sn)uN^T7U<1HeZ<@+-pF@ihGJ0G)8^<7kf{M~=CWU8G;;e9O!P@?QN#s#g5S z$o+=@eBoNVyoJs*RWm9l!<8TMR1^pFMwRU+CR@ziScOPR1exB@g?1jukPyR zwbssAyWpg%FH^Pd%lfW6w*Asgr|Dk_8T~T#K?y~YeT0P=OJG)8Y z2gRhzQ`Jk5w6x1#I>X;#r$Q8&ZWyjL+BKn@jgCn62R=64zAB?$aXIw7mHIEVv+5JEzaX*UWtSkn`;P2>lQ7v8!(Zy<=Nd5auN z^R04>wJva(f8QUA-})q_i^&knzdiI*=yCXDt?=PbQBk!F_zMFWMPYnm9F?A4`q7^O z$@pLY?s0^bKkb4mwk<}63%oer^PP6jFz>wJ^!{Ui*kjDox3L8^#sxXxPv|;PxfGo0 zb44cL%<~UjAYz#lb8dcp%$8Rk&Z`Iy#7`_HW9=-g$F9Xy%C|NVUneGO$1d1?e#f3S zeD&4)tYOByD(i#Lb)s@1Uz{G*7bW2Gl*eX8p3o2yMOLJYkzs~r1@y} zb;EHc`4GBEj#yScY?5$|&LL+ZgjU;!dK(}1a#}tV^Ygi+S{e(ES?sji1yu`&JXhhAy> zno+9_dE>276S_SY*)JjA-$qyF`9ZVH?px0*UTx!pJhTDSeF|5-c;b_Tc3an5@-uXy zm1d`l{~*sKHx?4iAFvrs4gEMilXh(r28&E51E3u%-&M=5?EB2d`6ckyjpS>mi+}#0 zAucm-y?GP*pHVLiUL*&@CQY7&&l4+*HHLFX2`mCcFXoJmwx_Yi)iWn_)E1t9-@fa* z|JG{&M`2{Z9B#SrZFW&X{upE!ukNtCzzmP9S z9>RCk@$va?DC(%)bYbR8zYRQWx}9&KD=h2ICVc0hR(T8E6Zyu%jeKLg;nMLv$LnX+ z3+?wmj=mp9o+s;s_|LO>Qb%p~BhS0E)4eAiXn!7||E}l3<9m${1jqOO1I1&} zE3GL0^N`moFDQAzeWYvby{x=2tiL^Q6}nDTE=|e@?-JY?<#T2A`XhWd_n-Jg?MWhk zh4tU%{Ik=K$JAe$cRaovzrS7r^-vDBTQbiOizCq=yB#a6L)*F%_`U7f*5#sUYN88G zeg1sPUzzux|8!0ce?$T`h%Do<)fl%>S26(FNdQMO%SW}+o^Lm8WexlX&g=61JD+s@ zE(LTN84nBHphmC8=U$lqagB8QC*#L>IXG6+m=dZ8VbXXkf+lKDnHu>aT52rszr~5y znV#@I-))(H!)21bkyk6tP8a_iY(#hC_c*v_VJ;0TZjot}!Brq|E{R6vqoF!FE^OpW z_(}V>DTdW}!}i+R>V+#7+?%3}J@U5$9$Yx6>XH$R9hI-p4Qli%KO)E0cztepxOb8# zj0wu#kxAz9xq*!0Cg0mIdn~0m=5Hc_=K3u=dr}W*%X_~{V|`Tb>2A)%@{{==#-YEY zC-;(eta~*q{Z%7=Vyk|1$Kpl8sCf#_vH#l=h*e)$AGr3s1HgGj(W&Ni4ncGy;pD!h z_V3k8d%WM9e@ppv!Z{L%RbN!8PzPC01ai+XbaT8wKN_)(JL|PMT_#=iV;btc_%~-u zo)X7y+tX9IlCUaGbtm#y!#eK&h6Dyc;al=v@@Gk7Yw2W5(vi9q?^z@rH7scYHLiqF z{peQd3{M&jZMH8GhBo_eq48b~gImY^%_ZQ}A8P?oe`%x+&@Fl`ex%Vz81W~KZj~-H zv8Aps48uD0hm!f{nndHZ|HqTr^)k^tc~ZmBE%&0k3?n*9xA==qn%zh`5=QRTG{ui` zr7lP~)lbrnMH4^A{^vh0ZXl8Sbv| z7nSO>^xV>I*?+hQ`LWK)^U=+^rhebk>6?D5kDqenc_8aXp3hDfe{gE(@=gD;`n#ns#tX@sqTCFQ>aeDHZiKAewYKP>y(`kj%iJ<$7& z!Ta4jeJ1^A$Orcm30)^D7xFREQ-T!*mIY-ARN)i^Qy1!OC)5>qG{jA!F-3J$6^2CbP zw;IVXpCc$`lWs{IH!=6Kf~f9;E-1xWDcE<*H5yfqY7_92R+Fr4eE0eThG!kNtUJCn zq2XL3%TMS!QMp+6`$qOZt1RfDYj71kN;=Cb7yJI_{AtPBE?FynJiPSae6F9-2p>W> zsL`v950OA*=d&t@I$Qqsa@lllvX(n`+`_BwZuO*H4nmLSY`CoXTlYPy!cg@it=1|B zJ0DCrJ$<{i{cb;W*5dg_KB6B&H>lAo`AEFqIm%J2aTwb@Y5PR)nL|t5QBMB9E|s_c zZ_Z9`|0N03L(!U>HNiY{QO;czG9rA8T5K& zU))SY6nQM4ZGCV42!nx-fz*rff6-YT@|nj=3r?JM`ue*LmHdPsJ6-%+%nuIME#jdk zB}PSC(!t=XrRN?5p5YGVc9E2T#PQXq8zs%%!tGfc70e*wb zGZOepxd*T(AaglsaCZf|0s8>^0{a2`1Koji-~ix2pa*aea4_Hk4gq=s6dEUUdILBX z!8wl(GN=Tm0GvNzC7TN1hzRX;;0)kQfCog>0A~Z|0MmeTf%Aa#feQfk4;KO#0n>qt zflGi(fy)5C&t4A90ImS81UUJ3HE<2UdT=c;3z!XD2V4)_0Ne=F12+LT1GfOT0=EIT z19t#(fVse(z+J#R;BMd^U_P(_xEHt&xF2``SO`1_JOnHP9tIu(9t9o)a72c-7D}dL4*MXJ58^9`HHSi|z7VtK(26zWp3#&iz`MYE!27@lz=uF1@DcDa z@CooK@EPzq@CC35_!9UE_!{^I_!jsM_#W5{`~dt2`~>_A`~v(6{04BMuNANjur1IU zXaj5qY!4&>$v|769k2tC0<;G@0I5JnU`K%G8SMn@4D15z3Umg#0J{OZ1A72_0(${_ z18G24pc}9curIJ5us^_q2h)KAfCGUZz(K&lfD1ST=m{JO^a6SVeSp5eVZh-)Ki~-9 zNPq_w9t9i?90ME+3;;5Kfj}lO2p9|u0fquuKsGQ8I1U&N27Evn;0FRgIdCcv z1VTUfpdUqz`4MA!1=%hKrL_~a1k&axEQzu zxD>byr~@tsW&l?JR{~c7R|D4oGl6S?S-@=II^cTX2H-}Z9=Hj(8MpIS z1Iz{P1nvUn0e1uU0P}$bz`ekI!2Q4jz(U|b;2~fU@G$TQ@F?&Y@Hns-cmh}gJP9lX zo&uHuPXo^Y&jJm=bHMY!3&4xOOTf#(E5LH#RbU118t^)>5_khx1*`_%1l|JP2G#)Y z0BeDDz?SSopBp?}R3$z1v08)VVKnEZd=m_ix zbOLq)b_R9q%vV0H_5n1TF%m0~Z6A0G9%n0d>ITzzpCD;7Z^s;A-F+U?y-aFbkLs zTnAha+yLAN)B`sGHv_i-w*t2Tw*z+obAY+PoxokdJm7BN9$-GO0Js;p54azA09Xh- z2s{KV0v-k)0UiY&10Dw!15W@;fG2^az*E37;A!9);8~yncn)|Tcma43cnNqJcm-Gv zyb7!UUIShSRswGTtAN$Oo4{MZ+rS#&9bhf64pWbNd`eB);JANR#mBgg5v9*8T~mxZnqm5X&~q!BzMu zz1}Jp`~1^_o07GQPij|s&4qK%WnV(G4?sSIt`n7um5)gFG1r$j+48rSOa3kR&UE7Z z+F5gs$P_t9{z6x>)}7Y;t?SDXZV*z{kDA-9aliM4<8ozuU1 zX#E@R5Biu7Kt1F6{zA7umw8lMWWXW6Pz(fRlrjYWk22N>8CT_}-o{U?@zJY0ZF}{Q z!AGAyWP2lL^3xss2;HDYuQA6*Agbf%LD~5Q5~BtV8Mmg*vC7BJ&!V}>+N2-9{N<5% zF5Yj`s6F%~vT)_NRp>fVxmd@Ik@0hcg&KsF{OfJ`+sDm~^OCjFU++G&)lPf=Jl1UN z1|UB37dmb&#+pB~jSQLfaO(R*I-ZXv1E8Gk&tH2_vbJlx3%8x!rpI`B{s9Qa{DsbF zs3Nswa^V}^h!QNBby&LM>&es z&m6<-kh7^ zptsv#6B*gAg-M>{oENB9x}olrs{QQdt8NX7Z!djQRyzi zp>74xF90T)6y$q_4N{@hYnt)Jj* znP<;`Ao~2xS$Mp$!WVLCQf}Xw?IF zwHkm+12!Vf+pd@1#olwy>)jVF-~R%TEv7m8a8ISjH)xc{@wQd1e^hGh9}|A(w1D3> zPcV+5@45&iJZ{`5p|S zIzOWSAOMPrO6-w?MlI$4a00#_P1crAUGUJfw+`HtcPUqyj6KJkClI>I6W!K%g2+5c z6IN6{R@?Zn_X9l_V}JL&Tjp-A?pL?1DW5%&7x@r+d_Jt%t1~C+_@MNW`0`l(1m;a9 z@7cQW+cOv2(Fo%k#E19jflIKC%87HQoq7e>IFjb*@`O0#17tm7=O+syiCOasAgNppMsS zF)rczcm_ayp_^@&dcMy~r+)vdyKe9OMW1MM-a_cOwU`3;B#(Z85C0*R@1D%x3YPGX zojBFT_@#JA53ll(x-2mtv+Is{f9J9LoNwnt=oTh$(>x!>i9?6>?5Rho!Bxihb>M^P zX8^R>zVoGhKyS>WPArETKYiiOrG1X?XXI<}$?_1o> z>Aemfzf*86W>^d(eAwyYABzwCvAhW*Djy44z{lOc9`IGt<*&;0oUT7C9XmZ9A9zol z!wf$^y+uh;MsP2C7TcDne-cF@(!k3+H_~ILk80~NqzRVw;#$eCF-})Bt_x(E` zuJ#`=eZAx_{MqT^-y;4ZjAi=^NEk5@7y8j zO1^fw_&3S7paN@h{y?SM2vGw|^3Q)c@pHfa!*-8NaCPCfA>By+cDndC$v?+k;`dJS zdib#iObsCUFK-(ClE0m9_+kuZ*S8Y_fwDqRl?*i0et7IFiJ!mo z{`FlJO&i_E$TvEE6uRUqc9Z-w^0Py(QP~+4;Q$t+@GEm8WDP8l!|E3B@qNd2$KE&l zu2Uo*k%OHs{!REm16nk>`Z!N@)Axx9%dPFEeIA-=cDeDV13!GHk)I9fhWT?nQs^c* zVijOQKDxeE;0acGi#)Epptr>94;dcC46K$%qm2&+u#cnX?mV}Dh41rsJDE9=k51r2 z=q5R0#pZ*54~}xjz$zc*uUh31i;w!VTi^2iy))0Z^C9#I1E!-nKJb4u3nwZcGhd6( z$7b;P@Pfvr%N9>xxWAbX%ZKX<?!#QCSoe1%e(#s)t~ypRwlg>}lHX4c)X;TXz3P z;Ek>w4F~Kwxs2J2*MV6D;u*7gPi%VYHYR#KB6K$l#K+d0>#rXCwHe$pDyt ztaj$Lq3?WOG3VzKsu>W5;daGU=sHokSos`-nG?^T3Ud!iOL=5+HGs&obfs0EN$?}* z@}I{6tCO{vucv06T=&hr13{!u*!pj0j`17cEkL}n=c*A zJf55|^tvmD?am`IbVHl-EJ8QQ5zD&L7TrO_Ej#Lrk1ChcRf+rSw9d<(J+AN`9+9IP z@=0#(be)V#bA0Ik<#ZRZ!ybZ7As+StH0pcM9PmRU<;1;2?5~nez_-W^+4}dkH%xtJ z*^}#59iRuq#gI=c%}y788$T3>*X{F8)rSr)_9CIeK&H>*#!=t_bIyZtRla6IKiLlm zUv%5&DF?n*cjgV}UUI6zkHHtqOXy5fHSzh<86tDs36@t8F2Wh*M(nY$)PBU!Q#ED7 z-5kAXNQ0v4Mf#i8aqTJ+3ZFeWU6<sI(YA?!>nuLxsLT4|toaIqIXl{!slsYkVMTjdsupS(9- z8n(?S{n3*o?e?4!!?`2t0JD|HQa2YuE0pK?or?y?YO z|NZDoJwbExoMk?!^P0r<`=gH^d}Zp26K6=)27gJKoi6?bo}vnU*RR;D`E}0nm=s zE+75s@q4}4E-%s?9@U09AJxWACzZykPl^KNuy@dZwG2k}t|DX(%Zw465#6Hio!49S zz2@qfdVf|w2xp&6`1Y=>TN6Vg@ecGYJ*rn)a$FUt1x|wXm5MP7*RM{UsjLp__b2x}>Q*;a0zAI2!s1bi%*jqSmuH z3G}9ZVMlFj&DaO32M4@sl6aaM_L&0I8=>1p(gM919+(nUnmI^7#_#zX64(3dUcK<0 zH7B<|fI34%yA`fN*NMsnZT2MUslUjRDq@~L7u;5Q3QMsUdQ^Ea8-1-FX^A{%ZnW}gA79Nm zI8{6Dvfpla{mlvCB2)tU46On zx+B}1KFli&h#c*7@gLpKRe;T}69ZKkH+Zc3z!xAt8YwrsJm}Yc^_&mxbnR+3YuZ9EJ|mgQelh{JFn5ANfoAS!g6FbG6-A4}Thwqy2mCq=! zD?j#ft?HAi4ZV7sO7DT6jA4DHVYyPzg{~8o%NCX^mvbt@rT&Z%c;^^LinbPMO1Y+f zVC9p25&2N}p)9KS^6j(c-BTc}h`!tD;t#ovafix`ZzRxG=%e+3pYz37LEv1F5mGI` zdK({2$}cNLt4dz<)#W|bod2<+UzC^7C4aGFmtS@$;NzDZP0Oza5k)R(A6n&NFTXk2 zDLDIUtv|TyokMq}&|pNLglcX%(dm9x;JoEa{Wjmzw}jX%7BBcmL3_8GDU5I#~r zHpV#vKx2Cps~wm={k*P=4!Q6Uj&EpabDSe|ov2)LM+~;8dTt=h)jJMNbfdoa%|ZS& z(tg|D7wGrhfXcbOj(P3jjb|AZj(f!R#7;4xGmL8VH<)0xYqU3n>7?S}UjO8fi{BXO zpKuNL_)Eg2d4A4zc!J93eHJ~>|0MDFuXOPdXO{KeBTF^{&~Akj>4mQHMECC<|Aoo} z{!nxqh2?##u?2iyTRqJ;=-o~a2tNaL$3V?a7k?}_y3F@HV+qhTC{R?vZ`{~$c#1h0 zWAQg5s^wbqX=3>ed;a3ZyDmK8Gs#!@veU)CdA_p!_^%<$Iu=`&@j~inR(-SAJLWa^ z`b%DUcG}a^C12soP8a`Nccr&PZ=|e(!v7(>*lAZ*<_$-KAd=eu4frBHKlR{u_p{#! zpEY(x7q8h)kstPdLKi;7j%H@(Ck8W!RF8_!_CVI@_*X?ese{uROp2bQd`XY3L8odt0 zJk(??1yE5fH9csI924mW%T9EGSyD#`(rCnX^uv(H*1oFkN!{1+^IU_~(U+*a|7@4qPp5yAxSw9u z?eJw!1#^#<`b)bNN=@i?euumLB^8+78sstG09}PchNE}pEQpVPcWzt z4plu~1iol80Jbmoe!5{qiuUW-1KZxPVwZ00uV~n3v0oIrPE;<69%qzbG-J*uW0q)W zFo5?X{WZvg*Jn;FA)d-l<9G4-$@(@~`|Ty)?sM+Rd-gE1Giz`1BXoro-Kp>+LwB=I z@u$dGGx7TM`X=%0^@{H+(zZ$%)fPXK9o6f1xwlq2zbo^9KqOUPI{y$~U#h-O)}9$U zckJHnbKD1*&nEgJbo(PWt1tR;i2g!v(HXnG@V%)y!?G1Hj8oRlNowoSRehP0KwoOy z?X_7ip7HSXV-}sjdQU^WVS6WZov2(CeUV`u-bg~_Zu|y*l;4MUIejKvrZM&ZSjjkZ z?2qyFH?63>)++VA#^mqMIaK)B%j8Gs3M;x(;YS@u#9%4IUyQ|nAO2_u#N z+tMJa^C{~S@VkD;9kqw{x--0S$I0VleUR&Yl%LRB%C9HvE-Dp?B9dB;-?Ks8%zd7K0ontXYE&CC8D;V-^M=us9G4>jM*@xn90@oQa3tVJz>$C>0Y?Ik1RM!C5^yBoNWhVRBLPPO zjszSDI1$C> z0Y?Ik1RM!C68O7FfM>}##*u&{fxo{5oc)A<|1xqobR^(Nz>$C>0Y?Ik1RM!C5^yBo zNZ_9@0ls@V?_dA?a&(@+k$@usM*@xn90@oQa3tVJz>$C>0Y?Ik1RM!C5^yBoNWhVR zBLPPOjszSDI1+Fq;7GucfFl7%0*(Y62{;mPB;ZKEk$@usM*@xn90@oQa3tVJz>$C> z0Y?Ik1RM!C5^yBoNWhVRBLPPOjszSDI1+Fq;7GucfFl7%0*(Y62{;mPB;ZKEk$@us zM*@xn90@oQa3tVJz>$C>0Y?Ik1RM!C5^yBoNWhVRBLPPOjszSDI1+Fq;7GucfFl7% z0{;&Q)FBh^jOvC?#}|KDx2Ub2Wd^SNN8o^g9kgDw`)b-xqnDhz>A|+z{4@3((RT9f z2bZN7e-Z2t|KDJQj$4Zv-Op9vcbA7s1K~lQkSFMM`@B;4g5u47CaJPUs4}#s~y*| zctoerUVYA-(^^k?^mc~62;H6?^d&P;R_^tA3W|c>@+K-`*N;qu+!bQ{*Mm%{)~@q-KmO&1taZ-&<$$z8r2J<-Ed{Pi%LBMJ*DnS zZ=fQmEkRJVUtu|&fyIi4lf}5pS_=+ z3Hi=X%lx(Mnh))yAKW)aHLlWr)9=4xYVn|=A2rLY`jOgQ)Agef1EXdh)Dfm8!PyGSjPT^ z-ZGBU?0UksA`M{wtJeKkWfO~rXbFuyp8Y;y0{@`^YQMAKnfQ8=`gB|E`HlC#m@&QQ zwQTEY*q2gIgsu~n%iyZ8#~<AnV9b`p{~%_^@U?M(G{m0 zbrJog7qwkk-4I`2`aRoLn{h?=w}$)AXxQ6qgr!{(y8U5dwJX_vZ`hbuFdG#_vg-+T zgJTPhJE$)N#|-jrAiBdgM`&lp;@;`9Z z4tEb+eqEBJFZtW);@?dE(zKBU-Kcydy=aw#eVkVMd|U0|R`)-%X6dPW@3wtsJ^rCk zR<^G~m;A*Z==1s~yK>xK|B#@&%;OqWUW`7N^~9AQ^bE<&Hv`)1i^Sg&oBGar#rJ1& z$F$1;&JpGUPXjf;F#!7o8SAspr<-w^2J4{ILpYs!1R1D$((~o`dQt~Hx~OO8K}TKu zn)k@#4%3^VI=oy_PlQgnswSSE1VZ76qHGO4k$hRke5dA|3&A-URxsLQfC1qAJKzQ2 z0$>GbR|A|F&Ia}bIL@H%@ZFK^HrsUS5#5OLpEK%sZAk(>(MsEE=XZYO*S)V!zdKOM z8BwF|Qcr|#7hoJc$tWoadP>l`6e}$Y8|+9s|4Mwl?RiRj?QU)L>`PYOGJ9UVku%#8 z@*{ME8oe6)aLPCk!YIIB0%w^wthRFr`P!6#ujP~5YkBj#>^ha&M|KxG?0%tDP?XarqqPu5^d=WtA3iYNV+4J4vs_=XXJQd+kYI zj|)$j)oHiM{jK^abm3EMgWr6NPvQ$sZP#Wd;3GfSUORdD(^q})eQj>eETe>_e1$Ig zi*51|^dx3QkD|&Y?e+L_*%WH8T{d-U@-1Jvj=JGz_D<3IAatFmTnv5+!qq;@n5{`$ zrpjeO0zT?0+H2PptUKVx4b>?}OlMCS?Jllh9-HljZgo`#gG+I=Ir~Z$Z1N%4u~1zLsOr;fxOBf~y`F z+2*XHIg*IVN$9cp%J6&3&;iD80`#aVKc#QPms9!F_S(3y7fl{B>$LjsPBL;9ISD;B zKV#h9@Q@ZY@NttLEJsRWHa` zx0#lv-V>~!%r_{;GWd)-^k z91>B>x&F<>@*6hmxFhDAxQ?%xx)J{Dbn!R%%l8D!ydh3M4)%G<(2#5~uM3c%lym-D ziTSMmaK?^5t+=^S_z*trbn!R%%JwACJc@tcS1 zGfvk|;e;a$-)Si~q3cBDV(^8wy2w+k_xc(B;-JX!-byE@8zrW`uKb`9<-zOb@8kYADk1KR&9=q7=!g*=)#ZK z24B(fM)M+z)_umU2c#Welz^|X=e5^fKceeG|C<{M+kDO0vgmkL=sHokw4AS|I>uzw z^32~5Uv3QFw_BUNzPfPHP`YVE&+K%=SH_bCm?7{Md72km6XxoXfXHoA0>08~+iSUJ zRIceh@BHL+Gh^vrgf9GuZOCmDrY;5ry?8a*0@m~-RJqk|j4!u_3)^d+`yM#E*LJ-( z-FUY3Jw@okm)Hh>`EJaz=-o^~smIfj7dy58>-=tfzDlP<-vSjMY`Wvvhy4N0?koCc z(uE(f4ZbppiaZ#OP4xP_;rM;BIzC*IfFI^@^k=QB8j`-aQSuZ0veU)ilv9A*U@vMl z24KN}A6u7;v4j)w8B;yI;x=h|QdPK$zO8;gzTEn~*H&8`n)Zq(yzktb%4_xbr(=UM z+Yg}&e_|Um1S37zYEcwj{Y3kK&Ybz$_ffNtXN$?%UN-6n0bK#krMrOrfTMxwz($}O zA`th(Jq;)YCIJn=0ib6Bg}_n3FyI={tAWD+zS47V7snaQ6W)$7B~Sxf^kVae@%3Wt z2W_>J?;m_a|J)zOzqPY5KG+8WrCtc#E?Civi4|U-Igl(2dh~@qJ!o_KA?c8#RGdS!u%XSZ-3jh_>*KfE7l5t3ra%b&l*~>%$ZPEzlVYCi#IL0CYwY{xvwCaa_ zf7YBn9klbFUa>xJQ&k_?yUN!N>W9!RiQ{IZ$6xFTV#;L*KE=RNFy^g-)w+97pv)Y; zac03&Y{XRirL>RY^P|UT=(78{_dR@}8dU9R5>kZ0bhHq+}w59 znhOq>_`;W+F8)@&3aUe4PuUQ+&o|LsG}#qHR4P9MK5nb)eg+a_+b8v40t#vLt@j;M zIw3_X72Jky>?Uilbf9s_EM?PZYmoNEDvHvYSHA(BcSFfq% zU$xcFb#3>2*0H;{KlzBootcKzW1*9#8e2Wq7X>QaK6?jjugETmmr;WGxsmuX*W8b2 z@2Azg{!VVT1vIqTuCVQp_e?l-I_;Jid;OKP)wp&V^NeRCyreDnvErzH&85pQfA%+K zv3PT6@g<#VC!Uw^iHk@1Yj!s0kw==LYK)o*!! zHdf5yjJwrzR2>ujq`nbS@93tV_|uj;tI}A935gGMDAwlY?GGC-rw*z4_j)axtSU42#H%9X_@a#9M0bJ(o6 zLf47PrDgS&-!yX1n>$=oYM(6BH!e1r7gMrG=xk2^S?^ef)p{*;opIE7_IqY3@#t>O zsA)78#-TeB*xC|Uf&`^rYi+Fc+WtPh9QD5Mnh*Pro1J@I4LMKf%wt5{I zZ`(TLgcZBF7wjz^f2+LxKiyKlX|p|0K|aKv?kzR3;@WBUdwU*<{O#cr-7`IYL*|&j zmjsr89jWh|lH%9*C1?*W_ioecwXuh+Kik%i3*G*7Tdlq~^TPdm>w7HyCQa?f=@v+M zyUpiK)SpWnhINc1fxl7$>ic$8vbDY!gE9NL0C$({7+hMmj9$9oxShScovxE{Y4TnE zV1M!WCST=S*Uh!IiTPNgU3&8!7Y!IA`3N6&y7)KYBO4zy#b89;Pf!OwSXVOu+MJCb zX9KV~XI0*Y3276$;EkX_=cDted-4m=zCCtJQEUM^+r9L-QOljvCZSN6LeD^>b>}jt@D*H)j@Z|(w?bza)mZe_&{RWv_0Ku1^>+#KXSx|` z0yg*b<$GV>Kkf3fg)C)zv5hYNmi&#Jal%Nr0>_IKd*r}81Wp4ehx*$;xNJT6Q1f9P zYJEydjW4It_U*KDdVaTS*A3nuPBR(g`3bB~LdUJeM5~Nhhl~wP#$h1JMxlD7M?UTQ zMJ~-9mG0LjvkLWYR8H{jkq>u7>{9WM6X{JzRzEkLSx!T^7npvlC<@pDBDhmSvU#Nf^`2&9JQS=+i@y_p1aHDb?Yy__=N_` zyrZrj7# z{kQa<={fVBTPn3bKl~D8A@#j+&-nFy(QfUu9+}S_G2_@3zwFo9&>-p0g>L6~E7tdz zGoM?tzNv|Ml!ZdJf$*@*R_%Zun|iPT-UP7A^644tDz%dGKj+ z(3MdfC=cg*%RSitTj4V{0IPg#ZUG-3UFfUq+mIJIcSZQH)8p}x;|Z2{@^Mgz+ZPg6 zY7jx%zs_Bowtt)lmh$vGPKv3v@a zB{`%m<*ECkDu=Qs~SL%S8OLf47PrC?yD z&x@_``K8`aDL!m-W%}HBp`GMKy)ky~7=cwj(z{vtU?0VI*?jy=Va3u{_F{}a*B}2v z@Z~#t+4&GU!>FbSAK7I%41I9fL{Blk-;A=N@{zx9{Q9y0d=6ZH(I+dezP$SbKO4F2 z0%c@<5xU9)-EvwaMG^TX5(m`axJF}Zg!%D#JqkdrH}-VcKeLVC|0Vd%`I*4;!1(~n zZ#Zxu&=ugBu&g&b0BrxZ#83|$(^LYgo~(wRuskSt%8PEcNfV%){5};g- za-3jj7}~ASq6yt3M=a5eKCYqV6(imFTsG*Ps;}n^_PcSCLa`ZAUDrzLZq?UDFv0dc z=>+`St0DWW(*4?L3+E+&_QIS=`7fLLdXU+^3q8Vs>4>SXLJS0r`R@@GZu#+CEWM?U zzHTZK<&tKmO}&g|*p80_*as|P<%gLB#pNDg$NVt~)F8Ty2Wp`&ES3y_Hrob@yAB6h zJl6Z*8Jo`Opv`_iJ#W+x<9g|hF8rurY~O^ATZ_?;{mcsZirK*F2TK|sT=X$RsruSE z-Kwwlbx%gQ=JHc(LJu@-l1z;Dezzuc@mJP^oB0pMD1WFNA6KIXVjZdhL>{RJSmnX? zQXhxmOF;1FebbC8U zJ)%B!24oz|_OAm#StkKBA_Lld8n%}-w59LR3ApeHB)rgAhnXJhvGIiBW3?GZHTHYe z@89UI$3uz!=ew+W!*w3^oASTb1<x}D8g_Q?3=hR z0C@fo$LTCl?M`ja`1;cb{W^0(=i77EKb&_lUwC0ee}ryOqu1v3XNVUkqQQiN|I2iwuCr{VK0D=0$^8FKJ+c%%$?qLsPm+3f(3T%m z@W|eQd6yhy7TA4=PdyR3{Rx_HUkY%dRX%_Q#uCUlAfEjqjivqTYvs@0e>Q^u-pQBL zjamC#&%@fJ>G7rg6S_`RE|#oaYX6B%YQ|5>>`k8@+pgDa&kh2n0mnf$4?(fd2PWY@ z1K1x(1=#jcbZpxghc^3Mj?dV4O1sIk14v^W_PdOy_M>#O?l3Nmgkjxc`jQ82hGSmh z2j{=u%)t|iUN1k~syFubujgUyv{};*-+a=ZE9Q@&z+kE%aO$*@FJ)SEO+XN=nI^V`9DfPokyte zZ+&m~fR9PQ*!S=bd;Hx`Oz786dt_G9r-AazZo7+vAebH~IO>tm4Qli%dQ^bFUl&*S z(1i+xn>`Cl@e9^s?y2VcKg|H7r}n2qP`O1%=ubVNk$TU%Pa5xq2B)RpWf+3(1C4~` zJ>$|(XcAV^gqQ9oad}U}aAG7b?c5HQ-G8h1#R6{Xzr$I9HMedTpb}4W~Bg$M;sw zee2rO>84>H&8wZRlX1cSP6r2rfnW$#H!#JI)?YvMu_|l^D22`ZPwe*bV-kmYM17+! zu^zE+XPsu>&bb_p1NeT;^~*GX>n&^#h5#o5mB1{3{G+Kk3zlV{dg{^Ec54RwuK-Fv z-B$a$q0dT&zc=^E&@1EbpU-}WhLUN6tI&0#axvzsaBjB#XDT#XL-4QY3jB^K;Pc}1 zlq@t``mg8J@!K5m!RO2X)Mu9Ui_%3MwJGE0fBxDPC6%1NqTw^M{S>-RR4xV|S>8|> zU%F7Q0)Fb0Uec{zk*U7jPR7?zdLV*hWw*s$dSnY}aYn0uLYb5$094?j} z%BXaEeOv*`@KFkaS6VZRN$eYrg*ehKX_} z7R#6N6FSpWjs7$80u(C6CtYF&dPDtOL;M%O46OFg+JN|c^aCIFo;3Hdo4?$<-p+^6 zRUYUT7R>F@a@#CN^@t;KsRutaqVG-q4-0;tcp&YSsz<*)_Fz^B7?vO9B6OXoT$=3PdXmL$S?e{)yUiwkK@UlK{5sd|#vVnLp=RIG-x-dz?Sz>@VAV z_D3?W%J%`*8@7pDpP~-$0dQTOb8UMAX+T$?8?XV{hN!>+fRpg&h``&5@_KJ3x{QYt@8 zJ}MRUL+A!IdbPG^{3fs5=Lvg8jT~-hNIlwZ<}drsu0e(Fi~+<-(Dw$m1Ncsm3zPyJ zud%+e&QpJ=M+6OmHZieiO#(TDW+kAuYw20m{z2MgS$|GDY)7r(i+lGu{e`MWZ#Glp zc#rxabbCgIe&l${F#ObqCK#;XJXbIN+KxFMV>H~0ziwxPhqf;0E!T%G^+-tcwjlvu zW3OzlJvZXaPI((9<>#9W@E;!JOX#urLf5Jf^~{FNH4vxZmjvv3@H$knYO?{wlIC=pg{0^hGD_ME*^<@t9>7>_py`*Ar_cN2n7@3K_2;I&?tnr-w zvN5P4s5i-Ggsq_`e9vVYk_w2PuumbVAM}^L9Ztt=fdtfkdwssO-JPlr-~Djr*en(VjP#E}{~vqT0bWJXcIT!*AOS+?O+)V;sR|(h2|e`CG$8~M z2}wvoSGcGYD?v~Y6@wK4F$f~^DWaf)NKq64MI(wJ7C=!^6#sMf-ZyvdB)JKw-{&uP zp6BfBzB@bn?#!8Y%FfO@q^|9t*m3dU7@h?Z$fP48h`(xYgFReDrOP<+hQoj`}Cv@!Z z(%y^Q5^5XG-a96|Ih#)DY!&3wP1N;K1Kss8+y603ORMT(wU)knIKAmbHp<~dACWtx zuB}6#{Q9lAi*dMhS#^Cf4Sme?Q4eA~qVEU8%ay;kKl}Q0qL0WOQrEU1eey{f>mt1z zH5lYMeX^F9R?SBy54!rT`06VLJMJm^h}@-#W3M26Ty5U`(@C!fqK3HZWu{X$^q%57 z>gJtmI~*CsMjG620C^;GOQ>xedP$Q~+P_@v#cE6R!J0|Qann_v{{4K!!7&vXd#4>I zSpUqf7^t8_V3xjW1nIWz98y2_%_~4WW-xPX-$j5 z58c2htbWE>A(uR!ovrDA#?ara&vG6qtrkB%a(1=%KHhgy1eA&+R{KIc_ zl3Vl@d7=6`-n=-z2fD;}1&mv_CoM*}>uavNvutH)b=}*eZ~ZW$^2k4;9h!;0A~*GQ z@FQ|?-#(-R8<%9k;1rpL9W{Ak>fjW-t--Hp)7mIyM+CyxfRXO)+yI z+XvauH(~EBE$?0QR?{lZ^kX-g_D$qCbaPTabKD8TPu3(8XvN&L!tt?mdnOlmkRABE z72h>niqq@&Oyjv|-)QsXy)WY}J^GF}$~@X6ocnZ+`&G*$cbrvfSo|1k=9R;0r#I`L zk$`uZR!dlgtaKd#6r4$G8V?xc#XF_4ph7S1uj(2*g(8 zmQdT|uSdTW45m4C7#JU$F0;Md-*;i+ z5PcFbjy+*Pg&m#y{9cy2(lJe`kH{^dwkeuE-7u{~8^p%-x?T%zbk9GtzS`U>SUujk z%*KZOBi?j2&#dti>LqebC2LpgSE26>`=uo7uMYM6+Z^jzugWojs%Mv;Bcf&v*a=f$ zIrdknm&l#sT(4lgT>Twgr7RFSKRYWClJB&O>$`Ssg%#q#4Zxyrtc&RO1xoc6l^ZVH6rcC<5GzcvfJIXiK6m7%}izJgk? z?P>?4y%`$s&MR|Xd^YNlDIZO5bto=$B-L+aW(c%`?0BN8SjPq1bQqPd&f z?%;Q{F_YczuRizMN>fNtj>A1;RVaWYO?z*#MFYo=G?Qk~3 z`^HYA4s@IGKum}Kuk&`A;2D|%&4A`W3xHz|Y@f9T_?)x_ZGm<`dw^|vwo5tze6M{S z&>83ggaK?LgaZ*kH=sLkJVE9hW1a1Ll19O1e zfVseY;11v};2vNhun1TT+z%`T9t0i&9swQ&RsxR$PXW&WYk}v0=Ybc1&A@+vt-x!* z4&W`|ZD0?uA24>%0u04IRcz|X)RKyeuSGC(EZYM?&Q0_XsQ1HFO4z-V9`kOE8xZUgQC zmI5n*HNYm|HQ*iKL*N+jE$|EA?~616Y5)y^Yk+W|KQIbN1f~GD1NQ-0z&hX+;2q#2 z;1uu+P{I%C3N!>d0KI^bKoW2Zun<@YYyjQ_4g=o+e*oqD@r*zxAPR^FW&oMMQ^3o> z0pJv1L&LiY&=Tkgi~(i>_XE!XyMQl%KY(h*QAUBmz$D;aU@h=A@D&h%PFMpV5=aE@ z1l9t3fwMsQ5-8umC}0loG_VIa2UJ7F904Q&_XDp2UjgM|dO1Bc33w2A3-}4B3j;d@ zms2>AmHX^g_%1Y87eY>GBnGw1=# zX%5@l0`D+@tu0X=TA{48#u#xM=m5NM4Qy9il;L);)9o?Wvjf5cpLGN$I-#swi|4ow zbN)Mn?_E%q!j!tZE4UkuG93Z_cEh+_ca-7lVS{=obv_bY>;-$#8_(GXVfuo9{g6jd z&|?7X!a#%_gt9yYdJe_?hvA*}aI66^0=8@<>V?s;fj6Mc#3=P-EXqI}I6M~Dj#KL0 z@!(J*?A8R#MNh)>CnJ4RVK*izwIm&RJQ?-WRJ@oeNOj??f8i1KuozeP4vcUfa=4Vg` zu7%B5hdf=6GO`i2;ziiom+(w4L(f;C^Xn)RZ{WFhf_uARd-sCB@1c(Q0OkA;^7Uiz z?Ng<`JOkel~SWfK4q9vZk)KM_hFx16isB6Gb_lBXq4~F`C80rbn*wjTB>NPObX)x4-VW_l?6lH6Nb7147D!| zbp;se-Z0cp!cf;q^-;TEsF%P{&xN600Ym*M40YsMA9VzV`T-c~TVSXc!cgylp>Fq` zkJ<}Ey%>giJ`DA080z0)sOPlxRc#}DRgEZL)o!$}ntPM43Yg}rw$1fb>lXW}_gDI= zR@uI4=T={}Y>%&c{9|AB6@EN2;exMf9O$PSR`XNi8vCg)I{B%``}nCRM*FFg$$n~* z-A{G7&rc0{!cRT73H~lW)%9aPHRH6O`ojn9#ftvw`$qn1Oc#Gud$7N1o9M3|ndPsd zm-ws1)i}S+U)}eizk2pNoG(^P{Zylvs^7Ml+T5?0T0Op)`ooU><;B#88;hyY`--VP zr;5S87gtF&i>s{bimQkb#nrH>#nmTEimM~f7gv4XEw0+1DXvzO2~hUt0V=0|fZCQC zplaP0paM1qsEmUFD&dy^^=0)E>TFmEb!U7DweijpYEpIywf$fT_3ZB@RLi<0)quVw zRq&LOD)rHlDt%W;RpVSqm4dYrCt}`Im1%)$@{@sT?twtmt3m4RmO;vYOpyBHz96+_ zN093HbC9~VQ7N?qV`LeNOR0LhN~yJflu{+zmBw0drPT*x0h_>EUJ7^()G%bDx)0n;M0v%(M_S?>`~xVgGXK z!>DrV+DFQ%eW%K)`#Y3Zi|;6}_8cj%BAZrFCFWF66%STW=}juCdbd|pt&dhzE8A6q zK9$t-XDX@K{*~4I=PIj)Wvi&Z8CBFThpMR7U8*Xdr>m+7!PV5{nblPNlhxF`q1Dy$ zH><0}_BGV6Yig*$HLp^$mtCdil)YNT-hH*IUm{d}G(S|`9#B&?x~r!8piC`w_XD+5 z^wqUh*VVOERJ%Ir?l%Xq6*37A=eyUPmJ-o5LdU8MmRsC!ORbp{NHMLzM zmGVg=bzy#ERj*AG_3N=FYR;0T>dnYz>is{OsZB36SJS4nP<7h2RBxVdsczcZN>!iV zTAdi!Mjfhojr#3}Yt)Uq+N#ozwNn*mwO6-~?x4nnbyU0RbyEKczE<_Vc&(au`Z_i9 zi_WUU(JpG=;V{+bNLTghC*i97i3s)958c$we%GsnDm~Ogts+&usGh1?S}%3ivfgU` z_CBiC4}I0d`u)|-F;OaZ#Q@d(vw`Z@27}cHlZU7e-WsY(T^+3!&m6919vz`R>NZO4 zTt8Y3uXCe%{NWh2wdxqPZAF~g)*xPexOtqa-akRD`Z`f9zITH9x!pwd-HBwiXho{J zFfvW`2+dHLUr$zNUzw`rFP*NEr_EH`V{TE8N6l7EBIl@EdfcWq_M5BDjGnIsPQF9^ zvg9sR?3H`eL*Fh`hwI&^jwLKnhc`T+jun4Ug~mUmHt&8!?dz1K?tI}fRi?v}YTlbq zs|q))R$u(FR#jj7oceOi^D3#%3+nKh7uB$xTU5xJS5&(Px2YfQ+paQ}y{S$m4=z>^^m%{sDFFri1FYEr-=rm5-`>Z_QEmUq4rk>?hRg<-S(4U-(Wv82`QMS?4FU z>+COT(B9uw?JYLj#jGP;}XhM1nV;Hmv=pRXKbtNU5Bt-&=n*gCI>vu&xK zXgiyoY->L8#Z`$6r@3ED7?0ws9pMGR}xWnhRUD>B>H+TQu*7*D{wm!RTKG83g z@Y%VutWTBmReW~!sO1yAxsgxLUaftuzSzkp=KXFyOZN2jx&G8pAD_lCK0`ATeGXJj z_X*m4v(M6%^Lzpy&GfPDSngA)?2|sH<~`?Az1|j|0jGEPH2Zv?&uE{IeD3J`rO%CT zob_3B)9*g-URT2RV3!KM!zb1Bt$3iR@9y}Hz8xF&@NH0Yu&vtss_o3AreOCt$U6fy+kYK;}YKQtA&uHN{ zr&w3NCk_wr8+dw*-+hr8eyLy1_4{?#Qoru!p7Bc<_p;yYn*03L)H~)^cIuCQN6MA( zZ*#G_|G;)F{gbwJ_usmFg#R6HrTCYRoa?{3#zX!O^<3|N?Vh*%Pd@XBKgR_y6gwNO zDYx;1lg9Xg`TlO(Tcy>*y<(dOj>>s-c~xHR8ov;^L+aXk9zRG-M)S;aXs+arqohs= zv}9<4ImWz<2$O*Szj%=>E(^f&_1LK0yw@ba!aUfJnCV6^X1S)*W{MxV41At{^5kz@`lFdbCwhq7A$4u@>S4XTOt)Tkk97^G=z7?vx~GRZewy=jY1M7v zf?gx~C;f;0T{_W2-^2JOK`?sZ4{aY(7zIM~pmCX!2MDEhS zvFBNju2`lSA1oqkbUiW+JNltO92~teIFZ> z>A0ilA@aiY7@ioPG&bJ)$jn7kH$586a8D2B3%WHbVN!s)=BidRvdflHj~p9PuF|5N z6^3EWz^L8u!^xSzPv8_CU-qVeo1<`XzHd%`T5KFXKbC=EX0wb-?=#ME~D+3-V<<-b?Sn;~&N|9>+JZ=P-_pe!G7qo0{3grsj4> zzdFvQxNc|h=WWbRRic@X3cSllg_ZJEnfrZJ1@s|9R~EPCAlPq50`MWI2qVJ<(jEy# zZZm&m9tD%XD9(mJ#Qzk)u@G}4mTc~v4ZA5-IA{mPP*C5A`jWssUdY~~-2dDus4p7O88#JJIpEupq?v`@_M6(m`#pX9b;@GL;|P;(1k zALjbIj{o%W(x)4QImu4nrowC@XPmn8{9RPf^oWG`IK0hwd<8$Yf3kCxVJL2`;o+7} z4d#1Jrv=czWw*KsN2fmcNdVd#bkvXOByxw;wJj)}9Jklf3GwK5hwZ~#fi?h|Il1d& zQ$wjgSzodqC74{gjbhzKnO?{7Si)l0a#9~loFZpfuXCkhy`#b*8N? zuSSpT^ioLoE8WNKC_0CuNXU$g{gS?3Y zSa#V?7zd085`aX2!!;8CbY-o1Ov&(5fK-4s4BcC6P80iLcvWt#<;T7kc{UwDkJFmt zbTj;00Ca<`xlVTYbAVfc+ko4FxxhSNK0y0=2XH5F7jQR#SL^CtU?D)ew+Ofoz-xB3 z1i-6yg)X%0Z#*~fMM z%{i+GAHyW7GEfDm3RDBC0~{;33gEg%p#Y{ks9Hd6pbk(Ms0ZN9nrZ+v1R4RD4xupY zqM8C6XKxO)09pdAfYtz}N~mjqwm>_eJvH0?U90f#twMz{9{JzzX0|APZOtJO(@tJOMljJOw-rtOA|^Rs(B*wZOB$ zI^a1V8(0rK4{QK70xtlYfER(yz)Qdu;6K32z$?I3;8kE7@EY(supQU|yaBukyant8 zb^&h#yMcFrJ-}XIAFv;I7kCdi0K5-;02~B91P%d*fg`|2z{kK*;1l3eAP4viI0k$U zd;uH>z64GHCxNekQ^422H^8^Rcfe`j3~(0s9{2$`2mA>91pEw~2Yvy51ug);0lxzm zfjx5b1_1m$(;$HJREGdVfnfmKa%iT_W<4nFy@Vx&_qRiLpM7S?h>6dKF^}Nr z+prb6CDb;ukSInP#!ill*Oq6M7GTe)2rlG_PYM&qO}CaT;ljFh#36b`Kj7XDZH#kG z09p6)B=r97n`jwc(GD+74KHH%pcSv2^eAc~$ZZbaMuwT5tKJHz`88>68>Wb6zQrCIbGvyG5?M=~t70#o0S^DF&weJf* z2BeYySY9(A>ht5ner*G>grBbUKCFQ%=SU+y7w;+49QSOoEKnsDOa1+V&uhOu#Ds_If`BYPB6mn#+x*9=94k@9C&f;0NdEmU6k?^yL}}Bje(YZ z8oy@m^w9$$j?^P>$rF*AX_`MzoCB=jtu>;F@@MjdeYb%?6`(v&1}FxQ6XXc_BU}-g z@P)qQH~stovE?Kl`f`o)l-JWzKyN2xKJ3}PRo+)h-S}xvm(;jb+k%{Nu%Absh+K=> z+RdLQ)~XWmSj;nb-C|5&=$}j*9ubSh9^AjrZt#d_y?CRjn%mOvy86qjN|beIKp$_% z%Zl6~b!{C3mr*GxNzH~NC*x1`>FKd)(}!U_^2w>LnGL8<;vMUb%9R|Skoq7SdeLpDSnsQ5wjs9hQRN7>G-Jg+`!nMZnH$<%b6z^E$#65i? zSGc#Mq})io6o!2JbnCkNFMiefL^J1&+QVnQiCpe4zBvx<{2DPlDJ5W+yfMc|?ReT(rQ-XKo8Q2<8iNDXYjcCu_)3-4bD_0W$M&t& zx9fVTUdNNvk+)W;<+q-*Kk}{w~wEZ@J`3}7%1!JIL=WN2fABh zqeTh(-wdPo>#|q5+Z)#7W1&pIXBfZh>D$SU@0Zq2>TvJVr&i3Y66w%#3lfFtE^<@% z0@JH`*){+UVd{{yO&?{JB6@kFzz(>;NfK}>nyCu0T4JTzalqNt4QT{5EjF8 zUYLbw_3}%5sq>H;vYfKKv5e}jl`|l_-Zs5Z>4Ciae<}rZzGSU)=Zk6YQ`ZElk8WtS zut~MUbw!K%G{Eyy zfV+T|06CZhu#RB;Fa#J0+yHcPqBDGsyR-u$fa`#o0IQ!C0P7a+6Vydy9k9>(hUXgt zyoU7->loG_Yi%I;=;?bEY!upizFq*$7Kw%{+xs5eDOarOcQp7$pYbZy|qiN za=|oY84m}>1M`6gfh=GKz<6j=x&qw+wl!%NssJqaEbnYPG9IP_^MhrJWuEqcVR)W$ zmVJhk@+tYp>m&|22hkPbmf2`m%lka9#3=_EbQbzK=ue8ePUP%y&AG3wO-x zdCdDU936eR))HXDFybUW9!p%@r(EKqFXu!qGKLjL8J)x_$L90vVHj49#n#nN z@xr-h-(Bc<{=M*64~pC&b#3`a>-6-*F^Nfu8Pl8LH|OJ0(k8~@#ac7|i{Kho{{#C^o!UQLQ~ahJ8^7}{UeUI z5mLUyCWu|YsXWeGj`AdlvO^^NIr*|XfB4-r`?n2xfFmE~Y>oU+pn9pr{cn9b96y2@o z&qICR8C{XQ%e}5hk^jpA+3`HWkAPP_^CRJvK(*=Q&TCf_q*PF09^hB58O9muOsk=WaS6+i~? zDsFWFiT*4yWjOp|@Z%wW2J$1w9L`ft#C7i>PCGCbXbsc?_}+)6j{S0K%)DcMijQ4| zOD#uvK~BOHbpGEex8uQtACcSL`C*RZtO9?|oIZB_z=ow}^xpcJMG)bK$jx-h!w+lx zm@f()Ax(am*B5lmn{#Y-H1G|;?-m|F20xDzRl%JDKu_>!CQu4^9>*Wz+yLNpgyTGW z&gbVh2K-in-wn_XMFAfozIOnQ6HNjVfbl>bfbXwqOX>sEK{!QUfGGYoZW^9M_!0Al zJ3q|#Qrp0v;ChvJ-(B+T)Y8jXA~EKML}B|?;DcIO37 z`Nd;%5`3v$CcS1R7PWq_-giBBe6jb7_nI=7@I8~07b3TW+6KHBgrA;`NtqTuw)-?J zP?a2;6h&^tr=`nUW(>~no2ZAU`A)ne`N94O`N4Jo>kO7-wnb=1Dg*4h)B+j+d|$+O zMcse_Kn#!u%m=c7t-vv$6z(4ekemGWiQnqX0)7Ipysl~vyYmb16_h9j1%^X`Z_s{b zlKDV^C(&8ji9wTFQIVa&OQ_a0Q76K<9BYQ}uR!*;;rLFgAHFezp}Q&tdf$%gABJ7q zg73kOBEI5Sv$(xYok+K-A78SmYw&SV?NlGN@wkt=X_Bv+RLM_m#hScr-||<7j$(~n zEMT7gdIXh2p2K3p-~x*O?Dp7WKFN0~HIY7a%opZ~>5!C`V}Fy8(9x%y;N^sbV?1&WySdJJ zo7`{=Lq5oL3@CANpYiaX^chZf!eK=Ba1&ej-MExj33lt z+^B!j*g>hWak$at*jbh%+FEK&d&|BTZEhKWV??yQAppx0Z7}<3eE$wpXxU@Fi>nI2 zEL!a@+UKhPnI~2g`?Y}DKpmhiP!E9lv}|}o_)LbzKofv{L6}u*yqfmCCBX3$_9fZ? z*8mva_O`W8vkQhe3YuJttqQv0h_ZG9Q@Uv|-F6`ULGTeSg5u>C?v1 zKFYD26Z^<(M8>dUUwK}Rc|GMkrej=kj=sb#=Y%tin_w8mC-KNVcwd6YJWro->G8{T za-L!67?(U3k9iHxQKmaRye{|d|2tA(0Ukr_YYx`*r|SwZ-{XO?fY{e;*xzsOXwtFt z$jmzrcEJg_3=oF)Rpbt-YwOv*a!!WBz?$#XTroKIgqz|E$5}R525JGcbq#>}0Bs(9 z+FIJndO#>Z+e*7jyGonPvc~IKKImBfrOdD_$o(i|Sg{ZErOaU03dgW?3`e_8TTlB! z9VIU8T47CJuBDug$08HoI-zZJxxTLj$u|y$)t^zGU1a+8-u-`O3h3o_*@vFXZNmG3 zD!bB)n<9?3+sQR8=%n0=+#z*sJ(t@)Db8k5p8D1XqO+aBa>nw-G9r$3nH;kY7AO3Z zW3TT`fq!cX*zsUe-=6>2z1(u%GV9#RhXPel#%&X~9S&5(?mE`!L*Ki zZ$<8qy0$2{Jt79h#ZHOG@&fn~xpR*{1GWPF-TfH$VOaLrcVSzbeHPZgHGw(+9?`0& zX(QPGV4s8IOq|ag0Yn1*fWZLU?PGwO0FFJ)1m*&n0EU39wY^?|zXNz5I1c;_1j5FJ z0_^~fXHNhY09+4f7r?b|Dk2@b0x7^s;6s4__KO0R07ro)Fjlt$d|wlRM#6JI9T=;} zfJSHlyaJ4ZQ7ev0ejBg=6@Lt}v?mN-cNn-KXaLMa1LP%i_JYwMxD6e>a!8;Z=;STM zfLkUSA?q=qei5Cz88z_@VjYA-0wH_zj2BJCb1_ZXwqTov{TKG>x&cf_re_0y?HW>r zeM~2O1*AWvJ_%IY zlg=)!^wWkfJ7IjAPR6T5?vT2+p4(;C%S9`2Vf`srjGp&k2CY5}?FgTS_JX#9Hi$CX zd+G16O~-xOAKIbX&V3%!Uh%y2i5QO8GcMXH_Lpdz#I`XU?GwY$r=0CXhT%0L=Q)vc zpLUEobDz2rycg{n<-DHYzJ%3n9%Vch8Fv4aJ>>OX_s>s(1yE7SZS?1^a?5`c@&6mG za6U5h4uMByCokXnk>AR}k;~p;66f+n z&pc^xGEnunc)U}}8?xv5b;Ji*`R5+_ccsIw%mJ&|~XCvxn`XIS!r zkbQD0zxoE^JRG7uqT{s$uN9t&FFd9F5F5t$`M#3&h;eYu+<%+1Jb=DXy%@Pheo)>EvXSXkH&VcR4XxCvmr6bi7mafmpO5gm z{8PXVvGCIVoo8O;fH$u_(DtEj4L_;AmIWA2cp-9!)V0-l!NE(%`hG5Mn*3n?h5_UU z?StffE$lZ3NazTl5kSte-^#G;o3bq;wkp4T7aN3NURT5vup?Y9KhC=IgE_@KP^SY` znOENm&w+nm@Xbeeem$hpH48#{CYK)~w}je8=STN(;}YW%v6|v^7e8_kmiI4gUL?7~ z@d1uEkPk9$!TwBFAR3?zd>r@$Xa<5j1aMCNd7vZ=&}RJz1JxZ97cZ+3 zI%?_oYR#+F7LOxFVVpT|@d#uJHG_#(&jg)_`=sb|Rnf@Owf1+Ooxd1w9M&j%6! z_9a;7@*47l_LXIe?G@Tx!s{FoI6j(A_&J#BNyWz58=m$w7~f>)k{w}cD7D- z>=4KG!V{4@q^_;blZX^+K@rSr92lDs@3NH)oehw$GVU}A$81wE4|Q&k3q%0GGB07M zIrF^^fGOG5drZlDi2ib?r(430p4-J)*M+D7FE#sO-n7?CZlm&Wl5Qe*NL^b!-S|)D z+=X(DMzS53NI75dvwQxT?cUo-z9{A1ZjSslP^G?b%iIY`OJlP`=-q^>Q} zZ}8-_F)7!_Cb#T8I8m0jSMnWUVdENXmvd}`?R56P*k5BVQ&WzKvainedoaL$JccZ+ zJ{t3#{WJFKD*^1=V<^Mw>#=>${+|9FQcWD!2I>O!frdb1pefKCXbH3i+5&8sUJLNk zfpDNZ5D9SHAqp4_L<8)5!~)}h2|y|^8JG#o0oc#H7q}mI7Ij)gD7?=cP0@=WO zz>h#x7^tqmO~C!Y>%du{7L3n%789Emk zdITBTrw!&uB17**hQ?lt@gihsS~&FXj=7#a@&80*=(H%L1v2zrWayWpFyA~D<6q-2 z&l4GHPeqze!9Ng@p*eHFhXt6Ei3~l14DIy@(&$NW?pfr;3(#{b#?;=z_}jbqf8j^C z$CtSFdwd`KJLXrGw5j+?HdUprO-*ZUQ+J2k)M)(Z=*KbeGi-|GkaH=KvMLJc%knDy zTO@@wrZ*mbdtegqG!Oyc(JhW6DXh7x9OpoCT5=?#RW6W3RvAJTTm4>^A0(qyPqCaJ z+pPMF<;(`~ddldKU6zblj%>B!V>rf99AJ5C1W*rTvsJF(xxK4koV>Rdb&2@v$pncdY=hgiud+wj# z%4wu;LpZkoM2lSFoMK_E#{#r{j5s6;4V!2BIt0EyI(GeK}vo zGhd=h2dR~18_zx-nb^J|6BbVRB65e+wJj=NjOFa|9S?NH>e^!-GC$d_W!sl|O84)`xWI_Yz)UZ*gs?ciG3_`k2Z%s>q6lhb}i?LWBGAXuKPFoc082Wn{0zO(sqz} zhM8x|s??xECB7~@@aS%5V$^}p`bp$Yajpm6^oZ!09G7ObT4Iy>#-{PVqmH+!2xSN4 z{`{og^0a3< zhsY5gixbXx;+2H;`j?gh(-2(v5m~`AKN`#mQNO(LlnUzl;QUU`4C0#2yFR0Gq4bK?mWlqCnqH} zle)K=R&My$)5%G(X%dOaTag#!3rBfgxJ+LloacFRpK|hEoLukaxTJ_@e-%y(Z}(U6 z%%2vOgH)yVwol6Xtl4SuN95++E|)*XZ(;J-Kl483vG9O$FOSUB`RkAEh*Ege;%avu z;gl^No2aTmYR$QdPoA$9q;{{0taP$jR>-4G+3R)x?;4eZ1Fbs??@y@Xn$$*5AgvjEJFV2Ox3#PQkyR@5K9y z$Djn>NzC~K?^*n8svce>jf}UcS&!LNrBgO_`Z^yKn&qQvl=D?@KIp5axARl=&-kf{ zJN?y$H;So#-xXI+_bj0%=9E-#zZ|5VK2=(sn_5;Cn_OP~cCM1@h!--y90^rtrq@#y z$~0B;cC=9s?7mJFzadi1dUddB)g?}y=#ZhpsxMGe;~!Obtlpx|Jjgd)%7*OCvu*@W z{C{%DPRk)X3v?1DzW_W(u!N9zx??>i*LsRyzs9?NWu(9YJf_&!&3WysAMLBG=X~<} zvTFJ}JJ*f)sm{r3Z*VZFF3!`wirh>!*w@_koFh_G`4xD6%Q?HP9}!yDwDWdrUTs)t zkXrc8(`8TA#5m!o{ue%<^?9+)huG_N{4~nL> zhx5KU=EHZW>_^rH8UihV_CQyl4?vqg4wwqS%&IJ43vdXy0MtRj9SqzB>;|}g&qRRl z-y>15-vv@(_Z#{nFl_#>Kn>Xa6xjV=FfgzkN__~W!eRGAVE2dNJ$PNbs9l8WaZ??v zkKYLIe_P_ce+Se_5zx0E))X3nwSf|$!wl35sEF!5g*gnbVO{DRywmr$sc)Ox)Z|#3 z3dRQ^r9ZK$pYbin;(0#mhtv3;0}}y?{en6GKY6(0Mt}8UmtrcpTXFSRdVmUhzl0i^ z9H_eXE~UPlTt=PwwXCZ8Re3dUKxI`kvbw7DMW`APR!@cB+(d=H+*)mIbgi=e(p|;G z3{VRmzd`v1C*vXQi_tM^D6j1O94CXEcX6T z1J8Cg3wF4^t>wz~L3=laE_Ju}A~zqz&E8{`Q`5-GJT94!k{_qdI4||MC~-0;CH>Q9c4<+R_psDBb%IE*)!Kw2q9W2i7f#pJ-TT|{hi*`8QD{1Amdun1* z%J|7N1D3O6EBD{l!t?zXK))M;=D)N3yLtV%7ARdPKzku_%5<0K{!?P(CgbZ$36r1Q zkaN0k+5_4S0af9?IN4`i%Y9x;C&%2EYxH>KI-b|}dF*xG6!<5lfL_nHZ|S+*2HX~+ zChs{i_~U0st>9P#T`0hED{{(oXO>%-ki_%^$660!FHW}ceBW&7H9EZ0k6Z2@H}N-T zfeOV;#YhUPg zDyNY9hs_I7rRUVF`hAZLb2t}{E)<}>5IJSKGwsEosqyit2w(@~xntUTe(q^^gs99_ z{YF34`GH1{I}J!EuIGJ4jzc$R-B+7;;GC~BX!1lyFgrZC|AO}J_g9(tE(hmxpjVUk z&(f5s<5M2!`Ng7-&IMUVj`xw}@r8@X8Af-w|FGEfiQSXOCnm@Djn9Z38=Db32><8q zofyt=m-{{vL&15zgA0a??ib{hR<(!I9^>7s0(n+8m|Veb&J};zYgdI@O|YV zU=%P8m;~Gc+yyKL)&O{2s15+90ACo(tAWk{hK|*IU_Fonlt3KMU-|IQMppb06TtAuIY}0A?G;x<}x_YU07F;K3qMF>b_z z#o@t5XyIedThI-d7K{Db;CjL8Ss)IxlRmEPT^_9ozAzyZ)}HZIBK$*PX-JTd3V z2XqKhjgMrvdwbEZ!yd1P3*nmKS;=syw)>68gvR$ z&(_Zrx1yA#ziLeE1<#;H{wf@xzScQjbAd>w8<;c+PET4WI~Fa~b%4 zi}M<2!y|zhAQ~7B^Z@V*%DM(c)q01GVr;$BKoPh4bT9#K{KKK;$V-7!^sn&jcnaai z$ka00CxG<; zZOYBS!@v?C3z!VV1H%Avg0pfk4aJ&UDtYSAIBz~mzRG!A=5@{#u)`OA1ax)hhdJLp zp-YhJv9IyfeV+UBlNz6Gw_*_cA#!K5xn4f}aGTm*5I=GwxP%?%FZ+C)8`T(y0LUX$ zy^7ZEHekH-I1PRr&>cXvZOx?$h0pixMW`jcc3y5V@ID`S2qmB{^<#S{i2bYE1F+#7wz=*0Ii$=clbAhLUjles=oxmIbT|R3bF1f<%SZ^>6 zhsN$c`$Jw=cna7NMCzR^{tynXE5I~0`@JeMNbT=gvT==Gb&~pxbfmBy6*&97BIotG z15dD!KVEjlcb|fU>RcTzj@zb|5@NcpfqH~ zfIYwg9Md+m25JETfN+F-5xan(9$jJQJzo4TJDG{+5q`Aj<<1ZDdpC7Yi0ZL2YMuSJ zSCWrA6Y)c29{C}1GkL%dtm~iucSYK;9=9eyCeWrzlsJmA$yDDdU^JaCO zHx6_1Rpft0pJtdKE7$9K#q{=^PL;z$RGo|C?~IM=Gn2ff`>v)VokZ@Cy0%44Cu`hQ zQ*0Wdko-FYy?DE>0DanA)}ivfN#KRQaO+*jnAt zI{IFhHwAQF*rPr3A_u&AqEWTP9@oA3D&K?C2`@zMkh->ccrh$KmSY+D@j~o7edaIA zJo8w}KIObEW%MPlvFmkzaSGTGpVTK=BRum$4G&Vo6Far3vgPpE4S^0tgcl+=)zf)l zteas4&5s{u9Qv`&1@eQAGIEEY&7e<5xp0WSgpu&{39lv>zld#eVQY%6LpCyx_isk@FH4&zbv_ zd7bAJ(0Ov^2G2Z+8XcqtFFM^Tc1y!_uD?wuJQ2A=>e_nZiQYubk0-8J9D8Q|3J0i) z*bvf}$EMw23=HpemzM%MPo~}InJ3%2g{YOkeYE-6mv+A$>b#xsMC7Ixo_Hd2GI@=z zM^>z7JycAP+PLoNBhNHlc$e8868WX*;cOaNm*mG+@=oAwADJop-#ylOvNO&zPa2E~ zQeXZt@~al#-y0kp;Lua}DsoeMPkil~kuotc&T&P4JTc?ak7=XCPLWI8m-dg?INCNk z;h2PTNL|;+vDYs+1$3UAiTBKtsIi!r&}aP@>$=%|0-cQ#;fcu2I~C3oM{~*K3F|Q# zZ;|{LF3^`e*JZr7Q!R@(JZCz}@{^n4yvOb-pubNHP4LVU`?w(W>!vQXR=23J!E7gq z+&y;ZcM#71gd6>>W)6E|y^qcv(KGpC#>ZpfhV1j0ydlJvc-u=%oxk4ce910^FEQ7L zsCGSHxcNkfofSi!s)$_?xv60h?26uOa%(poy2&$t+b0GopFs@*%FaH&&TKb{{4(^h znos%hRyavt>NM7IH*wT&m<<~MJ`jyl@UxSh156lnXbwPrlGORkQYmKf2GbbRu&cdACJL0i7?) z3gHXm+gS0b;Z?3$F-zj6o#QBiDVOs_<%<}*Ww=nrMfdXuUT|Fj=B@c&zD077>M+?> zcG=0zJx*~#H=OWSXfIg~xKF<8 zT$g>h9;dyofE2JpF1$H2$(=V!x&Ie7Dm6%*i;Oz@!`D4txN8HyEOL#5iQE!u8=W`( z$J`VjmyzBqJboNzoi?+kcbIlgyY#=ZOOEJHxI-ED$uG`llzs_)^BRc$wa$(w6Mh6| zc;-iHT9A6O`K|$@d-tq2;&iB$CbV;`7e#IfwM~Bf=sGSVKFvXoeBZ}um;Y_MW*+mH zTo9jq)L?+Nhw>}c+411Qj}}ur^CJ`d**Prn_E8nTYI@a<_EwS!KSXY(V}AU&J}o|e z?EjD-lHbAw@kMtY({_*}!Vexx8y~w@jI-lOg&$GVJo6(P{Q2Qvol2!ge7|Ga5BKP2z8DE{;=^P8a4ec7j+`7aPo@I3cfr|_H}9*0+i z)7#N8GfjRdA1oiBa=@DkOZR4Nn;xX60hI zbo5Ue+ao?XJ}ovQF(tWKpTvoY8Lgc5BnJ_Yub%#c%yP^&0hU9s)_151zb=5~-K}*S zIFE$w@k0Q9AFDP3Ng&=NWbzlt@N)6zHM&Qu=O^EyrVn^trKbI^9_q+N6O<3C;Mwr=ln2WG8&1j{ec?HMej7yoOBulK z6vUo8?y6OfelUMej_V zaZA?B8<}Le_D6K_Pl9iwsfmOSkRv`D#+v8Ha+c zn~8lBxl04bo~}ptX&4Vl#@D#c{tds^vm=9qjq82;ji51oM@Jg3)x%0}!Raf?;^xYA4HrjGfi*Rc4+@d+6& z>+4uoh3Qt*aS9AGSZhz#htHAMC;-C@>Pg^Rfd4=`0c=5{@;Q*D)_6f-`J7*X@T=Y0!l7gGk0{Su}(4xpG9se=P`fsSU;um zOF!O<5PQY6;Xcz#_IXVAccqgf_Pkr2-wAhnUVor{uMk!HaPi4A)^Cb3*B=nMc?UiH zhNQ=*g(s!N@rTX$|7>hJ2IHiGp^t-P-Rqu@=6VF`o**^q?C{<9pA1ho*CP;lk@fJj zH~}KbLWW$5y)y56ImhIH@IZW>L*xp1LmSBQ#$!2;-7Cu3@w8I@w`IEX#+(Ncx)AGr zzPzPMjYsEqG1n&$xtVwc^4Ce+znUMC-=-eAoO#V-<~yP9)20X?L=KS^hSyzbPPcC- z@AJ%$$VEYFXih}W0VUJFHrFW-xtV?*`JsIw_E+&l=K*!mkGZesvCa?5<(M{uVI{om z>po6jQBLPc@co{7lDarZ&HkfI!t&R*l`_{Y5V@Ino_XT>LaZn}VLs_j@?7$d`AZp( zrF|j3@W712Jl5m)?z>Vz=Slmeo_VqiJo-4f{v%OKJ8v-8FA%vaX2+gqp2+OKg4-pY z@{#BC^W0~BA#%1S^fsw*2;$u9%++_6&Xbr2J@aH6cy!>{t0OOtu{Sa2p^MzS zgJ+(&zTnG3hMDbGsR!sYznRap4`LfAXFgLV+`z8a{S7Ig_g^y~^30Pn;8BI&Ls}oO z-MQCX-$3N1iUsl{pS~-v&5ti;ocghD56Blf%E%>xHibT&&MDy=&q;Xtgx3|E0yr=!p$`YCpRVfJZGNRrlg#xFL~h=xsC<#8Z5A@jv@epMv?F3ecptGV+-Ddb(+NMg zFJa`o#Km*wK4o6#IR*4_mGh5!=1cSn{AVX_U(+=ii?Yq{`9yBst;l?FHF2#d^5cye zx0&C<335bi3+)S!O?$$)7~bnHF9mcvvmnbeZ^C+qs1L61x4Ogc(c?p%x2pr6?+HY1 zYEfj~IGen>KARu&tWV{YLF(n(mOOFf!Vk^O_LRskTOaSbQD)NpBad~yoP5GFUm_n5 zQZYYAd{g!L*{_)EB8c34$RhLCxky4$?45oO+AgtQQYX^p3266d^XQ}vFX0?g_xe&~ zUO)d7(Cf+2r#!=&wO66I!Ha-cl56%8Z9|&wzEY3XZ4bito-;aT%|8{p!5Ue9C=Nd@Y~eK zd;Hg=Ko+8r_pk};Jo9EJcooz0n~ER5w8h6D>ev2z0GLt{#2W=dE+Bk7y z6Y0}2jI^^DR-Euj_ZgN>WR4^6wkRo(g+Riefag5(hw*j1>Z#7*2e#!|U%`|!EZt@C zM~ot_Uj>MMQR_YHmks^LkFbxh9U0QdTyH_-)Jb=jrJuR@0wOeduHU1uec>&Aa#?)t z)4sBtNO{o9g6zxn2=D*+6rS?JpaC7|yk(;+EkVp9~ z#(<0e3}4K9U(PW(qdVaeW!xv#WP=0HwURh zb>}^k)Vb<qv;Rw%jpLGz= z>EUsBMYt?HWo|q8Ws@)N>o;VBPxmzZJudnAGpEe;8$@m77m3!nOi;c=M4B2_4aptHf#*M+Fb8Ig_$#u~?9~4uZ&CnmP6g*Ds$%5pd~$o7bXuL3S|! z0a%xM*F|uol+K&1?Vfp~UWZ-0uzUUEPd2{JTo*y)lK$csnKy<({9o`!w{f~Xq@1>p z+@USxKHFheveS9fen%m^K|+nlJW_nhqdQKS>m#`2?x|U1-WY~Z?^onDi3==$Wd zm;x>?YPllk39+NRFOO+E$$hpFWK4`qka`V0gmaFbAz8J6gttg7h8}oiVCU5A(=RP?^o(NaS9pRSnOZX;X^y?Aa z>$DWm?M&+1?z|a`aQgZR+rX>Dy|b%+G`j5wbA1JoYf)Rf1@b1p#TIZyHo*3BQP*+P zxghz?8;f0G-TQa0x1gtA_HOs|GuK;CI6vWZtzigF1rK16@1%R+3@KT>-S?lseRIY>PDFBA&A^muITBP zpY_V0kHR^zH)4O7ezMPVbbnX6IbzSdod%JlXXSnF>1lpnJ`L$zZOnTIj(?MK@gNHd zTpfV(pha#8wT+&h{G_~DL~1HeXW>E3a?59DIxtPRucw86EOK2YX)H1xGcH1S$#as< z*!4OODPYGr;YIs*J@aB2c(Z+9^6AGun;RC(%!3nNh} zgdZYzNL|}J{BV9>Blg3NpmP612R!q${d+;G?7k$Q3Uv;IS2p-5a@U<5dwK3}&6Sb6 z=jEr^a^V_d5&r3M^Spp^u~C#!H96)vFE5!2m*?!bO!yJ~zGr@H8xW!fO?j$Ql`f+j zHgw)j_$hKzi#+_`L{1kylz#td2R+~a5cKPG_(YqCsSo!o=B%LP{v!8uf1@R0X<^z= za*NP8rSnkYm-A9j@>tr&49|V9`|~NV08t1()rX$>5i=-61^TpD*!Z>jv)F&26Ml%? zA$4taewzHyt6E);1%>FLhJ>iyYX_b<_VY&*Ogk=emj;eKPkQJkUDqS{kmvNs8XBTz z{Pfzo*~7ctRE-3Mlk^a|L+aXk(nB}xx*p34(IYH6M9oUuz2U2^dpq0kI=)O(<5hih-#X$|Eq`F2dB?--cZs*p{{HKyFb@EMknq7z<_K_i~RPYz4 z8ZBBgdOpmE}^4C)V)hT-QVlsVYN)Yiu^M4(P`_Z&;CO6*>*#S zx_0i;uyPM=2@NpPN932Gk4|4VePTZHoIWuzA?oD&Z=7A6xuUDdUy)yiK01xv-WQ%P zL?1OKM3s2y`+%#XdZdpu(nsW%qK`RMUaOwn^ve9$b2??k!S1!0uJ*Q`-M*w@Z$y5% zdbwpDBGJqJ=1<)9Qp$ZCzw*%_RsOus)}MSgMw|0zMea$je5TCiCXv~GFyr~VkJ;AH zowP?N<36*2<8*9~a14sRc@0GWTBq|QC&x2S!afaBJKnAr{@}8we9U>XA~zFCucw43 zuBo!QG|9K0ZpQU@9GiK~V{$@#av~UzHZOLsNT>58;B(JBN%$;Cl}KLGYt%Q(7n<{B zMQ$cyemrqak^SHD#A&K?IU(GTXW%hyiHu=0JdfFzmusR`}3C}#q29JjJ9@X>p9|GDw#-ED8Nxwwo4ykLa^F(`9ocrn^3yIGA%lp3k#v}B6 z;l7k>+2`FPZ|T#~21uUj*IOsOnFL}Rvq~jLC50RTU zE`T5A5J&Ed1d}iM<*}LHJk~+}NEq%5pTrI@PRi(nPmUw+wy+e?>z&P~-1#yV7whv0 z0&u={r;FVpSKW5uS60$+!WWS{q^_;bmwcuWO^=Z9U%b8MuwO#4GAvw)l-cewA&670Dji(C&Q_D5u5i^K+rTsUb(>fIEW0(v=WaKeUbfD z^L@C;i>yZhZ3L6IjL#jIIvAd5I#ogxaP+-kN-IRngYfx?VdA(aSy|MAb}~`|IeRU;ojp2Sl!^ zWbGDNFQZD(^@{n~b9#kN3{iC&-?Q>S*L&8P@6Sbk*?PIEhCJzYz7V~(C5NbYzOJfW$UHCY)2$nfQ+xT z_{FncDlJ5%R4iROZP>4+&G+ph|Fe1-^mo&5edub$H{Y;uT-s=8t3jNaGVq@6AKD)K+8pHUp#^b5Y=S-+eqA?o-ugSwXvzkj<~ z9z_0U^)rfvn||4a=x3jXd7WbdzdgEg+6eP~y~rs zDQS+Mk>(C=AriB_W5)Y;A4@x5?j!9d9&?}Vs4Mw>zTQ6GtV%IiR9C=}ZtlFP{0H8v zY;1eo^pBUMn(y;PZbhJN3T#&hZ;Y4w|0}+jJmImlx#@e~>pL=4=gUbS&wPorl~Vs% z_xq~YjD)G?dwr2>RIzpo<%{u>|9`<3@`29eh(qd-)3$iu@4L_AtnBZZFVlQWsl7d3 zIy-sl&Nb%yeUVEVi(epL3V7LX@hZkGJeShaUJv>BL zgwyRyWO2`YSp`0YK67Z$3mqS;WWMJYxtVAM@+H5Q{1Gz%bkwUWt8RoRrZCuN+6-ZDA>(^JZsBcixP}#rpgI$~a%|jX8TBoA_II^Zoz- zv3Di#Q50Ff0ti8lgn){Q8u1`_i~$ruQ44%$VYiUK-*av?9p{cdiJR4-D^l&iSiOL6vxM(J@H+@>^A^zW1q*)6 zJST(w@9|9;*S-DzPh<58gyxHg9uXf-qUjS=(-oUfbu-oo0Y&-3ctgQrdZIxLWN?m3 zthb2X88--#XdY!rzka;_$^{yxPxV^`?Ae=f_i{K}jaC|<>D^{RHo=d%=*Xr7kwiq8*?zv}g4 z8bPpxZ%qIA_|_kvH}Ju^ci|FnPfd+mtd_8BMVPjt$c+*tYNd7XZz-R8ou+0Zb{`bP6jJ-{E= zt+DM!7u$8Rs1N9mVbKqD5bY4K=!Z60)0sG!M`z(geuwRRKh4Wi3WINs%S*H|Xhdlav;R&o1na59Xl);JYt z5j^&(isDcl7^e{|)w67`aQ^|%)yx^6#zumhIjA37(XipF&46QCR-ZT5y45*fy{~f;|odzX|MjVC$fQI|wSApTO<`mCcz@xeSDgXIOXyx6v16}iFtRsKnpklXT_bU!K=-TS^C|XEyzG3j*{dirM3tor=>td{Xt-$Oz zpLzYjB~b3^wm1I%g@=9!!0ZV??t=Q|B2e0u{TVBV3QU1I2Kfd>!s~+|q=nB%@7JK5Cu1NwH{>Q0 z*9;q<17f|Dv%gXP<@&mML>jwqlr?+W=BeF5EVv>0C%T+t2l*HDuR!&dmPrT@%i01T!TsrW)1+y z`ibZoHT<6#o&u;%wK#>~i24*xNxPZ^`B57t`-%6Ba3iOKbqDr6M01F6gKaaFyFl*L zct6khLUO$6S(yMDDbFOB)T-}6+n=lz*?Vr2)0+GnC`)bKw| z3zR}z>MxF-2Un4vdX!Q+^t&{o{fY-yNNQ4fes% z5H6x?)bKx{h=r@NvLi4N*CxP)*%806A*%#C>p!3yr#|>pb3q!*e5=fH&#{H;HlV_Q zAzVb)sNw%aa3Q~}ir0?a>nh9?OcPit$NGa}kH;~5TEh{oW9}V02AU0S&`p6JFwu2# z$btFRa(A`O?QkiM3H5fxgKC5HQM8qKT^CQa&yf&@xgV9A?g$EmPHQum<wAqZ!AcAa z;Uc<54gYJn;0+qiBB&lTNVXcqjkus`nyz?Y?hrb!BP|6^x6=pph}Gux0RdB42bS=) z4UNsWrm--t99q2ivfs}A{SCbWC458=Bh#)ld?anfstwvn31gXB?tx}YDGki^Dn2y; ziizQ-D1NWg?i*?8Sm>6i%7Ur3I%gHH@?ajdu&m5l;>G_`9YBllT-Arfey*$&)7T&T z+`OoCuf_js$Ho~9Jr~h6YWQD!F0uXX!1#Qp1D^xNPW+h)ylSlwUQbGFmp21W)DzOD zRJg`I^4jtg_EMh<-^M5h-`rOI`~JgUJPL2XAkH4}PjpTc{)%C~IRGkD?n6Do5sSx9 zv|P7iR;{bhU+Y2&4`I-w=0lBm5DTyG_F?R!Azy!l*$h1X`m4PgKgpV+=ZScF0Uo03 z4(LypEn(Q@}rHumC*8P z25}*`WV+_d*c6-FSqVc*OQFpNQ}8hT;%~6H!xc;;1f=|%6UhJ6NB);SqWWd5mbjt( zWjgss%->fHnmdQ15ZkB0hsS^Z0smqb*q*)&yE@!Z{xY5XBj)c=e0HysH&qm_5iW=i zOA^5GgtLB?vvt7vTK<~6;`pEFlrFguarpc;;6uRcGPaL{hsEc^2@`%#-{P6sK@Mbk z%={frpT}iuz%XJt1QW>rlXWLPRWR)PI!d3)L8g;`#OGJNPVB2h(}&Eg_Q2lYc}U9^a| zuV2n_@?NBI{dfi75ZkpLkQfdtn_+)1D5t=OC9|Tx_euoo=b_`+3gRYpi#*4jIJx#IS z8a%oqUhGfj9LLy}8Ex~~QT2gAY z2BRKWNUpWH?TV!oT3MJdSO}dht*OleDXLO*%?bh|u%4&+uIHh@hja2ddIs1{!Z|yf z>&I~cmYd#n;ylD_>>?sRk$Va>yBPv)91jVS&x-(59F2@}`zrCY4TA{0mfXjXnVnFQd2u z&`Zek!n%~(5AsA6vse$c13omlV6ludpX$cPW6j?}9dO;lZ=zrSyhqY}qn+R5H5!yH z{FmvR41YrRzr?M*+fnXzL3cYeB-26$!680X9}}BT7-Qn7wI%gWe_+FFG=xK@YrX~? zq}@esP<-g&I$&UuAMn6T9Nf%w`m13`i+d5E{c<_-sug<;D0d4aMEKIPjeNrWNvQv+ zvtfR^z39Ak*TVR4>1CgvaN~(%jzmU+xf(2%Bhfig_=~0gZif{rB&f;^fhN>JN%|~S z7-i$|1p$Dm2TM4!MjCO-1I!SWzqgToFmhR3>yjLy1H{e*tN zYSVOr1LF8~1;_>RHWw_q*al!Z(L8tSVQK7{H+~p(&9d};^l3LX9Q;u(hz_>~({Y>~ zX`Y+U67hIqd)joY5f91+3|*OZR6lm!26j~&xC3&|o^$h8XAE45K*1~rVL&`Y*Qnut z4NtDyS*y)G&^9B*5uz2?oUVXZp&e~nTn{)X$KrZ9@`z*)Wfc2F#IsbmrtvnmohZks zb^XC&osv6{NBwmqxrGo$8et6@%uLI*x-cv8n&A?bJPom3sQh@K1D36#lg5!1Wa$ z%%k}HIP2u~=lcCht;g>xhqf73k3nSZQ*iU)NW(axdUX7D@t!~L+;r}jL!Lz(XwXf8 zf1-1u@D~|Rfz9Qb%X=09ZMxZjW62m}yOJ}xnD^H=0Y3Y%Pv2O-1m-=G_FHjsaUh89S?=sGF#lsFSFR zsDn75qBU&P8Em7D1v?IG0oZ9^aW70Q*mJ>N3-&&+&w~9o*j|8V1Xvr`8^OL0_Aq#2 zl)nvNXF!AXA=rf=-`P-cbOUAh8EiUK95bQfcoQb-aQ5e70QM#TI~#yq3&0M8hOy{C zs4EVEK1CMbJqGG$s05BYg|VZG7+X^Y>CI(q)qKXDzL2rop+bGR73?c8cm6eFuVtjL zvXfKTQ=Sxd_yZ~I)o)VRktcOyKP>LX_D|`~zFgRy^-S%-7Cz8}y;;2n8PGKMR?tp%5%^_**w#x>v<<>z=Y1)TfJ$`@o&UFW|qZb{@rp!5lmF+cx z1wI(VUiw!qLpgvVJ`dQ!8o^S1FnDZic}c$|jh%DWk#D{I_PB@7-gg*QuY7+l$_vqv zCK`jh$U*`EgJ3ED6;l54Iy0s__lwQZ9IA5+Z*i!O*}hxzQD z^ZV>~V)emUm@gW1Q{bQIoGAQ>^~wwzj9}-wV37lAz3JED>~XQ{_153h*tx^bAKPL*WvKS_+BhA{ zpXih>xs-3A%`x6(bJvt9^*rw;2oNfF$QMm6SWH*ei?!Y~HuJb+zPji5$5XKWMuR-T ze2LD9!k;kS!}$sqU;MMc+5v1*D*{chlrFG&Abc}e!cllqY#bgt^cN2PuC;2V!$r6kHW}cun&lM zh|Y<^pMXbX39-Y_zFJR?!w-KNJ8!~)qt~9%@T*17gUW^ILe~7UL;hF}oE_7ZTGg*m zc(GreeoAb)+z2?2dS&S8-jmBU4;n(QQybp8gZmUdRV_S9Rz!Ud-Tt&|1*uf@#*P%@0s@NInZ_D z2Fn`dis(8yY2kS100JW3Ykv+G4r?ZSsWfz#L=Drj;vW*j?A}KETen~hfF7bBaYGr9}IM8 zbYan0!GntRPDNg9y~(~MgB^D3Ua9vS@w}JIFQhOCEXoJbDSvWlKMkk`ER^~zGsf`d z343Qwms042o=M4EpNc&-$M}Xk=q2zL+aR}_02k^5$qC9N%BT3A+2J$oqeiX$&QAGi zbyPPd)5$*pToV(0<%snQ@`>n#gWL%E z9PoHxGSmnAq4j!d}0y@R#16-(bd6 zGgR-%bn=gdi&s51-hBA@_8J)+BqH*yEe^i+acRtT*3Zv>G3?Cg)W#6sh)%f3jfGF+ zTV!NGNPzfOQ4mM&R}NtIJ2qT(=(^lrQ4Y}%E~0DH@PB+<8ndQ2eYn+#@7?F6swW}V z+neIxt3El6JyAcc=cOmUa2esl`T^yQ=wW2qRk)?V+JHCvu)nC*2@@g?4OwZxTWPZ^ z6Kdz828ehXCmQ8UUattkddkUt)=a(OjB(dptiO?m^#$S~dJH^b#$~Dj9q>xu@*>us z)ul!}ayybeKaE{F{?$>Rt;wJE8#caRh(AQvsNsLDzf_!OwOZhBf=j{8fP5uT_2Slk z3K;~3qa0EHi0EDEQkkMoV1E-0(X>1BKN<(NrhJIUR2Pv;bj(w{j)Wnef226O6K!kC zN9Gfi57NbJu?)m(F^rs+d9QJxtICJQ6Ucum19FMiq94&rH#P^lqI{6=s0&mcR1S1c z2;_UBn{IRtbVd0@OI@tLsLbTBa+%5ZVj6PX-Qiv?AFQXM@sjvKJS3OsrrY%#5XT*x zFp8NBW*{fEMI7^4J2e>%yAi9iD7zgE6K^H%~e{mwLTzFtpq5@L@e0;>C zisO#Pve@H}!j=8l`vup3_4a-#g zlb+AcTn*#xyEm-w*L>iFTlEbVSPx-25gl#~MkpuZ%k+R7-oE$1vc1<2<3#Q4cVtyK z>_{U>NKq`moEfqCh5*if!1-!hVAKc#gYtx{Q!<_W!+Be{(C~!@KHs0`Qr!yfG2mmz zMuF7}=(`_YB*_ucWn4o2qxB!P zT2k+mP%jeJkDzi8+hIAKWbUz^L3r3V!TJhayhn?EWZ}{@334C{!inXB`k_gSF#)mv zJ;oMWo-pRYg=5Zra8(&b<3>9VWJm`(`3v&IWk}nAXUT^*KXJpX_HGGZaD#fQ0C(WI z9I#2E$X%&gO8jt|r=E}~_igcTZb)NiSSM|qmc1EHBGb(N;NUoc=sG#%2snj)r?3x7 z-!LN93$y0N=2v0Qbav_q3u{-s_t~@QdQR8|BMzd60O%J24(x(7=v#hVaEz-0r#Haf zMR-+{bFvf;v@3C=KSmYn&y8_#we(15bIurd!pom!-%I<%2p7@g;o_&HOjn}dGLDy8 zD`WF%W3P0!^66JAGt|bpG9IGGz=K=oaBMr%>45h}Y0TtPcoeywLOmdZ^-4UWSDW#I znf{&RfLuPf&zts$V3P65D4u^OVVTi%4m5&GbJ^AJ?&S(IblaX?>}|A z9IeCqn1&-l%iRi`7>b8S7FqMAz@{45J%=ywDeyWZ-*4p5I!17&O10{MBQB~b{Y z^P02d`XhR*J>V6}mvG5+@;BhhgXRO?aOFU>qlm`4;EnE4);z;|kwL(L>E?n(7uyJY zKdUvf7wb`Z%=>W3>c6YHXKqG*sJhnL{XII+F)W&5rA~3>kDuVKv*1CK^qRZz`R5s* zU!IR_a;G!zyh;DFxCV^QJSUZ>3$Kds_MPaQDE!gn0zZo!T6lDe;e-@FFyB%RZxg}m z=Av58E^vDW0#C$LhvEQ>E{PFp7!D`RnalhXNN6wc^8>jpmf^ehZOkpye{0XOZ zN?3Pvrr~KxfRsaq?L`yv@=J3Kay!dqEH^AOluPk^hI{W_chbDg-%ZnSXt;6zF3|}G zxnVqdf$8tl)k6T1m$g#9k>sVl>hclyKk#&ieZxej{K)N)??}x@tjDTrjn9j^fa5uO zj}T)#QMTxZQ`f8b+7&nG;`0(+Cx;y9+~o#f8~`ucX{RYzW;)#tb%D>Kv0i^Y9*(Vm zs@bda1U8u zd~$@))I$W)t1M4^{_K0^vQu8X>GIGrgeK=HOr{eKlIA?cpIZknIAiYU*9eyKZAlFk<`J8qG2na07Ukl*CHYAr4iQvv}{`yt6ynEU6x*zew ztJCEughQ8q)mvbzb-Ef@CIrOt$NpT2ZE+63?nnALmIk)d(q zsyzW5kM1{P(qn@Q@pXT0&_z8bx=s!`k#QJU!NWGfKb2Quy|I58X`Fog*)^v%=MTM| zGScv*FquyN9dPh><~a_o=|Lg?jgWu5ex&cc)v1#&D7;wa1JNm8a!Fq32w7gmBq7pb zy;$E6AK$Y-Tkd;xL*q;tAJGXHxgGeU0gWIrS_~0S>O$i!jo$)g17X9&sS()v{2vxJ^o1z-?6x$=d_n^OLB?!hOmV~6gU-^qr_bR2cJXDME%w6aUK&sC#V2F zzoZ!kqN2Rw^TdXd^%zKjqCI?Iom>e)U5RU_9dlZjDroYJnlLICPOb%=h4v6!2 z?27pFF-K+0-uKCuUxd>rHG?kBn-N{c99|y|uag_s$EU;UxN%=#6W~CDbWC5K_uzhS zpH!LG=br_~VgNAc><$09I-L`Rzc3DZK|)%l*I*ddchavkj-Mm#FB#$PGeo)Y+|arn z&cEO+j7%peMQ-@G3hb&W%D2E)n=%!?8wF>M@u?tumkWo=+=%6}1aQP#-&wfF>!&|7 z9u8z~h+i_D{0s7?h=-KJi#JX$Y`hX_z`rV3Sl2c%agI*MPg&vT8N)0M zf`G{L0F*~(T;eafbSBXzXD%H$4-?>t?GLu+qLJ@KKk>S&%URYX`CiQ1ypGQSxqM`P z%J=b8G(&VH2WY*Q)-R)_9j%}cmoFUOoo4=bE5D^+k^N%AvnR8pJ9*hk~*CHpv^qh<$~|1!B^B^ z0~5Ry44atXgRv!*m3kUMa0%a-8{^|+4_xqUA4PeG_=GNw4~ecP8*-AwSE#@)Rv+y7 z_30SJ@yGfE@GZ}O`r9=pd~%M=Kca_#=@&`j)A$FU#+7lB++jI;Zi+w7?mMyfe_q`D z%_5nPM3-@f$G72e_DrwM<53*KUUYqs3z0=U?B@96?bn|CvB&5-_a6)NjRuHoKPXqC zN5>NyZ^weeG9dw!GaP5;+|`e*9JlFh`~Hq&YZo6f9rFsppV)pL0<=WiObBY4ZOj3= zd~glkET3)6^dyp(%Lk7mFvrwMFmM|OHOprkGk7bLm&*s+B%Iqs9l~qV>{t#oLH5*7 zZHN8?mP;;JEE~MWZi{%n|5FVYF1)nry1S|D(8Yc#(c#u$BK5EI7k^8gRc?4$sN*_@ z_3rrns$OHh%6RJ5=|8R3D`Uj5FW?}$0R-HHafJF+kzg3sG1dW&c>Fl^)!%P;?6UQB zGCznO9Y?sosRNk-A3CmV(7T%AenijTjQoi7KJ%TkCw_6j6~~X)*`b$T3M0CVLwHX- ze3D>^d%9v*oOSR`NC#gofOp)SZvIL(#TRj<-V-0!tA+3W{h^F4izq(!Z}97uGM)Sd zT+zQOM)33nAdDLXOLE+j051FDu^$glTh|EDxY5clg~@dCkAw?92hs79XA!_bB0;c( zukhaZe7oh*!}?{hFt>Z}EP6&)ECxuim2k z37J^iP0!NxrxQvy+f^l z$0vEtzCSE4c-BbUu-^Q8n9WOjunRtFJsmmq=J25xqz(2R@TPv=8S?r#sHKRGVMG(! zZ=dIKqR?216+g}F}Ejx z`|m$HQct<$_Ah1JL>DpRbtiE1BwFF0_}TJMe17&g{hGpI`#<;j9e8j9806>i@K1D3 z6#k;)!kVE>)p=OpRcpiS;~eh5aGq*5bPN*JPXR_kmphvt?reAxVxk#nr{X{m(2#x? zE;G&tr-5HO*ev+ot?ivd{tK7v>v>z!t3UYL2(2d2^c!Ol9m9wwx_;}Lt$pS@*B@D( z4gHh#kA~|Xlzq9sncmuu9aCaCxAE-W1E14DWP*$DPZ3=wha5bUrUKE?; z*U{$JNYBZQ7EaF7yic41UDa+-8O6&v(Qxt7G5t*r>ED?z_rcacH+OFRyBt$#KoC(d^v z|52v3b=Hn~C0m}D0;Y+2iT!>|n=D+Kri(cs?k`>ca{P95e($mO{O`xHtyo5AwDRx9 zh^|q?|JrwZ3KaNO2w(T7ZyWgxjc52wKu;l*)f{VT@yQ2x$e(|c)boTvWYC%?JjU78=j^1^jVqRae>_8mLaZkbO0(fAbpteydmVV_O*Yq9y${;xE4$1}d`{{F8O@6or4h(AOp9OOpB6XAP* z24F!*fY#xwUpL~y^%VS$LC$fEZJE(F-@0EKd;HO#DxZ9G=(I;}&~nD}`B9#Tu2IAP zGsak8Uc%#aDW!I=)8n7ww0l)Jv|n{QeBk5u1!@)TsA*jCu7Yn{!`e$Vd?(eRrBMiu z*q^U}d#Z1!p3t{YX%V9Q%j@OeKsfPRT@+0Yhx~`-qz*>ZL$=nqe*v~Fu!F!hZvm_e z7W}yJmJGJzrugU#*uko8oTYsizitI*KT@9!a;Nq173%5#E~mKVppxR z%Q)nFl1Y&+((sz@Wmk-YGEQMB9MNdK3F+cB#-}kUmLus2xfGt#q4epV!l8>6(?S>P z9-^U3>A)qY<2@R5F)X?iPIkd7x~y!=BFYEFo+S`1)_7J@F(+SycfPz z1ZVzpz9^1jwaV$X=-+I@XqjM%AK8G1_|ePuObI@-=)WFLZzliqyFFTu{&KyE^-8h^ z(-Dn)AI~pRc%qRjreR*29N1ADko9GI;Gi}ab%8A9E9wVb%V8+2>6#qa-W)LXWqWhn z%x_obz|N*GA}_J;ipFeTG(MRBJDvlkzU=riFcIuJ9M}>1Li3EsC9w^Wxkl{@xw5}` zZ*pLJb6|Vx3(7t&k)WQC-QLe^=4W!CvmDso`hq$_`hvPc?Mr9zoAFEzY)=ksZ++>? zXG4AKN<;lV>@T9F^vUhYyv($AO%BNWcThHH50&^tre1})Vd_ zVP2S5kvU-MOPDXFzJz&UUPb0WqW!iOh>rW&@cS1{zZ>@zSA4Ph zRJVRY5S$BKKLO9+q~m4T3IS)%AF**Z4jRC|e5v4-1HXCX6&WYdlfW4TVxhCD+NyZ% zc#xb6&JFDVnP<@?;BJ?2H-0mkpRdFY@5ZkG#!{EL_W(9@&_51-`0RD5`+lg+tPp>R zo&@fqsaAaHQi~ztu>NV}-$oex;d=?Gvl+Xqz34oQadzMPZ+f$4__esl5)I<$2LD9o zMBy(+IRg&(ZjDdDWA+T^0B<@*d($8n=vb#k!l4{<#E8IAdrX&c5FOJLO$;1U1GR#r z=^ylz+ZDvIBh2>9m-0fFEJ_<*(|jI<*%7=j^W1qkVCqX)PfUH;dF6CxK_=_V&Vnlu z9C8~V-$zOV!-(N%ZW+Uhbn!Y;Iwo!R0yZI_AB} zft^)fI#V)<$U24*!Aq@)H^76XNxyNJlU& z>W5Lf6qj70o9^z*fvy@~c1ETs4xVR*vWoX)ci$2*KDk^zczz}E%^1?W+Yua)%O?@} zjaGiB1GM%Y=~>XisoYm*snzpK|>m_R+++;nPl zSiMfw>-0BR3cSkvfa10{lvL*0{Q;ZHs`{Mx{)`1))(~;#jOfq%EV+;w=8vy@RDzxL zA2=KP)CZq}OZLc>_g<8KQG2BWZ@^$U2mBMA6NSGdaKcw7DxD4hszdc| z;W-djE?9IU@%zvx@4A1Fd%G`&S8BMyaI+ya(RFgj>AL5Dcap-7VHu_8&;~ByZyFUJ z|A+P8toZY>Pye9r+#vqmfS>4kvLPo4{9$w*2LYanFV_?nNAO&eeZ=U<8=6%ir1ky3RJg055Awm-&<-D@^4Ncf7?9w0#Cu; zKB4rrGZXe?GM)URU67q)r{)eR_Kb95Ov34v*^fOXX3a=O1Zb3d$-OI;%pYkzXv= z>^Et12FN3kcj9#{{+WKe7YBmyxKtm^ni#GRQ2*#X*ICPYv1x^^_akTe<{kG&#>vn3 z{U8JHG#SeVNh7*O4gZJQmkISA_)JnQ^qp)ji`H1EUPb%R6}>HNDO0@gim}Z#!wEem zp2!#&2p~SHFOrdCdM7fBrt?>nFS_D2r6|+PISJy7>Fx*)?5cXxl{&j4_-^L8Yja>% z?>|Q3KDABgCtgPjOJT%0I595yM~ZLKb}tT?`V!VDY`esMAL$9XyO(5`PaBB?Z9q(B zJcF`Bb0Lw^+upQH$Pn@4_b}^Wy!b%+$bI%(J+J@D#f!EeR?)u={3qRg`x^D#BQwZ9 zOOH?ExoGS5t$H{--^x>H9GA8Y>&?$!YF^rdUGP!s=@69F7oX9z;?TAuXX?tPVMz(m zF^p(JQ4zGAC^$^4O)skS<2mCf%|-KBn;*I%X59YYRqWvUJn*$7Tfd^>u|Dq(M0Ssp&!|8 z3dl^{|1(kJs4GtJn{|zkc`fli`wGF#5)xx$_6Si`QthHha$wbj=si zii87Bx|@rufG!ubG|&L?uiY!q%&h+TXG!^uj1otks_{*3E=9s zU)_H{T(;_U85hyF3fF{Mo6}X|b~PB~v~gN|ez|}A`5xy*Pf>HOmsJXr>4Z<_S81TC z3R-CpPR=fYeImDvxCT#;k88w=+5WrVTYL=VtMM&`$#n8h0++xoqyDrcfa}_KoTcy1 zYFb435-yoe{vlkGm4+#b-|Mvd=$q}+72GER@+5Mq86r}DY)olEs{6)3Lm?Z^_$We~eIIBA$&2;Mx4b&-bou zc`?*J5gwVI9G-B2iFoSE(kCB>i3*N`4JwOPW~bONaYn~jH)cls^6Z`U)6(Wg>-Bm{lS8cEi4MsbObD-7o~pODG%&Z;>GNTu zI#u;kD8(TZEl(#1|D=!W62RC0%vsaleq!=ajgMh`L^ptg8_L;|D86t}^Q1E2pZL2O z@DYE{pMLHr?3alCg|ox{3&!<09^3w|ny(X|7m|%?C|uM4Tj_!6Z|gj^5~3M>7v?|^ zuv2}o5%dX7E?AVg#v7LK^S6WfjGb8V(*x-D$gjsgG5PjOuUkC;@3e6HLTI9E)bRgw z#qChMinr8WtvCWM#cP=sPy!0l3e zd9n%%W8eSsRPPntGT70!bI<#6VGWDbb+?7BGhY-?Hu zdn+Sj>V-d^@XOx%&RJ{@u%0EloJ+KN7N%P8?E%%RM`!_;>ieM6Sl{D*J>2)cwvn-_ zNzZ2&9+S=%KQi1uqIeo?2V$^oPUZ zS2UdN0MPeBzaZm?xEqNJ}QZ7;ksGmdj^*@D1~zIVO?c zNKa&}EXMh(U(4ka>3NeWGvd8Ai)ivY5F$VIHtlTD0TOo!wue+WDa{27avW+rBeZa2g)Q(9}oUd)WDE55q zdYI4cb<>NFIaU`n_toK|Ug3N#(dDPm=4%U7uU&DJ`WswIE^aq!Py_zRQ?`-h1^F(U zU0IIgXW5nR|$9`eVs_U6c%+-Oe2xFf7LK@`OrMx_Ih3_6Y9@wuY7lve8l&S zHeV9EzHPE(u>bouebHg%d+ts0jddZ`w?vnpTdQv;+3IXQyVvRQ=d1Pr9?qq$k43I? zF%4O6C_g#*%|DL55LX4=Tz$z{3S+62K5o; zhUnpxwJS|-%6*DA-wQ|Dx?{+VR|&1I8s7(7ab0X&?ISYS{=G)t^3}_)-HYb~pdooC zx<(EECxJ^`_U$0gbZ%-mW#bjeoRMnYZ7UAQ_06`*CsMjp)+l?)%x6VP>#s^nrhJf} z+rm&E0?UcYY+K~BE2fzZpvCtxa33MsXlKeK8$Oxx$1xza)v_$e_Yl-HUBH1z<%7IN zok17NgN$4T@;!w!-LB(+2be7CC#Fn&9=tZo0J+e0CXzlRlRB0Mwli3lMQd-&GE0V| z#;`%S4ZYv8$oM`x_QA02Y8uMeocCVEE!XV3N4hVY^ltto;yhz_C>^3>7}03sgegib z95Ik*gO@JhHJ3V@%L%(e;oWen>T=o}Mp~?1#iiODmb}tZJ{ehBtti?FEQOGmsIN!q zg&ptx77+tpH|go%d+=G;8=sTf$>zNndves#*JAko?|MFd?%#XzcTDkK%QmG09sST~ z&&j`wFkXcb5C2jLeWC|DVV%WjE~zY zRHX9h>b&rMB&sXP?dm-Ks_7+KK3G3dKM;9Ad`6erNTi#lYdMf;`E+frT54FfXsGPT zCA#Ljd;cd}J|ge%nsh4C_3q8tu6g=;NQTB)?ROjd{Wv#>a}YW35xRFvHdMeRd*|I- zJ|1=Z>M=CV83eR$Y*2`fVML?#`}5(GZ16=k-mS+I6}#^IDKW3@agB0FGAha@(a4|f z2@~CuOLWsUIgkhk#PNB>-;8=1X?*^V+y6dp*rO#+Qrb9|fU{LHo%|CUpLd)G2|@x? zf3SPv<2vt>XL|)_-}wsVOSoh@`6q@eA5Nc&Fi8W6i1RD0`=;?^bKxKLP(HV-3Glnw z)2$co)#qdHK|Cm*-@|oqqHEOfzlP7i7dWR^4Z!|2?bKd;#TbGo+YW|vhX0u#jfys-jPlHs8he)UU~<6ZfXM-q111M{E)I0ncM3c6RPvgZc#qfey||_+`(yqT zp4`r0GUJ#Wh{XYO|4A(Fn0`B&1KXnRi)^BhQ|eB{)z zyy(nV+0VT1S`Kuke6VcLnr7Q`Ad&JhzZ0e)UU~<6ZfXM-q111Md4wxJ;Igl6!cI0_aGD3M>h|UZ_I$GK*&TwF7(iaiGs1q_B^@el@{bapDTD17+XBv|Oo#j9f1ZzippHJMQCt^3{ zT;v9PClhYzd!n26H-4`(eHddS!GGg$#x^_8S&T71?)#fMf6@7$;x!s=uXpzjbj_Es zVw<}vV5?H{6~AKlJ5{%(tf1KGSEj)CiCva*kHh9yAdJlzi2L#{d2UPj5oLkuM8Zuj zh7rRNo!nS{6y~q&Hp9b_{IngE#(9+sG~^5JS?&e4X((fJ-h1_ExMcU=|7A|z>@yqi zTi0li?|Z;M(K%80)4umw>~z-@!Z&9XuccVEIq=q3;8kli8cGXANmgFu^22+wn5OJc z`NZ=R! z`gqTt|S8|gGFwj9S9ct7wKTJe#15}73>~h@jW!8p}~84w+7`9 z=~{iKU86tJdVs}zuuh~jNVYYuhU+1u6Adn-8Vn~Iii0j)Q(9tJ#EbXnVmR`{d(-Uv z91!()^I<5hjOBvGa+JTno_=T=E4%&>?>@zQz1-h^5(Z_YzeMLm;V)7BEp;wbFj}JZ zJ<8W}U{TL%!43ySKwUsH3@qvh>S_kqZXlTGq9NC%-SU6bS2U++PSk%27d60c;30p9 zo$3ax+xAJ~`IkUg>IXI-9={*xdVB7gPZrJlm9o(4nG`0|$zPMZDN3#CZOF6Ps};+1 zrOxJZ!uSCO6;{>dv^R{jnc{+MF}%CX526cD_@xn#fgc9JXoAp$BYSv!zD!iE z?{{lSk9jg*h#nh92fl=4RMea5Bje+^ym#Zw6-U&*DdQk|XK-{ZrNrxPIlpA?vChZ- z56U=-JM}lH4g!*CqHsWz-{zy^%gtl+$9VsFY2CD2v4I7HJRc1IMCU}|Pt&6U#c!{M zns$Cb@%g7KJ~iOAE4*uNLDhorK}ZPoXhiwJr5GL4B}?r$(a}YN{?SY1Ch%>hv#Cz3v) zANgZFjA2Os;F6n2@yO3~<8weRpJ?laVoJnwaz#J$x@$Qgmk-X3ntbnC9&b%*k;-Rl z(u)_@EcHT1VV?ZDhu=hOH5J8Eoka}@`VBF@LG zNC3~opHBPnmeSzulpo=d>Ey4?$7oY67Gc`Og4<=L!}3T2fb!eC{t5MpJ)mvKf~9u8 zmQM5GIXT98B9wb<3o7Eu6CnVYA26^n+Brh4V?7dSpX3Jjstu0?G7BkHt?lT>WIFlldaL;JRJF#*=h(SdEV&Z< zX*5rOG_?3kL=&G+!@-m0VYI8n##UlninqJFa`}jSr?Nm@#{M0Z2l9-{1YNR77mdkp zksF=6&H<*2df&NJx;7S-J*FyOlPnM&Wq_{9#dxA@$Z^mgjTl~|bo`gYP+HOAi}_M& zlm@wS+-T1r=0$0l?#{&lvH#49jqP3z^v^~D+??YW+cKkVe#N9T_C)>bE3a8xIP)Id z2nl8wSlkavbWRlhasz&~(&=(pU{x79fL51BKN${)`x2TYdD#dIMtMn{&DdS-MdxMT zn8C)~xjB9E$xjuJ)-%C9xF|0~m-7zE%Y=Hr*Jk&Fc+{4=)dgFhb^#V780_Opky9Q%QTIEb!M!~Y>1M!D5q zXhBfgCN%-2FW2pWafY+9!D{pQV7r)u(#WkM>F&7SIh^D6y^?hR??sw;FSiL|I2m;; zKMYI$qD$9uTIRjUfp%a4>3MaTQO|L|GwONu{8V<_fg=}=nU=;z-819W)r-%0ZR%r} zry}=A&xwvS(U6Yn?NgE4uXthKss83#XB6E+NpiJ^O;rlEZ1Q^!A_nt1c@9vWL2jfJ zL_hIb4y$)%WU_g`134h-eZ{QUdY@gM#vVI#jq8n)(Thi|Q+ZL7-VG>(n|d#EKK8w=r}BNQ*w|0Od6;P9(O7X!zny~vL4ZN+Jv-I7K7eC5 zEZ=6>O#0-gqpyWa_Img4^SrnIb0UrH&`p7n9?>z3Xkx#w-ocl@s1B8(Cg2gc^jh8bA^kByUAUfO{j5bfKO%nTX zC$^=?V~1hIR7HU*Wu##pCv|ojmvzh^lSjG7=cjd?wKrw3mA4LfaPt|9o~Jd9gTWv3 zCpz33%yb3c=z#Y%`5O#AOQFqIQm1$;aih56usZ7%mk%R|^9D=e;Mfc}hAjH3=-8Ia zTVxzWH-Lbf*f{cR9*>B|_})p|>EUwG*q+13rR>{2EbXZm#%G?E#=OhjC%nHhkp6@g zfb9)=B43CuXUtUfJv(vNWUfB1* zdvZC^{M%+65Z7mConfqBWc@)9IkyHk{4aRcBmy*uUkvI%Cx1(f*T z6lqGp<#&2q%0$Jjcx`^wo9A*uZ=uKm8YSve(;TDxQoTa+a2o;lGsDXkU$!OnwSOP3 z<&695QGSU|c*rGvI#xrYVJoxwYVrdB1=h05eHN>`$}-Ut;8EhqF{PWVOKmjPQ&^wl zJ|s~el1*=S4KL2awc29KOL|2b%Q^Nc=T(>YDwE}f=rSJ@kr$K|Q%+>g?OgX_y;40l zc7GuU{13Y4>W?nDV76PU=d`mCuwEg${B(J0tw;4a{V=x=Z|7o#SDa_fv$-Ak=B~o) zLFhwx9Sdw;-i6A71jP0cb)WJQ({9wm4LsHH-A2HL;c~&E8>t_7#)5HAf7yH430M!J zK{o~diOz|_Us%3DiiPT$`g$VY>g}=lhRIIca`((h7Y}=Zve0ns)qzg_G4qF+Zm$nU zk@lLIaEJyUNd_Sz^*aYU;^P_k(2%MDw#K=XANHHE_bk)NpZ3j6aA;*&>QP*-ylTZ> zQx2zh{0DoGSXak(~A>ZzQ)8@TiEYJrq*gm4Z z5gl#~CWOPdE+L>o23ZPJd%&kS^p!PuHQQaKO-Sqv^ARW;oiUw_*O|P`I3@>>1L8X4 zI+szO<@JXaXBs=A)#5CD%Rb=7JCEiJBz-2j%vDLBL+cL-DRkte2A;*vpy%?l?&|mP z>YsT2yZZD0mGQU2!%@4v!V_E1n`+b8{g>Z(;KQr0*|#R^V9plObE3<<+B!Y&xU^vE zx6I+h?>nQXor#k;A~WQ+=76}rJH5`R-}3w#V%hVGzt`U}&r-R3u$)C6#!4a4aIw-b{bF-K zE+6E%%y;=dc8VS2#|v-zN9TaJp3)-KtC8NDd112ena@6QoROy|iDfqsN|fkwPP|@) zrAK>>Wv0{ZP#5?tVUm7u6)j;{ro!Y@ol@dewEM^F*5f|BDlffBWNF_2L_G!2}G>=ixjN(K%80 zllq&q?^+&K(gE#0KOcF*hTG7jk(Su@>}ST(<7j>|UAz~s1=g6CCI_||2gLcJ)bosb zEzcLN1HB(I=8B8*?tkLA_aA?lV!|ZZF%&!EtkL$=bNQM6>i1X=#j1;v z>2v<2m-)Ok z_wn>vOxx6PksG_t^%#H}Y5oS6Yg1!9hPWPWz1UbkRD7YmCzm<7H~aFKHD9(u{o#4y zjYnP|QvL91eH}O((#HNh(dDeHa0WVVGlw@R;f)pOx5L0kTM`C}C*aRlT(*W$(dVB? zcFD!`abE?>DOwz6;F>tT+m6qv!_vn^Krl_0a6sH=l73lOPLTI)!+P`m0?kW%unRtF zJ$*gM(bY902BbgM`=-^urStqrPKYjpiYF(y#n|V!)p|fy(EJtpfh4Qi6LtKL=if1g zks_Wgf_kD4$&G=`yWN5VqW*3I{l)q;7c9C|cUC}!TDNERgF*1Wc|p*d+U`FD_nV`k z@gC7NYWP3Y4-B6=75da(DL<|q_WF2h%b*FUQM`;ajd8Reg0D`{Dh$%Lbis`Y#{#dy797=`qpe zXO;9g>b#V!$Pp)_Ao0IKKSbuy&U7EC4kH@6I0i7yuEPOQzw57$t>1;$rm@fa9`nrA z1NPmk=3kHSha~+by8Psw*6&D@P>{H(-!g}{?w)ivS}Npk>UJ~^?c8*6oH1*$ahx$2 zpyTV0i~#?K!C-vBwHA-Rv_No^dt6o&4%cAkLJOT-OAAnKnLE-{ub z@sGxlo1y%RPMCV#(Ra5UPw!JBRxDql%X!8sUws@I>)5J<#+Af3IqyjK;W*lw6+=i-34F1Yzl<2Ws6 zaxq`;*)+Nzvk&|9jdo}k_gY`_?;$?~zW>*KSMur<`$^c&6J35f{#I-;yn5}nH&~{q z@DeC&{qw=Apq4V#Z*%EB=J-qIn|P0m#x`z8wR4oOh{?R(u^bTfw)LLadfRvxydQSV zCnMW`n7{0ZD~)g{xRz24SAan1Ht=3MyR)Y~vG%qxup;=IZF7Ng$E`*3pZ zO=G7Fxc75mEv?fco&4Z3ros4R#ef(;8G~tvM!pyQ{z})Pyre%6TV6c(rLosPdi?R% z9{uyUyjL_Xkh~CG=1mNFK`ALyrz-V+tIeq&hriYD50WgPeBt~XTD(R&?e~I9P9u54 zd+{3Yh;G0K)KS7O~l*N8=w8LDS? zhx$P-hwXje3K^1It3v< zHph`CMBa136)A7b8o7y{0_!PUEtcuz-+6iBJ*a5`CBQ$Um7!4dlIUrh%P^0g7U-<+?6V) zGPM{^-whKdxM2}Z9vF%3S$iD(Y;y+NkTUb@v=^0UW&A|n#`r^eA>z(l9h>isPo}Zp ztv?Q$|I&>M&(S;G#CM{15;tFzEO*=NcKoa#oIQev`i5DKBM2kU<@Q0&7w>6YKy3%! zQ=5S_Y)8;gIPI?EJ<&}!aSn*>gQqRFT&)GU`}4WC_ZV32{)a4AM3-|;P@fZ#E3ONs zJjop1x$eb!s{NVR@|5*-8hh!-ThINb?vJq->&i{_6w&3UOHiJ|RT8uUWvX_1JD<@VO)gy#gYY6p5zkQw)dhuRlg8hp4vg)_Fb6%$LW8jPp{NrQ9VU;8Et~{ zBvnjhDtw;&7F#iYNLw0K)k?B||LE@s^r@kB;Z_btswy^xo^(UWmf?LK*^sdHBEwb1zt#~yy z&Ng_CSKc|Jcjo3hZhl7}d=g)Y-btKNzcem;BlaWYyrbQtNYMBhuWA1XUXzU$*Q6)L z0a0IDUym(U>93`+@;?SNUireWcgS)@bUD`q^);Scks6rtBr|v?yBFn&y%}4cD%Pg4 z$!_mKxo@6!^C*Y*AXHBgU4Fa-<;l3XM%_~5)E-Y-?w88>C2~)7k=R!y8oFrErFlTQ zCqKN8XCj4-M2nZsuI4Yc&xQYtEl({VZ)({m{r+?N3B6@`BD(ziTPIJUYH6$LCBlT| ziPn@O;z-xIV*e@lPHZ`1Z>O9fqRYt2s$sLF!>Xz- zOS#*v;0q%*Z^KMmjS}!!=p(U~@o>6dl^2#s^LoGAQh`N9X%>uf&D)IhCvrTAbgJ-!+iwSQ^W4FVH) z;H6w|32J=zB3MUP~2Lx0%B+>|$@UhQ~^`Bht zR{ST8jd}col<{MK=#KRw8a%fR>p!A%qVP9Gsa3rV7OTx$W1H(zifW;y@GRL-LXOMOZ$5gvyW318)Mk`Tf$DuWGw9gB^9uL^k;L zTL+%?m{nn< z>cQCcV1EQV8yfC*u&2O5O>JN&!vgjvU@uN(>^OK?`UkLWAau9Ep@moXW$YR_wD3N7 zX&4j_ z!r0@WENe$Y*b`wrEr+qACouN(B*tE}GB#x#=d@qG5?2*P5YLy+qg3)Nt z4JqucUftN!Bf7ElIo(*V=5Fk}XS=b?Kf19mPwdW?pWB`N>-p|%-Jl-qAZHIY^4T8j z*2DK;zclZ`{@cALJFu}Qo7J-yt6bcR4LdfKUHM@uyLnM>=AOML8=c*UjoYU$`!u~D zd-%ZqTn?ZLI1kH7ZZDD6)dq?R0 z0#H5BB-8`Qce$Oww2pP$dgWQGuk(W%af9J{Ln#qmCx;wp#|l)p-!k51bJvu?nFyuT z>H_{osTQOe9Lm4&n{YjZ=>{)J;pb>ooZge2rOquF{AC)Obi^&o?zP>1di&X0e5!|t zu2IAPH1%?9coJqhybS=O1e>ph?=B9#Y+s^!c8&A25-C^W0P+#Tql-Ev8l;h-aCnc` zbe~9GVmg$b>FypJ2*P8M{to`$sJ{;ILtFiJ3hTc2(#JM}e*a_su(21Zw)3^GWNK#z zV?UGV5Zqu&;hVvZfC~=av1n7Q*a`QlE|=o9CqZ81Rj&$WqFkEWjx#aerLn8y`SIAZ^v*z z)a&+NV(ayipJBdj_Ww>iW92mGSvp+OYog0fk%V5mW2kk9_8RpC$AQ#`#eAvV#_O#$ ze?@)#D?ZcKmh)dVzNpvhem8!90j8c9zDF|aKa4e<`ruQZU(?u#f=eFG%>BQm`pS8$g?IACR{4XU5RPqwOE(py)FvL zC2EG=t{i}AXM_IW`iWSs1g23BH}F))ceDO5)(2S5*p@cK9QTu>j=nZ$LpmGhuB#b( zaWEf_nB-;z{A2%}=sG#%gy+*HdIEgar`+R$?^nY+)PAgQ#QD69kUz>=E?AN~oP(;^ zkFgndFFzSB*}cUtHVkyVhS9je{9%^81D%uMFJ}H0e*8zVYOk4zb9@d6FXBn(UndIV zk>@wte#~HNpFbn*^QJSF9;;^vO9Y%BMAyk7hw$k2B+N?WJAHPq;#c_RyY&M<6&l7c zT%Z)|K}-mF6R9lGZ+jWB9hucFoo7qshU-DNE|_y1V_Rml&0m4%b}c>p`Y~hY-gkSR zh7fy{C^tmcsNsL(dAV+z%TlUV`ls6JoK^gcLCaLtKSBFARk_zSq1NMX(7trQ&(O_< z&2?H@L12`~KWx9Yr-@Wfk!af!)6SGvD}bT-z^2|tIl}pTl%uSPAS>^#U!B@Lon;*` z?&vp$9(yo;9}Er25z#ej_!KdaRZL)3j3zV9alZ`SgG=J>xFHU zi`Ku|o5^(YFSNOL9IsNogiEHAf1#n9OD2irQGjyIT!NbF%#Q~G3l}KY(62K9TB|n*}~vwd*j|o zG=zuf8a4c%XDzoxWY%QG>sDO+oeB&s;%JM5W6a6v?7t`7@>1TnzaB7EA6O9%qK6S^ zS5a}`w^BkVjPp9y0kQdkDSue>@ByQrD9*V4yWC(dM%}jzc|lo4bPwy z!m!p7;t=)=#P%G;GSb*~g&q#;?=}H9&M&qN>&^G?G%xMJF8HYRbRaRe?U!EPt^c&? zCk-&yhmr74bPOY!(0CobLIPUovlJ_~8j$aixOLp8Xh$!qxpQrxnr_QfWdYx|6Miba z`6+Tc{Z5!+#3?;)M1ETbhWQ;0_sBQSe(2tz=bSI&COV}{Zc?}*QVUqBFE%HDr}V8Y z^OisN{5n>G1ugb_a`rOnInEW~6J#9-`>EeKqT|BDtfxTh;Pb0)WxP_UdX*&9CkPA?>xEE; z+vq}EYuZLx{H2mL%V*~{Xd_7^+WwD|L@z)OJ=9rByB0@PCnn=&70ks@4k6+?Ck8!p=ATs z-PT+K<+zmJN3`u0ef&V)iSA!7x%jh(xNg$h3UPwvDieO|z>_y&9792gHc1lZDVm6J z$RjaVr*lf^#gfctY@b9exHN1j9<%p&pZ1*Ey_;=81+`1b(RnSfWw|DlHWBy?a=7fJ z^a3Z>UFa;Jm&|Yh1Sq$6XSb{ zpn9)rdQx4^*Qn>p|E)BUwNZD+YWh%2R3;__qvXCoD?Ne=*~`0R#7Fs!`Z1=Z;l20W zcfIw?VOeKVKBBZy(~qC|;bpn~Km%&})RYqEKY34SP2e(>!X|(E&n}WZa9Diqp}5~u z=~ENkb;CuG-ow-+%!BP3HGSxtTLS5g?3e8yhoS#$*R*aX1 z^?3F8XFs=U2Ra$)Zp1zTgd& zAImvh-mCo5^7FCmmOplWh=};f;~_X~-g6nx|6|?Lb(X801_D<4)J}nQeDy4Z&-r^R z@;A9Ofby@|d$hJ~#V>=~1%9CO$m#tIjf5)KeT5ihAMdl}rPFd2G#`v}opJ@f^p)JXAURSH?q(t>FFi-)UJpEEH3oIP_-yl zV9Wf)@aX*44=P{#&KvKIW`4|Hm9u|M`BVFJh{Nsh(#Nt9?qH?Fe`O5(<9ePu?~_lu zuVH@7UzM|eP5JY1jL}YePNCgPp9=)P4KPgxL4-IR=8cG+4sZYYVDA~1T~f?E`94%R z``7e7vWkj5UL*nT1Li~n&7F2v#d#Om2xXAm2}RcJ%uxZ!$jp-#N$3 zVZMAns+|36dOstkz@%I>hl2K@MkVF}iT92ecz^fFtiM;y>W3AUbjQ3^Is4a=x8Zx; z1?NQ9>y@{Bzq)hjl7~2c=BLWpzn1(k_d>p_gud|Co=`HpUXNF+0T&?xwuiAJqw}7> zCh=FHvT<4qK7;t(Q=D|EwIs4a! z=U{)aL64cEqU-Uq4Y{vuIdMWU$Itv!Is4a!U#1@fgHBHG9Wn5H_2e}j-*xSp%-1td zRnGpk78uU3YH@ZGgTlneZ^ixm0nRzfzRnGpk;i<1wqldHzJI+6uqbu{I##6$1 zLOi%KOIw#sTy^X4(&Ikc!aSI#Drf(QJlPX-u{wMhF^LY7aOLHroHX3y*5+o_&LA%G z^VJ&grTEhT+Sdo@JsHn8j6-qHOJ}_7d2`vj+y_GE#p7(2(>bzZO56_4L01w=$xwF= znmO8oOgS!My_JtK>Ma?5^o}kM^4tHl+i@tGcY08Kw;+qmS98RJSgUePjE%}e(aWHc zVwW=?WP*=Xq6e-aKJvPT`n~Epp}AO+0esS?rK9|u({*fg{>^Th^T2T*-*z>E&>Ztu z!>GvuYcM5$?G^?=B3KnzY;G`Q89+VI(?1; zNyWW&W2Cubf+KZhUSrQS>dTDRJL&hf%sqAIwHz<=QswMlEneA$P9K)3qH9+GY=>>n zGx9Qf?z+6-wD~7CY4Ql0&V)}F+&5_3z08yE zLzT0CP48n*JlAx+F#7!rn{>;^3qI?Bl~{Gh_oK?$zoz$7o#&dBG4S3v|9_oM`Zk%S zjn^FWR^{wpOWua(nzC`x^}6Vz3(s8gRI%Q6014)&%J&ezn4W8TToj%6`GvinI-yZd zJM&`Rs+|2J>a~{7H5+2!`|GCj9vO1$N!0w&9P?G>>>rV@S-Bp=bIr88=z48D|C*dr zUVN<5`&d=JCwQvQHOcnq{AS%fdrOnX$3M&QvmRAB``1Q~RXx|NjDhDV3&*ZH;=8NQ zW**E_m9u|sd73@f6pxRt&zF8|G4`1&-dn;vn5Qad|Jv}Z>bWL4zcNqtx#rkq%}TR& zPX3j7Fi%y^{t#qva zQm;tj=O&NI>crISn`mIHuCWSVbYwg}ya)bWl%6wSPJa}IvA5scUR-!#!3y}(gsp>hA-@j2MLf^PhoHU+>*wQq( z)OmUgU<2qS&TwD?K#lPyfveH4M-fj}oC&`Ah% zI|3~_R*0G1am|@Re3*@QMNX_wf1MB+i-q{$2O)mx5hoVUi4#vB7B8kh6fZKo^~4jG z*B47aZy?eiZYZAF)kqACJ6yE*Gg0jB&|18?@hEYB;5gBsWlwNQ6_ZMH#5tQ?;+y}Q zBi^ySC?2|Mr`YuG>2XJYbXQ#0_u9k{e)pyLNf+Hz@9e-s^(URy?6A_0zisIIc4*`4 zT6qrtYv|QUN4>wXHKh^E_6j*2vnNJQ$IKIw#EGZ}mRhPY&;M+qtv*=}iPAgO(3jE>X}9tK>1vQ{bH7#03x{3=4emjv{)V#hjuaZvFTIE zx`I~*5HO`1kMlVia?0TZavZ<@Pv4S^^QJ7fj`zF<0tk}xRVEcuaA^Rg0d=?#czy9* zs}sdZ;)|D?eAW33wma%)qxy~I_-k;H);G*5aD^7`;^ho^KH?F0XPpOy_sF?HH*U{E9tGd&7uw zz#FVr0tkckR^~G5&5YOB$1WJr>8pO*IcnlX>{L1XN9C37a@gG^#rj9~IVIZolOQ(= zBN-rm^qpV;{CHgH*ON}pqPPP=e;U7-S`>YJ;48(Q;|Je*uQ@6|mQ$Frt3JO>vdqR(=VjwSEk9^*J+%vl)z|mGBQp9Qi<9f~MYu2G znFi3F+7i@0UQ>u?tN4>nz@cdSJLTJn3!^n1>tV{*(xmFvEhc?3WHpx0w~feYiosw5PT%%gBhbbY+o z@Un+qym2}-q&w!J%GqDF7lS?qqZJZVh|FWwR3i_X)3phZiZ}S5j`%8%!d`##FZW+N z?8Ti8=now6Xn-xtHKDXod9Xf^k$iq?AP3Lo{G+xr^!p44sQwT8)XkAxzqFkeT|Y+@ zjdA3jHG6=nAC{{uqv{6>$>f)K9V5I>d;(@{*Dj5Lk9XYPtxoN9M~2FW<<;kdPTE|b zJjBD}Mb`$0Q-%Ysk5fvG`a*FJTQQC|S@6{4vv+s?;R}d0$9ApC*}n>X<#D8`XoAL_<)$@2P90<~^%=e^$eSKrAJ2|j zvE}o2SyXLmj`g9+*&*&8w zli!5ze!BbYl||R*Q)3v8&N~uYmTN+3qt<&gByy0$@8Bs--4k67lA#Nu*yF|md(P=v z+bMuBxZPAfGkSfz_LbMWJ@oMf*K^dwi`c1h_K(bKsK+yz`hrz<;f|I70%CqWt~BaR zT@RGvOnIqb<+9$d-u)2$fg^scuw}U>ls1w1Rc3~dHzzo!Ie3_b2p}xxw?^S-_C4zl zuRhx|^FHrO7X~>Hzazkp5~8o)bGUQT5OE0vt$hf@Q2$kJMJ{L|IFsSTGM6H zkT(5xcPG7*qxyyViCL}*rH%ReU?dGLN|$cON1_F2kZL`BwA?net!x~`f%Y6M*SCBR zdumT%6R6+FdKTVOT0OYJIneS;U23263)c^vH+f%|aa&;@7#gthOE{gZ{1VoMb!4sq zE5C&GV&#{xF03PS4Xl8epRX3(6@I>=*A6R=Z={WnD_>Y&%-p=_f_d*?-Ik-C`MT2u zr}oG>LVr`t--EDRjV1JamF{w4(3;OiPf+L%Mn5_RvtcY-FIzS~74Zk3wualMI45f3 zl}336JH0+XJ|4k{c0Y!eX{Xt6UA~6~L}GG47v5kjkob?CADREkcN4`m?H_yKoJ&v1 zQ~9$zI{)}pZgLzKrmW!`7(hc_FCR`6Fs@zj!< zS6nW?uOfY#<)0P7^Jtt?;UkgDrM#v|;`DDDJ^SOot%fcQju=kB_4Iub%kkIXDwnHx zxr<(_UN*C0bCf4-yxm=ZFYtytrfQ#GhYMQ%atTwrJ85!AJ(~Ts9aYt{v68|3 zKa{TAhN>zoRj&Sz5{2b`kZ53k%`f{>y_|QL1O2BwMg3ju8-~Ys^EeeXKKZ|y z9TQ(OxqMx9jw^7o+zzSEwZwz??9WbZ2h%rJds2V<^SvJk+|=}W7KuaYW0pp$oc?ni zV0Qk2aR2)|$8r$l@^$ROaQRC5HXD~1f9uzSOP@~(&8wt8CpHqQobQ`HEW^S+F7)S2 z)ILYFrTHe~QxxqB3mjINiPi?_Wr``D#lb3DvLm9u|k9!3Ik{1q|8zx%SA&bVywcb9Sa9KR}O z|H|>>BSiGKaazcBQT$Z&``%NIu*(nMA~G3V zB=ZqZN9WTxdsxLqH?I4g<6}Omoc$~FAxSkY^C7j@3p7B8hw6|zn?mO?zp2jtYj)&|EqHLkIoZwYn9kt zL({Xfd|5@IFaFi?hQm8h_BAP^qImSyI17e4+!OtU zSV@J>2+lt>%rnVTG|FptV#E$+%kbIhd6`}ft9C^3(6<%|bYQuCt^u?3p|qj#Lzdh3 z8c@?mZ~0Z-cTTN60_AW1rfJ{b#lg!UfLr5sdBxk|b~)*v%0B|nD_m?#5*NSMw(RMY zJG$@!QcdAc<91k%zXn&sd4+Scf}yDPV+cIPKU`RQVGEXQAitMt5^gDDa9N%l-f?(xM3`tvT|$DY`erU_KG&@-^E`S2bh%N^nx zu<}dT0Id8H)`fLst^u?B!p|Ob1(&hv)hy>{6!s6j0A_);w={4NX+Ul#u0T7H>^}{l z{J`xJdHsX0?b|zL)VpRe=L_1$;fpSo$*eZ5&d$!iWvn^4)F79_S)#YPL6+d#01a%zj5R`zxqOzv%k(O(~dZ_wj+?iV3G z_3>jlog+JQJz?=H2PRX5n+32w#(o?<{?6q&FRjX${~f0j@vRTmET=GK7a@Mbic&I< ziWqpjusQw2uBi{LR`tMgnFAe1;t~GV$7mmApGVinoZONb>6!CBSM|a2n(+v$CIAIf z`pDy|xlPY|N(0O78x5GH&%R+&Iaaa@`gWG~hpLSfqOy_mPi=HT^;R?&%QXh-&nvM5e&E*NTQ>g!y<@jrGydG$99&9I8Qo_<&wyY6n+1-;%xg||&D-UzJ zF)*AjmfO_}6kh7OiOIJmiHqvZm@<9mwp&$REaz}}ACVWnr|{cd22N$TklVEhUmEpv zG9o2Cb={mOT3md@hJZUsypr?VPP2xKd+nB95T8CTDz?!Kx0#A9qM)fE!@@t=mZ=K z91olXU>Rb8<$**Ba3+ur&^xkhU<_~(PzZQ|O96U6cN_2k@C@)8@G(FS9sd9=K%Vpl zm0W?phUchxQS_TyoFx8x?ZY$U^B4b1_d>2AK>B65CX_Z2^=p$`?D|FW^Fwk)Nu4L%d5vD zV;Uxdp{3A*BNg?PU3|74hUdI#Uq#jr#o6M=BbL2+*=wP?0!feKxRAVhyuxb-lRe7q zF$#z8y^|WK^gn=O&d+VXHa?ee-dU3yC*Eyx<$Aho=1B`qf34$HaK!ICY+0@erHv^+dW?5vOv6G{^l6H=zP=?azFvrjOQ|0Vm4gK|s#&1Uq{BkFK<-XLJmCErm zKUL2D)!^4V8o%=IqU&$O%c<9vue*t=PR%htRnGp^;MXS_zaHO5=eOE6Kku8#)1Tz{ znV%|W|7!3%B^tjqG4R{|l>O7~U*C5*$Itv!Ir~?GU*Bl_inm7BU+x$4cJ-Tc)5c(R zua(;c*s`2?@xB`TPBr5vm)FTZL@%#b{F=V?!NL}U@`5Ec>8~gFv7CAFJ{EqV@>*+V zD=d}rTIO5vqfwt`_4Jy1ZyfagCtd$wKAhgFoc&|s>zH82I>e!6iF5p@#(fI!V1S8; zkjihlf0g5^>0ZBw@YU-7u+RQ?v;dU2KAW{IQF~5Fi$HU6=ZkY&Uvc)AayyGoUlNq7 zmzt)Zu{~wW_V_6AxXm@nQ#{l@-r>Rs?4n{ka%x#G837Yd8mF`XJY^oFZ}~p5e~O-O zuKcOp`v2SgUf<7yD^5}vly6v$zXoS|AL%YTnu!x=5n{B*M$*#UKEF-NHK9CYyjM|% zP+8w=z?0%7ebb(w1?6>KOI}TT{HqB)M!;KhbRM0p$~7@I!yH8(Z>de+4Js)r9#P`Q z*WID#_GFyHdfb8ddA!#-{{HR1V5 zz=4#B)DRz2*Ef9X)roq<{K(wC)$nb!m8; zrZpy=^0Nx zFAl!!bEJC;_`zT+0-*Ti_g54*_qk5QvDS9ReiASlpm~9c05{+PD38-(z0^Za{kc@O zlmJtJslYUV%7W>@B>=sLqKUky^M_tCl>sw=nZT96RlwE2HNdsNEZ{oedf*0NHZTXc z5x5B`2W|##0d56u18xWA0(SuPuI5hQE?_=zH*gPdFK{0a0PY7K03HM$0v-k)0UibD z8S^pVao`DHAwV5#PXSK@ivW6;_AIa%SOPo;JP*78ECpT!UIJbQ=tbeHz%pPtumX4u zcpZ2HcoTRFcpG>JSP85G-UZ$R-Un6#9{?W$Yk-e{wZO-~I$%BU3GgYf0oVv^0zLyi z2fhF{1789az*oT6z!u;e;9KB3;Co;z@B{E8unqVL_!-y^`~vI%b^^ZwzX87ke*k|1 z{{wabe*u33{{a67{0saC>;|YZhy&t*dO&@k0dN@55J&(T0gZtsKvUpwpc&8{puU|X zfZkoU1X=+{0Ih*G0F^!MfcC(Vz)`@_KnI{BkPLJJIs?Z5#{$OzU4Y|(uD}VviNHw! zy&vrc*nsXp51=Q|3+N5>0Zsw>0;d8gz-a(IXrBS}1I`5c0|S6mAPpD@qyvM13}7%Y z1jq!kfU|(JfuX=KU^p-W$Og^#Asj)Fcvr$I1e}HH-Wc+w}E$nmB1?CUEn?7ePA{4 z0q`NP2KWeA3w#W$1J(nd0G|RIfQ`T=;4|QJ;0s_g@Fh?Id02~H11QLKoKx3c@&=fcvXa+O~5`iS31<(>`1<rvQC{Q-KuV zG~jgL44@xyCeR-k0HgwGz(61!7zAVhgMlGHCXfZ31)L2G1%?5`fe}D9a1JmM$N@$H zxxi?E+7M_yUqN*!w=>4ZB?(e{nqKsV#-q?+lg&r{Ox1!&`uBv}`rf%QwITh1qkSB< zEZ2n6Ce+Rt?(k3bcqe0E0xeF1?orIU>9C<|-s{IK(}wR#cf`PB-1qlCa?-iKwNQDm zT%w>I#>k^myS)rovwn)>jrutZeiZ+#&L}T8uI`3I;W+x9+*Pw@t~i4Jz>$AFY+0@e zrA>%eaKwhDl~Imq{@^)f*mL|ll=xe~uO+bS?RYV7yO){THXmgRR8*>bcK^bn|R$GqCskIt)0>i5ll{xmy9<;8M6)bKXMtCC)9 z!#&<2j5hPq{Judg8NZ_lD10c+1RxK2Zc5`G)I<~)Uvf+1lecaEN3|1{(>b!!?wz`@ z`CzDH3SNmYO^qeJ87ad>te4~lM!htEAK7enYt#v^f7k(sV!_-ow|2PYIBNcBPS;Pv zN^G*Ly)b~*6BqZ#mP0=nv zW|)2?>gld%)AU3AelF^ktI^(h3-#c!abhkS0WVz@FD`kdp7`hb2BPC>38G2wrlMQB z7UJ5C?M2V^$BW%<&JZo07$eSUK2vn~ZH4%LK!>=b#}~v6jGq!;{_rF92H!EMLF*Qc z5=f6!c7u}k3>8Z6CW^jMg;0T>&@f4~w=Ma-ctDc4Vbg!}9@sH-bU(UrIMz4Ib!m7T z(l;OEIHx<{-4@qJ(<{`Y>6Y!Eblezd0zhS&zMEm+97qI+J(nr1a11jQZGrXxr3o2q zGC+pX1vmjX8R!o522KUe08)Vr;4B~;7!6zq6aX%O%GS$(Yk^yUdw|D)=YcnYkAZK1 zKY>QjUk9KMFcg>o%me}ewautaMC}i%-!B4g0^R`r0ZxUDOaqnyji9gdfM0Nn{x=trC}(S zauDu$(6t>lUWj&CG1`QsXv1HL_U0Ufi;CdahtSS@25r9OP|SyDgM5j$IC1tRaiZg$*uNMjcB64wgofN|G?vao10)Ce;J@eN#lt_N-s)OU z*b3{3Hy73u%m1t=ZWvr&+;ew*;s2|?n0H|VarY|ZmHvl`_g+3soSWWIl&^0n2Ky33 z{?U!ZSL+&y)ps=(S;bAnO{1HNox=|opPkoCd~!*1al_(7@kYHCVzRrXnD<93F>8Kn z@yPhL;>Ka^MdC$AiN1GrKs&0FSb5hm;)aP`#6s5z;?Ac|7VUcV5V`-?TYS+XMLcs! zKXKNXY2v|ggGKuHXN#;a&k@r`j1}o=7m3f7O%VM*c8kpGr;0asl!?n)-5_%7&lTsc zxnFF$?kRCq`YYnnr1!*SjXo294*W@U|MWjm^i_+vwpVnG+xFprxTF6Z8#k}DKklS+ zZ;o5Jby3`FzpafseBuA%%7=7}pNtmW$Rno3f4}On_@gI&8UNrJ?dqL(_n3Mgd~;X5 zWmC7*dun;l`ZK#04SM@W>(i_Sj*`4gFJ|Zunlevl3ow zzB6H9(!-4|KYe23$qQ1NOuVsu(|=EGcKE8sM>M;3R*&YH=ZsHWf84^Pv>%(dd}hH- zt;XKgt@Vf<57*s#7ToXzgE~ab)OU7dXM65*U#j;(l(N4!yt>g;e zTrMwHw4f3v+}>5kKUTOfPWXlqT?gz~UVl7Q5^%Jm_*t$ArHvXt|EIAFm{FbDy&joU zA^NF@Vp%bFJ~A8Jf%cvY#a|_7CaZK(1ObXpsrBC&>d$86=k?f=@EpeSg*Vg3vs=~G82ag8O ztq^)1+lu;#TpEC`53%C-Mp~au`NH~Q=H^8gwC#d%5FP%y@Yp#wXRGr`vYf7$U8HeJ zRj=xR{t*Pi&xz&j!@S6j)#p@-Z|d&mt@`)&-kr~Lx7)B*#wgEF3=VS?WEG%~0L$_@CVDYW3<)dS2h0{)P?RjL-8lo{PpC@H}wI zB}t;?{1XrB`p@FVG%kr8_cyRymxi~I=LJLOgVR&s%r}3pLhoD1o-Dfw>vLZn$^Aa5 zy^VIF&R@7M;bIEXZ$KF7Ahy-_}3`#*?o^?x*YT;Bt%VOX^=|IsO`4r1b;!*YvRs#jx3r+JEyG$6Pm=F@mJ+|&eSh%9#O+VVb**&Ys+=is{FzQ4mgO!D-FX>K;QLNE z-FV+-@y4H&zUIXbSFPu8S>LLh{W)H3@-{VcoFw0OSq$+Hd462Kf406nox|t&RXO`} z{Q9cnzR-Qk@$QNt-sKs)ThDs&4EpRva~!WKXMc`&AXYmsvU?|U%yPWNXGGWc#`4Xd zi5=IZbGRI@DrbL=cd#8(D|_4=twGOQV~Dpre*S~MELbvvk4Dmmem-5S$ zNzK3F@Hu`}&i)+#7{~ZQcE6o(+o12U_&$$Z8bINh<*OsN{qgWR&-_AXjA&2MHBYe@nmdHXiOBQC z{d`THZP$=TPpTihNzy5;r_S=AIJ6s*oogG^dr;3_!L{kMX~5uH25|mudydgg>03Io zRe2qevD=*^|9WPOpVN@`n7v1^9DfZi6mO<;Vj)&F$tlF=Q(kQWH+scj{B8>IlS>0A zTq?upq+I~b>w=w_k@oZK4*tb74Wi~~ABUQqLXwjsqO!yJCEGvB9QDwiWEBk?^M#LSD1shr4bk2#_qdX}d95|6+6 z>A&YSyU9++H1mw6wICl^FWEWK_40GvjXfTE_=)E@KIWs!*+0`^ zFV_29X)eDkH;(gZA=wN!RXhbY*pqgute1)yc>MV9O^xEOZg|dl!H8%dhm{jq&hhhp zRH4^lFUa1NV@%D`$(^Pz#V;-uU{S7==8*Im#z2p|l>pjVQcAaa~i?}#mtE;ldCW%LGNXuMt zdy@F>r*3CFJhQL&#b8NHe5k$6a^}H%)KQ_&jXiEBRZ(d)LFGh8dUoz@TC~!U#7!T0A+nC}{oBNsOMlJxJ0R9F>qH=8vso5IiX8Ik0xwJ9A;UwHl z32tUnGUnpO&3ulVxdk`#F>dB*+)T;<%*!|!e!~$b#@wv2WB$k@% zJ9`1j9qG!9_b>p9TbhX}&AiH6?E)8#^*bOfw5;7dzN~nJ5aeibz z6w8bbhjFMg7&<)AcY~92YDAn)?@PB7&o`ezxLCLd%nLEwnvWiNa@OQO(<=m z@Iwp4s4tn%jwpPx?@JPQzxv5F-`v$~{1D_La?FS2x-`6v!Y9|SEtD7LB=ae|FtUEi z9!L_&>&IU5@zYyuZBQnVV?Hd`rQvN9KEYYT&G{sbi_C{&`SzFQm!F?H@js4{?Ov6$ ze-u6={8;ci%*NR6m=}f5qKA{jJwNrGyxcYEug$4?jI1A)GY{TJ;iC;tqI2bR>UvRR zy;Lkn65D_K=Y@qwKC)cp!E%nD_p$J>g*z+^e3pU_nL`>td#bAvfvz2}zQiZT{D4Ez z=%jZr;Aqr~t>_ON>7_BYEZ2n6#)MC<54CI#hH={Q0flX-$32mU`r^7|fXX47mvjU8 z@VunI-+Vqz(J#t^{xmP?*u3cN+BUs=%uf8_#^+I;X^!@BqJdy}P#oI9X8fK(18up* z1$a0Nu5lh7-f7@B4e>L-8yYXpLDgyS?>Z^$AGmi{bK+mu{qCU~se=QuiMn=sBaXVh z2P^zNrvWR!MAoI1Un1-0Q1i9&OXL){@=Ij>9BRJQXTs0D6=<)KO9Ra2H6*{!ceJQ~ z@&hSHou5Vj^mg(fv?y7wOT%04g0!W(oOq)3*|Y{`KDxOxd-lZW>f-S0-fYaj=SLqH z_4I~Y=%YN^qO8NvqY94+B`)nWZOuUDy=ZcD-hEPCO9M-fdr9TZ@-Sols1k3QhYtkM zcS&8%9&fLjlZOsy@fTWOie55k5z5a+shH279Hj&0SF?WfZ#|#gb8P;cU~iv(9&J@Q zg+nf<(Bt*zm-v0q{}d-)iP=WD3NqY&Zz)!~)#m&6*+#gt&=aViAHa_FTjq|=XZW=r zZXda5?vwh}VLqyy{VVg)csL41c(dI4n!IN_O0g1G6(j>t4Ds6+B6y_ zrH_?=SUdZEZ>7(^PlHGds!AWc2DIv*NQ&D_erD-IX+yBuTze@IB1EI6553m2(j|hz z_Oh4!Jehp6@%c@iPmZWHpE}AmGV%Q@ISpw~<1AUO(vLh(nD#=8p5i?2;DxEkxYc=H z>yGRAIZKV(`fq9AP}6`~-d?(|Ypf)9a*Tr)DHMq(=vYl>xrRSJxcWK|41<%gL zUhbdQ@6Qlawf+PUfE=Fn-mY5etMiks^r>?d*D8X8tv$@;6)Q#k&vI*TX`m(=IN0(_ zO>_{;HPP~2H2+xQu+G{4HE^)!m%6g!x(avyx0pklp;>-8RBYi;xz9t}!uRamo8^~1 z8$;}&nc1(IEcOtsGc675Squ`Ax0GplcsF?bY)8f0;@zz~Cr; zde6mjO(<=Q@sGh&*AD3|n-HluSAHMG^#|{zpiB?d_a&w$#UP9|J~^nGTq9q9C>$@q zO|pHheAZ}RW!w8|bIGnL6Jp|7Z}%X5O#S?n5q(FCs}h3?Ly(R;qE*3iI!AWl2}wdT zfY@>zc5i-RhI^vZ?Fdilfthr}f71MZM^UjqJi*`oP;aq4@m{{q>KsSAKAOK8S9Q-< zuebgmd>Tl`Em6Lvc|^7%U%z|V2mkHPasIu;yW&@}mw7>dnh&#LarF5xcdxYF_h0j( zbE(cFr;kghCs?ja!`mw7!5?g=#U)Do1)izytO?m3pU;W8eDrm%ad{pf*EcklLv^*W z_c8>=w84GOT^dT&Fqx%9cUI23P=`nOxrCx0A$*C+a&Q`|jJ-m#p{ zksVLuO!GC-Vgy5-6EI6qk)yXQ1Law%2;gLnKlKIUxD{g40$7yXP}HB$eUo@DNnFw7 z=^sw7f92Xl$jK24s?S-j38hVS^^Vzt?4_7+-xvJiG=Q*V{nI#^+PK=Jm07%MdxGXe z?+nnMbVGb8&YHwqlWP!F%#On6Z*%Fmwz`cu;=OpH{QdMA*f+T}fbN&_7R^n+3*dEP z<_H8TqK~XNqHcUf;C$2JY-)3r0wMD3`K4C=Tty?HjDB;l})64n$s5xAv4o92ZJ9P#znsq~p0=S-!v_I)$mh{IKL@(g)A&HY3!Q&g?9}uzyT3s2 zJgRSZDRxM859NylEOztY$}DX?f|fhJ{Pu|cn>$mvMvlU4jxEbIp|lCEzc#3(h?eEi zXQ~_Q!2(57waNE%iLaL}KmVeOuwqeG5$4h!gsfBG&{l>qvS7*1;apKp8@z@`3Vw^76>}Y7OkD-p# zV;VKUv}%x=V|I7Jz>*0Q9Nw7iha#*h&8w1!NLmLq*1#-W$@a70t;qJ1@Me;z=(lCd z3l~gl`#IK;B1dbFko~Y+6H1%t_M@L1shr{Tr#+V+e9TeF|LK^(PCjNC?W>Z@=UB(O z2IPM09q$>RUZ6bwQ==7 zpJ(l3(}3L1U-+KUe$;Z3LTulB>5e1r%k8C~snBrw``pDC#@Yyj`&c&2g@~~ zv@zqO%R=pF>ij@ItEa@9@1O;iwW|Zza(T2u;bmq|ZJV^ZYURthpY!_*;zjnvaxGA4 zW5&zOo=nLh9NFH-eh}TRy1d!j`G2o;&){ca;@1HDST0f14o&$Y1A&G_iDkbR9#$?|zzSS^n(kkc)3jggO;T@Agl{lZQY<7ZQQpB(Wy99x!a zLTO{h$IPw_q;S2grvP|SJZS*!&C01q&+py3{YedXtMlT|YAF z$;^(v{<}-y=s#Y_?m!IzIO5$BTb64=X=BDGY)4@>a(b;$c$lTvEpNU1*}rR!9o8%u z7xAF?J2c~AmR{L*?__%SljHZIquXaluk5wa(`&(nJN`ZL!!sAF^$N>l;w7b5 zBt8}3LyqmoEWHAsf4}?2O@rrkSJI2+vG56}m&(SN&!&BBBjO{_(V!K?L~yon9mZ{MNhZ)zgRW(%#>FiRnv{-G4V1aGAo}<$srWk-j{+O#mDJr z)*iU&`ZZ(X-aL1wYF8`|5epue@{{Z;7GBvKje0YyXR>-ekr7zDe8lWv0ZRAL3U|Zu zSa^l)t14E;a=ju3UXS)2vEkJt;iOJ~QgY z%zir7f8oELw| zd(l^19OU%n+r0%^+p^G()eH5rxDR6y0_JjRgTm9yj;_th{JG%dMpq_CJjt$E9t%%1 zJBo=c0+;n#_C<6%t616S!X5F8o>J|M#=QknAaxL~{CUje*B; z)6Z!1<6~w=22!|IwxhA% zM7N`NJ+n9kDzXK4Cjj*%+U* zW_=r-&limcJaTH=rJoXKa%4x;55#g!C~eHrO|c_me}XNopumg4-8seh_|e#2>G7SB zpP5~KJ?WNf-e11T9aNXbuRgXcm#ArnX8g?TDk4dQ6acs#xCT5)FPyGs&x4!Je(;DJ zum0-~)y`Os%MH$yr(|c<;aB{X}9&3Krl&*+pK z>8a3Y$1A}rS~+lH? z@CoO8m5p({d_@d=cE0%Cs=nX#FXwSKq)%#ZvOE?(NFx{@w*X(d_2=8}(vlFEb0~^eef%|JyGs_QLX5c!ceRSs3$o+wIYLJneY=;i=tP?z}!xkCF7( z4q9Y+EId>@kuvruuRVVX*!vFzay7A zA#w;rZii?865Wn$|83rw);{lA)s9%sym)WQPqrg7r766&f)}|ofb?NzS7UqJxU|*m z4<7ljEuE>K*B)oHT$hHoX1pZ3s)CiVeK~KZk(ZjDTW@G7W_;EsL zJ8W6*e6J&vm<1*I!L&m-ivZ@A{AXl-I~uhVlXuSVJACVwmsNf&m#Arnwc>}KI90(D zwxJIDWXO76yQ=vN#e^usFgh9&8n_(;9TQMgtI9$^D*;Z=yuZTfN$IrW zLjC*km8}!R_%=>0+B?ts{l+)$zObOH_D?SpX}ku@gW}LG#BZp*)Kh|qmwbNvc&E$h zFGY1YExn|u1S2(_Qye*k&I$gUd?JY{%aGC|+`1AmtCKb}!x$&hd8%!Qy|`zO9zBYD zbonXTkrr0~TfPtRxA8uxa#H7q$T;Jw)kj@@IDa;cJ0KS)RJkU`Cc=Hha1+LM;R1DDKghZ1`XQgw4No3YJ5}^GN8C<;;)wA)eY4T=slQdwg9< zY;%1MZ%FEK4@DE!onNXD)Y`b&4h$W~N=_~m3orw%b!C`c&Y15O{cFs3X8otLmw5-x zUQ$}7+X2`0af0Q{pZ7VA{1QxRS8B_#VfH-|j|@=d}$@&qlsQW#}l# zD!^P;!<^F`1p|i+9)dvR{+;aIM*AlFasX}57Q%n->3>t4=X71r?!1;$uRW3ez!AR_ zv1Pd?lr~}e#>|bFQV)da0VQni7Y#?XBE&RYBipeQgmy^ncyhWv^y59TmG6Ipa{p9! zYU7GW;9b(HO?@f8ueyJ~ZS8~&zpL+=S*~&l-9Hsr8SVmoDyvGjZ%BtcZI&&m9|H3n zQd)>E@#6OFwkdSDuG^98M3Xz($n6bk53!uikzI%feS$v1O>BBqW+6l}E~0dxdD+Uq zl%>D*|ANG z<*az{t0bxq$_{HGu5h=X-!-9y7~1Q-MIZk6`u$(dI9&^X?3v10mg}L0x9G2j4n!!9XrB5x5Mv19$=W0%(Fr(t&G%jX*y{xC9uC zNdE-hL&U2QaRWqpMS>8Sh}4Tn6A|edh%^b2K8J_ooMg-ge7q3nb{As!X+oTzA;eDf zT+c%r+`1w~ z9J^?c7}GgNjJ&r%JpN9pIKSXlQLo@x@#xl1Mb%lul9)F z_{1ae>nEO4Z*kYJ>pjzdas6Gx7By%$_v^#vX67c$-FZag$N%ipv`3G(n~_~0$+h{} z_Evd|q&eUn%t>>+Kj3f3x`AqIKrU~Sn@28hcc47}eeo$jJ#kLLb$OTEL&cp|{!w|$ za+N^1yd8))w)(q{Sjt-~AFGbNdLm;3FLTSv~v#3SYN-J@F#d^6O4 zOYIoS&8l1zV}pF0F%5locr6}7YYA-|v`y;jxs>cw=c}_*Z5L5%?J@FYKY6cTWo<1D z>^~X^z(D2vqUT_pAK5NDvtyD`exSYV&(~P{+G{{fAJ%zoLblSXHrg{@E7yP7ZH@Jx z+CRGp_2axZPFQ(Ve#$9${M8)Q8Ptwtc~BhMX)!R`rqstOIAG%$o8`6sL1w` zcw`H4SXQUcw|{Ws`%ea6m~r{Say9lC?Il#i)W%+_Q@&WXq^4AC|7CkgJvy?zP>8+z zf3aZa=COBCKQcK=qj>ySt_h`0&|avA+J}i+FlJ)Jc#QwRxMdug6ftr?&$Nz_`D_5+ zyq~hSv^}B1nHG$bI(w+RW4S~{JB*!A$b_})sW~qs_CxPnEZbo1 z?)!ZiD6svcbdGL6&D%Vc9_ZY9@dJ35MUK+44Yn-TgwjU0A8pW{se#DjT=I^M9RCXN zTk`R-f6n{-(%bMFOmp1MW4RQyb{LG`>!?g2)V8A&RXbI~iRC}(!m{mHG*$g`%5VwW zX<3)Zc2WU5dMM+{^V9BYRIxHxQL&w{TxFo!Nshl1NO3$U_D1Ms9h~=74+UW6T;$sn)L+kp|28~zU|0UPE8%~O>kCYRU zUydAq&4!%ACd~}i`~1Aja*2v|sPjp4JB!f$W>5&{82yR>Zj91J{Z3O2ue$#^pU`zy zKB=zu!sp9&l6P`sJE5ztKJA{o4;ue5@|0i@qZ$2hn)2)mCM%vDg^fBt5J1`Mg*8SpRFL0X2O{ zzm|?`rpvmxN==_=aZuWEzKM3O{Tju=qdQF7H`x?dwhhnFv~L=WByg zA*1JrKGld;4Tqo4_&F)opv>%r<|?mlII+fOomV{#$mPlgrCd?xi&%L@3-QAEr+)f- zVM15={T!7mELUSsEAe|KI5A1h@RFkO4)2HwgD|NO-qqnV)xr3r#N*XJ-!pvwxS+qW zd{cQ8&S)VT_I`5Rs;?T)<~9qLZ!C|>W3bm=d#`iCX_ZY%{PXr1&mXoO~foQUM-Xb*fPHzG4NY9 zck0R?G8`RLek_-$X@|AoXP6C5uAfDwQIG0)PKvnG&}~;;cj-hdfzf#iA4Im)7U3n}97_@{JuR9YC(K^}}8c@^czD`1r2~e3x z-{I1}GeFM+)b^(LaAX@)L=)(kK#uqNKWn=uG+_DD8p_18yC&b{JkrO#ebbB!aB$FBx%G`0uCgYnwDYg;iv!j-pAJ(nVx{#&P! zx1I3xq{LuhK)Xzo@GMt}m`oov%07OiV+!UT^9Lt%wgsCDE|1UAD;R)kH)^K{GvR6DimpZ&|It@PQy(nDpVrjP1h*Z-|@KC*_@^r2@ycF~>(qWN<; z*1qN%P}8Rsf}&?}eox2G;uci~pRT)H<+d~>q z)2Fi(F6lm!i{>BcTFWms4XEiueOU6le$E?|77UWf$DGeNukkgpF|f{xqyaU3tokRC zw)VcCnm#mdCck6hd_wty^AzvpvW@f7-e-UC$Ec>y(YR&OH=uUKhOLj~9JGBtgy_CYNbx`!`U(}z|Rp}qsk zLj-CMP~KsXOwLR4F}y6dhc%$454GL6e3R3H(?{KN8q%|m_58Dk69>U90_5=r)c3}E zrr0RGC_k}`_T=PzBOmL&b+=XdQhyZL2yvu-DbD+5&jIk>>rS=*&Ju%YdW+^S1!W!9 zPy=fESoM1i6YZ$DWK34fwLq*onWor6Z{m*rz=o$vArjJ$s)KHOi zbeWnyR{wJyDY}Nis_A3(Ki5!^b#$4UK34mnjuc(PVAb^LgmCD2T6Na5sH%~@^IuIL zt9`I{^d4(0YWi6H&#`K5@0_QmkJbOYck~`>ENXwQ)&Cr;=3+a~`p!kylUfc8ML|Go z>r#Irzu)MBV`}>_a2Rsj{^9ou>_Kw&W0|$Dz6R9vp%7TFysv(!))jk718Vwkn(%&4 z#bbq2GYzQoG_^r6^sbiQ*H#s(m3~!e#*!Zj8c_31Yuq%~|2*b_^kC(aL%|xXdyG{B zYQCZOij;4teavI-C@eYOaK0irIoXf?lYey`g~8$Qp2Cpja+rJ$?`1#h*wR2j9oSqHz&{TK>92n+ zr&k8z#dYI5oHlw^4>~4C`Iok;ToYrHgB)2<;=+R9SR5Ryu_7}T4E5wsPRqZzgr<(d zYOLDg-~;VG2gz;eUe2+UBP!XC6Jhe$N3sFVhdK|ARo~10+!mwyKz3%=$^O=HWDTh0 z6dB13b^zNUC$ab>~lsNIr0-&pUM%>#XXQ_=F8 zjvFrLu$yTI&4emv|KK_*UPrOriz$qA{GMW3R0TIf)lKDg35_Q)b6TZm=3&X|R0C?g zLUTCM^PB2oJ#Q8+Eny~8uZ#8no(wD2IQQrC z%0Q0uaq0s`dkI_jki+A>*=dpd%+9xD zmIkV$0kyuRwwPse)zM(xo@;2IEiks5sc(hmXqeSmh>JF^)>>q)vWH)Pb-4Eto{xVJ z{OgNBg5@gP%I#*%#gA&Yz)oGN*&dfOzqFTa5Z;1d*&w&yu#VnVg%7oFiBmRSGOT_5 z!ww7J|L!T1GP@S83QP`0+zESXFS0x+4(;UrgMp5TPB-=5YHR7)=m;(N5| z%g=FY{*!{J)*L9(d+RAcwn%ouaw%x-Fshx{hI{mNa`h|sl)X@BRoROk6F+n7HbVBoc4XNL zYpC*G?qA&idm&w=1$F1ZegZJ|8;K47~c7@si8olxHLJ+6CTYZ@cP;+Y)YCm>P_jcv1dhIrHJY8LzYK?#Zf> zQkCZhvUlpMubu_vZK11>@G+{^J1BNUZi8$Zs|PvKeq*BnS2~6T-lGViF6&u zL)Vy{XC{-wmyfG+u6&(*TvZrV$>nRU+>@Jmvq{yAJp$ zitj%O9Yjh3BBIiyh{gaa*a-=}B#_W-fUqa%_KZ^spUaxyPx?a~j(NR6NQ?_@%J##C~d7j|ScEqdKrt4si*NJ(a z$=SN+x*pcejSo{_8TH}gD>ZS|AI*VPs4zHhc`jV93z5fXQeDO=RX*e3pZse(steOc zeYfZO>t+seI-2XG^t%O*)36Y)UJte&-`lVBY02PYDk;=_4_@$z*yez)fAyuemsfhZ z+gn!R{y&BT0aPP;KK=RVdQOVkpLWS zQHIc`UI?cz(sS{mm(Tg=?N0CipVTk(nRv;MgTDPWyQ3w;NeyUpZdeyir)e((XvZTP zcde}{zU(5tOUfYjQt&o5bc{r&y-pEgUcJPjm`L`~Tq92CZ;0QCRDuKKKmZ{2XVt6G z^}6!qj;eC#VVCZ+s_PYnjxuqLkbaQhaT*pP>2>6F3r)`_XN;6WOug21TCQOnNw)o zDtw||^9g{7m;6Y2UB~ay^jKd<*}roCfHd=?}7?RcKhOL8F* z5*!F|K%YnX--)irqu=bP{Fhyj_n*(6y!I1EncAW#`Z0nJm29UX>2XXyW^8WwBnm~D z`rQzJMrhg={g-i*&vt%ZgNf0=Hv0p!*M9 z-i@x`tg-F#52`-xu#Zn_r+x!l2QT@N^t+Bf6G5K?C_v^5w&`ok75fU5-aX^1=Rr+yseIB~8qZ+p2<>VF1Jx$s>MQ}ZqevaTnCEKY; z`W)HMkvH_bKIiFG2%&jBrk-;hn0hU7LdVS>NSr4)5WX(k{*&l>PJT^po7B<$=Hm|v z@9gI;ZR+49Ka!r;@pmF>v|WO3ht?SMMe=*Lyt(gp4^@xdPwE%?OuXdBLErw?7nHpC z$Z2#FWEB~}QT()JpGW6s{-%!V?cZPg@QUOgel+c-;Dt_!BhhR7K_MnK#7=U}hc;5? zhZ0MDi8#T51PAPI;fh|@d=;+OrX9-pqN92%cg?q3-g@;x`TmjkLxMMX8cDAs`9l$m z(L{VIWT9KW?Wy@hti#;DC;pJG^Cm5c^8^PH9I!bMKqPvfzByd)3z0|Nm;HN4s+016 zcwzQ+_fKV-LHrLBZ|BCjuP2Iz>;6%#L7!=tSm$YH{`BtDOEMmn`h`9dFZq$|lHtEK z$Rz3O=e55?=V$enj_QOHXDs=BR>~67jtXArlsFQ-_4r3oxLSAJh<;KtfXpKkev)uJ z5hpkh;y?fjLVG!IN{?J(?RDo+{@3!^+#CHQzU)TrYKT3Zvmb6|L?W2xw zsJ+zhm2xBDB=4URC;I2F-IERNAJGHKE}uEkk6^l?`hZ&!Ar1~C`X>%1{fUb^O?%w%!O|1IxKKdCJON_%z2zpLc$a&%My&ttiX!df1vQ@1hc&>hN{^(Z7e&%{d%S|0_6+L0dmwu^o3bhR5euK!30~-xSXP($Uzy-PGR9|S<+&@%L8z;^*t-ay z$8fvKyd~r8KV=L`8||4>l$A4vWt0MRzwmO$0Dd3gXBAIMrP~qf^WvdRQY@RBf%4c* zrkrgBzn;$N)9Su)t@`3u3sxX`Hi#TqJRF{eOUwYWL#X+HpL<~14qiY`G2`* zeN*DXm>kgk&<*XwevIX+&F)0%HUZy*+n-)M0pXs zS)t6sy}t1-{Dqr8hp~RsG6wQteSsVQNX5^&!++g^LTUk&Jz%Vx zYm_YkoR-tK<9{Lf&w4B!sNR4yz#)L~fLVYgfExg>0y?6=S%7B%6H)L_fDI`8`=&}2 zq2LiHcqIy6i-Mm+!CO)A&AVe=qK{I=1C@H=2&ImhtW@4yrLyqH+XL=U>d6n4n%Xx> zjXWVq4f!HTl^&O@rtXjbll5w<$WO3}Bs5qr*!KEDw7mN6iH2u+Tuze|dG`?D|KeD9%aZa3ve@Fw3Q$dC56V?vHhe*Im~bvardLyp+S$G$&x z(!00!oO+8hu2C0zVP+?IlMfN($XIWUPnPuYcWbxk@;-gH6gAD>8$alKPUJ& z=&WbIW_e3 zz^;IWm`7vMTrq3Dr#y6(HJ3&qjVU+ORUJ&4<2`2?|JI<}A%BnPa#IVrn%ku9^QXKz zqg^Xb01#vzAb1-aI))@7I1dP+Li2#QWQnEz5%R=({>?JM_HS#@qEB`X`MEbW^mbUkPlZSt&^8kpId1d=P(dDVM zcZ%xqP3ldj%xwFEIj#xbYOQ{IlZRGxnmEzLmn1U2e~Uq@Fp7~ z$dNg(j7ygE@i%8cbUIg|9h-WODt~M4(n`~x6MP(W);F(=i{1bjL;Ei8JDK%u&$(_l z|IIdVdw8hJ{jz5%HdmpxGS>#h_a1d$`b z+t|=CBoV=RLBr*UJ4LXHk>{Q4E^yG-zHLZq9WE9*D;*SF z&elN=*YAJy#}~}}{G#?J+vtvJ8aqfZ@p)t)xzMBW5%@-rkM+aqteB34+a zUF0gYPVJf+Q@+f$$hj_eB2yB}HHp~fz#2p%U+F`l%U8_-De9WD4*qrZz=KA~3x6VC zf;aiPgXBwu%9by9{!-7j$d|}MBsr0C6Y-AWfIeQTq0!}wHEx`^`8xNC=daD}YWEW5 zt2ewe!JAa=IQfE5#hL`5@-+a_mo;&;=cWUWA9c>akv&d++oqg8`d;wV1#e?R#|Z5S zp+e6y8t!{KRn#ID`iC77y*~m6rKszgjbHx2y9cHwVUH+-te*?s#)gg|VuRyJ2(>-* z$KgAZifyq6A?o8x>2@Q&I}%q32WpWJ`CD^XbouLkDE67Q{(REHK|^{j>SC85@+WvH zSK^Sc?P&Rn&!=u|`IE6r+H1yozMeL(`?sF!<5Bvs=<-){c#2xQcaIla&i?JX^9=bD zyvfJLlfTG5c4Nz%**-ZJ*)n6vPsBC{ba@L5k1lU2BSmH1;P&2H@<1TpVW8MM!JB+- zM0tzob8m~hiHwkTNlR?DCvm=g9H_y?99W)Bihia%#7m?RqJ1z2W5v z-o}QGjVo`leeg9PMcP+8B6|CVWu++3RrzPR|2N^;{a>=%Ao?WuP|NI8g!V<+|FO;f z_qOPdNn>N4|J!}rS}<4SD}Qu!`C2nFMGYRGHspq{&-}(k#vzD&3Eswrj*TW?fAaju zX};Cagl!M?cSBRPxIyHvc5HO{8#X3IZGI|ea8=dlPjBOkpa>#=g151uW8=x+pFcm+ zWiZs@`cnxxt;-wTU(J~iUH(>$OHto1Zu;V+=WcD$D%CDa)&ia1ZOLYiUGz+hOw~p_y`%kQ3oXs#rPIP%A1wHP5_4|7Vd|a|td(WNoBf;|;Jv6So#hxFn0x{CQ&6A_IFK1GUI_}3o zt}h>Zy1BWZO7MEyn2yjs?q~i-&xdGZ{;ff`&-qiL%hQ_N6t!yS+A%HD$6sRZs}j7) z#~mh5f1&wL!j7B09RIm4Z|kN-m$&q(DQb^9W*vR=>el};_g4wtta-=D+h1e86U$%F z^YygJmw)T|8Z=zS%k(3o%UjL#6!nU#`t^=i4n54=UnO{xk2_A@{#x@JktH)W+y8Gr zUjqh+eAOHsUA{I${yH6V=I+g#-Ez0Nze?~XKX;&f?XdZb$b>!)3eKcIalU;V(8tUC zW1`C!Yr1awq$Qnqs;)8jR|(#vX2;4`?D@-T5Fq-pdS>+YbU8Lf%}!pqTXEIYx6JvA z;NxhI{ytq|9%C}>A9B7yldJSu(dDWpKSkYosQ>L1Z{9u8oW}^>WJ?4+**>{S%x6p% z|1HmTxm#WsUG7>Iq^Jva-)YX&L2tA&=QDygnXu#KE-|k$dHi=g*WZV0KPS4}mAX?@ z`otEc3#zX9z?|0z-sHiKm%GIL#^mwe;ar!qN>6k-+WYtC;3Z??G+ zI~oVn5EjLlhi+b%_;k2Lxgsj-+kDoIgj2SwQS?$Kg}gqIQ{ot|^Y)ALEkG{<{5|sf#+bw_Ct=?TK~?-o}QGjnl69d^S>{uNTzJ zkKMk5s|Ve4$~i5j{LCNJA+UXW;3#+tsT~@peUW_wR;#xsza(~hl7GAL&3${nd09_~ zX0~T1%AtdI(7~vY+7odMVx_eJk-uTy*zFnC?UY^KIlZ>+`Ga}4-9Nq29>Lq#(6RB_ z6Wi92iZuXfpDK;rzN0ETmp486>6gv-=LF9(^$?+b^?g5Po9tdKDiiwszUcJVqJ5*5 zce~-;3(sq9zCR~;opz=hmHs&FUjPch_BF=$a-^;Ly0G99aeN%ugv&(!T2@4tzoN1f zb?DEXep}annlj&?6TDe#`mq6S2(!UGBD4MVGtjl_|>i(I?&BIDEIB z`3?hRzo_6%zBaPl)$8|di`aoQaZ_OOoe`Gbiy3lvj1aBd=LxgtbdCOhJ z&fEHb$oCsGa<(ZcIwt!<<$Rk8`_aB9aJA3x$4)7}Z* zY*Pfe;ePqQwVeDL?Ou&0C;d)|E+^F|rKtSjU;g))X;l}Qaw7OR;l8_gZVSn*+ zU0znlkQX-Pw~TkbIdiW;|1Dc;H;lHpFT8re+t|=Cl3j6?mAifQjFI~Im~(1$`DHDW z_AXws)7Z2}&2d}sAxi921bXUQcMX$eolpMLqtjIjx-Z&u>b+|Iw^P1$2$1g&3O*)X zX=6$Y@``+JS7Dm{O;pc({9Y)_Q&#FKFDTj}{wMp+`COVwPU3t!IiSnSsxzX?OZ#ek z5&yMbliR4#*^}+*N$@+*f;Y*jBgdM&h>-C6%_W6ypWC6X&rx zpxeFbbE3=3=rdE)?o};*Ui|$JqyOv33-y@u0>PU#Mw1u*^V>ExVJ6QiqOs-$@@yp` zH)c;Y?7T7h=a24_Kf1n#ad`W#*2jS^=SJ6S*0j%r!)Gq|pxbZljC~A(H>s(k*Mrh> zVf2T)=Xgpu@przbj?3^tf7~1Z$UJg&9Q5oqZvOvOW{+*>m>J8?C*vsi?V=}bw5z1B z*gdACw4!{(Lj2UCENp!w=e*eb8hGsyEqio%=k*Sb5HU&xeS+UU`fMlFjY0wd;oIgo z=z8vr$uF+&birQ7IRucd4xmf$4mub$s2|gE%d3jrQ%Vc*%Soq%0Aiu9rY1JuKDp)k zRdXKR^8#mkmesHAaTI)zFelM4`o_DeycOj-fy*`ehMpgrzVFX^{n4)7=0N91@5vk&n!=Id6iD3u|5|Eor^2J=$pP`>$Is3A*7Rh6ui(Ual`1uzg|kA z#8BJ-3XuLSy&yLKT3wfa=;R-df48+$G3javx&-f_gHglilB+!>b1dZz*V~pC#-?xC z@oy}h_IXu}d>=*lCioy>PC{z*`hx44_1n3$9GhvlHvka6Esuk)y}sMB_Qp#NY2VAK zmvnL8mEaw8FlrcGay9>`Qr8}jz9=@|z8n1BYsdb0YPo%-?RU2ZeS!}X<|L%X`1oe) z0<_odE3*sG^>%X{^p)?Oa@03tm-ZXm(!QVk+a2@?-XSX(HH^OCu!g?J?`f>Z<8JF4 z`#PP=E{@H|-Ctfc<*EmhelW*b!3PO+5)tT(w60#iOgiPPMlAA}b4hGEk6ChS+pYJ0 zz0n+h1;4}Tj4&p%j#V1n>eASBx4Gr}m-C)Fs<}BX3x3Db9U7}mdRN6k?~%=FPn!Nv z<+bK`E%+TzZ}=Fl^EZE4Z2lgp&KN#((24EM@mugap5E{=U6vHAP{+Hu_;`?}qI z_LU*OLGVJa#8T_F^Ecd=Sc8ItHV?zYXB%A(&;DtVk8%}4qzo65%E)M#h@%v_8R`b+t zroSL~p-bY1(--a^==7BaV)JkP=`(ISvuf!|(?1Zr&?Rxh=?nJy=B)@m}ykm&6UHPwogG-*tPqH4ZxcZSO5DnP0n?Ilc>C=#yA#)yALb z_Rty6b^ZmekIlblHr#N`rT6^sKXW`6ywD?Y!|9Sc!pH9b3KTgUc0+7BUzk+<(BoT9 zaNb-Fjo*S7`XrWGB@>(Qn-=so$~2m5r$etd{IUJG96lz7|e4Ij64I%{r@&DUMLo1Z%B@pg6AxS^W^L9x_+12Hgg(f z1sTUpyyR~?osq|Lov$@3V)Hd`^Ba9@M!t58Ii3q%=#+Td=?x#(b-oV!Pi#6*%U`gz z|Ne82FvoSl3w;uAJDqZ8`1l?`!D3HqYU5LU_S6~Y zb$-^|5}TjvC%yF57h`J9HOG0u3tbX#JAHCz_;|0&>Cjta)9YLC_BBHvnCkpVIW*o2 zUg(rqYHc__!^eGnJ!EqnbbkGP`Ko5mK5~>f?h9V%lX%B`vr?bYSp z?;c#d`;r44!f3a4#(JdS9ds~?KsQkKGaO!21CaXFZL#amT{3S@zf-^6&#YhY!HS(k zg!&_`cLizkYxMZzpl8dXq-U@ArQMSzJ%W#e9{T6O`m442TizaQ^Y2VP*ZtIzXh6qI`wy2?G? z61gvcgviOzRk8WsRa8g+iHjf1|=9)16W zpLaj0l}VrAg)WIB&_}tcmmYndnSV!Yel=M+@4)je>fFqvNAN<2#1ZJx<)~h|{3t;B zu{I96X8iAhn$HfNk~hn#m~zGaAcA+$!6*VowVU>P@5G#nILU4oB;F3L|GI&?X%iGz-Fcgfo8h>E1| zO*#Z02OYZH)S*Z3uYPyO=F6SCEp5K&%%#VgMxbtu%)n_@SZM(ej;X_ZrZ{@`avA_T`73cMN`H_$0?G4AEoaQH&LG z+`idf-+Wg|LC~~JDRcYsDoSW^Cb;K&eO0-xg>K&jZ=ric38^Z?Jq6g;WZfUYQRvIR zKQ?_UPMEv(v+q2=TQ}n%{4(*9ADzD8u5!Gh6^%fBoZkfcV)f^HN59*2udAMvVJAqR zi4W4}^Uj7@PRsHXX1UACecq}Z8#CMuzPfXZD#{DJi%P=gU6l`nkE@#?RD)1p%OjP# ze(jhgEc@g=Cf|AVNR^m#4VG=gxqD%`YvtH}9da06^%>c_=pD%HA)X zb?$`B0-;0bH1U!jH=UM|m}im~=GSfjeGC}@*4w_XEoYnhE49^g!llg1KBL>RPx{^P z3)2ijpNY3~l^TN=wJP0(S;H}fE-80cmWzO8RrvG?q%L1Y4~N?Yt`)Wc41*W+diMMI zEW7mU_5BZ=TQQVr2BE{m+qp`O_LM>5tI{%y-7ep7pLbCi>{XVl+?AH+Dw{{&5nU&= z;U+&o`fZaz4{bW%OA73&)WGAWyo#i{tWVAZ>z7`>(5AztCka#up4aHX(fTyU2*5+j zo;^FS$W5{GVdrNhE|&V$qv8CBRR4QFowwl9oBG`fi!#Niy!Ymtqn8F6L1^KYLK_VV{YQLw#rl zXaQ&i;A=kZ0i6Kd0DA!j0x|$o0X_f?3I~W*C}<|&Wk3-MOoxCUgaR)`fpbvc3n=g> z6u2M$vHWOfrF!n6)F-e_ukWwak0X>?akNr*FIMV=>+qh@>q>3zmZWm4lGH8VB&pjj zPF6#Uo2bdvP1PByxq9&H7HZLHtyR~}Z58>2R|~E2vl?`WzSV-SASGxA*&ge8#V$&{ z+wIGDajH7yo%iYcPkd3pb~Et$rZ@`TLTU%{72vQo&+VJQztug_UvIpyFOuqlA6IN@pSS-a_B{jZZ-%4bEu?k`)t@yuYv90< zZnWMpKh{-#9HsvJC&JrLdE#%jtM`OGZ@P1LB-MMJ&w2XWBllg!G=t5Dq&j#z*OqU) z{Z{=PxjmQ^FNWbQt0*oHv%4FN`cqK|Fz&KLBZ~WxzfnVRGl!=#ot6q=KT~Hoe8S$2+Wy5m=`^y|1fVWnI8-)Lx z;-I7Vpq}l1J9+6bQjgGK;w3*a9iv^o!bNbv>(Zn5hguunA3abgR8ZwVouYPaz1H%} z7R?&+`VVOzKWECJ;Dru}NzWKKWW}ROD=@M2xXWx=4B!ItA(ovNnP`dY#XizUquqyP z#WN?R+5tpoJ0i`|N^}TjT)~{GE&#Yu3R7gY8-QcQ?f{s0e8*dI_?KDE!Pll^Hr`$ z#0d`kH8`*gWQcuAe=%HdyFZd_%}Z*&!hV7a?|6k2FUz=WO5gd5AIx^hr(E;>V!=D; zU}U`#Sy4(KI&HkyRhWl~iA+>7@hpSSH1fO{%t9U=O-0!I4Qu0|>-hPf1?siU-iJ3j>ky{<8`EEk&963Bj@)@%=@Hi*Y|th6AVE$d zB3+q9SggXjt*0)l{J2m0&;N3W9{P7Rn4FQB8$jn{ElcJisXjhu?dqo<@ISFPPY}o_ z{!c{k7E(K~-vGhhu{(^NI2E%vyzhYmSikOfugN6?!Fm;mqsE(SaT z_!7_^275Z-62O~)y)c$k0$z3IwJVxp?*$rnD_}Sp_zB=Dj9;_iOl4tkJ*YMObvRQC z;7r{QXKF7vQun}-@?vnC3J0nb&eNk^uoef0sRtaT!+R*TvbR!;`YCneJ{YG5DmCpu zrM@`?^$Z8Sqm^2kgZcGzrG9n6&ni}G#3ImlvQqn=uhf75%3r0_w~r~+`E{kne~CGF zvm~{?dy-myc#_rs;(z(kc99eHN^C!5`H?xl-}%62y}=eMFs2_Qcn2MfpeSjheD*XU z(^XI;&k*E-QY57Q(m3iLwcfj>$A|MXXZtvJb zo>_DDi#M+8=@iH~2@)uH2OW$of5cw&wwL6l;uUq+GG}4l#$^;2dmVF9fiFC`3xmtc zVe7Zc;-K%@{WmX9TX^L=W`77iNSKqD;4bvIu$Q`w+f<9)ShIB(PW2SJy;)eOEOe)h z9(16kzty;2`lb7;vHA4UNlRzVd#}hP^+~^&c*&204r@NH)3H1bI_7_|@2ou^x#2vi zN9Zu|k{^qXsW}H(m+Ew+uaC`-1sy(nvdyStp}BStI!wIe$D$)+s$G;HH%Py%0v#+j z1Hf43V)}YU|1Q^ecy7tuBZv0G1qfYWv)bY)cpDo!QeSNG9W$TLljzT5Wj&%lpS~fy ze%fR#P0bstZHB$0~wstg#W53D#gLE=< zCb5YSHwXN`gYf(l?VJ`lVK$+C(*%}8uufF@;b0ZcHp&Micp-1oz zIvB;ICu7bWpL-658&VVQ$FF`fI)7@AU-D+pm)mu`HBacNfI~<-BKRO7PC}$?gRecxYdSO$OGMGu&(TZ#n9bI`ujNI1xFV{#JDQdEbpE?{&(# z9X39}Gz019(ZmzW5R?8KPo=wff_EVVU?e^d1usKuMfm&H>h0L{sS7_m=D$byf3Ry0 z(P!c%zajK-3@P+^OC!-4K!L)?Kpb@5(pDXrkv;QJp+op+;w3*Ool{EO^JlpW;ey#8 zAmAON_tkmf1@=o}8C*zF%-1vdg1*dndoqV6vFZ7vs$=B)2^cH)4qg?YVFv#ip zI{H11NFh7Nb+bV@9|jNU=c#KJEC*c&S3jA*VcOR6-cN9)*6u&*hu|%wcF^mss~@5& z?kQ!?Jpm|zZuhjJ;!1M(pAYx~@Xqs<3!vjEgRXW0*_L}&;H{J2>3 zsObH0c`^4Ft%W>w|90f0I}iJH{6V?410wcR@Mhh*yvTUNAtr57g{u%k5=}nP#nw1& z+EJcM9_wRT!g!pV*wUWk?*|gQBV#OX;DgCSG2iYl7bfDkIIs*?iF^b$MwbuuL5i9) z=J3zgweFw)>M?e&lsV(A;LS?wm5=O#g5nBm2At_CF5rVo&W5?%XB81mZuC0n%kz0u zI)HW}6EGQYDPTI}q6%c*3^_Rv7xsdDaNog0z`u?BD*#v`vGytOKF(3P1IPuIiQ5z| z4U<2dS~%kW%|RcBR(%|jo4{#FYH7B;KPCOc6jkf~@wN6JrKqp&UYV0}`>r(~zTF2a zS4xT82;Ssny>gR*N4l7R@=0nT>aaVK)bO=Q%3qtLTK<%z zK2J?nhYn0uJ7*`WijrhieO|IU`p#t4`t@XW%dg35MxQ2X;G`xh=fo!J)s;=ud+#+- z7o;{-9mh9Sr=HeSr99D8ecZH}8Zf4r>TrHD^~~GN)M=Q=`u)w-<_*nN%7HCZ|79&y z#qTZD;l(Z0OYgQ+3#YYGr@hunO*^`^%KEgmy6uEE>Ze_IQWrhEllpRATXlTToz=r1 z?5u{YY^TajYOk6Ubg=k{p?V417l6Q-Vqq_q2OY4QxtL>uxA|eEGM#oib=#sDAo| zg4gS2TCXz8+Gio(=9f(t&Xy<8MCY&;_n7)fTIlal1~G(N&zEUuA;#7of{uvED^7v9 zH=rkgHhn+95Wq0NH~^Nn)f_+-;9S5>fX4tE0j<%TA%J24H_c#cm>Lb6e=DE|4Elcn zV=)di2QeQ2HiDq`AZ7v9<97xzU+;uEu@3(T7Jb%Yv1bY<@+aZ}!_hr#KGvs?REvLe*um@EfxAm0Ncg;$P*cBkhI1Z#ta}o5w?K?`uJ4(MMxjW zPt)&R2Yq>?dFIs}KRo^6m05OWGCm33Bq3ZMtW92NBjLo9yG!&LW2U#lejy@~{f4Ni z^B{BYK=yv703^bn#sS?APX99cx=2gp4;pyJs8i;DRQVYnHX+^JufpZM&bk2T@0>Q{{o37z zE-5LtOQ0V``!9GYS7LkpldZs8Em(ZV?mlY`Ad+0mJ=+sg9XKv(K`M( zP>E0v2XwjavN_x@!SIAVyjWAhp!?w9eJ`km+$?Fc?6xzWeCMwH@VuE}3zm&27lOC3 zp<@)e4oY(dK2<-bgxlMO3_buQ3Wpk3$e!^GRUQT?18mydghxpHp*(rS3c?AdN#mWvO>!PjE^}648DQcICk7{xH% zv4=s}6M7x8BPL&W4beR(^JHt{0_FZ4(p zg)Ym+SdWp*oH z2IM>xuo?xdLIKC2fCVUEXEeFVZdmW>gLjLu$MM_oSVx(UXM>kxuJx8uPal}1&RdUVEmmI&RKTwdlKSb=iysYSHZh z_2M%d)y7YUCy|eIZ9z`N^;P1d1-4%g;#&|;J`l)<=9uX3iI{zM1Yi{|JQrK_NsCeGt5j4IR0^j4w&cyFj*wZ~xz|%>HC6o=;`__%4;th0mfn zpF|sqBJ}aM0~d7=W>E>E1YN&Ne~rH0z+zsSKX=rzzVo?!Xa#E;14%LQlF#`%w=9%n zD|p46A}r3%@ww(_a;L4abIHD=8j;Mami-=XZ_M?Bt)TbRw>pmP^GNaw|J{w;w`H62 zM8R7~?Lhtp-^aAq4`_ls_H#cz_OrJX1kj;6KeZwnHA&qiaIYWrkliPC4at9`PO)7L z4Sw7pa?-`x4QcBk*HpV-+robTV>I5`UU+yd%l6%s-S$ViN%hMbZCxV7#{peVike23leLhe zmrs5*eev<0vqo~jMi4m>yp0VVBg={9HR)oqO>)A1=6FV1L_5UspS~4AWI$q|>V#-{ zbuRvwBP!8;v1k6~(dDETa&-2i%lBQnuAp1Dhd5f;z8dX`;4P$fu-DDUdrIaxL$I@R z?#~+Mgf!Y30&S1jB+5-fcEAJ#KS1Ony>(r=C`7)zpR8J>s-mGUK2`hV702wo!uHge zPq`30PQwE2$7EL-oJsoy8-BTQzB|u55}TrmaOEHIUUC>gahy=%MLsx&@tpEQ`_vA= zbxw|B1mbv&9^`&ob3!>%CNWGiU%ywb*RSKX3_6Z!IhWYHhUba!&*Oj}O%i?G0DYy* zWB@1!B2U5hKahXVtEc?*OF@elpK|7FpChKe3LdwG1?p>_&s9=}CqC9J3Lh6J$5-L- ze4nab=Q%C?T`5~HNcT%r+i<($|Gxt*|9G7r`&-67m7d=wRjt^2%M}kS`u)v$2T`N! zGD)Z4Eu?m+ODFA0t_R<791nAYZ#dc)2f!HeOWr%$2Wa{iO5@#{S;b0-Y>e(G;us<8bw&Z@~PisJ%M?;zT@;?AN2Ks^mftZqy}iA5jr+u3+0-dy z->C=w!|iplqLfti)4NxFH##*{{jX>0l(wC}xp~Ou{j3^gJzMZ58Ju@!SCp4llsj*6 zrR8Gjx3Ho(_zg09B3g?ZNr%2~o-|O`sDsoy+Heo)vi0P8`>rywL9MBD`; zuw`Cd2_p7{qVEd(at$_=JdgGLhhbzc-wXA?iFtf~n}0B6OHkD|t-tWTcmnO$v4AdU zLmp^v37TDiBLEA~4i9jf_iv3|dl0sI)}t&*A|6MzNQ}x`xY%|B_|ayeW`{_xSU_yCncQ zx_IEO19olOeUCBFLk9LG{TsnsNbNv5vEOSDS>fwwSv>oLA#ZOV&QRJ}>cGz0aT zx*RFUHIecXxcE5`z@;KD{%+Cbr55t^!jb=Z@vaNb-||jZy9dOs2;QtYvb@-$g3l{h zpC6YWIN((^euOkkf}+U}{n&3o#s~zqPK$+%v%&|cab_;Y& zBHd69_;G{CPkQ%o`588DyfvrVd|+Eu(D$R4)$XaPVAb3G_I|zNsl!K3x2j@4(cTE& zLTU%T&t-jE0!uUV(%`KPuPCe1B;>ES{;QGS=t;^jfif<>DE&~%x~w_TPojA@LGIOU ztl)5YBK!k6P>nW;zHaUnzW%WmdCve=LyylJe%nko|Gabd+4}s(0_$B&p3~m*XyS=w z;CyPN8>^`HmLU9J!drqrq~h%^eiOuA7~yrY9-_~uD0||&bL^)Ki%e6#DcAJ#Vd@+0 zyUIOLb}vA0z+QkpfWCl!0FEbn0|o#vg;M(h(g2)krUM27xNn2=yZr%N-@%qV>z&M@ zhz|lB3^)Y9`5)&wn8I3n-G(8~01O9Y0Ui zz+^x!AP+DFFcm->OKUp=a3p}8$$8c>0M5(U(fI%uU>2YNPzZ1XW&`E`iU1zKT);d) zF$pEB7hT6KVT`~B*4jlQvjy| zP6M0{s0N$?I1_Ld;B3G-fO7%o0crr}11w)+W@x%Rsrq++zGe~a5vx{z`cO~ z0#*a=1KbaI0PrB-A;80cM*wR8j{+V8JPvpQ@Fd_Vz|(-W01T5$$OqBit$k8)X3I@8 z#5uTe5aP<-sp|7l$NW5fuT=H?L1VwI=)CI6rn8$T@mlfM1W%kEf?mD$T`az!l;`F9 zJkCRT+)xW39lHLKhUS14fR=#PfSmyC0389H0lNWu0Qvz20uBL;22e&RUz7#*5qY!` zkOHdtP0@=0p8+N(E42>bX<~n;0-qO9olt2$D&2xgH=xo!ZIMQ$Q&J$4yFgC6fhRq& z2GSq>1qPKL2KgEbT{sf*10jAL!j^Ka%|G%O)i&yS2+KDEdy=wTi8c;H`+R8MF95z9 z{RHBc!2N)H%KXuQOu(*y?tmVEJpp?F&|GVMw>@I=d}jdrp$%XF;GYtx@1h6&`bXD; z>b|M!*psSe9ra2|-{U&JX0br@K=3ACqUb^R`k-@Tw0VkI_V%2!KTiW-Ter%9Oz?gA zvmhTIBOV4>nTzyhBe?WA3Sp#`GXU%6Do=W?0%bu-hl|pt?@D@@#M3NWGU1Tx2(6*uQj;s$+;|E}{ zskElC z_A~pJ^1!$gfE?j@2LNpc>takCW9Boajo~%4^SqaMvGu%%bn=>iN(i7KA~%73qsxuj zCsloY=ykrNV@Eua?8>rOAa+LZCST%{n=E%JehLA%8lPM&^A<037s^O%%FpZQ+!l}p z`Xaf2Nr0Y!?f~{1#|*Y&FTn0j%yEI^Fex4mm;lHGV3@RgTjq0Ip`36WVSlrqX(uQL zv>lWMf{Zo9QFeF@@8LPqq=9k*5w@JH!5FzY=h%)xVS-+-k{?^gUzNOF2N%mVB^& z-oxvO<295i;(5Ow^Il#fWgz*F2sLPh$WI_We7;WJkPiVUHUGO*hJb->LF#H zc9b@gy2Vy;PDTCP4Zv}?2cS2gA7CHAK)`_j>f~_17{DX|rasmj-;4M-KsDeJz)gVF zfad_UfUN*Nhu#m64e$Xj13UpBA7#Fz_p=%tE~liEHeLU&`hhQ9x3MB{^yO?PgRRTS zO7J!|bYwqIbI+>tr#L?@k$&!eKzKi!&qe*9YvWYU(KLj7D(N3}6 z@coRF-B1SWe=Bg`>ex@}1N({gj(tiUC9r*9R~X>b!ZVgUrWtr{^TbYD$i$(+9MJ7& z&X92VF!zzJg8cY?8r=P({%?Q&WY6=hxfKFlqF_|Y)TYPs9KGk}iO?Wb9u zoSX6>cr)g842&sf5(F>jjA=(0sB@G}2Fe)i4Q&n6dY~--+kzhr7JIS|@ z04{A>!M5iu>)<6nLj6=2FTdH%;0FZTe^7Y)Bh^2&U+tMY_u1t!-pe5Mn|M1nBLAKG zZ4Ol9LaBd49QFTv(2+wASX{uN+X_;@iI@EP+n+X(|K})nF4XDBKR7lY+V<>pcArm% zza;et9VTA#W76RWgignrBSQ9*;~T#VP>6UF=zF=%tDR~NO;t0;EgpB|6|SXT$Cz-w z$?;Y2QoqEcLl#MVS+mR1Y^BJpD6?j~);P;+`3(g2i|#*>2Kq(f6Qv+cf2b>fzECef ze*k^fp@0m)cmQqsYyj6t&IDWwcmTlllivXSP#3?6TmyIoum{?*2=FdoDvaz0fKy=z zGSTbZF)8T*13DfIUk)RB7=$zx4!}@Ma_{W`e-$^9c$Mxs!4Fn4uscv z*&$fV9RYtU2Wxi6V7@*d{w`LZJ6?qO)~#6ATMHlUQ#_++m!x((G)cYh#h;UIO;Q>`>T&ocl8^qdQ6!VVx_$C< zX;tO!AM6H;-U{AiLqxrG93^}@98*eHRZw|xv#Gykd7_gt{&HNFwB+#~NlR>&6YZSk z@je36J0h5LnCCm9jzk&%J`OBHlVzT#Mu*R@=#Rp^56<(~LBHSYu{H0y-+ny{F1;1{ z;>dZ8;2m@@(x1!J{XbOb)j<1OcA@Y6a;`$UWPP3U8L2Z^xR%h{F?4Lm4pC3c{r=0) z&f)`ZIB)+`KP$MC3qA}cQegki%+XMcsm#K zWZAbJdJ;kGz(viPa9J*+lwE?731sicyonA=!9J4>-^Y&`Z<0HKbWRXknbWO ziRUE;?~$d>d4_2Qso%ugx!B|8c9r7GHnTm&{29rZ66Y@<_&S1XR*ADS%6^>vie)*z`1?bnthRejYkpbcb;gR!0OcbVzJ3v*dWa#c5MYO59Xqm#=D? zYn~fFmCy9z>wP8VnMI!B!ZiFg);$Lw$FslR;70+{PdO99<%TlBH5qOec(>b^?`{U& zA3uD~^J}Ls_?FL*7#1U@-4wiy4IL*=8j&_RFE1^7RvB1f|1#cN;Ui0|kdLEoANO#| z9S1y<&S@~sXE6;4I^Q>;eX-=A_jMf>uUy@Foz!91pQKE@FRs-;RQ2JeHE)rcHnr%QO(5Lx!6bS z@VyRQBT5SMyf{QAOZicN$U`6}hTdjlf6SoUF8bxj{~La`W6U|;Q62;@^hhjpWtWV| z%;R8GQEmx^ezRmUUck z4WNr51Hkr2^0Qmt_E^&&KY3@D2OJ@1v`$&BGtH|!vF=f`)H~U(>A9JRM`@7~mX)EZQc+n}7Kl-$$ z>IG&ZUhjCD?*3;B_o8YH>J0C6WSX~k6!5d!7;a_SnjD+Cfmzan|P_Pp7!F0@|>9A z0eHD*p*zP_UW6|S>n*NC0V22gGh)l_0V7xW5A~hJN4i#6=p0SFldUYevT}001@qkH z(>x`3Z_(QF=*I<8Zwx&?1mAasj-T0cY37Ni3xN2lA5@~D&gcq!+4 z*?PW?Po#G&2dYt=$VdLMA^BkUo8!P5$j_5oON)Z9cbrb?v_ZrktFOa!CUr5&nD*=zdjAesnq63^_`^yyo*$hJClez7p>gJ8~j; zvqiKc0Iq#$qJeR6K?S^Z_~UN;jiIz6Xjx2onTGN?hZngt%TLIW$&toA*ZqegSNM1- z^XnWu40z?Sm-gs~{C&@Tule#1``>hx(@}FBc@exxZAQ)*{L0zOUz=xG%VStr<+l4U zoc*t7eAcbN>uhgO!%&bu9j$b`6^qy&Gs7_^BrEAO0273^ogs>fr5M>}m7NFD-W4o=rxnwX|I3!RNf~SJ|vrBdkkxI&uoa z`Ab(v_p^9I)=pn0Z+d&hO!^B9q$3$e!COe}VA3%LuhUhIxpw!QxRx6k@$<8Ye~GIk{?!Lv*~M5H4)J#tTQmlt_Sh)zd-VYuBj-)ms` z!|ph4=D?j>2bZj*UrfBv5|Ivk^Nn9?#xyLugfw9?rqi*>pd)}ijuz9fr(xyHM>ewT z=gvvF_WLIepDXnU9VTA#O*$+|;a^OG6xdhlbdI+3PyF#J-S@ogk-z=QVmT>9GE*!Ut7eOJbED z7fbyCPdFd=K7-XCeUjD1|ChF~batv*zuWW{zw{aQygUeKiTmld30|+8Y4PiGtDvOw z^RQVA3;&+t3ZL5^f+OuSVVkHMHji0KD2RTBFyX04_k>@OI7@Kg@5=!{NEdz0nIBzW zyU$HkSAWu~>#3J^>uKt%;7v}5zB=!Phv_P>P3Wu1vBY_T1NC!2UuSGz67Gj`p2=s# z)jjdetT$fRcP;ce^|jS+UF7oIAp4v69UhLaf;Ve2^feRC=NzxE%K8S9?#J`_Bgbla zCT*5e-?<+dVsC0de^Z=i)ORuPyPmRW|Nws z*c~zJ58U+ed8<&rUOvnAJNbMcd|heC9!6T1O!ua$8%8gkH00=Im%Q%~)&=*Izk^nf20lp`Rjcmvg;fJzvKs(mR#|x}U#nLAd^z>j%@3 z|LKYsmmk{Xx|*>L8IPh9DIbD2siS;k6ytYNCDxM$XTKHqp@kl{@Sb4+T}~FET&aWk zvBD}`AbPl|EF|ZYG5!OR&$(LSC64RYj#)C=m#Uulp>5f(<-@C=q2eQyIPDO;jSU^y zj=X|W`*{VoagF!zmlJs8=bi67X0!K2;K3UnZ)Fr0dkd_GZ`kft;NnKjJg=l!s;L*0 zcLCBYKpbrfW7;RCUk0!}X@Ks4MA-2h(DkCUJX|l>2j==n`JqP)XmQvp*S*b-Ltu+TyTvwdvOm09IsFD=v{ta3H|}a6s4F zRnS}NN(O*&B>U02^4*dj_d9n5vaLY9rS_V53yp*5Ev$y7s%aVJSVbx=kG#)2y(+eU zy7~F+11cw7zWF^4I0)hoZ*lN8Hgps^ocXZrpN_;I-JDChBNqQO2lY$&^nY2lzRq8L zT)2Ic=jJt7{jRz2j#oC}{t4Ho47h6bX%jwk=%$%D;3Z#|8!pP`E-aWey1cwp*EUPoof~w0UkiHJ|Dx|qb3B&! z83M>(IqTimJ{bS;0DfbG0bBSjITpNy)D9*+*uZ1$n#wG3&38}6#z~*OagzF=`_X)+ zBz0)Th1n;+KV0ujzar-Z{FkzLzgr-kdQ>EG5upGW&2`tF<; zU+8y_Gf;7zoBplf^|F~3eI1>bmy?@2H4{6z=nGh`3buheUharWY?Uvc=*3=VEFU|* zI=x+H_z;(rJ72;IpkCd7U>zhy))RP6eHS2}X$JE;;`IA?o(S8=f#tYe?El*8= z^i=iQ_)%9+JN%oK>{kYnC&Am;&~ZEEDWkB^XT3uiNsd^Hj1>+!);VQ_K09Nz|FYa5aTN!dBc$2E_l%vU9J7<}z0j53D z?G3LXNd&=Dmc-vd(h8utZ#XyHPMPz|<={`(r_P@G z?ZKzI@wq)K@UaZXJ;B@9&{5j&jAh2GGV(r*(A{=QWI*sdr#y%pIiv*T%e-Fh6PqUI zi8#T5zZ(bqAXxO(e_r(UtLey}6}Y+hg->4fVoRzOL|+B(po5XP1h1FPH0i{1 zUObb-M>@(KQq#s`+X!}0%Q`Wx3xGh~e$u9k9gvviMGI_WO910U*s&bY*N2NP4#^35 zy{2y~Yu|3aeVeF2ZI50MK5``r1gBW{)U_<^tB<} zN?iMAa6lh#mqTAU|IUa)$cUwv7Ti8%z|+|$G{2bp046yD(MShx-b#ISz8zt`qT^1> zEiJ6#mb=-rJp~yhCEoDwRCPxIv>)6TyB73FeWN-*nZ)Ozdj2LY|CDFeB$E_9zvbnj z`=@^KcoXi4)${vl`6VqoHXncj^!(9Ue%JSIZ%(_Q^GjV3-QV7T`yc+Q&yW#!UC~7N zl#e<%KNdWS3=8$}3y+N>v&{6r>3d6EdcpdBjiLP5K0*cn~sJ)=tYVvCpj!m}ENNYqP$|D|ZG!fbNfv!#Urj zq#TkqvBkWe=ZWyga=?%3WIS(wb@+N1=Rll4$@ec;L#__H{;TBY0+}nDGXtRjokn>V zyp0VVDL1mu*o}`pmU|1l#Z$`g+OmDkbVRy*P&Q}>L^gPp$jFEW2#7u(-5jG`%aDK6 zsgIrb{xj!z_#Bo&p2rH_#)gjdw`-KwJEz!bUES}~a6WAA`;cZy9IB=Mlpk5rZ`FbD zejA3o3_$5M`2Th9_fJ7mEz4bf`m1lf^$zu%fpHR!g151uqv$)<1=7%Ml~vrjraf=& zg8Ny&{vQ$+&A#FshWgF5OZrG0M?{vS{qjyV|5-wt#&rs=Z*~Nv0BFIu*3I=+_62P_ z*9f`-@Cy;^pS`;y=KoFju1R-54?s^qFF-3^A{ZRd{g0aK!}XfHCLiTHOVg3x`l|nY zR=TzG%yXS`M1BNs6mPAgMUbC~c>4-pCc`HI#YQ_fQtowm>BCM$=nkOV)ED%2biX0I z9U>?C_XE~kKelXe%hj2teGP*HJ@$Y>AN$)M zzjrel83eYQdMS7t8#>lQkL?qO94A{PM-Qx{htHrW+Bx>I!{V^DAma7FYa(68YlOd) z73v}FFNbU5^?O8bfldU21IutOcD#Cdba~kXd78HKDUUQ;IJLPcFM>CUuTKx_lb5tH zISV-?CFI6roWvh`~?ULT!@-xN$KnOEXnRHD=dOjvaPNXkpZ2@WJUP?rNGh9RL}nh1X` z2ROIj{67&A97u2=!GQz^5*$cyAi;qI2NE1ea3H~f1PA_o9H>N-<@ra^qoH-|Nc;KM zVm+=^=Zx2%yz%*SPdeUS0F>{%3*O`)*W375j1R=}yw-1$hU2f`b=Ir-d|#FnCFYtk z1J}ysnJAYP_`FM=abaoB+5^Eo1AN}kXO-Om+;_nJ2E0z5NgGQN$Vr6yIN(Qy$VI=$ z!q=K;iZ-p<8)D$f5y?GG-EDLc~bv+mXF?ecg?pIC3C@1=LR<>@N#{at;-oPv2> z3aAvkgAPXF_2O~9^;t(eAHWsTU+GUqueSzt?Orfy`RA`3)29D(cF}Av`%Cb_3Y|oF zy&1F0yu}qz<2rh5-lw0lZF*oo2r$pgH*rVdnyCQp7vf_Pt|@X45%*aUC-wr#L~uAz zjacMj`qRA5uyGP|d1xz!{qQiiri6@pJf}GF~fRxz( zAz6iMr2c--hRdn>{n+ZYsp|P3))$;G?1rN!a^nlaVUC;%-o}QG9B&%%{n*LwVz;Zz zUC+m3QLHJ?v^}(CAj1OjIq0_#M<0gQ+y>wtMfxY)cWAK6sGvz_9`zObKG)~6F_Af`5lhT(`mHYUKCk`ooByveI*a>8p(`Oy17?>D{Qd7pkA&l!jl-RJcL!Abvf5B~Pr5fotsmj6$; zBl`H#^3`zp@NfPpnG@=2$W5vexU1IOWZ#( z_|YhlkI~NGc{6|`?@YV69P%^y@(K56%{lM%CHKE&u~XKy1&`apf-WC9KKE=7|FNRY zXalH7mydp7cZW`7UmSg4+DFQU_`{S9(#t+(Uo)TYz>z@82uz_RKfIoSc*+Ok_5iMl zF;DW5v;yUUHrZ+@;(xn*6uoI{ugHfvKU@p>xo6A12R84y&-44XW3MPxj*j8DDR>L1 z9d!8!&dcy$aO)?V7`sgQ5I=?eEkV*|%zWZ(O6;rI?>r}njbK{t<@=3!0GXfdg>)A{ zVtxiDL`4FGd26Yj1e!c+vT%YAG6d-ITyNnR!Ev!afPvTD1mJkUYZ&yhY)s-P99V{g$j9nW!sWx9H+A_qRsEFtQ@@>_ zZ94k>WP5a;iq4_GBX}uSV%U4Wx9a?-R6c=Xn}6rY8mzzlc?IWM>(++Kjnr3POlm0y z0+cDc1@;|-5lseg-x}N`>pL`@OL5N4wLZ$8$RFG)OSULq1o{)YjImsq{~;L+`ZYo1 z-!u^b-6A(zKaDOo(>JB6i_Smpo0kr2*D0lk-C%j%C3uq!+aNb-W3tANkaGTL`H9rG zlraIJi?P@x9mnhbO+lZJ`#*~=Kjh1INvhl3`{jQxJUZQC*y%|oUh*S6&xhOTJkrl{ zmzDdxRou&@+rKWKhtr`>zpx1|QL8-IkM~ZSr&#u?)vr9aAn(7|U+;7nqdm~eg6B1Q z$X!sJ#xZghcb~}fS|H);W|z7x!0jZyt|`k3$~%sCzw8hzdMkLd z4TjztmLqNI1gdgbbibRv34^Xzl9n~Yc=gUMDRFEl2lRE8)!&B8i8=06Z%I}6y|Cq| znG+xAZrXRjoArmw$%smPPKKik9qqbC9ycfKyvf1Dd4dD=b3peSbH0nNzbvKm8)Yxg zc;dLLDmZyWpuO#bqu?#1cA);&@f+zej=?)Nz7kh)J({eKKN}3X@;|e`liGb;EA{z) zkAKeUTu&XHabDFU4`Rr$0_o!WDuQ>=!N~Mg(@00?YfD+foht)~Wqw%sefT;u=gVB< z8HP#s>)G$;BdHeee8b8sbMC*4X$FozJeqh5jRV(_O^~rNzdzIKo#%1ecSN$k zQdVQfGWJW{*!3mKPjFy+Ip9YDVqZ4>8eM-^L%)|ky6V^us=i1)a}0M(*zcWDe+6$L zwL`f76r3LiRW_2oa$QH(32Ek;rmd4SO$UK^3641lKJz4A^pJU6OXRu4OiMnJR(W!6 z<_VtHHCB*1>Z@DNZ!8)T<^J_K;0KAKuPv=r_0apf=DfJ*w^X%gdDAZ^ZaDRoNmL+& zYykCD@D@@#gzKxVrlHwz^!c!}WM=6Sixin<+Hu#IwDS2pKo2C(wmv#Gyo~Ui#91T` z=zi;(CN`HdaG})~#yV^b%=ji&=9*W_ay8(7?%itTMp>+D1VFSdYjX-k#q5$q^z4EG%85K#_~pZKBIXm)4!sosYkE z-`G~u@10G7KoGeQyp0VVHMwxMd}fz$SCCxsN6UxQn~)RXMD$qq*K6BGmycmPbyBVV zpS?2ytfIQ!_yk;V$0dk++;NMD8?Gg?1z8daC|0e+P(og*7oMbWdwhOj=>5{__#B0D|ApZ?<7ijue-8RcvKZMe4XCISkZfqKp zo|LL@O!TYivrc|{mcrfxy8Yy{bH3POQC*xO`vS7QYWg-q;)UdWW?Q?VYeKlCUr*(6 z@?Mbn!oMe69v@tueL}-D5rO|g0`B#ue7$78_1h2UAYZTY+`D_8^~;%O{VF~d%eSWY z4>6fCrpsC;s(jA^hl( z_ugOnMe!H^^vieC`<5jAB-xJWcul)@MDq!i?>o)_`Kt(}sp);D%(tDlBf2>_ioq>U#&1v0@=R#eW-LM zZTWP}nDUB>g9jF4{GfEEnnR&C77wd$~2G&&8PvmyE;Eder@lT^V?ui{ z4n|eFz8*wME5=leZJ3zBOW%!SGpuX1KrH>Kn|6M_>Ysmd;ubA)d(ch>&I|Bo`cUai zj7Lm@woFK6N>YtOt0r?Z_k8r&tn=f)W0l#rFWT(&34BM8f$y7k!_@Sl(wX?_52>xM z9$DE`RRb3u)(~6ee8JQ0PukiAdrs=V4vH4L!~oW2796_PrR?o zsc%t|6Y~^(#r+=m>>amR?as>7!IpGXE_Vxjy{-4{ipdO5O&eL;IGMnbS3;N5eAv@j zJ}>+8K65iCY%s>si{5WoCGhpO-s~Benby#h9#~h4*P}45{e;?y#pUUS<~n|AeMlxf zd0=IIy1urmvMySg@TZxZCpr1~X&l!7{^BL`?x^ndi>O=-f^}d3ud}8%du(oYnLo!} zZbvsY4Q{M$0;p6)x;ax7UrnPi`Ix`#`3ldKrDbvEn!D$_Xp7GI_TBU2g;y0m$sstx zz~kW2`1(+diGLge>(Y&Q_YL2=MZT!7#kcJ1YLBz>3){Qrd)!v}%gwp4ci)E}-+Sfx z(?&&pm*r}Dv%}_|Jta+eBd!5uCaNw#8Wp2aSL^1gD*UwlT2TPGe0ySrrD@w}{@oF1 zLDF`83AWDf#|zZft%evR9PpI*QMOD|vO@%pO zKSHu$J(JfU_8;Rr5FDq1EJkJobcQZ9mQ1z}xdXUOi5eIbJ&BOw^JDX4-R z18IR=0J$D=ALMz+$B^~Fdv6H8`*11bDah(5s45`WvB1KGp$76AWC9%SD+u`kP0sO} zu*cUL=rb@Wte?Y#c7f|@W>-V5ILMUT$^U;XxYz6Q9h3QB4$dX>!2;xugDxukYR>kB z!ApatT>a2GAOHNeQz8;pewg0p2$^9%DTEZ18~HbC|krkF2bDUgFAj1&u{E% zZDpF36@Gr;*jsF?=k=835&PD1tO$Mwieubu4%r&AJ)|#$_A@UJhKz!YgH%J@JaHX< z{}%EL;ogufN;dnec(v5AzOhVIeuID0p@i%z^t~sLB0(1 zah5H}!a0MVKO&FGx#{;(>E?%);$(jC+bI?yzZ`S+O=rHbN8^s83s-( zeu$huyhKISL{tN6GU@tsbeU@Ryl6|r@1Fxdjb-_b=oJ0~0&YE`$Ii+64D%GvmD_G~ z^vyLhx0w0lT$W7?oEKnf`cUaie1FN-YxsFI-bq%Z>Lw)HBWA%4h7t(Ruis9~b!Xr6 z-klc@e)J_SGt`8RP*dRRqqW(3mDOj^DjT-G#+91J15y+4@?_}8;Vy1ID({=W{@e%a zH=lL-S;KaD{}q<&3_pS}ADKQ>I+KpM45>>W3rZNEr7rFn#@+fr-21J)@Y~YjdJC@I zJ$A`&_afN+{5pr;TYTO{w_99hx9KfjoBMWGG~rHha&DWs&+^#af7j&s_v^E>a9kUe z&Di3(m7bq^DhqprZ6V}s`cUai+S#3~&$itj*eF=JJZe0Fo-_mN+w>RH zhe~Hcf8ki@@Cf&LL#RuY)D+Qs~h z*KXQtdN*z^cV=(g>U>CTQ%y--LwzZInZdW8=~CHP% z+1>6@*&aaqP4C9dxrdmskugS$O(g z8}D}C<>UDSp(kV|Oidpuor#qvgD~Q6Ln^LypuMayT_0}c@|ubC8A>2z>z8L-*SqJe zAK&xJjA3j)Vc@&~Q`3h^XJYAF{ij`d7H`{vxp5ePf0ZXjLUR%5oWN{s zV%PuvCHeC)V>@TeWiNMM?W8yT^2GFhieY)O4EeaDdZ_zcJQ$qc&ILG*qiY}d*Y-We zpJDA*tOv55V*0Pi&YblZwndZA*V*pr+pFIq@O>oU)?cP0AG40n`<{+MP3FTnEAI8e zj<(+NbFHVh_5OWN_U62*l26yI3tAC&V7b?N!&~Rih8=D?Ov7z&S~xUW-uTZ|`VT1# zraZjLqb>Ut_gR${ECj~E^2YR`(wX>n4z90a4=h+XxDlgg*VQ(ndgD}VS`jbpwf+^1 z%75k+Cmp83WtKsvP*?hW&c(5hp#dO`LWs=JXfS z`zHDRGB90Pmujp+_m;3dK2te4?CBCeg=^n#a~vYHwA{E|yXPI4^mD%*zGzrskU3?Y z87uba_sqk5Ac61{gm#-gR5}yiZm(a-kaXtQ%1m`d*qxZWtOg&?*<&^AFAo@WnCHa~n7K{!&s^m1<}jSTlqkZf)@g*H)sDvXT3_^}^{Rlm6?M z(~Dv6W5aLgJ#+054;02Hj_qjlU(>s`aM`mb+g~#5E*o{)>Pmk}KVJK7{$q3VFaD;O zkD5Q)ewzPh1YEzFSC-#zibfR%8}C#8#p!2%Ic-#YqU`!^dfyt)Z^B`N`Sct0k96IX z6yI|ilMee*XC`N#k>@V|TtBdMVl O5D8pK$K`lI^Sc@)L0DuchVruk%c$arlW9 zQx;DP%PRh+-*D>dLp3J8-(-DbSVMU_UB`D>7^Xt(zJ2`Yr2qQQ59Yzn$M(4F(?j-o zpx>V1-r4%8>0@=<%2rv#?O8d+_vqPoAJaUSh;5UNSmFSU&POq+OCJ`$qjX>rc}F2q3 zjbC<|Pg(iKZ4~}<0`7IN&)ClI$8S61mZwM0IR53UcfW?+R>Qo``R%cu%Wj~*#J&=} zV-mi#S3D+DIbj0c-m9-qql-Ixy?gKf79kS5KQDz{mhSEo7p*{FaP3}%_4JDp2>po5 z+{W$4HgJ`XZg^(QF@K_-A@Zm0f$1Y{cG`j6rIn5OO?R&kJ;vqFe>Dde1`}rwIP3zG}`3WkVVcj$QEKY}R)9(82$7{b`zoE{2hk7pa zK9GLHWreSgKntR>dfyWG4SAP9I45t`!R-Cid02l@^QjL!y2*oovFENID1NkoPpEfBLeI6P@D`;PR4^ub3+E1%!;orc2-gBj1Q zSn;P%ZuqJKdIq!C^pQ3@?ZDo)o;Fq=a@$S0x7p2Q_P=BxyKg#}J$(Odp2x#Ke>1Uu zlM7#)w)RWqr&vDXob45+_wDU~M|l2nJzMLG2;B2YKVq-@Xp`xaT+A#Xqm+?{*&icwM{a9GSG+&!`t6l?$govH2b+tN5{Z*Uw3FhgjRknsLX$z?mNCPSZ8M0b9-F3 z@~76v)5^|zEUn7# zALEWH3=aS8V^1CUMOhEls~N03G<~GaPCN0B;)&_>M2@)P`$wRgK`)>4>aQ$+b6$YlZhGHF-%rY#o607XWvWvd=N$&@WaTUC9}TIb z9V}ZYEfZG?_S@*F@}5|K?E4!vj(%hK=M&-ttvoY*tZtk6cGx4Eid0h*`pP#Jhhy}V z*EKhm)x&Lr@esFsYl{dAmPbry&yehQSLW`0*6fMNG6)NoLY)u!BUwKwT(>`c$dCk7=fQ(ld=AH{W9+U`S|a$^6Rz6^_u}T z`Td3|x7_x^k3Tu=m0hD6Tr}MlwYjW5XnS^ASih)YbYRqw?(|fO zVk*Ln$HV?g<6x(22W^-eujg^}oYeVo{PE1%6DH1j;&$v7hHc~dpFDl64xdZ?C&%F& z>7e??=oKTp3KA3{0Xwd~u-mnZHnqmjy=9*-MG2z=abk%yR=Ii>T-L#qakT!1564<@<`Cn{y!&~<}cmVVaX1D1hZFcJ0 zT`?ja?{845s+MCB#+#O6p6fWWF?H>j+Qes%)9dQ|W#}cv|#*;i0LfLABw?M3tHBSA|=#qxnUTW0K{*|D3TVT^QW|=AkFe z*l_D2yLXSv->*z>cG$cldnzZU%IXKzHcl!YnQE%6u57AA6GGTgvUo5CG7H}+V;p|{ zih0Ze{V1Q$+jg3Na|BuuwfWC%_)oraomTAd>{t7bT=SA6B0rAm6$S8T({md)bnZXH z8eI>XR#qRr=`^-66-JY&|7DW??T@R@9sYgQGpoOb52gXSfN#+i!w zsR*U7>HTA7{_Xs`9_@3od;JMcOxopt_mpW~Fl_5dH(bAI_hE4c=d3sEGQDq?mtxr8 zJv+YjpaX1sm(MKE4*xpHeSY`+123Licl1M6=Fkp~UtoHR*XF(*_B9TEYco~dwsvrR zbwj$gzNs;8R!y{H_B|=dCzo9x{N?A@OuS;#t9`pnZ}!-{E#;^#-}aS|4(uA5NjEpp zIQP8Ggd4mq#kBtX;yH6py8P9-TxN*c>{n{1kJbi3{N2g;^}|#(%qy>} z1ew&-rh_Z%&?XaY>Dtlz^dz5|Fs2%t4LG?l=>N(FS1)cU3~oH}u@8@YW0iMzj1!_A zyzel5tZtjdb_}YV)>u(nUxinFCS+2LHF!U4bgBvM4pS=Y!fpAT7S>-nYS(2QhIJBa z_5deEsj&nJ1KNo z3O0ijK{khM0of9=6=ZA3HW0R7ZUPG14A}*OhXmo+#_WsF*XZ_va7d_MUcxNS3|Cc+yc21 zat~x4WIkj8WFce`RIkbgl|0`H!XjUd}V`a$-G90)lCQVq#KPJz%5aEedHZaLqJ zr#@G(IwW>i5P=^g0r$E%?u=yldJ~8+ug^ib`_alrjv}B>e*D|f;~Ty_xjfD^ye=Gt ztApvejT_?fHGV8mGBFjFvLh-Ro5nVv6*V=iz7*fnXdE$SFrLdFl1fdAcmBSWw|!tY z%iQfDEO&YRVcA;@Vfot^!ZH|_*03Dj4fEY0dq7wo_lN8S*&DJiWPiv2$N>Sq#!jAvaN?417VqcEaW)IiI5fu%kDEE zXG6||TnM=oayjHG$S)u)$LSYV-n#y?qznGD_FcR6|NZ5=JUbh4Fwl*T!qoJk(wUh5 zRAp)#n!4^jiTBiM&W!3W0}wCM>jvo#aqBO4H1x>ycw&V$pbkUi-UWfLxAlB>#Bmr? z=+d4+{jM=Zq7g@HUtWxK8A>3GFV}POb9UI^;u%~1bv16sVCnk$Xl?YoEqvr$Hi4g^ zs^Bx|%&__i>BeY_7R)UD*6GRTPb**@uX*;KbPd+uvi-S(-<($bd~fI(IA?vy^r6z3 zgzeiEBSxhrrtu9Ke58kuRMBm)DP5IjeV{+YZRc4%-q+?%REfnF{4%?X&g%R*^43@1 z{Kg-yTX^Jtr$^D4{oBO)MCAAp+g(vRu^ykc$fQc@CZ;nObaHaMVG-s`pU=4mAbpF! z0MJ&&I(PkeXMK09CsTKQi?e=(9#K7TDz>rX8-I54yfA(`fIUZBiv6c-vg5nQK09$Y z*3lU3yqG@HW~cG-wY`=z2v4bM>l(v+@176(J)ecatVCET@oU+COvf&Ee2Z~>%wr`G z`g5-QcJLZEW$xPbj_!8eI4{6anjSwBAwIs*sruOS@Tik+U(wvahZXjEYT~}7VMgb6 zR6Ow91#=I1`a0hZ(b zg0Tg`v;Y^pgk*KYWh&=Okz9mLL0uhUV^dk)0ts|8c_~4 z*M$X93%0fNOD{;4L%i><#`=bH3WEhzuPp6-9{N8V_FVeiCsOs7tr;c4^jQv=KGJ5V zar#GQ-xIdcHIL*aF8I2y-@I2^7s4Z1AF=^tV+ikswt#E{*&b31*%i_s!fWUt$Z$vn zgx5u03)2u@_s)b|0=W)yH)KBK704%$HE_bVgOoy!hMW(X3waZ=J{+1KzM28~1Ee=H z)zOgugY-dpa4BRh6bhF>wnN5x64HW9Hv}hsbDa2fk>NK*h987NaXPLz?}PcYo~SRZ zgZsnvuuU(-hZC@5L)|99#{E?@wm$`Rg7dK*F5WG-A+32qF!@e&=du#o_-)0f!&@yB`VA zEmvUqYWo6l+_n%!MLkY|f(U#o1R9Wvm8(53%wMk0MY+5B(Rbbc@W;>m?xff{D_2eL z8y%OccpW3^%rh=d&+U)o?}K6^kth81xqeTD(vD*~j)Qr&B-e(quFvbOskh(yV5fus z5mk|S91PpV`si17+ID@YZKz3QDw@&1AY565Dbo$dKSR0}ZvhH-+TgCA@2u~J^~~q) z`o+%ro##buX)V~sj;rRP&X4QvKaNP>eaxi`w}~r)c3i)X^@uJJ?6}auZSd5p8h+)q zc<{hMrGw+GiZHk1n~wA?eqOV9p4|1bo%Mgm1&(#F7Kqv3=i<)oKjF`N75;nC8oca< z!R$ZL)7yHp-??rN=0|jGeGwMS{!*mx#?QE?#_QR?Z64Ma;CBgx^L~)<+Iw`j;Ecup zhpQa!RsV6wX58sdIXw26xDLNC zW&cIkG5pFXbQ%isG z&yvUQzfVwlX<_i@=pTLg;W1~WhVz1nFb*78pEG@=%}%rFk4hh0nVA;%6OKNT9=;J4 zZQF`?XorUCf1+xw>>vI zb+=2_I5p1DR-Tw1yCp)_PX^-?Q`1JLj*h-E%3jtSERt=PZaKo82gY$nUYm%n(;qB< z?09-#ne==A`Y`p1!eE~tZ*$kiQ^xJM1uGp0xCIN#N7IK&XTs|yj|uM%6!WGZ^Fu0Y zn^-dP+a>AdrjjXWaN(OX6%ExWKEn^gx6cPolsOmeUWX{`z9z;JZtpJVjKEXI#lNT3 zPa`lB3+6YaS10|(zpl=PU)^*;pFi&N@J_33A4gz*V|t6%=GlDE!F4tCrf`(WaF?S1dY;q`^N!@&*Jvu((iAd zKns#I|5$iqe*fry1M2B3{<5a*ovE3-*x-av6#IwiBW-q?^^a(nM7DWEo)K-+iv8XC z2^r6z3w6&cU_bncSu~zGb zmC;A|(rmbu?;mU%V!NT00sgtP^UArE4~&S*6w})}{`Ge7Ixwv zjAhRUyT5(fw)@0a9b;e6PH!o8P_9I!O8ioOJSIgrxN|>epx)w&=Bg?*urMyS{A>7S zvK`CH2Ly-xqz# z%YPWmK3{L^m*2kPVdYbHON=*Db9?fC-scnsFHbJLVaSWOeq?18 ze4x{TLj-UnKmej57y?GtdH+mzp#zu#IPtl#dUpZ?+Zhrd6Z^=1b1 zchg7O?38{Jbr=mBrifzrBlK@Adbc zdgYDxEWFd=GJ8$$#?58gJ9hMl@HM53SzDU;8c$h0%Q-%9M(C>DE!ft|y*_s*^QYh5 zI~~V${u)oe*z32GSKge7Aeh~zkF?pT&l&H5u|X!vojIP1aZlb)F)x}>r|{hnaP#3D z_y?~wB@mt)|GGm9fARDYJI`2nFT3A|f&M`+@%5n^6W>3^q|+lS>!&4rgxj`4%umaI z-MJm-A3o>Pqvs56vxD~1YF{6!F`*q0|GqB!>SW}x@u+Lrk0jV7u@!NceKY4K^O4`r zeF^LzUbWhZHy*e6=3%h`mXAyytJ`Kir-LvW-K65|h=ySw_(N(^=plh|*!U%fQR$}G zT1L_e0B$)(o!wvXJerV`E8I@un3>gQu+=lqU)t^eF57-kY#O@A zhV>-V`xbZEf3j{9dHjgl$>^&V-J~MYTzfn$)a@XAKDh$~-OHEzy|sO?@4gVeQ_Q~ie6M%_qy%yRWFUn3 zcQ9lKWGJK*!fV2T5cbm_0T~Gy1u27+Lk@zBhEzbtK*mCNp*sXJ4ss~u$B@Gy?Bjm~ z$#HkfR_~5N2$)T}^;Ygw#N4AxA?dLFypv3d;I$8qxsa`*Ilw8ywghuNg80 zax7#jWE$i+$ng+%bUYEl{=R%6xdn0xx~spF^&MTm`ur(h9i-@(akdkn14VLvDcF z2$>DJ334;!7RarTUqWt!+zy!oxdU=1nl_A7TSif?tRT*v3z z?;g{N@$u!_?^`uoiHU#+h`@g#0bV!l{-WiP&flZB?%1na4*gC2NmF`GXSE`H&ye%$ zV?CGMz!rGtOIm+3)TB4p?aPBj*bu^YdeetWXF_`*e)~%9 z=QDWB(298JANG7<4aCKy>>3{@>!grebk}p4%sF@U$vyOISqQM6ZRN?-C-VEtLip2( z=Rfo2iVys#*!LIH`)MzuzeEqo5Q+T8C;8v?+bw5iKb7BadOTSe?7!>C`!nx7w&l)o z#$6qU!*a&-{?T>dH#wgNj!GTd&R;A(l`}@-yPdn`OwAwiUnd7({oV_guKV%gn^xfY zW3cOz=_74++JV1x(C%-o{q3Kx^+uGIW;XU@e~j|ylK#&7eTucm1y2_S+y8X6!l(Xv z;6>@!-#5Z~`n&1fxVcRG-RGEj+T-jKP+=6g+86Bl$m3WW^1pViWW7&81VlgtMBwWs z;9jQ}d)GPt{*fu4JF@pZZ){ZF*R0@mj!&O_y{)(F+`yVldU9>^xy4&aq0@c`!gR!grQeF_4V=Uw(D_XR}@lj--sMyo*F@xg|qo*Q`bQy<(CozZN2i0Lg}n`htaNW6C%K`5`xG@>iE zjTOdyrbCR!0@%ajGag)K8<6$4oQ?JUyYIN>!8^Ufp?AZuE~c!vnLbvx&9e5``51x+ zs5SLCLBksPvG;h(KA5}hAnV|_rO_4{7Fr-??~<4D`+50`=zq4)ZEsFEyX@gf@dKd# z*q`>A9zPSIgZ}G>V9dbq9JazJ*Urtcx3#%2BD0xuTXywaW{CVKyA8J`YX;jd*PJ@r zH{4j01OeBdr@q{I`|p=;-164rLoYvK`1~lE@iFwTVtpcV{9yhb$c{%7YO62|raKNF z@_qPCxp0>vOz9_V_niehEFG@g2T}yF^>dx|eD=CEY;eo-@;`Te95;Wl?e@+06`y#{ zT8IF_%FkP3eWcA!t=!CAo>$ga*I^WzfpzJ|6t;8*Z2mzM;+V$g#uBmotMTo+Vs}y!wx{TRB zt{P`O9$$yY)rvXy=lDoHUhVw2Zr*S8*V708m5<)TV8?Zfr?>T8Kd$TuPj+mKqX=Th z*9Z2w=`-!A@p{@nU{U^ZwH5n+-fO=F$Bg*d&F?&p9T7Ic`DM9k`be9djyh;?@#ryQ zqOqNd%hQduO|?@{qPAi`+GXwE**)4XVberlIcUOl{(5fg>JG#2gCRV+H6gs#^7^$J zggPsKv8WIeaLd!0*OPux^gy?0{HqU8XS(Q)Kh1~V3^@Lp_akyME*Pg{$Yj z3K0RfUOVfr`Tb-m{OH{iZhG&<*CtfFwsEvS%UJq}>3yy_{RDkD!!hHk@krKln6KMk z%r9t{{KY>z%l_NF-i&`Uc^|~8dJo8WfaW+NpJM{e9eUiJ{iNe@efSzTadl) zD6ed4N@duukD(lr>v~g!6TCsVMU?kfjh8!{xyKQ_mH+-}A&%q5bDu0)sqEve*N+Pl zI}X$P>1B^&SmUU4_=VhXlRlWb$FUQBTbynjZuvbO_A%KK2(nD2zlL@(a9)6^=_74+nzb)+zlqP9M)#Th;!Ryn3*)EzW=G%VsDEbgc44sD z%8$J`dvRg#{BI^zy|?y?n>M@@op9r1`m6=fQq~T>;ndhTCOs%!pX&Fuk4N1T$?@KF zJqXLJ-Vi=}VKKHDWDCgF5Og63`_t}%Il=A&;qeZIjDn1X908dCX@DFLVPg#YdHw>z zzLyU{o`o!id7ek=6(+!pEWfVg&st-B$O{^*Ole-I29gg&JQqOa&d=v#Xz z?5%{aPQtO^yraku`+?>fj~a&+2AlIb%w-%}D5eiLiYHvxS#aY3k}yu{7(au>>&9g| z+n48*=NLG`x+LQP!f=^&9_oQL)Ukfa@`T$kPNrkWg2gacywuw^TtPkK;eCc{1AZm~ z_hI}vt!>*SHt>EhE{o4wrJvse0&clJ^8TMwH3VKU$P&uMxrDGc^_;4jZ!eA^Y1kBBR$mTyh(8<)+u2c#yXGb!ZP zYHrgC=XdLi7eL2)3!4jB2V`B)@|Mk+$9PSlaG806*CPJrHvDbNSPb(Y>qcB>*D>mC ze=aNJCNLdpo*%ZqE%-RUU-bQ`FnH{N?WdkGVCN67iwiy0FIb+N-cKc$Ulb3ltZzbd zVKv&~()E>f7)C=T)(ONA%+$lwE4|k_zgLgKsZl9*lscIujoH;=r8%YXK>=7 zhxEVTleZ@y%pVBc?qEz!A1a;60r+%aT`fL%fws9~=e25-F;#q@+AZfwKTG&im~ZKsJ-*)7 zXY+NUU2jlr2IKjsGt;6MTB0_-;z6nE@M(B8@--qbzv=l!(k`}5@ZPE%4QGFP=;`p0 z?x&|-w9CwU3Y(!0gW2WlZG8uJ;roD4JT?TzGQxs~1lB$kI3ae7&t-4*L$opkt_gMKQSb!2bVA@?%{cO>sdVkgI%t z%XhfPGuOOPG^G2g!??^~_WAl~E#AAwv$pV=Npa%5a=fMJWX2o1cFcnv3?&f8pUdBm zyyn-NK7GPv2h?&y1a8+0Q`3h^XOhQ`=m}sv)Sqid>AyR-qv-L13s&mC;U$)o@$mJw zz5_c3`{NXTE@akm0g+-nn+<@6~Ddfm=k7Lml%)axveb2e|#P}&__PqFdZp)D0 z4vgWPsvgvwL9aiW6pyva{oHc0;mf4IT39ov!{>NVvL5# z{LCiq6ZmbSVop#})m2tm9;+BQrlgrS5cLzoUEK3ED{LX}*l(7?-W%@!$)o?c>gmg$ zh)z^!59=GIH#=;ev?r`mfD6ass4sSHX+?a@=UwSnU~zYK9-G>w&6j1{E=Bl1vXSez zeF|_vKq!HbSFZf@k5g8-d*^>QEar9$5!Zsi*GFsdJc18|Yn!IIPEm|O*-*b|#AwAS zly-FNwjA#IZF%>kJ$`vN2loEr#C@9%pL@*Km-dfRWd5h$n%?ZNdCuq8ai>)DSgqwp ziKp$}zFutmyL0m?&TZLUZ_6F6Gd<@$AS*yvR#5nxbGwh@x~|^OVblNl(266p`oqi> z^ZUsX_|fh~FC8^`#y>B+e9s8Y_L$L6Odn~pQ}_wr9p?AFYpYWBDseO%VmvM`in?fc z*Ld6F(qThO2Um;#yKh5N+IonQ@rgBY!^Xy>hQ$ zpM?vK-}{k6o}9~vs|ZCfnEA-`kv2Qc+L3JsN0m43FVw!A<@JbB^Z2YioJ@=h=VU`) zH-G23;yJT2lE2B2!oYpjff!fQ+xFZ>Avb~PP@8`YSS6WH>^!*lx96^V+@~$;p8K)+ zDa)m9xZ5`D zY!fF)JLspT@1h-OTWv&*HfxC0m-5wTUH|ga`MQ6%B0@VqOTmSq1VW$B)jqRf-;Xxl z{>s_cvJHTN^8!pwA1a-Re||a~2Q(i0(;vjqc=374^woNWd6f2b6qa1u?TFE5&q@D0 z-oX6m!&vX{=i7&#Sq*&FhWntf+x5V7bt-yyE84RNGx7?*e++vpJ^Ba5T|eJh&-PcY zcaLY>>YX3Y4IB2Gwfmz@KeHRXRS*Zmjj=xZm7V&>GrBQ;>8$N&SS3kiY>y%=*zrt- zJ(eDAW&U*6&vMr1I-WjjbbdT<3@+Pk(;vUR+E$30f$1>(HP%PJveV9w$2~hqdrM)D zrN?wAZaL7fR?^@7`-278|K#D5_8juyQCl8$SClJvM8;q_VEU}3(Gu8 zt^IWi(Y6J5ndgAPbT*H)*(t4~aJ{>Yl_fhtk8WFG-^iYrv(b*NFuX?cS(5FK#c-L| zHWNORbmOE=yhge@{0#Tw{C^?1?Xrv3OZo|pZ`Eo{di3lSob*Jmf6Q6CS8&){AFaIc zZ;KDw_()QV#22bVc@sSn0dQ@3m%tkAGaW#7FaajF?G`}Ss z?>igNnO~P>d{Ul2mVQGjoKAL`GqqrYR%f?)m9f?)C41;Ln? z3xdt}?G{`&r(5v)zTJb{-|QazdCm&K(bumSJo3a!!8*k~f-@Gb58O8nfBfc$ zS9o{z`&JyZ!rLpo`^qS0iB(xNU>-8zdCGU4=XU=Mp$JA4L+H7z2P=rcw@tvU7q#}z zU*0wp;<~>6)*sJ1VbjBRefa6nR1_WIb=ma3{hgM#=s(khGT4gRZ@WLF*~{y&1$UV` z=1INv5*>UhFyh=K^X1l;^Pe&hW4x9nt#J?PL_MWU)NtdR_4uBA(ltoylgsdYs+pPw*1TW z+i{X7DF5bx^8;Pgg5zd=mF+AonJAy?Bj>cvFqA0fhHErVo|Q zBulN9=i1)ZX`XC1 znO&6hkCr8$cjI%@>3>`=*z#X%_2{u#ui!Ut?KSO3f4On>OWx$2X4XGUA1a-R>mTKr z)P%4@*#XmZZ5#6un_F8Px3yr~+V3CQ zd=?Ja%8^A|B>luMM+R)(E2zD`&#wKp`?TPW7$&`i<%sEhe(;knKUZz*^o&S+zhS)o zxnkKu9nZU+dn~pKTxZ+4ao9f8`Rm>7+z30;yW9K_mRoU<<~K!K=l7eIEqevU>$jdT zc*3IEJK_clwqw$7Oz$&WF25-rIe5^pu_GB*D^8SqeWEVcxuY(Zp4(fnZOo5M@6X-! z9mUy^-jC~l{kPk$KO6o-E+r7ob3Ko5_@M8#Z{4%uxTq(h^>bJ`Ful(!d;ek2;}5Ky zQdv=zscmQ)Q&XF%Mkm##X;GW0`SH|k^4rk|>wmNBPuG6+nM0pFAx^MA=JaFJFN+=A zwjAR7DfK%->{%FpcQv$NLpz=YJ0$bvT(s?0WBpPb$5*Sa`q$Pzy@D6M+UnUg*Z%qT z&w2Gi)BEXWxhCHCFUG(FjQSgS@1OTSe4fuSgZLbaKENYmzX8@`@j86iHoh6=n?tsQ zYz^5Kf+p*5Jb=EKv(0=D$legV9v^-qYY67UAv_ObA%{UKArm3>kY>nHwya)L=WKB465oA}$P{`qsM#v1v^^gZ4uR{I}*%XCF31lMVe8_Jh ziy<4};x-a;I^+S!myi(1;}1Fch^9ABIBF^SphBEXG1o?HJaDy z3f`pR-1GdyRXc3&hB;xdIg$+XBg|=6|BklIf8Dih{JF(Xy)E0^-`4+4TioF8XUm+M zxZ8HL?C#gmHq!sF3AEzytz7L{oGe%UdUC^#y@K2C`{>QLzj*u3uKaH>RH_P0C5SG6^A@)u)uUWh`urdRS;WCP>usxh}7Dtxnuo$)x z@L`;*qu$T!)O}xrd!IEM{=;J{f$*5Q%(B+)|99*cznOFR^;QL1X+TH*3Mr368O$0Yyo*Vvlb>Bpq z-}gA(d^c{l{Qfc*{`5-vlA8EdT=cIa zi{V$d3@Yp~V9z0^@;ovWL0Hb1o;o*l;5TtGS%Ft3t5W@nOWAxJhCZ0OD{=w+=1Pt{h|)4VL2JUz=3kK{dbwZ z$@0pLTjisF=5qg@4z*oR=fht*t1sO<>)y9!4STk&$)qTZwkYuRmKy!Vx&9ZkHKU)*K@=Ug#kzl$Fp@oBVol;1e@^|qdNj2%59deO+NC>@f) zTh;bGrLuZ9y2LrowP$e`?3q1wzs(N6?0^-E;siM_fIX&<)onAMOH{##GSMNmO*Iwi zs!1shUQ>_v(b44NUdLMY>YUFFy|20bUsDgg!V)YB7m5O3Z|ghA*ByR8%L*pfe@gdD zmXj$&J^^CmDD>F7S8&$j_wIQAo~8fy2HH;;iXbd+Oi!H~j8pW1hsO3JDO65mGQj{; z?A`LwjpLhKW;x>r=Ao_zE3>#yuKjGi8z1js+`w(z?c8N<=l`~SbERkNI-9#`+OnmC zCNhQZ83DJvTZnwjPy*pO&Go*^n}^2_V7-A;UmvP5v3wj?aEi<7D^g8- ztG=-~D*CG93PifOz6phkYfsJoo!hhiX&VnaWUCn;M|N00{2qbn%?_LAv8SYpL-!}m zNtD0Ak2<%f{KMk=KK%DuPx|(l-t4e>9(!Uw7|11uWiF?gU9juUfzwvIq;z0h+smFe zU*840%A?nTlAxwyN2^ct7|{89FMBP$^q571HvQEEHgF*ng;P8`i1qQ$wwZCV*8un) z5?2;Mm@eNx>VtGG-uck;d4;>a)LCB)2giTH-xgv$btMqaS;iBX``x4yrwzZPX5!&> zTS3pj3Q>1VO&=ylPT9JTzo#nG3 zOVf#7i{BA}7Nl$WZzlYP=cWY0c`iS0-eJ}E%Pu;euX=_ds@Sg{_5vV%{z!_g&E)sd!gSiL)ZaL|Gsj7P)ZBo9`Bd3_j!%Hy9M+7>v8|h5ZP#tFKz~@);FjriTUhk*&@sG#!e){c?CpwU?`#9Y4b%A#rJSTj%;(n*De)h$)?kK1S_#L+c)F7@($JI?T&bowX;~la@A?t%K`c!-jh1*j z_LrSAESc~8>sHTFJiqHZc;d*C*H^B_Gjj&^IiUTf50%b@_R~ia?~!7h*Q!)qxK%64 z5!X(hOBO9A+=$Bz{@ir_{Z+WJv%USc?cLwYvut)O&%WQcecbY+&w=^^R4S3uD^pZGE;}ZcG&qp4`whZ4`1?vY+mpE~MM?kIDnC-SF{uEZ))K!sx)) z+xj?N+|)!%d~FJk+8Uh;M7Zf}OznCwZg{f%WO?k@Ghg3*joo&tx#%oQC-Tkifv>mq zCFR442Tz!QMx*c^CY`}mAnHL>99J+8n8vTHw5j>=&f<#ZqZ%tGH`KLNKNIhR_Z^Y6 z)4y&l!f}i_WC)0;YXM*y{t>?!-^N(*dqU;bG-l*O4 zL?`NRWU(h=WzlPGL7dYM$#!}8Vz>Y4;Fe$g%kt-o#qh7+y?fFNr`-Ot9y`WVEMJ)3 zht)n`3_(fKasNg3)w6Tw$CdB*OsuqgFdxUkPy*pO&(+>DY1f{UZd!8i>)ehZ@{NMP z*GFsP_MRFHP+C2x7G)8JU(ZY%Sy_)_CsS6>4(QRV3nMG1M(?J%_Kd>~0^>J(;%;@p z0CX&Tq3kc?nZ^!FPoI9#KF!Y=~?Fqj&WuH?XjPc0AQ5M4iL4sE7Xnbak zPV({VF-u|Zt!Jk{8Ik_@)5{`5!oIaECrod4*nC;aiMIaw&PZsjNQd_2dyhUgC1hjE zmcBdhXr1Xfw`F%fEq6@7EholTB>maHe)h!rf0W&_-K9rQzS-VEWIcfXV|qWO_T|LD ziVAGh(e;x1+x_0MoXhFh&+@@y*vU`=VH|!w;JSH}C+>D#?rzcc$-hVy)zK906+mh*f&9qjX+cOE-~&7)uWr!81*$FmUjGL%3V zN3Qe!QrQ}{KOgk++Li|A1^6>PekMZpc%1R;#x_)Ac(Q74=w1(M4o>pSRZqU*q^sX~ z>%oJrvP7&M%h%g_`W>H3ht!r?DFa1ae}P3^Zc6L?67&4@&OvHS^<{lrK56xdFldYgU#(6+HcLfPM{T=TE1EE zerWwApFgUNWRM)7TWgB8HZe#^Sc_ zCgFhRZ3CZ&W6(^+clj!-r;SO61N9x$jKRTDjcmpbgWGP}3VWG;354@p+*TM1(z&Wp@rVo|QqziV1BY^nEwIU8XzYAd((%$X|nB06Y{wJMt`*P*i@BGWyUF~(j@I5xZ z&F1UPNZ&pTojxcvp|ZIS-q=(#C^az?eTKlThb(~|^cQmKDBM5cn4KRzXv0tX#-OY| z|3Iww_w((Ddwk)Bd0<_-G1WFYrH$rTga~-v_?)}vk-Y*-kB`sSgt+VbI_r6(%xlYR zNZWbG`p%B0X19vF>xVpbfPXx-u^!PS!m=GtFo|Ll&#t%QbjyP|SkJ)oM!y|!z*^z+zX5pJ&sa#YeT78&ky$@0ox!A(n# zt(bA|V^{Tz6J7^%)+0@C_Sn1~|ID<8ru67kQ>L=MadItMr_sNrW9;qfmwaB!@_>G# z@ZA$|{kl&ozyD0H>J>b=^&Z3S88&?7`0-j;F4BKY?;nxxKWLzXYd7L+6MUdBx+%@h zsd#>QY$aap&ZH-1@GWx2(Ta@4{A%|lb`4>EQ~2%)w7>)__e&=x{l>3{%!Xf;-FN)2 z_F8nrJNCTW${o}DN96krKSjdcef*v>xApzQ>SVru_`m&h^8Nl#_RSaX4`E#k4$}N% zzULqQb%{Jqeg5rPr=M5Yz-0#d2dBP1RAZ9EKStJ~lEo%>79ehYuVqrwKU?14BOFg5 z*rr=>$@|4q%4>QB6W%$b<-zLp&lzzfYdul=EZ0mQDxHa+e)f88cNx*f-_`h*j;Y_t zVy?VnI`=(d>g*mMpP{y|>)mb>CkC?)_2Ex@5l1Rc-`NpEGIKg|BR5M{MPWuebGn zzQql9)Jj~8FI{CbaX;I>6$@65&FO+Y8$UE=jnX}T{;2J5_V{{RpU0jw$H}d&tSe8Y zGHqtYjVocbn{l*4%)au;NnW|`OFsYG+>6TR-u@i-Wib1EeYCcHIXkw#I#tDcfXbul z(65Ux6=CGKsuU`7)vU@5iq^J$_@D(5nSBdjAM5=k7I}{OE3b}QbC2%7+@_TetPmpm zFz!mMkF?pT&yV*|2lJa{al=y)Hf8#}zg>d#E&g)o8Mo_iE%ix$emw@82ZulYz&{oo z_10@#W-xxfK3dzJU&&GUidw2V(bqlhyBF4bTdwLR3~B z1exr5+RtZvE%Ewrd{(SyV0lGfZtx#C5S4hRA-@TRpw4_w5H&-1Z)o zvKt$>Jet##KmDGKy@H|7R$Q}a-|Gi4pE59g=6}z2jHt{^^lJdg>*<0n z*mK2G#~k|mOTTD)uh{JI^&QzWtiCFZj__6XYBR3;!v?k0NRsvhQ}go~Kc!c2=p8q= zp83vsKk6ALX!*(XW{1svKKbfL+{e#Pd@h2bC(Kh_xesC-3f~+7H$Tnn#9wH|z`Iv} z>e$q}yhMb-{MXmpdf#6LH8<3S--6Fw{3hBldQZ#mzf5C`la7C3LjQfPxAe>&UvKMu zd*aW-h22;h@tR3gvro3Cw06Oceyg8+!bQjJ*vHZ_JAA#Z&u@pd`UQd84{q-9NgjSb zqTa{hInHBuu3tU+wR1+q30ZzNy`^t+-;R;B^`pm(X`gRxd*)rJ{ucZs@EzC-(|Q-MscH zZw+2^hko(NW4)L4YSa4`weyegemX2h+lu(=iW=PfXB(Lq#{isg`t7oOXO49S>%-1_ z7T%w;)tWZ4-r|qD%cJcL*$}cZWK&2HWDCgF5EjyW&!!l%3j~j`@g`#Qow@@sXJwJ) z=V-_{2>X^zfYd{#Ku(6Rz5PPSm5`etcS9b6EP$}FWC^4jjKmBYem8;*7 zeeF3aN63ZkLFKT^(q+FImQzI#Ti@WU9|AqHZleEC@6$U!uHz~nxn}Ma&p+)S*YU9) zQ6|Fj99ORHEJcXbj-x;9G&^z~=QwA*9cN3tKiicScHua8Yr1@+FXk-WpXEElO3^IX zJ=VuR+h#mYcU-ig>5^kB@o`hDzZYRkvwtblxA=Ju70JN4}gy{fvbK6*PU=_j+0zQxZNm_`xA?4Rqb$7LY&qn3Dm$oI_T z^_|}m?uYe#UhNsIb4=mF{%75kf<%LG_I;rXF|jGvz0KN#t{!&a(ZanrkhX9-09 z-J_k})_eX@auhlurtA5jC+R4z9gATH^Ir*s=bg*+XLmg5&tALb`o~`XpzV2`+2QN4 zTNv8xKtC$9g%!u`Hc76TYT}J=2_>cek zJ$u?jWjphW=|iP6p&hyVGg|)$yeOHfipC?vem~TH5)QJqMJoe%Uuesm+j856c@~ys z+dR=|)qg1g_kMQqdCB}6d{PkhZyIoJuVCTrPo2d>SaI^$jUU9#+L|x!4=(VR^or-qHOm>(#6`uLt1~@*bAYxq1J( zIfVDF+d+8Wx+{eDtUrPbfsBIik!K~O4l)&T2ILaR4Ul^ve}KFR`3kZzfb0ty519_R z3-TspV-(7VLav0o1KAG+^c9fq$ehPQmO`fELf;3Kl$Rjapm;n9g>(}R>I~eZ{{|KB z)o@e#(={=+Jr3wg+?=nB1Hup&!5?uztvH|uaX|ZSfwZ;>g2~$l!9F|VTkN|b-n|iT z3Ff6iaDRCaynZO|@vCtUoQBQEqYOSf2yVU%_aC?5Ui^N<{S4&YAo%r41wr#x1;K@b z3xfKi3xZ=WDhRgb$7|phD6&t+;RZzzt55YfALB%Qbkxt@fA8g|cdgjF7Y-@W?%el+ zq<{JCtk^uL8@FNq>b+*M=^zY@gRP>zK2&2eY%(uMmGws1!V*D*)*c>~w`+rSMJVghbC)c4|~pZM)+^WjIAjj7&w>dPzjU_NAEeTVf3 z(}zlD;@2ah$0Q@tjg6!6YVVN)%SMeFJaEjgvQbA49#cAa^r*p6b8O(Z3pr6P_oD9y z%M+0shr7HyacQ6Lo`74QA9rce|8K>0f%l#BwkZtmeQWf+bCEwzd-c4^*WWBSG=+5x ztWDGZO&=1xK)x>)Zk_9T%5sS3QRR^X z^gCK~ucvb_&+jL_FY6WDnb~-SGpa6FXV2JP<}3P%>HWi?pFlXKm^)5y+l$iiIMrb{ z06I-^DQnjGpKtnUi19EWo~aPzpWl- zdfy5ZCG3vgHpqH-W9X{PtJ>}iqZs`1#?HTdz$g6O{BA+A)-Kv`W#{dY6JFcLwbVxV-B}kv~l|VSh?Q~c_n!W{|IluVS zPWTyo^4Zff|90c{cUt{{+i~0g({md)u)G^n**Ix*GcJW0bZ834b}rA++bm9hUZ1(1Qau`Kdgqa=3RM_d- z!Q*ht@1ECmejHUpPoKGE@W!M5aa70pDAnwA*^VRk^WDC%%T3qkzpx8-k9hO3^u3E; zT*0?{WUS9x94#%6-MP*}5u!8xOJS#L2alsQUQa)o^^4B=U(@fht%g0Y^nL6W2FAhg z3r`*Ie7V{d0aXu=4I>Z@mV) zg~9BD$@l1!ku06EH&DVXe>->1W=w5LDsZT8&ZuZ*o{L9nZ z`v2f~vY7*s6+!Gc%3-H#2W^-eujhH`aee2<@ykPoewfzn?2b91r(Pv0I?_1Ibaeu<{-FxY*H>0@=<%s(#o{r}?V z4DfM8NnJyIc!$yoqj(mv(w_f|+I@?8063kyr?_=`)C0o9>J*mp!HG1ysbF|;f>+8$ApQWq$e>Z_vn8$LK z*Rv(J<~6Md!3DSR*lYO>xu9`?HS(3Td6@ou>@S$_KU=0({5fzMBV=8D!2 zKC|{F#=-V|)8l6%@OV&HcDmj*mNZq=G&fbJkFCd+em&XZWh8b^6A|jiw@Sc$PT1pD zo%?&{jRDiwseEvW^%FOLZ;bW6@qT^`Tix&_pEwUR=IW2#2X0na|$1S zYXfVZ2%kIf>4UE~j(PnAEBSzRU`=KH#8hLri<_?(b-|w1PB}F_eEYASu=Ju{*DD9U z-qz=}C-mOZ+9sId+R@{lBo{yb)cmGb@T<4GukhyPOzeVcb+ zN7x;qIGkdzPi*X8hiw0^Yfis+gZtZ-ZEoAS*Fw`R%RB_MEIa%cZ|nNWO!x^|l|VSp zRla{dws^!iI+l~7CHow1ekAgL}SY^x>PZa$9 z{OC$ZJNm#5(?_vprybal^w)M)C7&0}_w4ff^Dwp7?mx8Vw0oaG58WuxF4FY%(b_Kc zk1cL{LQsL>bon?FFPk)?pEd_ybI)J-y`9%1t}h+1L;aIQTd*%SgXM)AVtu5|PRY%w zWEO|@h`17weXA=7im(gIVZI;O06Q!l#!qRD*RwsL=Y2^(qc3qA_x|IeHNHCito{2; ziTFkS$omh|WAjAt?d;^d^XvyZmX%iMZS`isA>b^oO=y#{p{>^%E= zTc7L)&CbxHQw?>MRhTtm@c6vvm~puIqx5&l{E^EKfAhP)6?XgeKfBe$06E(P{7i3l z**t0AA@H(PTZ3vo|7$@6#%(_AVmc)d&T~E2KjNPHw?Fx0yBn}N4BU=e`}$Cg$%u4S zB|fGTet5EYP$h;VMD36xq{kbyU~cIzejv%kzs{B3-z)g!@#>lPOyA@9qxb9)#=v*z zd7U$TsB|VHQd3fOgAO<(Q`yjfeg(KK#9-)yQgxN68#1)w0GNJf&m*F(zusxC`X2KV znbK$3ui%Fs-1_0vc}f3hJ)h;LB(4X57p_eZ8$u_-9$B z0aZc!OezLiY%IeseCoTo!3Oel^Ks7yJMV{6cTmsr&DUFad}K$q95lVzVe^DNVSUgw z2acPlqKjve{*{l6DPv zDB?8$@zJha*Nu%UGCThInIm4u>M%sLgB1c_Z|hyV;@&#NY(^P`W|ZQQmD7$&4a%gE z^{d@VK6ai8v2tfF?4mu!D_6NU`n`pxKUDF^29Z6H{rql>>CGOSTT@PG4BK?rkq0-u zE!e=)?f-D{JQY3AE%fJ^AKY8dgs2Y0hPVqp60M`ij@ z=}g+vAB_(1DSY`H-@r)YraV{redGO%d#?0v{z+rgfphj4$8;GuXFbC7q0*V;NWTJK zb+hE1Ewv~DA|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F z0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+ zA|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`H zAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F z0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+ zA|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`H zAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F z0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+ zA|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`H zAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F z0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+ zA|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`H zAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F z0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+ zA|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`H zAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F z0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+ zA|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`H zAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F z0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+ zA|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`H zAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F z0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+ zA|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`H zAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F z0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+ zA|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`H zAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F z0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+ zA|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`H zAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F z0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+ zA|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`H zAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F z0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+ zA|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`H zAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F z0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+ zA|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`H zAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F z0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+ zA|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`H zAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F z0wN#+A|L`HAOa#F0wN#+A|L`HAOa#F0wN#+|KAQB2mk;800{E89^^vEfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK xfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwQ8VGB7i=_Yn literal 0 HcmV?d00001 diff --git a/Covance_UCO3001/browser_profile_1/Default/Code Cache/js/251793a2effe09b5_0 b/Covance_UCO3001/browser_profile_1/Default/Code Cache/js/251793a2effe09b5_0 new file mode 100644 index 0000000000000000000000000000000000000000..820b1771f1f375496327d889a2e5df3db2b571b4 GIT binary patch literal 112176 zcmeFa33OD&);4^4N@rjQ5HJD6Fo=MN%mN}e2_z6MLks~C6;3DVBu$d;knRM+b%=L2 z*RDO)u3dGiyWUy+LW{y*esvgzk%0FPf6ICjA4Z=+DM=}PQw9#|+q-XKa*yQhU3;e_ zb?x0PrEB+|1AF#L>YY3&u~*8V?kPRG4eH*rYp=wvJqD)q=+U!x*WSGbCiU)a1CCE( z>OD?ee60;T^xl~t<9^?`G|WhR#JipiAl>k zey{C)!W8CvtA<3@7Y{Th@a>QF4xZSAU zp;8usuaBP=Gt zaK`dGDhzYp)iB(!v>Vwde*aVd%DW2n@&bV(f4>`VEb$iQ=XS~R72a4{;!fypxC9pb zNyyY~#`4PKeM@z{+srB8TdW=bqho~_EWIhQm-A69B{oFVZEcHnzHZ5m2bim|VI0D{ zbr*~A5UyL>jy0epi=2RYID&orev)MA8Z_D*%+5)!Z&;efJL_Ar!oYIg7BBRs+_1!^ zWrw9@42{68fTz%1oKoV=!gq56kXTx#xg+O3u(LjH@H0%a2LA00mHO{6P9*qxn1JVw{D6G=whn3 zlvHMv6}g84nJZT`l@3hP4NH7lPP6xJNQgmIf1a@5z_<%CZ2v|MI^vH{&cr1 zE8r<*)vdTuE{coyu6L0?{?gomK5xK z_9w5=$ed?C$z&rr1ttExQCWFzx`E5QzoR}t{dR`;ex!_5dDiu zUgWv_1M^(oTz57KN2tP0=7{HM5)fOidyp&O!gsSBT69K4n`iN9>5!JUEg|BA<|y#^ zVHWPJfYAMsIT`LkP!e#X_WT^yCTM%$CFi#&1b`r6G0L z4~Z3x!XIxgMPryV6!bRpK&cSD2e{p7u0URTve^%Xr3`#CzsL&(8N$MN@6*?wxW$_B;YCzKx8AqcykGg!DbK{ zdF#V|+R<%^83TtTr%xC-EIDz+=rqGzLXn}1k@HS@$k8HKvEL1WxeI{)G`a}%fNyr| zvSZW>IZlLV_#3zh13;BFjjnsOrpiEHVG-0f8(0pb3G@XcOZVqCePjoK&zt2ohv5q) z(cO~Pss+A#{KClyZSn?^vpoSdWb$cLN z=sBDry%qhzz&v+WKBQs}MI}k@h(;sRIf%Im3Vf5@*@FvwnXUpqFynaxD(E!~VK!XMK-bu}u3oVj(q!nF8 zq4beUZ~eXvX~-6CA+fmFRc4r*af6*(ab`v*_Q99wcNfEZnj2VvR#)9R_)WHo5yDqc z>Q3<#1f&Mtdh0 zyNW>fXDBEaI5y3D$Pq&M-`!;>z9=aNacl0kb(Qk+X3*D}rC<&q(ZKF~Q-2l)S`zRL z^k2c4{)#b`>sqA~ebD}rfc^E8WGT0xN>Zb;bu-P->`DRE#-f}0nHvlorPD!__nm5W>s6zBPT`50de^F@WWS>=Pn>33bh zv5S3_EX1JDe*M&X92CSL4Hp|UT^*Ek2Oc?=^*%e{X-XVniSVajNwM&E4EabyzxC|` z2!V`1u?u6g-)(Lux1cNi8b6&%$lMZFadv9*s4;_+N^)^+#zS7Lkd)r?9(t)lj75^u zBjD^%p*b-?oGD5Fm`3;E@h6o)(^9>9^qSDkFz2Fx8aK3in}3jlSp{%DV-$wzxKS>~ zzjSNn?Ti+)WhB7PGPDZz*ep`yjw!w~i_~~2Tn_5WvztHSCObOj>~ptM?_Am0G)lw# zgd8B5=~K#umlJ9c#4LDe#-b7^0env5)$PeBc6TJbZZp;L#HE9;l`KvxKrk{gb0P*o zR5Tg-NIfV`TKqlL68a&%STVfgLfjC3s{3c3Q%Q2&UeUK=H^M?Mm@M0!Htp|KRFXnp zi5#g`p-7^gGygytdFSzZ0?AVX(0R0)sRTQxc*qX+cS1=~HrQsE>sbJ~Riy8`o17BS z%Ro5oOjj1w&wLFX0%DlL((WDpjaI-+Uy+%FFJ!=qv%{Q3m@UFRFt7p&2^t~9HI<9< zsILfxvht;gz=UuE#b|Lu@in~#hd}2rPmVjQEQ`}7!^|NI0l%T~j?v@~h6h(kK>(`i z3Yc9;FSLDAjxV5{+Mi}0DOfaC^pO~EJW*v(%`-sO+E;pwbkD;b`}* zS5rrd-G#nV_do_u=r{OJ3>VYSEu;dMc=Nr!$zB!M4|G8qhkxtEkcmW_M7k;psdsbS7)AJA-I>a%sqzOD|SuJ z@Qun7fe<3QY@fHFETzDeYaT!$i5u#FybnVq8FD2T76rtNCN^h?wNNIEi7pKg3?<#iGUj$;hT(t znX0{<57yl$l*?D7M?r*Is7cfld#ouY#YF`rS@{?OFjvyXWSHBf)FIU3wsTUY6$Z3z zAsSM>9zSaO;|x7Ka$*{s(}|heXY2#W8}RAhgoA>I7e2_`!5)L_IiLP(EV*7YH%8=- z>9Ki|6#zNy)gG_XH5B@?@&~z#;45)K$Qk~|cMx(^>hQE-$rDD5Odp;&EOlJ6`70}+ zbF=(+9UYfslj&%bf3Cs85AP;DLY&zRg!G=QUeUprj*{xVx;a~b2MTt%Y{hqm(bffhKZNJ*b*0bb1*iS7G?gRJCi4ZcaW$A)Rji|Y9 zFQ@5h@LNmLP?$cjGM-!)o;%em!_3Bj1X*aHvUvVG{68$nhd&pKVA-E?j0e4~= zzoAMvqneS_FxNtQl7nq}K6(>52>I0n`qF_LW||}l9;8!7v!^)BaLUa1bTDQ!u3W|- zA_W9LimGyu8;~77hYjYH73I0T9NN)`KKMgVG$7{wpNU80hZ2KBO3mDEzN8GC96IQx zLDVdIG)6s~W12b2B1W|9^Cp>;?NO?_8SRr3>4At`hC%Ru-hd}iW~SgmXj0FYXOk?V z6Z0*6H@j1dA(nCHpPxs!R_H3rtO-|9;W*KPnDH@NmlGOe@F;hI3ZTMN;n1zeHV2hd z$90b=(TrFaDG17UmvNl%oBdHxE|7Yse|nrqC+OgoB<&zc=!o~VJy!`0bB`Fs$kuEr z;Xv(F`|c!K{qV%G6Go>EO3X-}FmUAP5gBFxurlcZ3R@U$E_28C%{Y6VY3d5Hr(MXXbx4zk~%@P$tF+<|fDkodMD(Vt)FN zEDSn+B4yatQ&s`mrOPKS6|zCFFJ?a7f!29#gxOfNyCUPg<ZW!x-;}008j~)}u>r;+KyK-| zC5M75l9O1@zzwrXLZWy_c6tl8D&l~oVuYa>rmAFjP+WO_Lvy+a=s1Es;Ta9H05`~v z{R^Y|kR3wZn4beX#DLuoGMXi-oZY%+BgNqHV-7mP7Z^_8ifgk0RR9fK46H6Bc_IO! z*=eAC4wIL+9-R+LnT#^bqr3@!`1{tMb7OE5?#1JWYa8Tt7bPL3h7^L|3{#qAT{N-} zxeTwIMqY{9n zy_1*Z$j}a)l+Ip;6};0~@0%w(r$s!n(ReBnP?VRD`)Abo9mGNX61 zCn}T+Ix;Wx=ubM(YhN+qu>k4lgkneqO-yyPP9ocahMDRWGeEOkeiXGr---+K1yTFQWG6>h2q1UUg5uz55gA2_$0+)&O|Sq z57#&Ap`s%;=|Z^q1k?&c5xTyiWJ3dXU8+@$PMIfgQx3>mN)Fw|Dgj?^Zh?EG$ViEV z+gjWtj%|)zchE}x;4Q5I^ADK?d_)QnL~n7gxRXR95laCgJX2k*9R2F|cTNmWhsy|#05Ei((!|f3X(W#RC30IjN8+aM;T^1Zj=kuhhBfQ3sDO#r)r_-*bTW;4~E>;5Z$!UU%9bG>E-VWG&a#$?2hAd!|D*5(luh$-KUor~xT zF(dKiyO|9YnQ4*U5jwg`sxNq&p3`*`!wKbl#Ucr_7v@^UlQG-=_>49pgK!a8aghf> zD|kY($2F@MN%t)(AVwFFua-<3RcZYGCSQ^4pdYH48T!r6k{YmY+?ba-&^>?!BN6fy z56Kul%zT+R;AAF-WjEtQHmjr<4qfpN-O&?KGbzaD(isDGYB5m%gl>KoZ06pSpMPMn zl(QK5u~>y0?BOE#?NO62~MB6@6p8Woj!a4&8W`I7eKkI|uk2Qn3OfUSZ#D{>laBh^JR zU`frvck_3eDGFDm#P_0R)g(Mo*oB+}$~8x`gjIO_vO6XvPT8%w*y9b#&f^#9L7Ki^ zdNs^d3iXEeNdqYqkN>vdIAnGJQSh_Cv17%zU(m9!T95|+=nWY(F*A~u0Y$4E^V1+U z%fW86n2KgIi1eFtfk|4&p%p$cQ>S%Ej-wCR;9I%q;?bioiUb-XX@=sIt2qK)oCe?D z_|tH+3(!+hE;c*$I!7asr$D9J!3=PEl^idJWgL{g4O5#etklL61Bm^-V(^WWVy4UQ z4$f@-fE*^8V5>zK}{nF;Nq)-|S7<5cNY(*Q`nk_KQg;mZVt$(rGq$;yg+x zs5Ho5V9iYo%ccPm<&3v`?&cO8CBz6TQZktFc4q6q(cRhRTN*FO({YuUW^+l)ECLRa z*l)7?2uaj#z?{PZkT_uRj?ZQ9lYBl-sI^PGTS^w*KIN)A?*hGsNN+5`7a|-w_}>j_ z2d<)`g0c}9wCt1`RuV^SygP*}iGQ}h5C1a+-Vg(kA}f94h6-Xql1a2{zO8sZ=C)N4 zLs_eusjxV6uK_6={q|0KETKYoFmvJao;iORN zlwx0@7^QVcc^Vbi;i*phljPv2QRx#BGcwZ6G!{VB?!E5nw$x|vKgCn*7mi9>6c)k z+>?d4*yYbp@k}wyXh|L@58HmvP<9Ds$*>$b6TpIJu$jhV4=(0lPQ7EM155sXl`e%( zV-ujh*_WFmsXcziT`DtYW(4`(=Eu`fLjSNj7Z7oojPA^7fT1O{?^7|VCBBRGsYL9+ z!19ldTDTVAM@(t{t{Uq!cIdRx+iMNjm$tC{IrqI>y z+yBTE+M}0p2Cx7f?cJy34|Y_fmqYW)xMzNeKhB8y<|cd!U$FgJk!&pSdYJD^cjv;a zSaA$1z!N0B_zzBgi~_DReNP2}B$D26|3*G2Q-!2y%5YF;r6j<~-r*hYS9Yitv4AuM z!X}BG#=hZ{qg-k(0ua3$NLs;b5(k9H|h6&9~zPhiPYXBJ-I^wL9RC@2U{u*FD-`(`~< z1RgMaPHdll(<*YjU=f4V-s}y!I)8hULSd|amCPsHHvBRJa)$n7Qti4h+-VtL2uF0j_q%)AyYZBGl3yy%5!joaJz?O zbrJsFQ=C;&;3_unrYfPJvcr@wSs-Q<@WHr5Vo8TRC*s_7L=Ht&(`7lyFvC@+=9ihjNU}zh6lNltYlGTgDq3CgamOaqWF-_# zn81wFQf8ogMfHrUWQc-H9D`szot=&<62tm8+czeL0$&z5E&4)i=2#pjZ=lLkY^41(xxcT;bAD0FVD=YNK0gi5+kXvpq z9>8`HSaZ_|SO&@?m7KSgoqJifo9a#Vig4GRQS5e`1-in+8$_%RWeVO2WaH zv#CD~mGVGDkUXixRe(l@pf=U}?3<_h3oU}1W|U=qiPjyl#nuS(q$Cv>tj8~%BKo|L zty|`cs=HyE9^JzsLuGXahAadjY-ckNdsruTB0D=lT1!m;XjNDmMEXA=7BNQO4?GOAIt?Hx;l>fpkN zm$m`losFW*si*)s(p6kOeMrqL@;sSHP-Y{?GZ_oC9IU2+z;e+{`tdENDJZ%3ScYik z2ucw+#;m&9MI2B+_yf2ru~}8l*v;u^3OGQ`_$PjOi!9=Rkm1S7H#Y~V@OHZ85wdtP zmYZsH32gR*8yP`imrm^aq@+TJC@9_zI1UV@6A#~jnugm41v?MYWUJFUP51{}g{zWr zKoKPdvCP=CrkG}j1QOS-_i5k=X3gv>*+utwr^3spczd_0WXOh`11Q0u`Hg zWRy}YZm++j*gX(y&uC;2F|hD*- z$xAuN2h&+%CI%mkd*(&_A^k^=FBDrbrR$dN&74L4gT=?k^?sfF!=4uIOx3g@7fEOk zcjQ3nb;1JS@`Y*dCeHwQc4)UQ)IO*s9B{hWbR&HF0ic%4zL8HhdP#DQgPGzS9%2w= zHJJUjP53>%L`!?^4TR+eyVmUbgC2G*Q*Mh3`f%72R@H;tZ;U?KqCSf^JP{5|2qBM*Hqf9 zHXKkujVF6LeZ8|O4TFI~4nEDj3aU$sg%b#sfgP};5GRcsfx-k31g{08Nwc35gYATX zPi^i&F&zkzM!qyPj|u^QE91(sif2Rb82PYJBifo89L@d|B~T9iY2A%%ksO0Ou(l7B z^U?-KTMxEk-jQB+6r=L>gC-PtP(_3Iy78k;}CrG-JSujE% z2kjMajlPRxe$ZaTN`uOEv9Wfb9aX{2Rd+m*ETyjJ2q+$lI#Pa{?#LGjmqPWhfiR6v z$Vv2j^Uk#4lpkD)++g-H3xIUX-=DgLNVC+=ele42Mf$=2ZEtmaff^5~2en;>mT38~ z>g0~UH?>pu`tY`Kfc z91ljxMXQr{^etx!F<(Fn>5DV-w*l7mird4UR^~A*+$TI1@xO@g~gaaC#MI#M5_s*f& z)Rw4PmTM!WiDsJB8-2HmVA5UL9$%2Jb|snSFAvHQu1e;7xk`>lD)5J5YxV0F$LT*9 z9Jtw4I+uxrgs@w+99AZWXYXKc12z-LW1#y9KCDciQi!iU1|X ztRf^ifldad{rVsLnFi+Zi~KY~_}YnMGn2f7HV?S-@?kEoTAlto;tfi zMG!*a&Gw`nY)N@!?ntsl+Ok}DbmQ7wgFiBlFz(k~AF=PkD@dy|Ok9hIWqkh+52Clm z1h`!j?nd-G^UnE^bW&n_jY`3p6{H#R8h7WwYn75Cy^EDGZYAZo4gm8A=*9Bs`Eawl zVy?Gk%Wugh#Fg$Tocm299`LXD#80PLz|9!ghXKpQ1-U-{8~FN%gmM z*uWXI9++6j!VfCsP-Y0h?rpg}pB-W_Y97HCqP+LlgdfQQvDOB0i1yYHB?_nAIpd^o z$;uJ1FJ=;OlnWWn`StVVoY-K-h5hY1=%dKFcN8rjW+Uj({LXJrrHqsiisdtw;8?{s z1HUB4RD@F#T;iVDk5oVv<`mpWs8-x z2)Q^IBsaL0ZjK?*2zb~3`p1Jc0k0meujt{gtPI9(>ikbX87re>gqIn7aY8Lu}UBi|u;F6C0KtYqA$j~CW@D}8Q*?{zb*aMHeB0?&tw@R0Q ziGx((k*B_EM#G@)i=9uTU3?i51@zeyHfh~ls zzW+tW0PrB#H4WHjAq|9-(3v&|JNJ~ccC~94&mRUE!KyrHT-V%HK$&QqG){hbGHquU7Xdyvl(VeOd};5NEH{lGim zB=cx_W*)wg3tfJ`Tum-`uz5}{jRR#X6oN_UWXi!s@3NCvGLVtueq69%X#Jh{u>i(` zc`{(eQ%!(y#KF~rh!C3*u!?{}()bMv!I<=eF<;Tq1P4MvW6gZPyo^Ft9JA||&a4PM z5c}$a+=FKkyQrHf)gO1uzwf7KQ;vrbq2Fvz_JWr5p9hJh>%}| z`a-yN4V=1V`lg5h*R-mh~!+Ad9rAuB05f(qqSsz&vu7LLAzE3{RLgp<;$il>`qk$?$E zWbnZ?p&>=MLDi`keor9>kt{!+Zp4-nvjdw06PEn8^(Pvx21*xcJd94+y)7ut8}DS-_b&Zo79$|LNZ}XAp+^Pe@?Y?7Mkhu6bKi5CoTYs zu5Gwwz+2KMX?@Oi2eb8$k!yg@eCO*INEDqPbC>2+6aXHgKTzoY7ey}}MIs+=z$S#? z)4^E2fy#qDAoJ+KU$zP|Wz-y8N;9WQYIwxK$$z%`fi2PWV`G=NolzlmsHK&A|^en!*65@*Py22|TAVK8RIfCw?6 z2H!@N6=wPhP}wXcGz!x<&lVf$@gQ@yPaI1C!E~W*pm2;gaw>TSXC(H~3zkj;LFJ-& z{D^)dSd85Dl%fJp79SHf$10(YU-N_5Ul#PbL0+MO4N@%7(V_Pqex5!^joeg0Ow6#k zR7_^r15_&AeA{)bge|dhXM~7b)T34}f>?2Lc>SSc|EBJUH6Jyz7SqBEwhqV*OYS&IQ-i23hPT!7V3 zkIkFEY)e?Z!9Nww-p%!k?lRQ|Wr)pfu40!95~7Mlm+!57nGH>*i@+25uC# z0Rc22HQCJOO)#SUA1f0$d};j|Ug8go_6r}0Ee2B1XmP-eyU$UJrtqm5?&!H!btS1` zw@r*A{B9)P#3QP(;%$=8AZX}~eJ=|(hzyi;UFHzLmW!UIkF4rJv3i7A)wnlvNwCVe zQ|FtqN>S~TDh#s?`-~opzoyA{ic-g1!ROW(8njZ3$^6&N;#o{8n0V5Ig~M2g$BZ)H zUHAMoz)%zSiY+>NtkSbIn2zf7MBl0*GND9>d?npQiPu$JhQlqy^Jv)8W==;H4Af|5^Qo); zPEmRMe-blvlGFgxwr8&K&>QGQ^1;a&8OiA&_$dkucy{;>qP zHVHKp=>!#fA{jw3km!-qzb4TliGt8woTox9iy;Qc_sHMeTcpv-O<3kPBoL5C8+sQ~ z!-E5&QcyEep*}wHv#Ui2AfAsH$bgRl9l|V12E91B=l4J4reV5H5yA{~6$P*`A~tGb zOCh@pUYz_}$w8`t%vW>k60me-GblX%N1j;eM!*-;BlB)jPe@XZLjZm38%f{mJtGs*bM9&;Lo?P`Ll;cee9?s;&Pi zZU3G6e?|MB-M{i4udlrKBJTaCw}uJ*WPN?j@BcgB#7lfve*UL6blv|{=f7L_{}dPD zL*M`1cK`o+|9kc5Kk+kEKB3?L3Wjz5s*Lyls{F6+{}rzPZhh7Zeg74{|C{$o-~Y|_ zb=#!lzk2Js|0h2+P5&p`{C`7R?DwD1QR@Iro+cXO++}H%?8-&(_Y~gZd`)|V%|6!N z$89mJ27~Z~Miv8Mo$({5r+A6;FMIO%OXls=@t5~Rm@E?~mO9HCAr>?ME?-f$*5g-% zMcLxVZ&W9Ic9y4KCYI|e5`>Ayu~14>7r0@o z8OW4f@HiIF6CGeMOfW(muLU+A{q6{WVL_mk;R;Cint76+>Hy6Hz<7`$TRP@cKryN% z&eu+a0(B*;7%3}OJztwu*(eENRhzJlxE8oAb=dSHg8ng>E!yu1`wKQTQEcMu;O9^( z6r1kCy(M@{;;*$YS}fSaq!ro3ndr${U~|Ey&S1nuyd}^(8i>;-0P4&Gy5P z9^0aM2r8xMh&^&3+s9@q6#jRR)E(UVGqN-qqEyn-WYIZ^G#@^vbj2T=vbRT(Hn`N*V(jj5!D`*pa98fd z3+L_ES$o)QVSAd`acMgrURiHnk7`Hc(-eAcLj$k|BMxIKjDwh+~T{}HNTQxb@amCh#* z&c}{kT%j7;pJc{EYw?zkoASu&gheLWMrO3G*P*2~R2}4aSsmKJAr-C61OkRHzS=%X zQ8^EXNY5A9eM|oZI3qeyP{+onv^I<{+pwLq%n_~oy-v2~cyW!C(ER9Vv1p$qw!9&q z*a3yKCKfg?t0<(>io$Hg$t%rEux<#gsvoKbX!hP7m#o%(4fo_$UAkz$&NdsumNviG5;Hf8T;a$= z?Ib&O)F6WmxF%!nQ8_XR_QX2(FhNB+h?}dbqZY*)^`ol(MEKfvUh85Q zJ>h`ldE&x$l$QrD4`*}O<7=&93pbMNE#u*-;mT-4@Dief@hJW+)QHBigIthS9sD+= zgHTy-9~1$NctzP?>R5j1l}l?c8udO|-Rj)=b(hXvG*&j;R~c2++kWn%dESP+NW5FRt!pdz%zr=dnF(bh2XX%KEIJ~^UH zR*^q45X%9Rri4NEXt=1Ku&9-MmOi}VYI{>vd2VZ4^gI>5;jmz)b2oo#|CAVSQ_cIK|o+=iw~I)_gf)x<>F* zu@|G9!NK=B+NY`;3mf!zQn*k8xxy7GpxJws%#f8*x>Q4j>;xBL6oyb z_VFtnrz4tyC|C!(sek7StHBwNgb>Z z;bbi7g^1eY&iqijSMKE|ID~}|x+Na&C5K}-U)yeZ3eSKgtV*1bq`i!i{rirE6~ace z6A*n4mA%rl2cZ&=2t=K}rVj2Bs0-))&?9;rUt9v|k?ojl>K!B)d zII&2D99sW6qeyHT!Kc*q1wghCh}xmwQfc47^n4tMK9H9in5M~=JExx;kc_&QG zSv1g%0168QN~5Buv03Ty3YG4PU(;wwMW?ztZ>{INI?~eB8E46i#&tN}{B-_cbw2An zXkFkuW*zAK);e(h!UFQs0Xq2t3!yU>Yvn^$d&k{Tj(!(xj;OF{{Vv#@Eo_%s*e|-P ztLzaCu8b>*p05?zhS4Pltg&1%W1)VNoqUDGbd4*wSgGH3G+a;V3%riu4DG4Xm&bb; z#@9V5q0r%Iao&Cp6@@x1*&P=?Z-G!iJ<9-Njqp%}!bc?Gu43JyP}bG_5D8a!-o5>H zk}HRz_$=-rhRwxBU|Nz->(^02lnp-!(((b^5qz^C`nKBk=3KHlf+i=)s~dwCO)-oP zWng`5<>UxyUV5+~w}cA-+E>f1;pO;L3W(@HSXVFHS`cbo$_NS*4PzbN0-*&sZ z0C+G6lx($+m7LJ3a~q%<)`5yGGK?g=B_|%XEmktoy&4Co=vq)R0rdc+{P;gKTsJ+I z(H_YRZfL^*zQ( zC#;>diF*P*8;9Z+gKJx0{nu@f|LOdxhsk0ZGNimd~b2>{3A z8t4(#kXBvjs1a8Ora9`53BtrVIQ64xX)T0;8qMoK6#!yo5XuoYPidiUYa*ap)Pj;? zcpEUkYdCUr{P2gwZbEK*<VAF+z_Ja)mY#YjMjCq)PLGA{)V@7#TZq* zrR(kyv7~+;GAD>h3vUuIwW)(C16YE!f;&yc~RRhb7&uUCyM}ymP=QvQc#0!StQ(@8U2;kPWb+8NqhRM%q zEMUi>rU~*ybZQ@{VdDyu?pXMa(L_@|$1ft%FUQhbUBQ1L0ExL6K&PXn><1>EU5U&PlaG`|1Xx^gE`zqZr* z%P0Ku?k?+3yZEJiw{_ia*;uCxtd`;F7|_FrB@)7oQzN@rYi$3k(^n$fEhVnn9meT0i=fG=KA{ zwc;~5c9a8JGU$CL5R*Mxj`yLcQz&AQ+x;9!8@{B0Mn@=Wv?HDdpzG@Zbp*ga)@h)X zb^uX>^)ST%ig|dxq#$G};%R`Sy~<8-2-Mwp^Ly)?Kd>90{$Sm5lwS<%vw)P{NOcN1 zGqk)0H_4&t_`D$$z2fw}uNlThyrqR=_S0r|*KK5L%@fPw2zg_Xp4v!!51~qzP<*kR zvVHyN;RBE6PEdX*L zJD?415rBHu0owVwVLY>61Etn13&yLqD)8B>7ML7J&wODR8@|+lw}w^7Ri@?&Y%xB2 z*8<}_^AiBH{z?PQ3s*o*6cC~Zpr<{bcrH$X> zh^y~3P*W>_Lgk2|*yvlQr8@xd?nw=_&jBEEP|FGqY0f1J&XrSjD0HR~iK+gbZKph}206qu;^|C1Pnkn+0#iux>9-or!B<~;q?*CP{ zbT#`#@-z?zEF+;#OT&IMjKP0spc}#j2g!I1wiIBApIo0NLeIcb|5V>!ajGNkh1m*%YY&&v@zu-qrxo4t#~Y2 zg57EX7`sMyOewFx=fGNEi@=Ys0N{$yKu;5hs-Yd)3ji8a2dE4HpW@^n+0rpY#7d)d zTNu=g|$FUbRGJ_6nn%F}M!UYyjjU z87B#JL;#5T)ItGalrx6Z0+I^94C1!LYtH?<}8JF(x3e z=k*h#qht?w@^a_}iqf&0>vf)YoRU z$Ia-A)xx-k`r7Q_aqaus9FcL?;U`_|#XZv3=4=o*v#%{YI&M~9TSViy*?n!1F>wR? z+M=4pCH1w{i;bJt*H*uI+}ysl1})>}_q8=_6}O~x zUc^H9b2zt+B+-cKy!KDt!35FO=nVCD4XXb=R6Ue2?`UQ*4z|!*^||wk+3hO;8&(U9 zv+)Z6_&XjJma2GzT}^MbRjvil@H#*f0dOD))Hgx_XR|egVKTENsb^F4zD> z1JgspdH{_K1ycTS3qV?SfIk#TLLCeJ@sWMsC)kw_pBFC?c0;NME`=zyp}z{0X|+&t z6uk+^rV51ff}zznd+itY3UrZ*zGT~ig|&?Gbs!Tz(SuJpHb@6Bm#DhxZhdG4Sm;cD zBdVv@q2U?;RP_X4pLzM$5h30`9=6Z^jx;R)&c5OYetGK$`+4zY<5Bxh$AtHfLS5vu z@gZKPezfm8R?GFjsM^=EcmwrDg|;su{l>j4#<|{_=&MO|Xi%^jKpCMxN)`=nvKVLZ zt}Tm|r|jRI63nwcD`jy{O`xuQ+PgqGIuxZIf$-4#<9JKJIL4-ApAJvn2iTZeU<_zq z1wd(E4fGUX=sq>f7QozA2j(}_Z{JVBaOU5=$H=XW%S&)@A|Fx)779WSV;`VsY#l7C zfnk3rma{KxeMVv7F-BKn*$OPT*TFLBW{a@|Z_#P4MJ2h8JWtgIEx~8_6+PM#KSc4k zI+$JqmihfPCx%-UkdA`30qBlUASKAww_txy!j*zNd)dDB7dzH!knNMCVd7MA%PJq^ zfAN@@I=T>p2PaNsx(;VBTQKgd)e^l+JG9Y$Fxu(4Q0O@-87F2qUV6yU*hu(#rsMI4 z`Q^lH$BsuFQ24d~bj+W_FI?4-8u3+4^sYPgF_7F9+EjlIkL__+W&dwzXyQT*kHLLg zDTt`BWn)y0tVm-VrOVDSYgkN#)V$Qh+8N(4dqu?S)*)!vl#fbaw*w5d-S%?u^Qpa07#zn zoB1Lski^L|l?7PBJQKIk11w{ZiB`P1O^xm8+%Lq3L25Tj7S>wDVBqs4df>v7dQ!H1 z!&Km-CA$wm6G9~`oYeyW$Q-4CdW8ds&gvReW=oa$G(&-ujz0j9rrFTFAqb?4ZbmJ> zX0CRuT}>4`u-ftLdIzHB?du&sz0NO-HaPaZ!7q=#=h(A_b>7_SSi4Q=W8^DG$`#cs zrE{b5w*o?v@F_lBp(H5h)(6dxfj^VoecV1@E@NrR4*)E)78vueg#ehCqk$qK6p-f8 z*8mdRKkzB_lt8lq@Kz9L7h58M4N!>$euK~KIxX!1fRU?P`ZinvX%Bc1K<-c=#n@{A z5|($R^Ek2FasOV)t8&@jLK)`IG& zKh)xD*875+_Nb?PAKzy+)*OSj!UT((HWf)_J`pVr2N1iCp#2pCZXZhRck>6V{h`_) zT*X6*z3uQqQZ%06{V0mi1z8k`a5U38nNP48?eGi4p-yFF7VkRorjfJMb&JPh6y_@y zB-?j2L@-0vX%BJ)mH!svLHd0&SL|a1a2A|_L@y+yeFz~HdQro*5a`QrxN7a;d+!&H zm0wE1JuCR1tgKSE{2lO!1sb-37`yS*O*|17oyy6PotoRq5+l1r0%e;yIj(2WR<9!6 zr7N)hfSQRR{h3t}Cw{TFog3$LuqEMxfmwOnU~g2p>rP;<41{10^|wcXAxV2gep32; zapPe11B|z>qerv`J>ooYRdNnjAyN2C|TqNFt zfpnoq!&-F^N)+;Yj};md_z6ru0|QpN#Y^`#+4VNC+*PhH*>6EqD<_9K33U?nC)RVsim9oQ$Wd!JpeuIetG0XAVw_>_!b+GQUw zO@B}`;$zEV={$A7aSoNep(Kd?>U4N23h+dmxKL3*aQCF81MQTtmV!0xuUllJWQo?c z;P@*Kk1|}lK*_FIiW)h-hg#2;Z9k7^#u3*JPvg9HI(^MWNcI z2C4)!+kd5EoxPh)<=ONk_IH3yss+a7gRuZO7zBFW0U#Pv94gZf{DIHnIzWE_;H#H( zONq?rQQ>s#Kz8}-0R0AlX{$BRKXpE@wQ9)%pgzV2CUaW)slm-z2H!91DN>54zyikU&*dZZ&-}k?`gniF)D;Yg#l`Et;XnBUO@c~ z?`xP|b^wJk&Hrl0pz&4>w20|Ewxnm%5dfN6 z2WUG0E`OwfuGK(#=7toe@sBz{-)+anzmF9VM~qcBPhUj0BhL3wXM3P|3Oz>A90g2w z*TIwoEU#%y_V>fZ3m-$!J-~GRCmI|4(l|?2nL}g4C$NOBK{f!E`$DlO>mC3cLw|sEzXW+srY$U*@qu&QHhx+A zvGbFU`Q^zS&JTC+i-CA<(_Id#oUhDpeP0o+s z!Vj^rzH~viGx!c&U}*^Ml!tOBhCCh*zWCu01rUSSajUcEFpR_zLE?9_m83YZ(6zJy zmiy~qnF9q zpbnN}z;N>^g~jI(F;LeZ=K-vlI8cuW0*(~4}p z#LoDl#P1&H_v6eD`~*3|6{?eVe?5R}b|@~fyqp_hHP%Kk-B7c@eQII&s>LJ|`Veek zw`IpJs)uX==hOK`?ujkv5ekV^Wo%)_tIY`6+7^jt8pH4vbZ@%57M4bQNJ%4fot ztPZz15;m+3U-yb=Gi>R!%cug@Ef9N`S^vT3!cRXR?zAN=UJ*WjwP0L5EQkxkXZbrz z!+%^J9%W6yRyn{0_c6>|7XHFAV*S^$@M`fzsJQAC_HK?l*EN~iE6)HGN5KRS98vt! zF$L1J#y>-QC!QeVj9LY{)s0MCT$%2wd1B3qLcW*ZXg8+yu#3rWy7llH26>#lii49o z;DVvs{_T-%X)N*}ARY@funa#WE-4SLT8OzBGqD%I;J4$HLL}QAjjx!sCV==pDw@pU zCkf$8%)|Jo%WOz;qcX(B;z0x!lezTza`_k=&tqtoNMIR@;k@_?jVZnW1@Gh3E@{o9 zuiPn`2#7~RIViSDegObi3k`IPK(uA8R7n7uTL&n*mDP9zZ>gT(SHEqCcamQ|Z>=+D zxB)kG2p$M*^Xg!`_Zq9Q4DTSeBb7}L5Svtsphgf|sD~Z|Z1d}2vs`C2?!;Sip-gi@ z+jKI37SsWn1c1y=8t5yrUzUV71{Gv^3ZNE-LKQICI-LSg52-aaaiO%Y9oHho9IU^3 zUQ$f6m@Qa}^90+>hV~(Ykm+u73#E&5p5Oq|vUi`45`-7MJE!gkSJb;%x% zIhUkpu1HbP8PbZPI-4T*O2v>X@cLQvTS3yIP??F&tw6^%4c3yjU{8mfhG z)40{e=R;9MSKtaLSdAzfSAn;|2(!zGZji)7B>MX@PvAoVKJ-A`mqZ5#AS&OHz@EMaPo}J`MpGTNx?$Cr}l&jbcnU z`Y|ZND>x3#3+5mhS7YEQ@+*9XZK$WaRb8XH2Dh^Q@=e6*gFK_^rBVU; znprs;MEAv{ZRWn&Ru1YG>uj49ckK4r4jTvgu(o00a9PgCy*+H<^>#Oj*wv!?99>p} zD+(fawWtyW(X6;PZbIKnQH|wSv+t#PG2-j&`gZui2FAS>sa zL*g7#KJSX(gcZM&TWcIbYW%Qx0G5Igdy!((5Md;U?}%8$KMDhCET>->;$h<1;L>A% z5|w`nrmvi&&91doo%*3|JRe|7L(NV+wfO-6?!+PNmX>mN4k{VPzK>Y_ql`7slbYQx z$A5@;^hY5>z47rKeTa!3#IXWpEDLQ!tSFbDfkjg^Wgpr>8HK1Ff)7B;LxIE)AZ%X7 zyzhrPgy3>xN{vU?%1A|`GEU&3tN89ZhE~VluWhByHi1cKxo?QVmELi?IQ>V%*K+XU z`D77FR$Hxqtpiie*o|#ghtPrXoqjK*Gaxxa1%l82&NXqnW?`RfcXXEFi*)FE{i_H? zkJpkmBj@Sp)6nUfqqjR%wwgSniWCEAMJPwbDBuG?_)HD-VYrH{+bAGEfL^Er)CmCo zhc(b@olMtxaV!WLFNOlC0cFO|@~gLX$-$XmVv}lPZ)AUtl#BFV>V!a>BU~Om}Z8 zz*f})V}|ct05pF>10Cc-K7p`VXzf|D^lH#g;C)dWT-;;dZxBW<}vV&xya zsGZB|^}u$^Wnp-9*1i$<1PkkWsj&9;(){1P(-O%JIahVC5e4YjtS9 z6ytX-w;FTSY95})gOg;TPH#>F)S6mQT%&mt_5ZzI!_O^5b};*8zgF%VCmni{_8?HM z3q`5A+!MQSpLs)5^1e+i9B4QA5Wv>g0^_nu&UUL&xKjhY4HzasbW`&H^J*xJIIv7?YHYq8FgEyHyk|-8eJ1p8?V4y&4(PcHT>)#m~b?WctKqi4>0opig2y zD={tv#ytw7mtEw@$=4jiCJuSA>y$v8by?Fm+cHO-ePf&*AGVDmCx#G$i7{z3HJLGT zk3+G{R_TMm=A*UOLWNbt7@8os(Z>w=WNivR5>kZV9_~Up<_-a!b`EXH->%J<3+O zyuJ~4l?9cmBXC_E>`RRU&@8$5yu*mcF+lc@uh< z3SSTHxkymW0D$WGSD`%*I=3PC#jx*jG}n=D!~N7LSR)%TW*9s+3jLm3Wn0m+N43Si z7Y9e#!gl9gs=g4uxBefc$mXwT+@snWDGKU|f(AHIDth0dn~X;6=U=$F5$NH8mFQ*M z6>csT8&7C;e7#ye)(FROQ}`vE9?IQeFoM@|Oa;`B>*>v42zV`#Uo^fM7nO@hk|#9+O=mXu@h)WN$lFtu65GLLwvlQv{tnj-Qxk6(ch?_%HF^Gw-b7kCMfZvqmZ?@o|3pG^7a~$s%-v(ut?2(fRI0o-FUE&AUs^X8AKko-f z{8CqOVSK4?0)e^qv>6NMW2h) z7OB@J7EGwD*1d5z;4C@#Z|~t;nWjHq&S$d-m>P#RZ*78CSg$f zgsKMnnm7}x8t%j9*yy;XmHE}S#>*PTbw>U07*W63@)%h^Le!6C%{c1G6;_~K=ABTH zq1&J)ldc$_;+=Skbb1O}(TCr0NUB_BZ?JLZzBn7~x!SrsQM&C*_l4~o2Q@g0jO3+W)y_R_EGuH- zTAS;t*%#N#1JdKu*jjDbrz5MJeXV;!- zQtzYHgHN7XclP9&CM)}VvMcIb@9L9hV)n$f*p~nExn{fL>Tk{e>0)e)s-Ih2IDsMY zVnxG;?9DrFjk?(HCr68@pKkv7#MSFhE*fZDQ_)#A7`CH{b9;|d;jKT8tM^g<$?CQr zHHp}kcly-HpRY|g6ThS2>>2xYQB`zUH=?`^Jn*ovmhm6(gCM$$H=ar@Ch^ zYxHNT_F<&+*$SL0RZC$i7XQf|DA4ZyiT@r5lKxtORCUMgO(H(ZI|GfmKH+TpodxI4+Ha_v1<<-uu*YF^ z`5e09vDMX;8>t9*IXWj8jzRYJ;av|KU7I8{Dlh*yRA02N=;3V{bmgs3UAddX+fpD> zZfa$yssxW}V^lt^_?4}U3xYq0hmqS->-h}fsqT+(K1)~7{oV#*1C!c~X;dt-zteQG z2?QY{y-~S*C?t_me&Ll1YtLKj?O1*DnX~IIoH=h@*?G^tsEfU;&z!gIjf?m=|MVrt z^05kE+<>zPo!jn~(&Okc5O9LLdoQLK7q?(os-) zc_IO_Nj62&Ora?Hz^(|7BqUgou42dD5xW$HC)S68J{t--?`z7cGD)yg)ZvEB}lV%sh&+kAn)II4gB-21Q6+2rqg2vQb0J&r`V_1i0ZwZqFT zx{FW9qKm-YR4rA?F)T3>!=PzwxJZtB3_@vh>}kuObEh3m&OL1%7;J5>j}x(c(`1JE z2HWsqXY6}Qn$I{RgM^hTs4;~c`x4jF=h1#O*UWA9(6xpyEEcDuda}O>Tzk#RwHh%f z-i?eawjH*z&A$?Tg>^nkg*D|Xr|~`x5;vE}vTeP4rjrPBET*7%>`d|`^8W7HPyR_$ zvmCstj66<3f5MF-Tq53YZHtm{8Y;q8-hek$ro!TL@IxxEi0W853_mc3;XQ;kI)`1r zHbaIZMXY1|PQ>rMiOxOk%-sl5+GO9|&an$$PMW(C?O5MBUfkSdh9FicSB3vZ4Y}(( zr?Cp`QIO1?wQWldW= zxpV8b&t9UQF_-5u;xF$V`T5`}a?HCBXVm3aiF>byeRhzwR!W02I{9VMGi^Ee?Oz-> zJ2t@Wt}-1j3RzUf?hB)Y2|Wb?@r_!*|Z+c$=TCH+s@v7pY^I;z(a?K?_No;Z#T z_D$zH1>OtgJsyLl$h8s#91$C8#22&m#w5OxB;GK0wsY+0f81=nBhmh0@yQd8s8mzD z=8V}mI%2Q-iVTFr?g>A$pgDeX?;x-G_al&qdoYHop0b)x6XK>oX>tW#D2*A;j*#(IAe%Gk6 zq1gRk1w8`LwjfZ#A9mx4a~gDy10V_ky_&cMpf{}`Wl^gKamt#tR(IQUH)Zw27! zjBszL!)O(zQIWRQ(u0BH87+xV0Q7bcC<%aRK2VbrAZlegr6&P;CkRvmzJ(Ktd{f|dY725Xb$)4;qJgh|Ew9olHjKCywrn!T++y>CUSYAFTg zb6kO|#v2}t*!!TU7QJk<2&|P6lyu&o0mTmjDAFEx7__!Wk=|;bv&kLnB3@l5sA*@( zhS1suh$J|2E0#Y8Vjo(GsruauQa42FV!46hvQ~sby#Uk>D@vRl!TGro?VI9r@I%=p zeC8HmJ$x83XxRa6j6wUHdJi#ZlWKEFp0oRbNmu66s|8CtSdl9!@#aq|sVNjP5<|GK zO>O@+lw$SkAF4j3SXD3LNX;-|w~D^25AN!@aQ(;q(W5tnBSLHz>L$EtFO*s5M}?=F z9j=ce&n-L^w%HkOe<3mHqe$DXl2fNowqgj`2)uB{-a0YtBZN+m5MSD`Fy@mc0G7fYPF|vDx z7&7p?-X_N4a9s>`07Gx8OR+>kaPD-rTC(IaF?r!6nV01_gfQ@S7;LOBfyGyFNXLhk zkj-DMM|BEcQGSmDHuoxqC|^P$$j=&NvjEvN<5a-Th8*6u#Wv>g z6{I6##`3$238ce1V>g4b^MAFH@BhA)46E&&<0kdcx=v=3dT&)%M?^yo6T(O}_At&k*bP*l?9@(BY7rbd*g5BOr2Zk|1F_W{S^mIIwwk=+d?V*49^~+Jpki>i1@;$~z!b6-57asO9F<8HasSZrY#^x?t;5Mg8IC(*Gt(f%>C-P6WJ%?>VU z2R3d?e~lU(V%&;LpC>U~k`>LE9Ooz0ugL22B;G)gKGceATpTszki9oGkr$#Q>Y!XM zavquWjW~f;GTeWHE}y;pLYX{`((8fT_CJe$+BOWNbcdzm=P4T4Z*T7ix2M|SN7ugz z>OGc2?HgL%zKc<4!cXpjs(2;@UgY=_`U2+wSTi*+zjCzN(9ZW0E^hr#IwE$>YdYEb z?|4iC7Gbs&U!cS&3*}CE`$tHm;Cma1wI3jjJrFL}7YI1bP!$f;lQ&_5? zj)?wQO%Vh1ugD9tnj*9Guhti3 zHMJfRe=dUsZZmZEG8nIR7B-zcF&shru}-GxM~_6B7d4$8t$~h+tfrVt@hco{CW)633fi z(pc-BWQ1>XhUP4Fwpwc-Ci)V4{MseXRyj*KS9Qhb*zED!(5_hP(oI{pw%2fXf)bkO z8b$o7+q&?7k3cjcBhr>`Uj{PqkWg0dh*m$O=iT7 z$9o(<@${+VP39x*KHih~%ZF&m&JWr;-tTbwNb#|w4%gP>4ao+Ahy!oc2P_@;B*b9I zFo^!F|FKep=}P#LB@ucMic#|ua`_``iCg-jKW;6tZ>f(Z?jAX&DhIiu*2)j9#;SA! z{iVy$rR#{&9hapGKRvMdc$4eB4yS)(5yMc#R3n^4{F@REMCs-aM+skQVU>-=S{Nk_ zKP;hP^DP+Z8Q7aB;m6hzigQga0YHs7@0_=U!Qs54QTV}K;Kipd>+LC zbf7C>+Gzl5wK287>4@lHHgCW} zc2={aHHbz*Up8a7nj}_-%=q>up&^1~xA=2m0-CTf;Wk(MbgZQgZVv6h|HC?UXvXv( z6uRhabw#$i;T4Q>-NWe_V{J-M;q(YLVwV*#;QC|HaDhDYV)BmRMK3YT z?^PY7!Jm(o0Dhb~OR%O4sRn6AYXFu364n|KQS4J{2|$ajw{eTdeDPCk9iM%BcH*1i zK8m3lwi??-XHNTeh1c0)>wOv=Gs(^-r@#8Fi?=}hW#vA0brK$H1FnU5hOj$gn*>Cv zIRD1y-Dd8AV668EMj3iWCjpNDAsDwKi9Oa%q^5h9baxnaxTJ{f9>(cBbzHrB?;YUw z2H-g7+ysOTrY4CR653*K!MgzcI|$Scfbet;YH%o!p3c7q&?iBl9spe2Q-f@FfM_sb z4bX7F<-dJa&`hC@Vh?~84nq=h@UEJW7Ev7)nsHFyJ&K*}SHjg+2?uI4{r;RiG!j@k z23}fHp6e+YK4~m|i&Fd6m8etpS*1?}Z0KZ8S1GRU3SBOri6fKZ6MxQavkU{ZLjPCK zjJj(=j8}2BY}d>I<-wfQ5m!igP*zY}2=`~+x9)&|ceOcIrY(9LBr2WM07x--JzO_fuqdoXRd)y0=xzy_`c>Xdt6FoeomiKN?)Y(cm(? zriPmbtS!o?Lac(=))NACPK~T~o>A9~PSn;m%wgZt&Cb;VoR`rCJ~F48Tv%NRK3{}m z2|sDr!2dEXJ&vf_71n7AIDVYN9IcihYL2g{=MFJVuS9Ft}O?9 zik36nYX}c*NUSVKuVvhH)hsq$A&(&;*g~?qtxJ1jV@&w?w$N7T9~rS{&V_^g;8S7P z{L&SFTSXf2XN0ME@TqWYN120r5z*nNvQ9^~1uFi`T9(oJV%F*S zbY=rz@lxAV{MRl6#_}`g5C+cJT>>um;;+8=#dqeNJ_Y0SnREU8zx(ocfB*0P{LL+< z>iq$FU7^8tabxL);36BV+-t_eT|yF|2gg$vUIHCh=)z*X#xB|#9n+`>OB)HC(}d*u zH^|?sD#+i|5ijOahjG_fE$}>ut0i$dFvi!weP)$-V&CRwAg&&#QA-`GWa#8}$R@?) zHvoMe1X>EfKQ7mx=^+Xft3U?;`XUHa48TJgB$m|_jLTI_>mXoX2EpD0SKeJGft8nGzhTy6SPoCFkLGMS<`#OLg-AMlerGr;ms68>~lVcQw z#Z}YG=9QH%C>t$Zg%mYiy+484H$l|yn&~ihT&0V&35`NBg7T0&M;HR*KoIJCAWE|p z%9*si&fX9hrTGwGVj&7-WE*7GZwKTTKdfK9hG`D|0@$}fsX1pmj3Ky04Lg%^8wq2} z*R}O4VBZD7W&pC>58Ga=VezVL2##RMx#9qHDt*Vz`hTHbpm9f zA9lQpE}L%jh^k=x5Ckg#4cS<{kBg=Q`G>qsnv^0yi@ba zE1*(nYP!;45i))aqBbJWVJx{?F~)q&sj{Hi(hShyAkb<6o}H&b(KgjiH0XDLjs$_8 zD|Hyoat(@f@<23>oH2@be*pDc5UMi}lPfgJ6WSpC<#nO{1n6iGs0@H<@CB5TvBm`u z+p$)_&jNJJ3R*7x-uxQwro3*_a>Rq1SZnp`c1!xsufNN@>J&)3B8i(%$fbw4CcPLY<~GX z??{oy%Md4`3ip`K4-dWcIY)c8Yc^??=t%vmr&uCSe*O$HRlEyYJ)fMu%TH^R3{Xa5 zqy=2h-=E2*O++$LLh0zzzI4{794F-c;br;octK{S2wrPE%D1IH<_yax9fK_8L)s(0 zdZ>wwIIqZ?H*Zu;MG3u98C?LGW7^xJpLH|s0-Q%WHhJQ&ylg%C&{Q@=iSvs0Lw;&IgS0$VtVcGi@yv;FJ=Z4m>OjlC|La-HcmHp{Thd~q z_{+PyCmWw^NTR`vsVU2&U#INO0h2^E;|{HI80ENRe}65}d^%C-?ph?BLzkbdrzxCX zs+HqAfLc_oSB|yS?ByRLpZX~hN~ICHMACdSQSCHi-YDq}NPsC;f?~s8JxEp8=#0EW z5Ql3GvI8{L3KAh|RsnD!9HgxwYTo@d^7P?Ix)kWOYn#r2R%;v}HqA;*G2?F(n>FqvcIjBH0wKW62*MQO{qDDE%$`KG9Y{-O7eN0A z0$m0`)-ny+M-Wrez89eYT^R(L2*BfaY0wu0QKV}PISingL7*J~ytP7u_G^$HU$GC* zxGDf7)z+^8S@JIpJ9wVv6b|I903`Q+uLI_iT8;ZYQEiXY!w%vE8QDRgh&qSSqd|jy zCWuXj!i?<{0eqAR#HKy!jX(*YQMw+0>4De3IB0cdUzXf^=7 z@716tf~+cG6hJuvAj!fj0r_E#hBYe|a=1@c1&apK6M$qePV+&BvF}NZJDZ4bRP>1+0B4`pAX|HY$ifaPrM3X&1%VQ`I*cQ@WdC*#+v-B^I~gFvCrAXw|` z8Wctl`L6qS96;V6P&WYn^M(dR5=0j2ejE>w*l&yMT4$~Azv(cl_G(ySdnweIN3Crl zCX!JYkQ{dy)&bN16OHTCULDD$XBr6ri4`Iyhmqmd&WGl6WGEFewW_e3kcd4?*sf%| zVA8z#*Ny!x6%RcOIq%LZ!BFAmzV70@k(Td5>vW4CJ7P7MxtNF?4ERaqg6Ujx{Fg*0 zNQu!7e~~Sgg@Y;=ffJFfVpW#tYm`|9ViunjM(2*FVNkKBI=NRZH3Xa8?WwM1ro)~Z zy3A?XQ(G+yaoSVEm$^dhsS(RUUG~(-WnrQA)Yi*dh1pZvEDLXCPmNj@fwj@-Wswo~ z)R<+hBkieem$hkaPmNs`)yAG0w=6o!o*KU_Cfc6bZduzHduqb6*tYi6#AR`@_SE*v z;^XY89hS9=x2JYqme9_g+U53CM}J2mj%;_!S0Og0bb~8k_q`28wjS;5GgDLT4eN}w zh}5u{)Q<6|V~vm6b|Urk)K1GfCn&F)Rkj@0f%zF=Iol>T!bUIsnU2~~SVD?2mg2IR zp+>>o)WFcexHZCoafO?`;O2^d@}3KS>311|zfRiG#8Xzj^nB{5!fgEoUfma9uMts9 ze|8vO;*uTnX9r!jNLTk4gwirjShaUGlph9W>oE+Y0f(Kw_MbLC?}um`_VYJwHXP&^ zL`d5-Oi_Q%R;Okmx=(ck^^;cWYE(T7%C9u(TwNbpCyyo2gBF5o8BGB&4ym62Fz%EF zxq({djU`_>L=HUG&PixFEI6=yz$n=2F6{yoesAE8so>eF+mp`02{0fzBsj!M8 zBaC{PXRQ+@gVLEGN=rcHBb%uhwA2L1Ds#F4)NBPQ?*9Ntv6B%X7`R0%QY&tcs=Xsh zs4+>hKF2!i!EwqzosASw{M|}XaeN1;T^Fh{!XnjOa6=D&k%Ry;>g9}C)9L|Qe^_aW z0F9AhrZFWRd9ws)yl+d?{f}bw8fJt|pS@s`D(*fT2(pg!Fpvs@e_9EO1C5J7>`*(+ zBd4$(v5D$&ARVZ)L8$Htrcr`RGNLPuXawns?FrCdR*>TCQ-JhMMD7DZEgpV4>ZYya zY{S;5&EgAkjgR88oyI^?*9|lSPtRGYD=v=$<>R;{Zn}My+{CWCLneuGc)&*vPVA!2 z_NcxN8q|PL1%asEK-q#&R{`<854Dd|dA2Ogv_1gYgFt5inA}Mxb&VaMP^`e{`soXh zBM4LpfU~m(J*KAr+V`{{FlG>@1Kz(bRbvvvXr5q7I(uC1bq1iMrgJwi-O@B}zoQ{A zjQRzDg#^H84;%u({&WqRj<`fpoz;5I0H9n!sIPmP#`SKE@`Na-Wi1#70u&kqS_{D4 zy)-D=1rXas5-ODX<%Ix+1%aLd;DJmH%Caet<~q05w+aH;5cjcTKMmRyLicBObgf{* zkVNnS6j)p4M>Bx(V0cstT(rN%+)*v%1M1d&c2pR%Vn;_7?0SFtcvscqH zsQe`WMFoMn0`SE}8Win29bB`0C{WP>D9OO1z%*Q}abb4l39g0WFu-C0V00fZ8)6#M zMk$amxAf{Nc2z(T^p+rAi}Kjkl3+Nfv<;$C0SXt4)k*J%Bn(t;M*tNYgc=XTN8>cA zDFiFfY$$qQ90^cd5a_=EOdGF3ySQvkke>650w_KRR1UzTsT#DDVg3lx%J67_#Q8YB zWw8a)2PWnB?Y0D%!im=pi##{l&+^)G!3Ax0U+6R zPXKaop@zMrVS1=S=tv_u07fxZy2v!PE!Lnom)2pmCNTr3Zb7KJ8%<-`Z3;zwYR0=4 zAMoo_ViIT6$wf{rI%a}Wij|UT>5CC$_47Mhw)9)-V;-)LVcQH-ZDl4#Hc3(E?J7|0 z9zcXJfv2j*M)2F6N!*Woec?u|y_fL+l^9%BQo2u5DykQ&CLai4^*5(3!i(#o?V& zKy$SiIJXri&T1J0MD|8<)qhsYJ@3ctdq0K|h$2)`yM`g0BZ=wp`)UyDWhEv8d9B!F z8vAg`tWS2T7?51Z;82VJd`6}fr1jqE-F<(>{C;~|hYdr)jawe>3F6>OgD=eGJvX&IdK;`&!*E{~aXdpkkuN&YYmjIk zYoe-hwj#;7?`qC?ojm%+I;7SB*Eax1YumLzyzE1jsFQE>FgG8VenFU5-ZPC0KhP;P zxfDppMOy$+{~*v<03OsJDjO@J_lRIRbFuEp?Fpd5V(M{dA*ftnrJ`!G_H&GgU$8Y< zXPH~Jwmq^{@U4|<)o0PFrJ+(wvL&E6z)DduZVjmIN901u?`uLhwvlmq-gF~y1Fg6O zj?8}oG3RUM!@oi7nOEC>{%TuFKW(y)3$2yg>ol>OKTN+W;CI1Udph#Q~ktbCBq= zP+BoWoIK;A0F)fsz5wRlgBn-sMniW>JIi4D2@xD zNZZX}&{{DU^hVW}^#_^*RC818&-cb*TzcmIxZm%O1KHIN#2ws#<&0tHHpK0Gig$i| zD(=oV;#woc)?5C(dI=^a^Zs9ut6K)M)zqC$Ls|jD@G^VW8puSFZsD&O+cL6jlAT5Fl z0qC|~gF2ZCq@~7gfTjn5MgU-L)F2N*f=E8aG5o4%K7NUchErVOq}uq|;02TLEznRvd|c z_qTYqd|TA8CAyn04TX-%%GA2Yzd`gWD^a24TmW+EujrgC!Z8Rs-Y>>XsMGs^niYh~ z1>(@F8a3UiO)+}X@hMQ*0VrASkk_2XPqE$WL@mY>dv!GHdJMe*p6Yz^E^*1K>L!$g9uj((QgfK)FGnvjE(W z=tMG$8&yJDaC{9+UJxegQ>W4MGmW|4ra*ci{RW`?Akbw1JokkL9n%4abxS({kT(c4 z32}E;ATEu_9d(SCf4%KhYO58M-f31f16g1n(v9LEs1*cJdjypJ(A3QRGE^@4sypnr zfQeY~J|QHVVCDBt<7Zql8&Q*@BaY16QbI5HYWRG@34m$qsq1$jQWTIjjR?O3UjBoh zMDCc|mi|f#jDgsK!hb=bIEccaLr&wSUo->XG!;n8!tVjPItX+>02lnKlLZ4ObiZ8W z6l&E}vHCBa+YC@6Cv+YD0BZAssEq@q2}gAnx-ts{=??NEKqWz-VgQ~$sX;Y7%Z%*O zJpT!x(jd@>0EC{_pk}*DNf-8KfXaeEnE)i8(V%S#(+y0fR5}Dqc@SpyIdIh;qT2s* zmLtq_1uNN;vT^zH`sYgwIy;3wVf+?1E=axKmiUdKeF{v1UNa2qazwzcL9c4O1{J zBaQ=B835zhcozTz+h|avU4eA9p8%-J3KCP~(ExPA0;P3|y#K+3HEUJgb+^dfvSv{g zivkBfI)$*BX_X}RPvU-c5akO%^)i^i11PUecx%0&+)9?swNwgDYbQGeay3?RVlj6a z)aYc4YLX>~?Kl>VAl+&ZD9D%}1R4ZDo6Z`v+*BalsQ(0Lffc0cKLe0=yCUlWXGA>t zTEbgz$jq-r$yH7s2vtP2d^!uF3#~*|o&EuWb5nF)YW=NI3vmQ3G8P2@Dfw>z#QJE?&*LeA{0hoxxf1)q2W{6 z9G3XYy^lE|QQg_?AiCH}RFyje1ot80g{-&-;3LHLTnJ<8V35kc4CGQ)`KBG8-jw*lEs2l^AFW7S`Y(Pl>NCcgO3r_J_9c8f^{G%~p_N=6*o7OxBG^&pn@5pSWwiEVht{vfPi@K$MF#* zZjikVm(0&n**eKkt-Qnncv}FFvi4p;R?g6{bsWR2tuqdw+k-$G04V#1294$+o=izM z>3D$d2m;*{=EL{t19sInqHL>X#!7H>id}OKnhPKFl z0*EfN5>?E43pq5a{0k^j)Aqy+Q$E ztI*;l1)#NfPg%P^o+T+9UVS$Qt;lO^pTvTAQ^|KyGQvgPLX@88TXkKfXM$1VKw z<8AGqxt(8{m$iRc14RJcPXIglADGSmnxUstCMh3hft6QO=6#O zHya};*zJ2%WdBqLy!4ebDPlCZ4xj@_6<5UM$9Fj;O$I6UwN#{VkCmq_&%o<$<>~*3 z60!>X9NaY$<17yOy!6mRR3I5JlpB|@KgJNDLu`mu+v?XYGudg?J|+3MQtUkv5v>F_ z0=Af3iQpnvu@nrkH(cch!9_aO=FkDdc0rvlHf{t9K!;0qUvLq*;l4yt^0>j@8K&sSaI?|)q|feRzc3EU#2_ zWE&gLnzfE1eZltw{abDv#iRGpKw~ zJD4iS%2wOAt1YS_m!wFR?3Xqr1h^ONt2fBqZ*?%PX54{BzAsNJsgYckVcgQV&yQoK zGwGmH?Cmw3p|BrBC#?VRo)dT1t)|6EeC~c#BU5HV$ zUTGV`t(Y}^_uK7%db>T>(d|pMdZuv`$NaL9*HD}#;mIt#=crrQeN$5032}`73v>5 z2xr_oY6Zt5Y=3a0ZMeld{I6FPH!Zr0t61&ZKNBG~Ti-b#oYmedEqeh+KGD5J=sFGp zs!@JmZInKthu|4aGSr>oXgu_Yk+?)bNBc|=Y;ufN!94AJ760K=n1ufrFM*%_DDd9I z_6(|H|EQ?har#tXP)$oK+13p@LkiaML>j{ybBGsmok|{Sf{}4RPX%Jok$pI0U1P0H z;Sz&*!^RiB3}bjj2H+_qv&%u}K@CCgSu=mrF+R&4kv5BGlK8kKNKJ$~)QC%#y#*b7|o`?`yr)Et{01=YLhHmb^L`X!Z$+>ANk_l#@m0~F2)=2?)dT=>?!BFFF&|M zn4n8}$1C5>>>YKdpYHSuWY)`fKb%*;g=LZZ2JkML|5aBFkEZyOc~F~cRsP0&c`}yV z!&cnt%JM~^F7utc`oiBZz zbyv+Kmx`;Vs8epZ>jNDao5kzQri40fueEpn^g*^woOxE|omAqf=90S##Zkw+toZU| zZ`KcwX_<~!;G&6XgC}exllZj59}&#Y+>&C*(nWbCUb$Zzfrl93XJ+!M2D2u)akaT9 z*}Oj4T$*fqcvAGnOM1Ev-v^XDT`0SzPoEJN^8b;2dhySwf#Ux`;>Q^AV~qIG|H4st z(*MFSc+z*wm@(Nk{Q$xb{K1ocefslBzdjfA;r|zsTED)7_}a)m;>VcL_|d;lpT2l9 z>OvA2lO>*v88wnWMvdWXpghXpQApUozviEJ6;n#innR(jjy^)IU-J1&PqWrDQ|4yp z&xUV)LxeNQ=5QuG-GNMdV$jx$*w|~(+lRwQj&?!#@1cBXpFZgTtG%?U*t@v8vN#{l z@h|~H45BZyO|>5K?-*)hd?P6y!2{}Qpoc96I6J-V;+6{cQ&PhV)V80h1tE+0859g8XoQH)QVY|GcNoDvr>T_ zfyMK^AQ^P}4^A6jD+F&JDqTWXR;QXK=Kv`uN-e{AMW<$+FRCNo=ZB||4ZH@^OCh~6 z5`Ay;aQNYXgTdPtyGs1T$Y9{e3H=jej=_AljO=w~4jvf6fxY_U?i!`TAh4G+X)QPz z9lPb8COa##8ltY3DmZlUA-4P;#xUIH5Q|kL zfx~z7hRYTX=0-=Iis&GWJdh`O-YWEWG|e9>%ybsjTQ*-bhC2t$h+qxOm_B;$=m|5# zz1=6zJ|cvZ5R_N}V5{OV%}=|*TP{rOzoAbG#GZ3gdN*kAJilmT2mK8{?IHNj5xTdn zIlmb`vV$9)F{y*w4c0-oWh`q+&M=-uo5@~)RuL^vD_f;wJjY_Z~-1|WcKla78RXx>%EmnIp)os%L0uWJ!9I$iC0XWd+8MuM-0DW?qw4vUOsoO z>-tD%!rsy_*EJC?r#vrO#7gH>NbxnUTMmAxNw`mUlH0dYcfmEqY7!ZA31OzI`D6k1iBK_Kw7 zZdTouQW8uEp)Cy0MIci7cZ9M)XsaRw)v~}($`X8=d4hoUpeY)j2SDm8D>+#gQuP{) zH=a@C#O`I?VwRyr?;UEho#(7UK*VSLVr-ZEr%ywy&EZ|4A@YmKALtdF*wpFz7uxAS zJb6&FnTpmlc90o-UkZuY-E#0lRitlbCYb-!%Fa2hkw;r-Z6~u-y;tAWk-sV@6A*Tm zR@2MZv$G&fkNADnu+_bp8LDK6qjZDa9NvZRO}JviNYSYf8il_@K8wy}C*}zv&V;Qu zhEat6Rr**yrF%h{2-LH%8sB-p{p_AO^1hzj%loG`B)uc=i?AhQ^YOk}97Dl6FlqEH z)Hi%{2!*61|6%B|cWJEiJwxP=YEM}n_-62|7}w(wX0x3MKaujx8n#M|^yTH%GC&CL z_xp3#4@|hY3U&{knTPKb)@%AD{7FfG`z078@_BFEnx40^RTo!H6iE<2Zu_VL()Hj7 zw!AUW&&n$o@&1HMCtgar;{JF9FvNE=D=c~yiShwIh+hiMg_~K}q8;wcvLoblNS56Z z67I^fo1v|!ajC136d}fOYFG8G>+x(oo z1)E*(LcZ6X=Ul2j@*Qyixj2yA{S@Z6xcJv{L5OinAdYeqvI3pmXh$C4gV6^=%oy`* z9M*O%QiJJZ3~{Y>?YEC|9kh@1%cAoPU$ue5m;4z+62ZflXUL^kp~EGF4bt$*GFAzv zfavf>g34b*DGO;c*xJQ81@^r@>m5YC`B7VQ_ifIQ^j*tBZ1%w?T`n&y4q^YJ=Who? zpZJ%r=c~CPtprpz*ok-oAxu4Bm<{toCaxoA4#Cs4*4{6sv}U^9^B2lZrq|_} zJ^`B%Cn-*Fo=O9ruGx_&^uwAHD&~TD(BT;jK;vWu;yl#~8U@fJ3gmhq!Zv79NkQ18 zz8Sb(Rb5`;hI`C>2n~0Yx1_+GS6x}+t|}@nsCIiws@19U+Q-5xKJx)$S)=uEXOI5!5MM-}I4Z3!y_ zllr+;ovgTeq$3qjk;*1pKq@e=d0s#YP5)4-GzQshE=4+z1yn0nxw>5m3)M^oGMhtG zP$4pqW_t7%<8doUn9j_19G-B@REpNeZ1 zZ6YI1$@Y3EOj1n9j9dX?PgzSQEM+}#S1AeCq=2MW5`1yk{ZY#KkS(HYJGRz;go>{* zg-))6zsd=KUm}n8Ou*Ro2`;4_UZ0}$Rt}3)4=3WUn5*G$U_@Tr5QA;M1<%~bffZ^T zkJ-Rm&~9Q^b+$J2QQnG7{oL~hl1s;nQfE|4n7X5*KO1dXG5ByOzP9?7)_f-8m5BuW zDfp&Cv_)VxKQW&IQuHj#`<`h?>`dO@BnaVQ#Oeg8J3L?YK8us@t$+#Z?~9|Kdy?={ zB&zYe#X+Ao;uLjguCt`(DjKXcyW|g!?=3D^1U?P`v7ZW&azOlpH9Kri?qK7&ZP_%E0LCG)2~ z#6+A(oy`QL5`56wzWuWqdG3p4N%5{vu`%##z))d>E8lBmg+XE$m9xTduVBSRC_da}7DX>#G4femLEbpQzHn_CE_xHfni~LTriI zI-Bxo?%ervX^1Q!8BA_2x$5KN2{;xfmIa~!5T^}>3JH8H;(@2Oz0>bva#Y^;da7VV#v>&mS$(TK zx4i}}2$$d}OcrYWN(8f!E3_k7U|xdCxVjm@}mflW2S(P4^yEa2pQ3vRZ$;{YV1nM`{zNX=8RZ29D%*bY!CA&z zp1VQ%qrW5n3rMwAJIGe8_I({$s2~%Lz5bbDXXLGpS^Y9Bc<3n7cKdfxQeiP#4MQb~idf;-0=QJQ|a44OCNi&*t zuHgjmB@M*r(dx@fh4ah;Mi|A0-_ewK{Z3q0#ZHuzhrXVRl^YfmFW+$Cov#y{1eKY) zgL&`xPcwx~O=90JtEq4;k8njs$%52&Hgh~{5lw6jSRyjC8h&TiX5>b8URK!w8@#CJ zNms{2<=&ivWM-A;UX7LEr12ct5NC9vIR3y}32P75w6LC2UO8I?-*%0UH2d0uCmR$! zA?r%+6r!idgEc7R8goJqh+F3St36jZ?8a7HGLJ#?^n*@alM3V zUjz{AB37B5aNV`abcU=l6P>Hf$@n=F-@SakC$zzwj<`*6kqtP9sR4@>4Q5wdZ{q%d zXuL2wtkLWn)o6~#^##Hcd7~R~oP49}9ejTd^F{OL)~n4XT(&l=%|u*hovU48k*m$u z5Q^s=QrH*0(mWQuk`gcanbjOZfPTFc8uSyo|HT0Jg*-$SWaUN$vgxm6&ytb6FF%!mvztk+vta*W@* z|LZLr$5w(a)L>;0AQGuvGR3B;&6^D95t)bG)tRChN zq~F6F-NPK)!yMnkoZQ2l-ou>P!<^m2^z=XuMc-;U6c_i%L81QFlESSSIJdaJ>WF5k zboHehCHctV_%ie?yB@_Rv4bSx37_)gJ3D5zZ<5Gr`-c>jnGk}8=X#JIH&7)py2U(s zEXX@FdGxlI`_6fZof1<_%%so*MgIqN-vp6OaHSsBC>J>$<-492kjS1`qpiTU=;)a@t9`B^DqctUm~N5k~LYfaxS(_;TL3?tFo^ zWpOO();~swbIf2s713=Q%r6qfgE^0t#hH7hUQ(0o(TT-}mp2P;iB zp-ja#PxuDAF@K}ZX;UK@lbx*i!Ul<4I`SXu`k;y8?MU@4m8vWX#g#e0;TZ&S&%C0t zyAlRHt73d7U~dP&R(CePcX>VpV9~1zRNDds^N8_IOVB+w&sqRRyrDpKEkJhx^lnSg zaHl61fQj1_sJ;bgIY94OL6T8>T%JXM?0iQviqf5*rMHJ~xig&BH*=DZJqNP|7=UtQR$+tF~B-Xi#IbEsB#4J7u2{Gg{KjF>|sp00vgm5!C zWK)dMF5I@at+A)18Jk?gaTaZ2oNaFjR{UV<S(2x^DwAb2v=2y>>p-qXno(#Ta&Lk5|7ZZqKU6F?ukR*U zE1ds3gPt9v-iD(seaAxj^UONnCwYt0xC>VcJ0~-zUlEFh z^kGKkVkuPbM&`Eo29fg^32kXPq%PgYeU*;W>VyeSQxcrrc7o#HH;=W$!HG0~b?zpK&Y2;sCRE!HfJ zEn=KU=SBFw*&=FlT0V&WsRFkc@SC5+LGvA<_RY@L?H%}P%C9C4M{U;)&d2>v*zCJ_ zEOi@kJ~Y}^Vi()44k0Hxn8!Ofj}_y{=MX%0;$+g>_a=7TRdN!pN8#q9H!V5&@%iB^vk@7@#MG_d*TiSUo{*F1V6@*^D6+$quV{=DB#x7iSTvpu@| z`w{PjpC0ntk(ds@oeuvk{B(!r-#VN*vaxml(~j783lE<@72k*xso$M<_*BBiknmHD z(KnmzyT2RpPWY)Ihkxx5e)yu_j&$03w4vJQa-L;xrPCO{KIt@$KCf#@_X06Vm%Tt( zICL*aaUCd360G8KIC??UuxP_(@6m?ece*+zfsd$ADU9qcIkm~YhKR%rur*-CD z__EAJC zGEH2UfWNoDflxEGv1UW8=V9DpEw^O3kYpT4rCP=s%ES;hA0DSV=VBsAJq6pp5vJpf zZ}f<0Zc0NtM9zGJ;u^NYS3v_GaWI1xLV7jF5pLqBd9))ensNQcH+0n5C|`*K3316d z8(Q{1fZHEgTX@SE_nQ{JK=5}p zw;bM=j-FB(lYQ+$XGPSuvuM` z1~XW4159`gFzGeGpeN=gjR*T};Q%e2P~RiL1qo->-(6ozesPo!XY+IRL8tunkQ#L{tMDOOShC zC;Jd|_bR%z=PPW0NkwS2mW>vk384Iek9t;1>N`OF--@~*E*IKk>xH$3+Oy9FB!q?9 zAL98ABrnGvK@p{-fC@SFf*l7Uo;(=ANNNWo-u#wd4EVP<`us}%JP@(&Ai|5_HtNTJ zfBCl&&wQ)yOE$o;%z3Pp5j&C9PpnxLo<#nPw&btcp5pN$n=5ch!hMsKD~s0b_kira z0J74iq}O8E&I9MMsylcd0@04xl_m)vOKU-RF9?6C2sZ||=sMS0v72Ij+J`C3OG48Clg5Ir_0}0(p)R>nDgz$Wq<0adRWt?Th zKcDMh@g)vpFD_BK+MwF_9HskAmCihPo)r(*_jcD>Sh*(UzrN?a518vJo;)c}2*RG& zN%OvZJG66m+%GP}=;>x*JUHObEoVSS z=BQR5qc4!V&wZ6T>FVG2TyPtOWS%@m6U!vkJY&#}6Y>fR#kZ;oZ%K(bo{#H3a~`NW zmW=m>w;N71LdKB8MHO_^t0?gl3)c6Ni_PH7JjsDPfc}sL3v(HmH38)7r8|i;k-zl0|Fd> z%dn}cq>9doCCDcJ7IqYizrGZ3KyM}JU{7Qj{4cRp2Cm2pi|P9)Jpr^6WIn!dod|gq z>EVypQ(A&%qM8jKlvm0+#`+wN5cc90D$vVKOQkfMyXO~I74!UZ$goL816`Z9anvZP zuC5r|yZ3?x3o;k<&n&Mj?AMno_JK864{L|N6)X!bi-(7TpyJ&#BXrQ~Ou(G_S!d>Q>kLnkD>(G|xyYtb| zOWgU@?t+NahIY~yUR=5!pGHJQ{wixbKRcY z+)8(Delf0cH@@c4QhW3Juf#O1S;pbuW?saxX~XftMlBIHMxu2 zXpo-L3OBk(34CQMJY_f=t+E_aq^c$tSB1N}xYX;eanJWux)&e?Apt!#`NicRh^O4F zh?bh~Ek{bZXv1EtQnc}!$~@%AQ#Rj&l=3QzE2`PAz?xDp6yi<_Y&Ql2?pA=i zF(knP3>Kx3hNz6(lJdNH*VLeWxQh$G60aNE70av91phNJ`g1nG-MG-G-JY^yG-WWW zxRNa^ucWvFmiQufUQH!L1w|rdXjLAP!Xq@(g5nYus{lFZRe%%7S$r?ISqfJGccHtm zWKl&C+K;Eu%jOI@hb90-siz7}yBNFP$_jhQmqbeV4+J6E%1ag%g2DVNaFrbBsumPe zDpiSTgBT6Pe*#%8S`OqPnu2!$3g?@oQ3LOn_w4gj&Tx1xq8EA!J$~c&OgyY zuNR*K4~H06V8a=9po-l1Hh@K8{zvh`4-SvB*sO$!gXXHQwP1r6dgf!t_om}jwjOtx zbgAe5x&`HxLiksLbzb!05-_dAT~k?tcWo7%8}-3AuAlI)h}hs-i$%G5d#&)-!2dY= z9RK4ebNr8!$?-o98pr=zo%|oifY+L{6Kl<4Ts4Wfg9F_K0f7`iffF!+5}>;JRkpO1 z0kb7xOsh3ti>o!erdm~bWlNy$juA3bP7I(Ed42i7<}ZFyRNt62y-MXd1~NVJRMr|n$~u&t0jYyJ zQxPs_n;h1(t>fili>I_Ha^`sVq({YMRJk5Bm}l*c!CPa*`0Zp&PQ!Y zt8$q`W}jq5RvH=`{`Nky@a_8Dr|I-D3*j3wGqQWlP05};8^1Xi+kcLGj52BNTzD+u z_wjje?UBFpFgULYZY@Y_wJI@}kM*2{W*qkX!H@5}i4%0Grt+S}uA`U6-h_v2GcLiT z)h#w0jt3vU(|ib0ApESC%X?ySINI|fj=t$W-^A2|n+CL*>+3_&%YTjLyBuU^7A^XjM8T+6b-KGL-qTWp}gl~t#pTt0bchPgb6*W;9@ zC8|ITSbVo?{{KJ{-|Hm&ZBN-$$h1Slen6BQI8S(U=Wz*@6_H%@@|DcU`0{JT?-h3z z8~`C~x7LX>64nbybkU6};n7Ig+UT#u`#YKs(g(sLXHwtioJrR-vSV%Dl9t3CAelDJm!vRjg`2H8sazl!>VGyG zn*p3j>mGL|*=k8+#6Jt7XgrlPhKuo-*&_}6UDfY!CMs$8o{WmAgh2;*PaK`~4#1?Ppb$jTUQI(m1iV z5^tUNV+(3kIEWX5@o@WwRjj1wgzXiNT}KYfi5+;GhpqdC*m|!^@`DwaD4ynrlh*0m6@cXY=GO;+SN)l<&=NV7+eLx9UOi!ng9MT+<}eltD?0E@5YD zc4<2sSpruE1Vxbcb5AZZ_r||l%9hvGw7u`awph+G^zkjTGg_?BUWcszqL`{u_S@e$ z;i#)-vyZ*!0@W)4V;f+|1Yu_ z5D#|yyKV1!PcS5O1m2RppdRC}HEVYwYlpSS5GgeVxHO4$w1-p&q>=t3S+Uv|IP9?< zZExPmR6g0+_JLh8xnVjrDiGGx?m}uutf|RGd{r)C0AjgR**znW);?T4YX)dshH@^j4xH{aq!e#Ci%_zP<=gzJR9TW52`X7L)#cQVWmGHkc6%Dou3 zxctMWda1BdfBm1G9a$ZoiVCp_zJcg#+uyj9qB##XCvjs%o76!h$3z-j$4qzx!Ls~Q z`AQ03%t_z{%!96J9>;?oG06pd02k!>Uh9K*&p4i?gcXQs<>HY*G}`7*=L3Q8JwU%2 zSCM_1nH31(pD787PS1K_aVb&!DKF=v`i{k@%)=l(WomQSYWs( z$j+4*_>gX&9Df$^DJVRHn(MjU+(lgjiYeB(Z}IP+oN@;Z9vO78qm_< zr#?N@<2Y&>DY!(FTGe8FZUpF<57g4_>r&H}A=g3e`Y&+8+Odo#~Ok+W!0(zr464_NJxcs22M$qmRhG z^q04mdNm4gTo)jCC|J}Dtsj}&zOL#6cA?U8U;8uaYRw^T+n|-XG}JTaY&j@y9elX! zP}(}I_|#$bLvB)SA+hOnMKNDD`M@9!F8)$qO0x?%V)5pb@t=f8v*%fx)A-DR(g&!C z_um}5`?grR1F10F(oSj}h2YUq1Jyb3bbB8$OOT0(I`j9dS7_Cr|*y5wmy~%9GDnePJUVPVC=f} zvL;m~`Xb^{z&genWTHveW6-W-inZUL{C)&qz^3Ezs6~o3|2W}mja~4DZ&8{RYBB1w zp17K2oewB#o<%6iiMW>4a{S@gS09n51uc=>yTdI+vUQHQ4p~2?vVI@))mmo2Gitnt zvQo|`tohlD{G8UT1mix9Ypkb0*Lc}@s9I-t#Nka{G$E`OSlin}AoGOQdY~)DcX(kC zn?v?>+1I7PH!yQ?cID9Qvh<9h>Dkw3UymVjQsIiv&-CXuy;;37du9xslXBhlY3Yk+ zWzR>FZq_9TiV9(N4VRLW`MCSw50JwhuhEiX{fV3>sP@+E^zUQE%JEz z^eQq|#zLSj!}VJoY+Fv_0CCQc)}wwO!1EI21D@ycpTqc?1>!rUri zH?%b1N*+pswz4!!TfH{U`t8OoI3;ZPup|q{8@4MaRS*0+V$WExoURXPv+#d%>cy92 z_Z~7kBOM)#H;1J2|Dl7E@i=*Q&-CPs#i{t3im#~|ixp+GJ$Cw|-CS)IWSNO8j7cYZegIsVQboIcd`fs?n| zzj&m8kU3CP*~j~BnEwpNYQeJX-b2$bk)-Avy>J+zb1u&A&A!=r$@*sY%~^9Uncb7` zK+n76=$8wqt<1T&>!^t%r_G!+I*E@n@K_j*zI27`BL>g2VS5qx?tRCBbMoZ9S$q#g zeSO)=&ne~9ih^3IQ7g54=Q1i%TsWiIhJz4GvUNwuTIR4vN%cjpxDehNc)>k57ZJA# zajR1Z^F1Q;XjkT;2hH~vVfcC+eo5Fa7XIJsn2jD-H^E)Q^_tUM-qkf;@TfB3sx5*{ zx2%g?W5xSF+|>6S@qV}dS>pXSoy_^EH@r8ol6rvQCDn@ys~0nw#UQ#EFQ#8)b5APX z{_=|#a1=fNJBtx_cX2noDr#f<;3*==CfwtNU7j+^F9gkXA)Y4&Asbmr-pO6V*0JhI z)a@Ty(xZA?uc{Rxqvi}-JZCgF*|Ssl-c?g_KV+2+PRs0x*MwTwIca(! z)eUAeJCkMM%yqEAW;pP&>2s)ZW@pZtlZhN4zeCUuk(HEms+6q{e!4(l=l5bb+_b?k z#h|z%{lA_c@``BI*_GL47*WZa%%b{1O*o^2OQzO!dp;15ew*e zN5uVPSWoB?bt}y;dYSusHE;lITsLMs2f#UKObb%x&dykzjaHJ5MwOjTF+Ajw#dEZS z8rlpR8sCH99g2t9X`rjIJ+Owo_Ls3)3)VJn)n@X+$^?rhR$TwVypxhas5AVB$! zw$S3{;_O+eLeLLQosI9wLjDg;=6BQ$|FlHRPVbo#?D)_MZ(_~U$PospcU(C%39;VC#ocoooWLzOcLUl8I0!T9`b zDC%;t494ms$81-w4DjYNkM*)e)Jfef>T>lL`-^^zd6y*`jbgG8#}k~wQxCsA6)1(- z)QhS2{QhpS$6y)?j!j{c^8V^^Xdv@Bnq~|9HJgLTyEX~2I_1HC4&_{bD%q0jsWi_9 zy~z{?=l%6NnKT_tVgjG$-#C?$1feO)7vQF8%RFEHCw%bmc(R3!l^yt!Gj)qNJrFS7 z#COvf3`Gj9x*Y7xB1}=N7VzF}^4UEETs<(u0QapuS$KEERrngy9>r~KNc+y)j@;x+ zn>X=H)l$7=xL!QK%TE+Gh%l}rpi$};BU-?_Z_U_6aWx7n)!fHN=G-{-hMBA-+>?_X z5u7Lmca(Q;LuL+ss7(U?;6#9S?h!JS(BgtLWCl@Y+0Voa^Z5g@yj02Iom31(9adu~OxN*hr;ix2+P|{&@$N?qf-Lg2#@ZBvo z6#Rl3|5FcTIn)5GLQMuqfKSblR((fty)8v7Pl>1qld#_g3)D0orD0%|ZRU`zU?izw zX#GE}eF>aSRrvpTo;x#^JA?7s-Z$GYHUA7d*An+SM^_hpUW&pqed``#-r7gKWi zuG{aE`{nW-h#LrM=|0Ye_Zc1Ux|+sGC=FVI;i;_=zjTS^7u&1CqH z$7vhC*shD+GWyTfrOvV=6;CtC(?1K*&lbw#Xy3MJyRlk9l6V*mKdY@A*SvYq^vv#j>9KpG0klsB@_Lg4=GdMC_=v&^a2HCh1(J z7rsG?Cd7;P2Ed)QAmVymXL04c7g(;=fdP{rK43z>s&P~U_a?944rE81W88k|v}8@W zAJ@2_5ew``o4cRCk^QJFaOEf1`RLXpa~}Tn5*K?r=bypoI{EKm6bMzbsz$4?t49Za zl`|(<0&aW2U1rGJ-@@@bM6U;r9AvzwUrP|JZaoq8$m6l^N#A`7z=KCAedN&-JZys} zA9~~27d#dtj|)8~&r^-4nUARO7ff>OUn~9c!md$8sW*5 zVR*yy$l4?O;l<>&GvuirY&>PU!fX5FW-Fd$aU6Gg2|ke$cvuiR!*Ek@D4vVK>!Aj^ zkLIKd8ZJ*9_8cy+O|KnXGT6T)6OT2-L2<8PD7GTke3Ci=(W^<9YN56-wwVg=7;$c68=L$inRa<6LmmPW`@_%@`8bgV!pcRt+` zkrx+xxp6;Cp}{wQ;$>V4x6#WF^~-NIbOhcG#X8bh%sR?MSgZ?~$OzVjO;jZ7BBoFj z>!PM`A=c5RNMY77rf3n?#f)8)b#W7Ivo2v`qFKk9Vlk{sn&QP+drXPqtV@~L60FOb zlCiA4##53{no=G?cegZ1!_=$GhfMu?tb3XU^;th> z8a80v%QR}py0^Kr5$ist@tu6o+|`(MU(@6+K49){!n&VndN=F-rdd;d*WA;L_nUj~ zVLiY!zn6Vi&3(<;cg5U)AN#&BiTAS}Xj&w)?`!iw3-(<$4?e&;)wFz&^$?TPl69JS zD2a8tdH5mrT{5j6X5Uw)bt~2*%_FT@k1~%w!aBpWd6e~N)3y!kG3K$htjC(iA7eev zw0oTOc+*q~}_N*tGCpxgsG98~_J;`+H$a=Er+==xR^JHh%+2*MySx+@xo?<=C zbnU`=x_P=QYh$`S&H4q?y&LNs^GtWvGt9Hku%2m>pJhGE^hjns+w|&*CZtY0(Fk7vE!WIoS&gPD-YzH?^c z1onMyvL>?LWF}>?-fSjMV&7+G%4F8tO!gGkd1h)h`_7taQ(12})2Fe1!E(F!1_D$`bO5@n@z8?zGgOWV*P{JvYGXdX6qK# z*Uh%AtbaCn+gSf%w&$_FVcyuz`lfmF4c5P!9dEM!&FtL4zPHS-oveR1yLYk9H+y!o z{=>Yrhkbj@+i$V{%j|ud^)0h+FYCX}JNsDs&Hi^-X+`GU{cwrQfp_6DnS%%5T4W9# zgd0WXJ^XlE7b0^QKj7Ad$-IwG)9WH+K6oE)Q8Gt9fLn^p(Iaq6lR0)2ZW%Hk;;Zet zEScl@5W6l%<^;a2u6<-q;%n*p4l<`s!Yxncqf>AzkU9Mk+=^sA#<$3IB{H9U47W0w zPd|YhN9GK^0IsW$IeP|fRWhHQg&R-i^UvT`BXjO^xYfygaSm<`GGF2+cDg2+^IyWP zMdreJxV6b#ya2Z@nXfLwtw-k4S8(f-xqJz312SJ;Y%WO{U^8&k@@*L z+=t2h@-y64WN!Qdw>6oY_}Z?1gv_ru;XX&htdEB0+vhVY&a_H9t|211ba%2G-xr35!xNJI29B63}^`|F7#Q@SSo?|E0rlpu_8-`%tIxG_5dwK z9t1B}2ESDm*>jMUq0&NoftIB*LUGr}l%ujj`+$0>oY20YKJp6f2YLtjgr>Wub#Xt5BTKA)r;MiqJIBc&aKi9W;UB zg$@O+MhQakOBAE2n$R(z)kzB-3tEG!3mpeqlWGXXYeh^gswwn&(ArcBwXjr~I=Gn+ zSr%kc1y5A3*S0L0eFw(6yisPz#~!Kp&(BguVvak{%Sg9yEzs z3f&0$5G4tH9rR&(Na!ZeR`jsY&7iHRmC!Aqk5Fr&TR|VCM}%$zZ9|U=%>!*qZIIhV z$~;DGMfL_{kJDp9-vn((j|<%a+Me18-3i)(+6&zU`UG_lx*N13Jt1@tXea6@^excN z)Jf>upifd~p?g7}q9=v!1MNaj34I5&D|HdNAM|PJD)b;|H+ov=A<*vBP3U`|&ro-v z_z9nRmYzWwa+FD?XF*<2rUxa1Ojo8S^#GZs%yZOJ)W3jwFM3Ysm!Q3=mrxvTm_F27 zXg+9P>Lc_I(0S4chQvHi<577NmC2;% zMOF&336u%yd)}|iM4BLUJZKh86oqn7m_%739RulPnj}&$q*G|JP&^}TvT2IYJ3yyW zw$SpR(`c&Dc+lxIO=tqBq3J@afxbXSs0PiU7eIZZk;Dwj5t;!ylV*rQO(@KwnL=xU z&Zb#HYlF_gGozq&K;v$(OjYRKD&40IVS6?zZoa#|+z zUeFb^TxfI9m9#?WeW0sorO^99b7_^(M9|fgE3^gZ8d@#%0nk@zjnIcc*V3y(9|m1V zYlXG~eT~)$Z4J7fUK9EV=muIZ^ij}_v_WVa(AR0B(8oYG(d$AV2i;7Ygti0SLYsxQ z2i;0rKz*aoEZbh=f>B-BF1(F97`~gLF$TP)9KQz>63oXsCI`AE zi($nU48|lSsSl8l5?I0g@6EnVCDF%K)?O-wovrpMvyZk*F(i6EqL)UuR^}agBV1S( z9b9GYC$Ge*pv=1@r3}UKVezM`9w6ND43sXsBnJsM+*TD)_HSwdUZnH8uB6N%+Ci-2 zm3fbLf+Q%6<5VZWPEfr7J4p?cx2lAmqDIP_AnYS* z90)y4O_Y68WFJ#gyk8;RuWPHUPe=}MbsbgpQ@Yo!4-bBKD}4d^K1;aQjC_0RI2ms= z*#8+NLV`kg@KZV9+R`@X0 zGrEztky?eERQ-Y;apR&peo44VBP|7fo^S&uz%NicaMmqeT_Jc}a zQ72c)>BcwwPhz&PZ>UwZ@iELB{!7%w4fR}h3kaPAi{G>)Ftaz2&op5qQJjSLr4J!&z4;yM)O3nJ7hC6ZGDL@K2LLI@BfG`aH zYcvXTX-VBwT5L5w*Wvf0ML)Q`+x|eK-9$Y2-& zMSEmYLYDfc`(MVDrntUenOpQ$fpjr0FUtH)Z=)m+1Sd}nEGf7%c`n732KzAH3x$WV z5956xtyDboayQ#jbmo;|S;@t<$J<)1N>xFFSP_K`uEFKVTieN1D4zJ;rumT8!V-9P z1ivOti&iv|{Ejs3V1E>^$Fzd1rAx!I+K2}!WXjs4RCXcWBKjz-Da`vtKiyx1x4P5N zqbj>7=LN%Ue%B5EnYO#(ZLsO%11MP%wtRdLq^*iC#&4=BQED|#jjI;po#+v`7@6XH zh&Wn5Hf6Vd9NRyB56bPZ`QyU{wYmovOmBP1OmWFzNq$>R*{3_)e!Y_`g6pa+@+K7w`_iXAE+1sR6@DIb&UNk5jW_(i2h#E{O6VLhR^#wNWw ze^`+HOW1i8*IP>Jtuejy?kQjEJyX8XZ%x&2Pt|)%>U|~kJJEW7v_7D!*5E5{-6PXA z`CDveq>wX|_fEBPDk|T-(zu0kih9U!`t<5-KLL~@ooBkrH|jPkAoVNGiV>n z=iBrx(kG_sQzd<;)RailXG`kORQz2WMKY~|c=GeUi3;4`inB7vOR*Kz_6n1yx{KaVw=kj09 zv_dQ(RwNv$8t_U{7U-nC`^f%{tCyw{L(?r?#aW!)1LA26I4Bo+hjm_x&d@59Atgqq|xrS3% z+?lSL$hBZXdcIU*9aLfo^o|z%k;G67q^mr@ryY;yLAP%VI0nsnU!;!B!+BX-YoyM(jvJl6%N^NO`a^2}zoh z@1XKve-e`1Prd`ngKbJk(t>>NDo@)m$%EwEuRPelgmjWfUs9gO*|+cZsW7+=QQ7VI zVXRNl8umWbY>2--w<3G5unznP+209!g4>Y&t+0;#7%{HIn<}g`cOd(+uqU}A z*;j-;#huCiMpzeqitMk2b>*&PUlsN=cO&};Vcqx{^7azeos-GiN7ysmlf1o!J`*UFfcs$vk2^+|nCr;`1Xur!`d_C;ao`~uk*gbn2xWS<@&E<5gt8FKj%o zCi}3k=lNB#-xHR}>&QMNYyz(*`=GFiypik!!m@Z1+3yOQ#9PSTFKjYzBl{g;Qy4G8 z3~XNCB;VU*?{j7gY((-gKkOuZIa*)AK?r|ba9P<+`l`yF%5TXC#+2b)Lx09%%Vkkm zOgX!xZ&mg*tXXR4pQ81j-g%C$-|5kqn0C>-fzd3pG|tYlr(@9(Sn3%51j#i^_rHMk z2M$sAQ`b8K7iXNF@EO-T3s*%PoA6oJI|tW3XDzEE==MP}7gr9aTwa9u+;xSl7*1iE z8!6e=HW+5$_<5K?WNE95lggTpY+%Q)apT%7;LnhXjs;!Fp9@74^CF)UikM~*e<8FO z=u7;iP|VHdWj-%7h60O2TwjmTr%230^7d0FQ|1-ME2Nx!VOg~p#Zfl$2)+a<6{s!c zi%^4j8In?sZeqoBK44)ve}!ZMCA*1|T_kUu%M9M^zJuko*xfSomr)JMWH;qO5g`7O-<7W_E<427SAALpJS|5^BP;u-RP z0Y8@ilh!kFg48*V8erGGel?d4$Q!PPxb7Di?V0$;~HXqkl%ZcYBmTvU7U;dmPUzCI1BwB z7{uLD$KZah>l(xf7XK*a5vw>h4Oqod>HpcP=Rm;HL2eYt8d_nH{}5xT7%+l^Q>Rp@ zm3=Za+VkBU+!?-y=+bYc5Y5=PBPc%{CdaX2pW>D% zt!@*t_EDHMESGfKPzY`SqlC8|RAQ~9AA`Y(X&l1XJ`2_wzmrVjN7rjMc6&ufoPz^!Y=SLY`-S#A}6!GPS{u6lkK&_E^#jo zUOfA-?^Tt3nfpn9L60|I^KU3UhRab(!NB^4e|NoCcmTXtIp6ip;Z$dwt?_$XI1vN; z8uwUv%3#z4#z<&AZmA)tk4~7&zU6exD!Mb;?K>VCNY&ew+$4vgce?xvk3f3g^B=+V zMmg!_V$uoUQvYYGj7D1Bkk&OG8#Zs+Ym_q=jtk70c5cuw6UHix=pXobH$(PHH#?c^ zvMW5%Nqq&Be&k63rRA>DWVRi4g|i){WjJ5^iKpS19Zz_oA74jqCcu^3@>sc@QmgJ% z_AhEx9c&Jq`4jbyS-kNt{^?=;=LK-c8>@_T{|v@K<#g28FFZ3?V>y8un}r&4`4ygn z8oR-N25W4dlbt2V^G#k5$n#=1&kNah*cD#nD7}J~|CRqjOlJa+Jvx5RtLNYv_Z!O( zaFt#F{yQ&m_(F`Ae7*&B{UYl54_+#5x(L!g`R{Ne%b@WxGX58@2xQ=8Hv=o#cGwlp zbu#c0D(x1pajd@rJAbo3+|H}8vy5bOkE74VsEy^QP@FmG6>#yOo?aR7uY!x;`03n$ zd^KE#e+{O5#91{4l^%X7U|H)}t*h}5X@s?&)mjgp%Z@}`u^Hvsye)1aYvX^!Eo^NH z#4Un2l73MqeaSo?YrM^ZZEaz-s(DC?$ro!(M=I?Aevq~~9U&O6VCvb9Pc{}o%xLRP zFgXm1u@s|9UPVI{vvxXFxxuM39J*&0w{`_uV3FGbyV-VF3F|F%n^=nw7sI}!h3lJ) zTfC)Zs_#XdbXo6&526+BpxGZBM9V^cr|;NHLVip7lKo1^AL0043i%@)|BFGt48nyd z^Fo}9$aM@^zyg0E2Ie95El}B|tiw_On0!^%52da5*x)2a zFN`6rcd8%Pu3G>yozJ<>@-#WYZR>|HUmfeGFkf8@GgK&EJ?lo8uReZ~P!QI@`aR6o(E20H*U0)S%y*~tcbKoS zg`qm>E{iR!E7N3MiM9x=A!S)_S(pbMnUnkG0T~)f^qgrwAPcS>n^+j2=s0uGrg!6$ z1?c|oV)kfi6%l#>E!4~^WVwsLIa05yxv+)DO01%8YwTeRPQ;(>_r^J0F8f|9TJ+Iz z0#%XbZ*E~^g?#r}#VzIB!=B|PR0;_tTDF_egIosQ z7FKjH-E#0gV8yszJQr%I><6v#fuv1KtC)nO`ID>)R5nB*R@8ak7OOn8r4c-UI1->Krc{=5D! z`faSc!}MqPo86YWyK2W~ACoU`@y?f9yx2D*CvB~J|5Fo>=~%_tsfNd``z(nlH*B3* z78Qu+b*vI-no#!*-0n`aR91WI0ZaDX*!yR7upV^y`{<2NSg~#l_wXCPaM3sq$nI!8 zgx@quqvS}#b+R6|>=%S}wpu$)Xwc42T8{>lrn^dQEPI-(^q8YG6-rN8?cC0QM}4f4 zZkOt6wRgg^{lV4g({4REtNSM`-;|)dTbR6)<(nLocMp?4i98=ev7WJ<-$rSiSY$nG zb+u$+a2%JoWLFpMca|g_)HrS-W7OiNvU>{|+|vUg;ZtsR%Qs1R@KVBn=2?2ywc~jX zF1G8=&E`q|L4Jwp&gExG!elP*1vhAI5_YA%EnimnZSCF&cXM!-@Jm98?;P4^`BPk9 zXmv_z0Lq86maINjs#B(uSh*M6AeY!dOM~3Fo_=tHIm|*1hy2TCI&9*kCM(4nhFfk* ze+1s&8t&LX4L-mc;qZ?``-g#!joWr7BVptdnyNGoU$RrJ479Vx{rapy)@Y}H;m{>( zur9f+U@lFPC8k05Ddfwp|z=v6x4!;OK+?wF< zufRuG6Pc z;Y&L96k*e?TnjTa*lAj0*^`ACYc1v}%*)`%={3vVF6D~i>k@7@|>!v06xRo?(mA>Gp#oqUI|q;%X$-2jIIni+u9*C4hxn!Rw?Nx zRUn;f?Q~0_yzt66^2|fiU_=a%EA%cW2lK5x$Y(HoL0I_PPWVD=UsyP*E);*i6TZkg z5EhQ=422(Z!e6!yhlQhxL*XAd;ft-KVc|={!asDvms)sfXDENm!op8E;mfVlVc{#n z!as4sS6XM#c9?fGPLZ-#S)T=}#KtpnXnuHRir6(i}se8rO_b&I_nZR<~Yx5aPd4u-@%w^QvF}MQaqls z-ns%Vb1V9T#Of<&afAHdS}HNk|2<@45tiY*=K8{By&sT=2mdn<8(nKo9)1Gx5*sS!ILC$hNl-%ykZ(k;w`sxP}n^xK#w<_?=bQ3MUk9@~m>fm4h7-Qt@_R zS#WH(Vj}*r^l{b>Z~KcE=-PN(54vwyv5qYG^Tmj#C_id`?9C_-e({BeJ)Lh(MU`r& zB1P9|{S^C+`jdlTvn`GG6kKGL*^lYVBt8jAA#LKbuj@-dgVXmUfb z!PTNmY(m~)w?us>j$8h)yp}*cQdG5wBN9JR{UUZG4^CA8VoOphgxC>yfu$Qu{CMxV6Xt3}!7ne&l>ZiT5X_>9CQBK}075sp$ zo1*2!m2kIYZu+9-rY3ojlqEFMi5rv$_1%)WsY|{hpcO2Q=mtwJIdn@eF@x!dRo9}# zapOsOq(qWuSL&8dxT`G|#Bv1u_}CWoT-%~2AqBY)&uu|m(JA=vT61$63<;Jlm{-^D z=15W$Jy#}qmG5~*0Kt3~`B46L8+@Nb>!At&|X1KL^IecMe5d` z=n-s7h})t;y@Eb0JuPT2m^h=h9mof$ zXt{_YKn0*N&=%+fqyjm>fw*!Jr-94Bbzp7LL>QC+;2dxr$QK}xssMJmh*&_b!Q~>7 zz}nh~(gmakkOE8=!5-*d24+JLTeVz798d>n3M2s=Am0IW0Z#$;0T;xD>@aW*{3Z|? zkGMc%APHz2FR6j_5RwWq0hkRe2l9Y@@shI>uyF=B2T49~0X!xF6#*mwSK+_zl;IXw zWHds7(m)(g184v=1zG^DflfeoAO%PRGJwgzY+w_06l;dAPvX>CIHib*}x)TIj|Pk z4D0~*IjNigI|Ez*t^(JAe1M9fQvk6*Dli-v2TTTXiXrJm@+TL*4aKq)N(6R5L?=Mb z02hF3Kt2#z9K|V)zzW5s#5Le;0dxXVf#JZo;*$_E4Qw{B2v`oRl}LFYdw|QpO%W6+ zftmqQQ6J-g9AGi98Q2HZKv-j-IgkXjFM&wiL3#rjz%*bnkXJ&oz7Om$Z~{03TmY^L zhp7v|b?|(EVv#fu3wVJ9pbpR!NQ#YCFx4G21xN$N0h588SfsuPWI3=F$cN3CYOn#s z0h?o`x%VLCu&ADiodWMocw(bWgs6Y;z1@#dyq7c0Mr4R1FeBhKo4M?C@lub^@zPZ zusy(0;3{w($OovDw0BG?7z8Q+2?CAw0g`}D;zHII=mc~x1;Z&IDH>!rLdOA0rP>)z#bs7H0m8_3ycGDfy2O6AhHa~ z3p56r14(6&V0(}*Ko1}VNCPr}2@;qie-^>F9M}w80ImbxvX~!$PC#!U2UrX215N{1 z0dF~E1*icu0Agz(d7wGawuaPQ3Rniv6rt^bRA4f&2v`jHKHvm!0k{fW2l5cM2RHy6 z1x^F!fXhJXnn)422A&T@deJ^WX`lj-0Mr2*1I>XXpe@h|=mDexEfBvg&;`hVe*!QK zm<=ofmIDbs*zuuinu4?t(iWr>&>iRvqyoc%alm9C2bd2m26BN7KpwCMH~<_4P6OwF z%fL-wIC2nq2TE{<^g=IK98d#j05k`Z?m*J*LAnb`0Z9Wg9R0~)Ilz2iF^~&v0P=u6 zzyaVWa2hxVTn4TIH-TF~WO<|vlm;pQHGl>{Q=kRV8faf0$#$1NDe$EM%ca)fP6l#- z`M{2vP*@C-3v2+6Lg^}y2fj~YAC*66;LC?Jt`-_x1lJ(A3EV0#*NGw((1R*KTmdAZ zf`}S8e_O!c8fXu60U98Fd!TnMC}-4?y6Y|R(h!y*WHLw&FdtY922z3Hz&KzskORyI76ZA!1|SdEBSsE`oB+-M7l5n4 zbqTly5?KjJ1EqlqKmyPJXbL0&?SU>pZy*&I4vYh4*G0;3b1KPrT@02BY^VgYd*she zgh$o`ISla$;EYHwgIoh{0=Gm^q%s;0@B(p_A*fSXYON`}Er8ZQdl7ec#3}Hm0U5vq zV44KY2U!f{0vmulU=MHrI0~Ew&Hdg>@7=DeDBzK6Qry`X9QNFg>qsdTK209i7a8|AAVA#PE;jz9B)Zb z9}fH-uU(MWQMoVpp~{7tQ?JDODie~>zd=bc1s{Jt{~XSG99vO%U|g2QfrYRmEaAQm z=yIeR*)AIT_i2lmg-L_|a2`@z(YozBLF*k?)*PFg-z3iL*pjpU7tfO$8jddc;`FxP VEU8lB;LQnjX9wfSk~{q0{{quelHvdW literal 0 HcmV?d00001 diff --git a/Covance_UCO3001/browser_profile_1/Default/Code Cache/js/74fa76d16c1c4ce0_0 b/Covance_UCO3001/browser_profile_1/Default/Code Cache/js/74fa76d16c1c4ce0_0 new file mode 100644 index 0000000000000000000000000000000000000000..3366f939b80fba5e8a64e0610a515b0e5a8a11bf GIT binary patch literal 30120 zcmWjL1$a}}8^`fqleS44Xi=RNPaDap-EoDI7EQJ}+@uO5=pQSNorU~c3pQM_cCVkNVRyGj;yWtAvi zw0K6z%+k)niTo?>EK;mQcJb0>G72ZMr%d7E#fp_KmRPK$D>17`M#>-Fp?`s4G>vTDpZMlun#xzM`dYA z73lzaSEWx)=?jL|lKw@(I#MS*=q4q0mp)0p1g`2j#a??SizjjmQFK+tc zZcsB1gUEK?idgR4}hW8?Y;%LG|(*^mhS+V*Cy2i3p->-kgSo#!jqn%V3}D>f3@SR% zpe}<9+J^0e4e}mhkP};nGA9^*Hz*yu@Y@I;k2I+7D1%;(Wh^urN3IhL(nNy>;g3no z83!jDWS>Ib_%M~+rx{cXJ8%hIW*HPR+n}Vm2CbTBP~rIo4Z|cj78(@2#Gt%?7<6;F zL1R~t|0;t{uQTX68f`MjeV;+cP-MSBC*XdFH929>i!QNkZe)L9{I3S(_-0T)T*3bDtfQMzOASUHGa8lK)2N?KM(xEgvr&`auo&f! zR#u}r+KtNPFe(^R@Db&GjcSka*nl0mjJky2+(z9%S{|dOVqRXOUgR^XWPYQ%<1_pV z7}W?nFr=VSBmIpUP{^oTXc%CWSCCPsgN>RP!ZtV~j2azfRM%MUCm40lY1B=ZQTY;$ znp4!MH@H#EsCOleic2zTV6st-Q;j->m{LZ)#;|mwR^tKUGK?C7S?HHZZdpd%MnGxy z!M}`AyKuKG^Dbvp2CATbd86)QN(H0VS2Xf>$*AFouWVG*PexTnJ>08iRJrQ3!I7Vh z>Qd7v-&#g3z!6+Rt=dM-tYg$N+{5C!Mt!Ph)b^%EJ;6szZpN6+nOiHPnzlA-TpOd_ z!qncV-_WMBQHQ%2Rj>!^fNMRCdj6|Xqk6G!efbMK%&1=IG~B4xBaM25;88{unZTO< z-xTseo~gvalWE+aZd8ZaMm?TmRQ|a}HOHxW^j~OH#1f-wtR~(%qmFJcYQ#ory@?z* z8?|byQL)>}afeY?F><$2RrfIFVQPAY_}A!n-KflmjEjEA_lWhxxW^m|PmD@@X5{Y{ zb4TmvMwNJBRR5P8k648k?~R)9!Kf72pYX&B?a@S%cw02j8w(i>7o>(1d-_c#s zo!k}JnVh@0t3g+HHR?-F{oIv2z+F{wd5F7~4|Uh};qJPMGb4yQ%3VQY+_iBIZ5Oz! z?Lv1=UgWOgi`~@?yRm$gyLN1F*H;|h=&sWi4;8U`$kXnj%sd|2o6kdAgFKWG=Ap{5 z9=e&}p^GjLxfk)!qGV)wD65KxUe)x_zWN>-+T268dU)t`Zx6-)<{{@mwhgB591le; z_R#9}9vZpFLv@aM==@m^wLR}4x62+{ao-p z_IYZ?V^1x#nzX=XQvduWO~p<;!SsSAE%P^NNq|Y`F+0$txC!H-WM||q&PX_W4cK{Wte2oH0clALe4Cce#V%xCe6gHa^#5L z%A0f#T`O=O9+gbmj01RtmX%HVvx-R{kol8Id+{2Ts+rUaE09&4{IL=rvE^rz%GKZ& z%WIjmw6;kn>zH&CP3xKz(7>ejxQC>MCY8lhJVTX6jE%dEO)C70NhO<@RI@4la0A)R zs0Y5n(cC0g3zO0?r4{$vndIKyq^J0VJ{?WG2sCK~{5qR7xGS|rOgEEW;7)gP>}gWi zuO{W|%NW?-pW6IpQrtk3stq!!5jG5_{}AqDHF6B44!@gZ9BxwX5hk@8MJ@0N$466> zF|5M`lR8f1c$rMyr}7wo;1zOAHz^P&adDPOHD;63923tij*+=0`7AJL?h=zCmYHN* zZc@dSCN18?8f>O+TTB{{<+y{fTTL=-Gbu05VBQ{+n(Q;FCw|#)(!PV#_>f6`u@k=@ zX6=r!rr3LoV-~kD<+w@1PjVcbV$9PfrJrTa=ULkeChfXJjjymD30F?n0nDtL>vxe6( zYcEdXBkDCUYYl#2c0;prHZm&+b5XE~SvtA%$h*`&Q8Sl_zC}R#Y%Y{XFgOIk#ij5KTCII|XyCoWE+(FE3LB6FQY{*%qxg=2V#4O7@Z)vS)ViJ{ZX z`Z~j`K{L%7hn0w(W!4ouLfzRsp2K*kGtaC!$iILX*uBs!!y@Lf*sN9XT548hJjbwQ zW)=R!taLQQL+o2_)+szi`xT7$r&+mHnpJX*S!K`+Z!l{k$J!?1ZXy3|W)FPN2eiDME^F0O=DnsyI0DOC`v1oWGqA!@=|*^0=-ld-oaj~in}3RiVXGAY0M4t(w{htO5t8I#?T&d z_zSg*dTB{9FRjNZ)GO{K&l2Q}kvNs?rJN~V3PKu=p>n#H+9JEOm&RZwHlsxuFV!vQ zC6Dr6%7wWVymYyWm#S3tQrDlnv=1Gsd8t2MqF602b*xSO>Ue2VU1HTE7B-_neJ`0C zcquQAH=%D+FHLLdrN!8bYOTC9t}XetBj5Jqi=G|4bO|Loc`2|zH5%Zhq~E+`A4ngZ z#1r%zA0OdJhVa6yx!`BRl(lchH4?+GKYC97h1wEf*9zDzaqW0A0?x_ zH9Oi{%MldotuFW;=dF72-g=ket)whsAv4=s$B!y8 zf5$xE6Aw8)ctu3mD4QSJrekj-8qMAtVV9`Vr?r6~;oh|x~ zs$DGl(#@hP-7QM#VNo{>gj-LGTJ*Q52Lc9I^kI-i#=#c#9%9jOcnr0u6e=TOm_@00 zjUO2CJL8VD=pV$4vZxhS;2E5w83V`Ba*Rb=(P^AT(V!g2Ucwx~MZqw-XX zMoyz0c1~yf85S+T8swYB{Ll=0W?M954)cU_o<*H80Egxidx1r{k+G0DV%-047g@9e zN0GXO+TsXmEwgAU7Gu>P7Trau736`6e=-IpApc6%4GmYZHmjL0=B=^l7G5CdI$~iZ zw&BHk>b1e5VVI1A8!d9*#9Xl%2NAWInxO}JZQ(fCYS9CvZ)1%y0>`#9pB>Bx**jSi zOhxlu7A?X$4Bkzx&~^`f_ga*=&!Rm0smno&(lF+4@;*upk1^-t9J6S1f>f~tkr9aX1}%Q9kSlh2i4zOH2;G|FOmI`$Jh?%CypWLGi!*pIEBFfc+Oxi z@_wS;s8!Oc6-Y|5>JolVw(1UArLZ5lQ?2@e7HL-fiP@#Bx=_=q zy0xr&fHAeL>RiVv@48m~f&UspwHfI>t-R*8>NqO&u_~*tRh!_} z->UY5t=cl&DxaxVeOX{t-bK`Bu~p?U7`HKhwN)?i6&=@DwHHxqt?GxPh*)P;+x1pm zMzf7pb=^Xot<(%X@h@s^vugiNYQ2m3?6xX-4|Ul~t@p8izf}_s5c8l_o_||)4I7VG zm2lLmllbWvIUT2-NIPLw;7O}`qu(joq0njSamK25SbWwh=Q*nmV%vH0xnR|fi>%2d ztJYx2b*t9@YgMHiR;|S2n^xVp#aiCAs_{MM_tdHxSc>FlL<~V{6aDQP{YwW^t z6n|;eAdE-uS5~z|cRWJL*H)FqVdQ&5oiH1(@Ez^nTD2WVkonH4iI|Uk@2zTz&bWk_ z55&S!e1Q8$>WaT{9+f}Q533RXnc84D-XQ%yt1MrLi5Yl^_vrqWyl@d^zp)R?Q0Y7M zz$Numj)SZ7Shm(+J!}4Nsev;v?csHeN^BRM>3OP&`ALmrXMe;cZh9w7~+{ zEjHD~4ivH4G#OT#O)Kp-74os^68?7B6zyx%960=JI*393^e<$SXMjzmu?-)vJJ6;o zK{ho($6%Wtph}2MXK){pp*GdSP)rK5X)ErcRJcun5#){q=o)ELMwCsD@d3A^$uo|a zFvZ(cCc&mJsOn@4mrY9&ZR$|OrvFf(DEEuo)U*WcOWL$I$)=cOn?_@5icP+$HoZx+ z$x_Oui*Qf3sSb)|5DQ&0ZCa1dh|jj^J$96~>DMwgJw=|f%n8PFjEisZE^kvJdSD3F zRkZ0kE?2h6t%^;dXn;02g1yyP7kq~OXX4bbDZQpml`$4a(76`%t!>kvXj8|g`E_kd zsb|v~1lG5yTmzd$ z-)&RNy{!KMo)<^RAB&IKRO=+i4%VDvEiT#=gbHxGL_XMw)0b&?h3C$7#{8GOQRaq? z^J_MRVHVEf23FmozIcHmw>f5T29+OD6X+4+JZ2oYJ+&zn#h)|Q3u^I_W8{@hMPJ)A z;2nQo-gCTspg&rDwCU$hHue3?Sh)Bf^Z7zuzVjTAT@MU)RdTm$qRFmnX1khu+4T@D zEq3Ly+BMA2uCY1o8lTIq0lDqElgF-}dF`5sf03Net`^virx>5#uDv)3?*ew-H`w(R zUIp!1gH8cH|wCQ2jVbuQBE=w=w*_-kEFt5IL4eD=Kz;DcHApP(e;|AFkJ%kz#v#ZzdcKtkp zv5+*{uA*buHrB3u{>eAt|~L^ zx{V$)?YcgjeCOB|KG&|Gd3LRxPo4|y>b}7)x6RDsfL%L}Q0Jp|#o_gNa{b4yAvf$g zRmexRB779lz(+-pr@N0rF&LY$4*@-BgJvky(?>D5h~dBbXbPJ3^3fmY(%VM^5ZK2@ zaTp3?UmrQ(>gS`D=!UNSeY6g{&}o2=`k~fu#DQ@T?a>j9hWcpy?>_o~y2E|+YJ`ts zNBXEFW{&pJ+HpQwIiBs4d~|BEj}}k!QLE`bIyA#aD`xp)2h=q0m%^Vk$V)t)fFI zl^v?~lS5fQJJh3wL!W9ow6>N*LAA-XjzeYYJ9rQ7(16DDYvRzeri|U(q2Lw{eQ4>> zvQ`c~MS5F@_TmRhwqtHshnt9O@6b@(#Jdg-xpj0Xwu?i(x;vEF!=b>Q4psiup|@Du z%b{<*9V$G)p}~V3x-i6{+xT;sL(#*z9mO0*JJe>3Lx!;q-5=*r&G8O3oj{yP%xkhk zep4N4jU3Y)syp2w=S+uMq8nBselGp+2EWg9$hC-h?4V9~it0P5$1aB^;51@(J5&P0 zkhX_y2U)Mb9cqq0u>}tfIn?n8;~r(rjysfi(xIxS9BP1>XBhviL(fs?x!(5&~YC;EJ%J)WV{XNUU1 z@}GnEZw}oeGC+>>+&v{j@X4Pc@_bG~MZ^B^d1TQ<1`c zDqh4-*;V~i4I8TY>AxC&s#}v=bgJ#A?sfgtu%4d^)c2F4iJxvZ_0zs)etOixPb*sb zDY7+f+xV$qJ3mF?EIPLL(>)aG;HR;eg?8QjIHvvdc%YxIjv&rNKee3drx&aJGnhvd>S zyeXASCo*y=rc5p+RLZ59)pMy%om}dGt|M~kr?I(IcycZomgM5KTrSQV zE^WX^^thNyzSnc<>Em3=_av8^Jk6yg*oMP!zRaag8M!sFUv5mKrGPQEK&Yy_fmOPJtVIdVNc1tI+T%D1fO;_CA#@*0j?oecYj4-9;)^7*APs^SG4TyuayYw z7womrwb9;Yngmnrv!2;Yz>{NfXz*0QGifQzR z|8#1DqBH!}2`jLBroX-*W|qHhW8rLSj=FRFwH zkt;SpM=`f*fd0X_p8_-wZL0;SZtDPTf!YKp4X@$WHb6^Juw8(9U=luIVfz5Bg?EPl zO~oy|K-G=`It|ZG0UCvcoda|ele&-x%5)9TZZz%|pbj{Ui)kG^y!hBpplZ^rDgzuXIl>4s$b;R!o-yERQ zD7+;=6}Qq3y|x8t1@5Boc5=e89RaGmGeAvo4C8kPsQ;b-oyDeo}dr*8EzJV&&FHpw*v>g5EGGWSKwU-jD)L($sMGjkO`zP@2FiO~pk`w^ zCae$C9UR#ZsEQi{H5vaPep8@oZVpu1)v|RA)Rx@yCH$j3qAu^$Fi!k?Wg4Jw}I*f!c#}sPTzfeht(w-viYVmwyCm zj)Jtv5Ttb|>>i}QaoZZCAfF(0@e9%eLmdJR79Q^Fa!@7^FMscPU7h(Ec)Qt^}#?qadw%9;6{JgVg$akct|D zm5FnhVhq+w{Dbc(>>jNC2=)k8Y0qFqn1U5&4%Q3w^$ONRSiOT)0pDP=1ZzDatifuJ z19*%FwqQ;n5X&c6as+c7bFgmv2J;#)SQjzE6|5OZNhA+ED;%u0MS?Z5Sg@{PQ^{bp zDn+dHV12+J8NqVT43-~8;U4N|1?vnP*}+Oe3mn5Y)G8gU33y&6Sm(jtk%B=YY~1757yuj$gXJ|pSXo%GAeeJp!D@3nnDg+#YH))2;~WxC2J`t8 zxtt1COZ3HZ{Dm*5a5`9Za1LG01Z(HnVE)Ea({sV9i^Fi757w_2s2%K=s4JGiewle+ z57tuD`IkKL0u^rt>lE(7`!@UHLv#h5GeUF`US&f#XBwgf*aMYgA1YT3QOBP{GyrRA zglJc{5dG9ML@Ry`(Pnh+6{5e;u6KyepiiF=EyV`hM_Atw6~!>n- zxVVh<14C5p_YgIm6r!CoL-;&2L|gG0>9a%hH_UTF6piNCH#bDS^FuiA7b3&@5H;Qq zqM92+G;>dg^6m{$%OfEghO@{z8lq#^bu2_r@d>Su6CZ~#`9z35VCu;b`J4*TeB45x z)AUE$8S=z5JcIdch>D(PKbBy?1=`~?)?EtG9r#^lT=c@f`14wb?jhrPh+=P$&+`yI z8wpX9m*o8_L_NNR=qMU0RQ+Ig3spU|!ckNjA86TCSLS>1jEf%7Ae5hI`gsQePRQ+9{Dp8bJ#Y5FB zDO8tILisL1sAi;52P`N>4!D{g%HM=gJYPjqV*s{K7f)#F!c-J6(wLse}sbsI+Ck)fJ4HdHOfhpOB(#+gZ*m7!XS z;j2UWEH6}P|1jPQ<`5F5uMNXgr%{-kO~UjG)}c_-FwMm__%sVsdwfKp=3%OZJ1Ev7 zOi#OnDXeRl26tn7_b_D)4^v-U89}U3Val8lrhzCtGfY`HityQC@}Co?oeRS>ouyh4OeKpaBUtGu2-l$BwSHL!?ky0xc)=!(cy|86Rw6+!!;XKriH5! z?jd7FxSpfJ+;IMuglojgaQ%RFRk#Xo2v@0%w8eTjHifG?mf;jW!}G6jrC|srqUz>w zZNb<7-);$4fvw@%bUa*3Plam(qEClw4KADs=l|Mp%|Y4)#)bJ}xbj{KSF_9E>VnEw z!_^c8u7&Ffs{IqL^Qd|~Tm#_$Z@79Q=tj6!;WE123|FyR;W`1&+r+vPt_S#n8F$0E z?k8MVQ1m~xVVoj#1Yw2IFdI)@AF5fPoW5HMZ16q^@Uqtgc=1!Xl8JP zyi+5TjfH7!D;2@@>Jhq)wCo63N=N8v`3OZ-h|qOBL)VHCI$bG3ODadGaJ2|cN7Z@} zob!p$gZdGg)F48;TGF>wget<=CW7|_5n9|KLRlRnvIwjO5yoNWDSfPm!EYjMN2G`7ctF5cY+~-y@Z*D4m0cTa*Uj z6gC>7bQb}}DAmFUoJ3ytDAmJ4+=Q=3lrqp6OK=rt&nT5dS1iRP*i2DMLkG;mDY%=X zl#EVTii_~{ic%{2VkNG_;T@%PbjBJqu|%m0KB9&#O4;@(J)UFj&TK!Y+-YL7RlT8>=G zGw({waZ8kbL*mvbW#S0Jwi9Dll!ji8(vw?JD*rHwbG%VXdK9G!@OjMkmr)9R#h9<7 zRP;@h9)65c(5EO3_)OmaMQPKID7`>Mw`dhML~EI6v~D5Q94(7iw6^<2>l0Syh}I5d zUp_kE$LC}|I`F`aw3jByxCj`62=ojQL#3%#-#u&vpV$>DGa0Q{h zF-pXG4DpN6HN@nIQD)0!m?uU*P%&?e>S9#B z82yV1VKJ(W{kRq$qbH~v5u;W(7a1eJm>9i5+gQfHI-Eq4xEQU*4rIp1s98dcuA{Is zhV$An`UIORMoB1(@wkN-_&qU3o3Oudj7k-W(QbGZjZt^3!gBS|Ucdl48^@ zIYxh>MM{iPQi+F(X)(G9d#M<8!)LTer)HRw5u5TiAdwy3iNL5Ya70IlD9eK{1+( z{|3kC_E5&27Ng|p%opFWeMXG-%ws#&&5zMulvzMc7sjafq8Odn!T#Os$GSc2N146s z-xs6C`(xDMNQ_pZ(a{)nME+yc`xLjQSr7b+iDzQe@)Gq&?aQnoo}tQ=mksscCfSgz5J)pWeG#OkOuR{i{9wHY~b z#_9|@=8e^Ic;t`Oc9_FsRR*8o6%niPcorF}f1_hndS9%5!}a~K`tv}n{yq{b<5A+_ z5Goyu)r#Y>+Iu2a&YQ6sgCDoa^G>X$-HlcCd$9_77_0i&`Y2ZOAIIwTf5iO~%ejSE z)xySau^RE6JWO%Q#NXyP_4kg`Fk75F^2TW_?D^vKuuzhtf z9;Z2|7ZIoC#pARUg;L_w06wX43cykrO2uglo>z=hM5QRmLDsY;9|HSEc+`Ud6 zZji@aYJlwfaVqs7PRn1!Y4f)@y+Y+5aeOWpCttUCwMU$LygK>DYc+oHi&tml%n`3q zc!)E(<7LkiuYEX+9(m*S6ch5r>vLedx&+ZDDqde;j*eGk{df&Ua-(>SN9Shox`bD) zFc=bL&n}hM{i9UbF%k2<# zz}Lg^8gL|DqfzW=yjC5f|M7SQoMdii;uZEUac{=Uaw}e&(fD?}BJRX%(PQ#>LLRmR zCEF8J4sVg}NZ|Xz33}|Cpvk!t^a@S$Cg^Uy1QpMpplrNE;ey=yCunFug4{#d9+sfG z;R*cBPEgi*y9sqb|xqn_97-RL5&M1XkL*7{aiFb=h6~1Fe5=@Q6iH*h{#G% z`??8gRX>5>LrCEJkqP=8iH#DZz6q*@X0Z25P?i3~9gv{WgA&wmaDqA@a!7*qO(Orv z30jPnQxY_IMuKY0Oi**=nU$b=a}v~NNrJ{<+Uf-LTAQF@aIQMGW+G>YmA|H*hyQ)dsb^oLXjeDzD9{Fr0zI$Em>%r+VjdYG!Ws zqgo!PmLfE-Q?J9FIv?TGt|{L9ar8?C*&8c3PRm!R5 z|Ciy^S9oPQwF$3LsI*gE@f)JcIQ45;C*Rw1YF-6mS9R)iHK*$Q>{L=sr`BR8TGetY zqmENm(FBLEv942(>N_>Ip;O}m#*O@#;(O2V607>IxdZ`>(Z%uE^TY%Qdld-#rxJS&1&n?D}2N9cEoN^ z?2azQcVR4i>*~_%?k;|Z#-+ABU0g3lP0$hfdNa>HF8TE%&OqYe8+Z(&v9&dVR~K?GIgYJaVZy=HVo+A?q=Zu?jyuaj7d#A@!+Cm+&5c zK6Av`19AM0F~ksD8MI_gGtjd@-S7qCO$3a-vS)A@){DREMgG8vRqE9$-%OMEU)k zs7BZX_ZsAa+sLk&sQ6lmItWvpL{+Fu8x*WZ9pG1=`8G(@fnO4JzDc4sHzm&&i5l1@ zQTf|ar*?^4lg0c|vqPeW;RPymOw<$1?L@3DiAu#4jP9DK1<2~g9C{||YoA2*?whC? zza^^6Ks9)zKYCZDK zP1F)>!N3hg)!;=5Ex-fhds#x2F%l=>_o{>{VkmatHKJdaP;<<|d3e7mp>*`XDm+E_ z+Y)MssW=JayAmpiE?9=!$osy8YQR;Zq>@XPRNd5)YS^@-3LY-0w{b~|j8Eb_he?`^ z8wgBDQWMO>HRN_CsU3F0?n+Vvtc6=*lB!}bE}=;IBz}V=NnsU|R1`aqw^EWm;Bw6* zwXdC|kB!;ZJV{xtl2oQml7^yq+a#66Q_O9bq<=83J>w&@Ly|tBSjQwi#%KK1DM`NF z85@QkN%F%CyziN$4ZkMo@6kyzj!DvH973hBNm?;3NiD}G>F&}b`7cXSpFfh+ZF!RB zZ%yL+TEyRu9nAk&k_sMA(rMg8ixWxOe=$vd$vDaI)UwTghZqOG;MlQpuW#7wO5` zkddt4$|UPN9#u_N_D{+Df1WI_>d9*PbFxxuBun*^m4xXHlGU(bvYt0iR>UvK8rmdT z8BLQ_r**O>;bog-t!kUBA??Wr`8y`-6&CbP)-@FGo2*>@lI1ocS*7p>hLOn{f%~Hv zb4;>YtW4H?d|gFetCKYa9&3`7{8zGi;N0e9E!vu_u&0cP6NVH88dLPIM~d=zrf9J# zMVBop^0lUDYTgu03rx`k3=c}tbod9Ss82|WDukwJcXW!{mrl{2XjmqN>xfeH7C)6s zk-dD1R#!{WQ_QQLqBSV;bBZR`NKw6-jMIWKk<=b_u<0pkjGZ%5 zGtuq^K1BM)0c?-9qjkDXIZ}DMEQL7yr4XYMCKb(VnSljRK}r#b7<`Ua5S2 zIaU8UQuRJpsuFUiYD}I~mB^c_te8{{LXp^1W#bqk;#2hi?Nd|rCmN=ussrBQr}R{P zMNoxQHHKfsR0U%>JSsCD4AoPWf|)<3s!9#w)FciX)*=qx;-@;~RX0`U_Nh7p?+&SI z)iG5CJEh9iIaQqy+$B|s*os`;$O+Sirs@KQ4@=c_Wc{A1t5awLF&WCMP)8q-yNiRFzzpsw3M{<+(jo+i(>+0s-xJB`|@$>GGYCu0Lj` zD|L3d&d*6#>v`$=F+W|?7N#q1ak}>UXQ*~ShF%0_@VikNoS(?hYTSv;(1GX-t%%Q1 zRIv=jRm@O36snZL_!)YJRW&k{Su;cPFrr?D4xxAb42?vo1{uoNoY?Sgk)iy!jScNH zYa+yoSu+^Nb9+24^S@ zw};brM261c4pxlJ&=xcqlc8NWhNt5)RA+pK`pwAD6NJsl&>+-blA)QXv@}Bvkg_a; z&&4yib|ph)Hf5+5O8u3gE=MzX-;klE$1>CvQ;%n;@U09DNB=t++JTODGc*95?`0_a zWrhZ$=&KBshT%1Hd7q)O zjqC@R8jn|xGv)V`Ibrd$OvOLX)Mnhmy4P%flc_3b@{YAej`x`w{3%n*;r*F;e z$vBO7m=~VK`FZX~WT|c>`>_Q3@B_J`vy_bAFb3mevQ#WKOWWX#%Ti^uh|kh!RM3TJ6E&K1eh^#wQOH*rPX;#fF?L|zjETy8=|J5d5ohrGKvvdv59#X?cS?c&aOH=Ukt1R`$FYmMTJCZ-KE(rcco+zMfl}3y?Th-9Y zlC5tAvK3M=TWtffH3d~-v(+7`3GBzs#B6yL&Q_zM*&2Z zC`}OQNDoE21cXop5;{l|snVo{-lX%=2?zmEdI|OY@}Bq4IiEAx-MPG`F15k$NI|g)E;Yi>NJhdW7k_t>!(^B0 zqVp8`MeeDzMcJ7y`LGDbkZCqK;98o>>a!0$> z4O3gW^?uN;$sxB&MBG~3#x4KXZe?iaR%I;h;#R4yZmsF&R>K}{u2pvH;P-CbNBh2R z^~3yk`nlDpzgwpUxYcx^TR-6($_(N)P9p`Y2D|kTf5s7Ks9R@IX@pxDN4a$^p1cyN z4R+uJuHf7}x5_SXYuRGj;rAtOMQ^8XT*lTNjCYq?#rEH>7-kGQ1Fyn_0PD~ z7I!bWmG`1s<#Fy3ukracYK_S$#6_O#)H2nr1`nt!4m@=09$G(gYaA{;aVz~(K1ai6 zZti2{Jrqx4+hBV-L)mg0stR|0L*L?BAw$pbQDGD@v=e2E8k$qw(4}`u7#dvC(1p(o z?*BG8SHn6;vJCx(3-5Rh4Qyg4bCjXvSYo#@Gy`XmrH#SwRzn@y85)mtor#aXyBo^W z!_fKO29r=5>Vh~dedl|Fx!Me^$H0DuUiLTi-9UqTAPm(SWGD*9QEsrIAvl80afXiK z8L|#BwD$)?=TLBjp(+@K3#c*DP>)fDR^p%0hFXs`Gz?oX;769@4ZXmI35I$m7}|ro zC^^MYN9@G-sfO<1tLePPWn`RTs5pF>iygR%mNO0g=VycSHPjSGv0{#)50VV+n@fG> z8O%AuXY*NifuZ_K_#7WDHS`AUml<3`WvDLRuB4W$cyG0#$w*kkx@!$pT5ss&?}oN+ zHk5+o?bH|PcNi*)&(Q=ocM~g_*EoYKd&qk){bL>uy|a(~V!xro2Ms+$)rgcMKn53T$H#- zTeQ8*`bc``ilHyB@;(x;GbZG{!FE8UzsUb4{ogW_E0x;fU!1>fsLUNho&GVDh7R`( zuCX>a&&8M?7|eBH=niT=Hq;D#pO7m`J|!o##suVkPCfB)nxPnU!3fMlyBCJW;J_>L z$>dQJv_PZG9=*x#kyXZ{=IDi)e1}aJlavsqg3Sh!lU0%rn*Nl__wAnK(s^oa|EjD1G-=lD}NACwbs(=+ZfK+@H<56!M!KbnGg^oCk+sM+4xcI2K zM-33dMWkVNOOLjoNh{hQ9_w(XH9vsU<71O}fXJ49}(>CS#kEvA5ZfGjDv8iG%Q{EP)8n-l6zP+j2Jxo2tf}W-d z_A(XjW9sAYO+6c6D#Jiici{{&l{VN^yEs$Lhnl)M%+ws_{ zJMxS&)e;Nv6b(n48i9QXjxlux`No<`!b)U}H}wI06HLxon%rY=DjCP|<4>k?&M;LJ zV^QE|#)>wx7&{8hHu+t~IOot7JrWsb5^WZ;&JuFNmrG5hTW0DtjOC`jUSX;`F0L|l zc(tje8%*`zXlfLyZ#DH7eA`W~H8+)chp8I7Ou4WeS$8vL)I?Y8!f7bkR1P%42uw!y zJ*Flg+g|cRXrHO7``HEus6WmhHr4ZpsSPJhy**7Wu9|v-U#?MW)J$Q_$adY-09-|- z8+?w^f0^8KLLG0Kio?ICa?9i%A5*`fZK|oc`1&?&@0i+)0)JDhd#3t4=CdcJZXx)T z+;9h7o>5cedTy#44qK9SsIGe z_blyAZ}DA^r7|d-(b9PQp2S3_c3|GRhHb#Sz27d;(G#%?*%NGwJd#I z+fp(%xGc^IFn-fgHylAl%hCk=1E1H@3S@6$={p?7>ZX>e`pDg})H2G_BQ%M&6bx88 z2Um>6{~aymjkV;*11xE7sZI-v^9=Ocl9;V%)7ny{prsrkOM`J22P4Eo;WmsP(O;1> zI(==abX!Z0v8SEIc`r*2x*{H{aS{)ar-P+0&>Z8i7iBxL9dR5Lzp<2v%AG82LyykX z0eQY9C#3H}fB5A)OLkXFGqD3_x>+jGoo$0NNY~R+Q_MuQUY3gYwzMAa^|4eCUYtea zI7^c;Vu+<{$om7iqS{DmKGxDREE>ml`H?!|Ha;D1sXNYNSUl@s^#tlP(b9Zef_`F& zJJ>YI(#{0-jVTuYzoK?isogY7`%r5-+iwQ7n#uk;oAD)D%w0iUP%?>qdak8}d6sg` zx6}YlF!L8)FJnK($>rp_l5K~Bt1R{WmHlxw2c@3m~7_0(+x$H(u~ zf0Ly`n=Osm%GkEiC%XS(G0y=x;}mWodOLaSCii4Z{r6ZJg~59*RoKt*g~bQhUI*z1 zmk(LWblB35$Z*6`+%fXU=93)1c>grp`7C*!w^aRtrHdCWeR7%o4sWpW3dhV<_U9DF zf1P~_i8m~r_{&ngTb8D!ay;F(^cL}dv+vv`FVuX%zVnoQ9NC{)s)09X{G5F}jat3r z*h8mR9BbLV%#r0)ksMyNMBAKRjVs_)!-8J@i1|gm%Kwp9)k}Nz9PK~$>b+0Aij?)L zRTZyB;~0{wdUY0stI-C(;vRB;?o|imsP2`4N431FSKF(~b@&|KdR~>PPkelf5qOHi z4ZJFYURc-AtA}`tmW{kR1aD)n{=jE0`bK4gb+HjI(a7V~7#ziWCh_qN79kZSEn*=7 ze_ZpH`*%~24Ow^L8*XO%@L1Xc#MiM#Ks()K;~Gl>Z2zX;tGm3 z^QsvpU=PwzwK=sw5>6sV3$IKJ$0j^N<(6Kq)$(dNZsX%t)C&`ljHjsD+RL?E)D$;R zD(F=R({TdXLtZsTKdi(}lnfIG2{?*;5$e?5E33O##mDhFuTLFX`LqztTlHUmFeiy|KK*dedE*NPCmY)^l5uHpE~#QY2HAeu3+*YpXQ_7V4p_D`4m6I zr?Vq{svqxDo(Vp+$KHuPW%$Xbjo1g@B%hW|_Gw6hPrYXO^c&jE_Ng~spm`$eB>5ED zHFr+un}>1TWjob~CetMq~A*T_4?r-TPS9mj}=K21T9M?Up^>{Hh#{G7p73%sAv zR#D8un@qMUWU&=p&Q^xDCERcvLcWy?SsvevdW5qIm@ zTo-TaL1SB0T((m15dGXX&$Y6()nhBK&sG%D+qOQyOgwdL-H5W)sDrJkU1^UteQmA7 zxc;^d4`4aS)@3}5vsHD7t?PJ%{zGk@8D?wva9fim+d78f3AQGq&=m5YYU`tE^u5;B z3#?pcYa1G`w>5Wzt)?4o{d&^YKbU*U)@sx^Z7bo7tuN2o%8_EL3Em**bz4*L;D)Wm zf7#q`Y-<(1x^1fmir=wy>!GcmAKM!7)Rz66_tF^W3);Q3HT#v#e4w_DytTO&$I+bk z94$@nXnY1o-7-1~WN}nGhoiDN9j(gcXj5)Sqd#zz_>rS<1xF7)b#$Ymqtlff?W^o) zK~+c7K65monxns~J33y&QF2X3TWS%rwxgnT9o@#xdcnvkadg&n zG|zH$1(Usw=A&E_M#gL6L-227oPRLJ?X=nF=qeKSGcJ@r;AqrAN3KJT@?3G`;JvGk z@?r*_T%*qv>Tt_Z##D!EuO01&ecRFUJC2(F&A9J5dW$vp9p;61c#fN+MGxusk)yHC zX^R1Aj>aMP3rF9*bX52i%XCp%j_`X?>WatkXNb~kE5X*EtX#u)A>~!A?!=<*CQOx;8%f+e#K?+YfOH>ZlO^@ zzoHBIH3_#+vanw*iuiRO`HT9Q3(l`UKlJM|I)3C=`_g_L!TFE<%GZJSyArFLUt933 zyI*mMxl`!(>K zU!RtXR&tAI{n0jBAGeQI?mp3~zcgAMc1LSCx*dqthsUFJ2V+h|tJm3RJwe^v0d>e5 zQ0eG^wtOAX&UOLqY9CNS=YS65S+9Vy_YP<#!ruoJ)jyzCg8~|W=Ys=EjteMud_a#T z26S<1K;@DG5m48c0p)!akd2v`kTFK{-j7iVe#;)CZ`;M_7+&Da(ilx##u5*f$Efp) z7;QzN)iDaJiP6_J2z9It<8A;K~M`j1huD2 zP{X?i^{7u!?fVCH6yFaFY7BlE6x668K}{VR34H8Y2F1*39?)Ff9(|K<)UPo5CRDxZB4(ph&%KN}%U_Jwr1Ur3)1 z2`Tr`kh~Z&Go*`iLMoCN(h*!jLQ+T-=7w|~kMMe4NYxe+A6F2!D5Mj^PX z{V8L_ZN#UAbPX?Fgw*C`NZrzhwGwSIgw-ASGKO_AQ&>eZhjj#(kdP&;YFWeDj@azH zkHt z^DgTZji}Z~5uKLR*_7E@Ulb*Dv`2S1`^IE@q(m>yAc zw8t)#pFz7>5uS+=QSmvL8_{y)nitVO7&1Sim)Nu*qC$%zx_~x|BkHg=qHoVcbn;w8 zS26H^B07dUNOwM>s;G|{c#cdLBC38dqE?q8I@d7Aba%HGkJIs3)7g`TK4bBJfBJs2 tcl4%D3cc~}wdX`HsF^zT?%VXon%W1CWZV8Z-O>dWF8V!{GO+VPKW4y-*^4r`o4et>u>0EpHsDm z+I!coUAyX3ce%Ux#pZ>-{^l?YBOdSBT{{=z!x+#fp+}Fzu8F+|c1cR^IxwMUpI&_u z61pdK>ozc{Yxm?^1}1mw)w4@tQqP{ry?Q72zNL4MgaJuCdknm#d!JrO1G{vy0mrA& zkxvpAUu#1Sy?^GX*ee^Ch8PKt*>^eKJD;<6qeT|tucgcF*V^KpTU(kPc@^r6ZE&sK zZnC_Uv!r1wTeNev#SCE?YfhWf(tMp4p>wabN1OO&w3^?_)^>qeA733Y)@fmu=+w;P z_uD=oOrbZcq`-~p(Wwoi8b$mZ$D3L1>^u)|Mx|yPzxl+wWZ6}iWjGxXjyQ`0w;M(t z>iPa@-XC4!Hp-&##b!vJ+Zsk|=Ze_27HezA3ys=X?3EMjA^ZAN8=( z&(JhucxCdwr8@Esb28)>W5@rf7@-DBFKXsGd7^{L4sCtw~8V;g^%C`GykM4Lg_*-7;bOOrTfJxgW?M9$mdh1QfCmYCG6 zkks@cVYubbD|8npmv}Pq-P`~qmKLe*@Hr3dtcM#pZhx9<(!jjp;jTg`*)ZRP=m;IY z_rZTh;6|QrBuWP4<`rZa=2XxHa=)PBv6pwZlAtTNPPDIkFUs;=^o}PG8d2xOt1C(L*pDMoLJ(9?SOu%Vz71jq8G`advZ~+ z+vfxBRIiT}P7o3twA?%FJ8}T)%t|eGmnIds3*8>SVOk*xOWV|(&T;2kH9-Y5F~w6# zF4N13+{1v(l_N-{0n;?Y5|^6Y^!=OSqfynD>n$nB8tBgSX1RyECl$c(edcoDLp5L= zz9cEMDXL|9J*Dnqf0CyJl6CprS&#v_H>U`UX#V|S<^c#|st~}0(~qqP2Uwmj&F#wc z=asVRR@^8T#l?HqyC@%DY0dzz$L|8sVlxKN_L5ICNF=+U#FslVGuKTwP<*>ki8)&-WOnLpLy0BNm+URh$ji!dd(vGwz|xHJ z29}DVYySlkHZqIdkcl9~_P8heQK<*9K!i`lkEx(ipwuF_Cu^8DD=$0GT|CTHobN8i zeX|lGoFQ7Ze($q4&;pAJU^BVif-F=p?`M-?Hychbd5+#G1KMxf6>xoVL0N2w`qiW? za$UXwxh_wRI}3%wRpBOc_zUb3P+N|Bpv&*Vce5=hI>VyOv-q^MPtDyHANFB06y*8P zE!>%YVf!Pp)7^#O#P3Gy0n~$y2Du&YmrtbfG7DTV((JOdr14$N7Q_U>Z%KW%0d3d^ zjTMc=A5RWdW0=zw^fvQAsZf0$aJy4o{@k=Avo8wE1@Z$?UE^6?;Pv|4DV{9%HpG?7lUFEuUy>&)sg!*HB!)mx63f}O6|DskzpK~}m5qSl&BZ8&n89TD z?T`A{kM2lFA22v6ZTx_tNeRP8r5fg9stipGpL;5g5-oBS``l2Ny8!4c)-|Fy*@J7doucn)xW_|<4Pt?VSn(s{i1WFk@j*H0%}Uaj_V0E$(84anW3X7bW^(S zjAMaPuVFrc0!Pf2gP|rs1!B+hJHI62w1nY3w`=6jbGiIeRG7e2mr5_IVTgzst6x+ocz~JU(!N(E!cr&khUjJrkQP7gi+k$X;|A zh0;eZz5R#QWh&s_}fX>MQvsIIzw&|9R65yD$g z>Q2rp@JlZe$<~AFs;)P$A@^V@hb}3_?=CbCk!P60ddqW9(_x`$lgsYNL+5j6kMc|^ zb`^o|&rwh=aBQ0Uh$D#ezq`v&d{J@^=GHuD>mv2#NvE$fOCcOUg23*5Q+^R0w8ZZn z;JZpN{ghxT*R@O|`au6n1p22G|N9f}I4t;wuXGoW^rM?+n$fE8faQtD2$}6IM*o)s zxcNQ`K^-=F#PZ2t&@f8!Fmj*8Z7J!Kmcl4P!CzqvOD*=YwF8y5&(58^mxVpQXkTmI!|ekrWGm$B>Ua^j+W9 zj}XZ47rQV<``qSsN(;8qx6!jHgv=>%6=$U+jT}8Fu_OoAW*qdz3W;eg?xU9~#8@OH zJsi#s6`BzP)R~<4kEwJYdA`IFSXzolk6z=u8s;1n(Bg)4YyA&OFtY&8XSBjF4L8cg z_?KqQxRcRhmW%}0ScX=C7Mn$i-OR(;pK!`1TYI(nlY#ZP5__XXmvXZip?ECuiI2np0IS#^-{#C1qen)WK6&y zh>9jdA87}riHm-qS;9V~7b}K$T!0(GPj&nJ3mQp|+auam>_%AVfsiHLsZ;-6MI$Nn zmdKH66^bO<+4ByRQFeKrJb%(;KWrXUGn8Uy7Z2XS_Kq(p%7WMob3F^7w~DlV_fk?K zdKmzxo#D!)`I)byK|qYIu(VtIe}f8y=`Au7@r43dadxPa2(v`E2LV>VAi*P)xTbPp zF6|YeP-edDBIrW6fnreHP<&l4AtCTNG%wqoS(eFZlVN64gn-}BXvZkZ2g8G_q`(hT zb@|QCb0spe8oG>yUN?cjO~3t@gID|-$WPLGi;6qOY)0#ur;FdXf+ z^;+6UvAfV)>K?%03GIgbiQ!_}xdk-f5>LLzJISL0`vER!12HdKk4BzcdhvUzNQg!_ zUZ7t943Hd}S-<BJ4C@L=TxCM=n@sy{Vej|Fgbh*eL=rKSVH@16MDlfy9v~KP1nT2g*wG;Ofj1EQIuum$^q%dd03u z>E4mKA`n7km*w>olqDCqa?ArLBy&T2PxfZ0Btx#G!Xkf}@OfsrsxbVuvrWi{ocE-7 ze0~>v4frrg3d&CVe&IJ%cAz(m%!ID8I7Kl`%!Y-4`oDH-PdN;VaXtYc>lw+LIm*M;;f`>bW*>-jCg#Nmc;l)YrPdM%Pg2&CDO@E`qPb1tF*V8r?<6ktxGchbE05J|b;c!qAklN#<{? zfX2=A-E)L;lQZE_!quwTEe1j|1}w9`f3Y478i5A_D)=^Uv7FazL4|U`K}DO{Uy_46 zTz+(0^qbvEv=zRkzf+ZHRKV|@7>@Pi#ob zb$d8XSA*YLvWCL60hMu-y71g79vNmf0wmZ1fy&}}?^5m_w>!%>Tn()F5Ip4@W;vS-xXLyglF2Y+nNX1D@(BxgAFTl=5cQGQM)jtsi`_Zy$w|IU zSCN?ABi;yz`grE)678nDp{n@={=f@@>J{IXzexjEk{AbmMZw7DtJK&b{Eg{Hft+?X zn|4!`a7HyFsbQ{#_M`+`_jvpkN)Y<13G}4{H_TMY6g)`B^rp{nnBkO}@#!GUW?VUp zK|~4&eiT*ZAlE-DbT$d*mKEi?JsjH6hTix?Pt-s9!C#0+SoZVB+~q0IShl~|2+OYf0>z#3t>q;UYSL< zh)&G6@ZIc2D~4Leo_}F3-CCimETbk|MTO%;3ueYeZ(UAkjKL$_1uB3FQH4Xc9@`u+ zQXSVlrc^V0LAYQj-(ALW!e{nFLAgNcnfBRnA|0=TTe7r+ETJKu*Y{i_EX+N8BqLk1 zg@gmQQ|!AF+3SZTj2S;Fbznkz()a-*Mh#Cl{eYFB*YqEb2qols5{tc)Ff$O5PB1q?A7~7aJ{A4* zM-*Ye@e?V-wjQzy&@Np*VX4p!f_*Xb=?1jU>%+`OitdW^_m|VYWf%e2XeHrQZP(sH zTPSqpyTz21Imf1C3c6X*L^UQFvkWMivYQ$ z$Chj=u1HQ|IRiJ$DhY|=9a(A3NmaxFiNy#*F-%p-=AgLp{Dx+95wLLtd%`msW&v(c z9QzkU^rkq3xiLQnafkuCFLX3hR5`nK%|@yr&xbkaaIb$DeJifb`ZNI$xaeP9NcKbm zLW|P?eGZeCw;r7bPMM4{%%i*se|TlC`(oSl~gdg-_zwDpVjxrCMxxsYREx?xUG&>`*%ZxecwtJu>P{>f|v+H$_w+L5%C z`W2BoNSft!-JVSF^8rZfVG zv{%yNY#G`?lG54Bu%ZiDgLCQo@Xo){x%fo-O%DfhMkZ!0=TS((_U(DWNx?FiNq>n* z%P`+jSo$Yb|BdlH%Aj(8jaSqO#(T*Ru`Fyemik9EkB?4~X{XVua7a?=Bf=-Rijdyo zgbyToptkeLNV8JP1#Rm8@P!sM6LzRn1n!X9fDATzhH7-TFBbfh6(;58`K7N-OJekH z_CSSl!AHi0?)}IITJ0@HJmx1K9Z?LefW#C>t3-+|&@odyVg_jT3Rv>g>!%(ivo7Xo zU}%0X2&}*j>Sk)s7e>-5ME=w-5-WP5>@!Vm- zxUI!a;@IZcbr*Z753*%%!2CmI0Uwh}1k+pGEAA%KNW@Zs2+vegD@VQd1LayX8G#%; zs;}<9uw+|f6vAz>Z(}aQxuwd2CJNoyJDGR0HrP0F{geM-`_bJ&0-0$&M$Z;CDZAr8 zMs((wsInBu8RCKxKk4|O*fl-kGR{n;YpbD{#yC zml;Rd1M%gOjnmk#rCV;>O)gdf@#T-&cHjVpRJtEMlGzp5jcT8Dn`M}6pGUfTcsZY# zks*K85jqm6->})pvqx&j4Y3l6S+uPM|iCfx<-ocKa9)bDl8$K*B8=X3%)DjvnOuBp_!%I#vW@ z&q&75>WA?bnB+#-d_6|?NT$;jF~h5|9=o4#`) zeIaHf-h4N+p&~Oa(mTRNS4s1QOw+QvY+^W}oUd3UVfMmYt7I~I+aI5^kH{cg1Xf(+ zLC^}BknOQeD@M?LiwcO*MdYhB(^^#;x4-e%WIN!8YG#H$vy@ zES7o}BR>|aaHCw<+4RxN^VnprN6Czt9DmJ5z(B*DnfyU~U>Kx7{td#CInAfGH5@?` z61^heDpBQiCC|khR&*h9Ur7-?wl9^2$~?FSH;H_4yYeUKP#^=D3OYcl5YCG1`rF8L zkqlT;vhm%#!fuMfRmpKZX<0Q1PZV~hofpi=UDcLc^EvptxCp9PK`E57@ZJqxP^sql}Upg|KeBiS=xXqBUX z9!Rnr>_&;HXcmJ=pE(DZWbZh%!YgL#>>X0#XhRm{RxX-&^yo_>fyPLhp*Zzw4o4HG z!uL1&EY$1_^fZ)1DqbE$IBt<2c>Vr)Fu-vwQTcey0I?Gs3_gJymimbV^ ziAG=UjU+j!yjHh2zhVU_u-T#uDP$BAHR1ZrUepayKk{tNs-zIVm~>)EniZg(rh_KT zrFH^FgZu^7+{CbK8emb*c)R6nZq89cjIbglgBfopQU{K1&eq?t^MXAcSBYshm$b|x z;2?{AC%KQ1MePR6*(?By{TJ={Lbg89>*a)6yR>_yX5sCVuetjk@N0@5_dv<@jxqXHW|#c6+<5*#@)ZG1v{dYYNa0+`zUH(c9>_6+$a=N0=zBqCNr zRXW8S0?CvM9Mi8kzL7YwtqM@@z&)RS);$H18hviMq z^Prl^B}Ft68r<^Y^bQo2c9$}Dh$@G06Le8!#~m5{sAO41CyG$zc!0IaTe839XphyN z(Sz`5K0!@@vC1zu=2JxoZgO%svXlliQ2B^4Q^a3txqCnX7S9R01Xbwvj(l8MP0syZ z44Gny6@|1_DUL&5zWy1-;YA=?h%nsj1aU}5eR)!Q5!$KcMimzW`ZUc9O}cW;v@6tp z2^PxpG7%TMeEG?FlMORUvIovXw%<2|O+vS1SdN?tU?DT~nMPv{F5+NLyJMyUOa4BU zE`?7c32@)^tIgrG9v|Z_m6UuqU+ZT`{r+zKiv# z1nj`T@{f*MxEA0;Ole+G#5xZCSDctBz`Lr*8*@k1*v?}%jHP!@7B+pibN#u85+^L=UV z9CRyI9L);w1c@*GgOeYlfa^>@&_JMx#5di)Qx2-DLeuQZa8PHZCLqaPq3s`3{ZK7p z0ckRnO%^+jdDAIJxs)6PAbK~D>;BS zYuOVxLg}=Wn2;TU9AyTqbnxsAv`8P)W1~GPEMCQypeIk6QFwvV%RCxGK|x@GEk;7z zHzQFIcp&iEF}?rIUXksAh!~{yVr$UUdD|Noiq7g&$$Y|X!yhCTAi*`0dodjbeZUJ2 z#Wx~bA2Z;r?0cALus&6Zet@DaPuw+~MerChq8JN0Xe}u1*#7n!3Y8-}6BuHqJR3I% zw|j7AXW{SjiZe?JT*cQHS*NM98roxj{KfY^K71u2IC}+);}ovyPOx$_U1>NirQkOL z_`NEejK>8#YT75)?PEu+2}0An+?{52LA%igsBhd`SyL!&jAay!T*wYb@neFq`#b#e zJEEqA&^MS2v82PE9d_;pB8Q=>>9U+;n4zjs^UBO$C0oNw3NsMRwMK0S6;v00(xEXe zSt$h*CJ5uS)EW3*Q9b<{8KNK)#~@fwXQ!cx#IXLYc8!Rkz?%tQEX&Qwqzw4=)f=Ov z=NOKyjk(1xAEqU6FXj`h0Q#HWdh|nv&`3dYo{u6dZ_QSPoA12;N!g*%%L?=407th@ z$Srpk_a|Kh*4#7#k%9AYrRQyB=U$O?Q#>gi5$?Lvi`{OsKv#HlgNXHEOo9E4G;p(& z_6?KT9s6qqLkl$ustHS0P2#4Cm|z&YzrL>>$JIQnv|zVHvNyBDhY<(CG1BZU(2{Z? zi34w~*-Zy2HUtFR8(7W-9_SGykAHH*%d}#dP^ihUshkFq6G|>8KgoQHrlRwioTr&f z$vEV4Hs$9bQXhy2k|vh83P5BqYSX;WzICdfup+o=Mp@=ppzeq%wuYG}C9A+-J$~sF z(dPzj-7;TN%?;V~_#O@!DyuUfXdwt;JIO%pAsyWbZ0va1TWSJ8tHM%0-1jN5h&h4? zx|0IC`pjfD6U>I}xYC5o7I<^SEZtlKXc!#`v~1QfhIUDl56sMQZDydu5VrNqgmvu4 zoT*}rzybo0O4!arD#RpK@|FzyU@idB)p69P1Up|IKZiD1(^=bgHDky*5chh@%pziB zoLpjiX=}*c*)YPKf(pH!lMT$}Hq~CSie=gVj_pST4w<9p7@AijsSe zWr$`Drxt-@^r~xJ!~yezKY+Uun^onE-JAwezyWT?J@xC`6cGo6^t{Y`b8~4ZK{OD=SXg5vFf1PGRWivOu_!`50DSKARLtf3RLo=B|TnrIW z53{Fq*+)CX@@GkrTSfwAM+yinpWSzC4+jddeT(`9&mbWcyf}Q!@1m=5|EmZL35zNx zQICihZ+hBGzar*zvJA@$M2x}}&HD6YVJ3I(xUuDj$Tv~@XyB>|{fb32&n+|1s#v>X zg(y^z)HiG@J4A1+90xoXcO4+Pw}LpJ+D)qt8gv-ghdSWzi6h30PfHk>GD7Z1Gz|(0 zTx{NvUP`sNJ-(7+_W-OtgUCQ)VBzKP71A#<4J4v9qzI*YKwwAT@6Xi?RfF7qG$UZ- zKPVi#58P5HjXWRGru2~J7Eq*ccZYYp%n+;4?IL*uoVX|#v=8(>e~fU!nRl}iT%#DY zk4%`fl!JUAoh4>s@X@$uUc?{rf8_WAu@zIgZt334nUp_7e0*%LHz+^sY2nUP%^Px& zga&g*4wT*?dLUfB=-Rs}GeDjl(zP?K4`vAmoF+Ei2%mlcsO7S6_|pwvmXhOOrX+`l z7zA7OXT4(+eorsavcL8M!g7O6YkK3sJT@&uZi@@}aP%jvst2UsGXI)sls-fX-&;_I z$Vsk^(gq5YdRyPvtR+cd_Qvtvk3}?0-Ef2LXm{hF6>P`w5#x10BLW%o6;^=!I{w|; zMD|(TalipBp5p2F&CVw57z`A$@oDZ=P@S7E7*D8l?0_AKIBCRi6vl%gcr74Job|jI zY{&b(YI6^Y=|G4y{N*XRGzj=x8CQ-`G8=N&h)0DPv9GDY(d|WzV|w$(Yw5Z4GX!QgT!?~iUid*uEhVWB?wJ%_ zxhR_V_MZ8wXv9bsO&|>PRPk$J7r{R^>J|=$v@=3?d=XP(&C}@fVIoe z5|j_CM(+4~6FY5B?m@!-9JMLhoCy+A(fjk$?ok11N_KFX?QU8TBzfT0uDP;;e}K$k z%Uw+7I0#BETAjSBPdTf|8U4s~9aETXfumetx%hUsZ>Wzv-vDm`cO$@-gg!pSO}6La z&XY&k9_j6_+AcMQjuE_EetA|pv7lcD8qHwbv?{B%p161uMJBx$m(L)LP(Y)xAX2|m zuWWXk+8R~Ma;>E{L8fWssC!ieljh3G^9JNZGTHmhZxyk` zXU?ur5ri;!vmJSdSdt%`GlF7~eOWF%x^Zo;!5^7N82j6y?osy^EDGZYAZo4gm8A_{H++ z`B1Z)60WC3i|;5V#Fg&Jocm2B9>}lw#LuT$z|9!ghk>4p3rc<5x4uzSq?q<|z{YoT zlWK42&;irgd(g##7Jg76n>s@Xc7KcQ`D_q_QS%7C5as>9#s5SRh_yDTL(p48lqj5f z_wuJA1o9?(qh;d{nWQFPadeyr1 zEt;=nkC2Ol0d@mx>E>uMjevLkZ+|>o6Y%Qc`l=TG#>x=vrcVF#QLr*PMtGU-9Z`^# zl0`c<*RT;#@1}P$=du%LtBH&7^Sx;;5W$w;e3|r;Qn^s-WRb1IPBV}wH%Mg1ryq@~ zArh3xAd&iPA1dvB?6R1`)GYJ`nuaY`z$G2~fr7?AQ=mn1;VmEsvp)F&vj-k~RfJS9 zZC)-P0W6&Dl0v}hNdE^!f4U;yxDFs2Bc?iXj3B(q1@If&^vAF}~Gl*Q4$5Rs| zgT4^5`oWhN1Hgk|*EC?4KpO}tVKc1{cIqK#?P}L9o<9r-f>j4AR@)78Kh3zmX70ni zdxJ!HZXQ7;@B-0yzNy1dHk_hKDlFXy!nz{H!DRlnjay6xphs|?xX&fk9q7XttBa;shaX%$kO;9E0jmfoB#+;+5Q0fN82vRJO<*7tJl4zy%*!Zb#nHQN z>%@w%1F^3zAU${%v5UH?GX1f){rf?BHsyF25&Fz_6fby5`(>b5x=t9LGAuzxw}zQW zUZCKNXD@_m*TAV;hIg_Ua80XfN%rdN%ZM5y7ej^=dUrEb33I|dKm3k*c*YoRJz6p2 z8FsjoJ{T*+#caG-swN6D;~BQ%TNb)9Gu=gc_llp8(D3kkZnX=;zIysg=`EqIAe1S? zQpZZ6h({0bNGu-1_4s{5-JTqOE-Geg&aXX`%wB{&pA30qGB#JWd+e@;rL+@a_aZP8 zV>|jFDmda2J6g@^?zIXByG=G?m)Kw2}%v{8Sj4cBAKG|WA4(Nf&#!p^#=;w|Dx)pqe$Sx z4cLSbcsdx%H!yjK2W%ca`0G}|ri_{cOKIj5$qkPTD<(03#XK@zxlxO-y9?xgaKwG7LJGPuVOPT>PNqJeqMTpJ^5VM&if_8QrxBg}J zUpyl_GS|x|`K7I!)1?VOpnVU0KAFwT^2+T+=5pm2`k!nj_IU+1PcUlR&q5&Xe`sx- zh&K`8r+BcNTIS*KpsLby^5)@JXd_wfQa@JdeI}xP0h!$2`Z>E6mNuXGrnziAufC6#!^Za|!I*cpy=3lOW_+pm+9( zFpuLC<1qBUrvDEn6(v(D$k+~7Dqer+*uQBzV$Da*ti`l2ozwxjVewr@*_C1U*<${C z6c-RR%wzNBui6k+Z}3lnvv+g-;s>eK$*>(3HN^lXi+%Ly@f!qaX?gwgF<%nn4diL(XD6eNb^OSIp-v9kBDyUYz z6|oc_7B!2dg3yYKht|!fsmc(W+g!yi7bHZLh%Vn>`3eb5qKm*3-Y@6I7>!r~VeFOq zC(kg9RUKzoDlDqcakrWU=2JwsIsu_$vn6U_ns8fb>-#) zQ+o4+l5PFxK3t*V5!WPOGk4&Rlx@@NdUvCw(fQP(H;Q)?F$CZAUu8!q_?pusFz##v zQow?4)5mw-tY+RdQ!b(}umc`CZFlM)Eon(=V`o=0jZy&OjyL~$t?YQ}(O6nSJJe*v z)$xxTF9888AtlMo;!Oym-5)FCIecmR8CK%+kMap0i7f_F(V*D>=H2ILMU(l|40rV0 zubPtBpz9{a5k5B(Z{iVE^x|z&&R}TB&3!HlF^CM5bY13Pz?O@arj4lTPPOKVZdK#n z%*BB!V^5uL!YW0zPpUA?)@(CcFz&j>+o?(&a|NDTV`$J)2`1xTw~A*mX<*_>4;Bt( zAs#czcyHYc*8xLK+$*-|=&?%A($IBOqbGP*4Q7WITcJf94s5G%gUazd5Wh`yIFN!Q zG0H0_&vpCGDw9yd6retr4JF(keZ&*f`FN-RzTRi{hqBPkAjRpgK5>AMjQub}^_H;r zjHMBx{WHfe7IDgWlm_Aeu{euL6BO;)*X52T2K@jCMi}%zsV3m4c(1ug31@OqgoiZ* z7A2rfyTb9*dv@`#C;}oe8A8KxrUICRlZDlKZa!a0cTwVT6_?>~3-LS}wzQekPz3`u z$ZS4!&EKi2Jl~(h3>_smz_jhT>+El!TJgQ{#P)p^H*iO|5xRIb^ot${deoLUhw;`@crMs zPyYUI($}=f$A9(Kb^lL(YM%a2()@n|Ew=m5_^5S&CQlQMcJ8vYOmgKQ_iEn1!c3Nl6HA?C4G{|(0GF=_ zTdQ#^LLzK&<2I@jK0C?NFB8gjm9fCR6>obhhdkrcKE@=lv(TzIsc%@L$O*zk<5(~! zstMe%)f8;XCgeF5%@qw`FibE)9Ipj75AE&%fT01Pm7xkqx0-p9pX&h41;9A4At@bm zDxhdZiSxA+!9ZOoDn`mmR4>#PRTfHuMAbTEBd!H*OC2%&grI*kW{dXwLjFQbjg^=< zJNPA-3niv|aBnf*lKJcH3l|A7F=<6HaVC1Q7T6q!sS^Y-0dEQPt_I??i9l@IsbHY1 zPqY0fsKvG@9)e0OI%19-2zA~WnM-k74NNQWijCOU9l5Z|oa!o@wX(6Lv^vW84+7!g zd_2O^{=B7@KrB(t!x<#PmjeWp6*X1jVVdD|Fw06jeWATFyk$%8bIe~@OFW#loT&v? z0r7kafLkGO33Pj?0%Ag!;^A~lY`e#&=sVE_N(I240MN6Vl9nl_f9L8@x)J)ZK-_{7 zCZ<=hM`J%<2Z+0;xD!IMmt?n(S?IPJHbd*2;=fP_svAUfAKnt`VaEa`K@G*vi@{Lk z;y_&7Rc2l<+{A@C!?-<_PC}L*y6aOr?EVKZ+w2Ef;RL21Lrr=udsnBR8n2ze?UAsR z&q5tB^Dc%uzi@UhJ}5R%zs_W&WBfxqoh_9n|*@Vq@!fr zAl4#mJ*)qd!CwJO-5{+$V@snUN~JB$7M+tw^Wk%H7yPlQ{`NT12AA4cjNRQYSgm^+ z?8>=#;k^9@Yj>M1WKUx|E^X&SD{6Z77kr}P)b=cDys0MPptPXDA;EI-JJOM)& zU2C7HxSWear00q3zNO!MoDrQMxFhk&tqkL<)})h~F}zjZHz?L@53Z3Cnimx%7VR^| zmN(=R+oO=ZiG|I|Dhg?|qA*KI^6Ks-L^qhdsxPW4bDbL`I+*K(I1~kZwQV2FwaTbm z);QL-50;UC(PrIqD`XdO@jv+ND70WVTLH$__o)9R%~dj%>=6==x8EnJ*6M7bQHQlv zH-tRjM`z=vlEH$zm0 zu|VQtHzO`4pT(K>_!Jt=rADXlN_K`%f;3t)7!P))gcVbs+A&1fm)Rnl+2JZJdn4=# zmyF6b7Tey4OU0L}EslK=)ekuLj&)W>Tw0F4A735X(-wAXRdvL|7^7Z9)t@L|_np@} z8%7T}AbFm+=sU{GLzaiLIPCGY*06;diS`z8@YHZ+>_qSqqJeQJ{ykV&W7t40NUH{Z z7t}zQtfx1MfJVF`>@RmHzx3**wHJ-ZPgl1*cYfWaa~F-34fa(=RQ0l-yJ)%9R%Kg% zZecUS5n)3!{=x&ij~2}93f7LQ>f}0%8;B`BOfiLiuK<`=*huRPxGu)sdw85vLMk+yTDCIN|HzWi zaFnfF!pIFaB@VZh-R%}@b6eFi`*izW1b3Glf9YPIfx<%i)C_S-w9(GPnT)OZazu9t z#*D+{_SYGMCwfH7_tp$P%+KiyYFmIEGro%kfDY ztPtU34EcqM+To5RSVhXc+yaNN07|#S!M$X2?B;9RZO`Btu=rI8(-XCqQM&)Yv7kcq z5$yy-n}ZQ6J9`*L(X6dDnZ5Qg5={G{8$rbu3>L%aKLY?wu4kL(23*~fDRYLP4F&>4 z#lwk(D&)}i*9k>p(+EDLtL7BqC4tMm3q=e6OMF3wm>Mij1TH~e(|Xmu`e z9<VU6L4>dwi?#9*tG&bS2uI%wHb+Fr)V>$&&gQmD&FvT6 z)m8Se`d7!5M9Z84-KrJN83ASO>VP(J`g)B)Ns z7|Kl1KwsMx5Jg8yKxstQ0XhSKnL{70crfSz!blAF`gGWfjiyc*a`A)DIXZ zo#^eXP2A)0*(eyd7+l)`>%V3xhH!QPLpF}C4CM%wfzQTupiTl}`{TM9@7m^|`SfoZ zDicuAwV-74@0)|=`MDbICd-_8!hq=cNenK-Xi^J|ZgCL+4r(9<)0?+Xh^Lz=R!_Jo zEDaSF7_!l{4wkp);YsrOn)IC^3P>v~8$j380dfIg=o1BfynPu%X^5(w%DD`4I!FejRiizXjKPGy=M*MZ+J^rj8Vl? zy6!#^OX}w#vjdp4@+JaP>pGayfo1Vx-ExN=EvH3lJ1GWGn>s+R1K_9Ug2?xp`tUH4 zS7*?Oo#9G`n!FFiZR=pF29}$bXiN}C{X24IJ5aU61A*XEVbS97!ZljU zabMc%Z5EOEr=M$%o3z$ae2NE9@hPIX7!G*P0-5C%XTA>j8G3RxQqWWH55t_;QPgBz!Y@CQMA z%}ZKP5ch;9KR(WSVmCjer0_6IXDjZN-+pGT z_*{-1<$#s~`oIaq6pz;911Rbkj9BD$zW~w(FKeJtVTv2=h^GSR#yUV90Pv4>8fc{* zK(t^zOfi6B9-c3$2$_m_79gpwu@M{sbu-@j!TQ#ZY{q9lTDKhK7sI*)kg^#mPN8Rp zme=7XB{U76HwB|tlD_|S!`O(o?4g+bw4T*v8^v1l#IiU--dL!oHWJ?>sM0wYUks4TKD9xfIBc4uwn)dlK2SpaADhN7$5A_Ky&R1s5L5+iv{@XUI%DD06whLKp$BEn zceI57>QM)1=NE?Y+x7*gp$(6?{LJ` z_Zp~)6+ppy#87PXsYB^50K9in1MPDFh!WJg!pLj%tpijEfa=p4s0?c_2t}ykC{(Am zFoYVn)&i3feBulkKdS*d*cQnt1rh@S45OXVuND~H@=O5Sd`ScS5&|F!LrV~&opD#7&Opx0P0@{$OC{613*13ioK?ay(Rb*r_|$9ik<8o1i*v8X-e0! zO=M34VZbut>rfi{yI~CaLj&CuA|yz`Yp|sNO9%#21K{fb+TgGl7A8?d&$FQBOH=Ky z&9pl$$kK|3`GWnzvya*@K8ln@JZ1;7M~2zw%oSSJeqk9p+13l~n5L?v(mDwtca>k%KK(hdlgJhg! z&=Ce8+Ea4{gi+2ITnk7V{62teX{5oP*R-_YUjbN3Eif*ku54^E{=i$(vXB-T)Ih5N zG$a^k4l_gWggU*^q`rv@l>!~g%n-dOmsi$2(Cr5+zK=)v%j^CtpZZc*WCVrxGs^` zM;}})uXE(Jb@OYFigL^~S%1wn^-9Hckzw2mz6@UQ75mRVHvDbe$7Zp{Htb`w+GD5p z!D?abBYkZ4(Aai;Y>x2Q8}O5^k+F~Uu{rC<&gf$cjf$Pw#}?Koc2*x-cy#Q5KDLOa zv59?bkukAz``GF=i=ETQR=-8;ygs%DEo0~Ru|>tzNuO!*@pzzO15PBhCxi;6>qRVt zKZkQ#OBRiYPHX?<9Y_#ei^kA?*P!~}gUv&A<{eEf#=+*=s=jbuHM@NkU_)zxaW;Md z0Ds5B!qOCPva9K>?v-l+G^`HL1OOZe0QCt|K)SE21JLj~K)(WD85XuAr3*Fyv4iQM zVLgCG1Oq95xCJ0B+QT1;B%zLl{`lCw?^Eo`htG?X2)iQH1D8USx}(1al&Q5)aumG< z$fgK{a|5B(w|ngu_6l_2ioYb=`~|f-!ZR^*wo5{=I$0kNooXkM{H8%f_SjpN|ReAA!2aXX8V> zPW@!xb*z@_e@W5Tx_A@yMh4Rtk$$6|7UNtm&GfZoIyflU450L2Af=1?w^)obc-Pj& z%2W35PYK~!mq=aQR}-jfpY|S5jtWMpM<6`({v_TKFqW|?#izrQ4*)j078nEC*8ou3 zM*}?r7`jglvjs4B)PeaO_1pDTFr4{!>po&DS|FpyGYtJ|=@C;nP#mHOTf!)-Z9ZxNVh}@xORX zOdVZ_!GjYg3SEaYm@OE0*P=x4(iSw@4Fa7W3xu7cl5t|XP%Eli8NRuqs-e3gMMYp0BUo%!a)~=?B z9a!yHvfhEHdHZ_D&u{R{!VQjnZ}Q9I?>qKvVV$?OI@WFz_89)^k#fcLO6lBa{4Ify zEPRGfS1=38x%CG5(eP)oxlh{X$z?3f`2m1s)B>AO$`q&?t40J(#Klwhv|NJ#G0&f~;x z$Af#NtjcA33uTZ`KJ%@V)m-$I7py;+6>c zC#hbkDSr<$e^T|o$Y!Kw0ailCS8T~N7PIR zYR}AySn-R!ZQVGhgOr3124>}P1FcczuDgM`(jSC9*xw!nhD7ZV`AO~b#f^j24>8`l zfgaHs@Q8CEmBZ+-a&%yCvx$G)?MKYfc(W^ghmzc2Ta0E5ttY71&3v)fv+GKUkpe4 zhB#*HO}s5J3j&dK)wGb;9u9%%AU@f<_u2L8s&3L5U=y7QpHdJ^yX*s|X%A~bd}3K7 zou>{s&Y`j=m<6$4oeob$0eMj-E>si{*ga`!&wk2SOTilUH!PAUMWU@OF#gKJqYT$B zaI$Nr;zo||!M*bW5Dw7R4D~N=^}+2V(iRWNX1e7shDa(4&{uR!!J!&4Mf4&U-2tO4 z=Rt@4;V9Rypj0?ZQ&T~m?vEEyZ=j|HN7l@E_g-GM#ZUD4i@jw5I;!W8578%8xoZ(H zKRD+vup_NzBq{7!_zu0v7kUd8-2XCu=of+Y;#Syp2P@jt+9rMxq(J{7vHDpCVE}s5 zDPss?X4AQQk6lj(|FWx{#~p95iq!zL1iZ&R1BiHx?4GWu#n;)FLguWdrG2_O;(uEkvVI-E7@>RP0V6H)jhbwfo=l4btOds9gE0U&7yx>~0U&m!SX8DT_yeECb%6c=z}GKpN(s#9(cpCK zKymr%0R0YtsjD^6KXpE@m7-(;kiQPl699O6tp@5421=Yo>wv=wpprU3i`Q9<{_8bR zwUi+GUSO!V0Zja22WZ#yuO!!{H!a4j_ch=Wj0(X}A%L1xix?fti>SZh0}a#D4xnHG zIsr7f4$#Cc7GwB_8t4tH0*X_z2nA4C9iRdLG}@|x7BZbjN_sXO2B0Z*fVKnR^2ZwJ zdJUv!Zb)Go|EL4>{dR2p`$Pe8#8`Ffw1sp#;(QNvwg<>l>CuYk2w=Lm4yHt4d0k_& ze-J7r9|Y6hKN4W~)dG{=e-D5Xc4!vRZyUY+^Qs1#g^@VYNU@;;LyZraQse$w_!xrj z0j3*2)!5*d##%DV92y%wfhBkivOcgp5R66j?*70rwNh+ zC%W!0&pD4j@2qdcUtH>(yUdC1J!84^U(5OB^b5{sSFp}IE1Y{)Ic=8s%9owLzs#Z^ zUU62f;g?Noo!_nHmuJ^G7p!+8rT)g7&cpAsa>W+srY$U*{-JZ-Hhx+AiSyG>_~q#x z&X0ERi-CA<<*z4TvoRHcG|cf8&JR|RF8B<-U%AdXYrTL9t#$vzCg&$_N-U%H?> z8GHvXurz>l%7dj7O&O1aTzp4^WxP6THp5695hQ*$TWN{|3tdZVV0o|(mf65?@h64F z-Zcb3G;*!pHUOGh2PpKI#Yp-ki1fC%y<+JtPyQyORxj;`q}u|^Lv^qm1BP2qDJ;&9 zNSdwYbecfd187*h7HAZp)5cG!IDu=hOK_ z?uiui2!%wd@mL)SbMb358?FI`9`h%(0s>SrzF8c);W<*Md@gkH>QI{_e#7d}b*~DV zAxo!TMiq!|zSz6W`VT)JdisS>r!9WbiqLthh2SEwATByS%imoZ`qT2z2x~mH$^kC0 zk735L&=;2x>%W$TR*Nsf#8s=XcXRByE=jarc?PIB3MO#ih?1XU3Al6Khr!^1b|KyD_!9T}*z{tcTYy$m8r)9Gu)97YyC@Zx3(7&LR&2 z;;~Qz%J4(tlJmf-g_xT$6MF#yekWELM3UXn=&D(3JecpTqRDK2k`cbdJdBUJ%z`F2 zs*bowJcz(z3YT7AE+1p#xp;^c2`poFuqc#SehCgfz^PrbH;=k{r)UDe9J1c6cY{<@MA$bA}smgNNV&z&5uIw)?NM z8q4qwU^`OTxmThD^^ zA%l?NZhafIi*ugf08+DdpN|kfndI}9V7A0VmG~eSD8Ga+{MBLch{7ThSG8iv7Y165 zuke=g1EPwjZF~Tf!{OwzLE_X_!|tY0(xlko`1}>}iN@Y{hz!_|VJ|(OD5o_yPO=(< z@ebgd{kl~g5i0QEv}zu$s-ky|3|U5FpGFo|Pj1imbpdL-uwed59iQsLGh7jl8>~&M zj~n}7^OinURzqIcEV!^++c@la<|`xwPo(W;!LH`Ei|(pR_E5~ZBu8^Zih|CNy(prS zDRQqg47mcYpEbW7EG-PynP}V!G;Gr#t!WGPbjWFl)^s|cDuSWZkg^Xj5hLJ7Yi&q) zWq#PQXT!vXgjI|-EHU!}bN;o9!p=Sg|6a2p;hs>vrI=!)U5x^@MZwfmSH2FEo*${X z{Kzp!E~jZD9s{r^YJqX2e;oi{rfZ;BJAi1zItscIKu^{IiW_A$`rM^~!Y~L*C_TjT ze5|K}p~5UQeg1fhGW`$!-1GxkM*>q*D>m4TN}Tj-&ue7TqU}FPgI4K8m>_p*KdcN< zq#*(+0{VIT?-onchz#}^_N2}@^UKu&N2)!6x4?vSp|)|IB)A)FR%){pkBl@t(OV!O z8tH$lV3gLTRks>@CtNb_scc#mX6((sNKrtWAwRX4X;QSm)#wf$mN{@*sQz5R)0^UmKR?LMiEtkE1+OC zqHI(VA`vKT-5u8GW$KnSTw=UrZMv70N-r7K6%E8adJz(B~uiBiphTPhsIRI#oP7$@_Xsi5z3@!mX!+)qeGGdn{P% zfz_qD!)>F@c4PL3QtRzWes%4~!-FTqJ;z&(EiR=^4#N{p?R%4cRBswozRa*+(2Ay+ z(wXts7d}&p{;x;aIkiSuwq7~`>@5%@>^->kOmOR!6F3Uy24^r_!=x-Q@0q(b?8B|K zI(kA#g+xfZWj`MegwF;e6uxLYQ2m5HDy-N3o$y8MvD!Ph0JXRll$^2t4w$qY4fln3 zP9u1<$^hJRwcwbX%?HFoxf*J<9mz~4ICLg46F^IXftItMGs~v>dDq4!F4Pb=kVBj> zshUMXm1yJ0lZ7Ab!YXNJJd|U&X60Fp*YQ@Jl=~BCin@Y51}9i~pf$g+Wqr#bK?O{)e|Fk^5YhARQLUgnFyCLx6x4@L=_Hom+bY}*XV9h60Qs6xISWkp!K7`*zFAfd z>K5xPn-zEL_E`=a2lO4%?|-^Hx6O9w2-@VP{}yKb1F|DbAn^R}922)|7WOH2M<*G+NQbW1zlu=wLa=azL!X8=4Vk7T zdZ$xmt0^;@NHKs`)B*AWAasTX`Y2RI)~ywg4?r*00qO_<-=i96wN9q%yf_vFjhBLf z)Bv^!ATQxaW=n5)fr1Vo!Pl~=l+3?pF^GoIP;lD2n$EK8Z%fp|3fnSW! z_3K$zjaBklli*}g2}rICCaLT{biUPCv`BM0(Fx~5Fx|W<09#cHj2XW70MP6y4RnwT z`2@Ni3{a5&0MN^IfVu$S@c>XO8-QrfdMbM_fL;j(63gf0Lk(~pqD@?=0WM(AgXnNK zXC4=8l;g*HurmP=2u?=#*xZDRRpS|*h_iC#kF@0wiIsowqIE8d?2hf0%R=zztbHTy z2@%%yQe%2L3~Mh3jwPslJXEb?2^@&nl;eq2!ODGT*XrPQDZ%erZZ&4F)iOMf2PY{) zo!*=Zs5P~qm<@Of_5ZzI!_*4{5JlJ?TvP530qE5_K%uW$jrU*IKn?Zz2ioeV0cdS7 zkg~-u0J0XRpwwQ6|Ls_K^>O^5b|Cv@zh3SdCm(u}_ApSc3r4A$+ylFCpLx%l-t{JH=KstG4={F#mu#|ZNnW>*2e zXXtDI6=HW>^$dC-5=(L&*@dpKTeXSU*3A5_k|B%Ozm~WctKqi4>0opiN>wD={tr#ytw7hfUy$vOby<^G+cHP2ePgU0AGVDmCx#G$i80w}YBFP#9*1I?t%X9gOydp z7$|38mU}XhnEqL-BhhaoI9SuxWH7t=s5a-L6pZ$gFvV7s3q%IM*<@Lou6gfO) zsG=p#&dIN`+n0w#*ee=NvxHo~FA^uN+*WnT8BtYXkFZrPuV=(wV?m|rFkDv$+EU{H zv`8+#;4tEF43Pbkt9D06V~v>O6<>@*&RN9a0_+jZl@q7{hi?S8TqLNb13>)@6L zoZDdhV%QHjn(N4Sp+4FadLxM#(+wUQg?3M>vaRURz1m{mi-V(VA-i)fRbL3*Tknrj zWb;=v>RxRP7X^``pgvBNirTmE7Na5C`4?_(I9hmMC0ZGKm79yf#uN5BzFsRIV}#=@IZ*>jthBJm#{^?)xLtNYJ2ELwC$><(XRRG{EEY9wgydeUv;ny z708I3FP>FoM@|OK;`B>5>q#_gV{o&s_A_BkOoGb;UurgTpl?t4@k8<3m4R`{hdm+j zsH?R}MZSDP&B-|}^vOB(_Ej3O%`H3g&x&(%VhjhfY=5P>!5^S`ThP4gud>f59Gs!v9Q zH;ujLuDfr#yK|SD`izGj*>Rmc>(Qqk?=+?*XCU` z;GhdNRL5}~?;F<|WtOZFlL$B(@7A5;2GpwJi<3X^2T1% zn*iu7j>8WZh!f}I_!Ao%voFr&3*tL3t8bjqa9S5&(dXi{LF%=!1rsW(b#LrVI1A2Z z-;LAXaxdXDxDa&D;wt2+aO#O8TpY|8xvZISO@yVgaR|&lzN-Gd#?JVv2K%r%HY&DB zWq!4-(XxiIolrkCTGVg4JX+Qd6ZK0HrlsoW&%>zl1DgyQ*&rz zFoFzhc%r8zo9KRq^Nc;w(l51e$R6J)Xh>F#D}+|#GTd?UcT9Y7{7Gu)3BTkNCw}80 z4nJ|^cTENWR=8{7TjX4_$dZ~`yvqNbH4*r<$-!Dm+;Om-IByZHA+EJxs&(Hu_heWJ z9)*o_dE&&c3DE}dUH*DTr#R3+Q;r<|yV#(gQR0uwfze2tKj>(9dNQc!!|ymGRW7sF z-#BAmtPTCS+PXYJy6sC3gzOv(GdPQkF(HiTl0Uu7}LD!m*y8vU`V`J(clq#vkqG$F82M|(LCbk zTYoum?fR1o2N>5?bdm%^b~JWw?|v$@)hDr$ALpN}Zu4>Dux+`gPo4bb`uH<(I||O8 zvEL9;g@=|p)On~#51WY}JB+ovVQ&|#!Xg99bDf-r^KOKU_;SG3qAb>S^`qv5mA8fm z9vadj?n9nDV{OWE*dB+|Yn1IRg^_Ivw!J!8?+5?X_UvU1|IE}r3U@B4z^PKT45nhy zpWJ}~?e3TG?*U-xuMJ4nd;aZ!Yt%|jMnt!g^zPwxHUKmcu zq)VYIuBX9-?WB?H;Md5$XKeK&&fHpcHY(!MosIS`Y;QEKSP)x}fYHlcu#>yW&%JtX z?b)W0+gGQaI=$}Psk2R2ChXc1alTjesk7I>K0eAnaUr((`Cpn>om_rRY^#qRu{W3I zVQW!v;^zx3VK9!k4j)Ba=zGG}D&oYgCx2hs z?d?Ll95%W%j&E3A{z$Oa)<8X6td_da5oi8m3$0~4!|&| zDw~G!agTyf>I_FhDd=3Qp~ZM4)PTWOXF42><(n4O$2r*grMKyiINIBc0Up9i6jYf; z9Qz8_OV`nUCD+tldhhj$Gb|QON9AOH3%K@GLWt(dy`WEecloZzZ zuZ_wlI7nPw9Y$^IqqZ(A%rTpS;<3?eji&ntYd-%snVR|FRj%aH6!d4@D8$9${nm6S z2~9&;*vh-{hRBppL^ghK!Q8AMfF0gQd$-M2Q}p3AB;*p%18a|i|tdtrGCaHtmExA z2b!bk|LvSzY%h;g(Y?)8=;Y28E2DBhg_7?Rb6HgvLEKrf>&rJu&zMi=GU9)_ckY){ zSBPV_#W!L4KsT~-5+V#H{hZgxG!4&sr~XLLr{XsUNeSl&hT#*Uy%W?up@qLi`pZ$ z_VEB4L-zT#54;#DNkpS~?XzQ>8~Q4pS0)%E)n~g`U4HTM_Dfy-_dXwS{=!R_&tK~D zjOp-#E3I93oNowG%#ns?`|?-1P*zx)an2^W58sOt?>k+Wc0akpZ`7g`!lypT?T%$hOf@mHA3ehi=ecR zJ`1Y5wNyp9C#nYJC6htm+TmEs-TfpEe$&baZa8vAc+}gV`1(jxfUb#qFwl5Lmc$nT z`p^Sp24IF0)M5mPv@)5}ivaEM0675I2!B*wu2UuflGU;uppQI29{>=HBcwT~3K(Lr zG+Dj`%*P&>1iT;HNn(z&4IJ9+?EvZ%ElN~N5irMaxvv^;deXo7Nmea#*=7k?%Ofbs zyuS>Jd)+9KJ?<=M?G7S(O-^T%2RHb?y@64a&XNt@H4P9+aO4&&e-*?&)e;l++YC~7 z2g_nvfTCqBe}Q@(sC`-#J3E5r=R&k^iO9weVV7{4TbT9mX~dwV4ydCTw6BWy5QElS zlTGAlc0b5`YaV&EU}*;{at?hXvICEA0l;p@3_PulQ^=`srVfHXjPm9dKM} zz3fXNWc~3%n?5kw=MX}t2Qi4OUdf(rSQP-a+??xht|bl2T9DcB2^QZ%LpnZW3EBGfMpP&B6;)_ZVls~YXA83iw*8ei ze4VA9LX=mL5TwsKWHTSxRKrEU&W3EdtqW_+rB{#+iy2Gbc}yS~))~7Ql>Ps!mHhb6 ztt7psYqo``d)IbRTf}?y-3|T?*_04QTDBZ3Ygmak>yA(*A9g?+)1#JE@Lh;C!TC~G zk&dA_>yw?F@34)IjmMP8t=aes?rAJp#-Qz_>QiTsoPG<%oFqAoHu>nDvED}DB$@vk zx2xT_U5l)3L)O$S!dzIxGZ9wn!EG7%l`l2#L^cj+xt&fk4(bM?Pj-o9lsW{5_H@oU zhSWbD>BU;jxz$hXr&g0|&r`C0rh^<_a#!rtlt|XA4={~$4Bi!~4b-NVMdrKSlojs# zSUQ?DKNWZKQoWR2lo~j9`pMs(CC*K+#QBi)HrnmqTT|)iQ{2l@tfX4fC3=jgH`36k z$8g;W^_IlbZXlYkePiuSH0O`SVXyd~bTrMHNJ_LpDZs_MD73v_2t?!lFOSCE zajDU+VHxz{f+!H7#!jDTLvytLFtpuPWmvm`mbBd)x2C@a4fRr1;F9M_jOJunGbWDH z$J?dI%JU@NLy{74Echi|I!MV5OOBsc$iTib#^9$<(8G^zKnv7+EQjhh`K~-bQE2=wAAzda<^?Zu z{OA2T%>l4xs$hO)@ZA*Y{0SGg0hbN_2Ntwk4m`ZM6Wx#HueAojA5NcOh&CMTVGP+n z;F4Du<_b_@O%eMFpbHX)QhpjFKS<uEnm1m*A_kk;ZqQ2q)SoYoSMCVvGEOKS-n5pgY<3fyVb!BsF`?JsD#d}%a- z_G6t)(hnYsG>5gcW=NpHKdmL?M*Q+a8AB)FOT@MA`U5NX!z?)9q9KV*4{lCt37Z65 zTl*BOv!Sk7pJ>$G)Kof^)g0!3VcQjNGmSUt+*oVLRQz@sy|b4aeb+09iC(3TSYKuI z&0bD(RZ~Q^P9L!g?TTuhyJ^eT_73h&7D5wUqmaJJw$A+D{Sl2w3D70!SHX;dXhdl8 zTrEqA#HLUdVF4uIf5UN{IwoaIk$fAE4r*m##}gB3G+oW$w7x(#ptCY3tapbLu(jm* z!dP6E%`!-mh_Bz%WMAL>Y`>~2FJ9T+qWbT9zSqS|FI~CVqCOLO_(=4xpQ0rj_l6oi ziETY+zi{4Q+HtWVPC*cH;I;aIrsH0Q81zbq=ui6}D@B;D_*GT;%Rwka%uk5RhqNW` z=!^cmw#3e*J}Pm~fbr$o$Q5a=^dYOUDBU1e>5^sXI-_(KdFlLG2en^pF?}4{`a2cT z2SrR!{HTckP{Khd-NMl*;hP<-vSC;YBS}LaDxsotE*Qxf*!w8qVQmT7xh5k45F^f> z>z2@Se0v2MNS}yISh5p=R$p@WJ$1?FaWsGqawTwFn}AEHb^0_@`=#rlF<#0INC1lo zECnfuk8nI2eojIQCI>901)mj!p#}G?Var^o7t;kVW~B)28A&Vt&P6JGzftWHLE}lg z=^yNZumCpHHwJ$ggqJZTz+YOY-V{R`62=iM4BgVE*Wsw7W{fE9Ua#W-rBFSc%eB=h zJ!#Fy+jYNx#I*oD8NhruCk#*x{;_KNCM;y9wHpFKGzj{#8bYf{Y;{PDh*1gZ#Ypyu zxaPy4QJbS4FvTQcEp=$ScP#z&=@Q$H=|3oRliBKyZ1un^80C8Uk!OsyDM5vkBiO95 za2EoTrSdHIjnf3z6^n)z$Wwuo{>qwBY+9U-ALky zwiAiz-pHN?r4|<#u|0igI!`*T+`YF4xMnvT%{jLKp@XT3qeggl*jw-sK%aSlA_4GA zlAs2I0Lkh6#{hlq0qO<7@ZJ)n(*r~X6RH6+9MJOLQ7vdTQ%A7}KnjNuQQ3G`Oh^k! z9c7xaN8deKL6l0l!(Po$E@ZQ}(Twrvf%~ zQD=%2o4P}n%cI1RN%o1jX3=Seff}a&i)Tvh9bU@YxH`6L$^prPc}@PeaCuOiZ!duR zGu_wjfPi<(j8S-y{Y)#y^zU9lmq)5lA4XqDWWgY9_M2ZtGyk8tt4f*H;U8_(_+$nHdu zU1DjoZ~UV)htSYKMsYeFq_Ar=xP?Z8oA8<#Zl2J#D5nZh53wyL1mc_;UhQ;7T{}8a zs4m^0Khi@_s|7eOqZ52&uC$o2y5f1h2#qE5NyG;Jow(#UB5Ider%Axk$Cz&LtwPis zXHn7LQ8Qm6@tZ|aY0wA{4<4a|?vJj`2YV7NZM4@A9@>ytX^>v4Xwy|Y+jNCIdU;_B z$-z*Q^v1@RaQFdl-=srISlcx}kRN)*2b*8Iz39U+C8Ez zne>vd9*0+j8}y8CJ@M***3blGF|9QsiL!yOcqudie8UNbt}#VZPWa0KbX zRnUQ%F3i?z^sEBNF^%+KZX)br5Ek;o>A$?pI<<^fs`z`t&mpqX9*6ed6?0XpshvIFpx1hHi` z0i)$AO6wG0UwOdZ2jnLl&&o%PCk*lkN}0p&f%@75rJH0>#!i-~S55U?+n1mp0Q$xQ zG!KA2Q=A}g0g^+;e*rq-2IAXjcF%xed!~Sq_#eOKgI}mnkgIUzr47O5rPf@V(t+Mj zp!cmCJ#r)c8?7K}C zX$u+!X9USZ;yJ<)C?`EoKLSydB~V85?pl3=dz9ugfU$)rkm2H%vc3|KUtO^NbrL2y z_$y%Fd!%NZYfwhuVl`|u=QI+GTE48U-vIl;12zkg)h^iX8VQRKWkYZT<-Z=VEr58< zbEa0-gdce8>GQ|bE*iDvAHhM%=P)>Wm@&S3o1=GiNgq;WMClA;Q zfE;tdb{J*Zq|S2zu%A6(zXK98-&wZW011qsFH%{)mjq6}Or3Q0{?IxIrUZywafY{0FXT@h3 z(`jvoLEu4`;V7C=JS($|YM-Ew{$`G0`Ynz;s<7cH?yHwc5Fd>Bqnz3d>ETY(ETKSk z&3D6NsW*vpl7Mu*L4CmM?l86zfpsEV8CosT`!=@oRcg^Z^JB@&9!~W<7y12X4kOhH zrvzCmatoPWN$Jd+`}Hi!y}fv0$pYJ0mdBeAC!!qpD4o+!y?KmAdurFzq^U&b>fXLW zC9>w_%_63| zg3L@~yq0*BZ(ChR8t zuZ+3AjhkybR1ZGo2bD$6-GsXnFk{I*Vvo%c&lz zVNIf(D9dPVLaq*U{QrMF>-g^f?RQ67)F}S89qdhwk2fUNV8&M#=aOG1@6K+MM4{k$ zmm8E4T)e-(6Ro}!Ep&G&lCGi4PZhd581+b%Uml>F07zRUK}QKhDM{Z8Z-8#~08Ihl`G+Ow zIDtr{OAXlvpxGXveE@v0MuJXAkQ`sJ4^O$x4aC*fZvm&= z_i>_N!9ZHwkQ9tlebS&DeNp1BMk5>*dCG zD0+uMIfsk)ZzF-I6-r$<44^y@koU_7*7~jl`4EWsF8g;lKsFCh4*REI)@flucGzk#!VNTw93y{pAfXlA8Vt*s{;J>2_dTj1M~@@t2zbh6T(&nbt_ls&Cq%6Z3)Lq?uL=*-C&a9Z2-hdXu8NG%Cv;sE6{%0?wlcvmzz~fi zTMaS#1l2!5A4%SXt=DED&#<<{s*A38ZLN(qxNb)32ez0FuJ9RlrN!63c|cpN|DyK5 zt+t3(qjHGWWIJJ1l;aQJ)yu&HTSCcCCVVq3S-L%n9M}?#G&;vJT$cm#;eOyQbsKoO z`+)*%Oz8nvz@E(wg}Ppm`q>Ey`i2ckqJM%p|>4N&Jx>_*{k$tK&s9)An7o+M` zP=2dL=4zRDEkBk(4q6DVrL?%gXh{7WfQeTmC=VEtOLBBH19Qa#GY{{-*eWp>-~`E! zB9j9`cc5B5P#1tGx++klT%K+_`xYtPTw!HLMksYW&r&Cf1En?(N>!k8NT&)0Emr~3 z%A6hmwQE6w`=AbAquB94GlFvk?!9e`qNRj_(7t zySzn4s7SRp+}+DnBqo5AIzD5Tw0eQopITZhKx2T9s!WSO-ZTLkAKMo6__G+j(iNYX za~EZb;vUt3Ak~o^1``bKOk&)SssENvPAPK0e9;lvCs^Y-K8PT1L zXatfK+Z&+2wIIRS?SS-)M(*80EuMWT=-wT~*@hiKTiF-n8Xv)BJsAUux@@4yczR7s zU2u6EC||_IaWnPxd=tCu4yiWh`2281ebNA&?p=YhHnh##G(qcoML zmL-|i7a+X{=qdnHyU3*O&;#U+6&P7R{Qxp}fXV*tA9v~g!K6dUeK?l6Z{h2ztR50O4sQ9^|I0qYn*@}3Pya^_m8hKO+2^$KS zzZ;CazDEpHm5FH*bW**QtIe{uh5^JZFV1#LpxXdgDM2QmAcT5HLuKo9#Eano1$v~^ z1i(%SQhmGxh(sKLMgY{w1N0dHK0{^pDmw<19|=&92dFy$$A?K!u=8|q$@Wn|1-qd* z1J47~FkIq%^uiNd3dMB5Lfl~FK3+URRc4G6AZBh!>CSdlKoPV#5U)jeY)eTn8dO3( zsFZ@j4HIP2Cm;#kmD@2ug?XSR0dZ)eM74Nf1)3U)92my}6z&1~F90(pNzegWwkD9A z^Na&1!UI$SK<0D_T25j92qcx^41n1AIL>B5tSOj*wWxnd&}<)yDM*8YM2!b3N}H6B z)XBiizO~~R_`-|9pKr%(2a3mf-o%%KP5hi(*~V`K#b`H*rWr_nb97V8EhX*Csq zE^vn6xgTwy^TJ7n$O+ahKy~&&rR1r~mn8y4_NFU4Pd@Fkp^cj|DU*VZAu^o%v09Ts zt&0b>%b@gCsmy~-FF=xkQvmAf0r~@grZNe7$tXZF;%z2C-8?|A12DWog6@F+$@3>s zQ-LyjpsE%^%r26s3tmFklPsD6Po}Wz_=$Mf%jNkA|Og=~HYHr_}OAPANKOgHpVfl4$8m5oGn) zLmgZC{dFNv*M(5q^bu`kHbyp1QReM7Q0(bOkt`>9a4kKxhUmG@$~*f=NZndaEuFW# z3%WY@>}7#iFD)_A%CCV`Q?+E!R1;v-e`RAKSC#}Vj70>iZd8@CxU`YKwml#6)AKMo zxXf^AOn)V6Qt((oEm2D?jAV#kldAlRi|70qy--wTdm!(nBoC1PBdSu1i-X=Y3Xp6K zc>wj+f~1BB$nwXKa|?8DyP3oSK0mx1^5QF$_x-Pg9DkJ<+45@0p4WJ3s$Qt#iRcjf zhp+O!+Eyhbthxs>n`eiz)qi?iBY9(;}+;B9H zxf6(;PLxBOd?Sasg~0Upz`XUbstn#MQ))2@kc^AA2%rHTpa}pxDM6%ctO-8Cg6Yi1 zx+iT<02L~x9ETQz$_-j7q9$vOVMIJmtw}q}+_oe1+z!S!U(u?sqE&N4rIchDsGUIMLeB3yyl8AA#>sipJ-`jp;-Y9|{tJkC-%>tY8^m6IJM`Gwp(OpJ$v)h> zhHtNv#O?*L!CGQrWbh~hpqd ziU;6pCn#8^BqtCL05sGCbPj;hlQN}OA<=oEq+*CTdCD+16d&4-1M}!9iK{WvC`DP6 zUHn1dhP&ZN*ZAO!s_gw$qKt-G_x*a+0FCefodMwCvl28_f~4H60cfNLXcGYC=Ok!5 z5~3C;+e}{Nf$S#4KRHL-1l$-m9Lb+{AO=TD)DbV3Z?qsptW(B%fTja*I7))nN|0<9TL2p8 z0gC8uREG7Gpmv?GF3Dl>8Gtf8K>q^Zu|xqPrEp^GJ?p5~SCmoO(F$GJD?~m_-12SLFg3^s1lm=j5(}omD3HdtH zrD7J1D{lGX)To)rsmgPpc9RFS*Fb4os-%W|gcPXs-QWyyvMKq8jPDNFAuDM-e@83>$e%c=X(0k#5NHK8RU$<9bQc`E5QHefZ)`WlA z$ezJj=%mciKvPE-j~&R-&DtCZA^cX3QQ49!_@y53ZfLTR43_QhO~7u^!q~Fu4*(R^ zp&*XBMgKx3@RG9b)9|)^l-sR`!`B@Nhl;WDNcbB+gqw8f-~151<1{_`;&k|1XXwkl z=fW?nh=|muuX-Tj>jxuHwAKeBe%wG`?%f!%e=B`ae79XYgTiV~5BcW1@V4&=uc+yC z76&y2`rLmxysm|k{IVr{^&jj7osub-0S{cg4~nH7%XcEjleEQRC;Z)uBAvp;yZwVk zfV5KcV}K@mfc^r&+9*NossPE}gZPWe6c5l{0Bn3jg6<~}WlzeNy#Qr;fZhNgv_2tIOOi)T$QHgIFy__(_H*kb zX*GW9jLNk264cKq4z-Zu=>dRdxTQs)0swk!l%OuE07P>j+S{x}i7&R{^7cO5#Sy z$f0uVX$EYz7AEy9K)Sq%zU3C@V9mLRkA9D!mahv+uaez-xi@rFs!XYSd_H&sN9YyD*GE3{>H-K5) zV5Bc>0N@8F$R^L|lI{KkKsg?us{lNX=tMk=n?*uWaC{3)t_LRQ3!~EeONm*g6CgQ| zeg{yV2k0gMUOg^B7i7R;+0sq|Wb*)JBJR!_#HC@mBOPPsZx6gp+G=T;ZH89OKo+PE z$wqMs)bc&3Jp)RAN^0r}9x9jkDm(1=fU#KdP9embVA+pG;fyyUctM9%mJmj6Z+CR8q^keP@4!!lh4a6 zbf+v3NOq8)0CISM>;SxWS%NC*EHh%4WC0W>C04nwXr2-Jw zCPBLdrU#fzQt1pZB_5c$*T7Z1muUa1VHyzPSjyGk04vqPM6X{9kb)p02!WrXE1(WT z>erhqqP|}dgdR{S0v_VSyWmw7 z?i5A{x0*RNyuZ+Wrd<0C&h>L)gxxr{`d>DX1og^qgFF>-|F9B4p1+gh| z1^_*~|vBlg~P^058s&ST_)#F$+0?Af`Ktakv56}<*I(3zx z)v5r=M*SB+i?kq7|H*)S)E!xOJ0s%7ccMOck7s^8N-lEpgts6n<hw<# zoF6aqQsZikQivmHk+Q@MNRt0cj2U}&NQ^)v!RYq&HK zpbFCgbe9$+$~_a1XoSLWFZU0hM>TxGn?seW+(#)VL{xTmJ%}#V5*6i62En6FGzmMdLp*J&Z&_|5KzDn9rULNl2njl26d>6JyZ~ZB z+)xarh>CJI17c36rmD49?Yb6q@fs_)tn1a@f}qrEOdwdL%>^^24h5;an?NqU-Z|~~ z;@;@j?~jH&IJ72u`G4q(qHjPpI9Jk4AWU;9IXL@(@Nz9-!ORMfjhrA0_$F^eBvIrD zx6d)uhBq&?$d$B7pp_n=O#l@COM)`!5Kl@;Ht7g}9`pd+2fz_0=!67G5f%y1Lt2oih5rIF zXpXD}Y8~`>Ye#g;%ZyiOYxwX|_w(+M{U{J!r6nqu^&AK`X2}BBx#*^5D+i_+03UV( zlES_XkZJQJ>RBkD{V*y(20a^*b4^Ge|3F?kqlL+e!&>9brBiBoL4HqxhBq^F@ z_PPM{9}mzz0DSEd6f8#;DVDneRP6yW1Mv0j5_E(>B-3QIbOWfy4aBw0-vR0Akgy_H zX@xM9%rFC3>jtDjARUmqizMu<0iu_BjTF7z0jl!=tp#9AsRTW!c97R`0M&bdiUHVs zhXmcP7oa4;_8tH=cz`|wpx+`1O7RAWT7?uZ@c=b?fW`vw&SC*Vh_e=gQ74k)LQlY& zJYdHFd2oqL>j1HWKvHn_0_YJfh=t5ZNA|@YW?lDe{1AJFoO_r>kfu9Eqg^VjZ)9Ea zS26{G>LuAJ#-X7L9ag|BKs#8;H58|NfD#LbP^qatGFyC zKfd!RX&gvVUrRs=YqdP>cm`fiEl>YPl#qJxb7=PfjI%i8^Tsnzkpf8pLuum@_QxnJ zbchbIYJGp}Hk&%F*r&uFm$AJ^ETR?ThT9gCTM=C3HYx>$*c&bKgWw{aYqH4!Lw7^1 zGvpZ6@L$MDUy+lpg@2BhIg!Decup{)0+BJdGpL+VJ1A9<<*l|~cU@3J4v`|V#C~p5LV$bLzWRXN zquTaWL2(Bf>3x1$NhRkp595|d`}}CkG@4Ht+1_5&=neZpaMZ@1)<)AvH{5D2EVJd0 zi1Ur>Gm@x8Wd?_Rv@-uUa=RIxXJ2Tx@@LczS9~~RD%t$)#l^NVI&T2qS-?f+b-(5y zYzpvR=+Uq5F#KOh43R8WBB$#&h4w&nkpVc`4bfx{7qsJmRwZFNR)41J5oczzS14?# zp=w&Y5o+6XJw=P50|>l)n?p_PZU1Kf#qDyBy$ITOhbw4bSwevFRU$eJTH?E}WIaWq z5u3877nW2y^2XV6u?WL??Cc9sCRfmD>dk(1zQ8z$H0c|~Sw0Xfe@x4AF~UFgq?hua z^-{XF8-#sT4xmE-dt3_>+D6F+FQsy$&^DM`G1c@VAIALrVGOOK>#NAIfI1m{-u*D< zs}Ez45qxJYgjl`1b^GHahHUxyI1B&-2G{rHV1PIr$`c}GCUG}@?roZY$d|iMc#k(d z6F?jqzo9gp`f9nOq{2c0aM)o~sDJDrob~9qH8dV!`-25-!@}O7KPlz3Y0+XYr)uB* zB@3|`_|QNLg|A$Ud$4|OLv8Ua0GEG|~i45tZ# znjA%|pgiq=8-MUAFyjx!OQ6pH6u3D$hJxzo4;8i>TCcbV)zq|-T|J;P#A6+grIFs4 zO?W2PNy(#{pvX9&Cjv3Z$UZbCUFj(N#f)dBQ*u;P$Mp0_70@T{Jvh+=uux-0vMYCR5Og$Af%Lxi$UuFr6Et| z0%cV;$Xu|!EC9W)x7Gu&MS>bSq}LOmjS@s#7@r!^Leq{stU#u)^G3>2uo;%^$mC}r zG46%koK4MAZI49kDeSmGAVdGgZ1yPq=4>hi8_i~Z^eIV~92*u##U@#5)e(c^nQsOk zKJwVRjVpiJ&Bhz{?xd1R>?x;rcRpFgOwdJi$Hw1H?GyBni|)))WY$LSe!8G;8O9{$P51mn_pR8vxe&DF{WX7g z`HS+HXLCKFH0~U*kBL}YSy@ThSZirTCHAipEj)|clo80fAEMIO%CNmT-$wgX*|UR> zL|vu4aR$S@o4de?D?5EYg}S+XW-ln9U9pPp5jv`59G=ACB8g9`LGkS76cR@z>=2Pj zwz2}-bgceX*b3}yo3Uv<@u#aY9Ofs80;m(cJyBaa5HHJX?v}{ z>laT_+r*h?<+eA3r{;vOhrhf&cKNf8PQ0q<`NV z`qJOQM6G|nA@thVzU;^N4Ez|-w{Jf@88?^+j89`v#*Z6IKgNxx*FbrkLPsHC|Ngpv zKWrx{IcFXTZE^GwYJKFfH(#P!PmQ0Sl{Xi@`3?R?v(8{NzZ6SMdtu0qVbs_w(c4GE zNRD)rXr z$7rOmV6(vQtW0XRcH(nxz$2R`i=l`Illy660 zD_NY?ClRnD$g0u7rY^pem3b5WE>TuWu_MsF&<2tor~lxz@%2pb_9dl@>B@Y3dp|B4 zNIp^O7|ts=A?~(849w?rHy$0a!CLz!f*vn{M4^9S$ZCl%-r;4nAs7nzAhb}%sm)A>4$9)=N zu?mYWmygTzrdKx2>Z%zJ@`wkE@mP%Uzi4=1a2~y3()oe8!9iF2W0{c$@+8+*j{c6O zdAd|hqN3W07qZ6i(7;*#l*d^!Gv;SZp2hARynOW;CY+d{#0mhlDjKHg6FGF-;OGIH z`o=@-8Mh?$fc8%37j2G}-|$oKg+B)G=1_HEJA7n^HX1_`hDHvRLAQA3GvbXZxaoLQSNsNDbizJlZT+3@s`+e#N6@=V{EFKc5OT zE@Re=DN}BlKL5sBri>YV%lwE zh)K9pcjDteH~f z7@uydNG-IME7oQZ4#D|jTrYv8P^;n$0f87n8Xo)qLX zcahQr-=;i4KwHri73&iq^|h89uM4hv4aFOs1v$2RS+MXu9OEywxL6{!)`?mC^K9m_!$q+~BZoN9X z8@)IAmQ7<>r$T5H`t9{)a1M21Izhx3wc{Qi5}|(=J(ow)J-?U*>RDWY?{q(AZtrY< zUrz4%{VSWyd-#18wq!yc-dF7*Bv=QTGwvsS!#Rf#NRs5IN3HsZjCIaui2PAuEzSks z6gn%$^t`{?uBU`wh<|wrVs3jKb_3MY5Jfzd<%}ppO9Yo z6PoDfo2C!zjTgf$_#KhjVZw_Lr^IdgT)rQhT^~liH(cjjs=oXkb^tj$kleBz^IKf> zzvhAvqb-3r%8khibao|DbR3L67-Gh&SHs<<2BnWN#I)XYLO;%QNmi>@<#)wmB| z{AUP}@EpFZBW}bB9WEwpkcLy1QI*gX5FK8L68UQ=qC)BvYVGWt0)4a7dIyoO9tu?t zK4A1pIO^z`Axu4Bm=5zpN?bwY{HBY1JgX^>38t(VIk>>N-rc(gAx)!ako8e3%OJ39bnU--$p*ODvU`W#OwW z&obFM8B_1^berbj^pokl;~gc|3jTFMafKz1nL1`po8bC}zQgDD7F#jdLFl3Lo9iKB zbR~F^i$}I3TwOQB!gBEe>)tHhJ$lhWLW)O(WWSM3w$XHxznPe@sKrUM*PMSVlJqs4A!9l zG)@&Dnx|?(;{bX_fJ{&L>xN`H@_jPaYW|a2HKs4}1bfmKQZd_Dyd)Lz zo*-+UnTA1bhA2ukYunnHdIsKS6IJ|A*2RuzPX_zREYYy<$`tiSHN)FY7sSwQwIQiH zG5)a5RMUZT;{keBaIQudRqb}lAbMUcueds-!xd1L$`+klDlo5EUq=cp{}QP*df04k zL^{v8RV%G>^|%!ls@VdhwtI=7Lc~Ba)1$X2&uc-YXGhNNh~N|1SuFrny|t;vICY-ug1=O`9)}-0GyQmYacn(JeD| zUDXHm){TIy&!((2ID-Scy-Rms7t4r|v%L-q6BiRaBe#Iqb}cbxDeHy1LP@wI9weob z;EcoWic(Gw*>JuaTk8*@;wx3Algr?*d;;K-$Qjnj7~4L_CA7n3@j`E|Qy9ulBs%_}wY^AC4x%E#ZmxLF&&M1~JWk*MU zRzj&_@S&mj&Wig3=^2k##u9L);G7PTEdsOoDS0FySs{z4rVi;Nw6L z`?&xqyTw0Pw@>%tK59IV9nigb0DEE6;nfT3*G+ah9z=*_S->0}ZqSDWAuXo8uMQK&Dk`CW}$R2 zu|9<}z{|eJ9~`!XpFiMF4*iLvpYjkBb|Q5aP@;XG(zb8cY=)ovqFGXW_zP?d{1z}& z*wC_%8>zw|u?tJ6!f-Et+yxeDsie$~lb@^(=aS<;cZ9tQu&upB@RMk)xxDlQ6||@l z9)MUYQ_sr2LBfs%5k!DW3=(`8?;07Tt%7Wf^*DBe4T{uL$x?x?-BsP!mBb8>oNZ(3gjHD#FAQAQ zZPpO)O0Y;s9oVyw$}3y;Dw?}teoxWu5rVqSpeJ2U)~7|pv8=)!_G$b9TP!X(wYi3D zy6da~J$@K1ke{eh_x3*rPhJ)^K!w;AvSTjEr}^_2&L=};K9RxXX5?*$FA{&~ewlUA zjFM?KYhFpQ105V48^+hzA+{*(^XY{+tE^;^e2t8#>IjoMft}+pZTssRNvyH??Idd% zg^Z->mG7SZ!-=E(zRg+=BQhQd2}#vgZ++k$XhFCbM`5xM>sM0XK8)92kp*J4-q^Ll z`UwCV-xZ(+;Zh|bs{whn10=(G46om}OV%79T2sIpKwi^AI@&Sr&^AL?&led&_=`%N za?c{2XoML)f_@n2QWN|c|NDuS;oc|kfX#Ft`u>So)H};6i#6!JF0> zkmSuvM6!JJ*B0v+fc#~He6t&G`(!HN6B&|+PMVZ>Dttbz$3f5MPDv9!*~p+%(LIB= z0%SojLGSf=G%eUECHeUx+b;5+S;kw|M?m_}Kau|xqyhzbqxt)*x{g_TMooiNgSDgTuIgyL_377j%BQ$kf2i)j zeih>64Q)H+df;kmnw_|14Jc&jKB!jz6%K z!Pll2yZUfF?* z=h0)no`PJyC7DJR=kN2YSJ04v8PNn7bn@)9NXP1~u4|L^sEWC@QBs5Jw6?^lp!K$- z<%G<@>ks}Dqz@qP2#DGz=Bv%Z`qeJS*;`YVdxAaU7 zVW_B6SNqqg%f0H<_f2)`DSUq(*PFPG`UA1Szh3Qv>*0FU=vA*q8|&4n_&FQjZS?$z zcY`_;aht*e8gLF%0~RY9)b6<6$Nho9cp<~5QSBGhs7}Il9N~#(r!19%H zWmGci7*&iKM*X6C)rV2Js9RJmY8DlXYDKN0Qt8~k?!l-{R3@qtHHnHuJ)#;>i>O4@ zA!-m6i26hIq4rR5s5jIaDosu6rH(-Qz0{0e>V#hEq+aUOUh2$V>g-z^(-YXl0`d>>5E0S?;@c_{g)gtcdOKz0JM;eZALeJ96Q7n@>h#61lDSco-;GMe3 zIZ32y`xh6LsStvSbs5M{93+y+=rB*70P+S&9=&a6zj<#`r^FN!Gb!{y*8f4>IYFc* zSS^P&>hd%lrFX5bBavN$H3?~lwTVaw0U+52vw9cZ1}pX9P+VwveA-EJi!DGvSc7u8 zwLhYUbsMUotQA)`gR)UlekYt$=9U{yn{o`+y5*VsC@9vKK=nmL{9uK+GhF8O{A45lkR0glCj$6*eNy1nSMH zwuM$lB_ub#TgRm9mH*(nF73&n?JYCkgh?;5x1B)#y}f{8up1+p!(V^MefIfk8M1_LUKZrh+9k7f_%Jy#S) zy-PU9D16GvbSPI}q-l?u;v=ioh@YuM8vk1tKBiY*enRkC#qsWPqZu_UvOnC7^1dg= z>^fIHa(%lqUUHg&SW}caB-#f-H~mRTyGw%DdnGADwN-Wr%8eZB&pJ*Dm>L zY@~G_6UCKC^#hSAFA9k(b)dmI1ms?ROJuhi20g7}{19Lty1|;dsy~{np8~MtZ2_w3 z0D^f$+0zlUR%cxgz?k<0sI~*>VSqmB2pVm)<^V8dmjKmu0Ide-V=ag?>WIm@1d#oE zB%?^W(`Wfgzikisk@Zc@WU{BhgHdZh@)Iq|4(*@Xl6n@-8hl-Vrm)O+!?kKao$mXm zs@|vhj?ICNEnX#M1C|v2BK7Y&DR-I86W$Z0Jc|VhcF0SK4P{^dn#nJtVRy^ z${a$Yn)P1yOnRmvps24Vuv+eT`00U!Y`iJ71Ap=$rd;Yur`$;+Vh*kug*I~>Ej-7W zxoerZoO#)rb8Kd-IbR%ZV6G^%R+!6d@OvvR$9){yoPs{Z7J$t(fY{9TVzYB?*v!_s z>@-~|PsJ?WjD#rUGJX7vn-cug%~5`8oY$5RCDKpV9I6~~v}2R2AI_qU4%an1u;K?( zCw+}Iw8g5evBoR*_BI2Z5y^Svav3H~f6!IkJxU9%D$p~KOZ z&SN26d8Rs`Puw=6@-VIrc23Hie1$0%+=p3a?h#~epKK4LJ9RV?>JqbwI(Hj)Ryt0r zVYcuO|HJa+roc6fIno6VdpJO`qr?3k}}- zt;WC@1HP*KtBS)>BYPlM11{g`NhlIFZufKeSY!z3ol(hf64b5`@tiAErZ(6U-CPQ|JC!C z0uJGr<}T5OPZs>%+G$hRefr>@pZI_5*E-_&b0M+6xBC6=*BaaYdu-de&4B}24PhS@ zoNc`l(TEeNKU#41O4MdAzblQw_o*>GKl0z>cV)!c-(vmF4*UIFmmTLDDwJ;5S@sq> zjq=-zM&{9zPV{}hsk0e;M1^u; zgrMjc(H}$29ne;21$oBQf{3Wk3~hZnO@nf?P-P1wS8J?#CDzzN zW_Aby#&@`WVFQm&6&rZGPz^^MZLAtL`||Iq?{y8wk{?6gK!6bh=-{o^rPZV%8%(Nm zt#|-_GO5mg_NS+F!==ugf}c(DhXp@ia^o-d(mv^lAEdvoh+WN>BG?iK+~dT{Bs-jB zx@gHnYM(^l2WE^CMFWQu#chaM?VUs}op(zhv0g|E6LJ7l;om0Yo3<7oM=c(d^6id9 z?gYrrK&GOLnp}I`nsn_LQz=bcBf;O5?;+GoO_pUAT$~wWW-9H zOXw4;=o7fhsJx9!J)mR5J#@Ehy3ZXwxiZH4+LOr1VVRTRnMDT=ujR(Wsdpbm|b{AM-Fg2LBHJuS-{nVlE13%7@skKsJH3&aO~?5EP72Nfo2@j(>LB-9)-CS& z>aBrP>DC+?kaH`>qKCm|bw?u1U~vsF;Wfad*8qbao0~MA>c5Q!Xzm=3&6m2wI;XEA zrA0k$$JKkXi9hz@Tt_9g1To~qr~dkzZrT=$n^?sh1iM>%qIxw^GoA!ZWOFOL$v&ph z7;*68b?m3mxgOoSuNzy^vBEw)i-N$R!q&SKYnNo9Sq-sa=h$KsX=yiu4Wl_1kY|_H zs8J$`ec*$X)_(Yzn(Io)TAplB-c2=d%|{JL^03VAMMF6v8j6_2)nLZY6C*WL?ULly z@5HtY>q$`Uk8NnIA)*@KSc2R;JK3k8+brnTT(7WhCKaaDYBpL}Cxh}{C-tX@~LvhB11F<~M0hgg3A$(yl9kVPrUCxx8!f_*3bUp(bck!kmNQwT4D+o&Jc{ng+5zx=(p&)EROGR8JCAk($?c9AHE4qXADG=?9U1^-~g~Seon?d*s zLAcSgMc10vv)vRM6F-foyu{nfxiuBv5w^t5<^W>^GuMU;o>@yRGrqi>mL4cbkjJ|< zd>|or5;5jQ1HnAs`FKg~MKjJ)!@r*Epnar4X~xA$SL0C|$56U2Md{R2*IDr}{irvs zhm|Wc@7*IG@1 z04ucRc+b`Nv2(=Q45j(=(IS8Kn4@ZajE*CB$DEa#dHWwnZg_x%WG+8O6U!tObjF|s zC*&0ruy5t1Hiv^9&qwP%^PZ@^5Qq1fw;N71LdKB8C8gx3SL(3Z8S7K{;xx||e3({R z9~)y(-Wx0O#HYF1iTzi|)p41t2X#||@7K|YiB&>{tz_p{IvnK?3$|hl^P{y`D=SL! zOL8mA**7G-#KN)&=S9*vAi(i|F*a2>%E>v=fo$Ucd}}4#@x=e~een~n832nPoW=Y% zTom){<;03SxH9tpY2#0E31*gd%-d|1LVF%IrdV)9p$&^yMeq_Kze(&|t$_Dr5&Rb6 zM_I&oG&)M)ELenW*h|4>o@j9iZH%?hHl=d=oi=-|IQR}KyMl7U{7Q*{4cRp z2Cm49?d1E&JprT>WFEfIIuY{9(!+l?Ymo!ZL^Kr z2ha(CzL6l0UD{+6$$#}M?U+`|7sAb*c2P7w_1CXtPw^}%_DuEdL+`QG|F4$Szd`B} zm{mw!;;T^&&rp}}#DPOY`jD?H`$LsdQMZmK=*UC#TGklV`_OV!_v3@)RbAUke#BEP46G7F&_UZds6% z2LfdaEO%JSN-gLQWfi%WvdWw#7Bom}QK<#p!vSB}Qfo2JMk_0U6e+LF!BuLhuou}Z zm6nCpGRq>Qz$BoxGS6NDf_O@s712`jY$Zr32W^-yM3Z;2wFqszvMd)lvKBA2BBk6i zduavrEB*y%bf9~Z^x|dDMe%TPW{JMR>Y{?xO$9ngAyTyDR8~}gRa8WWy`0!*bL3%t z8TC+x(lTl7u;zfe!-kz~C_2dllG~iL5a1=16(rZC0G9&YDd!j%4ZLt>H(Uid~dl|K?T!+0BmiR(TZe$7MjhZv$9GUgOZ98_o6&IxNmsm>p z1A>rjC5|NpU@-m9aAh>ml`pcBR4QlF1~wY9KMYyHS`OqPnu2W+3g?`pkp|vB_m$U3 zIm6+(h+b$du=bsS8NGv#+jcook|nUe7)!pY~F2!G<&JKxMgcZU76y{Ex&7eQ&fps?YVF#GzuvC^g@UE_u=0<(- zjn+@-e-^R9v>uCcb^03SuYtcf`y799lsW$5WODq)LF4$l!$^N|40w$?H@Zf(b)9c!TRgcOOdgNf7>BpKDE$BSj@2&(iCZ)1C2WrYV?3W+rvNlhI#98Llsevo|dP#|2a=gWI+a+qO#14rNVT&QB| zL7N7ond{p#!K;4@rpcY&%+m67{+ou>{wq^M`L`}x{4AA!UP=mc&b)p5x;v?Cu#a@N zV~Y(mxZ;X{z(wRc59h9MZ$U=i7vTEB%FbSwT=E(ynk9I{69EZ zP3f&!Hvch7FRL6|ty$rS{%)K{)2H?y=+6iJpCo5!m3Ut=kgK z)B`xvW;l~%W-UK8kS3Lj7(-ppGO!uIXx{L=(X6YX42=1Aeh?W?IgQb5Jf`ds4gJFv zduS%gX*iz|3DCIb4;}tU*US2@Y8Rt*BF^Et6W2d9HCki)S+Wb>!*_0-RYz9cteix~ z0MccaLMcm1v@DIs$f8SZ^6Y-qYEkcMNTq6x)N%Df;)nX9yT1wFM4?!tK2?=&`$X;< zMTk496|&ziLEe55d27^I!^{)e-b%c6-H*(p)Rm}I_`Z_8_-dfjof z{z>A6bLCOErg5eTgOU_o%+A(sl6E#?30xTv6oK2%tvSftd!KcbE$^%geeB6lEN3b5 z_?EfJ9ad=XLe_s3Sr;k0>~A#TsnZ(cU;t6A$=2_YQY8+I(P^S(ZhS8E=yRc1uYTc$ z(C=Shr?oI!I+vepB+&|-Wk~lok#3Xc=!MWSZ0y1!bY^aC^zh+{R;H<9IEOR~ z3RwJIlu82_UbVi5^HKEwMHb!S!S4Pj^x=;gL%he}E#3?2Fb-?8_7JjmR@Npi>rnU(t6Z}xYl>adoUvQ6*}guXN8p5-K(b76C0 zH`a7Y7((PIkp|NR6&^vbEdN|mO~My*5_kdALDys+$AexWaryKBF31aQ+6N!C8D1d~ z%Mde4*dvB$)GeGz4;aGv0R3uWX;v#`mLZsbCMU=`UE^B+Z|NaJxjjTCd@t|rOAO}) z`1m=EdFaHHu# zAN5GGdNf%*o?NY-NLEiJt3M{Iza*qjsomK+8Dq*3#goKGWN3IIk-4xLA{_?=U_$0(8L%qL~4)kBY+@gsMyC zYawS7$EvX9YI>$q?IO-m9bc?Gd5-GXHPqq0*3(H^h}R=CA7ZH$^CHcuYgK=SUi_0f z(=&gE{_;0{d7~=q-sSA57Ja(Xmt~*(%WF&BgaTZY1@IgSmh?dDN9J~KDBnw6sHnu* z{*>Apb%aGXq&kNT^^|ieGKyOZAMRR|wiYWswOIY&n^ZeUY;w9HF<(3Nm{!G7~#8^dUU0~2G-$uCt;hHco$Yf@yQA0i&Ptz)c1CR$`YdhALjvG&J{KaQan zu<3XbYLUd6Yn*Vl#%_4SxhPE)sxj(QJ<)2Gc0M4eS(l(Fm%=+%%f+X|-hPIk7F5N# z_n?J|WbGVr1G0WaWc@lKSxvEEtea}Vqy?M0Rb7PoYPcF6POY-Gc~TO!%K7tQ(8w*E zkG;Oys@2SZXI0u#Gq2APAuE@#eI4#!6Zhao&Pv>$a@eX1>=lKTIjPXT`Yf!p-Cju$IZ>RLP;F?`h zX@-^23_s>#7^qkl;5MdBg+{tm-$~X5HZyIHGgp+D$>+?BoWYtW!k3xpE%Ty68(~Ww zB}<4HW!&{js_%504et>NnAFVhUXz(-Ic4_sf=XC7`*0Fe##FKvBcH)5&G<_KkUr5C z>{LWNppntTH^)Q|cSgNbqWkI)p|Gv>irN_0!{BuU7u;1;Z-l>85&qIRunqApy?DG! zM#L1@9MZLYOH#Zc2r-WS0Ta?3>di1=9m0hm@*&F){=6~7R~a+Px1%#wXVXa=i75IQ z!_wi?Q>Cb3rEGhub43#}AM=2xP_{PNd@)Cfh<$wsiJ`2!vhGTRPipGYtg=yA#YxGd zlCqX%EmLS0lw`EU~g%?X^mQ$DJQ8;KRmKCtU zsmM}!3T?1VkzF3&tuy)Kd~NO3ROIiGpnX zu$FU^JGU!~r2=mL#?ld1!4_K((GwPM&0>a|T^H{~Kmt*yTtng&PX0~{4oi7u1enpppHNzyfX4nlTw(BpJ@cg^X;>@<6d%Yz9 zO5NQC&sI&ul8LnWd#s&^)fk#UUvDjj7I)-I4POrc=hzC6SS_H%7TEfknV-cB>9}yf zdB_)1#0m#rBa({(uJwuzoMLN8SixY7S9G^#Rt);q|HuTeoLp`a=iqN#!tjwz}JN2r2;cz_{eNPl9EPIRaRu)HL|EFFkjLI zdSMFeeJOL3hb~QDI&^7|q^vn}<{^<$S#!0C_Wu7)l)C=pgyo&dl0Ang)fti$XJ%uXH?QiPHNuy!RZ8@H$1Bk^~|nS8{4U8&Y3rIZf|-A^NW$^ zzgk3E^1R{Q$4wbKV|HeSnI0$OF*8_xW%4>o7(CB{&5zxCbdLe&GxB?L=sgtm-Bs1c zNXm(oEU`o=JOt>Sn@EAD1zR!~lE9*p?AYhEo^sgBQ8COE?nSo--LMwtapG11ZgugZ ze2?)y-<|T%iy=7UWdDi=^dlGy1Qu-<55}EZQB@`9%;i& z6WIHw@9npTz29R%8hihJBjxZqmXDQ-6FYSR>S#9hdI*kQ)#kLH#9z-(Ar4y?gysR$_K{nEayz|^<`y%T0Pbue7 zy@B;LEL7RN^riC_!i8ZdGD6k9Lf5&LrlGjGl%5S;IuAbAnYUm0>pM#v?kCR4D$kle zw>QS3@?;dwUc9s$I?~lVvw+lG%4k+9 zm4z%OLltU;2$i#6-4vaDi^sKlGp!nz^En>psJ{HzN0Aerv#+q%TlKn4y-xx#2P4~nXxa?Qsw zWyO;DjK;gK`WhI27Z*8-%ZE;$j(C|=w(&`U%tkYh-9i36rUYtAH`98po$xwSXkB81 z+qes}M-u|rHK~)jHPzPXvKw*|kssm->nzj`hQC)s-JDd)+zK9id@O8(66sx7hM4roeFn?^I*8uNvWG ztJUs))s1RsBCGfOnd6GcLg7LV>y0L%=n69zpIP10l120>9yEmF{CLPn5Fq)Ew$S0` z(yTcNOwf-?n2YamO#Y9GqwlC2`mZBmZc^`fPmfEIGpT7Me~}u21!N_A5M>89r@dn? zpqp50SNK$6k13l>kyP&!!`D7Q@&ik|xi4 zSM^_hpUI$Y7g;&kkK86UzFhT+r8ADAh=ovmq5nL%Q)B&rmLN5 zN%e`w=+0$VoFa`$XdIcjmGA1!;2`$I*A@0ki8`T}Qiz|b#@Z92un(SqQp8khEUDK& z`>6eGOCJ;*OVpl2|E~MZHImOxvRwu<#{VzzCGzdC+I#hbZDmvDc2Uca!I?4D{}obF zXg&1rKSW7=p(IJ*!(lUTmmY^JQN~Y!V@%?IM(eTf>F%NyX{^$|Z~T2xmP{aRG;suv zN&a_Kq)@u%=^9dm-XT@n=uOHElkQ=ohdg3Z5IyqFGfH>gml#h_1LVyJ|jq~q$gR1skh zg^P;hpIjS{^^!Mn_ts0_BBj5imhq2LWd;yEsCk!j;4IhorJHq>_q<8=wWz&~qbGjn zg@X~YX;}{sRzydQenTT}5@~p}%B6Nn9^Z{eebiPS-=Vl6ua4fCIz)}FMX?zCps6=U zZ`~<*m0R$Z+KZd)Zt?Wo`5i@pxDgK@t2yT4opoco*<5?s@oIhN=u=B$lB{o|jfM~j!Ky7(`XO99Jv zed92m_ey(bg|z(e%*#ftx^=_(_WW!~nj-9SiP*fs{6+thh|Lf&=6qv`y0>i39siT4 z%@K9MKi{gy?5w%ezLJp!(690^eESwvi2ax`FqbWfNoZmxSN1+?d0K}$jK4`LEdTs9 zmkklZzWZSR?8?o~RU4}Qu)+I$U1&Yp#{2A&G;5jQ%1{4`(5y+uJp3CbCf0WL zpF!_B`tNQO@>L7!#H+9B#fLW_7Nm;D6+f(yp6OlOhaXnhEr;LXbUECGq`zlgNS06o zhal?y+Y;W9w)+}@18->~>ZX!M512i8zmiYstoXN5ay^O_GzYLng^}{SCuY2ArN7IZ5`A@G=HBru|y7 z#IaZmVmH_u)UP?-Ga!{caL80Ctde=+rY9f%T(AbpNsKMq}QA83uM{rVbp~IHkUx zTHCtRj=0pGnrdBABQ67z20k!#;Ix0Zrv58js-zXQ*|Tk7oVvIuF4W9gCWemp$dpeG zyj+cnwLi iQ#-V#@dJb}o%me*@ko(LYY|T!UD_aC7;`#)~}ouzy*+S$hjEm8*+y zxI`pHZ`EEa4J*{h?I(j`3KA2}wj6~aG<@SME`d`xzEN#rP<|_saG3>o^nR zur6U@V_26oaj~pRnG$iVOPi7x|XR@nRTM6T7`9ODv(S7Tkz)Tqun#ni09y0NKMlXVl5Sc`QtQ#+C0HFaw9K9f|3 zbvu)s#QG*vH<@)uqwBK1-PF^p`kaenQ+=%sH z)1)!KZJIV=J;XF?%6h12-i-Ay)1o=+;pXZVtVfuZSMy$TO-t4z&9&F?9&_EbtVfwv z*RdXLTDRi2%=N8#x4GeZ)?-YY8#r*@+}MT#=S2o{lS*C9v*0W8&zO3h% zJNmKCHFw^@damhzC+m4;K!4Wr&0Pan8#C}O)(@FM16k*py9cp;*xYkB>qkuLJ**d) z!KthlnjwQ(FET@iuwHD24Q0K=3?IgNsTnbx^)fSZ1ncEy)JWEknzT`@SD4XhtRFLD zMzen0j2*-J36nmS^-41?o%Jd+ejMx7X2N*ZYfQ!j4t!xUGdOVCOw8oKDRb{c)@#kA zdpYpAnLLU0lV-|f4t!?ro5FgX$-0kqzPUe(^?LKb{j4{bsSmJz+Dx0udXt$xjrB9; z!Rf4@HQ5ic-fU)MbKsjE=3mjfrv zyt%AjF!SfJe$klutY0z@8P+>Z-b1WkHV@~qe#JcUFzdI>f=5{IGYc26e%CBo$of6A zcoFOUX31jK2h7qX95`;4EoFVwEMLZfkIkdYIq;EL@hIyL%wsD!@S%D9G1kY-6OVJ? zm|6J*2R<;XRyORaHLQ=DC)cw6)I9Yh>(gf4Qye&A^4BpwCA2=D z1Bc9p^&B{8p5DOv3$yWQ)?b=U8#(Z%d1ey_-Z0NT!}=?;`B~Oqn=PAJe`}uG!umV2 z^*PoT%(ktpzc<^rvHrpA*v|T*d431$pG?8?tbaBy6tMoqy!Zm^OXj5)S^sKwzQp=B z^YTs(yk=f`nf34H)mK;-nZj3D|6yJ$MrNiy&5gIS8qd+)+5O=kal zFe{Qdupee6G6xU9tW4(6L6}v@96kiIDw!jPVFt(?Jp%J8GVdRSS&hsG@58K4=GX@? zYmoWy7|fbvKKc-5EixZ}1T&G$aeR4R*Cun~ILta^J~;t1iOi>;z^qH=-}n#}ogFk6!O24B$D*O2-48<^LU`3`e-eI1z#-@$A}=KBjUTa)?Wdk(y8 ze*6KpPGm0r2=it#KV5`*3z?sPg4vnOFF(WVLgo^_@~m$q^Xny;UCH2kRDl=F@4s=N zz!YIhqkEJ2qlg2~n?L{Hzz*}*pB&h3F8{@WZRYRG9N21te{owYhQh5fRT4T3vzl80QFNrTAiv19Rpf}stX+pS`$}ggQkPlqMAa-fhJNdq2oboQ=-rb zpmnIW&$wKi9D5I&a&<8;4krp}?G==I3od#N;QiS3<8`FU5 z3w;o@AvJ&&Rx8s8he+U-1GmO_Q35&(v7!OnhV;TnhBi;+Jc%3 z#pJ_WO)Z4teiYM^t`>@0Ps}yc5^1ee=32T&+#Z43b#$%J1)#0yI-v_eTT?5ci$Sla z)SgZ8FgLSF&Boq7v> z6|@iCF0>G|FZB`n8fZW2EA(~HJE)(~H$d;CJB026?N4_KeG_y5^%uGu^e!48bT8;Y zx=ZNWpo3_j(04%Zra?mS(@}E|-HkHjDU(X~fIOtkU`hp@0 zXsFQ7L5I^Yq1fCoBWSqLBG8dELg*i$qiCeiKS9%Il+eFGM^l>6%b;Uuw9vmn$I=*~ zLC|y>D-d%1(nO&pKqt|? zLQ8^9rb$9efli^xLQ8|*M^l8lpjmXE(0I`MDNAS>&&_y__4B7~EF)b3>7<36O7TN@KDJ>D&6m%Ia z71|7RIV}^~9Q09IF0=*c3VKxN)u4~j3ZX4QAE(EJ;ubyg1U)YFTF{mBgwX3iSJ6tL ztw2}PDxs}G*U)OA*MqL5H9~IyeUjD+Z3FrgJt_1?&~@~b(6*rYv`%O{(Djrrv_0qs zS}(K%=+m@8=*^%T>1m<2fNr9VLOX*#Lz{$l0ezO95qc}=W_ng=SI{lAS!g%V=V*)2 z9-v$4Iia_KZlkS2dxCDKZ9;p2?x5|Uf%{M`&(jW}lRyjTc?obQ0=z&4;(BjT)xn5^ zFC%3HRf~+^OK??Xg&sjkdhB&CeR31IT4>g*xB@eGwNx+HrE zFWlCZQtoeR87^@8UDs6RZQ4n!lazUfUIs~4zI~+Yt6A?-EtRYrs9En(qDnrfa`#hh zeA!B*hLjAQwwMq+Ky{E-MzEX;jE9m%#p8p?cm@YP7 zu_M$Z#Ew!k<*y^Y?^6rqPZst8wG8_9Ylx4q{t`Sx{XJjbS+9Ty z^$Tj^F6$bv?#m1g!kF@35%2@LQ16fkcNa%U#mMtt5x%}6!rz6d#2J(8~FTs&YUmFsfbDq+!2s!$SkYmwWz)FS@qa?|SHr!L=D|n{@Y>wZG$SPE7sweeeFnl1 z1#&`Ba|SNkot$dc+HYw)qDwj0(OO&kU9HCoM%_ zm5@x<;`%^}(dN#MCL{ESpBYSF~gTOtp_~U)WS}nu_)89)n zQ%*8ifnQg1cIn<%KJVm-p!hBj0B?8~WGI*}OGeP%PxmEaprx$NrugV8Q zBfOsvhgg7dFP|Otui_6ph24dfC%;!*;t!P`sC?L4O;f%atj8%|P1fW8t83KakCmR} zpQP3eQur&yK>ttV6KKF)qg-n9r*LT%*d>pTEIkMhf|`@?Wi0hQ~$?${CiA>GKug9nweU>h~)I-dA&CNuQ{oKT%27a2&~? z)&=UjhD(M99~mP{lUmmz+7(5(mg8*_-ebBf>CdpJ=c6d^$pna9)|jL!pvEM8T+qrr z0}1%NV3gd7q@EJF5m(5475gu?I_%@Ws>gkp$WKOPLcyyPn$PFqI4I($R;f{wkpKmb zs!$br>b{<CSN&N z*sXk6zeK`xB7H{rZsWkND~H1HGDPL}S;U454Evzs1B!9ZFe%zbfv%>D+KIEPgb|?2E_iJJO`A%}b5;lMbkb7R(T|AK7 z?}ZKIyU9OH*dR_N{|I4s^APe67j_R1Blm)^R31V8A;JdpD006OHiSo$f26RXJeK?u zgbm|ydbko$qK2|SnFABAP`d~&}KmdOv1ds^5; zewf@-!tUh-#8Ymd%^UeOuTJewN(5!e;Uo za`yRqkAVO?ohf4EqfI36m|4#bGjKS4rQf+>y+`<=2bKu1{539NFTXCI@Bz{wQwc_6QxdyDSq9UztA=hFl z>MJPfYg}8B%?!G)NM2s&I!F=o2Yr2%j$eiru@8F1Jl$K`BBZSeZvyxVVT(*!s_zY$ zD0}WMP7(3rg8u7O>v34=VqbK)R7#A(Ug-ZoAl{Z*fxEe}ClEVW{DYK7q+;7NBo$kw z|7WSbJt0YZxkV^zsD*LCw;5B#kPvK~+EPI)yQFLM;_EoPGJFTorQJ#)T617$*nMA= zJGM>r4d@Z?qPuY5rErk3LorXD7G^yE}w^!adpDF6?^l&8~gmf69H>-70P;xgWcBitriV$?g_$`^>vx3r=Nsldvy&2)i4Fo#9~|et3@Hz|$)CERT}*f);PS;@?nube98^ zhK}_$|L$4O@fcXobCG9V#Ob!5Z3z0?+lZlcjkm2lXFN24J`$OaJ8A;-(HCRcH=K!4 zMfXF!eajO=srm)U(d>O&@qtNpoyjtpX z1zi8+zoUh$L5RnZ@xS=VPzE0NGVm0;mYw5#n}Nrmw9CA~N`C@!{^nq`oTnjY4awpj zTc0hVjkQoH_MG&SFqNb9Qz830nD~vK&JVe-hsm&Sz>tqP>mGp8qjv=yXA`SUDgSVd zah_$h(T8){v4|@&<2;#H#4X`$`H#3Iovop`r4UEbFKyG8%;Q+&6%t%$JF9hVBCZ&G zF~_v7QV-yJ>3Q1_!tsiSo)_?`&{BvQ@4N&in_*=f#Zbx9sHn2e%T|?}t9cfGM6A^oiwLccI$6EWNVY_s~pnl+ZoD2&_PIYd9Z;Bh++ay%2i|&jC}* ziSw-I_ynwpP6^Li+xgTs_$BC;b)3&avHcK+w33|9*}q&X=Jnn>Po8 zw|358GEmR?%H}D>ITvNC?|cKB-Qz&W2F`a;wua94QMN|Tk5RV94o0X*ye7^sQMRV| zNkXw-Gw1gxTXW}+C|e8XuPEEq&fihCmJYh=tZN*0Ft5yzc_r#1G>4RFz2jgUv~D){ zZ9;CSC<$kW{g7LD=6J1x4vL1e2z7cLK9zyy{}x7%R!%9Qdr(8Iof3{W30x$4UC$*Q z94m23d$m!>=$weZFz8RTO)mEaCtkv%;e=F?5p3h2XGLr`I^`T?Uve%ACOClw%Gbb2 zU7&K?IzFeQ$Z!{U2~|Ww?Ht!j=q9cVYkMa?oNiTEJ2+)LE6#;FD)%O*S}1AL(J3oF z8Np6Ybthcde6DFT`v}^^%}!#dSPLb!Tb$aC`-rg4PLd7uaA@|5R*%J77pE>-KJxaG z%=wN{JtsU1jP_N2OnTsdnCkzhzq?a>k5I$^_I*Ko-zVJ29-3iB%XSOI_b4@WLYfY* zaxlo<>NK~5g$#II9UQh6^;;D$4qo$r3E$1RE-L)P!PZx#?#(VbwraS|xzUk`^1{}RvQQw->p106HIe2Udfna5Q8~Sw4vwt5vG&jD z?c8MfyJ(HKI|*J4Z}S_!aM9Qg$nE3YjNdd$rQ}J)^>uD>+=qnqbGq0nG^po0oUWlj z^Swab9Cw}BN(c7MAQm=ks%80FsA z3Cs?=4~lZX19?7(V%_c7-$rTdSmfN}3~*#(a2SucR4***?*vIY&^TTpqu1i4viAxZ z+&36L(L?SaCooI-a2aMO;A5Q0mVX#oKa909u2`K+fsl`A zuF}|i$xU~%P|q6g>vP6A_uKY`O_!YU&I6Wz5)tHO<_bYmAqcxNCd2WefoQy?&&hPA z+YDegCTF7apyj8*?{%^*{{noHGsE&P!6!R2Z8~Sbr#Ly*{Ve!>&MeEZE0dGu%(nb% z@cW%PHaxavavpGUt^0ZKsm@%>u_u!=&6#Jzd<#C^nQz^(Khq*NIKVNUO6?n?JY@d@ z8X9t`v1gN$?L1<`mS>eS!&zXtY&Fbu7KX;fnbJ#goJF=5%m}Jkvz#UJ+zIWXxW=1! zEVa)Z%qr$a?6!BiGs1RxK4hbp&32ZDM6VXnNzS7fnQ=-Be2()NIF4z7=Q>Z=B&Q+D zTxV4%O15}ac2*-8Jixm;YaRDRVe{|>CwGpp`A)ur5gP0mZE)P#!i=*K;}pha@Wb?s z#ldc2XOzi=CIfQYb&H(vN&gP&McgW8?|_ip{}Nrx5uJ z`!9>~f8F{ocXmbjLv@k(yRH8UXHS$r)EV)A+xkE5?2Gb;iX;B-S^t&Jfhhk~QT~Ul z|7r)9#YXbCCd&VP>%Z1H7UlnBl>bN8|0(A<>JHc**z$YA6MBqvBEKX{0H-MSaW2(qde2lXC_f zW1R09m^cqHay&+w^x#*XD~{(p>zo6Zu@&t>VvUr&xN*U69Mvu(_#NCtA|%6h!Lvn; zdfy`tH~nWGws_KP9)1M>cOHK7Tx}kH0hc_WEk@SN~)uLsK&hjnpW4`E+)60BSJ=Zi6S zQc>LEgiE-V3AZ`nVIto;i>ufZzw>RUV!Lt4)C#F8c7H238z17$rnssh)RizXFn&zYGL+uZgzHmd?SrZuF38Kzo!1|Y~fCPHn2u<**EY>&BH+D>OxXq}%)r72gzjki0;C%>FcMO8#Qsf;^jEmWnHnd{j%tT}}v7 z5hm=5B`q%vNyh`yiEk=0|33h_iRl(sHMMd(Twe;E%;1uzP-eH`R_G1+fhpYG->Q^N zKf6dxM0tKD2Vslzv6#4YYIBjnb>qu#McyH|d{Z08D}Pj8%R`S8S2t$A#BZm57CDlK z+U-<^=n6bLyOp;2svtV^^cH8sH?0YM)s=YGKNLQ-dFsFQvA;xBNgL$~)dA9#v?_+m zB=rtmyA9i^i4{VA-Ox55-)jT5Zc2)7Vo?6ngI(0bgRQgx{&godZ(7rqP4XLVPiR}I z@Lz1(7+3Y$TFA8eLY<3V+jWkZi>3Ziw`;OvD`#iND*3(pfB(ncg_7lAu_+9%GNEK_7jY9$am1{bG#vBZx1_N|{6A`W)Bs8#+u z$U!)V5#ub0BWM29b%1cf1A}Nb+tc@FX4~O?k=A|zAib1Gw zX(Vj8Yls=d(B;;hcE-k-w6TS1Vq8FU5ay zNg3M#JHX+px5>u)J{Yq>XrKhjSQ~?U}_o^l}}J zFZJT-Lgb4K`5*3eULGV3uSUJx$zPeI{^Q<1+1LC!7Ju-sYD`9{sxeu>JYXTP0$2-d z19k$tfaAbv;5={+T{-e~`gI8ZcWN3K8}!un-Ojb*jcB0*!!HKqp``+;;-~ z!P9_Uz-ckzwhy=fehG+8LR_FF&>j% zC@3#k-vzc0I0768P6OwKL)2;DB6tx%2}l}90Q^8Q&*6aq(pvp^A0%7;u;@*!y;8E6Ew z0lENvfx*Bu3A7R<-zV}4zzTr_z!FL)k8^{BeisM?441~x6Rsi|HKDZUYJO-QxzX0LW$q0(cP+>qq?nm4NC%GSCQU3A6z^0o{SV zz+fO9Xpi{af&M@i>@$FQz(QaJuog%TKu!RvX$8_=NOzFFz#w2akPb`&rUA2oJYXrX z637QO0|h`Kum?B*90N`QXMsz=B;+9WDwNU4^83feaFo29g0} z+3>T$@_?nlN+2KD3={x`z#iZLa11yJoCPibmw?MaY&E0|R0664DL^xz70@2&0`#he zWCzKgG}tnLwW2kcvw=KdDX_CX0;~kd2Q~u-5a>Km0KQ9NACN!CVJm`bVgppTI9!0k zCE#*3c}|q7juuoM&ecJZtBX@J`?o#pU4ULdf1nxS_X37DK;WzfqPyV|F9UvALS}>H z0ZW0EK)!GZoNogcAns;36##|69^e2_rXiF8BsP?^J2gavL9nJbloayBdJLgX0%w73 z@Y)4j1TMgS37{H~0{DT%Mrckzat%amRzsc-?cv;|#(c0rV8elQU=lD5m<{9sOM#U@ zKCl@m018FOK9D28ao{v?9=IqTmqB7{B59x!P#s7HngOkVPCzf9KQJ6f2POg2fNhPD zGR(Z1(qC7CM09*nti$kees64tKZw=Z&?0ox#$!-19H`S59%nuJ;B40Tt#;W8za>!9Q&NIClVRcIz!BCkwL z$5FN5B2!rTho2OwBXvj}#w`iz&{$luZLg#9F8HBZCEC!ic1=~b1P%Wi*QreCJ}P`C z=hRT_^;lVPNK2;1p^30{EbmX~<^t*LzIZc6-MNI0HMxugI6FN3=$NdN!< literal 0 HcmV?d00001 diff --git a/Covance_UCO3001/browser_profile_1/Default/Code Cache/js/d5693db2464dcdc5_0 b/Covance_UCO3001/browser_profile_1/Default/Code Cache/js/d5693db2464dcdc5_0 new file mode 100644 index 0000000000000000000000000000000000000000..cdb576ba7d8e3458355098c7f2d66b44e66cf466 GIT binary patch literal 112424 zcmeFa33OD&);4^4N@oHB1WW)i3?d*Rvw+CWK!9)=VhD(+a5_n6AW3&fcLL!$L_|dJ zB4cnw1w=tXKm|obMMMOdqN1X35tS>5%tL|--}BVa=@7l|`>y|6-}kS7{SBS&bE@`G zd+*w{Yge7>E_WBd)V%Pw-yMcw#N&PC4d-|GFnaguk$6j=0o{7{=$)LDkl3^LEnT{I z?U9^(%PqI`!c|gopIdtMNk|&lvs-fSq%OS&_PXVku1Q@I`*cg})1_OV9=&Y9@mX}_ zlf=c>nvjDZoc=lX@`fcLM#5wEosRd<<)p5+$U^+Jbh-UnTfB2iOS2=dLY=V(edZ}1{??zQ%46W@$h^IO^4E->rkt0TrbEzA;~ntAMg z+lPcH^k$V5xKTYiwP94Fh+pD(Gs~Tw=i$w$)Qn>{AAgT5y9%=mrz64yYJ5 z+gKwjyI0%lFN@^2{AzntMXR>gMc9@)+BljvvrVwa?CoO1q&d24QC>*E1|l;+*v?nIRB4Z;KaNQ*KydQnNx* z(}#rNmOro1T|BVFlZo#pZOPIi)g3T_6X1(><K zm|7kxEr`T-5AgVkT$%1+t|D^*$-wkle=s!8fx?L;ZrBd!mnsHZmoIvW47w*56}x>t z;7;}WSm8J!!9mMC!@eg6u+FU1Vs~kBfxFP{@f)TUlCZQ*&FLI>u2mCMKoe6urQ|Zb ztjIkK$Xq#sR2nc%Gc0kb*-byVDLxuieYxI}f~*1VOmCKZxO-9o4Buxi13pv(#^KK= zhc-pEOs}WZUF=Wxlt8jBzdH*uAou1Jff3EWKg`?@K};0_m~iT`<>3I!^QF06nf|;| zR^5Ud<)XNF&pH?7<15Wc@_PI(5G^)i08P$HKbShAF$%NFAiliJgyNh8zrQ#yqr~qv z%x72$5}s22+&B`*goF$7rnu9RL7)q6fNe->=A1Gc`@65qlR47uFDV*X;Ppe6WVmD+W2(dlx$$nJoK`apAQ}JUes1zu*$nD7*=FQ5>&T|(Ja~0>ii*etq zga~JdR;}Cf>iAK6DFr zreE0pi0pKCAvp27(Ru*&V5329`v>I{sl3br7mPH!EG>C_SF;5%LGYVXUu!@c_CaGs zBk{+RL)94ObOpWD++QkGp9kFTRF^+DE!pgg!g7Ipe^l3a78iKEK6i>I%RPBSwmAeh zq}3iX{FM!HJHi4K4&tsCC(dQFuiZ($M4Hw#z}fdtxuk)_)U8$YoF!0X9$n?v!1n&@Up zZP^^(^L)a|2y62Ale6;tu8ab=>~!Yj04Mz|2ft)XqydtQ*CRYaDD?pgP3-zmmaua; zLwYOvgQQ${Wb{lg4p`TS;(;Dqo9z^RPs80FDlA7}9PILB6}Xd&i)m1X`6|T?%PwyC z&_H;7x-If&m_rE-J(NE9%4+rppW81wR~l(AVy9`U zDD@iV6DV-RY(5Zb0#qROys+adB2G&fJ}7y7`iQ?L569rDsLq_&{8d^{QL#4@u9M!! zXGTF)j+iqCL(Run4Q-z{vHyE)JGxzZvCHEF7Z?rDtp4n<;NCN_*)m~85|8Xfmry8u z1*PtR zc?EvyMIzaHP+i&e=GEjLEalK8rTE>2=0Wldb6972?rAzKG;MO(9eL<{?(9*XNyV-r z@cjh}$_0*%b02X8asGFA8Hz7R&cWR32W?%XzC7vlb!I7q14t0qwRg&|qJx(By-B{S z1k+CmrgCk|G@=jmzeJ#aO7Xuh;f_OsfA~sw@kl?qd8Qey3in%{c#M$Q-eUBBIe?oV zpb*qyqlYb@4h9XQBo8C^8QhkVK4B@0A{6`;#<0|4FIzi6Y5UCF$$MB>gn=O41t&@0 zy#zNT?7pt;exsH+Febvyi;lAgM9?cBil&tdT@DoIdcFA=UkvkQg|=zs!^7xzU4gNS zZImL!pwMpJlt>N=VvvT54Rl={lyn0gIhOT0GyYj>9ASy@rw~c8@OKRP$V1TsX~lJQqsfW z>`02|BDD$ruHNU=M*`0h+{`L-?s~Uwla;$#Hu`+lt)?3q26Bq&s!$->YaOh29c5 zQmsUhL_2%l{xZrg&y(j*p6rLsgKCCS?Cj#f+u7dnB}G{fn_;eF0rXapw)b92N<=S7 zaM~HJOq!qh1{ws!=n6}^wf{G$K$zYlGZ9}XfaPa~I*Bk#gnJNR1q>2ALW!#@7v|Dl z5ejAI%PxX0gc~RZ#r4J4^%4>SpF{Jq-I-;XoHiL|Hbn^d^^LZVqI@tsxJnBAFjbe| z>`Z=P?He1NI!bE~XjX<92n&6TWDK)6Doz)8DjWSM+?N=7rFZk0n~4Yf?`yqqF8PO? zMJQvMXdE$k71$@apbf;lY&{xzV#$Rcs3IX6;dp_5 z0Wd&vXlDKHN9(bl`Ep&wZp;t7MR0ay12~rzLzB6OoIsb2y1$jeprNR^#N!q;l0E)n z3_e95R4%Ni+3V4(fEd;QBl#J(F?@a%YIedcQ~)payU!iZ)(BptUoy-~5*{Qvcc0r( zcpkS$>M%+86@(nr3E-P8{qUiHxk;B{m@`=j=w6xLOEpoA5(e~Pa*9pk?)$?8KiMmy z8+uDMtN-VH$FNfbVt$BVG6$|+N&|@_Pkcn4DG!vD=E2pO$5{yJ4P5FTP3aZ8CZ&5v z=88ZFkzJP8Q&2Xrz?Ea}Mk~l7`psse_8_CKl-5) zZ$efG9T7ag3rP^|xW@Y)rWGQ9_ZDX*XQPw)1!mkc?Q1I}=2btU1Vn{vv^M8$@)NAI(i2N}< zHczkuAg8|G{dKyALT_gN0Cy35B`yd#-PhIwX9YBF zrthA^l$)Fhj}op{&2BLek}+VJ{liQ3XwV2e5KzIld5h(|W-}_33l1vU%>IfT+~M-0 z+oIp>QlhQ!E%}40M56+J&)h@4LA`#PZ}yUUrkn@+Xa&N3;GQ`FN@j0aGJj%2TCUr} zX}TKx){r$6rX^LzQR>2Tr+8$T*$9we3j`{Q=e-KPHM;m(M4?R);=m&o#9+4kP2n;DTbGvzxGe~mCfLjL8 zvgpwm^>B`9W~&}CylwBdDWt4CWvZJ%pOQ%PhvhH~g8%dQ^ZaGzKwJn*>hbC2*H(D{&GWOhybLrL!U1b?H;VLQ|BU&&sE_%x{LSqab=`K(KRER1ZvgPQefRXCB z?lGmB;S0hAL;3D9juSq!9}3C^QqQ!{j}hs39o&+o?PLiJ@w~D78ew7X;UgK@nk^(8 zxSe9(mB?N{EMd&}QK!u=SeK~PQuK9s59_~t)1z& z&Z7|q5)Hx~p#tX@q&+iz^V<|6S}PJ_W~yq;yf5aJupkr0#5lp+2z{V2K>AelFCSBc z0mo0I4BL9hDnPqr*@PuRHwgB{%%>aBI{|?5d+M>B1ZvU@QXU<{q1~ zskkCJiRBF3FsmdainnK_H78XO2P76F48<^2C7Xld%5&?R(M7<<5$p-iXqW}KL2>L` z5Ye0B5a!1G9K<08?7q;^Oi|^`mem`mhCCnUpu@fXVf3xIHtW*_K;VLZRUz3E2?#At z1N1peUfObG9ynz($}o@cCj8;$Ex+bO<0jloo)4~VfZJV^h?E*q2tG4JS(bI-h~AVk zymEG44(O%hg3#74+vgHmM&v?{f$4@hK|zPO&%Zi~Tlgol5opW#Vrxh87V1|- z?jUKF1EyRwrDMAktpR zi?d~D2T4k2FT;v1WDU-x@54L(M(5%a={G$b$QhZKwVXpC1>3jhc_#(SWG4M3A}zyw zS7GU&T>Ur3^C*ML{WV@uCm8P~Kg6=I%~DDHpV<|HJ27&`j8&QW3aAYDpPv^bFPLZeK3=Co4?K&GSoNo0iPz-Ryx1 z<${ll^WFQA5474_jCjmXK02ZpS^=m%&sn<_ELS|je)4Jylw3ggvp@D`$z-~8)hbdLQN&pZTl5{}3$e{} ztm#Kn5X6SL{kh&OpZPM0p|j5W>C+?ZteI+}V=h;6nB6n!cN;XVmzm{&fZ8y1C3B;E^Zrgza7*gqe^hjn`U^l9L)~%LdvV9)u?&0NpVn&Ai zRY&MZpnlV4BhMnCN9YO^fGs$<`n{%5rfmx9n-}>Oeyd3V{9@79mIG{#%PmXcHV5<{BlF(Oa*4!9F5`a1mH>kq1F5 zWJ0#bHmw*z_bnHT+THPHTqZGI6TbN|3!e`2xJ zvl#iYScMzq!p^3TUY5rub3ICC%;flMHUb73?#zK7#s`K$`s3drESb}MYHPz0G$GL| z0Id zy&C39g?fFv#3U*u&v!>)95UO3Dfn67*uMPxuh_G&T969==m{D$F*A}q1BO;P`j-JD z%fW7xn2KgGi1e9rfJyd_gUh{Qrq13WC5|>^L2l)uiARpSED~spq#24+ujX(xaVmU& zqt8Rl&OlE?xzP0Fn;eZqo&uF>2Q$FwQF^=-l72w?HcV|Yu~HjH3}E(h#h{z1#SE9v z9hlkr06A2UBat)vjyyzb3^=2aMefWzS3zK@xg1r&IIuO!`LMH$^>mLFi>=6-E1PKa z)t*R_gUV}ld-H2nfC8H>I-f#DF;Nq)-|R)*5cMO^)~rej@ry|(mZVt$+G#py!dz-6 zU^K{IV9iYo%ccPq<&3vm&Zg!ZCBz6TQZktFb|Q7)=;mzwJv%Sh({YuUW^+l)ECLR) z*msiqFj>@Yz?{tju-Jdm_Ah1Y6TMzesI^PGS85jCe&98C-vfRPk=|I0FGM(G(7zk7 zAGnH&3d)9K(6Uo&SVjYr)BX zfq~^89kp;Rz=xR9ysU_I9Q?01F;jqdRgpL5j;gVp$E+Vq@0>97j)Xf$2IUejlN6fT zZQGR$VLf^&r#}nO&|bYuuCSpZy&RlZ#y#_E{BefWGdJQ>_=0WMi)3SoCy)8QGJ?SY6Gr1oNK(A0U`8W)Pr>Ql*l!fnMLBo-jS)suTM9R_{C3l7CM zB3l=ebVl|)%rsb^szg6P(dH-an$9A43>i_31s${&l(uhsXElY&k(~()F;kw68-&|6 zIJ2|x_j$#cB?Ycx^In<~3M$)A{+b11Mgf0p{thN&r#LvHz{bIdo2O*xN+GKaQ0-A5 z2cr|A^$)Uz9=Oec%+un#Ih;)aQ)hAqY@!(}W8i8hnj?7z^-E72y@k}dCCTMSOdJP^ z0xcvHzT&Y7xIhdFbOZ23wz5%&^m9bWu^zcWIZAAz!ho((*cZ8!4#q9+^nzEEjRCsW z)jzBTS-75IKJ#we209vB%Al{<9~6H~QXrHq;Nm;f3jm_+{PyrS$fcC5-)owPTGAKk48FDmbi6oL>_68z{p{nV!oMf1xs!{XG%-$;_;uAAqNL{- zj;)Qk#V#MFC2%k16RZIG8{dBPBZkmOL2{mtA}nvsR)w4Hy#Gnrq0!3<^W*?Ww@%2- zcNX_2T?E$LGy;)<^Khl-tz~Clm2^`)DIO8-y3>o@ZnHpFcyzsp^< z4cfY8zO0%XvhnfV95Pf^Cn;zl2w^+PKzN5_*^fC> z#TbDF1R#~LorhG2Nvz~;Anb#=07O^EP@fX)d};g~+GI^nSsfh>>w} ziS4DWA$MoP2y+T5K#z14mrfm2GmG533?wMCkmH$z1zHYPQ^8=lAd_}%^C>Dy?mdLxEc4;$nw*ig=L+OM=H=(BC_QJraAXT_3 z83zBHLniMWD0RHL_|Hz zp3-G6?GVeKB}Hx-378!zAhdjT-?2R$D8%+H>K8nNgjDe2@G*aguEzbZA}}N@s+>SQ zB3``lX)pbXnA6EJEH4l-3YRzQ)02gn+_~e%mLDSDNbRG6D<||T7STMn%s{JR?TQtm zP(e~(zp?Bfy|Ho}@Lb$=faKnC;(%&5t~_ASVPGF>(%%zDj2WMnFd$`w+>vM+6co7F zv^~9)YH@pfCB^O}tUZIs0AgU_rSRp_FER}zqBW!lrFuYMd*2_<)(lmH+ON%_dR!%aKV{(vl3jR7_<*h zn6!k0d?1}AW@7NsxMyC#AM$_r*aEQ?Q@U>H-prYlKSX?NY_B&dKkRAY&Q#4Ca*>1v zbBFhr-XMA)T)ybqyC^e2o*B}$Gp!G12?v}eHr)uHz8|RNvTyj)4PTLx<6x#Fhldyh zTlHtXYZHD?FVV8U_5#9kgH3CC18K0WF^5>G$;#BdbGgCTe=AWfY0f*5Sa z`@L#&4~pqPh&23_DY-NV_*)rQj!`lja@UAQg&DE0sln0gM^yslkYCo`Op25k^ntZ~ zpqvMavZsuFCt(QNDe@S?MPV5o`4{ssN(mAlm*2`lQHqoyM|hDNO^3JkUroYR0JLLz^TuoFx%4vxW;a}jf^T2^QA#Z(xexA{6kWL} zn)lA``KoBdNES^X4D?j-TVWT$KQ`(V`(?x@GCzHlDL<9}vX9;ZyRx_t#yvsOoy( z52;3O|9cZVZBOn&!u}k!DcYO~5>nCo^3(270cuKiaGLFIS`j3<|JJU#vVuQJ=CI{1 zCUYDFB^Rwu+|{R?Rpg9*WV((i%(lQ$F0fp9r`xyGN1iXqTfp52uqC07&v29Nxv=BJ z5w=HqyQ{WKjiF-%FPC1Kl};?^mw`qz7&ooTs;$Q_+(eN{@5SXaNFx-`Xe@}-@6;=s z-KMri)v{b`sZEe+8ae7-6~UyrvhutEx!RRxn!P$8TevEj^W`cz9;v_|s;%YkUmc_W zU~u4OQ|VkL5E9C6*iml5=kU*1O2fEo>H`I^J!+mnH&~ z7_*9ywOs>smBl z!5$$O2LtQ|*3!+;rgl;{?5t}?8Z+2^ii-fI!1Vz?j2E(m6Am} zHdnI|Q18ZfGv~4sXRC>e@bkTCEfB%x-+h_%l2W-)>SU3v!%j1hC^txC`)41Isv#1T z$RLsWY#%D^dhC*z!qhDE1)7E}SHLA5`~HH)zfhn>a^Wo?2eUr;0kiubdrgE?FmIJE zfe;6%!o$z}(3Bm6wl8)*k%Q4Fl#cX7zZr>iq+AzE(0k%kKG0mCM0Vodm;NPtZ_w&m ziYMDkTw~B0-~u0)pLygK3JsGsxhVxfn|Tn$kO{;Va^OKRK(V<4e?|f5-p=>t$gII5Z>lC||$a1c-!oT+ArG79ghmcLu<(605=#a$a@>at77VGk;{g_+ zvtXVKm~k`{ARK;R)c_*IW(2GvppZO%$3h4u?LhQ5bTom1Q1DnYA22VWkQGPoysZ-} z!Vbi~x`6cHS;Q{trpolk-uCYY>DiRyVMORN+flsWCGFP%V(B_zc*?K@8QmIYB6)#= zGoC#ks$B!8ZW-RmV!$=6swLU0t}i2Mj9d&EQs~{yR3*#__x$(=>fsqD?=SLPEpC@43}34EyToFQxZ9bp@eJ8J0R$ z3Pn76fJb8S7_P_f8|wDt_;XP)TXTNx!GY{W*z?JdMd@vZ{(_n`DxK z@knIw!8KtaMYuuJsTg)&AqSC6AD(W+mJ+i)$w3H<|Jd>iJFW&w6KOn*Ww>V&g>(Wd z|Jd_eV_dDGTvv2zxh;mRuzF8FR- z02WPKe_Q`|q)*cJoaGK=>z|<10H5*Rw=abGOdxwE7hAd{4rC0vB)d;l?+B%)Wub(Vp-rlo_0n*heo!Iu#6+ zi{f#^`wnL@a@UiK3i2}fn6NoUDRtcHpTz#MfY%Mk3Ix_mwZKM)+<)jr`XDuO(*!Xw z!{$;knPCf1sdUpFH?R`6#LAr!B5qNSTD=TrrHZG|zSTy4a=B|I-8+n_05e4KGktdT zOw}1uJba>3?{fu!nWaQEd)&naVqo&stTC8Xs6lDW8~0oS`!*g(l-nc-ITq-heIm?b z_{2C2{jcu-qe(@{lnOGo!V~vEUhf?DfPB z5A>U6;8%9teFqaWG=nL$Chfdp_{6|Y#lG@nW)l8!lfVkt$zg;Uko_aKvme3A08F6*I za^poHfF-0Pn_0XGLA1NFBA&ySwx3}oKL046@R8VJAQcUY{cqlNmR2;GPt9;g&;6TqacjaJqc(D~)#NoiU5;v$E&jayWMTY|^ND`yG zg7RFq_lzoQ5hGs6l4a z$!q>jRpt5qBxdL+xdEoF&s~>CZ=e^+2PLPcC#QkoXQ(jX+3ww+Lp;a?scf9q6)N3} z0_Tc)W=nihc$GK*E_NLRXVc8F#Dqv@-<5uA#oV5|D8&;}X_#^&MwA<^46{9$XX|#| ze6$VwB+O8x6IASpWCYbfrbkTsmQ0Hz3PN{ro(iojni!zp!+&#cmYr5^!ZN=jgMd8J zz_WlB9vBdnftuk8^|29OTq{BV@q9!Q13m_H2(zdewBp3>%U9&4VY*Hc!X&wh{8$(f z8#S?|kj;fGPW-Lp0L?(=tGRUvSh|o53XfgM6)W8c_yTrh-b?NY>Fx3mJqrqU+Gt`rga9_n+PxCis)}^)A-pJ?d1|EbP@x9tBZ zF2V=D|GRYm|9by>?dU(rGgv>t-~S4Rb^fZ1_y4N=ukQa9uK#X*)(d|B6~6zQ_sQS? zP5PQP`S`Eiy6*qUPtDW+Nt*v}pv89o86UL{(Bx^N(axQgmdUOh1b@%qEzZ}phuQ37 z?7iI}aJQ%18Ma4*2iR#7LqRK)^kf>URY{0d^ZK)%spAqzr#%$4kU&vpGsj(6hX9vFq zbD_j^5AH3-TQYyWec>V@CMK;YCeB1p)B>9WF?E6|3M%;oR3FX z+F!8L5{M6{ z_Gs+q>Hu-~6n8>M_LA-PF$>*R!)9omQ~c-aKy`zN?!#L`J?vPZB&ebIc_A38TpWmt zyUNV#g`2ogXBfAq(n-kDLw9{@huwcaW}E#WE1baeQ>aO=W$)?~RO7W1xIGfK@_DEu zX5NKR=a-JbLW;dfFODeX0lck(=|z$rvExX?OQG4MtX)m4wX!>U@ZM|~SkG$v20^NB zSF1n<@Ce?@W!hsUdSO`f3w$}E%C%vI(Xg;DlKHP|+4=CQag@}mVzW;Wn{7IgPl1S z&Y!d2VC`&qTJdk5FvKX;DJi9k z!6v0T-M93ck29hZ1a~Apxs_pj-I{b#GlsY7`zFPj?ZGutLi3`c#G-ws*z$&a zVtW*_H?go;Sw$g@RupC_NnYK(gy;sdSM^0zWv+9BL>Xw)HX)eRxf z5761TDdjqX<5i2Z*@m@6b%gB(D=d3Y_ls8R-UhpKsxDrz-(Z^sWy?Ol$Pzs#lTzWx zL+hkCb<`k(4Y(%bQn12eoO>BB-3XH#32jyai?1c?AVrld+GPD-558%Ms#QeEt?pMj3t{NX*AOfGp#EQ|xJw$ITFxVJwii z*v*KG$!Bq1i zChO^qBA^kk2>UA?$}hflam@uI^0QSf&z@U*@$3a-MT5PS5mmkHXD?W8wN=^Hon6?> za75V9jKA;zAD{*Ex`MT%c4e_LT&-oW(H3Vn#k+O@=)Zflv7ICK`{N^p~-8N6=8Fz_Yb66ie(;!qpHV}=_vgf{pz)JP?04W*n0;HHw3Bf?}A z`6B}{95C6HFvuPW74_p6wv^A(hgMu`Z=x#CX=RI=tHL)N7R+?+rqAu4vkPFe8;-J- zOBlJqro`d4vb)`4ZEmYtYM*Z3gW&F><1gLoGf-GapPC^~i8k7KD3h@@UykT5Vf<9$ z#VBWR@Vx=ICMbV^fxjPvh5Yuo$+3nnG4RjA#Af$&>#p1?+lBKsczmm)vawAt<*ZS; z@Vw;`%rM%5rvc!JIrf<|w%pE0i<=n&P3AJYu;v9O30YzmW|2d>7ROL)csV|4gB2p2 zj3K{JQ9InR1gl87ms{Wv7C`BiIJlQ=j@^81z3mx10~WtBVS1wWGD`O!Iu=xjKBAp~ zXmc=PWoHk=D4Mm^CbP#rMuKTSbR($Pg27@K{bvB6$@Og0+<>clGG)#Xw821tsCYQO zP=y@Y{yL#ZY#PC*wDtKwwg8CQqTSMH-@^2ReOvPl=U_O38Hgs#R`j&EZW`vj5H)Af zKsN&@Bp4`_hMr2Y(&H5>+ZDg2(Sn9fb9LSx>AW`F(#08T$%w)=?S`MupRCU3od>M* zoky)n&hM>B^A;3Po(}NI7eok~u~;h~vD!QAig5HjZ*xS1OznH#?rd(m*xY`>U0r1l ztABM|N%VXz&oYe8*$|E8su>IIo8sgvB)Us%xy4HRwu5k_vKM$A!x`LCWiL;5H;iw4 zP(#7P(W2aac{CK-uoQP}=-m0j0QD>bf;B>e5egrXh`UO33xh>h^Ft(D;d%egJISsb zisCZ4hZub>CJfV(eD;1FB}CZpgCH#)!W|(u3!-nUZBO<^n-{@gQ3h6 z4fKs&0a0|M1e8W(9iYD&RR26dofiVPzWZz+jKZHtsnbgRY!DykNgOh7#ZEkF4W4cAqVW$cd> z1~<1g3Nb7VhCp!Fl6KC%219_8Tf2m2kHbMwmq(!@t$oCnos|xp)vs# zT?tK0j9-bthuSwq-qJXr*vH^5W9UvC~hCZQzk_p6S>Tx6oKrwZIG63LsQUg7v z2x-%WjT*6aV49)+=m1QtgHu0tEp3G`P@`ELr~*K&2tYYP<|-@Hv?c(mc`YcZhIavT zS;JAHlshj`0AuvhzBhPG5@0Y0y-1N0&Q zik?VC5+z_Jq)mY#Yj8=89)O*%2{)V@7#TZpQrEBjK zv7~+;GCP1tD{mq&wXTCH9at7G)-89~(Q;a(wv%E2wW$O21^|A3E{J@usSgh$d36Sj z*cq;5sLA_K+_ny;YGAqfd5sC;sDDS!YzL~AcpwmbDlA$Ye%!jg4weDHFzE%21>!i^ zBwn6~PU{0VB(5;&mX+XEyI@SpH7*368OyY5WY6SlvI^1z`Zh5dwa1p^&w)K;~O@Ivc?uP&ec4AFXfy#AbZ{lXdeEele`i15!34#VPd6(DFLm zq=cs7^QK_*O49egVHg|mmOT`+pVqUwY^7Lho>&$~$Qujw)JEca1XVf*x^)p~< z@Gh9`G(V4&`C9yob?R|)c=VKY;{|@%eZl(BMIn0QOu3>A9UnXY?^igyabp=DCILkX zNK17Fif*n$@r4hNY}yQpG4r!H3iI{RgSMw1wtFwa4#e6sCMtpt!xNXH;!GV1puO%0) zLV%FgrFA|JMcslC3NCCr4CBK+8fdOv0kuYDa8t7vSfE>sU=#I7! zKt1XJ?fB9#p4+E^Qfih3;}oq5eDwuQlN9Ar*3!shI*>gwI~Jz&OwR z3;?aZ(Li%U6;NXZgy_Mzr4CRM04^WWKs%iPqETqGeiA_9pksW>Nhm38_#Q`G{h)!G zSOFBQM-0VApE{K80>JwxG|*lLfG9z&D~!BG-#S2*0H{8tfy%J4AijzV>63qz=J zYb`J-!6#0G@iQ8*gKd$VQXnxPz%bew{c3^HEzbnN%@;M$uOR@UFth|Q+8MXi0s033 zTK=YiUT^@2jzI%G2cZ6SfII;BC;-&cqS$My*n1wI;*@%PO0ko@0|0pNcTMS9wu$U% zAPiVWd>u+d|1gX}S2WN~Awq%_yarnWu!LYRH2}T=p!E)mVPO(Q^gIh{zC6|b`b@ji zf-J3gm@n8bJo~8q!lOu8#A9|Kdt{h>&Rn5o?H85;MPe{9{o!KM`*AIEpzA9@-!;|G_Vek9{>gQG|Wan|;|kuAmW8y)paxn6pdrCP zbC?-|C)DYUCiP8Rs1)c>W`^iRxxBLafo?xq@qIkPUtafL@zhu1+9R(o%+KmAu6^=4 zJLU8D#5KZu)<68r^$&?_zr5Z&F zv*mT`ho5{+l;_LqMjey8it7w{J@A+P?~ChFd7b$05xvAU(-**3dd=-0it7@2edNK# z@;XOeTQ|M_s3^x=ll50$Q?FE97a7LA;LG3zU$Ot}W5eIZeQXwMY{Nb_t37slAFLL} zKGMf#4~=ct$L0u+y#YVz8X5aoADgp&?2JCP(5Tp%eQaTkVrTWSg-6FG^|3`XjZN%h zi;Rh#+s9U~S?ruXw)!n%=k>8QXc;@dk1Z;$PWnufkH-TQ>v1BfJt0&mT`yuG{5h1< zTC!+FbXxN#??8g+S~Q0CyBgL19&8?}GjDHdF%C4>R`sRxs@d&p02^8hjI;6c0Qfr| z7M7-XlU+@3b+23lpkZ}@CIDc60H{xx0@8hDEr5pC0s0L9OR=yeDV?_gh#gE14eJ0j zA{a>d!_5F`(H{O#BnfpabmbHK-p{ZrA3iTmBJ7G(4_pdS>W=<8P^Q*G$x-wcAe$l( z&JBcC-|exV-y_h4EB=yg^B2_Wly3r=_=z5T%CSK@fH_3fMK|kXE5L$h`WsL^tqu>@ z0idb}0DI5Pzkvwx{`ru7)(_-i*$?*RKk>^uKiSWTFB^{7e>p0=e+23xpN$XkI{CAG z=h0fO|7AsA>*6ic8yQSrMEZ?-T8y*3G}G6T>ENJX6M)i#fs`)l-(oRN<6T=9D^A*f zI4Oi@eO~I~zM4Q?`?U9ga#S!%Jp$pO_b2g|fU%5CDLx&ZdqYlg;sNb%yg5k`+TlW!L7?+pe;6y&83@lWH9>zXG(U>||RsqAlU@T`| z+VY&j!eflC#47SRm{im5k%l9j`p%Xk^5HJHzqhqx^DwmSg*4 z4jBBJe>&#P<`=GNNQ?NUCVJP6`V>g+2`1H#!(%(#RoVZW8ko3H!((9I)<8s5STmur z>@3EMq91-=Nmowi+v?-lct5bm&=T$Z$>PGuA=W4Doh&gUvUnAacjq7w*RN=0++d}M zWZ{Zv$HdGfzTNm7NYZ%G`1UQkPy9sAczHmLqFB*V<7WrQPndVs<*pRqe&BYE9{~gK z1h6wS7^JZ0MBzd&V#F?xn}+hMtE>^WzgZ0YTDjD0ojrQnW?PNWr2wQ%`p$Tn97yKm znaTnzey)kzXaSZnC`2pX+@?l)I`<3pVUXH|l5xRG5`O1tw7`WY^`vh5gs8wrYj!Vy z#@7LQ2ml!)HBiq`0MS`phsvZ>iBB^aNZI&90BMp1+Z&8Py69Ha;%mk#$C_0%vHhzY z&#!YJYTmZa@ynb1vT(g)?_2!x_y>;Nn_1`WEsix?g*}G9cDP(|y+S%S8h=Y5BnzM8 z(-q8ua&Emrel+}%kkhI zDXVhX-a;AVlMg*29|X$mV3bNw9f9s3-U?8st6C}c58*Q>80_jE|6y>CuUYR4Y}%up z@_lTt)mVKL)`~7z+@y&}D)WhGaX5h3bp-3L=zr%BTECk=VC@UG{=h08QtWMp6_TTI z1n)~#1TV;py@8*boi~!DrGmz+ohO`eMq(U!hxE26?84g#iJ$&!^%CX{WskrBb{F7C$ z)Rcb!9a`V(p<1hr>o zMXdP6-nMR>(?LqY2LrS6xPjKFa@XC!TW3I_-9V3M z4S2-4kjf$SS2;Scx7ox$?)D?*XuR2#zDG%Juq{S2s2utLa*=oo0n&vY32E707*Wvg zJyvK;kS8$x3QSn(7BAh}WY@dEa! z`Z@`q{8~UVc-;t))ema6G1_}dpA)~;n*%3F$)5bb=9Z)$iXJEinGd!=nt>PH?hw zrs779@4>zEJP;;nYliw4xBBpQ5^0NvWHa6J7egeK1?Vd}rr=PGm?C-<; z7ubhdT}dkyMq;NY;6<22vVSbky!mKgD?QS>69@9 zF|+C1y~nPngMZo8&f$(XSjB1pdLF#TJp+h%jO?DSsKwWrmqX^PqNRPdD&+Ci{IYj- z$o|*(<%u;RpREZAG2(w;6S8hCzZju=;sGNq^39rTl%7LWp|B{Jv>K@5LAKutB|3Xo zo6584N$h2SO{@jR<%2N*I1m7O(E%WKrdU*_AGm_g;yOTA0PxK#nojMq=JVu3Js1QI+szr>BYa|AHmTL)7ju)Lu$**^>w zlMjMv?;i=U`)Ywn@4p*B3EMRb=(mmD`DJAT&B90=X{6XtfuY8SOsR2yEqn|?cLURn zpJ{CHOJgmWWe$xEpTH8l23a3i9tg&wdUt=|81fT(_si(r4WF0|NV+QjoV89sh1R-%e53Qzckn}OtS?>AoeaK% z7g!oVI_1IAiKdLlK`y={!7^TzHJf21jtCOJo2@j(frYN6HLyHb2g__=xbU;WV(%IP zAR4(=ZyNwjtpgN#)M6z68bo^QJ6^H$mM4FcQLC5sL(*-5<)J!QjsnB2Clwaw$0W^G zb2?3+>j5;a4$w#dB%Ia!ep=(Lb-!o_u!n=eVz^F`1&}u9VMr}1+~kU{Z+>=G9F>~t zz-uY}pP209oH7o#$j1#pI6WAlcK<+Uzop-Rhz#gdu#%zBK0QyyFpl=)s zNKdmm0%%4ZppOAiTCIWJCMEhwJwDwCphts&ROfjQfqctQOmJ!~tN%7Dbk1ztjsNQL z&^dELX{g~J1X}-x6evB0=BW$N&kRPd+J6g>RN*beMyD0tYO$U1MTyUyt#W`1>|>a* zH1wsV#QLwLq1EDxFmcr??A;uDwo5XtSDpbXj)DmsIHKgIV+y2cjeiEWPCP-z8MO*@ zs~eiQxH{cc^Te7Jg?ul&*=|hjZWoi^H0z<&4DvX86$dA`#|1;TecQs@u(Qa6fOsra zQW<_oTyh>*wGeYNW@67n!0*N?gGjbJ8eKJOjR*6+RWzB+Pcp)nn1}IEms!x{2GtQ4 zi3br_OySb&%jIKiJQokqB7tSh4i<$n%dfz}hd8xM_U2Jn?-We{*yFXp7?phm09SJj zbd*5s%i5?C0W_x$P*h8+@fhCHJRz^XTMzA^yu6-TXU=c~ZtxJC1Z;EbV7vc1tFaXC z0Jg)GP4*L;G>d>m5L>W^9sq3f>R_|nU^VW>TS}o!OF{SPWB|>t12ho;867pyH)6jm z8E*tG=m`e`YC$km0h6uMP^zr&&PFCKl=ZdcTBMkR^;6GFifIYS`U0N}3cq9G|~JKGE3oE|CHIQS7DX6Xmq##>rM=Fx~-t zv){0aBSHl}oL0@FRaNw^ks-@y?A6G^>dEc-zAiv*7Z%K4spC^!c!n#&af7vK^)X{F zY~IqR%4*09n*|qkYa53h&wPc1;EA+dEZEuHcEMeB(H@F9m*i-UNKw!kvKK{kGDYr{ zh9Otr^|R);gQbPRIungsj)rXdM!F(hDOsmmfRk z$mKL`#A5*VL@h9m^lt#*t8@(%YX=Z*SVuv30_e#)Kyjn2MxVPhP#6Y538jZvo{#lZ zFjSa@rq3U5QKtXlpPPOl>quZ~YWaG*QHhg&?Rkw%TD1LVY0xU22ovN^?T3{iiZnzZ zML<7q|HER58j-;s!=BU`XMVX_;7GM6@D`YmF4Q)zlLU8z%}Q;S;*pVt$9oF|L?iug z6^zo_wCYx4&xDJ{J(W$X!i+un7ai7RJ)2e?GxkJOFNG2v;3Ca0L{sMwE>z zLL>r(t-He-y;R+@hD(eWtxfl^Qt3s*y1aq7M=wI6Z5%PXyI%-twkOuQlLenOx1D$6 zX~`BkOEFh0uQN*zX&CmXcw}4F;3+J8MyHBrCwX6QDUoB$UAXmhu-dO4ZjT0QJ+Qh| zcerh|$!^U4NNT-3$*-#YczE!nxaWAQvDu}x$zgcH$-QsUkLpc>%9k1T^IFj~Q#v#L z`oiZ*(f{=bJEztN%hpRLfV~A`guMs1o(XQfaso%d+~5p`YnYS;<~?(_gnhK7R!2_= zsgMY1x9sQRf$-U2gu)k%2dbaZM}_s;zZbrUJyv@M7oZl`f|4`VKLC@Kqv5_3&uIjY zRvCbMt`;1Vv-yB{C|5(RvLl(v1c%NfW&-H>V4!8}=ghLHe%`gQi3>Hv4d4(bOsZy) zP$k+p@?_x$yRb^y84u+cu333j;|;u3C*}SGnxgKb7}Jfu42tjyj6-t+IY`FU7Lu50C*99MjdvYOzIE zbRLL$=l=y;xj=TCZlmx+1G)Gz@1^}K9l+m~@*>B$cj348B2Cg(G#d91DGZ!^@SpT~ zZ9#~2#`S8M!}%_9o%m5gw`{4fQJuNv@F=pKB9DSNq63anUhjeFwt(pdwzB^AUD&Dv z!gP(nfKVz@(^0LUJTTv1%M{dyPw6C<;M*$P4QJ4$(g69IQ8^1t_rauX#@<<04(b-` zESnW~?Dkm>8wdH2HX)&KSY+ikqF01}k1>rlJSBZisR@@UizR$&o zM)IrK=VD~E_&Tee9e%KWQ|<2RK8e4o6_qlWU&A@mg!b+>C}Ri}RF zKAsP-CBb0gsm+f7a5oNNx3rMEb5O}R`eWFtpJl9pmelNiIrdZ7<39@>>Wz=@=|fEP zAdVF%V`(rEu?$@T0t+W=&OWw-Gb&L#1TTP=1p|p8K=gU}Wafv#4k57IIIzZ}Yh$D# z(HO_`&{ceQ9R<~K59+>BXPdx8Q0^0CaHV(MDNg^<@Uo zJs6-M{{f&^>Hu{Cz~cd+RyF|9p7m7rUI4us3?!D%$%h)?Iz*eePy<}Ro(Iw4Zpu6+ z)+oo1_h4rNAP}64?y;!}7pulIIuU2(${%UVArdS9;6>|P8rdD&EtiJi(OLTj+!G?K z>!rr@bQsoN4jfBR`*^5Y#}YUYu_?zBtAdsL(5_X%?NWl@xy)+JUZZ7r4i8RJggU)B z6;P{dK`|TfHtPR-orb9w1|W*CJ-DXa9|F*8b$~)&w;CV3p@ACe^AEJuPXo}JU?63S zUjk$ePC==?4*&bn@akjuLG3{H%YMDwHBLVCB<*3KTpNs1HMs|N;Xe14=Hx@0S~$>d z@DYHms|ChomF#U+qi}}?dKWNEfM`;40rPq=j5x4jECiyg=Dt6*8q0v-nLpusFLD?a zFTep|Jl~fP(wi1iT1aP;nmKy?xj*RdGIR0kbNF=u4pb9P-1rL}Cyo*3G0d(4e9zF? z04l`pxat}7KqQvzI=mBIVV7zXv8|r@eI-K{v41U#Kk+rtV}CSSgoAzjANZWZXjuJl)Ba!J7mnBj>7JxR1{j9{e02p^Gj2V(|QF2x$OQPr?S4ndqRUw-x%uFLX;bCSA5*p}572T|nkl%a~2 zI6Ei5%5Gm45@D}sIL#7r{oY8NxN=+7MQ21+g+0PnxvZWMdyNH^s>5(y9cW991JEM5 z@S?+r!!bbiPp{e?9gQ_&j#qp!5;+;WkinhpTf@^6A$9&m1h z@rz+U;%KhJ--r5WQ|OH(VoW!9Y!uo(smivzNB3%reGd+fvW4u*xmbNZbWgo2rO4(l zZ`8fo8ZHVVML~U>C>6DL;Vni(w(~FC+;FsT{|dA+_9{0QgN-Nbb$q>EKE?>eaZ~su zobJlqVdNEavqj)=eQ--n>bM9%s->rcTN=g}yGVw+ob3sF`XxdxBO?#diI}SohW7h{atqW(CjE{*XK^;oAdEja_Zr(;{*j|tL+E#n3Q{H82_vjqoT zsG&NJ<9Oe=)+n=NjhIBh(RjD+9G6t9iZ4$7ydNO(OI^iz^u?o6Efj-MIF&sTJYvTwIrhK`s>GJnH+fH%(L^~aU?+;QS3T5kfN zw>SW8~6i#x)U^%Elou`}nH*dmB6Bs~YUZ=Gds%CYAZs zwnj@E#&$ye&}dP=>9S~9KTOn*Va-_D$yL2TyUe>`B15*qOeS76KE*i?WpfJwUm=WR z(82BTgOP=bH|F4;GMkpFqrU*Nc{|u_>WR$bHr!TrbNip#4F}YX%Ss;M{7ucFjll>q zu;GcGmTaQ?8P3!8L`%Qa!XdkTqo5&KHLeg^jmvPy$=@;Y#qlSpp(p&3Q=IsXhdBJi zk>52L09fI!g>RAb`9+r0)Z&%?@2!czr%evlQsRz-?ZkPDXbo|#1yim2#yz+WY}W!&8$%MIV00A*phyz5a$7 zdt+_r&(+pt3DRv}d>~}USeU^XWF#;4tak2hZCM^2+Z=T+gzb978qwj_s`HT*^{L_= zjcwcW&z!Emu!j*QLvQB0X#-e&R6J?1H_Ww+f34EYEdv9?H8BGUCetTZ^(-+trVn6IR|D9(ZU- zi@1+?@{F}9%VB#QPOnk6w**GEG1&I%WW68!Q`@tbHT*ME`#9YBd<9OGs%0=0i~i&e z3}{!sgnuW2rN1^Hx!2&oV?p+bO#=3E{Lk%W2ZU>Fex@qc_F4YfYWuQok$Ye`A(JkK zF29}z6Sjj!vYlTe`<}Mdk2rm6)tRV>i+48Kv#`CaX=I4HGUUg#GHLI<{pILkU^f~K_PP_L;T0``NaUSh%B{1JZyl(*8-qx~>X{<{D5^Ou5 zWt%hb7me!Q?fCd@ayI$r9)gsaPLCr|9{S<7lt{eXp}RPREV>BXO~q0rAH$*pFbt~7 z`WyMUM?olch9jXAbgtFVVmuORz+kI09gfEGO^fQ|9BlnE+Vn>p?QO;Y4`C$=s!Sn{ zeT{3|b+li}HFdY%dyV1@i$&8>IoaO`uIZi+Hkz%`bpK$@=l>>CGatMvlsuY({)`(%xLCa3nhqtQ zX($U@c`x1&nevIq!4IyyBC2C~27X`;L-!EY=o)qb>l7Z26tRx+I~u>6qm4%*)q@C9 z+M+)gX*hr{m(>H&daQ3n z;+SnA&Zx_;VE5kf`SK*yS}_@%(aCQPo~g^hZ`b0u+PMXOAkNt^&3z9k5iQqZkm!L( z$mYwJ@Y6?r*KhCxOVTduv7k<`br!Eh>-RY>U%H45_AS@CxZm@pdvpwzAm_^n82r~) zu`g=i1~a{3W^btbBMtk~E~X?gGq$;*uhMyGf-zEkp?me^Etj`m>f-;&OA+TUY`c8^QkUmV zhv!{s?YjMZLx^IIG`!H4ztSDA^yIH}e;!MrEz!!yk?Kc|-_Nzit@i>V9*FKruV^Em zoUPPZYU~N%FiOJ}P0X8V$hav-6E4R7O@O?k?P9{XH8-}j(DbIa6a;x}vf>TF#jbRMz@O8e*w zpt?s(Rg`mNKroJw=Add|h{4ii zxeb_)JTM7(Kem&^9Az6gwAtGZ)W=$ssFq@2j^T1&HD3RWfAce}TI90LBCwW6P?C9n z1r$GVqe%9+v!Jyni0CyrolPED>;LvzMol_PHh9-GKqSGDTd;fwh<&OhChE5tr0xxt z#j*fJ%Ub>d^*T`dv?z9V1kKNdXx|u-gCD{!;WW1}>)~^VK}#J_M=@x3i1!eK)?AZA zc+378Op5jP~nw!gXvJfwS`xFHW~f&uSc5?1?UbquC!kE zr4X|Ic%e-n80~Wiq0@tyPsRo;F5+uiiyC&Q2$5#nA{wLc96_?9Hgrles4)n)UWEAS zZJiNay(>$=48p8E3De#}*9jRXdU`3@y}cA3_+4%jqvFuI80-Lw+*B8@iG*O>Z}hFM zzL`y4Xp&5q<~Rf&@HPWB);Gc8TWLtghb$qRzFCLrWWJ&b4N6SL(f@2=*1)#E@`kUo z)KiG^Y7&CL$`Hdjd}D6(qS=U={t`JB*QvmH-obOf3=cR|J+J4 zYP#lFh`M)e7qvyaSKr;>-;hHIVWeftv9gAhXtVAJRq|m6v@tzuSq0yPSQDHta~0_r zinAu!$@vc3=-7BniQJZhzu=z6l4T6qN~%6}2FdBSP|OLE(`b`V>>cfG1WuCqzj1q| z8@Fqbwav(yx>1-5Yj`HYYCX6u1Hba6=AFpK0WG&PXvRU^K=jEjk&IG@;Lx7VImeLt zr^CHit2wv)>HXAd^6dFa&d+p^!!~!tUQLN)z4`#tI7i`Kk=g)lYT0DI>rGkVzK>-i zS@TnICqLCo*-fc|bElvA?FHi8)GC}0NpGXw{=F%cjy}b`T*XSNC0(M&ha0O0hzeLY*D1_6$H=aWx=PJsN>%-2dg#xH~R2 z+BGbLK3o_DBGlOF6K!aY)*ptp+p65yZlEP?_r|U1uR%k+l!tK1^CU)cvaA^s$LZtk zQe@?M67Ql&pGrkGJe)LSujcz(h!?CR;-FkwrOgVt z?RplxO_u>uvcr<&=M^%rFO4zy=@azuqf2XndXME${d(V}2Pg`S-{m7v72CYvMUMZx zU#B?$)=U-5uMEEHBb`6t;+A&V;D2CV%jLks8#>YbSpHgT5d7iv35ICH!5+qt{b`rH z!Z25W3TukkR|t(bD!s)NgNJD?rp^bW4e2f3Sh_hF4(;sU<^wa$iTL7oIlV>K9e0VW z8Dwd)k#@=8zaJ{Kp+|a)p(h?j>(g6&5*Q^z63F=`ZwMj44U~^)17!^@4G-8;zdrow z0N2xgj0no%pO)U@KS2Hp7?j=;kS>1(-k9DJI4t5?G8MSfh=a>uyxL#ba{1Co1ntK< znWP^)8fo6x(wZrO2LJSykel$!4`mD;hc6M=y6X=t-4C;1+C@VWn;zVf-V!zexVH95 zSZ70Bu|CnLySb@sGOIbv|H8H^-ewwaGPtqUlBM|VHhSkQG5W4i5EH#xAF-y|=$o^I z=BlQM9GyO5H`*1|I(O5St!)?XP832DU89J;%C^q@-~ADdND0s->6gKbfoMc%@?0%T zio~W+7GVJ-;D5t$oH{0DOp$yWj}B^OVaF2_YBXKV;IzI#HlVXIC#-h{7qYeFxx!dn zp2IRol8CS0(_~-Y{6fF#D_gE?ZBhOAz0~XCrEOO(wy4iX9zGKN>!)bR#!o^GAIG+y zvtKxGFm1os5T_uBIPhA1K+|zALkxOlK=h~okCh@!SNy80{pBDOBIYN=_CR@pGDg^{G850y~SITwuN4D3CW@UXUo>|B%K0EiK1?{!P) zIljG$3}lQ)CM-FLK&#u_eNSETc?=Dp16>JxrA@%4)H;2dsr}OR=qNAc1|)#R1eSsn z#78)u4L>KK1(O37(}K?m!q9^I*05zR)QjnY7qe1?_Kc(zf9E0KlVU2*S&l65ubbQ?HL94GH527KUzZ)9Y|lQZq)BcCXiQfKsTQ&gI(Vl%BNa zFtI<5DkL9tcK8P5?dWoBVts7dNGncBCh!` zXw-(NhfOg_SW6w!?j1{ieY(W9WBLyY-DI}9BU?T23P!n}e&iXWZAwt#-0HoOZ0JrFvFZ$TEJbRWI;UXdp=V?g@CaanaSxI>qU}Ut zx;MP1L8-;XMQl$Wn$DAsD|heh1+Li*M{~}NK>GS}R!Gvmn36Crz<*9%TUDW9! z#is7ik#P0Z<5&39EaTB$`+GO8`gjUqWR`(Z(75iVBfOn88C zs$f5~;iI5BPEwWoeAE#o=k*XiS>xwJ}d&Bb;+>mxTBln-(7yn-3d2^-Ju7s&2-kzHbG zvv2$pG>6d8Kt^#o9i*^pG`N*UgPZZ17;c`{wkW3xQ4g^#Cj{c08eZ*mMqN8PQK&A% zpg+<>PpbtuFQXHDWUjQBu)5-Tz6gya^hv}9{++nwI3jA7S*J9QEAW!4-X!ugYJ*6%?EoDEp4>d5FXl)Sm}^n%V^V8JKJ=HJbHOy3(3Jy zlk~>Mm~i-EZ{MUtN?6-9Kad}C#Rr>Ty5oP}041W0nTm&8@xykMIk@K^>~|%-H6RqI zh_<=d52J>&uQ~V{7|Fh##Me$Zh3@dOAUK4#2FKznHhe*u4e26|uj`iH8rnUgEt&L^ zupWn(g&XvYZ$0s9T5D(mvY6f)kwn?RSG*LOfIpGRFqXGnLl`*apaWb^pn zdIiSmwrl-ezx&beG}rGm`b}F*#rp%~xqw0QlD}5;WaQfWidm1VCSTfb0M~D?w~oO~7cm ziqbj>*w-Gg_W=0`$FuSg<7tCDf>P%22cW+3K$ytE;>qRg6SQ##Q53G}{m zqepI}e}mG=+ceZ(p7Z$y5`^}O=_T_@N*9!5a#tZiO;+#Ep!U57wZ~=}lzq3$B5g#Y z;EW)7NIXXv0_B7U>J$*g*#c!W@2S-{xJPL|0~lL~0vRrDDeFrC`PBvMUngObgTDgy zgGXw{*#>18E>^=vb8aKSsO8Jr`VFujJzz5cS?+@EsgbYy(5%oc> zkT`S+RL*!%DFKCNoK(;aUViw7Mbyrq3`~RFXLM-^7BVZbnU=RDS-Y1(?N<+KZ-CMz zEj9hapJ$S)0cuk#7ddQG^GeI0Qb=mD(qR!&e)FICbk+mZ z1i-8FBq&%X+KB}H0nj-Q(2in*Vl0)Q03#iUMk8m4;N71<{qBM43dH0xiL!b(aDRDO zsJ{R@?*S?SU>bY@xn!&|0YvRsD&SWEx}XIu=YDT44R>R74ss$I=RMA z>cmi7r_pIE51SOzCtjpqu$GWh%_f25n)R4=v+t;yziUdwubJP+lou)+X#TMQWs5YI}d%9IhEFS z7z7@4nU3OdB{Qf|;=X#B1o6R`KPsrrkRI+d%@PV!SA0J- zmU@#oCkaT`8`KB9?hRur5m+a(m7~=Xz3*Z>U!@k!Ge4TV?BP_;b5YQL`i-Po;gle2 zWnK}}D=D2hv%i@^xwn_hFP&!_&GL9N;zU&79;I{o**A~TXix2$nlzQ@T;1DOs6^KM z{29bl_AY4k-ZK4wi`Ez(pp1wSE#P|p@k%z?L^u;UlpI}Rif4U6;{?AyvLqiKFUZUk z#%qa3`8L;uv{CuEW00nNNPE;b&$dt_&MUIz%^Ooy<{+ipwC6gTabbr(0s!yn5%ZMv1OL!k?)lSZSiVbTlE8`fKDJ%5sTuIa@8bFH{<(D(p z*HKnGOv4P<*!jk6J{(SgTZFCLme1p)5HABW&rGF;$Z^=u2wGl0ht42c)(WaeYFHB} zC(1pvHX&CBI{yE^o^^cp|Mt5hEou~h+Ya`o#>X2HYcON0O7h6BlXqvgNup5jyekY! zDK6gMcSWn)qJ{1*Mbb5N`N=|eXT!2sIerAFMU`^pSX#|?{uHqF=Kv^`igz`q`Chcx zX-0V?Nv}WxOwkf#8~*A*s#*X)UJ}fauqQ!O~DVeu@HcAJwUAhT-_!?x)^|ng|Q-~P=NA0K+)R` z$~j!Te;Wxztx)Q^VF2ZOfV^Kpu-11Z$cI40ciF$g0kV03dI0e4yAl*YAY!5H#}NRr z{kF)i%Rqzki{CRS70nVB9m9nh4^Wx+O>R)>>fFK9{&IG2%!rIn#&&h^-J& zau^vN>Uw5AjSR&srd9=(6QZ$a3EP!)H)PG5fA_fG6Y$VVA?Gc54h$6*+ShH*8?E`y zv`z~Pvcpz`DHoHFg8@H_Tu?g0Fa8>B1SvM!;eTX{%0h!GEdoa)TXs>F;5&s`1!5MT z6-w96tuUzQ6O6Q1Ex`+$-Sr8kWvW4+;JwVK>JxmIc^UNye#=Z=`UL-F-X?uQz%n0i zeL~j+yS6Y1io7382{TH+cZn8zR z8kIw|CffBRhG zu$a5vvlrZ4@sHm#;eYbG^uqr} zvZJx5RQcTVsk6d2n*9x4!I6@Ec+01jbK5Tlp!`;g z%+)>KwftBDIcOocmeS$|qapQk0LEXDpnPCRF3Hi+49pb|%pAPGrBz}szzLEcMJ5M? z?m)GApe_JWd{v-Gxjfx=_AOGnxx&hhj8N)$o~2F{2TE-ol&V4HkWLj0TA~7^l{q~C zYS)4U_fG?2H&O%$3fv+UsTE6uY90wI8O3UW+NUH|Iktt9N!0OcYBMB zP?2hHxVM+9NK61Jb$rGwY4rlFKee=2fW`nHRhbfjylDb7KDjyQsTVMMWhg$=XD`SS z#XYJ6L8>D;3?zWyUs{4;G)fhL*qKPlBO|jNQ4^KpKoU?_Jy1QPRKF}**@o>wo7flR8Xv)BJsAUux@@4yczR7sU2u5} zC||_Iantqnd=tCu4yiWh`2281ebNA&?p=YhH%h*M6~QJTtA%aTm% z3y|IebQOTfU1U;s>H+e`3XH6uegGLfK;-}!yGqcDV)`$APx}L-dSGJl{@n=@6YWFh z2}((3kCuClZYZwlJPu5cM2S0YXmAgsegj}$ZZNV34g=tLk_1ghTq3T{N*tA9v~g!K6dUeK?l6Z{h2ztR50O4sQ9^|I0qYn*@SqJya^_m8hKO+2^#{KzZ;Ca zzK0D^mGS8kbV9w2tIe{uZUl%~UYzZgK(_<1RDw)CK?wDZhRW9Ih!;Zv3iL>+34omv zr22RX5Q#Vf4Fjl?2k0{Ze1^#ERdoz1KOCSS4^VdizPeF@f}N*>OSX>yD%cIh8F(I; zhM^MYqZgjwQYdBs7UBjY_wkZpsxobi05Nk*N_V!a0*au`fp{&#V_Qmsk)RUlL8S~7 zZWt$%J`PFfuH23SD$D~l0fE6~(XBQQD-0q)rBA z=4~Cvz?ZiKf4&v79Vi}acoSa&Ht}`hm8o_Nk>LmM+`LKX!bLu5GjW3?uNS{Dy$ zmqF?4GMNXPUVtP6Cjr#e1M~*~P301_%_u-J;%yc{-8?|A12D8wg6@R=$@3>slYugO zpsMFX%r20q3tmFklPsDBPOMel4$9R5oGn)qa9oN zgLNU#)rC;o^bu`kCPp?+QReM-Q0(bOkt`?qa4kK#g6O%<$~*gbNZl$}7*kFD)_A%CCV`(@M#p$tJ+4|H{Tft}F>!7>fwDvQbse;?hR`+Wb<;PcOmf;4;Id zGyRpQNx@?UwL~qoFp?pDO{(%ME}rw}^+HjV?SZ_Pk~~2EkE=>8E)IIrC_u6`Y*dw_xOmnl8$}FATF9WG7yNqrQ0!>D>DP)kQ-QDQ0BC*xeTL{#BxT^zV>AmWCR17z*y&{9JDk2VWYTVJ=tQ zAA0^_SgSH{pBHfgg?b{s$VBf%qJ6cAiptrJB)}VBY#jRR(<`Q))2@kc^AA0H8Dv&^Q2|kswkwRstFd}|Mtw}q}+`K*X+;+w{U(u?sqE&N4rIcjVpg2HFQ7~>b zs2xY-LeB3yy=ZJB#>sipeZURW;-Y9|{tJjX-%&nX8^m6DJM`Gwp(OpJ$v)h>hHtNv z#O?>NL0V#AWbh~lq20K676QBgBKaaE=7RtY_5ghcfcN(j^d_Z5AlZo@0w~=B6c4~R zPEfE+NlqXh255)}=o|oLCuB-HAklfDq+*CTdCHA$C_c1(1Ts`AON5@j^hy6@Lp3D7VP&=~+8J1aqxB}mH68i0m-fYt+0aZZA^A|Yyl zvc1#-Gr|K?i}ySKE;0R7kvmzxbpT~}fYJb{ae|7ZJxiuk570eGwdf-O6;Yj|p12HI4qKyjK6p9d(@1N1Kdo=g-VQVPe%-nW{1ePy||q=MrA&^jb$AA*{cMVmow ztOvENptLSYQiDn}B=xVsWSlItl~Ay>`2P4VI3V-&0w~?&K`9OUn%1UBO32rlE|oKA zTye`6r$)_0PE}q6wVOSty#`8~QzbRzE9ByqZ?yU9=b5jUKxv$ok`Q^3=|<%kE_adl z;-#?WOJO8z6wyGAI2Bdd!M1|pcsGh9ZO($$in*XSrmiFnXd0l}Tf%;MA{^t=D^G?0 z@l-g-Ha#7Fay^zaGOn!;-@lda{IoUv(RafGkz(NHzwW5Uq@>P9qY{0-tO@_Jkv)U6 z&F9@~+lTeLY6Linv*qp~qi@Jl`5-Oyws87$l1n}FS_g|TJR9|0(?LqQyM z3;u;n;3Z}Cr{Qh;D7Tvqhp#>o4i#hPk?=Qu3^(aAzWp(L`)PXg#p&?3&d`_p&xK!j zC?ZmyvFzc9Zyt$2(OMsgIJK6(+`lej|0epP_-?*-28Gp}9`fz?;ced&UQsjXEDmZ4 z^m*`dcwGx6`DIJ^@;}%MIweam10J|~9~4VFmhVK4CuobsPWZbYMLLO#cl$?-0BNP> zM*vOq0R07kwNZlFRRNN{2k{q`NgklP0a*9A1U*O~%AS-jp8%BQ0eS;~kf$VQBuszq z`TG>8$sVXgAYOB#0t}=(YD={bs3~qJE(7-i)B3bbElD0VAzS!wGTcV~Lr71>EI=%oZ+YQCb?X}CO{ESQVB08g< zvM43Wmw?T7gOTo`yn`$rk)ZCn4rkOK189y1XaoRW%@TBvUVvm1{R*JDT9Dwd84%^O zj$(c7#>lTXMiPgWYM%AU*gn!>;QtyVbF?Id6paG8(Vxql=qNfbm04O3zXiUl^6%UrNk9IsuXc>GuHT zdw^~RV8>SybU_9jmM!fBKsFCh7UJ%#KwKJ@JJK_mud>7b02qrE?-WA336`HSD!<_3*$B!C_CGgsvxB_cE8+7A zCjd%YPF;Tlks`OW$%ya=;H9TsByz_-yyQ2cKrs+IQ1~w>*gYr=K4Vnw|5Y;ZJyn3D zEIb9!9Uh>k0Jz~dnJgGMvF9x;r%ysLV&^xPEMt!-GzJQ1L@Gf{&g*%0o zt7q}>PHhIHj6mWQ@GIl6VjlsMGU6g&oC!b= zEKq8v$j6_FTD?Z(U3QDy&8rtxP*LFEM@}JB&197%?qA0JN)O66fa=XKfxA&&6ZQT& zM%kB_&9sCIPHiW<0&-Paa%?eo8Pw=FjB1=EXZ1K1jX<*1AW)Dp-vcxlfKFW{Xt^pt zvQhs9&;l(;)PFJ{A9hF9-Oh;EvMcKScX{U5pyVPaPkRfZQa)V;(S=%~qE7z=!MX7= zFEy^#D1|tJ7AcF|fF$|v1>~Uw30v;f$kjhNtp^K~yF5Tm01Qc#pq@s6XbqPp0#so- zfbQ0UM7gH}5{*z8?&bdR^QeX|cyp+BmHQ~=gow({t_RV@TB4%d$sl+X5ifYfJq=F@ z^g;qkE0PM}J#Ih}sy_oVI9&48FQsHtl0RlBc6UA)H1E$e!@w;(9>8WRXsYjeSjsY5_2|7MVjuXj#6zPLa7 z^#`LN4-Tz}Uh*IMqUalt4bGKx6A05>N)FCGAiP9NSTM5^WFyDP0=~%`5lIv|Liq!D zpBs=oTy6lQ#R;pDhu_L#1ORlu2PhC*jX#_q(>m_m!D}=Spa--d!OY`;Y@RF|k(_(J zye|5{I$mrh5qY_v*MTT`4oZpK2}B=sBT8+dVTzX$IGq^U=#;ddKO24RSt7Xh`RI?I z=ai>88EU6PfvLU7<)B~?en?ALFw_FF598wbS;AWiMQ1PSVnT$2dv4A2S>kR#7ac?}mY*90k=W%jxN z^dAq>)7Acmy0<_WtWCq}yJ0$1`fk>vwYUu`0jT?w-o4*6n(;;ESu+j=) zD4Agfu+|MogFpr#_ZCaoSp!5b^%^O9y8~3`0a^vXs4@w9MC~B2;{dAn0F?l+;Z6y9 zP%l79g6%y3YVZJk20*_B5|rW%5VZ;^Ug802^Z<9@u<3dlsnmk~~ z0C{AQOzQx#fj9~ z1F$Q4U6c<_0d18~!`o$`*t=Ol;AD6SeM=YWh83=I&E|}`r*ZLAO z(vg+#+~iIk+09roO2Pq-Ls|_w3ehxKucw0>+YLinRij_)>%cLN@)Jd=rfI%Yr_+;w zQIHF9EFhwSvnJOUx8{kAxt&4fjM_n|f-G;f{krRd8ghvgktOzXn-T)tv-Z^oC-(FH;E2r}Y@SO!*WM20x4#K7Y z?}Z-y`re5DtB4_z#Y*H<{rb=zh%SHh6`?h8n7- zw;Q3hP1RGh7&?H!%eOhy#NPIA_Fvd8_t=Y|eRsNo_LV0DC|@U{!=NR;^J@09BpR_P zdumZ>l_P(QEf0$@oX5_-5M^=&ou=OGN9PNSfk>0SQJm!i!15=xEEgmElh1f5|5+oY zYr8?%SLFaY7_g_bFrjUfuJux?)(LHcxfN4QKmI|?&mY9lI=a4^91EzE(dV5HV!r+$ z1{uM3)afp1m=eYM+)AIqu zp|NYrGN`XsI7%xm6aa@EMuqyv4#F8vj9EeB5w<^A&^9dW9r}|}L7NsW_6n-@JzugA zn}LrG@S|!^Nz7hABOmMDEOcEW{o;-C6K$h(3OxkRXyKvm1VDdS*q=kh&_cJHwa|t-5^;1;;7gpORYL$P(1U^;KN5g zd$)1vPkY#S!`_`xT7^C3^zP1Qs+kG8nC{s4yQzJG9(B>3UWUxt=-p4})orG-@O=Y# z7tR0n+eZeI_~UsHn`=e>#(sS{jJSubxRvFli$I;{JGbe+pXk07TQ}!}w!FXM?=F8) z9`kLkCzQrrY5SOnwUw8bmXEfURaRmDD$&BTxb>NVtotDoVfDS=ToSg%V+k&LfRFp=pLt|O2*(x94?ahq#BgWY)&C@RLTw!nP4j~ zv`xk8Z>6o!&bAqw))0TXDnns@f+&DmL0k66PzHzWy!;ns0`cwgtJq%EY4$Sw9;?35Qe21-k6g?O}U>S47TVO3O5%-l*M7Ozj$UrK9y|4t8 zpD)5&U>i9a3T`X2)T8=ZoP1MDFQ?vp`%L1Jy<&;3pLlog>W?X%PS{2vWq%Mk6?}<~F#Oa>P3f?fhx9RMYK=IRsva9;`9W{vl zj_#X6|BV^Q{tjk8#e?Mj? zDLHEn32kxo5o&$-u{XC-t*6G%&CZ_<-~0xDqgiJ#nzzLg(_S9D{YGl+Rp{*_VI)Vp zAow5N^iV%N>jYJMafRKsxU$@ykLP$8g&_vfm#Iw!4*M*GlpcD+oSxd3?)C0`(~~q( z*zyZ)eegfsE2!IenffN0PI;*v?HCohIVkvPs!)4b5eB8j_A+Ze{*>ZRX$7VJXs4ha zRG)c8<)y{8>^|A~$xK$PSo<84uVqEnlFHKJJ1|Ni%j+(Y!eblz!b^WpQ!22duaz#$ z?vn^u5@glLU{e=g%F3MaewQdKW!MpDpKk+6kJEo}+V~nKc>9vl#dKvpzP%Th10yCVDQ$3)w7=%85A5jA%9}bQ7GRX zBYWMJg9nOdV6QaXT`vSW0(%+FYrx6iu+6Jl^i+|R5Opb{;Lyc~>GFFi8MseFELLIB z8Kjm@8^vt=L6KAk{2QOcJo(U%=D6s-St%`$lt9?;(D{Gtu9@*95Yz3|82-5jdUZ-^)kkD7$$zqIUR4B=xkp!P^gKN6{#WIfJYkyi=jmY$3OH$`FR@i=FX)8jmexb zZPKJ$r_R0U)=8sA-a7Z@Nt14wJJ)nifHA7M*vE9IzsV@hi{{pk$eZ3m=)H-z zt{=^+8NoW}x7U}!xzw!aObcVw_WOLOQ~zE3Vm`^6f)W-wW??11)BTv)y>s||Io;&< zudFxk<@Z@2jd3)vs`e1->I2Q057G$e)M^EiWXtIh%RVIYk@Fd1QB+z>^1wIDk*v|C zm;BXsJth2d{41-eYhdgtEv@7sE9idzzYd(HgzXiWiPI@=_)g+ub^oZpsBPlD17a(m z?u}pF`ypz)_KHa?3Br%xGp2y(T5%{?-dJc1rR9t0{=}Om-9&WR{Rs%Ehwo~-PjEdE zr3dsuL``tcPff?BVLxNK9zl@3()9)}KU2D1^$twe8-4w})Ae5d_-YEoAMYUi@d@!$ zWA*JDywX(Pu=IA{2tS{6y0}O0*9XPnTW~!7g!ICn&_qAq zbbVNFycll5?}*e6Q!oVGByQ8^@`KoZ`55xO_Btme_2uudBeB^L*_N%Cap9u>H5a-S zZBoPGVr;@olhR1y0X~q25PDqzRkZPtirsMiCrjz>7Tsx+YbRB`p zBN;jcD*yQp0@XU~Caf9ZV%-pFut^DOoK*=;O3+1>D3QO~Vk)Fgq1MhK=j)rD_9O@) z^-!pK@L{7@(t%}OI{lE#CX)?wV4v%pd&%(lvj+@)`9IEHUYA1;Ffg59^F!)HbS55* z56BMAO?B)2!|-&Iw)eA1mYSru{*CfHakD7XN?}>2CPwAS!2i!m*yodi4^v@2#x)KB zB@tR@k);ZHKfc=XEfcL1F&P|7w`o>LKbaOb)=_G$DXA$QxjVdj5*sLWM=(LCwWSL?s%v@Mz znP4rmOtn>7#!sCz(Sqb1mQnUX%0{{E&MJ)lylpgfRc$8g^oiIWmnAq+BP{!p6Qfb+ z=OicC%n6{A2I~+28Yc@-Z3hsk;Li(?>1lu6;4DXhPgcKV+^(oBEwjL3V?Kn2rNZVY zu;f*iJ1iAN_JT@_)lq3FMz6Qn7D6UmPx(OLOs;%j-++6orcjz;P3~#}|4FSH3bi~_ zokp-!=)VgWr6K|mWX$klOAg)?J8!WH?4|QC`x5m@!A)Yq0u3ceX>f=If!P zm(u5how`@w){#Y8kgNeg5)C9NsGE($|1S%IrrDa2UtOiQz5;qv<_aXYgJ`Se7GSry zWoBhp^%1>w9UyCRC@Zzj?dosu)*aZ*GGgRxUx}$cWkj~}TS08AmKd|$^uk@CBn*fL zNvR|_BZIr*X46BGL?wH$+4~SGzDi|Uq6|mMRZ^Ek&a_U%*!DRt)(o1|k?}&4B5_VO z^hx-i%^vW-dyH7zV1sS{1+Uykf*&!n=->yu1?>i|588%4##WXppIiS#a!GiRC7CH4 zwImDBpOsLm7<_0bzN_-VKzha_Xt4xbDL55$njPab#!2}kAX(4SylSbE_FI1)v(QTO9OhC0tO4nQj)h6|n}Z%`Wi=2g=$D z7J-igK498iz^Idl=>)3D6jv;%~{JNgWIB zf~np~oJw8(1ODLnAN>3ge{$(h9Q~BXYOphsvw;%rd!x2}J8hGmi(HR=fvsxa0fq`2 zQvOjRRTw08Q7Kgz?iGx=z=HpjmfLX_k=5Z`1pDWX@X0)Ev@R9=BpNF&FFsBMEv|x3 z8dh)AZL)8Wup>bP5v7;~mrD}ygBC&P<6OatXrE3I#s{=vEh?hDk8&iUeFh6rOI2`? zj-_VDgRmN?!$5K(PX(MR3kPSj|M^n8>zVARncjF&u>7c&<*s!_)`|J-=O@gFYcUaHxl|``-wl$1q`Z@i zpb88Ud>HE*8RYDltX?&8vP?ad=FaHaUDbVENzCwA&Nik_Se1qF3&3^VW)1PK1dD{! z_V^+yuWZ@NzQoMBpMQ$_buX|QI5bV?VBb@#(IJLRj9J=eQ0X=>gEs&q6Qup>h z3r}7VH9&>f9I|~j$)~w<=g%e6SOJm2qxA@BxWt2U@fO0hBUqM-P?aCag^V; zSu0@H#3LagsrqWH5AT8&go|;sh7G}5%lKn>{Z&~YR_k?LYpovxuOzSbc{=jZobHa&FiuDzMyrzY)Q^+E4SB`8wbMQk&r;;mPI02 zKKg5!_X|M&vO&Jtjko;;W|_JaB+;ZiN|c6zR8p1k zzx66;hWuNTZ7m~y!yBChT^6Futy_-J>Hf#WYUmlglKZz_E(0~?fEKB6uHlG=A|8_) z&IoS9(NB2wb5(`}IxConryTyu=pNOcECTFWp^1 zJ;I!azMhM<1S%+AzIV{0?-14um6`Ud(!Gm6&tx*yOntkgs?4<9-xLtU3)0wC&9SaQ ze5=)949ieGLP2Vqkp#YX8vK<%C zBV(F2mnq2QTasyH1O1_3S+9;{PQBF%M6|~-# zw49J>c>R%og7g7omw>1}2%7pD%0Q`6(rVR7onICWf{Iw4M-9H(Z+QMJtY z>P!=98~sxUrS=<$3>?wX2z&y!sF(D`MXx>a^cv<8hXthyiYT>^;>JqP&>U*Y@>PdWm3D=vrj`{XR|s#7Q6`pTygyZVX~`(f0w9}= zVmS#}oAghH`lCGdB1tzVs)Q{r z(!@6_|IE$1-}YkUGPluLjhtqurjP+NMU+ST@+sAp6& zY8jP`Iz|b_nDK<3(gy|v z-l^-IlSHbve{oTn3L&Ui?*aMo14R;<9p=g7K;9t9qqptsH|I_2l$c^-CWRiz`ah^U zCy3MpamFAY)~L(Vbd=t;zK%q857H#09oEJpA%rAkAI$1qbZf2DhskbNZ3}Su3t?0cE44yephjChqFOIBm)?SnHN&zG|*mw}I*w#Gqngm1`wh z+P8wXm!v(RC#MayL1a|RYtn|SgAti(9il&Raves*2_R+?#EjsuE^vZv5U6=Mm(Ds%Yt%`SM)UDbY-B^&%r{z|!kvRAd*LCSm z0$m?Lm!xsXx(`m#&q`>|`8deIl~5h4N6#Y2H>n7JBbkk({~@U?B;_lT`hQh?zL=pZ z)d-m*CZ$60F`G`%B!X##@Jv#;>O<-e{p+Xz-Gp0Acfb>O#g_^N8~kXp!E=MWPXK25 zjkz?%qzMkaKqJzqL4)VfJ%{zKMHsys-KLZD!q@Z0_oNrdwhX_^ti0`ij$$Wk!GOx* zt=6hvMY9KUUMvoy-X+{M6h7r-I+Uv~(zHiS@sZVP#LrYBjsLClpVTX_JS}*w9`EI$ zXWfhPzAMITzV->n8>w&83ZK&q#G0baA<;evx*5+%+9!JnPkVZgtbkB$mED4JovVd# zO`hDHnq-cd{1D;ktusOK!a6~<9yGP`qZ%~d6Ey2P(u~#8q$ZRq*k<)xuUF=8kU2d? zIn`2K0;+o?Rnsaz(@`H9py#hTUO-YKam0{0i)W?Got?zpz*xH6M*4}Dbpy7$cio9b z#rBMlETGScOTO1G`D$#WD?KKPOOfjPB2``#5?AT~gLN>-z4DgGZiCqNDB1cbU>~@_ z>bt6^Ox8~USoF34HFf~OJfiIF2wJ7Ht^r`wy8_hI0rVI^A9e(dG+J{3n6z7fR(1d_ z2k0X$h%@Sl$+`%T{d*;&NV?N!$x^?~kNT1IP0eDmr`Cf}D?svNEy)h;pW2do7VZOl zU4W*r%$vZqYCxUthi9wbqh4xrpqGkQN!frUg}+GM7mlwQn(OnxQ}CmQ_!c_0&MrHg)qY%%M)6`=y zOR`p0q*56b>6H*a2@PQRr-J3`$R3Qf%pJWe=m{IhHVtdxx#H%b ztVD(XQku(G-iU6lvy4_l?;P&M2U_*D zNNcv>& z1v?HQ_QGQ$&dOZc9NqnZ<1(CK{L~ljufDwH^43ef{-3YgIAkw~H=QUnGgi@ZIC?=)MzEsO_v%F7 z_nSJK!ADdm7e)xvjS77dHFrQ;q0EcE7DPmS`XuHMMearKG!4q_D^-bjChLc!K=7t; z;`@ZjPGzp!j=-9Dz=n(p&E`j+E_Jg@a5lC-|HHVB|nC|fshvn z8NpkvORGsoHkefBT5%eFGO5mg_NS+_!==ugf}i#BhXp@ia^o-d(mv^lAEa+R6uX=+ zMX)6fI{SyeOtQmCri+$Lr1lA!SutajC>l7NC~ia4YVRa+=>%2+iS@!TEKJA&P=&{p zkZ;;rd?mVhEcLA4r*VHWB2L)_V~+;@$7%h^X2V#Y(3f6jxI_d>b_IVMhf> zAtYCG41OvOKSw*lq8Y8(jV>NZZ0Y&bS}c@CAaOCQd@& zkb}`?2#rPv8L?9568gj{`ULJaDsSUb59ru%58W+??sL~eZBCv+P7ceQ49zM&cz9Xo zzIby^BKO-^%>6qS3vZ6a@@$;NQx_HImO2)5?~SB*vVOc1Ir>rvVY4fGI|p@WoaD)= zSr!z2=%&d5rc8g+avz<4eGX7)!{gcZE&47$y4%Q95RacknA+)0%xpT!|94vbm}j$< zrC1&05X!p6eP6#dfGXXZO9OIVU)Wr@g!(G zn_J;c_A!mbh=UieV?Tw?^~5Lpy0Il4E9}EFC@dK&Y>i8?c1aeR)eswYjxI4#W4#4z z7|FQ+Hn_A#jS@-h10STcCY>cU&y|q1BH5t4lWO3ak9s80!!r8`8p;vTP{bsz5z{Q5 z7^$J^$waq)CpHRLPk?HFY>Z+J5!C?466D^gd43AI&4O;@^$P1|QX&4xNf8Mo>qJog z#7RB9BlUft{+Xc8i1UT^u$63;Cc|{9pM&+~;h7VVU;JY8kN~S^Zp_ zRpv?L%4kRaiVYK18?w0q7bn~=PPnp2A$A00kGhfNHYK?hOMS|H9xJ+o^;r<@jD1p^ z@Q%a|gquP53qiQfvqd+V)?nhDmA@|W(|F2DyuE^3Q}G>JsN8H0Fh($QZOEYMwbU}> zD=KK|fx^~!yxYhJ5^^UIV_q~6%om#vfz)0!<197&>-b_@?ZXX9GcH!TMvvM!hSGg0 zN~fN@&WeZWl-{%kR<5l4caD7Y3FW$i&O+p8)?k-r*1WGj@b20Z_w6MZJuOriD~_DA z@EH)fm|?{Q9%rS6SfQ=Jd#=Why$sgo41@CdNRhu9%u%)LtzRK`$DEa#b;ln^Zg`l4 zWF9}*5z8c%bn2Z2XSNjS)BoDxtzwvJ0vl zjtYncTZx7F(ORrkm8Auxc~uqc8xme*VOfOpBIz6u;P}4;+k6}qTd z;(z(R_zBkxfW;5aV*VR0iuv{mVnse&8TtRT6{VyUGfO+>Z8l4hJs(>oEI2gJhQ+I5 zc!`kTB=%BP!h5n9ev9yk5C7S$#SSzR(QN2JX*sWB ztk2<4TN`en0&TR7rkKp;mihJyJDsQv8J1Nv(6nhcjT%Ljm1RTv^jWZALF$6E)Y9_8 zKK;_u)B7xR*h}U)D|)%!`dubY;TkJyx&b0vYi;@l75cTTXR)xRR(V?|0kBGf$bnD` z`WB#XI)aQw>n;E;Nl;S<&~bpil^~CO!(4IgCHhIh_vk6zay>zc z9hThE{6!Yp0&XcnZCZ$-++~!Dg-UxRS_+mJsIyzFm)nWe-!AJxxxd!a4Qx8$RtJ1qH?791s?hYf5ngwR(w zd|1ltd92Yq93$mRoZ3?YK%U_?kza!sPI4 zAwz~Gzo5ioE4J7z^K$b+pnRU?PD^>21^uDCGS5<8mAlA-25BuWv!Hu8;452ZEx~DB z<)x4!6;-*o$}E-kVw9xl!-(KlFKRI<9MLuqcK!L}lbUO7rI3 zS%vmtu@`_PHVZb;mBKKt`*u?BF=~JZaiLLLtR;3dWiZQLPAx0XVK0LvzQ~eSRSr=> zB9UZhMIMsEBQ($69Ek<_tN9CICdS zwE|7sj(u1qg(>_cmJYCQMCR*tA>~rEdFXdKjfx@0hmK%6e z<h@UE_m=0-GGqxBQ|pT!U`t-+#PoxYLzYv3u?j&4-#xT>OY2S3hj1)+$^p#55NmdSVR}+dV<+OG&R5 z>Z(>bX$7Sdf|8iOxJZ%uMx^8_mGuJ1^vV-is{<+RP}T-gCuOGmO~y_+RMWc7x3Eoz z+@?rtVvlFNz$T-@^`KV0s;~3h8pGblBz0GKE%+v~#tjs2;XK1ZIAxACEn3idqTk&K zq_9_&-=9*l}A!VP)vaHnB)&Aps zWZ{Q(2V2SMV-^Amq$X#l%#F{UJsZDiFxLMP{vyewxpU#Mgx?qEy?=!N&conb8-eD?vs>Wb_F*7vceJlJvbqyPwhX@p9}gwN&4jZb=s%v zSJcI!Ba~FIWgg@e)2){?R@_b8-~%4HQsF)YP5GlTJdRqX3&7m<8K~E_FFTRF(h0&N zqq*M>qxsH82Hvze(M(-{b8VV4O=j2fQv+#Mxqxxh^(+&+0gUFgFB#3c8tR>+{#_76 z)>BSnBpZ+^e?&w7Smj=tigFsxXG8)t?)yWBKhpQIrmNb;XdU0EDtF=fhqjgje*G-@ z1^3~*HqEFbvu<{7B4Yq4GmD{>B_&!G$75*GCDwcPzXr8m?*@pa294NpbwlEZddl75 zgzutItWlq;O1FI?cXi^dYS~B^A#cBkywz#UVdn8{b0x@L_oMS@RyZ3LlJRUzZA~4k zr9EXY-c20lGdu7Wr@NOFVmG)L8Zxa*52#A&K{u|U>`rUbUC7xP$u;vzH|a;6XVc`( z?Brg)mT${vfeyAGt$&7i;aqwYzG<9k!lEQ)7c;cAo1~$QSOQ-L?9=B4bZag$_wHvM zh0Cthp-(;&iuEi-o+#2ixx*6e-N^c{BI_b$mjRAuJS(-G4it;rpVTeSW|P4y;brvC2R{hg^gtYu~J zb0Pyb(09e$w}fPK9*j=x#)?h}gNYm^Qfs<^;2vaJ{<(A|NncD#;08=*FB2ROdWFOl z&;$4&&$nqGeAs4ql|(Ey#22 zCzC#uUxn3tNSE51Opo}e4aw@NWcBIf26b(+x-nUOK3RP!S>2Yb?nqYOOjdU#tM4Ui zgxqyjG1R@unjwC<(Yg(%vwSa4XyL|3?O5A@mT}&#rNL2sy0_JEURC08u_jg1VSsJ~ z=z3@x`hW=ctZdLmlpGT_vT7cnvc1 z0oGbEG143aR{dw_#XqStJ^y#;FMrdQH>$(#U&2lg(Pt=qS@yZZytdR$D8NNo0MDUd zSP!&*WNy#eichEu6_+~OpVHK*>MXj!4Y_2gr<_xfQQRgtaW|o~O<3}2!tw{-rP@Ja zlh+ju-?fuZ45q=wRqC6_?gEZz+&OtjBIeR;eN|^vzBHipZhGQV4}=|jIE?&(L}X}g zDAkTaaA{LmG!sgh4PD$O&lgkJ;%vC(x(q*$jF;LoO9mMmlf(KSSf z1z?Q^EmsgyL2!I9%F%hHGve8{r^0rx3!@bd%#5S>edJcDekN?~I$o0^6aC_l32o_C zBNHt$6CPn&NUZ&_<Oe!KTzqh z+Yn+7G57D$b#de|W1yw?;BK!v@5HiwU)-<4LY`bqo3UZ9cvkL}jSt*K!-TEaUI{-; zxER7k<{tdf5Ae|~o^%h5DWr>!fjccC4CKR|%VtJl&0}oyD-jEz!i*IV8&vty5;K%j zvlZT7WH5ps*L<6!w2bUucm-ZxcElR64e=#QYz2(fh4#v#s@zm)Uw!6R+3u*IzbODQ zqG$%zINht0g11uo8*$Antun*RXoe$m2`p4B3-BA$ra~iKs_z8rJe!&J$C)cj&E#}u zM$TZ)6A`t{^p<%+k&Uorj?zU$j56+eCDnJT&4%}g1Z-+%xUb1fvz#&mdtnvKn|(M5 zDq|{{i;>UZrDpsk0Z5-{3$`jEM9uK%p&MeNhdKi>D$#v)2%6W{dPQxF>tXOZf(!mC zsy8Ass))#F9MFakj9xqhBO_u8Y!2z#zA-7@5QMNh|9}Z;4)tc3unzG;5R8xI2Y=oe z?5m6#;oH$0tF!5ZjYJfEjA0pY>Zw-Lurjtk)w!eznGY+(vnX4eY`&PIM8v*6n8Z-_ z-Pw01!YMU%ad!EL?2@G95lPwiWZ$FEHpmsn+R|u$=&Y2~-pM28#NT~SV$$MS*|QNz zDx29Eoboc$+ShDUuHj<+Ia8bpBh{+U{!l0)4&37+T$tOEr8!0Gwk>Kw`Oo zR$E}~XLf!TG^FFo0p}rKNfApNe33}53b+<5I&g|DB4G)GF<#N#mQ^|MJO3l&z;g1r zNt}hhaS20*XZIO4J2?p*jBXA~qQ4`C#Nlz=?A}Rn$%_;4H344}k{1iiu%W|q07*(3 zK~-6qb@%Y%roaM87wGvZF!-g+P9Cy2WATv1J(99#&6{;0<*{OX~(&zFUGzxuj`o~i0sg67}%@>*v2hIwE6PcApVR!#Sxr=LcmFbk5N1KGZY2R&4 z*1#K9;fP4wD#WcWUX<@q-sihh9(vKb(Tz}>UV=j$_9^=P_ioBYFD%&Mu439{RF`)* zO<+7KkGg#`Bhw@OM$RK=B%Y%`P zbRqBfv_Y#QZ9(1sDdjw>H?Y2j#VVVVv3SmW_%IAXMyT2!(siz-X((a01b$N};@4E+#UiBF=bOyJ2c z7BKAm6p9R-I0Pm@6qlv{_iMx6V$C|cJi7!VD)A<@sBSRvW|ld-AiI)1NT&Pxwl48B zkbwhIt}q(S1EXrFTywEbS-EH~qw&rTUjyUs!eU2B#gK_p5yFwmHa01c*=XjlJIKGs zlt4}CW?G}Q6JBQutxK$R8+T#$s7D05dUZm#`lgk-oZ8$(#PzIX06off ztF54N5uow_SUeJ^Dt4SBl_a52 zWhaps9yWaO9O)T}HiL#n??Ld6z{BiBR__JV#}t!=!iBuCH=2Z^E6Q4UW_eFbHqoaL z#Sn^f;~^tKfaE*cLWi4+vu7nRK|dm4HonI(`9C6#zN2pFzmAC6NxkDeT`oz^q^6ht zMQQ|Akd>T)lpWlhvddgZH?i2R@TtOHQx2ITsouwjuX>o|2iA7;Z1_JXgB}1C_tc{C zB#$w*R&s9TH-r60MLc?nB#;Aa&KXa4DKO>f9z%+V2%@$WVJ$<+nMhASKB1<|2yU)-ser{XeaJ3z$t+`1g9>Ju@zQT*h&kb8;JoW!x{Rs40q~D1;(v+{txD zXbKHu3|7irD%Xr#h%^-`=l?w4%=0_@x88Mo z*LAP8_S$P7Yb3GPFMP_r+|nHh#}u{8fWPa0dyVMXUY5&njXCkJ;7jD$ZnfL;$8M5E znY$%h`uEF-IrT4>5<}|&fBzww)B~9$5qvyw>fO@fa3;#=2@u8<{-?J)_pR$J*&>xy z>i3Pm&&!knr1d63@R)P|_KFxv*Em&OlF%)b)z*8Has#D#SnnZ=nDg)+dFUCHcR!RE zQXp~51W-KB%Kafb61NCp7b>ODvD4wFR&cy|$U=Lf?adfbhHH$i0eg4%JRsdwJ8Y4V z7f2;@rrtfdmy{A@-XzMm4$R4XKGAIch@w@B$G|$5%&ua)|lw4h}I7txErUSHS)vS9SWs zRWVe;4$^UUTbcxM#jXH3$sF?~Z{Y6Dm%c+xe@Q8e+cX&gM0aZ5=^WV1^+V}q?c_mk zvVAUUkK^cq7rn4ELKZFS;l>K@DA8|e@GTM=Zmn{vos!#k&69nQ-*)P}xo&Zk*aeCAxoak+rq&E8fh{UnP<*JnwUEbQ6f32&=FVBW zNnd&_3u^S|-h99|dx^Rar&_8Rl-BN?dxJu45y=U7pMSdSTw>-@PfM;qJ0l|3R^ z?$)6Ob0WIIL|*5zPD2mH&*IT{cdVaXx!AdEZQ_q>y)UYT=A)_Jmw=>N%K%s2{Vzhb zCh7C=H&Cva+u1*Z)^+6H%_wB6=G2Z?U)PHdFF-6z6N@X}tdN%Jo!o~vE9{cP?+{%M zHz8^78RzSWt3LhVb^l!n?@HZ$9l(yaVS{DQ6LxuFQ`sPFy25@e*{3!@Ht`J_fgfyH z8rrbmgnrnf*&oBw;jofDOatU`h-}@$<}vJX!j*ub&akcD%}MtFO|hK(90TV4B)lN00{hKCH;J~w2X ztRdlH4313uwPcB-vFOBZu!nkIbF5213cFALiIP|)Ih@IuD=O^l6+@Ur(%MCAA`wS`*W(BrPK8licUgiG3#hLz?z4cWDw=)MC%pxpC^kytq&` zYnc?<-y=gl+3|8U3f8`p0W-cN^ORw`DglH0G?#N;O>6t*0SE;M}PEKY$_*uPPAY*1bn(lI!e zjCHJWn01_qaaflyu`#Smnz&fjrA&!9)}>9!60GA*sgkVAn9`+Kmo;u_*5ypR%euTN z6VE!qlr6)$f+<&)wa=6<$GW0PD9^fzsgS_hZ+sQ_h^gq~!=_S2K4dCaVqMczsmwab zBvxTv%lH#n*ERt^e_*Z(u&!&WUd39QYE@a+Gu5lHPBAsAvup|w~7OV%GmRIv$b4^RuL(H|; z@E&vBwXBDlR@bq9(6nyFZ=35|^KNs)^{j`R)EhW(&fJ*FfwShO8#(ZeX>$|n5vFY$ z4t#BHZp(o}bIZ-FN1ArGupVRDw_}}dZf(yx!`yZ&2hNxdw{hSr)3F2V3Fh{WtRFUa z+|D}Fbh?A}Bc^jF){mMyJF}i>?z)rpB-7E@oEtaHu1_pqK}dfm%^_^(=E=Z`Q{2xsUbZrf(nCv(5c|SwCSO zxS#ctChY;%b4jW)88VplVl#9I>!-}H zp{$pf2ZynK+6;e?^)qI~aMsV7kt0|yHKRtdUS>v*V!hmq8O?fyNgu<3(senBblt%m`5LBz1B>8l=V6@ zX(HzJ zJo7Z`qvqLXIB?V~eU<|snPp2^e{7a7WBrL)v7Gg%X5|Xj$IPmgtUou;tzv!3tbUFI zhfUsU#@B7uc&8Cg4zcHIP zvHs4yu$lGuX3Gn#&zr4VSpQ&N+{*e#v+YIJ7tBlBSpRJDUt;}>c{!i;Mf1wbtS^~Y zUt#^L+5Rf)-^`Bf9C+RA+`;;H^V&|SYI}~-emo^ zd21KzpxONvE3L@9y&G2|v*&GGnap0CZ=fAA@9f1jj?B9_H9(gjvkxZ+=#pgK+lOl@ zGVi~KYiTn3-^aBgnFITAtwiSF0bDDS`QRX~RmdE|H|cdEnZx+Zybh2#f)B^*tH^wa zFTv}oWIp;3*J@;reuQgvG9Tl!?79Y-Pd>)ACYet^!8M7@F?ytV8C9Vy~oH~hXLo%mN;o6wYSEq4pLgvg@ zxHctIcm~&IWWFxMwK)XlvdI{G%$lw!6ftStizi}Yn6k$lCyOH^$hyyQ~KmXvsHuKk?9C*=O{)+=!&EJvUYQsI4Qx;*mSRBGD-(wSHzK*4 z@U2Y3;pa+s2Q5h@gx&*Mib@K-7qm2$650#YrPA=fMwxhgMgp?lkd>i$q4$B7r7}YM zf|jGQLhlDHPvwL@0GdGM;r}^hDo}#R(jfCu1)=>wE0Pb^E0w`Z(jprGS!JpubRcLI zsw@-}D3eH4gboJvQ=-rzpaJp=9SV9C1%wU*tx8u3eGs%7RTVlMv^rH2Is&u?PFw;V z30jkC2pt8QL^Xwu2CYR&LdSsCrdmSNL6fPr&xJTE3zJGWAgE`Qxsg&uhBuzgO?0DByjE@6 z&`m;@gSMqMLf3=dOl^g30KJ877WzDBJGw>aM$q=uPUvRPTdBR!7eH^LTZL``?LfB) z-3r=~ItYCc^mghfbQ|a$bi2@(Ks(VLLi0g8QzvM@K=f=&PVz=q{n# zLAz2Hp*ujkQCFcmLGPw+LSF;zPIn6}0PR8Dg}x5jlX?h!1N0v1DfCUyd+8pbyFh!< zy+Ypt?M=Oe?gqV&dJEkP+K28F`VMGc>Lc`B(EF*cP`o>89-#Y?hS|!b(E}ilE7OnC zKxQe^pZbB!RAvD67w2EV`9K;V^h?k|G*BoOH_TufB(w;02n`nc2k1~5BJ@wtVKh|e zU!V`tFrk-0htq>X{{|gF!-WPxN74wPn3u=V&r0 zU1%)mSjrF@2l^0=6H+2YrMxg_Z$* zlpYaU7IY##DzqHvB$_C+0_bF#Boup>%wseenKxCLEP7026(O5KS)hT(g33&#DMBZM zX46!0kO&9UC|jhDLYhO24jOm_Q9MDjg=T_2Nl%D_`fxCZo)p>ubS}*i+7NUe_9}xm0-aCu zgf<3UK=Xw*0bNK7gf<0TL<@yB16@pugf<6#iWUoP0lI{q5_&c0)3iirOVDTNX`whq z&pb=d2)!0`DLpInI?!dbRA?*E<+My_YtR+6T^m*DKv?J(7dS2-5 zpqpr;&^tgk(tto#r5zx3ly4vD`fA#H zR8!T_4b-&vDM{5isB-sHEfsG=4P`R&w8fa<0jiC-(u3txU^FsWvUqf`4j#c}1P_u{ z;q?Cxjft%E)%arY9`qLO zMYXyiz6*LWc!qj;w!T6yfpB#ZC2^mX#;b=jf_>4a{Fev3K^JNr;^F>c4{7Lm{>#HR zS9s`G>|uZs=c4*q!nznNytIBrgRCR31zrpeQTp0Yz}e?$*cC1xyu#%O)YdrVzou_E z;BQGDeiR2h`U>aiVFi#Q-x1dKBvZ4$r*YPg*9Ax-$E*G561;|fo*qVDT0ysx5?h1s z!~}yV(f6;cwm;A#UZlPsk$BXM+@ENoN>PE4=!Y)QPPD+*BZEKFB>4Xs)n5(rdYZ=~ zHNdNLztEIWI2RGlXlXMD3|zXjqbP+j%a>od)wTeiIIE!#s?4fpk#G%qu;$ zCF#u1MX8d9dyl`PT0K&Q1H_0Z65v|gj{FU+RuO+<_KM~MT91&xb7S~u`*sun*6EAk#>lBBc}zbCPJZR$rjeFwTm-+L?bKI_!qGwezNd>_-` z8T#G?-AmQ`J9}M;Iem)dp0mi|6w%5OkKk_o{KFmD%{o)jVtaKmc!`kXF z<*Uwml=9VJJ^H_zMos=y>2dyXYIR?QUr7dT{z-fs75I)QNiF^yl2%cY+WZA1I!cnv zCm}%%GXh5Mk=hpu#wg&L$Y96pB6SGadbAD*E< ztPuE6O^+pgyn_BrC11mFB%NAEWZyMhGSvAK4&bB;i_)w^4Yv>9VB1z@(m! zAiXCN5bUDHBt?O2Ovcv*ZMbI;0=_R86>ddR&q=ruDZ+gX>o2xA?Cn3%<30@J$D=Tj z!OIk?&zE68NaE)KR?|wt1L9hw zPpTG2f~lNr{rFGXBFepy>ypIj5+7=jRF#|gs5SU*@#@C#gK*h|0tb|@U6iC51@2_nff%xDUBM2!NTt6{^TDd>;WD~?s;KpJed6b zh4tg1f8r-Y5=C&)c1>>-{*?w7*G@jUWd+wr`B{11pMju(+XP1po} zirmA(9_FXXJtQoXpC$JLVUO@Kat{c5lvj|uU)V%mMeh5;Ch=-=-xD^O*O0qU*kino z+;@d#@dk3=5jKT4lDk*fRNhSP9%0$Mh1|D=P2(5I-7PGKUn2J{Vbd8Wu!bhDuTtQR zDmU8R0uzxU^bb2o7sl(eSP0>di*GBhkv^w#XYlLNg3)Ezd+5&?Yp`c~!6 z#F!;T{}iwP^e?b(gSJMaW7gpYZ~Ik+og*@TaK#(B8+*|DsSp(`87eB3!~y8N⪼gBgF?@(=Zmg)ST`=^( z$qUef$k0}oBbB`nYGB5%@!;Al;?EF^P5@oZp9_T-^Aw*D3ZG^Pe<8Fi=+peAQ1s2_ z89phr421@VxW68xPZ61qXl7j&h+R_%g&)>})xohBJs)AS%`3 z5=KlXLm{l>uMkZrWtWh$)8uau&gzPMCgf}tSj3rR0On^AEuP~-FZlCxHcGsjzZT^% zl|amc`CBOG@zMN!gy-=O5x$0hit@gezwtsH#XloI*6~@%4?l8uJ!77N+^qw?fiW2Y z$30-$^ZYB-!OR+gG)2VH;TNEa{1#Z*+3YZ%FI;u!W;EOIwa%qWmjKqpzNhnsi<+(Oik-f-eSfzS0TlxrR8)Lmw<^^a7YdC>b z?n~@rG!ckQKA%HI!qv-+wa$>MJg$rdt5;A+w)MQqvdX!gzw?Y8Sk^RmpxCT!JC?=F zoqXOi-pbWsd<_L@Z40<2OHy|tsjqV_i8dqX?i5|#;M#~0;|G0xR37g@E@B<@igCI( zwS`Mt65arCCt-<9YO3!|T#@$NU7RApj|%#)SFJ~3ri*paK~g9&3TvVNivaPo)CRbl z8+!p_1&e=_^hl^!HVuV}rPBX7RNtOZNPD?ONHvtgsNg${p<*ZyES%a@Ay;-u)9A|A zad>9py}h9`qdJ&g>0(UXt6{alVt?ZNfg|F6_Q2?0W9TuD#)Z&fVGFBC-?Q zlU+MR_=4|cceBX8t&v=%H!+4I1JmWkbY1`S_pues47@F63%gWP7 zBPY;CBI9vKjX{3&KwtJPXP{TnJyCAo@z_wT{@&z8`4DQS$ItS3#P>b_5svR+8($te zo#-j`f0oK4h^r6cI?ofM`b~GOvVGyCP@n1Mh0W4otVWCefgke}a-Z|m$zqS4<*7FI zRdDnpPYXF(={d?_*Rr#mYaOk?`r1!C6U*$_;fZ>D0oqK#RUXS@Xg0N+b5*@_VMSKRfy%xY07_>6a61(U_FGLB+o z$vPBNS!ajM%1t)Uu;`v!&e<6%fhArEyvD9&<(=12Z4w-UUo`s)4(@N#ZgD!$jKEV^ z>2ltRZbYlRMzcHIh*m_*w(hvgB4$VGlKX7L9AnK-N6fL-{8ZR1jc_s2ycp{uavy^V z7~n5P!+eJWi&Sn!XP+bhL9UbWLnY@ub{7e&?BEtNd=0AXK@KeRw^XaIL$-K}H(n-s zOUww+R|QHT3r(WKNUn5Ik=2$%7^wK2BVHz9gNFkrk|9?)A0mIM;)5R6Sk1vb#Ev2` z1IexKd=mCh!-@4=>?Pa>Oid@wGoIz+FeW)AJYy~Ab6epTpjp;-z6kmDBQV63?0m`Y z0%3KWQ`XshIIHV?6&kX6V=!22=L`k|^_;J*PASgWC{umsTbS$`2V6FAzK=3Bbbg33 zHFAE6GBtM4Lq+^GaV|!gn&Op&V!LL}?@^}a&L2^x7S3N$rmLO5qf9LwG}UR>IP73t znJ(i>ltpL^DZ_flK|g3^R{PYD3WGc!R)slCNvHq=RiGPHC?+3K)$O{^th$Nw&)6-r&TGdsLiIR-^}09ki^7 z=|-oVqwGV@dBFrHFh}_sIB9cK?oE!*DJfyNbG(QuBBC~q>qT@6SB9~z6CaK@5yqRH zGM*9pLLHTRi&HfewQ1*+6`S;6d#4({CIM}rdmh)Y%07uYajTOQO4eMly3MKOxK9e} z;3Qi|PlQIVsP&kN(+2V6?6BW6%TpLsb7i?cMESdzc#jx9!Vf z`yt^-_Rt73I&3#zY>!Y=CzR9SSq?h6+nwgNvycw&4hNg9CHrj_&ktVn|8U>Qxh~56 z6T#M3#O{sSG1*7wi$}Z*jia)=IyXBq@5bCeyPI>1*;i~MQBjY_c(Wi9L@3^b#mO9o})XhqZx2?uhYe=4A|=9RPd@)Z>OuZ z&kcr0r}ugJWJmXRJAvt8d7mhG4=0clmiLX4-vgZwB3bu4_T4Cr6^rZ#oZgNM3=ZKI zm*%-e`5h;T2RV*M$Y`~AsO&vL2KV)YO>~#r*9lBhKAeUba(SE{@WSy8z!lSV`>=Uh za8yuydVTqE5lYSXvPV0QTK-ui zAWxYq0-A_`uqtEH9Um%)##8$23}>=c0IM-Os#Ar6uKaYwAEj89`va_5gt=safvZpw6ESIH*sm|O`zc^J| zNwzc3wt^`^HEo)+K<+!CRTS5F1CNFFo`X@vjELE`Zg)!9Ecb^jw6Yv$aVY5J5_Gcj z6nbXt(gL6EJPnR*THv|Pvo^{}@G`?$7V?rMR+XLQa0UzTJDin{`--rc_=J-?UDzxq z&p{6jc9hmSZjLbHtVchEei{4_J@2?L3;U2ZIcoT?(CY<9%#S-;ZKM!DR;H=Stv_f?2$tO^^m1&ol3~k0K&jS#?vUF z6pW3Edzp2JQ}Pz&Ej>$%QNaz)8F2J*zUOhpeuyEX(bJ3!e(g!IJ!hkH7F_yP)Cci3 zMAqU)1;2GvoAluKkV%LL8K(1|DXQ1|0Xp3BpE_*zLbE#j1paRwe)gnRhl}8%1L|Uw z4!_!1e}_zT*kVmM`&vvq?xmu*ISH3=EE7(1!p%fJb{1E$i;6AZM#XmGl4%vv zRP6p%ZWg}8n?-SnA=DK&G3Do|68MakoTs!+ap|nA4r*@Jb#7KxFMK48ORmW32)m~K ztSsS9d={`maoIQVP35f6bw$=b71OY(Kdt!~71xO?r&VYQ|A@Ewn<~C3bP!z-e$4)1 z_A2_tzK!r~e3>e)JoKoVhO?aDrXsE|&zHEoI3ykqh$p_Og!%sg$eWl>afxY_+u*%h zcvc>=*xS)Grc_=uoSTN|(F>&&q10tzH!*&%At#v+kSLKz`K~f7U+a zKCOA$zw={%iA0GT=?awr;+426hSDVEj=Xjowozj%gzP$@ZXkTG4%o6ODR~ov^rs!{ zsKy>_r3J9BJGOb#8a8dBZ@508Zl%F~zO7@N=+(8*)#ewP|H5MMUSy2*B{K2z@Bgq=LJNl}VM%Ny z;5!Bfr+U7`j05+ro#!GBW;v);{vBu#)==EXTC=b?tDB?bo5}L;#pqbSV(+EQi(g!M zv577cv)IO3e_?spy_YgCcF`*)61L|uoO037OTG9E$0MP7?nEC?CrOW_NObn3Uh0H< zt|bJ~ECyzLiuDVZmghIDwd9u^`zycURC#fRLl&3eTIt0Tc1Q3bHeQK_-4)ki zsm0+?!kS4P@!}3^7!KRJ7U!X-XV|}#OIR`6+DISLd47l8Gp+aN%(08RiGfFc1bsTSZS#v}l84^E6}57ya*mtG+KfMGz62nyh~ z5SR-=LhUN}ON`kBz8$DmJ29pakOSlayCB;KYz5yA>;npcBA`?<{3j#8Y9MulGy`c5 z^Z*6{nLtjmXmc2090OKDQUII+KP*?^oB-wvR`1JTvGIv9Wq?XR5|9Ek16l!XfsQ~A zpf4~CNCz^39AGZ61jqxn0tL9kL+|*h_&o-5p*3FsD*~vD*p?}i7~?N91xJ?Hp0keUH6(q7euuVWdPyieT z3V|Y^ln+W&@*!%V4$ufl1v&yffPTOvakLa9&nMyKgB1V=fOEhFpa`IfQr=}MB0!)T zPzN{%y^4TR8W{<+hpaQu1L#{30S^Odq(NH2wk^;R=nC`_;UJK7xX1*S0C~V{$ntSL z3Ty&DkLxa6j{&ju;1L)HOaWpmp*aDafk{9fun#x~#8yVkKuaJMXkQr-b_MAL^aF+g z=|CnhMJ#8_&k~qc0$YJozy-jM9;_MA0~iF%2G#?+fTO@Uz@G?JfE1t^a1`oY04N2e zpCWnJ2rLz71>3H`NFWDT0`!AC2UrN?0h@q)0qhEZJ-`9rC~yKO1dhSJ5I7HB1jPDL zK0qa)8c+vl1hfQFf%ZUWpa;+o7zxDIhju_UAQR>(z)WB+umo5M)CnM*0J5ePNLwMD zL3#jvfkD7XU>qp3xTCT92MT~azyaVWZ~`a2MT~azyaVWZ~`a<&I6Z#%Rp>Z z#0*pdssSlLGoTgF7U&3ct%_*-%Fi&E(t$yeYq;hBvw?-cr225M6eJJW1k8n_O+Y^Q zF7bUpevZLZ0BIp`N(AR2xCC6TD))&})le?gAg%^dr<#bG+26J>cLcfuy?{&bU#S5U zZUD!r4J7XdiNAE%WeUjwnGGximI8S|FL6A~I?jaOO%UY+1;8HQ0B{)cV?bd8t4>3B zNNNZr8cGaZ#ds91P5_0#I9TNX`M`OYF9B2?Sqk`pLdg3zLQ1N`W3%dVe`pJF$Lh1d z`hpDtMgrr2Nk9%T8(0V|1@eGRKt50)f$Rf03>*Va0q1}VVsRNHwg#dGDgo7iIzTg^ z70@2&3iJX70V9ENz$CdgM$EX*t|9GpDOet`sRn{Ake_3)Ki3#!AH;`&Vdh+6}DUq}D_ EAJ=Q@Q2+n{ literal 0 HcmV?d00001 diff --git a/Covance_UCO3001/browser_profile_1/Default/Code Cache/js/d69123c49689f336_0 b/Covance_UCO3001/browser_profile_1/Default/Code Cache/js/d69123c49689f336_0 new file mode 100644 index 0000000000000000000000000000000000000000..2273d4d00eec98cce9deadc564571f81235a574f GIT binary patch literal 19480 zcmY-1cXU+M8}9LMGCkCUObSQ~BxEKtlWFNQ3BC6&s5C{8qKI^C2q?YxDjrnK)NEmSG~{gu66&oto2!E=A6CX{qA?4WF}|M;CfX%E?97~;tZFs=-l{eHRec%0oXpIesx`B{{;X;~UzKV#YE;PydaGw;_<~hx zQ(&)#W)aKc*g%?{qNtilW7tE+s2Duk1k8UNZ2hijc{6QO5(OmwZO?D zP_!uAl0S>Xp^~sU2)|~7HCKJ*WJq~dhmtj*OJi8k1WGrBw(^TqYX&_esX1gwZF#Si z`pVwc@b%jovj@D>6YfZ{-eB*iSp5}i0AvkWzZdk~11=O6RfATLz7TujIve#hU~_u7;R3;QA5P`~+KN!CF|n zQMqk~jj~Vjwm==R{0a$jL@r6Q?XY799G7uBVV)G<1$FnR4r2cel4Yv=z8B8Qlzs4x z#O+t@55qEf=LqzXYr-+rUgk>hIMk5;q}U1gOvcKbldA1mF#Q2r&O_7%C?&_`sgx z&Mn1|xwm1ZbiD%u{ubhx8k{1<0eK8k`AWpuL@gy%8MAiXc8af;uu<&PtgaJ(npmEkA<&RU;Tz zErRydBS@$b!CN&o5AoNI;E=@CjbNB`sTaYD`Vo|F5P?&6H&mXDBN!|rWP9@nY%L?` zFTpJk4Q#1Rs7K!MX(zv|JRy*1Zu}_D9g~e@;cP`E&%H zGZF0jBZ3m=BltqPn<80bj--Mml3Il$8CxWhf2DU^BY9#gL ztekK~Qq>blBT4c`ve*|%hCh-C@=o>Pnb<0l{;eZ1zpfnGM3UG(l06+Gxi24fie%_J zk&NgPNujQhGEj{^$=l;2iJuV3n-e41CsC6kc~|bs zYm*~6ELY@-Bu4!*` zh;_BbmJ9Os&ygJ49LYslvn`UxJ0hvGGm-_8xhs-E^1Xbj7onYdA_@Mc<1#|B4yjg$ zBgr`#NwZVRSx!srS&exv65oYL3SW$*%B@JQ-&RfUsOEQ-*AwOVRCzzs`0~A!ex>~W zjijv6K+D1gW*0F~sHlOn#SDxsZeXqyi8jzI#=v$NS;D|9X%TDS9XTmw;?!2|#v6!8 zFt9=PN;uKL(2@ooN=8`&HHC5pipvoBt-OJpBm=uE7&s*pD;iiJvB?J7rYMFa`3wZ) zmb{Yp_3FJgU?3%E;O$HUeIz~0K!N-qPqPhl$uY1lWZ-uh8a6Ol%=rcy6d2efi>es- zN#3t&;8VFL+0_j!k52;_~#&yuV>f;2DY>|U~6Zf zq#Tng(z3mQIUQ8Hj_T7@HG5C-<#sm%d%7z|PXqCNH1ALK{4+ftV&G%B|Am47q}MP5 zQ@%9NbcBKH1hVOo~|0p%2@`Tf2y0Dk`_x1ER{Ro z8F*`%fo`&6xq+7}4Afq!HCv^cO4JVqX8fcYOWTLr(?-=;;u7L{o40z>%il}HH7aamK@lS>CAp}P zjdH7)kx!zH_+pGykyY}zgi+_Kk+N|{h9(+0nPlWrs*&_GBlX-yQanZq`HVF68(AGR z(mcz^D|si|NJ5U0RGB8{a*fo_Gtx$m<{Md3*+@(kBR#7b*;2=dyRMPm^%PqsG&GXg z$jEHD)Y!-!Y1hO^;iej=nUQUBKx(%%(n4;^Gx?yEk%4WDtZA$58%7e}G_pgY+8G%j zAGJ5~Yeypw-cdg9D%URBO857S92QqMBOi7*(&z&to8*IDMn01}lF{49B3Uh+`lwbC z=%*Traj=n366A8|07_ouGQmF*1Fw zk@NG6G?;IsqZC@K`h0I>gdAL9B!8umrK^lI`N7CXa{kFk%e6WtcYZdq zeuI$`8;$Ie6H;T7kx`qCJQwR0`FpRC z;ropIcfd%mLq`6Pq$65?>3GVB?Xrd%bqk)kh*d@OJLXXL(QN0=yTHStjqlg>vIr{phbRm{Yk;wB15o48uZ#E4WA2OTC_ zr;U+S)`v zalURMSC-11HYSd~VdA1Ze#^v>4ko5{GVw}Qy=`Kvq`zaLPiGTX5uPj8#>-!V~Devl`3P3*j@lBi8QlBHpzdo(`cri$;m`Q%ujIFDgmjgBKV2vSThANL?dOqCDl`qXWN0^x*EoPgU zHOEZUTr*{*!F)4o)@i);W-J@bd?!6NszzH?uV2j!mG5?$xx3p;yFF&QOQF4Hn(R}Z zKljWHfHcDESgPA`_Z?NJvS}8DF86}4;R<1@_@fEVt zudtQ4qEgx0P*TDPg6S-O4069cN{Kyp?hZRyrqINqx=ARQaQ{mCwsq zSy0x>E2&oA%4&H##mYb8OSLjzz88X4+Gbe!In&B1X`5x`QyG$NWwF%Cv9ebpLspLE zTX|4m<@I`2R>;HpRysAX@_~FS`x+{TM#{CZm2)zzsg>X5q%>@1U+ull%4$7^wm56sWeitii<)aU+Y!&lIR{F>g8PLZ{tG-sE`dM`j zSQ#M)`&-E$VAX4y@{l#dt+e>kiuEfi3G$`vA7Ldl(n=HQE|F7|pG=-=<<2xKdDB(D z8Ol{^&a$#l{+_M;=2-F1v+{}Tm~X|tz)A=CcA=Fgi>$o!jg@7KmCLtQ(q-CmD>c?w z`9-?@Xl0Px5bs(m^W;aFu*pjQZOTbXY}dRbd57jA2Y2e+*lT6nF)KI4f5OVwa_5Yd zH_z&P5X(6$ePz~V)#IA_$uTK=UF#{Sf2nq|{%homVc$t11l+ytb8M-p6HyA&z@O1@m%N83!SSkH4oV)H{|#KG$uBBM%Wl6 zXCy1q#>WO5Bjt{CGursUWTUgy#=>GYY{hLfing&?j>>I$A*W(&WR|coIM&7pIVzvq zZS0P-(Kx}z_1A0!O4}Gv#>QWAvaF2?W@@*>XW%PgZ^@HWDh? z7$ZkhZB%vGi1gZ6Aj5q&_W5n(1vHMhb8RfGZ^P5T#zzfp`u%33Lt`5oC9+lZCSPi<6_)iULC8_%Wk7mE3njqalqOUz?z^pV}<7~7aZ=>Y|8*Aj*M9q1IjaO1_mSRc7JR3b^&3qfv7TD;u&_>bK%0qr%qdb1J zvGXSzg??6^viTPqx7KMbHYk=@_o!ZS=QkT~{chvfUK=I%YYkACb8#iRFsbAZG112F6exbHB#qK81hL>`^o*7sYhh zFV}OU@aIMGv4jeuI3(+;L{YhF6wVq^d?Gt)MiHnL#gf`lG;0+_f5~kfh4pnkmz*|H zINC<>k@y!y^Re9cC7O(N(HvbL&A|=Pl-w9ikxkM3Bsz(?DaW=(Q+8W4vwn?c)b?nm z?TBW??r4VWiDtj#{1#2`z0quzZ}&y>;6OC<4o6e@Xf%tDMRQLa$D`SKA)4ZUMq|Ak zO*08xjb^~#(X6-;%`^G!pJ@Bj<|7=(Q$>ju?#L1OIo>D`pU_aSh_l6`BCbp#j@8QOI#q9dpWU$ za$~ug7t8VdSUznL%kNV9tyng6jK$n3meaDRODuQf%|5YI>KjXuezAB5#4l4NLG?r1H#S%G0ZRPtfV(B$BmW?uXSS+bu#nM~yC&kicYAoMK)oHQh&4^{VG@lvE z!#S}O%#CI2yjV2lMSiY8H2Vyz%FqY&;u_Qc?WzxT~oR>z}`CaT0b`~1!bTQdkBbgRE{jGMki^pc? zQBgaUi`f}p+)nXmJ8h+0j9u@K?evk{SUbb*b`DG3I6EgLDc;U%Szb=%>d}e39M15}O^cQw24z;sVW{t3OO)ieI>q9rimLrqwjGAxfgmhhGXTZ01 zHh*Www#-h)<#sGol2Kgw=1gcZ9DJC%sY1OKeSWf zg`IweI9*bV>lc8OMh*AuEo`x!NbyLUF9hkK=_rsvJktYH`ewqSfOlUq6oSvb|v( z)7!*xSu)$l(V}A@Ss{?2@-e#<5iTO^jpPH*pkRtQgDU7_cIa9kOsu98G?VW40L9t2R61D6%V# zvissFvpZWJmQ|1Eac#A)6Aw+|dDS9b*FfWW**2c{ z--&0vZ0izF+aB>OmU$m2pI-4akrC3WuX2&M2gGxFP&^d}$Fov8e6Cz2W0+!%h^N-b zcno9X2~3FR6S*qG=f!haHZO_in`QCbl?&g;6aPaz9c88r`7xgTvTLqv1#WVeJJeOq+349%!z)k7nO<=1e`VwfLk-%<=$xL9T)Xz%blJv+) zpl@CR+oXO-+bRhZu9`qpwFJu7Q=G;LWHm|9HNpg5wMw9N>jZ|kN#OXq36$%SfU#!+ znI9(bxqRAN`}!o%O&-g;eG^zMRr@6n**}4YQtC6s{6aB@Ch&B40$oQW@S_xrRQ$1u zKTi86B(QI40`b$-cc!*;6X+-}=OwUnegeh6PT;i#dM>pVCeUnA0^2JkQZzLYZ+arl z@)DUVJF6vPsh&t>@zh9UfNZOo$lh9s#MMrur!;7i$aGoSG?CcmiF_@8NTn8u{3Lm; z6B#a*+9tB@?L>_4BvQOnDfcpwFQZCwMEclEaxJ+ezLb)@ z$}dT&Y9;9`=h~FyXpfSV=~W$6mkDpLWczXEYxD$qd|4Xi-@Pbx4?%8shQ_z4v_E8XW-pzo#%ER)^aDiHIl zVjZqPozoSVER`-*&~=y!)VQW?bVV{_Dl(;0MXJ76kuj3guOchux%m56 z&kYs1vArT0J1VmML`6!zsK_*uxg^2j$ux*fX1ZjTOXi=XWHKuxP zE33Xp=GG|XJUW?wCnod7H02>RXQ=P2WX4FZ*~#>uo6L4epO;LLWr`;~en@7)X7!hM zcP3M2Uou_AyFZzFCzF{fef~%$`9d-u$jK|o{CZve|4Qc3tz=$3N~ZSXWX?U+++HNJ zPVT=<=9)1DpDBgnQ7O0zrO;1W7Ehr^bPB)7wwM%V#HMgXI@#4WA%($Gv1AIvWJjqK zioKRXm(nTRNJ$~1lKMJRcp&*{DO{KO=_yQ;xS-!GQLe=~fcGXNFx>gG3o2AgF zbqZT$<(nxK?wUd?S=w7|KS^Prq>M^oz<7-(X;V{J{7nk?q{!M7Mr=>vm<;(%dHtTk zx`Qbg52euiSPHdHq%cvQoKB(HpDE0h<=55zb_!+hq_Fc@3L9Umgr#&PE@V}rSau~E z$aHBIuEbpFUZoQ2-l&A}%}SK&TZu;hv!D_)rT5NCR69{g_dr$R<<&|&yk3cdzbY~E zb|ro8pnbCHVI>TS4hR;Pu1t2seIlvl^gG*lF>PpM(?Gv%gpDgZ2m75V}yg= z@|oO_JWiLEn}RuF1Xj4k9}^*eLrXzoUa;og6%p9bFw9 zmvQeom?zQQ9JKE4(7gi=iVsje12s=M@`;1Q&m4@9UPB!G@`Z!cp$?XO<08o1e8Nzc`q+PI1=j@g_aqtjAk4#&!qR9S$1p zbg)GV?b8|@aM10bgR}DUVTbPbbFloVgV&BZ@W}uvIH9~xI(RIFPC2N4Uh}!_;HNuU ztGfVs=&z?JodZGHsF{$~|!I)P%52RUylbMlDq6|((M>#oK$Vs)rPL>yQ@B+}ENkmHc~#d*k9tmiYUreWBPZWBR{JJS<}`J3rI}OrmN@Au>*c4{ zoxE)0qsId%}L~Tjs2UGMrSm(lsxOiDgXTGWZz}g zS*Bf4PLg<4ZLT>vBv+;JO($*dsg9Cz-$|w{kvk8R$3rI{$%SWH$A6uCDOLV+(nPjP zR74sBWt==Wr}0gpG}g)oh12*vl1 zbWcuWO-dRSDy5Mv3tegamYv2KnVgfxB8kgQ*NQMyYmbjFKUp(wHO--qvwBC~=+B7%sEK+&zsCKT6{Z3HMPu*&^nC zY4nv*@_29>w??E99F@k=(P>%|!_r zCi_ae2$gZssho@N%DX6;Ti}tB54#`%h3yaIeM7N973>WWbx)>~u zEEgYSyYyM9i(7Ix*F{#y#kW$rz{T5@UG$P$60GXtK`j?W>$+%B&&5tTBah|7rY_bs zQ@rLb@}+!R<=tKL>EU9(T#`EPyEy!Xi-ch=lBMEs7u~*eaaR74j1kIdq>B;qKt_*t zF-KaBaq+I4mU81T~jn=5|k1otVX`Vl8p1)|GvU@)=VCY`JRjZ zvgN*u^an0lKGJ+2Yi*xueN1lFn%$&W-0ZWuDG}x73+YvJMECz9RNOmUN(>ZZHH%^$MY=_bbIW{BKLca!OJ>)u&6 z8|1#<&9<-`Yk`~o@~XC*qIKNtkyBE)uA2$<+(guO)2E>uTO&7(8@t&m3!A(7vXz_Z z(zLakj&e*&wQ(~_Zp!qwZZ5px=6O3eRXS*H9o-Ci*Uk1WZX6%Db&rpmX&<^d-&^`9 z?|yEk$aj)Iz)iEEZe|X16E)mThcDfF&*A1LNgAQrjCAYzqnlde6>qZIOm#C*PR~%i zX1N(J?s;xLn(yX{T=-V?UFz0n=&IccH!D}VDZ9!|_0`IEjhh$p{!dzmwVLZjH{svi zG!*MzHwiLQn(cS^u)kf|dS6+WAuZwQpxZ>u)OEmvdZ^&= zP%h2GyDpFJt@aRC-NTzTJnWa}wLH3p=HUlf(ZIu_h92H&sM*ZJ!Z$qJ zc+-QSork*ZJ+zX~J9u=jw1@0Y%2SSZ)z||y_8^b0rFrzez(c_>4=ZK+mmZ=tQ>4&N4^4M@ z_*D+d(A`?!JzB%xbRNiA`Fg*HzYch4eNeSL>|w$Y4-rQ_lsN98%?S^`OO;a|Zb|Tr zhea~-4-bdWY5#c-LoRsu?N1MHT=dXY9!co3hvl+Px?lBhL~dXA5c{`>jdJ6r2j6Xt zEjjl+eD=V@U3n#yAF7t}(IXEV9&1fy;1dtqo_eVN+{1NCx;_s{XRfS@O6N(TblxqT zPDJr^YDcGIiBIQoX>H4-vrP_5wX*4qESJu6c|R$gwH4C&tztUGQ_?w@rfqsUt-R^% zmh1j>Vgl*B9!w`8SKDwp^YhiFAf5jzr&F`4VpdDn``&b_*H`}r=}d2#&V^R#G-|CJ z+NLw^jdU7zOlRRc>D=g?PMderDc?1nF7KstN``hzXK(j(@_M9G?EQ3Fevr;CIV(xM z(s2$>r`N~nT$B%orc-KIIvt0nb3}d^kxu84>3ly*vB#$48=ubC(qVEsOQtC2sp*`X zo=(M?=}eaYW+~@6nzKxwr#$B?&#(1(SvuC`>AG)P^;wn9pFgBiur{6HKc_Qdb2>c^ zr}N_x#W|`rXVvChI;F3q^VaQjzPXc*{cbuZAExu!Bh~G3I$2LN=clT%RC%sEr7T`L zM|e3Qn+#rzCNCe!yB04itX|64yaeReqF(yOdiheS*uDCF;$^!;#d{ej?MixCT*^z_ zYhLzN^b(WeWrz%Rsh!))(sVC(y7U_cOQu)%(0e%}<#W7Dkik{dzN*Ho z=4G2St?p$<4KKZFDwkS{EirWzTb4BRa;K5NCu%*Ab07QpZPYKJw34FaGgf7Kmx0mqwGloSf?A z+%zv0XLy+`=Vy9Jp6z9d^qTACmw8@N=c|oWT%b1caFLh1#a`V<hqMkyy?k}d z%TsB3+RKbHULK$I5vmm*4;Nl6z74%k^tsX5II4>4Dlm^z!KwFT0*H85rF38hd z9|a*Dm)2n)^YVQZEAU~c>f#SCO(G9;if(k zn)_JT!bjV7J{Gjsu?{{O%lDGg(MKmq=;R|!@})y(A3bHOxVrcV%M-D5^)W!UzUN~} zcOPqIM-S!xp>pr7++}YcA0PGgF-!{j`Di5D#5%x7e;F?22Krb%$j7t6KDvIa`F^VY zpZgdrLx%eJZJ6>J?xXpa%0>E&@R2#v#~oQb%Eud{eZ-FOu|@if_2C}p)AuZV%pLFJ z-w8g}OjI2v`PehZ$H}=q-kqnd+?=mkEzq%rT7z#?S6ME`#j4}CTB9XCOyBu*jYQ+D z@e%it)(w)%1yK_*CbOEO_qY?-xE^f2n={`Ph%2aD<^V3+O%B!7>mZM32s#WmQE6vXk z3Ay~#m(61G_~|3_0)DOqbv(n*?HoTDd49f;4h4ReRQ407svPPlhkAa-)c5nEiJz*? z{H&JPmVVl{^0QY?$^O^mj4KhHY(^?flv-}Uly??c7y?WgG=KQjjV zsrZTJKibb*WBeSDk0<%rF#6XQu1%Oh3zK`6;zbV=PzSm8#K3Kc8*# z>)Myb+~Mc$PCtWo`}yiOKL>wTP4@bEAi4WBzHE`l2mHK$(9geTmG>WhV$N&sGEUCQ z-iw-x47}uL+hsq#D}M52rkuH|JgzGznJc&Do4@?r{M*kPH~h5z$Il11{rr5#Po=wx zbI(uN2O9gK>ikr7e&(m;b3dJAiPU@HXW~oM_LZNh|N1%ipUw*cw2>{w0A_Q5zB0iQ zV6Jqw1}Iu6K#RfwcFLbc0^E{>=m70v0vwc@u>r=|1H6(E@c|Ac1gM-CU{2`(eaZxQ zw`_nFazOX12S}A^gA{XcfVhtXH2OTi)FGPNR{@5O4zPDjfV{B*wvSUT69NpBAEpO*IwL@rnVQe+ z09WP&Xg*i-ogd)X*8!?82vBlSfDYdTI4svBa_+4|@8{o9m z*&ks1fdCu~@bQrVjgJQCb}YdA|ES;X0Nw8dD7dS2xfdY%Nr2W*1MHD?&y{yXklltL zMNL6IkxBB0JTeC{TY_wrLsHcmWP~k9pW;EjFB9Zp*&uJ13$iLHNXrUA=2Q$)BsoZO zr6Ao?6+<>SgG9Q5d?>rTI_?khv24x^V#-!5DIN;aDjZ~Sevn%QL6+AD(y)GzDGk)7 zVUU_FgN$hv)MwK{zI;8%fi^*2eUJbHS3J(u5?aLt6Q9&Aw4zfiaj|~zY zuX)SHi9vn$Gl*ewkWI2*3Z?{^FW09k?lc{n9wb%{$a!fzLosItvCImRJ3GkdbAsHH znRA0&oTqwyty(V*>Kce*$`NV3BFLG|8gomKJzJIQF6FX2Ncx_jzONM2=V_|%0nPKG z^1rMxqh&eWc60$_@*fVGsmw`JmgO5sP5Ga>{twIKkD`v1&{*|`L8C;j>lni#sX}KxI zoEf|(-KCBzgYoVRdU`VWDLsQ^Zw8fe^gK6%VGS~LFLwr^Mj50x&7g0y47#??(7jKJ z^R~w9oWXlNGO+Z_V6N<%ltGax8AL3|p!P!TU#eV}E7$Kc7`QS6GXjM}A~j%KjtSOyi2XE6Vi@;{wHt1}tYJfDH-Vg_f-nUuF?vfP$Q zM9EBQm&)YmYni;6naQH8OitxwGOSr9`-p(TBVHSNV zWV5kiwyry7^SdXTXm2*3%e}m8vcuUdkzUoa`K3lSsWr2yRWF;d^|R^QFq@U#vU%KH z?R#c3;^S-%eUeS(PqTUOSvI*tviVN7$bymC+@79I#>{NKk@aGqm5q5$HVx)xvq_Ff zw?)}3{5G2#OR{ORG@JJ&YGpQYtFw7?O*Z@Gl04dwP5i-Z-a3@c0l6##Pw4R}#XXbF zFgfyPHi?&%m#n^@&9evD9DSaxb1jFHo*eSBa&#|q4&#UG`Ik9N9g{=jaXCyIpTj2; zbJ#g4hm6TN)RoRsb!rYHrseQV-d>i&vgJ9H`aTD*43QhFa`3Ir;cI!dCx`04>)2uS zyQY5EbEthQhslp~IQt}rnXhuVS~wS1(Oj~M<eyXJ9xY#y(T&ttTFz95f13-iccr1p#R81k*!hwq-!7{UH1s-x<`o5WNE7UI6_QvhA^as80HDFFFi!a8=_KB z<79*wBqcLLbjS*ESlZ=V#-oH^i?ptiED4 zP|SuQS~m(YuW^WCO+xHxs%`TSpUSKjAuhF4pH?C2ycuHrTOnu{VrBafk2{3u+);5m zhp5^m#A@mKUWirQLX_(sqM%oZ;UB7<6z?CR)d0<3h7HxY!!+*j5I>Go|4|{jjaIG3 zt5y?2{4LccswR^{JeLndW zLyX-N;`rteHMWGPyCcMeogpH2g&4Xw#NK@&t{n{VM1D9FVw7hAEvAW=W+meS={(WrT5OhN+nq zW=wXN`uSn@*9j9_FU(N+vVNEY4Z`F%3}a{&4ML%m*#P{3+|(gn9FgFz-p* zH^VG=E6hr{-ad?{W0<)zqEnbdZ-=S;j^cM#{4Rl_!QMr zZprMaVQ!0gdKlx3F!g4J*&usl&@AOYJB)u$n5Of>%$Ogh_2Mu;t_bsDWthlc!o0mB z%(9)T;odNnPH1i?!#q0`X8gG@C(nnebwTs{Q#o7;vqomzQtfXmpF7IszH0p-tnW00 zDe@#t^QWq%1k2|$C@G)Z)O?&Z^XXM9pNkSzFP|p$^Vue@M)~w^oX=%B*fgKG=J^bl z7A^Cc-725Lt@9c9y4tqM=dU_T3md_Kpb~PXO^?dAq=VL5WK)tdBoG4eow5n50>%t0;FTPiRzTv60!GO9n+kZixqv^m7I5@L z0VPirP)TZ@R{Jw*FRs4}=zXJr&m{9^0UzHg;Fc7*TR`)B1?-Ug2L%j!SinS?^QeGv zPYReVr>Yd0R^$EW4}>y9}_x`8C1S_;ao@cdQ)oMDmCZKAM0+% XZ|i@pZS9(UU;Mv*`X46#zkmM+Ur-K_ literal 0 HcmV?d00001 diff --git a/Covance_UCO3001/browser_profile_1/Default/Code Cache/js/e5193c0b625471bb_0 b/Covance_UCO3001/browser_profile_1/Default/Code Cache/js/e5193c0b625471bb_0 new file mode 100644 index 0000000000000000000000000000000000000000..95eebec9afddd6efe74bd1ff52b4ec727a0a7a96 GIT binary patch literal 18228 zcmY-1cX(6v8~5>do1{s~Y-u_`R-vUyvy<+mW$(Qem7yTW5|Qly1eCq^lqCoPf{JXA zsqDQ3m8rNzVCx@9%xzCry)+Q@n3}_;so7FJ78}%2M+}^YyyH z@2yciJCIW~qgwUqfvn7GIf3jzFql=XYL%>vDpdmBtSVJ9GHX=zW>@vq$f^>oRwFa3 zS`~kdOmB@qPR$w_UV~yBiYq+xf3g1eugtsY5&yeQ5WntSmVS}2S7sUEtXP%AZJB0< zKZ?VVlCU)hKWBp_SL5Y$2y&`J$r{kPF|29=rJKS}Qmq*zH-`+VE$_F|9Qo>9=-319 zNU`2v>!-Q>HFp4H4TA4JfhV6rr_Z3<5Li1Ds(cRdBjC+1po?UF3CrcqNO*e`bd`Fe zp|#|UQQxG~IOr{d#>1ELVuIpLhKLz3UA|unvFpJ3J*@iyw#&jF;elLO4^uX1|0Z}T zOE;?@TVb;tki2bR{uvVGm|T)(J7L!@I4R?I!+a^e2kP#FHe&k)Qe>L^x*yKV)B~_Y z;t#6tM`49@JO+J)6A(NJHRL}jb_xc|IO%>KOuxalixB-gl#-KjRa*W5jsApoQt}cw zWVU>K8OBPjE6_^z{m)e$Ynglv7D?Q7sPMPemD}>K^t=JD{(+)5HD1n0om(*PHmsH| zcVK|rkc0Q(qRe;z%OvR`+OcG5J6@6P6iqy7%eqS5wws!GRhpmY-wSMprf3Uyyyt(OH`o<;^j*zUo-;0+?1En zqgVuQ#pqVjVk5|wZzMJ`f(mj$Zb{oD%_|*2HF+gP%0%#)WF<#XTOuoHjtrAYa=u~& zJyRl>VUOT0B>@RrMn%-5`R!4V7Qx2tJmPva@*v)|L_Um)UPe z@Ml})-9Ca(I;d}QS?updFjKzo6v2!4BIw#Vf{R@uNa?Cr-POk_5lo&Mfnl2Jn-{^^ z`O0%a1Rs7C!G?tqv|Jp)_Wco<4@S`Mf6hd(^=t(0a}gZ)ErJpkBlujpnIc&i6-fni zB((}hGOkD@|4Q%pNH!)!(kdyEFH<8qTq%-*v`Fg9c{$~bq^diTMw0A}WTHQkj@2Xi ztwtoD*No(u6x5Dnl@zNR$tSY2UL^kdk-TgYNv~#+ly4r%Qn}e8k~S?P=`8(QM-uhA z)_Eh6q;`?)>k!F(`S6`chINc&Wamf#GDUlqNEAm8=W<(O08A)YnG$)da(qvvFrN4@#`JzbvkbX-dnYC20 zzmDYVWs%%k9?3i3Me_SvZCfA7iLH@j?ulfOd@G;n1$+0tNP@paQb$Hg))CczR5_hd ztS5^5RO>y{eEC*Nzf#P9BPnY%(6X?BIYkTFU|@?Zu43Q^=~>mlXL3)ns~cD*Lux4xsbAZ`n{r5Obqy@2XP{bh1I?vq z3)L(WvPRJE$+0MY+_Uc^+&FP|^y|4IkyQ_hH-4vsTfrLJ)`!hWr ztj9wQ-2Ys;O)}t|Y~aHw23|}x@YM|UPgc)1==q?YNQ>nLmdl-Q47|OpTY8gDQ#ZKDCxCIdfhHt@j~1J}j1O~+jLS;tn6>{Ksz>GTLr(?il#~u7L{o3_OsW2dY^z9vK+) z*ua-!dtzXT{PR@LkLT)fVIvER7+EbTMUC7lX5`ZtBfeN8Rb-7kE@9Mj%}CjJBg2x6 zoK7}!Db0u{-AFx`kyN*lLOvr+{YKUXjWo|P@=7{p8%fMDk|xvTLaveec}99vGqSCY z5m#L!z3VBKOl)W*vyqWGa;dSAJJPm^k-|+Cx0#V0QoE&*n=))X2y3kNAcec`@9m_clhN#;djoMmEV2DLT=}@wrB3%rkOv zzL5qCjC7DfOO3>SYhH?nb) zkrJDY?2%JaV~df|Ta7%I)IF+Ae%foK(mwU^7v=b?a+F?2jQl3a$BbAn8#yDjuNoP5 z%}CvwIxY{4To(HyBR@#QVN@^b^PHCURxD+i7 zSg|LYI3^9Jn3yuvq~F6P5@p$R6M-crewE^1oA^?`{n14FdK1GX>n9U)r2PgHT{fCn zy~#wG&6*>Nw`l$j6W{!7;;FRUWn!WHwOfz(n0R}yiFNX9pNY=DsP2Qx?~rObto>p- zW}<^EJ8mN3go&uLCf<+*=S&nkuijkL_&-cEmbFsuPZOOknW%Z$#O+%qKD%wgf5${s z`A(kPHL?4i3HKutljZDV6Sbe1xbf74_qmDrvix7=@t=v8@(EEqketXUmdO_RPj(xl zsAq~|VpNpgq(@#Hi^L(MXk&zwr59CC?|^6vO@0VM$s-W zirD-phRgnfC~_-D;j0=&RJADTSC8U#DOw|nv2wg-6jf_Q5z$bwCAU!&r<+94wP_UJ zHH%_uizrUCkK*GFQT!$Dccb{dV-zXxMPcm{#mj-3|FOo(*kOt{T#rXYapj9B93!Kc zDJ|wiF?((l(et7xD-9Mzv2H^Y&o@S4-W0_*(tWdP-LATSj$)X6vnPtXd!uN(PxbAO zqR9c(Dkr7mp(v8?MA7AL6n*7}`0hvXm7IU5eUGE?$ZJoc=q#(AMp62i>U$Bz&6iQM zc@@QhNHbLoX1*|*c`R15nMM{fTV-7lGf_p&)GuacKyfn%r9`Zma^fgq<~w;3XXf`( zW?oe=^F~E83sTG!OEojClD5g3G&9@9V>i>sVdjeDI5ke1xy-yH$0X6C93;YLrn8jt zn@N{h@<%{91gPE*+GqvPLd0AklYh^RxI%a0b z#kyu1)H8Frp_v_x%v5e{X15e-YG!XMGZovISt_w_nrZ!(w#lCMX3BRk^WHmVhIBG> zRnj{vFNyA9CZngBK_8ge_mP>#eN=Z}Gp2rKO3F9=%{WJ!`EZPxKjpE+j5Tv>l9_E& z%pCYyYb{q?nI`+cG4s)8)hGp9%~aZL=AX-EdS5ZK;i{RmYpO*)m$^60H2+6=+|)6< zWu}b0C0{=@Q~Htm`dEFH>*9Z+HJ_R3_T0?c7pmu_nM|4Z%FMh73%^O-NDC7T7FKyq>P1yWi7mtYUM4gm3LDu{3E_J3k&4+dKOm6!}=E9X<*?4`C1M% zRIEl?v$2H>GQ6pUU!`F)3*X4y<`&wvu<+R%7LH5On-;zlQ(FtIWnMcAMcP~Vwv&a3 z_mppE3qQ(7A6nQhQ6E|8BLn(aXw}z3bU%xZp@orhxW9$`0T#WsYkgTa!a|ELELgs@ zkSJfs!I2h1qbxL$ZW1|Fxyh7i7Vb>9kT*m1&s3gLbGC&=^7kC&HrIlGzJ*U^*8&T+ zg%;Y&*NZGXS!|)>5(_JqDwnSuD~pO*u@<+|D8|ZGIWD*5 zg`A1Cl3Bva$8lCh%5fQDv$8kdO5;Q;*I%;|C~ajx87qIu>9STTl(W*MyynW_WUVjd zDq0yYbL4kb1v8`^Hu_OJq~!-AZF$w{k?{+gQ2TUhBPY<-C;dW@UnG?QX^1!%EMdRxV0PFXix& zm6y`Ek5#WZR=ws}*)GBURt64G?VnkhI>gFzsr?QvFC$i4Aa z+D)+1a-x-W@@$f7nQ7&fRGV#OtwhYX(p}aqurht2m0pXi6kTg&nEblVO3wFIcK=|d z(0Z*eTYs{0YlC{cNwLJTPkoR(zgT(uS1Tv>TPb-^$42JK@k6Tbl$E9OyWBZrCI7sY zhVs#GRyN2l5_iE$Md@(S%C|E4cRdeeoz(fm$`o1or>(dw}8DhC0%c5f$ zS}2x-Qm=3<3yQ?@k6b7ktJnHiI>^qLSo+1q^0Qb<#WJ~HEEnaAZ?*jgZI_shv1}C6 zChe1^dt;d^tBxrCdBvACf5p=5W-Rk$=v~cw5KEDVvD|$X%d{dT_)|((DnUazTeSog ztCgU3_Y!m;Sc0Eq!_X3xnqGoV;$L2Zxob-BmsH$Wf=^GD;1{`gy#zo0U4n=kB^YqK z1jAmG;IRDgZwXfZSAr+<4smRajKgY(;~!%j|C-`x9TmqSF`MIPFDs>lC61WrINp?E z#WX%Pj^;AZ7Dv0pI97xtiX**T9DU_Zt6P8?@tapySh$Xk8lsMI%(BK_j<4v1rr{2_}6D%Pip z^;sOF2geaPRAc4a&*SJdERM}GZFn4MU&hf}@+Zgf#|KK=x?#HQ`}Y?kBZu; zT+GIV;x>xM*k~i=Vr_cAX`_$i#@QHQvvE}F#@je8$q6>r%F1#YmuBO3x=rsfZRELZ zl=RprEsHtMxjesA08DzkgosM*uTL}~tkjilZ--jywVY+M>>!!^i8 zyH9Pj7;IyKL=UlX_H!E*huK&yvq##vCV!5$=}QR3mSdA`j9y^llyq5aW5Cxowti#7 zy23_>l{U;j+Gr}h*K4hfiX)cIHl}S=9BHu4#`^6xB6n!LpKZJ?%jHkGvde~Nw~ZZp zZT!1mF^?#386&k$+L$E2%2(%X+?0yvZTxo0My1Q@+ZFZpwvCQ5>yC~44{cO< z{zCc59(j9IJj%5FPh}GHzB_?i@~m6}ITaH0T}J}bD<-ftB>`({0##(W zD}jgdwm*T7g9$p%lE4Ky7fN72)dY6Qis}hGuC4KP5}-)}uUaJNJX-=U+a%DlV*(px zN9P3EbWdQZ%>O|7^h%(KjFeV=m5aPPAc3=k5~%ob0;{F{5alWv!xd{}0<}gZU>KJ` zU}6HF%2gRLKY^pNby)&SRwQs&e*ZRsgzpmQAhTrX_X!-7%|9ma`ql&%OZn{y4Bwr= z5m~!OYwS&6u=w|>2m2GaB<&6)u;5Sv|484%8h2E+$(P3xSac$R+w#*%#Xgll;^_n$ z%kuN;m)yCKz>LQUT$Xht@>N_SH>Hm^k?oS?OQc;!B6}q^Gm%+RKP!<-(mf}UzIlo4 zkoqCrR!O9A)kLDJB~reg;xtYqt4X5HXC?BgRU)-pCot&Mo5)(J+AopF{)s%4QiB!qbHyB%$kP#tbQzh*_fjxQ@y99tcx|7U z$bo5zBuv-bS-PEhzT_cGBvZH1a`)ef;Upt8&(x6EaGh}(wB;uMU@s<20m0Be6gXFbNVuVy` zlf;I1lQ4EnqIj1iT69ZdfmG?Pb$cjY&m`5TcyelR5|2h{-O)+JPEO+X>?CsLX#4ym z&M!+Mb$Jq>tw`ei@3n?FeoCU(&q-{S68n=_cp!;eQvHy&iTSYBl7u5kbdXsx=5!LL z<+V$idqv}9_4OpS|CL0czmu5sPZISWCNWLQy-ebZ=#m_hKDLrvODTyjwIr|dOH!&@ zNjk}eH%fB6dr8XlD9QPq<(Yf8Jh9Kq^OhJ2B{Lu{nO*X?BN@9dnUCaDm1KrhO{PK9 zWM;_x_Q`B|FPW&$$&~MvOe+~D-waCTkxUw%Op7m*Ss=s4CiCmWWNecZXRhYVOD01s z%ads)%Qq+E-ImNC`D$k}OMXe_uKapDnJ#CN`Ci&xOQzw&WM;}Ka|JAgD$q=#lPd7C zbOmaaser>@f%wi9XfKNgR-pc;6__q%M^|9N#0s33Zu2V8cS{9U$le_li2Yfyj#i+~ z*$PaNN|!3=JV*sij;g&k?EvxNrJ^wXb_je49PB+!avC=WL8MQRWU{9BJ@}WI#URHQrO{5 z;e{`Sn*J0P$^2jnH{?)83Tv{pPZs5-P&cH<`FbpYf)sjGP9eQYihe((=w~2>0X0*& zS0{xB^-|c{Q0p{FVNbIZ%DtXKS6SC4g{p6*=zFOYT6ajn*(-&9;u@s=pQP}ktob~J zTcefpm=ykQ;m%_rWnlJC|PNB?! z6uOA_U<&n4r!Y?~^&^L5StD}_h5Qh4J1IbTM<+{}Oq%vLNgNl=riYGUfs`;txshLVltyC^HOQlciRJP0N zw^AwGC6!jPytl@Fn#w>)9i7U630hCmr=_xVNhhrr*_CJ@Go)F# z67!^6l}c=Qvl7O)Dp9I$B^v$D!b;4N-n%PN?NlXQA5w{zS1a-GdL;_}s>G<`A?CdRSC$pHH9~14oO0v_vq@6jX?OZNnr&(D$sVUl)YUhGfwA(o- zap`u3Ne7=Do8L}~OqJgPcIpT1w92>BS&|Fv_+_#DQ`t_NDt7*;W7p54ofUQMY!X*J zJ0I1zb44ySv-3c{ZEk0acv{%$+tSW8x!2B4WP3ZC<$&aOurvG}JC9^n7dt0q{QGw1 zOH5Zgt-IOvJ+htR1C-A|)hWk5wUad1&PeGs)XquC-Hdot;VFE6*R) z=b!A%-e9NDM%~|{`&)H?o96AbW7%b=(QZ52q|gEN^^l#ehwYq~^+)ZxrpeCA<91#< zVaF!}q~MftIc?{$6gp$4`bFh<+s+Sn)c?D7a^>_RJI|imiGHD;$O)$T0A(N6FoUP!X zPDKZ^?V2N<91i-*U*d5(xb1V0kmKO(TnD8qJGfB8LB(1QrpS+V9K5RQpnE+BKQwgE zu91VU8*6+M2XmV`xYEp_YX=;3k&W`h>keMN;hrmdjSL$E9;VF`b*T zG)ZHnU)glZR!qk$H{`i=OG#&4YC07vrIRg-oay|Moz6L#l9SG2iO)^vt-N#&$|V_I zC7tRG(`g~a8Y!kslrxRfsog|lWnas5PP~;)skZ5imZ9&YGg%tEtNn6V;ya}?LS{=; zw{$-ID4owG+(+YNn?&_Xr>~5b#~-J2Yh*gX(dir?lg<^HH#VJB(sOb;X)|>@E1ln^ z&m6^;%5&3cEI*5NemVnWoIG2sKCMW{^ldr|SEaM!yL2{7-?f@2Po?1dbXLnQ@oY@z z&F$*Xj&w@=thHqF-gLe?l+Ie|b~v4n<+fxT)$x%!r_-5mCY}E0(wTlgor@3B_1-X@ z*B+P0$x<-3>Zyzxpg|4k?6zjWH-WNCzx_(&&j8J#RPIf;vMQasj4 zs}kCtu&I*`%@nJ-lYA-PM)`JA9o?NAluJ^lr<0?fJ4qbwBtRbEVZ-C-2EwDL3B9iV03?PjT|qG$(7N+jPy7+mbQUN!>Y4rY&)D zVX2b_Uu(UUT3hCP>tv;rS>>eTY9}Wpa;e}g~)M+Oj&ZsYEogBNQb#FSEc*{w|Z6`zTI7z>&VYkJSvhBVT z&jTkdAE~y-I(ARhf0K(JqgFS>AM*hr&3(hOm&fx=AxV3#c#6T;Ud=QVyN8lxXARmSSp+3zTd@; zunS9pi~jPewu_>5T}8tx)`gp2lHxb%L&#SfA^QoR}F(z!twwI(Ru6pfkYVxXLzsea9NF+p7O zU3|2_#TEJeYxQ@zOW!Z6cdJ~iUhSgn8W+{qD&KW3UP#X$bR2$Et(#qhe|6DNEc;y~ z$|z}e(8aq_=8y}w96YSC$6bt&$|uwtxpPu^{h_@6bn)gD7Y|;#$o*F}$-4j43*49^ z+n&CQf}H|G=F)Jt^ZDdnc`Yi_Pd_p)xjFQ+ldZn{-+vo6g|1-qMa>2BV0 zx^-QuoA~N(-m2l|pggbT*7+?r-^r>5ZXPvs)3K48@lD*EYU-wDGdGLgbaUe^H-@%u z>b7&!N`|y|>l#!y+3zS%Io?HU57gR&+&a(Y=IQ5d3WmE`Ejzz(6Ft(+K$$e!&Dk+- z>WpE_E_Zl+41-ENxh zar3hz>{G9Q(eaY64!Zg4kek+rRqs(Z6OXxxIPRvzNjGnta`UTHIpgM*1kbryETevN zbM%6?Uvx9{cQ?QM;pWXh)lUgscC%7$+;ro+t@x62-_76$ZtluQkKAl}tbWSCCvJ8; zbyNSjo9kwez9;Z7Pu4_xcv8s2dxbqj6!%a&#)CP*!{gGrE#qN_9F=NiJ&Y>n;kooo z_V8l`55H9OP(0Pc;dI@4Jhbw9*elol9%2I?UJrUm%++n!!-9N`De&-LWe+v0DrPm0 z-aC4zUSIPYc$m@B!|$y;G-|CJ+ISfMriX?dJS^(y;YKG9Z@lNBd>0R$-}i7vhIRF@ zznh1=?jDNu^w9DH4}0XiB=_>*_}D|QPdxl79}e?SYPg3EBRm|F??!s)G|I!bqZNCc z2j2t_UrGBZ9+pj2&eJ?xnBk$~EDuxUzuC%pu4Cv^Q>dzVv ze|+bm;71Q5)_WMa)kF8A9=<=OIL9^SyvAJcQ2L68w{Lq`a>s-1u7}ePJq&)NzCHGk z^+Yv4Rgb00bLA;z@zN>6%PHAn@M1K1`AFU~ds$`iQpV~fAU_xN(l^e_7gELM)z7k* zof4hkWuUYz>1AmtFY&K=*%bUR`JG z<(!ny@iI|9uA=c(wPrOhJEUoKFS}}Z=~Yv?)KYATt)tkotf7}Xjg)5#FJ;@Rj&`a; z{*j@bycFr-rFl=ym-D^6B==UneY`k6RlLulfrAfH2Y5L%HQj}cz^J+K!$Jd;@YU=u*u66nYz`>Z`*WCc6f3B z;-$~8UV=w-9FBYW@`RVC()6sCndiJbKJO)b!OOSu`R`tS{liP{pUPjZU-L5izL!f6 zH2$HN&z^YM^Hl5o>t$c8kJ{yZj8FFQpX^NW5naj0KuJ#XvD)F|ak`HoE+1(=pRO7A z@w+_D^-&PgerX-{F+bl&u>v24sy=>@m(_fHQNu^YdOo_=_izK>^!m}qPwRbD+u)<=79TUW`mk>Eae9Z3GCO^Ylj#S1Ts-Kb;UVRG)JOht zAFJfd2_K_Qs?JkBMxIq~FZ-x@)yI#r@49;Rw~x=H;Xgj6-c;Xi`>1=z$3~g{ST#NI zG2*FuFAJah`1^&A*I#Pee?AW4Cmi7?Wbo5K%tk*6GE$D1{8Wze)1#=L&m^aqpE|Nh zB4hk~C?ym9q{~%#B=05pSyj?cnNofV%K2$5(d9Kx#>nwxKh-Mu>6PwhsDzw;>dRI! zx&8E!`2j!Ig4&tj66R}qz=h-`c{k@2vZ+iK;_o3qT_S1BbpP3)~sraet9^>cjv3?H8 zCzJi`nxeT={hX8X)BQ}8b2D^*mY_ycq`~UPa@RFY$m;LyzXw9oy z^SaiTC4c$3`L~}pZ}@5bkDm{2`&oa-Po=wl&fN1;_JQI*R1cr3htK@9eD0^-3qO-y zs$Z}CO#9c*h5vM{39!u=ASx=rM00?mg#xrF9N>>40TN>Zw2cjLSZc-v7;6jgN=7CG zIFcBka#Db~r33US6X3nF0ald@P^Nr<7gDuCfCzg4qcfnt0SFKs2=GltfP0w%)`S$d zAi&bf0bQRPAh}+EF7*SXH4W&x+W^0{3{bySfbneudJWdv?E`FlNAWra7}F_0T=xKN zdIY%EGk~psfHwyOI3R5YDdxuk;y(${Xh?u*LsiR{0fvnUuzzfTym0|`j#n-d0}Pb! zW(0UTGeGBAs$))oD{})hpQkz(1UT_kfa(halw2I3{gMDj<(fn;ReoOwsIWZ1WLYL9 zR;z|zRm1)OXQj@;022-c;BbIXjs<9ZJV4hI0eb$UdA9>}yAz<`Zh$xL1&DbPp!L%L z`((p&0Qq>Yo zR@Mm8uzrxK4K$`Do6VNSqv!i_&ikprU)CCOOp>muCVBr_kngSs3H=>p*MlI19tBC1F>?HIkhhd%F*N842Czz(Dk?( zgc@bwX_`UbW*Ky8ouTVs6z5&7*(rnfyJukTk-%id298Y`?A@$&wrQR18I0beoQ`L(?nDL^PG+#+jPgI5L925a z)V!F1>CX(#MP*XnlF3SICJ`kwsa-0QS2>U?z1JW-@V+<}c19UOLFCZ!&qbB9rLV^1J5!kxBS^CbPcg^N;H;wO+&B#x(Ir3>Xl|Reo!QgCihi3DQY?FnfvbjAYn~Yi6 zERl_3o1IP6+-w@m%Vvulldg-iS@d-_HO7!Y%;@4*L*1BvC$|ZTUDVv1D z*}Q!un?rJ02A4zph6aJ6tQ&Z4(v2M0zeu0=X>B$>mmVE~7%ZjO&og$#-)3zJD$+2ISIpU@kkxcslE*tG^7tk$kCL`LJ>PX(CXZ24zFZ!i%jZ!w zEstR>^Yp$aPuEi9(OCApp2y7&c?90g<9?SsPL9jtwF!BQks%B7*taN;?8O?tG>@TQ zYm7v#$)mw{c@$o+bIdeIOU zi-q_{rWOzJTTF=hu_4ODh1e@a<3oHZyAwhbP73j~Y)GH`L;9>A(r5h;gJpS|=Ga3_ zc7!mbhZyb-aljKIbw9ij>CE#2O0j8VsB9FjUmQu32}03h#K2M)ZG-iI=vAjMx%z`OliceKP<(ABu7Us4@%?M+h8K&N>Fq>qb44SPP=7jOj4byaf zn3)U0v|bwK`&D6HtPT_TQ9!%g#vZ=TNxY0)yDIj!<3+&Z6uuWRfZ`3!EC&!v9(*aze@Q$|hC z=je=ls?5x%+=6`G`zoK)vUYhs&%Vj0%ZhxRXU*q}9r-+wYghAeUC+n%cRt241=K5B zz^QTte4Sdr?Mel_omRl>jsg~>7ckIYK>3aZbnaBZ8M)ZKfRvsEOqH6$3K%=QfLC&C zdI3o@3m7TiZYkj5)&hRpUcm8F1(ZBfKqaYpR^!iUyg2_Zp!bae221A60zSD_z%40q zw}9sN3fLw24+5 z?`rbCkDPO!CnfTxzWQBOWNZKRo4=%D_;&JMe|{)u?(`C6%H+>kCRcj?eCauI=E>(P znY(nJ;`x2WbLGyPqeQ7PIdbMLnX5#eJY{_8W%89NlP6#P9KO6cikHciyHuVWxr~f) zE`wv%|Hu0Ozt2~a{Qm!QFqWZ78R-%pmX-3AlO{psB`1!fUWF{3N;$eopRjX+lx2|=i>m03jktlwsIi#XZ~?vd zNqw$Ko??F5jQzNWM#cR!3I|L0=^u0`>8HNvQ_4>PW&D&Geari)UPV9k!>phD^s%L% z%&q*i3&-JU?WbhaKodl_@zXI}#JRS9N^R$-A}G|=PrZBlX#~pl_0x-fej3op({H1Q55c4Tz1E--Sg9<=YD#R_AmUj9(7*&Y1%74ZGY{j zBPjO9PnEy=>8r`0rv3)~5n|9*w?PN-G=o7$LJi8E*`UqXo5i5ISq(ax&7h<(gL>ei z$Do!G2JJ6l(4Qz>(xBs|4SG_}AWLO~8dWi<9dcARs3;D=S;L^#ScGmh83Wzw8T4CI zgSs{|=zS-H5;_|+1~X8ui$MeNsVld;8I-lVL2>xj!=T2!=-b<%IoONvKEwt~e}fw0 zcf1|IyaNr&J;Jz9mB{8h7kr8!(I#=#r@F+^&Ml-tMSZ*h7*W& zl0lkm&|s{XLe4lc)u6!Nh#McK5&Lw5@?bYEqw{QoqUIP>V4gv1=NpuBfkDGD1+GN~ zB`!56^9qA*uQX`|F8I8JyBAJYuhWVL|s+z^9m&l*hsBZX-uxv&(#60ZA(CkKy4l`;%xKVe| zz+=<}SR;)(?=@<26vxpc+Nig&M)~558k=BLmt=0I8TG(t)a`Vmvg9yoZf@G(Rvx3? zXO^~xLd5WiJ0%3jf^O$e`K)JUXOHmY(}&LiO`Zlf;RRwHJV`$jG9&3sO5NoC3TGYRM)6oO^kYqkC@t&IGT}jOQV{!GHOC= zqYmL;JZfu{xt&o15!k_~7?i^$wC-fo@yt=(Z% z@-A}NO`f=h(finE`-$T?>ve(ouG9CXQ6(M`2l^q)WA+LrJYmm0Wv=Jc1|QMtg;Dul z8rA<5j|Hqn^Y=zg`oNlhG|KqNs09|2CRj}>Wix3RmfKBQ?J&veG^q|A2Ab5l=Fh)K!Fl$D>@iKE#~+U_wahu5ToxQn_`CN+xY9Fk&8dVyB)CV3M~%AIJ^4)pe! zv?qs2vvZkLD>r@em=v1dq|qo{(4=W7S;(Y`Xj#~#y(m(|q~pa*`n{YsQx)vjvNE^PbRqylwJ8e7k#>Wxe~(%7W+O-worTT_#s!><{+V-YeoH)$p&wKQo7 z(ps5Rp^Zrg+A(K)`gAZUv7<>5ov2l3lj?UdsbOF8?PpTK0VY*N=|Lu48EVqXVJ2Ni zmJ!4<(xhv+Fp4?Gm=rmVF(;T*ZmLOrF=4t%i)T=)S=0g_kUra_xi|^;9Fw-pHL1x$ z=0clACe6px#U|xlVp3P^!*|qLX3_xcN5FEEj4O#{Epub{W|O|*^cM2l%35w?o%fq` zA4?CL)b1#;Tx1=Q?Wl3lX~1H&ljwV{M8ZZc7L5mE{DGY0{!JiiA??)nAu+k zviNIcc7Fwh`D-;gg!^k7P9v+wU(c~S!e2Wg{Z%~1UsW(8)?ZoT{8b&Dll(Oim6QE- zJI!A&a4FqirdOg-Lf^U$&ejDts2Pim%c`z9b zhtd}%hWTqdl85_i5i*SM*C>3!htd8TI?-QYQ^*Hruyd-vmdx;1rkVaag5){=GR`GW z)I-yG{u;8tUn_ANVGD^FwHNyHmLue|^HYn%c!#vGsx?f~t9Uxon1 zVF%oy0ot7rnFG{5TY&n72WT|5!t3ESj$mwLfM((_(!8|8b_7QUsDFHb+9m|37cSu* z&Lsxu22Lae=oJbl2dFC6!7n91r|}HsQv>t?gVO@E32S`;x`Sgm1JpQofWF{Zo&bH! z$N2dJRJTBYVhRSRUJ+ud7@$^_83*;M1?bPg#5OuWZBTv;alti~{(~1D) zT^XR%RRM}v9iS;20@Ps(^ZXv5k~;$Azb8QH2Lq^WfYzhIE%JU6phXU|7CO!9pVh2s z*n_8-k=?B2VP-A$nDrOtM3_}4lD1K19m7RDj5h0EyojM+Ea&3PT90$_X5GZM1hZ_3 zX0=E%s~aXIn>8OhQp_ryYSsn(jVWnnEx^w{vl_vbZdMr1;2MtSFso`#vo_>5>wO-x zqVf_iJ{B|Ur{ZP>mN07t?jS=+vwp!}C{W6*{iVqVjAn{;5L?4 zG|Rt|S=(?JkI|yCS*xp<^#LV*GV2X0RWoZ9O8!hPSc8w){)<`Vs`C>oYnrvJmRX+q zX0^iu6lh>pSxm!oRB6aOxZlXEoWGitzp+_0nwZrDw@|7n^}si{nwgc}+^ix9Y-!eS zNN;PFshwHR@Cki7n0dix)+mH@GHXZ|>W!qXX1&C{Zp7BZteBo=W$DX2IMknd3^Xfc zkXh9Ro7E7ThtPj0x3LcHVP+i|VU}^ESs6!}l{Ut#w&;aVI6annjAK0}nbl!3duA&2 zpT>Qxz-zc?m=%GuxHQ|W>T`%|u9@E-?3H);V;e$1@C*n^(OS-TUgCk~uq z|KcuwJ8jm;v+RR&%z56dVt=p){-g$fvBnq8+IyM0U!@JwuCXTg9XoGO$D8b(TkJ_> zzRen<0eWFGHrz4m2s++nUGVWfIX$4Zus@^^rr`iSp!z@L06ifV6h=!-#0zA5YF0cl zyiy)gt<H0{cO?C)h)VF%c7CBEjoa+_=vjoEn1HsnA5LiR7S+UkjO=BRtG7kf`&e`nS^H5}Jnc`P z0Tyi>Xi=U)7PT5|(Mx>8>LC^tA8OGlT){hZA4W{WElS5?yhV!<7M(`Vk<5cnm^R9y z)}t-zfxt1;6XS7kf<;RvG9S*O;UwyeKk@HmYBYs0kYTDtdvOYnu=zLIPP3>3Ze!SV zVw`Ew;8_+;z#1gaw&*Gzqs|=e&m|Vro^R1yWL?M@*tf_c!(wt>V$oVymswO9FED($ zMLAbkR16L92=8!krA6oP4DD7i=W2^W*I1N)y+viv6mKzm3wwDhV{a#iofhTY#rnax z+oDpZsP$>q2UpPJ4D(|r>Yt_V_=-vAEK2%=I{#@=D!To}I$X4<^PTtTZc6tXH3MQ{q0i&@nMrAk{h4zsWg&C6KT1$D|< zaP|T~q{J2uZsw!2js*f%|S#=QYt69|_uka1sezxk5U##j=-Ksn_86R_S8y#v< z=h{|Hsl%LgnG@Skzn)c=`c`Ge>BfxP#H#5ntXhHtsMgY|hM3TX+}e^`J90yh_EufS zePr)oRlbf^mBv%#?_^a(e`-9ys<9|A(5k>ejEA#$ihhHwGLN=uIdYG+YCq#tXhc*N3D8+gyYl^*-nrHao~Djx z*pJuQUw>P9li8{;e1z#X>wMR$E%(S3K@Z92AJ*uRRagJ-u~ol4p-xY&8u*-j{=%vx zxL;8(%zA6pg@4)S@7cc}*?$Q7WK{#Sf$_6dqrMW`H}>au+W6Vj)L>I*95mW=9!>mh zIul^iV6#mVa0JDjHYEnx3Mm$4};!phoIy*y*#I4&Z%qD`ZqO3aVpm2DbO zg<2tdRh$0A?4NA<150Yyvq_!iWmBKkHdR_f?bq2fX^Tzsu>W_~4qdm|^bG+!iEWono%Y(~Jz&$%XoT_yZOU=j zrikM<-N$RxJV6~#(iZ&@c8YmW;j~S?&)D?*tWBR$_Z;;-Z`0Nb)Z(H|4KLZ$7I)F@ zGVSo`icL?i*|hhLO|g%O2ks}-5j*e&C7#+e8P_rFxlMK6+SK7+Zoi|J?->v74>nza z^`lL*upIM0G5%-r`eM_6Us;!LHs#J@SH-M$MP##Ud3L)j;dZ5Y?7D=WQFevL*!4Nq zu9Jy&Ig{WphBSkkU?7+Bt})|Kt@RI#fPdSVIA!BxkuFzl*Fzxs9^#M@?e z{Xpa9cJ+a`m0fkQ8LivU59Qj~RRaav+cgh=KbyJ4$lC)J`A?YIK-~rL+u&~|6z6&MP;N7x2rJT;0H#HVBXPo-9XY9yINuu zp2IhmIdB>+#@V$49Vgf|V-kH}nQYfyoJR0eyMD%dRGwzn=;^e>o*B$P)2@YBk1Vsv z4^6Ruj$K3Nk|%ug?dpU9IJSVX7uuB(#TStyCj9^BV!L+ZBnmI3wm5;B%k7$mC0M({ zuKOsuia1blHFIDRvaYc!9u3yAHtWb2^Vi#T2QQIfBV%C=cH-qG>b2Rf;h2geTkJAz zC0A_25hQG*X6TMy+u0vG?D_}AcCyA8g;Tr8XE*tv)E?FZ)6i_MU5l|1L-tWCwAoMJ z19s&&Xji5~)a8g>MKJCtai64yr^xvC_0vnc4&l@**6NL2bN;pK z9ZJ5V4}N}c*Mbjry+Wyv+{Z5XKCy?O&#WQZ;2a{p@R-2?Wd3Sb_HWFC`B?HFk2}1; z7es%jUNHWk=D39oa_F$Zp+`oC3Yi@0hTr@h`qk`Edn^fdC_^TPx<+yvckvQ8z5I-F zC??vWz!-<>V=4;AazD}2MaVU4XLwj>NbPD-$IW!H6@gE4%zBB zv;tr1J2arVLu2u|l|!{VJG2eOdN_F9@Gs5knZqaDJ}Q;!P{y~C0}9P<6?&=KtXi+C6Sxl z@Z`2bx9+f(_Z@2Vfc&00G!x5E@Huh6aHtth-~&uA9cqQWIE}oo92$&?$oSf!7U+h@ z$p6NnvN(<`Z>baJ;5ELZ-Mdk=g?#N~Ap-4A)xmD$ayT^=4yRLV z0-XvEa_TaUx|~W3c4{tMAx<5^;4u1!I~Cw@sx)@u1NKEYRVC7?#^~U6>K{~za_Rye zB0k!wx)_EjF;4BkeH4v#Dk6^9u@GJ2ohqK-)DwKb-9+L{VN94)ohp;&)K^sXF-N*n zOLI8YK9^HpP$4(B^E%ZeAMNuyb)bM#Nd=u6i)n?N3NGx_+agZci#l})reaRjMxNq~ zh0Z0M+Jw(YE#=gE>@Mw8&oWLuL#DFi1YuPBp1-EvHtab#12>)N!g%U8mL~qMlRb>N|A? z5e=LgfsJ_3(5aBdPVGmJCY;B{rmRmhr?N&Q=6$jTiKYMZ**!1 zP9SI#dkDX7b}IiC>b%vd)4vnbc4CHkCv`{XUDS0qG3=q%dx?FYQ!Ng#{)c&7oFINI zIptK%v+NzLKgU{Jaw-xP;CGpLum|U_(C#Xaotw=0H*urPEhq1u_GbP*4gf$B9PP``{~E)*CWsNCZ? zHa<{UCIs^M3DgP%O$<~jE=~$mjmd#}g2ht;^=>M$PYYC+>491{BT!Xl2I?-l&kEGd zImA0RP_gp@6*)gp8x|1fqCj=q94NnSsqAk~Zu zQe6EYGgQWNaJfmJ~|3-cQ0UKgYz>x0y3bC7Oh)Ak^(-@*CaL3*$+NM#QM>GNO>Ozsm9A7y?RHkpMo^*zaY)_b7=*x8(lm{ zcF7s&QdW!&a;dD#rOo&VQ?QHcI9ytW1|cp@!Q*T$y~n5smzJPtq)T&=>UC)hK4M;! zOBthG$`s?$IJAj%>9+)zawWPHo5tLET-uVC0fN<< zUCKGYr6Ge|x;WIOyI4KkrNoi^977IcU1~kfCBt}^9!_wn#zdEzOk$iV*wjgTK5h2BPz#r()E<_Iy-abU*F&k~Wg|MeX^kh(ou8m@x$suYnEkrNZg=pUT5FOhP zqE~pnHAKH{3(;Ft-w~oM2-+EDB=yWDT|DI)>b0Io>F+@i$6W5gx4Y(en6L8!JQNf!bTKP9I-44;< z`ymSWCq&bpgs9=m5Y5DCOnAlp*CD$3gPib_+zRz`YdmJ-q`|GuMz{Vnxs~Ma)?H)^ zaI2Tut*>xd+`0mT)vX|G!8Ds&b27NqE~8r;(L9S=+q1frA)8wxaUL(SyR|mVtzsUx zQX<@H7U|aDXv8pgoLg_PBi^md32t@5twgs9CNWML{e5n|Nq1|04!3S&a89=_p+8H#Xc?Mm=k3$*s^i>AU{E$Jv<24feLiM{n zRNDhXHPscWS7;R#s^xfFG*oAbhbpN|sM0EhYSz!8s$Dx&?a^gasD2tBs+?0pWmp=@ zYk*MRZwytheW4n8BvhO65#29^D)?roo;?XwmZza={47*Uu@lGPdljmV#WQMhzl^Fj zETc+|$*5VAGU^DdlQVM7SVo;#mQjg!GU^g){+m&&zh=~9?9G&k>$fs#Zk9~SQa6)Y zH^`*$HktIWLne*vo=NQoX41OjnPfbdN&eq6X@()QdV4eT8a%Upj>@dX*q=YMjup?W zY-KX5J&G>R%zLYu`JJCxbu(qrnfNR`9M}(?(S9 z8>Ukj)h|qS267&Qa0-QohAG#uFr^F+Qvv*o1|!1s5p73>sTX#k<>)YV!&Y1y6Q)O) zF*Zy$$Au|mVwlF_9$sPkq%ggo!ttqLTsIV^EpYrsZLkmzkvuI-&9MysVAXW`BWwmW zLhhMi>WEd?H!DnEku*C@cd=*=>x4RUi4B?OaSX{z!ZdAZn3f>tvM`liPW&*hWZm#& zO_)9)W*z6T6SFpjY4jFy!3Tu>&f4z?Q!O;dNtD|grp5ciH1h!c4u$HUYe-%f@p{EsmGf?shFB`<|3>kak=#^VHr-VD=TWW5!pdDx6~x5)>0?}q8q zy)b3?hgcqkam`Sec08s1voQHR50m#5{n7g!aiiLMV*9|HpTl^cI!wpEvtNFYXGFM~ zBWq;1+)?3bjlD>T4p%~axWatl>VV70QaN1btAy*wPvJWHOSlZx!f!A-(dplP_`nuY6o%W!RP8?FWI!_}}uxbk-l*O*S>itG}u7G1-2wp+NI zJs1N`dWEZ8?{Iy=fxh9o)h}Gn@ohl3Mh^^^Wl*?G!@^}B8LqTZ;e4(Xt|61d^%_A_ z!j*k)xN@O6`r{BX&I?!aBId&3#o_WT4d=6+aE-ume1-qEa1GlLt}~~|?ay$o0Sng( z6uus=dAGxr`*pbHdOi9EZ?s2gxP;U=j}|9*G$7H#b>SX`CVO-emocxZM>jCxCy(Z% zO*M~tp~cT0?MC0~9vN$TxSqkIlv*B5s_oJEIv)Lpzw2_YzDJ$l*TADnnAy;y0>63` z)7T?J6OVGBEdrW)v>xte9#w$1IsH(eg+~`#dQ_*CN86#+9u>hG__gt98M3$as5_?M z6Bf1eXaj8RJt~E1xPzCd+JX3R9swOa8iPfhJi3i3ov8!Lbn$2(8g=!kJ&xlN=6Cbx z32OJC4m~}(hLycMa`yHp8}9b;D6y|c&2X?E?fZMQ20aIQv=?0l(Fa|JlG`xqJKUoz zlemo$zfp_n9&N!tI5v}UXAv*f&L)1;n!`MEJ?c2mqoDa7Jw(bPk0KXy4%c8^;?W?y zUPe8ad-MgP))41f>b2RU8fb|rSb)oDyoE7w9pATll<{|uI$#81w|P_=Ik$UMaR+VD zYo|x6a348$Q6rq%?NQ}D9yP%!T)_|I+w0MAOx)+uTtw{ms6YO|)`R48i1?0r^cX{r zdGr^&$2~fPQzsY)!6&IXTHrlOpJJTTtU2zV@u=uIk7{1@$al%36S$6XS3H`9($~oO zI{OrxF#8UuN z*3azufC#SNj?htrSt69(8lePKvqxxCc!cUEMCfLL2-%B8Xb-NIiqJ#EmXFY?3K80d zlqwN?50dtHS1Uq(wIkFGh3iJB0!lWFP|fzt(J4ZI;$4>rg>+*alGeYh@ zwC@|Ca{VG?>`&Xl5vn~jLSIKlXy_8gUlXBgNL)*N>mqa>E7nKIv>`&ajS-rIm6)_C zLiccDbA&2xiO^KsKn=bCjSws_`f3MxfH2;=yy3%m(lJDZLUVD z@8d|VeG$q3PmyZ%JyN+1UX{R~_|53m8r;BlWRj=y&9dztLu1#t@*t=h?Yf}tC&|Gu%ftErV?I-U<@9h zUP-Smz*Wl2_32(U$0_`Wnx(y(gcoJJ`m3y0caW)^R|RW()g6D<@#thqNAcaRD7~l<#rF-P)Zv#X4Z!;9QQCtJHKSy%6{RD{T8DNGqPX@yO1GOv@fmuQ zob94m+bHGl5T(6ciJ?c78emn=C~ZThUQzlTZF@)Q0{Zlc(lTtuL&WrrQclc6YQHGC z`$uU8ZlcNnV!;(`8Wg2!Bcjw~3USSf;@X)g?Z9Ugn-is@u*{88BAVggyeI`Ph*CH* zE{syyRZ+T(6C0ys*c7Eko1;`?3*%wL|80v>{PrkK+D%>eM=A4xD782drQ!GkB~M1_ z6!xBq(ldNQtJB1QW0-m-N*^%oY?Ok|MQH)Wcr>qj>8oktxF-%dWh=oXf;8z zjL}>R8Ldv4qcsR`@BQj(7Q?s*jg3|mrs4^HkBe5`c;-jtglO3lX^TZ@mKv=V zY0;|Xi&p>iXm!p(4!IaFZ?u{gh}Pvo(JELtS~H7K7c4AF47gS-n%}?CdR9DIwh|n} z6Pzj;t*fP@m8DFyOckTm2xpMLQnZ%i3u;y-S9EO}twTMc)x9UR@6DKfqg8DPwHr>~ z(b1YdK3dHuMyuR(=9xvCHPKpzk?V+Qf3%9+V7`~+5f!6v4PsQgVT@YfD~>dZQR`o0 z^cJSZG4kP8Y(#jI7|p{@1T~FOJA6cVvl!LHJ>+Q~qi3CC6w@U}L%MRjTa1d2j8R`) z9mQBesC!;tY}j7noLw&E$W zUW(zf&((QQ0O^wk(WxE7;@*JD)g2J_vF(G}#n6(j5I82$M;Mvf<}$x~|b zEJlfFjH1tDwBu!rK48@=)x$M8BTR&P+HO{}8Z#`0aPSZx~|tJkPJG*$`2VwDFi z@o7Y?ei<371EXX01+~V;Ds^0}3St|Ij*r#9_%*QEfoD!>jXfQ2Sb5Lb^ ztQz70iqDMI3sjgF%kSY>UYo?~2OMi-m2)%WZJ{kT!L>D3KVv!0;WGk$k5v&2#bi|7 z7OU;}2J3ciBioKxZ9N^UW#?kG8Hwj(wH_BQ#PXajR&!D0B6GuXDOQ;;$ExX-San9q z)mW`S#xSJ3q~wYw9mGYGiLxc6f9 z558jNePY5{ggqeUN3mRY9;-%AWA*rXtZu)cCNHVan^<-E5X&{WvAT-fU+53Z*I4C4 zZ%j~}P9Vk*C#x||8IjWzCxd^S9-@XhPU)HA)D|Z)$LW1m&Si^JXQX70Q=jlS?Lb>k zoch8qB2En><21_~rxkdQ^RaO{5YKoCak3STQzmb8yk$qsRHb&S(I4Co!F!#Ewp*^Kdg7bRZ#@5XBtz9GlGcy-1VJVnC&c;&%x9L680@F1T5 zr{mTBVZ2`9KMZ>mulhsLS>Q4MdI|2`YgTh}p$B zdlNM5N`ju=Nl^Jm34CUppaPE*Q~^Ox5)_7-PZRV7tDjNV7YX|LC2R1CK8Suzyl)be z`z_<*JPiLP=+VanMSe=)IUY6nlAvnnj;%iu^b!^Q5|z`CsA3q7Qu{R$Ef+80Vx ze;5lV>enKPN-mnH0@#i(=vypNC(9&iZ>2C;n%zWA-6SeVWqQYM#DhZKa6BYc8`^feqQ61s+OVY1!88*vtm zQgO?bQBS~9vC})zgFzM{N2T#esy8u7 z*{39_?r+36JxK*;a1P(GYi5%6&*wNcE=bY=lv&6cEJ{-E#YsA|oAdiPkB$2|k1_{1 ze=tdn4kfAmi6pH-!;?wsfUKujn{)g;&-&qSOumq$7MEEo)VjjD;{_^QOH#Y*?8*OF z2UvfwHaLy1hGbrMChIxAVTdVNxBZj(4tcWHAeT8=E^D%?z|WS#xbm(KcBNU~8AG zyzPm(W3r}nO6K$7WUc6tEOXCfjlBev-#<%Mh0)1+GB#ObCnWQkWwNeLN>;P!$;!SUS-ln|D}HgZN*_$tK-@gU*oTv~ z9glGIM6!%0sS}Q&(y3&vI-RToXOeXe31^e_5dU1H-=$SV`}guS!?m;3o(7A9kPE*R!waAFIl6$Cu*cM1Na~hC5R<1^$^+G#-IjQdA$$v!-Z9wiG=IPf?^NMFS#IR3I`%WziOS zyeYbcIWZ}^hHLp_^PC+Dkd~e(HRVElA?(SZJMGk%~G_hc?#D}rf3~(15&gfXJ8(fq7}G4Dn%Ja zr>OIo6orjVQ6dJQ}o-S6lGeRq9MyUjtMJM^!KV1ty-O;`zW@S zI^Z*MtxM5D?B1Tja}Mf(Q*iH0QDeN{m7i4BXaw%xWbJOz z9_#M2UMTf2MMeLi4OYHP(YF6m^ct0akPG-rF$(reRXe1ZQq?gyRqOC;NUAy^gF97Y z@CX+&rYbN~st)20bkCfsXPA^FRi7hL)j5(r390%DOJb_x>!oTK3N}pDM09GJs>^uY zDpjRgr|J`Gv`LlPrm8y1bY(oO>y@e@z3D$KRl|`oJ5_BFJ||VF_!H&krfLN8&r4N# z6i&B-eI8}vF9U)6o^?ey}FHhAS3|m25t5daXZK^74NLBB{v^kQh9_Vv4Rer~) z1HK(k)qoSJ8jCz9Q?>RK{ZFULbC%pLq$=ib#=V^?`<+y6L!-N?io2Jp#ZQRiDRDT{ zR4_128J4DDo-~=FIUbXy zI&P#i!~jx;sOnWp)<()3I2H2qm5O@oT3X*}|kpbz3o zrm0<>G_|ak#^0Ar<8RWWX#{dKOq2SisV15tuwR<0^k>`wX&O5?O$~;msXgL{rs?1m z;-8wPC1~+mnug3wQ}tPCYKBa+(^PkEn))nF(*#Ukm!@7D(li{tjcHoDDNTu+)6{lr znvNYx)1;$mnul`7hz}W$r|Bs+ok`QgOKI}nPSf$b+<(LUcWIi7vhUM06X&tvW1439 z`Q&f#sSws1eJbkj(+OO{pa7p9n00M0j?mQhPZs{9qQAp zjGRZcOg=3`bY`F4#QOACoKJfb=$Gizm|Q;nhuHi+eS)QcPZ0%uO2zcTKD8?1Q!mUe z>eI^qEAG=bSWEb{6>kt;+NUlUh{Q5J^(^b-Z=LuwzXD@d_33;ypKAZ&Q-K;jZNMJ1 ztm#wn+CEi9V;sYlIzBzF=hOHGK22=I9KZUM5eE^{*r)PX*o^qv`7{*^QL#OB=|C=> zd_1S|XZ(r-ulaQ97WKXB zQ-%*dwLwpKKl;?Q>Pr4>!KFUX=YfNN1f8QpZ?_Qx^kwas~Dc4 zwJ%-s($iHXXS#;wP1lpc>FQgQ@k^)cIv!z4nRI<9n=VtibY(|GK1WPPcUa#&5dX^hoD>7}NwEkfk?y_W55;_W|Za`Nezu zM=t^be-WfeQ+iA2Da)p30!el^yVTtTq^R_&(u+uw-VseN!FB^cTCFPhd2X>gEv?-(4_L;v)y2m?hG?2Hr%B4C^&)|e>7>{ zNRuv)GU?VBlMakEsl+(?fyGD}Z_?5UCS9CpQt`>uGnM5(ne=*wNk?Xy^h>%)17=a{ zY#v{1QimlbO7;jy(Q4cTbY`M*re;Y8oJnv}53 zq%PapKReiGyG$ywmwmX8mOE~z861ZDj7i^}HR;7U zlO9|&>5uCs<-K82E2QH9PQ!JR`&f#ETPAhILD+AbbOKMX_>M`{?vmSoCjE<18O(gn zH!A^~kR`L3b9&7hlFzIuNX&0m3mieAkIWj1n#IlXLM6<~i-Fix(#-oPv&L00Yc5hN zn$;fXP`a{NW5KrW~HNXJ+r>TKPc{CeU$f`)yXic53b?~ zehrW>#@09MIb1=r_TxG>hs^2_HtWX(v#w!Al3Dp9W<{|YnUl!{m*7q@t4c$&wj*0( zvjR<62SuCG2jp)?y{TqxYi`!j7G|yef;?NBHQ;Nr3b&bMRVAc=#4}p$m z-NMXH#Oh*}9jEYPSF>ir)r}gyG3#|NvwHS6YifV9x(uLy_!TEmWT07?1S z(-gDrA>&lDTB0)!qTV#}|A~0`aJpIF&M@mY6q;$)e5}KOl{J<6UmeZHHGFcfj)EAD z{m6g6j_PADHsAp&JgB2qn1Q3n`LK@S(F03y8)Y8VQ5q)U05UzUqq^vVg}8)5PwFTc zraE~)p)MO_u$RacKHTU4%!g}Fy8nvU}*QPrXrNXKb>T+O0(*oZtPi&F6` zGMFt2V-QZDhGAhYQj0zhSX2`mP^f`LPjNEEqV|m}dKP0@D~nuTTIBuOqQR)$)*>Hn zV`e*x&R}$V#)q?mMbA;IqeVCI0&6;1l&?EuBV!MX@?$EVd}GndZ!OyKqeYoUTKH|m zqMc|k%A#LJThwNZMOPMBRBWL|y?(Z++aikwU z>Jf|f9kb~EKNgidZP5>Sd&Z)cXDzyf+UG3#?1F_k4J_(=i$0>`Z41XnS(Nz>`{u5N z-vuo?g{k)}+V#ky?;cxJ@QFnuQT(Yzjh|aMXN4ZVuxRpY_EiR}`of&i%Cy^7xieYS zHM3Q(b6Hg@w^bAJSoPM;iXi??c}!>UcVgZ^Htj^aj`@e^1V6LABF60ORSWL2ApmHCp1 z*UTylrleYxmS$C3jKkfSRb`u7HMoUUjxVeVp*L>8*V3xht*uIGV^!m?tQwDdUt6`b ztySxB5#P6`P89BF)qT7{$xg(^LuBaAa?I{&)oIl3ZB>CjR+WN*^?j+kAL|XXsvaI9 z<8Z5n;olL|Fw&~lORSoO*Gs8+88srya;vOstm=UyYpt65yH&s9DAG5xZ?;)ECf=(0 zJFLpN+p2zhtlE9RD%TOK8XUFi(lPeON!G=Sf2^8%+RE=?R{ee1s?TpzD`sKjU90wI zw5dcUo6cpisbE%{=4G>K1x|ioQ@&g_O)6w#&M%uLm$2y=hL*Hx3W}AosaI*60-xE` z2nEX9^j8I&+IwtTj5M!}oP$pMxx zZMud>Xz-Pd_aipW@v*5?N1FzJV^foFi95umpOJZ(OllXqVAmA5hS>GbMAn~TSBB{ zfnC2Wwd*>5T1Jkjw%o2!zuHxIg9ao>Ip%>UhrndqGdi#;Fau;cujui_=^DT|Q11(WXM2?pI_P+Ej|uD!j!1D#xiL zdf_RWRgKfAYH^%T6Q{p$!xYCHmvP#FQPtx#6aE@;Y6z1hP783%7N@ItjLh~peT2_Y z18yXv6}n?ECSpET;{k@$i&GIt9LJ`_$>WaWGew*_`G{r2X<8soRT{);TQH9Kz~fYP zB4Z`i)687)Dm^w{>&L|_JRzR*BjVM2a=h|Qjn~i9;$@#6ucI^K^;LSj-pz{F%G zJTG3Gi#gP&xI_Pya4^5QgYWAcT87Kz9NJdFpd+^xh>e`B9V(1VSlQm8tQ{Q6+>veZ1X(&U4vKenC=GeL zI8*}LVd?7Ny`4j?dpWcoOM5%`yyD<@XNOFK9E!uGp=>+Mp(D7AUxqvQ`{GcGkq-Td zy|_Kvp~hnz>NC}$Tljp2Lj%!lzC+W{V1Yxauq||Oe42w}a~<-ocBmoht#PQ!9tWRM z9r|LgLtQaxpF`CzIy4l0FFUjW9j`dl51p?%5As>QpD>D(+Nq1m7#+)Lm>Uo4fUkm6 z$M6WBR%1Ed;gX3s)t$^??o>Z4ufsUVSl6i{Lr!Y3x+#3Dk(#bYf!IJf|k1_-~AfroTH?cfC_w zbVa#wVV_gy4zSHZry61zK0V~r;=@k;jSfeg8i1AW9VO>u#63ryc#FK}owB@lf&GF* z7oB>7qL-YCLjumD*kz|`B8W*ikBnEGO2kOCyGlQ?@?WR^!2{&D=2RKDF$VWm;S<4RB7%~GOlBJOP5X|{wtTpcXa7@?Ca{%L*(q{QYlz)0MGF9 zJC{oIq#lgMYP{%2j6p8Fg<}Nc!av%@9Cj{EpY75jJVT*1E;ZQhQdivA?^2!v(hyjmvyV{f4SAx7-14AecDEAoVaBHW}t@|h(b}JrJu@z4e-71pgRyWK< z-4wTCScgl<*VwJvxZKpOT+Q5?6LV`9#(v@E8Y^y@+Pc*U89TUD2?x5mmHj)n%qZ5+ zEf@Y9;8vl5EdRl+DmXOMtrxKT=vH(5j>{-I+ASx3!gfp;=jQ*hb>w{Tt4WIAUugJE5JTduaw>IL-#cqwmtQBtUK(XK4@?qC1 zxAv}~pO@XL3hyE&#Cg=g=g}3vM{NThd6GQpgh@?3 z`XJS#@o64?8uMsjbB_|g@F;UDkE&o%dk>#GJX+bwBS#kx=a_l4_ZyGyqxH8QeTTX4 zedm$0r$@(ndDNh{M`LjcW%_U*$8j0U`+D>cfA=HK0FO?h@?ej$4DsmFDDq0DH`t6L zxPahnj}|Xv8)W#|qu-IViLr4W8#hz$R*#DAWEq<8@@OWC?xyxV9!2+gIIfl24ly2P z9rb7j&Z6Kk_5yaSvmTYlsdL;%^-Js*jK53{$ajUl-|#5z0s8=Z z9(r^S=bm_!=_$+Mc;?~#Gs{ry1^W-1GI*6UuUFOJDd1H*Tq@+%GnD)Ug}vH>Yel@8 zSAY%>epvM0H(usp_i7DZ_4KMkZ!hO5dsU~8R|z_awSMrb%Mh=Y;qFkcnhp1AAU2@akKB&*>Lu2W_Nway zuUbr@E}Tb}sa_RB5VNrv7tv&zSMfi2`OeU*U9+iej+gmE>C;>uo9C7NXD{=FdR1bP zS8vgJv6tg?y|UunGWxKbWh=ZIj|nSTca>L_*LW2{FC6{dtBrqnbr}secr_H;H_?=@4a2@-`!r$Z}sXSa_sY}Exy|CRSyh0;MEm0 zIONrR4F21z#khypcyh$6O-H@zf6S}Uaq2{m6JAZn8{|LfmF>M#UY&*WG_mpNS++;Z z^Q@0q?_Kb!-bI!p{R(v<|5dMwqw>GhaE%IK@|^K!nJm+x1p;{pGE z=w<#wuWq66W3OtXA-;V=o+$p5T+j@ok@q=0#b+D4goc}*T!eX5Vf zaAx!AZ7!dTGCnmzH%u$%Q_J!`<*ne;mWn0+%oo4Pt7p|OR)v_ThND=KF)9Q zsah+>#|^Y@Pn(pJq<=Y2s#|Hf^PjZ9XmB>(k`pr+zv8 z+MUPGdGCIe`rNNytNE22=a;FTpWjye^2Pgg12Y_crMUbm>h>$p*e_QTzsk4v>t+|f zo?>2CzY2EqE84@a&%W{NSuejb_x9@!!hQUD(bun5{rqY)z^`iq{d$B#-}^NJXYl!8 zzdGPDn*HF{CgdC9R};*`Q#gkDH5j{)I?S&V_-MFav#<b#@Xe5?O);7qP2eYT<6yi)ZFOTzX)#fbMBX4**5!CYpY*wEJ2QK)QsBb zh^;sdZTBlToEVJp$hE_-(a5=z{E)WGuWGwlhSPBE@hbsSaTCvwZJ%Gi;q-pLx*qUr z?NPtp9j8wh{d$XEF0mg_`!fAN&MSWP!bMcR%Ht^gub*>q>G3tc`r$uRz3%7SXJVt} z4ZmjNi<@kF%degI_%?mK=U0!%Jodz|>qvb{-nfPK&*(QkeC}5#?86@~i1Cv6h`l0b z*j`f~_TZN{vFYE+A6M z&>}p*?$X5jj6C5kOYY?iEv#VhTb99ZSBCs`41H18&~~hK8+?yI{eDB8Z~&DIL!)sQ z!GNKq$W`A^2OPwT28OBy$vteSNrItAsGnpgHDc%#+{p%?DGlXMF_ef0__>iGOJjrY zCK$H~F`KeYGeebA4dqTV)E9TKH%2^s(wzE{)PkJx^%sUpw>0z^J6aihUuGzbju?d% zIEshJ*Tzr{G{Ok%MAmJq#5@04L$!wo&d zf)VVOAL$crqT)zHopBliN3jl8jHXXx49&$kXe_t5h4teMZJA*3S&KeTqIXD|Y-kti zOkw{`rB~BiR3s#}(9rp}!eAhObr{I*#tE*gtFN+ge^9ztjKqh6?>*XxK(-`;#%z`7eVx?#LO( za2-jT$YUG%Z#UF)hoK?pyVFpG-MqfAa1Z-yFXQ0+K0{ge8~PEM4;boqi2U)#QC`28 zf6UMa$Jy5>$@R3Mnr95Pz}d6({+yxD&+{C_Tdcdl>*pfR?aTDy3ePX3Uo~{(UqiO* zh9=+OwRO|bJB+%`^XLvaqV@xx>rd(HGefoT7Ov+!*I&@HSG)%C^=n>pxdP0S98lrh z0j{SRP|G|4jrceqN5O!8#M~kQ6(|`{&C&rqN9)f5%J_Lev9bZ}DIZYn3IXlLiHZTm zR|@DbPE`)5Y1M#+;t;l13vjIrV&PZZL*D8EwL$Kh0eSJLPC&N00adZ^I0CkS)}oZ1 zvC$5L@f4rL1ylyzu-XyOL%c&1XF&T9a0T=iOm4z9bUod3uqV)BBP)9_zDYf z1H}zuVFLa}fdKVj6t>|FEcFBGg5|h^LJb0{kHOf9SEv(YT&%-eSV94=?GVr^+(G#; z{X{xW<9`VOg)tI4ks&c4E4t!moJ0PkfZXVVHMomXk$@Uu6t?0qDkT#eGjRmjQUbE0 zE9T<@iZl$UAx2{dUZ7eddVyIuirkF@@?#Lz;}NPf32@9|Kud5FpEadl7=!J2ifYXQ z9Fs^-aTTRf14_db96_$MfL!BD`9o0lQ9sA9u8{k5qfbvC<~^X2r6+<%JSzy=7A4t$6FrH z98zO^kR_xdn1i=jL#mKHq@;2oWiB7$`j8>5MC(c+^}s7Mt`gE2+{gD-L&{z!Brjed zN8OOd;EpB4IZPovaD`OW9nxhy#CM*Mj(bDe=nH8tO8Y~~9}Fo0nL;7`57Y289MaVU zwn4qbkbX}I$=N2PNgaua=HG_28Y6m!w7(a(eL~Df71C{d*q814g;cG7NLTO(JqLtz zVqi#v28A?kd`O2dXhKNiQD`EyO$w>xWb#@S(n~B`9nzn0tqE!N+K?Ko3+dORA>GC7 zVYn0I6;0VL&|+Qr22S^JXb=RhzD0gTKI2>d169ZjutmV>VjgoLc0Diq@Ny# zH27&qq30}nLG3Tu?o~)LUWd3=MMwwUg*cuqteF|ZT9hfQk(tBllqIZ4_OR;a4y$aQ zu$F%q*803*4gFtO=_SL8RtW1s#jvhc3hQ{~uy$1mYhJamCY!<p&9DyF3Tu1q zur|~oX5FxgSi`!BEjD5~!isl=b;}*rTW?rD`@%Zu4{MGQ)&-0Ygf$oC>WB41gRrs( z!zzaUDA+fw6lCugRw1P0RsXR14G3!jo?y;&;$Zv?;-K72;-s_9EaIRC_HN+*M)Jcx zB>qXAe^KKmw%HZdMNHUDT`0dNtRZ{Da_St^^adYfN#Hox1kK2rpb9w>lqqL|^5#iUkq;Bp5L@8Po1h%| z5_BJRKW28)f(e?1g-TSV42i0XH0;Whs7KhJIZ+>HNmRe=i5gZQQP<%tn5d*ei5iFN zDE>*J8W&E~eH18?$Xw-#`nyD;&g09HiE3RsQ3r7PvqXK=hUFcJ)hSUM@T_y9@_n1A z(t{F}b9ka=PDs@9iHXWThgkCx^&PI`_|J*@bWNh#V)ceZ`8Fo1<6qqFPE_wxiK93Ya`mA-5^7crQeNmFyY)jH0blQ`o5{Hv?3&V~isoTjUJ%KfEL~Zg%R5~f5 z4PQjGrBy^*TSqjZZAAO=tXo96x<@n((QhJ3=owMdJ`wf8^S%*n?-x-GKS42HFNA%H_h^lUj zXu%G0+R3{3aCbym_C!>EZ$yrL5!F2w(Z?qvs(_VeBl`YaM3XK?v>Hn;G0x?PMn8#Y z#*2tNFC*&sDx&RTp70~1r!qic%%BU7|y zUW!)iO3^k9+(V50DKcM4QMwwcS%!w{iI=q+Dx1+z*0v2*Xk$aJotUcmZBn(PeX0g^ zPSv9xscPLbRR{4+?^F%LFMU!qq<^X=4M^quzEqh;af|6=Q&nnQs%lS6)yzq$a!*a= zJcm>*ot~rr)uHvN`s0sO<@_^M4vgBAs!f|y_1&&i6*-owi(G+v)P_Ia94deZchH%;S%X*&L0 znyU9tQ{Dk-3ZVbAG@YH9ro!oII)HPSFe^29^uWLG@0iU9~aPXL7H+e=00w$ zN|SAMnhadSt2Jq=vNlbFFa~Gv@wzmHFc;a^r>Ot}8`HE9jW?(1F-jat(?Q%im&Wgp zX>vay25LT~M%=`x7iqeLmoL-Q{8gGdWr}JUnrDuxGd{`^)!D3370wpb0i45x>`|F> zM70Sixmb?JMWRY98dVerk+WD-E+k+EP9pE8Q58e1R8+^yMrA4&)#8d#B~^|x$3j$J zyP~R_7}bR&)`>(_t0~(;v8aY)aL=etVMnhhbM!~G7CX_WPgF(vM%4tl`bAX~r%~>Q zsM_F@AyJjb0c05#RSOIsK`pS4imErNjE*V}xyMAgmRVFiv2A=*feBI0v54vnwxvgv zVOErDAxE_xy=F%>W=@oS8P$=w)HjcHa1=kykE-F)s3yXFSRj|eQoDoxMtC+rQ9n*ZI42$U(Y{YBi7#@=yBQOBiWYY~x~Tg>gv7HPjv-lLuSSd_s)(zcH1Y7}IXtL*q#? z4a6~6C&##sTTF{_9GCI&l$aW!HMXMs)R-*OSccuxV_Y*creZTOJEkT0a868j(SL4C zudsezOobN2bOy~A#?)q2Ozlp@bo5kA7t#Blm=56|&sPp;3t@AcHKbjLAIzP~CPh4b!ZQK4i#Sd9q9x1c% Q@VNiKU8euP!T-DcKec_bQ2+n{ literal 0 HcmV?d00001 diff --git a/Covance_UCO3001/browser_profile_1/Default/Local Storage/leveldb/000004.log b/Covance_UCO3001/browser_profile_1/Default/Local Storage/leveldb/000004.log new file mode 100644 index 0000000000000000000000000000000000000000..5c0a4c392623cb5adec9202bd67c82d4d709e398 GIT binary patch literal 6713 zcmc&2ONc93wd03T7{raZ5s5)mw5wB9`BV}VCjX@K>F#_wFa40>rs`IzlKSP|s{9@g z{D2ErGYBezgQy@PE=Cu^Ll9TO;6iXA2+m5}_`sD*XFRu3dHtE>y?*`B*Ne`rbI(2Z z{Li`PU+LMmzJ3sS{b2L=LH5JRy63qx7mu6H*szaGG*TSm9x0A>5OJm+;yg?}j(QG3 zV|?)0R=JnY7mMX?H@E-bry17%{a1dUNPgxMk?(|jyaKC_y<2j0BR;ICBBAre0m!P7f z;#e*wNn%nIghao1lHhqEb{M0sV^fE;k;V3pkxePKqa92!B8nbGwi+$rIW`^F!nSu9 zZ8nRshmlJazK?Z#EY?*MA6W=gi_QXdmg$ZanMO)^FtVyuIEWNfRhW7u%Vt!c#PLVQaE13}N3 zV*9Ryg2O<>rLe_B@axcx+H_qsQkW2XZN<0q#SA%49L6vQLcXRLm5w*y*j2 zWN+nSDpTKe9pbSVxF1uPk3(Fj@>X~TiQfF)Zf@bxE#Mk<2!%L%a-{{-Zd^G7FImBz z8e|F`#P32TPHxw*~L>c-fI<^O{pen`)g(MmOTa5RS zbUYW(Sb#t#WxVq&gKh#cen~HGX^7k42G>57q%*obNx%hdQhzkT%1(W{{s>gZkhZ3l zsWG+ zN0d6uw}S-yq@u_ymq5aVYO3CF_)Qg&DOL#f!2gNIbP+J@8PGw&+G6;I z%65Ue!eBOQuHeT|rs2|sT#gCBs?6$Z2pk)8sQ2NAWvI|aZND^R8RlyHwN-TRD+7my zWzebO-DgN#NV)sZ2Q(Ikj^y}&nJw<1s+kuW2-SVFu~@?AfB#*+5qUg zY@y1529PJ~(53=d*({hIp+w4xj!YBVW4zmlPg1Py5r?{vyjgO+W4{C)R!9W+xcsd8T~f;~*G_HiEZ z;VDD#2F2M__h;4ZTHsWNv08UibZcE!ZCNee*5qw5-oVQtyd2_}1AK7cFfp-+e&Jqz zL+e^g@A?$-Xkfof@>^N&7y_V0kaUEUDFmKvV{_9W$|^P?p^%llqi=N`(`0$?>M163 zSpJ!jw_N@IRPQ?OEgLju*jpM@hb{yY${ux_XC*ubA!V50yB1n<(AInB z(GSsvOe0Kp3>7pIbkKkgEz-7-$0rotl0g+Ppw_`=54<+YXQRiy9Tj;o9TkKepU9@;)PM(4 ztisoO+&YUZ)Aqp9NxoVw49kAIe!9L_FDm2eGKC9$adL4&ra%D-6Py9-GcjS6Kg$lVyAR-#fn#W^a?lv5$TGyoE$}d-nrg~AB$^8LeTTZxiDScAt+IZe^$v{n+ zjhWO!iiD2y$X}lKYQm{Dt&X(xJS8`K_M*QU%p0p_)ww9%MZu~@YyyjG_qWMy>NSG@9e@I)(mGT z7i(@gfsHz+jtbQioM~s3LMoMcx(%1J25Pj7ska!`*Y;v^kfM{tvn)i!Mxs>7>ld;4Xq$C>m%2oNymHOR!Zz_?3J8#YgGCASv zO;R&zTJrRyC6w7beL{TVD>zTql3lUlB*A|_* zHcg2$T}|dYnq^j+<5>qLGRb0l+9%p5-&5wux2Eext-%c>zfr|Dr}E9xx^EB6ML|xF zCQ@mx&un`+S2Nwrx!A`|WlfjEUT2o@xZ%(nq&wv@Y0FXpms$xV)k}%KwV?M(ZGk&0 zo99{FTjbYNYzT7exSdrOMKnCF>GG(qpWnl)rhm~~t?RXX-5E5``ZF7)xC^i$B-LA_ zoFvSggsk+UNoRo7!>Evgq+@Q94rCl5n-de;r1S9L3;Snn;iRq`&N;udACo;}t_?*a zu^mIv8>7IFe&qXa{pY=(y#4r-kxyM4j^4m~^$Fg`fA`vN8jrsF>OtfO;hdEH{QZk> z&Hs1_`VbqP-gW+%$|fcLf2EUWNcqEme&dawf;K?P^NX)x5b4cO$`=tSE2guF^h*-y z&wu^XFGG>udG9aZTSp>44n_Jfv(jw`+~2&@fIF3xpc2CKGnjc7+3+tHONyDKloiER zsRRS=1mwWo1MX8D5eq5UXXB1&`~2=R?QAA3W`&nzfJZ<7(c6Ime)Zay@jKrJpZeL0 z`&5Qc@#%EtC5iO!zdim(DAFGuz5A|z5cx$Y(g&DN-7WGnd|JpP63+R|Bme*a literal 0 HcmV?d00001 diff --git a/Covance_UCO3001/browser_profile_1/Default/Local Storage/leveldb/000005.ldb b/Covance_UCO3001/browser_profile_1/Default/Local Storage/leveldb/000005.ldb new file mode 100644 index 0000000000000000000000000000000000000000..00e5145a4910ab8e73ab9aa5dfb85bbc04fdea32 GIT binary patch literal 27475 zcmeI537i~Nz3)#YGp0M~saY}^hLD7rCV>DmNmX@i-GrFlyQi0#>1BFm6q@Q!cp7@OM{c9#G zSqK5-zUSmKCv&Q%s=DUXsZ+oDpa1VWJDD5NxhUk0*=?C>wWQfLZY-$jY;i+DNQr8t zv_Vv7&X{T^(nbW;M*#RTqk)j5*q{>x?Tm89x5i zU%vMFCto?E>+#&`C8lggAAiM<{>S4_Jq&A}oQ5?%So7rPAHU^}ufUqUBd}&wM_$*qw?R*+*^**=-Hu@-R^!HzV{p)A;q06EA*@qsu4XRtAy7#*0_qXpv|BN|M0~SBE z@0u4o`V45TiArLFXKnZdLRyE#bko(pcpARJky7yaKYQlI&-?@ST>D)p3A=pb%YV56 z4)!6azI@$-zh6hT51|QI_~ch#{z-cuY!rco>py)*E)p>)sq9}I#MFFM z7_Q1%by%ya6(KF7Pa3VJ4NFiC&T6%B>El6!a3im;F~B(*&quZlWQ3SotH7LHN&TDYR>D@{$! zRD;cm%RFSRW@q5H7iLNwKSxaaRRavMZID<|tIpi~G-}&|+Ob(UFEJw&i!z*>*_Exx zViit>W$IZi3vG7CPK503AuLR4%<7A^P4!f*B^2_)mTXnqkSpdMb4uoIE6+m3H075H z@`f1!Ze4k{l&v(8Y>ajd8*t2FT!yf9Px=@R&YrT+=iwj7N`-7OjVc$NXxlkC+7u7~_qY4);D-DZkQOTxj6`>04X0~lL%Y(=yYxe58 zUzA9Ku)x=lxgu*NwWz@b*=o*eT1~E)ZFe`30a_Bf)}&Ult@g}75;{Uj%@(WoxsYjN zo!r>%MzZ~CgPNCL^rQBR*TdE|O|E2%iu%G$sCx@C4-R&vvs$(C#4php>>w7ha} z>R#R5zoMJkfI9lnCDde;S%hWIj^cM}e-K#!l1i}od}6tyywEU6l1vOm*q zT9t%Op~2mNjdi6fLa`ct6p{PR7qIKs!d}^#QXwm5v2cGyR-i#LD_&St5;U!$R;0mS z^Od44D_0d;NvH@jnoaIQw)Pwv9=xF6Cdu`zD0j!PjoCHbzS94L+rl!6y_y1tHSF5FRvKSe| zdP}twoE5f?{0))Rvgso9o}^GnCwJXzb1v$NL@9=)D702Cij`(bzr;BP_1lL>?e4K* zY?EQg9O>>fSa^CvCo(W3b?G!Rz_yVaU?bSo>kMI>K@(NSYm2tn$NWxc2QejWlxM3I zLBz8LgHWvr=R<3$wGw6wX5b1{YFXH-AZ9j}Dyot#*rx`s&1{%y+C@>V6{{PBQppaT z5-xOB6yQ$Ub)lgu7kfT#GRz1?`y*)RK?WHrvS7dMstmgI!)SU8ZTK2I0+jm@dmfqy zqAnS3rb5bzjB6%r=+Z$9`*WMUBs?zv7-`cVg!ZhYh2r;Z)8`;lDWev5KRPjt!KSyP z;oqnJE9xGY*bIH6SA*L{s^Pf7Ff5epp=&>=cjk_{|JM!fHg-u8Tx0u3+COXO)+!3z zm2y%LMdO*DyuqMps{QBp{FfiYvuE)Be&{sSj4IjwVexl8a1CU!B3F|sL4)58?fP(c z-?&!HOj zT3c4Yf^G8bj{R-9>Y%CpD+U;~u-~)^GZ@j9m9RA?ID&}vwiSi;vrNUTnD1D&wgjD1 zu2f_xx%;w?6}{q-`DGpY6$dP`ZcTB~69^)}=bjDFZsQyT8|_SOBVY^9o!g!UC} z`sHtvlIs@r3)N&s&@zKNjK;Q0hF)^6O~N=@D9FXMJh2P=nz*W1t*BZ_7Vo*_dBS+6 zd-qTzg7%LsdTMNusUp|a?C)QA4uKTN4_=EIZ2`3Zhv=yv!bLAiNv*Hc@xqT#7YHG> zHhAxa z7q()Cl3Kc=i2Cj_4nBA5zheCvS&-z4hX1&u?-IOCRCk<qX=6@P@k={;0-c|eHCPv`$wLE#bzr1c z9H0n_9Uw^?LD`_<4aLmcwrv~gxo}xzec$F?cw3$9`<=;gKi*G}G)422aCYCPP1rd- zD?0{kAKGfpSDR)V{&!0s`=_=-y4~de%cJ=$jJIYF;g1cstguACcp)&% zGfG)#i1smixWu$3rfAoQP>?b{E;X$=>qI)|i{@pg>anx-Ms#{4&8MuIm~>>b6-r2y zgCl7o84akM*ROC>&6?ZeEJ)Liax$JEe6zV>*2RuGqD8qLDOC~@QwWr~kRWoxh+U}7 zPQ-lVn3DIV6t>PJgRx>G-b~a3&7fDEc1{kDyEK0+7#2dFj1qEZrfOWl;Y;vE|7f&T zNLVrzZ;2~QN{O3Fg!8RTd6+GZk>v??c%(T_PUIY(VXZtJR6Ju0HPUJ^Bk6H%HWzGo zrXos_^28Y@HSCMT{R+V~MtEe&CG*rg>TcO^aIWQek_l@m(>m$AfRb!|LU z8n1B^8IRqQiF?MBrnO;B%&?RsGTuyc+`MfFu3hWf*u9Q`b=co(lwyV0_;hK?msO{d zPG8Awk+c3`Ddq5v%6!-=Iv9qpe;eC-DK=XU2!T*GUu{hJTg66e#uaGJFr{kPMP?!? zZ%ws3q)3iQkTI*~C7rZ5mJl>oI#rK5gGm=N9LS|P!okr(I_CB!$4gv1>W}5QilbBy zmJ`X!DB%xQd|97DkBx>%_himdCZ^+bI7G=pJ|3lKeb(7hYuw#x1xqc9lXU0(yrXV~ z`@t3WH6nE-&rs!zMB5|EOu-XOmm{D;XlFPduP7;dOsosFnS3kY3k)Z?TEHt8hb1ED zYQ>9*Lc@_{Q#sC6&y`3Wj62gQ~)I~9wRE!E+vscM3axZRa-l5@zekVWA9 zE=zo-p-sBNCLMYsZ5U~WIb_6eXe{XDb?mPG2bF-%ptce6uBzCvPK_6Relr4V%)t4qXr)o!seR_+8M(VXe{Z`%(FMR+o2TLP9@ zdq^pozi>z@u99JBsGd|SnslvrzVE@&w-Sq}GJKkHu}v%4`%R!2rOl@;82$G5RxtL? z2}ZMU>zraVfMP74mSEg+lwj0fxHkU)J0ux<=Ov^3Bjt1j5sR_nwP9hlR z-lae?-gDQxuNb>@#VDsTy0+8>qp}J4mrsLWj1lvKQGY!hk`1n5N@X*p6d;(x-o2XUO}==q%q*+4Y*9;F$L7p{8O6eH5Gy@mzFxS$vp z6yr%1WB&og_?gJF!3J<%UZkfcU>wzpVh`;st$p>hsMD0mOrI&Io^amzuNFdl7D9+`sSvlFZGQ2CFpmy73B!;zQq%--FoTBIyo#f1 zdS1ctSMfbgM(_%erpp@~53nV5N~W9Ma@k5aOW{;ugt61(s&m}SCPH+qNY)b>dDK#z zo*J#XeJmdt6(T-8FA00x})V zHX(aP?rMuy2Cu^HCcL|Ad#V%n;43b|?=&H;?>YPl59+q95j&r7pq{T7dU`qybv6Iw zchFtW-1Bc=T>iukWaJGn*}C%I4VU@#d2vD&NTxz)WL~6Z#y#OOS>@aB>6hlx#^O}9 z({_0`+Sq=6-^;im)-2h7w{i#G*EHdmb(()~?3p!O@F$}IW(x6H6UO{@=OXt`G_;a6 z?isb2xr)1L^|M|dpRu|;(VD->`@*~$q!NKh!Q=J?XqP_}9*gJFE=HP^=oA+h#>*}` z+ng0zS!xO<)gUWKt;kXMCiLt!^xEbU%liJ&fF}Al43u(9?tL;+UXF83CWd-fc@`~h~oXGp57A24$VWo;)3tB8A#7Kc=3wB<=>=Go@z;)leZ?VD3 zbNlx#KG9cw-{QHZZSLC>5eX)*5X!7nu9OHuh{vRQ&B=-KL|CiH0eMUkNY?5dp9+mu z)D&Y^GF1n(Zn+wa(}K_HNFUv*kQ*bLr}r(smxaVejwe~g%5c1>$O1(|4x}Pm^&CY- zmMB)_2!W+V-n#i0i?{Dvyr-Gd!hw3wUQdak7%N5#p3%~bCpIxkPYt_$%^8Q(s22TR zF%_T4&ox=P=BO7Vp6Myk$?|a}L(mn8EKjCet`WwghGHX?dL}+TE#wL#oMcHTK_W^y zCTp&^AJP;YMdEOiQEx2iXDl?$6YPna4Aw)dq4fTpi=frEj70s_Y;9t?F{w?KF%ZngGtsiEHCmtL()EmwQd6!F@AXXh6iTVOLt!d55pB9N zAu17zjkKoo@ldUqaK*>RJb8;6H&5(cmfeT=lefshezZl*j7~>`9yqnK+drNfBf}{- z>nHPy)jAa$4U9#&u_+=`D!VcsM&1 zD?n=c1@w|OX5aM=0A+l64 zuR4RHL0^JOC%m&Y337;wFw&e-YiypPGFx+zPOGcl7@wY&Ev|Yi6XQ!o0-srpvN!MP91yKM4ndUNOA(F{Q>{Nuy(s`e? zm1^h>Qfnx(oXeG_)6Ce|lvGh>>!s43$S z$~~I%RrrG5PX??c%Mvt06Z`irJJDBt@3Mm(Wpk!gtYv0LoxaiNG@Bs{6W%~5R~MWfJHLzSs$EToB2X|@9Az-N46e8=D&`xf6xiV8ff6qcnpQs7gZ zM6e>kkro(!70RM8FybmH#gY7r2{Uf2ku07BB~arYtC4> zrHrJU=^0Pm?;lMK^KMtBFdNd_$8MR3gve@D4a#}DchZt=jkhdzI+4$g6lY1+8S#*s zClV~S#0U{Q?k<3M#9cgBbu;Qr(@BvG*@#7Lb@4ZTb`05;!P*ackf+xuShba z$fRhCm9)wvLXt#_H04+|Je8zQH7&5pq`6- zC`U|0uTnE&EBj9D?<17xu@X4Ja%*U|2#S^YS-kOv!dW}55iG< zVH3iFtMnu$IbJE;SD(*vUvUw3W&eS+_Bq|S>Odk>5!7Qlr!VPgt-5?P@&m9mm%Un@ z6Oq?|h&0bH%UMiJofnqU{VG0+ zsJTpO_&%SBEt^4O>KQn&4|F#F&R$5y)KiEr-y^@fI&)4D%?nNV{ZvVwn9nn||M7vh zp*77z>-uTu!Q|nPo@PC`&7`NaZ(fb|K!)o3B{*TIGlAF~I*CfC99ElK-m%)$b<={j z{M*u&&UdUW;mz-6co6*OmzOZXG%qiiliW~8yuNK&(3eN5?RTgzOS;;Ao8t1>w;?W% zk_+1%clQ1BfG!taKl}9MLjQtXSda_Hgr*kc!hzt_f?W993q`$8a^cyx5sfF`i3607$FWq^4K*lRvg) z{f8i6k=2|TSg%>q*f)IEP_UyhuQ4F+vy8sg`im7+o} zmkus~$j2@(xX!}D%w3CTM_}$zlZyjmFc&!^h;mIgpbvy6%-hy4xe=TB_4UZaT4};@ zJ>ofzqG9gF5_gWmamdv5s1%VkS*VDa0ih@jxa7KAP)h(2fb_Uv(23nbSXoGtpg5K%H!Q(-*!mH8 z1tDGs3)`rEw3e{K^nk^J7@TUFsQrt>b%bVF4{$LcI?QmeSykW1!gG`r7K&^?GI3Tb z(cX_PTis8OX1n2v+s!+5P`1v5{9CEEATdS1@K9LfUzC=P!mcGN(ss(P^O^7 zpo~EYK(Rq#p-@nUpsa^-j&bRizl%_>(PCP;a_6}{#?E3RO6a9Z0p@0#fhW% z7=5>x)*hx~;FF#B9k?uZ&G{aC7I*gQwnr zJ)`&wI{xBPFU*m2Pj*o(ebIuTGWx`29N9y+u0MA(bIQaAhBB9m@n z#J8IU4pT4AHO*5mP#S-98D{K10KLE`dJF))SaW+fkbZ6t9?!stU%ku##EYKm4Rgqg z`+DaMj1L_IUf98-d|c#3&tpBu@-BAu&G9aJ=Xe*{?;ZkP;O8to8S&zwL&S>*TGMqN~oKwTW2d9?D5emr9AeG};7ryrODU7UGB%Eh*m zP%iLKuDs`=7ruoZ7j$7v!kBXibnz}E9rez$E_!ZWbqIAKt~x!`1tg_^1fu>Ya4lNq zlG5?-tmwON8Q!+$?%$c(Y+Jhp3Wi6kaQ3w&m^IL#hEWj=P_TUy4g0yk~w^)A!+~V3J*%m!#^lfUH5IPS>Xb%*C zTOjODSKFRGo@wz&%Hi>-7G`}08ur(z7CH|I=xRLLBfJYZ3*D{A@W*GKnKM=6VV=bS z@Y(vqI1Ag|r^>U?iDL6Q@D$)@Z58?a(*#;{XohzLv-s=K&)om^PU&aI6@rIg7Vt=Y z$NaN*;#R!(cxvzf|Lh>nLZ@^>{TKuqD&G8-5HvJ1y$hWXgZAD+Esmm~EkG^aO9+HPK-f&&!H9xYz~9=E*g{;8^wm z1#Q8yxL{dauq?humc_S}iAOjVKmVD_IzP`I>sWj%aoDpU4o?Y=yC4qVEjaFiI6MVJ z?t(a65QoRX6J- z@aFuA*oAFb?TOcsA*?55_iO9StBYL%HbO$^92Pq8Xph%8>Lp> zW2sJ2ye#;~VhKVHP_ttV5BR<6lSi2ld*RAayyZm37+4S97?e8TLG+6SAo1okh0CzH zsZ@S8GajSpNQ`O3r=peyFzy56o`So``V-ztp*iai<1wczm?=129*>;J%~{K=FhMP_ zGDC|rC2>}Qv=EFei-bi0E0w@9Rt3CO6j;n8a`VrYYzKRcb0T1=jxcm8#Z8GpQJHM0 zq(2$+HbzV3R467n{4KG<%GIfAyV*rP|BqwF!u52ZQ1(_!au z%gaaGV-5~I$Fs*Ah_60^Cf^iZh2Ez7V$9F~|7(od{Ei2=$s-20BYiRLKkJ=$#kl|Y zz}pz!%tP%LpWGDlK8$g?3p=7auq~(PiFtnpx-D;SpgShB>B>WyO@B9++0=r}k~)+! z6amVmP^O{8p^QTbLb(VE2gL$qSpST3!Y;O0&e2x@5gegMU%%^ttJ=SV=*4f5GI=xs{AwVGFY3B+6{6c7 zv>_z6^IhmOt8VZ8=0ylOjTiMkMBLVk?Az(P#RJ>jwj``w)_#{!j9K zU3$IW=<9#J_EGpNH0@Lv>zyCb25+3W27{EEi@JWb1G{qIo0||a8#nd;<}U1W`e)3d z+!%&PqksK14`Gk2K*sjVu)i3wt|z~T?KEJkZimxDH7E~2c>~H8_`TtH=-c}54-Mjn kvJ|S=EuVG2`iW;S!{?sCuF@OoWd9O>y8IJsYu=yzUt=!Vy#N3J literal 0 HcmV?d00001 diff --git a/Covance_UCO3001/browser_profile_1/Default/Network/Network Persistent State~RF12f27d9.TMP b/Covance_UCO3001/browser_profile_1/Default/Network/Network Persistent State~RF12f27d9.TMP new file mode 100644 index 0000000..954f6c4 --- /dev/null +++ b/Covance_UCO3001/browser_profile_1/Default/Network/Network Persistent State~RF12f27d9.TMP @@ -0,0 +1 @@ +{"net":{"http_server_properties":{"servers":[{"anonymization":["GAAAABMAAABodHRwczovL2NvdmFuY2UuY29tAA==",false,0],"server":"https://cdn.pendo.io","supports_spdy":true},{"anonymization":["GAAAABMAAABodHRwczovL2NvdmFuY2UuY29tAA==",false,0],"server":"https://data.pendo.io","supports_spdy":true},{"alternative_service":[{"advertised_alpns":["h3"],"expiration":"13427121683294912","port":443,"protocol_str":"quic"}],"anonymization":["GAAAABMAAABodHRwczovL2NvdmFuY2UuY29tAA==",false,0],"network_stats":{"srtt":3994},"server":"https://content-autofill.googleapis.com","supports_spdy":true},{"anonymization":["GAAAABMAAABodHRwczovL2NvdmFuY2UuY29tAA==",false,0],"server":"https://login.labcorp.com","supports_spdy":true},{"anonymization":["GAAAABMAAABodHRwczovL2NvdmFuY2UuY29tAA==",true,0],"server":"https://login.labcorp.com","supports_spdy":true},{"alternative_service":[{"advertised_alpns":["h3"],"expiration":"13425476591115015","port":443,"protocol_str":"quic"}],"anonymization":["GAAAABMAAABodHRwczovL2NvdmFuY2UuY29tAA==",false,0],"network_stats":{"srtt":3819},"server":"https://unpkg.com"},{"alternative_service":[{"advertised_alpns":["h3"],"expiration":"13427982191463738","port":443,"protocol_str":"quic"}],"anonymization":["GAAAABIAAABodHRwczovL2dvb2dsZS5jb20AAA==",false,0],"network_stats":{"srtt":14727},"server":"https://accounts.google.com","supports_spdy":true},{"anonymization":["GAAAABMAAABodHRwczovL2xhYmNvcnAuY29tAA==",false,0],"network_stats":{"srtt":8905},"server":"https://fonts.gstatic.com"},{"alternative_service":[{"advertised_alpns":["h3"],"expiration":"13427982205233366","port":443,"protocol_str":"quic"}],"anonymization":["GAAAABMAAABodHRwczovL2xhYmNvcnAuY29tAA==",false,0],"network_stats":{"srtt":9333},"server":"https://fonts.googleapis.com","supports_spdy":true},{"alternative_service":[{"advertised_alpns":["h3"],"expiration":"13427982231737187","port":443,"protocol_str":"quic"}],"anonymization":["MAAAACwAAABodHRwczovL3Bhc3N3b3Jkc2xlYWtjaGVjay1wYS5nb29nbGVhcGlzLmNvbQ==",false,0],"network_stats":{"srtt":13097},"server":"https://passwordsleakcheck-pa.googleapis.com","supports_spdy":true},{"alternative_service":[{"advertised_alpns":["h3"],"expiration":"13427982274345475","port":443,"protocol_str":"quic"}],"anonymization":["GAAAABIAAABodHRwczovL2dvb2dsZS5jb20AAA==",false,0],"network_stats":{"srtt":7863},"server":"https://android.clients.google.com","supports_spdy":true},{"alternative_service":[{"advertised_alpns":["h3"],"expiration":"13425476676858943","port":443,"protocol_str":"quic"}],"anonymization":["GAAAABMAAABodHRwczovL2xhYmNvcnAuY29tAA==",false,0],"network_stats":{"srtt":13075},"server":"https://unpkg.com"},{"anonymization":["GAAAABMAAABodHRwczovL2xhYmNvcnAuY29tAA==",false,0],"server":"https://login.labcorp.com","supports_spdy":true},{"alternative_service":[{"advertised_alpns":["h3"],"expiration":"13427982190915339","port":443,"protocol_str":"quic"}],"anonymization":["GAAAABIAAABodHRwczovL2dvb2dsZS5jb20AAA==",false,0],"network_stats":{"srtt":5727},"server":"https://www.google.com"},{"alternative_service":[{"advertised_alpns":["h3"],"expiration":"13427982319602835","port":443,"protocol_str":"quic"}],"anonymization":["GAAAABMAAABodHRwczovL2xhYmNvcnAuY29tAA==",false,0],"network_stats":{"srtt":9297},"server":"https://content-autofill.googleapis.com","supports_spdy":true}],"supports_quic":{"address":"192.168.1.87","used_quic":true},"version":5},"network_qualities":{"CAESABiAgICA+P////8B":"4G"}}} \ No newline at end of file diff --git a/Covance_UCO3001/browser_profile_1/Default/Preferences~RF12f273d.TMP b/Covance_UCO3001/browser_profile_1/Default/Preferences~RF12f273d.TMP new file mode 100644 index 0000000..3f8c305 --- /dev/null +++ b/Covance_UCO3001/browser_profile_1/Default/Preferences~RF12f273d.TMP @@ -0,0 +1 @@ +{"accessibility":{"captions":{"headless_caption_enabled":false}},"account_tracker_service_last_update":"13425390190152650","aim_eligibility_service":{"aim_eligibility_response":"CAEQARgAIAAwADqZAQohEgIBAiILCAEQCioDCQQCQAEiDAgCEAoqAgkCOgIBAzgKIicIARIQUMWZaWRhdCBvYnLDoXpreRoLCAEQCioDCQQCQAEiAghdKAEiJwgCEg9QxZlpZGF0IHNvdWJvcnkaDAgCEAoqAgkCOgIBAyICCFwoAzoLCglOw6FzdHJvamVKFVplcHRlanRlIHNlIG5hIGNva29saUINCgkKA3VkbRICNTAQAUgBUAE="},"alternate_error_pages":{"backup":true},"apps":{"shortcuts_arch":"","shortcuts_version":1},"autocomplete":{"retention_policy_last_version":145},"autofill":{"last_version_deduped":145,"ran_extra_deduplication":true},"bookmark":{"storage_computation_last_update":"13425390189990404"},"browser":{"window_placement":{"bottom":1390,"left":10,"maximized":true,"right":1276,"top":10,"work_area_bottom":1400,"work_area_left":0,"work_area_right":2560,"work_area_top":0}},"commerce_daily_metrics_last_update_time":"13425390189992152","countryid_at_install":17242,"default_search_provider":{"choice_screen_random_shuffle_seed":"4319271516958647163"},"domain_diversity":{"last_reporting_timestamp":"13425390190129450","last_reporting_timestamp_v4":"13425390190129494"},"download_bubble":{"partial_view_impressions":6},"enterprise_profile_guid":"8c59e58c-0299-44f7-bf6a-2c1c2aec1135","extensions":{"alerts":{"initialized":true},"chrome_url_overrides":{},"last_chrome_version":"145.0.7632.6"},"gaia_cookie":{"changed_time":1780054705.65835,"hash":"2jmj7l5rSw0yVb/vlWAYkK/YBwk=","last_list_accounts_binary_data":"","periodic_report_time_2":"13425390189631409"},"gcm":{"product_category_for_subtypes":"com.googlechromefortesting.windows"},"google":{"services":{"signin_scoped_device_id":"2eee3c3b-6875-4932-a46c-aa665927f474"}},"https_upgrade_navigations":{"2026-05-29":20,"2026-06-01":10,"2026-06-08":10},"in_product_help":{"recent_session_enabled_time":"13424528301349696","recent_session_start_times":["13425390189653142","13424783161920705","13424528301349696"],"session_last_active_time":"13425390189653142","session_number":4,"session_start_time":"13425390189653142"},"intl":{"selected_languages":"en-US,en"},"invalidation":{"per_sender_registered_for_invalidation":{"1013309121859":{},"947318989803":{}}},"login_detection":{"oauth_signed_in_origins":{"https://covance.com":"13425390209374836"}},"media":{"engagement":{"schema_version":5}},"migrated_user_scripts_toggle":true,"ntp":{"num_personal_suggestions":3},"password_manager":{"account_store_backup_password_cleaning_last_timestamp":"13424528361292832","account_store_migrated_to_os_crypt_async":true,"profile_store_backup_password_cleaning_last_timestamp":"13424528361293097","profile_store_migrated_to_os_crypt_async":true},"privacy_sandbox":{"first_party_sets_data_access_allowed_initialized":true},"profile":{"avatar_index":26,"background_password_check":{"check_fri_weight":9,"check_interval":"2592000000000","check_mon_weight":6,"check_sat_weight":6,"check_sun_weight":6,"check_thu_weight":9,"check_tue_weight":9,"check_wed_weight":9,"next_check_time":"13425468652160257"},"content_settings":{"exceptions":{"3pcd_heuristics_grants":{"https://[*.]labcorp.com,https://[*.]covance.com":{"expiration":"13425391109373680","last_modified":"13425390209373691","lifetime":"900000000","setting":1}},"abusive_notification_permissions":{},"access_to_get_all_screens_media_in_session":{},"anti_abuse":{},"app_banner":{},"ar":{},"are_suspicious_notifications_allowlisted_by_user":{},"auto_picture_in_picture":{},"auto_select_certificate":{},"automatic_downloads":{},"automatic_fullscreen":{},"autoplay":{},"background_sync":{},"bluetooth_chooser_data":{},"bluetooth_guard":{},"bluetooth_scanning":{},"camera_pan_tilt_zoom":{},"captured_surface_control":{},"client_hints":{"https://login.labcorp.com:443,*":{"last_modified":"13425390209158802","setting":{"client_hints":[14]}}},"clipboard":{},"controlled_frame":{},"cookie_controls_metadata":{"https://[*.]covance.com,*":{"last_modified":"13425390209373438","setting":{}},"https://[*.]labcorp.com,*":{"last_modified":"13425390403848855","setting":{}}},"cookies":{},"direct_sockets":{},"direct_sockets_private_network_access":{},"display_media_system_audio":{},"disruptive_notification_permissions":{},"durable_storage":{},"fedcm_idp_registration":{},"fedcm_idp_signin":{"https://accounts.google.com:443,*":{"last_modified":"13424528305659510","setting":{"chosen-objects":[{"idp-origin":"https://accounts.google.com","idp-signin-status":false}]}}},"fedcm_share":{},"file_system_access_chooser_data":{},"file_system_access_extended_permission":{},"file_system_access_restore_permission":{},"file_system_last_picked_directory":{},"file_system_read_guard":{},"file_system_write_guard":{},"formfill_metadata":{},"geolocation":{},"geolocation_with_options":{},"hand_tracking":{},"has_migrated_local_network_access":true,"hid_chooser_data":{},"hid_guard":{},"http_allowed":{},"https_enforced":{},"idle_detection":{},"images":{},"important_site_info":{},"initialized_translations":{},"intent_picker_auto_display":{},"javascript":{},"javascript_jit":{},"javascript_optimizer":{},"keyboard_lock":{},"legacy_cookie_access":{},"legacy_cookie_scope":{},"local_fonts":{},"local_network":{},"local_network_access":{},"loopback_network":{},"media_engagement":{"https://login.labcorp.com:443,*":{"expiration":"13433166209374934","last_modified":"13425390209374939","lifetime":"7776000000000","setting":{"hasHighScore":false,"lastMediaPlaybackTime":0.0,"mediaPlaybacks":0,"visits":4}},"https://xsp.covance.com:443,*":{"expiration":"13433166211909783","last_modified":"13425390211909790","lifetime":"7776000000000","setting":{"hasHighScore":false,"lastMediaPlaybackTime":0.0,"mediaPlaybacks":0,"visits":8}},"https://xsp.labcorp.com:443,*":{"expiration":"13432559431322296","last_modified":"13424783431322307","lifetime":"7776000000000","setting":{"hasHighScore":false,"lastMediaPlaybackTime":0.0,"mediaPlaybacks":0,"visits":4}}},"media_stream_camera":{},"media_stream_mic":{},"midi_sysex":{},"mixed_script":{},"nfc_devices":{},"notification_interactions":{},"notification_permission_review":{},"notifications":{},"ondevice_languages_downloaded":{},"password_protection":{},"payment_handler":{},"permission_actions_history":{},"permission_autoblocking_data":{},"permission_autorevocation_data":{},"pointer_lock":{},"popups":{},"protected_media_identifier":{},"protocol_handler":{},"reduced_accept_language":{},"safe_browsing_url_check_data":{},"sensors":{},"serial_chooser_data":{},"serial_guard":{},"site_engagement":{"https://xsp.covance.com:443,*":{"last_modified":"13425390191062059","setting":{"lastEngagementTime":1.342539019106202e+16,"lastShortcutLaunchTime":0.0,"pointsAddedToday":3.0,"rawScore":11.086217964212176}},"https://xsp.labcorp.com:443,*":{"last_modified":"13425390403851992","setting":{"lastEngagementTime":1.3425390403851954e+16,"lastShortcutLaunchTime":0.0,"pointsAddedToday":15.0,"rawScore":42.24694252205045}}},"sound":{},"speaker_selection":{},"ssl_cert_decisions":{},"storage_access":{},"storage_access_header_origin_trial":{},"subresource_filter":{},"subresource_filter_data":{},"suspicious_notification_ids":{},"suspicious_notification_show_original":{},"third_party_storage_partitioning":{},"top_level_storage_access":{},"tracking_protection":{},"unused_site_permissions":{},"usb_chooser_data":{},"usb_guard":{},"vr":{},"web_app_installation":{},"webid_api":{},"webid_auto_reauthn":{},"window_placement":{}},"pref_version":1},"created_by_version":"145.0.7632.6","creation_time":"13424528301241374","default_content_setting_values":{"has_migrated_local_network_access":true},"exit_type":"Crashed","family_member_role":"not_in_family","last_engagement_time":"13425390403851954","last_time_obsolete_http_credentials_removed":1780054761.292902,"last_time_password_store_metrics_reported":1780916619.637988,"managed":{"locally_parent_approved_extensions":{},"locally_parent_approved_extensions_migration_state":1},"managed_user_id":"","name":"Your Chromium","password_hash_data_list":[],"were_old_google_logins_removed":true},"safebrowsing":{"event_timestamps":{},"metrics_last_log_time":"13425390189","scout_reporting_enabled_when_deprecated":false},"safety_hub":{"unused_site_permissions_revocation":{"migration_completed":true}},"saved_tab_groups":{"did_enable_shared_tab_groups_in_last_session":false,"specifics_to_data_migration":true},"segmentation_platform":{"client_result_prefs":"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","device_switcher_util":{"result":{"labels":["NotSynced"]}},"last_db_compaction_time":"13425263999000000","uma_in_sql_start_time":"13424528301297310"},"sessions":{"event_log":[{"crashed":false,"time":"13424528301295659","type":0},{"crashed":true,"time":"13424528933193892","type":0},{"did_schedule_command":false,"first_session_service":true,"tab_count":2,"time":"13424529231452850","type":2,"window_count":1},{"crashed":true,"time":"13424529669798370","type":0},{"did_schedule_command":false,"first_session_service":true,"tab_count":2,"time":"13424529946115499","type":2,"window_count":1},{"crashed":true,"time":"13424783161899107","type":0},{"did_schedule_command":false,"first_session_service":true,"tab_count":2,"time":"13424783431303530","type":2,"window_count":1},{"crashed":true,"time":"13425390189635210","type":0}],"session_data_status":1},"settings":{"force_google_safesearch":false},"signin":{"accounts_metadata_dict":{},"allowed":true,"cookie_clear_on_exit_migration_notice_complete":true},"site_search_settings":{"overridden_keywords":[]},"spellcheck":{"dictionaries":["en-US"],"dictionary":""},"syncing_theme_prefs_migrated_to_non_syncing":true,"toolbar":{"pinned_cast_migration_complete":true,"pinned_chrome_labs_migration_complete":true,"tab_search_migration_complete":true},"total_passwords_available_for_account":0,"total_passwords_available_for_profile":0,"translate_site_blacklist":[],"translate_site_blocklist_with_time":{},"web_apps":{"did_migrate_default_chrome_apps":["MigrateDefaultChromeAppToWebAppsGSuite","MigrateDefaultChromeAppToWebAppsNonGSuite"],"last_preinstall_synchronize_version":"145"}} \ No newline at end of file diff --git a/Covance_UCO3001/browser_profile_1/Default/Sessions/Tabs_13425390192637903 b/Covance_UCO3001/browser_profile_1/Default/Sessions/Tabs_13425390192637903 new file mode 100644 index 0000000000000000000000000000000000000000..486b78a5f77bd1bb23efda199d3e08e6acb0cedc GIT binary patch literal 130584 zcmeI53vgY>dEXCg#ikNjmJ?f6T{pRuL)KH7!o}m_AsZ3Fm%s<8OFXV0EJyWjrz+wU=SaA@eYQ53yDy7{PrU+;cv zzD40{^!q1Yc=V?}{7h@~tvcuTw>L#m|6DFtba#OSMQGg&TV^k_qT8B+_|T) ztvA1?ZCgj%&bIch?w*d`!jA7(Mjda8Zu+8%b`kgYx!1IOQIE0YZ&PY%q&8c>XJn!@ zc_PkpK-UNK+pO4jg?G3+quWy9CLf*7Df8je7#_t)8M73x(sz>+eY$7T}lM!#6&Tscw*rPl= zGOr&8@ueJAuH{X~b9NykwCCG>7B4FQck5S)+VtyGefX84ZHkRVqfu37opCs-vk_hE ziQ09R*Ofy2<7&6gdiA$`!TVeJT`IGndkIHW;3N^>)}jmj04IEKWZ4?%z=FwyY%mpVzc}LysVt zXrtc!0bM_mp^*n8x2pjlOjLoE4N2Cd(m<#fv&;G_=RPuA&}SP=BSj_Uf#n zAETj7y>dinC8hSpS38umLw&YWJv6T$=j5?^Ei9kw^#691mRDIL`Zwy!FRN6>03(XB zw&};1ENh$)=5>YK~*pD%M3Dr=wg{jKjK8CX|oK;-ViepKW5e zTvS;cmt7ETN_2CkwwS^yIN*oLpbxkEd`DB^l#gFZl#?ii)A&e#PP%j4HhSNBG^O{y zCu-HdvpSoK?$!sYsa=>F%4!`KKdI~Ka;$r#)8D1?zg@qV-trIe^ZlQf-dMZymdVoT z@#CfXcx`fTWpB%4am}q9>P14{-#~mRhdtl&rsFxgkP+JRzf0HOs$WK*S@8Zv z@%goDAVBc9srxfoFaQ}^OgU~?Fl8`kDr((=hDTY$p2J zk19Ob`C>dYZ3tSNds=R4`FlSEHBzFx^vh_@)`{Bj@yUCqtM%FG$>HgVzAf#0qBkr5 zf%qlqgwyJd*AB*wh#OqA!zlsI1S=U04~ zoRw5;WV2E+H7uW`uj+U@720sj(Ey3VXS-rbi?*mc>`~e2=UKa?)0aGaZ(7dqU3;_W^$z!ucrY>GyZzicsubomhGUn$064TK zo^LrT>ngv_c=%S8-X0I;bh{VzjUXol{j0=;p{%^%*FtHJLFiE{hNLwgRM zYOD8bE!Qg5W96~Z#6)%Sc(w15nS=XJALu_lQXYJ;t2{KZ=l-dadmcP|f9FHnb`P98 zxubHXKDqb4^2qSv6RBH|oviASmA;|&Lf6*Gnjk`7IbS$2njbw|IW;|%&zFWDtel?R z*HQ`#kS7WOZ94B@2W>DaoVr#n8j6w8q|QJ~ zzy10sx}@J`-FH#p^^)9+bPOGreR#!(q;Yy#i+zq~zI^*Wmc`HdaJygV98HC1ef+Wy z-Q8CKl|>hjz#cs;?w=`=J5N&Yju*)z8h~y(nny!54RaRKV;XX;8gx|+I#MQ-)++qe zroWbhd&i?kmFHfSG@RaEZJ4Q5x99B&hf9f&a$)q!;ci>%yRPTbGxK-uU z^aDfo>2F@CC)7p|r?bj=O7A+QSYB^2tol?`-`QxVNF#R~)_cq-M^$fA6&?pMwW-uz z)$EXJJ*e7GtNam_+OHB>Qti-rB|55->w5oTypq+(i@gk?@{F`tIiX8+e5mxM=fwr->6fi^yq3u?R7N%MtgM+%eVb1 zX`gac^q&2C;sK?0C?&7ogzoFo-~PBK&8Xy>ucHemiZ1vtz2bSi#a%GSm7Y4sbeS@~HF|?a*cMT% z9jZAX@r2I#B8)#qiyMU%rH<g$>Ff5L8kO8AKlj7P zpf8`*-*kEQygWDS;5+mDWSn$&tUYMBSrz+7`eou4U-R^P7nKf#1Ej(JgN8FJz<6Z! z25^Hajp|DP5qmW@VM{{s7|pOp7}tQg9#ONb@>w-@>3WaKg~kH{0fan>r}8WyB2VND z$O%&tD$H6EX3(g@*yIf0vg31`TjmTLerWkuAjbLDUh-OWN zOI}s41EyG_&t#G)2w+=GjJos}23T2tVN5}ydPRmfBXqkptau@45Gi(3;7~&x)9q^{ zmX&Z`Ik~%{QrzB4yJD2jiWtHQ7o6)5$PuLw>rlN4G2w)ht?puIk9d(* zn{J({&sNU0c69Z2=3DF4nff-Z-?Vz2Y3=RE7Yc2T^{vpBcC>04TE(Ta#6%)+RqUse^3((BEhM&?bwDy~=p|T#7UpUm$~GW_a4Dn@1jg1^ zN8IX;U(Y5R1PNY$URNAxV!g_iH5<%)XIOZkKS)*A)$wBAp{RZcx`gpaIgm0}0)!S^ zN%?Nmjq>RSpg%Uc+jIsO0Ne*DWG5kcFeF|Hx-Kbe`m+R z*>i(uIt%&k;zONXd(Z8CIVNMGuZpf`GZ}|!XO0Y?+I4WW+(gS*;>Pj?sl?-S>(CTqcKc0^F+SYJ%WN5xd@ z6q9ODWMoo=WKhIvpO~A+#e(Y6BvTW)sfpCUirb-U$73Ql5gieG@{H~!$AHLCN%x!( zV{2F}ltD39U`J)KHkZa^JRo-15itl0DrrbhKcae#s!nJ1q`j)g1G+w}a76Vur(8S5 z{@SOfck1_E{rYvaSGmgi)pXYhF^ooHM&$mOupZQOdrozQ0SAKY7Gv@uop-79bNV&Q zWNf^~a1;6UFd2vR7H8B7!(tuo(tEH+)vojX`a7WXZoOki9D`B1Q;fs`F=EHm4rPVA zb$7QQ#v#4o1DbA%Dq)u&c=LX>v}4Cs^cDN{?dtl%uq|elYrnn#EYHAX3`|Bx zDPLJ8qfzUHp}||bl8)!>LPkh_mJkNh=5)@~abCaV@j^19bK_i)%yOpa*CB8C@XzjN z)9Y3r&iVAGQlW7;Y`H@@jShPstKY-Q1cYCVX3GgAWQ6wo z&AQ$U6B#zGTS`>bzTJ91_!^|RWds}+n8?V$vdAdtT8DDN;AM%y-CfFK^|yKzRWFti za9a>ga&oYg>J|)c8G&pATookz$mIl>Sk&|=rJ`D}^~S=b+4rOt)D%%Aqy>>1EU0uR zKE)D-G&nuTQE(Lwj(bl;oJN(mLw9DqC#^>w+J%itT92po#Ak4fcst7Hon4Ez|(O)`qu)8f~p zGQw}FXliGNS4ObpM&jB*8NoG{5wKU9uxAmPSA#Nwv8U4^Ur5Rbm(;ucvN`@{UKxR8 z;*ENDP)3MbYKgFA?d_FkjfS9%5Gy0l^+BO2=hZf&CGc@rdVS^p;sqUEV1L5xdj}Q5msCo zfgv1}5!?_C$_POj!H9X9loMyFgOQq)j4>m>=~Lf%X$3ta{FaKQc6NAW1WRrtuD#mI2q*sMADl!RZo-EzSY2t7#Bs%+n-*Q- z(lw`P0(WC=$6xd4Ya&(;OH9Xeb|E7)0&VwMyr}#TY-i)$S;ui!cQ7#KtnOfc2kSX# zci{~I{U>Lo$EBksg)s`u0A`hsg&hoAI}7lXFe05QbkHD_=x3o{Rno+P@d@njP%2MG z$GfV#vEH*Z&j@e);QK#gHgjkW(=f1fQ%0~jd8CZ+A3Z;YD97y0EmP9nCz)vTmVOGE zmVUOX{GqD`Au;cgwqxy#tD<8$Z=5A3t!roAB`1yRq+{~G-)5D&Ng)!`9QJiA zv|cc$YmH#vc0X!tl$=kDBDmN&-?Z=k=Kq*v)V;@tb3Xm4RCv+H?~pOr~wZV0*$(&Ycq?);$R`oP9mD8$J*N$m3Ij!n{W+JB`4OVCRasCTz%e>RQ zUHUz&z0>JSHj(ohXG8mW75|U*`-*!^G~gR>%!iNraL$KM`S79-H+fC9JA4?+JF6^w z*l>*b@T?E#d}yYSKI`L`eE7T%ulR5iokIuq);VHfN`(VHe$|Jygs;*n1=5>@X3$-vLUfc zihJ@NJ@fI8e~xrRVixC~uf4YAFO?72Mc09JBo*Njo0!Y;%7c@u7xmk$@?KC#xf~2V z4hyY)=9C6nInTw!anYY&_TeTf>5usJe0;x$LI->}<RwyLp(maEl{MX|PaYk;8CxPB~ZrIii4LD`%7>+uQ~vI2Rx| z+oA-lG-IooArH}j4B$4zIS|3X6hF7y?MISem?sB;q z*v<*lr0&m@w!RFOGUS|U;Br=E>G!sAkxpOoYV1{NuoNPPze?OjIJASYP>2GHa$?~J{t%>=XM>F3 zUD=w+_54?guJH8lIMTl;NiP~1NKd<2(=qv) zVUn>*qU^wYQX}X{w|legoAuqY(wlwWoqC7Be3AiBwFAr{95~{*8DBs!kysV-&lzT9 zJq!AUl@Fw2UCBlqh7qwqk2y_O7LGGmodN;fCLxR| z+@}NjSdn6`5%{;_E73wWrctv*Z~ybDi;Y&ILvPv{!!ct%S)6+kunUs24A@oZ>~6o- zyGKuNPj~0W-SeCEaO?ECf?Y6Gy45)s+w;SMr?WB|_WYs%yW;(_wX^4UkLVJ1f|IbT zGX=YL$Dj*mh65tKSQJNYz#UA#95y{$m`*1iVAp&*8O%1mLb|=O+A%A=+4jvUH!Ho_ z=LOgm51Xs7%ehp9ArGg@vG|dKa*2OWVqhBT_5#u>tAhH*oDFNAZiu3U29#`3bK1Gw`)-3cUrsg zC8Zw_IYv+r3zw&rvQ)Ux>@*#?T}&wRur1y0&9-kAyvj;%_IUwzx$jw20JjTH7u+pe zdEhY-&J!Ds@TJ)N1N6Y{V!MzHLp)8b{qiyxH%7vJIovKhC~X|r70WuQ@o!_}U&lLr zxZQ^j`*6yK=Y4p=hfn+Pq7T2~!xw#MqKvo2GJh)HhueKv^x?xkJnO?bAEx`~nCh6< zFG#rawdSX9BKDX9dm|_MH7yeCI9=)XH9C+^Cmy(5^X(nDTr07; zs7{q}SpT!j>3GgAWQ5j_uUAqX2!pRxWToIm!9hZE#K~^4RR@2GG&T-_Ja{={n-FKv zaG;R-DlC{^i>fd1j7>%$7#`M~b{~FEDaCC(!qZ}d5=}tLcRt~e?n1ZF@viV&r|H;U zHG<^cNNhq=-|@Ha|IJ45>B2)l^ra+xvN-p6?_a;|CDmAMC{{rf>5zTj%Q0P$S$=?1hcTROA>VPAivD%>&zanH!g!tK>p;(_DX z$0*{ubqs3{1`5*M$dogvoC`))IPIAO5toH-aIrFBpfiZ8@fl*3FqWO90E}bj^_@Wu zabUo*e~&V5635cR8}+$g*!%394IaLy-D9lYbVwd4-2Se5w`C>Cd;cPtXrm_u?_adc zJZRavHu;QcH1{zcd4bF!LEDm?}7UuqB?bnm!rGL)Y1 z9uBj0Qe+Gt!^BT&Rh#a1Ho2tJmn`|;;`Fes9O{)l45@kJ!=7(f)A5{L$O!HEjnH7C z&n$TVqRL~~1@B)AynitSndk1(FKY;FW+9v9G1cRmpWPE$R*Ajoi;n%M}!kV zejrB{aiBi*1#y$@RBezMMX?4o9S|ct@Vu_|DqdAOOu}rPMZ^?PzCo_kDe17JqCO37N^8@=pVs+|&Q2&_yHMAmXpgKxoKi|%BxP${ z51w^QXU-Z4eA~(Bxc>Ge zKK;!r^@JytXO;6*+@9E4Dd{;6D&@4=bEgO+cO2Gx%qT}yZ&Q`D7+ZsFDz#TNJEU3< zs`gmTfZx@xQnB>DL+6z!c>fCCzk*?2NA--(z1)5T){n>oHFA_`Tw@9+w+8QD!TZ-5^Zo@KXUL|RV%KX4=!;rXu&vKf zL6?|vIgC_TXe4M(*Fb0I$&@%Q`t!>^%(4XZ=`Y{Dj~$ZF_;9<&c1Kg8SqQr1)9q2I z=+$~!{a`-DZ6hGDek=jm+bs;O{q0IRp0f)Xp|wjRrdXoSENI7~%7ZBuynn5@_b-NU z@c!lcE1ZR={h0n-iZtZlcIbHZTJ|YutrRT#1n*zyFu6@>Y$d`4fT0LFg%z1R7&14^ zVpyRq(_$EPXu|s!BoS1xT1>`ZiGTT)_;1(uIiT(~&qT|K&9hf*o59G5AP#A%d0ecb zoKh#FC$tis({HoxJFoD%k);-05ZJQXQZ7)5jNlc$;S;zSD;}33qdB z_hIn<6}*2T;D<qbu7?u_FX2P=85y!;Rg!S7OGbr7*HfqTB-pDkU#qHtGv$XVY*?{1F?5fJy?RQ9tPhIx z!&E*cmTJ3LzDHF5v#JZRlHxnXbR7^Qc1*P^E8MNSyH(yHz2O65J{MKOE=?fAV$|~H z{bI#Bc5Fq=*nT~~E(SD0iL=VJUr(nt)Xde5a9=;xkru4CTB_k1qHyy@Gta#a&=7;YdGcOlg#{ z+QQ{e=$U);1I{E@rZ;YrA{V_c{z_?9U{1oCx#%6fCDZK#1Cgf7Qth|z^vW<9Rk4i2 z-oq}Z<2k#K5t5(xw*EP%bNbtP{gTHE$%xL4b3rmwlgV_x;ln?>A5O=uKAiLY@u^g3 z91dIVP)?)6-pA_qureW{vsizsX{!be%z5D-sG1wir!_XGMR{74GODvuya9A~Twc=I zu01b!{|er}=$Gk!SX3IEB4;EBNn5r8k)pulyOXwMp2bK5@)XW=J6AhIW1K+<^cOMD zfS`O<`Pk1Q55`d0m~>Ja7*gd730>qVC?9za&XA`-*d7D9NDfm2b4tORIJZz?&CwU{ zk8J7a*YZyP&(2KUonQ?rW$Sb`HZ5H}RzEjY?JL(R)vYu2QoY(YR6BEI_|&e0qviHf z``ZVObf4|m-(DKnd3fN#vHtRdyKCJuhdLkVDIVO_Hhg;dYYx6q6W+i6la`fGTUNy% z+xGAO7O`xmH-1ejBV1O|D&^|ol@Tntk+}A1d;j{0kAD8An1FuLhgT;qKLJ_YulN(2 zxGX&#rU&LmRYpMQA5UATFQfkKY|T{TGX%F>8miarI(NRi5E26jV;T@sf{SSdp;&-f zK>j)v1W1=tY(OIkqUns~L+UVfk0&rZFO@{x@M;17ry7G3`$qKeMt$z*zkT86Zeamtf2!tZ&0j1_w9>PNhG2Z8(}^!d7A0$0+DJFL5G8e^_lbVOoWw9qT?~p@Erb@r*&9_q z=niEE!^>&}9V`9)v%Xtadb9oQPQ61gygYAsnS~hw?#{^%HuzYq6*O0{JnN3J5sNa! z?OD9J#UVoS*z`l|nme<_=}`@3Ip-FPXi$TMoX-ocfQ%>~vokCS(YmHan4|$;p}*1WpEV1E zvgk@ydb7_9u*-eNq5`OWQc zUyWeb|NW6q#c<4Em&Lg!!R2Cc-!$x6#5v?vmA{g1##Wolb;84~i4Du;V$&#axdNAK zZ5dwf5#0dNBrO15>*M|b!Al485n$LPY{HIRqhIfFi!E_0@rfnNwhU=W#|K-_|1HUd5sX3HuImU{;0*af5% z2jMVOhKXeaBY<0&JA-!yuZ<^=hM#+9E0Fz1cy4gOTIRdp%5b?B!7{Y%@4oGi{&yp| zwRz|3;&g*s7Uv%C=K?MlOtGfn)*>FzRvK=-S^elX{Wh!KY%W6fI2djm7Fu_kQyPq^ z^IS|EFSn_f^W3cO_b}_9Z(uIhM%q-|1Fs7x;N)^KV3d zQHldJ0g>QJAv^_yLMC)%!Mt2lJHthT$AvAgPW^*x1(yp^E>}LBEudJBQt^KQj}5zB z*oNf^P9FmsvMUa|7Qr;CcJzf`y7ey`!LB=65C27SbJ615lYm_e!DYa%WqUwd@38Af zJ>2@(x`JKH@pHkNV&ibRHhFjyU>A)4^}D$kyt+cDot(O+6iqtrSSq~QC@?7NJ+ji9 zg?RyXxqfD_2>Eul?*LG^34`ARmkF@N%)w?KCQRXoq1=O%ms7WaCk5{depNmbb|J}* zJwc@3;bS=?sBB15KIJ<1V$SOZY4FW-lj z`pyo10la`n^aBp-Csuw*K#Fn^zIWS*$d4fp2E@X?4*<-$LUT6iF*F7219ZVBLlv>Q z@~~?WOv8KJ{E=H;Yy`W0eE75vFZ%E+K77%KrmAwA-!u$fUE}VsfUGt< z-8Rx(3|?L5r!AYl($iU1db8gntK6*g_4d3w)s36qTy$fh(O>&cb}b#x*@cYI+WC5A zw9qlcjsk-4&fN}T>Hrqt4VD_5)dt6#axQqVw2DOrpcfuj@yu%Vw)zxRUp5Q556cV~ zt3enZzpVf$TnHfp<{%Z%1Ga68p9m+5QrS|3H^x?C6PtyNxmJr{6Po(O^KXhRpm2Uk zKTp=9fBHS||5_40S)6>{tLuOEnusAo z>AyBGvIa`<>Uz`ft9N@DzPRa{4=PAK1MJFqzL z)px}%z6X7{otM#JW*{w`^66&Y(dBYo+0F^m-G%NQw~gK~X(rT+%VLN%cy(=UP4$@t z?O0Shg4Tjp*9Bf(8G<0WyY$N%g2Ah+8b^oCLf@zJxV@G+Ea$EJ-YcSogFP%sPip^n zTI8$G+mBvI2JE?M@~~tk(@o29%Dnbw(MF5E#1xS^+*xR`kPBX2TceYmZs=P`fBxvV zwVW5~gaokuTP@?K!K-WV>Uuf35K`as0Eu21A8At8qYfJP&lJg>C#hMc_FILKf>&33 z$p){k*W+-ZR}K;e#i!e?Rmia1C7ck~u1$u~PpL(RWw+rW^{yS_6b@>l!O6k>a;|Vn z#{IjL_l$Ue`1r*h*-m+}#q;i7-Gltxew_!euB&B2DL7oH$}vcN0aP*zoq11pS#d&( zlW~7Z!P<0xaLnPLeu{A-#i7QDJTf(a>I%3)B~@}}cCyO0qYcc9TK zIniepkp7~|gDDogx~{laSB7x#>gxI{oQ0?T@-BFFo$*XQL^7SwW$^0i+*T#sOu3#D zML9dk2%9B+om#VDG|_1gIc0HVJ}{H$EchU1i-;^Dv8Z~ZMvka$TfBxt5Vu`%BiU9T zBdstVofHW6rYWIKaqRR^K2PSXq-#ixY-q2pkVJSstHoptUR{^(Vd-{#pWxMXaW8s} z{dulUCgY>>{n;rd)u71KqzKHQh}FL6QEi|PiD==Mvs*vRm>m@ht6k}ks0n!yeMGFQ zfjGy2SXCw6b3%-*VX?IaWuMwSlOEIAn66IfAATj5&SX3wcGwa58ZGGgLwfoV)eD=l zXZ57LD(3-RA67V`dYn_Po$@2PPfzdE@4fo<>uRrZmG!IXt`n-kh!}1&Vyi(|4{B%a zoazb#E_ihfUR_tmPJ3W7t^|`Y1M4Z-V3y@b$8&ZeBP2g75rb)SItP=S*Drazkc{Zu z#CS+%IaBn@nc&s6OWPvtnniYKF|$ildWZh@h&t~U4Q7FZ&^3^k6r8r~Qr=yfW41-# zqjt3KusGA1R&RWyzkfQOYkb?)RD1qrr8L7t?$DdLr39{JoWTOj9bg6l_z#B#y**@L zorpMd6r$m@k-Hn)QC5GeS5ftXLxYGo<`l3?<%}!11%q2gU=YC>0_8bQM-Nj7EH4l+ z$5s|4bj21bn|V)afxvt4>bmFPskVC0R-B(6E02{XCaROit9@b3vHUd$gRu#(u799q zCDa%Zwm-e=Uw`w9E9ceq4^=d^v%@PRSaKtA?bTLB_-A+C@-uf2y)L@ThgT;qKS5d5 zulN(2xGX&#rU}qS_3DbX8fR&yJ)WR2@rQ$GXW|b|4ICgGMMFNZ+zijgDPs4=3l*$B zw`CG+%nPD;-KD(FZVk?+&1)>C3tjm<9lj4sFmfI%6Tizf$F@iwoq7IdTEAYtS6=Vq*tZglYKI=_s{8gE(Yj7tO!a7nkAY|yLK z;^3WXo91<+*PhJO^$H4rPB07uKEd?Mwm9sF&sYFsdIrPG>}#Uy?0j5Q6^<&cOS#+h zZ?R=AdfNEB05`FuMRcE1+-@0Iirq4toVlenI@Fk9hS@;PF!0<7i^sZrO!{vmmQfdp zzQ4WoFAafRQXCc$NBeI*{1>Df0<$>Ryahnu7FfOMDsEt}t`!fnsy+-}UFksc+)(T5 z7QWJOYmHoUxDee7BbfDrMVNN`R(-0A3Ug@Y1#w>`j|_TKPj3x{%2yKm`! znAJaCA?4oj-1Oc$5vvG z0Y(#G3$rsoB_I?w|JVV*bPeh!7*J04i}~_lNR^cj1{lB!VI^$;0lR>DfH~M-7=Okr zGbNMi7*!a7MubT?#=6AHz^+9w4K1|ui(hXDyL!IX7pEKSvN-o7xLnLqO~bB5JfUq> z`Rm!MYu&@G*$vC(3SM0q5*IvN3l;!rjd>bono)3_IMU?PXk9v;cr#oTHp785NyE$6 z!mi-eRn4<%-y`cgXQem${jTr_MF0`Uql$l?t1&j@o= zbrsk}U3ym@ZY_dkXrJ2m{=i>1;&OHT@kjnD$>p**_awMnFvXgNTZ?!=TWPqp+Fo6M z*u$)Uxq-P{!K-WVb8#l-5G`~<|4PBF;MEmE9o&m$!K+y5pB zyDZN4NWd;uqRW6?jcrMH7BZ{2-eK3rJ>2@lx`JK7t83U?T;H3E!Ki8T)(lu)=t+8yWm5?kt*w-^Wf@KjGTNG##4bs*fDU9z<^AEq&EF!n-Cuv z*h5HvzoIG#w~ITSy###0QWmo9Jk4z`I+=K^VU$%SPlBI@eLU2RoSIWrVH2=x*_ej5 zeN*ed_*x^__3K~#L=4AlbJ615lYm{pt1As6%}RYYJKzB3ymrFV9&SCeVPO|+8mY5A7r}5W7(#hh*Unx$=}WT z6rta)Zg#Cq7b3Z7nJ)TjT|G7@YarNlsHl%RM+518nAJbY*UTnpkm+*t;6}A?R=HW} z&3@0Y$>_dkQ30?B2!whdpa(F8R24E_aGuzBgd@c!BW~{jO~_#({{{C7ScF_xN%8b} zwDQ@UL?R3?t?<0yrlAY&$}&%~fGzhVU?AIyqY9m#dWW8P17O$7cy;~KGeh5K1iRk- z`hWNJB)7}rw5s>&Y6^`_bGsJtoVL>3u0MHw6n#a%&3cW?3L$$O_E{~oVL7L3AgJ?X zN*vo;T%_p3H0-*=!>&snZawG2;MLW&Te_XCz0>Kd4ZDKo;>LhojWid7SJ!!2yR7k+ zmCm?q23}^Bo0Y!ap0_e^D>1>OPK_>Fayp)~3mKuc^YwDA;3^>r1vd&{#CG63ykQ&A z+3my%17~o!;8r=YcAyaQRh6srtktKe`U20e4}mNeI*ka>W0?~!mT|2BUu+fv*f_&@ z&q#a^unS&UUU#j&SJ#*R>=*y85qugxa9f;iTq}$7dAwKGi(V7aO9OLdrM$ZSs<$Z- zm#IJAkcuTYGHS8fhE#%ASNk~EhBh#4fLq)KO7QA>)32#_dw3nUo%iZWGVw;eJ9u?< zz07(OBJZqR;s#SleEwK_3iMf{A$WC-y}Hu%`JAj~vs_9BudWNt3+lCUR@c2Ai2A;o3k}|byef&uvsX0b#?7wvzv>}Gb62?xX$8xOnXEt?X)3yb)B9Z zo}TF2(!M8d{vVk9z{fu9jr(0vikX%%FRtm3o4i+7NC4Sa%i%)s>KeSdUQRBA)c5>$ z1idmojIzAbEJWW& zW$mpZAEncBs*u;elAiORQcg=4WoOL2s_MBoQ$R#zzkWqsh2I7b>^}K7eMp91?$^~? z%tz~2iA)ANVxHPjm0XwLz_7SyCB0d%(vRyMD61lKF@$C1I2JoUAD1OU?yajX_(tlG zsqii0*6s0s7stddXYlH3<0(D95cNR9^rg4_gByVE?@Mp2JrvVNysx~=OJyt(ARqew9|5oWw)vJBIy9O(}_YNOC zG14}6sye*Jyt)F%8M0}nSi(bR@an4enFj;+NPf0eP-RBY;BHAEmg1pS6GWkd7{yZ`iXZx7q7H!i`3%W^QLcU zxkVEF4B_C_l?HK)h^OO$5=FtQYw+qypRjQZsk>1O!o+mB2x$slU8^&*6ZIM4rQVKw zq0pw2Y$fv}hi+e#BpNBSkZ(PFYfJG~M-o{;t`=|&9+sBxVJUcZ_5JfIo5>+dbXtyU zkv+Kxx~vJo%<8@|VV73n7?z2optIE~hFP2bS`Luuxcrw^#R4fS2g`Ss^2c;m5t}Qo z=fOlPC|_QvwoU9f7N{r1P}?JR+bN~gg^3nt_x0%s!K-WV>RJ?|^gf|<*s&EcWBc{D zF2B97EoRk|_RIL}R`oL0NmJ^HeLkFwdn1ff?Dn2ij~rKDb@3_n%$j;QDb)qjYjS#L z3b42_uL6^iw!U_CdVTaG7rih3N@-SLPQseG=pFiU9JZpg@36L+jB%A4{;~J4i|KgI zE@Xt{XC-3oFsE}c$$9;f#|z1b&W*WEG8?6)JQKXS2CuF#d4pG1I7J1`F^Ijx>B+}u zXtra03r03ZBXG-uJ$M_pHV%twL)sCaxa1)}*1ISb;|_?`qu0oFS3aI>IfHwI=sgCy z(MO~PW`>R3%?d02BSf6c)+x*o5tEzwI}AK{P1Y=f%vrSoS$H2A=?tt+LE@LyCk z75tfGg7Zd9M+iVLpJT|T-XNRQ2p>evG;Y!5nG z=8Wk$lg(HsbjW`ntrdUSB?I=`aL8gE(Yj7v6Pf@4=Tf{rwux>ISvvFp6c3lIu>@gNk$ zm{4~Hvp8!s;3#ATaCd=48T^B}U4NXwB07bjC-^4a&PBB|D?nC}*q#BI|o;skB0%3nzjW2^1*;>SG9dcucu9^pQf3NQNj9pKl*ky;Ba z=zh;CZ`}SOgigMAX(B}k9O1}vCT8b4BYv~$oaeOJgApb=WM1cx*G8uNT9unuA3EY z8g?z>3~i-h*DY$?P5N!-Jrpv1aMoXge%N1N*1jnvxZBy|*qDybnZys*pVDeg5 z7yBe;i_m^f7A|Hb42=LZil!V(g(uCz0^=4A$?8W=loSDN9Kx*D^RwViR(iAVn^kUB z`g(g_fL-zM(TK9mzit5|r|@gMt%~9f7MVL&tSA7poXW6+MJNs9!P}X~7r8oP20d~dR?kem;x(e9DMjmohaJHPuD!5TdUjdca9_)>;;y{B< zK{S$aX5s9=WV^^fMvDzh_+#k*0Icw2#u?l$G!zgp8_j5Y>u&Tsp-wal8yen0J~iODk@-;kcqSu1FpTX#z)?Z5(FOh1$_KbrV$g*hXJ8$hhFCXs zu**qz@$3$j=_JbVW`=|rIe~s`X0ABwS_IS3La+PLr}s62T`&Fh|J$47c3GTzykl23 z84(+78g^}9$FAS>aO;W>gJV}Z(9+3&&|GxwH5WwbBhCPIQRU2@IRNb literal 0 HcmV?d00001 diff --git a/Covance_UCO3001/browser_profile_2/BrowserMetrics-spare.pma b/Covance_UCO3001/browser_profile_2/BrowserMetrics-spare.pma new file mode 100644 index 0000000000000000000000000000000000000000..98fc2c0bd7fa41623709dbf737993f8b9e26311d GIT binary patch literal 4194304 zcmeIufdBvi0K=g9Qy=7oP+`D;0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj G_#PMozyJXN literal 0 HcmV?d00001 diff --git a/Covance_UCO3001/browser_profile_2/BrowserMetrics/BrowserMetrics-6A26A176-4C38.pma b/Covance_UCO3001/browser_profile_2/BrowserMetrics/BrowserMetrics-6A26A176-4C38.pma new file mode 100644 index 0000000000000000000000000000000000000000..5617b2786f8a4cb945790b4f47ed1fb7b763551d GIT binary patch literal 4194304 zcmeFa349aP*FJt*7Rw@37A+!D5EPJxvIqr42`$hfg-R)l3z9Y|4YWx}(hU@>GR;hgNtz! zwIJ5}3Op1&n;k@VexBLjSF}!l2rN-B?Zh)SJ}~c8urx>E5)qpDIy-zb>)oK}9FIFV z#T6(o4QgRCaBYg78GkYqO7ZgMw;sF-N=^JJK_spH;^xgQJ9Hj6hXsgtI5Xgx3;5e5!VA2MXnqSh^| zGKQWvbV%}se-ct^YIg6s>tOeuU9$61&l)s1J$0(L(&bN`?)A?L1RX)Q*VCt2dQGQ{ zP@6HWlaR^BqQH(2xtHZ`8B_3C>6S4rA=aNhH>Gvk@h(rf+vCdd1YM=cFE4AGl9Zaz zM_iO3E>95mC+H$qCnQX0ePr1QBW88pddX)q@%x&mr$65L(_{!E!woYbjQtu z?`yOC`2pM4r#*V$>@Am$3l16a!`!sR{TB6qwM*L_ttLJ(wPVgd-49OfzU-%r`*$~c z-L=RTOlgLNrH3>JJ{(K~wyEm&0FFLXovP9W4&kS96>aug~Z9%+X@W z_F;0c1Sv#tQr$Mi$@F^zfh<>ryU0b+sC}5^H8Fu4@rTGd-ylBKr7~Bx%TZBH@f$p! z9E4Zfq0Rsrjh3e z1S-9LXRgD8hx13pt;g-I#?5jB9fgj7%kFb$mb#Infri-iGSNegE6W6lixdciX$*I_ z2JyXRK5xL4hmz%`Cyy4_qQ0rGnB)!SS9^-67>ed7gw(!MIh^V!9Pjs*`_7ZT{IAw7 z7kIpt9>j*1%y69M-^L4g8A3zH>4N(^1W)GZOdFps}DcKzSgx<;=!!dL~Tt7aQ$3 zNn}uhqvxhMP3pQt&3@LW6XwY4-~E~Voua*~``-ZNLeaFF?_3fpy@o9h`Ozg|9fTf4jF+r(aIL$x(Q^s(g)&OJjP* z9MN4|9Wj{UQ5xu((uP{Xc1gm#LJvoF)fy*XwlI#<(0sUe7ppsVg7G7?(YWn?G3Y zqqtPQ)pDZZCw#2;8a+Hc$7oEBjn6@IXewhgY5wH6??0iRXFhf3({+EhN|X3yc(M;O zpTZa&)$7bsm%}r*${m!zGrb;ZE-tDbtkpp)c&T2q-IQ=K{yO}o_=JBeP440BAi_uU zeyRieL2TciT>fFexBJ8-urw#1BSENq_BZ51SpS)RN1!A>h`Kp1%N;24yL=8$QMHVL zA|J*xBL(ds{wF+*xpOA9{-y2GWP+$UiARWY6+Zh%!y}>CG+3^H44H}>=_Pc}SIet_ z!zhPj81V`{yC3(zO48sll;lioysZmHKyT0<#enk z==b`n^S$N%BG=SvA2q!3+5;|!D-f2;VGY_vYA+Zcw;i*=pLW+{r;*rA8`qumMXQu= z={GrvGob-r`kLB*tDKjcbv>O&S!LwT7R4k{u3kHennyy|KSYgRu5)4;e1y449S3JqSxWX z(ps6r11qed(aiLgqo5l4EQ*^AYAm0*esI5JY)7emC)`|)jrA-E2HJS#q0P4C_C2@E zxexI*C(AMPp!1Qm$r+xH?8KQR4v)uGD#GQI+N(a0YfP8YtO0TTS_OaN*+F#Y=QGy- zb#DxvG z*&&Ocqj2QtPVEo#HKyTWke}~zIVtZWgA#=c08==Hp+JQ=Y3JAe$vqy{^Y1gi)W#NC87kQ44-{^LD9}V8Rt0JSju{ zMf988B>k%LH8w5=xf9)G?qI+c=Ah}xcQ0_+vRuUuUMBr7*DpN->DbtQ`BLMzUmqr( zd(2-?{jrgsLzbTeq4L>3-&ItO#;MvizS3t8I6O8xifjc&g-%a@D9te*mCyb$@Z@2T>Zban&F&Oj#&J`f1zb7D4z8Oe_I6;oj7#OS zKNj$Om}C{ZOEJZ=<#_Z77y5ihVJVcQ&ofQ+Jh^9l{aoGS>`SL4KXE0?k$^e~mCych zaG2^v$b$T5JuA~!9w?ssp)P>#C@q5dESK+7OE7G8=6SuPwgR-gH0gBstEW5WxypU4 z1RKT?t~ppC^Egf8uIv-c^_0itDd3;?;hVH=Lacal>b?73?|KEb$>bWo=R>#s&|HP!H@9s_m2Pkj`=I= zMy%_D5uS7sM}koK?BDSD_59FVDr0+6Z$W-t_8@Wa#g)s|=Vw04<$FW<5e^M(IGm~d zKT&e+xRD%WQ-k?wZS%J)C-&X7gT`~@s6ATGk6aa{LX=q%5a_tU1<`38=Is(CAS&r&}sh`+n0mr8!FC3DR8F+@}(6bN@mCye1 zaSY1Pfanp7`8cDmWX96V;v1?4y?eu7FS0zwqw?85DjvPcM^TSSKf5j988GvQMIUU? zOvRc=#-s9^j7L{f4I*-Tn0>NLh4qt+az@QoNk7=C+!x$PzWwq8voCm|&rFF!mK*Ay zm@iX^Tqoye`m23G8+P4cU|Xd9CL1z`sK*bIAI%QH^{fTLaG#!p-!wO*c>_$o+IXBQ zT?z=(FKyo>6+7yuhl8>}WDA%LqQ>u1Pzdw_=rd4TJjiLF1)vu}ozd7-gZ6*Ghx>H$lHh zHfI0-WX}bEp6)971W+_bchWEOb$0j`O~2tr1EFd`EPuZ?5{k$lJ*K_Z*5~yX;-^2> zwMzb>rFdz?PkmdBzyGXn&Xppl9Q@yxMM0*O0V?ktFEqZ<# zb`>6^srd{wYk5s}0GcDxe3sgIs9Rf8=z=>;8X^_c3q;jv0O%CZsUXVxToBDsogm8p zi$K?bR)N-mXk7X`s0;9o29<(t1#JVRAhQZVPlJv@Sy&26L|Lc<4MKVN7PJ;+;(;TC zcn;;_M*yAzuwS5XK8(WoG|EO2z&?oefrn5)y8!F~%pEax|#Qr11LmgX*FA7?V*IsEO zmK7f%p+pj-y`gbGSJSqEM8LlltGoRucU1T&O$A|U> zu(sN>Xn07A2IT>b9cdwqGCiyj#|q$}bnPIzBm1>|;IjdU_f22>@O5RMbm=;aFp{HiWRGCJ#xz`1 z9QrP0IW=UXFT&S=xIU+#k&CB~FM1v6U)Zhh1{Os)2#v~Te-%egU?O(TmxhOqH3-P^ zS6GnWZrhjF@91B?kke=RDxduuk)P`*D!~LodH#X%pFjJJKgXYyIX65HX89_g<)hEW z)YDyv`8bRh=*Y`qt*F*#;|OFd2O$gc-+Hd~!Vk8VF7BWUpnC$w&CF-Hd^e5@z1T93 zR~E7z0a&YxXeydlz=o>Th`{-fhe}D$We3q6%~OMQ$*Zz+F4;Tg${@Tn$9hot>`#kI zn(cwi5_X>trblhr&+e?CF|-o}Gl;F!u$stfo8_W^ftD<%b6~i@3Y2ES&=WN3Z9DMB zE4M$bTzPWm@lX88co?tBXMcShX3xuk87)r}H+a~Xt zO)(N*S^31e)XP@N=a%8A9b-O)F}i{?at-ghO!Ur~;zG48waMHOVl)Di{HBbvxc{ZT zAyto0^N)1k=lRF9H&d~4Ze9n=MxRE!Oc33Bf=&RfLcCE=gu44aPY~Bknwu8fclqkS z^arG_hQ=Ap$G;|r=g{k>Y-r5*+KN!)bG-BY=yr5nznvEeu|Ny({KJ@;3H)i5@?RX9f{D) z*V*A4l{fvRs(hE9-X?$%5!OscDVdTZ{b)U6SkV*pWt8uvmt;_95ItjW5Slv;`!w7M z?De2mK#2f36|^2SDG~8ei4KA?TVU*r@lh%gY=H#dZ!g40orI`_;`(C@bQk*3b*JGz z1^Y2dv8Q7>bg>p=r~PPW$0vxwM=-C*NEB!8NfawSY$m#PXd#|@sHJ#sbCTG0eH+ub zr3N^-ex(nS`n7`xNKxCvD<(a=uzqOwg_MWn=$V`0%6yG!xaj>cHEX_7M|F;K99{;H zcC{QQ!qtFS{%Q;IeFyH};II7gXH`D)4WhN5G30AYmZ`dYs-IgSpX=wWGj5tlIxx0- z*%?}r;c^&lp4Vr~Z>KfC=lo-lotmRGX#B!_ogKd6<%0ma%PP9(c;F~@^5?bhbk+qu0|Qj~%#TQxzhcNYDZ-ThBV^oIdf3o? z?=5M^_UT3WPLA%>|1e);8ZL}OFQ;J*)F2G&f0G5dBf2{dly*$Sdu`IOT;}WS@GYub z!;>5JpEpuQv*SkTM$7->pKY1_#`$-C&jKWl1flZTpElY!{7xDrWnt?`wf?`{9Yq@+ z^nf+EvmUluz%lEG+gh&f;yIh;Fb3V0cq8f&-} zAkL2}y|ay_kAIeyK9>0PuA{WbxUfD{KKnO{1O3JVmuI>=Sb}%GDp78v;hEzZ^&`+X zl8c4w%MRUs|MAQ1Gi1mJE|t&zDy}K6QY`5=D6XbuoPN_d(KI7o~_`Cv4eErT!yxB-|@=}*yn}5){Zmf!f`7EFB`Pg8U6Y!R5!fiQNtqQu(&!d=-onW#bdmOPDC$g?))XRDT z0>^k%d+Um|M~SCCYXAD_E8iZrRR-1cM)M%%>+J9?w!JlHG6yuaZ!^ZoF|ZDYgP87> zRYzRgw`;~2qh2ULmCiQ>#y=+e0B!lD-$82;y2#3jf0Z8~3aBUkIVr_t#V+Pl6KI~ByZ(}Bw< zmt=-?f7-9OIt%~6*+Jx2bHfTb&qKVCvwwYH_qDgc(%5^ycuzAoc@43=`BonE}jqt~s|6{7A*)a(crfS;U zkLI?0K$uc!XG^$ozXr4!bSxh3Qqb|JbhKX5u{rkLW6rl7lgQ6t)aZgle!_gOJrX$+ ziR?upH{}X(|2(t}m^_}oMTpC~Cx{=gyI^78MDg{(MB(b&T%53>h1issB*t}XBbLu= zFLpUQiw7U>CMs=x#Zx_pixFcdi-f<*G`&J)ivh*dUnP$tPDKCs*_`It=_n-4PTY7t z`5nEja^}i!=Q{48hlT@u@4!RHY3&;Vz9sunEFsMW{1J2b+LM+ET`Xm&VQO64LeQzP& zhD~84YW-5b5SQEyo$kfE5?Gyk=jR0B#ah6iPO$%f*+Nt=O%ff>Y%Auxd6YQixh|sp zz~18K7f%uIKb9+g$n}YJQ|=J=-1@C}x?6ri!AajHbgFoTRMMRFYpj>66#c5@d&Y^0 z!re{m3jHcxoQG#1N9BmhH}f^7;bN(LPxi>hBmm=<3qwk$xxE-YUM6VAjl`A_R|usDX#hD7+dP#w0KpxQhA{EU`4h}m2rh2n#$uE z;61pl{sr>A`|V~wzmT5c3A81|5GP%Iofs$ZXFGq87jas7s?50bGO^@PSi%&lK#MY zUq*r;eQ`OggM~^lEaL&gS>1dL|5hJbQaQ`%9p!@cb1=U>y%Sc%T*X6AkMnsK0g? z8;3&|m8i$fp^rVspbn!kICwnvm7ak5-baY1($E$UK{(76-I>riGNE8P-g7E~Ep9$^ zUL(W}*FdNDATOTBy8L$7?0$pn6wJ}FpuKG_baqREIQj#uHXM^ES~(KMh$j<8yUxu- zkBgd#>;uij$}5@+fBzPu_VX6v`^Q^q`irLLTId;B9PZEXm;#R(-v3gI%ztS4y)W$e z@cL)d!6!#$hw3}?HKyUBy?;X+Ui6WaEsv(q`PxAiQq|azU*I#1d)Gq;MjWXA+WT-R zX9y9TIYJxzw|jeN?Ub~nM_Ckwr&ubV{b`)3Lzw6;b|J4_V=K^k1{#h&wW;I3UB^cD z|F_wjQFOF*@ZPwe2%ufqWU)mgkq|#xsSzt9B4c!8-(hpRaIn@)|TYrJ_&?w zOMAcZOx&k{@33wC1FdIJK)9noRDPMSF%6g8JUfmF!fIEf2v2mBd$8=} zM|pC|-&ro0ie)5Y|G67@2nXYF;WwHAVSG>Z*Sga-F23J?zl<&M&{gHLKh-DnRSnKN zi@c7b?QYi2KnuUDipaGf){_sJV#I|eO4EaJzx$5Y{%URr$KNFtn$5 zRixNGhjs$d`CGP39IAs^m0Z;^)$?o=3?mM%GgM&OzV;CnO|dwAs>}Dt+B}wnrWUSc z13vpVj$;b;9p_iWGE{~ZCx})kKy`x3t<`=MO?=dI;HVrL#{uh==OWA$*SJqPw5I!x zO*aK-E0X5uPV;2u>+JANYe%*7kaC>z1u^NBiW}jlc~(8-@_N9#mtWM1(lp|l0WBK! z&CfF%oh9#Q_~nC_Y6jlA;T4&Bq#srJ>`zA+VfSYs;48r%Pi=NcO^m1kae3RW=bjxr zlCRcFutfGV2fq0ErTd>DOynrs5x6p6V;U}v*2{5je;{aFaL25i*(RtxgG({U(bDqjw%HCe8XbvI zK89l2c-Q#e^F5=czIwrjuVV+5babbB#(bR}zOj64g&0FGAcP@c^=%3rYU!$QL{{6) z?dm244~Bvb-d}#|(wVoMl$E_$#l!qC5dDXWXRJrtTM2`OEx+97^ZJ7m>GVTWzGPG9 z3TFqA94Ck><$e&qhy3X6SKFUyf9}1qoXK#s?#FxtH95wi%lG=B4}B`4g){aqTP?^R zkTbW>fZ?y-tLlOICgJ#}QTaA|1=eGz`e{*C;L7E*ga#OJvGmYl$XWAle&ObyWk{(9 zx~hEkZyd)|7Y>i}V~crdb%DoW0)@y%T-u-~9Td z5jehZ9tJW&S5=VTBhb0|4v(|YTSZM0id-Gya(UYdTvVSJ7yYKb#`xY(TE$meE8cjy zg7A~0JGDp5*O-P&rq?^q?Sd5wy&An$QH{Y%fM+r;=U7kB?RU`-%S%~o)>AeOsNon7 z&0DD*D48L|otttNli&35*NeM*HdeW9nQc)|b(9bn>=l>BmShh1?w zw$&kWJ&5!a%Pz_7H}@mlequTu-UptH-yJ}mK*xY!V$f_(J#g<0qWRAN5Y269*)bDD z^AT#2sB@hMssddKqB8XWXgz2&i?zQ)GIg5D=#+>OICOUL^CUVlK3 z7(&9N_kjgH&^yU@t#vP5Cd-c8$zS5(kdgmYek8=Gh=QZQ% zli5sks@mFm`?4SVQX5B(`Yf_LFkfRDE|bn2iQY!z$jSnfX>8LWo%l; z3J~7Znxi$a`et0jH}>bNU_2o_b`ag$f!c#+fL}SIjRQZ$fesHWd1mXq|4E{M;3!-Y zuFTh%hD#n+Na+PT>^{Uv*VqV_>n`$p$wq<&(<0i2D+AM%@87ofM#v?M4BJ3`C!TRUGJCd+9ZL_1h4mYz zxBT`kmcuwyKKnBcj4JU$We}$+OfGH=3&k;($KA7KDzWf%Un~%deWFJGE!b*V*Blile|&PDj?s(i;dD6H~s_6w2s!E$!&_W%%7YpLqAN^TYN) zi6=p*dmi^z#BvpY@>f*|Fcqb|Ry`Mu_H>G(5t^Lqg zkJjU8Zl40`2I>jw14;)C2W5d^))uoteh}4%J3udjz5>zwoi_bl1lkPhiAlm`pyti6 zjtLzVnLz7Th0Cnt1zEi)ni zhzk=s?079DV|_3V<{Kbr zKg~GCR^iwzda1I3QjGJ;KC+63=Wi+wO8B#!R`rvw8+gLh>!d`|8`Wp#OK#*!I2zPv zs>ytCV*^AoZaRuDwfAgCA}-ZiR3Yu1Dz3X7bv|WJ8xX3R7LLLi!=w6Xb6|>3VaO47 zR8?4M(ktno+A^}2(b&Y;o{=Br2jv_6 zCW_XcQGQTfQJS1LoabQukGaF`+5ecT|IZ4l!;^*Qd&;;(o$rtmuIe%B-o$U0{(YjZ z5i0k|s13~5+2Nb*_&4jCZ0Dx7CK*I+4Xtrf`-7>7wrB8Y+^OH7c~KV-t$WflV2aY{xdbP`kNT6| zAj${Q3m#b;{~O1d=~$p8wKS%``buC*%k{N5b##HMKjtI4$yv~!jb5#v;+lhxwEBTS zx;y|e_M6mhszg|s^k~|RcG_W1Ro3zYpv4zcy!#?cjQp zS}GHE5SI_?YmNIouDWvhnA$~|kCHz*S$5D4>U_zKT&I@coi3Ypr6woWjn5a;MA2q1 zrGs;;C4=8?Hrs#lVBMnh?YbPASJAk{xF7D$+OOXq>3aGr6%X?f+~lHf4{=vx>+AJ^VB?6QM}z51y*nUCa5PCute z-e^m9rOY#9`4Q*Gmz(*z`^7Dj-#SN?%Y2hi{9``XY9cnMW;(R5xZ3nnlJs?K+K)o6 z2E_enjRicfTy@%u7hE*wB8p2+;z|%IU;4(tqXSrlfGoey1u~XhPuGb%1=|neeT#eM z&+=bZ*N@?c<*R%|(cCn*3wzM@)3s^!Hq%?`rPq43jiorkgwN1%ViyFK(GVib0rue1Y(?<6r9nl1+f1(Rh%?djmkDLDNAP_G-`j zA?_yvI34cY6^-9Vpq(fbry@gAkkBpIXx9RR(7Q13{0f6iM=IWvIT`!iM&doTJd8KX z&}LtYy+oVP{Z67ojz3~#8<+SXz2M^^wBR2A+=qt&1KFGp;54(m1?s?;2Xr+rS$ z*V*A4+Bzpr`qv25BiNshwN`xDI9n1+kK zwm^RYfkXzX-^{#(BaT;GlFF2Z~RF@kMT@TXsC%=V!c`C>`Bt{g?SVJA6}d znDd3dks-Cl>Y~U-TzMDA$JM>Xn?u$RY(|vw$nP z^3t#G%E+0j;$r@x;ld)JUq74y@2}(73O%3AdaGR$UvD#~273-Y@crLvelq{i@a2?Y z!qeNUxR`H%r2Vvp zOZ$4EeqyL8J5BiZTflej6BUmS{~~y*ijVn+hA$UG1c&x{x-#rjktm)5yFVj(mqi@0xjpZ&KgF7lmb`afLfYf>2f*d(!7CACtHQWKNQL#b)dH@YroPhSmxM1rQE@Tf1PcFH!!_MiI0hea z3*ze%CF9F+d{9(;zRTk4t$NQzpMUpK-&E2oIl5DS#e9uvxLCtC1~xGJsa4sOi2CwD=Q2J>U)8=z@Ft>Lqm2fcK>Wms*d{xoC(*P3BpjQ{faqZ+)w z#r#9Vg*RJ0k-VfdjQYyBBEG)pBMUvCRO{NsqCKhE&0dSm{f;iGRZqNkUW zM-x6{z9uh=k8fx0H&;B|uG4X9J!Sr(;iGzh^PlhqUIw?yptm&^aLp?{_Nrf|ozYIk z#r#9V6&Z(2#$de6y+G;x&Gn-GDk;T|8{we$l8(nc5By#8#SZfQ^ttrcW>+;km41_x zc(Jcq;Y;7R?Qmq8U@Owz2-Bwv;r(dw=C9O$(HxfMD`XR-d29y|t#Q!4uU?=uPzGom zh~~4HhHCqk?#KN-5WV1z&m)NcfSO?deG#Y!p1ra6vZ|IN5}X}`C{gtkS~{%jvqe>3 zQaExHj;<fb6SJ0w9(3f8sX=p$OXahF({bg~IsIPGWRLb9p|O6>xLT$fOK)|7oNK0?R8PfA zbBs^rvwzd^Y55s3H|Pni#+}<=-!+oSILV+$>v~Dx?;7)^_LlO<9sK@}J?S?&&OeneeGjER%J0Ta$N4UFz^|&D(MUL!URuDP+OT90 zwOd0$#^*KmbNiL&jn+;VpY+V;z|K1}k&Nc}c~w69TQ3JV-3oJVj%UPGcb(*NK19QH z?V_9?AN^>^#T=h;seJagj%zOF-1vw&=G+w5h^x=_GPPK^9;rNT(U#H=o@Tj>OXah_ zbzDBpw!`s^xYk?1b>x?~eLAi6t#5LC#-;Mvzp1$NZp5Uo88^t(V(Dwg+j}w|$T{OQ zmdm(QKKnNrm+VGNxb|7Vl|JXb^vRo^n8$J%m&#{<>$v8)u;L@lCx~q9KUUl*Q;Vgq zWxcMtws2hUek_-9seJZ7BwT5gI3_yH+nC)ooeCdZESwh{(W2d~XItMbLq^(3mCydx zaeBN#cQM;|O#0hy0ay8iBS%g>wTB)uf=lH$9hU=R_p|^G3@!?$6}j+fUk#*7Psmtb zeJdq1mi{)is3>xUwk%;BoX;ws{jKY-%w6Sjrf~}wLION4NWMv?77N$*mf3r5OTF(; zmdm(QKKnNT7um+ru=mF0C`&7I7s(VtxG}!f7Vyn`<=U(fJ5KJx@)@7XXa7UQSEO0T zkVpu``0{R+sm9V@@xFU zd}ppn>-6S7`FmJC>rdsgzjb_6KX9O>yC@CEuz9r8-;s#1Uew+qQ;ns+M>^Yjzt!)+ z8kW!aR6hG#$5-Zdy3+#H0aq2p4S`s1ef~q7*zH}%1LKZ9*rxBtGGruQRX+P$#}x>a zYVApyQ{UO5jhT%7##RgXUOMlj>)rN&b6Gy?P35z{b$nFr(B`2{Dbs2&4#>hGFvV_J z0*(1wa;r=|R{kEeKlsz)oBm$UI2fnOXMgKB@nPGvLI;-OwVDw^0-V1|x5?CE;mWwD z%fOj~9{Ukfdd(3oT3=H^jF9W18H+; zWk63LggfJ_yH@^$Yf-WG8?-hcV}@{Jy{)%^>*5P?Upn#aRcl!;<5KzTZylGL zj#mphJi#=r2D?4QUL;~{mrL%Hsm9V<>mkn{z5EJicb3oiR6hG#$LGU2Yi`X{l}0Ko z)Hj^ybtHrYS&vDYWg~X|_~GLFoujhGHL%yJ{HEg!MD_-xVegCnO$(zQS6je$S-U^; zyL(^l!17s-DxdwW>#-p|p6gOtMw~P5mZ`_eZ_i(?XKnkuAXSEpv@{>kPDaOG#RX+P$ z$LYf%vN(0mnWhhLG~(*Y1Z+JC`(ogKbe$0tWy z>cF86DKWmS7VzD;VeRoP&tGu@17Q8BeD=4F58q<(I8FUX2^B)PSo&K1?h$9&PxmKE z9I}4U`Zx1s3X!XIJVn}R#cBAQZxADB$n0g zPrz_K9unaE3*9GEi>0qeM3(>d*MHv4av7J(XMgLse2!`wkD8~GCcS0Q!WUdDd^w?& z!RA9ANRlBV?VZYJf9v>Y+!q;98QZsd3%F8ucf51v;JGy{m-VLd+21-YlrK`7&yCl# z{94zW=9C}rq_jdH&fl5`h!b0Xx4*algyZ&ZA~U|`7^li-|0dvskpOc_{cFk`-&ikF z9+ccz`Md7@(`UXj=AKC$pYf@D_P34?<9U2dma{m71XyotEZ}-!-+}R83>&wUFT*xcOCj0%V&HlpZ%@lD{(tHQxQ1?;(V=pSf&vGASKG5f|xmt1?53>m?v^4Z@yzEam5Y$Q*U+Z)mxMf4tqd0e;M z0=_#|wtjKPJu}l-KIf~-XMgMXXx}>7&+tKmv`Rl2H6pFEx%~O`Sz;_bcH2HXFEnRZ zd&a>yRX+P$$LT4C1=2-dtR_R6vEN8}RHhaS*SinCoKbmGvmPv$ajAUvw~i}PZyT0E zv;J0Fz&Y@#!o;)pY?;A07^li-f9p6gj`9_H*^*(@-;Bp(YO(aUZLK%6wST8RvWe6W zmEUw+0Y|Ybtq|Wf4WP+OEBC`{TH-32r%x`7GaHh3C{erja-*7Vy)}P8}f9v|I z(Cm*!JXMd!*PEv@H*3@rts1OrsQjkmacFpq`I!1dd^}@T+;h%^QO9>>d8{9m&;Hi+ zV{Aw06;o3)Vrq}qTfn*EmS*!RuUP#D<6xXBpZ%@l)a{|+mRP0`!j1cj*-uJdtorcL zwsv>77aOu=$Vh!q`RsqF_}FF*?Lw7mevdXla0@-XUe5Cj>|v#(zNtN-{HAML^N z8K25$|3k)yqmT8^0cr~zMx6UB;QV9q=BWc)Ke&={Fiw@v{{IH&RIg8dBm{|tKwKW{ z*2vV2`c(IgHY+=@w&u%MK9V6L^+n~gzjd5)NjJ^s@T3J{hD=-F^_H3Or9TrN-{#BT z|NEIopI^lCS&u58{jKA}H@mTLng&yNkzt|8IIiDh0biFH*WNRHLV<2kjp$G1Hys~s zYAH=C#w)lquA(6x=WEroGPPLwI(ymn-`m@=*0EgHo62W@>v~h{;C@$yzWc^#b~NGb z^IUwqmmd4k6KO3^N@hHaSLL(6b-c#@uM{scOG|6TQH^1`Pg6^*#OGQa@j92Bee-rS!oJD16 z0s7)2B8Na+PLrRPsl~$e^Ha6WF8%T7VKQW-{-}KRw~i~a?=Wqyo0ox2_*PrM=RB}? z?n`@{>6WDkK9&D(@kJX?AIf9I6Ee`%=a?zSwS^Ht@u|Do#77G>YxZVUKY{)zDfaNnjmCydx@s$LFzBC7)yb(eIT<&W1Rxeh$+hp8jKTFe$#Q$*Avj@ zlw$iv&=FohH})&3>t(93@O7laJ^Y?0q@Zd|2+TA?n8@6@8sxC>q*Sln1+k>{4dt}5x3Ka z_5V3Av&uw_`Cjs}A4 z^4Z@yPQ4wXUA{0&lm|<+95?E5#;Y>bSouBj!#!VKdCXlMSU%%Z`Rs2UU!*+x5PZ*s(kjhj+e$00c;#Z|BdFI>_G2<%XNPar zaq9~#MRb-Fj>It!i%dAPUz5ql!nvr+&&@Z?D!7J$uzpoO`&-93*jMCCD{1nRGd9P^eMj4#JFdyT zKo1!iH>rG1|6k$8SvxQkxQwuk#$1}&;0o1zZ=-kResa)1$-_C?J$wA9Le2jW_R4RRjn;!rqRY&lYJ_A zOMG0-tIvF^);Bxc?=mix-*j9)uQr*KuuS8l^%iiQcF&pp_K&?indLGrmCydx^+iKA z97LJc$UIHY;Sdt$`a658loG3cbZv25&#vda!P_IX`5Bc$mEUx{I0;faVb8pO)7TCs zy&WH4N#BL7pKkra6)d0isq)$1x;~@eW1|`pGvZur0p}ep?&l}|1~%x z8;gxNXS^d*kCopmo@|%uR-(;tcF7=Hlj&i44TN?}^K`xj3E#RDT z)uf-Yp3KZ;9IQ{3&;Hi)-C*aXH*9g33N6?f^%#0rrW#9+XMVk7(??ItsbTqyPvx`! zzrzy`UDxdxTCC+fcG>*^qTfq6zx|I)H`9=CsjDvBi zeD=4F)4WdrBX)-qy|x!e!D28Rq&<$5rm~9?} zy*>(Dvhg&{chf(JkL&E0mTa3f=c!XzF5^=9>~9?x>@Tna`!IzF;G^RB?5{TDG3Il< z1$;X{T{G>DAsc>W`HWBHv%htG=J5`C9UT0MO>iDp5N{F8W206G33EGCvrS5gmCu)~ z4i-H1N5}q*hw-X>_P37Lyq_>oY2(_q1f5Z;_nVlmcO~AFqqc_{Q>D_o3v)((lGA624yZ;(f=+kdg7Z%4dJ;_|RYa%h3VF z9@2%7FzYj2-*piS@3HSK>$dgD(gy1-D!=J?<^BStI+@zdO&0K--t4vW)(&-#W%*p6 zR6hG#*QW`esT`KpF1Ft&D?ls(kjh zj?*1EnxDEyPe67-dX5=!&fY0gkCoq}L(MZj|K^9A83*H3`Rs2UXCrN9n%hZGjX0A& ziI4M-t4EY3j+?ogaWGDm&;HhNMr>;68?}W~yqiUXrD{sc*iNpofOGvDdCn*Moz{kN zFiw@v{?>6erq4hLc4Nt59ENZ;NSNEnj8EgABR^tX=375*Pa4U17_Z7_|1mh#u*~6~ zhi^ydzs5N5r2$~jmZ8Gu9BSVW*(GDyaietUdk|!(*aTc_bDC)~f0{Vr&WhaL`pi<| zrK`%9DG8A+v&J?JA6G%AJJIa{lx#cK~$+bp}zV*ag%T)D6@f)DzSj)CY7jhz7`mKtn+zK&OMUKodZD zATrFI3!?713{(NC0bLHd9&|hCVbEI8X3!3hHkpB9JA+OJWrEHHRfAT5o&oIyHOJzF z4Rki>O3;g-KS3F=b}R(F3_7YgWP{d&PH2H|B7hPwJzfNAafA>zf=)@od6}Rap`ck% z&?!*R@lepQP*6W8C=Uv{3JUrP3OWnQ+0#jg+m05ZJVl84$KpG~$6?RG@j}e)f%EWs z$@0MG-__uGxZLjBg@54eAix))OA<8Qtr?H=^0w8#Kz{T8uKoPy5f8jizsXTJx~hDQ zjSH97fGrd6g9dGrJ^CjOCVCyt!RGHA)O;pmv3%MmL3wA~PkYIX8AVa<-73_HMg&G^?fAQp zijL+OkIHBN2%ZA$GSv@KRZ!)*u%hP)Vv|NefLHcbBVo!XtLGu2xM=49TCGngGXJID zb))*%7t{|#^^hhoX&|bP13>AZfgs9X()$q5DIlt+!$29J;UKEB)L@+o8U;EHM0I#H zi1K9&C=-+g8Vec+LU9$@Aexj+0G$Dv2+9Rb0!;={-9HmF1(Xk(3Mv3mdoUd|12hwK z7U*oyIUs5$W`WKF%?3F@g`gsk6GY{M>s1|obG@4JCH{dUyvRmv|BqU(kDR&wv#t-k zdpCt6N8#wI@-;RtR?5*-FDA-*5i;W0Z2`|~qdv=6^z8w9bj>jymCydx@o3vpO!X|~ zYjZv8jzm*IHD4kBTYS2UWIXxyf#kbA&n=eJ$zB zq^JMx{{6qZJ)*XV+97I#sQsa~huR%#bEv(cwuagn(lNC!V?oreP@6(+3AG{Ac2Ju^ zZ3R^nY8xCN%8NOmc_1$+0ICEn1T6+#45|e!16>2U5p)aacF?_`hd_^mo&l``Z2-Lq zdJnV%^f~A|(9fX1K`oHEbl`Uis3(ZZ1DBf+{J9<4r<5DQN$t>n5P#3Cb=Ui9C;UZU zwwDe`!6gWlFMTbQ8*UmfVC5>8gO@}}E9UPCRedW{wc|!|qv6~9YwH(=-oGiYr3{L* zG-%Y?OfX+(hi?=0?T!Tjbf-4Ewg-}Va!5iNFykQQl6=O|0>4R~@wC+4s$Q5+VT?}4lV{J3eEQCYk5gf;Q>_D`?@mfEh)DH@%kwJWAvvrc`c37* z_`S=_?!TYtSa(%Nur){dL{FjeH8w6fp0QQFQWzeC^55_`9koxy(kC=bIMTnDu^C6S z@9(W!8=7Cct$H8JVH_%-{U=GYalXq>wh?WhI@LR#w)kW^@LnraqrLuZn)j`@fMdpn zFCJXb{x2F9X^wHIeD-e~$0YAG(*4@!+q}nGZG)LOr|u2*ttPa2+Tj`gGR*$E(K=tK+XEgl!Ev5|j+0F+&$nDyT1L2xtt5lt+Cr>HZjzHhtN{D~jVD8Z#{X1Ha6)Bi^U~u~6NkRnCZFC)tJ0=l}(b->k zG3*iOyeGehdHs-u#L0bBk zUfYcNn!FNxmv(0x8h(gdx8KwDmhMwmtbq>5QGMu#EAus`;gUbU)E4gW^2@d6$_6Hk zN0ad(QJQ$$&?kx-#Nqbb_mf#4P_;+}@jM{8C{c8~_PHg;KJ?ATkput^*+9BI$b5}y zxWL*F^rDREtwSM|zWksgSg!XdA%tc5eSR^^hgZUAT#|nl;=z`KP!f>0J#X3cNVjFz z(r=?{jIX`u3i);)juERuw}wv@yUH|68SXH4Vt!`J)Q+agj2s#rVAW~mG+KRV)uXvM zYD|(iwy3S>xg=TiyStMZv>`=|{Q5YNnbbp^(YLqApU_vFGcQdzuN){!A38+@-x@A1 z*gHxrO&%kb4IC$~pE5z*8ki*Rxo(Ph_{nMFsSnN)>wcdlHl`GbEyL%CZD-9B^$WdX z_bmaj@A*ox|C5C%A2p&?k0p>@E4mb2DS9lagY4@ddxaSB^(|sd((RCaH)P)@&Yt&> zD7x}d$bJ&CpAqNpeO@d{ehIQSK=$k6KY_Qz-PgSX*&jgmN8*LwKM@;XT-h@GYsmgi ze7bP2`1+QgA^Ug8{)^O|!1bsO|8TyoLB5gW@*A!HJ@KX&u1`65HLPLM$>NhJR6hIX z>8HQtIy@LSV(J*k^jG_Wb~+-{Hr^G?p;c%Yj;J70oKz6uq3=6y2Oj>u^KS{=@~KW4 z+gtIQxttvje=6&~Us10rE48Ny{L;R|=zd-F9zuqvtI9_-&FSNoG4g{|+O}#~Vzr}q z9i;($l2)>4ygAuJl|YZjdi>vDSE9T%woA3p6Xg@ z>>qpFi#8YmxxS_Bm$6uWwE8CYC1qZ*e9m@GpXIB3_8&`It?9cu0h_FHboShNQ(VQ^ z%ZzTwG|pY6$QM!itFD!OYqoEDc>1kLQUb~E1FbQi&kB|A>lboD1?@ zQP7z2>{jqlUQscb4dE57(`kq(E-1*mZEcICA5nWlj>-?6+sS;5X}CniBj?k)a_}ud zv@#sU*v|RTwNd(Zkd)K#`{>8L{?PsxZy!x&Da}beB?^_#{(AY5H?$|(=jA6?xcq*c z&u$n18FB0f4oa7C&~LT9?f3A_)xBD6XhS&3(VgC>WWL5UTyz{+u3`tqp7KBWW%OLP z-;b9RoHDSnKJ__Z)I z1{U)2$av2ZDfaQPm>NUJiJgD9Px;_-6dW)<8(jb9d?H`@P9=EAryGEzVNd(*MCr*;NR>=V_oKvKRM%_ ze@mak*F)97;r8rMHFr4P|BD(h&i`s#%T~w^MQFd2@w^Boh$km3Z2j2}Km0!QLa8n4 z?`b^Gd{u{0$Bkeb*CW{GOJnK~h{v&gFx#c{84r&~jN_!i>+H7X@uoVjUsKjx{GIV~yQ@yVqK?OQoUhDhe0;ZzQ@42-=O_E) z;Mos6%icct)ze#czM$e^KI7nf6Y+#KWt^YXVEvHths#?u`_y&kpZVUjs&$vBvA0)c>aco_J^Vr7szHdzVSy%jdwH8!s zZz(^RFS(Ix)b_lA9Uy{89gk7Algg7oWUr?Mb{ZE`S)x1n(Qk4TmVOh_Z}~LxH~!WB zXCD7g_rvb62LAu5fe;FGy!j>72imj3^`#wtQ(a=m^@ska-xQ7<-HqWi=HW||G;p{* zYm&MS2mXIt1IBStdKdHfn)cjL+f|Qo%4dlu_a#;Jd%w-rt4f!L?cTC2OKiZWu;h58 z!QIJfE*=-ZQae9Dn2pc9U3qTu zr}2z&9(#7aIC0gIdwDpok987+%11QK@m_YD-EEuf!?q}zU|@G0&oelj5yy&S&HAS? z7>&PXga3M)i?uzswntyO>-EZKpXB(gf0fVvs{Uz{cCLP)HSIbbON-6OgA7Dys{TpW ztMquZA82$}Gk$m_jK;;dPq5RQk6(P|$FIH#w#hZdx3*8vTUJKz2IgU1$yKUt-p8Dd zOPMAogeyItwy)O$&g(rLy5$^m-DVR={L>iU63#3)juXL7vm6{w8rjOIi7?JDtB#AW z$D=miJz&Fd$K5Kv#`u=-Wx_gP(wceRo7^ovu3v}T`@vfm9-yhY$u-8egp2iN(3z>; z02kE*JBa2R(duufz-#?GK09?5`IDnNJq`0Urr{E)zfLEXC|`Ux8RU#=(381np-S2klyP<0S{bGb$8g`B`HDN76TsjJTk7^6`zi*Us8}wu+1SjpB+X9D$APW|f``cJL|vXzv*;*!p~U zAkbwXLNg!#nq0nX4($}wHs$4Ek(s_`V59yPFA;g^9U1LB0@|tI)n7?q#zd^rV^h4I znh|Ge4|Dyey}79%-iKaN+fv*x&T&KH8;f$f>G7#9lD&fYIy-!eiZkC;Dz|x#bKv8N zPV`d&Z28PA!D|sP&Q)S-xF36^V5y@=lt~%O*_t>wH@(nOq`8+axqhlWW4Mll`g_93 z{4hZMM-y<$?F|GHagDh0ddAjYXn9NV!FTV>T>9Gl78$x+#>M=9gR8{r^PykVkcE&C zm;ZfnaAiNxQh4w8uYY-a(m@p$^Zx~|Oush}$kNWb(Upe8jQHwKh^@DMkG2$97p-{g zH}_FqH9wjEFYwXpA!V*?m!pDSN}x=I3xQaF>Ahm(t4TRZypez6-nSO~`16Sr8IJ1( z^CdTOZ9;jIs>`o*(XoB(2-LnDh4zK{Iy-!80=|MN z6SdP(G(F;AEw5*a!-Kc5w6sFFvL35?$I;^&SVz7e-1WxPUG3F;W_}o;{-X&vm7%iC zYa_mt6Jz5ek?$67a}9iZTa~Iu=IgM+w0@Ks&bQat*^2OUat za(+8;-dv))MTXk3i*s#bT+Nw}&q`9+q?_r~~^#@(6vyehxE5a)cm zwYtltP!|xwo%1)NZ+x7tcgB7B@|NlC86V#p<6FY1E19NM3OrN)yVU}|X9oZ9(A+Oh zpe0(9Ym9FVA3lWRC^bPdj;pHr#n;=ds~^co9@XJ_6Da)C7{3X)^zl1hh%9!SC(TH| z3dH%l4>-x$LG&xyIQ5txt2_PD%TBM7YEIg=n+uiC{^K)q_1FBg!k^_Tb!bCRW4)}! zkT>4^uEWmx<5sR*^@Kzy@sU=U&+_=LPh<4W1ej7~Iy|{JH(ux4<@d(TlgG~84S;&?Uq!TA&du6X(y`0ll*%&Yf*!|@rH%4dIUx2V8p)@@ndN#3AlVbKxk z2#oXKK51sX&={6<6Y7FF%ff>9C{0`1=eN9=v+GnTHr!Ypx>+zVrxJqe#URu*8 zd-OJQupZdBzPbiD;_2bzuHU%CNkw#2ndazD=$Wsx!?!RFnwaCI2)tArbjcCFc8Zn` zC!8-vy^OZS$8#X#{9#)*ZEav@RQU`jf=7QxF5l-WEyX~vXdaIBiJ%D~0+)|^3pm{G zFB|vVe-`wkydy{V1YDV~F%1{JeB|ShWZLeHLW1|RsCK#i@>PMHfVQcbI^KMFcmtUq zwYpBpgg}h1WN(HXaD;9*U74Wn9uV0-WZN?u#?~*AH9Ewt)ET66;D6i7tQdDbp3P#%VqtjeD=47 z%dDT-gX8O`?CT!Aj;Y^$y{aGPvwXfchQsd6g%t_k*CCTp6g3(9jeWosPd|_Ty7A+{ z-RmA@xvU?R&;Cuqg-A6ZZf|@;Wa@VC=$E=*3M|q7wT?%oUbg2J!cC6C(R-`R*O-P& z_>Gf*jkddCyo15M&+CD9v{(0y^=ZEa`HQm7yEnJZ-r=fz<{Lz7KjX-^v8AO7p~HGO z#jFP>{HUX)O3deUr7s%)p?h5QN)-q55!B=w;*edpQSNRFayPZj=;lmGq2)TwNu&uv z<+Hy*E><__tXQWexCR0Ec}s?xpEp{*UoiUiZh3Qxc{;DW;~2+ar!fj_a_$@b0Z~3wlxNPHNY3IeX4!@+H=0% za>gl)L)M2xq4L?^pdS;EXy+`5;qmn|BQ<^H74uJ?tdu-HvQCj7 zZQSvn?;dSik4D=G{ zZ_o%#3N8R`0CmR1b1rBDs4oiR^`KTTBVP(?k5%eBK=vemwST4IA^e9Cdc93t1lHQTgoOIG(|A@vOIi=iWcx9JVHF zDLsbf7>~+l|Hkp?`k?^y-nAaVsGq#kWa@VK(XVLw>D}VqR}zw%En#_#N9D7B<9Kxa z#K2Q;0nev@-r)RbY|gn7hr~_20P`6K-y6rH>&MWRQXHdxe5Xq(cJS#}H2w5{=9H?} z%kTJ(;*ygw5`@Z^zBs4WbdHX(JnQ;V@R-KG7VxwmH#{)?x1L*B9^+B@?B6&ZT|aqV z9JE<&+NV}CTBd5(pEsIbGAd@AdiB^IKd~Ifq4L?kaU8l{bR5R~Nw&wwv0%iBi&m8# zp|8$I@<-*z$D!+^z~jTmTKHHLQ+Wwlz*Deo|Cf%Uebl{aj`gDQ**~sc6g(>sk^6&; zG3N16bNJCX$Y>WXTa)!$%FE5Do6sENQTgoOIG#MOk4_OFyBf}B4Jr+@5!Y4=xMnTB z<;RTiMW3=<#-;Mv-#RV|8EFuWxJqDsB{_Bw-J|L2<@#e*o%hMwM2Sa+qgc#mJbbr~ z%Utn|xM<)J4_DPw-ZkfZa`jl2EAb@=mCydxahVHP2nlfc3R%GQ{PmywIN{Fvek_-9 zseJagj*B~fyT@tB(kcVK6#eiNJ9s2FT03=Q(u_TSJ#y01ET8eIeD*is)8?%{AB}L# z>r-_W9c&5&;E-1Jhc7T?-fB%gMi`Zw;=zd@|3&w^jH<(^jW^j zXMa_`zJ)HV0i*onY?+!Jk?B{o=kH#;tMs=krcdYeS-#3=e?@-y-)Q=;vmpPnHV60o z@pOj<_DYo>PrfYu=Jkk_ocPb*VfwoE`_oV6;jpGB(w54PC!Z8Sy$I{U*zVL>z;VI+ ziO0>lfBMlZhx0+@vwv9e(oQw~gN%D>3(-juv|NQmq9seFQZVac-@>M?jEAl6K!;A<93TwoXdPaObe70!u zlM7!P)}S7${3tlsPD+a#E`OO@JGnKW7X;(@bhQN>{ogwO|6}hv;G-(K_HPoDfDJ3L z2N4OD6$BNzQ||N`{@Jy^e=l-GA0}Viqdz}{xlN8A za@B-?sDCn+?{Lq!93d!pA_yq?qwCo^*B z@Q0e&F$9Q9XKfgP_`tI*uXgwaz%7}cEFYcOrwihv;t_rNW zV8yII*C!$W*!{6S!See;l>JVHDYB~ToD8iJ&ew?WA%c^ zw^(|3^Qz?}^?bQ03HepS`dzks)4aDNevxnT#a)v>1X;j` z-G3#Xq3EtwpB^ewy&F%lg8QB+!oG1>1FYe9akguErqz(Zjf6N{3?vKJLB^wWY z9ca%x=jBWqan6ZgyG(QZq}B<_dB!*+U0u&!z}wmFPq?0cvT&k1f43K8|Nf@^40g+2hV@(u@rUb<=vA=OJthv}>lpa% zI!9hD;_Q#zV8Q5kd<1?({@Ntu@3p%9clX?PXer~Sv2oyh7K3lQ#**JRP^u2Gw|(g4 zrVw|cB+94j?p|N^bA1oBc2bvb@)OI)Wivc>)L1~J<7ogM{yr~=Hp@&akiLHN(jA`p z<+#>2?qchqF<%HD-d(0?di25Gu3C@I=bBEx6H3pgHKP*ir#N@aduRVPc)bXbC7b5{&Z%)_1gFUtcbDFrtnDo2&gTUVZ18L&WEFKLp42bT zF~~Tz@f?HE2TiUdrikOteeHAMPU8hBw{MP7^T4xlB0|Z)RbA4LoE5|#wL8>rFHY50Uh3r|3%g?(pU7vOu^mXC_ZYFb*PJbPSFWT#8rlpc ze8torSd3CoQGuIUF=6&gs(wSuX0CX^YMb)3g(VY2YXs1^mdVj&60jB~KJfAvz zGh93z^qUEie3J+Hdi;!guH(*pvndID>Fqyw`p!2?=9&1~IDACsGV$MJp@=#Mhiz+M%wx*NKyFeC)cb zf8+jR8z0u2ID9i)RD4r>L$QD?7Mg@s^gkHE-|hrzrE|)@#~IlGOud#1zXa%@^K=nmedhM zAmzJVVd8r4<{M8c?s-RnEEiOIrPfTo;F5ZGK%l6i1l#s2FzSgLkQAGKYBc%l4f#BL zgBiXMjY{6zG6U|%m(Cy8dED}g*_NYWdz1N1_=>4LMwR-)Aq;QwyUIO@1+|r`X3B#f z{%*PdL(-o?^>;0*xUYJBUFb{PzN+qdUYnD4*frXIkjR_kJN?JLfogm~xK~GAF_(ks zq^in(+Wvt$L?r2HjZchY@StTy4VMI0$Zw|2Tp)bGC3Y^(r^P}4*y~n>nY3WYGZ5F_ z1pKuj`()d4Kc`azY8@~(cVT3N^Z8W06G0tp!51mArFy~R+gcdEOL_H!RzQ4L2 zk!MY@vBforyMs7Evp0wfn>&CG0UZwF?>r8~-#!R55>x~_3p5pU4d`yrv!IVasrcd8 zK5Jnpz`79h6o{4VKoo#FP$~*U5cEChVpP^$(O}sOT8H(4)GLaJI!`KsxJ3WFAQMq2 z476jdKb?L>mkZkN^Gp%fSJJRdrs64l#nc|I_T$JNYOsB=Af+eA33H%=66@#X&!*l`Gv*;?ab*OL$rtye@IXH~Wli_}Z%P8s z+h_f-_aE0ibg#%0JSJb<6XUUuOTc)8mTGQ2)s!aIQ^D@7Mh?5}n{Py};4=B*o){O( zR}L;=M-Pi(>OfNOWt1hxbKm--+PB&F)d>tsBX~@{?V4o1?j0(YA>QbSy%T|6FV+Dc z<#`>ssLm}^<*xqc`Zen-7JPm6Ti9Zv4DA%_*c9R0+{Wi{f1ntxYJW{Q*B6|SQ+4*) zyfU}aKfEds>gOvjACHyMXSi4m{S&>Vxh2fs(<#+KMW+)pY%5mb>+jCWUGT$o-e= zFT?$SJ^LQ^ecQncDVJtKt}S2qHn;I<%eTe#M*i!AK6ELZGeP{_94E?#TsiOZhJO7} zi@4njHTV3P2cXsMc8_T8lTQ0e?LyOk*A}=ZYJUuR`{Bo}-HLZQ7;)3kPQg?7im5$D z4DqTxX!hz7dvuS^bs$O4x`3TXUhw#KfPHx)Aq+y z5I+6rhNDP*i>vH@K2BLs4Q~%oRQoaQRaQ}q1XhCpo*`uc+%<~)*DV)qcPEl`2qM0} z+V0&E@v!a7b|Txq?LhiIoIUVAHxRKs+#ZwxV!L=B(7qsS#Zzr$E*v=!lnLqpItbJe zM7{H)&h|6QSQe-Yhz+2_Kx|VV0rG&31a$><1F@WR2lW7P6WK8!cDj0k*l0N(MEy(q zxDM}$v^5I~}jqSNnEKed-9_G+`UsOef(x?5Oou(&?xk zOenhvG8Y2=x6+Ae#PrDoF4oX8l z;D$ivhgkWh<}3(+@e&&-R=#PddBRiJ_t&Y@n3-YdZycV&S4`~@JKqc_E^oGU>$%1~ zF4hn<@ZmSJoU{Xf{40;Km{_&#?#{So<*q+0bTBZ)!N4bchaI(&#+MtkD<6Bh!>UIN ze@A}S``oN&SjVt#VZS>QbTEkdlzEiDmF52=P+!mx5c6Xph>f7hpbJ4)gYEz=1HBCT z1oS6pUnrv&h{JdngB}EZ24bE%4O9n`e8GGy^+`?0{T*!$w{%b;{L8(>wX zW@lw+GnDWhcGQZk_u+nYEW>u~&simRyQb@8Hx6Pj+f(0-?pb>7`%m0v;t+lmfb$X? zM}BEVFkFB|j?s3Vd9J+~&p+*d`Tc(d*S{0?ugGf&^WUcdegmccSYeb~R2vpPO|J2> zhKGLfc77vcFUfnfS=xnt5Y?^O{!&vbt5q#)bXl24CD`<8elHZ7|BKu9x)&4zqv404Mys z;`qVgzR!pp!C~^nJvI*L1?$>y0dTFF!jQ>Y1eyzybgHbiWA}om-i-UHC}X#ctIqi3 zz+Nv*zm)&k{(8c<@NI76Gv<9rVCwhV@jNPju(vz#=ioJmYsr)pYrxWu ze`Yj1b-AA(1sHx8@GaXae8tor?)$2u_h!X{qC)BUXU5rXJ(=f%)Ss7P-Lqu$l8dXh zUo*^+DR_jhK~b*;9#bRHd$e@DWZ-wxG^dwHB*pqR>x%rxznpofsTbj^2(*VAhx;C_ zSjy4!&ys2J@lecjSuf82a_`=yZ(U{!WeDaU;oIECC-KO^jh_4}%vs|s_$K#hHANQd zd(AqBhBAfZf8FN$|D>_C_CG1HMOKRj+#0AuCggWO=9P6@20%B*#9{V zwA5$+Io-Cz{NJYmy`7Xj-QC`2Tc2(1yuB>zwUw`OXwW+As;@@v*t^3CdR@o!`-D$F zx{2M+R{f13{y>!)Kq#u>iQ;x+TgPL~NQ~!_hMVVl=WKtP-eySy9^va)_}&a2e^||x zbEbkbWi}j+BgLvu%sBsv|NoV?(q9SlPyFpInEv-Pp!aj;qWsc$L3}g&e{}ol4d16r z_qc||Oc~ldzghSWJ8IeUiq1B356^_eLDIab3@g_$)p<7NID1!=t7CVo%P~7nB#xV#jM<(yMA50`jn@#S^v=x7yHS=S4{0;<8p~s3(@2b zY`tDv2>Gl(MK7_&c~-RgY{|8MU?ZIvyTVOv!gt(_{Zs+0i|}(bKu$#s&ilqnIBo+Q z5RhZpT;m3rm)l|lk2w$C^HSVPe$V80*1d86P3@j?YJOPMhwufa*ls+Sp`3t=ow%>a zQxNp~F+~ud-;3Iqpy59ApNFa{`=q+yT@MME{(_+8eYJ zh;szwF-%*~jv)GFnsWGqHpjF$PS0;0iNB885W;JVfd+CxX8Ih}AM>tM)HWEseprTl z$KYNNZL_`6b8#!{&u-)Ar`&k$qBV}3t?jkK|xHfAz{^z_r>rJ*_PX+Y` z9Sq{S3-Y;!f{ppzL1@}5V*SWElXW5AIk(FCl04RxtV_9$gY_=m`8_0`^`%buR~i0p zA-apv--Wj=HsjO{<0BT@B2V07@x-mg{{KS*b;uOvcT0Xb+X^(2ZG?fpLJF@5YvWr8QXOoK-4YkE4KC69%Ojxy&Z`2No@16?%E9`?M0>uc?`#NH|sN| zDS2WfjcF6382w#%+hQ|5-7r4Nr7beWJr+;gTI~NnG*E+|DebcLXpb;YctMgcnRg12 zsYl+v^d!7m@BSQW|Kdf}+)|{Bou^Wwe1{#iq$S3?*VPuZzBSkp7ILi@&ch-_)^n8G zoT-_2c9&fS{d6nqOd642>+o%E<5T3y9Hw)qy_E?s{JmT+TnV{)yo__M4LVz$q~jL~i%5E$a0guQb(-NoH*oSOhw z?u{wd#GcW3Xvh#t;MtI^8zKT?PxbZlt*$5-%y!;XahuNOasKa`Rf>}@Pd+ILlntBnw z20^{Lal~xbH=;raJ^$o7tKs71pSM;YcJrq34d3432&N|YM*b1L!;V_SBYC>{dHE*# ziaG8~SuEcqmOuS}^V`7xX=u|wzk_VsGdYFF@Zyi}rqOx&yXmjx{}v7WZ)*TmMYHXE zVl(qE+lL%S6l1yzzqxk1xVPBJX~1mfGZb~+QlBNKzZPHre`z3spDXRP)keF-oS&g) zUI}mbXyJ9&9m;x*hGnZYp2Am5?IG>$#>UWqu)lE`zZHRBk-y}2yLR+~$2Z4i{6ToNw$DCg*|9%Yy~B4JJ48wozU_+rHO@Faj=@s%boT9T_7T1GQwpN|=Ju;` z?1gO^_T6P1pa{E8+B~L$k^!EG*hW@w5Q}~LhJw)GqDvGLjwPb!(3C_0-V`k9SzuK>i`rFFSvWvC9}Sl@PfnSi+eLTDsXF7O}NTeE+sO80Fp08FHEeDf-A<} zIrQOgIK-xm;4t~(9veqaMa9HPzTia5l`q#PA%FENUln%W=kt3devxnT#l0E%Rb}O2 zbrOS~4uy*n|Nf84ULU-*{#2A$+lYLVFYdABJN3jVRb||}P7?u1I@BkDyBkRlZO7dK1}$EsXavgss3PvQ%6cwrB5Qea8%ySSQ~M~ zswXGU{^+3gr+<5yh_XYZSSDZG1&0W?>q!lj<58cVwC+iaaF~2? zkBx&jO_n>E(~U_lCo_`3bJOM(-d8_3_*9W6cuc;y$HwD8>4#%4YHgo7j&_R^>!st_ zX+6KY`yoy-C?hybzPQK6(a(=%j6v)j^812CrSuyCNqLzK92{@)f*8My!|3C+)5dSe zJNn(gBseQ0I845{3l6MU#L<7FeApElstptk@r8>@{UOV$gGZ6ym7AntM1HJxWaZR{ zZ(5$&f0goxhsZbi;x6*NRpE*vTsw-R%WxtXbF0T*Yh<4bg+tAXtL$?MaYU?xjdAGX zZ>y8Qcg6hQGrgz$d=lqvXo#;Zp2Am5?U5|Ld~9UJ(Pq7?oO?_4arVq5ZoRR59|alN z_hDVsS>JIBvQ_r+Q*9qTjs&qH&ISzvjRuu~_**Xr-40p-st0Y4A8-^1M^#z#K^sB5 zG@BPzw?Sok8K@(`ya~DkmF`>sdH{g_Oh=waC!{yp*~8IreH4>$)E9=1&quVbdUMkQ zh!n;P;+vTt7eenZ7hQ8jsQ=AR6vCZ`zl-D0!dFb~A$m=aADgT<16l%fB0gc82Pj#|zNU;8*IG=jLFk(aySR-^n% zoE_(^XvM1iP(=Wh@iK&re&-%ajOXYN-uotablp`Vka(ElCSTkW;jw|@%qMoFozr;L z0z&`}kMW1?bE%8fiNb?@RROzoV0`});NCPc&DwFt?Kd8J&lBrq?F#kD`cU|SSL|kS zJ6cqV9pbAUj{`?1`t4JV7`6^1`Ye6etxx#|NjtkIc3+%7q+rPLYp%bQYcOa8m+)@33^OS59qsod){9$H6-l-7|Ru!pUx{jmfk;FKj?YrrRecN|hBXX!GYRlw{ zdlMX7Xx;>cTOW0g#>dgMUu)~;i9J8uTJ-3j_;f47@jT`u;XCZ8)dWYspl_1DDUdpd z*6ZzP1WCTIK1DM^_2t;cAwJgowC!JomlpGvHIRvrOdqbNSb=;Z=dTq{SU!;Y)${YR z$K2(fZ7;4%%LTvuv^P)7eLTfFbKUS;`+k1q^w*rkL6<}2BjMv;ml+U1WsY;q!nywP zN}N+2m{3;Y$@2wyLZG??!SP)Qn>e?%9n5kq-ygPzW$YBq(3t0yAQ2kpE1_~fT^z|DX6IA>D^SJYKQCPXrL1n z%fhyp%x&@fH~OtZT*R-=zlT1lN6{zCILBl3e(#Cv#vJg{4#Svq%Iu{oroFZ^`QpxV z_!_T!QvLrD)JP%E5T0_c7A>i*K=?-;4vhPSoD+)e81#JJ^+`8A)<3M53jtKlZTjKp z%U}Ct&-$}PzRDN)RVH8D3xYg9yLhCpsyvK)1j-@Z$5YX<%MnLW;&5tzKDz1d@qs14 zK_hxH*Tdv4$N3#Q9P{Ecq0eW$ZF^PuoAtKvMZVbX^)S(OLeZ=ifk#QFt~_)aM&z5{ z(VCSh*7RwSt9LtY=a<-Dq+xwyFfJ?iB@_j$J-OdRyzZRH#7ZoH%+?`nReU>M>MJcX~A+JiU} zuLEjC6l=a*+Fi}{Ic(H_?{`w-)P73KYl{Z{aT=&YM%BNUIzTBevGOwO`sPe5|IPVr z;m6lNton>?0M=>E>DlC)|HqdY+x72=BX-O!+!hV|eHvJZsH9!ifc6OMFfWMtm+xl# zdGaSu4ZOzlA-ibG*aID%Et4dq!gKd_`|xC1#7Qt!qlf;R;m2pp(8rLev`VLHy#nq~1>3VHQ0`I*`=Dl$L zuc;pj9>Ht!#XUj#_xIxv1?RBwc*$?oAwtpX>=zU3^^M2<<u)9B+{gS(1EZ^%oOe}Vr zGUAPNjQe)H_?otDPM@=Ryd$_fZ0bw+f=BF;J{$`QYHV35Ii0$*ysR!Y^K;R!O-{8J4o;TXNDi}l+?96pAm*>>lGX)sPP^qIP z51fc}Jv9Iy<%*uzC2b9o`y1+k@BQ-zKXXDwtCu@E;g5z*e8P9wQA@*z84WBf;AjSp zT2af>aOc4Ae!0DUA-}8N9C;-^j;zm9tXxJN)D*IMhAYnER|H@mF+A>%(<)5nx6eEQK%6S;Y4 zIrxIksvGw>%52D|5&g#+M_IXY?x%Y%I_~;oY_IBf^BfJ~>$3SCa~uUs*Enh^F7*!J znq>Ib%Spz%_;{9J5c{Um1Fs*FvE2$Q#hzhXggBTVqI`nTjC*{kaePgKpnOO0lysSE z;4sJ8>fglucq=pie0@m6y_=lzrE?LUIE1ev)gEpf1tLB=(5CAl(;2L9E?puRTxl<#5h|Nk=ZZhcb|>Z3=pdXuBYL*g>wnCSwC=Snl{S}iDU9C(UMZ% zwMIV6Rg3xiG+@?eth1`-n+4V=5h7Eu{bDWzoa(di@WyE&5lJgpa@xkhB+9CxPpeqFEaUPJC;+$dz#wlP~UaPi3^R z)OS*4xE6P6_Ad2t!;3CI@}XTCya>!UbDb{Z^h|rQ`ut-iT`zS!{c-=H@aac4&We59 zP-q{Tfvs>3YXB4xvU;NOF~2j6Q%H}i<-J7%EgG;jFaws<8|n4#{y)F#{Lbs=dH1}n z<8=>T9ga4`rm1MAStehx@xVR6{s1q1$7MqP@x%RRRXMvzYie=pX&GHOMCTfJtut`2 zj$q$vEd~qU9`;coUM=rQTZcUG>)ng_P9r!>zU|r^jz&nhZQP5?=8nV%-kzXw0Q zs^r%lPIy3mhpo>8ER!$pvGQ-9GOqXwhS|(Rb5D8IaV$&%$8D4EKcjoQV;>Yb_5{$w zmdO|QSU4yjqthjr8w;U%7bw9#e;r3xUTz8F1@X-+&&wW2v+loP>1`vtE3P|{9$}b& zIUXr|#nc{+rNv{Y!7~I6OjWSxy$&Sx@mk=Ze8Iso#BY{9PVPPCmYX*C_Z@fy_%!U- zrr{}k#nc|yCxTfOR3q+L?kL-tZW->c3i-X&7&G>bS0_eG6uO?~ViTN>&-|W_hWo+i zFTZ@{exqN%$ccb9^(1_WS8Ufk_rnXgB07Wv8iLOGclQ1kc+Ljt<-E5Of!NN!&06~J z$i#dQjp*4-?~ER;taj&C->~PLpJuTxqv;Id?-0IXYL8g?P7=N`FSy$U?Y@kUW7*NI ztnYRleNd;HAFmV~lJA7CK~S&B;c(|c2FwEK`sH`RMn~61lZ#i~AMtR}1^qI=CTsq# zcqk+ z@^1Rz_>0OG93dS)?vtT@gdYdbfDq-X1tw_K$X-1sKm@krqeucAOU`R;eZS15WSG?Grjx4Df^O)oYMH6f1;dAwT$-e!PAe)_lZ^-!OhZf)1Cdc&8`9J-$~{U6;= zA^b+k_FG)}+Gi!A;h2#CN6oGH-ah}+Zg+f8x+muyX+#ggx4Df^7Y-c9G11Q^9(T#w zesn#wYlyFhtlL^yk015cZL=PD?LJe!@EaxDZ<>7eXv@&H#1Rj?XxI%T0`HO@vw?#~ z%5CQIRJ9(%YCs!r&i${o8=GbgYrplUKR9>9VF!}^5vneY`;dnCfeDo!s@bqFi@ zxaRx#dg|&=v!48Z@vJX4-TuCbNB9~P^|}ps3{BZF>E+$}!Tmil$F=HF-qT+_BhvQk zyB2P8fJl8K{5bgRFOIhaV>P|Yxyy|sH6iSCW0)FHR8PRcc7c?4zOx;#@B7

      +e_m z;a$@KY-Q}^+s88b;;!jwK&U?lA8i*szoh@@P9L-VvVO;O>-vV?s}}V7X|VJwq+AJK z(YcTc*M>x;~7Be>NE6Zi?Mhd zo$nfMfaK;!|F8g?o$##Z*ChrHrU|j=<7dBQuNe8qvA-4BDQn{(df|(Fv18+iUK8iX z`Szt10HWjQ`LjFU#G28?{L2tL*G%~Iqnjo;qPNot0^9dO zM8xv@pWb)PedKIwu)K5K2*=klK?i{j2C)NlD2V;pt{|=}=GjHPKqrHGgK|MbK*K?! zL1%#22IRUwHiM>srh~2kT?d*Ex(Boj^c?7Q(8r+7pfvpMJwY5#JpnWvR0f&~x*3Em z@74y;ub}-=7;->og02BQ1Ns4!g~TWX-2{3Ml-UY#fF1$0#b8kpXeFpK21w_CTDQhL z2dH&A;sG6wLDg44Q&3^|K!fxb&`X%eU5rNhJXBE32l%9&54f)U(vU=c*`<2%ms=mW zGbbDPX=t5@r|=b1do;-}Lwq%{vW#ASYN#9-FNkkuy-T;-eth)!Z(pCcZXW-Ep}!0~ zg|C>}qX`Z*6M$K!f(li$h}Q^SxP{?2HH!T{q1 zDNUH?Cv2B$l@40^=Q*Fe{o}pQ+J5=u?-xG9>n6E%ozdiIa(@DGu+HIl9mfhdZcH0R zQ?2C`9*U>p*(r#BVDxwWf1Pjt3gzAP(EYd^{>^{>O1#Zs{5PSr1phD4Kpip^>yKFL zI`IiohWUr(q#X#KH&upqhb?)L?tG_Bca|-_OPQk0+LnaRUX)LNVk9p4zs0sSV6N+= zo;au89>lr~O$3!LQlBx6*r#DSkaWH3?{HFX$D`ha5-}Rr0HyPP2e*W1Sm%<6oD_$C;630Z&22L`>;%7SDraUDztA7$Nj3)UXuKJ{XDH=!%QE@mJ}kd?u(mSnQKxm|bnGJjhi+{@UwQd>U(v*Z3j2I8 zyWD%2t72d-I)!Z2&$^zGCBHpH%K~4*0hc-FUd<6(P*NYM13|5qL-W9`T7+?_?q3edcgTvYj(B1 zJ@$wj?iky5Kij8WuGrrezKTG5ASZ-8`TlZ$k-b@8w#H||5B1ISBdr}%qvuCvEWAg> zt-EJx?(Nn;a5!b_<-K7SH*V{;RBJW-EJL_y*GwLRSF0xXjlR#Uy=^()Y3vZGP58De z@{d1=V-_ZHHh73H0R06$_$kA2yGy7nTo6RbBFC92R7`5hitab~Pv#?*4UR#u&7J|m zF$!w@lVcLhANzwiuG|6C5!4C9anLTH!$3!Xjs$fB^#E}^^mq{0H<0rGyrres2p@YXby;D$vn~z+nKo}!9w+Jbp&OD&H$YUx&^cnv=Ov3@+~jw7!TsY zv*n=gK!>1kjRjo?dIPj4I+9~R^Fd#MdZ8km3Hl6_gO25Gpf>526$X6@Ivr!G8$e^x z@Y@7Bdk6HL(5ZbGREUn#?x-YR1zm%Vl)oMDp_AKrH~cpvZ1 z;+NrUN+jC;NVG$5MK~ndOe9(Z67AJhz_QM=GT(!aHd@x>-!r{atPgg=yv@G26YS6w zYvS>^qX{Rzc04`BDhS|S-3zey{TjI4m16Dtbc%J=`V^}-=BH0a-E!?Asn%(|Q?2>F zRBOrwNGOz3)``dlu5sv^cJ6wS-yW#cb#K*_3o?%GHog7M`!FyJVng4R@!EXF)E;PO z`zk9vjWb%@LRA&Sbe1;h2>&xc(vGlpb>k?8n;(<`9f!vp|0`atp}rfAFFRsUA7o2q zXtNz5e1{#iFc&-llUN?-ToqQx)qb8p>NtqU2wnt7#K3{9+~hkk^Q=W9CO&Zzi?cE| zo)pXEi@V@J69!w$c-CnM%9&&z8VgVQcdFfP)NbQ=Il(yReLyfd=hw8x)B5msh8p8T!~ z-(g3sM!dLsO`!1=3ur3JtNjBj#-CE(Z^+j}Jc8)9c$# zsG5}NhbQp}-(g3sWbvTD@vG@7XQg|%^<(0pko5=d?S13*`I4N`{AKb5P@?=L>(?U) zAo*&>UTz#_I&A{ZpN9Q@&{a!!e`s7^TT(ZC52zR6i+r)U9VX-%!JLCNRXE^eu&)*e zOoha~4jGv8WxRAV98z1^cccu#J3b+*ZHmu}8s}tsFwf)Dr1o6fi0%Kk2ao@g4hQW3 zVt!&w@;$p+3(a>u9?66>+-v8 zou*jd8+>s`uP7Loy|1G_y!l{n7|i$Cyf@(c?&0L5zrFOn{Gz(FKl5aZ{&`91i2w@=2N z+WDbeI4NV}NwZA8xHrL(UsYL&yPZP0eTLIdCW!LY`S*}7=iiUs;!&z!=(uyecIn=U z^>pn1p5;&P)%tA&Q-;5TzsBS%HXd64#OdIMutWxHsH!mpf&RZI2VE5VdxUu-;{F$K4#)bQ!B}a86`)a=Rs<1B zdd~(<%JqV1v)*HUsE=QqJ@bZTPtUzzjE&Fs$99?U;oW8Iv()>RPw?dUefZMjAMOtaYrSD?Vy_H`>@)xJtBRrv zbMaLDp;>-eC;j2ishsbs6KBw#quE5m_tg%%ahTi|3 zbx!Cus&Tb;uy+HoU(fzLzww!%P9QdT*j7YWPxZ^$Cg6ZZ2?*Ud>k<&xz&s3k4YV25 z9zQMz6b3B@VcEFV3o4oe`UMn#4t@k(i3IA41lkh?Xgd_3ebUkQMtf!rN_Q2&`OxvY z9^kTe2PQNkE<}H|YJUhg2y3T0W6c!$qyy38IPC=V_4}fH=An;&I>sF)qJKICYn^7I z-+nv#z)zu1ijM!NKhXC*IK{f?loadQ3sbCn(LZe4I@Q{HRH`-gfmG}81JDk>KFuob z+{!w0O)Klk8QWQXing~R<62v{PffR$yw=9La^wzHzrA*{+U~oHHLYS->yHEXuofNP z-rDr)KGv<953uf9*3s(PtBaL;-H{ga0h(s2e;EO6sXx}n$S>6KZ1^l0xT-5&ttaOE zaAV1rOU~Ir%P)H(zX+dxbYtX~QDuSRipkD5jQ-|=M1JXkNCX%!2uY)Gn(`-JwKBZ# zk>idUM~^V{w=WJzU+ zhxa%N-(g2B!Q+%`kESnmwFXz1(zC9Yb{(4HD25-se(`;`rd!Rsb2~dtG?iYR@DzR& zfb$|a&|~8-*XozyRe=Fm`#QM7=_%O(7Q&KrT4vyh)ehWc`)_~lbA5fW({)#P4#ZRV zCZ687A-T+t8%BbmFs{)F*W&xf7DZXO4D%Uh+xwTQc=Q0ijocf-mCINZJQ#grcxCog zM$hMY2f6hY3+KvyoA!9KewXKLpYr{}xs48A;uSkKPDxGY2vqcZxhA%;_24dlo07nl z)~EB^OP_q@B2$0D7d&Fe$2A1keQDTm#6@}7r-JJGif~X9#tULTj-{`xm&Y`;@3v$k z$31w7n2+-X|hry|#B zdTI|m!f%2HEoWTZKB^+ff&F}p@}Q}Vj9ya4jR`oi*5+V-ORZjwBD4zxYh1es)FEOi zr=vT$+e2KUc_66rN3_u@TW{cFoyN*fAK&bCL-`l}#jQu7nV<~q z6twDu@35nmj4O`d=$M-GaSv`r;8Wz!?c&xCvkpJE`Z(T~N9}psi5Csy(rIOAvmGyd zhaI()GB6Ly#LPpfr15z&IrOn?b<0!T)n}?=Si}@eWK&S7!$UN)iD4iSMRddfb`ttS&lyK8r~?wQl@%&O^&?_@uXh8A%MUoo{u|GW_%kkiVy zAw)Z+@Ta$5 zaF3_Ag%`K7I^D3c;j^vXcbD&j=uP;D&Sl)^I1a(iwtnS4bmn!rrAN5sn&VrUGg?{q z4_f)txHAvipZI7fpXnuh#nc{dxjC4ovimu@+;+#iE zJ@2mm`r=h=xWY_=JLL-B<~Bava?vgJ<_+NFM+N{h9sal1Nl2S46PP-H4gz%q9SrIO zIs}BF4t1_e7ubh_I3{yA2*V$i2XrK;D~Nq!wgS6@I1zg^=ok>D>aCuj<3Jq8=>@`& ziCS-Q66}*f*&r_{2hjF`uz&JR39xbPfnh5Ule+=Yt}k3qVsr(?HWf7lJMV zT?}G<#<8wTL6?Cp2VDW037Q3BJ#!`KD$pFz)u3xY*MhDCF}q$5Vnh2z&`qG5LGwVj zfa*Z=LAQc#1Kkd~19T^70cas;5$G<^-Jp9wi$V8-?gK3W-49v{dI0nw=poR4tfLhCg?5D+o1KJ4WM^G?}FX~y$|{T^dYDo^bzP|(7!;RfIbC%2HFVP1o|BG z1?WrASD>#!-+;aaHGsYYZ3cZ0`T_JK=qJ$6pe>+ZK)-^11N{#A1N0|oD~NRss*&?E z((QUdZ=ciozsdCZKlWn|0bZ7+WX(Rwdi)3bO9i$p2j7AJV4VM#q3!U08GH-&77es$ z;D1a5b&w?e=_Tl=(0D;;HZ&P`$jVEzUap>$@lxo8?Vj6?KJ7h@?57Cd<~Bav{S<8! z!sGN=j>27*{>dKP7e5YNm~lhBBM0>N7W9=E*uE5exlSiu@R{d-tUe{p>T=b`r)T|g zP1maJ?HKrtAwJtzV9} z3LoBGM!(?E9&*+=_HBGnpiCq|ug-0u7?V{iE9wxN;9GV=VtfaTnK!#<&d#IxJ7{PV zpYRn^duV7paqyYIWO<|OsZ=E>lyVH+y#6;7} z?tt7dTi?FkPB6-S+FU z;DU2*xN?WXZ6DHyIm+Ri;fSM85PK1VIaMWEfkMT|TBcU~XW~Wbk7d9ia_G+Anh6s3 z^_n~DP1Ajg<~}`!dqz%U{2b>n!}rwOKaSx(T61S$GklHaeq;>yxtco{5}M(cY3`@R za9^*vm&S14qPd4+xM%ck{QVr9#-Ei568-kn+%JvcK3a318N{f!T+RKN z81Bn7_vd4{uh-mhHFJ~Sw?%V*HHLde-^Sn11{wY=T|YfF_cvm=kJj9|cg_r7qq)E3 zxa;4^^nUL8j&%;d0s4B*st%D2XS`8#BG}4M1|^w%#m0m6jQv?2R#9nxfjrSSZ=e|8 z$>=8>OO0Ih?`+_q@q#FaEgn|*99xuooDVBHc;yv?)^hk!89PL(W%9*cuFCS*dpa?v z=f^D>er)?hi-Jp_oJB;L2q5Kd32?}I@1dD57gC0*5=$C9#9kH3@o>e%f5 zsn+20$M)~CeQ+@A4VpbbZ2t>iF||kYI7bAE?7JBH2Gr(nyCIl|c!^iqtrQcFG*QZ* z{4Zhj|K(k5`iW(9zQiLo{p;_s!vB+adOIKk^QAOi5cf!D&Tp;qVdemgwO5~1Pq$GU zcU%0~;@7Ym)i(UC{Kdkzxs6X8z3jso0`{^aIT2)704qo*=3}AHpd81mj-yV)!T8O2 zWd^x@?9@Ad`u$%utRHD;alM%E6;pfUU>zXtVV;Oh+YT7cDi>66on&+|5ei)-aF7vm^!Wf2p{uJ6o3;GlfLf!8MbId$$#@1DP%{#7~$E$Bf}iY0u-)E-Ic2Z!GJihXJYYaPO} zym7rm?oc-#v%Rozeya7@^Rpg!r}OK@>5fd={O$?gVMi^|LrlGJj}s12R!6Z^g}JdB z*Y1>K(I~H0P$#0e_BS;oz*i4^(?1$~#g=^@7-QlSeiWGV5+7exS$TLsAPJbRd_QBD zJAaw$TQhEHWxX`5?a!Yq9Dm8$U2GuKHT5X`L^yeRO%s)=11<8)(D-47Q&H&S6q$Jm z()adMYtc*9dv=@i(Xt&K0JMoq_=#|dK2^Tg6<3ZG@r}u9)gdCucPkR$st2w;r>^>Z z(Xc&dn7D+$ZMd4Is{v1~2M~Ofr^HWB%HDK%`RQ*Ra?;IuebFBEh42&Mvri+kRisXO znSjzzrdB7TRh@(7S-d)IKtLU8q89P9K50zrOb8%ejvLMfUTNQM&6wVsb%x%)%^dFj zJ+a#19fp6C_Rx$&mI-dg!P>{RSAx!f#*z+q+cFzh@4|Dp2F>4uJo&i zJB=4aw^-k=>2KfoOz)>JU(bF$4K21Cg|C>}!*&1I$R5&yb+41x7AWfVN=<TP8nQTsioLae!DaZ?luYaols?T@+qEn@enz5&f8aagVDXXY*%Gc!;l@ zo3Rl{Pp@?B*JJ!%5N-CsyMwYurdk(mdbTZItu?LhIN-{CXE!NtCZB$3;^E;QBVQ0} zZjtf*D430?>~%}b_y3LS2vI$pujj|v&^wLjJytn+bI;WFn_GYWjPi&F(}z!!uh@9R z(>u!vbe+SEd3t`#9Gy7*TYYuzqtDjmFBLh0!{m#5JRDB?YiQi%bRqE2#M8^{Wv4xM z-uG8Eh&;h#^2I$K9_nSpcDPtJ{;CUOLa$rtx{I2!Yb zpt0ALN;_;d@X&ZcloPA`jIBHAiVJM_ku7S*bA=ieE?LnG-{he;uRdzbY`AM5S< zrtq-$2F9F{B79QE=$E&NyIdD|Ir#^%)@rs>`c3?%Y7K?o_Q}5^YW({y*q>}Cy{zN=nJ9)R0jd9XJovS@cH_n3?dE)Irl)TjW&8YD)hPYtvS9^Uy^2Bl-lFW zE56M>eg!LLm^L8hTj49F_HdOWr#!Rj&GX?x>Vk?9flBqF#t<1y$J3AiPoyl(x-4tZ zmOpQNsC1EmNB9~P_3Faolw*6BT5Lo*p2+z4`pKM_W_fqt@JRi-bNj9|@CZLHo~HWg zhYRRRweG1)Kbghx@vJCMv%Xt#_lO-&O3As~z$5&)cw*_tK*Zr~y?){MFRrz-OOQUq=mpVc+h9A8K2Lqi?{{o|HhuAaU@K$)CbVY^zPRh>eWL@! z!81<|Pj^%Yeq)xn+E>n5V(}lri_|Y&{fX#FY3dg$pIZ&nRX-N{ezFK_$yv)_#bGw@|g3IKKd$PF1zuqp(ElsSa zi+6r>!4pTk{Go&wJSJb<6XCJfu7w8U*oOcA&sr~^mmzWm zm&q6RZNz1yqB|XH$`b3Xy3M$;GZ!3mvd9;FCSTmQ4WAoN`k9IGocQP5tS-;|(naJ6 z9+NNbiSUf{mzEXbd}K*LJzv!&f#$N8Rcay)Zc+7;;>&vW(iS;z__6t`H z9lz5ekt=#K`Qo0Wo?PRyE0VzR+kUrYebwf$!$pqZF!|!12**&>ll7GkP}O)e*<9tW zuspGTE_!nF=NHV+zf-vk&I=uejRosrNjNmc(;+_c4pa5>ez#2HLj_?QVdomgm6Ok+gNj=&#kQm>H z#kbsA-m1i&L`GP_XY&6Yd`%J+k?Hlt+9Yu1@A2NWfjfP^N^l5HlP~UnL60h^j;pjH zvHq4uCQmx!=7*+;T)}1X#XS+O;r`+v&VOx^vUP|+(lxy@F|H@-pMCm;%`Yz&xq{2& zi~F|WYMP>YJ7;bZ_>K#lx95u~0S-+mBlt|dxNj3a1k%&7>sg8QHT~wBdk7P+di!ij<>CXDJ=COsWb*$qJ}0359d9sjnd6BJ^69rXJ#xUFC*B}(MQ#_J!{N(Rqhe~GWi*;%3I^GL|8pIA6fxVp=8ZLKf3ZA%%!Ve-X29u6$H<{{hm z{HhZ`$I~vH7|%toF6%MBU-9lDPw<$0aZduz(277KBt4zxCV}VFMR&IFI3wY=+w+vnaL9j*}^CVv}n@QgxN`(;TII4)W=wBXX4b~{Yu z2o94k?n&r_*M;<*76<%efZ(cFz z3Xv5WbLDJFkgaA1phxO8Y)(Zm2##x`}ZBz@|Vz_sC|Hfx{1jXMx*BlIxnRIsJ(T+h+zpS$p>uuVY6WiAIT6dDj7knmP+!Nrl8yE1br{9VsaMW(;e(T;J zKh&gOV)C~MM~nolLj;n3g;NsiXO~;w4t`MSnJIEbKPF$?lhTjEHL?sBjQGl#fZDok zU2j{Gz<26`?=PzD9nD_R{+!9*c6uPu{emy6wO6er)nx zGx^Qn8Zh1$(3h3E@>9EW-ST7AOP?I``6r*8xUtE&j>&H#UrUw|yq1G&C!7)K=>Hlr z{rgd8;EJV}-jx$xf8~p-9uT>bpG>~ENApuopt2lummwUs8RBXQ=MoM;Qy0~Ue?9;7 zJkLG5D`nKH${QP~|ld`Ua>v1{HDtrx+dQA$K zeXE;>%07RO^?|Gpka(Fcu}It#*){MW^-P`ddtBD=Ww^zZqWB=8+`^^k(pr+>JW<%Nd$w#QTWim5$f>y32^ zu0F&z9`UN;n_hfxtH={PCSTlR z;z18QnuVGva(a2oo}O4wEAPwttkab*eI{}Rm&q6Rn7I1*C-|z$!%ftsRRlV&^-175 zWXg|ApW3~U$Ji(%xJxcYAHpPe z6_1`V>P~^C<4V6MF|Ombe|^KN^AEd9(}f{+&E8xu;HM3;J@Q)uWCDXxpvaN2X^aKXto!GFZjf^%Ooyf&`Kyq zLDcE&Y_qX#KvRex%yj*4+_%vkzpn>~AA@5+$AWr-jsqPJ;w0h;ARd~*4lyV5vq4@^ z4yZS%52!Dw9|+5PlRp0$P1p0`-8J5{Hi>lZl(F%&!QqE)G}Br5j8iuW)7jGxOI5~4 zzwCPbQhKSoUuEt;YrrMlQ;$8c)quS6!#g+)j8+iNcDe9%EPQwFkr|G~!|E<&UX+)M zp*T-|B{ncQ3+$XeOmpk}wivj~_0@&AIIX_t@+WKC%_=GDVj~y|i@1bua~q!yuKc1> ze{mJ2Ry`vI6qE*We-f^f4^12vz{QMMN33RYR3N?GG2=3~o=iMeWtufLH8^X*(HGo* z-ww7+!6W=eB=%bZJQF4ufOI?=m%Hl=j#W(nW&8`{zhf3JuRANv>iF@j4w*lV_iVqr zEl=%fGb}wH1IHwYzNZU{XKN!uVr73`ScHGS*B{I^8Qib zHzKj$oDo}gcf;5y7{FDKA+E;9%nc3;z>SRdTnVePaj0{x2!hG?DeH>F>;B%0tXngE zZFYmmm3rUgi@O^SJLL8SjKxa2d%R>Jm*raOPcN{^I2b8a~Cg~J~((?j?oS8TWZgy~@)6Hsj5 z|HC-+{JS3bs3Fl0--$!t_wwqch2JeL>v#{?%7}hUzPP*b8R^pmjeDM?a8}~Gnlkuj0~+FYjTdoA5=x*lxYVPd6JG?{UF# zH$~+>EK(0*I}Fc(s+1mCorZS_@Fq&fp%)eHx#;-UZxK9_jwWB+-FWqMOa`5M96I;P z#OeCv#k~CW^H2JadMbkAQxH?22>AVTJs0YdavC8Ma7N?e^wV8gfna;u& zJYu``7C)VF+CWJ;zr~yacOuZ+qm@@BPS^b!>Yhq{b&+%GMWfzKer$Yty1LQmIJN)> zjp!*>J^Isx@Pikx8S=5nk^E)y#oeu^X!^N9z_Z>?nmxyj!@77*S~2|OmEwG*_jg#u zxPKn`ba=`Gzu&yb_Nvmi1D?XCAKm1iRo=Ko#o3ML0TUgYVU_*>n?}y@H(an_e{&gL z*H6aP@o|m5Hr1+lB&VX}%ZK0H(-F=PY$pldVMi_EQr{R>19@kpAV(9Pkwb_pq#jn&Z=3KysdNahs~omlkvx43;u>-IijRd~xR) zT^z6SV7#cvuMQPv1Eh}+T_3z~GJ#VbMZvO4w&&D*dh}dXM6wVh`08#++#h0uM6@HL3)H9pR!=kFze>(c8M;HB|`n4aeT``ksXtTBgnxa6_jUY`0UJ;D$- z`!B**OzjaLZ^Cmbadl}JJ9}$gdd;{sKF&>dwX#~j7#{F+{|&F3IEAl4RIl-ICaqV2 ztL8QI_JN+hrfmKHp7`glgsXGH@x0Mx&<`~v>Bx6;Jn!8eUw=^5_JfEsjiBxyNx@V2 z2;wsF^`oVu>%hlov2f+H!rKz#8+-EjAC?EKR1=@@UEuIfe0)vQuNj!Gaa-&5`1!16 zVO#6v(o420?V7!8odbw?SssMHZ8)3NV>Dms^yx+PmXS?^Hd0 z=6~VSk8U_Zrn=9Z;m|({eS^V@pl3K{u7>-I@WHT$L89YTdVkvfM#|Wn9(!z__>ge& z|G#5L5LmvWE1)MDsVB_wycG*lt%1wCpHews^<3Mhtw-i>;j0L=hny4Crvf`5?9X_& zKEB#uYm}>O8%@*kU#40O11Wi zymI5L3nzYImJi{Zl4Il#yL>ncKy>+qh@U22{`_t5PSf6fr0j7se+pkkpgm&9x64Ni z`H_1P%g>3_ba<`X3%{E3g|CTLuQB91<--QhQa((L{j>hh1RRzRo~KiX{2}M*JThuS zSJq*=`wFs^6$3xRNG*m!h0v49O9Z!V7EHJ1F0+f$Db1dw`QlYzthPHwsv>%zJZKID*n zJNGi{0pW{$v1612yB^>IDVPXI1H_;KKhJ3po zh#`N*lEm^q+;QsR2j8{F^`?B`>$3SCL%vfF*Z^AU0aIiDtp76sN9uuv$RAP<+<#wD zF7s%_ac6%t>;A;&zdv?D!<$9>7WWwZ>^En9gs_J>6YY;Xe6U<*#GoObzPNx72UOvH zzKY69f3b&qU~na0t}j$-Wx}`M%Y}T2f9k?{ukJFNk(K5EmB9IjeZJ zo-g=%W>JSf77H%gDL^TF`q51ce9Bqxr{pblm#bLyTc7lTsbW%>4cuM+gf?P?TD_^?*L~icT^;GkKTTf>FSNBaj z>(|1)Pt2P+|5s<)*4l_T*iR8Y{&g8Hq6vk{#^W-GaIFVR>C^=f*w*FojxGrL{aC3B zJyp~?%_0|`^am4`9;|WN4+s$ z3Ezn}YT-cT5SFl_k%5yVkgagZb8*FFtR06B>f=APuAA#8SV`;+BG&yu2Z9a)bpmC9 zxEa&~;&0^oYp%KG0=hmRt}7S@8UZ>TR0QJYqcG@P(8ZvuK=VL%gB}G@Ur@#Quw3?;{k|DsOta&Q2gdvnI_d+GU4F zE_?C7u$ivH*JbnFB_HX^d*8^9fFz%{Tju`V^gvy20m;0{Vdr&!_R%{%yMd*QltYs* z?vU%8*Uc#s^(t9QL6`xLB7bfY@>hnwUiW1EyB|yZBH!eTyIX!<8P3Dzq2VqJ^cw*Q zj*LeW>tXb1?;pI!GjEMzSQ^1$@@-c`{{sR_5n3|1>gRu8H|hOT@>m3w5j-Ye+#B)quE6bHl~{Zn z6N>&FU18ub>){#WceQ@~^q?EkBj47u9YDi+nB`LVim5$f)x(W#5Y-;z)L&WHS+E*G zSji{Zk0<_)K6T5}yZ%(S?g7C=o9FEdUxT7vv7V5Z(|JZz7Nf-@3$hwF`0M&u3;8r& z5aTuVv7$E3T6O8$<6nPq%@M2@X_zk5hwv3sdo=!br(5X{;nv;(S~?ImCyaPuC}q zZ=IWF9rE+M;R`2FU`uFJFr{Y?vHjfaR^`J zi`^)T%PAZ6;6bCyUxFJE0z89?Z9+^?SFqJ!ht&16B>}GNNSbv_b)U1RwqG&v#Xaos zl3#=`c*JfNmn)aJ^)vga`1+~8060eNcVF%~3%+QA!{Lj3u@mDkQ_K!o2TSsA*X8kX zMW&@$ADwBvv3T}*mzcPOFL=aG0$1D=)YETS0(_Ylrdc~qeP!}aS?A37eLouk+f^*@ z!WUd(H;XSH1>DI|^sBdr^H#*y(~67ItTsD#oZ0D>QNv9f!Wa2sCxata3f3V4Nxy~! zxC&>aS!XO+-~G`gL-#Rp319GtofNJ(DX7=ik*DM9&AK$r>K3uynA88>n-6mKebHk2 z314uDofJN;EY=~Q=qqz&d^~lRrCImff6`r7d-s3Y#3OvcA@;W6X_}%-G<<6l;LE-u z&AR4{{=2N4U-`U=PxyjM>}|vsCuQvz_3}CTnfUswpNV>Hmv67ms9sXPos+)OJ`uj) z6kEfq26yHAHv--1a{E)rCc3M9HYC6inVn|6;r;I01D`%?l!-(5B46xea5PO#cRzpj zv+?zlc~zRV|A(0eowI53(Izh83m&nP!WAbK_4Lbl&OLtA3PRYw)At=7_to7ePG0ne zh_^bcx6YQy7Y`b~zP@02tvyz+nor!unm^fB$r*W9`YiztYD(I5eCKeYzMrkOq05vp zJAZ$-?0=x0V(nrHAOE@xS_RcOl+x2@KwiElCp?LF9u(oC$*`Y8X&!8Ov`3WuAvHu3 zJugGA_j6Yz#&zr&S$%K+*MaBS?SH$ynSxfQ@Lizrj|&$EjMN1^(W#AQab+Sb>oLyb zlmeHGzfFGYsRLQ2boUvW`;Wtq>%=r&=!EC^Y1iiy|E}ffzTdAn^}3G`Oc{HWzlUY= z#T|XSNo5$I<84rVYbyQNWr`6nUpcOZ!jJUmw?c(*EK^Q-1+F|U?o)+3T`)RO72P~YQ`ER!$p(et7DRjI3@@_a#b#k?VAN>AhIey;v$?&`$) z+Iq=nd%Sw(MV&;B;4t~(9v25%yn$k0c}2kAyP5+#FuGpWCcrb}thUzCm%Y_-_RO(& zv!6smJp8T-Uoo{uTs+Pxko2zO82v(gy(|HaFM3`1-j_2zy~D&Id<}wnjf+E_(m5

      UwpEqs2U$dmLj`QjcIhwE%iJA{s>=EeAWVTg0KAG=%qo5k0O zJi%k~#XT+_?Jg4Wuj5HylNe9g_8TwW^#9nq3-Bne_VN1z2@b`rSa1(61quWLBxvwJ ziv$uN5RwqVB}jo{#k~-uxKk)j3KVyT;uLo+R{HFI|EuPo3rWcqiF}D zJFy(jRO+~}{6Xt@k}%A4U4j#|m$E*%q-}828joD_<=Dd|%X^!a7Ij`hrCX9Cd$Etl znLi85)84rs%_}&--!g|V`YOH+#AomO@r>8|z;mxU9aRCycY>U4Fs7^F>UyqwaA{A^ z20>*!JtcEOd47$zkBk!rwfypj>@R;?-8vIbd5wB$Uat8(M?99V(q*3dPA$K2r+`pD zZ}Zt7OPXo4FkaR2oeo=$i(lcGhzh>)AA{O1_$%oxSo|Rz;n! zQ0Y-?Xnq&{db;{{=-?B?m$YmsrekWELLX1nBlgR^;FcUuPSk2XQ!Q6*r^a+O+*UkX zFl*GLuK5l`V^sR@o4v7!r@Gs#=A*OzHCruDZ3o75HQZi2Dr59V4mSEAd8H-&?-=L^Wo!Wj>x+OWX z7wvH^2lCR6itIe1@~oz>zi%)th-&n=3-_I2|X&t|W}wrLXm@6HI~kxm^S8LxA= zk)OvJFS_5@H_L|masWjqzsu$LUZtB7buU)WS2q0xs(L4%_FbGKFZM)LVt4Q0#^#6S zGQB>ZJWg51751>KCdWgIvc}gYJ#_9ai#r~^*r)LEf>q+1M>QSa<>ghS%Q*VZbaFp5 z(7C2>P;iLu;*_)XhGiN}rqjoBB^L4AEFY}(E!zLmMmfl&lkAfA0aUsvQTGzdc+`e& z^?Rt(Y3uwkmRrOG2W`j}N7t}^?+cZ;EK`-6O4o&AdaKKl$dd$IpfWE%s?4n7cuX9! zo~r&h@?Pq+ITPTNm26mQiu2?*o-?6$Bq*h$Hei&io6}Jf;47JMr0= z%g1w6BCTfYf(L%?xTk$d!*-?8V~B_L&;mk2{5Ye*c@G*6^a+y7hn5NSaf~&@A={9A z!M}psckpU-BJK2~Qkj0F)79`8<1k%LZRFD}lzX)-6X@evWr)X^FEYuTM(e+O)bIPrYI!Oi zW4an1V?3sO;kvIbAbmNNKOb}cw4KCG<-~%42Yzh*MfzgqCCYKRY)2|x#i9E8c&Hux zmsY-K)|J`@SXtQG+Zw z!)Y8m&5*42z z7fJrURNm1Gw0jK69-xrsp3)TQIVM6*^0+}O~5B8rnvO^wAW5tS7tb9 zHU9Sc@_Cbqz5OlwZ55YFk4;>W`O_r8{QauSCw)AgmtxK*S=QF{ZEntXnzlVr!Tk1cH#;9(LtNgWZ;s`$3~1b?x$3`ibM5n z#beq})#%yYkArLuVtqOgT~mKQImZ?m*&=43_6t)l$DB`2vmLZO1Ity(P<)b0Ik|98 zr+(L{baQId>qo|AbxaTyrS*1L;7ZJK7C+~xU2XsFo@eOxJL-g_s$VKSDnj!+TX9;- z)1AgRKPb^~CR6#g*G@b~&pT?jg6^cNI_-FKXUl?BzNvIea%3--@kEgVtJwuxn7<#R>YGZJdFs1Z#$}yvx+ue#nTjur_@qs_WLvw{?8AGS{=^ z>HgUDTrI*}eDO46x*Gn$@*9Twgvz;W(=k52E7?|VK? zEtg9dbeT0{x*BdPF4qS2ET;+NI)(WXbQlw;`m)Lphw*b8@h=3;y`9|=~+zc=jv4=7=n+u(l7r@U1AMf37G?`BC? z%T;}sz`$x=TzO^b?*73X_nNYwBTwD62N~B1k`Hpd+mkrdauSd(rK6AY3d5y~Zo7&I zchG#(WUOB2V4>;eG0peg%W=9&H_brzVza!|?{3qb+~$$P=&AB*d(%1&V|jJTo?826 z&6wFu*Hn#X`MRT|%)b{@x_Pcque$wDEXoGgowlhu+BD&3MC*`s7E|GBZcs;@4tnNMCZc3Vh3{1ewp2ycMC zypOV;(nVL^J%3?6+c->a@lEB%s=OoD(~@qQf$k-m@}}j8Kq+mGcg!O@(Np#EF>$E- zFv@LjSyuKo|?|fl;-y`*Lds>pk2n@1;}wTVuL;s3!l1WfM}{j(Vt7 zwO+D8%Q*V|y>`d`@}0iE(fw|%k)_o9)$)z$YIsb`=Oz!+Lwx;uSvGBUY5H;-9*cN# zovM?kS)=Na=NnW!#&knGuD-p=I3f&j*g9@$^&mxx-Q#o4 zQp-_s7}M2oOB_x8ea+uO+@a(zWg-XXG_cBjV&?s;{&>anzWw}Y_&ojfF?V-1Qp-_s z7}M2oIXGhHQrDM9JT&#^M2k14ICpMO>Hq zhqPZ8JXC#6NA72g>9*pM7-JWe^?jMcAK1^Y@VTc-t(yPqFtuEjU&eGbJeK*z&3%%K zQ8}j1FQ#t@FiJ zJnxFEuUB~C+8kn68G$5RWM|V>yK}p*lX-o?35T zX&9Ckk;lgYNwqxfZ#raKu)Stt(xpoXIX+hDrbOL~IuPcF%=BPtKW9?|W9l|4tNWa% zvV2FTb>Y9mj4UF8y+4+4}vZ$FrF4>yVh1ynUJ|aB9~& z`nctPe=1$Z(RU4kd^vO9B#8gWv-9ESAYXv|AlD^Z!f$7aKGgL0e`XK{Rh~zQ%U*uw z^>8Zr=#NU(c4)8fU!WYvSOUyvN!Q0D?|I@%lYjtXs_yC`=cl<5w`Nd4SCwp)Z;x5N zn*XRiGajX4dMBuSP4zr#`1&O8c1f)I;l*{sCtaSO!8qJQH{7LHGVcDeo<2}F{74Gz zf^qm*-SCIiH$2@8(CsjB%;-kBCcELVdf&k>#o{H;-5L^J{AB z11~llo#JkcOQlB_m-YXkd8T+sWC*57^xv;nViCvok(2vfytm+kI8=IcaoDIojeR=G zIa7E44gpay>FZI?*Y@+}`(j^~ZQ1O4HDkW0^pAr2=h`}wkS zL6r$ta}B)0q^8cCKk+nUx*BeEKNmmas|N&h@%4#pfxDy{PhVeBy|q3b^JXL&@fB2i z7y0IOJJ6?ZiW_Qr6^Aih4Y&M`uI0liU1_pN&LhC@JWpn+BIxbM@riJQWbO(NRjt6DWWcf-n#Py1}q;r8R z*VgZ_u}$aapSbjZduCBvG464r`|qvA^p6{8;Z4(KQ_>* z`(*D}(#@$+ueQtC{Ipuri6d9;nW3@7UfkZ)-iLRxvC}z0mGdg%Qp=TNSILVFmf^B} zcKX|XId614aLQ$F!u{raj4Ef9&g`tZ*vGBDZoJKZ(Bz1m`|G;$m!2MSuDgbRM^1&w z_mO$_5%kn{y^5nKiN^)fmwOwfd4K|>w`#d`5pT5>uKTL=4jL`Z#+f>E{P8|WSHoi; zw`#k@xtW)ruebTeDUODusS0ikk8UN@_r*VP{X~A_O0|+}PIBM7v^$jva?Mii!?N7_ zY5G5kRr$v=-!!Z8(bo1fvE%d%_i6@pH0NJb`KxqhZ`FN5K3bk)Z9Xj;UH+|NDXRQ4 z#dolKT-`4Fjc3b?75$){8kKGpG#_Fgx13^YmR=H~>p9hN6vwH-MH2t@d*f#A~lUtk^g+N!p^*O>I|8SQ4+CZ&K-!rte}O zufASK1v!?PsrWn++mCPiNZ)O5U)|b}$`XY1)-vBsI7l$nhza;Pv@DJgNQd%x6eo zXtIIz%Ng@orK@;V{}bZ2+Rlve>i4_Fli9BqLw|KIR5oX;yvBG{x{6cvV;`?>J2M8! z%$%U=w+C^m`Yr7dNG$q%*OJ>`kJ2?GF7D6s%+?bT;*<*?k;nd6S98PnD9*vA`l{k9oA3(;?% zJyY1P=OHU*cbT5G$}w}?QTr2>uHshxPl(^Do<|qAzP>wsVZWY~$k4lZL-)rsjd81V z6|d^YK5kuow-KxpGgS4xDsig%?o7JGqR;-U$%Q`_GT zw)nq4+4{!PZN~be(pB85AN%-q+d&LLJ27LmJ$MkW+8*wZ^~UWXaT@#U^E~IRPE%TE z8Dv}^m9Ex9^*>^LjN3!?pn%|D^H-Yuh_KAbGUEvPsvhknZi&YQ(zo?Jkn3^r(jKX=jU9FI%kO2CuHshxPl(@Y zJBTiBtNNeLetmgXC8_6|Ib&~|^V?iL^7}%it9VsE_Hpa#e{{hzQzt~$f8tg3|GusI zpWgoZWIt3j4eDo zPrR!BKeE(+{rYH`?5|JZyo09Hs=q#g)HCU%FWa+9Hzn#`K4N{0_1|#m&wL^&f_bZY zA3?mbd>2UHR=wZ3zSZ+X^CqZjV;WD!Hl{PVsf&HQG1q&W!LtN?z3-XXe!VZ=bbRqs z3orR4vcxCrnTYsRx+OWX_X+V^)%)n;*4L8)U)rxH?W*-C_vX}&?Gmqa(wBOo(oKoF zm)OUxtM}0b%Y2=n>b)EBs(Sy#M!kO(i}m@d)mOfg%THf!TpyLLTNTsWk60gLy;nC~ zxCHuE_w(h7oZQP30afoeWU*iGQ=Y$nDu0rviA}-qVvd^@UJdDLcs`k6Q0f1{dKl}w z`4Xh;-gOtDBP{D9*UcAYw_o2qr%!v3x_#-dRa~mR8`IVB*ynr9_1$LhEJR=5+vc!e z-+#<|-?hV}2_NLQN>_2K{wKt5Ro|nFTfd)AS(@}E>+mv2ATE$P~39bkL$sd*)3W;AJxzpmrB>iB=0{aE>k<89eLtP4gXMeLMWVh zsC>H}i}*Yr`;B&dv+`$Sd@5aH(s!Q}A9r|!%Aa)T^xIE(F8ld6q*C~Z1SvhoS(H z@5tA}7`IA~irD<_KZx7v>asr0$FYd>yFT5MRB^bv#~7zd|D16~T`jb}J`tYBet!0T zS$A9abuH!?<5cONF-{v-Tdd>t$ZJ2|gbx>P`6@Jj3S+z~{WHdE<7~P0c9uAw{dkY& zS>Sr@$mN8_cvbpmj5mg}n$~eg#3Jqtbsx@O)_d0n^+Kh8#<*iR8)Y4L&;0iDJ3REU zHgA5nCdT|$>7Oy~7|tSC*XsfW?8p6f&KJikubtY^7`ICQjB(ri6{tUsIU9?3>)mg^ zvu>)^uZ{7l^v@WtjiYz#{2gAXWx%)=ghyv>b! zxwey=txdDgAGfxZhbhy!K$dIkzWHCW-f^0;EiApeF8`buTcykN`Ysmnng7mc3dwvg zzf2zvm2X-R>$q&?Th*pL;+G%y`h)uqjp;IP>0%L=d6c^R0fQEPjTxsuF5EzT_U>;w zTh{I8kTbP^Fqfw}f8{)sN;gLp^=h-;SrYZP4>? zU5CGdoyu8?+q9n2exgc`irD<_KZ@Jx$k04L{qbQcXZ!KqTR0-PX0$me+iL&i4e!^_y=9D7rGM6VV>m+8$9*LhabHSU z#vQ{EqCW1aCG6*So$e_H4p{Ep-x#+_|EzJxaD=Fj+oPoYxEI%O+u-<3(iXv^Nq-b73I049UMTw?48ylDTDWBB^y~u_PnTdWKWuEG@asJVztGcMBH6Q&Lr~beB zc{r=3j{B~}qF(iAec*KB3FS7XvSf$!<-Tl{Zpo)`%Bv) za{f_0e}uPMn|yHA6m0*6Xp4z&c8wC3J%O7k*IQOW} zhubV)?zeGK6Wi#I8y2?pMBrYR6@AS)k;gL5cuTr*67y3MeJyPOHuv>+@o*33@g^Z; zP#_JC^s<}-bz(xv2WhV{aXAM~EytCXU6M0Qe|)xz;nGQ*vi@O{r<#7>9IdWt72Cd8 z8d%;ztNiMRLMZ}^9GoK~(#h{e`QNKbHzn#`tmCAK0r}&r7ms{&w!~c0xtXs|59g-! zT-vY-ZEDqM(#E4v1CJVwnzU%s%%yJA8s?dW(^KW?K^)SlIIC7mX^yjuroC+z(JfU4 z2d#=*^+R?1w(OX1*%&21B~F!Ynt|@cZk%=^bYfmApI23k%IB)&^A`*YCqrepala+` zES=hC$Y-JdEW_1!@;z&aDZQT zA9+Hq^=Toi>xG%B#vD)ExenUGC%;bG)geQ= z#(FHf&vHm?TtM9C|4I%R%O@LA$bLljF+%NA)ILZ0Qg%{pWSG=6HLj&9krLN^t{l)G zw}l(FYg^CNn*Xq7#>PE{7nOSiq?0m{=UAz9Q=;yL!^5Buo~u*H7X{*gM-mWt3lY4PRd{S#`36Lf7MY0Cw z{hdmedFnfPrlxl&k8kPdY>B~xKa0ptq>hgd2aqbjrtapc^zlU4iD!7%B-*31nbQvV zbM^G9mX;OY5wPrkRk}VFc^}(&+*vQ_oS=@kt`Ltpt}Vs!mb3}8$TD2+`x#!%djD)Z zuI<#=L37QPdH#saN4|8hY*ez1NxUkZk5--C<3$_CwbdFlt?%kyzgD9f)tk7~uT@v} z&EZhrYaZ3D<1`-ECT{AWJvh^$(BpuR>G=$Cs&uO$`CvCrtK-@aBP?KvPaU_)ViOn_ z!sjrk^(gP^VA@Z)kTwsM$jtQgkFtK(R!mL9TWwF`7ZJB6ugIbrRFQU7lJFriT}IM% zx<(XD&)syc)`*4(y*fD8sP5XB1$AOvS-!rV4q5hmMBrCk!ByPBUC7274_S~EVUR|m zreQjg5O-2kgscPAVL%v@srB3ti}fs!ZIg4_MBm3VKe*UjHCQ9wY5 zTF>E(tCnB2hW+1_yR(kykiTV*;NrwDT}pFL+ha+$e2na==SEl>taLUt{_Nu4zEePu zv*}qDmJ4G}Od)Z|@5;8sp_U^vlHZm3{l#O3%i>)?wwm5cP1m=l_wA!a3#Y8hbVa6> zPWth9Rq3Wg-HZJ=8-#{5=)iCD5BH}9+^n~=i2O-R&r1xe>7a#Q$(eg>8%J$*w(b+t z^j}^zv1OT(Z?Zp7>AFx%Z&f^z&--uhngv z>t#Dr=PD!)`K>McHrZArf8=*%D#!*U?Z`-54)O<8Ii|>oyeNd?C=0o%u?FNKnf=)`%r?HhUs+|OW zpTH{-^ag_NNYD)kx(7kuCg^1ZeTbkvc@V%ixisx&KGv@Y^De=6TX{`;P({x)GFrTj`$3THK`A> zt&;^>IMnvG*G|2W@hgp(kTm7w153#!Qzw17PN>o?$&tN}s5j2F0s=bv`84+p>Ez-U z=1>T#{q*SuZvzy-_~P4Af0-Sib^-9M!nYa z=^8*|Xtg|=(%P_B7xTxaa!g#3w$D4#teE*mhtILUlvre+DRnC~(n5|)WWOo@3zoLX zJOCdy+*IsW4`L?!)0J6{M#=*9&dH|CFFs0WS3T$SCwu`)V&yfUvZMzJD`X8DaIZ= z5)*hz{)Y4IQz`rh>7Px^n|AQRNe!i@Qr48OELWwg<*B~;(mVGv@x#vY8`HV2 zS1%g!Hs4{QLZKKV*MBN;NWQv2`aYo8BcB_`Tg`RAnD&3HT3%4zOE;D{RxQ+k4g&&GCjb_xnZc6dYnMC z=k3)jr9QC9nn;?wXA_OKll+xV#*6Fz^Bf2#LuETwzfWb3Dvzc1NIpxS-K8nrT%%%N zPD~b8R+0&y*x4$dPnngJsVdh`nLchB+d1&L%16yTuAEd(e4f4&vr)%Wd-*<8?WO0d z*M5Z@66uF~Hg||@?>u4k@{6S`0xi?4{iAUklKtZ6?DWSKkBLY2zb=sFs(rCK@3SZ( zk#_8$&x3)Z)?4meHt(n9_(r80W3wF7m=7dRv)$!g~PxH5cic5|=<+x%jzxX@W-d#MEdm=4kQ23mOC8|H$VL4)y ze3H0SIv=gNkBLi;!5aH=4}`h}ojK|Atw4*I<6Bibk@of7?|KJbcbk9A5T8o73XTsk z$7jjNdS1QS`AFWWqeSc9&3o;{{!rpq|`F52>}(UU)ua`dl4bLZiUmcKXn zc)R#}^DszPwhA?`;=C~)KgoWjm>R**FK=Uf8O0p0VPxG$d*3r^zoh!QNuzx$h%2Ai<tKsT;M$Lfsq5Q0tzp3(2G5@IBW-TM? zaTG5q{I`)+FAM$-DWV=zv zqcU8MSLL(x)v>FjOWDY{3U4DjRgS9sWE}NAa-?X|^uzyG-rFi4RW{sCV=5Q9Pe_he zBrj!{bkbL4p+2kfFy^^@mQJPHDi8A*aj(W4s7fXq&r2J}(SKHXtNJo5y7y{28Lr0B zzc)^+##encu9{YjuhP|c(pPmw)dks}^_@&3<47mN)I3$4k-nN%#!=&{@zgTaXBkIL zqtc`=)2aEWY2>pkQ=iVq$WA|=N>uYwpX2)f&K$6{f0MG4dm!Vw|9%ccS3YW6{O?Ej zza2qz}+eBl5yg?e=Y}NDxXhTs=mC`af><@lHW=~KFfG& zT-7Hjt~2C7T=^I>jGtS*+TRsr{Y$YzQgtqb>*H%14(O z|H8L%&VR@4+jNBx!`ry>i6L|T1%u+s=U-3=F@*3>mQQrY zZ*lv!7z)HND6V`A8S*dt7*{_3vH~%L6Pxl;=gidkQRxf$ohip;s*7pACBxKkV_!`l z*Z(jF;>zd4Joz`J#Ffv#sWd)}#aKSl9EsewBh-HE!>OY7Rknu3rG35}FqV&T&g#2D zo##}arLVq^jML~ptMOHud=@f4nO+T7*M>-nygnrF)o|69wEv~fSUz$eqRKzXLwT?A zM&+lia#7=`{{K=Q{*&u!EFamgNhkM>syeQ&2dMHfUjH;rV0ej5IqAny?^R#T&iGlS z|F86o$6I^yM0Ne4uj3x^J(1tjGTN zPsZ|*IoK*6{dns8PL2EVOZ~qyg|U1xSyoM-U;lU3_WyrtVl1D$tb*)oWZ$FTr^#ov zKa%ezDL<9QThr&bGL@Y8yxk&Zr`iKs#Q&6~bAjZwvHe#WHhfmCdug7YYas8X`^xfa zOgAO-qI;f&xrJ)^qjFGypC6CbaA_an+ug^VKQ0G#_wrMXR6D!)_fk!^s;697w83>8%O}LiQ+|U& zjFEos_L)-=qqNa1?ORJT#_1p};AVid*DU+H%%JIbEemMc*wpU5wBMW)xgpzJeiTGu z6os^FRRX0^4izBn;#Wm=)I@F6MW^^F*sZp<=8mBQ^_4{YHCD!do_^`MR$aI}L-eURo;{6k9R~-6w*gvws>It&Lpi^qo|EX`-5DtPQ(qeLa0;C(giu3AIySJZP|H!__LrI8}O7gywgj9;Y!!&GXZ@ zGdXstb@?0X>Dm1WwS6v)%Y`*sIaKmnI+d>~-JBZr8dJRTaI5IH_i$#Rw)eIxt>ZFo z@2iF+)CSBQwByd;%d_+4GA~>9@A5sT(#@$+ud$BHcD89e`rGRNsFvMK)B^s4cd?z9 zt??vHjw_{;y4 z>tyq}AufJ?0qwm)d;|O&2ZZuWfv87_I5+M@^T6Jw)`EJ5m>xo4o?|#YwclA}C(gu0 z5^0TVG?{X->#7mH=2bF1he_g8>7OS~(*qM4hlIA%oGkIlbGG&ppKAYk*1Hrf<(j~7 z%W!$loyThHd^SGk&TYP<)^*~I@#)t$edf-wqIA;kvBa;^O^Ldf>VCd7ujIxLiF6G!-pq}quptJWmqcT0sVg9ilJT^k1r*P<{|fb9X)) zBAdNdaTwD-Dh}uR0s0W#y!<%=4r=7nktVunrrw*Gh3Vo<%#U@c!!C%fJCnLl*e<6& ziHB~i+F!Q6Y?cwvTGEZvxv{8#jzL~sotp#%)bsN1RV}oA7aw-!C5ji9w!fVq`6S;j z1z5hCf5!`5!{op2VV2>tpLmtp(X@R@e6mfA;bhDYSj2RBt2}Q}by5ONrt6f@_vq=% zQoGRUvsC%i#BWSzGuB>`MsGJbvOU5fCG{`5|GL8pl9wa{fb3J9*vR_mC zQ~3^&?O)m;PmCmx@=FFej*#_``-7xCpHDrnl$~ki+>#S=A{TNa5Aq@(0HsEA6C^HcKdu_~wv7gR%axS|GX zq88lXj@qb$x~PZxXaEm1L?g%^wF#P{8JfcrEg&a+z5$N_(^{c5+Mq4G&<^e44Ze0v zzsEb$?*w0TMi=mvsC9)u0uYF92!fO`U)fqHx}yhrq8ECj4|wdD>Dg-i>B|YMFbu>X z48{(7?3%_AE z_FymeVLuMwAP(U$j^HSc;W$pT*eh##Wh^VAGm>=xP{xe zgS)tg`*?tdc!bAzf~Rc6=NXoSXSf~IJO=I}%dw8S@%^U^g&(7?3%_AE_FymeVLuMwAP(U$ zj^HSc;W$pT*eh##Wh^VAGm>=xP{xegS)tg`*?tdc!bAz zf~R}v8100b636ThLeMCLCI~nhjBL%(yj{(+F zAvMwWJeA-At!P{uEXR(UgU#3$Fl$mq7VwB2#UfP#URh& zE`gFLh0-X4vM7i0_zD%Eo;&_E?<+&D`Ba4qs-ZeuQ3Ewm3vQ6#_O($5bx{xU`?di* z&=8H#7)`*Vk+o)M4o|c|OMHWGA=jB&qYc`^3+>Pz-ta*ObVMikqBFX{4_)Dp00g2N zf)I=lgrYlopeK5vH~K)XZ}mfe3_utLVh{#n2)@Hm48w4Ij}aJ&Q5cOe_yJ=v4&yNa z6EO*sF$GgG4bw3LGw~y4VK%}s2XiqG^YIfFU?CP^F_vH{mSH(oU?o;zHP&D)e#Sbi z$1m7`jo5_E*n+LthV6*Juh@Z|*oEJ)8+))9`>-Dea1e)Z7)Njv$8a1ca1y6*8fS18 z=Wrgs;{qJB~l?Z(jYC;Aw4o6BQhZ~zC;#e zMK)wd4mcqvav?YJATRPEKMJ5A3PB!fRs==ijAAGbxjrk;_$`IfD1)*nhw}Ie6;KhC z@HHw!p0!>TE~tj;a77K&L@l_%9ko#hbs>*!mPg$3m{-jM4bcdV(F9Gwqvf>bkVm7* zW4?HlmgySuxAa?~HQJypywDEq;SC>jKu2_foEz_6T9#mc4H6rVjuS701o014&w-p;uwzO1Ww`CfiG(&TEq6J#w8+?maXpJ^#3oo=odw9bK9ncY- zz~kw)&gcR^bcH_x5QuIFLNG!Qitgxvp6G?%=!3rKhyECVFbu>X48{CoI51EW%5rJQ^13R$`zhO7_U@!JzKMvp^4&gA4 z;3$saI8NXsPT@4p;4IGJJbuRoT*M_@#uZ$}HC)FZxPhCvh16PCTNOgXbw-b zKudgsZ_x^^(FSedg?4BUZ}^}CI-(PN(HULfhpzBP00PksK?p_&LeU*P&=bAT8-36h z{m>r+5Qc#mguxhs?=Td@FdW}w1V&;MMq>xV;WzBY9_+89sa_5{0%K3+dtyN0ggz3 zgh+(MNP?tDhU7?rFOU+ckQ!-_7U_^48ITc~kQrYh3$h{`vLgqakQ2F(8+niy`H&w4 zP!NSs7)4MN&M1cBD1nlYYa^vm24ztWaYg9%RRD}zwp*mbq12s_#Zg59! z)InX;Lwz)W2O6Rg8lwrCq8XaQ6D`mZ-{4!cLTj`^TX>-z+QS<@=zxys1YdMU7xaA|_!nreG?jVLE1DCVs>$%tkooU@qoiK7PUiEW{!##u6;WGAzdm zti&p;#u}`}&sc}`_yrrV5u30XTd)<|upJTj6+5sKyYL%!V-NOXANJz_4&o3F;|Px8 z7>?rvPT~|!;|$K?9M0o+T);(K!ev~+Rb0b${DB*|iCeghJGhH`xQ_>Th(~ygCwPiy zc#ao%i9hiQuki+N@eY6CJ^qH4i0vQo;Q&V@Ktd!!VkALQBtvqfz!yk~R7j09NQ-nx zj||9&OvsEckp)?i4cUOe2vPef~s&qHB^TyYM>@+!3{jVT;mbpS{?96Zmk~bgWEVX4>Uw0 zG)5CNMKd&qCt9E-zQMO>h1O_;w(vqbw1+o*&;cFM3BKrzF7QKF_#*&;=!PH!BLt!7 zjvnZVUg(WJ=!<^nj{yk7Kn%iQ48eC8ieVUz?=b=+F$$wG20vgd#$h}rU?L`AGNxcE zreQi}U?zUVEX+nY=3p-7VLpDs0xZNLEXEQn#WF0%3arE`ti~Fw#m`uW_4oxFuo0WE z8C$Rw+prxG_!T>_6T9#mc4H6rVjuS701o014&w-p;uwzO1Ww`5v{7kP(@X8DAm`vLYL@BL|$2 z6SjWjj|rHFNtlc&n2Kqbjv1JVA2AEF5so>Si+PxjpRfQ6u?UN?1WU0D z%drA0u?nlP25a#%)?qz*Ki$w;0A8u7H;DX?&2Qq;{hJx5gy|S zp5hsv;{{&gPrSlwyun+%!(VuhzacmG#6x^Iz!3?M5Q&f&NstuDkQ^!S1yUjvQX>u0 zA|28r12Q5LGUH2RK~`i#cI1E)av~RUBM$^8O2Z>B~TKjP#R@W z7UfVLU!ejjq7uGFWmG{`xS$%U!xc496Sd$5chp85)I~kiM+11EAsV4EnxH9~p*cL! z0xj_kzC|mvMjNz+7uumcyy1fm=!j16MQ3z@AG*RH0SH7l1R)q92t{}FKu`2SZ}dT5 z^h19PKo|yM5C&rizQa%q!*G0$5g3V47>zOb0b?-^<1qmfF$t3~1yeB%(=h`x@grto zHo`Fnb1@I|@e>wcAr@gVmS8ECVL4V{C01cI)?h7u#yYIWFW7*M*o4j4g00ww?TEmy z*nyqch2O9nd$1S#upb9-5QlIWM{pF!a2zLa5~pw)XK)tha2~(o0xsebF5?QW;u@~w z58S{_+`?_#!Cl9UclZnM@i*kgzIcca2RI@D z5+V^2BMFis8ImIfzCcQ(LTaQzTBJjIWI#q_LS}r4EXay%$c`LvLQdpDZsb8;~<117^MO4DqsEjJ83KvvEb-1DiYN8h0;Evj; zgSx1P`e*@D092E3`%%w1pSip*_6egAVA3PVhx%bb%kb z!XE($L^lK>7$FEncl1C{^g?g+L0|Mke+)nv24WBfV+g*(Pz=Lxe2)W??qMF$Z%o5A*R87GNP3VKJ6qDVAY5R$wJoVKvrZ zEq=y2tj90dfQ{IM&Desi*oN(hz^~YWo!Eunup4`@7yGau2XGLFa2Q8$6vuEJCvXy{ za2jWD7UystzvBWf;u0?73a;WBuHz5fz)jr3ZQQ|K+{1l5z(YL3V?4oAJi~Lmz)Spz zS9py#c#C)V3-9qac6=N}?1>qYTQT9LnP>R6s>k z!q=#bDyRwZ#Sj_)x7BQXl2F$O8KuMHBX_P@(ltX!Zg$k&MO86R;Q3X}uf@-J^SJXgF)Pft_Q5$to7xhpd4d8)> zXoSXSf~IJO=I}%dw8S^~7Ol`4ZO|58XovRjh7UTRBRatsozVq;=n8)XAQ0UUgkXdq z6y4DSJ<$uj(Fc9e5B)I!VHk)(7>ptK4nr{v!|^>vU?fIiG{)cujKw&N#{^8oBuvH> zOvN-z#|+HGkC=to2*(`E#XQW%PgsD3ScJt`f~8o7>#!cbU;{Q{ z6Eu0A|28r12Q5LGUH2RK~`i#cI1E) zav~RUBM$^8O2Z>B~TKjP#R@W7UfVLU!ejjq7uGFWmG{`xS$%U z!xc496Sd$5chp85)I~kiM+11EAsV4EnxH9~p*cL!0xj_kzC|mvMjNz+7uumcyy1fm z=!j16MQ3z@AG*RH0SH7l1R)q92t{}FKu`2SZ}dT5^h19PKo|yM5C&rizQa%q!*G0$ z5g3V47>zOb0b?-^<1qmfF$t3~1yeB%(=h`x@grtoHo`Fnb1@I|@e>wcAr@gVmS8EC zVL4V{C01cI)?h7u#yYIWFW7*M*o4j4g00ww?TEmy*nyqch2O9nd$1S#upb9-5QlIW zM{pF!a2zLa5~pw)XK)tha2~(o0xsebF5?QW;u@~w58S{_+`?_#!Cl9UclZnM@i*j;eDM$;4sb*QBt#-4MiL}NG9*U|e1Vimh15uc zv`B~a$bgKTpF3)I=?~!5y_x2X#>o_0a$xXoyB=j3#J`W@rvi zv_MOIgKyCatMZw z7yZy50}zIR7=*zXg6}XC!!R7*V+2NG6h>nVe!y6a!+1=@e4L!BQ{|(wqPr^VLKx5 zD|TQfcHuYd#vbg&KJ3Q<9K<0U#t|IFF&xJUoWv=d#u=Q&Ih@DuxPXhegv+>stGI^i z_yad^6Sr_1cW@W?a32rw5RdQ}Pw*7a@EkAj5`W?qUgHhk;vN3Nd;AUg6K_1khXWju z011%@iID_JkqpU^0$(5{QXw_cAT81%Ju)C8G9fd*L>6R4He^Q*I3Xu;Avf|MFY+Nj z3ZNhgp)iV|D4bCY#Zdw!Q3|C|24ztWaYg9%RRD}zwp*mbq12s_#Zg59! z)InX;Lwz)W2O6Rg8lwrCq8XaQ6D`mZ-{4!cLTj`^TX>-z+QS<@=zxys1YdMU7xMDhTuC4#V`!V_ZWeZ7=_UogC8&! z<1ii*FcFh58B;J7(=Z(~FcUvw7G@(Hb1)b4Fdsi*0TyBr7GnvPVi}fW1y*7eR$~p; z;%BVGdi;V7*oaNoj4jxTZP<&yRip*u@C!k00(ghhj9c)aSX?C0w-|_ zr*Q^naSrG4J1*cNF5xn+;3}@+I{v^7+{7*1#vR16wJj5eB#uGfnGd#x&yu_b) zh1Yn4w|IxY@E(6d{=gp(@!4?3VDI>8s6(FK0!3V#G35Zw@jV1ytP-O&R*(F?uN2Yt~G{V@Px7>Gd_ zj3M|ALop1)@jXUhBt~I0#^48x#W;+|1Wd#vOvV&U#WYOE49vujn1$I0#~jSXJj};W zSb&9CgvD5brC5gLSb>#Th1FPtwfGt9upYl)12$q4He(C6VjH$20>5Ghc48NP!*1-s zUhKnu9Kb;w!eJc2Q5?f@oWMz(!fBkrS)9Xp{EiE_h)cMPE4YelxQ;(?12=ICw{Zt| zaS!+L01xp9kMRUg@eI%L0x$6=Ug0&~;4R+aFTBV9WA8k`qbS+{yrG6Fhzba3=pb+) zO{AF+2t-OE3B4Z4ksKs<;VuCJA`uj#f+9+>ps|7-J9g~YQBklXHpGSlT-krT~cW1u+rqAxp{tL1wYy?z-%1{NWLN%xkkx&C_LM^Bbb)YUB2lb#n z91jiP1UL~+f`-rt8pFxZ1e!uKI0a6HC}<8Xpe3||*3bspLOW;=r$Gnk2%W$IouLby z4qc%ebcY_$6V8BMa3=JIKF}BXL4P<4q9FzbKr9S|K@bOnVF<*-*)SA_!EhJ>36Kcq zz(`1fWEcgbVGN9gaWEbxz(kk?lVJ)>1t&~{6i5XZOouc`2RF=snUDdQ-~lgW!7T8B zAF?3_X2Tqq3%M{4=EJ$L0M3JjkO$|(B3KL;z=f~`mO?&U1Q)|4und;NrEnRnfXiVe zTme_YDp(C`U@cq)SHm@MEv$p<;Cd*48{kH`32ug4;8s`<8{js$9qxcT;V!rv?tzVP zFWd+B!vpXjJOmHJCU^uMg~#A=cmke;r(iQY4bQ-{@Ekl3FTjhi1zv)e;T3olUW3=+ z4cH2A!dvh*Y=d{;UDysg;5~RBK7bG5Bls9Tft~Ov?1InWbNB+jgs)&Xd<}cx8~7H! zgYV%7*b6_xPw+GR0>8p<@H^~-KVU!n34g)g@DKb8vLJK>RD#M-1*$?ds1A`(18PDo zs10?XE*uB-pgtTA4d4Vg5l(`J&q2HHY9Xb-1B z2j~c$zyY113!DyJp&N9E9?%ocfL?GW^oBmr7y3beI18d71_nSZ41_@t2ZLb<#KYMz z6o$cY7y${82M99wxv=ffgc3>UzKumqMuK3oJB!zHi` zmcylR8LWWIVI^DvSHdb-4QpU6Tm@IdHE=DggX`dWD1aN_Mz{%XhFjoPSPvWEHn<(` zfIHzXxEt<)jc_mA2lvAR@E|+{55p#S1RjOQ;Bj~Yo`k1hGdvB?z_aiiJP$9xi?9V= zf|ubHcoklQ*WnG=3U9(&@HT9Nci>&v4m;pIcppB158)&D7(RiW@G0zq&){?T0=|T= zU^jdXd*B=R7QTb;;Ro0YKf+J&GyDR-!f)_9?1MjGKl}-Q!Qb!?{0p)ed<0a2%1{NW zLN%xkkx&C_LM^Bbb)YUB2lb#n91jiP1UL~+f`-rt8pFxZ1e!uKI0a6HC}<8Xpe3|| z*3bspLOW;=r$Gnk2%W$IouLby4qc%ebcY_$6V8BMa3=JIKF}BXL4P<4q9FzbKr9S| zK@bOnVF<*-*)SA_!EhJ>36Kcqz(`1fWEcgbVGN9gaWEbxz(kk?lVJ)>1t&~{6i5XZ zOouc`2RF=snUDdQ-~lgW!7T8BAF?3_X2Tqq3%M{4=EJ$L0M3JjkO$|(B3KL;z=f~` zmO?&U1Q)|4und;NrEnRnfXiVeTme_YDp(C`U@cq)SHm@MEv$p<;Cd*48{kH`32ug4 z;8s`<8{js$9qxcT;V!rv?tzVPFWd+B!vpXjJOmHJCU^uMg~#A=cmke;r(iQY4bQ-{ z@Ekl3FTjhi1zv)e;T3olUW3=+4cH2A!dvh*Y=d{;UDysg;5~RBK7bG5Bls9Tft~Ov z?1InWbNB+jgs)&Xd<}cx8~7H!gYV%7*b6_xPw+GR0>8p<@H^~-KVU!n34g)g@DKb8 z@*#)_s05Xv3RHz^P#q$n2GoRFP#fw%T{sTvL47zL8o&u~BAf&bp%FBOlc5PTg=TOH zoC;CU99lq2Xa%jI4YY-J&>l{M4$u)gfde{27dRcdLO19RJ)kF?0lnZ%=nZ|KFZ6@{ za27;E3=Du+7zl$P4hF*zh=;RbC=7$)Fai=F5zc{;kOavv3P!^i7z^WIJWPOzFbO8Z z6qpK5mEQd?sGFSnZ!%DaUu7p*v8rHyCxC*X@Yv5W~2iL*% zPyjc;jc^m(47b3oupTzRZE!o>0e8Y(a5vlo8{uBK5AKHt;6Zo@9)?Zu2s{dp!Q=1* zJPA+1W_TK&foI`4cphGW7hwy$1TVuY@G86pufrR#72brm;BD9j@4&mT9d^Kb@IHJ1 zAHqlQF?<3$;ZxWJpTXzw1$+r#!EX2(_P{srEqn*x!w;|*euSUkXZQtvh2P+J*av^W ze)tpqg1_M(_!s0OFcDA*Dnk{h3e})GL_!Uy3ALa$)PcHi9MpsQa6B}C6W~NR2^vBp zXbdMq6KD#};1oC&qM$jnfR@k-T0bcQZ)I&_6@&>ea}PdEd5 z!I{t-`aoak2mRqJh=v##0I@I-20I zm=EW|0yqyALLQtCi(oNa02jg%SPJ=Y5nK$Hz%p14m%?SR0xpM@a0Ofmt6(*(fwgcI zTn*R2wXhDZgX^IHZh#x%Cb$`Hfm>lcY=GO~cDMuXguCEwxCb`Ey>K7g4-deD@DMx< zo8S?66dr@e;R$#Wo`TKrG&}>(!gKIEyZ|r47I+C>hF9QKcnw~MH()Eg32(vMunpdU zcVRp1fcM~i_y9hHkKkkY1a`uwunRte&*2OB625}n@HOm#Z{S<_4!(yUU@!a#Kf%xN z3;YVd!SApS{($}PC;SC}!$0sZ$OoVzpb}JuDo_=wL3N0P8c-8zL2al5b>TRu2le52 zXaFa`iEt7$ghtR9PKGAX6q>;)a4JMWb7%oAp%t`-HqaK@L3=n2IzUJ01PRZ6U@VM-@h|}bV9xQ}BI3E_lVz>Y^iXm`8r&YB#~9bNfn$SE}Na5fBuVK5vC;0m&|NU@qjsJeUvX!U8xC7D67J4~t+iTmTos5?BgS zZZ3k0;SyK|%i&VE3|7G9uoA9-D`6F^hBdGju7a!K8n_nL!F6yw6u=E|BisZx!!2+t ztcMM78{7_ez@2ax+zt1@Mz|O5gZtqDcn}_fhhY;u0*}ID@HjjHPr_5M8J>n`;8}PM zo`)CUMc4u_!OQRpyb7+l9_g*V|XcpJ9CJMb=ShaK=9ybmA1hwu@644=SG_!M@* zXYe_E0bjybup7RHJ@5^D3*W)_@B{3HAK@qX8GeCZ;Wzjl_Q4;pAO3{D;BWW`{spN3 zBcKvghAL1MszG&#gc?v2YC&zN19jmzs0a1ocxV78z=?1YG=xUb7*2*J&=i`%DR3%8 zL33yUEuj^(hBnX^+Ch6b4LU$a=mZYv3|-)K=nCDSJM@5_a0c{(God&1fxgfW`omce z4KXkPVqqW*f;boqLm(c`hM_PFhQkO*fJ8V4MnV!K!zdUHV_+&k38Jm=p=<{Z|eA#Z7pZl(Bx0C&_SARGQq9FzbKr9S|K@bOnVF<*-*)SA_ z!EhJ>36Kcqz(`1fWEcgbVGN9gaWEbxz(kk?lVJ)>1t&~{6i5XZOouc`2RF=snUDdQ z-~lgW!7T6r$!oWh*uZWl?RL^`C;yx63k?1WEY7kmbv!x!)+d$pNP!*~{ zb%=x-P!noFZKwlv;W(%V_2GDE04KnSa1u0xM$i~eh9=Myn!zb>DnvnZXaOyu6|{yn z&=%T3dpHd`Ku72V4(JSB;B@E;-Jm=4fSzy$^nx>?H}rwN&=2~{+U~-#SOaU}D!3Z1fonm=!ue!9H4YxzzT|Q6j`7vC z+a74QW!2cZC#*Y_3vn_YlX0+;>q67!fN^k)$DQfS=99{yoc$oKN~^Eq7up_%o`>J+{lo<6L~h@5JdO*$iR zeJ%W|S}jeuD!9YOJmOw2juUe_t(Y%p~pm>sRo8$4>3V zt`j2q|I)b9qQx2L}gJ!>vuia^=>(xPGHz^yark6LB z{$0A2Y~K~9SJ5WDoPF(_H@?1kQc9?Om0ZF!yJGBXd{{iSt3H1$@vHBmo3AZyA5(@n z>+g_*fgf^bf^-E1*_U*)UC9O5vh7N76^W z6P`%zyx6VN%AH)lZ05p~zV@^m z&6F}-uCD(j#KhqD;D@+9*^Z=az8)^~_PxNI zpQH>{3xucqz|RoRnh#rXRPu@Kjt&c0(?{};ojylL+K3kBdSEy8fVdct`nFzM<`wYM zPh%d%yR)(YSZ7Owv zS)aMR!sx?A5BVy!T`=XOz3O@%@8aqnAXmqea;EuQes2!L%s6*Owu_3%Io&nD=bhuH zx^g6Yvz-~S>8_NS(&gi#Jdk=x-Y?r{(I=H-VxN65W%;}nJ4aU6wy%Bk{f!y^zA{HG zt}#eGspPuQvaq zS>@`uDgKe9j~|N!MM@*T7$Y>T%zCx!9bT_fTD>xP&Y~YwwE7&r%;a0;>V%*Yg?1S< z*Oii!&BTGO%@}t^2CauLd!%btj?1qMCgVV5uZ8+8OhdBMQ8E&j5eKUWo*OTq@ zW@Na016>)eG$s!Tz^qqP|B}0`~7s!BhfwQR1HL~+6yH&>m>Uoy{siX*=wk& zm-^7!$atSnmHRE|B{nL_UQun=^}H+on-n8|8+MJrx=L=2P9 z?$tEGx|8;;GVPm^2gHS5LZ-((%{!Oww$qoAPWOAdi;Bvjc61#*X(L@uztAUe=j2ww6;OIonrr)~P=vKO^%e;>3?&tK_=Sv`M1Q_PMij9YIS3Dr|LR zm}|BxLo47Km412A;nUAOzRvddT&-$Y^ShFpRM2-rTKOS~BaIth{9WPP8gz3|h(_JH7DPCV{ z;DQ2tWv`8;(5Lq=xmWc}8dX@YD}Ai;Qt1;ko!HCNf0E&x)Dofn%IE>%?Uk{=$9c6c zkCv%2-6{R7a&_DstHYX}BfQ!Ayw6kaef*WR7D|S z$Xj2!{jQCps%tm39e?3hch}xCKM;Y~Mf(3r9uOCLA$AEgDyrM<2-K7V(Z=mD>LR7j zgcf@qSAm%O1kxf)TPt%W)j{S_WUN*bGQ+wlI_D~TK}uMJ+No%@6WcCA2>;$%50Tf7n(L@w2wm{yYY-5 zk1$le*=W(LsQ%OTw_CkCrv6Kxs;JdC(kfTSL-f)k9p%e#$m0R8N6s;q>t2Jym+R(V zwwm_hglV$$rtZX#pq*FpfVj{LiJ#Ui*6Go;80gG)PILN=N|>|rK-ppHkkIsL$+1?j z3H=8CTJs-vwYA?owz}t!A3nHDe&9rpnrxL^7n(L9dKB6LTO_5VyBI-l;9QCSNat56 zr}AVX3YtR;kozwxAMe9X;$k2ItmBiY?#F9!jXu5qj>~qBkuoMuz8xv$T*(b-a67`4 z?I`SMs{$TwaKh!PyvzJUetc;9sj@xwYPRxcFKFNb=rAc z4J~bG!OUHsui9E!Dr=n5N68Ioa9e~vm~FH(!=0+DNzI&-k?n}d%5r&9xy-E32J{hE zT)IWyTU{GA$QAkiPj|MKIzXHnk0`kz4Q_+oR);bAFrH8)dsQ!1+6mKOMCEr$uf(Ax z>$8)Oik`XlkzME2+1Fj_WpPR$B{!tOtw|sL){sJ9H7HTp%9yUP4xda)5}es?JJB=T zcq#p+Q*Zq1`73!EX*kucTIK5af%SsXxJfO^FjE@&jNwj(CNc=Ynf1vUR|>RyZ?iD$8?PxmN6{%AnM-Qax;jEGiK61ubMyfWsMqSUY?TWF0xqr5`6!~cJmly6C{qFQdDmayot#Wmozai@l1@lD-)0h~Y z&FsiPcd9=5G1~3Vab{%Xj_`U0WoBjPCi2&5$=l-0<$Y>mX#URozNh{_pbbqcX{)|> z%$D=Nt=)K^KYhVl%L471q<=?pfs)HPW*6_FFYnAiy;1S15VtZz=SdcwOElzHhV_tokUqSr^$aQlF8o3?|+NM5tokTFn!$%NBMwcadO7y6B6_i=etrk7SUa6dzcuQri^WC5JU3+;ot;_jM_SXF8;t7q6 z?5V~C|0=l(SNY}8Gb!Cm7tx}rSzw~-C z`xBd$Q=C;d5}?X|?M8>{X|?B;E30X5udj9Mi%WdNKQ>M+w5O6Q{ghvBJ&UwzXg=L) z(bt+!H@#U+`(XRUZBFUDsD{jsh*Ne|azh&2mO)=n31$r`PjknVY}b8js(zu^cnLVDH2n|Ar`xJ&MgUIc68qPYdav#ilzw zX)gM-^2lhoH`SHw9l`vF-cO15&}wE$I2(vS^gG!3E_v=Iwv;(p>8r?Gtjxj6+-nrH zf_5PJK>7f^;4Fv(>Bq=_@12kVGIz5S*1&D>1iTI3LL~aOg?RA7)gb@%l)+VBSP1gp zFZs`s{D)>2NVU2H-1LEJF<#pY7tw&Sn4PUnA1XE2x6k9Y?1zpi00iu^Q%e%DO?mo|t0 zqg}{(tN2gYt%UI?N0bm_Q%5777A8at^noJM;Mgk=_r*9J&)zi&MVw ztN5)tPx%slQE?O>!hhpPS<|PY?n>EJe6_E_w*FS~|3_asqUQ1={U<38%GtJ3mau)> z0>=Mz&EB{3jz%Ra-{kpEG1+nf79V0ZWTpce%I_vX?4!3`bdhcAq*Z?XY z=6S>G*Z8a-E?9fwn#C%9rJq%7zKZAs66U881=RPihQta5d{%=(eesV-O6 z6u<#8GRO)@KOu74W& z!s}b*=c~^B@T8q147(cTP5xh_D?=>dMUZm zNBL#YOTA?hQo_yUd#XRY-8$cKY3JKpekjW}>P~#Io012_g{z_M1%#{8eIxpYYY!ve9+0~ybJ;$nm(sh2 zMXrvQL0?NvWP}ifC;CZyz7_q<@k`w1d@(mCy#8GtpIC2(Z+E5rq zci8(_i=JjZtoIQ;JAA$wv1{_0-B0&ckK6TjSnkFuFUNh9SmT=W_uf+I`P&Uy37x+F zkf%?EGxAG>W|gbs<*;{&`kM2{+BxCvdgTvq)<}MRHc!k#^|i{?@iOR(p2fEeX1flV z8(z=Rc~drAxvVu${zCP%%GL2Q=&AB?iTdUdu&OuOfj*Bb?#Fwlf?+WBos)kgl z8^x~HHS7B`N4~eao$QN~^JHt4>tZ%Z?lh0v6QX6D)18syV{9reBwsBMYX#%a>-K3x zD!(Jot)hK@>$!i+vC);kx}@b$g}qof!7f9|L?WLZx3DIOo)X9m;@eJ1XsgD zupQ)&QXRRW6u22={pn$3Dp_w=)?IxS#6$^X;=z>P3?BBpNcnZr>cvrh7xOMbdlKwy z-iP?RA@T4o#6`_n6ONY#b~$*jfp;J-iQ(Og;j9fjfp>H`nkE{Qa!k%gY;+ z_ESByi_j`hW^BrbH0rTBqUFwFWmv zYOQEZ-F-Wrz?4PW23gK_g3wP?!Rd#HfVN!i-mFr?Q2j&+tu)HFyubvXjGtrzY z<;q;&O4w2dkW6~Hm%2u(S$QT$GU>Xh`!LrNkqg7$$CFPD{dRn_y2gowrS8Kj=aBA- zxsQaLY|D)V&Nth2MJe=oX4u?U8%3@BA#i!2K32Ipet#4YFKfr@_x@k@9yAifx1(p0Tq#;#VW z*RcGQsr#@;FDuU+?_T_$6;keY3S2 z^+m#`Q#UWFqTT-0$aQdF)>$*M+9df$=B%+-Yg(F~Tcvnwj%u0r87d z_iud@J0lTCTjHHW_ ztN4{4_(KG%+3}a`G{0l8i-Ia`RzRZng;)>Bq0AMyFdbj=i}`&s$*X2({cS#0+I{PD zpo$2yv~eHG^NyAKIFvTB!!El8Hgbuo$0L`9))#rJ*BbRjENkaa{q>H#i>hc7o4oj9 z_fuOwH7SrGWWUnsd%1L`T6sGep#{-L&Fh4V}&D+xRJ7g|hWyuYi%^cOnEsNpeF zkWLvqD0xca$b`f}Ba_EX867ih)Sy7X1^7ze^!$?bjk=_YcHNZ&FKzN%%dMvcu9tR6 z^i}eJxX>%7z9V8r#}AH49;APl(p=ApnN-C z;x%9QegA~_zj*Zr>2L(%l>a3vxgia1L+v}r!;*-uQGS>H->XrcY`3wdU1H^~`f)#=<%~7jQRCh#p@)(OH8A#y(?gcL<{#yLvo3N)0md}jS7c&eLE;n* zrT@(9-+{KAonl;h(xsT7Y;nK>MWv4_17dGUAC+FV(GI@_%=OBU<)PyRNgL~UrNPR? zykDBEJ6maL{5`RWW|gbs#?n%bI2P@Y|LF(TqGM&V+1{B9ixX+WbY~tn>_87GyD=bn zL-r-lOy!RzYF)v(aXG_p`SnL;A`B< ze_3cdU>(nF=~-P%i);H~!wqY0JtffK-$f|W-YdC^U-_Z!fVqD%+~rGi#f(k%xm=^N zSbW8ps5JMNdaWo~pMunC+Ht=;@z%C8GCyhij&bhy0ezHQ>7o4M^$GleHspliP7m#s zuXpbRPl$YwEdA-1F{jynTP*s@I9bk-k1emb;@-Dp_wA1+FaM{*xUn+LE>6-tlC6^K zLenNBT8AEQU|kl5hqAm#HwNrvc-Df{uQKa1_VSYL7d^e2_Qkz}MmPIz_#7RK9{;cG&HZT*4e*&M4yO37s<8a`@!7_$f8O{_ueIcJ@Uk+;yr;c{As*hY_E_Ycg!|Sv9%h(=^ z9~mXfJLyj5bY*7OD%Ztq!s)}hf%>UtJ@#4ju+Hzu1@C>mYuDi4nq8$|%tq;9m8;_= z=#lNq4K4v~PM`cMLi0;e{lNN@ZauHdm^$CD4n!pB(}?s@auvVwL-iQL3V6Z4hFa4` zuE_&6{)oJ?WPPH3t){h1d3pSYH&uV>dgi>viCrZBD!DE+ZA#Kd(#C9$wZtE;{aQbB z@;A*qUyL&HsgYmheF`NvMXm3e?^(~Tx=8{PU92uA3pgg_dQ#MN1?(t$^jcN2J>;72 z`~Ut$uc5nl%D%WWq|?mSDi^7^Qmh*`z{Qx-CCfbpY994wp0`8awGWW1<0a~8UN6e56c?N4V-wewY`@K))z-TGR^_#e*0+$)2vl5v`72yeJ7iLe5XNr$|30)b#=+%*Ima)o9b-J$ke`ukd-k%Kuim((AzQMihP= z%v?0|MbqS(C{XFR6@64Xe%xVaABoG{j!nHLw4WnQLL^Kjac9@;B3*c`){cGae%>(E zY3OOJV-!IyRB}1T>`KsA|Av|VBx|56h2;$N1xwBP?6v4)9q&jy-j1I*I(2ONf{Ihw z&nj2POQnyzBN4cu0AJO+E3OTn&tkTX+0d!|lesEBrH@svjtBEuQVx&RSYVeWxB}f} zz0vaPNolmL`eM@b=Yto8yua6LU3mTK-2C#V+v@e<>AvBVepb0U9*oMQUp(t3dS|i* z)=U?x7nZDGAfN(#Wyc+*(6iA$oiE>(zU>mFhtkt3SI3LglOg^Mf|Q<>d`n z|I(J*hjtBgI7L5cCzM?2rTpUbQ;!b|zYkHgdPUC5s<12Cm$s%TSDd`4bN}CD=6bc@ z#?bteiZNvVVIQdH;tRiOkuu_s2|bmajBLbuH5R!#p6K-Z=>Vn%W=aUU_H;=*lwr=;PC0Ka*EH0$(mR1`OOqAON$y z^6w07|E=@4iSw#!Im2srS$E$HH|7McA5Uc?{YNENdMUri`44PlnP`x1q<%?ptM=he4f$vTN+=JG!Gu9D09iqSPRZ|63? z)=v&(#X`f$V_PZjN*)jwdZw4f3fEf?)|rF&VqdPYP^AnmaM57x@9R4{o@piuUC6FB1lSHuu^sfk4m0m-|t2Yg|cgc{UL1jQcy`GI<5yW;)c z4C$YW9)?C|C-K$Vbmwe0AB;7w$iq|ZO(gd#bzclfG_o%?QSVP|MUTek-@E9`!RO5G zj9eUl?a=L^kv7?6sepFIe`u`vtvjI?zQ|G-ld)q?*Qpyz&R=rHXA9PB zOf}l3nWs&-+JZ^ z{aN#ZdTr+YI$?+Ln3rS8AX}?k7qcl+4}GF>P(qyXEL=Y|kF84I^m`3^L?aVDihSvgB>@t#Glju)wi*dw5W*$#V&U!2O{*8WQL7uB_s&s^1J`o*rk!^KEA ziC@aQlIud#=79JIy8SaH{$Z3nPfFqZtyzzKlp}G)>9O|3YFe)oS38?6`J=`wf#-tK z{}MfvTo1ssIY1Ai>SX14^@U;M{4C`s66F744WJ{G$F<`kbGQ9J6KZ*!tMcWB2SfFc_oP!L zum`GWJx=L5Z^KQI+JGH#zpQnA7Pakt7WKs`J(OG*nl?r2p})$ee^I$2{`V*Ukvsup zd@t{3ML}!m05Ut)8wNrGOoW-R09L~7AP+mfg1QvOK9B`>!*6gll|O&I(@voQxEZ1` z(QoiF>F^Ad$7f6|^q`S?ib8w|gO8heAEF@&@%K9|9)%nz^eF$|tbsy(P-r#^eT72L zpipcg>znXr#EF@_=gaEFl~?hfL!JuNdWHS((Cvf>?dJgz+Wxr_S}j(NxGkcRwsuS< zZTDj+bb4j&o<}Ncea2PMavN0DKKZt)cJrQUeBU}!yCtIr>qXbnJlkt)>3`SNTnp=K zFJ+vdE!*BuTfeP|w))&C?fY+9Yc&UU)IPkUo3yLZ{wHh;)ZtHkrov$936LG5CD!CyIZVxE8Qh&r| zc>S)>3dCG)Hlc^a9}VJTm5_FtpW2qkx3BrUMWd;*FHZE3tyQjz*&LvUv@5zErplc2 z3P6>cu@9HrU*J@2{~aI9yQJrRUt7ngN-pP^o%!LTLkbaN=4_Y#8A3;#Gn2m^@PW7N z+~KZlpF2g0lU}a%Hy!j~%y!yY3jJ>Fa9+J0vAJE84n_)B(X4WHoNtK8-<{_K`>12w z+388nOjiQ`XLEZvuAdskR_rAG>ZzN8{p#iC{&JGMIy5zKT+PGsvsfp#lQb@iGxyu~ z62Dxp@@-N1WpUlNuAjBM>&e#nP$jpRT3h3X@HZ>lxDV*R-3cOU0{S3`U8&K~{O)j8uhl@5|7qK}fx>1Kx& z`1^U`Y|B7i7t%AaETSOiZ3Kzmn*PfE=CD+pX4&E1FHT=ouFd)!4f>k%+g?lhO5a!J z#nt=HTJuOP?!+Je_MOu^k0wiZDt(naATIQRp!1*Ja4WW&d3*yG^<=4FH)c6bhj^+SHQD*0aO0d zIUs`vEj;%h7atfG;2Oj$zc0Fo%_YxCe8++G?L>tWLDF9OcQQ~DTektaRQmc3J@I9*6bnN^#%+_q z4KnAt7_NYuVH3O#UqS?WL;>9_Egh}^S^Vk`=s^LV3(rDBGG`8a49S>p2V_uL*QXG@ z3|CQ*@*;_cO7j+OYuYdC_}PT{YcZU z{T*AK$eIy7Bec($SZ;kmgqC<;gtqUC2<`b(D`~!|m9#fERMKAgqmq`!8+b3%Z|vKl ziq`RV`t`l4YAv@{)&9t@ru~{wU0dgf)bj&Lt@r!P`MK9-ZW+HU7 z=CmoxR!ZZJQ}u_E8`9vm)cGdaYdjuEqDJ9zZojY|*&Rl&6%!)0c~fqyTX*%+GZHO& zDS1#MW3LQ)@fpOCJOcI6u+c}<*ZvHAQkIV-PGderLfinV-dpi>$#&d4IZ|^~uUX^V zduQKyoJC(HH?$0H4^H1;$u#TP>zR`E-0O_gzNk|-X41${PCbP(AWo&Xk{i2L1TlY4C|;6qk$Lq}|_wUaH-HC#F$7u}Oa5xIC{+d_H`;KjQnVcU~U%mpG}Np{$9~DFK}G++{~^aW|cLf%jPFzK>)f2q8xpcQg)5=LdVO0Ek{nh=(AK562E9+m8;{y^wl3G%Uda!Dc(QO&q^M?ENuuUO8jcPL36G< zn(H#TqQWU_7!qMcg;PL6n(s@(rrV;Yuat7NFX=7FeJkX+j60-Pq=L5yHDzYQ7RllHj%>A@jF z=s2Ym`VGm7zNY6@v%JzD6(@cKTP4?prcF`$(R63$_+|de_)4JEw4*#TJz}&1u2uGm zenm=3u)efDH<4p^zA-h@@$IAZ$_;0vU!4Qw>UdH5@S1hdWI^SO5p}9e2Ko!%`!MIL zF0Y2Br`SU3B(+}E7WDU?xo*^hSD!JqQ9yxu_|gwj@_@L|lh}eodG+`6phV5%q;rM2 z{!!^+SgbI(!X2rP%Hz!UyD7~5&h1fOt8>k9{Z?N3^|_IO$fP?h_p9Vq9e55Ola=KN z-XMSTWgQP+yvLtScb+d)XJz@h$gD^7YbEE4y#>sNpBi`k{r@&dZyShE#<8M@l3Vo% z775e5%5djgeI7CRH&QK+3swHyj2>dw7?3(%_N6{o&#l?j8vZi)tGFL)NjFP(Mm}hC zfLt99nNN&K$C7kMl;_>;u|I3 z$L_31ZTHaozrFRi4}NJH&{W-rk{8}UV8;|?;dF55{CSD@VNpBTYZ`PE-h)JCzK=#* zOTLeMU!-$@c;`7JdWX9`t%Bp9_9(Mdj1<13lgP<;Wb zPUhd%>tsAqn(J0@p31jd!`N-^XEn8%GvAmovsy%kGKONL})f;_LQ(K+${BKe3 zwL3%7Pn^<6$qi|6TWWnA{OK|9Np-n83PdlNzsN@~H7~HrcS?1MyC85}<^|flTXO!} zy&zJ{@6zw{CTmZ-P1&&#*NYvMoSz}iq_^ah43(@jX0Vw^H+>i#hMd=q($y*yMi+<*GpSrzd`$?=(+i&{n$q%l( zNogSZ$rBE%TpbUqpQ%PSt7g_~Ul_gWT~S?o?Ui4z@A%1S51$rg#H{S57RosQD6%c?*&$aR}1*gi1bzGIdFj9NI**~+-Yh!dlT;Pa8G zdS@TyTGAi}#FsI-jOW@hYMwOyjt%T;Z=D$RO~<4&*2})Q7E-X-TIC`YS2+J%xL~xB z(CqQbfiayE+TO1HD7+q3Ke#Tp>hdcdHez8+ukTFNta5c+#mX8V*)E?fT&*N#JsdIF z#?RQmqe|Yo%X0Ezi;#J^b{_}pKk1)X-xnCNI8y8WSIZf<<|KCMX?YH#?;mPy0-N_G7C)O0M)!ei`&}NWVbl zy+X(DMo4Bo=YCSM-8Nhlsa5_a_rDgU&wr?-VY7Pl|ITpKreZ((wpMVa11&9^fK5l|AEkUScP8}U+zhq z^uMM4QBJiJ>i41Wc}=Cn@s%2n9BkZ@9%XfMO?j>>YdlBde6jnnt>p7`u*D%JvaS_JKB&Z9~yZBI$<&wrtut9vqs}d>j)z-6rKjy5 z9t)W3Mf3i_#xD7+ym?2Jr-Rj@yw{7~N_X?Vgr~}nI$qv54#jmx+HMtnPs+y1w}vnG z8)+5Vzr$KU<>9a=+9&*9TR`=9%WDLAH{xh^)_TSIyF9v=rfikwobtq7QP)VlS`oG= zPM^|_pCtbrOdhJp{!DTAQd+s#^JvmX>3uZnq;xwReo1pkha>*~dK^+dt$D~?za7eY z=M;BsY5M-*@`q}R4@QsT^s6Yjyc1i|PWoU6bI;1I5{~N6DZiq1EpK=SbARQH z(|n!8uk2)&7q@S=pLxHy^D9z*xZ|rx-TzBr9cy#&6>WR5Pq@5jwqa3aJlyrAZJR3k z-mKvjrMo)Ed`#`Dwo09IwEALyHSQN%3nD8jUCL5F5`^vkqZSDFKGuKqw#uZolw)(< zRi=yWlaD$JNP4Qexj5yDs`H9F_i)HnU3@6wI@<2_P~79O5~khm2LHcURGO;)p6Y*- zvz(x8r+mv{`)4^V@L%cQmUMe|o+!yW6@N^|8Ks#AtoWGAAEKQ{%5OXS%F&-^c0z&w6C zmh-@|Fwb=~+=Ds4{Fm~%t*dQ;BWZz>%B~zM>G+Y<`$)unB-^3?+Pu_}NFO^++XA)) zj&2L6wLgz;Ep6?Nv<2+G$B|BfBNP9joC_{4Z0XmP)VEW|lz(I_b7*2c7VqiMSnB8x zRq9M@9=DF)WS*qFb0yZWOKTCCf3B$iJ|E3<*`>9|;W)3nX(jc6*x0TY4o51L9EVCn z@$GzHvaRf+wgqep*cPxYU|YbpfNcTW0=5Ng3)mL0Enr)~wt#H`+XA))Yzx>Huq|L) zz_x&G0oww$1#Ao07O*W~Tfnw}Z2{W?wgqep*cPxYU|YbpfNcTW0=5Ng3)mL0Enr)~ zwt#H`+XA))Yzx>Huq|L)z_x&G0oww$1#Ao07O*W~Tfnw}Z2{W?wgqep*cPxYU|Ybp zfNcTW0=5Ng3)mL0Enr)~wt#H`+XA))Yzx>Huq|L)z_x&G0owwH&I0)lXqtOv?v~R> zHBTyUENb0+Su0cAywaXq(dnl0l=90HereNB?4oR={PM(SUsJIbu+t)FPjensQfYfi zYJZMY*;V@4zF~o*B^?f?E>&r%+JuVgbEt5SCBL-oj@+}PNl|6{NZ7+#-2R~S(PHk&3WIar%^Y{3QA3VDeB!_GgN_m(t3`o=1~DO7BCN z&MJ1fvbXwgl|r!`-j>$m^M{8d!__Wx*yaCy|WN%0o4ZBx8$tVgW%k98bu zJ#M}JzxexDyeE|o=DdF_->16Y|DrGHVos;x?x8g26nAZD`u^eahiZ!tMvvn3t0;N( ziVDaSj`YC}=AM;ZB^=eCQ@$yhBf5Jq_g4{$OZ>`Cr3ue$Kl6TRu07au4tIP9tM7mH zdTZaKxcewez9}w@|Ds&%6D}{BZCF$p4|l!Twy5h4x4nweL3C64sXUh>B&HlwSWi>7Q@-`M{kwb?I1>Ha z@@ZQ9RmJ6r;^f7Lbnr)1oXS7=5RbkPWSmi&dBCGd^Fx^)hcfJ=$%eKrC0n4RwyoqV zkId0<{b;3CY0p#VAI<)M`Cg8+?ngTQqd8yMx|M7JX(NyJcCxJVL?z#G#U2f3yKu*g z(#9^&MOo#)B{PrT%998FD|dS=%yS(L_h8O1|CO}2^|UQ;q%BZV*_C4@9Y4~#AMW^% zWIOaHuq|L)z_x&G z0oww$1#Ao07O*W~Tfnw}Z2{W?wgqep*cPxYU|YbpfNcTW0=5Ng3)mL0Enr)~wt#H` z+XA))Yzx>Huq|L)z_x&G0oww$1#Ao07O*W~Tfnw}Z2{W?wgqep*cPxYU|YbpfNcTW z0=5Ng3)mL0Enr)~wt#H`+XA))Yzx>Huq|L)z_x&G0oww$1#Ao07O*W~Tfnw}Z2{W? zwgqep9C{0MsiSG`mAP9^AJsfbVhgw4y>*TJgVj*h>n_Xs=|#m~l&q|JsrAE)x~`;S zMV()qth{=b_qyWrD6L%G_tEq{wL@VGb)TiNi{w>BY0j5(%BypEuPd!yr8zHLeNdV( z{;TIyl>JrxR+fBrIBcf$DoEDUsj#rqehOw@9WbosqGz7+i=L@r0FHzh|-GXjai6a5Nq{qnLb^n0}L-gi=(q;@|~dnQrh zHru(;_)z_=`7ZIMn%bN5#``8~SKf1m5xhRG7yXqyATIR6+j-zLWm;}UGUf269Gh zhRf-3rH;xP;F|9Bxf01cWF@kOk#7qKQ00fI6H2z{mg^$5^DoGnaZ`)BbL&MKnyCDs z)oZ$dg89 zmJEA(j|5+!Xc@Lm_NF>>6MRG5Y3Y>C>F(4*D{I96L!lw9;tHk9wk$v8)i z+mu|LTNXcxlU4an#15)_uWk2ZKM8kk;JCCakS)sCzPQ*O1jHMPw8z4qLE$Gba61`O05U&^hLTkV$Q&dkbi#X3{cU37g?U5Bid z#nc0OIsO!%JBvQf29tg}O!`SZvAJyxO*#c1>zY)&a?liq|P4>pQeg5pEoM}E&pDZcc>9gpWmlCvNQF^w!DpI?4 z#@GE$sNVL@sZz1wl%7g%NQ2w3dd7M)Gu_!qw6i7ZnMaT+y|vV!o|2r_{@~6pt7~hQ zzxs6JH#dCQ>NG=_et2R}B{!tO?E(32h|8Jk@+G)gDQikakMy#`*yy zJ02IHS-?LYU(#LLLCGg_zO;LSx?X&7DlX&K|L?Xe=~G%ON!p2>#qN?8bSt&SAn7G( zDZcbWBn?#hsQ!qgnV|9jyZ_hDJkQW*MripiSQ4Sv*IDV+wE5m?aRr;JX=lB^wAU+% z{U2%fgkd(-t|__Im?K>tsuP#5yF(u(F^(VUlmULS(?2uW%h*{Bg&YZ9>8o!bVWhs9 z&|=TyDlAo2CEX<5B`rl$Nn=T0bN^kH&$`H^Un*tx1d#a1G zKf+XQ=mSXQrv8FkxUs3+SQl=rAve~Lil!Tx+RKf-PG(Ocb62L4`ivXyn8C~wA8ddZ3(}Frj6^OX?OO}v{ik$*8!U5iPy9X&e62<#%o$ms-|7&)wI{< z6ZS=#b~yvM$+vMISbfu0O}qaqP3svEp&td}vg6ztE=LkmEzS)0JiT2n%rOJJ z-kF(B-^}4IUz#g5DaSY6nc_41MCo!GGKvsp9&yLbJab{>fx9U6g_iEZlyFKwI zkNIYnp{J35q#aXo6|VA2qi;+`hGy1d2YN{OF(5ukqKU$dhH6^&xZeBO)lPV!-ktaK z8dG_rRBE_Cp&nZ$*M+9dX!ks(rYK+@XT|_mT3`w)Z)#&b{nRt`jGI1Y0H7g{BSNpDZsEdNOU2 zOcD=wdPprF(+}R9wDjSwOqmP}R2g!ad43@(Gc^4Qu#MPm^Y0PbT~nU=EZ9y}l733A3r(Bi^f5FU?r`r6uOl|y>G8NS9AlVDawU65(nSjl z3r6_^7nsv))2z^ZC2geChdUcZQ2%sjAC+21JLj6#i`MtdT|Zqi9&RRx9!jnYO`8Mt z80kuJxo5kEGaZX@0u!^zxmiY$OXOO~U*>t2I#LUn=_EPaKkzuqDDKc&Oof95Z}@5R$@H=Z2P zh0spb+7`;KHVV|x#wd0ek3O=8)5FlTJW%cI#xU`2ji|2m*))9rZQCB*?$Ud88ZjF6 zkdpH=#D&BgGu!FTa89H3(Bqa9^FYPl#UEM^O3gGK8hxf|`Qz?-DywpJt!V>yt+o$b z`sdHJIDk{}E4d*JZbRbdVMB^M07`R>@&}$jnd{-5OM`ZoHZ{6VW!>(Z(W_(BpFMiL zR84E>{iM!C8~l0Qvy6)Pbk37{SjmGi8+*mIQ^8)fU-ggl3wE*R#ndB)_c>3 zJ%z}8M3z8g+lZ_k{nh#ORU=yxZwH>6cGomVjHY#CwAyZlLf5h#j2a+J3;ckv@gmjx%^h; zLhZ|MB@^GAch$c6dbKaUx>m_lyCQPczR59h*7L1#sdMy`?Tu}L3a~&l8L}eB>BXs} z@_2E_4@O?ru;qN~HATrpCv~3rxY`$A^#RqnMV+tCQRP`(C+)V3IHWCC$CNMOiId;9 zJ9;f(mmec-RGF}*R8i$YovX@0N#{s-cKNYd_1O6xuD^CT?$n$QReh`Sq&a?(Sur1% zee-qZbIs?eb5vZ`V@fW*oU43ucuJC8+5h)37_s;lPJ z_3u}&j;`~Eqt4s7aR|SKOSia$N@w@Hf=qvHbIlDW)|5 zSgA^Lnj|ng({HqsH#-{R`mLJ|Kdd=qng6{qGOmt1R_E`V?&>6_w106)(?@q?@i#d_ zU|gN)*4SxXg;u8T<$!GFS9pT7m!Q&x_4?C20nIhOrV5j;c~up)<7#MmfyUFWB194K ze8XzO1w3xjFlqQ(Uz<{NV1iiJW!`J_R}?ND6gYizx8dlkL&0BXdNN%nN)KCH*_tO< zLwg;)E4tQ8|?YsEGCK8Q0kzi*c-`T1DJv*VV9woGOm zj8mnvdptO4Nn}k$(3NgMXhtCC_vHDp`PjQ4d-=e_hI|THg#x}rdNN%nN{@K(h54v2 z@Uox`^HIhruCekFSdvJ~!00q-~0> zLSOY5&vaV6gPGf!pgBz}QYk{n71m$PCY&-3V6eE~-AVM_HvOhAx4iX#ogST=i}9V^ z^_|1-ubTW_z~2c3L6;BJU$p=1hOkih&onl5hd3XMg~PIG7o73K4{JMravUxBQ~k*C z$Zj&-vF}+9v{YWu)}W8bbDpY90X54G?5g^;@>@i?GLvOn16{|IA8v!mPjQ_Bzk zSIZB|l~aDe)!(+-)%~@deOpylIX;yx|8L38VeL!~qnhx`vK%cO+z{3-JiEb+S8+V? z`gi>884iRfqcHx)`_oX*K{<7u!G}Hll*e&X?}uz$lD^G^A;eyKXI#&q?4Y{zk1 znpey8`vQS1ZKk&v8-4s{SUpPYiQ)Ny^$JeA`L%ZrT(W7z|LquDVgf>af%!G2o8+)z zi!;{zS`@s?C}zf6-w=C#=$IL&A8`FkcO1chjQTA>sC0IZ2XATvvHi?{5J`7S8t>0j|;c`e4IUgGh$gTCO;5+e(wC&PQ3c{(VMq|&rmQS7fjcQ(jy++()?VDSebCpzH5^#S!TC4Tq+4TeVLgYEJMm1_rBcK^PnSwKWgNgD zzsFi~2hB|yrd_$&du;04*Y;l1S#777PQfh7R{mOQr%*vvYIK6r%-U$})a-|>IPL1s zi%+=eidP!}km~H_{e{6BaYNw*$mFuJQhhx{HJFXp-nf8x=ay6>+AGx5?8FxH* z!}X}qPT8YX>QPx9nh3Wn4|aS$d&%M7pT2)*95bUU_y=y4u9N8z5AJX~Wsg{oO6KnZ zY}O^ka%1uy@%osSu8$ajKZx*mb_hzDnwzeYP{k5=KYj5}wkmA`i7?fCpr zwRydI{*$3Ge^olW$A#OzowCPoMl8#PcqDc^^~8Orz24*El5zvDQJHsyS4pnSu3qB{!UVF#_ee17$=>3rR7y(Ykc*6xE?jyDI2trN>rAE*^kHOZ~vp__P*rA_Olre<5lVG9uI#Z-un7Q z8>AeM{9T>)kJx)b@$#950*k;0*KCXrFA*M))e@Z6dtjlbbZmMAGW_ zlY3$2*PmZh^%ru|74uc4vwK{4?b{_A+}8SF!SdMc(XBgr_uf!>8=8kOUbII{XPj)t zgI8*gY%wA(r#)hh8m25~87pG9N3RqQ{@bBPz3<~#IR7>%bauDRH=Epvr%ghfsigV) zsfh5(cz|V*>5g;ewv#((ZqhLA%FV)_?=8Rn=b`(m?Gn=|m_^yXPfP7mf#&fSm+Q?@ zh+^S!vPDl=aoM#)eV(4%q40sHGjMhe6z~tEC)0JJ^svPhs~wW?$@O@~ld{Y(P(!f=pxmkC4ZX;C(?E6Dci4?fA_@YKb^ViaXO*W zP>fThvwJ)^!|hE3p`|}mw=y>WrkvlS{Re;D>wTP^1O;44^klkDlpgWm3iHogCm)tR ziGOlFr>(N`&#rtVeU~^ksY7xZLt*}@basymr+vF3aZ`v8Mabo)>8aT5N%rOaI)8W0 zz8@L*41S_LVLIbuGaj5$dt$+cIGlEbIcb=(T-DLJzOlY*#+`rOmc35SI1FQNP@He$ zO}aJq7V3{kuEg7Xh*XN0+mDpzI|&&FF#Oi$y;VN6=0EckCfl(t1GN+Sk0|fFPJ^tv zA9;=&c4z()oN-i390-wMp*-=tcT4_cI%JXM4D#1e`Y-!)>^skaw&YK|sUjb7<|Ee= z$Vb#IFu6ZXR!2qQKs~u}KWFy8jDBMV(ZE}Eyk~o6XVLwxcH5u5CGmo;CWGlHXnhWg z>Gap4n%&2NdtfsCwBc8?+ytY_2_2=W--Cd50&O{$S{{E7BncKihm8f6ptiF`sHar-axnf=0qU%0^^OeoOp{OgW?(ubNq zC_l_2JASbn*u`b$Ps+Mq<+VeU3fHqm>y3KWO*G_9iK%^eCW%8sd_EJeWQL~MFs5xA6-(Rg}=>nwGwYl zC0|7_I?s$_SKd>CHaUefUF)Hr$J~QV+*yMA^>8*b9ht1(UDAup14-koW;#My97Gy- znb5T#B9-)^qz@zAm-OMJk05;{>3*csNMo?MKWWH1+9BL~g7aIBC7n(hXHR4NY7l8U zmRZo%A!0CTI;LL?A&ol}hLJvz^hu5-(fNsl6(LwYpn zQ%Rpj8fQ!Ak{(MMJk2LPj`Voa1*8i}Par*!^d!=gNuN#{14C0tW5OJhC^(;b8tEd^ z9@5iELp~_$_4A?Cat_`=n%a?0Ff|#D+Cv;@pme#MC%%H5iHr}b;(>hb*OHo=V@e?4m*86TI|2sO)>JK}KRsXqQ=vBwg zda=EUg>f?7B!`XoapsklW>(ikM@!>zB;4|M9_j#KVYv?{>{#{)2jqF2#8;!sQ|OaU zBJlY6$8MT5bu8ovisgyv1~u|*g*;WoAx@Tg`N^+a$DuV!wv;rVBeedrPU6m&UmKOT zqxYqcLf}X-UZxw=$g`DrBR4O&tPQkTT${;1>I*<&-9fT54QNnC*bV<%QfNCI)pibq zC@9za+ex0F+@!%*wcgLTHCdeVV$ZsVhun1JktXBO|3SUaboy&i(c~#g|Bl5+)KP4V zZ}uBje05(A*852dsE1K@>T~EiiNgGKXLUU+=K|QF448DTmqIsOF+NVW*wY>1`qWRj zGB5Pi6qjQ*&2mqeXo{V_cJOrz3l5mHhU4e-RXV%3kUlO`3F-h$j|<3TK2*PH#Uai- zvLpJ73kctZGl!x(CSE95=)Iuxl*0#f!9Rl!`w=&oZcrmnTO7Hb*#ojXwXR9tV7ad* zXx;^{9~8KWf&!0xp9$U-Wtht@P+}Ye_gOYUyNLzM_7n52Iz+s-;TUoA{1IZy{YBy&?^WXLuU{0yhNLB& zd&)xzxt~|J+kXF*?ZHP9Wxc;D^IL3;&F>G6T603>r_*axelwk3)1uV|rY;m~SSZas$(+bGQ&$Se~{jc~;=9KD`D&ucbz2dA{7<~=@A%{vukOG0!;NKw zP<`nNCg#tXZj!@B{)Ak&Ydl>D>7$DwGdD~&ueNm(1?rd8ky4{Z!X!2=g!qOhr z6Fw+6X+3?LcHor<@4Bb)Ro6!{Um!UG0cpT7SP>`-W<@KotKnI5+592kJhT~ack(vzzN{oZ0Dgx&l%P=P0gOc?&0 zr^5k<1I@=p`V&)(GU;&Vx4;3lKI1vB-vTxVgTsN}8VA(!f_@I_Gj9KXYj_)-YyUNvp~dy9x{s_wD=%ijbX2b;0NvU@!KTk_LdI;ZKFzYPwk?al5$ z1sP$Dwv6qZ7Jt*@Kg$!FOv8V)flzE3|BR=df7P$-hr`;@*v&B=4yYWE_qR3CcoAgL zO&W3pJLFp)w|eIB0`0$z^HvjCSH?Pr?n0%rdyc27Y?3EPtC?usQlL;@%9K-6RmKaJ z%sXOSqw@?m8Z!1*dMYgA)z#Z#<9cVs4}C`*Qt}d~%eYiJyT^-b!e}e5I*NeDLAS<% z>xMNGFTApA4W@N;g}G?#EK}(^nI0|Ta#zvK^VV_3+26$G%aniY^>Y884#3ost~h;_ z&hF9D&-BxXY%ygHDS4bR@!Qzrj8`=E-|L=R{`Cu|1G$29sdRQ9U0Ln(2R&86Y;T1| zW59l|r@}kOgZp~Ivyo$b1ZEm;MbRvH77-rEFUv8~LY*9<1!@D%o$xBsDDHo4hgU;a zVd`P4cPk!%8n0DXc#8Sr6B!G_$m7AQ{~Mh@tAE-@Jhf!D`?7sE4gUeaNdXV$ zkD0C$rH2*IB+8k{oPmrbMDgva{v@E8@N|4!KY#|jYyu|SWWS*Cf7l&ma6qnqw{MRw zCkWy7Y<_>=s&}4bUc$t@3e$~PBTuWG*q5UMx(Lg!P0ROdrJ7%>qI;y8k3(XuC#M;S z-LdT{4#@Ry{r9ouX71Bj30KxVa24al+5@aWQ0eR*kKD)tBg=8>53%dt{_R}#AFO>A z%V>3F$X0?->FjRB)4cw*lVOCF`P4|bpxmU9p51&{*Gs>ze7mM>$9eEb3jPkDC)0JJ z^swTx*28v~I*cdx>`QBg-+bv9B-3uq(TBdi&~pjuQz)ZeZ5O5+)X1~Y zGu<`H@2kNzdxd^aRe+joU)4YhAC@WUqV87P#{t{(-q`ETc37ICE0!0P&hAz|G|wMd zRuD#RA2WW6o-d15rHJ(Nru^sl$>*-#WPV%$586kjGY&Sbc&zy%W07&Jje!Gkzy1Bx za~`|#06lN;pXFAi!wrh^L(dMH$HoPt`f@6!WrkO=Sox8^BRW42?@MnyJgo7^udy^< zSByiYvpc70;>fGks+c6hu;fcq95_D9zy7Js!w=iY=`aqJ&hDJ3i6gVZ7tl(WC?S#a zrRe9_{CItF%8es7mA$~}Fbl16hjFNM zcIPBb9LADwCh9m`SZZb|zq5ad%@5bR8~V;)b^FDf4&zYi?9NGA_|YO7tGx2=OgBY_ zbnNQY<^LLTo|wFD6Q{>`R64sWcvbxl1$}j7z{cLj$b zCoQ6}wl}E>sLi9dH@~D8Oqso^=tfSD@u+lmSMb;&88`%tF_oqLiv!Q}{Ix@#JLq_9 z;n5Z2QR(ci;AxpZCaP2li0={HE7;hnvsiJ`*4K)AmmGIzyZeuZREH?RUG=@f7~?gM zAdlS6#vA6(<}ZUf3wtVmey_ZizlC8(7X})A7-&cRc{m`~#~J1+%Wiso)Uzd|v0i;U z>1kKbfmbo=hsB2%&D?r>BL0wqKb*hLbe$+Y%(durMRXuI(M!F5>Rr)bReJ7#=wvmioFH2l2oJHs`X(r4j|*%90#7qU;gE^_ntdx8uAYcc=n2%_ z6_1=x)k#+V*yYnf=Rdahn=|%)nv>*wQt9l@`9#+N7m&~dTzZCO`+b$Bimr!Q!=z3fVKY(K%CGnlF-QrI1Spx{SUayT_E{tuJw99|A5+u5(` zpTn`q{_vmuGEFuSH~*LI97awXaj_rS&VHGunsOL9Ev9pLIW4xc8%$Zj9m*~~4$JOr zGF=V>H>RupI1SKc6^$Otjnifm@pAfX!VPwqC=)WB{zg^s%L?Ilm1-$2&{a34F`dnw z#UjVccIFfRXLD!MYD@TCnKt5Ti)w2)H7&b%nAfV`mgw+j7mpe~p8p&Vo3X;cA8R|m z?8foQ|JiOA4m3GTOMY5Qj}<4otLZZxrfhFZ`kaqD6HjZ?RsHjOu*vSg2Bp$fto+~b zy>m~Fi__k@*dqBO$HQsJv_Fa+@AgN2zgYS7XMXosym8ze4mcceIN)%=;ef*dhXW1= z91b`fa5&&_z~O+y0fz$)2X;RP65**t<2m+7MUE@N(Q>}sEdyl5(xd$h2Qo5O+MG6z~)UZTB=T{&sZy3mehVe}A`AC%t*#Ax24KTui5678On~%U4{3rDe3P4VP?0THr#T z+HV*+ll*0S{Wxt>=3C-`==d7lN#eF=I%iKB_V4SyKGuql=@xMGCmwuYn2ZT=gh(^r z8e-sD_G+TIbJ3M=X*XWGugW*3BTiX`aT)!WfNKopDrMe4iF33Q+aGMsK0TTcJsDrl z!03G2l$9i|_XV!mv|ru>D&LqcV}rdF_`>Yd@gh@6ttZX+dJc+?ujgBd;>QlJ-#=#Q zpr=&+Fi1c|kfUfoW}&Q6wwB&*m8Klk;w(_+>+5 z-!5lA<5%B@>C&s{*0|n>UQge`G;QECpMTmQ*G|08YD$&!r{TEh`IC~9B$l7}Q0HFj z*L|tV57XQ9KCQ@~u#lPchK#@b_~`gEPD>I;eV;dLK-Ys3Rs2kE6aH4@hl+oh#Q)U6 z(eV%I-Ca!Y{PK-UCzX9CdK&c}>Tk3cVY>1H&E!cx@V3}j;mR2>U?&7e{@yDe5*>G9 zYIm{Z^UrQxo8EunfWB7TOjlqxuXp0btuQ!5?JDG(&;7#PLUgoyi~UFRFB^Bc+77`3hF50fV`f3t0YI@qk8Uk(b7b5=Cs3~{_NSBuP)fzkR$Gw zFkNM;zE>No$z5aU#GD#xS+let*22^2-+bT+!laUhoM8W4%FxLExyRPbOF_*o{)0E^Cy=P_`Q&~?e(J!lK0Ike=~KNPMp${@!zOZva+Ah;ip#EVkJd83T!`84 zbkW!JH%=WqVOrnDQ9~eLq~Px`dNN%nN{@nbDqP{?qQl2npF?MTYxBtWDV@dbx2%}7Y2Ilrx6Ux*zB8oH^yum9Z|<6y3mkL^2Ps+Z%IW=}+@$sB zmHb$n(OFE(ysh1e33XSg@6U8S0_kCW|B$b-LAgu z)>AuTqXjA8O`|8%b)xjJl?zCOe*G04a;_k<``+g|kLy5053xkr&|DwF9rdNoLo!t* z(~Z)r`iT8sjw7~j$A`m#-OGUx38dV=kW)i>fKp`^W8Ekxj@tbkaO$(&&toTrKMn`f z`V0pZp??e2);8M+-TbN6i_LvRD7!lCNX)-4n>`E){N{Rw96H0nRZ#8mYbGJrQ#+jwshXkT*dKx) znY0+Mol~O)=t?|QzNI8uWo@Y(fG)eq|7AK7Q~$RLz#r7JlRv-hjCJzox1B$7`%phN zcKdMtO*dTh(fQLJ;kV-UL8Y_1wSCB?qewKP5y-2?fz&ls-e9dO8wZfM3Tmd8`aR|m zHgyyMk5e|}Tl+ieIN^{7=pNP!7T)`HmzNJb-Aowm1Nu8mH_2fmQq{XM{Ti+Stfrwl z8Zf3C;>Ty_?6P_v38F0no>+ZZySiVdAudN59FWIx)5k@ZkF6&piO#D!-BBubm?u3N zc>?)hy2@8cKC-+e`ph9aDFV4wv70_+T6(w2TKs9az7@?KY!AldWDhQ`#e0lQt==?!i z-{x)qcI!S(Wt=W#7F<&4>^@1Osc3yIXdrJob+l&E>P%*oggMMBIlt-(W8*2^-fR9> z3xjWSdW=V(*DbrMJ>qm>8rWotv6tSQ!m&Cy|Dtk0E>Art z#Fmq}Pd8Kmpr9yTK&Xyr;pg$3`rGDOXJY$ zS%`LW%IW`JO*vmeldRv7nD0NBbmGVk;)wZgJcxIE;+#W*rw`j$%Lk={C!MJTGaY_p zRp2Sr^lwSj{N_g`iwQ}P{*{rYA&Xm)#UROpk)c{AiCLWdwm9C9S)qBVYO0Ns%B}Oh`Da+=6?g1l{A?@X>ri^^#@V-a7X8{yT~gU~zuVWD z@&X*FN0{Df99de0r*^#N2^a@f7EuI{(^CLze3s)Nn;8c>yLPx z2K5Z`6MdN!(s&Pocp(`gl{DhV`ig3LUtS+^dc_SN-mkc?pA~U;&s_GzaB|Nv!}B^G zxehb>PUImD)zZ0v=5%@-F|^Lh?uxf{DBA9u=P=`m0kY6m)mlEu)uwE3Yx;XK+|KZA zPvUmcb~xa0;P=Ua*4DSb&$o0?I~;I0;BdgB$!`zhk;=hH@Ava0684u=}NIf@L-H#1%3SnKzV zcq?gBiDh26o^bKKwSxjRwMe>=H0F(QFW!(^D{l4v!s@R&i~N0#9Xxl*J{vw;X&`iy z0o+VCsFA0;xLBiW@uquer+h6PspO}%bCsT|V!9H~*g0VFkn5=;(Eee=@~UvFAvOzS zmeaWcnz5;zqLtTWtX1%;>s3=SlEmCegO47%+;zM0W|8%XOphQnY>`zDxJi(1=fkf0 zysGh9v4$0^TAxad$aU9{P&D!;~ko9t?sCM&GOUG#5v#=VOm?$Kz{D0O+A9o8zTYwZ9~ zmZzc%qp$y3eQlCBpz9-I@8@frp(+s6+my&sQn{Vj zN;sh0q><0f+T(Fa;?cifEru@0t(m(od`8*{rW@4AQ^J8FhIM!toik_k@V}{en2tDQ6?u1; zZNABPR9+z-S*~&}vhqu<$Kn5sW9N-|ebtVVd6ox@a`S3}mUY~-=f&pJvLzpkTy@u}cX7ImOQo}W+_)r62rHMvl#8R|N?Y7n z{N+*Y`SZ`b{YzfsZLYceh3SlkO$nF6s?2h&cn0NXHF1u3#Edfo&L)%PzCH%7`VW)D zxCg$@y=2_buejafa>#VX!={AG+__@7$nxCtlIZ+c`vk3%{dv{035Q;JE~nd{qCxp* zI;Y2`l&-ssj;bo4>!wR;DrlAWD7p^2THh)>p3YpQzO}C=s9DNaLkv9Wlas_jTTgwh z?EG)9Wjx$|Fr9I*DdFLLKD3?2q#C__xp-OHv-C@?{88JH^`|F^gAaM@-o$_0{cce& zBSpr;bjHD^ghwx5+=8eLh@4NWW8kQsk|gR2x4hKzpd)Kk98Bl**^G%psSHCDkma@L zvgmwCnM&)?gNK$s9yoQ9iihcpgU#4@=<7!_u2eU>w)uXq&re^OdK7X$WOEFBoAyr> zTjykoRgcwmaiM^d;_}3FgBp3Zh)-@n$h%zM)YV7lQ(ezQvE;C!uJ;EvWU4rr9zkH( z;=-Zi9YTgkbN;1X9vxTefr;YHlg9c|CO_O)#l>{QDXaK!wVa2tyf?(5j1FdZ0V)jB-Q zGqjN+V|?Pu==ipJlEh_Ci;sRTz5E>&AJb)Qu(uLl%Nc7%Ea&e61+UtV3LTUvLRpu7 z{&RM}rW2HYC)1=RMH zqmN(!lF4nQMA~K6-5K{T1GxtyvdbT5>}?Nbh?2D2UZ*dx)}v~@)G#Metf@Y=%lK!5 zKHh_j{aNS_GhK;Zu1E1LM;&1rOg7G+m-m(DmwN&logZCe+`nV}?pz%M7t;K8;k3%< z)|~JRr*G^7?ADCV?oxdd#uW{a+}`Bh7@bc!=Ov0m?rMKZkIGZ4joz8Dj}3fcI^$q7 zK0JlKh(B}Vq`r?5hYUq{hd9-8$LYi}+ftt)3^ew3p=@&;Ffpdebh3usVE;3#c=Ct& zxU+mhJkZDoF1LsiG)OXNTqp0UG%3p8wX(|}@CNdXZ(Nm6>VM{ETbZE7*VcIcsNw49 z#kl{vK1O{E9(*t$>xFYd6NkVKW%Lt|Xht_&E&YF*Lehen<=%=CzgETW^7r=So1(V| z>Gvjz%1d0nb*m1Y%K3_6ceDpg=Xlw)I|s!Wz|nin`gkO+M3Hf9ih(2Xsm|if;lr*! z;fq6;;S2*P#=&%h8hJ+A8~T92nRnq%J5DF?*AxeR`X`0_eN(+C!Vk=IsP_S-Kb|N) zP7OU*GNS0b1;dS!g1$WX!So0M!xml-kni!@UIs+>cLajEqaGkcPnM5mH%IV*|LQna z(ZVG0RmQo4-deF`;xcTMC&hS}Zcro7FrK*2we*&T4-KGb`1_0ZpJTig^|LWv-n@Q^ zr2OmJ7Arrq=elT9gwC4cV+gLx=@Ym?$W=#)v7Bx#c?DgKZ{%>=?8*7swuS{1{k>n(o zS~|V8HCtZ!gf{c6HlNWP=liLPQWbOu^{Psb5*;16+(UlQ#_+lW-IL8ju2(ZcbY2Yk zaohM~(hGC?eSY;B$4}<}ET`)fI=j zps%vfOJ`-}Rq0Lo*kConrjo|{U>vZBaLMT+O}XA(aEEnW4|tFF2+-5` z+Bo5(pN>Ix>dI($yEdb<`$#&I&R^~K(porNi$hZ|LCrYacf$BF6E%N{w>W5AmS}`f z%Q2`aq``mY5onIuGaQiRy!`Ii^?msVPtLll+bvHsT9y};&hAn<4v#OH<6Z@|RmDbI zq?t!qOJg?~B&>3|#q=D|L1uP`-0*iQ$IbN=-h*lEN2b9J#eR%`(VwmH8$Bk+)!~3W z2jp@s?ulNm^9Lu1%a{9lY)CqL!RcmnDA#D8nXaZHm1|l@Va%~%Ssq`RDZ7UUvni5P z(%gQf5-whs{=~)0d!Ss%?N_6MyY9wC`aKNmGle*@=)3!?PfikVe(=^)ANAPl)`@1J z;(i6wDN2jVp}XyI(XZLyj`3E_2)J@QfpTh%E3^p#YLICSI#JyvB^Xzb@nkeaZ%-F3 zNfa+%^3Q8KE4VJ>fx}R zhaL5nd>-zJ=LIiFzVy*&h^#B{2dGrKPNs(~9)dzg;?kOY58W~Cv>mrzXwgzZ1jp4od_&<2Wyh0lI56ud0&`@j||D5OU;D9X8A(9{P+)Wy03Td?a zypLk?tw|!a=)eUtuDt$=v!;>*sYBC^dWz`=HS&zHk3zr3(o5eA973))>mH3>zSghq zEWWwG)9~nR7vyk%0sU)~ccyc^Y_{UO_V9NP!iI<;a({^9V-x&>mQ}noIgDd(8wb)T zn4CYT*H|Xx7}b2lJPI_Fntuk>dH$LlQ1b`lgvduHZ+^{OXgMu4f6&j8+wYb`IxfEk z2h{vQ+2OHvrwsiXIS@UKI&$Xzx_B)1xaQZD_w|~%)Z zx96b!KUg}7>m=ZAM|had@v_+x9=gp<@07~p>`hAg>ilhWS(3>3w%_eno^|~29W#)! zF=mGTDAPGzHpBC`nHA^;2js2V=B{k%+BWm5gp$!E6&l?t#0&8$vJh$JQ_tmAKB+iU zyh&oZZ{ug_i}#(Z;$%AGW3%lzjTqE=iRb+dE^#W3xu-Z#M+vk1WYB&iC^zZNsCdpi zvLg+}h(#n<@76xHVf}rHqW|@4_r9v(^r;zrjn)NE$T`#LuSM}dv&-BxGR9j<8`&zg zL8h+;5(K0#pVN=Di|K=I3+Z~AfE-L6^&d#TPVinzq_s4ZXfNu3%%sl#&r~t~g9cab zrVrK)J%kuR8<~IUN%sx(5#mxh2cWbs)_(|b=g~r>4iw^48UPu5iV#0#Q@A`KE}?<9 z%jhLPtQO+A3xt?DUx@eqO6k%~V7I*>MA-*Iobs~}^A4gr=`#{UxAFurVIi5%C5Vr9 zB#2v1Y9~6*YbSbbXeU1I-(LK6etU7-&+Wxo=XDS_C3O_8hK?fpj80?GnX4 zza)w=2PTUtle>t^R(2JkvE4-1?kVD(Fvje(I*cQS6w+&9RJr0aqqP`BJYB6;`4b^MDnwxVorHLyma$ivF-9}#oN9+ zMaJd-5Z>M|i?rY;;{DIsCp`9k--M>;MkRFFzd9l3jKv8{j$NOSH!`W+QAMNM9XIvb zcDEk)LAwKXoYemAukL8SX2yOU4*ltd4#($qPYBcDM^-J$30-U%zQBwEsP)NTh-Sns$L84g6bID&K{bN>;XGnH|KC$M z|E%e%`D2VrNAd@JL6Md7N4Ec2`SxqQw>q9hO`z>~mg*0AgtDfpWkle5d%-i2dRx!a zcPjOHoyMm-i?8M%le78FB(dS`f-@W5-gM;J!;P2_C)#(WtMOaMRioXLjA`fsFP%gL zPnh&Edj$GIC|@lt!U%t|P&>Ve5>opGzzo?0Ch!I0chnuw*C#=aaXtq6m*C9_q{omh zCw&d+XG!l(5!8@Qph%u3{Q^aF9Q7~y5nEoPKE)-}m$;D@cFm`C8i(~2BA3Rv%SVto zh58cb3$gG4Ax3VY{zG=;UCdS9C~Y_`0>>)qC6`_1g7pU z8lE~>c(VJ80f!6||JY2O4dOSqr}B7r+8S%V*nQs|QFl$>N9(S+c?IEt0xt&8lj%B9 zdeG+FnI4*($r_zspr5>u?e|qiCI^j)L(JFU>th6c^b~7)X!$#^=-CJ^tQ*01Aa#|* zGQvA9r|~`n_%Z*QgBA?>;b6HQ=|H%c4nMLAe^0c{expk4<>yw=~1M|kv@~Om-KAXmy^DY^xsLp zNct1for%Fmlg9k!rKF!E{R3$?$<4K-w~(Gd^7Aj!1tg5Ss~M`0-)XA00uM zNq}FSNO4am8ud@luA_C~*9o!oZXrHjDTJqq`mX;K;{BcpqC-Z4xV0idl>aqBjD9mg zoY=dam|EIS{O^f&;=+U4izQdJ7el&q5HoM>AYMA9qe%X-qd04QCozNaa$-}Wc)drm z7;|nH(X{VgqUMusV*ejg#Jb5n#D9|a7l$9zOMG)%A94N7siOSwBShA?{$lyybX^`; zo(WpGp4milL#zsqAEc07o=>8`;{G95fB2UUnTwEzP%snd$#k74Jtmx%>!LO3S(CHr zQrjB8R-n;0bC%zyUrI;*8c1_JSN|Mk04X<`oViD{*Z#d6nZjU zCrXd7+(!9c*DsdSztJaogLH*ya7<>tB;0yzA$o>!z7!kht)BZ5pICNVt%{TB5=7nF zR-7D9I>|He@p@gR?=BO3hk{8(Dy*3fH#-Htsvq^gT{ws4a9~$*KrJt5n`G4*nT+K( zmb;v;V|O_4Tjanp0>$lL#>~Yj~cz`$KF@HR)9aGPzHL?lj%B9dNgbQ z#%P`y)YTkF2WEvY8>U5G(>+xsv}u`^gXaay<-3x3AS!$txe>YCFJ2!9?vK}PaSa?k zwm`+rbP2L>GX@351OxXer#eC$blWP1E~@EsRsp!KUlpHz_< zZ9VTcZGCi{_3tE!y!Tc-@y;^|*S&?#J1MmD`2J+NPLv)k^Nll-K6+@|dc66(h~j4X zTupevCpT%B_|`yQHjVo1p4a<+N>(wgxc#;={|H$qFSUilz;-9_jh)%JkkuhoWws&PS%}MCs8o zt}&iKFc%vlg1#!vIHI7{rH8OlTEH)l^MhB&UtpupCqbW2`ZqnKgg&3*x{sGWr}S?> z`lQmo|M3k-pH?K>#@{h!T!^sY5M=yOX~$Y01I(@k>NXbb-k zIF&T`f_d3xgp1eZ?sxqZuU~O*lHB{geoEyLF+E0yf^>M5O@Ry zGl8B=*NM`jK=aS^7HgAy{u#996Ssh8dMa?79IcTpp_6iGS+8+q27SaEpGFh>6%<~s zFU6~|aXm2bqxtg|>~|?A&F5#Rbav18&B7W~kAFrkO?bOTSJBzKbjB?R$cju~1s&E* zXWvyC!x|PorxG6K^WBeJ-VS34G9QV`5el!&o0x66? zKt7nR6QxI3KH}c5TS^OVt+?`Ev*J?6iSobQM_jpb|C44dJ+lwW4-^eS=(w1!6QzfB z{ElygAI%56=6Yu9GvaiRxH(*BhL!VolY$HLcLT{^`DB`RTRZx~^oJ9Le_g@o`o-Ix zrr{A?F)pT?+JYX2G%ukimL?QBx^ABSWs3-XTaU`-&?&pte zdEwSl*rDJbPnE8d=}|zd*GaBibavEqmvMJ|me)^PuxL>`ZP2f&puB>T`Ld`fdVXzR z(Ot|Kf5E8vpQ}x(*ZVgvJI^b zm@uPqWL3~#tA`2Ei=lqu?|GIB<9&_#HypWSLA~s#-Oqv9lmxfyDR0JJ7qrP=``jff zmwa$;pAvmYi1YD%lddA3MAfu!7A-IF1dGeZXfrib&ZJUFbGwsH>B{jU&N|Z_`wJT5 zz%`_2^}WOA_~)J5$78`Y)TC2%7S$ZrX_~)Es~CiegH$SM#o9|w*r zZhvlS;icV=Q*kg|f}mR^9CXe+oq1hoq-}Zsw_?BliO+UBd2KK4a5Y_~x0G(a$4~9O zR*_Xvfe$EZ_(xV@@}|TLV0r&Ia4gN4`|QWv_jYl52A%|=(%GHg-(5V$Q%n0$j4@Uv z|KE=N{;TJnS@!n@r}yJ{IbD^`?woF3m6kR7UcU*95!o8rKc_w$1p zuim@<22O`@sC0I383)aq%?Q#N&;}g2-Kl;jHa|wb+tq!*bw}ZoMpukOrL%h!9KPZj zG)VyqW9ld%*K1n|50slU(oyd@f!j4xr*xjx*ro46{2>K@7>{SVPLv)Ka@{UE!ZDZ5 zy`UrAMwjr+5qk-dh0|Z~uC+fvP6-+GNcl#H2RaQz_fP!oy=}L*zv=DMV3$=(biFFg z8sTzRSNnal>F$@HmaA3jo7u>uP61sZ;&RsneWi34gxiZwYDFf2HM^shenRSdR{o%D zp&HyydfL@k{^OQo|r&6N-|*XUvzgHKnW3Mbc#YFzJSv^t?eL7!sx8=rdthxGI8H4*_Qg!C6x~`~F%Ff^?lEzI zAK9LYfHqbuqu$<3Q*dPdH))tWwy}T~C_FjnnClStVH>CQ@ZQN1 z57c+z%1&>H3`fiR|Hu0N>b_lsC^)(Ikdg)G9G$=U5G1Lmi**D{2TfK;S3gN#|GuXY zpc4Jtu%be#a2HV^u5Y&!4n*!IttUc82HEBM_US`kIrgiBb&nF+qFSQIRo@l_{oWZg zHLMR=7}3hO7JL{RSJBBmO26*Z2TMsTswH|{xJK0AtQ~V%w-Ie48O*P`&DMOgtN*|F zF>piQx%<7zpbWky2$jz6G(R3B84b7!Jhb4pHm7E~%RRj&K=sI2U(j3XH7@(2&-zLT zv#)BrHq*QS44=5gGb(6cN6&Y2L41f31YZ7*#F`3P)}W8yAx$%%TQuPZvJQW$hTG04 zPJ3tK_`Qb>5fkM6L7lTR>KG+3kK2IU(%3*tbS0{0f7=?aSwz2KLLFh_@-9A&-9Mjr z@0AbVG~&3s`IQVAPY^1d-MN2G=70ecs>}S;!y8%QE%Va18vMxL2Mgjzf8Xq<`yBc3 zn8P`KPG6<7yCwY`kH2J=$4@K$&Z(h6GX3kom6<<5uTYE-GM?1WV)LWn(&I0vUpD?H zF6%Jy{myj8!DehcMmL=y$#@#$z;o+0U%tEIy&3CNJWOXCY{tfu-ORV6afz$Ei$eH?h6ou^%UZNVMuI6cOr(%C&Wp2Gax z2z&H(dt9D!zOc6IcKxjz{x#+4tOMU0#OW~}mCo*TnV*LSboJ7~VXyz#&rbih^%GUN}M znVkM0S;bndQG4L^HydDwGTNmM&FF?J^-onC7*)`5$fNAd_kmPV1l*VAxa>@W|1Gy+ z?2fRq-7YSN)-ne|#5}n_(y~v(h5G>Dx!O7_rPe#t&1MowYS4D|`q5nfi|`Oc{4C1>JLp{ihM zO$DEvEaS@979CgG%0%&Y-Zdxp`|7M~uPn6UV!Dh8c3WID$Q{tAy7dPOefpt~&2cqS zSZ;5&#=tdsb)vZQw8u-2>)ZQWm0wJc3s+>lzCAA2$l1jeH6_%~!ib)}wVJB!V(NW~ zWfI;SjzT5QmDtYt`_rk`(^=lHv;%$9;pEbDtZ@eym^Oxx@;vJ2HDXTmcG{Y3- zU~Gk+ClZH>-SRdW*PQ1$V4ZpIN2I z(2#}YAO^nehj$lGFaKoU{-e@g{?D0)e4>1z+%SFD;KO~@)&*;8C7jE?i`{>84}B@; zwnKL0FdpDUZJ^TGJzS0~>lsE@Ro4W~T^)v9x-dj9VAQ#oNrS#LlWwk&2lP?2xQN#D z^A+Xto5Js2>5QMv@O!jM9xw}4SX-@O{a~b!B2Kyf z690>iH|@nl@pWOJbFRB&{8?XLZy-V&2KivRL5)1aczGX!e*aw_T~O|=aB{HVO*;6SpS60Y1>qe!sdox@SwzN=pVIr0GNSHlx zIiK^lN9Wt*mlMVL$GdklRo#}O<}=e77n{xS8H*GZ^S6$72ik4TmMR; z*!aUCW4@YJevjHtF`aR;89&}Q8ZU}8L^_=RG4O7FBT?M;DAG+ z^lAEPV5YTREQI_X=|4t)kA@EuMb$f_Ut9m`;t!v)Ox4KOpEU_EorY1`KEeU>Wa%pQ7`9 z>rvgsi=`L;Ja5P?-`+LO+AcGlak3dd-uTL+EGLt9#K8M$qR7|YfBP>>F1SsV6Q(mx zHt9%q^a=I3kgBp=jb=uQu?nb6gK)dJ^=OTRbBk?8ZKPCB2G=W_=snP$aJz!ZP`w{P zoyvFnYu7U2C5G2`t~mUY(~-li{T>YiXrl#uz&9$=hMkomZ7q*K zu)jZ>>EzFEJIB@hL4Qz|>)$r|KR&uNdPUTKJU@&6ywPX3zPp-_R@Ytk53<2^pCc#n z^VP|p_<6M_e6FTMxxbUxIZ=n;rl;MwDI5njj!!vg(Pht{V-^A!hf>YSboh}~vmRRb zJIe0kKD-YP0}*j;WR%AzLb33FOlLrxu<^E|itio%A7eX#{+{TsFC9s2CD zYy%nOAd}>P=>|3OY?+Vdlq7vtw_;nP<@>*=3+->Cq<|Nuy00;1ONt1Nz3Bbar8oU# zZfgnWJJTab4O`22)qRb&>=c_Q8oB*KtiTqpV!v$08}8Tgw}}#J>-*uIjPcmk@#NQf zH>6WXn(M_)BwtW&(!j3HPs43o-NjwL-gIqW*rAM4+^!kjaHX=MA5@e>Qw+4E4ZEDI z)6$moi@I9n8*!`Sn-5&F-|^npvVJtu<-STg!E{cSO*#Du)g`nVK)>ODkBhae3z*%_ z`u-&piMpP9()B~Geju^tWi@@KbGmFcPajLSn}65p^Ezgr-)dRlcltA!@;qGn-VwR5 z>o08Yog^N+^zVni*YB5sQ!Y2S1Gz@3TI}`%FG8N%S6e$^0Hmr}S6f zhv{v4A9Y-IC*DVvtF#``^Jn|g?&9sO`*b+^jv;++*H3db>O064(__AmWqh{nz(Z6i zsqLVec3c13)psh5|FhZFwEn2!>gmO}+^_B(kt^^^ZO215CyU&dpXjl8+)c;)Vlss5 zE2gV_vYbnZ(P_CdCDAc z@<-;zZ_n=J&u=eJWJC+-5BE#*&C_k%L_?jUp3jr^agvy};l2%v${z02VD898dyM`r z)9J58MOLX`tv?om8b>74Suegoz+9vlIiXsFC^X~Q8UxSTPm;uswR`O|b=EEORXj|$ zfT2IF#M5jcn!FxjQ>wKer}C@((7+^gg8FhBAk~H1~zc zs+U)oj@q>xNTujdAL;8~4vnmT3BFR>9(j;sy7T-n%QyOP;X@0^9!tsf%63Wz%1zpC zJgf1`B=O-j)9UsecV6EC5C~FOdyaaT={iw*gvYZiLkyAH&|F*`A;^mgvEPuE66+*0 zP8n~*VbSq!`Z`H;J10~>b;lz;D$IdY#>;dGs&3s$yn$+8mAUo6h*`!vxo>p5Dc>cD zCFeE#bo5`pzip|4m+89{FP4sJejETeot9|3OY&(BxPXcWji^kt&G4NLZm?SRhe7dV--!9+gD|ne6L2B4`3U3VlmLCzF zzoDO##2MKS{}Mc=&o9?0c$vPd@J0%tc?Ugh<3ZfAJoG#=I^OjO$>NAtraZZ3WN zhS#t>Fujd<^+`s#IxrWZH50i=;v3_hT7JdmY}(SSE5^(82vWlqH(tGXMXFoCwJUKl-n6vn zc#FCui`%>UA9nA3!Xv{?V2qdPJBL@{F9BBhE03#hih*}Qw`4J)zx%~oA0AnIqJo#{ zJA>DXjb{5jGrc$q$X8`8b4Wv8*D?Dq(fM5WU5Z#-a`tBL;{J5YhoP9yOgG74BPuCyQ}&a&kT!{=k-V%}yiZ zVtN>mX^8`uiP(T7<5?5~&(?jD#i&EZzVP{vA7vMrgI$b=>21JM5U2>V$FiR+6Ae`7rUGU_ua8}tTBpSpUKayi~gIMIJZ z9S9RhkX^igD8D!1yw%&U{@u>QdEG)7r%5O878TA%+x>+0AR`!QLAbt=6nnCaXhUSM z+$}gdI$viK-k)ceo&Ea$Zyl}jmFX6+^e2qBm3-xRcSOKcLl=_#&GX z+QMQP=OR~hc}+YbS$z1>y}kOMb{*Yv<9>$3~Zf^t5D= zeP_3%{r=bOwCQx$6BO4+OlN#-hH++A*SHFOK~Kem0Br&h_2hx`aZ!wPi;hYbC)}~c zGj`h@lht&Y&grq)Lb{P*AoB=K8Aocm_5IcR#um7e#XW^TBqaBL?X8>4l{@_YOy~63 z4C8=>8?EqIROApdx&2%g1IOwC)DNsY|Cbl;er(Doj~FSjyfB^9XEQz=#`V~`yqf`K zT=@f{^JnXE$)d-_C*O3=2_r6<^|iHqU^?SrGfrICtSiH^^fxvuxYT<*QimjqgU=m0 z`Soo}OE=wYq>T0g?H1D+51V0Jyi-Zu=W5>^=s_Fk$#T75V1!>NEhVJYby)j1be>gm z*I~FGPFEN!!Kjr=*U9vVfvc8wwCV@sP4`yN;HE3Hrm}`k>Ba%F<=)a@K{1J*9+ljl zW($3|HzteI$8Y(|fQ+W8LAt{a z3d3Y57fjcQ(xX|vQre|-2E2z3C2oFiJl{iyaT}Y<<0;+{X)Z6zV&F}AJ6UvjW#1g_ zj)C{xJ;}g}abMtNI{me%oy2SD9~TX_=CjJrw36=P+U!r>s7&)rxR>tihC(?3KBntL z=@Ab;y2dXiBSRD?^HH1-9p_rDyLdHtt^Y68%b&?Q$(rv>mmuoaw&LV?Qpo~*7#~h0 ze0=}KW&50ZCd#Jlo*}t+IQoclRreyvz5b$k`RFq>nDOI0_QWBP_qQ7t&Ob3(RF7U; z_tTOc-PL{}(K&osixe8|b`UySz*k>-3{OYUezGe{$s z)bAW3iQ(OT`1y){4}F979|~pyJ(;c(rAM>(D5#n4r^DrI{KfjtTx>w1Nu$AxEe@7m`bs+oYfOP=5O8NZTdmmYfX2^N&c|ta#DA4vPl2>t&gwn|K<`^ zPMB^1Pk)->k7r$J>pn2_B<1($d1CbUXmlrwg4zq7y$zt)yE6%v~#rgv;>0%7fpv*v?m`;B!DpERKBdf}& z0mosG*m7f>ykU{&Aty!ni1gKaWDxNy-EOY=VWGc<6G8guSEzJ$Zzd1!k^tQcIGGdVX8SCS~H)-1;oxlCp*GBhDM}~O13YBieZX>V2 z7Y8`GKUOq6Hs20;YH`7&DaT-HR#(h7mCo+Ae2c;?nNQmZ5Ax4V8m30NlyuMk&^d;u zKll_`#g4T0*L>4={?V{QF&>p}xVFG2cLkjrMx$3Q>I4--uJC<3qBf`nh>J!@8P|f7 zW8)gV8-*wRtwIeo~(>a&Oec1%|Ai+&fz;H^^`>M-Gw7hPRU6Y zU)<=P`Si@&8;8#^QU)%RJEk)pHf{4S%r7bc?h+YQc>h&A_p<>l+I37h;%+6}xrTe! zk0d>SbOz}H(iNnyCcTXGR?~9#qz;)gBp1@!&6x9^_S4uCG^p1^fm(KDI0VlVaY&IM?txrSWS3j{-7m5g%|2Y z`FHMwSIH{Mr@S{NcxC5dJ@JPW@U){R({-Zs2;-qPti&8Ai=4VjWr6&1{%xZ4Isb-i z%j$->Wp^9 zyroLl$@B=npJiP`fv+?eX(7RJYKZh8C^O9OoGdGz)l&^T<(Y|M`T<^%e_FB#%ztCU znQLC}avcDZ0v^;4OxKChBaDZx)ltSQaOa!Nu!XBY(@%;wPU>}y@>CBQ&w23ru$5W3`k=NG?p)LVltRq4Lh57{RiVh{6Mw*Jh!2DVc=}Dx|COwz*V$x_# zHk0l}?>&Ju3c!C!d#HZ-59zrioEapXX;dAIppVr>l;{bx;KfB9^#xSd)TB@y(?bXd zsz&wAeSLA~tPmF-C&bcIgvibn0{rHBWG$t|`I0g+k^V*GM9r72V`%<$X}h0pe|X|U zYQ8XCk3f3ZjeqarEYeex9ldF|?neY(A{grTy$t8{jcB42jGB|;RC`I?b! z<*OZ@OHVoC!L5(>KAh8IJSv^tG(Cz`dIBH5pNj||*FUGP7+Zq0WqxiYcM`#H z{h`*6`R^r*pHAy~+R+)uB=dQjhy&%7>Gap4!u+(K8v!C_Q5rz(F!vS@$Sx*d-NI}8|QCcyc_bdwx5?D-MSA52W5dbEt2r;d*B z!7g7K3CG-Rt8UzQ(DS~%m3(1(7=UT9$I(K*xTr&@i;s0&VRZ~#NNRoX@UnkRE$V*c zXd_|pa~N@z=>|3OY#lD62Qp!_367$vC(ZJcbE-A})bfQ?54!lLS>7oJFM=J4>j#x? zxJvCa&o_)AdD2H=v{^1=%1rm#Ku^Z8m2g10N#p(1dMa&GvIyqR$op#L8DnujGZf1a z(+z6mX&$booZCi4D$-3b7JtySS&($P+@-iY7neKo8E=Nr%l(Ij(~NN}#!1bhWxifd z{e^zHWB+~AnT&+_B@{Zl?>x@YfqWkhfA)GRbo@rlsbp|HyOwZsJ?o!+sSlXyOm~bQ z<&3e)0r-!;de777o8k0fKh&L`EJnUM=e@>vKRCM>8AOWt&vb(tc@}8JHCUGJ!o|3e z5erwr$jk}jM_TLorWoljJ2P1vb^p}!A362rHTd>{LOq6hp6NPKdbF6nevMC|w|d%y zsu@*uhnpFuj!c%v$+=d3;9aSUBZPU*bHmHs#ef<8Cl_y8G)J$D$cg#Ebangq1*V(iun|t5E&7E|t~@Nk zq6-s@OCiX&+}>_gaH#o!$R~9klXJnc$}LBmDM2nekaRHJB!>-7USAa<pm~`y{?xy3?UO-qVmS3hD)X1~Y@2LvV46GJePBPw8 zg}cnNv|<_q^qB=o#?e4HkT&GFC3Vzofqfom_X$2#bOjtxM=NxLDn!dTCep2@VHhHn z0x-YU5)L^Xq#@(XA7|wkE-eF~oD~V8V#;e%@=KG&t9NZX!QW|?cRJCbm|sjcsF9}) z&O$m|x=iz1`Bg_jxZYW>;AmFvK1deJkE-j?{{6gKHQ$&XL15Tya2UseSD=@xS?Znq z@m4;l>E~1W+qQK-dPC!9lhyQ@9!L7&J~rAIIUkxReJHN??E16!YG*v>{{F%@b&vEg zFjRv{xk{BRFW67pD*JmDu|8ahzH*L;OabW+cWZ`m@ zQkW<>y`H~(LaREh`L~GNW8ppZuD`DFy>Zk&D&EsfI;YE~4PHZj6tt-nfN?G(9Gnj0 zY%twXKNd}h-jB;KOBVlLepl%UnG3QKOdwp|nQoH9h7Hcq0b9AbTDud9&q9BQ^M9;K4+AtUb~yDrBq|EAfHlZ?I9w`On6D`l z69uQY;--Z^s_o7qa*u_#Zo>4rx2(B7Tg5xqq;tA#+ThjmUqvh9Tt+xJ9mXm1wQ-WQ ze4`JyFXpd%vfgOs=w@No$ZQCW(GZvm2=PVmJT}}bP*Vc^h z;rkjqM_-i3_|R6-aIrX;^x>rYlg9gyDCpz$@_T1Yw$|_90^%$>FhQ*AGVit2|0Ii( z=RA=9`4x>Dx)U9W<(}yVHS)B{A5-eB?`{r;TiWHusz^Vk=fdyx@#md6uOx!1bvBf7 zeEY&guZ_z*S;LBH>?iEtSR4-QK@RMx@`8FEDq4BrGGlxR8UCH8!+|}?fjwDXqO~1x zbIQw}lnf_rI}WJjh3kFx%QDL*(_1oI+ZM>>LXESvajD^*{|*OsH3!u4va92_iw|Wa z*7u7X&aTfEZ~2wuaqJEUc9sKss=S~Ka5;$9#^C+fpZu;)d6Bu{*nce!?1}P%cZ0m6 z@5f~&mi!y5pAa&lVugwLbZia>b`1xxa0%n=nD5n=e z%BcI>h3N)0@(j=47x0`t?$yBhL2Pw2hQjHZ4deLB$o8{l=QQf;<|5JB+S*!v+8WLl z#Giy1BBnuZ_?$nyHuwmc;l4I#j@mOEu*;v_i3E9%_D}8$f(8x6^@Z`zdD`U<%1tyr zF)!J)8yryc2UM&*!r<9)N-C3G&CJCNfg z)7Xfi$_LhnBF|O1;P@Q#*X6*T7{}-QhYWCi5Un0ye==vH`Ir4Uc83GIk^@e8*_GUM z;`*a=z$q_(^c;5HZ&z}_DKEQ{n@(JRbPj~*1^N3n=eo##N~~j0&#eb9(kg!*{_b~I z73W|AgA~3a`qPu?I#GIr&$;1qWazrfps(0h;mR3EM-cb}d3mzq&suq3Y7@y1c;_~G3Oo4A_u!CKtP1?H;I$_|eiU{nLyS5! zqZ_W4dtY(Fh>wng^!d$;%(Rjb8lCk{$JJI=dV|IZF7*_U@9P z^+6Qr2pT-xiz0oPHW;5xo1(9y1D9?%jK+;S=BN#gqV(k}n_&DXORN_dd(OlKTyN_fm< z?K3_^0a*UFFSg=P&*z_fTcXGb6`!i5KY9I9Ga>K=IGApd!$!D1ZFcURd6`S5r?_0B zV~HY1sOzUo2ZFT~kfA-*Kf();i0X<&Hf%RZ%?$W~Ovwr~M>!n$H94S`7nVUbA){<( zGah{K%Ubo{Qar7ttMNMj9S-bn4unWZ(f+CHZCjG{*5GML{#z5rpWSbW7{L9L*$vVA zCyj+kA}Rf<*_R#F=|J>Tp}2p-bb}gswzYratuzj+N~fq~`9XSoMp-14h|NykBCajl zAWP_vz(gI+nykA`{Tby~&7YBNi1~fDz)=bIy%XT(p&rD+zZn9nW>)2y+K;Flha&PqhCt|zu)TS{T?_PC3 z#zLXM`)>4Px=xfHG5en_jEtpH9O!rAJ`3?s90kN*Q!c1KOHMi^S#A%QPvnQ-ONE( z77Vi7qAf%!h2na*L8^CGp0_d?WkJTdzA-w^$?qqL$-{p6%j1t_&Hkj?fP*pxoJ=>U zk!Q;|=_1-vT!uMqtj}H2to{d^?Dn}tVs>o5CI{qs=%VEjIe`qR^KQ#-P7;IjC#_3; z`03D>bjKMK&SHj~FkL4~4|g%7*lS*6KXN8r)M83D-B64fwn46JuRjpvAR$Uv9>-$( zt~Bv((G=Vr z!a0xf0*$)Wsb85Zj>#O5$2roUkMu|E)>YuVZvobxqLR*kRaxk&P(&207Y=L|2c} zSDp*!6#Hs|xRi2~76{h(H5X5An8z1uB~JUy{FY6p+{@f>>@o+Oc2ees)$WX!Soz`n zbJ`a>8F1PcJFYl1aNzgUzUo)8->(H13 zPI+NYL`T6x5D_>on3 zor2wYzFEHFno8OkXRcU?ELAASzdXQoR~b!*&sBWEQS`t&vb_IRCoROPU-<{x#bGmqVzH-C0YDlq`{5zYe%QTbkR z($?3CdzTzHr{Vd2ke4FUozFSM`OU1bc2iX-@2yewwkC8{rm7)d8ih#e~9U7+L=Dz46o+Ot1>JBV}G+&;u_%z7MB-z z=isnlQZkMO-$ci;_3K2@xbXR}yPW^*14kLb_5H`d!E}=xHd@3{=nHx(OjLp9=dXk# z*a-`G37t;*WYRcy`%u!@*N^iJxNd+Sr;Z>dL{TAP66BT31H8&}Q&ECCPQL;NTFM{0 zq#^f?`gJ)V?-xz`HhMj~c1NNZ@zA7Kt}oek{q<(WbOgagJ`XxUzlz zO477K*fpWL#1qsC{hF3n%1ede?8>U~^F0P3iiq2xwF<73enM}D%KHnk-FyB`YadM# z{TBB;IepnvA9gnZpj`wmrkmuj5yq9}_tHY<@w9@O4vi`Fd&|l+KfsKf9rSyOgI-_N zNIHF{I_S#Ap)8rcnkxOQjS$7e_{zVF&bPX%B(c}o&%bih`=K|_GZ8R8riX!VG~=sR@TvKmSeGQazW49i7vCLxjqxT%TZ#N-I^vX77@zq~sDG{imOD^eRV;*j zZcESqCF(Oqt*E7!c}i^fQ})eehyu>8Vvfq(@E&e5cOm-KSG2Dit(uYXzY|EW`E`yw0{1p zgPHiw^Jc#rBK~!Z;40 z6p=4X4+AhQDvofz1oVt?jjyQ+Bckq?1<&djc#uTqQ-izIr8dnnlhf}r!L24Lo!w*M zG3qM)atl33h@PBJMc-TbqxO$`x{^fI#HPJ^pOZcJ4zs@ON#VgCrt6VPk1!rg06nS-ibx10!Gr`7AXtziwhouth+PVhM2lPH~)N;FYYl5`$nu@0<7GHyzwp2%Il71}L#KD!I zUxD8%+eX@DhYeE@VM!TC%17gi;*a(H8EWg&y#iT~zBf(r(>(;$i!>(^%>|54$SB{Y zp*p=8pt=d4lu^D_(-Q0B0ojwjO^naXDDCKWSku%>9RTIUWY7_G0-Zq@Ky_O;fXj%K z0(t;kN+h~>I1%7eHOe<|dSgv(^uB;T_R=2=0J!~;P64NafnX58r){Lu0ev^;3_$Jr zGr>?m_8$h)z;G}Ej0B@VI>-Q{!C4>^WC8m2PBzE^W5GC(3-Z8tFab;i`Ct+_8=M2q z1?Pdu;CwIzSiw|K0BnHjoN1sC6alJ3rh^&40g8bWxPTkX1Rg-;kuH9IPy(osm4Y%b z8(aYB`gRex7+eC%!KGjhm<#5C%fRK}3Qz&A1XqFi;A(IUxE5RoD!~G<5L^!yfg8Y$ zU@=$%ZUQ%hTfkCqE4U5Z4g%l~a3{D6+zsvl_k#PtGO!%104u>Na6fnetOjeqgWw_X zFn9z!3LXQGgDUU@coIAXo(9i=wcuH>4m<~*2QPs2;6?Bfco}Q}uYgy_?36L! z0&!|N7w@}NA9V@u;C)zqY}WyGwRJts4=d9hCJU4!T)qzMLVlt2PX&}Nv|SsB-$zSW zebV1=HN0vE=NDSXp;l%&{_0#XzhrnvIIUA1=)vKxV`V=o*BrkaHGHi2a~r?VaKNOm zk2l88a$V&36D592uD#GH+p_&sSBZM;tAQRv$8LM~k2fth81-OzL_Jb%Hr(8JEfMTN z^%&cuA}+Q){@B?lz1(%hV@5q#egJwzv`bR0*!nc6>uCDm-o@t`^z(ED*s`onyu|BKZqFy!@s&d=$g&4>OyaIxR+@CmA#|PR zbm~(_Zx3U;mk#*RUT4FOL8It0sW{S~Y80bf5o3|-mK~0?BDr9OMOn(WiO|j~mBWwY zT~mX2r|oF;N78bo$)*I&@fzidCl*4yS$40NwBV?fUCOcK`1{n2ecl&4Z+~aentmgd zgR$WFjdJ!E;vXlw9o7O}?E3cnni|BPIH<_>anp@EIed=aC})2m{@fzhEN8AC9U!<< zbvdcEr?&6-{8Mn>8LJ-8zvsbjvl^}~SL0RBKMq!4ImgRuA%5*T(ogXc>+L-WvE%LZ z=ocMV&wcg}4wui{C})2mUS$)rspiU_5_^Gc(diLDKy?1x&Y|n3=*S*?t}Lhj)ZS6c zAWO~l;jn-)eU39kVy2J5Aph{+a>U2=$IyoQ>lociDEF8R5~Lp9s(FF-obI0a;-HA&tGse$yF>cz98oywPWb8|J zpz#WOpa+jvIQj8&$57cV)%=@Jvi(rhSl@o4IsfTuUzCr&nGG42#DA0|J<>rF@iP@4RV-g-4Jj(&+%akO&y#trWDfX@!g>!p%$J%8dCrOi5JvI5A zAq5L=C8NNxy;-hGLrX)vc;qwQBn+KC@hTkKm0!zpLv&uSqo<1I}+&D zb~u#hHE11Xy3qHf-JBtuWq|c_H;t}eKJ;r?dDGRLpdw*lA!~tAyPidvU4z_?F-H*E) z)RLAyY&)64&TZhh^ozRfZsamWWvv!U9Ls4R(J7rX7%+i;!HIUK4WmoYKj?84%gVS4 z*_-QkyIme%Kg%$e(gIn6gIS+_HPGkhAD8#oHEBb4j#DlBagtHa{x#Mo-S6~LZ=%*- z7xk)a9otT?40~e9$%Sux$?>vYMmhV}Sg$b{VO1h)TB*-Z*bG=+zQmRLa_F7j1y?Q8MptEGF6P>T2m!K;U3G2N9dQ)F;su;0h zyYA^@{>hgVq4uk%`+RQh*3b5g@OWIFG?z`5q+}dOdeC!^ zUC@K$*#J4kQLgzb&plvIa-=7fN8|XRbt@Aj*Yh`>_Wm3sEbZ;p6vaI5VwYUzXj; zZ#I-;Z%(f&JZGW%ezpT`8^FmIr|&*m}rFxq0##4_-cxu zpGQ!5438nBG>PRzdk*ap{XEilCP{IRzuaQ*dABy^eh#)L%Z>2`&qIBl#Ca~=>K$(N zS@Ce2o^RtI@&0Zb^oW)Ji_Y)=Ny~*(5`4>+FB;~JJjCc0SXF{~{3E=G(qQA16}iqB^a^cD3XUBvvB zeq!wNnYH1#&y#Mw5j`U|B?3O5QcbQ1g+-+Ev8d%Bd}hP($$<4Pf?i_06sMS@r$BMJ;9djmo zr#9-Ss>}7yN=>di3H*t59%6oqb|%RPi_c>p^kh8}8moC)^snk2@~_ie^$*}=>3FWE z5nNbDHlezK&Z|D4|McjZ&l8(LM}DR|G!_v1`P2JEZ_h}p6QnOP&pG?4Pg9Q1)e?qQ z)Sh9vQ7eAF&Ck0rELt8W`)0|qQ+ec_>a?lZPdiZ5XIl(?0&5ba4PBnKRXy;1`8b0< zERUs+8hPk?=$&Y_3(YOvcIt%47E}wmx9V55L$g?o@j#E}H(`ha*z4f3UAGD_i`dt4> z%8ie2YVej(AC`-{(6%wXLY5)Jp!wo=D2j;n@REMf+f5YieRnrneP^?74%#NCHizq0 zldHbf^~lBDf?eboLiv+U@t zbmaaS(}&6q)p1<6@%qSVcx=aPOrKcRplegZSUZ{ihs*-T^x^s~Tm)uW3TKtWEBhzz zM-T5AL=Sy`^Az1jP#rxIT5wN$&UkXM=~e?fSz9lun|5WkJY)2V`ct!U#u+ zGo}wcA28GBC`lZsVN9PxshKgIBegG#`yEOh{_SCz>2q|apqW0$Zu%I{JW@RtNp3v; zSp0uD%a75Xk=4P=)KD|(?k8El&6jJ7}A;4dh4n#1>VZW zVn0t^32&}wa@t39!TwRhJKu$}_TdBNWnCLy7;*VM1xi;cz4~LZPovN69bEe|R=G6# z^M788=V5M#x4?mxZ?dsS_|Q%1!CK%z(zCPy6 zh<<&n>f2PRHDrwK^Zb?NO9rdwMeo|tb2*l)($F$^eGJZ%B73Ic5uMdpAoII|nQ1wB zE_z@n+cInp<)ucs(1S10;=!Q!+;CfQbp7)CHsl+a#W6J zX_PBsER65h;saJC_?(r?X?5gUOXQLGa)RF@_lwwHDdsEM=6AM9cXFb?DlwOb!vf-a z{cDg<$fW|ZfBEiHlyMN1_#$TE=$HBwJ(eJqC2u`{+xtIUw6F>7sgB8}`j+LYG_(wk zgD`$~ZM@TGcVsy6Rb=(6-!$L?E*WsX-g9wi-kKqmALo-!704)JIU-ps7iphJ@>t=C z{)ZwAF+6kIw7|c?0%ke8rO zp8u@))BD=&z3-k6*)Hn+T%2T-vw!e@HuT|UORmpjpCQxdR4~k+`apy)qKf@6%Px(r z&*IuY4s-jDujKnmTGMw`Sk8LzI;c;c$LjQAYE|4%tOKT41c!6i>prcP~WuJ|6VjVc6s{q>yv-JZ1WN~ z^)HfB=Mtzbv0RmgmboZF8D5t|IblnNm-{(sI_O;g)MC5Oho=J0;WSS(W-qp(-&6Ud zqL@B=pckcCDxfv#P5r4kEhTBo^PA{2r3H=mPHfh;)pFVQqhT{w|4$&*%Jv;YS!F@lEnPA&9n$OpR%0e z<#jNh(gsh5Z3)eWndWjhlzwQc{a}v(4rF@-4Ek(>-)6Am*Ldl?QOoVvl>Tn>af?aG zuP)(!cuGGTQjz7fkLYTw4<%1Oo@E&}v#T)#5E$z>^m4tu!s+)%X5iZ7!pYyNHGrDG z=qQ$py3zK2>KB}K+-p&FTqfwZs|Nb@zhX?nyce4eFxrph2dSSrqiD9Lnw|kc&x$Le z*N>z_*VkHZ|M{|07ST32&i6*S>MPpOZqd53@h#pF=*0Gwjdy!}9@$!)W_8-^He|bz z_+VbJd{E7SGKYXToi|*mPv>O#bp)*{@Ll$O7wuYu^;>>jyTcKWzI!1d_S^qqEGo-S#H0!Mb@=VVm=$njd- zW*M!;?Qr{$jGefzxXu2wX1ORklG~hKRIg9DD)x2n{jWdodha!V)8`-+r=CxoWR$ai zF#qT>jwQosEuib0eX2uNCc5{IlZ#y?vdxm`@>w1F`c;~*&(~DfHw6_Z;JXlY8Yfd+ zAFS^)?Z-~5pQ394Int{MmMm9(!bOU6J6wm|o1ib*gCw>yJfZm`F=nLpEXMZpN&<9#i0jGk2 zU=TPBoDOI>%Nbw@I1>y7sbCmL1H-`xFcORc=^z7)24{gxkOjtoY>)%Sf^i@hp&$~02YGl0bTfS05^igfXe4h;AU_OSPE_hw}IP10NerY1b2bE!9Cz!a35F( zmV*^wC0GUS2M>VNU=4T>JOmyFkAO$PW8iU61)cy;f~UaK;2E$MJPX!==fLye1+X5x z2wnm&gAL#n@G5u>ybd;kH^3&a8N3O$fVaTg;2p3PybHF0_rUw$1Mnf(4n6`OgB@Te z_yl|kJ_DbFFTj^z7x)T%4ZZ>2g73g?@IBZAegHp$|AD>WC-5`)1?&UAg5SXJ;1BR8 z_zV0E=t2<(YJu9I4xo?E)&uoHJV*cyKq6=e8iB^32}lA>K{L=Cv;fC}mf(0m?T*%< z4QLD6f%c#SH~}Psj-V6h47z}>pd088Qa}&T6Z8Tnf|Gy+^ag!EU(gTq2Lr&#;1qBw z7zhS|)4=I~>RxIOrQp=X_E0VSZ$S1iILhDLzARmsp!lX@iD0UYE8qNflJvp44$u94 z-cSABZ>sF7gh~AaELWwWehbgL*Hx&9iRk2<(2hY7el|KZAnt6 z3GuV@mV7+fs2|G@PCs0fwGoDzDRVq_mj|~NIy*`?>g{Ok_aPmwb9VX7_Wn1Gk~D=V z{S%Q3SgwhKtB_gfwnlc?oiZAI!BIJRuG9h_KG_u7O-X%A@WW>TL?GtRV892tL3$fq zJqT)R!f^h^{muXS`%d>_eg2t(%DNwnREd1`P45@JiNCn1)OzKWE$ei@!(!2lR~Kul z7g%nzX>h!1Fw>OqnGu1E%MNSV0OimfSWL z-AMWm0a@UDPy!YLy0-2BRKHIGt3Y#9o(loZ>9rSpSqIkvWU4FcqYZ?J79pau5z%Xi zs7Xt-iQ3}&))Cj3p13|h{Y68eM-JjEz%}Orv_sHnNWw*$>G&nl?Y-=h zrjqT+aa}Y2xbh>Ty;)9Sif(*XswKxO`)w}EewkjpJ}eRRqHBrq`;$9PZYp(OfAYs? zHhz9j?=dhO9Ona;D?(vWBW0+D@%pUA?g6@bZQxDO?L^TeFW7jIvq_6QB$?t!t2(IH zSgwhKtDrtS&O6QH@_Ms9_CmWeRKZ2ctNMP_J-6ufqx&@*V#+xY?U`SnO;~nnGpW}T z|6AL9!o`!jlcC^9PbxPoSA@bM%Qf9)8R4|$xvK7%38IEnW-GHce0`iX`E8%TmMcPG!Oug`PSHN3WYNBbn(g$9+S3AHIm=-WCU|PVmfN6mk7BH_zF$`pSn-(xFU|PVmz&~Pv z0B&}~`y;xCqI)d52Qu%2{*fez8i_G|qV8NnPwGRbw57G^jOoq)sej0H;Vlp@eaLQX zU+Pyg-I23Exb*p_wBho@>whZVe^WeW`W)S<6@YrwKA`^Oflun6gBa(l+kyV(%hDdW zqVj%aScY<9bnT$$AS_pe!Xo&bWUe@;ks9d!rVN97Dz|jV*8Sx-?2*C z<1+pmacxXz+7XX!mFJQX4>CReF$;uCpTiNkcr6vT4@X@8r7(@@6U}zf{QgTeIhxLe z$7k?+50P|>ls1v%k-~{34`2tr?r+0&pTbWCwC3@o;(JrOGw+!8*87bU&w@WW+V3nZ zS*{3$1&;++28Bm^k4yL7RQ9xKS{MPWS-;Y!V(TZZoU=Yrmba2#3XA>J zPk0|m)lnQ@nEZ5X{T>?r-1je>_Q^#?`>|Y5P1)Q}{ldIArRph;7pQ`si7$~~wrBq7`Mdal?(hd z*f+dUaGaQL_Pi8bABtwus<)?STR(lEZ6|%cVY#4+vPt?>%Quu`lyQcbWiWzf;l9_Y zqY>55-_p|m_ zJFR!_ypG}`r^Xd08Re=k-k-pPCRU5GOh+5sv6v?9#@AouOlN7+-)r_;rpz5Tn4e$Le)X_7%V{6cWm^5tf+D3f&?`B*`-7y{VxM>Oy#u#RnswS`945s_ z+8O2SujB#QlRL}qD=0!SRIRRQk>RBoI1Ia}M~e3?%b*uIwuAA0j{G)m{d{uj)*o)7 zZE{_-rBSYku^1!!EaS&zDqj!q%N3!pm|*qTmDe}DmUJ0kHt={! zO=XT3MXbJek3vMVJK#9cPMe_*xoCE}^XySyx1WFNFl9$9IQ@)r_7A;KXc_C5{q)Wl zIs%;IZ$LCbNPyYBeq@ziwAw&qsg{%j+gCal(T<0y-F~jOAWG?5<~z?)^Ax2^jrE!*G7FN z>`=2ij%EFfawTvqBI(C3iYnzMaze}RzI}`1XZ?(F_Q#wP zX?SEvGvH)T^~#%nqW8d@6k zU<(9$!bCgd<2=cw0ww(o=~A^dK^l`k`OzEhk9*E&2bL=V2n&7u`qCvDL(Cr)A4J!K zf=@}Q_tC(6``$d{VSWB!xuAlwNqWTY{|aejyiX*15Y(QfHN~pfNLXVt=-4kP_z!O! zOXvC@PR4^ewE!{!)nnnFw~1|DV_s29uNt+{@1PVi57t@0tj~1ji2BFOhf&RQOn64C z&x{5*nEVp%*l;pqoX7hADj0y<%|ky7wHL$9zd^Rz(xcOyCat{f7pXU_O55!;ELm=} zXK)-P&v%h2TW44cG36|EMU0?ZMP=q588c3#PQ^r}n8*pUB4zu~c@nz$87Di@H6Sa~ zhoiedw(0r-w$(uIM}M}(pLzN1-x&2~`619-31SVFY|pA4vF%ys+y&{~+rIc^o_0q| zdG-w0ljSwni|%BDHl%*0konZPk&Fgcf;L{yjPV`n|3_n)JQ{U6)OI(+J2VyuAQ&#+ z@!#nCLwWuWo=2Qw{BHX1Nkt#r)0dy)P+p^XOju6)h%Rz{snw3-WUJTZO!ZZ(Kh;nU zcX^IfRwBv8b2GP13mk102q5E%_uF-#pqZDCo>VfX&p)9V^-Yp9^MPuIXiGDFqFLw2 z`ko}vNkMy($E~b+FSVHJAMv@;hHv%l&7ts51#58JH(hql!=~i@ z;FZP;-~Hwh+9s#gVR6;us&Do0r4KK2T8r_?0?fvrR%CS+%Gv-M{{BTx=SQWddvy1E zp!4Ll!m+IZ&8dp%PNjCBJ>W4R$=L1)I)ToBZlAk?ZlF6z0X;xZ&d202O}nlF^)icnbatc6)tCwfghmXR2wfgwhz`1A#4EOi#p zcN20UaLD8F^cZPJgCyXR0q3h7(2Mic`!9XplCE!4G=F~1Kyw+AQ}c_ueK1S$Ii!2H z-Y!W9nC3|2?{BQxm?X8_xN=kZ9Lr3~H{?i1dM?azMJOzccF_jasCJQUnJ$`7RsHmo za#S*wY>!Il!}h3eeLkDcS@iGIwL#GT(pry{lE3l3iqj8XilcoPO%!!S=eIwO!j9zj zH>^nEm~ztshspxR@^YxcjTR1-5h|CorZN$!%&^=nH!zavjtUDL$?`%5pt2CDJecL> zsK_Fw5`qPeWO?E1i=a+$ll;u`5;TXoag!aBM#`0obUykO~GIcxB7Km0}SU0ZwdChWj zZCc=1vp`MC%aO1Nwbx8%THt82z|mA*%rbJcbSit<7>3vW2;&w}4q*^!A{CW_hV@6H}sE zz$`D-bAnl3s@uers1~ScyKNbE=l2Y^;r%pnsesyfQ@&Q;W30Rp?}7Gy;hSCgO(pl# z9ryh-=*Id*+Kob8>__j@u^fMOE;#Rq@*Nv%fe*7CV@4sG&3vNEJc#Lu?vF(>3!9rd`Y@%L&ha3mp7FzY`Eg)Ei-y7 zjMw5~JyioM zq+=uyV|n>Eopw#G1;%~oI>OfyYBQM5w7~vY;Ako@#=OnvL2}CDHrMgW_iE06}yj0H#W_hV@6H{WAmq>ZQEH9BPW6F=k>x+0#!uS8Q zrgCCB(*n^f5J2V;$1g|QH=3WA2czvL`tdP5c0u$rw^a)m(}(5@XSvVb@q zxkwxJnTnk$AB7tq`iOr)(X^FU{LSI1`7KT|%Gp0SJ~a5<*tDD+OGYt1fhUTiyedHSvub?>Xa znDt}*jdJ!sboyf~cu0K7qx$d9f6_R`%|e?Rv5Uvw-v*54>seT8xBvGa3C zyK4Cay6aPivbf@=U>WKDN!3l=kMD6rnd%dLXt7C#4S4Jg}fw;jF>x=!V4{CC68PYWR7RO6#ahs14Wwd=L zAtelFQM1D&@0EMu%C_Cl-A?sDe(tR7#U zYos0XN{o|jc8^?uwb$)(dX>&ybkJEHj;Ypy8T$U)%{9>X<>MY`o8@2A;YUp;)|cgi zs>Z_a!LK6F#mpNkFwQIK@9`3pCiPM@0de((qS$?SWlx^dvciijK6g?8x6-onc z|IjvLJV*Xd`_ew9Gc9nWEf9bL+>ck~3YBZhpGn=d`B-{N(mwk|i`~Tyq~6(`$AxKk ze0HlNqu7l(dJu}S-aj6)q47yl`dByhjPy?w{D=>jz)IDNafQ zstb=MmkedNow5z(;mN^!-YIBn8_>P&NEhi^q4`t$Vv1Y;94#Jxl;@_jiIZMUocj(o zrIkBQYw}G0j1II-PCegR)#R!#o{9Q>u4#6M!!l8xnw^(p$tiL<9S*c;(9p5uSUp}DO&h;M?RD4BtF&!qY`t#oFm}`Gd6`2wUe?PfXMdx8vYj-I zmrPX)9+bO^$-lr=>~_dLdi-6j{x}h`aP@()o{6-dXm_`#2In_>?xe*JUGg=@N$WWL zZr0?aqv(R?H`4EP$_|S#Q&j3SpX^aAZcFv%mAPe0s?Fw+y~+$yqF(Xd*m~7!Q}WgJ z)z54)>cw(VC)(aGy+#yU?T&1xqfDPq12xdgx%cOL?em_!g5y{9i<69U_BZO4>n|)s zYY>@JF_&OI(OP=F2Kr*#t8dlWzPsOB+?(TNy^M19-w(Y6Yw63+h8pO#aH~D{-TaD0 z953r-l(ToT+ihDW83Mpm5=o~KYLL% zeT?$`(nqk6sLw9wL+6_cXdSNp9s5&{pIgj(yo%#v`xxcyAGA-VYy| z-}mIQSAy3k*2gH{KYc<8ChD^U`cU|(fY#yCD>3Ie`%|S2vN%50$0%q2pnVMK6*7)K z!IE(xU*D^s4`1IeSoLLXiYuV`)Ac>SG`9T`Qhr)h`ADg9J~&iaQ~l0zl8G*;ub7@L zPjRk)YOx&&ii_$Pmyh?7Z9>v2!3416^0==C`Zb=MKkl8U&g!JvF{B^MMcrtdW46>( zzfe*uK_z3!_D#PqWZz52UEH7AC5Q9=oX(NY6Pr30Nv_+ehJT{PQ^O$4-AoJA$O2;h zxeethRy%)6Pv?&p%>3YP+K(Kql#5tBw0ydm)C@ zjFSswj5W1s$B6nAT@<~)V97TPq<8zy>V1-B*^W3(AzD#?0m}tdl+7sm43{0&GHT) zxJqs)b-d>LtG5h(XyZ%DU7I8=gg@!Wa{Se~1JEzG$mQ{|hRYBd>z8v$bo<56Zz26$ zQEOzs)Y_$-zu0~(*C~fTHP;Vw^QO7|;jO6ef8J-%(`d(CMGd7n-EZ1-|J3E*?NLuD zXh)VGGCg(H)aw~2k8aOaj)u~Vq9)H|KRRG(J53?BC(92)PiGW!>iYB3FV*X5v}aXu zL#f+uvsRoiXZlrJwE@MPFIj%5^fZ`Lr{^B%N!Q*~Kx?W3#PRLB+zq8yQu=>my`|sj z1)830PnP2lo!gK6N%qtx+QtJPi>{dK^jtD0x}GV%hSH_`ej3=Va_YFeKB_uwPnPSH z#GeD#Q*TkRpPPVv1#(Glima87yHoK{`D`&)tt}8xG%+vJBhCkJlEDvdpI%ocV3|_E2k&##NKkzT}kDDe(KexbT+Xs^+l_xB9G8tzJ3T zJ{uWayxwlBLHzcDyk0wZe)p;xI=6@8B%_@DqsMQ_cGyPXdS{oFP9_{Arc<9A^!fZN zq{Y|3eOUu(#m!A}D2|P5&bj%*9V`2Cd{k~pE2EtKYphSGBr1ol!-Gajr*k@e{WOO~ zanW^(vPd0J7t{mw0pEL4iqf;>hJc`hBLuXkP3!@G%y^D03*RDkPb4yXmA$D1a#9q22fd|#2X97 zfn1OW#)Ao9BFG1mz}es&a4t9xOa}DQ&JH-VeMEnq3Q72F1H2LW&gxD(t3?gsaOd%=BR z8CVWhfR$hsxF0+KR)aO*LGTcG7(4_HSjvv2;Kmjz-I6!*aF@HZ-aNhR`4#^2HpejgAc%mU_1B-d<=Gg zo!}GjDfkS04!!_if?eP%@HO}bd<(tu85f}g<8;1{qD{0e>pzk@%( zpWrX>H=v3)4%7nFu~P@s1@%CE5DyYS1CR(Bf<~Y*XabTzQ_u`F2Q9#Hpd~mSv;wUG z9`#6VK|9bMbO0xSWY7^%$4h6>1#|`7KzEP=dVrpw7dR1|1T3I8=mYwKexN@X08R#{ zfK$OhFbJFmP6va*8DI!F6AT5ZU>HaP!@&qJ5{v@rAOnmBXMs$R1;&7EkORhoaUd7u zf$?AhmKPhJa_@D2QPw`z{_9* zcm=!)UIVX#jo=Ni32X*$f-T@J@HTh{Yz6OvZQwodKKKB92)2Wdz{g+**a44Qx>&=fQS%|Q!r9B2uS2dzMB&<3;x_;ilc z9&`XFfMn1SbON107tj@S1KmLi=mC0yUf@J<60m^YpbzK^`T^=V9RN-Sr+`zzKrjfL z22KZq!5Lr(I1>y7sbCmL1H-`xFcORc=^z7)24{gxkOjtoY>)%Sf^i@h|i>W0UV$hH~~FqcY~S01H8Zo{GbHP z0@MLf24;f`z=hx9xcoaMa9tTz63GgI%3Oo&-0c*jtU>$f4JP%#~>%oiQCGaxX0A2yFg4e+7 zU?X?~Yyz9Xn_vrg3%m{90b9YlU>kT3ybnGAAA;@RBk(cU0d|5Q4zvWvgI1t5Xam}UcA!1z08RkOpd;u6 zI)g5tE9eHggA~vM^aQ=YiQpt)0lfh|C+Q3Nf&O3sI2oJ*P6hOy)*x^iI2{ZIXMiE# zOfVFrf?*&H3={1DAs;hi_blF@&&Gi7_ zewNMXS0I-P=u#d)qpcs-Rim)~yF1pFK9(ds^L^_@lea#3%G`K(z;y!D|HE=cC@j?B zh8Er1#1rjKn`@TWl5X|bMp`k3$ve{TputzN4ZRDwa)HZf;~?mMkoB8#qrTrmhTk;M z>Qm$^ZJrHl`PT6}O9!n^q7#54{o=7?xgr!6(e$G++)zs%j}QFWXDdU@b>q->#n7i! zRg%;*Fn4`=;ER^jMkB}eV!0{}Ez@$whd0()vIpamf*FIYik}><Y?R{uhs4P z_7k)!k6lR4V>@ur0Oe7jz4!xO!Mp`-$b6IJnZr>XiJQ~ zad~VQeIvHBTHUGFN0K+TKMP@RgPsqsZTVt+y{6I`V?LyFUu97 zu!yJ+8HF04X_#;aDL51r3gxp{&)FzeYT`8nN#Hop7IX#{Fc^#h)4*kbo_%}*x+8q* zx21kQ>W7(tyn8k(`}^zSz7c`mhd>u2&>0AHIs)B|K#RNJKCd^9IRp1DIk?xf<9_i< z-0$MS$s1pxKcP>Y^e{SiSJ$g0%|=Je2;5Yzyts~3^XWx3MWj~voxe_SKIYR7Wlh_?{$5K;BbfgZF&zUj z($O8?RO&hC>lyu1e;@U1bFyS89a*jjg+;`4q(Ug9qnN+@+!Z}PtyzrxG<(|CMgta2 z`u=>n@`m(axuAlw8Bvccm(4!SjytSSo}vSi0p%-tKX}jG4W#lXM<*?>RlfG=X4~9! z?G7M6i0uLVRj%n=f8npvxSb(Ek)dNeGD?(wBWA%Dxp(@O>I+1ZamQk`V)#1o=722I%3*86i+A$D5 z!>LXGB_-on&QAg8)A`4#i+6wb!KTdk2?Hs{a?PK{c_-hizh6v*AC$=w^|d5j`~k#I`88Dwm$oU-i|=na z-oLM@|B}}ls_}ALHcnzWcGo#${4}nc26Wn;>TdM>n(Ra8Kk&ZT@i#2Zc>BRs+g|5L z`23A>_BX~q%7z5x z5&t9Bi#ezzH&i{eQIw5DqX<)c7rJTtmr{M*=+22`xJ->~t!i)fo1 z>t&RyzA^MtF0(u?afDh$s`H%q{9ZML09LGD<^6iQ(fudcj>oyv5lQ}9nU~FKQAOM2 zSU;m&^{uYoF#lA#p8DNxdIOeTo6>4ZZwAf3;=}DGUTw^yi>`8I5!>CZ9?+5WJWz{nh4}`~lI8MyNS4*UqS6JyiN&?0V?LS=Xj5`upy^953r-l(Tnf7V2 z54Ru|`s>{idHq>9kaz!XChI#Ph68Aw_ zR=ZPuG0BTJleAagE#okG0A5*AU%^+767y5a!+N_I^`Qf9e=co^KfPnM_P$ZhD%DsY z%xHj*7g!zIfu&e;eHegVls{4dt;q(|kJPF&uD9=Pq$*0<;MrV|`twBUI#L|xC!?JG zN2O&2N7P%g-LiK3ql_=+c#|H{+hgdkCQ3fpd@{zCOjtLQ!kT;iEmwbAvgrm6m*X|c z*`MN78tpWU|EyuUdVh%_zHs-)r~dZgO>Oda=5~?Qm?&TLz?Gim91pLR^Q0H#WLuuq zJ0tj(8m7mx+R8!?O3QHopLeTA_4cMV1YH9v(XaM&|C1J0!vB%}TSs)gbN&+YBS(5r zzGS%~6c(h%IJpp)Uyt&jI*sQ0p$oFsP!Q951Hvbl3g|4u*?r8tANa5RS#rKbD8nN9m=Y8P}16Wp_0dltap~?O@b{0)Dp5xKrmXo^%I| zBO*unqcfH)SA@bMZ2q8}p|mjZey%~IaL-Mt%urpbMXB^PQM{BCv?jv2aPn}naK|1= z8S6;rOZ682r!{X!)2}A`L_6N}`}bHNfW#KB3!>)S?QgCF9v9*MtQ9fu97S_o^kNwbXt=%)Hvn-K|I#c-d(0+*8pxORzV*MKNV$;Vi_nLu%OOd1&5IPihI~sk2VSs9FqGp(jB4@hMZDkF9Ur7k2d=e8RU^ zi@MTwB>6$d?ATy+*~+-*A586n5WK0Kwx?I+LAl8ggb&lKn(#zS$GYyR{c za#;=ZocPJT?q@q~=)R=lngkrm`AEvwz&xNVb?0qeH` z@r&V;eqz7Ll=b@Z6t3Uoqo)4&gsc~z!Y#DoD2ya%$#P8`T;CsoB%@LawWYOTd(}(=Vo`@Ie0fmOnQ;^jB@sm zsaKjqwmSW8RXy#-Rnv{aNCs@zWa!7w-#?jtVg|(>(EKUg*TJ8z+o^#3`1&qB|9;xt zsn*CFt}pKke{!^r!;toxjvV1IlSeAD7Za6hK&P-zhJ}*025A zUgInG{d$d2Kb8xsDVzJRUpo3!T!kKM@d&5CST~L?9{rfH>^ER<^KVX?J7%I$Kb9Xt z{U%r)e$=F@E60lMnDUCgKBZhsmHuWt;(9lG=M-#8$qRlNwtdE4dW~IilpiRijdDed z1=T}oMRLImJJOLSg6GaA_y-UG#n1gdeB8mV$=>8t{X%P1dSFWq^T3Y&cOF#^wK;z* zL;j%q_0%Y*@?Nk1J#|J-ujRZ8+y8xooc)#j5xhL5Tb-DL#)GRAU!jt*BgIeG(G7@S z44=X-*ZirTN`Fr)GK*1 z4q!X&fgWN!6o+`7tawd-Jqp(kR{w@s#V37m>u7qXogA$?V99btC@jMEgFz_vlPVwF zz=fVh9{aTC(xUy6UXQNVx{VE_&9m1$KKK2edsg41?o03OQ2Mc4P)XU;_Y(&DORK3O z>aoP2hq1qO&t}Y@v+Azp`^pAZ*4FI9dayjY9{T8mou)WQygx|6`I1WoN;HQ4?8+?- zq~m9_uao!F#cPfBV7U^2u+ZB>-*2kdNirfqsn zhWcDB)xI~UdNS?<8stNHyGE>;fw9SKJUiXyWg7^ zK5$>Bi!L?l&2kQx*ZZY64q67t-ekvZHP9#bt>33V^y1TFu4<^pNOl|mJF;ArhL(}_ zp$F(e3)1w`A>%35RX=j0Y$7> zb)xOadSzO@zAQYWKyR8;R^LR~kK!ZRv;1Ry`qTJADqvMF)R)GluUSEQ{PD=w4LVJ} zCoNgsRk3F;ELl$bh%Tr%Z6IsX#N#9JWTMc6eqUQ~_FQ^B#pU#{G}Q{A;wqKmETCA~e=- zRL3X}jl(D-wkHCgM6ajU{gxy>{pOQNo~$=k&8A8G;OGdtzOY;o3X5Ppt(#Fwd3irf zb)A8aY+%eDJ;WQIF~RQTw^SoPpWyR~RF4X(n45>u0s|4YnD3(HIZ=(A13XR)L)<>p z;U#PO(Q}V=C?EVi?m7=C)89&>{|@-`_qfCPOP@B7vYvc(?0v27JwKfP!0#|VVf@rf zZ+_wWk?fzZ#V+~TAS%^bmvOND!C~{7_chmt&jLfyz%Z64ddGv( zz)Xk3XLmE?|AqyO<%h=ho8{-fk+$Yp9DWN#Y9AbE%m;JLI+$Y*RNtfhxJoEU?E~ru z-hg%^xm2Lo$}m2G{N8L)`^J$Y&bY916Y9B8_Zx=2S*{3$McDBG5Q^hShG*pD@*(Be zV13eeN7rY^_YI_Jzy0v%liRQEx-q|n5=1(dbRWrbMJO!v<0XRQM}jJpV_%McgCTz7 zxRIp)HIRz_y1#E+ixd9H*BZM+aXiJ(a{Sdfef$)yI9fzMjyMPBM=nx&tl5k4B8gYl zzNK!j^ZERTVt&%xdFALK=m8o=PUCej~ajQ>=WyLEDsnl{}0!-HY)3h`0^0avZJcSoWj; zd@OD6kE1Zi8RJ)_>awO`i~I4m7_Jy5ZSy|HZR39C|Np)P0>}*FeV=&7Vjg8V_XWg5 zK+y9j%1=D59-F2+gcb-_pHaF{Jw){vZPVB{advK zAht)``}FM*W4nyb_@-&|=PkUl_t;k2MUhtRP-<9iv`UW0UScgMvnVaHV8a9r5_MV) zWfm10xxmMjV}sj?d!P@6p9*MAWsu6BI6v4GllxEDn|+!#`=+`d%}dB~?5=ZR^$AV4 zDV1Yyj^F)j$R6~LRPr75C7OLAIRo!`lnmK{P3gnr=L_Dve#NI<=nov}NlTV1e}zTZ z_|;FODtnb<$?@+I;-_%KrN=W*oqtPWMs4~mk>Y5-T8N+JnmD)$8~+G=8nsM)>8S#H za{Q&gh0Z@x{G*Dltna=tLzy##BH{Bl%2|Q1@u$mHhp#A0nOD=R<_1v@>36*zHUviL zun+M3bw3n-opQ!0bMEJOSP!F|{U^#(@v0@g^@)jBeOCHbibb2jQ+WGJf8S7113gmu zopgQ+&qsI@RCTO}QO^G1^cZgU(tL0DM7#2eoU*HEkEB0h+vEPfdi)r_;7xT<1wvpw zjPhuD;C0Ap_CoFT2~8Do+{m&T=rR1u0b5GG>0Q9_upUM^`-ihfn#<$yyM6Rx+jvX| zr6d;;ZW?Ba3K~eXPoF+FM5D6cus2td~*F{^9h>P*oAM(C3$`8tBpM!pUQv zyrsiDj)(Oy%Gp1h9zmlhk8M?T#Ckpbuh{n3*{FE&jz+$#I3Cu+C};nudgQwNo&tHC zT=JBwt;G@(W)ML=x7D(FYoY1WUn zsZArkAG~YN(zwNQ7Srd6703D+km3RLwcuRbA>O|`FD+e6!z*@26J$L$q zyW35uHJiibc#U%QuNLnZs|QUwWo|FpM?CK}HHd$1$2aS@|D>vl!{_*oa`vwt|AgUW z*K)w;-KTc!^SQ@7$vVy+Uax<@%y9RHdc#Q*lM^`4$$ zY0bB!!Rxe99x?tbD<(sy7wW6W-=|LO^FQ$AvdrIsDvL)MNrw<9J9(38z&7YB8Pp?O~>&o)umY?o- z?EbWc78B{w0(!7q69-q}^~l1U3L))iXVD&;YoJHq(mHqj^5Bxoje4*=sDQQ+Ne`P{ zuZgI~zWC_&$giI$J+Wrj^Xu2nf3$}d52X)12Vi;4^a$A^7vI65o815mOZ9{}Zpau` zr2mvA2kQ<+7zeAv(R}uk_RK{Y3dvdtEaF; zJ<}WL^K-a*=B-iNfAKH-CnmG5J__m4ClDCu6&#T<~;4sL^(L4lH?pUq}g@wLf0gwNJZ~d$F zvDn_vPmFD+)SX|rJ9&DTwZfMwz z@((#$$6?8GMJO!BXQf*3VK*-(p}`<#e0s-KK&@8G2&>0Y7Mz;KYvH$)v`#7Aybu9{ zUg73Xx^4FM_0N6$ZV!%HO}9A7C})3zowUiNwXft_=<4RpbJ1Ky9*b~yp}&va&^UJb zef9NYn`Uo0XCcR{+ATpc%Gn>^zVoBdmsv*5a;JK&^mzgwdUWvy9%gqU>jf>P9wDaR zlqRwD8TMA?#kbA7W~MP;vz+zdb#yx^1|nloPjj~4SAdW8RM)Fd4eWIHxT3r^p3|3d zylf|m%s8Gmni+No73>E_9;KDtm>L5{n-A+MPIFd<(8eBzEzTt zZltK5W;yG@Yc5y0m`>Z~#~e16v3}W)PT0cWWn~Pe4zoH?p}HvJX$Okexjs!}=c}b} zUb+3l^Xl}VxoybN8nbIiELViW0(AmSSw>Tp@uviWWl$C;%TIIR>s@xIa;pLBDN{8G zB~sLL8}uZX3dlI&>aWp{J)hRF_@&@|FQ=zbPT`Q7V3+Zw?=dbXPgFm~U!3N0xI9SM z5<8j)_-=?YFFmGfr`POY*lgz*Xj>xZ6=BZ6@opOxUR}RQX*0c^;o1#nUHA8GZ@=fi zQ`Lg!J4ld>a`vyLCtdt<@$LxET^B(yWokeK;s$&j*aiK_er!i-gB$xz-q^MDw7M6L zw!=$tY)7M<{U;2x0>!)JF9z& zcIk6mbh}jaNR&zws(xJ1>%+_USVDS`U0BZX^E$j;GQ2L#aTv}nO&J=F(~0G(G_>UUQ>(buPiCNz?oghj>icVRTI%g#{652m6BDK9 z7GAe!cGWGb_nofB!SS;^6tlXeyg%-D2d^6zda0kvHXfxZ9}`LQV3JZ??5JlMFN%3& zk8%jU<_AIod5A9}kTb~N^&o1#$!1+@SJ zSaUiqIX=1_2peG{dg!>+yePTzg@hJ#g2SU;8<_2a~|XxEuctKV5r1dY^mR4hoxlmoU?0D4f_ z9}1|x4p$G%pMP1$s@_-j=6U649f!L+mgBF^jTt*am(|C(l<7llypwpnO>Z5$T~M@k z(8b05+odOI0nj=Qvj?!8!{zmXwhO#&m(v@1yra8+*a1Ds@%7But|Gsmhn6hwH{`7+ zKE^jk$J(@yp$>1GVRV8UJK0)t4txBDLV^&McGce3za?8Lf}Ki z_IhcX*!IimxXwHOgfBW=p-rqnYmByN$Z`&s*J=fo<8nDH<7skTJgl&K$|hQ8$YLcD zdexMV6YKRU=no*r_Ntb@2PaB@T{^76ZChG)8mI*jk2TfnEZ4-rRcLYyOKKrnC0ctF zt&&lgp}=iXsxcW)f2bjYqw)debMCKGH3|k7+=wI(?qJvu&vQ?V^IVslD1G|SqRCA< zO!jQ21_~U-N9W0MMJOy{^-Cx{Izq>Us84yj=ys=QmUel)dyCNHk{Zod!R z6GblD2%8;!7~*gUo!zE%h;6sV+m?N?!g4%)PDXKRbELLpl(YYS+KneAR@=QHv+4AV zKOwfBqi(EKV(Em4b=Q#ny zPv=STM{@HwpK$Bx$qO!Je~O>n)dsmL#k@D-xIr~$v^mgiNfWu^{#W@P7j{ktWCyx$ zn$jsz662vb0$7OkHbhFhM6DN8JCKYW>&5@Wt;6lZGG2?vi866p+~-)`7TdAAkbdM+ z0ojS}YpL$cIZ={+{Po#{itCf4b~(~}AOA7=r-T;g!$*Bbg|2@rSA@bM%QfAF&MsS? z3yVyYC}%<0c%ge2&1_|Fu^p6*el2pWhp~ND-Z@bkI={v3e>i@+!lCS`_D7H&EZ4-r z6}P9O^n0b-3yUzD6LP-L@f9xr1_RYL#5^T#^M2uE>}ReI&H`e-$w$8nxk&j&`l7Ma z`s$UNrY!mVJo(Cdlzr*>3FRA>D?(vWgM2eV_Tb4yA=)NF#;HlZp*pZGpf%kO(yc2! zd!o9W^rCAkLH}t@`|+BN6XkRqheu(tKW&R)(LQv&q+@9xg7YV@AqqO$pXA~Ef;;^S zH^lZtdjIJ8W>@QGQhs^VSfwzt8W69?GbFPOneZ+XF zj2NAmCbZ4}X+Pt(_}>`LvGo5?r;k{7v5jd>giABBHSb5;rqf&CP^J&31KV3%)3%vD zdfV6J-=R#OXz_8{h1-YIk^IE{L^&TP$|7y^zW;@_*w3-q(B3!pb0l|aCcV|H*_gR| zPy5wHH&1YMhd}LpmMcPG5uu+W4PS?Id8v0;+gH3_EgBH}dCyH{a~;D!ZT<*HHB#9a zDH-MLkKy?E-nlY7RUIO48SX0Z)29LHL9uM3PIR4r7`>#EW9v2g)vMPY|LED@alEXT zQO^F6^~!J-VYmav#Dr5zH}0YmdXY;7lxM^Bv*zD=&8C;9n8f6Tc8|A@^gY6gQDk` zp#u}8^?%j7J@ESco68OPh2=&?hGAUc3@vZyGqC!Q$Cy8o5dfvXnD(3(IDhcHC#}hG z{-CwEt$3P?gR+2FpCsWqI=NIpb~e^;?$Z*bL zzbqRTJ-@`KCQ2`jTAqJG<1FiF&5)d5SZ=gi#QdVXjzDb}eV#Gq7j?!6W2oW(M@m~! zE^dpVM3Rg9nA`gMqJe4A^9$MQ=GQNJV*Ze-v)Ohj%0@~xIr|IwguSu%Z4~;4d8b7t{UhQm-N}LgkR?HXU*{qVRHDAutBbfu@LkT+f`vyN_E;W zh|Q7hutD(*=QNkr_{wmK72^NdyAJRwimp931p*`_bP$Bld*~e{A(RAx1VU3lxg-}7 zN#iDg04hOgc8UeT60E2wsGwj$#1^cGBA}><1?)jlvH$P8dr$7%O>z_b@caCA=Xu_p z*|RgVXV08DQ+9S%pP$Gc;$MD=t!t~tn%F5YK^q?_9M)GyQXS4_hf8Xt;l#RSu>o}GogFPC0 z_~&DJ!*F%|oQ*G5JNnct`OZT6LqacMz!RtpAKo5OLT0+>!%Us8NhAH2+cxn1a?Y`{ zZq6)@;+lFok&n<#s`pqHUnO?P?BS2gDw!(v7GGKRh~>q8zSTak3|XGKy}+sM{z3^v zB5!Hm@}W2TYjr4iE^?)28XYoOHE0vjF+RILY{I5%We4aIcF zXMermCC|!#nk}|(LdU6(GuvG(OE}(0x60jv;OTd_C16XymVhk*TLQKOYzf#Buq9wiz?Oh50b2sL z1Z)Y|60jv;OTd_C16XymVhk*TLQKOYzf#Buq9wiz?Oh5 z0b2sL1Z)Y|60jv;OTd_C16XymVhk* zTLQKOYzf#Buq9wiz?Oh50b2sL1Z)Y|60jv;OTd_C16XymVhk*TLQKOYzf#Buq9wiz?Oh50b2sL1Z)Y|60jv;OTdf@L*Oi|;DlOTamE=m!%1p`e zq$UbB|0cnol`4i zOr4yjJzu$+l2@utu&FOXH;CE+`VyO!k)4+AN=kO8WtUPBtA6xH+E`@$2mIAQ9M6HF zo^Vh2jes+N8bBCO7pMc&0;&T-rw{g2AYj!Aa&JBX0v<&K)jp{m*Y`*&x(|HO~$S&(qc0ooIx8$|8k)em3eVbu#sBITo(Da$wnVA<1;0H_N@ zIKa3pTiOJ%3-l!~DR+p5Lx(=(22 z7wBk9#L+getq{Esy7(<5@E7@dJDpm?SAN!Zx(M>!6dC(_#*IfGDjsHPX9oB(+G!8n z%BEF*dhLoDon=TfDj_%3#({-ghjFZWf+ z?sai9Lrg3i>Wk0~qIU4=%Sh+^dAhckkt(AfT6X0Ir94@_1f9^t*J*lKzbXef1-vtupi@wS!V8(=NU-qGqV-6SlGXyRX(s81E4Y`&HBrp<5*d z{TP{*>`b4SmYI?@H_@GyKQAiQ?Q-Ty-+x?Mh6{^eMCVNE3Y}G7*nY5GvGs$}`QJO;u7uR}uP>>!L)EI)ZQmK0d2vxSPXUTu5xVt> z%Cal*nQ6J^yn@H5Adyv1m=E=YeSP}WPu<4gw4@Kgu;`Q3=QZ2?=MpGD7SjGKx9CX< zu5sS!Byhpi^J#+A>mO}xzJB$(H4M|W^Bk>ogN%b_SK>1-bS38|*d^EOdDA+oL*o0Ht^-c+D}^pKDRp_ zdEwBm+0Cj=p=DKS9~wy7SD_n3?Jzh!Ept}XC}&#cFt;)HTE92^7k zsd&z@cw3+k5D)YQ1_7KS;MknHRSlrdh@LPn+bKn3DR!;60zHZRvZh+v@bTZ9-O%oV z{_k;?)RZapMCb-lJNVI)n3*%(u9>hdDVk-W!4`g&pHYF{epORFpbo6Ndfy%E9^7Ky zlx0kQgs!n-1WkT8Wt^3RUO?td1T)fdbvsufUy+Ud^R?o5O_i{zQG;m>UkLtipf6uS zuaK|!%+`p8~(CunmGyihf`EyM*b+8y6U4g7ekIWiZy2)%56l5*#z`}7%0F{8_6TBLuu6#QOO-JJA6 z`=39Y7xwG7A;v9*522UM$4KYAtUMnDDaD8vCG&+`pW5I>Ob(;pe;eZy6gLHi11HuYD4F*?h%h zre&Z3_HTlWq&hzhTlnW^T41<3f6^7RCazsj*mI(JXOWZ8%jRdIGc9*mr5YIBe($V+ zAKojg`N8gIRo!3;2j}F6M=RYR<6zeFA!#|;>CSnWnVeO+sd2e0Avc}R)Rz9`#(U2U zuiGm)HcqBZOZc?Xefjhn>OaY*Dny22w?kT0%;yV-8qL{$B;!lrL*!|t%XL$pockY{ z~O2zYMf?VbtCJ`D&lr7ZP@vPp5c%bJKphbIr}pa{CCiqAISpAAQ^Um*<|4aCPe~*Q^MwwsHS09~?KPD}+CxmoVlD znEXvh%gJ-5n_LcY!6H?}me05@wY`77ioo|1ubkLk7;}+|xtN2_X9G{1FB=c{W+|MH5i8Lp00DT=>m-HsQw?ey)R30?RR-{dPUEq9zN z=g;z0Q~_U;I@ea;rK}DA^wONm274+N=gC;_g)aPvZ}R2sZX*=&r|v4xS7{w%K6-ho&i?sh{9Y}Bn|^!ww&4uZiJn>M z=2huWCSismE!kDR&`L2^hzvw-g%$7>S0`MJzIe`|wi}mLYvZ}Gv@b#ze#AHBHXc(a zL)>W?nw$b_Mi#o<`bPPe+p)Ug%JuM;Mcu3PC|+NOv-jR{iqH+Bb};!%bYhmrXl9a9 zU9QRu?DX+UQ3ZT0uMd68%KNnVodZ^LY%Du?IYav)bm32YbB1873rjtcy>DM(AJBmF zzGbcB=FAM=`7{Jt1Dtto33LVcu83>OZv^fKP69sxd=9=c<9noNfbRqP0nI&NH;4TR z=F1Y7eguLgVVy?$zu6Vw;YBYt^zg42A>BjO)JKNiI$-oq7YrY7&a3T!FsTMQxLq0#=Mn#o)I3BmEq~Wac04lVkTMxPxN(91^gH(iW)Uu{P6b6 z<(A~f;L1Xm>y_sx%1~`dr^{(tFaL64nx^|sHh=EWGQQe0obY9(%XMGAlIG>)x-y12 z)6=IrlV?ShAu64pV(>%Vjsd9i46{y5!_t8XcRqY}@yj(;(%5U?J305pbtWICEoQk1 z9npPUOkQr*jI{Lhs38fXe2OVPGa(NzZ!++*xMZ~fQZ5Ii+&1*{l@He~vv?CbDfR77 zPgl$D9jeZM|GMB$-kH+onorH!j)6yhglN~Iro?` z#F^_v+kywz+at<@c0p_eWg`$8??Rf$j$zsrIY-d2QH(Ei(s-SY@x@6R`V!_f3DXxx zyC?B&7EPyHuk+kWV|?5FyCtC8+w8Oa*W2j+p=xE#_xI1bZP%`r@0xNO z0+01p=vHY~uHJh3x2(p-7YJq7W48BFXQ|7lQjbOVnZCSwEOGb@l0U^6XHxII7A^ zaf2GyT)cdTvA|I3vCyrOwA5qcrNA6#y0rneR^%v27c&#{b7S#kFb8*V)^^&Y{{4@% zK^%MPZ9chXo%Cl1Xmj*>D`D}Ohd*b%Us-X>ilfu?u%2G%H2LQ9!S2YqkdB_S=U%cL`PZ2 zWX#VnugP_uiw=tql5t()^1M7(*}7O>dYvwO>9qeeEHcpZA&t*QUw>waBWcRICUI>4 ze=h-j{Cq6Vw|-m4&)ZP{YmK{e?F|hwJHYh}gdb)kzdY0Aq- zuG{{UHSofb-XlzB%gknnul*dM$J-_m+BH(%-f;$Q4%X@&?$aqyKH?`M+__ z_FT6oa!=X>+L7{{ziZ{C(dm`3IhBc{=UHBu`w`jh?GJ$nr1!P5e| zzd5PP;Q&uzN_`i)_32JqeJ^LgeLCyAwAcE(E*W!69iXp=<$0}ii6hr--dnBxZ?t@LvFh{p#_WiX=4qwfS?d05whv@5Eqc4ch7u3Gi{>_wgm zF8jX-UG6XbXzb61Z-)7ir?EkSvF5|gJs|NFulJ(QI)a@Q@X@t>xVp6K4-J}snD*0m zo*Qv}7{^mWm-~zFy_M(Q=E4he(*$inLje* zSy|~hNn9|Qm5H?=ndW!9v8m3?nX+uh@A#4|{h4_q&!d#g1MysF@*LuqN0;liZ%g3s zB!Qh^M(j((1-|v$I=(!N`rrAX#r02qaQLbPTf=?EmqNEbo27o2JHD*Af|otQJe~bb zEAM~hIqeWpmc8&dhP2uqNiTjyJXa=OW#UwHA6~b|mz9yye>cuf+)nDdO7>sh_rM-> zjNRRD)u6qKOTj}Oi zrAB34n1#t|EX&3!uVfcKNpnZVq-161CZ=V(uom!5`kc`iV(Bu}9+jyTf9F)Zmx)2~Sy$-{cRtaG7J7Pk9)OTb!R zsEcrjOFZGNytw}I)b+c(^rXwZ%8KLf zT3PYSqn)mN%FExT|K}1YL?P+z|Mkd{^}||r)^pyuEE?&yJAD!;%bw}Ev%ZTxV_V8L zU(R`rG-+d5UJQ$Uk$4h^=Y*U~I_U%8l23Y`(=lH{@{|0nyfLoiDY_$Zh0b%KF}}pp zeO|XZxlTI6lAj)rbcrWEuj^rdc{5Mj{kyOk2J&n{KiCbR% zVSUl-kBnWIm+k(Z5-5aX=7d~F)={Fv!pOa`rRV+`gXA!zd z^&XS(_rsJt{QP5P)VNgqcPoXPb#UV-%)fG}&yYN~x#}hf8++z@|LkY&=X-PfYeKqC z@eXn>x+ygJq|r$n`gC&6upURwd0p}opV#QhicdPzSnGv;KgOYxdo!-?c&^9id3pDe zbP`{WD`~`+xVHcIkbwUFWYWbIzd!lx^7J{qiV{W(_wxS4N|)2T} zNrPk4)3B98Vrp7WDqEe{bSD-D;w_^)%KXyIjIHyr+`4(xqA1zJ3mYoq_a^42Jf6)Gt@Xy55A8n7CK6}^xPe=NhXB?c z?v>aRhy>VwCzytHMSO+{+nu@ubUo>Nng9LNn0xbGZw%~oVRjD3OLX)dI11e$Y6sDc zo>9ZI^Ts-{y_-92zR@!qn(4&OpX>+H>FWkkm-y-{`-@zco;pdXJBs2L7J<*L8>@Zw z@`f3S(~VlB)KbKuz6#yQR6CTZuR_dno9m#*+<;+ZWMJ3I3X6JyQ(S~9KGA}+8dlPfLznP;|j~uvf3@)_- zxaoHY;9;r6o`Gb$|B?iByHjwbZ@<9>9%cXyKf?Da=RWXs^zu;k_}Y*!v$C(fYe+kj z!Pcng)FYu=*%m$Wj91Y_3xywDm_t{76T*K0(nZ6L>2_xsl!J4;ARB!L`m`-{v_V$g z;kjIA*m@3J_vCfCm&6rc;)-vj%emE;_`(~n%RO|TbX_JAkG`ap zyhszL(ljn}U+V{CR z=AaE}*b?9M9elO(Nj&$Vn6w#(cE2(}bi59(^SOnNQy*8>a}UnrU&732l%MsvC2yaM zDmc;S4fC({ZPyEzI*fiG|6=gR{=+*C;5nZUx$TUb9~w3A0S>_79su|pLN|!op{(Z^ zotMGAyUlS+&X_z`o-1Xr3oX6N{6h?r7vf>`=c68>DaRLx=2)KXxQy*N_e{=de+bHf zK56oeg3v`q5=YKiW{fNG5VV~i2^8X*=>N8rzIwy&204D%(@UveChVNua7CyJyLZXz zqzSugy!aR;j52~py%D-W)DFIXPS84i*xNgcKUEmwn&EQ0T`3+d8ksi3l{_yQzc$Fl z_`J0KP+vG#)DJihVErMFtcUXMg6$3CQP0@+Qs+2UW*p8JL;!qJp0j>acbG=nX+9ax z>4eUB42!<;n(ci5r&7Gyzy2hy3RRa(Yk2pl!`l-s@Kk8gAE8@iTE6}aOT(X4)8=C$ zg+{0%z3GgMcL4JN>JR@3KwaQCoVvmPOw;E%^?;xb*>(g%_zT=}8>0kvbImmhh@*Y&a#*Cm-YoD+x-_MP>6epo=jTfUr)9{kM?v*dc0ZI#;aR+cw7&k zdLncWxx_2qz9ivK6o~)~j87!<$F6L1=&bs4HE86L{SZ3Q8}Uu5ef)1pK<^i?SnI1l z*8WW~^s7g;t5-~Xe|Oi^;cW4}{TrcM`Swu_--#~F*s_5t)ifDdSoMZBhx4K10q)It zmdB@^V?TzVEz)h1*eL22!E?4*Y}eSgVH3--6Z<=S8n$oDhhfQw=S;`A^yNMX{;OR9 zo?h%u{yJa1DZ(|*X-9y*{Fuv$pqlaX$NTPm=cbDoro*c$<7lNDWE>{+jT-89XSs7Q zm6bI&6CGpYuPOPto(QS%dH=~RK7Ufuu#Bk#EGL$ql%2%=k*I7*(5)zF?Fg&37v6t zXO0{3-#O#Y@@RpFxtzIq_?>xHdRp?ls5q=Zak-H|ucvFk2cI(r(4To46r2C2>ASC% zntQ>fuisofb529g&G^i;^FsHKOFWa0xU`(yEcd)9{AV>S*Of9dEpt{*RD4d7Gd*`0 z`U~DoR#+;zxfrDDe09CWS3ZZ$;!ijU(r><+o!0K&2BjD8Z|Z#{U=v$d``?9XIeVnNX2B%i%HH+n`6AB z8tIzjN@rfn0pWAnt-kUTJ(llC+cgYV`>q;&=(`_polYA@$MU88gl-VE1Af`K5fm0Y+uq1&xf~TD zmB?kqZNB!!x-Mf)*V^joEs?M1Kk@ybH#|3H3d%+39&(9Ss@{#u!m^NY&RMQZzG21= z&SPEt2Qqp$-MML`xv>(9*34oLJmGIzp)Y^d?~(g*SX@)yc-c6S<=g;@Z1F0X=5ENRKk!doJ~RdPj@{;O2fXxChC4Mw$&8#gX7!Odfm zD!_f^c{Z%~)x(as)(JR_=lt@jH*VgB^1tf4{YTUnEe6o0(#i7(-K2Vtqw%*&?_Njo znKQDy6^5~Bb9w)Y>^bcT+vgB~cAf1qZ7lE4z5vIkB5BNCu(VtKU$S^=$rHb7gT9ncMN+ae6V?yAOr@jjS>D~FNb|}xDn2tU z7yT1CE%=^oC>XawTA_$jIx`^up1OH65%J zaFM8p)DNMXRPWK(o^h|Z>~vSIYy8-eriPT#4=6?zG}_0J#dhFfAQqSc%=GxwAJ%X7 zGw7&GP%}fHY@MP+PM_25TElyM+Xu19@*e0wkJ_r}n}=Fn^m6_ag&r2z-=lsA-O8D% zAER6u=zbbq6LePaKcuu2qq}7GhPz`<+%R~sb?&rmqwB)_MQ^uNz*lOMaJ75PC3O-$ zoROI5VPGN@hI|RVY`)O68eKh)VT&4!zevt>XW>1STp8xVR`E%B+3Yi*QO?cFF>_k3 z@pt%M|Me<*L#TSG`I4BmFUH@srIpzrJdHX){)ApOf5zP*F~jT%OGdLG@vZes=;isW zR||l70NX{Lvt4ET*8`BYlx-`)IK6DVxxaO$-XaC z&CFkT+f(B&yYPuoW@gep3*CAPvwoGYCsMT}-Kpw}q|<%c1@^o6G_=t?C#21{Z8U`O zC!KCr`abAiU)DgMro7eQ>b#+CFL^V;yrJle(5-Bg)t@s48}b2+C&B5`6WSN{-K}~8 z^JnOb=XSPtiW1P5Iv(3|X1ID}Y372Fvq#^`F)bZauwNi_gQy)edv7j0@pPSX*efVw zn5gqpY~jb+|Icm~u9`%*xbcmHIh`AvXWmr!5xT~T5j6QJYus8gZ{{;()%huS$iI9d znqxj<)V_1;)V(Hwc7#s&5xPnB9?RpW4AB^g^m^3rVPAf%^4Z)XTy>e8nbhn>SCcMd z%zFwyLiciFhRWl|+vhD?PI@~Ky~UR=s~#1C?>T`}E-KpC@0~w5;Q{vxKs^$=LDUW= zU(%(N{%xD6uv>oN{6E8Q_fa>X^0FXP;fPX`w(WgHV)wY(^w!L zAS)beu%A#BK-7}5X1P_j>lS9g8PS6{4lC9zewsT*Ue#_;# zA5&0Ygzh1ic&1&k&Tr$rM6N5*>BgrHiCHwCQHJv&`TKg1Wf&i8#ihs)q$N$c3j3~$#TfV zyo~H|S$JE61qAM%N);fTl=n&SLpu-y&<_DP7cuP&hkB{TW%~+oJ@vJVyIr&L#mOVfxo2}iv@D@prF06uTUcMYfF^!B~rao^{nrn2pm z_rA=x=G4od55KL`V20_;`!y~_H?Jx+(KX%p63MjMIp&52QN~Emm6DW;3Yh`n`<8da z6TW=NJCp41(f-bzdxCk7dt~w5sp^jB+k50oK5Bp)q09ZnFPo3iS(r@o@G#cp%#p93 zeBYZ!KIzMkyaSqazEX21)o`u>ztj3H_-S~xjt`vY>4dPnSl&VxKE${3Goi1id5cTS z%w>i4%#|>F{Y^}l!wqws`u!(eIK1=PT9t1V&e=?2f&k5w-a$s`IZysg4mABym8+y zm|=Y6@XIwjp7oXV75n2l`4YM(+Y-;Lmle$$d*_RFIUTNmpPjvGt69tIJ$LrV-)gZ> zK}VUAAE6sW?NB*>hG1ETHi?b&I$sTU`j(%yy~^Jas_r;Dd`tU;*cT!__hvtvdERrua;bXKPR>aY+BWVLHjZX%PCo7jQ>x&(ac*Dn8hvjKV)KPdjZ#7o8$J>lV0 z^hW5`2Pj`}yyH<_Wy;bQYo4szw1;L-%j;X?+2^NU0=m8&u;`1mU(dVue7EJV+iK5y zQaGW$a8z%l%k}c~MVnXA)y2o|Wk2g*e+$q))H?q9iJy;b{XNoiL(yNM3m@W_$4^=F zDmr7#pLVbC?oY2>0ltoB+}CKrZ;NkbzT~n1koGp>IbXi5>+=y+&3SiT_XElD=P@%6 z2XYcRPMX4<-+5z*pcM1HOsu7Oo~=6Rh6& z;;H`6c{-p>!S+Jv`n?%0eSc3soZawI&V2Gfw+&4;B{gMFy-)o-*@V)0CAR1sFfgSKzUR>w!CfyMcRwjld@0VPGq;4R`|B0Xzdd2fPTp1iT9D0p0}O1`Yy;fDeEpz$d_G zz*oR=;CtXF;5WeGz+56w4G05j0rdcm@y-OA1FeA$Ko_7V&<{8phy~(+QNUP$?>(jf zPGAO*4!D7Q;1Xala0RdexB<8sxEK1bAWNcRA2^>1IaMfCIjif#lW?| zdf*Y@1>hj?CGZDOCm7EN3;+@V7cd`K0o)Bd3A_n>4mi-+Yy@-z;(_VF0^oXJ6R;cj z82AHdTorW`7zfM-t^qazF9DwcA(#kg2gCtsz!kto;5FblP`4WDH!uZQ1l$9>3Y-8M zqr(ylqyyIjPXnI;b+OPP8b}9j0$v1u09wPq^7o_IB1CaI=X2o9Fw|{eDewev9B7BZ z>NMac;7y=rIAjSd1)c>Q5y&4X0GP?8MP2AD z@GMZT9`?Bbo&xG%;nan|v%r}RpwqxUphrX0Yv2Shu@QI#nxBET1~?8(X^eH6K<_5F zAJE`T@B#b*%xS9B*Fb7Blm{?961oSZG*{{vkl6xq0Sa28?P~>l0d#5&IRfL_KsSJ; zZNYOpJSQ-{J=O|zK=}aUJEC%Tf-V9VbjDhgDDVL+>H^!_RjFTr9oTn;}>AqO&*$;7n5BozW2B5AC#B-d5HUDQr-v^;CMJshx40Lxe>U1ph zcL?U?hN2D+gAE#v|JTMr7e~NeoP*~ai8!O6f1^=GiQr=l?7~>YO+sBB4?ZX0{u42$ zeXdg3=fRduM!PT-Ht>AZnQ2Ph8+K#1 zQrG36jPuY=&BfgIJnR8CANRdTsmCsXdTmO528#TLLJ!xTk#m|?RGrV zli>4d@VpCk;(0t*5p?fm*xuKmzkAWf>_a_2fO0(qefvPEPmh51Da!jZ=+jqd7mvec zoKR}lNyz$Fwl5AfH^`wb4soc}p$@ej6aU3^9jXru^|dh6Ct;{_+BmSV)}d~Lp-zOM zt^-5;*;x*?cd$dfKHQ-Wk94SD80xcOsIP*d{sxA6=1hk=0YiNw4D}co>gF)iAu!Zc zVW`i9p*{zOdKC=yw=mSR?scf&VW{tip?1SikAtBe14Dfw4E1d=)WtB==O1&Z&ta%n z!%$C#p^kx}9u7mD4nzGg40XeH0jdy&Iv$3)9t?FL40Syi>T_VI?}DLjl^vjV!%$xb zL%jrs`c@d~4`8U{HU_A7V5o0^p}rV~`dS$3S7E68d>x=(gP~pxL%j@!`aT%y-(aX0 z^$t|MV*}NhiGixm)Ihc5!ax<0AEq0L!K!y!u)5`vU^VHwV3l?suI~(1tM&)02foJj zDpk}EXI4>ddsk80Mpsey&8(vSC_s2^6}5j$6*cwsDr)5CRbbz%s`TbnRpD7xRqT0H z)x^0~)%({~Rqs4pRgHS1s_I)@Ro#kTau#$6QHK*k)XwY>)nZkM3fU5(a^DV7sXv9N zPn%Rz$D^yMD_qsomMf~M*_*4WXWy=-9{8=A>ejlt8Z)Z8ikMSfW#3j^7nWme0%*k`pf-)#Mi+A))#x|F)hD$gRPLAv_4~>Q zwd~CZ*w|X?o^xxdVR&PI;-gyX(GIoM3U_U_^oiQ)=HNPNe_|aq@RmC2_0Q|5>-*JJ zt1qvsUVW#oitAiYRa;a~)qlI5%IQ>JwOL$W^?0woTHmJu_-UXXE^eTl2@Tb|$GYu;2X zT+>u7s?|(6uWF{+R*O{cE{jx)Lz=4&S2kDs!ds}TZfKzcSn}Rg+~s)X}j$)q&={)UV(5QWxy* zt!m!hN7cWiuUb5{pPCWfU+r!)Ks^yLP@VJpK(+Lnv($o*&sP238>C)87_COW6QiDf zf3WI%G*-R%-4JzA&@h$SXt-L}Jx;Yrj8~1_Bh-~^&QZ&r9jRJ;H%eu+O;8t2OH|HV z$EYqJj#WRm8>jZ=jaU0#oS?#*O;W2DoU0bRcbEyRTeHnT)Lgaf z#(63;e}Q^-+QsUQ#D%I;+#+@H@XOSe(MweE)MaXH-sS42>#kH)p1NAC`|4VCu+1uU zB=tIV@R1wTk*YVTNY^^G?d4n4>jMha6DUS(Ury1$FG+-RhDTUr{rUzpmbF`=&Z^;oIuh z#}BHe4c}AOTzXg){QQyXP;gZ3s`G_fxb9yZf%f}s#ysg2G zWjm`mZg@A$aimIZ$Hu|+9X+o-!|~LYO&ym{Zs~ac-L?*u*~!tnb~i^+Q7^~uEBiZ| zXAW{)JavfU{Auxyh`FO3AFWSvwEl3Cqg}7_9cSN~?0CFMn&bH9Oh@0zxsIca=Q}2T zx6tw7hf5qE9=+1BC3ux%+kiEWkyqU6*n9j=$42-4jzM7$JBpv#=4iX}X~)O~FF0N* zc-0Yh`&*97K6ux0bH9%qyElLCxM=9Nj*cgPa*W*V2$;0JT0l`zt$;=+8wKnh-XdVq zwhjUDBYFfh`+Y#bw6}%?T=(jzfMK6c2ngsnEnvcmw179y$O#C2`J#Xu*DnpIaodUj z$8&1~8q~Tg;Pa)M0-CgWJYdW>&jmz%^m@S5fOi8fAN6U#1O>TMc|J?YXTn_aChLk z`?dt$I`-MXn|kgI%pUV$VAy@dfl~&lppmsBg7&tI4EiLuYtW)9F+q1891}G5o9RKT z;&OwsKV1^^^X?mihMu@LD0Rk@K?|F|9&~@3BSE$1ejoHsooc~7e{T{zwokX<^qoV4 zcdR`x`0^LCg6qaD3BK>lb;0Z69||7$>Wjh0?tMR)^8y(1FGO$3Xa3-TW&XhW{w_N) zT-`jv*`>ym!?#)I4}{J}Aq=-l;IK7@X1e8k{)m-t{2MWgdku-{i6*7qWN=7y^~FX+4W_p#B5 zRz8G&YJ7MVMCT*qfG;1``M&IV;cCfCHG@{Cj~+0{b3>+}eh9r{K77BWGA90zNatgP zg%4|eiC7S>roX>EijSOFjHZi!HHUD5TO zk3IQdAB@fDgb$&cRPWI*A6_-};iKIWp`hF?j4KA z?lcXE@F8?B2WF@=AMu&ldAYHvSZI=r&yQtdcm<-%y!18;A1o8{fnk`s;OhB|s&;SK z)TLYdF>f(UXL24|if&#lYhKt>E(QaG=iy6sH>QY*=_qR&T=kl4mw?Rfb~Y`22neBmtvIuUxV?vwJSao;=!jxvT!|Wlq)4I zFT?Zeh7HI|_)~}c^H~8f!+d^86*tm=T+uS2maCp76rw zh6?yheKtY`ocH5^sgI9IYhvM3=>GwqnSR(b_O2H`6W{ZF-|xarX8^MA>6#ZJRJUPE zABv3mcvpC!$&tuY=>H*~*f$~>yQ}l#cb{VSsjq8};5`X$6ayHwG47aSI>HCQf9}Y! z{qjEuRZl$@?pS%rqUBfIhKUZi7$l%x3f&-T2d&)Y8~3OoZs%OlM%F{RLfnw@D(n48 z5Uz&+5kMpm4HN(dlT<)Y1Z+d6b^^l@@ogZx7UsZeV~z}1UI*_C>cZ~SL*2)GUvvY^ z{WZjVO(W!qxxDRAkR?qqC({h`Uy<17usOP2Eim=c3UflOac|7YJ=6~Kd$8Lnoe(by zbBkS3jy)g)%&ocmVJ;YRXbv=Vjbrd`0ygfMp_o66!(2Az$s$K%{%wp>UyQ@t=p?-B z#T?iMC+3r(2$!Z~p3aTAD$HjEU@oiIrQmBR=vRV|6_{tc0sP*KdCJ@IT$rD_7V}bp zk7LgGS-jhN6_0-q&-e+x%|4;jtRTz>HE^f}og8Y(P|WuvI~4bItopD+p*U5wr~p;t z$^aD|7N}P22~_nkw-LF%sO2ie68~{h2ZmK<|mD2y*hee{Aj+#H`lq4522H$JHP9F zz1ts{KN>*7Lflx_TRpG;R+!H&`cIwaIi2V^!$M=&pJTm3H~Amq3h*SNFI~U%)!UA^ z)(MdPopwT>zJ79k#3Q4t&EDt{SReS*7oj7%k1Jz;Cv1@>?KZ|FNN?4TCR$;f;gj3{ z{zPN#f6vUH;23E)GAO&y%Gk}>uDv$M=}0OF%LdQ&c+(Ti{M`jU^s8AB`koy2)Gou3|I^-0hR*G0Jf)>16KeT z_N%LatAT5PYXP=%D}hzOYT!EHdH_=c#@fR*@NWXv0_y-w7Z~dhZ-svwPzbCCZU^oF z?gZ`v?gs7wHURem_W}0<8-WLa2Z2q%X5b;Tim08au> z0Xu-Fft|oJz%Jlf;5p!V;054Cpa|Fvyac=qyaK!myav1u>;c{Y_5yDLZvp#&w}Jh@ z0RYn=>K))+;1KX0@ILSXa2WUyI0AeGd<=X7d_ z4ImWY+Rd6kIDn-=#yZa0@aq6rCSiNOcCH04zOHU4d>ucc2G=rAVq5&>LWz*ca#r z^auFUlYs!1DH&@@2f>d9VgQa0xW;q{FccUD3y00My^AQ-3uU^$%%0jdGjff_(45C+r) zxF$LRs0Gvp>Hu|tdO&>u%kWe~pb>Be&=_a}oC!1qxRyE+;AB$^pe4`>;J?+{0Br#* z;ZyB_4nRks6VMsJbg}9JV0oYF26P8{06l?TKyRQA&==?j^aln21A()Evw=ZCG!O#} z24aCBz))ZqFdT>j;(-ysIlxF@6fhb{01|;Qz*ry&;5zW}zyx3-z`h*1X$#p7N`G$~ z`gh#;Qjd>&m`Pm@@GCHk+*(5U%O7bQwMR_{}BE|PF5_}USkqJ z`efqIJ(0|CNyvwm+e$aDLhkrtb{6(Y^4(w1Gm(hDJ@RuKe4d{$V=T6~cKN>l@A`A7 zkxdMayp46fbp`lMtCIcOF9FZ|%Juei(TK=?z0ggn_gFSR=FVRwldXtehc9jx5~6^J@M+TF{6q4SBQLcJ-H4Ur2x$Uaz%Sk1zJ7cbLoV^k z))QkF4;MC1E!ig;3q}$$X~Sck*j&R`fAfFyufM$6?3aG%dS?3@4$F;O8G%-%=yF}( zF(A>Mhg}PD-C5j29e-QHj#e&n?-t+h@*{rtoky|CXF2A3KiKi$^}m1C<7j8kjrzi; ze1tCd7vDPH>-oxZaC%nqEbe+zdM6GurCx4v=HDkv%FR0ey8(P3`YHaJZs!bYa3Pt7 zV>KsVLN|!o!SDQU$(|gZe~f86`xQcQ^!l!4S#FRl38YP+{#jjFG;19D+`k0!aasB^ z(SdBSz4e{z2fO2ZC-kXyc;{yd9bxK|g}Zk2dF=d{%RB|s6+ZPw=tc(G0eUmmHFIcw zHs2BCVr|;29OLR?9C=@V^MbVf)c|tEzE=~VJuncM2rL9R*HROT!0{sc*h9h3b1?Yd zA#sc97+2NAIIdVC_p`TPoT=icP$q^ zk8e=M)lknYiBK~eG*p`+TdMwjd#JA-9HB;hlCIu)@m95V@ljQDkBsq69e4D0;swD9mWzVn9O?8G9sA*V>`A zn|j{;8;VdbdLQlDY3zf8Z|&@9=zjI+z0eWe$C>RMzt2yeh6!V*WPfvl7jQ14=`^M zA2=W`7~fjW?sv^SpWnJ*FzPYgcL42;&<&z?C|B+=)3Fn~E5#5$2T?R^aI{~#{Mk>8 z0AMlExVYO$~Tj z5?{gw(Q}aWLbIL=-S%w>{HGGo>+go@zV+Ao{Y6N%Fcq}q?SpI9x4JgCxp`-)ze2b2 zQ>pr!giZcD2@9d@di|xn)b*eBw-G>2>jSzw&vU}|*KUJ#$(+8ht}m%Ief7m^@B7vW zQ}3SN{n}2A54L*!agzsWXN7L%tXzFDKGm^W`_lHF(~7qMi9kD`DL_4`1+X0;*!QIU zC-=1LRRPjT6FPmyYXH;*Bpus{mH_jkjxiqnaDeeiXPEJsj{3^>gXg>-!91ibVcWs` z^PE209tpE;VY@-_T3KT#y}dycpSr?&qt_i?FV9srUU}(l`u`6JEC-v?Pi`0P+fSyx zQU6w;v-D(-&Z~-1zn9I89sX1GuTM~a>G}ceuL<2CY6t6l2lv&qu5U}i`Zms+SnWLZ zo{lNh837>>Arahp& zpbVru5HuX~WlNhe{k0sofzT>u&AdWBPC{AcYebmIk&6TOr3|HRkl z?F#Gp)-U#PW&rYi)U?`RYQ=jSmaMyL--kE1HSf9;9`#e`Ce?eC_jI1`k1zlg3ioR? zmuqqx>fZSEyW3^{!-}b+p%A)UI)f(d3-yP3L(oxo#OeAY*M+8^GrpdV=c02GpENp2 zXP%kq^fJ~&G^Uiwih zkVNWJK_mZsF!zj$67tUPT=k*?PiKdESR2|XbjHzLg?vPf&KjSM&n?&}!xaF+k2=G* zd_@1HU%V$gLaqCxUBdXE&hO6g9v#b%auK>g)DDR#gxt8SbpFU0KSIK%{pMHnJw0*s ze#08vpH9k!-?_5CxNSJ@vH$Rnf{5BGH}LMKS7g64aU(mBa2#{;{z5m1+Ch2=W%nDR z#yN9l;r*=l`*caF^VPMnf4(AX*H#(7Upioa?;$JSqd?$JL}X|k#CMmxw~iFfw!nQaKe|+O{(`;8NMhl?+55+TD^WHHu2?) zB4NK>z8^ZdtCpG-|KR7J47+McYtOA|msyTN_mE3GU9Y`m$^GWJHUB7#walmm@I;@p zoBA)eJ>YYD*Xv*WsQQd^KVk)kJFAn)htN%`_lR-QDCf*{*PMjxTxD;`cXW57i7V*vO1yB*ZW-7c>1}d(P?(LauO&&G|`V0k^c3g82a<*v7&(+ zCe*KUX!#W52BIHAx8AjsehkfbCFhB?Ev+Bc^ktp1yjg!*0_5Um;5ZP23tT75HJvvB zO;E=t02_dNfg6An09ykXd**TtC*R$+1D-+pYk&)Yfk1nJZ7%JD%+s+?#QSob7z|K9 z31nBME`$94-WA{pL_apS@UI^c&BN51!C_bS?ssR{Gd(C3ul*3ZLDUYV^ux2%L<~qF z%7*us^@qhsdjo`i39t&d4af($4>7-ZydVCx@NWeg16;Gqb<>H!R-~oAaPF!P!2T}F zmu1Q@eIzmZw6xI-6G&uOu{OT?VI610wGLAeZ5qCORrTX@6P`1loZl<3A0%|EJfI)L zV?F;2+JTh3|KyNr2m;Rk^ChO`nK~* zz^8xQ$yYBBD~Q!QyKR_i8J^R;Vf!$(x6Rk_&wc#b$3F$J)|%h2P%ngT5VZsJA_+g^ zo1T^LN*S7uoxw7l>50@0mpe!H*kg2l7exK^w_c6{?Wii0KXaHH!f`3egLrTv+4px{0aCBOjLog zo(l%PgfV#u1B3uDa2Fpd9XH;u-(SyN%_ zvcUIZq(_Ho0Sw-{_mE#z?4{k;p^oM_)c4yRsuw=WX_+0MwtNzxE}R{xW;X~@JFr)D z?-zryPZsum#>V&~ z*c?Z|-VW0PI-jvG;OHi7f(>0jF)!?kklqiV{iTDL4BKj)Xa~<_qfKWVoBKkB?BhQ{0=j)o?L`aa zJO7-5bFr^|yN9W-F7MR8=HwMu9N<6%j^BCHz6#x>dXN6?E7#PR2G+XX*_(qmMExVE zqoU)~XX-EQsn}N9(Qn^f=7f4v=<<>?lcYHzPX{^W-BM0Aw>Agkjw8Bg#U%n{ zQnGW73)?Wb@$YUk#I+Mfq`!I`!+Ov03&$>Oe>rC1c%?be3cw>8W0KDBy8*ob&NH12 z!~$`^XkZ+G85cDjxDepn(*j@#umZpokg+G$R`|~WZvmeGKLRx%qe!3+!1pGzfaL)9 z(cvC8+%u*=3{VV^1*`}51N`S?B5)n>9?%Jm;ibR_KrA{Ln}Am6P~Q%8fU$ZCn1aqg zRT!_Gz;X;KrlB(tkHOwh6zzC)DDZ0w{5KB$liJu<2py9;5YTfNR)_}yp?FKp7g19PuweA**;ip7r$5je=m{XXA#08y*$3j>9{V;-$8iAr zEqD~855#jkq5+7*=vUDvjZUXAY&%;5{~sh!04Bx0_8m;k_l{?*_EilEQ)647xc;jn zBTleB(TRN(x=HmO%dxLxv$Aq?7|S}(`!FgG=YH%u zfD}OHA$Fo(KbwC1#s)t;@~Mi(1vr`KEuov_lB56ejPX+5h+CO?2u37ddYxui+E{YW zI?wi(-8P=nzL3T+$2!t3OIYS3c~0o(Z1aW2uzrp0Iq%E-2!_!uG2*i=mo{JGF&{e8 zd7W{2jbPpq<~8PpZjnLbIj_+tjS!lgQw9=7u*B(dDk0i|e}n||dfPD0TW|TVIsUhX z>wP2R(Z8N^_Tl_tVd|{@CqffuT-71v;HOl*l6ot2t58bnZJf)Qo#f z-<6eZ0uP1AuN44_S?szw7{kU&0KbvAK z(G#JQrn~a=1pj$6RK%(umDLT#WBG|)6w@9Q6{U~|)pxY9wp0GZ$48^e=38Aq~?+mm7SjWi?%e50Q1h@c50Bm=9B%tfb z^3neFo#NOC8xXa<+3v; zD>Lfcth~&b5+ff0xqsvsub#5JI1j;oQ7VLfGVS6U3&7uye&5Wi5g)en>xpI#a(|(l zRPRy0zkXw@Ub3vISA^&Yb79%@oOJR;@SHx=u(D7W&jRKGBY|jubGt+cAo?bGfMhu4 zVY{*=Pyn*%MRbyXy(om}-{iZxW`3dIch_Hh?~L zf?(f-oV5a|(4zsq?x)UjKA-Q-+3vC28J~Kfm$@FsCEJ~X1PTzhL_a3@>IZ8e%U~z; zCj99a2N#YDQ>!8_davk<@eQi=WNCQqme38NcF^@>=!_X@$!XX{cAi&14kIq_U(tGE z+6dYQ&TFtg%6?Kypeqmqa128mcn9!45Cx@J2hhHr1gb-67D9REBco2p=xsdeUUY)j zqJ#Tp3-p_yaM{s#X9IgU00yY*?f6#a5c(H87*9 z>TyPORs2+#n(|O>H6x>uT6seYb$ci^H@akfm{tFAv0O(z)^*#IuvuSNXIKYX1Ji(w zz;J-_VEy5BrWYV+*jGHd;q%;fr6r*E?@}lE*Z(5akIOSwuQ@Yv%8h5dLT&WwztF9B zC`bQGnaWeq6a5}6Z#wD?={B()E%amxT0?$+0G&XT~7+n z_0^LU#AS0CvI_qc8T`rkV(8KICN*arIo@jXwlQW#(vAweDCeBa0RP;`LT%W`s^K6N1+XaUp$!3m$`Pd)i7oG!O^=lSm!A0AL!joBXc z@zVTV)vf(vp<8*><%YQzcgY6fmQHd35=uK4H^sO7to`E+;Irz_^NOcm{d^~D|5)gi z=EKujw$^X9XRL1o>nzKFj^)X7(pg>v&*?Lb-A{%P{sOlGd5V7IpYLBk4nTjFEFJG0 zzVxxjt^H)7TUjhuPfN7~W=gBRu)oYYN}oDH*!^Y*;eX_Gec3S0S6`I!?Kg*95T>%X zUc6*h`gIGe{br$CAER7-DXSBW#8!Q==BJ<2meAhNr;~P{`bF6NOiJbSx;4m7?91Wl z{`Do=iG2aaT)cVEJ&!(Q?Pm(z%3Wpjr7Tl(Dte>eQ`a5p65A+(Vd@k0$nJMS2>+qe z?Mz{cuim5}Z@u4{os9odyjrlb{n<0GxAr@QZe^!jy(y;?`v0x}S%3%D`^$X(mH^** z>8_P_!nXBvInGH)y)Vr4EkEv0RfOveU6@0-`R)UWsbT7^SE~O||Bm(58;meH=z|Ky z^|wN|@`dsnm*<|IHO!gW?VNFG@>`LTbzv3FtFWH3U&($2`xC6Q>|?SGAh#SNa=Z`$ z$a_Q1zfkWursR8M&d)Xk_^y!iGJKcFwW9j>gUxYHxwi(|0_}m0Kxcq6Cf$G@0N0lG z0|o+vfWg2}APyJ_Bmx|}P6DO?PGANw3&;lY0FG}L0n31Efa`&qfja@tn`{A|0$u?2 z0Pg^w0L8$sKnRRmJ)kAf4TuJ~u6G(R8@LR(0k{v~xQ_35_e24;6mVfU>9&4Xn}H`09*w;4>+KN(ZHnuJ|$NXD5xpGMt}u23D^SE zL&41lJ_g320CxjJP>9b1BTib0h3Xn;V95ofK?G#?~FnnhLn=D9VpbAP4Mqi6zE~R%t(pEe`A{CU!g4_`_@R`7UhWojY5Hr zM1d|rfxd$R9oZA>no*$Fpg^4i@vj;bsCzK@9*X)GkNss(p!tcA1q$>U6zHc@@GZU* z^KUb-J{tvEkPVs6!9PDypobShAC_Y+H43yC1v=su$mlNU+yf|!t>AM9=JZ~~{NEec z>)>77<5Q&l7T@*%hIP@^9m>_fp&H@mGxZ-vGHFYe$-=7XY*P&Psxds}NRf&+V zZZB9LGJ!Dw^%1NYx`anI>IlSQ=sx2isZnPl;X{l@-GNArHW5W{oTHeGYw(PE1GO<6 zirjE03L`#Gm?y6@EsD@c2URiXjL&)oksEc6aU%gbhM@)}`7pgWrZ3AejqPj+*b=ZM zU`yciNni!ClK$VGY&5`dF#zp)sr|mP!qkYvPwzPvzh~KAMu0mPVE<3(22nd`{Xf}J z5*wH&Wa9sb$+O0~veU7f1h$+Gmtn&;^{=M%7B!#)!G zQs|l*`pCWy&v}jdDE%2*Cw>3J+BeU?zN~>ht*_N_;U{rveeYxk6;AX;=qA;BtgOCR zwxK-b`AC)}%b#T(0q{xaOWCu`#TFrGIMD++xBbdXU=5;5yOcfGS8uHQ4DNwmy}B^D zu+@RPPlTqhc6#+j=mt?cR90^++f$yB-e|Y0bdY++wvFQ*`fT?^&nN|+m!)eU+YS;a z07P$!Eqa5g0b^cG);SheudT8}4^;c2*4Xzh#5Fpa9rkC0ZV*a6-?RBP7x4-JxqrlbU%j=y$IZ^i{@j~3d_A>llSs}9(aHUVZc@F+a_(>ZZkn;I z?ICTFfbA0Zj1H+?AsrrSxJX@)?H2dY`3@mYL{?=z{2m7Nt_bKbx*nng4?#72;V$FH$e@uNOto zo6*1Cv@Z8}&ag>lx7zq#hI%1%t7r_ph#HD*FmkcMzx+`uYFJ)+dX)5y@c)VuyM{&F zGxO4&Zpp`LSA<@XFXc}?q8$>w5<1fhjn_rrgic?ao|4~`ZK6k4DnNJF~N zNScHsg%%Z~zrR}VA|QAYFRbEG4i!-j#iNQM-W5f`3sh7P4-}98d%OFR*-5fVFGRYN z&+N>+o#XAB@4T6vnVr-ZKf>RY1?eHNoN!^Pdjm(|B-A)`FJwbFO1xH!Be)eK!6oIY zIJW%fV;-u#8ooQL%IdP)YoZ>ZJnG4P0DD+YdGi!1ox~6F^Zt3U(xPo^3$?eh&6am;gwER}VJ~&^rP% zzru^537B~mCJEkwMV4t@p$u4znRNoJUBTka_EQ;q`b=0;8Up`ikqzhROn~=G5bh{g zPrBg-SYNsyn1D5-t3HKwuvRhbWLW6CSc+lu?vG(zzKvl&p5KD?^0i>cb!y38frISJ zVIj8f-d3!nrZrpjavL`KhqmnD>~^eVM|<}A^GC6Vzl~=<&*{k8lpf9g{J9G|7Z%KZ z-`0!mEkBucPB@ia`_dWg_RZ(BwwGkFc^mTCzzZyF*Et@R)}w;Wk(RRSA6?7#-hnHT zEC#xnp!0a}#(&8`b;<^+Go+#WA#Vba(m}Ncz4v23Mux`R6gJ%EErAMneA2H=g7s@F z)UR|-epXx(D}STriAlenxcjCOMQ)^Di7rYL^sE1z{7k14PYDQhOg`iJU^j_+-YcIm z((Af7cIz7tcdV&^dECik4t_E3i#9iG$60vgdtMxG5?zmvd{?O(P9_M+M}74@&X3^S z8*+p5Be>@SWrJ%2_@3VfY(KCmU{k@SgUtbpI)6G?_=JXmnq@w)Yr)onJqY$hX!!YH zZv?v;ES`&20v7j2WI@Az8>|x=bwAMgIO+Qb*yBL&J3#OM4oqzVralCwGC=Pqf!?18 z`xH)sh4A^ugT6nJv6cPd8=li)U&cA`ZFDB^I~vYvn*?XBS%HVS&@bEq@t46KlNaE; z{~fUBqIC@W{aqR2T1h)5&j;#APN3(0kc4a4I^LP(Mh)nIac!9RvisvS#RK~FjyI%RhQ^%Zi z+VyH7xK9qpM?@FPmgiGw;%yY1oM4mW$u_aQVmib-wlN;-7)Fb2hy37`4If6oo{4l{ zFRgLUkig+00WUB@?R9sA_KH03xns_?T|Q`wuLrWh_KGt{B3&lKMQpFboK~A-Mk&6o z$;Jy;D&MzQUtbh2jANG^b=@1Aez8n_0PKih06_5aIt@Hwl2lvsi^poXv4If8L7wR6xFOe!lAx{dQY9Gl`YHxh?;b$0y&5d%w_7 zyCu3p4P3=`3thg|U96l1Li(cSt_bAG|s#UoS7?Uh|fK7apJ5 zYu4TR?G+_8J;n7{!r85rMKK7|_(G&(Tr^^P&2>36;|pF-9aySg{zl+0{;CtY|1@IN zRm1@43!*Ef2CicHd2=Mm3AaUk0aKl_ZlHJYKn{k_kbofpl7JUHq%W!;&~LA0zBpD{ zHG0ajA-DG*t#(?}UWrcmk}J1YZoiJY4>7N_M2R7`TU@T-$L|*^NV4 zG^|7t9fBGI?RKKsT{6r*!)ljCNgi{N*<;SL&Xq2-W?;mItcT(r7+e!Yu5n!|5iIHv z{Kgmg>IxQ?BIWhb6Tm$QEUuBB3U(mav%#JZb|_ffACm_bK6#ecOJ{+51=t(G-U)U& zSlFJz-Ua(D*p|?sj|V#hEG$*B>%gu6y94aeAe+%(Zvp#0*b`y!a2eQ7z>WYZt_Pa| z3hF(uvtd0I|4V8g*ex*F*aYjU@4~t&J{TTvyb&I35Ol?;K8QA z!tWy|z_-xwU{m42K7|L{1`k%43agkyV86~VSiglu;C|zwjxT{{fcLQW9{A67FPx=# z3#{Yb3vr%=@3CKmeL5d9_R$Zp1{@p1ZiVl%-NRzomST7qzyPj?LJ~ht4m^w!5C7d< z!Lm3uU|aRsuh0Ku;<{uxD*F_k9p{IMu22J4zzLn3K;O;LCvtKmAFzTrrE}Jhh*27hrb_yETcAci5qpMM^HpBJPYZOu8->DqpT{9 zJ$~|As|!qhwtaHra9Ik352A~r34ss#Bu{hbuus5BCw;tjsuJL zU|Wma-yl9fjmz~+b&L6-p|BD%uHhu$g&TyAf+w{25Wjz01Na&7)_~)4p8WdL-`h`- zvm|^FT`VUAJ~W@Y>ET1nE1EFYKel_+8?Xh6O$3WrngbU5s%c;?V26U802aDw`9CDO zfQ#c87zW6g^*hMiA-X8ea5#a(K%~0h1WUty1%?1fyj;=*RxVFwslE3sI@x+55B>C*pZAxlhHht=a7d z95?br+Y=)coE#68hwr^a7fS}5z#j|2<_c-pZ1}p`YH>O8B#Xmd@mtsQ-RHR=Zv+k6s&E$m;}n5N+jx74M|Ne+#|0<(Zb7vNFfre!nu3qH>AO6)Ai9a`UYv zQl8ark#fv#kHU(~14i`0gW~h^^V?!xjU7hWiiT+PzJO1uJZYdm!!$$_(;ul}9-n(R zYH=d!|J)66tXJMG%Wrz%v&t4{C=wx@5M7iLj}t#AAW~D{g6df0f#~R>#eM``s%xTA zSacz(Y%pGPF+46}H|gV|_=PyuWI4d7-P3*aQy9E{I>jX#y3NIS;X$cCtB8OLmYKwc^gBOc@4{=ly{tAW!UfSqxdq_@ z$FF9KJm$x^JT84N>*JEW6vrNW`_LabykR6fxaYTz1FzPf?V2bErzeoTE_ zjgG-mQ1=j~5J%{zxIFH7j6oE`M34ZFi#4z6#`!7{7g%pp$13FHtf+2D*I=0HU5)@3qs~bZjpuqHE7DiBuj%6=wI+^TWF34) zx3wSbYl9O=UK7yMb%|lT z$Jaa3&=6e-DOaMA%jXr&&!;#1O!GdSyhR@;6@a7s`9F>{ukGi4Nfj{Rgy^D7^>D%u zfkNSg&x`7lT)anp4%R;!bdiP@4aVi;%S7W+FA4DaBzLPmPO1S%_x<_tn#Z5r{5s+T z4dI073N>)m!wG%sfw4uL;KV$ROVCoigV!+sk_331l)a;mlUl&h>L(uF_QOJW;bC~j!TM5De4QxlDFhha42Dxu&o(G6ESKB@UYA1BH0 z!~US06<Xl;Nz16Rc;dU(Aid16``_0LI0RV#1Eg3 zn8u&j@I;gVkC((9`gp<2Rv)wMqHaC!oktlf{ZZ#2I^B;JFVq<=frK<~ob|arKUKi* zIi)cjm+W3MVv(wR2){%pKFE!hAKW)*lK(X*&*N|g&-+k*b#-xioA8Q$YzKsGa``+d zE>AQ3!4mKSiEvZ=r4~1grOErUHs-~#gblA|)Bvu2&dS}s|GN=S^?ou#&WzsEh%T1E z<7UjXOC^iP4LfIH*Q_M}M@-Q8Nlf3A;ZPVMTw%F{E2N?2`|D6?G0l-?yzoGTkBYDL z@v$55^U!Ipjh%8~_Q}%tPO>NnA4C`B6AB;c(><^YTUoO7fuOPcL%ClMc??y*gaf>X zItcNAmLI=Cuvr-|JT2j)YPUW?#TzmN#b^AKGoa+gr}819m! zq6Xq4RQ+LULO)p^FX%@)Vg>!p#dzUC2_H4z>fe=rgA=>NPx|Sx zqIvj*ZU7%dmxT{R)^h`V=b|I2CDjG2c$u~UflcJ=P^ARtS78H()GBMf!~cIw@F~}`_GfWo(c9s zu(%Hk$K$nN2SMW1U~Q1WEXd$XPyjze2A@L)N5Kb#zd<)y2p^H;C&PIM@WE->SU4NT z&Dg>R8T;-V#>#VI*v+*u?4hMC*wVEv**iI{S$RcU_WSDgZ1dR(tp9zTS*P_q+2<<; zuvOiMu;Ydmu$84(u=24hnbY+byX#y$T!yuPSJNxO4QdZaI~0bnk7c2s4C%w>-VR6} z{CiyDUj6pq{2`8we{1l;{LS6F-+71p*_(gegy@tnxly!-Oyy&IY7t6GAE4+^j>8bN zWY8~K!V9^GBR&nKZ7wdaM|}}+gEG1Ij6RbFPWtmp=Iw<;Ss6D2;OeI%kuy=?W|X;1 zRicoNpLebKNgv0_``{en4c%AYdABtAsn{&JRMP82=U9=wA^90$b4)YaGz$Gt!FeGGz1Of`_4)7(O=8mGjjy%%W>&hr6i1GM_Zp(hMDD`#F{}*cL+o&Bf%<-f z-&1-aE|uTwfLOkE-p&jBojI-G+v)xO82%9+TmgpK4bc^9;HoKq`gE(sD%maYZiQu| z5!(rm<3KLKKEgNR8U4Keqj4eLLyIQbe3jV7l_bEoldM1V@lgf%`QV9zKJ^(mTi$7?Ky!6>8ubT3!<+>x^PgK>IRQ3`tOK(auxgY&@Q~*cWUn*j%tM&A=W4 z`#o6vZ_-_0*MczdIcUB>tRILPWT+l^7xg-Z`MSV*YHCvn1rVMK{?@ObDyYBlvF+zC zzh=tdGgaoPeuyset6M)o+K;hN^5f-zev}d77X4^Rj^Ne!G2GOK$M+79AM%n87G3dt zh_vBJtj|YnOXse5I#)a&g6JZ@y!^(yC0B;cVVP-_&)G4%VKR;e82mg)*BCr$E5L_% zUPReHacuIwi#9LXo#7VGiy(T`eCQn>0h#zf5WKz;^KFVS%3d@?L)`G#!FY%v(tqf0 zPR0ulOYJ|kr4~2h`4LM1SC2oxw%c(_ue(4zKZ59@?84$#1#VN|gX&u3h3M#_#X3iq z>YQj47F~!c8;sXn46ok`TkGRvBj9Jkj?C<_?cLvr=SUD;l$$O-xGyXl3nzMYhxhpV zs3$0lSfKmpr!aW^bc#zfbeoIeak4uCPO?TMu`B;cD8BQ>jd9|+5=0l}rjL`rmUNzv z#8`d2I@`pvPwai~$z42TRUuY37#hzIU7-f9`h3vtvby(sqOKtlO=$ocR$~7@!!+Drz}vjCY%smEKwgPfiL)cP;vbD2ik#Ipm$?#*dm@kL3B*do3J3?DIVz>o=#;@J`^@wMFKotmc;AhG}UHd~n;r{iliJU80N66g6IqbJs-C9hPApFNIz7@v;%{RQOxwp6)BJTqmAe zL3HsUqsEJRh=r(M#QZ{q`Thp`BAV|*I`vVQj^fdK7xhu(VjMJLSfLtMlmNf}u%w$l zUJd}B-m{Eq`}n+vg3hlXx+v8;;)RC4LGMdg?^NGd28GGRdptHU4j-Qnhl+>yMPuMb zlt>`V<7Vrz`nXBy9?!OK{rk<9+g`s_9RCtMkh9{eD{g2Q?1M_<=ViovsZPno`^NZJ zlv2}$dECVI)W=P6k9gK??nebrw3ysm9RCtsQG$XeL<14eAvdkI?%wmW6b*q-)S0Z9fE24O34E_#hq4 z(|CL9<7NlosxW)cF`qoUwuN}!1<^$|qQ*_A!!IDSQ1~Hi@Z(-87w_=~!(@3p@iZ|F zpWg86OTY)W2|vC1=;H@-I=APtAsO#(3_AZpq+?t(^}-KzT9Cd9Eb&)-l0JVm!2gU% z-bpdr#`hP`!yr2H#G88YCmxOg8HzaP%czT=_S<0^^dsgG-@FS!zcH}y7lp2epEp?2 zSBoRYwEOH20M1VP>(UGQe9$^WJRgJTVqsx%6zZ@HNZeR>5&4KF911gpFHBE(LmFDX zzYmob(;R7r$4gB=eY_+m$FnUhE6dmPyYo8nybPj?@`;ES{_qS){BPkURDBaJ@E+RaSR42x+f zOfJSpKUp3>=tnwY2mQ^(@OVi!>Eos1lz3Kq(zTD+hIC&co~J={QEp-JLLZ-TXRlyd zQNJ9Dx*&XzOJx!!h>mV^?1T6^^+CWt4o(sAqCH=u2Jm!qzrQT@m3zMx&(|P2pEvr$ z;w75HHXyx-A2I)?3KLc^f5H#?NuM-#+@LJb_`ni=ss`%gC-(Gsmizh-IjdH8I9@!D zg6NnhZ|aI4@tf^KjUUo2_zdV5E#Zb-n%Cl=xjFfL@UVoRtU>ztLAl)8nk_$l`GrHo zb1D3EjKrC`;)nl+8?)i(PrYaA^S1-|?=<=3Eql*xbCh^a1<^UyWN&2tLL6EFDGxQS ziEllU|_ZcrwZDz~+rz4WDT#q%oybgkr~#*Lr|`S*$) z5%}7jmBdbwzUlMQX`a#Ic@{+1a-}m)40X5#B;e*t?TW{}m^UA$Hi7s@Kd(1w+==(lqKP(NCAM)T3GnSI>wJB@Q~{oP zp8fSP+fP3`Nj&d@=#($HVcXTP0A50U;!t1QP`SKI*dR*)W9_?ZbBV~0m-Vt;&_?PJEl4h zS95_@e&Tr;UE%)B9|yGmb4}M`@jMKoi(Et@Kh5D7 zqWr}CFidjdUDV4M=4FL)Y-;0!0_gpyYr4MtiqqoRl`qW6akn@rQ#`MN=pw(-%P*An z3dSSm&&vhw4+B4Ddd3nRj6F>Pk zWjdXBU)1wR!#0T7qUEthejxh|(a6Ocm>$EF9{v1%2pT3z33wqM;UagKJ}#;OH=EwF z|9Jn-Ytph*ffFu>E*2Yv3wfu6E|`O;KBIvD@W>=zZdu${L!v6GUwc#JxK)u;gjfk zL&sI{E0O=`uOO2VLa>5 zBIVWrFZ7)!sl^dKh%R!$<5R>3-_?pZ!LcdgfX55wO;{lpX=uc7IGP;UxYSt!JWkR^ z>EonkR1(|#*tlJv|Mu}rsu#iu(M1OIaKd-FJRiklBJmN==KlJ^6IWg|^wKZX0*Mcz z*M$$h>kWlhzR#uSru?ZtMLONX_~gfU6bJo=X_y3foa~K&lj1Q+Y@TcLs&Cf6`3cnr z;e_ZSH+p#GyI`J=vRr+<#*R&5r#iNNb9ZW@J4-E)_#k>+_)tDsRR#n6d{69HeLkwj zC9$}~FTd@-;EV<5349Q}9(?fXUb9ZHBmzHK`AO`S#h+~*dH2NLV*L=k9{liXMZ-_> zIDPqGS?67|IIYuNYkN_-SWh^sDAMV^9$wUX;?;|WpEVKq**!jq?SAj&eG4k@O&8@u zbmD{DDEQ%FtXXf*&C{1p#l$4m?%AJWkIx<9?yVL`I3_yrL9QM@;-@Cu@K(cD#dv+b zb_3s=&nRbG23?u@slXS}i63&KBJyDAr#HQ77 zN4(*2QhSj;PErfv*-NjVoN>pJWi7<-0*EdOEEG-xp91({5~NSWe3~juSm5&~Jm5WC ze?eTJMO-vj!{dZa*2hWVq$fYs~3q(h^IrcStU3wuv^Tt_)`Z%cq98I`za`ub+W6$b`3jknfyiIh48o2T} z;kLr~mqvY13H-b*zyB$ai{j(!jp`EbU>&OL$ZZ{I6c_!5slNpH_xZAE`uL~?{G99F z_ULPg3*TFS2Z4Ygd=Oos2CiZ7Ax`1?7fMCEQ2Pz!80h(bFq|+ymG^ z8tD+yFN705eq;H0xuq6qzG9qiTi)HgTJ`z%{!faFGWk+0BlPD zZjHc4E$}g7=`%NW9Q^aHJ^~*^uM;0(TfO%GLJv&W%17L{Qy|5&M-QAgu%GwiOmW{1 z(e?P!{O^pvr&3ag`Uk0^9zhzfZ!k=TFhwrXF+GL}U*XbXT*K%~fNw{=tok_d&WLCC zwk;U_p8c(E;yxati>2}HC>SS!spn8QG4}I_(){C9!D(Pn4Fs7T-+m zmh>&r#V66niDpSaPRir9cBVdVQ!kBYztn!P{o&-5^JxPI@k8{w@e`O;7IACr^ARQa z?}mAt6x#H0k~|sK8{hlKGtJ&@fQVb7i%+AE+rUx{-+n6X`h4sKKL5OV@1uXs_ihmP z`w%^9KEjL)LPXhe7vc{>8mt;pgyJ5h_n+i%6 zZ58+b5MAUVEN(@-1iENB3lTTQejrh@|8AJaP2ntk+|*1-VkZ<|^T(9mUi^jHI`xZ0 z7oR3-+z4GZ&({*SK3@lb?-K{yeBZn2H$U-($^h|2^m_9Z=(^=BLg5*8AsLbjg=x-% zbRW{`eMF2yVZ*Jz1bEz}c=T~oJT-~E@m-e%=b!uQEUGuc4beqTqQ-NeE0?q2`KpP) zSFAaSO}hG_;?W<**|Sszh%chon=gJd5oF>6OY_skrTX%!nwG>I$Hd3GCjJpG?k6I8 zL-`WA4-J2@v-SDQDgymvtNQV`JAd6S)+f;$%AcU7H2hUX;1A2r?Y`==xfc#6_T>3E zoRt&l#Anoa3$^(OGVy_>`puf7FTdSV68q|rykYSfi#8F1ggc@WU*y)6KcQJ@_}d+U zzls^~-N&>J-*3OKY*KHP0pgG7#22|y^A~1wk`FQ>`6bWQmtRF$Je&W~ou}TlXM2vg zFNx^H7rFJ~kL#1_(jQ@+QoZtiqd%hBXndE~`-PWl@xz#Qf6_+4*XhL_3tvb*cagY1 ziRdDSVezB4SqU-`aUa)%- z|74+4+^O zdZae*sdMk|BJN`%I-fWC!{Q~>rY49l;syJGaE7l(s#}bUb!zNu3MaLO(fM(2!FBq0 zSp#^Qzqo_@o`PRL756m}UF0SjyogiNxXDSx4Yg}Ae?E-(A&YeMBaSF7VG3QtG)w|K zZhRG5+!R69{QjoBfUA>VzUs~UOa2@t?r$Qx$W2(>=xug_Osc^~yN{ADldys`^rIoY zL%30>jeF(gn0mcdjzRmKtVwKj?Eq)%nH_B6ekY=f+(jYB;LT5vi4QEzr_@H^s}}ew zyzrE#$82A}ypPHN&G!&pCHtM|`3j{S7%SuW%e_G>x1MnCc(Bf2p#9I8^K-?eN$j_0 z_a-fPf7>tXRSt+hqN`-TBlCxooa#j4ILYjG*tPqwYN1@jMmku+4`QaUJM@zet{jr~ zass>a-d8GrxZoVOx(!t3>mM*g_ZO&oGHh1+Ow+J3r{uDhNOq4IPEK+-W?Ch;Dcflo zElEWZHZSG{OZAg_Q{egA13fJxfei$=;Kq2irhMnk#lXkdpmdMyHP%i%i8Q*sT z{C`n@#*RG;@H!NpX(D4YppIg1V(gw3jAiX)Y{PLe%z0@HdwO#W>pG$ZTl_@}*5%Qb zZ2Lp4*jZn-W<%$;W$i9+$5ysIN|qal5AOBRn*G{#nxYjsLWRDL{{dvm;uvvjzHeBf9L$3?jy>~~&# zt7lbB0!uW%{nU4>RzHaHM}zGE>zU{>k-O;NEz@i%mT~}mrOt7ZyVT~vis$*+A@GCP zZw1!Zjj_`&8~+{_Q#Psn`oVh-{6zRiHwMs0bd19r9e##eU2czp$Z^uFQpxRsgnT^} z-x6pCq3WsN@dTFh{88gQZ+XTeHqij9vV4dx6S)i2iU*oup5*aZ?K9k_beqjFC(q+> znP*7p7K`L|=at(n+V)scsn5r5;PbTq4W4_}1=l`zr&<=)Bi0kqITmDZj>BTMspXnR zIWBczo6L9QqL#o2K6qfh-^047uR+^QmVg(?q^~O$Xz{_iGFe~8&W~q* ztn*CY4er5(`_9`p^r__I)a(c!L>Eg5!bhHUu9R)RFhh;F16)yGV|`-(MeUaK3GV#> zmCM?J#rBFiJppVISnM~k%^+XB!6t(}4eZ%q)4}F|y$Gxo?B!r@1N#`**TMb(wks5x z4fcOvUj^F*7(ku>71&~6qy;FDXTaVB%v=W#{RA-69vFE5^#A{X{$C5C8xI|f1bqO? z4VsLsuSNW$9*Sh3c#RRmnwv(TK@#BmjWvt3_!s-rt_$PYBZG2N#vT~mQq+$`7nupd zKc^puJ6z-KMUw0EloWq^5b* zWKI6M0Q3l&8n7+lN_3gXU6gT#GRY|qbWG!<*=C!y$n3E??70q`)lxptG|r4;RWv+5 zy%y{9Qw#haeCxB%lXg9L`+QWYV5Wj{!Tz1-3N>(zj-TN$8d1_@fy4Lrft(cINGK0= zbtF>(5vX6Pg6Bfc(XcX$Mc4Cc2*i z)sqY3wH$}J$dnD^IhP$?tMW>nP8W>dfUnsw!gGVdfDvAXG~MBna?Mt|XAma!fhGCu z5cs0^tgUAGGB_YMp@l%s8;#iL9SIb3op3D-xA;t#|w!2a3-z8_{%=* z`@p4iABP`k(gnIgWo)7}Efaub8tSl=;(NSFDw8ZQmrw#t0ps)ni{<;4eSPa1D4)+C z^XBU{_bzR{Vg~pwb^z?uo99*@cq)O7I{4Nd@tuldMEMaNqH2tyZ*t7#j#7^)Z^DS| z5&$AhH9*6JCNicJ8cB)6?ZGBG++|kYF)#z3uiXM)-rJYRd~MBSY;fT(%a=Tpz_YHi zF128ZzruU;`CH;lVgq~UEWZBFd4Ij8_GiQ&(F2?*K7~I*8)~{B9`haJozT5Wd8N}p z?>S0c7Fi>Xk~}V}#XZmzT1f^`EPD zZ36qd%UuieIxqfhTda}+Jr~i{Z2gY%Tzo$rB>17$B79z$qmZ9zxXV$(#aDCU`|l;d zC$(dd%;6Etp>g#jR*Fg zF=VyZy>2yD2`R-z9xl?5>`0>!1D9Z2n3A@_-!u9ZGsu(I?q|^P7 zUhq&oY>a}B%tgL?&d>k!Af+chL^|CM$%oYfBR(YtFNdrLBFkZ&+12i*z9%oH{Hc7A zPWMBW4``GmJG2Uq%7wN*wno9n8(*LI)%>ZQdQmyVhe)UUq4_8_yQHZA${CXS+M~fm z!Gn?I(S5<)&h8g<`i#mUK14d*56OqqTD`IuoTnd+8sDr2fu9z|-`!3rMI_9Hl^#n;bDcoBSl(5W~T$M&3X=kl+w zdw0H4en3wU9pmuE&j*fWq-^YEVI@F#ekd0W^{2fyw2;SvY%i3(V8uIlFFtcsg8MA% zPv}R3^NDyB=`tBE+^}PeT^Y)cx7(nb_YVb?m_Bf*eR`Kg#>0p~TgQ~W@UdA*9pFQx z(|wMQakAtkSGL{iu|m%Z?~?AJrB0YBfWSnnrx=FP`Nc4_Dt6e4GK(e4%z-d3!SPp9 zrIiz|??Mz-TmbW%HQ84tKOE0Yk6pj(+&c!R_EH%@Wr*_zL|4gvM_GfgPP5vq(2?d! zE_i({G21PYDG%7q1q%aEO(f;5&6EqHdmJ_)17LhG5JEZ9x$!t?#W4uZwV=Uq5*l)q zka0a!67WGmg!AG@^l{$Rlf+Gy$mwpCKcf2?Q$2Z}avQ8c+XHiS_}UeWTa1nvrMasl@FO>!z~VXv&WYjL zD6aqEI9r{bGjI*EXbQu>cO^ci?VrSX+#Smk*o$xPA2k2T#4a!dl?_hrB5sMUlKoEb z`(dbgTzPgwPJ=HBgwq|5YxzN3z$+K40zR+Y$!_in_dBLtKJ~6WQ#z%oitu{?7xF`N zIaBVU@RM%0mMHJcxP8RownA^=rwun-ZKW=Wc9bZIo!}r}{C)}^$JCdT%wi!vy(eN{ zj?D=1jabLNH4!ZC!$ABa_Hj;$un+8CSp#7#kMzA23kzXPA!s})l@EX)_ud>z2MI#HM@^aju z%5ehH!^kv{d%#zr=F{n-qJ6d1TK$=JVGhILUdog4%+mL(w>O@Y$bQ-K*D1H(R@!xv zYo(kCVgR3m=rWPJ$i03J3{>ova@apm>Xt@1X2TFh9!{xrj9vvi*B6I~LF62O^v-&UmkFlkoI5t;YWgjd!o}IezL^f(_f0p0*bXNLt zDtrBtbcQ&9Dwfx~y&xOHeZdNSyzEU*WLI1^;NAD%KX1jS{a%KYfqg+lmxTrP)8 z$-xT_@mDGECyvw7U>uoz#WQ)A4^Hd-jrvaq*q%|(5M9YNa8=~wUr-oo_Lwu_t$BvB zYf<~&*mbqOe5(FVU=z>$l@9xPQtUy(hbdmklup`R|ciXy^sPaB1Y&SGs8VngynUpuWUa-`@ z_5y!s(!rvB6x;s}3G{N;pKtcvJ>d!*tD(X766BxgGLgFk$x#6k>|Q8={#=V|?=$-H z!)$lGI&;?A*sn)Y5!i?0Xi}upeXjgGn6;+`rvMrCO`d=LP=l-3HQIgxF)OZf%zwGZ z`^Dp)cnal(2HhC=5nU#7mk{f~j_IBNJFuu_alnfr-`r1`KH5B^x!EkQg;a}3urn7(Pc7Rbjvr%Z}W0go{wbQ+y^FHd%=6j1qTNV z%`JQq{b+~}k*?eo`N%7G!vKPMZIdDjIjR?~R3BBq2jY(Shy_1lm0urhGpj@Q!Nn&e z<2w}^bYtL3beYIq`0>L8v&(9pW`jjz7~PCRsA%gW8L|3SRE0vpNF3PZ(?KAVGGP!KNzgZKZ+=9!J*h%+vj$PLO6_=tXm3JJJJJACr zDn8l=0xA&}_}r!msq(M{M`u=>lm*+2++(J>9XL`e$|%o-+K?rq(N|gPwDo|x2=x-b zFYDxqmO+EI?xW#}S|2dN7U;xZ6nu@4?2-%TxiJl|KWl*>2yD!v9VRk-7oA@D6ztTzet(>&ntCJH(R7(CDV{2o}c3N+V&!@KlosO(U1nhZ%$@zt_d!~Y!YrNLMXwf2)NaoV)AnFZqUj_87jd_GHmjjHeKGn#LHz#1U?Gh zif6MbC-vK$+V1k3RJjlzMCVwLySGF5L`BV8K zo$hnxbMLM4OOhSqq=Cifr}q!)f5=tU2u2NQe9%$y>9KiH-x)H2O4N&^cTX=*<6f`? zd_eN!`{l^^x@6mnIa?n){&UJn>D5{=kxutHe370s;kXYpH*EWqm3C&a6}~)lIm+;3 z)1jr%^;72tnegMJ9TE83`d&QCov~^B_bd0*i2VxDi7#@a;7`#H0%N>hcfO*Pn>cRv zeGt#i8glHmtfG{hM4^8nI`KoU((mS3%y!ttm+O+`EeIet(3C*)t4mm!#7zM<&A5cU zs?X2X+IaTE|NT95<<+b9O;Z~(^)o~#KFHPKNA2qTtjI}t`BV!0hX?K^k)ih+hZae{FPBjh5@ zF!hr_G9=^2Iau$wE-spA+dHMBx*?b7zAo|jG)JmmtRK|3*q(S<^8Q0D zhkvu|L;b9w$`k7c-#>Vn@cvNgo09f#mfe)kRhPW^aaJ0PGts1jMcIh`CEokx(s7qp z{CUnTH>tuyrzgZFI>zA**I&~6gwk)q3k05uG0|-G$g9!*85kwCh#Nl7#_+4`N0n7w z;zpI>5fDkNA91YG*pC=Z{uIZkueyytv93sF6hkRN~2 zJ0k9d3uVOi7Aj6C8omx=yFl58l7A>#sC*2Xz6ALBlibfD_oK7gowMw>pUg@Oy@iSFz8BpKp890XN6NZ&Kt4n#KFAHn zPl$CF4P!pYfYv>$KiA4hJilni(ggPG>R+ZmzqMJQk}h%2l&qRT|?0_RVud##im zSfi{Kmm?3hz1fT0a0ho~Dm$)Bfn9O<5wE#O$s`LLemsxgs*oNbH<2qZoL8Ke#{E9{ zEsSXR_LcR8cHb9#uA({Dc*zw>tlPVt+D$xA-W$J@K|}k9h^|lrS8?B$dPGfz&0(1d zn|Ms49iBW7JU;GK9jBgojH&tcm#x4Tnsl&OtXNN}_b0HTlkT_g@35`=b!vx7^+a?` z&znF!4V7RMEi9$NrY63!)X03h^6k>+qxJ##w&v$+Mw+^o>^&&(L3Ex6^auEefEP7k zwEdM>PN*>93Hvl0H=@kYPjv8VOgOqGQZo-UM*W17b2vJQJk))p5uIF$AFW&8bkXL2 zDC6<^E)~9OL6Z&^pHb{5*W8}SekeREeRIaXlmAi&+SG3o9nUnD6q_Zl>g!-kz zAGLgm`|}ExB(lY;`gtbYxa*Ib1ipyQ^Mw8od_}cCPhd0X+y>Mc4aEngCs*X%2uCjg zQU9C*N%^_E=yNh+HiZPl`e}+X>XRq7J=ASD{#I2=eX{w_r)jGC38&lCZD#&Ch5x(& zoA?3v@p#I9p`R4a1KkV#=#owSYI;~w&wN4Ui~4V(i|i`zmG}yWr)a=SNw(ct3g6Kv zpJmFE&-}V40oSz z&+Iq-_KbP7$v)weAGX}`#>Hxe*klWr(p`~`z2 z+V+g`sPC;$dOppO?ypPzL@R%Mhe3nw*J#7CDC&LjLQ4O8?4SDW*$eGGq01AQzTU^I zx);vJK|}pB(G_aosk zSTNaOyv`7t=n6G(RoB(z(=S84^E3rM0;Naq!{@-hg4!~M4b$}cRZq_RJ@TWAb%b?g znCR+}Q?izZz(aUzv_B;Ri={Z>~wQ+#yM8f_*t%EbC1xrL6ceFu*em(K&` zPjz98M|jET`^Eau#ZlS6Uk=i8j^^~aAXZ4=lV>9>4;eTSuA?>S#- zJy=(`|B2`#&&v35g4JDWwkhLBQhIw$El%ZA1>+n_PirOzdf@K39Rj%uRUF~KD!dnX-9+l7~3<^Wg>S`+B2LeX_1QL zQxxG?67^sFLN;j;FIY!<`n^7N$gyX5>nH)Se(IP!Y;>webjgN|%-uk2pykH{-0f!P z73=3v%Z2I@%cZ($c9o#>!2JHfu1Wg(_JApg-TGtV!js0gKZbN5$`$o3(Z!+^eLK=T z+w7K4@T3Ee6=fT8$wSUU#0}M>n7>|_cnlS%uK5vm4mEy5@qReac-&M+zzyegJP&%P%L@N5t%DnvAXQb?E0B8JdGv+QQtIL#!+NMx`^gz$c-Xt zvx!pI`XQM%R6u+_G=`u#pN8grB&AP*hvC2T!hN8zV8iLThQ_CUSUDFvSd#F!LK=QB z1|OHN*WlC!rLGdFYx@k9Kdt>>--q=>bwqBcGzKj?3HTryt+QA6NRVZl4m6Z4&LLrY zrT=*YFWa}O<&z^n9C|ID|Az*3UQ4(VT_$oDWn9GlZ#?{?O5ndHa~<$6ujPSnSu^wU zIG zN23%Q6GT_;GNwGIe2#pE14elAKO@55gTP;3d&;>FKKb!6Gimtg- zdJXw#3EU8!$|tvO@|L-jllmZIUd~8FJ&on6B1e*8{v`>7s-MPY1=|4DH;=W(F5^he zFI4?d`@v^6+R(pS^P%deu{pxNQqj*!&PJU_FX3qFhh&TTiRM9QOc;GhM$Gz1Ae#EA zPrlKl!ForF`jqNDnsm)6PF?GVWQsDv@h@6KwkVCJG4-h*s*h0hgY{>a#*;t_bSmQe zPvhm@v^h~9h%WYxeA~v7#W2zgV@RMO65!`CmP9d+@yybv&g;8+%=1(x>NMmDj%1);Hh0VOQh5N==d56=bV{>nS)HSRQ~Ay#?GOP z!L5r<57nO_?>LuD{RWq{;XT9>$c6tr{;&2YhgeibasN>Xi25p2n5U7ST>h~`(dfS3 zJ&F^pOL>tSZ92Vpb;+wParMeH?ims=Bw$FukbofpLjr~b3<($#FeG3|z>t6;0Yd_Y z1Plon5-=oSNWhSQApt`Ih6D@=7!vp|OW?n-KMU9PXm2w5X|0d;V^Emf|8jj8ydT~Y zF!rAu-t}W}*Ki4ldNfp+r;(pro`X;{y03SS;za9GUgSobPA^_v@~TT*y)un^h6D@= z7!oifU`W7_fFS`x0)_+(2^bPEBw$FukbofpLjr~b3<($#FeG3|z>t6;0Yd_Y1pdns z2zA~@G|z))YT~(ohG|*})VF>_uCTuF9A0CcRFq7^!u72mqy02Y?$M^MPyHBm6RmU` z9xs~uG5*J(;c~8T4#s}F`by47XGq|`ErCd5#Yp!L<t6;0Yd_Y1Plon5-=oSNWhSQ zApt`Ih6D@=7!oifU`W7_fFXfHC4p%6J2V9^{2mHEe`9Tjmj+`M5TyTEOTITjzL^eJ zl#}=NC2SzLTQeCOT=>iK3iuy3JA0w}f1Nvg)*1d63l08P**{>2E)%(n@;_^uzfc<| zxgDi0i)6|*yWCQ~wM2sWO@R}92C^JW8ZX{AOk@d^K@`G?4{(BVO9zW?d$8Evwhm(K z!!bJx!OK4Q@b1qBEnT0Qi~%r5gKYs!F@yy`3Tqrr3B@G8<}GF)=Z_8Fy6+EB?OSv*#U z-IPB($Lf(r0UtKgcxRE>BS9RqHj;c-My?O?ApX4fY2|`#qczyd&Wt@j=+xW5%ie1F zQ>N>l_eLmu(f@q5^wTj8Z}j;Kx+^o5=K-eGOq!xyVb=V90}N9;A{S|B#IQmQTqE5N z#5^*6mGD@EpR$Lv_`&_lxaYiUAI7GB^yaB3fkz+xE-iD?CFR)W&|p2ZhAYu!B6m^R zRgTp@GYkI9QgWGc9Ofbnx`(?QB?=8eLrJi`B0u!Mmfu16D7wkHb;T85&*&$MS@QR| zB4n@LJu$8k4oIM`^+PFnd6SOfX%vrKy?YeLaDyelxBJvbg8Q{1NK*3|^c&eN2gfc; zU;`d|woRM!694b!bCtZ>K;_`Li|AqrO1sa>AC)uQ?DpiEJ;m~9%Vo+dwOAy#dwQwO zKm5Wmo_H?n7@*w?b`;p-!1e;$MYY)1Bgd$NP(PuIx(aFNqP~a)+YT(oh3-%8|B;Ti z8(6#-2Nv&RT+9P)q8i42lk!GC>N&KCH?(5^gIGn2aVZYPBbU-c6xkr%Fop!`BLTks z7BAPfU-7-E2HJQ2qCT!JIh{8zeq2E=wO^u(JVe`m^Q?2_zS{?2=KF0iKWuL&g2lG@ zGT825dw{(XEVdamFr1d(=LUm&7T6JBaompWvnyES9LERLo{aVb!iduF?@!5(Y4IYy z$E|-WI+@j7o;~42gd}G zNA&Uk6TcDo$GT4ki*BfKs_p%0n?7H7=^vD_f|VF1(&@g!|0t=%;VREGTZ$#qIBB-o zW`*}Jcqz+u*sPZFfhPI?*yXoFO2_kc;EBk5ji3I;XE|5Adl5gjX$en3bjp|9==e%^ zm)k9Q7MIoOQ4{*$fqA)i0y@f`=+YWA4NkIPXeyu1*X%0CcA z`8(!yzpd3nN2lJRDr+piGn7wsu4vh-EnhC$Wy_K5Gd#ueeZK#ysE+*nTVLL^W6Y^H zye>XJ(e=xhhnn2;o5tJWUG(%6G?~R_mv$a9aYbZ)P97Y0zO_}qmZCg}uFsD~9wuI) zR6s(imnBi~F+y4tch8tsmx^*Bx;`I4a`Cgm>$Q}Xk>zniJMY9b{Y%~v`5=0I_z12g zZ9SDeADOSGXQjH{yKeT_h4So$(r$VHZiyb6ui=u%QVc!7tWwGCq4{ELIM4+^D}qEm zXaKx^#rA*}4K@+-lPlj)FFcL+^KlG+!z3Wq4~=7@%@ym#sGDe|Rrh#e{ouQ|A@91& zv8hsos-LDROU&26fhdvSuvkCAG3rmjcLeOi=p6-fGU^1S5WNxW2j8FTYf$!>p05Mm zU*CM2b2|S0V|R^q9O=6@h82NuoW*U}WsYgXW7j3Hk^S#}@?rDR$tx~Xq=s|HIR8y_ zQI_K*e8Z4jXTT^@@tMZKL^#ZfnB6n;9Uil7XsJt{TQH4rID_ZE#r*y&VG)<4Ly*qj zBR{$Hd}277`3g)crlb4}_sEohs9$mX_+K|i5{C8a=SX_a|0?Ei9fhC22>1Ra)?;Ho zZ)0I078ncHS2Q-yhf{uHJ>q&OB{$Ago3fpj(GJgONrDZn12y}s z_d@yDF4Mtc_UOlPdLb;zPk3O~QInp`g%^Ws>-hF3FUHzzRHO8dFn)|Mu&5bA~KB0tKCvT3N*Z85uw z%+qXAy3OXW$ZvkMcLLM+AU_^oVm@LR_fsGXoix6S~W-tP4Uz8dYlZSe-U$gk+as&cNZyv{@y)C%Xt* z6yKhlZ)x#MdS&aGj2)b?an@Gg`^A3wi?2TzyJgu7rDW18L??d8rS^1&!i~Zk&SB8> z#dxibcn7o0o(#QIW$x^hA#t9nIcpR36F;r6$tp z{zPe7ro$zfh7~Dwl;@Oew#;J5GIP9Ja;3|kD&<&9tnjH1ezcV3@R;%>oAL=0=HUfP z{1v#O1eeLc4u_@%&|*F(6%L8 zQKqBR?!hvAV5!~g*rw$J$8*^Bb5CLHr{6cUs|G$TJ$^j)&I6raE5X4L7{mnPmgq8( zyZHIg;+EqIH#nJwJ1nJcsYpdIY>~6ikkwAmcN$#Q|B5$S{6`z_UwH_l&?8m?Yv9SK zJ=c7yZO^#R7uz#i-HM&rbKu-1A1AQ>)h27+yOxe)p0mm_q4rF4naEv)_MB~pC1%*S zZi=cwn<#bq4Ctp|pQEI7R*=8=Jr-A_;cY|-M5C9YiPMNI8Clgs0@aX)+IiLI`t7{z zvjq0&4R`chv3`EH2ad^?OQUv9bdd#WsV1f0u46kNI%ZU+15|?@ULxQtY*0Ez`xYhK z@Nj+FX?@Z(oKqu*x=MiW$1A_qwr_D`%Z z;ph~HcPTEpbT3>!bl-5Brvz%?v8f-g_*UD_#qoNg6U*3{0Ji;LH^L^`dtpQFEwBhX9|mHNz`}YhJo@pl8RaT? zpnqVa?%iAlmBFEMwQz>;rM($D{UorU&>aI9+iPO%Sy+hO3I|Y~ z2M1BLOk?cSVT`>1JNaJAh4wL#v4Ts0Hwox=I4^DvJck$d+~3Gp#_f!m?`Lf8lkhC- z82kPW#yr~@8~Y<;OIyUS%eus{Hl`RhZFmfOsxXEnUlGH;zAJ_uzYgd-W7xZGTd)^S zZ^06$wqR{5Td;jEwP3yeZo$4A+>))F*OGnmN=sIIbSrkewG|uqQY&`P$*tM%m95z~ zE!(i3-ZreDOh;!gkC)sXaR@r2{*!%TesB#5lI1XS|F9PyzBf zwm4o?5EFWih3YX{7pgld6K%YxGBY9>5@Mnv|owOx&?vCOj^892}urp6`G?X)e#O zGRab^92ku!nDcsnEAWNo5MQ8THT(OqtaHXVA3T2X>v#;GY=|$BPWNd)n8KM`Va+6S zA{FI%T#^~LL237075<^+qbFnrDwjEbf%m34bAHCWGh58Qcjbz|N8_2CXpoO?a3#7- zo2 zBfQtsygfHhFYl)rA;~*_(2o@fPl0p#kP*MGutwldoNvT(=L|Zd|1mp1`>Wr_y)Y>A zcM)8PE)%(nz+c#P!_W+do?FE1`Ss4?KeciV#rFwMy|`e{J=0^}ja5$lL-9@kzKPDU zEPETschKAj|DLx);5XEGey4ri&ZkRzWf5Q4hVX4)q|<%1-AW$i6C7Bjg#iK>zFijo zrInMouWU_u5A_!@J=t#&+?EaTC(`MDefZ-ywEBP%79Pt3aO`%U=>-l`R&)MX1M z(&>I3^)G%;z;_R<3Nj-8SZt!4Z8}`B?!|H3R^b1&VL5;PeVgMNXKOhseCeR{qeNGz zfvdkC)!!FQf5_tY$RjD($nD=Gt>h)XPX|h9ja zMM)ppu+hd3t-KprS}J6~&y!Go*of7kIFU3iKTnpDq}30F-zwik zBIV3^f1tF;KD~5$_xPNnjmM`k{DuUYQUcYGIkn@mp4xUS&P!z-o5=QWoA%_HF7hh0~Xla#@0rlUh zCu-j_y23r&Z@3%U{bEP_wS|2W*=@&38{hx!+W$SH7L4-=IG;pxmF#!??K{MK2K>i4 zynE2lJHOm1!G3c{iTv>U;i-?ncW9bR!ZX$BJqX{Mkq_~5^Qsq|1TNXzp@tmST5~bf}pM;oQH};{TaCwhr*HO0w{iCxIV~) z>Noi$ZT*t`=smI)>OcG3(F;y}aO2r1M>NPQ)-TazB6rcNU-dmw@7RT?-YZFNT(M!j z{Cj1uQ}mw~Gimej%PX$h)b(@34;n11HC%}<6S+$i&r4DG<0XuKiIX9Dsa>PY(PEe^ z#W@tNURypChMF^pFnYP8%5VJhmQpKb-~)xwC`zY z7v{+8JtZyJquD@sl~$3guZwppX!36@oJqwwvva*%$zElf#dkDm7Vz?%KDp4^tJ zZMQ@hlFW z!DsNYq5Ty^r+mrP*srq=?u_B2LS~~Lk_@~$QD^eRZjpvCj zvZ8#43rCqd9d3_E$3? zITD@nB{!rTbK##~?A8+bFJFec%wi3nKxvQxH7=hHVAAp~>T|4CR0Y`X zA{o-_k>VNm>o0+7NJ{N<$NBoWN;@x+J>Gfd^m&Ufxm3gz(M3)g4_DA;A#(#yqJ$5x zFt4YU4AI9^ucwk&n>jbeyj?JGFX;o)Q$!b^uKswERoB>3sTB8tOM;rxoNtkJfj-|G zpH5Ta_~GG3WSA%+!~&Gd+=YsO`FF z`!3h(zp0FooQYmfe&s)e6NH=Z$bo-{3lN9dVG>guIEeaEEME*0o@oq>VYC>gdtw?R zTz?7h`m%VKKE7%Ie>-C)exLA~^pc1#qKlkFsV}3&m%m*YxDq9Oc!hafZ5*MGt6sws zneU#TkDm4V9dmQk#~{5$bn)q;#Ff0LGTv^sSnv<;;Oqqa)5d_x3hs%+;fnMRzN7Po zbQ0a??-~BamjK^?Cyvy|l`|`m{qyqstvijkKO^Fb=pu)Wh$~rF8F&&Ue0YU8ubC7uMul<$E5Rfny|!Agps z*G|mU=QnL#5=$78-==M^i8Ug>L=SMP_!@y<8T`Cl3&-j6xe=Zt-w2iTXGy9G}SE_+U!AUI*^G zYlxtih%P=|lsFQ`r4iLrz4R0DMtTW#6k60*hG|?0@cmuxMf$j^2HcJRyQBA}SO2(A z#1+v+?ivYKq^1l!i2^>%!aSaQ7whARO-f`J+Fi$|zjN_j;{`oMbn)?`#FKV$jfSPc z%Mta$6OE5hACZnim*xWLzR0@~uDb;I@zd@p`gqEkoX8ycpT~W<^xSqLo`^1T&@ept z)slfDQLu+um>)m+F44!)j`d0G#NO}!dh5Dl9W&HH2ff!3U3|Q{;K;vUDe~)`W_`MH znm*s&jY+J_6(64Y{qHBmiF^~iiTL(6glOL*NJoGRuLUZgWWtAch87;+P$b6Fjei%AoN(m#yJF#1imAd4v;ItdA39?Tn&(Zn|v!0uTO= z8yaly_%ClnmxI3>E0Yv7u0k-sULX0=&8y2a7JMjOk#zegXfhchTb;z{^aF2Vd{JXvLr+41mFSMQ|m$ zOyn-G5aV>XtseNw(3EerNu$hm7|yt4e>MzuY}O)K8KlEEEto7BEdLz%9*Sj%hUa^4 ziB^w^{Vk^5`pT4qUH{MCb-+haeE$taLJ>$njo5-U7LEW4D4?X0Ac08e7IGw)nc;;MF0IK};C1*N>h|UOf+q*BXi~Ub zW%*M$gxd@|$MH|tHHd`E`*OE2eJP(&`?L-lSuO3;<3{DMIAx%_vh?UH1L=Bop_~kN zD({((zXro{I@LC$yh1&_d~`WAsWErQPhp7ZqS-Z%W5vrnZB0mO2hBkE{!gdL!3=^}u_;g5&?!|MW@oXAIF|r0?@259Vv! z(ABtp(rtIy@;pU;q4kENQ!}*9%0_!#8D-_DCDloq>Y7T<1r6&%z4{GBw1@A^^wx~G zhhglq!7l_d)}y&TqaFpWic#B9OQ175-`}`=2lOoIh=D!cI{MV^3Hlqc9x-2j(dO$> zt_O>B_10B%`ec^AW;_|I^}qQN;QE8=;bgy2pXB^ zF<(X`ltB2VT~)338PzR3hS{qf-ceqML+w=N;Xv#WZgQtE>OidLD`4P?NoD>|C;`HY^F062%`^0W5al`RuN$*eR8&e&ZdtXbX=Odp{7fShV z=K7D%JL~Pc=$?!ge@p|u=1S+b_AtL0O8>Y|Ha|yjZj6@!MVK;n7+GUzQV% zpgy+LYFf#yF8Nl+`LUDJSf{_lQ{hjm@cBJu6kvIY7dyqMQLMz3@eiJ2Og}UH>(cAq ze&vPN#xOp{FZ0=bSMk$ki$kz_-HT>RxHniO;E%0}j6bH=__^=B*K;l7WBf9o-FFrL zNJoJK%kK-vIPG~Qb}u!z!zF`4fH)o2NAVsn|9VfK%PzU7oN@Ad$b5F+)%QR)^LUX2 zcn_#kA?5;N&>*9#KpiUx^GZvE_o=InoGx|kC#C&0>zG-Lm)}R`v-_^T&xlH>l*`p9 z@_>Lld1_?bU%glR`|8?(hcPb3E%VvEnYaz>TsKF7@A4bJUUPKy;(IxM#wYXHy_xuI zPz_f_A=F(hp)$N)k5_H;EJOsX-*YdDEZ2F9AIh73;qNCfF2*hM**z?7489eVx}4PI z$aDG~TvUe3kYc}N@WqkwzW$~A=GfaGNM}5ZSLU;OSiENCI)SCmFP3WK%ZS(Gq?!fo zND#|)V-z?OV~)Q5g|p7!<-@`HN9I%5WSWCB(_e1r-_>3cS&kpBAH8(bNk!#a?4kNm z=CgZq@MZY{P&ZAx5?|!#EX*&+cJy zvLpKT4j<0ZM)N3CdHE%u+)MWZ|53g`>_?=T7!b)GPu9}nE}swUR?ev zkLeNK7RXJ^$6teCNZgLgt9BQll++t<>gY@#dY}%(IMxCOnG_I(p9net6afE!f7$K0 zRXTOQNBOEgo76%zs?aZyQ1IvJMHQDk1!6#Df8LAIXLBhP5#Wta;&}W+D+}- zo$xrv&-i3MyEg}4WBr=gYa-)3ZNa$J2Yq$r*^Gm6%6xWjE>5$4&B7>fKJ#t-xW}fw zwwQ4+PMOc{&B57Nzb60MhVqpAHODURSe?DS^hd_QIAuP&hsDW`P3YH%?cN;{UbA-Z zn8ORcdGhlYds07x4B0WbGGAp17aAAGtRf!`uDJb}hE0=+JYHLd-Rr8(0@qWFF?(!5 z>Q`qVGX#L)6)B+|z_H zTZY>{$%T=3J>3lb<8eq2N{18>*^~?DEUwz46eX)w$3)yJkH2`bH}2iPg5#oEKedX$2}|lJ@sBrmJe@VEK-tfE*dOy|))q{Q!<+c%cDSpOl z_C3fpcVL@^+fR3LSY*@pAm)o<(>>uGm7CKLDW+OfsB`YLCqx`2b&+v&IC1`SPp$1r z)B04S;fYaXKD#%9W3;=}jd_OI>FlotH=N%#0|$kh0wSB{akT;kFzL0|MWf%vt@200 zJzcyhcL(J04d#;{(WH5+%l#f3lFwgZcb)C1&Z{V=F9+;LltcLqoz?g#{>IF?Oa8uT z{<>2yI8kX^L;0L=k~vT3YyU!5J^oSUW$KtS13}*#c^+`sXCiJ$4uSi>y1ouL#CRwU zv0O^LF>-o+RycUef|{HL<5n`C<7b??IU~yH;})_#W3>%;OaW3AGT0eu>3J!^bMw^k z0pKBwBsa1t%}D>naj6F$SU+g;j_v1=I~lS`kD0GBg-ZyJo?zN>eTH~D&o;(urZ20C zXZCvVq352E<7K`OrFz>SUaB}@sz9u#;{wKb`Mkevii z2U7rvBG$vr2`k*Qa@t4wA10w59J*qGIIWr|7*Uit0jTvOCS+Ja6fn4eVvu8+ird7hXb+) zaarD2`=Gfx+1%%w|K|UV5E@ILU41)F7q)jb9P2qv0#^F$+nOMb=Wj##M1dRu5rZ-~RMPBk4>V)v(F z0$PEiP+jybj)PX+Z^T9OYUJ-n6X*W#q*iN>cwLK?+Ym8|%x8B4t~4y$z@%*zh&l@n z%h0j-u1{{7Vct>a2aMxv^v$OYDB&2)huW~F2ZjCYsGEKoztQsnmmg%)xFYk(k7%%1 z15;f}Xui0%x*RjE-G!bhKASegsm~2{b_){wFP8WUUAh#M2k2}WJM~>H5{=*m7P3ZjtJxhk;mHC>h zqHw$!?gE#+607frjI)UVYT%LMuZ<%9H4ko9zDs^m9jm7}IDVN=Ze&d2?=1qTfgg@P zc7Ejdzh=kjXB^P4GD(Y9i=Xs?`4p#UZhEZi-d zg0e*aENGNd@IuuyWb>CdFyX@f12-Y1r7sp)CPx?E7BUg2-}6ov{3l+cWeCn$p z6)nb&24$#uMtQO914njh<-8y)1R4-Mj{4^LGPIgD}N*LLdr! zS5H2x*JCeKJ}Kj4zKpMdUXef}=vC6Ak>#|w+nAwGCS(QYX%HUD=gf}|hd~tTBQ?0P zUeyB!nG_I(Z`N+=cX8>tb?HanN&d)aa*0u7zUHbZ4dkKDRa0@OQWVLszvJM{fH)aEvRKOc#&=f-s%n}LH2@hP6f z6)n{Ewz3WN%IwG9R^8SODoShrZsv(P5V8)2?-ZR+enb<(!CQ|=pYb&qhVr@mabtVi z?7Ma^cl*N~mtPue*HV2?qwq4Hv1Ge_e%jV4JKct^$0$#!gO+V$t+LNgi%Tkao}HL3 zJAi}c5Rg0?GgDi?dEO(3A2*uaH5`g^k;G^BFgS)g{Oa6{G*qWbA|BxOPQoIbJ0OHd zaftQEO1M)x5KgjVK_r;`ZZXQM?Jr-4TV>A5SIVbedhdyJPln|s^EFpR$xO=;x4ZFS z2STr-z%TM3zhX>a($R7cI|_xlBD#{{IT6oB;330uGt>7smj2wTZ>9V1L_J{%PXh2TUkyOG zgzyCQJscc^-j_TPSw1VOFP}Q2c=o-re3&mlQEx+dLh{MM1U57Q@|?wPOloUb4r~Js zGU4RXrvKLX6}ON4-dHKigZTmk z^)`f~fjq`w!?&VpT~z`Ikn$hTqodd4`9x%sp*Z!|SMOD($%V$0#b?+H&&^}(%(v{w z5*Q4jis=*S36e3T0~4hOr5*D*ZJEbu!Zy5G#*)B)MgmREKmX z*?!*DytJ#&?Jl`DCH`=J!?_VwZX+>nZo~6`%ii}SAkIH3f7LjCO?xKM#u^(FVwBHY zoUD#nCwx16=R2Jf=CLl2P2-;Yz{$no*uSOnG6%z7cNy^A^Ak^AtPX6o&X+ zqAm(too?RxVba_c2g$gY9|@NPA&W-T-I#wQ;z)Sim~LkCqP{&R|M_p0Cnj=y8lD(M z=CeCXA(U=NEk8CU%*44IwDwY82PxtRNH}Q1QV~cz2Vm>P6+ic%dizk0hjGY!c9(I` zQA@NR8KysA11%`eNPLEbXAwuzn#l5ay3Hl`K7HNPqd6YNA@kW?#-VC2%R}AnR}+Yc zBkK(#4my*7_U~TXM^WA%@mW5Fz3zq|?wXPF^mZD9CPO${c;bJ_nVJb&MW*?OC#Xm@lJ@C?A|BgB=$fBfL&E zM+Xo9jUUju<*GL$r#FM?DLs4V(cgT`&$C|3e0Fa{UU{AhZvlZ2)2nu^Q9fqzf3WO~vj(1Z$oCvR$1n5Q zU5;O!q~jZn?dVX@=*pe#9)@EW`lZ{eeTMmutbA@uYyrHj~%eOP}v??>pzsgtKbMANiK~ zDjS#ZxQ2N=r4{83(FK>;8}QY=W0aeGP6Nf+|Cz#7%lj<5?Oq)K;p+-~%-7jLD?Gl2 z$S||8$XUgwUK!<={H_t7*}U;@mOb7p>rU@8Wdc5$FT(sFF#RSxK7Dt+hA@K%h6NA~ zr|-fIk<<64Q+_<5%^7W`YU!%!0ktcc-!yzFI6$R(D!#1C>K9Dl03srMa{VaBvn&7k z9r#(&=hpfk*^T{Jwow9B`WWT0ul=*qXJ1PZBc1^Ma`{{Hv9W$In_so|_{l>K8Mw12 zhoY5JF^bG*_ux508C970j$C9o&chvvsnf04iYo9Rc>5$|75 z)Zulx{X6(eWBb=^e57V^>AFRw!_{v*B&k?cT(OGGSJ}8wgBHzP49no#6>TJ(=kO0p z%gqg)1DJ(lG;v(9et`N)Ji~bMw}$XgK3sW1TlM_C9m`rN(?3~wUdhNf<%}=eKK|`r zU59;L2@f!YhxQj`zRDCX!S;BX%ZawQ&qjl8XpQ&Q&azEIjSe=xWU1%Hj`E~TvSXRM zn-&47+eU|Qr+Tsa-QlG}1f8@Gu@=d`*j|_Oh1hQ9d$t8pDP}y;o$tvX#}Vx_{H$f~ z-xAmt^UK~&5z0f<-XNQZ>Nm?+5+DgI1abXX^L_aGaqj3i<&LvvZI3Vcrp4x5t%TPz8?PVr`VJM~C{MJtVd%SPG~W-*>JGwd#+PwN`+p-miv5acpCf;SLu>Ce<*9$x zZz7_j_oMyL2XDjq%mcTrD>$t1)F}g7^`m}F052iF|EJ*5xCqzZxV6k)lt3Ng=KQ@D z=|?67M7n3z9&a)G^UUfe`~OJ($Y|pZZ55fXxgspy4+S%|)M;e46kjQ(5U5|qeWN@y zl|YzYW|%KDZhK@rXAbT;t@|@+_i=oTN9MD8Lp-A}_yHfv6Xo zqlkag@Z`4wFARTz!{_*AKD#%JKg)pwSA5v+OYghU5eAj$8);97c&dJiERS}%IU6Tl z_wLUeALEhv?A{O$aSCwSp$oGnQv6uBKdHj+2qLP*gRCFQ&yn%8dfnY`%8|ERc&r{F z;c123!+gfUc0)XQ*vH7>m4zeXsEq>0(;LUl?0M>68?yu)vB1H6j-Ty@I54pfNn>~E zJ3HwTslfv*kJw)#%j3zZUnRWK?f76*lha4$H;w}{LscXifGQ#Wg*zh0|Ki8~Pp3b; z=@FM60ma`Aa$r8k%XULK;Ith$%KZtNM<^RAOD$tbz>HE9UxRvG z=0}KswAba!u~!XqxQqQIGLFH&N0!5=F{PKEIJ*-KL92$#OPSB^jmQBwa_D^Hpgd~u z0H;S{4DBQozWq11(sN?Vk*gZukojsrxEOHIflg9-$mJ(L_iwVBQod8ahx2%J`8j? z3-j#MkIcrmJ}-8EqcG|~T<>PJh>Yu$7RyEydG7j&c zWxmQ3F6MHgopDc7eTnU|+?J8!Ke{gOnbjHdzTyrf;cW%f%on0oZ^Oi|Zi(yElEu(I zTptCFr#?wLDQWP%Yh*bvzbQCE-+GPuvA$hodCVGJaamf{+>c~=Fn`x@ghUg7fJr~Z zado*~k^jqaTL1T)1WF)$IeqqAYz;%E{KrPTCm#Jb< z&Y0;P*XxaiWAXP535e~ZlJ>@NiJCcc)qR)OrYXvR{9hg-#E(_>pBH=Bmhp^U(}$P_ ze0ER6N<$}((ZK2mM;`Wj#gMkf@})ay#J>=`4ES-ddPTYRL=CK9`>2Bv&nbwER+(=G z&iD%tT3=Eer!39;>C)}@ZM=-vmyu2L#F&r22BUxNw&mEJ?olN;b-K`pxnafFei_K% zb0di2KlkWwm-2)3j#TGrZ7*$ZBF{OG1z#J}*4DOD`-Jz6=!AP3aiX{A0-|}Rhk$T= zH`bIY%8{V%pkqNNfKCR{0u(HdSNeknfgpM%88 zy#u1g;~$`SfG4>@B-8NM&>kLlV0ih)I^&eTpL=sqi-JXe$?|1Bg(;e_^0kRAFYPI@ zJ-RUhp8CmgN`kB9hR=JIT`J>YzKDhH!{ecK*4h(d|D~#9c)4V`;*`toJ#tOToMjit zIGEow92r%Zov7svb)KTOve{=#HnfwKPT_G;oblftwEV?ONDDNBq=$)Vz}H+O$w!+6 z>4IlbK651;BtpuUJ3td>O|7eXAWoUwJ>%ZB8}7W4@(mfvJCrY(uQG)Tr<1-;+KDfc zC@pN+BZk`DrPbV{^W{3cIZih|5b~p9`IXe!C?EN}fh7;dDHB^>RylS1mf12c=5x4g zhsA~O>L}L?m;!h(SbhNy$v*`|HkTFRe(2Lru0P|sqprAs2YSh08~A2E{u)f4qgY*Q zM#WVwKFk$iI}$!oLqDsAR-dUGxZBblmCgc3-V`TBq8(IX824*0k2B&Up%#I}{Yv_K z&hYrod40$PdKiZAO~94;DpR! z$#rl}kC}bCy}bp_s$sk`pWUOut1a%fB}+)vAOg5DzWgqc@#X!n{--C$U7^nk(B6Zt zGJhBF^@@Z~=^7c|rez=AzirH#Opc%BC-d383G(Y5311)ze4{6S=DygOJ(%NXd@`Ti zn}DxRBz%JpiY&ho&kmkZ_wM!7R8S4$llko41bnAP!nZLBd~0m;^1mpZ`Y^}O_+&o2 zHv!*ik?_?V99e$fKVpCX`_J#Zl;dZ7GN0X>fUj>Pe2Ird#y9%oxjP2Vx_*P+yiv=c zLR^{8xY%w2zJ6x-#PWJA@R3OYkzCBm>y;}Occ@XGX7%*iJFZKA{k^1L7!;?s%xCwg@H&d@6)sw7TInpr=(cuRiG*7Z zurng0@>?7ixM0d;H9<{ITGA7-C~hC&)NFV?uk@FdiF;JaknY}Lo zt2{HN0oA)yrcv2um1joTSpOQXOCp(2Sr%^zXP=NjB2aMqG$|=AxUQ_r4JTYcdD<%P z8YUB!c|=xu*HAY5J4gIZlGroUpEKL%qP{#%shZsJz?bG1J>7jR6k&~jzIj8mHvmFw}iY@c5=hfBOsyJAezh@6PWgYQ&9PwD&Q0q;V2X2Xi0$AJc@AUq>GF4FO73BUuOrc2JJmz zoI{-rYUiSYKE10=ylgkVx?@(komSeFgBV}p8OC-=BHX%z5^CEjopxNZIRN*vpMP4` zX7s?tReA+|EZhkn^YPbU(mhk$F6@DdkNw#3z-MR&tsNLXz9j?Vl+;((#cjEMRhAqd z^9_;Vj})IR6Wf)Kbht5XM4Q-&BMJ@Wr2IVnCz%tGVO#qb{>snE&oIBK;f0TF_qtkg zF_&iz*qlH5XT+)B@KV4l1dT-=_yziuJ19=s(JA#ru#~{8tLKbAtn21Pst8~x?H#x> zUu6oHpuT4L{pI?kZbzD@kSq4hn21C1i|Z^XZgQtN$i*PF?uR`YR0^Vb=yZM)t<&&; zD34zVqM6M;5KUIC0MVAgQ$ST9DhsB9E&|bd3EH@eChgH;h#Jskpy{B?L05pT1YHH1 z0jdRE4VnqM26QcG7U(+A^&skt-2l1~G#fNx7oaaeUxB^`Z3cY< z`WCbWv=#In=zGu)plzV-pdUd$fqn-40{Rv7f1n+p-$1{E{s8?6`U~_oXeWpor!k-w zpq8Lkpw^%RKy5&=pthiPp!T2+paVf2L7hM}Coc{}YizoJx`ODS(}O{WfT-*_6x0oL z80c`&5uhVMM}ZPS-9bl#jsYDDIu3L^=mby_=tR&-pp!wgj;9C62I>h)2K55<2K51* z3OWtc7t{~bA9Om1I>G}$13`m8XM)ZG4F;uvQbB2;bWjE;6Ep;r1#T zASY-ts1)P^m4VzK52ze;A;=5zf&8EfP$g&zs0vgKnhLrIbTQ}>(50Yhpc>F+py{B? zL05pT1YHH10jdRE4VnqM26QcG7U(+A^`JV?4WJuAvq3k3{s)=^x*0SVbPMQK&^*v> zpxZ%rfbIkZKzD)e2HgX?7jz%!e$WG;deD5(gP?~%3qTKp9sxZHS_pa!^f+h{Xffys z(37C2KubVRgPs9B3t9?V23ihU0a^)q4)i?e1<;G2mq0IrUIDEFtp>dcdJXhCXbtEM z(3_yOptnG8gWdtX3t9(y5A;50J!k{y1JH+{k3b)TJ^_6S+6ej#^f_n~=nK%7pszq* zgEoV{0euVF0@@1t4)i_f2hcXqcF>QYpFlr@egXXo`ajSP&~KpML4Sb$1pNj28?+Nd zgE29n7NC}(R-o3P13+y+v7ok~cA)m44xj@;9YLKyok4M+cu*HmSI|MAgF%OY5OoF7a^d0^0ml3uW&2UTPXB zYsa;p5!>&w17*1|pZtg>7{8hl=q;(k@PtD1MQtRGe_Issw|sxX=D)YEx>}B(`C{C3 zAB;cS?NbjvPIY+-N~zB{2FJGX6lhzv-%+NYjI4z~Z9B$QlNDJm#}EFx<9F}p_Lp%n zUkf#K4dQAb7u#?w>BFi*ucydKUnVpo=A+nbBOcO`SWrIlTxGjtY9cBZUUXx-Q?`8n zhpZ>eCqJT5Plcu-IKCO?sH8P-dN)@^Ni*7O@DR(TR>IL5Zltrh2cu4S{>>wCtJKdK zJNw8RkE7HYQKY)pF%z! zcOgZinvJ-UJj8yCUbP@!YWb67(iU_ei1O3npp!sng3bd`+EN?)6g)`v^G!&{cku86 z2y`+M_F^RBmB@@!4?{hjgf`7U)bHa_w_J(#&P%8VkBw30pb_xQ6)lvDmbO&>nAuu6 z>hxHpeV-0Wk3-{?85_DOz1E$e>^x+E693Rx<(y8_l_P&zseFCbkuh-(*2ko_sBBSp z-~BB!Z=T%x;P|$&Bu6T{0V(456M9E_Up9P?S1_0h;PGQpQW&b6EVFwgP=#PPKPH_c zq(4BnA&+E3 zP^}=SH$e3e)@%r?4#K(%!deAk9RNX{4?(?&!sLR3AWO8LK7yduLQq>FsNP4R578ZM zwqqfu6VU!U34NCyXlwRD+xJw+?R11Y2z{Sa^a+Nb-pE0{k%w?6K-PAYK_zH6m!r*I zjXu`p=nu?7xTvUqycg~8$IvEU0l~b9HsYsf>u-a5%NXU;cO7v^GlJx;9FtFIFiyqOJ1TyKR*AXSQakTp<^D+t%5^#2l+F_m zSNh(1B-**%l~uPMqg+#byt2S`qH@b4rznT^PF6<$*+=;}zQ6L=MFW+ggHn`xF342U zzCK&Y{`4HBYQ#7tEoGwe;qoHo%y-;M*32o&i`#0HOS)d8jBYhY8Nc=}<%6pqQLac^ zs$3lRnsQ0o50zh2w<#yt1a z+c5_&_`jICAxE_+MT>jnK~*ijUOm6X5yhXjxM#qjEhpSIw&fdN+}d*alua!kS<$Q2 z^qyC>IzH{QRv9&Etq+{?aO;*Y9Cg6g?dKgZ|A53c{>n$&yw+oA>~o#A$EL>J*Y?sg zirbae_itZ(UAGQ@_3L=x>UIZpoKc(HDeIg`o!1?=ATH(GPF)_WzrO3Zn|d6)xWm>% z+TOM1(C%H=9X27q^^t9s+7pkvQ)u1FEmo=x=S@-+51Td@+?2m0jeMBY&MEyPaT#lhj3A>azB-xn6k4|*E9S6dKul5AzXBo`6?Ti@VKfy z6@GlMz}f_DUTj)L88(rpxv_aA&LV#v4%~5QAuWW(IJ4}Lai0Fhwz*vf|Br^aRKqxB zKD##`r@GZ@rWeZ;DNIqW+XTF3>AhoSoDzG+?|-~IbmrA^dNZGKvfTi$dPGrU>ns}A z08uYDmqlJ@@%tku%(>u*^{W^M%T?yHdt{uL3teG%0e-eGy9_6pYfsAc|Dj-OIe|mA z?7b-gIeqpfmT+-XTc5{V!uk8Jx&2$xhuTk8`e-s>IauY~-p`G4{t?R&D}Ai=+4~aM zw-H$RXWverTEOG}RA=nZLM8=7WgE@Uq3@G?{zSt3IHk+HlMYDwV^KSN%2y44A7sAH z4qCi~+VuPhn(pNE6gmqUj>A&8gn`I1dtU-#|1jw~qn^m;4vbq6r@S|~e%gX*t7$5T zYFJO0FTYWEJsDZyc4H3X2)C0G2e;a?4 z;usL7C98Z`VGTXYhQs0iY>R%F*O)E)mH#*PTyy#VR6NbaX+6JtBoIJ?HeZFiW4t{O&HkT(5=8qq{54 ze``2q=|klfkNf^x-|N4E+pNFyUwOA(eGhB=Vpk>i-+#`^FAdY!$}bINVsSJHRKeo; z0|Du~u)MyQp13nB%eHL!xOv*sJa!h-fY0vwZYbJeo%&u3XXcoVNTevb}Z6{F5u zSc0|wJKx{9oc#NhS@Rxj_s2GDE1()`)3rq_pZPjFXf=p;B<-f-!;Eyzi}>DirTER> z`;Cu_zkf6)slj{8dI_fDuYzPDMtEly5b`}CWuX`4dTXl+^S zh%fQko#RyxN0lRoC-J@OqKJRUlNSv9WAn39Ied;^=CeD;pXTwDIvu{?dyDbL-Vph{ zS7huwxc2D*wEcx@I9{30?i_C_;w`g#OF3pS-kK=l-B9<*hsw6A(l}g>SLU-j$D3)d zbYi0&j@BUO9Z|$v*J9p1Kh!TC$>DOmGN0W!UL4|^=fqAwEa)0|VEwAPF|wSG?!T$i zuhY6d!{KtgGN0W!-Z4%eqAeWebO%MPdJ*NlEsFRb$?yL|<>XGEarhj+%x8Cwf2?Ct zy4`Q**EYzzWOn5DK5WY`U%&mBGKs_Gcx67jbG#W<*!#eTZ4vaC#rNG9MZ6!R+S{tm;H`6^SmM1cd7&^ZY|K!>mBiLOnTVYh3`2rO6HrF!+C!eR<{eFkHI^F3j zD4|7JIoK%pG{ej$Q7#F$M#j-UcX`1vTQ0dv#=-oi;0PTi6M__gpedbpb)7V&)9y68 zJG|YAZEu8Cfd^Fy1U@aS0a5=9SoS)&P~uE}8;u*iW?{@smjbQMgoBlBXRY+Q$i& za#_lE*Bo~%dmT0)oMGu7)wfh zwjt#eIS#+qS>V&27VE3z+aj;qeDKBh|C-S8dOOEWxTw~W`RvZyW7>vHDNpg)-P(~g z*ubd}>s$#XA%bVIzFHXtj*UH^II7juIixbGVH`4_-NWEex0j-wrc|lvctp8m-5yyk z-^E;)eD8e^J;CuY9+}VXSq^)-*0!R(RkPi=FTmMhwhT8la0+eEC)KNnV=Zuy38yz7 zOlit4!gd&zshc#?V1zd3=6bUb)?i0|;o+Do{J{KUe*5+Zj*8_W^VvPmUgS`*kT^z;vZdJzN*p> zA7|46m71%J`AWGnaynhKY3RdQvwC;uco~<>XZNtU(p(O^y8_2G5ZFRG3eH#JaZz?w z_b6p~)dCk8PB$}oUEMdMbJjJj6I745FfN(T?gm`EIC_+))ZxZZ2dh8 zf6cmaZhvJxDKVca5P4SZ8sHq8*I6$ z90bCao9e!#N5D=59SceV^#D;;?hm5fZOXH+&)JA<*xjk!UzB26cz*=7ElBjeY(>g?O3n*h};$&?k7I zFYrRKXb=p?%RG&j8IG5U$IG80EBM zVw6|XW0ZcAW0W1UW0aZC$0$>=L4Of#UJrf1)*aLE%7*%KTNHXTrC-~Lk0;%F-IE#g zv{o++hu$z>C0IYqy*IKRUv}gLkF}q-h_;MX4U!BdMv?g{8Wf=DPHKaEMuzb8 z#+CUhQ@BLHGup3i=n}#t;@KPpp2T(IE_&zDO}6=ZoP_6C;9e9M6u2 zBg^N@A39xn?%?9TIbPN$na}PK@Qm=6s5`z>+fjWafB;Fqd7K5MhHA8U^gouh*CZgP z52cHhMtdze8bmCokCiqJM6_2KX6ZwD$SU9VYO(|)uf-j=uWBBNTp!-PwQuPP*W}-- z>A(UQO2zp!L8EvoLf7pn)sR@&*Kb|Q$-{LeR>+l%6=(cNj^`N0b#kEKqlJ4R`(Fkfc}EwrHgp7d1P=<-4g2If_$$6DLc9YyvE7mYY2f*4;u;%9u< zv|B_+XBqazi+#+PzJpUcsr}~MQ*Z{uZ!6laT7h$I-W&YR(ys?6(Rp8F$fA7^nXfX1 z3-2eO%_GoG-5xQ?=kTKQETrp5$AuLb?X{&>c(L7}$8F22nB=q5*7b#2V2QB!J(7Tv z-($ip-3O4I7wYaL=k*cZ174L;H_h(;Ox`75QNNlDh0zID=BrHMl1C#`6)qZ8)6SAA z#7A?S=#)}$VFi6crw#TovZn3(9~=ZFAGS2FE(F?pgM&=OP4Io5h*OUFanjA-fA`^= z>$*I4DPghZzpK3n!yJpocK%dP49~%EH=Zr3 zaH-yG2n2JE==?zXXrV?b*1NS&hTeyC-)!9bOV5Y5A6qah_#H>fBQc81=QqkL@p%0O z6@DKokV+>$vDrqr3Nze(Ooni1=Y{xeBiz{->C~PGz+(B9JQEqu@ELD@KXT!mhdDmR zBlFq4As!Wnqi}>b+pV3sezv0;CoMJtGJpsOANSWe+`VaQ@2nxvhjI2MoV^;ioIc#X z5oNSj0q*CKi{;JW7mV#{{uY6WW=eT?Sk5Y%-7jL zDx!q*yNM-<-%Y{d*+7UW6y;C-wXAhXrGE{(%Aif zPqNk<{TC(hPvnfM+%7C=$_i``Iw_H=HAC?T7|N6mF>>IJC%*+_B`1! z@Wp)cBbr9%g=N}la$|+R5C<`47v*|l z^Mk6F;*@FaAN}TxR+qos8GJH?i`rw%SDC`4skqP^vsYt+md~RNVdWz%F?}%Qqk(Bo znNow$`27=J4)r%_k5lEm<6G0P;M}L%D4$e6@iuOi7f1coqwKw3j`-_pO-m^59!MGH zlONIW#0&Jj)d_>coJBY#v&_-QmQhyjuT}!^EWRJ>o)|_`?wcbEvv|bzdc7bYiic!F zbAfh%cpmJW%oBbYc<7mf!BUNe2j_Q7e0I;nhj5H(j>MoW&U~?rcGD0AO?ZNmj`d>6 zP=?p*@$zi2(0*f-kFs6~rB`F)FFo6I8`AQqm~@(FM24*HxH4a53YUiCFAjStIupHZ z>WGRqChO-Bl~JCQNjOIx;pu=Y z^HrvBX&lcm6g)Xj7bUFQk?O##His-MgtH37`ET&*P;Tt0XN}nRJL#jrEqH zKVSF4ZRZ#EQU7W9=&hKqvx8O;-!Qv;=unQm%Iw^s6u+9%Bix!0ZMuezbt0Xo*oN54 zdnG3)V`erUKTW+;;|k!)@3B#O53_udG2n_dhhKT%at2E8OK&6d**(mAMDY^F?=Q8l zhUDB>z8Rf3sNlgT{LjrBq#gS-e5=TL) zew4ApMr#(e1FF(W?CxUq6Hx#WiRCrL+uSmnu~~NWC9n`da6YVB6Vh`^r^FR4)cQ)< zhH`rLV`_bV`TGx#8In14c5k8lJs$eQd>K(t&v|@a{E(|pe-C{|9_#d%;HWbi!*>*B z7oy#j#VK^tL{?G|srp!2r{=ks@Pr{Y?DpRRodTt$Z>*x4+0M6H;RM4 zGLLW*n%)gjC`uw8qpsXuiedDDrHPJTg;jPRxaHS=|L&@w58M%gEgbX3x$fl*$2K`B1H zQJRkOq`5pk2esSD1Q4)TpAnDZBEz=!&${jn3CQWgX~Op2z+}Z4l0Xt}#r#9*k`QtZ z-UV>S?GoiZWB!-RA$q9Gwoku2=*&-!mgfyIpZthM-}fNBqKuX)YG2wjJ@n~Iojjm% ze7$W21rsM?1*dxAW;(jsg${M)o?(1yF7VNNq=3jaYj@A;+TOP8stxM+58)txEpcT& z@kC>a&*`?i^3d|G@I{3y`F*3@YUa#U+jDEv6lFmEFAq_Cga4@5@aS#*CdBHI6E3QE znXj{hmKiQ}Y>djvMo}5-w{aVcxa9O)0^H|xT~pXP@2Bs$!`BrEsD5L95RiUjhRY;9 z8`7#<)JqhJ2 zC0CE%ti9Y?4~*usMr&%|k>4llBctBS`LQ1F`{ld^Gl!mV!OVGQXfg2nFkg<>?0tgy z5uO83Zn3eTk2?TJ@`ceByc>UN6{rU3vXUZ2R zKA27GN6Bz|oB0|ybT!itjYn0VT4<|dv{kf7Ppt+qoP*`Gg{c)qMGkLN`V%SbBe{pr zT6ayAfY@JKxG}u`bpA9>**I|1rl-!UN?1yn7KX|)s#lq>GKEWI{n0!(R?diN&*cR3 zNO#H5e$XT$^TiWM7|kMbhqxCE`b0ZVLh6=DSZ2kLjQ8ux)WcRL5SbUm9Hb`yW0-T+wj6CU5Dsut=6wJ-oX5*a0&S? z9G*JhA(H|k9hCDKx%s-cx#x|CYsPM+KQQF4Gp@{6nZm_PPN94zqcP4GO4=M5Ptm4p z7IkTt@+-}cCPR2=+=KZlQ@EJn(RjgjGz}GDUWTUv+hyi@JTCR=0Ipmft&(t==~F`c zu2-yjcJxP`^|%Qa=@avHcF;1zWu{N2;1G(a@A=)(nSPdSNrbQkpB4hdmPA#XduNjr%Tgdexu5 z?XSb$9JENTSC}6aE+M_b;n@s4WKux%{$}YF_~`4M*L{#VcPn{-A&b(B`6^Smn8_)W zUNRbEKCAiOh{r75emc12$~9Z()E%hDNqA^J81n@v>a7``aOtLgh`?4jVm|BqL*#UO z{o~bB2K8V1fShj3j|!Jbx|!h#01ufI5WT-yy3POi#pwguF8laT@&H2?r5p2Arf@Nn zQ^Ry)G{$u6zb!JJ#h>2x!s4+@hGI&FY6uUd8}oH`&@#iL@q*(g=bj-Fq7$Xlgyxy}5j za2fTfQ9Rp#hfE5H(#1@lF353BRkC*sJzpO+gdDqMAk#*M}=3= z!(G9t{9oksPwzFj{F{`;ZCdITJEebD$d&og;0)`Wq%apDea# z+W;r?qroZZshWv~q-jrz^;hB!quk8&vF3(V=il;LxA$W8h)Hg-z{C7#@R;c%gA)54 z^}s{nr+~;dEB7YHlnlx7A|BFT<_l2NTQfXn`of?@eOV7Yk@V%E)bckDSU4-V9~H}o`BC8! z^u-KE{vSrUnCZ(otIs}a>pY)rw4^W0j|N9bUl@f^U$#Yo-@ps%0Wi0pn&foD!->4nLd^G^!VwP?pJ(AHF`&o7BD&O#UK5lo`{rwV_ynnJD zC*h%f7V`xt>a7_bNso-<3AU8NLQIzT;T($shp~OzKPFxcljUWmSD#P5@v7HXtakJI z0m4V;&M-e3d}ewT79;`D>UfBG)T{Alo)=^cX-+fj+F zBJ0;2$LGgSfB&+FW&L7)RCt7P%nV08aFAg=H`AjB=O5CeF7wkDe$z7~rPD!>3-i?g zgiClmVid;uW^ijG4zu*>w0%K~`CEPS<#rVF1qkY`84k1b8PgvpMg>O^jC#BlxafUZ zK4#^>Nqs7Bbxj&@nXEU=j|!KNPT}z6A7GS|S$f^!KC*K4OQV){&=rT%i}}&u3FUhk zjd8yG<|y!NfBLJ{eZM-hPVAphe~J0g;F0oqUa8Y=XcttqG0MeEfAR)Z^?!W)1vuS9 zGi1~HV&+GK!%TlvFnCzZ-%4y`y?OG4n+Hz2{nR`;e=|QSJc8bs;iv@;GOWL5`ZB$6 z*1(EO&wQEAWFf=)!hDSzx|-#ykiIYqWByKT8yUx=jtB3X(xc1vFZHMh2h|764pF&}?C*teeJCtM^Yna}QKxJ>oN3>*Rx+u`HdMb;zR z-=Azq>6Sl3)+6RKF1AhaiFyy~uA_Ko|G(mR?Yw}T-!<})6)&2R~N z)d(t#jUixax5?`wI&;7gY_3n(8{w3B?6xo40f6K7>)Z~;^pW>}t$HC|=~hwj?)8pS zT0E$~6xClezmWMlJ7|sRZySXPD2n7|yQVQ&=1x=`Pc*hG#uzNnlqc5P%{! zmTy>3*%spee==YE-`KOFpZ(=NT>4NNa9PE+EEn=48dK!qJ-67Lx!f4D-V|)=K-?LxYX7}dU(S#}Muoxdb&%}HVlmA=xzAJ%x zK;w31z0}T>`*+FT$19h8>b>ah_l{oNSugNNH>e%VeECiFev0AjhTz_i`WfW8*uniOxwXL~b8u!SwbtpF@?xAB?DSxpMt!#(^pm0Vjn(6!SQ@_* z^Ne_J_CzFivuE~qo}50U5B$x9?)PPx%Gkn{$N$!J7RPZ`9bwGh$~~XOQAacJ@OWjK zyW2c^$6>u+TlnVR&)@as*Q3-|rnJmNiZWki3K#TuX@5hk#tQXabDRZU4>ln4xC?!@ z&~B3Gmiw_0Yk?mdYwglG)3ipC=K0bZ4SJJcpA#MEJW%>q@5Az07M#xNT2A2 z^P3ZKX7dS(GQOvx3_o2_&dpGi?RgkCb0D0lit_eNa9<4l{{Ux1x50SRSux7==`qUd z@5Cs!zAcoLhg&EU2enkzY-y={yS$a+Ufx=H^rr)q-<`3_U$%D2kh~7cXWw>I+INgs z5DOxxGcA(rNke%8pGoW%kPc%CQU6m9ay7GZGGsR*sD9el%lEUX> zda?c=?HtoJ^+n!ZO0UyfHQ=)lkdHH}95|TE5l!y>XU+)}b(ZhRrg~nk>-j(XPX}UZCu3^I8mrrfftQ(<%l>6O zVZLZbqc_p`5yQ0Zqmw`lys@72KRLXfP>Aj^>@%?@Th`4Nq#CwcyA z?A>mrBsK8N@oyd&KK>=Z_n?2xD@pTy-~7BD3F|5I#klESi(fmu!VEw(`YDG=|IPH# zjA!<&#fx47yCZ$%xd73}ZuyKP0Xcmr4{+Zi(zBNPo|k}}KH*}du`6-DXgI%?+wPHo zS^7{OqO>5QykylY5W-$ES%_Es9;Z*MRMX|uCSa1&`9aQTCSh3VZ6cIC%#zbtKklW; zb(x&bl!wV!X{yO#Z(slE?`bxSMcwy zXDm5rk_^D&@tWE}#_<|?y#qaAzhU`Kp1USmhxa6U@ z!e#fWq15Bb_>#|zjBojzDXYH8a2zS)W4-`Qy=?|Q!)ga{e0G)Fh*KV)rHH!^+j7PE z<44pK>VQa&w0{`$b#~CwaMFM*4lKhtM%W|_#{`dXhh`mUUIPe7Y~Ox_IU$taqRHaX z_z42CZgxoma{9c4^x^R=>WffX(HtS_Cvsnr(xtJqX^f9YEVBy|Fsm2B1w(VWDE*pa z_Qf=m_0;VBWZd+h2r3;kbkFrYmqYANem?k+brVqn(WFnrK$_u!$|&CJuNlGoXCJl7 z5iMz>(Nnn`;PSyLNA`U7h$emZBnqn>2`^naeY(QCoL|C+V7cx|30Uc~C#Bo`u&wlI zz6|$d2v+*+N$EB}Y&m^+Y{IOKMzKXxH$~&8`N;Q=5ajfs{kOT@EYI7CR_@XI+dm}S zytkCo$7;VdPoBH`X)Aqpw?ubucyjts{lnv}V)@osnbjD7_oCc?L*xC(c;7gh21V(@ zW4-(hgX*MxAuVLQvA{+8#F%lb-jlsA7+L?V`eR>6l@JCieL}L>7w@d}*%wnKgvm;u zkSzAaJ2`!<{{Oy}N^<&G{r`PCeXRDIl|K8H1omw-a`|TU|M#u*lKazE|9|(Uk2Q}- zlc&6oJe_Y$<4HWuM85Wg@g>4x8A}5DiUh>{GxI(1>eyxqz)@bIF;5zo&BuO_WA1(Y zOx!BB22Oq}(KEXT-IJmD&2*LdDjSz9ySsR--Ct0GopG~$+G!S974Bl3Tj4Hrcpctc zucrXV*x9m2XpZ`WBCZ`#;CkCR zt@|ul*NwN?3Cc_6HyIc0O6u`B{T{DDZgP8w!;QwKwC1%2(fGIgG+hFN@rbzoMht=F zFY@I3=A^G2miV8)zi_@6-RRz`J7tNO|4#y2OkbJ_q(pUV} zhQF2xBLO*m=saMOAsZ_{uq5`5EvFB!jpOo*^j=J_y@PW9ja6*Ft-Z*2z8<9wwKM9F zsh0NXaU)6TmYN}fo++_c(><9Zj@GU+Uvc!It87mf2~!t1ZXr^MQjlWx2!a zuO99xq;1#r6M za=U)q#gW%%-|%t#szu-AzB{*0i;?0!1PGWfz?<9;`wH~E8N`?j+icMYm9m{IJJ|~8}+wI+RjP9Q{GL z+?B(l|Bbb&8snRVVexiN0yTJy^YOOnMtuof6{G6Qk|EHE_ct!jy)0gt@$9t=7LB{$ z<1_U_m-U7DG73Ro9A2k-jH#$H4eDk2`G4v^>6)c)4W(TJ7VAgnD~G6ruKlJ<7y6(L!}`H|jT^c`Ke*IDqfIS2RQ>R2$L#!L`oU?>b_k($7fu3VeG`Cw zko;0WWK%s!-~AF$xlG)!MjbnL)!g^|vfz(_|WijhLK z;h*bqISZyNM(BMWe#5-@f7EgDVZFC z{Jo0#{{~x6vb_d%Z^ysaUfhaU5zCp_nc?#_iL1cw-}v-}wsIC7XLqxF+@QQmak+wHtolHeh-+>X zxDNU1#3SciQS~y%%eZ7dyGMcRRGSGdar`WQc6fOu*2OF1Zo1-|n_{nDkgP{cxM^ELBjsYRQw<;Fv}`dW@7+<(@2w$1!T z>lV%*hf98BfAW9!8;#wZXQK(<^7G%6fS9lABjjt6z}=@`b>@q0(sEcD+#itn>~5B? z&H5>MjteUsZp%snQ58cf1Gd`Km z?$P4I=O1sO2|lr(mvvWoe6e@LD_>r@?AVrD$1j)rdCX^AY@6W=_Va|q3|DV(ACGJ@ zY}36}&XN=?v%gC~ET0qa3!jfSBA@3?oZC9) z7Z~%kJg+7&KVGT1<;GDDe*4m0kLu#UXA$-L3iD+tMVqe;-m`4HS`Y6 z&7VzqzA1iLzLx#plz>=omp>dnf0G0btpB|Fo48ZFEDg%vG^1bUv%6XTZZM8xlAi+z zfXkiEj~H>8eFyJ9{m-%sCv6XY2WMO|zX`Yu^K4{@qTCXnH{z4a#d_c$Uox)l$3x%m zcc2b{%SGlhF1F3&)?mJk3moYEInNvymlWrB7rT?M)wY`s^we&U0iFS^b|~m89`GD}9Xe*w_9A z0EovcS4!i7X5*Euy5IZxWtaYNBfkf=^{B-s^VwZn51ryJC<*Ov-Fw*_6+zM zess`h-*fzoPv*0G6!;9^+Z%%#K!7aA{I`raOF(P~WvvUJuRFgTuMD35R*U)d&X!$t!EwH3 zzAR6(d~Mzi;+=;1papf`OYP(Zq0|hQ&*ix3znJI6do#Zl&yv7@RRRIL7}wvMBjj_E z!N>z+;vFBnu$1n}a63chYpzkYgF;zc$kAE|VmUPTJ!3g!)(+bKL62XS)eh~+@iRV| z&+caBkkn2)RVZ<^vt9&-3^;&*S)Sz|81c&Oq5kj3DdiNSa+5L_Ad#DZgLC|#~PYJKqB&{o96yat)C zvT@PoHDH=Tx!vm+<;nAV%5&{rI&^B3vkV2ESRTf1HkL1PdAJJrUdcVa?bBzsJpo6t zsD}Gr%-7jL%dC8fvYn>w_0!DuSrEuB+=Oe-g>&15sH{gU3H&1x5Z8SMr2KByKKr2j z(pUfYQT{g!j@v&npWV&!yVU-{e)Q@tUWS}4wsW$+311FTTwC3#pMO+0c^t>fxMV)N zM}fw z>ABeyP&tV3@&4=+!(`Z0L(IGON1k`LYoTaQg@M|fV553=Z^j)Jz+Lndz;mpxfuD^1 z20Aa1>Z06J6y?X?RbXDmX1yjm20!M@aYdV-F*x8?b2p9=@D!NkY%OHDexUey zj+z{|_5YujKpmpw`l066cy(Mo1w2Y8D*I_3eSSAZ8FTOBXW~}*Hn;r1gbiQtae}Hp z@-6epFPYIfDYhJk--{y!^BmqvXMqF93A*XHu@UZKEQTo_=D{7cY$myA94P=|Jc<8j zY+uRaOz^7w-_eitS&@29Ke{JFxalhMRW>ddQ!4U!%V=Frj@^wTtG%|-K8JTyg`27{ z?L6i@I}WkV!Ev1#ZbDV4k3*?J1aM`1E2F?S|B}f&zWv3yQ+*g0#wYXHJv_ctyC18E zs>1-R74T*4h@76Ep7;OkT?c$r#rB@i1hD{#ii!$|5DRNipJFE@fdGMoBor$w$wF3= z-DP(J3AR;Hv4S1@+M_--)`yCM9Xl2jeHJXwUa&p;^Z$Kw@7bMuv)M((^4FdHeRuAj znLBgtxo6JQJNLCt+g<$749Q>kbJHap)1lM-^*&FrzqZ&HiH3vCHf6XEa`jc!HAZXk za+BkGcB{Y#T_M2q--A-=@k;c{uUJ0nXoelPb>%GwS56+yb2{O}O}9do!T@C$PtQ|T zhw;i<`Bxqg20Y^$8>(j2mxRN?F!xM1^}O!e%yRkep(XqEKKO{`lArM7rc1bR&@Mlv z-iXPMIgZieyUhFq-+X7QVSTQzll+7qH(kOr@>7W&$f4%Vd^>Gaz#kpq_18CseT7i4 zhEUYUb|GCH5Pff53qB)ngr=Q7wy1{J(g~k#x)r(>&r$f)Mq;L$J!R_q(C?jkmTFwQ z{G>jM-p#-A2gzUfbJHb!6dJTmzS`p9R`a$gDhgKI7}jqe+7V6tS`I##ZXrOQb8PGz zuGm$n7t7z6ic=N(eC77LAJ#aO=XAn{n{I`oPl=ZagW+bp`RMb8hlhi6I5c1Eje0%R z-pI`HjlM=aI^hi$#Q=G3r9U|Np-t}u#5Y%J$l(*7$EiAhV8z`lkGWvB#fQZY+X+Hv z9MdK2fMo<=M$4y9udeg)afP8gO^7V{PyJu!{9pfW!L0MH&i|+6@t{6=P`T+6Zdq!4 zTNxjyh1!<+X8Y=CQ{uP*<}3YQiT`VTkxP5&Fg#P7_OAUq(M`Qr{FAf1s>WWrURVWv zIeD*TFH1xQ!2GM9TcreNps1sTOKAK)pDq z{|AXRmV92)#$kEr46FxmPbZG!^Z+&iFr1^d1BL*F02d*I0Zz2Bg6M{XIL`76P=^HB zr`;0?o`(cyAi*b*;CD!HXAJJ%x2aP7w^r)iL9hk8DfMlMQr8}g@uIm(9eKG@JH4pX znm#$IsyRnp|3!|v@th87XnjXjIlq%S316IE^7(pd&I#+QE!JR%MaT<7NxJ?t?cgw# zt96mQf+c-FdY*qXrC#gv@oONdO{y2X|HgwK)$qRQ7_SqKLf1s&K)C|8XsdnU27f@? zzpAJ=+8EI?W^~gIt^gmDukazVHrtc))m~c{tJ5BptjGtsanmKd)aMOZwukMtQ30DF zkKI)BjPph31j94!wkEz$iwngL&F^Hb8WVop;~$fAa@An(QAc*abNV+IQxV`c1~^_P zbWJo4V}pkUk$G)(5Qj1^20&_>Cqz6&b^iL=QRUW(QATfXoWn@!SDjjNlXWpkUlOIw zr~J)$axQViZ;vkFSwAa*-&z8Tkb#ujzMV7MkuKx+`fB|5Lx=}V>&5UrcF;L6PV}S6bx}>+Waq#`ly{A2~ zeDbU>cd!dp6MWhep)*a>jT>L$sjRN{lutvibhc$-gN@-DpB-r`eC99h8&nnAjl_|s z_TR+0%qLp0G9OL3FT(w0vfl$P?>YB|#p|z-l&$=8l$$Q$a(|`%XcQKlk0DYQtgrQ8 zYmY!A6bwf_BQVJ^4f}jlHP-O4SXY{S6|9$;uR*8oS98Ge&!fd{Ijf%Qq}+4~Z>m#NWcV3ft(-mZs1HIHe#95P$^#`u)tnq^M16}* zPb54Jft&gu^q=dasiMbv_`KOyVY^41B|G_-^?!~8%=Sl9_w@R)3i@;Xr#m*i7&`Oe zXZaxD1_RU&p=+XXpnfEZjy4>r73JsZNf$d0mghWx?I3Y%OJv=;l|UTHNxiao!}NO6 zdxKo{UHwsSoVcvx>AGEyYx%sWCqlLZk}e zdM2+i5Z$$)3VnHOtfbRPr9V{BtZi_J`49VJ_Pa_q%3MD#tk~1@)Px5v6^5nWcGD%C z`cpiv$}=G}BkZm9VXk+&pZzaiy?=%ugXEs#U|m(nSL2`V*JFofeZ6`u_}R1Y={-tr z|4Eu}y8Xh|jGMmJ{7eYcVOKDW-j|11Us_tMR0|T2ayEbC^yQ3st$*YFoxXkd)y)=L z0@8eKjib|GdAjc?kpIDj_%8C81l?_?=wNhYt)5|f`U zdaA$X{Vu}&W@`UFxy74@T%W6WnRdKi-nE-37b&(K;-YFz>ht z35eeI=#^P-|1qL9womvJJ%+}-gPMV$a?>>#2hCS;MHQB4_@a~ifuj0ggnf<}Ao(sw zzP!CcfIe+M+l>p+SX{E};4>E@ymg%a>2p6WIAx9f{I5bJK7XMjy2CMF+Lh8^BwFOf zViHdo>ZZn!L>h_{^EvN;|E%j8nRyx)LzwXWUS3jOtS|d6?V!gQ^U<&wy6m|xN^^77 zOG|DjyyEM^-H+7IPpQ*vzJ>12O86H2tPV!K_102(9W{=0OummqdRCdVWJkGW>rb~- zf4~0@`?^_DKlu3F{kG61x$2>BLiPLKefzbdb_)=ZdM$J}=WLfJ?EJW3)IYr$BcGdQIJ?e15!Vl*S`)ZZ6%WG{t5xV;x zXh#5!SsSW>dQjJgXpj564Mm~Ggk^E-%Rxw=rZ%f9Zpr>J|IPM8?=775C2cY!P3GUbiY znjqiZq8kR7^$}@@7)oRI?-}NH=6$Wna9^zm_Z)uKhHoCba^j(OLZ{pJC3JWC?cSHK zW`r+VQ|GupWD*d|vE~=9M3~ctF5y-FhEToFYS|Qq^w4qyQ~8`GLU+8eK59oa<=dl=)6S?9&+1rM)`pQGT0PTyt zmZlgZ1n3c9G@RF)@>#x3dcGEc@9vLudcUc%bKNQXTDe2jbv-F`i<&%=FRH7r!54_) z%oj?{N_+EX_U-Egc`pCW^JH$$c`=F0aJI$VPQn?+bMYmfgwq#DSSDYt%@i*io|V8a zk$_ol*YtCiTX*}mqHnJ1l)I=V+N;d>jGdX3TcNvoaFtuV3NL9nJQK&VC`Zz-$LVS( zYL*2#=ePo$yUbbC>~UR5z--^PZs*h!cfAwqpR4YC^0R}cjJvz9+rA6k&6iV8N}7B% zjfrLv zPAtD|+Kp^6j^cML0@j#Uik72U|EzHFHT45){rAFiyQvR%e&9pq>3#U%!UfGsm*m?F zupZbLdk3c$@)}2ZzU19*TO5C0pZ@OhDs;Duq`YEq zAXq=!=P0X;n=P+yiDmz1CD6VEnh+%Ab>Ys=`k!O5T;|<-Tdd!I>B+&R2+wpZUkHerG`e@|X1epfl~5 z9iDqY?PnFcB<*3UdDd23e`V=0P#$o0&0_d`#pA40dN$s_fn zuwHjXxN^dN@1wdoIcU*7ZXD@$|5#Z?O;3#y9nmmf#EDl8MwR$|O_hXi&$Q$xb^JC_R z6Fep#Eqglk+TH(b+C5kO&~)=vUp{f_mgJFcdw}Ir=$dF8gpbj|X;|Ub=+m=1c*)(E z?AEc}?b_`?l{}2(vZq-IWF-IznB}%$ugvyi{ifFf-|l?+wIV#0Tb5ooUBac@!fF^r z)nmVZ&-&GhY0e)k10Qr^$K3M=3>$gl8QZ>m&cUP4p@D;=Iol3Lp=+XXNICupqB(C} z9d3+7tAjIrSmkTVrD?zP{FLsUtA=+t^xIRv@4xy!+pcbeylKybZm^4t?T-D-0#l z^It9jQ%@!rJN3j}-{co!-R{SqeDl5M`~SM_yU^X7IQ7IiUu|ejn{imCBYKgw?{2AP z|Nq@3V9ryo$xv=7s{@y`HeXjVU_!uNz{#?;BTAUi-ST9)%{)(SmS8Idldt@dPJ1Hn ziKsQ`i=TD#v-3-G)z~X?cf5G<31e@y4f_Bj!}g-k-F&svjvf_=U?mJ@iOZvPT)k_( z>TXTR>Lk+DL#CZ!y+cU5lH=JN!^yheRsv?fXEF4K&!iBb&*x!|YvQkZa?D|mT-@Z- zd++eSrPdp_p)-um)EiFPSIw@ORvL|l%-)!}j=-!J>q^tVw>AvnH%xo&g*VII*-_q8 z;QRj6W1(v%jDwpWys)O<5-bXM8|+QLB8;97nC&O7uaG<#F3#k)Z<({)xyPN>fZyBe zci!yykG9-oFA5k=_!YWEO&;C+CJLOZsHN(sB~!7UC$lu$e)69*o1Mg%9j_G{&$BKo zfxnUjVz?QZ2U$^`zTC!9u5UhL(?Nyj7mbv$Tq(Cgcgse~tz*2{F0+j5F0Y(kk+j`u zW&dX-@OPJhId9pw(pg^J?b}#It}2b)^VMljJ(<6)U5Rn;7q$z8?v|&N*V5|himIxK zMR;?O8-VJj3bsA4Te(;T>8pv33*z1WU>H&K+9tMk84!jaz}wS0={WK=+Yj#i_@At? z?q!?T^x5Xh*1ZtIZ|GW(w%Gr=>h$`w9QyV`*~m*K?f1nE-`PBgJ_+5;>aWzN!rI!f z-ZLzd9!cAcb%&f&pQu0C{*(Kuto#3_9xb2X>_1UQ*iHzo-$7k;YwbUJApAeAkLCT~ zyMDeDaM7a#-NoXs)T2tStzeRif%fcCd$y)4u3;ary>J92!hWl^OB{JfIbA-{Dc^1g z(|s~~KiE2icdyCYH*(zKd${INAz8fGJnXOPoFABY%I9 zAH!90|4j!v?UcKJSvo0KZSnA_6TjT+c;Cl%Zav_$-V?e_PIz+vc3tM`Rkm%XCN8v3 zs2c*35~;Bd(2AU|EC0EU|Y&---FVRUwwn}JS~1r{gdxL9~4_5 zs?C^N!pcE>s?!LAD7(~?9grH zB`>$yjS6|MR_JEhJSU%62Z%LW*pxPEv+A)omX>j1#EXML(|(%m7}JJivKbto%er+h z0dst~t2e19d>+dNb<^*4#YS{g@zwpdT?IXAIr8xrj`Kcn{u3@e5xSd0Tc4-s`bWP~ zJEbsCJEgj)Vv4Oh*u!CptvA@6-92vNPLF(1Z%ik;BfhCujAzo#>oT2lj^ej!_hiaD z8=jTG+DIUVNKzjyu1#Nl=c9bTGyayrD??Xaf2*tf3f-Njw(}_qs}=L-mRBi@^yS$$=DC$y`eU}drk77P^pBT-S>KlWGQTHPa?E)(H%-{_k!ABwx}N%7Z5N6WHr;(k zEU)%nsYTe6EsEWeLbc6&C1d(@e@$T^fc+o2v4vdM7bmnId~d1_{78NyH+?8aw-t@> z`9}D>N0)UVE9UhrM)<^!9_Yw-GR*MhMtGoWuP!?y0WDhc za@9vuhCMN&_L0M^m`c^yd<)%7o9E=4{Q_&}y%E@{kzd`ycjfd>e0sy)BK!LUc){PR z_sHUPainXu$0y)F+t%>fw5u3D>waGe#E_lT=dFI{co@g)I3_0h7*9s{zE^zO;qiFU z4Sg8^=d<-j=oU43q~6GTXg++DC>pE@)=!Aw6NOfs$?#15pnfx7Q$OT<6i?RDnf=j) z&~jc{2+()m*HDBXbo~8Cz47R2eva?aNq%sL7+0 zcZ>`0yJ1bue6_)tZ;m6Xx}sW?)^W- z+~}8H`PmQdCBg}_U5qgRrVz*dnR@jlXdFA|n4ydt;?&`6(P$mvx%_7&8Ap)o>9c<1 zK8Vy676)lpGR&MSG1Ea%)%~MfN2_;hXv*-zDk`dT%>UD$l%+7T0}H4|p%;_av8HF*>qq z*TqHdawv3n9_`$RRSxV~y%F99f4yDfn*6K^r7xF5gSqO^f9tj7^M>^8v4nfJ~1 zi_q7SAFJ(`Y#>-gvUEtBa`+??q}@>u9~#byrrFIPwe8>7ooeeYDa(D(-+UEirKp{4Y&Qy>Wy2nf9!wL z&J1fzuQze%)z(jUcs2I+^0_g)-N-%w?TpafchipEln${hpVl9AD`{uYPMFh1U)<^a z(*Lw20;VCh#Y~ShbDlO;95epk@!Zsxy4lY9z6S)tI$=IOP*U1yqrNMkPyI)Xd#iB6 z&CZ>}4gnlK`>ORt=oU43#5b85!+3Qcja5HB59ovbu(?BEbl@We#B4to(hQO z`^?rigsdwvjRQ-%zlZNu1^55ogNJM$SqY?*z$$FqW%h5<#m$CgCGdBbK+x3?u$!%a zcd`7T_s>USwzL0GX0n<8?h?qhtA2NpXEV%7AS;2a1hNvyN+2tNtOT+W$V%W(C4nYz zBlDN73zFl~sop#3aXR+L+qCe-hpu|!^ox(SdK0I@kg2ktN=Sc&bJhG$pTps#vmeX<7qlePMmAnXfu4S)Q1jdmZW2GjdhW z>mO+j-nB(|noiY{E6bD6ZF0hM=8NSxSRFjur`nXK#05BE-uiY7qR`xQBTC|QZQ>*% zXHQZ}z|@Q0=cLz*Cg{ypH6vR-eD;v;GjFz%qdrnEgznD7sTYOQuoFfj%xoLIFrOvQ zSr+IEUC!k{^O1A$g~n^?xE^y9Py!4FxJHwOy;Qvh;N)fmS3Xdb03*r=GaK6S4++^u*UIYmOXt<-tX^qU?hQM*AUj zH)pJmf5vx0D)A9Qe(_sA4dVPr2oiVeleFQeHw4=d^r>U?X-i1E2M)*8tBcoKWyA}#bvqbmHUIEC+2>)-v)2caw{eJA#_bN4yJx^U@KCE z5e+1|8gZx>2lfA8i9|PbgU^=r0_D#-fShd!a1HHHfX_GrTm^g#@SWB7fF)3lkMLmQ zV6P`0?ir{&&h4Spqo`E+^jGS`0;DlQsS9iIO`L_e<|(D_%+FCLUYn!#pVmPQoY_%z zf47rbwcdJaz$WXf^BOl&hb_rdOP6e=4!vpzbyWVo>bct{Deogks%NI&rtZ3-L(ZD7 z!#NkKybhEXiptSor;Xlo+^sz)bt}Uu1A@|}p3~?3v#%HiBg z6i*&GYRD8Bz>6WSCQ!y0bO| zain6}WsV7Fa&qs~JGQ&{pK{_@vbcS4!f&@Sn*jjZanx_d<#hzlsnaYIOvkOiZ0`|t zjLSHGHy6VVi+(JGeozjD0Dam;%3Qvmi&J&xx7WVcqk6YFv=?-Y*BM8lYoc*T>Syt; z#Y2XSz}5=*EJB%Ywy$2tis2~vx3;9$&mPz0s>%z--c>wf!HJXh{DE03nfDMnX{Iyv zvm)%9?&r5ebp^q9{oC44+Wk~c>Sx+V)(_M#>JFKpZqldzP}lel#?}D!jXH{|K*tgL zEBeWBrpGZkrsdW@(s&J>q;LKE`y6AqRnd=vYn}Ru>elhT4W;t>rl&pf<$;4+c}}O5 z1V=aB3Ps(Vu%B8#lkbn%Z`s5UQSxs^{&a-^({=aH^RL5q3_csYdzbz@J@L+QmbHl@ zBHOh>=k=yD^)t~g#`s{7x2BF`f@ZsE`Ss5Gr>>d%s50HXPJOGxYxjh2qmI#$&rUcB zT@#H1@4sYZS+PG7!fqGI@BYPcA@5t>D-t`&OWk&qH0C3Y;qqU6mJ!kk@+NV3&aeSM zIl%Tb>xf-}UI6u<<$`vI*Dx-xk@hspCI8b&Ui78B>VUuCA%=Sry)6A_=6SVFdw%#; zhvTMPXUd4}3Zc72lqeTP-atu1V?AC)LnEV#k43xrI7YDV$wB*fWSz!9KMbk(s~Q?_}P?fGS`na58WU@D8v&^5asD zPkCpr|)*`N3b5{v!RU`0MLeTZ&;RhxsE>T8Txcm?s?95bj;W7SZ_+*Dc3TN zT;q=aSNp#ZHzegy-I`fX2JF&*rf-?33dK z|MKaRFp}+y*e@gxZyp;wj0;tUK`BlBJqQ^|UWr7rCs_$(C6H1Aj`qdBoaMP6uILYx zg1-6s%gBr$WUVyK4s&JSbd~8;<)Q~ zro}pd^$gQz8wORk?z^x)V*Nt9&-#G<8X0e8UBim8C(sLEYeo8Y>DnWP5Me@QrmnyW$^8eLr#8tkvLa=iA@d z_Wa33!S$cET6|((g{~7Y4vuyg$M}sl7o)|&xM@#~OH-cmKKVS%x|=lqm-?Rnc~05z z*;WBN0(1%98$Lj zlI_Jsh%5OoLjH7x0Mm7k=X70?tG+AxE`Ni^I+gxsj`dV0A|m?*Lg)3SL;cVFT3{+> z`)jzRkN#^l2kd?R?CpMbkwATU2uImu zP&+Nyq?ek-aly|iCz4KkKBZ%V{17Y?1npD>!0{d0I&@jIjiU`@xuSjK^|S(v&;Rrp zCbk-<+A&?RQ#R=@=Q-^6GN=9Kz3cu1Du&nkeEb@3{@+{tbm~>!?t55TYRSF>o`BHZ z0%AF-n(6lr_hNsXKy6~+FOGJ!~RACb5@8HkJO^W`!2fd{$1SmVVeP!5J zIjYZXJ5T*D&*@ImLOv6@X@?*-S z;2|eJY!@Mls@O@X&%a&TP2HcX#_d~l%Cf2NzqKC?CLG&^ELTF;MB~8jq^AT0If#S( zS&#`4&qV)R89xbz8U6R#Z;FqRpbe)ir9258B<L$c^IN&!GVR}r=WM#ap9Esa zO62d<@%WWS`U4*`J=qZ5cbrp_c2&*g|3Olf&0Z(;nM=T7lkvQenSth zWCdsXeTdgyd1bj`-;$sXvrWJEm&$ zj(@h99U-`4fObUanrIxHcEmCto{3{=Q1q?EabwJ1=JSn9^%@lZPgS01U&OHd6ott{Q_z93%2g_AFL{a5;AuJV_+&K|H~`w3@M);kdM&Y@R6!q7uAJ>4Zg8nf1r(Ierdf-K1>K7 zsmh*&nelm^t(QeIS^xiw1Y%%R>c6QkB<%>t`xZ{YIso|dpUGACcMTkdQ}xbi%NIX< zckIDo`~ye5-yBDwYoc+`^AQyj61A>2YTAlS-$CyDVA@Ziw@ExlZ-)u7+tJVnV$fqECc;7(RJ^Y@)(2uSRzD0R@7GVM8wOx5 zFCXt^V9ca&h*FaUo%lK6?>M{{e+K4m;z++$ zsW0!xc;$;qm3^$#lbv(a%Dy?OWxpJ)k9gF2olARm9wPbEIy{ngUAnM#FUkgFC9swf zh#{WX`N=P4p2uoAu;Qm%?*3qa=p}v5?+M+VEqYd-kzs4OpI#$f67Wu|*HcI7*p53#eHBZzv zzT)93gcx$)t5Lr(okD>5@*Jkn@t)7fmBG*Yz1_el+A$tuyXl&YgPzw67uU$`#&H4j zOVyu~Yu3iM@^!{cMRUf;{>vnR7$S&1yq7@_=f9k*Zh7E^J4bh$e8;|26gbgCp-xE^ z>+~$H|2{{vzFiJI;d3tpC|91l>%EH)p7-hAeftkUQ(ZgySY@V!Zj%$9UZwcxl$Evm96n?|ntj$B#bj!2fblCEPeD?}j)E-J&LswqBz88`Xf10DHKO z#@;(oM{>yFEoc7hn-2okfUmuCpLizzX094OM!irr<%E|Op|4EG{5jqrbc>oiy7RZH zUCqmgV7S2>wWFe&tL0#hGf>7-HksYe8F%P`_&ouxM_{cWvP2jCXRTB1kNDdH=*Fw< z0Lp}Y?ou$v=O*o1@<~@FC)VHWF@ppaB3$&p>Fvz+VB!!S^qo=0n4Y*6O7m=CO=h; z;pyHQpKuTivtB6*hMMhVOOXm+ctqIS;KQ}~fT{n_As>-}na3hKUhV<4pG|$o**x^2wA(V5a>Hjgxp3q)Qkzz0(=1gJkecen4Z-%uS`SU!cX)oCa4a?>R|qr4^r zd=1llwdgulVx6ilT;YvGe932Owm+Lba@MotjrE)P-RiqTvrgP%btQ+lwG;l_bO|^4 zD+<;J!y~;7ji_8xjSGuRcrDMxr8*ay_!750pZ6kh?INuIlP3Rpt;FH^@9qA`ynpX| z&F1&>Bw*J61)n;Bz2-kOb=9PAqI19JY#3_<%bp3{ox531+t#;I_4+16 z>KReJ6~u0=c@LMg;OzHDD_{wtbpq+PBI47S zYi-2&P6%W;%jCZRFOYS=Oakei58EDed?xZ-Gyw;(3;fS8J`egP9e=a#S4zO_C*^;Y zzWmPrB3I2Awcm#;*57{WK}T6n>{+|s5xSe5cFS*hO-+5Ho)IbX*4JrIPKn(Yx|_px?S3J)D8hsQ zcb=(5J8l>I!qxC;@6B;|^5VTPN9}uajvBr^N5xj>sIK4Ts1NfxsC|ZXP#cwZP>q2O zYW{)_>fl>CsP$j$psxS1gF0YfM>S-8M^$lDNA>&-9o6fvcT{KQbyB^`I;rDN=%jKV z?4;i5)LHE~sEQKM@%!tm8;|U+zT12Qb@sg*sE=oEsE+8rk-GQIjnp1DY^);3_D~&b zdTKeMiLKYkrK-;!$2z_VxbN}6HYlvU;b(GOvzT@3UIH;BDgBrpKRUG#w zsQQCe9)weMX2Yl5C++loxQjh9%kt12r9$Y8V>-NOn%MlT)+`)+xvepx*Of~C-+Z4e zkJ^Txcvi<+Bvw&}b)&C#f0*f>`eNYQy*_PRa}7JvaE!MTjzZT&R3_D}gb~CTOYU_^H+kIBN4G~-DjAJ@ij=BNpSU6@! zHtki5o>jB>;M|<_ck};;{-x)R&2yr3!-NGZjiyca%Op0)d3F@t`NXuQ0{S;p*eZ#r7lI6 z^m_ZmdplAA;iNnW-J&Ls&hnr)zx9kjCk-D$G-n!$_(ngkiX&r|2bq^9?Xr!O8Uo$O zx<6h5aj+ouOH;=@ttX-{K7>sNWM4m=s(BCBUUK0Tn;*t=x@TZ7cy!ZArE}^F_oYnO z&kDQ|>i5=jrrV>ZafdffpY976d$};gy4pG4+@q6IpT)k{q4D#L|H$)r%{?zHed)CN z!|tbDp`+e&KNq2EqH%E7GvgXDYZfk_u6G{7)R{d~i_IZIL4P0`k#^}Kq#<&9Z@u(# zYXRT>7oX{S-QfT2z5OUFbIOh5tU@JZp4lq<8m9ooaPu`uttc7$2h zGND|ERIa@+R3F-2OE`VXd3z%f{%0M>;!RWmW_c z*JpihI=PSjCK2c4n{G>BM}3w({8=Snmh0Z#GTWO^-?-?q85eGSsoUNN-F=@4i(;+) z@MN$zBg4VQ5RHz5uMN}Nn^oX@vvUqw@5CuzwYcq#(A|8krM=Nx?VAQ?J`xf;80+ff zi{+E$dm-8uOLiT6W*mGSQhU_vXMR1Ud9uxb2R`kf&~0+U<9AJlT zG^wlE1~9+Vw9HfYz_g>U-CT5mehzxZLdRc+OO*fW>WZqWiA5fKCn*@NEsaJ)5o|CU z!M+D!pQofLgqG#Fpf4Q8DnT?XBYe4y37K|t1^6Rh!XG2J+qd7GbHb(DpVwN$Yw4tY z>!w?wYu&yrX^MuurrnGo0g>BcmpymeP3E;#{Pt^Jo4)70Jf}OG|)9P*BoIcFXqc8jps;?5dO-^|3{73i$ zwPU@}nmUZrj0)LY+25++MW&uK^~lW6QA5|#$qDag@MG0% z_LZiby7qMP#j-_Nnd|ggb{g3I7O!ujWNbYzycg=COSqdaTQXyO&13x$EQhbDbJnz` zoZ{ez^=u))e0c6I@8z%Ty*PZt=G6$&&T1ofQ*OG13qM8S=1??PRPV=D#YMrubpH%b zMKGklr&2otyNeWg1Hl0HV5zqP9r{$)%PA+fJ{2JRk+atEnl-F7s{l$*0iGw0SOkmSPX-NS$}4kMlaP z5^npzaw2f2Vg5J!TRk>&^2_lQwx`VR4sLn-$@SIGAMv!Lv6(I)o8`Fa5-$A0tg_+2 zwKw_$92MN}IBHKyA+pIw?=75mf%}zkoNN*JyZfEWyPJCFsZBq9DNuW`@0BBU?Qe~P zP;Nq({KXeO#NJ}d`dXU@*eA67w5dux-@;pzx=3ul$fhg8SO={S&>n9HVA?~!o5ist z&gXF+hLhQSfdRnwz|O!w04~rk2F3!DfEr*H5ChHtt^$?-F92Tvd0=KQzz3WQJPB+7 z<~T=krOjj=j3uU`)pRiX6F~VvH0{n0BiVK4kd>AdSwYrq9O=K-aVnB>Ul(cpT3*)m z^=5sYzm>Bbv_haP2Q4Tc7FL*p@`;&)V zSGTbL!Y3BfM$ysF!BOa%XdK-7l5E%T(+%uNR{82N2xRJQsIOCR-Sg&5{^UD9zUAza zhhLVgxW^lJdUMky+|38Z{l_=@8hv)7CNkVNJs9?BJ=T|){N(pb-+opI@3&~)Nu!2* z@+xf)-L3%3kWn5y%^yy z^g7^f&*^8~BxwoXLYH*Kck^8pMNhFIHP5`}m+;+Vfb;pg+q0qmd1}k@Q~Iy$@)MxqsprE6I`zf< zUS1sfblZso&#C&R+h^=Y(0Ksri_kUEIJou2s^>;}Lm2<|;maAd<9yz51qN;GYf|aU zV1#M2WTcxt{bM9x)^ls1FD!e70H2SPLzyR8j_^Ty2A*Cr;P{cbHoM!xr@jc?CMP`V z3-|SdMws7G(KKJFKPnO3_OJ&6BoB#0-yHXwKPWxFjDN=9xmVtC_-#XYPG{*I)_1z- zR;V>Dl8#?{)OnIWT31*f3Y4;5pflw-G(SCGJrJJz-1u{^+iCVcq|L|vKIJHMov3lh zBuAUCHuVat0m;KiPQ~y?+Bb{A59K1yUF_^sTsV9Ef*W|-n3U zh>!$NmZBC3HF}^mb$Z;5=3OMc>&S@=kn5+9Rx2Xg7qOl8+Sil^)0UObFB<3_Hj1b70Mhmp_q+ z+nz98j_2~e#Rg=uClXJ5rr~z!!rXDQ|FaVKvr3=^j7j}Jbx8Vh%zHSs`uu-)?0(dL z-1bE1?)z-7z0_VgZm(Tuwm0+tk)F?Qa36>Hm;SIr*QqCru^D3fi}pt7>xj>k_J-{? zI2dTqn3{`W! zDp%(pFiXw3DXyM+^ey$)`@?f6N0{7SHBU|3$T?^_(@s(j1m(~RO2N5D&cE*koDcA2 zAIfHbz;vv)m=4>31nUJXKiBVHN}WbJ`=Fe+WG|U=W_#5K{8e3F+!)&d@vGliuo~sT zEO#t(W_jtcx3j#s=j}p!=Be2abbC0quP1+m{m_^O>tCVcufxeWg_PTpKn+*;VSPzS z1aBYL`y*)X8x8$9(j~w0-k_-)X2N`y43qFw=k7SXUgGmS>wdlj%=X%9=nLgp2+*g^ zXPK7wK3WjodDxBJmyf-q$0sy$aAIGDZc&p*?$eAl!x5}+uyz2_ZwPXlq}~@P4EV9) z61r0!)}M*;>V-=B;-NU2dUFsJ6K;+ae(P_WqpAP-`=%dP4DEyQ{Ow2GvG|aq9_Rbd zbY}z9f1zulad7K@QP7JUsljqEJ%7brY?F(ta9uuN-p6eGm%NN*9pyHEg0tMZ=dI>f z<*D#7y-w-eb(iNJ;=&EMr2zRBx+WS2H{Y&xSlBarjyGIerI+FJvKTfzN7U3f^a51)#)W{&nm=$dF8s3(=)2)>DE zeMlp$cSNZUj=*Mlb%>X0T-3PycRNj`H>NG(Il(zcw(V)V>?VPxQ#Tnd>A26$|A?j? zY2tXD2{TOM(3kX0nw+N#lQ>!b|F;BUU|-5>(}?u#y$Xci{`|b}eyCaRsaD&rzXG4- zRp@SMu)J1>y@3ecdebcvPYIS(HIKl)C^Q9a+9@0Wk+jXU%=#x@>a;7dPj=Vqix;8? zK4bL51!`oTx^{=pF1&lrPcI)))m10MG|8vX&9r&mmQQxVs{DZ(Um48Jgow|&!re|8 z1Tve{1j{UQ<6QL~zzX1Wn6*AANcA`$1b-GHmEfG>V|=#DSngTYXaSiH%PQ01_$uQ_ z+VY?AHvlY)iIc2LNWkpBtQehMPYOoiJ^W6So7aEmq?Plw7_8F}JrQ~$Vf&=5o{aT2 zmHH#mV3=>=wNaY(^o7ru;B%K}%;#z90H5>Dc=+{bv@F0m<1-w?S^7G7T2JVc&UEqt zrpW~;tXJsxzZ@9LKUwFHKokCn{d=#>sW0ySPw5!EzvDUJjn!KYJ^B$gXyI6I)2;|z z6ODt_Pva=5zusrGWaD@!zqG$&B;W2SZ3gv+HiNoB9U!u9?Id8@k*2Zf>qVycbi-jI z4-KF3nxxMD1$!B8x`b0N_$iVo7U?(6sKe%Ycq<)m^P=zW>d9MInEZ4dmzkdreq7M4 z!}05l-^I?5ehz9$p$i}4SJz?urM4m%tjD4Qyz%CXM7-hVNqA9@dyJqG#|VdS26(lq zZO6DlK}GsLdSA=nV^-Ak`SCc*TFQL7 z(9OJgZrS%Te_*Cvge|rFMdK9iwAaOd>LzuP^#NVB4zT24+S5fC$EI8gZTV1EtTSal ziOCo*uG_Ka_r<$?`ok-r(`}9mSnmtnq9%{pWctv1sKSd_VSE9U`^uJwG2S^5I}6lW zWBEniM(I}+;8L?az&Sa|E17EYEROum_{or8cgA@G&M#7D*nVU`MA{D=Lt}r%bYkx~ zu0|Qs(I=h0v`Zxnq`!qT?M@u?5xoCGfPO9D1A33aw|)-T>$`%9d1{Y+hdgw0x8Zwj zXulZI8N#Q22_4ZLu4*PeFI&|(t-)_^Bx!xu%rOsAcYrfrc@{Ds#RSjZ?2QvV#of;2 zbEcz@UBnY~O*9Vfc@TcyHWV$Y)6-J&PR2yP7mL*+ylf~6lc}d{hin7*dsyF<*dFJ6 zua>$-TgADZ-T>o}7nVip62nA?Oj{=U$F{D-qn=7!`lPddW*oO;IMbugJmegw+DSU{ zKkH{D@OwyL5i*f>Q~V%jyT!c@K^>T<9vyRa?}a_fmQJu0mSuqUL+EavUFA5r-;CaF z$lCORt!&u~U9OKKeX~3Z-R+YNmOHcj@La(73@7L$p7<6ud;GZ)n2!rYZ(0sb>J4pM zY(HxshWvx`)OW94{8iUO^3-$v^CoP#=@-{jHTBh5$$A8#Yoc*rd$+tX8fuK%U&-@S zae;bcz5ZfFy|+1HHGo&+8uDT8zd#;jOoFzZZ3eclsjGayhIIhfC~Xd~9vA@Z2o{tLfBVZ*Mc^`}vfQehd z1U^-vE&>zVpibHx6Ec@#Q0EEEZ{Leb=z{H#&rZl=H%opfQW#}M+YsrmO*vrP_8gLE z<0v1>hWC9f&=HYt1plvr{|kTuoCiR=8)0F9GGSa!$Fpt5dJeav+Rh(%*S5Hlr1IpZOKZi}pQ+@WX_@3|`=;z`l@;OO-d6x2@ad~e3CoSvN zUIM25tn)hc#yuXq2I1Fiaf@fxM)&Y@655IV6uLWS_6y7L@$QCD5c}m}lTK`aQ08s+ zg(G8wwf^aTU#)e8$w$}P%;SBLF-KO-ey>@#xtW4BezK8r(}f?m{w8&FREVR1!iU?= zJ&DOJxmQUm>;G{QF#DOSW~A5Gq0`Y$-2MEoC+)p-7gTB5iJcR=`%Xkp3bC|swroTQ zEi=bY7S=fPjh(wlkL#@{!uqhOUtPZl`g_ih&3D{JaU#&^6IGu$)-m znUS)>E!c|r2SBeETQ%xI6#E*to*GGIJT+}9Bd4>U>B2H*^f!*+em+u9v3(--7|*lr zkC8we*-F2msV;qa?&{A|Pab&PQ@5UZ#%FgtZ}BVjp3vQQk-9uvMH!y}D8c|~xB`2@ zVBZG&dr}cc2{-LcX}yy_cYChousl`0;dzIu8wdSwqFrFc&I#SkpV&EjU4EiJ40}`W zi~8Dhh28pWrpLUtM!qwl*e}E0J%I-Hbo{>t^iqKH_w47;6jJAC^o+g@HiOexJhi{frnA5j(grBO8yQn_B#Hs2v_VYH3DF}M(CPo9Qd6>JywpTWive(O&Q)8X*Mj~ zpJn~3!Se5VD&mxCF;UIIh8ShLO&4N#`!VLbpP*$G@@!`r_tTUim&>E6S_b ziGR#k-HCc&_M<~l=X}_5gg*)lot38+48L&-PSt|bcKYUtw`vaJIUU(Mx$)*IkBD#r!c-sl7H-BFIKa&E0J&=2SjYzqtk zwgUzNgMfTsdte8EaP6kc^P6bW_P6rkM z3xP9$Gl8>!vw?GfbAj`KMZo#M1;B;CMZm?tCBUUX9Jma)9Jm6w61WPu8n^~%0j>qE z1Fi@D3ETkO2;2m;0yhJ<0Jj3S0k;Ep0RI9O19t*<0e1sSfO~*@fu+DQ;6C7f-~r%4 z;342);1OUsfNJz;-iOr3T^loxgB5lA{OaebXFb~i*U{0>!BOa%XdK#UCzN_4>6;3C zKEhXzraYZuA&#Aa3f#~x@E3yL4@VyIeQ0)`dScJfUp8*qdeOXND8=M^pF-C}_%t+KY@3e>FfpOuIrJx&Z3|U4iw14Sn12@Du zGM$i%va%VF4?Ti_qWePcN281$2)%B=8ZZ=s+{-Na@!2EWbu!Pwbk^2U zMk9eT+~aw;zXIIbC%8v^+FE@N`qco-`D9>6UGN zz&5~N#nBE)IT$uKeL0AuoE&;=^R$DW%^g(y04-Xw90*+#jYFDp;GB1~uSwPKGm=|p zrz}rUU0p6B(3AIo@|ZC;8>2>zY@A88VA=njwi99 zuss(in=6?0O8ltwdaI7iQ>QKaVAaE(w?8}Rig7wO8SfIh!Gb!4zraw*8%o_InVk(Ujl3Md?5FW!8Q}yZ}mVKFaX#IpzUD2&H9D*1J$Xn%UPe3#&W^@ zSbxzrvF;%cv?26a?~q2DBX)=JXlI!2U&Wc_dQ~i0u30ABw*1B9XCn>j*D_IjrxLMXov)Siq*8Ktr#Bq(( zOHIcl^(Iw&{u_jUzR%_1oI^{Np5iIixk-H>bT53?&oNTuXT@#H%JNn*M!K;I98$n3Nt#3xs+SajuOWi&O zSP47?1Go>2;_<+LQ6T*Aw*c*Fgq;Lb0^0%Xd+~00J;8FrGA?BZmuMPwg}TFVvB&fo z*OGvYEhKF-Z8E_$=;*uu>wv$&!K`POLw|Umg@D{MWi=HKXyTQ(>=#G)E<;WlIj`YA zO+6R@Hv~T0@j|z#$)i($@Bv@@H3wf9Up|J34D)>lHlhP~=^(1VXsa*I$I&bY{qSG% zOs4Lfe_C{+)1Hb>$a@k~5q@;{MK_-G(5tt~2KwvcM#;a>&9r%*hW`ZDg^`GVMxX&( zd+{4QRtiJmnfzN+tG&p3Y0t$FAmzDbzVm))3)v3LM@Q28!nW`CM))Z!J6ApX<<&op z0i90j2ccWk00J;^B#svvoYqai)y@Cnb8 zm#xlxy}9Sh6~|DI>Bx5n9EGll#-SZ~==w6%-o7S3%U%4qpAWOSuSfl*TSSi7mG*{? z{B*`q=$dF8+Tq7~J}DTQk84F=Vkf7UPX)qXKJtazPMOeSH|hx;>rd*x&^6IGw8M`n zA04{@M^kS^Uub_*Ig{_9r#bm{%dzFuJhkmRxue&j+a5QC^A!;@_g9J>w zwmO4;FsXy@di2TB-lbILf3ANbclY!7b8)$DxiR%7o5lfSjmn`-PA?JM$zyfyx4v!ynU@>_7WQ=e0Pzw^=^`h0NK&Xbq)wGBU?hO+%nQIIco?^@tXy}jt1%T!Qyh@zGx@yq;}8W1zu-SF?RbA^+1cCMj57`PV}x##6W-5#KBFS` z)2#GiZ;#qG`x{cfB=1BfIGGQ~eXItb)Wt%8zI!|ZBvrh@#~t2#<=QFk{;JR!$8=SG z>W#GnV__)d8HF*FrV-qej3d0|0d6|Q_$D89i=2G0T)6wq8(wk7E2sSDt>NU8j(!e) zLf1s&kdhDkBkrjD#`>alK{8_Uu?Bq5i9Fo(GQ)=5eE5_h8?7%x44Mye;-)h$T}nRi zE*^KM^!w2GAWyKVCLc}bJNbyC!%1G3eVwCjn6mUOru+D5xtIO-!Tk>7Ih`e!oHleT zv@IX{39%WF;J}J$^0DfYBp+;#@%t0{;a!08(f#>NS}x2}Q^w34bKr&EV`keAhGXW` zbD>NA;`99snVb$6Pmg%44Z*4!BYH+6@ks)HYlC`f+D-DnF?QPO9suV6IH$<*S*~5! z7NE|vug~!p3xn+`HLa4A2DhA;g(o~*B5iI+u_;lggFV+ z$me4M@qhoZrVh#l|^m%YAax8^Ija|DQRk z@bet?N>K;3^70Pq;GP}Tk7smLt%EwL_f~dNE%DCkl2f~=Juh8PJ@r~wb$8|Z>a30% zsPgYORHv2nP)~o_ORea(se1LQ%~jD$TdBvF^jGB#`O3S&&MNP|-PIe5_gA;(k5>K0 zO;j(0YSq4PN0qz~v5{rH@XC!OT@4vBjmIYgCk zv>6bm21KWQ2`4@4vJ&{aNx-zPQ!h>0SC)rVc7Ax-@Ha1*{NgB)lT~hVl$$Q$?)nDZ zzLcik( zo!frsm)g(^tPbjyyrZ4k_sY!e_D%OXI{&sghYXQC=4w9X=D6t+?(S#Xy__+==CS?= zK0;JeXT@xSCvsTj;)87sjuBO$aro^0Pj9^l;Y)5mcKLbnKrxzS+R6B#&~0+UBOj&F zXsFURtI>x6vuMOxqB0CIn6EkB&s%D5{X-%_`^2=nEmt|^N1i!X(0f~~=Y8qP!BY{w z-GcA8x%!$7%)IzAu))F%_q3@J6rhedf0(-Nth|J}VyGbWO%V_lxViVXR#B>#t5> zx8N%5XX5jW^hFaS^rSo`;czgl;!ww(C0p;dJDO z{THEYqH$=CAMXtGr0@d8Ob@!2UhKQ+#Z;c|&3H;0LQyV1(k>20Ou6ggfDrNRXbF#W z2@^jNm_1qN5{M&3(VyPerXS~F<~u(B(|%(&I_D5ek1hSlfffm!aZHz4e?~=24QehA z=r4xLhapV+5nl`bUU})%)}tkr^FT2bsM3tMQ#H2F|BIm;RQ(HtkpzYgE=dUf+lS6q+%i;jHsvng+N`;h%~I`YAC zCUi|S4mKaf*yv4v9HY`VJ?x9rVR!IKA4g7Rd+T-VRO19JC+vH&ugQG)Y{a&9#W}j| zdVYzvX#;?Ej&_x8PmU|FZQBdr_yX^Y>-RX$z_rl50j`VYm;>t)jvsUVA@7T8zWM_F zfc^l?xL#Yh9sGg7AYgldV}XN#odH&iFpv73#y#Ng31FB&zr(mc{6e4@7zvC9#sU~V z(CZr~!ao2w7?=uB=5+ui69S?D4bM@)aR8s$X~0>)`M{;XRlxPYEx?_?GGIBd0$2sC z1~4R{J_mjPxldFTPQM(qLmaQdV7p>G4TE-%Ppm|C_zd2jjH4I{>u1I{~!49)R|@ z0H6)V5PZh>%lAQ?{eWS>aDaAs1W*dlHkSc>7_`roKs7)cJsCI0KEBakQ^mQ@@TkD_pxr)bLPW`b=q*+|Y8Yrt zw*x>MFY9)3s%{Q-4R?LK(}p~!llV6vKEjZ}k z^Ez#+;wZrOn0lfXr`MCIcVHg<&d_H!-BdEwttUcv^PW*pJQzoUjfz9xsITTYPF7Fc(){E8 z$B?zylNHbt+NVN*KF7$q0#i|u%wE6Xh8V(6{a}x6j@|8?4d*ceoY)hgTh!z+sVDk7 zk(Iu~@OlS^$2iK@2>oCk?$(bIJMCZcK9|{^>w33S@7?u7-JN-A?*j+k)@SzQoqBh+ zcxFG9_EG4`JF(7KAM>8Dmc=s`{dM@0y#6RH<0L=UIy6QLXM6qiT**}xs)hN)J0Tnl zOjQotY4g9$Mw=j8B)U#-6Sx+HPHPe8?;K?zZeGg4(0iPEc+$KO)|rkx2bO|LI2pilb` z>X6@Y@T)!D`XY2U?`xqis9#-5gG91=%ZAwn}45EZ`}3Md(f-JJ^OV$C2vA$ zx!sWNkK3W05xV>Cl6q5)grQT462e%FKNbR)IkN9MTcR;byJFRZQAAMp0-c35@L z(vKJ-O8)r|rq6#q_&c@p4Rz)3H-(Say?bkqBObNvBNA#og z;q>~^0{!{%^H;`hcK7Ey$LxhhQ*b@?L+EDOJWq_VcnUn#*vq$mR5{z!oZQt>-TJW` zsC@3UVSMKDym6X%-aHp)+BnkWd5cb%;bxemD>Pm!`owe7nQ=_|-{G9&KB6CMGUx~8 zvB!NK-#u>7-kj>w&XQeD8@hzE-v!JGhG!bq%VWKkVlN)C-=)x-yYFJZBVCI9e9Uj2 zneDduk2w3g)Fs*u*(ZQ`d%rCxI_>5!?v!yX^4SsEBXq_wT|0b^^UVlG{TT4C#VefA zU=2RY?A)k2jzmO$`ODLnFXs1HF#q1q7ah=t=X4@JH{A-g)_0_kpJj|`oGnSR%sE6? zx~r8!9G>vEd@cC9f8wW)f3*5*cB`}#{@ip4Z%1xx!JlVT#q8Z2?@7fTbv{?I`7#bZ z8R5Nd?mzFFvOBM}&6A#MrhO8+@Fjjb{Mr5cDoos!f_;aT^`O28c7t$QN<`k7$}-~O!QpL*orPsUgpX05HD-U!`&H`E(z!buNc zc@p1+4Tj6Z{uzD@X=#^_qp2sfpOS|a!#bMdD}A3#&+j+j_o^kwUVP1+t1z=`Hx2TP-yuE{vK^`kl%9P14%&@0 z5`2(fa_y#TG7jVeaJRpbZ~9ppYrid=Y}-hc7)KhyU(2)3a^#*T@A^!h8dKB#$ZO`l zcOB>R>7*P9-J&LsZaIy|Thuc>$v5%!9Qvd>AKnAR`@@`p7#ED%+%lCo1Yp`R(%9$Z zGc-Xtr2@!V_Zv!}1!;@^ta(1Y{!~1drv^Ot!nqwDJbwpKaLy&M{t&vG)wR~2q}o^- zU*^Zh>*VW-sr5+4AhLSomiq7i-)x6;ech=?%fSv2TbZYB+U&wEi&y2TTlOgXvNbZY z<9&7qQ0$P<-FM*DBg+D@XNqODoC>VuR}Qsxs`3S*+3$!zfLss2^ z10}!+U?flqi~>djV*suN8w-pB%7F@CJiv8fRX{Z`0iYe21WX1F09daa1aPg`ApqBl zag1sz;02}uH2_DSe86;o9iuwH4;%)}1nPkXfbHQR5CUcaVF1(HdYxG#{Mi84n{oWV z8Q{7zj&X89)RDkZz|lYqI0iTtI1ZQx91olToCwSZP6AE_P618@P6JK{768=mGXSn# zI}11)I0rZvI1gZd^L&77+Aahx0xkwF0WJmNz-7SYz!kuiz*WH2z%@V%!1Zs}0oMcn z1a1Is1a1Oaft!I_fLnpvfZKsPfPVptfjfb_fV+Vuz&*gdz*1lta363#@Br{2@DT7Y zupEF1r2w`{9DSDhkSfeg>z4Y`KLs_@{gFxDkK9uy*MEj*T~-2F31lUZ zm4GDy)|=A5ScG;VZDwH_;aoZA(%1q23LLenY$2N;`aLH4SJ`x)n~v>5d$8CV({AVc zm2%Dhv3Dl`epL10z<=Qqb_#%l!ujpC7z1QIzC2uP?}S&|KjB-yaLfkd>f zXQO!F9nZ!pil7x06zhdrDFf?Qe!uZmjr|NYMI_jczu*=&N<((30WZ|1je zt~Z}~^X8uEi65Dt>itiVpEAAIJ$<`LS+Cc-Z>n`a;{IQnlzFdrzq8i;BNy(yU32)U z*N=_=WmkW2`{wY|Yu*2C;3wNRhhJ3d-t+S#cWicFTkF1R=RJ1H?N>d28*1I(ckI92 zBd1?q9@DvI*2w%sY@S~k|N2Kwh=9Z*6?KcMIfxcBxO!xoP6^az~V>7rgdsH|_Yjr}Z|=OG)n@ z`xei~ZK=GpFOtPbl$)mH|E|C5^~|NWOk8eyZoXgZsRteX*})%QzF)Z?`(80SSCN11p}cJ2yni{{zxnm=2gHcWH0#r-=YQGl-Q_)x_cNCBaZ_)*U+a-C z+hxjCKY02Z@_FbC4~&@Qy`)!(wMOQ@ejRgy^Ks?Xr`6EoonI(rIrm>CM;vc{YLosy z_cPZ`fdByl1pc%F_3d2ij_&PT^Y}5R{OY5pe)7f#EjXa$BDZt7wQHuA?qxeSYuVty z%H?ZT&RVfNE-$q&QFbna$D64Jmc;E{v-?-{tt-RT^R;0c^7ZzA-1o&heCFTtQbZM| zbehfdPUq447q&HD?K=k=$NxW_c)up6b>;i7eb6@+?6slo)ZQ@L(i8sf z5#K)~FAY_py{|B-)l4tlGe5`muO5h76XFZu?P-sFMXK9l`p>$jzjKTvuUDKLA4t1m zmzR7!$9Z`F*Jr)(s@vm@K<$w2Nv->hrgxG@TVwa%kKX+mkGU;hRa1pLKa=}yCB2h8+8WDGSssVS1=MA$ zVp+@^%8wa#`kWT+`gxH1#NTBaqa%wSBN0n}H~zfauetn|MfVFH`RX}0t?T_p?&oF5 za-R7u=~ZH_k;`x4!lTCS^UYVDmwSDqzv&U{`P{8DY%aTr!bo&1`R@6}*3V1s{}1Qi z_|^ArdQR`M_E_8NXS_qGlir+GC*KR>!)5V6?qL7S6{iji#)GV-;P!N;pXVWG#PrMf z^CaUg(XHP7! zUVG}n2S<8_vRq1fJ9VttnZMERxXzBZ#w}kl)V_{eyFWL}Yc7i{3-u6}8UI^heGFaZ z@79>ViPn>x&@*=Xz~Ds(ePsKx+_F6>=CY(`KlRX=zxak;=MM9@#UNh~vT)7ntV~94 zOsVH%^?zCgSIcI{ZEfASC8*ZWuh>VBtncm{G4qwj*tz}N zE8;^U?i=x85g!?`H{wANvmSbC#Mu##jJPo3vm*9K%sMsiOURA;n8g!i}>A$ zzlgY7ET~6BoE!1E5nmhel884&d_WZLVE9Ib z5wT)j8FAzuv8{>)zfUaq`^E~tcdYQU!+L#GkU!Zy?v;oN_%X4u*gY22KKGCDO^tWD z?-}0u;pTv&f;+{1BgY_EP;E!*n;g68{@W7hvUXBy)sXdP)>|1$yFQ+h*6u@-z@JZGb&R^ytCN2>alL*?)VsSr_o5Gf@#kOrOxcf{ z62oV`TGE?2?bNIB8NBxUG!}KHSDvqF_Md;>JK|m4e%JR$*2jEAl~rw@a(v^3X*X=_ zzvbrJA9MLdxu?>uhqL{NPI~^XhtciB^3}`w2N$l1dq=CzJ<&|R+|N2Mrd!54DJu8O zL%sWDweH(R_pC$e-EXaRf9$1ghmq)~ET3h+-}-!A{Qr&`xcKxpZ~Fd<7%)OEp9~-G zq__VXYnJ(n7f8=pyLegOs#D{6qFJ-&>~h6YVm8>tp(5{JG7_l{ zNT+*#k7?PY_S9xZ+N6lhfct+9pYV^55I z^{N1Ej0t7_%KETx44d1BoPLIEXRL2;N?Pfj?Pe&$)YCJq9-4pGyZPM~SRbuYe(#9# zv9)^T_cvZ}^A$(D?b#o=ygmHM9ppcB(wnYXerM%_4NI3Vj{VL0{%@RDsNSt!4bl_M zQjRBYH>FjklO3NJu_t2ben74Jha>&rk%tYP?pe++i|$*SkMn=~@JFusbngrPrE|br z&d*%XNsrNWg`AJPUNiprqP|s2R>b?iXRR0*>W@BaYiLi5rR4k8$XA)}l1R_BvEF^> zIJz3`9`ls*P@k`j(S2+4^@YWI9J}~u?>uR044a|M*B3kK?bNa6w$E4loL!lz;LH&cnutIead!ksY=^U*|t%*Bb_&@q-Iuuqu@Kx}cF>x^Me@ zjn%AW-f|p05zG8-jQrK7pVO{yk1yG2;(B%Jj#FB{x&KqHIsK@&oPW=}2|2?3WBF#i zTGHF8W6fiZozr{V@yEB{G1e|ClZyTq;zwLi)*rJbGX z!^B}vbuaszXg?-m9%ANRL>%^1$HCdXJ;(7w=n|;cr`PY?T`qb)w_WuP($*bu-t-M0 z`L`MOn9`bY*1Lba^mV@+I5qZ{GQ^=|RW3?;l~`+Jxz2Nt`JT7xeH8g*eB8meIL?t( z6;!9+W;v;iVw->FHaU;gvR$^%`FF-rUNU{Wu%-0z`u%H6J11tk)PIwAnYf&+zUP$I zkDmX5AAjq*r3*imC#WOj5Lthe^eVB|7`L3nGh)@dYnN&s;cXKnCqkaTTi=j=iltU>FHnYz|M{yv%Hk_7^EwVUDsI9 zH$2=wxT@22LA2}Jn=;V8F}|{ok$K4TquUbd^Raf~N8SUJ*WtoZ7q+REN_m96H5i$2Q4vd(vajLW` z-$z9In20Ate0Id85m!e%E8^crd}G9ajF`JsUx*l|OIx=_{C&jS$2uV5(Ggcfd`-lQ zB7QgGy@Kh`h^I&VV8s83__!#1FO2xLh>wk()Hg=lZpWBb#6LtlCw5+YV`ckJ#J9#y z(6T7>N5;9~S+R4pFbc=>qi}pac9QmwnZ6*-51bI&^l7o^9v&wXo)J5ZpL|fX_m1i8 z6a7Cl&iOt(rWXbAt&feo9vst{9?$y4N$?r79>JhkaViODy+T zg|~PfIA*Ks*gF2K)~k9uf7e3}lcBWRe~sS^qAFxN`_EW@=XzVlQPQ$q()WqqG5giG zQF8ye>`P{u$n@O(3DWA=AlrGI5X{x^u^6i9L~C?3n9~ye@&(q%ES7qG=ljP>8DVC`ECbE@bW_x~N58A*fvZKjv?Hpf%e+gx{Z_`9;+=CrK0fgp4V)c1pWrgpEl&GXkIv0gv^bKk%AjsNua zm8a#-T7J*=JL-y za_!4!JocwQ>cHmlO4jEky*d8z%0=(2zE#6c;b`S*8Q;GAfc?f%-mCN3wNq8$C;mId#;_ZMDv#VH-Y+$Lo?De0Z$(biZw zsm{iYUJlFCatrzg>+b}u-Wj_w7F@kv$@<`~F3XAfpQzhtrv2EWz=r5j%FBg&Ph4Im zKX^*(sZYE3%Xi*zZgM-5`&Z57oqv}YKR4^1 zX&K6JrQJ>)zgZvO_ubdfpYwmY?xXjB#|L4LnR8Tcybtn}{=xZ6s~1~l%7TFv%NNIY zm^%a1^Ru9*J3r0+wj5;dcV2VWJ-#vhH)VPyKh5;geVg;sIiXh1&-Ia?9RJLS+0Om1 zT$eV+0nUMEosg%HTE95_!Dnu~?iH`h-x=Dg_ja45x4XvmvXyyTYwRE7x6yjD5jkAZ zx43g!uXo|B<7ckP9f$U7Y`earzVm()`z+gMO6z@}{o8;2<-4waTb{?tkon1arlePi zwMKV-s;Xr6n!$X>*Q&0(Y>e^Mw@0;6{8@f>vR}FXStjroHqv^z-Owl}d7zTT`_72Z zdG+(M*VZpzw8O=Z{oU$Y^LK`}_oU6z+g;;4WL`O3KD@48D01bFdSxiyy4)Y1R?LDu z)LzfK??*V`p<7>%2Jidi@0`BfS1v2lEBR@rm+oWR$FB3^vzHIXUCRT5>)J08XrC+Z zo!!5rx~n80HpU1_{d-L#UwQnM+sg%U(&FE~aCIKWwSM*DHyn7*C#S5*-x*52n(6JX z_3u=4K`uadOVgARdVmbReh_6mJJM7qu3bDlE2mace{<3zYAXf z!ZqJ}{TV+i(=YjJrkCzpaGNN9Pmh;_$5Bjs4E5uwI~)1S``{)=oECC@-`MZA9O7&5 zzOm=FDtHfGk3r?Aj_LcO`b5-?x?ELVp=cDI}Nw3>!`krqplPVs~^wNC``IxgRKW;v{ zwso&>8yoo;Z~Z^-qhEjWt3LRGxC^}Y7d(0RS(lu?|BIj8o^sY(x&12XB|oJ-?)B@=LvQg!-12-FXx$;3?-!Th zbH3a2-cG6iF8$oqc8(*ryLrr(`wJO&?zFRhDc39FXV7WfXwfJ#?MyYvmbc*<@;Uq=&AWfgghs^T{KI2l~`+x)qkD)9>zXhH~09X zkLo(Ey5@kf@|)*{M!tCYq^yHmZ;R)#cDZ)S#>n5T&;0OlU+G;p{N?tCuc~iEW%(`X zwMkb$k63U*@505)`j@O((LXqQ=}_W{IlNtPo2}@mB*xLmh|kW9>zRI@1JOhwENzc>sXnm z44J3QTh^B)Eq?w{p*ej1T~Dk3{-Y+)7^sY|v>ToMNno1)|0+;;*}#=(L~rcddzyHq_2-%nZ>gXV!y?$_t_ zthj}x+Aig`DYrx8UC%1@OLotEXUsY{(=+7XrJpLH*2r$cmIa#iXt=T8Z$GSh2D`E$Qvlv1T5Bc8(Y7*YM^Z*nSMA zIt|r1u$b`sWLL!~vwqEept5g2HkJ0TvW}Pbc-^yJE%j{H(YZgD_uynbQHINQ`5ixn zaRlo7&(}w}Nw1j^vz^N)_fhND0bYII=lyErzOVjy*?&&^?P5z=(&NvrkmaWSUcY=L z%yGl!wW2y}@`m>bxTqb|+urVf393~&y zU7w71{cO(zezw;m-+A79O5WPXHaoORdNaSx<*~)@Ky|+T)UIa6KH@V{%ijS{>CRvC zdvE7N{%?H7@-M&mQ4f6Cg?Telgp(p>c`4~tVy%(OsjBFf_77Iih{V&GYlix(lcIS| zZ)2<==~I^1qa!W%5wjfR{$Pf-LHl<$bDheVq5ix4U3KVmE9I%AY2P)0vOeYWlqWx} zyL^oNwlLrn8P;D(Z=of zf0dzLUe?dp`t!GUyl1;-ANR@&2XeR!ox{@BPdn-D)Ujr>zKbVuR_DEyaZamx%y!nm zlK%F)0NcaV_vbc6esY=3jF|1_cKN*Me%(HI9{-QO|6RV)rwW;$tlvs{Cwa7$=Yp$; zXyYw*3)c)TjVtprPd#<8|J1&?su*=$yc}w9LEq5O?7o$Kr}mevRIAk!W5{|h-+ysO ztXIV$x4&869nk4s>cyT%A^$r3mS%Z*e-SxnQk)JZXQr_zM?K!-Az5PWLhP>W6W6qS;OP;^(pv=nw zpWpj=w|?``ix22zEbF*?M@?7KJISN1XDokSZ}rvSd8^_MurvBr#9LFBw?8R7yryr( zSnATg>Wy;O$B?;xJagY4e!7e#%VgF~r9RDVXy(6MN6BN!tUvNxU>@(}{#|ZMCr8{P zVy-)R%$dgd%vPR1+$Z8gBTkE$`-BHZe0;>b%zIeGyg}gDh<_7tNyLGOXGL5e@y!w6 z7x9vaUx|2q#5*JI5gC1K#Q6~iBfd4_zeG&OsN$>V-$tUpoWI=P*%;o@X^Y#7=+s&; z__o%CFZ^UF9##Ljb!nz&zZt6ImcHS|%a#nBdi=7%{=Ox>bI!;c?K&azU#5TA-0tPw zJfA!5h$*cX9(mdm4*&cq`)xR&y>)n0dtUxf(#v>DJIiOD)9rfBzj^)p;LZ2T(;-7? zZ|m=BphhEenlZ;!%FILJ_uPnCp0iAp&+l?!A6jOxnwFQmdI>x^JnR_O6UKT}DqM5zF*1YfQha=X3Xp z=VA}t_2wMsPkZ;cdH5%Xd@_G$Xzyq5xLJC;>$vMl9vBR)>8vRu(PNqZ+^2WX|9I1% zKJEHf?*6a`e4&iLOuw04x{oveo$0p)>g(w>+c5p#KJjm+AM(7#?a9VO%JiG*+c5oO z1_oD_+pD_v>n0!FU0=kw?v-`pvLmOo{_ZRH|K*10{>+Yh!K&fD6|rNR6<6F;v@Y(ls$L&my@WNNTxo|t=6UbjM&$M( zw+(r2^L`PtV$GY5_KWz)h`Et_O2n-H7e#z-#F2<^izS?7-n6nc zeDh0McYNVpt*amKxz>#BZf^bkx9&IT>L(pNY1so_H|f?d-7x9O`_I|#$d#YkZu)oU zZU3ude!2Y>=YMgBAMN_-9cS-w%T7P~?lCdPt$UU2UA-J%wqWb)(Qf-rdDX*iIqd2f zM-@srZl;&+6Rbz=a@?st#25xyov(_e**+|68s1<9Wq+&GYcWPL+Rmt-n#NkB0j1Ow9GOq-DGO z&Tb`SKh03@ul$b9Mzz0L`pv&HWP6|L*OnW(EfWaT1?ubX)DtFNf6t5Vd)|Kfx;@_e z>!-bQ@|D$S%KBT<>*LPfTU~#v$4blE+x@+bMJILd2jmVz9#7T3x3SY+um0&JlWx5z zrIO+5WgQNL{X{Wq`Jd+nna zmv!NSI2Oy}(2^db>k9ea($NPEMOFj_eE934O zkw5MhfsvSMDIXi2J#qQCGs^G17jA#qk*~aUx0#*FF3$sG`6%hlnHcxHX8Wa-Rjx$hN7lRTvfpmke^&$6x|hGlYv*t!mb$z?uF@@st^aP0s|?dj|4aY7ejeh|=X95k zkvo2~U7i=dW8-~W`~BCwckcPyDXmZ3{KR!n`~LfPecEyPM*a4AqAVXJy-KV#>g8j> zVE@wUf%nlGB;LRhyC2#6c;%!vnr;4BmSbsWSW%OG}oMl3pd&8c|NR`MIyrm$Jn0 z&2p2Y%w?7PfMq$Cw0b*#H^Y{eaY@g1#(F(d%2$r7bkE<-P{z?r|4aXSW6WSFH`A9) zTy8d;GNsk~fQ`?ev-JAq?}+_~40&EU%S}nI5^Ie=s@(J*J!kg36OPW&Y^nTgX?bla zJ;$}BZY4e28SCY;UVd^MLbpKI_9@Cw`pt}(?Q)&_g5W%v2s z*G{@N2CYIq{+i{uq<4}>TVv-9HqS@)v>;-AKf4T=*K6~-+g%MKF+f=_FFCb)y}Tqw zm^=5AmriN@;a>Op!SrQQTHpM`L$BTaKJR$siH-fjlHQ#D*!*<8kGMB(EUb4hQYq{L-8!;{=wQ{cV{)XK4JTPKjKgerZdChyDi2Fs{KjOn9 z#-*m}eZ>bvJFj)+Jr7Tcm=9eZ7V+?iM@G!$a6-gqM(m4tYQ(%QyC&ibBEBr*Ya+fS z;=3b$Fybd7elg-T5x*Dl#}R)QarY?1JrNIzn2(n}E84x@$(VC7x8xy_l`0? zGvcWc^IJau9P!qO4~&h`(Gg!7@pBP>A8}@E{MJXjHsby}w%>RB&1gR{>eP2foE$68 z%Oma(J36n7_`rbuNW_I5++6-qR5!aXW7%olWW8!O)2rlY95t}GZ$-Y=JMPkp1Kr`iQ~Ki8)7AZHnqj>2Q8~_-ozA$k zud(0l>9y19&3bzMcfFrKhxRN+Zum=t2vE7#ouLp*gZxzGvcEnX7#pz#N2jd-4)eiRgdJHXN;=zum1j~`f=Wj zRa<`_!I{7P#D&i~_qSgPx+*-h(`=@9I=A8j$)}#!zUa_9Z>W7I-rO~D6ZZ+j%U8rJ zU^*X1@0~Zl-K`8)&)24H$k)qnyllyZfB4*U%kU*%&GgcJTl1A49IoeVBt}ryw?zY6 zzpwRA zo@nRv^M3ZVG5s?B<&mD_9_e(?`zkk_-d!IwpCh?5hX2JCOV0V^`p2L3ko*`zgvk-J zJ}Bu`Vy$sh{~7%&W*>IqU|-x^UcJe1u5`+Ms{-pSg~Y7jj+C zb-!KXjkU+?_b)wdZOmXPzjFt>_wUju_p{E4V)N;P9`pLi(fy0}+2N12L8+pYR@!tK}8ryqHCO)R$^BNe{3dD-)>A^GjVy@7~Q`+@S^vANdUFDIvAp!o zTX4p~IgWZco^fV(zBaymQguJ}B}YVA{pR(b&Hi^j`-nHqdE0r_u=#hpTuj<5J-cP- zI_`juDFE7_bdCBEJGh(*O zzH50;)UvfxS{KZovh$259RA|69DAa_toKTK{Mi+@P>ws*_QH6z3GJ|KVp(xNS*3_ELrRd`xOJ(@XcemjALAcGnAw&g#xr zbNhBl$lEvfq0BwEFqo<+k}ggY5s3!;XCO#cz7S&iVX6hFs?NiDpT!5^Ig4 z`&Y)>f_w99eD$@CnJZQdEbfiB8ZRG+cLpz5GZ?227p^&FsBh)!6?ulaUO(;pg0{nuxbkFtsgyW8C zzc8~bt+~~chR5|U?vHN{N3EIrv3X%XLOnmz{%-5#=e!f1@{nh}^{^d#s-au0Y)^`2 zN$(_&wlY8U^3&dtZdW!ZE+1aDaA5Ii{rM4=RdHieEV%k|yL21!^S-I?{_uaTJ?ZUb zf<4ubo>nuxbl*b#H*Zyxs_F|c?W}d)+L3$s?NDFO*1x!W``aJAER9&c2Qc@AQ(CXM z;!}_Q>=Wkx%MauHdWN2eSudCLOsj|DG&k<6idS`S{zZT|Kc4;1h=cn2_N_jSKlkrk zZ%R4c+O)F2@j{Mcys)MI>;2~WjBV+!K1}}J(lnd>)&DNjsSlfJ^_XW!N`LiX{r=x8 zP_OT%zNC9QHQsxHZaV3rmwf1e7yqWrQQ0mu(@XcV9(Q(}dt(>1e>lGqG1S|x`j&Kd zwDPzsDwleG&fA9kJm4jJ%{%d-XaBsNkM?$IQf#eCddWv=PmrIPi}Mro-P!4?e`maO z>ply9+WYCB{_fsaHuF=`OFl|_g8X!R;)5jPu2x%v88z-Izms?jBCuD^v<87t&*Se zm}kCUB|G*+%<1O&-eob}GTzG~J+EumyRWZx?~RHo{&$tPsW0!|j-^q8mGgb^v-N^? zN4{yAbpP48(>F*!4|3e@A@~0#?jPM5v3#%O_vc-;{b&B|_unkT_f$W6 zTFvy*y_1j8{rcEpuCg>VZ&m#>t6lZdrpQOmW+^ARid`pURoe88MjkDhtMJ>EOHJ(j7_%KVq~cIsF& z^Ph(sUGKe!?=CLxUs3h6F&1P!pKUJL^_TQ}Bxa`6gX>?_z24=$Ke_Im919}vzndQ2_xtUg5Bc)PHk^G*q-S_+#4H~r zy-KV##_kg<_r1ltERSElYTdkiZ`YRZd&}$jxxKopVQmah=4ZjHC!U{Hbl?9&r|xn8 zpY$KvoS%~3oc`wX)1Hw9o#{5OgZ{Dev9UHE=e%~}_4baKk1Jn2yyL%KHEG{h_QZe@ z@>*Limy%v3)*7+i*03tAdD|i zUk`SU9lo@h88Pd&{GEp7dP4kcU3T(quX)Amo-{juXUJ#Ive`_plA|%UT_5W2owIWF z@VaAS%h~;%p>wujx+A~rJM2AsUU6F)@3Ga7V_VJi(!Dd?IOuBs%5!sZ%f?V`2czn> zzF)KKbraVEQ=|Lwr_XrYo_Fl_{#;)(~+33)Zf0?e|X>W6>A2g2v?zgJbLmQwtoD#$MpRc%z43AcB|(vM|9s#dV8#6 z&27ow=&KZCC%h*HO|LvI9EtqYr{7!yjx9520Jx)7l@@XHq;~6)U9OXDtwV7VJ zXMPthix1^3nY}#DE5zrt2iG0lw<@;bgYhESpC#n#3cu#~s!-`wrfEN?U3G^O>yR}TE*sDYpV>b*O*rxrC~uH(Vxdk|y2-xvdx_3@f*$j8F__Z|ID zPdWb3Wsg14S(~=@18v`%R+{1Pl{$quM%sG zbgF-MU_oDACp)5Vb-9Yy>31aB#cA5xCN6iIBA*{Rf9LrxK6}z<^0+NSdS$sQ=~ZH_ zF>bl5Js34n`77nFv}>c?;?I%jQs(E5#{A?tuXHQVo17QjfAQ<9&-vl|ANkST|Id(R zKIf;TSBbSoy5=X@j$0E~9P>rd)j6;70m}BfFq`#kJ^y9&yDc?~`}B=ds^;)%QMDyh}MP=_Mbf-CSShuNj`dbpBvmOYL4~Hpapn zZ~4}jaT%xf|GYrGoGjSbT~3ArSsc)6D`HP!61*x5ncviiWUZ!8#&3r`R%{v3*gwm`P z14HfS-|F9*>4^bzeX5>+i~N-7yojUg& zS+94dp11Y+JbC5WKiKo>hwi>_XSrp)lcBGZ-u`Q>dDrH%d^N9o`Am;|mFebuWgXNL zvCQ|PTKAl<+?LjtU+V)~pRecjed*noy!{(jH|OiDPI`>8EBrC@HQrL}iLsXX=!txm ze2h1rGiu$-eAbuWrs$qwX2e`P&Fw~ZoA%Rrmw)3y-y3~iDA$EtBbw<|ax}IwpS@8Z z5wZ#+l=W2l6KL zxWDJjzIfHo;6QvqY-lJ4Z^|H?FLqxbV}5*Uf;=6ap?Ev>$=yWBMQhpvfoHUHCR zee8+XKl`?A%)vr43 zpiSR>See^WZ#2_O_vU(gWdFMMRhxX4acm_no2jn->rLB`pS`|t{BCof@Q!~i(<}LD zrkCy$Ph$0fh{;U#ZaaLI?i zUZ!92*Gwzn3&Om=(L6`%X%HK*L1pWCWJ@oT1+?#=woJY`@o zE)jM;)6%&JTJ86a#DHaaUiQiE{4|&6v`eP6e*Dar{A}TIbI#7=*bJGU+#fILRbs8t z%uj4L+h4>Oj@MGG9NKKZJI~SNeVz4C>f+L_ck}ztD=-qHFXdzIKW}|~`tU`U-*ob- z=?6V)b~|6~^4e-$*hz2Zwpl*fUu|6&pGG};cun-&6S1sM%VPRv{5Qn-3GvyfeVYnDO)| z=Wp`7QJGd5r}o_^P%kgbK09%F$y^?I#TEOXJN+9+lpL4x+DtFqw_IM1>Wg*?WWH}`$suUbA8HlTDd;uxr-9At`Y7YfqMD9 zWGm$*b2#hbU9UQ`|Gv42s6r{f&Ggc}SzczZSshO}#ywh_tx4@6>gO?Ld|~49n?vmT zcV~Tb>GVU-Ez>LcX{ML%&HQv;yiwg&HWat#wfF41&!=3r4f%N7t}lH48=m**X=OSk zAIysUpoRXC#OX1(4VKFdTY7o|*OyTmLv<#%&ffB*Ld z>esn8UDjPb@;Lv8XZ^Zp0W+k07+8gn}h=)XcV#Itl{;-I-vv^d* z<03AK_?(DKBd&^gM#TJ3L2jpBAMu?LbDg?4;uj)b6ERPg+!1lRn6W7l9})3s5l@V` zI%0lrA-_lQ<%qXM+%0DQ;D~=4@$877ig^0wKb_yl0* z6kyan@gmXAX|AsOFxFqu?NG{4{eJTs4%zMC$1HopE6Q}*`=2|un(3wc%mwp$=PX^C zw*uumYpU->w7)FU+j*hLVe7h*^OL4sZ-i@)>B4B0i8>XP3}BEM-lb8K>({W^H~Z4dhGg?BzR`^ylEz6ytQ z(mQ{SwsQH_-_Lf$z|1rI){X6V^+caJ{XBoUDW+e>pX1Fq(&?V(TNYip_58iAs=XJyze% z@_)%!yUW9)V`1llxOJENwDvfC%BHDTO=-R6KmPf!d;RC*o|ogzkonK^9VNX=tTjgS z-#)(?C;2_^Z(KJsV}sr-(FwxePt!ROuw|p?xl}c+$=k6O_}$W%k{gY$Ddsx*6;drJ^8Y;C2Lm1lc42; zGkK@$De=;RrJYNp`LO6v?@{r}x}o9NIa|};9^H7`?XC&^5r33AvJ7gSC=z$Qy)gzU z+o{Rl>@G*+?dL!Bm0$S7@GghnQl`|d!**;n(@XcQm!m8!aiErWN^f3#y6z9#unqZJ zv1rffOP;vlkTU&TS8}W0OfTK%t;`K~->Tumm#>K9pg5?=w;OjIepJ1VM6)D zmea^GxiK#8A9&UY*T&D*4ZnW!E3SR!TSoV9N8sKd}L;h>tDU1Z*jDS)~p!r z+Mk&I?TMGuhREOSzklBoKXcBzZ(rMw8IWPj#%>J^d30mk;-s4SChmpJP29 zoBHP4#(KB%yR7G>UDCC?-{U_0yWQoZdEV@rC_isKe#v9kerKnh59;7$`OWfC(wnBu z{k`^OkfR2MhK`GiBF~vM|CnRu%sPJF{9~Ro=lHpEjyq;foQuz}EOxqcy(!0Sxexx| z4cof>x3$0jZhj1Z_Y367;8H)Yy{^0bw|+6Hx{vspST8nx_^N6bXvdW&?DeI`{QQ}R zce0*k<-u{3Skjww)Hz>OJtms3f;}o;ft&Zy&0k&J$vpa$X!BIspYr>?d7gBSi1&+F z&J{l>e&>1OeIo83@evVwBj$RY=Z5nHX3pa=5%ZlaeGykg%+qu)kNBpD?~C}!h+mC( zQ^Y?++$%ty9P#9c>myziF`wm&Td`XwMSN$(+af+Cwl8mwxP4S0XGXj;;`-Prn6^{A zt0UsO<3RH7c5bzX?-|pJli{C;6ZE^piSU>09^Vp<8Tx&k_`OHW(2+4i|8Ht+Lt}K%X zy)b6CH4?FupF5-cMAy;t1~E(3x&8Wi*+ZXx|F>^HZ{FFR&1=w$CV#(sefnTzD9`t8c)9|~$)m02_9U(x$0x+|EJnWftoML&y{?{*4UK$^w}1NRMFYQ_ z{OPMNZMu~7(F}BcH1qL{*!_!FE0=pza<8=NvtGX(a6`Apc=`C~;9fhteDUk{cyMPr znV)-yM@jD_kG3)&5%ZX<{+_+j6XKos&sUfIt6k-}?Jf66jG>g<1wZJ{SMxaV!pQgM ze)Gbwy?x{Dzb@rA%XV(}OZsSrIzOs>tyx(+)iX46I6vUBBtGC0{cMaGt8d@ScysWw z3_7FIx*G)Q>(8brAGy3|PLPkm8)vNFqwn)~l;=*f{|rN&^!8t4&F1=3U3Z8pO`Ws% zL*re4xHIxmrjz9*r;*#EQjS;O)Ls9Te(J|pFL};=4($Kc>wel3!)1s~Nu1xE+$!l+ zVy%(+%FuuV`;EsbpY3uIg(x=+^-pBg*Xs+nAwRpk z=*0s^KJpJ=Dbp+YX{ML%6PDX5S96yS55>M%3{ckFO+V~*X|6xhZ=2Hk*e%=d@bM@7 z%}f9APq`P_zDFXrKPA0PzqGfIk7_gBTQ%dM&q|~L`nx`_{ zw)X$OxxacjIr&Fhuit-jLhn)Uy748iEe7eC@5?Od&3WBIIq7Y`K_hGZ_7L^`xH}^s z8D>Vz@i)tBcAK=@zV|$S->*!X`?LJ3-QRxEcS&!jjy1QCkM8oiS+1h|#wf~qwBbLx z^EKZ7<#nGuY1vCY^_4inX@_=so78Him+sx?_r^WX*<0;+=IPLd@z{Ty0bCasSBK&_ zHy;wKFTb82Z+$=F+_^Izwd%^AedDmN3T40WeVz1@uhLGp+D>L~wI9*hi5R<&)2}u9{$lCFMGz?X1+@LpCDiH#_6#O#v5aVWqmj= z@|O-}Ii^f5>-u&4uYO|A^RKz**&oaPGGsfChf8{uSZg%h+V#Z3{=UJ*@rjuB#r^6- zTXB)UeGnG+QuUrNR9-Z+F~(K$H}{V2{AJ#A}|J-g_2QXWCKCGlyBd9gH^VfB~ zV8XoB_wyJ1wA(GuapZnUd2ek_?zkUsdg&Jye(8Z_+nM>=A@Wtyv!8k>ho;p>M)Mdo zPjJM^ijnB4EU!&5-3-N}=X2Xt=QHx=$8+BBk$=l>znO9KrN>UNPO0 zp8eFr*mUF4&8p$}L{_{%H%=bJq^mFz%`*K(KkJ_UlIWKG-5IfbAL^>t|JUlHZomEF zEK3=3`gwk-q*sZx#_05qixVmR@kOS1_s~Fm4tl)lAJ7@D%>Q`PKmTushM#`n;}_+0 zGh{p0r;=VJ)*9nXe__1cwoJa(r=J7}5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&U zAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C7 z2oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N z0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+ z009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBly zK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF z5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk z1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs z0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZ zfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&U zAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C7 z2oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N z0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+ z009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBly zK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF z5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk z1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs z0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZ zfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&U zAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C7 z2oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N z0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+ z009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBly zK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF z5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk z1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs z0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZ zfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&U zAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C7 z2oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N z0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+ z009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBly zK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF z5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk z1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs z0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZ zfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&U zAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C7 z2oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N z0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+ z009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBly zK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF z5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk z1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs z0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZ zfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&U zAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C7 z2oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N z0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+ z009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBly zK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF z5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk z1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs z0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZ zfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&U zAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C7 z2oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N z0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+ z009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBly zK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF z5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk z1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs z0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZ zfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&U zAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C7 z2oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N z0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+ z009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBly zK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF z5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk z1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs z0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZ zfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&U zAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C7 z2oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N z0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+ z009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBly zK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF z5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk z1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs z0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZ zfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&U zAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C7 z2oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N z0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+ z009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBly zK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF z5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk z1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs z0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZ zfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&U zAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C7 z2oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N z0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+ z009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBly zK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF z5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk z1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs z0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZ zfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&U zAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C7 z2oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N z0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+ z009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBly zK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF z5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk z1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs z0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZ zfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&U zAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C7 z2oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N z0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+ z009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBly zK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF z5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk z1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs z0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZ zfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&U zAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C7 z2oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N z0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+ z009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBly zK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF z5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk z1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs z0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZ zfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&U zAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C7 z2oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N z0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+ z009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBly zK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF z5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk z1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs z0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZ zfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&U zAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C7 z2oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N z0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+ z009C72oNAZfB*pk1PBlyK!5-N0t5&UAV7cs0RjXF5FkK+009C72oNAZfB*pk|GynN zAOQdX01)*5bvpu`paBC03>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r v3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz`$uBSGRGs literal 0 HcmV?d00001 diff --git a/Covance_UCO3001/browser_profile_2/Default/Code Cache/js/260964320a10260b_0 b/Covance_UCO3001/browser_profile_2/Default/Code Cache/js/260964320a10260b_0 new file mode 100644 index 0000000000000000000000000000000000000000..3dfb44343427385785a2d0f1e2ca85cfb8bf3410 GIT binary patch literal 18228 zcmY-1cX(6v8~5>do1{s~Y-u_`R-vUyvy<+mW$(Qel_dzWL}WV<0cG#KryvLjin2kb zvNwpJG8Nf->ht+M*Y*7Ia9yt}$vNNe{k`w|q-k<;iucVAzADw@#Y+=VStc}ml&Bl3 z)y&GO5v-9_!|SV2Etui+Ru5(d{n`FNutwDy**Vp#RLiNFl~Xn74OFdJBjC^URjKB$ z?hV%TWd(zo)w8M_6ytDQ;hF!7^}l~7r=>^y?>0gFx_4RnN5VdtWrTBLRT8&lni>8m z4o6GEwjlhJ4VGMumop*AsSYJ;K$pg_x(SqS3O`DWzlh zk~0QsO6PIVM+T3FFXhDq#hVNfGhn)Ww+>?0gY!FB|2^!GMH}FOT=)T|Y}EeE@KTm- zQ9ri97C9(++rj)3B+7BQB+Yig?%i-o#_xgoQhYDe-4AWV_A{i&H2LKKoR_HwVX4F) zQs0lkO6hbQ`U)o@cnWIBe^Tr;43Tlt<2;ytgY6d~`gbTLr{t=%`~w>O3GJlhC2+`W z`RFo?m0DMzmF)kYt2)*)`5G*ixa&~iZ>=l0`noRvDaVBT$5BVF&n zK)E4@?!!fy@c@=f(nGla2n>&5s~nR2C$QnEo@?^iGngom&*9w{FhKk-p{lHxPLUDx z6R#nH%JQuYGDa|3YM3HuA$w(%IfB{J!V*CzIW2k75!9EcLJ`Evmr}lH1b(?GFQsR( z2;Pd(t)#_9kS$+JY+?iz^-I)ZBQN{W<;;8V#;j-a+gR?r+7CX?iR#Rz(( zL@>i1!S9X;8tKRFP1ztloDo#?MsPeUf`se{>c|*5FJ*G{SfZ*p1e??fI=wBiME>0{5>G9Q-YU5*H)*T)LYgSsxWi1#={| z3P&=oNF@JCpZG{NB}CFHDUvT!BRNtjl7h5I>dSdK?TnBl)dH zB%jxeoQEhFh716oHC^}5!1 zBa)#2yB1tnM3CxV7vNW0#$wg^0FOt#=BWb=kl0T&X(nw}4Q|zxI z`D%G2w^l^b@!Lp#U#D$9L~?RlB$<0787$w(r+UHOvp&0-Dgl2IiL%$62$ z20Fo-EhJ_7G zk*ItF4GIiwl_gaSd@sGK8u(Q1Np^Ju%jL6L%0uecHt?n#7F%5d3+frD*4#jIDcV9c z%LF;o(!loC2CQujl$4WlMOwBqFt@#W*Fkf-s%P&hzTEC+V1IYT=xHFKuj>9(kB8{- zPy_crS8kIGI42wUV2XhkQw=Pfq5jF5*##7w~870B*us@)<_juE00SU^;|PjHr~jvBqL{% zja*7I;z>7B&t)XlZKROTNK?O&bwMM|vy8lwPT58hbBv_Pbh(ggq<)@}p4E(OuVchj z*GQjwiX{^p8p&*AWR6^FY~+r#ZDOQwQ^jp&WT(__Y2>C1decbKTSj(EbXy|><->MH ze(GT4K_{*Au5#$2Tj~Cukz?ZQX5@qJMjE|uWUIX2+sF{PBN=^+ERl|VRlfxKt0!Xo z$jGO%aEOsIpBdRG-G>_aNd6JuFe5L98};7CNYr@MHo?edIVwdb8aXl7$c%YLF3va7 zV1bbiQfQfx*l&!Clq0K+Zxk3Bn&JRX5Z8lP3 zi;=x@T54=HGJ2bl=aRZtwaJhBj8xjMKK`s6e^HLo`>2uMB>A`z>t!QnrS?@L{)Jzq?mmA|A_ zF%xr(nt^D#jO=b=rdWEIXxP)lR+-+%M5zx=wC`);s0`|_^#_=kAk_w%XeK|2Ww6$kGao7T zWE01w;S>{7rkeD7*hHc%pKcU#WXV>|-)Z9OpG-WJmb*>e?=!Jpp6xf$NckOBO-Hm}Ovg=h zkmV;#B%Cx6b5^}=SwDPUN&+2mWfYqoABQ;QB}T` zCwEQkxo5)t$i!qh_t-@3Cnjz@HQ{}3V!o{SS9$zr;-!2{6b~dPGK%H0RsNGb#whBU zqL>&Jr8ntO*yNZciX*NlK5$2IPqMsGER)S*@I_H8Gm0JAQ54FFqP47)d%01x%Znm5 zKZ@aUpdgCe%2D{LMiEsliu%=~cwLIth+?dqs2N4oT2VwaRBXv@6vde)QFLn>#kb9( znA#$WlkKDUs6!NgiTj->e(w}T%DYimyGHSHkmi4+u`+g;;tkj15m8+EA_~XIC}v8F zIZ@1>8%6ZID9TEM1yQWu7{&8VQJ6PJ@wN2WqFQ&T?w_I2x@XHpt5YGu5fCP*XGeTA8WX#>_H_ebY?qx3o?6wl`D0gPC_bn)$4=nX8iC zMR`edPcs?4%nW|t%>EC}H14aq`~f+RO)I%={^jC1$LdTa(OepJL|V zS6XX@;>t8R@U@u_x2Q%b*k-2E9y9-3Hq+;dnT=P?q+L@j^0~~tVW#;%%HyVv*)20= zPA|aV6fmaS}2IJ zFj|h8EnJPZ;45UIe_;#pMJ;rY<;5%{6u0PemxY~TE@7dT&BA0k7jNNEf`xL47CI+c zNPEq~H2JNxh0n@ZSX9=+E2&oA!a8{;)xtmGOS7;*Uax0iwLGkEp<@FJ@5@(mu%Ti# z(wdDeT#(^SE&L)4n_2i;?l!m3wuOaH->`5(lHRoNrI^}UXf5;FSt!!p!Z)2QM7*nf zyI9yDAAVqAheUm7p|1?=YoS#?3(@^8I))ZT%8>yU@&{V<+OG9w{Rj&!zOZ2V(n6wq zA%{j<2#vDPM7m4lROKd9rdhZ%-9p|B)jv~tO3m387R%prl-pbj{`nR@k=+X{*cMr6 zFJCRT@MMXFPD?GUT&7&Uvfz>Ft1Q%5Z{bJj_ML^naznfuEX0{7e0M7oWLpm__MTRH^|EqNQhF8M? zD=jBlSuf8fsg{{mUP-mtR@O#gK`XJya#Rto)~ z^<~?SR&H%nk2fopSoW(Aa_46&Z~tQD*3npA*JH_fBN}^~Xg(DG zk{CXg8$ZU7u`z}dn_@V!Ifjy3VkojThVMmBPHxJ{9Wj*M8N=+KVi>(EhUvRw7`ZQo zq5ESvBso9F(C0u5+vKZ*F+4aN!~A10R6Y^IvXe2~6Z@$c_WT}0@jqg)T#lic1g^#~ z@b4H_--zLv{QOT0MQ_FMy2Rg(q2K)&c1o*<>6%$MUxLAG?OQ~2U_mAbGeDRI8f3NKlvniHMV%n^I z(sW-eb7l2W#Xqn3vi7f7n%#_Lo(#RKc@JVK@-UXWuVR^2qy&FT=}IMNDCeq{pklQW z)b3G&9)n8oqih^nf>P5<&{_N|N-%eA3I39b`%Cc2sS^Aw7q6FK!`~%{xKV;A{~iiTVxzoLmdAY?Py)s8k&3<>KfkXHw(n>WJezsh=Ll0e>9vfjI8v#1YDk<7!?U zr}E?Yv_%}hNa?rZ*xVtGsE%=*lOXvQg4w zqmbXm&`cYLWJH#YZ*pxsm92R;8i#GPt!m?I*-=e%>)JS2&qhLh8y`rUhBkd3u(7F; z9yie(S=-dcpDk@TTiK}BTKTgk~5*q`*va#)J8`hOJ zI;^r`-e9At^!Y(+ZBiVuY_TzIo8m}=?KXbcVIy*<*89oE+py(X2@{26|)y7S!c;3cumuytJtiD}QZ*SY^B(v_=xc|^bg%>vZ8{&0p zDxT+(Q6!!r@=eirmL$Y;N5&+@v+T8a?uos0JjYVvc`Y@bE0yB0c;aa$yZrHt3&e9y zMhD}mlo`(lGBGQj%DLJm)k5*C&5!4WJgOW|(`xa|m7>+-DPKRH?y{?4JTu;i=dxtB zi>F10crHmwr+D6%nVsYL=)HLMiKjKV@}2@i_rOF8ygJgtVsvq&0_(Ar-p zKiMm9kBVo7^q&;Z&ZY4bUZxl;;~BU*p53x|eLPLRi)W4)HmNsz;wiE>p0WqyDRU^E zu5weR9nn0geM+@nj%TaXzY$OJ-FSM)sweSmc@dBKWxU=WCD753z-oyzB~UFofpOw5 zl)&Z^2}H#uF!i+r+LumXmHb#HLGQa0xFyfZC6H4gLEm*GFuh^|+fov+rY2BDR=5&) zC~x}{_$Zj5^DGHmkY7Uy46K^KZdqA9fycEqzD@!(N#IqB1f6F~;ANWxdUZ-*lkDu0 zK${*3ER*@~E1%v8G?9_gs-JR^cLpYKZg2t>KT2SYwEs-GO2%--8ks_RT>nTp-M6#MB>U>rruUaKiyLBQX-bm!syNQ(Rl8CWqBAFi~@|k?v zN89=)(oG)AyZsVbCsq3=5;-7|hf->YVt%fe!xDKqB9X2m6ZuXGMk)R{#UHQj6B9W& zEs=!jnmbFk^AhPGFXtz+XF(#x7bf!BB0ZK`ixX+KB#~W}k|>&%gx8Zqv%Dnc$)0LS zn5!pIS==>}7$`eyCUKxv67jW@=qU}FBr!u)G)*F|c@hidH>uPjiSH$^brK__Qkx_; zzLSKpQxe6yCefmM5(}hC53So%@p>hxM#YoULy~wjO6!hJB6e~Tw`V7jGe_I!Cvkpx z5~(Ya_;h6w?|r8=#PMSiy?;t#iq+>+{twN1=Nw3Z|sO`?O$k}+qJI3urJ z(%dT=Cu^=JvE#2K3jLkLq<@mA_b`cRQto9EUqqMWxb(G^}UY@taP$-#!amnnKza7cgeaU<%r>i70tZFh1nkF+t z=C@B~^SjAJbxEdt?_^rZIQe>TGLK}^@MKzinalziHa3}GCMIK>q&RamXI?THVp)+) zGg+}E8SnOF2Ft=-$t?XjnY;4KiDbH-P3AjkcP*KQ50jZGr_B|x6skZoiB77(%hDC7 zRi*+Ce+A;ZRG_^q8B~G#pHyJFlpS4x2@@-DUb@e#K)54f~#VR&PC|4405Ir_N1`Wo5BlU z3N`&HESCAf6mH1jj1<;pYo9F6O`&c`kMs3d0tG4bteir6l@$GcO3}|i3Il7VaIa1Z z59+0`t)bRwlEU6*DU^FXg>JIGO$t@tO40XHDYWj8g0puD{lzs{`#(-$gRK2Lg(e%I_(>FK4c#@Y8k8|0{(@w^DfZD23XOQ@HR{wY^ATquhU)!Zl+m zK2s{iqf>DfN~OQFES^e_m{fk0ow2FRj7#N;bhK$~Vk#d=#geHEm))gODfU__T}r2N zBQ=$bN}B6P<$>gfHy-~_EF>C;kKwltM{Qe;CaBX^~8QilGlynab#4VQ<)@B&ZW}qk5uN#s_PnmJC(9`QrYt?l`XGT!d$u%zh_mVSau~E$P8%~uEad) zUZoNn->ii3txA;YSBXadv#1iYq|cs8R6AWs*N0T%<<&|&yk3cdzbY~6b|sx(*EU)E zuo4Dq8V%*|m^AW|(ikDjDx_idr|J8&G(KyZ#*I#CWOPoW(R*nu|0InE;##V4tJ1h9 zv$myiYEK&F_NFoZcpBfIN`uqd{%acNFQ$?Ddm3}DrcwV|8k4T4F<-9zm4@?18nb26 zKWVy-B#m0P(zql&ZfoqFG}_7sGUa}n&OxWK@ zhDisX9h=`yicFQ?0(R;L?X=3b(?yaC?D%Dg{8QOZn<{qxsAJd9qn(v??Q9lTJv$%P zw{t}DSWEHM!T$PGoyKTjZeRcd#?Oqn$^xyQ`g3GX6a~^ChO6 zoz~s$`X1R%@qx-`km{7u&+ViQv$On5yRMD0({_}dA12xPce0(H zQ|!dfwliXmYMyH+JkQS4`F08x+WBRXom$K7j9a0xGT~c0P1o6}x8BaA@092F>hq6w zW^c4pXp`=5)%|U{zg_co*|F@l(`b*K?NaEV`g+(-wy+BRkKY+lhXmp2$h5`O?nVS30)REW*L8 zNC(jd2V7$K9A9h|G+piV^x zv+bHAogEJP$zS4eI=Jm~kdWix?OX??D?7MQ!$HMb4yMS4Iu2gdbW`{&fd0-*C{qjf1OiIvD?!gVS$2Xy493>uwI_cXv>% zhl69i9VGT~@TIIC;9$E99Oz)Aqz!g(eTajnvhFhnKS^+?gTbFW_($Fu?x6ga4t|m1 zqa19M_r|CPW0kjDl-ts7oN^tnTqihqcbe9j?x5aG2iN8}aLv>F`3}x5b5M4<@|5?! zR!%D&v|Xhh%Az$6{$A@~`347LH#s=D*+KO!>dQ85+wNe?4hNfeI*8n*HGg){=vS>N zCC@u>$UlELICxq8l<8NLizHpum}?G>%2jE6(?Oei>X)S6caSN|<<0};@zBAC^7}I# zuYVnUAyxi!&_s4gbVNFXWV}3&N@r=IbT-KQh0_@#_a&!jIxA$G*yGYUpP0@~S(c=+ z(!XpvWhRmD0(U#m;no&Q9l7nUa&v5{b`E=dHYS4#_1MUL~FC z4by2M#TqH5Oq8>Y)2ZD=V`YEKbWXmNPN}x(jFzDt)0r#{-qC(JBJrKm86mSJs(U&g ze3;JX67H*UvR$J3r_)bH%j1vIxivDK;OKNtj7jH;%p04|YUwpOowS*{ot4h-(szzx zOXa!gG?t&lIzOF(GESZ?QJ+?(WBMkYMXS?U`E5E|q~AKtlc!SfT{>%Iw|F+C^X3lq zXJz8&Y5&3oK0uIujx#`pU%Yx>3VON&TEg; z>G(u7Nb%?Cw0e=wKKb@#I&ZvE%zx8~`7fQeI9V3qBtFu~TSg~KOitpWoD`3B(yD~E zCppP3<)n@nUUO1HhReayPC{jzbS&rO>+()YCOf%W!HF})$s9?l&5bCl6{lDO%S_i+WD> z$glEPK4|J>V>88S?j&Ezw^6>`RYwmehvbsf>E-0u=S~ubJ4um>Bb;>m!pV8b80qAr zQBFq60~s^M$y{kQ*2%kaPRfmUvT}lx+Ebh?oaSVmbf2zya$7QHI;lIy$+V?TE-Z7> z;47`SN^8rUZ=9@>GOL|*TI1xDM6Od0<&a#EM(Z{AJ10@!tHvKxX^u5iMr=xfNa0-#Ph&O z%SWp1v5wtS_21-TLzIhDvx|ck7bT)yd@fxJxma7+MY$p_uEn`<#k-g*LUHE`2xS;&h6OnyD^Q(p+@6yZB8GI9$X!T?~~w9v7KD7t3U`-1ocK8FpbQ za4|q$)pk*|j*IFf5z2@ec^eF4*yK)+n?52AqH|x{fRIs}#m+t0Wr(4&h zx{0su=B*lT4$1RcZk^w9^R29I;O0?7H=P=}8Q;Xs>85UKHgmK1O*c2*a${)grfxeo zt>m-zZe4@wCcC5ZloMUG_8_f2*sb$iZk~SbreL_6HL~jqH_;>A43bHs-JBcarp{P5 zGse65eS&hDsP(33jj3*)$lPgeu1t4xPyU5Pz zg#GIE&pKYR@Q|Co4!dc6MD-qXGx4~ah!bu~oO1KVX*a(}m9uVcN$^)UOJvkS<4^Iktc(<^Jh~ge<$9OO&cz9e|w`Dx+lw(q@tcOwMJUo|P$sRUT z@bGg*55-eG97)%$$3rWxhkbJ0?;$qe;q{=0#9ZBmJuJxAm;w*~RrXM`s$y32=)I$d z>h(3hfrl9_J^bFvL!;Kpp^b;}Z+d9h!NcNC9&U8@@W#6y%6Ik942fBO6 z>*1kTFApu>_pn#aOLA`yj*mR_{@BBx^1(0}9pZOBt(|fc#X{OTRcTUq}_3S3k>Mc1d)C zmqF6Dq?cu-yu`oeL*v8i5$%12I(b9q_e@p9MerJc{q!JwA`8D6$$dUc(#mtUoP zj+cq@Q5B7^sx_;5*(pt{d)ZyXOYfS>rIun#Y#qgxe4Bk_#rwUN1u}f27uO~ohs|ED$kc6Ke%r2NveS$EXD@w! z@e(|$<8Z>umnXeEm8R#s%>32M-W+6a-gq|5BvETE(QI4G?JZS z8R%nxtQ+j(*+)LQeym(S)x6KN?l2!e5BJgh3m<Rs-`^tF$+>wGL* z?<4*@AH6sD`0)oH)i(NQy4Ayc{kCErp+si&`UiGm-_Fq@8{`T>yH2lZM)SK$tZ69^-_}C=VAFHM(K1MuM z?`6?*AAi5_@%l?``_IQA{DdR?gbaQfh}q~TK}O0^lb^~_etH)5^Qq(%^HWDQOJt0n z52R$GpLDq@kL2AXKdVdnDO1W%K{-E-CAz%E$rw42?5A1*8KzyGFg);%CTKzs|L2&E0&td|eArK~BYyrpuY7;=6MIoL%Yi@r47%iJ=Vd>>D_Zla*1WFu zW$9mjZvO4(%^QAN|KsQV+kSqyY2AF78>)x&3gT0Zwv?}eX9FV(MC zey08F=fZzF)&$sY3=kC+V4^ud(Lw=Q6b|r5kpPJ?0ouj}I3hLU0*tio1Ou# z^$K7c5a7*$0S-#r!HW4&fcTFCH2N&Sw4tiy%K*d11UN7@K;F0jyT&V*i2(-5w=)7f zof)9ZEY&e5z?HcHn$J_63j&;67@+#1040|MXumYTF}Ws@%aq?&0V=ErFj z7u9eez&WXND8Pin0XP!i~>Hpn~Wf~-vr(y~I3 zxfO#HNePltDMAIM&>_WOf;EZZ`Jn6ed1iid)<3I|!1ALLd+kX1E; zG^`(FY6FdF7^G&)AY)qv_1$EUFJ2FF_>Ca1zZv9w+aSs9gG`d@9fOR1C#Z8EL6-Lq za%Vu0moj=_kU7$FP>{}YR?2=9M=FlJmK37drZCFsBiGu8r!XtuA|00NGbdW}4 zf^3(^c2UIEtU+N z)(l=0&!B2-290F9M8#!LLYB)NTLx|8Gw3eQBsVbwS5gKamdqefE(2?Y3>sI=V2AuG zZBjD0E-|SY?3HtJQ;InULUCMRCYSWu(@Ub)WD~zGo43|yb4V`9qs`eQ9LeVG zquCsm%QEP+?w?iMU$Yr5$N$JC>5}r2b@#J*_8^-R&$IPh%i)YWhrFyDiVeXb7(w1hv^e?_+(NJdnV_QF(rq((pjob%VFg79G=NLD|1-6Du+_vFqD%RK3}HkWnZ=FkUb1ivvERo08ae0)q<>~pZ+cJ5KlJe#9=u$q9s%d!) zYni9_J$bs8B9F$h_w_t(cE}^}P9FEW=5cCV9}9KV`J()B#`QtSPl$C?{?Y>}*g^7!Ot9=B!F?K~px z=228u%cFaFbh@9%vuAl!exbPXqx|xcANKg1AOk)}EJ5R)At z4Cx_;yF(oGga~;SIh>A*)T-wMj_@m4pFR0i2Y4<+dRalGP^~HOD#30Rfsxog_!Vm z2-=2N(=Np0_8~fVP~6TTs&)ynPP)DqVr{n&<+_I`=pACj2O1~E2ZU%fQ1#33VOn>% z)*TVzyHT1yIz+cI>eU4GYGR1LrP?I*WO9h-^8QTqcUFjg3lwv)VlGikDYP`il2sx0 zey`*3gN}m?|533wD)y!jzUncz);@k!G;$nynw?p(1*PReyStF0{swel< zLuvLj#H?o_qMwJ@PME03Fqh0>$|Q#AloaNalqs$IWprQelnaxY9Hw@KFsCbqDV-W- zd8IJ@f?>91gmGntshJgKY<8IX`C$@_W@%rN<)ewf1z!sIs$V`vz6n!@_vwoRk}(8fBCm`yx!0FT*sH*im6#AFX(DTAX8);)psV$v$J6)TnKaKVwhULtF}Ls!=*6m zW#%pQ|F-hEqg?K*-w(pN#yw1tCt;dDRX-(IKA*wK`Q)bM>K$EX_wEX{`uGk<}*`9P0#1p zjC`uh%%|LfeBND{&ly>_BA;hp=hJm%zRt7e^Tp15p2)SU`M9p`_2UuL7n@&0z(M9bUjIIX=CB zq?rYbly9~c@NioJzwIdC#OVS`o-Lq~)I6v0ziPZV|1O}t<6{U7hvqQC$E literal 0 HcmV?d00001 diff --git a/Covance_UCO3001/browser_profile_2/Default/Code Cache/js/4b8939c9f36bbeb9_0 b/Covance_UCO3001/browser_profile_2/Default/Code Cache/js/4b8939c9f36bbeb9_0 new file mode 100644 index 0000000000000000000000000000000000000000..814ddde5d893ff78bf587b591cc9838693d549b6 GIT binary patch literal 206 zcmXqrDOxU_`}+?o0|SE-5K9QUqyQ;~`0UimjFOUqVk>?9isAyjoW!K${GtNA=%D@;^5?{4XrckW8zL8TEHFJe?rRep)Jg8kpAFRdvB;f G4FCY$Nj_Ns literal 0 HcmV?d00001 diff --git a/Covance_UCO3001/browser_profile_2/Default/Code Cache/js/65a2ea42c560b83e_0 b/Covance_UCO3001/browser_profile_2/Default/Code Cache/js/65a2ea42c560b83e_0 new file mode 100644 index 0000000000000000000000000000000000000000..7cf2220f5a115dda30253d79b06d6bb0b214519c GIT binary patch literal 30120 zcmWjL1$a}}8^`fqleS44Xi=RNPaDap-EoDI7EQJ}+@uO5=pF|k3H-?>rItfGYrm&`6)q-a)|(wQZ* zv$7IhiDg{bMM{(?T(m^#%&g2Z&Z5OLN*Bp2UZPCVlEq4wahA*|S*CQ+5?R@aSy_dR z#5k4HI`jXr{{Qd%v>3Pl-wwi3G%X`t#Qm~TiE`2esJvvuVI)_O8X&TwRH%~V!am%< zAC;vgRip#xU6npHr7sv-OZpcD>qwpOpqrG~UHXJ=Hh_zel zb5#mRchd&!!5uWtaMK9v%XHHNbj)&7U-Zd#lV=$>tq?t;$DA(1X-|(p$_q!XEzlT8)_}bH;CcWs}+o0Llg+hJE4d(s^HNszbGk|e_ zGpOi5gSredXdAWM-Jo>r!fzvZJkp@PqYQdEma))i9Jx*~@We1^ z5dN6NoN;inLG~%+jSo}FeVReVumhLSWtKr9vkgj`YtX8B1{I!f&@fDbW1&IOOAN~U zhe0=&8#HzW`L8nQ^g4sCqtPaV-1ixD3`O=EbOP>&Sd$Y5y*NW&*9`Ld$DsMR^p2cA zQp3*%4a9Ohgx7xtP0@IO6E7J zJ3hm|fKiRG149ZLHPYXx0fmgZg@yq}c?B7DI@qX*A#8&)!l=>5s5wQAdV?FqjCxnnsJJAf1|}QTIMt|Ah$&^%YYa;_YBe4pF2krXn1z0sS)Wf}MMwP2h z8yxxBs4g{)@~vgm0vy35)T(XN%sNIb!#ymnYt*NDMs06u)DwKfMPQ#6AJ<_O02p(lr zkqNBn|4ktup9CsLX6(e^WRdo+z9;T*eh<}ZK*Nw`2$hhc-e2-X9jC;(n@WiOZ zXGZ>RF?Y0nZd8dEM)iNm@rYGu@!qHjABcV(rxYdl(|x@#BG(%f}8 z-Cci`bCaGLuZsx9M7}wlg3z55pyJlcQD|anMLTh(bXzQ-M?TOWa z_8r|7-N{{noyob2yBc(LSEIh<)X!bX1Kd>=mxs7(`A~OlAMUQJI5UE{qudoV#$6ld z&~|~l+Aeh0!F(o9=hoAkb4miElNg~hq9`8=v7S*?W^yhq0K#XtA~e9_x4cyZys_EWZPi+ z&hb#xVh^oe@1c=V_@#%6fAi27d1{o&Q)_d0YDaG5 z^;Cxfp6XY~Q=@}CVE7$5VWW z_tc?cp88mV{v|zCFUeD3$)2j8M*NDNYF(Ljs9()f=LUHyVWg+pqWmbvg<~}Rae2I_ zI&SooYoDiPJoeN=t4RxNCiTy6(p2ok6HG5?(lUROmIRn|99a)}(pZ8fQ}Jc$3cHUrb6cX+Eku zO==8>%OroCz*QVhG^uJ~lhzhB>3uPiLW+|!KBk-WQ-(?QOq2e=E#%BH>1T{7Ytl^I zDo2j^t-MM1(6s{h;Zez?%{YKZXj$2$KdYGZ0hvFUv=^^YshUZ>umV}t$sa565nFyX zsay?ivAmW^OKY2SvW`hN(X_5f0S!!Qk9$aJXi`~B#WPfC#Mrpo*rdY0m{hWfNj00& z4>yqAjC$ZJ9L-H~wJ<3SQ(AGqok{NPO?rw?=+n`}i$Ie`z^}7OgS%2|#B?+11@3ew z$DSsI{c2LazKntW{i)4wCdCajsoEfu8ezj=`VZkgRwKty>hQZs#^EOA9$`|uQPcvT zaC|g18N)hEFsb82j+e>QeJYRf2VNn^bdv&c5*KHgRAV+d%`x%Z;ux80lFtH@<}NWQ zVwp*{&jSrdB z7d!FmVb<;lYl^+cIA(DhQ;wT7{3OT0DaJf)Qul`mPIPQ@5ChLTT=!Fefd&{JQ=yaR)N@kv8X1%G**j3Ex^OITKtD9B5hFSmA zHfwktv-aX7KB8U&v)14TW;Zk|XCt$MFc$@znDxA=S^b)smC)R*M!1I8-OO_9P7Wyd zD=~YS<>+lzjXq{wNB(})2T%IbW`J4ielx4sK(ks8GV290hM08>m+=lghBD?bvs_q& zH)#30S;z6~aN^?=rj9VH%}BHMjWcWUc;ezD8ckr0CNkGaqi_KaEucc;H z#&Zl?W>(=p%t}W?JjA}`W}U)Qv|qt^f0~tRrCBA{m{kVN@CLIsa;$A4?iTXjW>)d- z)E~wjW@R6vhR4n7kIU$Jg0Zm;4Ng)|e8GfMX2qPPj_1sZNB8s8`GQ$lmpCTzF2%bGVJ~nDvGB-x$;E zr5avdYJvgq_4ZOBtiS~%TD+9o?xhf<<1o7Ucxebe;IN;UY&pD?AI0%Ey5#iIAiPEA zTwcn~?WIL|y;Ls0m&T%GLB>KvAuqLuBhX7V;T`Oys<<2CrN~e(oyOcSFa3$bs1)uc zV+`#Phrdv}sF#)$^U`{pLcQW%@+?8l7>QHKUdox`r68o?7%HcGsV%Zgdua@2Vl!Hl z@lxG#Uh*jKrCgX>!AqB`c&SQNFLnLNOZ(8FnwR?HC5qMZQpeiVua1`{)g@LvVqr5H z)c2CPftT{)coX_I_0qJKURsR3sMg9$`S0-3(w)?A7dh=_t+4>>_HZ0rV_pCC;-rh0{P7X) zH>vM!FKxU-o;d%&OH&?m96k3^4060=K4|!fy2JR{OU(@4+Gq4uQx9*Q@buOolefm< zAfkP|72xnzEV|(i`uTcmV{UJ4$wM17&FigBSQYH8ZKxLFEpwQ+a-k*sB8Y*W_$$&| z`%yB=TeG9RwH!gQ-s*zyao(yI@2z(k-b%_M7BaKFbqrahy;TbXF&PJN38pgM$`Ajt z-l|dFTa$1Y7vNjbTO*)K-im~|vbTm|Ko#bJf>phB4zqsp)>$mB>8aAxdsq1NP zZ8}4q7rfQzqPN=NHo9M8KR#Xd)|0E=+I7oY;g6^>ay({^*oyy<`NUfjaScPCd8_Ul zZ*_dj{ddgsJ@Js^gSReY=120zyidgbOfCNN*0(Rz>#Mhl=Ci0`ev1MNShTF5Mdm^l zB?MS>5x<65R4B}%&*2swjkd@ZYf*lb$h4>nt|B?hqH-vfZBb-73$ITtYE#*wfGQSM z!mn72Q*hL^$RFG5)4zd5`|zf@ML*D_g++Z3+}fgg*nl=|>4$RdEvkv+4i-&B;f@yl z(b=N!sM^J%FWoG<(%qtz9u{@OK)Cg^s6~H^dLUqcMIQ!PWE^Z!?;#cqhsRKhN})0m zhFO$~*Z6@EzccPgi~d2(D2rNQ1)jk`z*?{pSm2hC=Fx&Chw!v@ECJG&M}KNCx~^D zyiZwl1Cvf$)aZ;w8_%+~sB(@upSLLJ0>==tFS70!c*&x;%hVEcuCV{AMbq&18teOy zMMZ9q^DT?QZ*%;i0Vd!9ir(coyvMqu(|zjkfEwb!L+bK~V+8FVTU6}{$M92&{zlPf z#6$XXi+*}x(S96z$y&X(X!cu+-XZH9eNg?qMe{#c^b*-0d5rCFe&QH{KC^~si&F^v zkLL{bBJUTA3VvlA%){buJn!%v{~`1{^@8ySHOCFCl~o4}Ry{OYmEvwycTDlH>KBt$ z9kAHfs+@VO>K4R(+{O!B59T(+s<2S2>|s_lz+|L`^Ekq)nOKJJQN)Y3Y9SWHSyj|! z)vm%;9YcvCR!zks{8!AX$HlGsfLbN3T7je_t1jW^WUKC=RSNr&JJqTmXpv^spO{_B zstYx(s$0vd2N+Y^s?K$+@~&&uANa3dZtB#{WAFHzZ zTD1vo{jF+0*s3kVt@4>_)t3cUBsTdd_>s~X>9eow8Mfu%@(M&8e@YK|lL0QVPG zwZ<+SNAZ_d4Z?Wjeq~ilbjKr_8E#O_O1@*|gGbQz0LlF5z#7P0_wK&4I(urh^#dPya$Tc?Q^28r$#z zy8~^i5@b^obPTrX0jh-9bO!ek8ER8K48^1{o3`REN`>1L7(wn>fUc1?WklKZ7$0yu znmpr(2~)gHWfE-qf~ro&aM`pZ(WVYXZ2AusigLfWO-)PCzNAfilWdAfwrMn`rr6}0 zYSWuEn=GYlx(N4lo9dug2C>j3)28+KjQDJu-eX5;n|>{0(^KRr%bZ{=$GG?g@A5V! zq6daxT}7L&<8o!2+^X0ViUw$dBiLJwb-`!Ye9AR2gG&1f6S9-`Y0)i8gg? znqSwZlzKL;L12BG$~Ca*1Ogk{^gGt!UL%|Qn%J}lJ)5#0>zc7X&24Jdg8W)BH|$2v zHjIVW?QIJ0VAENobhN2Fmf&h9=HHpM>%yG7GXHL@-6$KcRcsoM&+r^go;U!FVI46Q zmyvHQ`)~vi?lWxK2*XU9l4o&@ z!!?iCs5alGX}E>r3y6g=n7@!YEwbsC#WposLOx45CYIThV>x54u&Mo@HeJEKl{N*h zwkZLDYdFT?Sj+K`=LlVA(_kEd&w7p_{IbEOk{hY>CYz4`MNV7D8K!O29bL9l*B#`r zlUna0_uV$N+{^kO;CXR`{IU3$O|?#P>|o6)*5aZ~L8t(?OXP!{IDMIRS9tDRXUu=e z8)a_TIKO677-r!tZeZ0d>WddBa+_lYXHfYeHGv*6&SS=b+f$oTQT#b$y`UB^IYwUD zRP?n?1K#oX>8WXuJO6-8j#zrJ9+Htnb)qF_!r6f>}rASc#84)?b?fz@GfBI zeS=+J;Z@MCHRu#zmjdnD_kWRgortolRX z#fVYdt~_Xsb|vguiLJPYJW0esqh!10;9ja-2h;3&-pZ~oXx7%Q4(;q}+}>p(ZgMw=dX9Y*b6?XvV@p1m2r5A*74*P#A(1^mXG2GS3oF>a7u(L<==FuQvF zZr9Hv7z;_G?J7EkZDZ}qH_p!U$F4u%Gv2OvT$o^2&53qB#-d4fy_-z#Q|; z?W!`vuG{D_)2{2Y$#;%j;dAW@nrGMA`Q*9KuI?M`a@)*24%oHx2z5ScR~%lSC)a=M z8gj#~Q-yp~E5b(+4SZAtdAj>36oat|`w-BBHfV-IJ$)2|ix~c^kEWnmFCYDZF1>v; z0D*mc6o;WO_Vtkiu6{mhiEilH-$(1P3!Mh|s2^(mMjRLi(H|P%oKH#G(2Ys~qZy!B8?xSDM`sn^8YVnVc>fH8G@kc(Y`NBsp-!a!uJ{t4Q zN3+}<`UBUD4qhWWWV1VzAESL7D(i4)13tpt*P)VFiiUm;O~RuB4!y^SK!+BiRFFe+ z5FhN&D15}+5QlPyI+Q2Op)qJ1?$DGdhl)fy6rRA?#T?pLob4qXx{lo?9STi#D5io# z-6}eiQrV$uKRJ~3vqL>o`=VzJvGR4h?8bza|bnYs%Qo9SUyY z(1(@|Eo3?bXfJ-CWIN`Db-0Ph_6`ljO}y*ikXuKGV!JrhtGh#)Jsb+`=}_fg z9eRtky&U@1+o8e(92z{xp$kJCx{W`FITSsd+fmG6v_oyiIAj>>(EV`^)g13o(+R|x z#JnauMS@dhBv&0!|}l zw?ic`3~77Vc98Y@+o9(86I<}$kV74hFz!*-?6^aTCmpJK%Ap3Bd4}=NI`kZMt~)gR zmP74tJ7l`!P*3!}%eIHq`H@4r9@F=UgU`zyy84tlz2LZc>CmCq4$XScdZN!K+T$5I zeRilHEdM!p|K`v=l=#RFZZ{zWOKG zSAMC!8kELZSW=3yGJG{G(^r96z8V30X}Oxi#6G;N?W>XXe3kf%uc{63)u_?Fsy@wE%O27<&`&#q{8Tf_Pt%=#T7tnY zKNTtLr{YEYlwH+N)v%$OpZ=@ir@A${MW@<+>R#7R4eR--Kz%ImXY^i#{JetNOm zPjlD!>Cjp~z1hqd2mN#r*MHC!x!iJSEN*+`Pyx>z>SfBIFL0Q1$l#SjZ)fCC*_k=i z0B@mLIh2iwn2-Fkb7&K~%*~;7_=HmPc#QWry(EX0t)cz89O}M}Z7^=np+-A%=oQNE z%Au7gvO9++q4=I0Dvh~&bEx70_Ti6%In?Y>4xPiuqdAm#EQgwY$)N?vpC_lvpce|~ z&B<$moT{BKr)D{Gs!*Mrn%*L(F5<`joO<#yr)GS}slV_FQEs{PmnE0B*mG&JBbQ#H zbx1BP!<$mMbRr{{V#?%FLZw`qSv{BP)XAj|=sF^oej1xgg(v5dVM#7t%jM#{Q7-k` zolC?<&nqtJeqFEtKPwRc`ub$)kE@X5%!eKt3w%iRiI2>bwH_Q zc{xXxm*;L?)ytDlCnED{OF}+9E|yQj%I4F|y7?5)C!Y$w&L`g<1?9f7ppw=U)bb+* z_5El;KFjo1b*wGvuf!yOmBk*c&-Pd0(*8=vSlohV8GoHB>#q&v{S{ilUu)2(qQ7n+ zv9iCapaCjZ_g6h6*YsC;yvD0${>p6QuihQ~Ric}}7T_9kb@x{U=Al|Ie+|Jzd_~LN z{#uE^KK@#V8h!nB4B`F!H3D^iqYVb)7*dD$tH@A)#SQaU65itD@BV5x!e716YNWrq zV-v29^4CL5AMLN}WBlbe-e03}2QM*gg1_ERV*6x&KDYPRMp&m%6D+`e#7^~B3oOM0 zte8fB_)n)cC_2Mmov;GCXZq_4VrKd4HWtpN=BPWzU)zy)F53{h*k4nZ_-io=FZEaH zW#o>>EB*BWVXN7WZJ4>__gog%rE6kXquvqC#>mDWo~U0s4yI&;TXiBH|+gv?wY- z1EK@86}e&qbQE)|2IwD*`zb*4(6(BD>b4Hh7N|{t((oE?Z3DCv1=|Iv2PWYY7Pb%2 zT6lK|&{W*Q3smhGpwsZ|6rfR9*f~HqF{ulApiI{Q?MCBn0qTImxQKb(1N0bmdXmep z0lJFiy#i$G9iRfZ-6ufNeFM}S`})zoKe=rPP))SLB+SPpG}#!SPWZklK)L@4P)GcZ z@XY}#jlx?3RBZDWbD#=(1u6>FEP+~IC{XpH0(CtpP?q#S?ZlPrK;1`p z`9Q6x5U9)#<<~&{@;y); zarsA}<|s&u3_)6l!tO!(8@H`N3i1h37r!7qKvY1G>PG}=R7{ZKiUes*N|1Wg4^r7q zL3-RPNaj^RYH%<}|C|oe#Ir$)JRhWhi$S`BewTuD3GFY_=1P$IJ_^#R=Rq3sGDxkz z2dStbSeZD7DaK%}#6S3s!tTN9k6@2rmG%r)geh2Y=3u=*U$0 z!WyjhIDp4^U<>9H0D57r0#kr6ES%wYLp6z-vZR%ksYigw7@ZZL#@)mntogO!B^3xYYv6|6SLgEKG3(-$KL$u=85N$^1ULpDm?Rtmk4Epp5(Nb){eT4N5QDMwQe7_Lo=pUl# zxQ;3Vh>OcuKQKhqeh*R8Ng>)fGlb7WL$np2kv=;_f5SW{MA2xDeRD(PJ3oZ;ejzff z4^iU{A*#7CL^JnoJ6Le&p;w@}qXD;z~-L#XPbq%l+%u+lwLAK~EjH&hq>LUkWCa)hcW4(16}=e(gB zh}Zam!2F>)f$OMTfIP4SKNSqsFF1>v_|rdBThJ&VRPC?`?E^zK1&gsRI8?jf5fZ9d zc!Y#dV&f5}gb^3H!b25;$#{&vB0^O>lJQYFDpZze+F~J^$A_wALa1sxL)G6EsuD$s zRXkM9l0tPUC6wk8vz3R98xeDqopUxmOHT zW1K+AN}*bY|4^$k^F+61q1xXwR6TyB*1d_@H&oRIQ@3IC9T}==V?)(qe5lGzW1N|^ zSsALO7`{4`&+yoI4bxm~gHN+CwZ}&kY96Lq zxPxLX!t}IDn8Lb-X>d2TcMns>@G$kol@Y`m6{gG?VH$|SGsBdHqX?fJCjU8M+PN@H zL;ecWF67@5raW7Tb1+PM(d}>cA>t5u;5B+2p+EjP7N)@CVH%5z2t5&|i70e3Ohb|T zLYPWp5H{fn@?Q+&+oz;T|$(gzGsf%nj#nNw`L=4A&1>SB0zahH#bINL#FjV^g@QV;N52Gd%waR~m+3 zBC2i<*A{&J|LvA=71$cCO~=Ev^i;SuAo_H;*5JaKaQ?3i*Bqo>U|g6lhAZ!-a5cLe zt}dv2HC#wdy@1x5d38^$R@M-XO+ke4w+t~?QHha-6-^ge%t`V@-LRNXw3prF4XzmXAjt0jF~MW`Z-Z6bJ25TV5#B9zrJLXJ)mnu`IwBNY2vghrwH zzzF3T9HGvbJtRW!#zg4m+6a~37@_T`xhX>5k45k~c!XZ!2Ns`*(9dTgv<>wyFc(z1 z7@-Exr3m#z!E5A>i0h1TKSKL(GIu1`G)AiA?MSV_S0vtvR2N*v6GYvOR51+00h~pJ zdy(3L4)-JV65lZNVWjpviqyiVk-CYvXOZfLm1zGwQgiSQp)Vrk|1wgqQRr2q2EK`u z+uKN$#!2LU7pcbh1IO?goj#D~$4IUXiPReu{uIgi#7JF0mH#3&31MG&{5?|1iqbiF zxJ79YPGO@VN_P=pj8ZL(z)9qFk5WA>#7+2mL@5KEu>@CP_KZ?Vbj4C!g3T1AG<3i` zoPxVKO3CPirML)BuPCLWFIM6@9Ntk%M`x@-6HAo3;3I0-qLgiq(&JoF3eF#;_kmGL z2#V5};3!QGiBj_@Zi_`JNAW0C#-AmaV@cwcic;?MD0Rz-QbcBy+Leyd3N$DarS^D( zs^!R~JoB!^9JfU2HzaP2QYMZdY&$V_MQP~eC_T9qrScD>IL8~Mq(@Pz0H4Qfe;K9F zSB&{ON=4s9>EXvH1$~OrfY0RpUz9feh|&vGbc%N4Emxw#(@&GRu@R|2C|KPXzAVGfSwHE^`7g`?G`NVLL>Myp>kanK

      6jn*$|(TXhT8m~y>&(_@P1_Z%3mCpTTGQdbCt7{>lFPnm?LQGMos8B-96+yA z(JK3dzPR%=TE(74Yu$@z6?z%17zBNZmhV>{qri`7bwaRPjDA55LySTYV2n|mBSu{@ z3|A298>2+5#}L05T|-Qc7y5F`9rfxni^!NAMQP9itNHkJ0#!ig{x60~Pbe zs4hn3i_yQR5Ei4_*pF-BF?xc!5ix3obCEIfi;2-2w2fs9tiwq(iHp%{>_BFGjG86H z=sF5JV>quJqffB8Vw8lk7>`?cf!`Bjvd(u$PKaH+)8mbZUk<88P~n8Kbl;@+%#~b0bC#%E#zA z-dChfm12}#k6Pmun$(ZcS=>dD1~ICHrVXhxp0%SU?PHYHIYxs}qzip<3=!R8l(ReY z9~7gx_-}BGZVzSbX)#Kk&V2D5+h@dR&pftc-TWBsMVSTEbYYBoFN)EL9qixDeyrQW zew5kE{(UiOygx=Aj>Kps8Xb*MN8~?7y-#s_n)SfHn0O{eEiX}j)V|Cb;yEf@jZyn+ z9ADq4FT8$Gb9^zx@)|r=&+rw4-D7prBbM*9#LD3nt158wj^!HtSWU+}ORSDsW7W?u zR-2I{XROYkW8PRThe!TcZHGBLR%P%RUJhB}5 zG9D!!4x!SqSgkl7tGy>;<-8fIG5B$tJnzJ6+TB=HzZa{Zhq0=Ut&d_g|8cBd|3};} zv7B3oRV{4%7ON58$-@+!k#Zq4-3U9C?HM)0^^hv6sOr? zak`2z;c=RSdJ%DIUOY})Q79!&4d9a+rvNO4p;Vl<;CaP3MO2E@(8`QgB~Ig-#OVZn zYZ|BV$ki-PU7N>gdy6)MZqh{71)W(Cj$vK;F4=x`=;Q z#A(H!ak`82RdITTO1tAU3aNYIR2k>t+!v?o7=1iWN73&D^MK#UICVM|rvj(x_fMRD z$KC7H;Rbo!r3T2pAE#0e;{$E%ZXyjJ5Ezj$>< z&K&U?g@-tkJ6`rY@!E&8=#e*GPcb21ygmoUt4k1lqT=-h=ID4u){oavBsYrJcyw+S zuSx)Bend&O&TZ~9M-*D%D*idQ=nnjNoroI|-e@%kMl z=fZ-VaTOHlFr3ChMx6fVfEe}aYvB*;CK z?O_S38=k=5>;(0VPS7RXg*`q&W@mzOVJ~756V$kHg60)T(9cB^bS^DH12Ymd79}$2 zgNUpIwXd6?R`nD3J%j|lADN)vk=Q6f>YJciXa;+~1Xbxz+yMz1Jt#p92PdclB8Mbs z-z4&%oS?;MIVC}ZXC$b`%mg(@o>>X1Hzz@TmLzB#rmap;ueAvp2Ism2ty-U;=nV;K zw<$q~_9tk<-wB$Fa)-zdxeq7k3D%!T(D;i93ci`3!?$_-n#b=FGzVqhCujyvW9`QT z&2)3h!{Ag3))<{C<>Ay3T*N?6r|y}YdINW}Q*BVo%c*5nr}EmI3d0#Ve4HBWaH@AM zr)K76KdR+%YAHhVI`ul-sq+y|?TVsbv{R#sIQ0$TC7t>NbCOem$xg*%TB=j6)12ys zS*4s>{(l)xeT7%1Q=9M_g-Scs6~7_6j8ngsb@IJEr{+~4c2%cNS97Y)&rT)PbZRYj zqE#)YGU_;06-{sm8|ymtsJ>HU8#*<FnhHHK*qGck=$5G0|ZhH5|_vs5OBcXFBmh)?xbLJz5@RPIz*GT3mMOJ62qAs?k-aj@_WX zx1GxQ!Kt?R6~P~!YWm5k3!j~O`PHdc->DIn|6mSsDTkX&bv#^Zn%ku&d0c##$Hh4z z7vJM?X$V)(vadVJx+D0ZzFy}~yv zZ%6F*#O~-)d>6*Tx2`VD?(X7uXk2RB)5Y~-)C3)ouQ&7TUSpM!3{?q)Y9QXB2ZB?b6~gF5MaH(v$Hnot)rO;6&FXSq&dqgc#XOe=&S$O**#D-=D zeVbkSeWyz|cDwj~F?HYX(oY9m>T;0v`I|L6>{5Yatl@EDo@9MbyA*lOrOFqm)kWrT znK@lyzSmp|$5~|m<5I8dE`9#jrPsGy+Wycb$0L`TV;)Z88nPbq7_0Ep6PLQ;6jGnM zbP4bA=QEd_&&lnDOZPF>Em7%)ME!(4@NiG$y9bH--8WIwQOz$=O>ho*b0%syiUuUA z3>26s2L|DAP@;+jCu(AJq86b+OrqN3UxdUZY7+VvPSiM*E0U->I0~O)i5h^hX^EPL zI;9fT8dnjJL3>1%OH`-wiRy=Yc#pLe$QKhTCh8NiDktg$9%65mM0Kc|sL?+q>H+3d zPn6%!iE4yRaIZlwxQ*%%NwZzV=B} z@4kte@mr$045WToi%TdlC{b}ks5QDHZYXt{o~V~F%t%x-bjB%^no0h%hzFn9iTZU; zqShnt+(a$G77W}_R1IE~&;mR_zLzCb86$B5ey>WXB8FlIUL*Q-2{p$YoQL?5-p=z*@K^CaEe0;}VLLPvSR7k`z`UNky>(c`GI9 z11{H0Qv2FT`q-Fl&6AYXDoJJ9Bxxv$w@p%6JjL90N%{xl+A}^fJ0$57igirVV|>P6 zos#6+ov~r)kt9FN!26y_+VE?V{vMqqzLiW?wWMU#E|si_ zc#)p04H?P$txU4c<5AUQW&f1S|L4i_s-CQtKPM}tMzT~tSxK1QAXyC?ChK|QWJUav ztf5VkmC-a=by_ED5?;1R)~dG28q%J8kiTQHUSUD+WL-n?zRAkfFIjFQl2rKRK z5x75!F~=mU#mZ#O$JbTlwK`c-;ISrI$$urQ2hMFy)}pP+3VX_!IAKUppfN@NdZZ|i zXNne^QgqppB42BYrshr2w7?Wy!0@0HO^1JQiu#14s6uFpc1NeEed!eaiH2oTxQ-}A zZ}C&P6xqwCXmzy|J;l80DO!UfKc{G7jTF_Z$v7<-6G^R7^Z*@xPthN6ACaQ{2%Daw z#@IO{MPp~Ca1K00Kd@mQ`%!Lwik2=&(Y=K!TDLDnz4xbR!GRPRZl@?6Z(+QXqLFxT zH${`~r6}!riuxhpMT$z{Zv?+e(Jkcuk)j&lmm-u0bMc>Bs+Jj2744a-)+k^~RSed{ z?v={dms9nxBUSHnr79tJs>b9=Rf)W*%8E(VAQXvBRW^N7nDDx;lk+(^KU(n{D$` zwP#_fzG2;>RP9BX#i?9dl&Y#rQ?+7Msvct2YI1^eO{&JOO;yQtsXDSPRi4{ZwGBs6 zbw{dJ?MzjZU8y>GI8_yoP~*?cFCtAXF)uPr-*F}?O}Ef8I!&))(lpkYrX7jg7EaS# zlq-@ZS5lgm;zCNA?%^HWQ`3|ap(uiE)If7|$52ec5^Tb2{9YH1@4x>9GS>-?N_wVs!*AM?{SZDG3N7N={ke}-xYWavd;2EQAX!TE^{t;U_m3>}Eh z(2DpBMHS0XT*VBvL!n9;jGv)rSXCoKnKd&s4&(KJeYLKCP&4~@~78%Nq z+t|=PL!KQnbc0q10a)>T)!L_YE0pdMra-G4*(c3g61maP+^Ep&jUWH$wx^ z`Cf*yUuI}9ioVKFX&7EJm-iVujtO5fbP9vMW@sXce#_8Gq*O=l z%RN(v@EBD+GWl(ROfAG3d_%HlrpjYI(oLC~52ra(4bTlUaVdYM&im7@P^LP;8jz^~ zRQ|ufOg+b*@J!vuPZ62=5Sgj=QJI>AlPDXVsS9|ELQb~h2X4EFQ#g~~*UHoYtSP}b zC{i+0vB{aLjtiy8E1h_lkK;I$k*SyHo|&mDh|bDX9qh|y&X`a-Qyt4>DzsdtTu7~v zsb;uaCsQGlnI9U@CMHHK&eT){tY=Kr+nTA8+cL$EHp+&Z$20ZsN&1}1R4uGVq0^cA z^K7Qhpu@RL4aA23J5SCRi2E;d#CJGuWGdUQq<6My}T`!iUe~V|yuSAwi$yo|QYZy}LkF@_w%hC;a zWMnB8WiqoAnnjM~vNW|umS)w=(q6>W%2Fy?{a*r*b>>)LLl%w@5K2AX^~?v(+{rTT@UaHe211n!tYCOw5*7;cPW3nynF-QZk$G(PYarHCs+R zOwX2YMz#)>&DJaAubQoN%)oxUua>O>)w9(Nb5XKpwi;s#Zo{`uwu<9Uy=+nWVT#wvsD|04%v$RUrl!b9mVzbar{SdiWisCLW>nEEiU~7yR$P3JCn^O z=n5@Xq&UTc6fc27&;kh##Y)j)#e!RLUYy_*ic8S<%X{8G=X}m&XXifmxzEf7n4P(U zL)~4<)W@aDC>rNd1N=MKr2<1(Kis7XI5N_uRMh<0rIz>;DJU||rTX|4$w-*s;_ps! znCMb1beKfH$T^v|C^g+B9~R&UGR!0gTuF54!z7nR&v)r}WL!X=n6k*F&1kp8r3pw{ z>C!F~{lg^>_N;bk|61yq;!;HzH(ct3C&+M2}}`Opz#u@cAd40(&XRU0iZ05h-= zXTb?Wl|~eLVj6bfE?R%#);Kh&;MNeNe(hF?DsE-3?pAd?tm9VUx^Dg8aqFt-RtK+J z?r68VU~+S}J`B1wG33_A5w{k$bj$ypTj^T6RRN1TxmCQgTdTUbRj-?yYn9#F|D#(E z(5AOreK7aEK5o_T>(+^WZZ+!f)-O1Nk^^{+lSsjefo?s*-*Lnl?AB?NALds25pG?H zC$B_mgKap5OE@#fty1&cTC$LK_;Zn4(Oc;o7qNL8cK>AP4Dt^%R1qU^4poO6>NdjAa@-qfsKsbQL$C?`er7q=&`YcvXQ+FE zp#Fel<8>LrrlQ%Vrt+D9O;C z+0ydbsF(LOg_5;daC;uDtf74KoThtc+;_PihCGQw&f6q`V z+TJ&~#@gUK7h`&8FxQ2lJE-==P-FCdO0FpOjGWK{D_lXj^5EZXw&(9{qumRXmEpztuddP{Sj$E^%=OMeBJ~$mLxUScmz3kHXO&eHielES6y(ZsFS)k9y(|zKEqSw8KH%MyAHZ z#iva?s*4cLBNa27d9(=)o6`pISc6k7_&LNlaSaQ?9woyS@u($6U>UaK!MBXRl}DFQ zsWtuL7TUD+=pU4A=TUR)LWl3k1?}5=RJwylZ+d!|7ac!(v|XzQKn8I&uCLgSdR4ZrappioXI&$lY8t4=G zX{HKeH1hq*SkZC@V@H9RCcn!V=PcTyTO#93qRo7^SwwF5X0fR>OH93ivDDOe%S?5} z`4y%Pt~9lHovFU-O^ra6&8Duyx7FlYb5j|&nX0?S{i_L!=)mwm90`s3_DQ{4}lT6f&kyOY%7vZ=TD?FzLUhIc9R5YcnrZ5-g|25 zCW6n%4R_G#IW#fmnwTvQ#9E zrNOxMfu-GPExzlqR1yW#TN;Z$Gg#`C(b6jH&t$23W=nIBJ&UCuaT&26TH1@RvRX<) z)@+vg;~IR~EiHgAhs8WO7S|0}TAJHZu!}yYgAeo1a)1UBJ?_f|gzsvNWNv zrQSs>r7LP_DoTEAX+2sLvy}N0OP3HRZfP+dVs8oJeMX*el_K}jmKK(^_@2PxdjU&k zbxYsXu#}8-E{k&ljNi1>1&2`1vNR6&;PYBqhO7-O{eZ(**~n5QAGtf0nnhW9jE2#c zf&ois;EJ*MzoVtxv6lRJh(%2-)of~Uo`HUw5wkgMT39L{w3IDmX&~-me}s4_*pl%h z`de~F`|m83Xl3aMcD1%R?`6qBXT)PAj^hz>wYBs$nqUleqf|TgBaWin_m&b-p}nOo z=+=QcAXi6nLfTIBhu?m%WOueS9oulKi=~gdvTtw-X}Vi#gz2cTjXK5ma4YG6vxql*8R31*vM_YQ11!LGRKT{{%#usBPb;Vf>iDw(E97mnTTbhdt z&@U`;2OB0>+Md9%G0EcpSJZAYwVPsT52{aP|4pM-(>Y#eGQLEMxhtp(iY0MO&$g5> z$5M{Dmg=G*rvJw4B^<{%zLZ>-v+uBfg{AJlb3CqOJQ(?hr4#smm8FyDxtjg6mb$Iu z^YJJ3-(ac0MoXhMGqx@CiLQTH%yU4_IDwmp-bx-j$vxRp-(8kQVBl^`W%u&=!oq#* zul@9ciw7)aIB4l-q&s9O?g;r~<8eN}`0ynA`80W+wN&MtrSs=4eSVSS4sWsk5}%pN z9M36?|0>5660cc0cHL6#o0g{B;`4Od(mTZe!?AOhyin~S$Idg3ab$gNsVd&0!3&P@ zRBH8#&mP*p=ChX7%N$u=70TvSGqlR?)tG!<)ywbI&zM`-tGu6jRi%ViFVN;QuRi$P zt4JxYnpgB{B#t1tl2@luurh7%JMJUrS6;P6wklp3cwF79+BLkYP?PuJt?gCuI>bju z48t=Ntm{=t^uU^WUOmD)G^_8`0eBmD^%uT$(Kjj>Y>V}Hh58<^M&U3%Fo}=vu>iMF z%pw*N@Hg^$84u#I6K_znp;z6o0#{L>kyi~d47>3P)qV7f^>~Y#wwJj(y;_aCDC1Bw zB;qVSit@_ASnNg`zgM-;9gA=Qxud;uVF1?R9*PINYJzy|z!Q{K*l5iZ^ntEkoC^q0RDm3$Qt(I3yaT}jCr(PJ3WIRKq7GAF9 zqNccp;z6%Mn2KY_8uF?E`d~S3pjenVNWfv_iBP9DURhneDmsSOxqWKe+^6|y(!xi4 zpYFjM;z3AZpKi7Fsbo8!{s*_w<$IqFw)gQJrB7SC_|&0?PjmYFbO{p&_%s)#2l_NT z&Zqc6KAj%!Q=NF9a*gw;4R(+BDcvtVt;ZhtCit{uqECYoeCjd7r$5korcXWb5=|1> zCdsGJ2A^iY-sn>p*HCY>Po=i_^zUAu%IzZu+()ndJ{>#Y(};sUy*TVs)g$DNR1Est zr}IaB`sEnoJLywROg-gO;IvQQUZxMcxI*43J|#T#=_rOh@@WzZJ@%>h6Q4Ri<>z#^ zn&QLswhCho-e#~>Hj}OB(zeo-v3UlAtyO4K&Q>qHLemPi&fx)ms%R@ybz25fk-3Jg z@wi*l=DK)W4;$F3=(3f9N9g0Wd9IbM%^q91eYT>I*0%K#rsJ7o>spkp`fY7Z?o4~M z>}_ie#`Lvyupi3-wl3mPoUKZOY+c1;^c`&L)DT-khuWGj(bf?RO|Uf)1tyXIWLuw3 zq3_kUUSjzgTU*dzt*zPXY&BYM>-Xcf?qT)`TPsoZq^*Qgw!S%SD_e@KhIotYS8Ywg z!)vw{Ubng5*wzYsd)rnw6uo2X<|A9bKCw0InJxPT>rxr#OWM7%HS@L2e4w@ty|cL% z$I+}094$`kXly!1UD7)WWO7s^o1;?M9j(aWXhTj%BR_JK_^G3CSw|1QaCEJlqm$(w z?Wy2sUL{9UzH~IMvZH^hI67L@QF1j$o2nDDhNHr@9NotD+Qh2o=syh{-Eld3YdBiu zadg^rG{&@hc1MqKQoPROKt+d(W=rR)aGA@+a=V-)!N3H{oa$R!d z;DgJKa$_2vUZKwv>TuIh`dbdyUOU}d20+M-{oqcO<&($NpE92I=cGEJ10BK$#=I^zla>7w)oIkQKpaE>T7#&+b-8KwHj zoGVHXP$ORy&r^s}5_)cr(uBiNx_=@{3*}e2G=9}U2z%1{^%w`!`IRrdUvZiI8kN_t zo2Z}Pujm4PO~6eQE9h6#LVi6!-ok$7g7fR|PyD)wcAxsyri5RIaP~95^0Z}rXJU2n zYZIP#^($9zze)`CE6ZrVW+nKwVv=9E=MZb2Uwv>BCl~qk@mjw+V9h4KJe&RM{1?l; ze)T`&*B7OumE1I1f3=F%XKkXDvsbk0ERI&&ozWVKF8iYO$Tx<+Pf;sp zKy7meR3bW{P2UByy>&o4+60u)A)teJ-Xox_Jp-DK@Q(pS^$n=`fPnhp#lV1);{u8u z8_?tN0iB;5Q0XZFX=*@?aT+au4ahY&pfvLWdbpIhn*zFzqniWju_d4pc!hy~1=MR> zKzX(YRB>lO3wDvyZni~^y#b})7f_k~0o6MYP>mA-y`z8F1! z5TmGvG3uH*R{8V9syf!8bKY1jMBeobG8y^c8RgF3PysEr$g%CaS>dWhc|)Yff5_1P0t;S)h!P6=w! zqo9%=2f6trVMO+j8s-S;-<%=k$`#_X%6p%OblM%#uSQ4{eIcFf z6Vg|MLdrQfBrgU{59$1@kP0P+bO;xakQ7qc*&$uUW4xIYQsw!?$0fuq2r1hVUgOs4 zkZP|9$-)i1S{qV@bs-JKc$`DN^qi%c6r$_wx2kQSopwve9SlOrJ=#+?fxzRL^A z^^_Q>@{BR!HsVu5x`LN4Lu&adq%LX0T8@_K!s?1V>BBmoA*@0f!#acuNXQgc<;-Di zMQm2q<4NJL{6)eF<1n%m4XXj7FcYVd^W(6JB2ql8lcmD?vUFHWz6dM2e3*Mx!)o6k ztQ!8XE=99VAgrp*X$wWd8jWFn!#aaq{ld(F7}h%M#()7~6&@H?Gh~ems|e1b^zg9S zqTqSP$xdD{-`i6th&fHKFnP4VfDq%iD7vY!dx33);a7<3@c4i zSZk1sezU_GKPSw-4C~lj#y5{`a2&tR53BLAuqMH?Jgg@8d_`Cp)`a!-pJC=tr(S!* z>VyU8ewXbEM^ydOh>q2YsBG;B|IUvn*gB$iZ6cbF*ijMvhRt}5%%dZ!gE5$f3}YgC zgN8px)C(uDdMvTxBf9lVL=z@NRBd8JM-w6{Jt@NT>LR+2rjywgwWdUv2S1`EIEfVG zn;KCQw80LPnMS)A5uS+=QPEkL9nn(cm=n=G44NC!D{Pn-QGo>!okPoo5w%?%QO8pe z9X}J%W%U1_h>qY6(wvQ`66#gZe_8zB xpCxt9Zf{%rdY`J1VI7;z+}pU8vG;NHVM)Pzm#2=u-Z5qVf7_+~Z-f6|{x7|}-S7Ya literal 0 HcmV?d00001 diff --git a/Covance_UCO3001/browser_profile_2/Default/Code Cache/js/79fced940f0d6da1_0 b/Covance_UCO3001/browser_profile_2/Default/Code Cache/js/79fced940f0d6da1_0 new file mode 100644 index 0000000000000000000000000000000000000000..ad47b32ffca0cb578d904bc25a9bd9f3fc1eae22 GIT binary patch literal 249 zcmXqrDOxU_`}+?o0|P@Y5DTB}`2wUE;;%)r9faS%a>{PrOgP6oHuy(!b4y@r4T1001ENPAC8X literal 0 HcmV?d00001 diff --git a/Covance_UCO3001/browser_profile_2/Default/Code Cache/js/8484823b1f8ea286_0 b/Covance_UCO3001/browser_profile_2/Default/Code Cache/js/8484823b1f8ea286_0 new file mode 100644 index 0000000000000000000000000000000000000000..0d843c1c31f4548ddc0dde403071f01d52122123 GIT binary patch literal 256 zcmXqrDOxU_`}+?o0|P?|5F6X^?*UQ_@!6@B86_nJ#a8PT>arZY~DK&IZMSP97nJ z!A6y4CczQ@@!l2X#fA!8Ftd@(z2V3^-8KK$7eE5b7q zCVkFD53Jn7CN=Ax=J|PEseG#{tlsaGpLWKvw=MZ3+m;5alHE7^VP=E$m+bbuuL3my E0Kw8uXaE2J literal 0 HcmV?d00001 diff --git a/Covance_UCO3001/browser_profile_2/Default/Code Cache/js/ec8b27730da46865_0 b/Covance_UCO3001/browser_profile_2/Default/Code Cache/js/ec8b27730da46865_0 new file mode 100644 index 0000000000000000000000000000000000000000..489336c0741f3a2e9d3a39ea99a1adfce021abfb GIT binary patch literal 35308 zcmWjL1$dL!7sv5mleFaK-5Kugvf(hC;W``!|L>pY z`8;j%-uK*d&b=v3@}_C^yDZPv{_8h?NySho;@e8TsATa{rE?X}nKNIm+@=-X)St!MzD!O9>Zs0L$EFw3Y zN3Xq7?`x8`n4dObAMT-1aX*d3ff9cD2OUcKsSkRW@>4(=KV?Rr@_wpU(NBFb^Cv%j zZ0RR+D?jbTF?d`1DG4>u1W|4LbQBkHwymF1+WDyn3U&2UuU>u{j0nlX3=GDjU?Oib3s=qq;#wu^-MF2DQdQbgM}WbgO63 z?@bNr+RUK$oeYZaY|v;-N4YKr4Zx?aeBaHWtlbTY#kU>?HSWo|y$qU-JqYVfZm{$- zs3HEq+y2Zuz@Xd%4eC6|pdHvb*dW^wgVL~lC^f+_+@NCEg8?JCJ<6ayqYZjBj=9iq zJh@IZNRtd2gyoZ|8HcAB6~oyNX(26b4^e8|4RpmVs1hFc6W9Wdx5avfwW zOh*}W+Mt)`$@#iL)*A+;qalW3KGtCJ-v-UNZBVm2tT_taC6{{!g*-Iq6!t$dsQy#t zd126^mj*5Qms;K#bRW_0>CH!j0#O2MVEWA3VIWrE5v*Sf%7{{58S~8`&wmE>#Z?^q z&i?T;YN^4flSZR51{n2=*{J;(W-)3q?pcj;+l>lEONUW4T}E|4h}$S1e#b|Y4>GD9 zCSVgTVONMzm*LB3)GZXrWYkp5%WPEDEJnRV{;WoI!)JtMGpZrxVi$&FH)>RM1^AN>k=;MvX0vYSPN6@vV(Ih=1{@ ztx@K7Mh$?ggHh2ahf8SP$*5zUjmqAg^~3cZM!opWsL?%Hi(agIAEWy8GwP=SM*TgA z`3AF3hVsA5Fr#{+;|QZ#jWX&ne4~vzJi(}36WJ&K_d7Kp(^Tfb(`kG^-Kh4nje0W2 zsH}61YKF7(h_TS9*d<2gSZP!noL*&A^|i#`VAP3CMvdIenr)%RtwyccZdB4vYS=}c zxQ0=C*;o6>;~496p82kG?oFdgJR%SDMV80x4UB)n9(&4M&*=?5qSXtd^1U>w-z)Y$ z)}Z-&qb7bZYUM|xjGv5}Z!u}S)ud83la^wc-K13xldMjY>foWvq~F{oZ9x7Yld=Sx zl!Q!K`HCGllHH_jUXyb8OgezOs2gcgqbQRSqfPR~o75}Kq}@5VKaWYJ3z{?)B@3A} z0WAxgv|x$x_~=E_j5a6*#YoNwuq*v=du@HmN`zlg89Dsd^)m4mUPw zT@#ZI!PeBI=kRMrU08^W%}ttti7ic9jMP>pRcK?<{&vjSo^v{wl+e+n@J{rhvq|;4 znAETjwe&TqV1JXUqVzzMt_(40#ZZ&3Bg=4d8DY{joFB;?qfLq!Yf{WO;*K||+!T}g zVEiCe6c?MJDB4Y*JV3#lEE`1uQek zxPlzkFei3xGU*#mZKkd*tj|`~Zl6i_vE-0R?T(PwS=R2nN%^jt6nE349=ECOg-Idu zS4WI7_$%G+uXD)d@K=D#UmldmgX9J|8( zwLQXL#iRXI1=C~vl_l0+)zLZ8UlUL{$zQiq{q+Ku(*0%1<*!8rQPN)}tN8164SyY| z=dYp7{FSE-_qAm_ero5h`5pZAp_9LoJNv6Oj&6}XMi1>}s{i~JS8*k5Zm z`fJoaZlCnmUl;t<<}ZKwU7^pgT=m!J>;7`y@K+xkL+6|RdV{)u(|i25<*#|SS%W+N zTKUjljb8aH?|=Rps{oBQ2WY(~K)d0WAwaR%4o^scc4b870JYB+puS-N8ig(JdHEiP zF(x8FGjIs0KE`1if}#S{FD^iB;{((amv9ef69RMt#}fne3WbvbR26ICmmHu|c!u&R z0s4SJsR7!EHE995gQGbE)Hrv5zTjw{0Da6y{QLo`TOdHu1p`#C2su>@P^-$sLA`1L z`g0JujS5g3lpjrAaF5}9T$vD{J`>4ld4Te+2vEw(0EMp#(B$<2>adx4{s>UX?E&)N z9ia3B0rWON>(Jm9bw3HvLWfxkoM!dQYSvWj##2nsZq~9;vzB#+n2P79(vW#@zmZuve>E$A zW3y^BF{=q~p;S})fp2g(Gb_EhSw-M#Y1Z#ZZ)=vRomtQD3B5a*dD3RqNCbB>Yj79( zjl`~Iy~Mq4-#v#Jd;t06WG=KLXikG1d&HEaKHvy3Cm z$~e-j)X`?OMNfRfsWJ3pEbB4RtPYddGgIjQRBmHAUc)optZ4Xd zugo=T%Y3r}7nn77iCMAB=p&pf%&NHB%+GrIzm-02Giw4?;2y?pH_NcYtjsu%dHc+2 ze88+8`1PP!2M*Koqh|HNZv1wPwL8vwV*g3@FYe;^Q)Z1g!#+66oaf9cc7Z+cCq4L! zHNI%pp3C(8Dr1m(jWxj^*l~kC-em9GVoxITZPpMC&=Z@m{*GCP(eWffk z{UPUID)!?8s{ca`&=Yb&VYI{qyg;_6X2l`X8}_EbB7dVrUc>}gG#7VK!EDjL2((#L z4(;t0SzQ(_a9i{Q{en0aY|#|hGFarvWKqj37Jc#&FVdnP=oD>HSgb``@k^>jJuwV3 z(<~a0Zc)}87LCP~oEE)Dy<8T}&ufuApGBF`7$@>ul&gS6ZP63PLKeM7rQ#N;v_(!d z!(V7xhB(c8-8R>h*;KUvi6XN!KWZqbce7LBNF(SDr4 zN7Suv(K`IV>;@KPXlPLc<|2Dzi(WLbsBcq?Qkz-S5ZCdkxkcsMS@fo>MSk7L1^tlP zogV&XQBB;(h@KX?ds$Syw?#LRwJ&|e(|(-O-=YlzEXp&`qE>?}dWmmXHQ1u!Lo7Op zD|mPw`lPM=EE5@oJgPX zC;pv8k0uiX8KzjY2Pg3en|^2PREs*`Hik|k#~Bt4nrYE^tVYr-i>~4^>dfZ$9CAVJ zc^1t<)&<1C-h~z!7E$YBi`Kxp)S}9Gfnm!m%DLR4VrYOzc!vWkEINy4Xt$C%S6LLY z+M@jHEGmPhc#Bz^*~?pqy^R`nSd@1s>j&d5i%OlO*QZz?TtSc1%#R(Ye}=x}D<+<` zDDeV){?noqbo+~SxM)$y%NG5Or&ri7DDjYb(d;RCKVz>wXKi2bSiyjoJSJXS^al>& zHs-ydPdEXu76Et=v{E$z#<vcH zWK{%;;3O&+v#JeBm9}auW@0Ovm$9k~>Xfs}zr0l;m|KDQaixk?RjOK5A6HykT zv#K9n;TyXBY}JKdtm<9esysD`kJ-454z=iWZL22NVa~eDiLIz#&nioOt1{zMW8yZk zYFZ1c7GpoEwX~`s#++R&rDRhMxe**jR3ucK9^@f7(xSry)o9{0Cu3n*3<87LqVABdjB#|S&C)-pv#io{UrrER_zogrE?aHQcNX}`~(%jUN$ELWvHXXxb z%*bz3l>#=N8`@O5kWG^d+qAHVO{0q1^cwGq+f<+=xuHZUn@*x+X`5nMmYuL0A?`qoAyp~PN z@B+o_*fe1t;}+3F)L6_KEwL$enN4|@+w|)S>R4%0?^QNcT21fQ+B9*qO>?pD57rJ{ zx7zd#0XxWTr%j#q*yP)9)6Zyx@&|0namc3dV>aE#Yt%eWA5SnA{SbPRc~Ie$O}$Rr z^!$uXpHcTL{XJ*Xmh<%DqD>7i+0+(y(d{zh@ac+8Pp{du=Z;M=kI4s~C-f29@dYKG z+B6B*G4#1jb>7<4;a|RgM=#$K51tP;U4iwZO*63!^F9&(Gj)Bj>A$b6%Qu^HXR)hd zR=dKp*|jXYU6wGrQoVLv!f%mwg+<%-ImWIN33fS??8=IKCG6^qYbaRKu5uVq-mcb_ z?ebQ!s}g?0Vw{D$j$NVHS&#GT+jRhMo7wdPjhoxm8@^U{)x{>XZo_#f*UqjQDA?Yv zNyyp3uH~KV`i`od?fTl)uB+YbD%9Pst{4cv9(FbFXIFQ4``h(lkX^>XcJ&%!*9iCz zwW}y9BXyWvh4BVIFmgEajX=9iJr_f@oUE9%dyj{~Lat&4opPW)po_9!5Y?PE%jpF zI=k-RB{FOv7FJ^iUT&mco9r5fDLA~@F4Goj#a0|f{8oB~?&!IV{juGye^6`(YmAXN zxs!T!Q4dP(W=${^&Gy)}2pceXFTFyWeVn`Bt{eyK%5;#v9JZ?n#vUQ>6ZG&THJ@Uy zqV;KFogweDcHP3{b9Oa6Z`bAvtSzeiNzH%R6>*V0gi@DScMQC2SMn8li8)s}e$B3F z`1d;Nd&90=x5)X9T`_mrf2fa%_y@V~vkxDz?&$cCe*8lZap)0!dCVR`yC-&4d&(Yu zX4etqeoj0Tdtuj4FYP*rldo8-H+Ieb*RFRc`Hpk&^LxAIf3WKnN`2%ub|UQ)dkFf> z8lnx(BK!-F8SF>quXbhs#ypsZ#sBfR!wY;t)OY#?;}3d{TUalL4jCMJWOS&I$)Rre z-QS^K%?`E4;vk1IWOAr$1mEK>UgD;YuaOQ#M>*t*cBnq4pl}SgV;!1_W%wRXyab09 zVnMP)xziomlhdJ-$d}8ZsaS+Bc^rC@*P#!nnctz6C{Vzm%lM_BL-)|K5XX_RutPu4 zyof`qFuSNj7i&0Fr=~;yU~DaiI@NZ_R>z^`_)_1Y{>>d4gU_uTs@>V4tti&R!Sg1E zPN70?hf4NwXbb%MIn-{jL)%6;6gbtPuL~T?yomlRcBniC<1Xf}b?6nop~E_d_9K41 zLw#`qu^Sv}v(cd|Xu8>TUWW?qqc8jE^#P6_bZFus zVjgxV;D|%lvH7?|sV5vdgP%^4(<%CiBBvb+KjTm@^gYWsgq@=w=N)>7#TOh(`_rMr z*zp(nTy$vHCD!D!L+h~Qrb8S5cBs-VhgRdsZHI2%VJ+`F)aU{AJ#%OVmZIQu@_yk^ zGaSbUm|i;63VU!0d0#m+2osR;wL>k?4UdukjYDN|3|ZdNC(Oocd`G)~9omWGDDlpr zNtll;?;UD_PPmN355&S!e1PdAeZ>*{h032e4{MR~nciRo-lEtShwNX8i5Yl=_vrSG zyl@F+|Kk{zq0)EyfrkdC+(xHbV;8=goXY3#)JWV%^#G@q;v-VbPJSnJDyPM%p?HoW zR;Okl*5*_$w8jFs>`v9eF644JH3bf*Q>$H0g#|iw8AsesB?LJ&2ku~}4r5R#=Z85J z;B~4rcHjf{hC5Xy!l}mS;B)F9REc!zJRTx0%Bi{-ipkMVZO45Sjd3bGmfW!bUE-W7 z9`Do>e8AlV@=PWs%qdQlNpHMXIMqIvQ(sUaH{a)Vs!2Y^=XYv<0jClR zIyDAU3po{3*r~TgoU#{n>Jm)FoT`mH#fgQ^C7jxb&qyid)O+kI?bL5&oO*^#WvL0q za?FeWU@Pxb4s^#5Y^dneOkwYgsdDw5I*srKP7TKfJZR`taAT+Tp+^&rV?$HcrIELeh9Z!z9i$W8~3t1;R^$n#aIW-H*k!3Rd!|`eKWx7-KV4C67 zW*BBVRd5!29O?6jjcW6qnua^byMS02i}?$wX^~UEE_SNn67pHfo>=CTX9aVvbgJDd zr>^3_YNvc_ok~UcI`%l+>)HQ!fv62m4aRWk znO(YWajBWrrAKICcPYf-(y(Bc#$|A6LWoQKGrDvylS@4^yEGGjqhJ=7nqw!PVM11y z_Tvm}*<3tdaOoSY*CC|oGx9( zzFaO9&rObbh>_Q&OlXC+`CM9!?RbDp1&D)&1znnh2ZdcaT*RdpEnWJGrfpnm-`1r@ z?ObxScd0ri<8TL;4s~U2wC?WGG1U6aC3{cm?8W@OsjH7mgZjDT9Y9S3IS-#PevnHE zL+If!mwFC&>6ekrg#u$-$~~6*#<`Sbyo<+=OUn^B!KD;joaj=GNiIFXqRB43n?mkW zUFtH;rKQtdsxrf+yXZdCrJJ+KcaBRjb6tv<=hFK5HyN5x)iMcQox8 zsO9L~D^UFr-aAmq7z$&bK)I3LH&89m6Q=d zTDP6!y8`uKZ=lNV57ed~n{{dyr#4=>Y;8-c2QH&A&W2dc))K)rfL zt)Bul_P;>Q@^foBt{dI_j_j7xyQOaqIVZw{j)86_d)`dEDBZm;3X%brXB@ zyA@T~t;7m$b*<=Dp~`Mm`^l}6zqr-Cx?7)WxV65fTM@O$wYFPj>bZFi?pFUsoY&Z` z=S`TqnOnZ*ZhdIs*0PpvJwvfJZtcep07Nn_K^4eNVUk>*ZF?{%#E(-RHhX^!c${d!BIaQ#aQExpnOseR|2hdF9s8H*U>( z&w8TwC&uGBI(~MmFYI63Jb!cR0m}U6)>%yZ;nrvL4GGc?9EBxgkd9>v((%kex`Z=X zgVZ=INUg(z)G;DRF}@%@#ly%T?T!l4)#xBCi3!sBxF9W04ATCjAkE4Vq`7&6v?pJX z3gl;8fgs%|7^L9BK^jzqxv-=ta}^KLuo6KEFBznfaFq_yI@rqu=~o;=nQ}pzT|P(= zmB|Gqs|INczG2PJL5lt*NHcK&uWAKpRNWxu_%%q?`Uh$Bm>~T;ElA5Aac+39c1HxO zMtrcQrv+;X2B!xrSI%JN%@wRtRfAOxo2mutOZ8yYsliuttQD+ob%NEPZm_b|3zoZa zux>XA)`6zMdfYr%D_aCBt`%cj2P=EqV8!DCIU+it<^>0mt>7_4g} zi8Co!Ev5$R<=SA)T^FpQ>x1?E|`2QnAa48brPLU6XR^K4qXh^;mhQ7C0PBh2kST- zH-c60X0TTLO+L4SHRyh@0{#is)F;8xvtTuR8LSyNh4HVr{W@4Te^3*Cl1Cwa9*x5+ zoG^IQ+33-qCXW*RJ-Ul*0Uq@?Xj@i~ zGGy~;1kT|_c8}JCdQ{BoQF6FP%_2Nn9qG}aC`2=VtVeILJCK4-^ z7-=58N%v@84v%hQP)?67pA-3`dIp+`p=dGy<_9_4N9QF>Ey zZtl@pv}i#NEj=3E%A-ZYJxUnu(ImV_w}~G8JA-&LJ*tm?p;;c4!X(T`*4Z9yLFc)w z1wNtZJZ|GX&Mon1**eB=Al?q{gK?)v4R^DKc#ZOVSQ|V*uDu>jM&5lMmB!rt9#uTV zaV$UVQPZRB6^uIJQI3-yHTmk%0%XmUL1oYrIWuSAcghT^l_i5_rDaf9?F^dUJcBOb z$H5GG`YMBFe8`|b@EY-cA^O7}qHV4aO>u|l6(T3G~JL{ zy?mK@E}mIGM`qR{?8~27M~i1xwlbO39z~aB<~7#L{Or%Hx|y=*bX*o56It{mPZkX; zn?*D0WRbUb7G-~vMM2%O%d|SX3arbn700vd`-$va=Mbu&u|9vOauf(vS?t4UtS%U; zDuqII9<>XH>L9ul4OR7Gp~_PtlBe1i+SkOJyg|t zhH3~V;Tu}?B432}4%G%!?-Qz%7}+;ebp~)8191|ChlDEE&`>203snL9iw46(^$~4H zhN>raqUESib;A~18y%`gm_8;{H^+u5ctWVg;2vIK+Qd-3pUnMJLb-M*RGZ=Wo!(#p z9wKRKsG4Ib{=v#=oR84y^a#0UgsLM}V(-jQeMRD|P~FAC*{l)j%po^qp38kmS{$mW zOG336IhTg2^fL0tlhvX6fatZ{j~$q~F;t^AQv*IA^bgj1d#GxmIZmM5o=`2?7pfWi zIqyKI&Y|5w*7OklLBqqLYIQ7B-SO>2sKPFU>KFWqizs<1R9SDZA21HbG2~{b_8{x6 zP|d|Ati4SgxO+ELpYDY!!$0KmD3t4kLbd%V^uA92X%&rsX4Mngvk>brq0FgC9sVgyM}7&D zp?a9|)ZqS_Vd_;oOj{a-sZ8TAT|-clFcoMTrr2g-`ra~3+uDX{e)}*r>=35>9m6!b zQFrDcZCT9;~ph?d#mFpFzFWBEFOt<=m={dgj57VdtVX_PilWAy}>?6XI zIx>v+l)^N4QkY&NaB`Tk&k0j5G)F%iM8>&cN?OQVIJ78CX-mR*Unfk%aSUH^`Xn{| z8OC*AVOoyD*TXc&=hZj(qP$AQC8Wf9wJ6@J{s~@fM@W)aCvX{at9o?<DSKFZ0UKPO`__gtBDYCcqsyim*6Bf4f zYCUZ2y()#NxPzCd+JW3~4gnp#8jXdWyt<9ao#_F}bn$908g=!mJ&xfL=5_Px32OJC z2fulB4J&$j?veqw5fQF_gXz^D4_kuZI6l z{nNbKjDK)+2JvQ+C)Ug&Z`7Ji{5f8AoaOsX5GRil2SF$3H(KC5N}nXoDb^eJPkUALtXDNJdX;v`tK+ziu~)pBiPG1o`8xX( z8!_t+wLPGJ|FAC}dDRMuPpR!0`yOMk52c@bxn9bvQEwRYmj3?h)hq1yz@Gi+Ro2h! z^?-1$(GJ%Ugj&Lt-5RcVRI`U`V_3NA#)s=>fpFQ2g=;simI~KH#FP)$$_nAyisUNc zd|r|9cvmZ2ezn8Z4TbB5s{%?k3|Gze%+V=af8t%2a0PcG4odb2=ek$o{T41yZ^rit zSGm67GWKKapm5b560WZ!!Zl;9LY;3s;K=;pz(4!*H%W3)d=? zdK|7!c#gbJ!nGJ1aNudUiarn57JPaUuG}x_13uyVYif8Kt|w^!F-TVVz?C22nxhCUGDK(ta+)G^1a}<~iU^EQ=imtagLrR*>cvKAbYg^(b46%fp$K)a z7ooBpBlM(age+?!RR3^`zu1;OA)$W}lKRKD|UAt51{Qu=!L0|G{bZ zX(M7CKDEOkJi$LsA1{#-E6^voeSF5vr@KMKLDgWNHih`~BBM|HB78jW_308uru#Gl zg>sM^p6B$bO)j5)L*v{&jmqQGbv(kB{5~B(%c9Iz%%=}nUfd^B37>*78V^vfq)+GJ zF6HC;bDx^yB>qFq(mqYZi!wg_Ro16F$W+d!g0+3>jz8=8bgeG6z}M8LdCh(L(Skm; zXP%BewHof@`3v`r@M-W!>Ok31K2=9w3?J>2-#F@??2~oAPbINnfsgkFd|HFhMLsQD z>{Hv-)V`K@>wF4YPv15&?*X4$pYrh@r%&}y(|i1h9A|vI_fL&yeQJR|Sb;zA6&23; zR2zSy^Ld|kU-0q!4Eg`*QymZ+g+bB<0caB`PAzX=REOg@-zDL+^0ORSi9GZdF#`Dbb04fgAeozzbaA#{UT*I zL}~1kuukc)L~?;!?*^KT-zV1+f5^Rk33S&c9E=Y zr1E!&)Sj;7&?8a}u=2M^ZAGV^k@^E|dqwIzdiRdhQf$IQME8kQPRvD0-$;4-MQS>3 zqDp^q!4+&A7^!N*Bh_RwdCiRE+L%af$7d9q9jPO*%!yP2n&H6QNCnN0R2VWYh*a5? zk-CiI8zN=c7^y~^B2{BE@i6@Vwni#$TcjrLqObcRm3e=pS{#qmFkC>%6OlTJJtrge z44=^I6gl81rksw{2TVN^slc<5nvXl^eU9@{j;y9L||3${*Gd5g~ z)I9`WVP5pa-&l1$QV&r4W~7pC(Q~xHkb9BZ_8?OCA4V$VF) zM`(HJxagg0&ZhfXq2|$Nm!H`dZW}9i;zD&O21<k0vfcVxkm@DR_cEVxyEdj`>kJK1%ik#$q9wr9`PkYLsfFMX6tU zlsf02hFrwU8>OZNqI9`XlnNG((u^YX1q+Ij1FjW|;%9G^o)wRhtpxYs2~L)b($&&Y z%2FmurixK&gwx1hDN4)m1vM*EE4ns~(!m~4>i!$O??uc$QK~kW-VNj2QBj&UE=tWO zM5){~=9$Tu)lpiC5o^h5UzCd6V7`~s5gDy-4Wd=MVYFJ{D-Jh`R_kA*^%kba(MrRw z*nqGm(VB}L2y7aycKC>}X3?sNd&tu~TF*L1E4oXx26yHDZqX_}B3gZLbtJJyN2@*N z;u1>Ch}J;loEfc>IDwei(F&at&1Y<)H4!)FMyu?+XpO`n>|PkHllW~>w1SsJbB%tq zR<4NFE5xpk){sAoIzYYByr^7pmTjQGbN~9itwIxD}%{xPq>?>D`?eokqZ2;@*qVKlq9n_sI!o z5c+_eAH{G@d5ju8jnU)hF}nSNp1h<#Z(`KtLk!p3#^@??f8l&szQ!mYdSSd`bsW)# zSXqs+%7~n%Sk*AcDm_!I+TwWTSiR30D?_$ebw+abSoIEz)poS?#;One!eiAiB33hf zv09GzI2RME{c*8+7#}NJ;aHWz!Xk_-%6V8`B35@%q*SczrDK&Dzu_{Tm5)_?g;?Fh zb9AXlyh^cJQaM(eFuE#vR*ThiEW!2av8q}(miKaE^-sN6O|BoS`FMwI4Pw=+QLOf~ zV4jw-s)&GAu`;%f<#~Rr7PpU8$qun{cZ}6s^zRj`qyfxlDX>hDMVfGN>jg8gq z^|30yIaWJSV@s^QpN!?2w^+Tx4=g?%t6$E?Y6t3Fq$j9!DOUBN%dzT#?ANIeu{W9H zVXO||OvX4qTN0=IcjL4Y-;m>8oI2wQo+AE!obq584&eeSJc#4}ts|aVn^I{Rw}+cs{ETud~=}h}V61 zjq$39kvN0Qrg+uGLfl4>f4qvL6PDl_ECKP#k1kk>%W#_GRRrxZ4`*Sr#H%1WVks^m zz#6Z@=!4a`3AZg?#n1`s(AXZY&iIJx&Ulq_#p_8(ygnc-W4wG>lHE-A&;W*%2+I3U5m#n zwnV&gp>64StwjAY@oI;+s9KKv%hRh$^krMT1|Y}wc$L6$MDHZdo_Gzt60fIs;#K}p zJnsR=tH9%URY2gAc!i?o(|CQss%P}|MZA7~$r`-k97Me)-#78f{g${m2gASddh{_~ z5uf7uy^fxIiB~mr$Ce-QdWnjD3Cd|mP%#X{vVa8LL19aR?A8Qj#?IgbeZp!_f_9;J zh6K$EN#K3E1oehrrUX4lc;*C+M6av~e7>6T*%DMIJLA0x{H#gP)$jz>i%3u>SbPZz zK@}{)Unmxxpb9YwJWoxKBWHqI=SomaZt_DT^esp(XkREn{a`GdpkIq5D5+?I3Sb+) zpii*`ohXx_J(Uvl73(S|XfL`}Nsy~vf-2z$0_!JeD&97ro`&SwDnV25x^)7tB_?PS zE~C+m1kJ>UnF(4nD?#fKH9J8w@W-+Qo!_3o^|uL{wkJUsF=B6mrXzG8{n<|q2NHDf zbb@pyL7Q<1Jv8W{g7Q31(1w=@3VW5HL_~Z|P|!DSBioMzb%f6^QNO}tNK_=e#zZB%6V(O7 za1~KOiOPYE7!sVQ>qzt@suQ;33Mytu)I^jCNz`H-$G=df!e<#0bi7Ggq zWB87pGZM9L9`|Fz{6y_XnFaKJVWN61O4R9H9N)`vY}m(fl-bYm1Bq&MFj4J~Cu%hs zo=8*&WIf5coaO5|)((GT()mQSxXe1C))m$qFHqrHqS{?&KmNxW!1{xA!6|$-B=KA` zNzd^OgH1`g?VrSF!jrTbxy(s&Ta#1;ezqh&i<+eAcxO-22}hFp1}AANJQ@~Te~FXZBNb}lQg+g67TaS zX?c$%nSV>tSRCn$3&?J3An_)@(O|m3a7?q?a zW0Evxd=l?JCh6+LBsH6sr0nyP)N^5y;ua;T^noM|z|DiiK9r{GBBIxXXIoOVYIaN&5Lg z64(8691)L_R1e!9(}O2TT7x%V$muKNko{YdYGU($NgDY*NmF4lC#wXGSd#T8`q`2- z%$cmo@XwsAad2fxR((9rnyl&BlJzJoSrOi3^$$;0frw<4MO)SuMOOT z4(i4xt6AP;ZO0Lm&6lj-5LSq|2rQf|FP6ekG@1WvlJ%luvSKSGYiMQitCFm$7~eQq zr!k;OvL+y;X|lRBOV-Zj$y^7SthKQ9Pu4!1hIv4;mgD-!WMvqYtj?p86*?wa2^cgx zS-X&VZn7@n9GM$cv3VPk8nO?id>mebO0C7 zJ#&hlVPcjPeGX4i=LpV;PtjLc5>gabFGWL9uwjZOpi|QnUB>HHDJs=EMW0ZkO^Vbu zMb%NJEAgny*F17un4-i*DJqQW z2wsw+?@P&hS&Hsp=yLK}m7=9+XQ=IbilYA}?(G!W@1$re8r@A%?7b8%dO{vg$-|kdg057R!@nrzPUY`| zrRqsgs-|R2)oV1#oT~d-Qk6Grs!HJ%a%SgiXsU*KQ)PKOnNY!QB zhbtvjmb6rbU_TObq^eQQRL#qks$X)a>dzvn8dyA4DtIh9gJARH;v@YN9DzeN$DXA94GqYRsTiH5i<#_J|vjssoeBe@dzrqs8y38ayLa z)n}%v88XdERoywM>b)dY<1uY*s(P+Z)i9)ONY$E+sY=+Cs76~a1Wnu_|T z={PQ7U_hE4nA7wYCQF)Hqoy@Y%N%LS>`YTM&chv;rorws^$JPT%#0jIwM=PRim1$K zdJ~hTzhcw0C!X^X(lk0(n*Kvf{xp4pr9hg(3#KUr(+a1lRgpCH#H^xeTJe9y)ASA2 z5^36kHwY`8rY;zOgfeORt!x^9yChBXDiFJBn$A^AQ|({URG>zh)?+tX)=X3J+G(na z#yE=2b<*^>UYf==NYjKy%<*fQGU5P&8>gu}7BnNjc4?Y|1*q7bzI33LPHFs3lcu@- z(s+%KInjPRJ)FQCs5y}wXQpvITbioFJUdOF=cVb?{50Lb_yuYDu$X=?Nz+yIU7DuI z#kFeqgH7H#kzjW31Pgj$S>1v!QozL#4^O|-#pV?2> zhAip2oh@Ajz3G~Sc_<&AuF(B^a!u3~tG)@kXQ zo1U&JIny;HZ@QioPFJ6z#4nw$>v)98WzzMbY`RS4(v=Z?(5ig8##Bz%W7MshF8^xj z{7o+Ihv(;X)xwEi(siQ-bJwH>7;7=6cDg3iN!QuB>DtjSUC}L>7w=o8YgU_dy~cl7 z(U#clh}|JwDV>=M|8+^%>~87&-Q9Gx>5-orZH5!$!cE~iE8pot-@z`|T8<(!96Vi2NV!Fa7{ja9`fO4wr!ae@bi*%(( zkt)4S=qbab=LC|>OlGK)1Qbx|Riz6bQj{Vc1ZL>cMXCr&?@j3<9i$_@xBKU=d%v}Q zE9R8_?!8aKH%ZQU5BuWLBIOr^o4=3~HUt z`XzDdvNTRpmc{AO@;K?|ICWYXr{lk{?J8ogj#FqY>(<3-_@+3W`y-AyndtkrI3;e6 zQ;!`SpPd}D-Ek_hk7Kx>m@I8K?3+zSy`X&v+n0S-Y(W0?QpW|Jl>P`$UtjVrH^Qg~BF9u?AUF$ORYSN;RowGm~~8 zM+=kuE!hSoThRv;YE8XqCT(wH($Tgit^0&L+ne;w7bX?&NS`{HxORd1k=n(iZ}A`e zT}`@)S>1@$!z3F{;rpH@&4#lVHGFB(t9~Z+?Qhbw!6xKy+&`; z7)GC_nsgVLrGjocX^|9Zqdf13!P0f0Olc{EPZf@4o7|Yt3<^0Sn&lhG5LxYZH zd2tJ~I+^tk#&%|WIJ%hi4E4L3bpy|_wwqZ6dowmN_c5ywrs46IX07_ltexMRm1VS< z-$TsWg{EW7T0GXQ4&%(ayuhqd3(e~HlUcnMne`2JqS|7!GJZ8P#{pyghK=Ni&FHbo ztXx~D8$ToSRYIXjcEjW{pChzs#z2 z#H{_t%)0ltS!GX~^(`)*p$BKps&L-SyaZ+qyh-oS^_H1)pUld7o8xiE%o|`r06~`x&MFU~VY+?Fqi(FYO>Y3G|S9vU| zpVy*^`7HW9zeW3CDqztcg)H(FvuG&Je`sM|MvL~MX9$<7SBrkeQKWC-xNNs@F1tldc3PBsk41y_ zTD0e&Mb0A@H9cz4#bX?clWdFUe_J%|w1wZiEc)}3MIYayR%BrG9g7ZRwyI1PtIlS# zs%Unr=H;+zB~HF)Rlz(~O)h3-&MvE_l(Fg1)}`lG5< zo!wR~LBwO_ymhM{BGG46KEtZzNmkuLda_k3P&aJV_!O&Jr7~`Na)9|WtFGc9ntpEO z?++{2=vY;*t5w6kw5sJ-#2s$cPslpbs%fUNq-)&aS-fmUqi&iDzA+lVuY80+swrau^tK#oi zH2}5#v#K$6qTD^JE}+O;t5U#hh$@O%c#+Abg_&)tn%$<)Q6h&;)$j}Q<+3q#l})#h zKetV13)u9yuuZj!*fhGRO%03LgVk)Y)d! z5=7!{>Vk(zOt9${a@%b>gzOHRR->%nrWgt}v8fyuAzOgFkU7~VE2f8S3Z~f98bi=I zmH3D>BR(D?u?2Osw5cREV_Pemwx`*2C1TUwm`yo5+w>=Lcd_ZSu58!MrYZ;_uDea$ zP_BnfCj5%Ry{HY3(5$yjQ-;}e3?sg^X)2t+fTJA(+rknFzy_iUSs84o3_9+ z&&Ij(jIqF`#mj8Eh98%cJ8G}6Y0S?yHCk!Yo(=TlH=8zKFG3q_TDHliw!f1XcH`h~ zo0{ygsRh1&NZn7U<0*AKcndne0Ag13~}aoEx<8rysqF8vfASH z0V<#_Tu4DX^u{nu!hEd3eGG3LuM+ln&Pj=v+ZE5}igUF^!*m3{FT*}5?fN_V#_ zf&xA4DuW#`_q6l(on7tw*|h=7`rG-;V&}JKyW)o06_1M}*mtB|M{o&?N7?x|$F8=c z?fM=2aBHkxEyme3V47Vw@$pQ%hM@I)yQZV*0=v>+U1;Z=G&|?w+T~eeS2HwTYgdoG zc0Q-t^~pZFdSdc^yXsu9YXk;fvTGx{Ubbrxx?i!&b=R(;sCUmUH!|O+mdAGO#}6;< zI)ovw>>7`HukBh2>l?egnH^e+(^(u`zwFT0SsmJi8wh1{Fn^sxbFc!hVae{0fnSi2 z!=Vh+&goDZdSND`i+M&`2yi>-ZJJ?*&p?{HB$)P8e9qL@gp$Rw$ zZ&inm;UPY%&2qfO#W>>BaWF5rLxZrQA>$x(BZumuy2YVn9BWK&3B*JO_QP+dF5E?L zheK7J4z<8m7j@$Yw?kb$4ps0u6bD<1L!aVu3x~>2q(;PM5ECQkIW!rie_>3t`qiOE z8ywP}=yJrNZ?Ni}qvU*yxM!&oZ&2WzL*{qR zb6jxvf{9jXWy#^K%# zhl<>!=O}cG`r*g7n0MQuns*#phYMJFpY;zM3Zm^JUL$z_u|q?jIkX4|UpSQSr9($v zIrIuiZy6U^7Ck6-N$N^Q$N&kY8{T$ zb?Qugr_MHTs!&6xa#)-yi_ekS#{P(ZC*G-Z$Yyt{I$ZELoT}g?PoGnhQ=IxS)u}D0 z*32mzK6|G*Fp>Gi2^6+E#_hk&b@QesX?clI`Owtui!rCR3{9@n#)d|#_enL^SV=A z?>IFH;d@REM4QJ>4Tt3!#|Y(KlP5~ZB{!<&bSVj+z30;F5-yc5=~BniE=@wPx=X!b ztHpYpH@TFnj!V&cE{(*bMlR+-a4EaZrP{cb;8H=mOS`---9zz^O9_~UZFrpIQi)`j zdSMnCrMeWudR#=o7A`fwrB*KGY3%vwyZHZDa+u(f1sx|b zE(%O$UsRgzQUD8Z7};l%11_e!^j?NbqvpHxGjc2-PfYpArA_#3iA&>=vC^fTDD{g= zUhH1&(!RCy^O8%o;JNBjXFNjoYxMJ->n{BX+YJ}rOSx3|wu^I`T#BF%7T|XjcuH)z zpSe`$xl6}kenGuh^46tH9O+j%+?rd|tq)7O6+kD9#!4K)6BI7xmKCir05k9#PJ=JA zRT+usjcM41+h|wKt+8lc)2$(RUe~Si_1wzW(5;5JZ*!|eyjxwoZe8}d)zR;kJK3#n znB2;(_tM;&5OM3Hm|F|mxRvyYTUpz=RTGOkyZJ2Q)~ar9*?YLTp3JR%U%GVC;ci_VLtg3h z23v3h=Mk9g){=$ngG@iU^(&G$Gd9j)(-!L8=2ppFEJK^!Zp}i;J=DI}t>}I?=d)7V zVa7woQMY#D42mA(IKXzotxxeca-XEH|F~7?j9XQ3>MYMu=OV`i6E2Yh3SOq~*WHT0 z&oRK>2X5WP*~e~WdBSqopSt#Bzm+XmAEZDnue3e*~Y`a zzaDjH=h0|n>gZ7=-0JR8!5$u+?(N}*aUONXAS`<4OAm9ad$blW`+C%+zlZCNJ!&|> zqeT3Lr-MAoHQ1wF|MTb+iVpLr7KY;=)c@9_9>YCajyoefYCX!MA=rq1-}5-yqZe2= z)}x*iJ!(6Zx^NEJrg>Bf0nEl0TtLg|9wq$f;d?`mcF(4^IUeQ&rB8ENH_s#6Pafv} z^r*}tkKUmD5)bF+dSt=d<@8|%%T{_c0TWlT?P`x|to102emMH8N1J~0=n|T3^k@Wj zY^GPpvc;nksDmcBx}DfNc#ab|zmvRokq_oz|2w-mzI!}ezv|Hg)|>v58ts; z$9?|$frmK>J-UhFk34FCX87tcd7|_aazSg1MS*AZ6cwI(l!DF}hB;{W!lRMc`-(iW zd({Lj;K=0_6}@VXUYK6lt52(VRiLU@TdR3>7z3+&Rj!6tmYS@?>RMjyMXdyskcfzQjld0ytf z@M=X+VaUd@{3)ub(6ZQe#5+r3)2&#NiN$?*g+PkB}T481?=RlW=K0V6JP>~QF+ zSA%l)CxO_pwhu*Y+tT-lw?6K7L>E$(!KQb?eEiVga-KZe4tP52Km(d8=tNY@#!Io{m-ZG z@DDy7=2I73LhEmR+Kht3eQJq$cmn$fpN3&K(nk7p0w0X>DFe%qZH!OvBQVy-_vb$5 zMe}j5HlO~&_docQZ<Nlw*re^|$%t!cyeg zPR(e5uGog-&<>yS!hvC!fIK^W8jIY!$Pba-KGojCGMt8UuTP1Xh8uW_9Q#>!z^9%E zeOhhp+okA1p^v?t_@o9O(MUL*fApSoc`etS-g7sN;G zB{{?TirTOji(ixD8(xDb_tvL@Scl;XEwAei^1=ahAQI2Y=%bT*X)M+ zZ^2n#?X0$ z%NbgP``A;ScooPKu1e%y+0eqO2ESz){B~u?*U-=>jSTI;I+wwB2-NR0)C~tw-7qv3 zcM$L!T82DL40XXFtZZtic7WVNhFT^XdWa^;hSI`@PQjI8@Ojcup;SXjxR0Nj8#1>r z_+El>TN1Ms`?NMxBh66Wh@pYFjeRlV;lno6kL0%Gj4wVhRQ^*#kFc|y!FOebLgG>!_ zPqE-Tj?4G-2{%w}w4v@ejUi*$1}n$Xr*Ven;wDnrN7do{;rEqzV=;L#|2Jr^#&-4Ddz-#*wy|~Ql3+Y!39r@Rg z^_rn6*LiQ{qOkUwfYGUn6iBJ8Jv6_XV-=Gwz~59ltstZ#};}c-YV{Ya_pEnpqFO)vt9Z zXJc%1!Z19+hw*+@L@%td`}F{C(bD19e)ye!{ed_aW22^rZLuCN;qdx35{Ho4M|^ya z1-OpV2C*;^f1sr_z7oGDA_L;24F4jpj_Cm<`{!*c!cUH#KtTfL5@_v zZ0L#kIFAy|{Az}=*oo(;-JD(^14og!gzl?w)8v>ev;BNs%aRv5G0af}vp#Sy+RDCab;x78^ z3+TxHfQBCkXcA80*`a{yAEr(`$KXE$I`daRKOCVK#{)8B>WP5DCj)AOj8lyBcRC zK5I}d@Lsl{N?;D&WDlxp&Y+Sj2bHx-ko!FbwF>R42h|5J(V}Kh|KJ|}S1YKT4TJLF zIdU}$Y8-BxgIvcH)O}}AwOm16!UKHm4syTypf-7f+K2MKpb78)QzHpjM#mji7p<)Xku-JqYT@ zM?npH5>)UR%brvF3-)^%)XY~w?mZFI!M8!qXA5ao=8zU;32AiJkh*0HDV#H;MtMW3 zlrN+e`9s=JAfyrRhm>A6q-fQU?pF)xO7)PA*9d8M&5-8R4rxkUNMlVQ-KrPTU-d)U z(IBLa4T;$(q!N~pZeXjGSoV+-oFUzGh4jV~(of!yPWnQcV}x`b6Z|2~Mdcpbz$KH<7W2R9nu9%+(TWcvNxpR`$BT<52@h!kV43OA*4c>hQ}8f^Adfy7E-qB zA+E^?X%B)oLRxw=q~^D%`)){YvFcuk`@@CgyC2em2aNkLq*2e<7yX`x^c@Pk2&v1< zkUo6HW2QtcMKp7wy5bR%vL@;^-piKAd9aC^nLSZeb0sQE?nD*Hm#7l?6V(h`;V6)( zTm=(#4~>d2+i1~5WniI_R6SFY8X|VSvN8ANV0mJOx9yq3WU|6P*~-Y z!`k>sSX4){a48rH&5k;kdBQ zOb)B^l&~~4tY$cgHa~{tnj2Q8d12jOO5BZM-Nj#RDFfcAEl~Gxl{$pr)pruR1HZ=RiB=z@{LZ_ z+Igv3xjR+cF=Q_>4y4L-IaTRurq-F7sV`pCZ>AhZGg&$|Q?X6WxEErY=66Wb&dzBX z+C5DV`=qIT-!vV-*9aH-<;d_#sW@#;2*lq%_T%oF><_ zG_G?<)3O<9`gdlUZmc8D`ZOKhkfz^$OH=OO(`3h(&1u@aB~4%NPE(0vX}WMJO+P(I zQ^vzIuFFc(hAa`evqsb)M?~i_JYPgj@<;SvfrttgjPU+s-NzA~bVu}~C!z^~h>m|9 zQJujN75FA1KL$^a=*+B$il;|(5N9zlBciIaBf5--cs(Z~(|qFNJO(X@DDM)UW&YxMRg{7RK;^dbr5GUF=te!Tv2UC zY95y3QHiLMN=6mMA>=LRmCj%rD@sFG_$nO`BQFPu>| zN{Z@yGTVfss^5xzp;%O-FsyG>r?9hMlsWgKT8CX2Fd(WD1EXq*JcFVtiPNb3ZB!lb z;qa)c;2^S%jH)e0eMc>@jftv1YL1O69(l(_xi?u_tz-*>!M$K zqUwwV=y{v%O2pK#Y)nTiF;%t3_?!__TDzD&Yai2mq>hYfF*e~9a*c|~hVL*9*}seF zHJW@MQy(0|>e0j+6Vvq{Vj4d_rUnyY{EZt^)HeJJsFo#iL9T^Kfo_ z&BOow--&CLGWHuoTAtrm<94p%Bd2Z2-|W$;!i|@29G|=Yp~2(6{Qvu9`TslozsLUr D=p%|i literal 0 HcmV?d00001 diff --git a/Covance_UCO3001/browser_profile_2/Default/Code Cache/js/faf61171456283ca_0 b/Covance_UCO3001/browser_profile_2/Default/Code Cache/js/faf61171456283ca_0 new file mode 100644 index 0000000000000000000000000000000000000000..c265a9c4d008bea3cc35d34f13e2ea6bb64fbf82 GIT binary patch literal 19324 zcmY-1cXU+M8}9LMGBu$lWKuv{AR#lEnM_NcN$9AmWGes`_=$7QY0I&;q1``zz;_enB2bAqSMN8gs{@#?h+s3>22(dC*p z1S)6xGqS5?SMg+2Pp|B+lvOn&P{r%1TFvLp)}FU&R%WKBs^3$|SG9VTDp~%Ftn7?x zS=m`ts%Clvm9wiD6ytDA!CC){^}m17g`Hvl+s27cudYb{aM&lajc`^Xl*C<`Zh_N< zpm1ThBYzczqs3uc0Dj2=YmWNL=^$iRh2qtqOG8-I2ue1F4N|2EBsPU~sVN_{P#-za z625*i}d=>xX@iZMVj214dw_~8?H_9=A!47z^~YllIlFCca#wD}UcO2${P zT<(p6cSl1vsWS#zO7>W&E}h3i9~nFWzLHlH6>kdsxK=e;2hJa1-A}MX7OjV+Ta?>2 z*dhldcRSP)%P$Zw$K|p#*#*0I!|yU-4=j+Pd!hDzXf3v1AxWmoZwKI%ES8uXQ0}J2mb>z=^tuIa{!w1H)n3j>tviY# z^Y6lH>3REk1dSo_%O=JdATEP6V$(C7**tr6e<=VCQFU-VVslw zNny;ihjGynMuXHa+Q@q8p)d9Fo-mGQh7p$)MlBgD=cH7&_GOyP$P438V&bXZWtx&h2fBW^_6GCFowt|+0`_Rh~{AokU8&$ zajC8HZy&}d9aKxXBKG&fm?b}U4&&APVRY*f#)Yn7Bz04)9;)lqFs4ik!!TX*oFB&7 z1PcqG+z?Njssy>4u#SGf6j!l?Q9tCKf*ZpXBfpUgz<%RH-)p#98Nh) zI5i4}Grmwb|4N_Oa5lw-(;^|9uad(#QX!oDlyK_GIXUGFr?NYo29oFrXQ?-wbYD1= zq*K*!{;U?xEBT^&I4>l>W;m;4vpkm~wZr*DcGU^TS2vv3jl${OB%HEM6-#b63#WDS zaJtBCncO0r0WHHZzpWfvg_F=Ooc$fbc_<%s3}<+!a7J|rr$Ep%23;E}woB zPW>U_+#DB9+Jta|^4`R7;wFXj&g5_oO5~Jq-j|2+*3@v0$yIqK2{Xg-&kCoaG?*LC z1u6M;I87Ia^OyAhCY;$z74zG0zFij1o#o+l{2`oWVqL4T<)Xazb2ulrg>y;P?F{GX z?r>`D31^XH>V+;RJrwc^M^{M^&q1;bflj|!l9(g|t&rUsfy;bxk%OqA2j4Qy{|Afl~-;&M{1O7nIG=CxPtI;c-q)$9Ysm%H5z z?C-7^Jq^V5)x1B`{!r}?Gw_K#{KCM0GVMzPjYkzS&rte#`gb*Gxi8ELlMz;e0woq=~(80aRuR~mS|%0SK4TCX*#r$qi>VAfBn zulRpf{pI!s0}VGCn7+w?X|sW7X(Ai882E6jfg9r5u4_g3Mc0HJ-K90yt?Oow)^@Mv zw9i21egk!mX-<-L!oar@{ioJI3>P#Xxpvn;&wB=bylbQ&~yNwj^8fok^vNm9(X{M1k(kaVGe72DknIY$MjMU9F(n@+(F|xgu z5m#*^ed;KlOsa1rqk)mRa=D?Ad(yU%k%EmCyNQvVQnR^H-?xmskU_1CtZS`p8zTwt z7}+h6ZH)|+kJ}mfrGt@2oiy(I%BhRC()|M?$Hdvq$Vc6cH2BcSR{5~Ek)d)=()$=$ zB5S2%U)4nX{Z%J14l(kXd_B}isn3mUlH&L`*)N4(8Tmxo{Ac8$WQCb1Y&G$5A(O5<6KCXaX;H+)yrL!wMwz%) z!NjN(6G!YOTBe%lB$Zqy>Um83EFXAH43e9Y<~K24R?6gT6LoX6%{37gG!ZK^E1M|W zNaM+-#wP4dOjui*=r4}9P2|XOx!20Xi8dxK$@GpU-pHEwOze=fPA2+xHgQ!RO22L< zPRXe5CT5AXhl%<C6|GNX@)5+9pr-`B)Z8Ps373@|ZKsth#IM1B$LVC5mFhiHr` zCXP$}sV1gQGwFSZiFjEy!-W4E6TeB(Z%uq9->)~3`m>1@ zYK!{FlCA2$)5Lebn0PMDcbixwfA7)$UK8)`GqFxy>^ITnSJmK<@;j_~9npC)9XHWI zmYpyWchZFUtcg~#@DCG3&Z$Nh)c!9M4P~vAxn!dAWfRq}n7Dh##AkO+`0kmgEI-Jz z`zH20P@Tp7#KaUi`_x3uXC`hvH{p3{Vu7rb<^L+5|4h7=PcZXHvct_RldbZf>@k|D zV=^|`eCeKS*KRTnc6UCqSGf&pe;4^l2eG^UIjuG~gwf25hKUz%}@GBZn-O0&6U=FBq_ zIp0ia$&scDl-ELyExo=s(`mJtbsLq}CNq}JX1Q_39{hxl-T4&IT4LHngxu3N*H`uZ4w^GW=}|@_El~ASupjtP+YznV8J=Y z!bf8*T#}~}HO|7F$riRxwQ%rTjkR2HWx5>r&cerAG3z>JzLeqbg$8D|a9Sf!89r^aLg_2KH_ou46+z{V0jrqbt_m>vdzS4YNTgZ?} zZ!F9Yv+}3Z4!1JVV8vy$l5e&$MvhsmT#K~gEnua8K`XI^t#puOMXbaXwd(g`D?7zf z%t{TLl__#I*2<-sI-+gQl+ewwenuFm4C#WVr8Lx zF9fW#PPg)NhLtnYI@8K$GAzr=QmK(`<$#0-t(?rW@+jZR+jXq0lE-zebgXCPL-|$? z)>jSsMCdq(~A9;l?+++kChU4)K9kDweqWk?rSX`Xl))^IV@M?Un%g&O7asc-$;pP zx+Y}k3oEBy>Nk`W9n6~W(fx^x8P z%0$q$toq8(M2#UdJ%kFKSJNrB52<*f-Mr>Sb4Wl+qWY)DzU92xZPgkeGtJpDce1QiL$Ln z1ooa0^y(GC1xf0y96pZVwKVJ-q3>T2`u-Kc4ham1V9>w_Zc2qg5e%0igCoe6yAn1e zf*8s8EP^VsR;GO(!Aq(5g<^gcLH99=CFXGv^p%?9BUm91CPdI~Vg$`6MX*j@OxB!d zMes(d%uy@}TM$7HS+_8P8H*z5y*PrxYn6xmwoZBc7{Q*OA}H{)@|0~GBDk|rYq43e z#JXSgl6${K@a}IBoIDUg@k3fenJ*^}s}83kSSlCg-kAvU&P7mPKK?U;jq4=s;s;e!83Ut6G;_YB=yQfGE)x8jhsk)xsiM#!Td;$%En5O zRID6{qgo`N%I@ls_-jP6tY#!lT0}BHa#}`WeOvpI-6|4$>qtHp-;yXkky{(0NZ%O6 ziA_-)*&IdjEm0KO8pThdiUiekp@C`RpzV%YvD4oUW}QS>+AQS^Hl#ZGDQIEqi7DBovM?3ZrOqnK=n=DaM6jAmGYXbwr8g3&B26wNnkKiSnJ>fctKXw&3O$bI{+no~7b?ajDOsTy_2q2kVwA5^jG8@)(PL0CHps?d z#V9eO7@ftpycqM=6yt9xzrPrt{$7k<<-(0(tiM@|uv^6#c()kCUlrqs{Pb@zR{mFv zXVQ@vwuQ$KVTj=$V+{YAVrXfOVX;^&F|?PJQp_4dRAdZoq(~99kB*_K46?=0EeI+Nx#z>ouV^TZT#%W26v$0lImQlMD8+TJ}df#g!*JY!4nvDWJ8^bbe9Fmcl zHoniX@m#j%+GrTE(YCUU?_@_6^{s8=U>zHAb!~hkt?S$LyO51d4Yc1#ePm5z8<(2f zaJH~fr={|H*G4y))6+)vUN$C4(+_PV^s(`tZ0&2~@*o?o!8Y1`YNOdu8w(}!a~o&B zuu*=vjny(|l#T0hX^c%DfGM^dpJHRoLK~-~>k=CSzqPULI~x%zY;;&@!?NB+W9jp= z#@eJfV%=h6`ZmRpdfRRMyu(KLPL21Ajdx|aT#~E1ZKUn7v2&k|e-9|;QROXTrN-|z zCd+T~^&d8FOZjs){=96X!WGr+s%m@JMkkql&&I>YHp;!S(cciO+kdgVl=MQe43+N- z$Fd|YmU}WbA(o|Y#qvPxC1W|36w6!5v0SYXi#08lCbG*H%Xoh*XJt$vmI@iMd?b@H zW2u;c=v(RV-H|qg^b`I>d5Wk~+om zq0H(W%a9LZ*(Yf|Vwo0Vsr+QGygNFU<Rk7@r#p_~e^kXb@#jr`W*%M2ly|I)&7)z-`v2>N&GX049NzLCi z*DJAXmAbcLNxUCR4_WyvmMyPhvAmAe`=~fN8sbqz@FODIBINf)O z*IKPTO3QI?2b4_?1|&3tlg_I_Qf$&eEU^{ z194oIb_e5FcsP!Kq~8&>JEpnGSI6U6d@_!^vf+2dJ{3p&={Oq7@^h+}+&dq~%%^c& zk#)rLbxb_BrLQNR9g^UUr(JqH`y@Iep4n12GoH)RBRigcx$*3jxvX;(5~|o|-M=8QChH-`|g?OqY0!J>$vvD4x&dvpzc3H=b_tRNn6w z&swS6Kc4Ub@jR9iLlyH2#T*{b^O5m%9Tm@yl0RDU$1DB>9iJ4>!RhhD%~0Rj+Rl%s zgS=i4&z^RY;(4N&=p=1e)X~FkkjmNx)Jyfr{d;mcT&S zSv`RRH4=!enLtme*C>IRvb=EuF-;TrTK<#@%@X)Ya$6=aQYy4gVB>oU7&|3Uv}*#* zx+kzuD)rE~Jr%E4g661ra%yM-PeyCpF$qLZN#O3B1hVJq_<{t^ElVJIc>0tvJ_{isMZ#&YQgAl&Dgi&T_t0aZdCoPN|;7 zIk&4U^X``=`ej+(5krAQ2F4_^TW&fMv3nEwSWZ<+WO(I7>NQSerYvZm$maJGF?UI% zZ0|%`$awi~a3W7+@`yy5eU->U89pwN-zFtuo2)qV)MtJo>0(`;NE2DUB@xf|LOW3omYlMb!&;ymO(Zg*9Is23qeiK6IDF-Z?NW~R zvSd&>>V8^|8B%&oIVMgj$2sXfza0IxmSctN+gXn2Uli+DIcl9P$5g3sxt#93l%v{p zZKKMQ5nY~X9m`YsgYt}%#Qx=3Eic74pgey`+cD+&PI_)G&#hhMN#9+bU8l-Z{8f2o zki=yP6iuRDOcFCCt4tFABqotjE(urpB;Ehez6^3E5lTy9rzeS5-XyB~l2|MY0!iGG z!|6$^$gmtn;5Fv0m1Ek;I)b%6V)O|4vTgiy6v8 zs?Sp2IZ2F@-gA=}Fh7Z1lC~g;LMs$cdi;>YqHXFg@9#;X)WIaWisw)gbxtQSUHbl+ zMAF41K9ti}llbL^`v0B8lRHVgd6GoUr%9ZDuDQKRVxv5Koy2uxGG0?MMI)1O7D%SQ zG%uP=kEmoe$j<0wX2m3PRXW<#Ha?jlQoeXHBV>1pWQx3%OqY_$+)7R+y@L8Wl6fR~ zsma`sx@pPGkl29YWG9oBlT78jWcF51CaOj<7n&r~w`DRrWc54A6zrNz3t8SrZ9h$B zkR*>uX5d7PC#lnuS^7;f52VogWJc{u=A;b!ReAlE%*G?h7>_2?=VUT9P9-y0o}Epm z$zRFLmz6iv{%$g*?d8!L5~{#_>0YS<8{1UC_)Y~% z^s7LF|5;Rl+0tiE1*)8?py!b)@cLQ>9^a@y{@)cCeYb)>W6&{K^SAnTjWk-`GG{&xz_TPe(u$^WG2nWYqJ+)3fG z^th|G_flvpAIa2*DY`eF!iq;JJe1ilQ`q)j3dS%yePpQYmBI!)O^tST$;pCtJ}+cv zUtv2LMeMAPxAP{!PLJYt=9aW`rIei}rR^jq=~%Lz^HSb!=a9st+8Hh#ymo9pJ4rH4 z{`A|a8?e(N&rTOf%(vr{CGt;2JFP3(`Ky*)UypWH)V8x(Ty^YxT-VN3x!lCgBl*6m zovo7A%uc`NcCO2Vc6P$s+u0%qC9i{>5gqM3k=&X#jftGt6bcJ-0Y4hQ|@Z%K1Hxa)Ngm+j!)90w&UIyhg=LHQaErpo$S4&Kyu z(4&rnpXxhk*TBKI4b{GpgL#b|Ty5geGawGS$|m{gZ3nMgIq2Tn!L>FHCcNX|)VmJa zw{y_4n}Y@29Te%|;8<@5@qHY8C94KF*e(MHIv6D>gB{!$>fpJo{oKJX5*X%S@D~pL zk>~Q>2nS`qa`2m+k>;Zu6dkSnWutsBRy7%?dB_F1EA7TB_X)~4%)6%ZDrAF2RGL^Shn85xJ?dDZgx<0i|Vya z$F@7zvctjVoesixY3yGeH26bfOYw6K9P-a!4h~*Xon^*VylF`S0R-wS?o;Z*Q`|j zkg3_JERoopRNl!=<&a#K5tUM@T0fO$Qlx=m$|O0{FqN8()K>O4Pvzu0sg!7&$`~2e zF_kG&?>(KDBNE#=m60+>%-vJ@=;KtrkWgQ>lkH;epGrR&BTt8={r}krQ*C)8pvSp; z&!jTok5pznOy$C(RK34U<*lcwbbO{cNYR(6w0M=uKKbEwDy`lq=D(>#{g+BxoGcA< z5*zO19ix*aCMPjwCq<*3v?!+I2~M&~IH@Iux11D{5puAklVB+)9m_cRuB?;diB7JS zbK*>LGFK8RIBA#SoZgqn(VBM>2M-lX=o&oRjzEtdyDHWW_`$HK#iH zdb*Rf(tU>d$z4gG<)rppC)2-ia(=0kdf#fyl^S2>e(z+Zlv?G~XX{RWm+-Z!ryP>= z(qNtX{^-Q~ljixe=D9)hl(n0jyx8ny_*N%Jc4}_BoRm22q{A82=B$&pe>pjR*~vv| zam~rgzg6#B%H_6`Nq3xt-E}hTo|Dx3S~Gbn<_As&$o7X$(jGZ!{zUVAs{Fxj0(drO%06 zoJw+0J=sN4ii_@c7k|nDhl^;Zi(zsv%|(XSrRQ5+Y?g;U7dt~Ptobem$eWrj3fFS6 zU(QJF+Ab#5aS>M6Mc?`^A{w}8*wDoeS=`jcmn~e(l*TPxbdZx$qLqs=a$9D$c5$(d ziub;FI>owOcE<(S#s4vz7F5+dhG&$trJt=kAgqO)$buJ+VZ(iIY)sw1At61>F=ZwAxF2F*hkPTQ0@8X=HOVHP+3! zI5&0T-K3Rp)9)=e*QG~kH$Rq9n?yI=E4W#g;-;M4O_@|T?>pUk{@G1zRX6Wcb8|>u z)^O_{nwuYFRXsOP>bvRGz|Dk4Zca6JQ@x3s#ckZ&ddH2St()5I+_aF-+q?BVvzx4r z%2Q5s)!2hH_F%W}rMdOKz)k)LH>+jWmu@0Qxfvvr$GAB=)=jN(Ze~t!b8(__nxyfj zYK&=ap2@uFZm!O7^FaQashZ4EJ83uD&3S1!$ISt$I@iry88^?($@$t};HK?D&0EGT za?@e4o8?Q~Bz)s$uzV#WzH@VMh1OuDa*%4@yBWL6%`7Ro+Rb}wRIl|~v!C6}k!4bS zgPT`d-MrYQHQM23jck<)J5{?~io4s*G%2vhP2;_8evuXe(`q|zBTcO>wKn-YsX!!Ek{^)EMV zF1hI{Pb7H7%}UuQ-LJVhE_ZLZiMi=!i`=^H#(P&|OZG!ILm#=hFK?vcW7SeVe&S~H zQ?02Cdgf;5b2oKgy18LV)8`>+%$GHhX*?^C#`^`+2rHUK&8RdiacMj)scoq=cFHlS zQaX*%Wzu*ly%N({UoMSb%coH^IgKN!+NPz^!jr~6x#3GA+MmYTfi&WCv<;=PFi&mr z)A+Aq8r3T+W|cI(?@gm>UG=Y*#?0nvTx^j>gO^8jCxnajSD0t=>2UTHM{Fpa%(P7-^k;TV!e?@!XWBp(e=qr`|bI*d%? zxco3Gjn1Rf_Omfjq77wee9!f=c z@XIfSJ@kw5@TF9;dG!6n!!C)8^Ds!-7Wc5UgooI-JRB(RAv)Q^Fd5=hJC}#$X&&x- zJhbzAI2iCSAl<|E43D05_wa|5&Gs-!hE!7f${MqZhn>>6s)yaxJoK)vTxuw`MAuSm zSytb}y#~s&nTOJCHIH_hhx{YMI(sP8(?io<>M!Sddr0h~eEWKEe5!b#d3Zh4!-V1L zGs2^vBN}(K&X3i6A3k86L{d@-S5{%=VBp*TXdFJ>SEI z1s+lss*RLiq&D(+iHF>!9z8qbp~|-!Q>rZYuuclD@zCT4jVm|TdGP$?VWEuJ=)tu~ z>#*6wRhhQU!=Kx=CObX2fA!G!HxGfMT89%JzB=jQximiOVb&iWo}Tj%I`83o`QoC7 z-~RHDb4mHjjq4ufJoIq+k=j4@@YypDd!K8(e?9Dv_ENK~mkEhp{*!{`yzENy5?R5^ zAo)@fQ@o@}H@lbB4lhqry?pNSlH&F1?-;yXl;=5K@`E}rEkj-wOVclvi}W4k zC1bRgd$M$lmo{U)#EkQ@UHXpq;+o*)hRmPn<=;tO)=gF&rg+&u&&%ogUfy4zt=wLy zS}oGK#ae@JR99Ik#-*y`w_2lRUQFM4b&o{jtn(84qnF<6y=?f|OO=gY8gKP7Ynzvd z?TWY4OQ~I6#> zXeg0o)lSCBi9{b&%K7M>>SLG$oj&TyHZi$<^pypEAJ+pqpYG#swvY5&AKys(d>_jy z`tVm)4z-j+9UtTB`gqmIN986y)=ErsAFW&XI3OKb`Sd)okH9-R*TKh&jz0bEmXGgx z`*`q?;`Q;-c(9LILwuC~RP!F|Q^5}ep4+D_;@5ahcv!ym#2q)^g80> z-*d|MPan}2G-sJ0=j6a8A7^CHWgk1Q`0!r!kteg|k88@~hH{ema#z0j+sEyjKHA*! z(efW3AKvxx^F1FG?kmm%AEh5@?8mC_bJh2SkLE9Zbd+UM=arAiuT|4GKBoWcB6WaRqvqyQf_p_;^;&t*fwzHp@9)4Q) z^mDzJAKL&wZ3g-|C~XHT<`6%zpZIC;xu5C7G{3L>3?J*~z&Jm-me2j{ zmyIu#cUXXZh5&_40X~%}@~1p82QXU#?2w~U*&1L}M1a0U1AJd9z~j;Z-YXMeO=5uN zo659uuELA%O81r60_oo6Z z>mT6WfB>&$%)kJ1rTL%$o#l*_9unZYPc-JR00X|zoTSR|fPNnhuty4x3^3!%0M;=9 z8jKCFU7n5)5SplY%a+Lj{rzPC!_)v<<&fl03$RdbOjq0)IyW;wj2xB=(r}hy&JJLi z6Ch`9fY0Xzcp$Uq2e`CA_4-=1UK-Fn4#kw?(sEURKelPi?E&`hP_BEG%f0|<`vdx$ zqJTaxQ+*F>o|lyW6^$XsCE=RpBp+N4@WYJ&!J7egKMGLbNq~46D<_@?c=x&LZ%Jp1 zH63R}IZFX`PhL z4T(xlXRn-<+fu}l&Rf!5YB|%H=t`%jJDs1>(n<29Qz2XXIq8h3m#*it(+M_6C#`Wh z{hFlHwPm`VZBm@~G-l^?KIoB-rDrbT-SCjp;Zxr?YR1#@ViMcBC_AuW~w(&bpK7l>0rMg=dui*>qa`kxums>6k91 z^M^Tuvepb%Mr06HJcF7gGC1*82Jd8Kup~2sGuau8Xp+IfrWpjAWza}g%kd90Ncbp& zPX=XBdr=0H7OVe~3}U5&tokm4Co3|DTrC&X@2?C(H!_%AI+IIfGHFycle1MaDN`+z zf^{>=o0Q3j$(h`ooymurGx>Q-CY85ka_wLy&cm6^mBN2!((HUDd*sUBnK*7`GF!^r z$>jaJnIu2Xq;I(_wv^A(eZ?$(b7v9d$>MW)kefwTD2rv%yJ{92s%4QQjzSycQii$_DV$QhQ!cd}g;jn3lk%q-GpXYq|}65E_C z%=5CSH$RK5a$LGC$zt)hS=?HdMXTjm^peQcS;Vf*;+=I_9FoiOWOEjAN3wYLXcmX% ziVQlX*Jl*>k1R&W@xQW2xU9Tn?ZYfyJj&w4%Pd`M*_?J~lbe~XXO**=I8ysxW;1lpH9wZ&y;M^r)E=II!op0*^HWz%?o*NMK&u|W>ez(Y&P$JFn-`rXK;=ACS&KF#LbvutL+$>v(Y9Gr!7$SjgWhnO5H#^&f}TaJFV z<*?Y1L$TBxzVYXorEHm8x|GeOa!M}4o9F6% zQm&ql$)%y}eLI)i9dhx%m&?Phx%@spm$xS7GFCocl*|6bxnwO-`=z-I`&Mnlye5}= zKjc#IXN`La^z~R?qlSVa3fc>)Oa^@S$!*)Et2_9E}!1c<*sbHn@iaJTnfu7 zdGa8aP7iZ=@gkRsuM}4{$bYYM>GekWg$F5Q4DyNmYzgwOHAv5hATtUFxlkm?KQgUo zkUyh>)Qt{ODkjK2DI6Q*Q`r+2q+mjj=cR+X#}U+hjiByp1Q{yJQ`E;EWQrq*AvMSd zcaVc=L4uwj6#^P3J;-1wo)M&dW{_jjHaE!9V362QklU4m_^Sq4ELE!q8B-(3D=APb zNaNZ;evuJ%6|rK1k;dirYCzYBf={niS-wRGF-rObPN*KAffc&JNOVp<*sp%q5B`1-=QgWMz=OKWQC) z);h?D4T`-{u{Q-7zctA3+k#Zv9;Ei}Ad~h43ELZF_<KRS3~9 z5Mpb32vX{+NWre7l7vfN@5HWQ^43{tKhB#a=L|*+6hK3<(Hwv*y>`g;_*et|f zvZ+;wciM#bKw7^OV$r)HR?CfcA>188%$HFeLmYiCM8!^u-&ygyD8B6J7NTH}5DBtd z3iJvQFN@^nhasNI;EzK5(kH|b8TN6AU;Anv(z9QPpZbUR_!Di1g?Rl%h=}1KJaSgb zjMUs@v>f{~M5V7n)R!+MdUS}l$0(MZ66aXuH!eingb?LriZC%mu8frvlR~<7LNt`O zr-WEIHAK;As-@hKxzj`374ysx##tfi%nq?x_RHWo%71PM-@Fiw7lfF#Fht9xA%0vH z;??R9;TuA{w>!j&J*we>5EV{oZl^=MI1^&x`4Fcsgs5>*^ZQFVTn@2LX5CTk?<${r z%H^SI{V1frSqM?+S%{|3RZ9t!&0}z49yuv_II8E-yG93mL=$>-bTeC}4r z=iQWi-ge}(Fg2e+zI@7d%BM@`e9p*)9{D8o%4eEXAD+*+5&684<1_L}n3c~c`F?9Y zkGJLX=Z<_%oXV&8nS3fp^|NaKhuVwtW)&kZx@a2U)TEo`ssgr`2YU>AM)wjcK`qY literal 0 HcmV?d00001 diff --git a/Covance_UCO3001/browser_profile_2/Default/Sessions/Session_13425390201372580 b/Covance_UCO3001/browser_profile_2/Default/Sessions/Session_13425390201372580 new file mode 100644 index 0000000000000000000000000000000000000000..3c2576fa363613fb1163b2e25441221202b00417 GIT binary patch literal 55501 zcmeHQYiwM{b-t2qO0pf>iIdtc+GN>Us?dnqySv<%VMY{bQ53BQ^?npBwcLleBDqT~ zm!v4Cs8S@Y0H=U{q=3>tRgE@PgSHR~w-A~X;13s&0XJ2U0BzAAHCiN40UH&JCUt%! z?)S~i(OwRBDRNiK$L5Z7dFFNJK6cJI-<&x!_vpc+M;~zVFpG)-)AHcGVJc|oFVyjs|zFUD#i=h+>o!sv^j;dm$&&&0z+ zsZ1_0)R|1=h7zf4c&IZK%Vguj@mx3&-QsMPJNUTsDY@47PQTrCV5~#|Mu(PUbPk;gd(5=UfmLZv%a8cTXag?AhJf(YI%JxTCYTFWQlG`$8R&P;V$4 zizgzAdt=*M8}*~%GR_k?Qp3fm@=L>Gslq6;oc$>8$I*^> zH|X;!*KwY)D1QKkt2o+lTw%f!Zg}F1-t?qdU&{aX>AgSt#?dzC?+m>w^)^UE(+^E@ z(8`}*t8$;4O~I!@)pI(-PSKfi%FauOjX5c&;P8p%xum{L6R5*Wx;Pk^UP_R5rLLV0 zNI?xM_aWy=dJy&5EptxDiQ`G4PRvQ-X*!UTLMn<_r;~BQP8zWk$~sjnjk*yhi~J~R zX7RTZ&y-y7{L=m~T2G@!0{>DtgRQzaJEmeO#5xg6pv??g>rgGas%@T=QP<`5_*+Xr zcdFXw{v`G-#VArw&iSZDU_Eep2JE7v8yV%V1WuP+mQ)Ld(^<`MI-`oyGpTGOnTZZ{ zX2Rg~h#MM8X0nN)NGzAmX2R)oF60_c=e5A;a;^9O{yXXcz-p59lZ|cvi|3VOHCFpP z$}i$*M`IJ9&1SVf{j~#%)&9)T=lK)}uAw^RINMG7vXw98LhY{ETvofcOIVLx)EneJ zB(GLlScv5izRn1Q!8k;LT|XcV)u7&XSVhuBrmsGUO|W1VO{rr0%wbQo8qUd2hU8a!IWD)Q@$~=5sO#Yf8RwsH9oPZ~=RdhYOfw4<9L)CnjGC1}{!d>`WJ@ zQ-yREbUcV6Cj%}xYdGRm0~|5O#ysJ+C(h`cNq^07!k-(eBt6Q6GfXw-8N&%m#z-cp z%^=c~q(`vFs%J(|D?1a;B$Q7O|1Kgn;q1h(SahcGTNDt>n)Eoz?RKO+p=_7ec5yH; zy_6vBN?ki0kb)Xit}o|FdJy%M1V!)4;$I9sGOK!iLh%6=M5pS9R7zA2uIi&n(-+x4 zLwFBqD3HV=J)i9+P&a|vRDK;eBLm7-$zxHp+kx}rsKaX}R9OhMV`!axlTa!O?@n&r zK{tC~zxHRikl?~2Ei-R(%2L6a&c%<#~0D+QJ{iOzvJd5i4&|9YQ zbd%^&dFLFStBhV$astkvqGjZap&o(WoZ+Qg4}q8NpiPF&yk`@LU4;p3Ug|dWPFZxq zq;GrL@ib#vUI@(C$JM)eNW5hCVPgJI;P~iMKf8YqOg>%wl_v|S>HN7=IbSU7%k10m zn!0o8K)f$zxaKUTmlEXqQrAugq@V_s>wgC2&*7*cR~N{VLDXFdUX6k)!{9|q1oCzV zI5h`;)LM}GjQ}!T3zI%_;sRujatHEG0grri~!R_Fbfh(NZO#yDyu!c=qf6Qa5*#6<*lV_DKu? zscV^JPZ#c1+`MxvHJmP%h)lL0&! zY2d)I6Y0!UVLa}p2d1Y-_8yCjq*BF#Yn?hYp2a0IT}Q*w*tS9uV7aS5Hgjw+e)!Db z`Gc`!raaJ_cc&&J;mJekNVaD%-a8Q6H#Kvt7|l(cj_oP#ezhlYJa;61>SX-X@mJ0t zjwZL2vYC7-n=TJcmGWKc@wY~HLwMo81f9)^AK6V*LJK`5X>y?mm{INaZ zwkOS~lz;q<(I3+o^$A1OFcIa?KdMg_>YDTwL#1g;U@qXO1TLofoFySE5^$$7O%c%& z)5#ctV}c_1m*%Sx@KaFnHw`{hs9#2U8ay1lUxVl7olD@oU1(_x@hs$N*%?AC1BvRY z)Cm#u;!Lnvn*8f6&|p_bgY+|MBHmztZpKMnm&{T@LZ z9qQfk{Sp}vp%WvdR9iacBF+&wTPJ$ws5v$7>8ZJWy}7pa=GEsvs5%Ccv5!sp1Di1r z)#34{+6JHUQPO%qNxy)fYd<)&f*1mj-uocq4>$qvb^vmkR-yu8v>bf}Q;%11wBx)h zpp7D`I|fO8XegRhBknsuYYaA`dd3)#w;LJ&8fWM>^qQeM_r7sSk_#lAkEnb^jG#K(cpR=DyMO@$ zK${%5aFRZtFfOq(#~*rJlR<6{PhA3TWVs;SfU=F3kdsF#rCtc_22{IUK%w?^zk+Mh zwp797dWNQXBeH<=8@M+jbdJdKcnXfrXutnW9KUMbq}<;e)Eg|K;Fd~QLuR}p7_yMn_T?s^l5OTS|_Rns6FLHNP<-cTd_ z9~yeqe0!SOOQdI$bxaBe}Jl?S@-LtDCq5XPoGK>W1H^#UElafFc5i#i;C z^dKjRafb^^M-RGs^x_|9%=%Eywm*mK$aPn%KgjjlaW606sA;`J8H4@%3?h#sBaWZa zcve~|X^-G|h@(&)%c)$Byf~Z5xr>;3Kde8DbNQAsI6qgjecB|VIFs*@a~y1+lw&;3 zgmRW&w@<4n^N8R$j^?jGr_mo2$N$+_8)p6(C*uTd*}EuuAYhB4;;ZJ z@O*re9e4w@NV7J_ml6EaDgIUx{1N8bx6FPm^6ai^vurZ*6zZL2n|iWs;z@s4*^0x; zHzAjA;-FZ*0otr#`R~4`jAEmP-ZS+! z8{?PI?IwNMGKzVcPI{RhkKAZ zT4+eF-;Uq55n~jWz-Y%n8qv61g@(qIad&WG9HQfcHo8R+(~bywk${Ubx-sO?g8iNb zabGXuNTM|wyl6(F!y(O0Nwh*!8_jRp5t55;XnyCy7;Tt}BSohOE*hXavUjk^u0F!U zxa2R;_}UFPST2rc3qf(M+ofFOjxn#x4e!incFrE^JKEoWao}7bJ}{EqpG;mTo!c{! z+1(lIo0&-zlQVk@+4B<@(zulK-v=kF8dvOTdr9-0zuMAv!}n}l7oLsFowI)rbLn?+ zkp12Ttydk0mt(Ct`&!18v(%Lc7cF|tr0*H3Yx#5bz89qL1-X)5khVIMx!_uJ_M*-g zhZAdWy=|lL!=DTDS1B}Ol|lo9QfPDM?MK?)!f1?xQYQD~5U|NXsdq(+T8U9C1t-f> znb}|@mh5zcixp-)iMEw_W&?|!LxFUEeJ%`VD7J1rh zVHod+tILweqc=I%OmNV~)nOqFpE!_8BUY<@4!7vrFpN4JgmJJ(|18};eIOX)N;N&S zr*}I&A~>X@=Rg)`(=#3YLvG#S0IeB3lY9TG^9Et^N@dVxQ)7loye4#U z@zr|3(YISQX15Z1RyC&}W1T1RIs9nbewY%P1%#F(`F23sZ8wrH(17F!|qiC}#NFR4>`m&){4ZUILoT0WD9l<@iI97VK4f{9c#6fUO0LKg_ zVY%MHzCT%g(uukZcDcwJJD+KG^#`qLskMsc6`adm412Mbo#RqYNxHaGuA_Vf_qh{y zPRjzn*uy<(-VU+cMQ~xN4+qp&;hE{rzBLcjixd|y zZ&Q|gxcVPAwapoP-wdv96yJXtH+2O^JMQ{2DD^di=x3qwny;da&vAv7JV9_|Ei=Mx zgYRvLu-V}EfJGA~eRbX8`}!n;{hpU=M!1gOq7i(5n_vY&%s2N;+IFlI1NWf8?IVU> zH1vw0*A2a8sQr8+xR#5<$M<~e6*2Y_;&foF;QKHnsu$mL{LbCQIFj$jU*h@{+(mV; z-?Q+oozHY5;}9R$>-Rk$*P9=q3X%6OMRqzM1vRMrj`id8=4y1#m~zIM7=XKca^{t5 z$mt|YU7rBAb1s#LfiBT>dDS~(^D_?A{FIwbm^ZDW(SNf3}m@`hG2&-rR!Tny_``(_{y z&F?kOG1;(rt~0Xg=DF96S?Efr}>YcY~p&jIR4V~ zM`Ip0po*a`fj%Ux2;7Hbo~yz$SNA{B;|24$eH8@6+mwYKuJ(BJG=rxrY7snX#78g>vzLePMfE3iAa{YQu1frbLT2A2-joLZpV>0A-%GW}2gK2N&PBaT6&jz||t zv+Vs%ZFh~Spcx{iQH%eZFb~i~(2iTZ(L__hoU!=ZV#YP5fPRafHR)UH&Q!2EV&*!2 zzeY?2BId=j=dKa^N>iilfU(?**zY&#vxZI>dfCuxhTb$(#FmJo5wz*z@Gbs$2?+9D zVuzH{{TcIO(F+C`6WGm6QnXjC+!He-#gQd44K8$;(PGmMcxmsVJCdhss4<05PHW5Tu--G9?#x(FpEo&m+O379<5onOjeT?Zk&y8j{IM?5y z)t_3YiGbLJAe-JjdI+CHovb>GD;aHVGKhXn69IRa<|PF3TU&ItU7uL1ot}m{@bh|AP95bE%yhUXi{>r+WZm&-w z*qpM`<~e`5T`~22+koK8l{U{2H*!k5VxHsnkY4lL5t!pBH%pjor>TzHZ!X*bL~y9x zubB4Da!Vg)$$MNJ&+EQZ?XSFlDYMf7DX2l^`t^FtHCvO@x0cv|Q)~3crPk(lr`i{n z%jT)c`H53*gGz5XYJ3`#Gtl3hp5tbyP4LC7qRBgc^65QZO)h3R(eR?lCC#72<1M!q z)%Qw!%h~E%)O723%lYb?-QM?>Tl}l;waiVv`u5Fngjf7}z4vSL1@<~SxBHpfL*e?i?hj2Z5mEo+XW8LIWnaWr>vo7ga5a{_Q6TcdLq$`tfIKgLQ=cp?U32x13n zYpu~~c;mu+`qyWb0gpa*A)Ln=L;x$H(ck>i(Y|VCInnf@(Irj3^6YoD7S;Gld&}8s zycNCWd^PTS%hkIry|2b8G<|P5fmy3%p7YgyWie|#YTpdxpFmgknCF;WhIua984u6@ z=w~9Ch<+(Mw;rXqHQ2**^EF;j&qp z`RKLB?dX#*1kxvuV4gc=(Nq_21k5j)XI}V&Tl2s?wGM-Tc$>1!!_^*K-wdv9)I7J+ zxZais>jT#}Un1D%6W=^X15^rTr@V6s@*o3aR1SV(C77cE>O;)jnk9?)H2#*5!;dYu z;y$+Ad27CTZjUm~jUu;SJ^MJ`Q-NX!!R|+5REE9Nxy!j`rt3$(;!LCIjOFv%DFOy zoJj5?mS=5pEGN^$_xqLfr$KZQu7aVN-Nh9+D$qOO@?4Ik*j5Br*5d}6@VN<27I_>` za79i^@j55^V-KIJtMJTsM*eUfS4%$^Zni1QJzVX<_08bw^@i(hiO_nuzCMXyOWqym zMa%hG^>x(uH>p|wxV{^|)PX^AP|ytfBK9ZFIyCL>wuD0JN5;<&YLu+7T*j-;g_P_0f72o;lEcWgb_PYZ-)_ZOSr(>&eER?^85` ztBK|IL9^3pISE~#ch2G6ag%9&UUE=TB7iZ}+kxeL+i|ob9sq50RA1{;u_GIB0R)@- zZ|HjQ!K|eUmy3|7;Cv0Ua;DFb?s}mbm1ZZ%BUoyhqe%K{!edmtECii1YP^I u13&E*{PGQ5`?HWMJeTqb-Be!n!?6WckuLxFUlaSPVFr;pB3&d+zWRSARg)Y5 literal 0 HcmV?d00001 diff --git a/Covance_UCO3001/browser_profile_2/Default/Sessions/Tabs_13425390201779235 b/Covance_UCO3001/browser_profile_2/Default/Sessions/Tabs_13425390201779235 new file mode 100644 index 0000000000000000000000000000000000000000..86597ca6bbf5469f70b3b10884964f35f5847dfa GIT binary patch literal 59197 zcmeI5eUK(aeaC0v1mr~_MnNRx!9?;%obNEiN?sj-fp~osoOm` zAVx5Skm99Is!WhnB@mMe@JEUyh9cp>Gg`?~Mx()0LTSYc#(2n!fMT$cNWP!>_3!q% z-Wk~4*<0AXo~_xQ?&;~7r>DEWzxUbx{_We3&a&*o+3PP;a@pMTV@*nr(tgiHe{OF5uNArajY-wxmIRC=V=HB{+tabSU+4LL)&E89^{hj`VK{5cy0Z~IRkQMSrS<%1NNKl@2C{Y?_3DWKgITLe z>bhn?M|GX+Uhw<9{ZX~utGy!|Qv0oHp;NgowZWabmC}BXTI$K$=Z+nD9opx}&hV~% z({QqP5skSkFMMJzquw{a#>-y{o9C&g(fz?Nas0BM9M$wA-GX9@ibnTu>HHq;jP7Zr zhkJBy{N>?%bT^0ev@m+>(I`GUYSCN%rv`ZaH;ByDVmDxUAxF|(mlV|h3qjm!z=0OPz%BbU+Ip(EzNplS{2xLM0 zPmlK2{C+;N`3)L=g=6%e-~D9aZ18fQ4W6g1vyN^$Lm1&Rf?+*2J3BqIxus>#%=D(A zsVfF1heni6w7f~@wrcUaLXSP8*D;>$(1Xruaom;Fvi>}sRmo1(8`d*k9;VA>6{gF6 zwbi)IHD+|YKjb%sY0?tXeC5?SpEjXdc5;{|Ic|EP(s=gxF!R^RaL)Tizjrp9*6-h( zwdik;j;6Cs8XQyV7odSf&+-#GAGhP}c}lz7yRMy${9-n5*Xzdlnx801{r-NP=lfNk zX~FW`re9)%a8v_xP(yZ5d8S31{+Jd6%6F<(bAE0_M=bBd+PhQ>7$|GMT{YS?v}tEV z|Ctt}x(;aIN~Rn4>{QQi)TJ_>hAB6sT1>(L?dm&!^n6<6@2F(_(iOMu>-m%e#vBD< z^Kzdep67I+wm#HAZ4Gw+%NJLW+WPfkYRij@@MyKEtry1xN?G42vr?O8OuQZq@($I9+G^8~FPlhhsyV6}w8g}0 z)^%WqO;jci_%f)pGrto@!>Ti^lu0_I=VMAO249++{`G#JJiKPV#>;*3c%C|7fTPDVbc1;bAPwkxAan;YMz3p0*r?eQ)6o6Ar{ZY#<5qu2^ zxTe%MwVhK((&C&SyI^i4S4G7&R(74=iNx9hRrFno-jkE8)gbz z*?!0xZ4Z6o_9iHOP~vmhEV~GJCp%k0NZ>Y zlAje9G^{>q(TIUAf^TS1sgVQCx}Kxm>dRTBEvf+z(W!dv%1xB?c-)`fuW|WC{f?i} z{?eO&s{aSKm)eW$8GvfLi39vAxG-%DS}`%2{` z!L^}$e@MR;(gPvQaYk*{Aj7oPLkjQ92HC>~m%w&yNN*46eIbp1-s?WHwQ|F%F`B=%2_5lvAjU>?41u;wC5-Dyw(4@UXJ6n9d?7dNsq0Y1I(f{~5Z?~03wZ-SVRCcQN z^Ro};zXS@oQ%}k)evh7WQ}$l{a(?F}c@My=&lI$CxSr4ZZ@Y-&TK21Yl5zdYnFYV& zaNWPG-Lmqk@59^eQ6D#HuWM%`Kfk^9IKZFR!!eFZux7#g>Q`MzVMtHo4Ixk=Mn_e~ zs%E5WYmTcu8r{Y#LMDT%t?ChukhXyD@woQ(A+f0ik2s`ykk!NbGkHvxN{##;&>i3( zA+SeOpIHE=_v(MIYU^G2tI3zBmBv+dMfO*g-%mxZfx2ejva-u+Ma6^Vj96_w8PtTMpdM1-Somfcbw6X-|Oj{wN&_ z`Tc7S?irSA5ANp}oZ9{^q|b)*xB%B@hqNc8{UIF-DZ)Xv8$)_$NFNAkJdVaxx2`?G zJ-s%+cJ=A_4DIu9k2tOo?wxoa({i{|XWo~SIU`y;Cq-4%n1l*udr*H!y_!|ttsQ9?N)DK8M8!P|#$&(w46=gr2nI&9 z3JmEF8P|ZI-pC3VCjp68kdE}s>!GVHhat|;uUHkbd+0QcWow_JX^Cdt}^{rv&v6PM4VHQNEYWVN|` zU<62=hkf*3jj(^IV4lTxm$++40Ax`Mr4$M7)rs1wk~iLuycfnpokq2-SGY$RWpYq} z89*P*^JcYxjGQvFOh8=)hYopwgdQ!hX>A8f;eJ5Za|d+F*hZj9hIlYNK$}PbjQ^11Oa*hEF{`g7d^7xg}<7W;qoI~9J zv|nI9A$8O)@%sZj{(@!J*F<2Ctuddt{Q3Uy_g$uJ@qRl}VBa|IVe#DqIn1Iy?-k)` zuy4j;Mhd`(W2J()9g#d@evG;h%a_AGmNFQ2p@KuikL&;<06~6-u1E9_*dt*;%-^lM zjH*Rcr;ry&0lM_J;;ZQ}@B4fs?0cST8epGkwglMk?C5SgRF~h= z+tb~#wuSpmzhk=mqe8kig!|~Suv2_FT|TzDW|NYH`&pKR`^(eiZ`K;|R_%?j-x0z7 z1v%({RHYZ^-2Q|X%Sm0s7Q?&4Ra{O!!G41McwF>rTp)Z$kd9RyMy{BcB3{Sp4$dB{ zY}P|yA7fr%xvu|c=Ueq3s5TFXa^XHU-=o^m*aPUM9&qznd@JDg;s3EL$D#lW0LTEW z^0*qizV0fpzbJfFS7fKoe)kJSuz&3Pp3lhv7w&tWYZ_o5^>k&}Z(rNo{;2`(Pg}RJ zj{t1#3HKAX&tzQ)1FOyL_vsl9)#;;CJ(SzOL`x;2{Q;G4)519^F)2p5cvZy9c!GW2 zY7+7<)sznhEHvn*)d%c>TysOjk*i&BY&v(u?q-$`bA%=zo}43KJsyuvR-m;BV z^IS8sq3Lpw)o##V8TQ+{S5&9JQJROdwV$O&ttmyH$mXxhQ(r#z>fCZn`No>^X0w(6 z_w|t89m@AdshgC!rMO-FYFX|th1)O+M2W~;#Aw59Pu!Y6NGFkRwIOvbc z{k*3>34CxLUI%c$>%!EZ!_UO|nx801{rUYm&-bf7tUWBWG49CTVdD*fEzki|&rIyi zjT@^zWbI%u8YnzkQRojJ1dX_TrXI3<+Mzafdmuc{;YLGnC-Z=18seJAgv87r79aBh zS^#)_!$7WR%+=oVg~uJEsq5ExxlbO?Q%4SWmlr$SQA~{`!1lUyxV!3<>;8b5b#+LS z!yThyo=ox)zfon$;VwDcC5O9wdK|PV@c9uVP+2+kswgA8-Ipha*N?*;0ff49jKs~( z2xP3^jl4x{4^a!3ZJae6GpGtVjdmUpI%V_Y$>(?dPt*4(cM8DsToZ)zz&$i!Ww?(V z0;>AgueK@P4FTqF4C&g?$uGsfJ~`Ym?2}G@c{=$%_1&Su`Q&iNc#7e}VR*6S)Jw2$ zVZ<6@x-95dhh?=QY|qT(34ZVq>l4HhW}VE{+eL{$KzkJ(?Fu5Z&hVX6;>m9fB&@RhOm;+dB{Q3U&s zJpM~LIpDDGd9Dc#cffvfxXZHN4{(3`y5;hd!yUsuh1FRe?88l-rhVQNFFD*Xo_uZh zG{HT+vT*bMS+0@{4LPvRPUsu7;XuE^F@b|kaRxzv6d$QRL2-b5lxrxy(8$N{$H@s4 zZ`8y9k8nKL){{3q0MdACpF08f+}qS}fIOg&m;GUY`vQl%|J{7u_lw~El+S)XCj%Vr zJWAo;-dJ{dy0m|B(Y2fcNMc zARePS6bdHDCkijNF$B2A3WvCT80lFgcT*xzf91LSL-Cc-_}J0+Jy`_%=e9kTlLHR> zp68kd*k{-+0rnT=5U|#S`ws=Ue|Sy7K7$zzRdTpX(e#+q^IT`VtW|}VaW?eo2EPFJ-{WsPv>?emihJDiMFHgANr@lK>r=J||7*8>IRmRnql~*Olyxk+kl+Q%; zfG?aiV2nQB%=RD!%=`}U9~Kb9_XF7&%p>jx@@b(Q_A$F>r+v)&h^lAb+X42`*_*>1 zJ~ighhYt*adr&6eLBq$ada7{y#js!CaCgVDTj`P?6U00Vb>mqDrEK z`9~ZvNTLkkrEwSV5(qH4FM3EKe6y@o5GocgGtqped%y94Pv@R;9M5TYi{TB=J(e#& z&Ruw(dcomtAXp4zK6Jyqr~mLvE9Y=G7<`Yo8(a9Euoo9OKdtr`?)t93{*N|oKPKA} z(gXIS$>A>aL)qjQ($v5<4xuIyZ*ZwYVsETHVor-^3zCEJ7WUq3@el!Etk0S9_F?S_ zvxkcwGJ9IIud!k-KzmRQgvv+W&vav2kLU>JJ`2#_anN~=pHt>=_r>g_1B`m#+~Lm4 zee!sodUCiM(&+Z86a`Z}ipeekwio3XP!+aUJNEt7TQ}Ur%zAG~lfxaOqB?BfsW#FV z?$Q_ToLuoVUP;MU(NSY2NZaWPcj|2;<}9cV z35<3gt{Uw+C<_k9A=`J`iC3vXCZ+I|j+C z5BGBnPHi5JD1G71c)M3W8eVd^V_e4YQAW;`l~*Nmyxk*3I8US;1mRe~w+eb;+$|_B zQZu5}1NOkb0W_ompbz^^>>FfVXzSzm=CDs(9T;~U>xgg%;Q+&L&UG;G2<(ZBgQ%Xf z?K+DnfD&YCNa#9O9`*|y?rv+__H+^K|KRsNmXiYx`<`dKHgNgL;V#Q|1h^ktw_JX5 zxMSEShr8wJEv+7C`xeeuxY)KWi>x2Nu4}du96IyJaHxA-I2NjxCFKVgbnWD z%z=6W=23<+tu6@1U!E(0dY2fmc!(EnL6=44Ab(9|kK)q%a_!6TD_N8$hdaZuSL!G4&$xff%BfdHnc?joDO^4(c|aW*6JGDwt^maz z_69XMuy65ifofdns838iELX73FOQ~&!5yH_CvC8zK>?339%=+c_z3S&&%^t3Cyf74 zI1uQX&)krs{))qX!58k1{`d*c7Qy~aXPoRMBoRPi(&;lAd|N*{eXQDzdxz_XpT|WGt9M`-TX_Wj_{f_; z9@{y@?by;AnA@jqW3sGYU4>2`&K~hTwJ?eW;*k!xP9Lj2%CO*vC_wsv5iDSD7Wh2H zVK9k}@Rc{)yzL{;6~X@Z-!_<&1J3Pxo@*Mo{p4_$WuFaj|0nAf_LIXM!#+9OEsxvp zQ{N?rJNq^dW+t!nefbzxoGXvZ$tP}q@!@q4)dS6N{qWYVzqdH{fU!X}P>*1q$oG8f z4#+p3c*_tyV2l&bo$NKZ1B1B;@5)D-Cw`)q8A>NXVCp2 zJwWHMK|?fbFNWjvkvrqQnHyNuBhY8Iq07gR&V=p&vzgW*=I02a0OLAz|7iD_eR#>m z*|>XVIP(nd-G~Q-^{5ZbG!H(X5IW{iYrc8rMS#5k_vL<#PH|;EcXxGt^&CdM zZ+?xJ`~2}d_2hH6L!+Cj-wvZYSmRNAtcsU_+{IP{9f!v2tBTyK?Q?h2t~dQRGwbG% zCZ9XTO?BkHQ*9)lyX14{46CQ{N?Mh1P4anWtMpZtg#YVDK5vn0@T5a|4n~9IMoVK3 zPpEp-^2R_z|AO}fribCiY7PdxJPs~&u!Xw^o1qZ+#2wh}@_*VVAf5>V5F8L2#{y^& zUf(kwE3G#X1o+(%v?jxUos&K#BAG!NX zfcZN@ntbjUB(FZ)C!afe4-S)V4VHZFtY2cXA;G@&%ld_VgJm;HiI>m|A{|->JZrXJl8aE`L9>DGVDjb0aamtwYmIz0^Hxb zZn^yAbH}hxK6lGg%L5}oYVx^b6fGo&oh*ytq^z8JNgcm^1-7%nOR({*%{kdJpB!<$IoM8n}Eohstmt`2%Ov;U%9t7Qe&iq)-O$W#tL>XQyX2FCO+Wj=_{3H9YZh;OGf|Yi{-S z6OSFR-E``K(F+j$T^t#`7l<_9IIkI&^s*ul3A zc(u>dWBv}9BkG46NBa&bfSsNh%wvsb2K9C&#_`zDmBBuuc`Rx%!S_hHSl}92VVZjc z{`mcICzJ<3JwynE266PUGN=Iii^5mB_Z`RIa8VKLzx9>}a&o|7-}7A40Q)B@TN(DF zkMOKD*#B;T`~Ov}2B6U=Mh|KP#Q3NPxD)rZ5PO8v!$gp?#ObAd z2n~z111YfLupi+oYuV;2uDrMi_8%SlbWRR9?0cST!bk2fYwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj G_#PMozyJXN literal 0 HcmV?d00001 diff --git a/Covance_UCO3001/browser_profile_3/BrowserMetrics/BrowserMetrics-6A26A181-6610.pma b/Covance_UCO3001/browser_profile_3/BrowserMetrics/BrowserMetrics-6A26A181-6610.pma new file mode 100644 index 0000000000000000000000000000000000000000..2c014781b463f4ab0d62011345d7c5c74158bbcb GIT binary patch literal 4194304 zcmeFa2YeJ&_cwkw5C}zx2nr$+niRh#fmB3Rn=uf)y0eU`0j2j*9Sp&)hk?GdIcZfY0y$`TgIQ`^lNvoLkO!&h6*k zx${Zl#Ti2257Y$L%pK=mhnvQsJMqYE>v61@21>?no5m4hChjR9&$Tt1aMRrAfUhd( z4&=H+0Z&m-h~?mt|1r~DKW)<^I>4i!F3=#*KG1nf=PkocjH|h7c~oyk&E?%1;RIJdXL<8|kFL+-NVmzK8fn3Q7c zBQCOuD{SI^n=W#-%{IQ}QRO{G&gih^($A;k_q9(?eZ0eG$BjQ7zZ2W+{k22w(hFYC z6SI>@SUPgN)}}qza+}y^d$W6O0`w!DZE=FQHlgRhS;LB)&Y{JrBZfMMrVbfg>`EQs zb`Hm-C~d^h^x=bD?m?>(E=_nWVU^8w;)r)|+njgm@XsGw@XBJ*Z^5S3W!rBVd|#`p zpC7Poed?nJ&VKu{v7sR&f1I7Vu-}6IuXJj?y~Ttl3XaM7r|ZFju1kMTzkgSg*WC*` z7ge2jLCqQWdroXUc4_UON%w#8_eA@~g>SjODH}R#-<^vG_&#ztcVArIbIOG+j@^`z zb>PY5%ijHPW6PDDe@pynM5`Tl_RhLECv|PBTZ+Cf-;sa&3vW-a+!Y*M_r>>@ELn4K z!Y@ai`%}V$GbSvl+M9sF-V_C&$`I9&e0NDXD!G;|=Vg`#eC6&5zN$hrH)Fgd&Js6y zQvEFS2Hj=uqL3REqA4m;fAFXdn&RiXoq?iKimcV?hT>3tHODFS`TZVmi55$?50gTr zNFj=o>b5CPX22H=X1OapMQ(~l?ZZT$i3#M0KSb8~dhw|)mAkXu&dM5!U+?+!c%4&45EZAvdSUg6{kQ#?Ughs*s`113AYbF^oymj*Hh;zf#@MxHYmtnvk1 zxlS)0F3=!uJ#JSuZk99ToaGF<9ez({nFl!@uFLegot_H&+*(2_V299Xphz5>m;D`o}XyAwjj%eVB2L7+nz%o1u+cUy2u#kPi z0irvmPnxYI9sFkfJKcwWMbisc%{$JsVmSRay2kisdq&ibWVRdGF}HB#6@`Q-MWPMa zHOO8>wjr_wk?n`(Wi(GA`_9QAOh+}F&M4e7Kx05>fbu|W%bAJa^h}uOFErY5lE|P0 zN6$@jnv``3n*FR#d(4s7zxNCIJ%9A+Z_jzc<}=!HNK4G8Fh(b*Om<9pirm3qJ|?$i z?vT%GFYuJR3ouW0J3|CT)PdCJB@FbeWdEXht?_yL;{QRQQ$h56=YZydmVh1ry$eb} z=A8;!1lj@00qD0tb76oR(NqX~q7Y|8p>M!obqyv|&$kky1O~SUq1;EHi(6q#yEg^8 z#>A@MK+LN!FKj+uh^;V)Rr`e41m$hJSBT%<6yn+au(=Jhi6!UT#P9FIqIhb8ra#g# zpqT7sYmheJM9LSSXtuy*;IAE=dM$;oJg6y}|{A9Z%VP39>BfDxX6mP@}wP|+CJn-Lr@oh3Siu~oDcRXgqstxp;9OG5_ z(pQKn&VWZVv;^&As$p7nxn23rVt203<+hJ@JBxhYv7Rz_K8!JLM+mn-sKQTiseG&D zM8!||SnsuZczTWuOpcAuL33y-V>D_0^n@QirJrX$b=T9&_P0ot_+@yq4>O;_7#-E? z%rdvrJEqzblE5>4UTH2asu?UY5ZDS{s@H5cC0vYunI50;Z=uOOoC8GoXx>kCU>}I> z+mk9j3i@}QlmwRMT9dF#?eZ^_iT{0eci!e{>&ILEqS5*zFElvM;6tq>`Q$awnzk5L}s zt=9cXubbdcJO_yGTrb1m51e24K3L*|a~}78RryaQ`IDnNl~d+xOv8oB=@@S);Pcny z`ziuO?t&UWHN5fK11^Wl5ti^1zFM@4)Lt+?ZaZdzKjrSnP9w3KUR~Gw%N8BKqu=Bt zPFp>`^fk2yV|{?<8tZYFxeCxolm#OV0DQ;*9`J&hr? z^!Rz!O+Wsy{q5Zg&)WiZYyAptqNmQM-$s`ga2E&dB7=lxzh_P ztfA4&^i`ms8u~1Xn+<9#pSgZ;zhrDjseLEhT#k+PEC~kMc;%th)~g-6Z!NhG@iiyQ zG4!DGk+jJfo{#LrnWavz*Igze<&@g1K9Flnm(r{Sas65af8senbm!+Y*8g>H44XJ< zTd#V0SNVvpIRmadUzw+f)JsdKx*6IezZN~ZQ9iFf_5t7dVUKSq!CrrL-~8;5h0jqq za&)Kmhxr=Qa52cwce`Db_t8NK!c7DHoBXA5qH(J}eQyBW8p z4A?)7hEbYhJSw04W8lfdAk{bvK$GholyDg9|wnNoU;b< z>A4&ry7L%#G5F_w^d@an5X+w|xOeaCotID>NRGla!Ik+M({RBU#~ttoJVAG6sk>;7 zeNw(0=%gWx)%Ha#*V#Sd>#20><~?7|+Uz8J=|G2D0M`Fv&eLiAWPS$76%raI@i zEBst|>==K!OR%!&b(zZ1w4U+x(`V@?1O9H_?(n-D8gvw|C`uU-kSH0ylwr~EE;>%x_JxCnfu;OYdH(Fnq&vN-*Uw)KB11%0` z%oovHrW;EScc%xgm?^{pj!*qE_0B4v{V`xI_R*NN$SoBRz`T@1rOy(Q;>07_j~v(@8qlPu((OrO}ljyDxduu!c*!gb4B1dwH+l9JSm7s?I4Xq zR|5~vN8Y>WT^r?vF(1?WNGYtphRXGIQ~tT<(zg5O$&gatbXEE6pYJL0dc5|D73H(s zfl0+$Z|-&!715YKXrJH=hK6T3Yl5cn(>nS;pmYt0 z9>JK8)A~wgEWIqev3k&ZH~zhWM`kOmjyfnrvJF$!;PA$SQE*3 zRQ@63(bZIoh&+GEK3S&1`bkDPqh_MCA8b{g3vMFce)++f7rfACy2K&N4fU7ImnlTA zlkzhIHU5wtyY4WsEz*9I4VgpK;fK}!y*a`rfoN_>^9GoFwedJrx{e@BzqEamRP53~ zBS2Z8GeI*!)Yx1G3WHt%eGY1k2RRKi53~W)0gY}AXfJ31D*8#N=s$u!NfhFD40Of- z!22zPco>t@otU^RNQO-a>kB!s@jZZ6xh@5JKA|_B$J9aw>vt3Mi)3TA?@xB0_t)v} z(oX?Jb95*DGGAv$ZVl--(r6&mVi3#Ur;W^_@-s%a)%v`={zClx=eicl-fAvh9QkwK z7US+eYlPmzkY4dD2bmuctpCXM&Guoi>MHQzG6C%=ERKcIZMEq6Wx!Q<11&O_bWngZE*VA2pNpq?PAP6I$gL8pKy?{h)ZKrRsF|3#qdL90OPKp%nr z0CfVs3{V;9Hqcg3M`YG4(9@vfP!<+}5>OVFfd-*Gd{smfvLP3t17tL%)$Frt#6)U$=7?pVQ-6!aKNr^zmiSqXP50^xep!2nV52`RuRa$O%rs&iS&)P^}gLS^jbh^4o0v>W1z8E9P_h zEMMibeq6(!~B8yESK-baiI@e=JCoxwlfH8brDUC^9tEe zwHgsPAM#Ks>A4&rx}$ljw=Q{AcFv`HMqe3%m*!XxDxdvnQAx8skXgdv_rvt4E&DlK zl{AKSpqC77RT>qu#awZ@hB*^NJNGcNq7?UyO(G zs(kj>$6=1V9GKB^owT_*I2Pl3v@VkfBCkVMBSJ)PgC&j(@F;!4q_!t>_uag^^}Lim zT#xBac6;XIUz4Nt8m-1eUVV_>wYag|s&LO!<) zPwg1&ZQ94mUFzKq6Qq!-c!Jv%*PFA$nL z4f_<_3G5A^mq7^tSpZrOnwWt2s6+=rnTZ%XV|^Pg4^$6w_=?UV@-3em(M@>ZMc8TJthnk7^Hz$d$ zH?%U1TWW!W>sQ)vsW%6BfYe}nxMbq9^XrCnov#mbwP$XEEAtV}Yj4bN!rg#?2E* z2gY_UI~@!-)=xw8ygqOLep=I&=O2&k)EuQj;}_=Z?8pr-9|X}|R?|Jl>%bITde!2_ zdf8+_?$URQI~{k7vz02B`4NHokNR@$d1VzP=z(&ynTJt+_6Qj%)^jKB_MKIEW&b6r zeCEfJkG@-GlR*K-`oG13{5fsgpLId^-~d%V^AAD3NfD;}9~oZ{8@ukgHTC#DJt^PG z(VhAq=4(vDh4Vo#rx6X*B1|OzEyx|&)p?-om;}7nCLPOVzRr%^8kB2za-;t9M#*Rn z+$i0K%KeGYHp_nF{JVZ&0TPEzsC@RPjW*7Ji$+OV*g8_9|1Wn((S`>-U@h*fhbJzft)Z zC^~8B4`X+7#{8(Wfa9IZCnS6#&aIapDqp6KIe%mMkxz{RUIwPd8g4m=^P?K`Z*sBp z@z0{N#}dBTNkaq8u|8Bj`!|XM{l+}Ecd92;ig&%LP;R8*nd2GtBhWXJi-qf}c3uAX z>8owiWJp=A>8kSCU&S@qU4|w7dd1b$pVeBx@%VF&!e!UbeS+n%epEjDH-W0?gUiOj<<3!i7jCxs5K;RgUYHwXL z=V>WBWF3v>XHLa5#wRURB-vy1t#$ zM;rA*0jhPrDKP#q*#~ILFD=&>`dzR9+hKp!wknRsf^(VMXpI&k1#zj}rEzLCa2e&2 zY$NXE%=oxd|D5hwbK{7=#vm>^#&6g8k{i8R$32BkkI>%rrPwJT#+?RSM!6(2toze` z#noB(2hIT^zuFs@%XuE+jhgw}11X;;iPNjkdHS-}&UIhGPE3yGnUwF$*O-Qj(Jmz4 zo{p&b%nEm)hGu$p*oSi6&LC_a^vZj#v>(Yt>To0cvF87ns%h&hG%vN#!2PFDx< z;KN-+mA$Wcs{05ra?B)Q`@3AzD^#`+P)y|}TQ3Za>3?y*1mWo-c7}fw8}0{ga@|3s zf97jU!^M*RCwXOI55oB3#*hbN4P$w(i-W5VZ1}0=?;cgs;o6I`2XD}%GcM*EAZb4> z;hOB8TY<5U4o-__Y^O@c%5uv3qP81Z8Cl=y@U-Q*|`Rcoq4|4n;R52V)< z)C+VHs5gk}CYF-4^I=ZLy+0@wL`ydVK$KsUS7c{`c~Lu;0p=#{T_dW~=^&bx($tKm zB{U?b;V=#PXtw zA|F%$Dg==YX)0(MXgcUD5KVT@0i6q)0Xh#f6XXQV0u_O%OrY2;ti_$j@0xJ@&*c|C zo6_^909ccgUOgW_#j#tfrmy&JwsU1O`cIA%+M%~)zT`%)6Wt+u*2H{!mN%H~3!=Da zueE4fcClf=L-ziq!_MLdTOTMkJ_jk7Tl`liGXiB=p z-DEGCMi~po`VC)d)5=pdGX3Dzx);dro_Cu3@A#?j_V*qG4i5SHUhAOmt(B+Mkzc~~ea`#w zhnN0ZP5;12{U${Ck{i9&)9aWZ+B}TPWTVT=M-A$kFa+@IZSm|cg08~zS2o8wG<5I) z3bL&g${fn01C84V=%NbcvMKbj`#6+I6z+p3qCMz=^4mvMS?g)>2n zd@@0_>Ci-UyQqoCKF~z0SkhDk`X`FTUnGhj9&e`UuOU5W=bHN!Dl12WjQhB^zxH>_ z-pxK3&YDD)!?hGDpZyJb#w!rTo)X&OLgz}^GjUi9W(#t)!qmT|Of=(wDz&y@8}PM$ z?PJtzyqA$y;PyYVHjm{%{cz3e@!7v|9FwsxG`|KGk83r8(FW} z#z`N@er;WVbi53|xg4*?bCIKRjH*=6u9k*I{nHh#`W@BkK+8E45RUYZbPh6KV;U~G zc@7-Igw@385MqL}!i#0S0Qz&c{GH{7DPBfejvM32M*B!O7!RtYHkLKM2mITz(_US8 zf8c%@TjHUs%4dHX&tR-o?>xEa>rUG4aqWz`$jiWpTn%De>lIwohLMhq`=-Ndx^CZe zbC9+oX^!qRPiDT(j@-0ymUbRej!V8ECcRQ{Be^uss)Jl!4|wm2i&{{cMqJZS+KA@> z(Vg>sCK?;w&+zMqFV+scZR5-E)*QD(Dxdx72qWx*4F>(C*z2mz4hNB6Er|88O)upv zw;_9M_A>{*{N=^_pF#7ZIl`9&l+4%Jkz1qXW~?U=44LImLz_+Mv3xXt0?l7!+)Ig` zI`H{$@4jhY({FP8+$vxCqK!j2$qHcXpMyz2xv!Gez>PCtqu#ezkl!iykDFe4U^I1K znq&DYpZyK;3-d=uC8r<&mxsNO%jKa}@0t@y2S)$o$x;6cI@ESh{nHHo9ZFswL}Qy; z5a;V^_){DQi0%!Qr^iODe6D18HVsoXN8u>6%GcPq@IJS!JS_2JKws%`p(WteZL=LH z0|QN?d~{{?-g{noYQZZPeDpeYP)SF3s%OmC*^wK|$5x2Zw2?jn0jqD5=}=2|r8BzP zZnkr8Qt(h&*7_IpoBaOrQYDxNW3ZEqzE7WVuKzuy-KO`y{c zP5F{tAR{|)BRMV*Rmy!Jeh>N4JFam&)ArnZWjT}KXx)$b2x@YSLznLhKp*;0P7Ajf zS1uP@EXW^_GrP}#5wG8?>Vf$t;rORf`F2Mo)?=vpX;GFNaFiCxRAT8NamZP7Zh7IB zUt~zB2fC_!_HP_Vfg6X%1+c}utftWGG=V~7BQ9-H1YS&BD}tXrGV=P~s(uo6KI7qg z?Tra5Zwsnu8c8XFh= zd7tX)90Jxabs4BUX9)^slgyG$d(SbYm7JK3Akw}>Z2?+>nVG> zOo;K&xS!gA(rH56wJ8TP7|hMb-7vQ0j;cj6WHdijKKnO}Cjx-b0VYmK$*<6M*cDe` zTOA_Tfhd1t*(JIC=6;0RPacnAI-<@0+Tq?Fgl1LSpVI~RZlGSEexL!Mp&+txWP;8B zQIkZSD~(I5L6?E3Og#Wv584KzM&M{<$Y2nr+Ts$>lc3!om=XmYs`5MtQxj1QB7O2a zgwo>nug-$r_s!V&>Tki9b|RYQAOa4jyefQ+jf(}nPsIELhi8_J2?TtBpdK-dJL9S) z;|rVvMDiM{-?v}BXVYJM{JSX}ImV^(rEg=n%oRPWLayn+lI?Vvipn5UzeR>2lE?UX zE@Ip-cVd3;mmdE4D_D@Fqwv&kF<)m#ZuRF)+8d&7*n4P+$<(eahkQzx<0?PHXk6?J*9&2u*aKaUSC#B`M~*XsVX zE|;y(q8#9np9`dpfA1TSxWCHvb-jL=`G{h2mwb+4R@G+%x?0Ei$CcKf0=X_Gdi&!XoVtr#*qH zVvIQa&iFV!{NtSCn{`~ep5?G!R6hHwIOL0yDhjhc_F2I3*Tzdn-tg^uT7K0W-KoD} zzRr%^R2+rg3Oce*mfm2bn3(dVc9x9p(9&+WzKpnM#}n^8cK&b{B=OjU%4dHShgwGD zTcqakb8=C99NqW1D%bWscsk2r94epv8Aq)0%2+6lv79Wofaj^yXI56(O6@F<@u+W8 zoF6Km{Z;wqa%pb2{2m#L<%`R%YeH3J6L3}UXtj}iAGduy&;9dc``t94fg|}Ri;0vL^Z6UTqr?-UW($XXkMCGtm5s)}{y&t<%t)x+93@ z)7?RRKxv>6pezu~$zmob0HShuCujrcYY@$wX|vr$pv|D}3E1-kYT5+rf1s?USQ}5o zyrdcSEi^~`B+S6Reo;}a=8n?U#tO+;{XQ}IM{qWCkh znYgoWb5VIolK3*Er6_3CS}dO2Mzl^kT0Ec8Ud-vxQQUOb2{=!xyKpV+BhK!VCPrnA z5dAx4iCh256YI~IDVALn5QQf%7CU#}A+E;|A^*=W#huy7w)U@O+VY!UXlu9qHQT6) zl!SNumn9^8V{1a?f$ao<9jQ0_;*^{49M~jYdB4+#FP&4@fev|vdj&-EI_7Ik!-dL? zW}2d%Vff|t*DESoXd{l=*)jnKZpgZNc7ZKu#R7j;Hw!-AecO%6GVE&H2nX{eH+nVW zh?Z3Qlw1PU;J7&n&r6PRsP)M2$9n(F!2MaFp0~3;7zguZ3el?>$CzpyS4A%~)>Ddc zz8%)lHHL#y|2(Hf-K6UW_PCymQE;TU{0#)7=i4NQ z>MGS;$_lE#2%^pFs2&s1yr~rkRZd%zL3PvY0jPf3|EQLNep5Uma+EId>8?8BF{ys^ zKgZ#FLt(7&SO#HI(_%kkIt_&}`XBlI|DFcIC=|x}V$=Y(uxO6U4b`EpIxj`PCmDDY zj_hbupUBbw=)SZ%#Px>wRBw(rYZ_47Gm1s}wZ zwRJ?CFO*kD+A}EOi2MJw29^Om&$H4(@=+YPQTc9Y{pPA}r{0_J-J<=}zmubIiMTRf zV;U~TZ`DO?yM=SgBV!d>%Av7|9>+LtToVV+z8A3P|IFJSt;+skJe|Kpj>arBZe+g3 zG+Y|p*OOm?WeRL>r$tUUBaVF)@;O;Az2V;nlmY(7DQ};@7^h?{ABDXk{9{_3iL zDK*!hcuGd0sz2sannq_qe|CDcezLm+A88E$fpmGuA7lSbZMaI5g-m)h?WSjKeEQAA{R#hXjPt+s_Yr;mcXP(r9X;T#s^G#szPXteaPaXx-2#^$nrFMkY3-3->xKUL@$+%*-NP?GIICwr6({qNoXP3u6v-QH8LpCfW-LGA{P=P+U-xWy zd(vCysB)Qa5{iG!=UPp`2GvZb_7zvVeoB(Q&tQ-qu@-k8U({N_^YT@vZMfi~l8f}{ zT6v>Vr}EjqQ9L?;RR;NeE|9StxY6^vKoo2ri1#h-o;xFO`LcctKO$e{BZ}sxc-+{l zub-|>tGAiHG9SIxt8FaB5hi?wjtjd~u-##jcOvRrrCY0k@;z6AA;KWm(I`C@wjfe>S1=r7zx-GU22FS3ZnGApq6RDQg&*_J*5G!C3F|7MR-sYLjSg zWIV_AuARS}@K5A(ysUQq{wdef^_mcpe4)^Yi#_wa$ z4it)0kRctB(5;wYCt?tKHwKY>(0O9B2YmHI?JJLEldXgtg=>y0^EIa7qVN5R4AXg?ZA^8MTk9`^ zGVpTTxIV7|4oa7Cp!n1qU*xvGb^FtOe!-hv($SsPf0?hdBR3U?IbZl28B%MkE{bf# zm3MJ`TwN329J2QL3wx;f#ry~${f9MNc|L!I-v~>qZ>+Dq7H}n3UG~l0={W@|F6JK| zE=-mK`r!&>uq{LsQa)3KkQfYllg~-FQ*(EhfI1i=4Z;H__*4f zmUfP9=~ox2xR`%e#QB2MvzMQNa zyb>{{I)W>VR9J6YEa1Ai;N@<=+P?Z!#l?IRDEwm$*Hrhc(fEj42w&MK9an+lgBrx= zzdXL)YIa}r#rH4vO(DIKqdWCi%-5KPi#2?sVKbB;V$rA0^j@x(iZNf4u85EC;H&8? zbLVxdH$P^+0h;#H8a_uw$VbOpM$~5NPs0{)tr`C1xUZf+y59R+%s)I_c(c_T%}Ywd zsIT-T@%8oB|G9YCpDFz;*NNTgzX#>*IR3n16VW# zUGi|7_9v+Il=+8;kLm%=f5I1d8Qdy^-qu*aHK*+OtA3qwMjI6u^A8VKbR04XgYk0D zJf-(H*NeKVq!b5kgoEBoIuZ9g@ORD?+sXH{=h9xAS>5Cm`b|#a#lC8VFMZ>-!_jGi zy-0gQO`k4A-iM1ff2ID5=CCwhA)6r0W7~mfjf3`|^#rAY(m`WEG@r#ZR9pACANTh` z^nyD+k0Aa7YJvguMWAkY_Qu}Js=gYL;2a=CX;4q$MZ-HkTU7lOg(FAd=&JHHHZF16 z+xmKfAs5C#Q@fVDOr{nK*RPA7T~l#ln{Qbz<5KzTf9SZh8M3L}SZx84?1(m z)Sx-WrSjST&~fF{IsHEGB(L@!p|O5WyGEuOOK;19IoD3DzJn_cTA7*x>-{csl%9p-}Q||cv&b99q->wevc$< z8#DNWpSsg;a;z7XFMSV3FY>!_Q*r(X9q_9vCj$w`(n})zsSQg8QM)w^WPDy@KetbL z-iF%g;@;0}4(_-s6Uk_fpI7CxzxDEp(}6JO=6FV2%dVGP&WDC@UAG|Tr$;{?axuqe zTq>Xat>c=FIX6CHjyX5QHR9@XgG?T{mlNuYN3- zajAUvKP+6SRX8R()z_HaHH``%Tr8XyG*4_Z{-{v}r*zXpMscb9L&xRB*gZ9f1A~h~sYPyl+E)YV))O+;SN{shjHSO#iIqj} z@Y|O#4$fzl&;Hi+SMI5HyHdG@3nKv@7bM>-Q;UUbTeIxlx2N3q7t3W_Dxdui0T#8;$Q$B;-E#Q5@Vk*UVg zU-90RIlbmN*2|F5@~86I-#R`&zKrB6@|C4xHyEbj0hvM=H^#Tu0=_fXq_%(apZwh{ zpY^Bm+21-osvkHI&{LF(F-FyST7deDpQT6zehUQd%e}~z#5j%_*6doTgO-K zad}dMH9>bZ#SMd4Z+-qloY?K%F$cyTd$3jCPh`kwzN&oow~i|qEYsSPRF}T9MH@32 z`;9FY@V$6m?;AXhfwNgY>rLgezjb_6?$G9;O)1xEFb>GVAuz=rSptpuTY8&JJy!l6 zbUgU;!khQ6XB>=E<+HzaocOS9>MSRg;??V&O_(*=gYPL67}}DZSd)^P>#3SFw(TY}Lry(6Wk5XPPHt+Ie`L+R31=bp1lv#n4PtT&ZUe&np< zbK$fUoMwfVS+kwV=%)IS9hS^k`nxFkvAG>Se(7sHdIX=!XMgMXDuT08i%NYy92$~} zW8j@Kg)nZczg_eXTr7MuAGrOdp_P609ww?kl`m5|6#dQOg@M!(S{cw22;~Zoif!}_&!W^I68m3k*3p{ zV|*%~{jKLO^&7M{AY+DcW4*1nfa~H5a$h{@omFdDF5^=9>~9^HhmKbZIlZA&tpE5vZ~I-r#{6v7^li-f9p8?I7Akw?zvL+ z0gl{L97aN1Z!+$csm9XdUEjOi$GrApuO>PG!bkfrn6I-VH|zN1XiFV9EJI3+Z;J(d zH*H*dVzcv?_h105Kb6n^*74z6EMAwXA1S3m2p3CVtKVyWrsMQLg2W-~2d#fIU#1Yf zTE|nQomQNR&-sQhf;NszwZrh^;HtT9dB+<*eQ+~NW<9BV_P35J==KI1J|8c9pG+;5 zz8(=-fjeIRWf#k3Tq>Xat>f}LYiK-bo=%$dmQD*_aIx^^gja-`4tXF+hK#m%DxdwW z-aF9$Jb;zi^E8O^|r zvGn%h@M+uI9rN8Rme2T9KKon87oBh53z1$rGLh0S=IdSy_->zg&FpJB5Br_vGd`8i z{?_r8dR&~Th#UrSzAk%MrWQ+Y3xD|bl!pd%KUs#1wkIl|{SOV7lBq}}3}Sp~kH}PG z;XCJ;?3*6FkvvsyZ%B0((R&!?aosix`0iZMa>MqO(^FYK z=c~$Rf9v>Y-#XdP@ZpElssI@^qOG&J{Q31+Vk|v&*)}sTTr#{Z<6xXBpZ%@l^cKSc z>83AMlOfI6Z*+WArWOm=dk?;pUUhSmZY-B^seJagjw@Pk>z6{a{#IMSIq<1j31{zq zdm7_loGPFFt>eTv%0J7;mJFl*radN8i>1G&I5j-Rd`x*FKAzFbSDrKe)Dt_iJl2oOXMgMZF}5T0im9m?F}26* zE#O>!Ym+%uOIH8MI2fnOXMgKBb$e)}C6+0KapV4C=97{at3G_ZwaqctSx~YDrH#Gz^Wa>PhuiT6;?V0%aHed0<{%0P2egVs8J*s^6 zw~i0r?8d@rDoo);hJ_;IxPFrbe4VCUw{pbzLfxVo)t|~gbbPd_r7X1=ui(rJtP2i%qV?i-`o(S*0pbMf(BcKpXrq&DlF z%y<~D%4dJ;c#ZvE8D3_VmIN1!2zZqkYj8DMl1BY*vw-)xwf*1mddKZ$Jd9W6v;X1Y zm9vrtmg7wGPrtqz6RSMj^77~Ny1sHe6(!9vUX{=Ohk)1ZDk@J6(idS7ISk@*n*6*> zEf%g{o?6`GvY(C}E<;A^kIH9%>$sx(4pV1)cp2D)Z?y${t^<2!zqqG~Zdr=rQ~CcE zUqj=Gycgo@@0`*PE(>?x)tcpVzN&ooKV1FU8`$@^%L2Y;Kfij>{a0-t!15WN%4dJ; z_)0?|f2xyD-UuTBE_aLdRxeh$+w15!>aNqq*Bd9Q{6oh@Ur#`rQ-U>gXgDreQGDmXT7O>_P4ILD)%f{jGX$R#>R2YCJVTJdbN602jBC5vs}id z^4Z@yF5^DLR5JSFU@m$mRyJ8ioc;|mbq8)FzoGriZ#?bn)@04)^~PT+|Il&bSc-}w z?9QRK*&j+R!&zY!*lVIEWb8*$UX;vOI7`+(@Y2=ich*N5(e_2~9?>cFcHEowM*65Q=MTf5IDOYO(Y;X7sVI?R;VJJuH`TseJag zjw?hbv|##&Z`wslBK@a*9E)F<7GWgJyltUz%>5QFtu_Vg0In_P366u)oNaTI$9rVffN|Q7{z;^U0~VmXuMS zd#&KCZn|sCrOnP^91)xfpZ%@lq|IkEhox_EVVuN2^@NP&b=B*V8B3q%-F@M&HH$qL zFb>A4^4Z@yPUE~=FT42IrrYbn*eTk7a=ONLYue`cxbJM;efzc97w93Q<0h5Q>HjO- zIBN%n0=E&iu{?-3;^R&4`E$YGJ?}oucv#OWpZ%@lEyDSKC<=H5r6N!aTNYL{wVEbV z3ggD@SJ(p19hV*R>B{fs>lToxURC~~GfLybix~;q*^l z+F#FpuJR8ZU(oM%(hd{(%8}fiX2w@%0pEUaX-?BoyaE-~pUOXUe9~T(8pJtg_y{Y< zH;zN9--@rlOMW312I%0F~mexEj(l(0-wT08xEpOZDgLN=WrMa zbN!vUMM{ZPKRPF#(7p3{Z}9d=ZGJ|jP~{&wUYrD}ov>%#ziDg-lirDsue9&{mQS~Q zVF}A;eX4x+x313y@Uc-1i5YROwt(}_W_OnDIPIT^-H>sr{QnNl=*D6r&S~$;)MMrM z^5@T3+GAg2TX7`6RsNyl)Hm7bqf31winGGy(bfjTNRZ3rJ_|S}Up4XPtS2*b83*fA z<+H!_d^gy6=?z;Pra}vLMm>h#lc~nivKQIo)sq)$XU*e1uOyl@$p9P#BuUqlJm0zYE%{UmR%4dJ;IL-S6Fk*MQ z&};i}6f6eAA==|eX&U>*Wgkc>vGRY*Q$znrn)j2P@i1PM&;Hi&((9wZB^yuEd^hdG z__)q~@sh1GN}d|Zav7J(XMgLsV1I!X*pDeh5FZuCXMeRJk1?O?Ea2Pm*_tVL4%zq{ z%V&HlpZ%@lGmm%B>)_y5Y=ZN;LwJi|4jZ+?NSNE9+O1MbtbD$7b*S*EKac6pco?tB zXMgK>&HD+1MLs_nWY&WiU&c0>YAk$B+h#rRg|}@zdz;FaDILmtb6B6l6d{P2qsLbf zGz~j~avh}%GhfUjX4Ry^n1nWzTo}ao>nz}ZeRe4S{trK@XLncmlr}l*`Yn>vnld0P z4&Zfh8Q)l5mwhC8vGn`u65BUxHr#id3>h7tt9>*tk39~-a^j#OR z@E-sE(k@$`EUUNPqVf+NuiRgtR3}rrxyb^))0@0@-r8ZFF)W|!lgej*>-sd|GnK>A z?J~7kdTVya`Rlrgg2+6HajE>n!R7PQJD%JU$rOzJc=9Ll@pZkd-$R#t{?V;0pYf@D z_P4G#A1o}i8#l5t6^tAZ0JEkM=Nbz*FSvHiX`KhIxs7o!PLap@WBiuCoi*J9tg>f)WmCydxaW>Lsrg~fi)rd3c)A%_5yk=xs!r1A% z7zg82`Rs2UXVj*KzEN8^#k*NFSgN74jP2wa3pm%mk>`4{-)XHF2jf)v>~9@sWBLr1 zVmFo?#$gCoi-ftIO#dwYIr1aNX1?{)wxm&vhw-X>_8*N?4a=Q@Irw&j{%f=oUm5@g zZ5b+Z&Y|}GkexD?12;;Sz6U{uicP?^Hm8Xu^XCa8@2br0rOzxSUb?D$nUWCMGHdKp z@NpG%x)VHJK*@FnOAF|5fP741CV91=nOGbPxy9jp|F;E%wFFTnwgw#qY6EHuN(Ry3 zydCHmPzMloik(26L0v#yLES;UKz%?bgJ^&}2s8{d5_CE!3p5^-2O`7VxghGE%R!Z( zTF@1s8$fq}9tN!iZ3b-zX_FZ!wgc#7P$uYHPz`7~=o!!sP*W^U*gE{auf9J28BWFIj}plJqXOR zXW|vn5J@n9U!eALDW7pbCH2mi?vnZ3fwrbb2SVR{l3)M3?KHyX5$X zzI}C+t{BQk)PaM{$G;|r4{?NiS)RyP&`=S2YlOI9Wj@@TPi z;8=0P$K8|S{zkG0B+rOzh)g0qc`Rv~~j)}f0XmjMZlOk|T zc)}L&oOJUGH*`FB4SGH4WOYvvDxdxH^iv*konCZM0sEw2W}wC&a?nvY_Hph|4q2P< zl}%C@#o>BS^($Rpm5P;5r{DDcoRa@sfF4*n){n|(|Hk#Bw?tS-hv7@M&N9oisK)ZM zUcuGS_jy`wSl2VTta|~=Wn3zs{q=$~6{aj`Nq!|0-ye19o#z?u8m%)o>*sqJoAr~j zE$*qZCEuA(U;EO6YX;Q&J`eL*KHtqabm_q3bm{#UwKVi0Pqa~-XB4*% z)KI&_eO6QWQ(sEsnj{dl(=`6Xuu3}{nZ}tZpuV6XpwS>w-W(9={vi-ePpN%#fnElk zhQvPt-G)wa1q5t^fO3rId>F_5gVy&HjN8se&$t}pvH|R59O;32 zbCs{LacR64J1`n zzv5pJ{IzYnjDDT=&~I`Sj;<ty7|aAeaBM}%~5!YrSdg4F0sd-=JK1a zmr9l|F1xOY3u$aZy{+ESY9poD?wgG>zU(^cweHlAz>)luab>>7G+grMmf3l*WY4eA zx@9|CV2N`Sx&wyc72?-|sNRuY)+o3ds{dkdQs$DYOSZ9S){Dw#|1q=` ziq5?c+GSTsXTzK~*buGBhJ1V@vojmMcU zQ;1$kFEswvUVXzax4%(UXpxNdXN!VI)kmM-Fdkk#ZS`dp%{EWcMKT`dN0G>13LZ5_ z>{D_HW6-3RnRsq;jp=36??UY9vo!y?@2~2o>V^3-h3M6cV@$QXsDj1^jVi}De%be@ zOs6qC{0=Pa zmd~kC8%J#&$yA-}uT*a1|2LFIdC7I()w#7A$Y;-{$H++}n>cX!MHq?7F& zta%Eb{iR*Wo>}U{j3>)ItD?kS=$+%m@|kA02-M_grVO6;n8s}#VXC9_8Bas=jD$U3 zb+ny_wNe8fT905p%XIpkvpg8yd)z^Lo;wiK_O$4ja-E?foL7nIgbB|o z3wYA+eWk2w^Y6c^c$m*P_}(C%v2MtByXvDc<4NCd)(_=X5@;rbSGG(e(}=jBFz@!Y ziHkm_F&#P5C!K@Je2rAv8kLYmlZAQ#iIf`+-zh1#ZGGTr(eQ*AR*B{!q;f{<` zIlk0Wf>8PFua_Tr!@RT-$J_@dVHy^|55vNM5l8kv@#o9^9=@ffXN!%kWcihPq4!gn z&+_@MCCUSAH+-{NnJNrZjm_#+Kpf zs`A-C9*#^pduvifsK_VnrbfNYJP=#Dwmj{uh|J=3-N54R!4d!> zhe2#V=!kqLEZp8Tglq8FzxLM7nCU|>&B^j>6Dptm8JELTKBf#?U$r)`#%}nnpI&5M zdmK}Z_K=p`R)HAbdJFh+b|ufBILxijaHHi}<^Nakk!2zfs_-K*W4+6>QB98OQSCP} z%A1P)=`Xdp>f|NMxLqV&!~S=W`HYY6mi4H&Nyhp9t~hvVfoJJE2fu#$?Hwuu0Q|G_oq~!eLm@s9O*R?SLSO>!$tpoDlEP-Yx1zVL){1S zY5kX+F~39;S&ALtYrh(>=XI{?Tf1%R!&A>Akb1b@2+e%Sjb0nHhk$9c=Q)b88^I$t zG^Zdcm2vO%0gF z|Aui1ok5mzM{{jIPTd(oY^^-4jx_YNSW$V!tBa2tqN_``Teb*aXGd=8{wc!tiH>t$UOYFbj&qm6pKv%pbSHlrpBU%KXXlHPR$X#0!`8x4XqAs> zn&Umdc8AA4$&YPbG*Q6rPM$AtxK;SU^Un0PW*qRcW#D4mPuc#>$1gtflULpZ+vFPK zTiZ|RD=&A$*p&xskGo9UGz_aCt5uT|#+7kyvw-skZ@Vrz$6deK1QP!=#RVh_7_Fh7~c{u)|)|R#(B*$;G!}gtNgbQzSjSkXA5Rf{UAqodK%_yOv5Ew{#`DZ z#)9^opuWY%Tmy_aI<||Clvq!n^P^r%qv}aZp>6;82R*(@__A&AGGo$G0CtD6Y_e~WS z^DX0oqDH&D?qW|U*bp*fyR{d%NS*_v%dOXLwYa;)c2!mK233Azd`smzQ*XEOD`v^> zO=HPJseiQ)$n91~yigOboPYYsO}W?2*nGDB9NP2H(=lJgA1PlADG7m%dJ5AEJ#Y>X z{c32x>b%X59o*XFP50~7^yZHYHxQwjPduZ`cbCvkDb2W(2g5X-wrZz+hj_`tM|-Zd z_oZmZj!)m(%8UuHVtb2f^u&zy(BIySQ?)N_dDtdy+qSaxtz8S22Ybo{NUvn~VZIR~ z{cg~{0H)DSg?DI7`pQ1mT&~pjE>_QNCT<+-yfNX81vy=GfsBLs^>8$#uYB#R>QK^H zCq6Rc!fxLnwghIDVw*3FdR2JkAb>RxSolcQGDTy(tc!zl%k|Afs%Oz9HxxM1N9cfP zd_nqR{=dK}mmvrw5;5YcJ}$QY_FmaceE9vl(-*xqH!)qo#r%JRtJLTBV;rF&3nQUO zJ;WwvDq#)~-PL@}xU8A*-5*&0(zc|7DlXQ z4!-oun~AK8mOu8p=V+grpUgLb!#{_BZ?ZdBQSQ!mJ1gmB7s^z)Fo^L@>l8msiy%opD#z#`K#;iQ;ixx+}j8_UZ zN9EvXlm_PO?8xm9@D)y;puI(^=@ADI_`H*yUc6PHr4`1N^%#zWGkFPi2K+F%^Gzu` z+p77@{0Kn($06WUrZzIKjrcM;$JgU~#arD2-`QHN>XG^X0w4FJ4!=jPand@O5no*# zeCq?v#G_Aq*sd%m=SQ`DX8ymxC);OIo1t+w;;TI&zW(m*-Y)%-f*;OQ^~d~wgU^RA zI0xP6hs%9b3bmw+?Q=(c6wB=(&6x)wl=1s6ou2Ekd(!>m=P?edC)8@HeD-g+{NZII z{mq1+9q-ZwwJi<~df`xCRy5`78sH*1jEe+j;9{JIy5Al9)k|+rZ40)^HO99zp3}k8 z^o|Q3CvMbR-ih(?Ju~>nhh~4-gO*H9t}(tfd^m{PS!RM}9N+D;fa|u^kEAD`+U|K1 zDE!kH{}6EL^9Y9ddEk`1*S}qwa&jzD>hboQ?4<;mpEzs4^^)W{nor zNSNDUks?bqm$!z-#mD_r)Be|<4tfPjbJ7;xRH%IRAD5Y{zb2{`@+`Ohg?D2)S`NAK z<^%0^%pJR8#i}PHLOEU`?J=L_@m-(Z>6;BO)y#Byb8(KQ&UeV~GmNgGm!6F?VI!`z zZsz=39~<}a(Zm{iHXZ9c))NSZa(ym(*CQ0d z7)_s>N16m`hBQ};E9cW{;EJcOf$v>6bWUC1TNzvGi>@l4{jnXR5}%#4XZa@jLYn1C zN2DV#&P&p}oAp9tXwpr%lMn;v7rswv+Ec%{bwke1Q`G!oK7}zlUa!Y=$xTI5x6)1W z>TTm-J+QImX19Nh^$^L2LQ7QsOiN^ENKm*LB~a%7Kw+Js~{*z1NESUC8OPe3j4s5&3LY zZs46e3TtZrPBQC(wlK5;Z9!$+I%(%j{1kOf+6!|<&* z9B$69|BdwpfR9e<=D5aswg$N3>1T%hp08iu_0c|#&-zjM>~9U1SwDHbLzFrVe~y)hhPVGqHq6)fSQc`hUgn#Kac+Q>L+|Mk(q503HQ+D?0x~KCsGIfcQt}37Xqw?uRKmm6vXib1P@bMf?t){%_5y6?i<_s=S)-{e>yDqs2< z^-+kgK6>V9hFS#`w&fR*4Y$ON$*fDpT#bY&pZ+(zFV6P4Zh+Pu)C1HL)C)xRrQV=E zpuV7fpp!xULA00I4jKST0}TYx0EYBV1CgPiVIZ1hq=U%DLi>+LfldLP3OWsRIw%9= z0F4G^g0etkKr{dz2g(NJfKYS=mYc-{P%da9Xc8z7bS7vrC?8Y+Dg@ES=c%A+py{Bq zKxc!_0i6q)0Xh#f6XXQV0u_NMo2Y!igu4(oQ@P%Sazu{s(yxZf^-29Prh>?`5y0cm#{p>qw?9`fCmPlvA#0AKA}`I{w%E4FmXJip0d-- zdZKKkd=3Ne36DCCrZ|7C9sAAFj}~3T@fnxOXMYR0OnCmM&$Vk0U>!img6Mp^j-XDU z<3XK4CxFOScOr=Mr5k>C2U)52ROhL_Q(dQePIa8>H`Q&b*HouZ2RT4gkEsq*{iV7~ zb(ZQX)lsUOR41uGQXO=HC@)Gtb3i^&5L5-4528wVF^I-%OF`FyZUWs3x&w4C=poSK zpl3kqKpR1Cg5C#h2Ymth9`p-nKM32KMH>*ExzZg(<$>#a82;Rk?o!GP;iPtMABfMj zYuWj}#pC~;MzA%9q~L5q@Fesdai6SI3SmIBAL0CR9HA8{}g537z5T(gfEc06(u7B2#gIN52}%_X{%a=#p1b zOihyJSgy)ve}h~--zmEXHK^}u$fxvJek=TL4a!C%_{6BzUsIY_oUy)Bud#n!l1Tr+ zQFwYUg!vlNa52co5q1;wPeBh7wFtw{z0ZPNn|*WFvNKNomgc_XD8Caar**!@G+YdF zC;GftNe|K&nxgW<2+Q)94~_raTQBba=;*4ae5!or8$@eAW6PiF36)~m5EeF^%1d^~ zNyWuHSsJXxuf>(|bsQFdp0xP!>(2S+?K7x*(VVOg2}0$wzX6{KNJHoTEQkDf&fC{WWT%$IKv~WXgDEWzVYTBRiFR3 zh#LsfUkhlF`HX|_20U5LnxHl*)6T*xE7OA1A^|E7|5NiH0!`x|8vAqxQ3FHco$jDs zAezsd45Il9HC!}Lp}7f-U9vzl&!9O4%^%JMxk2TiN>DB63eXLpJ3tSE)`B*JXq@o_ zhzb~O2cj`W7Kk?1%>%6fJq!92l!(k706GV>6!ao!KWJnVyzdO!2HJ`&1+bAafV3q*Nh z9AB;evdNUkXXLyMw&r9En^5`eZ;+4kri}GrkThKIc|v*w<2+%L1w0#H&3pUkvs+xq z@)(cGXaC0W433Lu+9;X21BubEhV*mqUvCayleLH*LvxHr<+Fd|cy#?x06K3;k6_f# zE(>^iCEok8Evd;RERXT1eD-e~kFK8>c&hc)pji6(?5`VLACJj7SK^R*q*j>ujDzou zq_sLoA1JsC@Qs9EYxtLa!em(O~nRsl2409$znoTlanCEZU0}Tsp?1 z^4Y&}Ji1;KJj)T0%gYwvq4XUfx})pC*c4?PohqLbUcM&l_l_?$IU8)vF&>rA{*B|w z^Z6^}r!ewyW_JjiTa68m5m#wOd|WdY-uhGexT4QkF5^=9>~9?xg^V_cMqI)XAJ~)xby20is_G^|wbQP22tVBfX!d zaO4=D%9p6YJXe|v?~Ww|P!{SA82=F5IRStiW$)m0Yc z{^##U{{CouuSJ|L%T@X8UtcaOTRwL!0&;oiLjz~JzjySAHJ47OaO7CN z%9pAiv$z zb#3>hoy^1GNcmIw@#GT_>P1)&#&)OAxcGXwVD5wyX52rO%=?;SJ*a&4k36{4LqRDP zvPpI=D3bpctpZyiN+7Zp}fI~Zcp5z3NxC7-L?IiJ_ zUJ#7q)9jr1`sn}G`IEoCasMwYhxMWI*+265LF}>mKkR)6d{o8u|4l)Hm4_lImM9Z5$lTX`1qMAoK{js@R)pY*YP9*p{GmHu+;kKaqj$u3vXYuN#YmzCSTk&`SvP2 z`w%o!4X*sLJ`EhDJ7F^-yMb_$PV zPgng_IU=<_j(zOaxw}8LGl%e$5j-Ye++)(Qc5E6Zm8!ATPQ9?O07VoYB|SE#A^+>M zr``4Svu!6y{374vi@PSD?KX_3s{*Sg0L}U{I5PF`KYY&#`z-F(_hN}(d^7VWf9hF)SwW9}L z{P@Nj*Gc>$-{gzCCVwQdfDe~0S9nHYmCrQXTjcz&;5Y&FdMn3So#%xc62Sz$Ld8S>diPGZS`>()`P=lZu`NPUw*%?#+HQPaJ7$8_#$8IboQOfMl61` z8$gm@R{#&=7d(8&kh|+#i0vw#-+g%YCplm%WB-B-%jApuSd2AS@yOE}9v6wb4yMFb zd85NAH&qm1Rld1?#f~8gOYr4GAF1$#HfN97^Yf->M84oN`QmQhv?9kR4xNhHY=m!; zzgj9*J^yYgv11ecB+9>ou6f|>W&0m8)AnhnD|`3C7rA0PtMxpiYNt-Z0jQIm|HIyh z^XA;ClIWZsiQ~W7rk+Gs|INQ+EB5~^4MYJ)>W#Xwsq2mHzq$6n{v|uyEqT$-ml>Au z&0kln-?O7OHx0q*5uw=pkS>2q8uE8t-RbMQ|JtikYi=Uykj6GE@o8-OR(ccr}W__t60X~cRFDEcw^ z;;zf(UaQHt#f5lOI{|C4#h&;s^V>zy(!@ZhshWB)^O;2E>N*AAu4yx z!>mXH&yqvVy70xlPTAc|C*cbYv30q+UZhPj!ta|>5~!$<9Vv|nDCM~Fcw34WJiaCR z{^mb@*XMT+Kj?6gXNSnJOuo3g@YqRIFe8Xd3{@kRGxP`dH@JHwG<>cb5BT(bMdbY6&ve+#!3X+2u_nP?g?wQ1=RH^}jNcXg@-Ve7VeZ*jr#fs^Z+Nw?ulTWY!{6WV6!RY# z#<2sQ!dFb~;cPqfs8d?}_NFa;N0MGn3r}?G)jX#qibW+C-}%j9&5`yQpR+*2ctKd- z@tg1!Q+u$ztm*}|pCxuauVhCituj$OC4E;LILvi?O()^^-gW-;J?`yx`Jgs-c)=lj zn;U<+am2*OPUqG2P=xqt7^iwO`VC8b8P+dj+f;1Kd}9w&55iXwXb-o1_qn_=H1Mz2 zS54)~anxUf@7Iv-iwbH_xOmG=wlF3O(?j?g1ofJ*|I*@I-Z-KLKw!G)_gqPw{HD-Q zCYJxGZw!+IOMuiJ7_gLavP$e-!qLXEqOImnXdqF)B?s~Gn~!B#Y95_>=Ko9^+H_~m z;ycrZWal)zz>rTvo}PA!x%IJC1OLSu*jirxixY1v^#5}W=c4D)E z2TPG#tZScrY0q=E-Tlcjwn=EPd>P-gwwCY}Q+v4j0pt3rNe~_YfnIkQ7Z|z5x$7pU z?oXauRXOXBdnTSDA}F6IOuo1$l8;kg6pnGe>Z)?bquyS%Dr{|g;l?-m;cz$y`DMS@ z?Yq|uU2@Fqw``xbKcYd;IJjLnNr<4=I&3mugp+wQsQaNd^oE6 zix0lD@Yfo@?L+kQk;6B`i4GF!g?{yPsfYYj`j~pa)VqqCLa}vcl0Qto;7F(sbwWw( zOc&)f7fxS*NDf@6+=J-1}DXOGiljcKYHzV1qC23H7U&KjycQzUt||kjgO) z2q^VY1MtvzL3~S84&PmT?VK$Wo@5hT8Np-n#U00-)P%8^3S}^e<*H?BzrX6#V|Zjb z22NrgMB{qtbfzI_^|^*?(0^~L>OiZG70z;qV2Q*fH@f@r}X;tx(Ke z;5h+vVM{uf0+%kAGWGn~40jqYh;NDXdj6EWHut`f)nY%V@EKk=FWd9YU*;a{R8c%HBX=1UF6!o1mp1rU)<9w z7h|W##&dK$jcMR{;p18J>yCerNvw?EG5O-279Nz-f+~ArS5LS6n$-Gv3 z(3-M91%5^Vs{+gXJf1G3_MFtgqon)X)7*Mxn}i>%iBKNzN6m-(k(D=}(&LoJFOab! z>XqLM;p1PI8DHs(gt7dOgTXu_v}8t5eLqEyGQMd44m+s+?usnQKMin`-_bjiI{%Is zzO=0Q!q5tlMVr4~_@<~r-0z5sDRCBLEmnAk!k%Hc*0shzBW&LcS?%XC{~EPF9fu!c z#SYJr6D1?E29V%e61Js!!Q>+Yw(42F)7T+0TJUXG z>@_#>4foHO9tf2W@ZqdIb##Gx3lGLAvYa-CK~B2xaFd-uTsX`< zvD^>44`@Ho0U-WPHp=+hhl5x^%Rr}rW`VfZ^)Ap;p!Y$U_~Ch=V$gY@$3SeH3`53i z0A(U0hCrJ^7ofoOMuFJ`dKm-E)T@*;J)cjExbr#lIQN_8f&big=e~|ttL~-)-dkR} z44^*K_a6+n$@g>_LIV za>*XA$rpFCzAMJjzPL-mhh4Kib}I()l3pa1{ynd&r557#t~pOcxA!(x?bZ3K6*qnA zD2^ezL2tsRAKfIJmjF{g&)>=0Dp(XxDMwpU;F&u;!#ZrkS);#QRQZ>piI=PJ%P=_3 z`bzkUsXg5DHL-cC7=$SNiu}51Zhe^ZRVz-|(v_(uOb<@bwx;j0L=hg-gTzAB~! z_}BBr+_RJ8VD!sNUVP(GpZCuFSlD0~g7=XMUoo`@ameS_Q(TL22;BYBV!kSl$Q<7# zzI^1t%_s=x;(ZioAbFtPprMY<#scf6eL!77Tv*-##Ca|9c69#V1vWprv{}Ego@1Ry zy9lrRH;Df5=~emvP}mZl zd5fO|wkOGB-eXxI<$@$H(v8NcBJ6*RC)*YOKNzz<<8SWh5Yy)%5ZhC%zgTDSf3~%# zAJ$QwL2Q5Vf7W57eH>frFR9O%uJkW;9phtKvMwW!Hq(yj#CnbCL~5;$fs-orZsR%V38m@@F`F&8vD9xzZML4qLKv z;mZ1(>&qG-SC5x*MjdyK^XHypOYwrI-i&tQoJ%vTzyEgAKfeCJ`uU!rtikQ`hS*LO zzG7+*cRMlGPUh8H%GBd2?c}8?0FF=^xL%H(`zp)IKCu6FCi z#6t<|R`0)Hz%)2BTJzii~U(=A! zch-Jve=<4wzxWqh!io(qt(tWFv>JG;!&VLa3pCJxOv&$0qJAI6nR%9d1oi>MnC`;g zS6;T-e@X*e>$5+lzO8}(KhuC&Uih76Q=Q`(9ADyCF6%Fj$@1II@eA6l*JzVirwQRT z_AYgu*mO%|#9fagk-z^d9(AzQY}G&_4KyH=w)XvZx>Tyo%Xtl!AGV=6ugft*$>-7* zrcHNgC$lU`8=B>e#CEjs=_W?vlK;2bwgwW_XB@|+{+SL;7qdR2URj^fCW&r!oA2^} zs`^3v>0uE3-)2(b{kH+zD)`^70e!rtJ@!R1&w4?$Sr%CL=T z!I9|Rrp8%)f9Q4j$PLOP9yXpinI>P{6W|!hlig}6hE&f8R>qD7GV2cs|G!|{TD5

      T3Fx@~L ze-^%CY7cet(LjG0j)Dkzig2da*s39u>u@%3pm<6_Rb;9!XnT&rl6ir(299#L9Sqt6 z;=Z2B*E6hLKK6b1@)0N0z2Fpt@21;0gb%MSGp@=%J&ZH2r*SV4R{n(t;u`0giV?mU zfm$vEtpkbt!t34jsI=qe>dk@JS5yh-C`jb4hFlsih;OF;>Gon|!~2cbUfYZPIU4$Fi>L4vQ+qfg#`xtj3B;rA zV%4SVcjsdl0pk<-Y*TUWTfZ-*`GKb=blUB~QW0T)MlvmvFYcJ>kf}RhsERn-$*f#> z;P2-A-9*Th^C9LB9*kW(mdib=xffrym(O%>(A=k<`1xTu2(PDS=LMEADf{?!ZCiwf24(+&Zon+G3v?&*{Kvr&WP+WNiC#%#l?! zp0WIT_bJ3$T_=JZ2q3;cyMCK(aJI+UM`BgLaR#>0x%PtVG`Q|U)>W|m{?ED>k83^- z1bIMQ^U)jB2gLf}5Kvzbs;h+eVLEeDYTbDQ{75=&X>g}g0~$>e;Xd)E4C{zJ+nj_~ z>+>$%Gaox}i*ylV>16Whm*$V8)4_e2P+=9m{@<8RdjJ8)ka9sR2dv}w1Lc8wfvA7# zo%%iubOeaH%?Awx6@o^9jsuMYaTCx)&}2|GhYbnhUxPbPMQi&_kdnK+l8L zgFXUn24z4e?LoPqJ|G^ajw7hJ9nRtsOf-M3dqB^CJ^*o@^q!fxD-m=G=v>eu(90m+ z|I-tl_v1mAfL4Nj0v(=>yAVN-fU=Mecrg|813qyr@=g8C5CG#PHc+B`(_FXQGjY(5 zv(D>5pSHhK;9K}MH~vhVZ-$mvw_3XOT;ranY=5hP55Jk^r1vcu)}$Agv6xsh+TYdr z>Xm=_rqO}G5L~Y;e1{#g(#BU9vMV3^m?NtRG5j;?9T@}I8S$~6VI9M|g=@cZLES*i zr_7`Lt^Gj9fChm^f|wsCg4k){r~5q6RiN8JOF=JyJ_P*=>H=l-2b}`C0Q3OpV-WMy ziJ%6Mr^*+YW z3yC^A_L2R9c4ng^j;wgGr zYTz)}S6FvqKg`P9Utb;Be9s+hgu+BY#36k0bmPVm6CYbwq3a zHs8hAzuM8gFddt2;%+#pf0MZ-^8ZJ9iR2{W{n7ZhhWqc-Km#%X>#;=ZD7ra6NzW%N zPyD|ti2X_$e#=>&$lo5c)%^1`VAf}>m#BC4#n^Y-0n`R0br)?C>oeA4bYr^E*8Mrv zuX5AV7v2<4xA`uHeog=4Mmw3C?(fgOCz6wh_h;p74gcSz0kgdPr=xEz&$h<@Pyanz z@%?vc;J>ZBh<1NZ`S?A4CH}4URt+T5Kom^r_b)+zm+dGoh5!&AC_JI$*?Kw zX2V$-j&pIe%j7FI9&&C>tkXMaYA`Z`XUbIicoa}Q{D}O*hf>QAmhCaJ?W*oWqzusJ zxRCHguGqy@I9;X2QxcfsuTlHMJVX4vHb*hS=#Aqr5KKH_v`U@kR~6v^FpNGPu@<-} z#|xs(J^|aQ>qp}K**7`VY~6HupJ$poMr8U+`J-=>Pro$9Ra1l2e)|-V0holu(NQ?n zJRI@Yl+BR2DEiZJl>W_)gY9Crf%SD1TbggB*wv+xhl+zo{r0w zB9#FE(Q#BRwPW`>@h6&>Jgm6ltKDaQvn%^|Gz_sFp2Am5?U5JBi8qk5H&YFR5@hOl0ozY+0y?OMz56_xUUC}T^7M{XaOzqJEhsr9&(1akc zJvSmEmY@HNd9%(C$+4$I^DsTYH|Jmu2d_WqSkM4aAqYjr8Urc?oec7WI1Y*-VzqaD zHtb75*Me>a-3{XS_tT(PK_7rNfwJ(sJA(2+M}fwGa6F+k3xsJ*i%GHp^dpGl;su~n zL05yG1bqX_Lt;z>-2i$Ul#5JU1^OFkTNJD^&`MAb3brF3LkajLAGpB-#5Ip=0sF8$`B9hf8jgqnAHj%KNhO^ z%4cw;4p%tZa5$gXfCyU~_l!k~7hA5|CQpd^;=36AU3gpV->-ps1d(=b?q|1 zLxE{kSbHOZqj(WqOMr`b1XnrUSy65oY*~@xkNmOo<_xRjU%r^O`nbpPSqIPvF5%nU z_|wMa5*_<2(U)G1@>iz*4y?%jc*!-t@M~|IpViyX875!cjr$I3aIU7GtA+~#b^b6f zWa2fALuckr(VT>=^f>Iq`IjB|k;ODAfnXYjh!{0lWu zh`7yq_jHu5$E4t!22!dFb~VXgxmJ7$C&CV*~v*owlh$X~k3Eq@Lc+i+c95%|0B zb>zN`cANa;mLC3n?VEh3u|s6E;M=ZPN9E{6>P6O^2V?!BFH}}ZKYUPrYyB&xO%4c6 zezoprAJ|;$HwJVL=y^~9K>PyghC=xr8gZ|qt~eR}1mZ`Mwdfz@bDBRcFfoz}Md`7Xz5gaC8+!NzK`?3soTH<6~@u%Zx zN(0BzXU@56)rFUDmhghZQF7^oJ4QY9Wfzen zI845{C&p0_2uzvk3r(?H`LZbu`Kw?2eBvRye|nF^FY-;kxVIv|wyGMvMR?NFp>j>? z-~WEqt0R7EI)Oti%7}cEFYbxuJN3kIwN>`6Dz_dsrh(&}d)h893ZESnIfBFFi+f@m z&f&@M#E2vxR6d_t50@YE@|~6U&5Mm6h)8_hJ4271<}q1@w=dp%l2Pr z9sSspmk*bA8U3;UCw%+i$xf5 z5Vgq{cfldT?Rru}<#^QF%{edHu_nWD()fY<>@i~GLn23Tn0#?hjAKNg%vbGXPB$jK zoXkxF&kdVacwc(A+X*61@R)pYPmITbG8o$t6U-xYekrwHx}KiZ@9VoBRAU&FB{)oe zavX#G7*z^k3?CK!|LBKkFNGbaL#!c{TO%@`Tf?~v5EXd?a1J)hi-U0cgQMLt%I z`QkphctB`IFyc{K0g5vI2ZXX$wIslkzTN%LqL5k6{$TVR_F^?s@X5O%tjk`)B7bGfrlnpx?Otn&$-^?zCWh7Bak7sM=le- z!;V?$rdu%m{acQD*1zJmVwX&{9s#a-Be;D* z%s&T#_<_m?4F{EiDnR_Lmw;{qtpGKFw!sfL7~}_WyT>P>BamsY1GPh8z8KUMU|t8^ zj*n420Nszw^D6*F(K#D{{>K<(mWSKh{fk8XkeoLVDU27yH?y3shTdN&yZX}bkOj-{ zrbig|$Jh@QzG7;RG}F7qcqXP+)EKXgNYYP>IE_~cn}*k|UQ%eF0m@`Kkaf1NPq*_q zvY4tnMc2rVNzEU1XZ#|A0`&j&_f+vG1@~Xl6PkP^B;0++r=NwFQ>**`sAnAY9ZI@-8J+frvk!!BIg=54tf=l=|H~wrL7j`lY ztqDgsX6;ISFSh(v)No9PvCIJpzV>h0spkccZ{~alSXP(k&MtX&09|Zjj~{N^f-ml) zeAB8b?EStZJB&=Z-Ijo z9xYI~^|9jZ)cRO3rQdtMl|B5c$U&0^W@pRfi+c+kgG0Wl{+2)*AX=}tC49OzniZ;V z%X*%~|Jl}|{r_uSi=X~aGr5R~>BI8}D&L8pKTtmT@nOt0dVbD*&t2}B9?Y*3kr1+< z^P592dF6+WO{ascjGgl`ER!$pB_ZCURX)y#%XM)tXf?{XkGGPcOW?6@%(MF`I*umf zXU6LV(PrBgQ}I?a@K>Ms`iT?Y&9F{=dCV7Uo9L?c`=LVn(SL5_6 z;I5aSVfdehZT#P3a(|EKf1+Q#U9bfChepyZ(RtA~jA-}zmFGq0t>i}qh9S5QTlk8p zJreG31k<(uH4x-&nal!K6hwXUJpA5G$?*g~%&>-Tci3}JhCiL7I%5dSbmR9``1sdl zh=gxaEu3 z*tS=z5q?E}>HDe29j1Ty*s!ZT@3Dv})6IFBe8<_s4D(c;M}=>qXHZ=blgs=<`>JtB z2rrTzhqVBK0lpwdi*W5@0oq2mD{Ww{za)URMy>k5s;FG$9XM%P%QyL-W?1i!xoMjR zhFo=(q?71L_$mVJ;ntI}KUWe9{`LGD{2)0FM&D=UYwfSUu({|FexzU+Vm~~EubA3{ zIMUdk8$+b0U+2H4PQRI(er@`?^tsr4gruLz7f316&s$qwl~(#KL4=aeR;Ph;^R>_1 zKJK^YWAkZ()8wa#6UXh~zGT&Itj4?&vSZTRX1U5m@blDqy=Tdd&))lE=6ixi@S1#a zPodW#ek_)84zo#CEUZNPO|l_`*^PP4&Y>dJZ6|Z1&s6U2*tY(+RRjO|8fZYKW<4b1 zMml2YKP1ZcY}>YG68UepB&Lv*R2}(&(%N!ph>%` z{THd*DX%@^uYRUv3YTvx!*(%y5hh=;@zBO~oFO@TNiX{7Xh98>xy1EzmN21rQI%k!6kMwd{`|}TV2it{hVnn z@MEc~e{4;)+EAwB%EukNtYf?&))9Q?c#=LJJ)`G!7r*s$*VuZ29Jq6|!{jSA9<7gG z+N0BITy+rET0xPcBbEM;8gF&?M^^wB@dz$rV%tvkxfNnuwd(~}Z`uc(*WiN|t+kc_VNnOP{=qOzVfY2mQ8dyS*}P#5PXqLHIfb zzH9jg`*XP8V?b>vgs!PGm%v7p zFYV5F>!p>A#U>8n#{f7l8V*cU@RoRQdFyE07?^K)lG9X3ch6XkUXCH0QA z$*mWbAxufT)<=EuVE@R3?MzpjG#Y^WP*DX zByyvMT(kT#y17+{>^JHCH3Ln#!lxhIw2)hb5fxv^S?%MlZ=1hQUTzrg+t+u>J)-F+ z5wFS_f4RvQ4DS5{9JxVV;_M|0bFZ$yoSCF}2J-7v;UjQA{CMg`Z+BD2LK6R0d#eVv zY9OwG1{4sz+}QO}+%=39M=z2 zQ|;q%-)Jb=Dr*g&-VZ3mW_^|~FNk&`z1>k+aNW3Ve!EZP3qF%C?uqdMD(C521BJkP zzFNye1YiW0IWI)Fj2<_3U3mHMM!wU?e7(uHT`da;FsX^W6$y`?ggt-Lur$S9$eUW<0bmWGYM9yyNWjD*@i+fxe7ROFzcT8_;$Jf2^ya&BLmhiIPM*dI7 zwzZj#&*byFGB%c8O#e5&^z@p`&1W!@UWxK=w?|f0{J7mw_X|2(pLt@H5J%T zrsHTxfny8CLGGP@->qZ4E3Pee1Tp`zUnG2yFSee4-D>cR#6d@@V9{>_Nb2K!90X5| zNV+8I7kLl6>4pvdF2j1k9}VZbv+xwYVrmbpyF)LUmzu=8^_cCAv7PSq7=LZp@12G- zsC|>vPEd(L*Hez_fyMEe-_zB=-|g(jFIl-q>8ocr5zwZdgfH=mUF@6eS7S5CAf7QL z>ewS}1PqPCNC>{A_Ig2h&Ijq`{1_(!v7LWgwe;UH*XdP>p3VGUx_h?O{>*9fJI?#= za`t~|x`FsRgs+&|BT>GS{2$K??sh>m%kJj2hGR>YZ0qaoOZV-*;E|xzDU$DmuR&0+ z>EUqaK?ckN>H6h&f_c$2g<$CZh=<=c`elAi*Zi~MX@FoIPfrJcU>93(ng25dq_b_h zNtmtnAJ;%5f--%$o+mFmd48vqA4g>#aOqpcJw&1%BC`cw+~Z}-gTd}VBvS2H%fZ|$ zM#fiFR}TnGomv%f2F7vVoEjVnNjwdB5uB^jz?o6A>W=+CIN&)6FE~xUxVMH=ZoyHj zkdnaE*SVCo;Ye7#9&V3!uH&7vH`Z`x@0iXQ_aPI9@HGhPwFM3} z0PC#3hL1U#{JOTu^^o&HTdPfBdq8l#<#`Co*E8TAteEI9#l!duI&zXmD9N?BhkaW4p>*JHWcCfCQ@_F2{&*EiQ3H1pzbX0wumk^Cuqn;U<|g{gTo zQy*FmwZrJ+4NFtt>D?jAy5;2A$5pJ|?>Q5X@Z(7Ax3uvXn$q=DxLtBRt=&1x+F|y} zC09MtVf)q0Ffgo7SdR!_F||i3T&&{s0@Z-9l8-m0z!U74Wj(ri@#UXwyzLzmkMK1p z>h*WvF*Iezq?h;L_U`W^>o(3?%XnMe4cS)COD9LS{o>BXb$0MrITOCaj#(N$`-|hP zz*xWpI z$JBV{PI~n8zMs7m+iyQu2_9^je8JO7KgZtN9miGZtHG6IKquo5x}I`&a_5s>5IGl8 zHvsPq_m>|^S%=>Da0hN%QGzx*rrE1()UTmRkl#_vuvUgzsH-1ku7Y0{04{ce-b-$0Y_cas@ri@W7d z*UL%!_U`;)-ou=;;V;%#haWiq_6dXbuzlL?Io5B&w^78O*ry%Fu}#%}+&Ia_6|$5e z7hb4u?x*PuxpJRp=f=BL+`4;_=H7n&{RdFCp09IvapSgb&9qj-&qjnh_v-1#3Q)KzQWC-$kK{OCdc{=J4YB#$ ze`P+BeLS52mh}|-{wxn%yw34K?p;S0#A0RE71SNXjvV{s`-2VyaZfwP7W#q?2OSAI z8k7$j02%@s4jK*OSQ{6dp9J!OCWEGcP6Kf~`%KVm(8ZuDLGwYkfbIm{4_Xdd1zHPw z3-mE)6X-Y4_8Gtq>IpgmG!%3Ks2X%OXdb8$grh|*T;pqD>5qkGq}3Ia4>}oi7U(9> zO3)`DG@mRU=rRd(Ip}fF*P#6{FfsvjE$B5+M+}@D54sujIjH|OmUS8EV^9GGoNfiR z%fT6oppQT&Ve!=l&;)$QHiAyy4*TlSad`+d5f%5&7zBI?bTu|C`P&2EU!eC6_>Vh4;Z4ovx7E9qWnqL%#`$)_s5I z9EtWc5^W%|*@sB9g-Eo^k!Uv}(bnZdcLNa~iFVO&%Q^#zb}JGsvlQnMBGE!V%ertf ze!~>>OOR;Ok!TMh(T2>%x~Pk>Ck=_VClamKEeMB1y9|lej6{2B6|lT)S-EdRN1x!1 z%gs#h4C~z;aBg`Q+#%d6!lPHheW1ugzCX?Sb!RC&Y$#Y;U+zGCB%sNFESW*ll)d)!+M!KgU`JH!%LqK{_aAtEn`zmxCO ziHs}Y)!JOuf6p^k72KG|e_&{5;3<5?)E@DSfgySHAF)Zb{*LbD)Dq_!<=Tnl2s`IDR!<<*Ysh9tv2$_iop6MifkuSD=&hA*| z9L#!QL7IJ~dsy5Xkbx;*)_?sB2cBX72r~3kyt96r2Z9*2hxh>4H25^B|82zf|M-Nd zvOrz~hXmT^rIV*@7PYgrj|LNqO;feI!qO84xXZqBBvK1c+B#`0Q+7% zWmIPSc9pE3X^4mC>j_^mwMU^ZR6ZSRiai+Y=6UmWhru(t#sMf^qj(V=v0VDVl>FMx2J&!-JYuh)JM?4q@pC(_i@zDAwP6s#a8Ok-c+=GvvmWNj= z*xw`cTRa1TwVsizfGX_lCEYL=&iuVn;~aI_)qVQq%s}hcHiFaSi~AqIIR<05BQR2c z5!@I|D~bpuy;lGy<%&MhTz9Q2$G_I;m(5@LMEyC(+xTpKvRx*8`q7PjhQgrg$({ng z51&(f{3EqNWIE@}HN6}b?VVar+n#sjMaMilkyW=cq9>Ct?k(hx@kc^4yb-Jx4o1TE z9u4POViiO$hwFhy*GHoK|L$M+9=>+}9aft95We6LJB}x|QcErB_6(}w926Dfr{6k| zq)Sn*8%H+W+JNM|8@yV_ZCN+6Z|?JPruanqgqc?f_!Hp8fefK)ImqAU1f|R^&H)0B9tL0~!?|bmOcGK{tXP z0=)v-1nLA#1)vCMF^Jn$`a?zYKtF(Lpo4EgS0I4~A%Qxg0JTAbV)q>Mz0tp2gVJ3K za6WXrt^>Hdoq-Ac*7ML`t=$s>_Ql;nJ%9y$(qZUvoOl%a`h%c{BJ}Z3!nnf}^iOBv zuAj@$Z@&$F;K$G>MaO^qFX;Pr%dpNrF2lO!ybS9e^bfbioYZdPGp$+oXIcmBm1PaZ z8lUnW+19CRvaLtww6O-3ZDU1oi2rS~a;zny}M>S$8h&YW42l(<;37AdC3`O*7TMi~_dgQ#E*i|GglnM){+T=fY>j zuvNYBYAv7l&Gi-kSaJr>>!YE+j(7@RF|~)0U+fEIoNpMt)q_NSJqIsflF6TP<;qBx zgHAd4IOWrpzXRk8-(klrkG>;?tnKO2D~z5nOrQQsc@w zuJo7Qp&wrv=R`og5SQ>JUa?!?GJ#-<4C@7^;?&O;=O`~p1JAejSDyMn-S!&>8+e2- zIK&n_PPz7I`cg;g$Q?wwUh=!Q)Jr)c)aw`D*K7LJy;a}i3MvGKR#!ZQubA3HaG>+X zU#`_JV`^)L;+)hG0jH;A2h!UU8x1^(+JQT5^VRnQuWKqlU&FH(@CaXnqFx8!B<(6c zP8JGoqM>x?1q&ph$i4r7-)2}yW8fJ^u$F3JD$eMK2S z#>aLw=KWZ<^T$eoEB_mK%=vrDdZNXh6hLpU&y&ZVzFISB=ZpeU5(m^y%La z!`Hj5e)oaXXU^w4jSV-W1>bhXc(K}FHxP?|BDixfgn9J3l0a=)rD~joolc6sykLgC z)6C18u|jCcO86*V1Yb@sH$K*BY+dQ&oBiikf97A@c07irm7$%1Um<*l9kXOyaV$s2 z)SQoda5D;@B7gOPZu!hQ{M_o}c>g%K;}J)nKYD?aj7mRj#|t0cT}CMbOVyc}MJRPV zKS@_X10te)8E;`=J#Kbv&@57hct{*;AujrJvUe;DSX<3MQ3Hw6=Z{9uu}euerkzeq zM@e_5iRTg{Ze+^4*vaw${fIxYT@nA6|I+~cQhqBvwkEvb@wb}$nA>Bubo<3$Uv~Rv z4I6f0A%f`u;&`d>6;pd?;{`JBibWmjL|A^+XQ;OANdMG8XvRpKVTaCgR&PLvOW4fG#qCoKH)2-_83{@#SKI_aj62fd>cZn zQwo2&9_stJ>sj_YcL2#f$@Pb2S_|*IW$IZO_m0MNq%tfMlrMaT9kWLHBh&G%EVe(J zo*^OJEKrR0Anvk?FT#QE24oDgzKuna;Dz}}NSygUHK><6-4EYQBYw#jzlr>r;r@U7 zUvKB-9h|AYecmKWh%Ot}eoY_% z_Z&!wT)Z&9a9p(zctqYQcOIdd;th^F$5l7NooPzEw3%o5?Ur*u@M_IIYW^=@HoxH9 zY$168=S4bv`q7Pkz?|KL(m3{MAn4mm#|X8RbBZI{7;2=j0g*|$pL0lRe0v>#gs+&|Lqp?9g3kmd(_OB5p?zO>y~Oq(Td`X}a*oOVW!+X@I()5as}hDC zBGWSYbfb}@4RCED*T|rbL&ncX<-RbHGW2}e9`zIT z;sw#h(36_a&9AkrH*;T_uma&noIPPk&uu~@PNWBzT|lhAgs+&|qjj8PamKjXn>MIM zT?T?pYA{8JSFgt?CK+j>lt1}j!s!3YyV&%T$mo2DM{N4n-xG!ZPvYs{r}l@(^C8!q z<=)&@<-?}omi5N8W15J2{3jh2f4umWrAIhF!q!DbjPI~x7M7ypax$kICkKb(8n>$O z6kgUoyuk5U2U}0qSOf`PY?-!$jW~g)G+BDTzY)KmaeG0IjEsD|H+_VA*0(vB%~)&s z$eRl)R&CeMat4^_kM%^1Pfwb0?%DQWxQ*w(OvP|LT1}V=s-}(B6FO*~;!4c4u^AHy z40IHdi#ViQt_ChCm%nwMJ%BRxbSvr?PdB=m?HaJG+a}Dq&&8(%0&>t83Yc&nOAnlS(KsIAL;@Y@Vp?pC93E48S`b< zgLC#<3TI{LkG@U5V&f5;6)6b>aOHDoWT4z%t*`3AVn==aN!QyPUI+t|3{UXXW4A1r zvPX+~WRtHV!Xt*q;{Zy81$xu<()ma?jzsA<`;F_L9Pq>?>-*aZQTpS2vhYQ|*sgt~ z-blX_lP`6CzCJkt>E#n67XR6*?@5QK&%6< zX7=J0m(>{WVOTxA`f>6EM$#)0u1OEfy?E-(%C5>I9)io{i+d_u1=uOawbFWetxf~S z5l?@8e&q4FKZqQ`Ve-X2DGp~6ur4yvSItRz1k%$h|7dr;#kRvCpovFiTIX+kO3e|k zX?y!#S9F=%A|IRlbntMj*%xw-yGMqPqe5MY2v{Hdk$E^)u+k^OlvmR8<}nRsbpmw; z?FQod9QK(wXUC~A8RN^v`#zw3LCh50K;1$6fu#L{rJYtU(EgwUK$uRmn6a_UQ=M1W z2R3zzX3W`oeq0T`(2}2o94k?x}D{SuB_}Was-FT7xz>+ ziZScRBPR5G63tJYPu_mwif)hAM^6+vg2UvCdompHd?IKtHidw!AJ}iSys6V?Lc=k~ z<_x>(9+4+_Ouo1$!$UuMy3B!m#^(jmPE>DRTNF6M`uW`N;jE0vH~He8OunrT+oz7B zeSupKiN62uWnA#aZzJ!yV7~2D_5b$7Q}`lZ>>^({jDewY8N8GK*_y*m2AEH@KmH8} zAnCCLICOnv!>tWS){O+O&a{?2bNT&m_IR~C2YedZ?B5ArF|~)tO^AbQqp*3(gOhc5 zFC`Xa#wYmw?wJxd@Yu1zDYXrX8?~k~2%kK9dZ{ica22H&t$H!}hht{M4 z)Ac=W22L6;hz-EoeIOZXZj^(r_L=ew5aYQVFWX!zCxA5ClNNw?v!8G|YVntQ$GzASO5nh&O&Y z>L~vTB@_?pj!%=X*m$JEH6&Pz6(Yd^cFVCF=f@s9?(hX4i9Eq$^2I$3 zJY#rPaH#5Zm5n8w{yoecnp#fZy1nx^U zcP^YZ!>`xeInHjnZ_(T<6S#LC5&!++1n&JbcTV=0@t11u7bS47)7&ph;9jq}U!TBz zspft|0{8Wr`;7_Qw`lISC2;RNGXDFyE*F1RE=clEKh1qf0{2qQ{k{b5b(;GF3Eb;7 z_eT=AFV)wYYmcYGEbLU=R zGkm?~zRq#izms{R-Sr*o9K9ccf34bmq8m*FCkycrlgw{!IXTCA@w}(5XmfA>BKaV3pDf$W!pFZZQ;231 zM*nfa9KOtcF5jGjn+~w9BH%5@ExS0AF%%5p@OBBLw{Mz{bGJv$anPcoOzW?W2ete5 zs%fX#da>sViAVSnuh+NX`uX-vPvtD;u&**U?hMQ1i+eHdV8*(Ek^lxCFp$blm8XEa zg%t<0n3TU2mA@iom;d zsOQzn^0ggD@|{NTn|#|9x^TvAuz-ICstT;i4V9}YLu?wuYi#aKPuHBWsd0S#_YDFkCZyf{poTQ?%>I7Jn7a>q3_DY7 zBX~@{xTlSWE4Tci@je`k!^&RQQ}1!9_4N7TdvDBLy_s8&lo4DeU)o;jtd z^>y^G^?5y?{DD(r$_O5lFYc-EjPqAkmEpV%NkBbc8jmHLtK2oEf$RK7H+_1}&Bb?!T+xro7xz^9F>sm5=c+%0C#Kfh>(?#p z@b&7v{vu!SnS62oefZqdkt?`NzPP8tHO5~a!g&HMQnmpRNV?8BIkmo) zH$C;lvzuO6EOG^x$rtzEhpT0Z>g}A)r=-SrM9o$0cdt znZ01afMF|pRf;^(m&q6RRQeiRT~$%Z*#tBP?fD)1OWA-3Bpr(;rq_*7LbFDK(CxuIl;pw$^8y7E?yj&*Y1H zEd3JTa1Io+SC2UXbUbs@z;pgfOZ(nDxO``kCwNT0xTk??V!s=p5QV0;+_mo zNg%?mx-xn_Q{+#rmz|os|MHl(-P=R2wp5QV0;%?xc35svgYi>&qhvM~+$ZBPB=&Ajuo+e-W*-{gyXa{2M5t)5?^ z6{+=*H~g6uL!bDhML)&l{~jD3CeWy=vMDu88QV0#lJv=~OpR;9G40kqb8GHUCwOe! z!sLs4I{Hz#hGL0Ab(QMf*^Ng#20i^6)4+G`@kehvqyNjthE7V@=Z z8Ovkdxbwmpk&gYZA=AGfxz%o5iS#lcIQi8VKfCgNkt_MhXXTJFBZ^czVzEbv6*{_&iD1Ko zGB?ecu&i{^3s2elvipzRwYX%<5@q%c#2eF|j z_Yvh?nQ3k7>s|QU+ee1GfKNj`bADF%im5%YV{8acwGCoF7RGYQz8dHUN+8D;~Hi!XwF3)*AmEQtX>dp4nFJ% z+7igHKFHj^=jy53Sy#STHS>b88?(61hDPKI-{!`jE#>q22nPe2l{}r6Sx!Re`KmDJ z)`xY$ye!rctFf-H?w#$_Sl9RCo`}r6|K|m#<=8P07SI0?zQikb@oClZsaq#Ed%%QZ zcx^ownL67OSqM~Bu7c|I#M%_Na?i-L0)HzARQ%(ixAt)a^OrE4gfDo+CNA#fR>w-< z%^yq*MaNNknp;2SI{GbVXIcaQ>YKaf&hOT7eFlx-5WdZgKMfpeqo$(?&$yAq)pDKZ zMgxbLPW9(xTK87(|MV5(t2dbX5Plqi{pQBuzRk_vKI%>%J>Nt_ZoQazC}CmKMF%b` z88vuYr$@_tvp@2U@NE?FC-KOpLXYGd<`{MOX^pQsadNrJSNpIVmziFa)@8w)|Jczx z;Xdgg5La8^5`G+!{U&MS(n%aCP;tgz0mT7V?sjG)@GyQah&GE*J5U}DaC~mNbJaNu z=X`z8h7Rk0`p_v}$`4N6vxE=tE;D*+O%=}K@Zi8IwH*W7Q&lsdV1|93ImWBAnh z^V;dUdivEzlH}>rwfh@H@=%C43hs{F4?g`&4`l70&)gSk}+7o7o_y*GyO=QBy9Zn|yIkB-i7tA1~)!b;a09SyqW-5DI1#1*)rL+)&4rKP|OB z@{fA6?!bA=uNS$3%jAoDLR>Z$Zv}1!uJEC{Z-L4^pVgEGu6|cs_-gpzHQb)5jNmf) z;+_y!OkYY@N%865gUact^>)}*BTF)$_~sUAw-VnrNKfGlF0m8hQ*CHm9f9pk;!nrX zoCc2BQ}Z@|e$S-4rCuS99N-YX#4C0}99X^-3a7o{e zhl(6YFOx6s331r@$gbd29*XUXclEV}tY-v3IGEBZ3|;+{}n$X}_TH6jA}z7?SzN;zH-?L^D7q})X-=wHA8O^`^H-P@bt!l#zfzDkz?bK|B~Ck$8YkOwz_WB zz<;I&^m4s=cIt9{Ro5CGDbv|A7+Xaq#YP(Raxig@dpy-VcciIHmUVt+-%~IBD*woAZd`)l_$J2* zg|C>}!!=*w%$slutjJdz#&LjSYl7+p(*$-P9Zz!#JkdR~tc&x8Z~6852P?m^p~vtD zUxT7vU3i@N68qHU#E5h}(F>F7CwK2G%e(W2zcsyl=AaxyKf+Inr=@-d<3jXG4uwlN z9Z&mePJ+!F$ zfN$E{5@noO_<}=h=U$01nB-D-t8#v;Fc6M-ii0@F&PhOL4!Six^}EQ3+9RJZTPO_=CEbq4yKKiYoSj=sER_S*bru$7@d`ZoEBjfWc#r*-WMzRHz! z_q=GoOWgS;(YmgiMjcS-xp2bC62Hhd`Qq-DKLST|V7x$t!&3uDe*b#NXMA1|?L_I3 zF>v1eqn|zCeltCUk6|=e(?fWGdkzTGUFHN03FI_b8>-(y@-Yp;;E^M&hyk0x2VK6*iiIsHFh7CXm8@R|I?_+sgr5?li!kaVt_ zn>wBUzBscYtKIBwW;zRB@QCf!Tk>?qsZAFXA!(*8*Es|+^ zRnM@tG5Lw{>FMf5qvMzZ95l(&@4Ly72QFAM@&l10>1XoA-L0os`nf^Ca|1}yYX#N= z(Fl%myt6&O1tjOcm$$3^^uCgwY@RA3I845{b8VGBRL1+~uys})0?&!>fjCjU8ZR6S z=8$z+s4B>%J8C{OcCIrbk#>PT&uh!H>wJ+Twz$dvx}D5T_m|FlBRq-TD(9unM-O!0 z^P1T`=I_mK6b6HqUE=c!WhsQ~{J73nrN-H-^0`}w$4raT7{S5`!DLc$D}UYo8?jx%~|w$=8z$j~Q-Y{aS(Ps-IT_CrxYR zq5byltrsdUY*X1gf9Vs-r+wZa%Y*P8cFanSvsFFD@|9i>HsO3sn%3|w*`d94$n}?Y z9evcg921}LW5Ar3r&qL zuY*S)@IJyG=`@HQarinWzKZMH!zPRH&M|GKIO(Z;e z5*j<0_y!0LLX4~OPbVC^NghQ2$uD!$z%lu(Yi@jUb943Hjv%JrPDl~qJM5T+`?)*= z{GrG=oOn683LrShF&0PDRNENzbjiKJt%q{NVzvYSy6@)2yL|Z6HzI)YnIlZTxVMmx z+uLgWNDEv%8jgg=SNdz>%0M6;&k_TVnJ!y~>}Yl0W&dAp={}xUT`RL6o~-wT@33Rm zDBrXytS#dKwgUrYwd@Rf!{I;~j=J@ib3y4qzzWrtp}D2P=;bAEfji$ODlZc&x(+MN zJYff(=TAdB15e>AruJZYv9FT~OL~`o8od1Y%kMnqQ?QlcT5_%^H~ET<2b-EWb`7^ZV2c(mI`xe5PcOpqYv>R4Oc6Fq zAP@O)9YCb4l3^M^l8@_dOpRyR=i}y$9@gs-hNTfaCf|1beR$Niw*a~qlSA0}W*7K+ zL?rmy-{j8cX1=1#M}8{V5Iz3HvqV01&f6YLzPKkU?*p;DON7vy> zWv(lC0_ypzvcZjOHTmxXabG?$ao;R!JG{SadVXi#NWvI z6waY=0BRtJb0VDo7z;WHR0iVWMsBb>6LbOSO3;mq^jy-rzFtGwyyI`QV@>Dtge%PQMxyT4uh+};sWzVLO~ ze0Rx5y7FEm@}nU6-A#sEdZ4bifTUl)|5=AT_3#~@4qz!G<6; zU7lPwo?&SOhsn2H4gC+TQHs!#!Bs!k-I`ht8@rFX_~7ZUzAEvHe3LKkZaoaB4Mze~ zv4g0*Ws2A#^mMUqOO2<~RbNki=eQykL1hGw$rtxHo&f>eq7cO3eL^VucWbVJBT+s4 z<460>&xwB3Byyx4Hu>V7s2+}g^Hn>ULsL}|XTVp-lY6^cFD9P+#%ycVMQ==c^|>_% z`W%7O3+rFu3l6d4vYqCiKZMVM!}YT9Mp zU*Z+JHTi5`#NFcKf9$8MNP#2TE6d8QAJ!*p=ZCwRID{|q#g5D36kG`BUfO!_pwZ*6 zz)r^+o~gpwLJVLA_|>*U>iQ{Mm|Q=(2V_}?O&fUntWGPYEZEr&FZo6If=BFDak+Ad zTR%-HaI82GIL7bs*TORve%1nq!x#Btr^aEXm>seKmgL`PV{-jWJSfY0|5WR>#dFWP z(8MKt!6SAWxRR!zo_;xtlH;@bWLewKdU5&=d1uTCvJnHrWMuggzG7;RR`C_1fIB&g z-s?f4r-l?b8V=5~+HK$UvhFXAA7kPWz6L?Prh_9<3N~oC^6yNppM1>HoxEiIArCJZ zwY!N+_$NHHH65B|^@&=q%^Pyhf}6IrkB4B9L?p-j!Tm z(ZjQ>yYD^b&a1q8zF^`J{-49sGDVkY_;T+~jxYC!EbHo%hwQZS=HN3XKH>jKd`VK) zj#)3CjVbW1z+lv2JAHLk=V?otPIbo3uusu zS=MXbufN*+iPOfLIE4R4aI{QKcR#x+1upBDENjpAa`!!B}0 zxW`MfA*>BZUpI5a=XV`FebH+%7~RxcH_POU2d!Qkj_b-;gY z2(ndNxrl)E7{`s50+)<8O<(ue-YiqP`+Cj&+c8IUXPP!T;nlp)lGOTsJjeI*r6*kb zK7uLJ+j*LN$Js*P%DG`Z>={%S#Aqgm?tIla@&P~6qo4K=#xW!6swfQT)nbhxdgrxj z#E)_5`7`I<)HpB6n6_rvo%7BU9QL?gFU#bMd+fZE!L{m$haz7HT_LYJQ^6BIt;*Fu ztWN{SZx?>N%S%_B-(BPg4wEnLNpYaXTT||<4%GMuOyj@`jINj5`;zOW@t7U0LoZ&} zb?#*o?#i%(t8q?#SB3AeV^&f;&Z%bftm9}*fnzOjeAfSpxBoHcquWg!!jA!PUXtQa zr_PP8sYY90Z)fzoKe;{_^`;fy?wj5C%rKEB>0|Q6Jt+>?S#Nd-9nb1C@SL&Dgbq!w zmtQOL1dquV_oR5Vv-QQlj;Hj2)cUE~=93FH7F9na;RTP$7x$!iM%SpGv&<1PjE-j` z@Gw7kLA2R4;J2p%gKK?ej#VF<_1|Z%=v0syThAin8zvvYl)-2+4&DpYVoA$jT*`=v z6jrVr^1{_?IQ>plFxtRw142o=aL$8nJY4gAQP;@owH-*;etz_w7FS#e@4z zARk8hiNd$J@n`yYJXq|;TP-o?;tS(u8QVl*3BH_%Qm5Y=zF&hIwp6Zlf~#=`jy9Nl zahLmChKBo=mW~b`T3Slw)Z#vdazFh4)~`ok1ohtoNZlDdRYH1PrtAO$Eay2 zpY@&a6;pd??UYz=p&0WhQ=Od>mGDdX|ElqKKvU!3dbzNcCjXu5@jJ&xkKJ$ZsUDx* z4vXhQ;cGupy|(^42Ubm<><{51&4QxZ)C{2GnF~B@SxY(PJIks*Z`E`8-e12uWc&?a zD!rt`z8@eC;3GXBy%ez{5H+4-@vW%9*66&_KH zj-vrM^!khKE6#(v?vI=_@u2xvMjsYAg5w*5FYbwOIBNyAfs9j+1Vhy4y`> zl$;=PBz;W2xTnBjCXclg0i~R7H1JR-`nrMohqJ9VjhnAuqXR?2AwXLA6_}5R>}YV_+YmvH~ImcjF^&J({?i zfcw-5k9W&_xAPG7T|ijDE&MoQ`|S_n9*52MfdRf?q!za@mm~u22wDMK@K-KRjz4c1 z>Wzn|&p0XXfGrg@J@f3Z|ebhakV9qlHq0g6#8$U0u z>az3}Rs=AtkNLe3zG7+**S+6r&D(%Vf7ujIY_cPsiHDYli|xba5MI|)?qhCT(Jv3P z%Hd~yZl-nhm!4@9_e#Se|NgJ^JofLlS5;5(d^h3Kk8af9dTr1%xGEHmXp=K))+3Hd zd1E*o&yqCoeB3W=opIn(xrBYqJfJgW?H~vf$j}&xQf27~zZvB|)Hm6%#YxeT& zfzdO6?ZtU)8c8?d+uZn5Q%S6ojtL@Leq28;94mlB|32`iGf&I7%9d5xR@OFqPu_IM z4OV$UZj5GSv8r%E)^96s<^(qxUn}*1D>tpS*p_ zz(WNG$5oh*g|9(SuSsyk+EI27%?_!5H`fCXjTc1ynCX+ZUt4SN$vxLRQ1MJzPkMxr z^bx+zjXyO!C6%E-BvOqL1&ljjBdkB9Z5Y#WOnkzPqa4xkJHG|QdH2;l+FI+bKBV&l z5BEmTz&3(I_zpW}CB>m;ziqF2`ZOCjOnorK;RhY^%j<_fwon8S2eo4I#XTtwHJ#}! z?Q#O>c%mzl>xDsX9`n$7U!8g3H6l;&n0#?hibv@M^R8;GnH@q;r<^C9P9IEas3B(~fn!&J?-ICEDHXtJTUKKu-Tu=GlEUV37uZ6zc?xypX z{6F^Y0xpWK5A^sdsMy_w-H44XiV7wMiVealC;}2HCN_2}Hg+clZ6B-90cn zB8$F0_kHetna}6DvwLQD=0E40iJdrO2te$QihPpkhUCazR1mr=5_S0$m1YR6sZVun zN9F!kR3<97rx7ONi>Pj6x{Lo8q7!o@;*;sRM8!)~EK%{Pf{~{VqJrZ0 z%KGlRKjwT3w&VQy_&5El9Zl7)rv9rMS-)huA|&10=;G3E&sH#Rim_pC4xpyf~QAcm zxOuUY%}%Vg1JOBodx>LQk&!KC1aiILamYkI)iu)`>|d^G2J1<-RSbW~pCBqq7e|hVet0 zZ=r`{&bN=p%{34F9;K@`^-Oco_JinTzR7fbYSe2iBu2mmQ=8KiMKSdsh7voUwhmMU!e8rktBredZaxOW2 z8J{{`4v#)Qj)XS#A%xh7P`bt)Ed-RK+Ow!wc$uiw@IXtVnuBPFKdIPM5=#as4vC zeu~QYe_t4JiRsuv^wry0F|9mq^WsnKsHoG$cSRR<9k%Yu1EYs^h})ZL8txs` z4XwpP);JKX*qj+{Ppr=v=bQTZ7uNO7H4!$ub_Asw)3LUtZt@yY;l%$cnXXTbdNs7i zBTj|62l7Z*D<=nztB4BM)YZRpL+={Cfsy-~;#bP;TeyjMPBox?p!j}c7M1D0=D0Y> zPAB7$>H5^DR}=Ac=%5Nn8IR-Hn9I-C(Oi?~_Ly9j@7r5B81{c>AcLl%0O7BEB08xnHEYU>rwu`>P`}AGZI^zA{oi``RyE5lV-4!ZmB^xIcuK7=rRbABV%f4}My2HOwpvtr8oT81y^r_Xsm zL%RBR>=jlQ57%MphMhxE9Xax)xb{H&#u6eQ#Px2Ai9=2&0qG)FlyO>LG|s2!mMhOR z8Ee!%R(Kje)pfGG)ai0~wB;p_`-|c-d@-25EU(q7IDRUx@2NDc){dU-w6?!{LME=LI(jD&qxx7Lz8L#isFcvW#8`49c`|Y_5U8kMd zt!|Kkk?_B+tsqH_%9o57_Pf7 zhT&peCzc=4SC@xPEelOvxBF(<7w)QM*c|H46N&PW>HN&7lNry_qkFKYmzC}YdU@H7 z(e~K!ig7-PI$IJSA@48DKd5F02JeOase7ne3aeh#Ai4dPx znXXGzyhJnoa=)5>$PLrew{))IG~1(e5B2nAx?UngFfv-qzufq zxbDB71HptK>!-!dnCpi{M0`z#;1kow4DS3`y?n@Y^&CZ0KlICoVF^`EKg7iJ#kjxJ zOFr=GCeLl^`YF?6F@62=5zX`$-->zu#ki{n_sDgo#Np5C>C5z3Oy974=mUsbKGZq( z@A_;>IC4Ma5cMO^>-JNgKf8KzQ}fH#VjUK27%uih>~9>BRTM^Q~mME>ZC!uPs-%Z|ASOtDW67-DzRt{SOzzMNu*i^>$W_-tP3f zq3uge{ONd(I$egMj-$EOwX@;ME^&Pq?FGB~`-_J6413DTe0dm)c)k|hSii`kbvfnq zM81gJQK!q{a&j_XqT&(nn%2g>Qmc+}}~cntCALQ|JhFh7*rpAc0%(beCt{o9Xw zcdl$teH{AwE1n-9(`6j8uZ}0Gob(qhDW`97-#9;_oBn{+-Je$|P^OT2`Z8TkSN7G@ zSCo$~0A)QLtD1gv*B#D(UMpjh?jgnUo9m|_;t<#Q$#gkg*=IGu!k49C+954f%8 z*ai%Xf)_WQ7A z+97d)ADsn3i~V+)u1}46jcq&*hL%5q`Khd@)(?&AiF!Gd@D#?NBW%j z{-cTK=WA`h4i)*P9B!`|u5CB|ggRdjFVq}((^JnoaYWT*) zU-yYvmBR}vhEKXVKZAO>y<)g+P*Uy=F#f%VV))7AnrrIeA&TM8YiuhaidH%O#fsq- z=7;uI|Nf9-xF{d>@P~@wV|Q3{w}tWeEuKfs|3Ifjd(^)#s2D!}O|hiv;r5E*=I@*N zsE2znT-Kj3kB|N1F@5EB^drMXXA3b*UGF0r(N4lg7oT0Jef`QB>V+NO6ZKxE^Us8^Hm)Zp?V@z@?+`GsOdG`!Uuw0IZ(VDieWoTAfpqL-Ktk?H#6$XC%e zEDghQE1On#AD~tB##Z&Tt{tpu*05{Bggp4Bn7;D7inuCUP!^g;;YzNnn*H*fVpKQI| zJZLOL*EVmE{;QVsL>yv&q8f3?>4>4?{Eu?Ic8cL*^0pvbb??pSEAO9e{bKQ=DH}3H zh~J7%^hNt2GF_LbcrhJk!@z)s9XKWal&4qj@3~Q7{Wz<9i zIKv%X5sYyV%gR=q#S5e)pi*d!;n;~!5X(Xc#OVrg>&XffB4F`Q1}B0}LeLkmga3GY z3H&L6S0d=m1l^IK8xnMPf__NQ%L)28K|6CIwpDJ8=6-(WuPEa#!GBpBjpi9QsJYr} zG;bPdG>2(mHH9bdxx;Ve5ZYH|W3_0xM$>z*M$_!NMl+qWWxH6IYud)s?C#7nq^8Hy zG&vJb^F3vJ&1t9jnh4r)bo(A(v%}3y)Axdz#>?4UGwg}ECd>E)nzaoQYASMHT)Yex z8c`p_vQ8Fg!XTHo#U|>F%UCl_rQs8jq?~*-vb_3lTmexu%4)%Nk>c`>5Z zU|TO=Z+qPtEampP+6OVUsO3yuug6X>)2#IGHE`el$%Z?5^mR$pYng5o93Or^KK&Ss zmVXm*S-O~OX5`n_`M5YFd0ImNqF#%*WV#_avM1uI&okjY^~)6(94i|SH{6$_xI!z8 zU&?ay{TOpTiHVf!YCAo<&*`Q5Z|c`s@mO=obnzW!_gnEqQP>v6G;7VDsoKJhfS;}SZojXKaGF_LbcrkhoUvt{8)YAOD*0Y;d9);33ZmDZ4OZ?0da=Wvc zc;x@s4ZYiC5R+7HA0K`(&PNUF2N6%T&+#=kc9iPkQpH@;c&C}m_b;ix)MvdVI4dkZExmd7~2JAurxEcg&9nBoVK}dGjr4fideUP7xOOH3uC`B zGjz6KHh=p6C5DB}s{JI*>&u3tj{3I2#j849d{=aej2JjjOvC0b>8C8fu^x>YxD{qZwMF9YkKU8=~<> z0D2-ALophYFcS-~0voXlhjA7+@Cfe^pNb~-v$CToDxxmLK9@Jd|B*>pif~-S3s_JE z@}Mf(pf`BDf@T-Q>9oYu37Un~v_c3rLDZAz>V3!$en4jnMjdUvPgHx|u`3Uzi!9J} zA|FL=s?&AJyu`jfH8i?*SzY^AGcH;0ZFK)CqvBN8`|#4{8lQ)@Q+FQmYCG5vh^+TA zUB)N-e;jADwO_TIs^V22&k->=wZ7@y@!;srG9H<)>U25$H{w-Zqpr?YqjnHO;!!c^ zWcjP}^<_D8O{$M2QdV3tqh%x2`b4J7_+a{X)_Up%QcDo!o$S=~q8?`K(& z>-^1ncQ`Vl;F_T+^pVK&m+AV{sMp_&GwPalRgNm_X@rS5$J&}}&Zl_RaP8(>Rn>9I z^r#5+@BTbab&l%C$7V5dx$0qNT>k2M>gZ;!Ic(dcTyW!6L#m1bpp*G3)AgxQuQA0d zPHO&YYZt~Sncz$zfvsVWa8h$UD2^aY!(+$ayy@p-9J=^>AV4s$WMjo{=-oFl0 zO*eRQsP35TsTyp@T;46Kmc>l-Ed85_`O*$t7r$F$G-kK9F~?`f$oj59?X@EBEi3kF6Q`TedCU7U-1Mp&f9U!OZ;BBUz93i%*%oJ{!Z+R0X_I4~4a$MHDQLZ0E zx>(N@6>p;HY)DgoUwlm;Z!|wJB!y8h(fv;TLX?~EJDsSFfAYKEna2OhcTJU#IvGJ)-K0NE4m%yZV&4S9K1=m5(|{{#~E{cKN91PPzQZ1B;{gdUR-u{SvKanQ4NB^E&`1eKoiCjm7_sT~{iW zd0uMyGC5cJZApBMI$aKz$D3;LuxtKSi@!PCRIO;z-0($Z9G01k|Bs3PTH-%h!GL(0 zBS{CI7eD#*rfu0GZw~MzAbls6OK}!krW=wYd-C|(PwhbKTVmu7zy8@2!TdtzM_9dB z{QsK0JN5gp)9d86RrJMuF*^D^kNv0n&|*BY6XQ~Tmg)aL_W!heME(e3+adn*ifaHaU;u?t znM84&;&?unhd7T}0OGu;I1VAoOCI0lt!_O3EBP(v_jkHKEgv}zu|ARO6xmnjwM>`4 ziR;Hc2mX`tQI?IEqAZ8F@`-)^oBHN|Qa-XwWVy(GT=|&F_1F*pPs&G>hbRkK9&zOp z`+Se>H=`>bk>7GZEVko```$m3199c^&*bah8f#qn{H>h)XT}p<`TXgWl-nXP4)Iz1 zKN5ZMpHd#X7XN=_Cx*p!zs`ZU^7(b%{2PYEmCwJS6n-7U-!32Zl$7f?xh|9Y;o`e8 zP5ryL&-xsQE1!RNO^7R>|K0Kt>n`Q`O{~|%XL+vS-<>o6j_Cf$Cr-OSyg$ z$I|3?M7kU%`yvA6d+|B0i+v8nl~3&R>c8>LxbpdL#NI0T+1dpkuS0wWL}DNb^eL8xcn5k z@XvJW@)1)JW%IvYZ~vLx{{6A4%ST+_DauB@zLDi6`(jG+d&)GqEGg5(cYoEz_Itnj z{r~Uj>hej-49n|pMcyfoWvcU1d=}*)`f`};lN8teg&a_qj~JyW6S>_M`7QtB$nBB% zEXz%nhv+Nc^Uy#e6k*>*Qe_5 z%g_I7{n(VxpXNzSWv4D5F%4Os%HJv9|7jfmFaJ*2E`?2fGu?X2Hij9RvchFvo+Z8w zWWLFMs3BebQ=Y%A_4D=fBPV~inQ!?F< z9NBB==h@NIyQv=yQuxzCr=LHqRcO5f6v>A0+v}nabaT`C`}1pMTp-A(J&)Q|S~Y4Srp;7t5jc^}^5Si}|D_UOCKr>4lq1nA0J zl%q_K49M{27jf~hBxMxFaacQ=&Yvk|#}A%ZabXK}{>b#$#X);4Za#tD0sfJ}DDz`; zEaKR8J!k!T3;Nws$05^y6-PAn$Ihp_w-?pQt~x(b))z;f7h!7onsKFOZujOVgVk}! z^xud>R+=V(?fu>SJblHZRwDC9*{+qPlj*p2jhNi$`jdq})fbum8*v#P{o>%=!6!1D zpYET`!U)Cvqaq(fo{3KE3(9>EktUB}h_@#82LN(d+|B0`@I|pBXgDax8~#L z>UD=-8qu&R<>$({9GmHDhpl0H>h|-*)W$l^FEDZ0(dy#8==AZ$`zc*N zl=iS=y?>#Li$<~ZzYL=%?-zfmip!m0qJ6lJkk2FEH*Ki7)etvVl60MnOPwx<$09EM zSNv_=-L>x3wLAbzYu8=`sT+kd-$I%j=bO4cQ1OFJ*&bO=*%_SP@JLf#zUAUorpvfw zKNj)ncPn)vMc+PLL1*K*qRY2xPTk|%jQi9;PFLoeI$aKrMO^x?@JPnafxiCgj8o=Y zIPr;fj4i};<@!mvKRc{=ma;9I-KnmRD{48A=`t?am-|7Ypj7*fO*}h#yLyRTa$2XP zS@8~@iaj)CT+S^_|37$m{95{XRW=uIlTJTnaXd?Oj|}PhPf@SYKTl2D!Ig#^>eEi9 zmz~y&R{Uuy-_V}FzM5$)8HN0R(1W<-bW@Qo@?^7NxOk3`bxYIvxyAhGdE2=OkErug zrZYODF7|QD-3IsiqUAj;PgwKd!D`xiKHZ)CwSG0dJCf_-k#hRchtreGcMlrf7V+3Z z^hH~%qFwTr%ukz^%NFxiv(oNx)t-K%MAPQFP9J}~pVH;<*vBo~h_Gr#n|$uBVlT{! zS|tAGXx)D~6LSAm`TQgildQw$ycgS5(Y}D#4-)%Ivi(C*SHyjbqOAha?6P=Xfhf=4 zX}6sw5_RqI8@mX^P`ek@_^@c%OZ zRx=e@{t?7&YCX_C$GtZziWmE-JrJ306f_@VA9oYiZahOnG@$a!U>Tn!p&}e<( z($@5HSN+K>`vDaDt9T##cop?q9VFwigsj(> zh*NG~M7!W37Ug^dyO^Gj7K1L$dmWO%LOmZcolzQfzcC*_)oU$BTRe2N+ITx?<7&EI z`#z1h(Al;9d>M>B-gp{yx*Q(+I8D@RWzdXVS+5@wx9Dsk;)!nk{UGnvwI{Rns3z)@ z=*0I#`%E%jm#BF8gSd_BwJP4Rj9aefdbBrPA9juK-1+6>gUzW7F^PUWwstaI5vuO3 z+Upy1n z(@oo?yQkQl^D~T7xxW$SZhASJS|&WXW{&F_8InHkcp7!O93K04V_weG!7KCGQEPfR z(+=_tOxnLeIdwkEbQ!Pg|3TbF%b7Y}<$Cuc@tUgFLv}k9E}N@OK6Sh@UB)Tim}JGH%)bgZPc=`LE(u*7t|RZK|G>$k5Zek;BUw>bPaPj92z! zAGe~uM-!|iBb4>s!ZWJATahkeQRaU*!%fY{R>y1E8%|y^PCXwoolzQfzcC-``p)Cp zn|bo65bAFP4%OA{#QT;a+zjA%~k@!v3 zpY7h?&$Yd`Ogw5<*NMK^ACT#Wpv`cK@Z>dTv|Nt{2=8T(LOUu3!>WZm1?$E~RUzY3NyS|YOk`$X0M zr_t4ahMSt79LK9=eDdn8m3n?;x^5;EFTXKA>iVzS4ruMQuHAx6)PG;o_1|Vl7q1x~ zx9N^aitzOD$J40OW$3YwJLdZTtC=vW|6NVj|CM!G*gF?%P)2z!Gy!uV(`DSU{|E6K z)&F0`ZB+k>+f;oqZ|@%T@?wUc_TOZ>j92z!AGf0Z|0-BUYKh4D?-y17Ul{7Ya()gm z+|>LO$v0q1?FJhYsO!H>m-8X}zcD}R`tRuK@88|WkK?4?oSN{{A4m!}%#S#q65?;V z-tXPm=I!x$6J)iCtoQ2l-;X!udLM1@Ohj4ls|A>@_tsA1tYoiAbT?h^XLU+HcVf*1 zh9|q}w^w4WWx9-8_WvM$qk8|VxRw8VBZ%8nJt_TTM&i+{_HI_!6PYgKmHpVqt*H0W z1Z&9%WqsH5h^p`Jqp9z!8E$Gmisq_&bX3?U@rZO?C;H-li%d5pNA`YWKGgMHe;!(_ z-W4aI!x^)z@4i8%>$~%`sn1fol@^b@)^)PJtJCH1*vA`leUCPHCZeqG1$&yV?=$l~ zwd*ix!cX}v(`DSU{|E6K)%Rb;tz6GvB5qUlr1I$;cidhz?4_~H(QQvC@5AwM$L!KzTq&8Q?)J%>3Dxn+ z^uHKy3`aGM;|}R>I-fJtdp>`8&wW4D3z_~G-&Qw_!+DIL@O#h2cd+)~i>o~}Cyf4$`-diAdC0lj8GW{>c8|~g#7!#2DT`yJfTJDOkyZ+nxG1sF{ zSfjhP;OT~WH(b{a9rr}+P|}I*a~57@x-L=i^6TxKdn;kd=gN(7Zu+N} z8{bFOW3cJ{*zRqQUa*)@Zi}TM2GNhFvDC3=ouX!mIJQ&29CJw}?&?_1mN zZ-2S+`h9i%mg#>r?r8RGl==K{vgvs5)Ee@6pl6b~>Ud@PUyV1~JsbTLtl0$<`!^+= zay1bt;yw^r_WEzcy~gE0Tn@+_P%kfH`IXDC{7zgyE(hXrK%WEZxafNTy(Y& z;|rb~syl9Vs)j~W(dFH;h#BUZE)(yKPruRW&341aOk79Ky}dtVIvktsChI9&QA)|{=ndTlbt&&TBR&}AGl-6#k?#1sc7 zv)r|Q_CEgH>mAH@<#D`F6LAF3GS_sv^mSXY*~g~rQRRnBk98bPeF9v)jHh31s_}V# zkt^bQ*Dx;rF44>BoEZ1TGl6?*Hu4!E?tc`W{yxZzk?H!>sMiLr-8?($ZyMK~p6$r> zG))5hIA_~5$d_}C>Ut&C!Sa}D)L4v<+lNk%xxDP(B-E_RJ2CU^>yxyFE9x^!#3|~H zOjnLuyjR3oTN_Y|leJn=K(&1QqK1gGku*|f=jpCH2C9u3(pcLyQ0pIH<=}7Mw5el5 zKk=&j+wxPpK;l9;k*DH3uH4?pzKB%3HxzATpQO0%AIbsc`p9yIalKNvQxbYUrKWkn zlb};49@)tY8bw_d^-89z!;GpURt>%NjeR)jTGwhwV-_B)j|@$dEar!DJ#ffG95xqI zYI1lb+v<|&c5!taGX0O@pxHfTi1x1D?p|8I#@deJItxFoJ0lHN#A!d%bUPpyQx^{2 zXW7dle#VMZL_Uf8Iz@NMkgop}^%{AtgjG`?AFezNsvhXpS7HviZ8-|PRi_J&l_1WkQ8qF9yA`K3nl zm<$zh%5+_#;-$Kmr*~&7R%NtvE!Umq1CBLTQwN$gOg)L3va_MO1>g2&@XKq8e;b z9W`Kwny7`^u!jTcpf2j6J{q7Q9MK4kA=ao(;e=*r4rjCg*{*4Y)@XyaXa^U#qCMQ; z4lO#MBRt@VPUs9ai5hW@jyHVZi>?rNfr&C^ldTCvH*`l2h;v>&(F?uN2Yn$f_76sX z48TAP!e9)+P=sI@hGPUqViZPW48~#{#$y5|ViG1}3PLdz(=Z(~FcY&d8)2A(xtNFf zSb&9CgvD5brC5gLSb>#Th1FPtwOEJs*no}Lgw5E3t=NX`*nyqcg>dY~9_+{B48sr~t96RSA_L8fL4CYOqCh)PNmoq84hy9->jk zIuMPr)6n3;n1$I0!yL@TJj}-eEW{!##u6;WGAzdmti&p; z#u}`}I;_VAY{VvP#ujYFHf+ZZ?8GjFV>k9-FZN+S4&WdT;V_QiD30McPT(X?;WW zCS*nyWJNY)M-JqKC2}D*@*pqrAwLSBAPS){il8Wp!3xD;jS?t{QYeiwC<}41fep%| z0xF^sDx(Ujq8e;b9W`Kwny7`^u!jTcpf2j6J{q7Q9MK4k(F9H5gl1?CXNZ%6Ezt_C z(FSeN4lZy-d$_?JT6921c)$~#&>3Fn0&n=h7hT~8e*_>9-OwF95QLuSh2H1`ae}oU zg3%uXFc5<<7(*}=AsB|?7=e)(h0z#;u^5N(n1G3xgvpqKP)x-%OvenOB480KIu z=3zb-U?CP^F_vH{mSH(oU?o;zHP&D))?qz1U?VnRGqzwWwqZMVU?+AV9J{dxd$AAu zaR3K#2#0Y5M{x|taRMiC3a4=fXK@baaRC=`372sNS8)y3aRWCIfm^tZJGhH`xQ_>T zh(~ygCwPiyc#ao%iC1`yH+YM8c#jYGh)?*8FZhaY_>LdYn6dmLKFnZ_1W1TPuz5e1kQ;fB7x|DM1yB%$P#8r} z6vbeL;tIlXG(l51p&6RP87y5tA?(QxJ-&n1<MCL(YPw{Zt|aS!+L01xp9kMRUg@eI%L0x$6j zuki+N@ec3t0Uz-RpYa7>@eSYc0~&Ldf5e9w%#i>Ikq8z@j3h{kWJrz_NQqQPjWkG$ zbV!d3$cRkHj4a5CY{-rr$O%j2LT=YTa zftF~6)@XyaXa^U#qCMQ;4lO#MBRt@VPUs9Tbb&W~;ES&CgFgZgh;HbP9tc8D^g?g+ zL0|MkF#2Nv24WBfV+e*K1j8^KBQO%9FdAbp7UM7;6EG2zFd0)2im8}}>6n3;n1$I0 z!yL@TJj}-eEW{!##u6;WGAzdmti&p;#u}`}I;_VAY{VvP#ujYFHf+ZZ?8GjFV>k9- zFZN+S4&WdT;V_QiD30McPT(X?;WWOn}0TLn+ zERYyUkQB*~94U|zsgN3JkQV8X9vP4knUEP-kQLdG9XXH_mdJ(N$b-Ddhx{mjf+&Q- zD1xFW1}lhz%ho7?k|>4J5RE{TMLF1@JSw0fDxor}pem}t7S&M$;=p-L)Ix38!vS?r z7xhpd4bTvdXoSXSf~IgnGc<=YTA(Fbp*7l|E!x2au4oT8xI>E$=m-yZq7yp93tiw1 zANZmx{NRrO1fmgkmbDVLE1DCT3wa!Y~JOF%R>x01L4Qi?IYtu?)+x0xPi!tFZ=au@398 z0UNOio3RC3u?^d?13R$`;nH)NPvV$1Pdfa5+p@3Bu5IQL@K048l*)!q(=s1L?&cL7Gy;> zWJeC z4erpQ13JP3p6G zqYTQT9Bfb?;)ec;sD#R>f~u$nTU194*r6tBp*HN{fI6s)dZ>>EXb4A$oAMi@37WzQ z&CndqXn~e!h1O_;wrB?zxS~DW;0`T1pd&osiB9MY(a=v9c*6(2=n6mhBLIQuhVJNr zAoN5p^hO`_MLz_iKL%hR24OIUU?@T`48t)3BQXl2F$QBX4&yNa6EO*sF$JNRifNdR z8JLM#n2j*Z!CcJ4d@R61EW%_RwpV-NOXANJz_4&o3F;|Px87>?rvPT~|!;|$K?9M0ncF5(g{;|i|g8m{98ZXyD= za2t1U7x!=<5AYC=@EA|<6wmM+FYpqt@EULM7Vq#LAMg>M@EKq572oh3KOioWi--6y zgEep)W$1FS^1H{s=%Ix}iIIAP7Ct3%$_?ebEoW=#K#yh(Q>PAsC7f48w4Yz(|b3XpF&F zjKg?Lz(h>KWK2OQreYeVV+Lko7G@(1b1)b4FdqxB5R0%FORyBnupBF}605KpYp@pU zupS$*5u30XTd)<|upK+F6T1+O-PnV@*oXZ%fP*-M!#IMYIELdmfs;6e(>Q~(IEVAN zfQz_<%eaE8xQ6Svft!fHE!@T(+{HcI#{)dXBRs|vJjF9S#|yl~E4;=Vyu~}b#|M1G zCw#^ie8o3>#}9~$8RH>7%wUcL5Dhpaf&~&I36dfiL}L^wkP@ko8flOg>5v{7kP(@X z8Cj4O*^nJMkQ0{3h1|%4yvT?AD1d?}gu*C-q9_I{6o)lRpd?D6G|HeX%E1QZQ2`ZE z36)U=RZ$J%Ci&{90Xx)0E!2iR98d>!Q4jUe01e>?(TG7~G=XS{!3oXK9L^Apw}^|2 zTcI`Dpe@?L1+HihH@HKK4(JFEc%lva@jK>5_#3W3{6og_breQi}U?yf^Ho`Cm zb1@I|u>cFP2#c`vcx3ahaOYq1XNu>l*g37fG6Td@t>u>(7?3*p#}J=lwV z*pCA^h(kDxBRGmkLSaDgk@!wv4xq60d@1D@!F&hSDPc*6(2=n6mh zBLIQuhVJNrAoN5p^hO`_MLz_iKL%hR24OIUU?@T`48t)3BQXl2F$QBX4&yNa6EO*s zF$JNRifNdR8JLM#n2j*Z!CcJ4d@R61EW%_RwpV-NOXANJz_4&o3F;|Px87>?rvPT~|!;|$K?9M0ncF5(g{;|i|g z8m{98ZXyD=a2t1U7x!=<5AYC=@EA|<6wmM+FYpqt@EULM7Vq#LAMg>M@EKq572oh3 zKcGp<@{jm1gEep)W$1FS^1H{s=%Ix}iIIAP7Ct3%$_?ebEoW=#K#yh(Q>PAsC7f48w4Y zz(|b3XpF&FjKg?Lz(h>KWK2OQreYeVV+Lko7G@(1b1)b4FdqxB5R0%FORyBnupBF} z605KpYp@pUupS$*5u30XTd)<|upK+F6T1+O-PnV@*oXZ%fP*-M!#IMYIELdmfs;6e z(>Q~(IEVANfQz_<%eaE8xQ6Svft!fHE!@T(+{HcI#{)dXBRs|vJjF9S#|yl~E4;=V zyu~}b#|M1GCw#^ie8o3>#}9}HS;j+rn86$gkPwMrfy79Hq)3M3NP(0{h15ucv`B~a z$bgK%eMqngHVKl~IEXH9xCSW2aVKSy56jLz`(=h`xF$=R1hB=sv zd6T$8PMwUhKnu z9Kb;w!eJc2Q5?f@oWMz(!fBkrS)9XpT);(K!ev~+Rb0b$+`vsl;1+J<4({R}?&AR- z;t?L>37+B^p5p~x;uT)w4c_7%-s1y4;uAjO3%=qTzT*ePLu}(AKFnZ_1W1TPus~uY zK~f|`a-={?q(W+>L0Y6kdSpOGWI|?SK~`i#cH}@#SRxm4BM$k z7_3kn)+m9JD237}gR&?G8=HQ1s$YQPRPQ46(U4+qpiUDQK;G(bZ* zq7fRS37WzQ&CndqXn~e!h1O_;wrB?zxS~DW;0`T1pd&osiB9MYFLZ%7eBg_&@Pj`B z5QuK*jvfd?PxL}>^g&va@jK>5_#3W3{6og_breQi}U?yf^Ho`Cmb1@I|u>cFP2#c`vcx z3ahaOYq1XNu>l*g37fG6Td@t>u>(7?3*p#}J=lwV*pCA^h(kDxBRGmIkq8z@j3h{kWJrz_NQqQPjWkG$bV!d3 z$cRkHj4a5CY{-rr$O%j2LT=CfiIH4Ju!x=5m60Oi0 zZO|6&-~v~)ha23XMF(_*2RzXUo#BNp@P-e3(G`C1M*srR4c*ZLLFkEI=#4(;i+%`3 ze+08 zQY1riq(DlfLTaQzTBJjIWI#q_LS|$^R%AnVq7VwB2#TT@ ztWX@*D1nkFh0-X4vM2`|lt%?rL?u*46;wqv*rGaWzz#K03$4b)I)tVKtnj9 z5gMZjn!*Xq&>YTaftF~6)@XyaXa^U#qCMQ;4lO#MBRt@VPUs9Tbb&W~;ES&CgFgZg zh;HbP9tc8D^g?g+L0|MkF#2Nv24WBfV+e*K1j8^KBQO%9FdAbp7UM7;6EG2zFd0)2 zim8}}>6n3;n1$I0!yL@TJj}-eEW{!##u6;WGAzdmti&p;#u}`}I;_VAY{VvP#ujYF zHf+ZZ?8GjFV>k9-FZN+S4&WdT;V_QiD30McPT(X?;WWzr3$h{`vLgp_!VY^U%qX8Pi5slCoP0$ohXolu+Mhmn=E3`%%v_(6(z!mM`26t%D0UhB1 zPjo_Oc%cit;R9cEg&+J8fIxIZcl1CIdZHJ4qYwI`AA->z127PSFc?EH6d@Rf;TVCD z7=_UogRvNg@tA;#n1sogf>2DwG)%_~%)~6rMi}N`F6LoA7GNP3VKJ6qDVAY5R$wJo zVKvrZE!JT@Hee$*VKcU1E4E=fc3>xVAsoB02Yay(`*8pVaR`TT1V?cU$8iEDaSEq# z24`^&=WziSaS4}k1y^wm*Kq?k5rJE{jXSuDd$^AWc!)=Mj3;=CXLybmc!^hdjW>9U zcX*Ev_=r#Vj4$|#Z}^TM(4=AcM|_yU90`yRiC}@mNP?tDhU7?rlt_itNQ1OUhxEvR zjL3w{$bziMhV00JoUlYLcMxgr4Yy-spqA=!anR z#{dk(APmM33`GcrVK_!$Bt~I0#$YVQVLT>aA|_!nrXUnkF%8o(12ZuTvk`_lnEQX& zI}h+Es;&V~s6hoIAfi|TBB02MAc%rUC;=2mB%zD2Bulc8?8Z$31Vtk#VnMNE&u7Js z9sTSTJ9g~IXTgpg`~RMqJ=xjGW_JStfq(8k@67DEGxwf3x6YlJJ8&&r2iL<5a3d^( zo8V@+1#X4g;C8qJmcyNJ7u*f^z`bxE+z%_@0eBGp3lG7=@CZB#kHO>c1Uv~(!PD>z zJPRw~Id~pkfEVE;OB$PS6}$z|N2cyFg251+8IMXal=JTi6};fOfDa>;-$nK9COW zp#$s-9brG{1f8J^><wP?r<>lfSzy&^n%`SDD;8D;Be>*{on}b4@bfP z$bf+`2nNFt$b_LV42Hu|a5Rj7kuVCfARCT>(U1eVFb2lLI2aETU?NO{V_`BJ2UB1w zcwrjkK|c6kIut-5_+bXjgd!-000f}~j)xGGLK&39ESL>*paSN?32-9JgOlK7sDx8s zJ}iJ!;WStXr^6yR1I~oA;A~h7=fJtJ1kQu=;R3i2E`p2U5?BhC!ewwdTme_YRd6*_ z!GGWyxE8L1>){5t5thMCa5LNjx5903JKO=w;ZC>46nc{coklQ*WnF#6W)TiVKux1@4|cV zK70Tl!bh+MK8CgMKllVbh0ow~SO;Igm+%#Q4d1}G@Exp&@8Jjd5q^T7;TQN7Ho$N2 zJNyBE!e8(=`~ya7%0D!KhR_HaLlbBUsn85|fE{5cXbvr4XGnuxpe3||*03wIf!&}j z><)WCJJ=KUg1uoMNQd^&0rrKCupe}S&d>$+hXbH190=XO0|!BOI2d|BPdEg6L2oz| z`oLjuIP`^na0K*+BVhn!z(5!TgJB3{!cZ6n!{I168b-iK7zJ674adM}$bnoK17l$v zjE4y@5hlU0Fd2@6DKHhhFb(n`AAB$!3ZM}DFau^n5fnoJf=~j-LkLQt49Z~^%!WBo z0dwI5I1%Q-NpLb$!YMEx7Qm@+8Z3m3%it!s8E%1F;WoG(?ttZRC)@>h!#!{> z+z0o=3U~k>g#W@r@Gv|AkHTZ{I6MJQ!c*`xJOj_dN_Y;QhZo>QcnMyHS6~&q3a`QI z@CLjIZ^7HJ8s33-;XQaCK7bG5BUl3;!&>+sd;*`sXYe_!gD>Dq_zJ#;Z{S<_4%Wl> z@B{n^Kf%xN3;YTj;5Yak{(wK>FZdh&0b^InKQw@b&M!dY-OEQWL7 zTv!63j zHn<(`faP!}+y!^TJ#a7F2lvAYcmN)R|H4D?FgyZ}!ej6_JONL_Q}8rA1JA-rcn+S2 z7vM#B30{U*U=_Ryufgl^2D}Mx!P~GJ-hp@FJ$N5JfDhp#SOXu!TKFG)0-wTX@Hwo5 zFW^h~3ciMK;9K|(*2DMk1N;a-!O!pu{0bZ3H~1a?fIs0c_#6HKqYdRB8bCv61dX8y zG=)@X20OrxuoEAU1egeu;8>Up$H5es3SO87d5{l2 zm<|O{2!5CWGoc8IApk)rf#V?rrBDXtFbihG9H@Y~Z~~kN^WY>n87kovm=6o!R5%S5 z!s)OG&VV!FEI1n$!#Th-)F-Etg>=5_@k}f0^%k4gNCaWCqAu z!Z;UnzUwtipd-iak`ZY3+8zFHbcZ zMd_jQj!tEwtUvO~3fA{)Vw~9Z^JXu0{`Bs=6H?qJbF<(4$Etf9v^-?YKwBa?5- zJO&cKJMT8-4zmpa$p-^r5DbPPkO@O!7z~G_;Aj{DBViO|K{gx%qag=!VGN9gaWEbx zz(kk?$HHVd4yM3V@WM36gM9G8bSQvA@WTw42}K}TApk)rf#V?rrBDXtFbihG9H@Y~ zZ~~kN^WY>n87kovm=6o!R5%S5!s#I8<_tI!&VsXHF`NVE!V)+S&W8)&LbwPnhD%^6 zTnd-LiYv5YA4z7nA;6_*mH^I$t3)~8~!R>GdEQdScF1Q=+fqUUT zxF1%)1Mnb7*?9;ahDYF0cnltgC*VnV3Z8~%;8|D+&%yKX0=x(>!OQRptb$kJHFzD~ zfH&bScpFy3JMb>N2k*lN@F9EzYv5y83;%;p;8XYvK8JPi1$+r#!PoE&d<);fdiWlG zfFI!}_!)kIUtt6M2EW4}@F)BQf5Sf@6;KK^fQHZr8bcFk3aQWxc7PpWCuj~WU}s2! zU7#hjg4VDrw1M5AE$j|^Ks(qI_JX}(A4rGx&;j;^j<6qeg3izd_J;$YD;x;jzyk+C zcQ_b&KueE6#Bqna5(gZesBczha+JCWWYce1cPA+WWrDw2E*YfI2uO4NEiiK zkPXMcXvl$F7z1Nr9E^tvFcBufu`n5qgDEf-yf6*&ARl}%9SWcj{4fJ%LJ<^00D@2g z$3qB8p$y7l7R-h@Pyut{1UM1q!AWp3RKh7R9~Qu=a2hOx(_s;u0cXNla5gN4bKqQ9 z0_VZ`Z~7S8Zce%gkJ4ZK`!_B!@q@7f`DYPwWw3CB!a`^Ogi7!;<_my(q zE!=kU2<+7#j)Vb_0Rv$W42B_)2}5BR42PrOXcz$_VH9LRHXH+^AqR3{42*?wFdinr zM3@A}!elrOrodG2!ZgT(eDJ|^D1bun!wi@SMNkX@2to-Q4<|;lJ<@JPeP( zqwp9!4o|?7@Dw}^&%m>=5}t$S;RSdRUV@k56<7tY!fWt4ya8{*TktllhIimycn{u( z58y-i2-d*IuonIYpTMW^8GH`w;0yQ?zJjme8~7H!gZ1z|`~W|~Pw+GR0>8or_zixC zKj2UJ3;u?Gz-T}}85%%CXatR+2{eUNXa+mLj<6FnhZe9iq`@xG5?VoP*cIBqZqOEX zhdrPj>PVK9~*#PzZjQ0W+ZpiXi|&D1qZ41f@_0mB z!liH-Tn<;jm2eeY4OQ?TxCX9;>)?900d9n4a1-1Nx4^A%8{7_ez;d_~?t;7F9=I3o zgZp6xJOB^Ef8il`7#@K~;W2m|o`5IeDR>&5foEYQJO|Ii3-BVm1TVuYunJy<*Wh({ z1KxzU;B8n9@4&n89=s19z=!Y=tbvbVE&LBYfluKx_#D>37w{!~1z*EA@GX1?>*0I& z0e*y^;Ai*+euWM28~hG`z@P9J{0;wr(U9^F4WJ=3g2vDUnnEfxgB@T;*a@0L3)mUb zU>9f!t)MmR3TJ5p(E@EouD&xf&JkC=n4lyH}Jqg z&>aqj9?%mGfnLxX4uw8&7#t3Lp&uLp{ozO$02we42Ekw$0+}!rhQV++3XX;mFcL;V z7G%RQFdA|o7skL?7zg8F0!)NSa4bxQ<6sI*1usm4Jje$hOosv}1V7AxnNS495P%?* z!0`}*QYeFRm<6+84phKgH~~(Cd2kY(43%&S%!dVVDx3xj;dEF8XTX_o7Mu->;T$*@ zmcV&%K3o77!bNZ~TmnnsQn(B*hbus?g%^?a^g4KHg6rS`$2B)@x~I#^i^k7sec7HI zh?8qHxeivjDYPwWTnA?a{KeifU%umdcqzxI9!pwAUyq-U-v!V;t&#EL%0p!M%b0b? zS9kjx$W!3at~PlMJ+ghFVt;9=KNu*@4i@?IDm-KT!6NGmxkCcegP}aR{4?7HcRbs@ zPCtpfAOlC0a0<+a1#l{y1`FYIkn(f}oC#;a*{~SSfpcLAoClJprToc%&G+f866gDS zS_CS0OKT>>4^gf*c@p_Pqo^o2yGJ-QyFSa4(C6S0jYgF>Id`%izXRbkHg+&n9;GCI zlF(-uU*q+K!U0xsjM^u=bz=LBy}RIyMK8=Pcg9_@}~7&RSriqP=mP|7KL+K7irygm>9&L9wmVVsHIHG?)qh#D<%qZM$+MYXge)h?hkL}QEuU{wb)a_{Bi$lb2QZ`V{EN^PxlHKFm zchzoa&I}j+P*3`g||K%+8zpPzXy9KH+u;h<}$F$F>eXp86vC<`$%zmVlBXMr}SawKena)m4_Uv|k`W}spvuB>%=8Hg= zfvu5?lQ5+IRJkd%Eu`A?2MV(JYPvtKEEw|S_{v5M%Fd2_4}O?GQ0B=gtFQJnGdD*k^K|pspwGLf1Aq!&h(M|Bl*ispUq|Qx`k`62fFMnDP!Fa zl=MmK%(w#U!UGsb@z1*?ExRdmU*9*b|5dlh^vI@@{*BZFDi4dRSCR7W8R#qU2O|H6 z7nc-ys-LFP1MK>&NT81#b6==I=Xq1wtk>h|I^mkvkgI=A`LvL)G+54MW~RTW%tyuK zo$ebL3eGO2y7J@(%e+N{3VnGqrOU@bm7x8gKKn%5Cm%nt&jy&XcMlVJKKuR^%HLEDx0FF81s5RgU^ z!+xLBoiv@MkIFS%UEAUxP5P8#k%&k&Divcyr_l{T8fhe7MGIC0j}jx%!(q#TUw%?JvtKB=-!NgT(^gq8xvjuL$$y z_~%NtiFz(^PWx#4#L{Cz$JA?H`|`5WG#=H%DOdm6^cWiQRn(@3`4LP4$N&jHmL3=U zx5wE3?m0p(t4*hRIOXc^)ML2MSM0Qf>}$_2OFKl{BUXNCH|ec$-7;Fgs_{rUlG5aq ztADKgGRqezOO$EsdUfA7v0h)7{F0sddEg3-SM_qr)xS2q2A7A-F|XS4vR$v0=q1-9 znr^Z!<$LNLjI&;MSAU7CVEBesw~an6$I{2DcT%vI%4HwBv*|Tv^a$y#k(q~iO9vJC zv6}SFN(Ti4WuahEkuNmZSL7>T@Q?uPdQI&Z-(Jg)X=>d0?exF{1A5PPwihb5>m=JY zy__XHH)yG8mip-0$a1~k+`GNy zkf*xL$jDgu)@3xsrW5~$?4|OsxO$aU9Pm#I&Y`>Q4doTm{hsclqVnj5sbipEw9i`_ z3`pB$uP@U(MeD<(QpV0O{y4_c$M5KsNRA5aaQr^sAA$M$_*x^hlK7{S%wN{f@6=GiQERxlILgGpdyzmOVPxGdw_r zUEpU#$+npp4CVOD(dn$vh+v*sM9t&v>6YC&v3|o&>wD#xMR$LsdT2f2l&gPS{j#P{ z&n@(g_T>db`QZbqSgXC(C!x>bKUG}XJ7-LFy{`H=jv~c z{kdJ7`Ag-hhprRoGc*`1pl3%9ub9rJHz3!>=AriTSCxcbhwZ+k>cIQk%45i;Q#(23 z>K|9H@aqF)uPFQUIUuop)?U!hGkNi$evL=q}_^ zr3I?moqM1sjCq4iqyPLDp84|rp@+z}IH^-*>6Dvd7Pj`zGl+`HpGW_H*l0SGRP6ZM z%l+!E(ecZeu8cPfL%!cRZ{N0_413TkJFoJvxOx>8KdspyZ@|=Iu(!-R&0A_!!t7lM zYKJOMbo%UzpQOVE^c(#14u7+0EdA=g7x(`D{d?!jADrm1151^gLfaxrk7_$$i=4bd zA6L-J*jM8JxAUu%(|sTv+CvAB^N*E}`yA8=pGd#Vd4003RZAnY?Zi4yS(4F61^n843KpyNWZ#ESqk5eSn%c|KEV3W zy)zcxwB({=nrE*IeS&sFF{ASHk>ap(sm1?ac-GASlvO%=y1;J27_z=53 z%C?G4#P~W4%TGd{a$o z=JKL4Pew_JFObh+c74{Nk2tlDGu^Utni?a9_)_2f;nw{cn|oUAgV;yqVR7{;(rxuv zS0C0Ls@$OVVx^t1U5sdcm-JdSIKDpXbDJ86Eq!3^NzFGL!ce>Ebi798)ry2SZ2It8 zLmqwAh(xoMHC*Goe6lG?Sn}MEl*?r9-$*+v$tP>4lYD4L_LKj*mi_Ji@?V|g7jf!u z-*(D0JiFXHxR!EY(Ri;fD|REH3$^ ziSeKDqucKM!3|I3g-?G+)-vv>^02siHPTnipsQzS_83pL&pXrlD>pT*d(t`P6Kp*q zZz$vxdU@0~JZ2lY4Qo^pqK^N!&5W;S)#pu&oFTcFd{DgnOnC=Roa(7^OBz{joSwsr zd9xy?tbAJ3`0XV9aUE?_oPuIGy^S{WQG7VegcE8%>8n*b${<@#aW3BDs#`1S% zTbBi@NU$w6-XM8H^M`#~ETZycty97{(LBE63;9Ba zc*322&uFi_e3a`gooRLZ!!Jm9vVtWXCi9?4d9IJ=$mD)~OK1&kK%QZ52l9+qd)N>5 zhi)L3g@?isFc^*odEr^+v78R_oaa0^3oe6O;1PHoRVzY4oSkkaVYE*^P$|cB66WNkbE)fq9vS^m2Gm zzu_*-p~Q*FcR4b7@boR7i@lxsV&3Axw{iP2|4(Pa@5+2U-I+(K7xUEgR7XaV9c%4hef&kU5^Xf(xF(`~*DUdE8B$$3x5|wTd~WK9@OoQ;akAN-=)#mtuT8 zCB@7SBz2AFK`X~{0=Nv|bZfj%D1Hk*JMGJ{Z%v;s+v4Q?@4D0C;A`AQst)5wiq7Z*WvvLZ#A25g@m*AIDa5N zINM|Ds5;s8sY*hhW3Q?_EA*A|j8h+#+f*?(W9l>7SHz1x1Ix?Gf`MptqM!dBpV&TE zl`T8{(|fLL;?zgw8>vq?ZKszPg$-r5)3OQCdOhB`nOQzpqVG;OHvfChv5kyY@9y#V zUZ3uH_v>CVI_@9Jh}1(Wcj`4XQ)@O%1W5mfuC_pyi}H^NWbf0Ms$op^Maqh2xp4 zZsl;Zy#Iaoz;T_vZ+YgSvI9<5omr~f6xtTd`ynqQ&GP$ZTccjV9A*dbWlT5g{%O{G zmF!;ysz=-7qV-5;;<|kNSD|0W#XrBurg8GerN5v2@GH%i%O9NR(UGOfO`&ZORX(E1 z#h^lOpuk66BCiIG4CecCgQIv3*32Kn187?!!PHlKB=1*IZJTq%NFI^*1xQkJzL<2@ z9iaAuO`oYN{ zbNtENbTU`kT9E2{HTcPUJJS9<24|87i)e!i$%pf4gC3@Q?MeG{eGBGyBcl(Y{V610 zzCgoTPWuz2{dt1+r($2`JM2teI*|6}VA_yFX)9?|*AAw=8v$b|r&Gx9Gns#IHuDai z#(ozu_umbK@gVOFtU~8?%sI%UIXye182b%QF?ODjV)!piG46jd#aPTlpXc{%V4PIm zz>xf*`MHX7lzf!TbFNs!xQ6o)hbc@aCgQZsYdA|1Sz;pdIdYL;rfMh0h{H_gvw^a$ zGF^)-p40twEpgf7h?!fv`;}(g zk^xXAC2aTSLk3uRunsGPr1PF}CeFE29Z ztSRK;#Ju%y&DP)c7(MGv^49=1=;ubpOo0tmrTO zSs7oEyeVTWbO+78ty~AuEj0VMwY`_u5&!+56VPomo1y(#9{^o}Zlu{K_OLz(x&z%x z^ZG;{4mbpQL2sa|Y0fWp7;7$(42C_->o2;WTjh69B!6iCbqU*=k5mn6o^P2uxrkFPp~6~Dzw2=NTzeB)h{&>t>@sctACgD99 z_hwig{#(7$`D`-$#Y4>L zTKq*an~ZInH-bx;Oq^-c@_mMp&XIbZu?T(a@kv}u!~XJqZhCQIedpix!Hy>!@q4CI z-vwbg!9}^c>8m5f(Rx3IUiNrJ?*Sm^rQ;ZCH;LT7E&pS=0SGtc_^R;nVz;S*#LuC< zGr!=fwB4@ziNj21>6l_Tse||cQl22 z6uvoDo2+&mUy|64O&0e4$2aEq(Hg(%=aj2|o%JJ~^L@UODW&FwRuMyn1C&05>YI9e zVtxNSHgn#K=N((ao=*9u=*x!|3Vc%vd;y;|$D3Vgd;L?Dguab_y!6EP+pHO7+0`oR zGEbSxRZm?fZ{O$=R7C)4#{r?lcKrR(z#g5?xm~(!rjxbkrSh=2dQ}I#^zKWbNq?w@foBiNQx zJyjkSSFh@zr_GMF>sv+0n(lqd61Rt`uMe#FviR%`s*vj4%pq6*I_T@DiL4OPS&4o! zZa5zO?D0$7_IzQKC)U6FL&v7g2(2r&LXWha2Rr2IUkClw-U-hm9X;)OIL~7x{#^c; z{V4I1Z5h9@KLll8SHjlm4u#S zE2k{G@a+A#vt~Kf(N-$NR`lVGw>nHcI^YQP) zhrkZH{o{VCmNqfkFaGZA*ZSS{(td;R!2JhAKb4z8+hQa1%P9;pRZv(%d%j%Z(9dbV z^o420FN+#v_Q+^BN5)yisr^)LNh8bT^<(zGK_%s}tr%UuPMsUyj>Z*DjQO1}edV@k zH+^$4<2B;cjw-jLk>y6~8D-6AJyTDJ*3)Uv<$JU=W)|-JaMrztT*1(i>C~Pok7#IZ z)j`id9CJpsSIZrGI`d`stD6{|exH5wKJ#asd9FM#f>V2{+>%C?8>^?ooKbp?KQVfq zFD|pqXWy0`kYX&FaNDCBRx~l5>(cWp@8v!E-XVjnIJKwBEoo#~M?Lv!SRV5d)31&$ z=23bY^Wy8-=bm=Jr>lJOTsOR+_Lod-x>{XlFvB!ru96R(%8S*!s*j3z44!I>| zT-fXPdNRt(3NvMXWCpxPFnN1MUY^XoU+Q7Dz9FGdFeGD2rRE{&EVUoH27T=DNnDj- ze{+1~ zK01dQTY$0oho9G z|JhWYqoOyRNqJkqO|AV&u%lY@tx)bSOy>T=8SVLI7dN8Ta>FS|9d}j+&rFS^{@@17 zxFU3|lmAMz@hojaJvB8vFIy!FX_&os7eWv@lNoD9sr5V=Lp4i+3}2{iK~S z?Durz_rE$BC+y)dQWo?!_9z=*OzAbknA2{eG4IS7#>x%zjG;eV$TL^VjkSlbGQK8mFXdt|C? zi^HVm(kVB^ENbQ#GO#>SX@1=zl4l06ujE_%{UixnuX#i>lBxO`ERxC8P0wQq|25yQ zOX55pdGzS7C+^k4I$@60^Ki=XGF>g_kyT#iIFa!F_HtOVAhBJa7%}I?w&~}87e2gN zAE#XXYv^Nru|%q^h*8mNmmy+uE-u(>`zaT!;Jq_?cZyr*?75)jzDq z@KWo=^QgFGpGwg9OHPfh55+2yruuy;HjM^-rY%0|)6Ys|Tb$@9OQ+lvvk1p8bD{_G zxNpgv{3YSxHglIsmKy(hNBokvrM_9kjpDbnKAxJou#s`|=cBJ&|J8&$sSZph@k_g= z^02siRWttFkiS6goQ?|06QcHfS$SG?K5#z2T0;C^T)o?~yLX#1Za?ZKaT>qMEoo#~ zGydux{Fsv5V9#QIpwyF7o+mSe%2D=wS#?IVKKc0f02$Pg@7S<1x{kSP^@6*HWXiTU zO%JEs^5r|gq2P3q!85A7c$zPiHC>xh8i%l#wPztKNf*73AyO-^S^ly9M|_gsa^A;v z#*utTTi2f3%Xw^FR&}+p*H_)ojIOVxN|GAGKF|I^rHe=PO&M~AT29*wr(FH{+83iA z-ar{&-SYA7NfDp3C@J#hu`(xg&JC6G`d9u~FS9$#G4}duMH2d4{Mn#h3mzCF-9^(` z17rIbPPzIg(ub*5%w6qz3^*&=F3xsD4tVE_wQGm|ve%^=kLux+tA89l%0d;9Pl4If zXBB#g%K)*v^ZHTzcA0#`N!`aa|29wl;AFoxELCm_ZHs6<#_=VD$RlLVw2{LqLEG2t zv*YX2=dLEkzIo42eE-^}&pp{uj<)7vm-bcVmNc@Ar;ntK-5%W+C+^?eIPQU z73+T$LbdNI&QDwhh~BZ%``iA%e%j~gb!+f8U4_|^sc7PqtA7&n(GT?THFlp&BOab< zT%WX%FseZHD>)~z{qHkwxvqEriRZMDgK@G>VX1OcXj{ac7iM^=Irob^yH@0**2oIf z(6EZIRKK)yy&Gz|t zXNcDUGXnWxCCyNlu~hw5B+zf&M@@~1-_JVY=7kjxIrUSyO*M0K6ZG?BlDWwrv-#Fl z)bldgOXAy6B3^RTl9ieJUv`b^BX$&PI_2sgS5N!=KX#=!*gl@NE(yJQ{?h2BGj8mV ztMO|2aLUy`iSiM%WZ3npJTJbz*4>}Nc45wunQ9F)po^Sy?S*zsd^kz^S@KBde!_M zY4u0v?M1_!1WS%d2TjL9^wD(uu5|_PQ++=k@_2pH{1A>^pG6l&>myB+=%n8Zk$8d! ze&p$P;GWOOwm7w)Q*QY(4p8HJuGRL7=p$ph;RC8zYrWg$qQvQ$@y57i-S&T^LgQ0? zoO1P#Q*htIX#&nT^ZMZQlP z`+K7?Dis2;>z93LeEkOO+SI759C+h%D{nqp#=*sje$qctxhb?QYST|giK@Rl8e2W1 zii$(h*FH{T3%=eqsfuE{+T<~J{(mU6*Q zJLT%1?JX^(1DLPxgXDN;`SRtanR>`XmFDHC#1!d|+4GC^E8;mz2Wt

      m`dYkzEO z)2j>TYcF4N?pB>+*+ZB1@rQM!v+SqsxopeWjC~ycpY`AU(qKiGQ5u%4g-c29=wSyy_fN@j{NV>+KBB`MTjzz zhL?u>JOjOXGYdl8I?eax_u!k}j3*WQ!xsuw94PgMTn}geCw@Kl*t(|1YeVjQq^!@i z>DuOrKGHu^x$2?o>Z=s%1GJ?wDaA}4Z|cG47pv3-SY~3lFj(Sqx$oSj<%CnB^y!hG+C9UzZm-n6Dvd7P02li`1Dz0&+9TeDO{$E^q_D*{_oK?;nC>oV{PWl=G2xHUnfW?XR4n z-fv7F+r)Te`e#{#|2OA~hmnh$15$sf+!WdtIexh}Fv!cZeI9v=PaY2mn5QvZUUXwf z-uh6zU61q|qxFzJTQkt_>#iT)#5iP!Rug{PsqOJSL{Z!oAbP0W6xtR!+(;W<8Z46j zspw&8bX1OKps&z7%g<*Vteq=aX?s(J9#Z$IJ!IS7&tFxXYV3Z>o%25%dd#c?@Dsr&V1m(@UC8<5ziDT)nC_{_J2G z5B4&3qV**SX_IZ13TsDRz~0XMCV`7>Bq;>hR@khT%eFe%&vo^0fhvO3{8M>z{QM)a z|9;DRbIt^|{KOiVb6^T|QhR^Cwc}jqnF%mRf&C1Q`#{m)m%9(Ab7&TC(3UyXu1;qLVIYPLwA;XN1XQiRc=WmORT_S+||AR!Q8$!GqFrg zCwnc2SoNIRKN8aB885SkpUie``f9nhhoLsI%eM5kJ-@ZRBRYMZ_oKRe)6~e^_4~g< z#~fa%?VP5s%ANX0%75e@tXW?T2^4U7S4>+s!Z*ujJzT`WIzB1anX4W8IQu~o*S_Z- ze&Z)oTkfIpTKS?)4Y~Tq)F-#lAIi_>p#&Z!{w+=m(xkZ1bM9$ps$u;)W5 zi+XLVVaqxlv_9K_{#u_6IJoc85{CW!mMl+P-%S4P(Y})(Tlgb~nojBgsSTWRQ_P~e zB}Y=uUUZTC zCUHsIAdjZVdnBzu-j8StGS8CKg&m+1bcOEF8~VW@I2z=^hvUEx<*)!Qfa_odybPZK zQ+u0p5D#Qs2p537ocmVxFgl408N$ zB6G!_nqp+%m11o8G{ty&p9V%~Y6IidWetoMersS9ly^)p(@&y1Qmhn{xJi&RLwK zr{o)zn?l3owLw1%s4s8Kkc(>L>v)FWy4#MdjmbE+|S%1td=TzvYWgB*IP+@_Mb zSqHtCetk4U@*x^FeI8{5bD;P_gP5Fs8vT0-a2ZH`7kyVG&^P;lRKwSFhh`_O&Pb;y*npJVQrt{MK;@fXI zA2;Z^_Qy6aJw4#MI~@5^<(r_FRbIjanEBy=?E3Y&KfZozdZOP;XFYSwCs!OXMJi&P zrmxB^X=GUkyQzL9MHS&fO)&O!U6nw;v_n&kQ>Q+$Pp`hiPd_-^PN{w>k7#CX)j>Z# zvk(~}Pv>xL_t&GBw)<~pv`v#Z7lr+$e9u{txZNN1?PY7u%luQj^`>3Lx=uO4nvREi zf+4zC71rg|P{vo}RP0@ObH8+!s^?PlP(7bMp?^^HtPJ~$o^2n9?hnd6At}Z*7uC;8 zy`OXLTR%0tsH#13aS}#DmMS-ewndIFuUsxnJ-T7`{vtOUD%n@dN7_S)?exGGqlV4s zJ@!bALgE)KoO1P#q_25%L++Adrs1W7OX(wpN{nIbDDms{Ce69&q&=&Pixo~?!;tvu zE1W9&EB5n}ut`RGlGb&lZp(i`&RdaMfUZpSJwP^HSI-t$M0lF-my+)#4KhI1vC7?l zu5Nwq`ENb4+RE=%xs&Gw>_)7~Tmk80=<*7nv`SX09h(yP63OT}F|7d!oR)-Y5 zA@$M5IQ#joNpQX^&PX$wU%vAZ=b!V%iQ(>*c|9rTt8%9f+!x9yDY2a(@3)TOyGz3Z zrDb&I`7%yPNht?ag64~e$$q{OY<&VeLV>J^RH$LIJ)xBQ-d=pU0dh;-ANyeyPT~qwoIuhMnL0iA#6W z>3OI;EUsSJqO2Ycjvhacdmaw8bAz^vj_Pxe$n57a;K}&s(YAl8amJu|6Dl+I9CDZA zI#cD00j}f2dE90s7=OL=~ee30{0TcSxcy8S(mwm<6=XpeK zy+lsIK0dKLf&MFwOf|mP?Y?(z{OQ1F-my-#x?HH-(mJx-MEz^1yn>+B-i1%cxA*vr zRHNnm!yoVb_djQz9PadL{#SWKQ)_Dz^$lm0VNCq*3zbI99F^a@KNDZ?4Fgk+iPQeL zc>j;*_8J*hQ1w>%X4N}RmbaJN!e`^3$ACjx7%z;w{N;rQt?Y2P<2+QpdCo(}w{$Sh zma5Vtp(5==#FCHn`byee?F%?{vj2A;C)Xp%9Jhr1G~aGWV7GNY>}<@O`O1tL-@J15 zG2zH14rzZ>9u`-xY-eb;AQ|~HcyU{9Yw!eHfj6%rJ6KvKAMp$yAq~9hvt(s-f6Ry9 zbkKRk7X7rdadG+6zofs@<;m30vCn$ zZYpJLmoaJ35jZp zqZ>7SaU&c?6>GKY`ULu|Ik2hmpTSQC)0+0U@y_;E0IHwL!@*XsV(AyRv2y5VPxnR7 z$G2bQKdDCg+t+^n$a`1uRfcH&R9>xEcq5^Hwi?~8nq9B-7ZT{@X==Rm!p~P9_|XCP zcX8NF<;mz3QKh=V(~7%VwJHMA^n5IVUg_PN8c*-__pHOZT>6PN@S2_~Pe!lkMxsRTv z={SyzBS?PIJSB1JxQ}eBT-PFVUHw|XnLbv|vEtCQu-ji{vWLobUB8;Sp@{_+fz~_e ztD@UyxwkCOJ*=O|e039VS;nUE+OFwe9hh_Ijj}Cnx;bz$y@6A1`P%N!o743MyhYW| zzR>LP$bmJS6W!iEmV_RS-@B@!@!|{a*LbY!=i>~gT>Y!Z!Q<-T$tbhb(p!~-{iP*d zCWwq0hs%C7QvXSJzsB(mTQdH-#HD#k*L68o_f0na z#4c(ZU27Qb`rosFn-&q<+w-VOC4a}u%9^F@U)&GgsTUx(F`ndk}YXN(` zXy4w{Sfng$Y~HDB9^F)3oyUvbs=Iw#_R})1{?23n&Hw+l-Rk??)yBGZhA-z^o1b%E z_kY9!nujA2cgwXvO$%s$x28{WlC3?TIqMGR|K!dxdaq>8IhlQ;L*26fHg~<6?Ddn_ zX;W-fpZ%FlO##VUTa!L|K3k(ss@s-WZ*P63Enzcz98x}=dB|R7>!VJ!$G0tP$Ex4{ zKiVNtTDdl<-9oNyYPXHk$65c>)!(_l`~TmyfIaUgO51-|)BnG*OS;(8sWwX_vrlcu z+WQf;?UN{fXj{A~dejzoeaSaRA5?6&Dd((qm2fm2bX{NPy{X}B%K2?-+;Y6cuXai% zJiGnu+sPcesrzi{_%>DFZT0xgQI@w=Tg1{^?2{-j+HDxCj3+ui*|sT`e)TDfrMrf2 z_tR}{t8|~ObuIQ6#LkM!oI2N~esmt|{@->iAZ6BGZnquH>rYcD$N%4LP=D6^_d}BO z)VjGgZ4$LbwH>#)mE}b@4xSPus|DVHk+uiu{Fw5(4iZh?6?R4$*cmHpk1-6y` zZM?H{^F%!B)W2VC*A?|2Q~ibL=8^idr5jRg3z)BW$M)K$rHT66+tSHx%jfcM>+aT} z+fq*7x^&$Z^3K*gPL#-giTt;&+~8_cUly=mzirQXV0#$n+8WNmo?q%K54z#F7TDe` z5U=cRi{l}iGrj)Jb|_vtZO(Ic!*(s;TEMkHeOW-}Wp$lvfkYN?`yPobw0-(-&avRy z!j^tryuO|K>3Vyz{PuWG+f(|~lwr#+9VRPuMcJpON$UDeNBTNc<_(qU8TQcX*36Y8taq2X>% z>v(0-d7hFcvC6h{zb*0KS>MWes4USrslV=D7k%p^U)Ci))iv2;wzPi9>gDcNKNhgp z&-U$24PDB@#^#;6=Fv^n)p@+=t-9N{Wj`(B>hC=E-~9h?+pWIOU2UvuXZX(X2&cdM zKeh!l56AX(rLF}m3uu3LW9_lE=QC%$;{3lc=bg+sC$rDS#9d#^TgbId?Y43HIO`v0o$mB^9=|RA-yY9N)4`tix99WJ^W7HLk}mdis_h(-*{8N+ z?fr<__DPgKv@PBgJ!*@)zU0pOsy@OM+il7@t6e1=O$S}qhko@D#-^NKeZ{YKN+vwJ z{p{Px9J{IeZ0YzmRo`v(_+-m+UGmMgYKvHUi+vL1MY|1SmGMN!i)~{a7fYYbDT}3p z=%)H<9+3THTidG5sgpBo)xj=TnXK)|KJs7eFWCK5hB(T}KCavTEg)sqUT(MlGp>1t zQjY6t1GjwCwByzyk@SpJhuif_)E3$I-4fecKW~n>wzhNK9Ot;bgz45RhS4BSVv3*Q z+)Zt#Yp1{af8#9hZ}e|BPSe_tsx42{Ca*oDP503_b-n2!Zhaxtc3rXcX&TXJbEe1U z3_EfL?$*|Bfp~4()~I`;ezfYG?0&lc*1X=9&*k6N{ojs%YtC1$Zt*Q3ZRFP8PS$mt zDE=AOuWusTCGwA@ja!~$S!LUj*{|O=CJ$^YXS+R&b8QXhV9zhxO4_@6x)%7iEfBBl zZj0j~o70~EW;+xwoi^t=yJ5Q)a4q0kpuQ~7u)YFv!`ZGa;PySX>*THVJR| zT>Eyh_EDMcQ>*gZpvU%jPTOEI)QieeXKG&60G-zjGETCwV$~;`g~q{`IJfNKHQ0RYs#vN%s~q~IKia^w$M`P|W61?~zSd__ zs>h~{ec3{ zXkTftJd|hdgvjT~59XE2ZdMq}SgC$`*YzS6Yg~BfKPTUWI2&sL1s3<(omJvlKn6 zZusonrRe!!zx8kCwaY)`B;$!}v61~e28@h<9$luV8n4cs7&^|l@Qy+=bnCia?5y&z zxO$cNJO)ow)iJqb%u&AT(;RM{ghS7D=-B|7mJivMZ`w}X!!X8PcUONljVD4^?*D=J zlMb>i&br>%v4-68HH^f1hAls+$mb3C^2d}6^i2amxsKvi(#xJAkDYgS&8j9H1qYg$EUwJ*Rr2w#}uroa@9-M zN$NMuS02J_{yfi+KmmnL3f95BvO?jkYuPq8nD4E~3JvoY6q5U=`}3=u|3KiE6B;Tss6xtSbJr6y!gblH; zj(e$GbW$6pvMtv+dfldS-M235bavMAJqJ5z`Ci)P`y(XWIbnZkSGwoM&yVXl{^lpT zEuOpg?_Hifh68cmf!ImqrqH&?IljmOg1(dxNwyvMqA4pV(2hg~lMq*~61CrHvH1Yzyko=KovgOrQ2)ONf2y(`k6M z*Jrv8W}r0^y-))zimhhXKpF`Qf^i5v_-=H&meDJ zp)bEiFQ_yxq5~_<#pC?ly{cDz--iVgPHzNX<1JBw2-aOmQ&^pIrPjP8(+^2(^8EqW_)o( z>!zJ=-9ai1oZ3<4mNc?VY{y`6vA-;b_ARcS-3iiJU-m>cBobBB)}rwKQm?P(yrc|e zfUKpi6ZNZhH;jW%81n|3#{cGBvMO($*=)++aJWNi$W2ccIsW33BA=NF=z8Y+%nClM z#23g8`KC*kVkAQLv+FT+oTbMA8#X=3!*^QLkShWWhtzEF;TuH^RU{GL5AzI}(C+tg?_*Kf z_$8eO6$MLu(Ftu&=hf&T`D_5lTABc<1MJsBD<69Ml21Ccor>6WqK9bXl$&A}HS~}U zo~ehe(6OIgkExTQ>mjLw~=nzMyvC)D}QQt+O7j=EI=-9;iT-~v6)6>?CzDwg% zeVlUjuSK7T2BOqxs_KwjG?iw1SxZf6Pp`De(di|*xvA{a!7!%0^HMisR8ynJr02iu zf7|judWR#H^pg5P3c_d0I(9vlI`qgVG%0NxG7Y0_!r{M5;H{rYyY-Gf z;~K8oS^gQuUy#O9<)+ZK80(+Q&<-Of0dLVjUqN_iDaRbrA@|@h%Ui_$RiO1rpW~v- zv$LPIW?B>D_hG+pc(Tvb!#WP&KwKvfd#KzL+7=1>2iPQfoJo6FRv`9#y%PNr`oHl-O^laYmj5#C=^xK+E)^0^^bvch+!Wdt zwdrGNGNu&e#ufSkcJ<7om$TG#Oq&|5m$Utq1JXU63ZHzW_0{IVETo>0rBiN-Sq#Ta zp)zm4EaM)kA-}iCKi6#Zba2HpFc_R!>@P?;(ln9%r0mFbmZpj9BQhMmdoy z;-TBJ)^aRz*SQwh5*CP6UL=o8eiUcVlbT1>PyA(D|I5DiawPs6<21Z2eeA}>x3R}; z$~kUqobGX(ZUOs!rtveQ`-znoFE#JiuNq_+eW(6>i^Mji>-xV>IQ_0?U+%Lfot{D0IO>aE-_OtIx%Vovej(AmW z3T=z1cr#{s{YBnsTqT)t%WjpR@h=KSUr+n+n-0qkNHG>oxb4yI*EcctY~|mv^F8PM z@nCqoP0m~T$13MZ0h28Ak0$~+mRjF&Qsk|+Oo@*>k)R5Z<-H#0XV z1F4KVQPAqzAD6PJ?W5FQdhIH4*GKoa2ov&uL;zYWTuct3SPFuwFOF5z_9fJUVplzxWEwXA-6E$S(4h@vK>~NA7@3 z^OpKNqszJP=*`ax6jdBk&hVm7hsmPu%cqq`_ebPjfl%*KY@3`PiiL=eJi3^VW zY0;f>tu9XTZBv#iH-)xEOuaI>`&Z7haMceZdWM8T!H{QAC|FuL*e7>v=&*#s$C{xn zW2yb76-ns1^QiRq&ujN&Q>UIPx2b4u)=5vfFH!8{PT#DGczRBqmDrwNKiTxmgZ8}X zIH#T}-y}V=y``nIgQ5KJAie0S;Z?Dr_B3WE)-(6Yo~0AkwK&45r^+>4UDwH;IfcQJ z62`o33fjl#mpk-x_LC*f5B9if&A?aw>YX1}K=Nfi`BLR!arG*ue)5b$(U3X5ymBc< zo{7FtaICkeTprq#essM2Y1en^oM?N-()ZLuFZt~L^w}>t^;LPbqT!8=(l<^%wdN**{t=qkx?zL!a24%PJD)bbW0TREn9TmU4CXIUCd*wGf zTYFmj$=Rt~_OZKU^sKgTZcttVh}~*A>}%J1(TUOajn&S+{Kljks-E6ZBVRb>s(Vs; z`=)z&{)uLH7SBe9JUsGNR?eFOwYR#_&+T=em-zZ;-kW_FzcqZ_dS|{+x$3LyWc1GQ z&I&&YP`j>n`>sPzaq;rSU*`=S)aCxCqw_2T=UufxT?I-oI%Go{2C8M{k+|{b9y&p0D zl*IXB!kO)EH$GoDS(Q=yI_2u0jGoo`!YX$$dJ&OKVYjO>KRQ3eDsKmLJ*C}geH+eE zeNX>LSBzOyMmrZnQw_&%*X8IbE(0X~Snb?ry>}Y4p!7zbps}3nCugVfu(*1a zjGonYwaQxzZ6kKI>pOKpv|VGBvy2M|egD<`K=>(3>%3&?l&iu?=^MM8#n3ytT}wSR zarwIZuXgQTE51U8HB2XKDPJlNi>p`3=xZxqF?E!{?D=&$dWy>ci9c38NHHE8S9ZX= z-^+gDEPX}OXu0KE%eaB#I;c7ySmn#!>#fcJRRpO0-t5z&(?3?Zx_7|S$E>LOX1wa5 zdOGFmpNu`L%avWjZ~%5YZa_bA@$A?xC-Z?G9r}FXEKe#A2V1>LM!#x1TII>EWwjmc zdR8rrwqvYvl-07u%+@yzU#g0z9i4LZPfE|&<;bqDQAL2&>Afg%`FW+%_w&4VKdiO% zv+||nN|mdAx=uz zyDM%s#~fwcQP1_Tu-tiQ%=B_xS$ML8rM5SaJ-NY>5#DJ$$0rYQmY11#DANg8@|8Sa z*!B$GH?Zj;I@tY(o!P|L_lIeheEZFNuQa*ml#z|`ukUmx$QtRbwh+Iq-PzN9J@!hJ z?uYO7@M(*S{*Wr$bb79R9dh-LneL9>VqMcc{p==&T@TU0O;@$JwYK-SR$;G1>H2D3 z@9W!l{n&bqgCI0rUvtPcmYC@pqnDCQ+De$|pyk@&{)Szj&5^!(eiFBC>sn-6yR(!jWdZ3pO8Ut2P{w(Q`?jqug5`AJ9Yo;3R+bV5xFbXj{b8%W>UP9(EB~h$PPzIgqhIy)MEJU_+IrPj6VdPAtU*tSHv?oH%Z?xR zec;byAGvR$>Y;i%gFHI^Wx$}uVyS&ZVGLS zWb~@GU-){gT05Kl?CIS7!f5-YnmR<^A8+<^>ZoRob|_F))P7F6`X{AlE!Sh!`Vv?b zXgOYUQR3^d%riPS{rULTpIZ7^_LS=}m8*WbPDW4r^_X2Z3B&EbsU@woJzp)lIC1-a z%)Ar7Y2JT82e}p#r|C92ERPPomT{d({gq_vZW!qVtnK?U^t9_CIxGtNo9)MSRyiJk zO#Et$Pd(Md*yXwg8=k%_^`vj5LxYp|y5)RSZVGLS8t)aG?>EcqY8a$tGja^<1w@y+^v1{c;@SDxZ6O|MSjj zGw+ymMY^vEdhRl(3&~jb)V8EF;QyS4@_#uF_Dk`Rp)_W{WV2scM(rN*N09T0%o$GF zwQO@(9G@H>pOc&H&eu>FWaz(Y*blq$fAXiElZ@|^&dKm~`oG}uucQIByii-C9S~*M z^f>_KeNI!ZpC}LcGlAUIYklP-_QPS3%{eXwf8E>?%Uca?3u^jJ%Llr=w-2PH95Q2X1$Mo&J0`5NSY;R z7iGAR`Q(>VPVn|4sq1=J5}Jwl*T)vl`|;YjoW8_|-t$*10-X#N=*kjDYa7n{qsulmMe+xuyYyq&Le9wD3h4_U5itv2;d8a}*m*+*(C zM(WFuiE86V)ThI7s&NGW|L-**Kc`}z4V-UoUz-?mfANxO%#_!yQ|0Vln|vc@m?B)r zOVp}Z0YkWK8U{o+}#4(D~&b#Aw1w(Tx{PLUmgT9D=VYchjuqpiJN&O-WJX^_j7 zr$3syn)*RwmIT(rj$cQNfAQh7J)h3&c{)U>a*iDFYSHQ|XJhINzC2)Ag0qmf88Go! zQwtvNeY~tk#f9Hr%JDD{RnG1lr@@0(6lIZ2!^9(bX<&WqOP#fPZ_oDIIUeSr%GsSG zHF#(%O=hxCVj}lXSJr~ZmiZA6$5&---=3*cc%G9$5S;F11ZV0~P> z_RWR6*LN!Cc$kMOXLpX$;1P!v{wJ7uSi2w9yRMlV}mtNaUs`ZrM2L5B06n&(W+4ob9~H4m9x9T$CqBZ#*ktRBlC$|9#}u4 zQ#Zt{KkssSTx*8;sB(5!_|&W)gO$vu0(>a^IDl+w%hLO&yq9(4L=z^%;%9Z28@Yu954RtuOf3Pi*JrV)cTexO-Yu^&CQtZW!W2 z??)`xgwnyxM_c&NGkh&`DT4xjulFF*C4=n=p7a&|Z8lj`}_R~wtImCKWO(SQCW|4r`xHFrm0 z*0D47f~2KsdmLF#eq>|jWzN68ILUlU!H4cU4j`MNRLggl!vj7Jd$JBKbE+9`SE_P$ zH}k2kC%H{Y*U06&#0wG3!U>5{YZ5 zeAE2s81UfrSD&o&Y-bDHWW8-rcxJ+#=0_a{MoynhUPbRC^UohO;ow4Q7n33V(s~Xo z*M!o6_dQC%RBmJQ9a;w1jq^fVP9pkn@^c&+#^yn|PS#uM%l`F7(JUT&@7H@5_DbO> zi4U<-xe&h%Su>u(KKk^|w8h0c+N2v1 z5s#+e!E!_FvHII5;t@uxH(MnZ)Rozobw3SxxSAJ$(pG=j6_79@7{z$*C`p`UFW%|AXeQs{vo-=dZ+; z^D5gX!>y)kR5|^Z%K-iVqstFHd;OIkDob3ha2hm!Q4PrL^N2O(=ODG82&MLVqV8Es zUK(XTOEnT!XSPjWLr(yIjtk9IVID2OEKSUg}cp znU2C->wto6ZP6zA`8)@_C{M=$WD`rdUo-u~2r;hDbNjwXns!$&xRIe|DDh&sCX^2H zJ_-g$FiHeLjLF$)g1PQl)=%`>!1IjXd@0TTbH&s(92K|ARXMw3JCv-UHtZKg`f%$i zN-o5xpfTEKtQltQGeCE<_QyhJ*qKA-wV@WgcD{O~LwwuJ_c&hWrOMg8w!8-SG4m=$ z0Njt0{AOT%J+yAfZTB}R9Ln+DtexB}R5`oX$SW>S>${QjO=T_OAO3RK`<;%SP1_!6 zhT~V|?CvlA1Z>ZMcYz%8TMn=uiq-|zgS&6H$jAes>p7kl+DQwc%Gn)Dbmcm*v8^-D zZQi0++XBQIkEJxT&~2ZWNy}*>XT|4W5ZRuYScv^2(D_x!Z!EID=Ik+-GYcZ4_K&94-B4me%WrF2~*ke)Sw~yP275eNb`kBU#X+z`EQmpazZ0u2o&0WZI z849-C4yG4dYMaT1%04~kR6}yv(0`Vxw(L(nXMeJc&TEpZ{{FxJKa2#C(}(VtzD?ma zGTAD~54&?an*OUszK;C)`cHCp#QW%S8^C&sk6WpY79)>r}4)J>#aZ zPQ{$+b!uF`!eL#jeruAGKVRXf*VpDhhr@QDYseqNmtS_{@Z|q|?&~^|$=B56=Vax9 z!enrol9QWyk=1m_t9F9Yl z{eL;9d;9-W2ZIS>c4;YhBypsy-nO&^|@)8H6=-;jv&>iR-?#lBX zD)$BE^-aeemM>DLywCBTshylDR5`n+*~bS zabWAR!LA(ePQa$3_Dl%9cf;YR>!+~1Cc8HM+rha4HEAy>|GR78WXsFRmIZ(Q$<3EL z$!Hp)FSozDzJvV#-Wrgf&)MIY+YRD~KCd?RNFA~3jc&Q4p0tRsn>P9Uy{bYn%*f32 zyrFgj%T;X{``-6X9c)dt+s5gC<8m;|PkRuiX>EqC*m22dUZjn4*eDEnzTZKGSMhgO zXziKO+l0vKyFS|Tm_^(;^8B^?-YPus_GXaoyAiibK|4Iot!aZ?-;jN6Xl(+&EmS8GW8$9ihtE z-8(Olc0L_wFLYzq)4WWyxCXc|H#pZ(fC-D_3Cr^o=Ae-Q5A@BH+`frEWS%cc^Wo^* zkz~x3TX9vBFDb6CZ;0x)_tt_pTGAgF$_e#wWVt4k4#u?Kf#70y8SSoQe0ye1%eQ%U z5Kgg88jX+L$JyyKX3+OGZwA`O7uwwg)#p=6Q3O2IQ@Unvr zybMZF=Tp{J4}tVa?(9cCr|?-W$K^{VyZ;lXQQVgx|tn$`#3 z`=j}}uYOmW+&@&jee3K+-#32$9Quxi3|&FbeU@uN>ENyEu_7F;3Z9maRiyC1#quWu zlai~=qn9o{sZ*MJPi<>%UsD~S>&zPr*BflJ3;k!XENJT*klSDRKl#reYd*7x&{Ykd z7$c6I;P2I`jY0W?<*Ht#{E_I$#9D?ft#gKYl1%wjE@M-p+cI`nACwsfeFtL2zB_1BVP*S#`tm8>J_a9*56;U$Cz9!V{yE@9CJvzd zq?VszS2OYBfWto?JY#DXxszf2uw0jVk3;RFjXo>)fYEMrCec@4hN2|S9$m@lwdSyY zK9L2@#F)daW*nGZutVj;axWA8Oo}re9a(wa|5za*$D3xS^E^`H(ooEMGc;*vkN-ZH`mLEC%b6G3wc$qzE_0%5%K+Bf z!2rC-45hU%=Lj)Lrw(Id6>09ba4d6eRo?7W8ZYC_rvm2x*y!0wnXO0t|OhUk=?APaX)K7fb-A60QVy-4aF;0Jr~-l za?^Ke{$cqk-Oov+k0+BE^@hy9qK^Och;H0aT>R^RiCvnUXHogH{FL~gM0%+FS4#TN zuIrzFMS6r79s2&m%ZFzDw9t4npmsLB$FV#he>_DBoEgp>YjT$^r;%~w=UzlT|GcY) zM~DUA?0a-Wbf?+Td-eL7d9(a?yHoRUK*&(8bV7bb( z#(wsM9J?*AFkfGB*u1`6Nqt%=&ig*v4Cl0tMik`r#$396&Q+nJW1SHTa+{pFaHXy; zFwoPP<@jqd0eK|ab8M3a+HGzpR{a-Z6hP&Ec>8^?(| z>N#pdQQMl<=Arj@TH`7Lp!+~p#Hf!DkpP8H<1*#AuM1KmyB_%b>i99MTP?c~Zl#7h z^>4*A@a7-wcJG;07fk}OAxns&osHMyR8)+(V(`cg6}^WV`XK8(FlIUVkxkn89BZPj zz&0BD9-t+ZkzsdZiQn-#7>Uu=UUuZ#v6LECgElTIhRyZh$^d*)Eumt}+p8uwwQsD9 zG&-{)aXpnomgBF<5Fb1j3+&W3!kIl^d&lxnD28v2KPJ?yk81rDjYGx4$6g&;HT62{ zC5ApCaXrP)a{M(JbNpJg)*&gx!>##~%gGugexamCWLT&enJ}-;tAmTDsrS!vQ{?z# zj=xtCIvYKEQ+SjBe{#M^jWFv$8Y>x^*%L*_##px#-knSkAV|G59B_fxn3c z%8-Gn9^-w>W!hA3$f$Xo=IT*-3YtG&1Ht<2kJoW9hW|erh{UaMJ2oHfkp{)dQ*T-N zh&G}`ZDHBH6z<&49hURZ=ie&s6_R`0gq5$QDejeU=XI&OxeF(?g1g)=mfg(U9#ZFx zrxr(u>2F8%zH3$C=T>6}f%XW4+J!8~Uz73l@AN9lx4Y2x$-@RI+H^0Y1Fzb=aYrt? zr%dg%!wN68y(+%4h}(x=(YgC8)`j#AL5AKTh!@K>p>*)}8`6r$SZ$7)WdrgC+B57l zLTz{FW5qgZ*&Ac#a{D#1h57x8-%U!|qA$E&cqB#h^Vt7hSu*3MFK;m7yaaX~afwH6 zh&`6pFK8W%kv?t92fedcp4V$8%GNVs?Wa`c-Yas(({epp{OlL&q00$ zvJH{R)Fd}~3jR514antbCGrWGIDqu6=G(Hp7SV3TpqHk!`1Og4$RiA;ALUz?YeMND z=ckMAr749|^o3ln&mwtUmRW;Bvb8`z*Sw4B-B#y#e?{9C}E(R!x4F@;w=Df3RGadXEynG|Zvavy)e-Rp*|@2QHKI zRm8de`A{sA97Emfr(dnEqJY5u&39mr}{p{@iH$}&hEA5C2^u_WqrlA_OGwxo}uER752Ap zxpColJg0-&bd=v&&V1OGcqyt%$hK#Uqh-6HIp~NLXIxkWoAdq30K8T{6DF=-@_ou( z*LOd_`HIUS%b5?`5-($>n(iX!=j8MJ>!angY%gIptg!I93O(-3t zc;m9r$oH@M-) zd3~5ZXGrzdzFfRa&$Cf&%=%HEBUJ}2qD|XR7Fk|?de=7PIl^-0!M4OlD_{HsQ6C_( zUJeG}QGCcEN(SwJujP3c7OFg0&hfJykcUzkmf=FqucdAM>m~9>i^wi$m;I6(6FU^W zu$+0Y9heW^e(d@Z;YQOo)#Y$v1#@i~byK>vjP%cM%}*9_aB_lJ^zj%IJVyOu5ewRPw|?5SJVE8ba*m(vTJccQj;<{OIQ>%F`PYy5)grcC z-QO9JzN~}Fi{%uiY--1=<}{S^dsP5_Wk)PxQsvwOH%`0kLyJ){kwx_q%VlnKUORr? zs-O(lu)d1h``1_OQH$9B!GdFX`6W|SJ}f5=vN<_E)f2P=fib`64*vO79kYmg)`~BV zkGXfJ%8%tTH#$E_el;ho5wM)TYZSg}J1YB|P*Ik6_czCrI&OW}xSpSPEH}g+OX6!h zhxMkEl|SO6X{h+_z-3%f4x9CteZK$q7P_Qj+p3MDH?@j3F4yV{Y7MJ$cCVR_BU9Vk zptrq1n>9yIL}*X)Zz39r0Es7!Z)acR?YH}2?z}{5lB@60G)_)!7b*|(I0(HT`+7(A zC4<+X`JFVNrcZk%+>_P+$@*8K3;tC!;46KMM~dPz`1jAyfZU!Eoy^ZU^|?X(*5&tY zJn*doCv&B_Lo|a(m9x84@6x+AZKkBZ_zrT)-}$6wV}1|jv3b4-m!D^)wcz#R?2)R#JCw{L#D5h3xR_7lsQ2ivvdGsx-n zXG~<*=C#vD-(KBOm}M!{J9T8c*2#}Nu9BO|(!VUnBF0xFT@>%_{ea(vM#Mas^*c<(x{pDra{|FEobZ zbUUC3qe*Me)LY_u4^vm|5;>iUt~BQt`tFf@%>mERh247{9%>OAM=oA9?X5E>e_~V` z#E105a^}IdnGcqG(gqF;Ufjlp=PH28O`z{Bh#`%^Q(qCKAI*)Wsa#ZUtiaVkf4~k* z1r`H4fk^P32+-#>G$_;q4T5gS^b>IdG<*|}K*JE|GJLEt7MbwDbA))PJ?c_Se434q zOM3PbqI(A7xgFo4lnb$HyAaD;hlsmfA>!&im{0GnBerAmXuFQ}M0r+y@d3VpApJo# z+V>uEx?5rbr@MVu*@VjO80-r#lTXV(k(w;pKEM1s^hT0Mw)LmeYOC zFpHSAJL=vqw{1x(BM&f~?kv}(-lN3Fh}L()m*EnwFSm9#^H9gFVoMr|1F<)E`{dRA zL)KHlg`vJg%6}}^gwo*@=I@R1d=!jukklGKp07>$j_OKd_(jtf{{HDk?r+HNVb-Is z{)SQQzS{nC*=nwCweOVZYb90AHzuX0RNYf2u(p1NUhhjTe4Wh8g73D-a6a?JtL}{3 zGgphZzUJ%o=^KrNDra|zSKx7fERko+$kr~E%VW&dfq9+TqT<3Q-mwhic$t?fXZKq3 zGB}mtLMjKG&!~>`XXx=n^_@{1{dxUe+~oRVO#ppu9T6(pe$;C7KFfXI>w41rN2r{# zTqPyxOV33^9QKKnz08kuQ@djCHG$JDIjvi0Y|Hk?I6h7{RnG3!cno!9X4wm>F`;@; zPA>}r;CD)+>A*n-?LR>STyN9&lN+w}|GeEhAXF4Cs28^TP^TSe7HB3MN6N1(H^d%G z$|or{N1oRDM2nnSqVft%##&5Hy?L7ILX$nOAg(~GswaPiqQF;SdKJl2}oye_`%uyKBIh zghF?LGk1^!YvByY!>8u%g8l{hbZsO+_e0};#o#5!OL5BeZbiJgJx;o(`zXW2{w_BU z{t%}kx@`O4FOFV9$*CEhH>1kgy%&9^nD266?mKQ|`cn56W*F6p0jM6#gyb2K35^OB^%^?ml9*C##|{@7Y(%lSo>v%6G|)p3-xNqHGu zqLo2;A!3nP<#HQ=04cvv-Oo6g{1eD8hfTcsJkT}lmuz1~zFt1}iyVJ`Tyg2iGqhUe)62zP3 z_-iu8qKRqt0xTJp<+ftFO@h-o&S5ts{29J7ELm+_(iABE5O<*MB1#Q2L+pi!NZ+E=*+pO1*dYXaMCZU#zD%Zp~#HIGZ_`lPI23uT) zwwMPkQa_Ov)793Xb6-X?b=@|a)}0CeGM_o%LnaQOd{F%G96cW=2yxY@pPsGg5iYjv z`DFDM&BNwCXk-*_AG4gUmrXL3PIS5^S&fEcKS$m;w>8=3&PJ;;$3EB%o&)ko8kec< zXe0B9y3T)lo#MG_O2Ms-?q2aG$4Pvs|3a0syH7rd8%w1+^Ac=Wbv`qG(q++?vHvoh zP(48J57{YZ{iyvG8;I}Z25;YS?y799a}C#W{lsz(mu=>gkb{=A-Q~ve_h`8m6&U|% zwbar5upCNW#w06fYHD<&3r+WqHZsydZhug_nT(M1=_LHK8W)Z*Y~-LTMapO=K^kP z(7P>}Lxx=c=RNkf7g&3_T-Z<4nQ3?9gCb9BReu$Wgjb56#uF+LzZ^cLyZqibY8d4f z={;82XN}yxfBd^QCeOcobKN2IPk(+!;wj2Q|a-sIj z!FdG^ZAnDFq8KNvuPTL)`rb&_{F>6T+gW>-_m-a-b-;(^$4%#+`4qe!cdFer#_7tXWi3){d3ddN zNh@<3TN7mV$;`217a#r*7U7futf#2q{&}vP9VSLQx9^Ld-y&V*$#Mi|GN;Z{52hFv z^Gn5eHW|wIdnsezcwv3&Ln#OEU6WqiT$N-Ion~!lI<0)zh=K?85oW5VNRKSXUz6d1 z1*`EWN1h))&_D`XcFu2BH_f zQQc9;BF;Er5&h0-B!;Iq7Wcf-M3nUp7fqT)h@Fkj5PRZVh&R`qC7MrfC8jKIEjGtQ zifb=DU*tRyC6+I|MD)3)o0xWgcX9dSv0~B8WHI2@>%})yhl@sUjS-Wx-QvARZx@H| zohf!WpA@n8zAPN)zAvH*z7n7As~hs-ryWAJuJ0Yv_^kYp_1YbMs2-(1l2)77Rf6>5e3Fg#crrER6LO1x zW>SX^uReTp6QjUW9Y(bf%eBAKp~ifIjS4**Qo(I#C*`W+en%FNh3py`ZJ*&Rng3J#uuY zI56XqG{EOO(-4A{eS-URi$C=GzT8fl5F#ZS*T=&ij%U>^n18!Oh+g~g zd`b!tx2_2h^Rw%SwFByk`=-|uuJ{I`-CXR8@nK_;ofsk9BhC`#tJ?@$QYX=+Z4dGC zUOdd8Z?3Q9e%U!ny7+3JT~Pc$hZV&SJbFfd+z1Tmq6>~J*M!mmi+fD4q0c_CPimUB zl2nq*nd=>F)CVG|ADWiZd-DsmCTPE4Jc>nBW~jJ6xneP0@LTEw z=aqIl(uV7I;zjIOuKkq`p7s!(AWP8JAKnHTf8%KFZ!8QZe6>G_3-u#X-9_n6Q*bG} z(z_axPM~QaB7yUPi-1dkD}ZZ&-oW($jo&(eBH&(N9`HQy4)7HaiW}(+3<2&2UI&f< zamY6`Cx1UM82N`5s!GGnQ(I_0@{%2yl7?ebkTDC9r`CgP652sWLG}R1c0~Sq4zpcL z&&D_#&F#j>mvo+CO89F{k`N%=dm; zh;QBy!nPG{qo0NNv}K5>7aJnx=7fms$3sM)Z6V^SbL)r^W9o=sUaKQ+JFl)-Fs-hL zX(NM&ef|X^@%m2Ul`EpP{J{Ac)I9Y}>KOC5Vg%eMjrjWpoQh{- zrhk4>y@WYXjb_LW!HhGO8)A<&__`D;zWGQ@Pr@dcg)SO~c3Tr&PHht__$mjuo;!^A z$;1IjGNHb2klU+I^bUKa;SmQ^uNm?e2Hz|<#2(9&Z~eS)(3TcC>Lhde`Y7XWVF8UM40iV0yW> zLwanEBg-|Rbf}pRy~lYJXnw2EI)$;aDVjmLqOtB5!sPUxlkZ<|sSCoyfZeaY zw)4%92j8FuBMd$3>HU-Cnov5_%##xmNsDDwYMah;5H|CT9&c{P(z^z=Wuwq$w{7Y0 zHPINEQTNcQuUDkgy9gQ5E43q8t_h_>&3uh4sc-!iS7277Sc5Q_SH8>4i{5$gDj^Pn z@8|ctnOO2gsMxxB;tMU`dL!D{UcmDn&vJM-nVNa^v$+dW=mU!aXP#aEaQCE358fRS z8}XO>kx5sSzIcVw-skc9q`lKqF2U=QHpa&9dh~ukI;OEVP6x^&c%9PT{qRbqz5mlY zAYQFROMvvk?Q)kVMETg_GGGvF~$Z}069n!F+y(7au)ae?B5ii=+Il-2LRk*T}9C?^?OFM_Vw7Gfc zWYJ$;2fK1`z09lS1aG}e`9|%3s_f8Q-2cW|S5I7iV{0mxWT>4><$>jzP&%0V1$k%c zKD_XJimgZ+Da5Fq(G6%^D?ew;6<##%)D`}+(=lGOq0eoW3&VtKQ(B*r`G?k`+eI_X zi{*ycW7W9-A{b#EZo4ZNUzvG2BHgBO-I$4i({D-FFJ??FJ(H^qt+PU%la#s zOwYCo) zmy568T$8k`)cT3?7rona{Y3RYpVI|=&Nj&cnUnDwD6D^)dkJos@)ON3kC<$JF7or0 z_d6xsoRRX)3;Q?D9m9Ikbsthq&hEyy09LHoI@+r5(VmE%#A#U+>~iYHCeXT1Ip3Cn z2bnm4!p{V#+#d!;PM=I(MYqhQw}15HWb~BkhIy!Rc1Pb~TzJj_Ft zv%4=IH0vKN4lUO*lOkNe^-B7!f#+*gxhAc@>x~6_Zf>2~m*UcSU~I#XbNp-%Mf1iv z(TyF@3No_$*(cbkQ3DeR@bj?<@yg*+n8k)W)pv($!7HX^{-U0fT~lvvZ8P!eZpaaw z$yDcc9k#2r=X9eA3?>p_el2ec6>|8*PfouwxYP474j?yvSK|GEAQE%yj{joXmdPpP zPKN9d{8+9Dr33TBCs4_btZY=l&K%DUzk{$jnpXSi<6@kCEsF#5xNqV55rgh-cA3h9 zmfv_a(3r<2jtlkF+^;qkIT_*Q-D=_apt*w6OX7n0^k3D<4a>dTvYiG z$HP2SIlI@)1M>mK6<}{1osQftSXm1my>>N;JNvc8`4&+VpBkN;BE#hyH zw6^ty%le(q;dA_|oZU_FC)-?^6KyWc*ce}kMw_M$YeMQ^ZEGI=3Yky(oq_dHe)r|K zmaH6jROjKXuUO7J*bdAm1-s$6CNU+M&)!<_nft(ZyI$QrZj;J~<;;Wazoa&`~Q2dkpwQX=Y{Wc^s~4$SARsrH#O)1KJG@i8A& z&hCNv3`$M$s>f8%7K0Ck9|w?K51@u@DLO%3?{>+9I28}QJA7^8IlD1SLO0Aum9slG zb+q9n!+7n-r^%@5$W5-_57#2zkN-XU^7VU`QIlLV9Iq;8_teBBs}Z*+PI4;-xc(@* z$J|a-zuPDO4~!TdI#3DIt)&Uqi^+7u)Y|UV(*j5Giun2eBTEV zKZO?uknKy~?YEC??s&4^Z$|fk=C3Y}Ea!09ruaRPOLs0m*NRHa_pN^CO<|>7b8bv# z>G;m;_9YWFEnb@M#B!3!hT_$-mDbONp6X1kuPG--Q9v0kV*R(g*L?qQ3W>#`>I)&3 zH0VlGjKsfoA6i)Vksa63xom2ZYfaI_czVZlIg79dZ-E^Zl=iW?UQuCdT5DWkfpZM@ z7>#pKr%z4-5=+aJh+q!D{3>d}Z*98|E78H zn6Q}q$o}YB0vWbtciqK%tc@S9?|;^rnm*i5d#YNvNV!n2NpvBngW|=LhN?W!|C+)J zblu;{y#i#pzKNM(u9q|6ruMsi`BGv%6;jnKTN3n2mxBQetzI`iERvriYZSifxJAjW z5#r-V4i4)%F0|D`BQYueQU5l}nJ3$64qBN+tC6u3272VFIX4vB`;vK{dJViszrogWf_k9&)c~_3^(^ zp0GJ2-B#-_{?E4Ax4AwfH}V&#JOpxA{*qCSX)cyHtLTM?7dQ@8X_W zb*ap6$U^&gXXEvB!2s9&SEc{jdg%5E+T~h4xDrQ}>r(GAZG4V298{<;0R$lm(13h< z9!(yx4#+RSP+NSCO)uWs#d3L?6M$FrQ=#J8igTAWi(YVO@1!n~KaMa+X;?YW*_mnNab@*)*&gx zjJn|Dd{d$DsFqHPLPhzf8{^*?H27WC2lHULL_s?>^XOHCZ@6ek&$m)=g`97aXPfm> zjSu_}Tk_%90k+Sc`@BexnNo@J4a;?@_egwbq0G_PCkiV>>G_6o3@EM~yk&4w-3qXQCSn$pk8|2g$9n~DQ zt7JXpKjhVuFFt#hTEsJ7AB`S!eArz>TI(gA`LJA~qMg=`4+=h(Y$_O2n8VCuUY3Xb z^J=-=B6bXT;F^vHZklOtYUaiATJb_BtJ{uJ=fZ0Hnx3ljlG`6E1Mo^-VG&PW_tKcl zI-Gm6sxOw;idVJtQ+Qc>6=mcUW}@GVMh3M{uF(w0KyR2>i3qs8l>dmiKIb_~ynb5I z%h;FxQ0sGVx}xM?{368Z%kmoea=yn1ho6k65;tZoB9oe@RfsZ)cf=h3>3I`xizKeUyeKY88<%YPq! zcv*LuCxUK}coshzxc@A!`+Ldr+8#@0KKg)YL!rvq-BZ4M73JGqcv|Ka*m5u}B)^a= zAN^d~C{8P2Xsk}a;4zj-HoiR}>b)^(58ujIjovT$PULbI{h0s!u=h2KXco8b+`g+O zhN$_0<;O= zWI6L>+ryW?@6q<99^gXHd!Dt1x{IzY132Gi&kdX(hPL_PsN?!E@6xqos6L>hD%Zp~ zRO97Ui|;yB``8cP9vMBPayqx1=Rcj3-?WHZE{{95HE&+Bn$9d|UTjz6r%zV0CJ!2f z4-Zc!@%0d8z8eDYEqco$wjXKR@4(3HXVm8u%b6$JwdY%lhZh2sp9jVB{p+`6W<&Af z-Or!DyW@$jVzADLYAJEjRT6%conp7;;i=$h5tJc(&bN^Z{PW)Wjz!FS zeebI~Gafmt<_nf9w5#V^&pdo@2KLu7kn7pK0r+Kqg!2CLJ24*~`n0>skL3aRrC^l6 zfqq(JG+3)fM@Em-z7AlSUkxjdVk1KNJ}Msfuje`V4l{3OpN}d(OdqA*2g^_CK5$!F z_sPhvBb~01-Ae=6P zKdB4--_PDh8j5p!+%=>5^5LD-`|-$6<$lz3IgR^~>rL^5|NA-YiV&~dvf-Y%f4`HW zwx3w8+)nlKjP_-LGsBriU&F7+O(<$sfYPd#JE^-uH?|GcYqT12Y- z(;XKrxOJXd|FGQ4SU~CN$1dzGCy|=F5Lj7SuoyRKV{awJ50t(?LO@} zm~)&-%ZJiStILUr(D+u+mN|(AS#+Ppu=u_spEK*5#@gxwJTGq!+*fql((8gJ?w><$ zWVpYL<+{{+Bp&kTiQ0%e4bTQnNzRH)G^<{w@_4`H@gosUzr+$T=>8hOH_OS7Z2H--1X{MHRqacS zIdJ6rj#(b~zMKCTvvt_S9(Qq=eBY{^-Hk5!w22OUzk=jU$j16?m}8=`=;Nk!6%;S} zm8BA|4d6wF_26q9Rt)dhD|7nl%?pef#l-7U(wZUH0+0?q$6+Cq$M4g!ovs3m7gO5E z`6Kmt|9tko5GwY3Hvgi2$yfaQ0b@P^jhRvZC(9)&+NpV*+B0r1Q_%bs(fb(hw=x_vt_w1^&W`_7tor= z>Aj59b}ofabsaq?=$wJmYKGkYPUi2%_wS_Je+t(!WTKj$k3>FY2U!aqj?a=R%1^}yeOfBSs>bpvK?u(5`?F59oj*`40wQWDbiaR$828uMLw zN-Sn@>pml4QN2p*ER}+X91q1&Y`AOdV7y^&H>vGMcooN-=PpUT{~Udh6a3eChE$W2 zUoxH+5yo{UIIupNrxisn{^t3fWwnUkkum7vPe0wiNe|r{zba>U|M6P~~p%Grw` z=?S?8U-nWu{;$^&qxIEjEj3zOn${TScg{$hw*%1iBsu`+0~Y`n0v&-UfWBFw=Jmxu zXMj4W=tJ>KfoOn~MlYQ-W#=;Ba^MPp)-aC&x&yS($yLDBKu_QrfEJI41>%5sAOT1O zdI3p5Zy*`y1M~&xBes4(3P2rW^i3fp-u1vhAPpD<(A1P6z)*nRkA?v^09XcHTQ_?I z?3;j*z$m~5j0Q4*On_2q43Gt60}fy;Fb>E8asldJa{~Fmc)$hF`y|a$F9hiIa3W9y zP$8QP+zd_>A(!&0iYC^2|NhQ z0%il$dG|2z2teiFQQ$FPE-(+64=ey42g-njz!Siez*E4#fTw|HfO23Fuo!q2SOP2s zo&%Nv6~J=fdEfzcn5eFcn^3V_zzGCd;n|){tJ8vd<1L(J_fb|+koxBC%_J1C$J0H4O9W20(*eZ zfX{(1fG>fsfW5%iz&_v`;9Fon@EvdfI0$?X90Gm-egu93eg=L44giZ=wP1JniT0ri0f0IlI}0U830fW|-*APfixXg`1mpc!xmKpShf0L}!?0?r1o zw7O^ooCBN-v<9%%jA#S21tNiVKzpDAKnqb^09*)k1fqb8fKI^00Iey1319^-1)_m2 zKv$p}KnrNlCkv4s6SxMr7KjDnfOsGQNCbKTNkDIazMky^^aZX1 z`T?|9NPl1ekP2K63u*1aDJqyxi%8-U@!jlc-tCSW8m3a|mAfeauMumfX& zEFc?j0Aqo10G6m1xj-J^1oDCLfD3Q~=pxnjXqW(dB2WZO0wx1D15bYK{8127!85f}m71dIem0XASXkO5=@c3=#U1!MybU@R~W$N_SJJirO$1LFY~ z;06kSLSO1J46504snOftP@nftA23z^lM(!0W&pz$#!hum)HQya}uW z{tdhZtOwo(HUJxeO~5n`5zrWD0)zqKKvN(BXa<}CGzVG$ zX98ydX9F#PR=_#Hxj<_G+o^~)KwBUZXa}?hIsoSb7XTLm9f2s|BA^p+G0+*f1h4{^ z0@R<>1?UQN11-0oi~97z>O8a)4YQ4{!qcz<9s~xPbzo5SRc=1d4!3z+~WNUdPz>A- z+yP7l?gZ`v?gs7wN`QNT`+)m_X~1+~2Jiq-3d{r^1ZDxVfro&Hfk%Kjz@xxpz+7M+ zFdtX|JPwor3xOwqCxNGce*sSe&j97XB49D_EU*Mv3Oola11f;!!1KThzzX0+;3eQ? zU?uPh@G9^c@H+4YunJfWtO3>nZvyLpe*w&j{4ZucV6Yvi3F7O`kKJXu)68Hev z4Ez`P5cmk#0(=Z?1-1d(flq)Pz)oNnup6iXJ_Yswp8=l(UjSbMUjci8uK^74-A2uI zdY|HPx-}n!l1Rh>^e9*7Hype@LJW_LpExc3=@s9FlTUpgAsR1axi0k{Ju^?0DYKr< zrf9{xLUbw6^i=Je(lM9ELsm8A5p; z0w#!OI%p+fTu1#p%x7x=KKUPpiV;`j+%)H^n-09WCtZuR6OL4`uv`;L2lM#5XC8t~ zLGxXVBlAfAuURi@KXTc}p<>#Njk6!QchQ~Ho+EQUKs;Ek38jOXhbMZU^AM_(_|@CFDoHBe$*< z10&9xbI;oaMj<4t9ZDq2$&YM2{f7L-x@Wx-UyJ{E_P?ZsifXlisNC;a@|l1B$xE^K z`jy+~U7WF~=lbjQ8=z+b)%PryxzqV6@;B|z8S}Y+UPToVV%z*hd&9rV&U%kJ^kJA6 z%Qc~NsF@dazIycNYadZxiZ}7y8-Op-xNU0F4W*IY-+KFcofK)a7xDqib*cAQGhgF# z94udR65EN2G6c=}Hu)=a`DzNc2!Qt!OABAib89EJU*e}}wFZdsOs6u?FdVh3Jq<=Dh)%z<3H_l%hkiW>p0mN7B zZzQ+ti|=gwebvkkbWTQZuhgj~*IhBDnB&0g%VaD;=+?heH7|o~YCk6LHRo>%n`#Mp zzoI2~oq4(AqeL3Y)ePCRzAeiQvB#3*ADo|w4#toenGkuArkcPiC!|}7+5PPiZ@#}4P^|?j*_VwH>?b&2zGr zH8^h3IZ*o2bBX0%X8M_z1%0bZ3xOs$b8{U9*bC6YGnC+&TSN$5d|_MG$9!jht^Izw_o>U-eMr`Y`eN10#!DTtB5l zPJKOWdJmv-&T=(IPd#KBclVb5YAYwpi~o7w3|y#^G$Zq^48S*aW0(jZUsf{W*bB`+ zZK7Y#d|7S;>#&|%ih7L9*Qh|oDPUzU5B>Sw3LH-LUizxS`-h%I5_hNNXD3NC4V z;tqu`%YQGv-V&)lhttrQqOj%s5PQf!-`H(o;(`x`zrJolT0^Jq)sr7seu{jxmlU}= zFc!J3mLp`o2Ltd;t!gSBJ-7LUH~KiA8e$OR{J`?l<11xXgRq(8^?`oiqKN}S9$^+*4FOJbUdg-u+`;+kIhg7KQ|$qy_) zJ-&*5L0HxAN<_fzM$1qB`4)fHR1EGE_s-m9y(V2@5aay7^3&mK=7!z^+XM&gS?tU+ zmpO_NTSi-gpkn2AN@uIA;Th98Vv#M8?YXL|H zPdcBZUO5Q4p2`2!KfjW1!^GB$pSj|vxI3*XKbCX2Y@aGWKU-F4L6_smdTn{cKktJkEti`6onn6Tug?gq@|E;tc*8S)3BT^aJh~Ha{m60? zN&NBfOvo>^4sv1>h{1092D$`poQ`V(#2fo-n7HzZ{kHyxo=8{YWqB>*^>#BDTSUt| zl8>72zxcZ=wC{kUGDF4n$rX$9kA{h71|11$)aj#7-lU2AFkBzAyha|R2!3dJ`Z~Ou zddknwssKDHzHBOvuGrV8{Z0Q$D7Zn7k@6JP!z@2F9-bwOX|EP72$@&WF|&Tu@v2Jf z=-TGy?&(_&Eg!S^A)NvDtFgRBUOZkU?^ofw+SP)P%U9%aFE7fKzWPhgDi58Q`BZyu zCTa5pY1W`BXMWy%t92Z^^?p8M9}R4Ej-4sAjaf%KFqLdbz%tw`T_{_jJpEP?8_MIC%u%DGW9o!N(IbF+*9;`S7N)fC5%~fAF6~hMZzo<*> z))CL$q{qzVmF3Kb?P}?YxW_nMxi)NWZ)_YZZQo_=m7_J-Gy7m_iq%`u=^>WE;`%l@ z#G(mn;#>SpQ_=W?7RmM}x-M4vvRn_z9xkP?2Q_lJ!_x$G;va_74kYx-QCptrHb$spzx=%7>hv3L^O(-3z-A7vCXqWWK7Hz+mY{S5jeS*VT=pN#5J20lC zKVK-AGJyFV20t>f0P$0wZ;|_(idl;*SH$+~9d3MHrtzcp0LyWi$<&5lqHU5p&4CK1 zpUqvMFpNZKoX=X;_v*KJ{-Lg<>VUjT5R%tlsE8yAEO$Di?m6%zIE&7L80n>uw1$Y?X*_+q3*A83inZr z*f>8$g?jIU@)Ngnw?@_x4}E8yP#P94=J&eqhMDh_oRdl)oWf9NiC!YBv51!T9vMHW z!0v_?^($pwk&OcL>a&0PN1OI8YRmC5FICR&KJ%B#%UG>VW+ta!X=8J~5|yD^zOMk^ zpKj}Q&6>d6>Vevsz5w6MBhaz2_~sgc_Rhuk`!nz@{ww%?{(F2I-y=jk`Dlo^|I9k#J1i>E z9v{Ph`&d13&j|zyJ)&yT>WxUm&(Ea_=$oJW&3~BGl5{DjM{JY8`Q*-i$IDBmjwr*W zn&Et+%Gup_dgxnP4sqBg=3~j}xXeU*9-jBqK`ryC1RpY7p4570)EVJoTduW^>%X_r zvOSvN{K0ZV?6Iox8Im1IQ{YwKc`>Jp~P?sTXrv% z+(+joHCEj#B=^i4ayyc{tnb)xv%WLouFkV+Gy4l$+~*_4!$~s~2HmA9*Tgt@?$0!T zAk8_Z!25(GjTajID^zA!-&>oS`K%dX@Bz=!XFIT{N4Rj$_;~Y;>$Ws*tv{AEebaN9 z<;;U^51;CN7AdwOU)>hgG`ri4F`l80yiDgrYj0bAm+0u|TsOK2iZ0jANJmuw@vcoh zLcIudXH=Kav<4b_rw0_}nR9`5Koo%DudNN340|Xr7PuXl575J8FVHFk^#VWzfYw&B zp?;zDT4?QzSY*y9R0r|+Aa)KSy%H}hRwP&{>YBm`)G^Jm{zywar%>N4?tuBT7h_)S zWmvc3TC6jYg8A3bH`gN@5ErLQS%d}uyya3&m$Ea%#gOH7jxJm_8na>+p>Wm@4OYRnG2y@|Um7CCYFi>$S2LeD1#Xf~5yn zoO?dU$9z;dyVp*yKB;LzMB+&N=>7R1_;LL+?A8966t}F;;xqi$k88d|Kkao*uIn6o zNhAJ-l)|9$%5wZQ8IL|q^#@6{7qBD;#*F1J4`eC6!$sYjHXVDhpk9|a zBLYqzmUFyp`__jieP{rXsz=j!cm;Tnp*Vb{OA&b7erVOh+s}L3`LdEOEY|{%4!(KR zkSxQ%&2TslivBhNdMGaJe-7ghG9L9B%dEH zdVM%~cg3zfV`Ir94C|ley3~72vu702^kQooR$}q?SXk3~B@7amR3R z@v|dtd7&`Obr*cm9Jj=Z?>t{8_Z$nCB|Em0vgY(AaIVa{B7Z$_j{J2-)Lv1QF zal}@%VVZ2*ens>r%|w@RozgR^=1jIiPKNcta$V{@diYQQ>6J&@Xt|wv9(9<~BfFKk zJn(ad`;S(33KvVW4j!7b`l`zYDfJo4y)o-&p7^QHXh0sZ=<1E#TrV6%{BnNa_T?yK z_z8`omr{uJ|8=~g&7S(p+8Ghi{nv#SSZ;_tmM4Bb>1Ur{&#?}msZRMAnxgzhMtA*hmvHgnQ-`i}HJIoa200nl7t3|2_vnM?AeSR6%kDDks~DGXy))`O zGY_@gZa?TY5DZX-noc~Mg>`2Ww+ zfLdPEyvg~NZJDPp8N0I^+bmb@n%q?$@^v*`Bl`)S2Q~0VXh1D5e?%O+f;Qta`j$34#1 z+6oHY^r@rX6^>7G<I1GD8r~BN&kJN54E{jf25;R$=gBQ{yw=# zO&@#`B}lidUrr}EHg=O`@_8V4*>CXNzXo`|7q_p;H(kQ(}&UwHhn%DeakIwys&;Itn%TZV%MY>H_z!4 zE;@hgeBj1K*3_lZkGoRlNS#eZVC; zK2NEfad}gpGjbWMseH?Rd`1uy1~u?IYe0R@{m#Mr4K7$-{HiDD_!rbbu)O>Q6D3IL zFROuIdHKsGO_11MPy=P)#P3mCZ}h%L(KlV{y3<5ID))HLT|Z6BSY*6BkkuY<{46Iw zvhjQ+%mTN0?Il{##Of}XltYUN{1w{g zbVF(#rPg6`eMbIOcajB7Py>Io2GsJR=1Vz#a^rRt$=R=L^EqFq{%5&rtNzsgs{i2s zpa%X74XEuIE)SGnedSq_aa%|BrX|ZOhGjtqu&qk>x5$`g|eY<(%lIwtT8> z9Bq4;r7hseO?rLZA~m0=;nem&!2lG;GHRs=78JxLa;V|+EnK*#-tG)+TBsCNb zqo)U*FgS6@^v3PH*5wY2^ety!fSIlmX@neRhg7qEP; zMSOnK{QXJ$E}c@BZUBbDr1x2tYeMNj%hL97JF%yr9or;i+O^kLYu_|$5-kMmk%(ek z!}=`GH}fcdc#gJKv2a?%{Lnjt1y-wexgYx@C2!oC2w7@)PndH{*Q0Du-Q9tYe4JP0fX)&pMw z;ox!=kPkcu(Eb2@QHYlSZP1u{3W$aNe+D+8gYZpEiv0}Jt}aI+uWls7{aC>Dsc`TB zp&yzH(FcUA*r4FmwpfP@gsuXi2_W^n<*E z^Znq~B1HTUA0mzvg^0#0L&TzxI%3YyI%4l@Ak?LP2k`9a%M}BjP@RfH6N`GWAZJo7Z=!f%3)OhoEW~Bc!fT;SRqTZNG zx9`2YnRvQ&m&kz+H2#_wKBcxOy6 z;ztr_<=zyC^yhfllihY_*6;9t>|F_b6h->&2q*yw0X$&60*c_lhzJUzNC-!Q1Of?% zg20e8$;f18n3;qGuPCVT1OXNA@di)4R=n|!H=?e1qwXrY9^kRY)xZAV>+Wx+x-*#x ziYvQx&F^*fd{tfb`m3*wuCDGD5%Z_})gd>f_+Cu%{5|;i&4_R~7-o%O+#G;<;QRg8 zf`^(9^HASMH#2OnPukf_Ta_VBLpi>i`(AsRo%ZT3tu7fk;^>o?e`EF*Fgcu8MqJJ~ zswOL-{2aGwX;RQv-a!eg|q}(>7;ZqZBtIhuR=Kp)} zz4LokMOdToT?>HaCUQflY{2 zem;l=499kx`HS2TDjR$LJaf;aLeen1bDQ04bmZ?WkNn!U+V1VoX>~=LgJ#J2Oa3BP zvNm?@`H!f^kv^`Gsr!_r`!8|Sc(PAlz<8>YII7Iu-@Y^ugAuSDQ=hjG4bZ0PR6A*Jij40Tv0m{% z!_8LJ3Us}#rh#Pb8QU;vqoh5P_J_Wdo5&cKPTD$&!*X-mGeb4*=6^&3^*9e1muaV@ zpKrNh@t}X~I%VIpq>ZD``4*8o)zbWYOI}4dSgGTiaK<4jkNOtyxaNx&Zh4~raRZ$^ zM82gw`dK_y;Xu*Hz*FtlHwelYip_?9;979Uen!)N#~H8px^M0NXG3gr&B=|=feat! z$qj|V!5YjKMD;?w5+COE)5l5%yfhux=6JD2Soxd`-acJAM-S&#dwqWIEFVVswfx|` zj_XC_DttGzfNz^8Hy(J@K3|+~Ba1)H$$uB$5!JXDFp1VFJZGMk{<>}QM>mBY>(S6_ zdHn?(ipKlYDVCfv)tO%z#Ft&YVdQB&)HD{~>cz*gD-baUpq_ZWR)_r6^l3wCcnsln z501`WxkKHfx31ZEd~necrih zbif*vunclgq9S)@nDlxNLUkTsq%Rza8lP${)}u+Tha1!ITCuRLws!ui`xm@@;HGa% zILl*xzn9nJB2UIE$$UT)D)l%}+ON6=cKtZ#1=gS4R=ef4>sL0`4qV)dih#xY-0a}MSQ=IqtF zq}t7j^HcNT5uLtilRx#417_dNiC8%DJ``J#8$xB1)NY#06EtP!9ADE+G36PbCy=&8 zva*Uv{u;i>=*zw>LJGMv-k<%yIsVCbZAsi@$GfusJ`KcB=xYD0o&oC(ooW|yeQFGP z%wQv2jbn*jZ!2iPZO`mV+!8z6lDPI<+<*VA8c@ec123?TOPu31p5tY+&s(_UoI}Ph zw2Xz`-e}Q8?$kq3*jMc>t@RjpaN;*IFfcK12YUFXN#4Sc;$a<1LUxG%loSWSDgddLPu)!xl{qV(0Jw|u-G|G=3%Gvabn zn%E}gXWmjbBGq9l`dP2!&vcWO*CP+jxT1YQtG`>9A4dK=U@LMXQDu`f{}F*`xYqox zaJ`cM%teXwZ!Z5)73b^}x}?CkC(3N({GD>4kTm~%-RqB5SRXhxtwrUr(ZQn(iE({E zBQWEF`808DbNT1Jk3Rei+=Vxt@Nmi{e6l_ZQ#$;@vM&&cdi{QUZh1t2(>hpoQ56t# zvE7FZEw<|;8IRum`pnoR{QkF+kMMBHB|I6A;l4-{BC0+bTfpP?Uk>=D?M1J~&qH`P z<*9h!Q-HI5<<@Otpz*{nu6h^N>=>M|e2p5}r&SdBJeFDir1C2`2`u z;^L>V@vXvmNvZnjy2Q>aS-t6Y%})n@`rgK`ob^WJ!bg1j=c0|zcbDqc$KxXAccf_! zHhYOVcqFrzmAkGST;>1j<1SW4)K3@GB9U9-xR;zqq3#VNK4#6xsy=!zwd*4pkJ#z0 zum9n$+gDQ*R)w@&Mo`@dyZ{c4*wgmR6ALp#!h&~IcGe2#i*i+3ORdeSDbPQPu8v! zm@U83irDMT%u7<+E7Lycni6H>#yORQc3hnqDur24`eb))9kpLv(E>h87QS)gbAw)4 zCiw{;r(D95@qt=Of)^yV zMZAXVv%OXRXcBrhej8iB?}zt3T^~5$ybY4S@N>!~yhZ%t#0mn%6}o?Ryj0Q7AR)P4 zsEH-67alqJk#@{Gh7H5zevah3HGK2j(x=3DSk8)3gX^3caF$O8MBrQv%`z6k_#a6_Z9MpIWbB1r} ze@V9`zBBEX9OK5>HZ-sTG^9Vzxi7MG5gkJH%Jxio+$ zT`s`j%su{8f_YT=ciOZ)UR4a?{Q$w%apuJ|@SoJP^Z!!V13k#vRE7Z|Sly|qTvt=TU~-cFyC zIc}n}=$n6%{Er8?JFW({K@H3VC-pi+y&rAXVmoQ4z1u^Z{`*hV$ELadcFC5WUrTaQ z)8zQAjdGA0rik6$?NkG9eK8AOtrybQGDMYcrzYZ_wxR)b{xs*I#JH2=TjzUUm;1A| zEB|)y!-q!iJ96?XrX{hz!so!@+2E*Kb7; z$QOv~WyY)7u|}P166jU|!n^N#>3J`_^m;(gB3GyyyDjF6_i9IUV<|{U&{*@IoUhxCCN%7} zqX}KOd&xCW53#gI%a!^~+Zj5nqw&7RwF5Nmr%7w(uISZ4t2pL^18?fO+n&ZpIS_~Q zi+p}Zycm^+bN;|qFtY2z?2zKfZ7fu_o1&89>}iFvT_q1BDayipJsU&@9wf#;nDsWGNe9!>wAHu&at`XGfuA7PK72Nj zI;P%5_gg0?H}H2Hf(o z>tkE{_eYkG^IWCgNWBu@8PENn(12S$30-W9dpRJ*>r;LQBPSzMduGpbXZJdOUSu8Q zwC_K%{G9cN*SG@gx~>HpaLcC!O8OI{xaIRFD!&C;|B>b6%-%VEV7RjlbRM(4|98u0 z+qM9=eBAO84Y+NYXrkr*f3p6#<Cu<_o6Jk(lCSG;-x~ODTkj^NwYBY7 z(sS#JXxR0WX~3;7rdHhglFT|>nNtI9eR1oH(i&1+x(CZO6p*Q?lQX*0k>a@&K8>P2i=uwFA*S$T{?2vZ1G6)=VRuY^ zb!pi*OV77%igZUjUgwEi<;eZqs%UUFK5gq684OnfcvGimVyFxkd?jIBA2(ZG*~ws! zd;t!}sl3*AO6ZTgcd*I7_k@gYH-NlEZU~jl7V(52O?%e;l&v$p`FLE_+?x)D#Q|v1b=w;)oqKK#RXuC^#9z(~kfAi;8Jr_H9h`d=I zxn*T&bRwQ+^r3#gad``P{QO~u{JP-Te|7Q@`ETIStX^_`p2I6_CMLp_U&;6=kXKC-~ zQy(J7Uz>CCk^lTutUkOcDTR>BbAuZA4D)6L}a&_7j!+KrSbx7aUkNv$X z|G;tDdk1VqZU~i4+^&X)eRzTS1iZN%rCSpAm7|ntUn6RwVQ*>F7YvN3Db+(!&&aU1 zQjdShK8Cb}Ur{$ZKWD$T@%T)w!->zndg+I;w?Y;N@?$xR+!DvVE$62U){sgaApF)k z_&N0#@}rzTc&+w@_YYsh{*I30BJvZtAyhVTe$IMnR!dvGocWj3cE)7yeeSHXiU%7H zV;!Mmz1#smksCr~6VHE4u+;0%*Q>(5NYqyv@fdcmm*qyIVc#qis&$Oozik8`y5{Vu zW{*s*=5xQ!=CU_G(Ap@ZA8STm(_cx=FxSpOzn*Q zx_r?%^wcZ9kjrt^&R$@JM#3Q=0GTZoi1|WA%2_> z`$&NE2e{r+rwtLdaZsRM-Hz#jH~A%L(TP?3|VbsRFUbRb62BQi&3+_7QP z69XZqWBIvIErq3}N`#;VXv;|nI zoG0S5_3Q^a09imsfa9W00PAHJfZwm@+6m5g@OfB{M>xjCC8Wl-o6pDY1#mFRvd;m! z13iF!f&GAJJ9`0DRu|5TGw`D8Tub!vH>ui`N2ZhXY3d)Y~B7 zNMJB<6mT@ai`ipr&84s>&$wuX9=2lF!51Dw_f2ir`DK~f+`GD! z4;Z=NH75^|+eqL~G9Du;y*~fAfWH>usva8Bp$TBX=7QpYOL@s$CYiKxgTp*VjQ-ym1)NnQ#9@RhJw@b zPs-LF=yv~W^?BJh(Z1+|Q>f!(Osq?FfSh;E{&s!G&dM;_jT%($ zU*FvD=*E+?wc~DkX!;vNN-w&aN`Vu7i`H>DCg05fW7=)LD*U#hVwgN)Jk8@_zv2w7t}vIx$=TqQ*Y)th~+18M7O#4 zd5pw6q#}CRNSY5Wq_H(F?x(;unZMg_{P*`8L6m$5m&U;(fYI1@MvI2&Mld=79fa2{|zZ~<^3un1TTTm&oumIBLw zi-AjkOM&IUWx(aY6~L9iRlwE2H9!ow7Pt<$9=HLx5x5Ds8CU_V1a1Lt1#Saw2krpw z1Xcle0e1uU0QUm-0e=PV2UY_Q01pBW0S^O@0FMHX0c(KAfhT|`fv13{foFhcfd=3? z;CbK$;6>mi;AMdI6;+XHv|SI^ADFscubSLJ>pk$EYkw>sv8%IQi=1hyE=|4m6k}3n z9A{6Jt%!UU6?@m!wdu9~V0%B5^VkkXKQ!fY z*u&Dh*5x0Psl9Z~qWAmVlQ&A`%l2F3TgEqyUaj@6Ow*>)=~ba?jPGd&(!Z)aoO!GN2jb6fIWC5NTRo0xLS%sZs%x$Oargft8gP~m z%U}m9XYv0dMBGf0YQQa@q-xn_gj2voZQo>^;Uw6c+!;^)bG*lNdEFa2%-*j!@5gM~ ztAqCO-OHwT+zSW2_KlXnjmvqH1!fh;XX{~2?K~b@1xHsyZ<&EI=jv;)Tm-nzd zlfynN@$psa)&VLXt$%7hJmkv#UhMu#pBfH<4aYX0t-e!kh_Ok>XM*l6D+-3HLKdeQ z93%Rvaqw}@TQZMte61Tc3>wAZs^Nr>Q!e4fA>HrKtI$j5c#N%HHW_zyBU&9INWP6N z$anUJ4nJqFG^X5a`8wrE@-6g5B4i<18&T@8mHcZ4*vlc=d7m1%=8a{m`i+$I<-DD8 z30Ka0f*$gFOKrK^=LZ^FkbnC@6=ffEdg((+U-Ea#C0xnBxFR?&P+Wx@thiH$c@ZOu zTJE94(~q~O+<4di^LBo;&dgWF9vPa*C13HC{H^sj=1fvOB8c7_Taa&$`#$M@=Yq$6 zmUQL3opK3R@-=pGC!RAyzET}eSsCkqOdcx~9w`uFR>s_rIbLWW$V>uEOeGMFF=UIj@o=qdb^?&fR zaesSh^bQyAY|S_&)=7z+aa1?4Fqi8oBDjl-cXa3a{kW}*B@Lbt-mt$mAJSks?!QOk zpA^RgR~WZ@ZP$+t;6;7p0xTcyW7@{He(ST(|N6@ObyJr>Y&i2wGBu}M!i)7%+**#- zdPdC)#PcF5?Z<*sxGg-zNnMbI4nmH&vpBpArl>8+;n3wm46FyG4gs0$xTfI?y zXFV7&wCCWZw)dM_z-z{-v%)WpKlx+HS9m$)5}vPnL*`-_Sh}YmfPG%7im^M`nDZB6 zPm7PVU-u^~x1(P@ZtoY{k83aaeP;BFpS5<%CERXLiUAb{s{+vxHC!zaC^zPZBV3z; z#XXp=t@3joh)ylXhNJBEUU$iI!`|2C;hxIO?{DorI8*y(ucw!N_SAD%{B6wF#_^m7 zVSg=hL#S-zhFLLg+?7@NvGxQLw^ceg$vO_tSlnUr`cZ*{G(hWE=lD@=2N{L-F0!4l zzdOKdLW2JZ>bH&J%l?j*oIb}JJce=kUyi4oGOAyWW1a+Mj3;%E@wjgkm9-DgaKcgk z|F8Hfa3W&Yp`+8+|0`cT=e>7NXnjB@O9AvVa7R((PQ9RwoK3q3ld=O#UYCkh&sF@r2vA#RU zvr|@f(0cuN<{Lh3ar=EehyceU*lvp45Got;3wT43iePj&37UpKAy^#3(6-Q58V;g| z3d zRg&nX4hM=}HaYk>>s9YqrgnR)_XFYGZy9wa3ldKFh}@JWw$i^@9e+th7#Dm6l_5XI z20rK{hNzPN;$e1uIOl^KuFcdQU$SV^{MA?7`9xPU56NHTiJZ+nDN!v}3x zxB0;sj!dxL+OX}Cpingq!TPu{!C=VNJ`T)F&9CD6OzoY1mt?J*yX2zhXi#v%PvoXF zv2C7TZYbpUVepHAob_3iqy(*`V(>+e>(lUTdn4@l;&nIv>#}9f&v) zig2(Joscikj0%ke)cQAbxLuD&h!$xn3SvHF=Y-l{-p z1sIv-Xwc^|b%5w;19-6R4+Ut>$=ZSQ&O5XF>O;;sWFLgn(a*qEu zQQvHzd|k+XU#WgX`f)+Uqk~SZJZ#VWY%34?8CY#3awThH_qUD<%oPfWfq^>i%^7Jg zFXyCh0J{RQtR1u~?gMg7kd;_07ryHXhf|OY$TivUkcQyv2O- zs{#?uLR#y_R9@Mm)AM?6*aOQ4l)wC`g-;Q5ayTCvE<1Y6~zDFB7M{7>Ggy$9&c&zyd^W#VH zkJ_2vt>Yw}E!;X#<+Z*AyhcBN{-e9!cl?)Gy z+im7G<*Ex_d3M3m=SjZ8%PE&|rQMdNtPMqlJ;Qxi{#RM)izcGrAhlg+Ov5LCMW(jL z>3@r!Hf3G6BTR!b*3PmY5xMXXKarWe;KH6HWN=U&Amfsn!qocNxH40F>X#j_iM@E< zZ9%0)cM!nnyKynmw^vI`SHvvhCA{Xx#TOpq7UN% zDywizW!MQBhp2WO10QCS3(!y2ZXa~db2~oTdvP0!ju9^dTag=yDw`zrJ|SwR?dIVz zK+0+8xb(bsKjz%;hlF>&k;l@R{4zAB+zdtk!#3I8pCm+1UXC`LX{dTz-vWM{?jOC+ z%E-0llE3hC$|XEOCf?sAL{5H6Tb_dis5j0RG=f*pqMUwT|NW?8d-UA=4*Oa)ylYV+ zeB>&<4a3#zhZw>!&5&}wqs`#4Ki}N%#-G-5q7zQ;)9z@=O=)5qUms?!o6V0#L$Yjl zTzEt{91Q0f^Da3!M9yOkct}1CkTZ`uE1dUthmKEOkJg{uK?^={*}*@xx^IV_+u%Sr zronba>;uHJ1=D-X$ErOris2;F$- z)f0b85MPAEdgyThGA<2b1_w_z+UxCF@KW<-o;iTjmrV$l=KzkqYieKWXoVHd`m($v z{dxKGU$|`M;;&!DVTP0Qs&vRDJg#5Id5y2aOgV1n<(8L+bzJc2X-+f;3Cek_22Yg- zIjpk6c^(xL)1SxrdFziGeA0FOjR%NutenRMB8NCR(VZG4S-nlmv|&4DN9QxCo> zA97LcEoV~t^O@JM>p!xux&%+mmKhny`P5i)L#S+;J0Fi(50V=jj?V#v_fYUs^JSi@ zJ#B0O?{6ngn|J)g1(<0yo$&t7l3U`q*BtMr_LTZWa*(2&N88Dnn##j@9;*HAj4$_nJSPP!QBQwjiX*GP465hIt8Lo~y z>!zgcFT2)t&^{S6_4tQA?!EgH)_L$e*630E~`elxGhw0IIx{g`ZU|7!$l$obz z9ij5cJ}xz%)u(sR8uojvZ1o*q*E#u!JWj;gaq=-UPqep@$zESH(Vc5KI8OB27kp&g zwBJROU*x%~_P!qBl;r}nA?`c-*_&_ZaOZWM_xB^naI`DlnRUtyF*Z&3VkXS5PmJi{ z09MTNH5lc=s6=v}45FE>fqh&u6YoJFKjF#y${eQ2b5~RF{-3>X|7z$-pZukBHso|| z0hY7K4WY6T3UV`481nghqa(APgsR6e)F<2N`e}9^zUn@`!Fh7HFuqrHmU5GtE^ z`-=t%RSGYI3P*H~^(F?QK7T;~i?PhNj+o2Cv>Y5O?ZA{diE-4B#UD&zmh~_WhRZy( zMMKH4>27mznv*w8p?S&HNTd1G-4Is;+olHGdbn+ti_2>J(tukJx3BVc&vx6?fLjl@ z&2n*BZC@HtuV**n`jOYCxd5-zxbK`Ns{HuozkGM|jqf7JaOU+~hUSz@c>H=c@n9F$ zFNA$_bS|3+W1%JHK$JIdsq-+|f%JSXZS~EtP}S~><+_qS@9&CSc!(e8Qxf(DBADvu z1CT*uDH+xRMyn!L#26A%ubZvga7L))C26|;e_jJQ$WrD#`od1+{!y#B{_!jy)sBjS zspo4qoYg@)^|FtOc7ExQH_dsx#5|42ooAS^BXgc6Vcw(kfb~!wH15vNv zc(u7Tv1QzpEyI1yU{$yjtKzKH*S^_&jjpEUATcT5>`-EUd)h_Wf;6ERz8tRDu2#JjBPaDdoPHZ-R4;JpKKk@r|* zSF1R9bjE|D|1p#Mbi%_aH$!nw@*Rq}GA4QbReF&ZdI{s%V71?hIr8s_M0kIo_uhDS z;NSNBtnH!>T5jQj%*Tv42{_J!S@-h1?2r>*wudh%Llt0m-GB`xer49l|hRlXB^eFm=E7Z)=%!1LT5fR zhZqtQej8fA@8>bG3v z?$qC@Kau}Ve&!vkap5LBV+zmSRjKp zjlkr8w02@B62(&~m3esJ%g0Z$jKqTCc>Q37wXa{Sm}l2x4l?NutOoCnji+oZs?OA2 zJ9O5F@m;^~@~lMww`YxdA#zI`_Y&o7ey71|6!7E@9%bUHBVQO#=LM{5b=y}rxzjC>};mq^N(42A!kK2#UaPZKVx0Fv^`S6g3v0x=K0Z+_T<0<-*AO;Th z_B94x%tv^!t>>7a9uMKG?wC_ol=9K!`9XDX75@%KkAHqVyqk9#e34k*O~3Udknhe{&U~|hWm8VE;!|8 zsM;`>cSOQtf}Tco$zqV%}|Ahu}Xr&5{?NB1?5IX ziF{PYK7O!`r?k`U`Z)@Pb2Knzex~NT1}}xBTk`VYrz3~;l6+ZyMkzYv5{@Tt;%~JP z8kWrZoP_akVf=+R7%r;2QcNz%js3AQu=0p&IHZ^&IVY|&jHQ__z=SRzy-jCz#?EVa1pQsSPCoyE(R_E zE(KUWF9R+It^lqCt^%$Gt^s1ewZL`2^}r3ljlfO7&A5j0C*612zVHH1b7s93|Ip^4m<%o2|NWn4Lk!p3p4=F0nY<3 z051YB0WSlu0BeC)fpx%Z!0W&pz~6v3f%U*!z}vt(z`MYE!27@lzy{z$;3ME;;P1dc zfKPx=fsMdtz~{g}fiHkBfv;2Ypu;5*=Z;9tNGKqK%Y@NeKJ;Ai0ffM0-L z0d^D_zz#qwpf$jU2X+K@0@?zZKs%s4urtsB$O1Y7*+3_tGtdRt1=tnX4cHyvxT72J z7hn%yPhc-#Z(tuF2j~v;0QLp;19}2nKhg{64IBU*2pj|)4DDQf3UH!|l zm2dQ)et?!)$Lnn7PdCkyoBtA9EB}&ErSVXO5HTOC1s#c*gB|LD&x`a14>cd=!S+}5 zv>M?&|6IU4|EA;D56g!B^R~J|HZ_Jbd1h!%xr7VPqQdx4Lb!Uy>hr) zdub>?_t0Bzef&Q2{1f?#T+NgFP4ew$#>jyu<g zv8I`|7!H+s(wK%%g`TaQ(f@%jr3C{Y$D~1gHEc-`@7+Vkm564Pe&XXoF=U|Hr;_yV+9hwN zCg*Qg|y|w*~gEnAGdui#s0P}AT(4N_k?F#$_ z$N|_klK&8(5SRf}151GWfDHhz4~_$F1G>O)mH>UxQGW+~iq2^l7}YsD;TjqlEkj1f zBcm6PQODhIO}z)MkGf;Leju(dK!4d#@F+rlrMPA}3D>d9ab1FoJn9im=V{2!HXpMw zjlS2Mm#vjOIHBj5pU-*Usc(@pP1PCiSB&UYWx@FOj1%=Wh3Zv1s5w7j2knsfnqKBp zWI1=W*3Ni;)wG!xWNW>i8t}m}Sx;=Lc+0G9Vh18uIdQ*5cEA=U67^Pw`rG=4t`{Wu zpqLDOs&=_}akiFo(MzWUI_^@^)ykNx*k6g<634wbpFF>h)8=@QOfV8Lzc`UzVfJxM z4E)F|7oeYPoVWC&-k03}O1sxgZJBKp?&4}9j}x;d z&qk1;{mA#Mn8(%g-+Suu58gb0`*fy$GMdQE&?bE1FHJOGRb;%k7egSw?&S+6@Mcpv zPUW=`ywd4u*lUYVy?WsVbDiZSa!FTwhn^g~3_>Kwa>NJ5af4MikF19$`ziyj=t2VnmH-ZNp<;=%9PBp^bIC^$o``1SfwTRH$ z4Y6}AIpe4yYwCbJ+D5&ZGk#4!MMv zRQSSWM!mxOBk`VDe0ZHbq4`wY2z+ro7>=lh!#?Sc7)J@8Khn2~=8w$6u#Z1912^&i zDh;^xC3SKAC+cKs25#uKqye|Sq%IA&zNFUA_7=JtCoJRTwaWM~+4VAYv+V5h7raM$ zrrgd6Z#df1LD-7i5GtD{*Qc06<$_4RC%>O_ZLcp7wWd@O({Lq0<4T}V_XhAd`|K)z z5nc$4tB@MxA-waiv|leKyAM#ax%{SCorlY1t8w3icTb#hp*}{h*8RhWjR;hGifaR< z@e5V;`eH5erOO4V2dowPlRw6{L^dHVOKSvm9ik=OGg$6uQ( z44xRoM=i=qg4kFe;+v>^mIP;S#E)Ss=O4Pt&cpd0-MaTXY4`m5h=-27=Io^#G2cT+ zI^-d8L#S-zy~ioOA2Ff^s|hiciqEH%O2B zZS;`l$AQ|0P@vbfuuY-^Pd^(wlRGO>mn+nY+a>iKT%@?jaV zZDScpd2Lm~+gV~;t9+VMn_90JN6ODxcFzCK^qk?&|IYaTEB~G4gIlM@+8?$}Y9G&i z0qWcqexAis9T=`JnEFZ7*#OPW3 z7~g-8me%Iet%LXHU&3mvDuT`dynOl<=l;d}Q4}&R+)N1%cT?EYxDdSYT@q)%n%> zG<=J`?WEnm_bt(nI?tKzw+MBG&-qo63s3Qz!*7dKMTKI;~ z-@mkrHh5nvqr>2nhsY&=@f9A%S7U~cD>T2K<}uWWZ@Naq!P@xpx+dd_UPy@j1jmT@p-gnQZaw1X|V^*8RB->(`mdp6(Z zUacP=3|1OpIoPs(^Et61gBxz`iG$&!K8f6v zCbo(l%Xla8;DYf^gT%85Jj&UBB~ohHUOJn0hRc7}5$?;_isP(gbw}d2jLrXEtQby7 z`iq>0Qrk;SRhD+&NAK-i)M3Ej&n?CAHW%AHkvlb%(q6dK8h6j}^o{id6Tg32Ycrtb z3cuB9_^leyLA$K)rfcS|T{pSdA|m`mzD4}Zr!@KHQyV9yq4rxtAGY7;mpKD@ZZ-dx zj#}?|jd>k92uM8>c}sXHO2T785u?vn^|L+=j~ei}xcatdGe3P~&hA!*GF}z= zZ{d*`vBp1RX?qSM`?1t^6?!BS-@V#+^p$~4o~Io85qV2^arA6FKxGazN`moEAts71 zS$o7bf_9>|7tGJuHt@f+D-tF?x(R z{AfF)jB+7oIb4V}B#VHJSGCf59`oICYj8Y|+dTKHlm2ldBEa!kCbm~1H-yT@?04}s z6=QL@9`@wU3RXpj`MrTTtUA0apXA23!re8gMn>YQWWis{vO7t_EBUxEgRZ;A+6t zfU5yl1Fi;K4Y(R`HQ;K%)qtx3R|BpFTn)Gya5dm+z}0}O0apWCt^xPmGh41R_Xt-5 ze})F!^@M+h*4;c^4Y(R`HQ;K%)qtx3R|BpFTn)Gy*xoe2YcKcuYkMno_k3LqxEgRZ z;A+6tfU5yl1Fi;K4Y(R`HQ;K%)qtx3R|BpFTn)Gya5dm+z}0}O0apXA23!re8gMn> zYQWWis{vO7t_EBUxEgRZ;A+6tfU5yl1Fi;K4Y(R`HQ;K%)qtx3R|BpFTn)Gya5dm+ zz}0}O0apXA23!re8gMn>YQWWis{vO7t_EBUxEgRZ;A+6tfU5yl1Fi;K4Y(R`HQ;K% z)qtx3R|BpFTn)Gya5dm+z}0}O0apXA23!re8gMo6+cdBkhxwM&Hgq|zY;#R@J0p=? zZ267Ap~E_A{ot=1plLr%S~GWjw4HY6DSM4?H|M54JML+IMeqoO{|YB^{I$7B13kq7 zZzxg`j1Jc$df4an`{wI;!9Y~6i5B`w!@**`G#Dt0SVzT>EcqNdv3s#Cp{?}CWUXmD z(~dv~pe?}n{I{}viG#ncb7-Ir|HWRG*QB4b@(rKvFRkcT~PO|qnqB#(EL;1nA#WN`#&`Dhf_YgVV7rF zIpL(;5V-0s$n+5wS9 z7QnJjR^EGB$NW*A+E3@4YS*8$pRPL@{d7*=FO`>mde^+0O>1SnH2P^v?&RszpIW;- zV}ph^J>#Mkde}TNhGbQJI@6Q?)D`O->k`3wM4xBC`p9z62B=?_1>=%2( zNnAC8dFHBQ``NF*S*_2h+hZ&b$qCB8}>2RZG8Wlam*3E)0`wh6BLb2Om#JIfcQwv$HK(eoeO z^J4CKeJ|tqimod_I}y1dR5l}OqIw|W3kD*d;l47{Ld+iAx<;HaS)WzpEvK!}Iqikx zclIf?71#aw8c^GnHD{%^mz*=(X-k&&dV5UZl!i|%>e8-=+<8XH+LeNUFKW&!Sd9t} za@q;g;h2KseYPpI8IC`sZ=o+^59}uGFDQ52*3m#6l9B#r=-GBVDMJ|Nof?4|7tCi9 zq`mU-eci8Jdc|_?)Ah8rPPrk*Mrl_H0w?OF(c-8#9G#IDiR1;V0#Qx1(}ou0f8d)t z-#%>Zl{6W{N&Zf`gg2AFG;O3{IF-kybL@I>j?;?j+i4GE-1E%4Pt4ut>d&%`tMuxqWx@Tgj41F-`iKi&6kIXBwA||UZl158>8B4Jqv5v7_ z9s^VXg8*Jjy$ehNdH@V(eIq!&XMH4CM{sI4N zUkQD|IH$+sX@A?ZV`C}p>WVaW5-ZBm&g%N$FZ*25`}Pi{W_v=*qMeA` zsmm00l3QLL*2~ellqoF>8*Je-^n%oOJ9I*pcDuIziVNPj{)%fCm^lj{ktgTFDdS)S zqkup;b}M~RwVg}LYkeAC8;Y~Ead&pxeP-8Z+VtTK4>;i^a#NbvntD=r6$C<6(MVce zYWY=Mm|9F7Q<~UXdctk0a0H_VT%e4bh1*xvUhbwXMNM0Qq=aAo;?#O$uGby9%UO+Q))fi^ z^N4m$&)Y`w8#Aiopb! zRq6t=4piH(HEH+^osp#tnEcx4X>0fJpMScU0MCH!smQHlqZklqFN7Z zVLM;6EVZ6C%*@hG={P<7=Dicz6c1nvpC~Vp#|c?GCa>IpuM!<{>L$QALM^uqY53I5 z%F?D!Id{(F%TJ0OGsMhL^d$1+d?tH+(UHkIoF;apwx9JEr`8Yi3U+_1-_bj*FqMP< z<`M0h$c2}wpW(hp$nUMiOywM-&9pW3dbkC8Q+f8iBt6gaj=KzKlb1hHcnD9YT*6JB ziH7nw($r!|P}=#mE#UdgyWOfE_^9#=;UPSoatSwi@?OB0pto$xS*rX(m!{X_x;G_Sm{MbP&rhYJ1@)v$ixrCeiiu7=$ zFT&~25q`ZA4apXBRr~XX7VwOHx}@_@>#o}gBCB99ZZc1(Vge32@z-()#lM~jq>mZrAX zeXmT-YcY5~^x}69#Bxv8=C?I7=2{2pP2|aWp{*{}%Zy$>H&E8J*G*g}{FZqEHrBje zH%CO~e!KyPocj`nUDy2%4XAe9kj`FwSz5cgD++gb^!UqrXPYG=^-SbWDyAK$vzI2_ zyr%M+c~xpVW}c@9mw!37{TW;`VmR}Nc1`3GZt^njB?Y3xgQZn$Rn3Z)vW}^|8q@IV zJ10x~Xvcx*@7!7Yw(RnbpPUg{ zaGo_W#_G>{FLL1{zR4>w-e_KBiMr2YV}P{deXmK)tD-VXdwo#%`vPx$Sn}6@+w~=K zrm4D?^J;2iOh+xxhBW*be?X5mdw+Az>QUUM6FYOt%}`A<`4wY^z*nj_ue2uQVn{&r zRuN0Bw}GK7ZR{!4@AkUwtjxQthLK0GJVh>i#5Z|O#MH&`un(6eTR_c7Le-mgZEAk& z=Vod8-S?i}Z^y$n4cp7!ZirlXiEr{N@?w_7=w^y5biE}PcJ)X=^j4paSI5rUmEV|Ig@@aV*(UZz2~y;+wp3OG|YO$7cEbzNoEFjvK$)4|lyTwSH`8l~<5j!5ZCK z3K#PS@4P;-EZZE=b2Slp?XmFg2hNc^&D%xTI^+`Ga(nR@ zO^+O>+Huh>sqL7@?EOY#_ov=H+q(N`wiDbs<&wUgS8;75s#lKm`u(%KrE@$5;TovwCRbr7re3c50RL6JA@38BK>)l!XiVoJaZ+?6%v*Olv+VuCAwfV=} z)Ak=>)yo2elaI)4Wbh}>2ZICLHO6?Z)ECh`Shf@PmU51|a=16@)wI4iado^veXt$p zx&>*&sT;}(I?CxpZ`_wQo^j+j$_P1De2C&Q*%x2(5TA0%pZltl^u%YFdYl^9xi9C? z()iBf-T&LC2GsU;=H035ZQncFX%}U^|K^-)o_ON@6HI;ac|F!!kvp~6vU+P>f3O-G zPp%}d$2%c$jvA#tN<9*rmpVY7VRUMJRga^bPU@PZA^*+Lrdx?8$2N^&PgCNHpDeyA zlXGZkeDzp&fBV(IDxA7phYkI!y&iL2Y8h1%Y^x2}yWjlmd)jFWJv%<1f6N|Pqo(%a zWsmXPE$gw!DN~)J9ve50s=a<^2kflK9yuvt9fl}`>cynAK7lO zjA|HYR&F8|Z{5&teP^0#n6!<~IFbhEP+YfdX+W*tIS;0; z-$hs-+-IF)pU-{y zPg`dFqaBM~b6@P5GRBqv*fktwzt?SzG@9d}rY+~yTwIYep6EgLB}`3EWUjw$YCyey zUjK-_emk$9SD^lPD!JkEOHST!x?Df=nGN>eB6pspqkhZvvw3GV#kgBdN9vW>nK^@- zh#}#$J3{?W8?hkkG9j6w!h@!;IcQ$-nS|b??15KirlHsmepH6i_5i<-e_rsbF$D_ z;M!zf%$d)Y{8#G;>ka4D=qM*zQm+}GPEE^{xLa2Pf4&CRfP&QP*wglU?Yy22J<(1Z z@b0IBr(ZGl%2%H2Zgg`}uSM=WBS*cCkGCBia@vaB+y(Y;9e+D{{-^#+J0SgcvTJGS zqtkJcw9>_s@Ko_rg~{<-;xj$ok8s_#rGYh|BlUgpbE)h5%x5qU?%Sc?Yf}!{@NY*y zE^_DDZMFK|%mw$>sPC$+b6*{=vrngtbx;NV+MJq(Ex`TbYG51EfO@^%^?7@JF9Xkh zKqDaUv$(yybNGqMrx;{7_V2ul?vxv1Y?{1JVnm>9Mw7Qm*zcRiTEOF7?ZWGBK6mJ3 z$wzoNlXRG!fNheD7bsKzvsqTh3l>dCUH5x5pxVi% zms8tG(M#>LGy48(_wFD1ejI8QKnG+_I}y2)OTrW^+b|c#m@h+77M#S89{X$Ox=?3& z@?XlIesea%xDro}bN%0@fjS%}oo+oA6BIz;S+>ALnoE&P6`-p|_fy4^mU^WAG;KXrMz^&h?c@`s(Q0+8!# zkvkbV#@o%zcYDSKhU?WO!Jt1<%m)X80jzZknD39stMCTOW!Y%T`7^N(`m~*N^WtK6 zs_*3Q{&zL-->iW(ATRCzhV}OP?VLYb^+r3b&s__5Yy4ot`9+)ev(2B0+^Gvk{cd*t zEPVw}K7+P3uBV-x|H%K+FG*X(cF5@%raC!Bm2tm0xig;pm-ym~oPIKy8os6bOwXM^ z+fuFl@$uIn3#spG-%VZLV{f(74$6CO(2`@;{ohG_OiPviT;xv1Td}?;ok9B}>bq+D ztb6KMl3`Luxi4b}^}N;NRr!|eZ;dpX%kPg&ySY4F`L>|}_4$*T@7e3SbH0d-FTH4P zUF6<|O~T$>W7xHcT*8%kt7hIaJuwgo;USROK4Xlo&P!|rAKGRvK%e!DbuWgGMjU$5 z#MiN_RUBOOdO@&v{QYfwhb7-+>69B{Yzl)X25~bEkDXu@YpIS$v%{X;vS27$H!Vo;_sai9!_~G9))_iTra|lQoR0%P^rTK(jG6~U@sr% zdulg<=PjfA51MqyAqy`))U4G9;^9Wl(}-O17vFrYIIqg@hdR^;z^w=|B*Xk=er6iv zkE4<61L)Z2YpA&J_;BEI;3Z%HKt&7$Sa$mXIY2hRXE~`GX+!CA-2ox@DX{Ch7HUAX z)2<)d?UdHS_p`1&Ow-;R_u)(?Ip*ITb~$u`|2ebXn$KBh;Av}-Gmh$thvoTwSn^#| z;fqw@fh|v---`=u)Yh=aT#;hNR(Zr6Ja`?=@-2d)tb5{>y?I3ctB!ji{PNBHoIFI% zII3&Hqo5Kmryo%{OE1H7qX{Z1kA{y^*O%TO;rkmK&i&`QOD^j5=n6BpA7R(5FCtet za9`fuNmaz3^}`E#@VZL#mcRATyR+Un(_!so+3>k$>R=}DIIs{H0kHlY2vAvkmYHB( z;c@DC1Akrj8#JKWNzva^KX=LGyFc;jQ3szGig4bWj(!HVA~%G}Mr@a%G{SN`Op zu=+`nJE@8t72|7gWmSH3(IVl^zmf`klBkULj%gEgLty~wIP+5&0>=!r4P+JX_h=sk z?S*nW`c5#894E&xuI$qnC-LahF>N&-_ZcQ!u-ha*Ifh}*V} zk4T)K{FivD?@U9DtHx91>OS-2`%&^m==$5F2I{~{`h~hL?fpUn!i;eyur}p^#VL68O zMf+jhVBO)^f!BDnC%(Ue*Mb};;BsEe0XW`edoU813RDBUrX+uKS*O9Xy`Q4(SN3*m z3BviFsJ_{)wQn2xzrpx-jeR`w%8YyNlyM0)(*|z|5;^0j&b%JRd)tgRqodgxiEpP> z;dS6azpu2`laFT0_!Q%E93=XVfd|hs7f{bx-rKSM(oWjE8Fzm5+S2ms-K@-Ho>b(P zIPRG|@_mtLFkI`wdrE!yzQY)NQzqgmh!lJM(UIX`W#Z;JOC=ih>$dmp4gA`!AL^fN zs$7SK26WK6mfn8;v|)$dF6}U{H#j~Jd7O~7GX^(Pt8nEtF@lYU?`aD~MTS?E$}2|H zSjLenuoZo60IyW~;sN*G{=vvDNAGouaWFQ#R^rwvH^kT!SIr9R5qxp9R3GW{W3-+4 z_71xl&jj>AcxbsGl3VTd`8fj54baS(nYSEw1gCO>(LV>7GXN`l7Mt{4iQn8FL;`+CMGTK6=4 z+m2_fJ}*&&QLXb!N{YsXxh>Y}kgJ@}s&DOfco4$y3Lb4E&hv}&U%hg5O_p~4w{L!= z{j7Ta9rpRPS;d%`xoEx>l2nrGf@-+7Hp zK5XZ+0ltH;Gr%^V{SB`JSYOx{(r(!g@SSb^4khP1_5#=*@p>}{=nnJ%_67C>dII|c zyr$?48~_{$P(Ls=qrXtw>HP2PcHy+!-t)7xuIoat?sN8nO~q!^xE@80q;1Z$i{esm z0IeTZr}$C!G}wL~$`U&DSRc!igX^#(KpC$;k4V0 zu%BhEp6vF_rw3(y%1Q+HASx#9L*%A3v9-5nT%#HC>rs8;gfXUt#4wOy{xa`B44vO5 z9M0yJ*N4-A{y;8J4wL|_yR6${H%P+fod0cs?w>8vfZDF*{AlkVq)o2xfpzb1z0@bx zrL)%X^`z&H%!8MFpi58b*5C8ThR5hixh^_SFkQuA{=t-R*6YaW@n;KVm4n2AdN zEOKX7>Fh+RmK?Vw_9DkPecA=bU$g;fBk0o>cx^+!xwacYu1lc-wOtu%j2aX30nYw9 z278+J`tBE0jp%jie0H30VlN^$rHQR+FZS`Aaj`MHDr_{#R@ALwC$x5HFK8ca0oP6} z1^-S@?YGxwv^VNpF4AP(lk1)QgIa4nFMRX%^{}JbPkiTn{OR&3FR;?WN&hHvQ<~To zduQvzFhdtnZ&1tZkn~8yaWUWvsAgjjP{(_BCX$Tr?HAuOue+4L#xDCPahz-VZ*ppT zU$FyQ%0&HjUXSIYcHDDT;G{8g$6n2PLdPRGE)cmPR5nU`KfX$@GQQQyp;LsTf+UxT zDxXFNA7^{A_LMAb&!Igoef6zKpVy|DnF=3~D^!eKlTWhi*7(C&wo6u(PkpP@`U#ze z`G~?dj_b0^h2z-Y&1GBr@V&$IfTpNu#2 z6h0zPFfsR<oMR{e z)n4+E)Dp<5fcLP^+xi^Z@_J$>z-mM)Z2vgdr`mwn5Pj(f7*4mnm9u%)zkj<1Nyzoc zz)ZWnINOy~XJl!euI;t|t3QNZx0YkX+h3788JX>hbAB85C8GEeEiL%=K7Xs9UD3wkN&Y+xa@5!(4oJmUi^>C!FzSUe~FMSkd8xugFblVr$w*eo5gN znga)yw1Sf0aDBEO4r4e|RT(M?;%*H-Nfhp{X>~YM>{Z*@KF;O!1pA-f(G2bR_6y!v z0lpP4pK|Dh7d_jjm8HM22xobV9Di+2`e)8NVfx8fWCB(!O(WhEY}NKm4hFTjV^-F5 zXG6Y*sF3_@g1x-EcChPL?wQnlfj)WOyziKH$vq2is?e@~x{IY>@@S8<7rEpwesUgT zgP2USI84yJ5n1hJzi-+*%g#sc0ZqZA@w_SRy)p2eIq0MxM`a##`yN)u!2X2gEpp)@ zzLU?SfmZjH@55)G6El2LJ~D4@ovtJk_i2Nw<9$GmkG7Um$ERzc54v1{e4PFJl))Xe zx6XQS$LgQP=kLqOIyjaO^&xUYsBBX9?_-1Jlx;!4?+aK10P9$_oha&PFDH)acrQ=p zjT_HH$=$Qzg{*^){!;pH3`q=LBDa!_duF{%H*cJnFIM%mF%6&kT{~-Y>UVu=$e91@ zB;(V;79WwviC8-=<1-w~I+RIl9INuG%eI%Fv%gvkUe^!lc<%w@@}Akx$~PN6%TMH% zIPOXNmG-{j*kC}tb*Pr#s?Mo-Wp`??6&zD=e9@`n8=i6S5_z1EwbMMW#PyC!$vJLx zrpNy*D~L% zQLfunbFtN{^$tGHdKKEev({(RMRKf7CJt@@qXe(Otfrt;c|jz_RP5V;{# zHYRU%e3e&G6_{hJLgSc4`n4{{m2Fpj3BKwsccfY;lc zzvOwckK=VN?~x7!1_4I`>}xnr&v)<-0geHN0_@j0z{>-M10#Tuz$hReC;)ih?pR<9 zPzZ2*I}RuUIQHSSbumx^OavwYlYuF~alrAwRDjcaCjb~qX)}PCfEOqQIP&Gacpoqa zs04z*Tp$8e0rP-b;3VJ_;56WLU;%I@a5iuba2{|0un4#aSPEPWTnbzUTmf7KTmxJS zTo2p?tORZY?gZ`z?gLf>4*`z?j{{Eu&jQZ_F9Bo~>%(*Pe(4J-tf05RYW;1S?O;2q#|;71@69d|e20ALU>8kh?Bfm47* zz_q|Vz%#&Gz!$);K$kW+M_@2e1n9tgU@>qL@G$Ti@HvoyL1;JNP@n*q1)Kz24BQDk z2mBrQ71(1Z)KQ=Wm?vv%tTAo@nSN0%rlMfzN@xI-qU?X8{iZn}OaK zQqKe~16~8NIzpGgS-_J(20FN*KppTn(5e&K65w3m6#zp`?F8T^U=uL73+gQJI?!Vm z*eviQu%KVE4Vi1NarF-doeY0xI@Fc>uF=V0%DWcdSbU0zIG?pl)Bx5AKKd0ywxQ^azyf z58D9F>IKfdah|}e12Ct2Aj$`rcn~W0!LUVOMjza>_J9X)`XOk0`)b--vG2-hocT3fp&Tz)*}rv=)RBA9 zR@{&F_5qyJ!{GTCI6r|p@ifk>0k-!7+TNF8zw6M)yn%YY9_9Kj?Ck?h`{X0YK0$eZ z27CGv{o-b{8Q*Ez6OGXI&+K0^w0W&Fv{TwqOn&^GOop&fySdJ!7xMl{rs z{WGv&B}2Og4RsM3>Mm%gKRY@@TQ@92du3FHwqZ<$)&>pr5H!^1qoMv94Rv{WhV~sA z>Pyj3k4Hn@9SwC`G}Jqxq23D(^|5HEm!P5k1`YL`l^NPEXsB;RLmfs#U4n*sJR0f~ z(NJH5hI$hk>ggLZw9nB{FGWK=6%BPR8tPGKsQqZD??yx2wf7EM3=MSw8tPrqP`5%u zy(=2(W6@CGh=zK<&<@&jXsDN=p+58f*}D$#DvGu{Hw6L-5J2f*=%IzCbS3oALob3R zBo`70Nl1Yp3PGjVgP@=&1}lOE1r_-evB!d7r-()r!48UuV)@V6d*9r-lbcQ8LqC7H z^E_u~_TAap*>}#oGdnvw3q!pIhWZm2>X?TD)Lt0sTVbfLfT6w#hI$7Kb?5H_)LSsr z%VDUOz)-J;q5d6)dSRzP)u~UQsvjGuI!_K%i>3#vkeooZeNmu#WO<-^Z*8FJurW{- zYztJYb_A+>J_=M{ejTW0oD5X0LW5L`x!hbDD_4+7CUG{yD`ZECi#TvothnB%=O3z@`cyzGplpL(?oFA;luLxGj z>v4R0u)6ufVD<2KI9{%tI$pn=YTl`w+A^%1T0gCv`ZE{d+smmBHVih-!3m zhzi*pqOv{+QAxjqs4wbOP)DOHsB4`S)aGj|s975;s24w|pdS9cf@?#`c>44@m17@TdJsG z?^aOp5!qHRq@ud(TlZZO&B{7M`nWd~mMHY+XY&ySj$zxW9&4+qow4 zQ&T;Dq^61=UP~=`w3cd7wYD0XRa^bCySD1svyKXQppKdmURPz$tE-wHuB#T0t*35( zrJhReQeXYLp}rd3uz^~zs)1Tq^*j}S{duZ+g$T88NrbvOq@ikgT|@PLl}76NTN|nI z=QUQn);CtMotvoZF@o{uxTfl{ubZk33!ACqwVSIuHaA!IjfhnBjz+2q%Uh^9om;B3 zk6WsfOIoRB=eJhB9%!u=u4toPiHTD0{TZd6e7dd5ncYq`>C|4ma-zMOzO93*x1^&w zH1d44yWs`uw;wN1m%i3XRld8ksxiNdx_WX~H8r}MdaYS^^`Gz_YVaRD)Z*_iRP#Q+ zNOj%cQ|;Unt%mIFrJnn^x9W1Jk9zgTzUuOz{wk^V0JXY9jA|A;P}R*Cq^?^vSS@*R zh-&oXP&KppaCLcHtcqVVLbd&Lr1~{-w0b{#jC%jov8vK}FVUg z8EQa8mdg7&TOECNj#{#Eu1d|Br(TS^LfsR)K(&rpsIC}rmD)UPkvcMYi5i)GjrwK9 zb*kL6H>lO$-lX<4yICDbTA}uAx>X%0f18SMu2x&#xKr)yp0BQb;%-%?>wRkRD-Wo1 zFIlfX|MMYL@1aN47gHWrDNUYGdyYJ%#uaQ;)iykDr?m%>hOcFsrj$I zsiqy>sorh=t~xgT1NGb1J*q*i{p!Xm3svr~pQ)C)htvzzzg7#L_)gvC{6P(Da$LQ3 z^cOYit>0DStqw=_6Tyxp+bcM3-B-zRpj*i>f+S75x8Ilzkr!OzxM)p+V{5%+ z$I*?cjxHBxIS$pm%rWlA1&&WYUF7)m&~=W@!8bd$bYJBda_t(&J4f$zJe0A)(X-Oy zjw8=+aWr4{oMXtmR~)bB?r>DP`#r~1pX_to(e*ROYa73ET;A^oN2?RRIEK9D2pIo# zg@A&BssXi6)DC!UK%;>1TUrJT9Mm!3yg#}J#J$%yV8xE10sX%k8xYVcE?{h4a=^QF zG6TZixIAFx+Qk8(cjW~*Ub;P?X4U%wzFPcfK)q&L14exRQb5#aI|C*M>=xLq<$%D*hNA-~4~`GK=fTv#f*zL# z-Whyt;Lky;0w3;vf8gr%n*-O3d@=C0^WOL)6M9|3Zrv%*`lNFTy#iF2JUt1Z}@7RMuNmHK*TF`K3(1vCQf~wB>DQIu? z3c=_9Q7?F8=k~!V+xrD?yM1EtHLs=xpA)kvczylV!K(*87TjaUtHFmK#Gh#}E`TA2 z1?WwAjUPle4W-C>ZbhqWjYp$fQuJTvybYDr9fRWAhE6KH>-Bn!=^4Kexl8KV+K(S3 zr=ojiIdoTw#!(84e3;`H+aJMqIuY}~TrvHb%{Mi4ozI+e97W_Vsb_1O59^yES5EYN z#5OCg4|FYy-oJ;xRT&Qk0gvBz__wV+sW3Rnhsa%0&$f6zthZyC*2~mH&wz@akKIN- z%<;L6J1eWcH!U4Bad^sqS{V5dxhDs%P$~H+Di}QUIXDy$p z=|mqQcS${4`+W4mGEDd&4n?Eq--W$UYw) zg6R23kM!1uIo_A|US+lD^~yoZQ-*cNqlV=~A0l^)i@f6b@SfXg4g4Xto{tkoKFs>k z?t{u|%EwQKY#Q`K{0-yO!;1cY@Y=dZ+qQ2p;ys8g=Q<-)nQ}Q^ zqCTt)^qz|^r86)@Y`v4_IXYjH+F?8zvR;67*D;43QxIN>oQGGMw=g7jbZn_oCfAcj?9fSmN8EfuR1pH_q z7qBwPT(~1(8kX7)3<$^bJdj=$V-3|X76B}+j9v#~4?Mu8A?0T6iw5tyBcY zOrA!&xu^l2eb2)TCGxcx^6QWf5ayy=k>5Ko9&|VE3*!Jc;rTysE871T@!k{l zBxn!r@gTmjJce;(Jhunebf|f)9cocOJXa?;RQ_T-V?XXtC{9%&DnNx^7oegm1**JV zf$Cg5Lq@DEZ}lm1uZ9A66U+z`!wJ$Ki2yOkTX|1U^_RtwM_~Yp#VRiD6XcnMS%e}( zP;sA5%Dp_o!9YcT@kCA;Q2`)77!O5l@dU+fePfCuvc~5hhyMw{F=GrRSmW4NV;{v~ zy*EIyTi@M)3Mv9%I+ff$uZtdqbq~A_^Ugfdr(>Q7-N|v0i!X7^eUbb9|DPIIg=~vm zSM9y+y4f$}9q#zx;3d62IC`7hEzAsDlVWl?&hNkRvF8v>L5Bf%uO87a$C;4L@B6G7 ze&dq4C}g60txW4vHt%^ydB_)e*9)Lu4q%;;`6CFbijIeFYT4-SEY?{%#tFbyR_*@!x&tTZTwhh^waY& zBIRkc0OXypTu z5mX!;eFwH8cS${4`|mmiX7)*PCg5$c>nq;G;i<71X$klf0y1u`LExpQ!t?F*6x}gY zweQD>edYv1-PSu+v=&xB5lyXSlgSm9 zkJxquEjjf`N7WJH#E!~w`aDkiPG95*`gElo_j%I4OsLnVqzmlpcdchDsb>#ueQwds zQ`!x7>tPyv@?ga9ABK2VH z89Rpc2wk|)YDQbR^C5CGAGY)7Jf9Q8GGb~NPR<8`bl#fj{hj;5XVwj!|7KYB#nSGkpg*HIR4MULoR&c}Kw zSaL|(1w0$ze3Kt1wG{AZ@Q-r7IPs6lU@4i&!Eq_?oIc*=JsyU90*!gMQ1$(x^-VUe zKSxczxck%9`t=OBfsKdl)1L3|F7{y*C~JXZc~>*BB;v;pwA`LCM)GzIsQ0MJ%DfvEu7q9h<0 zm=4SUQh=F2Dv$=G1G9h(AQQ*}*dLh<;PtyA&*lPng0<#MT@L>W0FTwy+^Jmn3xO+v ztAMM4MZjWU3BdOB8sJ*sI^cTX2H-~ECV=hSGT>%lIj{n_1;8V^HP?#I0qoS@4y*?7 z*lx|cS_A(sARkx@+zs3V+zZ?X+z&hetOFhd)&m=Whk%EHM}S9xjQ}41t+`s8;BN+= z0GY%d1K>koH?RlT3+w|v0`>zR1AP821U>~00G|P$0|$XGfJ4Ax z;7i~u;A`L;;9KB3;CtW*a1{6f_z^e;`~(~aeg;kezW~1iwCBG8zXN{&e*$cP9Y6pO z2w=EG1q0=P@&KkhSo6~=!Vd+)0M1pb3{(Ly6~dagRt-MC&0sskIczlm47;dWKy9E7 zP#35NV9JDQ0GtOz0GK|Z8Uc-gCO}i58Gtu+DiYwkf|dZLS11hQs5U?pfTs z1mK*zVZd-878n7H1V#a)fib{XU>qG8wo8xD<#3;(;kZ0+0wefvLbW zAPGnYrUNs86ksNh3ZwySw`TzvKqim{WCOE-IY16D7q|?V2V4$Z0dP*>0w5Py2wVwV z1zZg*0u}>HfTh4Sz_q}2!1cflz>UC7KpwCRxEWXutN?BSZUt5XtAN{p+kw@<9l)Ky z8sIJ&cfQNxcfJcFiz+=GUz$Rcb@C5KA@D#8G zcpBIW{0Ddjcox_OJO^wCo(En4UIbnOUItzPUIhw(*MQf7H-I;R9l%?_PGA@CHt-Jc zF7O`kKJWqXA+Q_R1MCI%0UrVTfscVtfI{F?-~jL$@Huc0_yRZt90tAwz5>1mz5%`k zz5~7ojsQo2AAlc$W57?qao}g*1n>*+D{vC{4fq}S1Nal*L!|=<00My^AQ&hIVET{> z0V)6$flwd}s0367I0rNws0vgAssrZ$=K?hVOgmDwfZ9MEpe|4ks1Gy%ICnGxXb3a{ z8Usy$ra&{GIe;lkss+#zXa%$e+5i}~Rc!%GXHxBf4nRlXeBc706VMsx0(1qs0o{Qf zz=gm?Ku;hVU|*^?&1ArJ{ATS8PbSX6i7zzvnh6Ay{2w)^I3gEogF~C@0 z9KgODx@im84oZJ7yl?5_D-mxTeQ?agnU6=XjNs@yuobx_)Hbs4B}SGKvlE=!a-z}$ z92nb&3s2$`xa6sGttB?N5Ns~ekbLDKUqRUKrKM{IWA3>9q__CF;5as5iy z>jfiXKRYxvB!k^Op+yQH42@BFw{(kU9uL-c&4L%qoR z3HA@F0fB(~QdSuBv>fv%j&ZoJ%glX=Ys%#uQ!erSzDon_R|{`94z%YX-#qc~)*8`7{WE!TB@!A7)CH;oZo%cn9gJG^5(08bVVInv4 zDCg_-Dhcyv>3RX=ooRo0Y}V_? z+tqJzYazpQjoe#PZi%tczYLDe$i~;nSs7_uD;diOVC5R8YmEkP{iq?{<2&Rv>wvsZ ziNiSbC)*ym<&Q5r9%|vf5UQqCZX$P!i#&52+Woa#@07HJ87M0sU);M+)%nzAn74k+ zap_ga_eZ}Bys`b@o;9mq&$b_{nJhN-*R3KZbaIvb|bub!+BgCaC{^9RIN&z=ktb#s)Gw&*w*=} zOL}FvI~&JQP~?rsO}&6OBc0Rw<)ri7MHc1=&B(N(6k^Nk+KpG1L!1f#xyd%G9>99k z0~iM^05}Fz8HLK{SoZz|Lt zVW8)uHV)MU50fu13{WpU5UA4eeZl1~<6D5yq3ZcX;c8mVTI$h=#;RMFj_TV-2B|>@ zQ`Fv9*QndCKBRJ&k8qsdU)~GtIPZ;)ZL;6} zy&BNllXWA#?KsPWTstx`P)(k=Vcizgi%y5ywI2CM?=>fzx$^lENJ-v{+|0eJ{pEMl z{qd8v*m!HHAIwRMvL@Q%xx@WKPmc5H{rOaB;2~#QBJGBx&u9L!xcZ26P8s8tCA~8h zM}MwM8tZLu*p4USLIoH=eP&=__b#JC)kCwo-uS>*Yv%pHh7)cSltR6W+$HsFOVoR> zDOhnC>j81mC{81xVS_XO%S@Yd4#3CY&cGyK4A2#53Pb`hCDwldSdSU67QpU1_hD|V z{|3P1s0cS0W}3WPhN}Rq`|L9DdLaPYI+|1#Kf^40DL(NbvYffk_~OiCB0tmq-*ufc zoo|17|D6W(`nzhpcl|Zz!Jk0=4qEiVo>gm`-1K-|7h|OUirmaindQI+5k-ewlnM}vYp}aMgZHE+5ovq zkjqew73TOK$4seRf?Ox>*~YMKpdSRVeId;Sl$o^WKF^Uj;zMLP*)PdwB$gb(^qH0b z!J>2}OkW(+^t*qS2K0V%t;yc~WZ_gE$oovkHa8cdelMBRXTUENzdJ_0(vjoruZi3e zY8!LBgX`y+^X^7r-dz`*qxX|pm&kECa;+qniv#j}+vQSk`%`RO1oxNP^$>|O|01`9+Qu3eNlC#!>PK0B{=jmi$(*U2>5h{RQtSEFPPOU+`+hY5_93Hz z;lL2!Vqhddd%}B1*VyWN^4WxaPClPVJ!c=1bw}!*)J^WQ&a=NMbzQGxQZIRoad}K+ z2%Z&A=XYMBH$Tkp>9&JEJHETC?hEmCw?(?O!~Q<`A#zh`eK3U`3#s={OU>$wIiy45 zQ}I1vM%1wEnM32#)18UF@x>D<7bz3^dij~x^6&q38Ze&|c_rE()-Qr}kmV(1 zCG|~YtX~W>E`7G$Qs)q~%Jp>0wxn}PlJi=0r5$(0Dm|X0BfgyH%a=IxCG0DnU-tiB z1G%^bX?Me&_Wgz<302hUgOS6>{BlVL_Ic@OiD_3wZV9zbEdJJ=6_b|2A6nvv5cmYu z^|dGa*L14@x&GlK@9R5pY$_oC5nqS=tt;7b12jIFoto)aw^akBLlrEq{djZrIOey%xE7lblImb>U%FdON2jr+StbW~gZ3 zUeCv>8Q%TIV&h=QXY$=Iw7hum6a6Z2vLc-1L*%EB4~|}sDa-SPnPzGGdVP{QM_)kw zN*sp8iH!StSdO2~zCQkyGs~VQkyyNO=HS%fE^YYg;z`u7 zv@z-Ue2tABTs{g&Z+~3U)7wf}(-*!-O2Qe5qw_`L`2FG<$c4x(pJtG`r)3tM!0|$H z91lEG&ewC!nMzyI5l)yK5xE(!Ec;$uwSId z)$^do)APym==3~G+O8x1?LS=uxyYbAXRONfw(nezg#G)RL9pQ;7H&HM`~P&iTVDOF z;?xN;czIqfxb|BX*U^Va~z&TfmKs8`Hj<*D` z{Eqdl%qX1u1x|S!$N^9ttoLQSMg+j|?`i!T{bnfHC0>050O)* zyJGyX-kbB$!4)eXO4s?JpIcIxWyZ4Ryo>R`4qy(_;kRiY;^1w_S$#wZ0hi(cEbFY^ z!G0Zp^EX!`PBy@A!T9Z80+0ek1Dvz*J<_`g*bFoU_%5s;Fa_Wk4u|j%&C79Lhu6XX z$2+vA!jJIFz4>8|L!@68s=}MqdgJ0 zcSR(V7n~Ep`G%a!z_O>VQG8bYhG&IY=R>#y$775m&LXRON0(Ei@9SYX*Y6kCfIdEz zv(TFth#lm_W)=9-xJqWj==q`Qoo3$+eChMIKL4y8OV9QFDS07sOQ>zYi&6Ml<&?A> zXJWq`Ec}Rx|FPtTGb2;h2xWAB=SzOt&GSa}x7q`KlSF>-y&C%ge7DNC@SN+ywuEz9 z8v&$lJAhp43vg^N4#)tO0QtZ+-~dnw*N+A+2lx#zzge9R90wMGbZv3FzW`q%6XlSB z3CO@VFe0x*WdX>*eR#Mos17>{V|D~D-#a$Mx7c_Ye*i}2DNOq5)EnO`55rub$@um) z4f(zr=ih;EvbVyH?MHg$@h^Zb4s|Hgp?<;#%NO7y+s5euYV*MWHGNi~npHDMZNpmk zon8%AyZ2-5di)q9^YIF*%HmM9{jo}_LH}@7IJUaVI$1+)8eUgz%8F30E^DUNzu!iE zKBtq)+#0Q3`g({8NydzUwJ9p5=0Y_f={B`@=#%Qey}Q+(OowB`5A7Z0R?Kir58vn* zndu04r{$D@Hg(<)IP@qM@dp=B%nQ08q}%x$pes5?V40ZCeb_212{SIkvQHnXwf0%Y zP?^SzG1s)W?5ES_a?BZK&%gc;bTASa1&jv90Aqo10Qf2kXa{LOY0n7SGw#!l>b8{eL`GlYFg}lw zi4sYW&lfp2LP@~$2H)%&RQ=Z4Ok0s+?@Z+jRjT!`+?TzFkcCL0`x&c|0vJ| zjsD$0OEi?v0+T|}W}>699axG^LL7>8ARaFIq0=x14}0@aZcn505suEsRp?|?hk{s3=Dn;yI6+XI7+NqQ^>WdQT$bl4PpZB{tlP93d`G}J1k@3mAwCaL z#%Chh75CKl#_RJKE7p;MMdQpOr%ZQ6^)|*CpFS#{|7)=-E9Mu^OwPi> zDelPmARF@`>rYZl{+)^=x9NBu!>kMBGwYM2MY$fvuH~d&@R)$-OMQ~GnO-Y^eLR}3 zHb7Hg06<-}1X=(RAHjcx%f(#?Pa^NI=gCs=sA~4@+x7*m9eq6i8mg>_CnBdzcO~%z z|J$=Dl8-{s`5|Sfr%_UvWk_2``^m7Buj%V$#;{yNcp&NUhG@&#F0kK8F0h{(;RgHt zl+mZ0^GF&245&U^$QD(0OOWNL|evYzqAn&V+_}zc60i7o~`Sv{7 z4IT~n<6!rY)hFMKPIj;>RAfg)Zsy1bPw-dQ%h~=^Nh${QqLAV!Ths6a}!dWSV%HHGc7f0 zLRxm}G>MUefLuTP9uH4>eU4SItxrNhoJhW6W%}As)wk>Sb3+GKTD)wMD+Rf}$X!y; zR=>V};e1>`w_hw@d2V1>_{Mw)n5uAxwvJ)?%ynzv5`gcO`vYu?IEKQui}9ESoun&a zOK5B)t|30Fc5`vJ!i#qI+4CX~ym|iCPOJO2__$sNHZpL+3z55|o~_Oc4qm#}HTH1R zU2PEZaKhRtVdLk5Z^h(7 zT*Qxc-uzH1+OiuP!J8`2z1lnP{!n#u_~rWxz8+I^+<#b-9)5`25^5WrAN{6IO-@M0 zD$;X3{3t|RUcaD1Oc{ z`Nsg28yKV>%??&QW|mhS>r_-nu(tK2$EvBRGi$45w>DCDhan*qT{O?dMX z)gn7bIrqtT+EU(o6Ce@D2Y4mc4VD_?us%sz^!4+3jA^hQNgM>vdZ+jA#;>>M{}$Ab zYi2HARX<|V%4;@I^B(?-+*D`@{4ZuI%fb^gZQ0j3!?1v5PMgWQBKRJM&HZJ-U;tIX zs#C%X#wS0>CB09G-Lu~5JjvVO&67lEhy9a~o3UO>?}K9s!J{elD$h7@w8_TlgIubU zc2wl1LUo?>NwXGG!|G`x@x8joR`Q&UfZpHYby?me)oIGbHn5!8H)H$T4EPQh4Y164 z?5}XT-fBH$-!IOKsHR3d9rgL*oEIvZ{bG@udDQiWv6qaZ9|Rbkc{g$#|J!4qPkmV)dHCQ%MC&g#({rzNW=ghf0 zBqjVv+Gx*@0`O?e!d%vp&%E!Gma&NTVr?>Czo{on5Ed|CClH(!+U z?l+$RpVFVWV$qD074yt~v&hZ6DUmO}I?*`UPS6(l`Y zzxQ=J6aJ((Z_IvY+!OdO&5qn@4~lx>yPV_ z6yW$$=ylQ^_wU~Rbf|jo&5Fls+_Sb~g^4arwSiIOJU)^8(BJ6nj45gT<5SxY9-S<| z^-=O2VQJ$Uw6|>A*$?Ei8pk-8OZLUByz#YK7z(c@h;91}mU>C3#I0zg8egi_#D4h#5 z2HFGB0OtqB0keRsfLnp}0RM5z|IzZlvHZ6y|Gmn8qVhkbvw%EcBk&IJ6Ho_@UN2xe za0~DPa1>|+qcs+|9(WmWpxmQ@D*=3xs=`rFlYoZ+7T9=TGjJ{n?lRzWU^EKwHJ~pF z@nrzN7gKwIG!$ki3iDCmViaf<6zH44&Ec3gi9+pxLT!jbt%^deghD+Rh1wE@IuwOE zABDONg<82D{)vnNEkuDPMqnL^hWLkYW9Ysq&To$LM1e-3K!>0}7okA+qCkh7kNJ@( z&>K;p@jdXp778?@H}c&NW32=6A7K<|PAqhR0=*Fh`o$!C(;JWRuc>&Khyu+`hfZhX zU%)8P!iC_&Qam%FK#!n62i*xB-3QJ+jIwwF`P_yvwO29z_BQ_GyARj+0_XmK?}LBG z{K|?B<*eyYwVOIrPDh8jzPCe79*OUOr@+s0DAq&HrG#cxEcDCzD)TC!5^FB06aGa2 zvS$4s9oe?V!WzLR-=Q*#`%tUJd#Ki`D;!g17)5N=6BLtGZ$KBTzTk3}W4)te++Zu@ zs)sy};BnSH6k$;u)-|Z!x*m$%8o!2T)ni@bQ|GR#AE+Y!DrjR*27Vp~|Y?BiAj*awzpOv-qS{E#vgA0odyO%3S0 zDJ<~jjk#V~^sD&a&Vq#eCcE!H=DdMVIv(DL+{{K&8c=N{W&&0hJs#@*c*!lHkzm7|Y za4F?ED3|>ik-MaxtqQH-MoFtDIT>rqjz$ z51aA)`(@KWE}{uPB6isGBNzO6xY^Fl$Kp70~?ZEt><{gUnA&w!n+ z&KvUR7ay;lbGem(@I&OTR6ScC{P606*zv=YO4&o~N3iZU0r*~nZPeAkRlsauGC+Qj zOBnvP{yW(WKJ5(qz~mGADQGr}`XmURwQecyT==o{U3-2U27i8dzqj+mAFUdj{1CaR zNFV&@la`v0osoe-6pbl}i_)^XtpK`y(PZ6xuUPSf7GICk?K~~ZCm;JL-QljL+8~+6^vTOKwcv^N!e1;^Ej{;}@ zWWJ5aOY_MSY1bH6>#6PCtcf~cZ4kF=CtxxUwlk-Was@cWyan*ng1txz) zZeHPZ`D6UfxtJX?uT#>#pGPHW=FG}-k(}@-=L>Hh;gG|L%_{I~!?7CoMSq6%PS(ZL zJRFr@Eol*ZF0MIlv_m4dgxUr?8Z@eJa%OsbRzlL~_$evQeyLd*$xitR%IU6W$((Zh zh4Uf!o`~aoe4eTgGy)=lwm@ef8W;?W2c`jY0rt`F2VMX^127fQT5pp7QR4j3AAuMc zrH6oqFjnhee?dROK&;QS+Z0 ztvd8fP=~r^spxu3)g0$t>YDXi)sfrwB2&tN;w`qGB@g_6awyI+xsu|629{(02}SMY z}%0~ruw9(b9FjjznSt{*D~oFGatFuy2VS8znk8CplZ7>F@I^&@ROg-|E$~- z*K?Fyscr!CA#zKoZS;JM&dAQhig-Trak}=N^G#UqI4?lvq0~T_&oF$>Zw#~m+5ugF zUceB5Hh(HG2Y{JX`M_3SH*gYYf(kntxDI#&;JU(`Bla+T;BxUNS`XL4Jo} zt>cMUvp5-fxD4$A8ltB6;~m8F_+M5bzBLGTsBhakRCc^Wg=3+L${#z_&sbw(`QiZe z$#+8;=9w%t`>DbTkJHG}>(m*Z_h`o;!wxrhv|syJ*jrDYY~gM1 zMQ&b4x3gS0&@{60eVIJBm&R{1{j%<#Zn{#RO1qBKH~l&=y;h%Jmz9=||F~ZRWzj$m zB1yg7^`m#avY#YGqMLF{jEz}e`=uwRq)p4F8L(U~wsQTD6ZY5Nh5TI-w&cwhzgs-) z8h3>hdm(aHs-A7J>(7o)$i}Kq62q6>kYlpsMo5@;g<+m2kbQ~6^W~VN zPnqBOHSkZ>fZopMmQrtX@Bx1Ij=iHldU(>B4(=P0dMk4CKFxZICO_xlZ z?Cr$~VJdIku*vsdbZbk_(V&z1Dsq?9v$g80HqXsHe|J>&OjjJU-m<dcByjL(W6m3*0VaB^=({BPzF zus6>fbN(1!-COesIERcg9XO|;7C^hgc?AuDrU2&_U<#M@-wVzuyAbFL3@I^cF-1Au8=>RsR~AP^P)Jm4Y#ulUsx;4z>OI0pt{7;q!-KF|cZng@IY41gB5 z0lo3?{vI$JhKm0%J_@{r`3Ns!KEk`0kH8xnh8x?C8=HtuNJHFMZQNK4ZfrAdECDw* z88`M|Lwt{d8@m)Y_Azd3F9tZ`y1*V^gn4fLFz;aq?in8}C0~Mj!1zVQEPT_Fi+^8W zzC!&qi1R4EXL-c5%bEvnHa5LZl=MmtPBA%=Y_2!AWF2M=# zXxG4st?CbIlCll+Am}1+ubg)xa!aUfz!Urs3xl)HezWm)Msh+%+9+p2T54jZD^fm^ zAy4IfsCH^mkd&m|$5cFP4a(c#PXQ(XcK}O)*8!-*`ksUw;XDAUTX(J;du+OX%pdlx zfjo%Cjuce#=7;(HOk`M?8n8C@k=);&P5s`TTt9H1{1CZ$6|4O(VII8JEx;Uk*La!9 zm-0xT&)(z*s-$HrP~}ufWo^o3AE)@;8PLEgq#=BXt8CAg+$Po3_3KwPD15PP)MWRy z?|1V>5w2{LlCWiS5}xuh$8S@UH* zk7^mqK?0($^eSN%Z+k(;%c2?Z`aW)Z^J?nP=?^Rljqm;F9vq{S{9H*UE8o=@_w9N^NH@KfZb4t1Uskphv<6fa6DZ#^Go9CCp&mb>tRI`;gCs}-gmdi$wY z?|gfH#gXjP!wEk`?vi@8#rWZV0ZMjPIw`5m(;V>d0~8qZ$&cs;W^Vg z6YdDF7>CardVKvHJ&b66r)hv=f5MNr2z!2P2Y)jAFR9$(@QS+@QQ>gH z50Sg1o~;c(q)Tc=_QeyHn}Crd%<>kemo3A>7y7=y^Yrt%Pp7BjlK8i}26Ub*ZDh}r z!{E{AW#12q-`XPcKDV-kCnDF=X4sA=dKa}Mo|x%zU&>VM1ozqgFiVt)T=pUIyZ=%H zI!`t>vFAy6<1n@Mw|!e4e)^5q$qzc=iO5}2&(@A7GFOGMO`iDYt9W$yPYCHe+1<>Z zCtaF`sm+f(u=l|>H(j^Soq6Gj$jy7Q&{9vmYyRuf(xa2A=5M*<$?^rdLuqid=ZaeSd$J8vE;<&X=Wa?fG&TeCj;# ziOUalEvP|zLML`bGSM|++`cL-DC zURaqpw#CA8o3X&)IA@FV!bENfwT&H5$}%sE{E)tegy|FFRX9<`jn{Ru&riq&VXAAkqw1=| zTL!FiKbHxAMK1XezpVM;yv8VNweV3{Y3aqseI&h8^~qPA-<%6enJ#x%MT_&Nn*P}u zKNmMHyea77%^Rhnt$A}B?+aB`o_n=-Walt-EGBmUk6#aXV!|HIMECTkL~aSSjn13l zQ>Hr;vNEH3JEx{)IHRoTQTZr9yE$#$5pSHzaOU$sE;?{~Sl zMd8QcZub0$=^Cc)Yx~-W$%6+ryXqt@iiaN}w}jfp7e9JU&2nbA=uxbHt)2Rp2TS4x z<>UlyPzYeggXpYrxwuo|N63Zt{7C8^rV7R-Up=YDmu+6!-_FvJ^shy3D$W-_`e!(u ziT^`>NO{wzji4`J{w2(&RqToQ?&g-!&I*@{yA*yz_O$26Qt;=;51Q1hJn@Hz(hK+} z6_5Q8xh2##IzNUwXQpM$jne5+%zm(JPS?q~;`>TRKPF)*d+swV`x0h*!tXuKMyL0q zyYx2sp#r!L&KB_I+?8+TuZj*+P4Z_~9dd2Pc~yt;>o^ZTL~aSSjm{7Jz%4U-CQQfh zl*9qfRA)wfR&rWu)R5$v$ypuT_M{N!lCKvx`sx`;M#@e40xT;|$H8ZB)>`mv>6!u; z0PGcU9v1uKyMc~48J}9H6cqL>B=9*Jj$=sR01^npH*-JZ=S*=}w|#V^QX{cuZ_WsO z+lFt+R@|%9*I#1o_#qB;!)}MV@2&uK*VaJw&X8a=cWHU`%jSyejm}k6%eCjK>f0Kq z1CO;*o9bMo>h~M39?!l)%^mT$O3(ORt?tH;<5U11O&7o~Rv#$)I~=*rjF^r(WE)D| z`kjk6VlUJC+Si9&s4ru7c0W1#jXHH&Cl0XGC+(@oO`VpZKJ;<@n^UaW)k$r~O!TkR)q-Ez7eRsHOF!xPq=-*{q&iNAfWa#vcaBX3$^ zbi7DzrRv#~fj2|rbKFK0r|ILakpt}WvlRKA{9K*Qx8LEMH1%L#>!QMAk$ZCD3i-^> zfRwZ;@hM&g{qN?jUM{_J?-%h3JZe9_CFVSS(XBDRiwMDpoudw!q}bf?>u!czFc^L|?T@{0ZS zpFD!U^RTO7z5i>Ctw&C&$Jy~kH*mQ)McV1OLH4{Yh^(fZE4RNE@a3#tSI=|B72b;6 zlLJ>s&qu!;jEAIRwE_3@4ZnBQub(@_yuSCiT_N&!!Ibe|O>OaO|D(JxoLpbzE~#hh zb^WPRlM|AisR?+t;Gx4CZ8?t%%=&;sepdz!==EgXFnfN4 z3=LBsJhCtHiry1`jC|LXxbQ>d<|RwuN3l;1%E}WneSM!C5Ku0*(Bz23q0Qtmom)K5 z?}}?67b3A^yN7%8BoW8BMoq}gN`2b<;Fw4p-?_MP)hFUx?itQPfD@jG+$HsFb)NJ| zOG&{C06cS##LChxTe1;RPxZNiWlKk&WzKSDcJ#12dyt-4r`M~T5#IVbjEqoUaj{{l z_fsFPE`T4taL|9M_IYb!HTU8zqA!t~x$~{Ban9svNm(B2t5gzBq~6LpPJv+ttE`&C z?*haE7-q2k8~rVO{*&ksuoX(>eaLu0Y2`zmn~pN-pAQz|OI7p|Cb#0K&>A@z*>A*bk{jV>2A zE%krZIB(vV>wBC4uO5D8Ywh}XE$L~l?;&zihb8jYP24lZkCMt=&yN{LZx4kZQcKAxqyym}YU+2l;i|u(5Gcimp__IpV?JsPvWUl)ma#J_9Px8sSg zGNDZ5^jV(tS>_B&*)uH1B7hhO@0;Vcqmb*B;j2RZ*(DwzN zr=QP#Iz1hi#J|-wppUEUnrhFNc22CPp0KmchOA{9&F?KmuBXj#nfc=B;#x_R#2Yhx z?n@bq{op>^De{3bk;^_re)nH$K({k0*`7CX)56sI{fDjZ`uq54?6=TK|3&03sb^be z-nhHGCSSsl6w8}qsis{JzId+Y5B=2|(D~AChCN^Mz^7-fT5<2*lRvgK`@14H^IK-V z_}9fVRrinF*ZC4R)1EKe!Kb*N`+QU9@deMC>xzinyvZ{2#l6UgX%57cZO@y0@am4ClYgzya>X9AA1re7Zcddq zG7@a^hBkzd{)&X9?eUKTo0|V?_w$jw%wx#SvFA-8cojGBn;IWIy*0pGk3{5VZp+LY zUyG9RKDnoo8aXCC0|P73gzU8e|;1DFA#c=cIw1Jd%ld%#eC9A2@hP;YUvPj zeG`!*IWJc#U%Xbc_}}nFctW2xguZ|`BVm4VbG;LhQ@^?^kuUObptd#+&ok`{%j$HUoGZSsbo65q7A|m~VcD0k%w6}D-oIUz zj~f*GlC;?5i}(5`1>n;SEq+f(ef-E*=K3chH}zE_U&^u=3KBE`Z|eVU{^*=xSl?%# zhVujH%QzSJ&t{j8n-~7XTw~84>glFnwW0ln!55k9h7`#eNpq)afAnwcnT$SuntPpn z{tA)*>XVwib);LlFmoLdk!xAAf~Dur$D$%Q^Y7-hdYZYr?MyfF;o-_0AH2Mp``yeF}V?1Pb4XIp=r zI?$cYo7fxedBgK2=It#%`>vP1GS?UJ$o16A(w@5QjbRA&=ZeBo@|E7InriL*vhho8 zvxb@LjfmVkS2p?bwfG25*7Fm-%+!S(-&~vtp5Bl6(e?;VE&ySDANN{pl z>y_9}>0h!wNSOAMprc&+2s|z@>ks4lUFjOo>s8Ehd%mm#pBi-jqQ?IAovWGak%-*9 zVu|*+pNB8LK5-~3Z_MlI`{aaxaT{$JsA{T1Be ztv_?Ul3F-Ef7?#(6o=ao`}fJ{FPmQzO0vTK8g;7U!phaP;8HxkH2d_2Nx23 zw!6(+pXPhtJm|ably}}e_)Xd$*BJl57P*;kU7uW%A*xS$I^+1V^W;!zJkoW^boBV5 zU&^Uh?(21(a`Sx3#K|$)Kb!qr+`RB2cC|e(Hi9=V?o9pu?oSs*U+69n`MyNtrY?)| z!g|;5CI=$>;)mF1rX{x9EHm!wGV*{~5*hc!2{*Ve$K{ycx7R=}4huhamBJ6EbbYf8 zG2g|si)NV4H4n3HF}drg_w$d-Zlujjk59-F`;m)?a{VKB+VeB^jxbeqXG*}iP2TNY z(>=f_{1mxdSNvl9wC2jl)r<4fovd}b&Lur8Y15}%_{=aNwoH8eT%D_k>eK1*eMUHo zgt@p^;Ya!!dwztssisEFzQ23zo|9YDck4*_A#zi7#rVOAoE~~8{rY+N_SZjx{B_@R z==?r&?ie`Tu%9BgyS~vAv2u|QGVuPTU(961X6kAA;+1ew_r-2XeDRqU;}L#Wb`9w3 zPi(o{o*%W=hN;kib~m+pzWMw>x1xogA~&zB^V8&q-qe~rp-mF5h_9C|W!%@fq;rA! zkoe+L=69#30i7q&_t^7OS<$aBZS)$hc->Z5(lCpC&!8e z{y?c3(0OvC6rOC1s;1^=ys_!aZ96_P+g*{H7qsJv-URFUsI|_XuQ~UJsWxf5zPzJL zc;-v)3kqLFek%EJeX{E6448ZkK|;bi@=I)|_+npm?#VHciErk~zkli)(8uG}mBN$Q zcGXm+@Xx<$x%~X)v)z{xo`~GcfgNAnJkgtDulG1z9<=8zuXW?fPj(HuV_YM-uGo81 zF2~D|AKmPGP9mp%b*J;B*r!b% zniR7qEThwPa<2Hk($SAeSlSxyGc5ZOW;-L}hQ8ALH_LKybMjs+@;~-GSqdJF9Xx5^ z3qOW*%C70siu7wmZt6O@4$D`Li4T$Aoq`7R z=lAi?+Vf)z_|q+O@A}umSG?B=|H`Hleu&&9^=wPvhxv-CXd;No7b)YimaoLq&lBE= zJrJL{WPCZtlWTvdBn{~O*t~7td`ZMf`h3tr@Tp_>Kl;Y3yXxfk?#{mOMdapnbiVkQ z0$SAaY{ZHB`|h&Z6<&|!FHXvz=X0$7uloK%*IU7J-g+xG4;05wMwD-}B)N_+l z^d@r2zxclOrcM2HYtGc0*i)uMz3~3cF$T&-PYC|4P9K+v+itJ7ypGk>fV-Z$u4?yV zhvMA16upVu%)G7MO0-hm{ja4jc<0NUM|l|eUVoxThZec}`k3=5MQ)cbum7|awXCi) zOnXTw?Hys~#O8^w$EQs8SueORbw+$SPkjAazGV9Gvnj0C`;9Nz^CbMmFtw)q_+js* z?yPOjs}#AZJDtD9dE$B1+>|T!TL4!gGcRv2Eh(=jt3rRG&_d?=!+#B-D9wq!gY+pO5(; z@BNuICAD@d^ZlR5P1V`+#PjM;uRjs5+w(QIAWZ#s!;$sBFUx(-oPR0uGUua&K7z?x za*ffdz9*1FZ5>NL1e(4&}d9%F~-V|O?O}+Vb&E*$%J3h;7zeR3d zvCO>jH04$jdcID)ZO`ZNyTa7OEALAh_F<*em)seU=YEl&cE0q!KW8ANm&H0@oH*-*CKKq*N ziNy5$b$Qo5f4p|Xly%?#eEaeJ4AT|0ABNm@)cZR+ukir0-yyvA{>;uRe>v~l=WjRi zA6sYByvqjncSN`|AoWh@=Yxu7{~3NhvLW@a)(7_diRfBQ9ei+9 zzskLDdC_c7L~h>Isq)8YR=oHtoBcz~d7>gW@21TB*7>6uNs~Y3yBza+ z+-LuTU|jZ1q(3748iSOS#p&al>Jxk3#O=pC zp3R*uocqy=baVcw$W6VK${S-c>Hm^1C2@sva>PH6)O&rvcAwhwB@cZ1&m+IDi_c1$ zW6mQL`6=_om{j_|;EV8tKJ5j40q;k`{`sWde2M$ao-fNF$qf>#C?WkU&3sEWIWSXn*U~*-X7&0wCBqa@G0WK z-J_o9c6Uv4Ua81UU6sfeUz1F6vdI^=17&e~*-E*yufekAKGR`&%Q5jG^1D;efZp#d zIAqV4$S?5Rv@$gF&hf`THs_g&+`M#I_+k!$anh;D8!79umb1ju&lCQLoe-aSW_&rv zya)e&aSiCa3IEcYH;IU@&o_-b9HyGRyl}_eGk@!6&Nmggd4&>rV>kH}iEIS)=cTgR z8(yD$5GQ=#`Fxk~SIs}w^*H`3Z#|mxPuD@un|HTL51tX4V$MGmx#VB`GU&1RWK^7N z>QU@2)1{vNY4cI@ktZ4dIZ=upw|A?i;s&>Va`^sj8{%*tos1uf+$HsF%dSUX)=a4! zBqjMv|Ju8p8{pV^K+ZSN?VLHs(z{nvKR+Vc1J{^yvOc>p} zis}GA=bJFKW$vdp6d)fXB17NV-DmNOvzp-m9P`6`h};rt8&^KummZC*crMSRRUyFZ zU)<=cXSh$tYxBQ3RRO-Q;Jr2hqJVC|Am9>U4zLo~4jcn6fby0CM}gT;;(1WwPe3p# z$tCD`R)@j32#NoJ+ng7!)FBwdtDxhx4e@`^mf%_^^o#o9p2jIP4P_K^y;65Rrc}(Q zNU&vvRpIgq>hbbnmfoO}1;~n8mYRIK+I=hOl2A3uV9a!p;UEt*WT-__v?e<@x ztxtSHl5+^imz_S+nVFrE#e&!KqrUgf54q3#&#$di`*~yD<5hAdR@~P8$cZ1w4LbS` zY(;JfwT(@F`X^^(X1N$S(m5;JnVE(2^m2+k>Zu35%4sR`JLH+LFk?K$ z8q^0J?SeSwt0ZT4%sl5*;+p54jr+N{X{pcaO5sU*jVh|`RoyS^)N}EFM9-{ex`4Qj6tT@`^ zXx}FyoAYEixxUCA$(q6x7WNkX|q^w#h$P)0+Xw_6gKS` zZ94f}4LBD-^;Ue3*$9XP+5(+{UceAw0+0+`4%`ep1iTJ>2h_qv2Le|CuL3oZ0owe7 zKoTlU05b9va6K}!1ULN%GE)&5xd(=Wzd77mS*bB-V4P?Js5caeWv|Wp$NM=Ihpbpm z{8KsCAGdT3=Vux20_2C~-V315y2d)N6a>F?&yF?-s&ya4j7p1{^hIs(lx`Cch^@#ip|)|g zW3E9zt09dV>6{&(lAIWym7JCuo0gKCFt5taVbxsUCy*=}!r=dmt7+n4*UhE>$; z#6vxUA8L~=|_oNPn+Rbw8KNv;uE6=qMgo2MR$2rc6xdS+GS^Azu9QHGeHEj z+`XMs(=wc~@yV%K9eG|pAoh5-kuT{#@47&#lVi8fV*Fb!i}|HO`fn2%renUiHRYBV z8@qg2S;d;)AVOxJwCvO@Gjlj!*IW7tZ@roMOK)67rOZ42%2&-V87X#8^d@r2m-u%1 zbLq`@&hn9f=q>yg`{$qVrd3qJ+D~t2vb)!>?rKxiFBZAvNBq+B5{Gol7&j!w#O#wW&P zr%prlripQ8#Ac+iR~R*Lxa*+%L_J^8zuN1Kr+n~Yp`%7#@A>Z2i}Gd4<#?I%<$0X8 zPR++w%CoQx`MM=PxZ{@h>&%nuioQ&_94~Xe_?(@VnT(#bm)`XLebUL&^;TtW%Z*(g z=-S2o8xN}wZ4TmxSuw})~%v`dNiTk#$jXE{OmHYMfnoBmL)6bJ71&IFmU1;wJ0HP`8Zq3 zb9X8EI#RESimFw&UAbGzcN)S6YB|@O6(XqobxEGE%IFV zrT4pvDZX!VBJUSt8rD7a&q$l8#doKq_s0$+pR6aM{}6;}Um~*{>h;j8-sdR|S8pHl zd)*eVMREs@`3%BVy?@~er8Hc*31-2tQcPPC>Kv; zdVZJ}UXOzrAJ_Z#V+N~tzU9V@!v`Y!a|e#c%VR5YOQ>x|XT+ywrl7Q=Bo}?1Ss0Fj zH7t^h#hB#O!?>gq@^F2nw*skjiK+E**7~KJ$menOU_DyiDVm=nUt22*eA)EFayRn7YRxJ zA_Gd#-;wh#+MJuYb%0#oDqobJDVO6z<5QETVn{41CO#8g5DXt@&5cU+7-IeU>&kHb z37dWnZ=duA&9~*``leit`@B9hkdbw%l?$CG?E*``|EeFUE90NP#$_OI5xKr8x4nL% zGczG0*=o`yUM>Ps4japmkN+g+Je$0+>O$A`UHRbnrN|{+@qOzdD;|2t&Peg*LA#*R z_0X-~@8KuY#}(s&DYw0TVsd7BO8i{L(aT{=8Lod|clYP|H~(R_q%Y-Q%H_Dv`%lYA z=Bo@E6N#6LfRsa*;L`Qb=a&3CFC6{xNjYEgVanyW&wL~&;EBr>L)XLhGF<=J_>BK! z?>gY4sF^_~C=T@bv=a12XobZ(FA>O2{{G8O=_@?5p4eybK3C7Z z+l>4HGSQD`x|}BLO~^b&tO$jJ6cL*>oR_`iWbbAMn{@8t4Q z+^d&(cFn8>H+3I)3C}BLQ+UV=(^Vcw@*-C$T%EL%56u5V+4*PiVMjmZb|<$_a`_14 z^b!|LIOw=FXVw1?Z8a3ee~=HR>qP0%Njekx!28SjIU4EJlmiaQepA|SYY&m+2M|^haN_a^NO_e44acU`#+(20hi)T9Ep?w2dbe!8#y^ zt0N1`$uhzN#e7lcSH~TdBOZ!;a>5Vwr@VOMsk&FugBSxmOgE^pXGOT)OMB*gu{B>z z`=++J2bAn!5ZQA~5pkDS=^Q^Yp$eeu7~@9$FFY-Y$BqID8$qICF?l`;Q`b=(lm z+l9iIugja(cb9^^r)#Sl$rL6o&JoW^ZeLsN)JmKl}47_l}wP1Gc5;s>*z- zbkkYT_{LE+wbYpCrr9}vIPBFX&>Bkwvl9AJ!E}$;TSjX?G|HfSYj;=&tV{CIx%%A1Zh0bpDRd11Oqjv73v=s?yvux-d0tk>;D1?A*RZvO)N zq~_0Rzu$e=QGYpt6X0>NN@w?^={t03*1gI&wxoe$@QfdiEG(b3l+$4xDxKY}I4bHx zB)BXs4uciC*9LlWe$?%ooF5H~`-)@Sw_SD4GuMUxW|pJA6dw7(bUjk(LF;ik_s4sk zzIl~eUAUsgzfhMG!&4I(oPKuy-&n6d#s#t<5^>`EAC@u=lFds>dTZ2am`pRO!C?Hm9hg%H5Q zbe$+YjC!TCpuF5cj|pB4i>8<{pao=XePgfk`r~rKk*t2}|7>4z_-%V<-#zrjV73_n z%L&stUN(8%mYQ6eXbw51jn=0vP>XoHS}|=m36;$b`B9^|$JZD5-I_k_V#%-K{jKdl zyn6SD>8??u)_m*Ybd6l=Bvd-Pr-5st=F@^$zd)D<(k#!b6g=PsvPE9+>N>y2{wLNP zGPobnp_M96{l>kN zBM$wn|FYAr>aNQbVqhFh2TfL7ujo=x?BVHG%Xx-z1Cq-r;yZuPg=1REPZ?;`r?L4) zrpsx<&gm9A-O(xybh&)2qjaJ8ebsVWesV8y`Uz*(KE3|a=U>%*8e<>uo#`eyYDo14 zElbtan?ouu9jDM}H-Q$cq$zQudZU96Wj?qguw0+j9GD!}=2Lo!nP-hX;nh!v-}9Q8 zGRg;VG2J9b4HXwQE>I^v0WPb2HXWQCPg8y`@x*hh=k)bA%vSL*JqpCMNO+J{*g`Sg zUX z&l}+U^|N1~jfDcfF7#x&PLv)N{uqK@Kz*5Nf3Utn3of9|Oi>o;p&IDP`PD*rpqNi; zI|sL8du3ldH!|ih6%W(lM^+X*1_A?Bp{B3A%knb(uwME)7}8Iqu3U5QZ71ekb0NEf zA5d2*bc3qMi;*(M`4QS+?A9Dp{6?=+h&&1aK42eVIpL7gK^ij7b>t3}Pa19wUmvH- zbrVT+^`sYv&p0|)1m{lrkHg#NIDZ#o#vC$-c9-e&*P;q)JaoLx+#_q6rL=P;OtT}7 zDw>_}g!O$2ay`&+cnc<_yI0T*Xprh$$Haw!{E*W}TT%7tbK2E7nI>udE=FVqkolB-WNJL; zAAQCBOZqrZZcxb0gn08$HeLD9PTyj0!lm@PfPSt(dFc&c>9 z!M(2nEu6o=>G2|UxHXXGbQ{x1Hx&5hAHO|g%aWS0}tED|}nps?}d|H+U zo<1|WPkOxb!+&J{z=XUoopG?qc#7+3XuhDFc7s#3Pmax`xtx>_PtAwZ{&~#%2faB6 z!zEn}F`p{kbk6*Inqxfe8mG&~XxN50nn^Rh&1vAg;9z<>* zm!-h7_`Y7^y`mewd}sfxV%`S@0R$eVGY&Q-JUnC}4$*p*KK_jkRxI_vxKYXZg1F~5 zoiXIq(cRDGbc}+~qZOUq6XG~6qDAzX{uma7k>zQVf=3FHq z>uQ$t%a2dZhns#o`&Sz;=swYioyS{y2$jz6Qu=y=5;OF(3**Qm-k-;DTrsnm%@HLq zo2dej!(*I|Iw6r_H#QUb13eu-$->)iO8b|FeEs^pzm%@I@8FM_cc>3AtE1A{U6L=Z zCmopnrkb0M)9RHrPm$H((yzjZF|p6#Pi{}?MSb^W&P!CvCHlMi^W*gd>-oWZc@y#P#SJZu{4w-qj@k4{HY zcS=73NPMH3l4#NDl164Yl;^dyGc76bv^?BPe0}lHg%4fy@V9}UMvC0tF`aR+nFNnH zFBgTP2a)+R`UER~)c!#6qrJq$UmbZv_Va;jxlA)2rZWyU6X9vi86$)&M{5*3YJP2c zte0?HxBqF`1G}$snIl!k!*s^MW+FTzX>XIBc?p2Y?OfhT$@$c{yqD-%^V7{YJ+k%# zjC-IM7t;-D>?z5&(LXUtp;^tFSx4U0dO8+EW;V`0m?(Rw@6o4%32ll$*=&^w2L_X8 zxgABmn?=_WO^fNT-|6meSEZ0A1U#g8^!fKcU5Q}2>Tf<(y6N1izhZ1KbQIEwOKh+- z&MNDhQ>osf#YHdO?nj$;OMG+ujqO}x$-UICk@|9tzTg|{x4_UxJ6uPMV^`(B8I)GsF8_!oP& zI)81s>bc6N(aq1e1h}NUU@~1JMw@EN=~^Y)#AWQ@a2p*}S{|(NyXmTr8jd-SEWnNV z_rZjlasBe=S8hNbQ+6+w+<#hmy50ws-D@QG>W`OnRl_$*?x+68bG+)_BDsJ1_2reS z`zpzO=tDhbq5R3|Z<5^4+W#1j8a{hs?EOy3xjzDTd3?2)+(FAH4S9eaeQo*vm&T{= z%Wn+*cqZJTU}8R>={iw*&@M16{&^j2$@kDTuWrq&Z>-VBdKD2DZhkWY$^E&!;?#J? zpYhD^Z!7x0X(}G3OHg#Hz5?lvxWdJnH{d9ots~&YAbl4NwzX)MdBc`8a6C5i<=0(z zygydO!SwWS=p9}IfEfTCYA#phC8_x_;>wr*^y|J8yebZ+t2k&qD(o*D??C^1f{$*f z(n4l_IErW{Jc6a4YAQ`QCP4dmT=VFln6Z8;F^eK?mT+!P1LrsE|GRX2bLAZ>PNug5 zP75<-xvHC#nva*yJ!Qm$D;GSb;$ymsua#VZp(*4_oSGWPBl}OA^jQC5r;3B=>EW=j zLJ!hFPnN3&!U2^}8tKH_hk5+D^M2J-IPiA(gEH`B36*ZR(p|+^>6goye(#iyLoeyg z05;{l*QA)_uKn{hU4zkzLkHw2ZzFM`6T}ldm{y=s7q2pMl&cZwSS714Zmv?hJ+K zA{uNFp|pXQD!#i{SVmrKl+N z&ZU|^sra4By`3T2(b*iZIbd_Z=D=>i0lPig4Kmq&MVkXQ2W$@P1RU5xC%o115%yAG zY`QJfwu*OKV2u}NCipY)tEQD{Sb5AU+tqk?hX0wq`_AxAHb$ERHU~N`2kbhhkPOHV14D*c`AqU~|CcfXxA$1DS9@-M5SL(>wdR zStjq_(fz9Vv$c4Ux7f=M4aIpan`}3HSf9zk9PpNw;jf)nS&-Q;ofPo2cD2R4pvIw@BSzwm&~d;WaIuV$JRJbypj~^`Z&wx%qa*&5^;4IMH$Wa zE3G(Hey$joE8e=N$K5Yo8l0?OqDo*j)7@zmb;4h;?2@4RnK0bsr|J%-S* zwH2qzR#{H-uC|^7$3;4GNVg27`&3T9|Jl5Wx#I3|Yp*JuKl8iao0lyyKbgLjIO)?G zF1p!+j`=&R#b1`wH7Rh;nv^T<91%HS*+Hj|D=;&j`N{P5!>MxAhy$9NlCsAAcpcHKd!5 z=q}Eh_$Lop#n+{G%z5j*-aSsmA5y?`Dm|I56Qu`VL!{qFz9UWQuFVj!sotOdBVr%sr+Ml6qsqr5TC)nvS2HmjT9gAG5gxo_k}!L z|C_TftG@0om5)qUamMcFh}{=rUJO>@srJ#0CdOSMGL9y~0hLc0>BPHNrQ7H)`#yWy z)PFBFCq&_IKl06V`fE`!9MKvg9t_KUQ!{Q%&5zSp|8(PHmv300@`LFX5cDU8qZL1< zX+h7Ndh_a(W{ME`lBzyX^r$i1!Ub@Xs{{&egdY9@GGuWg}n z43$qBa;nxRbuZ_NPA5-se==i9!_Fue!SUj z*7@I+o=k@ySxNU>#=dw`=9{XyG|vKUDs>NnbiX8h+s)(Cuae}jGOi72;96b0_R$CW z{&+oy$DK&H8A+wHyM&9z@&0hwt4*k*Z_n{Jb?LLRUN6HlZ+t@7X3{K&4L7Ccmuu0O zkA~!|YoK7dGV0YVq0-qs9kZFOVNSaAAzPy`L`vbY#*7S#aM^5{alw~&3q5qd znjvU0_-24+iV%2GwaZ4joJ#s;ym0Yo>BqQx`CLw~%kq+aTTEUsU$K9LniZPanR| zL|>M3y22F8VA67ZgMK8^R8@P_OW<`|R9nNfB`rIQ&4KpdKr;!gT&@ODq`ddBJ>s|H z*g6iV`C~3K>yg^^&DQa@JwmJb(;jgqiUawL8f0(B**^by`yES&} zzjXasL+#%G)cisHhJE3->KGhQ^JiP2O1Ipk>u+0N?5J^Ol0VEpm~6*;$@XOLnXbQN zaqMnxndA?6!+C@CUf9{Rc@OTizmnHI20xK}-edFQIbweIF?avx`!UNnKhPJ$`X$p< zgvR%ci!}PitG>?0-=q%d3o;e0z5$)7ydXVQX81p2lrb@lP1()1r{;i~KUnXud6}AT z+slWVKb$V|2z4oso$x=?e3Sjlc22`KQ*$6u{>ULYZ;)54;m&ln!?acVazI`mU7@sx z4L2?pBPqEx1wx!S>)%V7p3D(r19kU2_4SQwdCZ0~hW3!@DmtS*tZ+Gf^qq6shUzsx ztVUZ;iROqlh*SJNW6{=Y#2~lR zdY(^Y{xF?!u$c(YNbDs>CME#ZOcC(9SL4%GT;s;)81i(i5I;^^F@JMbj(Gf$f6sa9 zk%6b3ukUs?zPSu}VmjktbJ}P}0qtt`c(n>w&=Uwx_PB!n3eDyBxkKdQ3q@+pwI(bv z8N0%a142d&#U?)9XEKfcqt1ciIv(dRQz>pG{Ds(gbeMb~$G-M4Nxdd;P9?_^ja+ zKkb{K^HKQ5p|K=r1eNy%w-7F$i zRH)JRA6nY;oUO^3W%`!ORsZLcuibp1SphK)rdvSJpBRo5@?r)| zr@d0sXzPELH#QNEY;SA4yK*=?e>!&V+WFJ5^Cyqsp?$_aBc>+@?-_sH$l z8gd6MpES(wq|qMXL#H1O`07Jgk9hqrv#Ule-Jkmv@YjWWGaY_p#b0UVz1&5#y_cG% z{7{IF`CyYbZRV~Zf>*1eX2a*K)r`=2WH9dX7h<^Id-0on(0W`(4ca!cLFW!Cl=q!+juf(iQwbv1$A> zo+?fL&vrKDaI!s-yNW{&W7};G>?jVX=a&w(9LUifSbmzVg+Y^u$Hj>iGDykKpuBdB;|mX3hS#;|*Hpd*zRyNvAKvbZz6 zy;@#&2F#4Hy~jNqA58QaVKR-=w9Va{1L}TW$Va?BnO&}8a>8W@rd_ULe6ejY4%p=- z#tXZ=#CT!b;&Z?*FEPH@Gs=NC^(->TTc6-q4G&X#%6sk^mA!}E4qs> zhOPXf<*8f|n7!eie~-Db+am|UXYAf`rW@4QGkPDR{@E$I!;o&(rX&A2f;HVA427|q zJ?iB5mD0V4K36^6w_P^@ciZx{&0;x4$v6YwC&yX*Os@Fim7>=U`ugG5RGdtYAvA1B za3+9Q?5VCXKchpZ?nbtTtVi4^;ohR)Zut5*{eIwed7Z=!Upp3TdNx-K-0RPWJb3Q9 z?B;(Mvnl9nV}Cr;4YaXm65J(I%5k}Z;aA4d@NX;s@I4xwXRVnb#2;3bT(GWhA8~Ha zdvAVo-jHjthaZY@Fx{ZWp2>00H%dYpuCKJ*uigAhavbol4I4Tla?~DE@f}Dg;OIn8 zrt3uMkp#z-NUbDkAtR95u5jHdMY&zA+arB74gAMi5w91i?%S0Cc48fx19o{a+D5y) zbZ9Z{FyPek(qVw50fgHDHq!_a^@1?aymtoKBhOjkJY?oN63bz`yu^56+v0P; zE-x{@*ySb03)>c-13PnhiT_3hRhIo^{@4xvvEqY%7!-#${@G8P0|p10NieVu%J+G- zl`omfm+T*Ndh)$yZN;!FhEwwg^FuQ4cExwznchjwpLEYGB+5g~?j?$Y*Hd>U{_JS1 zcK+<>97vx2uFzlOvdm`kH#S`17usIWN{3svALf9(zpnoQv2`QJlDhAzW}iOdk;pYQ zbCz883y%XJZ`l9EbdHzJ=z3Ox*F*c|LXOgc@^VK>Ev;^q(rxs#&#pY^@drKOdPh-E zn;*gMy0SU>u5iTZE%%2!*pKI+&0jLk6@(M`@=3$Q7P2{{TZU$d#?$YAHoJcx@$gmm zT%3FHsyRo&11ZMIbb}guW`L7!tDoa>6HqM<&{Y&A?*nWcker{(PwXR3J!EvRSALkY z7xNQsGWf~#7(&CA0nSQ)*y&BoR4moSUS-ViO8b+`t8WgLssz)?AE-fxCnm&2bq(f4Blhe}V4W3rRJ1s3H;0|nsxXgM@B zKNc_W59vI0RVy4SJuZ%bKS-Znx8%nxGyQnuYO~1cQ5k&Cd`xHen_}Z6nV+0LwrO)f z=0G$3;rd|Rh**6PZ@&$~^(;8{jlL(p*z;RlI8O>PHjJK3*NM_2+P+Mv3(#j+YN_w! z^g4{j!XMO(59CC*16684Ix)ceI?;TA1TSqXr^_Y+vOS*J zo@u8I()MU`z~sQrT5h;3*%@hbU`KFZSLi>+;~SSNHskq`Y4C?OjK}lohLhv4?Ylk) z?D7)JW4pY>cwyV(b6^FLGa1jI-sQQF_%Uu@Y91vA{P=#`78)-u$sM`x{?E+q{luc{ ze*{+9ecZ_2V$xl=uk^1yvM;+2HpBCHF44OEGSgqb)7{^0rg)(8NyGn&LEZK9+<6an z5f^>9>`b`Tm7dkO{IC^A4hINQFb<|C({-Zsh>lC6^ZA-{9!=(tbWCwB@Kig)9>1?5 z>zz&Cd9}{#FCLW|?@N0>aKPlqvV#s+ z@G@P3s#~`ful_C+QwwPx@0X8Fjq~s$zI}M;md8)v`E#i~h& zz7|VN7owRGlFJDv!F4Qfq%+1g*~`Igvz<7wBint>dzi`gek76)TPE5`2<&Lm=73tC z;l2;7&DpABa6rwUbWmYz+>!cb>0sVj{mAR5>!f}Q>T-1*Id6JzQQK$q=XWi6cSD6) z*&jy!upfcxDjzC5wE?eI;B?h!jsm}1a};_)^9ud`TJxqP_Mb1yhB#8WWxzLPmd}&2zDr=&Fa*OZn#n(I1={Hp>GyD zrfajyD$5<^HGZE~?u~?u|FD%+7Ff?w_dmI}9&bKH0(Kw`w41Z`r|;9>_0Y*=6&D?M zQ`h|Yeb&MbWyp2+R&>KP0S>zPXEt^*c)iq9rVg~D+!+jM)Mbu%`FwX1MZo>fEotDo z`JmJOy7c1GahxvWQt9lj@~6y))90F=rA0x1E!e)HMCIepPX7ktiX!px!{)1v@POZ5GUB0itybx1cYnP=&V+rKGp2V zce{gHNZ(5#;~G3JHLgzkFZkyNOP~I$ii_!6g=<2s)8j4kdF!omx*`o+zVCmy+jH@= zmvQE5x#5vqG6ma<5KDDo&he2 zTh@EMHl=~<+IKw_YiBfG&*?HQmCo)_T&HUFleKWr;|e*MXp6kY^ z=F&{>-KPgO{lT|NXZI+c*7+6troEJ5 zGM>SOsqt)i>4$rsXn8r>J~4k(dS-ZH87AXdPIwSM^Cw<=*`xe9&y#g~PUiF&k4k6v zD1VgviZREUVR;mg+xK;Zhuima?)$7W(rPx{F)vj&AvOQH5B~RkO^?*+??pj%6ZJdO zL6cP!ubiL$U~NTYcC9BALZdpxA7)>gTgqBJnr3=(`?`E$YJ9zaJ!9%SPo6r^;A0FQ z(`9V1bIOi%@x`)QkE)pxlG|IpZ;;br9Q@xlw=W0sD7mQoll-v!UpV#rQK+wE_bp{H z_l0A-9FM-4n!kq=&CXL|LI+XpHE+jx%4RyRmx61X85q5HV4|D11%IK_djP<$JQ4ikGNM5>xfMk2vI%h z#o;agmm?NEJS05r%Fq5c#_+1oOJSal=_a1g`=5uR7EjTseEA{&W@@j2?zqZyB zj`_u{;T~U6(8;>1>bx@yaOH1fb)&Z4XQxC5>icfILpvT3qq?DbtwmTbs`A z627hZBlA2SuViZl#d=9AjBl9(Wh^?b?{KzvX{6`#ZKg{=dsi|(r8?0?7+ZPrup52Ysp82ElPR$e59sk*nTrbA+x4Y6( zzbk^vl8nkWew~Z3s@!lH<9L&q@GJY5?a9KaZX6HFbz9?5 zQRSAOtK-rc8{Ur9~3uE5jo)LJv$Bu5QHZt&^s!XRBS>PsRwLCt8Y z^{_IoRp%s^X9PH)+sIqLeD(EvfCmcs+?k$C*NM_216Qh_DxGlb*ESP#U^qF+ z^&2i$#afbauB~;rO#Q3*kGZM#R;n!Eze;QGGB z7TT}IfkMn&zxrshifSSCrS@voG@9dr6ZHZ>HDeL0;ktQ zQ;c-ht=#YRxavnb%7dEM?{qr~Dk}8J$ch?GGftEjQ(SU+?PX^8VNx3DSR2iF@Sda3 zv%V+Z0ps|ly@hyc)X~=>zTRsCAHDGRJ(s`^Wh9%`if*`C?x`Q|rxB0-@Z;Lc{wm37*ADMTsvqt@;maCnO7ab9A zd!J+7-tWlmnkqNI0UFDU?7qD*+Ue~&9FWIhGpG4m2zWf+@Kb7B7hL*$x8^hMe2vp(Tq>R2)5BFrS3$)Yj8i1)c>EZSn9NMd zX8FO^alI6cZM8YD%W@!I838RGy)8^YJISiO;!G!=RDM#qGiEk3_0QoFne824qI7J! z%>kPOHV14D*c`AqU~|CcfXxA$12zY24%i&9Ibd_Z=77xsn*%lnY!28QusL9Jz~+F> zf%f3Qj@bXxmNhkm;WbL^`GEqBwN5Y}ZHZqFZ`*ASB;tU*|0EG-Z2GRufp~Rlyt=oo zJm9(=;p3&%mUz>NCzYR6?x}F?=0hkPOHV14D*c`AqU~|CcfXxA$12zZRlLO7PKqlYQm~Py-(~Q5NkZu^;U*;T0 zCx6me<3wKJj*)cyW{z_A4Uta%sN6vwAV2K#qjIMG|FkPOHV14D*c`AqU~|CcfXxA$12zY24%i&9Ibd_Z=77xsn*%ln zYz}N|4(y2gp3-?I`Th_1=kK~P9qSOR(}~aaV{@QAIM7kc3%^^U^*PW{cDVeo$>C%( zUb#vXuN=;{+Z<3ikj{QOHB5W_m-pz&@!4`Lb3=$m`pe&mZ26_P?wC(c@TuX(#bP9x zYYK!oan`?=WdGb-_{4L|ezSLvkM=o8_p0yV{)H6N4QlLZd?(WKeafj?$R7#1G)K8J z7}6>|wHkTf7IK1jNLJ4Qr7aKOLTc4aURX|wMUEbTffb1OQ#mpXmb5ofhlsD(9G*yHy(DvL@zVQsSCt$7_)0k<=(ksqhk zlkTcZP#s0Y_*M`;Z1|l-h00oS8&F! z>$(0!`PqXw!*uwOmBE)%k8fTved|>VI!gUcH~xl-g8o{A22dPkTaE%eHGKkg$|0l=Bz-99{YdXi zdN0zsq~RC-@E`VU(x`Lb)}1ukDQM7P_9TtA6?T|t!(gJVg&(x3ps`>4=Xl`GVc{Qc z_|I(y%epGdOee3pQvZXK z2KO!9`_<`>mFO?R<(KK|+ofB6D?DfGeXDfqd&u7lq)|4Ur1u~T$^q1&q)`@zkVe^i znFJ3e6q`Qdul_{&hAK6TgwOpGy6ip<4fLwq53lK!TwcJH^B?|n@yoZ@ep!e=q)-R+ zq$ksLqVzE2Wr`MF=nu{_M%IPSu(N7vsWHHAAitdcrZm#uaQ^<+cKPF8qkn4(2h!i0 z(r3Dqv~IPguO}V!mTJE0aEiaW2dHQ{P9C1v9G zoJ`hg{lWSIr>jOIX<6X(dfZM-W|sTC9#{QHspc=H2;_Md&ig(@hfY_?_4c|H?}a$M z@62BL@%3~6$MK_GNAE(VvwM2)RY-Gx(#ug`8P}}Clk*#CRn2+rqtf%5(3;{7}8mRpAPH0%0?(T24{#8a$99x2-#j19txGFxID)u$n)ZSFy`aTCCeH zp5o=twoKU0`^>nj=1*p!GpiNda1~;TbAhK? zpW|>86_ghRowZs;WOl756ryR5N`FNpILGPICe+S0CsgHmfyN_J~72p7(;%CH2im9JJM8|rl==SVP`Nrp-yu}jE!d4f!Ih9@H~9(AnSYu_>Xys zS+tNf?XHJTMp|Ra0(Tv}=#}Ww7UNRs@C!9vn_b`!Y7PTg$bjb1k!bFUa8PsBdVJNC z59F6|6d!5Dfi0H@ldk)cWMbjM@5w3(IxYD9Ll6Eu1#9Y1z_A}anXVJ1M|>Pp{NX4D zVp7N-UFK8e40BW1OQ))4N?4X#)jgB{;5FU@CU|e~mMn2pGPgM1cUzL0KiFR(E1Qop zH@3fh93?52AC$3N6Gl3DQ)h8lV`kvnSSR}6){-BIDrjt=BV8lW5LR3qB>@*zS5q{NHsX$K)t^B))En3%1bqx?>^nl;*^e|T z>^#$swl$kH#?9Quny`psDE#L!0=u!verz)_2jq6O#*w4*IiI|Phibc;cXMCy#BF`< z-*VRVFB+00goFG+KA5hiG*!dOKJ7c!*Kb3PVrQsqffk&D1v|}M?y1wfA%v0J)h#J- z6cdgC*MC`ZOv@E5Dh{S+hNHk42*_xx`w#L)#LA5!TjTU{v+R#OM9#A>jc*v1BZ3e4 zPI&K$NbX`&_^?k7d||qZ$5@GS6na7~XVC4O?bY(VUcXE4sqvm6gi+fC(99%Yjpmd7 zhaM;|aA%Y0wz+LMAorJ-lbnF}`J`d0gt36j=(XCRI7pAMJ zrXw$q6lW5NQe)AT+9yvg<2iqXmCH1GHv@nqd!pSWgG@$~Ppp_bI4 zq*1RiT_;M9X!_Kbr2&6=P;+@g)T#B&(SoJU*_yY=ADrOTY6+7bN|jgim({j6(|QR0 z0XNfdIw1RD;ecGP6_2sX%O+|pMw0KE8FYqXRmlYiSa{!)pHFz;?TdN*4Ks^QJ1`x7 zWEGW{33cJ1(-kK1s4ZLQ)7*|CkLGn3_#?hB(vam=oRGYqy^e4meD`lZy!4_oe7x6) z+heB77+^2(*9QC{PncxZVKm021?2@!pBp=zG-LB*G4(VTI)fVg4<;?Q$7nY>Ex5C4 zAPblG2Eq-Q%qI;qUU@%j;n?TC=)Uv>;Dv&jMNg*dMClQ07pV4^x;cDCQs!IkiOKnf zXea)7*Yru340?%^FmUYEiq7sy)2BQPhQg(O*SzU;NJpO`mE~zM;eld)sPZ)K*}h`z zom+BGJ^9(v;bwxE2SokDbdwx4;>lB$&)-U-mQ#pmzMNvkf&QJF+{=#=;$Q!LwtM+l zI^W>wy4TB3-u?Wvvy7xLe*qj!H>j~^6o<7QG!FVg$c;^OlGKOteQp}~d*;-aJ3}Gb z=I-V=@~gSFY<-R?mg0`FL5|}o(Brvrzmnb9j2DMYLpZ2({TsgR=kCsdRm1=;=XC|v za*lIMDCfeTEsi~CS^+r>%Zw(Rr^Q_Qjdl>Y%R$pqw)uG+A*Obr|Km#240r zv@g~?(chMW?%*i(Vo#f~wJ;^9o?nzP*!H$@AX!}^yUF%=DP_ka+O!?Y0lC}aw z73law2|bC9RL<3R-dX=AtCy0w?X2&+JKURRzY?!DrsgC2b5n*I9a z8Cxj1oHJeJ-PV=!)rDHC=z1rEdG)-W-tkq103+A2*C6_oH4LcxLeA z%D;2|A4h=EFK4=n-`Iy@O#e^wXbS`WU|4U=L*{j$Q|V}ZSkpI{WA9(c@Y-sfiME`? zodd5UI@eDd2p?2FY2Z`$tH5o~D<7@9W7@5?gYkzH>Zk7XWV%k29k^gn`@q9y2t1CFAOnxti#W$WyJ+1heZ{1qw=TWMdHb0U|6(A( zUP|OA(^XutbuYF#recjNh&?=&{;<;0{O%DPO9;>^*_s>8Xk0>m&Ck= zt&($~nVh-&6wgRr{t?qJSx;X+{-kDZ; zR_6^i6aJScl>Xn(*ZMEn3yaL8P~ITVOxKChL+O7cnm6E!ibF=_MGN-PNdzOZ_Uv~g zl5GigT&o;TwzFr@;?ddNHf;`UFAm7_2idc%xz4idE-P<#hJSK7AM8$E&R0-9@WbCj zU!HTug^?cyc=Xrfa?W)1o!g_Fx1L3?_Z_Hw-kSe%8CK)rGOe1bKl^{j=D=uz7jK+r zjIR@8Z#2WYyB|mb7P-v;EL|zi(xCjSVr|n;K?^0{_B962V2a6G|xXUT}`Q+ zzUYB%1+){J2C39xKiNzKLN%JWpqeX;rp@u~Avjq`HEAM(CFVo1ZA&&)Ps z<@aN{nppJxto!QKT8`CusTzNd`0l;gOZPhK%>V8&<&XL+aye$Y`rb-8PB<^67UZ~-Q55;E&<|00 z)KUJc^&0<8L2jTuI;J{fN+;!E9G``@B+A5bcW;AgB3-)T@oH7>UF;2p__wbGc|AKX7 z#v9)dIj&;4kLSo`flcg;nwC2ULaz1N3>po5zatvu!>FmzCiz;y4SHw#f zf#J%lAbmwzpSGprp#i@yr154W%RQfKF0kSmcWS9VKe&Z(x(0pnM)SEj;@_|TbkvR4 zM*2@%f1aKs$`j;*>5PL-{Wg(Ox)Q9M4XNS{Xf*Q9GnpHKQ)(tjfTJn6ra?nZbaVlJktcN$-!1AS4#?^(zBs$H=$hR{oV}!r zc(Y~?F{rSs7&E?`XspQ=;itQcnZ-TC+CII+%0qL+?=SBo9xC5UXpQ@d-;O^(ynEfj z;^^xS6O(5S6_tCB5Rvysi&y@ZFCYh$#rl06cE5^*!&D>^miZw3C(($~@E?k4?4SJ^ zuGS}q0adnJeYO6ViQm?tZOXRdKm$e0?NGySlGm^04LRbxbB=uLop;7Q_~QfUBzjsU)4&LJlo|p#xbg{EoBP-(T{`)#U}ayu(L)+pr46ytSSxzx@=edssA(a ztA@4zZ#xdi>*}K~OI}{HFU}ErZz%iwfbSyzn$hh-9TfM6n64tVlvlk!L|bP=bhK9K z5!vN7#yPcZ!++NB#qKD}OlKOmz3?Y1b_Y$i%YNe7Gw~ZQyiMCS9FWWH<|~qy+Z9x< z?;ZB>$W`CXU)t@%1|1NWTc)chTbJ9ZbWGpbs^Hq?HpV%%tl&Ru_+odv+{SpeyV;uP zg}Hy6ceSH}_}mrd47m+~yrSQRc}K`B`h?Id$7HoArn3o0*yHsh*$jCW*X2N-F(Rw7PJ)(_>yo+van6oQEu1 zELSvrr0?m0jIo>nBm6<;WW{pCrtBu$Q@P82cQt!6y%5(gP1husm(3(kqi&z{Rqw~1 z81i$T!3pjcFx{ZWp2j&{b6S=5$oi;8ao}p7=)PIH)n~G^PVYbPtgC~*J%DA7kZ7~~ z#1L5PALKP;3mSIF73aS?=42UUlf1@NsodiR+C_*h^d2lf>#j>KKclbB5extBy6n|{ zQzxnN!*rD`ZIho$XP^vUA8^g%_?jt`qxN=lZH;nl_wffa!`b`1GqzD^)7uZP-U6H!(IWcCq7*g@na?dZCg=0!wSC2X&JXkV>wn-<6*tqj8E%8k z7Cz5flpJr<`o5ympwhkmGy0^bH<`eg&rIJMyiulB`jZPYB_i`VcX4vu!{6^KETdLw_`ZmICa#@HKlmOQoft!=#T|@8FV_p9nKKLy7%4-7*WXxx#w-K*?F}uRt zN`EQcU=bru@X;iu+Aw9>E^!+qo7{&1O{TLQ@6^`54Z_Ot;Q#KV!)?jsYR%vJisswC-)sIWH=W&J z7DleOn6AEEnsTMDh*tTWE*CxwLU)hg<2JD>3q2rfoh7#q!+)O~ci_Xm;+GfR*`r^T z@6Rf3rf);sdRdV9+}NBP?Dlhy!0AIy-n=;RmW*FY?SEOG2LCa+JT?9yN9=cY?$2lbk~{TW6Bf4zOjpsS zDNjnpROzShIMLSQ)|Hf6KVe=rQ60l{$W)?!sEXJAzjYjt=j8(TB$uZ(ByTw-@u%c+lt*7b9)Hn2?q}bxUpmulSh!wdy83o$ z%8^+O(fkE{zsF~M44`$TM3JlVq^76-=Q;^+v7Us!6D#u-_^)lY0|(@KDf_Fwg zjySvO%?&4?cY;rqC#I{AwpO0F$7IWq%Gr+fUmn-ZdLX$Rtspsj?cKAw=WV&;mQiL0 zgzF`yt8bU494Y3?^qa>aBNMmxzBS5vk;sSNI5|7Cd+4=0zWSr6ujQ+>gM^WXf{EsG8|UWDr@ zrmL@)raV~}*LYZGo!Zl*&a~Y_Ag+5D8~=yN8g&-xD=0P-jRiTp;k)%Sm3!+DyADO} zKNUZkT%KA;-u#sx_xi`}Cv;ckiRmh5woaa+)l!@4B{g69KTOuP9H}|hw*PYfsrk>z z}^?zc!iylazOsn}SqKu2A~vIV;=Uv~Wj z4rQj~_Aam@xm=Ym&k_5cxAxet{(E>YRj!z>rru6+6|Jb6Df8`pVJeq9&VMz3xU6;@ zgu6EqHGh~JT(9zf+uSi6NR&VE&~Vv;X{+tSfq402m!0jy`*c#NBTu})aFf!XQSYPK zFtD%KSoUPY;J%UZ{2?RUw}Sg$n69R2^k>Q=wSh|iJk94ho4$C3(^d^qx-HLJ`%!Lk z8%cT#>6urb-9(1C_my?~6_x&hr=bMOaA$fl9e!kGq+8(hEpUb$QzEs7O$*VMXdLlr z)z9YlK^&0Jbd+6>q{F4Q`H5F=v@NFip*Zh&JcR$a2aEs54`oxC1B=PR^+w%`*89Zv zAvfHqHtvNSaluA$^)fR1j5~McEnlA1FN}>8q^hZqq26G+L5)3)@*6$9;GhN4fIsA+ zEqqa0k<;Ui1huJj3fu4FkO8s)*Y>zKj^JOg%1n>Xi>_qBVnC*Ol=5Hwo39X#SN?D7 zzYUZ?G(TUm<|o#SQ8pR}QhmIB_0d}>zyJ8%8{d8v8GrH^b3u6lEz}@CnNHpoVm!wak3grgU-;+LrDwb8GPoa8r1?f|%qWzfkCDcwHOTzXY=@oP# z)$i$2)8Ep4g4gt-dkX1J!FBZN2UF#CAqo61)Cs?pDvL9y(H%<{A5NeOqmC{=Tt{nc za|hBrhKG|LEQJ3^AvQaNc$_-dYv>^S*b}M0Gmh>?oIrOCP7>nfav>&97h(oojQG7q zbZS*|7t(t)(4DGR3Nijhx)1SAy7O=;z01==d_{K>hCiUY6u+T+3Oi+qbN0;=T^(6s zc2SmibXJxad|sCL^p-4f@Y6)!m?hro)=4}!qLav-*-3P3>Lk8>zLUuNxs&+f#LnWO z^E->bz1Uf-qYscC?CBy#KHo*$cEldyzfF6He|GLF4r=HsW_0Z)<}B(a1|5?vuKFNb z+;V+);X7kbaoq48V(h*>#V5JF#DfR**5!bz;tPU}JR#K5KXx}HI`J}FC+s#NYt z1KW-^2RaxBxL?oxFu;S1?`S!1CJbEfFQn(8**K_0z6C zf5x#J@jALP@MpE6vwMc$TQ2Z>-83elBSpS2-Qqy|GD$PObyPX0!Z+dhyMDNP>5v-` z7K-tybi*~{??LPMD(HqP`f!^*IBKQ@fRFRFh9lm==8l%D9sK&yDZYs&r{T_H+tduW*Jh)^>~wpN9Mir@VqHB z0x=W~he&0&q8qM4;9I41lN)VNc6(f5f6!5(g-Z*{%cnROc&hc=PKxQyE{DGMfH2LZ zxxLPQ&x)t{(ky-bp^nBxzpUNxOyJmD@$@(QUH|KMpE%Be%YjJ^A&vPSrt3uMVU8mw z)CII4t#{Co4zFXn$LIDh3^|IOL3fce;thw2BHlS3uUB)^vP6aE^7}A_qAQtSiwPg< z7v>iY%>?G1T83tc#?$YAcHFsrgtOt@s*QDHmQFS+BF4vbJyPkB3?CLq2$ohA_IN#K z>&&x!Cm`?rs~mBeb*dKhY2IkQHBu1H zx0Vz*%1_7@|2*l|R|>xQ-+=>Z{0zl7m~K#G&xAN|r&kmO%>_~r#xd(}$@ziUKPY+d zz~i1Q9gg&&U}n*i={iw*B*kIyWGZrogV6Ba(!YZk&~!m7wVWu7yZ;9T)=oo=k@ySw-*9quZ&_H+Gb2&UqwHBQfO`(u^bF{`}caDhfWw z6m4NyxJC=cO6m9@l@Q#X<_UXfW;AYjXh{S2$T!Y?;GTi!U8v$_x{Mk2jBu0x7Shbe z@()wC=RWkpQ&awEW(xA>7~&(->90j4#seX&WDXVu{k1XX85cOk7)>!QBh5I) zN2zhPELeZeM?GB)Do&PYIC6rc4^kN%>((UJ+g{H=Dn<;=;E^a2@I9 z`Q5}nF8fR2rblu`@iV>3em?e$>t-S_DHI>H7fjcQ(jzf0T(UEnYU5DY@6*O>bNoRq zgW{vke|4uc!K1dQwuWmN z-;?GtO;V@V~$sodM1a>op5=TFDX7e=M#k2x*D&KA?0da}^$ zKiifA!zp^TenTCSs2?rQqvZa}IzQ3y^>O<5M+dvRiPMUg-MeLVu6XK=Cvt<6U%zkt z5m@mx_GV#R&2*h8J)+}k%jBYdEo2dmq^pB;FQhwqFMo;8tpzlC_`+2s(>%1_l%rDR zj_LefyIVcU@840((F8=6yJRvaV=ixFI5`g4-rn)$nfRLT{`7alseCNS9l7uR&&=)J zL9b?)pIs+^?Kj!B9B88G(f;V`fYdKRo0CtP%aFR?bJkGbzs{Ne{$1QA!OWr` z)9J58@#-XR;-ri2+!1}VB%K4P_Bp*%HJ3);^Wp_)8Bb&9Ts&bigUYRSL59k{|~2^lJf^Vg~r*;cq);9bK6X-AerPp$|~AFn6}zJ z9Eg`c>e_#za<+XC?%t`W`Gc|%FF)eZc5lvYpSRDWWKe%%-lc`w`{G+~e&L(0B_|=D z&=-;2SCMhqy8R%l|FKi+YxZk3NCRhHjs^o(Hfj*-4^Re#y zKA)~f+)&tGj(JU{>qO~c?%%Aar*pTp#-CD8i1yn}sH<^Ca2Qwr0O`i^usfvlX3RnBRS57k8;J&>(B4}^M^ltjC((z7$?&WYV5f+IE#Xs#yFcO zO5_LngDoj==55Rsr;Ph-pN%#7v6-RkVy+VJ`O})ZK3d(o_ z-K=~Q+Uf&OCHLW7bH&5Y?DN8kk8{OIQ{Hbp=(+t~I&w8?;TRsK>qP015D%DwN$moB z&`5}JR6zhos{0P`{zw`7P=p>v{_)49}# zg?Rm+LVPnkOFVpamRQ=glQ{dXPGUl^vsiL|7qR?rdx(NRb`uY7=`O}+^%8x5$Q8dF zw2ydx{Qz-C^WkETej^CeI5D@rLY(%YSN!Aut`;vj9v63A{H=KJrxUUceBRAnBHCM-}%XO!^cnEl`hAc`RJ<;b^Knax zd>s4o<%;RVGK)%>k0^vvJ~mM(mZ!#SS9p9b4cmZ?KzU?AO%UwKYye1WeYS+@4p zGox3M04MT|=^QVcD!zQpTcO~rGUT{KTT%IPo;mCo*oaGa{uODKep+leg-4mU-HYI_T5zIX4G zDV+vy`G>fZ(*fVWJ(bSxN$a~3e29}+;-RLKJ%&cFi8J9|D zcg`m6r&(~N!MA3Li1Rhj&&oH9gTcGeKXnqr9@vN>h{%m}D!pXkUdv&JVtgvyaBZEh zaO4?n!Zv_c~qkyi|2-?h3l8FJxAgiDUqAwvcALo72Gi+9$q6*|*(O$aom9N@w?^ zc;nUU09)az(ddKY`962h??KCF9UnLCpPH|ESp$E!@{|*fU>uB7rL+6i;4BIUEPNb& zKx%yNud90M??dMVIDN*a(%F4$@D+y%psD2i-jD{)r;l25@GIUe^Ef=?RO#%#wK&ag zq=lc215)#I%zbO;6&!#3HH?FCs&sbW8l3u3d^4hDWODf#ePC;x=sfZIg&ySM>!#En z{{G+1;L(1YQ0VNQ6el}Q@l#=^9U3 c#QoC`nWNz6rH~aJ}vWSmg253c?FM<&%cl zg*0YK`Tkb2irbzz@k#&l&%DBOA@J9Ud@~(>WW|uUA6!9GNmNTlhY{4x(FZb36o~oO zaFCU6dE|!Wh;pLe@RQR?R*`eaAH=6EB@ka-0S8d4be&8O6^Fu?!brgDaS<4ESf$_Z z3Ow=F2f!1$PEzEN##}fVmhoZ#gHz-0{kyC0Jp8TeFF{x+#;?*1*Od4tdqTC&FjbSZ zC*SfW^7w0+f(tdNI&Q7JKlGQ6M%_=V4u)b}DxKY1@s;kIrY$#~kmiUD&25xosZFifO*$=?cY|6YgVO!|LAMhZ@%LqZ!0-e>067xE#sP|fvNdF ze#wBl@`~Pih4C@}RXV$?a*;0ow`N>3>(JEi@oo0nmfH)z_&wv~_fYBV-q!bMk8w@^ z!&1M`#{e_I_Z%I0(zSR42(~uw-dg!#x;3Iq{jWLnvo9-={~~AxEQxeXZNIh-O6#z zsx%BAXo_O7nXzF#vcvU*PC&e4DUQc6OQ!^+vU-!J_(u!jr|5K~=Se4!$IMs1Y z?%>q;8gISo?>+V$^bn`dd{pV|zBPPIG_F~m2F_#eoAL7ApI(CPC%R&sDxKZ87H7P1 z&8#7*`T4}>eP=v)!K;rj4#ug{*?ntp%HtY&oUn;-qW_;y8tKE1Idl0Q;YxS!>6L3I zmtqV71v87DOxKChgXYJ>{=)H&s(_n%;S~{my~Es6&MOS?zKk^Y&lV4D%`bI)b=Wh# z>r1|!_b*P0`K8j?Jt@D~F@y0{lZ1EhkygC%*3st8+V6&M{<$$)p21geSEcJ@dQ@oD z`YnmLuDIOm4AV7NwGL*OBj4?=s&!7*HyjutWIW3WPpW);^0>+#-~Z<#mzs}EXB=!+ z)&w=DyWH>hI;wm=ItvgAIfM1nsox(7ILu4x9OG$P$~Zx6*)LOkl$Af~e!t>xa>eC6 zU;JIs_qF*L4?a@fp}cbp3QS-3o>^j;RqJ?F6YV^LgvdF!H!$ zLkc_ya{F@yCr648X|*3jr8A_o@i>gD{JdtsIx<=Aw>Yfh^myfO%-;qS-Iz1%Btzbf za*F*HOlLf7R!z>=Q>@VDM`-hh#`I>20O|5R3Z`$Z30$lZ7vtQTc)^F=P096g!?4ul z*|B(Rw`Jds@i4!QJjfDESNR9Is4SmsR3Ra%r5Dgqnjq~EqEGM`m9!B;#*sZdHIAM` z{`B0R*X(r@r)S{F5-OeD6X2-w&GY#e`brAfpNyl4a3J1%(lAlG;JZeR2h*OmF1_=} zDjs_N$Y7the~PYS7&6qU6&-$|fFqw4gQj_ckx*-{gy?o!-Je{K3?7lZUPFKn`$V$4 zPk!M^>@S5f@McBn1~vAKTkoTiqnq`eRDR8-vqWFHqJ4@%bKh$-MZxvRsx)xT_|utX zhin}CHKz<*K&R5#JteLJujcec0>)u6Q-n-xh$D|Q@L|8=Cc?-26+fPPR0+~=@K;EnmN8=TL1A^2c5MOe34qqJo=jQ)cB71zTX!||7OZ`6(7^v z5#KbYH?qyz9moze%C~I7&Wh=3J0kmGzZ?($-`&h+Vv5`^KtFX4(&(3=ugE-PKJkBY zvMA;`_b+9Ch!2YS&!$1OpUF5djxt2fAJs2-scPgQ@((6!_(9%qp2FmCWR2zx?6$Hw zu&Zz&Rr%ST?}_r3O2zXdm(xVyIh<^Aoy{~kEZn$`W;>??Qx3~?rooi!d3KlMx9z(I z2ikJKE#x7UisvVp9I5`}`HklXI8=HfY>;bJ$zf$X`-?|oH{0C(I1sPAa32gNJwK=f09Eew5lEs-!j#al*|2ds_{^HS8|FR$1&i+(W^&|gJWLM*` z|L@)$=t$!k&Iws|nU>7V)PJJ5+9Mv0118&%9@}M;{lG*Uj`kdi{lsh64IlQiqi~=j zmY*HP8{uMgw7=G|(8ou^aw)sYv_x_#`$5=v z{^HT(blPH<8Pq0CGi$6#Fd9hsPM8_(xWc+YG(w%Of7M%ECn9DzG0A#g4>FGIn+(&T)yqev!?X!-h zD^E~)v7G#roytq0kZRAz`WMRlW-;l;c%yG?G+wRvG|Ut6>Du$i|DT3utom_9d^{bK z)A>YIk?U8h>PL$$AAaz}svLRr2Rsdcgp>7As_>wX?AZXXgG~2t`%l4di8CJi2U9;~uU;mADVM~2tOOAW7j^rbm7p&{Kd4^__BtHukgm-W#f zqaOSUk$EJIGV-8x8ECGnb@&tQlVM+Hkl!2b_~oIShP<>>{svtiT46ceBRiD`>jMeN z>!SfV{+l`dsN?DM_YC@|o(HcSoFjQ$=(-5>b3)!2$EZQKUaabecnHk6VWuCX_ZRuR-={c1&yJ z%=gitVr@thCQzXwl`|#%;eTU&SW-(whjJcA`sTDt56jmg^31yFU#$Tvz39=)>4NrD zpJc~!KDYMAwg%*KuN>tbxnzLsB&km`?Z5wZ=L@lSbj1~PE&Kaz_g}I)Z+0eChT-VG zw%D><6G|Jk+@oLn`#O9MUJArDIoCll43f@wyS$Ec=S;2cR0cn|-jtdVzC2$4>Z%yt$!_;*1Azhb+QpV|LpKQ4c+bLxYh zm-)v==Eri0nsykPpZ_oTsx(JB^R(zS@Y^^weEiNm_t!HUUf6J^9gt1i{!DR?Y9v2&p0Qh^18kTi_=ry3mPi-<_8)HAI&Pj1^#XoB#{N9S6@H#r2 zcUbXrIJF->>_gp-k@Gx0=Dp0;OeSBi$#HG^Rg-Y7d;fhJD8nmpeY`N&Sl=~UPh(w& zDFa&d+J{wCbf?>5lu+e--F%&MlA=nBYNRd2PP3|^fuQxg4tCqKsIF_{=i_le{OEtx zu`^=C%e{7N$ZVU{t?a*hno<4YP^Wk1wZHp=nRaEr={uO^EDfj{INH*S%D*E2S#1_PJp4cBXQ=#HZXl17s{B*Z(rQFm_fa07 zR&=BByNTJj!K^={^QSjIb!U>F5XDSA%y7kWzc{c<$-%7L4qM+b9xMdWA4>cl;Md$J^Q9$ zJAw31aZD(2)Dv}EE_`88i{|3RE6%*&2Dkm%ILOISen{;EmTN+3LrZ{V70^1_Hhmgr zs`z`{xw)8(mS*3ahBeQ94$m}uZr=i|ok){A4?zo}AkU`HVy@cHW0K#Y4lVl$rJdTl zRt~S&esYRK+fQYy=Hj%3VR;>v{IihOrzgku!*X33+(vFc!?Lqe@(awZ$k?8Yxj8h? zn6}MDolF1dIsWD0PU1(7d9qxW2Ddff=?X#9(C$sR)7YMLAUOH|ucT9&i_ZOLEsjtA zcGdNMgJ+&B4>Ht`YREIqf!|hKK73X+CQFe6@8oi#kv|}+m(`|I)4!SDYFekVpJZw| zquyucmnEy22CVq0nZ6G7-T#Ju^MjRc*h)V$(Q$CDM_k)eV8$kyipRBfz_NlyqS>CSw#45RBl3RRwY=e|UQ2h>!v(lhfZ8i8*M!ohFIJ_< z#itB?;Y+V5!Zi*r?QUazEFRb7@Dk_7h(2#`h~0Yo>Qps6mg5nFQ^K?LM|b}ShYM?U zI6QP?YZ#SW&oVshKcPAo*SmOccAqNa=hSCdPWP+VR6h>axuq9#%@;w;_PXqW7_D4O zhK$tZ9(T7g)gtaOJQ@{WipO)04Fd7parREt)x5v(+3DQKxv$QZleT1KTy#WCI!GW zU^-9;(7I1Efh&Rk09OH51GK~mJz(U|@;2GdqU=gqwcn(+sECrqiUI1PMmH{sTF9WXtuL8>f`mt>#PyxIKtO8yK z-T>YN-U9vytOnKqZv*cD?*eOq_kj0-b-)L}df-FgBVYsYG4Khn5%?6?1bha34$uS% zUjknNmB81)H^64#Ti`q3d*BCP3-BZG6R;K725bj@27Uo{06T$SfnC6F!0*6r;16IA z@F(yWuow70;BVj`U>`t@zbK#%P#35N)CU>>4S{H&5zrVo4rl@#4>Sdu0Wm-<5C=2| zS^zZROiQ2@KzYxJKpUVfa1wAba0+lL5D&BiP6JK{+5=|*9e^`|j=)*K*}yr#xxjgV z4d?_U0G)v@Kv$p}a6Zr-=m8`G7XTLmJ%L^TEg04txEM$Rl7T)z3eXqm2lNL90I2{i z$}bm;y`%a)CU+1z>6hB2Ce~$ zfNO#4fa`%9fE$5Xz)e6ga5FF)xCOWsxDA*C+zylgcK~++cL8&OyMcMYJwPdNFK{0) zAGjZQ0QfKPAW#N81Uw8p0z3*l20RWt0h9v^fG2^cfQ7)*z%#(Jz#?EV@EouNSPDE3 zya2oiECXHwUItzPUImr|D}a?i1@IcM3V0oO19%g73-}+f8dw9o4ZH)q3#H^&I4>fCm;dn40Hjy0^NY~f$l&LAQ89#xDe0{wvgzyKf>7zhjkE&&DuLx7>cFdz*W4vYZOfsw!{U^GB= z2vnc1p)!=~8A<;&){7hAT4O-8f=!&Xor(n!`}bLMyWjh1QZ${w(LM@WmTN+36R2kl zb@-;cJyY@7fCdNQ`v6UrWlQ(jJ-(ri>4y1hHb%f>!VeEUe$KdEaVig%OBA%j2zgYg zw-@1Q*3Z}njrwVTYYhQ;J~7A14~$xK>va{aAty)t>SD`sO(<;wy!->HG_8zu6#D%4 z6k*TdZ&bpM!?or>;>J3n^k)xM4aB;!$K4d&^S`VGUNN3g^AZn*=hY$Uho;*Uj&wEunVL9C+J8gC@r*DR?1RM-@OmpPg zn5M=O)8C0AJj6VrA2#ZxKCY3?rnN+wu>jk)WTJI|o%pXPM^L|2jXbq-KZ zxi)-P@GHV^GIG4Mek?|NEE!wM&c&*&$92K36uchF?mV%yPORvDb*svp9^+$M^k343 zZlUn0UC(lo$u1CnAG<4Sx--j{<6nWk&kUc#3p!Ag+m%JZXs!}l(udrR@fR&xo2nkJ zlTIkFJ076)bP{kj&>OfMptz+v_PKbF%ICR=#}DhGyoW-kfbf5spk9K+FtaVn>5iz= z^g{VQ4rR-YsPDXqa;-*jAh|U|% z6#H8B6md_D5yP8ZCr;T_A%3{{l&IJz%cJ_#nO3LdvB&H7zh_GQmT`@uNsp9wgOXN9 zq4(qQG$fN9s0so*J|-Oy$k9Fln_ox~aNpwHELS@kD1bJNDZd2iq>XLq zZ;AC{#VwouDSddy;L%hkAjj!}<+?Pu4WtJ?@K5y88ipOt?m0i;{E5r^apt>{FS*dTK@(2Dx*qL;+u(00 z>e-K?9=;fL@|94``=}#+g}VL@T(27?y0wlH7uhhgOaCbG=)@>-$(2#!)O)diDN5`^ zG!!Kp8jAkjXpwnxBk}b|jl|mf8jFGX$BElVHxWCB9xpz- zw5j;`%4Xu0B{Aalx^ZHvtGOusy@e>A-%>n2skN9hq>YG~c#`OT-zli)wiB!GJ6+r| zxr11kdzQHOnRCU7T@u8o|LZEgh)WcUuk0lTU6d>ynb2RP{BVgF_|IWUyJGt0y3efaT<^M0v+8w7`MO@eqLli_Pk*|8 z-PccT@WXNQ8!TuL-_SSh*@o|&Hz@kGW;>(%#6H&O>I)|~o?4!G+~hfJn*80P>G5kC zpV0KC;)G_Y!zaaTIAdXK@=wj0FD}2m#n`#$wOra{TdPJ7tv#__iw$ir&8UA$!&mL` zXZ&~jX;-|y@Qlq}AL)31>V|XrJ~yD#_G|WaxxPc49&3t6X-SUDi+Gp@v9!=0R87B4i0ugF*YU=XBL$k?n`&^t|k<{%?Xw)-bH5 zi_PqJn33+}NvNly0fRQKHV`iO15F=~d%D-*8R&8%0bl}YJ(MHyJO81wZwiNj;@MDd zmIUKsm+oBZa5MqSifSqCX_bSmyiDP4h7&ycci7E{tZ{IZ%IK_IW)6tD$mX2RUVE| zP>K5@<)eB@Jc!Sc?8-n=em^v81Dr$YQN4yHb)fuKuN}$nf24CO0YOf`d!+PBI#%09 z^e%Po`lkPk7ZQJ^V{&>kDY}YWzlypt77#(db}s${pR6rAV@vi<#gYTsO!{8>={q-9 zT8_rBzDUusV17~^pWaEGu4(sj%3~ZJ^HJq|y(*uPSfOIFLt6tuB2t70STEwG@I3Cw z-}>^c?U#MS;V=(X&eyB*Fls^$zbJz6_g!^+&#U@>Pu*Oa3Kk8&WxO z&PTs-c+5wY^YyBHNRp|y;vLC8pT{|=z~=}sD#n9sA01x_ub+DFx_V4M<=!h2`~ec5 z21q?DXCAz-$|oIvL($g}Z61Yya%3KhBH-~-<=EMsy8T_5;SY#-GzJfrbNIZk$^#1l zA#{7LbEbCS*GLf_V0|RK8eShS%>2If|Jrn@$KenU%1u-`U$4poD@jQN3UMQczwF)c z;lJ^P@2l&c-uz67KL8593BqSNhs%4D@N;uwJD>$DGCPaA@FYPA`$zHQhsLfZBWN{p$JQ z(7zSt(WQZ-IlZu^_s8z}87@=EFP5>t*51;9ssXjWT-!Diseg1I-^*nIpR1gYrE@EO zj_lYj2R-hG$XFZfhcF#4a9XU0zVNTT9}Sv)^QrVR1swH5(0EmrYeH#L^?OLD`6&n6 zJ(C?(Cewf?B%$f5hoV;;0Qz4$jR+aPh@H{cgPk}vma7x-h@4&pk zO1xHiZGGop8?yG{HSljpFJ^Da{UB6-rLhJyl$`cd7a*BjKfq~NSChI!P3{dFuyw-` zrGZqiq4Jr>TM{|4EplXY^nE&#_*d&;G^U;FsW{YJB>wQd*1mQ%P!8|79#*_DSP!E( z$?}8eFI;v;thi+6+rPZ|#bO$QuQ|$Vs2;|0zc{dqe7-bw<~jekl~DsVzf?QIF#j6o zZ2?l&L9J_G5qxAj+PEpS9c}3tD^_g2`hr_KO@D{-0&;9eEZ3#MZRB=jK98Z%nyP+} zq*%3LmCzk8d;I;<#WH#TVYEIgm zBW(YPpBw-GbRgJlp#1D8Q9SPHm8qR##Ut-+7%=SbwzDqt7kG=|X^_cNRcwXn$Sw1Y={m?EB zTjy67a{?IUd|l_2YWLED8BVW5WjMfNcNOH?v08-w-${|grxJWfKddMIUoRE^mM!hs zZWcd>nuA$* zWFzFrPV_uWJ3Zz$IVgD4^mC*rf#S%lKFD!L*ZBBI;cW3R*T9i%XT(^xBRW>0zLk8x zdd)gNd>S}f?2PP(@~>mL>^Xc^a^NA$?WE$LjP2v1d8OKX0qasQ??=Y(Pf=)#rzOsh zZo73HhpguxQB~x8J;m*w>eS{5%XOqXyj~1t*G1mG4*ak0$QtI-<~}OO*PoEvlkr=P ze5fB$p1&YtdaRhzuHU2UK7H^;Zm*LaQa>WgnFsIv%~zX$%2cd-;sPt%z+r>zuBkJ) z1xXVT4RN~g0|GxM>uHg~i`L^IUO8hi&*18T*N7RhVq)EEr_J2C^)8hc%h_MvhvbF- zc6^wzO6F9A2e};;v)!mCn&*i4By5WjaaWwMF?wRGcr|_3)jJ=nyq4Qh)CW&`VmVF? zj`86sD!B%yhW>-HF#0Xeh!y|5_Wnh6GMD_#`lWX#{j!|=lwC;u z+T@n1{*>H)@Az}*_)eXKc{OtDe)>)4ysMcH$2ZGmE_584&nPd?Zy=}7iZDF3WX6hX zA3bGl^1S5}R30p^8IOL2n8`!WL$rDB(lb5Id@OpJVEB)1%Z||cp)liqI$^~dSG^Xf zFCpr292Jn)j90LSqYNI&?GP#(sn3A?x7^{^Kp7}-zFEA}*zd!6R7YQwc>B2PHxS$F z&MCj}wNr1HKzSHBipPf7vRo5Nn{>zIJX)xSvdJ|3FqMtT25tQvb|0oj#7ujcR0Lvj z#C{%++hgnNnC8rMq)&JHusRpzROs6Um|w!LMt)QnWz#+W{$Cu5ME8Ym@9=jAU}`DN z5x+~pkL7-GU}wsYx(Rdp6=MEIqHVj>;c;vKi~4(i&3Gk6u#MitUq3S zQrd)Bm;6Nck)!))tI9PoHj(fQe(59r3QJphK_+S2?_nAC%(rM)c)cbKId68?HtVYrwB_IDQoo z@Y}rnv&VOgUfZ9;XMU=juh)QImvHlTh*Sp@vn+U93`J9XyM96s|?<$S#c{LT-@FX@l) z`uq7A`zJqt^WfDSKJ!!Me7y$zx`*Re83DghUzG0Yb=&QqQk#Yx@yo)N<(g31)PP?P zGk$V@U9u;9eqHfv%9clR;`-+Kb8O<*8T?o-QPU11;TOoSwdRb%QpvAnzG;6M+cYJT0IY5Ir5I=ddwcgAJu`AL(p7u+7+W(UUSJ;ay^S~U+R~ukDA7xu|8!>b9*WB zxXv}woj=$<2^9sJD-cb4E$PL>V~RJLPqFph7$Nf@ear8W@pt%ibN#jxH~inece;1_ zS!YasP`Y8cE)8x?-yoDx=3>=Dr<;hQeot-d@j>*w|v{mJr7@HxEJhx{C z76+wW--5jSVFf<9kUu+}N7rA7B(zZHpX+lw~D4f#t_%|11zf?9yPuUcg)L+PQoElt}|9ddx z$uSI5DLGxHGnewi@i^dgzeh^<&F?r<>(eOnU#Izkm&FBn6RQl={iq)~e|96WwbScc zw{(vctG`)0Y|NVH_T3FRIp)oBT^ihm;;r?z+qK2VM>_MUTSS|Kb)XBSGrkVkY2=id z-3NU?GLQ5a)$?rn9zl*|3{CJa*~FkSu9h2-yc+8$l6&bMRd>{{8mW`Rl8+;Op6=V< z=V}s$b+4rXO9Pe$EDcy1I9fGOhJsS94^Y_|3PYnoF`1ZHmk#^5rdQQOoPb^p8C{+Jb^|SRDzxynccu}bI;fVUh z_5iew7ItF#zGf|Yci(+29h1}Tt6>$neih>sF$2$Fw>`_2lIz5HA+Js9&l_x?;V$rD zK~J9zUQhR1?$Bx=2^BQC{!VdYxg$pd+@E~pFtV7)8mPbt zr62m9(y^N{Kd$nh0Pel#r|a+UT0DY=t7}eAZ&6j`e7#D!feGExY}$lwRGi==N}9*% zrr*x>@dEulGgvb&0!nk^yOeke>R4;xH26HBi)@7Y+Zzv{#nz9 zc5kKYL#ywD725u!A1m$;R%}@Q9&H*p*89KY_~N=Z?P)9)pUd}H$H%q?%+d>$C$g=` z$H%s|thYbbHK3*!PAgU#Io2)1dVezwsOg3JX(_E({k3M=vSi1)2GsWdk)V&7mTfh? z|6smjq+BAoFOqu>=DS#ahu1(EB1!)KME^x`nL|&@aY)Bp4#{%5Pj%t0tM^;y<{Bu2 zn7?nVR=#i0cX0yG^S<%oSaHQWt&5&byr+X5a&j~W5dG)Ea!n|0Ld{P+Fe}#)`2TST z)@3fpv-#((@z3sVoL@HWeB<{QbzY=mN33W*|Lg`G_bzEnc1Di+S%@FYHKDW#Jx>lM z%y7E1oSDY;ev0wm47p^0>`?svWK4|Y0=M;OG9{>Lqc-d^stV?$=!tZtv2`u0T9iF|#v zbbV2Dr)lc-u@?oOzc2fRDRjLIFA(niaht(${=<4<9q`_8vvqPn8c^FCG!AHgofSX( zt2yhrqeTN|`5Dqzw^mTN+36EQFUG+ok^ha=q~24>3oOhWxq)+d$kq_4D= zLabl){wYM~^Yb^1JG1`2cj=fMU8k)o*TmRF%p2ow^!dDWh044V`x|+w@tis}R;(@P zR5qmHFN4*1W;yfWeRy8M^&O>X7HWA){&9VVj`i52BmJ1pRhf422;Rtik6@Y>wWB}- zYI-5tvdYq9Q=MKPW^@X? zc@b{l_wJZ#d~dUG>ztFa?xpwFXmi<;->h#{PS?nBxY}f6YT&pozjs*#;SYFWLa)7B zUYV(Rjtz&e%K18n@1G<-@ZNH`tp|pG@0I=bwJd(AXD<88;i_`J&f)gKeD!&D&s48J zWI5cD2*Ule*j#(+}FNdqj`8tQ&-;Sw(-7XH+py%j8;orBU&iqGyDPKB*{pD~~ zIbY{+F)3cU)8`0;TZ9|fzKSCV_q4>#&30eY;$`-i!&T*cox>gN#4vP6)?lYAplaNK4@bCRhM&d8irZoGS{paviIbY}S$2cbSwfpR*_Ei``xNW!o{=@pkViNny;i_`J z&fx}TFgLNU9T9}PDfz+EzZ~>ym3ehlxf*VAetwF(z!jJ;xEMEZJQof&>RJ4y_v0u1 zRY!ceylWo$Re0k4onEbI-SF0Sy3h2!Ly?+Uu1kYk|9o`)3iHt=uFZ&@YfGMHcjnqB zL;B!$`gx9dL=Q2xn<%Tz2ITp!i!V=0^bP5~stx4ih({Z2S*{7CO$0prvs~*B z$$BYK_^9nTdg9{L?Z2OWYqyb@21#>NSFDE`Bg_5bz%JDKbaGFbEprl1}ejhKQi+HJ$&I;;**d z!SJ)TIUZ{N>Tmu;xU+kUw5>pbs1Rh z7YBBMa8sR=b1+M4dX61a^=cE^YaKJCxRb-rA8yR&=vyV-v2iSoLsPrmWV-ih9eKe6ESKY#j#gJONCa=xB!&vs~BNF5_a+EVOTieiY}h2PUXSR~1wi(X{M zXorWokTq6%cc+kftp+a&hxJ3ps{LNMdC=3Tw{>a9;W95(&eucoO38I#b=`c>1KBKE zp2(Zy&ZTHEtOJuaD!jgK?%ppZ^_KdrIb7zY%K5s17kA2zbWe4-&_u+Am`Q?FQzd%1wEsrg6;Kup)5|di=AUg*p?NN5<&z`shCN-Om46kP-MFm3gT0 za6I}Kryfx>;7dRZ|q00HXAzoM;Y{#0tjLIid=KEzn9mg5< zBCe>TjbkYq6DuCSB{`Lz`F`7ZJs-QSyC<%m?gORoZb;uO*QLQN$^=^a#g1QVhq$r+ zF^YubX$}vPRZ7~Z3wYRyKjGuCa(GDP)Pb(2Me_mE+cXDG0B9X8swA;Nut()~2unbrWdPLz5PmdD+>l-C{Oo;lo-Z&N-{1D zZ^zf3GGXy?^Ox-AFo_S9RH~e>N6078tPR$Mg0@Y5l>uB26PJbOdCA%DW?w)2`9MCz zJXJaQO|GUq`(fcfUL1g)m-B;?2>5yT_||_?`M?kNokdUU<^3S&k>$EHxDCS()efV+ zWIpkihu7Er%Rip=?R`xr{Q`3(NBZiFEz32bvS@f*fo`Qfvh zZIAoIBtGrIhvgC#?Jx|Vp$^}4w`Zz3pQQ2O_4C~?&91&IY4SfDF58nT=j&nk4D(^Z zt{@v@y<>F*d>+`=ed@~GDSy6vk{%-Q=@0#|oO$p*3?Hq#mhP3~Y3zjXdiiJMty|E>8C~ z#@#HZdt_(AXOtJEY;n91fp_;`Hrybk{o=q5bxNPRZy(#J{48|V z^5Dq6`bu=TOC6sSc+fg9Xh7GqF0#^!K{dzJNj~0IuFuoUqbo|QGad}PIMm@Ciu@py zo%Z@xqqb4ZR{U0`=0il`?CkyXWkb0-l^Mrlu+gTj_EmWj}Pmpdr^?< ztHut?&Fbg!VNpg$u7kdIdTqm81Mx*bf1(UKu1_qxB0Qg=H@*M!h(+_B=J1%0D(CA} z`Di>GS;IU7UHaN<`VYJHRyVWoT4@ZsIZBY3hO>d)E;`#JsBN%#D`{j>Ks zG+%r*#SuPr1njHmn(+12=(lWdxBhm}s~o?yr|;M-$Em@gV-}x@Cu8`7X9i}I^?BU6 z_>A7yorgb=FzUhK(+`tfS$voNi5b5m(Uj-;xLNa0wKMAfV-AJ@t&_u|0V{qEi`pX& zRE-~+XJLPwmFD(GYvG?!gjYmv7SBPK#T&Y#s03#p55W zOba=&pNFE~k;6LD_i`LqdD@X4TZf0Am0p5+m(vUPCkC%tN0tVx@7%HtSm{O9hIMSF z0r|Vuq7q~MQJwdco^LjNq-{jZyVtW{x{XCuk@NM?^Nnf)Z0T!~n=6P`dB>Uy_EC_I zt@>e5FV;~|16Fzo>OwB>@Vl7hEDcoAKs+S;-FqF%ySJ};@1K3?&cBv=Dt;yVDfM5c zby!#55&paPzSXt||7n&tj{20z>3z#}1n!PaVXvx z`S*EwAOC)G+vfV4Q`k22Be9(BksbelX!HO4G}xJqQ7w6nuC{)8`Mw#4bbM;0dNRAu zOeVjlb!=(iP-vhGfpB_VHqZEf9Hrhkpkw`pqF#2VO|5bLn&Y1R@xpr7uaAM89Hm;C zhnMA=P}e^0sa=Rz>o?w1Q;ZVOh{o}swd?EIZ zuDBwmd2_L>&n5Gozx%4_?U0kB_aXhUToXzg|NK$LZt=jhNNEM0$qrk3!6YvaWs>=b zQX?PAdx_5;fajZ;*Z<7ld!5)j2_ntu`iT;%oUf;2vJ$kiF!eB|6mZx^xjc?cH%%;n zLS_smd~x*ic-$VIbwU5vUyeWWAJZdOadLTCs_-@&7x{BW_vCl_?Cd~u2aqFwn`6sz zO(<=oIiiM!glyE7j9QiV!_Bet(L>OWIrT>9hCuxRl2Y5&s6@#d4Vw z9h>peenQqFu{v!T|C27c-^fdi&mG`Byv5qA`sus2ukaISfjy;Hmixtlof$8a_%!{` zm)<#2P`)7}K)^bv6%7=@7f$yX4}?xvF}Pmv*}f%<#Fwou^@q-O!g7_AshtGVl}Pi4 z&;NnT&vPFR{l6ZmE5eQZK1B~2?Osifm3W`;<}aK*=*$VT&rR1u;P+v<8m`&<1kxjJ zE`wpq<$(G;pOgL9#8DccXGkZM-%)*}rhed&W8RfP18g4^4~4dm_%hf>hnMr0#y>f* z!ml}s2g(;&?iUAkX7-`WsOZx&ZEajYAr;74F-XO;-Idj+AUoUPiO7B;jrU0J3y`-C z!fK!xcd-3zc_g&`q&^%gDtm3-{Nm+>t?%=9uu)z{_QP^D!0`5?KM^XQ;dtkAlg{Z_ zc6u*_F5$d|pOf#ij`vRk^8X+Sj~neot$&p~8Y@!kjD2K5*@mb6)6{73MRvk+m4%s| znAE>)Au}6z8p@8;Fy(VITQQT#&sfJb*FYH_;rwPD?1*%n4A9=J-Sgex4Xx&!(J`6l z^`W#~AJ)WjoEn^|9R=%W;q3>$F~67vMmtyQTlr7Kil$#R_~z=$X`i?D4@ekl+i}8!qq^vprl*6Z zNDVAkLo>4_?HWGv-qS^6;`{|a-4}f>&f zeWfAb{ za>4rZFP_r7{xW~Sq$lc+WO*cf6#E*TIMD0P#q2QjtQ>D?&lvS%W>8ay({mX7ScvvL}^~ z+&;>A)~F{lJNo9Y4rM3*{$kph{*04&w*Y&V8_3|qj8D*xf^6jY5{ryH%;M|LH{bs3 z?{)2mH1!8aJSe_c9tjV#_`(N`sr1bt9dpvVCVLI>RRUfVPBK7yv-m0>zvJ(=?_ab; zEmv3`5icpeLh*@TY}Auke3gCv!@fD2`j;ju@x}5;_ypriWn)Zd%M?Cl@wTgF-HNr_ z=9L`p5191W1lnYIBz!`}oAx2XYfNXU&xMb-cfVLO{i4KIpHSnCv}d?{smW1NKcf`Sgv^>Z9=CrjyGmwjJNzH;rT56>i*Z4j#)M+)gLCu z8_Ojs+MyXAT^6VhfRwb(f!_l;ABbLRg_8`>-Yg$DWBzFirndTEs+w=JJV3~QV9LvAPu242_`Fe1X7)5;NbXEA zaL=Gem3)BZk?=9(0|qumd#Z?lPi60IZ{^M$HGp(Tj`T?R0LwL@v@z3jF*``nUaG) zvc2yCKMId@LVGj2x_$P#F;Q=f+o{?W%kh}OnevnDDiU5LFB{n$;x4S z75iejffP>6cm?gNI#$McTN0Or=e2P1su%ja`&?VOylDvSvOE%Aik+q8Ix$CjU#By@jL1)dPcQFmPf=_vcvu1nfP+}`0v{}DgVdhr41AO{rQxxPJmun9tqE& zT}H~%SpQfZ0naD858HUhq*V!W`y(1WSsn>b#ZI+EG$2KPQZB#7zGBpynLQTWv3mTy z@3i?i+8;3Kjrg!U5|H%OD&GNk|Q8`INif`Pc+8fIw;v?Cc8IPP- zje0T5=T5En;y<15dOvowVoxlOgh$Yxn1#_^_C&zru}-gDJmK8Dv-v+k(i`Ggj>0Lvcq=k4LN%;+N~v;8qXY7Iu6QlalQv zW<_{=d8$wTdkq%d7MNd_^~3TY6aC1Pk7O@qJW9cXTrxoZo7v0oHJ6;aZNAr*uh3P|i@d(-rvoP9A$CcrEoH4U!qo<3#$E)odmdhOI*o=oR3)J8BQ+>FXp&nDA@G-NO zU3s_OvvSf&&1CzfaaAmjgpXPNVju-iWIIl)2yZvHUi-$iOS`mPspc~*kBFCKH=+1c zf)BY+_H*1{l{2%(_dn$>#eP^G37??-sBDb-$$u?8pLeePp>kNy_T@DGmK@nVl?yD_ zgwjS2(U{J4S-_44rlq9h*j+AdT|~J)9KFiO$IOoID`>nv>92b-)c9h#L`6F^<6~w= z22yxZwxd$;qW9)_Gb^v&cE2#}|L&_hQ{~0-h zbjc$p%(?N;-&H$fc|<%VJF5x5Mc_w{(}9`YedIf@+x*KO9LyadYROP+v#X|Dc?2tW)@y*OVsQ3)R8LfO%i3tF95(*LX1 zr}`@l6i+P?Pb}9wkTz!de9(@Vg|YvoaJ7+#S^PBHxvTKD&u8aL->>QZeeV*ve}(FsERTeblFrkoI_-vf!6Jo+ znf;_+RG9eOxCvNIQFpYb`KeeQ2@f;-(a7LoIejO-6W(rKIP;!f*F4ZIT}|ICkBEUd$}&_wq6BS_kQbs#a>t*36G$?FbiY)9{X;19?v?Sd~Eu8&3AV3M-c5u zi!6_XhiWHM!XD|dXHLbiVM95;N8x2=H#gd&zW5@^yOG1!=|u@u&etQ&cjR0rKn|YB z_3)Cl;qA!w&zGMjx5>CkwIh}@FW#H-lkLb%X$r57?}d-gu?cgQwYc@Y$G`D+OpxAM zAwF5oe0XohOR}qKSQ+b=8{aqbQsc9zU2}2mSDq^${`j<|U-=6X+R?Z=mNOsT`+4;% z%y)S3JDAI7&&B-Wv`9AAqxP@yp61b3GS_eI?{@q0@eSK&OYph7I4ju;o3+FUxd0sXF9OVdZxz_h|H`4tcmQ%b9=BPuVLQ9jE}>KG$ zo`ip!+%6O;Sy>KDS|zt%OCsRc^r@%+sa!fex6=Tf1*O>(@MF2mjgG75=l??=KS+;s zGaF;QDdA&dz2rprM{Bz8xT2x>_NG;R$^X5JCk!3YGGUZDK7{3TkL;@FGZ+(?48f>l z{9x{K^l@Mndxxqlc(fYe_}l}2L&bRif9_4A#iUkFx+Lx$^xK@*?;oFawsxl9 zNBs{h_lpC&0KdWZ8SVn#K$q8NpQNoxjbf%Sr68{WBOsmA9O*gEY+rgNk@RUXJsQ8OApM2i;+WUS*Q+!+uek^BRybtix(}fci zsL9g$%_H4|?U>@AN&@PlXxm^9<(q;$Dg2C|bUo(JZX~vLdVMQ}J^IRxfAo(2a@YNS zB6J`1)3V$z4(tLv15?dSbKtKayKsOj8V_lgu6oOja5sO7*S!gV6 zj%)#Dpw(LX7IxMVRMk#z<%W#G%L* zg($>BvYp6&&@rV?a%4ZX>E!oM_}uvZl=sv4pN&KCjbY8E?iB9VoqpK5K6~SD{_X~i z5A_GJobHib;QcAV^`ljrXeyX0uW#soSq2{Dk^y?(qMy5K<@v_=I^yo1ZPV!5N9VQu zNE~-hE1Oha_Qu^Tr+Z`<;6cA84|5TlE>&3w5s!x`9<=qZz~kj!J2qst&FVIHROwhs zx3a!6zA*As+p8tt#)=mwJ+tkvh0z`B`N?p5mF0eMV3%Crb7woz*cn=oH_71{mfaVP zQ;f(%R?{E(k>1Ercx(y7BjNj4(Xi{&AFcVi@vWTqFb|do2>1`G@X+Q^(P+3mdDM>a zYAepk{T=a@Mtz7!>S+1+mY6!?`n#u(Bd=%fYByr;SL=Wz-)#WI0_sn-?@Oc zjdpluP!ABgf83NsYhHx18#RpDJl`L?*`H@>lk?&5OO2m+C}9GO;Wdzy9U zB7$_?2SroAY?K<9dL)pt%iytE9&kMKUJc7SKXe*Uvf_lJ&&6_S|-?R_s9V3?HBbG zV@^vKBmSEup8Veoaaq<~qHfl6;)yMvh=IfFN3HDNE2_skS4Y(w@_y81%My z9)bP*w&eV6PYsX0dDm5sX+%`CZjc(EB zjVk?hs+_rjSHD8^0r(t|ShKNxS)uTuGzPOU^hf+(kDp&!yzclH$kxfxJ_=iwYeH#* z*|^ZW#2lmgyq|%}FxpxEOZv@4*ipKo`L2_;8TCT#acXCkAZ8~IdW({a7@79=geIq@ zUQNg3D86W`$~7@I{_ypAtOG1Yx(hOMhF~&GLpytQ1mQbQxpQuMt1+*${~W$5=j+vk zProJkGy?t`4fgS~Q4ci#HR)mOcI120EYL?wO@oU> z-^rPo_(bc|o-4+d(?QxV#`rf&2g94ZUU~ZRZzjup&P4pP+&~5=rhGW!B_d@Kj~xmR zGduh}cHt#+O8@#m=0SGI@`!k_9S(K-hUNPlSp!`o-DHJ+yOih|^7rB$;q}zx_Sy9> zSiWYT%#ZZM@`(7^!V{D2sr61HFEhQp@xM7g&)D_dDw!AQjpY&XV!iqGG{ie;5)Z zxarQxE=Sg|0v}z1CxsHfgkO#NGUGS0SIgv<3kM8S`LUdN@!r(laj^_wy{tpHROnX# zlz-AO<)#^^FO7cmx!yPwAGKWl?WW0HDf`kK?P**I%l+cOE^XA1WZMYGWPF*i=cd^6 z^^bo}hnGu2r6d}GYNrQlTCxX4IADG|elzOD%#J>I`q3vAePsJi)(hDY%h_Mvo9e}H zM|4jaUXa4)@kcrXe!BWSvUG&1gYIH|(Xr)fPXls3Q}nyhKGgn93iX~|dwVwhU;E`$ zE|a5pq5tJst_h`$_Q#{vL~_&Ws;u2F8;E1o!;sH=)K61{%C$jmTN+3qw7x_Y-dmq*9GPNix{o9 zTN+nmvTn=L58Ll9{ro?38~Veb@M(SwmP%?iYWNgWQwSHU* zo;%;_Gj{NvZl71^pAQ1{EtYE@NShEm0=7c8mmxs4o+WuxD~I$>1k2T214Vd*)61Uv zq3vWD>}cVx;y32E{BMKG)_Pdf-lcM!<+?Pu)$JtRHv@g(a@&cG{3`s}~`J~^L{j}D!Fiy9#Pww*LG$d~L-}0~gj6Jy3=hKG^jq=2%@it4_|(9m{*!UZR_X zwinXVyUBC5-+bJI-~V}$t~Ju_$*^aZ>(byh5_{pg6g?&LDU1!zC+dUo=Uv=qRg-6; z^)QJK{ddlCT^ii#d{QwM9HajFx-$#t?+V?J4K~c2_Sb$X9kJbU*&k$K9o3cw%;Jaj zPGQK$wH2o2Pvjb?E`BIYSnlv^K(1GnwhNQr#>I(lO}DLWGHpjveLr=sf3sYDBR#*x zr~(>4=Kq1#tlnbTiK@9H>zt~Gay^dYpVDzc4XCQ|yb%>+E03;$0uS=7YCL0zvF2); zU#sySn*`NSLPJS-#ci&7nZA$8qxfXnDWLrh2vz*zU9%pDwp_0r-bLX zV&3%CKlXE+qVi*TE%GzW-l*0Wbf#)(q0bL-G7L@TUv^cEpTcM%+T$H5FQPgFIa&Ym zv3^zGRwtM5v5sr50X2U9SQ4fEuSowb(%3WVkD`7kiZ6--1`Y#`{Qo_WvAx$aimDq_`$FBfqDpWRLeK3zxL3^ zoE1NZR^K%ZO^qM=(}U88Tqlv!5X*T_;i+j#zDCzAxBnVYDlL~>8iN9)Maz|ok;3HQ9pA>94e^&?9I^1Lqb{f*-p62{cm=Fu&~ zIEUWno)BHsH%?6Ge*fmYJf{JJn=EuvDEU!}FB@rQ=BE&8ED7#;VeMveb^C`LbzF+4g`9=m`u4CIK|r^P|8= zKpc#B60imsiWm6{*ocI-8-;NWIw1PNAYIsab9q)n1Pv8gN)DA-AcE7L~{Qc@Pk5X zyIihK8?8;hWW60N$K@c(_A~a9(Dt(o_VxKs+c$l+{K01{wA@UupHMl#a`nAU>}OE= z{@D3ZU`NNYEy?wXk|Ck(Xb0@<_FLMweD&R7cbq~M2{_u39kE;!N*fb9!m54An86NH z*I|*h^nyv4^DuZ9*C*8eEXm6QK9u8IK0aWNk0B4_@-}H`XuBb`B(3=K>y((c_D%IG zoOUfy-m+X(UC<%|^-#0&HX>Uhzsms5FN@Mb^R2}DwAHdoFGE{V(gU*I$^+Tb8S8FtH=kB6g%3)4O{yw~aP| zZ1AZ=QU0o&_vf7Qv12(eTaEYU@~m)7Xgk^nJG-_=ao2la@%}x*uQawJmaB0Pw1`0Y zTXQ?I>5q(bWAzIMmK_dy%4T*@`c>#%*fw~tzMpj-nFiM3Hny`Z<3ih6>ex83q1)x( z-#KyX+}Y@pBgb~ea$OqS22J8X?96XpSwY`414Hw|XZQH}dhF9V#DmqY2xn*Et~0-5 zeP00uu)U>T9@^f@FO3slT(aPf6JC3(`_1&D4;{#&bLkT{e2iaG9 zrNM3O*%yo|Tq6L%Rsft{5;MZTkMn_yTO1z_dE2Y4s;1Y&+M_nc^5C23M<(xM*3VP( zx~D&&O6-|`YkPS9T?gBGJo@YGUHCkxIZ7{a;LmcuIIuft{3ED46NyTI-)~O@@3-Tv zw5~H|r2cp-Jq*Y1$8ud7+#bC5i>%Hjr>E7E!pGn4nf2Zq{?5XNSOrvb^nNGeEm4_qX@-|Fnp@7K{0C$9Xni+%g5|20tiYgit^`%%B~ ze&=^(P$Jblcn+ zqd!yIFD#GXedKWqRy#&j*uUg_qhwdn(?Z)-jt}dy^(y*&!KS4{)piWaRkfI;lLNCW zt39Kt_^3RW?XIXWwB1$0F7G_K$>h;pK5eA7XIQQ(q4w?0YS*YbJ{r&E@itp#hPJ!Z z8F3iB3lm+dU=s?c_}=*l>e)n-%0?hA7VsqGt< ztM7ae?96KCs7gKx&gF8nV$&T|6lF?ma1;&ziDIe*+%h!SV>+Yoyy}&-ITcI%wk=RUQX&&V2~HKM=o;wr5L0 znC+u7jD66%HG2JA2Va_qWZeFXjlaOug7xr{Y>mcZg(G*_Ck3&xntd4a&8K3FRNisb59-p zg2?-A)a|;;w0TU(URdrI2XG?1ko}(X*N=#nJ)i zGb#@{m+i;09WxC@E|cvhdXCX<%4S7r^B5HlLS5yP$`v`c#tC2D$5)o*ZyHm1x*kRm zc2q90Tn(9Xko3$PM^-_u!((F!RmW{3?cS-wTq*eleG5F=ACUZfb@g9bKjs|ZY=FjM zlHJlTPGl2g3#vV+=eR|4vJF)yQ}3a3RmRUAYkS#ll1f6`O&RPe@1N^>e$u_~9h+%! zN4O$@?1tqelO0=0D7(qdu4*`{-H>h2T#+=l)tLa<3{fCCLADQyTlri*#wE?w#0D%| zVXX!CvfZ?vOC$P)NCs%{0J4Gdv!g`uxTjZcgk8mdI5O+;ZmAnHF@G4jB7p3M4KkOe`wx#+4+;JEYjwd=jZ4`V?aJ9naq{WRmb=9UcRo%=$zkIzRx;7ax@^f zSGL>}I$aZM+dVyR&L6k9E87Xhaa~vu%hfmI`lr)1**4Od>lk8pA?M$iEZU1-Bzy3NlH#m&%x>JhB&=mr0_J4JKy2) z%^2#=a`bn5`sF(EP*xAj!gH$KXr3t>uD5ZSLFWWMS8mr%`5C^Zp0nKAht@zxT$c0Q zQ*lo94An(?Uojr!e)c`ELvqOg<(WnEO11Xsx)jV+oALWobnT8W;#M#DG3}#m_tBXi zb}KMoxh@TExxQ!{n1}MjYa2Gr;mLNOht!dk<}7sNdi}S`Jc{Or=W+eD<8S(HVbP^3 z50(cR=tm)Vq}cQG18n4U+4_ECx>W1WsJy}SdU2Vy^xq&q6SCGtWQ3SkNeSg*|^KK}7i^FAJ zs+_M!z^j`XFFD={%R=ib@qsuocJ2*7&W*l(;Q)WY#EaS+EN4EvH{&(P?wYD9No`+{ z{Wbt7PhwDc$8`bTLu5Hi1IN4uZ;-@_8ip$oHEa*M=Wv{+h`stm?v3>rv`` z>N)!_%jILf&U^Kmdd~M*`y*2Wa=PwV9y(obLAu|&vsIHZYt9@xSxMI{SKl(ybgfn% z)bd)kW3sVOP&x29#RkDjl|vmBn;J`#WAd-$05vY*w-Sk8O-nd*+i-5c(Db^coN z!=nK?T~~xj*TnGQ3ug6xqhZPrW=rL@5Us1o`MO!UHfyJ(JFX~jxH28wj+1$fT@X6I zp|FPit?sRH;q1w)4x%zgIrfaq8 zpqAIN9g~fPg35u2$%S*;|orP=kO=?enA$;R5{Hp@#{;q@pzn{9{;fclmh^Ftz^nHcpI5oIP z({)!{@b@n1Fz}g*Jyq9{X8EzS50%D3T??fn`8oMG)H8IgCijN(%esE>G*AYwIh~ij z96Fs7ikDqj;?Px)`fiP^cob)2?6wLl*ci+Nf=fbu_sM~KfU?TLVrTybj)&9uV(2uY&}Mr z!G`@)(|4$J9O@eTNBcz@$Pgyk#^m}{U2V$N@3Dvkf;#h|s+1=n*hS9#y_G*7C>z(&j{M4SV_s1tSeq!JW$IbruXFXH98nEK0cJ*1?zNzs;X-7^!T-Nx1 zml9mY@I8E;^TFEYcdYwo#m|v#0c!j(TTUN*&Ue^FXU254{A-&3#Mqu*S6^)GkgvgY)04$(rD^L4%bmF&vQ3C;uL!Y^v} zOrO*38i_q-Cb6aDIy0vZcH^TRgyU?3?XE0urad17mcb+Dm-BUaeqXgbcm25;v2P^M z3&0V-4%o6>6H1#J@WZsqK0AIz?C){sp+Py#=`Qf5xt;VjecjVtGHc9%h%lIU%s0k% zZBn0RTDx}L`9ka+U2z4`X|S-v-H8`WTENuw@nX%Y$oYC2X1f{ewrAM}Qur==t}Wf2 z?Hg*J=A5i4(KgiW>zC*B`5alJJh}by@_jS(MGDd|ZL5!GSrcLrJY=2~3Qu+ZSPHx2 z$-U0|;IwY-m-?eRJ%$Mth*P2aU%m#-v55^_s>LhpjDFyc)Oe zfiLCpcXjavlI3)d>~wn=;>dG*W~A6Na~!r5kK60*>&`5oIjl5M)(D5!U4Z!~yTZO; zXQV$KHzfO2+sF0&9`e4n{XY=@)`d&PPWa;2R=Nt{t0v0K3J~m z0rtVU1|})gat_Ttyn2>$NbQ5$A}UAgym}4D<;~cw#(DsK6KDt&pC-h_PuFTCOm5L* ztCkP-JigAK5&Lkxp705lt07gb2aIq8XQ@qdqry6)i>k0^L4X)NEuhsO{=N9y-r`~EJ*XR3|r=#^P7>cnr|lT zj1!;ld+*!%b^iF%Uk%jsN%DK<>B8 z*kerBYCaVIdz|pMCVIS|4J$(RcHF(yTsYk{Jy}2iY_S&rvSbi6{(pJ_)N{ zq-x$ew=___2Fh@W%X9IkG2N@>Ir(y3#vg05AAWf>9h2kwhbq^vnx}iE{?XMIB8AKK zqeTioHD97IXU+cW%hB_aU*qtZpDO3;X7vq)UyZV)a(K-8EcrXMKF9tQC$74B+%@|q zHNU2{pAhk-`Vq^SC-2SpR#QI;q1CG6U%9==^(3p0gEemLEe!-UAm>L({}}r@6UNln zz7v+E#EIVLo}gtt4et2ri;9YSK8@+6`$6feJz66y5BjVh1zS0T?LJJTicYJbC{XvY z^>Ivgx@a9xeXU`9S#f1)GWv^Ill?z?*8v|@vGpf3K@^chL@X~9A%LtD6%-300YXh6 zp{OWXk_}l1*=2VF3AWgySYpQ>JL*%hy${P1?6G43u_0KoW5@pe|M%XrJ9o0#1Vx`^ zXMg9;?3uYUXU?2CQ}2uuu}<%%X3#s~lQUCZ`hM|vlU~6$gWg8;PV;Ei>8<;vY5vY> zx&6~8y>#dfcRGZTzp3D_;G02jJpPU>FV4h@_X3mwHX&Ec!pdwcSY!Onvu-<#t;ffc zhmAc)M_!wAe5FaR;G02jWBhFv%`1_Bv`-yVQmy1N@g(2k(R=;AM~^;p;HYjhM_NIx zaC_n@cpDpg#<-MFe&e#VAb@51FmDOuwt`qpI=|N=DWQK;Gw8p%_4uXtt=lhcwL>EF znFjg=@1UbrEY+<{zsJrp?|3fqVLTH{NY9>H4@x9|t6DT&K5e%BXwrf~L%RR$Ol&ZJ zU6DV*M>FO)V##jp{5kn5j-_B_jC=UKp-6VfyO1QT0!aSqS~i`(MSZ(H+qUHAtAB27 zXMp+J75Njqjg38Hsc-H4MYDk%E%XMhzwZ15TQ!}Z>}!32f0y4^w}(SA^RpfDBluWO zY}fCYAIXHBA7~GzxE>(olh?ZG{9G_3_wg4Go17LrfN$G+gzcN)ZEWoM`{oCkXhMms z1Syigj%}LG-{F;=Bdtz+{CQLV2|kuH+Z88&jp^%Or32S%^lxeg{iB!ecI~?J&feD4 ze}ex*>2HP(+^FSm?KVx9&w)Se^z*7d)0C6#S6a*sPGN%Q%Ue@WVYX)7D`j#EH-B{0qCS8J$QDnPfL`3@yjp=O{ZFP8E__b_1 zjyz)hf8OQ19UupLT<#jS-Fw5~|9?0B;2+d^_qwjmgwJ9G;CzqZ5!_{jF5bf%y|Zw9 zR(64}GJ*}R-mSFc2;QV2-uzcH*AeWyHli|S$E?fM zW`o{%^PjH?Y0a?@$@Z}<+W>dZUu?UZrCnyL;CA*7S?FL(zXwc^p) z$b4r*;t-3uZzdYC;c%*jReueyNYRR0`CC42% z@7xcpZ~pn;9+1Q7LqZ`VLeZ@HVVs2*9{0culnc<-rIGE6b zLkc6-zf8=?7cm45B9IAtZpv~ZHsy)sVr>*N6HfmBpKySaSu*dgdZk+5S7rjoa-z;= zU$d~QQd6(J<6t<|hk3#6yS(zw0=jAJdX~}vZ~H1WWkRNBf-e&C7lreEp#}aThz^7b z@|9aY8;6t39v^^KHars=!!m^qt2{M!GEq%ZWDc=1n6-v}=bObJybAh1TGuO9TV426I3%Ja<` z>ssx3`J=NXeWB09i$6X~DZwEZo@{?{wl5qB1*#m(2p{N7qYwLXU|Tf1#jJdUCvBogRI?tF}+m^aS2| zZ};K5-CQc^2|XrW{F|f)TQ>p_^D3SeG^X4i8RhktRfK$*5HK9Z<6}EQQwI=vAJDgH zI>Q@+v(B23Rm68`giaH0`zqCJIxQtJ*CbEr^1dAO(PRRcZoKn(b5GlC$@>}C{>X4N zLZ6AZeU%!62C&jsoIS#B4l5%fVA&NRYulz1P?xWqer~%efm0`AYDM z)qVDxQ!$io8ll6)+rC&+$Kg&m@&_kT`MjYKp};~O5uELfcs&K)@Z3oiz6unb(1w?) z0a9-D20hg2oOi3+MX7;DO?e4Ub#bq}`&J)+$pV`Wo1PRO;iuqN&sp!x1^+? z)JL%jL3k<=SkhnL-_4JB>A(5?+4C>DKI7k##=Dl|U1j3M-`3PTI5`}K*pBxt@Rd=g z)FA^*SJwX}{BN~|FNxyWT455U@mKfLKjSXSY8hya*A_Mug8G z!tW8`-Z=d0!Olu?^Vj>mp$qm=>bsFj-8cjLWfm!Q%+*Tm^|Df%c1uzDRVnJ`FH_X5 z7qn1A%UY_*HLcWXI7j^cFSbz&PuW&=-L$_W{z@bLc;~L1``wKjI~MG-kY!K9^f^8fyoJ;rvGlVCXAc}W%7@%L>cLYV`S@3d^#*4p^K3i`4^eC(&SCmCudUv^zKEGY2 zJlAz-p)R|#cwfeOz!`71Soh!1U8Woeo?&#u^hb^!j}CjV%v)7Z#WN6TssWPkp@W+4 zC$!rCqpw?>IP)g6+y&1#bra2ZmbZN5yoxe>r~)C#M~iA3U9T)d`iwUdKs#Q!zy1Cf z13%gB4cT65g=4u3-i|f)Wcny^bnlAou|b*br`NlogPYEG@q#0l4O@LHMZq$5{!^5R z7k?{Vf5=x9{T>G+a8E9JZeV}dsRQV()#3%=e|d4RirW6saz3`te}y~iHY z{+^P}x3ZG~LmA-yK*3u`?J*%RC*T>$&pz;Qw(d>|d$LOXWyNE1?UP~{+*~)*qS$Iq z@<=!QZ}ZKz#b0baEZvRa&2U@#|M!Y_OX*04|Lbr-ueSpZPF!!*uv9hipsd9!3qN@K zV>Tc#Y#&%}1#cm>MIk|7@1UbrT)HxYL7e+3!}3rh4q^H@VN)~cYJb_N4&#D{Ts_91OYl*G97kNbvPv<@ zjP(|OLsnJeJt@B~BVv5wc)S*qDr9DGc&d7+ZTTEH)q7{wFMsU5>PHUb9~knf3!Z|v zklKUg28fo9U0__noQl~OtR*1=rmv3|n09l=2OQ6nYL2Tp9^hDjT{-ssy90Uw`T{(F z!GNIvE~I4x#sTsHnEtWWwdTV<25>rna=jFA58!FQ2Eb-OC(!EwOaKG`7XVfOJ^`dd zVNVBK2zV8+C+49l0WUf8Q8z-__eAFY4H$t8z7Mz@^HU{g!?MvS-hW%1UxY!>e9Tqd zi$Tzy7y#Xk0Z;&q+f)pEf*ABX*hQ&a40O6-fOBv+rEckov0H{x*X@P=^+2Vj?Wfe2 z!;sDh(3_*w@et_erz`c77vm$0nMW=JeJ3i_{~V?I)gk_6N`3W^Qk`E`YWyddD{Gyi zR;Q<^r3a^2<&P%Sn%}BM-bGH9Ku(aoXn&q=WYM)wx%9BSU+%c?!=7M^WoUE!B6tTK zwNQgSqeJ%a-a2jBS^JX!K{zD+wpmT5KYDfG^KS3V%ar$RI#QI07k|oWb|||@lC9Iy zTiT5D#twU8sf zVK0D0Pz#6fV`z5M{P^&vv)i>ed7DX;c^cX&cnaP^Y7cuPlNSh-d8U+?;|Pgx*c+;v z=AG+vl<_F6HqH(OD(uhrUF$$An?cW$`)pe3S#a4KcDdMkgz_PHjTFl{!B_0}da#I> z2}YFReh@5?P4yT10@+ybDE4`B2JL6*lNy8;zT}K-nlI0taQv*fZ~wV;FXW&&u-oQ^&(+NaAkJ3e*XoWri80*CnyN@jaJ1#e?x zPu5?%>WrDkb!pBEV1+L3yukD^?(~@imIGAb=u`|Xo_@Y#PO2I)POTX~^ORRUWn%=x z^f|r|yp4@L&Ga=|P*di4BTi7LTZ<2Rdq*CK4n-4Tt%IOxu+~D_!j}0GG!53e$nP;f z)*W&80H8Us)>_CD>i!%M$8wYPJkm+?tvKwz$!8NBsD{7DzZ#pk9 zK0&i?88qpZ{0ZJcN390!Cp*hI{>Yee`__{Tgw)HCbE^_}G!i)UcBQrnI{Dtzr~4e& zYxnOdCYGU1JuY|$9kpb%&D}oEB8JBrgctkrypd8*cOKl6SzgQ|Zzz*GJ?Y~T^NoqT zwC?MtMlKq{Zkc6-9>F{4sMRDrnX_l3p+j>+YTV__#<*y zJ-%svUU%Z2C!Mw9+mA>bq+hA0(oDSgH%Y&BX268N0tmn;e;IaD>A7&-X*H7kf$1*~n zi5GvJzN|o5AT-)LuOi~Eufe?7c#^Vc-fOlBbRAIhXyMvvn$JD_#P)5$)aMXp{$_KTrh*?uY>A13wbb5x{nu zd`+4y<3Kfni=5U@cFT*oPjM6EDgCQalkPa^r}0w;+Z_;*7r~pU>+&M)4VxIxqzZ2_ zgrq6?U@CS>cFf|Ye29$DJ_L{65Q5oo-v&WoA8k(n<#2!eZv`lZJ88Cz14|HGfaw4*qD>wtWg$yk(b8y`xVAZ>HX;eB>4tl~q_H@+@yz5jQ+=bk6BVD~hJ% zM$*CbjHWsF(_(VNyW@_}b@sVUNmc88->n%sHC26f*DZOe zx9w8f@{|@mnR}5N!J8auRBke{H3S1t?#L*Ho*Cr4xE?m;SReP17Vo7g>Y&?G)QI{N zRlPn%wf#OteU#Qh9XPOs>X6$)Rg||-HD|X_Gwx`iwtcyUy7{LT>d;;-)xb$DRo<~J z)l0XuRByi7Qk|RDN_86FN}YU4E0y|4EA?Kh)~er_)@sLdTB|2sZ>>(*tBtCzZlgA> zZKG26+eYyFPNimV68)o3)&+lc0&6!}WO0tdFDxT|C#k3+G(emUFz!z94zU zH3sf6>JFe@-y1LlFdRU6$8@{Z52%8D7J$0^A;8;!ZIPWJfHD9#-(icX%7NbhH=rBZ zftvthq1fAin706LgP@M+SIoyGPzMn6#db&&#H>I?Ay1}sQR-MMc+BW#^Rcn|xHHlo z4dA%oRKUf6PDpDx;-850`Xc>1fV&C6wuyC?x(i81`?U!2s|>Q3GzJIs_G!rxvHCz> znf>0)s4uUy$-1J`JEuOdE6SNh>Vx2IZ0zZ-57uT;&nR?a@I|3MV$8w>euQtu)8BVt zNVXasjYEEI!NhQkk@1aM!^|udxB>?@qyptX)zT(nrc9{dTWhgI{8WV5( zy5}3Rt^KZ1{b_w_>Mi4poX47O8c|VFf;-K@q2tImnZM>IN>F#!oI1rC-cgfC%;V`WzRP#$ zC;r6s1c;$OSxlU}}0h-VtZ#|!&waa?m3Lmo3PH2rO> z!ISMM*X5Ju&&vV5UT^dzuGdRZ?{~i7@NG_=`Snt>UJKsLX*27!bq20pv6J=M=47&7 zn-Z1$-y9C;^}4zwalK}In=d%!%03q@E0VaSKVjmX%&ahnryk>+O?{=(hg+3Hz>D>}T52j}W}jBX$D1EFEJXY3=lVisO$H zrTu2zV>^c-l+|W)oX9aE=jrwY>;o7JAYm5(UIg^R%S!==qVX<31j`Y@GDL6`#&`1( z0ghf)EwR6ATrbQEVlUTM zr~$9GQwzS`US0TfsybxH-PD>VdaI*m4^<1l&Q%v5I$tfktxi4r#M|oa4@RVrkByBJ zL1MFw^glR86oVmyHD>Gx`#OwQ*~a$)3EW_d_>%%6Mpt zKb%%S3BwUJ9B?UsV{^u16+CQ~%iqoD^|Ww~yPgVvYB4Es|KR@TX28Go@LSv0Pq?CE zUkW0O)Ca-a*w~Z%R`gqt>>hp&zT_$Mg`;Pe=Z5&LSICPissiQK%Pdd5UwtPF17;`4 zaUxR*PZ`HlmbvS88laylT8SWas}@5!%q8ry3{i)X%1 zW2>N4I)HL2c;a-!dS`z}9sR1+7TV|rX?qF#_mo?mp2pnF4Rvk@0QC(aX<{6xhEwEZ znI+9Qsfj3^7t%J(nw zjT?b*x}2_^pIA-XI&N~ zmXk`z(HRde?SK5LqTO!%)aEkVVd@jXn+e$cv+@4&xlR*oH*>#QF3k9U>woGU_TQSL zdwy$Lf2H@UL9DcM^;He!q8R>i?&T85P3h2QA6x(ErAK5e!Ga|W{V5lMw~*R{`oq3Z z$Nr!rWNo!62#mreoKl4QBfh8C$Z6Cmx`g9Y-N=9HB!cLxws2Et(VsxMqKq*fiA!vt zES$t8|7i=3VI?lX%YTVeZ2C*w3?uInuNw)YuW*CTOP(rpf!rZp%@XIW+)$oWjN`}x*NNj61N_g-Y;2l zv|F!Kf4ZO5f3C%%+3c~84cH7iZ|wW|rS~oT<<+B|5C0h_=@h&kH{A{CR{JC zRtzF1f;So4P);UzEA2xc@kMu81EDeHr9UEMS<ZalQ;s)cp3!bQT)lp zOLOs`av^${@8}@l}Lzr%y>MipZ+q;FcycMEf zs84kLLR}$gMI+T5dOv*ViEjFf5sqqW^C+bvhaT{~s!mly4jTCA>Fq`w&}M%-k~9pY zNx$H=s4Ztc&Q5Z!N7la|X>flb$9>}g8#>}VMF?3>xVe{%GDx|mKE!f`rT3(tBl?Vd zCQvr13q@wd79GjGb;Jo?WSRbaUpEqlIEIt|rXBAc(m*5i$^MsoCOPoiIZ%Trq? z#QEyUFGcmY-`*;Ahv8&xsF{=UJ08T&!&VaK07_b_Id;mfQfQUOm1h$x~ z%Rt1xpj&nU%dSKt`7{*E1K3D(3D~lDFQkD*RPqn1j9aIE*Lec+h55e~P>OtDo4xXY z?k<2Ak(VccTL(YpKNm0%z;>TJq^=@w1;}gRGx?9#U4W=9-9e@}6bQ=UQ1<=No=nI8<-i{S;P|ZzfNcod0?HHRD4wju!y#zW zG{J#t_>271)Vk$o__*=b{PgBUJE)@G?>;~M%v4ph?DdSkFLye5(O|apC^rE0jo>Y$ z_TcwV*5-IjEzR|yw>F|8T%}3KpJo19Bl!u4x%>CJC?zQ>pw~JU!Ekk|J z-lU1QeKDrNc*>f;vA4S6UY9_*&-xmQXK3VC%t9A|VTVEhsWhAc@?$;+%w7f70#>d2H>}b9G75Nq|yQ10NnvS z06hU1Dp}_o_J*AS=mY2r=m*#fz%dHjn7si5035e)JUSS#4`5%wet;o>p#V-H9RL^x z;P~$#0ES@d5WsLiCSU|03y=*M2^a+!4afnE0gMHV1B?eu089i>ljZ>?0VV_T0R@05 zfT;j}3N#&XDBv&v3v&j5ZRC*v7IY!N3z!8c0u%#$fD*uLKq11tyJ1GpD( zAK-q#e*q5wRsdE49t1oDco^^q;8DP1fX4y#05p@wkq^?|=3SJEf41DThMk8O2f<#2 zdi~MpBYs$RL8^Ls|FK_HbY6DZ$tSF1(C9c&@D@^gM0@qxIZ`~=qaeWV)SOKP2)`a+ z)?d=l2CxmFEnr)~c7PoKodBHyy8^laG5`Ys!vHw|$|&WFvcNJTkKP8Prr2kKo)7y& zz~mOlAHd%d^|Te*G$gtc5-micpCi$=NVM1Xa3fJ1L!jpG3_0Bm^4A@6Abn6?U{K^B z$k$lZg~K2}5aO31Y^hh-{3DN%?C&}s!uWNAtXMjWb#xEp@jJl1K(<2uK1E)S0r1;q z%2F6G2|&K>1?U3k2I%OxcY;mee?kWUdA}o|7vS$=YLOAC2h|rRt_SN;PmVmHYS!T| zr1q|9!&(@t2ZFbd+9N?dux}ET`9bHM#>OdHl)u>tF|gXTJlLNDaHNGQ0dgbLEF?AM?EP`Rp4DEf&Z)SMVlZ;>iofE;5;1Z0k_;j;w>Eaq%8>Dz#}-a)Y9@ z`sdW8)TzY)>cULuhkTU#(Xer)miiF*CjeAlM*)0*BETHL6u?lxo&c6B%bP&mkmk6l zBlv$80K-rY_@6ezl4H~-@-E*aO_Uqje4o0W;r9UiT}&M^B673&^2Bm8{jyZ`#er9c zQjQ$C;?o}{SS%2^5xmKl=E+UAFNn)nuq=ur3d4c21-@cwiB0(_MWH>3L>2)u0ch&1 zJ}=9ZWyHEqVELs3*e0+Y=?xeJ7z-E;m;|7nITXM+7>>Db2VfbqtSOJg(QV2BWrBFx zlD5bm!}2}$6LcA4SctSGgRuSS3l^C^5mSmLkD9p~m_+iTo>qzsUkvhQXs z=z6o;=7Ot#{%J8~goc`jd=$Ke)E+t?8=n8EiGp=HNsNyJ5Qol37MrB0MIUwQ@;v;y zm_DRDo9k0`$Yl1zvw5vq`S8$l4M|u12uR`y{o$^CO7Oe@Vo0`*!7U7=i9%uQ}BjVHFMmeafe;% zJwD$N#$Dl0`4>F?x{OutoRM89yCm$fFKWoI2wOcb>wX-*z;CTdhdysf8mMmBmth~7 z)N!r@YT4=w_kfM52WyUSDC|tYc))Z(34r6Y(*aij?gP9E_!*Faw78yC3wQyr2lBEI zunsU4mHsUN+u$rH(R4Jf-O$jEhyGfM#`Yj|($dg)4@IZzKM>~2(c$|E9lwvjh-1?+ zhq5PRaxb*ygE4M|QkpRmb5!W?Z8`#N#ysdL3?w?8kNK8=W4^5(RFtF zc;Do0)p;$qQ@KBEug)Ba?@2%Fq*k@-tlqe87nSwO?&_)gyQ|!J8Opoe-YV_E{nUo# zhp0O<#;R@;r>Zra6-U$JwsbkX8?Tx5Hx^UFIxOQBwz<;& zN<9)=f4?y|!wN7AgU)f(~x}4WzznXJ<90SR`Fy{MQVf|XsYVb$ePxU{3Lcd*3F5J$JdpsE8f;TB?C?Dphm$~IUXFlSy-!$dLj8B&b)6e`ba+3(J zhoSDEZlPYGVV$F47~(`;iKC%z`KOs`WLWgcD##0YlL??L{E_)!pj2My61D8Od#Hjf z!*C33;w>~DmLB75e{o>8Jr(8|xd1ch;$IDiq@Q3inkwq*pW21xp=jP#`)%E7*$yM}G|9^?Gn)9Jm)r~BHQKk(nyS8W>L8I~qa`m8Vk z-o-^z4UqKn?sexsUiw2b)}P*?*Uk^|T^dQ>#M{1!(ziLlc2Lq^+l=&o*#EGh`z|VC z(`^|^-^7c5mhrt!?pi+8VWn{~CMC-uX`i$D32ja50%nDUYUE{ZF|>Kwkrp^Q$* zMc35|Q`M*g_Q+OeJ|Xc-`X*ldb9~+)P8urlm+>-^G3CxJAULhUJFCoB?3w6` zEDVI^=KDem{6%O}mf%H^*CoxMr_H1TzMk~M&=IUlG_+Ij6ugDh9trPN&I;g^&GJZA zslTk)}%3+exCg@!Q0r_ zbK<0tp2-CTp4?esu)@A`I#3ZJODt1}C)1aH*^f5b+T+V4oMbGUZuYIW#OQqQxT0w} z=y~;yi*8xI?J7ybPCrGNc=4C~;Y!p9B!R^cE)9UqR%bLA2t_=jyk%vxaOGn@@7fNt zGYX^AwX_*@^*-a^qC-!9X|Vmatns%}CSLp-rE6q)aX|o&_++{Cdi{fm>uttL?DrXT z>-j$(_UVW|wgR!nGL#3w3q4{BUAg5WvkJIaSrM^>Lj3E%a9th*-&|Yz@9Z;Cep>;E zV_#onDcT4Cmo!_(0lmH3^l)PN$a^SN-TYa<%9n%ZKDNT?#P&mSln=q1sZ&0pRmV~s z@daf|<%BZ8J~i80%0x%UhSgxqM_khUHV)L`b!k@yJeF8aY9GP*1!c!>ICW*qv#j<8 z@3O2YCxXXcmqGjLLDwS^@)t#XxEL%j*YBI)Eyv9ILcu(Gv`pH2)h8=>4~qkRPg#OaRMmY3&AX30~+C+pb8SQT|Xk!V8hA@_mso_~eiHaURhktL>K0QBfhi#Z~xH20cCB zqzYfi?+bJOmPT(kYCvaG<@wQ$H+xU4Pvw=!mZ6=3QWv~~j#@0wNfrL0eDtvRMgAz9 z#8zsT>X@)~bdnuZFUQI!-2Gj4Vf1lQI{YV|f70Z4Kd7zxhzbd2Fc?O?BzPMedyap$1daxNf!QotOoc<9JR z+}yesGgq~i10R-wJPr1qnehJU?Q=3NeQ z9{l^C^=6x;@ASEz>(4Yizm0lD@HRH~%*-2utDFP8+C0;m9>c^cm*-tL`>tmkQ&$w2 z=d<4(4oh#3h^6d^!M5LoM$cF2i;44<0e{a?=WYMi39F~haANg2`4YUDSfly!6^-&? zS;>_@EoZ|Kk)AK+DP4=aseI|}z$PPK9E`9YubqJX+E2X7?FMS>!UrB}x#8f?=%%q* zn9=}m`(kgje_pW6XZLI}gFy_f%ftRKW|yr`^QAHv8iX+-^Vr%bTFM>zctSHWZ@DKTqMGgTPO>IrrG?+!PGPMctT=J z+W%_~=<>4u6}P;oQ_pLOB2@LWagMmlX_*2RRoXM8W@R>VI-X1uITs%FE;gaXPCNG$0yy5b3h+Q zl)mkj53@fubbYGw=Pp|`eCN9_5PdH4A$T(-w|tDO^c7Xe{+%ZKVWQV5it+S1bubOf zUCLf$$;9)&X+*CRFYhJwy2+*F|34!K^l?8Us9CYH`-`5I9|U@i|$Y16dfVNnEwTzw38h8y*Z%IORj99{*snu z%U^hEe!>4;)4>s1TDzjv6TC@p-1-ZoJ`aNPS3)?U4LfVFlI{&vF%Dg?R~UZu zt>^T3^@15=H}MaQ&?R^q8+$f~u7XfSI8qRp>%;B`y?@g7Md6Vj9EKUypli=+4Q+vPR#M=O32YY&wPIP%!&7agRS6 zD0#e`)bl0>lmC+(Xq*FjKepzJ#Pyf4bbclL{GpE=b$MH7@`n1hJ2bH1&6MKy7aNR2 z8`fmK{pt9no36qS?ehkLr?*od?fvjaOw;?=jLfsER@|TK5J0**fiA&2=%{6;Xk9lR z-7f3P9^r(ngB_iJ1s#kx6F{4L`nYDXYB0`b&)rZ6r&`qE+FLHmyZ2(cY1sboY2qz3 z9$X(cY2ls&Y;3l^avoV3^y{5`Y}NIQ421$ACxS}YLSOyYiTRZA6~6P>t+wqioet?& z?YvL=*uNIMgN|Cxj4&5*T->Px0~%|Wqc1npL0*c{-GWQnTh4)MydrY3@!Q05k@HQe zy5r$B_l#{f{Xd&+fwkn8av^w=0!=PPlyUQJac((J0+n!EQ$8e4v6~|!%?Ts%{S$4M ze*HeNd;~YAs&>BOFNgj6lljiJi>Q1E-sGVsAGyJ>BO=)qJ{<2{7MSHN%MIFZm~yf; z%WZ4MW#;dn@?V#e`k&l#V)pNsK#oSVIP$wQe(1jbHito6BcvV?yva9r|3123K%YXg zUP;uiXF1DyqocmeWVYykQf{`0UCF?ILJsKlcGEBJdTY+#UTXJsjIASvKB1a@+P*m-scL0LsoWh%ZWKpk<&g+oj>UId7hm; zPm6vRIT5@`fm=@8{a8b4tXJddd3xyb@mut}(8u_adS1AZwEwCc(EE)YcSu}+na49; zF8}U;&nh;(=nM>54|<_?3Et!b>u=NhVH?(Dz5Q8Y&=qeT@|-by&b|J+JzC1Q4Wz3* z=n}k1myu#)%aE>f2nTd@^T%ulnZ|$Dta#jWty8` zJg1rqRcq5*s0%*zEXdgr{f1qqZ}VfX;ZJ8e1hCg{^&1?#gN|BUx8=E1`BhsEkE zVsKESzpNtUvyV(L^*>+K^Bj!`4wj98;Q3#S?iO6qPIBPy#DQvLM(S%um&EmTGwSmd z@3-rE@mTO>C_{4I(*XE?aO1N}4{UjLZI+Yrg(x`IKfycbs73k6EQ|O;<<`lN&iVMf zHz0O6CIb%#==Cul@k$!>Z^|q~0LjP7Jz{cBx!MR}<9Ugt)0MiWe#~*{yQir~zTH0j zQ)EOGn56ch#R^Cj~FfwJ-bdH%>`9MKw>=NyY_pJR=KQgIwfMb5w6 z^@3%=x*_L=GWE!ThxFU#pck&bjfDn7I|Wa{+t}Ds^k#N>*g1=st};KbZSV%YvvAKu zgdgJRbf_L~xi-h2t3c{ zkC3-Ktex{{_G^3Lb&*lVV7>qtlVoGcg?<;eSN&v2ULH?aZnIC!xJyQ-26v z(idCkFwZ~sj1B~5m-&dcf)2&gZ13p7b}W&phNraa^`MWuBOe$PLRS6F}SScQe&z#?5*B z@=D)2x@mTBo+jQxz&yz+6a2@F57$OlRw^dr&(k$jL<818ykC?^hPV3QPs?TQ7i_#ETvA-reX4Q zvy24?r-i4VLmp8LOjG_1UPvO69Qc!Qpc?c<+w;8>*V`qi*SDY3xp(HpS)*kt)>cIWgel7t06|4wNmh zrYh(W!jwgM#JQoh4(aOs2c{==nzppLbW7itZXNJ9Y9xFVk#zhf4lKpnqW=r`Ni0t* zA#ZEOkG^8s!C&5z!2*I2c@n&hjXi&(JY^Oahpan0E|Lexn>s=G;Hy zTn;exk)D<*FY>=F0y(5cbr#jH9`z0O^GX0gF(uZdqcjGS7PotfJ z)l|VVjBb7ne{mmOn71u6o;pC3z9H`NZwEhX%;?->tl;0iDD9x|iOc`nAAU5VM+9$U zW6xhhALeK#7X^wf`U(-1UhW+4iLuA-^6%H#)p$+v-*K2*kDBA(^~itM$Ih7g)d45_ zHaN-2cbS4WsgV3TZLKltZP<_2-`8bSWLR+2lcp{dKRpi9E%BK6ec=ZuWu^dG%Qy>O}vH1!=%gM%s5}w1b-N}j24x;SD17@wLPS1xygNf z*z(ZPyA()z>@)Cmc@r=GLQhtxDi{ek3-$IT!g+yUMH%*$6^{x9=4E-y1LgiAZ<)QS z?~ zW10 zor+6sePpS9>9Dm|LYrIUyLBj7oxjwvlBUF+wEuS;s7BJ#z6{SwEXQ5o-}Rw$M}&O+ zF1^Dcc@WB%^-=Iz~D)C3?+ypwPFERnNO}()k{!d=> z^N*dMI^wMU@TZ|oIt6bbwTIA|gB@()Qtw=!b@+8d{lI!FpuOI}Sp$sFTbb>qmut%$ z56V7XzP#(*r$8K5(AM59NdEv8tVI;%pbX1Ra z>xF-#^D>BmMy9Fz-kW^idf1&md!@X1hVS(?i|C=02SC0F-a={*p+od-zOTI4p~1h% zCl{qFwI1(~ABT7U@P2unS)?wI_K|%l;Z0k(W!%a&PwEZwo!@`))E(}_MRSU~+m%WO z^aS()>FAsG%S4Wb6QR$XY|(Fh`5cuEKPkF5RejNV?? zj&;|AWymn=LC2glHR-&ae%S>3)$9dVKGf;U%e+U}tmq4i^+50@gUotR5D4VY^Olu4 zZ8fSz#I6?3i|b+kmioXx3dcYl0i6KM5vF%kR{*~O=myvmK)MG2_5&OQ7zvmNm<}ig z=yl>+{J$6QBH%N?4iJ*TfEj?(0S^Ga0}O)@o&tCcFbwr!DWE5KNIw2i^#SBH+px}n zG?$_NrG7E-5{U2UhP?he8NEKN9Ph3VW`8k#T$-AH`i-Z)yKaFGAf0EDt83*)!#Kws+dEvaWtb1Zx zks7-4#V>Ovq^Ya!4YX*t`ifVx*r32rH&I>$Zy~h@gA`mYXN zd-Eux{tDjAn5F0AR#rRYuc@z6$HbO2`Co9REnyPb$@-dzJ4wGk0|)f>b|dO5Wi~Sb zVIz;fsOYvS{T`n(=g!AjW&1l7W0Zq8UuAuD=63A4UQd3oxQd^4mX!F5GRw;YxRe~T zPx4+m9Mm8DKBVomG$rYc?)+#9`&_zzhUS0L6DwPg6x}~Z^Pl?h!!0@Iqx+X?{^e~u zwP}wCbpIO7zw4W~wPD+>^K1C@CgwZg|G;OxhK#)P(w4#}&JnR6D|kfdGL7&H+xz3Q zECX-r;~vg)Nm_cu`uu+7VQ#%_j@QksRpIEqFa{x=A-T8RkbY zqd#vHzI4Q?0G`}(`#&datFkbiF$>d+xIo3rPcbc1hj?}R_r(8>@Sz-HS|Dlu#~i3e z`qG}~9qyiomO0jpNQ!#0{fVnLL#__G=Cc-0)n(nXD?MQjcH~CzHa7O8+{pLrzPwN% z5-19kO$mEv`|L2BXVT?^^HwtUlD;%;B%|bv1vr~DH3%X38ZaYqzSbh&hoAh=u^XN^ z)6acyG_r4A@HRH~Y&>7CWnXI^P0t_4!;(LVjd`OH+y0mMSq*Q=U;Pp8{0)a+CSV!z z{ZY>iC&8(fn z;QVGU02fuMNBaOc-`Nka7ob1D1K^s#0Kh;1=XnPM_5pC6fb*h507C)$0}cQT191I- z^Q8v^4gm}YKF;i%iG9$3cor@Rxy4^CHn{GT*72lW2OD##CcmI)Bvk)N`kXbJqcz5J#RgPS|g zJl=jiDnEjE&{3-q`I(4QejgU8dfAxK^HJz^=Yw)a8PWH< zth{DycyQb0S*CsxyqQiT`LOGOvnzd+cb>n@>51s{)D|VKmzzNEk^2sMue#&WeIH{+ zVVG~$OTpXN*s~FO>^^a<E(dv3kgq$a;tU{2Q%@jp3voa(z_l zA#n^(n?`@v#w4HQz!HGy@p@lkdC4eFQ`0(}w4(KbsclSo5xmLOEtD6}n7jpSl9F;` zGV)LMU)M96XD61M=_P4ukLOyvQTadoiBWz zohz8hU^eAN@HRH~%;&KeI2s9^c>e;l?~ot%9W#rHuqV%xRq896tL>hR={@NmvX8wd zfc?AXm=3>FgQDx><=_+P$pkPty4k0Y^A_M#FV}v1^3E#^r(9ll7Q}7m2 zd$7Li`>$h*Sk{?v*g>1`D=Tr&Tde{eG{PVAJU9BCe$OX&oImohSLvo1XqDT*6ccaz z#`crRJ}#V7ZJmGRY~~7&@Ri{5TxURzNd+%TV-2FXI9xd}V)KQcd!MkI(w%=9MW?FqNAzc9 zz^y+y7HSJ91hW=wJKz>L)dg!$x@)(6?!Tmve_&WXZSWMlh14FRC$d8U9x7>XGs1Lr z*jbX$`K5yH^hvKi-e$Df+kMhv!r9$~3%q(qzF@d&3BE{apcpUdbab5W z*4x8J>|o80t-{3E4^vmpXBxwAKWgT{4%SQ6{1r+Ew9d@%Rzq=(bgn;AQu=DG2{cltSLu%1${2wqFt za$0&tQ_M3l@hsbP7{FZjXZ@ql>GhD|;u*UPY#zk(PvVjs_`7jH*IR3wsISa>|I;eo zdUV&xtMt0U_C)X|e;U-+QT|XkV%A!BKdEj}V!aVui1Tp1OkdC z_H3*_Vtq$soh6O_U9r{OtKy`HyctiQu)o1JpGNp#|8qaZPi(hu@?Vkze?JZ^MV6%h zQF(0QdYp4qnmVK4;@4WXKlWYjA);YB&GujL7E*g`X+3Ui{A1Q@NkZzX*n&^mNe=vz zIiSyD3_l@pz3zBinwsNZ@nhe%g{N?yfQI9G)@#9ANbT_}>vehLWv%yrncJW&BlX#D;KiTy*tHH39jn{dw#Xtv)6{~8+dWo&kS9aF_hTH?H-g7smoe!aSzg2w zNU$V2G91BSX#OyU1KL2K4vK~J%6gad55$(p`9GfSA)fPd1o4M6X|@svba`0?c_EK8 z0a701yR7>yh5ucB#{6gb5yw824m{0S0LqKtEu{7^%L|qORXV^lI^C+qE$0o^zfMV0q2oI(Zryg!i?2Bo`TvIqNw?t5_)WTv^)Fl& zwa^p-VO!2Jq>-|u&G7=uRQ%xl zM;KjRY9TMoe=x?6rtJ)Ln{ntEc~^<8Rr9KV8R0?=@8FXdP87E*f{^vDOj z&T&!pp(WNP7H!WlU#~;_di~R)bU7U|qB>dr(_!JE_>a%0`w&2z-i|KJ(dyg#QPfK3u5{?NSGUWxc}BQn7>#4Wby zDfurp@j96FCIA0A4%FZ^)@$|)Yaln|aVCI#r(195@mGb%9h1LcW0j?=_}}io?$7{F zKN?eRVzMzN$m3r5u>N@#^xl3Ke>-j1ia|18E%GaPJJ#4!=*YyG zObg^-G~~k6Ys@qAPQ5Sge`32B=_7u5r_E$yQL+w)z*Owfoyf7vwDJxQOi%l7#k^i&_$##%j+4@Fr2TRXwdOUvX zDK|eidGS%NwQDu23#nnfr@76++y7!u%8UEETaL~fes}9W^;4;IL_z&#-G2y zuW!XPb-L5fYg!Lywfo}w7YpXUAoS8s0ri5%Uzcfw?s(t7x=7dChnx!%*T1Epd-l@d zr{4N@-vfp_0x$JX@Ghe8$Ebgv=mtWkFCmi#b%?Jy{ZENsbhrE`IWoqPIw^ih`?qsI z*VF34#PYiqa@1|fNvDk&_~{!mPUSa#9JdJGq{x($SU+MEE=Nd?830{g zxB*boqQ4lO?&VF;T?_v;oesUvbJlscNnAp=;3ZzMO}d@=jkq-Po#xW5>x)fG64%ST zi_%nZ^i|IfOr6}D_eax6y%fBSjXh1e*}=E^`qtS#jaJhJ{i#@t@m*3E9kQUq?6xu4 zKE~(QZ^c$4f@nYcV)uLp`?=)1d>_V>Pey_C5C=d%h|T>MiF5PFwg;-;6hbOdDJTS4!d9v`H`fAQ+p`7eBR{VzGd z(+ItSx3RHjBlJdhs)~M)d1`r6=;nXfgsI~s+}5^*9*)<7m%903mfvvr?|$x^RXe_# zcf8ay+SIdxH|cAHA6EIrTl*h?2=wyQ>#-R(|LgSEUgoCXEKddh2RoKs*)@FhV9s08 z2>pV$v9V_(^xNebCj&x{S-z4F#;m(zDg8dK8bmAdo^!dIKW6!Mf&Z(=thsCPl#csw z4w#1Xk}O}rTS)EE2!HhQwL+WaDzYu*phampb-D|$aMNv;>nhOQr|V&dcSM8`L?G+i0CiD zoAjA{v3K0zWAZ?Wwc2L(o7o4JHdb^(WAfb?-lQS<|JQRsuQyAtPAng7uS!!h?tS8! zu|MRtZR;c{`cUvDB~8eOXSQ|yIof;_wywwZctj4w*8P(1KZXOM*Vyh4y~Zsk4dzEd z(p{(ax*&gZyU+J=$fKQt6+^+BRGV^Qf3P#!8530; z6#^QQUzsD3$VuCl8a=c{svaL?cDR(8}1lhBL>bU>A?px1-#@g%Nz6-;X`L0-~*$N zOKWaOOxH%xz0z+Pq zP?0^F;QhdypA)>qD>moncpNwv#R~$~p*bU}BEAOeo?V<5%rOf8bIi)IEB6o3=F$#v zgb4tClh++E0MHe{Gi3Qa7WZaIIKG!O&F4Thf{I)eu5|A!Ay2uVArA+*zwpp=d!)nv zvbKFQFB$*UdCve(GtrR?!Q0r_lXAh`qqqkcpDYK8v9`zqUY*q}rG_J@J}>(|{!BO!ZwBb5`O$frcngik#7QGPlM4zwBSWD; z$TKF){dV-z)7|t?tUfVa^Sg<>2h-G!H$Pq#xVLMlj4#8GudGjkw~*Syoi461z-?0t ze5yfx(q4({Bo9cFK-@r%e`9`0eDgV=%SGEq6U#;E!`MGqGi z;LViXa*;U;Uk6q|%{Gt=mUkkTAyX61eXmX&Q2% z1}M?910GK-7qyU^mg=dudTclIQEVu%OeP9|av^vJ9knPI*%cw{PCCy-+<8(`WiQi* zWoL&Sv<~s;`t~6Fmokn<_A4BSCTX?;2bLiYk(25t+;U>>gINzbdivYdMaK-kcE&f( zriQMLoCw||iS04&o6Zju&Gkk2f#`VuJbz@ex4bwo&%ekPAM2oaKhGBNO!k%GOktmO z;2_T#E(lC1FY?mmL~P0vWr?yNx`llR{XhLL2kh>I;rFFHYbh0wG+Unoy54E~q+6cM zehO1By>9l67w!1Xc%h`ks@NqdCSLsG=$*+v*KJ+4r0DHp`qPQ&s0N*9=J}_rTl2;> zuU$?_LVwVaYr#wUV$1l0_qr9}Zq732EF4olIaUzav}2CnH?p!VkvleV1imM7&ixyd zakhPI3%dg{0o-@J3xEd^vEA$lU|6=53@v|{_6F|`3GfmTe7t7Li5bt9{AU>vSjGez zkry2=Whvq9koHsj1Sj#x|9_fYjSNe>Sh^~)oYX^(d`C|_c1YQZ7au;&=A7IoBY2a4 ziR6S~P5EG5mU7d}N_U%S$bWf{l!;t0KDra>5z2aV^a%Bf7^d}4&?9>LQuv}mfHie%zt$%IDM6>kkFSPEGy(;5`npxh3-$f*1aYt;+`|wy?ddoagzkM*zxY zWBV6buGH=PhK+MoR9n2~vo~NUAP*1*TnG3BP=Es42)G}@@i7Xn4&?0!p*RPfqzh5_ zPoOc`tvmKH4nQ2El)AK7snNA~=UJuh$w*PB-k72enbkt|n%h#ff4`MlyUjML=T6(I ziz+&(Irpcj75DG1j=Zj~IyU1V_2OOAl=tyt)boXRse5l}k+SLAP|Bq$tp)i7m3kb= zX(0F59@nU0KhCagvARL-5=Wc<xATBbeyL>eY$mem&~N zD_{0oH^0Z1Yd>4u-zqARd%>HjHjsN6PC7Gqrd~`W9}+ip5)I3rau82P@q2RipZWsQ z0eb^v-?oIO&HfzIWIW6eaboC4nWG_If8Rp>10L1LqsT|y%ZcSftw~dpFPU&}_UyAy z?Up^Q*>@D6LEmM$OBaT(^Ptjl2H$cI@*jEH4pn#OR% zlQNq+TMj5o1hzrl0le3m?JxBUWrz3EqG`3lu&tIhi*a%MMI3={G4!L1={Wkuql@^z zs;L3tqCYmi=9Uk$UzPJ}nwpyXX6DFeSMA*Xiwvs>L_P#>@WZNqMlHQD<){6Rvil)Jz+~zX!JA2Cdn4W{n22-})1Jsgk^mgCWIi^Ua6HR z_||AZPKAJ6h5JgM$iN!nK3EUUQYtb{sYioK%{fP@6Yf*$$Avce0Yg-E z-_fe#k;7GwDGMyVfhBSK;UGJz=cEtC3P(Kkl4;nVV%ymlK>1DwbO*3M&iBR0`?P69 z?&+3rk`8e+49jrT-C~F%$UDSKoOJ))42ED)`LBG_y^ijKUkPAo-xO7I=q)Rlci-e& zBPR{~_(r;EDF1w#cw%X&C#OsvKR&=uFEMcy2nIr&q0cR`?j{X8pRbOnnh==71?p;m z)W;9nBT8%2EBXVy`jg&)3XA#`?K}4>0x~oyoJ;ruKLKauvQlttPTn3{XXs0 zxK7eV`JrryA&&pqcGFFun{6&-d>o($fQEh-0w`}H|9V_NCymB|C2)&;ta{rmA7;OA zz*}kR`>gLXwtKQwPW$6*uJT@8%7@^!s4XYtmG?2{-|Jvdk`*xC(^n=9H zdT&eR#!OfLFET@lMHVO<#M36E0}clC2CxqR^=^$PsVha+SR)vgaZvWy7bMs<1r8XA zlm5CP{_kY!kQtGij_)Owo8UWX>ilz#`trGhcG&3*G8abX>jiIPW6xh9H=Z%s<3~yi zf0X>NTy zk9RO~u#L^Hlm>Y5r<_z}uf2z#ta}L_D3@s{r{OTVmE(L>6a3+M-bhiY9ee;R@Fb(3q)& zhwv@DQ{U>fYHv4-SAE&7Y-aYi##a;JI=iUVx z(nEbGcnhgL$d~*$^mu3E=ILyIc&-OmaeIp~is!sA`+c5~^Ma8oi6WjJqa zCuBvX*ZWP)pzrlp&RBNrCF_<89n_=LrY2tevjTy+e#oqS?Ut`Nv%EO3%wnIm@ zw zgu0OPI$T5P2;i8AYi*bgv-bY7FVDGi>Iio4IiF7b&Gl`r&v1_)^Mz?Ml@90zfa^))c3Frmj*sBkqAAm}kYki!rf_hZ@0)_zg2Mh!78<0Z)nSgA-Xuw#&1VA1jA21bg zC}0Ml5I~-@86#(cfCzw!=UBjr0Lsppfb#$s1Fi&I2e=u)`NDeuD*^R@Re-gC^?(lm zUjVpgyA7Dz5wI(u7hn+JU;yubnFc5ZgaF3_C zJpk(80RZaYK>+IEeE`(O`vItrhXVeey*mM{qbmD9e$y7HtYt~5h!8-eY@zHG5F5JC zLYL4KC<4-u+%|zU30a_J(Xd(pp~zN6F^E7}l(H!ZLP1d$k-mahMWBK}QGtRY1zzF* zduHajIWtLaQvQIx@;&XDnVi|qeCEuVeeUNJ_fp(P(XOG5Qru6`>g92Y;}xxLo~URm z!|La$iqjOWj-IagMMbNpzoa-r@n}Wcqt_`KZlmIHidJWzpm?IrZ%NxJ>Iiay$ryogPG+c+G&%Yy>znwdmU9m>A?8^?+dC>9uF4Lg7 zzn*^n;ZL41XlSm}{)*@SY0bZo9w!%?UGvumGso38XoEdbXB?J|Xqb6w`urEZonHRz zeUQO#ZIpX{>KER9?YOVyH@1SHu)6^4yvNhy)UIaN{3kaZV&`D-_W~#CaIrml88#WT zQ`510`1!LX+xBDmvu$BRMLRdOGMEjv4lEKrJb|#BEcxH!PGs;O;^WXP(hi2{dN$0=P^|)=ngB53JBR+o35kII@|8xJc z=jNyFcJVrgCmXQWC!VgsQ=zMzjMY!>%$=G)CLdkiv8!9{Dj&8F&DJAZCeyY$WK~0W zJT>y&^zv90I7rd2FWR(QHr(gQ;|4tZfOT7lXI;`QJ?^VxfWrPTRX>iYZ_#o!wagve zlGkBX{0&t-%~4ygpWU|W^PQT2J1@=TYc=&-T`|0V_~vOB?mYjF(sm_B!Sj_(_x`=) zYihnxzZ*NH#hxoEWUEq_*&20utFgMdwXP}NuXJicp1(QorQLeU-}T@4O8e8_IR15? zzvnNT?)~3K{tnQQX=8HwpZZSpq7pk(?>gSd?)Qi2uH4>V{Oqlp9zT7DHEo3}*!jQh z_dGpH3>tnN)ZVw6r0XDRA6i}CW(NU>*0Pf%Lb;)P4;+c)PU05wHFNkpS^#! z<656h#Oy%X%8jRIA$uv;UB^pNX^MWmIU2Q7D>z%7BK5)mU*3Xs~PtRtnALT{IO_@TYiBN8`lK)wMhv(rV2B*tScKk5jvvUFD*pwl@0EL3MO|J*}zd^09@c*W0@6nkro%l|YAP$ncc70v$l4%z>b&g!kr(N*tYM- zCYI*shF+Ge8ngaMb(XX8Yuz@SP3IGeHlC&1I5w;WA3pvoT~B%1$GP31h4=C?f8FBc zV};7kzh3|2q>b-CQPw&p7>=q4VNt++bAt8 z7q%`vShw#ttlOjSH>_=GUY2a#+uzpqZgm#Mvu;9hfraYrLtpj&9_3) z*T2;Z^OgO(cHPl#d*rI$8Zr9oH~sw%uP1D{fg0M=ZJ03hl23hTPT!8QOE7xHpslH< zsUgUpjo+#0e$7Mr_Is#l_}#BBIBZiJ*MjBCn%VRyS&d%u6<5YqImeRS=*I6FPoYyS z&)<;s`_A8ehrIgm-HE6+52yd1mLq-ygleJk8R#$3-ePR>mt7Z5?IH`#kmE_QErN{mUa>IdB8@ zx8UX7)8o{xrj?uUIqQm=ntXHHXnP=PN=yB$db@vYVYp&gPHeyH^RWIN!s}mkrN#3* zO8u|8>$LA&bH~z~eOjJhPxtA1+w$A>9#@jv@zM1z|FXiAMyuzN`mDeC?$8X}dEUn9 z?K6AbZn^S({yLBTe&|nTuaO)U7o0ua^Xu)b^W^r~c48fGow_fP-41O$%Z06HkCsOG z_XvdB;gDg)%eCe3dygKu(>Y7;v|H0ruySo%V>UfXRwG+JrZqK9s&1T{DkC;*r=pkB zMg7Rf`9~~z^O!|r3;D3JWF;z_9wn<``B2Orf7$Z@_0mTyx^`>&7J+@a^BzljK4x>vWKQ-SgP;u3yxQ z-UT?cF0UsT^m~c+V7ES&kmS}T($jWk=bl!VhS9e#fua#R=h;Q@mdB2E`vJ{!sBo#YKuYDc-Dj zi{h<{w<-Qe@yCj{E8d~_6U93f?^67!;@yh(C@xmKSMff@pDF%a@qWc$C_bR5D%_ZI zm8-|wjh~-dnuh`EDDgk~(Y9fG8-9&`jQ>#&(o=r3`45K~lq{dQ5D-8B0R++lwqN!0 zi={d)wED9`(c0@N4pAJwnT`#f*y<&9<{rD^xw3Hs*PLM87Hl|cX49i&HM;J9rk>Zd z54Xe*X(j`P`Is@hG)nb+WS`%#o=08rqs<;Y`J4Ose#-K(hVtR*(FB4gy-kp-*n%&A;8}+#62$v~^qXd}Pz(zP+xOBp-T~K`(;0x9Fm{WhuEfZsXd_JYPe$ zOP7~{>Sz1h@cG_E?6qS&@1mreKnRrwliE^Twe0$Q$%+Lig1R^467tG2U(UD(3I{7m1mG}>+|d}2Mc zzkkAaI}ZDCdxK<{tCIBWD0V)c+@y=|bw+nJ%5@KU=FIwKD$Rqx|^%E;wL7i7k8Be?icH|DpGn*ft;bzdh)G)1u7=WXE3`^gr{_ z8wO^_Um5iOP17p_v*Qmd@5*1<-w#~P>XdN)BZK~pgEz2OsZ;%@2mP-;=r?QF{KNIJ zT>WjD6^b^lbz9x$_fgfEJ8$hZestkq2K?36gSAVvRy^H?2}3XIV|;aM&#NTN&#;|~ z*K2cjD$UJ(^6qcvk9~f_oh-u&8!KA9=IK#l(6Ia{X0L1ad|zDGvO6{1uzp)x(~9fz zV4^{1l8qpxtJC_erdVwJuA%Abk3e|5P`PXI^0G+f>6G&ydw#WhzEGYmFP@&A=PH($ z_~8UigmROW{LlJ3tY!iC|UVd<^@?-;FQ;TEujHhRpu9tGt<8v63 z^CxsGFE+it>XPg{{cq|Sm-yh?VLdZykK+5uVd}rv(v=(jefhP6d>#6J$!rN( za=+E@vUYzSW2h$V^9<(^=70F-)8+jE4H(7bKFCt#f4ei+Dt+Y72VCgoeVB%^^6u&3 zw5{9nA3i@)r|Y_we~Y%Cv~%&EmPg6|XM-Jg5fDHC0R%o+fp9;!IJ2M2 zUKg`De|^%hJD&SgYB$t^+e^S3u34ExzZAOdAjGv+nz7G{+lT2iTD~l8=(uE%}shZD?U>2 z>(Ct<(XX@CeIb3F)%Kfq{v1B9e?`fjU*7glyW1`KD8$DKCAn<6_qY7Sm!xzhHCbWP z<~HZOe|TQ7GBf|d8t4;>!`t-S{aUC0*2Wo^|Ly3nJo4)G8`>WV)-F-g)1$OXSe4(lGW<4g8wyeO=%rX9C=dXijdb>+v`$G8@K z2eDBrXhQ23^DRxuki*puuY(NH-#(AR#MIHD==ptMzvAV5c!i$(-TQ~n&pdm|&q|Yv zBD-pQ%de;F&s6B;y`ks=wGG&*OojQ}LTOfpJy@P?R@Sy?A#7W}aQJ9|U>N_~+u?LP zjdt$>VR^0`-S_q1cb~idg@^Y4){)2F98YuaWM#dVq-W=3+xKXD;8Rz7_4(A?x^fGfvM`x*Vrc!R#qHM*gxHLoGZwzM?0#N(E!<@p}3 zeEEE9m2Ufxuzy|HU(00mYq(swv3)PseKi{#RP*|G4)f*l_Ro@ZO)?ewzg+R&!WXSf zQ}N|0Q@(t@Hu3CojSBkfv7z|hTr$4BFSM*5%XQu7*M7F?kU!faPf_sYx;~Tc{rkUM zqnjEV<8Kl9ve`7s6n*(}gS_!^Rh{SLbN_w}*ay$#D}ey{`RYji~TX zMXOgmJxUB3_Pu|7OF#bRU3q0wt8O(Ouf1ZY%7x|2@9*i)qQUxy!-U=8h)H!H4Qtm% z_Ey|SaSKITpSIrY9=GjtE!uSeLU)0%J{@&Hx?GgqGa$NOKK(B`X1egE-*l?nj5_Ix zmuFt^M$@w729Awk<-*gmbFgx4#|Ww4gV!B4-Sx{y7krWtvgIT@oxc9Ia^m}C-v?Wo z)k)$0*vpf*eY#$r{BPQ6f$+Gtd1CQ$vP9+RuP0yo^6#ISSyi2s6Wb=OoOpVA>hblz zZsnx#`;^@a%!gH8tgKL8vTJA6{|@&zBPXTL!@ORep^eVI&$nFV>6^zsH~8&!mmY9t zvLSAz4b;kur)P7}b>2}~-KL+q^&9e)8Zg}7_;_|R-uJ<_?b~@+e?qt%OSK%9y$VH} zhILz6@%!70)c=~V|Eg^DDSzMkEu~xV2IHA z*Vys%-8P)<*Jn&lJKMcxJ6v2kN#DhI@DFxanyXy#>swDd@}Vm%Uly!gqNbqLafYeqPVHz=89V?Zmqbj;*N?t zD;lgFe^|NLUvaYH!HP#J&QxqxJW0_m#$2TMJwtYK)%cKS0muAEb904pV-s^&G{qS{AK$ZNky> z_al_YuskdK(YB*Si?$`TqF{gj{{$aDoUV0i_R)Mi-G{S$SP)SZ>~AsV$`ozgTNw~h zbo^-Bla&n-MZduy(x@J>y2PfRjW#WxpE{#%Uv3}P`ujPC=f#G#;CZxe8{Wsw4rl#6 zgyVP`?f-iM^OR+;*Xs_o64$lg$=0VMr!*r@ZhWpnRrP(ozm4EH>qq6E{J1oDp-?Qz(%eZYr z9@QD$FR{OE7@Lmm>#W@C@S?Cys52VJrr{y%_Oy?4JFL$a9$vg$4E|zi?!kMun{(Ev zonAX8uFfNOtIs_>YuQt|C?Bo&0d%?09{bl1)7e)Sx|Ne;^3l3n)pgd>@cl{aX_)Nt zd|dwyud^&YvUoWec|>XM&o5SfXTAH*d}#dy)wWS9C!U^l>?$YI^dx&j;dYq4%%f-S z!*8WU-_pz0E4J-hSe12{9X9)SJjHagKf|QQ_;~)cK#T3ii9==-FE7ns(sQU^xb2rK zpM7rb=E;U{=QCDbJUy$p3gxA657nlTEjPBGv32V8jSb`L*xQ!o!P9(r``goen7-Pp zI(%Q#`)}&sp@s2sGhgM#tSS_(omZTxxNy6Y+`PknV6WNdPC4w*kr({q#n}hj9||_y z!D@PXlo&Mj(`O4C>h&I)uFdI(bqk-fP#sgFQ;gJmBW2a;a-03Wk4^T{M+Tkq(zCDH zY@-l&lypn?{)J~W^aGKT$4<0YijK~=Oqm(KDX5gnriS_&y*ikT5Z1ekGWp3Kx7jG0 zeP_u@YdkUXZJ(d#C!6m5`<oF!|uyeRZZ;r&SXVHbEAK2Qp4%ePU?8l&Y>*W{-s#xP*2bIa^=hN zT2W+#t-pKSbHD!n(xY~7iwClNTlj2}9{<(VO!8e-KdVtc#L|+lXqeTc_s8mHCxeu! zZS%ML@`Gzib3T20*~;=B_8%Vfx0k8RH0(b<=s!pYz*dKa$M?f))9b~iuS;u%-xFS} z@sI!X4u3u2@magsH9`x%UOYWc?P?~=H(qz>TkEQi)z2BX>E}CI7`v8tV7Y~KjheSJvrkq@pbi)Gxh!Tnx|GSn^l_opTmFK^w)>; zjYrzW4+WdQ)dQX$B?gUT{zr8^RdCcqJ@?XBGxw;dCi?G(!u?O86XhjfWK`mWD`YF8;9p=kT4CdCsKzp8k#;`bGAQ+z=2DaC&%uA>#U zt>SpaV-(LRS2?jdM&cx42!ypQ`T=ov-08 z*ZhB|c`epAgdW#+_?Kwi_IQ0=i~j!|MAGfNP;Boz*tk~5THB&{3&H1ANT36O4^g05 z)Ao9Gsp?fLj}?m6&erQ4>c93ex8C@(zd!cVs8ZH2Uaxw(l2Re5R}Zn**zIj`+aK8c z{5h!9z{ww~I=b!8dm1iGo1;H`IVv0aKHeJsY-j$(7hc_QWm|kiXUkz>+ax{ytE*Yq zKh!tZ)Wj6&E?7zZNAa-kD9Mfw?y|4ZMzQp&kyzn#*d zVSKqp%qkj?oZ8j&#Nr zX#Z@-6`mfab~P=3cI_bb+*k6DetBg}y&bgA)xNJ&Gqik!+lA%9Vi>Z2hy8l%4#%-> zD|Z%b{n&A=l~dc+ty{bDC|I`*8;%?I`FJ)vwb))x=Cl+qCree1b}#$G(X-F_=Qoeh zy0!3GMJp$s9wi11l@t4xLRG%y`1+c>e_A0rOK-8u2KxC&)t~Xt3?##rkDsvr__0;f zqN(&$euBw=pq*YO>=?$%iA5_vR<6AKSef$Syse~Y*MD|CJwRvGo^Hd0q3il&@*G&#Ptc8@Hfdt2p6h7s`#kdA z+vlBn-AR}H(B^Bw+9hgwdXyM6y5?Vaek+rMc;F7T+@Z6*_;!?Q)9-*TU2@W1_aFMJ zOZEJX1$%zYwj)oEQ@fg7`RKYYSYCL3vU@#i=T16BiSCX2Jv}SWR+haEw0hFlk*zQ5 zXXV@aTib$d3)XGJ**4(QvUD5AhPB|s$A88Byqk9Vy@{nK6fYkmk1x%=`q19Xo|-)R z?qib;0YnQn3JwweLD@mEBEycPkggu!>|9{_gA)^4$xNY>Dk#> zxe33^V6XH|ZPN>@_HxwZrbd4cG|b1Gx#@hYr-|Azvwsh9x$^mF>8blX_p5`(*)x?E zEFV^WJv~Yc8olI0_b6MN8iS0?*Er@89#007i8`%3TJX9l{_DeOc51S|eukZx-mZJP z&#}pf*EiknI}82iHKXmJL`_f6<}&Nj>+cvOzg-Y-?p+_DcQ1Q>c%kxV+h0X?Cc)n; zt{iaW)Uy{got&gueQ)8lBt8DCtC`K8o^WoqXIAv~Y;?Xdx~VoFzXKhQQ>K=A*?Hvy z%8$>__C=Pru>bO)zwOJc428=x=cK-u=ju&%S+M&r+Ahs5&oxQ9CYcJ^<(b-=yu4jl z8atHDxA;h9>hR@Rp#1p!dRm^_gZ@1&&-j!3UY_U1PT6g~-ba~I7SFX_bUpesDJ;&X9^j44W8*i2V{FA455pseN@)U!FGyvFXQuy6BMT_9;4Wy_$|dd6rWLCTPu0A z;+cw%EAFZScD15CgZqTy!Eba$8kW)qYg( z6=d^i`)m(kx24(k>1o#XZtLg4hRKF-IPX?RyjhV4TL2!sOR_SyDli2ZFvGeTgJpSE( z+qSu;qHm+&w(Mz^NAC`|Vc&kO|7WaGB(VJ!!TFf>>dq)ZeTI;`1(dR$@y!8CD*P#|F ze^2f4)UB6y{Po5|bsl2DuJhRWmZwLFK||-|;eEWSn!0>#dxM_+oiJruU5lM{`4hO6 z@ztMc)vd?2mQQRtA>Z0|PVMZ8JYVJK z$1i+t?ic=a&Duk!+LJ$B<-^mX#GnzDkII((%;*J(LQSkU@>Ei6@N79*)$-u8^zpoH zWx=|`I?lU&7;A?y+O_xuleQ0=N&eXUxj;+m<)rT7bUDe^BM+z?)n7Gy*Il-Kv!ux` z0xDQ(v3kVQqr{+*sppbEdw%Yv@RFX!@2T8)T@bFbusfJ-(ax|;*zvAUBU``tM0|Mr z+lTdjAJ=xL7Tn9t!b^*no57cq=E^tjJbCQQW%ZSI^IO5LBU`!g^e8cCysvUoK56Wj z2?tNI$@ElyeBF6FnB6LOdYK5P*5N?|r-<$Aq zocm_+d@NEvf4u9N>p%V2VUHh|%**a~SUL9eAPZ4vv3%G7m5Mh1?Dd7=N>4Tw8?4`< zLqq!VOusz6UEZz<+R~`9u8JKT(MelmSUq~yW%N|XDXhjc&XwQiZ>|!Sn+3y zOBA10d|B~ditB3QFH_uAaeu`l6k8R~QM^j=Ud5*s|E0K@%6Nt1EXDH`f1;?}Fh-@p2u+Mm!ORc74`nm-6v;`8W!8o*LGdR!920;vwQ@nC}O!EneP-FD%Xd>g=Iw zm#_Ef&wF{d>015h>EX1kyO(^A-=&B5K6?8d(d;xosK2QnS6yq|%k8p$S<)AeLt6Q8N*-~F1ee1Gks zJ9oHy&+$M1w62?2@OskI*;enC?)`l`P7ZL&r|9!oZEbq)qP0A(`f8H{h^F?& zHdQWRepd7&KO3LE>4ZZ+bI#x6e8ks4N^~W}(>)*FE|Q;$8vCiKbaqnp@4TD(_NjcW z{I1vjwVr+ADGJuM{CIkjTxb=^PvWBw5B89=&}rDsedp`u(R0_jc>L(X>7%c=Y`SNx zNWPK>uhLL+G@>6*%vXNww7bG5)@rQ0>Lu>X>vzx|%L{-?^@j9b$CvFvpa4W2t??tvHA%{roC z3;RPsm;7~3uvQ^GN(>sxclbQp=%$uddz_=8epX%Eq$lYp>h?eP<(m$)ZVU0b!LV-Wao<%tjvqUxzSTBW8@EHz*YBKL`*v#I ze$7{=TzHbbvKs|+GOcWSl&prWU&DzG(OO$a*X3)D?fQCM`a3hZ+tTy5LT%-_Qa7!B zbKj#;QToYVU)_G|&wToLmb0^G>j=XF-Jso##sq{gGsr0`itUtl(nX(Y ziH7ZMy>6hsmZwz>VZA*6j`VWbwr0o*pFz4Xgij zo|6{JM*kS!(W#8u+&Z8q4&b}Mad{??Y&F=4( zDE~K(7&~iH#j|S+(>tmbtY!K4^e8cCSpKcdq`n_Ey1KC@-w+MeslpKE({AN^`N+0| z$rgqQ(|YT+WiJ-`>hI(BcQ_yZzoFf!h4AB!AwMl%K5Tg}s$BYmKm6hM*IBoPcpa8> zOON~ZdOQ>#+$I}c^8K)U{PnPL`i`+^TZyDG#q> z`vD7H#x_jS`VR&w7sH{Fdah>E7S+TUA%xlCK?8uk$JWTu95@N!5)yW@wqxXb+&qk1kKD zo)f)1P*6peqQKzRJVOy$JZONFAf zv)j#l_5bN#zx=yXZ@hG{9Vb}u<33N1Q@fhokNd{y2(m))N( z@7d##j-Qq0ZaBN?9}}DY{^oN@L9}JH^6u&SGZj?c!|MUbpM5;9AAG5@Q}gN1c93Kz zHSfOu2*a13`7yhS#4@`bEKvV9rd+@6CCALZ&dRF=yOv?)$J3+4 zpwWFh7+qDR{=J>=*r4%@6ws$rko*w4Gy5HaSIC09M$%H!8_WUhV z{)(;d`Rf0J>jqCb?VOUI4o=4R{iCNR$%R&r>pOVBzSw&A_3iD#M2mEEsGl#-j0gJm z{=<}Y>c2haNiV)hol%m@ru!_rmM8eW=)ujk`V3&L4HF&@uF(8LPbB!+?S5?sI3yDh99R2Qhb?w|~P0~Xve zKWJLR#9OXuTHltzLcBcs;%<^2r*<`MzaL(INsd7DGa{4fTXj{vrmoyO^0njY^9@PP z!h8+;O?rLzbp7t!lkdOxwINq7vHV!Dc8UIZdXyM6`jM~b3r^Y0b!r;EUT;^vY(5o= z*0y8a?ER5bH~Z3`PTB0O_q;B#;Ra}EPuHKR(2sm&vZSlFN7w7e{Zv3Tr4B{U-^j;` z-zTvd&wOUDd;eB_=Y4j(X~EhhYI=H<7&Hp+)|cznNZo$zb~SCvfp$|QE>+=iZ-LsJO(N}WDJ{kGjzL%$Nx2oG3$33!Nc6sWPbWJi9R&9B- z@{`|N)N;?PZ<$@FP|7q_U(V^ur{|-m<(w1r_vH+?`yo&Cy__>u+U0mg~go`>(kD zvL_zRF4sv(x+a+l?`OGsT8m|xsxQZ|-<9S(A3ZJS$e_P3XSn{BsJ{i@{n1a{`oNAmJv~V-w7U7X%x!LKnwoEGscvkYU9W>s zJ@?lWcrt}fm0xrB_xEj^xBW?c98j1I9seeQuw0M-WAXB{Q0431t@oI4$Akmd@cPKh zkEdrBBU^rS<4{GrHDA+i2Y6H4n(U!@Js)vGwLUq~(lo0@xAbfp*>Yq1Z=Yv&9{l~$ z3v_6fwq4tEA9YWs%T4xp=mC|hDR-T8%jcFI`O=2crg`%9INN%cBNwj))mK*Hno&S%r*v*VRLqVK#cEgO)#_?7bGo1ZDo&3x(5 zj(cl2K6kqpea`WI(bIjt-p-cKuKl&2O~*t2yS{Jj`TQu`#kQBQpKYgM=+Ci$jqm50 z;kb1FcL{{|k48L~-fnxUH*$}jd+e@DpZcsT6t><>y7$j+x4K{x-@PiY%@>-}BqQ@cDUuvgzKxNPe2^JNfn14VC$POCg)d!$#3zw@sr{ z(eu~*=d@Q(=Ou6d<@O6JZ@=-kHm(KFUp77N+r6GWxUn{0W9IpuXQM*i{ZwtpS zV%nkHn7D7@hmSfmAW@!FC{b#kk+O#{8{&rrl ztRMM%>)wWS-dX$YqsNTbhzg#+x0CcZwX2!UU;Ha;J?Ag?QfbboZ}o|tLzXFe{>y^? zmVYbf9Z7%7f2aCes8F=Bp56Ye-)TENv&YJ_W^HKQ7UKNtxHXd=_w8OENL8o3N9X;- zCajN^{I&S}NBpHUxBuf+S1jA-sxf|SWb?P}-_w1*-p=}UJ+GOm%##s1wczIE*KgKQ zy3fm}N&DX?5SEu2e=A;IESEb!^w8Er?Fb$i~TTPj)TTwkO-qS{-A-+wosCKT3gcds@^-d9i$r zzHRMCPRMUq;d%7(n@#ur+43@`y}6;jMo-W6T>Yl5V~ku;y!_fcw*2x*zneL7@2h-% zo}X;G_s`}h`FYsr@w!&M#ugvhr?00h?ngd$S^Fy|UwGmU!+k!Uk8Ha4FP;y->X&{# zcj@bCkL>djBVW^fx(9FGxOVC@=O%|2(f--?kDl)H_jWcPlj<9%PMg+!yY=C1TU}kz z+7@j)_Wh&%P55X8Iy4(UE?)VM;^kuc-}QUKyF9&b<=UmcyfMk1l}{@do}MHZTG?_@ zHM^;)O+WS#6%Gy6sg)fbCly9aI=oDT^}KgmKQAjjTy}i^{{IsQ?{h8rXS#gYdH#W# z{QNgcb9+wT-v-T1zHa?byfAj%?R~EChqKo1mhSz#m5=CrI;utsReWt#olgF{E;8A; zqmpuS_?Casudv3!%7T>xD<3*7iOyTBjslC}jcSKL`~cg4>seqM1uMLSrWs5n(| zy5doaGZpQ*oZ}V0qBu|S8;ajiyjJlx#rqVODB8u66^aA2V5N%NDtsLB7UEl62-%LNZ12y`gT%g>Ov`@WvDTidrj_0FP|`&vC&>P@BJ9A046j`}DQBMbqv``rGx8Mg7R%x9-^VrQ@D_rPk^z3*Npg zNsm*zn%VqCPnqeHe$j(w8mvsw^S4Cv_vzadY}v~cz5j}!zn8s^q`&2V$iLFt=ME~A zcAY{^ z_x_pkQE{{$Fl=hH8vyBo66T}q-M*i1ee0R)uX^y=SAXmC@qA>{y?-GedcH>2NXnDz zrtQtmIwWa5G=Fsb;mXwgkYy!y`6@Yi&fO4%eS)G0cCaK$)`T z`@`ITp}DPIKl;*FUVie?U90vQYWvHuo|&iq7Ah32d}WVUtzX0RO-9y!Zo%%>Z6QA1 z7}PC2?wiX^m~9nGbz|GO`Ubt1p_fOh8|qI?y=D>(+M%Y`yMqVXo5o%Fu<~v5>D0ry zJD+s$FUu>d*aj{uQtOCfN{e{#MUpGiv{0u?+{$fuJQ?@-V4B%|1m)y|as9tG zm2f{%xn{cjXZI6}w0-O_z3Gi1cRjk;&iyS|IkNKa=}}_P$d>;@w42bUGX420d%qzX zx~F2Fo}SINl@rD6_tOe5 zuqNMoj&55;KLtL1*Ju(QYWn`YZmsn3h3&hooX*$ffV+0x(Jou&_C8?fWdkQnILD8z zEnfqbFHg5&!jQaIn>@N@-%hO3E?xz=EkCDC1I}0U`LE2(-{x)SYvK29FBx;jw4-ON zZkIu$U~PNP)6fWH=iKJ3 zJv4XE+h2L?vd&lEGAj#yyyNL{YF9H_PwlgVQ@hrRwyL`Jw%Vo>>`G~;7AV|rxwB8f zm)rlQ{m}}9^?j$xhpq35B3Wp8Zq&RDs_$J9-xu-o0{xC>lAawkTi-|5`SeD2a<#0r zr|W%-l@FhfpA*c{guNV(Tra&{`!L~o!|6w@zjOZ03tlTrGGzAz2Iww{rzgpUmgUpF z?>D}wwJrLQc70c{x;39VZY&~mB@ug*pN*{XRlRNnmSvj%0eA#sGU$mU4r|l?5*XhR&^R3Y+;dVV|gLJv= zDL-qSdRo(g+r9U&&(HIdP51sq^AnZc@%3%WN|=w%jnetZZa=vVhvsg1ap0gI?fJzs z@~cmaPDv~uc0B3nK7Vibl8@-HvOH?)B|{CI-4FTr|E_j;zUBMcRn1E{ja41@KW+H1 zoD47RyMBNB;PQ!=KX~F=*)%5fzF=+IXk92wMmMfKCO~dzpGlr(~l|3)B**$aj zVRfh9`S4@bZNc(o&1`yulbMVGPb3PwG zMhNTak)KREX6wZT8vo1}$J9LdwSC?#PcmZV&FUjhPm&9*Y(B&HSCiFhugg?4G&e?P zES*|0;qh@{LPa{_by;M9Os`cPJ~R5q`p>XFSdu9(+52J!b@1JE+am2*x_Mjb zS+?IlvZFe4N8Zu+;y?be?bX(8A1OQL$&kon77AC3pS7I3p;DH{fnn3lP$C+=8w-ejM?wdmg?qa z{iL}*mZguejLA1t>m1QSrxw8G|6$!Hi09ICGhTvpKl8L`W!B=yJ%q;}!^+a-qw}ni z=z7AO15^fnx9o1S8hp%V##-`=`q1l$K_l68dNJ^rC00e#Wm&KT*}* z>@O0B+wmgh$Li(^MVn7g^>o8QLn^n}Xz59DKH}l5p7wOlhqqJtiOvhd?5N=8^;T>l zSILK@HFB7*@muumwASO_eSOcDYQO07b*F5)_g}SqxmG$~%akuO8l~8q*QQl1JN)Re zBcJv8#^-v2a@ln6ALc8$s;uATXm1;%%cA=4ejYROc=W6t6TYvZTe}uw&){RnspR9 z)b#mJ-zq)-TJ^KxRx0}Mx;^rZ|81W5>Z`YTU1amO>;0atKU1MF|EYPs0k2YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK TfB^#r3>YwAz<>b*1`K>4KOtc7 literal 0 HcmV?d00001 diff --git a/Covance_UCO3001/browser_profile_3/Default/Code Cache/js/29e52b350ca3c067_0 b/Covance_UCO3001/browser_profile_3/Default/Code Cache/js/29e52b350ca3c067_0 new file mode 100644 index 0000000000000000000000000000000000000000..becceb656dbfa43de6ddcaf053eb1bab8bf0cf5b GIT binary patch literal 112368 zcmeFa33OD&);4^4N@rjQ5HJD6Fo=MN%o0Ry1_Ff35JNyjh0{qo14+6=x)TUjy%7-+ zyvP_F5dl$95Kuu;Q4tYArl_bWh^SmaWF8V!{GO+VPKW4y-*^4r`o4et>u>0EpHsDW z?b=iA+Eu5z>)pjKv?%=bH-}*u@p!LaG~J31V?dwoy>986n3R~5(6d)uT-WYNUArcA zO&ZWAE^c7YZUYj#-qI@}uFow!diCnlyIZ%UsNO;t~%kl2{oahY}S%|-uuD4%ni+65qWp?6Ks57SFwRXG7 z^489hMy+j8&eaw(gk`KbZB8rmHC}|yz1ALO;+xTWersF11!e<$bwpdIg;}CfGmqbI zd!I0c-mH=WH>yXaHi~Q<@pCM1X1TNTJiHm1nsNN*6Yr2@S7DanbVN8}Ee_mnRPRu) z_fGTv=n}V47Ktx5L(<&NFxog*#I&x7gueBMpRYwYiA8_6SAUN zTWh__9@Vx6%j@x5eziTaqIElaV?a3D+M_DMB5cbXZ5_>;+a}nf_r=*lnnzSM*k~B$ zl|TOY!_vWdnbAB;J72eC#RAL)42SS;-Nj-& zjO*66V+|+Q_8lpJc4nm(yGxS`+=XtB-!QGB>pdOfA?Vt=xy1e|sG-C5uPsW+zxjOhOTVdeoaVya-kgwv0%2nSf6FU{@B^yihb z>Q>w+7sbVU*Sp9cUujN~*W-7g(PA?i(4?&Ny{RLbpfIZp?90ncD9%an`-}53O8joa ze43TO;VI?Mj$;Fv;BZ0S6n9!O8t94}ARC;TIj77_=Xs zk=aW=$zUVd1tq@Rk(s$}x`E=`g-FcVN+7dSZyQQ1dA@<(;*7kkEVn1!l>;oz$!}n( zD7yAr8bW5V8$1yWu|Mv~epKp7EMVc2@nb3|6bQA*?a3PE&C1Kpa~BVD73aH)ao?;2 z3ulO4t>6314b;G*0_aSxw;&4@%=_78=*@=HOP-~7%7FCSbpu>qT#y$VB7Zf>i(Hp4 zDc9x6ac7}$xGLOa4u75|0kP${2e|w$d^g*nMQ2!~c^03R4yn1@;=?{@j)FWN%)*`N z7rH+pJKbFfO8jp09zZ?WX*9Rvz4D0^US@#{N}64kmOQ?j*^-#R_${fgG^7suAhDv6 z_~Xf;Xbf|@g5G8xC>5g518#S!%b%N;Z1zQAxj=p(vRgch3%p*RJH?abo;)Jk9D*BC zYmXcL%0{?ydGZQ{^(A|~U^9pezx@#( z?dXn#^rXSbY2%ZICMOIZm1>xaDKd01eD0|{a~lk4?gF4cjV=N`;G5mP>=^Yz zjuSx|{swNs08ph(qZ?kWsgmR^EQ0!G0n1@Dfxcj5>HgfNkL&>OdNSSSP<){zx?56P zwZQj0pKvlln>_yHtUSLfqrfeV&YT>eq`&3R=j@48KsMv`2#*j-c|b!GyFHjC^c>ER z-irPpDc7Bu52=_#P)U+IywQj>4q~o?0`DYu)}R7!hO58_xz4~%Fb(8ppZPik9Au{r zb1c5Fo7t^4ei0__6y@mW82GF2&gFuJFX|xBv+mvY6e45=%#er8Os7C zUc-DG1&-(~2SZJO3dEl0c78#`X$ivzC67-Z@%QB67+h7WGbgrqnc7oS?9GJhr1$Ze zkr0(5`s|@l^HEkq-{(#2{|@^Ovr8{_d3>M(qXD|rp9Tx+JrkQR7g{9oNGrOGLg^!y z-u^=y(vT(GLPBw|tIRMr;|4po;>`3;?1MMM=Pri#G&isSt**L#(3@-(BZRl0)IBh- zz%RW>J@y{0uIhI48d49Ea_Ev${O&^Y5NU=wthYS-6de}2Ho5GMJQ$xldz5EVv8xDl ze};l`fn(F$haEwb|J_}N;){}U5Vz(5TURMBPda^_SqkO=5)JI$H{};$pe259lJ6?U z^izzfT-Pd%=mYkb2=q@X`u8W?aahm~U+FF$>4%wTno+9ofaUQ=37PFJhW*O{+5Tv`{Bv)73#qci@p@S?{yspP|GNmI!|emJ|zr$B>US^j+W1j}XZ4 z7rQV<``qSsatpfBxA8M6gv=>%6=$U+j~qQHu_OoAW-R2z3W;eg@1vJ0#8@ObJsi#s z6`B(R#5pkWA5-Z*@_dOU(6khf9=*nQGt4Dg_jd*5x^{XX-12tr@`R;>u9qxMEkH0bB4YvuK~yvu z`ba$}Oq_Cx2^S7 zA-&M{O^r_)drwcrljeijCOANizyZOv5!~^>Gw^=xs^n=eL zlrc?ok*yzS-1}p)kpl1*ilEpqC$kW(A4+?t4`(-=5YR`v3etpc(V?1o8GR@h4IH)R zU7@7lKqO(GsO}x_eyW9(6IEj{tQ}NuVIkD-WM!|x!s#*6g`lzmN`Oj}6^5hTw_Zyf zDRvinOWjEfp3rabpBOHtom)T!F7f1hypudCuupP98i;w>dvx;T(u?0yM1nQK@dEt< zU;yXP%?3S=)u)~La$Uu4%n!UpaCT(_IF}Velew3aK$eYryph77p{TgT;}&fsd;G;1 ze2UOexzL{GuSTr~VrT=DQ*0`C-|r{*NnR1% z&>N~-{XgwHhDH&H`N4w89JqQb2_%j@`2lGrKTuYh2UlmFU?I3SaG85FxmWC(l?}@zF+t?g&nYlk(rQH7N;nNiP^AVQ2$qN?InjnG0rDo=<=KWsR`)+=m$@} z4qhR2MDYAJI6<`In(TjwT8IGNTbz}g4I}jn%(!RXO|-C}aq~-W=OhAdY`Aw43TCMG zvOie&PoZ4iB0UNs)Iv?7p3q}WF)1!8D9Oyn5P-RoHYUT|E~O5k7Pp<9BCXJ`Z41$m z>h-vh)1F}HktZjnfjOO+xqZeyfV}>n{!KV2czEH1%pL48xSsv#w`0ilnz=C|e@u_f zldJ&9sjv2Um9C-Co0&hrT?Ai=3qnr!HNK0GBU6T@4ox0Ed_>x?grO;8lg-~)0iB!a zyXOe`CTGH)wU3l&kj|?*#0}^DRfy&}}?~v~vw>!%>Tn()f@QGOSGHrj;iM4_yaG9R0-6D+)$FSEa@d;crYo3gooA`Lvs= zgfprcNey!?q$fGprsrd~kb{t4O`tCwxM8MBqToR~r8j$;!wjd)j86w)Hsi`+3?foM z@S~_I2f6-Pp|jawZdp;T+ryz9edvQf^hEum9{7cLM1CkCFr?JX?dD0!z{w#4ZW%z$ zqDN!Y!#Spztt?`AyFPD{Nm+SHRX3x3aw5$imcuXz{?Fsj^Ou*z?cNrCTd>m1Wd~tEh0CXhF=lsIAKhjWKwnyFdj{A*yi5)?=FkN~+_! zN0n%XF9;U|<-5x`PWa4zC@2?5J<~otPNd^?a7&VQkR)`(^V*(kgoe3?k7Q(Pwv=$7 zc8Yy>BCUQ{!kF=+QU@fYCy!4WF=}|a=?AO~y{7+gL61}Ee@GSv z96ymVZ0jkj0PWJ{6P60uAlMf(pYA~GygtlqtlC|X{@!xxw+tfy8>KkBs@>XKs0)Rz ze7BggGUwQgL_szydY%x`8QeYwwF2Q_%qf5bVQ6(zyBTjvQyqm#7v|UiV-X;?^xTq7 z!4=6#EN9?`StTJ+ydx{E1zQzyKw>e%Pz+O5vO6fQJinniT?BL-!JhDphFO3cWXJvm z5q-!Gp>E92fgNJN?h6^s6jjb{U9*v5$n#+iI^63YM&F8SvjJ5A4P5lEE+ly(0ioGx zpnVRLm$x3B2TGZYGR&jA34eHH>n}M`xC!@?=Ywk-;C2@!BBh2Dg3k<5nq^%$q7S(Y zubiEigZ9#KL1^pe9dZdRBXYsVz;wf$prAwC7v3WDBv-Mg9sHBo7;Ve>VjD;DR?1gI z?r7312TZx>N~c~ss)R9TrF(Ve&3qA(KrveGp1dZFUP!h)V8pPYBp=F01!_hm084u( zFV2>s9XKhSy$mb5k~BD%z7OsE8=Z?!q~G*#AZKJ^)^Z+&WNhDF7o21)lbQ6Fh_npz zZH1+Oa`oRB&!Y??_t$tuonX9|^bpI!wqq%ORP*@g6q$A!tqO-Emp&|ff~yGWEl&8* zL{HRqK2guClzc&-`ag7`CDnumm5RU}TuaJer)Q{6cmI6BzgS^XZk}KI+O%Xw?`BU_ zC>L~OTnwgn6`#Uo~bX77L|PrZKXQ4;H7o(78M z_o9InxIx)W?e+XfYK6$3`bAq6e5V;;$Cq#iAExp0z`PGx>`Bv)gQ>$n#lI4}H)UVrYq*)~N2wi~!kOc?Vp!XEY6qD`(7$?4v4Gnr<^ATwc*qlyaM+Vr?yyA}O zq;~vxrtot-W(8rP$gM`FN0A_rmKu;(n#WZrEGjU9FyB*rZqq(Cmkr1nkd75W*wd0Q z^t#iwcZK(mi3X9Z!9)$Df^HOd&z|CWKPSsHyPlW-A z{d*rjz<`-UnQM~r+_DA3+^-lraC-d@X^`~5X>O51<%(H$-ehEL9z}te@=f2lkiHNz z5^uhn*-(+07U>|eyIc916VKuAz$&} z^kGBImx%*TW-hZbS1NBen=4XLs?jQKek1UpQ z79&3vt8k-S=-Kqq%k$V}u1Cp?nH+!3#=t07PV*$uXl>LMAi zq-5i}d4*<*!c_xfdr`A$5}qjRLe2r@nxmP*D)M}?J0>Mg*{!+Q;|J9A^lPHut-yMN*$m{^3;Aeqj$BOU1pk-mTAQk@66EtXIW+W{GidH%L=K*Y% zgWV`G70qH0=`-g5leCUQE4*T+PV0~yM<24lw{p?Nqeov92{cC148W81HS(Oy*7n4pbNwWf^(`?X$xs*;o zX^_9bnwuDwO#>v#8E^NT%`G@eh!Iw#WH96H%+`UUyR*%AG+vOW<0>)D=8~3K1RNx> z?bEZ zxQdDj%7$amvQuhUNgTfM-ho_6{Idmq_@BY>h8TzxS!o+LR1gc2Orl-$ZN>A^cdQB{ z&lO{8)c$-xWz!ZtP#JK2HHiYloCoAmWhZ=bd_K(%`dEV@O%{XH(ift>j6tyqCxucE zEcO*>E|r-x(*t~O^V8`Fp?_GN^NYAlMt9~^z|a!f_o*1!65qx8R04Kj zVEIQ!EnExmA*M91sKz=C{x(+36yRM|TH)W8^+Q*Ck(wK;m(mkxx_1M3SI5K z{f`WxJ$fmpKMT;&-hE2`U`IuIIXJJ3d*+w;;|!~BZo;SV1>3I|$;J{-9`k)^?i`pE zD~@Ibc!Ig5KD3_9h07UNwl2-7V#DQkUzWDK6@&KD+utlJZZ3vl|(?CbLpd{lb*IHTv zM<|_^5)-mR;G@idl@6Z0fg0&UdTg{ug~hAb6Ik+;8HE=(z09LB6chv|*kUBaeX|}a z0uLBIJG#%mX%*QXu!uowZ}tXVowvP7p)gjTO6C)88~z}%01mF1+?(kz$OB$*D83Qd z`sk#y()KXZV10@bc7UQSkKZ+&MerChq8N*I&|9>$WBXfc$W)H(Okjwa@@(87-0s1d zU4*~SE6yw_a21>PQk76p*W4g$G@TNXew@rz<^(M_)0KqNQVM<}fZwaa z$#`7QP}4rXZXXS`CJ0UQa(9~975zpZAii;LW=$ctF_w`vav?h$#g7WY?(g`o?}(Zj zLf>FA#F7qscG$Tah#ZQlrpt1YVTP(s%_}p1m1GSsDa=4L*9Nu0RJ6MIQ{fVp(oZX3KzIU%fF>dXC}P z+L&AH@?ly6_hLTI3TS`Rn~!|J5E>~+&ht@(<*nJOaPyt_KOqeoR#uoN2ROQQLTPV6S90D~cJ5`_Zi*+xBf?#Gda>JW7U&9(Y!IQoo^6 zyJLQ>U}&L6K{a8?s!7~b5fc<+_gD9|=eU}Ol@{!l80gI`@nOV4aEvs2OZ22%aN@w5 zYj)E?iVXn)_Xd)4fd_I#lgB^4;U#LZOeoZ3*i=pf$qB`mlOJckNmbGLOwQBHr6e4D zIh*qH5GfBt1j!RiTm@)kFltl1&%Sx8pU@(>X+~M*muTG)U2F|APfAjO!Fv4CDWcB} z+PY=FsJa`n>9IW=GE`P4DQF=GVLO|F*h4zG6WH1D(pqW)K&!&iAl&x}v4}Z>2)dI4 zyZX$5>?Vi}*>R;Qi7oKvh*`S12GCGCG|;Mfr)cUWRX#8?$F-ROgCT62nF;G?$DFBR zjKBf{kV@DtLn_21R?;>Q`oUZPqO0SmPY!muJbn&!vc_23bu*($IS}`L(##@aWSm@L zdubc+-PtI@oPr9FBVEPi(}&c|A~!Ds3Cb+wcqU_hZ;6{2t*rgNVo|07P5Cz5C0mp%%bi(1AP}6XGp4jGr_DkNgQXcYZULBgr6yjpAh;o=c zrRzTGA(lT&irg|1FguY!==tovV|zMKi0xaHFK9*+QoxJD$NVl#jr(6kU`SY0If;5i zym-@7UiuX=r;}w^ULax=u4o?Di-noox#Px`A0ppG>7#?ICiE*7(LA@zK&oQxiWMSJ zLAJhOQ`sSUW92yDxwz{9$-NcC0nu(+bw<)ZBaea{~wTyW;ytOV64M%zaw zOj^o8K9J55GcovR+%qrY59vR0e1X`CDP6a8Z{|$$A1ppTw)gAgANI6xXR4+Rxky5T zxFZKjZx9v;moH3vH+crgvqQRdq4q&7;egY`rW@hY4*<1X_6>ik(MytZ9LyBw@DPI_ ztHG?dZNl&AC0g2RZy+o;*tKRi9?WCcGUT?nfDeZ~VO2fA{Z{$cOe6QfQuyA2GDJ>t zZIn7tpv2qe#^$Zq6lQN6@BLUr!_*Bo*pK!%4qCx}3?DIG2Q(s(F<)i{@UPR~y-lUf zYQq5q)OfO|)7Lwj(l8h(WaHD^tDw5HSTLSY>DU1~5^>Uq;V6s;LGW5YnmFq@G1!jx zd)4M16w`qaY4}T1a;XsTw=%9Aqj)ytt`Uz2HKMJl!O`qTQ3B1PPc?zj*IUqAnYJ)rF}v_#8? zRVR1+y{VnLC-)#>e~#J|ZO%j!QqcSJ)9z6LYD#u+n(c0C5jc6^)^547fys>xqjuk!8|*arq3~2n94ci$)rB?ww7u zsVz~pEZ0U#6U{WMH|ky$!KAse^1K1Q+LdIQzdRsYxGI_R0Bld62flPa%h=vLp-EF^@Dgu-k zvx<=91Uea*_U(7@7aCZePvoZ&!q-k5n;GOCw7LJ?mk)D!np`HTWa*2xEWS^%46nyn?hk!^E|SSjP4H@F03? zjECDb;ci5~Gwz-jPA4U{*QgYnSwWg1ud#P0U9XfJ>0PXhaVsgubpV)0Krfb0&xe}b z6>~i;TYg72A+B^!=G<>8@qmBDCw@N70&d2@J`7kcF39z9-}pvRkYd`;0UO`VO{%}8 zLzAY{dSGHf3qPokO_?DCyT9f3e0GSzsCfimi1Pm5;(sCw#9AA~A=+C*lqj5f_wf z#D&ee0mEa(^Q;KfSo+N?&(ScG$D|HTNlHk>&OWhdYmTN;p~CFDH+Gkn>k%;pQY<3R zWKLHVR(Rn*B+)qX5uD^UfQ|cdg^b`raP_?VjLL?USYbvUiEH$%N8qX z5pr=bKyF|y-5gD#5%8}6?T?3Q0$x2_U)96kSQ(7n)cIdNGFC>%2rtvUBMP!ovZ%-A z8g>HW-Sl?mTpDqM&$%mtA8VO2d zu#pDrA1dvB^s<=3)GYJ`x`r)Rz$G2~fr2JKlc7a&;Vr-ivjOP=u?HS~MTAsPZ;)}pzYGvd*9pT@h9$`8)-V%E3k00; z%!N?x8aQ>!@J<#3u4z?0$zFYZ8Bt^8V#ts}?{20lW=^>0hu={T<n4M=4@F!w#3y z2V;e}n4K3()kHyJJi}Ie!$MbPrn^Y*UhxwW5*~ift#+ZR8DX z@#p~_iN#~M9=~s>+mqwZMa67Q`L%}z(u%O>lOc~x#^$PikKNU%lzJlcUIb=hY=;e^ zf+IGulhs_Vs?J(4Y?4U{I*co@rY&m;=z1XlgN z_tz%4f*ud|imiaCBIg-ct(KI5-|JVOX&)G4`GhI4jKd$&u>N0zI&)-(R&!gwVeVE1 z8}1oWPU4v0z5`=|xeXFRSLsNvy{m-?H>oWFg=E5(LIl!n|C(awEHuNFS0G&Q-M9cO zy0+oA{%=X2r1d$=9mv){PObqyKvAC3`op2QEdKejvp5TT$}{~UkLNRIps!NCom$PECDj0#q`WNQB82e)#B44bK|i~XTmKU67thF! z%=Pj~eyQu`bg2ShXx~GhO=dTTtfE?K0`Wa0NOPoQI8c=Pggu$5M{lmnB z8hjgBR+!-}KxMO(&?rpXJWFh($AipSUU4h|1k;7Kfx^+A@G0aOoRQc^FIYMi1eJ^8 zal`u#XEAculZy)SGWnRWIYtR}+?pT7{<47A4e$yLY>;Asjt;s1@bmORYUHL0Vq%8P zrD8I}9-va`<~wd+C2Wb6J0nEgq8_z+5yVOnPoI6Ojr8Pl*Gjr~7*hdeh@xlu?CP1y z7*afZqEhd31%R2QST%dxrG{c)^3|*{m{q7jZp<6^Yyxc?40jO}nG;`N7){hPWY)_l~=T1*Sm**YLMEWYa~O&NNhE#|*RaRF9C zJvMLtvMpit2LBW|dpFlFexRrTyJhyN6l$GZ8bzjz-2g1;-qGdWd4er?Mjv}UvBLv) z(;W0l)7^h4!9~<^zZ~ZUau=YvAE;%OBc5UFY2ATQUe9*sDdrx%|NC7OP_29`Vktf> zY8FcYp%)hqt(#9(l_55_xr$vbNQf#HUB18aWi~X4E&@|{znmLmG-3sWu~!CF?0 zw+){CV15m&P z0Rc22CE3j4O)#SUA1mWId};j|R^s!I@(CY_Ee2B1XtDpzyU$UJCiAHo?&!H+btSQ3 zw@r*Ad~PJ(#3QP(;%$=8AZWS~TDh#s?`-~opyRON0ic-g1f#=p38njZ3$@unG@hm14Og!nq!l5k0V@4V8 zu6zDEV5o_E#TFesR_R$9OhND9=i zjJ;$cw)L}D_8j^j)P5D6y>t@Ye|zLM^u#N#S1!{HXOFLe-blvlGFgxwr8))qc_ltbt6%L%`oiyC}sIQfZiSBSw@PtqijRh-dG1-+Zhs zZ4zoI(g`Z|L^6V6AkibHeNCc85(S~VI8TLI7DWt@?~%W`w@9Ovo3PApNFX4OHuNl@ zh6e^jrJ!cGLVbM1XV;1lKs+Cj#DI?h9l|V12E91B=gJ>)(=c792w{?3MSd)dh>e=q zQpoOt7bpK#a*%2u^VQtC1T0-@*O+vwOPy>bm;A{$%-oRY%w5=l`T`Fx>z2JKOm`)z<%% zw*OB3zoPxm?q7Y6*H_PnTf+o@vcA6N_y3)5;w8STKmSu3y6%6f^WQD|e~OFn z!SDZWyZ?W^|Gj$jpZFOppWyF*1;aXjRmS^&RsL7^{|eWCw?69yzyAu~|IPcP@Be1| zx^2?&U%hqR|C67ZrvH;|{=cCu_WRH1sC9rQPZN!D?y|H>cI6=Wdm3+XzNS6QW*=kk zCG&Rb_{;mkOqPigOPytn5DOXrm#+w0>v1bW zB5bkaHmVaoJIm8A6Uud!vB13*Z+mNpJmb?o#w4(_(5fhDU|1tb3Bp9Hy6Jz&Ma0TRP@cKvAkC z&ey&V2I@*yF;Z5ndcHQRvQQGlsx~1TaV>CL>agi21pT8iTeRO7@)vAsqS(aQf!O1L zPa!bHrh7oyV!S2s*V`8^5^Q49ifrOc^v7W0qvn83oxz9+cuSynG!Umv1Y+Ng1_NDv zn(c={J+?*i5L8Oh5q;!9sPoQxxn#H1z_bFdn23EnkPEBKsjjkFE1OtKt0Rs7zz`nJ z$0IE5&sl0Q#1iQ|oWVx;a-adFMa>j@m}dBQFv*HNeIdOvyk$@CbIe~@i#?pR{8S69 z0_^z&0JnnS66p3&1;m6d*~979u{uDh0N4`%dPcXTdCKYE@j5^^LOvF-TeO6U=~d)W z*?+DB#NAWe2_eZ#w%f-nbXyIZp=D0?pQr=X9W1&JZwd8~V}atJhT`Wh!BFMmKwR8a zYF zT?}=8?ief-x)0lnB}#b!Z|mUp>ajgy$B~AYL$lekb~Q29${w)bec4d3Ue)%EqN%#3 zR)GxQQM{GQw8u#FLb2!<_;N&+YsCtqVqsq-^IuUkKD=riC8es!j0+-@j*@kQNQF+L}E#UGopx5tn+xYX8S?Cx>FYTeUtSI)%? z=j}IGd)RCtdz#pBX*(ZUS#MvDYDf5_s(LG8Vyt^2s(Mw|-`(ieix(P3RNdKV-@=wg z;|Tlm&{-jdwIXDe(_)3e3a-wv#LmqoM@SjZW_CoT8jUQ@SY}tP_%}}|Vx%%ka_MBS zN-3ip24i5xR;uD^j7}0xt0I#wr-I>xYKWYTRE;}>cy0?)4fr3S8a5??m}u#Ia^ZaJ z=*3m4q5VllEVLGH`M4>Mtd3u3f(B$p>v|npT0_-Aj+du{2_0O~%8Vyq=%Q=w6BU(n zaftLhk=?iSn~yW169jc^d~$2U__7V#NzEAEy6@{`Yqkg1ND0l0j1-IZnPSTu@`)W# zNNZwY^RkLUDy=BYQk=Znyo9}D@O*!rFgzM#5F!UlQ-$K&ny$yRF_TWI8At<{ad&-Y+# z+?3Lc;CR)dY_?%-Ssh`!!3xdZ+vAeey077$oT^I~?KjwFLDsT%&It6!?L_ZFaXw6_e*qIVmOnz#|5Mf_ttJmBPS83TBVNbYZRJOI) z_C{PPzEo{-?2D-Wr*rREXJy2t<*@zu>d;=cuv@FDBNj#*^&_hOMEKfvUh85QJ>h`l zdE&x$l$QrD4`*@M<7=&93pEn$Eo0%S;mT-4@Diefu_!(t+`%#IAQz-n2fqvIAXL`V z2Sq?5UJ>?}I+kC0<o!z-KBFEjg<}eRYp|xwx7Fbxz$!>TYqk0bHfo~ zLpT1y1H6YG%dESP+NW5FRt!pdz%z=cQnvq2$v5+*N#XM3}fx19UV8Oqvn~ z*`uLC*W(wqlF!nIR$Oausw&TEZHt_%!Z#ci%yjPNPwk)51hCl+N7>3HjND*V;&5Bp z!)~#*uvIOyPq*(yaCgb^m+tjx2rMM7W{6X)jdC8&WNgisBdTi{KNWj1${8GdZ@{f> z%8oGb_hYb--vKu{*6<|;{#lsV?3r%eom*wQc)!$~G1MAfj!)`fg$O63NiRgy9(SHo z^ai_^Ti_5DK-F$7k?P)v%7QZTCdZP9+O7`zN7E}lu(N2JUt`3&H(zA!4 z6wTXdmDy__Bf+#Ex)ETPgTbO1{bvB6>GkZ>+<>clB4y4H^ua)YsAxE`P=y>?|2m`S z*I;B(^MPyu5Vb?UrP98E=?86F(+%ffh#%y@r(lSH*#=9C?XF?o2~l$v4RkXq{~p{> zDiuAIDCF>8sB~BSnnp`1I@Q&Adp+m1;g+t>7)wSZu0!$Wr}IavbBXhyb-weMHOcv% zHEG_00`k)VI{5+%p)(e1<-=Bc$K4T*z87qch>)p$FW8+eY?oTtFS@I%>|qVAjw^|t zuN7H_(Ip$IYq@I1Lj5K?`3i~Z8dGkuQorqJxSrA%cpXC=--^#*eR-mXVSL?_5(*xU z7Uk~GqoPoUCA(un=gt=jsAm~qtno)M>x7R;BznoZg~6<=`5_Xn@VtBHog`NdMX{OO zLkydX4#Tu0pVqIVga{jc5TxaUxFh&xLG*34?ajVqa|BFIl2G^=*mf9 z(!BIwL2d~b0JN``TSLq7sT2^=fv~P#xV1Fcx|9(VCK$##yahrFmH_w1-!Go>wVa&i!kwBRXr9KX9i@`O?<%BQ*F?pha`k}J54$y|d(6tl| z^p#x!k#%edC=FX3pfdoNIaC8ZVo^Za6eu~dQ460nxU;_zbTDbrKNUAJg4<$2JGur+?E> znShF@1tq(G-yAH@&(&}@S?0_W3PjJ(#^5rHdbPmlN*4j(paxYDCt7X^#4%128cTPW@;NV$yotaRQwLKzuq^RgkUY>|f?E^JzTw&5ZE5WU6gE1-BxDa?|EZ44)mdV$ut=1p6(KY_D&3bveaE;b- z+?Tp~n?)r4>E~MDCbhK`pRH=4=YaPN5PM$$@}BcVe2q%R4 zW&L>r^A_-p$VzgaHso2>88)g4f0ZnQzsdD?{;h!L6$y`~kGR=0(jY zuzSK2A01~sv6~-UQg|4qvlsW{Gd37cG<)$bFr=>{i{|BM27O*>{peHD{LQD z^)ST%s%5no?EW?MN|P+(urYe_}x5Fn&> zX_?PMQO96}QKZ7Q(=guOtAXa)6;K;gCKU_t*{KfDegJ$>sewMU0LWp41pMPd0Nq#z zXy@lhf9=;mDK*Q2v8t^Kd~$J!FUcl3ke>O%FgARt0dEhfkgH71QH>-n!sku3z&OwR z1OTnS(m-=V6;Klegy_NOQU@pr09Oucpj}P?Q7N=qKLMbd>i}*14o6&luYsCc0Te7p z48=y*IzV>;;N6oNXrBW>cDA=Kzz3ruqG z@iT_e=d1?oXj>$w6i5sRFpPFak6K`KXfpwD^Cb=RO9+6-49!7|c1F)SK>q+ht6w$H za}EH}F=(J?0o1DwkOu%C1b}*36nV`Qc}wuwyAIGn06g%UZs}U~iR5V@3|Pi3b%2Kc zZWx39&_FkZ2o93*8f+=R#97w(6gsFJ<7)ug;IJ4LCQ*dtSy1D}srFZA+MO0m3B<#E z!G7VHN9-3L!SpE}vjb_7VfHz5g_N~lSOyevwP=*$iU_e7x8t#B33j^$VC))46-s#p zKKs@JTL^J|1prr=26~1-R1NLWUI5Uob%4qM@F`CIku4oVM65JQw}nB?=vN2q7l5Qk zXs`z?bLZ9aG%EpgTOA-j01E1Bpog3QVy{}FGJAzl&gfqUXcho+kc^WAI>G=%eQKeA zFv=O?2Mq8T>@xNNWJ_ZW_MC1@GyY|Q*J_Ic?aC$=;}5)LTNbuO0yWTT03`$i&0%H; zo=~SZnl>w!NXcvoDP%Im~`kLWF~nZ5wN(ra#iUtE{S>!S}Wme)D* z+PeAGM?^X1nykO(n);>Uy2vo@1ziR&_=@=#f8jQ!Nu14MjcF8Tv)W^($6>WF=HWP- zJv63$oXrs)a|3?TwO-7laW-dzm>F@l(8!pXakj9=F|*=q;ZZS3akhwNF^O@udeJd+ z<81Yt$IOYdHE0<#FV5DmRm}W2TV!mV^qFox9uHJ(z=@>xgis-Ly@-Vjz~P)Wl0+k- z^V&ao2NFcrqBGRrHK?8#tR5=n+0o2m9BiSr>T~B+v)fkymQ)Ljv+)Z6_&XjJma2G@ zT}^MbRjvilfI2`E0B|4x6c?s|w5_ZIP;wohUjeWT3tO_K3pN1J!1U0t9zX+wfs{Yo z0+5y+;15NTP{%@ld}QDE33lbf=fz5d-H_^mOCd^a=&u6hpjs$7Uf%*_Qv|}ffzaxk zz4i-x1-fuWU$Slff?7uTI*<(xMy9wvhp4*hZhdG4Sny1LBfwIE!9;HQIsjDl1Yn=J z`8S{jUHngn?X$io4a>i`ulSK)-ulsgUVPbj)c*4^;r$~}7x`>_h}Wr~?7NQDa{Vu= z_O&eDK)oTs?TbjiaW9K;uD2%oS`r-`6l@02--CgaEE?QmG0xy!TNW!%*}p#}m}gxg zWpQ6kpssz|yFfWK7^Pxg1Ri>S0&fWz!`PJU)8Wbc02@{djG^SK04R;qKu-gP?o-2T z0nG3^Fu$XI`@RZ>Gym>AMr>tVUV?)Y`H(WOP!M_;`v65F>R?$74EuwzoPA;IvkD83 zF}fPdR$xi3gJt5a7Gp8qqSIW9N^~80o~jL60?+U(dbA~eh+^>*QTVJ0?Oy|ydHpme zhFKMmj)JzKa$0cnN|3E@!~UN5s|9)XvVHBZcC6JP(<4d4#Hr%8RbIyb;xRFGbRh;0 zPMpYe9nN63V2rHQ61_`1w9$SL+UdDK=s7AGC#E}Idf3s}i2r(qQHkfaAU)sMqtd)!so|C<_`xKP7mVBgk2L{wNap|I>M z#*3^UeqTv9PUqX{GBrK)UEw)Z%N#YRB5u zRIvlA9ZS|b5H)XK@A&z3ep$G|vF{CjdF(yMo-M5N=2pkrZ9*TzUpZ2)s9q_Z83+6ogaZrW7j==emmI2=IiI)e6B^uKcmwcpJju=WLOe_$04DfYI*3Q5s8 zg7>A42QSE?K!l?i)=7MV&1i>TAP#maBQkl{i8qa$rLNoZEJk6zVnMQfS3?9dWS#aP zM^L$UkO%4e%^b0}0>GJY1`@rHkoF;jROm$w*8-p~!{Ms6hwr^#I97fs1-C@-KUrC& zZuxuQ5vLNf6~x$$r)=Vhxad@Nw(QiLR+cE)B@!sx%+7W_i?(_d=`LM`^+(j~6V#uX z6*1x$d)v8jP6t~OJ{Xvl#|`vGmAmc+=1PAM_F#W|6d2;PN8~4^&lfiiRzJvi>jrv6 zYrrGU1y>HkUghXOYqN=e-0erqQFznVzeCCLT8@oD<{s z&H>0B3?%le)8VNoATQFyg^B_KyC*FjXs3*|6s%!?-4bM)O4|bCuRJ`;aP0ymyJjkC z*jpB8NA-nt2%A*pu0_E7z?{Fp zjA{7X|ik2}u?o0=McmVoxyrvVXHz%?fT^oB(7$v(ueEB)0-*dlK#v39skIuYV;EZEELsN~Rsa>$0b0DyV)S3H zfvP13p^t%~-Ucu+LZa;&`$~3Qdc$JOdQSr`!Ke@n6#^(vt;XnBUO@c~?`xP|b^rx4 z&ot&`xgmvV6xRXzemge)eXM{uVywD#+CsV=alVH-+XKy0=uwL12w?Kn!ITIruW3y7 z_d~_xgJ9bG*8`Zp7MS$@djOQMLz4izZT!~Hs~Tz&M&d{#MTQCtH9llYjgngU7`N^L zrW-%e*x;AOS~ANV8XG==C3p?80kDXlbU~3&5M|x{fn&&zuy+j7Uzd- zn!V<9nn2eB=pS`}Mgkz=oTm5V8gH%bqCLRw4F-$mIz<*h+FpPnwXATHD!#t@$ysqs zN~$BTCHH@1vX67hSll8VHvr*%!3eec2Ri#DO-YyqU?g7$G93YSe=RUhdZPi*uSx@b zp$3o}K38kWjzlZy>_rFVq(qm|vx&r+J!RS^0Zvm1jyagbgR(R{hcE%SaK6jGO zhciF$6XXb2s7~7b^#HD^!MMbddQO^D# z-7BKakfl>EqY79zU+i6G{fC|lJ^g&B(-yyIMd-ZMf^qe*ATA7_Ci<_tIB1`okWz&4`} zw)?NM8q4qwU^`OT^Z>C*wFqbgu?2hR0l@Z19c-2xtj67VOD>dYE@+!h2GGnpKobFw z(Mbb+CHBjb@W!Bmo^T+bW(7kPFxff{rAqtmY;58}X4u_M=28mN!4ZE94NtL3(@%by{6OFxZ6B)1{!(MtmQBG}c zl58~w;~l^^`!%aLB2?hRY1KShRYmU_8M2JVK8-A_zTBSg>k8C%p~3u>IzH8fXSgC9 zH&~lhA2;?v=PhwnRzqIcEV!^++dAxc<|`xwPo(W;!LAmzi|(pR_E5~ZBt>&Xih|CN zRus|M6uDO_hFpQy&zj#3k{%6~ndsaKbZpZgEolq(bjWFlmUKFx{uKnDeh)6n6GW`1hI(3HOBREyZLT^=cGan;qPmGUe;g z(sLsJ)^sfQni*yYXV+Rm*SVuv30%%Shpx9AXBknE@6ox@i zLg^uv=VQ$ch6=M#_4(s1O7-9WbJY)I9SKZHt=M2UDsj@UJ+HC&wP^cKQlV8k5h}=? z+7Bs3WNcoOBA}nQ|8B8Fj>w?J(2}~~%r93<9I5s=-U1WSg<8jTlHhKTS*g`hJTlVg zL?3~GXr%wGf>K(WRo!arop8yxr?Od9n6WqilEb>ZSF@_)#@>kP<&n**&KY~4kogxc z*efEMRh>8Rw4@^>?vf=`)M-}L)`+`g4X;QSmpvSodds^2uz3%Mt-+qgtu8(vj3TlE zS3tpPMA^6^L?TewdN{06%hWAvxWstL+H5Z?m0mKeD;kP>^dfAuts{C*kBcGA_r_Rv zvEY*ywhL}NE!k3MDdvjhb!O?o4Z|K8k8I0YJcWhNs8sRnB=74jC31|p3%BM4i~Z{1 z_E@mg1FK7Qhug-R?Z)g6q|`aO+E>?pJUn<(+-tnm*y2*sK|zol|RsW$&dEz}^Be!rp^h^MiY@oWM~KH#mdg8YX3ddC%Of zVIOR*W#|bZ6%rx!mUccK2p0q+6uxLYQ2hiO720e6PWU2Pto9BrKrO5VC1XgTeiSvFiZR{jrh=ouI5anq@n&3& zfv3o)@VR~gs%s`_beK8?Bg+P|?h2Vytr|=m5;b9P9)>FsSoZxDrW|1Ep~(uXe>JjN zWYHB}0HQwme?e9*koDBagdZBnoaMY14yb8XH2DY;P`c2sC zgFpXgZN|P?Ru1YG z>nxiUckK3A4jTvgkhUSAa9Pgqy*+H9^>#N2+ts4_99>p}s|vz*wWtyWk*v5kW_;YG zh{p1(8F#5(l=wQUz8!wBK{M^{>OP6qeV^SZ#cype$jbiakT{2w&%5F`Va4y{)*6S9 z8b2%^fTdu>UZm($L>TenJ0ceGkHUZ&%jp+}c$jz=xb(uGMCG4?=_@B{vukZtr+#P~ z&j;8O!Dc6R#(V&PyKxA+rKQ}RgG$D+AHr7uBx4Qqq-OWa@gKt;`$@=9Z+v`5A7Y{h zajZZYPX;$4R+LN7z{1IzvJdT`j6&27!3&_Lf`P6+nBo0khY(n999ZMgwK7tXsEp%z z=qkRuj-l0Y4`^GdvrS+kTJ9R8aHV(MDNa+-@Ur-;dRM`sznNQbW1zlu=wVl8Pia-N1h4Vk7ndZ$xm ztLZ1HBEZ4{6XK#S`Dbpn9z5e>9jC)0Ia91DWRv%x@W z09yo*7jY!Br4PJ7K}R&f*RrR=e|kC`YP|26@YfdeOXYLnzb^~Nrj&Kd!=HMdUyRW8 z>seQgRq|Pr;ABw=np_gxqzYw2=Ua_Mi!`MZop3G$)7_f_u;*%lF^l>x0GdCkfevyZ zpFr1x05b9)09slHs4D;-3jnpY0f_pnr?U3~Xjw3jSUx8mYJlq)W#U2&Z~=WDM2EXM z^SD@>7(d>Foe6+Ia5B2*=B8Y%8qerNoRuqoq%DU?to(x)wR2g$9@uWVECi3v+Bf2! zU}0S^HKv!tu=aM~Sc2NeL)AK#z=4QOIi465tlWowEf4OOV*IYCLHtdcGDEms{RM{eQ35F!jR#L>6`c)#Uqw09sK8DD+jU@!o41sF6PZKx_Rp0KE_l zq;&CffULzSD7Dw&e>)aleH=fi9msy!ua~>VNr#@KJp`052BTD6?ulKv&%U84dEcfM z4zwG57+@=FfpJ+Sd%M*r+^K=y1`HD*x~aKjE68CY-$SXF5(CBg|u%T?P1_ zp|b%Lh~073Gw6XxEZKEr7ffNd>Jzc8nfYBMLl&`rEsH<#HPB;!Bua&1Oj0t6o{!G% zR#CKc;c`l6-KMy03=@XYFQal!bK8gLT#JB($_b7}Wc9CwCui1u8 z9P(n`c~`PsG0&EUdt+1y8=?FpPRmM?(`;4NJWti1X#kPkZ6IEMGV$scVF7c>{3}MGj9H zs%V9?bMmX~_T?cF_KHT+EFstLtA`U;ZmYWFjHs%xN7yQt*EeFWv7l0Q7_O@WeW`H( znk5&XcNnoa2FU*LRlB1(9C5tji;>7Vi#S|>7STdEfeKLga&XT@f@(SdRL{Q(?s>qu z4aP5q{eYvnj(ivDqfWsZ*@!XS;IUEY_oOP@ik>~HE%v=QILa2XJLgjMh0wkA|0qQ^ ze?{XS)z)xPP)`&zz==|k`xf3}G-5yh!p#jw4-c$FFJrE9bJ5PjS+qL7UM(MEgyOg< z{1Q$NI#$QT(ZaST}zyBTyE1d>e_D^5aMW>bd@ zRYJPsb+8Nt z$cUUTo>gQ=P6plL^h1QMk&Qhcs zuNl_vN@6-+y#!r*CAe!#D6tc0NJ;Ga;I4J$%rXjv&iCtC;B40XyW2*p#kjj%H%&>n zY3x0B-F?&DUAo>BHy(1N;W~TOr%yfJc}y$LKV)abc|A8>>)>2VY|`0pqWX z2z;@5p4eP}VL`80Uy(Z#=f2}-#_{tNT_Eh+?Utb+$+yOMLEF@e{2# z0nl3heJUczZ`Au!M4D&(nf>WL#<9L!j6S##r>2uo#?5U728RfBy^obgo+_hEBvWK7e_ z{Ayd{WsPDwqkd?VsNZaPl&l{n>PNF?4E5wHE6^_UZm7tRZBUbmSB+1x&coTEYExfi9=GGR(wp1=RBt$-ZdzXQFz0V-4s8rZ zkbwsw#23q-q=uaEOHQ%kHy&c~ z6Gwj6WB_1=yB5Ah&LxX1sj0=Q{NGsJv|+BI4&; ze>rjO`jZQjjO!{o%LYSsG;wb4aVoU+$1(Lj%0F4%_M;|Y+j38zI{C}>@n>Rp6r4R{ zzagRu4=r`9^H7lN-3T7><$$h5TCD9GM9v8-ZvziJ zG^Azh2RwPk+KlDUJr1YWDBW8MC0iG)dv&tj5B#a_*~=RJnW}vl?p#uVQ>AJtOvR!< zxdR2--7n$aNg(O36-e$i`0r?tePYvqzMS}Tec1`-T3ej0im`o?f3DiTynDU9P@IrS zmqJ%uPlXBFNhR6Aul4$#u{DS|b8FSv$cRgKHr~6igVCg7K}>xDMlE+iPwpx|_sY4o zXPedAzB={P>2>E$oo%)l4o{4nA|-xIdh5hrdv`AggNrxp%1u9ph)Nt2MBO`IS1I30S!j+lDe z^G{WG+}c8Iw%=KB?yUW$x>*3ND+PNTMwic_D|xoMx^goW0WU}Ac*8Nk z-afSJVWVr4_(tXB9|!A;))hUxErYJC57w1?IlL_eBITx52CGWos5Xw=Q;T2O%D5o# zgLoLZvA`7ce1`B;4}>|F&=qvQzk%3}p>|^$6$|a}G@WDuLC{EVR4yL^NenE%@XCd? z=dJa2tiJWk*>xAroVTv*yk}p;#opCt&fE6JgngWU`jTUL%)=IE$B!Z|^*w0~mR`n873b0JR{Zna)cZz=?Paaln8msr zAR)E`TCq6-e^Iag?aq(iio%2c+(M8tv*~dp%ChfoO9{urotle7$)bs1xv7|{EH8_b3RZ&d?G}LFd{HZN`>h13Fus>9a^o-?XV-j?UI6{ffS&sN;&!&rMm0 zj4D$}V#n~_ejV#qN=@CZ_gt$u!eY^IR1WqxL29pPrB=l{#mB(75Zf88*qk%bw`#|u zWU$74ZB#x+kZE;g2-U3*uXMXWJtiB1;=j>sjil=bYrpt6xte+BRiWh45cFqUD8!q^ z`>pMi6B>rHu$A}X3Bir#wPJEOqmkbnI7^p}-_FT#wQC#JfjCCPH1<8Dgtc9Z zLZS!4p_?yV#7{5zUBA%>A{lT=j|p{ptgCn|Qopb0(!~qdVBdDFo9i`Cx<aKrO``6DrSB%VJK^Bkr^+ai^Z!_|+9em~nDyTJp9I3Qw_ zUXeyVIIGcFYV8S-Fml5UO^lmq%F`GU5Lm4|mZauQP*hX{YVq9T6Ds=t&4BFGHZkE` z^1Y~6JT6N=(LlB(fktq0h1avdz3PG^Pi7AwKKetV#(QG-gBJ80K(D!hBL37Xw_cN= z)dqk_3CP*REdaf)1qqK@Js_tI80@h*9)IMFUgsb1z3)L^wk%VZf#0m+t8;WsuzAQM zDE*_)gX$Yvsv_SLRD-hJWDvLxEUe|r{Ui?Srj=bTI9iPGxTit!_L3++T{B<7K>Znc z5?=!7O*fDkfawlUn-L(g%4AAg0eZ^~R0P0!tViYfI%yIhSuEQCdfN^3J^+C@LYjlB zfgu4)m*sX~-f_bu;Q8n-5_6bs;Lx(S1E_bkC{ZlMz#PHbb=G*p)4r`wvtp6cHj5!z z9zjX+{xT@;cA-fAxHF)&CxGZRI~JQfyw3Nnb&Q%^EZOK;+X$6}h1^2qJ3;I{EiqBP ztsr%8pv;y9D4N#t6{y#M+M`9Wvm!!bux$JgehG)Wg?SI3MGRVMfI5mnyHh-e z7_{cvY$8vi`$6X0@@Q2HrgktRS5#!n%PguYU^)_AIP*>I`QDS%>bIvVz9h9O9>kHF zUd(S5_-J2Tm1E)h&jz4HZ}35c*ff-lPg^UDS>vIC%N+*OA-`*jE_-b@`siPaG#~QQ z9Voioe#x6c$ok@eD|-J(uR{o(9>CUQY{cXuz7A+pLk<-p((IM6rU=|eknD(!T?QD` zD1=)tM11utT@hWqJ4?U}!mK_C*WM!M2^lBiJ(R589tscqF1LwMc4%GuI0P@qHXT0JHz49M)TQG^o{-I7uSapRwW11jN=(Pme>O2| zVB24L#n)LHC`5TRDM5Oz0h{??QwZ4wY1wqFEMX#99LheGX z3CWi^vvdU6S)1&Te5Y-6tUsniZp+3eq^I#@83VS#3Sf;vO8QM?bF7p!>g3~l$9Nin zlVtucY1g<&yAG^v0c+|e;V!J@OoY_ANm~Yf1ov4zc;7S(WkhUqgctb zq_=1>qTI+rqZY$$E0kLjPrH$5zWR-|H_@Co28X@kKiO!SIgyk|gHnJuZ=$dYM_jY) zB0U6x4yT_wDqNI#DDKb<2Ca1aL|A>&i9F6^44@RZ96t0orC1?yq0R|aNSzD8pJ%$X_}Um3hNggbs>iQ9ln2Hyko+b;Qkwy_IckLHiH2Vgy% zKEV)aIM~w|w12=wj}VL%V8WWh_7%V)j!0`WMd9XvHdEJwk%qK3PfXn$425;}Z}Wj! z=0tq)xs=wXi@{YQYX(^wYz(+)@ZArS+R!tt%@B{9k@~bYuLMTPkOXqx$s227W=o5D&C?Sn{@81wPY$jyN#aNOO4)Z z6~siZ)`zXFHhO0-rLn3hEL*1!+l_ifrOuaW%i8ufu4V|OiKbCVUu9iq>)(A5jY#p+ zCFxhdje%%HsPfz_OA5!PP{%?HA9NCg!+y6#!rF`A4j*JwVyv{FzvX|7^@(NIPh9~K+|w9K@EDOL-nWqkC`G2SA43gePt&U zB*rHs$s4v+m~vtYBJz#jM~nf-tP$zO`(c3*}-u@4>tj!SUfVvX9;vrL166R8ec6dh9r&qV=4h;W6p@(EE25j}jBk1MgeQ0HjwkpAd zlRenXF<34HAxq;~?i;58t}_-5O^~M!BiT`S(GiOJqbP$!tmh+70KJUa)tFO;R)aPp zZvdtNBGxLt0o10%6o6D)AK=nWLT%Z#{j+1wPFM$)kD{xFuSR#{m3GIj@H$;cy~Bbd zCaJOU;jcXF;(ZX`E0&MlVa9Fgz|{~>W`0L(lYmNP=ifM1x2Y{qjP(x1$V1P_B(NfY zDaJiW;$v+i62rX_@dl+1Z?0nFy=XX313q%7(#U)-aG$u~Xw10@2pwEa95vjt)82v) z0s7Pp6b^t-k_0sx1V|3&KLTi<8>klm!+J}QP7e?{OsE8iJ(~X8uLaFw<|y_6NaZj* zA{)<&0cjzbqs%gPYrE&L@A)BzuKjv*w}VfdjXa|({=3*2&}GF$MdxLQHzwYtYTk)hmoTGI+j)QT@_7Ms*#k8YKw58NDG;L zFd?)UZ_=S`a&Iq~}^A=EEb!x3go%-K8 zcBQ_dk!<~CKTJ76?YpYdUSy0Y&-YTV8lA?vbK}Q#+IVRW&5~PlupQ6(@QnuLL%cb! z5QbyG#@YQ6?2ZybAd$9u$30GC2n`J|iqq+!g`K^@t<)RbjK@TG^OUwmIZTKKsBJkQ z5a-nJVy83eI-q@nb?F9uOHVz`7T~;$E?6UTxy^*x75DQ+q&<{~ZOXgwmi>q*UFMx8 z1xGJqy1}~|QF9zwMSDlde1*h65GsW_jnL4*;X2s}xi@`iHZxC-JolPNDm3MF19rw+BY!D>i(=m<{SC zj<4&H)*c)ab|snYl8~OCtq3*fncU*>=z#X%1hAOa9+pIG;42;qPQXWaGMwdCt|1JZ zaalfI2jn@Ti_0AH6GiyxfzH%CP>s$Ljw<;91b=~O@0T^Ave%c0RDB01kLaepb!B% zK>~0C*#US)g4nd0fYEdnrF9ap7B|>?fc%8xS$U7~ltCUrDLMQes8%pmg#!4Yil%esP`@p}k^8$^4Sig(Vq$sgR&1i}zSlqjnaG?up@4;<$(O^ zg!QkNFe$-b0XymjGtMz6!|`S%Y&7RI5sYfSEUn)FJLU$P3CKz(Y)`F(g^9c&ID+!E z8*CFG9&;V3m3Jc;Iqk_&Ln1i~*f(ylZh%a7!Y=fXd6ShMQ5BTqZm@hn9&^I<(Vb!E z0Q=Sr_7WgRoUk26nKxjr8D;Fb9j6sQyRM1uYR=tnou&SHaNER`TXBOQoFJ!cSDCE5K6 z)G0SqcOa&eNtD&Ik*}ARnfeQ$pWHwt08GbPK&~09OaM_mmInA$fPU73R`PXkP78Na zWHz`G7VZON;j*!DH=Ug0Cv##L-ltGLm7kdu(!aVxSVoo;kBBg}cuWrJ5T5r=yRw$9m)nX< z7uX1ZzET%Sb34mE&zMGYI}CyqbQwj(<4a~{mQ(2y^zq-!QOv%@kw=v_+{JbE5-H+? zQGZlWogq8i;hH5BsIK~MSTwaJaZVDD&L^l1c-$Mp#s`=uvX!IO61{JuyI!Rl&6yuV ztL(9;o^z4kf5weuTH%x+Yh`XBvnwf`xpTgrN!;5@7L?AnjbS|Aj5rY$xJK!mdghHI z)Z0_NrYcQ2I$QtNWy+B?FK;FZl|2huy|>Od;G{K{2Ph+AL<_jyf4rPUJ`pZN4yA=I zQN^>rq<(^5A61fv6)#|BDwDOuBY#`!gRW5i_`)Df{*dAs;r1s zrBZYOFh^msEX11zSc^VJzW!q*XU1>q*wFF;>Pi zDHAJn?`%oLXzD-<7w46;rLUu{cDRNauBq#dS-d-(ie(YDa$6pclR~oe&p17eDk8_( z*z+Dg2hSv0)(R>|s#p_=6XhP7n~<{uo&W!@d!3*CzkYY7MU~=j+ri#c`FKTQ6=qyj zNiMDHnFc$Kl{O`R6MIW&G#b3PBY?-w3Px4FkVZLZTPDPsmdzJ$X)_bcP&ABfF@``EJRHM z0E4kWS{tI~!{7Yc&-l@j0y%fBlN?C1#sFfsXo(47+zC=ct0fNygfQqxH>qijK;G(t zq^)(cfVuSniMxbdI$E!Q2QU-eFm^m2|B%GAM2hV|QahUfn&bw$8Gy7E5_FhAl#*O~ z;R(=WH_&7NUVK!7juMDey0nnJ0HPz~>BT!<%F;dn-d`m_$0bPiuh@r&Qz^6{Znl04 zNcDdt?BsQ-lMj$nU68c@dmS(%Y9;Q+NU=Rmb~}g@q)c-I`PLbfUX2p;3xTN0kTRos zhFYjhcLR+C;D#m%Izu2jp+y$3KR`3wKr;Xs^_T>mmnlj1x&SoO4KxRUK95UK8-cVY zVE{n?ashD>-Ui62H4@e#L`dCztjJg(khi%YDHx~vv_Uz%RpPEjA{-U1pphjO1kfxu zP&)uuw@Z*N3Lp|;v`8r!pxfO*kvj~^S-g4sHWG+xp|o{F0GjOv@_ZS=THlc%F9MO= zW%~{VD9a7h6M%2tl^{O?kqBiw4g+Y83y6#G{O<|4 zX{C_!mfRwA6&BjpZO3n%&w>l;fks^THPQ%Dthd8|utj;H zPL(EsBf(a-U@P!W;Z}i~#cP$)y=yxhD*6N??Nv+gz-D)Sf@y_n&?k7VFsk|l?-d?K zeS*&llZQURcZH`(pWwH`%Tu4=zrx!~pU`E6kGDP{V1+N{Mgv#)`RWsbR`~nr6M|QC z@z*DWtO)3$PY7KR7@$uGTM-nfPY7QT9HdW(SP>GePl#L*8lq2#S`ikiPl#R-9;Q#| zz9J%ApU`7@f?Z-PFYRui^gn+cxbZHZPFUiR2r7in-_4A&2AGaX#! zb>rnWZ{OAdSE79vcKC0$h2aqDLo_Gb1+$_Ye*lkO3LMxLOzUJqH`0`)%dPN%ZIMW$ zYc#`kJ0NfF2kv5zftO+q6kuaYPb>wDZ*45p^$OR|N=VQ*u2T|y6TE^Fx`wrfD2IZ( z5%r{mZY#P+h*dQWx@^;l1<4RO)lJ$68@TirTBsd>DWm{pDc(BOQ^|jfEHE@M+8SX% zze1b6u*?;I{F({>Y2Bp<{u{}U#_m$#^Oa9s6~58zZ^&xPF`^}vHr1TlelaM=@a7Hk z7XvNXBD%7@Ae5GJT5G+FuKWxzJI~$Y&c0@5Fu?-x}d&O zS0_dxvQ2db^u_fC-l+C=VFYOR{$~ z19Qd=GZ)WqZI_tySOm$BB9k3L3{Yp?Q0IXtzA8{;T%Nje=1nrXxxvbgj8N)1&(bD} z1*PBJC{=^XA)P7&v{VI1t8;n+bWRHr(mw@=-AEB2C~%83q*g5tsC_tqnK5Qwp5u-6 zkT~f-$wnL~p4U%m67ZQ5N=u*kyA_1+3i#MorWhh2o2rphko$ za7Fb2>WUlcb|8Lqpbpbeo@$m9T3>)V+(1_Wn9@xqb*CO6Pt3r`^63ZAA8w#>0F2!w z=mjzSmupY^1M{aFCK}J*ogguhUgVyjlq7pJ-TRjdig(kG0n;;4;*J{{UBjr~0N7O* z7&03J(`pge^D`Z~|1_&yey__DaZ2&x#DnV&F0g_Uut@S!LkPdMlyY`o$10J;enHst@FtLzO z(Yv6y1e<`_jChf}3MQGFcvJ}q8w!}g1xBmBhYwVh3272^LcNWf&9by^1W0uQ-44KV z2{L&FAk;fD!sh8n7Q+BCx`CPj*d;-#mxln6iX+f)fIQqlp9A1ERI*pqIjH;yfJ|QCBs!^`d9&C?v|7o zwyOe$psfh;TEvQNsR>4binkk;GElf-yiEEyG@+|;I~ph-H`GKR4o#4#HV@1|Q$>*- z;~0Q^-9Y~ZVERM}IzZFb1d?N(u>dh&8_I=OWXfeJ0GZPyXeovHBak$PGXU~;OQ~Qw z=A!;3L9@IlrXY0+5;YE}E?Sh()XBiix~+2`_|n$EFScQ{1H)r2ui{G~CVoz?tm8L< zVt@-pS`tt)OI7}zP5oB0Bc9ZX*8{6}2U3r!Bi|8kG^Tj3T5e9uS~(sB1GNN&x~~Pf z0alr{t9k*G!{}Q83vz*xwweM!H!OzW+>bKQdEul(W=nnvz%Oz;LQGjH` z+f0DM+(54ZFsxF7?u7lx`ID$AK(RBG92JdZRJ{OdcA-R__Yk(86w!2mB3zQ!GCu*|LDE75Wa$&&+ydL%ZYH&W*AFiTZGDA! z-~UR`(VZm7ww*zHU*)-}eyN%#qC@N-KFcRrL(^7bwW$c9?nerJH%R7Io2YvyEg+?8 z2d<|U$IfaQ2SnCJlB)Bpmen5z9sW3oA`tnCtj2gDoFfsF{r4Rp7N;e~0(q_4q$-E; z=B!UKiWrbIkwINC0`MvET9A;>Pk@|#4LsZc`ONRdqyww$yP&ooNE)ku40`-$`tsoE zpr_Ar`P_$xbQ2!gQY|#Bx)(Z|vq&n8QY%Jkyzk-$8#Y4>st~72LPw+1?-yximV$T&})9_}oMAR;A-Q&*DT1^+a-!iQb7s6SRqn z!r6f&=Y1$8V>8mxH`*?>3b;fU9F1e{0%Df~RU}Tnk=@(^V3OQ0Z+@gIgFlfewV4D+ z#zk8QP;WQTcmST3ATl;q1-7sqfb%f#N!t@Zg|aF8p+%sQtfeAKvi1mi#G_Q3w4=-| zJA%*dU~=;owfZV*HFs1>O;!zx7A-{~xHX`59FYsTyzlg&zKsMY$4&PEm!ic*P|y4q z5OcpJKAaoGUVbb1$Xmgr{iMr2)U%dvuam^?2eDKwF}Bd89E5h`%~|mC0EqO9)R+$f z)W;3nUaPf z;^Zm)T~NGhI||I>Cnc`dNWB!XD4Y1hzzuN0Q9t_rX;t~;SBWwj>Rk8h)c|yZ8|X9u zkDigBDH0_0W-UMi-9Q@vs5mP@+mH~|Kv`evfEnb5sl)SKf0vkks^CtRZ#_VR-9Q5X zsC9q}r9Vri)Bw;B7Z8_URG3lu4sTv9<`~FtLh_Si#0|iux!_3ubO13pT%uY$;J(p< z5V1}f>IRwyz-JK>v|55>z1RfMjc%Z@7^8AyyaaXVgm+1Hi_ZZx%nkG}0G>z`ATkOk zMBlfDT76}?wWNaL|Ij=nMjwKj)J0oBZMYk?ZJ@M1Nm7GJGc@(DA>^Dau$54-w7CBG zE+ioNdLEQUxKSE_eNF39Bqi{5x?AN;>Q`L&;?$^`$f3#$pf=Kt+N+?nB~?-bUqKhP zey!!JpF3YKf>OGcl2Cc!X-4G;-mWU|g^MAr7eh$dD58S2I1E+Uz_x+nC>M(4yEy|| ztLA~;*!q$IKvM_R(H8Q{BbV<)>|-kGvb| zj}-m4{B=h)1|{`2>XqpARc+{3P3#^P3!RW04K#IL;;{o9jn;A`l<=E5MrBj3ke7PE zv$5GmI#|}fHvk)>g|TVV9{?z>M@EY37yb)O;2~wrr=eH&5x1K^3tiI^3KL^jOX%xA zgqn2e-~14|;}qTc@>J-Xr|HZ6XG6~~3k%n$uXrfz>xaXTwf2X@eq2Xi?q46ae=~hi zytiCCjm&CJ5BcW1&@0~&UQyHOEDov)^m_18Xnh+c`Bhu!%0JixIweyG11oU#UdWcV zFW&`@$7-|1&gHuwSvrX~Z}txx0n%#Cj{wSW1N{YnwMl|HQ~{E$2k{q`ac-cy0a*W- z1U*O~Vo&OqPXM~f4fHwyK~GB1D7gMy`TG>8o83@}K)mWe`5DM|)aGg*P~%-tTnFw4 zru`|IT9Q0!Le}v8fK70LkyYcf#;8nPD?$B?;!q3OpB@0{7B^4<06o`BP&ZY8q}DhH z(5-Hu(Ez9$CCEx3lA!Dk4goaL4b%gGBby{>iClLm%jz?LCb@ww08qJEg6y7T-)Rf0 z1*pj`C@#Pi!04ZmxZyH#sO)=M0n60Fq@4vww>QwXT;d$8Ive)k?_pH)bph$svY9XS zgpEptDQ%C>L3E0iD6?{I0J)?$B`1q<41$dJ3%v((`Y=#a-B39|oPJB9W*DU_Mh-f@ z1d1(eK?CGoAD(ZIw~flrc#Bp+3d!AKMg85>~1?>r=3Oq*KR#3?%=hB`LIM z1jvo~LUN*`=)9C?={@`gu-jZ zd<)F&ZkT{CjY{vYB<3ES0LhN@JAh`pfo=w1=TQkdF9QzCnsx%9EH_Xl;_j?MTpGq5 z*%-Tid+05)R?Et5)3s&>SfDl}E5%7ro8w09IZ*mjQd5ufP`M;m*6N>;SZ8>!P0Yv7x5FsbRAApyha+1gy_t4Vchyukx z>_p+eppflGVaREta{sSVfbXdSBz57B09oBYPXchmZ!%d3a8mp&j8m9Z)7b1kU)-jE z8c9Ny;VDqdaicZ?lqQ{%EW{8C1dN zeeM2F#Kr&6GplPNzN(=wkRe{Y30_sPoI)$rGq_pk!Z)v!5lFlO>&iH+*h|2qj<^7r z-33M+>Z1S*>LNjYdI6Hfei5KMv>-M_&H$h%CMdN-0iS2`EHbN0M(n}0(YUjHsbyDjIuY+n`tRmoZ3cq8RUwzB{Kw0<%mAI5-nmop-^z8&%Y zyPWy8$hqL;DNjLE>Zhw9TB;=~^!}e9I4@4}QtPaZQi&sIky7RYB+Y*>Aj=XYY^6sN zH~-|Y9wJcgbOSX5Ff>tu;*9{&94-w6sK9gpm1{vF-!lM-L?{f`eE;x8MB|sdI#fIJ zeV8~QqO!5;L9{|kROCAu1P>$P1uwX#uu=l8kbu&Qqykv!0wksSGay6KBmhM7~=AF{e{i)%vS;UyHbKjpbXG^-51cP}(&n z5M1a&kPMWeAeDDB$i+1{h8e8* z;y;4~+T_r*Upy0e?HMAt?zza1pW~FLI|OQ{LxHKj$myU!5WYuCSP0YtvJc_S`B}jETQ`#2yqGbL;t^k3PfAHv=`et* z-BNl0fEEYnxCBWR77ox-El8BYe*qaZTb2UV4tl-0BeLyfCM(o6ym+qrd3Ity0z~iA z5*5OF0R)?}WCrY9byKyK9a9v5_qzb8J!}DF>O2X1inK80TdMA8fF5uIEeGHS2WX-M z#ei#4VO;@w&<#|S>!G}gH_z8ZshTBw-2htV2HFRJw_Sn)WzQnja(93pas!zG`1%eB zY9SEmG+8V?09x(>;vM_%fW#L`STVe`LK#Y7m;rp)1xTGhIw1EJOV}9$R4=s}sd{4o zdc+O18i3Jd67;azNnghTw89Nk0>H*QCFnuD03`{r_XOxsH_+z*^jj!FDV_jPt&r*^ z4xp88pfLcvy-0u%;;fBe)QDui5D(ZYH`ozC9$qZdIzXZzkW`$#0Q!#>#6o7IgMG1w zSr?OyA7amtV-K?k(sbu2)Jui6jjW5lN~XUbc15p`@KPW2wkF~RZIw_%UE_Spt7l5X zm(!Py6;Us)q%Vq|BE|3;ecq({#h}KJbV)(clH5e(I8Q9ey~B))GK2y@XcGIJd+I2H zf?nSuBKs#8uu5MnCPj<}(+M;HZsM|-{P@m?q_H4HZ7l&Q)M#be`3$^xtxW$%l#m9< zb7+ho`dJ+EdDH1<$bh7Pp|o)c`(qRqIz)$9wcfw=m_?0N>{H^m%h}!|7SW1H!)1%f zZ3r%MJLQ5x?2QuqAh<}^+H6{Yp}V2Z5ps-5_%CqMS8&q3@Xv9Q6B)dTbAmC|)cEi2 zpgzo%6Hy-NYCoQmw(Orpx%<>mXGMbtGCk;Zv?gk6Z4_LUo9m<6n&}H>?P>%aUdJX< z$!dF%evo^vC|R9bG-L)sT!HhZdiJ%U#Ef)g;X5|D(~9g?Oc^EN0LP*21|5ZHnxfa! z!Hpe;q3x>Cr~NhHm_+%BqEyl}-l^B=Nx>-KLL3W-sNk&1^~I(4kI_90yNE#&DZLy~ zJ1A9<<+Zk7j4q%thwc+udY1c?5a6EGuRb96ydcLUSxIpRn&^3cT1iz*HhzdUn@Ico zsLwQ-Pa4_YUe)Lc|3P5H`kz)uQcpL`YA!6d0XW(X(PTa==)eK3O2RbE{!G&&&df%SVE9mj)wB*H%(iKIiWWl$5O{dE2AkN^ zzOBBCI^-UE5w!14XVAX#1V80iA{q>8;ybToJwvJyo3f`BmR1$zjkV=s5{Apz(H0_1 z&Y;uOntkYefw53&a%~hB`9O&L1+BwbtDE)ymq4!p z$Z%_96b04MA1drHv|n}&s;Q|ZyL%#ZZyY8ZSQ_a~*@S0$os2vx35tvZdLj^mjO;@r z)<$h@0WFpTaM3}B@YXO}viCJ907S+ii%dAgT1I&n6gN#c+eBQ+W3P!rxf z@101I`@LC~=wWYo0+^TqR5Og$0HlAKaf9aY|@=~A9?KArsY5FVf_tzc4BE2_LS4J zyPmFQzQtm?V&l)I_6c~zNq0sWn6=TfpU$t}LV4l)2JkGZ|LwPr3MBQ%c@Udx1%Km? zT?!%TVJmKBdFf(M=X~ch-}e(;w_@w&0??M%SN+}XFXA!J=Db5`+%;eyQ?a)4^3w7# z*0Rbf>|Z5XxEH%2!=E)jM5VEnV|#PHjrOUsdj}tjxJtZn0mHqUJKupTKXopJnz_7Z zFDRg0v5M|7IsjlS?!@9v8lOyql3A@Oq>f72AtDoPgeIryKkRGQnFV}6{pO|i1=E{)w8H+BsD7(0$01Ld&_9fgGb`)mIFsGYRr?75`0#nDG7^$|zj*iNOM z8aFR1Zw}UOH~JdQI)l-?J(`5}(vTfDQf03~YaazCIqC($|L~-n`WcxgsMw1u?6xJ9 z<@P+>$IS?IF^IlQb;^JE=Rsub&=cmg)V_4Bch{Sqpq|2(S77Ud|8yVpCcY@DF zVx4GP;UV#Z|*Nf^%&(n)eAscij zI&9t{iJ-#np}7X&*%yTsg3w$>^IFIvFl5W>Ha!(ZC6rZ)U>#HVdA*c$T%|4&Q)Fl| z`FNY&@W`f7Sp&;M9_3*XZi_zps3s2v$I%%koezW)7;xD)nvKz+4{~i4Xs@VRr^?hM z>M3m{3s_-3GH|9ZNpR+jjCmQ8X0mGsFI|0(DHo>b;D4oBLES99!iR1d964Y^-#Dl( zj9CSy>-(D0!yL9@}nGkW-V1*M*~5ak-k z&l{_eQJO$G_{-8y;ns9WdVJbCgh^X8fE@iRuW7JHfQ^fej9iO<}BF$MPYA2_*-6|B=Zl&{+@xDKj9~?h za2xd7ns$;ci%`=z9OZ4xFNd?G+eH(>ZMTP6}X6|A@b+cH(*w6i*&qo3N($ zGOE7zipeYq!cW*UHlOHPajaMFIQ03Y<%{Y1q?;z+M0DBpi3o~^?`oP?U;`1Q8}vd< zOi0d0O~bZdA7h#xVT?V}^ac+fQ<`4&^iR_py?s2>^d7$WYVya2X8=CDf_&6yeaA+R z0jhUMT8DR-k5`)BCjxhTqwwL^H7HH*-yI)a%zeYX|3tFeyr)Fehjy7sUg8Q|50b9>PI#> z2W#$w>msRP($jWVD;cbMvtTeD?D`ip_fc18%D8S*EzY8;qkEt0)6Q}j#l2BO*hcB zoM0n7YD9FZ9oz?ChfXHtjA6V7#)jkWR&DEN!z49HZ~YtjdHiOPrv}W2XvZDtfUS{g z?2E~PpHXH$#(O+MLLxZMVoMb)cYL+wSteO0VK_IAF4MS@66kYm90%Us1S2rZHDBmlyUotLN zRF;-mu;gL^l!m3kR+Mkatt>CHR216tD=pTdN=q?Xy~VZ&I^lZe143VN^C6_ZQ>~_8 zm?8D9wVMB=S`Cv}o{CO3M=C7XMT=7rLkPO&xvALBGF@b)mepq7hD4}-^lXH zQrV<)Nd+z&>uX4%?O!65W;Z{;O-N^hNJo;)u=czS2c^#vAhp8-lUmd&NPxRh7tmUi zjam?M$EbS^Rv%cuc38)JMw2W{dVR1<_sUy3@+k|FjUY&^lQacYuJQQ4Nf0#6(e(W4 zYQ6Pk(3?6>Ah{<)TP(K#yG`4&BO1D^59_V#0a=?(tTZ_`oWHeOcVIVT#3)AiSmeXi z1ZU({5PL?OGvrtFX(Tvedpjdv(@oZ$@4*(`Ln!zvmD!0hpy+Mc^n_C* zXILkpZ~FpoRt@UaesRK*B6Ut)@X7e^MS{Z1HOecyf{wNS!k6zO#gC|0baaED-q>AR z(Z|}#QssT?pGYnV53(dPI{7Qmo)vGI9=hVYDj)PGCBS1~u>_ncIQkPB-_~mrOw~MZ zosPt=Dk?8y68Gam9oFBU^tEL;f=Vi>8{MZ#arDByfb^knpi5pQa4{Exh6^jq4oP}0hFIe2;4PvbI* zyCs{3Wh^`k25TpAu5|hL_`m@^`1u1qa_A$Le#(O}*eS8E+~7R)2(RzAMd;AX__pIspN(Dicb!s(?`ZPvWfk|H#4 zG;BEZqKDWbwD+eK;{2=9h4L|S%&Ego>UefGz|?K8ttW#4PAzNsL~A*PA*A7z_ul@) zNTU3@%~}D+ByI@}NyXP_eduij9>$wVw2^heS{w6GJpMe@bG&%jHFs~aehk3+cLb;j zk>a#{-by_BLMKRu^#~q+V7Dwe5nN8%Z>s=#Q43+`h=oy_yyeHoXXA$${yJMetA@0e zXLyxPxo@FPRKg4|K|cf-s)9e`KaajlxzM%=qDmv(N4|e*CbiD;suGQOoVBzI?lrsE zFL=`W5|X@Su}GHp{#xPv0+2yg$Txa$`PITI;^P|9hYp&Qcq-NrT91OB*Ikk(7NLMa z#}MW;oJsC-pKuT$TzF^x)-koJUWqk~!5B(GQUqQ+!$Q#YyU)6PHnVJ+d z(d1l8l)8dcGL`Y)dKEN-{;gqKD~R9lgomJuAtU98zgV*zsnh+Bfz`0ndL`#?y`0FY z&nBcxcSKzgkE#vtnoD=|6CQm4f(yIHbE0JljXdJpeoH?g^zg%q_C zn@BU5zvANE71SckxoGP-m<^ze;^BJ-Kk^P?%`lm1$0=RA@bjzy5~P{hc1cy4X{E2p zFMwyHuDhCTU5f}+YakfLPz@HRYO9e2>}(h8KnymNbLJgE0XYxEf#mGcoI5bvXr4$t z8)8>ZW+C-$c8jv1&@J+Amfe7^|kms>5T|QL*aySao8o zIwe-kh^1ngdGvHMSsVRR2dDNM1O{4kq-{>%619@Pc++E#Ked*vXTp?F1w{u%hde5% zfg1FebKcZ5J%p~JL0#$Fpf2@jP~S5(s3-CLMZDj@`>-z%>wFv4Zg@Z1s2V*Q)ks7o zo`RpV@ZCoDTRfZ88D33ls9zJ#_Gy9xyh)A0`#oGA7>EZlyqeX10nO?}ypMV`tF}PQ zegrm~_Tu|aj2G2k{A<)Uymeh_)JVLq8f$Q@Lyh{jp+?s8;uQy z5|465F{6}G$S7kJF-jQai{e!uMd6}sQM4#o6fBArrHVqOv*cm|QJN@B6eUU$1&MM* zF`^Vvh$uspAPNxWhvGx&q2N$%C^ZzCdL~{yAFsB>s~z#`)p%9cOEvaVy?UvBz0|;7 zYG^NT$l6xtuDDyTY-H;CT`{)^mnGvY+ySB?s>OWyC@sw+IZ}6gGg?-M)P|YVK+L#9 zcj*NO0&mncjzJ<7+rPM~Oob9utoMNYgh3*Sj85a^@gV<)B#+j%tKZx=s8M2wiIEgq zAZ!1i?ie6a6|9xr8X;*oO3zwfLn6BeYZB6SYZH*rpCTcQ>Ya4?87kzrM9rI=M-7_v zR;p0epj=_?k4RKKhH5Bl)zvMa{FkKsb||Mz(#2_;Rw73nL$oeD^LcN@x*b%vB8n7K ztK2Hl(!Le6uS(j(<2h}Z4T4dvtjQX(4nb_G^@!iZ$#v=xCxY1Df|$|V|1lv1vO+kc zRI2b1aUoD^PPHwt7F9uWxYxTG_LJy|q@nN~u zV-$|=!~42)Cxb2<5aAzb9L3;FsF}&yJqz+lfUJKbnN4HBiD%A*jBL=1Q*+@;%nN25X5Wy@$tSwTw=|koZ{dG2gZo;M49o?SR@TE+_ z2S0{<@Z2Hq<%dyzor^DzdZf{Vhs;;;aFO+{#pu23T!xeMz_Ixg;^_hMEjN)ocleFBlLsV5jHE3kcIz zc}-AmcGeJX$wx8D+KMOw%v)!H;`#N0Y7J;=^+z?8j-Xl7nI@L(fLlS6st_tSTc=|6 z*`QYzY?PcHCQh|fmxAgWlB#L7kLj=%bbKP+cbw+#||cok6R0*0lhPepi6%JAobr=j8bP&~tcwBJzgG&1v^%|)F8A5;h!1(+)J&#(n%o4n3MAik z;e+dSIr&9(Nj-zvEaiDJhpqKoKVq~@>-1$+uK|aUB%azO(Y~`jo$7Z&g^F_dXb7i5m(p+xC zTB?!?T*pDcDQHt{0@zF)h|O#-F+1jl&1{~_PQ#UoRE*-yNQlDt(#yxVA;Cx87~!MF zdTa_(!hLkD!AeU}2R2Un;C$1_P+e;gX8hplq_5G2E759uwDGdNhAJOo!tV9Y+m1d8RU;SL_y}@+jV&{G7y`e1sVm zd|j+$?lCa;hNBa~0R)|$ggZ5y861U<6VR9oPEuw(1}o_XrA3L10H;@U*IO?mAHV%2 zqp}C@>+s6URZ%_zV-O@)e%uB6I4zk2SX-yt0R+bz=Y@%-Q0yKD$~Kpz{-M_)O+(SJa@A>_k?GwqkdnsCbThx5-|j@anobGa$-0W~WA zL*KnVmxrJEE!yYIjlZAmw&Pr5rPAX%-Wg%jD8FqrD(7C6r6gMc8>I7Az&sqX6~viN z6quQ)XgVCNARs+Z(dm12q3`=mUCodq3Y04&1lmTw`vgkv1F4M2aA)h_>p(=5XNR^t z9j-yS0i`MtPs;KkEfBall;qwL?a>~sUXC`lk((WgfXN-pk+3O5r;1G>9w>&EqARQz zHhS~#s`qsr$5I|cUq{di1byJO)@jwGfeohBxm7#>KbcnNKl{_&Iib>KPQlL_`NM)A zaJlgZdui{);|JMW%c58EsR%a3L8tfdhe>xh$aK?^3D@2sH!DVr5=9+{1I2xaTI-!u zE}fxDATeJUVsakZt765K&~MsOd=jO&SL(O;#9F4{*txotby1QN6SMKdZDh%hipMS_ z6*uWU0`gt{F2a}8hNz7p)@N~vO1ZPhnI@x-l#dUngi_IkEx;;9$vGPcQum83#R&cI z?su|BRA(iMnNHa$u0akCyagI~*@>1^LUK08;G^RBa?~SCn$i4?qwA<=C$19?B!rF5 zZ46$+pTgx2wKcr+h`UN77bt!jI5|@HQMW*8G(pLTnL4M^CsEPMf45P23vcy+j&=92 z-LmOAUwWwJq4pX7Rz#R&?!)C+8;ebsJ0g`i>=HHOCTpy3LYli;Htgixfdbn37;X)UH^T2QPcH%;*~W%!y_dg**?vVlS!p1?L>(RcaM z-9`hLIQ%5SR8MbWZqw1ezmtJ8-)1XIu@=#iPSz~$JND*4Dky6Xb;!AuW6;9jvx-lI z8!Wa7F1#kV^qSz%V`G!1ll`|)2hA5;W7&uOV=u`qs=_uChMe%s zUu*eYNx%d)wgQ~JOry}_;KA$oPhoRC{>i=`Y)Z!p|L{x- zEQSJG%bHE6@e++{NDRBil$fZp-U2a<;!=PZoK~a8h$Qhr4pLi_&61kyOvqZ1Y*5}w zHE_#EeJ|0?Gy4fD%EzLjh(TN(hFMNCRBcIgX?J3&zx4#D_Q%#HRuNGQSXct?9hT>( zp!kKXb)*%qkOWS9X=qYEX1Az z>klA#3-+C{$QSu!kds}o?}YExlfD$4>!j~{-_sWbYo?nW8+!ga;k)i6LRR21%Ex(q z<@dfXe=n|cF~G4*J6^Sd*bi3sX<20}iJXjfmao|IV6}nGRd{p4{bI#Z7OBKqKz6?i zS=X@#wJFD#lb*vu3EKRjSf2sWuGs0s32#d5M7R}%4+z4|?lrpJv=#&J%)Ir9pT-d{ zarO%CO~rRzM2(Bj0nP~Kt_>PIqmF83Ttx*Vrd4z;s+No|BWSzdG-ntMIM$i^8d7%q@)xh zOFPDGHcO#B51SnX zy+&bWW!ca^eHJcUn7VL4YH4{vpMGg+X?+$I*-Pd-3VNm9`fUcz(HbX8x)v&1>uvfP z1==FZnb}jQ9aWyz$pEaDAX-4E1$_fhYiE$rXnh-iixO1d33MEw&n3uh=Px-$@^_x0 zUARic0xWZvl&~t3||JXeZuamh1VHHx7I5x8JIcgH_I7nzn zA6o0mK4@dCZmE89;5~Xuw_Hz<;v!2?bkwG zUSP>XMK7}CRa$Tud@i=2!4X1VvEai}X3wP^X_mrri@mr2%vg%is4b;M7PiLKQdMNJ zT5>GboSbq?PM#g_QVYK3(n?`k@M|GQh9xh*#9}M9*e&yO@<5<`zU59!d6@<6p}aEJ zQeKs_*n$daEiSX5c@$x-Y?-wL=WUgjLW@*X<=|arsk9f{ELD~T)^f{2q`)+wwJOhE z3WB&x8{kk=^K7L^DF=0!Pejw|WNR_%cvX2WII@;3up*`0a(h`NwJZJw=RTl$lJ??x z&qem|=E4$fgOx=kE1OC*kV2$r$*HQWgs3QsMfM63pRFhl^UElQa^#k2>mq9os2AC= zI|^AReL#AflNJiRw5pQyx>Vp&p*!?Ev{kQRYxiXl*_JFc)T z=nQDL0+t&?6D&k$Q4DQ}!pJEq&7FT|73zn@o)3}OEZ7293dgwao5_Jkr~)3u83_A+?l3oW@-2 zVV!fJg;vjAC!Y0CZp9`j>}q7(U^P`X-C*NCQZMwvfn*w=6?1W%LTZO4k64AC`oe`) zjFMQaJxd8+QcpX+7M7MX)3h?eBwN9eByX)eB!igeB$tGeC{yPCyth`Q|DmEr5*38NL;}o;fw%7G9be-7(+2o zeM6%zvDRg@#GGk$>f51p>fv5mQ(pKI$aY5$naT$SunE405gw8w%8~EMl#%JA^?Dg{ z`cle?bv4czVo6WTfnviZXniH=HNjlf8Yk_b^p&6_#xG7%WWEt=a+b<^9%Opu3f7uI zO52rP0jVRBDPNPZOE#6XuInvq+aUKT(wx|1na{Jqs91W?q+ZoGyKjwQ&ts7Kc4!mi zrkNkhu)c{C2?yhxI99c2Lg(>*cPEg+UR9C8lZDCm9A<0I&y04 zy>p$&uf?diakzXj6Z zPH$#uxi9{kiqyWAsUiQH?^*Ob<$rEU3R|3c$F?v{Qrd{zL7~d>z?qbkkC%2pF-pnES|9C%%>?-Du~#^UAGY< z6HD)6zgInye*%QCg;yp{;l*ABl>%A#z~*Lf1p1P^uLuEqusBkyt*HyCJq~+q=HTJAYlwBUrJwfH>n5S;n7km zT&J)ne^iFXQq6P%*m8Xa>UHg_F65zhfN;xb?zhuuzO#veH*ZNaQxo7)o9;-H`L%ph ze;QRTWD<4W%fM~`qj}wnMzfAB4I2IL`~dQvavGyphfMqt4gI5)dub@jX*li?3DCIj z4;?<_+Dim+=w`G|z~L@;;r$PFEgSNBQ_gx|`S4wvXV#NjH!CNR34n~5C9ukp5-m&O z(6#6iYuwvkts2w27HX+hqjsFlkmRBM=(^y9@1jtw5ud6`k9~r>W)TQeYVF0~?Sv@H zW{o?{Jb`Vl1ljAp+^ZE%cZFs=6V=q%%t~ob*$a1*g!#x0vc>uAB?Z{eExLvb>+%Dt zl6ufZYRJ38+jJK=drL~q+~A`9sPSx`vV}z&;&b`7JgOYF9fup9CRsS99>v-;E;Qj$ zlDdmI+B!_q(MBS{S_bU2=MHph4w!rQ^UliU?KQzqJROYrEJdCP5}4d+iuP`>{=E>Y zNZILtqY+Po)*A;8h#Hz~{T?Y*;S>^GT%#id)A|>J55EwM3G0_$3jY2jb_57>rgH_# zx)QC%xd-X~AkwXI@4gVPgmqq+h0e^aYdW%(bPw;JXlj}YhD%5@qk!4pg{jno;Zf_m zICMk*U$E#BWOUDm!H<5#1mZawPw`gJfR0$p+9P1?zfxzgl$u@EG_iE#5~*mUk@ORZ zqQ)VL7xo1|u%A--Vt?>c2Y7PnGBvUww5dIc)PB^a#=Wv4U(5qU`4V}zjz(IC@n&LG zGm@ELX-S-HCI11vQ-WTdd)+5_uKDDF2aVu|9dd{Na0f%XPU^Q~4t3d-y(V>WvU*Rl zZh2$QFkGVfAF8T1F*o(M-|X*7#bGTg!#XE&a07i;)O|}yH|N6X#4fDrk}!nGQ6f#I z^D34E!L|HzX$@`(#Jm`+b7IBxU`ip{4RScAO4roHju6~il}Vi{t3DZ9lGO}Yg$ z=mtYLZlGOFD9dUmW*LGl(BuSJqib62`z_sMD3_aH!u!&mz9ev-G0p|7mdyNBufDg9 zyt@2`28L^l?98M2OR1CK4+w79O^Cby^xu=o9?Gl2Y(BJ0(@my_5%VrteK=WNnOv*Z zCaaCf>gr_msbqCsvbrf*eJ)vjF`B#)rqrI#?Gz|*R@NXq>FehnE3#6tr!?-j`FJhGx)-v)R><8JNTEs>C5ZYA@?t3 z=YQzamA;I9zF=OP>tym`WZjV39P-o? z=Tvi$-FhtIu19XMjS>Ij6ZtOHP8yq5U6Govn{r|ZbuP|a-$Z^FNJO)olLr-IOPZ~( z=#0u&2IStwPJHr#kb@6}(0U*d+nGB`wY?CQv?-@$PFdH*ee!%Vg-y;HE!P$JIV2Z? zm|R?`Y)b634h-wrlwY-karB7n6~qLv#)6hJ2&o`AArSfK+Te&;w*ASF-RnbWh65vG z&0%QOPlv2q&r4D;(JvNEXmhs)O#CL9a0|3TYVD7$KaQpcuv!8I(#vXXW zF)K|4s`2VmIni{Mc0eGgSr;QK7ehN2%Y|n{-g=H7K~v48H{8NhvUZTT4y>OMtY1eZ zt0$Au*BLDswP07bstZ$hhN_{VR4eORCniy?oHq|1joiX{*zBt~+q|qoR5fQ-*;3>9 z;&sJ(ceGK#iUcl7KA_O@vl;xHm7;{;z6@=uCxtHYEQO5}H{>#<$2U$bw!|2QnRe=m zb8t<6>H8_BVg8or!rvwqHe-gY_G&ROe`_P5}AAOp&#g_TQd0`>Ql%TAB*L*h%k_c zD=IA`{}&#?sxLcY4cLZy zlP9(U&guetWnooLDy*+Q3#x2)RM2M%K#VA=fi+h5%H+Upl>R2XXO&i&;bt^rA#({l zRE!0z8`GvjJzc8zMC*K;nfAw-D@)C^=*$ex;LZ~XpQHfk6=}g%MeJf95jkvQ zROB#6C`Bc*uMT1FuC!lPn__z!JX-L^dKJ|ZF%?zBR5T8}f*^_>JcuGAV)Abd>fW&_ zDb5gpz&rnd32F`YWSEdn@j^7=c3vOit&AS&-FY=uSJMd_sVI6GL(;LRr&>`%$`sn4 z>X_1m&W9J`8RYG4X>DVS5*Gd15K==~cW2$5h()QXOR~yGW|br*k4(zCC+i-Cwn45s za%BMR51pNo+BRBXy zPPQGlfFx>+5AU<7O6z=Y$);kUhP>gwwnbcxL_!>Aga zFC9|rO5>&I#6y)rOyPW&nxno((6>$GI z=8iB8w#b4ok#K=)W;0wI^B8EteGk7rXzRvimQH%1@X%mG=1CerEe zHhChZV`u<g z9XqFYQf%^)1bj`v*M#IH0yBKrh-^TTl15TdR%YHkqPW>VU(yA7K?)pxDRYvCE=gZ9 zbV<*otl6{YB9W0S~6R!UZC-;}g@`~vktU!MA* zl$z?C-ry6z^?RF>srivQq2G^uHDf3J&KjCD()5XuE=9e5HlHAKF+idg-hab_m#HIW zBFpMCGHC=SHTT@$bb`(umeq$^X7}p#9n>;s&mA$RH$8*##fWpq7Lt`bcUa8W$z!I^ z%FHm+?PT0$9?N4UkHdt){VX{B*tN&^8gS?zzc!nmLss8eQFDZ}oS4cIbA)1v06lXv z8Spe?Oa4MKekdn9_Ia!&4to_<-e?N-pi6^pSdBv-aj5{8x_J=aqdm{X5D&d*-snb{ zO)p|W9QG;t{P%8RqZcOZa8)tAZB$prm?knAl}FsZg^}r*cB5%Ld;Zk@{r0lwdk#or z&%b9R&M&`fyPpcF7X)5Zxul?S2_>@xM3>;fq#JdXO#7Z)uirq{+x4GWf*`_6dg4)5 z8heILWf4QMFM~}8k&bd2PU<=j>q|qxMw-xf?)z-FqHHfnJ&)q`Z>VLl%I2monY#dM z7>0roD)wc%u5~mF#l;&6=IsJ8MoHJ$L)moKLC9h9;)=#$#+a(%n3xfXrNCG%Jh9D0r(w`b_iDDl4vO7fAY(P47(tOV*4fzg$oebW$FL@>hL#NwazNfDnXA* zvPmthA40O3ZO+Qis$@5k>AL<(w>av^AOWdY7>(9J5w(=Bd6=iHTs)7_cxR`#fysAK zaZyRd&`Hw}gpu+#F3F#n)N|Pt@b5MxP*ZxC)@uEP*BL_V5}RE5UAR4J5W%iSo!FzM zzCoAWl#>X4NG7bYP(2v-ZY?!)GAVN_c|_|m@Fmv3Xs=OQk`UxOGw+W9fz|Yoy<$cQ z=3_Cth%pD2-(W-nG5!&?xG#~z1oUXzt+xEi$ym98XKFFsSBn^>aG(0rHmfhDsM}K- zr~_bD4fU}d!tGyy28vwr&q>XvWPwf8HQ4v7Y7{)0;Jzj7dl;Bk~KSlDf*EKbMQTu z>Hm?j^c`hG|2iY)B=wGSUvf!$CN-_}FES%AgREo^B6e_b>f7c5x`@ekg%1_>nzG3i zN##BvboE1|KQOnOYs3HSbh-gl?30TpkUqxHTFJhZUkvme9rnnNq=AYc=IjY{l|oaV z>N&KKh#+c9A?7la>`8P7MD7@EJ5P_(=DqApd_ioPd@LoU**N^dGq*5Pi;9mVrn{}# zWf`fuH^pJO{lC_}1kT1P{Qo@9J2RGdEaO_{-t03RV_%{uMNx!8D5A!0vd#!8Gz_PzhE`fVf8 zv!!g8!HhZbujmWp*kQHfl4tIe?*E_^ORt_8F~|SqQ&MQs`|m%bkUFD~B!Q3nOn6Xw z9PUIJIts#=-2V)A|DjjfNwG*{mG*tdwb`R(0%?PZ5IpAOzk?!$!WGVzmn?J)6}1gs zr&u599yWN$A?7rKM_zhHmE8{o`tO#sWdSIGr)B?;6-ir!a0}JaY_Gt>Z>`{YegAp( zPTIRLqYSqg+X4>m>vBYfs}?vSAwM9M!kO^kxUN!5ka>%2dn;BlB%vj6TJ2O=LJQga zTd@$deAT!+C1_f|YETAO=1M;wvbpJO>2fLFkB=%2!9g{7@-EFB7#SNzdjtKq?l;Hc4Wso&kwX7Fg0 zTkVuQzH1NomdvlZBEgqLWt%VdI zuEfI)=(#RlTGz6h&4o8FvD1#hI7TPO&hQgZIN%)Qw{6?4ubQ7EPC?@L+!ZS|ZCWv; z1dga+L-C1D)ub^w@y~vt1#3I|&!Bgm_;)u7xvH5-@#^bp@!<`K zS*hZ1!!IkOXL>jHg>NIf2GN`0EeGlE8JDYwukO7N^zZ`-?@HT!6TpeLw0?5t38%bp zsH`szUEw^IoKx#9hxqyq!XF%28c?(6sGc~Y*$dOsfpC&DOuglGh#cL*;W3b za9#DNnxh8bmi3yWrCl~j&MDvwFElGKQ#dvf=u$8;b2 z4{7SZ{H01-QJXy*XT_;2v*SX|tYM|l`5u|_$%&VnQL$G;jSSy{@j}kWse|qF;?&=O zw@LJmqdbie>bFp+aFGA)X6?PWRjw*N3=)YcdaL#p#PoY8Ci@+ln5~r(E;Jl~AvApD zEN+2QIKNSLcu;;Uq+@U`8S7Z%FzYxIPe$>>g!TK>%t0wDIQ@a-Ho~BN1e#g|U!@8HLSC@5fQ@Fpf2WbSCn zfs5wOJ2>!-X?7>;L8f^#4t#CyYR-WR=I*;#4>m3CWI;8)=!)J+p!*F9=MV z9Xqg|U>@wqI?Hr=ko82uKhZZmf;z z{s`-5O^@!Zr<+H6u%2NadzAHaCiOAaGfmG_*0W5no~&n^-o04QF@1Woo@@H{VLi|E z>&tq+>EDm_0yCgL>*r0{0M-l5<7up4FasZF{h}E(ko8Mu@F3QU%#gvX7n`9&ST8Zd zhO%C2(uZ;2oXJS%z*#dqg9B&G6T?|AGb5hhz?Wv^2-Yu~Q6o9lJ47ldN;h zQ=?h0G*3UpdX*XTH0xK)*fFfvm~mrSziOTt$9k>Fe1`QpGd`08r_F@%9QfR1O<=vj zOw3}v(M+1ifzQn3NvyY+?8&URnkm^FIAx|zVZF^vo67oiW2Uiw!#rzPZ#UDQWxd19 zn9h2qd2R;l{buHKtPh!4Gg-f9X3t{%zL_(d^hxOm)?Y*pnX5ZVav?8;AA50>1U_VSIa}f6%Xot)@2VusMc^9_^ z=mKO8;pPBckj#6BU=||t{(CSBlR5l8%#vh|9EMqn%+Vt-OOyHFD9kcsj^V5FI+4tA zd?;QA$eh5Z-}OyoKE$`&by+eWeF(E0ncRgr_9d+uzB&i94w>^`!K_Q>!g-kW$b5YPW_>c>d=0Y!nTy}RyqV0Ui!d9K`4*pL){V$~ z_btp@$b64EyS|mo~ee7RV+ zBJ=AnFk6$kicbgY`^fxu6=oYU_{dRUo4NKo2ez6#OlfpSGJoW8V2kSGp5uK`J2hA<#lpQ0T*;g{hFxuAnXzM);M=#N$H}kadHs z2*nG11hgm>5!wT^7!?)zC}?piCiF4T1S*d3%atiX2_j2{%ts}J_5>|SJ~%H^20xM( zS#QWnQz@Z+K+8~Rp;$nfL@Fb+AE=)ah4u#xkYDHk(3>bAG!3*Y-6ZsJ&~j8(=s?i& zR8Ht1&O!9Ztw}Xd3QLr!MKwj11zBypC;^=a zT8C;2odjB!>Ij_-T94`q%?7Pc^@L6ZZ9w&fV)9{brUpWBL5gWeHw(qJC#DfKL|TiK zxrG{u>^aD8rCWr~1Z_;W3Y`Vogc=K-19}@Z5jq$2cDhX{ZniK@>2^f*qB3_-Q;{u# z>`uBvD1KILn$ev?mw+~>WK0BuG03f&0Wnpz3n1bQE}7P=X<4c#Yn3us$vBXlchJ8BDU7b6 z3w;B$Jv|_FJ7@=LFLVcJN9rJSC+LIJQRptvPV}JA-JqSRlh8LoyHIDLZ-G8UU4-rd zeV85+x)-!7JuLKX&~DUK=swU#sGHD(pxx;aq3?k9pzcE71$~ry2*qzl&13W^@-SVQ zRC)~LS!H@sD#$ctdQnf1smk=GUgG@=c<)2Kg?chf{{oIM63(xX=QiBj^dC1wlvB2%&{QN6|>3g+ZUBQ9@nN(e$Ly zc+jV4w9q1;Pt#LEi-L}!r-c>+9ZO?`mH-_`V};`El6i*4q3|XslS$8rtR!UPDHAmC zOi-B#G+yX9&@7rD9unbUB4vs6X-Fs0M3MR-olKL2;&8snrpZEY0-ZwHLd$|qr71#_ zL8sAFp;){cL(_y-1$~x`Pz^ero&^m&g(POsbfKd`pQ9P#p*lRwr00az0G&lMh1LX} zjkC(2wLs_4Y@xM5=h7UZbwKCQT%mPA=hHl)^*|TUe4+J0pQi;v8-OmP=Y`%3`T{K! z+7R?bdO;|z(K9d6i$ZS!T|_Sly%lsZEfU%obO|jM+5~hdEfIPf=rUR=^mfpfX_?Tb zpv&oHp?83;pyfjE1kIrpLYslEq#U8mL08dAp?874LaT({1G<`C5qdA^8d@#173iz9 zMrdo$we+gc`#{&xTA^(~*V8(oZ9!k7^+N9l-9WDieE@VLZ4lZXbQ5h9+5vPkZ2}EE ziE7zGn}v=5-AY@;!^7~fjkb#PiJ(fth@(^>J*XO_2j75D1u}wDRA5+8_0I^V2Zsgm zJxx|g+i~B!IH?91!5z3|PCMbCo@^(sfe*XyqImQHe@SciVL(Fk2{y_>UX(>KV+%WD zkdo8~ic4|K;Qsf~zC|U_##PoHDv6b?4k)viwn;W5cpie6LbF!pZF)UgSOyJTW$h!s zgej-Yev({9!UQn+Q%MI1Z#+Y}i_XbG!V9+*g_QfdnvWZtuIUQOyhGcGb+R(=(hiU+ z%6Eu#bv5xls;H{y8fxPER7q7isV(({s;B%(;`$*qQ2r{yKB9&p*Ic?q zxmQK@F*U}mRT)8DQ)PWZvVp5>siaTocCS2q_`$cd1?YW>@U9tp`)gUn8w?G8M$I5W zCVcpfZD2@H4e&BEBzTwgDe8H2g{P8j}&c2Yp&4e?hJAm99s11Ahax z0-7X!LHBuK(Hy@dyrhwu0zX4|0Tbe9sXaL2?k90~R7cbblwa04>IC(}p1z{ao+sOk ze+@o_(Zc;zt*D7Fd;S_cPhCA%-vuv&@bxQd;t?y2S5IaHdtglYuK@T3U8r|RfJgHK zq+;axuK?fN5TIv%fZj^Hi|Q8%`(kkL^7<9^wVu2l_-nAg(zk>n&bmZtH~4(~2A_k_ zTH}^Lgv+&3x%1JYJOfo8CfB?g|f{=vb0*J9sX^lLqTB-UAQ!VjaeN zL0YL~=4GDRl6B_gQL5zN+2e1mRt#3*2r(myM7Ro%BY#b+RV19)y{h?uRwE|x>==Gk zsus0qV)<>U+M&TXUW;J`s%1#UvRaRW6f$IOP%66sZxa8=tSQL*#D7Mx5O4N|p*AYJ zFmDaJyS(3X|CzRV?rpK?;{(W9ODy^LAV@ovT$JBXmE+V(>>4K(;t{0?!v zzJKyA{Q#DK{4PAV$KsC<<(KMiJTUzoM44iuUf9T} zGlKrk;n6@c`nJ+t)I=ZeS5@9s4So!kz)Q|A`4s?xv_Lk;D)~mlu z*q223K9<2#^ur0dtI96JN4#?J#`Q!#8XDpKd@RHQjEni~sDBfGSb6gM`8obr z>F&yhz11}3E6;j}@>O6x^uM}BMgCOj5&jWsMGu9)k`46#N{p8rE80X!D)Z-%G>(!a z@fVQjC`mG(fdnnkRN=#@hv8VE@)3|Hus-FZqMo#4d5WJ?dSnsOnMGKSFQ&0buf`wb ztA8FVuVQ*r3B9>UAH8ex*LwHlZ}gi}^jlN(o)UU*3H^4w-WRVAsH7CW=#@Q`uFl_L zF(a9rq5Lh~r2Gwbm%UMqDs7_{bPpnAC~}(NbjL7LK<`c#r9# zq`$zTo=+gZrxOtE{MsZ{fnrR?*9C37=Me+GFBlbXNm9!t-iQ?O?!x|ytq%M6PxQDC z6Zw&-Ocd~9h34~RI1IA*xh>SF$w+_#Cse2kz2d%&%X;x7-OlB~h6T%fX$xea%+4xW zNq9nBne-Xe;6$(~C)+UoGq#Gd@8GKBjf1GA6X?7{gBpv`JNd&%mNCCdZpJA#vv@O| z)QoE&3TgRLh_z6N#nC#N^G6aw&6lQf7w1}w?{2Sc3_J>-btrH|`C3Ft>QUgZ^0kbT zG@!uy%7?{=jbB1Fq`-U1hc!q_az&_=}`X%D0CF%3Z_W%d>-Z&J7mmw;QG@ zDQd&rtC|c8cHmaz?h)3J?<4m+VGnX!a=#VUiSH->5NDEqqp-m|f!vRU4dIF8<_a6i zlga%^*f5?#?oYzfc^bLrgk|uv}g&~?qOkL_+@h67dDnxko%snalDe; zL&BcnSIB)=SSGI__Z?y5c`dmIg-zh~48KtpzmOTxVj?h%c@Fz&FNk;Hl%s;S+ z!k>E98F)Bj_k>S+)|q%JV%vmIdDhu@_Sw0tj-eYn$s9a6Y`*+(33&4gnK68bWp1pf ztz9sTz{ztlg2>cX7bBH54{Bh=ukqsA%;(RLicSDsz@H065c52r7K)H&A%7vXDCi6P zrBIB`=0!duv>0*?4 z1%EBdVJU%>`|-C>&f`P*`v}kBA0m7u{}dH`6@TN!I)r~ldA!0Gr9Av7-PMeB3QD&M z_!`Dy1RT$RiLdf+R0S(*L{b+C%YeTdP2~3|`D##AvB2{uk`u23p_ zrE7HHTRFTkd>6r`-AX2!aA12_eke+gZBu+QABi!E z(wK*Ywn0CQN*7Zn-QgcmL>WoXYMRVPA1Cc2^5K&wV)j z@a)HdS5)=|9w6-nE#7?1za#hPE=MR09qSvu=2uf zY17NWpcB2M{?A%@3TbsmT9;w5ay;EI8y1)#!}i48}&~G?dsc{9L%iriV&wCQ8iX7kM^H z>{tFXTw-&rI*Xz6Rh}Qxd6B2{0(LFC$P2Bfmr(P+@m~mO2LM^4<9FnGHlA_6v;6Q| z>G|N-c(LUR&|mWSI=t)WQO5RM7TXZQ;qr%`ZLH=OLdbaM4KUdZ zE8-|dk-UP6D(dX8MY+zF88+Rsi#a<(HL%dDfnDrcR@`|L%_hMighjV6;o$iu{T8DBI1>-%+-P4!Y{Z zMh-ieSEkFn5_J)pL&~(?aWD>Anbp2&NQR0Me|Fdp$-*y%O5!)S3F-O^#oU?-oPGF|;)o@a0s_Z)*pHoocaA$f6l|(|#9M?$KtKEQxz>Ay1gNDzFey2glB=#uF8)|58RJY_5XBtw~Om>s`=lp z+r;%l!jf6CW2D~;74qHp{+ajJ5Z1jKe-`2S` z%KwaDlN(a^X6;z)WAMc*-g)wh7wcwd($2a4KYikuj#G?nF+AYh;YdJvVQWWO6d=y) zIK@#lk>(qE-QCPlSsk3a99ef`?Vr`rx!dyh&>A0f61))J<~M%fqOl*4-O0HJziE_8 znJyLA*}2zopB2`{X>F^}pq?Lc+Jrn!^E|b6+^L?Y`>m%b@bs|L-fIjv>f@B~np8KZ zgLTgihG(abc;#eg_YXRO$zgf-D0ycmFexnW5hZ^JIv+*09(C+*qcnCbvL17~IWjRg zhDThg=NI*NiX3*kGM4v&8IEltR;7KNKvwi??Y?mLG&n{0C8313oAz13G|v{9ost@e z{9&&ptDiI2=II1x?)fjsC3HBZAzoPD0GMG7v!LOyf5n-BII&ZcmF7HwS8hsw1pc@) z!p5HqKF}Fy`Nxs$8S9Pucc`O_!{p&eN8E z7KzAH=7xyIAR_F_m~_X72BPtnJ}bi+XBEJ1OxAGc8OzUtKjCCrehz$uGv4yAz(+b0 zY&z$`M>$zmegXVRXQJiUmB||IOtSnN@TZ)~)<3povYvLbt^5-B7-x#**ptZ`>rAzN zz5^fUOtW(A&osymc5{qZr1p)`bf|wB4Gmgq?Ac^xI?q|Z#aU&IcV=2HTMZMOS)p-p zg7lIsXSVGHx5CwH>2 zX-)quf8R?n@lp78}uTX_Whi)_s|i8|D6Tl=~;veYtZI zb%$|BV;3oVh4WdcNL-weLj~kGpTil4k`=`lNn5S4k7#jrx4unJFBP}PQ=}8brQof2RA0-#ov)-!m-UM67!F# zkDWWb6)cwT*Tr!?_XQ~4DjF#M|v{`ZC%*B#jF$&1?;~ zy8g^e;ZA%euvBr;J&FrvhRmgzhg3|>y8hJq!&F>bE}dGUF2W<-`g>G-UFaaXApV%c zY1S0|V)r9Ho8D*@R~&kjO~qYK@KX{d>~kb7FAYh@1Ja4FD{=mR0Lmt&ZCqk%>1Me2 z2xT&!3!Xuq-I^OvZqNs&aQATILN@)(JT)Bo`Gp+#&DUcNapBbZ5(ig}FTMe~Bi`b5 zZ5S{AQMwjKIZ|BJn8OmjnfgWI5gjTwQ|VGx;F+0?wbiSHl$lpiH9WJe?#zk|WXClX|%m z?)jD&M6(#!@s&6D^WqkN;*zg@w6^(S#ZUf!FE)uU%<@YktgDz3N;Hxbg?lp5RX!ve z1BCU=*CVWnS3dGr((!7=3-9UjPaf7qnDj!4F{6R0z${=PungD;YzOuNCxNrTCEyB>2T=nM=7 zrUM5mCC20e7l13k>cY(sp*R4ifh$0s0FG1{a1&z^0C@%{#Q29B1upP7y--!_Cj_DSO&ft*bd|Zmw-Hgk`ZB%i@9SW(@rV>C1yll3fOfzH5SU<5F>*hIKY1)Bvd1eO7-CD2xo-M|Ilst5`dM_B-sP#*Pw=0FFaFE9c~ zfm=hMDbNz=P#l4Jfb<1M15<%Tz}DiT`d+X@z;WOta2B`(Oh;7nfGgm603{%4AOY|L zRe)MRW1wY1yh2nxK+}M9U@R~Rn4W;t7lJGURs-u0=U(6lkPB=~km}wImqX(9WWr=v zufm#80wo4i0crt_ftEl!z+V;l1R4S@fzCi*U<5E8m<8kjo#8hf7z<1X=9Q4da=_LB zTY=rcao_@w2Nd!_iBdi!4O9VY0ZoC{Kxd#QFjhP*0?F}7d|SbG14n>Mz!e}5ppsJG zMM@$}je+JsYY}z^Nr#Woz(ODg z7z^1}n7P0r@XIha!aM|A1zJ}_@c`*SY$-GypdBz4$N>%kmw?#P$S=?kXbQ9}jRZS@ zbOm|>X+SzK8W=B*)8)@X*p>ksfwRCBz>g8E9?%)+3rq)A1ABp7;1b|ZgepJ^P!Bi& z_09rU07{XvE0+R=fW~m`01O5u0Sm26_U6fvX5l)e#OD4f}XtDliLJ2rL7t1Q1UE zMbj9hxsY}soq--eUtlmW0vHQS0;U7=fJHzKunyP?>;?`1M}S=5G;jg93Zy`T*qflq zP0|YeV3mLrpdQc^Xn7No?f}w5NE%2wFxvW`1U4O*2P^_|fOWuDU^j38I0EDXr-2K= zW#B4s9f&Q9lz~z}IUoh72Q&tn1FeA$Wsz(T`I81)I?!244dx_ZIxr6yTpb=3f#d+| zfbsCO2-pg~S3)0=KPSZ%(p=!I2rff#6}Vp3J}1gy%qRzOIgl#lL{!iIZ4P^Dpaakq zxPb7nHBewR;JH=}DZ9QBE*);8g-imO4$K1<0XaZx@!ZvVPD9vr5N!o^0|$U3z+T7? z0l76K?K}yPP!n}hQ&MPN6V_b#It^R^`od`hkON$X{VG7^QKWz$$c4OJE##y;0@f=p z&xhs^w=O>otOr+!@5?cXD z1Eqj+Koy`K&=_b5bO5>neSyKi2w<$(Ya?Zt(uS4zvb3h`5Ipr@@*Ij0VO7Q^jc>$RZ#I zSO;tcb^`~1BS0>28n^&l2Cf3vfrLs@wv{krYYKF&B9mCBC>VrYJSleDf z<_KF#W?Oz|52H>72e&>d9xHqM#e*x#{n#UU-34u>YcR#+TMUHtnz)(h(v z4*&bKd65MzhyG#DC6-vXe81<8TSPClNh|mH>6i8#z2nEX&fP;vub)Ya-&u89+Ao90 R+fvxQ%Z~o{zW@V72oeAQ literal 0 HcmV?d00001 diff --git a/Covance_UCO3001/browser_profile_3/Default/Code Cache/js/664317935b2662ec_0 b/Covance_UCO3001/browser_profile_3/Default/Code Cache/js/664317935b2662ec_0 new file mode 100644 index 0000000000000000000000000000000000000000..7b1c62c5a5ddc395563c696cb25e1cba2eadfb38 GIT binary patch literal 19832 zcmY-1cXX817w++IGBu$lWKuv{AR#lEnM_NcN$9V1B9t^3Dit6JYGYSl8+ z{TWrNR;upFHYmoSn1a*)7wdn2@+&yQ{&yQEKHa-2eZygo%rL@PiBJ-EWr_t(7lOit z;g0-S6pj>!Edlr~3#>VsE2o2yT@{K~gH8=$MI$KL7}iOZCXm<^(xs++)IxJ)e@po8 zeXZ3EKIjhjq)0EY^;L|1iqRi32f|OEsTZF^$1kAkSFn08RQeiXhrv7FKxfJL7M94p z;qcxF=puDSLQBaWr5;MhG0;l}j)iaK)i}kQ2tTie=r!Q{8P@y)+hqP)ShPvGZGla4 zKytT2EwTIt@p4SANRu6~b0?gXvAbZd6x|KA_d;v2{SHYoMfUB7^D_AWd@r#F)$^mU zOg=aUz2$~*LOqu`5;zIf7bYX1wXB>10dm1=~sOL~Tdu|q0^hw*{*5sx8^it>|el}uw8 z17xIBGlkJicFPD$7&E1rRdeN(T$9|$FzSlAKp3&|t&}YshEHzGYw2DjjCZ4SD=E=o zWXV!lC%tT8M8}6wPAT~ln>*)>`e+| znmvq5jxZXehVhQ9m2Ud0UfvVNvCJ^yvcjk(qvX7l%GP6JpV&bPZWtx&h2fAr^;Jj1 zFb2tR+0itNh~{DRlc7?iMHnZ=^>!E=TWM@-_4~arF1JzL?ZWu1z4kz^iv9gCrpwPA z!+7;!7+pGraj|n4NnJFroAzT;7!xOlVVI)+%n9S{T-7))j8DD`WBvRvnlB7v+x{>t z2gB(5KWD<&ayAV2xiAj=p_(s-@wId{g|o&SPB}|BH426^rcgNlO0U>(HpGR~A|ae_ zlfyY&A)Ne_aO%o=IpqwevOAmxlIRI%kvE)lUpV9CgR0^DQ7xQT@^$raUPyk;a8}4h zc`ik2hx3{2s1uH_ZaA+Sh10W1IAxnEmfUU@PV463bduXLp+z|TT83kOTRF4}C!uXP zd)tTeP(JAp&X5nn8Qv+J0-eKY^iep4J`Sh2eEvx|^#_IX_vmoa#)cD=_s4}3H$I$q zCxmlAA}5CPp*)ngCWUiUuE{e=m==zIdN>uO!K`pDO3ClSX}TbsKc(;Y;mla1m_LN` z!{Tu6ED5K>PvI;U>uRknm*o9l!#S}foXfIidpJ*bhEr=-IP)cAcQ^y(NBKf;PP_Jo z6Zl=P%W%m&qFx;hC;N0bP0lE1IV&;ewdRFzyqCf$csZO(cfz@OS3SL_p5Iqq&y?eH z<^4kI%a2m>jq>|9oYF=E%?lcsRmebr!UoP4F)*g6fjLqr%0QE713P3yF#|KDS&V@X z7@-+7s?nYDudee*yjvNwOZ3FY_7^u?JKvOB)Of}0m zIo;gA)|Lh$+88JQXsmFs2 zd?pXSHt?VH9BN?lHwGFHH*j;Ta-LwoInlr;lMGyzSCb7`rx-Xp)xdYt)MHsW)1c!| zeUmfNev$TRiGd|@Z>fRzmKo?GJC_@Hy~04vmD;ye>Z?TlWMKL)>a+NN)jr7Wbp{%) zH!x*`0n__!`>|8U&@S!sZq>KPK;~Wpb&je& z$vSS}2Z{be`yqyls!OilHPHQ@fuHXiDEGjCM;=M`BlS+wpBNbU)WEl5duHH!`RBQg zvzOYdf=1>SGO|*V3LDuZcZwMKJj#eS+DIi?B~ObPb=(>$9cyGrf|1jSMy{k7NlP_S z$7LkhZKQzLNMoOo)d3?-GmX5F53-EJXB$b8sd6F5NZni`t>k!~k;N5_L{~D>y^4{o zwT!rG8|hU?v1NRHBN+{h%#te&jogzqjf@m*taX|g*)E5qW^*IWXrEWs)u46WaJC^?n@)3zB002x(+rnNd6J;5F@XK8uhu-hhgTTMTWMs;DkF`4GV=RsBepe0 zTK{aMlZ+APFY1>xU#oF)?^h!mHX13m$;fUwCDk??8M(#COR;WM9kNs2+OB=vt=eVX z9wQa@8VN|o@2X*+YLMsh_kJV84jB3GkddB8jQk;q$8;>nj8n?{jFH}wa9;IaFcNXq z$Qh}5T{+$`Qv0@!g-1rNiv5X^UnK0Qks8mm7qU$9o*Sw9!pL4J{L08@^3H!o9!gf2 ziNaPBpB6Idm^E=m{*o3&Ow2B7qF|JX>lI84Pcd=WZlYzXiFzIrzsg5m69eRLN%NbS zBgNzw@u{861msP#PN4bT$ZQr znb_Rc#IbfJrgSjzMpnIVVwUz<2E#Ke}NCf*xn;=H6yG!c|zQh$<(Ns~?bd}JbC7Ed+tifT8_xQ zgX+;C_4lyGiRp-r6EPh#(OwoGHxYNjM0t58=CdYR$-HwWikvs`mQ0pwQtc1Lm6P)3 zqT>E(qM@voGM7zsykesIRqcn&lI^Tv;wl{#6bCnRqRqVdjx!hnra}o8>>*Wi(UAWM;hCtRFbd*yO0y z%wdFLnLct$ybsNMCoAOq zW4->=Oq#s)%uFX)@!U+w7wY{hGq+!xY5m5`fp80z3>LmIT6iiE77Gom7PiQmLKe)0 zEz~Vyp?^^e2c=lFg)-tOX5lA!7GvR32@7w^S!h+>!n`C4MUpK{si5a%Rf>gel4iHi z+hO6FJe2LJ7P6fhFHKw)I><4JPg5>3S;D*)I!Otig;bd#fBKbQz{0ySBHh9ZS)O5G zlcZ)^=$WN4a#wP4^m?v^w?YQtM5~^iknp~`HpZJ~T?3tm|y(eGGj`L14<-R&%tZExYj4i>)Z zXyLk~c2W%z+1)~V4+{f7wy^h83k`d#Uwtf?`dTP1OZ!=HjeYNbPVd;|x|@ zMl1PdD3{`m6W%vOp!lITKTG!mHDNuypbwpt*n;!ldb$C-V`hIMM^1%D17F3o^8^ zm3?wr>Nl~nRPHym(x#c#X=UZOB)ntgTQRk<(o*KMwNj{^mEzJx4DFR`M=N0;DxXeP z*2<@!SlK4#Pp$Np!P39Cl@@)hME2EO87_zWS;^~f)%&+{k~PDuH2cPi^;;|P@{JrE zZY4OvN+ani;gglCOqycl-c&2O)6~!D%3G?>w6Z|{o~2x8Tk*}c^11AsXT>((N;~;s zft6R%MVu4Wa@G&)z(;9CtZHFGEi=bXRVdF^0SQJY^C3JLie>#543L&tsIi8@~;$lWF`5DmG7m* zGaWPXXPkpOZNSzHHn~mSOf#*oMeVa@R=ck5pqwu7$f+}6hTL8 z1Ph8p5K%OO22l}gk>he#Udfs02r`OAFeoO1;c{HQvPG~bHiCxn5!`$$0)NQ}`j?8} zFF9R0f^uad=v-EF<;z5^FJ;O{Fji*CC3!nZ`6WjXUm=3gay%u1%JvAtJrT^8VcrN1 z_#(*lYaMarM6jf81nznfd|E$3{{}|Tu3-e5B)qZmZlSSnM{q=9TSsuao!0v(g7Z?g zYXswDOScH@-6QDHBZ7;P)KfWp8o_I6*gHc1)dbOl!{*~=C=`a9jRDi9vwk%sW~QsW%6Kb1Z~Gf(0qIZ zYvjcQ)jU0dH&SJ$VoBKC2)fCdc@a#VA3@Ir5fomnJY?S*|M#U2AUiC}v{T{)4`yx28KZ4>1wTCiCjvrDVPDQXtF3G(!ns+XOyz>#%mrwtQ zV7>e?bNUc93m?XG_kxY|=ax*6qUv4Cy zNiaW>BeK3yBo!-1;;0tM=d!bUB>ozaEUp%p?if>^Q zpUJItQKYYr;`oLr4sVR2_@*cdZI0p>(SgiuIk7E@(%Yk$`CAktcSJFDXB5NtL@{`8 z6bB{y_b7Vpk7A4ba3G3DhoYE!G>VGHqgZqziU(pp8O5$kQ55|%3hUJn;-T3FM3|0Hbk>QOdIu@ zG~N@(t#MZgvStJh~Xb&4F8&9XlagNfmkdtw3Fph%o;;fWDM^}ks=x& z9Ya$YV2hz`d<@IPUOa|DC1OY|6GI<4og71FM+`qp-P9QN`(lXo$M7IKhG0$%*K=by znHR$s&0^RmCEtr-WBVA)9bz~u3p>SdPu}evLxnyu6zUs;r+*9s|bu^j!=MrSp8%uq=ke<*NJF7$$6v;ewRf8bgbnG5UE?_3Vz};GP)$To^<1gE4$3 zCl1AM?r{uBPhyCF8NRY;-c&SR)x08~v;{c8EK|#*@M}Di*OZ zuBeToQ8rpjnP{6nOWWuzIWabd*=!t@+OalHOJbaj)v~;d#--S}n`+bNW*fOK8^zOX z6!6&?oMGdj49m3fV~&mIvN_jA!;pI@rksqZ`03VHa0ZS z<3^ezs~X$5+}wtD2~+IYU9^!Ho~`Sz29uSCrjkAT-#|QZI_Mhdu;r> zUonp;Zy6;uPTH6t`{cWGHf~G#^EUptVxz)U_3fH^d)LMXGUJ|&hmUQPdu5}qAy%hf zV|gj*g<|fz!nj!O$*6=_7QGeA1F@HkYvbag|tROW~@ql&u>}SJ_cNmT9eGxhffL zV`etTvGiXN%T8IaCYDA&$1+O{8`PU!u@u@JOX&l#lsXto zXSpp?4r`v&JgHi*#h;^<(AV}-<+;;0fC#~ASy zh+|{1ILt9|Onxhlb|vFjF6&Cg>1TsD?#PQWab%Z^)AyHgOf4VBmZUf$lH;f(OI&e0 zmiK&d3<|{Q99|q3eylx#wj}PM5Alo~| z(Yjk4i)8M{%BN=>jbymA=%ZZZ{r+*B9T-RXL2;~GAB5=!|$~NZrhMu1L4+c>3hVvt8;2 zbz3Q(f|cWmtP)SzI*QXUp3Fw^I#(Lcn-=lZY#Gn6R`HztFrG4<;xTrQC*zZNzLGC` z>ABwVbdjg>VV`(bOXa@tg!hZ*v6T2yF~3&KA@MvP7EkBl@%$|LBNTs(;*Ztyzl-Os`Fboh7R1wJVLUr3Bv3dd0Z&>2O>z^MBfF|3 zV5yowMR8Y4pucRdp1}SZ3B=Y+pu5y-l)yAu(l~*brU`r}e@KO93H&0tEfW|f6vS;b}xe1(K zoIvuD1io07z(+r84RNeXpyzK1Y?5O86PSM>fjd(5ke(CEVXY-`M-pf+Gi2211WwCa zS2XvU#>vW?32gf-fdYRgFyWsB>O4+hij;Ysz&DY_IVQbr#krAG9B*=Q-sBahM3v%n zlnbqjbG%z|N_8*J`5k4MeZMTxFU#_-7z!lPKPHi#^0y-qyElc4i*-pN zO=QWYL_Av)87SZFNaXw96S*(@jwjOjOd>x^+Z&10f1Jp4Ib|t_wLm$VNMu4eUY9IK zjZ)=s_{tI6sT}QO;ec|~{k$AgrS!;hj2mB$^U`%rIr?la$1>Toy&TcMDb~?))H+*^ zNmAiTIi0I1N3|QejVez@ba^IsC{N{&$}?IL`<7>=ycA!*^86`nMwVx(bl+H>TRX~= zzOy_#PL-$ltMW`Gi7OH)nnb;rB&JDLnI!&6Od_LP60Y(|I$xs4GQgQcC@qQYo+Ms* zlc?@XVu8#JBymd)r6;i}ORvd-oFr-o^*B$D#h;%<_lilRR!Y+QQeDrMW)h>N=d2|9%}HX1q|HsD&@#o7Za*b4e~aeJhr5y}bs&k( z;yIW^ozqE7k=}nKk#s4EkLC2WB!0W8`F|zxNe7$8#wRmK$`?;&sO&6}Op&*e=~ObA zTgl0!SI}HXGLIxLHJO`IH!Yc|5*tvQ>}1k%lBt}R%pE2J{4&2Kl3XvLwfD1K$TM!bX{2mUSF@kI?6DMnIhg{d^!&LL&Rmr?8!jB6ils+j)~@IqJ4rHG{_xwW8?e(N&rT;v%(vr{h4N2DJFP3(`LmW?e;@5Et8Hhaxa!#X zw62|Na;1r#NAhD+JDVk~nVmk(?c9(DZS91&v$IJKNM3t8Lp#`cB0D?VIVod5vNKnr zy4Y#i)voI;>=f;v*!gvWoqs3V z=|0I$^h`U$W~t`cc0zOPJfCYP|2sST=G&>U*v^yjn43 zuGCqh*MC+Gzt|}vN2Kdojrmo3vd+%T^@_7W_c!bQ7Tw>fHFnss?zGcjmz}Lr;DGkv zkex1v?VOiikJ@z&rJd!+?Ywouj#v6i{wd{s+RjrcaK=v6i>l|YonP*0ukPE)k<(A? zym)CR@|F50C#3poJEPy|IFKe`4rYWqh%`7D73tu30S8qII#^!B!8=7AEQoUGdl!eU z@pEue4wrHeTgJgKnULtzaZs|NgA3Ih zl&|4nlB})e;7x4@-Rd~_rM`o<4IKQ?P~#gpnBCaHwI&W-kK>@TY>;2xcJR8DgRZR| zTz|*G*moVAde1?-whmf$aWJ>5gCgA=9PQ~KzL$e!#b zDx{Jn3!JI^o|VcunUtN%LW#{u<=xy=4$2i7S}B#P^;2mkMH(okjF&SFQ>ocVV`Xpi zR8G8`N{Ke9jFiD0Qkf|A-q-7LSYkV-GE8QQxoaw)e45JF66&pSvQ^A|Q|Tik<>{bQ z?hH>QFfx_nqf)shb4I7KLV8S0C1tv9XQXmTde2g9sW>~8hVq+4%uS`gjFA@$)u&~t zn0`!U{)$wV{glck>9bn%EmWImyX)Q=F`pu2VHn?n?S}C$(oenex4p3yYl8`$20i*ZMN+M<>gr)Cwmb ztaNfx!dI)Ga!@WvgEgA_vlH_#s`FRXxlVP;>J3g_Y;-bYvy;QyRof0HB~CkajgxwF z)=8T`ogBO3h~?>a@)!HJ5IvxIvIS=N$P#=nLHKq11J4t>q94LkDN4r zqI#cdZ=Y*_OfJ@%T_jsv9I(157U|+^>0H3Ys)8=c6moGR#)T`^#cU~C+(oAnF8+PX zMYU2cj+A!kyCN5-l3Y|zc9E3gqO0A-AF|)!BHHO?k>PdedSe$G<)P2T_K*u} zzKeeHrlyO+wOs6#Gg7;@i}7__gw=J?yS|Hv1}+*lbg@kqG>s;yjgyP1pSZZ#OL{BszAh%qQpxM@ zqR9{!Glsf|9Ok0kH!gkVaPf;I4p(nRxOD!}MU8QaH%VirxELU3r>kExU5pdgTo<3t zb8$^B{h*fFC(PM zK^N~!sY5Q@a`3Rm9(OTJDxOep?BbnkE*`yhk@K%=k~ROS7r3#6x%oy8 zg}cc!xcR~4=C0Yzdlomr2sib_66q#RhRcxxZYmaZQ?QVmCWYPXkb2P?FY(3Pq{s}p z9OI^u&CR4(H|OKr)QNYKR>Do6x7^&2Zl&G)Tt;IO-E^(sW=)Ela&|XmQr&#$bnAL_ zH?dXSyj#u9L3vrjt#fE@ev%dS+&ro8=7R=q#x`Sm@amg?)=yxQ#M#TM<+HaDwevsBow-tAD_oo*&efn9DI?{@Q>9F`$_w7+|` zhrjDMkn{50K{tOLa?|p#dU@2%_+xIuj=L##(oL&VZuUu~Gj8rk;GCOz3C?AZ#SFd)@?W5yINbaAG-PSk(>MS zMk+p5FXhuGZZRstaX3}CX=$|Zq_IbC`qGH@r}1_m zjrbhhhSHdqr!o0y{8urJ>Xj9w42eV9hs&S`Y|D2+2Rq)Qt6yQY!bEsY{Q(rEs18oTAZB=$_hF({3mpQUkG zJ{gimiJ@t9Y>_`<4DCGlZJO(8sAB~Nog#etemH$aba2-&QqS>>He}btjp7Mow@q6DvdvXN+W-58pD1~WB8Udx*bj9=VOXcUQ6S>yJ>uXFAdxMG)_NGakRMsXV1L9y*43I3=469*iar zpUQ_84=b!5N=10^%Ws7}^ojBCja0IE^zVs>9TFMmVSuzL?qN|053z4~*k9g5bh3xR zGRUcME)Pr6JlywqXzTTGAmE{2x`(Y99{t{dhjUUk+rxMnR7vA2Yt1SiwoBux9(Gpq z(6hR7siD{sT}!cLaeWW>8Ys_Z9!j@S9c@*I{3C-qdMMQ0L(?9bFXwxDNbIG2dwXzv zu6SQ~c>Se^u|qUxs7LQ3T6ctAAEkQapD`YM<2=k4(*zF$HTh09#ZCMjFg|RG4gn!hulRTU0dU!$`4vosx0xaMhdR-(BvnrD}S%? z;Q7VFJQ=#)gKLBKVWWp@GI@)KKelR5wtH~@?xFWS4}l}vhvOc;J>lWGG(PKL`Z*6z z&wB`6@bII2eaXYVKRx7JR{nDHhKHFCJzROD@sB-x@yx^S=UVSy4|}7%)GX^|Y@(O{ zq+mHOJCeLaR`4=FzLCTfFKN=n?q#LJ%hOaZU%9-bc)j|a5-*qJd5)L-pk9}jAun_D zycEgzVyNup7kOPpv8s8QB>vi7%GXi6x?ax9U$Vb}m*_@b2FuaLUgDd2So#8I zx7BOyyfl;_CA+Oq%Ka1N z-b=a5{@z|b?c-&rpuzn6Y8Ov()KvU;GG7lXWX{!I0Lq4{5V86<;;c=>&( z@*3u)={L$ndJp%KF~Z9|Sv1niJEOeBjP|lsdXMqq8tc{Xrg)h%&da~!y{ws_K1}qo zcea<)bG&>wSGRI|o_aN3uPx9Xe6POBaxpGaAAisuE%sts>eV?Ct+U2U?9X0$uJy9+ zS1(o8duhDc%k(W?BDN~tb}yxNco`#84|utF&`bS8>an~!qJAA!FOPd!A!kl_8F5m3 zamq`j)5`yhm*HoPyljxEPu1sV>g#hIOEUkZm%m?mdHc1V`_Icke1yV$1PwmwiN)w6PKL`7laGpK zAKeT4_(HOa_^2ftB|OTsXsmU5`$V{}~~ zuNwKN+{DLfiD~YmbqgQ+<%}GB+eiCWK3(_hBk-=qwD<9%gHOMA=VNJ49}hlJ++IE! z5A-p8kdN}8tNu|w-W%=XkbE}L$IeNbJK4uMDLd82csVys_hHJGDFT?R~|Q&lgyF3^8H^vZvXA$om)Oy{^R50yFPxs z=cB@X#d+YP^dqhPSbcu3KELqM{H2c$vRLZ8@-gAHdi%!5lz)9(_)o_Lep<;^qaU-` zPahd?@iRv{TKyC*;HOzZKfC15LVoT@e3YLy(S8m~^%y^+ZGPU!@Hjt5;{8-i@H4xl zpWdbXd|2AgiZXsmmGzSvx{~MEds*zzVlOczMtX?{j~eu&r!J{;fs{t4}Qum@iS2tOR<%zVV`Q) z@8_)4I_PKIAwL}U^Vu;!4UhZja>7rKe>Cr|pRV`(YGS39u?LK=X0|W|t38 zC@DZvg#cYs6hk&T0)#sQd?LF&dfgY`Gue_6z?7v}QZyK#MJT|cya0Fd11zr=pnlx| zlj~_r{Q%XQ2N>NVpzo^#eDijIL#+b5{Z4@MZ2}~=3ot>db_g)?{eaGC1z6lSz`cF} zUdzb-0cJ__0RcM787Vy|z|zmO=HLMRzE(|AWk^6j!v@$T1&0Ng`b_}q$N&vS1=uQ2 z#{>wCQ{A#@LO{Pm8^ACrz-Bop`I7_8lbcf%cdA~S79d6r$wg^6T`^|_u*?jQGb_MX zvjaSk8FK<$o~wR+r(Q1#=)8zx$}wrVBEY#VT61fFz1x)QZsoEkK-%7be#a}I@7UDe zL#p$#^1rGzPY_g`~j7aBI z(R3v2vxL+hpM`tNjt4bn+#oKBx6>2z+H zuIr%`=Y6f&F`bXPrDN%y&K%i2F`Yt_(+QiOPR#{+eu;8ju3UdiXTZvIjK8K+XI(lQ z<#f)OGbn4# zV0lCaVZ}43St5huZ)NaqMg|KrGdPo-!O$id9B7(BuvrF;WThPYID>>wGWcvj2DRsB zFn)pNFU%lT+RKWi89Z5*LF7ugq4vYDK%l1Z6rnG~#>N#6KO zhEB-j?-`kVyfKqsH)T?JOD5M3Wa2!O$t)@SM<&fKWU@=H{*{U2Rwgr~%$-a=yqih# z<4k&&%VJacES-zYVxK#UC{Gq&$%EW1vO-xbmY!9!SXV8Jl@w8pT){9 zSv>8k@!hi+{#h1BKF^}!7g;>|GK-wSSuB;UGJixCcc*2MJ|m0oWrNseW?`P4MZGy$ zY?fovWnmTze#qk1;w)M%$)bluuFN8Kbr$cg$>N|~ktZ9oh&!Ccdq=W3Bv)m?DcwJ# zxaYDMD#!lJBH@bilGP8hc=0HU<1e#xtYvfBolS0Lwytr`X5276{wA9#qqAu^Hk+yA zviW>MHoGQflRhb%+R{-fPswKZ)NEeJ`^&Ofwmh2>KW5{R!E$R=Hs00Qd?#=AW>a;a zUOTFJH#F~NHZ|{LGwEqI=bvRW<4rc#3+CV~oI_@j9NNd^P%$<~?`=7HZ_8nUBZp$C zIehQWVNrGtcXDzV5zJvs`y5Vo$l>RHIlSthLze+LY#)<@bzBZN=j7m?m%|+CvMPtw zKjqN#*BqK`$zjIU93r>nQ07<;A0E%)w0wUqhui0KSavywzSncuazpcP=CJdA4h0_O zFi@t3<#I7Rm)X`_Iuy%gX-qD~ZMiz$bz3Tz5mL5HE}hEeQaL4;Aptaxr~yp=I63^K`vPfHGWYpgMZK%F|W#{-cPv{{8j6o z&*kTbh#*r72f0`z$UicGbwkXKTmR*=TEgZw5# z>ndhF#jGEsWrHAd8wM%TD9GN%x@{Wd3z^w0$d%@r(;`T%cY}<3F9>adtZWSuLGE3bLw8kTP9^=TWXqWyxj=&$-^=n$} zDD`TbdNn@C-%@3QdNMJ{OZj-Z`a2^?pLvS8Krt68rWE)-$in48cK@P%_*MHLL)R(x zdd1!lWX$FuC$|KtwlzrYok7O$3KF(E$dLU(_8$mx<8Y8?^3#zZ+okQXAPrBdpHkvf zkW|@sI!Li|L0X;HeVOn_kh2%mi;F?p-wo1BT=#;6WTia4ubwSFo zqIzbC(ODtt=7l&|D@0745JTjfx*-nL3z1hpgrQ-G+KobN5PQ=QA2$o}r)+2y;@x*b zd?c;k4Ke?{5G&N4k3=bAEM$1ir-Q3J1M^G>Jp-0w-5=kQwsD55ij%Q z?~g+~m4Tmx_^nrn!!r2O5Wn|U9n!r|h+q1K`1CW~4i549>ktt`LU`n?lo_VlWP}|3 zCPbxgL)4dVBzi=Mw?`_LoD%0KdXkSQTEEfnaY1w2;b}wjpv4#J}*SeMInA(5#rU#5aH`W zyuUNVvR&%o{ty*TskYN0UYrRr?m~#u7emyzr276;4p%~~k?D8T`@72Lo^pApUOx)y z_Z&hLdKRMTbM;aJW%C%Am`6@Z9**jH^sJG`Wr?hlN29uVY!_#PJbE?E^{9@^t<>k8if;@l0-9&%<>y58K~)7)#|-r*uB2%H;Dyaz1w}_?dhvNcFQCe@^4Y`FB3OZsqf(WZcf@vpf0RkwW+LY5E|aos#z`pP`TQnIN;D zO#e;R={=Jd=;r_a`TWCtpLuJWB2V64zN`NBZyT5NRH~Qw Zsr#$XVj7l-4c1xx|K{m`==lHs{2wL7bl(5~ literal 0 HcmV?d00001 diff --git a/Covance_UCO3001/browser_profile_3/Default/Code Cache/js/7f64ac16cc5859d1_0 b/Covance_UCO3001/browser_profile_3/Default/Code Cache/js/7f64ac16cc5859d1_0 new file mode 100644 index 0000000000000000000000000000000000000000..a3036637827bdf6437f9c106fc3237f0b5bbf79d GIT binary patch literal 18216 zcmY-1cXX5GANTQho1{s~Y-u_`R-vUyvy<+mW$(Qem7yTW5|Qly1eCq^p0Wf47aL?M zdxHonQ<1%=KA+!n&hy9PIj@uC&UJm)9ZH(q=za6UuS#`)@zMlTmTGY|&+3LiW_EVA zFA(%+c{4Jr)yS-tnNvN-7YqagnOTvu-+vnqrbqnmHbMNlcUk&H!akX0gmYq55w~TU8U82^M@z!C zApDdKmRzluGa<;S4kc?q=f<$636yRMKT5S`klY+Hq_(`@N_%ACyU?)*+>v6v!PZZE z`)lt2$QlISd;(8Cg-)MAw;`~8C{+0z;zz)nUqBbh{1R5kossbNDCjEnMnh}K83Q$? z(>UlYgT}*`@?wJGO@@dWFkQY~53w7-`7Lbt4tB_*@8N-5_yMMD)bpF+r7YW`d2E9% za!~TNgZU>&l;d(qn(cz!yWy0K-vjfd_+F^HAKHlRXGoE0^2-4@FH;Y~Qi(sLxgUd7 z((yR-5l%wz6x5Laq}XW~EaRm6c`*G3+b=@&?@&rk$yI6j2Q>N<+DXYv;E>t!@nsk* zwXQ%b+5bORb*^RdHCQZh*P+7S$}6|!U+H-RUi||_Z)&}ql{&Xz-fdVbUGBgDxgm${ z!$q0#0G3PAL%9D443A-}9FqJe@cmQ0)?~;tm?)9Y;k_5oU;Hnjs%(&skrDJ2uOWiU z@{J5MMlf1xm?CH)du5b4g4xo-56L zcSi(`^vCT@`Chs^BdF+&;CNO93E2_Ukuh>!%H-&=OqJ>R5ge)-!T4$sw5uLLVvPvi zuBqC^Ups=M5??oh;nKNY1Z(O?P`W_``x>gg#u0ohBV||f2&^q5=r6P1j^NL>s=Ivz zpLEdNou1!`8aKCcqEH!nM$%dOw~i$0b>(>@lB9N# z?C%iCefjX6NQQNcWMt<^3U!I3$@`HM`5=l4e8_m>EfBX*4I2i_&CXB&8Qd(tL3we@MTjk<41A*k48R)$&Mg zt%&5EZzB19y^j45$;oYzWbTb*kbEtl=?C_n{gDKJj--x^l&qub|Cnkzt5{DI_o?zd z(|-9{O21Ofei3T>y0SPA=7*^82L&+#>pr%mHKyeu=KbJR%$)({JGWfPvJYfp;?v^bt>%fdctPo@N{9oMT{P$iOc$ENozkMCBW3 zP+(xIEU9APJLy@~z-Mw#va1_dE<iaW29<0Yh4cz}+ zwM{bMoNVC3DF$9lHL!4o<|k`s8}xe6Or*sM11sdtN&|1NGVpSZf!b?z4%TT#GV?pl zO9DS=o^ta?1C2Ktn6}A)X|sVJw;1?ftAXp{+OBgh{G@X$M|WwKyLJBe=p5};ZTk#l z?Ke>GnCg@469&GL*xxiuF9(N3Ud)GjPdj=jz&I9!<8IKGMdTiiJu{|-c zRQ`FY*T-|sxUi8$MU1SKl%hs%6*KZ_j1ga~kt(uI9+xocwPvJjypdr^M$RM~xs+za zlWwG*%Sfu*NFkq*rhX&qgGQQX8F?igvyCL?7)g`qav|49{X8Q*su|f{$B3)0k>2$b zOC~lnlG(_}9J$ok$Q^0h#7N<$irdV{PO06}$W0merjew#jO>=^wnhfXN9~OK)WOJu zj>_|%YUr$6>Gr;nW8&;;b&NtFvfsqbU zXql1NuZ@h9BWsN0uQjq_oslNr82Nd<5!(hMZN62#-x+E7y`GahKN#7x*+_{kM)t~S zsj=0_=xs)xOX^BO`Vqq zMlOr}k&*8t;<1rhPmEN5W@Nt0kBXS|dNFZU{*qS3Ow28A zqHv6ftCdWQOfzxBZlZO%i3VO1Kgjz&69eUM@dQlFlhraQ$3*>H-R7By2$_hN8C6Y` zZ=yW1si_HjGZU89Ci;ovbrZR=Lhig_;>4RKroCh0m8^T$#18RvG|{J%i7V2#tBKPx zvYUySV(D(8VGk2qWqNNDr9LvzzK@BcGO(ZW_ct*?stqvFOnwr}Amx@bA1n4`6UU|D z6cbaXn)LUui9}gG-9%uiiC?7nS0=ucufI2u{)36(lJ%pBInsWki7uN=tley)%ogpD zC0n(Br-_w6nRqHKcbixwf9=uZy(Zq?XJUgq+i#-t&+7Y->N~8Sj_7$Y9XHWImY*<@ zaMDE7ITLTlf?rJ(JFnSX)cQY6G?w*J?oSh)E}5u#*~INzCO*4u!hgp^RryAq+%>W1 zo(cCO6O-lKV-vNXn7HxOg!j3L`Lg0))$yN+m+}cwJdm8oD3;4s`A_y3qo`+!Vq#R3 z-lRuilVg@Bj<}-u&>h7+$?`_AOg4+b7e%eiD0XB=Q79*h*0M_OQ|5AbtzgSim`H{W)xLxMG?_Zu_d=r6la=5(Y0w5-!zM2YKtgN zwvXcD4pICi?sud3y<-$9??qwl62;4b+W)cE%GhCwH(ZZLL~-SdC>$fBm?YqG)nZy~-)+ zcsPpWJ5hAG8%1BaA-?-jER^#P_1xnqJo4I;C_2lUr%{xCrv6?;ar0#qZC*ujFw#sF zgPAXkW*&>xY^IUL%r@Cj#7tCCGxdv^8BpBJAt@1SrkprRnE6JY#F_cMl$lo*%)C+2 z%z_j%#Zt{otE6MHF3rpi@z~AuahSOxIZmyUW-c@D$Z<*Zs0NAfndvO0{ASW+mi!S= zO+hoGGR!=a)tP3tNP3o;UfFtHUJIM`-oZ>(zL{F`y}T?i)3vgha2+!< z+|bO2X}W zE7Rn_N;4mAQIArv%}k{|X8yTsruP*y8?Ty4yQW^`bD4X?O!I$K$4#BHTV~40Tk_RI zGo>GCu8%cWxi0=E%K6Mpx94WozfeCf&1A~NS7zo#SolrqMp~F)u;4OUD2TE!T8^15 zT#dHiD`cTxVGHp^Ep(9O#VjNgx9ImS3p>SJ!a^;Zg~@U*-ol{-3*{0mbV{<2_L_xh z@>^*OL&{iKRMx^PsaD>?dU-e1!aw3mv#>y3uV-P6Jgjfwody;@kgw!mL&a*OoQ*A9 zkl{@&{2~pTSy(A|n_Fnx!op{7SU4d`Z(8_LOl>W+mU-rNIT-c!AuEqpH@ zeQ05aM15qTj|}Kzp;ccC(fuqshZaW4k^UC)2Uzs8UHN6h2n#K~uwePpLZW;jhelcm zjk3^0x=G|z)h1J>S-3OZLf#DZKT~x|&DjqPcdJx&{t+();z9hpPZDk*Daitw7)br+4Q#s z`wa`FZfU)2xoshQSF^vTb8+9oVYw{-N}&f9QXg4ZDy5!SSSEv?SvdV%=l+H2eyQ{M zpJHRBM}(C@@~dP;TKU9aWt7~Ju0|{0n5=ZNSXo@minX|vMln{l$qBhFFXU{jmCO=W zK8~|8QclPao0Wa>RvIT-x&E4!Kxr!j%2@eJ&Xl!Mp`4X2<+WD^Co8{{t7v7s%#q*a z^%T{YY9+Cfm9cUn%}Q0fl}N9ZMKZ!?<)Gh6UO;)om1|{1eJkz;Rz7NI)z2O)?HgO! zB9Tp1cPp)Z-O5pkZ)4?Vd*yrI%6Tc@&B_GX*4>J|hn1c^tz49pUaH|ED=(#SAFF=m zSoJf<$_@$kw=!^mdjHJI)FD=$OXbhC_Dd_>Mr(~kjkVH8YLBzBO74xf(r$v4mJ_XP zkY|(B%Sm_2omF}`(ftBfttn^xJrRaJq!{nC@R&u_zvgbQ1g?>!iL-{sC(EBWWGG?b5iv$9cs zmbeR6DoTfoR=$?Wzw31%8>G%3R;I}6Kdn5Gr*Y9#vqjUOTr@M}kX+A=#-A6>ClV@% z=BR9}5>4f*(Ku>E^Qr8v8BL&8G|Ov8)2vlA{Ux_`G?v%(SaRNo#@;5HkHo(uhEL?i zk1=FyjN!zl7>;a?q2!hrifoPHJJE}in{skT3}tu5F#D$%M(>JY`tBG;?u%jQ{umBP z&d)LQJ`lq;`RZT{4-UsL|5yx_PsFh7WDNJjekz7NzsFGgj~FbMV`wIUt1%4tJBBqk zVt6J${}V&eTQR&Y@wa2>dq0Mq(&}LhpFUE(Ph!|FU7yA<$q>s0SsoqB&_b~sl6r+> zSx_XFf8;{ZSpBSzrGxB>iKSm$EI)~*R4kMG#d1-;_*%!m({YK}6w4+tZPs(rbYCoU zWzA8=Kd<<*?yp#y-Hc_P485y;4`M0uFqXToVwqN?1b<5DN+oD0=c<;VVzm;~?p}iK z155CuY#dsGQqxP&N&G8HFn3)E{*sFOOYrHb68tO|ub1Haze^BtqXYwPmtfe75*(55 z{w=}k|4Q&g-XV@{k#SfJar|S9<6l!8t)t>tEM{{Y?Pax;u*4A)9mkteteDov#?f2` z+Tv)J7{@BHmyF}%QgNi0i=(fcNsXh6BaUySetH}S{Bgtw;<%R+M<_Rrt9fyp%8%o- z7IFL{rQeQYbB8#h-ihO!Ea@D_9eJxy9F_XUQKVlS-T`q8l0Rh0K*jo0u|A7q^x!xm zhia{S{dpX{hQ+Z(rVWoH?aMfNOaA0I-k280QmHyUj=Y(1jF9HD;&?bWj)Hk{jGG^a zX<;0VrOP7ququw^)$03)I3{h4?T==L)t#-pM(Di^acp}39W zF*e#rxmcUtZ`$Z1xp6i|*lZk=y74y7NOFRW^|HF0)}`6Foo>^6OdEMF8znt93i)je z&9reyMr7IeI@iWi*_vmgao9%Nsy0^2j%wOl*T%tmHWKRF_)yw3wCVQ&8=D&GaTD#4 zbxm#j+0urym5q9>Ro~k-y2|VxHfr{?F;SX-U?Zuwjdx{h9~+kj+HeiB(e6_lEe6|I zAkjl?ocr8H#bGwq%IuLguF0RHZTb>IvE}$=8>1K4I4xb4*ckAYjcqG!SXbHTu-bBXlRqV?M?9+~JTRUw<=BvTS`CY5ku)5k++V0Z*(-04 zif4uNn-tH^rSTMArWmW@8L%dv-LiN?JWalhXO0*)X*PS}DY7@7vIpZSb10rJa#N-q z(LSktO1)l=XRFk|5l`~nc)H8#C-H1~5s&$0yxt!r@QxvYH4A;K>T3zKFP*?@`LRrb-ghT(OP-ZWAg4ltzUxR}dc_2`r6gcYO`wXba3%0i-u5T( zaWFxjvm|gqehnosplSlUWmWYA9@p0TItkDufmbaO^f_AsFWV&0vtt6AWM}6D+H_A~ znauw{_4G=hiHww1eN~IRJ0O8`gA%CtaRO_l{SehE8N(H8WCFEDC14nrKwx45pUPDk zF+YK0vTb<+OIIauSAPFGfrM`o=peIX=(h2@Kzpz)@MhS2^}2 zFj)NiHG=~QT#|MN6IgIKfq$g$5v@C>-sH>U2`oODz-{^QlwzMwAn{BBjb+7o%}efF zNMOd}1TM=45?L6R$W7_vO=O28`4VZDk;p!Y%}ivL)Xz%fl622Wq;Fm#JEeX|w^b4; zTs4vCYKfGur#Ouh$!e0Q&$AMF)hdzNtrHpXMk1%)OQc-qM2tNW$^0;pA@W&o9qW@w zS9vV&^-W~GRPC2YWdB4SN~yt$`MF{aOXTT@M7oSj^1&I`2n8<63^jK;wPNdnAM0Qn5qG(zYUQZIu@{*V*d#WX2uAW3? zao0#N$8Ni3A#q*99{zLUJxNsN$6ZIamdZW6|h zNfhsrM2l`oERZVQmA8lD^-NNaiYKQBC-G>M@{Ud-c5)K8XD5*}N5|(UaejFcsVkEB zY*iBPf2$ng_%VrIKP9n6N*qXH(ZM8cN%g}zCgvl`B?(89=peIX%$X$4$ZMCh_lnlZ z+UrT|_$!G*e2L_G9St5D#;A1noNVH$;^=X?UUL3 zUNTXglPTXTnN~7RRt`$$kxUw%Op7m*Ss=s4CiBb0WNecZXRh|lOD01sE0Sp@E4C!# z-JZ-KS-2~ir9UTgSAIE>Oqa9Cd@Jp)CDZU>GBf40xdN6#6=){WNfmfmx&pPzRKVe{ zKz!#4w3j6VD^UN_3QU)>qbo3BVg=4iw|N!lyR`zVWZ%vT#QvmM$0|_gTm_~`rArm` zIYA)KhGdsZ;h*FbGApFus+gkBBJ@}WI#URHQrPKD;e{`Sn*J0P z%lu#pH{@_e3hT19Zz^YvH)1u68XoI-k)6#e~_qCW#E45*pHy*ep8sF%XF zhRV|i~+#0Q#$E5J@ zq!d1%t~#XVOzoYW!dU4wCx!m=QrIP)`6(1xrFhc)n-msp(|&nxPYPuYrqD&ahf=6_ zCWUFz=eHD6eox^8Iddh2pRQ~FUnxAgmBOn>Db#+P!iA^m?L`V3<^IbQt{GGDnNlep zor<$iD*dEo@l?9Ur1GQej7?=`Tq;-O9h=rBrt+~=ESbu1*gZGkOi(^apO(t9rK#MLBHyPna#t!RW$4eU>z7nE9!bS`G?m^bQ>k@2 zl}YmCTq@1}NM)X^zOMDRQz?5Vl|9c=+45Q?%%v;wdsZciWmlqs%#dc`O3agPRVuOZ z%}N;Gszj;2m1y)oiz+codhe-3wbPY!eMluy;?@s}iGbSJLO}IwtELR>ELS zqoMpAlSW=r8Y5&`g*43mG<~0z#*n6I+~}A_MyE6yy`RSNPt$lHuBBSHI*ofWYg-zp z_M}m6ZyMu|r}5pXG&rr}zov2iVj8Kxr!nVh8uhQGG3k05^X1xKX*h4BFQ|_nfGw3u{JxJre%zB>2w*S&FM%d{sgJrK2HP~rxw6jZ2 z7Pd2_h@E{!?PM0S^L?V7S4nodm$Wmdw4KXk>@+KDCpAUKQte!jigr7PBre^~FzMj4 zWAocdk*V@qz)t<3omTmFI!kha9ltD*e=6H)Q^n37b?o}{XlGSjJDbH-&(25n?Oc&d z&FnmoubbQ1DxMa0`nI%lP42a`6WQL*7C9*S9qbH$$Ic_!-Nnu+8UMbW`4ZFBPU~)V zeUEIX_yE;2P<_hrPwgZPwlh+C4Yl**=XTPD*;)RjUDrn0X*i#y}->!YT>{xc&X|%`Ab}4jFb3JUQ>k&KW<%eT-UDIS|^$9z#owVbV0a9>U zwVbi@SPGrBQ~jc9ylv;ZJDUGpJGpY^k)3DH?L@!OOys20d}(LwE1g?u7U5u4q=RUK zgE7$#P84!bt+0dD#T>j@+`-})hrVxc=-M6!r{qW(2l3?`jF3sm4$f6@P^Y4U*>>%b zP7Vis#h#wcXLpzyMtrB z93=L3@TIKj?_j$O7~o)}qz!U#eXxV4vVMqzpCmZc!Jy9_{3GuUcToOI2fs-1Q4TiB z`(reNv8r1x%57;kPPL9#trHx)H%)n_JE%9)!L>OKT=TSlzJs&N9F$$II_3S9s%e#j zwyQNmS+v%{-|HMK|K7paO%6_Oc2Iqb=CV!4wmaCe!@=gA4kC9c=g$rr{i>W&^1K6w z{PTx{gO@c=nSMpJNYYiUx#r-gT$RQ*9kjWpc}ePh2br>5?mSQ(4;_3YzdzIY`q#l1 zQsqAfO=OouN2D`Q#>?}lbe0xM=X?2}a5{tKzT^~5XN7DNdt5r_6VtgV%aXKK`jt(m zY{hiEazma=x0G}?q^47$QaahP*qP4H+3EZ$Q*zQ-BJsKDyp@;EA-N>OtE5xCVLC0O zSR=)hiE_4aI<=cjM3R(8@$Zb`7JlLxh&6s_x|MLj2bZ7}pLvl&#^mKCUb0>+zouo*`5l*^(;pDtzjCAtxC?_N3 zfs7gBWUjOt>*PH-C*{UFSvA2)?I}(cPIIzex=q(Uxh)wpoz$Jm=$s_4tE&{82s1`b|!rZFVwjtCJ%; z)z>a3rOr6%a8`3U=j8Y$<-O@-;w>i;x19{V<0SpA&WSvhsC!QO%l7+DJP(|-e5BqU z>)bun{7o*tk8+V}c5%?+qC~Wd&!tNt7wZbUC|AVAwKx~9co%b}d`TCbOS$;>H5WC? zxHwwYrSE23oKA63Gu1^(nu~6B7r)5?hl^OJi=lGI<08}NVwr4~`+gTY!!9fZF8a%> z+AfOLaj{>{O5M6HCf0KiQQt+MhAym)Tr_U%Vuvhl?&6D9E@nv6)-F28Nh$S)i_vmZ zX0&nf` zuQcBkE`7hO*{yN0cCCxD>s(Y{uX;DQcp*K%(|Pz_y>4+4{>4Q@u^e!bD5Ip=As6pT znZqvJa_ETGo^UZjDxcJBDG0rZsM!E zd8>w-L-M?qTc2;a`9{_>aPz34n~sg#jBn!RbW=Aqo4Hy1rkfjYxiPeLQ@5R)Rx+f$ zTi2kv$$m$5%84$@Jy5v^x%D}ho2Q?}JIhH%Uv~43gn1-5gw{ znXYzI<7+o#*0`A|rPsQ7cb%KrKe&0eO|#wMW}Q^o<>t%XZl+41J#L!rb@P)X?ANS+ z*7=f!hur*i*iGvr>i3wNiO1bUoN!a(l$$qByZJ?`oON?cg1@?1BBOqDbL@hSUvx9{ zcQ-%(;pWXhHBSj$cC%V;+;ro+t@x62-_76$ZtluQkKAm2ta-}7CvJ8=byNSjo9kwe zz9;Z7Pu4|ycv8s2dxbqj6!%a&#)CP*!{gGrE#qOQ9FuBgJ&Y>n;kooo_V9fL4?kD* zP(0Pck#ya9Jhbw9*eBQh9%2I?UJrUm%++n!!-9ORDe&-LWe+v0DrPm0-aC4zUSIng zc$m@B!|$y;G-|CH+ISfMriX?dJS^_$;YKG9Z@lNBd>0R$-}i7*_}D|QPdxl79}e?SYPg3EBRm|JZ$^6PG|I!*qZNCc2j2t_3#I)O z56h>j=4l=-%RhP%t2|g%dvqd&&5T@sz(WuUYz z>1A0dFY&K=IZ)9{Y^s-`^08CvTwYdqyxjGAY3K8DFzBU!hL`P`UR`JGJEduLFS~1a=~Yv;)KYATt)tkoyrGvnjZ|j~FJ;@Rk9O)q{*j@bycFr- zrFl>7m-D^6B==UmeY`k6RlLuMX?o7f%wN4cKJO)b!OPe3`R`tS`NK=@pQ>N3U-L5izL!f6wEm%&&z^YM z`&9Y<^|C+KNA2=H#wYvuPj;pFh_2*gpd_dHSnKfdINiq(mya}`PuGn5_+6gn`X~tL zd1)Q?F+bl&u>v24sy@Dxm(_fHQNu^YdOo_=_ibBJ@2&iDppTD_`uZ3y1^s+9lAU51;G@5+ zALQfN$3D7zqFO)Gz9Gsx%*W5eeKh~V$6t$mc$TVe34En~m-{fS^wD;`k7XNt#DD9f z*Y`et{J}@HjXs)g^)Yjs59@XxXLkB1v&+XgnSRj6#X~+C9#+lAeB__-u}03G^fBs` z`aJDpcPvs~-J&OAIOmd3(sUw>uGRDt`QZms` zx?Gh<@?MgkH6{I&Ddnf2oS()LU0&;CjGRdJQ>}uZUg>^@O33M_zHAed+fN^vAMkT6 zsOK~M+|Kcnk>_Wrv@h_pyt1D_Rn<^OHPrJnw!WViP5e}C=4ZXcwe-`bm7fFB;SE14 z+V}~+rRO^MdG?N9|6at;%3gl%eW-Z7{WKlqXXeL#Dt@ZI$M|`Bte?a3$z(sfr)cj~ zKfg-(>3$~4uQPOimY>zL{ghgz9ILf=t!A^u&)}_oeb%C!yZzkV<7d!5KVSar=g2Rb z#Q{GLB=?Z=%XWEu*iX+Re*QhLdVlj1dr>{hfj|8WyyR!+Wk0?v%6U~euPeVS{makI zzx}*^(naA1MAq&G4ya_{>ks=YHzF@H6S9=Jm?Yw153v z_)q7W0NafLqM`y!GzTbJC_szC0sbfwATcID+t>g{q-I=zv9W zIzXQ?0p2ScU`@FIWy%M5Ayq2`h_DARIs^JQ00E){0aj)NxR)7VT}W{Y0xYW>(Dk_i zlIsQNQa?ai(}1qK4e(pb0QFl17~eLapTWxAKES4T6t81|F`WX$bq~;{M}TWR1K9cp zcymC2gVJ`8VtyPT{*wTWh6I>4RK0u|VAz-d2gU}-8y8^Lc-1m7z(DzCMu4X?19YCH zKIR0tGB-f;dFpdPfRhUYR9_UJia4{g%trN%W^5PRz3Wp9u5RJ zCv^@5m~c1%M*@6uJV4_U0lJt)B+iFB_k$?ua1! z3_*&Tf_y5It1dAD4Ub;&_mRtPe;Vvr&! zK~gFO>6WG#ve^+N(i!AK+3VHw{ve;ow#*==Y{in|p&+foL6+qQxm6Hkb&Vhm>j#BgpG-207n0NOJoilcf4PK}NqD)Mp?;miG&Cr+<)_ zGI~IeInr`qkWO+|%6=SVfVwe(Ss~nPosX-RV^=XPbUC+%35+{e{qBNeVn6rYIX9vlh6J*HT zAopa}ydZzh*Sr>L*2{wWomw&FxU^mqk+2ZH)OMe{wZ zKL1qxmz6_~OVU;KB=27f^3C-ip}&Ldeh{S4qacYgMov5q^7d2B-<-h~O9oDB1}}Ya4_mURx-E;V2eWV<&SH)f{Vj_Y7qZwRm;cJbaU+XaQtnn3 z@7>NK^zVzxfV%H|h$HZk68hRD6VY_h}IESFx@v-z<`Hfc4psZ}qVarLw5 z+c2B8U9)-IP3wDPGxC#cj((a=<aR&jsLX1E;xBb%g4s!P`2&*s^KY)(AS)@vp9fEmBWm_1TrHf7vuG|^#d7HomrLdNT>br)tH0lJ zS?tKAM0zeu1Gy~A$>mmVE~7%ZjO&ogsdsYuwtp@!2ISIpU@kkyU9l4Y{p38eDaycVQf6e9Q`CL~0nM=Q`xoo?p{nvBZ zeK(gv_j4H}(F<4flX^%a`WJd@?dWhlf z5C=UWLf#OSg36N-Vvv-~4ADL-#4%}`7h+i`M0_~J&8i^+)k7?n>NP`*t`*{i6si-V zY26S%$?*D$*+4NHhG^X=#Qeq~iZuzbzo~AUhxklpw+L~mrS`N6QRl4?6W$I%+YoEp zg?QXPM5hjl+bKlV&LP%Im-j=g>l&h5w-5!rLX7xO>!f)95UmENe;GbZd50_Sh!Ee7 z(*DsQx{lGTCTLa@L;Nk(CTS*>H-#9tHN>fHA!=+7QFnKUiF-ms>9-K)E@&1PLv*+uqPMv2gb2%8d3;whxu+RQv!@|u zJqr>2Jj8awL`8F>ZtT1DlfyuPr?k5!Jq2!&@eAQ4`Uq` z#w+Kf+z9n3qvY5ZVXAx?rlG`+3iJAC#go(G9HSb?hDjJ7rlL%iF%!a^m>AaUCQM^_ zeR7xuQ^FLVsyWInnKMo2U`80@%rNz4h1o3oWzcNZJtvHRZkVR?!^~U|ruDKg->wPs zVr`hnAH%%6JIty*n%#jgl}@XtGhv>c4Kv|Fm@^l{)cRfh{Gt4p!fcS4w>0zHs^yOA zxUU&M2qzOJ=z7%Z7L3;5(#0k@>c-2$55D`2%Ka9}-*5tR>`{wE9|Ni&M;x&EW48PvBU8M$tUbJfR ganU(v-)-{6Z0L*AoQ>h=G(Pybr||NHO%0MKKb(*OVf literal 0 HcmV?d00001 diff --git a/Covance_UCO3001/browser_profile_3/Default/Code Cache/js/8cfdfc2210e9f894_0 b/Covance_UCO3001/browser_profile_3/Default/Code Cache/js/8cfdfc2210e9f894_0 new file mode 100644 index 0000000000000000000000000000000000000000..7282bfe1b523f0deae6ff14f9d9e46b4abe44872 GIT binary patch literal 112688 zcmeFa33OD&);4^4N@rjQ5HJD6Fo=MN%rePM0ttl65JNyjh0{qo14+6=x)TW3AtEAz z7a4;iA|MJ10xBpfDk37t6crT(5fufIc}P(4d!8CP9isPr-}Qg%`~LN>zoFB8PSxJE zYfrUnSDot4cNM+Rtl+ob9fo1V;T_YrV*x&l#GXBSCk?!%bA0C>U3>N#kTf9vmY%)3 zC-m&yBWYlKm!7?P_Uw{40AD*N^+@X0xmWkDJ$m;{=+z}Den6KVJrcWivjN8^QFWdm zF22@=9D47}&oNgvE)6l_AGPmtyn8--%tnhW#9vG2+pe|6Ik&bjJMb#h8B_mSyWM1Y zOJ{L|mbNJ8YKs}dGS-|nr-k_%FGA;DYmYMV&1gBlrLD~ZvmU-WqOH@yEKw;L$M3Vf zPnZI4W^uk7)uU1xL^h20C6+fc-C4OF-i%C1KYsIxcSy3UAk%OMZ}t(+@j+E}cu9M3mwZLwEOu!rpHU1fwuRF?N^V-0T=vZ6_A zYn_U2RknJ|>+oA%l|8b&WgB}#Ksa05qsqe~Y|9+29Zj0rCfK9*^|pmHji{`*(J;&_ zfByNWrJeIuOXk*zmNGk<&T*_|@H1vi%zyW_eVE`bGq;?i}S z4S8kqzNMz1}-^(e_gCtw~4V;_H*C|SA&jWz|dvl8nXmd3Hpx|WO(u$;HW3%w~bEYT^MAt`A? z!f?xSVUu(V0Z?i72zWn)x87n40Dq%y6v z&^-*uT-ljFE1CapA~(uOGZL`;pgZ zWcHFz(%DE>ez7lSWJZpgZlLHkArf=863Fb7TZa-$t}n@3l%AWJ>Gq_#vVo;3`3)@P zh1Y&dL&zv{gD0XP_QyThk4oK%1uT3rZcI6a0-+YVJ(5zV#E`aNU3-V$^m0W z$Z>hH-I*vHt_nAq!=I-~Ky2CWfiAxb-_15?(HRzLp2er7T}sZjxUdhJq9E4?vv6nl zh3=2YN^=*062BY02T*r*8qMu^uWTZPmyz#+l4g~rCXVl7HYX-9eoM+L^{K-?NUU%q z{&=z}8pE8fptqR^N`&Zhf!m$p^5>)`ntf1MCXgS9>=MV~e6QE%PWEKFCy&T7hv0_P z+T(`5q5-a4p4jV=N`;G5jG>=^Yz zjuSx|{swNs08ph>gBxD0t}?(|Pzd$S1eU{S0)4^A()GDbAK3xm^<=osq4+{cbhV_k zXol~(KH+49HhKJsnYn&fdcIp4ojEx`Nq@_s&)E~HfNaL=5gs9w@_>dWba^mS=sBDr zy%qhzfE;&59;9LpK_yA<@CGANIf%LP^SzVYnS=7Z>8^Yq{12aFCrg z%(3{wZf3RYwvFNrXxE6MBoD65wyJ$kgFPM!EL&h4?DAyhyAz9ws8ELaGT9ByE^6># z61+a$7U?t0p@fDUN*;J=4ei0__6y@mW!uYH2&gIXJFX|xBv-BM(qXD|rp9Tx+JrkQQ7g{9oNGrOGLg^!y z-u6Q)(vT_KLVQt?tJE+z;|4po;>`38?1MMm=PrWxG&isSt**Ll(3@-(BZN1<#GRCz z@0VVr4ttMQS9Q604XFo7*>p+Ces_U+h%`eT)?1!^iVh21n_PN(E{xBeHOe!o$W;is zKSM#8z_DrW!;T=z|LHD8@kL2Fh+Ff3t+SMuCyl<&ECF)>i3WD>oARqL&|<%LfbS~C z^izzfSl1$z=mYkb0Q65P`uE4*ept{CU+FFy>4%wTm{F?mfaUQ=37O?Bg8j<@+)73#qSKyIjSUS^jY7=j}XZ4 z7r8J-``qSsatpfBr{Ocngv>5>6=fzTjvPHGp*S1YW-R2z3JIyr@1>V2z*r=vuc>q&xxR#AXj-yIk6z=u80H)lP~(PlZS^m5Fe4w%XSBjF4L8cf_?K!; zzatt~nKBY!XBk=rdTbUdaz_{4l|gDe6fOsK<=M@jag!Y#efGIKsCTZ+Od6$OenJkA z%+$$c!pjM@2w)bxG^0@olmI@f;p(T2hCc}RC5B$<-F)U2;sO2pTP>VR`oU)r z%9tj)$kq=u?D;X-NC9{YL{My)lUaz?52e1-i?bU}2D zuTWBOAd;|8RQHZ|J=ILgiK;Oe)()z-un_8ZvZBXe;q(~kLQt6jB|xRg3d7N^Td$># z6uAq$CGG(Xp3rabpBOHto?Ac#F81VkypudCupi)pG!XN$_vqxwr5C@ahy-hd;|2N! zzyQvnoAtUKt4llc<+zI6m>+lx;p|EWaxN=|CUY+-fh-$#dn1`aLt#;|$1U1O^!SS~ z_!Od{GNC<9UyWJ~#LxyP$`t&H|a7Ab0!M`-7~{`xjL#*%z!*hPO+)neZHUICwYZ* zLvN^V_5ZZb7#c+&<_8NVbKvT!B#@vNc{L-X+SGIWog(Pl>?}=Uvm1M}3SWxIM6+X`_Qx%54dbTm?kn^5okI(Od zuK^t+HLwNR6&Cv;m=M2ZXZi!<^t1YoYDjma>#OQ}PsMXhHiODpti+d?#? zdOdFBv?myPsdTxx!AJb#= zBr5=N>Z{#erE4hgX5^;&yLdZPYO5By3zB0m%#7*eX|cJm}<;N*~jw+y6a z(W5cy;T+SDCHdrRmk-Dk>Z&S`afXYU^@BV+)dnBnchyytd~Wp<(XfBN^G6%_SVD zonqgeK&u}XKW6->l!5VSiQ@;17&Sc2^aECgUekX#B7~6ZNhtD8!pwlE)A5JBo$0sE zqY?%Z4Z~K?anGae}!C@<3;R^vS4SJ|qhR zj-N;wwsn_PfOhHf2}^}+5bTSYPgkIIULR&QRPC-vdv7`QTZR#UjZz$5)n@H2)P(|9 zo?A>=nR9GHq9B_U-A{<<3~nETTE1{F<`h7JFtoa<&5SptsgA;=3v+CMu?Ub`x^Ky% z;0om=mNRg}tdx)_-jSKwjID||AfX6hD2Ay@*&P&DoZrxtE&@7^U{82P!_3DGvSa^( zh+breP&el1zz#8B_koONiYjNfuGvU2wm2L8!xh_>Z?v6UlnE9EO9 zcQk310j5lJr9+P$mBN@a)4V$KX1)kXpcpN8OoFC<$YIAYjPk`Lvh0yUu$fTcYX z7iY=P4xE(EUWOH&NgA9>pNDq-gU-b#(rVa8PB7j>dWdCV>#>wSs(E~LicC9=R)s?nOCAq6e5V;;$CqViAExp0z`PGx>_;n)gQ>$>d6TB;8C`^ z|H6`OjZg@;Mcc+)hI31m1x*mLv3E4@Vr`IdKXPPZ+W53PQW8fRW-4x!3Dk#Pf2HrxD)UVrYq*)~N2wjc>kOc=vMUfzpmKvB_lFL;nEGjU9FyB*rZq+t6hYiRXkd75W*wd0Q z^t!{gcZK(mi3X9Z!9)$Df^HOd&6@VM4m9MT0O+5g5prbizpb#CI>CWKPSsHyM}+~2 z{d*oiz<`-UnQM~r+_DA3+^-m$G`;SJG)Q{jRJTZ>a>XnwcQUdzkD@?K`KIq&NMDE< zi8s&9Y^cagi}a4r(N$7?!PC^N&YKucDCa8{NtnGb*D9Wj-uCBbv=JGEi@=JDJP2CB z6Oui)N%;u6Z&3j;x`=$WWLl|8a&dNzIZ@?3VA>rpaeCdXg1Auv#JXC}QL7Z?WVkADZVWKQ$RZ4E|Hg@jcE zTqUZ!rueyd!-~#C?kg^&$M&UAQJDw#;3knTZd>*^9SV3LQ$YvVDwwk(tKK$JT_^*V zRwlZ5^yrHsfyPLhp*ZDg4o4TK!uL1) zG}P<_^i-6KO-{Ye(MaSeP^o4x1DqZu$IBsU2c>Vr)FuNfwXwtiVy~1Bx|vc;clq3b znXM0yLq&6JV4^kTg&S+$zJ0sVXA6RNGLsbwCYz?#D?<8YAZLwmp6e+I)FVjxmvrEc6%PAo_=iFVDm70*ZCzAB77 zSB$Av`||;nOO0USqxH3UWocK2E{6z6iS^` zuDij@1k7&65Y zD+;Nrk{yS>cjVdk%^l7RYx^(55X;&!yVl0&B zW*{zh`SOx-CmUv@BoCB_Y`=F1y9BdjSdN?tV8JukOv5n;7jZDB-Z9gGC4Zkvm%^v9 z2~gkU%gy1`9v|Z_m6U&=T7ADj(S#-^Kb=Ja%AU z`A0`BTnq3arZlgp#ySlCHdf3O;9XVZjk%-hY^O0B#?m{-54}D9j*&sR#4BtHUG2L4 z&vc646AEy!l&>B+pibN#$rz{^L?rAY?u`* zj%EdTf`k|U#mSG6&vm9Bs34F;!W-^C$OmPrkTgvh4(hCw1UT6@s{CF;TfK4&jB2daUgiOq7prcGslK!)6EiHi~ zluk>D3E3g=QD(qO2G8C=jr1WsHrk`Y;#KSkEP2X|f(x8p=298*^8*uXF%sgwSqBw? z2MnJb-Rmb>MV1FFVvyRCy+K#!ZEsW{jMb--`GnhsKS(TqgKH-DWI7D;fEOH!Z$!2} zdcav}dzfjkK1B&TK+%@R@0`vecnld)j72->En3>K{jD`*Do1uEFvLuGHf|7Z_u!09 z!r$i>WfbSTip+bcN+_skH~C8zh#3X^vH3fQkVbK6M!t=M5jRiC(3MP98=%^uKn_MH zL+c%44?S?3NzBvYyE&X)0a0gj25zPrD`ntnC%PkPM(dX!KXwaS=awXwA2D$(I104j zO!&%2C*T4xD9{bW7um~(?bFT^A;)^;2IVNRnF0g4hGC!OkUJQ+xYG+>QFaFCT2+0& z2F=3t4D*?H;Wp4w*^&o+L3>d2F-d_?HlK^{5HA3Tw$q!#Un7;0vwp8>;sQKEQJ*^^ zKBaVWeTkXe+Ggh90;r)q32%N~LhVT&o}88(KXkm_WiUE^=%_^8HG&1B^@>1DIT9Mf7Mq)_)kS7LAr-Y;*Cv%lKLCeiFCE?WM{ND-S_o{F* z4i_}k)Q_**M? zH<%2uq{E&acJ2luhoY+KvYcd?p{i5!O3mLSS;LD9(h<$ILTxY=tuFq!eIshJ5(*|v zV8&@FGtj-FYWg)YL_sEwL9m|APD2%mVf~wJ8xljlHv_&{mYb8=GT_%&ZH$zjV>q@p z<`lVnn3ll3n2)mp+TZl%BOfq?MhcSid=z1MYql!fe8+uHNP~uz739hRj&7ZhTka_8 z&vp@5bJGY|2Fk;goVS&pds()d>`C^BaMztyZGn znBU47TBuP_O;|Fk6E~H_1jX3>)xB*wuI6H;1-m7Zycxwlj5r96k!Ej>o|Fkr9C&lh zZaPS@At2!1KynW7K#pkg_{TTAL@kyHh3X8O%4r}uq4;w0^Z zJ~N5k1hFAIt~4gG`QB_XOE=d58cK%-S~TqtO}(Vb2WIBDHq&7+gl#o5ejV+YGgXWc zSU><$3EOE%xtPRC+LE9j%mpC2I*$6}V5iID=TIlBjkQe|Gn$kGanC2sOd>|c$tAXz zwgTUs4I<1br~oK>^ zZmQNLu-ON0qy>asGNJcVk_sK7pm;mrI53n^w-5txoMQ{$Feru1dxM zg_Ib?GJVsUBAOi%NL;&;`{U50>1PGRWivOu@G8T8$$M7HMPALTLo=B|TnrXb4zs6p z-bX#e@@H|OTSfwA2QmmfpWSC{cLxfweT(u1&1gajcyaicKZL1q|EmZL35zNxQICih zZ+gm0zar*zvJA@$M2x}}O?&rXVFq{ZxUuDj$Tv~?=-{de{fb01&n+{Ms#v>Xg-BG8 zt#8;=dWhawISzO(?m9qnZv}Bcw3}8PH0Us}4|Tvl6Gn^~pBg_fd4$}NXc}Y`sMx$C zt%PE6dwj)3?g3bPMk51>frXdDS4h9eG?0kakRp`gK?6Jbe1EQbs2b$F&x1dEbcXxP)%M7s!+%7hcfD;#GqU{5H&L1OOaOT~t0M#f)+eao$ zTFOB_kj@e_G5BcQGcV!~=|6IOf!K;EUAJ^^=1lS*EIvNA=j-Gj_Ox(ks-_LONJ4|S zBL_-u5EclRFHCzkc?QU{L%MXL_CYP-fK$b$8{yLr0JU894S%Y^OOkUO%oOMF5Q8AA z-mJH6!td!NTH0$*AS^T3wI(+n%w^Zo<+iwh4~IQrRXxD{7J1i9Blp2l_}=_dL{4&T zlsb^F#M|n|rY+bMW^Wwt{a8f9)D1V-kG3}sTETt{A2D7BG$N2OUuFgHufspRjit?M z!vO`Ig;nUo!pgJ{MFrH9p*a15dangw4D2xL^@LE8cFzY!n*pBym z)#e@)(}56a_)AlAs1WeCGOiq>csAtD5swHpqOGaH(d_E!5BsPT|`K-*<#iIxwm zPVV?;V>@+E?m@!-9JMLhoQWo+p!esc-mL=EyxmHq|Xr@V>QTM0_Ce@Xh>kaVLt|Zg+<$+nkRmq$$SIO~61^!TMEq?#vIQ<8M z12?-$=Q4qi5O#~^LrdlG>>0#uz-AoT45+q`zPpT+bMv>}MQ(0ow*b}QF8e)H5un7F zRfr@f(8<8GPrrk|(!g?kB0r4~zGmXsOegQ4&HeAXe3;8CS9{=uQfd9>H>$COr_ZiX z5rj~9vn^={Taq4~GlFc9wk#JO-MBW_;E&8BjQxGrN9?=s3exHf6W1bQ8Q1T_gXpa> z9&Xo!yAl0PziVDNos`&Kqf&5YIcbKx#@;pHdZpw@?_y<)TS+;t1He22da-VZd^6L9UPc#y5(B6w`hV*!XU4QvEF% zI$%1j2PPJ@@Pi6jlo>*>`}j1RT`erLwcv6kQJvZomu?$HIrD8nWJPz zT-dA|Fg#W~&x%lurQf{r91SyZOv=#Y0r3gg*(Vll&CygURG59&#;($GJtC$+ibdp^ z%;~Das!x6^U7#>(gz;boe4M1E#+CiU1{ z!%jfFo8HctOC!!w6BpsV>{Q*RbUZxTIr0kl*MRGPF=Gyao7R)+0S2_Q0dBh>!~Etz>dNKf{gkw8bvb+LH8Cr;%9%>{~OC+~UTTWP&Pt82-g zEH815L2rNybXu-r-9}*FgM5|P2j2lF znMcbpbMTE^==AI5Dsmwgo9E=xI8e4gA((_tCLLV(E<1@O0~tB)#{~<9)ZKYM3t%jm zCj(|2)dUEKA6z|<2(cLfs|YA0jo+{kj7dEh^%WgWU?3DUR?i2_%P3^U(YtQ#$coSd zv9B(`J$M$ei@J$Y{jsOCA&*SP=BR#;-PNFkdLr~*1ZHAvhYg~F zBQ~Lf)m*Ns&RjiKY^lPuU78X@R#J2X70Reo4eCrO7v9uN15t$?T^=NVY7mXv|t>sOy?8yI8xgekF%!ynSH{@;T-a%6^9b6dY*?p6gG z?jBM`;+WvR9bJ0F37&uoJ>WV{t}C`&w_3lS(EjuCU7#1GcjJ9+9Cs=e4hgbXkh%#1@5a$3^j z%9r1>I1_uyGyEct=QC%ZuTs7pTFjj#)c~2K+)Uvjgz*8yY$_W;Kf8`w{}SyN&&ZC< z@$yN2sq5x+sRCeVpF^KbW;Zjva(j`vTsemRC!30WUV+UMjN10I5QzI9S{p0kO+@&~ z9_*%;c{n_%s^pxsdH5CTNT$2Qk5zh~iD+LyCiS;|M$^I)XV9buRNEQJ=0~x=EZ}tmyg~yTq*$P%L+(5LJbjQFxv7Gfm|=6N zn9Q&Ts8q7~_8V9UTVmzT2oblaN3C82u~Nj-XZN*{o*eF4N%Ib4D!>d;^h}>!HB%Ww zvWHJp>V2*NFf$daW{NN(l5;e$;dE=gqr)}ebM7d3ZkYj<~**n5Kj!%rk zkpG(gKbRDhOsODaJ6wr){h?z&QFp|ekD6JFX<-^$2jqsucOIoFL+`W1{P!p>z-p++ z=FMNWCam7zpA2X3=K94C6cu2%%s!P&t&>Zm$ds`gfCb$zl#E@k#9vT#fL@B zA}JvB;^Luo^Qo#b#O5|vvC9PsQN^Om_f@>ih9=QPU<&V-b7PD~tbj1~O1+b37{;oR zm;Lb<6=xtV8CVcOdJmP+btq1V_lrA7mq@S%o*h(K*mfiyRE2v_is`y?bAc(nc|!5F z-m@R9Q1OUs60n&&@JI5t$#uQDlG89gwdjrF-9!w=H~F^o2pL~}ngqt3Z9ocGwAhfLd^`d15TlG@nW#Y`m^fVjiWzg;U0Pdyq-O=ydnjJP`ddE+G@ zfF>j-nwh)_MzsBNWgLeutv|zxeg08C;UlrdKnfZy_P=@eIcm{lJ~hJ~J@=`uB-HP+ ziE)I_jl`RHL={%NP4XE84Y|4ZWx)oKfs(Gv91Pep(bLosmE9=TTwzw#?#)~rs517{ z`NphLSo5R`!)(PqqX*-zYqXuB)G=4!xiy9cEfizYzwIlY#iW9XCp}m=l!bWADE-}a z&tC@&)p4)bqNB$uJxhb>s7_Dtt{O~(7h9o491d)&aD&3}+#k117#x}cCo#$^D9?5K z&MK8q!xW%ClN}}8pS{Hs(|LHP0KVR5_J^=wX5ixVR~|n=NXCAcp?ZsHJ!7ea=>N>| zi$$C=9;JaeKrGIp(gfA^?CWwy6N7#L1S1UWPl^dR%HM4!QoO)2?tl z`L10&EQ)|gOoq^LoT&gJ;bft;o}15C&|MUJTt%fg+(JB$hAnO8G*rPrjb=8Vy5^r0 zRj%(ZVulWq8erP?>~*>H26~ZvP-0qIVk!uJngRo!9o_@k#Dh$b%EoC~q0&7laIUOt zw!kNuS8?<2V%I@%Hq9JMOo(Lm|JiSynA>v~rFcRr6;p1+h;pNqVYUPD?A`90kF};v zLJdVaLB*a(Mo=OYF%;A23CFpH8wFHY{c@~7N1OxGzwm;tUrKNd#BMonxf zWOu=flm93_NHvi8YHnQumdFxX=JqrpUcbS_r2cxje zXmEGfi+|p4{D1ZRGy2ANaR2`5o-V(-uD-87S^i(u(RKOxKdBoG_dos4cK%Pb^*^QU zzf=G3X#cDGSKs6H)%RY+z5n#qFu|X!udn(2f9IQciSO#q|I~)A`=9Fkcgy~t;v#(T z`@h@n|6lKauO9s;eg?}Y`1{|%u+HC=@&4bH|K0t+!}Z^-&w9b{zr*)`^FHbOzuCTS zn{@nFZ(aBQ6$W#YtAXK4e(f(F3lE5g=t+=`G0 zTkN=v>V(gZ^7PC2GF@dXaBs!i-qIn@__U8P3G6JeDoW}Z)<{x?e~WK4VxM%HgR?!_ITh^ z2u!i*Zcw%uZ%O?1_JxZCo0zmBn>Z8wF_`$MIbc&qFk%AU66hTb#Ay?O*tes>Kv$n; z`(aRzZIL_#l~Qy>A2|@}yrWJI*=;p2t-vcLVqZ7p!YZ<>Ds9$^MwXJQNaH^+gopF- z2uu5OmKqGPL^=a{P!Bm4C=O~Ue*PK^RVEI^#a*T5 zb;C_us56Y)QRr;Q(p{TAr9<;SfZ1k0@Cqj|{TOP}YuURvMXPbz3EWl(y7FnLBYNJ& zQ0M24!9t;XvAtNLln3y(3~sLu+aq=yX?Qs_i!Ezc6JxFD1`FPo1qJI-W#1^8s%>iJ z$N(P2Te(boj6^RKi++JGM`W2+tS~AT_C+%P6-DF2tJ+ags*23sL1fZVvThJ*5w;#x z|4HGmfTXVA)?bmO(GaDQmL`kNNo+61=j6`#V^j9_7}5rpT3d|W-7Z+Id+P7XzIfrh z{RV3{n=NEdBRei_=R+&%?CVzL2%l70XGKhmbx%ZPkE*)68}z++p?*Z=9S!y^Y;H7+ zurCjt6=GP+LuNTGRv4_{>Kse#+$?g0l<{n4M`Vi8z~YQ$cGZf1^MoQsDx)NqP6n%# zGRk2v24-xfDz3)pB;m9wGU;+E7*42$$k|BMxFd+?wjkAj{}HNTQxb@Ymd+;!&c}{k zT%{V?pQOh^Yw?zkoASu&xP>NYKxVYI*P*4=R~_Vdc{-TT!R0N?I0A+)y4F5XQ8^cf zNY4}5eM`UjI3qeN+=wbx_v{u_y}oYTG`jYo$@KtWk_@A2cKH zqRqOeFL)Pm@jv+NNc3PgdjZ1Mcdz#a)m0Lf8KN?b1ris{ zjJTM5J{PQGIh5!W+*K0&I7p(^gYjTza##`hsU1UveVMIJQ#)LxWp9K%{*qDA+G5)q zajEE1mBq0yqUwI<-m%V#h)c_1`*BsFJ#1lpE2| zf8zn(Ll5S40cpqVN@HcXT0>!@EY7ZqcI^OQzs7}N+LfSNz#;C$TOhMf)WNHEa4;6* zVhu0`uiKj%#^-oTpm!{YLv09;8E#M!TI2IlFwju)X&~+@J~<*xT&Mv$ngb?H34`p> zP@(H_3tPx%=|jt}wKrCk=d`p%&Q;+X4hv>Fck`$APiX?!?1rOk|XA zSew}@m)WP=_aeBv=}09?oEF&6gvpa~MArdojux9DHxUt!>JV zF!1+du#nddH#yeuB?kUknAq%@Zrz)qMX$t7oN9Ff*D2|&@>P< zF~>f0#@5>yX>l_{pvzol7uvkQWJ8wdg_)#~uEjCb8eWD^>R`DDC!TM& zyO&$w5Eek_mRPu#ERNlLZM*epJOdWDDt>x`_A*NL?>iQh3mef+fPJnCmc7!mhoBTq z+h~>9Yab)Qv>&<=V3&izq8a_C1EBHs?9<$Ut9v4O&Jgs$K!B)dII&QL99sW6qUg6^ zWKr{hYyl9pLBFNazJcinZCld~=U|8*N+ zc?zUiusI?^ruMmDcQ&(KYG%LauBx<$)w?>bBznG9 zWEw`NEU2#Ksu>IQo9yH(B&u^vnZ-)|wxi)XN?+i03~_ubK7;k;iEf7Rb$3cAcsN>= zvp<)LLLHXujtQMRUnroSWq`59pTVpXJ|cnWCF>Rjv#$DwNVvlD?j3iKTsaiQW^fNN zY%V$s(~>+|zm5_jZ1_Qt<`3eI;F|@}x7D^c>yph8FgZzH?HIgpvSG9<1?!_LCWT4! z(t`!LC0qc|zFKAtEyJf$Ktu<^x_aQ&(qQXSMo89o>y%x zGRo(;!3?7raM5D>;?u&IfuACQG8amH9M~3vYm&?HVE|(CL<99hWos><4TGU;$r|V@ zy8pcY?`U9mj&pcP86@j>hPS>QZEvg7G%6;VH6oOHt4 zS(~`W<1;K6cN7QL*1-DhEJYB`E?~&U(UqYbq0;dgUJL3ZAhtiIyYY@~4!TeOrlB$b z6;T69cK_ZvSe~D&;cl|bnI{y8o}Z1uWf*m8fYFsM0>D8H#9(^!_6c!xGeznNH-)8v z!U9D$>ej;Y);v5(K3_L|M~DK_0?PtWy;?vn01SOx10@oO-PGeqHh}8a0!jyf;|UG) zsA@>7E_Bq0tOe5)^+yL_VjP_M(X_M{LP3oNwV?6=u`&SV2$`$2P`5P!Pz`H9Nin<) zm@68N93408VX>Q#+g^EeqjH~GE%ShvbNYhif-7`i{LoBl3D(HofgSa3&z{YJwb%oO;8S7I?C|4O^IBL20>h-|G#0Sq zP~$jxB09AX)Ua`dN%yQ6x2_Gwq+H`d;F+;pyGB|jU#qrSf80jb_~$n3 z>guf)k@%;dYlfTD))IWSsDYjX-ZMb#eF4b3&lB-ADj7d~Y+bpNs9)P@{p}Ned3Trf zmtFi)w%fXHw`{CKwXAzKJ)0i}KpY|9_ZA3V8w+Haj(Ds@aHKV}p z2~T` ziUCyXU?3&uX8@A&>eX_7^9SpjKe8L2{%GBDlwS<%5@3+sNOlT2Gqk)8H_4%C_-qr5 zUUB-q*9>DL-qJ!b`)M_+^ER@z`iW(6guJm(Pi-W=hf(GFV0_UWRX+iy`fr2Sj`MTb zGGB{-u}(cf3Xh$(Zo0@XdoEfZyd+p}oGnu=L&nE1{PYrsH*PHB!z5^t4ANYkfugpx zT72$3B%8LN#pwB&9EJJ%-~roH582R=VJ(vk`O%?}>0u9JxFMdq#-|LV7J>X@Ky-1N z=Hf#(0EHM%k%l4<=c01ES`;++2*dOaplLqe&AAa@Up{7AIag3%U(ahvMavK%q;_eU z&qGoBV1!Ym!nV^e-ruW%=GqldD^w;G3-H;Y7SMhGd{Ci*KC}SHVT1(y<3a%4SPN+9 z=SY9;*FeeD%Yw10t#W*FafmO;COMFv`NA+Ze5nC%3n`bYOifXZBrd||O*Ozc&-?@c zEx*!0b3+wSBL#%$!RS;AXaE4N9M(X)oB*OyXtjOyEh~(?MwePZ6#%F@t$|9h_JUA^B926LvI0Y>(X|Gc?Tl_U!06Cs0^sIL8tB&$0FfD*gBb0M?zMpa1%MX6X`tsE z0HR~iK+giGM=c-^06qu+^{^=Nnke#?;In5fpo0K-;CJ29wd@ng(?A%oj9Y2}4gJF~ z2K}jlZVC|`B;z&MQh*>XoctqOI);c?X_RgYgPPH=7TB)Ckb?f0f_q4OaWn( zGsF)V;4|1|>;uS_h8pZS-Iiwj%LK2{76;mujV#8Wc+0jdY>NbHpw$414+fgU%n&@G zPH!}>XW~MoK!-9jL@&zal{NQw{lSXw;}QPyy8p^2zYy0Rd3|wyW-oE=lh;|vpS~lm z5#F=@k*BYJP+a@v^_Gc=5`Ln*KKu2F&7vGL7}mGuoaOT>#&`twynb?2q^zGMuUkFz z#4DmaPhL0dkl00Br_1Z4Uk-1B>N#w!F4( ze)SPij=3i5ueqjfiMTE_jC(+r!3(}({@vS#zm0m^EY_F?y=_)|%=F$^EsS}%x6K|J z)3&$G5gu~`e$us0%%i<+&U!I3dfP%HV`lcYg*A+s)!P;x6*Hi>Euu+GLT_80=$N^^ zZFQT*%;{~b*F0ukZ(IEqG4p%dB4cZ%&vf%~c%WhfP9(L*hYF$VMJ!|h4rjNLBpMMN z*Z##jkRZAiouU4&LG^@S^-wX-jwTl4U^A^%pF6Lb-M#{_0X4ul8@~X6f8t?bsfst* z)$~?dwF|11KpNNcqDp z0BPP1{!k5=biXZvqtsm{@#g~mo?Y|ro-ai6$kG*Z-nw zU(4bR)Eg4qzKHZ2_OKY|dTOGtCDFk_!DaycGZ;w8qTVeQ;|$(4WwG*<{rgjbdDbOT z7WY;M>e{Eh3zS2HQ7ZOD;Gy>?@Roovj7`Zt9iF@ouwga87)rhhfRf%C=xM;veQKC3 zfEiv3<`2|w+eg80=HIp3h^>svi*axwA5sPu3PKNKAE0PNEi9{nVSg}|voCCYR$<{W zMpt9m3M?tLuuSZ0F&5)3I?c7H1lN)0soJ0=@C?7AM_b~DC>B2vh0p5H{xx8k*H3d| zm{kGkC}bP$65_CJ(4s`oXT%q?> z#EDGT;S6RA#>g5i(Yv%k8*K-no$d>So}-d+V!Gp{haC-#xUXk8o_K^`PRw%bc+>%f zU;A&zyxIK1RSl^TUsXr%x>FwmNm_7I{Wv_f#a)&Czp1{73pG3j_H890qQaU9g=J?k zUS$37dyBhpI^RYg&&Kw)Y42!>9+AnbaJ)MOfw+D}FJlKQK_m)S zL_H>EF7fTb=dElSFDl>u<@bu8$QdsWs8KDJx6t@$;P?siPP*Kc4BYqMrtu?S0Gdc61VH*o4b&qPKy+5up)y;lz~}A3KuX6S1W4md=-yxi(uI9di?1209cx!p z#SW}?ELrbB)VzJY+83<-fmJ-D*jo=PAVuQ{ z-iJCKydaAL5ss!?C-Dh3qYZw6IM}I-$lzTk-ZXNSx^B(27zKHX1&Q`u^%2aFb=rd* zLFJx79;DAVbHv^X0B67%Nc2KN+J_KQp%*n=3xK{9hpW~czW09NSox(C+!De6L}it_ zOsa^H_#(m z10HcMxN;cwDn|!en@#-VZa-pTC@{N6!d$K z(>et$UwcudeDYodK528q_f>v=5l3J){}&v1O5To;u(- z2OxJakl3$Iho_=|+(;7_Dhdefp0u>1oif%^u!jA0OORSwa+kDZHH8tM3hnH>e6Mg<7Z)u<%)fdtsY*LlG76J1EbN&W9 z(rSh{ei)ybctdXT1#7{Y>fgo>{UWel+!EXFphcTn*~Bk`g z>^gVv(e!liFHP+{?mQoCYH9#l0@`Dr21Fc2c25`7;_K{-A#+w!(>_@p^4J=F*|#R- zz$^Un_}Y+9)?(E^?)SAJ>(}v%5xO@HFj6C5ug*s4IYcE2vxBuu4ODSxw%=l6J)Bxl1!59D>3;;dv01%BS29;^if8rB6Uc^hvjzE6`;H#H(OYzL;QQ>s# zKz2>21@s31rmogN|JM1umZ~KSfbwbqJr01U)@q>kVQ7i7XdQ4^0hC`0Xz@CW(SN-L zs*)UpJ_d$*8^FW}iMFflE75i74T~}BJq@@7qe3uL2%tPQ8lz)*0rfY$uVH%F0Tj$Y zCxE=QfF^FS7{fo%K(AXBP^{ubD1ZuU0p$ar;Z_Z_km)?Oq-WD%0Ge0}XgdHdf24t~ z*Fbvah7_hzR14_)?b!JDu>#_Vv8wO1g>*aOd=GWD2b!nQqZG{%z~rliDFIks)0ph< zhl79#F0jd3>6q^e8`j<#WnCTZruY+ zH-4hA!7q)qWRyBIHhcn0@ET-2U=cs*f+C?H%DVdl$B-Xk-7mtr8$3Q6#dHxrKI44p zStm^Q*Jqu_pL5nT;w~q{4O z2ZQh61(y2Y&ZJsA9tXbojt291b>?h_kvJkq{BE|A6bBZ%mR7(rxfYh$z;N+rg~i?_ z1VB`BE#B4uDy;<+ddy-Z{uX zz2{a3Ex_&x28-r8MJ7O6Uw|StFL#qFzP|d|S$<4P zsy(kI_kU!vk8{dc+#($}0O7sC2(|kMI{PI}Ntgv-Bwq(I?E!XQ4KPl6qXE#bQUiVE zP(XT`)d4{F*8=(w03}r#=uNgnKdHy38v#@n45WyVhQc=U-!+qKNKO{rxF*Hq`f&PJD^s4{207)g@0+3ECyyap$)1)-}Jkxb}ApoQI*9lNL=vIU$^ z=M%XnwxCBSBvOqBYqc;Jzecm+8nn=T{)Co5fJ(;Ki$ga&%N8o04PCrC)aHoWusU?z zE27PirBg4X3RpK^>|JL4hn@>P{d}m?7Pn|c=)Bc}adogDE)1XL?<@`dd3k7rH4aJW@cX7Q7R@FnJ9eAHzY zB)L(k;v(@N0*lF9dVRTkjE(2wAzCD`j1|EFp;F5)K*9SswM**rsH=C1#sh46FbBm} z$u9ulYNmmX5s0>|l_~*157z>UY+*GX#apT;_|<3I;hp4{*Hh!n8E(K09)bq|+l*S+ z?z_%vEWlPBA^k(7VM!10^1|Cuvu=f8h7C>xlpRPplv!4Kr?FrO$0!C z2MzR<*e^@M8-faY!X!Y=3WmyOvUM6tmG<4y(8Pt(zBXKo6mzhC>Ul{q&0@A-Db5pY zH4EB@3_`lQ)vc5+&Uu0ZNXguNK0^FtlFwU=*%A*`;)7sl`9*x;uMUex6c(Adsu4>* zKhSD?iMQk*5S2e=;{%`^4kwom5~sErb~lxhDn*0i^H<0x8hhU+GGIT3z4UydoZ8$d z(P|9FJAiNYYgTbYsKAHQs(G}kirzIcWEqWp8d+Ffxjo<48K~_-gZV3Ue5wo2a78$7 zur{eWZtR23TY6Vo4S8X+;KFWg?XcsSuaFQtk+z!!yPDZ9x+^c)Low%)6wMJS3OYkt zQA9^mWwy+#Ra76q9Y#t5Ilec5rLTl&?ce z&yCbne(0DZm(#Qoj{(?YHNZI1zXpIW(lk(v9YEA!9R=M1pgFaGVn^omedJnez}_CNVUiD7MPGO)H<${1b2bV3aysnk&y-` zdIeTEXY7GO=3TsC zFOO(adEUU&l8%txmn@;8PLs;kM(<13@bWZq+09|8v%C`kn|5>9>g{RR;^OncC?d;o z1r)4Clnu*6Bm#x4o5LElOx?1EON^JSP4==<$tA@5%@?A^FEKe+eG2^D_srcI z_QBQ~h8`bME)i01Y3JjCa6vFa;fuxt)z7d|p}qF+gfF7SYVY6z)WRB2a>n`xU{bR+ z+~?vsjo{HL9dP9};Fz4v1H^+l8fvv2$xJ3VbS5zaK#PKbmebCeWm9(ErICpXHN*|% z5GPcsdXX?FX_$#0?7}K(Cp?s6xMt;Ajo0v2M#}vOR7Gv07}Jd|DmV&^LvsTeZ^qRa zcnWZ}2Q4i)_w!k?X{d61syD2YQ`=!=uP{iaZM9i1s*2d4mV4+Z?JJ*vk6bH({#} z3e`0R144;NO-HqWazT6#%~P~Kd`d^L^wvh?bS*0k5WW~KP<9lC< zXehs$y)V^?5?^Q4wZjkAYogsN5mrjQ5aBTIsL*A4-?M>mtOdbsQgnfedR=Lb}g;y)DLar zc>sGN*zCm4m=6GO7Y<>!G?%+`P{}yLrnA_ zjuj~5$>2uBigGa;SU6cz_Msh=QHa_hcmecOFwoTpGrS+{5CY4MN!1=*Dh;09YP1j zb+}SMXFzg<3Iv}2onzuQ%n(U=ikNJ7bd=$Xbm)5hs}Mym){r(M=V|EEkZGEucQ{qH zntqZhQUsu9f;lQi0WSbTXK0`gLsewmN&)!*w73>f2LSjU(Lk$pGF|7zu^?zX8w{id zutflQ5l1pxdch0iw?`9vEqf~b=cmJ=#`~TLe{C_pR6G~{$Fgv2N?Er&{Hf>p#Ry%$ zo^{n&C7(43P8JoT$tA%}s!%p`zSUT?NK-n|3FksE-MuLQd#(l;v#9R^py`tu=pYyJ z33NROAS3?;pry5dIs@Rb08mRCfT+)UDtixrmIVWe<#W=Z2DtW7CN9(f7trTHbhw){ zj*GR4@#8(%nE(g`C!@P>Zp_81@r+KyS-J8@+Omnn%0GBfJD1hzhV7QiLh$IUeIxD( z7S{GsV|q9YYflG`C8&8kRE=W^9EjMIp|4tv_g>RL4fOd3TI;6)=!IY) zrHh{fWGzlXsksjS`?2t<!uML_ zFv_2U1HyQ|KR%=vHKe2fXrNxBH=O^2{w^a2zdnaw7vMlO;pC0K&~f4zVIITm%E$L~ zoeiKs?2fCRK@UV?iLN8NU<$icpNMVE%4q^Ny#XBK03Qw zMbXlYGjsbH5N+P8ks)p8xim`rJd8x9Ph6Hr@mK)*B=)ls;{ssZqcD2dMY>hKW*atf z$ctU41Y)eq8pqg{Ib!S^W9;~_Z4@~%gb+-ONu#OGjFEdBieIeBqp=&Jnid^~6CG**s;a zyamqA$*Z*6mxn~y%NtCygj~O`4o+OTwepfPqO#l`VXIhP*NC~sf=X3kxULHHrP={# zmRx+^VZ`DXAp6Hx?T+Sf#PNzRMk41d;&1_4L^I_C%0c1F!95oVs_6hwJ^w1W=K<$7 z7{3_y1CHi8@?EHpIt6QFBgS-t$3~&wlPYa1x_7Ix*!SY#C|k(x>`PS_Lig7Fvjo}v z6%D&pS;Iv^9Z^sZCrU-`TX>7nfc^X%H#ZzTJg^eIjJe9qMLQ2?((3qnwQP(LisPp6 zOE}$>yTiyU=4OjP;p*U?nv`)NfK*S<1ot!`V`QYnF=U18X3%L6NH$rlI0ye zBXYiYR*@Y!8FY)&FWs#t(5*GW-MZS(gf%t^F3xDIJ_d`nJ>|y_#BWyy#vvb8kK<5R zOOt|p>4xf)bDHaubL#G^Fk+fncIKTG=jKEk4rbZ@PI80aNB6d%d)Hs3pOH8?OObB8 zW>~u_iRpax5_IjA;I1v9#7>|gC9&&+yVjXA%P15&->+kVvsv>~myJ}5ad*0Ini7B0 z*t_q%>!!Opb-t+DgNKJ|FVF)cU)xw}If-j5FBk3mduoh#)A1N^2ef3pP# zU8tctmg9Jz*j6aBWR93bz|nZO>J&SmMipPI{CPh>;+MLL3S#}eoj-RjS1YzH1w+tOIk~qJ8pJ=@a zfZn25{BVIdaXywmv7s^hVqLx3HtUK?33p|V={#@vLn;B5BY zIQ=c>5>A5)fq52HB2R@=PaNUmV8%Mjni|(cSSlKYK<(oy>+NggjH|4_51V5nV;WcF zRoNOYYY@{B^+TgX{U*z!Wc@HvKbkdTs3%uhfp(d9K}CjagPKgdYJ7@y9?s$x0=_~R z$H2htaf6YCiZkZmo>H3@%Fv&K+N=#$o4O+NxE;5Z-rV+=dcy&A)AHhnIe$}gXk##f z3~YF!rzM#%Kf`&(o?z*hQZQtXZxkdXtHu^UsdB z#=1PQ;@5hR+CW#19R8=+pr2mskIjbCNS#0EXmENmTG5B!aY(9IX0Nw# z#=aOE?77OiJYKr(OZSKD91Ar#i;U!@9#zggtt=~|Vw$1O#jxEETO-={t-MgDydFio zvyp8_-q|zt7Irrx%V)*ZC7uS$$3#@Ulv;N7m9uNlG^+E_>Om(@tvh@2Orw>(KG_v< zu4mQBGf{hDnr+Mb^<0zPF?F}*{c>&lM4qJ*Ohma4TkJ!KYPZ0 zLqsJWT54bGp&~tOCVb>D*6xPBU9bv`3@p!ebRN#V5j^6{0bPr-0Hes~2&mZ{^v@h)Z`g+`F)y(WrbuOkDy-Eq6gr?kqd^%DJ^? zo7CC9I_1>qb>~iA@@ryRe)zDxnN$y3 z^ZXOPTxbD>am2R&Fyca=6SkHSC;FcJwe|W_3x^ulONIHQQOM3l&X2pD4!vPVOr7m{ zr>fd-Zxr@X&KYRTjd5q&?#w@T)_zm%EP&RP{5=k%)928YTw85jxtWT9m!o5x;TULd z8`}A>(YaAvgR-)ZgY`x0iXPsUL08rX>&iVG-j)K9a#JgVRV8p#8%OS`MXzjSToCv{ zJdE5}UlFBZ;a$)Ux zYn>gd`<^+w?!uY#)|DOi?2EYAv+B%w+uoS4kMmAnax9N|*y3#eQN*P_C#|9UYYUG! z*|(~)&iXS5^VTikbd?`BgWy;7DCNJ2KDNeMNSprG{f zL;~a{*(57zrce}p!GdUnN4gd1Di#nsHbha8W}+ydDCh$f1!*BfMZW);vU@j+@B4k< z^1EdB-upju=FH5QGiPSbG__OnWXI9$Eq%;WRGde=_=|e=?_T@#ooKxH&n*NgGn*bqqAdU6*5nAh+^)Gel`NVFmYa&HO5TS>1)v*L zl?_9AzehnR4W_0L3Od(nYB4v3n9$i8ET2bV`ldzoadx(TX;+L*1#MT%0UpXqWK@|( z5<80PqxV|H85WC%qjIpn2~vAiFSQERDLx9uh1kyM#parczC}MCC4)8Y z8?*8$f=sI`L#b|ke5LaR>M_|66o1WDEsE|RsQ&Wbw=@LMfF0gQkoV12Q%amgz>IJ{-~XOwQcHm)Xvy|b)3Uq zfa)mPe;XGUbNNXV-P>A;M((V!GAj2o$oXC|mQ@YmB%S3uzkZ9PHlNOA#9z91_Lmcv zNn-ZJIHNA7jNNIWAo^1;(rFHFNOBbpK}Y6%2TVHu+sy)E2(E zw+Gl9yw|U7z=a4&A`01Sn;p|!-$&`RBHkRKKHshK($-7cE_U|c^J4h9^DkdIcd_$x zmd_VlZtb%DTz#-&jW9jmhriMduk_%rbbAg{p)FC$rxEHW1;3wdjosh{L>v&^l%7#$ zJ~&%#uvI(aAz|c(8=4q5)0C$)M^1aZNgxW&GB?V&ggUge*b$P@Mp_14e9vJD!w|`&;Xl*VcoQ{!wpA^5gzw8DZV}u6<}!OD;TIhBTwQ> z0KM%2vH~!}32HF|L{^zhX)8eQcz_B3SdaCnJYOd)0wjxN8$j=RfIb8u2uDbBP$e)V zVCk}a8JPDxF!6XlrlZ6hVjDR0>}?0?eLYGPOCd0aakx$sczHv~~p&y+-F^lZV#%zq5`}lZz$my{qe?lCY3li2OAW`#?`jly5Ug z-4i6UWdn+)wfqI@4WM@EQS9sp8lMZ*z9~EtKZIYx>26`(!)FnLmKvaeV$i-O-a`yp zYjq}(r_udD>#aGoss&R!n2{?eu;)xEsK{eF5?wg+P3`)@o7C!er^>z}wJKi3k(xft zZx!@NAKaB=;o8spqeXAuGG zx1Nvq>Q_1;x_TFufE9#UeG;y{#jX=Fj`#3VGJ1I_Jn*~RCPvwzc`^6_6uGG`P8SKm zywB`gS$Pv1ywD(-F5PhmK9Fr1e5`Ll#AB#S$A>&2o4;9);$&+@73!3jj-$V9V%EgA zzw(N2u+>qB@=8*I^jQNobHSz>CIWWWXVPs$XhSx=f^=BSSo+Rm0?Dw>*v+7P_`hn& z$$zdTY1LgaZA9I>rnA~2-mB|o@~_XNgwWHn=~!99N|e>mM1}l$0jx12N?C>6g<2Dm zFL7n*FtW2Y$tn4E+vr$-Oo`l@iT@!zohQp2xD8eSYYbA-ZzG#yrKC|OAKyL3+YFo} z^M8}}YBy=ufVC}PP2D8ih1Hyi&>9bE%fPREs(A<4_((79G#YVGGZ1aEa|ENreTA+O zhjU35$(63dNd2=BUaZ!fUHQ~Lsx{e;93}H-I>_N=cf(#yj$o~NKeIST<6V*30DWp1 zv1AlWNyVL<6fb2br3T5JdiuBLNpjOGa6Tlxje7g{<`g>m6!)?ejZ90r zM2ivSMiv^i7;amk+!A@(^+faaZ?#@TbN(0{_KLq`qv_^ElA}yY9xmQQVHJ+JX4^q} z2n3x@KXp`uDDyBpp&1NX>9$8$ebR|M&SDOv6t^5Y_&B9lCUT+94O4prAg;I?5TPCl zM>OvL@@U-cry3nPk-;9$iv$rW5c))!nxl-L!`f|ChPIh#O5441>)LDJ5HDppE_t5B zC{C7DW0E+1yj_N@JWt|%Wa%?$$cBZHh3wUQUkk~Cu=X}pjpydL0ouEt4 zcDzxys(NKf4twIF#zUF6^yS;z8fN(Ke5EE|0R?E{sk?UI()vdBi)bTueAnZJ)AM# z6lFTl-5k8H|3$A*j1^$QTEh3{!6J@KZLvh-VgD9Orvp)@)D~|{-5dymb@p%T{@K<9 zeDS-K+G6O2yF}IsvNYJ}f6?T>4<@y#duofR2OdTlQ(JuE86{I9$oVF13?{%0#7C5g zSVK+21NPLfH-9?7^|UV|f_(V*Pi^rZAb$l6N^J>9mA^U+O>OBgJp5V`Ww_(W166Qd z?aOPqba51d_G6w*(hnMgG>5jdrc0p7KeZ+JM*Q+a9z(|COZc^J#{Dby!7bSTf+>*= z4{lCv37rVsmA1*4XG2-BHql_Xsj*}#D>;n+Lboa2R_brkxU<$aMe*Bd_Rd^p_FbzW zCVHhYd~K!KH**<{RW0F}24nb6)GI1=zD!%zws&ziT_{a7jePnl>pENi?vH3hN`N8J zSOqr*q7k9WbF(Zl0-Hje3o-oANf3@x$DoWElJ9`}ZoMvSe_}$luBn-vx)8bnjg>9J zdT($ZbM?&^&f?Nc#vo}TK7UVxePi?UeJd|-y}YeO_22tq&kGk{zI>rYeJ+Jzu!@UGG=#>W5pZY&$iZER9tE}{wolvkC zpOBP4*5|nWTJ#t7Id)FNa#l}F?7onqX9=HHKRvq^LhgZD1{j5 zT&~Sd?MZV!-md%o!mkAw$pPlOF}}ZQ@{dv5HeezV`K`+-xQgxJL&JF*@R386M&`SL+vA3#G3O>A3~)7Z)Nt>1dka1W z=ra#c1OR@C5>#&zAUT}>1fabhpq>B>>m@-3BS7RZp%NhWX!>uT9yFVoqu2u=mBaAJ zOuQ=wr1@lyGRxSb?ViKF=UcJVRwxIuX!`v%cVqytv@r0-g5oT#VAPcH_|0Hm_&y&s+2kJhg_IG_2)YOJ7EoR_YPDC5`rjIM zr?#%1Z2jdwPCZWTyQ17tV2&)!^--^yUB{R;>1&kJgs6ksmIDHD zP7N=1I-{-)+Bd|IW->N)H_~hY&dcbCH8Pi5ESO#KJYPiGLkZZXyaSi)M?~o|?=&em z`k2#9zLkiYs_5Db#6%g#`^a!1h;UXHTl-3hgz-3T% zHeG>7FE4B%IS^uztFh51eEy)fZ{k5E^vX3qkRNi{2b*8I;jeFi5`KlbiiceG!*-N; zxaS|_cR95+AOxuJEAz1*Mh#a;QiNprJ;-!#y{1=e~XZe+D2m_}a zD1elc=~rL;qIVXwUWRk}%C&y3-+k$Kf7kE+^qaPriuVV|d4+nzu!h1xkRnx9zSoQn zckzmZ9UM-!a3ySDW(%|V8Y8P~v@nhAVD2Nq;xwkYz5w~>L;<;~I^xCLXi^>-FBP7K zxLO=117my#+yTADWBWEY19AHViCSi=P5{>A0s8=upKv@Y?=hY-$s;Hwhd%(-?13^&G$~^yNz`kW zI&SSt(2oFp;Q^WlK<~*;khcKIF5|xdedz|`+h}&pfMa{6fRXwix9Y=RC{xg@SjtNq zg3C&@Y`fBq-cO)+$c-K?BmEncPTZ=a_R_pB&yyl_l+7$!P*l9AD4j1A64Yez{tRkg zc~E;~wn^E0o6OQCR0=K#(uX8-gdtGA_CTEkqA)|C%+_5s#(MWC&8Go7>;YQ=$geI~ zzgh{C68sggBOWmGT$3^!7b{`2HLHPORP$wN{RY@k57;a~R=QxjswFI3 zn*i~e=S;1%Gr`DdPmUTA$yva@^?-E-WU>o(p{vZBtn`Sgpd9mnVF}eU7y~ol_Zd@Mgo(^@Y(?XB zNtW&Slua*m(OiD9@-p?u0ew1%=~_W=$!j(kJNSzgeT1eTyTH%I$cH`|2f9#0R4P zD5E+ zV^KZlBDdenp=4U&lpw7y7sGxxh_jpYH#h#1iVuGb&0WROpU3z0)#;P*!rONS8mPJ^GtxTBs6d=i9RvjIAgspjD|9 zT>#8c+Pi{YwNcu+IFEFE&f@V!lM8a_{^q3>d#GSbNGgmaypObMre-|Jx;4hicqV0H zg`S-)iX2THX#SF%QnvJUwB~?onBf{a4b9-);WR9Zu$S6%c$^fHWry_B)2SkIoSnVz z^>fH9qNSBlIa0-%NSr8l)7*rd9ccgee?4pe?*Hv~dshY_)B!LE z3#9cSYCirgp!G}uEh&(5*9OUfG;2&CcC((C5XK!KHKbDVuwMv+j&zfn)(qq=Zb;f% zHyfB+?w7br*rlWQ3U~oC(F5ba`#m0%n5HPP9Y|_t3qX@RKsN!9S|ve;2t+B#wHMw1 zP4)my2H?dnO~5_C+0WdDkNcsP|p58`I)cYsv> zN5W2Ar#kroIn518`@h!#Goo7JPDY9CakAS%oFHYo2gtw1r1Y$ppkD|?Rfd!q)icyW zWrhc6Bmg%wNYEJq(FrZGfI9#*(*raUfKiW1(0Q4XWUnJYvphg^0qFg>1ho)IZxRLq z^e;CM7vZgdoLVDcZ9;_9-N%ZI1p#@h88Y81jz(Fz(_V!;5-_5ig4 zaP?&gGDHJJB8(9!g#dJ$2PkU0NjZy)w{J6ns1{0FHx!^b9w6^m5Ulk*3GyKj$z8VZ zFn}^VK-~fO_I(KoAP|XAw&QSs=DLBn2tWP6q?9#FSX4AuYQ&?oHW3p^ndgS29fmc) z^#4-gI!B8mx#UPA5}^4Kgq~q}m(vTWXDDPbwaPG^5QRNU*sf%_VakGqca8r&9uGAN zId97@Kv!X-ecg`iF}m-}>a?*SJ8U+XxR?wM2K+3zpdM(%grH^y74RFg5@yUMH@<9(~V%*J@X zDvOsf-oMJ*VvG-{^6@stcc}99F~)bS^7A#u2UhuGZZxPWz~2}jT-71K7#~vAv4b%_ zv?{QpF+Qv+D9{)mUKJcldq zeAgB6rv9cV9NB7$HpZ*|@x};RP1t&E7I=oYB}QFz*=uu6l*x57!Z@JCa$vd7(912p z{>}Zb#P~02>#*4#jzg#q(wuBZ%!+dSe!O}qXh2H{t&<7cNK=+>k0J)NL?Mk%F$~vv zzkIk4xQkr}TGYlI2?3T^hn zGFSZL_bm8J>n^?U*Gzsi_LK^ruYBsH@Qr4FLsnak5-q8;spj1Ji%B_(i#N<)OtfT+ z=*sqjP+H1qz4b1-@-x6}KaXzI?Xc5#zwP+TF{rk*U%v0S;RJm_gtSd*g8FNQ8Zioy zZK@Nf|Ei}hdey6-{C11v>Td5Eek_6Pv=CfN`OOVR{m+*GOt>sTIlz!!lD(r9m@^)j zd3b+otHhkgB1nD|nd}g{0d>{`bsmVqs{%#F<*6%Y-X^1)8?5Ze2&IU{ZoKA%oG8F0=Gy*YSoIs>W2cE8Dr(;Io@0giIe`5 zY{Y@$c|AoT@x7pSm$zVqvQ%@!Jw07nVhTv9Jh0b1-Q5%x{(u&K(b(a0o0-g3CV5)q;C|scMG+6=H5yL6h+GvYxt-@>o#5fQ#d18teEbcG(>jO}m2k0sQQ#;F~?l1!6jTsnOK79fD!vjZ_0K4i2BahH< z0FEU}&`iW7;^wTha|QtQw+HIGUaE4pO`{;L&6W3bFu1^}>p} zLiXh#fS{t;$K|ow2EbD(5|nBXASrd)T5s?G84&leQ$GpX??ua>si8{)6AK9yqZ^7# zumPCOh!@GLV4|ggN0pGUA%L0OV6^Ic_yARzkSamP)mypQEK6%BK&l7mHUL&gki{nu zq27@ZHcv;g7zU8p1Jnq>4hd3yyab3;9D#-dqk;1CKurYV-~@?k@xlx=RTSAVjseKu z1N2`2W=xcz{WNV&AUWn43lQ_QpSFlD*~Eu%1h1d_&ZIzSyfQp%fwxu}0h z&}<)yDM+1yM2!QgqaGzRbrLYMZ*AWPzO*&y%WW9#!0=ehtN1dAiJy}z>-deJ80bck zmIM^dR+WEeQoq&cj3-s~W>DqMAnH*KAU0vRB{8^U| zZS3TUQz+;dBEz{Kt2GJKLOrNm0;QuRk_Wp{fTRE?0~F=~`U8N*QVDw5EI=~i?G%8* zJwR^&FsxjH?tuNt`ID%rK(RBGoE42^RJjmpc9BG#_Y$_A6wwTTBHfbWP4^-oCl*WC zTM{O_Duj+yqTFDl`wEw+%Fd+{6lRe&th6L%0Tu0ms<~HHsvZ<5vZrQ!JnXp3o??SI zrG`&(O4TtNlw$OhL``3cAghNTZeP(Yaip((s<1~Z>V)=F9XCn>xqe4ehs7=S4#m+wE#x#S5_8U%F;y- zV-dktH>k=PT>8jgTV4$Q=|wmlTyD5jX1@|OsdzL{>#C;~N{Yv?QB{7$#W{b@C=69u zA87TG)dS@JsH)W9;-I(80wilg4nW=XAZZ~2vg`?PZiDUZu##H9=f_uqx4ufe?|U`) z$ZI6Xme+!Jzs_@0`BEiM#DLg8e3nnLhNi8=>QfOy-G>zVY>>=7W})t#w1AYV1Gw&b z96PIJ91s~BNvf{1S|0l}_|T`p6oJTJWVM?Q!Z{K#*?->-VsUz6ERff#O{#JT7iWE{ zS;T;(i45wB5r9wWp$7^1`~=9^H^9RUkk5jiOgga2z7KBsk)-k1$>7I-rY{ei4u1M9 zm(RU;$uQyJEtNvUs=J}HIg6yiD78YQ*3&IDYMa-P&OIMdS=8r~VMZ>DomYZCyh?Nr z{T=+riV%|lUBSIup6vzVkW0NY%;jVEg`9g3-l{a*=UJRcp`J)CGSNGbXuLjAQ8?R? z^f?ES>#}K)Y%li&5>f1rATze<$ZRO7y1Z#6(Scz{j=@W>en znkqq3Z&m{|zyq`afU>g^v<(SS4V3kz2AF{!m>Rs_>350gs|xO9`PKq7$OF_LfNCcw zU;49TN_7AYb^~$wMTeV}?{V>JG1o+X6Ox}CBW?gL)eT4brwxcf5fatp1^0~}got&@ z5D(CF06veDpvNRg){9L54fOzpcQY$Pdq_~5L3o#BxA+`D!#qI$0^o@R0V1PtLd?Bu zsMVL3YDHxf|A*!wG5QeHq%PV5YQsIKZ3CtCiIN&jnjtBF4JPMgp1p{IrN#BbcOe1E z*Ylt>!h=$O>}y(=EGdDn)1Av_QNQBG7pF$mL=IJ60JV`G)LsXrEh&;3_zJ$T^&353 zeLeYl5tP#Ol!VHQNHr^mak;C!7cPc2UkoK>qlgO9t(p&d zV{42015F)NTTAFKkB6aOdgaNmKb{N&*~X{BPHez*M%uLvVf(hxou9UaJ^X%H2c+0x z%U`!wVo*|Rr(TIZUss2H-N2quTF)%eVV@9cQ)+&^6&^_TGfN$-#iqKthGKAesUdsxo>^=zRmPS@!fLm zG%~9@J>=W(!>)W!ctuU4vpA?K(C2|mVYMxkEB|0G7?deO7+8U8^g*`tefbV> zJXW7Ab}rw2$kGX1yxBiw21u_pKLIG+1N0XFT7v|&sRATh58^K><2*oj0kHm233`A) z#GceIdjPu81N0^U!B0xiD7gOI`TGp0n>NlRIWReW%W5glRQ8d04U!qK@M-S@AQS$1k_|V z6c=C>Fve#jZn%sbD*K*hz^3S7(#`^;^IK?JZgCD)oelr^_i(EDhQPE++02)D!$zgT zl(xqgAUah~lvz19fL!9+l9MGk20_OAh2DcXeF&&&9;hrJPQN2jGtJT!BL^K{0mT-! zpaF8P56`#PyJqEQT%r}x8TG`X)F@vAHp4A3vOSddz+#gGbu+X(qy8{JGd(~f0q|;; zpu3F%B&+BVfM)4ILc&%+lrP$=^>v#fj&6z|2`iPH^{LoC(yrq_3X=cQlN4Gs66D5w zDLFAvbY9A{^d5c-*sX3bvKQ6?@S_uCmuGazdVdU{*&d*)06dB4M4ZKqA|a_bz60hq z4@}@!W~JBH5_7jffMiGdJwS6jKsN#K+7SslF9QzCnsywZ3=hy0#NAnixHODAvN3l2 z_TW2Yt(KJ9XXwogut04{R*Dm#HrIpNbD;F6q^2I@p>j#CvcdiU*gQ8FuY#o~&B`yh zI2(aeg8a|U-cmrT+{>}%6N>;SZ8>!P5k%&@5g{kSAAlF1a*@ay_u#VMhyukxY)9e0 zppfZ7Veo0Qa^J5~fFGy=Bz56QfHV)#lK|ZCn@ko0oYdoH#wpCI>1_6&FK$ynjU*w< z@D!+Jc~F}GN|Vk>7P=7&1dK0A@Gw8dDLLY{CaD7H@vC&wmpt6)aQqF3W0 zIb+1JXathA27!Ww_hX<$;fFTJI)WZxA&Ee8OfC|h2P^lgy@;wufD1^dr&-agCM%I7Dt3#zL--n13 zA}SlZ5k$-ML`A-nK=2SEUhsl@3M(bh3JEB^NGgEkZa`A1KLav2Rl<%K5Ko)RTjtvg zP=yC*Dgdtym!M;20g_F?3!sI1kjQs4Al5Xhs(OFb&TEkuuCaW}vR>&e2ui!g0)mU& z2$F#^1f+6q0=c+4=dk0e`=Z`>APV~6;Hs!)|Di96vEEsUQY|1%V=37=`+)FbJz*it za*&M}FEjWSuSBF#WDn&J;1V|=t#G*kkQOJbLLPoAvk?H$ogSbL*lPUoM48qx?{=$3 zI{f@IGk)p8er9`pcN0r=*232Gt` z=`>j^T>)C*2I3w2?|}3ukg!5{X@xSB!mtAPkQ#NHjCM?64Z0MK`l1SNX|M72VympFh{ zdVt0N@a|#(LWr{#f>9%q{X!4GR(Ze<1M<)knbv+11%agE>mz;C2Yj^zJfN)-YM6VRPr3D3Z$SFo z39ITsw7#3rp_B}x1o2sYE$Yk4XsE2}d!x7BOJBC!AN}e5^yS3|qW3;PUw(Qp`jr** zrL8LZ#g+6$F;b)$UZc-j)PQcNF(h45P_!gB0XfbQOLA|w;-(Ctzz>?lKIiTRilAUL zHi^jo@g}U&7mG;|qrq|<4S<`tEG9p`^C4+0NKsphM+&R;GHrhbUJt!Y|3{RNI>>WK zw*d6BIOOxj)6b9rNdZG?;}Z7AC@ge{0kLX*f9pD%8m-u;#2=Tky+q)Yyv<0L0CcoXLYW2$LAzQ3LN zFn3Nwd8Da*c}n`Se-`ELx0*UD8a$BcL7yY5qqkN^!&SMtHoB#ezF^jFwV=c6*hDH> zeJ|1%a?cheYw(DM%s_}MaNbhOzSb34k&Y~U=O%Yrk==|bqeL9wIHc8Npb$+{jYc}S zvCTB3RWLZrnN zbedYTADu5S7Aj4yjp8C70Fl3-7rE%+pLp6!`OjLZUE55;zbZS>!GP83HG!};ir0B5 z73+ny!Il+MNk95g^v@qf(>%Jdk`@+FBcsoIA4MPiC>o65JF6ii>Rqkdo+LG7&&|bQ z064di+xxOJKpYOGPNd8zdf7dwrmmLk?2gdAahPymX{0q|5}xUGGV-V-C^8P{i9if8vJZ_| z>-D9{mc$_5uyVx7FuGSTfR#d=UFviiBm}Kz&B9IR=~>3;ggJC3iBnpP)MS`L4Y+vT z+mRyod!sDTL%#3?FfjwDrkk}uq?CkCiSyef}MF4$fcfIcv4bpULVp!#;{ z^#JHG38F2G&kS#&VMh*TAd}g7Bc;jM49j+8@-vW_^g?gWq-v?QMIiPRcHAJ4p?^ar zdz5x_CS`*4W-~wjjI>LZ9h0MClPuNh@Ii5G(w%o7Iqcnr6+i7_{SA9}VsQobl+(LA zo~~rR#X`Dc=kKQU4t&@}cV-EgwbQ$wEvVf>dExs8@Gh$VZMTgIBK6045SwcSf8&l` z3MJ`bD{gsd@e)wyd}lS@`xD*Quyu1GXv_Pn{_gx2@t9+GJ)t!2?7x?(SbJ${ap@SX zq`U(ASBVy$#coLNz?vVT(%4I}y*bxT`&8Mp1CK^tCEmDz;oi+&;KY@lI+sk%Tt0K; z<%ihULi9q3T`WN)I-J^oP1M5 zFQ?pf+ia4OqimWu<%V{BpaEmEc#YZ;Sz|!mG2JXqWO%WB)*FI)1Ua6U*Lc)U6Ng3=liu0c!(nW%#N+AS1V#0 z8r3DS>fN#GvRK2jQ-U^*=w&(c1W^2Rp^S=^nnb{xG1%3~Ee3JLr7*Zlht2WiPU^GIonqmNMPBM!gyGL?Et z-29B3xmdeh?{BsmOlIrLF(kB?25%oqmAwM3eH5JJs22qP!wEurDny zb>!eV9!8>zLG)#+QyqqX5lqGoyM86wdG_A;OZReXH(jE(iK_9z6fo=&5dWs6vQId~NX{n<`%fWxe_^-H(Qh&H(V0S9d?EKQ=LVHH`Sc7o8Whm zSSi7dK*vHmNP3+9gVV;>GR516j4oy?^ZxCF*i0a~(bYbjS5SQF^`bh``}Cnx$Ohhl z4x4vKBB-!uXs-Tv_eEiaAT*cRx)!ns3f=Npi;;?=9Lg$Lu#PGGoSsS=?ot$&?LwQ(?$D)ruqRWHHd31)w;0NIZ1zz@#VPkaYgKT>l+AFHosS-7j zdP;lILROd$518do5}Y+NeSZ3+S?u0{OIM#`%7rO9_+P13P&Z4Th#^}BMfKm%Ck|@M zyeY9etZzDhXk(20hMz_+{AcoR4pA4jVWHrV26J%ykcc5}L9@}nGkW;%Rg`+hB9vN8K|2rpc3UoAvlGi4F!?Xe^OPF+)ZbA|c&lR7Z8C_a@!4VGL_l z2yQ~Zy}l00qGn8IfS4n<-|It4@bAJGa;OY*i&&_g#pU=;_oL_b%H;Ru@SNYjyurGg z-)DhG#^>OD)e%gpaiBH*0kRmJqX2;EUqA0uqnAIvS~}oA??C+L6YQtP7~3{_ z^;dmEQ`>yQ{d`i5evx?MAC3P4It8a1J9NQ+9j!sB#=uy73yQ;k!9DR`NP?elsxh<| zUJSG0cX&#>AuEEElCcpid<1;2yUxi{efT^4IC0xH{ucq3+417?H~vD2(WX8e z#>R978oSbgWPlHkv^Y+^8iv_foz|fA(T7;pT8*LVcr zL@1&qwhD}s@YSAUo1{&`;CUR~rcpHgWLE3Af?}`Zp&fLikZ{KyS}0A@DaMr zUPPV@dg%P-dWdK@`L;e>>ba63sZ;=gS07O=@O|$2vFD|i7 z)Jkm7%eD#ACr`2=`2yQ$M;@_JYQLib))KE94P8{bMVmPZm1~NS#A>nFL`q@|GX1oa z1RH4rbi$+!0ia>309CgGjRk0}09l^$Hw>Oqkn1z0ZxU{ol^2)Tu)t*@l!mR$UXW|c zE-x*xmE}8f%WYagxvdbb-ezA6op3#44S`0vv4$`u zV?x)h*^$(p=zmyas&6N`aR99siPghp>wYVarJpT8YMYl>KtTc|M>|@JvQZCW&M$ShN%O;4!!eJw zO6;m9JDxrt?J&Ihj)6S*g5+utB-KEgg4D)%{M{r7TIO;)i#O26jM^)pH*LN^a=($j zSZ)S(o4#d7Hg-`TGHUAqS({0$xVC7$v(vDDCu79S#oh>mi5QW!{1y;*|TS z!bs5KKvEhB&PeL6IOFt?b?3XVA^IQ+zCvYIxeVWWYbL$n(#YxBB=l`x;u6+jVVtmA zsaquTa5Db-kf88!kEzSDLDHR@+ROs%gH&UAX&@Oy|2wcVpp>NAweh) z#ZM+kw!`aXpHg;m>?LqQ{d0EYbIppE0#J$N0Iwr= z3FJ5c#D300%5D)1*6cNG-Ak3{iT#GR_G33|8rEcj`gN0?jt2oE**yAdz(pT6F~EYu z;Mj|iMne>42N;EF)|1gIW?bBc`dtlN{}1DP5S!n8qM&NTXd6xk9>t~Q{MrG z0vl5LNdpxaGH+=5kW;M5kksE3HU*iM)Yyc_=UI4q=@VTu3+viysfv=6y7$Ah4iH& zI6%jEv*T1)3Gf*}6>usn95l}U@)h-mvA-W!?TWpS}K`(Xxd%Wyx5F22*?X2fluUm*F={Zehw zjN)l_EvLAs01X@s8}8GX!S+b~^Xd6GZLD~ae2v_o>TruXo}I)nZQC2`Nv*N*?L@7V zf#Lx4U9)ZLsIdr)*gHpVV-d@iNa+eW}sxB^9Wvlp6WS1yzFYa zRBN9Cu>L&(s>ZSueV?}yufEU@lCB-b>-X=JB`4O@$W&GV@}eHn-jAW_tD&pqI|F15 zuP`Y0E;5KpnC>I!hk`Cu!JqM$$GWCm=-UJyu#xV=KRh*yT4!lRkxo3WTG|oMYTWD> zys5o}ByV0KlI6X>zPI`XAd{?+Z*}GJBM%23*N{GR(xk*wuxe8~0(w4oN}8A*0fSBx z;56Ps&?xqy0ea6TqiD)aDbCFmY`e&NvW&O1M?w1FKau|xq|Ac6+4{p(LwlB~NkJ1$ z&Zb1ED@Y+z8Gp5_pc(vc9ou?A{DwEY1l|8vm&&lyMkVWSW4mdyNDQn%l<~kFDwG~g zopEvT?&v4nc~y2tC*dRRXY}Fo(d%oCW~;HY!5ldaUJX`{>bj_-jM}qr7?jU&vGzbS zT6*!TP$ygU^_1IzD@|G}AZu`}9D{K;8mW6(!OZ|}lR)$yzDI9lGh>S=Mku!Irjy3& zck!+=0$8)r*0V78g74JT+%xFm_Xul+$xQou>E4B(X9to%t<<)QDoQLX{Vf53JR_K8 z%hc8)9@rX)gfUc$b&L9Z*uc)qf*pv#j&h!IdvIXZ{c#{Ur#S0&%?f#ynleG6Sza^iPo9fV?3fYL8eoF;-2ERr|)O17g+GSao=;Ix1EjAFED`Rj0

      9JHS zvyPl@Bx|Ez%Al0K1HnL(fwawW+@e;}2N%8e_)}}y>M=~fl~F8KbjYKE8>vBmHTP{J z(?jSg8r7Bljp{P5M)d-cAxIV!B0YP{n-KR$F8(5=G#B~HmUf6?ba3Fk*WjDUR zhVi2MONUyu1(%^?tr~^vs<{@2Xw<6jV*BiFqHrjvPCXw~M+KhsW}H72cyZBa-GnJ7 z7pP{h`EpMsC{Zu57lnxM-|y9#y2(^X5-A(t5>3 z)7>Ua8FI_IXU=g(c#vQ@V_HXjeDksIwoo5mTqGaLDN~SE2L#ut-Fl+f)gC=j&M0P- zG71@Gj3Pz}qkK`k>LVyzlr4%DC5wVZv7%H_sC05)w;+@z3KK<%l0-qG98ruYMHC{+ z5G9BLMERlkPHA)OIF_J0Rv&B(igmE+KulHUSC!DH6h{-bJ@sqc%()9@IQO>?FO#CLo}!LAgxp zhqzx|hv+El)z!_Q{FkKsZWyP`JvW>-aSYMA@yu5lDB8=Qx)m|Im|EpliJtZ?pnX-+ zUebfphS?w()ytZ!A#E@sd96pZEKaUnk2n#;{uac{)_#u)A&?cq8KqK%kBAF_T62nh zp;k}<&5iHc=rp79A6(a^Jqfh0Nk-SjIT>{;HXNnNtr2=LC5I2oHLp=PC=u6n=}rb+ zHXy7+9C~m)MOu7tY-X7A=3D(EqubLyz-Qgwdxb^;W4}i`F&kfnMPMR za(lZINI2a4u}^a%IQ7wY{0Zt-Vl^)+Eb2Zl=T%+g!9*CgW~!1 zf@-aZU@mD^Qt1eqwe4wQffTqEG^q-qaACWYo%qN`j(_>dCbpp z$cH-Ug^wM}C9RP#a>%@;bCT!JP2|hwSi0Oty2ne~i0}YicA!$RJvO8Z=yUv{@3o7* zIv;7H$3SrfQr#g^Gs9RaFu z2ZDPPEbu2Z3!Uz zc1uB#cBjv>6@FVD_9O3`I)&+;Y7arJ0?GH?_~3e7PJU5cQqN$vi_Z(t5SC4Txn>Qh z(f#mDL2j80n|RdTk0;BK!=^Axcw08@8$X;WXK(Fhg?z zX8hplq^~iiD=}(ojQO&o?TU#`dE_#3E&3%(f%Zs4#plkyeCgap-{%|$n*3S@ww=4^ z_c{Km=Pm{u#6ioQqfDPJ_`S8`hS2+sK|Mb8|HQ9#`0r*eqUoGJbBf-{#RH+uP9ZV0+xjqdTW|8Bp_!_WK{<9BB0?`J!2KUZI_ zbiK~Bx3FoH-?o~SbFa%%lC6LZ(s?Uj9uCfMj6FNj_kEU5 zR>%E^?o*L~H)Z*d76{rLMsjb8 z@oJ4xFUOc$$juH#z~qj_U)X|UP{kG;FBC&l!4*~v8-4kA)%UuNV=0dzZz4npLTvC_ z>#}N6!3NXn+$!#mpG>RspZ)0R+%Rb~C*xLn)`x1(;ue*1dyz9u zMja_1A5aOUpbJ}wHKUSqHV~xl7aO<{Xyg6wWsj)VC!ijJGiRr`207UO4rt)xAX-uh z$=Mu}pNhlcQI9ZbM)Nn$uA_mSZ%;UoU>DyDC)Mjyxc#xdhPNMazpRrB6h94|oT>Y% zTc9)=pk%~MolEJHsOZySr&)Oim%87;x_j7enRK5o^yFSj-qxN5C!a`8hD|9v@Of3I zK6rCp0$;bWl&|ktDpqqWm1hYpoxY?ntGHk(U%inSN8XS3BF0<{CTvDoFK4F?i<4Hq z>ZS$7x_!&k086^RWu=e7zcv#n)ZqziyBmF%AH%IQfQiFTB24x4M&>ph?f*L&I1B9d zl4Pxb7SOV0aqrQ$2T(z2S=1qCmybaUgU?D!fEz5f8ZNwQxb&*w&|_nhh7=;vIAuH`> zh+!0$0(f>=jXEQe#0NP@ZS9AjDcP=sw6Y|V@?MIGTR!U51P{;b9#oW1MMV*VxO$BE zU1q2nkm%O##KsEkIH>l+Mlx0rQ4CmE0`8rS>@(2aBk0y&FSBkg6=v1ywn}J|KzWao zdTM*>dqMp(S-q+0^NIG*MmEYP>)Gi8V#-47@X&q)$(ymukHs0uC4-#og1yK6x1R8) zSZF8wKlp*ZC|IFh<6Kwr*Kz-KClDY6w^2T>`zwF&f8_^ppNj#GWtw)=3t}Hw-K%Gn ztt4_W+Frh5gNbGbo2zhf!hNxYz>RDZ$nJ9^>pu3NdhQ%^(t9bQIcU#-XeaC|@^~sxP{JmMZ@BmJT{bn3QH*EO+%DrEwU! zJ0NnWp1978hvlTvvKC&hDLL;oeX@tRE~B#}`58ah)jDOt(T}{l^uT>b5qeJ>Wk$mh zeKtMveYV;S=MsT2aJZy|7V4E0 zXbvX&WIj2~*}@v871|S{P0IUY1W$aJtDo^Y3a&nvTs>r%9Q1&JdQ8j`Dr_b@x1yk+ z3~Iq%WMk`SZCXWnac*&TMH%~sgqPSDi&(r!HU|_q{uW_dR6!XnPAmYM_?xR$U^$-n zE8iDCu`~l<@q>$)|Hcx<97h?6A_q$u`Cr<)Q&fzRr32$OyDi_5gRLbt95QIf^&{V>d8W^Tf{obLcS-lpcsn<3&Dn?1XAXS78TRhRvT?JDs$Xv$Ct8vErIru{JMBtUBhd*|$umIIWR2zCwT*}KB z^K&=^*p6E$Ks#+aDkQhLZK0#gK_`$yhfT>JXxY4zdX4<@@{%FFdoNnFC}mOql;YC7 z-hES3Q+qEia1_(|c_8|LEOyZ<4-(u=1%%935Hz95o3~93(WjH?4JL|Is#N!!qOKpu3HfZYlH~ z1rxJn73VCm(Uy5zK1$O@0_96axmqZ9l%u9#ih&xtO)JF-VD!5TmZ>clOW09A2}ghW z+VcC^^84HJZ?NSLu;mZ5<>!?aSCrU_w1p^swmS}Wd7&)_6}`ZgQ*O(3d{ z6$?IWC5~*`|7XiDwK)p&z>KXBjoMaRU}I}sZ50JJ&6Z`;va(8TSvd||#WsA+rj^39 z;MYcu3|mfak8Hc z)6GhYp+(9nvT&8y${mGvTZL_*R%%;>6qp9oDsmjfAc&{5-4Hc3$6kz-vQUTlL^Q2V z)(TO_D@wD$kyf-&LrU4Dj*@a}SNsc3*+BCo?Zxw+jqKs#!V+zRl|?x#n{qUee57d0 zswgjqs3?mCjxrLTy&wnk%P5CZW9sd3z67u*l<`3$GG9!$w7yy0v^DHN^R4M9H`0=mZOwvR(64-1fKYOTXsb$ zR0XL-(xGM9ND7ZoO>-Rul&xHFkerJ%#3}oB+9=7E0@(6wc?C;K@=<@ZJUdlq=s8pY zAPTiIRBZ?Ltrg`Z^Osmk_zwi3*@_F6e=V`vtG(A*m8zFq>LNq z2CzW**GRq42gkqZd{)fGaSEv&l00G+dddqInlVaZkqvD{d`Ug+uUk}H%9MX8L}y1E zE`ZPqY!#&ic-K%uHdh~fqxlp1%VI8A)?!i)=cBXr8u*`1FE?B1Fmkh%&KAew4;&S4 zwr1#nrj9*-&$b2K#=RkWN_9>3 zKi&rmKde8{N{c?`AOJ&3QbzLpxQw}T@tZnh<1b+^kWQLEA1jvd`@(_`oA~c+bk3_i zYYWn<6*;EqV>ur}ZX9a)Ltfl>9}Up$v?&87vfKDlPK|wl^_gwBn2>7QZ8)3=IUJR8 z@Gu};qUY0lY;c&ay@|tXdMs2i^w0;L`|fnm%HM)$aA&l#v^*F8O+#wm$kdSk&37+; zp7K90IhifaynWl6J1KAQk92cjiw!KeqVhQ8%c<{FABz@sH_mCQ6d9_<8m9c3aB#hzKOKGd_q5&oE@MtL&?o*JNKgz>msb;zWY`H!I^}P0V zNAg!XL3m`g_I=H4y`zDFH*ZO>QWM}(o8e58`L+Di4m7G<#3br^mX6&3X6w2a%~nG- zwa(H1&J85*DW@@tb;!gY(J($zzMF=koQCrmkpPW*|1jV`x%P5(7qzoln}DNq?!@&E zbuAO}dRxwVVEOQ!n`hOMTQ?&sfeC<&nWeDG5)*7oN&tc`d{ZQT0Bn#)%qgb29g(f^oQg<;&Tbo5X+DIf=%Ye8B z+<~rTfw}j;Xs=w}T@&)e(;=A8QsfCN6O-Ca(cT5te-J_yDZ3nSG~#L0d*k2%QKu$p zKOm(FocUsiTkQ;Zwf=>WLobA2!uq9`LVkFO9k{}r>0E)bu0*eK?nb&ligar|yDvnC zVVxIdp{HcmG#uVax`+2q3Z|y1V7P>IGYXjfU6evS7+%%h#}OyS|AIxgkgmHv4teAg zCJ^t@c#F4!Ms&n_)*c3H|CKs}rBvg#rirB^mq^7Rjl`cw6s{u&Uf3IQ|2|6P%Y7kF z?dQp*$<)Y#(5LnYQahMT zo^_w(xn|G(517FZJ5msT;SPp&oz!>xT!Ek-4eA z`*vR^Dh{orgzbW_CiI=r_bwydoDHWFyRoWc{9qzSiBwz8t5^~Q*YeNBt4aH!jjrJ_|L^D_L%BT!6TX*r^&x@tjBzetwM@xf_4)_f$g9gA=wP_V$j&;FyNo&s z{(|6!J%qUX&GEJ;0) zq@GMte@Rl$BENFHf}L&PRP;TaTLYlUq&0LiL&6n(3UX z#NlF9YIVB~x&fe{ouKyXzHU^{_u`Ww#}dY%GlM_;l6&U zlXMZU1v4LEt`!3#-N9*?6ehQn$m}{&lk+=bKQsx z{30{pVPU9_?x_7>Zr8f9J=BB>i=FjPX{c9|ZHB>hS>&lF&Z*`gyA4>x-GJOSV9KWf z(;s}7YCDZhtFEZ~u9(ZXFobvnjvo z3FG)?*(-<%VBO59oIywd!3jagM<;$57lt>=%TI>xTpvm^92gnv4(Y0VI&|H7UXp@| zzOi6JpSv|+;y1~J$GiZkwLi9=98E7^*YQM@BB?c3KjEy6UGauzMFamvZ%*mQ7qyF4D#Y4D@;tQhBaK|_Q7hbh4zBt67pi<6|CKIAYy=hh%fn5%iwa(bCl;-WTn7{ z>b*Yk9GimX2A$8Juz=j+m9+vM$QE6SkzFcnJ|B#$B(Z_)fRm@g9+YXUvL4Xp(8h zDRYzORlrHvo0FhCrjXMYdgyT|3Ds_cAq-M#GuzX6DQ3kL7Y%;AYh8T< z=KQMNW-m#jT_~PeMh%k()1c+=EQ78+@06c>I~+{pUdMNBMsKt78!oPke3F?i(sze1 zAus1e&KnK+lNVFdm`zZcMPxG#GII?wf5^nBw z3>V>qhj$*d4P&PiPkJH$;2?Z=`qF8lp`0cWxaYeJlL+KYCr31MsdFcLsc_dThGb0r zC9ucX_v&i$42$o_tE(-IdNJKg7(3blrPQfrv>J8U|l)N`>ZVqByEB1bs=Y0d;Ld*-cYp+DOD|G5nLe2AE+;8Q))x9^&EXeTK)6@-ZhCV0hg>y+|= z-}yIJ#nt z|D7l`{Yml5I*~(q4i8s2f9{-&cgbv#DtWX=@S$E^v+FWhSR(&dHu+Qp`2{r>$R3R z>{(Dg)Dq@Jw+7zu7!Jn7tvuZ7>_vQ!_CD8*c<4#9KSN>syohCO*lp~#C*MDaz0xvJ^j#pV}>>4tSMOnq}3O21nI?84K zsO!A6mj;84RH5(qkVkLnY(?2#ka`})+o7(SMI4)#wshV?tV9?BMyS}A8#>j{U=lZ% z(z78;=V9sel-n==^}Q_?_Y>x1lx0kx+Y5bBSrRhmC|X*a%f5>TiJ*hbeYRrYJ{m0B z&~$9*w&tQC;dTAb#F24$7cyV7>aN+u+PsW}r5TBF?A~`5x`feCabCuplwKKgB=k`5=nTEwsmlPMl@!Voy}kX@Gk->(mUn^o(K(u^YXs3e<|{Mx}Jn>p5u+>CPe zAc^i9uXK*1jtmlzdWF$w9vE3o`I?W}#_}ce8IAW|^EEN~E-ox6DjPCsIs#Wx-o_<% zV21HLb_e`>81`y%SIgS!|2+_HKM4TmMGfN6VLxiun)(Jq=IX2j@Ix|TjfLvLu=lH} znUhJGUCyI`kAX)J+f~DARLuQR2LI?ER7o#6%4QZ}RuyxESU-zJG#FPvjDJKg=|ki& zjXc_Zi#@k|GS*+Fjx8iVg9|yd7pjC}$e*(K^vWK# z45CkgnV}Tt$3aJe0O@zsg?2ZWX3U9aihgALTzrpZ`hR3BeMi~QpZ18kiM`@H7fzC% zNl7jKi_8ej11p&Wi5=XW_O3OLZeq$@;X{SpmP~ReQn^nEd+b5dADE%dw&QPR8a)6i z_Q@p^NFQT>tYqH8ZwC2~4uAM0X`lj#IdcNtrEs37x(~@GB8a_`j~NLia}qrPk=sZA zpVqzv&c-VI|2)q-GnRKO<67q4>}DKeUs6#MiXs$35jA$Q&IlXl^_q_csiMsp*FRcRz zZivBMj`8wN4L0bswNovrJ}EJJaMpE)L1V7fiOk$ew)JLk2=>^SQhOvvt&mO0#LtPb z_Mj*1y+$AxF;rJ#uX*}e`xBMU$T*H$cj)tX_47ALI$O!67tEO0y8jHmP@WxDJ1u#t znRNgArC56R%7`iQFHMP|X`jFUkV5K$LXrqR?K|my>2bK(WcU~eV~YK!w|n=lX)nbh zjaAzB?N?@xl?kNvCPMI-gnxTQ3`HxQtSDLN6e?=#y2Z>G}kNe@Vh4{Zx}Go-s5`*W|ZL;V_U$UU0wIfaMcnA z9pq=AQaF?DpU_Qe2{Lb~Z11*8f+Vz%T~;>@me4}B;BG5;tyn#-nRp%4zXlS6Ylfwt z58IMDTe@6|_Y(NPp)pi;^6A`(BAUD-|g?a>Z*2s zxM(ef>?D0o_y~E)sCWBve>>Jo-o)KoFMW?1w|Dy@T1t}{K=h#I-LZiqSr>~oXeqC2 zlkD3~d#OeT{9Fs?8)WOT1|FkPY@02!!N2|OBRr2_*JMgn+^7sz<4LP;+j>f@j zY-NhY;D?fW=h2PZq&np?yP5X>rI{k0kTbod6d*3P!v{o;xHHib?GAp?ElcdQV<-;8 z$>Fh?XlFC!G~@Yp?Ke~}h!STR@vH30RZ>$chZ2EAU11 zRwb;4gy8FkIGSEpoXfsFa<265u(Q2y5AHUp*8kHv-^lDKtbi1YcNKHU`k(OmFB77J zm#MnA&yu_Sino3HAfES1dq;k>{C>l~)V(X>B66!FKA7xq9(5vmUc!Av+yI|LESuS3k_~UBtJ944*XsY-9BWcz$!IfX| zUq!RNA`KD$>{o4Mn^684^sdAI?na&?T2Qrk^<9nl@CL-3G;z4@_YpEe&Xqv{uSUEs zbOoX}!&?s0-!m>Gi&l@`(Asxj!u!&8-vn@OZBTzXxrDP?I2zUuN2hSAN=}>gk)wG1 zhTsnl9u2JBYfLX3wCs&(>0mg?Nu)mVQbP`4;RqN`s^MVMW4PjbOzklPaWj4Gv2rL3 z3r`uYaO5Te%SxdpXp|@ckUmr<@(wHZM;74S1VG@D;sPaua<07V;JL z^1t13y&HGKRmaCvA|XXDLvBV$zlTDy-|mUoS|#Chp~_rhIL^R7t6YcDHO-Ls3}~Cb-XE3m~}Bzvzc}ySl2UEDzk22 zs#f6-Otq@K*CbVA-P|N6vA)w(PiEcH=<2NRH#Ict&L*V>>+Ysz3hSPxR!!Cqo7%Nl zKVs_CW}Rm0)?wYt)T_(ynfmou_cjgcv+iRWHelV?G-}AYpSiIS>;9(kjl9R))R^@E zbMsBS+uU+9>w%`pEvz3kO`Gt$=GLaX%iMM=>%k`VHV&LKx2JO8tZ8;T2hN!0%~%gH zEt+%SJ99@14xBc3-objPX?Z8>5vEm3*6HT1R;)A3-FI=|lxcl82fj6JTC*Nw?rFpN zantr5)?-b(wyd8p?c1?_(%jpg^*D3iy{yNZ4)?L1U^;eS{gmm{k@X~Ve<#*irt|%* zCz~#vS!bKBU06>s4|HXnV;+2f^;FaCLDthu_in7Gn}@oyHm1izte-YLd$7(m5BFsK zjCtf?)-z1nBdlkdUTLgnnclrv&o+H}vz}x6_F+BO^y|xdp6TC@^?Wm+KkEf%-~iUo znn43uFEo!1V*Q*M{3z?^&5*&YUob<5uwG<_4Q0L93?IgNi5W4R^-_~Qf&<@}jC2m1 zG$S)OaKbz`lJzn(>M;&{ZAOn`z1)l$&4I7X<6~H_G-DrUooAjH%X*c0@(I?f&A2C7 zuQB7tv0i5;jA#9#d1?admrUkUtk;`~nH)H7CQanPmnLfx>y2h|7VAwWdol;UFjKNw zzhZKxu-=5XMcnKqU6t7iH%)~^{eo%QSHX~TM($$gsjcJoXw>m6psGpye=GiR{g zYi7-4{ehW1i}ipU3*JSumdipPOeFaNsku@LATMnCBL9 z;8XMbbF7b;7oO+95wqw84t!!3FJk?vS+bb*XJ+XV)}NbYOIaT^%a^hK(yUm{`lMO8 zf&+(4-b%(deOBdh;3Kno6$cKOHLF>FW7e)={jFKImILpY7uRv%ZS&HLtiLnsUt)d6 zY*^3wd-L)J)<2kyFSEX2Hf>~m(QMwt`bV>6GwVy{l`X7)Hd|j|{fl{ZE9+m)Yp=4t zY+iqj^>1d|>#Tn_+qZGxO|xS=>nrAs9jvdK{5M$tVcyK=K)!kFP1b*zx8GuY&Fp-e z_21^5ovedq*E_7VBJ=Jpm_%mxyD*u|p4~7VGVkqy8As-Q{PtfLBC{92|JQ}de6Sa0 z5i%cs0JA8WeILRsO=kZ-m}STu*blQTnU4;@EJxWX_$1*_h0Ee9BtiMCSYRFmERF1Lo}d7BUxpfZ2r1 z#S1W-lKJr>2ezA^euS+RnM*&xyo=1wmtfva<`;bJS+^$h>n||dkhzS{E$e&8{B{{; zTQc}CRNz%}<#!HjHCHjE(VfWrag_tFm_PsEz!vk@pB&h1uKmSCVn5NKeXGO-i`vR0WmOt=xr{e+K460R^; zx-)2DDkSs)&>~b==!2j|sff^Spe_}K|5eJw-j5NLV2LFl8P6{x(>!JrkXg3uwLm2l%V=uptgR7vPC z&?;0}=y1@gR7L0r&}vjwXgX*TRTG*4noLPTM}k(TWTE&WlhIUN=#!u|NDCbYnnE>% zjt8wtDME28jj2U7g+2vZn`)sHmMBw)YKtrjvbuOt0y-JA9yTOEvq9@qJ)u)T8&G|r zIiL-xfzWB7ji{keOg_ww)JQ0fZj??h0X=Njcyf+`zcH+-G-o^SLSv~71<)ln$hh-@#ARIoSF$;0@{L_ z3tbC(2elBo4)jjCL+Fd3E$L37FM+nAmO?jx-bJm1z6^Rd-6eD*XluG#=qAuM)LQ6f z(0izj&@G^C=^ml4fVQKyLbrmpr*=r~LS^oy_9A-?vis;>p|68>p!-0h0KK0&34H^!GuMnE-Xb*Zw=zE|&sfW<_K_8}`Lh%bw^9VhRJme~qMvs6ztxPXU1DUQ&Z|Vgy zO_@H_ThzaTdSB`z^lQ+5)K@4rH%x!(C-f@l0O~LF572=$K>4y7SNu`)BmXsA%Y45wj28FT~<7wUkf(+HusmCayQLLw9< zQNH1GtXc!qL?js=}T&xk@zD9of8LTiD}qM1T#gU-f@W6(OFb7;2Ex}bAuj?j9b z^JuQn`k?b^p3nxM3uwO3hM>>V0-=pS7t*srZv=gg77A?)`aC@+6qn(d7wCDRH-j#s z7lhsdx|kLTZ34Q477J|(x|Eg(y%lsBEfsnj=yF;nG!=9OEf;z_=t^24v>9j~trXfE zbQR?ZZ2`KPRtdcWbPcT*dKc(gS|jvs&~>y{Xlu|HX`RqEpfAyjLhk`xPcI2=3%Y^U z3vCDbGHnogFX%>kS?GPBn`ooZ4xpQ9lhBT!TWB+A;Bi#TE3`%EDA29+iYPn?g;!~- zNFNKTY8Y{p3Zw^Bqx9hG5UM~%aH;(?r%^$`hdT*wfit2A@~FvuoBHm8}javy)zxY>4-(@LmSZTA6p~wP;~EG;o!*i~QoJf->)t@$g_WUcqGq50F;>56al9gYrjI zOZk(89i%!Tc8KbQ*kNj*{ME$uV``-Q$-+LN#v#`ubhC0Vi|kWsg1e_Og1WZK`ix`) zSJzS1KBwEf^6=qj+tL=0?qh^^%}BSuj!k%@;lVGcIV8x055JTR3=67(US@^`@35K@ zuF8;#CDjrgTltPdPny@bjNo19(<y8@Nwu%&9?vhDfu?WSjA?!3Qu}xWB5EwedC7UxTNp zo9F5~?PU;JzoI4{veJ0y$U?^QKBwM zKTFsbgM*jXZ>gVE@_OK}!2wF&911w=91Xfo^U>=xhoH5_DgRA9!vUWsdHGQg@bK%@ z)58fsiF{Ak+mk}g`hiASKi&`^nH;V5VMu@*I{yWF9AjxI-9&0^6~6Wo45CIqyuR69 zq$j*ceLo`eXc;*_(KwZ&0z)wlU7{W6flY@7f2Q&9|1+Au>gSC#PeodQ*XDkqiJ@?Q zML5Hy&mb^(K{z2VS-1-Vul%Lxa?^vCp_UOW`HF3N7SwJ|R{ zzf(4bdzEyBa-<=uRV|@#g{FBS4!(p2hRx!Yb@AfjD&=}ARiJW}W_T)Sn}5)(DD^pb zW~ih;X&#hS9%{GRpR^##eIbIw_P>?t+tqv=X)}LOz6?r8(xVx{=kcT|p_?gljovJf zF2dtQnZM~Ra5vUryc49gN@8B-C0nx2ydo+od3g5t z+o+X8RX9M*h#~>5#^cCe+omewPwZaRd_-#z5_nDwzbI9US~Rizj#TaNU>v`MVFgLc zkcwrs0S75$$l9n>P9feb`pB#)%)3NCBUpsDc*9Uzl~a_rhTUC$*K_}wUiIADVbRCC zk+W7<^6?&!_A043zpkprsa4oDu2!74qeb9hWJ>UR#PRyxDR1ceu>9lqq1*wBKi*qV zs`+?e`a4QuN=O1r@mp%jPTlGH=bbzebeC`oN2XBc-YA|C^mhr529nWtlHO&iF_b5!u$DPhy@te>)BEN2L8k=u!pentV`QiS_XR z>Kc{#bEQZ5N2!%P75+*#(EqD2UUIB#8zrgAUqaF(N>Yu#f<#A2lK2E9Xn`h~_n{s} zVui~4K_0{Uln+Sqq#ess{2Qf57bBfnjP=A48jJKA{82&jPhsU%LT@gmw-oEE-c4tY zw3fR3o04bB6{S|iqY&!xLF9c8md<<#82E}(17Y+?RGDa39wX#vP6j`{L<82h)W4bu$udt}+!^rRP1Oz+3E=g6O z7?bdgKpXBUgn+LEMul6N)CvhVB1O1wVE@Hdhkg7fdfbPJ{Ag4r3V5+X^Z7dL2U+~m z7HZUFBtU_~DpZADao@`2y>P1C#udRv1j~JG3uLg&&MI3;ctTv2^a<7Ia4?mVtRMdg zTSYmyb9M5@LDbS=bl%}Xjm2m){y36l%&(G~bBfI@-b`0(&b1JPw0tSVIw-`FXdNy1 z6Y-(uOH;Xnk64TEPOohYJ^;;n6xgqPEu$n2D6miYT1813QQ$-6!{Wn+FTNU6-~;8u z8YCjQnF4#24@;4VqzMJk8nGgYNN%OTd&-A}Nko!Lfj!EH^+`n1i~_rr56hH@qy+`u zRlfF7k~=A|OZl*ViRiQjSZMZvC(-Far+?w3Cg>~Y4 z$o*c}{oIb+^TImwz2tvXSQqX<{-MIUawl?63wwY&lY3U!gWQ$eGs3#@gXDfEtUGrn z_nfeYxCglxh4tWv$=_F4PfjC$e_;=EZ}RsO_6YYS_kyrA?oa;S!g}#Qa(@ukn;#|r z0AYQ22>C|{>&wH)JteFkk0AG3Vf{IS+|Ptvz}|v;RM-F>P5#5e2J++NelBbfKSBPN zg+0pS$o*2-V4gtk7s7^cCiyoB8_JW&{Z!a6o=ol$VZ(U}xt|Cd!BffoNmx2hC-)m+ z8T>T4CxwmVXUIJv>@l86?$^Rb;phK;>pGg}lK&Br#qoUdrwJRw&yssc*yH>hxd(-f zO4 zm&n~CY!YuEcek)C-bn7d!Y1=(a(4;K=2yslN7xj`J*uI_>+2MFtK98&w7^2-D#nNH zq)*4|v)BmXPYWI^Z;(Exa;EZ|(t|N%*k|a^m~4404wEUnN;jFCbtayQ z*f!x~o^>{!eReLZW9a%$G6zo%n=e0H0^YnrW(*%=nHwv~)-D)E;H0@2L1b#HOOVQ% zhh$*IukqsA%;zr1gZhj_jo zpwAJRkL2=Pn<(=F;|4ODE=;QyAv?-N8o?JMrUJDk{0-C~UW%wxqsy2vod|`njK4)R zp`2Yt&b}dkt#DD7=2IcH~bKO^qPVaL8_#C{BR?081(U%`&)|KyjLI9bXZTMY=;dw!)# z17t4d#pNyM!!mCG_BM1vGIc{n@D0r5*K-VeI~F+`I96zS(0xNSO%J}zaqO{;jP1|K zo4BaNIznQ_v?LU(Jn~!{tH?HUF;=Ob%+@}_*}~ZGlyw0*!YWQ+mGcVw7+nM+vz5=G zAffdtW3Mx$mB(eVVf7j+$@ZStS#~+M@%Ns!HOrpnc2t{nZOO8kxq~lw*1NbOtZ$$q zt!qA4X36RfWc5w1D$!;H-5rvax40T&#QZ_u8db*IQHt0Hy>6cFEp4G`Yr>lV?jUTD zNlW#;4HJ3K*~uvq{IH<^R@HPER=U_1?I)EIqp%nHKL`+SOKpI=xULrzwyC}iJ>mm&7Y@80R{1bW1$(GEmBKFjqFk_#s&9wq{d@`8)6F7E2cnd) zt*V=o@_hue1(Xk>2ZG)KdWe4!dMD^%bVJaV7=b_LmdLGc7YXf?sL(K7((NNIcma$Y zUbj(+xstvY0e*_U%z@XG`3xNyvitrq7>8Gb*qlGcc;?uBf-~d1NS7e|PetdxhjV}*_PV|!cKWpU)#MJ|F zUEpz1*|BhZXv}o;!gd)jR-#8=(7Ib%iFy1i&qj&;%72DSY_3htVx;*p&kv<} zk(cHL>{@n~7h0tkQ1id>U+`%M09m8s*Wh|Ko^ijk{Cr#K`QTT0vE>WUU#{{ssOx7@ z&VTR{sndm!{>gtw2eK3z&m-Y~@$ygtp7#>4f?dnba-L1Vb11ZHyxNBT0>b&5gVEuv zK{!iE7WdftY>d)ah62T&lU@!J2le!dkbNag{Kik`h2*PXGVH4{}7$NY4XcA=LOgok>?nafC>HrbjNr0|+3GqNp(6h3 zIlo5P>fM$TVRwi}(lqil^Gbk)f>IqYCwnJ)86)J13xDbsq# z!8mATHub3?87fNj?64n_g=da8JLsTjII~fwx8RExX#VeF^l0J~5xN^S)YK{Dc$2`{ zQm(7Gu!CbIPEoHm@)?~I{$~aKRcw>Xxy^|eeKed{%_Y;#r0#t#pHnhN&bcK@|CwOZ>tgq2?O5z%@Wm_M zdGd-E>t>{+y>r`tYT}rVQ-Wn-JOosJtr8Roj&B1lbzk)?*yiV zPd*s;iZ#OdzH#NZ$vacQ0|>hBmyJScIzLPoE} zOJ(mBGPti7T%w2Eo=#x0^5IU)kmfOZ#0$sQ2PT&5_GRTV!@hYB2JLy_T&0&QP1D!CEYJ2hE@oX7CWP3cd-A9Y6A@Q;8Gc1BzNX=ME{#D;O* z>SPQ8`HZG2jm?*wq0U&;v&Q@StYOX*wtZpKC2P3zq~%{k0`d}bT|nay5O!ruy5mCw z(RfRrmElaV3BYbl)=1|m%TIzo=44v_4frT$qUGO$k9H>6cus+jak8xZH2CArWXrKD zlQq`Kw)_nE6V4Q?k8PQ(C!HKCKLm+s3uQ#=E`#? zw2R^zZ{jh}K65aum>RL$-tA5d+vWL?iC&iNEC>a?M1oFop2f(FQ(E9toaexCOba~6 zdBH|G9$uz8i$h*A#i^{b1Zr>qZ|f{`+}DIn!-tsMDZ-{Zc@9Qsup_kEakGUPXD!Al zjLYB$=|#tVRoKV0-cf^pL%Lpe#QwCi$woTPzF>PYxCO;j4n>peY_&yG0sI-~Rm&@a z&v0I|yb_9Rrt><67+o23ma|Q06--!WJEf(aRE2bov)#*u^1~|q$Tt^NgB~$hp3pmN z3g$WaNN3o6ew6!L)_sAqGs+!B7xBN#x-WEgN4cXoBku26_vf9xQSK<>i2H}ueUY<2 z%6)N^`$yJ&iGw>|Bk5Zj<^HjCU*;T%a$g?h{+V@O;T%QXVcgN!Mao&}d=V-V7iZ*9 z0eQ}saK<4y@ICaEgNF>*D(6JVQw)jU1;17s2+ zLWb>vXNwy3E+P$g{%0CCc%j)e`~?2*H2myIZ5n9;-eI>Q0QTU~rnObI1*&p#&vvv0=9^h~^ciTsRt8_7*~LT_byBGJ^@v zA%x%O6oET_XB9QWiMX4sPGWfG;KoE${GC`P9IraXV*WApv2%yFf+Y%cT^!eg?rTnh zm4$!481o=qjhmlv8P_u5HYYqxpml#5I z(TOQJQx(F;u;f0aEsBd~X0}$dGH-D+GrQqaXIyw`W*fNG_h)7bcj7aFrHYHct+;Sz z$XuGaSH;w>?@wzuLdCV?vT3F2!$0C}__m6#k2FYH5PrZa@f=+3eu+NdWyf`Et4~QqezJ&Sz0Vtc8c5#VmWt-!ttSFO-T=)d??AG3hazlDx z3U~K4DPrT#ysAbbKfjOz-GX$?AugKMP{QEq@g+AR?FhGIee1`|e^gpaq8ur%ddxoY z-(3A7;Yb>)HdpCVR^XYLO|(r{DJe6r+~TZ${YogW>f+D3hxF4Lrv1A-_7zH$xRI|= z9Uxwbt8^$&Qtv2hw{~+ivQ)^e9oh!M_u7E1o5E5yG01<~fi`O7fhJl2_v#}X)~{sq zCg}~gC$z0JxX-a|j1#@K7BX#lq0XgTo41abbEN)Jw@Wi)%VuWAD*3(pfB(ncg_7lA zfhi1kutsF8Jpb|&OYgt17<|+y#`+SO`1$w$uv9_|hbdu6Y=z)E2G^f@zQm4e^R1hw z5eK_mw<`Y~q#&F^(T}xuVR1HXjtYPO*o)Dze#PC(nHRrkd9g`aBxZ4qwSL3$u)dcw zFLp^+479?z5#4akC52w@#b-Dk3DpZx{CNH(KawL!vnTa(C*0GP5G3Rn*zv74=y_p_ zp12gGK037penqF?zZaU9(y&W7cj2^pb}vN|qv&}uNvnJgHUBcy!1qua5&`XoQBJ|KvuvCVvP1#5MwxvVoDCYmL_?X zFv2Y<>^Cg+bft{Eatnu7kP^`hw@Q(Er6+oXu*Joz(Xd`Y8a4Ss+MKnl

      dQ*e}^UTmy@ZhYL^!r~;$_4S*&<3!n|q1?UM30@8u8 zKsGQ7SP0|+n}B>g?U9H0N%(sd_S4pW3G6CB#l*E(vBVgEv58=twN6gUZ-11J*TmruePy(U`5&%Dt4AcRd0Id?@ z6@uysItWMy#sk?vZUSOo2(k=V3!Fok*MK6`5f-p1L8?0+E_+4wXu=d&FT2|p*aYMQ`+<`{7wDz~ zn!vRqFcioJ76Q4DZvu7#hk&ENNnk77@`2sJe&7gj95@Zc)TF^~$h0@?#zfL_2*paJ}+0&Re?uulZ00keRGz%n2?fN%mRnkFDEgtQ0g0`vs> z0YiaNz<3}V$OYyBi-0^}J+KwX2X+Jdfg`|i;52X<=!X=<-hdq3Ag$03Rs~1_8UU$4 zs~Zq?N06RE27#mlW37HRSS~ORSOnw&>w&F6KCm0u4;%rG1E+xtz-8bX5L+HG17&~; zKnlnAt!sFb`N;6AFt!@__X~K9r6ETfujV@BQ-U zC~W5-O{j&67QqDwE(6!f%X6Yg1vpiJxB^IW1rar{e_O!b2IvTM1FFD(3!qCaC=aS7 zW!F#qrNeEkkZh1#U>>jt$OE!Pd7f3ygWvTKZ3Xgy-N1g}8sxFHk%-z7cjMad&>q&F zwIzn}Vm$(_i;}SRSyx5`xW_KU5C|QV(P=#D{>RB0UXq0k{lY6G4&6 zPy_rxmC6v*sVt?|1lATn8=#|zds^`zSkr;Az(io0IL!lD1mpqhfvrG3up8J990864 zr-2K=W#Af+P({kN3TAJqK({IqZwsV49kw7sv4*1V|u4pe_`5OQ>TdK;71^uB*Gt>Z@&acXwM|R(E%owd?BcF01{& z|31&>NpkOf&wI{!Z)mtla5U(;tU!k^Up*ydVD4WpFL9$1#j{E}3zx}uB{>|$3zu*v z70oK+Dp@+IgtK_jELZUonWc+4OO$bzF6Jm%yoAeHtaNEtQt6^4ixny2Dw*Uc<}?uF zbWY2R|Hu0OzilUD-Tr?&2uskkjC2Y2%Q9CvX*^V3vf>C*Do70wRZ%KbNpfNzZeUqu zX>k?l0D4ztOik$vhSrk)MZr2!Cp_pTC3TlRVcS?K-vX%z*5MyKLhs#DpQ}<}hMP8E z5AL9`%T2?vFVjsA&@szRebFb|Orfx#=ZV%^=ndH}$&Xriahm^d23ayJ-#TzHrl)S8h6pjMr|e{KZXQJlxgH z(_QEM-L)x)yY}HpPIn#5<*tHx-L(O`^0}*Ces>)z;I7yJclE@@KzFqYa@U?rcb!M+ zEO#9#?XJh=+-0iluEtf|)gDPT+*JyDVXf(|Hduh}wTOZ4_1!hOnY+3*ch~#Q?uzc> zu929Aa$Vi^8$Na8es_1}@8PaUeC_G3CcPNj+g-D;3x)cS8%+J()d+v#%>d^8&0R$Y zx~t0|cWuM=!S3=I;w}fa4y7iz|KY9-?80xuc|5{heMh?MV-d&pDu0dEf zk(zOElDlk^$r~T0ko#136~hi(MwglH3Z3PytIHP>B*=eg^5OoV-byJ8l*EAKLQ z-CXXjF)PS_mAlTYbJuk=+T<>eeeODrBKzHS5*~+HlauaxahANUxy$<>cg@4)cjWw$ z9)5P$KzRShJSKxC!frMw0J-c2ge?I+Mup++)p&< zp2MJ<{4~gyWYFxQ2EDCFdDdp~ZWH#(ywq#Yck-pA4F3@=&&qhn8Te*+chj9{Sbpp>@cU-$QZOhC>BC zv?b6(`$9Z)8;!#}6dUfLkZ2F>O!82@Vjjv$_0Tx9O7qYzq^Eo6NQQ_0D(4|nc@K5P z=IS0=)6_!;;M2@Q&oH*RhZZ1r3lB}l_*NcTgv8b!s?gR$d)pJM1IKstP)sKe1$8Fp zE*@&o)kBT?l2bnqr3~;;Ra_b3q2)t8w0)R|uHx));*RuC@MsThoXxTGJ=AuAhbArb zQ1L|`>W1A|zRE*8HhAbOPHgnh8MCK~SUlxr^HgRYPwma;sjb1Da)o=Ua-64bCVJ|U z(^DQrJhd>}df^i8;B<_a{=v~$FTF%soR_L%HQeI8bOKNDA;C+Bi+Sl|3C5T7 zQoUp^g{OF_eme0hdZ~3~jzj%wUOGR>ONk@A)E4DOGB50-7>_ICywq`{mz?{&H2txc z7Fdj$Z#Alaexs&fC!SzhL8F!i7_~Uis0)}CWK`W?jtw>HFfQVLm{D)>Jlv=+*crk8 zNTb%^bd*uo@ip2gpBSTB#v0Wf>iSl}<3~EdIsBM5E@Ry2Gf(use+kz)4)i zktCz47B*^aQKQ}$Gb*$=Ipbr7Q9rqivSk{z47ZRo%c!3*x~x$%aH||S;IF$K?1r4e)EZeybg|6)|hCPvk4$~fFWb~E~cudp{a z%GtuGbWCo={dPuqv^VN0KA}%XBQMH~8V>)?Mh)&tuMykLs28}?og8}_75=MH`T8;k z_V=eZzZn%j(5PyIjB11pgBd@B`&f+}L+QgGMj3_~m3z2R?MBiIe8P!Q^kg*aFy5$+ z6F6Tc(f27l#xlG@j%h{(;S?^-G^)lda++=Axy3m$$0*W2dA0yj8PfqsQChGd(o&}m+A4}>__5NqqhA+zpit>+~B-J-kYow z8lo3AVC^lV4x-a-`j3kD=pW4YIUZB67avgL0XajDnHyiU}0#A&JLY~*0kM1UU z8cYgAgqKNka2pkjCcTBPk4fdw!EBPZ&7}EulODs@-=sVb5t_%95d-nW#+D8QlFnp>R#QX>NQOIr?yGM>X@__r|=Q= z8kn>OKQODINjV#t6pT42*uPiVZZW^&pd8z%|6AcgAg?NJ#f0*>^Fk<5q zrVKZ!%?OkBjWub}IAY=y8jWXtCQ#=@a-U?)TF}8Ov*q* zJjA}`CY{Dpv|qt|f0~qQrAZ~%m{bPM@CGwCa-MA>?iTXjW>WF(^d5#CCS@O|e2Uf-#ZU9fFu6ivgYtseiX+cbjj(hL3oSKxxAH~+gl6sdaGQ1Z;e68g2YB- zA#b&ZJ;+-%;S=Jms<<2Kt*9_>oxz-NZ~ciQs1)HXLoCN59)F>BQEx3S=B@QOje5ns zIntV^tV#KLAYsP8RP18?QUi6)F~>aD3Qy|oB? zQLUA?#%UgYCd+QD6&hge744BIr%p;eD-a3d5Tc~S0 z`S0-7lAZK#7dh=_tuY_#_HZ6tV_pCC=7NW}0`L(YH|g(fZ*9Cop1AP9TazDqtI%_A z#UjT`>OsR#^c{xJ-fHIVqkRS+HTCq-NiQD_GWuvN4kE_aM}c-9#i1MSpr4Ez4 z5`6T|<)h>*Vj(lzN5_#>+DEl85R-5Kmtid9qx=Xc>!TXweKZkAa1nkLeKZ`ZpkH*dA*oD-++DGFz z`e@HzKB~UgM~zW_pO2Cb_$cUzkM5%LF&{lUMPJYOXwzBpyy&Awmwfc(s*iTv@=?Si z`iUHmsRvu}A2Of#XacTb=rbSHedD8!Z@K@Dn%?{9HgbIM(G|@2NRF8M$w!|)Q}=&9 z`u2t1eDzV$d}dY5Z&pwNvz8V#%T&m$#6Yty;nz^J3Wb~XIl`=CF=kog%*u}vnPzpt zRitE@RSw0n&59~#=5?o8Z7Q1;SjDVL_!WzA8uq$o1z>x9#y2o)AKo-K>j#>&Fslzj zTANi58_=dL<4~@>Sv8T;!K?`=+|jIMoz41=s$IDyPK8T!>n!?2)CYQwdikF z4+IV{>%$+;J;bbG@EmGZDO5({?`EapHGW|DAIv+#tbY(Y(yUfkfoE`xVh)@@ z%h6_SMW?Z5O&iY`m?oID3n$<=$*k&lkIGZb8ZnjQuyY#oPd95m)*#O(W^nPt|H z+0+TgT(df301nS1_I$H)!?l1KG4}tr3(eYrV@O*}Z*dg0mYOvMi?C{$S$9!t1$m(2 zpUi>r$iI?xL&H_9&1&k!+%;z1!VBbFM=Y$wHoRC*zc!flJ0{`aMzcINQ7bm%Afh+Z zGxR{OEu1G?&3b^0ZLBedyCk!&5FN5FERUX_Fpw?D&AgWeg845$PIG7Wmd#(&ObE3csxMSyPSvjSa)=~Pd^^e zLmYTWUmkIep#5XBsy*Qxernbs6n#cKWIQ+Prx#}J$MKh})oZh6y*29{vfeQU)!&;n z?}J${k^Pa!*bc`h&LQYCYlyZujiCQ{&R{R{ele@ySLVT7Ec(Xt4$tu)!oJfl7=F-m z+`w8{bim!BhX#vMJuK>u$(|PdVzj6O7Wr9}Gmk~xg1L{|c!BF7+=f~d9%hj(+@c1U zgtQ1AM_M!kOYuFLcrg|&!2EcNiaIUYRoJ5AC{e_sDOiaAidpoyxJ4gOtE5FMkeqDM zW&E6C(H*o(Wj}JKS@Z)f(k=QEvr1WXv8F|JYgzOFqib8#xsF9XbuC(k{~A~{poK-F z@VT``b-Gxz85un-yq31;1S<5gD66kUo8Z>pqV|I=+A_={-zgS-nQu|vh4g2UMddLV zw=r+EMKAFc9oJa27tw1i>W5>9TxU_+^%h-0vyB#Y-9ntL^b9@mFKTVGX#Y-ny^DHw zTa>bgzU-yf``EwVqVWfadC(%SLl#}b#-kP`9<%5aemYK0C+H{APg)do%A(%rcbel+ z=nVZhYtcI_I%kpNyhR7G?E?8+v}ngA*5tB9Yq0pbMeF~ysL~CKR^stZi*DRvE$>>? z_#X8=wP-q)Amtf(Kewnkj^YD6URcx`yKn-@Ck5KZpMP+dW`QFec z%)%>tNBg%HZO2h$zO!fo<{{sEi<+V{E+h5>v9JUm;PH{Z;t(#N@+Zb&H4;A48w|r6 zWc+85`3o^I9S`vy-M^9-E}`r<_F*Y1eWxF|?{1adU{xFJz;_R;N_bi|9CuN}%c>># zhymV_t@?th4(4!LwK&PD4n?f`4;6}X zzqnOROK^NitM(>a6`Nw!C`?JU$}i2TH|bWHOIdXZ9vN2EK`|Gx&?VEV_4tg0Y^&a5 zM`^2mEo0SFzE$NKSalLX4XyeE>u|4;RsKz^ z+Jl}=*^hP2SfA!rHEThBt*8yVk+ThR;dOhfB05-g4yhfjDv!mu+KKu*vvysmxhwT| zW9>#-d97mAIDCfJDDuPsXf*4HDY$}sW7vnIh#X6fxQ*0tt@?`W30BR-GUS^` z|8R6FeVJxeeRxc_Y9ridSd}u9a~#gO#74DwR!zk%6rWEljK;hL)U?p5Ulv)_XfgRL z;hb1%RgUG%xx%XUe_Hi7_N}xkWVKa^2wKBA4*Ocpe>_LnI;#fbD16s*4&j##R+ZdH zpEp@`;xBUALe4O5qwnaloxbiMhn@6#7rF1Ys^wnR{{YX6qvVf8$E~V$igO2RPO}!5 ztO`a2xLqb6?8KQX9QQZRo$Ji`FL|TP4J+5ptP00WoWl*Qx9+-<7lVbcVoP1j5|HTSmZAzGSk%4MW3baW9i?5$)@bWHvNq~MQm~vCC6gKC~i|8v_`uUHm$@~+(VvZ;-FEAO|x+?&8CCt zHa%};(-$;rYg31IHZ^WN3(5=P5H*!c>dV548G%RO2EbO zHr1S9(_<{0Xw$n%wc(`~wq9y4sZK8t*3+Y~X!rr^0Yt(`}n3vBAX z!6vuO)N#P3ok!{OF`MG?`U1KBW7CiuHk~fyt6Gu1ifrJkBFNL-S78{8P1uLP9vp*a zDAdzevABd`zxrx2n)UM4GIZ(fs{sh=~Qw;RZDb3*Z#g*hh6A2z*qfH z>o?-SFo@&P5silWYTO^b`hdE_eD!L$ui{4dsw8HN^3~e0zFIks?Gt@#JzA#3A_2XRgJ*ss!T_UnMU0Ra0!m-W9$&1>;KQ zUhS)cYkbvtgRgF4{T5%X*~c|0K{e93^s}K3=;R#>;a?V%xFVl;E zd{yVRuZlnNRm~T^dijo8Kly6(H($+kvuhcy8SK19w##a>D?dj0+EvzW*9Lrqho4;~ zu>=kM?V5;31?+l{;X!sSLaAW8W+NfQu95hNIiYst4znvyxLu>sHo~sS(RLMyu`42x zxr^Dgu{hgH*mWJdOWGBdW>;(lySi1hE48v+)qb)o>u0-q)UfMQO}p0CvMabYxz@3( zOnp1QgWENrG2@!p^{gp#H@7RKgzyfs*a04eM|dQSI#-iko=X z!7jIscExqEt57Ydp>%cDG$6@H^7?ue~zRR|U^!brpyB;(4iJkYs?YjDu zKE2?)d1=?-*LKZ(&w8TICyvK6boy*pKbZfs^ZT1!_fY1WU8gbihh3l1FPERT;V?|O z{d6RcpN{7B(3p4a{Zy z^a~E4OgTTzD(|P@%H)Eqs(#vpuUJ*xPvJlNX$JP;WoUfS*Q=@>BJx zep>pFu|fXY8SJl`(f*p|@YiAtcKWMGVSg1b;;-zg{;Gxz)%^8e4S&_G$t^n7_E-11 z{%TmyUj^#>%ihFaH=FuvUo(F_YT>UHE&UbMnq%Aet6)2SMdKVgw)fXP6zbrwF_?*V z-TgVI{q=aDzpf4^&IEt8oZ_z+tNk@+jlT}B_1Bxt%yH0PmvH?D$0C|hQxJDfx3 zG2&PbB^}S9reAVsKJw?usWRw=!g+J@njoiY=gX;?j+`n~C#R;h$f-;Cu|KDtyv(WT zA9Ct1yh5~FF8yWBr7gBxnq<$VmuMZDOH1*lR4$!#{o)u!Fg@0Uy!hQZD&j&!wl2b1C1GTx#+(mlk6i zj==FUmpZv}YeK)=sx~yYvPb6DjPbd35Z)7VYx%s~I=UpcVs7QuCDeMGTYrAZtw-3E zCl8-z$fMc$@+e=uJZjT0j|#QTqx&86XjqRt>hN10tv-@RhSPcE`8|)Ox#v~yki7gZ zl~>h6^J*dXl+3HcuDmKxCa*f6)Y80MBg@NkH?QjD$)}T1`Lrc5pB@*>r{Bxw(~P?L z6xb)93ck)Kza9nUv9h3&*A&$9qXqT-SV7*S3{Z8fEg7Js)UUoh}=o4dnwARv|!Z(5GU6ZXl_0fU2MYDpwCsJ*3nOPXG4>4_2fUb`YkpH*ZF^(dhx|gcaC5BS2peJ2ODHv0xUxM%~!~ z+K#+)*oL@80h+QnK#Nd#Nq|Z(C1*Td8K4gcU(I%G!;JL-8nKbw@c{vUv2I%fR2waD z4CQtOXyKj!P2bD7eE~Xy_WN1G1M~!q4hE?8kpT6;*JA-HbS^+Y;}={+)};XD|A+O* z7#zir>jBz@{5JwL2OF^ZW`G7yD5O{LomfZ(XBSctv_OCCNA5X=6t|#|TH?UMLUJrF zq}d^X`ihXSKqcZ55+Vb&Fgj2JVgj`lx#9wK40Eam>K}~#DNu9KwpyU-whq)5s7;{K z@fvPz1GNMN+XbozCgKwov=7u;_;d)=6x_lKRP7k3Gw|vZsF7IEIZ!t-u?u;iOxHl| zM&oXQ>VPA-gt^@V^%!+}lFP4wx{Bq!0%h$Tr~mj`#x+n*&uEg|`H%;#Q7BuWf-^fx9TYot$udN1!V23{+Db z$GF{r>c1yY=dfuX`RotW@I!%mgdv9mbpatq0<|BeK^~HM3yhYyk0(JjEpt2tZsx@MtkoQy85~HvOrJn`z zzI32QyyloU^zCh+USivaK!tw{RQ}I_n&lP5=f8q<2mz)b74!~LG^&|{w7yV~>O}|X zdUBA=89~~Kzq5mM9}(q)w4y?gHY2`D5TCo|c)Y6}B)2+2>W;K}L8^ePM#S$Nr1S9a z&Uj??4B~S=LCVpGWBLZE&X6DtSwxJLL0YyZNVC=jX*uq!57N;ML8`bhNdKVb<{+hS z4N|Y2L27r9JWdB`>^Y8y*VQ1kyceWyu-y+*_M;$m#xoRu9Hd29{31x7@cmVg3~z$; z7#%(aX%Eh$#wU94HAugF4^l^5`4Obq3f4mRV68)8k6<0bZA-9%eS_7-KUfbC9T=?o zk--`n8?5*u!CI3VtRD4)Rkl;G9`_2CX;rWq91PY!XM#21T(F`p1S{}Tu1SgpSYtEhX3GI1W04Ix^IfAAfJJwntUA)X;B?G>U(V~FBS zA$ozn-XWR*i%*Cu;2W&w5Uod~B}DCU0FUv&8p5yo#PSW1>>+$kI7GMoLU^qfqDvU= z4AFF?CXol86%J9`A|V=4EJW9^sbq*+l_FL~h(2JMD?}cdA@ava+(Z4W5S@iRJ4DH7 zf#djwTBSoY9?#2!=t9{LrPK*g51g+XqO0{n)cTJQEyRyuAsRfKyij&Th`i^8C=2uF zhj1+_L~TxlaJ@W44Ng)&&Linm2=612%jpocL|-h&U-*IwXF^m5=h5YCh<2U};b$^E zJs+aFI0E~H5dC_Q-obX6zG5kCSE&1Xh?bzvzvPJ*sCY9(r*RiPx7n8vs=v|M6{<_{ zE*r|V%}~w99;h7qP`PTTI{qB00a#NbRJ*!`>ZhKeTJdYBHluT|Q2m8=y+d^teforI z2{zz9!uy7*Fyy33)u z1OF?`i(dE_e_jjKJ-DuiD((jPJP+kPj8HXsN#3tQ)#F>Jj-jE#)DJedFx5jV97ARI zFx5v%LzpgNrAL@P!qYQMgE7{N$N1G4rcS0X$vaFB@D9KEglU2~OmorA5~iVc9^;;0 zm@fH;={{=Y2vbuW%oC>0dBZdiukiyx`NMP)*HO6ud0;VqDj23;a1J-|XF!;?piy9$ z+F>Eu2Zd=e7GYgTn0CQ4G)yz`2#I0D#v@D)CoXbDgeer0@ECtZhN*ZI^P_Tfn9MO8 ziv?(&5T=%iVXEy2Q-5ceN)#nl@h~+@4%6k-Fg~vzrs?VQ0rN|d1FmL-@iQSzPhDa1 z$z&TI<9Jq>{w^J+d}YGqQ87%7aS|mfg=s1NL#@ixiEhopw7+MVdi+YSdlR#7n5qq? zZ@)8kM3|Hrb zTtO$oH3pXub~0QOQ0P>+h9dXHaFxa&Y{C=dzZA|j?r`qIX(^7))(RWfE6$41^#>$&g;Giy+)O`5ejP;q0NIL^a_=SL@0V_ zg!Ybz(0`~sDnbdPBh+w8gl3`2)Ce`gJ-DVv=s7CPiQs2Rgodw-&<|KvMX2zG2$kB% zu~-lLrU+HXQk=$Tc>NWjbPT}+RNWk*E%^HX+bt0)ur)%PPDE(Q=?HB=%$W$S!Ns!? z{9hZP*+{?0yf9sgP~OWCYIY?;T~PUIgqotjwFo`Ig@1^DJwgKz@Na~ABKSsxR^bY| z-HcGNTM;@5uiM1A6QKwAg6Vf7_-syu{zlRN*oLu+)KP@HN6Om}DQBKYwZqZ8k$Rs$ zQhf?VYAf0WMyfB|f+E!@I8rl0BIT17scbArXIrUAJ}Vxn+epujl(}@Io|cbPbcIM= z$1`-T7^yRrBDJ`3qzYGy)HGDB7s+**NIj?@sfi6DwW}p#TSclOyjn-f&?b`C@R3^7 zAyQc#BW3RtsW}+XJ5q7KMQS9P4~$fv!IA2WSwkZAZgiw>u8marjgi`pnwui^{dgqr zS4Zk4eqhnbNd0^^Qrl4fBK4rsrARe^E=Q^-3SJ|BL|$i(`;pp*Q@Nw~oMDto-j31= zd_~foD0RUVJVEr`C>6u+IDm7ga4$+*(BXcRUg8^uK8(_yM^RevG)gxS|13(~uoCT` zM`1R4qp?<*B<8HExO4Z%Eo2txOz6_;zCKiq_C8(Ry+# zTIC-`b1gPn$&aE{0ltsf{xVu&ubA_7w2Hoo*29m{3jP$W0iVhHzi4gx5v>=f=oX{G z?lD^G6{A~7GsVd49i#33G5Um+IbyT}uADKNn=3}`b8|m1hUa9A{tk*!{oojNhAAY5 z*T6Bd6pm4wA~A|68l!$G#6gGD81;uCEk?hj$0)8;jCNIu(HE?#9HZUnRwYKZ`Z216 zAMkAuqbYdPka-)$@Vj=5CgD|^7=FKwQRC?`nt=~9Vzh8(jLvS2(bQcrx`<)BV>Ar` zdt%gQFS+cC(f*S$(y172!~yg=9iy^O7>hekV^r)}jMlw~QK6SHibe3382NqWF$(;M zQ744B#p)O2aF10e0u8Z>x5uh0e#hSk^NUpy)?2BAn7#^N|4yTvMJcWNILt2y{@aI9_*W$vl5N|{Ej_>S$f{dg?`A*N?O{L4>}CJHST)`ss}4tFwGxev#i}FnAE(!+xjn;L;9pEQ z8>^O=={;&+Vg2wN6|Tmr{WZ?5Z}b=5Kj=BWxX1DOJ5JB=6@xwEbkj4A?~}yI?j5Hp zaPx`dGxBkohIi&T9kax#pMRV-BS+3SokhpIaas<~{Bhb2Q$(D~;4{1<<1`M>qT=*# zOq@#Zi_>qozCTWX9*EPSqj54EBOVT;((yR0I1#74C*$O}8K=?sahp8v#A)i?I90zF zr{ITis*kOY;xzAZoL>J&+%IulSBO(BZ2T6d;or%_7_UqmGR3REPrQD&#>+EryvD$m zFJ2D|#Va^4UIT*Sl^h(eS>f@ziqR4AnvHsq@oHW?URzNpHC_$in-;G?EP;Eecx}P+ zit&o96tAI`nXgK`#x{x9N&MC{UgMCfS-iS7kJt7V@w_h_uhsAw5U)MBHauQAN5rek z$an>eir1i7@!EmBbK-Rg|E`GFia+CZ7a6PK^$eAE$7>|g_Qb0)F2J!bUe__|M7)ln z-%09#|EYL&IvuY9XBhWSy#B!5>-6CUdEBK3$i5%1QV-&_{6)Mre~Z^ERQ?gqduQ?T zb4yTr#Cs&DlV5^X;}`z~bwihjZwWH$hJ^K3{@92PLRWFk_+< z^aZAv1VzYpguIs~=oW@9BdY9X<0T3gGsKL_{Rbxh?nj_E5MAe&}s6LAmH5OA> zC#u)lMEwrOx@YW$%@%|W@tY@PbO;Ir9_3?Ow^Iv zJbumNcZr&fvhNc$9cQriW1?obIppc?P%73K94h7M&{15%Kre^x86A2950gV}P|Mq) zr51Mm~kq+&OW?YOzBa1ln4G|?B z`UF$5LqRDHC17frL#@*t>V=u599sT=E{DFtJJX>}c#T4(9qNkT5L3pXU&}i9&YVMY zD-gS?LuaZvROe@hl50A&7CX_ZmP4*O4pl`H9LC1F4n3;x(3pk}jcd#tzc`c|`{3Wi zq4JpDoc!85Gzs%ju>*bSNG+Wm{J-YVoc<1e_hwFX7)uYwF$ZdmC&w8M-h*|h28^>D z`aIX66Z0JU2V>_u^kEVGUhL4{=(oh7&}9z2hv#w!pFN=mYaFs{bSUcx>FZszb+b(BIn*<^14KTl|WUj}A5c>4!!*9(5vtC2+My^gPh9Y z=2RU|r<&$=s!1Lv->q?SJ;=%TYMfe^ XQoJt9FY69k>e2`NkgPnX2(#hvIom{VR zYCbAPIyD?MbKzT8r)G6`@;6zWYTMJvXS(PKIwD_h z>g?l`e?Q_3Bo4k|`5>pFhcIraQ_qGw)p&$c?U83BHI8y>(P*dcjB)D8IHyjHcPeNC z{lK57Ink+AlbpIW*{Q&()H9v!GoAW6+o|(&oLVv0se$vTbw2z5bgIKjr>3rQ>fLIm zwAQJ1>zul@o?|xXo9a8J@t*aJ_GB)%Vzq(A(U zG!51Klhg#~kvC_OhM{O+lFC3qNwQ-Qjsz#ESV)p4#3X4U8pI~4J^n>#e3B-jf8ivJ zMY$qLs)J+jEtaGK7?Yl)xu{brNv&}efi8|mbh#vTDxai&xQF*xTY-ErzG9L-A**td zPU0co*aVLn8ST1h$xW1S>bsLL@ZSdTuy zzdrRgNYa5{l60X-k~TLb&lX7<*d|H&+tR0YNqlaK`cbn(l77bvROpzbCz#WTSY48o zhQBeYYm(+8s~a`+Ow!jrN$TAqot>oh$U7%Vi?Ia*HxyNa7bP?w50LL=301}joP__Y5~_%y z*n!uGd0j%yF&h`)^QMF{&;zUR6cKMrs3E4{6b$c5s3f{zDQ+Y0`x2@FXNi(ZDOpl= z(@Lsg(~>H9q@>=)Co3u;nePB5YZh)GC^1=0Fc;U5+mWnx*a@36Sq-ojZb`|iiov*y zBIT3$`ya^)uaK;w*nzy2lJx;sY9_0F?PPsy%(mvq%4(IYGHsGI6vf*nt1O;kPP=6N zgR$+IADJDJ^$Eo~ChIXi-+i|M6rMJdvz3xQP}glePa;vihD$ zR{tl|gpN;>d7n2~9?$60^JK1TC+n*vMa8Tsnq*7SF5eWD%bTLXxS217zm1WiY0ea# zLqg#cy~VeZDXNy7qS~cWGyyL%QnbO9qTkA-=mH*9O;PqwDg1w)BJb)cYWZ`DQfs70 z^;49LX$?};uwjaxH%?LHFDV+@Bt@>KDXP;tMHBI|O^Q~vP0^6{R-=Pqcr>APnj8v|Fr|Jhb%w<2y%}dpi`Kh|MAXV%3rKghTFs3OM>tXXwWoYVx483XYe*OGWw_)V>{2>z4`b|bm(Jr3R*Z0I3!02}X%~*;=~$QQjB}~qbeEnW ze6~x2P=B#YGf-)XOAU~^)Wv(^E=@w2O)k|!slQz6a?Hi=4K6i3?owAwIpI>_TP_Vl z|2r=2K*zf-4M696E@i)TX)ubua;Y@jUsKC_mrh{(7ne?B&{vlxpy)T3RwDJgOJ&_N zwG!71nS7Q#Q@uPgbr_FP)iaat`e$kZ*5DgbyfRfD>ycs1)I2y$nQDM;n1RdrGj$<= z;|gV}6D)z53Pk1q3(C}U?1{+Kef$)esSi<^Y9F1ci8zI_F`2rEw?6nSM35A$#Whh3R^iSC)1`WrD>nW}?*+0=~jr8CvB zOs2xhWy*=P8kuT_yLB=ZI*Izwcos1+d{L&RAaFf%qTbd_mE4vo{+OYxxOpN||DIyZ z=}gtaY7{z?sXxzU>MS~(&(uI{_`eI}e37{SQX{^@ej`)K|96u$!I@i`dXIv)GnI~? za05l}a0~al#JQiTt9Xs<2bmg&SC2F0|CE}r=vk%`o@Z(^ZeiVPw!g_#6*PIrS|i8% zObz~&spatbOx-y3U#4td@HJEC@%8_{Woq{KOjY}lsb6sw24%_MmZe3AHe~4#Ug960 zEbX&q=>mp_aZGrYx?mE{;2q{hWN~et`;l3y8^wMs#yvUI&zmi{fCCI1pxGNxoH7_H%+ z#(1RvUwW2qz|)nbIF!lEQdkx_mdnzV8d;iIGfR6BTPsUxX!U=!iB~5}yX$A^9uj`Z zQVl%Bnr2!08yT&$G_hlrw&FzBEWLqGw=9Jq8K>|O|MkjJP;Y9$SZu=Q0mK-brSEW! zWImJ|o5kNA$kMF&Sz3;d$op58Djm#HS3EkICEF=-IZrOQh?mHB0T<~Z?3d{$7Ge`_ z{NI%<4fs1tm#=2&D@xzUQacRBrn_0XhG!4y;iD{de4eGr`1w_q`s0`PS^5JhpI8@! zd?Qa3P_{}V)|9PkXl2gUw*uJ;Etsvgf!UgjDskEBjk$7U-NGjR};CS>z}Cpk>aRtnlqW?tB*Fcy(BvQ-&Na0Xtp z$pN?LX3IP;TO$@{Yb}gR$P-hSWosu|{h6%^n71xlhY+wnTV-)%W44a}ML+LkD-mTL zWUD>i!RsOY{J%%pI*ZFs|5wv}fLBeveH{NG8`-iEP*9eDh_Yn(2YPan14(*%TILxj zLqTLCy9lzSAQS`yTFRCsGG)msd&wx}Wm8awD0`Ioetoa^&vkvSG$(oP+|Qk)7tKkY zM5*YlD8BcOQV9L95L;33F>&E}5~U9_qm+h^pVC(>eHEoF?B(Y2as7Wsm_Z53|;A@ZWpi_U324LR526)tTphqVMdDLRCN8jT#Dh^>DX~@9Jp&s4C z@A1U>#-nspAL&u{(H>n+Ag?59gY7tui#VO)QKk7FEnP%A{JPkqm~Ctu7qDeJ{oU!& zn|t^S?e}_=e8QvMD1OqTMyEXLfLmuhDtykPDmZ((xwC7txr%`;Qq4zNwXHjRApZ5?mgB7@hF+r6QiJ=a3^l;371VMi zpRF=91&OO!ca5Ry>kOUv)zFqrhBA=4jrt<%c0;A{A)4dQUBpUd9;a||H+k=2`$)mT zf9>VC*k|a_0YmqY`yjQ&7l#b>!-&I%uAs$HLw7LpcSB2Y8_)6ZxS?$)3^{4^3H?qP znuQlAoNlP$zfK!Eho)zUi?Ziviw+l9AIbl^Xy}tme2%0m^a+KpvL8_W5Ay$$?O!ug z;5xO%KR9#4P{o^uy8LY@6P<4x++S^Qor^x*H5iY=&`s2RV5lYfKO|R_dqhrXhlwco zgnHtgOhd8ghLK1?$ESwIV*hjU$>CLVv_{jMUcJogl~vKJR_KG7mA&dv#jAoK>DBBHyxLyNtLw=3kypQ(uFfjghl{|;VVM9q$D7uV6LvsZti>gQgy#cp){f?Uw0i&vGqdiA2Om+`{! zwO4!bNq?`#jq>W?Sg*z;c=?{zt2r~gn!4SqZ9B<-msg7pc=baXIi4csX|F1rqvq$m z%72OeV@wA73`hR-Dn5^?efdpotzfGByQY4wX)3m{sSiFexu$K(`yW%+F}sPWxMrr_ zj56hGZK_!tQ&l>dy3xzjBh2q@s(2q$;eMvx`P$UuL8h_|Hsua6l{wT@$9Pk%zA^RZ za8vg&{##RL@$N`dUm*kAMwu!!+Eg3N$0IZuV`?P!A~@F6DHIuJDj6$~J;Br)uqT>a zr!;x?-Bc=$;k)lm<)2}yG{&LWkMs}iXVG7jm~Ha=i@wdFEqW!d-1vOV*njxWUwD)ZSw157^sG?kzW!bGxZJJ55Dl8FKHU zzo?7u*oibK)l@z-#Yjv+-rc4qBF`T3Lujw5n)|5xerk?0hfMW8Y-;@pQ?Jsf#U)cO z@zZ5$jJg^08F{Xl8iY%zewF2@@Q10TDDtPNc>II+ubDiHW9k=lxNd4LKD$BNo2K@l z*k9D@wyAy(SoYA=H3T1#8*ZZ8V`_>5PfYc|L2Sw-##7=W@{F9(@Hzd$e*E-;9A9#L zq5LaTL$MyCW$Dcd7n!{4RoR(JOKrT!5a$8D4{ydhx z#wEnPZfPGr%xftbdGlEsjH|HoTUrRafW`PV7WWERT2|On)6P=$prw2v zOG9xB2O`8n$@cUgF`tq%x_oA-LI+C^u)CwhwJu98x+4Lra02&GsI#Sy&S3vDPxcK?Axm#dEiehif@s_4wVS!M?+Rm6m${%<;I2{$R{6mQLb} z)t1uGcMbbz9d%pJ`SC0D-)O1CCQDMs_x_b!lM1`uLEoc7YD)O> z?_S`z!%J+q$T@R~<2i%=U*VWS(p5{x|FG2Xnx!AEb3Wa$^a=@oaqQe8FVwxuvGa&y z9C;sGs)Ltk_Jm_RlUhCF+(Vb=oNIY~j9ukZseC@QL5KW4jW6a?lj1&ohk2!aD*Coh zwJZ4a1fAaT>9u!#id6Ec?fX8B!BM2v^eG)BYtaTj<2DL@=u>CptL>A4`}KTkSl_1_ zAF~|3hCY>VM0|XSk$8lXjeV+!K3Lntr+avXHcfpx2wyXwe!~Y*Y#TKU*2M-qLsPF$ zV{rtpnZ(BzScvN=XAujD_#H)k^alypg%|j^xlg^Y5?4^7g-^{f5_|9r^=!6_4S0!< z9Uo(A`m_eOP{pNYNWvMs5$%(U3D|=yexDkkHx}bO3di^qg&|mnzfnHmQ!6B3Cmx_$ zEU_^M$B{G6r$*?F1-OXPEq!W*Q#Q*HK~HQ8cnTj^4mbJaQdfjds+u zv!iLB2wRCAc4E4Yt=-#9uo+|h^;jwVlWbQB{J9Zf-r zspLP+(c3?;?KO^`V#QiVThVNtqq*xHwbS{GtY1Lirt>J2ZO;lIqqguF(o$RU%hN1XSS8>P{@2Uin@NAf?_-|Y# z;vrII5eHLd69<*&5GRQ?$;3fF9N5hK7V^VE__xx}-{|8u+U#|835omY7pm-cHTr<7 zsDrKwU3BH*wM(uFV+I~xW}6w*;hL-L*In+ncC`=A4Oh!SF!AV z#pm*CY*D|ip=oiyVoLZm8P`y*q+hK|`E>_HOZyq4&9C3z^6LUVf7`E475qAkGw=9S zq%)s)Csq%?Hsf(mzY6vDtHKDs@{IFqPNH8cr}|Ymg;?|b8h~p^TkKcab$)fl+Rc7> zxA@ilH>Ugi8hqNX_bSIIwRMbs>ky-NI>o49zZf-I5~I$$Vl)Ch_Q&Y0V==mkvBzW7 zCp|_F(V$>JoeKw4Ats>Bp9Qp|V?aAQ1(et|phI}vC!oB21Dc8O*8xQj45;mpfCk~o z(123o1B#mv(EUjPotqX=^|HcNuXv2Xq_9wgl8?Ye1v% z3`2hlsNeR0itGsJ{apbq+)YkUI2IP4fQ1@p66@DI&gPE9^Jyt2N$0`HAa#Vms=Fap>v3>btQw`pDufHWV^wEQtQH|@Z>%Qo zi`5(ZWA*q>tfKG6s%P#v6)zH}dRUL{MdP#xMT^HNjMd0fB2N9$t!$jWDjz4iLY#(H zjMH#`oci^SlQ|(y>*mL4)!sPm!tnjXI25N^SK^eUmTH%!r3T_@otDaJwN!(yEmdMm zOWr{c)Pl}I?d}%Th@L^+?-x|3fk7R?*Mox^i=T!BHF{W3)4mDvJW5a>BrwIS?}I8o zIjFi*gPJofsHho1?#T{n`K+M+m>txO^~Bi_)X|MWZQ2x6o~=POLBh76wrvk;z}}!r zpA70!Mo^3I1(ke1$TJr~ZOj^yCtFB$bB1&gqw|NK>KWA^+b{EVV%nnR;ip}9maVi z<_fD;?y$BYE-#?mLXoh>VdTKDPGk3=Fk=&jwH|vgWJp-0hlbS#dE>)+ z6K7C)R9Kx+a&%Z#a2VOghV?1Nji)bYln~Zn)R-7nW8|9@W(@bR24dHguzZPO?gtO+ zEOsS@l_fc>wMfOFxnWI839~Q5IzEs7&1W5)z>f>UYPmeDsqn4{s}aLk5aXkEj(oVJE80pxvwp@1=;S%pA;(Xc-EmMD#a?&5P(6HqMWz#KMTqqWz+X zIpj^ZY=oQbF=8es;WAjjE=YM+a!?fHmKH_12M)8pxbEWFlp zLB-pdO#biRud6o>FLvztvgK39zuL5<+OoW>^DlVZ;qK0`p~Kx_!(lkX-DU9o zKd$R{HF@7h&NNbcx*g@|G-JGJF0UWr~-`RVr`EoF#G;&z&zvzB2jCPl|D74uNYQK`UhF-NS*L+Hz`MV=@WKLkTNZj;!zbnumRWc2sIZI z8_uEk9;we&$x|#qo3Iym(YSbkMqz)60R4-OB?HtKeM$u=s7!z|qHp;C)vp+!ewg)B zfIhYgkhyh$cH$^JZ35&+O*BPp+W;NG1)OOYpw#vODuP1Y0@S;AfJUHf-vB-D7oY+C z12hgp1~S(00R1+K_z*feK!H;NrwYbfTq0+ z(6(0rI)q}c1628IfWDdxY8GhF`7ndFxDDEmC+Q426mC$~j0SDO?o0;N%WTl$ECwY< z7}OINJO;IjGH7oJgZ@J4k_H_uZP4R#23aZ_)VPX4?UAE~K}E3-j+zFw!6J08#Te*b z-=N=`8Pu)0LGL>o`w$x} z{S9h_Kk#M%^A0p9_aKA13^r&7b`CMfHq@YO*glM$U>IRgG3>^`QQRMGP~R~Iy&TV6 zXf%OXCmE#41`WoFDddbpQw?(dM%?%?jo7Cfln1+T30-Cz6f?)50`m-7JKvz33k({L zDR3<^C~2ud8CMu|Yo$TsR}ueOgYse8I)hGO?|Oqe{?2^Jy1}5cxPeAn3^MIE=mc^d zpe;;CXmiS-7w3rinnBj<24zPh48sDf#gu;xnt98h=C@gM6ud($cMS@EV9-hIduULD zC(QHQpv5l?TKbk;-WhZcaqp?kM}tC80&8LV%-UfPR^lP7Ukpl*QeSEF%^>%G2KB=g z9Qe-u2{3Az!Kf2PqtXW%Ro!gVJ`A@QH3fIAM!D=pMW9u%QMH^#bws$!C@+4)N0bjW zsy!xR6E0#`xKWqjO>fjq6v<%JG|bOvRMkvIy+HoVMs>$$L}W3l5$0hRhGsQtbc9g@ zB8|F@h90BN!5VGUS+7x(V>phUu|~a#H!53#QDc2Zb@g*Q&8Yj?jJlQGs7yJGnwy(8 zxS7YOclnJ=O1Rj7thU1}N?TFa<~IEG88Rokdpb&Oh$`&d%fs898b+S$~oC-{h|&4{BpIkz&Z zX=|ellB7QO7qKHEJ_!xP=_I z8nt%2QU0Ceu!}r#6{GjC&-N0>QP%4m^IfCw4WmjtBo6dLrbp}*OnA(md%|4Ls0}`% z^>d^0y)df(OCAeYix%&Vn)HD+|7eu)lTiySCQY!KRLW-3GAy^7v^v-%tHY$a@H$O; zfL~oEjll-w4>c)Mm`Q$Q$jnddz~QVWZS$Cv!)wxh+(EqO&VL@q#BJ)I@H9Z^-WDW2wO9go*|$)b-*H| zZ(-6*OloD)5~Q^@sX|+m_O)lu4)p10Qc@?AqB>KzE+#eTYEq-VNwb>%R^0CIn1PM$TWg@Mw)aL=SESh(abf*r08)b#gAwF2_}`BYEoZJm~PVI8PshS zb-@Q@pKa1y9EW?3Nt@@I)N~>9qU|D+=40w&lkzSxsT=m-J8Ca8X#n;jXt_zomBh4` z7_e)TN#AgCGr4YI%s*J)t?YrlCf&o*gC?~OKk%VIE9IqoMRgiD7}- z2LJFtEke2xff|J`_%J$9Lnj6*VhZ`-6n0Dv)RGy2$}lrfhv1(RDC1o6M13@y7pNf% z0<{vi5V4S$QDd9_P;LJXRKR8G49k^3jky*m$Mrz<#Zh#* z5vbRw_YbwlkDGy-e~UG^9jH|g0@e6spz{6~sBsF?7;}(*cL(WD1f&a60=B~)9;99A zkugXevIMDLWRON<3%nj~;}FJ12Wch_BF#%XY(r>lkoqSEshuxKy>JnCaV9B9*KsU4 zNG}oU4^m-N#X1C}1nDH6qI_zQK45TKkTzm%wjkZck(@zlk~>IWa3oKVKIUVN{6VT$ zAV_fqgY|nu~uBUO7mu zu?A0(vkK!@3sPqs#`Ri3`i5cksbkY1y=obxp@W0;7xs>%9;1WQ7UjoK3%JG-FD_3E zQr}5IdOkf!pXQL`+#rpg7o_Zqv5aw71S#*zAf>JfQq<}o8P^19%I`tyxS5>)2vW)I zK??knw)=yWe2my|_&nz?2C?=*T91Y|S(nGG(Wf9S3N~w@!>s<9&6Gdrv+73EHpZ+YxPS+-X1&GpIQqqNF2StzIFo4B4Se&NWlJ)vWwKe_G0AV% zd~8oKt8}Va=kO1vq?xqtXZ>gyBzUiV0p9dqiY3jV`)XR0xOxd6$kMM zEi0R~x{6sJP~s=EUZYYqvsR(x&*XwN_=s)Q%_>)epIBMTtYx*$@-#53J?^7GL$k_a z8lIs_Bj&-q#%AUG#jN~I%&OVctfsh$Qq8CbzQNVptn4k!DgtLKvwlPNc4nE{oAnf* z(5IuB7qw=MLRe?BhIFOgNbY9V3*7BaY(342`_-&WeVGRb`csdAW~B@=tJ+|*8e!8A z`VZwc*1Sq$5M}Rtj8p?I!d`Des59#t<-UwSrf4m zcQJmuS%w{EWyCqm-)mNr{bu#VF9*!pe~6kNF{>~B#IHwLyJM^;_MKq=;tqa0Y1YWo z?1MARdDg6A=h*{)QG>r(;|pf(zC_)x&<1H&Srhz$9oMPj4ff7W_9QaiVhzy{y|4+t z-!|(II^AJi@bMlw-KVy&KcEk$VIMxA#=qnMJth_uMk`Fjb7Xm9Rw6RIW^WoS3N%{e zL41%!^Kb_h%oe>xh|QvM=wP?V>a=K~%c95VAIiBfi>AVs&LVdPi&|x}=#!W6Vl4WB z&T$q+CRnr;)zd8Mh2fZ$&7y(XEy|q3qH(yK)1vpNpUa{Jc`dT%vnV5);COzEauu+s z9eTl7$f8%MRNNw!w#b3z_#4g2Fei@U0(O+OXmmMpDNhWQEIb}9dQ+L$s#w(LCyToO zY|+m(EV^FXqLFnh+K1Elhs)c(P*~=nVZ;NX5vFHXe_oJ?O(w{y9EZQ*8qCA5v zYCYJZ7x;$NLo6yj)S?r(jCbfUjF^U7lpTxl1}#TebP~UgWFCCNv{4qd8EsKdILA;= zjK}^77A={`d^n9plc+QP!rRHzXbNK>-BgQq;{+aJ({Hq$W>H7n!m#PYIMbrRvn-l` zHSo{2=n5X8?i}vVB^K0~Z_!+2UdR~Ov&bUDVsc$#(OOuSSyUO%F?_j2IagRz3=Q!R z@34QRMQ897?N>49YKy|xSd@RgMP<+oZ!mi^dwC0EZzG2t7UkW^`oXx%qEaWQ^-0zT zm(lYS^J51ZoTl#hib-cIN{zDkvW@V>Hebv?^U8tD;c^Cs4VVRc%qKv{mCU3tQ2mj8$Dxx13dh<*f?Gyb8>Z z%T=tZQq`&k==zgY`_ZAARsHc2-_ZSMtIk)qs!t88^3-B{%)u>mtWBNkSk)9e@E@ks zW&V21kF97>-zrN3t1{wb6Xs}Y)%2EDEx|riYh_gBr0rOeY1;n}7szd0ojoR!aw_R2(`;+z9O{{y^ zJ6MPfdl?&F_gi)2fK@#X65AoGR-(dTtDeJml$s*TF>=QxIFD1C6RhV+YI=&jd5yjH zkCivot%|@$m~OG=cdXicms}C@fPDUCy&hV1<^LX8_1k0W^u(%x&)DnP1`ci4v*0^qfMQ#0_C#Uc)!}FRatF{j<#v7 z*QOn)7Gsko&Zcm*L|6i2qbL4IwCMoy`)rz%WYbDS`-u_XQ*5f2YEvsXve~o-)wA1p zpU#n|hzJ>Dg(UKBL|l>U-9vE$67k1)CaOw5c8Lp!+4-;nQWC zo?NwQ_idZv9}y4SkEtWJ;|oeWv1u}{Vc0X9>b|k5<6CaOqn7U(5AF{(U553eO|!5Z z^FJ~EXY%@D(|=!Cmv1)Z&SY1`%yva(v1@r&yDX7*rFrbSh+kvuij1@CbG%*0lk9T% z?aGXNCG6^gt0-8~u5uVy-mW&4?ebKys}g?25}bjnu3Zt>S)YCl?Anhv&F%VuCN1ph z18-})>R}Vww51=)wYRG#3U;t-GIDmbYei?fzN2avyS{d_>q>XK3iYt78wMeur(G@j z+tmY}0d{>DY?pC}UA>3eH4=ft>?(@NNE>cfVZ6oMY9*V9a z4pdyt9GHa6YwSuy!?mo*FH3#8k?SXhG{c(IXsZL(`PrsB|MyG&ci6@JH6j5|!+$Eo27az4pkMVnKMb(*-(*mV;^0H-@`ycx_K)qV_JlqB)ULzG{fzNY?73Y(y|C*5PP}BTUfVV2tzGX>@*REf z^Lx7%e6Z^!N`2%$b|Tv+_7L=$HAGvSLDUx>GuVfWU+v2Jjd?I1Oa9|=hv)c$*zeQ} z#vjxiH}SiIb?5lrOObkZqeMv9lXE|FF#{~6&D*U zXI!uvU@8j7b3Y+iv#=cBeT;!@;_S&Bub3c05?8@zV)nI!QfI zpAq--U^T}ve1Pdiuv%j`P9pEiU=7AZq<<&S5z!eWxCHU~tG~bf^t> z;k(J9e1Q&)!adXoa%dSoBGv5RIiW*2Ee;LCGZe8pG!qFnhjO6}7Q$(Fs4jLPSFl4< z5$teijnkpX5Qi?|u*;#OP>1Hi73R<(4340Gq(ea-he~4yK44FjLsg<3YJ!elhyF#C z7>CZ`0TN>!s)u2i66er%+(XfLhoTaQ9ShMl(V^l#haTet?j#Xs3S+{Y>QI?9hrXg} zHs;9g(9#?Zb;#w=7gWg2?Ys^(%}4wE4(%)8P;x)3qHeHopEY7RIH{$l`$U2(76`%t?kfiw5j9Jg1QbBs^`#pMAdhw zTmy$rA*!K6Bd`JY8#xr##G$?D*_89x(2VtI?ohK9#Mg@4um|bdFc)68cPPGtL+4Sb zqeJDf6jwWue`nUN3psZs|8A_^7zfW)9GZyF2pUVAI0%hn9Wf1;k!d{Va103(h!J;C zXd-bT^CXA9q10rDW@801O`(1`Hl4c6aHu{^GacFt!z_mi&SsAz`+UYmwFM4M$8F?Y z$XFPM1&hdOu|vNsaj4N!;#tO?SniN}C3CKFsQqe(u3-NfhrH_?N<-9o_BdR>v;XlN zu^Sv3f@28T$R5Hkn;go&nL2NA=;R;7w2hcy-a*~bWhZsrMGSvZ>)ph@$Dx+{SpS1O zE{+jDmYi^?)@k+*)}LW5E;QG_iea>7jsKrb6$Sa3(zjkQAJN|!p&wlwp zf3*7OQ1wp^_5I9TxcG&9zEYR(JO<>{zXqo&nVgzzcIukNspeLv9-^h)sqkQ@hKD&d zKAlq&!<`zC-l@A8oa&j;sag031v5F-0z2^(6Ei!t52sePC4@;Id^ zr}qC}qEn}QPSr|s%9P^d^AxA@XLqVd4yQ`xbm|KB=5nfdZeq;C7ia7PWl~Z5QtgTZW+Bwy@y;H#*oT`B-IMmUpgWZ@LZF)F$ z6t#bK%HE4SdozC@^6Kl<;Qmf|29nbt`r$Js40bAMC^a1JRId?ERUgG%C@|Kk+~YVl z-lPNm|)B&TXlcIq(}PjTwqRAQgzRM+WFEt}y~m6=Z6L62EZ-IznX zbDfHx=T!83r+!~RoQs_5zR9V8t>kggsXvcV=i^SL;Pv0cdflm^H=Q~Y8KPPVAxdZv zqFl((Jw&k>f-Tq&PY>Fl86tazC>a+q^4AdkhGxA&v;tjvhiCwz`h+M2!(i+iA{Vmv z3sFmSL)ZQx+JN2YG$2I%P-`ILz&M!p=!izcLNswih(4h1$Pm366(axW5aq|Lu_5|> zLWtH($h`$SBUQK2~pX7Av$_6L{|=l zXx-ruJvDUqL=T;^;3w({THIy0WPh;HKU8?$SygY zE@j5p5SPljT-t<>Fon9fUd5$lXc*?w6gt)feXD!WweCzncA zcd17Wmp;{W>GxVLMb{?QIxdx|@8UJMO9L9yuZc^~nlg8Dm%J@p`q0v)<*i(LiehbD z+J_&=-;Ug{0k@FY-lbur$I>E*ZwV^k9NZH7B~%bQ0rCA+M<}g-vs*HQdu( zsyoA_Y_nWyiEdbf)Oqy78;qFm;`3{4^A#y0$W#HEhMnD;nqcG9IBr(LRg#-#?Bb&mPZyYw7&Zn!k^woC2rxMaTTQcv{0 z$FYah`H@SzAJg}Vi)*A@y84tly+>xM>B-#SjJFY#OchTY7!Z$Hc_GK6dkH~Z>XN&K}@Lr zj1AS5xKJ&P57qC9p<0m~s(t=Y&CU_3d3i&%J71^@+!UZ`^X5~^wgLN#V=sD7Rvs^t&q8x^KMqr+6w7p586!n71avWF>G&M@W86{b>E z!&D8Ms)gxGjWE@%$xn2u9j5Me!_=@|n6lIlldDOXZZ!?l{$^o%)FMo)T81gHHEr93 zDQmkh`EVW`+lT2sB0Gd>JZ7U^_b~Q!m>v%b)74RoGdWBxr-kXox-iXKAEqO}hv_9E zHizlimN5OcHB4_%V|$o3BV9OOarck=@^2qhpFI=Fs=ND z7;lAX@Vzhv{TrrfkBR9?nDjJEjb4OlCQf3)OYXl4(~TeGil5|Gcz|2uF&oDXZgnxb z^_R)5{h-M zxBBAK?pD6))R~`=2l=yw?332pVDq#gSh1`kL}9B+gdEgb}UXT0Fw7q%m$y#(R7jM@*C4 z>W;TF8Gjaa!&_*!Tct1=3y^t^TU*d&9&3qDC_10}c#pG7-CDk$_8S;)2ghLC=~kmZ z*#mfm^1IzygZs#}$E_*IyVtGKn75A{4{{zW4!PCr2>T7AkGqxQgj-F&y0s9QGo(`) z^g_;z>3F`HPPH?o)9h^N6j>*oX0%ABi}-OMou0f*r2`WuM6I{!wfbv%J;Lq`8Mvk`gXU(+piK2Ls7=ERifo%f z4?1Sh$Q~KgVPFQWJDNepGZ_^4J%eT#GOD*XBd_x_>gSk@T8zE5EWL1InS+(+5 zR((I7mFp=Y^fP|XAE6utB2*T8aSCe+MyN`m2%STn!Vx-v@h-BD5ZTDn{rga#Ut)G(hE_BUBFsYcf7w z<5jZ=m1q;8-W?;9uUmu`;u^xcM<@aF(YZ&2s`ZM{P)x=*wCqjXi0Tue4XDvKLMJe) zUxexocB0kj2zAF6TpbgkhnO)oLN~@m zC~RVc#^NqsV)~>Ay`RGIsS#YO6rs%s{*BsTAs)a#EkZ4@4F6))bowJ=1~o$NnGx!Q zRoF8tLSKVa>^BNTZ)Le=pLE}-Pa2xY#`zQA}K!_XTM+KtRNBQy`2u0eYzW=bpNtf zQ1)R2*D6J5`xE*+jZna|2zg&J2713Ec2s*$d>@$iGjV;PhS>Hkg7?QGbo4v>=LdO5 zMXCidM@PyX6R9@Xjg;6(`4S@)ku6dkaS53!N9t^qNFDkqQirQY%1|Rxd1`XJR-}5@ ziPVyT9BJ~X421IJ~z(`pJMancRQudLNN*fi)=UI^&GC5MO z5HclFS?5M77h0e{4j}!!Nck5r7Y;6tRJNs&e5Mqs5jcvkc(X22fmIAv{70GpI zky?Sm*CI9VR-|&jiqu@MN8jL$^(YM&k(%JqVxLC?k~~~?yU@3WN5)znuB-4UrM5?t>UcE1u1EjjpL(2Y;8AA;H1wzvW;XJu zz%L%fHSx&M)T10|hoEL2t%tk0M-||0K|d5|>CuH&9@TB_(Ke`!M@8@&0c|~6hOF&8 z>VYZvghlN=`W?0o9+kp0+{O!3?MQq$i=a*(jlrVM9^Jx}F4O{Lx_Yz+jk|f&0Y`BW z^SgWW7iqmcO?J;2rltSM3!c@({v zHnqL3@dNpGdo&yq_joiHQF}e=kMr2F zpWF@*-(im)VdxQ${)YFcM+b1?7~>%HIQ2(MyhrI1jB}Fp$Gub3^^8ZgE_jsfqDRMY z4dX6*Gz+D#lJhn8EH+~HZF0L$9sgyYJoKnFlAn;W<= ztw%4h;{*Hnqeq!Pv;Tvlxb8hlhY?|kQdVn}e5huR(#FUr)$>K^Mu8~Vi$&>ATqzZ$ z2Z%2prBxN8v=u2;qWJzP?eVU5lmhBRsXGeSi&6!YY!szh9hjqYl>WlIu2Bl>&NwL9 zGm7hU8SmF9x%<$*ZWL!i({LjRB>~Zrs6tMw?wJt)+iO(9;IG?MycH)<~b#U;_f4L}@>oJdIM(XHnXMPtT*2`vvvDCwzZJ zE^ngr7#%)FX)pdljZf72TaGz+d>y=+zor$9Lp3dDS1@K(9&%d6i)H zD#hZ}3-q;mH5tJ+uPWd_IP6|+L_)Av?Qsx~@vp)iAF% zg?qI(+RN*6uP$O#cCTilP!8h4vz%VF&E?gvXp-Bj(RsYOhKJaa->dy-Rg}4kdG!G+ zihE@$;Z+#M;6Cb?^y(a3rMz4-?^O$&z<;P!+N();UdF4x%X)Pi8OnJz6@9CDRj`g% zJ@8juuddc3ACzn0)hfg^q<)ROTG!aCN56PAyopzNno_f7UiCuu<{ZcT7GC{m>D9?r zUbSrPm7$GSdD~Ox4#e7tnsgzDZj9UAtD*h9N;kl()+4;U)}r4?uZE1GJ}5ids~YHs z5o5dx81GfZ$*dcSO`)!^F7T=(7B2MiIf++m5wX~-MN7QewaTkGtG#NshB~ifj`d!J z{?7Vr^lHgA^4srKo0DEX`}L~9De}i($Z^`sH4)VG4Dq8cR^ktQMTN6o)xlrra?Yzi z&wF|9MIHX~sxFSg^*3vHfjt7}CH4=N!+F`OENG4mXm!J@WvKHH@!E4qlMTDmE#=xV`TXl zzQY%z=M`f3j%kcKR*%sDtgjKHKhd#PjLfxTbO@R2(yn0)--U?Lt!6P?M-U@N`xy2_ zjPiGk(e7@<(KAL3vFg_tZAIr^G5Q1TddKJ-`t*s>GHk*F#Py9)PRv7UzZkju$7lv_ zpvnMZ!DVb56r*Y*V$^gBam|Y1`k@$Y$7d9q6Qjeh%#BeJnq&XG7=D?Ob>17JjQe8L@>q<9<2*_p zkI@P2J`tm*_=MIci3LY6^;C>LVA|;zg`8nL+(w_X^hc3%&X2Fv*v<^G%VSc(A` zXphg>a4AN25q6n*(F_0J307Z=(R~!Z5hMRi>W{VQ1CNIhR6?r552j=@6qgG#H)Z@Px9Y;gOsvn#Iv8snwIF8DOSk*^%eA4g>YOoFgYX(Z5S2Mrr*H$6vk()O;-{>!`UU543#%hywGEFWW7WtLt9Dq7 z{86#`4NI`W8>`(2jEU83q{T8e9^tn*#zlC1tYR<~kMT!Btnwx@KPvlTWly3l7NL1+ ztXihUs&=+m_0JxwE;+~{7vtrPRkH%Ix>P7u1q;V&W)bRwg++-0SBu5+dmvU%i^s}V zf@64$6D4DHrF5(^m5G(9VyqhD6!KS!)pC46t;*zzZp~tKpl7Ul{7UV6GiKjdRU1O> zhSPU+tfr5TRf~zSDmR^ZX3=I%td?QqI%3)zt0LE#?*)0p#OYhZIMrzsrcPvd_-jPIMu>kPMa+%kJ4$hygzNL-RCa!xM&Tg-Tok7h z_;qod!j{IV;PNc_r_vaVEqH>=7vuQMJx+bF1)-PYbPLZAdnHcyuf}QNwK&zk&U`oG zbQ!sB#>sjsPJca$Q}AQf>It=a8mA;QLD6S%>W+-hBwxpF9Iq}&xe~7xsC+eEO)&{suEpyKs$FLtQ1u3DfQWzM)f3S- z*HFjn3UYs;KP+G4l@Gl!K?ypBI75Q0#ssBDPE&#mfeCtmn&t#$&yb*YIF>O%?=y2Q zOM6P#z_6122(f;M4HRbsA|pcz<-Yc+_u zW&+<`Nl?{#34CUkpnvOgzd?c);2pL#Oi=H}3EJI~`C28YB7#~c$k--<_f8VDq(g#A zc1)0~Q-bDUK<@o}luZ6SNaGw-r5s(vm(J5c`u^+BbJ32FdcN>EQ^y+)o$xWOC`60{$u(NO%?C2G){L`ge(Hj1@S6&*=1lI6o$Gy>Fu4Am^te9DimScXe*n0+dO4w#QKFj;&mh)!6BiwLs%R2Y4+1~=fc`BV&@u^vtAK6SxI z)NuGz%IVYNaGyRPGQCgU%syqq6ugh}DJ|NkabBNh#Q4MIU1^_Ip+Om++T#tXmLvZ1)T)wC z*O6M48djs0)qQGPgM4dIyV}&Ku1{<0`Si9v{Tnf6bD#RP@M&6mpX^esq0LihGOq*AK$I_>DoM><}P3z7W$O9m|Rx+ zRA9AFXHjB}PfyqSc+SFlq3?R1oEuo9jXt$T@omh59NTG&V~E>H{=0n|cG;&Vw|y%A zkp3v}$fpVjdF)dJYCZAk3syg6KRoy8=NIgqm-IpGE9(5(r`&HC7iVF3>(j%JK1F}> z@f@19{NhtJ^uU%MKD|K2fF$KKB&isNV|h@LZlkazNp@?JGGb>~l0IRLJ4w4xJYACJ zhbQsbagzEVAVZR#Au3~%YGD+5XHMep0njH)lImtn(oz)nB=P@dlCDH0seW{lI>X{k zQaGw$DgH*WxFl7GPvU)wBn9V8Qkz^!iqB1)XpC}slGLvtaiK$@B=v`}aFTv0k|cl8 zBo)9md_mu0NjhF8NxLg0=_}S(PSPH9tCA#V{UlYw4}>&G(loqjNN$aYxpk7J;#Hd@ z-eXSECR{?}nMs<353`cAcy^M0N9>#=&BPzelXPx-64#0+Y5MLYUBJjaNt%I(z0_(S zdF)Tpfm2D+=_GB&LG(J4q!CDWj(BheN6u4&zlrO5k{;aR*zF`uxRa!c56JN$YlX5; zhylOj?$adYd6uLNFOn4bGD*pZ{+guFZ`?`qo^Y{z9(OqZ-lC=;HnB{+t+Q2J!$Lw}6LcT~)ftRJYDFsU5nxrIa9d@BaYO+je z$!dlh$eAsfYf_T+36AW^DuA+>h}(F95jm2z1qX5_D^spy6~!J{b0@1i*5Yr}&XcUU z7?v+t;RTY_u3)nMK#M}jDpZ&;QL#v}ZoyeJS>5m%Es9Y;%q^a*|4JmQNJ-)>oy`Af z$!btOS+VTtV(Fwkeb8ZhF$RmF%3X!N}Ex@o)kO-IA5AJ9QbHtaQej-4};wRb+pv0*{7_Myx|)?iVxdM{4asa>4k!+C7j%XyU9$NBxqYJ4DB9gZby z4H_L!R!3w$!P=bR=ULVd|6uaDWVO7+TA}u3)*a7L;cBwlUt>@H$2!3JgSEj)43}RM z0{r@F@bfy~uV?s%Att|W1^W4W27awUF0)@Qt6xI z>HIo}e_#vu^E=M3>?nc>h|S4O;vIgA^~)0PR~dYUHNmfmc$UbR zNq#*=LVns6@ar-L7xe2btYsJv!^--VT+Xk#75yq!$*(;>`xRf)&-a!6%2eC0JN5jU z(|~+`@he9=zZSsO-mknJ$gPuKQ#$*(#=x%?J^eEO>eo0N?(J8>K7Or6mcD*n9OTz? z6dU4K^`Xp*lEeJ^gto)|{9Qu7Dvb8)@mRmcPVn=Yw_jH#`PF>7Us)IU)oYQT-*bMI z-tX5y+&IA42mRWHhd6x9FXM6Qi6f|V!mm{){n~fRuQTwS_Ui%uy+FT@{z89SiiSHetr4$XTOng;RR237Nr05g|Hcin)gf~l3*XAkO*&>DOdsDOywgD;Hi&HQU zOwkHl8EsQHnAwPSKF%9LI!}Df(ws zidL;o(LEGfOC9hTxz?pvQ4s_c*nG&Rndrun(jR6Tc^{wk8D zLB-QF9{Ebp2MHz9)V^+-TGdbE@4lw-ca+jJ0y!F`Nqy5)3(er{m!>NH8FxUM#tu$X z!y#$vfW)C`+CPQ(r>1EMTK<-%Av4odV^*4)Bg5=8)tj59K13brru%?$s*2V){?UtofYL#l(n}J0%0PNR5-UupWrX#ecz;Ec}?nDz@(W4c^nCaOj?YO z3!8MmoJmK@oAi4{##J(DbWM|9qg*|co*}!{q*6AMs$rVLr1o(p^}%=bO<8+U}ty+&oGzPMGutKb$lv_K!(>&(YtDCVlwCqz?EJWuBV! z=`)j#J~!#^E0gZMp+{KymKtQ%2N}$2n#HV73!2rckeM|p%zW-(W-SV{RuwVpd@-|Z zCC!?MbQq<~8eQ7VnoMTS5j69;fLZgB8r98efLr+7WY!$BS>YOHeO1S- z8xFJj*C)Q$tW&s#Nj|fl_|3{3FsmT?qrG9)w;{8xqj|)vED2`TvST|wNHnVn_C(D( zoy^>gsR5aquuoI7#y2zTU~{uJ#LW7n9rNOGd$YdlVAegn#?p?&?nLY^W>xFXTzK8X ztXaLxti5ekhcC>WFGNq!1x5N&XFs#@4I*-Sfnbmo@S<_aS_2@^l^pjZ~SDAI}XZBr9>@{XZ*74YSvqo$(>)an^)*Yko zf0`A)&8+U*IX*i$X1mNPwwGhLkC+EIzK6`JaM-NSQF?WZ8ctBtN$NdiRyq6)&uO#z zoH6V9S+nk6FzdH#X63zZR%@i=08YVugZo&4_?u?+z(F`}nROhGvFx^4raR>JpIQH6 zYz7PO4_FkB&B&73!nx-bjmT%wbR^`rs1**Q@P`(CgIXmm@C<$J?jqw1i#|g)97O$@sIKavJC@)g z3O}x^B$(^gldWDoHFMNc>ZkQod{;d^tZG$-YF5_Bv1%61p;UFNS|J^$P|##mM{GhK zvsEeh2^lO_MKBDBZq;zq z>0p%~w=k!pRi`no6Z6B>*{Wx#-NmXKc#d^lt;*MnxskEARrxUkkH4^L^_N!d_|~dS zW2}5GWYtbI8f(=LPzfs*lfGS$o5(fj8+Ry44#!^F?f|Lu%6=^eAT2d`vgn z^f#*2u<0RG)27$;Y)Y`&)TBOh;J*eot#;b98MiUmXVVc}k1&5c`(g^N<4}T4ITCGZ z8?~{HIq_Q9WX1Fpn^IG4>VS#3lV(%-mNpG+pYO)7myRCAPJxX?vR{ z;qK=)t>|FW23){bov0HV1P|!U|_>Q>Km9A0nJf?sX=2}h8= zh2yi$#<>+XHQZrS&fPW*+QTu}Z`1ArHdQ`o(}+Vhxewda=!i`hkMh_F#^L!tHqAI? z<8wiqTAgO>S)2a4WYZ_N=mF+p%pH1nm*f1*rqj=D+Mm&`Qkm>Jo5ij|S?yYw&8}5A z@t$4za@jStu${H+?3z}}uA}&-v|ZCtqKsYr%GwqD*sdlhP|>bGD%sV^Yu7TQ`s|!% zVb?>%2kgpY*!5$AUAK^)XxB>AjM_CZ$*$(f%-e<>U~OmDRXjwa_I7?}v2(tfU1hr1 zHT(;^ntf^4E7b36*Y&}6)_Z225q5o#%p>jk6Nm5wzl>s@(RMx`w(FDWcBNs{47umff8*>wR0-`bS~Rt;4l%)yHc4lT*(P^GL6wMVgR4pqj_$dkjtvThFD z!uvTLI-A#_#|0d!UeKX2g&e9|*dcdihlZkN6^A_7i}KYRx{60wUEQH9CWqeEbf}ZV zp=C&obEq>OBEEq`uaMK}&_QH%IkX0)gAS!3e?y1LU@5YM$O{=09kOF))S+;aLoF~A zosx-<)W*ceL&P_wj%E&J@8r;5$l2MUc3m7Q-qoRsh``*RycGG z-~C9AFs*cG>`xBWTjkL14b=UcLmRLMk&OF-^mNRaA2214R<@#6yH9iz9-c2 zlscYq{GQX3@^Na5p7;yt72@;;e^rdr1+=Xcr+byzhPGAWv<5HmLDe{wMn613zUpym zfw87I&gF{JAGmIgV?Eb6ZN%6bahiib%{VoN*&3(CIBJj66+A*_N1Q&y$EXPplF%Bx zFdS2`2y1a4BkISgm@|&=8pX-$iQ{jPICb?C%ZSs=V4SKoiqp1G9BcZ=srnS=N~o_n zxf-bKga+C$v4J9!8*pAu1NEQQK>21g(DySN$T6#dj?8YL_UR4uc5VYro8LfH7dFtA z5>7QK>C}IvoLr~C$@_dx{fJ8yoZ42&sUNC2Rk5~HRU10h5g#>jGQU%|u_DPSSF%&- z7}?yZo#@-bsZpq(;#85=#753GP8G#PtnTDg*3M34?!s6+MwYJ3gOc5xN=4r8PL;xT zSbI46ozST^{hZo>75$z3o#W*5d8f?7oQlK6Zx}n$sl&L0A4WO(8RJx|F;4xCy|^{b zsixzd8Zg7DoA_k5Q$x{WkyA6#Xt7f%urG1)-9sne`F6^;)~Uv*zs{-ddz}1j>(r-v zo$7(9`<$wA!KrUB@RCy-(dDvJgV61YQ=Yp{4MVMaPI-~>KD9h{Y9A)Nbm}06zH(|J zYQ1)9IqYwo@@I5uIZkDAaW210eKNbW6E_ga;$kgFm*!(7Uc;8vB?CXBK{l7>!j#>m z6!gSQ953q9krM3pkxN~XtE5XM5qhVTOLwrjoJ;>AzPw9MD!A0CqDzx-0RBoY9mPX@ zWMVts;-Z;2HC$X%z@d+ zQT(Dyafrt`l(^(lErc)?=aBKTO9>c*j#ua>R{!hLKe&$^S6wOx560u(4VMbur02+g zi~147*I0PlrD}IvT8|4@b)Ux{xD-aKM?6RH!DE+(J#%R(4!m$F&r6pMzjEmn65cW| zGRduqncUieyEvWGt*yD;I)afOyOrq^x4L684&f0J%DI(}n|M^-t!5S22aB*3Z&9F< zTQ&^F7>uv%R_!WoZGfq&TOqWm=GM3Pu)162k?@Ymt@~JGace>ix7OouO}Ea}cI#{% zxANC@E1S)&(rAy24#p$yojAA7A&b+kD)7MPa_eI^c?R5?n&j4Z$!={y<;HF~(C(ck z#BAzT3Tm`)>knK(wU%xr;Tl$c=GI9xXz$jfE^hsbeLdWIfSf(uDg!GH;3;18ajR5c z>cKdy#q&YL80OX+I7c%t0^{7Q(dgE!d2TJmQxsn3R-^51^}zN0Zsj>ZE{DklM{yTL zj^HT$MBd}{77MTz=iWKt)}WJa9skFzSMZ*5t0RVC?Pa%4;r2E9dEKopciftS=smXv zqUB?^M!@!rV}vrV$rHuokr$P-dz657?|JmPm`7!cd(@$%M^g~4;!!U+s`EI`TRh59 z!=qR&k49ojJr8Swc$C%QkqOrtc$ClS(N4cd_fRzAQ3K4tpLm?$QL#jidSVXhC3}>H zUvLrmntD_RmzsN&tA$7N(>&UR37>knW|Bwd4jwf@#?Bs9!GRtgW$)vW1tkV~wP zJSset?O%IT4Trw*=sB$4dejoX;u4CF^T>toupN^pdiZ}VIZX1%h7MDh7kQ^L7UgGp z6vAR0Le|;jfQ#uKy*JmRQHwnK3E38tC#HSx(I&K8=FvpVUFFdZl=#^rKX$G0Xzx1u zdC8;d@Llz&6CNS!HTwC^b&vjndyrx%WYk8HYu2*$&-{DoUIIlYUy}BImszcB#Z=zRSF}1l@@1=M( zDb=fw(!5&I(yN3|y~^C$t7=%<$;;m&Uajuxm9x8-^BBF_`-NBc(B@08`e4C3eY|q@ z_3CIpuNw9DY64E8+yL(57%pMuK(8L)uR+8a;?)UM9qv_@5nf#!OJ3>p23v3#=MkFc z)v_gwL5AmeSPZO-^cm!KGhxIQ#}60(?LGv z80^!|uY5X*Lc@KkjuAMG+F$$BeS}Xx;?6fdwHW2oP;5lMZ@C@gV_gcL){pb4$7G*c zO{XrLLzWpnl|Tsdumu;;Y^F~QzVq>3qffi$QQLeU>*La=1w6LUC&%|b*1`3u)KZ_` zpv^KL-)r{ChPOY`hm~ww<A|D}ejvQ^a6Gb2SR0oampF7R^y_DotL0Y`{;T6xwR(Q-cK8*DBQ|cLgwwC09zWME^y|ZbpEV@?tl{F<%0_-| z!Y?7esz&_ki1k>M;8!fsulJ&URl*AF!F9As@~amPpmH+vpdI$(2C_FME=o7?D-NkR zgXbvO)Gr@qH}h*F8a8Jv#$qjwx8UEY)Qc-v9P?{CJZXNl#0adwR@`evA3pPQ?wVhw z*36IVXw%lOTd35|ujbf+4(-VapMUOGg${nb?&atDrTD_HU8w)1U!%VEYu`w}z8UN1 zdj@{Znc>%zEq-nOlRCEfwPdef(~gnjablkItLzzif7Y)&7w7}Nxx}%%pkUL0+|2^2*e0MG-2-}p zg*^f))H9%1?|?r3BA}=J0?OP!pxcNH2HZx0?IQZpkf$>g5OaqTF#<&6rLU6=NWa*VJy0*Q|Da9EMlMU$qn_F29#l0K(FCj z9?+*N0_uh{D+AiUDxjt71M2%rKqF9VQ$YVBv^l`}d;w+K5>V|w1M*-wa%`h!)Ik^g ziDS_AfO5ly;h2P6I|3SqoIA-6sk;I)?PeQJ!M!J-c+9{JJVmyB0sV|q`vdB6AfWX} z0(yIlK3xdt4Su-DaX_6*^aD9B2hC+cB0@d`gk{>-j8_faX{CQ@`Su`6P=#YZ@m93psv`5-<}iW1@V#glAK|G zMSa+VA6}E=8=i+K^ERM?SdS4hR6K*hd8&r4XEd}klfmbhhRUHx7DHq3YgR+Ovl&{A zz1a=b&0%Oh^5iu11uh`@Jwv-uBbTAM$d%hre_TN*kDGAvu)%j?3@y)ZDD4A7 zojx@519lWNRG<*CFsiVjCq)cBD{5$BF+*P#H1|EgU`GS1?n35w4R~uSnn}-AA$M1swswYry3fF+t`~%JQQh3{YY#@&iMROLuEfR^awjz8@yj;D1t5+i&Z#+ z2gujfP)#(!XzWD!b{t3ijVkR8rK8&ChJHu)4)g)}I+7DIbz(mJ(AiM9i=mm=g5zBc zebkL(gX751!%!p4gr%pU61@zqL&n~Q3L%ISa1Syx3Bv~)x`_N=kt-};)ALb=o?`K6 zj?1_72{%xAjG=Bgg`s2F2dl=>r}2gs;4CzOTinEkiH5dLHuzhMK2N20NStP97wS&u z_|2eKGkLzwroME8bvfw^O3vjuJg^G4luRFXMTPBg@J4M~)r#t~Au+ zC!UY1s0ZKtZ0IQ3uQqfHz1DDi*3q~1ygq)V{~HVy{>{+HP1N=~bE4ZH25UHyGmhdK z5;v2_HuB$YsP7I#BQS8Mp-Q`XePPKSj@Mr1!MS~gvhFwZEixZ4H0Tid*oT`?Mw9HGS4rhUomv}Uqkk5 zhNfNTwROYLTa3NM^XN7?qRxGu>rd$GQ$w}!2JUA(*Pqj~m%Ik?`72&?xq_?%9#qlX zL9UM*)Mt5u8eK3bXQ80J#e!l%6(}84t+GKqLz|C-%J@l8Y2}03Q!%JIm4e!hQW^qdgYm zI!YSE!esn~0zvA*SZu>Aeg&PIc5W}$(FHtwdy!ZugU=0Vkc1cica2pjP z^b_egg%9F`ieLu?8UqCqvmSp11csFFl%%)wz~OAg9` z9$19)DAqWr#u$ekcn(t&dV#q(g4|7m3SbyE;329t3-VpXpqAqXK5kCGFdp0S1f~{2 zzRO5YaRp^kf=b1797e9xpxo$#A8{2WW5mH^9K?rd^r=lyMz^3!jOKp+klHp6X%U*V z2oXP|I|!zRq*zGT+lExGT}c1n2D-KnY5(UTKAR3{bJvhM^bBc!|B%jO(twZ_pu)hA zz8)0P*uf#4_&OxV*pTv#3#koyU=2!*4{0)XBJ+fhe!(t;CWf?ZQb>a*Gai5AHI7XW z$uuLRp0h&w8LelB)C(`rB%N_{LrUEc(kz633n_*xaBd2z{O=+Cw>zXNd&m=a(R*)5 zhxdgvVt+_ea1zfBhE)3yb>cY&{}s}izeAdEm|h$U$%^U6LyDdVsU_x~WS)OQ`W;12 zkq_3N4yo~3YC)?DBA-RLG8=beV@88`~h>L=);h{d=yfb#~}?spC@d87UG%* zA?xSjSbL6NO)_B~uhBn)CR%@428`l1Q+ztq{23lCR@czKC4x-W^#=|r? ztjlnHaVji#X8`ke|uM2D5`mh@P z64p;g!n%WbN5fi$+Q-70e4IQ_gq8bJSPk(8c`k=F1^2InwdCJ0YZ8UE60L58)g2{n zhIQ>hSl>MgYxt9}!q3?DoF2Sj+{>_LzY24Gmaq=I4fEZ&h~{LBXlbU1#$=ADYnF(j z*(0i#JEHP=B3k)=L>ux(^vwqmrI(H5{Fs5q7n$=C zeYh4;mg^DD?}%tO!Z#vXelwybx2XGWL~pVBUWDr@MijUo(c%Zp`!J$W&lrn-&m$U* zye}f^{4$~t_j+R zr`-~i@5=<09hRV+qY^Y{a)MS)Nl^az#9El3KDdTs-zVs!bqVT#wHp)U-;|&(e{j1y zLH$oAsB(owZEu>WKR!#;$88dow|Al(OB2<0TcU=c>z+iF`a4lKG4gPtdY(wsW7zUW z)i!@rWfP;?_-RyITSxV0o2Vvth-yEc_KYf5uc&4s_C-|jeWPkVAgX?NHZZE~gQ7|v z6V=1705zc)qI^Y^Gm;3WqB5moOk zQGK{Is_NUKTD*gtcCs(t-yKz!JyBKM8exC-hwuW&mnLcaGH!8y zd6GJ;NYW-0UX`Ti>Lk|fNm89(lC&QCwk652JxQrJw^jG$k14Q@uGHPWiuMf)}gTqZ)(i7LsPV< zZHjhuO3|=xDSFsDMQ!?~=per6pQ4fYVL*yT3{KJ1At{_&m?HC7ZZT^@ipoq(QJpC% znlm*;o*5~eGm)Ydvr_c$>=fNtPn=&;bZA40e)}y&Ie$-)6Js~0X!Dj7_1Tr8VnO4l|Nmax5Q}tioROQQ;%IlNIK1tOHZ>qlY zrD{?rRmb|Is>a|{|E12~Jxb5m7mUaBtRAzsfr*uh<8c}Ve@Rss3y^(7stO>uDOF3*bW5rpq12&N z9mLJEseC4xD$iqLpw<&=#0`vno~ny@@gh|%U#6;SrkH+2%gix#!-rX7I+Hb~qS<0P zfU}sKJtj+zm^LFh7u)fuSWF4UV~XJ*a+Zk6jd;w)3FQ4KrV>ai6VtKsF_|mGw5)PW ziB)5)Q4!PU?wIN&#B@H9eWEedZq8UJEv8Wz-Z!R`*wHV>btz(6kDVAWAf{piV`_$6 zgJLRgHDOl?tQL`)TN09i)H)C!|UQwtnpW9pA;<6??K?(s3M-xpI~Y?~BQaB__E zHDWrAZRs&(m>c6-;4y7Szj-l@pC98`#&mcA^(|x{9Km;sVrsl1rYZ3M7*i8`vNEQu zYh$YUYm95!(XZVxb;4rwxXpgW(p0x}nhx92RLP#k-yUg7X`QBaZPK&|$s^PB12*9m za*Rro1EVnmSx2YoH5z`KrrtP;HDic1Hci(jq{%)pO|3Bz>9~qIlhWkHR1Erj>0xAjcXUCX&H{;5(-XFQxmkopQtz^P1c!g!|qvWTqib7CFWpW znwI1J`Dwa?!3)y#5*rq#sqo@7okq(gX==MBO&yP?>Bz}6T|obT(sT$nk>OODOmJWZ zo+0b$G}StjrsikUbkdo7y0`0#M;Ro|%;a9o&Hw&)x%l2PHE+M&Q?uQY4MRHYX<__V dw|~FZ_wFtJd-sZ}-ELR^|8bfAf589U{txD@x;g*= literal 0 HcmV?d00001 diff --git a/Covance_UCO3001/browser_profile_3/Default/Local Storage/leveldb/000004.log b/Covance_UCO3001/browser_profile_3/Default/Local Storage/leveldb/000004.log new file mode 100644 index 0000000000000000000000000000000000000000..aebbcc350d8dfc3e101663b116821fc9a5cbdab8 GIT binary patch literal 6589 zcmc&2ONc93^#v6b263Z;ip1a#?CMliQmG^$O#Vsd)7|-WUV4z?rs`IzlKSP|s{DqB z$bgEgam0n7E@W1-(~S%WIvW?h0e2z{$m~RL=faiZxs}T6&m{Bu^+R7TI=9X}_uTV8 z=bnGQHh$~74`Sbcu>Jc8`{5MB_dS|VCM|bjI>#0ot1j`5Ro8wHb7wx{d`x|g`Yu5e z{NO9?O21Gjl`6en{_w#sF|5P;-}%eyU;XlDVn2-d_&EH=zW#)d74>d%p&@FFT|~4p z^3m(D*sBTZ2im$u+`wySiTo?yK1!IhWMFlM;ZsKz#YYK`xW22pR&|!hr!u)Te+4SJ z8cyUBvMi=WK}ZcsrzxHn5=RN@xej$n2ia`@1UZyqC*H*rBcd8{hYP#fn2I(g8NXQGF{H75)ktl6*I$Yc6w(d z#b0}vDm3ssm-s9OUP-9T$005>WhXp?#BYD^Hh1v&4sZiIfg}*q_I8AR82;WU>$fdo=E2* zN|!FtU@IU_-o(D1_Ygrg&4*Eu4{zd_rt%tIm?~Bxq6~c-9lHb9P*rn`B9e^%9mWSp zy1oZ!EI=TWGTwQXLAL>!yrP%1b;NCP!)rg3q&vPlNx%hd(qKHr>Rx?%!5CD>kanh4 zs5x;=XQCi$qAZXV+_q=8CrX(cC$OWEwZ~G&ha4(!r-jNH$Ic!ly1nQ#l}%s&lmzh* zWw>N7I|ZOvE44#8RWR5s?<<@&N^pZZ){=MyfvK{hh5Ud8%7m2)wlKi_BrsuRsYVh? zgl<|aOqgwt?R7y_-N5mWk>?e_hTy}dilFj^`P;`1a#WVf9p=2xc8FlaT=VJo+>!PH zde@nzhdI58wx1S;nq?g%vEAK&@{od<@CA=Wa2V9|c>i&iOpp^*jsqy3;W~#6vEAKI zJTmz~xpw>ePe)J+6V#vAb(h^E?ENgh`B&M zR-l$BTZjWnWgMs$GVNQJK@R|D7SINSSqA>2fH|~@7%gZb;Q!QTx(FHeP3WLtZ8LmR zW4l0IWiW>|SMX!1vuNo-F2{smO=0yl0#3{Y)cfeeHZ|y?c3(QOO>4dT+9^8xRe(cN zH=zVxx5WkoV`U$JmaC#L;&0hSaRPfBO6QrX9}vdk5|63rv(*F|m~eA!65r53Z2$~B zw$PMN1ISklXj1{KZWm0CP$Cu8K$eA_3EpqSCn?tPiAz05-YmJ^vtNP^D+H!+!BLjUC^_8$$!9FI}`#7Hj z@RT8Vi{fsp`_t-nJ#?z0M7_5yy7eBbwyYNKYVxiaZ{d{)UWxE4AwD>8l$cmVKX)&` zrFEmF_W}xeG_>Cp`JJry3<1z0NIFL93-@)3{S=cq zD*w#LJFfnJs`p&)jtv?!>>UkiKo^1uWskb;vl5BTQ0ri`4_+JRbMceFiHp3Li3>uWPvz56 zyw>g~9zA-rZI$;<9d18j;k^_-cMiN&g{wCS6Kjk53M~9JFaqr-Fa`~7xZb+|%!CJ0 zqRKb=+$M*sv(C^qNTF6Mjw(T?akhEbD5;a$O2Wl~IK4b2GoS#43C@7^nV7IDoEM6) zgco#zwAX>$Y7eX?mzDH6TB?P!LdTOf7o&9f1X-FtwW)|)NF|Z0cLxofm)ED=0dCAX%gfXfopNP5)GB0hQj++2eKS=(Bpa!I ze?iaN-gzKj7}Y}67*x;nb#9p(+8I$(rJAumPdqw$x($oX9M{+^y}s2yzw}0R(;X?L zx>reIv%zWOV(k=XJ2|x|N!bs#;cDJQ&9*u7m!rnUS#Iodb8SnW-zf`5cU%kHLQ(5Z zrJ>Nz(V9?7t7k(*%aie9P--bK|4HqCmI8_Gemh8<4hTjkBb8CuJtk{M6s z^1_%q&T64$d)W(dfLrQ@u15XtJmqtvkw46ID;3gFV<|oY@HA04wAS_upuPXJEWX6 z%$!6)eBPup#M)6@kRa(;+oS^-N66*H)Gp~fdhm_Iv$kkb*Nf(y-#m=To-sFuqOruD zq3Eqq;3q%v#+(27!JB{l$LC^SyfGZTh4<1Eyifn`<cVnuyIGcb8+vPc9s{?+4PGtz~eU_|2Z_kuU~%Y?a#jhKJ|;|_o*zO TlBHbw1^LvU{`&6wkx2gqc^=kd literal 0 HcmV?d00001 diff --git a/Covance_UCO3001/browser_profile_3/Default/Local Storage/leveldb/000005.ldb b/Covance_UCO3001/browser_profile_3/Default/Local Storage/leveldb/000005.ldb new file mode 100644 index 0000000000000000000000000000000000000000..fb6f6693160f53edd64505bb1bf4ebf26b7b6e46 GIT binary patch literal 26137 zcmeHv3!EEQdG8r}7fZHQ-d(RZ8^@1b#R*Q>wdbLEEs3$-(n?yrAG;95Xl5jhq#ccB z^bQGexNr$+Q_>%W3&|}c)DXCVK<{mv(iDv+#OJ1>26&iQ}e%=iCax9>gZQWW*2UGtSzOEcyV9H=+Sin_lp6vc+F z?H3y>sDco-!M0};3St(hZbsAFH=|up>`=B?H;;~7VCxx}ceEp@qKrj`uyQ$1WO#Dood==4V`Osl_&@#L7jMC4hbNH*T1UU}^!q=6O^)8Qe{7p=*LQ}n>qZ=- z_rK@KPyabKnE3reu+LlJ7&GsfL|v$U^5%!$4f}o`n?(jR@BQJ=elUE`=;sfi zy*4t1%?$5vBh(n7Y=8fkUwZ_8!2t?zn!EnxuYTi0*e8c?L~n$ho_OXX*TLbkQ2piu z-~78vhM_+Rjk`Ymt}j9VB2+*8(B1zNss~};`yY7ZuWsG0qAQ^L9e?xmH=vt^>K6|m z`QzcqVHJ_kc;t^B|2_DU9|*$v_CxzaU%25qXn%o&_UoYinGb#T?=JZeT=#3CaqA7& z|2Z6FJ5;YfeB+V1KbRichg=?yFO{l(bOS0|S=%L>P{6u*2+jJwbv=*J9_sPaaE&%7R_kV)b@nwq=E|Ww!qhSulIrsQ z6#<5$BGnbOjBT(U*o&2fx*^YOMX8aGp|@M7Y?p09McDfdP%eNn3`g0q<4e1SpBxnh zu_BNCUC)TL$!3yEUWG)|Jm*h*@fKA3Hdt%aaP$(~ zrWILrZQ5CC=qm-SVPH1bUk=-L7FJ}#fLn;gN6WgPwifS2#PQ1n>?ZSCl@+b7hzhni zrOPF-N@e?FJ2k;Dx(!{L`5vdM^NQRm&1-@#tQhn1B$^+tqPdyNr{*QOqlofY20Nha z9wT=NRi4iyZgtilK?2=#KIBh=dm{|`2rOp!E0 zl4!52ih5r&Z+4YNQ?9v~%NL)+uCUBHl4Dyf6zAN(6|Ptok})5xOBg6o!d zR?r9EgqGuI{~sV^lsO~K-?#|AmH_u?$vqLUTxL^JTGM3)}2Gz@g z`nCDxi;+#MG}NPS&CX%4>8)t)N5$VmW7FA#Ff=9%m^V`U=#MRPg64|e@CI{4kF5TG z$;?sfs3e(_;jP2(cd>g*C779VK@dgjg}?b*7Q<+`zH{Wazi}HX%-lHzgQiu10rvRt z1Ae?<$f7Q{3Pr(yFNerU^vSE4?P#dlz0I{x)0K|Uk_#}RN5(B`Lp}1|QL!#4EAuM| zDZ^hF?ZD)kJzT=Rh1%FtLy7<}BlixU7^=2rY{Q?iw3HR>pN51L3?EV?Y_|=LAYv0k zsxW+!O;yC&$dFD~bf`%$R+mB&;a){+OLmhAle_ za6+Y|$k;9XZ`cM6RX+L?;U|`cD9BIG|2J&3pte_v!;ej9ir8xF*e52sa?wy)*k)T9 z=KJujsiLB{Dv~g~eaO7|LsH?A4O2p^P!WvE%wel_=&IQ#JbMdbMX1+hwJc{J!2Uqo zskZcnp~>Qrs~*Lz7y6FQCX?tye8WTW4K`iwG?X7b_AP|DQElc1%sL-NCmu!*J&bn3 z3Bk68an$BG0(KGV%Hi)Fegrk_8?2M=EjHLv__wdv4pfbX{mmmt zo($XH1AXbXJUfl^(+h2Nn#4(Fnjq$JY98mN1JShO8u+n)&3;7+L+D!@5ONP81RsQj zFWvUGZ@vEe$oZvRg;PFK&oDisRd;9ALs~<+Rk%3?b=X^AXZQiw8DnP8bgHmJ$Apzv zk3u-b(>%{TKMFZ2BX?bU3W;FSD+2+m?0pW3KKgQz2svhEY$gz07X1C#OCb@`=UyQY z4H=qi%2s$)U=(uwa=~a~6^tCh2UpR^0%+9yC4kYy8W_o6FTGMIdeb>jWcpt(4~yRQ zB3QKQi2)iNx$PGZMx!Pe$;FBZTP7Bju0Ww}%Ya2`d<~0C_wN;hQF0xO{=L8me5o}s zQW}qc9sLTyXye9TG#EYe3jm`XVf!7Yp@=*Kitu@onJ1{zP&BvcOS?7#z}s(n*giox z34-DT-{fa)*t1B1-v2K?_djgkml9gD(-b}(75Y0KwoeiB6bB)c<6-;GRd6%`a?hJC zee1{K#||Oaqp_DjSnxQ&f13mMS~UdGbl6YB?e%b^4aa1FTQwi{)H}6OxGHxHS6xlG zsECxVRXa{;&~B%izPhI^&_*rCh)Zpji}WBY>3Nf+Q}A^%a(>y2<|Ob%J>X}r22v36 z;W+JNDc;Eu5Vq;U*tPhXF`r}XPtHd82l77;@ZdnV^}6xc6$p#$H1Sx@==D!@*5bkK zugBg#bu#{Y(2vIEcf#gobf`Y)M#HSxGTp!0pM4owxoK#v`gpAe4@2`^j%y(5Sd9)t z5cE0lhCt9dZV)w*TuJyBn?#EnJ~Ayq{3^CGx^iV>{=*y4f#J)pSc_fL5S74g5GrCH z`832b5JZ}x<60yPr&^6C;P+a*B0H{{b(mlR`~34g8$$O?%sN(G?dy)oZqCj7-O-9W z(c{$PUGcfGovDq%kk-)U z6#N3X(%~Gdu|9mih9qa#{BhU6eOjUq}MlKSvvq*|GiHkVT z7HQ5gd&!j3bIQq%n$gJ2H8wNuJGcuS>%$jkJF#R!Z5LCn*s?M=ND78--~k`0EpQ$+ zy}+k&uXBlJoGqgZKH{vynbYY;eo=`l;;(9ZNqD6k1r%78u=bok9Yf#3?Fqi;+$E+{`1N*)&B{497G03mFLdJI6O7 z{=_{SOdH8Wx8hvVgD%~xm$PlgP~EjkmNk;g?uwSLY0F9=)JiXSz2zX0T38}e<#OET zS}-b6YMIi4$yFQC#iEmuX@yGS?wQ+_mYn1Bwsg| z$@84V#a8XX%B%p$Ll8xZlS!Q8S%M*WCo2^Rh7u*2;$@O$a6*<@(;lJ3a;se7vy9km zY6-0{NDR{5LYrv^`itzKnUX8f3QQ1%T&$V)(9^{XW#oEV-{q7Tu|h?fx)O^r0dFkd zbm!?XU+H+eq~B9XX|;+gTGumDDpwDb%Y=)F)?yBrL{khw06cOpWD@A_JZF`I-U_eg zNrTGxxKKl(gm#cp8gi)~s4G<`OZL+$tfVo&=gN!R&4i(+9)n28LaYfrqm}sXLbKT-X*&Hh@wd^b61A0kK`niOw+DoQ<^2v0y5_KnQTFsNAe2JzO38fP} zS0lZFcC*Aph+tHRtJy)F$;lN)S_n`sywV`#emEQP>#=HoiS4i2gTMun6c|<(SeP*^ zAb5!ti$#hk5*$ZUY)PbXie*Kfz)gFIU8A>{XnAV!2=$KIo)>)ZeW}S3mNn7rh;$kJ=%Vn9ipC+?_-S++wo?yiV)0(D!S?{M`FvO zZy-6UfVSL;?_TsmpTT!8I=!HzOGH9k5VL$3PgBIAx7V)Zg#pzlld@l2h~)H2Iv*42 zC7x=A-9<9lTOM#4v#?Z8#hGqZPM8ad215aN@&LI!thAiKIl;pdWRWX6IgzwKwRJCx zGYrlUBySFsM`%yG7ouHDnwl)K3MJ89TFtw)fvY2uewmxosU^SUsWXjQ!+hFzI{x_n zm8I|8b;yiA9)H6tk3WR<_+vf(SdTx}M=7k3UYuY3uO^c-7~A&h)d_t740U&RAJr`;{7iv8h>KB&_b?E$Zp|068 zfzBen{TE~(wTzhz`D&vX4afsqgNK49wEa+loT2Q5FuiTOA4Gq|1 zkn$Occ(7Y6Z^v@qy9J%N3|qJiLm@aARIi09_gwGHTCaK;_NE;d+0P>Vt+MX=*fk@c zI%K9`!V7sw!z6fO|0a8%oI?BHy)eyj3^ZHwQ)nki@hpjGJK499CpIp25YiYw8s#8A ziNrdn3ftHS*2zHqO}nPxP%KR{6i>qbd1eZYIyuM`z;Kj;4Ixv6BRKd=4E}y}G& zI4Q%BkbmNY132K&hu{lv6!BX7Yfds8w~p*NGG#N_jgxne454e+_>BW#a3UOC|C`v@ zm8fl{OwMByMot~dRZy0oq@l#2grUqsp`pw|xeUr)DC4WV$a^jwzumq@jCA~t9o4M6 zhp?+}-(|Ani}t?X2B*d~}roIex2sf`Ys}g0aU&9+*cmcJV{+v+v$x zAFfQFCYW6QFSctRwI7u14B17WBsPi$*5QTv3zOX!qIAcqrNG)7bdIm@axauG)}%_D*{U6C{P+5 zvlniCAx`6@b&PpxgU#fT*e|e6pQbe0Kfh&-(}>FUr7f6s>LjJn{=+c~P#SmBW57VZ zHS&BM68rQP3-B4oUu#(31R>r?QKL6B)ubjhVeBe!EljlKY zv;Y~-{@@5|AO66Q@N&qElaUFaqN?^A?Pj+1d6F4@?< ze|S>(i4FLSb!_5!2#pv2JfU%PmC$Jaiwo|XK+i{LL|09Idt#^{?*7okOK}|m$tN$bSVu^9jAHLEPf3ty1Jc+HDY810wtIP!;&eF1x37NfNQE6&zO zPZCG=oxx(9oY_2GIDZ=B#2Srp{J_prEJpkBi=J)GClvss~xo#q`cd;&F1zs*LXnR@Op)OT|Y;oD}bntRD zn5xO1hTp}wAX|Q+%oTYe8~iS;*w@V6QsI zc$t_xrOKV8rspKO9&WNxL1cvmm(cEI(?KF$ss)NArb8DZX|Qh6!ler1X6bgbDSEAr3UpJRnY?)+muQgyOdk34Jyq!MvW8AEHk&zPY~Iv z+dpSCmm?*AoF*3r1A3vHFnZNU*T0l3siZ$cd&s$9G82N_#(pfBkwdk`?lRRCVsl;t zGOYFTf``VN!9i8j1hzt@(;Xub)e>zsTk*U6l?)ID`h1tqtuUk{(t%1p0Td6ocY`lt zA9jcNxzM1irR(X$vbGdd8cPLFQ1el;5}K2W?m$fD7J1Q4kI(I_ei4J4(rbo=a8#+a zx=W#f+8wNT!~GRnYb|<-O0pPeH(YKhS*3GCnl}Q3$0^2hg5fO}I~h-;;HBrn)iR5_ zS*K7=`vQf8#%5BXbdA;BS|`%X74#S$is(TlSaQZ=QNow6x|{fN#<>`UY}Z;Q z8`?X8T}<%vBz1Fp{BO6<4r~Z*vLm$7Bt89c*m246OMz8<&!uO@`Df~`JRht0Vl!sV^co4ZbMJt{i2M6(| z_G=?{J3cc0LtFAryM^UAVbA1yZP>-u*X=y*Bff3(eg9+Vm3oMFWJ3n_V+**5M<4yM zVmgMVlL$^Hs41=ch`(GP@s5}6Bhp-F-9`M>x`T`%byUbDyXuNRyxurgCYbGv_FN6zsl z?Z-UkLkGnu3z8z$d^wk^M5Vlo0uEeLoa{TPxSkLB6HZa3*)|t)1x2>qJ_QpiR54a;mdjcdL{VB?ka$k-2p`^s)MQBATLuhSi*n`*KaZHE{0Y$=g< zFDTBGCp{^6)I!o*6!0G&^SGyjadk0QxJ)K&UOs%IO$2``UT9fw$si%{VUH=rNf9|O(jKcru z8c)C2HSa|Ix%O4o)JV>2;k)BJ7CuvSgK*b-q#Dx~dR(&_ zAsW#n-EYZ*jw;kMxir&@4l0t^>ET*&km1N~)LE-`wO<aCa+GZ>HBIpAdbf34X4A z1`p&=OeFHPL9m^pO68amZi(4UAl;A2hHsEsq{yUNXJg?Wo~`MzK)VuN1gW!x7dFo? zmEv7OR7{K18IBf7z(tZJiBfS*wx`Glyg&#HwqqaV1mzYShaOY&=@F$CPc|ck(2B$@ zIOp;p#nQ;q9=F73o_;t{sTqq@w5Zi6&~G{m33h&D?3PcBKToFXc_G2ruLlz3pC1Vv zkNyXi`&);Cm+1(fFBEuQH55Q#Vfu9Ej|PX%4-L-Aa(&zBEZ3`7vs^oncc?>If%0Z3 z%TO{<5>O&gUJr$VLO_{=a=Dr3NTI<|3u^7ZAE8UEj15v|w^=vOn$I>LhkVKn=G*TN zUiH@}%ns1%M(EzBZ~OGuhrf)R8_#-^{!;qfhY=dyFnaqq+BYh#+VI*jqe|Q4@^Lr5TScA5|S^U(f**|FwPW*P^ z*)7P)Ok)#k%h}A$*&8s(wtW56du!j_gPgR%k-qH+g4-kwi)~DJc?d>Vs0zQpdZcj?(dt zx;xSo& zDB?cP&ijh1Ay*%~JBp-s$h~)Gc6MfVcHVd1dFGwjk;5Y+PdSd$?zI2Gf22N&Gv@=& zhqiz$dOvZm_gTNU-HB+#c4zA!N)qkPWJpEy0JKk7{0*e)Ih2UjACtd5`l9 zuRiB|kmP+xlgAIAcAUa{9EVSycAkxa@Ny^U7xwmLy0d+IQ(Xi5_a?eh{R8Q)Y-}Lj zm5let6Wu+TWH#ORMON6|2ft6^?aq6(MBm=r_SR4~9t#5-(--y3VOoLl6=&x3l;>5MxSXU3^JFW{`?vW-nX(x&BE`+-{OX4hpSgseA!*3G4 ztdmE~JpLwdXL`x=Yx-%_Qje3sFJn$1tscZ@YD_Ev*u|V~<|*G2I9)?|WjQCD&S=8vJY|*k zWHY(+M7n1z6VFVHrLyVl*mx%1GnUOJyHnlyLOffD3#T(LaJuI8H|H;S4**uvpm#R6 z{Rq#i-sM>BRa~FL(SgLKL0ipguYB`|9;?j>-Oi_giwQM8$Jr_Vi&nT^S86xS*0S2| z-O74wqJF34(6AuCvJkIB_&P-hgDHptJAOnH3ZVXU7)AZVIA=Q|lNG=sWU!bp--O4W zWStb4s>frUEUuA>7_)#s7mPz@c0I-%zgsRl{RHBZjSWMRHOcI8q|EdSxSGdV7EG8! zUK9dxge5&@&fqr=#$+j!&G-yxe#^4vul=cM*^EP{_h`6ssQMX4xPYz4#|8AVg%|7f z>Dmj?=v-}jSH3cvE9YI%sVFWv1r+17aKvZ>9C3|_`P_BiIZv;N|AKJByiiZlAuI-QLg#fDM(EHRsjQDK%Y?bU7dc1Cc9S~c%>$P{bIC4Z6Lb3>B zM^*5;tb`Y%2cZ)PO(Awr`fS@7tlp3J=OLqG(C0)d~x^7@FTcB zgeEbIg4WP%CY>`Vb{$Qn>O`DjkJb@VLOg17*Mwo-Xad8$jWp@Du#n=Ypeke746{e# zjaqbC{MUWy_>z&7mug>Z$X?wviDB%9M8*DRaJ>7`pWZD4y&tMPzqOp3ojjAPPgcr9 zg`rJf@Jg<&gymvDOzxupVVvf#aczG@F9cA{{}Z_WERF!-8OSiLW=Lw1G5k^AB>R%3 z^I&v#Kq<7*aWFVLATo6UXGxrqQ73Q*1w|H2nZPgVRv-1D7;?)$eQh^~R&-=YuZ@B# zqbftHpYenn!6nW=KGpX3!j1HP8b?6QMoX15ljYr2w?0!XAFGyncO(X!N8!-#BZFHw zI*`XrP_}M5Z3#;C@fUE7o$Mt>^0`}ben+TZY2(wY()LBGOVcjvqSu}sN9kqp-xjJ_ zS>C(l)bjlbB6{`ph#Xpi+&TkUR(5tnj=8vd2DI!P!*9vyb#|Z~3?Oa0J~UrD{GmDd z>5ak39Es)d$FUeWi=7*J$tZm>gplVr%Ig8Yk<-|%CctZ1oO6UoUX3rQ-(l1_yKWcv zvV&yDob^&5KPT{KIGIaeLyjS(MYj^(;@#i=?-g@5S>d_% zwr4QPV_!=zTe@<$$IZJ+x$%6ZO7(LpTFK4Si-~B#oyg6U>e1PFlmV6M*Awr>n7A{9HaU_0quM^YMD7GhZpVWBFpPRC3E_+}?Em%-m3V@5$-%%i}$h z$wK;-ba}LIdVcS0J~7~Cx~j>O1BL!lcja8gx^-;IMV5u$kwm(?vs{5j+}WE6c;DPiaWprdtei=>1Nj4oPE?CWM~~!66WQeXgMH(Pm*-B+XQsOkoGgtD zcfWGheW|nR7AC81zCJcno$U1RJDx}^e9F;+4UYoNd606R;bhIK!A#W1w2HIstCS|g2PudBmCZ@)^M0ltfj;I*A+$NT&oTQb9Q? z56E>4rDPvbL`*)*2+Ezty`9LXf`f9Z*Ex#XiQ{SV&H)_9A)OB5Nsl7GIG%4G$~=P< zM)5@R2xI?4nKKyT&nS<&iYULoFV;nJG#{H*oX9iEzjT}y*^dr!} zyYakdkYFt0)jfN)NtBJ?f*JDdK&pGCe>1(@{fB=hj!B!tL_Ti~>5n13 z3-I&F*>d>CI=vABM+Xc&hp_V~+l%lGc{OnkSAGV1JyJg*^@9^AbTSC8YVa?T*=kau4hanCr1klHDfWAoLN#o!zeF%ZWDVP zt&A`dQ>E4&M~yOl>H$oj8UP39UEZ5u&rSfz45L}D{5?<4o;&O}*LJ@-wDrwp$3Qyv zu_<5hrl;Hf58V@0qm?LU&mf6IVBy8C>s~-2f~%_Le;oO2$H8uW8_$_PoU)%%Wv>NX zYv#a52RK(LGvJgeBoSc+_?$$$8)BDlV-I}R9=g6#aT^Yl7GV&DKa{d@3k(8|bf!Ms zR{U@{P+AWIrJu#?vL$anRI$Cz=bZ>T^$1i`0>x#V5j_604`7NNM+feE9dxDAR|idR zv%SFG5z2F(zKsDJojs`9Mo|v8Q)p(Z@sA3)6%MKhhpyJ3%GPc^4o0L^ z($a~MFL*4W)e?9fQD0ezl`IPQj>N$`3^SWh~uEMuj_kSF6HIo^M2x2tg|`% z+UaS2G2RTv_ssnLeuh8DX}TKE_DA$W0A>F~gy$gQ@+*|hUnnZd7cT*tjPw<{l{(gkh z_=_;qJ{F5B%4ejT^ZD7{r^O!?P&+2{ zs)TF%R(eaq_gJG~FLB?GU7z!~mc?Tyq6{^cKiYgzDB zL0P4KTVe4ra9u7OA#_~C|mAq$_(s~?r$b>I7!|y)b_8m};KZ9UrKlIp3Eb7;;m`M-pQ%Ck7AB&L0{5{KQa`3`S8T zhbv{~aF7e9L076xEBM7U>E2+MCXR}rNCSleYlFL;)T1F-5l2`J?_poCEX3j;{~3@iZq zaNhu?foVN<+_Rk=gEeCU)_Vs5vdzP0ZxqwU6Ns_4><8_7Q|&|Py}M!+b7 z@wCq;j7H#*wtlo5PJa^B$3MG)H*nskR@1y(#7BJ%&R|PbufO{`aijE7fSN zK2x|5O?GEfv1r|`)w^I2kL3WhXf_#3r@L`IS1#nLg)aX^q)YcbRMAZwY#ld1S1PUc zSYl+*^6T~Axbd1Ntrmn{lz4;;{cb`03iazXE83FQ^fg5E>MTH71;P7^w#uBYCCJY; zKAfP6q74!#ut*GJ}K~}r`ui?U8mJj;8E5C?t^67gQEkbF3OV$guTiHgF7WVUTa{r-L3~yfh>kNH8U!b&TwKSrXF)I;t`kk_gvW?P? z5|A>8d)t_G3!HeQ)Z(TUEE{DddkM75Rh34c-16glq!D?HPNkGeBlYvz{`R&#vJkP= zBB&GDjoe)<#17cD%r`cov_o0!QX?2Zn9ewY0fN6X{vLF|n>ad~6TSCp<51!Bn#guGpAY$q!D(+)AZb${HvRM>)uS%sVkyj*KyAK@_Z

      O zCRDqRqWI^8E(pCM^bMicg;Ig0yCZaq@E2E*(8Yuf3LO<%6natUWudkhFER}rt8I5k zzM-5tjDdUv$1C7IT722%Q#-tF#HF*ZtE{ub=_iy!rTTvMeL?nwpT)gDhoc{W0u@F6 zB~emJi+w2PF3>|r`y3SY9L|s9my1nv021iz^0ca)T8|?DEh11oxva2`GObqrLC+Nw z-spP?N;fEcz2)~j+76Z_V5usXfX<-jilBqPfM0S7dBnI3$R->ypI=VzOSD~RB-hNA<`YzrvG7@amprP|yUaE+SHB}VeO zJ>&tnpwV8C8l~#e6;YRzUK9UzKh%fxB^xg<{@CRU)u>R7ilJSEYLsCS<=aq=GWDTq zY>>LC^<~SIpm4@(M7<44Hz<6)<<}fFYJDvJ4%M#JRl5XBr>5YWQKPqE(;yy=a?{eJ{hx6l{XE!_Ma7K+=&k}>?f~_3x;7mIg z(AmAzFxo!n*}1ffTi6l`;X*O)hR025Ij7EfcFwLD44Wlj7`K1so{^Ahxn!B`U=hxyEtDV59`T@ZE;r<+0S5(a%)@s9_u1`G#j_nweQY7;&*LmsmO)-T%yfI^|Xy#ZH=n?7iaqX8kNjGI;v@@Re<{WdVFy9 zdQ+oT8_u@XsEr3_hiVjABD4xvTUG&~8pT%0X$~_b7Q)$Hb=*ZORGm;Y#P4rJEpCn) zwQ=C=Q0-cN$;C?4E`hT-;r-6y0ug!}hqHUu6rBCX0%QNl28OeHo*+0of#D8eZ1d?C ze(Q`wBre%93q-g>83#-p2GMw$3q}Y_a}#-j;54Ns=xs~uVYGe1*<5gDJ`lsDV*KC> z<&N&vWb!4P&8260m3bP_n_xJ%_RqIq@O6K_`qlV5_YA)9D4x?nmrZ%mCk1?PcB`ep zdWW-ZiLw#l>}E<7o6|x#+i+%Roo(tt_2mbRFJ3@&E;#nX+4ov!?}HrXzKPr?*Ff9+ z_zFL4O=q`5&DRd6zY)DXgtNWszB@i@cKrsux1jJw-)D2iVWv)&`_=lUM}6|LR$jcW^pgIF)nkXMrF(h_$faw%I6=oDo$BZr^>CmMz!+!+a>rIVXZ8+Ojqc$R(9jZ|woW0f-xrJ(!=|>-=Zfdux-Ld+W z+Trv!qBaJl8x+3Y@@tM7wQ=C=Q0-bC&R&VyB|sKg#Rq58+c2D+zCY}?+WQ^-g}~Tf z->`5tciMS!tg|`%;bHa|;y{S|q8aF#yMq|u+3ZYa?6kRQK8H;l6mi4+B!K8(IGej7 z@xvY*deIKtd~cP5E5hX_lzGxNTR+Od67aJI1i%TOvwTgrC3*l~{qF~B`}~71(`Vz8 zOaYG9eNv#ey)7fFWLqr-nhj_F8wQTtWTXR6^fqX#R>^Lsy%n4-QAQWDXaa~*%9nZYCiCG7U2Up zFF_*P^-K9iXNS|@$ao}#vAt>yVQf76i2_v&#EkAf;yP8IwxS(za}lafz=LLKY&EX!WY@_V37B(3P)hB%8 zRn((UeKO5e+o!^)tG!oSs6K_(*ldZmywrAShtuDPI{ZBDZ+wrojRaqZ>eg}_;IBm8 z65t9Nmmj{Sw_*4?xwf|J|CYekZ*5rknw$GSIq)?Xo^l9eAZZSYXj`4}20;9LhS~gs zU*G0uJi72pOKn;K@teAYuDKO|@RxJVM-T{)^ByjHhS1O1O7o5SlM$r*s>`v`lNtwyZ%;7fwjC{zb!4U$zW;Y zY}emhX<_R;j|xqz?nK?1RUKoqgromqoaV1_ZGS{B1W?U?r4Uf7r4hfx%?0@Uj1X6e zaN>-T%zT`LvWL=$5{S}=a*0q8m*;aLZ35@q-hcI_(dM(?zegG=1f)_*rIGsidOqLY zHYgBKt3^;JvTNr4M&Ad-a!Y2=xNU!{AfTNB>DXebDB%|^dRhFpg(?@UeF$i6iK&~Y zxJLFj+9ps=L}*6nu+V9t7lmFHYC}J7OZY9J_RLvC_$(vTo;jPA@Jm8p7ph`Y#bFW8 zOHmxoprI1rv|a{q&aPr{28}z_`Df4$VKenS7KFG6ebL+9sD|IF7j_P3vk=Xz2O&@n zvFzbKN2mliyPebD2t=dp!cI3RywUugM|m5Egjf^HJADqlYWpL4A%N<0hw9XLzEb6< zYp0?Q^^L;^4DMEU+svjB!8Qv-GKkAC&aH7> zej0wx;xV60^UWHQ_vfqMy?OD)70$4c?S1 zODG=ObDQ);sNE7Dzl9^`rkgisZ$ICo&cfY9Jv9PvZxJ|pyU>`>L7_#Vb3zw{UJ?3+ z(Cb2P3cVwAi@?;|g~o&q3LO<%6natUWubQc6!E+<93i}oN`O;+dg;EiG$!}M+gu(} z#TNej)Ir4Q^PufI7Ku!Hdmh>Ktm)d}^f#inhp@Ky+U~x$X4h}fdkYG0^nE^$$JxlR zcB?fiYEwBJ`~;HOpr4!ZPk7oHKZr!_$t)hBRgN;@VM7ORWUd&sOi-?`XZLQLDY*k*!9lx^zX&%ciBOGN zTd;PhMzK|f+xKf?6(M&eelU!S0qy0~TvHxpb!P#8+z~xa<@B4Z+{B~iW?m9Ktqm|&R;R?4q zrGYR()aHRtD$O!z3k2R`IOynq7^l)vY&S}yzY|%J~+G8QlJw#uV*;h zmMH53&VGCn#pbjS&NjRm!r7)CRKgSgVUH7JF0*vsSxzMS;p|h8ye^<@ZrLA!jH#fn zEWu}--3~QhJDmOy&R)b0AM{>=>MT({5CqA-D-`>>`cjBBxBHyXduAd zD7kFc7z5;?XBh(l#^Lfe?n}uJEyX;|i_77ty{)!J_1a&(HMAU@t(uloU5n3_bWueCBI1A#xWrbVbB~q_7wv>;eHKm~RKRIwV_x?x#J}!80GWRDUKyCH` z;m#nm%BF=+0kvYjM$0W>xg!yQZUWMTr;|(G<1iWm;d1VuL^!(}chSWY+9@Um;c{uw4e6`~retN(^_|kT*gD#u$x=#xD zw(oDX6lgY_z1rLN+Y)6|%!j5edP)2@h3Xr5(jdzAp5t&}%|(2)!-T-h^bQnDOlqYHva^C*cc1?fNOAj4>RcbvEDDq8R0Vx6k5O z+Rt+N(BtVKJh$X=fh;2;aV?lsi z0uZnyK*+Auy6Iv6NDdu4iKOG!Y@9f3Yv<6ekE5hMJ!~r5w2yO+{%BJsO?!0Q#Gzx^ zmL)k++#ajXZ|;4$tHBNgZ~=rwXMovv?wvb#?%cT_&wcKD-|5}o+k0ma1V10F?UVTQ zpXJ`sAbE%O^6+P$`j?+?3VvG0>@VFF1VcX+1O(rt{qgM`?XCHa?YYLT&h6R8+>Wl6 z#(cUf)7YHZk;%5UwKwNmIzFs`+TI%6^&5)XIo$8p?`U{dw=wTG%eQ}E{7m`5fl~k2 zsW8kwo!_l}gIwDr*Sjl&brHG7yDv!It^K@ro48~LUS6(p6W-4MvumH;{qn)PgO7T7 z-NKP2RokonxDfHL3KAY#I@kCU?~x3jGZ+ZQgEK)ncu+^Bpg$N3c;aYyyUt|0!f?y9 zb~fA#*(_cQ8+E7bM2xii+jZtHDE#}hXOxoupcrI>7X7sajX`TLtfRb+a^YWENB#0E zhJO7)vz|LAp8@S$(W<}VoaeXrhZVk6cgbt-*S#7gi^_#c{8{-8D9nI-8x>+mv1fHY zC%?R0&GH`(%Z5Foij#X6kuvwrKY#znDD}2cKG@9vHNTmgb1L1xsnTsh@%rmK8eY*Y z@WxrIbbm$Uat40HytU(o4xyqh(FI!y+upI@|NxwAF|R; zsi@v89p)G3wo=P^HD$qw>fdSAzG(QAMHC~e;~|K-3p%DYWL4g>DtDCVpt3+D071I--8% zbpJ-3cOU_ znW>2_gX3rW#|Dd%r<>lUa}TTWJFCP^>2-_-C-fj?HI9=(Dky}qET59X(OF#a)#aHw zs>>C{#rB*N!J4XKPS+N;uoA<*nw;=*n-A9)krUp1wJM&fXgCZvD`r+)D9&Nt=y}V* zgr5Jwph+k;MVktGUKNUJLFJ-?^y`SqK&8y78WmMhvI;+-W2)UyZ2bMok*uyK zbY8!Wiao9HxiEgJGDic7gLtWwY2AZPFBcwVbdD>OxAv$Z%nHjuO#RSf1;4-k8jje8I??LKM__y=JMs^ycERc)6e(yC*M45-?Cup2(n^nFlg!u(ofwJhDpk%yFHMO}SH zax6Hk-%_wOxL*aLOL0fX`RU07q1B`bR2hQCEX2qxoLYJEA!mQbUnZI2x7qu<2;mbwhF!KldVjdR-cZ zM#a~xBl=hx9j*q|HY=veb~AO6tG~K`{wBbxzDch6#Wy#c7wV)JrutA#tO*FK{FYMx zz~J~K{qgCh@%}UAk!;gYak&3XsoZon(}c(PX>42&VQcr{?3vlovBwTIx9&KZ zDP%jkIx_9u=f+z16!%PY?s%lVfBf9Qfq~rY%)WEm5AAK=dv+vK+L0{|bsg&%DwT&f zO%{hnCyRsS<7XyEw}y{@fAe;=aQcrx5&0Oqlahmv$K<@c0JNL-Fs|j-`ULcBYnlL!ti); zZ^u|}-$?Q3Z2P9E!Ewc?eQb2-{%pEYwF^YT?M@#FA04ffd{=qm4FSlsC4Hb2nm zi^v)8e$GpG^$kE}&N)@CT{jEMXQaukG^ty{L2{)#s-U59RXPUJBdU%~s&;^1d`j|b z5`N0)*Fw;hjRvy{^N=ckNykOyW;r;nqaiiXX*J>CgBFEL3x#DgC9Bf6%fKjJ!}->tgCfncwEPU_r#UDK>Lc}$JRp5TbC?$x<&{Wj|F zT+k8pCt-5MVJ`O`} zRV;_)e?}>!>wYXaq_njLJCxFl&~{d->C#Smx|NbKo!g^W_b3IO3iXKm`xV@ zImI)hbf44n9nw>^Yd@0P$4y7xnct+$ps%t4pQ(?+n8pp%5jwua8AzVl++-aqCRCnhY(>gz?xQ0WY zxdX&FDDiI9JP5qGBZ0@mI@zvYs%$!R1;Irxqa&Ut8r%tkT+yy`M5l@4r-OS{!|qpW z)uEJA(oX4^H^Q5ywzyh2BwzAoQcuZwdoL;FAYrEzj(3?-iAw92c(*FgqWArT?%Aci zQi9w_YWdoaRPc|KHd-6nkJ0drkm8hh)Ku{Id`?Ew$vbG!p3%-0J#X)+R?M}+b3H@` zWqC%w(fI6sX)e~rd*=StZv5SL>p{Z}O4vKK$Kn>B^5}CH`0$-MRK{AFnkcFMj36;Yi(NH5~uXcQ$-kFb6nJ zl?Ad{u?C4&gYjFL6ia&um@z0wd!nr`A}74tM&T~h0-&G*hIymrtQIN8TuCh$7;OUL zy21sIs&4~Qtg6h+(?qqY31hU%EX#lzropgTbfj2|nmrh3XfXChHAXatZTh3(V}zX5 zJ`fwfW1h2Ncp6toH&|xZ#6oxB$Gi>kIC_i`GqXdC!vTSiXeuuD%0g1?u*yMP{RjtX zHw6sFefJO7YpmGShr12saVx_@s)V+A? zyj`wjs+y*+S)npI0wZz_6L3saGmpUCsyC{{-$c7Y8XDg`FmID+O`%DyIecG3;Xc8ggqi;Gtd}!aubZ)43Xf$0q)Y@Av?kb-h+|xbN)3d}R<0mwFyr7-#P1xnjyFH>usdz+U}dg*)@fGpKlh2=BSeN?)K+lyp8F8c16$fUC9 zr-PzYAeLrDc^y}$byCgFgnS_;I@CRF7cE8O2Kh22@~U4{NnQ<2Mq#=n+eBW0-qIph zj3}!`Z7z&t>=YSsRGnR??pu<~iVOq+LOSL}9JVRV{km^iY3q~RE($cQR6%SV*4bXA zJu3=`CUQ#W9+U4W(Pszs6o(Y^sGblyac`LN9U-Y&(z$8Hl2`b8Nyge^4A+t049VE3 zoaht{xLaMpEU3$)k^_)kQ`W`*^A<6xE(h~~bAriJn`7tSYK~7EU z>4p^o0&!aJdq{CXrKXh|hZJM4@}#IclojWoNZW3`hn_G$5|S|?84X7M&614PTF;dR zv+PXNow5@#lJE>6>^U#!n6Bfz_Ui3=wL{0oT;R=crr^gRU;U*&-OHrc*Sx&o{VzqN zF&sABA)Z>BJ&&dDQ3V3R&qrF1tKFlmtW0-N-(78X6!|$#Z_&z6DijkyTf+FNwc6}{ zW4af!(Lbvmov9}VH)G*dOnG$Oh+(H%7T5x4&`!0gOysnwjc(O(r&^%2e7fWVs0PUH z)ZV3E`WRY#;{G|^$L?+#yhS&dUXCFgXVbcJu0BOF=BPoI-y&lU zs^)vXJz8^E`42V>hyEt3hn0RY!e_h&DWl@Q`p7HafUsjui@nap2*0JM70ZpyFGeu$ zTI$*>y%^y~Kl{QM9nfETdEFB0J0Nqu>JO~rGXJQIHbBd(t{uI5#ck;@pQt-!Ct{>E zpmv?P3kvTVRE9dt%h6ad>qlehn(myAUDHit3sp@+Lj&q~pnB-D9&$C?M{o@m9+lgqET7R&J#av z7l03#4-|7;H!O8dZJC3#Kr#Mcu1O8;DR7e(j+U%QQ*vWlR_1!1c7+6N-MRN!YbCGB z%`lGbSGP5N8ULu{+#`2498wcWlSqGhL3`X}-a}}DZf)GvHk}`B%O5y(dbrTvGO}yp zWO{#h_Vn4~r*`a{7|$L*vUjwn(Aj-9bHHnjW;#kU*|DC^Xau3Vfw zJJw%1eDqN3O!w@_(BRpb^u)mI;r8rwcka~5>4}-1;zYWmysz}wp~dI{EY)P+XZHJO`r-|(Gi{JR)E02Di&YUWlI++C^)ux6u@FpsA+MjjTkhSv6o z&Q6FaO^a{qR#iAH*6g@K>=3_(3Sm~RBjOlG#h?{5vhCLSjN*8`0%1nXTuD4zR%7WN zjiLAGxLu6pNyU;;EZySrS~SvznVVG%jJQkUGmnOh-Hgu9DkVUMv$_%mzXACi4y*69 z&gPV&lX`}UkjpDdrgg`%VlRd2n^6#CV94bBqwiZ!1E8|o*#%8qYpc>;>rsSNeSTsKiY8TvOA7fpbSF{#rGFdRhDnFV`G$qiUUh6~e~!O^9fF{`(MeS;Y@-qfe}9jn>3n18LV z<@DNy5lv3fweX7TS7m97Rb|Z(Nq|`iB>o44+ zc4Lk94LrN#dZae17ACEExuA0lG|m&KYTM?!4I7i5_ilpFjjZ>hlgqyQ_`H|rz5m6C ze8#)iX|+T3RuygN9ZlaCx49kay5OBCRKjZ1!)SK^;&u$O<^5!Yq3-5+#=bn5=;Cib=;-nlDe;zN}uIluO>%Rs==&@D61B&)cxb~JmTf3Lug%!boCVDxsjG_rM^Pf$VAd1<{F7crVb*ir|GJk^n3eMIiG{df zIr7qA)`WMT_wu5b(egQ>i__W@xD{sOjkdE(PMD1f+=5G}hFkm8DGmzc6y>|CYB-1A zDY-EOQ)w5hJun%454h`rhY9>r25MWb{Edq@&cELGxlzxOz%TWW$_L;P@XM*;!xzE~ zGNplD3h)bseW%kyC?;4?^k+gB7SFAuVv4xsMn7%u&EiKh3hfxex9is?a9sSD3_^Pd z{TFm%xF-`l_`_3Um4q?dFH zY}Q7M=s2xCfnVfGC0|fSh4rk4U$1Ao;JPNoFk!0#s}(TmWieiWuLO2k`HGe|-1WfB zxOn6IZ@2qxRQ@Ees{*?)yM_iyn`#?ccWy!!8yG+!rf*@r(Ak59V!b9)vp_Vo_ps6d ztcq8qMlG87G4%9zw$de{|@X;eglFTVHJ zzg7!&{rB&_9Ktb!UFPPRD%izh^hLm~mRwu*_3P!^^X+ZT`Be+MUh;73<=YB&p&|XY7B(+3U)a|db&tk6mBdR zEJ)Zcm*2~kzj5)#`PU2c64>S5XF&qC3yn8+0FG1l<(MT5z%KYNI4IUvp+F25Mm@#q z55LaREfa##`e^a9E)I2I){5~9aKp%&W4nNQOh7t&z1#`iI2LHI*a9WyX5A6^RR`=^ zG^QbkT3`6))mpIYn_vDw=x?yg++4GDZ9}_fyC7-mhF!Vbiovcw5u0>P`v#@^ImzW> zyG*z1p5Jz>D(>~N&$C(+5otPK&wGEenN7vvbz8LfEst*3Vqh0@=c@;Hg$%QDe4S^f zHha0v%SXMO@bbKu7rngf{cyIRAR@w^3!MewIs-#BA2?+v%t~ zWhY{!J@?HnEdT(a$;--3mdIl#7N*GA`C>IEps8P=$9;7K%`DVVnBr$qf*YjAFN{Zz z3*HHE#zF$(XPv5BS^!XUh7%c05Pv$0^U)cR`{i-XH**yJ;9};|t7IyzTzs8ljvH6AF=3Q%% z?Mg4~e&5(1Jk4^``@OvGQaT6myz2c;tIL8#rBw)f`>Sh>Wr;a*6+A+jQe~K;~4kV zI>t^A)U5ZR$`h7R(89i}HT#E${UCSFE4m`$;)TFyz1ri zUcTyOGWkx6QNaw>dqi7D-1Q7c=1#uD{ZtP}dc$QVw7E>aW7Q8vcu>FRbnj?-mMfhJ z3ruOKl!s`(*IN$a-dmi1z4zOwXQ_W!vU--Bu=1JNLQD`dnGVlOEko0hnMU|thn`@6 z8H8XW0;3a5*XI=$vp4;7>SICq?9dYfAWY$)JxTn0j1f#l{LbtR=!u0c3~fMWv;@wm z1Zf&pidyO!#w;4sP~Lz1$jR%5#IDM1!RJNWwQ?(bS6b)s zDG#@vUd6C$HLdVnUb&cELKC9uoA#|kWh6k-}3A_<5E$z&^W(N_d)xsTHV zmC$~KzT)GykX+PStbs-Aqs32HfE@6S#VN!9i)k{FQ4%8NiQ#ZdBw};yu9wEvB&E?i=6T@F|1O%Jk;CWb}8D# zuu5g<{zmXLuKvaO*ZY3r;*Ima-R`$h)=D{|!e7nE&tru#+uLpkl{dsR7*>gcJ8}NE8w`qjjyV5%pD%%30E7zc z8Wikt3sm?vh0}d!de3Rb7j@(etH5$OV=KTSw7>WW5Z_tms`yDpw;GsfLbTu=a3e0K z8IO*bo5bXsjqaZ4$UFUb?t;EPYkijU{_*T zg$$9oVZAroAT&~b67hd}xb?qoE7-M|6~2jK72bOSyKXJmHCMMQF|0y41y-;b>@c}d z|9WA`YQJ9syIlDyNTBi##KHI$*5mjrw)+w+e3YAPq^E)HLf?z2!WNxzp;3qjmSG?` z-mnU=jj2rcacy81_UtNOt>udiPIt_$8%CRqPmaN|!F&Pin0%}QcHNX=m9wvueozZ` zJ(>GgAsjQd%iQFuH>_d{92dcM)lT9nHmvfphg+|BnHW}~04==vU+KxlP@j_Y`ANdf zUT*X9Q7>)M@w|6m^fEf>c+LC2=w)=$F)^$X7Kb@-px*91F|6WD6vXMit#FI|@t(Iv&cwC#ONhhpgOpR)I8* zfx=cD_7;6$G{8`*ch=}IKkPKX;IrIkt^s9CEn>*lWc|f0y>|y|y}a&Hniy8``4Cr8sC>+(vmOLXN32nS zQE>Dw3XF_ss3@3=q?$694mZ{xUWEm1s$*RIZib%k+cC!vK@3@q85b%#mXzEY6^yeu zqMCTQ3(WzeADW2#4I?Q$4kf%+nLGHUi`Oajwt1>DFn=3+n454itn%9`-4+xt&jRC( za}mRlnAI?=*RaZ;e&93zhFbS$Uar2$_r$OYbs%AZZ!H#h?&N!7ScP&L?S%{$F4UiJ z$&!;mJ+9lL`L;B}lGS5a1#68=yECA0)9ZXn4x`wh8@_JBlsgy;Lv&yt%&1@-#o31h z-!LeN=5s;W&oG9`cX}X(L7*b^8~K)ro5+Vj=1xx2k@!JkO#ZuXr@%2Ye5%X5_M$Nj zCFf^8((-~KvFc&W$A4kuyZ9RtGdI^%!7hd|^~0`}Tj9IXI*%`Uxb?$T47(D;DhceG z4z0mW&S@TPsROJmTeSI%>-Gs(Pxn4|@;x!EvY7l|uJ;lbZ=8R<9R@@jLxV;s^S1PnNVWA~Re2ipMnM&-ear`Fpis*CY3S zF@$3VyUfis-mnU67ra{Cuxp;h$V$~|s=sRT`lTkRfW;XT{gRq$*6z5-E(5c?)CY+ z)cG6t-s1f0eV+;3a__Ss0UUBGZ~2GJjm#<}D~g@1J75}} z={TksM`%k7tK1uG4K~ezAqE$2RrA4JdUuIol?rTpBX}AIL*o4Fg(q?G#`)iF_eCzgTw**un4#>=P@OU`!9gKc<@`__K;#ai&|t3Uc- z2+NG^GB?*$O)@eOP(S>NUxd8W@N12@WCRj3k)Zr81@+m#qrp`1p$ zFYCq@>QA_OCVyA^{Sw$kDXUB}!eXJHj^;XS6u^oPV>#U`_pwk1i<~_>pinXV!>}-1 z6_bGNbIPs3EFOLaE7P&Zx#rj{zs-X$b-C??bT5x6Pl);i^mjQOgV;b`3 z>EXA(R10?XzG?Rlt648|b4?ZON(`%zA@PP)avpBA+*YtFF|4xQvtDU0cY8VF<&2jX zyi8!%tp&U0>UJfDRcNOc3a{eeQ3AW>Upc)|d0hWW-_@g1kC_yD6ISN3C=f8@K3T;P z%obW$e9hf09mLqL)75ex(n8@Kt}I$^4R&E<7`-jl9RsBrb%cqQ%7R3vQjdK+ObY}5 z+7u`2f>}*WYT(uCV7qEtEoqKlCP+Q}_#gfJ%e7$FN51o^5RMt!Wp1wVhE;5V<09Cu z+DV*e@$yo$U4QbXAh@P|gC65KNhVF$?6sP-X6J&=-L3sRfvUD`dQWTxFQfMC)^m}z zJsxiD^)fN6;_@Y$&z9d&|3tUT8TTJ9B$ zu8i0EwfAJ_qVANPh>`YQZ`QC1A9Dx(Fg1tW1k}_~SjTn)YZWnYf_@d6TF$B*+EZ{# z02`;e-Zl?w1p@});u{a>g`tgw3Vvm>5QTVWN(CSVXT?Y4S-;3PO8G<=tk;smr+Kgm zS^aDGJ@unn@aa?E{^%>!td+UBrXhIE+g7#J-)r8y*1ylJ=fUPxjoyM+tJn1m``_Q8k;jaGTGL)_U3#`$A=YAo2*ZK-kX{D zq>t9yRx$5db}sfQ8PE$G6vH;jo5e<#!ZcKVE>{jiEM@0^_oLtc(SMYchu`z^x`p$Y z%ABwI1H)S8AC*=otgOFB0mA20$r=yNNRRhH9hFpS#=>t>N5k87CfjvANlE(~;a01+1_PP)aHlR}VTGZG8`L;nm({wMDq@|mTRWT&YYEfq zO!LPNWvGcPIT;8;GFV}tLTtp(A{4hY1|!_mREAGE9Wkt;hGJb3rrJZ`@F^+bwaVOo z`d0bpDD}44HRf-_4|5YvrTYsi-2{E&JFe1rBG|kaF(Qds5EDOWqAo7wXM9(B{{5+I zANwn6-P2yKzWMjWwhFZ*A%br$A~>rcn_ITHk-B!;sijxy?l6r=I$i?f4rK zGdI^%!7g#B^{YMR;@2VH?y&1OJ>2@tDu!K&ZIuLeCAL+H!HlSeD13P%!Wyy#h|?Q9 z9Hi8ejs>HNWok}52@JZq{Ef@EIRAQKWdgfYn6(wOLt3F$2;723W`NFTc3I-<=Eqs| z%MmJzz$MfYokAisFkmgG7%p0W%*1moi-4iRSZxB-8`OQ6 zeTUd$r3vYSe%8>$ibP1u)=wqHV;b^j^Vk0Cj#{wmpJe_zgkuJ~%*{34whC+)X{|en z^Q=c+YS^{XwpIRvhg)CtGO?{f0jlUbSXnn2tzOCeyUVX+{@vw+m6JDuGt89$X%gEi zF5jZ{%JOlc{)9_du7u^9nVQ&A>K_;!pPbk-IDR@74gq-B2L*PR8+0p59JFE%kA=U$ zEff!#uZMdAd^s32D3FA@WIWt*^N-jY#%2m|jwQasayhtF^xRfnKHLelO3dG3UXPUF z0)QjR@%18fAKKu zSuYdYDiokw7j7lCRYs*6GA71_hAAb*o5Z#X<<;Pc$tX;z7mg%s7r9)?=cUfyxc3(4 zU+?=&*e>@z3lgwhOz8oJ9Hass!Chgp4tV6&p#aHHjARPZF=6ml*bfGJVRt1L3-3_u zVloj`FQ+b<53eeKC_x-@B8q^zPmrsCZnOzO8$ z?qcZMC^tuEr02=>iQA&hYg{w9(rnin)FQPdi+pcy_%&CzE3vIYxn5|!i>r_I!jian z1mfm854vqH#xmZ&YuNlwx zw$OuTiLle&LQ~6D!2q@ZbNn(1$q}FnfQIgvGqeXZTYA_Pk7>xCKYn&_cP-fU$>*Qg zRn2;tn`^3I7mE9ffL*m0`OdQr`F4k0-|=wkFK#Q?mDpBEVAt&pyAs*vGxrt1#JkkDPVGu6fokFE#91Y1=BVdAJq)kz3K2*jAwcEqv6y z(rj0#Pf7Yb>$TZS)|#_D>g9x&=e@k>Dlk7h4PHbXmGBJq4u~c!sW( z14Mk;iitt&xS*NkbhVfkbgUQ*7M~qu+7dpDZ^}DG-y7sU4)`Cy> P|G`i8RI^s*=9>Qpfw5rn literal 0 HcmV?d00001 diff --git a/Covance_UCO3001/browser_profile_4/BrowserMetrics-spare.pma b/Covance_UCO3001/browser_profile_4/BrowserMetrics-spare.pma new file mode 100644 index 0000000000000000000000000000000000000000..98fc2c0bd7fa41623709dbf737993f8b9e26311d GIT binary patch literal 4194304 zcmeIufdBvi0K=g9Qy=7oP+`D;0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj zFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r z3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@ z0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VK zfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5 zV8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM z7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b* z1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd z0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwA zz<>b*1`HT5V8DO@0|pEjFkrxd0RsjM7%*VKfB^#r3>YwAz<>b*1`HT5V8DO@0|pEj G_#PMozyJXN literal 0 HcmV?d00001 diff --git a/Covance_UCO3001/browser_profile_4/BrowserMetrics/BrowserMetrics-6A26A187-6974.pma b/Covance_UCO3001/browser_profile_4/BrowserMetrics/BrowserMetrics-6A26A187-6974.pma new file mode 100644 index 0000000000000000000000000000000000000000..cc27eba5447998105c07b8ca0892b24595195328 GIT binary patch literal 4194304 zcmeFa2YggT_cwkMS|~yU(I6tBDIi%o1hB9qK!OA!Aqa}dlHHJ%WH;o|$`g=T0`83qH^L|NVb2^U1mQ=1e)?J=4$3 zo%?Zdz&De3y^|%QR-HAtTYp0`)si0&$CkT#V%)~tv z^C^t#@^hSyTu&hA4Te0vkh8ehU*HP)1CG(IKyg(Txc=DzS4q&JgzN0C->%{G zNM<64esg0`6Hrr7Gf)z!Ij9AwC8!nX2vBQK8xZN`NKji)JJ3;}_MoFd$AD5m9YDu| zjsqPJN(FTVbqAdQ>Iv!%N(1!+4FnAV4FjDF8VSk-Wr4~u@XSCmZ*=N)6eBIM$KHmP*W5%6^=O(T9{?fjB z@rAGF8s{aEuyo{jb%OX^OB0NJ3EwrYPK17>OIVa>T$k8=*x+Hq1`RG8oHlrvXIR>x zA^iuYr4LS@l{R2NdcnYg^kGBbw<7V`#*ZbgNN^uN?A_Zp<(@M1vxnxtvdHK?f8(m+ z?Y9oRzvYtW`)*yA_UQhz-@bfIXwdK<&P!X+dw!o+I<(r}eEbuW+hzaV`M~7Pi+@UA zxvSCZp7|XMDvrOf>hzV~<6DhcT>X2}%Fq9t;MlO>E%(>OgJrdKW?qt=wx;E+1>cqI$h+f(x2Kiw3XZD% z{JTr9T76*r&qti|W8$_~rhRbqS1Y@q9-`n=8KOFp=b2rCN-nbH+>D}tzr-`%Uy+aI zX0&g%Yqp0xseb1Bf}UbeLCAv&(HIq}4|r4uE%Ea_u0TN%MHY2BRvfCY);LA}(o(N) zwumL$hl!ygq!7hPb=wjrBj67PGd<%Z*DP1i<1F=N6nl}Q!MfPZGJ)cu=~|Qt5*IBH z2vZ;KPIcn@OG^DgPcBN9pMH6)xHk1oeZ>TSD6h&_K*i8#j6z85JC(!9u32LP{<6|@ zr7!<0+U0zozru$YvBMX+0v>nF@JRNsJFJ1j8aS+h!x}iOfx{X&tbxNCIIMyHH5#bF zFJXH|7zP%yPdGtz$Mi|qTGGL9+NZ<)_}6HB(TaJ;c$W>OXVulmx7stJb|kCa$bq?q zJGUTY7)3}lmR*DFMPwTyTM*fPXkJG16teG}1j2Mw*mOqVJ`ywfCldUm7jp8R5aCO1^eU&( z4orCpJi%ZdCbz|&kl*K+>@D$3#yr*I3K0~e7Nq}P!a%>3>|ZpmRex_U{67G63W$E+ zbkJPTRiFnz?}8Em?iA2M&<;>Gj8AWY=E49stg&G@ni$5}Q0N;lSY3+=)$=V4V>S$K z4??+*Ko_^cn08+(bd8Bs@BWxqVP4p5oMCK%L9Ehm7#pFyt@jzmuWuU0vwy+nHYCBg z>VgF0w|8MtJS9=+k8}(u7JJ!hqzyQc@&zcu7FYxRnt^H8QTXz6`?P*1^~@{jnH+_u ztIii}TTT z#(10|+ybGpQi@CETQ4U%e!|CkuQtQe?-+^6vHCk`4ozi@Ce5E5_x&gIc*awAKV9=z z^E8QHh9~5{`+7VA54GT_htFt8RSon?o>{h zFPO@O%IRodDBv%x%JY{63OtjmN~z&(s6F6vxD;Wz99E-Ur1paGaoaHy{3-W5b}EV8 z`0Cmdzi6KFEj^QyI1}pdrLUzu7~=;#_ZY9I*gYAIL~$_E0KkU~-~k_)xx%bzq#^;r z6>FV^uveS@q*v-J8!89gewuaj58rQp`;yfK-{a>Pvq0p!n|%3S^qL#+6b2pR^8CI$ zEDL!Yd7jV|S8B6VM`btfyJS>j3P+Ca z3Ai#}FqMl^PUEz*X9m2o8@8;c)f^}Djq@4Zqv(&bz<**ytFK7Rg5TYtoT`BgCz8)P zpCKuD#`|4vEUlHee6YeQjb?_w3269wQmfWFmY>-I(panh%TIhE7xD_Eg<#M5~^v2w#ctWkFLt+^~avzyFTpp z4JFv)kFJ}Z9kk#%3P+Ca)c!DEFqMlUKhNWFQ{G1hB?vba^iT4a#);~BDKblpyVU&N zXXAIB+4_PHc8uFz!HT8dMeCHz$G;Y*{jU6=Y?dtbx)zHNsy>sE0*&7nfuGg5bt)y8 za8+Ah%8)<-J(HVYUUj};3>|m^czUWYWr21 z+Hm`|E%BUV{(S29SNV6y@{?fbeD=@t6qKQHs&b62D0K#1K8F)Uwj85EworX&tH`Um{m3{2Mni3sIb0$wR5S%uzWOtBozf8lw*ngZyaVEk$@pXKs>auJ5D?p(jW*pZKxmnNOA zK-HP9Ii9joR)PcL2+wS+konw}aaUG1Ydz&Lc?$UFZhMoqO&Cj`oP6Kj*E?QCZ8AB^ zmqxfUUoe#m#$292X}}xwWE6P{<~Szi$$?itgt6P+>Gf9~$fOnctv%pOnwxs__u{ z{XH7~{jRyoYKE`vi4mT35=Vle^Vz@d?>Fc>HkWF>wr;8fDQ!&2R&h0dwBS-B?V_capn93!`Q{oR)IkdJl z^6wrV@c3ZU@Jqmvv5l&q8VwKC*~TDsT=!e}EZ?Lh4p`izLsf_CX6StB3%gznJVoAO zcLa`0>?n!gNkv2|w=@o21w1?-dGF$P6DZHra+TgwN@4xQ%FpYk{C)3bZT^}kLrQ(q zRp+yRo_Ds->vK#fE1Bg9Oe_?=xyM;hKx6)(W4tRE8k*^<3R?P!jW%$6I^v>1DH*|M zSPuOb!lCoozhN8$(ghGRf|`$0dr4+Iy)3w?a=?2x{kfjyF&>@I{xR{GRX&D#Ec)4H z15e*+Kg|DdgD@2fk&H*@A2c3QP1T6V?P1nQG8NWOGRhe>TSdKLtMXoWGx_$;3(mao zg`U$S4q0xfe`3B&A$pydml3Ec4LPvu4g=c)@k};k4pEB-k{`CSglC!? z(!2pCUojr1N|yq{^h@lUq+&#rn44V+v7qVgFdjP#eZ7TMBLT@~e zsfG;J??&hs$;R#fpX@sCkJCIwp8$$*bSM2X-(*K_vGf~hG!SYLh~@7SBcZ7Lk)zs( zwm!FyVf^&_+UDucG&Nov{!_2!V^^Lv{81^QJ8t+b2beFp(QA(XJU<4j?#X^!#-lxj z#W6p+trk7M47&n9I)hSg2`Xx zeGcw4M|FcJ|1SpJ09pZB3)%+yH>d;fjRX~gZU=1vr699rfu05(gR-y?l!&rW0~&zx z@GWQ!%ESZB4C6VJiyr}a62N|e!uc=?=hG+~NdWsG)(0L!0qp?$%YMuqeE@qtz@7}S zuL10-ry!ltsAm%mW6oJvmnei^8Oqi|ZY0{zvZ{2o9#>;uXYJ0iJ0mZ;MK~RS%*Lr)f^~Mv<{BA_cC-HNIqi`(| zn)xO>a*K{eSVu(%nYmISPC4Jt`kIeWWU%4J`;d=-}Lnl-%#>NhmJD{ zBRL93_6X(+rgG77n7fqa)R2w72wx52`kaDBt|5JV(fx?P`JH-gU{QpF(CB>j*KuSA z$7APwab)ONjesnFsSWw9w|sfy_C96jbNVb_=d*u3@^f4TMVLTnzrTOOzd!4ZKgOPw zab9E|%<^?U%SWG$si$`q=HoD4pd&AXwW7+LjU$j+4#GC%zx7;;^FQ2Nyr8WqfbIzx zH#48*@?9Ml`mtpmuPkJ_g0NN>&{Q-xpAA*35P|a{7nPEJmlH&HG*5NbC9lcKzHHB^ zt3&V-j`g7P*`F4bgzbUM63)_6m>$KlpVM7VV`w)DW(ZrUVKtG}Hq%4@0xeliXTxxT z6)0iBFcVbuwiS3ADz`r^TXs_Wu}}QLco?tFXMb}X=FH8887;>}o124UFuq6YGLazi zI%FjxMD#XL;ur}YrB9gj_GIq9TXwgam)eu-G2O{-&wTuAakO3|YE0zS2kBjn8_P`| zWX&(Ob#DfqEfaUnq!@`WFMDEb>J`i6@0Q`I9b-O)QC1asNwwL#i2{<{$llpXVP_-b}^Hxpf^Z3w;{#GC*|i3hD-0fq17p5$?PS zo$GZI&PxmJy>ivB<`2ZsNQ^U>kAE!=zr(DPVwoX`A|zZG*F*hXG_Ig=B#kYo|7rtD z2GJOU>M4ygjsl_k7UK&ZS96NfVzKrsn^g_Cz-%h`=2MEobz&-_c0(&FqWl$nOP6n+5O-Mw1 zRH6f*j3yX6V||Q*j1J79)p(wq+KoBjd0Ze$&TFc@<9;YWhLFSeNIflrB^j>te1^8vuQV?LVvh>ONQL@|iDFh+b9s=(}Y$DGE^Q z|7IKV=d?NMtP8sa`|9$UAC)Yh;>fos!jk{PWn8WwvGlN^^Pbz%j_ui<@|_&rssCZV zU@8~JVV2W~2C5N;^}o@E+~J*F`-|Hp;=MNMST6HTcH|aQuJX%O{pXI5(VVzZy0L!u z@y|BRdgFq-zh?mwM}ndA*`GGrxB_k(C1qmkNR|1&+#N+59?XE%xU(KM+rTm7hdY|C z>fk$@(rBFtay6J9r5ZFR~BvE#p$zrozMRD%Ev&_MN5Ae zyOUG%qt*tFcdi(p__1+Lo&3=GGIh-P>&uTkY83D?Fg4b2OF^6;m6(5%i>Hsj7ZyL3 z`1MX28VJYw(E03NFAnq@^E|#Yy`dt!>s5hrBMr|SPt}iszL8u!Twk{B^zR?P+&Wc; zl;xVPI-mV@T$4P-SkkXkTrKTpwGAAPKj+M^xnb@TEQj@@^Vz>X9AWUP34 zD0r;;naQPTb><5?zajZrakb#6v4Nw>GgaftPcEb(lW?pDozMRD=|L;57Q1okNEthx zK8C#5ea1EGI>C}89pljX>|Y;_`iiSsPFIYSb0@|_eHVs*7Q4*0%Z~Wr;|KecN*uDB zQh&mH#=-Zox%rs*2HX{RvytZH#h!qef6_+N=xp4&Zj=rHBs(6CDZU|}OuDCLw2p)M zET8Xr*kF|%^cM@^j%=(}g*@ozQB25AFfo8Vj@XP7T~|}}vW|ejF&^FCYGfQ~JoQnV z*H2sa&d|9gAPkqqJc#)s0p$|k-kLp;gR1S@)KPK_Y{KCnmU~5Iv+H|xOdn;!5d9+s zs5JSO!1%{vAD}J2v^<_)>V^f_0sFJqsyGS@^~E058f_S`^r!ubt1|Hq zoD)QT)i*7b^E|{GG4t04rv8~^oK`vg>C0QW);6Pw794dfm@gh+zF;aB)h;C8o{p&b zj51H4ie`Ea*oSgFt{`k4^vZjVv>(YtYH=g{@#g8Ihr6&ke3URiC z7x(Kxn?T3n$6XFO9+i&POWHNYzI)91wqg?b8H^eokjPJ%@3lc9XCRS1NaU6r!&o^7 zZ38Bcr@d_$S9DG=e!%X6^Lr&4Umr*`JiQtl-8M8aHYO$+V>-1omdt5m>~yy`9(=fy zQQ_!iJk@oWF?{qyBjL{yp;ww?1B#{GWSNDbKK<7=O*FinjGf_MjrGldn;gyGN&n0j zOyy!r{}X+(um@p$@nFb8 z0#l3@|r|ca5k{r-Nu(N>ekMme7!#hQl=Eqv6g- z5S5EjAT(cMO^u2%vcwn*LY5iXpmCtnLE}NF;$k17a8!GeGBpW`bOxS)c+Cl?fEP1=YCo_+1Fc|6G3Y*qDBADu6XQ;nfT9 zXdJzzV%oBA&vPwrO8?1mLR*X$m@m1}>jY28kvSpHk?9L&`GY7f;{0O-VfS|_6SX&(FizKB^kyN6sQy1B2SJrjPH^0 z@4$vQ0*YN2FpSIYMIP4_c41TVI z(WZY7gZRPb+LYqFb(Oo3Bph| zLOo)AnDk4wN^~{CHrp9@(leEND$7(RsVr51(Crw{g1!NfaiawE8i)=!dIMD52xSfW zzW_pZK*-GyvL1a|IfQJ3kYm~#Mj`T|WfzpwUWV~1D%IwZu=yfG7kgj}hW0w$fx7rA z>cH>l*V7XW(iiJ>5#(~YT}Qy+oS3u{I>&F#M}?nVfc9%H zbY5*3H(dvvE=OKGkM?UTY|g(yb_#4v*pRX1Jm~DU1moxrv08RaqS4%yXbgWc(P-Vi zkx(`zw0JD-ea=*|fuj&Xsax;IJ6X7UXJ$rGHDEV8sDdind`Z@U?pFBh+lX zm(g#sr}U9Exhx0jhig`c&;Iq}n1ubbc~!7@l%S^#q4y2;L!>N_-TFnck@dnhPWnLh zi**6gaSfii9IwLfB1h#IRjH0$Z7J%-C(By)KBDFR7AOM3k^Yg+0p^?R$So(=iDQ_s zniw5IjCYm!u&ftAf9{dbnI4$pWt643F`g{6kA#EqK)e{ss_y~+T65~F3sweJ%Gk0z z&{gNNKaFQF)~a)!T=aD(v3p#cF&B9m7?CSMjBA~Si`p>KvARz=yt?!Djkg48E0S<@ zr+G5-O?Koa##!P#q-?i*K}>q3;zn|5o>dFEydLo0l@~XsG*w(vQQC;-1ks)IeI^f)fuSzyK~WItG_#z{0=$)zWJpG zMp5@69Lv}F?61hr&l?q$oQeRPAEl7X`O)&ks^bZR>R+SyU)a97z3#tC@ozu-^#R=x zzZ%4P?KjE#yJF?%W5bp|H+yIn4HJbU85B$B3pOsi&nz<+OY9g>mwVl)iM+aOwZp8_ z&URKInKx`^4Tx7z`YFWu>M5KxjOjK4{68 zjWhs;V;pWgQ>EAk;`e|bz4KbzQb9L^$@ClBJfgN8OJUgIGPMPYtF4N-1;+1 zl6VpfozMRDC{V<>L@V$Oq z=uNO49aGVmxYT@0qRA2*)t^h|BN`rb`i`B$6E-*~B< z@ROrEwMWbsOy!c{_s{WqFe?lML-bZd6$V*BwlsL$qkSQ7z(YepKV`91PaCJogcuKv zyQv-61)O(p%*G4?bK|i$j%l%@VxbHv@z7Q0vwv(n5dee^FmXyrUYXe8R#=8@ZHQb8 zqWq0#7v%Pv`w>h9BKvY_42$W2n18j!{V32eAWV_OzL+k!_W<<<^#u(Ek&Ph(MAJ%Y z3aE3P1F8gF4x%#k0B9X(D~K9_BatBkL73_qmx7)I?FRKmX8J+TgD^EPDnX=Ao(E7` z-0sYrhJWCkAVd}6biMDJvEkKUgD>r*aO5Z)U3I=-<6=Ya6EHu(;g!Xs0|9>^Xhsa< z&bWl}1OGFwSoQmkEB0*sV^8UBGkOG<&S(GFxU3aDvrMk3z>@58TZ+m6OTSfpmed2| zsvAi7iiYy(OMzhY`j7aooMZ6CPwna%h8i|~-6a7nl_Uoe$R zE>^(k1uE<=!%4>2=#%3u2>5A^h6S+#+GZ&OV@Usx+mj=Z24SW;oNA^=^OzOD&;8Fu zn2r$UYSW+AU3!w?5Y7oAzgXj|`-e68tHS+Nopzr26kl~1XX4#lPvpfX^M9_!7QL^s zA%A$m{Wt!;WII6~1ix`HZzq!*&?e9jC@f0qe9ujBOZaA~)w{OXi zQeSk{`Rva)FlxaIb0NGfKe4brEEGpAj~i{^`E=TAU+fur#b%brdeQmp&v^KSG}`}5 zd%kqVs5o-XSzJ85eE9F_$2Lt_ypH8C4xP{bIu7|_oQ}e(kF7Rv{ITJ(;WvJ>j+WPi zqdT={%s1JQn~o#jS4KyY$MgG(7!?N}ViOO?FN-q0&JE+=V>ygN=d-_#Lo2Tlm8dut&62U>;n@G%@kefd zDsZ%vFWVC;ugqupeAjVk3Imc#nc`RuRb(8{Z& zT-4Z*e_r_H$8LFVmygqD`8uEdS$>>yDuSx{kz)29@$}HX-`&m`eg4A8O*+P*^Vy$q z)K@+^Ts0mzKbG3Sap2qEW-Z#VIY-KmmJ8-{x_sAhSj(rizfUp89P#vU`4bf*k~LQpF)78QOxBXU}6+LvDD)e z+ko&cP~42Q&dD~6-V`XG65%U z$htb~dYjS91%9t=8hpI#*8McWgj)q79LyI?ys{VjV;>Za)-XwI3ikR1&DZCWELBw=@aWO7Li2jp`=& zsBXdrN_Ps2Dk#?d=uTmXAVN4wTX)2Z#n;3Ar~XHiAsox)J24q2J^$atMDh;1|9@y8 zjDn%o7Zo+Oun5Oxhw4LTlZS0B!X@F#JbI=&MfHi|&@KDEu{DPPs4f+l7D8e1aU|ZH+7Q1yi}G-^`1wLFCUV ziHw=+(HAUjE6tDzAgk(3;viY6r=V&<=zt zk=WCAH14$CO8V>oIu=B~0aK-V&n4&vzwV$Opc6o(7yRS}xLMY>`c=i(Uu^|2rR9`1 zIeBEhu0Q5enyRy*KL@>9Kgly2A88E$fpodZAGQCc_ERUyLMAhsxS3fSdDj0|!_u?r zullKcdS)UV{H%siuey;5w9ADicl+l?QsJK3&~!a?RCCMlG73@hF!U zx|6+}`S{o3CKutIE{C{Mlau4c=Zk5=>Tnj*!MRnE!EZNP+vQwXKPi1Di0(8NqVbXX z9gw>hef_}*&(mL#KRLP+9_94FMfR+{ZAz*ZN0A;uE{hQt2wxzNb_b85T1 zRl~z`RdqkX%4^TQ=Y~L0V;v9k6)55{f@iW{9tBhnkV=H+{wnwUhVyC7JwvZJFsplS z9S8I4;E?BJN({6mxI*TMT0UxR$jx}&yZ-HoZ%xK=lSPw5>bL#pFFP?od%ayni44u#Z_2MxBtWe}9T_|HYaietIAPTk* z#QP$5&z%vtqNX>)7vU(h&PNpCrg%Nri*KHuO{@1A{$fA9wktNS;)oJHBgc(hFxXBp z(KiA0soW!Kn0$|wU>IQ#>uH6CQy*th_%`KZnmsl2o0sUB9P3HvOJBSPWx+`UnLHSO zLI5hxA&U)6yul_@Q0rB{`BEP1k=h)Z6RGFa-o5kZ_5R(?wu`KJT!l9 zymF1B#^k4(@kw8t35x1k^T z-nV}Gi}UaBw^>AkEjY@@j<_;kFqO+e;fsQeyunb5v`BvqjTdQ7OL<1NK7vN$JsQu^ z-nx;XGeH>Eir>2p_Y(k|4)5-WPUs`h4it)$ks&Ea=r&B0n_!T64+fTBVG!v`#d{hj zVL#mnyyugP@ni|!ZMq(N+&1Ffy*3HPE%A>vLbZc=cH#FYq%W^+@NFAGuuY z`F9mmp@;Ma++stf+yOTVpBk8h`fZLovDIyMS+R>60@~JN?I$ZQYPkN?emQ)rduXR& zP^EBGE@+<{^G$Z-#<(OJQE~jm!TQix_aTVGN|BNiL~>%C7j|CXFTbyT<*_WXd61)U z&2VMDU@8}LZ&_p*&g;FSD+@fLzX-~}OL61+y!2wLUQm4Mj3082x^4T@J%7fVThh^; z#t+Ol*^!%$!fXoMbxWv~9%@aW_*=fPI)ds$Eo+y8O*cYLbb$rY}G<-Q2BDloo=Sr|omGhL+ z3WHdGm6tcHzhAz-u>6!+2P$-Y%%?O}XHS0$z6@6hj<$(FRLfm526t4BoFKY40qOI$ zdB2Z%#<}wBBpn~~5yj$c;>*s=#w!=2DxuX zG4{*nkF4{481oMe7v5a;Me~x-2G7pgh4eM>*w%?l-{C;{s*BkQ> z4Ih0|5k0+}JX-Ln`MTEzz8yK=T=j74qmI+-Df15vAJqe#?}RVxGPo6r-j*(ISZ{NR zkGT&mS270yV+_`eINQ{Pz0Z`H#lM2V@V z@WP=TpDn2TlERUraCFuAf{n{T>j{Qh7y~Ws+Fl#Dep&eJ>aycof5UPam(FMZgU2Oi z$d-1arbea~PhaCRmxLd5Ws|8vIL4*(+5g~i<|??1YCrK3GboQTUw8#y)$Hk>H_Ko8VDK*g83+NRudk@zChN? zNZ6Ffsd^E1Nbr;IeE%Nudn9q|=z$;n*p;5iv0ik(^gR^4$nV0PiStG10AF1>Bav`C zy)=P8wPDF1YPW`fD1T$wyS8e-Hcc;Yjgf;;ZcKoY|7@74M2Z@;|a^dHQ*IiA}8 zmfj$_oDZ>ZT|Ynj$45UJbP302Tsoiq?c+KRb8dX39CL1ptKv$!QKl9T*CQ3j&40W2 z!>3s;6<62>t|Pv@GGcKLa{s)W8>_#m5O20{_7EfQ> z-`So1K=$dUvRuZc^V$EPamjAPf@`x4T>WO>-*4i^C+4tR#-;Pw-#)I{9<2CC^9drW z{YT}^GPQX6THO7b>t~JW(VOKmE}hT*hlDGw0>?n7`RlX0CR5>qi-+^VW=&epc(%p8 zGGw%!)cNdhAE(bB@)oj<$D+U0HgJ`VJ7UD-le?H9qqubb!Q*ma?4B0Hfxrc!v;q%4 z-77$P%!JhXn!8Lglkx&j`0Yy>2j{cSXMg+pEAdu(+-cmxg^>XFe|v4<+S)X0 z_Z_MC|G{z@m(FMZgTO_$u{7+h@wiITO1uR!g)nZ6ujUrXi>J3aFJGTIeEUfqWXNd# z>U{P;M0^FpI)+5TAja44R+(x%e1&_LXZM)rTqi?D@#%c_w~wzBUq12|_>0r9+Y8h1 zfJ`Bb8{^w-1K$~|(~f%c@4VeCpYvDev%h_OR6lUwpSK_l$IF!8GtrtbN$yDR% z?~(S79&h#DznbMUKAq40_VJZ?-QKidRnSvOal;_iThhOX6TiJ{w|~sh2U_;}ScZ(| ztIlVC`?!L^V$q(Yxy_v`V$7uW8>?*Kd-2>8Z}d9*pU3i9Z#tj-?c<|zhc*vwN{Oh! zIDiX>%oKWM2~_hp>voxXy!<`jeDJ3QxBRt^aWGDu&;Ist;={FRvs_q;7d0b{1UP?p z*}#>)yhHzK10MSkQ+nYD7p<={-(*K__HhOAid>q3o^e z!RT)mFASv3rj-FRfiUijujo$6jE8UN<=Jzm?0tx;y>JQURp*=D2Vn=A6*q7O zT}!(xUYtb2@$h|^=5%)aW&@cSgkyXU{RMugALhc&^OFxoDg%B>D zzE-{0>be~rWQ|Mj~JPOJ752K7t3W_I-mXR<0^Gk(RkE4owVpJg%-Zx z;^E5Eh1%l$eVxKekuyL;Ne^Qu`c>rLmgzkOUN zU!=BDFJ8k6h^{xyEkDjlX@x%~4B_||@K+O&5^EuX;g8K2H)fBX0_p2yc>Ig7(cfc3WYL77^-a`(dC{bRov zI%XluWn4O+{SO+KHsuH-A;y>fkW4imz88m1-QKp{x3gG2}U9}Ls~_Ej2h9_*;@W`%~@hR zJ$BkUGdDbYXdA}CICVbz+sElEgay(=U!*2On%Zydvw`cq2VY9BxTR4Smdm(wKKt9p z6|J{*OQBVNHIK^F;M#{I>} zCne8`8_A8ekKv;&t?zAPY{-%!qxC`Ov;U#uW1B@72{FD}8~CmslGE{JSMn5=&-&B( z?0?AkOk0JDuiBi|$J5{7yGH%G`m}vydJ~TE>3sG-WPHxx97;p2Cq2zw9xA>82&0~t zU$ySn!13!J?ZWaIpU!9hL&k@rug%XXiUkf8=Vlu?f1kK%a{m?&E@K>wQ|Gh)KfyWK zUn)OBg2cigE{~O)GWz(n2sprp@#F zORV^kpJ^E1rYk@A>zPNNpU?7Hk2;_I?c>8Yxv_AX22*%}vQVUs>sQ#o*J0}Q%ZH82 zH!Z4B{ptLJ$48r5iqi`53NDSSXeh<`I`vtZTD*Lnxp?cp+c+}UvRu}i&S!u7deiLS z0Z+NP`$jc8TJR=4*D&78kNxP0w5BH}GakmP^V#1%UbX)##>>polHi6B0k0Bc4X#Qg zsp@yN4ZP2->GO`yH+C=MVZ1t@{SOVVoR!2_j9wUwlR6Fo?_PUK_Z6eri#p%YQt2D9dGBI-mXR~9}mQ7BZJ=Hin#!bpJ2U6I-9#mm>d&Xf^%pE|D2 zI8o;xJTCfr2HKorY~KjEA`9qhzhbPDsm83sILueS=%ELe665zBqV`-ieh>mWnfXy-eMS8_AC~ z4|wBgSC>Ysuc$Nr()kCE6US1N6<~J`waulWv|^kER))PMW&w^T10> zF6d~EG@|W`&OdmZ7JVw6HacvaMZ)QY@xb*aYymV=w%uP|eat;=Sw7>_`Rs2W zU$i_1cmc}#s(N{NTJ z$&8mSzVo}k&tyD|SLd_8eY`ZD2x8+P`foJv9Dg+)7~fVK_&z%S#p~1VZ1gk7XM8%J z{q5s3=K`oMvppdi_|Tqn4;H(5pQsPJ<;DIaN?WZ*)f=U>czS(mag(3=?DnopG=ULr z+Ks}9w_lfap&2qdZqoUj{y)Nvvvy!8@TjoW@=$97Z+iEiCJ)^6?!%0S^{n&R-#*>~ zod1WSfLBn;0)?<;VMSBaG?`KuH*UYG-;lg`Z#Il?=w%D0ef-j2b?oOl|KRZjOFb^yVIp5SlDpHa_}1CL_m{6I zyYYz1$5}q-v(9IK`}r*GRcS$-bB2$+a(s0hGW9LVjhDZde!u_J*T#(chT}6nozMRE z@y+p6iDk?*+8ArGPwlmVt8vvCZ!IdF8R>T!m(D+UT%~?7nUt_BA~4eRUF~CM6G4Qcb4T-5ZYu=Hm$J66o zP46n+aq8a@yCLJ$`TrT5(T&9_&h&R1#<}$Q(-(K!7ui-E$#0#1@Hov)cIN2P+=${T zb9=?wU>FHU{FM1*Mh@d(ed>Jnx1aBdotNIQ#bGM6V5jP_`aPLyy!<}n z>+KsqdSZ4p%V&H#pZ)(CzG%TzarS(_VVr|^RBp<<_q*>I2jkTF?EepOMhd1nKHF*o z=SORoJ#h6G{pjcj;TWgRXMg)Rt@{KpVt2XGYx{8&EC$0N+T%!Rs{LZ=2U1GB{NMc4 z;J=gR{peskj92HgzkR&)`Y3S8#?vz2P5!W9TxY*{>6RI@pBl_^8JEsyfBU##e}NUa z6jO*GK3a~?K8qobn$PQO;M?)(>M3^(+VCsOXM8%J{q5tkj(5=O;NVwmg7bMoc#B{T z8@0knnA@S5TcnhD`Fz=`Q2tZDx9h`r7_ZJ}fBSf?`w4>u{!%i?tOGH=)U7hrc=#H( z$$a2*UzrE zI=|8R>~9|*`pZBWI-vMNx-b%EeI}c`F5=-m_Wi}3Ha}ThXT3$|A3R>Uzd)-_mUeT6 z4Sc6HdhOgbL%gF|KG!Fm&;IuHX~AbHhgsWYYVq{e^v(;`b}=SL=1Gi8=N}3#e<{7= z$t{sgLG8!)+Q8TO^4&T53DF z^b?tSynJ8xMy~tG-lw)?9E?-vv%h_u_31NMgxy$j7>6NTH4^4_GUd~T&ygQKCgZIi zwKD=6qJC};OkhH=NyhEbMc7;}%s z_l%Fjo`d5J^Wr0EPB+Z_fMXp`d?9}y5uamSoh{ejDEY*DNYJ!Z9A5&;C(7`PgM@9;B+F%JpDH&lkcbjr<_5?5#q=luvfg zLqu^A=K!L(*s4z`GXK%Qp`dio zFc8&QYOqcQodP-)M0I#1i1K9=CCH{dU zyvRne|3@#^M@(DyS;q(7yO+X|qi}T9`GSp$opLnUkBPEbgj75mZQyzBl+V)Vf4iT4 zx^Rp~=d-_kJYrjlrJn8k%39AlBhggQOz?*{`E)1Ac=Db7$@lu6yOf^EF&>>SeJ%RI z+;EJ)7)BSZn(;Pt(J*nmrFi(CRL^3Sr+(i^v`*Ye4}EZ<^0(+~d|&ZVCwc+&Gi%0t zy?EQgi|Lsh>r3ZLUt9XJ=;^=RzyG(}BWjDN9ildf+8=6rsNJD9huRxzYp9(e9aH-< z8bs|1wJFq=P#Z#R2eld0R!~Kuw!sCWyqFD|1M-7{pbF6Wpaq~yK#M?&LDzw92Hgg_ z6LcTwA<*NXXFzK~8$fS@-Un?5eGd8#^fTx$P!nV>9r&FB>I$Orz~v?ke{P31YvqP; zQaiK{#NRV((eeI8h`i!SB5+&W#w8!{(U>X%=qwm&hN}n0fb+4`$=2IBenRs%YInhtwIq-2R%yp_v zAoN{H2?i0V-f($Y1Uw{%@z67s2lacF8J+)qf@|$H?Z6g}@`-+h&KGQ4Ogy72ON(K6 z49R~Z-)t10fTd4pSa2kNFJm)~Sl{1UyCyt$(Uz*cEQfLEeDFZ_dO7Xp_vg(1*M-NiJjSE**}r}~dGtnyI};m?urMG?k5rL}s+OB|HgNr% zHmLLU&$s-5<;wD$Xy|1|Y99es0Y}QY#@2Is{zqWgFaaS6i3dj1<`Rs2N zm@~2DfB}#ES~0!@?KT^k(>+zP8|QHjm78^Dsbn0fYZFDkPz!uD*FX9$r9JcM>t33F zZC@IG3&%KgKKom7n9_mAa%sf9kMoH<&0vro!_P5iq)Q-aLWrfrX08y)&=Rf ze&~Gm&oxie%5nM75o0JG%m`GKhMaWdpku5jlufI8n1~ZVic<~ZcE0E*YrlgmFj7H0 zKdAn_kJLtA%TeU3!NWeK7v~utPmkT%AVP3%%W167jlKl%$_EU&@4ao z7pr`DC5*%+>1V@uu;~DiGcR?$ZQ~=I7GDpx#ns0bFTg^+vlPdRRieAYCyG5K!h(i7 zjG&meIWokNRZ2z$Icr7vja5&YcWG=KIV#CGwxE^K_0nXc_q|6M12&`>BfdV)$Vlp9 zoZhR4kvFcFF?~*&;l8@RQT)(gBlOlVj}8H@XmF>ahR&bU1|!B~F7B;(;H zrx;Itc$TsD-!qI?Qwof?hs`#&oHfU&J>PHax-DqzeZIoj_sRJvk<~`?E|)^~BBMjW z)kc>~Yasgu$X;p;|N1s#RMMT0eJ^C+Z=5~nA*0~xMn36*ngO+i^Mh%DF?(~C7_w-zx z_uO~a^w#yl{P;LVS9%J{s2{FZIchsNbH7ZD^`he;-&cCRe&=@`GK#KfE5jz>)(54I z`H~yG#%u?v1?;-u+<1$4l$5-(d~> zf31Nq3bbBd7?ar*qn674llgR~dE;UC-`Bw5_Uyl}@1d;ce_57Jm%9ryM_4?ul^ z6GS?sXBtnbcDkE`{TKXwPxVn?3rFE7w9Xf7TueQ|+~ZNKbMz{t{Fm2FSueuQVFO1_ z()^ik^nK(bmcux7KKtk4)VWdSp>y~;d~gn4XLdN<~$x-6sDTe*w)1SP@r|emG z$90WGP!X;>uFRL*=r!iJ8%)*yVD2Rmk*aZ}`bPPan`p(O&yPfey-68YEt$PlJmVr` z;HvT2e>Aw$Q2=wT23p?uNpf!T}>ZTmnRsvZ(ZK%w$786 z-VU2LIV#IEUu3>uDi=HYz}kQj#!skk9Hk^DelPvzBoN7_XLj^VyuDmdRJJs1{pp0S!J^w z`Mxo0xK3p#q$z4s)diPtT@S{lvnPe%~v_6`OwhMaRSZ2oUoj zCY~`K$oIJGqOsyxt>K}(qWUuv!pmFqBa^UkVSer%Ynm+li0Ao~uXIj7^C^t#V&akO zXC@qcI~=_c$5Gpvk|>E8zZzj#{>UV&e7(IN*(Slb@7<&&gN7eH>$fjt*e{_7lFxiaw0N}2 zkL+4Btzg#nexoK||NXVe35N5_cEwk08L^UoKg(x+eEC*8SVRekq_!th>BG@*_2mQk zt(pARmgim0m4DNM2OPzqbpYlIrgDkd@6@q>MG>jxvle)$yfGen*2inTAHKD!d-Dw~ zC31;}N;UHpDB{s9pP8OQS6OjL{x{l(SD-Ln3k2}8x?9Fj^-|ixT2ErNBNugiap=uc z8a>GJB%TCA=d*u9I5OzW;E83S0>4~`Q1!A8cpB16M`yurf1Ug_1ryF;UUk0dZA>ij zd1v`69rQJ1Y$*5S2T*@Ju0TPNH2!1p8y|=WS;mc((0W5S`Y!psd-q{IYgrEC(E02i z3&*75c`V*C?@2z&nlG`+$Gyv*p8QVxOKCfua3jpC&Nsbd>H%$R8FYfhkjN;`)D2di zy;urIWZk~;EO;$YP}ZX$ypHEVpwXa#Aex(v1koPDR8T)qCs0>VA5gMMG_*S!M12Gi z^U3r~|I>mGO;ji@`BB~AF#xyaq!S`4kFre4aQIg^=BfWvcsovytHxn@bSEroSbpX( zdOY?2!_WUaH4sMT*Ei2dF@G|bk5>4fo{s_b038dWeQZ5J_k%`)s7}%PJGISJH>kdG zd>YdbQQaUOm2V0|^{cD-Kk?a-Uww}172rle(C>qAkIs=a~@LOalZ1M+81_eJ`#`q zr#N<;9#@USvgm%eJySJv_?a|N3F7(0B8*F@%sD|+Ug(+1jB01x{_o&1uU}Tako?Kf zoklav7fj{CGl(1|M#{PZ;9C4g~2KpU!9he}s=_h=EX9 zDH5vzu^wk0Z5>xq`=i=J7r7c6f2F_F`kIrjs^PYW^iK0Z=Hp+BvyIc7BQHg4#|$D{~a$Tgrcj__&fg zCK%7%7!LOy`|{Eq)cM1m45ISSe8E&MR(nWfzmlnD3ltGcEoZwlJaz0d$0rzPKQXsk zr_{>^o==4kj`1*Ga-&x(o;omM?pLZjHojhJJ7YiO1se%PG|dnjf*#{h8mD9}eIDkp>R8Xa7ijha>+#rh!!aULF_s!?=XUy)Q4C8>IeR z9nYFwk8B)cu(FTs^ zE}O9L`2=8@qS7Pe2-aWJ3d^F4wi zSANDD_KPCF8>euT7nm<&#a57tYo85VGYXbG*`ohBZ|b<1&v^J=FD@u*l*i{O^oD}5 zkX0iAD(AFMsPcq{_4UceH|JbGW7F9>F6J{HzDIDy5{^JC6#1zq%2b`;(NnDV<>qaA z?7)^rZ+b3SLMOz?aQzXQ`NUIQo@X}gOcJLW=3>!{zRKgE{e5^D)=%$xigR@^6Q1lh zU#(-tc&r-w3aZS+RGb@ulY}!)n#-nw_`Rv*tC|`&jd9(S_{RKfvKf=3Hi71o%oj}M z5))^hr&w-t8{@)9fZce@FNiH~8AW)#4@QIvyvh{7S}!aL^b=)bYB`(PGd|9m2b&sc z-i4RmIN6y#%)~iT>HXJjSs(jciO_&<~B(;0WdD+ z{}WtA{?by|WCXG>65{f|v{wWAx~-|AmCQOTDA1k$Lgb$A0r3>DTj<`TqdlBu}uc#FOQ5mD5Xfl&NrG5bJMi1Ne6JKGJw2 z?}R;X&HM4^6DTqq*9+!LZuEK(l(mEQr|1w;_3g+mP%cZ%#R|IPX~dI%{k6euiVQK zL=s^T>u+XSeEp?f-PCyWi4WTrXJ`MQx6jO%sG`?{z$e>hQk&8^tN08@e0(JJzOHT4 zADR698M^+MA4Mjg4hEmUq|_hup#LlJQz;Y)RO8C}s|G%DP7poCdVl_{(6*f`ZoauU zt$UKAaLsUKzF;aBwm(NrY;;zM*wQCLsr^GrU#t9B=aqGMuKn(bE62@a5i&-Cq4U{4 zwtn!Ew7K&?=)fveP~dUW3(Mv*ie(+FM#B|rd~(c>RY(2O-AS*)3ny)XjSZd8{$n$8 z%-4~H&`eLUOAI+wee~?t@VKn)j=5u&EnD$~)Pu|qDrL-Pd3-mAujXPGhSC`>Uk<)| zVe*~wdy1o~=#UU~q_5&y2V5l238FjwRD_v^WtH|}kyF<_rVeOW4GwPaZx)hjxg%PRWEpj4yRi!}z8@x}nX|(-z#M<6}Ohsk(!~XKu6}T~Zo~;HySr zj4up)4VCY1N4EdHG8i=9K$qp4t~#GFM)FZq`CR&199Y8Kfm2Vd_LiQ58`jVG@cHk( zR@nO@PG6Sq1ViVue?-1Gx(Ty`81EQSSWEi{9I773rcHYoH={CcnYeQ%9*x>Yt^1$( zWI1+FNJn>y#e9<;xkYej8HN+S@G&xe-D!+J0DSaiEsm(xv#cQv>t}}J-mhNYwQV2A zXZ`4W_P2-2s-IfmXh=Voywl>@KmYo5qOKq2vwXhShhq%p$2f@0>>uLmr)X%y`sqA> zs&9nnr<+(V>qqCazdc-5{TS&D>!;-FF5Qo*-F2g`ALg@szSoDt>CS=m0N)2AQ$Y+h zsr^O`aM8TX2_m`lOzn(n&wTXPS3eHkyY^AAg=78beD*&mT!<6~aeLEmm{m{kN*IZY zdQMFG^4mw1q}qHC%-nY zwL2p9iru%#kW#PotC&w=R2SKq9dyuk5sb$&XxQ#U?uny()cT%2ykYtCGta#*r{x|K zX;eP*RoV31fP4pA04fnSq6ZC!8-6qpphkwzLF_kw>^AS1s%2EB$PsdSUyAvHsa)#f zkV6YqZqE_c-yciv##ZT_+$kwMT@i9gy3S|Oirh?ZP`qO*1Xm*f|K1gv+*tX3;mA8X z<<2hTX=X&O&W|D2%y-J}0WtNRiqRweawmxH)c4Td;;iEg~7>^ceHU zrA_D`I0{Gmm6$J>%0>CzI6`T>zd%?{2UyB`*oNE$$EME3r=Ri-^@-#tznf4_n|#4k zE{faQD%X%MqO2fZ<%O!mt9aZs^Uzg8(MYMQ~FaJz$s0ijIjJ$EW zKFvoa78Y_NDo5Vc3chu~*HHVp=<(~PfBp99gBgdc4~d4(XMY8s1xU>IpHFRAKT}it zExT&&NfY&Q!F-m>cSU~WF`7HpdB6UI4pZ&0q8wiTg z9QB0x6h?Ilo=jI&P#ktH&RQ!j7Qw2K0F~GO*0}+^*SrIybp%lZL+cP-K|Me{LA0;k z0iuR$2xvIyG*BjJ94Hqw1#}L`11bTPgQ`JSf^G!e33?c`2DAyZ9rQg2suAb()0w!L zAX-qI2U-St7W4_I2{N}YXgX*y=ta<9py3!yTnO3#YTp>==YuwYdZ94h2x<=V=H;L^ z*!y-D$e9G0p!<+Hr6^3}(9jJ=LpKN;_{U-s$=o(L*EbpA+hU%8yv6dxf@(nI_9E8_ zFmO%~J;loZ^Y6cA$S20Ut$O}5pW>@7R{oE71w;9zZmb(w>qD(3-;IPQPt<;K)fbJX zJU%1)ZI&SsCm1@P{T2Cm|6Z*R1H|+VYh3a?E;E8UzAGJN)kiEm8(z(Q`^dAKU&Qhl zkIrZR`tb~G5RdrK0}^tANKPy~_x>1PPXcyvDd*N?~44+Ws}%FGC=eril> zNIX0}n%wttLQ6J#92rvTk$M5|Z|~Q$M+W9AsQ&*$1-D29EUdsV84My30>2hjHk9_OBm@sTUK6nm@T?8rH|W z;U~;rQPRv@HJ0Utt~$SA9Hu_dfC#UTSnU%VRt`pZ)8{lj|>~w{6MphqJFkTEnd3 zO3rE+*Ng?X{g^(s;8T{%xO6`I+s8#AqYa{pYlRJ5FV!Bi;@nTxBuYHd_J{e5hwt`r zSu4JZYh-rA`l@`&zk2#7*N$entS_C<{`PTM3s@KlaQUjWf$RAjKlyRo-L<`0F5}Yq z>~9|zcl=JDTglQ&1>e+hQkoMydWzNG9+5P4_n(iP_%zFBd^(@~6?|geT3SjY9P4{z zn{CJ)eShQ4zg7SG3a86*bw2yol}nZh>wGo$beW11k?1Mb@BP=GkNml9T#tpEF3Z*V z>|a+dD_j2VY6Rr+u-S(E^PYb1$YHB5o5tz0e4Wq!n*1z3eXP!G;t|p7sCz z&b?=M?qsvO_^+j9|)$T$3;EhFo=2 zoiE@~htg5L-acI)hx~0DUfS!|;|BGY_(i_S7k5Mc2!DtX#z4P1j)ELJ)@XY8^un3T zX1v(DRXH^I5pc*jDJNfifvKhHM8!%cBk1kZ&2iv3>ecf{eR1Qj+eD7&!{m#5=;v2r z?v>+*T#f4+;hTYwbAOcGMs5m3GUQT*D=iV<~n8Kqdl@UB9U)*&(kwEC_ z(h`UK!!Mb?aN#{`wo3dW-{gzCCf}Z&w+{s})!@n>!BMgGkiS>EVV54hq*UYx4wEnL zI*#xT*veKof(Rh#VW|^AqxW}nCw1tzVC+{PiX6dV^2J@lk%iT>6=s&u^XHs6DS5He<@BfDn6v+LdvOR)8Np-n z#XTe)bIQ{&sZ@rg(CUSS1t@~>DCsdL4*6SVPFuX?#rBgVevxnT#a)xn_9Dj9Re|NA zFr@>%e58(!{rh_#G``D{ZoRIO_(i_S7k5oQDhp>BRR1!6;S|jMs}U=^;tC>w=%GFi z9B-XFVOew4S;It*;4t~(9ubEoU(c86V`A%}dgP$1mT$c6ZHZsxn|yKC?f8P5L-juSvnm!)ywd3?|@FE6V8I54~&8mHqshPYkx=DQTX zy#LUo4as0DBREXHxR1uzZYhsqEa!1$IBRuEXtfnOcydB+f2@u(?_soK2*MJ4`T4Q& z1-2!PI_R6`7ev0`Gx_3f-@qitXk<@C?J>+d$yX*7nVw&oA)m$r;#;J4_`n+_5;|Fy;IOMhza^`^ux@=dmaZRgR0Y#(i+! zFT>W0P#af*W%9*cm&-MrlW{5m@u+$RmjjAFT`#F;$Hvh+`J+|29Up&B!V3cJEDH`7V@fgA))M0dTxI%6l0zW#jllD>0W7FVpa z^%<@=gs+KKuUK4>=lA1A0C`boMzdAKkri$|$t(@9;&3iB)9Z~Dz(eB!@hwt*yl4ON z?4_s8df&t&e1_MJ+^O33J*&3wAS}sm{R(2AAN1LX?yoNUaN+OeP6a4*W+j0^^QC9O-mg3k~@F&%)M_F-)7?L;P4Th%S6MMp|TNMDiu}YPXedm zMR2Ej6D(aWaW^>b#N7mU8V`tXk<$00B{$WzjDI$n{%GtF36{yXU2%sZt{$z#;3e+R zt>D$D_CyhT${C)r>8NNz9t634sjP(8^_nv&cDg^*rD0m%Q>WkZ_)Rzb!hN1LKCGW` z_!6(!A@Qy8jlhDaK*(L-IRVpPi(V^$OP5QTI_~5`8-)jazD3gOWmD33dhnfgx7t2! ze=PmNM=+NO;ffcxqgEYPLmarC`tH6PC%x9Y)jXle7jSXo%Ebv+T2coQft2sGqS*D` zf?G~2>T^#XR?FDN)?0#Q^2J^1-R$y0e=)X4`!R}#n>G}ieriA>f1@FvM^rJx7ogF^ zbKmRXesakj6Az!b{BpMCXxN@&eiOc8YLBrc-l|Fr*U4U^yxIy?Gv&Y!<;uA-lKu>; zziUxNeQkiN{Ej+b?Do~Lp-qLGuL!IVS+uEr;hVx_pWA@4YRt$4Dl>-QxcYKmZKZv} zV4088a`v4i*u;b$Hs^&|+?|LTU<lsIV3~YzZ-oyx*G~5biq!4LYN@e$tK=23Y^GvZ-L((C84(fRpIz66C0jV} z%|2swFW4OD=NdMyU+V%o40IHTzw;yze>>X_V?dmoIu~>?h-=dpgPsF@0!qXW$F_1c zba*N3r$MaTh9KiLfD(}r1E6i7%ad?MH5v+AL9bz*8TE>+iB^j{pEp7Oh(ckY%{ZL=C^!+D3zhVB!m*a!wy-_ea7kz8}8r0ZhmZ4vaCMvvAudF z=0+zRzfT1vZoF_x=!b{CPJZuK9=_y^51xMoY?o<^AJ;m0OwmvEp}N4fokCw3syH=@ zCi`@ioCZ84Ut6WIan396bWnEZ8`ii$;-9woapA<+O(Cym&n}7X7C$bW&gNrgI|H7p9h6cQ8{cEcZ(4HBXI(10)9<4)!lHb-Dc=(OLC&$%4UB70%f8n<`y!{?O95A#K@D#qy4L?Wu%5ecr zp0B1V%Nv;7zxurMc-3}=Z&Y=8EOvVSOewHozlOwYO2>MDM5shbSdz=^-%;j zwl`Wp+^5vgg!8bz@P78%NoUr)Vtci&pJ3wTfQxB z0P;a5`nn}>P6P3Gb3CU7a%DVc{-8lIrHr~7v; zg*)5%9uVF5j^>tY{$uDnk3L~_D%!0(_%yT=@D#pcYLC&wJ!S#Vmq4m6dV9L5X3e$7c3kCN&|HP9SZ6SV!5L3+1@@Jln&|v;)28@ zL2QE`4axu=1L_Gn7Q}LLJg67w1ki~fR;GPGY_D^V33V^+=?1(@I?buFweJCsZw)&k zZ@_Lr`ki#pPG{rQ`sRS{iBBKhva9VgoKC{0AKmXkS6lzbc)WMogbH z5YvTe!t`KTFde9W>Ye(go~d8zwjU@Hlm+5M^BExak2nZX0GbRc12Hewf`Xtr&>Yas zpgTeLgB}Gv19};>9`reA8z=!fNdcvSaFm7Gp24YJH1n*Ppc_FCfL;K73SvL&phU|$ z6*Lia31|`MH4yjv^gtyr4s11<(r<>5CG#LHc+H| zv$^KUjDmqbUwjEOGYtJr#8dc+sXZd+o9v>pHcPjjYuxSf#%TsV{AQMu)xbUJ)yG*( ztlE^tsq}d(B88Q4L^0VGYXFbC@hII?;lr&H` z5c4VXD1R%<|7oCspy43q#{v)=Bhx{bf^Goa18M@j0{RT}JLmu?qc3P8=yK2_pf5no zQ)hwLf0um0d@S`z&*|>(C_6pLpaS@p`v+^Utvh3{z`4xM%Ft#g;XCY*6)&}`Y{pbu5dED9-@>=K;b+A2)4|lw-}g+$NJgpp7`ob>>tf)k zIS=#tKPS!4-rDWCx)*Gjsj!gNe+WN}#C~(1FCRL0Ux%PP>iHzU)~y$FpLXK~30Bol zM;`ObTi4BSmiVaeDRBrtIu1>I=%jr+gpQ-xz+v8tn1#yKv(w;HN_Kjvm#GioN5|nl zZ(l>@>Sxwm?AC{ggEGGUOTi0=rkDPDbcHQZ@`>;x;gG&r+vn`-i0l~5bE(Ni@x>UL zZSYC3^Rn|l-DvO$QT~XFJo^{nq$`~JkuRVfKSI1LkGCm!KP!o%f5 z_BmXk_Nxv-1qtFQ?fR5iZoQc8*ZexHr&@g3^aCI4cI`kmm|z5l@NI7R>261d#D`k1 zx*qBc`DS~u<%$IBx6wNlZ%lmWKvNIG4@RCHEunaIGV1*`q;tU z7xk|`^Q!mWw&gHcm>$Bnx#4HT{L$)us4${P^*dGG5wr`4^7u|3-`P$jYQFRPOPfSP zzWs~Tzb?MG+b%nvJ2dd0seuM$@L26tmWN$IEFUa49P{R!h!`m^{GadAj-{>pqx%lC zeHz$NpKYJMcKH6^)_~qFvd|vo_uB)ay&H&i*HW}oK21E5(`nWbZ|$;fcG+21{fznQwP&yhE7gks>Iwwbzq?#m!T3EO+R`7= z_p>#u-F@qtwL>`Ft_=Orx5-y*JR;+9b^+L6lviCZa||5pV{!fVX#|JKw_V%90li>taRu(YQCm%9Qyl{7c+zfi>xF$pV#?XqvR+@gmP=@? zbFcqq?5+d4oMN{_Y&<+yT=?{(o5*@m=`!3`UacnD3#)k(kPS-5vosDoS8QHT@0q*v zS}qYXU1Ds@W;SM+gZrwxZqz)b2soJ>4SC*cbYvE6vEGI264xa7Y7 zjJ$x)howPS$EXraor;CEG=N}^$FMw&0&xLePf!<7H&7ag>wUP^kZTV)zR7h#9IN44 zp#4B8AohF6=Q<(we^^(L&pre58-EGYm3*eN@a$hGbq5@F7%K=JNcl;2b~}2&L$YCU z)ZBJOuvQmi-R+0Ftg2s-VEyfn+rQrOsrBoaZCv$fpV!U&B7DWv9`14X(EJ0=z_C3A zVTt@YL%vzBtVU)!xzE-GU*0sk|M998wyf(Bp7Mon#~OaR+gv!zu)5tR>{zZen0=ScYY{Z zY5QfK=Iy_!Vr+EsU%1Ta ze7@`d)3^D5TRigrl_nBS!4u6*{Oqv*J2ZeQsnz#Qei^@8G%Tb1p79&SvchlIULeUQ zbmu#5DNB6kcamj_Hp?4{EN_(hok-I-7YYz1L1~)(Q{P@oMEz1`q zEIX{pOuo3Ir6IEm*u7SY?q+3mS(UxFgmU$DhHsx~-|He_19#5G6pMIj1rD$&d zKQZo*^}nM5eOxE)K6iPSc1LL3>*gfu_hTpBk#Nh6iym?^>yJ${$2Bejy$tFP5Wj)Cp&{`j8f$N%@iqYs4!JW5UR>j`bK>}&zK-4}Gam0ZjbUjJ zy?UB_#l|D@?{vmvM~@mN{_5}|`cB0ul#JH{qRlZDwpsgNz-D^>E?&G^{{2gjx#F3} zPGFmqhW>WOQ}~LhJp@Olzp$EDg638ih@vRSQ(LT^2J^BAivwr zcO%Pj{2MNC&ce*J?Nd*W#yD{N^~bI||9aK=xgtk!n0#@Mj05Aog}gk*9}s^!j-K3v z3F86rEmC?ky>QXuRaacQjs9o^hsn2H+e#0dy-Q z(M|Rsm4?IQN5|3M@1HW&8^ESQU4GBM#MZ;=SHCGZe*Z5YkoZLpCSTkmr$_(l(z2@3 za(L3yp(zgepOn5a?2qO%CrJDv-{gyXWcf}#aYl8ieaeGd4}F%#*26^)w0|q4kALmHl85GU%eXQk-{gyXWce~ZQ|U^Feh<3q$s|O= z?}9#m)_0+G>eEwR>n(jr%ICa{@I|iJBL7TZ!0*(NQdQ_5O&5;Uz(L~y@hwuhoIdB1 zLpz`S-Bt8QV~0qvOup^fR=LzrIUe=#%Y3I%5DmxKV>7!PIBfW%B1dqTd~p|jh!X7j zk~eUcIhoUqNiQeOap1Xi>k7}>kGi3!VH?3?^2I$e9tX-G9FM{c@Gv@#l85bBqv@sV zdF}daS-i{{)efhR$+u%~D}4s}Fnt)n+@=pFW0lZv5G3VgBXF>PCOBlAL!W=XWYW7i zC%j)i72cE)eVBZ47kyx+5JyOk^2t>WTG zZ(W`?copAiM83(lUBi0tR9E>6aUE-!k2jw&mt@#;Vs-};$Ey}q+vi>4s9^^i<8ZZq zm&L|+%^km{dCvIhG|orSFhoZ@g|C>}L-Z31UoJLU$(vB+fj=R5%C z>SSJyjUl#)IbTO`Y@nxujsdYE?gttQ;-En>h`;q}(A}UFpk~m{_yNa(aAcx&2WSK6 zBxG1#+iARkB03(+3nwbobR8Z zTQfiWGi21$;+uN?>_nn6R zlJOM2Vrma(<(7R+9~$e0IKhmUMB;X|+zM~N=d4u1>at3IIT|lb2rKQvra17N@X-gG z0w*+FFCvMDs7$`N$HHR+#TkAacydlbR|Aj$Ts6*DW#0!-q)u`l=B+NbThs3LV$SmD zdThBr(b{#_oi`kD|C8&XT4ktDwjYG=utQdxxE(Dj#SZt@PV(j9Y99NPItFe4i9RCE;Hjd{8Zv6g$&fV9D9O{YMGWp`(3I`VuwnE{~NA;Jcot1wK7=~f^HKft z?s}4aC@iJ6N}fxw%FcT0to5+Zd2Q641HZg(*6U6JV(38ClfuWpE|Xo3j||SstjhA0 zRp8zNp4FRy^T2r`thyA(@m&F%IJdVyD|6laF0x-Mb0FwWMm!f2Rl4e5u7JCqZ-?N2 z8s@|8F=^Z5`5)-F5pfYe&v);)Dt5gz{j;Zs%**(gNvcdY=V|gCXG^=O6?aipV6ia2 z5Z*Ezx{9mZGR9zSw|{`Qf}>a&*_G;oL?4bm_2v2Tt*f@rd}CZX&W&;4oU!%y<}LXz zh2{eUr^$~Kr>DB8G%lP=5uxa_9tT*)s^_=e^uj%3{&+bwpCvd=ew;Y5+yeK!sPA(b z=5;VM7FDZmz4luj8}9>4Z+r2-f9DX~Xvyzt?=;7O^UWuG zWiRASxkYfW&C8ar$rpF+JLNQe?5zm6^&A?^l(EFIrBx+3a5=983-L?*Wku?C1vNH@ zh$P)>UW~5CjXx$@KfGNzao{Ll7pW(RkL^U^3ofyv;lpf2by*QNx^SekzYk0FeWTTZ z;qG=v%1hC4QC4k_o3DER*RG-Q`eX$lxfNecL$_D4wMQwGzt1;q2Z8SPPDZ5?-M<(WPCeW0P8fT!>kQ+q^^ zAFlpFr)#>~@lC)Ht-ff%>C%7yVBjD7b~rfEMr`Ax9)zz!P_J6P$@HmxPy?z10aU?G zpN+Y^f34l)!KYNEj_L$C5$SsB_p&>kWK3B0ZKZvfV10PuuxC&4C%w|e34bhX;uF5Z z4p|yLv{o^pP>GC!tw3s88fRgT8k9A_Tj_JHn_m|LM+tE3+2Q>6*RE{LHE{?(1i*RG zaG*oT+i5&SZKH9wck*AcQ^SL}_!hjeUge*4190wa!4Hf3oZQ}8`1v94eSFxf4==L| zlxnL|FTywR@Oq}~O21Qw+r3jB8|33Xmo=rnN@oC{W9d@wtOE|p7aS}@Yzs?25URV-^+MQXx%8__qnU2BhfVFi zNuzw{Ry(T&Yie=(N-15~By-K*Hyb#l53jFR_nh{}@P~h1yhP*(4wEnLk#U3};ocM8 zkW*e2@@O~a8W4ee4})*H^%Du#1kctl*526TDv>L=Ouo2>#JThX)!^o9v~$r=vQ^d= zzIqK`>f5pL-CNTC<}o|}@sP+Dd?sJqBjbbKI3C&-CjqF_Ba0BjGkTv z??%rz#NO?RRmDH=a>~Q8Fv5?9ECEoI4tmoEoRM?k%wOO85|CDGwIRBx$ zMtfG=)YlQj{7W3d7x`lA`PZ$6jN#tWa#gVCw*e&eaSCq3X3BU#v?KM4JSX0M>$|=K zh8zKR8jk z>*3yQ=JKmo9+>~e`A!71sVCt}ykfiVZy%M%5%Wqc#1D+YNC>{A_Pi`S_XFwW{4^&5 zv7LY0wDjLm;M{&CdN%9te($xnQZAS_f1kNOUdy_SrW=UAL->lRJtE~h$^YTJ;BFV> ze9Tl1r?-it`Th3RmR<7??Y`iN3c(@yPWT!G^%@@zcOGQGbdauJekW{nbPby*z7n$0-TqO`1xm!y_fIRoRP17&J(Bp~rL z;6-rOH`_VF10LVZatW4|P`>KkBR`eX*JbV&BUA>TerejmDYxgTmBC}%hRMNQ!I%Dt z`#T|Xe|0zvBP(h5v~^b|S(|fT>pFBz=@kzu>Gr*NtiOcsutS!HFSoh~9S7d7R9dcv zrZHmAnR>M*Wn`cf2XR)q#yOi};3>H($?9}h;~dXdGxjs_2tNeGd5H^8E~e;hK(6n3 zzfYr&vuz%pV&&ZW(aD#UE<9Ss$=Ly4^6lG2jO%QeoP!{0M=RO0?&1t{H(u4*F#QXvbEE()8761*&_~Q-;YN0 zAbgt}eroAr>p_>VeO7`9B6?UI1BZ2Wl9lqpkDc!MsAM0`ztg0Gm>$AcOzq*qfo&I4 z)J@`C-DP{y^^o&fbUiGE{3nik`>tyre*G_|eBo=N)vG3-J=#*VEwPlJ2j01X1mRos zunstAq+Ur|o~Xv(o4>=j^V|nt4`TjkWamGA{Qcu6_r4otnMU*=e4877YB*Sh)#o6C=xan<*iu%Qbh`BV5dH~b6>Q}bx1KC~QahtbCy>Uh~6Ok3$w@MxlS=Y&~j z6t6q%B@>VE?O4OlxbYa8()EbB^Gnv3?)+l5U$S;hwr<`$VAaCD zKMs@ju9Pd`i#)M4xw+_1+SN;#shTf($5t;_%`xy$#+*q{o!9HDwW0lPgOuPwt@whc zjed^3wlNoyOi@ zwSOzV?TWKFv0BI;o#Jp_z+c98(}?P+lY9Z2U5Ql?)9o>0hA9EDT>UfGfuS0hssHYh zuid{p(s-S>^HA@jS?5YOKJ>dye$?MhWmK}o-TJ53IKP|yf@a{Mk#b_*%UmP@T8Znb%Y3-0nuGPSlpzg%sBf+hw7vmNRfvh{qu`8zjm>#js=HT*Oo+$Hm-kHf1~llA7nXV=}eobNO?{=`;%+ZFjI zd~&565s#lT3cK(tORMq%IQta&Nxt-osiqq&nJ@fj<|A1j*%@G2PqFXM^1!h{t|RB3 zIyPInfVzUZgV>Q{pZrMB(ID=%ljbx6k9u%ORDXJfGWUC?-Z$Tot`+Xd&0 zpyTo=r~noBUT7Pw1cRw8}16qtg{~yJJ1kVd&o?(YhZAog>knN1|mSn|+2vTZlxv7KwHn67B7N z&|N0NBhjuLYFXza(e6T`CFWb!El9M0*RrmdjNdQ?{SqYFbR^m`B--FvIRES_+)a!` zI|zw(#GMF-M4OF7+l)k8y9!udv#hiaprZ}A8+#kmJHh&Bw*;%@fCTH+BND7BC*v%Q zAt=9RCs=vq30BQTsI%w6?LOS$`%Hp$J?10^Y)P3%HTpLiJ%0-hCiBFBq>FPndsl>CuZak-e0moq*Pb@Evx@ zLR$`(6Z|*MSe%uy@w98j z7k9yd)j3$Y;;+Vh7nC!VTe6kWzf&n&sfDl}%ytajy5DyH;9u8|`;zZ8#K)(}S8O~Y zwHrp3k3sEfk9(^j7&S*=hgb?r^sxeXnBE=`k@20sS8va4EA4yG`K$WhmJU7*?F2l9 zubA2+oG~yYkNzVzgW$8pUGf9VG0?*ONrnFMa(u?%fR(2K9HWk=L`B80(kZ^O+U#=7 z%=wA~P$YASyML9l&8pf9c$y77W_s4&nrzK^V%V7(eZT8|pd+)tgGcxp z6!jV}9uzo!HC^Sbb!i)N!@8q+*k@!F9Oc2A)104kt!?Geq{ObSH zoqQUx^)R+e+fVu(*0%G1oJ$ahC4VIU6i2;t;F+(^yJKgpFtm-W;{TUpY-dJ@KWRmVg;=-;C`amZi(Uf&Zo9e@8~2`}FPlP~Ua9>E}-yH#m-pM6Ey z<>BJ&cnrc8J*2e6{x0^NU-p%6N&B(MPI%f0*cT^!haIxydo-H0s_HAaKZ^SIr~&e6 zJRrWA^#$E7c>DR?UL5*ip)*9H{2hX)@aac4k`9jT)bDD!2P%Afy|cqq!Sr-V|GOKH zS#L1Fp;t{Ak(kn<#7++zH_!PIzK(_OS>8a=bnJ`Gz@R_xqp&+p86(RbfZ{)h7fF{! z;9&U^z3`p#^zY)Aojx0X=Hbh-z*a``hshWBRycC2D=KgnNo7{%DEdhQQ9k=|t07+8X?&YL~I>6!YA#@YC6e+(sj`q9k*Ox{iP z4J@0S(ckAqiwBLMs_F`4I_EAFy&R_hYR4+_Bjx*!mtKG6X)hMc6&ZGj1k2=$dn@^) zd{u#3PZd^8S5#HndsT9)3qunOdO2JQJd9uPM9Tjk{pFCM>yF%QrHv!358(?AvBP*m zE7sKF_Kbn$oQtDk*d`ow#Z*W|LZO=4NchHd_wwcl8 zRpS%GVY3NV3_^F-x&m|?=uyz?psk?Jz|zBj946|EOfeVqcThQW@B`>NBoObZ z-UkI}Cp4z^Pe%I*{roj3-PHi+MF;d|fJ@&Cn9!)Y6#e$BS9s{9=9JJrg#`p{R+Y4t{*5k9$PP`jq0Z*e{j{%UezhMlZTY`1j841>nmnK*b zpr72aeWJDB*hK4M%>5j7a62pe=5|)m;YrpxYm%&|>UOd+3wO4H6Wd#NUz}_$eZ7Nq z-I!ghLHq7zbv$4X>k|K-)^CUGZ7n*vv$b*U{??sa54P@W>T31u+r!Gb=@^Uo08LcY z&kh2%G{+d4OED;RTDyd#nc`~ez7l{a=u~o zRu2;S73ymhF0aIC%Aa!m%Blm7nRr~fBZKmHfqdaR?2sk$xvGGf6I~*;rOaNqiCv-< z_9<+?5oJU={Ka?T?)yS^)JebJNfU10E!;Bm?|?)41m3rmB&IM||0RWQ0O;EB`@ z++*kOe#*SLx#(04Pa5zD-^4QjCwi9pGSrqfY!|Pp#rKab3g?a!TW^tYt{k*+@3)%wc;11j@*VeC318wBJ2Fm5O=s&KMgRiX z`W0?HxXa(>IB>PgJp7%9o_h5%Q-8u2JYq-3H5|unXxOk+zpToug6jIJONyB|2*xp77MzSa)@ zWX4&icN%?W>~dZ^nGS)6hSkCSS4fu=o3AVi8mo zZdwaqJwZ*Lzq+tQHO?xXPKvLnf33aa&cmDY0%*xf_#j>cUs^{uJ|-QTM|!{M>*Mx0 z>D0?cF0gUg_}I!5KD@h(0)r*M278ZKbdzT@pV7{ zY3~gHEai6v$}f!v#NTP|r*7C8>&TaEnSIY!4e!oiCm9A)b86gH_=>4LwEnux|6+7Z zodCwKYOQKp4);y<2Wp4o%rX>jo>PLxrgQtG-hRu%+!t{PKK6GoU1+UGCuY|d-#fA2 zo{84N`|g~2VZwtWF&(H3(~RTF!gtsqYlN=~*OyOms_Trw0i3Lxi*^X^QV1`Cfo~nh zI^duY9A-PD2{?|JJMG;yyon30?5-pQY zHyYW3j%zu&mH}zU-CaI)NLwYFyiTJr4Soe@BXG$0-iWkU3W!R_*>m?qC0B6Lo%vY* zjwasv@aI1re8Hz+D|3YNH2IFRH8OWVpthnaL!BCp?`a|bL)&|h*S>)^&!3Cqq}}P8 zlHx9J=%TCnzkb!0^Rd+Zz-b{3Tlvp0zOOZbYZJ=)gSXq^40_A(7D zSKzRz2_^^eQg8Bor8Tw;CMff&1{FECduxQF@d$ShH z^Rs^*YQ&=Ory+=x%ly5<<F)JfzWO6|)&RQe-_i8F zZS8u%r(2}&QkPMi+AXU)tO?G_&>wx9e8t8iG|Ham_v4E3z;J(&uS{PpgGGe;c!pjc zm&Spo;+)f47EC$t4Us2!Ouo2>@ZhLS1t=00lt&#$pM7GtFJ8Lf)!+ZfE&ciR!e0u1 z$9G5C7i%28$QK(uNdmxkIWxx@a^iV1qtF7a@@4ua@w%h{Jg0#qee;1sAQTU3fJxrWDCAO8y?4#03 z(RgG6tI+y*UVdtH{gr&!&RX>Hw0(}9`$-e~Ml`gEOZbYZJxpBkzshI2;>s|B98OlN z0dYvaYl(rY0l49+1YO& zcG?2He5Rs&3SWWJ9wt8f)L&agYK8b@lm`1GJX|-@AKgkG8IWC$GXkfE$M|wXY0dT( z^(pNP_N!AI(!_>d_3uZ?{_fw`fSwQgH8n$!_U|-5om!u0HTPNmRBg(&#c~tfWVkb5 z2tO3D^Wuzv=i+vmqH3=BADzv^7rjLpdEUw?Bg?S>K(>0S5IUZg7b{6k;p`VAKYpaqQC|F{ddLLQvJzQk-M1CKJ^Pi3Y?a^-KOivGE-|?zTC7`tP1^ z;uF3GO}%PpGNRx!fyr`5E2!aH4}8=Y_1BhZSC!Re-rQ>Mv35~a{^>W#;hW(&4x>)x zEyIMtK-Rg?ZRKHim^~<0nZa`c zQ7v(M>TyK_yyerp_EJ#2oCObwjVou^JHMTBif@G@R{aj*GWp^j3)kR^YBVb={Mg-s zBIuqcOihc8=ap|xKYdK^1)qyN>Xmp*zPQJMXB5x&43wUy>IMm?w_h9Lz|}wfqxZL6 zIJ8yznS6;q7A~wSE-r&-9Y=bX*!nqY+aFV=ZaJHuH)TXWCSTm+!eR6~md1f&-j%1m ze(`fpba0BZ$~QzWe3379JUA*auBPjw&!MsFm17U=vGAhv=U=zWQMRN*9D&CzevsOVVBIHSy#m4*OPf8+y)$YDIxc^XLEYczMZTTJ(Q&3#q`_a@E# z)d=qEHTO>=xVLET6mH5-?Ha~^Oa%8nnmZTxnc?#_caC$K?lqcwNd)(L&Al>$dz0qQ zL2EPq^_u&Y5!_oe_t_ELQ@e$K|1A;R`)KaBMsUy9+;5BEUZc6+9l^a`bLaXo{8?!r z$v;h+JFglw-PddG4@Gcq(cF2kmKi>^d-(T15y8EW=KgF1_k7JAN6WX0zeaP%QPQp4 z>oxba5!{IFIhbRwuXs1N8Q(8-{_AS^9a z`*Tl&eLAQg$OGyR8UV@!4FnAW4F+X_vO(xdt9`t~U}L)38UY#!$^o4L8U@M)<$*?n z#(>6x@!ceG!qmAT?D!qbO~q{=u*&SpvysQ zk8n-!m7uFYSA(tr%?4cynghBHbUkP;=myX{(2by*K=q)TLGwYkfNljX0Nn<<9n=82 z19T_oF3{bedqDSs7J?cdTcc?o`{JKEvk>3*Y93pYHwB; zoIcBOxU0@LJ!AB6&qQ=#CXVoo$sX*<8z?c<<3;e*oZ!Z1-ZS5rlw|d|{?oJ5|30th z;0|^S{Kl}~D13=m?3no4K*n~l;7UHx-M>qM+fE?8e|`I}_iTMGdC7qym-?laO}@D6 z_m1{2Rg;Su{dsDJx_A_;5T|*|xC&AH2k|0!>VSuul62&IJCMG~GET^WHQwR8-dhVdF& zE2F1ta~wFn*!0YX89#0f}8Xlse)uEQ`4WXZI1V-mI+TzH#6z^p?5j7i#*% z*2}D)29LV`#HVM9Ji%k~#XY2#Sa`UC+7}p$<)pqU1lIMGd{S&&-z<6XwzSpT*ez5> zaG88@j~AEt*XxOfIPhG)`(q2AJo*)O(UcK9CSTlR;jzcuD~DklOL?VFQqS)HO1bQJ za%?@7Put^*_RDWe6}f`T zj6YI({c_-4>ECoX@+grbI845{$HFl}&3byvvQ;%6N;azj5lFdfiUZeWPi_73qC0Xq zETxR#GWp`Zow&^8bJd?&r^Qacw{Bk8Y0K(#4jCvT_)NaIZy!E)J+(0oJU3r{?orK; zuHvwjGJ?nCi+e0QL(6f>DE3%P>9DyWWYMI5*u3QnIoVZpK) zB3E#kd~uJ3Ym~1jfC-vbDcgVuBwY(UvGw(2^K;L!DI5pJr zT&08NpuNt~{!%s|0!hd80kLsq_fDL1%H6NLB60W$T zre1dpD%wlr2_BO#?s4E5;V%zE($i^k9C*%Lv^c5cp-(tPri|b*`Qjc2o-7` z9XJ(NfH91oK6B#0(`!M+8GG+{%(Ws<@R)pYkA^4DU&XGvGI~9eo)ud!du;Ch+tZ#7 zoHkTOaF~2?kBNhaD0s^}Me1|w6!%JZzpBZ=RfNco1GRu;pKR4CD|zdRq1T99!DaHr zJsK{xUcL-#6nQ<*G#}H=3L>CF#;j#60=E7~4)eZ<{uTcIn`P+|=z&wGf?5S!aM-UN+-qsnoBGr?(u9(*GZ#h4- z`mUM$HgIK6@|Nq{G+p_rWJGMee0JiOpM7@fhF0S`Ccl+@Em=nMm{0EIc1EN_|7*zf z_E?L7E0SIYR7`&3)vvC9Sma86GWp^j%1`~vE6Q+icqI-GspOFb&Y_-w<~o;1$5S`b zttWFo-^M2rt;-U7opa51{Z4*2$(Gmw7UzY8FF3>=?mx$m(>lC3VyaARZraQ7;^NUf z|LF1x^}-{%mC^B}=0wL+_f(>FRr=7D-)~t~vdX|Ce8C~M3yw2~JdH8%^n4-F z^6d5QUz=aMVBq@(9^nfPv0Zo^J!$$Ggo}ns+B#RH&l%D6vu<^wwPnTP(Yv0O(0{do zNBDw6Y!{wL`Y{mc_0Kv3kGa2h#kls?#k~(n%FZb}YKzm7-Wh_Ke}peM#CGdBtV7{9O9=xX*v%{2mR<8P7`=zG7+*NM;9+#i`1d zfipRNG6Jg|ZYEA?SB@G#{(Aj;vpIj{IZ@U=Cw*7e&A zCuOAEn|yJ1<6(if4~#8R((Uz&BEKNloo^zw6K@}JR940n<0nY`BH!eTyIcM+Y^A}; z+9DjD8bBi7%8Q*I37K=}pZela51Z*Be32`*TYk*+u(!(=+2^G(4!xYu0lrx2v-Zk@ zEf1A;yJ`6QDc8IPV`ZZJy`K+;%&1=f7&`TU2uS)xFGg6F$7Vj9V|!)6GW4bFXkrN@1B7AB_OEZF1>B z1xlWZw*gPVTQVkgI*z!kaGymdzj3>Ol5{lr;_k+)r(->hex?eZP6! z8C?qZmrQxlW)6XoxJP25=uWe2zYJ)NqXgsbK_u1FvlT^I#hr8P+pH=a8gEan0#^PnIGJj zjq{8#6|WBMLaJnB;^e6^yzttD-0De{g@ICaJeF$VhRzE@BxxYx<2sfK;FEJfKA7<9 z<&>?v&(Yj{6R&@j?z)~+&vgGjvt0r2)-wrvyj1w|B1WqW>m}AsCSS4fh;(0z-N@iF zDju|J7r7w(ik|C%gLR$<)RuYtl+AAy9#GWl`sJs;@diBoYD2f4aQJ4p(L;yhXm_=3 z8T$?W6%{zet$!^!wd(k`Gz1VmHbK6`e{th&69>Sp#&PF*pPpyA%WVqW*vyjqq48?H zkoWEE!Y;op5nQwrfKvGMqnil$l(YW5TmiW>)C^`FCe%?j-MBGp)+sDFp*deR!b$6cpynqk)c~DROTGj_NI-Z*GvFp+1K~Ijm_P*1; zv_sqb%lI_;;?AQ`a5WXK62VXt4#nW5t-KBr>52TDgTsTcOv_s~+*?&x!Y~aWDPO4* zV&i%In=x}o4msiphNZD52zRqgzU_+rO51@)4d3}utxXPuZYI9WE#LaOy8eA@aKwv$;Cl|PJt%f_( zJAGoJRdvRuXDVJwv{vqRPtB*toc_{&j$rDI`AYZ>J7lSQH1SXsJC>W;2kYDWaF|~I ztbK9&00Aor;yeI!5agxW&}h)vphD0T5C;k` z09_8c9>fK7i$RZps4u8uCM+umlKfZ~L$4_>CtCMCIq^j zeH)*sR(aFY)$&G9*QKu{T7`S;^4F_gI;6@>SK;fj`R^|bEohD*N5*W_#IFaXzB`={c($)eUNVu#Svr6CSHop0DO z^}{oASOk?3eVBZ452woj+?njHz@R}yDEfD+XOUYkk?P@}KRDZiqS|9@5|`p)AZABbI<1I-CuePSK0>=Qu1v-pIblXIPT_kiPrM@2Y$N8tNq^}+rt(~{Sc4vZEpCf z;ZdV)xIRRwLwxA@WOWSrb6!uh4*Ti0Q42r*sl6#*_!6(!ZOJz;g|9~d(L=%H=z8e+ zW}=l=KjheUdp*|G#36ix**Sfb7trMqZo_BHQ z6;r0}YloNoB7DIkcAL0(!^0r9XKbIkeuBl(^;7Wgm_7G`gO0K1j4W?Amp9_gBY`GI0oB}X#&rq-J@!bun z)0Q?b;shp)eE)=RbHh&!uNoYZ@84*2XUptQA)Cmq^4S~%N6Ht8)|;L!-yQPIxnoTn z!Ve>`-{Qg1IyK$>?BLYs`dPXm(K_hkv_sF|IQ;|@m+=1-t|+Ofr(bfpd;BH|!q~sk z=NV4=X7Q=h7rhyR(M`Q|vrN8t(DXLY8z`%_8&&GV$mzt~>D~&?)w$BI0XV2B>F@KM zX*SW@KjP!oEH}^4%l$)p=#tL zbk?w4Eu&3bX$a4HjN`odz$N2f)8Bsj5SA(3y+(8YVbn?8nWl|Sc#dDDRmA>X%agso zUUTM6pCFhrJ)Nh?cbqNst(+4xD>DYxRN#C+4kdca&<(|pw66>a9S4eg*3107og%Xu zYZK5ruMV9BsOQhdIB;H_Fm26{`{rIMIP7u8BP^3I?xA%XgLoTP8TKy*&=vAjGE?HR zW?6OT>UZ=xH@3e1xZ;bw*Isv7cabAFOuo2B#etT8d6BowU+x<)jRPw%x?Wbqz_aeQ zj@AiRz1?-r?D2~e?BMFWB7Rqe@32EwR6Ne=OnTOFWCfz@r3E;?>U-S>U)OzpkBLM0 zApp)xR2*vc?8x#mwDt9N#`+jI81>c_KOCCW_`(p8C+TDI#XTwx*P2y3gpQ}AGP+(E z;{2V*cWQpCD74;M@RuFC!0VO`H}kAA-I`kxY4bnc%Rnn#oI4U^BfX)v0M{W|I%r$IPm9aSkSR}OjM zXjZJ^RTYdju-kwz(k@J|cH?1Fr6Y&~q#qsl?MHRA-tH<>jPd<$F6NPVc z!_WBf@FsAcQeTAjP9;vBvrQ0|;A;fFSl`EYyuVkx+fuU539i~%Y;Bo*anHgrzPRHG zE7yAE=Z_4Wke^TGRAXOxk&k|YAd#OwEw=ophYh{qE$`Jo@>@hhI{{DOE2j1k`MD+j z>awEI6Tr|Y^oqZN0S)+reA2#Tm46oe|3+F@O zhkv2{*7onrES;=whQboTV&`&41kv&ItcjiOJ)S&d%Nv8o-YRmXoSJ-bkAw#kR-^KU zW%{u<0vGeRQR&~Cra15n$Z8pT&4It&F7oXBm};4PagT*ZbvEEx$I-9Wogdl0;`%z* z`O=dLj+uXb@G+4iIKDUd;vNZyvqphU6M^AMpLKEIIQ#ag``vzi-kBmt(#PbBdkh?A z@~HFdq@32B=hh2#!VL&=US&&TlC@Lgwp$i?dVS9FOC$BD@NI7R*=D;E4Qa0bW8n>B z9#mRhT8SG1a07@RElhjEU!K2Wm=F7Ov#{8}7s&CKm0}aw3WyNgSu>*J?zaf{b&p@( zE%Bq&!Rot!u!39oVZ`>^pTs?;w8-Zl;H^;iibe$P2wDMK@F$-i9e*A0kA7@=?b+!^ zZ8Gr---$M4{Ym_u>Y~!P@ay$Vy@5YcdD?jKtzT_Cpx0IbDEZjri@Un<7gs0xs(9{s zWk!y_f|Fvon4>Q*wtF7|HVm+wR0XNWQ}o&M0(ZaNocCAmyRBHdH`dcz{$ zk+1hSeU5{RR#$w9g)ex-R+9|X6&dPcY;AHz&3c3}DQ^s;UxT7v zHI;-q>6jq0<%jj-!cj2OT^`xCWuBICm72dMS?zW{Wb)SIC(n0=#ne1JaR}eU5f;Uz z(19vX(K(n?WFMPj25NjoWn?{lHpjrR6gb{4ZQAg`#LN=}2gg;2L-^Z)Bh-$vduVn@ z{kvHcbmtc{eNz4Htw9rdta+sPg+i_)ppkMVe4877YI?zaF#f8lGK?r-+#!?KUTO=~ zbsW}3ZX893jvv?-5a->SD%x9b&pST#k;i&2vwenf2tSO#ev67j&3@bd^z@ly;4t;U z5WSB%{iBxJSjK^n!U;4UnErjRqc5KRI6l?;H1Cv}VDC-G|v7R&{1G^RMs)huAtE3{hc? zr4Kj2aiGd|eUR0F0P;P^y2Py)6G!7+ds=r|2cQ1L#xEXqs$GlI8N?xckuP>69I9aF z`NK|*W-u&ew`4Sk4TwnaZH$3$^H+)1PA9$@*tE;-modF**d8T5;VY*02!l|UfGItN zc@D5Ve}7ycueHCzO4Prn!CBGuN3joQELpgD^Gfu9Y(qN%yT8(&YJ?#L57!jA`!EOdy5OV?AM%cAS4=cYt!;2+-ozt6kjyqQh` z5M08K2Ukcxd4Bu*s_99`vpNPI%6e*_iC^5FcJp&0mw4C`GWp^jDc!P*%W=6O(ku|b ztU(zj6RL5+4{rx>&l40}9$i1{zDu;`=3R8(6R%x4$E>G>FF3@Ggh$m=18WM)(8xw3 z);AgGMwgdyj4On!5fMnekX#oXSH+e@>xGMYpT2L;d7iJ0^$)@qJYsJrE?1i%jM7~W z>to=oc{<7Zr100T^Q)JCDGR_Pe+ggki5&^2lb+ewMAj-r8xT3q;VfYR?M$iBfy;WQp9amFfiuL)dcP5X&y~jA&Fd}*rKI7C) zoVeV2(@^SqOTH?4x>D|_w5MOl`aWBRc~w83y?v7}7$fx$w4n)EQ$Mf_Ba2vCKMlu! zaIn|aUzigIuBu))d^7gN?{5~l7@CIZY?*vh`$hPQsXesv7AjL2s(aZwy&7k`%X=rpLpfRC*KZ0u zzj-)*01uq0pR0Ef)`_g;SH ziL5(=jyvb|*TJ3DJ7^V zSs$40X`1_{0Z$yuJgLj?r@5becl||X_yWzH`yEa9pyod3sh&?Vck1ysXzrJcUbxZ> zze01re%sNznC{J*d(w|%{HD7#H@qLSp`_)a1jyI(>m0b#ctCVBzavezVSQLjfq(g) z6#?E;N7Em~@+y4A)E-*>jYHRQT0%LxE*N5|^p{QZaRt^eOth9`0>m+T`)KvN=y>uQ z60L<>o|*UDUn0(7%r@H@Wi-FLx>etehJYt&g5Mernp)?W|Exw=4Mlmpy;^l7$3D+9ATXx#8z< z-&8J7;I(}@KJOI!U$vI(xX{WD`fhac$v>(cz_QPL7WhN8T1LL1=I=nc?al75HB9M8T1@z8|ZMT zwE%QG=yT9HPh0zZ`yGZ~VaNhg#O|_<=j&2m0^>PsR_NgCAIhANT`) zV7Fnwn};D+{J;zG1CPWH{Qi9Wjw^7#9DZOg{J_WX15;kXUcgWBnjK)MC*O{}&r7 zP=;>g({9pVihbRvT8^z0ity84*q24%egsi1(mT9(0saw%0(}afl7oF3M zx|B4*t4cfi)pg8w^MCr?VOndTAC#wmFI)Tga~!5oEF))~`+5_X6E z@1=n>z>)7$%N^l<_F-A~9O!{t0}@s*U+mvAT_s;h-6na3`Bv&V$rH5Y-OLlhhnF4Z zPiVkQpKgeQWsqqg#AvB^64Q%DPZK>2^mp;60_=GFDGk&i6w43Cse*UfHKqqV>N(Q7 zq5I1V7r&nHV4ugGfHza)g>oRKY9P5~za}4dX9_&?3IanfCC7x^WA~;$M9A^K! z`G#a`*N--ReBYQYtJv2T7&e|jCNhe~t&as1J`H$47#*zm#!sBhQ!7u;z) zAnM(c8P(pRN+*zxCv9Qu z_3m8{`?B_|!_L3sqlMK;T29*)_w=feUxi_BkLT;hy!I0cse_3~*g zcI&4Bzr6^4nt*f3#N~fmH+WC$)lStvPI`XZwXZq#B=NAG5I*D7O+n?Y zfAly@3Sz}jL}-qJW7DkZxC|i`v_A;L64t?>G!V;fH_+iA3{O}`gL;B6L}B#?^#z>{ zLKSLdfrf)df$~8t`>fl_Kuq@;pjn`6KsSNz0NoF20zD6U1N13qE2tf^-9Dgn&?%r% zAf6R=F=zqkanQSqeibwWgCM;yp7VESOlJu?+qa=UX1+j@t8tbF;Lyt{ zenQ9qimLNy>jpto9VmSMFQz*%HUJA?TcN{7#c_wd-5LlYgtR{j?zc7W0gpN__{yHI z3ZmS9eay38gJtcqyy@6IfBUeZgOezWc{=|?vMr*TQJGsvGYGWWQQ;Uh=q4xE@X zYG7{ez)Y(do+&@x@luZOAiJqC9+p>@QI^d#5WfkWU&HXADsK~EPXk>KS_Wzcad2-O z=zh>%__>%ev3epieGl4zytOy-`xVGvVjjb=bU~B*dKD8Iz z`vFG|0X)D`Xuf6R1_M)pFJrdQB zGQ`90i0~bD$Z|eec5}};Hzj;txU>TEyicfW#lNJk1p!<+kQ8y?ux`tZKtU!GlY&Et~a@R?Kj zP5AV#o9KFz{D!Tx6+H10^PSaYs?XPmNJMY_aIXSWRPr0&`CZe`nRwcF+r!@;v}x7SgU8YT318cCu7Og&kmR-r~25=-NPl5B47vVtdOl(M#$k>)4PN^TrNA;-M zIRB5m`v8-oS{H>qI`FIfx>`go*(XMNvRdK|};a zK~%sD7)T087SnxehTaUbO=th-+`a#ES#jxFA1>H+T%nHFykS3G(8XB2TWRzbt`k_4AiS z^lyE`|5W`1KPt5R1j|lB*Os5ZU**^8=kJ%*zvG?%Q}q)pFNv3*VA~>CzX#*4rN37K z*Xrl*mD9iLUDJJWXnS_M?b%@7u1@e6Y(odz+T(jC348mxNgsI{_T!n(<%^%$c6pB> z{(Zqzq5R-I2~+5Qlz+M&JpPI-J96=T)Z{f$5J#}TTXfTv|4ZL|=JuE%j(=r73VuT% zaZ0%U`@Q!h9G`gFYp;L51pbx!`J-}9n18K)e!sl`tGUZe@Q>x(@)e}&1m&Cff69TC zGl#8wIPXITe!F9Iu)Yh@0|du!Liur-2?jx5M?HrGx0nfc-Mk&q;L4yFU4sXm5C$D) zMZ}%(?_Q>%OAEuRM~w(?8rvr#Cis|TgyPGv4kT*I(`?VB?R$>^5ZfS4E}}qbR`uN8;bD%=KmGJ|B2bjL2zu;VavGxE`n=b z@{o@L6ru>XP@LdDjFObb;mx@JG4AwOnQGLe4h?8R3);}0;8<%=#*su39PAj$c&0Iz zg*?dPtYR&j*g^0g#}^#s97)Ys!8zSGb1M~TNJpXwPF`Qg(`;rRCrPd93s99#=*lJR zL4sNKE7F)3O4EVqtRt8|RK25oSNBV~KGA%Xcs>u_e|~z>I%TRS8y-9lQZSzf!^HV< z*#>`qK5E*lSIvP#et&MiI?k@aA3IWY6hYkYNjSf6Uzs{=Vv!}gR&`(TeIduUgA|(I zL;3N!SBC#`oL9~DSI3!p>(y~4F3${AGl%u-bHl4mU%D;$Ybq{<+Ko{Dl?daX{TJel z`jg_ksz1`ziQ-J$e)Q>(GOX~WVNd6o*mvd+_2c6Rm1ijbzbno}#d%en?cTh4dn>}1 z_Tu89`0H*LcTO3$qiEUV-R>__aZRv5OQG@%<;Uk<8U7c`^U9U2S2xF3#TmBk&*R+R zEoIn*i{~m7p5ML2tl$q+DO8@J{P^4}!+$-_t4lQDapJ||3{q%0N<4p7*q<(}p`IJT6m^!FEu>L-XSXybwuY}W@u%Ts8*5*i=8C*kwp^|kchR|0=jKmY1CB&@68d5X&)6g&_9 zZx3FF_T?^*x>moTg7}@sYxVOxh4LSib*+B>gDT^9LiwMppWy2fwr@cj7p%uZ>#|^c zkP^0u@j2Iqp%S=OKcSNN&wRXAKmVEa5{l}7vVIb8zXg941cy1VwP&Hy|LezV_4C(d z^zVGfwfgyYmi}LV_y1)51mB)``z>hOuC;G}T`!?`T&tf@N&II%UaOz~%z6n$^>^wg z*q;owQ^9nheazrETH^d*{2!&?Yum21b$?V^@%h*4=g-UM-#zwP{rtOY;LpGR@6=Dw zj)mHxP}>%~PJA5g_r57KU1(hJIuQEI(CeU`41_-4)2mYA&$(*k|Kb;k>nHe+CRAoY z8D2iE=^ynI*Md$PvXx^SpK1U3Ccfs{#Pk+J%#En^qHa8*VaG3Uy^^Petv(-zn7c1euAlj zyu|erWa7CYf&-x}K+~POE~?txoV5w70=}v8#$3 znzq!c1C3LLy_aG@i{kgE8Je?e@DA5NxG*I+|2dQ&mziLY;QZ&yF*F-8U|`U{NyCVU zfi60_9AN9q=l3U!XZ>Hqvw2LKu#@|9WFB|n`K7so4#T9S0uJH{<;Uk<8UEdP>Nky_ zCa;H}e1hv8_lqZVUyX-;PTxL_aS7|O>$&(jJXC(;6ZP-7drtDO0r!5h;KsGB&y>Hs zFogSzAl^{Emsh2l{UdekR8OapgTw1Y=;GvZ7f)T><)K&5z0T!#Cye9BU&L|be44Ni zs;+(^U9(F&gZ48>p*TYM@wr!qe-=kfM3ftB2fYBrUxyT$pZc8t^YR!t&;7Oc|Gcrp z!#fvMOjI7B{3{W}Kl{Tt;%<_6_4jAEaP|Bgv`xX{v&;osrAM{?F!;oMdxmVO-8_0$ za4lDmg2yC=q5Qba1cL`adT#vx4~~aau3qALaDp zpO;g+N~yx0D|l~?L!U2(yM8FTqIH+pcY*Q!;srZK^=W!zUR^YsaTUr?T*^Us3kL3Ed^GVXbNv~iPO z8~k4=frRbAsYLTt;_GaJaN5QmAF=zrqqRbz#m}p0{wY5+{>nTO-ZU!Vttgugjfm-^ zJ-Xa=)l()2&EJbJT|IyQUL3jmr`ymq)uG_B$hZ`WBXNFc{NIWryonptUb$Oly>3xf zdoeBCyLPafTE*Q6Z@do-#hLx5zrJtNzKq4jZ_PU@b<%7V7X`~-aLs3s_FvAAe|2S8 z&sRnFj_EeQ-G-xe0y?6`kRJUaH0GsCl?wWP%1iM5!TP0w?+<-`@6QH|56-n7e|db+ ze{$+J$>Nr&>hgl+YHrrBuz9REU7@OH@2W5+MOZLhpOlfi&lM}@9bsYbYT$!7L-}!; z2?jM>3fwPTQxuC=|D z;CkC&{T9qzL74~F-3I;51((1Dm+J*3Ri4|az#RnF<5r{+!F9PoUx!txMo|7Ws7bKk z)TRz~sYiW+Yj+#ch{iM_*raGiaLrh7O>fYmwxTs{XiGcpBDmJK10Cr^XS&dpZgi&y zJ+az}yB@K($38^TmwxnT08vCUkU_){)Nw3B7|Jk)GlJln;!%ud3}Xo{+#SyZCNhc1 zOkpb1n9dAlGK<;FVJ`ES&)qEG9`0o!_pyk@EMY146I}NfT+93r53`I%c$CLj&f`46 zlRU)=o@OP_u!?7Sj@3NR3#{QqUScilSkKFBU?Z>aDzCAL&AiSQ-e4Uc&JNz@ z9d`0A@3D*Byw4s!;6pxQFZAz zB&Ya+)12Wf=Qz&=F7hLn_=%tSgwX9=3 zFSCJ-yuz!z#wIrNI$L;yt-Q%L-eNmDc$;_F$-BJAE_U-id-#A4`G~#jV?Q7B37_&A zpYsJ@a)5&z;w!%98@}Z*M>xtcj`JPgbApqc;s;K1hO?aGJQujgk6hv>e&!c`UN@3z3GjTt_<6b3HeZfsAA#=odH(Hy5`9`$KJLmJVTCN!lP&1pePTG5&|w51()(Vh-;BC9jzvzW~s z<}#1@+|2^+;a(PUAB$Mb5|(m55AYxl@i5DHghzRd zHfJjBB+;}IU^F_!Zr z$uq3tS)OAx&+`Inc#)S_%R1KcG8@>)E4<2UY+^I7vxPU<%A0KCEw;0Rw|R%1yvuv+ zVmI%zhY$FWkJ!sT_VY2H@F}11IbZN42RO(fzT#`X;ad)KgrgkeIN$L-CpgI|e&94` zILkTCbAgNe$R&Q_XMW*Vej_Zo<)5S^BRMHZNh(s4hO`7XPEJR9uIC0akdaJeCJQ$b z++;c%*~vjpZXy>qlbbx`B_H`IKtY0gRTQQOMY)Ay6z5h-5Ki#lNhwNGhO*p7Im&Z8 z6}W>tsYoR%Q-!KjqdGOHNiAwqhq~0GJ`HF{BZ7OjHlZoaXif`S(u&r!p)KvWi}rM& zBc13>7rN4o?)0E15%i)reF*L`(wBbpX8=(|Gmt^VFql||FqB~oX9Ob|#c0MbmT`<{ z0u!0UWTr5cX-sDZGnvI~<}jCe%;#Wj3&pS9q1z*u-XDXA5tzl{eYOTWn_s zZ}Sd2d6)Ot#ctkb4V_{J?3>aF%nN=K>e`kxTr<&-}u#{6<&`%Rfm;MsiY+l2oK74Z;0wt|J}kxt<%y zKt?i=nJnB$Rh$~2}kgPF`?HglNEJmzyZ3%G}SS;&1XVlhit%KbdRgFM8;EaMR# z|!_Xvxg7(kdN5QKKAo5pYSQ4@i|}cB?majA->{kzTsOAbA+QD z<2c{(JtsKHDSqHIXE@6_&U1l_{KzGK;%9#0SAHWbrRATbBqKQ~NJ%PElZLchM>^7T zJvWenjASA+!F_;kBrDm-P7ZQ%6S=sV+~grI`N&TJ3KI0SSeW2GT1B~qVif0AN)S#- zN>Q3Jl;t+cQJ&kWz#ZI4MJiF5DpaK!)u};EYEhdy)TJKvX+T37;k1dcCN!lP&1peP zTG5&|v_+SxVRz9U-5-W^q!YRr4C_Kyy3w5;^dy2_^rjDy^ravD89)@#3}g^73?`N# z3}qO@8No|B1oGqtj>uIC0akdaJeCJQ%`m26}u2RRAu<(Z3{$xR;el8^ippdf`POc9E5 z3&kkTt&|{~l9Zw}WhjeVO@)=iEuF%GoBz0lQrI2bNkyD`5muQhRHYi#sX=yOIp#IHngQ3chQ~>bfgoV=|We!(VZUjB!XV_rVo+yr62tn zKorpoWDqe7CYB)#Wf;R5!AM3inlX%J9OIe5L?$trDNJP=)0x3cW-*&N%w-<)xtj&t z!@VrzJ{GZoA=qn2Ykp!>}4PO`It}m zl+XB_FZhxJ9OMvR@ipJ@Er&V6QI2t(@A#e*oa7WgaGEomhfi+(tRdb2}BdgFC56B`Q;es#K#oHK<7~YEy^0 z)T2HPXhQ6M9_=g^dXYI^rJrm zh$5PS3?jH$!(d_=!cc}WoDqy<6r&l#SjI7)2~1=XlbOO)rZJrv%w!g`nZsP>F`v6x zz&+f{LhfS`i&?@_?&kp>Q3Jl;t+cQJ&kWz#ZI4MJiF5DpaK!)u};EYEhdy z)TJKvX+T37(U>MQr5Vj>K}%ZEnl=RYLT$%g1Sc1Fpd+2=Oc%P+jqdcIClU0bH+_ht zFa7Ax0HTOyAcKfuFtH3_D8m@e2u3oB(KyXIY%Jp#&jcniiOEc1D$|(G3}!Nm+00=s z^O(=wEZ`pQWg+*mh{Y^nDfjaL5AqNXvy4Z0l*d@k<2=EWJjDv0W+l(Cif4I_)jZD& ztl>poVlC@f&&zCJBd_o(ud#{Eyv`QhU@LF3jknm&4&LS+cJeOov5Vcj&mKPDLq1|J z``FLNe8Q)E#^-#&mmJ_Ahxm%G`G#*f%n^=qjN^RA_nhD)r}%->oZ&3zIL`$x@*|h{ ziJ$p}U-^yT#J(gXB^k*{K}u4Qnlz;4I?|Dz>$!mpWF!-r$-<3fB^%kvK~8QW7dMle zJme)G`6)m_3Q?FM6y+9*QJh;TK{zETMQO@VmfI*td2XiycW@^asYGR}P?c&_rv^2t zMQ!R(mwMEv0S#$HW17&EW;CY-Eont-+R&DE+(mmj(2-7brVCx^Mt6G9lL&gzn?6L+ zmwxnT08vCUkU_*Sm{^7|lwk~K1S1LVJ3g8*jAb0-nZQIQF_|e$Wg63&!Axc`n>oy7 z9`m`I1>D2EEaW~Gv6v++<$fOEK_22^mhlLW@)*l`oF{mar&z($tmGM1@hs1=n&)|e zHN416tYsbRd6^At3PxzG2_?$2Jk^>y%5MS{%-|#JmIl@tnah&h?o)etp6hCm9Go0ld=efW|e&iBA z@iV{hE58w()SHB)BqKQ~NJ%PElZLchM>^7TJvWenjASA+S-6p`WFtE{$jMFQ;%0J_ zhrHw?KLsdAAqrE3qTE6;igPO^2&W{aC`}p4avS9+&+Sy;4(_BPm8eV=s#1;W)SxD{ zs7)Q}QjhvHpdpQDOcR>YjOMhUC9P;p8`{#2yJ$}bI?{>GbfGKV=uQuM5C9jzvzW~s<}#1@ z+|2^+;a(PUAB$Mb5|(m55AYxl@i5DHghzRd zTCO7<>A9X8$UsIik(n&qNLI3uogC!kCUS8zxyeIb z@{ykc6r>P^DMC?hp%}%vl@f$gl2VkW3}v~Ea+K$GDsTsPQjtnjrV3T5Ms;dXlUmfK z4t1$VeHze^Ml_}gO=(7RTF{bKw5APhX~$i(rvn}7L}$9tm2PyW2R(_P7rp62Bz@^e ze+CdmGy@q#41 z%5MZ0^CTfD$w*ELQj&_)q#-TWk&g6S&kbZCBbmrd7H%Xf*~m@~a&i;7xS8DKAusvJ zPXP*2h{6=1D7R3I;@nCJ!YN59N>hfi+(tRdb2}BdgFC56B`Q;es#K#oHK<7~YEy^0 z)T2HPXhQ6M9_=g^dXYI^rJrm zh$5PS3?hcX#4?1T3}ZMW7|AF`GlsE@V>}a>$Rs8+g{e$qIy0EbEM_x@xy)lece8+d zxR-_8$08Q9gr(fi13bt>Jj^m4;ZYuAIgj%MPx2Hic$$?w!z!NTIac#LFR+Fed5N{G zV?8gkfsMSvtGvc0HuE}Lc!RCH$u{0%J3Dxrci73hyvHtf^FDj{fDieIz3gK@AM**H z@)@7=1z&Q2gB;>3zUCXgWF`wYl9g;^CkHvXiCo-FZt{?qeB`G9 z1t~;ficpkWC`NH^r3B%Wq!gtoLs@R49Ob#43f#e+RHPD>sX|q%QJospq!zWQLtW}o zp9VCf5shg=Q<~A77PO=lt!YDB+Hn`{=|D$1(U~rEr5oMpK~Ey+MQ{2LNniTWp8-S> z%|Heb!(d_=!cc}WoDqy<6r&l#SjI7)2~1=XlbOO)rZJrv%w!g`nZsP>F`v6xz&+f{ zLhfS`i&?@_?&kp>$GLn;ml%ygxX-La;q$54oa|0R3NG39qg&WCAHnNk0oZLh%ZYDQ*$V)!*Q-FdL zqA*1$$}JS5IJZ)Qa7t2&(v+brw^5Gr+)f4V;7%%1iON)=D%Ge?4Qf)0+SH*g^{7t+ z8q$cyG@&WYXif`S(u&r!p)KvWi}rM&Bc13>7rN4o?)0E15%i)reTbwl{pimCqKIZ7 zgNR`;u?%4-!x+v8Mly=gjA1O}7|#SIGKtAdVJg#@&J1QUi`mR!F7uer-7Mf9?qwnO zv53ViVJY|X01xsI53`I%c$CLj&f`46lRU)=o@OP_u!?7Sj@3NR3#{QqUScilSkKFB zU?Z>aDzCAL&AiSQ-e4Uc&JNz@9d`0A@3D*Byw4s!;6pxQFZAzB&Ya+)12Wf=Qz&=F7hLn_=%tSg^$tANeUjK?+fr zA{6Boicy?fDM2_TDMe|@P?p;$M|p0i0(WpH6{$pJs!)|`RHp_tsYPw-P?vhtrvVLV zL}QxJlx8%i1ubbsYueD3cHBjKI?$0$bfybk=|*>Y(31#y(VIR*(wBbpX8=(|Gmt^V zFql||FqB~oX9Ob|#c0MbmT`<{0u!0UWTr5cX-sDZGnvI~<}jCe%;#Wj3&p zS9q1z*u-XDXA5tzl{eYOTWn_sZ}Sd2d6)Ot#ctkb4V_{J?3>aF%nN=K>e`kxTr<&-}u#{6^4uM-q~f zjO3&sC8Qq70&94Ymsra>*7GtO*vKoq z%4=+5Gq1CSH`vOXY~wAqvxB#Jhn>93d+cI2@3V&w_>hm-%Rct=F`w`$pYb_g@FfR0 z$RWPsYrf%I4s(Q~9OF3O@jWLv$tix|G-o)=InHx|i~PtXe&T0-;a7em=(r~dNl8X> zQjn5Vq$Uk%xsG(C=X!1+0~yIgX0mW2S;a%CJ%YZM}7)WkU|uu2t~Pt zVif0AN)S#-N>Q3Jl;t+cQJ&kWz#ZI4MJiF5DpaK!)u};EYEhdy)TJKvX+T37(U>MQ zr5Vj>K}%ZEnl`kh9e2^54s@gwo#{eXy3w5;^dy2_^rjDy^ravD89)@#3}g^73?`N# z3}qO@8No|B1oG@%3R8rl+(I#m zb1NkXrzE8)O&Q8^8|5g^?Ns0n?xZ4>s7w{AQjO}=peD7bO&#h|kNPyAA&qEE6PnVD z=Cq(Ct!Paf+R~1@Xio<^(uvM=p)1|!P7it#K`(mKhe-O;kNylGif9Hhh!_SF%MgY# zjNy!6B%>J37{)S=@l0SMlbFmDrZSD`%wQ(7n9UsKGLQM(%>wS>UKVm6i&)GOmU2H2 z@E{NIFw1y^M|q6pJkAq5$y2Q0X;$(Kt9X{@Sk3diz#3lUCDyWz^}NgmHu4Iu@*11i z%~- zsYydxt|J}kxt<%yKt?i=nJnB$Rv8qknNG^PnnX-0Ee z(2`cPrVVXr$6d6i10Cr^XS&dpZgi&yJ&B+fz3D?Fed$Mk1`tIw0~tgNgNbDbLm9?! zMlh05jAjgD8OL}gFp)`2W(rf8#&l*dlUdAW4s)5ueC}oe_i!%@xsOFGW(iBVp9gr5 zhj^G}Ji?E|M zw(tg9d6R9t#ddb^Ht(>LcX^Lp?B;#;@Btt45qsIkem>?CKIJn$=L^2%00%k5SA5Mk ze9K{uaFk;l=R3aV1SdJg51i%rnCLt-wNKOh;l8V%% zAuZRDj`Up54P+oAnaE5QZX_$&$W9J&aud0@ncUw@{4Y+)4?; zDM=|xQ--qKMmfrJI~BNtJE=$|DpQ53RHHgIs7WnqQ-`|LqdpC2NFy54gr+p3IW1^O zD_YZrwzT6e+S7rKbfPm|=t?)b(}SKw(2L&mA(FoIqdxlxi z$tXrMhOvxeJQJA6BqlS3sZ3)!GnmONW;2Jm%ws-xvw(ZJmxbKNA{MiRrQFX0Jjg>l z%rYL~Q66JCkMjgi@)Rq0nw31mDxT#zR`WbBu!a|TiM6a_JukC?jl9CEyv8Or^Ez92 zgRQ*DHr`@8J9wLS*vY%R$1ZmBK706p5BZ3_>|;M4^9i5w8K3h7Uvhwh9O5g!<{Q4{ zFh@AbF^=;c-*bYKoZ<&gbB42=<2)C*$d6p&Cw}G^e&siUj(U@jlw>3)1u02IYSNIF z>qtj>uIC0akdaJeCJQ%`m26}u2RXTkT-;1<@{pH&LRG3!of_1n7PYBEUFuPv1~jA*jcGztn$esVw4@cS zX+vAuaTo3BKu0>!nJ#pt8{O$aPa^0=Z~72PU;5FX0YnkaKn4-RU}71FPK_{f?Gun=I_79W(;E)$9N_%kx5Ku3R9Uzu-wdGCbO8$9Og2Q`P|I{?%`e*avzIW z%o3JzKM(LA5AiU|c!WoJjO9Ge6FkXNtl()@@(inZmgiW_^Sruli-w(=(1c#G}q;BDSvC-3qeyV%Y9?BN4G>h_CpXZ}^tO9N{R(IL>!`&k0U)iXS-58P0N!^IYH}KXQqm_?ch$mEQ;&z$7Fk z8OcdON>Y)UG^FJ^(vhC)xq%F1Bomp*!i{7l8`;T0PHrL>HY1L}jW_m1+=(3W=GMSD8Xkxq1`3tj0(cY4s12zt?*K19-&e)MMmQA9J4LBuea zScWi^VGL&kBN@eL#xRy~jAsH9nZ#tKFqLUcX9hEw#cbvR>*kL!CSSWkxX<1!Nr{%Ji~vt`R>G12ZE6&o2b*zdmn+Iq6G@~T2rs!^R9 z)T9=*sY6}rQJ)4hq!Ep2LQ|U2oEEgC6|HGQTiS6K?dd>AI?v@?CY~&SQbq!%p7iJ$A91_u0b- ze8@-aWgq+bm{0hW&-k1#_>u!0f zMSkQGKk+la@GHL&meh7KNl8X>Qjn5Vq$Uk%xsG(C=X!1+0~yIgX0mW2S;a%CJ%YZM}7)WkU|uu2t~PtVif0AN)S#-N>Q3Jl;t+cQJ&kWz#ZI4MJiF5DpaK! z)u};EYEhdy)TJKvX+T37(U>MQr5Vj>K}%ZEnl`kh9e2^54s@gwo#{eXy3w5;^dy2_ z^rjDy^ravD89)@#3}g^73?`N#3}qO@8No|B1oGU*lYKvPzH-x!cy)h*vAd_g{PbKLi@pe z2K@Pc@I@V6u6VKN_J!?+XZbak38i2kE!YnZ<;P_v82rTTzb!cY6*ly_<7*<524{g^o&G5QpW%F{J$~ZSMT3HdRUpu zpO!G5@q_+)IV{~Md6OY2=XDBApVsH32um9l%D*Z|FaAb6_1uj&BIfc3E;CK2eDcQp zbv$j>^qw*OosmNlfA1gV|BZN>#Y7J6)?-A=h^WDlv5`X~G!Nan_m2pU5M6y7ar|J7 zs#Kj|lRj*Aq5i?oSSIc-mnC~YxM|UmA9|m?e*RCltSo&~@Q$$T1np-iKQ1%DpjEf- zgTtG3>mAW3x?9ii;3mZ_BcpmmRPPZ);=>Pk@1M0#DU44|Ix=%JB?ykI1vAl;Bol0K zjCFwRkS%^f(7%7mG`3UH$DflhFP|98ns=KSH`=!F>$U-lCkbn6r>l>RuNCc+hh@^q z`02rE!wQ$l5SBB0jw7OMYh!~VQ{mkmi4*6Hoo z2ZrrBy8P9~SC?-nKlsdq=?}^`{>I`x%fuZ&4!*y1>wGN}PWNZe6=hrsJ^tByL*tTr z5(rZ0dCK^g*M@&m0?QQgf3AD6g(62A_;FL(^qNy6vX>L+0d{r>a3vV-~w?i1eC z@>}3^_eCeZ|8!S}mlwrmFfQTxrs(ji+xMW%gZ3*p_v)3hB^I1A{p^0@vL1~pS|f}6 zAY~$GKSTL(nF$6#vl$uHyP3PDNA`$~jtOrW5!_q*j_Hp+O}05S{Zcj z9G8OjIrtr+{L9(@c(@X8cn$Y~kGk@@{(yn~!~bzMNN9qD@zfjf=kWy7tc^)pWK5T= zr$W>tC}^M2~*K zD$7LU3CcA%KW2NPczPNal+Q)F%o#bqRJBxL`xbBbWOe_+m4f4cLCQu@KB4@$%mjlg z!-w8-)&9lEzb=nm2R`q7>U5#Qq3MJA3D%;C^F!kke18k|GgygS z$qGd@I4F#(>ndSf7ym|FxeLD2dDz6@pZWL{Uq0KCB+d_wzY@eh%BA-3h#o_N{hYXH z+D7*8Z|;wYZ4ohONW|dS%M%9Mv7!1JKkDl8S~fLFTzw61picH3crBRZ^Gq*SnzTE` zotGz%-~KU7oF5t=H>X6zv>X;0+oO-Ur}l6q7S*kP%gES>{)(?<VT2}_(G8vjRe)QyQ4@kepY{~K}Kv$0H@jky{Hy9IG66i4Fx z(D=l0)Q^Z5khm;@_a>ZQijKLuJQBAv!TWFOu(xfA>RH|oo(Cydj)Gz0{J3m`-KQ#W2;;JzdPXqUA3He?^D&u75G}suojP#>W$1UP+W!C_i{l!jvGc)-4(ZYa26j zy>5eR_K#F*!MbH|&FHAunCSlfBVuYr^pEK6;D--L7}qIr1t}C);(8qKMjFqb=oR&H zwepv@faAC4gZ40#ANK(X1_|Oyyo9%kjt?_#slU24ia#GJwA?Qq_t)i>x5$I#SJgk> zBYyslFV`eWHwXf z4^0O|MRt!KZgZhqOpiV`A9_V-sKP@};$n>I-6Epf;OMAe-IcJtT%9N$r+S3lKm{iq z3~P5?x8O?}#H1aR=VYrb*@G8S@R-CflpmLwV9-*V9TOQlBK%58TyC&KV;V&ajp!e? z%rv3;Yc}Dp>o2l>`h6cq6ikzNeh=j*2qEt2RcrZr&04eyuOFqs?j325IKk68(J?I} z;*PF0jcF9!BW@9mn?7N^9rzpZ)tgfB!Pe8)d>M)()J`PM4~_rR_?q_W)v8ZKi-;c4 zF~K%Rkd_fDukjQAy1ec@J7P)smaYHMu7~1DoF9C4kp48DD@7NSSAy-QU~@ERC9d8+ z&M@h(q~SG8MD{f&59 z%~)Qo%CsFB6VG3v{7@XB$G?cDZgg~STXwea2H4o_78PvU$4#1W`71T~ugmF<9P^jm zx-NTg8f9Dxl~dyU(D*-%>+1&axc-!x`23!{EEBOnhhCv2}HC3!VolwEdenKYpzLY_6>D z!fR@%B74~Wuh+r`rH0*`5-#_Bre6L1!7-`a>=##|x%*ZHHz<3oNc$;=pG|ixIHxK| zLAeC$yHI{yW`e<0<#KtY658wzzuZ#R5=~@Od|MQXr$hc@uY^7(;Wj}~9w`X+@lz4( zr#U3%$fp0_2(4p6ZF>fJ8431BgM}{(c3Z=;62u;~?}|6frbbwBWGWZI@Ai}8j&mj4 z9tdto9>h|e;PIczM_!dBWnVnD`@$OqJr7b4Pcp+$eq3gP!GE!Q!sGVc9OE4CGyc&& zCW`C#wx9NWP;hVCj5`j7zB;rYnK(Z*{;Ig*zO;2r|M1}OW^{0B-Bs(=)YJcZxz6`( z!R~K$=pJ+(8kd5{B-Znx{L9(@c)05Ot<7q7i;9b)R=3!0-MbBrZ-l*jJfU(ZHRI~~ zDPUYs57Wh0>s;DjJq=rYeB*uPfB5XBiNOmgh$F3GC_gSU!QiSm{!tFfqGgXh5%!>; z^4{S4|K0Ozu$<;0FZsw%@cVynKHjdJf>fO(B;KwK#?{GwaLvkjN7@F@gB0A$F&HM! z4|0RlBqBEa9~;`C1^lmePD~eC-h<;0?PgwGf1zc2eD5Uszn}Ec;##S~UU{kS)D`m= zcFYnq0#Z9aAZUL=`SH0|hHbjVM8>r&gTv$hzZe{9b%M?Rh~cp{t6P8gd`w3+-BKpqqD!d{!p0W6_;NkNh`uMDFs}GfWFL;EnKrwF>JlK|9g0X6x zBWh(W*XYwH1tenPz6aJzc|IWW(9=uje`~`g3rDF5rIWtr$CJRimVjEXS8Mf}FA=dV zD#WI>4<7AXv10!&#*Je~_SpLUTc0ekfpP4`c1HL*-r>OtG_t;-g`<3h!N64OFDEh9 z9JI(>u|6dJM75|afJXy%8y%l^8I6co`uq8_Sc~HQn2s~+pe{zykm7moS1i7GXUnTO zMkG$*n-M6N*5S;rz?0yj>Y7Q8c}AZrwMHX9$B<(kBbtgcm$IU);_i;eTI|8|A*Ixu<<@(yyPS%*>omIH=5N21bOo2r7k77D(4&EP zc4jX?H6oz2drQ;6bNBK?cI>*#%abKN!K3rVJuN(gqNRhw(<;mH6vAA$;{z-^0#&cZ z&WraKOgGWI?7X+GeQMAXmo6V;_h_HmcWG(^ye&dtxj(csKPtp^4>3nfdg2%_cicLT=QO!gIQjT@p zGz;SgF}*~%Cfz^ll8V#IdeR?_;L`b)tF|6I`cRQm440^sT3(slxC@gC$KlU>e?j%* zvwoFy1c%NS_muKUQ03I}YQQF9#xHm{)-ZEBR$f?9uP?x4&Gu%dFRUPa}AA zzU7))F2h2VcnX6hDX#iz4Z#XT!18LZ>mpniVrQ`rs28X=XkQRJ*8M>TfDQyvu@3_E z0UZpYOfh_P?9a~R#%&mpdm?>&qkD%Pf9UeXQ>I5;MD99Y+*9g-)m55ZfvS)5frIf1 zjzs0(>FYBedb+XbUP(uA=zMWcg~Kj?1&woEFq@m%VFXVixy)K}(!*!{ID3_(CwO$e zxTnIy_CvaCwY^xB29Be@z5T&w5BYGQq$4(dT-1dF-)j>4>`7WmGrQ z2o9Yu?ru0_sHy5n6L2tIKZtfBJ$dhmEBAVIegj|0HjUuW`Qn}mM_f+?jdMPdbA!8F z#y1{wZ02zbnvGv{emZ#QM=h77NZ(B!^9sXf82_E|e-gjQL+6XTyF4tPYWqELfm05~ zg;#atynE>syr=g57XM<1{~P^8_38Kh_jCmw}%~`%b}cS3txd`-V&EN zt*^j#4BQ2)5<^jOR5d!~qmPfq{tfH=cL!#@aN95Z{E2AyL4x6Ng?-t8eXS+*7{)Ggpo&e_NM_@M8e%8z&Cu!g-?dQT1lN3mzu1aK*(3 zK3qH^_Yf{(!%%Pb!BzMsQ@IdNd=O;o4K*eotLEGgmbkba^S0i%Ipw667n9rN`ggwC z%0K?z&Fr*^Yct>yzRiwVQZ^2m#E}9Ow>g?XvH!C9I1M<)E_lk-2_>Faam2pq{=`D!y@PW z#|6*CJ3AWJmF<4@@E)5rUDugU@U62PIldRZ$y6@R@oa2-uR<_=H{dGkdUSXijX5|PsFt$pY_w-8=lk8sH z-E1|yo8OkWyT$9~-jcLDzZ;(f8leEm#?7(@py~+sOYnbBkhw4qn`;)VE96_PEN(p0 zCKAxwGqzRSH_Ucydl1WjZ5-Pyx=A_kp5-C!8vjeXMm~u~?!~saad+_}{B&)JKVARn z`g4od%{|?8JbxRf1k`cSN{mOS4}K7BsU!0KH*>h%?81hhcDepI-qUa&J+C_7WaDBz zH1y?S6E24(_Pb?xQ>ivQHCUQoILP+c09(d~We>QI-#;n2;`8ICzImP<+}!ui-TyjY z+~v7^Y;ZKBqN=){52DL(kiTvC&`|Ly1RhfDlf=1rEN^Tj=h98462f$Fk? z%Avt(P9*a1QVpgP>bmc&2i@hdV6P*)oWF8p?0KKy(fKZT;s^+8B;LA<1aaI+v=G~M zDmeyL^`*xWr@pW)W!ozIrf2>G``}J`{<~xDT>M)fJ7MYz$MM3q*)c1LoUGl-_8v2O zZUBkC%m)q{(c47NAAK_(tv$Pc#ntQ!XsF*^a23AER4#egy1|W%`IXjAL2TZ(S^3q$ zil`&~9uK81pR5I)@SXRvf1UQ_W0^7rV1Gn82wzFsyv+^ZHBFq2<;%xap649gzpBpm zsLmr6A${gY@~@WzgG`=zV^ychHB#No{*b+*&bOmCtoJT`#|P`V3(=hH^0nHs_zreH z)iIB3FoURg20ZL6k3{pD>xOlGWA^zCS9ND214H~haTUJFR4xhUHDEgCz2PdpvTZ)d zX+T)fk0ma63Loic#auRv&kFG+vEKb`W>=erG$ zcQnqM(J*J*!?$|zQad5pXDfW09kZP27u(6krn`=M+N7ngmq+#!9gUAhF6ey!&^dD? z|B}A&V+q?g&h)kUt_T5sRlO*D+9?Me2ctgt$=9>4y=Yb89~^+eP%rkzRrn@Txe!Mh z^W7LCeSFCHiHdcGhX0cpbv~QOPpYtq{Chl40_|M_jZkW~V~L&y#JmAHWmq}^Oxlqk5I?`AlhuRxXwKh6{vRe zK6m2Q_^IEeum0M7#dO}&Sal+!8Q*fnxyO;3C{EWM9pKxYoK5i^3~Q)tZ=fxzuPkxS zU&cP;#F1$HK4G63cU*YWZ@)=8fN z0pHz=4(j^zoZ1P}<}(E6FT$5}#g_Tg=nxL=43=VR;MAyZL`_9epu9SY(>CI7dq#1D z5ccv6tO=Eu8qLmoWIiQLiQBU`oCF$>w9IR=mZqNf66HNVe!g?JbI;AN^wp|AJfBGT z^rM<)>oj<|%U_FUnS9&|kLrA)5$V(TL5yFYSM~n2t5N#p)_+|!b3x-n^a#WCcIvJ0 zO{Q{j?B|S~1Hesi#eu1)KAZzfg<`M;;lqJ zo5#EL&NpD}l@w?Dw+eU|e@t$;=UE~%anM3ur>(NfKEU(fK%cxn-#a48vqNaOY(YH| zzR6TBSTPwI3D;C%6K*zFPRm+KM<_k_-h(03+m&_mW z{fEwnaEfj`GW^DYQ~tHZfJKFtq(n}_ryteW`xtoeKqOpe9tDpDE^~dyUg(Mjeb%N+ zyq8}c9z4(rt*%FAzv#rpK9lQea()9tob&xbZ*RN&w@>IsLpuXk;hRk5BIkYC3r@qs zrNL2AY*QXsKco`JZ3bDaSd0sp=PoO+G^)6=UP_H?32=|SdE5N|`?2GrQjY9vS&qV2 zAepym;j&JHR!~{rJ4-ZgvdYJ5uhe@z-DLl{{wMW)rk3AC`}-IEdURmB$v?cs^(-2u zxfQO$H<`*s%kQ9Yjk)aWSdY&Bw^PoE(*0!Xi<>^G9RGqu&2*W%&KLJY>B^UNOS!6N zElA?@*w|56W>B^Km!yF!=csq;4!r7-Yb9O5rSru-AubDxf69~yj}zokYZ@wyV-SIq z)7Y2YvH=>AI&?T$AjEhFWn^Tj*r?r6-)6nyE|;>p zdH=lb`S<>m^aPL27x#pCMuaP4DwL$ksr9Y*tM0g-yu0^jdtdqDXOgbq()r?^5ZB<~ zWX`9WiOW6{k6~3@O=;lT=k%ZNeQdjljo0* zm)#FOa-u$75I+5=#;TLp6RXrv3><4Aya>l^92?L~M21gE+h%1R4w)0?Gvq1?7SALELC@JZKn*n+-;Q3P6P* zmLG<$XTx&LizLJ}K6-tMy~za`*Y({d?~= z_q<-$?9O==4ebnEg>N#Ii+(F(?l|`=d;aF*vR`~a$0>XTqIoO0|(uFKy^jk9V_C!@>r)%i~hefu>Xr|=bs=51=6Y0FjMHv8^`TE2SP>VMXA>W@4h zOE+Aj9ggSg)xGPkckdqh%?CA`f6yS~Z`v7nYAt;Hb(qxhQOdErJW;i9=vnrA?)b(Z zJL#v#D~%31KH)pS;ZJIO&C4$dOvgN{2{>tz)rY$2S;k9c7j0J7CuhkPmRIw+KkI|= z%?OlBYMe>s7}G1Y9bEo?YJ5G;$TIp~ds)wdqu$Ka@d;mnX5Oa8=O)J(%x3zpmZP4g z`d`=obi=9ZfyRf7)MLiQHkC$f>z{Q^#1r>aZsI3hy8#}he`qt3 z>1QAPY3-LoFX52LG?Ko~7xz@@vyx-v@`Hu@B?TL`0%D zO=;jeusE}8ual16L(&&~I$zuqjQLgYo)7R{YJ^)lZy%xxf2wCx4xpWu-)aeEuMOiyObDwXQxqSRE+E zE@%W(zlhqoIMD5E7KXw1lw~kZOa2kPfYT(?2riv3 z?kX z-qQ#!oo~5fzeVgh8@8xNgN}!7d=NPV-~I^&`3Xx|2^P=;rlPVZ+A(L za-kG;zPL+rGS7_T;hnff9qSsim@rH#9Q_&(-DcMKua-(WfdE0qMSO?Ts48@? zLA=$29Y&+3R#>M^n?W0Jm42?zR~-!^qaNK1ItrD!JM5*v`|(}#x5cgTZ065RpU=H( z7kO!u@Veqpj89LB85E3EhbH5zD>xZ|%bvc0BYneyfyurhg9aBNp)&Yo`s(^8)4m1N z1bPCr0`w8+3y`@%Bm*@Fv<^f_my8&S(pNrGTXYbt} z_HEbYq73r^KEm=jepmcreEe5UqI`}FhpQ!@YP&Ju>yGAnlV6QMyZ_g&7fZ29mjYChn;_tS6KW_Z1OS7Kjy!@80eR;sb7C z-UGBZXg^RN5ZBGQK0X9A0yGxHJf8+?09^^X1@tiJH4v6KjjaKwFX&{@#h}MPzk*m7 zW`aHd9Sc$33ECHcxoA5Ipf?BTH$jhLk>M!-{~ExL0_Y_GJq4f(0D2lguLS5j0Qx0> z9{U%=IB8GA_-r5K?*PPoF!qQJFpO`GHH<)>Vf={2_~%YWo|~8 zG|qanqftJ#lX1~kos6AlZ)V(!w(`im@W$E>nFjTNbsZuw8bMOuo80sUevi8Ns?E2a z`@-!k3mS+Edz~_3e3PkMTA(*R>*HW!Le*vd@~XS=zlRFvxI$wC`>5Zi) zFdU8OvG6T!{Ms6P4BY?{xixCI^zmQgPaTcp9`AcXRsPcXqDN=~&H5#L{B;=F$2~Y) zf%l}%ap%E<1N9R|o3-1Sem3H#@q<_%dir$B3ElDT(I4;sU+NDH)93dlgl{sHOM>(d zOO}4lFYf7Qj~z5>LD`{odiugwk~VJ>q<_c&1wbP*O8LvWF}fAgF#n#}@DgYM1gRfQ zF8a~*e;th-8vcFl73WX=Qm-Gv*K?FWKdkz3h~-mFKL_#Cq^cjk4eK`J-3LSe)b&&N zW(3M5LHbtxNRa--U)|Fm*ig5}s|P=~Mo(Y(O48!hc2=9^*x}kW6=2GUKHZ${GdQdSrALorM%!ZF1%8PO%>{k0u2Zt?b>|c zpz(tkzuxc8|1b7;^&Pg)KD+edQh{lt-xt2kj#&xnwbib1qZ3R6NYd|t_-T@*Pq*7g z_J4c!gcT?2?TYZ}M>Pr3x7xJ?=@0nBJ^c^2JokXTZrlE9J$>P;Y4bio`gXf!0r1*2 zU1II)e>UJqyEYd3A??~dcbDX`j;Qr`1>DIK{lzkYxwfI6d$f8*uY+=Lc=%zdKlIP} zpYZY5VVc$B{L0c`9bX8=N-oaiujGR-givvm{prL(ttJ-ryU@SpG>!iKu-{6UJ`HU? zmlVFqR4$2e#9oRD;*n%o7(i4UtAK+>d*Ub9hhSm46UPqL-=L{%B2~O;eonDP*fZ< zH5`f732y%Rp(DO~?S@w_wu%r4taEjQuRt(wo8d4|TEct7#bHxp#lMOpt3xN~eq0{B zXL9O#=~K5Jd(}sKp0fgM(^z83Fm%4SJKnp*HiALn@YGPyk0+dX?om@^k7k{EIv+S# zGJc69fqmtL4UfK7wbWm8lC|PxPg{-IHeU~dN0|6>MraZ~wpd;78xyMZ7v@K~;Srmf ztFVMoj{}fuf`*ZefYQD!0S-xLFe(JcNQ-TEJ_jl5=+vKvx%18E`^yGl?SA6Vx94Pb zGEUy**=G;kz31a{9un6@x$Y%={B;;7PCU`%gOC7@>JrR{`0ywRg9nTps-wP9!~GMG zlL z%84UUf3;}$E?a+pY+#V+HS^AKmGD&zyibOs5W6{WrbJZ5LjR43P?axvG(^U)K9u6GpXE?h4J{!C6KIqSPw)eGI7uUEEje+yr<2!l=n0&k3?mXh-U`yE@??1 zQTebOC|Al}WQ>-EGOQx>{!2qaNEpC{cGmnG18X6BKVYX zYvwkTywWdg^MJCgI~m8UzGA;_RR_FSZ2F8pHx$0jj#Y(Hp39U#f@L>!(e>Y4m&xJIKH7>eLkMEt^2%u-klR~?)mqs5o-EOZNANq zr)=F}nJ5^kii9xaRJMPaZ&6~OU2U*@@Ibu865@IRP9?@}_mRQs2=;G|*WZM1p^aY)A|bqVS{%VgxUmU27_rv!s};5lf0Bvb z`T!$>tK<2G?c8zAKjnp=mn@r?uj3Ma9FcXGxI71849{KDlLFD8eRBk-v@{$#L<)nj>q5MefY4yo&AxHL-@&XB#@6B;btBkrS3B-+`(NQk6$wP z%=f>#wV56ZzXdq#t-|@0lfyBwIO_Y#H1NDQ|C+v?7uE*Igq08hf&AGIS;^|@h3 zcR5{j(9Zo&9Q~hxIxgY209R3H3cmAdze<7?!^t6~rm47k^l-^*={ceE*d|G>FUov={9TBExqR4{=z`s(^&X2n(-}H>;X-?-8OOI z`GFO(5tfYi3U_kiDuo*tvR8xTy{@OPxv-P(f|3AOrV(5^U)d5<-8x3@@|a_fn!@CBFHY2dTEYZFpzyRp%T2t;l( zcXpRs&Zub}23+~;2uWAurt`%;4P2I&VR-O>WBYW$sdCHS#eICU@}>8>-+auHgT`~= z8HQstnlEg=^)G%+{9c1~s*3rd9FAEG)dulJ3cR))#GO@~MmD05@l6hJNxIxiL76PE z-8n8?4R^Qx=%G$8yy3s8^YfNGtvJ|!3m?%rO!~N`IW8R@sK)MwsC^vnu<$g#Ym5~| ztl;t04lDX5SfUR(yLB@2;s=koxHp*J5m~ZpCu97Hw{wbR+%@>QW2Z+hi)~M_@MkpR z(=Sc>xMhs%i+}pUhtUBa6XC^0>w6{5Ga=&u^?eUwqWn1)r-pNGF6)h%xaWG7x__Q~ zNw{ADk3G$O^vvA0pzT0ZtL~s3KwQ7>0on<~{q>X&9>tjZ!yV-hInsz66Sb3brd+eb zSGkcXmi*%7FMKls<2R56}2w#D0-lmV6 zuM}E4Z<2yVjM*Tmhf9H1>LJUBvZRuVK3CzC8@GD+*xZ_hE0&+}s9p}jM|2L;g8W!- zQ02$!VNqGQstUtv^Ob*9UwUV|*SmpV-H`YB4|g?dhjqSyO&@3KdglO*$W?t=4%{?; z5apLh&mVo`jESf3{m9dnPs<;3D}07mO)GFa^jycQ>O;dG?)p&k$%9ACTk?H{t`EXj zvGP8Byo!G7AQ4YCNc6f9I7P47<`9dTkGwtI^D*wcGkJ( zy?gJ=yVm8feW9U0K2H!ItqZg=1{=3Z06B3_O+ zgioGo(#NanbsS_iA`^YC0zT1a_L)pum3Q{u?)Z0lY*FsAhFwo%SQ^1Ee2W{uwgA7b z&x3>bBv`O$T8P7^h#jTcUM~k;rtb&QPBc!sx?fW_EW&60x`SD9akNvj#^Cej}FxnXy6$xMPiY@Cm&UF$yH_jyiGl*L5J$kv3c1^LkH8`k-%!qFf! zsUplZJ~Q4XTt#mS@lq*q_(8N2)wkD989ec$AAjSp+%y*M3`6IOd-`}&*SCb=k%-z} zWbWs#=hb&Dn0n2w$G&3Wj_bMb1-IC(!0*uWWVls*Uku!C`hM^Z)BBu|zv?<2x9|n8 z*y-a|^gRLCY(yyfz6>};-+kZ{iz@$_`@84k;llTJE0}xdm3lsek0>3c1^LkR9mgh^ zUu)rH2WLz`<3|Q6r`kQuQlt{o`vctde(Azp<{s0bbA^Dj@Mjo0U)xVOAFs*DwkH|!=e9f_|^8Z3HaUW!6TJ_ynf23 zxAWC_)6ix=C48G5v(m?})PoeDvk|k@hZVpp^?^r~5Q|zL=KI|9^V1%mm(4q6mvi;} z2tSq)`=$l?(d)yYNH`j`x-?EA?3nC$n_!C`jXlV{KJ2-w&zoDnaOT~1a5L|efX)~9 z^l_)I56Lp2$~~)(dp&sn)3YjW9lNH;@@bVFb1i(qEp{vLJL*9)+z$N*Za4k^@z~AB zuDNm6N?l)sFL=dHAGf0a$-pAgY*0-9fmie&M~;{}pq9h@gWdDEl-PKN(oWm<@{QKk$nF^QaQaP|eS*L*4VU|K8`$8#>~F%`E+~ z;$VL!d_?ImEy$0q|Jo56)8Gg0e&0i8bH)Ow!~ zJQ7j$KC{2O-uD?byU!a7KPcy(Pa4Xd-%S_3$y6?_!0*ueWVls5SpwW{dOvC4w8PfC z@#N#Wo(NxoY~H4iThaSuU=d?BNc4U=@QU8^s1;&T^E2}>_x$`m{_xP;0oUBA=STR6 z(qUSVA6@TdvxL7YG^jkp*M|^u6G-$vZ-BerZ~e~KZ}jT=L#BYTaN~VAjW6!$<4vvi z3Be-~Rqu_%-Sz&4Q@h_ZXUJwpZuY~GcJ&`pS0^nJjQ?)pCVnybIrrsPl_VP+c9cbzZp>ElhU?+L*p z5mnz;0Y8l&L|loU8(hEl*Mlej^{Qs_7CytPrWN=d`koB8swa&{x$DW%ul(gdCEpjE zZpquqAIAg2S26QGecXz^Cj*Q4=7VB-a3Oy9QijDUP@o@{V&)n@}J+?59V;mfsJUJM_`5(c2Y%{HQ**By17t7PY{r8S1 z&j0Djea7jyh2Ms_9Z#24oDDhd@;(3b+OEfT{ODO7r|{bnXZ&fQv)}6DcgH#Xmtl|9 z{$t#YI!@uYA-F5^?FGfxPQBGt5=V?Z~h57ZsE5f?u4^IbsSSR#9hwAzb<)dSk@`{V!36c z{}6r~;!QAmcgnX%t~=gU+wb{QuRV|Q>v)CVhIkW>z8aB$j31V0c=hj~5zE*AxcP&? zy%%0-AHipigLlDI`1GTi-i;TLTJKv2q-sU501c_#9q>owusqX6L!%esk)uj=x8< z597R)hIR(7!Z(@9Wvy^KMi5q{>NsL)8hF22cyTm$;IW_Tc!jS(HE-7rZ+s-7%C#=v zU9SDc_ge7q(6`6v`XKx^#hG9vq2ld*oIBq8?)azw-Tz+sqK;SiZHhO+NJ6b|E7HI_ z{`n7={PDm|pX+#q-==s|j3iXt^N)9z^9P-W9KB%sIk)QiEBrRaonj=R;w~KKj{Er9 zZs(kRXX#lwZsE5n?i3>l6?f)vciev;lDDMONt=(;aSOjqaVH!}SShIWaY-7uKYHY| zM^@eS{%5*=3%^ZqCm2zva;_TTF6aN`Ua)3HX!DzNyuxo&ya`7XRths=$+%*58n~yO z^1_>$R~`0H4;vuu47`mYe48D!67NfNyfSI}ZNOD1H|CE_$JPB-y642`l=K!oP)cN(T_v<^oO|d+^Jgr*^ zsQuky^mnW){uD{R-sipg{A;$HzSQ<3I{t>u*Mk;RRE8#n>wNxD#gK9wgQ;Ewm)d*9#U^rP40>Ud|^d_?CkEyHVl zR=B3hi92&rCqqq_xN|`2I)uoLiL3YgpUC8Zxi;am?eJVD=?#4HJ&)OyM~`IsjkY`G zx)kngH~k>G@t*5N>iLInpF8D-tQ~LpNwCxAzA@qBufw!Ju4RGBDM4Q-Isqs4Kw-+E z70z=Ks!H7P?R4yS=gsdvZ-#)daAp`fU))=Ruc~zNgqo^y91RtR+K32cK9E)Fj`N}m zGv8?Zc*NU+LvZSRac?osC_l##uAC6!_fwqDshiTk*ZG3}e+EaLHd4|Td^%s;TZ|9o zTpA2kO^BM$`r?ALBU}tyl5RYt)i%E z`;2egl;1jzAI2Ac2$J>aArQ92V*R6lgd~IO;mlc<;7CeHxtHu}i7U0!d zA}fY$Sj5MEsR{Vh^qID*7iA%L{CyrdIqTHOO4%k0jkV0d8sBCcEx<4GcFo63;8bzw z`RH@1yWWiW_>_4opE!cYnVH7QM~0#E#k~djNZI15`n@6zoWI;yRdC=J?~M{1f>Y;< zdkb)iyi?*;^<(B#ce&2_?v<{^|E?V-cm%J`7xxz61gDTenV9(%_y?%6fNxFC{Y9QARA(HQMu zyn{uhJ#hBUqA8mhuV!{JC`T;un(tz(h@28T+`x`ES1Y69iu^&`TSLvY|oz0?(kRrO$Im3zOr#UUTudh*cg z`$@VGr)jp-_~Je^5DNJGHPvOgLGw5*^IaM&wufu@xiox@eMlq{j&M$IozR?(fYQ$| z0v96AOVb4a-q;O(1z@b0y_@%?ROk>I39=1UbKf{ zEbL_%AEPpd4>OEQ{DyJ%a6JDy2|8X5tPO@yi-#vW+-De%zlJbtuur3RhSBj9tSMZd zVHAClVO%+|gR#RM9gMeocQnR7($RPht0_8A#7`Wrh}=NJ?E4KwO?Ing-t z;!};KtIsrs{xHV~@4DFd_=si3cZdFBblbGQ z0(x}xE|UszYrOw)_VV$0k4@w~4Mb{Qb-u~QrMbR9f!V~Gud2m$CI^07sxQPQ`B2-5 z#cAZ@vB!`9`o!I~vNDW#Bp*5-PNqqckAj+NEhDynRjvbS+~xY@u(}s}WY7N24j#j! z^ToXxp5kzIpu9Pj1_Y4yUn<6@_e!?44Z zCHSgt#8*%ijF=noO)m|&O8QH*^r=5=Z)yq|NPCejr;ZnqwH?5Pg*JVGyxB}^av0%q%cRFyw zm=YEYjHEAoiyOZ-Pk(TYm3@4or8wNTB2*dm#gEHxb-OIGVm~kKGyAgbKy0JYJep@t z?*=;?v=^v1=s*z1Y6C#Wf^tC||BL|zKxi_JdeDU+G@HiXL63sabQ)iSGNFLIK>QFy z7<3KDJd_-QISO<(=y}j?kk@q3$Dq*=^KwuK%C!XwvI%rC+V*m^?Pcg>&P8S(MZxci zjQkC4{7G4cF=Sh~p`CwW2g9gAhZ9Cy|0Me9`kscd0PVg10Q4~jqu)3T-!MNK=?q4H zG7K~d`Y{3HwW)^j%rwJTdOrO973aI(iZ~uNjANDo^Gd^bxnqXWch3xCZ=6`T^{E*~ zXb#TK$7;%Dt22z*eLEOu)pRhZ57M5g?MD_nDHuNp**A5DGUeiid_Q3SQTHyNao-S% z*EA3bOb0{fn`~ULd0;ZCiw|F3o)nA}OqL-JI&s^{@>vFp^+)y{l1mJ#(f_M%>E7$l zJKG}8bkkm!{x+3-tVYabGw>+r{Y1IO(1{k9k1XEh9F9X=3O;p+&B z1C#K|7)~0-H{-ays5oqXW6M7oTc_b>oj!~}jUee?2b|?>rxMK@zdh#vJ{@rU$`uG^ zni*)DG1Bg=^DS5O6+ukSM-Jn6OOP<$SF5fr4-TmdmelZk10wTTpXeA9DlfNpM9Gs_ z#?c58e9M84+4qB3FL{sd!ZH4Nz_|UE{>PknIl2MU(9Xcu6@+iIW0vE4<@UOd!1U!u z2bBd&rt&qV@*q|d3M!i+Y(z|gukP&B@~is2i?P>?+YUT&kHQXDvlE8l_=V#W;hRk5 zk{Ta3!egytV6b{xFj#3WsQD{PZIEUxi*OZu*$t`jW&PR3IPv@1qi?&Q{t+FY@D*t0 z?ONdT<>Ku{=*P5hWU6BwYl#a^COqr7Sxa;Gz2+vtLpf5KI$zvV;xxzJ_%KVL{tyQ! z1XkBo3eQO`Kc?09mrgHTv~bU2NmuHJ&KLJI>PNzwq2gNUf@?8m=Yu+4n7!W_(Ql+b z6TK6@;1L_&U=B?&hvB{xYJxREv!)hQ+8?cv8tNO4)wf)n2ojWV*|?#;@i|K7xt)xM zk6QIc$u6abuAK7D<{X1I*zR0knF)8d`uy1rwG%JsIKUjABB*I+;3|CbRHNXIH9PpA zAaNE3s>>YfD_Jv~<;i`OrHHH$W5pkSeZ1?6H#!?{`nH*I;=s$hJ=WVwWg;xrSK(XS z_;q;r)G*%54OCVJ%Y9=ap=z|eBZGlb`>ozQ?NmuHj&KGxlY%dawhHLOW zz}!$dnlCKiPQfe8fl{AZMa{~{Fxeo{r?J2z`t-s6D~@DZ>ilda+$k16h&HAS=DO5G zC|T|1eeT3xV~gdhum5q;#DImthxjxbI_}(wRo^=zMXH>se6^rp;0I>ij+?K37&@cAhwS7wxLm$NS66!_#ogQ9O|2 zxoT4y_`2Ql{70{69f{RD%LqQ5FYfWA6nyznejNCvV0*AG%3Q`3?F|=) zPip;Q-mNyrl80Q?dGT_TGyVBNlpXK&`QD$azWb%alHMaEF4~;$2_JtQMrkM53zSR^ z%5=$>S6p0J5aG4RTKh}~uiD>dUFnYZmA7A-b7<{L-|KjV?*NNG3f_^y(`rH(JPpR1 z&n0}gZO`)@z{?Ou#jVGu|4&v9xD=7s z;FZt1EsI34tL;W(8tujhnZx_7?6OCd#3kcNoiFZ6yOAHY8;XJW{Q8s#c1GZX!iV?@ z@Cdh}B4ke#8WE7~2Iu8Dvs1TYE4yVHuMWBAvFZUgXG@<)JRF}1UvP*Wo8{R@QTv7k z15+{cI|Sds1)hlc*n+P^n#Xd<2ak~pI|5Z+i|0A}e|=t>HNJ~cGknWF*WdfEo5FVZ z0q8)8PxyjM?1bwukde0F!C|BsBw77h7j4_Rh*R>tsoGxowC|ElRzAs4U(e18My(6% zw>C4m&I`vHd)qAD>xOL=$0jr~CKub{Cclb5iI;e+)+l+HjnO3=pxGaA9d{YpTUmE| z@zocq@R;2(pRbzlY>)MQ5zPPDA4S)k{picxs_g=#91nu@g-<`KaqNS2?0@Cr>XabA zaE5(rJY=~zJR(?EZEiZu$1@P_+HlSnbFOyc)B6kh4@*}`|#Bz4MHo}MW&nu80iqQ|E9C=TDRNsqRbNjo~ zFX?~p7uGl-zRoFpcy}0e@zqy^WowKXs)Obs`oE8xU6Xc;)p@JlsEOjwg3Cj1PAG z=7UAMZ*Dw$N55mP?{?VMQVufC6utt*yoD67y*4)59E``drV{gTGH1hOm?2m3pmWY7cl-eXF~{S-$MA)#o2&yJi}>-M{}ma>5Y}*sf(7DPQ5+?3fj= z|M6#!W_uO?=EtyLZLnMd$a)y(H3Jqn@vzNg9caXUv4c+^^*Y1!yyA$3pG@3#XWr9T zda*+@zUAszpNUmFtdNHyrGo>p5+{TC}Y!Cpk?n`~TSHA&`eL&M=I z<-sEJEm>@kFkb+O7fNn8GIR`<&m7Oedf&v{S-6a1oUsvXP^uSJR39+R0g^Vgl&Yz zub_S?ygJZRpdF!{HJ}eb#SkC&Lzbhl-UgNEdC=9UNDY}t2aV?6kP&wD#mK~$7$+~z zGK@R6HH=Ro%K+NaeWA^{*x30*wqe}57y7h)4dXv}`Z%_)VMGtd{?#1A_+}{HTPZY* ztxhzIr%O>rRS0*MVeEIAVf=JG-bYys{xjH1|Gr^d_kWO8ckGGppJDvxMC^$?FT*Ij zH^W%{X@>F4?j4NC#16(Qi#ixD{Mx~oQryva{-KV>QTRsg0k?HB`VH93==s)W#;-Fw z8$TCxF|PMzn)-mEJ{#h3=yQ{c-sBZ$8jp2bdGFLo6E2-@&ktCh)EnV5PSvEXH^pIV zd87yrxex)eAM3ZOZbo6i_(6&Exo%9RF@3_{x7up%g@+B*a0%axK)JL47hba&i6!6& zIyTvdVQsG(gqLt8VU35;E&@qE+vAqhco&_RX#~4$-t~-oYVX)q!z+9Rs(HJ1c;huw z#o6S7bNTp8P}=*Vf?-mU6KjPqSk{)pmC5-%`u7=@q;K zGGf@uDM#nL`GE~Z+B4zD5n6XGz-bk>jjR#DrJPs0;K~eS8htF~ zKjB;4__YPNtomXvn4t+VO(U*?Z~m>RTHGXXczN+$i zyHX<>wOsowOpUK>N~Uq%#3y&}cVzyB*>*oA@)Ld>nRV9!e0ZHMz9O5A;L`6G0+;mr zZ}@v;G0mB_JI6K4;f^jNWxqe-+iO-_nfqUMWu{>qtUWs4WaEO(B;g2#SoPNQYABvJ zF)Qj&-t?M{tKeL%;C$xvW5P_M!FDIkx<$_M7srC=!VGj5vHdyk6PaXf-xCi(& zjH4s2!Z(@9r3gDoIWhIgjXC;@FK#!$ujpUZ?e21V=!+3~r}iJsR~<|va?<(Y9xq>W zF`ZB4Ag282;3&pOkt!n(9+|$(H_@G&hW$oMOrm&N8VA#Bt9TkQUQzSKxT%9+8>~fg z&;KOmTZrzQciK%j?mW}h5}1hyMekQb?^yuOzR6TB ziSVK8uC9r4{mNS9WJ^1$a%v@o)`+koucg34BjuK8-SUo?CuaJ-ei);2%UI>NrJ?i1 zJrN#kGmDEX4$hiUmvS*M8hh@g>eZ6FobqCO#B!7O@e1J{KK%Mo|G4I`u`<8s{EFjq z;R`OYnOb}*k0!J>R1);XIkJvZh5%~&Bju5-O<{Y~8l&cS#bTHIzM5rpyLRiNXJ7us z8B&ipr(}MGuVcVEvcIZI$spc48^05prhORvRzOQfH`rV&o;ZE`){8$F; z8zss3x?TGD&|nvbl}TAF4@^qUN7H?&%cH6?)3|8Rnd2J#yAGL)wHzABhwv?K{JNI; zP+;>tg_2;XmL+E%gz3mf6Ot6YYPdgjJ~D6G#yIlLe;4G8JF-|(`0*TAcWs%E z_@k+K7S#2dKL1FKKdUO!_+rNg-d_0A0sq>H163HoFMNv|zpf?zW{|mNDDqzEf_L$0 znZ~x~9`Qu4KmNS8Ul*>Iy8`wgLHL;rTKzHB zQ^wu-c-_P-V{XkezhuAN`!LxbB6x%!17hE#jfXGAlmI4H2N*OP#B$;Oiax+4>pOpq z{G|))K%?zWIWB`cO|p4FpXx5g%sxkdvdjGa{_Zn<#-G~?-)6@w1vfRNJXFaSaUFfJ zvs057DeM>;VN3f|^>Au@%WAq9Hx7O(oYm!!g+Jgq1dTjb7QV%eUlZX=*;#4$)N;@K zXKH+Tf7`~$e(UDXAA9$Po29=Je8P_-v+i8+DJ{ARO~uvdf~#s;7vrTDeqM0Ehx&o5^M0J;f_ITL_|`aIgg~4*RuLd}x03t8pr-RGciNvr; zqvnf&Lu9JlmOPOfUsin=k*CWW^ugh zx|G07L>}uGo^+0%r2feMnH48=HXfV&S;64{)LnOyT~MzgJjZjw*Rd9bc(%r%KuKB9 z$5R@4{8y#9eKMa1#d9^%951OjmTEXS<>5H3VM>Pa{1!9bSX|uMICS&v#{IfwkJApY z73UWlhwz)@sK!&9a5>+rA`T1DaYYyumEkA^ys&PCXn-a1$a^aF^Q7$gnZ{1%+;i?{ zLrI#;_0NPj@~k&C8sSyaU+I#5?;e{Q&mD2v_(_d7-^KMp8cARH z7B_xPntma+gI4mW+~L8BaHO8^k|>h0(V+|wmEbFTI<W)7R{XF;kE!e%AhT{m1 z4t2iC#>KJU&|iu-Sq9^9itwR*4z+x!da?@XQw{wf+T6>-b?7C#b~47Fc>5yU8n1TG z{_23D!xr+Mri-aBT{`G|%T?JAWqyRTGEg4dYlvYqws=utYp`J3hyWsoSNmUWss|+<97zT3t^c!VEEV%@a>kB{>VK4)<5H@4zYaaKK>T5ikE$uv5CRsU@6 z$d^{>IE9}Sr|h>YLd%FllFZjqp=)Ug6OpRp<; z+&3j7I;84vd(EHdl-RAonQr+}E+QMTTa%s_rfntQl|@{hs*VbmeNU?XXJe@6l9x@{ zZZGA~7C0COsjbEwn_{`A+wU;%?B7_oTM~xh)`ijATVfKP8$NLt|1H6{Hhp|c(hUJ_R(GU6tu2Puh9_>puHG{~sXyZ0+BDWhxD740w$78t zSZqChmW9_B>r!$5FFNe*)ARAaECCtswpIq*)7_qp-md8XTZ28Fx|NQf)}-B5Vc3tf zg)EZcNw>|W{;Z7-wdHswSzglRQ=aV!kKk^Pm;~GUuv4uet&j9K_B2>ObsbXMw{_W$ zv{%_BYTy1B<=|F6o=lQU$dgTS+2}5M`_oc)-M{yL!%9HaeYdjRut@)RQ)juT<&;bk z>G(+&Hl4A*n|?@Nyf!$J;cF}Yx)_6U47N6T7P&GW8PAE`R{37rc-AI=YnwL1GkuX$ zI`OIUQ}5FWyS9GTcY14!cVi8|sjb1cbvaNzZn~(-Fi{kxIaAKh{Q?tro#%JyzSU76tY^w>t^2Jf&?; z1};&Xm(1__;7eP)F4Agmd0iKI+*IQ9`d#ZRv1H{b@3YJMxT-&qo!F|Ici(ymY%Js3 zR5|o?B9(O7-i`B&bk+geKIPWO=;=u7W#@%VPXdYht@J{+Z(nZX?e>k{iEd-g%ZA48 zwV_U3^8TeSfsH|T+VeV*oBZ6|(=RE{=f)%fb^f*~>%gY4&eb0Bpz6!Uq~{)1PXZfK z0;%dQ-BP)4NZcDD?G4!vZEWjO8=`!?G(8D;5@_EN;Q6PX@g(3T0dMT#CZSE!eO;~v zCySfox>RF3aT9w}lKiHar%kDRT9OyGnYxba^Ea-Ow05mTk2_s#Tz_t>_fFdLT6Vhf zSRejcTUKljC}Xc(SRbX7It?j9+MeF0mX+t~Nx+kUCjn0ao&-DzcoOg=;7P!ffF}V@ z0-gjs33w9lB;ZNFlYl1yPXe9|O{0Z#&+1Uw0N67VG8Nx+kUCjn0a zo&-DzcoOg=;7P!ffF}V@0-gjs33w9lB;ZNFlYl1yPXe9|O{0Z#&+ z1Uw0N67VG8Nx+kUCjn0ao&-DzcoOg=;7P!ffF}V@0-gjs33w9lB;ZNFlYl1yPXe9< zJPCLb@FcMABrx-S!wAi;UwZJUJ&IbJikzFzv-0H}ZpPJC=h&yh#k0O8{Y3s+dw#zj zmzpo#E!lsDX-&9f@wGL7ZO*OV)XrEJ9ZFXw^p~#Rwk|i(DY07Q9*O_pS97Uwj9qS%S*a^%CkM; z5!~ytoF$F+Y^Pd7YR|aa3pUnIU9Z*l?SE0f618vti*j(&QBNkxCFIE_xomV7z5UVW z!MeL1eq;QjnQVgsO6L_59#B2A3A?s_)^~bqi+5uUua7;F z<)bBflPr#nkx%)!>7pvbM0MOPJY}0G-1?SRA`HYP_(TV!9g)6jec}`hYMR2MtrGq4 zKjkm;esL!+QMu6FGn>8y-1cK_`Vz3(9JTFAC(mB}NJmN=#t+-&L~Xc=CQ+NGy07nh zX`k0cy6r8m>mrYvN}OK1Vi+A#6eit-bZ;U%v2}Ovf9oW$A;!0@Lz+BPGMz}qPaf0S zyGWX1uYHW|F9yyt(pd*=PsrD0d92I0+mj4EEU6`ss&7jja>KZ~jiUusy8gs}d$u>` zyliOf8#?{=tXCek)DmDH+1~rfmaY?}&T-qiy2;MXJrNqOJ|~jO#>G?TZ>`aRjU~66 z!a7%b$b+gc8%x=HI6Vn$XbGgMyL3zCzM-+N@ANlhKeVx}ORev+@zV1o;7OqUOQ2)> zhv*?}2NLkc9_^qIHUNZmxptE*Zt`Vpm&lLs#Los0%Q{PPQ_Ryk6IMHqm~E!$szBA} zZ(Jv7?OKT*x1`}_bN#uk-aBc}YuRpcSfB2#Ei1MMl(E+?tk2R)oR*X!ZBOqL%gEz; z67VG8Nx+kUCjn0ao&-DzcoOg=;7P!ffF}V@0-gjs33w9lB;ZNFlYl1yPXe9|O{0Z#&+1Uw0N67VG8Nx+kUCjn0ao&-DzcoOg=;7P!ffF}V@0-gjs33w9l zB;ZNFlYl1yPXe9|O{0Z#&+1Uw0N67VG8Nx+kUCjn0ao&-DzcoOg= z;7P!ffF}V@0-gjs33w9lB;ZNFlYl1yPXe9GCDt?df}J>p~Wi&vfKM zT@^~lKmD{8b8Ew;iz^*}ZtX!jacr!9+DiV?zO_Wp)`!dlS8LL0E7`OrZ7+-`0Z#&+ z1Uw0N5?J37Xh4FTFKsuj^!ut~tuJ-?!DC;V)ypsrfnBzrVXO|FIj{GeF2)}h95d&< zZBM*L`r7T`{wIv^@z-I-1Sbs&S5^lrtD^;zqQOXQFybo?RhI|H1foU3YGW3BOZrAm z>hu}$pOGDh?mGPHXCx7(Zy4J*Yi7ZU6E<*G~(fpFPnT*x8Yk_DRO*Cc?jR)#;=8eDZydkK&fv?T~#m=s(@eu zpz>g#GFUpQYG813I1(&G*`TN(`sR8&c2H`0 zuD&MIIOn{oQ*YjLtGdz51dQmd@GWlqS`?TZ92f~tW0CucLe)WNKy|RBIux$-O+iv+!jA zrSRj(th+Sv9kH>7e3Djh4I))yp($n1{>h=zn3N4; zzLJmLLpq!7r04^&vKh$R)iCZqa?8(_AfIz=g7QG_~N%Eb~Zdq{hpZ@uix`~e}6RNZA5+(;YpMR>yWL6 zF`MF|EUC$KC+2NHJAue&yT2`HYtUAp?jS7vnf^C}%{3m{jF4p)B$h`fn^-Ok!~dcOtw|rjHz}izi+bcc+ZoD<@@hn7IQaBY zuQTHZMK2q1WX6z-cu!-=FryjYay5+nimGs=I#5}i8!8X_co`Y2Di4&viq@1@`-&s% z|4T;)@P}b$f~5U!Oasr{&j$6I@zAKhNP0cYn;wSF7k4*2{_=9utBRxdaZb5V$EbJ9 z`WnVt1s_dhfVaQ+_~W6!>~=NpX#|JPw_H=or8-hSC|qL?#MJUx0vt4c5aq6qo9VXA z_*>8FGp5_OFY^x!{q2ma@J*(2amr&1`qrRyrp?NR!5TnPJ_C+Vji=#-&PLCY=TCg^ z<}S}2#L5Xnxv*anzR6TBsqnCDRCz2#`mEO?58hK})p63osi%CkTji&tCNMN(8#!eOXyP+25g5iF{&ERi5}xDk0QD@ZMmoMD}f+nzk|vgvqdQ6hOjyCn0eI46VwwL_R zevskV7LX_RiP}-Ru^ecV{#Q*QGOm};3=S+{HiHl!fsk^JHjGk><$7&|FxB{ax`t?- z2bP@}DL>s7_e8e%P2{#I^BR#kX$Ptbo$Y`=pYMHJrs3cGkyl0y`E~V?w!m1=*bWF^ zmzC>$eo&yKELhrXRv#^igsRZ9E>iIII3bRY^}nfCS5prg8ao;1ez5rDs*5s>%Z}Oq z{~o`j?wV)pc3bcXzs2}Q1ZqQ5%t=~tI5!lDRu|PwiYRLkMb&|bhO@~9XXB-r#&xHD zarE|Gdfk!B!5)m@6u!lcU)|*xuBZrA7h%4Z5@$A|WO;MlA!}rOUeY&OQ@;z``q=L3 zJSiW%*uV+*s!_)q^AR7_!VjX&c2*yU{pZYi%Sz5Pr-^WtcrP+^zUhcdQK+J-JZLHj zmRd@KW`|Nx6|5|b1SfL}JseE`sY42KtudkLwEp?7h-zEBSOxGVGNF2>G>|8<|q7YC2(k{M5*^;!6muGr1e9~_EKWqH_( zMdDAzkvS?gj`0->k?8PT`dS%gP=Y40Tb^$ErPxux$er=Y& zykMX-7%2)(r?xxwJ!^Do`IbG>+30%eg|8pbz1!!VEUz*73O}B*b=NF?mh+(Ua5U&F zXtkX4%AEC%eKOksbzHmjk+;kCw zi43u^ZK62XK2ZIs7sAJFEG&7F7jdWUne-*l2a2H9!$cvatXM8W)E~;4ZoDV4%xIG* z<)Qi$KFd|^)$qKR{|qlg9@CY$RSaOq(wDI0(a=AQ#4B+KkMYYrZT_df7(J4PX3EOc!}ZSz3z`ZF$^n4{L!XS-7JoiC+X6b zFk*`v|BH--Cvkap`;$Np6jkkC^!l={5mQIfG3okC6j!RSqNAe6iNcddf1=mohhZo$ z+N|&NBkhU!7anc7XFRO)3`gSliQ(AZ@Se*?9M1EZy0jy>^-MdIfLDJky`~JOg>ZV&S6k1Fx@cdw7v)+It|gK3MQen`8n^64(^Gw*dbaaY~wU-id(lGF`V z-^GpLX^2DBRdJ_HzWkRo)c_8Ynea`fa&cWR$MTVLAE7*Pup-HZMSNT* z&kV)a$>;9y&J>Pq7TfOJ7rF%QG=g7WXQf-VZ=bTK9@~Ba?`fD%UUk07#>M$Oxd>Y! z1LdLV=Hh1TIrqSDcxpu;GIe+`G9_4AR1=wu{RssTEE8fAS`oG>Vgr}Nr>@iGoSGW% z>Sdjc_g7Zt?>y$K(=43US{mgoe2G`=bnx;y_#y;|mAeZL#y#_fp%tAG>WMwSn@O82y#?K6C3{Fp?ij zN5wg7s#9Jo(a4k{!Lp_f#zA*|bW~lmvvKi@4`;1@@Qb4kqH@3xC*>u4lc`);H{7R`*kM{x1T$TT!kW@+1$KCmO=9!(16&=r*{QM=o?>XMydmuQ45AP1sLY&whT!KfXXdr#g>aXhQtZ-_a zc@3S7H@5nw;NB%49joIMz5^uwv>vA}Q7h*8u%tchUF9r)z5dUf(b;&;UvyZ*$h$AN z&;}-Q6~4`mS*h^mmzKvjT{*>QG$IDUwN%5U>*avGyBKHRbncU1%=mD@uGkw)vpb0G zr|?ata!DIkVzD`%7Z+lDq3R>scIxEnT*Igycf=YdyZyhi?znrvn2wFyWCTNI7OuiK znaX8!XgXeDKu=Q{C?6P{V!uLBWDYre(gnf)OpwT__xVm7EKOF^9z6|X!rLz$*mUDI z#?<_~zWg-z((?y^Ps8d#ISJonDwjcFY-Gd>3FfwRt8YY4I2aux`pBUD@EradApqh~ zpZhD(tko@L%l!?UpOBa@j?H;*H$%AdOezVqbbcxGC&o!xvkYixlXM>cCo&R_Zj6&8 zVI`i;Y##X%4{iFD@G2g#V|?C=5x>c7`V%(^k|DP^q&z~m&kwBvQB5tZJZMwAcqI>Fp-phZn8He~)@5vLAaJ0!|T0;CU zd~u^qLqB5F^n^!S{EDr*dH0?KS}K7YC|zsE%WbKHEsab3i>>E78DICO{!b^2>PM}w z5|8lII6su!FdBo{?lFckH4O2#}e@BPrPu_(OcDz)RlM)@jlS2KdMwV-TOu; zgxddby-e0sr~|qlP=CmyVVmihbt{2JL@(=lRTr{k;_Ka|xF;>edSAyK?s#C<&6&pj z#{2)=;-fu}ypSGYxMzy%dcrrE$|ddf&*8z+P)&vY*vMF9>(5Dhe))(*D>}mVg*w7@ z9a)3S#69QC@(v5<(cGKD{asuV<(!&pkvwx?I}rD*bO$jXJA!(E__7U-0x|fW5tn&) z1My`X>TWh@573^Vo}j%zdxQ1?^#b(Jyoln2TO9S1rdGz>Hx zGy=qjhJ~OLKqEnX_n;Uw3N#ut1~e8l4s;^uB+$vA@t{*c6F?I|0nj86bpu6zHY~?` z!^TYK`mo4<@nspt#~t?HH!o)k(mis? z@HKyb{o%KEyQ>p}o4T|MuEIB&%Eghczcvsm4@@c#T4~c;14z=ZyU1A%l+0w1Jip3* zsk5=`cA+hL-GBLS0WN&QP?uQ_!Z(@9#gTse>C~vGeO^!l{7U+(kv@&cz43w!Q|@(8 z&OhH;@!0CSGL5(1dHlI_}mv;Q4B{lZZzJC<6>oArU|3tvgvyltL7US%vzqJ#*cJ~!!enfv?nUp>BN|1;is zhs}U#*lw`((D^1Cmx7`}k@~7?pFfKCjc^!F3IE}wp4>or`J_O})Z(!9HhmWIN4d22 zxrr?vN!GLz@f;r7@gGkf&cd0Gzfy0OLQnsnz3YIFs@VDyS~dYOhzba55S56!2CxJa zWl4a5gai_rh_ED^WFg6h-3`qa#e#~69Sgj*JdHheupr740iS-z6OA2t7Ay#2d05cz zf9Bq^J9n}z0Tp#;e{*N{O#9z6XUd&Q$^lJztk2Jq+r*YHFKzhv_8hX4GD5UzL^oW~ z*0{>#8EGV&1r<&|&c3R&)A>?Uoj#X+bWPQ0O!ehgRm>SxgJnT3ABU@hg>h9cw3cTZ z+^DUuElU#X+RocZVGgW2W8P`s&VQJ`xk(ZJWIUNJiOM4^t|8c+S%b5=f`_Bo2YbC9 zuRYuA@%eIGGu_25RCr!9tc*>?+4-v2IQJcy{_fRXS0(E>nXW*T)+XVkEr*pZ?8KZo zN5>gJY|PJPao{Xk($_a(OZx#jPNwe`PRw~%S7XMPK$;QNEBMM6S^229UlioMgO+X@ z^nbffEHT4VewQG>nQoGUMp!=5^m4`E*{^Qb(MnEj1Qu*5eoTMDkgd<#iU)-kE36C$?x^FA; z2u1!{;mLGKR37o*4Dz?gLx*REuU$3%s<;UHIBelMA)nExy4j7vb8C zX-g0PVZwpQ^m!{42GwrsHEJ$8>)|)Zbln4;=!$yyNFm-oa1kbEf+~*R?eb3Gq;#2|;mXl00V>h9tep zXN}n1@dn1jCi9p6vz<-$vp1V+zU3}$gTACuk3_egl`N<5#me1=tf3W=8U;6E@%O}$jokfLx&q(rF=yH0C%cWTEX?Y}2 zoF}?z0lb&~QRT4#`4meY`yc%5#aCARL`|Ml{LUw9baoG$Pg-xFsq$#My^T)cl}bMvwPTlRa>ceG8K`fLvuZ| z9ynDTgh3r=s=dQnkB|_SLi4;1tfIKffN}emUw9SOVWcPy8W&@_Br1=v?-6TUEJ}M9 zK-^sKrQaDFZ@1?!XjOFo^8;yKloa9ZgD2A^QF$~AuTuZ1{9F%wq#V$cZn*J}372<$ zP<(m`O@&HD{>ZmZmt;KR!58c&8vX4s+zfUXE&ZI?|BTJgUPoWh_2QFT&SpG}SEsXk zJa~is?l4F>9+j^dcg5!GCnvVcp69!}g4#+_gp>N;OqWFE5f9EFUyc5E7_=e2s(2fK zm(q7YlWBw2`{9o3vcLY~!m6X-Bo+B1-#T5A@rVm=_Gl~O;c{42jFHvcA` z+p*>5f9&(2;nToRZ^LxP!)83Vg8VbTW5e-J#hG@mm4D&NPs(?;ktwZG%NPgqPp7kc zTsXs*ABCIPH;4$iJz9BR>~b^YvYyG`&Dj5A1E0Z9DmP4Ld~C*pQzS8yU*^1Fs`W)Vb$u-RIPShtan`DbC-~Cfyo)gmyPn>f+5-OTLx^r;39x z)IxK;vIXv>9MID3s}tpVr)sQ_D;vH#liZ35)}7Vvu-x;=PKx}|Q>RNZ9)(!mMt5_` zDp;wIYs?eH=fe-DU;R+*^j(Ksb6sJlajQ6fPG6_9dxZ39(V3r`Rra??!Lg~{ibI@v zWNX>42mSn+{bV0{ZQ*t9^O7eX{(!mejBp$PJ}{l*Wiu>}Jm>7*InFuuac+OPr^avI z!6p|xZ9+ieOSE;Pgp&Gqv@Wb8G_CcdjvcMJq_vQgNl!wj0^Ehry)pQC93~6`_=sGF zz%L;1F<4l70~V2faxt+%XxI5xjGAHC|N%Fm|O==^3nUeluD;kTo>ICzhaDu+8YJhfrU z!KiktHuZRRbD4^#3-X`o7BKh|77u5<0we&xTpkub5}PmIb-4fZg^PcDO~pZS$n>~y zupEx``17kVZaA#USaxU1r2@~=-^_f}iZ2|WPP*#y*8QGc`>TqN_{8+M@Y!PnQ_Js4 z4Oh7G`>&T4el_Qtk6%!65#N{|7cS-d*q#V#P{V?soYY*Iccm3=3 zk5#^q95G!+pgh8&Fy)B6sd7C332XY{#&xDo>2m$H&pv#Rlc4!vnibaR>>jq?7+lBb zC@C3J=`=3SG(xELVjAv`h&6v!RMLK2(VKZA(8NeZW)em%nQoGU23_Cj$r)rHQ(Xda z<$JV9T5)oixxA7*t2k^c489Bmo$^KJOL<1J=x}F?oiE;OJMR~RA%gr;zl-VkYf+8v zKalq@&@~sh(kmQ5cA*0EZ`!A^dC5@(3&dJkz6Ut7|gwX~~ZMDG zO}Ih2>WAInO)AQZgtBrV-u?B~Q1SnxJW}(F@`Uq+>HMGbn(~R<$YeXLjTDDxlRU7U zOkJz)WRF*Iobmck`1|W}AOK-d>$6+%s`NcUvP*Kz@=7wpc32z9qUx^tK0H74RnYa&4bb#`Iu!aE=&zusKrp_9UJT)>fFM@4hF`pTe>9?p zATciz%SU3bBe4uLuxI1L*VY5+qA~vEcU<;X}CYLm?I% zkR&GKw$BglND`H;aIWatEhHboBKcjamj}R$r~p-#1Kk6a9V$b_7aAU*Tq8|%)@s>O z%Lu$!$_1st?rf5uzpJXli*x^crBWVlVXWA+&PMx2W{DKEZS0A+9oyky$pS0^(r?Y$fI3u5HOIWF{2)qPhBwl=wj`JV#K5=$8ZKQf(|&CuYy*z#T71soT`Q;q0!4ih zsy~@7iOM5xT;bVf83)Z;6MJ0bg(nJK-`CGu$q=Z2K)nQ=&hEL+sFgdY{cJBrAd8VXP>Y}$NBO$w<&FGb-q35GyKnyYuVg1>^Z{Eoq8qO9-Dfbu z12B_m*O$wJXD9He^(v)B?NOi$=8n!D^E#zb-0SLAuLl+kB|9m`qtgvn9nTPaVT^WF zSK$5xbJ2*3g~F)$G-Z8s{w(U=Q9QSFw&T+MHx0-$+j+u6<(}z`gH7xG3GyHg{=TuR zSOQ=K~crBwbN^{{lvep*yH{LZ`EP zJaVH7j4H<~frn(p0Zk^=ZF>KuR}1_6&1+sPf|FE+Y$XYu&hAz`jr%X*WSGLLd@6W7 zHlNyE@;tt(~8H+ z9~H}N1mOO7+FMq>5GvZo#`l6y+$~le)BTO>oELMSjLamorc5V4sw#3$wGZ`rYUr4l zBCoTGt_bl|^%3#RQ&Qf9Q1Z}v1BJ@$Y)X`y5Wj- ztM+xJuAkZ>7H-8^~*Y-8DSn zkesCRWy*W8`Lbs9ss|?azU@X%hjHk1cGqwiauN}ZwSTrf4m`hR7EYYKV#*Di9^=vJ z?5^PnhonyyF~(GC|15KRZ2n9wSd+E-;1g(?T`I<-)7f3a6PZ6Is(AV*9Cy5?fzj}- z+9QQ$KWwr;`mfX2jZJn}{gR#fJ$qVlS{$$XU$wJ)yrv$O`)u)sPx$-&I1sM9P<~N= zn@r9-%2PdGL5fRpI5r~%isT-N9x0xt(3=`}Q~fsuOTzEo&w+5|r8%f|Inw_}ij)1R zCfg~DY7Z9&x$AzojED2TJG5}=G$%fehfOsOqJ^WYeiHUSjspWRh?AJ_vhqKgyoPhr zX$UNt61b7(d$7b0 zZN!Y1JJ&vxb>oq|j+5q*Xg-bU_-j#dua~smgC*A(Q$*_cR^7MO@h!Snhwx4Lx{Wy7 zGj+(o7RlnYw=d0lx!~00|GLJ2(H#ciW4b{NJxAjf8<*GRJ)RdxDmz%LXHVpNsu65Y z-piGS_-NTFtyQ4CFSI6>2IdZdCfr9r9|cX55q+Rff*t^!1ARJlA@rHhrO-2==@6+a zpl^o04|)akf1p2yZiT|s9ohj+cm7-f{RH$U(A`k@#zEf%y&1YMD%>lfzlNUDN{Dx$ zOE4+;Gc=B16H_orn28C)PRRUD*sRhQi-0_sSbY_XKnqd8TVjp(fAM1f!;1~+B*Yt7 z2lyangx@$6>GZ(eQ#}#?(YS9bQ;7Rd5aRli@veh}s2V23MWb;31WuW%LB?L}5#p7z z5%*<6T#X6)v+lurJcBbR)(i3Ir?@*TDM?&*aFY1(lqB)tu95ZDdI$ecpSy0`i|;-BD(4}YNyt&A`r`8U&j;e6ZJ`?RAyZR99e+3pKzpl)5e?cb64Uxb-^s zPP^>0Ew>HM<0Ospnj~~OyE7iTZf}kPYRu>nz9M%eRcTVGd}+{d3>>ttWU4I(8 zlDgjF=eyo3ytnqJu1io^W6yCFy9;r$kPEkb$ZaJY zK*dx3io`jpB26+HU@57RkbHe=%HZN;PJ({>F{xO_VJ+{gEQYx=&= z8~J0%4V}ltbjHCZ=M(NGD1^}X>@vfKcs-S-i|ZxI0MqHeYG-$*M{;9#)qldicX1$G z|7q_+7(W`8Lo!KI|Bw2kRC`kUMSW`35B^G})A&C*s&>P7;`w*xfI5!RxlOW^F^4H9 zByUvTs`sqbeZu1gc8p^5bE?K^30j>8_HT8ds4A;~X{Ivr^k@TQBOdh5C6m*r}~l?-QQb?}j@b z9Wk<&4+tbPNjxZ+j=vT~jr1^|2R9tMO0sc2ZnhI!(Cyj+SxCM)zjnu?2rDlU#6)h#m)a!JBLxzrnuOTYG=Pp(@iyunikVJyqXr< z*^Nw9kvpky@o`voXOrn_7;m-Z z3csgRq_~K#yD^RFZ0;@=HD0zepZGtUyPH;X!tcqnDX!+I=7!VL3KtLaTK5}?PX5Bh zqlb^@KgYvntT5z{bvVE5#__5D*&Z$&(bO=J{4|vwD^7OT(`P!Fs=Ybsb3X1)JWWkk z_s{RaCc6_hQaWA7%Kr`DyZ7X{IPKkwEtEfMJe-C~`>WXL-Tun&7b~Cs&hH+JHwpIy z2NE1ea3H~f1P2lvNN^y*fdmH<97u2=!GQz^5*$cyAi;s(o&$Tsx)++?il)N3>oi(# zz%(*x&YVo9!77#hpNJ|=w^KZpe?zu%7o0c4Q6P5{dW z1h#zz&xTgzg;1$-pu3Sft4MCq*Zv&)D$mGkxwOpF-RVP5VrkE{V#6RxXe5I7_UHl8B0hxj3^F z7o_^I*(0)rP>EZzA<3hNbDLklrjI5Ds(!#kHk`=GGjm2FrRtZ zMQD+ftE7)TzbYp`FWZCNUsZm31LF=?bsg8hKCy9q(equ~#|7uS%IO{;Ee8ml&h9wL zdZxSBHO}Lmj+;4#xT{L&vRR+s*n2j_`zE)hdU!5rXGu7DnUp9Po=9*`0;>^j1KmYlQ zHQUy2G=MQKrmL99F3(t})ywt~xIwE1{g@mV_J^Y@LyM`6R+{{!L-T&4THxUQMvt$W zmqux*{Of#t?0!VU-4}KqSXSvkP^pamZwsN***&z*8aw9D$*S?W3UGu4dR+Nl+{s$$ z_G1Ayd9veh;R+QUzZ+HdNYFbXM0`f2NhQ1mMwIM+%sLHhvYVS-HQ=`j=Xpth4SG2jkRP4eHxQ3!WAjt>Qb!IB^k>f7G z9iU!0ct#_AmU=|3-#VWbyMFujp!0`3cl|xraeD2grM=MU?5^P8quYj|PIJ?~Lp$!= zMV~jv?W?96a0j_cagf58stOG9SaF?k}JLZklVNUJHOq&Uqcz$NfCeOsnaDH zk8!T4=9r={f2t3IeHi6qMk$zsyi)UPy(2oFK+6)3R&TpABjaCIc)Ehw2&m5VNpOLeV-V2(S_0oC#NCTKc`L2m+iUtBgq)jNepOV~S-wB2n{&&SO;7U;@|-rJjpZJ2<)=ZfcVvKD%$? zPc2==1>A>VIb^yHL6Jj4>Wtn|k;i;jT?o~2mW(0M@zmN^T@+&$QmlWe+ zx;Io?PW;-6kLk_9M;WeSqBsK3%r}u69oP2FHgU(|E8cP4aP|H= z-gTmseBacjKrnLPK@d zIJduia^~cGf4R%cv}VdErLDftz~Rx~r}j&m_;o{lkG9iZ@apfw^k%&eUQb>nH@VMb zk9Trk`)<6?N&sN_5vNCgpT!5Jh~+0gnA~Oky03KkVS2OPrwREJ6f(2kQ1P#ffqzYx z6mj$q`LlYrJJ_bbcq_Egw&d-vWA!BN}2^t|Y})0U@+rC)r0)0)g)*JaQF)KH9@>3a;f#$ffk zs}4A+AK-u{6lAAw6!pBGD~o2qBkIt*^Adjs6t)aK4R_kkO~r}QWdwVzj> zACfQ0j!Um?N#k5=%7mExUfb2Miuy?>j+xw}ekhIwmx_#ok#kHpsG(=!j0$^>)9;+> z^tsSeD#oSqxGHl-1!mIZU8=N#X;h8J?=*wd!sL2#OAI`sq^hsfnjM z!c#eAx*2WIAUtR{{VwV|!RD%#-(W!qweZR5mls(1p^sG*3=*7Rkv_OW?{!zcZzzR>ccU~ICOoPBGHr^eJS;P+2QER;UeEs5ig zHT}V}F&IfxhE^uPpDGu%6RdpDaZnn8A0KFc<)ya_e~APbirA5XC(|WSc@U09azPRy zj}NbMR%nRy^(GWQ)hkqX$WEHaJz)*n*$U3`zqFdlq{}%DP!oxD{4NvC>MW7%VDoXH3v`|?W=HC!qL(X zo`0qlm;OCaJ)?uTVBCqv^jmJfjq{nuotdsclGf0;EuF-U(`D&{D8Fj7tJp;=1YEvq zPnG;~GS`%--v{+)S-)@j+i?D&SaaB_eL5xZ{j~p_G=Je)pU^x3sbip9;K_7JR336% z7Kh-vyz(|5W3r*h>nu07L)X-Crr(wQAtm=~s0jqp|XH_u`Xz@}%b-bh=I7m65DgPU_U)d?*u}7{H z{TAibbf>{QD8|8bgBp4&IH-uxJgKu}PLao0o8Cu3VuZ1j|KjL)st2ctB`2m%dg;jH z57hB6J%q%t#f!&|3s6FSt>a1!F>uXpVH1~qmHENusYx?GFe?C(1FDyp-c(%KUXPFW zFH+b5G>`YqE{V>k&aG_Xz2akX=dK*^PaO}_DNa>|-rXKH-&8z0uP7c>u52zVKE3~u z=IbENIBwpEH&)F3H`hBXS4>y2kzK)8i2V+RIE9F^IuA*?b^bUI0}sVN$31q*k6(76 zq97IJAC21SbV-T!so#iROd+tD+LV~Rh}DSq`R{;P4xU_#j-KouQ;3K`6xs~{9rn#$EK35qYOj*p?mO#;yQc&)hgKN|5RBzDeOh!pxs$Q}$KSpD3E%K>Iv%Ds9S^>K zT*j3kX4kgB>-KoD>|aKu_CxAo;M>yCCbrMb7AqdFZ9Cpvpv2{g>2c#z8xRCi>zjeo zqw{J00XDJpuzvOr`_yIYIGEln99rH{906#~zfCc4WpuKMw@w-9NgMxA4;>fNDNa>I zlqZ!x*q{+94^?@uu87XJEmKm&ob|VCJ9EMDuXi*D)A@Ue=_)p|$A>Re6$B85`IS}~ z9nbu!DPrquOLtXO&p$`U!*s%+s;1#-oT2rIjPb3EfiI&ZMO^y4`1qI7%ih!RF({aY*6PF>d}6HZbQ9_mNwbV`VWY+S zS9c4SKO|oXwRdnpZLhbZe39aMK(Ch;&9sSC)x+D4e$nsYJfyWj)E{QLj6iuP<(j_b zDzNX~_^>MSsQY*d%CSBN>(qif^40pX))yTYCHL)hlPg!RI_U*YnsCv|C7sUh;c!I* zq_#KpbED(QoNW__-r4fBj+Mi!-DZN!C#EwFHsixn$K@U#5;;pFLy+v zAq=WBIq$emW0U+O)bGQAaQX9Fq)d5Bn%eVl`A#ySy5Vm^fdhL>{?IrvZ@&H?c{q`EO_yNxdq0Dr(Byx zd|^7{VAF~R$0x~wMiUqJnc#U7G|6eK_3?y|>S9_Cp9W3mLUx6we6mBI0zDGi1w9Y? zUg-Cr)4||b&|9F-2BZ6f(S5PJfzV1C+iMq1Z;x${c+~)_@ z$o2VZzOMnFW97T+{lLui{V+LbD$aME&hAz|htGGKlE7ILGUL^JFE~GXzNcMl6W4x_ zaoHzty)onw1rOyr(-{Yw3LZ1r@EIRK0Ir`F*IIGtyAgd)lUO!862how^>o8=wCG(F~>i1*j1y(-l-;acKO7~CS z{yy+raJd8RE1}&bI$e_SQ1Vl$Ua5YQ=N%aJtm4AqR9tJ~z}0f$1trgk7eC|hl)v<~ zq|@15!4-R+5J%48+H4tAEsr~~|A&+V8r4JC^C}M5zy8SEU$%`Vf20_fPB&aF{ECjt z#1ue4DhDiQRL4bARDV!?M|gh^rPdd<^P=->(~4wq=*BJ^KDS-|b!QWt4JMUSrt6rM zd^DtJtlKrKar0?u$LlVRj)T(3E$o{-u=8QNI6clcozCu!aEx=8l)3zkkOaVZHNU8S zraYtkpu9<_Kb8YrZ_{~B1(!r`Z>yh77Bx#-?eoEoUhh)fPKxS7l2@inqViDWB+u!t zlD$3jfT`!_@`g^#F>M~BJ6PaF7rDys@XIPe#-`Sf>6cpNdElUZW&dma2}1ldcIAvM zi;~4j&-;2kdBo#a#|bU#xmbeV=7`A1W6P=tyeq+@4=tdBzFj*`3lMwN9fORMe}kS=jwct-3uA zjn7y&I=DEQXk<<0RF^luG`q&<_f!_Sai&Us6}Bw<{3HF<6gC~2-iPKd8h}epm(o<* z1KZ`+^@zl3dXGRCA$p%Z=5<&_X5j5HAOCzTiJ4S9|F6^8eK5{L_f~t|Si?)(-Dp>^ z%Q&QS%;*tgUEUIRvEMkH)d->2FGQs-57#kPny4HT6+?ABCg+_18TXRy)b&Yo_|fUxNNznyzYwWI%1_< zWBr#=d}%o`A1R``2PfeWiKTtI%8IM@hQ&rdAzO%(r+jxGrTNz8cb@yW<36{HFom7^ zGb!lRFrECUDi=qS(ZS(ngF3=pHQi^=b^6ND+E%#6_|V|yR}s}wB5(9i@hk=&O2z?A zrruuGUuP4qUi`1CTR(hqfzkgC^{<$&Vj+82JVjotbOr!i?}2S7Xicm998SfPfqoLz zKa7X#B6VEthS;3b3R9G`hS`wzfE^)U56 z*8mSG#-q0nYpw_0xouv$u>Lv70nonDUMW4EBSjH==fh zzUycVj(AK%f5zE*ZX8hC^X-pW`xj|ILHikN3~;e|PxyXL!E^#smiv9N4=!(A4^N??RtIli)yt0|^c!IFR5#f&&Q- zBsh@ZK!O7a4kS2`;6Q={2@WJUkl;Xq0|^c!IKUiG*TZEkkG`%d_l0Ef&3Vqc$8J3@ zm)4t*qPcWhpU!kiR37peO`nG@LdMw%QSZ|ZuCu4$xzOr-EUisvMf1b)Dt#RQhvT_H zHknRlv^4?I+|)P{_V_rE0dHzP)0{iYmKuYekF@rQ=AgsnpBgS<|9v=6i)1JtX+7jJ z)FV_cIHDx|b>+QX#_qakDd#np?;R#x4?5E2w-5GuJ>G0jiOYwBtb(rKj^vaZ*x{pv)yzP1`WdCP{c&ZM-z{>N9(&RufChEAu`KSRzAg|so< zpoX4u#}BS2bChDWrunDH>6I{8smBs}t-LwKx%=JXdmZRLl)FE{JP6fyAIp0{0b)(Hc)Y&J?9txceM zpXqAaWDoAk<$E{_T;5WTw~~%i&U02_xv^Kdk<+}AxMWyKg-bcS5Ag(`8E57*(Q!5` zP7zZ*Z-1V-WdHFxPNpL|i)ubjBbr(mjBh;lMUo=9-$H_Y=8>&SVAKQm`*R-OkhRn% zdR@C_-vxCOCVls?G1JO?WIDWC6mJBvn}<=3aF^nM+)7tp(^nm`gVI;`)l=HVD1cj` z=cA%L5f$Z+&~E_VD@b-T677PDb|wnlFE}viNo+j23k$9`U=ib>1Cg(tu?86Hp)SGw z0;N3!_PGmj2i9AqV`usBEW~%35I+w=xO^clo*=}fc*&2dg;;%_5R(=P@xeck?xRB7 zx)$YWvk<5Kg1!0&V-NknB+Mv>v=6imklk%C%syVe=KY% zZvCaDIP08N;>MKL!d}-}3^}8X7<^c=co*kH@As=sj5sJ&OdQ`5M~5g6HCwCj*2 z-b>w2Y#y|~cwyy%qT`ia#5oUl6C1M9#c9VKE-G%%5D(vWtQdA`U$Nkde&U3G3>5cV zoh$Os8zsJ&H&LX%SSse0`@}0ZT_AQ`cC~odbB7ps*^|QE^;MDK|5SYVdCR27KkSjz zuzF}x+XJhUa?e}fZ=3o|)81CvM{+PU@#ZAx5zyt(S3$oBy)PoDflfjs z&qJ?8M8|`4R(N>*{b6oBhV(?b9PeYQ# zc`K8|lJXYf`TUmR@+(^j@1QoK`z^Q+`}MY>JSR=~CLJj1o;yT1hx8J?5A83W+=9jo z{O0;vFNX!dho(`k2c~zE`JNWlQX8f9D@#c-&Ck&XL z+~oz6sg$2ouQ6SJ`9e2cc#w_bUR>B3SAt#lZr}8AIHuiY?us)5s5o}6HTD?{gd3G9 zs%>r1Q&9M3re;0>t61ZzcisQSTXke7Wyn>xMs&j!_w4F8X!o|nf#cF@DuVk90!Wbf z!Tm0(Lnv)7_k>3+=c;V6A4-$`FpdASNq!DzY+`VKC9_YMQw@=(}n(1%zJutU(P{uyAmp;OWm{fP&$>2(qMQw?+`+#xUz6XMaH z*lT?(zT5Dj{RGa3`)Cj_qr>w0Sj0UQG<@$)tHpUG*WjGEyM*}SSs|Pa_!jB2Qe?GlC1&2zO1yGfYmxd> zYjM{4Hex#ZdSe@G;*E}}V#L{PMZ^C4h?-B^ivxd36YIuz6#q>W2pV3J{_G8OpSSMpq04r{d(%6iNQw? zTl`bk1skc)MvBTvM?9G>iOQo<`!~YnoQ|$$A6)E**4daU!=W!zomC}RAb{iF^8Mv5 z<(e8E*bbh#XGE^{i?e8A1Ihs%3HK-Kw%Yp)7+I*}X1a_(c{B~TwZF3|4m|Y_z4r7y z{ZBdKVlz$RV`uP@=?WBSjf{tm4+}ET`c)w(0aZq0E()=6elL16I^X7}rHcFyo_hMd z7m}{&kG?S}bhG7mInyOkc|^v^8HtY`T(1#tJ}*Yxj5njf+K)x|U7iu0fj+zQjUJy7 zjLF3%m6e|%2<0^m4ii^H^h+SKN z_oGW+$Vp4FiG~fc9_{?%vzc_3H7V*_(f9__B~f`q#x=s}^XJh4h<;C%%Q*16$)yKn z8fg)Jb>5J8MfpqE@cAUiwek5B94Dc+l)v@p`+#^%V_BRJ^xcQgDf#V(PbxXyOW%Mr zRNWbx_`=^OYQBoMqw{Y&_?L9xi+PXTxvJwOh=UZRPyA!LBr1>Q@Q;G0Lla+U9YH#9 zJ$1_Vjm2F{jz8eqiEg*<{z1sS#~Y_r9tQUSm`LGyoTocz#LtAr4)Ovg8=IHB133bCGPj&lX;h6!N`y)kW5}r(#MCDQF^3HS@yT*CE z)3HLRaJsuX+gX9z%*t>kUJ}vG2RM<*X4%BBdI-0sJ(*&dj3$} zP+x*nBA*OC{E<)fduslFW0&ju`+U4`-l7AzJ0|;r)FagC{7wa)S#)Nl(>pznX6uGk zmAbrMR|yfQtCsDl@ObGC?@D9ZL!=`h_rvOdhx=i7J$hLSk{cCo)<>c57?LGg|JH}h zaagyuX4v`LZ?g&Sy24@em+W|+`m>~{U7`LX(2+{aw~i4~7Nf0VwegSg_^15cUt@R{9c4v-Y%VY)#LJ+13FBsx@z z!>W9KT2V=;~dFr z$Dz0X{Ni<(l`<5yb2R&=(+yY5g*i)IEG_oza#!(mL$c9o((%6|JjKq6Jg2|7oC*w- zif0k7 zo}sQP7djc3Is%d*70xmZM<5Oy3)*eS>GJG8R6L|&96FudW8xU(_E$QqE%i*+XR-M) zyy&=>vt6ZBy-3A4bUM4o#6kQR;;itwM!L#)Q7Hne`Lr?)TvL_~Ehv9#WhSS~xO6(Z zhr=c1hVsbd4f$1ZN^s@&4og zc`t8WA*aJQbUM3-!$G^Ns8JxPWh5$&@n2ZSS$MoAYb5q-lpgms#l2tN7msdTdrK*& z!#H$0yBFeAakSrd+%-PcF7JDD<+#1L`T~cIt1DpCdSwf6ka9p%{CfLXKDUFIKKi_& z3r9Dk+(;gw+|blsGhGsuN1>~%5-TUK_)`IHkMWxeD?;l%iahf2 z66q*Isozy;TchL2Tw@b=fA(``=`Ry5?%dsqhv^CwX^jt0HXSlvJbsQ3**0v&aXwU+Qc2FKT&#o zkFICy{9<}sxEkf3hRZ&9c5y{b30BZjOD4AhVOd(S(_12zDR|SiS<4}hr8eYYTyyQ) zC$4E4jBGx+|CQ7!7!e(CO?R#5s6&wabes zA=HHx_{^%V;mXIbD;Jv^vqRaQndt1G1~=Ep5cHv#T)>(hyZI5MzKL4y*5f@$MUsci zH*BJVV^!DTD`q9>^1yV)&t~vFnk2q7msm8X+C}q+p+ZV=s`Xd-j_7!&yk!$#7j>I) z&Bde7`j{FBC>ndDa>sN@R31URybdYb>+$*Wz3wu1m0i~HT2V8@24J$>+P;Y`591E` z=4bb)(tmT(RQ{+G>U4H*ge%0B@O7$Ol!!G_=9h(<&&z<1RHS@f^sY^udxB$EL)ERh zdOkCqak1G5pYic;&n+s#0?DRiz7eB}xBT1acvpU46L0@`=!k8T%kS3PDW)?{Hsi+| zN8^P^)%GC$yXbgr1u5e3OCCA=gPy#Zs(Cf-EoTJEOlxR$+>`?Xv7w zejRk;6}p@=o$<37*L&#s(R}f@ywCO+?^8ZDMRe_d@xqP|Pwb_?57YTQ*o^Ca^nBTk z_fhN3zz@;$r~3E~V)?miE_M9tuBu?M41y?Zx9pj5mCKSsw} zw>C|@Tzb(j^RjOK*3-_~-(x!CWHWxeO|R!|KSjq&7~b8!U#nwo&+7KV5Cai?A7|q$ zndt^K^o)+T`GTR=KkH-Q&e&-a1+EX@J!2q4&3f- zuiZRo-6fwNWhPDEg@lXgAw-64kh6F?rbuVu+tb`6l|8Z$JEiDq*z9sA?pKqSnu#g! zPW3adS24abj5v(3Wy8)-;#*TxIy_VSw4P>JYg=$0=c&U#oj@frfC$y}n-X_({8E43 zs0l*z6!cC^W3xGN{}sa|@@MbPRXu;G-e_tW-MioL&y6kv@YVW_>L26V-TGd7K3ZM( z%s-Y3s^iGc|MyJnf9+Tj`LlQD?@GXbFsUkm(9^X>BHc%YK2CF>s}QohIH|a?h6bpO%+B^qkR?Vq8p*A6LwM4dEDX!CP&M z&PT#>{=9wHEK2Y9;?i6L8OcEooy{PTio38Fbc2Y(uZqbNtxMFNV z9$1izIc}dZ%Wge>Be>6m(qE7CDP0FNnG`qmhtzw!@4xtf6WkkfelpTE{3O9A)8XBs z)bz(xmtfV7y!n%lIh5xKaJ!J!-unLG)-#Q}HtWj!Z8fjz=`-DuIQ}$FpO!8){;s7t zUQ+bl3H8TwAOjH8a!>gZwqI`gBl)dY5!|r?Y$H`nl13 z2XCM=XXt5GHnfk6@MZ36mG6Or_Lb}P)}MfLLB_6}L1|t!X=3uM`nEkTHvtenI%k3D zCOK$~$#d9;y0Fr3i%ou!_Up zp4`!WN2{Nx+>;`IE%9W!Bq|R|KbSZse*7p~q~=3&x|wO#_pZHRvGLy7IKyMgclVM1 z!c)6ul`NWZjB9=`N>Zjv=e01MXsV)g<#I{6&j35^O5|GGiVBSZ0R&w$wJcRxV5o>F&3g~LsYt1IMypBcN_uPpBn8{hNYUpsDF(z?ei;P59BJuZBO7~P$Y zBSPfX4kKn2m)I{ht|_N>Ed9DoH(m}Cgcpe(7p_4yC1oVr@;F)}N_Bpr9=J$xeuir= zzWm8|eUA$cc*_XQ`JN@Czp{_HI|5gx}PkhxznzKgY<)#p98cS#kK zH{82naoIy{2Ah+9T+cFHPbJhl#b=+>>&MY`@-$hj0mu3`vx^!!F;)Z=JUe6HS=2RE z{4{5u{U*)2d7+Mn>AQ)i(LzDB9nCd&WjT-t)zLb?G7nA_U;fbl!oFGQ6*@kq?=C)c zJ6&a7oC8>5@)8Z32gh3)tJfQUU+U>a`_JtTo4Vgf^rrZWHx50{zsmn~ya<&)n)j}U zJn{ZT|7&wv(sxm=>CW@+%rELA7^M}KI8-hCa5>LB*e3fJ4$vq*ii^szI==Ez_MyFd ze)Y*1kfk#EBrSwaXZKw6H}REWA2WKyXwNK12@ceA_;TGatE3mT+-ySnq$vGx-^UH< zsp6xnCfDvi>YN@Q(uW}wRX5b1W4a_NkKp&QWqn1c_Gz@ULR}m<+BKsFOPM9fj8nzC z=#c1mZHK3d_A>(WC+&K)<5}i<5XQ@N1*){}CSG5)r^?*=V8pEA9e8MTyjeX{#nN-? zem>?OKiqn~hL`Dk6fZ5+ad~Nj{!}bCkx{F7x5vO+-V5uOk65>A$FFC6w4Zq>GV_<| zdk$}vvjS^zqVYG79-Y67k4+U9CQq=J?BDj=p&DMM?@_!l_*>9DI^H#zsp5|Td>CsFR7}pO> z-#xq5_~`u${y5^(t)lG}~ddoaJ~bG2}7= zOAc$Qg99&%5SID5JqE6215?GQxw*NY54eBpMbwdj;{0d2K@C0Qz-1yfAgOq2kBrWz zE!nAJ=%FLme(}@CLyFD89LB@+5E8={2cAM-MUXwB4#Ai|89k%p={ywe(SN&+XlR*P zGWS>m5cRvLKgINjcp|N=9pUtrq0gl4O6a3}%E>6za@+u%)ZdKM@5~(zoVU1p&VN67 z0MC~OahmjqIK%E|3=cAd5er@AMpoJrX2cwT!F-*a5uLBq!28SWvT1J|_|7ppUzr{e zZxi{-@u>Ao=26k{1@clw!_jx2_?_b-yN-|P950(eIcy@nC|g=()T+ET#K672AXTj0 z@!i!=)>Ti_aWkFqvPttW1wL0zi6^u;yos;S2xo1t=<+Ix@SXDUJzaX8eoaSRUYXAL z*bMTwDe~G#N{#dHSx$EXC#gu^QyJq@#gIGNryTIV_NNcZrV<#cADJ$R$|Hy~ySm0+ z&8?n%q;{&p-?u%ch_oSb6TRYwvn| z;wW>6Cf9FFZypZgI!P(-W&|p(tYf3|XG?La=y=hoH_kX|(8aI)pS68pdNXm+W?>bU zrN6OW!=s*#94mrEu_&0VuT)OWq1_B;$WO_tgy#7wzXB)mbkWtj($>nLbJ;X06 zE#c<#4y;R_RdVNHCvy5URzow{I-T7^axE9a_>A#SbN}xM=N#;)l@rJ21X^}YrFj=$ zVY$21Usw#$lToSdX~uD}ab7a7(>LwLb-R>tFixG$?t1`dsCh-CYQJfjhF71*lNcU& zr|#bOs@5_d?q3Rx&hC7!NMX4X$As}eIu@`3H^Gjqsic#xsNyn}S}qDQt^5mz=f&H* z*sdJb+o&`V2jkJ{96uunkEhU8fj%(C$m}#2;#07x`6_x_ap~jA>&K*t38S|j)q7yW zq`V16%2aBpKgV>&!)Bv=RiZtn9EiXX#kqbOCSc`>TzkJ?Q8qzx^C}t z??0|G5OFzXx?yoQK`&)^jaYErYbB9OtxQPvcCtr^Ywd?Q>(U&1hdJngBH8 zD>%X6^FYuDpWeQuO-K{h-n;&>fg^^tH-`fyKB`}sj$jrQ5564d9G|>7l8z?V5T+wG zma}T$<9U$UB|G{MZ`PRZw0M|2j|2>U)TjqQ6I7b*d9h~7DnkQKC)LnWf8*p2i#(@i zh4@J6>*sn>w6C?lspiM)yfvHzx8pjU-5c@IQR2gKLRBQTSW{;o;&oQyG}0Pc&+I6X z|9r-Gk`aU2&sY`*zHvJaP5$=ZUmM*sM8WuUdQ^OIfK&Tpx&31E?a=3z6povC?0%ds z(q)#uIT%A&>X+Zhg>#7s<>wNkBw{C)+;xz+j39vI#9-?)0>2Aq{}}G zJy{i*ntxkPw&tH$pDfq2+CcyA{K2Q%W?}uo4UU=5&%CYv*eWAs!bSBs(-{w&(fNe} z;3!d11^0c#b3X*3rMjG^9BIEiovBav{2mG28+ssgA#?@wmC(zew?p@XFf4}dh^pf; z=!?;q-hh(wLu(;k!u&*cMA{pX9*0P$BGR6SbmtL5_z~%}fkJ$ONQYM9-oJ&o?|!)u zv%VJMg8oV3j+>Ii6$i8sUp>)69Clet@#W2}#HGI?Qt%NhIv+`kbZBmuY^Q|UrH_Inn9t9zH*eqqxSpU9+k^UcaLx$5n;) zp4NP*crpf9t?5lw<_%|y#G0WDd8o>^1*b28hSRuQ&jHumf(yFtok&18~C)9 zrw8Cdl#)K87D2h4r~@9AKh!6p3NO$F`FHl1*I^aq6F(T?zaqIm$p$IH(*jSXOQP}! z;z1i$Vvdv1N+VwXoesa8e`}CF_bak?Ht@Qi^WLvBz&;g!JtK`YiiO^$8;2;e`l0))HnC`pgXUyPw;r$^LZNX4$Z@UQt+GW zku^w*^JQm@eA#j~=3gIf@$+pDjeSth7p5aRiwZaXy@#_%rl-pLe1}ca9C(6tVdcHs z#w*8mYrl4>^oR$`yH02KDDo9fxI_Q}nXegxV&l2wv?Cta{#e(;IX%Xs)7d>fzJ`S+ zqe#b-@X_~kF7R>vGvTR`C6u?ADN$e{aAlSn)vzjcBdaR@Yqz|;6QOud1X5O zT2zpqmimLJ@&imxzEgEsWA=MgJmuLTeo|TEem&nKJpbHO(R{xNb+Xuho>89li(?bXhTX-B1^2Lr0v=krfxI$eF zT$Iv!|KVl-o;0OH4(dlzl#eIl$#h9n9!l+$YQdSqWq($PM2gng7|p8VFct!j>5QR*^MbP>9r0|#?b&Aq_~{x{e<}wv41;n zdj7U&&lrj3MJkpfrkmuTVIF3sos)$k73wA!i$8E&JxMw?6&07u1O53-Eko$l{==f7 zvDb-;wLSAj{^v${=Ock(e(7`uy8AeX`3gLA__W)+kidvJ9R}C4^}x;btatV$9>P>> zy375KxmGzK{!?FlC&qsL6Z-!+dw!}I{QBGv>fhfyZ6FCK6!V|y1~v37bQRaovTHkC zz!4g;uon)_9y5BdwVq!YBmMd-QpM5tO*;3{;Ww>1&`h7|8LH=*9!lA;MND6AA1iWK zPaab>y$W|Hm;q~HvOEqPX5|OLSc$USda<<<=P14VMt3Qwj>qVnM6<*EoJA0mi_ zrM{eUdh~qhd`+sT-*?dcI}VvQcrbmKL$RDPU4bI4K|GdxX^bWvzPUWt0tc7pHRogx zq%`K6?o^&_Bdqz?3T~~Tc|UQ+q%<+^>Q0V^<1^M$SW+y%OgE^ZXOY)g<-`2|uF!Il z(atKmYb?iAj4?ouS&&p5i-3dDCOM9zj=t5m-~BB<<&L>^6OK@>v!%r$=ha@+ninu@{8&4Zc$-y z7U6K~GMCrNuUdrSdS{u2LoatzkZ;S6u5H!w!~8jVzA@bb0)N8bFped!Fa`zG^s`1< z`Jks?kMwu!=y1%2`p?Jf=`%f!^n-nDD)VYStVH^xxZVrbpS{O*#%jk8=f5RA;z4;y zPn|Bwc!YU>OoB5NVr%yERUEnbv2h%6{|8@gYFmxaD&+?_uuIvHS`&p< z{{cs=@^fEWpH2s@nAZLV$FpdynIG6UZ_+t^HpAdxc`%OK#1WS@XdKvoIxJj{b^;Hl z*ZJ2^_ox28%D38r*m#HE`HxkeH;>*=$9uX-=XBW&gV&HB4Q)CCFwOvQa5{{$&UB~x zF?Uq-eq8wtsp3D&?<_qjdr?l3354rMrkmuT5eDZlUs%o#tD>s{eCF8P2$SC|0G9R- zIAi61-c##F-QD@F$+`b{bt?6T3^^2Hq)86~G%ew9;y?^^9*bxJtDo_3xO7;UuRDQ< z(|hX1>wePPo!Zf{@z#!+dcn=Bt{tM|y}+b%x@?BQEAwARtKtj*2dBe0RlY7Rw3cuB zpxhri6ZCG!zxE)d{lmO>7i_=#*<;C0ip#f7H(VpuGZvnzTl&ipkoek^@jWVUgoFB` zJjO?D6^4riuJRU#L-&HF_kk$L@p|>WGm5PBJ8^;HtSw6t>)OuSSbJ8QICbv*nO|I9 zzab5DQY`mOH>ja!nEWxN-kL+^V7R4SUOX+-kLi5f4|4oD6Ca_(7vA3&O6j+=QBRFD zmvu^s?Yc>Bx?iFtRDuJ41PA_z@60`&dn#zGcs=P#MV|2Oa zvZB+&y=Odr!i7uF5*&z^1GI37#*^hbm-*K5Z+(7~;=Jzvo@?9V{cn2lm=&3Hjy}`L zkE(+6_r|%zSXe^m`P2GA+UjTwh2tPNb$hc69)R$xe3AFpa^xoN8Zcyaud{ptBb z?@D|mnPJ&T@Rhjo$Ea}m^IIaJaSuJ;DgT+q=5LAN&lIU(e*VpDY^dpz`T z@p3%T+}O|G(bV(jx8?!OHLH2ab~bS6o)u)ZL@~Z%&wK@%^3L^!y=S zQoTmwrlhGX5l!VW+u4M(#hv~q)SltMA2kk`7&qTD`Im_0_vJvMy!^iWPNeqd=0Kvn z{JHZlf&Ta9K%%_-zWh$4_UGn60PuNUc0J~0NjactPnmx1HMwO}{xabG?-mr-(?=*2 zePi13WV$3Ok4EQE;5sni{L#x1|7SP$OJ+j-HXO)6v}$>y_0DuwiLT~@z~9~LweN2IJgA-5rihQuTC#P> z=f|CMxH&FBang4;)Aji2IKp8*51nL&30^o=i&pu4nj(N*q!rX zIv`Ox*9OP2%5$L8VIBc}G&G$N(;qqqIv<)2teg&gF7!3f_d>6R{uH`Bu$&BC4gDZA zoeMo2h39_gLogt4C-gv6px;BUYc0eJ$cz7Cq4WvJ_F-Ps;E0O*^JLJR{S zI}WCP>QJ0N13)JO&`bdO6o6g;pzH$Ne~h!D&#VL=aEeXK>xK9lrw+D#8TPHfwttfN zW>Av&adwhuyDUlElhi^i9@j!_c^ZIvw-gU8Zz)cm&`Qkd*jjw>WovQg=WWD$``N@l zD^kP|oM=<^W;;>7tG#fY-$AUc*k3Govy-^{^{(QEbJE3EUmPJ)bB+=3-q%+&6r3X3 zmk$x1<3@`i+a`-2fAWa-%Ptg@{}3^GzD~G$2P}(AfsOJW95P8aw?3k<2^F3Ldj2@V zdy7d;@Hi%mn&lzZxJ*+c<#H4&9QoT5c}iuL)SigTh$-<*a3C@V)c(~Zy3LSsuvwmv^ zc3pAfDTi}?Ysgs(!E|`HC|ojUH!qqqj*%Vd@w-diXsAcJX5lR1D%_)t)2y>SKI7gi zb>I8q`snEG${-n#I3@W zOO7Y*ND>|!aX{}kknA1~O?QVK1WkEFvP|Q5r%kH{=rZ?5p&HNJ%ZKMx1=`fPWQlict()LpaNo;Q?n)KMyy>~>vUanJzkI`Jjp#}J2Bzx_iu}Et=X6)ei+*L0 z*?4mQWifD29qP~{Q~q!A&RKo&vr9Lh-K}IekvZQ!H0g?0X*F(>#0|bqOk>EqbqpWr zFeqKRZ*LjWRpX^NYfX1LA1CXP*toJfSKl*Wu6N$q-JBL&{Y*Ndv#7?nPIq~$Torw3 z0s<->n(>WC`fB`yPtCtga3{HSK$9EUsSTQfhH31bkDLmtxTWQcj~Bc#H;>#&k(q=a z(nGo7eDE+FJF%(^MP_gr!yXYe@8KH>BRLI1cDN`ynh_&uDsyPvPTw8 z=*jUKd`J>Ho!vRz{3=(D*FDo!IH#&u-i%`>Tk!QQILaT7{r>sCJTUO}d)8y-%213$ zr?Y!x962uEbib$Cgrk0E?2H4);P=}(I$d)#T^Au0hV;^sqR^d`?Kdfn@U*J@09g$C*^>aI4`}nCCT3!j9t!tukC7b%lBS! z^7tRRjcawd@ufokM#4AK$&acEXH?i}R&}b==fV(XF^y^3LBuq0ezi-Ma(jNYKflI5 zsKQx1y~1sNKdEvz{>kXL3YMgZ)9SlE)FE@}j(!VhWr@*8rgnqrDkicME-7ckQrKM8 za(Q`@23m^C7-ai|R+h!Sv`jwB+q$^9UJLfvVh9FN@BP z^xIQJ-G^%jJzF&9-^>rj!Sv`j2G7Rzfm{oR%^y{6vYv^KhtisG|LfE8o&SBXo5LzM zOb>^rk=&5P46E{^0mF4UXdl8L)4!kecz=ukO*uQRsp;!+%W{cG*yQ+Bf8=K52)j1+ zuZP$FheF1-?M~R(u_t`|mK;#)mGTwVa;%T*ExtZQoLDe!UHU`M2d+N&|Jl0^_$Z1m zyg^WsP=csLL<|TLM31i6kR+4@fdmqYog=qNPA+%H-6aHU5l~|XMT%I?h6pOyV+9d4 z76h>XDvBK&qJIna|MzzH-OWy}(Th9x`*!Ev%+7rKrtHk@%&g9ez6nY78_Q*`Sz3+n z9Op!hKgl+r61A=IW(!RmD#JZ(1D!sj(#OR?WF~r^?aJ>DC6ZrB6N&hf?{|OyUxOQ@ z^r8OB7Ae2<%WkgCYg*k~QT`mYY{HUx$x7MjA0InE{jfHvhGM9HP5Fi8vc7UWp7Bmp z>=;QUi(k(__(pIxb*%KcS#*uaBmD()zLj|dk4#pU%zWj?)QewwfE&cjgXIbH&^|$J zu)>3RSL9dfS5e;U19S#x4p};YDP0=qZmDf&nfMyWfER8b&v_->KAybbl}@DRJ<(o> z&w9swY){=q*HAl=K=$nk1D9E5Kh}U%Ud)M0WrfGVtny;kjrGqwzEbvXxSfJ&+4a`h zSG}C3-1^>Q&vp+ye)2&d>$!>gb<|#BxvbOBd*A{LcL&g*Mzh)`uBq2r*Ln1oT=T)# zTjiKF5k6B{rgjyTXUkX`5H+x`m6u)pETZtKoY4EZT^*O04wil2(7?V{UJ}*nj^uUg z`I4xX|9k$baLbX#J*oY-BY7^KCarQ>Uqe!5g6%LeS=hg zpu(rxc#@RyIV_r0VU>H-x7n^^-^c`@rl{AZ1qh}y91qyekE)XxXj^QFE{ zEQzjxeXYFg%04M+gu=JR7xlbh9qVggUn?*5?;x^dd&(7EL(dih*|#SQTxOa5SOZph zsh_x3d#t`rEQziGtGtABg7tg}>%y`{)__%B!g{gFOIR0{EwToz@={+fR(q_zPArM8 z0js>!&k0s}sjm}DqHCZQC!VKJhj|KQvVchQ&dIItt*4GnPkEsCAI3srYQyxvND|A* zk7z>k6mncn+LVCyD-C_$t-rBVL4@h({qu)nx3mB*(RY~8R)k`XI`8zb1d%ZBs^8-C zo;K^Tb&qyTUj3@Xo8=;Bvd82da}K>hyQIP;PNWz4Zv87h-`-n}oPKF}@!G?w@WPOu zGjU|OCKL_{^9_GHugIg#`H#%ksz(Lo8dj?wt*;YHqH7?C0vc&vW-R?snU)RBlP6f~ zOJvRL*ne^Vf?Di~NV?Ag=uG;ib>0QojAhO8Rc&EaZZE#v)wJE8%g9bfpS#kao?LgO z=Y`)t(c^OrwYxF7&Sx9w@s*Eq`mueD!&adB@YE}Dy40dcURA$hch#@Pk?Y%Kc=JHE*C6(dnhbqdmJ&(U}b(3V}hW0fLCv47Zk_I^$I@9_{ zmTN-cAeUeMUl{QC)NJfHh5h!i1BuHul=hdv;>jVNQm5OW<;U)06wCsE`DLWU=GVAs zveIPw$&bC!!uF2LkL3b2&B}bZe&PQ*zY3=-kmpW-X1#qVs3l5u07H(~`oDWM5JW~Gohv&6g=@d(IyT?sVA1Xg&thCYfu&0l5`cT=Swl|j{;%B85 zX<^S8u^m%~b_}IU7C>o2b{Yc__wgN?o8Rz zm3Q3mQIAJ+2G!_vG`&*$mF0#wbc)S4j$Vi0E1T}(Nfel<*M4ZHl8MH%rhT$9`^YX$ zsy5$vn9P&qS^&Z!HqXTLD$v#TJ`>wZV)_cv*0a){Y1?z%9OF9L*KVDpA9+8yWu23i z?1x6bb(7<#o80)WCYkmCr6bEVp>W8m2+&A@OB+DIAOcqA*+zODNT4F0s^*vQ5BA69uW>%;nI)__%B%=)m(i&-DmKeGlF;4k-|`W+SSKSi78_CT*j->u); z=F?`zhV<0N?}?T^%gv$3nJ*S&o*T_>6X&)C5fSkeziSY!k3sJ}Ewg(yFdflxK3a`@ zL}`-+&{=*D4UzKLt5-P6p5EG%(~8DW8{o%s@*|p1KYWO%*zU?zD}4CUk+axu)80F) zj;uhy=NyN@7vmxtcVj+dFm6bO`N-n}wOx~ys&8yPS6}~5(G!}_@VF1l4RPoc;$w^p z^j9(NgUy505H*_9;x~PFD6>Os9%H&ED^ohO{BCQ%OF}%3K#Vjl#_|vW!y@wtjZf&W z;B6x++#yEv9VEFNk>1JhS^pRPNd72I36|OU8nDu5=j(K5hA7r^wQu9cD)}GPvKfnESU7o?m3oCwhSo0EW(fm47}fztr`xajFXKY;X~4dej*fdRlkU=WZCz{v6<3;5>ldS&Rkjz&M~7Z~&B( zOMp_K3~&M$0OJ7{P!7<$91q|HCICKwo@ewDr2?n~sE}0w^ulg3a3OFJa4~QRa4Ap? zTn0=5rUKJ|%YiF^D}fr|D&T718sJ*sI^cTX24Ffc1Go{m3784o49o&%19O16z%9T$ z;8x%^;CA2+APC$E+y&eX+ymST%m?lR76A7H3xP$z1Hgm8L%?ES3GguR2=FNI81Ojo z1n?wK3p@op4Lk!p3p@ur4=e?i0WSc{ffs=lz)Qf(z$-u<@G9^c@H+4Yuo8F^SOuUc zk{V6znz3DCm+RF_l9kLpkKXxv>3~C1=wg@#0F`T&YeL}=r(D|#?d57d-m*C5aR#P%e9S)1R08^=M@$$jGz;D8H~=6AA|*zl7c+Mtwi5O+csG!~A@zIxhZv ziR8t{|NC~6t2gR*pg${;@Wf!bKuNQPc;)$x4-(@O*QF|TZ#8$SZ&)wN@$us?Z1!T4 zUT1#ON{*l9+YrC4&{^tM9r$!CE)sdvB*3HJ@O5kdddr3{8tR75qz9H8;?OCihb)H! zFYo=fDEgrKmGzNsi?5HrK53d;?YZ&^nFq^51Pn_8Jfi9)m;j%YMy?hQ|2+F#nGegO z^2xyxK4&1u?sG&`jaYvApub9W7?&Ti9{`B+k50Smn8RnTxc?KG2g|pQhe2w7#6KWxwplI&Z%Q^F2rA0=9%a&tiXgcjF@`ddb>wV_cDwNP?^jEC|t73&yz9tK77o? zCeK&v@#_AP;G5;R#AJl{jdl;U@XYOu=_kgIxBcT^wp%=P>0cZ;-?uDhcOhQQiWNzP zs;|;ntlCUG7k8VmiK|24E61(zrb=$C>%oV3L4kaUNre_M$=UDwHk>`@mu3Y z`~J8QvcaWd|EBEZ*!ii>ldNpc8eCm5_r#;+{KRr0D{0mk`N@_aC{umL1=TonzTOmv zM}a?Cneg!8rM(AEeOuiy(7!>H_58SXTnyz!~#=kq31 zzVtNNG#X=Qb$OR=dNWOV>hLGuuE|N8-yU)@G|ofipXHiRID~o9P;qEFwy9lGgLtW~ z&jRR7V@3x7=|^LnV*SeF`{gAoGm2WayK&UIzI`DllL=6~EZ2m>Arvn?l~mvG3e`7h zgzER=xvY{m@xGPQ;y)i#PT066`>d&j9ECohW_6l!<^#{1_io?f8UN4&5r*~6a$OoeO7UWf_eh^>i0Up4 zlxd!FaisXUAIDb?f#RF+p9Ibs@Wc6P6Yk^XHdmK)I%}eT4dj%D;`l;UUvv5%0{24! z?>9-xt&ci-!>SafxGwv$QJY!ZXQ40}AS9NPAJJ%y4!oQ}dv~a$J@EO=>5X(gdfue=G|QO}pCj-Ji=yN$x;6-K z{;JA~udi08U;Rs8Uz2<3S~9FJS+2XHd{CY-=l8Hk<|XAZ3PaReT6TPXTb>+z)cyWD zOF4e#C(GGAOeRzw!y=iVkk>L00M{dFgTl|JmNPn?M|D9E5tF-IUva$RnbTO5C2HT1 zYZHxQfAqI4>9Z~OFQy0Esa-(*LCYkr0V{nH*VUfzDfScQp#Gyac~%S}jZPW%*L^+i z{c|-nkYV(8DB8@1T$hHAQhP8r5b$y{INvwG=kxe-JPx#oGjIvl!?obS@zg<1aa0@b z)KBP>Yi_s7?;plKnXGu0&pqzX10HYiuTfyR-O6$VXEGAc5$c2r45NkDNQ!z|7AJn? zsbr<})W^T=JG%0)BaK)%ewLde$DhdY`}5pG?Eb(|r<-RyR>Lnp=WEa}p=T7O7u8W@ zr`r|Z554aHFz4e&hxde7GkSWZD6*X0B_5;gpb(ygq|X}>pNAA4Lr)cMOK^yh&!Rrl z2FJdS%r$9B(vzyzbjETQ|*`(K>ra_#>9_JAFOK{OtOi^O)x0`Q2J z|I5zr`RQRdj#cp{Sc{VMPR41-^?%`Gh=(>+seoSoX^Vtyq1l?YY&+&N<-5sev8UYY z!VFV$d8h*~FQhUxY&*`4W*|Vmk0szK@*oa04~Fym*dg)n&l)-PcDYXY z*^nbhlZnQ=etwF5BN+&l??V}utcX11`&aY8%4mta*XFkhp^&Tk+ zhVJtS99gajg@e401zy{$*=k^-s=Bo;*|OXY{q~G&L_TxQjL)a8!%|1>LqAl@d{{0} z(X28bJ@RmU>mO}*3Xk*s_Pd*;3?m6;6(#(CN3TyfBFp1GqXBEZW%Q)7%1dm?Q{o>S*XM8l}>bGF`LTxSj14( z?#5K3@W(C0ag24~O?f-Z;6r0E)V~N~@@w}CN4^8Aa?_`ovz}a)@;3J)=$wRhHp|J6 zXykTnxJ641S`2GcxM*6psee{|cI@#K@_*kwO&8yF@G&m3lOdjTl;xTj2bo79wBS-l z`cP`gwo*@kJ;{x4cyky5iTbL;D2k{r`MrDa>13ttgPZ$Z_+{&Z(~RpI<4o_} zS#F3!C#JyrD>6e`x2p}j7;nOZh?w$QBJXuVfhTC8dlC)5H<0C`AIommfR#RGee7-j ztn}I2QpC(>SEi3Srto-!RlmuaiT>Y8pXj>T8(ggP*&9+JI)@B6@%VU6X|mF>Afv|* zpP!n2M8_XLpf+`+^xM(78&>@mJw3M7B?A|5`YjOBZ{QNO5v8B#UMIMBm@)bdau@p% z)5n|p5i~V{`Uzv!E%T!vx_w#*8|NFAFWLk(?GQEVmemvk_N>0 zf*DxfLnaHLG^yTvf;J!Bi=8M+2fy5{=GkOrQpS7duY3Q;i!ap&EVMF3;{hzE>qQfK zA1kjb9_bD^U3vJzs;l7Yc7RUWv17d%63;K^V z=92|bKaK1(79_6EDF5uf)<55O?}rd;M(@uhDYBg1L;czCMlZHPY>7QyrDduO?HJs8z%tvXLn8#`4^;enC zCo7lC{j{LT%C2i^9F`2_eHy1>xh512;e6!8?&_uZb|mj(G)Q$*oR9ue5424f{KZ(ZlVKjRTz3_Cgp@JL?y67=?9hu3dt{0Abx?|*#){K`OlZLV-qByzElpOk zhE7ecOda$5!A1m}uUXFV@;RgjvheaQTX+^%j>qNF-YZaTiFIE=T*&(9cbQoqv@h>! zfcMdcRr$B|$A_Gm@!A~D@05NHq$117k7yF+L&?*FR}DdDPCbSo0%Lv~6X5sPkl^(h zrRRO8*BE;KqPt?b$c^mV$S<^t&TrE>E)e+DOo^|*o>vY_p7v6UUb6mJzJvVqnQ-~O zdOU*y&&;W@>r>*;@%6(t{CfEbGs#Yd^SvzBT}3@QZN|_y_F@@;LGQq%kzRkmr`pSN z>~4pXKCL$oAsE1NZJ9l;N5)d#hVJIB`a@tA2(ol`Y$bCF$hrI zN%cL;4RPocPG^0eSff(NE2mvkX!Whrr_zK>Za;86x;O39h1aZ1gFuB)UzXrjJ;>iN&Om#iI8>~4B>zo@l z%Yaq+U`4l*pV}{ehMomv$X|0DS*{6%Lx`8L$()Ivw*8cE5;i6&c9uAcHG)!J7u#8x zSDN`zTY#R4;(X$xk2q=JlUINA6I0-NL6)<7OnyR(T};1a;6aA<6luTE)2|qG{epSR zDmfnJAy>X z2ll4=sU2>rJ#aM80q6)E1CTN@fzAN6QM&-g0mlP2pexV~=nl|p(VjprfHulH0XPxp z1Dph$44eX-3Y-Se{%EHI{eUbW8^{6r0|S78z#t$O$O8rgX8=Qhp};U8A1DBZ10#S! zpa>WVi~_J7ob~+)=wL3ezkYvWHSX;#U=8p#@DA`U@E))hSO=^J-UmJaXaHpc@DcDa zuo3tK_!RgI_#F5G_!9UE*aUnHd;@$7d1)u=mH!E91qxl zu0S`SJJ18@3G@Pb11A6{0)2p!fRlk!0IGYbJw)}2*dA(t|9VACN(r0kuyQ{l{d(O; z7GwxU$ynMzt9LdcA*SE-@R~78)07XEwSD2=bARcvmKv5YbOp69S*{6%LwMy5hR5u_ zK#?cMQ;y!S_CXOmZK#oeL56W9J}h6sbwPmn)W+enby=D+rPoul=e*SQa+wdy1uB|# zoA}sH|Gw!Y>pPgB~DYCO4U&d2A;{8+wY{P0j#OMRXSH;*S2_?#Xe zx)vrq24|Rg%Hu@D;RbhyKOFCW+tf%_E&Wq*WO)ppwB>*cU*bcfFEop%$dgqZz!oH7 z?P;kW{#aEI8BENda`@Z(pYpA28bc6CF8j0ohczJ93*Bxs=by2ttf@Uxy{LimZPypS z%{aYXF4r|!yPTS!|5C`E*^#aSoA?vo#I>1n-sZ@>r@j$1~AINiiD+2vhmwgho zc+BH>b#eGC>(@eYJUyc0kiV|_Nan+GokjRKa%h&Vz^_&~JfZK!g!6L@YNDRT+!WSR z3WAo`ORmHINu5^o{`mA}%eOTDNzak2Czgj9>9&OQL?zH4u$Oy#naX|DEnz+so1AVG zL&l7i7rUDuQgommoi?6v0FEp-#GzA&53k?M@p=4y{mW4C6^8m9M8tAW4C&cKhR)Ql zVnhEM0mNO`mcAb_yGJ`y|BU_fwG!;7o)JY`$Q~F1eQ@qjSJCoDC7FG~S z5zEhx^4}RcjuZx$-5uq(uU&7Y&)%J4LD1v=MfyDR^HJ{acpJ4)8uT6J_+reW>dksH zL|e~7?HZQLcU$lIh!<@o7&^1Ni&b6=KP0E1$U|SG!y7?|OIx&WwBpU}oGtTX^GiFZ zg;G85v{&9b>6yo6ek|V!{Inn<}fb@91`a>~{V1`;wK*a~`^K z`h(hQDlJ6PG4(rGt_g)hsNW&&p;pSHs@mr94!kD!RQQUu?_txZp{>N@4p1<1{t@$m z5RGNsLmCk0fs9#Zo^R0#oYH|hh2!rzV?wW6bB5*0uo{j-) zc^oWW{S(h!P={r;G+=4K(txD_O9KgMzh>|zbb{rMe@j>deb z|HNZOa(Lt>LUy7$AeOP}q7b}{c&7oNTc9jNl5wJMEAkIspIOYG*ctlEPn)7G9 zH;<;V-7AljK0Av6m1i=1*8f?@ZP9?7KJj!J&wX3sw*1D|0MCEsb+^&3h?XwVuT2i>9ndRaO4{qQ;N*fnm8oO|xzzKVdz*&QV<7(rpZIwFzay{cv5>Q3!wBPJGEEE{e4E=f6e0A*}djNtQqo0 zzGb;4#$mM6?eI+W+i>pQeWbV4huL}qT+UKj&`f?f-)rAVdNF?dhYWn7%`uCIbl~tg zep$}$rucL1KF376PZifF+j0s<=9H<$y7di%b5qC zU|%OiAS9T@hbD^KRJu(bFG~e@*7Ya^}J3_<6}OuoZb7YC3buwE8B-crTSDN*-KRW1ncNz@eRYRo|MX_X^aqCgwZM_(nou}w?>qsgu|TsLVKKkyb>{SZk zx-?07Ep_UW}3&qa{M(Jefu(G4%-O3dpvT=P>(}(Y5AqX zk40x=;G5zX)6Eos@rU$4NYvE8Bi~p0tMTiHrOwyduW)~I1Bb82m88gWb{~q3pX@g6 znCtXoXSPW;-rrzA6$E&dt{IU>FaaJbC;ax0efm+foLDpZeJ3d_H^iY+p}j=a3L$Oo zRbU@a%kN5Q#VB6)>r+E?CL)i_*W&AA-t?2cICRX>SI9hA9wJ~^qVvcp!!9^#_io)Z zpCXSX3Gle%yVn;k?{y|Ei`ES5gXM-ebc)BLhrz>(D>#2-yl&3-*p^D62Sqv-oHv*_ zk(Q_{Z}>-jm^pRCsWg^DhIkx^Bg-|Ra2R5*a2JU=-HnR4aH2C%T!vz%Yu#Xx=ck>BBrp1v;&Uta4RigZTzS(04tT3W z?Oe4X^=0jfvpWrNT(@-1eMXH-G$Kg}XSa18l6%66^gneCH9^!=AF({lM7I$i?ZH8tAi<`3 z>rv1=R^!O|qhO_3FY<>8ohn>qdgRVwsPpW~!CWMX=V`J?PTvmRs~6mn+f zfgkmm-~E;W7wGYD{$RN-4Id-s56T(ZI%0ekMq(6c9x?R|2vnxXP@H;h(Ef%Fkz^sq zebBPM-OoOl1baQ@ATmj`_LcZ7lk*alCpNMh%dPW{Yrv|{!aB6_Sy&gAEwTo9eloSA zH=;d4c_s^>Gu3DGE-w9OMLB={%Hv^G>U^t#O>fQ z>&*I=$B|aU{jr|!4d{5+HFL;~4Dq1$ILkGma3CHd)Kc`A^?m=eWewCoH+DD|)4TEd z_|{8f$a38kd-icp0TcTxoeuQ$c-Vn5j(J=({e82(BE|14F6#2h zC*Ri_hm_@s#c#`ZIj|S5&#ChG#~fV9`tW{Z&Ocuxb9@6V0ndfEG%uhyRxUaFmWwtn zqAe0N!}^fr>>gVm0w1i~FGiQoUaDv8WzBV7yK9|8ItbI=MXiA&fHuI90FO0fz}^mM z4;&4206GH40G)tLpfhkR&;>XSpbE|gbOpKrq%<0Apg~;P-k>*N?JKD$6QKvHN2riZ z1}+3H0xkwF0cZhAHEOpxDmJs zm%fUUsqz#qV$z+b@M zz(2sh09CyIwS6UNPv5@4=|Ddq3&;j?fd0S$U?4CE$OZC%!N3{75MU@U49Eux0Q#WC z2%r!s0!9L(fYHDh;7s5w;B4R=;9TH5;Cx^#U6nX z1KbPD2krwF0QUn6fknUrz=Oa;z+zwt@G$TQ@F?&Y@Hp@U@FY+RJOw-rJOexnJO?}v zECrSUF96Gd7l9SPOTf#(D?lCaD)1WcI`9Ut5_l6>1*`_%0@eU;1MdLu0`CE9fpx%o z;Co@DcDauo3tK_!RgI_#F5G_!9UE*aUnHd;@$7d;r*=fW|;FkOHIvO@O9A zGoU$;2DAVU23i7#0EYsH0j+>^;BcTda0Ji>I1*?J90gH^&I8T| z#sYR=98e5602L?!N`W%K30we-2V6io;08Q^7nlI}06!1_Du7C0B2WcP0wx0&0v7=n z1D61o0@c7}z!YFAFb%jIxB|Emr~$45t_H3Ft_7|Gt_N-arUNs88-bgEnZV7!EMPV; z2bc@o0?Y$$1#Saw2kroZz@5Ndz}>(-z`ekH;67jha6hmRSOh!(JP14lEC!YU4+D%k7y=9hh5`9N0WcgG0Tcp7 zz(`;eFd7&GoC%x-oDG}oDYlz?7%pn7;pe8Py&W}fb!d8qcG{pZba)@HSd!*5e z`8Uiy=96iBJt`WXW#1<&C4c<*_tP7$?fCeX!?Yj<;z;9pEZ2m>!Ter1^nN`= zp&EWU{smI}^7z!2Ey+sRKM!_KI^?Lox=;ec^aUt>mTN-cV2+=n4ZTv=e2Mv{8}5%x zwELg_Q?k-3^{NBrHR^Ic-#^FCaxDPiV27^uoc_R2IcS6<%Qc~Ji1MB_^rlyAm(?Nuc!I~s{`bsj1zqmvP&s|xm*nhD^%2LqocBXTPwGkQa~-HZ&vH#D9L)Xc(0GDKLGxXWBd444x0#1Lu8^CQqFj4U zYT4|o?w{7$C@^hsJ@H_<7N~GA^9V&B8e9@)9tvX$ml%OA(%$Z}m8J`#`k;|gI$ zayy(t(%TApn3NwW2^dB;)p)QQomsA5wSC8(5ytk#9KMR%3e1J?O+2%2_QU_J^Zu`a zAQGMGF&>8#@0g$MoL9(=>?Ef%w}G3&PKN#QS(jSJ9nnCf`i#Pp(}r|ThSG%fPiOYW zXY#YXhU3`Y>vzU=R(-ZJw7CCrNbQkG^X4~P^wX0Y-?M+&%TNjBaoXpc<+7&e zvs+mD9BOdbLN;!t40O6weQq>ey9D5N;+TU{w6d86nNgOK`oZ2969^wTu!lBe`_Pnk zIz7Jnm@6SRnP~DMYNhJxpKZ(XdVQWMXE|2BVN!nrnecmVYRT{_V+vvqj$DVrBcQifKWTMG;i0^<( zaMy`eBR1w)4W9AFZ$^JQ-@CMZU8gxU*J+J)uFJ+4aua#{;r%ZPu;Ye1V0>tL7``!` zYxkGIJp-WlY1}4=_{H!kY|(ug+^e4+oOXYM>gN|NYg0t-G(VU5k4ZMSo8|rkyecc- z`{KN;_kN@)y_)G@9A&xTte}f$8#!W#_LVqa5thUU0xs3uj34cExkg}H0Uus9^D+ce zdwvsm5!Wn$&irmJ{pj#|mz1OjZaB96U4bS>#N?*|e6rjShfbsHKBt}DZ2N7wSoxv) z{6uq<-Q{#>V(cP-Z9cF>quf(TuO3A`Rj0()(_Lo``sT=MPR!;Ai8ryALd{vtOuj1J!ecZYEx@wM>^(D*MJrXY}l?h}mEr=kF%x_GS_QxiaWlQd9yssShsBlZ|y>{y;R#WzCIhCGb6Xt5ifo9_~ClIly^^tK3T3y!^h~n zsAdT1koGSLs}Do&zCb;NYk@}VpM_)GxwgHfZ0;>QcCL1<&~~*3f{1|Y%bHf^_9eaB zO#?F9Vs7qxM}G~g^8E#Wrj>ngZ+CHwiTY;S(N#&j1 zgR$HYhfalf5t!%qxTw)W?<{ld*lx@=xDZ?6(RQKPG>#E=D8R?(+-Tvr^2)vT;s8R) z1jO=;uB%qZgd#93ayy&G6WCZ~lQpsD&T{(fY9^HCa=Od^cQuE7DSRt^_U_cO(r52Z zpA68W=M;@6Z^3i)=~K77TYQA0*OK*F|Dy-Ce8>^!N%PaH)8q z;B#XjT)#R4C+6KaBh35#mwz~n-Z_pn+r^^?dm+=FGkGo~`n-cczQQYVXv*o+vN$yddy1g*3x<`AlxIUy@nI(!ie3z@8{C zG*-yvg6^5@;(wA^#?rvvr~$dW@c4Tyu2$ZTr5(#{f7XCpUUtX5((^^`!&_x=cWB;< zV@EY0mlx~#vZETcuHTUKpuPt7rt%`U(dx6cB$fvDtOn%r zvS-=s+}O9bPek)|Xda~XjN7^Cu|I?+uMeR-5~)pQm8<%xZI!F~Ir&S?-y6&19#tceev6| zf2S$laU1XZ<)m2$(f1$8(6?x4eGtnvp>PQ8H;{)-eXy%q0J}zEClRcavW@om`~g}m z6>{>phhQDEyLb}zld978ZsBc-wD09I&zh03c`E;=Dc`;}@Qt>cAALjS$#Q|BW{tr! z3dLM!X_@g6YwT#(qdsLV+!`F2ciJd3@9NDbC=R$U!G|wz-fXK3Vl`I#L!NB+@I~ty zKT99Tgkk-%ToVe17`*d_70{k7x@VEc9Ek^g%c}>xZ5oYloz>-Cy83_?%0*2U-m+$V z=Noz7GUmZ@fr4g@%_G00#IMqFbJPB5wbf>Q$UMlu+V$A(6~{FiVQdGa>7xOTEGIvr ziNRx7MY)jE{Q6aLJIu(|Vvu{pzB_nO95iM}pl8YMh!fFRW*^poRbH&}vJYq9-A-LD zFT0(<4n!F1c@WKw-vN<(BO~r;es_SHb?JVpfn8Bvc18Y+6s9N>?UYp9#v;4yMl#D- z8rU8U?27WTJv?^yHPOn5^?cdcn*MKvx4)JbO2uepCeak8>vuGaMB}pj?Hd}f%1ixp zvfjJY*NG+3HDHyO`Z>WWFZFd|Nv!e`Ee}}bC7Na|`TqEPiPYzaB%{>l{y&|0&a#y& zEDc1{KoA*;=3nssy3zc_lSj*sv99B5BF&eMb=`l-O->)05yE==FX>@#y;nJXxc-gB zH(L5pyM~ZR7_q{)+`<~L(kHBoz0tO>x7VVTo{guNzpFq~ZcBizpW@pJXFj-;;(qkn`=+H$t0S>y zn5Qgf_if;b@1>SF9U!VkAi4|z^8DjE@FbH3Q2deR+s^)G>a9I%Mx0On$S_Y?uDdGA zHt;O+1njQpN*(PCl!b4lTal-GHz;};B4YkEQ{(Ho!?SlUY;@lNvzZ_Bm*wof^Y~*f zc$mJerxC$2oSFZ+E93LuP_?=C-zUEKhxsvoSSk@OL%OhuB>wfx+ov-LhKk~S@wsDb}_dEs(ol@~ErSoUZd$bbX&XXv}LnX|&* zBfa{%Sr=0tT4uQO`(@5w5JxoR&SNDJJ?v&-2IAxU%fNg|LnG;6iQ$j-ndmp$+;3ghDOuYGp*q-5nex$+bKq5} z8ggz;ZHHxDcwm>pJQ5+ZocxF;)Nc)q>#Fwg7}V`y8)mO`mf8bOkGn8n_XUbP1D)7+ zVub2&`qW~a{a%mTuMPfU0MG7njk6bzH;?abN`UVxhdy+~(26B(|1?N3UzUqp$-bj} zwR=H0;yCoOdGYny@t7YUJ$CC;C$}^R5zm95SC$*%&}n;ls*VvfdhQPxMEBHlM{W~w z-sCggDBJ1G_K*TBi=}}*paJoF=E`m1a;@dhD{nf0_Km44MLoG8^<|=W(9ILekN@Dd z!9UUj3mEcuG>$CSguZXlj@Qrg+lm)0W zCl#szW4{!xZ@9jvAgPRTKSYRPk6JSjJ3rSlpg;aze5WG@dWdU{;ZDz^1#l;QWdU?< z4A3*Wx-?07Ep_UcuMe%c-v@oTz*l3t)R@~ zRtsDee*Hh$@{4lJ->vU=dx{n=^Po5=ImfnElu`FQ(wD-Xa>CpLvnI4yOLj7PTOzrh zTz8Ga13Tf2qqkKq7oLE4FxrsFeie_x3YR{LYu=|POO~^{ zte<>0Z40I5cpS)gK2JHh7kkRRE;T@}QzsXb2oc+k9 z-*B9CPQvdNLoV|O-QU0pw_A1Dgq?@7O0W}_rg2A>zi5(IwPiURK9oNSL*!KujIZ|w ztt-FYu=u%EGB1|z5U&B{cBd=f?V4ofwJ8B!?w^01@0_;uN{(OWm!!yYc9->4SW#Mv z)&nx9rY=E!qPEPus_%@iukN*H1@2ityDP`bykt4MZv!tuTjuhUc2|5}H@@dATsx*_ zCdbRXWI4Nsc%7k68mb0-&SF36YnKZftBp|Y4yT*yb0J?%$AwgWsJ;s(z~|&ePjov! ze`Y;CvV5EP2pSUkbh|r#{X6`Z&c7Zq?a5k>kM$$V**&D6A*$0m*;!goIXT#AuGHg0 z*4B*3XBqfV-J1naJdx_*b6b3vS9j!Sw|24Nk9^B=b`SBXpI%vhztbPEWB!JaU?QJ_ zd*bui`pU2OJ-y)7(DRA)Bg?mqPdLFuJ{!S@!e{+NdS0d$yx@GMDrG3g$9!ZtyNC26 zrB_%v<^;>Yh5US1?hQZRFMQyu11PSb;jZO(xW`M+1tp$~VBkOni{bBuHHsX?=q|2S%pQHQYdxJHmNz`AgKsXFO$MS2rSsK_; z4b&h2F7N3JWB2C@9!ODEPhRrm)c23w^8C1iwWyE8k@i_-xy*<9a~Ns~s5D~(Hq{%s z3n%gjN<7j!>HC0|9gDe(&WmRkJeH!Ax9IcDJ&WGkcm)-Dm<|B(V7Vp~4uwu?v**~0 z%T$}znD6iOkMHmClp8y{vR9Eu<|4B`WFFOvQQNqF*j~UQQR5bNqZZ^B7R27FSTCHge+N zBC-9y<#DrKWIhx}i=P_hp53)`iT7kZMyk(xq9$dzE)5@vPrZIW_4u_GHm34KVJ6r2 z)aR!@UL%0|s9cZo*~l(%F&lO_OZ9)T+#>nk)3QYQChBib-;Wjl&eK2;iB9#sI8Mf) z>!mteW=KxuiOP{aZbA}nQt=Xfyy~`v-|z-1jMqb^_bSShDcW-_OAjLAadM+o z=RDM=<4AVoymX-?XZIL9hN*!8KA#8gH5{svfeU#2A_F|ccqonqhC7W9)xn+e74f8V zV}KMRzW=p0iOYZ3mv1V9bvYg!q<_yhqSK3`phc@-VZ|kp3HxOmeUnvIue3}PM zqa$b_SH)G-lhaiy_D{ytn)?HCKZ)X=TXM~`8?Wj*{5@(+z|j5Bdq9?JLg7&0b5`2% z!HxcT1%=^`0XhUaExfmI2B=HGmsG>T{n&NjBkGN!q;^aYYYnl`GHdIqK*9 zliwkKWav!eYAn};!XY9bB4PNc#+lwn6bS0 zt(z8pM*UVYI*+7~T$hHA5#uj(PG$vE!z;(XPKckvjg%hGJ#+rN)Vu>e=X_268h{1M z@z-P`#y`Lv@J-6W%8P)he2slNeE-qnA5?bLLEc$;+B;&3i0@yPGl_`t=c;yBpv-v9 zpyvj$zS$)4a3C;RKeiP(|GLSPg_R#mzsWr9geeb_oecAk<+`h);5BKM*J~^AsZOeS z@TSsX8{oE&!&z5^;Zfw_ea5VhNIWuo9Dn{HzK{OL@h}fr&hC+TU`V4L5s}B%1b967 zPv@T+&v=Wobx0qwJQfdaL0_p+=TYW>5yuavKO0{k{lDt9rt;ga#T*aoLzc69Bz@#~ ze7*{=_9>r{ZX>yna3y{rr9}OtKNp`@#+2vh4Js%r<9L~uENAyfytHS9%O$WdzxNL& zz@y7W=M8&$UfXFL5A%@a>>i0nNGaMfDxHp4uXlSszCJ!_T0VPY)4>iUx zp{K%EjQ9QJo=PrGBA;am@LA+JKdtFI)uDL^%tw|d#0MqaL z^Iqrpn2#)H_n7+0a%1+I*JUrpe1r()YEuGyZk+b+y|13MY9`0Wd}KMhN8$su6nP9H zg#oiW_uGcA*10=hvytOxezKh1w@q((?!q$FRT4^7%%4I)tiK@m(Q`Trpm@nnZ5na@ z&8984Ce5BQ`#p#?!~A49yJu-LtDNJUm{~Q+HrnYPoHe=-j@1Cio3T88yysjn>Yg^E z8cgPJIbK=L?)BmwX7`~<=kXaH#QUC;K>SnNy>-x$pVroL_#D41XZQN?kLsTV$7+D@ zJN?D@_kHm#!?MbIZMcua<#=T|yVr}iumWvax2Mvs`>4i=I@nZbxE8^e(>31Bmb=doXH*tA)0 z$FrQS7fm51QVwvJVg@?BkSkPul}^m>$oDx*(LmB2sCjB?&v$#-%!540?dbatz5kR7 z*XGY!8j%s-mSD|tLmWCq<}p;YyTk0rv#5{S1b755Yk2o>56`(m=E3q10mBlFhr?-R zBJ$W+7h50wUP)1&TC!>Ris!F+{1_u1N*{VZ$@0W_gmqC^j8*QqCyMgO?P@g4h%l3H2m)m{ghpN6()lpdCD?w{9-{-)d3GUKDJZDkzDJ+p^x7W=1 zIZ{3I_Mi>FRV?`HtXT#T;+c-}&2mE=I+=Nn#>PczXm^H0IZ|NN0PAxJcv8Gs0G%5H z;&@oU*He@^@1*6PJN@T}PlX$qLjWpwEZ2m>!91>j!KTnqon9Y{?fp3jpA5$zNl#gy zeCciH8|36D^ea*nSx$xx=V>`axKWW$Z5%!n*R37iXt(P4s*5>Z z${&Jq$==v0yIayQq?|399G;M1jyxOtHd+Xb36aNm4h4H+~gQ4M`Y-X*@X(rHKA}A zIW)_LU72WRDB2HME|;g6TJN?2cAslfE~K7PpS|3VF=RLD9MxwG&YAknHE+gmSAG4> z6RRe#Ir~PATIZLn$Z~cs!~_;?ceFthy;**{+lH;tFoGPw@Z3<0(s_zQjPxr+J!Pzl z&*z>IWks!hr`*c%F&|mZ?lJh#$`$O_h8g4$c!~LbNdmmizhs<9L~uEN6EN znR=0VO3?4ar>^tduxm?fj4@0}OXhLA+|}lMUp;G%)(%{qqbR40{bf;LZTaw4tq5L=h^by+IrHE%=aWKA%yLw?RG)2lg<65Z)zZ-8Vi=~cVv{?czWtqX zp;#WbfESf7u9wL!_m6LV>#7YOp4+f9y>lW%XUs-YSgr|$1M+wY#f#a`L+x%nG=17D z2PfW~OjdKsoGyoEgI?<0Qz3yzEXCl5?Zo?WHETHlDK(7+J@A>@nl0v6V`y)ZI`R-w0i_e{xp${<9 zix)wv!!#b!XN{R>r03ijH~f41JL@a%Vjj#>ma}_3o>XNOVt!Y^&|?&0TJ?rNya3m0 z3&4*uSFH4YbJMLSH@axBljCQ8vYg#V^|2M&-Hvgds-g6n&eZP6d^`U8!iDEt_UfTO zSG`_iH2C%Sus+L>b3A+w$A^X+dSP1rq4zn1vNbOmIMV&n`tDrB&*A4b)az)mo>&KW zGOUk&+0FHG*;`Tm9JOr1makKkPQPFNu2Y$w+N-DLRjcQzT(Vr3hL6P0ZTI@iJc0g1 zP|ralJcVAgCx<$VeIC?s9=AhpC7JtaW8X3JiBukID}Mao(gz+YDLnv(hJKu zem+OmOP=53LNSVh^t#^56j^%jDX5i^p`( z1 z{JdLIln;8$YPM#=jWZsi#y<@6W4SI3AEWcbXtB$Q#tRPXvy{k>#3DIA~3A z-z1y11ET5};&hMq+j8yxvLbp#JVbSu2Fmi?)XPzQ!ZZd`JH6ZcW?phWYW!!4^3P@2 zDYvgVto_kO+*B;7{$#m8NwbD`y|87K(g>v9?!(i65Vmmi+O+CI#oH5VFyIPNPj%o! zch7o?l%M8Kn(FHRS9_4gE4(AX$dWU7NYTPAno zLXp?l590G0{Mxn8w|e}n?>S!PCCk}8I&VS7@N<6zfzPVE_*L<>6kT# zUq%%s4Dq4-#Bxn29Kw;A6V8WK9`(rJx@v&yCuKuyKDqy-C@cOs@Q&ac*W7Zg#E0bq z70sHBe${v*ZnJ{)KDwxn>2c!U^e@(RwC?lli=U01H$#e_<#POjJ_e#AZtNcuk&t$& zn2$3*il2{Hv_Emhi@sr}@rx%qCn*OiESLEVvAatv(0%HU_44|f{-S|Hkb9|>jZFyb ze$8U^oAAC?_4%~QT+~x7c#(;gkEb_CRVKdl@1tiu_k8#D1_9zl`G)0&ICK*96r&!} zRH$7O#F6vOn2+Q4KTdn=%(ic&=BILmn;MdBQ$tzK?&fh7VIXBFz3CrNg^?B1k=paa zZxnpfz6jL_i1`(4H1nfpMN?oMR=qZP_5Bmpf&Y)2e?I=RGk1>i1S_Ku-|UPrk6oEgP(>-{u#xuvjgdE?@zuIXEQ7RQ67elVTt$=O{fw_LqK zJ$|n}P+T_B?ZPu#8!_N+skwjgd3-+Ya{FBJ;B!UPjMU6g#!;3V&f@b>tZySw!sHzc z;=1x(4iL|Cmw0UX0X)f#fP%=7l#jXmaQ@_Y)bEQ`N#o+ zJ%FtM&nwMZk>0oT`Ha@gUDt7vBFovmsLbheXnPu=R>e4|AN_Z4MF7L+Wgf=>hZ9Xy zaoVCOUvH84L~7?XTeslLg|=30I6kVIXp~fzvwOVvBhvebkr*N}M%;~6q((qgkhp%H z^QBpDk$4W8)u7UO?6;$t2lJHW?7odWXkD2fEHQmEzcSb3#F`%D zt9xSpcK#=0VO56By10$~yrti2k9GW~^lgYE%gK*uOgyvkOvfBPj2O{QAB7nHL#>{T zmlWfB7UbwxRpZ2ZTL3;}vH*%FlHPhZZ9MIQijz9Xd{|D`i^jx9XP~p{ue$8md_;Vn zbi=qlg-h{AGuNy>>b6rdW?aVZ#FNaml3bTc?*sLiF@}J}1=`~5VIFOzHauqlqz4)Y zE%+rx5#ymaf;fovCPbPcHwFpFPHh2t&QV)P&sX6!LiC^RkvdPevpCQoJ1c!i-<&Rd=6J>QvC@ULlGu4?rBAHbIDOcU zoPI2q{jr?RV!FoiCtkBZ*u{Qp#_#5SD-BVW0Q|krjp#o;eM{r-Jl-4bUEV>z`*u(^ zjeoLS)(OA&4bRVFiS|ZXn{GgF%4qzUOg}U*#PL;lIoS#)PPyYZRjd?qY3BisOwnNvU!5H>G^ob4}KN{4&SS z{A4-1C(IA8pS|>5W{)qj9+9A8JxS@x^%}<|o+oA4 zqM>ISl}jEwq%R-X+!^awfV2756$c2 z^bvKzZ9PgGD}8o#E)0iX4J$v#8)NqUY!MjklPl_e%}q$A9eFCJ$z>zLmNVn&J3mIlD)Rzp&Wn z^ajGyFr&Ud;&9|MKcmGwEc=oF?~eLKj&pzcFXoe4DWBAP4|;tw<^6#-fA?E)$DHEoj)%o>4$)SZ= z%!B0#^U#(AW=ey5KH1oGdfNd>1N4|F zPm*3(u1mwm2zn8xdK+J>ljm6W2rJA8Y6;F<&jb&Qtv9+PDed!3$-hnMZd|VD6BgRk zle4?PbDQVi=_uiQY#pXLb^o{UOIMGroSWSKa+?tmuQy=1Ar75n9yUzS1Or>)M7x(fiRG?a zj_k8ow?3T(Y9gPT1!kO|T%MEepB*))Be<(Hsa(E`So#{M)Q(^BgISeK*k_m4tEyh6y_YmoyJYJz@6$h;zf@EveR=rG;V@dN`}iV%XMk^sPl@rsv^%{h;0bz<6vQBqR;OM1TaZd%{dW5}>SvK5y%8^#YeM0mWoBcda%gNR z3v0o&i9NZYeKW=U9gM?c8F)N=&i&8c_2W@NnFq@S3YwKE6ym#6XpQn;e%9AxB=YIj zG5gRss!iL6&&CU%wM&CIa(P=F zhfmc_&6LMK-O!|dEZ3#sV@y7y?N~bOE*+??CZ=WLv|b2%vR3Gu zuu>>u{w`}4TVI=sQkA*gw%jpc^_tP`4GPSU5Y^ zUENB90M#9ot}Hjip;H3<^hb?EOsp3&(_+^PwX>QjnG?6>G;NWQ*V%}f^FPZ&gbYh0 zUdE6!WiIXeaO73g&ob~J!}X@z-p&}Es=V&sblR=%EjCPD)C}`rxgidnBJl{7L%m^G zcu`#`p|})MdbW(Ap*D?LH7l2fqevUEYBW>3 z;~0R}#WXWOX-=RrMRHmzdoVzc7^=T1A5eav|HPW}g?W?< zJAc$5{~Yzv+E+avJ@ebsKwFUr!*`QlKxQTw}WMUvt=``xn_ zAm1GG%)s9+{`#InCQ?C#;d+DRx-@(Y=L@~wuxah`Y_-f@>BKI~$})JR_<21NU3mo( znbM!k;rdBCa$9_qAS1?9f5^`X_7eIaC<}J-S$s~Hb@{G8qj{VvYP`KNsLR}U}A zqg<*eR8La5V!0+14zm8l(uM7KG;N9tyrPviAxKlb$>oX47CnEd43eGJa#HzA16W4x zRHy39^|C1bhm&U5ozCQL)x)}8=vV`Ad0W=ToL}m-H;+hFPHg%>$_Fc3=Fg-=fawNM zeqp&L6b{HQT9;TKTtSPsYLc0A ze~A0yx~^2Y!EiZZxh@SKBbB4@4rfLog7--EE!C-1e^MEu_6+^!=M&{)t~1#V(QY&U zwQ^Jq&2oKP(9S&0&;@SC0X4`!-(CCGt==_Fl+DjhPJ47%@`TF`MIDAS)we8%caycwB^=#e}+}++9xIyr4GI+{-iCMR_eK z@2Nm-9GcgV25`TK`bg9^=5`vjkEoncn~4?#9|6#NEt+da?I2oXo&mH2+5<-e9e|F& zF+e9E6X*;a3y^+r>v+3ou8%fCk7Tj{x)*sLp-mXCIic?n@8>$Y4H<4c{OJnPBg^sE zWb|?G!eYA{qsjPq3azlGQieBukcD3NX}gVKk2q8P=xraHPx{_o;0i8mqLjUParf(IymCB$hk6+NQ+lu* ze@%w-2~CGVQPwtJ#ZZ6IB(JLZ6Z1p2W6beW)j@S+=zSXO&Cb2*rRH}Wm#tllgWf+p zyq=uh(Tc(6nN&ng4E%am2|ICNH$mFj3hkb9&@tC<{V>g0)C1R@>Hp%{J#pgC6n4?0 z)8>~ccfZuqD8R%c6>M0}@$)${59}%z;(%dkzsJq~t6`yZ;eIhiLw#|o??of_kLlU4 zvy7N7b&@{#S=8qoMVUAz)xH4vV(dv5{yr$V%Y%(5!C;01lrLDW35A2Kk5PS$;l*61 zJAj>s`1^liJvKJeTt4Lfb+?O}DC@6y`oPLRhvzn;haC**hj_4D6AFif`qz1GdTpj> zA>&%HzTYD8lIvHcV-w|>H-3I9n01lTiXQARlvc!x<(g19=;a1)#EL1KPI9SuEDo_x z@>B$D`c}I1aHP6+U`_#DRt<1D_I5VwN#^6ld+CLPd!00@Yu9Om=hD@R@+2A|#E0d& zG4(a zy7t@@Y7#;RX`%PfI|`vD)Ig|GwaRC0n=rLG>#AL@>?RK_ zYHk+Tc687vAEEPl-5F(ssaCAzNc6rP_}Z0Ptpl$Yi0T-o5=P(j(djw2ukv(L6#I0% zuh8{-GR*(VV3Te9)PCe}?Uhmw_#B7vX z+5r4~0PkP06S{q47Hn_W7pC3!bQ=x(?=dMxSs}{ME$SEP^qH3BNbp>Ixela4$2dCr zau0?DjHA=z^!yoTP0RD*T%b5!Bk|Tei_6cZpPLfU+rbqb1J~Q+b`{ml5r_88x@YUw zg!@c+oez)oR_InKmag7<+8$P8&&E0a>M`GAS&ymHQjb^{r9O(zOZ^pJ==4bwU#ArC%cr%!v$lJf>hj^SUQ<_%xbuk? zomh1X$3KKln(i!o7WN-32Bt(ti|YVw!OcX@<<1Yx|NdTK>gJT7j_*!rS8$_6&O+CD zXZSDUznBh@-hbO<;ooZCGY5pJy#6su4j+8`6PcJ2JrQ~d{1;>2qerF>aLpc*k&&9^ z`9Q)uXWBm*TZI&U__GB!5P9cb5Ln*%gTqwY$FHt&`s0G@$5!m@qc1`)f!|{FrDTTv zYmCl+_dbF7-#sKuweG*O$1Q#K{Mz9slT(qm(EmpM{c4QfAJ}5yKMBlq1Wp68|Ma6X ztGKtOy~-%VnQC8CS?Ln5t@ALy*B+Rjbdfo-u6-@-J5ITyudf{a@$sR$@!kio?K@uX zBYart5?_RmIBd1=hmky7Kz)>X7+%jIYvW~%Cmz>S0`U2s@K-s#JmO<~&?Qn$>^U#( z#RErQF8H3mf`0>febjI`Yr9h#* z=oeT%dEFw_MN@kBeB)^Q2W1{j_!7Ftk`c7>#j$h@^B2RHuimQuf%%E*5viVg`K=jM zGV-R2J_$cU55Nzm&v3Pi~m`TvC>2I>uO2 z%kmO>06w&tZG#DeDN} zTnk0V@(IIH=mt?cX!TgrS8Tq3{{=BwJ~FV{dFJWweN)TUCm2Xa0>$Z>ls27y&AAZP z=RcBTef7gSe_P8@MfJU|+C9Id{;>GyD`O1tuyaWJA#|(ElZc@s9y9hi}FQ^>Q%&DlOuUPAYBWQIz?*RYH^UY7KJOzd!9Ia%LB zY7MEV-mOw)#8szyp1FsMP2lK}AE6sW?O^;j2z|*h88{5XV&?S3xnr}8Z`RD+@jPk& z?D(*D%OXJ;Ut)wl=EQTBv(#yTZ*82XjANBh8 zw^Hk@eQf0RW}X)iekR6xD|D+=i?quwx4B-@+!sk-x?)^vZKp#(WgD&Qy&mR8C7m

      ?XMgH$;p;`AnE+^IBWU*@tn*nODZSE zOZoE((F4|7+Ig$3XBxVa@-|+4I5Iue z^WJLJ8|El|DXC-fK0~^UY1_KumHpotibCcbkK%gv0_e@Y%B}KVjhbI>P>WytvV8P@ z*6DDLe0kTi--yBFn}AI}2dSogPEE|5SW)r1lb3um|H%DF2*;ioyX8VRh}ywi?~mVY z8nZI|8Sr#`d(bb{iNSYwf;%xOBQbgqJ{r!!B79!9WMk3sGc7wiXiLDBfGq)A0=5Kf z3D^>_C16XymVhk*TLQKOYzf#Buq9wiz?Oh50b2sL1pZP9$U3aQG*de>TLQKOYzf#B zuq9wiz?Q(jSORwc>0ey9_M_Pnuq9wiz?Oh50b2sL1Z)Y|60jv;OTd_C16XymVhk*TLQKOYzf#B_y_C16XymVhk*TLQKOYzf#B zuq9wiz?Oh50b2sL1Z)Y|60jv;OTd_ zC16XymVhk*TLQKOYzf#Buq9wiz?Oh50b2sL1Z)Y|60jv;OTd_C16XymVhk*TLQKOYzdqr63D}Irra`jN7ac*CpT3NGoCsI zNB$!)@3s}HBmCX{mFhL^hevWF!c@QCdoKOzy)v0~;wu|ztKj%MoX`!Tb{N+^x_?Gm zW=g7Sm~-CT;VFskj09I=MtV|~nJ6DO;{7{}ZJ3~4R_Y-6BiMC09lLVF^U#Y(ZRRh=GzE#51vyLaXeYo|K z2GfpJGdOw?m4o$H=vFrSrKY6MiXQGvNgw2Prn#cWW+pkaU1L%ZjCZ>R^^f;lVAT_A zKBYaU9;wlm~)6V7+IUj{3=Ppt{U-=aSR)q+E@_dXii% zOkLZ))_~sEzne0s8(RRS272^F=vLVU(vys=>_SEPEA@nBOnX!bpg!=assasxLBJ>t zJrHgJFb#E!x>FG-1BmUCb^@ex)-A=8i#=IUf}TV^5TO>;dhWLdx3zfm`P!yEsetQg zPlRq2WB@&hnK{$#nhEQYq*;~~8b9r82G-jR4@Rg*)&5mCytii6H}lLp3qL~l&kwsO z8CfaWDd{s2OiRhu?Ocg`?I?k-_=h6Y$n~{rPOG&obXXf-zJy*PUvcS~IoVky@}-yG zgj#{+#e2rY*3RF$x5{swJPfcdR78ysx`$londKLkmYFIt%WxMJnYRG-@;gxiKPMiJ zP%ox7p1P;i$Jdg;t7TA z#0TVah;z0xE76^jnOzD_%^dZ1Ftbizx$b@}LcN^Y`kD(@Rz0ugdS87My6`E!$!|RR zOMwNa*HcwDFdwHkM5rmdU%U0_f0m4B+{%{^q09Zn_weC%mCTB9i7uBVCGb=0$q04R zym{r7sOgWl%bfasghg%9yfeiE|hruy_Di&V@!Tp;zbT)n_@Vcy5bUUpw>>u*vn zY0NXTEw2OnC3KVOJ(_$BbI#4k@hPBqPbWn$mlY-4f78YYb!WoIEr0rCZg|KSzH$({ z_s(Xhxce6ogy%w?pBD8?md7Wf`uv_S|NJdYJ%)f@WynM5{`rY@rYEJkj3#E_Y*)H( zJL5IxxLCL6TT0+(!qX9|%lLPPOx|55b$U&+cO`lv^gqClUs36Dif<5DPN$!VP?uGj z>fX0;bm*~%efbi)f4*YUQ_|2uDTV#k`6(!YpB2wWsHqdKoi%>t{QU0y%sY#mgzlf8 z@y?X&LH-)xA~Mq3lO<7s<->brG(6Dp{IYB1m8#HATj|1=sn-KivNBVhbBARl&NA8% zpQg{{E`{85KHE1ena`P(s&xtNA3Ij~koLq%mw1y;Z^Q8i*;M(+Q0&z1Qt-L$!`ic- zJ)HKH@F9F!=@Kt?VjhI)Ogeimb^bCNl`O|Sb>FtJU$o+*sD_!DE{)W4fQk-Yc z95T_%xmM$n`5UrwXpgm%J{}?W7yhhti8uL+ce&G2va-C-)DjQFrmFvnNu$S>dDgl-VEgUPQs3N$XoH77H}?IYBZs<_^M93`))=j)^6nVcY#N3Fvy$y?J20Dfd!@s*ty8c+lnxS2~ZHGXkPFLbq~Z>J8e` zL|2m0ON~iSD%wjd(yaRQhjy317w@?sW5w4aDqdM#?l1PiN|$((ul^Z$BTLU7kdc@} zD`qNoK%Lg*mE0n*yw+}sP>0Lxh4p$k9an|yiO_u@t7)2;Ps&+|**t6*z{+S{YyQ|Sjj z855H4t6xGFe#9?5Uqy9{dFbWYy;WejF@2Xtq4mGJX47DX=|s=0bTd{dlfMLvP^2Wf ziWgcD=JJt&v^V=p;A_Kc5o*L`vp;OUZc+K}o*PTO6uR&uzRA~E44n*cr{LA(ELbzL z(B+odIDRU*enm#XB*|W0;MEWS7h5#j=RR%q#Wx z1Jx!lUnh1z-!gKJo_Mg&v)?rEt)D^{e#AHVib+g#q5CsEB{d~Ga2u%i$6})c^TT_b z|8+?2j&k4LBli>iveG5qBc}{-dCup<9|mv&nsZJqfheFR!1;u70JTBdar$N{ zAYeNm3FP5S>_Kw-zaSJA!#HHq#sPcvWx^+#sudQ>j2Gx#sJHlI#dJToKgh9`6Ukf@@d!!C8zYM1E%#i zY337vXuD!1pxeFE7X64sA#k=axs_6=O@}wZMjaD)7riz^Hu-7(+yw!aB(-eUih-oCEk~>gt=MSuCzhU)YR$D z#97gPL`8e5zaMe#)Vzn}X!`A8DD`x{vHzSi)>Wym^!YsgY`Q-hpF*xJE}m)VB%OKY z|ETAohxODtT@U+9WAsU0x<<3SNm37FN+&kX}qUDn$Al}@p{_g!g?NhSWjOZT~AX| zxO_1pdnU!nQ-&73vE?nzSnj7TczjM!!l*Q&K$dZ#!E8e?|iNP_oj#zpyTd z?o&587C@gg`m7s&x8r@zCAS0*E8|O%@qyoq+sA~dE8G8Av*9NxXTJ3aiQ_mNKM=ZA zb|aj#Q?Le=i}cK8jpmE8x%jYlB;>hqG$cTIf5{q}<$t$YZb zX>?bFkGM4FOxM7)>8>QKBk;1K^AVfiJMLiJCu1%6>{oE@mwRrzx%q-Q=H1Gm(crj) z&~+Xdmai!(io&^hEI`HQgWgZ>kuDzvpw}B~J}e)uS>f6zu4P#aJO?}t3OvChbW zqtKZ~ccL4eqX%c^jCNw#hC5}RF|x|VX|eDyVdk;AZ`xkI3n`wBKE zj|o$+mAmJ>J0Bn3``I>T2KU0Fz6xFEfnk5^3rFOnaV?gquUVsVTsf|!ey$lAZtVTS z@9lV?F02(=%m@McnRbq zO2$`XC-~}3-+qku9)FTlh0Zb?Q!lz=GK6Qycb&GkDPDh&UObO_AC-1_*`cnY? zx_nx#2Zk3sJ94(i0E+$y-744O^=D8DzF1G0hX#~Js3g7NLb-1MHqUJU>I>I-vh1k` zT>D9us2id~jH8os7abAbjJ1z{L<0JH#|@Kx_2xJ#9P9M)@k*`P5qCx8q%if=y7FJY zv35rMp$6vN?nD~e9idx!@Y}xm!lzC&_S}ShDSz%N5C;Mi z0k^*dHti2fK<{VmpBh+Sx=#sHZ+&x5ovqF~o11v@BwWu+Tr9I&tIK({-?oizpx)tq!Fj`49zZnh^uGJM{DQll?k zkZV{TEHk~lrCiA&?GDSHV@FXyD}ZCMgMdlEY+xlo{-M%Wz*9>Ac~0f>9iO`eam$z} zJy?Ceqw{+VK0e~*tX&s9xt=;oXTGCVD5RTI@6jA*!1tfV4p029$K}kzPbYpk^R(FGTExh6ti^LsPBDNkGkx4<4pRKL10Xy}THXe9|5X-5_d*BJv)Sk?l+! zli&CCCOYQ#YZqR*$q$lt2NV?KkN5YTi%RN8{e2ZaLA7% zzM!tr34cO2sotZ>pL_*ue97hZtkm)@-5QgD(E@iiW5MTWS5{_5dX_8N*tK+I4uqeE z-JS{;b48DE&GB9v9hVh5W=#A@H;)M_54V=*S%K%FK8RklMz{^IB&wqN>iT!?oc4Bv zy8iopht-#jda-{=C(k2vlj=Q=z}Ld4x#{K}adGK0GQ5hxRC@c&Yd|AtR1Ngpja*s6=*SvpvfG30A@TrGF_mB%clP?cLqg|KeV4DH%c0}HoC?5sE z`%8W2H=HuA!#0ZLB<&D_w)-zjAP@Hw{m4x9)sG^23;kIh{7UU@$6819Zf7#O0-X)& zhtRF;``Q6xkMUGjwrlL@VWx&y^ z;8Q<@?jaX?rhW`}rDeG1_ID;GyD+OZ8{KK_UX8WAX78aRx3H$cgRSExlDs${5WQVn z0$-7PBGk@NmscJ6$&C0|UJTa_%0Rw^Zc@ERlP@$$MpwXN*rNO4tJ|4w?6#RCF@s#$ ziOC5$nQUv(m}Td1umMi*Z|%+qT(8=vhpE>aE{s{ZJ?{Q*PE(>vT@3{$e?m8i+QH<{ zxH}|fm|bDXXci=?wSEcR>a%XJDPpzG05El+I8n=SRlb{W{=Pj>1we5dKHJW^0NYo_ z)dHB7PfMFF^^J8=oY3U_T=$nk0HVjr9avAMWrnGlxmVot;@GP$4x4F8PTFUoTjg1j zo=DY_>q@IHlHQ-sK0Ny~Z0AEYu)X)!=G!^}!IaYJcBMsjV0~EveVV+t<_$Rmn_qq^ z*}Q@1i_opNHTA`}KWB8(2jsX7lkBILnHI9pFd5+(b(UD;&O z6KlUe7VY+vi_+&0yJW=O>{rpr`-sp@s`seb6>|ZBM`g0u`uKSr(fNtZ39Prd??$M) zeH-2W&Vj79k9gWs;Ya9RPRx+WkH7aL@B5?vYNYeC-@=boKDFM%`{MBTCRVL><4Cq~ zbi$9&O{(`;96x?UV_c;7vodD~md~d5BUHOd=?M+CyXtoJ)NA2K=w43DP;vZt`&K2( zDL>bjFYCCfniHlT>icBwv)fyK^>zpIz7L=>vmYaLD_`FK4w-#B{m(;q#m`8^Hoiu` z5L?*sTC3d|3R)Zt!wld>gvSHZf$qThz&M~Sz;dIE*f!CQ5bT%G-q6M{EHng-u=u3g zu5=REf@IR4nKsu~U##`&bZVrkyt;X_cm9*Pcb+GE(PN=o?`rC?bzI4f!A9($j?LZN z+#uW>?D|9FNE1Mev8Qa0RG#MRITy_%|iPf^e`s; z3cW;r_3tdta*U37>vnhdWxn#IJxM~E_%=#?cjl$?D?W%&=f6JX%6TK_&UvCZPgL!|?XH8d{bIO6B&Ey=D*iX{Lej;eQvygyZ zAEsR%czmVBVZ3oaS@1?g>+`=Bed2pM+gG7mZ*A6xlEzoO<0^VT+HVz;ux|*n{hJzS=MFwHsEuy!47NwdR6K8(WU-zm4^Y zE)pPLLN|!o!Q{(d|IsqOJ|ZJs??)C_zc`9RNS)DcWe5L@67Z>CR|VFaEzqmDK5-Yu zUp{KbhaMh9Z-j1Ty?DLx_NR4~DNbMXd|9_;o}PA|hkw&&M#qxgfSxY^U^io=Y2sppT=CkT~YWFnwM_pYf80 zzU{mc$U~5NL_Jwz(G%-Bd|oyCgSj2|Cq_-8j?vL~;3#y1s2xl_(ch!{C+DQkGFEr- z-B{Pt9V>nHRDJS8D0zsyE=&cl>Gf?U-diT!7^>d+^2MGHH8pP{@9{#{ZfyjM-rw^+ z&++Bq&Rlsv-&DzzLrLrBWUiX;+kAJW9+L-h&Uq^8FS0UpT-H)n#d$TLI>2%9nm{dp z@8_K7WRDZnfs4afj4 z0kVJ`U=9Ftqvivb0apMEfUAIoz+&JU;5y(2;3nW^U>R^La651ZunM>fxCdAbtN|VX z9swzbLr+`hs^T1}{W#Cm{JMcR27O)$57kD2y0DK613>*fI0G|V211EtWfHT0a zfWraX2b2fGfyzL2pf*qsXbA9sfBZFMJD@Yr1GoU-Z&YIe{up#LFdmo;I024rrvh#u z7q}d_8n_l%3futwGeBrCWCGL!S^`~w ze!xgzGLQny2KWz|TY!AvG2lhuP2dCI3*Zb;9t}iope4`)7y?WJQi02Wn}F58lfX9M z0Pq#?J5V(g&j|Da;sF;h4_FFtzTySoU4Xxebii=b208$7z;s|fa4WDL*a>_F{0`J9 zi#iI70WJY<1l9qs1D^xsV0>Btu|NuNEwB!F8#oD6E06jOOa>MJ4+3uir+_*zSp9)i z;8x%z;B%l_Mbvp96}SV~4*Uo-g<%^D@ReZ`@C8sW9CaI51UwI%1X{rGO#|)#Fzu!y zDnXXOBH$IkfkwYCkO#aB1XqSF0j>ph0r>TgngTokoB(=NMV$rq0*zoi-M}kA_3HRv z0PrGE6~^>p;1!@=P3Sc69?%KKbs2C97+)Ja0u5nkmjEY$$#t-%8R!b5`v6e09{2!$ z2WHpDcY;821C$3aJqo%9BsIkMXh3=+$OXu244dBs_5x_r6mkT{G=pvci<*Py7I;oz zdP}^6w?g> zL9juC@vntg=;9FAi=lYVVMsF^`Zoe)6c0W|!7hwO+62_)vEXwY?mr&w*+iu>FN7_d zgmz&HY~WPXnQ2Ph??fF)gbpX++8Ii{GZQ+L0=qR!sg0?4{&dJU6L#YgrIu%*jC0UV z%|X9xF82PIhx=ZNZ|p9IeDYvpuY_!_MtLoQ?OcNTel28l1N7!5*!P?9oXeE@?N-$D z6-c`h_qYr7?H-irYSfea@Qv~Vc;<)D2Cjq6cnoFwIO@no*otRhZ=c08y#PL60?%7f zCtkyI?SSsR0o(gF^mh;1nDO)X~GB9YuM64t@F>?czz;j8jT&Jq=m^ z!uG|X=7c!ZW#t@dS(rmT8|hFdsyS3Q80wo~s87RCXEk%6fp(~SV5s9^sH?(Ie}2A0 z?dj)Gy9PT{!7zskg`vIxhWdIK>ThAFXU=q}Q!v!G!%&Zcp>7C6T@Hr2EDUu$80w)g z)VIJ;e+NT7>mi5w4Tky=7-}~R^%xlHQ83gO!%*J?Lwy2cKG7sW8+}z);s}5v1~AsN-O$tHV$S!%$a;p&klDeLoC!lguEs6NY*@4D~`7>bqg6 zKZc=>T^FPd!cgA^Lwy+x^-VC;Z^2M^`zA=e4MV*QhI%m!^}{gKzrs*2=o+lL_77I| z;)7MUDZy&t#lfmvZm`;d_s7SU1*^TQgH^{3!D`3mV720{V72DMVDzlM19sPM6DSXqVAg#qK>DBs7vxfRG(WyRKk5BYW>sjcZR5#4@1VIKbHGWQ6b!d56 zb?}L@YWO>4RreER)!miKsl0aORKdt{YD;E0)##RTs@%qMD*OF%D)~$~b+m4Ib+T`H zb*-zs+IVewb;*YE>XrA)t4Dt=uR1iXphgX^pdx2iP?`5sP+2=GsCuU=sEh^`Roc*s zs&;Ngm2-bZwea1FXjifB5C1X=ogSusza>mP_iC8x`5&yoZWXSUPYqYu%feN&o#ATT z@8POKw+QS#5}__!8=(@=pYBkvk~%%1l6vIUN@~QrmDG{Skt%ysr26gVNVWLgNZ8oQ z>cNSX)u6j8t5cs=R!_I8qL#X=s723LQFn$`Rr}(rs@`{1RlB~Zs&4I3O)a~ontJPC zH5J>ox+=e*x~lPhb(PhohH7?o4b|zR8fta7n&79Vdg4S)<-{t8#p`RSmX&L(;n}s- znf#Y`jd%l|g*#)Y{M}5?;1AW!7gE8u*L;Y0uWBt|k z?+2($Lk6kj+Jn`qj=X`zsyl5U!0>B-#%BR=gwEJ zOuJ02iN8X%iCv&B8+?`8IAWnXF=eqDopX&kv-~<$=EWP-s;_TS2b$fY4ks^H2cEo5 z9WHx^igK+|o8Guf?dp}Uu6^oWRjJ4QYSFd_RrRS4tIvL4r|Pa-uZ~WCLZvo&N*y@y zj2ge=IaTG67ge`Awy5uKc|~Qf*rtv@v{PNa{Y^FVXGmc?99YGVGEg!UFN9CZ}r)vl89NZ{q!lqV1aYH%< zHTbPp(6qe+f|kEEJZR7t;584W2k+>8Y4Ba4*9QM5WJU0!y&ec&_3*~vyGOqg zd`IU!!I`5z2@ZewMDXN3Dr8ud$dEmaqe6~kw+~rRCMM**1EWGle>*+ome}l&%%clK ze%g6^$iPz%g(S~-A>@jNyFwmmb~vQ+oF76CRxKae`M0{Eqq}toP2Dmubo0s!L$BGM z5n3&FVd%s4R)wyLdpxxFTiZjAKXfRR;{q6(x&pl^pYenERbeC<@2zNcm31A!7Dpv@ z=MZPRijxcOv5p@I-N-;Y1Rg&~Nk{k0aOkcSj-%|i@L?UtI1y4wZH&77^W_)6u+hqg z&^_4}dI9+`zS%N4(fOEmXHj{eYpHg3G52%n+XNl+w}PIy|M)M@4WPi_Dgqq$6S_gv z4n_GeRzYMLi)NC%11dTn$1QwV#~%xtR#F3QS~BFqk*UvH`4GCsf)Ol%kHUh{`N+I0 zusrgbS5nQdthucB({ol^`4IZq@ewoI<;Fe&C>ouQ(-uCg^UhH%E2;Y~>b~-~(S75s zd=ATb3XpCFCRiLnU9Gnu2lR6&NA+&^Rd*z2g?PoH7fp&a;i)H zj`KDQt)%WcJhp1hn|D;t#d{T<$V2ER)q5RZG4 z%nOfI!MhZl@F8@Q>OBVJ!>gt~eB}G#!>}KC_FmI|cqDRkC3R@!RS(=San03jA21Dw z@F8?B2WF@!A93lKIobV_v0yC`Uuw$0@KPj~aq0G}edWP2As=`RQy1MZk4e?ewd>n; zXgO*x!*t|>M=RYR<4}|jPq`Qj^qb2+&_Y$P@XNenEj-~Tca1MU)_Sua{I0yJ+v&;m z_N>S2qu~~Yns!y_9&({4Q(yS9&24GyH zC%}VJzHAwq0@ZsYRIjMpJF`nD@70lhxOKj^zYfpTS8$akg3 z^RaIE*mEx}yk&a(k)Et*-l-=-_mB&{@viBHMK)J9W<`(d&N*)5OM>C9Y$rZ1bw&?% zWvg6VA@!;6VvfJ#YEXnzx*evPlHkS8)L|0O}fTM+$H;FbhZp(tvaz1He$Z zF|X-{kKuBa4dei`0e1DMXBawH7&@F1`jcnDxO{t;ju@F?&YupZa|VA$T6V|^0-M&K#nX#m6c z#+)mL@{K)?pNIbf@FK7ocnR17ybNpwUIAVOUIVrP+kqXxPT+Om4d6}SE#Pfn7qA<6 z2iOC=3+x5n1KtPr0sDaiz(L>x;6vae;1KXJPyl=a90ooGJ_C*bM}cF&ao}^{3*bxO zE8uJ38{k{u1b}G<^&Rj%a0>VV_!0OIa2hxR`~>_A`~v(6{096Eu<>vJK|nAN0)zr( zfU*FlDvWvM3h*len6@zHm?Pj<0x*SP%r{qoUlqV~hB5bC1Aa}Q7J%subskU$s0(1K zL)8Zw08s#@J@0E_{~0^W8 z3xP$zVqghy4R9@R9dJEx18^g76R;Gx8Mp;l1}q0|1#Saw2UY-g04sr2z@5Ndz}>(- zKt8Y7U>C3(cn8=6ybJ6F z-UHqT_5u5W1HeJx1K>m8Bj6D5F;D<}0vrZD1wI3g07rpiz;WPn;0xeO;49#3;2Ypu z-~@0I_zw6UI0gIw{0RI9I1QWuegb|5egS?3egl37*vWJNK|nAN0)zr(0Its{2b2dY z02P5SAROR!&Rn|@2~-BE09Ao%Ky{!7fayY23#bj82h;)T0`-9U0M~p(0S$phKx3c@ z&=hC}a6Jg78dXc670?=J1GELAfp!38U_ppMgSv$cwiJT8b|=RUS%vW4j2!x zFNbd06>JBkzqcR#J&;w5X?~4xFv9x#Q`8$L9~ygM+7pdfMsW1`{v>ph>OB^Y2jJB$ zC()&CCni0>xcL6ukZVLncFK&o#u8d?jJ6b62w&wkh8YKMA0~Q!<<1jKlTOB!Lv@@Oi z)U#hL^)B}r-+E^q*Vzw#Q_5ui`g73BzuZQpglht#b6QCtkfZMz%T?)srk_G!&=?L;~f3asY2jov7gPS-#XILdsgsK`M-+ z-JnhxjS758D?UgDjlS)QNE-Jc6=-`cN^P#1k%&?hr-?G}%k81JOi6QNu0;9pOS zuiIVNl&o<7MNC7COfMYr^0jkYz!zN%z;dVYXqAZwJVI6W*h+y8SC$i?N-e^}zF z#WA26YJv4G9T6_KIZRcl)b{1$@Q+-vb#u38rp92IqTxD(ntCI2lj=P}Z$`Uj4$RGD zA3Ym$t+QzH&G9PUH_-SoZ^8B;9HCz7^E` z(i$Q9`XH;`^F6)*{Iv(ad=|EAd^WnKre`1jixSZLLu#w99p{`Ub!}7K5H;n(N7hEZ z9HzP+Yu{${WBu;_nFR+2RWaC21>iZv~)41SK_fAQj94v)qg*M{{FP(HQ#oM?RXMcT8jbg7vh3@Ek(Jk zyQIgB4}Nj?e11nl$FXm=Q$jb0+M!sv$4ti#r>-PJ{CtU`VS}^&zn8YA5>N%G1+cEd zgcyBNwvjA;_Ag=f46u)C1>=}Tr_+|PJV|2_GYpg9)4t)OGdK{w84aE6*j?c9!;1 zuQRN#95*AUe8<#XyyqkmK4H7RUIMzlY8aJ)7q$1bk<~_EAkYXn51^jV{GN7% z$8>Bvq^;mRsDo@vq&*>x*Pv@^%gybtqYJHobu@$?xl?F+AGJoVjQ`yy=& zq7A3l3ki!aX>>nOoTMvF8cA#W|9cY9`^lMa`u3Bl_teFuP~sOlwY{Y~;up{9Kln_A zZ%#Qqk9skD_Sb~&As2eq@eY6MoD#6ksXMOF`^hbF-UMKsqn;P%@(>~Kw@cslwLeA1 zMZkZ0?`M*y$GLB~<~ok{W1bY9F7hvQgQy*hago$itZ_^*cG}1Go%nwVegor4V{MBKkB?4v&k==O2KJHGajGG&>>qr&dlx~qO<^GNl2my2Ut zB=5{`ii}cIEN6Nih zTTL4J)W8o?nbOn^@*#AS>OBVFgKyJg#op=ty@GcG^PwtKRcV)w%$eG@?4{*Qb8FZm z@*#9D2WF^5KB7ltn7{Nk(`P~e*80PBYvR~X`zN{o^*Xl#!W4VDX`gR>a3O96aQZOj zb0$9eQtsX`we+L43s>F$-X{@k%;BB`SpGsch}uD>?i28x^{n&O;XCwa=bo?hZ~nl-Fnr}NM70Bd6V{2wKOJa8lRdjA36 zdd+&lwocvy)?(wGRYzKk9D8PJN3pN$hp=7?9j87n9 zyPt$hh#d>dsNfpwp3XcNrjExCe7NbupH{5qDYQ7mQ$K`my^F`*Q#(u}&)?9xGw|l+ zj*d%8b;<92qKD&?vz)Z(k=e<{|5~l%`^-0x-cTQ?%c4tGT@k$!9kKe%-=C9o5@$UZ zy6%@Ijii^f;tT!%!~ZAn@c;4L|Au?!;UUD%Z~54_9_M2*e@DdU4nbYrSFkziP?&nQ z{jJ+StuSNaK~@a7P;{(VkA-ehy+@3f40p~(T{<-u0;GwS<+ecL+B;>?BhoR>^Ce2_5vfJK>XH%>-ld6IQQNdN;U}i0pSkt zkHfzO;JST&3o-;~1U!lBuLIJ7ejad~t{FgG<=7nO0oeCo)nJ>#K9Ia?AUne$t3ti@ zkp8E=Ja8}ip*{<&AJYzpsTKXguj|_5zVMkhnGzBG5V}QLkueKNrsP@Q|V(QAd6C!#WfyQrs_p12L=uc#`T5num;pCid36z%kjT-wOLN|!o0s1kxzvrJ?+$$n81Mi)Px9SCH z)gXBGcciXU_5}4n%0}i^SVoMa&p7&YR^OzWM~M@f^<3!m1I6j-{;lC9crek6{I7lW z0#PBX-dmtAjVom}OvYxxdzyU{_v&YFfA+;@mWuh^BK1P(22ndeFB0&xy6G9YuB3sv z*bpe)nHo>saJjQ&?%g0PLeo1Khx3ARpKa90tO1|GvPb0KYNiH<6bEKLXg!RJFt7o&i1w6J@}_L@@9b zIv%e>QG>w1{pgtNsEY4&u^{0D7CLrnh;MzHBkyQ@=h_Y5JNCo(urP27rl4)i0N+>R z`aAK>F9v2;eT4kVVvpGF4s|Tcp?<&zv0d;HXXDHuwed)hy7-b{bxF+-wHbS$cHJJT z_J4#uO|fBg))VDbr9~ChmdC?Y{XvncU|dy|{c{cV5?cj+nEH_3mEggN9sqP@+ zQq@W3%WEZn$%EHZN2nW&qpn!fkVeNfA`&(T_Q96G-y{Lu&Z_Ty?W_y;OafYb1Nt|! zcI^H(Ozj+bTs6;c-TY@ROn~D$ciLH@n^foZOnL&OifD2 zbSC0Pf5gu6{fhO8Z8ACM95`(*$NTs`M%!BjfcZ0QFzXfjSuln6e=#5ft~C>k2&Q9tI-b+fXBtBKY6u#RY2{kUhk3{~OeA5(Grd2)m`-?<{OB`1!E5PAv+~I2 zWuB4-!9u6g^l)JUJMgcPfNozm{TSH3E`k01`kFR9BPK1q_M7IW7`P`0?W@qO!U=3& z`9Y;=VExUD=y_3(sk5}H?61nYGxl4_3hOoPDs3(8XbXVpSa$`yo^^qBlIduJS-*8U z^XI)tmvmA;g$KqlPhLkFaW-{D(pr6FV>r?!js!hyB=AG?mqyakFDagB_?(nWY0@&i z?f(BHpx4{Xp90t0zW4{ihMLbj-T$L*JIqmUb1xs(TcKN@ByhbQmf`6Z6=`p|_Yvzy zbAauP?Q99y67WhO4?!6>+Wot4z2)~OF2tWeeGbdMDs9CtVQTz!hg(u!#T#75X|GI27wZyzGs|%ier+N}feWBN8uqSK&pkDg^W@ zUh-~7$7LyANFK-J+;8=Q99+j912sAcrQzVU9rb3Bp(JZ7N}vH0|7cut73o(sJsU(chYw068Lfj=XGJX|dH zbxANPAzTbV9kkllc#O!5ZhGq0uMZD7#c>xpv9CfmsorBT_H}edMs^lcS;u*~=OgPL z>zUQr^};F<`}|y$z!E&T)Z4ygee10YaY=xT^G1e*t5;G_-d^*^Cy(CC$_*#uyh1mr z-echR8Dmo3NL4(~4appNuDX4b#vkm{y)w zzh3fZS~|uN;`Ff4Z2#XU0lnTPm-p6N{tG5*by=fdS}+v->)96+>_ELfzvrp2ku$Du z)%k;9s!(CQ6}nYIh4nVp<;+ZQ@;@0yWyN<_X(`#*K*e)GJ`_%$UnTi$b&%-^>NI`U z3)TVFG0BTGaiaT7!@A9S$uQFpypDB>zSJqE##qbM3VtJibyf03@L%Kd z@FZg2msAX_C&!^jm2*~Z{vc%am?t0TX^33xyU?wIDNaxD{~|+0@=<`gen@#*^YM4i z@(>%!@}=YT0x2)?CEj2hCyfExc3w-LHlOdt>~qp*JYE5feYYCHr*8258Lx(gKCcm5 zjNre{>2_p8cwqgA3=3CpEX<0jzqsA4sy>8v+^V17OnS91yE}#L zjnJ*!`Oy>n%rPY`Cr#H9Rb+jhH7lf(D1jot#Z7vTFB<;;f?YqI>fF9q@tr!=+Xuvr09x@Igbnl(bkbZyt#`(B`-p;YzkTRzp zh>kE!9idMhBVVF_)CqFTYnuWSfiXZ=fYz4pFp`GX5u(EkTb)0eHO;wlo`(k&y;xc; zuwI;i-n@KU*Hr^r9;%zb&Ly1ah0sl^_o(ZI_X~8dZd&z&Z58berx#eJ)D`LhhO3Qw z!gg&0Kzq^1Lz8RdeUoL+YeWYSG<1T#I9mrq5`q0ZL>KBuO<(;`s;^-;BCCh1N-u5i zcLM$`k(Yk75A*wFB#atyP1byecMaaMz8)0-J7!+ zDn|c{n98%&6Xq^u$+8xZMtz|^P%l_-I6q2o-t$6$69?x5tV`4lrsws%Mx5j==jXbw z>&c1peDx#=!eJlf_|5nSRlg%+`yzgN-H2I-Pd3>QJKU63JBlslo&wzc;cCUG%Qp0R@ae~`{Y;@-SuBmd_%k(Ut2ewab%joJN7o;_-)YL`uR7{> zCbOxp-dOvcTcB4*-paeVx&aydFZDk;CLr}Lvz@Q}xS!7s z#2<%TC*S$N{-~DWYVVsBeyp)(bp>}nQ&JD0^TqYALN}@2Bjh(G$2~n`kTbo*&@n0U zd!NE}StX5Yu)eSl$aghaSHU?u+F^3bz8>d$*#5Ka=NJITKlr}EAv%t;^WCl%fT0Xy zT!j65&gF6JRK}hgBHS2Yzp**c5@-#y1vp~S0q6v9%$4tny@5Ue#V` z1-Pzu8gL146>uByFu;Eg^P3?4&zJw)bp~+zAZ8OWA9{ zFcjoLAOnTTDd_dUBot^R6zH44EsK;p z&feHl8wEJ2Cz>1M8zvpm~{)>1_O?83kIf z0Q#^5Ynf4?Cs3e6?t+Z&ht55UvUm!7ZpN6}c8tHhga0dkfO{Opwcp{p`d_gwxq?Hv zYC2TyrVf?c$)T?A=TK8dKD6kxmB{FdWmM_zlNA>6nIL<|SdKL9rP1 ziT8&p7;`-EjI=zLeB>UCBQO4(+{<5_O|vCnOTd83_u^}q0B$J2{-4kdqIS^wf3l+^eq%5)9sem!oHg2&nTp*UxV?jH z^O%o(_4bWfv3+1$#x?+51*7lAc0$@M1Ph&qt-^CV@YhN}*O%R$0_#irj^Qe9>x^dO zc4jv2HOXw*MPGz&<*u~)BHKRt(-&)=f5kcViv1P#gXoL?u|I^aYT^3{dt1EmaUe;8(&(+;t` zX@}U~WyW4$WrNz^;=fXkVyT(!OzwgStlDBaQKr7D3x-639bX?9H^EzItQr z&uoESwLZ9^+v_*~G`}B+) z#lEnQ&9NELL+T=NuIOGKo>lZC|AN5!q0SFiDP0mDOYg&gl7y*n0&Ift{EMJx_bwwQWlRSlH`++5phiK7{ zEq#6U!`d&2>VxkccC~IWZ2i$g?>(MlWGwn2bnD&x=!Z`iB#?es^D60_WlzWYF8YLF zabrArJp4F-dPMsX3sA3y1JOWrfaA#2Md}o7g!D^9uOxp&oilC;o>cVXc)!5<5gQY( zzI(5q>-2A}8(Z~5=vKk`(GUFTCNanD#vqEODYl+iCHK!d*YzZlo72F>0IV}sJCfNy zTqUJ#=s&W2*>=``h|qbx?)>P9p&k7&>^9SlFJqF-)PJR(u>VS1f~h#8ZMpzHtzITT z8^U&oeUA1(Utlo6xm4N_+8@5(NZ*5Ukg*g5&snGIN%z5l^<)L~=-K&0K0eSi=RdE9 znATU?8=+eTS)86=kk)lJdcwO&JJJea_C?ZwDF9V11-Qr)W?RBJc}xKpzU%OMg6)Xy z&Rzm}xJ25WO%^@Dl(^6Lb=`lftTMy)m;bWz=#L5zN7oqOd#}(9qIQ6u4DKJ7p6E74 z>z%2?o$guq*_yeE80qo=x&Qt+Up=+1AMPFtJzc-{n<-`MM&0DOhumN29&({q%>6Nq z;Lc_us~w~5V1I-LcI{WLDUY0UPKSX_KVs0v7Gz?IC@Y{YHGB+ zc;kPfg?0@e56{d=b-E=Bt6dR#Nxt5WQI|yDXpsm^_#VD54;dw(hzGln`6CYTl^=n3)WKNCof@kye`$>B*e6jP>yfSc)?K3Jxb9KcJp7zGamPV0r5q^UBKyEH z;(y7ZI1R@>adA%4_={&8!F3PpTk9^+b$U8GeC|nL2_9MO>xzj*>}v?^tNfpB+PH8v z_st!TUHD^@<6Q@uvJ(3$bgKkmUkm@w);}|oyVLpmJzL>-2lC%9Yd-q9=(E4N5`ly; ziAEnzzviz9%YE5bWSIA{oh^a?PYLMtS6yVSzj?-7bJT_5>ZUgzth{3q*8NQ$`SYij ze_EzZOTM9*^GEC-3ElcEdi@>a&dI_~l78#&AMGb`tdVn7tha2t*lXjsGr8mVSYx0i zz_ID>KnySpU|(qlFb6>QMCAj|0sDcUfhMS+V}R>`HvsNqp9b)InppIe-T^XEkz0l$ zG5ShB0rg-|GSFW-1EyX9Q~SVFKlGQXpuaR81EWpr;NQXx&`*NVd!iNgT*0K=OBg6` z(I5Pdz~1^7Vvqb3@GuYksT-000gR)+jQ=whV7@=pp}ubCP&rPAio^yl5r-V=KiHdP z8GbhV{kPbk1t0d5IfK5_-686li$c{ieafhG{6PKQta7UF-tuZ(dPNn3@tLDJmGIw# z%Idt&tEok!YN>{?bydyJqSS?bo2h=6wo(0F=%hBc>a84S2C8Y(MyVxhrmEn`bUb7p z`@u!}NqCe}JBaar!j+a!+Ha_U;W#&9J6i(9Ngxjq(ofnnJ+Ph4gB@<}=&<_nu(zMS z2z8u}^^A5_=mt?c=ysMHZd#43b-(=5>bQ1`QU(7^zPz@i>!rSt8TQ|3?@PLdX>Dgq z;EzZk7Z*vrO`hRfZ>|5iXrCCahSs{`{ikX)ZMV{Mv-9Ay-U{8y1M2PI{xV=a96Md6 zx{N_;YklQ))N^z@*xe{H#w_*1v=&I%h#E)Qp)qE{V@WK<=M^abSCqJTqKP4O{%?E8i>{ zF~d`F#a;+q@)f_x{bxH9bFf>Q#QU=w5~usRoscl?f!GAv842?`iDO#E`MZYc#7R0i zw|!dz|6~d1?R)@CVADw)+jFn5h6}t6Vt@Rd7eo9ty(f?R+o=2}= z)_m-9TLQKOeD{4I{6#Eic;0t|pIm_9`ojD3JznT?U-7N? zPnhF!Wg^mQFSwqAHi6RyVjB=F>|Zl%J6i(hx&-nd0I?Ux=LW8?8&IE@t{pMufeUVH zHPh2TO8YK!t2~YRs;v+8tb0$$Ni$Pg>#fvR)>)~y;`5ezyX-Hl(|DbJu7`Pdo=e_5 z_vftF_)BBcYzh3gC6I?3O1+J|)VJQMrPvP<@yYYTRhzvhjUnqJvu}(0?B)+no$z#s zInPxMvt2^RsgFaw9q-Ia8<;*bCEYdLmF-M&W;+v7=DCKZ^kc$5vyOmkF1eO~Tx06q zSWm#Umzcgc))dr&k12d(T|qEIx02ct5;#Z4-$AJQ%8jQgR;6~s*pb2C(ANUX$3@L5~`oTc$1!iM% zpcMusP6BUZg6tKnM|cyXTbPHg>0qn&%-}suwJ3w-AJ<@ z-=}ZI^X^mXz&BVsQO==m!v2?810Cw^WIPOX0Nto7a7m$_w7;AZ_kJg7-Opnw^k{cn zh1T_kG)b-B3VFay#j~+$9`3PyG_l1+Er-IbDLjBsZ#}u77w%{eoB8MbqZf zjqvD;&`qlMcsBYHjfJXmrOwyV1%dUrT$3uQ$!{~Sb;b{yztNKcmw!-?g)aI2AA8pU zA4T!~C)A)qLJ*BTiUm~82#P4EX+XdLkpzf{n&YyNlgnMWyFh|1_E^xMDEzFaKSk_d z#R}FRcI>D>6#QGTqge8@{@-_Z-`(uwvUdrgC_DF=otZbYGjHE~=S|t!Id+rfOP`NQ zj6r{~yi(7x|9_fA`(=o~PQC5??cI6z?rs9S58V&Gn9lsLYw%_H-$s0!B^so1v(K~2 zBWqa)y&qjejkxj3C2uqmUvItoaK~o~^T$oP-DovjF4MU@cI9$Qy;WL?*YDAa+@Y|+ zip~Sls_mKY-;^%;1=&E9tPk)`A5TbKwysk+?Y62bWPBE0V8w~5{}&OCvPv$y^U{BR z)OZUH9w5UwVY)$$U1gj^K|#@*8W(2s(HY_TM;`(|`VrJSEc}cOU;utjN8WAL$hatP zu*b!6!cCV6+bw+b^Y`xm>R>};j0>i#f>d$A1Axte3)C;yF}Hh!@s1IAU>aQ6Qc%YS z+-=p=(}Qz=R)4WQF4hokj_G%F+WL7H>~fQ-Xc-qwSLN6Y7nohRJv93`4(a3sZ!KL>2Xd?XF_4>pAx&HMtw`)RWkYRi<-Jr&<&G2Eq z0B8vp@$kU8aXSYzIUW3T%5*n(wD zVXgsVc7ahWArHscOF*8-HeF$lkFvSlMQHeiJ^HPicjF04f5LRNG#h;IkW{~=C7j50 z$bPu6sDHS?0_vW13tWz8KfAlQkVjCY&vKNbEV@Bqbo@q;S4HP8Jc4 zZuQW6XEEy zzfSxj`-jWYZ$YJzVSU1MgBrWq;UqU4sPcM@v?@+wIoSKS??EbH3;hgR#KCeHm}A|< zI3$u|l8}ImljYaj<0R`kI!m~K#G*Tgt6hO;V8^XdGA5X2vduxqO;Q5#`}p-Y+T*17hVJ6mhmPInj_f_|SI4nTSBp&oC-QK% z**HbcPp)Ie1YF<&t}~vMrL}4NGG4N7w#Q3-q`Np`r%Ovn3 z4{Mv@#TnPC65X<4xgRRL#U3w<2u~eK`lj|gtLYwfT+4LzX_CN;KD<@?A=V%0W1MlV zD%H&&mi0>QLVKL7A{PRb~s69Ul{U3Q5cVyMe6Hp zpvzc-ADDv6X^|e5(~(#A!*xvCBp~A@^)`FFpo9l@T6n@Pd)|Ppow`9kgi)?a*U5BA z7BAcxEuee&y+Y3I_WVSM-y>^MdM;SEbVQLkFWZOi2Y#8(e6X7=KiJpk(ofkh2?wg1 zulsO*aDm5`4B{BGaDi#Ku)sCOTCgxOt{MAAjB`ySfqF{7xGBHWiW?zv^nG*by}OIF zW&g=rPPqE9uz2-`uSPt0|3}01tbt?ThUq#{y2!X0JLOc(6AroZw5jxOA^Mr>&BjmC zt((QGVi0{X8^#$h#cNJxbKxZac(>`A5Pohwz+;QyL&XJHhVDr{rW5HjF%A;^hOK0gE^pFYrUR z#Jh*c|5#H`PsaFIzQi6MS&O@i4e#u`bB{?s+_mm%;|poV2h&wS$@mzpRRw}|E*T!p z^hbNiANg=z?1DGhk2*)+fpH4x2*bi~I__J5nQhU?ba8O6-shg6i;MBWbXA5jKIo4RLp4>TI>!1cMreL5=ni`WepivV${QYF z>XS8;0q}a_K3_i0d2!vLu24^C$I$=amOgjW&jj9&+{4KpM;80AFdkn;b|BsS09hYZ z{0z$A6UyL6%HU(lU~o)iaLwBhOXj&4{Rr1IwDORcvElD>&ZRE$4d?p_wRa)*kf3kxUc36 zQFr`(qB{78xb`S~949)^5bZ2-o3#hfHiwaM&wVJ$z!gQS|U6N=I`Np4va*Hr-ju48_F6_Q*l#1DCFF-3B z;Dd1i{Gctu1$|o^lhY$NGqN6CkN`Kh`G&*#Od2rh_fJIqC3B=6y4^=i(LQU-O+Pu4O+vpUa5WD9xu4_r-tX|t={9I_4JRBJrM?8 z4yJ324rhpCx26PqEZ#puX!Do9(BX?2xpPu+Qd6v-X1Y$4E;1j(YH2;h zPp1u-^Ba8cT2E=Y{LE#l9IWehwNG>xhfgW{a%#U{hmSE2p5k`Hbg5|FYbk%~RIkUY z`8_nZLfJ5CJ4vLw80T;~E#^fX$pZ6mVG)lo&zZ>Um^Mg2ZYMcU+2bQZ_<84^5Bi>w zcfy8&=8I3p2h&v+TEIuMPYzm(6SW*U3~Vq?fDzV}a5)Zsq+yr5jG5P3DXT~>?-3VKj8Dx3jmsPkE4^N z4PCOBlA?T`SFmn~<%Zboib>Cal_wT^%Xc{Pz7^B#Wp z+VW?*i}bTcJ=Qb-)k%k9p@0m_i|Gb6c8xEuiJEs>WjLmN>8vBV1#(Mvor0Db^fQJI zAa^j?VzM~0=2o)bki~xzeNOgK5+a_1*9+A8p`>vQ*9F}g)!)$Jtm6R}j*FW?I}sZx zAI5X>bN2NUq52!2y4~D6&p&BM0hlAxhb-nDOxKCh#kPK$X+I%ak{`3@{nAzF;%0fxK|lD@)PkLr0I)z5bqlfOUVrK{HEh1Byrm~LT$ z0xj}kcen@L7a>8&`by1rQ-pyD*`O|9fe*ARxT$0rKjhVEaJMy6PY=xPKl?>1Zq)NV z8VOf-KmO=0d)#>8vFiCAOjqUCB5q9JZfbm>-q|n?Q19?VkFd^_`$X0woR06`7F}7t zmA!0_kEMj432X949=~1aEA^ZYrmHfv#fS8T<>tT%>YM8v7=S?->!rX4)8NXMf;yhy zZmUMdN&Tz#I9WqDI_s~r%4?op-d#QSgXyXq?Qs&@lAZ`BvOeH4K;!y^A9ap?0(A~Q z$H7HBr-AF3)=5Cd$)c6^I7xl2yZEpFfa{CrA9KHY{s+_5((Q4=yZ>4qm)O-Q>K_Ju z2B(7`bjAxX11lR&E7Kgmy#!>OtbD^BC)uxe7jJ&N?8HB()E{gv$3*8POjk>@$4Tr9 zOI4qsE@5RIf&PJYgxpVXT9oZz08(gwBhO#O+x9pqf0On_{E;#6&6JB@RnG@uy2@dT zIEgcN#l0$C)cjfs10SqkI1R$kFTk4I52cz35C_B9V%MNL*LV_;@sj0cek?WHEaAAQ9xWEK3z&Zym$Fm<{)x@KzX`HYj0eM}e z@;!UJtROrc?0K#Ko#DBQ)$c8tuF5rOyu^mMdKN9=29a|8!q1j*!#ah>EWi;A;(;3& zIS+&4Tw5anSKgy=HFXA;_-9m-SYl#8xB#&yG&P~CTYAl=i;fN+bY8{UYb6#$4l9V-9`B? z`CspP-&s$n=ZY|0eaNKoVjeQ0>K8S?mcra8As&4W`X9E4<30&A9s`qCPwVtikVJAu z9>-*VY>$`5HFVy)XLQ%Q&%CwS`65hLOKl}yc=+3Fz9iQ-*FTS6;L0@M0l46J<_T$F zWPHeeBi6YlBLNvVm7mz-W(DDD^~yhA>G=MOm#gDnrmJPP7B@T$j!=cR^j=Y}Yxvm$ z7w|jdU$qw6KP=-W@|itu#HZcGF0+Eqe`19`Ky3r^7+U>x3@2TTprmIiWTHNqTu!ZE9__3HtJ2UktgS2<4_H}MW9q0ChLAb<2n7{Bm%1z3WSu?0Wq za5*i~b6*BJ47*0ixwcjU5xRl#voryIkoQr0E<7gh&E?I`CsFB03)3e2aHmE0FCxqQ ziEr)kUH)}O-)q?Gr^AE=&J!gTN?n>O*M9$rEj#=|+6V~0`1F{a@H^Ne%g9%D9G z7^LOAxNYbW&LyD)iH#1R|{+rNAV6bp_}dS zqUOCR!i*!%8+|z&#vL%meLLK3$;fyq|G^$F%Lz}fc5JL$+V7eR)$>f4uF5VUUgX0~ z=;kej7ZoRX4(KO-7mIHbo%2oT{{l%4+)p+BXpfimgr~c^dv3evpoSv#d=sWqb{3Nm zFP76RlE(|zFY1*2mV#RmKprsh@_|l)MVyQu_@R5^-9zMmtda4u{AYW-Wc}1#tlIB_ z+kMCExGy}nf8Y8q)$>o7uF9}Qyd-lN3S}0dijwi8 z=D(@JGETTpLRrpvAy$b;D9HH9`OO|b5yDsTi{BRA|G@Tpspo|--I}}2Jg)`(sNd9Y zZv3!b;pYI3ShoO2&^K^F-`2*y^vKOjgeZ)kH3{&8n=kJy?mYC){)7$4QOvcb$3TvtO#`i^S;Ga+Ai5q6p=AMQsXZ<}Ks7tY3yWSo@;SvxkJo zsOOC^-O80sKOgV#5xQCCXHiF$AM3hXYKIi zK3~n3!`v?5a$0_m4jqee0xauPp2HByF>R25+^*Jiw#Q3OrygR@BR<<{^`S>(sOOO| zU1g!gb~P-9mw2Bzv=%pNxpEj-VcY;iu)r2vj$>@GOHq!ok$|jcvbtJvQ$hF1=aW=- z=^?zYp0(=-Ck>jUo=?JbwWt>so&(L&WhS+V&8*hI4b>PpLcn~su$l^N!rt3uMBFhs;GPv@qs}WsKmdh=~ z!MkK~$wE$Qxr>OeXI}Gvck|lwa}F{E$>lN~_sgbPx%#_gvv5inp?qY$fqS{_vp$gX zGaolf0voVQ=P(k$@0g8~Kt0{g_*jtu9}5o75SQ+MXW_Sn**T~?7{&+F4QlM#3?Jsk z&v^J;*TWv4h249Ip0D{j^xpT)ynbfobNNh76xIa>jdZ0E)uAxTo|8~Y4-RS?8*=&GZzlo<=B%L9#MQUU1h2nKCn?R1`i>Z z-_X;({B^|NkoP`6EPvK@BM(;a$#lE&m7Y%LB0~Ad`V)8q?l2DEwJ$YK6b%a;BRz*% zhZ4y#?IeK)%7^i}xR*UX(ldI9?K@;&e$Z0~oH@`epY<2hRkmb&s`!w*S`{Z)F@{B* zvtD8sWdIY7*?ba^aWZ&Edz`E~BtyJ(*SOC={^f(|XzMVH6Q&!~*wqdva+fRfu{;4E zwKN%;{qs}zoOMFMsjrzuF&|8iabWoD_>j9^nUBKW_VUOam?6##zI6W=PrmYB#x3)~ z^w#hpt9Y4@l?nJ*dRT_&A6WUtb%WDGI9C#e`Cz(1ja}{JVSI9DbT*dx>Q46ZC>xX^ zx~G5g<$+fob|vd{=7Z@m4h&xse8}p=vd+0a0Y6PgWQfb=f3$Mcbrbhd@yhfz@FT<4 z!cYCq_VPhlL(iX|)9cztv$$Ny2eqZrIX(&b$ndrBlb&hM&w?W}#Jabh`~J$t8*)|r zGM)KgHwk`Z7+c;K7Vc`#&m!Wt+ao`u?o~V@)ZZ+S@xyfHgIzm*)UEQ;@TuASFP$>P z{0~O%n^-RF8Y!IXrj~$ZeL4Yd1`nZr>99KS>cF!GzhpATxM8}=Z?d?tG%m_S*2}4T zSn(``^*u}FZau_~O&y;6x#I(6>i%Y?+wm1=OLG*$>bOeHXH$pO_TcPmwn|*aN%mg$ zIB6stJ^SMRdH-6lu!Fj-_~7y?%KJqgl-?wGbqK<;-^`&sc)LD|atJ<9s_5Cez&Sx~s>+}}Po6)@`)rmLLD zc!{&cBii#UrW=#hD{>iNgRuf!z%WMOm**`Ax0jLSmUEz0Zt6adMw07qSzY_T^3s_f zoo_P0a$~y6SA4liTRTk2sdB^j8ju6GGspt%2?laX)b{j*oA4sf`&T89+p3`%V#JLP zU($2PkDniF^2Bmuy2`4p+*;I9)_H&VLDu?I_bW6UogwaM8akj~{RjE#J_)AV@n!iR zmT1pv+#%ztp}##J>xj=Ax|WT3%m3Og>b?o4w~mk4Qmm@Ck&m-~LY3y03(Ng{rpq2D zeUHr$QwHp--5H!e$5h+VaUj#xCz0Dx9J~gqs@8U-`@HwJjEYXZ&BPbU40sR+{RvA z$nB?TfIVKz4(%a+pR@jsKjzjiQ}`K4u5SFKd{TQFUHf);VB;w9Ea>shF{arR%RlHIal88<5u;HEM!L+o97 z{;wzf^7Kz?Kh1RYX_Cf`<*l~$d%f~O_IOS$$PoJ;H0P!_bLZTn?#EzyoB4`$-Fg-e$gHT}3m#8jrA-SK){ZG3lIJE62Rs-LLM~ zV0xSRk~eQqCK0l{9+*AYp09O<86vP#j~>B^zxLpHAj^yC8_SoXo-F*WOu%2mD8j#Q z(RaUG^YiLv_&4br%b(H=Ec{g;X)iyNUA*i4r_DZYIKxdJk6=|*r8A#Nw@?X}$3!6dI{xO|0cJ_g=bho@4Ar@GFtxtfT6{9o6-1n~Of9=<+i`0D}Ojn<% zP56--q1+$!J=ThEA*}mB8jkKE4z282{?y>3u2T1dFg45{=8e7ZZ~^R zr{=qnJp9C@7;y1O%3%waHhL0qM%m+~zOaXwJAeDo^<_VQsO}?Sy2?y4cu|)= zv8hDG4Y0s%T`hydzzWjH7-1{{Gr$n*1<)PSb_vM1sXWe#n+nQS-cPcWaJBz)XTNfD z)$ha9{Ul6RIcX6$cAHBmlf`6{)i-jPzy)ImIDuizz%S2x5N!0o#R$HwFy;Yh&?52}J0)gpXE#w+m?HQwK6&loms3*(y zvv_Q*eo#(MUYZy{?n>fsY2Dg6>xhrz`)>cns{9L{*<~k+AcJ(^gXua^x)^+zMVAsQ zvEq@nSVI=&pSaJLk0T6&Jn@2eL$u1}RBiX}AcnxH~ zCyRYSdyx=-BHNi1$H}B9deI=~7|Q%lT7Wz)U5L*~8J z-HAd>qdH2xREX=B2vN9Jh-G`Ei0V^Q#6vHoh|Cck#Qgv3Aa=f^qgZ`wCo$;L&Z1y; zSJCbCZsNYKJLqyFk(@;=S-xi)TpW`xvDoY!7Nq}U-jqYTjEFo1KMZ7nt4i0&bZIVM zI;hsKdBR%7SYJi4w^}n&%Hz)!#0SdHB?}jN6?(Log#E_TukG1zTAE0Azy9D?_djq8 z`U@Dw8`BMH>}rFze7C1kD1^ekZb#U4%IFwDE7Dl-fz# zJvn53(+`F`47sF`T$qkDva#W3xHlLI8;BgI&8X2rVY*S?7qN!;fnoWm`_FPtO%p|r z?=U|6T6lb#o{~;OBp2;~=_WbqP_2Zi8J1|_u-88=T!6STj9M9CGfE*@KR~;4#!A4C)blFkL4~m!g2j?K8`DjSid|K$|QL6hliO zSv^_S2j%0f<%>+A>w`7K*RM~6r!Fs{eUbV zpVw12z%|Z2%e+VCr);712Nj*b|fIvNi@w%zl?e&NCtxFNgg7tA@ znU$~T`0Q{Yew(m-M)~tS#Z|Kl|JSYh_etOz26_>EFx9U)oeCVxiOuRTTEiU3}KD-hC)=W`j|tnRWlcPyiq*KoY^IykIjUv{ryVf1N{-? z)RM{Be*9_g9`Nr|IUap2Os+yVs6tHCrsU)OX+gkKgL#NctJOR-7pfxGkS2>P>M64D zv&+|0`EvfqTgF$ziB^0eg8^il$euE1cH{EuG%@^{U!?(>$QiS!7I=%$y^Q$ZiY)WD;3RvwEgzR52JBNb|DxZ|{KJn1ONRMlx7Ax`ims8N!qU>>u|Zr*%%T^O z%g>c_vi)<3aGLmY=WFMc^q&9Aljy+7@N+TUpvJDobIJX5Gr<>lEAYHD$I_o^crZ{U zr8l#Z`|p*+C)x?xJKR*V&@1)RQpAhfpZhj>#opI0AOFX0{a)yc02%PviLOl7iPELW z?VnadO=x@w?FciQ>M+xC{S{?ZzQS;o4-`Fxr5#nCV&w@~#8sCC z*L~b~I09r4-<7UR*NM`lH0bt+d{o;m=Au9g)AX3MVU#j~)<~v$J$mKxt+IYzPkh0! zoU)d6Fy=wu(LDCbC2t_ENB;e3p+Vjs;D<5p=+TUB#0nw7X{_JqD#rVLRDIDVZlsKm z!?71UJI2#^93z2Qny zk)@T?WGVx`iu_8=Go6%gy~JO-J28Lj4?E_8`p}~zxO}~Sss2A zvKyC=P}og!s0sS4ILP!QmcvoQ{z(6=dSWvisC3)%E4-mmjQmu^jTRid=tm>4(4Z{mh3-=lHmMcs(>i zH&V!QSd>KhPq>5KEmyrBEQgmr8~W+oQ+j1_ zIn0Mj=lJ-1RJw!ODFn)CnmIkR;9_YKeC&GVb=A8b+v_7Phxt(H93PjD>R=!o@C1CP z7z6MiNky)goT-WB@yxSdPoEpS7fV>WVLntk$H(Pkny2cNkgnBF@#>>(>-&zS#0UC) z?$|JrNq zPw_sDx)QN&BCVgT7w8B*F~Qn^{*j=`06$CNZV*9N=|CW zMiWN6)f@0Qttt@KIDIX7Sl^{qTlI;$&Q$5|A?~aB^r)Zfj(z@6v%z0S_e0+?o%3b4 zBwXjCck=$&nm?9tn(Ggw2S%|BgLyd(5%hO$7#E;_>_rxX6?%oNuOs039ZZrCHj$Cn zaTX9RAnRPRaMkxhE8J<~>DM<5oO^Hj&OG5ch|&QUOsAm5G+%Fu_g+X}E!FRn*F!6V zR(^m9TEY?8GwA<<)`~e1a(m{Se#*69pVaFdbN%a6VjTQ1-NFn741RL`-YR1a4%=x0 zAup{`L}|m_USCa6;~h3e4(JQfe&qcnkP*KF08TOHWtpXtpVytxgfLMDzR~jVZaJMS z_N8Qy1?KU37i|I0NbH}rf?Rq0Sd7Brn1kccWD@qd$OiAOH>atm!dUNQhphF!`kO-SGPN-_+zC^E3oXCP<0`^~rRD8oR3X8Lh?AI(^GZAtjaN_=qV-FVS0)X)O1c zPsZhXdJens;tGmC_~m^j2ahSG-93guJ>WT*9?RMA8P8!XC{OTev#|E9zc&k+i;RXk z*L6I0U4@LK`hEoY`36&VT&7%x+z$<|>!Iu4TuPveqi|iy6!O=Gdx&t+xFa)X_7G1z zoR%{8%(EM=J#3wx%~Z1jNV$CZr&f;laUjwj=_ zBUE`RS+tETvN>ey$?8nvq09udolGnzJAx9vL$;b4(oWQnR*-F=##Ba)X$Uo@0o0gs zNMW3sDa8HMsbuXY#3Qr;>3rIdcQy@_=VS?S_ufLR-A9On_ND)5-p_bPyQDAe(Kt|u z3Tj+uQ%C$(wh&VXl3pA{cs!EY_0h!Av9!;N1b9Ne5Kj%G_fv(mPwY4CijI)*LVPsRp0cZnU+QR|xtX5p zcH(CV^^=bhPM@LoM6b}}zemsbDeYnVQHbfCQbgySQ^aX>kjeSOQp6sf6cM=~MRdI{ zMNoB$Zmteu`%5~AobDY(;fl?A(C$+2xHk}3($N0%Pu1Hi+xOjFC;W^;b*ZaOt?~h;o`=19$&!lI_wH7aOR7}gcSkByJWKZf z$aW=uuxH0j_FrV*C%Ye2(CK8?lAS@A~*q8V{g!&xn7Y?HS;NX#@yGie7PZ8pY8PqSFE5wZp zgm`H&*_WwL`bLOXGg3t9F)3nMb&A;k&J^*=w<+SFqdSNV^E-&$QaXySW_J`_Qag#+ zcXkqQRCX2z6m$_s=5-Yfm8l~9L^p9t;r8O)p54VWebU4Y7xfhP74ImthMmP_dAo^s zuG~xXpSQ0VeaeBNwD+N+=7YiF#sB6C;DGgeJ;?_3)a!(b?`u!D$4lAjG;zjh2fg|B z+e4R}cV-Dmke-t)#xYC>O*R(1s34()4P?1|afWp~$as+7)6RWv_qQv@-SePcINb|3 zg?>z@pvA=5PZO9Ljx`^8Deno;#I%v_Vm=xbK7hlXWE=LPuCY^(ti{>s;`L7_@3dXo zuV)ZsbVCr*<-l~49CdU#xNzcLF1;k4X-qasgWhS=v>>eu(l*{u4fbjA4H5D%KiOwm z>qTAf!#z{JY`Wvf5kI5b)6IDEs?yD9LFZ9G_>JD8e2UuWQWhlD@J@Ee*N<9 zPKAXCklB}P2f8v{CrTG%{EPi~A$p%43S;*{Fq|6>YgN_Z(0E!KrQOCPMbBt=*i$*c zf}_H-66@iGf8D(P%&&HT7JR_KO`$8(b)s~M&(CnT&o@P1*{w0Q9f^9nhwE(x@d3kf zQR^*InI_J@>iLgnbSwQAsSDje|DioG-6Thy=wKS6abbJ4J6NathvyelD!Dxs*V~tm zOkW8EDsDOW>HWC?ln*Ve(mCF?e3!oJqbHU5Sd|1Hean73sGzv~UM`3EQ0W|R<)fr7 zM8M$Ma2cY|lh)If>!a*!dwG;)rHjKVuD|rOC$9{n-+|$F&2)nryV5>1UHW-Gw|{!6 zRvRv<49wEokCCRH94>#AQog#*Ry#FK^gZL@lGBIe?Bkw}mSl`mfd{7RMCoGSGP=R6 zz#Vqy)7!ym##cDj{bbeW*td)FNQT(&`rfGv4}3molr98tiSn5)6|H-DA07=sXyZW0 zHDR#+`T$zP>(dHpyJ=|blu!T~q#~~_KTx6RuRkpML!4{XACNipDvz5Qh_C%8dIk<$ z`Mrm_WZj@9!57m_a@0wJuMwJG3t~SCZj$v`Bk=V z1;_uCY81)xVS1Di(_`ScD8IPaMVDbd4VyXvCHj;FpK@^edh&34>Pv$$$e-&8MPbY! z?=$N%WBXl)RPNoE+cVr08dWl#f)*p|`3dfz*FD8Yn-2-aG=@(hs z5!S5+P(ih$sI9!a=E>q))5R0t?K1D=cOD(|tl0tVP4U1H)0r=J&ErfgAF59D`YQsn zLbT;CSTWp9+ebolNc&V8<zcYSq?UDCxXEbxc{4t%9TZ|oln6nUD+ISk|dS~lX1ZHot7#5Fx|oo1@eo>TfgdMVI4N17h66InV3C- zag!{U6$(FqEY>*qy$0@hs(i$C^G59!{k{^_gn2B}kw!M=haR*`l|JB0Ll9)4Q%_Ilz6 zCYLOpSKXh5xEp4#e)g%4-t7lJ4ASAM(seRj6n>07#@uRLCG;XMR2s+Oa)iRF~{X5*PRoHu8N!H>Zg>Wk@|FT3`9=?sB6)FUrJ=(o!KYtCFNuCWF|uQbHq zFJk>+c>^g$ylnm?N3(ur;segEAF2(F|MZX%8H< zM;@(Yd#g{b)(>=Udz)nCZkNt3uD$u)n(|ZYClPOL=`S~j9#6#g-!(p)7?=A+$RAkU zv4sa}ZGCb!JQm{m-B#NJ%VSfy^8BUgdi#E~Aw6Bp=yv47Uw%AtG1mv$64nKnuJUQF zuW7W>b9{|fLo@%NhR-8$Oagt=VRoMSw2F4$(>e-eEaOYfuca{f0am~dVVRo2=M+B%_qFxj_&IJ{)OhvNk_1p+u(Hfq_UyKFZ+p=0)Sg?QM^Ld-c2g9uEB?^exj>ehhtE;&J=wD}7VfLe&m% zffiG^V*-A2?Z(JK?gz4NwCAg`ce)7Qvqsx6WVhj?O$L}RrniDG?gK0=$^0x<_=z{a z`}v!v-W_}AipRKIV_e@!sC15RNlqD zOlLmWZHb=&wC6zYFk4_OLK*OThx(hWe5vOO6_=)oM;`cT>f;aWbNp488zlo*;EU-7 zHFl-*XUuoY#vA9+UQaM!EZv7F2D@mCH_Wcs+cWvaLm_1)_vaI0Sx5V6gKH@wj<>Ip z&+8P%o)^`q>F^#jy0|GNmg_U~X6w2iZ7;K&7rN%V46)0by}C_os@rG1nFqgLWxABL z?p5E1n@6YQ`2wEl*rYusK+DMV(hGZ#=x(mh2=N7zOBQ-kthsva%EPnuZ3X9 zFds}esIhB|j|8|fZ&CX-$OC2Ym;+&0*{EST&d#sir-tqBMVy>o_N({V#i?nx_ORTZ zDsQ#oMb+2KpY18WEgzKoQr`Fbml%p#AGbpfFf??X#9Gk!a6%{3 zS+~YAv=?AN9H7$u}MidX3wSn#Z;t zR_iC8{MsTTH6M&uQ4fx3odh;j{j`pY_Dc;Mm`mX8m+2PFNq%os__Y1_vGR!?qU$v; zJXG=I$VQd{&oh{=K8i7Zq%ZhAT7~}gGri_E|Mel>a5CKK?xRM&`Sn@sxl=5uS!PpzLsa%`{X;Bw%ipX54WdV7`gch5(D?^^$?y}re>UjAMB zy#2;+w-d_|F21W`x+)Jt-;Q$6bcgg42lzlFL)j+3&co%Y`P+r%dt^V~6OYDm>>>?Y z#t_GC%dU)@%;)TJQ#L(aT(bJRtc52OU*a}}hBk@yK&Gp*G;o8DNDG2q`d>5~+ypi0 z{1BP1>euc0LYcdD9dO;(FTHvjkEK!99jV5dz7c#y*S3*IgfhmunEXAMnztHe+^KXY z-2M_!>!IZV%7^Bt$=33|j9MfC^*+i1{8}_ZjrZ!KiQ#Lj| z_r>OR!Dgi-ix<=}=8mlY*=?4gLugkCv{XNkKiZkv_PFqkZPT2OY5XQYf|o+~oeZms#oiT1rVA zkoS44QJxde0Nu>zlp(hs?^b{G-2ZKNC;Tu*u_?{yMlA0W($9^{3(yQn|K|ug7L)!$ zFI*>m$RN+-R(zOP-u?f$FhsZ4K)n?&&~-RID^ zJqgI;{PK?ykMkeC@xh@7JTUfgmK1avdJL7$@yU(zo6n~rlmXB8#G1r>opr&pT_clj zewoW;@>ZxT6}Kr?LYd+{Foj5 z;r$!aDQGbUf0m;0mku?wZ^otnr8BqA6W`&A;3BWF8kG_Ez#9<+j3Z47r=k; zuxX9_is`>p{*L_`Kda+95`YAf!F)1lSeo(D#-nk1)on}K*4(3(mrVHYGA~G04#}oV zMmA0wM*@xn90@oQa3tVJz>$C>0Y?Ik1RM!C5^yBoNWhVRBLPPOjszSDI1+Fq;7Guc zfFl7%0`Vm9ci1O}_hzb<-wn!senw8uVaIhO&>j+S_Mfze6rDV_v;>mbi;zqjevWu) zb50qYwl6YOC}tzUrFY^&7CG$IV78IbMx<%=SaYjfFl7%0*(Y62{;mPB;ZKE zk$@usM*@xn90@oQa3tVJz>$C>0Y?Ik1RM!C5^yB&&yhe|&+WkZk2p`yF`HHbZLJ@b zE7TXP^A1v#%*KV=T0c(v**Li;dv{yv$EllSrMvOzlBpl(yzz~fb6az8_S>~pa?X8@ z1lmsm+rqeQW1bQB+TCv#$F-D98cw^p+?IHf>9T)Q^OdNqMDd%NKPP`j0*(Y62{;mP zB;ZKEk$@usM*@xn90@oQa3tVJz>$C>0Y?Ik1RM!C5^yBoNWhW6=9a+LeBKk@-LQpR z*v~F#IFkcm7l4|JRv*fDi*HzVbjJn!IPshnzmz;rGCdd1rqLKaBC8 z%^jQ3jaVUy-2Q1b?rB~iNRQS3$#YZT zN5+Aw`{X!&4!9~^4a;e_6@P>tl=0IzAx)Q2F3}(x{Ff{CE;sfT;_-p~uOP2@t>X{* z!Ry}|!T?2JV~?L^u{v-{!UQTalUj0_zto9V{-7haC%bZ>5bus%TTWi_ z&b!xrH1NhJ2k(mjnGCWW=*o1RC|!*Iqb<-pgy)KpRfP1?x@s!CkBfC59_$nuV(#dtKw}8pcR5H_%Mm9#dMPC2(Li#UWE$Au=xGNA04G#vY z3>t*N_sIXtTYjRoo!5UmNN?xWX9+QF)brVkuTK}jQ%C*c^7R~a>Qkse{$l^?fsH@>m{5Ywj#mI>#G& zrMRZ5x->9d^LuA&LA@Wg=(AI-`UB-wPzH-WB0WE{>A}3mX0nO?hb{E-Qi08-@Jpak{S>?f}nKqG38Y8!sukDdX%egx-TUr8g`%Rx>ZNK$b zFVOq{mH9#pDgWutzU676^r}9=or`+E^oC}jmD?}V)#pjJ{g#kM!M%z48ML7+vc1SY zM;2{x7qTxyFB#U+k7o2CAF7WMOoP?01DWr55zaBb%?-JZ% zpumtlkByVbYJr(guM;Z1UqrY=9psXQ8*d!!dwa?=AJ04WSBln+QD-SarE|Q2yU|)z zAXu00_Ec)FaoS9`&r9=4nrs#ad|pr809OHxkzM-eobQwQ%JC%TYy8xgKPo!o%@gFY zO-FhPrgOgRCdXH9sLt;x@dUlqVe`g%a(UjcocMxad8zFbacAED*@72ttor&*1js;M z>2zhfPLwVNUt_fJtUz$OOYc$(++p|laYcGJFX|~Rm!DISxcoI|?s`S1TX!6Mnb{~& zes3zD=~B_U*IK?_bkJ9%`KN^|^>|rNtxTf)mCrr1W^Dh9UsRu;>GtKT&+i)Vr@7Rj z*)aK)?w}A2lmW}5OiL_}{fBfv+S{pLM^zq7x97(q4+~&rKGr0`#|Z7J?$?j)bgC*B zrrYz;OfJ#3Be$E(%Ea=xxLf_ir3Y5Mq4L4>w(!xsmJ;_TYB_BUW1I*bfIbE;tf8Y~ zE|DCgNI=GKc3ooJJTzl)@U07H9zVIz$OtmtgCxy#C3|7$mEl_0Q%OC*j2bNz9;bx@ zH9?OC#YSBKX*s$nLK(&D*N{K@IPT{VR*g)P{c1WV+;$15^@F*X+{TbI*HPO`aqeuZ z1l0OLx9_xtwo0@8?{n&>{bkyoIjZ%8b)!Vau6^0XCCb-{Z!Q6~elXs1WZYa%TZ$5| zel|BR4jx*TxLQA$CvA+u{j$7e|HkCIt=_BF5A@sL-Tag018V)GQsn^iD(=h@^Es-|ca`YkHo z*#8o5jH=?4%WJF4^GJ2B-`4!L_4{&205VQdhgeI2iHAcYCU&hSFRy#AJ0pfmy^8nm}X`U+~9pb(cb z69|vdG}=ftpxHVdueTz5v^O3Xz@NHk;z)*g^!lE6H=Q)^dF-Qr!Tt>3gXua^x{TBCCWiL4>2DrFu0nTc>`X048_MV% zUq!LER`Z3BT-KlBEPFmy5g)tH`+DSIi!NTI^1*b81>I}UN4~qdTIR<3zNqinv36r% zG)HeY>Aky)v}OOvYao7u_xX={|IwQCxh9Brq*5UlrmOrIZ#rEC-jK%~tZ+~9X}LaM zz@uw;ez%T$66t3YXBMd!k!pt7)rrn!lSx2+kG7m}g1X2h3l};~Za)+hIoC(l{t`KD z6#OvIuehpoolF-)zv_+0*qj;+8BK{A(&!pr*jw$>MreL5=ne;h`981a509*%7A3c* z_2*jg8`b-V3-Q~8g`&8DgNR7nKeCGM)Khm)p}}1~&$8rS8!5 zf*N9l#w6ou`>21KYeaR8eoG=8bH1&0xewv-23#1>Vc0c7EnkyO*K!Vj?-;os$h^QF zFSX~TiJZgcc;{T)wN%9m(^Y9CgBM`M!HFultt%|+m6e1Ow40Xn-6D$LYvE-dUU1GN zzoF-hePGZlOjn;SKTuU22zkR^(jA6UDatR-cl#@_6G+qbAdMk{6|>wy4fpmXE02$% zy|^sIv#BQ!k8_GIwCZV$K{0QUzi&8c*3hTE>UQr@(1S2=Q|QWcohV&m_$Cxf>YBe{ zkma_9%D0mnvK{f;EfYtbf53mZ2!oGa&FCC&TfS?!Hy8>R1w7Ly(xzN}hA8)2wGGzx z9&f%n;-?dTysjj2BbR6N5-CEZbG*@S8C#-U()K79K5H09+qmjz(i(OL!^3JdPmS?G z5zQVf`*g%b)_Q`>)c*9yvDLTiHUC8#p&EwyQt2E&QJaz<2x=~avyj1>OXozZC02Jp5j9)v?#@{@va^4>mJ^n<5StOgG632m)z;e4s`@onN7%?!QCrj$WxWawvy=pkA z44p)lcDzEt%Q|Yr14u^eCJOQI6(i4rxC-ui?8{;IymcP-;={mAp)1pMqI8MkWms)E z==OvO9#vy!`Lzntb(*gtKTzWjql^eyZZ``Wo8z{E;)|(q{P4eJ-74p#iASECa9`U0 z&3!w^taxApxMey8Ehfr`6}J*s*s$apq3ImL4+TiA9}H7Y>h}+p%r_#?Ubt-z@659^hd7;bM!p8Ju^L; zvFTCT^GJVK3(`JxS8@&7#kc29qmGI;E^53Vd{eb^mH%xuY^SH};A@C zUcSJ-oo8Q_CiZ^t=_|j!ern29kI+YqWVoF(T_;KxZm2G!-)?O?FBm&IKR~*{PqQle zY`bEU_2UxD|5$HZ+h<$v`^O6MZ}ecb#4ES&RZ9Dg`~9>3iM0>aWEJuwqJ5*4uT|(A zZ>~RRVdK>#wQ_yA$TA4_cCUuz=XLy! z1h%9E zbj4}ks(@P=Zc7_&%RQ}R%Spb8BoLv>!?>K!(P*z?TEc`($9pZu*h`>+qIupl_%^Hl zRo^!)zac{my}2pQu|?7dF9ZAStt=uuhU zWZr9S=jyy}9qECA3n#qtouG(%~9IFRf;3WBtCmX8ZIR&&jlj zXyK-(E%&H-IAN;<)b$F;IFX#~;_c$BB|D*HBoLuQ+^)sa#P6a1N_paK%0*V-fNH!my&>|GXk_{sY*IPNp+i%x{>k z6QzqX&S~jAH2<+kD6GHPqK&@Mm(oUN?KzHV3&!PpWWV&NQ7`MrD8cbK64=ZVkk==d zFSE95b={)z@iejf;7iWSzvHpP3vc*N=akzu(^dABcHQFpXq$!|ccG#^+qufK6K*a6 zRaYULNWV4D#i48|3CQhy%`^7xymon-`1$`rU!OMV?3y|Kmgp>VJ7>E39PQE0<1I`$ z?Oc^~`-ahm*AAO6oF^?9p)D5u2( zd^=ZvX9w}sA#p55-2)rmsB?~`455j8SL?p*-A_>Uf{jPW+hLi26 zyyXXU)Au9SM>>gfK3qI`0paMf>4)}Af2i9v9o{ug=3$&LU1c*7POx!16n0lt6INih zh5i9pmyH^h<5WNPF`&KJwSDy-C;ZQqfZTo;y=Xl*fc0xRDb$(UW#3&!@z>6Z1XEXp z`|MGvr7mE)7Nl>jDT8?WULJRtOGs)_al`WZ zc=f9>{e=9~b*h|~(!{^BzTLlH{ToltHFM+VW4c;M^!cp&ZKVA*{C&4BfH193>0fro z(^LG6?5btih1Gl1FyGq}o#P$Xk-*j{0eSy)@f+55tgcICy_P06yg%jM9Z#D4zbh(x z=#b}j%yjh`m3G|Xx)dGMU}?y47o#ZicYU{Eo&An| z`xbAeiO+X9p~<6N}m)b8g8dR#F0-86B<9@_G^f4Sh?hfT(?o`Cfvrkmub6K&sd z<{9+g(sU9!54}t4sx={M=}ycuPTc3q$2k+m73R~JV?d{1p3L(goBsU{W4wU!>)eKd8FOv3rWo@ zS#E0C@xlv;$j`eV!Smw&E+0I%N1mn5E-lgOWGSkCorSYz!+ z)%{?7|C=FJK7Uf$=M5*_wVPQsFpYX(y2O(1<#QxUa6EU7j}Gp}5!FGB&fdhbEgfl8 z9q@-V-V)~Ylac_rEyLwC4ETY4;Gs46qvRWHHg|a&&G0smfitd*RWjNI+6QoIye%-= z3i@Gw??c|rW}No2*+iXmLGpXboKLL%UCwbu#(6lidkD_~pT3^HHcj+iGxq;>-%#_z z_dSh~2gYyc@0hL@te8c!?x7%@ajF!7u!zdj8Mao z=ZBa>Vh)OSBex~Fjq&)=%p%(MIPAFXCjl8ReZR2BOT*`B;k0zagL!m?WR3ce$pr|93>dtS4F1? zj&|4T`jBVkF8VJiEQ8Uf9IC#F<(#|^cmQ6&GW?0~LrENyqy!dGI>yi9Z|w1t{xzLv z{ePYdU+Oh(l!_mwtHrhrKc(*KvG_MB&veeu!4XSh>vWeATa2UB_4YWb{5DOT_wn~j zB9m{v0c+VXtcRFxP-EA)I4Y(SP5s^~{U}rYFG-C*4aui}QNih^Mu!#~2I>E@;<92( z#TE1n)|2J2P>c)5x49*-mi8P12K&@CMNJ909V}0R z@4MU|=I)ZY$GyxK^R3c3zTNmXnt_nzT>GQFoSW8Uhz!qn|MNjP(ahXFl0& z4Zl&LmImxQ1Ik>MbKjrr`CjmGhB*6(C!RYhaC(u-H`AG4cH4<>Q_A#Cn=)qo*zk)z zzw79EwqKQb)#}fKFCJ@7vcNai7nsg`vYRBo`X9V0!YvIH(Z9XLh{OD}sHqO@RDH?i z$}W%pnZ|PgISd-onUBR$j=PZ(klXQ^|Jma!rzuUWO_}&j+6&sVD!!PmveVA^ina>} zSE{79uCR=&!N1$%YQe8*B69tYJI;9VU$f6KAA|K4)77U-5?A_5mhpbK$Adp?qq80G zr-Lz-)x0N;hbvx}U_He;i1iVNp`&EObeZP(H%FcUWD8Z)+gY5)u$O^k5>pTIHMRn}+XbcWoJW=X6Ndi_4`e zbfo&8EJC{>cbT33=j6ZA$KgF449l761~qm~QqGECO9S+O(6qI)xscU%i!~$YcdQ#Z zdOarhE#;HfwHrFw<7pk?E$x`nE?u)Gu2AvBboDvf0Z(!Dzk?%H(pxqx>(RlT?QvB5 zd4|Y4=eCMvAJpAjWGVsHOH5avCP^HbYKYb^=s!LE#-DdJS4xz*jQceS_|5zxL(Crk z#+qZ!ILfc`%k=iiJuP*3fFW04CW{8*HIjLJ#(@obtsK}M+ZRAtwR}+fY(oYq3 zwdcF+>kKje&z|*{{^!@5RKA(MiTGwQTlihj&7R*TdY{{ zH@RDFz8utS{ah`tr7-$l*@As}Ue?lm4!v~}u;`cV?eUbeUAhRAe%$?&8;|Oy;)&^M z=}GFt7Vs2>y@MlFuv=MJ*8hWh*yCuy4(Vdwect~0@+Wo+?5ONpVY>Qwt-(?BeR1OM zwavJa`GanPu44V<>}QdsvvK~#bUVKfS(Isyt969CozHmp@NfRNUw0K(Ojo&SCtO7p zl{$}9%S$Hg;3*j?wJnWWKae%7W3~xIeh**vZiX2A$OkETM{ekN zfLR*eC}IB%(@k>J8Ld?Xf_1K9cW}CUiccF^MdzBjCI-D>%~j%^t%(Lo$>o>r7AyZp z0tuf#x0v|)nhdQVdn|pFw4Cg5v>^U5+4EC{ zIGnz5*+6zVb@DgRha{KLM*)a zFgkpob`MIkmk_7!BgCQmk?ku)fIgO4?-Jq>I&603AWA!g+EtDa{f7zh)F>fdC>CP$ zL?OyfCf+on`{^8xS@azB^c~A3LgdkZX1Z?{V)niCEKdmW&C5cBR||3ccS79QAw`_F zbBgHVN)c0rr-%p3Q$*i0Qp9K1rii_sAo|)A@n+W!;;BPBi1brBh^~zt#P`p35LtiH znYTkaiu=y&DE|9=N3m+hPGT=_Co$mJPU8CgJB$A{b{1cB>>~E8?;^^&bQM$QcNGU5 zmMSh?ohq)K*G>2*Z6^k0Z!d=Kyo2~Oy}MYlXAd0*1hKPFPsDl@FPVGA@IqCkf6Gdu z5KUxHnKQd_72)ZQ7gy~vyy)KpsY-N1)u-c?=_Wbq81tiiw|}NP_$I z`FY{J{jTEjnLm}z@onL+gucwB1Hc2MzFX8koIkrN*3~elbKLfofU1AmH+Lg9)Flly z^tJ#$hv5Q$a2*q00)vSx_YXLe409 zrcL^ihIqO`oor7v!*r7zb@;F<^Z$xl`adr^UKPh9&6}?&y z8CfnThxyIf&&scQ9xU$o?ZXX+PMgq_(=#<2K^;RU(v|5tQMxGn+MNfRh~cC&G3$2$VEp2}kW>xqBxlS>vZ+AhYU zjWou8d|>}8R;Be6L;W+S?{j{npn~WyG_2RhsZ7_2(uL0%JIpnrx<;Q>jj#66|3%QA zx-bp(E$5uA@0++EyRGPjx?a9l8@ULS4=z+X$J>_g(m$st3V5bZq%SBmJW~!?$b-ja zoDW>cgQiEeCPIR1>3-WAZ6dkdqfTTCI>)hVlZ_Ka5&&=*?~4z%w%5o7Df-;3{QEBA zw7`_%_5IStr~|LN_cr&9lh3`*5FhTqIs(%TYU~=r8~a@2fURJuJ2YM21t0x*e{7)o z?|t47un5DLG(yG|G+>hBjPYg+uX0-WIWLvY;Y9JAPIcRQpPG*o-Z~_J2^P2CbuMfB z#rOv6Dk~4Cal(YDSqqRWlFZ9pe^DEu{X*hcWCPF}y_5QI$!=Vbi&lPEaMf4%G+!n<< zXlN&BA8_S1L&0bmeh15tLfedtoBBhnxPjgWZfa>Q@~?N-JXuzqF2WrbE^DlQe_|IL zXiSEdI(6JIT_;Kx*7mXURGBiG4*8)Cc%kWI{rS~3to`{`nXk-jd%l`xq>HLQ&l&RW zpn|#EnG1!?7t=Xkc9{!1zNSuX&X~+s;i1-XA;xV}$u@l~M8gSpFI%%mhRAxev|{05 zg{%50d@-H*VK*7RATMfx9&E&=B~9HhU-I}2?P5!}jYY%*>!rql)_PR+(t46-m%H}A zYVeU$ZvP?QcrJcFz;uHeyIRka^1FSmlEBpP823!?G+i0F#stE{jKi_V2Yth;s!4n4 z!wvn6sa!g#!^kT_f|B)=te;|~Z8~4PdWuKebR2BmIWH#m7)Q&Gvf@b9Q#psFi@tjd z?f?2dhwaV(U2czB9ezwu})uTFU5C7`x<&XMKMF4Ng< ziO%tk+ddLVR6i&sUR}hawGT&5F0urYsUJ=+*NN=sc*kvj3Di@T++XGlv5r$Qr^0+I zLSy(tPaFRhdBty;|Lzscy*Yw;77XgC16`S}6QxUju&z2Ba82+A!!>T-aavtTO?7o3 z80I7mr%puHIsnUs_!?EEo&~nGt;} zy+-VC`YiH*kI2H$E?-A{$mO7nMl&A&>rp#2@jC0;ikz?RsvrG-benDrK2wBB=XmC` zc=Xt6`X6At1!P`bW3*YsDewLtmS0ek8~xuF@Ux!yLH@a9;X;O(M)0~bdBttFtvdSD zrtgn8_%PC?P->92#>2~sX%`=Q$DL2{XJtBnD3|GSneaC& z7ZXb|Ja5teSLGP%xK7=_g!B(w5n26m>b>{C4`V!cN;A3|0M z4(zmY588oa80Jf*bG(JGd^))~s8#5U=~YT4O(ng?>Wyon*IyBs6>=HStU!$0H`?u| zsbuo9V1(Qn_-f>R zSY--%X^q$)rq30yxJ2!Im^(o2o*LTyR_7Wqt2#I2_PcWN*WUEbrh-nP1((c`d4nvcHA(Pu zX8()tzO$#Bc7hp(`BCW{Z^IAm*$aE2aCGS@e98K`GB>fDN;+KGsq-HdFL1fWaz~AUBmp?MpzN$rj~Bteqv1$eC%@ay~nj<|ZVTyA+@;^z-lfA`5{lLpYvI>T_eDxKrG++lu?&pne? zNk^2qWCrRfA(y`@puF{sY0`?kcaZPGnI6$RFd9dMa1W z7kSEhEPYtw`nh)TmDets+;b?GYw(pKR655ux5AcWfrpR>5~I>} zS}t8tPQ3B=5vNZ-v9VyE8})={I;2+V9N&x&{iT4;hrWgzp@dw1gv!Ufn9GMBb0T@4 zYv{cvQ;$2R@O)JcOsC`)!+05AT|tA#)i`mB|=I_~`UAMoowtk|@AJZ+&QJ|T8 z3`XN1#<)|)@6sgrIXGj|E|0(TLbb{d(^Y|F7%!Yd&q*3kk>|-vM-Gx=xfX(f3gF?-SIegz%pTAY}lk~e=l^}gpGAM-tZcLf7E9!6KD>qP0&GCyb%r7S^g!i@<} zm#!pe%5O1Q=5uKhd@h>#-f180;Hg*nWV*!S|Fd@;@KF?BcoSME0s$06g@6s)5kMgd zN92m^-xq$!62xpfG8GFQ7kB6L$IKtf(rjw zkpK5~_ub7-HrWlKSZ?n3?e4wZo%#07o3gW0)Wgboa!&xzqg9b?Mzq-8kUH4dUPRwO zNz)zLVBFY;r+!NWzWQX!6AfqFGMQ~%v-^mkoURdF<$QIU9D+s2(BzPBRHGr?#AO(H zQCAWS8Bum^si%B7{pH@p`nVei%O0aU z{#@~0gZ3jIPP|KR(WCTq4)S%DYrclI!E{as$jYg85d#!l<9uj0&kB|G?)+?Tfv}KV z03M6wd&tLQb5vEnQPsI)!}iFB`cH`;ikoo!R6X8V#oWGHs%Jmh# zUaWsBBQ5gjM$yWucb{+S8}RlMpI)!UE@jtLA7eTD%llwH-KP)@x~OuauWF9g^U@@{ zPVr>9@?6+>@-tF~y8Z58KZ45g1%9soVp?P!{~h*mAR*daRW>K`O+Cc>L_fsi!|h*; z&X2y|e<-n4Ve)@#N$uKkoUo1RfTACL3>7Cx}f`_Vbg%+8O-`2o+rG5FC|kBl-q zUz*)iDb5%(_1<-NCh_^xm}a|WPjy7T^DvoP6P31SeDZh z_4}c?5#!~^F$nt{*1$hk19JMIek$Sg^UsaXF!Q6U0l9ua-$l3%aCDi3Lo?Gr34~NX zp#HKQ+}7XmMxX8Z`Rc1aUdVB%)gdAjmdj!AR|lR{3E!!yHwtxIPIHgL__`skOqY9N z@WYbGCl2F7$t3_3j@ft4k2+22c%Ea?_Fi-$99`EOTb8RrVN(U4-mV;Hkv5A;wmVDv z%voW)vEWs;4vAM~PCO?bS9X0^9@0Pn3KQ$Mp)-{qk&YRaUll%cI5c1tKWy*xKEm%L z6fViBPYgM}M*A1u9!?F&@k4Pyt}>mAa`9NZE4)428i;|1l)q8CQK=u_vFG3W>Q8l3 zE~d0WaV5teM5?2>VaVx{ynuU%Z$7p#N+;bR2e?2CU+T;*oSp@08?NzoIT# zrd<)*l3aA+fALtnCVXtvzzqE5`fp6Wb^Z6nqU$G5A9rVk`Y+3kzKi43LjBkVxcq*6 zZKnD!J~vnFXSfJF$Rz+2k7oT0>&5ME_Tqg*_T8%+3SD<1u4Xy@8k|Z0H8UE9{*Id_ zTI*xP#shPoxq16Uwl~^SzkHS(NZ?P1M+JQh#dn>tMS7RM06eO0y-p5G{LlQvbVcX6 zjzMz1hU9!qdp;(4*l8Mw!H&zNJ+PDF=leBX99g_(RkJO5q*L)du6UBQJwGyH`R{XY zS{C)e2b#7iKRgS$BFpjD;8LA_|0J(3OCLz+z_?2cOY83)=l1y3UaDzsjJ>38i`s25 z*fHM#_?-Iln7e=c;p2DuM-7dm5R3Km^d1~jXzWi$T?DB=Tk^>mFWSA)*Em#G4!_BB z(u`>p#*NByx|W>GR~rb!vojjQ4%>>r-9?a}ChDQ`B?w544~>5k>N z+~DN!X?Tj30cn?s{cPfjtix|qnDW80C$>}=pDN3lgdBb^w>MWEV@ab$wO({d?i?E2 zrw+TQU9k*(ltQVFuAKuHn&_01NhUgcIK0uBkE|({h2By2R zhM@ycg1^XxEl9@(mu@>9}@0ktnQJs6L- zmgW4=>CQ2JM_Q(@V9Xd-R*EM$Z}I?df!{^L7WEmRL>}vH@Yt0+zHHhAR8CL;07=gB*^Q??ouGoX=O8-=%n*`m~WbF22y; zMZGnEE$72Zv9bK7vXk;Saek6>C(TNnb8z9W5UY-P$#Oo=!Et@VkPoZX4xS7GBebc= zKnpjO?ge`MiREi4_>oHhC|onWjXrqK_%D)Q3dSGvljYYMVQ0E>&fyvE_3<3bTRoQ^6YSZ)jaoH5v}~S^}1SreYSr`Go1+YWI6NW zeNA{K`CKmMSppAPpDQhR4sRZ<^o;-JgfFra;*03RJRI|6xh4&5E9I$<*9__sU#0MJ zfv-|xzFT~wQE!TC<0+TI>-Za*D$CcL@M?LBXyxL8AJ1s>(uuD-vNb}?hvgwA+EJx^ zNGa6mQJud9VZe|{FXDPsWZV31K=~VmNb|Q)UrKskA-0%OUZFK_P6cQVcSxg?UR+M*A zkrv%pFY0EjPqkc8-u_lmeu|Aymd}h(o~#?GOkNnN^zqeF9>1=(vhtHUO5(%ylx5}h zm0l6YDb4mbRSvc}L3w5C$;yJj=}MjEoxmwx8DEs94E`)f`SQ=1%Il8jl!Z6!Rkj_t zDB_fN?~Um2X3NN=H=d6iKWcWZO9KmQkH4^S-JG&x=}A?`Rfn2Z29zx zp6@N7d&$9E)U7O6#n{OCtD#&{(;Vlo$?hR8e-}ruBAP+Uk%2*n+T>eVm_bM#e36Lk z&YMdf=4JaZ>yjG8T5Oqrs~Oh(H}@`i@AY+W4pnc)hWX2KK7XkE>HWH|%R^IiVRo9z zpJ2Vff4dF-5uHYqe)wU>P0Ww^%W^({sQme}{7|e=o3(o;_(r2IQQ<$mFDPF}RQ3ZmZC;Jxb=P7A8 zCh@?`Q)eXY#JRtCny49NZ*B{RKeZ!0%R79wbdCPJ>Uqjx8 zahq#x@VowwZ#K3sTCtGBXMVDr&)1M2s#Tde1vC;~ZDCR80#s}8We9-nA@4S8z0OnqRQQTILCoB1$b zSX@f2 z=kqn?slNsr^jT(u=Y>yvG$FBDx7(Qq^OWU$z9u}?sSk9I%CKj<99>dTpW=I+ddm%W z4lFwTUHW?<;HGp!WxIbREsl%5qgGY?uhkLt72?q9+F;q7v$y8#FMB=YInq9 zM|{lQn@A@#k9rJ1?+Dl#=An$g!D2Fd}RA2WT4|K-oSEWz8D=9rf(=kpcx>dno=To!J>D@#yu7tI)H z4iUY_rpPPrPNTlec)gx@fAfrPd#7`_%uAN@`D*b>&35~tI=Xi)z;+lr$H>d^C z3+J8Pu;IIOFFEEV%eAu=<1v^J=(~|w`B#JYnmso7pLhG#JqxDgRIo!?UQ_;u@?Nv@ zE^Gbwdi>;tF-h;g!TebNvYgM$c41flHF>X@G1vMz_C|fQ=z-qf-_JbxIb=DXKh)DRq{2<*KNGll-z5r*9P-$O1t2>#TELK$nwL% zQ+}_Bn`g~$#{AoMHf(U_Qyf0)QI_-hn&`2z_nPfCcwX?t@D0a*eIqr?tB!ffaz0;E zo@VbgGv-_C^ZDryzuIz zysoPX(Ameu@&G)baI5M!!`D`4Pkd#^TxGf4|NIVT_xgXsb>jQ(7RfHis%ahX8Ew&L zuXf`YdfumAImZ|M!GT~qr>3*W3Ua!Z9N9$zmMXwB)&+ijH2{3On23R4KJ*Lo7vyLi z3q>BI1J?b&9Hl+#mF>OI&2dh9vQL()feRbrk)ArBA_FY#T-iL*yKL}ibk^dRp54^q z9u7+56QRg*K3@rs49^6QcakTiH(ytR15U4n3#!gv*0+sTZf^A2?4)0F6X?4oIcguE z@8K+0g~CRkj}nU`xIO9FSZ*)NpXjCKLDeCJLkc|9rFxJDGoouwd_QgaVAXu+jt5>! zyrdwxU4?#)vRwCGvCT)#Ww7#vext~1kqus-MHfWXAMol6^gWjx#TVsiYnONm^0dLBx{2%D$d4F+_|bTnZ1CfLygSC9n?hj+^z+n@H)^4EdR&#) zJ~HX9JBvHvK612=z?S8zP}o@WN5hFz9pI|v66%*sTGYeqA#VZz>vxe2ey6NCC!?hN zx0y0OmXn{Nt3JQr;wODP1-XXy*}Nsz`aA#E=HH)p{lH-|KbDK!=(q;_hB|W!DlMNW z?(68NjlE`vTK@<-uBwcrGMUR|z7Ha`-IVsCjQ)q6wFcs$P_lD7^(WFV#}UOL#TCUN z?Mcq@Lozz%>v0%%VGaB%HBg=O^G{X)rDbxw=VS4|dV#*-w9k7nKOh&Sz!wk%hL!bax7`anYR=hF+cel4dT zxt^;%XUIeOf9TASIWpvb%dPcueC{w;M!(y7%KBls%+gXnSU?6VTe=4M+!&H;eD4j| z;Nu(ldy8)E?(QS=VR`lWpwT(QFLqh+`p~_e{VB!)zn90XFzSoy48%k1KeK4*gi8;$ z|MpXeRmXNM%lUjI`bzT__*7dG8VIKsqi#6wqO_ysoyPOwfB$U_h~?fElzZe70J4?%UQN{g zpPMdFls|^9y^79_{d)KOOV{V#lBq9jK-Zmwt65Ihh)yn#sf%ZCSH6p<>hz4uaghuk zHS)Y3EF9;atk#_Z@PzA4g{!U0z~8YF_=l-U;-rNM;xM zKr8ZVwZ^Eoz)caV-U{)Sbnv6?YbeaP=d;$Y>9TtMLY)BdYXQBnTo(s-Rr9OJ41?*% zx(i+0ZA1ycC)VFeiJ#g00^hEFs#Ed_DSs)EUzBF1WXWHG#SQLX#@ul5b=}WzvOTZ7iL!mAPkm|ZyDqFC7b{G3(r6)6c+{38TE>~mZU^80Z+*{_%VvIFJA3h6 z%g*)TYyLYL__wB)LybX7XY?(U>b^BebB7v!_`bil2G)Wemw%-jL**YeJIL$T2f9UL z4%KBl+Fj8tcIGC{nxb$W_4j2t{u*4c{0pvMj}i{AgLsd|$83DdriJX?o_xJD46VJM z?oD$0{Q2k{j2^G~__VBE=D>ZJ919=p^Jxk%)=k=gxN}L8<5rUs!}r%@e&C3Y?Ofs9$SV zU#0wm9mRLp9Xkz}#n0hlL-8Dr-Pt1L_lW%s4`;lD{rYEWAP=;;zEp_xM7EUx&^`ue2duolzS5-p z+Fj*1pZn`CtLtU-Sg}HHc<(MEQi-&Yt`X3-O^O) z^~UDt?`N-1mcwJYAu#-r!gJ92X}rc7UE2x|Cgx}I{q&#mEY7!hZ+4w5zocf?68c9l^^ z3rF$o!j|Q#P}l_Rl?Ivf$IL`8FZZYHLWfQYUz{(9!p5tD+Q)Jn_G;OS{dj;T(4sMY zxd6JkDPDlmIDLfm0ra7dMv4{y6M;!UAwV6HCIeRk*8nu3@^t`B2vH171*QSl12+IS z0yhEEff>Nf0DVNg6}Szci3eu^vw;%ecHj=+PGAmj7cdvN8=!B=H1P9YU>-0ZxDTL7 zOCA6Mzyjbw;2~fk@G$TQ@F=hdSPVP{JPteoECH4RPXcAYGT#aD_#D^{d;#nLb^>1lUjbhO-vGOSZ-MWC?}6RG z55SMWPrx2vFYq()3-Bwj57-a<4=4wI1AYho0R99H0Dl1o0V)h4fJmSgP#dTN)CKAR zQ9ym50niYjML>=N8Uyq)*c6BcngPv$765gOJ^^S6P~LMQ&>A=iI2kwvXalqbVt{r) zd*D>yG~jgL41ned?f{$xoDG}IDn1-ru|hq0iA&^!1=%hKv$p}Knt#12wVho z2YLWBVE+=JClC)L0KI@jpf}J5NCNr-$p8)Z><3&5^aln21A#$6Dlixr0;B=yKn5@r z7zPXnMgW%qmjhP-R{|q}QNU=x35)?Ufh@oUj0MI4*?=1u4@>}ZfLy=>c!50ND!>Q$ zfqb9z<79@qf90lW#k1#AS~2HpWS0q+9u0q+AJ0GojifscSKz*b-z@G;%39z5>1mz5#Xt-vZwO-vhgWAAlc$pMX8UUf^fo7vNW5AFv>ClC)L0KI@jpf}J5NCNr-$v_Iw z54aTQ4-5bX0)v25U@$NQNCVP=3}7fgbqG|S4fBDw+F`60*GCjIpnSL`Y~th}s8~>< z51cip>pffJ>(U=M+DBl^a#bj7g7u7nu6(RhH399A)aZzT6zcTWSQ^5YKhQPF(9gQe z29J^7EO_Lc5x+E(d9YldpdQ-fQK8;mjJvrW7Q54^9}2r3AdY)+opN8shTEpCZ3a0x zx~3MkELVlXCdf-~pjEY!?kddJuPMf!!!MJXMRg<&Klw}J^P7cV>!Ztd{k3=f&2soG7sICGVE8HMOh*GH zdgXXCC!k^5p)P|*N^^o`~8o9$acbVx<+*B zC=z#mk){M3^mk2ke$!OFEdg7~&Xt$HZ`c{Tysw)o3&wUDmFkRE zx?b0Edv>=gqg!1#lCDts(R)41RiUs6hTqHS$(rQO%Fotk%Tl9m1QQdZI zNgv{Sj9#>;?^LyMo}QWVy5j&!PbULs1D60-02H@W$37P~Qu#aw@%Vl%l=o2Rctq?q zjZiN^L{2^l<#Y$sX?mc1AAz#vM$~s+MLBp{gfbVEfahP=oL9JvgF}MY9-x0 zzRn5F>PL|tDend)^&Ki0-``96MiD}aUypcb?O5^ao-xtNt=s-8eQ-~IDgsnT&rbSg zxh@Xwg8JqIy~ArOD9%c+Y;SD;T%I(9?@(EAyk`>}6Z2?*(gVdo3jk)Sv;tZK6enb` zF~F(78NgYRV4MpYBQBw=x=_@WP}Dn6)X3wZ zOO(%_KvA2ZsNGOh=eDS$wnLrZH0bF})Gy9P-S|AzWjdj5bw2cVA^g1U=LkG4G%b@;T~~dvLxM z);($!p`LCI7eDO6iq#l=&NwRxYWly!k?1Wkg~&{}Ca>SU$sy=_pBYNxEf_f+N9ac3w`v ztx87ixyp!53zTg)FI8?xT%}wS{ibql{g0LXy>=@dKl)3_{i0b!t0^5KzJI4@#3}oS zN0gqBA92oz+auQRDvNmOm-ix$d*Xi)C4JjQPC$)r$nk}d-)vYMdCIuYBOmI1Vy(;O z53BX|m-p6MGihh7r7w1>J+0$Swa-ZWqIRF+#5%`KT2iOhy0&${X*jR$;<_>Q@+Ur7 z@6Gf2MZMHyZ&a`7hwEQ=(YOW^7R5CjH>-7{1Kk=Qx1quDji=9uZIV2AOw-M$KM|eq zU6ba^7R_!ke9n0%tZ1~mW&H&kPi)s>^GTPDuG6O8Drd~;_y5rTs&!ACzO&0i9p)!* zKBxCneLMazV45lt6K+k=(*>`+V@hxa2!6%HEC!ohtK~LF&$ElORe`}8JrNO zY_wDN$B<%ACK4OmT7db*{~F?lte`?a0_DH7U+ZfY0^M99w18#Q}Pv!4F0 z+)DKLqxXX{#2>i?fZ|22pVPU>J9i`%Jrnmc9h0LtrmZYj#n{k9K3Ld3$AKA^)ajob z3H}L~`a_-3!cU!Lb8>`fp$z>=<9@T|b4h&1Deaz5e3-*yKC+z8SLBn9nPSGd)VW9m zBE`6Y?3VPh(gu&)^S*!nw$oPb;Bc6SEa&qTc^EYzh9CF4wH^*$JG=X}NncYli|ROh zSZN z<>@x5%{^De=m8R++DJDn*TunIMLuaRAJ$-$l_T=V{?l47&ut%mOULsMY>(GNA|6rr zu{=mXKd8t96LKMHoH_2v>VdA2VqDMq*kyyqGn2n=^?K_wxT*;TX=;kZ+;)=^lV45;WTeYOW|wG@-r$c@M$aT{stP5 zbz~RedW2D{;rKD?i`G!QH&cnKGxdcQ999k zR;?lHEAWuzrabbzK6M6aAwCuf;b%7t>A~##?4I;!CF-Kz|M;NaEjLf44z_Tl2l{@^ za#bj7Dz-mYHBP#}(??4_NrSt|J9O6w>M6EKw3_cGKt?Pm4@Q?1!+LSQFFkYa$Wykg zhgfwSU$UIfTl2(PKLySlSaym(B{w+3@ISqN&1D(u!D>&}^F36j7XMq_8$KV_fSBJj zZEBs4J9qi;n~dXncqx68qkROnELVlXCJ{47x?O6wXPSB%>68|7MQgY_OUwMxC77Q)DElnr3@5V)2 z>;2rw)q}=*7yQEEYy4_qOn_0&=QUo*PCre=fz{<@hJAfl{Vm6dSthi8LB+U{%e|H0 zL-|MoKzr^_nT)=FE4nxO8X}A_$UkFVo!DQgpCvisQyW{Bt3qL8uBQPQ5O{%l)eLMo z{P6Qu50)PqkC18tP_Uf-WIvD9e~SD6dV4@NDqWSu z59#MvJLW)p26N(b{6D<^`)Z&nJNvt_7VV0T>Ai$yy#Kp#4)f78@K3NavLOQ36^VJ+ zu1E|299ImgT<h)W}5bCU(X-(Yq0iX~57Oye(S!>!o)tj?7$sK-MqI$xqQ$sb7a!qt@;c>-UQ+__UgZ@fkU_w(jVZ zd!5XOX9-Jmec*BtC~lj zLW~HZr3&?yJ#FPBza!Sr9-Q5-YF-pxv+s^y^UAd^1@k@PPwNn{T;xQ@RrAsYdzkez zA%7{Kr7}G1j=cs%`&HT-?SxF6^38H!)Xd2xrPHI8@$LF7+_d$98~Oc|;*#=BmgBF% zv7P8s2e~I=l}Nwekus>C(=(xnTT*C1?f|z39o6_|v0bG^;QqK#GYz=kLSF+cwB_?M#JkjQyA0E zS#;4$ZEqM!c|AF@`+C^2Tono%({8yZ7<=ygo;7*F<-wD{Yb+ zUp!otqhp*V!2GsI{79)|f$|;rPNc7Q8Rxyo>mU49Ukv3`9r3#i{8+AwgF91x)a;Yf zrx4@u)xr0dxqM!=e=IbYiAiM5c$UFO<~iduqrI8++x@oZ$*Ci6y7W6HLOe;EvYgM` z;n};ur_C0i@|RemxiXWqt$P^2p80k--5Bp?dW|1&-Ys2PzxO@!VZO4Q&)eavtuvB$`)SKB&kVmo{booWFh5yN=g3uqUneVm*=JbmZ|CZdAK5c>W0Dqn zh@ULy^VQ(j*@|D(nb!O=#(&|t#+?$+;j{i^IiIfvzb;n%7TMr8=!N*{B_GVDs+{VW zpDgF|)!=u&6~E*T*81D%m^b>%36qy__{>k1^Z9Do4Qe(()cNXK&T3pKAKe!j|RCi}%&w*UgNdm|w@8ZJl4Q{W)>h zL)p!GkI{2%(qAX=V>$EUy&ZnR{8}xRC6-ctE%Gft$EZ)Ua(dJKvwFYvVTXOphvQq8 z^Lbl*U1OaEIW*( zqN+(R1|Czq(fF~o;3@JT{fp1BrHggCxqkPFoBurcX4kWS(ioE;lx|qANkd!H=Sa+P zqMA5XpA2b;>#72D`f#YJCYXkd&uTgjfZ8copP>-LN5?_~0T_auKTzB>Jr-obVOG$< zKfRw)g$Fte0%{YW_waBV&tXvJzsw6md($PMa*^6Y<@ImYj)+zY$2UIi)x~3<>rz4` zqE;?ZdlSo5p|GjY-w<7PT!S!F*6lH!xrT2Ir(@PcXdh0;Azg%zj2Z~17o$GtAEy^B zr>b~9Ecx$hAe>$*#(g-wRMbgWqG_NQJN~XwjCvyFsR;n>sjf(UnKyO8{Pcsq7>z@v zV0FS{UyO|%M91W`JUF6)Tsw>T&t17*Uy(!G^)ATG8&r^wSu=v)A7gMKx9u+ktDgI@tNML14?QQw^?NNAmnu(xH|dVcFLrgJV{*(-mTPD6 ztm;Q7_ZW8$P3DX-GWc>z3l;PE06dV}1=wGD_u^wM99|ia#p8d%^ZeU5 z9*O)ct`a4M^RG%26BhqtG;k!+%dvR)>ZC>bUPKV@5s!}r|8SW93=RBS(#zr2Hm4uj zi|qo3JDjk8|11s2^<^5D#E$Y{wiTAi|5+a19~ljZ-^ojb_6f7^)3V)T z^V2Xfmfk`t_5&>$Y0dM(xA&AbkH0I}Z<=|^^25i|K|=|Xe0V(aGhBYLW9hw+Q1JTYa%8h*cH9xN9qsE1Ya7*gQz;CtmDPfn4*iEcEr zUy_r4*mmid5Ozmj1C_*w8C^4Z7Ao|_WcUk+E6^LY+8$%&~=y&ewMpyy&6;g&?sd+4V{D~7PY9IhAk6^R@SBa%lSNq z8=SdX4_SQPsB5hCy)EH^Q$OqXbA@?AWw{(~LS9~QjX*jlm#f))!x7qR`Z+?L{|mhp zzq^)5cA@;P^*KzP8>xJ@x=SuSe&LDpJFZ&Ws$ODyO&O%`fyixHu1P~%eH?h7!aRIp z%|(wxXO1IbqSKw@9FybHP7dgW%S!;x4`Qx0jz_1Wa4aCsuRP<5)VTZsm%L2#^^+qW zCt=HSRVZw1@X%*f)@~B@vPj}XW8-NZD{-B#p2i5?!ka@5?NI*ZRibrTwfY8TiIX%n%nf*VKY4S+= zZT2jGcUcSwQaYk}Gs|HwJg>s74VI^oO^SA1Tx=`{vT$DRU;N3GO&4uBX?`QtGwo^J z0+!>i!Rh@QhPXVKnH7Z*P4bzH`92+Kc}|}zR5X<0E>7>QrW$#e)#qcDJi7SQ-@eml z@8s{B-q~+S^32Zd=$IT`Lt9y{im|DZS7MF}s}1IX9>`{; zXZu|KY;O)liy_|PrdjLj=B|C3Cf{186^F~bWI3NV@ZwJ5>D~!04_=9|<(L!gXRQq$ zPsELVW#eZ}gY{JAAn_xoh&+<7x7J73fp2xXX7OlRrbTtk zLzeS-gFXZvNd-AM#D(=CmRnnF@Q7P*LF{X@-hYO}VIH!a&l`BKHrS3;d&$TX=PeQI zd8s!T%M0qGME&ktor?7)wr)I+!ua8)(T?)IkDf#QA;^)P)B2DsSB1i+Z)%34cbDFs zI_qmE^mk2k(aTRU!0CCD6fU)O$@9q!|It0FzNyWYRVPUZT5{udoat_rY8JwTbuml-8B7c={5rCmgPdw>S4x!1S$mmcuhtn zCLt%so9V<0v!jpGms6y^zmCID1HYqhUcmrYzR#WM*L)D|bPsq@cnJVKFCEMI$z!j4 zbl|eavz<7lI<^m4&gavpxqzmy={qSe!SD2FQ`tE2%7gI_#F7}{V$n{EZ?fjGz2nnu zYfqlb-P%;H#8{Tw;F0R|<-2JC3sq}6A5kw+Sog$AFF!=gie32d<4<#VtQT3%=aXH| zJndbG3V;-kUKBa{c⩔<$yh@mx_8Rony`8y92Z9N8VU(FvTG`EiMxjmTS_`mNIc? zR;t&V6(KP-<3fkte5t=J z;x8RwJJ(Jp$oqP)6D zQ7&8suJ0;J+wbrkbt04tPK{7r?;W9Z8y}&R-x;CY@^XYSd4Gg5HWm*6d%%!C%mQp| z-xz(jwcSkWR)5q}9qyfVFp=)o-V5kE7RxnhXlr3NT6=e}#oIWKM^vdbpQ&v|E^9b% z`F;)&(FGTw$Z|e!lTYw7aH#DnWZUFd0N{4JMK*X|diGmmuOIw$upO0o%5w6XTy=T& z!2-6tI2he8<_B^2SnJVWp8wuQ+wc3PaSYw9#cN;ak>#2+w6)-e78;|zL_X_n@R`5* z!<)XmxAB<&!Cc9azB*yca#bj7Ecj&Ps}oj-IEj3Q-)pU(n9akle*ejxj;Hi6iO*@^ z!*YR&dT7CCpeuip*EhkO&n_E$zWS-jb(hDF`-{V6dy?gR-h$7dd@R@-Vq^Snk~hy< zKlknKI^o5f@xQ&Me^@3yNzf0=nFsGJ_^92R=vpzJl=;>?e*EQ+XP-Ffkr!niEa&if zZ-CcJ%R;gbb%jp`?nefT* zqm)g2+X9NfWX^1Z!#IWqFH(0Hz|QH&)e)s-f3RSdxV_S_$>oci;a zyMO%Q<99YUUv?ew3t&U%xm^&VqvlX_7iE8a}rB zWCSngH@~hGAfRp;GT2+^Y&xJMcpU{9jPM-28v7YgtP(t`2!y2%u0r5R^7vAeA zy(9p%r!fOmFW)i%#~ZeF#i8>0nLT%pTlFVTW2g63sZ~Kv*OE&}O>v~*s|A`;v?c5u z)T?fiD{F}Bssi+j^q=oYD;VQ<=H{W78?KK5sQjaLm8hlB${W|d{nx=X_wOrwYkwwA zV!uh{N$Yl%gXW^SNOxtc>M5TUJ^daIl~>Xa zoR|CIzEg(cn*%ut`&?{Ut_p<>e-Lo!jgkG`W6=tb>+0g@lbe@cWN3F^TV}KqV$%$W z8(2@NJ+|Yv7@VKd@X2p4s(t-?)GkMkXwrO#ELVlXrn-7p*F{6ebHCT4`Vzoa)PGIu zL^X*k;jw~;VmeD*7K%R#hvE*Oos@E5)Xd3rsWLa|%zZshyd<8E$!UBdD#*37_#TCh znrO5cf+U3wn&`Xfb7gwzLm`ZG7&_d#`uKcaANK+`en;6O@S*ocT)kZQ8tjsl1%K89 zoImUWKXM5Gg}e4j&Aw85Mk!-jy6Kd1PrqMht($*k*6Hd$?Ybton&rAUxC`>DIO+ZX zXQA1=`w98#Du#nRni3tlg${Ego+ml_I`cZk#>S!tI&Qx}JyOF8V9U=jV}D=Hkr9p3Z;i%=0w{#E@1C4KBIrHOvupd7S_{c9xcjx&XLtI#}600wGJ&D<_%n6BJD%A5`4jR*}Ezppd z?evUO%lQBT67y@VTxQ?H`(v#EIey44YFefq>u35mgx0*Sv}9=Cq<(h}5z5Cia5c;6e$fT+sYqt(eI?2!5tQzcvBZcrfvARs=HsaB`#IGI$Q|xD5}&_BdVaI_ z^)EVp^Zk2cxBSWb#ZWKQcR>f#|&{zq^R zVZ9uy*r*t803xpU2c&w7Tz{gwoA3GjtK%>EtUZliAxCjZ?VBuDg~CRkZ>x7fE=|Lr z^@vRJ(x)mkz_G;N*^!w!Y7}OuNXbQov^SdAvs~&-J%;a6aT|>9C1&kyGg~xttiEZh z`dx%*5Wia3vRt619-8uVdz?9GXmKm>+v2qeyvQX06khS%Qnj66Q=+1DAHDB!Iv4*( z!PY0|ce{+s4!Vxs7g$c$h|Y|c+KHU%c$Km;*2~M^H1d+;bNCz4%HS3ov+AV%@&h;Y zwg3sL53^k4M8{^lOyaXby_24|I-q*F2nsvw4xa{!;T5O*^>0<3t_pF!;NyeK%aqSr zUZzuEJ7KxZ%+yXo=}Jk}!#8`+ucLcL;}7h*VqD12v+Hf6-OK4Qd1JKl)x0Ne>38PH zTW-KN9CG|TEZ3x=t=aPg(<3emz_{i2tkB(|BT56+b(9Y1y_xb3+8>G^xa~jf0(g41 zj}GrvZ67n8+a<)ksMBC|Jjbj^JX&feE7Kf8VKMPwxhTY ztFE7s?_c%b+;Z0G9TNEa2-#5`q;8heHKH@Mqfq_K+J4{}^DEq9v~#(>wFUeee_nUT zb=xO?^0WTIgzcQ=A~!lV;}@)NS+YBH`<8i_{bzgUz1cNkS=Aa4zn3)KYP26YpCq4J zH(9yo_y;mNYgcOJS!0xHESEzwvmdj3G95j@^l4O8FU0!`hf<*HEFnDP?RT~&Nyw;A;$r!xx1->%+6Z!akxHh~ft9Pw$6Ez4D* zurcEkN@p?~V?W{bHu#L)dF%4#4HEX#_hWLz=QwOxt_p>X86Qm+tVdH*5&C0#3w)U_ znov`{JAf_cN7)}6^<-vGts1ttVf_mkpET9OCSGJuEZ4=sof$7Pdom>lUqpLXKC!l| zGhXT9{&Q8wKKw3B{OW)o%Y(%915JTW;y;EoEfi>eN|*7@`?G>nos8o-@Bma_)F@H*Fz;f6pt)7kij1_KAJ3OUqje$kon z3E5GIjTm3qpBs6Y#n&CLzVY#aO{WcLtOv&N#d47Y9h>nmi!V%eJc0U%r(q6g&p5v! zzRJOi!eRZGl`D&`+;iZhcP?Homn$r{#Y>2o2S zx?$4AajPDcQCR2;*I5Y_*9HHW@C)EEjIY9 z_0n6?1 zs>GgzNzaY;q@Pp8jozj#8+cPGgCHp^}CGTKw6d`iHF9Op}B_B3)p&SWK}yx*yM zM=pxL-?Wx08)_k^Kvir51$r*in>0z=xv0R{{9-8ry?5S4{ z76}_PX1q&Z5d^)?@IHyVxqi7`;$>z}9ZrmIe8Ux4g|yxQIpWn2Tb8RrVPnS2%$`ii z!5`7yM}KW?SF>-~G%Vtk5qo93V!1#~Jv8Mf*p(e#<={oGD*H<5^mw1Z@)rk9mF$b< zst3Zxj919MDr03FZxZ;%n%5KKUVf(6TTh)N#%DdmC(8v&>Y*7gO%}|zv>xES-Tq9c zFH5Z}WMgTZEbS_OCoO|-YBUhy|A0;VIdvnuz-91-4ipS}XA}v&Z7w z*I#+ho2@^LlK8OP4j(gnWK!aLNAma9_BK8uJAS~78@I{!#&TPH1bZ{%u?alLvE7^5 zQ`_3l{?+NuccMR(?1|-ec!cbUSs3kQ^lob&4|ja2=g4z&&!)6Vj_ifn8Cb3gg^itj z&FPuwM3JdF(O&jQe9Y`+Y~SYwk6yFCT;xOfEXxHd>Y*7QGkZzYNs0DS_=B~*Jl-qs z?Yd<%gYyTnepqgck661>O`IDMOyYqw2(W$KE~C%q`=Gc0F5yf@_~*iBV@lJ^+(WR~AF{C)f6 ztSgh+)YS#oVVAgA2U0;x1hm$@xR|aT8=N43slrYGd^Z^WFUn*MLSY{ zwzi`;yw42!^WIvMWnL_|#Y?cGs`!+E4>`7LGdp_feb3{4)_8v(FWC{x?eGcNk<7;U zo)!CxHJ?u#^n9dStCb&JqX$fOMD4#Ux5G!WBV&7lBOxmbgM9p0w=&aZtlw^t_?g+& zj`4Tg^wx_TJbJdR+BvPO$8tOT%)PlQOyWy+#Bw`4 zLUzO~jO{PmB_3w+(`4@xk&Acx7weyCRlP-G%W^wB%;INg99F~(wjvnqIIr9~p3d$v z@!p&<-KWZS!*W}^gm|iokMf&!eBJM9GjYSK>8mcz}{(k?EHduqf;tcIaE+S9xuEVskM z%zjidxLHi!0q`OJ6Vx!w)AuuH-rZx$ednji>6_)Y_y~4m#-qa@M!lG&?`c^xdlX!E z$!lqny|CO4kC44E3uF3TYlFv=uE!ppbYAnl{qzW;9chu}c6i8kA|z~m#ILcOAN{9M zKW27wqch^uPviYtIDCy>gd)rNyvD&nm2B>~jHOB|j^7b;ogg`QBG$vp!H>dA0BCPk zPB{MhY->X6(bHu+VmWRzI8%P29hoT&K8U>>wXRT~;+uM&UkJ5rC{w?to zEH{wCA2VKpT~)%$Sig)vXyhfwXXz=;m8qZmu72>t_AC181qtn_|0v5V;nk-w&*j5N zB2T_E2lETjBJCJIuCJ+_ilO%C{-8ZVlGmG`hi};Vj@W!}XH1)<`4|NSQ2kOKztKt# zu#*2=?(u2Tr>)gm;ciPw~Za`Jso# zIr=6#)YWh>qnF#Gtt0H9<;OAO8^)=*C%dq$ai&k5PD72%tOBfQ<;vBjNGKEdm8i1` zhSHzRFREp8Wy0QhT?g*k`GU-k<%gA@yy!7J7t5WMku>{Zh;MwaChGhbspl%n&%eE> ze&RSeRoVLapCk8)-;-M*U9w#DK-diMj`w2m=d5%uHvM7cp3I^Qnqo^!0;FQ~>Odv- z&0dkcnmJi6|EGJ*WTL#X^Jd}MksWUT?1XuwuL&RkPIu+CjdmjE-@|J)Q+FM-{qS{%Yj2jHvfuy4_~&Ok)V)~#$JI01kMhtL(OK}gq)szsil_BF3ZsAL zH_P7n>*WQW!j5W?)ZUzcnm@}`p|C-|P4o1jcX4Q8_W|xqpBEGGcs*HuM`%_=WZ(Ii zP&6|i6WkoqI)n5sLj6{#&mld@2>>ly)eh(Y!~z!qNdT>OKMuGSz*2k4v%sf7Ll{XS zFdf(m^ngLF0Fv+`xF2{E31%ZIWpz+#n}UKm8G-r`Xj25*9f3w8(5G8tzSJ1ZoqwjH zjDVU3UZ^OS_feF+X{c|x;Ll`5d2bHRuRtES4Qm9}L;a~|gfeYfg!0z=5sIU0q>`{C zQWL^eCQdjxi9i<#_G*J4cHB!F#uCdavaWf@m+wsaHzShcp zkuge>HD@U0I~~fMYvYvD%6coq+NUW)?$1&ld%Z}xJnK%SR@PI>qq{y*QU=$FcrmF* zM7KAui>N)|orud<$3|{_{E^7b<1VPRyu*%K%Pv`7yL>=dofGHos5>_~BWmv6;~PA- z|NKU=v9C2IyFiwqt}`gwkJ7Me``HBh`gQpQyB{AMb#vW*Z&9@umZRlAEGL=hLiW=O zbNh_*c?&#QcI-!NCF1O|7mY_Y`8f5=O3d1v0XLxxT@1JJyhH$2Zy%k z^$Jgypr&I=&9a;ofOOoa(1iuTTy|0~-sfRl;(L|$2B_H_mGS%?f&CBfkFEwpds!>l zi(Ky{W_S1aqkH4mPg||k8nk$%et;~O*{eM{)T)CQ6T6|hNyEh5`TBZ<>NxULpDQUb zRliZ>lZrBtTmnFOlo_8*C%shi?e?K9PDPncj;^Ee8!T6a!p06CuRlLXNaR!8)S6G} zy0g}woEdk4*xp0m$5<{{C3 z+egH^SDx3i*UOEX>IDwP7xjZ;xy)9xk7UfTiiuu(dov5D&0Jd?*kCPO=9t-w9h(rZ zA$y{_o+y)fh5sL#2E_K|!j{(dGW(g!E-7i4cH;`Y0!MLjGGd11G7Bzme0~i5E5i7{ zY?sTd_9pU(ZEelt{KmUCHk!C6Ud(H#p2Tu<9@^4S`XUjg_L__v#rF-ahmrlo%AQv7 z-^}i*jf3>1S2fk+D!d4vI)WOI;~7nJs-t+Wjw{B+Tpq`?Guo~EeWna{ea>^gtZ6>< zx{>41PDqaIi`v~;t_p=sCEsU)3$P!}_ARsg*GwkRHyqlzR=h?$Hh2{N6V|{XY9Jn& zub96dqBpi~WBcVj-6S5fCuTA}XSO%H-b^OmYjs|{mXGb;BVI?xVje30C%?t(`9H~I zIh_l;zn2CApu^?eTB*E~`%e&a=k04AtNp^P;->Tmj^dcw`&h0Dg^jKL9atL0*u`U9 zL5|a>`mzXH=2w<(ERW6jt(iM%{kMHwZDf8d7pSR+HQ;CH-4TEy#C(XpA97t&3^SZ2 zL~R_sV>y0mBU6h)@DxW>f2TZ-27S?<;z)#;|KU{F9RUrP^|z}kt+WIOZX-PcbdH&q zvYj4nB5e^Mzk?s`u>T3+h3!;}rLdj;y{*+OeyALyv`y_+RPKpo9sUL#%V|#_$9pap zxy?&E8{Sq|19JR?^WExd@W@^-$4`3%S5J)g&6*d0a<$nn!2eus5^7!_PYujKflKJV0CL1`o$Pc>BTVYpq6 zpLXz*^R2_+eb|c{YCw*kaQ&c$3O&rX%kdK~e-5*PYv`REKU9CCfj#njKbJ+6_l4_k zHB@>vZZE^N;`b){c0ql=xqcwF?^MIvBX+55PZSW_Ot?Mjh^gJS$8!9H%S+p;J1Q5- z@e?jDkBZuD2O`H$IQ`gG-BGzvj-POQ)KO8p?Lg%C3FmLNRd-Y_l;bDd9(7dIZaWY; ze!}fhwpDjjE|lXZTt7G}YPTJT96#am$F}N@%7t?LgxjNzirQ@l@=t4z3ispFqE=2< zwj!}p2pZ^sd&G8l`bPhti9cr7 zMVee!qWjl;MAqJz%V=hY(0n&89FGOccVHgT5ldc-&uFGN?(Tkb-iT#gIDW}b8h^@i z{53e5v`?RT$04kKtsbXfU85X#mOA@mg3slo8_mYo5hp^}g*6b?K-C(kN&a26&xiLc zRHTgTI)7(wdGjv3Kp5$a)}LfKT_ZZq zZ@oT!GUm>XUaoO&PfBiHPLj`=>q^Irsh%uVMw2tEGI+2ZpmOE%_TQ~y|0pcV-zl%B za-Hf{^zD?0(HyD7iRROzwz-pm(*Ot19q12?0j2;8fe(OY@Nf*U0T>96e+Ra}^ZoEV z8y@$8$4lVxdU*UMJT8aFk77ZqW<|MRnWDV+H^>6ug6|okiP+d;)D3^vcdPR4IiJsc;HtqnJ>%9Ptlq19g>h_pWh;Q z#{5dIwASY*-~F)d^VJVLDf45w$c>Io`1MOW1U(w+HzTcio;%=@QCICa`L93J+0eB- z>J+3mmfPT2F@2?b@i>@u5H|+^*4tVed``MF_s7CP{hDxni_&B*@L@Ur8k~vVD(B-! zc6zdMTXi6?!#WPbM_KEu(}JE+?OJ{M(P||^ohvlkJ*i?_7K93mg4*;yU zavQwf+&bj#&Bxzyx=IN55-*yUF(}7>(N&L^Iu(&NYnARv0DI#MGd9C?t_^1Mq<3w{VQL{^~zC zy2p^;uKBFF9x(Bu^%z;Mi-WuB@#3p7pQ$!qr$KK`Gp+fRUbA)Tu{xuc-4ws&@vkWxbWz;C1@Gz3U&I+r8-qJzS#K9K2Yri-WuB@#3pp zIH;H(r)F8}ZC{tqKOFhnjrqq5{3u>o9weq8aESKwrlkd>UYAc_@K;Q?@`pWXcO zU;0h$Fi(hA%8yxIGk(EpBjP?EHOYLZFW;3#eu_K;E^9rW@@`qieXAn=CzrDK?Adp6zk?SZkhFPI=U>>Ox%_5%kf?r8bH2thU9{sEw>96p7F_=5jEkDgWL}z@BNSQA=WEW_yo?w1 zyvYXdn3zY;`d`Zh_2u%N<;<7&HRl~F^T|(9&ojnb>$!2!C;cWAe~B_nbEIb~A6Tx7 zgS(pZWgkLy0rFhTk7FlT^KRaMeUoO-+*@0&53oE)SU=!Ug>tQ$=})U8i2B`SgXf}X z@0&%%t@Gvj0m~0RPkz!+oq@s-?YK0@TEAbczx3pne{S-eTyJ3c;pc6vORPlz!E!Ix zn(vqGSA2Fw3#mMyume-h9CH04Zpuae;HP0uzzk6H8@GX&Y{ek5*=V`1ji2SzL z;J2aJH|m~}*Otolg`iv_$f;P!ud0q;seT~xE6lUj-{$Efmflh{b%|U*V7Wxkti8*E zpRqn5+F{I9*8EEEfT>omh{AW4y z<9+pc8q0f8kJ&zJJubd`$-M)|yf;@a?^({gcwc>fe21}o7xP2KZ_Ts#xM%V_x!X^d z%XgMDKi+ew_S1`2o{RchWP{g+Eeo%_`|1C^FPG;mXFj~IJ}_@@`%Lb&MJ}&d&b)YEeSTG!&jEPM z`YbK5*5{eG4|;ua;)EyV@|oq#llLZk#qR-@<+P~J1y?b7}d|i_Y?eal6 z6V&&I&eQmQFY=5pwB~uUE1}7l%>}>6=S`!p zT7TC0<9o{GI?I_K?+=|P-)Su01Mryh(_J?B?t62%Z+}{oQ|0oV<;;`!9I8-0*|b-! zoEP<3dbPDaHxGX2r`;(fv*dD~<;;usht7}hG?w?GoyK2d&DVF;ClAEEF!X%6yk|M{ z8|_ve?@dE>>)<#M0p%#Zhn&a>+BzZe0qy%t_;t>05yJ+p7s z{n_MInGeft@S*p`VE8kH@S9Gt*2gKAF8wyOiQ{xRe3sh? zU(7#(Jj8ej*x+%+zDHUoj$d$AZGC+cvWvE`3zpm9fraR`;M2Vcv=74iWyJE@eTsIN^n_aU6LK+J8U)A#` zYh98*Vm+_JP1gMOKHp~7z*(KIm-(?=P01d-0y+M{f?blnmX)_PHKja(tIgx7O#>ZZo>v^Me1tqdFDN zXIUO%s2znu490i$c{;RP(!E1mnJ)K4s`=}MFh7Q}NqCOz8P?CS`TQ%szGKw)bJT>7 zd+9l-KSEHh(GPAzLDu9sbpBL-5g$PBY17;1oWudH#R11lhnuaR=hI6U-+uf{uXQ~T zrTIY5L;YG=u1Q1N5QCaLkJ>?qXyXYcIrG%NS{Q4wWB$8r@PFXeiw>;pbYWlWYfg^% z(>g#bSB1jnF!5*78h@m24nnl2mA6>yf9JqG54sk=wcy?pH6Mt7JMd>Y`^)>o#~-Av z5;+203vhfC-fI0k?)ygH>Uw{`8*+Zca()ipn>>$MIaK|$uLrOld*(m;?b229+UI8 zpj>(&lk|UR`ghpN&(}^|)Bh&sZ)!j#++oh|go5e~J8O+-V&j z$6tBNDRt{SzCzBwSbhZgo90)dJq@2@&HusSgQuL(Xhw;gU$Oki^0&^P#P0%4@3MZL zv5`wo$|)N9v7A4#+{W{W@3n`VPi;X!oDO!`;Qd68;!hTDTQN}1r&xZ(dE3md#OGQ& z*E&A#IHl3Jp`EwV&|TGWeJm)K9?T@as#$#4%(uk%{TX*#KUeI)dU;nBJ+MR0w^%Mc zmRY`4!{;*3zr^QAEwz4*tk&Ds?!PFfpPYZO{3tw!X+9>}S%-V9pJU?Emf6Xd&pt!W z$5?)Jp2IpnD+UqH7Z%xgt{MGu?kZ30bk;VE0VhZ4hdPn4Tono%lk}7B&3ESLtr>>? z#PRo9>$U#69iy*Y{!Ee_KFfum)kBl;&E9tnoan|G0PAJF4PLIy8=F16uIH69FP5uh zgpCO=sy9^NQ6lgdKF?Y|qkH}E?3Kfc=Eyu)E>KVpO?Zg;K$U!U+2Av$?a*hG++Q<# z>j9I!G=aUa+>(zYB`-5Q8?(}6In+kPbT`eN(A(|LbLMAe8@@Le&bQW2#D}L2X{aO* zqInR=asJP8O&Z!((2u}}Nl<&IC(Gq?`HcPJo8D*5=c$vX)}3_A)RA((0hWiDXh&7? z3HA(76*aiPRe-)Mx(B7$vpp}e!RxBAL(A$dUC@6y=7u0gdTNC&%T=MUsft%9!BsFP zr5JuNuMYPc^<}os_brW-<~Oz7avcXGMM| zWJt#NQWhBJU8)UF$o~>_K3Ub}ygSIxdy4x8IwnNjOvmI(+G<-_uAan(^@0E$T8}-N zeqw;zPZUyp-aMBtzi6O0%a!Ey^~rJN;tN0uHEsr=aMDYsjCN_{m!=sy(wyFW%zwlC zqpX1r2v3ZkOYoo4i0tI+DBfu97TL+yQGC-}m$I{a-3;8w>1qb-np^@v9E<0cDxI<4 zl!!TEM(=wZhyQ2qI^d%yzW)SJgIIt>#2!E)wljz&_JjloQW8igRydLiIZ5u0y9*@P zPDR0v9s8-M*s=Y7Siz1R3yK{(_Wl$5|NGtDcQ-q^T!LcxUC-qn z@msm2O|*Hx{$CHbmQj1sq`EiVed*#-<(0v$-5k*Mdg0CK^}6YX?&_znHr-&{6_Z<3sn1L9H-N@vK@4l{~Fk@ z*IPMHOSwXqiI@0x&}Eq#ldd>2NQ`qAw9T)PpC5MYvyo38l5&ME6EE@YplhVhS2Nlh ziTc7RDAei8zqM`p@PN#?NrT%>ms$FIkvgk7wW6T~$t)yH3`l zx1VK>^91kCJ@x!ntK+=Y(Cha0lcWzvy5t`5OPH#{d7yfdwEuF>YDx)@!c+a!qR0V5Oo5?fqlLecjbL1w+2uX4#b!V!+d}FU<87 z!COe}(q6qD;7P8|Yr(`am1J3n0`>Jy!T%F{u?wkaNf#&S+mlApX8a5XR)+&|Bo;l- ze;~b{GvBT!oqy6XFD*-~J5$f8?IzwrMqRlJ2>&qp3Y-%^9VRO{k(&z=7M z>zlm&xs)&TnRtnB2YtI~c1H`kNsViC&VM95A43mzSBu`=Y{i`V3(wuuAw=w@;DtW% zQ_*S9QzV(!Dsjl9J@!$zGZGeG=*ajP4*Z)q5XZxc{fRxEUa!j@?XH>%_q$-H1)E=d zo5Lj0Yr&hmOQqMT#y75h5O(59KJC$KN&9#Ee}^s6%hbbvH!m{f|Gga0_pNt*BE4Rd z(rRyX#a&Z9A)#9O6((NdQ|Wb!evhWd`aH^fgPv6VoSSDnR642asD4tO&|~5yz8&G@RnWOsE+{kQqkJ}YbN<`gXUPw+yI_^Ie>(XSC=a8rBi9rawFkCn1A zeue}8Ru1UnsEX&)>v7L#yQ|oRXIEYS@grAo9*9o#SnxJBc}=CqZT4fdH+dwd_UN~y z{k#3Ysy~sgoOE%2H-9qa|8*SD`wuJI&~H+;;rw@+KkBwqSSXbKgNc{;RQlbbKa)bA z|kr_Oj35n&v4-1#(_8*MA{p9FOko`p2mc1 zEu0Dd^&BXG!PM(#LxY4r+MoHO_Z#G7{$@Dvw{pO=XB+%ZYBGB9I~mu;ZKgeIBl%h# zEiy*m9#7bNAsHq}{94U~%)_PSfN9UxL28~iAoH~u8A;2&KRq&2KYu!l|4;#D{YYk_ zKm0E`M7`n}G4h{r8TaRMAX7hoE`R@M?yc2NYx#=q&}UmkpM9Ck+#8tiC%8=g{0U55 zgITU_{pdwgXJj0}wu!nV`lYAKgnvH=GWGNOdG}Y`8AlM6s6*t`VfLHM+6 zpe9o74S|4#$Vlj`_@Zt4-s-W_^E*xK_V9ZS0i>@l=o7rqCH`vAhvO@wUcBNzI2>%i z0g2Q6!Ny2M(9fqS4Nec}RJ*_HxbjOk-CV2Vex%tr3$d)zMtP*=lOFfq+kNS!Z#th3 zwA%KLxC)+WbZ65&!q*TCHwKP)a4-@n4OTbuOhgM+GujskHsWld0ZL`Vu<7&M zdR}Wf%zg=-`1Zel##P@x*7F_nda)?c)!Bqiau_7Lgahn-psD z;tTt|_5K+?U1VCEYii#ASN_k8FmH_z>tARsrEz4oaN5nQMf2n+A>ffxLw*Twx%}U4zZFVt$KKmxz3(&KVQWIWz zdS?VxeeCK7?;9Durj&o+*iYz$tKco9c4^rU810(|Gg4!9r7D8xST*nJDYcFR4+f%Y z0qzxfUHX%o9&>-u+*RFG(RI&txNg3`qjhXE?iG0zyhe%@Otrr#^}b6v={Xp7jw??h zv{%{Mv+sxnn{A=_KUErw;LIh%fwhnWaXgdgdFbc#dd|lmyVPZ%P<}FoL3WX zp>av2=PmYMrqpOV2i*?k{oby{4@DwIPh0-K!3j?wvJoh&32qLy&5{^ ziSu5c_>s^@edlVciI@0P`re{nltQ!h_u=x_b<<_qA(r)NVBkBi&pBeelq+gyjCb!OyUFHYKeud%ZW7^aiySBv8E9pf18X^F_tv(eZCqj$WAG)p4#Zg z5Sfd$_yC+|pf}S_Ts(UIRwb~SnxuZ z_^H~3cJ`x3Vk&f+Pre_lrMF8g^Q2RLd~@vi#ScjNLZ6A3_*8bu=gZz*I`+3oImepk_6c6-6h9Tct@N*3ClZ;h&bo|l2lcSf zl<_kh__uH%T|awubc1Ql^n#;r_xD<+`M2=-_daK)ets|K{+jz-?fI7J$3f#a%TeF% z*ZayDhkU)O=!(og3Erf-z2hK!6gz5-itvrvV0Eeyk)5;oKCbAfS#IWkh65Q6C=~}2 zWIR#0jl2KLZ+r2)fwC=?x?`UWKFHrHNB#G@pZvS_*ed>*qu~3%=X#vrk=*5EHJuY3 zGJ)Y4UQ$}+Yl>onw-?$x9iJ!jc_YEVF#F5gyL!s}lj}+=hBBiNK%Xc3(UrUVPqF*& z@A{XnJzCui9Tu(bZGR~J-%;itB6u}#o`duvuS+1WY+qRKd~Sw0ew?_uQe)@c#!ud> zk1IkO_I%~NX$;fZ{K;y8w_}wWGosit!WRwWQ|Xny@HBt5&r^ZPIf!q0U@~4lm^?g) z5G8j~J?Git0HLQY&#gaO|u8qH}4oUPGU(5LPCeCyCRJ8gIABa@|kq0huiJfl&jqc$s94?CZ5@k&=^sYxraecW8CfyYF5*|LJL3P5`qi;KO^mx1}U^|d@5fIPF#)itN^@GCUU^s%Cbb2bbZCh@CeB|E!dmeh!5-CsUG4T>F6tqfDnKz=- zqt9clY6m^RcRtvvXv-Vwq&%U=#7lge^o+&^d6=PQzO6Mh;ExXW`s*9RzG4`FhEUYU zxiq>sK+6=Yt~hO* za#ptkY`XvG3s`3P$y?6-Fn`|9Qohh<;w6447J8a|HKhaXWuK;~2v})j*xEwwB-G_= z0q9`9#Q^&21K2lPIzXwH%io@epbCAxZ2LWqXe?xyPUtZ4b}agIc)1R*vf)iYpEo=( z9Go6Ods6C+dOcO%$dplyzD87?(1x300I9cver|f$=5_+aH&d$rkz-y&P+i!!;+|#4 zT{O+6!=@(-R0*DGbeFKxwvk3NS6*9NRp(=Mg&{mmNG#>gZ%6rW{dnfo3$Dq(QOdZ- z3f!Yiyu{lrDc=3?MIsQ};l63Ude*gGuG-!$52~@dB@cP|IqHQWX za2LD`@jwrydT*`Nhmif3u?g>oK}ubBD8>UblsfuKrFME*sV}$8QkBhF>V|K!)XnF0 zP=)o_$2_}}IvHLt*Mhf@+J$r!j~p_5kf*XS6bgo;k<#%)hW4Kz1jLY5 z%AakNpXz;;vwyg5W!I|RrnBzpSpGV=3f@9$mt^^+14{e%AMC@^JK}Anis35dXYc5K ze#(>i-t1dFPJis%gLhtF-HeOPhb+AB>&8pGQ9fG+`>i{?E8AEfb?H~kC_fjOP@Y2{ zXQ@kWufbcQO6`5xyB*%VFMNk72ZCoB-Ld>ZLx!Wn9;){?S2gn;XSx_bo?GqIc01H* zuTQ?~aKeP^&3YF+^VD79xl6o(K@E-d-lz{kPzj4|JKe4{p?v0B44|K?-rxQ3>;9i@ z@W!uZy$jyXHF;(EsBv^3YV5H=y&b3Po!YtW=dPJ{_=0_w-Aqxioc;V+%EU{&Rjxnm ztBxi{{=tB!96bZDKjP>BdINKCgYbV&JLuSU*WMfddctvsNjXA?iI@1)bd-6+HPg|- zYe|n@AM-u#`sjsBdjqn8-)#LQR=Yoa(w;AW@A=?KQw{|$bcj!ShGL&b{g6;229|zb z#FoW45|9sV*?EzPY@`?aDDyKsLv8E72jCahg-r6M$w~VTi1@0I;p# ztC2AAY8yZvfX^#-TIWmNE^fZ0>WA!e?Y#dUw%NqHNFyEVsWYyEw~*R}d>Jx)XhW#p z$M@(HU7#4!hc z_9QRpn63k^g13;`#VT)#-#d^8Km=+MhETT$MZ3BCH|9R4uKjb=&fa5=?s8Y{ssq^Z zfTPTD{!j20QoD=@9uf2mLV-bChQkU5s+-3|JSBDh`kJBT_8T@#ZqD0lS*(#D`6JHe zmB>ia7hTrVG0gP({Su$?GaUH4IH2q8sy)-|?Gotq$o)!AT|DulcVA{h0mn9gdMkJf zsa;yp+p+!`(yj+Nr1;bIR!9IcD!b@D4iRVR##kHikI%^$ZVs zYphMg&M3GfjL{!A76;J@O^(Fa{ZKkx`FpiZ*HH~0$0OI?^~w~dWYWdAiUseW6JAQX zibElsmmtIPa5M#B`Z!@>JLu|i$>5EKg$}rq>n?Ppi}Npnw~*Q;C0!+Tn8d_-i@znS zVz^i8Z^b@IK5<+&2a_sfX5rpB>cQ;55eTXePG7R{(R*SK59S{@(z7|Pg13;`h4ltV z)Q(+Y+zCDwvoA``M+PikA1|=%_KpuYo+s5DS93hTc7S65_WgSU`T}+UcmM+cg#a$3 zl>&wVDgl`OvDUSw!ao{t3V`x6A8;4oDZtx+Re;<2m;OnECPH6$b+FC4>%w2 zDquSp_9noK&V1B$=#XuThr1Cl5D)kv;8OHEYcU8aMW=W#3_ylp5HuBYRd-_$v>iI5 zcVYk(#NcNv20kGSdLHPBIa&;KdSQUGe=ntO+E%IQ`AS{A6Z+Tvl^VB)Qs3-@at4Cl zGNq2Iz`WRarGD{Ze1tLcpy{CR1f_O9OQ{{>$bW%S-#(~RkC&Ai{u$=V*2z-K^0L(Y z{j;q4N0VyJZ^iKJA}15~ZF~GM|KN(>ZoB8>ZNV1H(dYO@@D4iRL4!R*!uIgqI;F;0 z`;!DA1f=|>?I?f9vfx*}-fJk9`)xY1l!=#k%4uo1v|5UdYvnB{YWsN)+~@Jdr#*A^ z(mW?a`dKPZ3En{`JgYxqFNWAtwPStZ2yB_NU}NK~y+O7)X{@gH`S4DKWDv&#kstCN zFYPJBEaUzm9LUtqKcpgBA!9c1VowT-+t%+VcKdR^XWAui*mlHj_h`=qZx%DcSL643 zu&7xK#jVGAl~^(y>#y+zOR)e{2xe^2OZBIf83-gZ`FCFJe!^@W#T2i z9duap&^jGu1KZ|D!>2n>+Gf$bGo>7%!^BH`TXc-A*vm?))3LN2bWH8`@grS^9FCUH zc0z}Vm-x2mC?0EP6~hf89~C9;`74=&)aUWH?|D_XCyzbi;4*eR;J6O8A+CbAvB@jj z8{7O3ZQwdR=drM2nQ|U$=^%Ic?9*WRN-YOn`{X?J-0adEHE@`EY50VbUU>?A3_6z2 z@vz`+Z1QTBuhBA?`*WgBQgjb2KIr{3@)+4C#;vQ#(FcI;kF_>P zp0KY{2IBN~k#y44O2Gb`xwgT97~)0#n+B)12Nj6-d@-=s7qdV5te2DT-tZ}Zf_Kmf zuSI{4gS#?+bZEdn-83I5^?GE#Uh+<4g1{UnUCu!@Uu6$TPbcpi`_%Tw_TB17iizdu z(~b+?K_@(!9pdgZXVJ}LO&ZnsD!kD;Pw&#OcY1N4rgFMBM48m-ncEI}UVQVrCkM^g zlfwwh2|a>$&u zoPbVGWn;M3TkR7Hf?>9QCBabhXy4RE?1PA4bKT&ux50;d&H9~za->YXj5z*?9Ik4E ze%^QW3ERy)quaX=GfYSNc{TCG(zQvywTE{^a2f<)u)iL=|MaJ@$B05-d}w<9S_Pi- z-eLbeAojf##zp8;243P?i1c!_V5 z&M^UB!z5n~hA{TF=?ZTo;!Ea5LIjOOs%azdYp zmw27Nl3;x>JjC13h(=D=*OkMQ^B*kNJkPmoSdQ9z_9GLQk6RTz`bv96kmXW81TW=@ zub10WKSWi0Vw`)k`MersCy1Ynx!zRWvs?l2mAxS46 z?BcLq&8`khCQk4+B|yM6;D&FqmBO@<>IOyI8GbGjoXE(GTWt=^#T_CaMWfQoM;!7q zdFcM1EM0&5iIFSqT4{FdiQr8FT9uFT>gxJNYX+&rTVKr$I-E`7bh(v9I=PWDNCB-H z=Tf%?^aij2AY1?#hy)WML~jGuf!s91F9dEe;y4ft0!9PM036(MD1<3YD^JR$%um@* z3WVd#|APNF`FcB4QI(V%o)LdsxxFuQDdcH|?}wKbjLuPC+;LMy&MlkGIs54Qt&_k- zZUk@gu2s1y##SZ_K)Hjc26kpw=f)NADaZP_kF7Wkk+fnr&)lpR((^0*6Q%CjITOHNe zxt&z^;hofpCv{Re4|h@@bXrI4ICLG=?W}dwpti~O>zAF7_eRcEEUDS`8ZJ^G*e*^W|lnvEUy*E<# zzq66r^QMhejxPCtbQJjs8sO|YX~a233bOQ)=)<~&FR}OnWt*c+SVq8)mIoBck<|mFp`|kPAiA7^`)Y5r%56%B}i<#RvJ$und z!6!?$Lwb>=*8al8+l0<$K4*~=;|_KXSKu~NA4vyImiU3>#!}5@t3}^i!!nm&sV%`C~3xc|Wn5k$;HUcqUV=XHmjld#I`Ygf3*_fV69kV6Y+=}$s3^v&5BgT?oBR)a^m&$%~ zTr(J#?bzAKxWAPHdOvt6ks6YxCaU`=5Mgn?W0itp=8z zWP8E7$k<9Sp&d?_>xGB8`z16xpq*ZLjWi3j^J%<@|uR)*Xt$F`%TX~WW8AvzMF6AwcyPs zY^PpV1*6`2U9mHIZF4fC*QP{e{b#RK-~NIH)snaLCrrG=w^OeN zHATZ-U9a`=>jJ;KKOcMO@vL1@K*8i3^;^03uDmVSib zg&y(K&}G>e`zR=9j8dag&gZb*rQWgaWnYr*JLlusUuQRq?>KG;;Mn3o00}z}@B&~* z+|0ey2O)zhWUvq!EI>OU?V(oN9-FOhQ@Iy7JI%Oj{VXNSTDZ_?;yX1HNriz z)R_yj)F~m%*EV)k-9PN4`hT;oDtNWCn)dyM>inm2)B)YLR4+Z=PaQeAP)+}?TwQq3 zR5ksUxO(RCch$Qe4a_1R*|h~ZDaYr;x5tqWbo3=mKClmhDI|3~#`wMA7Xl6doDR4G zzV9QzanfKvfI0p$5H06NLb{;&5A#8ubtu2a&_H}Ixs8;%%qc=)V0B?IafHO$0IJjd(YvJl0q z6pfSXFgZIJJ6Wu~O2*D5`;OW0WL#C);I=pB{J~t%d*W-|5A3_B!_((HZa=8Z9|&IP z5TE?D&tXWs6;Bi7x7Yo+>}PK&h(maFe#-rSl}}lsZed7l%{lPtsCR3lPT{du+r@B) z$jL%YPB^EUcg1@4`%}YkR>`#eS1|MN?d2Q(;JxiX`TPS%IpJ0C)?e+CLQV$O2PakH zJJG`iBAqU$D}w3ev?!3H3ja4@>-?W4hkxSYE*xGpvF0-bZy~jdtNi}`@!1Ewv*p9f z4pCo|HtqF?+6xv(xndj1^=6Sdku{*wx{NHQWseo9%Sm=Py`0pAa@2DtyjU>fDF3Ms zQ1RhJP6Tgblh@R8V)dGIG5K9`LVF{9Dar)Hlof{A-(vlXk6;Uzk&hNEX%*3g7_n!0 z(e!c>gB+dq!2F$$TUxzk&GU9|jO{SzM+I*dWY3!q_XnmpO|ad}{VusM^IjAGbvdJa zWn{? z5~tI^c(I9+RxeMdfq6*Tk{59qw{~zKhQ|g{FvyTypJ*w@pU_P`>AxdFMg&@)A3AF%8TG_Z1PHZ z8H~fje3i|C>M%AU;=72R@-PlJ9P6$3*VwzaOT3L@UuYY2`?53sOIgWWlOeqyo_$Pu z`^~#9J#^+5`{ecBc3&q8`dQfdEqDi=@JPQsFyr(WX8LOVP34%U(92zToSSboxZ4L< zHCUb(8talVk0IJ49qz^}kPq(gt- zfHY9gsFTz+Sp(vd0K1u-!{PK2b(*6@QnVvr0D$&u2%rj34QK>#ZRcvhLx2wfJj;js z{Eq|Rbq2L16gCFYCaV9Q@}D1@(~Cr01>x?2)t^bE&&nSz_#EMQR;H+ReTD@ z<$lbGUbG#`!3zWrp}{5pV9L<@RDat11jx2{v?ctxfX#vE0NRIu?nmMCK+U~@n}@g% zU?c$KS^L4sJ3NB5XNf#UQp-k>=eXSh)&cRvA-jZqBaZxETb!;3D^E)50r_jL*OZ-@ zqpscjHqX?J?pv2_2%W5l3EsvguWT>N@iKHnD2T5i^_hB1Kb2#ejQe98 zh~svVm+_~jmzRZ*r>76T{+Zj)KI^N6*popgc17?uHhE1gFSe-QSPJWN81lgeCjr|ecMA&4#fXkfFBIl1;93dGR?GXqji~KSpSc|8Mm4oh#|em zPxhH^`6(JU+?p4!n6Z(n?)Uz4%OPLY3trFP;pOfpj=aiim2@bsv^RpcklKas!C9NH zF{L%dgWlS}#z?a!A^*gAbB+8zJt#8F{t@k@$U4nA`=R1f{-uw^dmM9b*;o8c>1ca1 zZtdcL-j7^zwtN0#2_E%vz#QoDnFDX0z$ZWR^qp2c^=|bc4Aarx^J?OWrQ>+Ynm4ky zQsH|?!GOcV zxDs#`U>@LVz%_tt0rLUZ0j>w!0Jsrw6X0gREr11pTLHHLZU@`}xD)Unz<&V?0e1oJ z2HXR<7jPfoe!wEYV!#7{2LTTO9tJ!Dcogs$U42WXNGZ6`Y%+p4#icZyS3oxMY`KmNRLhzb1GKsa+DidhI+hzSvb20qX-c0Bj8C4(I{c0?-SP59klr2T%r}j8eWR3#=pZ=v_cgmVK7- zx$r**jP78sE%-ZP{H}K!{(4u;pA~^N&16v47fp2=h+m$h)Bc_FrGeGwzLN+Xb)`|K9?h zaz|Ym0@wpU{`GVKk7$MQh}QmNO2sCCZUFM1_0R=Cey=T#`Yw8)=BC$!iRb62!;f#C zbjb5L{kEM#%}nZn;4P$fNuvkVb-tR$dYK<|?nyUJ(X#!+LF(7;fL@S`|3FSSmllPb zT!t`lv^lhmwSc_Wy7Ep9FzMC7ILqV)1I z7xHxa;*Xa<>Ur<0s{Sw#a5BynyoJ;*spJJ?7nw}1v27@NN7e!O_#h>0Dy?Z-a)T;W z1nMwh0w5oVM*%ZY_lp30XZHo*p8}i*I0+C11OPPv+7;I2=71dltZT8!v>lrPXq&eJ zkTaAONkjWVd0^SJC$!&`pRUe-#&-rV9_H7wH@)DmEiR4+5xHr)B)!}$hg^NV@0H=K z!v`(8skqc)fyj;EO}?~GZc2S2d_;=ha>8f)g7wpUHPRBB@^dOGgt9&nz`ACCfOSTF zXT7n$Sa+=RK7c#`(-Z^t2aI;$5cnejdm~K!a6GeTmZNU$OF*U_yLEa-6?|o*#fwS5O*|S zIAC`GWu-fSa=^N$97sJgU)*NliDR8Jp1`#HPrRg|kK(L&$}htx+Dc2G!1Q#Cqa3X* zZZ;l7%rw~vK zpnQx6)B>ghP61p2xCihm;8y_KxAA~Efad{Q<5{Ky-UN(=FuVge5tUwoO3#DP^n%a~ zN2Sk)u$uRdONhIJE0Ff0OP@ZAj5+&Hmkrl zbq~Y1xdG!5^!~e_3p;ot#+ggdetv|$)y7$Bi+!`y+xVbL?;EpJ@z+`E^^y*1*_Aj) z4u?|ya#lyRpkF7oa#<%eKfaE-?6h^&UYD<@p20bA_l#a&ozrmxRsPe4>hwWf)w5r8 zS4%thP;XqlnJRf@EA`~Py;XTbzVdFci^_dq5B2uK1Jv#L2dZ8p$Eue?HEO^2qRQWS zwyGR;nVNRMLba^^C3XC%Kd5_;=$*CTr%_oOk2~4*UZXi5N}Uo1Rwf*EhI&PCM8%5J z(^v@Yk}gh5mI-D!@c)Jbx_w=GZF>6}hy8u~Wbe$t$rtSXFgrqUVqXPsW0TjG_7$Id zPqxm9^G{8^h1vRl;W9Si|3x*ebwtj=6G^{l&JF4HcH;aTwepZ#MnCCkj{4alffKzI zyp2s>Q|hfVn#YlsIGPh*H*K%?x^vV}F&7eip8R zw~*Q;sjAM1rX+~>cY^i!)Rm{WI_jV1vrcxHhSQZA@$oBeV&bQl8XG+2(K=t)TJI71 zmbZhx-Ua0ieQ*C2qXygAbaqrGUgFzNUwLh9NvJV3mG-)n&>6d_Z9aB5`1^ehyL%Lu zPb?>V6ui(U{%X(}NJFNJpLMso*PVSRjN?H$$1nfp9MymDNw?+|zxN==f^?*l<5`KXS~A3h{6CT2*!BufK5G+H#yTq@D}jK_@(YzO&``YP6$uty4Oa=Z|s@ zO4n=7i%6M?%(a029CdfN?W(ztb_t%Ne)oB2?snqG)isWg%5w-_%i0R2e~v*-)xJo? zK9j4Y-X99d_Ujh&wfg*yS%&#P-Se7hGyi`d2lR2tD##7(RxyA+rYNoX@YrO0m$S%}$hesISERv;%_IinM|(*ZqF>XdhliwC1ZLND&9ab$t&5 z$Ms9DJCVnHF4hS_oEg^tGmZYA{L%kQ9vQ!V9MJV-@m+5DFyD*MTbQH5KMu%yfBV-z z`QXA=tO7(n1aFqwQa;RAoXZ3JzDAUtPq;WLQnZk1m+nu4I>1Jk0BuCFK$QqufG3s!L?Vf|BKu&<(qhkZ>@Y!gV!HGq8LER zFS^J5{IqFo+sm+_=Z<|g_y9rmm8bg$(a(3ki(xv>H}PuXEi^7E%BR8v`3*w47(mKj z+>Y`K^H-d*QQu7;m~lzRcT1>^&E0&s829)NuT z0|7$;qX5|2Y0V)8;U5WLy`2xZ2CxwDBwz(#6@c&A?gA(WgaH=<@aZN+KB5bP6=6gE z4Svh_mg;sue*UAmO+r0=!>L=%$u7B)VLD`GT}`}&#)b7>im!oqh6ZYb_yA}&#A5Kb(s_1E)D!b1bj*PU?cjdxPL zuf{Xd7o8pqPpR~Ur}?XWZhjOjcI%_mD>nyf)p3zlRp7Kc%6lqP+RR$X|Y2zfB2%qvM^E5v>_!9Um!YL*Z<{p;SadVMa z?A;PPALY0hzO4p!3O;r$=)MUBZhuA|oR(8TKQ$JRK?yq;f`P`om{(K|an$1aBd=3)(SGl|;k->ZlJNRt!$@ z`$l*JSO^GvhWMg3B2tNXG=tWAYXb@@ebvE0O~lG2mHde9(2B_f|0WLT{iLQPZMTne zD)#a`Gv=Yogrnfe@(??ewiMfY#6{2Mw}Y;A zNA3OHsGkZ4vfoZeA79s1g13;`#U4Xf1cUXSF@b=O9T;!8d7O8OuQ3F@!m0X!Xi1$P z9iG9#ux~OBt+&rroR2(&u8Jqp>pzQI|K8%PV;+CziU?zOnWJK7ZLbFI>wA1KH4|65mpnX z6X#)uec_5=y}uf#VTL85Bpi%H%EM3s&Q{oae9itCc|*s&;kx7Z+}rE)=beaeeze8+ zr#FA+Fl-OvZIbeqz5@kPh^19-36I(jdT40Jx%;ReZ5?#=jr z9|vM6TI8bOS+{<2Ji$2;`Hsmd$jyS0{%6nstl-oQaP|a5r&n4xV^EG*kI#}~d`REiEE`H&g z1$eGk?!Bq_s_%>UnB@pxABS$i<2IKQy2XB2A0g5<)R}VK9r;n$$riDpEJ{GnJR|=) zH~yUPY-B5P-Sk3IKFE7>yuTds^T?`D{Q>vfc^&1Qj^FF1TnpaDCa)aNCEDSU!KlBs z*?M`&8smAbxiKrTDJONv*KS*rd1XR>9|!dQ`21z*wC5Mi`DA9%cgwpvB$qgH zB6#yjXh#5?o76-D{S>Ref^nP=UqK2rCM=67FNMgT_E6-~%s=!0ujPQ=zl*)(ZZBC! ztg8wv3OxVdvs)J-e&;jZT6g|?+h5a!dZZiX$cx}@Z1P%MG1OCu^9?cJFSe#tG4ajq z6D}MqO|&tBV?nEf4LWO&Ik>_mq&hg8}%6jh< z=eY!*DA)*YRr*zu=cF zb>8QmY0L3k%eEN5-p_rDo|*+b9ouuZ1A@1Z+C};amCcc;ub~Pr&tL-DU*8z^*(%-M zefLsT^a;|3(28nTQ1WS4;!L6p2mWCkh=Cr_*M)DU*Voz5=gU6qy!nY2Y}uRrJvz}> z!Q0s6RrJ+4r@*DFOqJ2sB(E}|3<3WyS?21v7!r%USq1ty?NFR1 zgD;;d-@R$nMPJTy8d|2O`^v%F|B_dO{z2g|&aNJeFW)#x^5C=l_%$D#*>gpXlKeT} z#=K)rJm)zI-$~lTRP!8jasRxs<3{ay=-l&>&^w|@riFuCV2tKT# zTI@R{e>3wOE*Ac+e_|+IQ}Z07WvE*$-N2UC7Gckt%JB;~_8*TMX|;q*s7A9Z%ine*1ZVDgbRN_oQds zn&*J77fm0y^@2J~-H>^AmLA>rfF0M{@A)flVCBKl&%#ykHa2+`y)6ykqY2g;Fhliz zE^B&2-bvU;7i~szosNQ!-EwV?kJX1c>gT3gum1L_)3$Jy=dAN{sGovQQecOKjst^} zutM2rjfy>ZyHT4Avl5#9?%u#k8D^fD{}~Sa+c}`??Lz1+%|bDNek%L1e$$(QA9gw8 zI^o;)R$zN&;w4`67FI)3RZnpgvs|I5yhY{Sr}5>dZu=qYa4WumEj#Dd=PN$RQ6sL( z+40haCyltDgu-nLp#2cMh14#s&@nU+@l|7z&3+pmA2hS(N)xl_E!#iIlEtzeB#$J_ z|D6H)*nv1g#{D@Q(AQmJpSk7N>=%-Pr-vQ!*riRrH-#E|-gn~`c!}5LhLf_D)2b(x zMWZ2Inyt>PbAzr=1)rziw~>wbnK+>4~3iu}PVucS5h=^}HE2 z=}jn{p=xHkt>@zuW$Bq7W}lP)SS^2$NU(Nn) z+5d7>S?s>=PJia<{N0>Jjq}{>-wNL3r|4^0RaHf0<=7JJ3}Iiu>Z)MduhYvN)PybD z(UC#yZN>Dlvv$SaE+fM5aa54~2521R>iq}3Jd&gX+gP&=W_z4zdv&g@+3vxBax|KA)68=rpf!6W zWjZ8Te;HMf zFF9)SM^793?cOK)Fx6u@(!h34@D4iR$@4pHnK7zteIG_511CTk&>iJPY>_TI3=8P# zGvN#e)&>s5@DQS}E1|E{i(&v}o?*7p^1jz%#7~M}TmSTjF9x0ENo%c-`YL!NcRA5l zj4PcvV4vMdbyAu0RxDTY)-#%oKSF2Mjd_sw||J-<|KkjRSodV1nay#8Mg>-R~RkEplzg3tIF4*XL% z5Cb7%=VR-q*WZfua@7Z;ZrgcTXxnPc=#p(drF;)?lwh!fH*clBI%frx z;GMUq&r=zyY37!;+FE~gaUc+MpO=(}3}`>Nudo30NO?ngJd(xnw;o@i#m{_vaR-v3 z$A`4|v7bKFk!QB)@pH8JKz8?ayCDNTet{Oh`CGTFOM9U6t8Rnz{p}*e-~UD5JqO)> zaYy0P0Vsq0ZNVc;murPzST;`0GPD2913IKEJ!AbnulPo8yKKG}t2WG4pH3)xYH-bC zM@WBTphLId^}HD--JHC(-)tO=H({|`+fyE}|62!ElsM;xS>Gs;`{T%0?~m_~{~WWx z%ea342V$T>+ViH3bFF$Q29EWU4WLfSIUae4-|wm~Iy@OKxoK}k!j&Q+^&UYPp0&sl4^^HfK$%!Lpt#?d#Hs>~gJU}l% zZ$KZwwt(#beF6Od`GD;KI{^mceo_gwX#4+r=bUo>pRIwTyf7<{EZ3Esvg zudEk<`QEvhVe4fN9#hB@rn!)~t2Q^nT;fi>$$t57fa6>T&tA~P$Dvg{CL9Mm zoyd>iZEW(|iu{bk+gCV=3P;n4jdpIK+*6)KUSyq#dPlu%&FRlEdlUC_h#Vxo$AL^1 zUv*$)K=#5C(>@8_ET@&{u=T)M?HufF@Yi!QJe*F?!cEibWzQbD>hRrn{UFx$s2%Qe z4vpe-Q!fQ?=bF5>LXX`iPIjDZl`QMuLJyxrRx;edgiKe8_is_&a|=Xn(`ueldr2OFP@c-nbx@IZkNioa<`LRaU1)@v(dpV>$Fkc0?1SE!6V-- z-f+|NH{(DFj^8V%ya?XLCa*X{wlR!X!qAEL<2Z940dP+N_Y;tQPMs2Xf5xpI2VzJraxrIs zd%l`{=UxCgC%ppkmt^lye9`c4&v_bnx=Keb1aD)LSIPx8>hm*Ag93Odj^C)n&J%9S zuv`(Yx_o?!|CEJVKzp1n*V((ZJ&!zhT^2&x?VsZZ|yE9K3t;@E9j!@|E-af|v5dcbALheCyc6mg|KqPaJhd zcY2(TPZ$0@_oU13-xjCKMPXrjxtI&N*{XWT{7;@gtjp%}Y)(-gDHnn_`RA64;z>B| zvytDPH|?xmkGfnCFLC0VWe8r<(wAvo?xh+6;NC0l^WrimZ7+S=V(#~n`w`4IhXb?W zi=CagcY3*447us3o_wdz1`{5k4W=6mrcy2hZ)1~J%7yWr8~ckC5gb(E!?(t2?6jtw zaDNWvBU5KdUjCh-7z!6TSUHOt&K&7FhLr>yHSh%emITgH(O_g+X2`Sv7Zuwj9cRz(CywrL!Qij5(}@pdh&G_ zbo<|MA*7xah_8H^c!^IT&(1fSWY?^1`1E#p=>cxJHt8tXKUbYz;UDwnOK)7&eZ1ZB zkq+8l!Atq#%lL=;s}pClBhr*l%AUxj-Y!e~D*4gpqg#*f_)H`B5-)O1pK?#&{^v3P z_j%y6^430Sw#nRg&3pO23EOJk&-9kLaC|*)psf5EFEkLhwmDrsR~4t1i}6Lds;2pj zef$0V=E2)>GY=fcpp*;2TS)DaQZAf*_uRu1C zVOmo@SZ88C^!m}mdKpsp^qEH2b^d2w^mRMJe*Pb^Be>mi%y(_KBYOMNb%f0bC9E3_v9pN}YxN-TAP2kK-kQ zEqg2VNdfX0tklId7!S_DJts{bqB$lywl~QBJ8X6^BXhTh}M*kZOsgv|1fcuV}11mP&TCQq^?=VtZTN3 zw4tnT$_U>#WEwp^|1+L*WRyw95p>7@v{}}J!e{>fHW$MKi+qGexaGqfmo0_--1*hc zd#u}gr>7ntVr$!IFpuq~;7$JN@{t&q;XBaQH_p*^nexH*fjLW^nEC1d^)w6%Zflqt#x+bXtEltsx)+9vvpm%I_Q=p>%Fwbkk4v$^GN`7rxc zs~|sP%ik&<^vu#tw~OCtu|?!V@Ft&h`DkfB_-d|wM;y6PPUSrc)>|sqmL1_e)N{TE zLOVhkAfdE5Vn?L@DTkCB#%J0YFd>bLAx`Yb+|fxnVY?kWf3DSj_pHcO+nje+{wnyF z6>cN_~I_XJc?_&X=+u&a#UDm4GRL zQvkOCJ^*Zw@{R?34mcVWy*nzp4-CXuDEZq^>bD>SAv6w)QSs}*ILv~8T!Ht79?!>| z?{4^RbqT&THBPBVLP{NRmQu&xqtp{$A%4#+)#dCg6~O5y$6wMxWgp&AoinbJI^@E2 z)PaTTsd43<)sU;L*;}{!zYr0r~>;`6$U#@E|`1WU+&ex-XI--ozbz^Zrf?%6>%E#mY0M&BHr+5gk)7^btoLB4O6iMM0z z^J2z~9zHy1edQc4m4||1p2k;RI}S5gzKHW8)xhQv!6SmWDFzUIEE|*5N7hf#z>O_^ zT#5r3ej2-Y>U_|<%bjocxo~_*a8(ssIh@6Sgw#jDTS)EV(npSkHC<#f(_U-0rVNrU z%8)Kw#PL7dZE*}!ekr5F0NVrTnC={a^dAIAKjT_*U@lN1AF*+6`7rx^D+q^SN~5+DJS$P zOCnF=6TcH+5J1jf=!G!*1~BllgkV+t}pwcgT%rXz6fPq2=OWKIxNwqTqjzpH6-x zKV7!c)jQJ>{_Soy7$EXfc5r(6A+Ns6Qd{1!%f$Z)-)b!;*Jhb`iBGW}iDuJTk}UN_ zqTygO_hRUDWFO*guc_zMZ8;ZaDd;?`=9st6{(eGpl~d4;@Yy~J-a#ikj%!LsR(i^U z5qqrb86FHyX$*Pn{h`7`+pgzX&lNv? zNX5l@LIdl7Ex(DEc+xkj5ho&6N3pp^PD~6o2C&`H7mkj_*IsJzie46~FV^H*5F0pJBT3&eg-_Rh45xlf&q&MaG2d z5g!9c`GtqIU0;Eho|@b{wlJG?($UYtPw*B}y9hrVPLP&bU%1#88B*QAWO{upLHTVx z|E-_$7Akax!+*m^rf-jY|gyfa0{{hb_$ zp>Szm7DH~*$?;soZ~oxf1H--@FTTPdItLX=eH6U;EQZ{8iX+W|YT2}i#Q9G7((exA zzvQjw)#RjOza>v&DR@0^hK0^DZ=fbp=beIcW;i`) zt+ng&OFa=V^U(k6{lrxUy&UVYAJwyuQWIWzdS~9Z#hs_rSG{=DvkcQ=O3=ERcngh- z(3||2g2$TBsqo@loG6KJj4-WEhpKbig&WaXdXm#gmiVDvo`YjahPFJ1}M9O`>L z|1jR2{C>3HZEW%?bV&aJQ#v&c4X{u6!k%TS+PB|4sx?2uH8~k$ zb6*_i;Q3xr9)R_`J%DrZn4YrE1uca?0)XjORSlR5hyl(5Tn)Gv@Dkt~0MAR>8{h++ z4|p1|0hFNSTU^q!9k7!{fDZoV&ndt(CS} zZ?C&faqGbXJT&!S4)kNxIh*_z!s)}WmQK6;!S3H&@&qRf;rak*KLl?fwTr0-Rl#6o z0}kSL6o50Gwpuv%tbk9ul5YP`I(?uG;@T4Xvz(vj6Y(5S_P4n{)eEp4faAdez#f48 z0D}M{0pkHR09_~M;s4!$7XV)XHinS!jPpYQrvUg(`5yrLKmbnyyaw0@`Y<1`EqF*i z{#E(_@>a`<&WKODLK`gq&CKwaE=L=*HaT4%iW=PdV9w*lp)XTUxo+0Gdqj3ZRa@=@ zT&WL&chCvX)CXJmttQIuCZZcq7Y+u3b~DwYpZIuT4&v|Mg?GzpTEL;U|A+?JsFUfulUpwVUveH*y>zyOTY9y**_*;>O+sq zgp(Z5cNe*{8EilO4=l|0WL1M!D2y&ND2Bys&L62C#0-c5VUU`|TBY_TFtz9Kvxa z9k%*d@*;Q(sa+^9+`|Zo(AOI*oUhCum87OUWM5y(kTmr5dB0F&dU~1utet1f`_GYg z^k({U%%6|-K9Uy z{xRenWt%Cr<}BLJh<7Ov5m3iM9VM}{98Dn%So)+EvM{*vri!FOcjXl zvG=k0cT7L5zto?+uOxW$Axt@Gxz1$YQ2}kJ<3Z41#cm>3+d)LM$U?TWi(<>;1(f`PA6|6oiZ-r|8!30clMEP zx~Uh`JDJB_jOW_!%%8To=7YN);9Lux&@Ffyo4lHIR}Od9e@lJU{s^`@IZ4alr+SWL zPVIZ9n3Ione)};-GhS&+4>Q%b)B!q+Md(Q2}HR+V^4$=89&2;wmC2#N!X8I`@f(KJ!WpFRbBX6$1cabZ`u>V zn+s=cgUW2(pwHe9Otp0BKS2#XN&#|^JU+KV@lfE zzpEedca@7r&bSN*TIGP=e^ImB{_c5Q_^So$?DaC27c3{^G{1qDc-kB8=aqSl={I&r8fcTR%BL6ImnKl>x--e?`0IPz_4yvG7W@AWw?!OOPmZLoHz zIjiR_*UzRPFDXmQ)+OhKr@Q6cTtAzO=L#R!{nT}`cYUD;H^{(U10dakw~*S!q}$jJ zHaHlb?hV&iU&FKd@Tufn%kFmvxd)7EIFx11n{%Fqdcgne8}PsGr2WnYQske$0NZ%E zU)MD~kF_zZ%lQ(>3;9tDpiiD~?nd5sK~SB$>DwoHN;{uTKGNCz%ue8KZ1QT#3qOb$ zik8$_5-w|KWBpz%E<|{j-Y-;h-12MM>4|6Ls>g?2({oO@;fw53N$kCZlwZLoDX~Ka zJ;{B});4$hEsgfN%+#fGFnsqAw zO}SxuksG;J?3Da(&6hk|i_hTQ`==K}Zpi;)fbg8W*7rR{h8U~jPi>A<&7s<&fPX1al#6PAzV>$xy1oJ+iT6L?Fw$)75 z@(8^hj6+`7hbvC=%r~EO!?UALJ@U2AohJ2UGWPfAZgKGTzvPwj;>e2qZkRPX_f&U58v+qNAp>HPIIFH}u^Ug)Kt z1?mNlzb@Ab-DTcLdeZgzjo3x$^=}2}o;<&3*3Iwku=neZu!{Z(-bEDt82aZ)Y(RAS z5;AEJM}E4UHuI7HPO&b%6C8coa>D93xqo%;`M0Ij<#*vF>E)#7#kndp2mpX3EUQ=c=_FA~L=KL74qF!^ortVVr z_?tYZ{g(Ycg@`|=@%TlLZuP+1d_Rs(p@;RCeYu+-X8p0`tJ~FM;XF7Rr?HQ!3HR;EYndtxQtJ1e~E5Wz!bIOk%^KXQl= z{TIARo5>e@M+nZf3)WhzCuTp0_L0tPpLBa*r}$&nHJ#rdqvoG`x2`u`=cShqKE{;5-ufygBTT;2m_rYePOflY_y@JZVU$qwpFx9p-$>T+q4ix}8V8cG{b_ zQ*Y@gPqaINw~*S!q@%nsT3%ZouJMJncSDfglvidUwqLT#$d+*8ulL2ivi;7#)-5M| zhnTP;(n;;N#iWWQkfZ6JZxI>&?yw(A9a6=f3Eq4HQ%+>bqtX|R;vJC)KEjE!sVeFl zBjo{zt(pkX+bKOiv2}tIS(X3o@%3@a#OvJ8YwE>f@MDuL&VT0d|1B!Adv?kGW)kl% zwaw=p;cc=%fH&M9iB{qa347r&m7chB{^$G?zMJ*&&!KS5Q=-ewsy5_?rN?f5`QUF4 zd1HXxgR`&w(3?x*-88mGZmM{QT!}a2t;V;Rob_s5e`jCsmgiLO3tzs&mLH$9%lLcq zXyD;kms{Z~cnhgr+N8^QH`jjuHR77bD!ai=5Bu1JJm7l|m~}Xd+3T#r}Or8mg2Wza4Nt+hy%=8ypKn@lCrg865|>^N72o0JyEmH=~#orOD5yJqBpuc%KL`gd{&=V&pY(M zJDkoF`%JyiPZT`U=&o{Vy@zK}PvTc9<-2Y`;!N!FkS}1ZYgC0BxoSJb7l^p}i%UQc z^QYX?r%v)cpXDPEe*9G)wW1E3e*dE#-`@WVhUu7&R}*icajEokLB;yIg{L?a;SmW<&qi9-Klu{7Ej?cxI~@MQX+QN|v4Ks1b!H6fSMXB4_~eT;Ge_+U2o^# z;nrJooi_XST-ABmCwrcJ)0~rUcOF9CyA!h2^!@8rL7AJa0U&0cX@&6bHbUB&0&@CrsyH{{$u6pFN&sY8A`RRYAeHXk*jayCz zHTkNo1)>)1UBP2=q+T+ zX1{f4pvKoU*k5m-pIRQ^mphnJrz87rHyvziNQE#v~(%yz#(FT za8Q@uhe4;+iiL@@fwu8E9!lHMX?~|wJT=Bn$_dkMRI-4(9E%0`1 zOFFEP1*g*z6xb7-uF z{t@F|KPE8wi7Pkp&a(-y_^~yvf@d1tnRHm2ldun|DriZpYrMH)k-L1e-CY3ss-{dD z+V{6AU$xUQqP}okC3wAThEwVBP7H+1FG! zJw6j&J2?=;V~M^lc*L!*W_#cDVXUjp@ATQo(^B}UfNc2gUQR=Ta#&?%Lj!!*Lbxxn2hjB~hZwe0R{nEO}-ST1f#|j_KRsQk? zGm197^E|QVA|HY`i*U<_dmbcV)Nxa5cAa8KSrB_pUu-h#nqjlf`CkCR7LIY!Ht3Ne zhhopg*VFu!VR;7nbmH6p>}x8V9-j%XogC2D+w-4JueYn9*A=@2a<1+1@t*r_Ve^Bs zO}j35lS|aww&y{T8k|ah%{>1p|5NEqD%?MX-V7aU9|xN7NYXDWde*JK6F+vo7j#1h z^~o*|eG-R$->~JJ|6}h?0PCpAK8)WkK-tR@D2NzYq->$=1r!>(kU}?_7K(y2B)3gy znuH{UmPNv%R#_~vSOqc2RyHXJS_Gk>D63T2iU?E?C@N4kDewv3|DBmPIWxJrX%P|S zIqjL5oY~I&=FFLWZod!K-*5Yg$;pUszn-2IN{+l%Ymy;`q@u1<-*gma}CNx^2AiV z-*{A2{n(~>jBGjiIJWPPV;)(L|JJ|5`(&k$q{~V6yv~+!{(?W;f6RoRU;0S0z-DdF z|9g6p+|ep{e5l0mI(ubpRkMCevraz&+}KdnJj+H7%kSdHi|1>e^1bG7`@S@D{3^BI zO-}aheLFjD_4JMmB^~MW&5rAbU9wW>cr~d)Qbw$rEr?}qm97FEf8+Exj&}2+w673$&2-z?*?kY+*+Eg z-#tB>xpX;6Ur+2($!lcl`K%y+BhbA-c-%PY>Ehe3O=Y7eT7G}nuTS{loyozC)vfkE zfTw5YWZQ4g*A=^N$>IKINhV*}>m@eNs^1)5{+(HO+}10|mmSY~dY61<_c&dyoWx^< zJ~N-`+2@}ZKfKo5eGh8-T{1)Sv3z)XmwXiR5n6a$JwD&m*lcetmN(Rl89pkSMCg-S zQv7`s8{tn+oH_q%KX`h9&p*E3wrZDj@1L9(CZE&I*J#$`>Z|JXP~6PcL#pa$&t>hCm`^t6bSb}?JuV5*Q+FA+xl|VyRWZy&Ke_4slgA|+ zjqMJP(v=8Lw_(DN)UV0QgymE7Q7t>Fs-<;eQ%zN?ZYEST&S-8KHDS2klRq?{pO%dL z-&WraRKBgw-A>W!UEBXy-CL$;_3t1>tAlq@w0d|qMXQVVP_+7Zu;N~ddnh4V#OaTT0L&%!t2|1b^HB=AxqQGhp(Z2Ybq|% z0zW?X&y&@eJAR$ZuDfX5FKo9Eh2BXso1XNJzN42tdaG>JPdS$j%iD)6htF)P3oi=l zS?#jn&CQL?$ppgky;%9PP_Agjw@~?B@21@b|MmwvKQhk-RIuTWQq$9;#Gv8jySllq zsddGRcj~(3oWG~@l|8SW{L+TGvmSlsqMvR1qmpBL$6_{y9oKkzkfo?IeO}vf-LlJ} zUiN&}mN%Y5yzKV31#5e^|84CR4K~d})3xy}Jv)6%59eop|GUG-J->hV@-Y36USPH+ z>Gj=$SJK;U_PXVOmp9BkI(FT+dtX_yn;pwq=&xwot*1wcK_k80W;WN(%a%p&tM*N% zS7@8+6U@u{`?eRR2ZPZ0AqD1WJTE6RUr(2lZ2eyG>V~=VcDZ4C*~VoLc>V6>#M86c zNSBlJb<0etiAF6{&xiG$cY8ZKzZLzPdVWQv819oS5FR)7f1~*JYs+!w;|=fZ{pyTm zqmqLh+m1?g1mo%1Wwq_M=j)bTx8$&1X;;2%KIMwmE_A%T<2q06^WAs8b(7COzUHw? zE}QQCqwmCIu3g5*+Xv)ZJ8r#q9%YC7!+~$6oeEt?J!jZJ4|L`NO_;#->}B z+Vw39wm$55z|*6|pwZp>sG6!bLWkA0Oe@nXvQ;{huF@w)qaPwG8$P|Mb(T+}UGuU0 zh2M=xX6=JS%brc^=$Ul%)c;={K0E%W^pj$^N)zP(+Dm8QBt+pjl%ZqF)l8*piPX71o0TmKQJIHo`9-yW@$o>W{uFsRonnuUAKU zHhEnffl=dVj;}e{1wR8tAD=elBpMN{-bQZ zJUyOjXR~9@@ja2U9`bcSbK{IA%Uqi#;p=nIJ87>%->o}y`%TU}W6QtTWs)ew+nM$o znRM@O>ofWU+}J7c&nN1eaLpqdrZl$1LxlCa9ah+xq2mPPA?dKL2cb+*jA4ROQ6=;GooXmNpIG%RTVj^m1qGL7Ud^mVAB5Dtiri zeX0GSVDtTqnw}md293`8*KVZQ+uwEC9VL0uaBYe{|9Qdu&AjxI)uLrza*(b=9lP%m z4VwGgY2W$Elc)FHDA#U(#qu}sUDu+zf^w3T`(*vyrtElqcFzatdfe|XPu9-t*fj=SH&gx3{Og{dJ9W47*RD!7 zXs=H^J-c+B<;1>lqHh%*osS-?wQmU8kCTo|<{#E01CwcQke%2H{2lJEbG_|Ocjta7 zyMLIhJK_6$`3pB~cI>1b-cIUA+d*3W=;_e}f`;uEZJG3~&9c#YjzH~0tLj>9XK`qq zz9BQCwfxwsx_bN4Y-Ll8s?U}dJw#l1I|wG5^J{6A)?Hoc>DKn{a2mzBlf^4G$fvqr zc)mNRZ@S!M_p5VMuC6*~;P3bO)sAc0a}XBn1kcKir$>oFqjNjxX1^Mhrs!8qqp=Fr zo3_qvJ+7)~$CoQx1~dxcBN7Pfnc7v0mzR4~p7z_O_rN|oKDA!9ym)#xTPsjrw13SM z8cl?9la>5r{T-e+we?Gvo9zB+iOSW2^*-O{j14DNj7d%?x6tBPJ>%)wrRyv=_VG76 zbBXr5UCM<$CuVg?KgB}zh^2+;VYhlk!P3J0N;poT;giv56%c4snjeR?uTi{Q zOYj4~{`(3xt?;xMUOu`*!6hU=rIr$>oFqnmt= z$xm%;t>UOR0~D=(^7JS%Xmpdm%DCFO#R}AUZ1gX!|S_~HzUl ze!Ok@if{Zx7qH68tE=-(twZgFm9forQ|s*cUJC;iLr1IceIC}|LwJ2ut;L#POq|+j-5N+luIVivMKV*aq8

    1. +h^WCNy_;xjT zqxAaEUKg6H<@(Or4?VHbFQ%`yd6F^Dx2Jo4y`6Q|{XaW#^Phw2a^7a+SuSjQ^=N5? z|BOJm9WGS)ux+oq?a*@g5Rp<+GF%lu<~KGTQ)sPRwG+JCNwsVu44VJu}KDeJM#1-xucbJI#|E*Hm$7lmja`E z*@xEJ_we=mX7*u^F^#QBZfzp%0to9dOS5|cwm!q?+g#YTVF~|Ufq9y|m!GAdDPDdm zHZ93*_3&dC^#1ktx6`foDA*lPJAUx=B)Oxt!sVy4*u*7%RNZvF;~Jj?X=;Vak)0oh zWyre2^5fkdnW5v~CJ-KnL+O5FxRjPcV+Nm<%(3%^p=~}t|Z+YK$pceR}djHJc3$}OA z?A>5{SaLtbA&TXS`zsDr9Huy2afIRliWQ0@6%SOjZQI^a8?87-(e@SN6c1J$uUM%# zL2;s@?dT3woTO;ar`Y>zUs1Go*p5*As-j&3nXFi)c$8wbqHWlD#VLw*;9aX&r+BpD zG{t(w>56td+^E>3Xz#r>E4C=MD$YI_&vqB zir-hXckM1zyh!nfiWe*XNU>e<62%`YUaEMR;^m50C|;>JPw^_ns}-+NyjJl##h)l% zuQ*@v2E`i{f2w$s;?0UbQ~bH&0>xVtf1!A*;%$n*RJ>jB4#kCvcPiec_$$RcL|GOl)WMMInVdcFs5QxfIX^4(q7`bSqk_q)p$A31Px zJcQ-j!WWYC_^-}plJCm8sSSEyuQ^{{Kee%054zbgkA+f2o4@^z_9V^Ur{7CxYi9b- z4Epy`|2~=ibA$eUwF5SDJ6`hTn>jGOUe-`Qn}@&m-(UTY{p=2ZJMNLGyA4#j1z#_o z9;bFTljWRaODyx{t<<<*V}tSp2f`*+xHMY?BeAYZ=Rwmo0B zIb`jtns3_mhCaUDtldjX>FL>dCd)TI-;mtl&?$&L#$P$3$zFNrIB^a0F?$8_QF+Is z=PWq%q06%Q@bqr-F?^FH5o&`3PuAFM8KsIF~n9yzR~^Cz_1G_22m@=hhu zm|hRqduBCCnXP;+s(xzupdCtbzyHdkjeom8->_y<5!n2#9`N*N0zo60|B?Fr?uPhD z*ds^jwv&Fw`^a5vu#ftCB^$Ur#mf|LR=h{?DaAJx*H(pT&yG|m9 z48`9m4$ww*wBoN72WmsQKyh7d^ye#XtBUUd#kSRS?xz+1d9C;jw83w#4StxcXRCsI zWgVSM_1E`L*4J|g8)}%1G`#`2+_Ft|j`3OjCSs|UYb(8jv5o499dzz9Nas1bYhL^4 zoU&Zyq(bLrV|5;LsLn?wYn-EX{xL(tpQ7_bolFhXNl}|lY-TUiIo=~WH~eeo`A7CW zXD#}_97GiDZ>*gSh0?OaWd9a%REJu+)nE2^7%Yu|z{erbq?vfVI&e_&dVP`V-L;Os z>H1&2@$fIJlgxR&>gm}$C-v$f`R4d}`$@_C{Qhosc>8-@MO8T~6~g0@b}fgEUtVMi z1D|crzxcwdJO1WuJ5q`3Vry@kq+53wI`$8BO||*v${D)09Q7_$)BNl>YoX@r)9ob~ z+m6HjOM?Er)!*uluzzmn&hd9z7(29S7+*ha>fh6H-TeDejW-{2!Q$0NYD5KFKNfzL zq{n}CHhsAc%Fh};v%0pbVXE$D4;@x9JQ<`^ZC}22&EKbQ`z%{eVgH3e|G#SoXL)T? z^!yLmrRV&g_@})}{<&mr+wDcc^M6t%-TQm~gZ*~+`KMI=CTsrT^ljR66g_{-Rv>?u z9rvTQ!+zfIwJpnTiHNkDi^Anedh%ySE6QJdg*kp^B)WUA!PSHuC+t|l-Hb~ z{~sD(>60CQe$c=4je}On_FokAZ|Jvv^vZjOIxmi!%eo=nf z^BWvy11Q*bV#l4H9wi11%a3CA{%zssi*(PnUDLJl;q~V_$+VK$1ye5G84j<*x-Q2c z#mA;^cLH}J^m1e8-&W6fdUol$DK`b5XB(40u1k6G>4o)%rxk05 z!&A=`lUlicVLh{0<;Bh+%N5Pry6srNpWB?T{(CQ8zQG$yuj=dT!}m*`uEA5GoAT1l zb4C6%QP<}Vb?P7GDK&BZ5$1p4{^{~=*DWmi{r;vemgKhk`kEyV{^h`P%aR2cp#E0g zJzamMg5^JaPO`}Tet!-z8o$u}OPi&;+A*&ire^qG{D&QP5fDHC0R%o;fp9-JX=r*s zmpy;9IiEFpz%9>xX51jph3)6;Ipl1*_xJtW(Awt4>2))v53R4$<7@FFkjZ1V!}8UQ zHF`ZkAIz?r<>Q6Q0&N_Ezf(jqWuyHR>Vc_(-90hF+}D zhjQ99qMy&@hNrKO+J4iHY3FFQ-nQ$G_Gnk`l3sg$ZQDQZ?zdr+V})K_(rs7^mYNS4d%-VJz($jsq-tK(AH1++97-3vh zbBkUjY?)Et>ch`ghkFbeQGERjQ2)Vwc39_-9bdAa=!k;d_p;+QPfwCNTAlgv^)aGZ zzsJ&`buqH#%lYQUWXOSPhu1;k>pmTm>F8)nhTGt*6yN?9D!-TS^ONVNe0%J# zev@Q)SB-D^_4JMjCmr3qe|f0x#YgL~UDFBkxs}GVV{`ZLb~s%-e$S@c-yUsP@9$~; zxAh~exIkE*m#Tc&HeFt1^!J~;=7swX_`wm6-5d`zB!T}RNzaaI+xJj=u|ZdRbw4@0 zzpd>)di^pQrBqETCw3p9-^h}j&&PW1p;)Tu{Ram9uUGmS%0pP6FI4}YmgDO8w%KmR zZDl7-P9A9S`tzD3U6V}(uQv4 z{<#B#{#qtmhH$y&s((+*byxNJ2UoxT!^3=ey#1>rU6V|O6<@A+pX!TNs;T&LEl|FE zzBcjfaxD(}+jB#<4DE_GzST=J59)cjuKvbo!1hzf5hTD|J&QDV>- zbMWx8@e?M*-pO4n|3JYOszFc6TJI!_%!DMjOWJ{R0%Y zRkU+{yS`?dinaB)L-e~{KED1WBm!Z5x_E55T$J9?JN^#mt2(YZ_l7?V9#fJVa>6Aq zPdVqU#&>N8u3%$Wx$yKTF=$x1wqpeQ&Rg`o1AFtjOph$-8Mx?zPcrO^mXl!8sZLwB zt0?-u*xDYf+tY1do(oFqhLAFJ7UqdYiqg|n2)Qx6e=5q(t<^yQv%`sW|7K^ZJ*_e*4CqF(KDcv1!>>I zY*YX5PkXN4yX!1I@H+{veY?`ii>GUpROmeK7+2NWns4?S^5ZmAq5X~B%=Ue-<-zs~ zD-y!xXsRrJ{#2p8fMj*!uls;=UZ7o}Fjsa*S*l(-?iZKN=)^zOQ!I-`#ZT5%*nU`LbZ`UTS)JoZ8v!%wOt! zQ=c1;&oiTkEj4)PRB>3kei$?(e%`ZbLP_p(tKIv=fI~`hkNtdF^~>w6viWn{#4FsL zJiRjqaaU(P>gN*7cyBA_*MvpXf7@}!j*2@g z8mu0LjNI)QWQ^iO#Um7_C^jjcplBCk&Qtuc;th&-DL$gORMFP$Mp_qx6h|x8E1s=* zlj2i~Ylvwd#bXq&Rs6f+F4~!$toX3vPC7_EPqDXlf+r|`pg2bduVvcUo>csPKfQCO zLVu7BhKA}9s!A1(6ID3w)B_1yYoV{viT*@ge9)ucxovc_=@32Oddp|j-dywfyoTRO z&vb61`E9Rh?WDZ!rg;q3yMFuTazlpcowWn??B~IHw)HUOw@S}ZOw+Pxy=xPW-ZLxo zoTswe5wti_@ODR!73>gE6s+yhr|*AzI~lZNc$=rs*V=ZBVB4P-Ir@E9duGGV1FUVw zlA?*e$!%$3jh>wscQl^O)6#4j)@}3jVAHnY!Zho)x+qNZyePRNSegx!9lv7$I{v2w zW@~Bud^2~1HcEwZMJof@`gD=%+tC-7ZgS2^&wOr=0deWE-!HTMr>EQaVd$nl)qz$+ zYj~Zb&~_V6=cDSj<+5OH+jcBicbFa}CJpcB+lsY)yWLXVR(Jb$Yx_XkZtWP<>UZ02 zRV7AgwvGC>YTK<%hwWAfgbyVU9tRCLGQHhq?;p+7cD=_Pe}3e=pIkV7dn=F%zTJ9y zoZ8v!+-~>JPtnh+YJ07*zU|r|!sFg{rP^T3lm8RlR-zrAs;S_2}*FbS>Tch27zBmhSa%m`?Y~3(V0dzTa=EE?!O+ zsT}>~#c@Ae_pYzscVsdv+s|1!@$_sCI?G9PHLl}!m|d0|mv0WgIT?MEG+VEDJ>q4; zrXO}^=a>DvyE2p=j=xt-V6F!9@-i=9yu9?Q(Q~N#-Td3-&ptQncgae#b6qPho}QiS zN|cw5d#E;zY`O7ctFWwu-9Fz!Y2MG;);}D^>zyzy9G>pN0&Pn6ax-vB`npkG{iY}` ze^&2o9(LUw>dc*V*r9{ZdGp2T6YUQL^PZ@tr$>oFV}E`AwZ2Y2yrpY%`T?|#&o-%! zskZMmh4tJ5&EG<~qD{BUckGn*y$AcA@zS%ecC6;OqgR)74H|`xXEX}_9^9DWqsBGX z*H!CxF_YoL{8UU$=O=sIW}|HW!$l{o_SoQelhKnh*{e&s_g~@sBp1}e?RtswW6N8v zXl*}VY1f5_ollr(mymMJ8+`G}V|w53hYKC~$)?+|7CN`<)OEdKbvhhmgEu|j=i?sPbno9yK8EW@w6yWZzglU-hTGe?X=x7? z`{+LCav*dwa`SF{^owU+dy?LckAvqUo9_LK=R?0Gk*^sxqghY=S(cJ-6Wh3< z&&=uRd}ZsU#me`OPx@l(;R}x0x}UDkS}0Sr{kx|}i9w^_eYfOcIz4GuXCEnhgyT)7^01&yF*#F0o+ycss7O`o-Gzw?#syK)X7<-doUEyqpYZD9P-ev6jD{o&)KeFH5o(CD0h$9>jJ4&s5^ z)N+R<&BeE)A;;)<4;L>wVeh*SeV{t2tn5CsZAYFSWFhM8%tz<-yRwew9JE3_jbo-o?uG`sf7MEE=XAbpM)qc!dIdnq#47;Eg|9nAeyO}$qczIo} z{9bYUSAX-?#Si_UEh#A0vhwQbo)2%Q^Anxo>o_I)1VUMumv$AjkE?$7yoGHq>tPz* zodRLG9e8ZIoYZJAJM9dQZ{Iql@69{?vuUYM!F;VY$)2Ydj(~fJCu1}dwF%t| z%vLYoKQC3eF|Tq(YZt12&)VSlx7#*2>kZp?S}^iv?dlg|6#uI_UMyw)^3{OU=WAwR@@Q=}}_P z$hvg<`xMDmI_ z?(V;7{oYX;--6XY7OqUvy&<{A_t_`waUJ z3HldWo<%FLJkJduyW8epesRrkyV7iOe@W7``22kRg!RCHlhfrr zyC0i*Qc3RQgQo2{;?ASCyn2;*tMvQ*o*w4ax-GwU&X9V3K6`ye*LvDj0h+tl1Nt*( z(SmRP*6nH59ft1GZ5W@HwQU_*9H^*A|8jN#%)U)w-@>$W5jzjF{iQKQCum7lNOztLNhPASQK<%QQ*+w2!*2hZIx zt{LqritR5vJ!{i>UO9YbQ@&Yua~t&Il6qyWs;0~?cFxk(-{^JO=%cmvBtRVI3Ej%g z%KUDIty^2y_H2nB8;zc;vhB~x!j_8LDcbuuUsALS*OL^FR%}!Jf#NNS&nT{?c@I_m zy5b{>yQ&~up=i&XJ*IfE7X3RaEH|jotfPweMir=QRKV8Mj9=`p>8jE=Ni#lPGd@8x zzF9M#su@3{8P7UU-&NJKsLxN!<(@u8_arXTbFR1P`o*()PF5S;#udGCOTXPKH{r=% zxzB&GckZ(Jy>rigu}|*$=lkUTG{0}|=*w5h-F^S6x%JEX<-W0a_1wcxteKlPbe-JT z?bplIUcF)NzGnvH&Rh1`+>F(?%I!XR``nz}cgr)5B?7caPg|^mv?az40+gczm6m-Y4;I+cwuw^ldcU zmOah#?cL!v?Ax#P-^vHe8+i$+g&(B}jYu0{$ zzH+Um@piQ#elOF?ho?u0K_e_5K2|yR z^m230dBw}kz;jD-WgEAjIDE>Ix?}BtNx`mfS^eVaQDV^eQ01m<^zdOLCyuts6e>UA zy7u)P%(C0gV#8+p`QJ7#i~hGwJnXi=Kg}Vve>y*Xf6uOISzSF@fc`vG)2o9nec_f( zC#|2L*>&zdy4vmONpeT4^Zdh~hdQw8*s99v=DMcV3AJ_2HF~(Ybyj@M)XQ<{1;z8R zNcsHvu3um8>4y({XCKUyJ)-XGRK9Uo}GW^@}#~KQKk=8*rfk0 z-;1zajjeZkG(nf7qvy5kxj5VR=n?&#T@STuZR=_e z#l02n-pc-pBNPu(wDmAi@hgf|ic=LE6lW-&r1*8kvlYLmc!}b*ia%HUmEt1BrxjmT z{HNkN+R#fCcU3$<@o>c!#WNHySG-g4X~lmkZmu$3t~gcEzRmIr#ifdyXvZ^J@pQ#I z6yH}Y*9qoq#YYsk)(*DLtKO45E{)L7K#}R4j_|b>AVZz}oJq*SA zg~QSPza!ADMe%xd!4K2*YW6sJz(pmw>u-Dg`4``N@y62@$ED>_jc@x2PtVG%%<)b# zY;d$w_;@EfkB{PSs}F36tp43y(Z1bdb+Y|!)r_j2=$P5NZCD$}_SY7yttu)pVSV<*%$+bOvo7Cb87Ja)>s_-UC5RV~w6%0@LFmv3o3ct(CkKAu#&RzjiUk&YRy zWJkD8!|v>4K8pQJcAEc-f46I)yd1S>%2Bo+vgP0R+jo7?y5@)%t=mGpkMG+hJ?ewomP51u#0pzKN zR<){lt7x~xMZ01~!_=~gt#$Q!J~sJyc}KDL@xtpIi&h|C-+1nxn)x5xakP)``O2ny z{}s)b{h)B1>v+tWYWezX`*HgG!`7A6m3H~gzNcQH{=ZtU?`yen3v2B9orUcbtzPi- zC^2ZLUMQ<3S?%{`y~9 zlDlZt{$H8#$D3|=HQB&7*Z7uSPY)&?by|Ltx-5LIxSQX9+oj8SzU`0xT_LQ$?AVde zvp~4rExn?6d8xQu`@P0fF1z9J6Rymb7f;X5aV5)3x4-{Jxyj1@Xa5fCnf5Ew^`ccJ zw*C40YBSaUnqejVhU_`wR9}x?&v<%vX}T#lNi|uiSIVpNyOdRUH5*-z3F}L%BYj@s zw8MNax~h12A2hEd_rSL|TB~f`&wk0vyG_^XM^6u@ZQb4EyJD9D?_Cu8-MZ{_KZ?Jp zA6H&+wnp*&|D>yXK3=+Y?yWD(9r=h|K97Qxb6rKsWz(Z%HLSb@`~Nb#YS+{{w01;e z^VsIPsdaXZ%R*Rgm##oQ&b;u9FP-szx27ozrX(~aX#Yw=xZT4PxpLyJL?i3V8k2Ip>?gb zm5tTY^7e7B27RwXmo~%wSpRE#&d(JCF1h~yW*&B-&(D3b>E6Ga?Yi6F7xaoLEI*5{ zPuG)nN;gH(zcVve`To{@x9)KJo)y1-#7@)|EMHdNczTo=G~6lv0i2euUz(|!8l5=~ zQH31VkHIAVt(}F=8&~Go%RbNeV0MR(3p;eVjn4jeE6FczLE=hX{hje!d&IYreE$8E70C+`31);8MgUPAG4cj3cml`J4ugIJDZ*# zf8E92x3j*bidO&Idv*&nU!U$hO1FD+VgJQJfBXGf{ZEy*+MlNPW3~(i=GQ^gnLBCL zLFd;_J-q(&_J@LQZRwm~&5raaF=!~?;dQN{jm<6g*iwDn)Y{h3`PSOTn)3R3T@0;B z#tHZLxtr4KHG7@IM%nVZ+5^sf`3Ad{7=`%UVAC$?-rpRPJcZXe3LeJ~pQ$&zlMfQK zX##${*rt4$UAdyQ3pvf$evMbgo_j)acQO!&c$( zM!%cW^S5{@@ zeikhL!v_uXF-Q5Z;10G9?f7W9qJK~7{do`e`Q;zpe_TmXuzSUJ$2glFC99F-!=4g| zzV4c@iBnoeHiVz=&b4V+UmufymiDmya6d(Vj-kK$Z~5Nx&;9nNbI12?YvlCk$ZMR2Ep*(qtEkb^VQA z$?ub09#7BCzw7eE3-a$=j&?1F9cy{{u@^r& zQf>(fYBXrLedKN_z8>c*pA(K5vdgB+*1mF^WJdO^g_TQB_xXFf>v~kVw2Rx(DP8o* zp=i+V*6aG}n^Xxt$rWmc_43@za@n?~#~pHQQ+ws^Tl2I>ZGsK+&YOF~xND!>+x}3n zb}uzOJxUB3R{!ZdHQC1Xe&>{Yb925q`kLh|oiuxo%II^6ohQ&?z9#*m_oRy1p25Y+hAFZCN^J12uM7KUlffNwo+|7wKCFEIq9i?G=l<-4?CVu>R%n-r}N*?ZdWFKKR4i)#mk2+&w1k( zU-!p9K5@05E1Ojxtw~R}VZvbLL(z`W!sDU%;5OOllJDT<0W>Emg9z>bpP66{%nv9lJv~r-CcK0<*(zD4LbNJ)dbATj)(72e!}^g zMSIfUwzqx@i+k4IuIt2SwXX7;2YYStN~uOvuzK3IH&2fegGOSxQr{CCHTF>doM4yx zYQd!cEuH-}RjW#DeZ*xY-u`|4*i0>*5DSFIX^T{T%%)t?+S%jIHueAI-@f+vDc66m zpY0DU`2O9~1qJJZ`iq3a&gcI`jys%3{f>p6|f zM6X;n-TPa;Qdz4H8P^P}({%;?Ohfam(NzsPc5WWqU@siRud0l$ni;=~80Kf0@)NpR z`Ly%QMS76*@v(oNZ1dQD`RTLI-RF@J)@{M_lTDBNCfDOL`H6m&&VP1&xW4~s`HX+* zHC0ax`gPhTyI-DjS4r;LZ#TXI^SRNNnpSs&+EmNK!kj%td zn`!Ai-G&K+)e~KgPqW_v(stjjk^DHQ^fx`{qjICF(LedpgnhF4@boYb*8SnONA0aaFT06VG+tvTNtNV>T^^9J>v~wp5wmsSU_Vg$*XcS!E!3!0|*1P4w zg16(piZ|QT+n1;5w>^9RaqQZ47Y%#Ti*GWoUb$?#&$V-Tg73vnY^u@c=xS`3aDR}y zC+%tFcoiE)*|O)eZ1^j__M?|xxbxtPt=od_FRYnOkCN4h_D^~~D>`kCk0y1YIk`$d zLRTd11i!hlKKekOh7Y%cf%g^nn63Pd&ri5};jufvy<<{QTApqFdb;Ps+bgsk==io> zD>1u$dtL0)`l#E5%1xoPk9xlUjnivarhU7qeV}+bxku&bGmYPR<<8gs_=B?&P&@9n za^mS(gAZL#C1)6g%8$+Z<6fU1_x!SspVYtSDPvxK`ajrnz4z?yYwxyW?YZCb<%#P8 zee)}m?)}ThjVv2JWr`lIi0<_@HtUEyexs}`xe>GfEITglNS-jONxy49-n_r8rA&b{`TyZ7^a#OuFTmvrxM_2IBFm1VkaWxERfhIDJWeh*t0 zeC?CF_OZ}-$oXoySH_8y*OqxlzGg&SzCPO9 zrhg}7=0j=6Lg#~Lo_P12ul2ulk>%ThwR`EGr$>oFV+HaReVHbkxpqy%*YAKuX)il= z%3gOqW%IB8`J~O?`M~#ymapE*m#6E`R9Jz0WwNBJVMo<9L@QoX3Xcogl|KvRiZEu#wlVA~x@dYszX%sM4cXz7G`XnkW#zT*;{e`T~(quP3l zzW=KH`26g>QCnwW|E8e7ozUApFsug${GsRNsokye=7tdu?w?(rx+GnbOof$Oo-(~= zP}5RdH7&2@o>JF5y`v&5)l_{s2P>bRk3!2iDd_LZ8P*5OR$w_NPe0=?n;y8&I$I>` z&9(sxRY`jMS7&qOmeaoionAlvA1=xHd~LZ_RV-EXee# z@l|(Uvf#qU9?CA)2}yc(ybrTnh1O!JChW_xT>12T6k5&!k979;XT}ZOS*qXD}^g zc8R`b?2Ojb`SP;I()qF~-*!mL741I#xJOHJS1muT@{C*Wz1a3a7OXz7<4{kJ5`#vU zd^OK%YHb{!Z*8t>XqjH8yQF%asStQFjdlTDeX9mLFXRR@K^)ubyECrsG>1?O|Zu_dTvkpNwd3oZ77S zsB9Y9a%0zqeV*BQ@b||r(56}1c5V09DxOT2o9yw>Je8}lx1I3Qy_OvD(hf;hz1(Po{ii_e(aHQy+VA z?&)WjG+DO=D<9U(rbo$Y6eu5~>vWK8w|1-o36Iy?o=KO_wpaFuzSA;a9|$@Bm9k^U z{i!53<)uU0?yTAP%qyRcAGq-H>FGXSZ)fMJ?|?N#W!mRjoEqMO2>2cq#_3XrkntZjL15_PVujk?HB`$rD zvO2GWxf(l^8y5HN_(7F6O~~`NNcppUbh%HwK>MkuC#|zbpXEc~@cZs~Ytd0JJY(G! z+%KCR_wDLeew2P5FJF^-w;*}^Dmw0M(}?cX{+D!qx~$LVN^&oM<+Rr;#}7YaKr%zi zkDbqXdXn7H%6jRzD*jS*t3F~fy`{@>x7EAxxogKHI_hHT(Dm(Uev+QeceZ@Q*ZC^zYVxC7XK3KkWd6224bl94`p;^^wrRH| z{q4M9;R@vMojdE-es8UJk6N^sMpW?py_=-Rsh!Pi{^DP6DxAM1n!it9KZz36J*AqI z*9W;5I{RDx?HXHK(%IN9yVu7%olEsr)#7_8nQe0&1o z_B5x5@?yCfdh=Qj9+%(1b`eqV@|#Wf{@L;}Y(`UkUA3NuDqQ`hu44>%xp?`td2I2u z6CR&3c%RFCex9Ffy7$lKC;8dQ=y9nQy`B>v*{83kw68!uc3JD>6VE+vkKAlJjlYw^eW3HtpTv@N|Fl0&SY4my5-(6)zWqm+5y(cX@i>achA&ZqG>v*r2&FSFgAF3&Yph-ZSCPnP$_yf0yzRoli&AXh#)aQ(3E%|IUj{ zHtrCucq_Ln^ZS){4DRnrSh=-#`PNaim(cqw+QYf)E80oPhKly>SUaBCRBao=oqtO!gTyc1==)sFSkooZglyf z=ylQET7U4F_vSC(*M_s;-ZxwHTN zi~ZO5$1cZP-Dtt`Z`-A(M~OkBBmePrQ{6mBp1@3o$!>p^tl35}8Kh{-hV>A3dm8P3 zO~Ce7zWp`5TfBVOoHiJ_YRxK}-~3CTYh1qjc1idCnetJ7lpZW>Y_JRe>4FmGW4ZES zWxHI_*12_CdG_ycsx$Y_GuK>x@3XHyYTXt*AKCP{Z+!nDtOt_or8AnEbSTntX#S}9 zLwu?GAPe44dt~pI&wj5Yx9hW)?mYesp&kEZ1;^{trZ<|N>d~4@Xkngwj zf@Z!t{vM!4;=Z}db+)Z6gu%*3Pl39lC!zn1{-s(B-ybg4_PgclM}6;=m!EuS*UG&& zvU1aw^tb)tqz`(oXQn)}_nm*Qy7ewEW7h7a8p+f3XDS5mE?2eG?mxqB439m?K9&-{ zP12^Jy}n(n`CGa4dd})Ft3|^1{PsC;qYL|t9C?P9c^lroZ{g|sGZm8eHkFNyEQ-49vGXW=<~1D8BsWYo3|aegx}S=VA$ysj+(rxot8ww+V@|0HpJD9Mr%Sr` zA35DB_^O815q0%?uSYMZRMpoVpL&fY8njJKcWLUCcCmTbx@p%#(mS6p@ey_Ao_*(w z-+JUL-|N^9dOou0HmrqoJ}fii^G)?t)oQiq<%U$boYTk7RJ(Urru+^2<`sMWa?T~M z{xK<-HhGF}iZZoj&M!D}#sM%@eldJaIBa!m*;pthx>~Tqa8Ge+u;_Y@t@=FDy47#X4J=X{^k!agJ&JHwuLNi2_W53i+4VXLR!%li)6=8Gpph;Ay3?YcZnV9(eXpf#kYC>p z^UVMlq3%#6L+xDNH9%Lcv%;w_|?XL7m$msLnx~FUJyF|l<^}*nN zX^%qrxUqS&zTc=mXMKCm$AaZ!9W^~YN(>s755??vvN~P_O}?8O-6o5EqNiflXzVsM zeLp&BjdZ@U&yg)qzVCSVA`SJRUsl$n|#4zkSYY zrRs0NuDSPC)6=8Gpkev6_q{6`TUw(ZG1qsPs#@}?``qnor?(%w{$TZ7lWsIjJ@7Y! za%*jryME$T=l%1QyT+H^6+f?U&y?G7pr;43j5@oSuRi;s!{gyIn{=>Vv;VBF+fjBp z|Ea&t--5O6eC5*`!t=O6>!iy`ww^VkuP&Kia^DM^?BrhYy9cXvN%#Im%ZYm0j$vr6 zek3g)J+7N7w+mJvKWm|e&-0T__x?rm6P4bIx>jW+RloF4yJWYYA?t3G z`{|2)`u=RsFQ0yL|B2C=l-*Ob?Z?x7{@(5;AJJ~QENbc{J`LQi0vhgzeEk1Z+qWB= zzb&Z8mB~*8v@#=nf`<*uN$q+)*YEF6EE{$4bEkdB4b0QNv*793MeU}Xl*MnHTdg0D z5gy0o)-PUOZH!)PZ?XD>E$;7i=pW+oEgxGdAD$kkb~d}oN4mUr$(72lCgJ2Ydj)7*lC%(Cb>A~}fYygQf6m1-1ovipY> z%7@R#rf)HpsnDO68?{l#I`_kQb(?+>&A6>K=WO6ciPV$jIuGkiZZS*`Xu zN_l-#Lv(~5mba!2)A`BX->}(CeByTp|MuETU+$e;XtMl_QGPr<$V$|i%}?j4i(hUk zl&f@k>tE7yz8YWO=Eha-Ib>!wU!MLEC?P0$1XAb3x*0wsq)^&J)>UTdM ze&V9l&+yN4M8ny6pQmf^RLHu;^+aX9s##yKNy=UH10nWcZ-ag+ph_PtDx28iALeM+ z)I5LVHcIEu@@B`h;qhwYdw*Z|_6z=KkEBGwmcy1Nn;s>rk=|arT)!;3t=crga<^3Z zv*3P(>XV=U@~G}8G?UEeI4w>C|~-D)>ZyVUC+>cRSh`;YtlhKo<|b!u&^2R&VXra~$|(Q$p49TnWX z-Wu%4Rr29fO(D!z#b$%<=|MKF~@2b3e6Tkjq`M2+~dAjGv+kQzd%8Xr`vm1cAc+sW-e7=h{Ukl}m zHoek2dPn7X$*VeUI`@X?2>0C~FDx9h=+v*a#V3f-aGR^?={9~CI_IlfYz?jYNu$>2 zBSD&V6x!7E`A_<6dj2))XTvR5^xyM&@Vo!lH0sq?Z%%eY(fsZHtEX$wROp!hcwIow z>lZ!rjiN?fTq!jFLCKiD{DtO!^;cV351hZpB=fOgZQFi4JxUB31?FF=uedObSQ~BxEKtlPT$$N$9zAe$?)oU|QQSMdiU0DxQ z%JNsqO0QnEN_JMIbYGxSHGf7{)y(vCZp8=EIVgGxK6~Df^D*X+xUuK)&oP;ZhyE5DY z)2(o(5EL#9cjV8aaI83NPlKPcz?P%=awZ7bRiSt_=+Y2YH-eIlp|$)ZRhmE#NoWe` zQd2%?p}BIfC4Bv!*6jhEda8CQ(g*DQ6>ETE4TQ|W@ck$7>{ICc8Fc>~)(umCzJQpK z(B@0%Dj8qFa=AAO-W?6yq|O*{f)etZ zT$kp5LW9fDPKsXvr_7NdS7DsgxCSlc!2ev=IUrMRz+#EM3FZFQ+HzO^m0q{t%|FWP zw#Lg@sdYy&Wd2=PBVF&oK)EG{AHqeM`3ROt{9~vf51)YXDQuI&lJ^Yi%0p@Y95%{+ z`TPY;62nXNQ{I22^H}_^p|Y%(T~hardLe&F?SEmd1pia5QjIY7O7E~Rc1s0A7@ee_ zc#UCHl<#GSWSYVlBx9tSIgDnqPexnAm?O<>nk%Q}n&d`=QCBPl!ibTtq-^0Z{Bm1f zOV1)H5DKw=m(9bsH@hS4A;j5e}Sdbq+U?+xQbW*D(qVbqeba$ZVh>$yx5e@+-P z^1?V=IgANa!f01DjJRrHyjxwhh`(kS$0Vk97$c-hoiJ9{4WneeFr2c#zH)6C#t<1L zyPJj)-aL!}GUweeF1J+;?Zfz_gZe2~#qnMkv*d@)VZ3@jjBZ`RxY#v}#BPe!L%p3E z#*}Gc7^kb&`C*(}pnMmG@zK{|Y+4jX^Ce;IJQ#-ca2Wmn=WH0;&xPUnJ&Z$tgi-8b z7+*+tvw`&%1Ldp+Y7{guzL0@`rB953&9Mer#2ff3$-vPH2J({))Rpsc+GU`!$3O!~ z@ETa^Gm!2#FiAR9HSk9@1Fz(Z>IPm&eoX_bWs5wQBDD>CBD?Dt@Ygl)x{-n2O$?N6 zs#tQnnSs{L4Rn#)GP#9;0WA$!-c}B+48*rHaG-;Mhw@QJ1H(HR7}do{5 zCu#g-1BWDHih=j#p}aNKz;U@I&m?}Pfxs*S6{W#k0~e*_*9Mv{Ht?tP|Hi=VrHc8j zfp3=?xU<|q$L|d+6WcoFC70yA9}S$^Zs4-4-(}$G9s{-Z8dxM5`wR@0@8mQ6VA^}Y zK-w=lE~6y#nEH9#K=v5}P0lK3IVaKQwdMr_zDouQUN%taj)9wZ)%Sbam;1`=nR0xt zykBU2`A$l{QGWj#C~Y#*yr7Y}g^Uy^Y~*|qBjbx2nJ)LzBVlnyw#Y#V#Tyx3+{j}|FKwi{P{v46879A!HIkiRWPdp$XJvAEBa0+D z(Mang#gGJ_k$~KhH`2>*WMjZcQks$XGK}<<)J!A!^1VFIGSVg6$flr?UuAg6$W*c9 z8L5|VWScChWMqT%s%+#lc_3L;jVzPTYbXz?ThmAzIU@GjMi$mFQl+Vprc$_>YL>RkuT>8hT6p!jmPn~?+E6{Dw-*uJX!Gd&-w=fjMA zA`ibX@}Kk`VPx8uMjDSYQf!=&n-i4xWFxLAMn0Nq6?w1w-||%Ci2r(BOh*4UgF-N^G22nKkFQkW4pB{dvqS{)n4yYjr)yc9xzhp zxN4NFlSaOks6VtPV!WujU!O7iFT7td*z5Oge8(l#VemJl@2a1QS=1O{Aun zsN*(~Sw+eRh|Hr6^#Oze^)QnR^)i`Od^BIl9_J-Wn6j*P3Yby@_AenXs=n z(fS7yU1YqtHmG0He51z6y&p|%-eRKIRulW=v{c(>V$60EFU7V)b;urhYnO=yyS115 zRKNVR-$aE2CekG17uE5r>X7I1_dydQ51IJyh>70EO#C4UCv-kY-f0uzS52Iin%9-r z4HLC*YyTgaxGIh(iYIMkgM>XbQRA8RLGqrfA5!&&i33vjm5EQJ&3`5yN>-Se!ZtG> z7c%QyHFH+}k`_hG%qwc9V5FJiQZC9&r($MiN1MsBo4H=W%tINKZ04xLOv@A|aSGj((Hm}@31XeLHxRyI?%k@AqujmvkYw}PgbTM<`12g@) znK><^x|^9LwjO5c_f#A?C^Pz)De4OVV)W{B3B zq8z0DR5Mejnf3n2Oq?v6VJ7g6nO~*ow`RVQ?>3rA`O(Y>$^6O8Txq|_OxMk3)@(6T zYOChRl5Lv5%glQ%uJDUPtDYPW~Q0UmRrxwcwd@XAgg5gzsm7HGq2?nEIg8I zgN0?XP5zU;CJS}U7A9FN`iGqbyBxP!IO?|Wk;lRV$@E%SDqFH&UX~8+l!Yo-TO-8FvV=N35!&nO`<1ADhZy|kx1=Bd-lKixvn85Z`;)Yw@TW{7#Vg=TXt%$a8)V!nmak|RwQsQ!hjQF?u6q0<`e z$65=c*ID>O=C4=o8lF0%T$g_19{?kfwoUt4JX z#=;?kl}bh{Uz)5um2j(-1~x0(Wqlzlmcmx*7O^t0sFlM~EXqn5aTc@ky*!Jya;b!s zH|4CfDsN?BqLm^^R;E|bYqB=k%1%jjSn2Dua!npewo7BBiQ7s?IU#YW%0s3}n9oWV zDdD%0BD3YsfO1Q-@{Wv7xAH<(WmwrNDVbJ!XK9Swm7E+M&$aSa$g203RxsFF)s5bdR=H0T=^dIGMTl;&*N-23qzI|+^2phfvHu@K|5mVSk2U%9cMr=`=t|{2q zCDvj#YS?W|k#jLN4#(Ok6KA7yyp80yY)qFwO4|6ml#NBDZM=~xWo@jJ_mXVjMYJj%DRx}uG@>*!G)*R|2H zo{bOXTRBu;xinDD4Q*VI5shv9DrcmA6B{e!ep4H5o7w0tk7a0ct=Y=PNr`V`<0~<@ zwb4@Mx3f{Gz4GmBBkXFnJH_&`jlMEW2KKelqMwb3{x+Q#Hb%+O0XFgm z+Vt~PIm!BwHky5D!}gVpIQdczkFpUQZKIKN7sE8=DpRN1xHrQ_?o9P`mhzVBb8IY@ zzvn8yc{cnDYx7RK^qfJ*|;tK(>A`Ad%xRw=e*7lv0kvz zPv%@zKW=EAoRZQvwZD@5mwG3g|F+?{Wg|mY|6`-X9nF)icWwM4q5Im42im8HHjc1+#UaglJsi-yx6GMw#lQtrwtIU5yDMzL^)M29mhScQsMk1XG(`tu1q*x%WAF+P0;#MrhGUPWUgG2w-c3LQaEuH!Wkzglf$X(2*=%RsPHsT!h&v~o<#ogH)C=e1`r-OM7f$w8)_J0)#EID-a;^S4wO z6wYudGB})Uxhr8q!ikoQ&%&u9>tx#J;k=ZJUnu5R;dCFPSYjC$PG6}xKAe^EU_v=hVS)iXYY<%6vI_M143N&QiG~_s)iscRrl@ z^6?+xY?5Cj`a(G6rNhN=zLP1JbiT-Xsr6?#Q)SiVaGuHY=m@IVBdAv#CA1O@1G+H zT#sbn-;u1o70CGnL5$;K!y$g+qi zh82k7u+%9S#lk{S{390%N9kuy6dh!DWEB0Qqxe~DC8C(pKZ=X;<#&30gI<@&%~5O? z^A;VG#`~j~C##Ps{&~fhwSPs?Pmavqv#{3@XM?vT0Z`O3WxmXYnsD#=Nz~_)E$kD8{G172_AVc(WKA|1L(@tzrzk zTa4kaig8pn{9BAw{}tnzbR?SXhG@c#(fnhI=3jF(EiKV37OORy_OeQf*`kSzh^CDc zDWdUF(KMAo_GsG0MYB>I#iJQgBAS#k(e#ruNzrt5M)QNzO^N29Kbn|8G!L?)3Fbs| zJvW-)@}l{ySv0>&$#$7Oa42{MxOk?G{FQVx^JesXCeMB_LUq#bL@}@-7YI-!^NaY#P3i#~|%dm4;MrPXiF2~Mu*_LakVaQI~%63-B&MKN)+s>gnc4F(=`AAyVx9i_& zb~ZQA^G2E@Ya83S+}w_MlH z)9zC{&4$`pC=s9AIroK~^26<{kvXI6+>py-?D{}avE{@RJ7X5wIW1k6*cte(o$V{^ zgs-&IVU->0MmvqA&yQMbv*L(ttDWiF6-Vmru=C?iJBD3a?`J#j%5u3Z*Y?;+-D_vp zemnmjRLo<_TgFO_-|S45U*+rH?cA2~=k5G)#ZHB*>f1H-_O6{yGW(vLhmY-)du6A; zF-Dg}V|Xd)g<=>g-xZEwNo)-FWNds4OW%s&fjCOWa6B=Fw~}JGRv`vkY79+ew?BsQ zff&xon6wxwWW?~1Ov;R*Vvb&uD!~}m=Ed+zo>YvXag`Y6N#Uw7l&u>>ciCM(hMBEm zxGEX#VrbSOhAWcTDTWVaR_7Rod=SHaN$nBCbh#|?J!4oUp+PZxCC5LHp~dhR7D@e) zTKh}oC;Q~x(J?HS{*zS7s{-#>5#;{H5-ijgNehfWi)w3A3zKX&6I!5oKV(Dm%Wwk_`W2q7m z%Xsk@h-FK$SS-=8OnWPq_9bIkB|nvl)%*Wg?#PQWv1FHv)#r$@%qSnr_QY7ilVYhP z%iXa&mUsQJ3`vXC^|M$m$nU{e23C$`kF2a3%hQ?~Un>?G#qy?Etghq6^15{_y*kCR zS$1`arFD;3mdb(;l~3>Z?@~K>xkqcruF58#I^3BRv?#rd`Vu}4emJTvohW!xBVcEJdmbbUZvP8=6jAg{$ zSdPiMeOhCGEJMYAKs`7Z%N1#ND3*msV);k<9o4wws!hH+5zFFJvD}rPepBqzvBaH; zrJ*c8uYSqB3$e_68p~B#PaI!I$8lTwdgItB@xD0PrN^;fqB7!`Ep;>FxFS8WnKjcI5Hc>={jW`Z(77rvt=A3TgCC)`*D=%5{Id092pisGpj&p_E#J)VO#;)$slPfw}WD4v4m{*VgI;@Kd%E#ny} z6AiSNo#H9lHJ)bO<5?(`dT8CAiq|V%H7cH*9vaV+(OP#*JW*5PxjQGG?74b< zK|JS|#gnu=p3hds^T7{VL!3Xw)BERmwo0*s@hmzN&mF0HM6ZeUsMeC$WASv5*)sM_ zJZI#sE1G*v<7Cavcy|63Pl3PVnfy;YbsonvUCO+U=gWxVoRGfu;@n6qjxVV=Z}N&$ zqDpZ(%Y|0OIoYE)rFs_U{O+>MyI+>5mt}cJj0F-H7@fc#`P-R*!3dneFB#>BNAx#RRRlT__zdqos@umvf|9socRf) zi*0!VO=S7j1iU*E7%X4!PT-qg61XqFo=l+Y*#v%&b~h5J|2TnJa@txBTY+*kk%;(m zye?Ue8l}qN^p_*1OF7!hl0oID`)N65Na-=DU{a=IQA9sm zw|18&eNTCIpDs`FSLK;OB3C4>Xd?BZ6PYPlWfJ)(A(4!7iMY!r>Y9k2%OF=Gq0~fn zc@uf%OQgC#k;SqgEsZ$xb3QCyB~=N$jhhL}ZO5E;dP`Z_6Zh z%9?kQDA+ZL7P7pL#(tW_AW0gN#K4JKPg15QvGkiH9!Q~$NsQW^#3>o}i}Lz4iA_h7 zFda*xG8oK9l0JUf>}lRuM~FRN~9{M{r<-%DceizK$bRRL?s3S7#pK#{Bp)RURg zBvgU<(!EjzHnpjM>75Fc=vRRT|Fft9v!&183RF2=LHBo6;Pv$iJib|h{J$zN`fde% z4x-m&?c)j(=Aq1fnauY8k}-uj=p#dA zpATTT^p@OdEz`wKhBDB@saoP#&<4tf-KFt?n z4h~Cnii6?O!RNs4caSL4af3Hc8EvPAx==%95a2Y=Rb=R_9sHgnLgxq}<>pq&Fldk0(PkmPl6FruS_C$gujgWqJr z2M!iUWH$#byE}9rgoC03mCqp6DJMR45I@wxDCs@S!B1Z}NFMHB*;fwT&*-4-Xa_$| zcJS{M2R)}ch??VI-Z0+5a$db_^fp*40pu#zr_fS-?q^f=*Tyanh!!lf{uv zeV*dfy>?E1lcS}a#FTL|QYI%jIakg}t@2LhI5bB(JDv2Cza-V=|0u7Q(p8)|$bC-WLRxz@y~`(&JSmCdr@Z6~i= zIqBZo$@Ml)CcNY1^t(>lw{z06o0A3IofPTeg2hs``pRTk~YlA;4hr~BhTf%5l+f}<>Xg6E6qnaDLPvD%O=?`)y6paV62n=Qf!=R zl8bUz+KpEo6I91UCy6pr-k+{qW;m%c%gK$oPTcbqe}UpJby9knYLO3CDDRa{+OATc zWziZZf3J12Y@?HLo1L86;-uyEPA6M-IWg?k+P^qy@VnNQ;^&<><)1&D z9J;EW%ZzKvN#d_-%nc{Un2uop*OpuqB6uv2t!bbV9U3*pXvp}ra? zJH*mIg?=(do(@Uj&Zrd9#-wm^Yzo(8{=Z6Z-?@q{73ZbUP=1#1 z1t|=a@$zDc`m{0y^LHsMTAjkm?^D<+{nlxoJeT|*QdlE~@iy?xI(Q ziy`93bn#)9OP`;*xFh#-Tx14ad@CjMUA$M(MQ^zyX_Z|(s^Ow=Z5PezxY#Sd%TxKN zv5QSj6tAg^JSp2+d3RSmJzN}?D^jbMi{oFoh#TP|QOb{W(d|nY=jAU+AElf|yBH;p zWb9ZM^Q6T%7w^kCDKo*v%84#&PIdA1bQkNS`wY#KyOKW3MeVsRrhnt&!crIYzSWwm zw7$&!&c!Mzwc4f6=3V?IhIQ(v9F_~xV7=!4;KH&&b^fS2e^Q;YZnKLQTU-p^=Hlos z)wbJ3i8C%boKRi*GKwIB~_rC3$gGd0*Ea{^jDOSZ^t>+b$;EaS?Xc#jtxW zQtoU2r8#mD;u4OseB1tgf5B_1%OwaMQ4% zo1L<_shclbxS1)9Te|5Wr=&zHH)G_s%xvxEQX4lf+q$XLUbS^_Gx&WsySun?eCXCa zac*XO8rf^yO|~{ByXUbCd1v#9^ocpq?`6%y7gYf%?3#rrQVEo>$;?y8WR<7 zs>V!rGf2+OQorW7nJDfBZa!Y<=9*mkR{dS>)@SVM-D)>$*0?FX)=kxQ%6Gk+SJG>P z_F1L!N?n zJbLXW=U>$%>;F?P@L&z|@TD9vc*rw)_}1*wp-Ix0^&*;Q)~(%OSPy2j?w`vnjABRs5; z-Cuf$80BG*OdjLm+*l8_#(9`I!NaAA%4w3;o2oUYd3YxCrhB+H!@~plZ>D-OOXH;7 zY!4Tt;T#VKrRrP{b7kB-52xnq`2r7Z7piU#U7R~@eu!whr#ldj9B5}&`RyW zD&-*6zVk44wTD?!a*c=g)~a6{wP!zim?O)i`cEESZS(MAyY^_OhqbazD(q74b}Q~4 z57VT;UJs4;dH7k5%JBW#-vipiUvwVGdHMRVhrf<^Xn9nJrw)RL#xvs zew9jRJ=~GB-#sjm(SLY2enGEa^f2s_hhP5m(B`s-uJS~JS3RtfP160khZA!5ribXi zJ#3X*w>|joYHi7W=waw15BKGbRD7&n%EwPUYhu5iZwQsrzQ1RDwSPwT&k2#WptTTUP`ZoR5q4N<(KlQ6irIy zXo?RcS_|}=Tus~pGw)TsdV`um9sLuTPg>;r;^(vl_I@T zY5rj<`{cYN^iIV&B$eKuq;gq48lFmt5vg<-naT{nUrYO` zsVtkOoTsO9VP-1jXQwh%{+pwm=c#6yxj=a?RGwe!>y@e4R;B8maP?VI)`~VE!&JZ{lv>|iHP+w zNZJM$;&Vq;?g*`m*uHm?t8to^LaUx=4C*-mmL{i{holA-=%D} zmq{|DlEzoonpM2)lEziN?5XCZcXj1bL$M{QmSW4Y`d;oeP@c`aly0j!+NlotM}~Fw zQmChwroA*@&iD3`&`0_9_2T?g@jmnNdZ?EP!!>7wS3gIz?r0q!t9s<0@m~BBy(|** zWG@Y-dO0)Q%Y_+U%FpsLRW8orSGp^ z(vE2#PI~$3l$Yny_?(wnzk7Ll-b?6$m+$0@OJ08c(@V}}4DG3YPP+JJCl(1s{XtOG!xfkt*FBKGryWJWcWOx!Xsw z&!^u3@o`C>=lIAE>bSHF`B;$Wqe#9FV`U#3O&aWfyS+xl44PRH8&Xei%Fb_X9FC9b276v>nJoqhC_o#N`^BP7qn z+SSKE+4+GFZ#N%xy8Bor8)Z)q)$oyO=%X6swjAv1=N5R9|L5h zlo{k>-C!RthWP0EiR%AMaX$AkM1~Fb@yiJ1InqbdFO{409pxiqw2ynTbc~NSV|_%A z^RYwvj`!i7;M4Dw_?SP@$G?+&te>pDO!0AGo{uy0eZ0Rwk8*pVdbdc&7HdzwQJ-a% zn3k%q-)hg6`7p2W=~{}`S??p}2OqsR`uOQbA5}K_XuQqGtnEI+cPQR2AEkEt7%wvp z`M7x4NBtw}+i~^uq>t5d_LPs&ziCfS`xtdj=g3tb)vv36a^R-+_-`MdN&SC(OuMbU z660MTweR`ZEHj>}htJfr=Q?j>(MunHzw+_+YrXcLkHh#0h4~2@{nQhy$xp0|l4E8+ z6)k>x7WVU*WEb&MOSXt1($7ayJkC#wT$d;Ee!QR6#r>2j;U~Y0pN0}qR^w!>oJ{aj zrJSGMDSn1Y(B-GDY!|b~PhVLO@N*+g$J71X&GwU?>*pJ3pYLZ`ML&Vc%AuBWsN-i` zT|ciH`KjE*&pL^2?x%GNKL@2lE5GiE_LKIGj&<AD=ZJhV#m}Cpnmf(U?^1S#pGorjOnp7u&#F0oO03ixt2B3wdb8Ef z&~1KQ3)7l={M_H`XYhVMU;X0e=&$O?(+fSQYep>$H=fk^xe!St^HX2eXjn#@YDRIpN_Ij>b&wZ`L%lb#?SPB{apA@=K}#+$qrKhizUD$ zYkl5q_Mn`%H;xtIRcnmisjb)K!6qL0Ul%oSR2$@`2m(z4Cwy(010&h zbgdg8xp6@E!fXBJ0qV90FrjTgKZ}${`v99eDqg1mV><_k?h&AM&j2@i1+WhY&}LwO zL(+DzVh#xq^GSdPp9h#eO!a*gVEEVo2ge1-9Uox#1m!X*z##d4W`O6j0(6T&9jknvRalUOD3GLIEELA(EG3LEAUAszSS^qTd4M^j) zj2W25TxmWijm~mbN)Jh6#V1;GSQ-PqP)$;0c$)rwn#Nu!I5LeHU#4LjlSYHFY3z`v zx-xq;X)Ua^0s~_NS40AWgq(m8Q?t z)ZZhj^Rn{4sx{<<#9voU^1+QXzQ379@b5JCJW8X$lQiOFtekwB#=Fnee``8hZRxne z(|J`ioyt+^G>{!)iB6}OER%coblS$G#8voldYpI;oA*>DMHk zt}WAb50v7(r!_mL^FfbvtUc42FZ-sXQ)pT`VT;nKxmd3+SFWp+>v!o4T9c0H$8_ra zl+G5px+xv!mUQ-S)jB)0&dzkk>{CuB(^-EiopQgWv+%6)KbKC6-_xmnF&*>ebbhyF zP}Y{gs_+cLif2%>LV&7|`7Os*fw#C0T-xl;I#OqyNDWUpNPD--9fOlC`&JDI$H zH@2>K&0?REg=JnA z_2y@>O-@L+C0Q)~Hj7)!vS_tDi(V43CX1MLS-i78i^Fn7o@~h?_GlLG9?Rm0T$Mqm z_4QfB{XL5ja^lY{;;$$#S@$rD7muz?LpCXUqeFSD6GE}MoE zvY9b4n@=Zavv*21=~J_*EuE$E^lV1W$mWH-w=$cRtFkHaT{d1BCb!mR<6D=_*Yf5- zHdTMsvE!O|L-THCQ}a$XQ=evY{#iD&-(+*WU=FUrIb;^ep+j^I6=QPrvn@wI+j3a! z%%NCH4&MZFSel)~otzv-2Xh$TA&1{O=J3OS99|8~q1&Jwc8$-$HZg~r^KId-uJl_ z{88(k&*g`!xg5QgtLqxM#NW(SFSXv^xvaUB%T~$!Cznre=WZ$n(-cUGoU)I!92~If4w8<;j}k2r|VP#F!FfgeS|b|g9NGuSu9nn2N_c%$SWyOD@fzo zL4KAIbrrLoV%87RvO$mq4TBVE6y!i-JvI&UnapVxJ3%JC8-%t&*0c-q zw0)4y9Tc~7kjh;$3y_yu{Z>cg_J(&{ZrF=L`{hb}8-$KP)te8s_Qwn?&WXY-^`!;AFe$+n5 zh@TXDlVWcUGJac--?j&-wj)UGJwYbz4HC95$nb+f4ju|}<7kj)^8K+OyQJNTAPs+0 zKc&R!ASv?enIOe}57O$qzLv><1UYv>y|@^p!`&c##CH`|8O9^-!8T4>J2j zkcgK-b`Zj12yw+4qEuXnPVpgrlTs!1bt!!<_sWFGNC;80T!_=OcJYEi zgfRRR;=Mf~R_;{~4~D34TD6@C@#1WVi5Ehgxfr6xCDr$*a<~#=z0A6!-rrR|_ms;+ z_4-jrzuOR^(6bOtpR1RWRyL2p33=os=i#iLNADVWT$YGBc{Hk<$1ZU-$fHlgJg&;o z#(Bgv&10lAYo5p47I_qGna7~FHMUhAL)+zXrGFldfqBf5(KGTmJ~NL>v+^jjFpu}Y z&f|=%Tb{>@6?t@BnWt;hd3?Dmk7sh@dLHhZdD#EX!&EAtI;HbDT_&Gzlk&M+A)j}X z^Lg8u&%%^^2Kn7klKB*ejoDQhj(n<3{B3Mo!GgCw^8wqvX47`8?j9 z&mTMUIe9vt;%D=zAl1)l{O=ksuD|o?b1R>rl5snqPwwP%M+)7~r|E-y_DJ5Nd`3LZ zXR^$DlFx)^`OKBGl?u(M*6ZctF#Q)*lap8Le+B!$e}0_&?yHRrRxf?yHiK9`O3IyqUrDD&88^D`#bSD`!^C z&aC1KW@l%6gV{#KI2==G_Wxr2?@!b!SH%AwTyHd0-*as-qK*bsanM2^akKpOY(B%{8@hPku4wXNH*iq2-bLb`+ zU%(2vI~v{|1Kp+WSZF2Lg_o&{{h=CK!J-;Qht+b(&A5O zcnR7|iOb-Wxia($jF*~Mp{4BqpKIEGnR*?TNX!i=|F_nbJMypez6r1YQC_z+Ud~AE z+lnCz?!X%9b{7W8O*!-cF37Bhuv`)zK}C7+7>rL~s~nQNr%+EGNQY;zLH5a~&tb9{ zUZ|h)?n@Xb{#Q^%*2_+*_gcM>zogE;uvS9u3q(*)ECnNol`o`RkqG>9OI}H@q7l3m zrAJALjv!0Ek)NcmJ%Z@?2+GTOxh?GyG`~~?Rpqr5E*-%ql9?DmEishW92p@~q-KQ( z&dL6y2xd7Vxaf?aVQK_zWrOt8U-=5&2##k)5SJA}Z5b!$q;$5P%XIPQL@+ZifJ}_SGVYuO7kMHB^iEYejHWV(UaOQo7cSV0FC+O4X0RDf=2I*G3TxmC>@RSp<?-6BZpu2?O&U#Syev8o`bO5m*mJFyMdAM6m5_1fJg`IQT~d#VjIVY!F2C8@rG?YZIfn`1e z>3#!~rE@g{e^fW{Qa-C;;JM`2GO$`U%QGoj$G}IjtF8fmJp->A8|c&2K)Gg$CAXRz zXw$+#SGgrqS{fMG%7Eof<qO*a~T@4iMW}xwV1`5A#poIL; z$H2!QXgz&1Z!pxrTOS*k_lbeB!wlS%)1Ml+Gu*(@kp})AZy;@=fsnj2$w1s>jh|xR zpcI&D;9YqjZ%i|AOs>jPNtk6IFxx;SX*kco1u6BVfo4k#{3!#zGB9VEVt#Gl>*WS+ zuQ1T*I|IwbwoZA;MS15(11Gl`xFqX$8hEnXKS1XLHkh|X)d3&Xi?y`H8kyopY)LNsxTdUqmf$xmW{z1K#z>nGsx%HEgMjMUH z*kr`K*+{fBm7lg4d4H?&68CnUH?l(bS?7ox-K9O*t@CJ)_Ij^s+-D?nzmdAfRHI~_ zF!HrT|Din*;|0|v*X|hUb=S!E_l%UkZ^SDPCHtZJC+Uxk40&SY3$Z^n@|FDaOy}AQ z?N=caiwm1rBS}R}+%9V3<0uopXcLuXtvo4i(s^s5Ost6!2_{Y_nz)=|A}!TKUAKv3 zkBNdl6HWXk)&)&8%QW#?I%k=P&o+@FGv$1aiF&yvTFZ$%6U!@^h^}m+S5*_+YnyP_ zG10fKV$0+PCNdhDm?xJTnYb(M8k;E8MC&v)u~QC9trjMl%Pn~>@3%BDxV4G(ZS>gI zM8aDpc1wYFCI-oe?M?jL(Zs{f%I96>+EtIz<2@6{#MRxz2R%$QeBZ=YdB2Z|VRBc} z`!edZ^-2N*)ITu|HSvjjIm|@qPfcu;9>Yxxm4C!H!oc@N&vlf`Ru+T*PMJ75*!DZ^twcHfWsO{n5mx%_fR(F|k)pN%gHJ#%?q5LTuYrhwPR&cA8kYOMAIj^~+ED zOjO)&A}ATZsE%J%hdh(N511Hr(8Pa-P4qcx;txqYuJb|iPML_jV&aU{x~9CYo2YY3 z`~T3y6>&UPJZURGNW>EpHJ@r9^4*1YvxCJ z&u3<^{4Hq#GYe#uOvyG=FGr8LW+FmnVr5npGvyj9582ejjH9U;TPrgI#QCO~99bcE zTbnu2*32b&^0t|+?adtTU}i=qGp}XsJ7#uBT4yu;x|q2t4`gCjGw0tk)4#i!Q!=`T znb~6NX{JFh#gPLtv#*(wADZdV&&*L7JV5ykG&4!64l>hJeiqvhIW<_r0DgPGJH&5V@HpUljY4javM+hk_VW;3O?XpSu1 zs`)$3eDkxJXA-;HObb~of9=t0d(FJP&&+yxzTZsOU(}mJ%JHyjJEG%aK5nL?EI(l; z?xY#ZSu?F=(eGx8o>RXrX#AgM8p%2-d&x|f%Vug^QJpeZvagxBbKA@(cg*~V>Sy%+!j9YShz2lUJJ`)vlx9AYGzp2k!7J^wuM%*Qtszi zXrF5#I?uvLIgoE5r;-I<6$_TC7V1^A@TL^0ZehHfs9~W>O$!kX6kBo{>bRV4Y@vG- z3*R-hP_~&~Z*F0_ESCDMH0DhUy<1yY(Z)ixwiaHeTlB*mkxloe-jE8oe}7%LY`T6taGO6v+% z7A09Jnrvl8MZG3#Q>^TeG>4UbPAgaCfn>WhR+_r4bduu|pQb!yx&t(kDw}r(7 z60U7!mRzV~rG8!2AXge#+1b!arAAivNWmsn_O-NfQbxRKr9vAkK3OKwZLPF=OUGqz z2P@?|T6wpVl~21^xhAPymAe$^WhK40l_Bq2+5e%HM*Y;I{#MKbtdx*%23m2AwerC@ zE0^SnM2)v{dy19q)2tl)T5GLPT$v#UzOnM*7S$;E+pJXFW96SKR{CDGvhkXglj={zxqYbyoM!vV}pG7fsGwv`Oro`87_nR*=X6{Mu7n~ofkGn%aMUL@&?)TvsF3C z`cXETe{RF}g^hUmTn>%45gKEovGfqbbmc13X4tqp(?;$r^>nuKmKt+yERnzGDZlwP z{0nV-EV~!kurIdJLB3vMb6HnT>CH_-3zLdMa+j#4o&JnSmx6xnbUQs`; zYo45xGB>oplJb{&C!7AZ;kaodLstJ|qvUPPlPz~_{379d+KcNIo(~GDhx7cT*(anIq|9 zi)2aBNFs|x(l9ELZE`~H$V)jB9Z5#u-|K}S|mFpI53jIgChA`Dh`fhgcKbT zNw(aPh@p|hNX93TRF!oy{nJQZNTtsd^NUD&j8!bLjE|(B)S3{gj-=0$NQ$ge9`fsYN) z`~n=6jg<>fsY(Hy)eG>k?50#{tu$qDJ>sG@$qBj`!tIE(*0Q!Q;gA^m*oYb8D21& zLsGX;G>ZyH^N*Y_60M&((R7quQPB*DiRNdqm5gTUfM_nr=iln}AN0CJZHi`-m^bT~ zG}#x;d|7=|@y{u~tou6>aF3u$>Rk1h?_p|DfM;?n>)r}=@i3RS=u#*yYg1Q7%KLUq40nhyn|vGB7e%#!HV^R`&kTqM#Qj1W{iv><%<~lO5W5MTF;2#E2%OwhTPdPjFM(^Vt6z^hWrIF zOjsC$`O6p@Nw>wSVPy=7t5o-oF-+MS!+9yaJ%*OMWAtxB)w4H-L;GUr_e%^d4#n`L zoID)E?~h_gdK^Riix{T<8^Z-@h@D@>9${yR(N0&ho%NDowKLFWXP0;)?L01Gr&3Wn zlZx3X7Gt&;Td)g$*4>_-{#nPCR=muGz!~kSH;dZvZJcz*0FQ2uAR7gc0Q0c4ea_inw?Dz z^}Mm>$l4}$F14`ZYH6o#E9LjLo$fNXmz^5D?M#+t@7qb}Yv&!=+Rx7A!FJq3?6m*b zPV-@Q7D<6m?VSD0PK6P6*2vt^cCO2%v37lssMvCRs-3Zm?3|KrOYIE$+RnCb>_o1# z({Ys@>jpbbr04jq%Cf^o`WocY2cV%2cEX&@A<-Ryd#d0humN$}Pxmqz6TUsnlWtTse34vJ7 z%Gh8m6*FS_KqhC#QYlBTN!3s+Yx81xDUU0~(xhrE^QB0&SjyFlrHAZl5X-FAv0Rai z_OUeY7|Ufz>Kx1aGP_GGL*I*KpQQDSWrkdmgkG_%lJMYIzK~;|#?o>`EQ_VVD6Rdu z@{_&t_Lx{!$bc!a?EEU0Ldz6mWh{eM$Ff_NtdFJf_p!_q<0kcHPb`J^#!}{BETs>{ z(oJs3j3b&SwSH5rS7O;J^=`(JcrTWovg&CpTVBRueHE+sQE_xK#<5yr%yCpL5XS`Z z7mQDpNw=jHcM9D}OFv0GMFi{nWxjjtUCjpKOTJWkhd<9O93j^3T)*d#l< z#?hu{9Lr?k`^u+J9F1kPwCt~3#v$*6^K9FuL!cEmAqPaH>O z-CnJ+FOFg2->)7Vh~u)fKN!cN!*Tp0{f}teG1Vqt9FJqk$vE!FProVlsW{?K$I(bu zoKwH#?)f-oJ&EIrtS6o?W8%3b{k-w)kOW^m?bGAgC(#-4%#nJT@m!Xk+41zxjc2FS z3+b_PJcX*nQ=n=*#@xqgu!F+q?0U?HZ4%S3DUX#Pg|q z(pRtbi>JFhk$3yYvreiEh{rH6o<~x0m|}jWm?PqOHY%QOqvQEr^2aFt1jV1I*C)qw za7H|FGc|XP9v8&ZQC=;KXV0Q|ihUW+8;kW^YA%VV>C$+1RZO5rN&?=r1e)e1ut4@y zO~6_$flA`3p1>g4StEf1H4})fl|V14-#CF;vZ6@>G0hVAQvQ&N%@g=Ra$6-ZN-DNV zVBk+LbaYqyAD05`o=>$&8 z8<#crs>aEh8wu?AD}jQ4Cotuo1nNFYV1|@^mB8l(N^o5I*-LOesRX{{61>hULCLBm z=pyG^m*7Ot5|r*$f^)mdG5=mUqF> z%#wv2650H2B9^X+l{AqHzUC}QBwcJP z5@{+cwj|=+p2!gSa#tc>{gTK%`SnC1-OeQPy|llcNP|a-%$8Hu^4JQNr>PW3D9@`> z<*8Y^JWhXkV!M{7gDf3fo_ZgbXQq@HTb@ai%X3b8EGSR^t>sxM`*xNm`e(&DR-W2t z%QH)*73xi4Al*8#stj*FfS(1}PosgdA>A3{*ljv0`iPXwT`uUWkzXM4Os*%L~ z+DSaDo5Z#TTBmUmdz&Uv_RS=^%lbA+RCy~&pQk3#s$&waK1mD^_YfWbD2WZS_Om2z zk5$g&lK6K@5}(af9#Uhr=FUxGy!4ru#J~kf?2@#FNfchGc+&H`Bo=See0g_I5~U9& z(M`OElBjz+i5b%Gk0g>VCh@+UzM90(H#GmRBp%;R;`QSsYCTEf{4>?|GKr1y;8haW zP09Go$rLM)jH_TW1EfW-$+VOeeKq#uWCly}*klGx(t46QBbjAiC39a2Z%AhJu4GQi@L!bIugPpYl8otS zGJQ`bQ}a|ZQ{?H{WSah&%mP_;L*wrxQ|4|md!8q=<&BD1OI74zW<`o-RiwVmlBVH` zERY_RE3&a|MNDs1q-6h!H2j~%6`3P__f(|nsfxON60% zCTky6#2A@E1Nl2Dh1`S`M#-}BDOmj}`s_A^Pn)E0vvUgRT~cWHUJA=UPT`@rztXr> zDcqMi+fw*#PYPxCrZDk%3P1do0;lx)?%1a9MiZ(b&5ww382H+Jh8bH&0>Z!xSFKoEIr<`!5AkgoC~^O!i6< zql0E92fO5CAqSrpcCfFAgN&jMHpDx4o#3En2?z5^Ik-~VLDMo0l9TjWvV-$d!QtSL z#H2bHAsu}V?0yGHGF|=%IH(tN&@#_KS4qrw;FqQHPbCL!Dm(bIwnKj(9jvV5V6(XE zI{2`jgR646se^~|Z8Ha3C9S!G{w*9_m;3D<7&N zP@=j!Xw}1^`yU(>8>D;&t4=xov4ezR4n|9#;SPTK%t6Ws2g|>3=srdV?Z!Cxaf*X~ zr#k30%|Y~B2czbx=J^i73miOK=pg?~2fr?MP;b6$sox;rMyo&cp?SQIH-0(_1tmr!(HvwJqI~* z`muxOFB}wjss71HsqxCe_}4lQq-lhcIR+;Mj84WCaB`xcld6TBtSaiHZ80ZHqMZ6X z#i@Jjoctz7N;`=y>tvKnNpy0yyp!4$oXmA-j&yN4=`Vjtn#;)@pOd(3CvWFCDOJhI z`RYz8)O0dUHq>_Vx{i~cb)Edsz)AatPQGrW@r|9#Z{p-?Q>X5aanemT$q#QjdDYrU zk2X%OwRJM_EhnemcG97}lUCiGEbQT=Xiq1{`Z$U2>*NbrJ3 z&t%=FPJWi)a3@1PbMlWolXpfsDffkwU*(Ln811Ck809Y;WuH_Z>*T$0P6kNv@v2EK z$Q@}vL3K=29h00S$tZbuhH{zdr0#4d*XKELFHro2ioeWBndPcQ-up&*uXNIGmHI4; z*Esomt&`;&oQ&V(zStmV?q%u_QNcu7DkJLV$%A_-?4E#NnnGaIA@Gw>HHB))xNh+P5ss<_cB9)de zQ`slqy-KC^YsLIGm8kzxX@`qt5iVj4F5WV^SZa0=V{uU|+C|IadOg8KR!JAN#rTGc z;xbYWmU0m)?V?jz7vGd~Q6kaBwel`pNiOC|LPZztQ(PRC9ZnZkmy0QG7b)p3dS|#8 zDvnGS?`OI6`KgQBaxce4X2`|YQYzoYJC$7Yk=qii;^JXV7e(s0XkORF9{F9K$Olba zY;3A{&0OS3xi-qXhwAC+;*eaH+Pz&I`^-iBNEb;`VU&yRpSw6Ge@XgiXM7&mt9VEfwKL9i?oL>T0B;t!@t5+!Qb1<}>M5(9POHZps#R zb3Mk5JJ!v7DObWx*OG4jeZx)l(r%8HaqIIVH>Z-^)JS%dl;Wm`!_6OZ!09I1>jsbL-w=H=E^w-_6dj8(Y4cf%3YRn*hr}H{XtSkBH?zvjA`B<_W7K3wGHs$Be9{axYKXYA_TYBy`vxGA&NO|^B(cfFgJ()$PP z!v@v5#ZCBEHx0ygz)if2k*0^-yd$L#yYa}OBN}_c%_ymKQoWJ8zbUUjmDeRVZLhj{ z_{vSrzp6>r|EFHy!5ZP=b2)7AkZ1Jpwb{cRi-)(Z9zu~G>Wj62hd3E6M+g*4Skl(R&9^)l+j*$d-a||Iw1Y?YihIcFq&($BH?2KbYY*}08k8Yk`N zcsMVO=6X0F)#iDaC*$XPIJrR27kX&7NOjBj#U45?@vvg4hlH;@43RHnlP?c>`0KETR!7v!V;&|S_YiTyL-F4{v_9qG zSE+o)!)*!v?qR8n`NPAp^LqV)hv64J{PL%VwwF9~lgARe;$f9+lpfbS9G5#cJjDF% zVT;_n<-vDHYfJV655pdMxF@fr(j)a!K78z9^Aqi<41Vfi=Q9uWUU;}+P1ENjX)KVn z1=4t0FpYN$r4dmqjapG@SmV-oQc91d)7UA;q-vQo#*|Ith4fBLV?+5geyNZ~vE($4 zr0Ov(jh5at_Q?%@8qt9?-VCM@pQFcc8jJEYCO?h;Dy31Qiegqx)BE8xs@2o{`f1E+ zk;cWAX*6u59NMHYv27X+I;OFta~e0hq|y4_G|F{Lqw9NVoRJaT(>Ty0johAT6z!cx zi}%ymE9WG!Pa4jlY4rIhjZ5;uh%`!$OrztdG>*%6qtoazCXH{$D)xjle3R1nQaVga zWBGLDJR^c=!jZ%d=+u{6Fvt~e(&=A6cyPovb;G~T|G##eXKu-{AL^rJL}JyzeIq>=elH9u32 zrSc2qDP{1|CBn-o*=qD+GJE+@-nDvJZSzt((n~;oF5;zsjF-=)vfZoiCth|*fjBRN zrCkXx%Sw8QeZ$Lv3SOd#g~6u8)_*zRI_s7w5-{_lcKR!@Nu!p*bVH`Z=O?$LRPt)g%8*@Zz83WwDs2 zcxgDz%jp?j&d>BxVYZiPa$$~_qW^ep=`yWs$~6g~b{pkCuALUFOw2HD0QI ztu>|U3NP!W&{{7|ztg(%_j)hhAG|D*ksH0ZH)$U>d$}spw|V(vyY^(K7tb$V`u*x9 zcvSmv!pj#Yy*!g9XT8k+-OH16Uc%?Sd@G+_^z!SUUUDuef4Onp%iITEESgaUt@p2&{n0*ZmGdz%(Z_#MsJxF|Nj?fx^f6dIm&6nwY0}-{V~x|tlT;s{x_zYh zeEQuF9~b3Wj*tA1j!UbskA-MCA6ALryRIndBY zbYmaGsSXLjpSR&?&zbF#CP(MDtXeOi;rHiLtI^bgypGN zyZIO-JKpo*?e3#)4xpI?!qkUwI@o`s{jrGxXoR66C zKDJB02|nBtefoV89}6b=_;<38^;6WBsXq44_i=iGk9Qa9QEn|#?-uLW679)X>a(m8 z(=zq-Ywg)`ALeg-x|X7K*87P4-bbGeK7RVqN7ao!nr!tkdz+8Q?TWY4N9kQYCdkZ# zJ}w;c(crN9c1%4z;bXO&Iq74}Z`zYnK1QF_Ida8Ejce+k?7yKs{@ceV(%>H-({E|7 z#CXR?ox46Z$;>C};ZybOna&$o{KCiIFMYiEO0WIr;}Cwr5q?5OKlR0G@)IYc<*3_^7Da|i1(8!*W|Iho8V`42|uMv`pGZrr;!vWr*Se)P9*xN zTHa5eR6oNdiQX9 z&(F)oeyTL}vrb}K_-WJ9&jIP!+OPYe{RH3Av5tP8ck=7^RIV>Md^|O1L=1%wXyOf*hXR`c0OJC3NvuduNk}I{wD$QM^-fZzR zY^z__!nEdYKlk?d8M4pM7r*#9@~e7rz|TX;Ii&SvyF5AUr}q&*|DIF6fB1>Mpqgc( zoRb5W{G5@&m;LO#;>UN@PoB(?->)f;8_G!*$Q}9WFF&{b_S5#JpH~0)dH;@|AMg69 zcu#Te`ziBKYd=zdpQ*pk{j_-Dr;{v~x-b1qd8MAd_A}#OKj;6``9OfyvfUKGVhJ$W z8lXtQ0L=>p__J_;_^1Hwq5~X}KcsH)05xI)jJF4PEd^o&jE)O%G(JG3gaGqP1?X2g zz`JDvtS%d%bh!Yj(nMZLmGS{1905!&#d2$YAiy{20q$o6SR2w>`2m(y3h3VX0Eu-2 zbgLI2rAa{d!E5~%0qV63FtJ@gKZ}${hX9*8DPHFQ~p9YvQT=jhsV8plp2gV1;oe*HxMCCF$z+m}qR)A--19Y9EdgcYV zIzK?O1*&;bfRkSasJ1vjiKPKLd==oBTo=PK<@a@f@+$&NmE}@=jcWK+H5>?VR%#y# zFzIjrjs*DVcz{MH0(3tap!YwTcPBuPy8-g=X+Q1~0&8KhsaAm5e_@~BLZcghA?n;4`;`5^Nv1Sy;pB&lMM z9w~|;o1H-nt{@-CUayY(gM1|0GJ=@16ibSQg0u_=S(X>%c7Bjm)q^ys7i4;UjcE|1 zMvEZhTL$$Rb&${B405=2kT=@~IoB>oVuv78q*|vSW8Vqt+EtL{1A^Qg803|V9Ta4q zv=|(ui=2@%LxX(tk=7g@WZ-A2Nve(r>ffh9_DG>oL1um)#5Oia!*M~j%aaK~!jn|D zY?%_&@396kP7AVC4oUv>AdBS248@(PW3z(9$YHr4jbWkFs4P)s>4tyTy5eVf+Y9%TOx<+@k7>9``(d08x-D$(gQ zlHLtEPLemBirIRelg`Nc>AI&oolwJc(wd~xziB$%TBYkAD8+e4 zYj#QJy`JeD2uxoy~G(V>-^w z>FnF0b+&7r9qEkStDH`xv;Jf{<$p_O(HZ4`Hl3Egr&HrXI_691{BFshoGpV@kr_mk z$e>oq3{Jd}!CM&_EX~Z|Om+q%n`UsZSq7oz88ntPa{T=a52#CRMg&a_wLyuEUwklOlg)()@fTd*sSrnK*A|GDphZ&g9)YnIu2Tq+j_g zwp7T{HODM|^<)v{&EiwJpPNNiIE&@dr&<<2RnH=&Miw>eW-*~&7X2G!v8H<#PkLy4 zuPjD?l*Q4Hv#9h*77vGIkuyAtZ)CeH9+SnLSy`md$>J;7B=)&kSmtL@e?b;o<+yZT zn#Gc@v$(lDi`FZ$=q&}-WD&bAi?`NiaY!!9C?$zCNS4zh^O0 zj{liO!e!+p>mFqB{9zU+US#Q9%jUEvo7~K7-P4@Sq)~eQc{Ve~XVYk6HZvz>^YN5y z_DszteOfkkq>EIUkER&BiOk<>uOKeCx9LQeN-RrrNJMc1-iG zYu=4)YTeFe+LLU~JujzS%E476hs>fmbd1TNQf!WXw&mz&TMkQ{ITTOL;j2In z%d&I0os+|uP!1D1=I~pm9KIiz!^=TAbRV3<&Ivi#CgpHrK@OfpIV_OwYjarlT@HPI z%%SPF9Oi7#p}>wD${x?*-4i*Smal%#;nukvR$j_sz_lEI4n zt79&KcXD~qEtlUW+S{~oerSpSaoX-Y8YZ+qYyT860oR)|S&hoD`EHSI$@=@6nzN5$!jOzA=Y*eQMN~j{5~N@eV}ntY+#6%gH*qa9HDhbYTZ#Gz8|CcV?%Twr(R7` zuO^51TdGb`Po{==A@9#tf9Hhgzeq8cDCSbdl!9M{Sh_02-XF9NKWZOjQ>Ss5P2y-4=Kbbj{*+Cv!@Sit%zM)2 ztuTw<4zosXv=8Iy7-oTt?iA+eJ7FqyR{SoC-&OHtPxml|dWK1m-BPf3n0Q$%f4?8* zi46H5%+Gzp9FgH4hWVwR>X2Uj!~8HH%!eQ8ad?_uT(EerGg>M$?YgfaXS=AGSP zR_;*`4}__BO0}I1^ZZPhN$10yz7VG7Mb-DGa=093z0AI?-rrF^ca_Tn_4;90zuOR| z@Y68Oo~f4-ESJZS#5{6R@^IG3qfgB|E=hs9c{Hw<$4+rI%%g9kJg&%*CV9j*%VU%@ zZ;{8mmU$FvmB-*WHMVsg!`kO@c|abHL3zxUF*EZxHY<46 z^O+}SDi@wvz4wbp5&EyGj<{;;f3^C*fByUBe6VB4cw|lMVxh67*<~)&&)bz+YjEvm Vzus!+-;}oY|IO3?kn#Wh`9BQYKK}p! literal 0 HcmV?d00001 diff --git a/Covance_UCO3001/browser_profile_4/Default/Code Cache/js/1bed9b9d0f6c45ea_0 b/Covance_UCO3001/browser_profile_4/Default/Code Cache/js/1bed9b9d0f6c45ea_0 new file mode 100644 index 0000000000000000000000000000000000000000..127c1e3f19ab74e01d1a8c8c468cdbcd531a922e GIT binary patch literal 19700 zcmY-1cXX817w++IriY%8Ndakrl$p#-rle;kq4(YelqLw$M5Kcv0!r__N)rSDK~XwL zReF&k0@4-fz3P2_cdh%!Wv$Pe@}9HL-ut|g;hi^n+kEtO$sVs>n}LebBB^;bJy1P8 zyLzTCy_&yL^-6(i0bd|9JtH%-QbwRsc4n0fZ{=!Pm8)0DuHwt8>aAM6a(bnz8C5g= z8Q#py%s^IEUs}3RF^)tPn*G06|NAqgqC4z=k1^ucv#ZkI0Q+T*3C>BllDI1~tZ=3< z6e$9CMp4wfrPinm`YUZwl#BQ$A>+ zxpJ^2eD$8z>;av6!aXV42kiY7Yk*=6gv`P4-B5V;33UDxx_<`iheM^$A$k7D};wQ2T)TAogD%L1xIW2jRR-KLpDp z`mlO`99BuE6VO*~2&dG0Ss-b@K{feLik^mHGC}5_QE$(K`48A}5ei&_lJc8em*#&$ zgUirPN?ZY_%#|TmVZ7A1rgKdW{Lgjmzf8RWOC;(hl>b|6%U$_bdfkFI|0u898ZT$1 z)*Z!=1$SYsbiD@y<(3?N2p476BUmAEk0D7OJ^|xX*d~W1?-|sUhtmEzY?S@-*$bE~ zhL`H6y#ERYi2pTImJPB?>b_Agnj<4*iqxnO z#(6oA5XLM=7?+%3G)M`fjck-2t}rTi!#I%{Mod;1wPc)}m(tmKEz`xH6UNNEFb-D^ zV`7ys+EooBwptkPR#z?JuNlTMiLM>SNa<21j5T$`C{-^Er|hqtxFgeyM~d_O|g2Yx6{IyIz0^I z4Ar_IjB^W>@1ih1`YMb~i^FKXG>n}G!>}F>qyPV$4P*PcFg(A9ap;dQieC)lbLnn2 zu)$)WywyOBLIx%jHt?_Xi8in~#z2cW179W@IGSW2KiNQCIWMPO1}b|DG>~|&f#p5} z>3#!~rBhV{e^fK@N0Z%s3BT&~G8iJN60Fxx;yX)w>gMJe@_fu>6g{3-pH8JM$NF~2tO^$G)b zRvPH|oq-i%Td%z2lDzk$fm7QJT$T;H3_RUqpw?akizQ>9fx+^ve5xNxdk+{$`$flP zv}7JrKaU&8K4YNCS>-I}B?_UFDOh%d)GBU5Qk%C2xoG)r*LNOx?q;Q0hCXq&V%b4Ou=1Q|DBc0@ol#bR| zxgTRBEY`>tIVhnxBO^)}c`WH=j8qrO8Yw2j<(G0svg3{HFK^_mOsQaGu|y>pX`QGT z67Mq-kUR25dijlP3>ZmFGxA=Bk-n0eX(V61ljm7Rx?~&K6g2Xyj0hQ-CYC%S_418u zlckl6{2;w58~IcoNLE!NE9A2p%0uebG}19(uZQXNa3e$I;payF zlinkZO#i}2@2)b^P4=ud@_LPtnrpRp>(pB*@STy_Kd9Fd_)&Wyw|_FyaFdZ4 zn~j*a7>Sf7^3zr$A8u1#;@+Y2Mpgl~3|yR|2KbRO;1Uhh+l`;BBCFjD8ZYLu*# zM!uHFKeQ)eyr{b5`duSE?-}|2zLD||jCkddWIs~>B>jnz!B35RDfVYZmdQWQb*{bC zeibsYxUh+}l2F9NouVc_i7?@dG*L;`$<2GVnsz0k(EsJtYTtEEfenA zCi>J-Y?)l&L`DM>^W;iH6ZfQTBNK%hYn>)0cF7T`+1x}kxh*f`!xkn6wKB1xwI17; zh#rWUP++8`X{C#CO(y~hM6e+nTbu(eYlAs@{jmNn0PhPq|cEiEECm-NhY?) zF)1=x{g`iJ)&dh37n-QI$V3MzxLp1D*2HKzy2eD_S`#bRnP~K#iC@;6ux~KY`g;>y zWP-SUP`{-4MvaquKbqLQ#YFL~Cicl`skY6;*zG1>ifxDLkUjF&E)xrPYcKbye)(y? ziKGK2(j?;-)$yz9kmvIEK@+16nfULBiQdOd{2}otbUsMlX%pdBO`MgQ*Ok`|6SZ$^ z{~wvSDvl?LCvD^h343ay#xw1M9D8n}>I)MGq{u51L#54sCLT&wn3*CrGanZ=>pV4c zR{oL}Ma|4FW~NYtnG#Yy(oCn~X68hh$+Mfeo@C~sj7~Ol)M2J&ijGSqx0!lgGe61) zJ~M;lZ%GZ9Ss<%rO17E0IeN@B6BaZREwd_{Dc4AO$mYgo98JvFTAJxE&bQ6v$V$1_ z%FM|&W-iOqcg<{TXXZqEGc!7xc_ZuIGqY1tJDKU**~~S0C=pEFnMqP*pqVD}v)BeJH#svzYfV)SQh%D6 zY17U6Y-A=@R?IXLSZ3x|DfYFQFXh{fW>S7MGg2~tGBZ!wZ!*($vzfJ9%#_}$IkI${ z=I=7|&Ch0@OY|Ny&1JFtwO8-$GxP3#GaKZ^0W)2GQEv__$0MrksE&*IgqaSq;-s0F zQ)VpZ%(Rk4zndv~Uj4eL@qe0WDC?!{Wiy?xn5lkMb;?}HzHa939W$TaHRHc$rm}n| z&+ePq`#^gko+oCe%DJazYCbd5OyzNg=~}m zWUt9W9kYeW7K{E-XTdJVZ5EEYEqvs$@IW%X7M9BvG5Rdj$gr?8%R<3y3oT`pJjk)o zF4sb2o`sQeFyBH>MGL;l7A#dP)U9gaZ7EXC!gx7Z-9qIW7Q*T)w&XO>aXHh-Lbt{i zzH4HkY*W48%))e8EcIGy%-a@vwX(3XwS}r}EWDHj?^@W@)yPkMc8q0?IJ#X1XP)?4^P z7Hm-7KPZol7B*~BPc~byZn5x<^w_Gs+^K#2*}@3>VtW+{u z`NCx7sf1gtG_YCOE*lD4u@tdVx2TnY#jG5b;*nO$inF+t@8nsOl}jb9yeV&`RRt@H z608(Wv@#<}@5#DkD?26CVWqFr$~Ac?*)ENhCT=So<%GnhDi4`1VLmHeq@>?Uip-He z1IjJU$~!V9-O3ADond9Gq-0v@oux5yS8{T6JlD!wA*()DTFK0_QbRV%>wGKSDyk+4 z)v_{6F4neEua0VvtM#qyYG9>eLo0iwU}G!$TUa?IBi^=Bp|usCESJbOR$9KJ4 zm2w@dyx-BvXPvEFmy|BbT?+KHlHSY8;18`F_}EIrzUomwE9U-IO2{_@thmNn`DmP# z%koqr##^~F#mbIpRt|lwwN@&w%#efMSowIXYLxu#R+9Ew`RA&YKG&>lx^5-;hH8_~ zW&SNIP5)6Ix3#}_tdy2_yWZ?Q2}j$3V9FJQx0&_@44HlmBz=pZYK+K4G;)3pQ}yTn@DMh&}- zsd6sb#^D$nWn*o0jcmW>(mM=2YhmA0|CjEy%^rJRlR@?N5if5ew;W08C-q}lMK z+h{F6X4p6@tut+WD#NpEESDPDHV%p*Xya6#jYs)5)>O3db{##+5=l~me18w@*s+?rQ zC>zbbuwnbsMyz}xhez88j5^|>~d$lvpn-+UYX zg*HBsJ&SDE7u#qrUoWxoY^jY-%WSM#u3Wyhkt#D++o-m|#!u4idmDr0mUuVXSSa7i z{3ore7EY7ggvT7j_%d@a?r-aQ#Njk|Fn&-s=eaNa()y;(_+*p^YPQRsNNNk8C79 zv9U}_KGQiO!(P}p{Zi-FE7kB?`~9ERA)KCJ;S84FCDRbjP-8e_qy=IE!VJFPuaE zaB>4$N8CB#tgIW3r(QT8*ALgb5Rm{D~FH6c`Xh5hU@RNaQ&SY&Q3`i5YC{1;ruO0gTfghMF)qI zEq5hsNH|fF@o6|!WW7xPES#58@pHxeGMw&X6-zAR!|5wECxo*~9!w0U-K21uPY!2; zyqKbzXNU7fs?1d^30oLW581FNoSBQm>AfVJBI}ih{JKGTd>_u%3FqBk!#Q;@oDzq%hq6FU9#J1ohqGKR$-T4T;m~r4bC3 zTR%mRzA1u}nt=|7Z?@PqyNH&Xki;hX- z{gKR6SuMqFQA8AoqKy!D9*{!E>YZ*clt(=)Gvy{{iE;>jAF3-DN6?_)+dVfX%u6J zMPV4OvGVQbQS=@W#a5XyGK%Ccqv#`fQ=@1#BZ_5Gd1e&3v!fU#P3J`MczzW53!<2? zFbeZmQ8bjUi&ev_DB@SE?jNI=vMq`WQhG-eE%rp|--fDZUlfP;N746}D4HLR;ww3I zB#Pf3N0IO(irAM?O#L^Ci_!o)zluG~&Jv@YE@nF$B*SWFfX&Ws@r2uXQp8ThqIM<~ zvr{a>PHQO}Y1e0DJAEZ5%FZaeo#RqF+Rhn?kFm2}R+rVdWIK0L?D|Y>C)aJKM5>*F zemlc6>>QR+nRdR-vGZKE<=SZ&veUM*oo{4k70s<}=TIFxF?H>HB(3Y)^=~vgn;YnL zBh8U@jqO}+ZpYQaPMwy@?_E3HWNuG8)qB~QEKNVO6W7Pid$O&sohyUvxCh&5_lccm z!|W`Q0-xDA_qm-4BkZh|xufmekjrE3`XW)W<-}AwV;9*uEnSz|8ThrG?cdl5UuCDm zYCG1Ab{b2cAGOwI#Sz<9J2SQ`j?~*>=f|CP47;@6&vxFGm2z3G?Xi=(*Uql}cK$u6 zn8%d2jFTF_*_k50%2&VJxh)mW+xg>)ousSk+cov}uANRY=boL1kL{FyWv9O}T9-nj zc`50IqZuaO7KvtQOf>goTwFBE--_meI7&rxJRzF55~I166pbx4nkKT_AI*e7H0NY& zS~N)+(R?J6Goz`PqxYmrFq(CF(Y%r;6{BffC7StCq-r$f>PFLDcGr()R;y^PN=CbA znstcgiX?Q3=0lm?Ihr9KM6+K~dqgusE=yd`XjV&TP&8l4@z0`ZF(R79Qh$`z{zCc5 zK6!UcG%Kb5lxTJ>i>A1z%|kAktG|VY4m+G^TfDWz1bU0;eFARITTIl!_jn= z+cM**=1I-pRO{7fwn^Pv(Zt`6riZM47R}aI(O6$c>vL2L9gQ)pktlNvRSLu~LHq?{ z*it+OOH>Tg--@AqsTfwvPo-n@`9Fp`@}g`E+2v#O{b39$fqyZXH9fPBCnjU0q^m z-6MwOvhYLY(>sPnGFn>nQ!et}z!=UAj-kSk7}iSr&y=gAk5sJDG1M3ngKvu;@q(|46^18h2c^$(JW$SaK?cyYka-ihVkU*fTLSl$Gbz zFS&OihFMQzxGEcn<*TSzZcATpEITF67fZYJSoTX~Ml5rrZe}c3q(^ov{c>a3C3S;( ztQ1S3%CQuv5=*%{iqkNb%to=gMj6YS7O~W98Ox|vvHbRaEM>dIV(J-7#z(PyCZG1v zdwpZ+CQs%4ezB~V%Kc+842b2ilpLm*pDX5wSe}oHrR(TezL)$lia$Z|C+hvlu^gHa zOUz8ooukJEv2>8v3uD>4D3)Sh#q!o-y_OnFVrjB8mfcBl6iJT5n;J)x+&C7<-YRie ztHx1LJk{bDD7&i1aj-@l(KX}fDfJq~F-ul9jw7mR9AC*FlGH4YA0)SB9HS(ubsU@C zi^J3@j$&QoXx2TBMN+AU*6pcyz2a1(;>qb@aXcBLb;rgLIW>;EbK}UKr}r1eaehS{ zi7VsybX6Q5e6Kac`BNOde~x3T6h9cp;zM!Vk*Y`Zo>-4+Er~f6M+ccBqMm+T&$1___TgziBSe_Za z>GC-J<%#Z6p7yeIPAs*m{kD~7mF(YDp2(jS>v(x;oh#2Y zNxD*A*JH|4?S>vBDv%Lbf$1G9Q2B!jjF(do1ZoHMI!~`9ke@)$iV37tO3=@z1pPOVz`*JWJgAkx zqdEy}udj6)C9tna0%hM$pqp%Hoj~Px67+p)0xdfv;Od<~e{m1i@u3N9ly#pcaA&M? z9+$wsQxf=mrt*;Lvo&{a0^_CkyaWa;NMN_5E=-{CD#eo?-zBhkyXMRLdlM*qD1olx zJ)A(DGYQO)zJDZ;a4CTg<;=ANe!i*seH1rQ6rIyO%mzbGLfCK_MJou zbxov&tn8z)pCmF!62~SoaFW)Olo^REUzW%NDZDX}(Yq5lCBuJFUcV-?>1ZORV~O-R zl}L@#iA<4a=Mri1XCez^^-Ybxn@E{^iR^um$kw-#u$D^VQf3lGvy!MMv!qEVi3QTV zQWBfmBw>0diIV-2Xz)Lalb9oY_9ju~bdv7tO5*kPBp%;PBLA->#@tQPcOZIC);&(b z7@kah`8y(++_+>$$@22aSpCWR?lzgv8YgqBQ!?qDlWFilGAlkw=8?FUY24~$9>|>S z$^5oAnX>zmnRp_ZAAU=Q(|Z5+WX@kqCh<}-^R6dT_eL^PZYHx(Zv2&u>sB&zWy(Lv zy7w!Y8h4VpB0cVE?7d{#%11KoVY059C$s8NG7n|W%Vf6ymy9XQK_3|=`=p4`K~s~1 z-EyjsgU<>(*k8m!Mo|YFV;#JSbI_xNgL$PKTrKUONf`%;33@Nl!3C+{aBx_nQXGts z4n7BVzk>vsE`J0Z)J=2HBF{k=iO+Z7m!7ID{c@Nr!S z*W^kQ2an|2rVh4AYBLA@nmf255862}w0E#o4oO}I2O~Q=cp`hcI`~Z{e&ArCM09h| zvb#g~KR75hQ27i}opRz62XVt3jF#TR9sKmUgX9qoR($EueT)v;j&bng6bJuKbr^Bsg1IC#F$LH<_`eqHRK#tH`$R%)yi{Ki3TnIeY9s2r2-8#U%f?a5CL=5A7)&3e8~&$sLO4z01K;2M zzsb?kPNK^?86{KVot!K0q*etda~+x^ot;kl$zPJ{a&p(_BqrO*yE#ruRdjNpnv)7O zoJ^CAwVb@E?W9K?CqLA8(yoD%uN!K7BPa74JGs`xsrzG`bd}BW!`n_?w{p_GwUg^@ zoJ@Sj$?12Uv~TC6Wj7}ayE`e`!^!d9PGb8w`BK&laI!-N4smlU+$#L3e_SXe51TqIcd9EeU`;*o&3Gd z$%>6m#&33VYKxPqTh+VmdT)o5tvj7;+2zErTWkN~q`~i6TS}aF;*@{>baLpbdM-1s zDJO}$t}!>99FyzP@V1lI57bjheCQ-YR>-|a%Hy$#}uYYz4vrnj!Jar6h_Hhv2;)2qmNVgTta;{PIic;e+vC% ztUMi(!ky76q>WAC0xv_DJgH6x!@me|Du%{AaBtQ}?Iv)sYm| zOZTHG43WE%eq8$_wa%n4>1+xEeotZM!xSz)O3`P{6yAE8LdR#SL5jUhp~b5d_RDv# zQ)u-@G5<{=;=dHy;$nH2i)e$3cT6spnq5R$Toj9R(W1ECk8_b#(nT#XzU890jFdyA zTm(zI=vdapH|1QEh<9B8!AF~#j7Io(CC3>QPhk?G>Y zESJ7Nb#X`T=eWoWy7*d3<-2&VqKn>gN75?0cvQnhk=ibr)p4;`ewU~6QDYaInkZgV z7kN^ywes$+dV07xELWsfFBiu@cM&_%MS@fq<)YgcF3!tel0I5Fjd3wr9?7_IF6K*% z@h;w%b5eGqi&c|c)STwxs~IlVOZSHT+CSJ;=*zl^}g1ctF^w&`_{#3 zDZR#}@8(_nCWiIuryQ0G(qMz;e(%EagX;WIb^fF}W&LIsFSfWCvCYNNU8-%ji;`zt zbU3TtoO99kPZ!HByEt*h#U*)hRe4|69{%OxrC4t%uiGvr-*FLk*TwLAE>iAm|KzDy z9=I4FJ07}7edMC~6V?7y`}|ycWp=aC;wI7R=8(-z@d9o>m#ziftSjWEY+*MyqTINn z-OQJACERo=>E_?J+*B*==2#iGzCUtvI>Al#L^lb^Zn`_%{2>ROZX#W7hReNFHyJ*+ z?j3fsMIQRy>G+j~qU#u_xV(l8UF)8@czJ^7>PGU3Syvnwv+j-Q@hM znqIELGVIIDaBL)w7Mh{<`J>0c;c-QJ781A8-SPOWFkPK-xcn{r^JZwnz zP~PF8Y>J2XT^`+A?jgFWhj*%ZI4mz~cyw*e!*{Z#o`)y(J#=c|VPYc>ryF~y-o(R_ zHXd%h!gA%CQYwX*vQ4+Tbh z7$j51dN?=EL#^>1W=-^PX_9i9to5d8jp-hq$^01}uFdrDK>nMhp3K%bX*b8i1!*|f z!$GM!&%-EL)%5FTgET;&|!&(l}kOuE%Pu~zLb&QcsR65d$3wLNVRW0 zj9cSjwv<}y;k|Y0*GBExj~?dA3aS2+hgaJ?yx6Wi+Ua4PY?Gv2>fLU|-Q!`p6x{2f z@jeef%TXDzU;BGNd-#ja1352W9rp0o5f3eos+Y$-Og`Zu?4*a{zj>8yu4 zlJ>iYr84FZ563U){fi!kU-IzFpB~y=_Rv+HNbstM)v`&tU-xiA?%wne^|yzua_hDS z-(9UO*$+Jod*tE1ypf8J)l2#KiH9vuwWl)ZnTK7^J=A^a;iffJ-;<=WK-LvV zcvIOgH~pzZ22y!DEtS|DJ%&%SR(pDLFEg4x>^zA>WNorSq6nz8$OB6H@U_O64nQKP{CN)0Oj# zR4&X)rNW$4rpbSEmGgYnEVC9W&qd1fD?MM8ifwhO?gdwW)}`|2cd6uWOl8!Msf^y9 zN{{2Ie1Af5PHN0~jk%CYscWgcdpDJ3_foOnPvy+xRE9lK-=3zD`AjuGSC6IAOXVqL z@X|TV%W2tW^kOo5`B>h!dRb%hQaapAKz=UbrC*enFQk&)tG`dY?3MyCUIt0q5?+>< z^b-A+mxC3&L?(I}E<;=z=k~HP)ysXamv%lchtj+ZNcXZM!>iv9@bbHq%l0x^hE&q{ z%38CEmtE4hs+T?0y!5WFTxuw`MAlMlSyA81y#~s&nU^wcRYyD3A^*tm&Rz=l^wPAK z=F9osUgG;G-@aa)pD5m^US1FLGI50FjP&Z~h}IpWFef0CEQVxHoq!89*t zW_YLqu%SNGI-sq(eflqxH| zY>-0hyfpbv>&o97ym)``vPed5^5WjCec0mVnoQsB<&PcOlU-gszj*2UtCzH6+J}=~ zzC7jSximiKW%lo0o}Tv-y5Qwo`TUZXU;p%yb6NSz%^P0kKJ;?sk;Xsv^64`#`<`pP zf4v-t^ii{%kBRX<{*yxGee6!~Q6S03Ao)V#lYOL0H;0e4P9INGe0=8ik?iy7cRzew zlIJ--@`E}qEkiyQ=J_a^@55Nx#}D$liegpsF--!seN?EUcy)c8m%rp-10Ru%d<>W4 zjeW#6^|7RxkJfE{EN-V`?R_+qZza2fkB$=C(MO8pN&C(|ddg05b@36BXJYN@W1#H( zz=yY+k2>9btdNber-y3zNHz3P4RTu!_VsaAKJMpZq~!Pa(Li>IZJ>_D{BYgZaQhAQ@(ew-DCVfZy$Qa|}o-7~hqs=%UQR98=kiHXq zxF`Db`y@UVO!D#XWFH%*s4r7}9GLIp%mN?pFVv&lUZmbF*0CkplV$3&tQOO9_4RA* z*$N-#Z+yCzqIEX-i2mM3?~Oiw`q4*~O+FfL^D%q7kMJFex64QA-99GB%tJmd9`;fH zi28P1Jw54TjhsE@W6W>blhZy%pVK*V)kpQ~>Yp6AsXhMN$EQ;NA0N|iYp=w3*GKJp zJ~qqDr|RJ|_3XLM8(I9)$KS7fy!~45{paH_enMe>f<`~}#A@;rBctV**-u4_pPohh zd@9*R{nU~zVu0GEPp$`>9giPwx~z z!zJkQQ&+Z&+2g0LEDZR$k*4G6e(q-bNze7OOxoxBSy9nXpt5qPr5x(`8DH1Wt44k* zH}SJxqMG|@-NMg7>Cnor`=R}$y`y6t{JiMs*YC;s`KGs@2OlY3A3u!;`3{2cvNy*TLSk>niK`m#fw9`V!bsGon&E8jo-L|#*vRNevhE*)_l2M4Fa30s6;kJwpDC}^(>H!*{Ojk!e>xus&`Nfg0$3~oCR+m(DHxzx zp#Xmt4iFm=plxJ;qwE2&&QK$s(d$)#9s%?||lCOyD|i~#F`S}Q-m@`?f7J0BpvPJpg;10**N z=stL@-#kFw76B%<4d`c)@@OAmb4SJN6kuHE08u>xwC)+;My~+&0Rh?!3~)%=4pz(| z0iuTnXz*Ep8N*fImjOnM3vh6JfZPcIc286;lLHKr?`8#fK082{IjUz~fNS#uG+m&Y z7X>)=Re-9C1C&@Ap#8D{$K{3?mMg!n1C(DGV5+Q;;%imIud3l-fOAsoaDYii0&q0I z&=Ua~o($0KRDfRpXx`lb-R}j+zpwpx5Fp}NfR@h#9FR>fm3LSg`;BQ7F{kl~OqD<6 zi6sq-HI1EeOe)*b7#*HQ-(qQeTRM%$Wzu-BY#Qt0(`a5kjrkSQD4dW+LQ)#tlNCd@ zIMXn=()dXBd3D^M#!%Uwk%l=-v7}fqjTWIamgl8$CqIqV)zYY6H;w7_G^TzU)tjd= zzD1h8qfXq;bA&8u9JZm?Bj>rZM)tG+nz&V@3Zo?hQ!ewTvB@#yn|0 zD2>i?R>}-XBn^H{FKfXxwM<#c|xWKhnQ!Rqh~ z!b)UNvt$M*-^$>fj0~1$W^gt;gON=#IMg(QV6zMw$yzz_VFqy@WiWJ52DKMwFnNjQ zFU=rYI>?%DGI+8og92;ilIH!HLFi@%bIN3Lxojql%4Kq{N+xBiWm2eaCV7)H8961B zzvpD~;g(E(+?q+{?U`IZl!@y|CiA4oADJ|}kjY-T`d22-Tbay}vUf6h|86FUk2C38 zK8vjtvUJTci(friM0m6KOdjNBkrm2fh4ikP#ZT3;NUokmjXGIOsGCK<`dO^)mc`TV z8s9UE(L=L1_DL2MKh5INuq<+hXYq~fki}!NxH~J0^f_59lg(nEn}ub57WEcnu}w}$ zx20Ju`8tbRE3#;{GK*ePU~LxB>$7-gLl%eSiagnpMao2mIF+Q7y6SJ8)DVtBG zWV3f_HtEx{sV$wQ@{DXo&&=k9ytgWwRjacp`E52{87{ZhW#e0)%~$f~KsHr>)v@E6 zcSG}TW>fP{Hq)MFbN*R2bKYcgy-*IWA~|Fh&7nh74i%$w^s_BTKihIx;>@9VN)F2c zIV{i4;Z9BtV}dzM=#ay29dr18Kn|}4=Fn|W4!b7gV4IY~%>_Al7Ui%&x~p2O|)Ijp*zL;veJY`>xTH*?r?KZk-3a~Lc$ z!*aQ3$Ys7QmyX4A`6eot682o3?|Lkq%NQwFHkU5ta;co0%ZTQ=`ka)j`)G1$DEr>d z<#vZ$0`KMWuxl>AO~~b~Nx6)Z&lcx$U`Z}nOErFZF2ldp7_qF&rQUbB6#7x?p3mj` ztGOJ#maFR;xy0SfRWG&P-?^;4mCIJi{3n-BZs&4WHs8%9?0zmqWQ{y|kV~hBxx9Fh zOT|};D?iD9uXE}3M)?_n6gCAJDnD9-{A&x+Gd#%5B0(+|4f2mnFBasFh#++%gOrX6 zvR{fs2l+(y#sn!87vy=FpsslYb)6%q>l{Ib$;xESaRiy_3}Q?PGSU;|P->8%H%L;N z)=3XCSW09BX`dP7xU|g;vOE|hIuzt~>OscV2=Yn_)(X;2SL_#3sSawko?|3Mt!7lQfxqw76Vnkj2xkLM{3e1P zQm-Zl`CF9kR61u z7(!gJhA15yqElRm-=uUYJuj{2a<6QNjQ9{W%ZE5!Aw;Rf5G#^G^h*n|Ej@%gBSiJg z5aY8#)XfWVxK@a$Iw3~L7j;7%sTU%zeh6d35VaeH*es5wAwFyt;!oM!D#SZ&LVO^t z-wCn!-4JW#X1frc4j~rE=#C+dy%(ZlC&llq_+1oV_I3+Vs7Hu6*&_veg@~2K^7n@! zp32~lLj2q(#8Dakafn~~st)PdFT@Z1Lwr0`kHbT}{yaqZh!9>mCuK*eHW?$wzX(z3 z%MkVD3yB;P;_b1DC8xzTPWg=w5i>DF1(_;L3Xv=08gD}-rwh&ppZY>@*pc&_rF7s5Y3MB{}aW-kiSa(RgF*MxYrHiY4)5bx~? zv1+e+crZlLY1MWn#EY{bCS3?|=3+*2+O)$2zg{cb~u z!p}l9eXd?gTDd$1$LEogoQJb|9=&Viaajt~$)i!-Ja&nzK^}b?=5bYyHqIluX&$4b zS@S&RwaBAT%RC0Xt+B207}hS2EB*6u49sJ;jG39o@mYCPnw>}4MR~mcRUT(#{mMLE ze3M7lRe8ELoyQlu@^~gUuIJ&tnTP%FJWQqYsZ%DO(`EDdIx(NSN%_2+oX^|Nd={nT zGsvG$xlZ|X>7375x!5D0gkJefm+B+(89y?gH*#WTK5?`287<##%jfa-eE!&(&&kvI zlsKDDl2kvZ@xN=lxc<(k&#iohNyhDbhTh5NjugJ1Ptyna?2)`j`HXy=&lH*eB%g`T z@|h=RD;1tut=G%PVftTFJz2S{tRDXFpNr>y`D5kTZ_myiy6?l2qqhzn^-rM}Z!hzG XxcpdB?xCEhdjD^p{tp@d-=F^jB}PL7 literal 0 HcmV?d00001 diff --git a/Covance_UCO3001/browser_profile_4/Default/Code Cache/js/1d2d577bdf1b36f7_0 b/Covance_UCO3001/browser_profile_4/Default/Code Cache/js/1d2d577bdf1b36f7_0 new file mode 100644 index 0000000000000000000000000000000000000000..7083916895bf7734ddd27fd965478955f6bd7878 GIT binary patch literal 37032 zcmXWj1$2|w|Htu9leDp>O&dy!q-oPOZECo?JB$t2;qEe=;qJrToiSjz!-m_iA;aC> z2mkl)?9Vx`lP1r7?)}OQZPF*r-k|I9EFC_736xYEyE`l{$c@SrD4V}@?y?0+mSA zle=W;Jo$~xaWX^j%>T{xzklm$rUm@(b`X}LX<6w!?v|7CmzO3&6(k1^p-@Gs0g@_7 z(Uqkf*oSLaUPW3`RXTv))i|f7^ch2IN&g^g9jO!Ub(3;-mp)+Icq!9D$%ks_f%Uk8 z2dKG-*l-%XcT0UPNuJ^X+JHT{g~lZUG!pwt2Iw9-mI_c`^eG*npt1pqLf;Ajs$VHU z{V?;p0KIP&Aam;gZO0*a+5{*SHPICDZ3FZt&f#Rc0HwDNP*D`_7NFj}12i1v`UdD} zzW@#BAE2=qJdnAD1?ZQN#D}m^0ScTPAlH-tJ;$1v%ylh5y>12Q{*wT`MTe&WT8FyN z0yOn`fVR8{&_NV`8K5ek1N7NsP_saT&V(DZ$z{+!Jj!6u!3cx0Mj5mLyD}M6FS9{^ zWHBhkZBS2~^BB}B#-KeV4f+dZN*Q#hj6n~}8)T_sP~)lwwMWhx1{K3zIBFWy1`E-> z7IUC`eS>~!W>B~02EFZUkiUyTqcI)jyBahQAG+~%cY`wbFenjUdK%QE7w7giXf}2s zx(~6z(%+y)_#LkXuqLVz$)G`4KAD_xaEd`8zYsUxO(phe2Ia*LTtJsu2F1-bsNh_K*32^~ z*L;J9VKSTx4N6{OP}FjRuCFj?+)CnKV^DrfU2D*B*w#^Bbo`Yyk#)U6r*IXGHW_5v zXV6jP-p_cL{$$K?gPxrx?#l*QuNagAjW87Ru?Ca>F=)nhgPPxdL8MNdz`MfdcHWJ=apZ5lZq9oS9^pXDIXRN?|SU(w*5v4yf=8HkD ze+}w~zp?)-dnmxDr3Ryp8jZ>rWYiC4qxNE$#i+@+Wi`raH_DAx!A8{zF{&dXoJM)^ z3*Mtbm{IL90UK~0J0gs_0B=U4uAyk8QByH5%BX6YjCzIwnT_g>k8o!(suAX52Zm%d zYLwfk0ntX?KtqpFr(umX>Xg^0NpU=mp7BP#@)?yq(Wo(gqq?T@bvC2!WH;)14x`>7 zQ%LgN%8TAswiW{{S_mEb?sIi!ZekF;wlu0pjK_8X4Wxk8SY?lU86qKGirNNqaNWsrZi*i=H%GQsHUxr z8sEmK{dkT0?Tj+FH)kVeF4CTAbFr#{*(+Hzlk22~3yrYdeIKimg6WJ^O^9wm3aw==!(KNoE zZd8ZaMm?NkROY!xHOI+$%(2j@#3e@MTxnEW9A9NrjkV0b-l!uRj2gL-o^2w>%|@-+ zYEilUBj%FsUx?hM4q| z)1=W@j{;#PWePVb6_J^_#Wwtr)ub&RlX7}Z+J~E{7iZF8G>+#uQW8vhiq=UcdHp8k zNj7OKdS^FjXHJu5%&aY}xooXg+$L8-%Dp=Q~G4)NV(b%MeO-x$X)T9HjH8bf60-93?EJVf@ zCe6UaRwgY*w$>(9Y-`fq_N>`~b2^%o+{vVv&eW}oNe#N1)Tl2x_cN)`0P2S_KbzEX zkVzMZn6zT3NtcmnIPr`y=@L$lq*kL?YqUwRV@>jnWB&0bm7ii#UyPq-(xU0qZ6 zKyAh`WcCE=33kK;YHMtuN+blTDyI7al_@b$HP9s`P!mukHBi^H1?nlz=LnQ3cc2y( zLa9KNsv4*lH3PM;J~1^9RNl5c){gP`u6>~9cMR0K&Vfqn5~wyf)HP5ydJuDO;z#a2 zfjWT}eFOCw|Pz#Y^ zc%Vk&6W)yq)Q|~*a!)279LKgPfm%F0P?0kNbr7ku17(~;o~Vyza|1PaexO$1I@}A0 z8Fdx~%D*^JYkv#Ws6E_28mO~p0@e0xpaL#ZXITCY)ac8Ba$E^iUmQZ0tATondjC*+ ze7hE?dDrQ|jXq(51C{UJK#f(9Mw^55t1C!55s)EBiP#EPM38o5L{yMEWC>Eg z=pc>4CU`x3je{5y8>AUHfNWmIVGF|IgVaAMNbUSV>V@;Tg_Frax`M+gL3)m`)c+LW zwi?zVAT3D8@E8@+gY*uAvIXfktjQjv8~8Id_M=*{AT5Qhc#s<4IPTy^338|uq!l=d$jU*QgMScFB}lEY8jq2yYLMEZ ze)S-A#viy+D@b23v_7?L8l)F3S+iA;h71bQU)VE(x{TsHR2WT7;2cBDxHut5eJ2L# z>9inym`$E@f;4V!ka8@-Qs!PBqVA*n`KKjt7VE=-7zuMta;d)W>%SW zvrgk5OwMN3e0-nXtj2KWFw2eOxP(JF&8n8mtY7n(^)|0raruZB?~9xDT?w;7N}9DC zH;|!}SwG+`3YIo&PZ{#T*m7pg#EtUAi-8r)x`VD2`5H?qnH5;stj#!p2WVNvtW{Ob zdWVwVne`HttDChFrM@Q@tj2q6`N6F6HMqr!T4pV+ZI-8jS?zHL1sj@G4pZ?2RU5Gm zZZ|e7*Nsl8c`@d150nt2gx z)<}eRHfwNK>W!3cW+$ef%CJ> zsxh0m=9u|^j=eJ1tWERH3SD5<+$CluE~AcctT3z6YBS%nsQ+f_xW%jqSbt9j~%?uCXT(b)6ofA$nm0e!XGVL3FxF zU-14mIo+YQu;1kzOvPTjLyddn06ioY6hSLYz*A&-WL6R)U$Qq176lqD^1v5l(Old_ zMYBb(QQc}$sLi7C=wP?V8e-7`r$rCZKa6AH7EOUIgGH`Li&|x}=!2Iz<1G4y&IuMp zCt9=_KV-A07lvVGc8dn)uqbm*i^k$&E{ooxer}8A=d;M3-=Ziq!I1(M< z&}xiDvv3Ie##^*_0_)=h8cn3`_zSNmQM1X+hYV9J+J&RIj}5;tcB(}kaUDaa5%Ua- z2F%{*&F~7dHnP7rG4~d7*k)0_?er7I9Tt^7 zO6`x)FI+^=zkv?%2ab^ptvbaX#UU(Q)n>Vif8;L%0)4@%x8Uo?M2 z+>hCNPw4eio;w)$jOWM;i+;y`T*thZ)Cq@Sf6e)y*u%JqubB0j@&B@>#i|-stD0Z{ z!faMWVh~9~Y}yRkfN`4bb&FtM;Kob*uX0IliF#_g0RV-LU{w^3HDTVSR!wVZ)ne>L^;T9jg1NO-gE77>IkqFm_T-439jv;5 z+sN9{s)NYi$*MAVgaVzddVqmltg?6ITwLvDRpH)NJw;4^dNIJNF(^3Ds*s;q7boxt z{RXl2D65ts&ls!rVD4C}&SJ_qt9DJWYU&L7i#_;Zrd7>nTh(`tRj)8_u2t(WU>^OR zPd(#{ptHXw?c-{DauxKSaHe zYx0-K}!tJxtfx4>zsac#B*SdY63e(aZZ*{rx`= ztor34HGD+fp74BlYE=qcz?zOw4{Yn~5p+2`-srwILERYSCe@uO8EKNH&*_VHK7 z1lZKfU{e?DGum_tO#^K@9%R!XvrXf15G5QoC5PJNaoUuMZn%YhVK!~dXw#NR#^E8F zM%mN}%TYdyjrX%{TA9_R*jSs^cx~E->Txz%5^Rbxv@{R7>e@769^)2K zL)2VMkCxb!ZJAB^mfQ5>3i4QKQ=e5fRbEZ)*V;63qfK+M=XZLCZkuiTf}m~0w%w-A zyKM6Awds2_MumMgfFuHa$6E(?`@hNqtY* zwCOapIA>F%^ES1^O?1D&IDEKh)1yl^?Yd!;?*Z|^^^iJZD?Xv*Bbz4SGKM~}sqQPA zI=<%XH`MYi^TGAbri-w?w`nGpVcrMk|43e+Z2I>zefeTjo=kRC%4}Cm7Q2>ZwaXH1 zS2mAb=kZgVUC{}4ee~INB-t)Us$H3pzocDVa0!J<*;O6`E7;Yhid~+nc2&ktSd5c! z*0sxx?e#gYfnEFXs<~a?(4>W3ec)|vS3PV%o3@;X^6l-ai9#LhnuJ^(?ONX1uCJ)p z#jelY?E1UAU4?tt)eS!*pr>6e`rFk5o&k2f8)TPpuwA`}*fj!yL+vVtD#$j>t|EAe zZx}h8bw}BC1u3KLYK4_}g6v~h1IN&EtX*5tX}n$2CvpxflkD1sV+fmK*Y|jfDpTzm zHH~rDIi2-q*tG!bkZBhAp&9nfwrj{7@{^8N7`&T$q3s^d-D_9QeRf6er#1)eDvGgx5c?78c$B=4v0u^VICGsK_LKj) z#_i-&b~QR}*TysS7*+ow_p^4zo?|be^m+P^pD);zc9EK5&fgrrWY;vjzD%F5*p>Sl zao@1ZcawdH2AGI@$a9tG%h|I2d_Pw@%yU#T06->5yV;a3IgfFW4-jln8x3RZXg5*Vx>&B5w` z#bLq95E-m)v3!l2c=rFUdigpoSPAjL3P}i7157~?ANLc3H51G5)z6&C!CHs~X~D{q zBUrm~1?wpC=ML6XEW)R}!Frf4Snp7)K(JP#V8LKrzz>CjbqlQua~v6q1nV1G6b;rY z%q|wJb2Woiw^p$3VQlSSb*>XETiswS$EOCt8qgwGWAL$cu!rn zKEW#0H&~kx&_7u12M24*h+u_I4c6xc!HQZ$jTQ&10tVwI=C2Lbb9_O^b-~&T|F6O7 zha*T_AFQ^&1?wW3Z46e|EzGl(nxQBDL9K1U+P{-}@A^-R-N7ofhuZ9==KC14KUfnF zFz>-&1^p4M%h-50SlNyQ>jb_#N?gaNDT*EsR?LZD^+vywj6?J(YH~VQZ?O1Gu(JOZ ztb^EgmYB{3YsY!|av@mju;gm6e)}g_m9GVBH6C6M*0me-^LDTr-yz4x!J2`kDD;Hb zp9ZTr4&xn6&w|w&yKoHoo(F3XCLrUBV6{YdJV1e$!77JC$n=U@VK!diE84#f)^;35 z$v458g!#zyHdsy385fZ9j=8WD?_hdQZSe=rqRI!(!&;<&q&66VS1A4|SoY7%i5a+$ zx9I+bxNsij{^b~!q4HPifx8BWoJNP*UL70k=0lf~4*iCYNH6WsTkI&~&`)I@ zdW^_&>|UpsGXhXn;02jJ?(A4?ZH~2j;2aQ1O}$ zRlztMM(0}8xVA&9(58+<^XocPxSm7n5L4fw@(mn1j+llH4aa)iY2;9N6NmPoXH$-2 zeKUI0+@WSIh_4m7VK*|gVJ*CD?~t#9LuXL9qeB(21eZFIe`osFg`B&Re>eI!+QH8; z4o$#E1dSn19Dv5sOH9Q@WE#gY97f`JV#G}pozzv)Jp%F^{=XeZE7}a0B@kFc-#R{z7tEIdtrI zV%kE?FmI#o=(3%3gE6)Li z=$;`&l}#arV1R4X||rnC@#Hxr@) zIYLx4XNXGY3en%#lRHEu@(^QQ=ExVKNVG<~{2^M6t+<28g3NVhGa(bd_+J10cGxgm<37ouP16X(JZ zb>9%8fX(D_AVfP4Q|BWgO2f;u#Cjz}L#~DBWOS%%C59@oL8x*gvU{lFF&LY$51t;3 zK{G`63{?uwW5iFP`UTB;g=#sv^bXYk#PkVO8ivByH&jmK=ohM%=!UNSL$w~e&}l%Z z`k~f9=7Dh#Nf8)fz6YVI`7Bh=-;nEvP>uaJRI>t{T8_&`CqFYgTW=GS6i4n&MRWRHs_QHO;BI)1Asb)2Wu|hSf-) z%XxT(;q#pQUYk62P$xXb_dBV_E~h5q6jF9Ol^?@UbPtamq+fqH)f}s^1^51Rs^ekS zJwnfpIhFH-Q`Js7)c`Y3v;G;Uo}$iGr$*dxs{Ku;%(tBCiQcz)>^^mV;MA^%ocqYh zbyiMYdQ6?3v2UI`_2)~cX1%4K=<|W`c!EwJo$3esCnvAxoVtUu|2lON)4nwhRNp*(<9uC3)9Z{F#VknrX{{G{hAb} zn;NEBIm0wJUzm2~4^zPcj4K$XD}}-oUL;I|in11#6l1LtVH#F4OfjXxG!h|Y z!n6+dvSIoW2T-~SehAY{?8EcgVH#C0OgVoHQ}qF1 z8a*aV-%ktEviqDH6Rw@H;i~Bm*Yxb+T7tnj!j(H$xbo!=SLtfus*VlS!}X~~xa!vA z7M*H`t9#vWHLMq|EcL_XY!a^PO~bXXS-2jw2-nJ%;Yw=F*f!zH+AdsvoI%I-;ktw9 z4&fSyS!mZioIM?`hd+nw(n#i+6t0$2!}V-!xaO`4*Pp+J>p9#T!}VlSxPI9ju2)#O zC0sSOhHE22w}tBmY(k0c;kpgau5e98^WEVx?hV%*l-(DuF}QMom=BU4&Li8O;p&RX zhnO3+4u|U~Iv)?$>l4g*GF%7Fh3nu2V!ary0hhyd7{OP zg=^|VVtN!VJq}l+XW^QGV;KLO`!B+E^&9!(JGm4Q;LW@DW zp6*fuY{|x2*7^=Ed2aamYiK^9ITr2C+??3!!Z4K5$m6|S9s_jy_dM;h6 z?^2NlF70ec4vk#;qp?dr{peD@Ce)xA`LuB9BwDs4=2paq;jLX-G~A`+(JoEGTYMV( zpV*1Si0*hjgEeMSSGi=F)e3K(Tq;$6K6Q;?lBpj9<@u+jtDd z?JhOi$$r5LRM_RxYTQBY-7ZZ=zCF|#bN7Qd9sE-gUj z$P6lrUdR=dfuCiI8DQ1g}dX zcyBa9y>>@v#K8z{z#sLA69Ex|S%LiXno>Qo}5CiTmx>O(WC z^yrM5IWeOS!a6A<*YRc4;iVasd?TaIqt@$;TJ<@j9$;5wB-hkMYEGs|WvUmcHVwIL z9I1x5)+AC@nnfzQZKPVakJR0cks8q>Qa|>JREL3)`fg{W)*gzK@noa|zeZ}hAxgcy zQM_*urSIdSv;9R{y6{(Kh4siP)9S1$xGt+!9L}m8IEAlAvg+3_S+($MR((Wo zn_EwU-O8KAErZ+5^(1b6k6#P8m9wB*<**0GvAU33RSUay8g+`ewI5xJx%D13iZe$^ zH=i?c>$lQwrtbxTSqan zpIdbYavVS7D2fbmEB8>h(uTQJ5U#AHrntFY%dL$F{)PHr0q!Dos#`6v6!)-l8t213ojM`U47WOA zC3eqr>oZbjxpfl@XVWXxokM(xn#*HIUF_D>C2lQ7uBC33Sw;?cxZ16ENLb6`*oK+E zxixAddEgz~zti`vZq-H$96|YAZY|p5){MQJx6iFpXuqGn9-u~ObkMEVhurFcFGt*p zKI7I8_z~w&>bzT-udpXD4u>)1s$08|`I=jEu>otZlLv0zbnC+{w=&#gpZvda_uX8p z<<{0mocGwRfG2KwpED17zaf59e@l$-SoYff4R#?dK3e{yXt}dTt0OKTXN72u$ApT}x{d6WqP4Vgv@%tR)~Tw|I{00*{`etU zh8oezTa(9YMXPt6Xl-g7t+Gv`bqQfjqxBdCn?)Zjvpn*zoNNLFIvk{8^M$sRtF z;88@XM@Mi0bE|oD1>?W-Xdc>D_ox@LeeY3A>_Fcd9vN$SxYop@wAvm`tmDzRx*q+D zf9i3pfk&MY(9omGn9<0if;(JbPeZPc~rNx zM_Zsa9u>t)1hn;NDYCZns0SwF0~WUT=vUY}cvKowaRbj#tt0W_6oNW=G#U##dvqO> zyHE?1?ds8PH16h62OPqA%Eq?Oo5?1u`$kE%QEV$XnqvXCGHOIbwjPLK! zYU~>5QP-atk8VS#$54-o4Wq`$G|{8szfgy19&N-uL{9hcUIO#ZBwmEg@@Nfip!RIm zn&VNYxgLei^XM)%&!?|QTj){jBF5kntcyMR85Ng$^aAUadGrZqmU}dEHLU+|oTIW2^_jKLn1dE(*PH;+cWWXvmS{Mw`E*!GV7{NAI?A9)@G#qe2y82tgaB}Q4T zG4i9jJx0Gp$Ecn^Mpp~Q$X+}~JMnkv7~O@hLX1{cjL~MKRgK~Exs1n~+A#{K6Qk}Z zQZGgoQL0glYIR_Z&N2E6Z@R`PygT!tRL>Z$Yi7QmV&v+>_`WeJ-!DeS{)`%Hb$qgd|ix8zsAV6K1Q>#0uz6W(JdU_5Ti;PV>AUV}ZJF1oXy>S3=~S=Pj= z!NFKvITfo(XJVCfHddbVvATtR7h-h*?JqLs?^yMH5UVv$WBDEztJYs*mB-*!N&JOh zj9#tA6?{c5lUM!W4fLu^kXMOjuhJ}DJwsosSCbHI^Qt2Lg~RUEZ%7RGsyzp;he;VC%L?8o7=0O z&?Jvnqw;!n8TYZNfLHs_su=4P_v#&%m+;C|(yMTc#vRlz<<)68OMCfzfmbbX6#t@D z8LuYdX<4t%mh_oX0V*g;(ENdUdRoS1nt6WoYA7zV_6+1Mzm^@y^tz3%PV- z?(SX<>F-tR;a*-Ra^48929KmhC^yQh8t8}NqrD0k=T)Ui|5?rL{}iA6pPSrT=X+HO z3l@;eLa)}qy~wMDi@n;h@;|dzdG$Z-R#X4Ath>&uuwUujZ(c3lLeBfVYIDrX@4mfi zaGbi}FXTMoWd#0r=J7jWH-cV1Zo@OG}9EPoaQ(#>yOhH8;=La={rZ9 zUSfzVPIc1b^fx+}h|_sk%f<0~(Ks!@9;iIW&>tfz#PRvZI6bWxrz+Lr)bWQn4Zyk@ zaoUNFwc=#19jAlHT$gbTasr>*#i;mV#s{=MMm+cv zQ;x^!9j2a$Q|L+N!wvK~#rY_Dn!GR#PhdF{r#xpljwKjyj`8@2^%vrF3*i@87rpQg z9%0qxINd>st8q%bMi0;yLvF=s%bhsgz8j~A2h5A4N5uRzj_Whx)Z{sNzaVd%ctw5Q z(JKu27^haB;?(2cI2}Pl#j77e0^(H*fq!)jB!-XkzDUV||{i2L}- z9IsB6c*z>Cdw7F^ws=jl$7>!e!SU*bK`88CozQrFK#DV7Loo@?uy~yhkJnw)aK)=B zJQ?HF90w!g)j29&KjS67p>3vk#bl1xaa=`}EX0Z>_%3U_e#9AE$0~Qcw%}oOys~)W z)d=md2nAx|^$Qkby*FOF5EvJ)S;!X8{CI$05||qizIer93LfJ3#CYXPA_i3P$IG6~ zSS&>I^mw(*7O&dbtCz@_5x zd@qUD;}Y?*mE&#@#>Ub^1h_%GDCtgLbu--FriA&Izh6$?E zC_ydp83!9DsLhWFdIeLH1ZBsMSdZwY37U&-2yK?2_IQuz<_W5WTgclYL65s6D4}bD z26yA}?g=U}B0+ue_eka%ouCewi}NTsBSAkS*USW!!V&mpC&)b~fzN~`XdI&2H1U^fWpp`2U^c?+HF%ApYBq;IM1P%E;LA#K7 zOM)V|CMX`|abi39?MTp+oe6rfD?xd76FZ9TP0&^p-j|@M7<@26d(rI==0f71Vr)PyO^Nsc!K!9 z6LjZNf)-p(Q2i^ccQrv5k^5SLtk)Ct*MkHFKcr`msM+HLC8G(7JxNe^L_H;kX9;?T zmCxxNR=wb{|2OwF{du3Dn+X2Ov2O`FEuX5Ie0m<_Q-%01^bpC$3BR(eH$Po6lRE++akG|8u&-}_|y!Kbq5i=j1r%3IsV-+=JR zTi2%*4Sf2&iBG>Z_3`@FrNKAk;SNg7@aZWk z&h_#A$H!|#azyYNpK@(r&W()4Z*Xq%>3b~0Nqj`m?>-g95KMw`vrpBq1z%v@!q>>M zl{y{sY3WIyHX!+wPwQ~*w2z;&eVT)!=U5+>^FBpg@Tu8FpSmFJZ=aT<$|awgVj{9! z_URF-U!gasc9p)s{f|#Q5qr(2HModw*QwzRpN=EwCiC8+xA=@1w}}ZS;J!o5_kDa8 z!>7iNe0uQ2r|VCt%QI^9(x{EX9#&{*_FcJ)jvKkYW5xGo> zs%cJCj>tr{!{Mkzz0I5`LzYB!L0Z;C^@&c@Rsmq}CMju8=5y#YA1j6LhV_oRt%` zq)MVTz*RL-r!l%3F;`F2bS%N;8i}e_FOlDQChA`OL``mxsQGwL4)`>ER@kIS_I#JtD{~Yx}<@1SZ09{B_Ph`DJo=CjP8g~=5 z4<|Av@j0#}6}XwCmH2|3x02Ka7x4)G+eylcVK{&@sCXxdpGlI`;ck+i<6jKDpQJqx zlCaTFiX z=^b&tPvZLNB)vke4@vxvJxS+K^;422BjGdmzb2`W{Q3)l0e(L3Y7UDX>0{tq1&RBv=umt&409~;Z7vM1aRTLdC4<})=_*DpK5@T+u)U*F@eP`|z)BHXXp_|C;+Sf0VJQ4xMU#5+W1 z^y_UT$D{lT$mEwdvtQXU8J)BE^;1@k$M}^k)~~T%zoy5L8@|N*wLZbm-x~6(TasVR z{ltM;*p=+p@7Wle*DqH-zp7wWe(G7kukkp5j)naihMYzGdX5Z5$*-7S8H+Pt3BM9c z`js2)%J{Vs4a)k}9(`oke!Z^G z`Hi^!k$Ic@)vtwLe|PiiNq4{U_n@ae{W{wled$Yo;vGP5hx_$$gkQBs`lZo+4IIz; zXfc6!C(_SJ^lye=L$GI-pTDKx*X6l>&6!WX7xXQ&jAtXzg<6~{0v3rf}v6tN`BZcSDcE`}y+i8EQ-!;|#^t6j<3ff5;#H7_EW z-}xu24+0{S^#n0d$*P5s=$$#4zYD=RS&~&ZEAya)Cz=1Vll6B@vg*est1~R#WJRDV zmf$RkCnT$)FPZmXk`NQa@Rh@eQF3k~I~t8j@Ed;%%L*DR|K)nfK3=wE-8< zct)~j;@!+-Et-|AUlBh$Su^navSjsGk*w2Oley+US<`kU>l{YxPS$j|_fV_7ELqXdla+$l&&dk=!hK}*6_p}W^bM7w zQdAeCGo|PsR7^-wZS2QoUy2@~ZeogB;jg3=)l5!NcuI<1p=~PbU_DNtNm`25Vh2j5 zr^u8oMa^&(xw5BlT~UfYz>y|Gv?!dS!bO-9m5Qe5Izo!2s2e__MRDqfIVDo`Z^;xDEk&GV zQuzNbMGY#X=qcV-qGpv-RJtB@#|t#6pQ1Ckjob}VR2fYhQghfFkx%0kEpL*dfTsVk zwM)?x)NP-lQk_#Y2)Vm3CypYqTZ%Gtr#6F9G#8%+r|9NTYJke)QdECJin2~lQN3S? zb6ScDP3IWCV*88~?U~2pSU*2Sdr@`)eOQ>H-iuOnd^cBZ2OsN_lkgCsyRNmuA z)f0TdU{k8D2d473F;cY}xy`A1hC-H9IjyOxiU3r>PT>^`h}-zGh7)` zbsGPmO=PM%Mx|;60yC#-I}YIueu+<&#h0qG_y}uaswUt`66YqT>M;@vFs@*#F8;qk zg;Mnz*0Rirq2*GQQa)94Dy6D;Sn$F%x*xQKc*^YyHw4G zt$nKUbs(2cshZq5mFq%MwY+Dl%s-`SEdJio~CdWzzMQ}x3T)<&tJ zsrrDn!&3QMmZ_>ZDpe21q-xCgRIV9F)!!3S)qGm2vd&LcuZ5|6-%M4ReW@CVtNWSz zK&rOjKK?kID&rCAhd)vIXsT8oOV!@vsX7V&iB#Riy>py*K2@<7Qh9%t`H}rPG2;kM z-$>QBoAmQms;1pe)%SN&`8*TH5qm#X^|AEEys*zt) zH5C?fno8miOPc;de_NV{Inp#4fl+B1hmcHZYJex1(=&enp!8S(&DltI~8E z#n(^=d_?ZGXhkD>BT-(yr1aG&eX~quX+?l5C_zjtNrK$4nG>t})J!z_f zv&gMzY_=z-iI!T>gvV;#rzD|C^>4sPc_mz+cT$SU|ekBh8eqPGRXQ!W75?nmUH~+`V32Qx{~Ur^Y^~eRj5(ACZKb( zbX~xU*6AwUCS4y;vu(Q6E?qTHwj1+dZLf3l-@)Hr1!dXM5GCbqA0yLrAu#8ReEpt$9?a8KcDX> zW-`xt&N-9i-A!hmSstg*syOx8#y;EQ^f~(Oh*OrG^Z_q+#cAN~IDLaUd*ZZwFXQ*c zsmuXt`y);to+a-2IK6ctPV13zF;0~(#c9C}^0-MJ`AxDHFe!-pXjst1T9PK+C}h&4 zq9)zJN5xILT*9QfB~9|;Hfp}dV`-Cyl`$#%2WeSq%PgRlK&)=7NXr`lZH+=DP@L9ZBT5cNiAlZ z)OV3dV=;AwNxfH@^cBpjOuyD}j#M)1wrZkt(U?PkScs?)6Y@n-eL%m!vHeZyte3*>Q|wGMajzR#@g7=)^R zv%UzJS>MU5%n-4oW*tg2t68#Hwp6oLVIw|iVwS6!Sy8mcPONQi*7cTVjY&6aTn2Nr zGOH-Ipm1xm49sgoex1ykgn4MxnZ9(Pme0)m&Sch{0cJj%W=?b-OAp5}2bzp0#~EhM zi8U()xn`O5G}EkobIm%9vGdG&w2*!;GV3JzFE*>fw`M&=j-_U-Gz??!2N$ zSo)e8WYIfWENYg+qK}GN)Vi33bxJIJuVP_+5{p)su;_d#i|l1Ant)6gWi1+2&cd2r z7OoGq@O_6x^U$c0MI(?}-J+T%iyGnu3@6z zqDKLXvIi|HihgKsSoBTUqU&f8wJ1lTh4m2Gj(3tQYKlF{7M)II?k3cLY)#pxnMLE8 zTXe96MH^xkefSCU;$eG>W_GaX4qjquM`Cv(b{C7{x-l1CcDHC&PYdg{Th!rm3)hL! z6Ldj|KGfOQqQd=&GnhDdiKRmT0Y653zID>GnIO#vwfyTFJ@bGc#cKiWm+_NF160%^<@@y{@$Xg z%Po4a!XmA*sN-sjj{U&CYlywpqUevjw%(%Q8!bBbyM?vu==)ZS61G{?Z9B(j2ghue zMWyy~4EGW90LS-`MU@X*6h2C?j#0x2YC1{1r!1<7KjA%XQSUPrJw0pD-3u1|a?PTG z*DY#;OdP-|cy90<%aL%?qV6~d=Piql;~|#)W0Cn^a{JGszcD6@mCqQgO28)M$Zll~ z0;`4>vT7O<3tQD1hf(}ptG-6v<@YG7CRDX*0n(~j)d^=&p@vlx zF`%YZV-c)nRWt0t+jXoOh%xb2WujRFtJ>o)lyR{?ssyd-YFO1DSMU(4Lgb6_jjVbC zPuQycxQ5LUt2#%m`X<4utC*c+RpDf-VpxalDdd8S@TOW7*Tkyr$koiMP;>UddoAb# z3b&-*G^@6?vg$}{tJZ%+o^7of{HawXJJ6?&R<6aOex!D`>MQ(*P#3FiVoq0Lb+gKe zllZ2)RrBEKK@Fc<^`fs;efn87eUMe%2Gc*R!f})uVpWYV={0(y#xVLc&8pkTI^C*| z@fi-H!3^@BNj$tg%c?JCTlE8q&#`I|e!}22wUzc?Jal(=0_VT{Cn6uwhWjW7(q z;x4M*t*17ajU&i=ubvvB7nb7|D&DWBbWFhkWP4Cg_0bJWa1q5H)>8^B_3F!BzrLC~ z>nr`E`g(6yeci8NQ{^}t>n7PW3+GVQWK(No;uMOSZR&`PC}6QE4XcpFYEu+LaU8V_ z8*572^kK-R+V~a48{6~Ra>1fkwjP1ny zaCf%p3F>sQ=?0$S$F4RN>dD;5+RLWGn2v{^+qC8jn|6F-Q?}7IzRR*{CmN5j>ASHu zwHs&C<;6CYUSd<DjFZh)lu?gKa+LUKAbz>E>Zn5dg zR-5W?v*`>bZMUi64tlrOruX*QbO`6scE3$q57^Z2kWC}e>rb0Zhi%$-)TTRs*;MY7 zO<&>S8G3NmrVq~BSbN2$0XOL#y4h<8`sg%x2HBueZld`V%Gpzv)Z|Bf?eKhc6HBg*Nc31)yZ$yqyl#R_O@Mn zVJ&Fa?}hCO7Po6C&X=&Weyv@5(7lvh^D)h0*Pn>1Y1e(ImR&FF+m&dut7!w~z<&+x zTH~^76aK*RhV0w3G8uB}~3?d)pS-mZzb{i$8cJJ_`W7w}~#YDCE{cHO~Clqxss;O|k?G1{)S-`h18 zFP2mD3cDsF$4a~GKibs`hu7P+;Agv5;RrG}v(HwJ&o(>P#n{zohh2Gh+cj_x$6&u* zyARk^?Vw$r!*(@3V%No^Y(K#`JpIeA>8I>`Z)sQS)BltAEaUOVCA&VnMK3THqyMFc zxBq9-6OK7fKmDKmSsf~y&7re794eO6p@q2|T8$HLIaDa0LsN=7SpU$Wsbw8Him%H# zG!3Q8JJh#=L!l2GYKkIN9QwVgL!EpMEknBB!8I`s-A6*up#p|OD-s>Lh0G*}R-#t2 zLlaUQYLUvkZOH+)PaL|6`)J(W!S5{&u2poXd>4lf_Ht<0=MFXh!l4&v(1+amIrtl% zxdssv*KuVC&xbqoEwYbrXe$ok5q=uUexn?G*X_`U(;Ujc#_0}?nc>h({EjVi9D0p4 znT$nnu0xCG5qCbl+2T;2tq#rG=1|s)4mHGmWV__hNL;<_(8Mba#sBM2f0+IwPwYVX zI}Tky(bo>8fE8&~40G@-i&IOoI#o5NQ|(bIms8d70}AAEvIL-0xA1mer_L61>R}P5 zOhugpZy{HuD)Kxsd8k18w%ucywa&LtDLI8+Ns?e=*KTkZNMHxe|2j4MyFc;Mqb#31G}7RwA-m>_~t%! zKcbGu)bWJl`jlQ(idQ@Iz#qu09IsdSqe{Fkpk38?-KoYlw5uMkwRnbiYQ(D?`r;7^ znc~$FW6bef!xyjLaorNHU#)Db8Lv4A){0jXSZwiHjH8ZtUBLrncgE{oe1KZ;A_Z;G z6T>hWi?9xNF}y*%O1a`W*D78jcdAR7 z7}3I|o#@ljrIBcm=2D3^#75q>E|tVZtm))Z&dx4n@4{F-M2@b^gEF7Fl#YVkTq=w0 zuyuFw`=d*3`?|CN%lov*rkv5 zy3`$0_PJE^f=gdxz$KS{MVHGi4a8?xT=L#_X((#namk0Qcd6x}OZzbXxl0EzehU$#7o$7x@F)8G|c7JT$ppa zm4+Uef#W6JI#Qbb-gm1j@|AI`48m`eb?aYjs_53=NT}r2qsne|s^Zo}96+F|TSsvp z@0;0<*SKgQPE9xWv2bf3R@P%4WUcR3EmXI=m4u@W$gLqUF&Fy~a#0s=gsvftR zVT+f#G2Z7^7r$E{1l_X0nc~*RxZKRG3X`Z28MBCq5ewa#f-*laCtCdMR{afbag#3P z$N7D3ojt&qgKjm!3cP>Ft!00@^#?j1c55)!ym5q_j}rGRb>bBYo^#9g#(9nl4qb5T zA>O;_Ry-1L4y7--RU2VU!8v5T>{cR1qvI9&i8X(_^%w3U&sDc7!i#aZbHlBoH|aSF z-=cnm@D&#R<5t|iZmq`!tiH?Z_uPu0^#k4`c;}&8L!Y>{6bGKURp7Z>hhMn$0*SAg z7un=dm24jEz-^q)>(Q3{9v#7m4?N2Dp-0^?35W0ii4{G{#7#V?SR3P--!3<9CElkstzywZjV0j5XVcdL64@Scr-KBqs^$+#3Ls@ zd7~+Dn|YLmnk_y09aj+7%A*uq!^)36I*EquJ(}3Xqo1*_yGQqsw}(gNVZ#AD#jjyI*=GcJ$eP#DCR|QtcP_zJ(@MoqosI^;y-%Sc)Lg4aeco>1rCtQVRFGy z+(wBbI7&}Z@HqX&0<6QiH%@po@T5n_|MKVseCIssh@n__*`rhV=Ndh|?opS2J(`T< zJ01-{tA`#9hy4l13FTjsCrZgHAFAc{DiNQ&<<-klUR8L{s}5znnv6(wuX@61;&q(2 zdX=Z9SFze&jlkskUe=EBDyP#cGp;rCs*ua8odK`zpk&mmhM116c$nx_sU)v@U=Hf1 zdX<5na1n)?c~uveT6mSOrC0MayxN8FA9=Yymsge!UNuG5&R$i=f$m=A?(LNor3ZTD z!GD9jDn5kmUwIXWLtlG2AIHm@OJ23Y&$xv5#(L$(Ol-%b310qxmK-K}Wk-j}%!`6k z7>i0Xyb5D64k71ka=^t*uil#L)yPF&twOHFVyZ#d5wO)aowvw;Jo4GvoEiT{Nv^PHm}mr3ybj^3O*(_d{4Zp z`P8dpusx$*EPL%$7LN3bTs|!*=2MCHdk=#N?W1*gCV=BkVY z^u%;*#Xo3M&8M+w8t2mxJgwzZh1xz9sOM8X+;#d?D&D8g0iP}hed-YM$(Q6)S4?T) z(_3jiO-%Rc{S2R$wDKwOBcHOj@hJ{VJNfv##iuo0eR6g4aZRXCdq4N-4%&Xr>-?K8?poRP4`l9K$879N^PE{4tO?gMB)I8pC|bG2Ew%W5_F$-e5Bh z<2=Iid|I}IG05_*Pd_7R6LaGnHg2ZgtvK2BeD3ES7k>SS=Y9O@+|SRN1b)@)?^go; z#N&Z}9V-_OmXDU+c&E z)qRp*t*22J&LPKize*#FdDx5#XgeOSr1)qYLHq&4ij)~^~r`jw2nIP$Y!8-MZZ5}N$#*Vov- ziC!VwX1_|ICK}=DHezq*IgaD}4)WefKA4YvZ|vgu?)Gc{Ucc@k&py98p#6TodSU1R zzb>QkA;0cm*dKl^!)?64!^3`UI^x%$qkct>Q73vG_iGkjqVNg79B-WT>kQndh>iEp zFdiSDV}Hzjb@n2$Ek{2GBhFUTWj zK#kB0?py)A$`_DPF`%aCff5pzJZ zEdgz|26P?yYX$TJD%K7t1^?9zupUrAyPW|AJDI$}K*B?c5r3h1rmfU06S_TV~Nrv%g!2T(1QdGHDL;|6j!Auh@_ z4JaPzID@As(<~rAW;YM$S2SwDSd76s9B;{gr&BMkU~w#ncFZwuA^WwPWbfGfGT$g=w;6U_sGTP0qsJAF9I6*RY3bj z1oZWo0OutHG-rB1lQ##nX)ASX3uwvSfTkWJ$K%928Bm2Y^!{u>1uoDBe0_;yhl5uG z8kjez-35ZIX%STU4})4|4k{%+C`*GN-{AxmXc*LW%ytEp>Iv#SZ&0CTL3x@7Ri$lE zH@XG&2n)LhRjfx)v0g!a@Oe;=`v#T0Ur_%b+CQkL1A=NZFsP=3gSt8-sQW1XWl*DV z8Xpb|sxvO35=CcHD_YH>b`+l- z`+=a=9|`L9G5T~Ns8{&zBF6!BFVPR=y&P0uTtJO0yp9Tg2f0q39$yV=ApV2tT99=K zh>ef02Q?2L-C*p^pmw6@E&6yns9q0v?O{;YkoJhYaTA>$({H@}B&e>~hhLr&;~DXh z@tmCDctL&GgYRCF<15~WDE~UB0a%aWGW1>+gX?+?UC(N0XEuZHJq=Yvi5!MTRX0(qh>xsbCEB(3aR>q@>ML(7q`k)h5wh}De^nZy5+5jE62!O(p)N-~s|Z0IDsDF%O68Y-M>C=qw@ zZBs+GW(J>8Fn4p}wqQ(4Lp9P20RLcb2Juj$6+J*wYx2gY9~r9fv7rap(Z=9& zGec2y!5FN@5!^$ec7|%9DMn!@Dt*GS#Gk0%-cTmuJ~i|kx^5($Hfp9>uZwhCbm2s*N`E8BSry81}*HvGi%2p#?Y#jpq?Jv0;LtEt3rX-lES_ z=pB-#8rp?=(>R9H>D3J0v$Lr$(_jr(`hqfZd0)>nG-mLjqMf){|j-lsTj?a(uZ9P9DKhysWhKm1UXv9Wp`;9sA z+3yDHeUdYd;u?}Rk;gXj-)^YS4nxB+V5gy~yZITzl06)+z08Ai`wZpWZ|ECjKVWF! zA@avBNB9}WqN9f1I>xa+L9V9^)jndA~oRw~r0g!7F&4@P2gw(;|^cUZj4jW|F1;wLsjU<|h5C2WmC>V}oLjN*+$YJ_3fiRY*nW?uY+ zSFlAw+y^J5wfF~BqVyA)IE8l-LW*KEb|On+NOp9`w>XQ!Ng;XBA3x$>lur(+DaK$c z9-w*(u`vgSkt;PMC%R)1&ZAV5keXmDcHk+@P3Z;Z;t29L3n_@9*ns_qnQVf}<%2u}!W z*~G90O=3L$#7i8T7M6K>SUqNi^#j_>4yz}gp=l=L=7yENA*@-5{1R3SSK!(hR;Ay< z`fqnw)%TDmZll-UunzAFYxw@KCgUWY91N?@A?n0a4EiIiGk=CP{xH2b7M2auj)#?e zBCJ-Jdy;wn3hOtNJVicOe>$u!XQ<_DSgkLR51w4450}UXbuLr)UFyQHd(4fJ_rv<) zL0DZLhSeXvAF=&On0sY}wc{19XOE~E-pUbCDa^;KoDo&c9Z^!{h_Y9Sa8KTd)}U?m zhi)cz0VxrX-5v{|hJ`wHj%VYlt zYs^J-3vUmI=pd>NWIW7+BD#$G=rcH?<3l1EIy9mQ6C*l=p_3w-h~kr}aY{txrjp;< zh@N4^x`=**=f{ZVt&gbjPZ6y;64AeycQm5asBQNo5 z5!J4^s1}-|nrew^tTn1zwWIp8PE_0LM)hkwV%CqUls&2&*y13TE2@T`sBU_rdgYJm z+dxz&f>F&kqB@U>p{N$1a-*oeY8+MWa8#u+2*n0Om5SU0qbiO}JRcO*z`;>X!b8lT zMI20=O&nC7L!3;;%q0$bVehXz-$;Jghs58g^LJ|8#F$-CUBIN>)P*X0q8h$8D(}9i z3Z0KCimVr+DvarPc#%0T(T8hM<+vW@x{#=LBXT3E?{7xc^cHpBj_Nhm+=+7E&ZvTS zqgs5AdGALx@(E+n_i0q4Q1Dq)ou5Zl;suXc67)S{SrgO+50IEWK`-%Ejs(udP0;L| z396bWLD}*qs9=Evm3litO|S*-f(gn~C_#5nzbLCT7faAwEK#DWXGv6jq+?gMMBT^! z?1?IxBT)l$Cu&5IL|ucsSfY}OCu#z&p-hQHH7l8@J19~rk^4C$>W{LCI)_inC8}+O zL><7X4-)lmJGOTrR@X%RipQTNs?ZmSsxUNBc}FH{&ZI=GoSdk_^NF=EQN3{u$G%O} z`#&bC1J?bTsKCZVb@`pg-HGaVGEvnkCuw`LB>nzzl0Imgq=LPY(vRd>{R$n|BkgV+kla)F;S@*{!>&%p7Ri2tGO-oi2oItCY$?`5pR+fdyy8AtG ze@)hH{JAk%J$_5pa6HF=-;>pAbF$vuk}T7w-6?u!Pl_JjNm0Vx6n&N_RmI*-RXwanmm;ZJf+EFI6~h|j zEuN|`(CPhDbuOQ(aD`M2sFH*?_Fssbu>*EE~V+)duf_`KaFd{(zGF4x_sHwRX10<&SQ9i zbTxWAUH=tKSD`}b{Cx7-hv_=uOV><)x+aFxb*y)~Y7R=P__`y7DjMIj*lwmt$SJ3|z(YAJY}LK3zjG4yRG{ zr*uWI0J%4$s|Z3H)3pT6HmB&UcgP@;)R6YCobz+`yQp>AHw#&(hWE zdAho0i)jT~Wsm7IyqhDYGdW`_nJcCPIEzWSW3uLnX%kZOu^kUe#gzD7Ofeip-qJC7 zkbv1Zfr9VHR2muOV>(tTCQId*mQ{->sYZ-7Ib!WB<|hmClFJR>vY#3)Qh&QTe9iALXKs27f6?Py|+$8~(D!(IeunZt}I_b(k&DZtWgDjGAd;goy!~gx?$wTXH#8ckc=2E%o@y9^&X+})kQkYPiH%W&7h81C*e z?Em@w_j_ zyULWw$;vM4&Muo(wpiJm;>C)Tak*VNWt>H`l8Y8CUdCOfOp&t1+(oiWWfv`3%vmD2 zR0$(7PUg1G`d_U7{Wth>oX7v)^1o$hR#v)zyXB;k<)w*G1<8g(NUbO}M06#oaAnDb zy|{*7t4K?$O8e2L8hvU>pD?Vp^e+n4l{({IcjnPU`hacYr2>njNK`{ltiwNefYXbK zwM*)ISqjSZ&<5hu*jL zkg1J_{=^{!we?UuYM~jz+j;09&f{cz4<&Z+PzKVvd#Fzz5B-92{XF!vzlR16@X%Nc z`I%V5Jv4PB`N4mbhrA|xDAyDZJ;&-<#Jc98-nTq-|A~j*qT^E!twp_O9@_H4LkE!g z(nD1~dFYd;LCw7kIul^frd$T?#iQH?9mr!)q5KAIz|H~&)h}q!U*8!N7idr~oDVXn zb+AFZvkW?mGT84>)1cDW16wVF+F}uU)FuXcG%#ptbA!6K zFz9U;gJQZGG#WEdzMDZm<3o4u_b{knPlKZHxtBprd(*d%L36MZh5M2l%mWN+j6d*d zAmjdQP_aP0{kwLLb z4a)zkLDyFpG;SsNuQuq^I)kpF@g{>j_ZoB*MfVwW9G(YRlj8d_>@PMm5HE3@v2Ts6e9z7B=bz8U-2U6JpeP;!55>kvBlxkFybfZopuC!4vF+9_#HMoZaw^3s;8~wA$ zE!(J@2r9!q1eP^wCvKNx-sO#QqbeFyFzPO*Ry1mTB_n^Aj2eN&Dn`Y8Z&Vf3$DQg% zm9Ie?9R9(muC9W1G5)Q9>;{n^Z@M|h7Z%^9-=b8Br> zvo=PJZ)?QGms3iV_iaHW?~Pk%CMbZ^$JAAf;|8`T?~M;O&+lu-{5 zI@+kB6Is*$nMyv$H;p)WG@bi1jOsYYsE2cnDmc%m7C1Sd{)>!?T543yHN;zI)R7HF zjoe7BH<9CJqgHPFJW$XC!)@z{pH3VCWvkf-*Bdg>;cgnKG3!c(C!p4yS@srtn|m7V6P322?}sh!Bk z@YJD9PyJEeQ|1bu>W0lVJhir&r}o3Qxu>3Bd<#!4Lf)31nu&?6J+%Z$Z9G-6ou~G6 zAXZ1(ck)zhXHNxpA?L21YS_(Fjr);Pe@~?j^i(xm8tSPP!#wrp2v1$c>5;@8?WvHl zp4vENAdQ^wcSfmx@}w4M8ko<+U1I2GAm%C73A7qz^!w}F?2weZr7o?bfD$4iMnd&xP7 zZA0ig*Gn-=ytHP$mqzXOQr)9oI(NoP?aq10p03t^S3*H73Mc{^8yl5bdq@G2ZHp3%G@ovEKRzhvU5U9O?1is)jZ2NbuG% zJjT03ZyhY|t@kDAU&>qcQ@ja7MD#INM7HdSbc2GzZFcCfdSMtQ3pDvV}aIL6Q) zmnL|t(?)N(_IhjPLvJmznzYbn(tv^{O~Vd6!i+*DEe|wlX^=_hFeligdLgt8GwC4C z<8HV~ukkd(q)*rp$^Iyl*5YKeNmubX#w6cZlUl`@)B_XaO`4Cb2_}_EH0d<{#pEQD z7NCaHq$Y5GxtLy)AB1SP62*`%II*cbjC-GU->`K<;dle!$pr zCe6Z)^5lr0E0}Z#-70b)UX@MSjQx0kR#i;;t*S}ykoCPud+-vKtDDptE0JA;{ILq} zvE>Jo%Gcx;D{7mxtd2=1>Y8*N&FYyH)X=03xPz2NCY8f9JVDjQjE&n(Oe*rDNu`>a zRI3^Na1A-lsRus8(ZVEGOOrA%wKezKo8;NSq{sMxzMV|G2sCLV0=k$qq#LzHTz8Y6 z;Z_fF>}68KPbL-U#~9c*fZF_QQoO+TTGgO6}W|QTTL=-Gbuk#WBzWFn(j5J7k=Dl(%u8q z_@GJsume9GV(kvIrr2|oV-`0t^_WQ`PH-HYWXw}0Wu9Tq=UChGChfdPjsIppk}jLH z?H}rOmE+|a#~t!tXPwXpy|Dqm-!SO_I^U%JsC0+=!E%@On1(%ghnn}u8G6XrNJnc- zz*Btp$fRiGd&%)=Fw4tmRuCe+&6O@VK2 zvvTD#>)-rlwJu=Rhfv~$ne`1_BFrirW!7f=kYrYGEGS`?rKDN;(G*8YnN>8!toG;) zW13knP}yyk%9v$C3!Fpqvc$w8oX56uW{oOOt`!)gvYF?YS+A-vc2%?bes5Nf8fMj~ zY1Th=%oll6-L416`w2@}D9c9+u@n$WVKwO+aX^< znpvH29mA%Z^?9aQgJ+pF9;*;P+pNFw0QKhZcrN3i?tHW6qToVeVAmqE42zk^60=sr zXPH@5@D#(Bn^ojjvog^L_px_{Sts!r9ab{lZ)W9LWmc)RW|c*Ayu$2_9BZ41yM_F> znN{LX>JQ^~vvQ77!((O*z$NrL&e+(7h9{^eK4IcXv*ONB$FpW7qQ^PveBP|=iyV`9 zbcyvw)?Ma`7LUmJF~`ai*6bG5f--Kd=wiG5;ks!eLlm)Bit?Io!lo%>G3C zFN|sSQB5BoHN`;q`}(LbR^mL8Ek4R?_fZ%!aR}Z0d^8mAa45h>wp>0ch!Xe#u#Y;x5$vN{@D24*HQWyKQFOSEPGMezkAA}; zRF3qKF^={~z#phn%tuR$`)EB*qJ9YqQ69{z=%Y(jeN?rYkGg&DqrK=@-A4oP9K~zk+Fy zv9K8p8~DiF&`0@ktSNn)`Dl78A1%QiRB!F0@$JaBJ^6MZU-ateql+ln*+;})A`Di(cjq%ZL%p2>YbC@#DM>{9@XxdC_j@|fSmXBJ@@ln6I zK6-`u^L(@x1Lv~_3&>@$j}D;Y7UuOQ`EU2pvK`cKCpqn6t+5d6c5@tDVO{_A;iQX? z0`VT6*QxJKA8ouvo;Y{UM^hhi96j|>9CAHpK4|oTy2JRK z6+~b;U)8MOtI0To^YE|atC3J;Uq!=Q#aF{IuqyLFp=!Q5i`n1%>I|0D^3{60sqL$l zb$qoPPqCq{uiW)~HDNw&7c=iQzM8nvSG)i4RgFEqYJv)TeU-f5SHXvTbsJrd`0B|C z>Uzpon@*GGd0#cY;H&nyi5?f(j}Mo8_2{y%cHZz+ zzN+`iSDjvS{|)neOFZOy=c`MY^`5*j{{yi1uUvm(4ye)ELvX3 zB6DGjl7cL{fS4u_(H{h1aJRwXI@N zP*sa6<0mY^NjU0R6o@|?(7&NYd-1A;Mc>f0rA2)a+Qy>#*nqa}=!fzhEUJanjuuTq zkxmx<+Qp);sMgh@Pu(s0yN5+-JuT{vLGb8hQOf}q^+eD>i{1^k$T-BJK0_@U0k2^e zl|~gL4Yw#AFYyf{e_`BF7X5>`(H6DFN<4vc3}fIJT8*`6D>{$2XvRePz&y#Koj3;n zDHhehTU425(WvRP!;Tq@KhvUxSc?L)nID>C_Z*9c&Sjo(&bO!w2IAlXVlT8PFWifm zBgX&lcCkg}c&7EQSRjuCWtXi@b?9K(+- z`U}OL5D%G8E&BeMMf-5{IcxROqB*ZEdV}mY^g)fc7A<&Z(R1Xy=P~|-^8?2a^pQ10 zJDf!De>`Wf2l+o)ROmC~U_O?7;dzIr_z&SB#)!4nuX=~8biETs}^Bl zf>p&_R_!ce)lrlzYSlC>#(%}FdRW4$cc@*;s+CAdvFajzNVVz~TBoredDE@>hL#yt z{f0TEtvX-Js(Q7px`(lKtm;zND&Klm{fhq@S~akxRb%k6ja7BKTD2LOy{x?Ew(1xv z_O&XzpH-XSF~F)0L#)~|!YaRMR()D%RsO})XNgr6Fa$TTV2xGJ@fn@gTD1o;zgyKG zM-a8ns&?zGx`gH%t?IUgI9sV1df{Kx-e%Rl9n^X!^Vwxp>Tc??hg$Dt|30fG?kDB} ztGxfR>Iya+i&m}0(yLaj|JSO@*Q{EFhu5vTc7wINZB>&y%5RyEJx+9)B|@7HaUzowZ(RP^|Yy^mrWya8#TRcT88&XG}(9^Wm6HeO~dd689p}6 zM3k>hMbQ=uVYk>+58F}HYSR>0Z8oj4+f>-kri=K?VN^N0u;~B>2hzW=P2NE^ zmBBW=!>(YPs)pFq6rDnCx`(P^Hl4;@M2Fi{AHy&?!ltdbjna`e1xJxP7NT3UP3{<* z9^xHt#*$|OF=0xysce!>pHR)o7%rQZCfn4ps7?Q&VlnQQu&G%|+Ly9vPl`=(sWy$l zv^1Oi(`|Z{VUwk_O&8#qX;WPkcM}U;vus+Ak4Vh1=`FUGvFWF>Ha$kZa?AX3UDlS#A$)l=G;b@4qIE+2jSr>eS{RiUIv?;TeO;s=shtZ`r^{r#m zZ)jWBrUmtEN~>?vS_C(+seD75jw85{O}}6r?liV3ps7u}(W@Ezv93Am)550aEy=Gn zbHgs=Zp&DB*}rR1}WV`8~YxmGadN}D?TX4Bu; zyUM1}H8v$7crC{`9KUn?<0-<|*)#-);kTY+2tRJHsnka5yve3xe~{A_a)xOebw}4f zsq1!f*g>s#lKU>3TJ2%|_w&3sO#WDM)TY`eICil1Bx`ZOrVvzw$3^nN4xG9~yT5tv zTxHCE$s1*_**L#uQv_z?46b4I4eE<$D0-7)2B%TwJ~e?JFwR59fyZN;(oy0mV?Co5 z&pAe3*i`JLO#|QX_vJ0e%RBm`^?RFs_+V4NkBo&2|1qCW)a5JB0oirWU{_^NyC#|J zx?;Agg^ykL(aK_19;;o$1MC`?+pY>8NYu3P!+>XqNFS@;*J1?*~xKk*n73fi>? zC*b>?o%aoPeTGjVyVjy}kX;J4Yw!O=+jTs~uG+D7c_!F7Pi|K!mt7gjcI6bY>u>BX zYL~khITj~I3A^&44ceEqYZbQQ4)UcC2aQwhnu|N>b{)vD>uGDdKB0L#yE?YFt4RmD ztR3yDiOD$7$*%p~85?bT+I0wZezMEbn|bzO{JzYqpIw6o*cJ3Ma~ecHe8l*{cEt{* zhQsaZ{fk{cjASgNjIpcOShkI`tH5|W&mX&fh2I3b5^;W_U9~3J^$?3E+x2D&xlgmJ z+jP5@&9JNLOuKHP=PbLf&LQ8qc16y!D`dW1zb_!qMRxVrV3)^c=CR+d9fzs&5xWxb z@*KJTW7p7YcAYHjr`l0|ifZVmqR7|7PvIDXP1uW|p0q)86z=7xI9$MppZqix&3pUl zS9I;;r-2CW>!$<^gR!5V9B}pbQ!8{ww*h`yhn?s=&`G>Px z`oT|QzxZjkheN;OiqXMqWQS~ahYDhhpF`yw4sF1Dc=|h33d_(az@f=_@SQ_%F*4Yp zB`6)@&|D;jIy4&ZF)z%ayx|Vzi*RTx+C@4vHO8T$u?|HhF?Ml>HkM#}Nr$dtS1E_W z(;bSd=ur1c4y9FbsQUK~W&hw%&zcT>sO8Y_wH*qnL#}llD%-%pdvJ#aHlbfrhn_TJ z>=q7%wsh!SD~Fc1cIYuO+c~rc-%zSObHh4ZM|1~=hT%Hibacq0lSA=c9qQe~p{$+` z1^05O%1;ix#_zoy`qIatA_E;7GT5Q>Lmj$_--bIBJA&KM%wdc}ZO1xf80XO4@eb9R z;83%P#F@;zrZ^NZ&7n5PHQk|lGaPcxa;O!$V-*tT(GRci%Y27iiV(Irv4eW- zbZ8<@A#RsLB{3WsyV-Vt_4>=97WfTYaPOc)oeneZ5!UROL&+x`s&>+$hM0Al@y|H) z6m_pUG~$Ls9d0^gy5&$W^tsKp`_%b?LpvYR_mP9o%N@G>m^wYfWh;?PM<|K`v~^v~n3Z8!*XUVk0R=dZ*0{dEB+3i_*Q zVSlv^_E+Z+e?^A+>k;mT`D;hGzy6N!*V0IT{T}VFU*r6>C*EJPll?WXguix{^jAtL z+NJpGpHzPZr2A`d24i7qX~uHo!KruLjP8|Yt2ZcKZXdGsveUAW+=>R<(6rjr^i8Coc zt)>O&*_r^&TN|K*zX#~mX2v)WpbNPAjkd_+kxS!n(<_(0^UkH-rd;|2hdGxFKDqRI zW-gVRl}ior8k(I;Ihce6C^#pVHlgdhTv~?@C_SIYc#Bg@b7}cn+ONx{9^2RkQnOFFv=9aJ zkDlk&%y+r<2VNk?Bai;D^`S&a&&sBw# zvbK;`94@4w?8f?>Kouzys7#E*4S1Ig)X8#z+E5`-;S~e5 z7JVxP>Kc-(1ga_;qDqZG)kkWrKvlp?yl5V%thRyb(FHlDj**{PtQSWEkU=WTXeQ2PH4hvMm@Ia;DHQxUcsP-cR z)f=rx1*!)&;qvG}-N%eEfx0?2PyrJHH3qlv9MdNT>g{BGVh73~Ga7GXvEbE3s=>7hPkfM$U|zK#{e$t}2WdXqRS#0VHbL3~wGC1RUc#eYkd~oP`ylni zWPHG)4ng`Iz8!-!4L9%%)j9>~6udhJX*3pf3DR{;?n)jg+bu}D(4>2iI^qy6V1ADv zJw)AJHBNL27}${b@gd+%^QM7FuI67T_Y9ZVXaqeBBhJ zynh6#6MjMD<{*_pku5>0w3T+~y)8&9aT`VcBqto*9;7Neg47I0F=1Db2J8;f8Eo21 zKKp_+@~9+CfJ))Zr~8)cpZ@mY3|M!lrX zE9&<;NYAnDU63N)2dUu4AkFa(=DM+9{e?htunPGED+bjq!CGH9SoLFqbu}eemds%7 zz~4E+x{JsP!CF}{SeubhHJIzeX^%H`g5^;+SUr$lKUfu!-8fjaJ2FO>V4cOAZovxZ zK^$cF3g)^X;{6n?TzzTZFIeUK2g^8swu6IJcWAIajR@AzCB$D9tjma9O@3>Fbqc?( z4VLHc!SY=ftT|YLiR*)P3x_uZtJ20`O~F4%+!U-@n}e0HHCVlO1grf4#yuIV@n`4@ z@5{kzbthQeVZR&9bpgTp4LJ{j)df#b;$g6sVCl19eZbcjQ28tfRW=qb4CNeGsM;P2LiN*m zY6ts8>WbyCUt-=@L$wTb|0Pd6L#6AXI*Hrxy~)1BF#U}#?l4_|Pq{G8nTBa0c0=Xa zhbq;=)ai#X4aC}-VcOX}OyBnk)5@R1v>9D`hv^Tr?-Qoe=-W3;%di1=5z#M9MKBME z{lk=NK$vFWDyj}7E-qpHpfFYcB}~mGhiS*GFg_0r(^h;$=A1D71@qi6#i9lF&I^TsBb;|#Kogy|@D9u3oDd_bFH#K%EQIUc5W zn06veeka4U05{P06#bELnmjQbPhdV1ref#VkEIxRp7!{Nbr-{Q3jvoH7rpT>e!CK; zJ8)kOQ~WjZc^bxNBVlU#oV;Izsppq49YG_7t3T`>;i`|;ID#sMa5X?FW4O*^m1nr# z!^n>{M3Rg26 z$QQ0I`NK5`FYyh*1;ce5S5f6V^1xDjUnpEZ;ta0ix4>|1LF1rswZ~#~2oBd&EWx_a zaP5RwSh!~60g}RrjR%+-L0sgC3|APY;358q3Rj6}#z&Qya9Lt$i$!RW7_L@H;i}^d z*8o?zN){tliEuSf3D?E6aK1|ru9+Fs0Sil$11@KV^EV+}kKN(&&0-rK;%Iib{w@=) z0%gPHSt(pia2%y7hif_hL+vWe6WyDKYhSN$_56ui_aSD#a8(~d-GG;DBSP*G5$cD(M-ppvgtBHvXb_6bicmI=AaYKG z0_R3($D#-g{UbsW zq40?a4MX1Z5h{bh*n~$Ycp-vw=Mn0QP4K@Iq3f7;HA0tA^jd^`u1DzXg9uq4MyTy0 za(o=2tIJF{ja1CANbMOFssB)COr#RW zMyk=YNX5*!TJ8;j8)KgTP7s=m}NR3<-sc*2Zj#QBikt)5Bwpb6xrbyMma-76R zc>fWp3=G92RNEY>E%^Mu+bxm$Zfm4A9gEbmlabnh*i(^Oi}R-=`L{MwbCGeLabdm? zsr(ls)%;SVx}wVENHxQES0eQY)&GgqIaIqEseuUmH&VS2axGG;aS7e8N2>UZNF9gw zO=8`O)IEH{%-fM%_Yr4>QTChjGQQ0%0%gLg($^TjM7y+LAOd#I#oGJ zORGewNcAYqK(+c&ob!p&y#`U5+%QTzThX_5lq$iyO_Ypnqj+Bsr6nDsl-(&xj?Ph< zhk<>f6#sLSMx(``DCHXxr7oB=G)iyAM(O(RQL3;pN`Io(rYLXt}@2mDDB0GywP0O7_Cw_qqP#Bk$fv!U2zGI z5OX_P#W5WFaRwFdL~9E=-i_9Ce8I5$(c1kWT8kb>>pBviM5{Yip~KT?&BYspKZ{o2 z^Ju+9;TO>w^eS2&ucK84Cy@6|w3^^o9K}a;en+0~qq#mLTCY&#Lp0|Uqjert|BKdS zM111$*J!0GMrYyW5u?F4iH(LB-A0fxMzt{#Cy?JWM)k1>*WvFKBR9HWDK5k89ivj{ zhGn=2n<+*a=!p3^2~Ts3QqdX9Z~@*vF-k{2tin||d}EY}E?A4EmKb%#d(^bWD90Y7 zhk0TYS};a$gJYBw5~H!9F`5w;qZTpT7LQS`5;3ZR-%2vaQp7DCqr90h>h6wFR91}I zmx<9zG%OpV4tRxX<;kT2^RCPsx5VgYByWvT77iogPh#wh(XdM~dUPX374FAyo;OA* z4`Ngieh=CHJVxO!81rR}ioJ@_{r52n`4FRlAIbZ_7;X9%qi3k(5vwAGSS|OC)eWSZ zV`cG))t>>e`hZorVznLa+_9RUCsrNuaz7}R=VYw@4vtlWkXUtrIW(5n!LhOyiB;R8 zv5G7ftNy9PLC3UM4S+E{RzGIMD!z2Ac2WX?WF$ zaT~|-{ykPx@S<%j@7ZJ3WM-^p;oYoQEuI~#(_3RTeP^uBW5ljl%|PJpSoPgQE_-9O z?|7_qB32u*AH7e;s@x;`;@0C>6@L<|b+=Cr(Rn7_XtcaVm)c z7=y2S1(&IQ@%?5pk-6eYg@Cr$?w46{prX8y%;BxH!E+yLiUHI-Ee$ zggC9ic4Q^Ssd-YIuA+!Dj&s{_`T(0NPAMpd3All0_$4_`o3O7)oJtps(=PZFi&GD* z#yQj}9;dk&Rx(a`QsUG;HBNt^Wm=rl(us#k8F9J}d+9iJ$49ixq-L1wj?-y5eU`{LB`aGX}5@sT)nLcycd`y{ugSP%S*NvGq~>LT?= zolC4Co}%LAICZ$f@%4rJ!si<`$0tKPufyZ@1fMa)GhWxd;`v@nyc|C9stOO^c&^ir z*9^R|#OsJPUi|~&wHdi`$LlmY<&W12comG-pD;(pt1LdkCn{bO@FY53|Hj6v%-(qY zjH~Mdq zL7h(~=(|(&`zJxa;PzGOaE&}}Qv>AOO;G8330maR-HC@ay%RO05B;YlYB&;RC#pRP z&q-7w&Z7L>ME!zN^Ac47Mdy>_qC~|lPEk?HMzP0~f&hCMM!W@nP}U=QMwlhmY0lI9mp(htRw zbT%VNgWO3Phmu+JK~#2jp{uCPEV5kxbGrNN$`Y^-EH1G>5%^lBy0M?!Y9C z8Jwg>Lz2`H(L z4(GZgtzMs`*bPZ)zbQ!v_a$lKUrCyW@(0Nec@HJ&5!N41(u5013ca4BLpOQ+lE-h7 zG#BOGCTS*4;rI7Rn&sh?m%*tttTj4S+RLfKxPU?4PTes%^$MP5r`n>nk5kL7PUW{b z6@k-m_&GJi;Z&bIPR+{8epJur)G~zUcj{%NQ|F?b+8IN?Sf@r8b?OTuOF8uc<`k!b zQ=Ll0^mM1%WH{9uvr9X*;(y#ueTGk#Q=9M-h08eA4L>8ctW!UgbMoCir{-5Ab~UF? zRd=fH4^E}ja_V>NK)_NBEJUS_)TI-1>Eh(yHK*ncaPl6UG0|~6HJrd0s6CM!XF2(d*QuH?&2j4Ee5Z~r zaOxk7U+C1kCDePVQ-7oXGN;0Rb?Pm=Ryet~g&M4N%DU01>_ha!TeLdDobc#8wYcQe zSFHTosm7O`I(m)z-gGMWJEz*=CxpIts@Vsp&VO|3`DdqIe5FQM@r^mirCc5^)%9|z zSzec#=5z6V9vA0@Tzr?urF8{dy8fL@sX;DH!hBQ+c4>5oi|=E)xK7l?c^j7&qEeJg zBT*~fr6Nf#W#Tc~I$fIQa;a(&mxh*b>0!D{{Yn$Rj7wK=ACt?v^sbysp5@)EMSEg*Aa*C061y@MzI1bGP7fEqMdMPtUM{W~qbBHt0)3cgUzY;< z6K4={@C7RdyA(5&e#2aPGSa0cqg?8Me50A;7?+leb?MePmmW=U>BK~rf+tZA{DxYS zU0OZGr5jUS3YyM*X0m;@OP}YubatLgE9bj3XaRFw$o}74>bT0K>8o9Ov&JR;?o#`8 zE?rnp+YQ9t=u)*m*tglGUv{{3ZI_Gh7*qFsE`7h>rLG59pTAhMLoR)Hlr=m?%oD8d zDVL(px>V&nwYtC@E-|OSneP>sB5?*e|G3oqs!JdLb?M~|m;Su(lH-9(EifM^a0S^9 zd5qQg{*g=Fa1!Z{UAl<3`0a^H&Zp$|%%!^+=aH;TL$bcdZg_bn^ZkQl{oy%oRTc_PmIH%vC?r|MLz6WrHd%|&FfLgg@Grs=k~J9viX>}1$`?&m zT^xa5@nj9exQt}YN8QrNYJ6$<&)L9LbCef4&LJTisXxlm6G)V*;SHt9QU!O zYO*?3OV*h0lXVYsYa}b+hh#OzCV18)7u-Zntz;$EPSydK>L#mVJ=&m9ed>UK2F$l% zviAR&taDA1wYeF2woKNbw#h2kjyknZ=DIBAk6Im*H5|`Su~V`hVP0oqbxl?}{>GSY z$y$i)?#!WAvOf1sR-b;!n)!3Gx(=d#_#GGV-QZ*;45ilSfrMeyX-2Z1!!R>h&CvxX zQF<2n&n6!H<|ONO6*DeAr=MGLm3@SQE<|B3C)|7eN|9ZS(ETt~~}DcW};Mg2~tXuu=p zgieoB_}n-}o=>RL(-h8cr|7daRmE+onqp7YPQO%@&!4IxxLzQY-{?ry3|FeoAhAfQ zUgJxtR8>z&Rh`nQnuKSWsoLO9)z4*9bq)`zr7Gw9RQ^3rl~0XSwfZ4dX*E-&2B}KH zjE1Rd)F@R?o1`l0$5ah#nksj*RMl;hs>yiXHdU+JrD|vg@M5O@-ImRHgors-8HzIaQ0drYhnw zW8%0WO~J-A{p*#ceBNnVVoK8`OPc(xX_}TlP1A$ZbRHu@(li5sp=s(HmZpl~Y1$Q= zrVeG&^cxzLP2*akG`+_6<iP-t9C^zLTbmr)lbsq-SX=jlU53B271t_gk83f?tbJKFq^^9_dPgizax(1_Ye7bUQ6j6!k zx`z(w>G}xLI7!QUT=}N<_AJSE|CUI&J2aReI z2e0vcUGl1zE^~);orZ76bhYl3u0oyDBG`>9wUaQYX-7^ zN!R76w40GGk2!2xkgnZ}()9)F7N=_u$}UOg`l57ITb8bstJ8HKv)7OloNLoH?)P++ zT9>ZF+tTIzXS%lG2&!#Q*XkYVYPvIBCk~~n(qU@+k@-bss1@c%XXq?Fn?NPLNyAg5CUf zl$-MtZmq$sXt(yqy0tRVt(f9&B~)^&JqlNLGrn6-u)3yOS+(4nkCFA=I*2|E+!}?_ z4c#ixg4pnF=~hA9#D)%Td3SWnvlD&s7G9kh2SHujY6M4Dw}Np1Dc#)sd+S!qzHV*9 z>V9rsL%R7q!!6ekw=!^Z1bs)kbr!dRnntLqUr?;G4|cGRtIn0CyqA~)O`fdRMN z+Kx`Q-5Q84cihT(?$!_#d*N0Y7+x}$w{9K7#7}OW#Nf|vO+v9RZmmMvSGUR;va||U zj9FYOpQYZOSvrV^sOFW$?+avU5!T`hQoXZO0qc=z%F+Tj%~@)Q?wEy(1+#Q6kamT$ z)EU;GECr#;{{(00DRxI@=`OyH%F?^&EOm&<(qx=Kx!5e7$7>XJvK`-W(?y&jS^UOU zmIh*NNyb6ZQdx>m%~B1VFHK&V#KQs{!$EhJo}))rmi|U;c9!a5Zw_*@ zV+{(Q%F=IVvUD09&t_>5HvG>yaz0Pof0-k`!f`E2DgSewHNmMHS$c~?H?x$1?{N*q zZgC64ZQ|U`(q+6v&b=&6z>9}j3V6(%u;fXW5}#&iGj3qrOSZqtQdKm4!&)QP+bj+F zkfjyy{m8s=;=e4}KjCwh&f@d`e96+>uUV@8ElWS)GK|WW(IZ<+5M#{NUwDpxe6zLJ zmaTIb8BUvsY<0yHoWdK-kId%$JolrrRWF+TSc<*)hCH#^O2y9@iwSYrDjuJ$ZEz-J zs|s2sW@`*`CuJ)N)&Iwtt(VxCoUMsPvb7m!i)QO;@ofEDB3l6^vt>%nRtVa_kWPPO z{7*)1h2wb%<9tTe})$>kbls%vMd@ z$J*xE`Wu;TvNgF=wzlF}w`{$FZ})74A_XV#9{=^uR&XEYfbrObj{}J@BwJtM9?f_t zKR%n^HpteTh1ptx_sIW8wkjXURyRC2o-O+cayd&bIFIKja1Q6GAsiQ}Cl+H9uKmxY zYz_Q7TNf{9>odw+%T{{~!KT~Ux`HS7so{fcb$XhusrcbVwg%wGx7qpysUKJugnl7U ze5V|hL7X{9)zR9Lqc7j(D6CM9+6CokDyqiks0Y%M*pKVUIr1rzqsGN@G!j!wcG(P|7yAmD5nQnXlcx8l4w3&je>WzqM`d)`0id`@;|a-aL$C&>bt z%9n1HsODC-nr_v^qk3)?s_)kK9=EQW zZgup!<&Ji%E2gw`>!YAs@gcX0M%-G|+AaS#Zl!JORz)o7>{jtEZmsU>R)g+tu2**J z;16y+M7ut2^~Jmo`nuJypIfK;yVYcXTR-C*N)F^TP9qsB2f6haf5j1Jh+Ah-VYplA zM!I!vJb5Kj8*Il3T*0}yZk3wv*3w0^!yk*?irz-wxQs2^8ShTF3h(7TwBF}d(n+`W zAm1ss>YZ_`4eniVE7wK0%HZ53UgL{v)Ee>0#6`~Q)bh4l^&e4J9C+;31GIYL)>vG6 z=2n{Le2xY$+}z8`dnl5^w!yYkhBD_cR2l9(hC1O|enT(tX#o^8v;(CI8JbWnxn`QQhG`PvMv!+^eqUiUNf{Q!geAPm(UXebKDQF@S} z!8n4BafXiK1u_jbwD(6t=a6r>p-LEu3#dNAQ1_9BR^a|9L#@Ub8j8*6{}an`hF)R) z1VcR%4DG=^6q{_Q19o8C6hja2^)z1NGSW>qR0KZE!FF6liy4Og^NYdx8fuE8SU%g( z$4Q3v&7nSX4d$KUvw5sL-%!29e2!0+7fesIpv zMKnB5Tok=XTeP{%`bhfVilMKr@;(x;GbZG^!FE7}zsdh5{ogW_{Wi75zc_!#P|3T7 zzPoQI1??XgTxV@?o{KR(GMMke&|TDcYN#ptJR?^WdrnShg$c;E89)+a9RqDTXe3c5VZ+3Zmg zjv%+`VNM2*RyOfy3pV&Xs^ECk3G1=I?@>6~qmKd}mBn%#z-@dT<54dhLAhA^LI)hi z9b{}uTzuNhqxuNpB2qA`g-4swxFu~c9&2%?6+edV5Gc(e~+_3>!T2#*ep z_Gr|258u;zG<&*7lec@cZ72Ef@@UaPkEWg`$1}t{=TV7^)clf1*{(8vj7nyk;pk0| z;xe1spUu?P5~hlOZtAznref-ws`8b|Ic-y(|CqXsSq)6ZHZoP%Wy;&!RHGKA%Cs|e zr@N`=nBT)xzMiJSy-j`ggQ*w&O{E=R>K>edrcwr(Y8z*&*$`7VhnjkV{6Cr+iwpRC zxT)`vj8-E|Z9~qHrdnV=o}Ti|&bxGl@0}SZ6W0;j1O4QY|(07READ z-z+!P4Hs9MI=sr%lJ%zgZ7?+w)wY=W8@_EO*PENlu-#Pkou*t^hD^H{Gism`wWPfR@D-K~(3Nc<0ACcGOjJj_a7Y^Xpx8(SaeGSFmn;L}m z7%5AIQ&}2<+o>(>O=Iz0kEN0*kj~OL{E^;L?+lh!<6uThH8WY7i)@)K{eY{8{m9aO ze38Xc60&5qGypf?%VudIeAzAL%CWd^z|yi@mLeZp>YUrsuh^5JZ0UO(#i}NjD*MRYvD6~U z(i1d}wiFClItN#b#s3{G<%+fB$0ICmW~p{_i}MWh+k%)aY17J5g`lOZAxndB4+kT} zLxI+eAJJcvGrs%AQi(Q}o?=g1i}PNV9CX2Wtink=M$Yz@zC<&O#a@)^z;?uOl>gRJ zA}W4oX)C&Sqz=g0iJXw8GyUP$?=9I~EX}}noat(*Xg9VE&LC9}OHD8XReM@0(#z61 zr0#7gAG|n=Msb$nF?_J4YsmE@xuWU_YCgu&3oIPVcKL}q;SS1;v(ydeF?2lZVATZb zG||#LT!MaPiM!Z1$fikOZ!lB8ryF=wVJ{HI*aioTFhTTT~I8E zeR__igt?Zo&$Cn?jWOd_UN2=o#>r*mx`J(ogDWld_>KK>730CE-z}ZOx2r9kMz1w& zpLNu2J;%o%)PJL;{F^L|-on_n(kHt8X))IUIpY*=A$l8m>>~Hwmiq0nG!ldMS}MDr z;|q%pu)Pk_4=x|Fl>V@#pOE&5rMP3{k4+~ze(}+1w)0u?Ja4Jm1xpt%TKfDl`yJk4 z!xfI1tL)FojQ=|O6cTS(I`Oxqy0>Pojha6C#Rj}XZQINIonEcM zJ(O{%84__GA4hrRU>x=$mEWs6=z+z!gj~^HxiApxa3943UNysb?8H-)k0CZ@;{-Cq zdQ}fSumD$3sHs;?F#&s!g38UP1(I+QS(|%hVi-2!2`aYma;=tE%WwyuwWMB{h~0RO z%B{Ry%SBCb1I2@0g)j{#kR{|*BlN`z+(fZ3agczc$Q_|h?Yy$Oc~xXAuXFj-zNJqK z(5#h@_&(i-H^jq`!am(@?^DSRKK&2wpzF6j9sbV8ca%PD>*`a-o<7YT;L{bv5AEnPwlXGqEBgm_Gtt5!8ggLrSU!uPVlMcOrL&7+gU#K z!YedOWSu0RLK}UW344=IVcbB2Ek2dn>eIjbeJX!|9Pj|W5BhZCkWV8I`}FdtPt}i+ zJ5n(CFP| z@{FI;+G>uE(%CA6xpp# zHKhyf(YlYVwHVva*5Upv2im%f$8okQ54Lq3Ptb3OtusSy4I5@_QoOBW7?xlw9{DGe z{}fxFPNnZPwq9YyT3cJuXq~M&>uojJVC%P&w(eujDO;;h{j{xwGq%1uYb$HAt;TqV zY}ai~#-kgy7X58=&#|qQ`1+2m?kIBC)~(03etBwZ_;XwKOWsRioUds2+SaT$Hgkg7 zI`ZD;S{z5SQ#)Fc#?iR6j=H9E6v*hPR#r!)vN>9r-O!?dP}R{t)f^qK?r3)nN1JOBvzDVmbsXKnj=IEZ;OIY%9Nl#} zdS^IV>~VC~bTrp;bOrHVNApm+v7-@99OiCzR0M;OZ;+!{WQ=o^ABlK9*iqaNM+ta_ zxig7__*uk3>Dk0dq)ifW&>IIg^Lh*U;Sl^=8RwsjaT{&+Il793{frA`4mcWl(2?tq zqnuY9IY@ogQ7%l!vupI3OdW1HN_X4g+G|JqVc&7I?5?9`|1jywW9)WSf+~7GK5n{sSBRMpEgQwkt17_3T2N{Q|v&# z98qeBOgW?U5Vi6~@l1s%C85`jC`~#Vr3a^?v`BuHPvuuFgs?A-Ur%s2tzUW5`4yMZ zuhDt@x`l@M{EE)+*CgCRu>yWIFX-1pY(kq}D2>%dJRKI{)4h*P2UJeRq zcU(ZR;{tjzF`$c60xCTI!52DiBXLWF}?I9>yr@QH;7}idDYcv8svn=#nQ^i;yQ@tio80%=u&02c3(?>igoc@|B3yppvl~ z>W@|L9YLNR6|H^ly%ka^?(itn%6CA)R%H^otQv zyf38FeM9kdELI5|TnHJ13;;c!IZcL#n!f__%_&g&}2K z%4^(S6H?u^Az8SI*Xu&6xIUy|n1~C=yCEbS^N?|4NO|Dh64D|x-yYIad~z(Lqquu1 z#CLfixte*_i-gq(QJ96Z$Wb(`B8U_Z>vXBGs+10EX}PeXD}=dU zHOwZ*E>q<211j4G`lD1GJtT7ngFRXLe(?85Sh+(bAUJM)2i1z|N^9@b=dR)p0IpRWun{o1g;{3Fa9 z>eOq0Se>yDJ?^nyp@?dJ8qtY55tXeQ;otcY1=~i{p~kZ!kHPaIdX0_qBg(%pq6=ufD5Caj zBIb|Cj#@ DrS#qu literal 0 HcmV?d00001 diff --git a/Covance_UCO3001/browser_profile_4/Default/Code Cache/js/317926e65137bc45_0 b/Covance_UCO3001/browser_profile_4/Default/Code Cache/js/317926e65137bc45_0 new file mode 100644 index 0000000000000000000000000000000000000000..da5dc018dfa3f1e6b98bb85f687afd89bda3dd77 GIT binary patch literal 36892 zcmWjL1$a|eAII@uleDp>O&bbD(zI!tHceaH-5th;>u`4&&T#kP?#>u6++o9Q*pT7w zHhl1YU!LdlG`;uSbN+Hd+w`V68g^Tewd3b6!IDZ~O=9=+d{CKOWeS$fS1MoGym@lx z%$ciXj)Hj$l*^efSGipI%a+Yws$AZZc?#qxP_9(2e7SO!E?7EmxpH}P<<5~WN2$`K z%a+YqI**Y#PGtz4_5Zp4|IfKLHR%5z2V)tUm6I;uUU{iN1!)pgQF7og3RjXEBDt~@ zQ$@;&{kV=5Ri&lXq=V>Fooi}IpE0bq^bfMtl{({ocPUp7=>xV;kTNfle5j6|*nq2e zh+2z@4QJ42kJR_FX=^*t(-!ef8DHo(@^s5-829<-< zAG5v-()-pyGPeoR4jhK3ZIDt?3(b(wE=YgkJWjO_QhJ9V6+@BkLF&^dNFz|bUyz>l z57NK^K^li4gP3c0kbW6Oe25qwq~Iw*a!n1=3#^^RT-Srt`*x5XJPp#n==dy1>rwA{ zkfyx|($<$jI)oChf>iZ$kUpCXY94IR*+_#nyA0Zo#~BPd6lGAhXoEIlcV>g?XEErH ztOf<#2KB;uk3p?t4cc4EpubSIv_Xf<8uX}wL6)ipHK}G$2jr@0P;u;oqn1H!u?RhC zGY5J!FzA=&26b;?(7#;_@^>|83}&E0H-iS@Lw6qcFepn;gOc#2mqAT?b8R1k=3qBs z`Vt!~0}N`6-|>1N>kcv~@6QHx9c<8c>=kK*p+j{DYPQS7yvTZQvG_IlXW`j)o z4LXKA2N)02pNu(S(DO6IeZ?T_RfBS(F@|9Q)?&&(2F<)-P>Y-N9ffZZ&uxRE?iq9( z`yLq7@GHxVN?f9#711e&M2cU!kf{k>nN7VsA-rVZB+HlMmZ)fn@z6GO8Z zHQH^|z!;-$qLIg_GqA=Pb=qsxNmtxF=`~zs~YA1&Zw%WkM=c)6&1c` z9FF{8RM%QYMbtKGA&%f8YS%GpR$Zf(<1UueGwMTqqjoei>M`D9YID|ZL5{7BYSzZ6 z32lu!fH!#1-Y9biqXr?YlTnGNfD35b#i+wwjmp-O9^y(bqn`a_)R^A%qYu6BXH>rd zMtwKPsDB2t-VpZ6FuuwRH>x)}k2I>yXrms&JI1I(6OGC8Ce_2eFq3|A znluI*P%y%z%#kLgB2yMVVmtoGX3|!VNx8fx?Z++Dk2mQEnj~-@fkcy@p-r+$UcX6s zQ%u^1J~>RQu>#Lbmx4KC?u;qJ`3e_`dYy*>OHZkc?Qx2IFo$inSX*w6{ech4-=-Fw0H(}n?+sl z4moF=G#5wVnq$(Yxh6GR$hv5^$fWt0y4a-rOHAsHJ@|?`%S_sfkmV*BR}#-!*2m6` zCVj#2P2{2>lkQ;YL6bWCL5!#9`x%bGdzQG*n^fR$lajBQ)awShKQk%v zGyPJqI%BLMSoe*=8WtR^YshI2)@kGk4OU24uv{pWDOiJ|gS9VnutsJJR=7J@tI;VY zSX*!$Sv_+eYa*(q2J1%lU_HZyoWU~X3D)Am zC>^ZQ)q?f1Rn;ipVI53HwI1{tbF?Ggzzc1*^%6VCDZWSmP9;G3F5c>I%^=1Z4S7zaVjN5S8*f|q8Err4N*~4 z$2tV1h3Gh*pkjK6-eGX|5dDU=IYM+3f94KR)4U=2gg^6z=zRg!C>Wypg+i2AI7H`) zgs4HW5RJnDR4*Q)Ww4b9QA3=-UEC~5{FOtr6339KN{Hs-A4F9RQ5&qm6XdSOoHat! z1%Kdb?GSyzum;qyS%_Y?V!hTO8ag;ce_`)P>M=S*?ND(HwSaRh@#50N5cQiBqG!`X z^kEJ;&JEG{c_GTV7|WP@MTqjR3{m>35XG(zk#S9kru-VBPMbp1bu)SY9-`9QLKM7< z@%xGAEaxt8?plb}qtSJG@`(O?2+^WYvlcqc8j!`TY1oCwn32t_1Lh5 zKbVr;tOfW!hgnVF%xRVzCvX{ubD32=w^_gDHS6DeX2s_xUc4`1)^{b%3M*yS3fx47 z(q{dDb0}2Cti5H)2jj|{H48T@5HAK*H0v(9RpK$0RyHfRidkE55D(F+s#&Y6ne`5( zzBB6;s?;!R6-s|kE?9&2*!qK66>9PkD{Gsztd3cphGuoZT@-3$R(VXrQ&elrI=Ius ztlU4ERj{d9wVIjL4A)VnIrYF7I9r&Nv!z+Z5Z2nPUy!rCS*8wVJ;4X`?PTVMSF=VT zvWr0Wgx|{VJw|fv@R)MJoYX+N7)W3X9`v2h6359Kk|!8OdR zeIv{=jx;OdD6_JUF{?d#;{%S5r5@wx$0V~lO=izbrT)|S94qh=t{G;<;v_E2Hml|w z;+kvb|2Ou^JhL`0Fe`kaS@V{fm9(5X!m-k<%4^Jgt)l*0sN+_%CSoOSWBfL=4BO3$ z#u?1tYgW_!X7$342h7@kh?@UtRzK{*PlxH<5&DUJ$JoEPg`osU0hu0{KB67NyJp+)QQ4Rab^-UBPZrh29gOU4k+Y9QHTzn04O#kAS3DlTH3Kc$Fvy~OKU>shutm@D z1*?ZxRC1_A$8ZU6(Q_Cv4Yw#K7UMNqjj(76j^n41tc4GlHp-&5qb=%%urbsWOV zR*gr&Y^;T(7^^zK8EaK7*t}L%$DMeqk`t^tjd_Vyt;S(g@mXaIFdk|69d+_rwKShq zzu^?>=eH`P05M}UP8GH)LlLXuPz=XVwS-meP^PR^<1hg)$<^+9kOaAD*Zw1@E@k$$a;ht z;UdD0Qp02P`Z)DI!M?r1KK#eZi|tmq@gAld?1x)cZMsda2){=@_vz&WtN#AKhgSXa zh#EeoZclkWJhLhQ*9+=}S+A`+^M>cczwGn(>{En)u&NQ-!T8atQJ;zJ3;XyhV}fjI zZm_8<_8VwIE0c8n^MAU@;GfuMR(jr{|K8lWwdE)CdT0rnnl~x z87ojBtBu#OZCaJhrnoqp)_QH)jvDbcSrToELMucjF*kbQ_hg$6prGHTIVm=+L|iH{ z;%k~s_0w%?4Mz@}*5HSnHeUC$X*|+$+q5h%x#Y7cIloPZ@enf$+ElHOjh}mMDqF;+ zDMf8sRLrK)#cg_twVRGQdOs*Fv?P`a#5wed5i;vg=Nfp_+27f87E5Z`^c&vRwy9+uo0j7lO4hS!;(W#}riQ4s zgdQ!mDf@Dp@~^Pz$Cc!<%BH@nZK|?{+OM-|(k7ecVejws4&Ard^aUZ?iEW2XU3S~# z-DlJHXo8CSZOV1frr5(a-N8%LK0+OjG8O~iKE^tzblj#sCv19p(x#87e~S8^wrTSj zYH{AC#usdAk6Y+*k#YEN$)?AbZQ6a)Cf`Hif$I@<#5R0FsmC@=#uW^EYE!+}Hg$T# zR+RKH2o&XZrHRro5T$s+`5H*sOLf&t{h;#;)uh zyDs3Tc)MZ}?fU4m>u8Eyj#Rs{pg<|Ry5celm$s_{2354HZB@HG)$FQ*pRfd{;H+nt z8#@|sT|>L}<8=$WzM*MLyZXZ0#;*Fyx4i!4sRSShX+BF%uJK43Oi(Ow)y{lcH zyW91554(!=w5vOQMo=%iS`M(QCp-h~dNnZ|c>}riwc#0fjSp&z>YMfo$(0PJgGbV8jER*fpjpK-zYS;Jp7geX(HF`SZ zuxkeE&$MeH)+6(5@aKN zwrepqV8|Y7g?4+ncAs6j_S==|0ChQJS22wHgSd}U!(-%poV|*+Cz$Ibai6m5I;Nbq ztMM7THl3xnsP-2*pR+6OJbMUbF3@-Ue9^A7OVko`|K|K3#Dxne z{~zbD996zj58N|2_nbWho&Ob;n12ehhoAVx`;oV4y8mmG#AcDhYn$|o9km73h_8p z7TfU-dtx1`7Uxh?bn-fMAJyU=I)i&iPH?C`hG9ygL)&l%#eELNCJ{RpqFb^D?Fy->Wz@5g!pUmN;<` z8b=>74VRF4Jm+u(NfU?>w@_pvaUshjhrXc9WQS&B1u{>eemF9ny3BB>0ZcO;+62Qa zhYHVTk0a-N=0=SL4o$~R5Om$Z4@dKQ3{o@lxVh#-3R2kZUDtu5zfuYKQ*D z{xuGH*Ey6OvFq96aQ@2v$1@~saA*jQApAG>5Psa~P{B>qd9y>ueLx>W;2E zsOwH**hQ^(6Z;;ATJ59%2YFr`A$}}5=1}dE>>aE>MK3Nm6o*O(x=1|Oh0~W9_cza- zYpnSXaiiRI2d~XKl!)0li|bf>lltO0^4wz2;0&rhpeE2m)_KG_2zugBQRIKdTFuF!hQK(=7ah!kNR=5T7zx4i%f->2aOAdX)f*-4b!1wVS3g&OrO!bU6?wy z4^xv4VG8XSrka?7L!H8Ousds`ZO0w$nBTUt1hUpf1&I;4DImA0ROul(xikly%Ul$PPqA>N?7^a{tJ9HB3XVhv`&IxN0YbE2&|)@*q=>a3x>}He)|LJsE@Mi0Kus04`wU zPvQCn&3lJy1-kYL*FePf4Obe5!PqZcPUP$#u2$%dZUe%#0lU$8V7U6D_8{hgaWLc2 z35|z^YvPD-y+gf`;d(hLT&bhORS>hrhU?b};aW41<5R+QYHGNaOb=J<8R7bKX1G?( z4%ZeGnG>$3^TL&Fez^Q-g+CCnkhPYEs|w7^!j*kxxSC-b_N@xnNtoBL_PTH#S|6@1 z8^d)2zikcI`fZ%w8Lqo~!c~4>xDFo-*WZW2weF8_Jvbh&AJ2yC-bHG0HC%OXg)9HV zaMgMqt`~2~^+UME{THs;K~Al}6{C~yk)3jcIh6%t!<{PcbZR5s!xZ7cUPGw4TY8=}6ochJ@RGt*4eA!t$pHrLi zbG(34*RZFcQwc?#3RH5cdu6AJRCTJxcTSc5!Kt1#o%&GAsb6b56<3E?>pE4gfs>!X zof_DL>zX?Cv>9u+aLU`#sdufMTHe~JCn(X*seSl{g6+u-8*l^39h@458+hB%si00y zrFM0ycMqpZ^>iw>ms3@La_S9!?d{ZmeVocY(5WGVojO0%sase*+^Lk2d>lg#W1VU{ z&MCuqr|wN~s@6oOnoVM!DdaWPsmN(gwSjB8Q}t#zm1CAut&Ca2Ji$EFIfA1gc5&<&@Al7i#ib+T|Yv(evD9!fe{)rHbUP|kI?c5 zTpJsyU2&1B<&V^i9FbazAvq(JCwHXs=ZRFA>XE8}jWr_msb-|=)#4*M*NIe*dXZ{W zKT=s6M9SGTQa74KYJc-cJ!~1NRjneG+=j7jBbBXvr2IIGP8}k37cm_pH6F9kzDFc` zI#Q2*j@0E*%riMst)@ll`MOBWTOX-Ee~r`&xHm=W>E=lNvL#Zlv1)6iYHo|vCWLQ~ z)DPH0H^&l}HB0pR}_CF)l4O0#?H)59 z5veyPne$Yn4xW$Hp^LomE_WEY)f`2+V4^qTu*VSaKNPkX)X=GpNLF%sUfyzXPq1_ z<;>~QE7Zv4(tO-NYHsGl1r*Nf(o)fFF9ppS#9CE4opX@=5KI&4gV=guO?9xJH$&^9m&>OjI2M)C7U6t8tgsrQ~JjXV^kjd+iq z7orq#ElN)wMJe;+C^dZ&rKQ-8!^rU>N}Wq))a3pdRbyC2l^K&!vnFNKAy_A8R;y0Y`mQtQQN2sFK6H)N?rzbl)ID0omq+uua5P`9qE$ar zW}QgR%=0g^9_8b4{>*AoAhY@u%B*rFGplLo%z9Tgvxb+?tXcIk%hNZrvc1Zz>Laq~ z!PzXj_*WK1^vovHnrtexKATn^$)=q+jjuDMpWwCHO#eMBFdTTesX%9qtGgWJu$ zA#Qz-UkkdGtB_meu@@(>rm$Ppinw(Kb&I-n0Nska^&T}#Fh?mj?-gQMlF#gE=I2S7`4T2q$R}2pBy81 zju>^qMdYd&qY0Q;DMojYqjHRvRf$pNsxdlUEk=jFi_srH#K=%HM)_)SympNG)Q!>R zCNV14G)9*Z(JV$!P^fu~l3K**YwH+oZ6Bir9b?qEQ;Z6Bj?tJdF^cOJqgLHxbh1Z` z9KDza&3ebELZ29Y!oGeny52uVPw{17j7ATNk>%$YnTEy4J~BqxN5$|vxEKwY9HW;A zpAw^Nb7PbTEinKGka1p&QWvon4lX9Ar7`>-EJh=67@rZkGDff0#puK_^7|`>d+lPh z0!6Pd{yH(=h|xUceHo*No zE?|BSj~=0JFKY3VN0+g(w?~dX9%aR?z8#HdbOcv0?vh8dQ1&u8Ut#a!H_X0CZg;8WefG-(kJ=#cnB1Q5yueuOMcJnw z?qBn0^ee`^rp9kPdV%fl*w61h%JPxtK}an3`N!%HxGk~DW{s5}HSDqaEhbj={js`M zC|33ovD$^d%f#v)d=+E0s#2`BAgx*~@2zD#-qwj#P~BMdK+*cKs)W*wV^zB&Yjla# zUwGRsR*^lJ2c>((a&I#8{S+%#U&i-~RfYbsG7ezu;8@ii8mrGEV>NUM^RJ23Wu&Yn zzICxWjTP%-W%@N%whghGgO!-{TdZ#5$i`Sz-W02;xQg`6v8uHtR>ii(s`su~wLiqV zr(!kXEY~9Ba;#e2ja7Gq-HYX3z*wzDnTN6Jf~Uy;C{|0b0s9}vs`%4bZN`UZvC8|L zI^YAoz9fg&v3i7#?_;$Wf1&0FYWyWuKYoo>CtUg#tGSBPVnduZAh#(_f8bVVoZ`ac z)HO0r_u==%sXCW6eyc#;dt2QIN{9MR& zBfT0jiW;H(Xs>FbKSqr4Drme{l_%3bl$b(&VO`)=X)Ihw{ENI=3-@BL7A^5==PIw} ztoEw?8fv|cHP(9-@hg4$&8sC_$#1_`ZI65T{k2yOPf!E=gUNw40E%Bq` z^>a|X?1p%aL>*(iW|`uZ%N);b`0@H;<9KMizH`Lu6^6RvRX06ef1^vucwKoqmYdK&-DBuU+U=J6`5G@j8So^%&PEp7(#m z>qhfvpLy??x11L8FU*HCRBvEUMZ`#D}UM#QVx6yll{&plA_+J=uPF(+Psz%n;pDQJQH z^Wqh;AYL)ZxR5wk#H;+OcwNMi4e>Jk7Oy57<5g=Db7I8*ZHZU%)_5)09bTSAv?slQBUpa41uPxGRy>MHP*zWZ8lycHqhM@;e!&uK@Fr+Cg5wi3 z8`%?>9}n?MB6B0km!Nn|#UuQll%V{{#DJ>)1ldymtfaX8nGPSEu632Hep zK^3O6&Md~PNzgKkTt`fM6IARf>pdrz_(Xkal&HFm6V(czai~e6+WwfR*Dy6rR1W-z z4Tx!$sCn3q@aBo?fcJ=Lk*M0ZjeIQ=^`vW}61yd8NOz9+NL0y@iRy>HM={r!M0LbG zTtKOriTWA2XC0!5QSP~kyoW1MlW=ujqRP)t)F>Rpu0@GDhMyKEDspL}3NKGo zH<(r=^4^a`ty-C=7Z|XbaagoAQAxihYUuBY+Knt*6P0OOq7qO6CwGwF&O}Y!m8hq? z6P0%lv7^|&L~TQn{fU}}A%_yR58eM@E+qX)9(aYGM~EF)k0tUwccRAQ0uoLnYBFL@ zCTbWmo=;R+48~?WMwSbS+-s1izSxY2ONqLHr%3oaQFkvVYT=bcHMq)p*AjIJd9EkQ zdLvPPJxo;SBYO6jnmtKW3Ywz$(?s<^^fPjJo~U8IYKDCJTX>y!To4r1H z;(fZ5X>G!5S{npIK&#^weLbY~2 zCA9bP{zIR(4EE_Ist)zZKa6Y98XrdZ^utJ>_Ko)G6Y7lhDSezzg|P+2$NTgK<0km@ z1)V4Qlx4C{m8bZ$2aTrrGzZnD`_veBQF5kF&roTekFPyGeikH0gs$}|_eSR2#8~_W z=VqV2$8wy)M}++DQ!xz1WEi*jR2^IK1=g)RM%HcA>9|kJPWiMEDW`o}kMn1Id_V2e zTogOc`mkK^Df*&M%`f@X6={F_v;tKx`_v4RkoAgBk5S_)y+QSB^abvJeCma`>prc; zC3L?*4R88%0wK4U_cp!7XUx1qOgIVmU1EOV<9!o8HF@mQ!>2yoct%~GQ=?Ztb$jRI zo^qf5M&3_c56fqt3ZM@rC`m_Y0qiB8hLS(0SPnxw8s z%a)|RF-h8n_MRm5Lr`pz8pkDRmN!W&@GnmLlC&>5N%#CovK38I87wNsxZ+%g=~z)J zNw-j}Op@$nlN61ga1l=`CdpqZN!Rcc-6}I@l_V{#nxu_zRZG&C>cm?kNi(n%S867y zdi^ARZ<(a~4U#maVUiZ$Ew(mFQlBPC+TDt^S|_P8jBS&6{Uu3DIwq-frzAN$CutrA z_DNFeAm&GlpOchnNRql>&QRtWm!uoNCaL14B<(=0%}M%tEQxzNlk@`Lu;fINemIk) z?PzeGx}eI1BsGLCCaD*)T_HatU1N=VN!pK-8IyUhRk8}+O4cfTL9W}$>WWKv4F8>E z<->3s#936jo6Pqi$?AA7SugM(hCN8u-iOIr^dwm~koGiL-LVE8o+WE8-Xh_7vfM9{ z^$IaBllAlKWCguRR#}`x#<$68f)zN1kLdi4INv98zjLx)Blm}7en+0H^QiVISyPbs zna{r_tFZj~3&BBt-jn0kDQq(Mbq5}!U$rp`ClPJ(t3DRt1|ov}Dv2&wip#Ks_*D?y zunZUBF#A;u9WfuLV6ymC7@e^U7Z76gt0?+m4X(jy^Q#29U_F}J{pyPMsOj*lOqgHa zu z0sUU+SMp-NO0Dth$yz_(AF&tEZ@ph(8~o}6$8UbM!SaoM`8NAC56<5?hmu=a54pB6 z2aX_d2esMl*RV@|J-+Ez#RtrbLJ$3_gz!gxxl#MEU!So034MCTUU<%aeZe(Icu5al z`IYxI^WroNZ~S`j-mkb1e!kCV|9tYR26|%iH@}{va!`tL8&XsP!?8RhMK@8@k|Mh` zMbWqvo}#7B6zzyi(Fd$?rD!KgW=PTes1$x@pQ649%9Ns~h>cEBZHz*nEGhi$2Cm7P zqI%hw2PHiz{9m1-zhhI>ATC8+VDY9X3e~U_=TIUsMU{LhyvCBE(A+6%n=gZqggGgiiQku}sOQQQ zo!OSceflYyzB@(dF>+6eX289dTJ0l`{V6(dB1JlxqD?r6-ltMD0vXN_6HejJv((@m zv0Y8ky&D|6nW71|QuOFfiYnhD*9Y_sgCC}-{A1$5uekjrMfsklXv6aq#k@#S0CAsF z6!C@6k@Z`OI>Q?j(2sB#0*Z&n7*Luspl%qBzmX6TP%iw2p^*VyLBJJI7i_~NRL&64 zB$SH^XbFzs4U{pU0vLd?_=?Jz0{Vu^(E-)Nn9KqFgGz}3)xiN=@dfl4^^yW=jlYru zs+AH@WFVl|XqU=5*npF0nikMH>_n;bfK1r~YL08jog=_~K>>Y$BWFN`P#zO;6VEXs zS3sL_Aa_8S^8{2Jdtl8QP!FudIn>D)&|C~F5KvU1fZ7)h=y$X%5>Sz%%!$gy0=j{) z;sJHXN3<+K{V=y=K>w8rs90&@EF0kezknK64CopDtxV0T1XQLzb;nCIZ4l5|+(Dj( z0aZb>M${bk#^lo^pcPF63ThURt$jdGQLjTlrMm<)7V%(8l|$`H;Q#D4+?C16uSVpjmHN?=5@zKl%sj zH+qWW7_L-J2ujswLn^Onr0OZYV2CMIH-c07+ZCx=gFNO`zILa|X-!o%1ldw~k9?|T z;H^DXM?+K9KQdKY;L4DyGx!H>Go`9ibgEV&I7_N_;4t3emxNSVe5opjkFX}CY9gK{ zb8Skho*=0p;|itf5(XDe)f-sLF&~DNPgS5os^(TsRf#I8+Vg#?e6><}&v~jc*Gbi_ z`l*`JklcPuRj&4_S^!&zRORnT4xLjqrAsRJccf}XuT+_TO4T_0(T6XuRcUmp9*s@a*a@lp?mtz3PfAsb>8Z-LAXU8= zrSf$$Rb}_5Y7nj+VD5vd+KLDG<4CHEN2weBM3rNyT6H{C`%a|l6#OSsbr1K?bKQkh z#a&G0HCX0HjvK^`qd0RjRo`yW!`rEvekWDm-%aIxN1R98gH$!ZwujWcRnj!9D)CiIQ*}&enx+#N)GSRC5!F0R-CCq+N6R$s!%ovW z*aoI)FHXQbC`~JHWmK9nj80S6F==v-O;ZX6&q>oxM9)jp1>8o~`DyxPQJOL>PScR( z9LI!}Y5HeXnpUk&(;bvpOC9hLdDf+AA$D#}fO;NI)7ax_I*R@$s3js#rm6EO;yj%uKZd|_ zE=^sK>k{)`P16Y6xkm4i&@Ys^m!{(P8H1J2)3oKkG`&RCZ{!00l9eKY($xWJ zrgU|VNY^_27@4jv$lyxX7(Bq4jOhx?l&<|ai=NTxdV)!r)AcbnU0vh2#-Fawu%x6b zxj{OAgDYKy8>ed`x-?JMMZ9d2t}<=Y^#QforAzJ8RTJg9GauIVPS=n=Tt6*c!;v;S zUF{JwCtd0I3l-+3YXl0;OIJnYnNN(1(iK>ouA-=k$ffD}x{SD&r|Tw$tst(|=~}in zU6p=KSD%B7Ih3wm|EuXfpqwhVzmNauML^(67pc;j6ne@)dQKq8RO(Cy6cDM>l-@+7 z_bM=SL_kD96h-O1DP4M#uJqpCFKhkZyVhsLoSbJrd+(Fs&LrnN2mN-$Da%g!fS0@C zG-!96#-Q$=IIY~v_T6lvzZjwiSlk5dd z3gQ786*RG~qe(XknKY%SNq6y4ag#2WFsWWilf1ZtTJQ5%+N9xSOv+x7?H`)dqLPW< z5lre|&7|YFi~?~cBCIwf+}B{v}H2+Pcdl`+D|oU z*i4gBW|`C$#lA7A#fWhmu}XC4CZKUR#9w0;WlO&nBSKCI-4~G^U=5qed$UqpPBhR$*j2p&3yjM zoai#19!_8mG@VF}v&@{^YE}wz%{J>!YV;9erljotI|aeNB(B>HJ}PQan_?E$4zcjviG?*oELvT{qVuIJ zvX`-F5;9?wwPU+QI13lYZS5_|4Xu{8TKSw zbUKx}n^FU^HDjOV7ENej(ZQA$ZHQU);U~6D=w`iGE-?QYTxqa*9P4rdm{HI`zzC`!^Q7oMX}9xfXqw zY0;2*)HTJ-RHi}Zs__%pL+rH{MStS8^%jlTXwkVpEUYI- z-?v(nu+5_G+c`cvIA*&nDz%qmxR00zIKGE0s&d$(@KJhoj2cc*(@E+*Wl<&k1@CE# z`kb-o*;$M3U9jlaYZeu}Zc$rg;s8#;bA#ttiG-UL^}sHEeiRKNh>VUsd#>M`q8nmjL zVbuU!!6W<-B412wY}HeE!dC6aHEfPp)g@}xm;|e?Vos7(g_Es{VI8ukkP9xtn`%{D zQ>(TkS97aEE!YR|x1Bk=n(o zukas2U9Gx_x!s7>-6|(eVoVRK=EKvI8a}t`Wk0L>_P1*0V5_5fbLj| zizxo6zEWVR-$3>T4b;NfKIn?%gCnLIES((o7x}~r%=>vQzvXh z0gFv(_yJk0HbpTE$5Gp`vA(lSABJqIgWpiRiA|4jBGsnO&1`y-!M3(Gc|Nhp|EW#G zQLm#-0o=mePBxv!_|D7^cNd$UqHb54Zr~Yy>Sj}+Ud)ZGy=^LtnRxWMO>4feX~!6w zvW>Ozos~^H(PW%W-;KAa{REpXFR`igQk(jHYg5l}efKB}m*)$5h z|FX$+*rt6)ZMyrnP32D6^c60ip$BJes(9YUx+pdcyh-oS^_Gou0&U8Eo8$4XjqjFi zI*FNgY})m}raljCD)z{xu_*J{rshv=T=z!bp4l}0CC4X=T?1jwYUdUPc6qbe)g!xI zFZ0<|H@{s|3fT4gyLRn`wV+*p6t*i^+^%6bU&79svUcr3k5YCmzzmCBe<7}xT@Rqz zcD-s~SE9|XW(}DG|248}jmxf0xQ)SnyN=*`l=&0b7uRtp(XKp6cC}Bo%aKB?R(9Di zBh9Y#bh|oY68_Dwt8#0*hPScH^^si>^v87sKDKLJJG+wF+ts{-U6XO=Q@d7nv}*${ z;LFa`h>~6Hx{FsR*Nxb?k1V~|j`@A~Fhfp0e}(q+M-JGw!Ti ze_pcd!&~$K^Dy>bdUuCo{M4?~&+OWt)uFQ496FoBp<+25T9nJ7)j08vLxu7=G_AOU z^#>iAUe=+b__~}!Gf=v`L;Wf^6sqV@GZd-n&>z(t>g;o9Inw29tG%3ZQmZ{9!jvQe7#G$KrfF>Or{Ep(_IzoracXjAsZ-<6|?of*_ z9D0d{eaWrAgTL3AYcMf!9ao0(e1t>aBKt^(w&D;TAX*A9I+!=VgpoaxZG zSq^=JKd@!4LvOGqld%ZSb7;wY;x3>!TO8`U)uH*@9Ljppp+f<2ssl>pa;iFhM1ed`mf&;h z7T(S4)Y*bgJu2dqsi;$9i#b)lxKp0$P7Ouv8cun!7nS3jx{8NbV{$5o*{L_Ro$Bm# zYB|#5o$7)INND8LOXPJqbr3n-POU|`kW(2b+}Nq|ScV*7@{KMhsa6<@ z&Z)#ldQ;-#0TP;1M+>Lk$0lrT>D0C~r>>+swI{==+?}2J6M4Hh^+{Lu>*iEdL}B^N zsctCW-6<=6L6M%+hKFd{%c<$ZojQuIzjA5@JR_X?dn)_Sa4O4ew#{SS1x~%f>V-~i zhJTTh>s^>*iBsRLbm|(u`JUWiUggxdADn8i+Ns?e=*O>4ZNMHxe{*W(MyJ~RPF~oB z1G}7RyxXbf81sO-A5+H@>Uhd=eMYY;$E!Vh;!k8&iPvlVSv6i4(7sx{?p9|T+SiEJ zT0F=9YR0P^`r$DOnc~$7ht_6|cDn){a+GSZwiHf}@UjUBN?S zcgE{IR77ofk%G49h2fZr#aM@X7|}3ZrCjlxI~6aVH=e&y;?*rcEF)gCLh*`g60dFH zc<$K{FVj@!N^GdP`5LLh#75dMsga^n8gboHBlVx&NQGuL(zml3$vL}`j?8JK4w;Sg zW?myrU(iT37d6u6(k?YC{ao6BmHl1({o~^N0+%eqT#CoVuNgbirNg*{??$=! zcgLkRV_o_kdvR;LOU);^G+?GnH}T;dmxiL%VwYy2$r6{+;8^P7oJ$wyySwCH=TcKN z{K=*6dtCg@>(WPiUFv~p`&_DZ!KJS;@RCcvq3dOr2H~?SE_v^`Gz@j_y5vLFd(`sC zrG1$A!li>4`qHIIsPoFD6>z+EDUj8z6*!g6%~}j@^~vtmPTW8=hnuxH-CBTEcm;b- zw+#G($EvLaJ-~jM@qBb2X1vkzA|o=LHMn*ZvBf*mE8IV36nI-J12fz41{W>FspaPW5pE5_s`|`>tPR|%jT&~hl5n&kxiumt=3yT~ zF6zP^^m4mZ&Er;cZ1GYzCi>j!>UXPR&@Bs`DQL841IESp4-Acq*bh<)6vF0DQ{>DAzx$0IW zcrgKYZ@5+TCOt>tThxybzQUs0ZpHoU)_PpP>U+F?->nGRJmfus|2=YR*i*Nb;lOjZ z3cPUZ@JqK|BJmCLBAYy_n$4pfxP#MqJ=&7rqazqu(W7i1dej|La0m~PSjnSI+{DAm z9<`{#K3I$`c!MIIdni)C*u+SR=h{&ki+Fs4S3;qdsNXw951;BJ(`x{ z(Ko3cZASH`9y#&JTg`~u+@mzqYUR-%xPrLW9;M(KR(0o(d_viEyEKO|H-2!+db-m z>-#+_aDZG6lM9aG4oV!sQF@Ak$LTK?Vja%Cb;6@TCp|j;w?{AGJLgd+48yw19-YGN zYxMNGM_vE*XeyHLdNdHNA9*wa_NN>tlz&B@C?&6asGi%aM11m&SFcKWRpEWFI+pQj zDk3$!>IJ8X*KywJRi0X2#p-x95>p#^S=Ys@oKCOIxYo$4LN2d%2E4k9l2NZ3VJ5cX zQKDC+lDz7PxoD8;RR(^>MHFi8RXtp4=~cc~UM+@0AqH?K$;g`5UjYaHL=6@@Zi)pGv&%Qy85v7OQa>k5QzwPY$%g z0L;d(I0Zf&R~00n7iMBBZli5=pT?tEoKHjXthP@T>iATkzEAaW&*@XCc%Qlie7YR; zsbk0|Uy@JVFs-Fe@1*%OIo+oZGJIOv+NZ>ie9GR|r#LL@?BnkipVoBq$<^J*^_)KK z{oJR!X!nIreX#JYK0dko`gF9PPfhy!G!Z9JX#mf0441HKpilSl=OE$?@#zF=4)-a? z2%j#FBd<()gUvXM^9axPY57vdAj`Kt{eq-T%#Cx{xS4vl`t<%zwxRVdpXTEI-PFFv zr`SFp=T=kOA?CxpBR=iG85BFpae(umtVmlP{42 z3SFk}*L{k=$1%X3`##;l*+)KQd(3vYp7{73nr$fkjN^w*S^Uad&@VH5Mf~c7i^ctV zf^sEL(yuMJTFS4vrTsel)(3tKEaPX*LO-8d@;c@je*K8kZ-xBo-`KBQ34U!)C2n)S zX5s{LxAybzuV3xk`ZX3=I{H-^w?6Z$P2$G#Vo%XedFhINWXT?r?v%t);Ok5 z3wdpkU(Rp+tYz$1*=2scM!V&H&d2u4jyK=ahgED_?bl>XS;M|-{i^wsU&-i)Bft2y z@mIetq3LgaeU0s#=oPYU_Nx?Xp)sy*BldQl<2cUmAn%>zg9X_4)-I0kZa>$R`*k0A z_W9Kj9rpXx8^aFxbs0?#`E?h=|MY7)?%*XJ9rkO}5x)i>^(%6WI??;MU$gNFg-`h9 zc0`(xf)=lyDUf$hk=OkF5^#ji4``42T*C5LN%Rl4cdr~mr( z4DIjuxgOKcXSURFkN>{!XN^_AZldHvzv`hWzIa5QDD#+H&pF3H!_Xz#0LSuNja% zj@Pi(6wn?-%mK}@1hm;2&~@am9ng=cR41Sm{8ul)nmqySb_NuTCpK=Pv@4*J-T?Qb z4CuXJfOS9vthp1=swM$##LwY?YDNRPK3K=oAS z!6(>{8_3<1xG2{wpm?O?44$D(^ML%A(;}eX(6}XIF%Ii+ycPeQPQAE-C9#0E!x`k?=1k@5c(6IwK;nPn8s?sr_SG@w@P|bz} zb#-V^4^aHephn{~J{%rY7hFQCuY%fyLL-7|fkk)>*VjP}$1bFe4C*-E8x_<%e2*OC zg8CoAMx9$7*v6oL6yQN6#a%;(RwzuqxhU4|DI9jT*jh%CUwqZ z%wqQWmfX;ASx{M)2lWd66+wNpGN{jRW>rx8R|mCheNcUW4r&DIYz*ojgf|7bmNBSY zn}e#mH7GAuAkQ{xMm==JRvd%22bCXg498^T+Y!`w04P*XbI%p4HIKYzE(P z8mfd6ISh@(FF6hM&Shu~_U1NJKaZgWD3I6C=eU5>cMR=Dt$c>&Azyw&{c#210*00# z{I0<|&Iaep7+O)-P{#iZb$-v#ci2(XP?2K9!l>eg9+xomw4|X)r3}vRHdOE0M3Up)NRx)lCeU!{i<{)FQ#q12j%Dl$LDhB)lmG ze^VMNoN6c$_wa2qL$>AypHDDv3u3lpOe;e*(+uTLH#88pu{VQwDAAhwk<^Bq@##l~ zDtv6{A$GJi_{_{u6kRb6t8oPPQK-G4+GvK+*on%Ya2)X$YIHD^iMUS<{f_P(=>rON zA}3_)%zXH+i=jwYL$k0M$GaK&;4_X5jw4GCLrpLX)}Dq+_cHVovi3Gq3?ZC=XON-E z7(Uq0MHK#$Tw(o+o{uv01WQJ9T*lBR+(7lQhCah73?0WlSUsLTO)#_&XQ7Ea;wCms zGPGri!QWc+c^bV#(sV<+P=5x;ZzjE(#rt&*^<^5Ytx8`|W*+b9`G%$}F!b(1L-A;g zS>N$|Iqzc}SwXJfbL_Bpm7yL#@P1rPJ^1=ZLr2kJjiF=cwU*=a6Mb9H&&MzHe}kdo zzZx33k=lM|PJH%bt|x2n^h5sM>CRzOZx;$7?V1;M_h# zIrkeHgX{+k4LU^r`1J@szgT?K&^yOC)+fmIl%YDO4ZeRebmk1bKWpg2bG!%f8b6=s z=jQ_N?Mw9HGVd>BUNLm|A8Na5$Z^fk^y~b5-7xe9<8JX@x=o&_caQh`V|x3^XY}m_KZp4AB|mrhLagT=Qpx-w?tvWA#|1(fT{I+Dv5>}KVX2Uclnbd&g^-@2 zUB!^Hei%|l<&gGN4XIwWkapvE^^h9X2WI$<~-qeOg2mCzIGTp``Z8?AvjIf z$4@e#BhSjlWSPS}xbsm!kgtZV=28Q+3ps>ab4(r5MVL8WzRcL%z?a%{jQFcODQ?L`+ zCx-Pib|E||tmTu#8a##Z_zSOaY(`k-nPK&u9oCO%J14AOc#dY7jGGr$`i8J(Bl2rl zF zHNyRHBU*!YH6rSb7ibez3CI?SaNTS~v+y_?(Uken!i4xCO=2?!;y&o#r&fYtw!Br5luNxo+l#8e<`BI zc#Q&=BbthPS0Y;aPlR=uB3gwuHzMke(l;Zzc0ZzT9!50$aYT`)Y6&mV>P4N6&KYab5zqUQH{4ob*oNPf7Oj@d%dWBt53`ZQI)bsbpu-*#BxQ| z$P?8~Z&a`SQGFYT>O?TA1x8foF*y{~LR4uS)mKfT${miXGzO#Cz^GD@dr(xxk%L2vB+jprN55Bre#J9Yj+jhh&=E2;~avYWb4 zbx%|y_D1F17geG2QALsULR5t@6OS%3=Oy}ZEvg*Xqg?+H)ow&?M782(RLyQt_noNT zV9nhq_sonccrU6Y_nG%WRHL3U7X6+@H5vtWm?c3g5X+jNu6T&V> zcXA|f&TWF`$(9(O0I|H(vEuaczg&6D)U$4RQ#E=dJ@C&{@i zN$s~KX&AcgNmALrl5`Uz4=1VTi6lLOyiWtPyyDfqx{c_vU21woi zRdsK&T>FyM;Apano=8?TtT~gcFV7}x+J$7T!-|W{b17NlA0=zfvt;?6C#&m=WEFmy ztO#ade2x??cqc`d@MFFdb!wZULwJtk%ThF9IghxvB1Iinrf4IIuTD|&niSS8N>RO^ zQ?wrYwx!6qJw@p_wMz+)Yu!y%c?xCsoDXOI3ZWN7o{$ zT8bjYQWe7*J%RhFjei|2KlDwokz_KrDOP=l=t^ExiD^1nl^1tQ=eUFDs?nX7cQmg+xuyn_aKdHz|yoKTe^JN z(^W55y3S)nfpj%~H(mb~Ojn^o>HK{1+K1^n;Y-&y{&Y{5Jix03>9Q^+KF(v%l62)?&U0K}n=Z$?bQ!pc7eA#d zZhg9jVFFI0=+EhjU?FmENLLYrHl}MSnr}|mLzF#~u7kLFHl6P!)8&0c4Agl{jktkv z&(d`f&!4BO^^0_M%NEo3Xq`Q#&+uN3n9k&ksbsF04&W@NUUu>HkQ)o(z>p5aNjcu7RWtkV_9`G@3N5A>OYe7Gv6oa&?__^lcC-? zinU{jH7-NfCuV5Uqzu)YoWbwC8LBchL%VSY&8KB(D2~EDJ%js9W@tH%;S!3@$WSx1 z!&X$CnIYROwqf_|4DRWhq0)0PKSL|ci@^&s^a2|eWvKX)44p>nr5S3!Hbb3` zXXwbu3|&C~zcX|QH<9I3hRkqcCY~ba=?v95lcAPpGj!6Ge}=Ey^M_f)ZC)4g!SMh6 y&zip1v;E@!_Ag$ye|EUslR=*jxm~B|iV{1ACr+9;X8obi{~wp_{}1@T$NvZJJ~?Lq literal 0 HcmV?d00001 diff --git a/Covance_UCO3001/browser_profile_4/Default/Code Cache/js/31959ccd0255ffc1_0 b/Covance_UCO3001/browser_profile_4/Default/Code Cache/js/31959ccd0255ffc1_0 new file mode 100644 index 0000000000000000000000000000000000000000..2195a34eb457b6e5260429545f83c3c506631107 GIT binary patch literal 19712 zcmY-1cXX817w++IriY%8Ndakrgv@06Bq3!cq4(YelqLw$M5Lo40!r__N)rSDL6Kgh zD!oV%0qKhLUiCh|yVm{Vvesu!X5Mr5*?XUtWO(NdzBV6yQ@qEk*Jhxiv^{k(S`SpH zli@C zAebpxfy}H*nN^L7aU`a|tpCOO-=E7@+!6nKjFW)Ax+?t*uwQ1I;G9G%iMuk~0@JN< zrXUn51b5`mB5y6;Mu3p`7`MLIjkE7mA-)3k(J-K5SKXen7^p}KS)4}E0t1o%o`O;o%o@WVQYUJtGxVEvD8EmxRYqULHOH<5Soshb8wJ)Rl+Q{yA)r{qp$> zm?Vam>ZiQ_3I<5vHB^@MvP;S5l@>1Od4%ucc?< z2;Pa(qohPfkSX8FM(JaZAUZyRvT{N0NZSO>FA+f%c_Rf&M(~+bNQ|JS7|Lpn4427L zqg({%ydGaV6Jaz@Y~HG(#>L3+3%DCdjdM1=_AG9#!ZW97V*%+hn2CV}h-X5>b2 zxN-y&szlJPY6S7sB6zpDYLP(A2#!f??FdFlmpT!wt{Xv#dJ#Bfe|_cJFoGd6N_IDm zAhLM`17yy-5nOJo8rnzjNeA^)u8QNm2xiF-og;YlegxgRL~yZd1WDZ#tA~0!HG(PA zA}~%@t@9%|w?O$WjNqfMBiOVkg62yi*m*Dl>){Cc|IgV7wx5f@^Lqq`{)nLH#R$HT z?q&n)Ee6V34b&)LV0=LX|4N@&1DoRvv`8@URkDGjhZuP0Qv-89Gf;Y{fm?Fsa|3sW88|k=z~AExcqbSL$$JwG#7)xp z$p#Kdz9|OYmxuD!R0GH5nmm()nFfNh3{;c`a}8XS5?>o=y4b*<(toLe*~=938w1}g zH*jZ#fsWrBST448%1bWEdp{XCwcWsFS-;D`(>(@i?KQASGWHo5EZ@mz`oXmKfPu7M zbX-PBg=6aHaRXUr3^X~boaLOvoY$Hc4EQe@C~(<8r8@?0-c{f4X2fx$=IY z_2oM$@kaUmYoL_LNb>?l<`y)PzmSphg^i3aVr0G)j55+B+Q@DhUDU`NX%=Iolbn%~ zu^KD)OyHFMP!)#QpQMDqLKY&jhvOq<%}$nm?R^u zlNCb}{YHXvN8U)UfRPPBBgtt--per3SG*OB`q>_;zrB`JmpUDIH-#dln@_7yAA$4mSX(LC(UfamRI!3BAHPTcHHB-$pQO-0s zvZJMu$hJm`$tk%e&D$B7*IvErpgCRDvkw$s?shYBpu1x9G!oZWb$_PkL-l-^kx%5| z7e@Y*-Xn}m`_f3`QAUc6Gjel+@}6wOHO0tBQ;l4fSJRBxrW-jo!^qb&)n{2V$Eb5q zy_2)jVVU-7g^?9AO>C17dz%<4 z_awcKi6yd5I`&nsB-mg56VnhApUKxlO_coH#3t!J%)}7+NBqN0yc%KB`$!X(3F^Z{ z6Iu^(Ol;m_qUcr=`{cA#+h$_Sb`vkfwnKHu9(ik*i3Pj0m-|$| zY}{|6`~eeblJSe`_*HetbNTzAiIIm){CC7e?_(zZki-)@A0+p*iO8!a&PvVe%Ik)S z+PAg;k4#(@#}mbqHu9rHJT+0{nf5_)pQ|5I^@WK8Qs|Y5Po&L%CLT&=gqcD%GanZ; z>s&Q+R{oL}h0V+>Vx~ZpnPO5l+DxaSW@g8j$+ergUf#?@8I@w@sKZRlR2`Q}ZZq|K zW`2?n{ALEp-{K9LnJ=qka+aC8*?P<|6A>~KD>EybDbq-K$mYgo98JvFTAJxE&bQ5E z%L=*I%FM|&W-iOqcg<{TXXZqEGt)boc_VAzGqY2?oy_#@Z04FglnGtTT=>9Dziwtu z%c$;VW{Itbnfg5yM-Ix2K4yx4Y^Hr*Gsk35f8{s8%tWa&&`cBgS!{!qo17ViDSx`oO$EJV~-Y{_n*<8r2v zg>H>4eBZ=E>85(UnT2VxNb0rJn71wTYGq+XYYSD|Sa>P(-?gx*t%X+YECkzII3<^5 zNCyjliRV2FmpWNUdf&oSS>44#WLFEZvaOqi7CkL27@&FvS$Hj#hiHA-F4aF#zQdL8 z2)#biLIZg!*S@si9A#maER!aq)u%BQ28v;Z7i%Ax`Pqyei zriBgDEVQ3)p~wsiduD3vEDJNlJljIExfbTkvygATg;J6&O&6&Cg{o0{eP^N58tung z3!~Rr_(SHeSMEP5mkk!yZ&F`2Td;1i@U8UNs{P!lz5Ut3aQSwhh5P$0v^}7j4_at+ z$ihzfO*$R1ka*8R*ZUUw$u03ewD7f@f2?CqEqLXvXBN81>gN_pywJL@EZlx=q4gUJ zhYVIK8LfP2vhq|StyUV?tZbL{1+7>LS*cst%D^I44olH!E2YI*)XMkrEXK;E;#S_2 zwbH7bm4!)G3MX5cUS6-s+7v50#p|%r*Jk;=Rg4rb&d~N*5^} zu#zgX<Dc&loZyzN%X@3r#JRV#h2S=n^m zO3Dq@CSSqdabFfA3f+DeuTPkFAt=qW(Ws|K+9xo@vb&R=U5mvhJ1Yd2J;_ zCcUvTKf=ZzQrlo-qS1!iWFyaFV~iZP+PI$2hCjcJ{snBr7P8SnmKU}WSHz}k3O06$ zwWy66b{kXVT&#`5aW+cF+vuENBjqg{)8&s6Ha;(DV^Jv^Z=^~Y8|&n~WE=m8KgGsE z`A$f);YqjAT7Jr~aaLMau<@A;%e1jfYGm0sD29-YQ@J)C<=I$W(Z<_#^eB((+UQu% z#)tBa9ICHe8Yt(6HZI7B#x{PHGg7~ajc?_CQyXoY+2}5hWoUD)*~-RANoZr^D>1jV z(NgBOvr(|U^6hLR;(g`Q#l{Bt_#+!T#qzO@zA{V(_O;QXpN)L|Z8|S(jFO`RY~&8K z>F29*lJz5PH2czq?JFDc@}(ReWg|4&MkDDihH1)GrcSqUZ-$MWnd<2*XM{Aszr|O)%kMJ#)MNgZcE^_jj!e2?>62!uX9AK7i{#C zIak$>8=5Dlq|{CAucZ8?-pS^_Z8&b($dJ|l*eHHS^JME?8^1{SzV_mQ_UWOGBXU*# zmHdxvBtNmSREj^-IU++}*f{-C=hiFL@LK!*pVlFgo)M7@mfxjkWV@V{yYfoTMn{rSG?F1Pk&Kd)^0_^d{jrfWjF05zTag4y zL^7~sB!9`7QjwG`9ZAvT)NGdxbG58`` zBqRNi9128|6Vy85&W>b7-AFw3BKf#}q`uEZ(!OCNTgA{=dAHEmw<9?wv8^My-CpZ` z5XpHd(>;=jvb{$nj-HY9>J`aFN$RZ}K91zIH0&Fx?`e_xo)*bYNgEK!pn;M6E#(JA zGF%D|jwDO&O2m*zVkG0UNUF#>nf7@kFQwuaiuqL}-Nz`FSjI)tS89%rWTiZq5J|g< zku;wa$$EJ)SvAj!#*XYxEIA64x6s8>24Gv%<{%+5z3 zCm)|kC@&w!WK*SlRIHp2XSIBMDtoHuBUmFJ%WLMNNsD|8knEQEu)VG4lGQ37j@J43 zSOQC;_(X1Pj3Rwg6el-Fadb-*#kNLKa9b2VicVr~%c-4Fl-d==oS&l@vpb3zd!iV% zKZ;=oqBtyBzeLgJU=-Wsn?q4NIugZ#<55&R8O5?wQ9KaGZ&B>M6h)Cgqp)3#();Hq zg4d%M_;(bmZ$ob6DyWh-P8IX#SB4g`)K{Cz=kjJ1Uy~G12@iw&KxD=^xES`SLrx{-a)(sLj!A z7V{Pzlg9g_nJ24{DgJrIm$iRI)8uwE^JUn5&3hD0!N<|ue-q90fkRsR*`nRFzE?S>d4jWPUVis4^#3@t4&EEcOZhW4^birQj`$`?Z$ zDO_0Nqhn|)gX}T1i;rQYIEuwEq<9RerDNzPXOd&+>WtwBshb+Z!9WbL!5AK7#SqGl z;d)LCzvag8S+f{^l@jm9u%$x`mX0x;lO<-r(xJm+sbynm7P^Ix3--_b?n5|weyj*u5Z`B z)9h?+py!P=N7gpBbGf-4R|`9JS}MPH?R1klJ?&KQWoME!{m@QAA3N{Kw!U_*46@@M zY^U9)cA5>fvrzJVZs*(=cFGO6vqt8OvU5W&kFo0mMa7mAQ|ydcXy>$aU1De8H+Hsv zYbSE0oerz)SU1>dEPZ~`TALL|Y+LP2->x`PZ-tTf46g6%AL3K#}zx}uc~j?)Z4puI?3#Nb{;;qQ}&ge z{>E5c5{>1hq!)~3sC-u_mL+kq+>@~hu`GKlmIvY}5zFzUSl&vGy{a9wU zish1_| zSV|s_rK{YQ=|?qBYW}8Lug0=X>fVYa@qR2lWYx1+w!VtR`Z`wcqvGgjjAOOLnB%CD zFOKmN$REd+qH$Pa;+XbU9PLZQu}U_UjMMx7IPS=c(s5*!jnn6dam*+e$M&Q+B9r5& zBrDu;JeGF@aSTa|)Ah4BF39hpI0jaZV~?z?8pqR`8ec088pZLZS)8up#__s!9KAZl zu~~L?iKBIoIF`wR50y{vI2y?)Y0*!)$a@3hI5#+sazo-+Bkey|u97}Nu|~yFV{{zG z@o@wv#qp_JmyrwNI4;|l$FX!}9QWnYcX7mhA4dn7EyI3@IRvZ8SUF-;TrTK;J-l|cT#6PWx@0(BlIFkMQ&PTF-rC<#`)c4n0LPn(J#yJju`VNGB75QJ@U6R5r;pKkL7fwM21&R zq+a7hX3B#0iEMd45lfdu%Jfd8g^ZVP2Pg7GCXYy@*;k1yl;PtN`E^nv_Q{GfPjluc zk}kFti8PTFTNCl^NMx{ly*rVmza(;Bem$8;*RzTIAnk4>QvY!xv*fh3EVle*X(IU& z%JRBIS!$Fli!)G`*e+#hFG~iMrS7L?nIWadlx5{#mh( zm!;OZvP_loSIX*oOj)Yk&|_3NGNQ{dtz$VVe^8EblGwi-YviQ_29)DZX*;GI-%8Id z<+!!G9O-+?vHNs6ioGhw43fAaX+@H#7n8(H$t<13KZ!|Xlug22E=ku!^jrqHk_dZ~ z*yT&&l|PBBWJbuI;>i?# zE151OlDUo1IMM++_AuPbR8HG8da9)3;?Z zJ7vu~$rR|CObc1jM`J%tW{@P0NoL?gttY9|lUcSjnFmsELo%awCv!@M{i3{nO=i>4 zWK74B>2oTX8mE()EYHp*)8x-&=F6&^8hl&5fJdFshb zX%a5aeCb}PJe%5-$MjBliuWr|ga27np4rl8Z+WVmF0cE$%Jceqc^=;^Pu^eU8GX0B zJ_pfjvi5O#jFBnSm%pP@$Vo_Hq%13&f;Et$&u~-tym1P*I;D`_IfVuvq_F(c6ds9t zsm85J;epKFp2BZ?Qz*SJg$XB8`0=+CIIY)zPvQK<6p}BcF!y>2b#J6F`DO|WP581P48eIhb3*!PSxunv`;ooTS&19bAxd z4hM%NCe^`k>EL%@4>(AYY4S(VLESV5Epi=nk;FU)0a+sdRCLg~l7l~MIrR6@!OGeW zwurlqgOBSvxF%PcICv!AHFdB}yv-c+YwqBNJZR^@(B8pTIV8Cq9E|Ab;EC+%>fkq- z@PUH`64lK?%kB={2jQT|K;<(?b;^lP9V85OFiLt4bFlFX2PwlHEdR=(`xzay9qr(! z$qxRV;-KeL2hnpJjGU{Q=Q#+^ckq0HgS@XD{JO|NjpYu;uh3Y@|E+`CGFc{m?_i!> zkjCp2Qx-^_^*a88YWUGXVL2w4s3fIG}!B4 zhvYw`Jvic^+ffJS<)`Bg-OK1;)kz0$opRupfs%Jxd7p9cRPvv7Q1znfx$EG^d)lk} z4zlIU69+F|I>`4*{gYEt{k4N}Z*(3=lL#lX4NmeIos7-rFjjUPyQ0G%gJ58lejD=?`AtG zQPIhTYEH`4a57ak)N=Bswv!%pocvhdNxKG4zGjaewMUhP6mJBSd^p~RJ zRFhnkyV7pF>X@K9COS!yk@Eg@g~%T7?x{ z^;s6Jaq{bZdLEL>$M$Dw(fMYWtS7fZms=`lLo(QZ7Fu%iBtah z)5)Q$>bcCgrko_UjTk;ck_=Bb=|CzaxDQyC+}I;Jv3>bw4^z4LC{^z@Q+exYDjlDx1}X9~ zl@_m3*)QL}PNmfw#r!vwsQ*%Fi;HCuE@BNX-Z8mYVs;T@aZx1NMT??(J;6n0aTm43 z_?C;JGC~fOa1ko$qGM?n-LORlv{v5TRZkBWhvkaY>gD427cSyQxJZ(6BVBa+(#3iCOVURvr_nA( z$s-v%*2O$&G0w&Na!yK5aItcti<(nid_CR8I_W+`^W?6i&vH?Fu8ZkQU0hh^qTV-J zbCuSYx!<{1B_&t8^x3?N-^8#^{glIUK^m;r+#g(6epH=5sm_h6Q`T*E@nVaM;oDps z-KE-gyC{CfMTfKM%{dos|8%kRvWpW}TwIbDSC#j5?crZ8UW)aW^1AI}(j6BOcU=s- z=OXpK_D`OQ<$;R=pDW^DmC zr3<>b5#z=k>t>#mDdwh2aX0_I<)&ImH^)l3_4$#T(@AcsC%Z{Xans%5<_|gObQA4z zGfeJz-DLRPx`)`!7I_$Ovn%Yzmgi=Gys7D?P%SqH2vjpIYN z?um0V<0Cg0`$%8q-QUeL`BriVx@j`p&Fm3w@{M%U{!6#si@5nw5=W^wqushL>88d+ z#ha=z)7=b`bF>^XUD8hrAIU z*2wNJJ>(nZVUSE7JdNNDn zq}^-}7o_1F4+o{{Tn}?)+&mAb=Ii+a4{aB!ZW*`8Lx;s4RxI(5u++m~`ASB7>*3H! z?ZGPLAl1I}Fm|>yme%-?fxqH(? z%-w$#!LMUUKV%qa;vkKR_}W$)749t54@a};oZC(?CvF}hnK>=yfpvN z%RV_TiM_ozhj{7ziI>ar(Qq%tM|kNl(#r|?ew3HaqrH4LMzP0x@lW*fwX~n=W%)Ga zJl)HMnO@4x_A*ueo1>iPsb-nEKzS}yo?q+hm0oPCyt*e`{aNef&+onDZSXSkCoiM6 zd+Bl9%MT|M=cLA**O&`lN?h~u?p-fS?|HG`_j2a3m!VJ8x2IkzJX6ij)nlpjQh7=# zd~}ZRaay(+eVEKXK9={bK33a&l#KKdl%EUv=ojPTOQ~e{>HCR~-I6cP#~^82%*V3g zK4RbUaj=|^=wu(mWQa@S+&)%#ecbo?Xy^BFD9y)!bRRo1eEK~BAHPePEFY6(NF|N0 ztTn6n*d>jt`q)#=NAK#&rG{clbS=e}<@J5sYoI)v`6$&^b+l6*@{bJb?4w{$A5D8{ zzMSvvBe9S2?d!w&sp5U+x~IlRm2b4BR9WF; zy%bpMqsjMLSN>k_!}p_)g)(B35BFy6!xkUcWZHHgf9%kn?DFCH#Yf*?eWV@JKAiON z)hQp(rSUl*vwrvS^t_Mo1s~tZ7ngke`lpZV%gSGF-taN!p^qz%H2$%V&z||%_gw4! z>*GMQpPFU-Oi1+epA;zTXLpjHeC7QNk}oAO#gA9IIsB|~`gxk_=X1B86u)1;1LEhB zJkR!%7t(QQ8TPXv*H7U*KgP;_ew5c$6sww_sS>R1r(7MytLx{y{3Qn)_=#@hXP6vs z>?gjdpT*7mv~KHXQ9B)L@28=BCs`f*bd>mxeo`e@+IRNTQ+A50i=VJO6KhvL17+t2 zetg~h)amYLxonUaX&vJB(J}p2C_?R1N{t;ky3h)pLK)% zycpuA>nE!JGsXGb&kz|l+|Mr~l;=o4O}|ub(sz`fjM0AX$+9ti+KlxRGtSQr={w$! zdxBrTSK?>>L_hyd^0R)j`ZC4Ofq8z;%=h#D0zJy@h3efR9b2qDS*kwEDlsinU%%0w zE%#&o)~{?bmwkKR<^F5RM2CG6tw8R#SjD870Te0V-Mo^ehzM zGs!9(pq6YALsWo|q*#1_RJkrsQESUm1;)v2rpoK$WrqdZz{$ zCLvdVy0Tr&o&bGiK`_9LG#yV5a5pPJdQO0)(mpT1@`?e1m6by+y@y76A@QhgJdI6CEJ!9Ubcs;6=xPeqS!Yx4i>A_(<{k1ZX@sz^oww%6+Q3 z#|C(JT!16;$&>(lrfTlA0KZF_8388A?=$uF>;S9g1Sq~zYpl}THR{dQ07JJ0bS+G4 z?g?;zZ-Bx31AO&MfTO>v7Y748lI+7;Uv|jTBLR9H4e;-I<@-l~=!>dZCdhd?csamX z8FVGUuB!q3*8=3qZ2A4V^0=v-WWL;$rGEvu{da&iw*s{MC%}hy1N?L^K>7QM^B_Q} zM_T)_`ukk{eG#Df%K#l^xzu?TVDfAA^i6>2{|315pUww@w2~dBAQnrIN!B2R@&{>F zAjqEugTzM#X&W8nsQe*yiUz436J(q{$Q#KQ8)Q^mkYn*dDkcP(S0YH?l0n`t6=Zek zASKHLNtMR(N-CEP65$A9aw(Qu^MgUYO%L)QBgop2*2)XAtYT32&j(4Y6Qpb1ASsQ5 zx))ySHxE*`MUV+?gZf#dJlY4@+)?p51sU5pNKB6)t$PN!(JP33K#(>AgB+5!gB5c~ zkl0UxH26Ho^kJ&+t02S2201t`NY3~myC*1@NkIn5_cMb$pB1FbY}GS2$hCPvn$B0v z3xk~cI!M(;L5eL2(tc@><8ng`%aq?YLCUTOGDVh4(KV{!SJiMZ$T_KXILO2!K{y)Z zlM_K2o($6MRFGc(Xx`l*-R}j-yRZFt5G3kZke1Jb9FR>fm3KrM`;BQ7GNbQ)_D(`a5cjd|tLD43K+Qu#ExrznPO zai(E#rSXyM^XYgXjZb8IMjGZ!#gZbSG+KnySeBc{oxC(wRZF9O-881v)0p~cRBxWf zxE5*pj5>`k-%jI5t2Ewjlg9bBX(YB!W3p83n8uj*(sb=AjphB*xHlk;*D_{c8gr%j zpfozmSt&Injc-5En#0l<@P%rUD#O$C@6$B)N`aAS%=j`5+n6*Oj7?*QJRP4#c%tf- zt&`LA`>bggr>3z@4olv&G#1Lu>54l;$7ZGxBS++-G@PZFv(vE7Nh5o18lTTgetum^|CZw|4>XhAuU&@@%whIxg(7OJC*A`<+48w?}0S^u2q^oS5tqFsLspE z|EkuI6OwRUHOU7z()j*n8lk__*z+ij{7=$|m$7p4X&Uc7SO2Z)Y_+B1icIHKk#s6Y zr_(@oh$SYSqOx4>+0$ton~pmnosWy96D*xhWZ85YmP==+{41@K(zz*7$?5Eqb8=e> zJJWefx=SrrIuqUL^z@|jqc@!-UpnQp^gKJA5%tn_Pj@<@2I+Vkr_--VI$c|)>mDe@ zc~5J0PUnLj=~#QFGhg;iNvGhnbRrg|Q**IiU!h!ADcA4P8MG!H(@*Kt*_h52xwwrL*v?@;{eOi{I0!elZ>M<#c|xWKhPI!K%m% zB8p{Dvv>w4-^$>fj0~1k$lz>N1|yneaHwepp=KF0k~MPT!weEW%HWeh8Pr~s!KB5S zza)cL=^(4W&EUz(4Dzj!OPcp*2H~3-%q~@d%cU#Os7wXURjEMfY85C@w*tA7DllSl z1^%90fe*J-;HRw>sJy)b*AG>|b)*7wrO+Q0Xm+6jd*$k16>#3Fz-%dfrvmTatw8eQ z3iK_T$<}h2y5^Y4ubxbze3^VM4{|ce3}>=jdRNV4W3^0Ds%KK8PA22)X40>ICTqH7 z^0d3g_snF}Cz%}kG?R*-W%6ifCfUO>`BrwwqS2Y$ota7c>`a!*X0gx7#4<0Fdh;{c zCMTrZl1vtVlgX{+nY3DwNiWH_CX?88nY^<;lf!aFo@~h^?r0|O9?Rs2T$Mqm_4QfB z{XLTra^lZS60RsOS@$rL7mqSI`7%@IS{7$KS>#m6(ml;tOdP4_UuH3VTow%{WHDo6 z7N1VeV(*kJ(x+xoTRKbS=~;}Lk;MynZ)FxMS7lNByDWS%Om3~s!oMzyujS2wEUNyh zW5+e`hUVSOqUN0}rasN${Ie`(zscfyfoxobvZ+uwn+`GARE*8m&$ev+Y|Cb`Gn=BR z*(?oavn(r{JK5Qc4rMdGLpHy4%;tvy*}NK>8hqZDKYz=V#+tn9Y3Ywl%x2I1Z1O+M zX0XhN$l;iNh>#<}Gqoqvg9J-Xrp>j$N!<*;meNv9@qsgJ6 z?0Y+h+Z}QUzL&$pt~vZRK8Lp^<}g-1UzEdv#W`dy(fDOK4Esi7#IiPrdf(?z;3utn zK8GK!=5X{{j;?FukZ?0cz0`Vt=dk8h4qK(dKRJAQJBPcn`ECvo_j4#DtL4dq96CMB z;l+y_D!x)&*(m?L&Y{;E5A>l`6n=Lj)WR-|Z-Bg7PE2xDr95uOl-ydgrq z5arXfPI`#JQY<4x`wAhBOWT|f%R(Vy!y#^04iT&xVzE@M9%4+55U(VEtq_fChxl1W z)K$!SidjEI%LXA9Gz?L=QHTSL_1HATXELW*h%3!Cr$vZb?}V86Zb<(DP>40{LOg9B zqH_nu?Hrjxp$b_-Fudx*T=Ax3_raZ+SJh!z7?zl<2Jbw_C3ks*ElOjb{(gm@_*&QgD8hv>IZF&8W562+AKOG7MK6=L6y+J~RC4>Dq- zVsBFH%^}8b3-R0b5Y={ssJ$n|q`e^`_JtUJFvP(_A#NNE@l3uy7GjsQI}xJcZ|bKM zKOG`femxVS=&qNsv8~zgL)e zStNgd80M)A{wU1PeZm}-VIPP2rLXFcp8dl7*gwq2pXhN|nAcx~i5worC+DQ}NYy5z z<@lFjDt#5EzI-Xsqr<#CMzQ3yxW+2Kabe;ngefOego$BtWUQQ=6xO*DrlGt&CCtL9 zVTw#sFXfKRogU_{SZ0PX%?eXzc9<=4KnBlI{&T|w=7njzAk3_VVOlN=^TX;euhxVy zYz*_>o-ix-s)q-|ls~Q7&V+e!Hq68eVa{9(Q{$5A`%^hw3A0{i-BIuFDxZ7G<)M20 zD6HRY2vhJ`n5NIwOGzt}%izRZvQu(#R?nq(ja)8EzB;)ys+-F$aW%-LPs3cU%F)KT z#5T=kq%>=u%iI>Z6lj^tptm))RW3u@<#MHeE{=h@%#zVFaydRTmrAp8DZMb4_rK2N zjI3Lc%ZqPw>AEsk*QRs%a#t?TWX`yq`zY2YKv~+(&tgc$~*% znfD}*3D5GFD`zVeoKdaU%f}J=FRG3%tzAzK|MySR5)m2A1L2a>PYx=x=I5_|J$&{v c@9xjM#*LY!_H{mAXYl`O&dy!q-oPOZECo?JB$t2;qEe=;qJrToiSjz!-m_iA;aC> z2mkl)?9Vx`lP1r7?)}OQZPF*r-k|I9EFC_736xYEhZ66O;6`N%N|(-Cx^(XBrOM{WQ>t{{GI{dl z%9*1?*-}R4IGG`M=KtpU-@nq!(*pi?I|xhBw5)UKr%)vpww zewg`PfZn$Xkhyh$w&M^yZ32{vnrMpnwgLJR=Ww!JfYRFss3;0|3sCRg0UC~SeFOBg zUw{Vm571Z)9>`q70`$vB;zQV|00mACkZVeSo@32S=DHT3Ubg~t|4D$}qQlbwtwY^s z0h;yFrEoi*tJ$G#k4R z-G|s<>2FXY{Ek-xSa+a7d44vi%OHccVf$c%Y(osnj;%w<35MYY6~`_N9LfDr2K60n z(DQMug+}9vb)rFX)d+L314FVJ zHOg(&fM}y`prOa8)3C-Gb;@hhq&OZ&&v>I=`Hae*Xw(?LQC(B{I-5~Mnk%Xq3H@QNJO&vQZ8DRMXZ* zjc;Sre!Ry0c1D@o8#NFi9gRvrd7MX^&PE;TVpP^1^bnVO8uj!iqel0lAHC^)U!(f= zH|o2AM*TC0^#-$7hVorzm{GmZX@pU&M;Y}1-qA)KoM2S$iR_jC`Gp)1Ih8f=Xc}Kn zH>$&IqaMyND)U^Un&ad==2&P{;u52Bt~9DGj;}JR##-iIZ`6?uMvdG^&o+_cW~0_@ zH7a#GIqV=$T*9c`?5#b-aftq$X1&Xtd)26t_lX1jkm&*Y1LGgE&mOVX6KaF^X#Lcv z{LhT)|D64gHE8kHsEO~4TKV26;|HVWTTB{nHL0}Cq@`G9H>p~%NvmLWm{b>cLrnU~ zY0_w{M}aVtGKHIzipb2|VjKR*YSI>uNjbeH?ZZvfi!gz%1<$=FUC(ZY0-4*Hj}#G z9dgVvX%3FSHQS_(b4+TwfOXM!p-J;FWsynw7Ms)!yYUsZmzuN(LCZ`st{|Q@tdAWV zO!|Uj8_9DM^Zib5H`Dt)Cf&x8117cqgBVZJ_tQKE?-}AgXHx#ZO-j0IQqSw;{?w%K z&-6=y>Vz?dK;1J2YG`1ft|Es$P^XYPI8Z?$fpVc_WS|B{1!`}mK#j;6s8DyHR-t2b zpf=+eGJ68`1Uq5^wKXKdpUJ&3tC@gsMi zK%GE~zJdCT@%;i7*FR9(kv=d`g^~T|K>ac(P}sD;Qd zJWwO?3GYS)YRH5@xhInkj$_-DKrNmgsK^<~w)E@314b<5)fogj;PyrXIGc11xYV_qmIj#h%FAky0)j+*Oy?>}Z zzFiB{yzBJfMxa*S4OHXjfy(!9pvEdlqs>A3)fJ?j2*?nmL~MmCB1k(jA}UB7vIMDL zbdW}26TBY2#zBmU4blu8KsGPqumxf9LF%6rq;~!w^}>1F!pYVJxG zTMcUwkQSt4c#I0^L3)Ql*@E;N)?^RT4g8raNKNtt=@b6U8>IL7S*Jjd>J8nT$~W3z7vD= zbXt%;%qGt{K^iwVNI4c^DRVCmQoa>IN?#eIm{mbCt`5@VUxUw*m;g!4bnO^yhd*x(x(qWS{Q8B0*6`sGn+LPJMjq9vzoQcZPpTxS!Xdj z#;m%rjEytvPn^Tuc(Y#PX#(f@IF@MEI-E>0>ngtZ&9Wt%)iTAb?wFWr);w%YGpkIx zS*P(2CTBBiKEBUxR%1AGnB~TCT*9H8W>w2&)~|WYdYjj*xO~Km_r=Znu7p`3CCyrn z8^}<~tRHX|1xuT?rwsXEY&o-L;zoJm#lQ+?-9guie2pcQ%nGb*)@B^Q1GKDS)~c#z zy+g_G%zBB+)y-OoQs0vcR^vUk{9so38r)(qoN+G%>4YQ?r`l8cH{#9{2)hbF*@^Fsmp+TAB3=aDyA^+rlJv!3BrcVg>lR>DtaW$Md1*x#Re3^Xh4XS1pgGOH0b4CeeHe2ukm z4K-`;aI=gf%*r^@tZbvrYKLC*fUe8|5WZ{IbOgu-K-d#!1-Bb z)tF6ObIkld$6lFh)~5Mpg)T5_?h>;Smr+MJR+v?3wVCf()PFN|++x-QtiUad+iI3! zn^{pfjd^>_YO>F)p7?RUS^ExB^FPh%i=FuC5WPE0Ke6{H`xiIy%Q3S?oM0cEWX)4% z6+gos_=_5xrN`&Y+I4}t|IHX=yF^d$JGNb+j#t?`*VvPYx=s(#5WTPgzuqwGAUfTo zFL-~OobFIt*za-O?sBX0=)Min6bg)}w4Y6o})1rsyAI7n8i>APq!6H|rMXfSf^uf!VaTa|;=LCzQ z6D`_|AF^503&SuoyF~+YSd=-ZMPqR>mql+;Ket8m^I2riZ&4JQ;79?Bau>9y9eTl7 z*rFGxT*AT|Mix2H9B0w2ENkKr&S6_Qi$;|vp9;iK*}`+uqE}Ujt*S+RzO$(N_ZEF$ z!=fv-EgDhBqP;kQ_o&yvqILL&*$pkq(8!`#%th8F7CmihQNLyuWovFxBV5LZ78X@# zZ_&$c76o)C7W7B99@OwBi)!IEM)b1C+1sKTeJr|)%>Ae<9`)y(0T!(vXi?suEowc; zqG$MmRf8=mF~p*yxQI9CF_f5wS(F2d@Cq%5TQnKR@Y4v^!Us$pX;GU|7WG8PXljaa zXf?*7SvZ7!<1Jb|f%S0$jV4le{Ds$(sM%!ZLxw39?ZQ#q$A(`RJJq6&xQ?OIh&OD3eAoBv|!0v?>85WWIVvE+my40d7c#2`mEXuXq zqT*ntjZW_X2J8`Ob-|*4@aQ7@2PN;4FPc9h z?#JxCC-nL$&m9bW#&hI_MZaS|u4CRy>V(6vzvlc;>|xx*SIqj%_RRZTDe zVK%Fxu@dKy({5G95Ub))9EZ>?)T$wPheP33Ib2p{Mn3$3E*Y#EgxBaCVO8mjRxOIM zs(fav#-Tt~)f!09AD7=d#ld;U{#+QR^_e5{FsgF=vbRN*Rg7H zUDm9}n%Im6^{uiruqq12nlNuutERQIYBBbrdMm3M!Q9%a!5H6`9NUp&dvZk24pv>j zZDj3e)j{O%WK|hFLV?a!J;1;&R@u99F0OX7s&H?so+73{y%=EC7!(|6Rmjh*ixYT+ zeuG$hlvT@+XN*;QFn6p~XE9}*Rl6owHFXC4#UA`H)2imPt?E0+s#lmd*Q#|GFpqxE zC!a;chz?t*+jeTO!>Xk_>D4ZB+0DMf0<7P|-1xkYc=ub?;{dT8v}y$^{z2^UAEMsK za+n(70z!^Z!=v>281+8RzP-#o{Kv|h?pC?+9;WN;hnrSyyhW}Ey-Pm#=;eK@{{Ei_ zR{ipj8a|?KPk25&wJHU!=hO=`Us-kfHP45)?DO~RQ-pr7sv+9K_|dA7pNZ`Y`}iwk z0&Hq#u&E378Era+rhzsc53*^H*{1P0h!PH)l0$9sIBiNrH{3$MFq<}Jv}sEu2{uKbCBhS#8$I!Rl1=+jz;Dy+WSdqX zHkBChHO;1a={B{3BfCwj@k0(9@Bi5}4r#e;TAGJk^4gS?&!$6ofEfjBs#?&->tCD7 z6t-z{5t|kkwP{o_n_l2e37ZO*A~uvPZPQVdDq~YE{ER6$fD15}wJ9^)96nsM>Cq*dcHOYa_keiddPp6y6`xS@kxi3u8AG4gRQHul z9bfbH8*2HM`QUnI(?wX{+cXo)Fz*BNe?)6e73^wL#V$`(yDH-+EXGMV z>)PeU_WGRHz^;9G)!eRcXwt&2KJd1-s~$F>OV}^Y(9^CK{q5=j&j7pL4YJEP*sk6~>>7c

      `ER6=WM`R}s9# zH;f$4x})s6f|SvAwZcj~LH04Mfn#Vn)~>DSG~TZ16FCQ#Np|hRF@#OA>wCOKm8o`( zn#MTnoX+|)>{@_z$TW-m&5(~)@o$t5Bo0(s#TuB1%&YB6Lc=xmW-a+*-a5N(;2AQkXD+P9 zHaz={dTsd6Fm9*d;6}Slo5&ZNaS;B^)D1n*YYTg1t6ld{d>ehnNF3cxPCLj6rFYU7 zOhxlub}hns4Bkz>&~^{!?zJoDKD#3KQ=5Z!6~)*;i2Vq4JWAfj*so}FoViXA`^o=Y z<96~XyBeLgYvUPujH-W;`&qkU&#{+K`aJ!|&ll`UyGTtj=WmW*vTGV%U#8Dj?8<$O zxNq3yyU9L815Cs{+4hzwS@SiZ(hJo|rFy?h-Ptc3Vrg(L*40j8jckNb(inu%rj>Sxa6U@gRgv|#1Q z5v*Ogf^`)6a|dfG7U5IgU_HzitaqqYAXqC=uwbw*;D~$T=pU^1gM+nYM6g1q2J7>JU_~vWMvH@00fTW9^VbIJIliFdx?t^v|JPvk z!x1E|4_4dXf^`wiHU_Kf7UtPX&CnD7pw_lv?cYhgcm1cu?qC(#Lv8j_^L>ojAFPQ7 znD=0?g8m5BWo$egtZYYubpqcVC9Y%C6h)5*E9OM7dZXV-#v%F?H8~xuH&}coSlRyy z))H+ac{^B*?~vo;V9mf%6naAJ zPlMGQhw%=kXTfTXT{wn(&x17x6Oi#muv(%!9-zR>V3ormWO_xdFdHxM742UKYda33 zQX7oGD-{0}Ec<8X#0=cW zTXg?ITsV(%|8fk=Q28tMz+HnwPNPF@umfLB4&@JYXe4f<-n%4&)AYXbOTI4y_JxC_2=k3;4t7P;%IR=5Xr_cjzDn zxtSx{p&*Y#Wv~tJusg<~s<93=K}WAc_fR#?q0_jFq*8P7DmauAJun38D>-x(7ppiFP}QM$G(a01#@_1m2Okmg1M}2ysCZ3> zs$d)rqjN24T-%{lXj8|b`E?yCT+g9(h^g;T`34RhM@&P9hGRYMG;%1si9>tPvnj{1 zz8O7g?ohK9#Mg@4up1fLuohmncgWYlp))Al(V+@hf=ivqzcc;oLe5>uzZ?A@+nCVcVS?qP>n8)0xKHs5fxPg2NmA@5p;vLR-jLv!H#mFEGTB7VI?gK-$4zp;n#;|7NcY^2Vc96I(p zF>N7cn72`PblFZ_cM!u)YQ2ltcRSQ_Fa1BjbK@}aWARakYMo&3VBJZ2ao(X=R7Ai9 z;=xXwy2!Y{dH!5w&3}j+Wv@AS-`1f7%)%L5!hD zg{TF#<1r>=4$)qmfGtZ1uO&kC1=g$~T8B=a5Gf`^`~D{>M92Lhs+AlfQ(6eWn+Z{Y z93d*2Geo6xh3IeW$sM8+d5AGDbL0zABwC|g{t&IkR@^~kLFPfDLLr)iJ4HftuxN;$ zwhGZ_G;1584(&qJxP6F%JA|kPCgWho5FO~o+Gx`wM2ArOrx4kDk!Nq#??YaFLo}#= zh&%(y>1WQvM~oj7qU0gea9D_X4G+-|BUuXt$Al=)SRNY}qDaWFIYK9dC>`e} zhN$MG5Iw}A$su|(h1jQtsOz*4Eu9{ssxv}#6Fp{z=<00Zof9J8+z`di3(>FhiF09y zx^DK#rQzjSV!aZgA=g55GCEYX5<`{PAXK>#**#S87>rHW2Tu>i zpc$fjhAIW;G2*9C{eot_LbV)SdWUKNV)}$C4MSn<8!9Jq^b1u>bVJwvp<0h!=rkZy z{ZMNl^T0TW@#u&~Lqj!Tc&Of??ubym7#XV6QK2e;nPWor>-bQup1|XiLv?aWs1{EP zRjcWt`g2C8R?Z65W)z+sswZVk`Ep4Alvk zSF`roP#s(ss?HlibsfKL3Dvr-9N!VDJG(cI*#(1Y96Py~0wmzqR@jI0} z*(qN(*3RqH#(X@U->IwEUBIdMB2J}LbgEk=rwUhbs`__MmHNS{9yOf$P}8YjYdIBL zn^@~ORkps9*XK?RXv}#{oO;rfwVONTZQ<0rmQF2e<WZ z4aIf5>EKjAN2gM|IMu7WQzd&i71PtHDnB{(8o%~(>fhc@ruGs#C4un&wp9=}u*z=~PQ}!)m0@ zKdms1mQ3Mspt%8y|vx`)RO(yu?9YK~Rdf_r~D)$uUv z9-(K)oXUB^scI*kYJi!iS^tbvPf_QpQzLFT)&8ba=37qnMDN=?cAq*waB9~>&VA(M zIxD9xJ*H02*f-Ce`tzkzv)9srrC0 zjUE%G@27=n*?rE93D?fpaMkpOYkKx@Ey3U%;mVyWT={Z`t8}$+RmX(5`q^&IYv;d-(uT)%7%*DI{t z60RCs!?h8i+rsq&Hlf7!aNUMySGXpl`R;HT_l9c@%I*u-7+g6(%m>L2=aKEtaCODx zL(Gj@hr@LgosWm>^$F%Y8Lk88!gcThv0e<){%7J6u8c z!Zr0FF+B>G9*3*ZvvAG8F^qrC{TJc7`i*??om`3taA_Q7;fTSdE=HIBGP#rz=+aGO z3392I*`?2LT3osagVm)_Y{XQXOR*VTnvM1uU0RP8nOv%!*`+PWkj14DIEBQlE zw@bx6E~Uk|GzX?wmzra`_dl!STpARQ1Y%2c=@qsnxfJDhsWYx6yHqH}rTl3w^~awG zPj{&Swq#?i>@MZV;nGV~&*{=UTt{lI{|w^xJPPG;X$fxScPYJqO9PQqkack${z5Jl zDD2YDh$!mPBa|sdOvPOaEalR>(&Smj#p@H7TxDGvg;%ImjyN!^yi3pjUxf-TjX`Wh zmpY(NC6`WMWM!91RB>q`3{_pK14lLHMAhmpu9bD^_aFYVwgzjWN==t4)pn^|J(n)k zcd1ANmv%NJhej^_(b%P*esn2c6Kc?md|J445-nR2b1UM*@YXIZ8tzi^XqP78Ek2F? zPwYfuM0dQN!5TBED_%phTq=!8n2*e}UD|{$bLl%ipx8X_<1J1tacS8)#;<3-Z9E3! zc9$CMWWV4AD(rG;HSQqyZkHw_-yZ6WxqHd;0LQWXpi9mEWN%{B5tnivb*brRmlhy% zWCoQ*FXW2Kz|XfCR6A1!&B~rZ(RDItdW#G?k8k@k=+W~Gn(;1!e#Z;=10wXhJwjVT zA~eMrq338F7olZ%RV+fsOGGH8Y=p8^j?m2SBUGnOggT(>$OwHmE<(AcM98otg4ZPx zyf+%5Ub`bS;$Va};5~Yrk5Jgv2t9rnp-hh=)Z}r5mS7tWA^Y-aM2@Y0M*zL8PqQR{U^t@@l%53nmTl56TBH78S~GS!Pzn}*yr zj#NWjYZ9p{%_0@uHd3wIN9u0JNR8+bsULeqs>8rYeYZ1GYY#=rcrsFfUn4c$5T)MU zDBd@S()V#uT7*3XqBN&)l>RIcr7UHm)B)!@M5$%RD1Fz75S@r9etXlXrt3IN) z&8;WFZspD5mci}jdJ?z3$FBw4%308@a@d38SY61is)gM;jXFi#+K;Zq+DTa+PtbIL6@yg37vevYcBRD!3J2(XDmpQ^~Ds$XSJX(EwGxcdH%>)pV-@ zUgAYFw@S8gt9M7Y@^^D<0WKq=yIYBvht56Rs@}`3A((_OXxW>X5!1)5^{CO;t)m#( z&#k%xIgX!k6h(%(m3ydLX~Wzqh}UR1oZQfEq+7kP9j!*W)g7B~X|!ASF@20%SI4>) zKEbUqn1@??7|3ZDR0C$l()vXp-ihEc&jq~B2PMwfvhFhJm z61!)*^%*I%+`5T{v*{J;&LKWT&E+wqE_Q3`61Ns3*HX92EF%XzT6MaSJ)F6hr<|h)vaB~e9f)7*nqXy$pbfUy7l3fTN&=LPyS!I`);n) za%<}&&U@@uz!SH;&zT3k-w;2lza_?Zto@PLK2bkx`Qqk1ezy*NW&eC5_n2t4K<3zJ zx#FVL2D^|JA1!}UwA|UF)e#qvvqH4SV?xDf-A49G(OOzLTA8Xu>r~Zf9sDj@fBX=vyP-J|8`$vkM(ea+!0k5%=|I%|)IU(VFA+=nK5@9%aLMq$hf`$nVjBWDlQ7 z@F*hHqa(P0xz#+ng7M#ZG!Jd7d(;crzW1mlcA#$!kBqfETx;S{T5XRe*70auU6207 zKlM1)z@yFxXy{R8%xL6M!5=+JXyTEfsYf}{4nfU4S_fBik1E33f^jW9x`uPDJgVE; zqb*PykBZ_Y0@`}C6j|GO)B}_80SnuE^eb!~JSvT;xPfP=){*#d3PGJb8jXdWJ-Uv` zU8n`hcJ*jC8h7)k0}kOl=5_bzA?oy`7C(7(2`hSe=hIiDE%YdM5o2%(*2NzEjEYM=dVzJzJo`@uy+Tu~At&BylZ62+}ZRFZc-Eee=M^$!u z)D%Z?5#Nx1mq)`eVYf$f5VOal{y2k8`^axU@%`b^0}T1oqqFcH@@PMf9%ded9ib0s ziMJ?olzEP^4{-Z9^*!lPt#ck_Kkw0DT*lao9?e9VOXPf+y^G&4>jt^qp_cd9FZVra zjg&{^_L%1d#$XT1Jn?Ytn@6KwGUgREe(lk7Ybm7T*l)~?HC2riBWeH zsTZS)DAg!NwK}jy=NSEkH(g^C-ko_+s%H$>H8bB&F>>``eBT(A?-wIuf5r}qQJo<% z`aB{=Ll!gt>KI)@@*3h>8>3TLzAi?lUt?rjAEVh=fr-Dx=oSudh*71DF`9xaNZ%Br znww)(bZd-y?Tk^ogRFZpM&r+LE`lz_sO6m)bwkMA7_K9X(JGXF5Tnj`f_x8Sv>5BL z?@^43J&DmKe0Un8JkO{DKH%#Ma(ES^hv@J=MtkrVYJ8x^Ut;v**BEug#cwg1qgX96 z#A-cqnPT+^ZU)CHHZ)dU!eez0eow6GC&p@YO03dy$7)^SSoNqMt8$%U^{`j0ENf!b z;9#t-oQlv3!quuL zMz2=m3cezj$*cbG26|N{$g4!NS7{cno}sVRt4Rp9c~uer!eRI7HzWpo)gA}%5ceEj z-l}G*f6iug+s+4zFgQa86>wlU!c4&F$4s zXp+aPQF*<(jQiMBz^i>|RgCqDd-V>>OL%1}=~XyJ;|}VV^6E64rM-N$Obg1*(gn*W1Wh3a_K1Ao=^>QX)OLiq+>twdZy>e$GuwT-=c z@S|75ns}ABDYa|nRWIad&f}QZ!mDpBy*k#)tCp?3GPLn3Uwi7^fp|OdcxUR^RysC>saGs^N=h#08 zxxn7SGK5_8DhrxpJz8D$YANdcLwtCKO4q$QiQBN<^ePHhk$lUm-uF4@p;wb1Q{yM} zL6gXq*;c4^*CG=#LQ<;`sbyoSs&UQi9#P24G!{ zIPFBoT5&Shj?+P8uFJTFaeSU6PS=~oaV5l7EBHN?uF;HXs5>K~`+xQeO+hy@q%+s|>TK0HoMCllAq zIIgLR(^h;$@!4_u1C}{)N=9?+n;WOF`EiOy#s$Q=JWl0S#_0kMuaA@Aw>UN45T}|O znG?hRXLFpAw!~@vwm4nc9;b;rsP&#WMeU7K%foRRhBGL2Bu+=M>u8)F;{#eBBOd&T zDaYgV4pUFWDfA@s;RgDg;(Qc6O3m zo{aHoj)Rf$>KqlXpYamk&^A-NVlv0;IIf~f7GlK`e3vy|KjI9oW0gBzTktSCURgZx zYJ_%JgaR?~`UQ)z-W#u72#kx@EM$vkemuZ03CxWMU%cWl1rPCiV!ZMt5d*6D<7H1~ zEEb}9dc0a@i&yRJ@#>!=UR`pMOYV5Ce`3yj@oH8uUKa|-t5A`6%_vIUu%H-m;8O8; zzL&)7afx`@O7a*U;%KRO{aq$rnaak?R4HDKaU2CI$7>lrp;i@gMz?11+TSx?J$|A$ zy_vIbys8hTj>9;2RJ^8*i&u*Y@hU%!b!IYVb-b2h#9Ct76R)CISnnCR#3krU!vxi7 zl%SUQjDw96)aJ(oy@IJpg0kaBtVeXy1kJ@Zgf>f1d%Q<<^90qxE#z&HpvPSjl+ZOn zgS+u~_XL#~k)Xc#dn9v>PEZHT#d(yRk)WTEYi5E<;Rt-Q6Xc$gz-Ph|G!a+kCaB!J z1dYT2>|B_jqxfl2g2I<1sL-+mb%kkp0-q&G(8?7FdXE097>9*x5|sFBf`p_BoAJVf&)a-GBlFr;F?AD?OTY4aeTUZBblpZr5P7p?GNxKBTf@M-TT zpFW}X7@yL|`cw#;QEZ$~uQ7JKPhZe!f=`(z`BZ7LPrK1@s!y{~b(&9&a0ex3`1BMN z=lb~m^gWj0Bt9bOcb|%42qwX}*{5pQf-kUc;cH~s zN}Z1RwDhD;8<2d;r*$}Y+Q-k?KFvYVbF2@`d7q*#_|)v8PhF7qw@=Ga<&sZLF%elV z`}7Fauh1J*yGmc+{>P`Dh`r|18eBxT>(uauPsb5-lX-8^TYSch+r)$uaNi;3`#wI4 z;Zx&BK0SEi)Ags+2Kuu#QCs%_9;JlW4sb|7zu_%S&fOxh+L*b z)ift6M`WVf;c!%<-eyjeAxomVAT4X6`a~ycE82My)fWLViE0#^sF~hGEyr7&@+E3- zQljqq6J;xssM1(ilySv457V%`WTI}OXz4`R%OolaKj8u%S4fnWin5!phI+oyajYL(em&ort6LqhCq9!*;)O@_bmWGMy-8fOZTC!fN zL{&mi>;D+rB=R0jq84{ZRH=@Ma&}78Tny-)sMLY1gXTXcDsph5I%D<_<{X=->%S(d z!p1~xN6k%%`g$~x>qHav9N)0`c%ptdov3Z7e~ucV^7%wHfG#AeC$e59S0r9#jk}53 zhZ7l-_$*hF3fxT6N_;`iTS@AIi+BY8?Ih*JFdV=cRJ@bK&m~Ffa5qWM@h^tnPtu+T zNm}?gN!O9~BuU+{8ttDZX%5~X{#laT&y(~L(Jzwp^Q$BUyiQUXoIu7mNotJcIEs(x z^o}^+CvgpRl3pR#ha`T_o}_cA`YB11k?@)OUz1cwe*J~O06(Ak@#`cu8vMEqkI}DM z7>N^zGWk^x3vnG`fqs=hXDq=bSc3d2fUa1I3vihIDvA!6hm$Z_{3?V_Sc>xqviem7 zeX$x>;k5Zx9G$TaP3(Sk!F$wj_*FW@ukZ0!s9#?Y5$@M)eCOgZEYINAs0hCv;vJ$h z`t>%F<57MEWb(_K*{|%FjLup7`Y9{NWBke%>(^MXU(@5r4PWB@TA$$O?+y9YEy=Iu ze&WC^>`M0Q_iT*K>z6B^UsbRwKlLo&*LWO2$HIOML(U?8Jx7M3^=nN%zh2kp z{6^gV$h^({>es@rzq|SMq`P1Fd(hLKex2=&zVxL(@eZK3!~Oa=!mrvR{nBW^29D=^ zw3tA=6Y1w9`ZvR`A=op^&)-w<>+)Q`=FF$x3;ar2g zZ2IQcGgJylRxU%bieng-1tseSidd3mw|WZk{aV>gmD{${cs-cDAfyX1PGzG2XV zWR-hFJopv29w#gBlVq)bmaORK$x1=&=VXO_;Xbl_OI9a%15)%OT!s|I!DCEOnlnXR zF${krJ}gB!@f(JOr|2?LTq){|t+Ds1%9x`3=#Me@ib|0w`i4qT zDXNRnnNsu*Dkh|;HumGPFGY_~H!(%6@K;ibY9^;BJS9c1&^DEIupTGSBrQd2u>&R3 zQ)J4PqGq^?T-j5&wkSm(;K-4pf+&XxxPfOFo-;+8us>IdGUZNDG3b6f&sm>`Hgxp=26GxHQEkzl+Q=364nu||^Q*?7EH9+NYDXKpqMOi1OsNOHc zIW0wnrgIEmv3*90_RQmPte>Bvy(qhYJ}gX8??ov(zJuetIga&vIF7P=IleDNjrXUh z!{HRIMx!Gs>WIuo>CZ`SPtimCgGr}T)baxTLhXz69#2v6Qi|GNPEj8m!J?}vGF(fM z_a=41**huPaE~<~u-_i0X#ArTEqtD$nXg&z4g2|DdI;+``if&1rc{j&NY!UUD(`co z>IuGJuqjp715^3?7^zx~+~!n0Lm^A5oYquTMSv}p&*GTHZ5N=ATkE7Ju|6-#)2Yg)Dtjb^hm6Jw@@ssrq3EYopZA zRDD3(VX6E*%T!eym8yqhQZ;6LD%TC9>hFoEYCbJhS?8y!*TPi3Z>FluzElmw)&0zU zAXQs%AAcN9mGKDm!=I>pG*v5)rE2f-RGozXM5^xM-Z{=YpQ_jksk}$a{K$Ttm~jNB zZ=~wmP5OB&Rnu;#>iavXe5Q%xh`pbx`q=t_8azzZ8oc~OOrIHttY1=93mgAU)yS`@ znhJ|KO(pS%B~5>!zb#F}9BG=2z^F8hLrA7HHNcb1X_}rTP4}bI6zfUTfS5EDj7?KH zv_oERnyz7XLYgjNtS?P-P%kk}&GV&cEB-*a{Av0L(S?~8p+(ZM}Y_?lEaf#-Q10+JUIKX*!Qv$TBZYzbs5s*g16h#G-C&G?o3m6{D#cC(o}hOnnt6@o-|d# zS!CarrmJ{_a{H<0p)`#-mZl@APtvc8@Vw@hnZ7|4q{iRQX0O;4fz>EFfL&k!DI)r?7Ob#gF0X>WmDo zbdAP+oX(i8kjQlH!x{95O4nmd%#^N=G3n|O%Q^mZeTF4DT}k!R`I}$qD%2=l6VSO? zx-Q^F>vWZFldcb_**0Bjm#!Kp+l~3KwpY3a_vZYm=^BQ#S?Owr=-KH?$6qKvCtbr) zU~al9Aoo0CT$rwuMd>Pn8VFyKuCGgpds(_}VCZt^^=5D-OCdT&aX-lVGZ-tL$CzyEdL zwLUB66cY0`~C zCQUAC(j9zM+@#ATOsZSbBrk5G=6gJrHfeYnld^xv_6jC7uV~_T29x?%HR(7mqd=TV zxy>dO!Ddvmnv_w~q|90-CD%6TaJ)%FTqcc0JvU=e$zxLI<|egoX=1%#6YFuAGy>L` zN$PJ>6MT#U15AnxB<>)Sz8-2)`Y@Bapz;?cZJ9*=lTBKPc2i6mHp8TpnI^SCv2RRj zG25hmi%c4aY2TaFXO&4`!o1p~6+f6%b&W}#)|s?(t4R}fm^25$o#cn2yG*)?ANHFx z{+LPS&YQIBBG2#g{DDcc5qN0Q3>?C$$0p6pVpfi6Uavx?_8s{;N&!MDvCR?w`zMa-I6l-H41%&f)uu((-wE1Gqrl3Bl1 zVO&+SM%OayB`Vf8>j`q(%qnX)D-P3~W_5@+s}H_uVAj$%TxPvM9=BQRa2N0U%<6%` zsOmTC^MIK(p3KS&5j$$up+vKqC7WeSHER_%qJ0yyT+PgiqBVA6ZF94(w=`>Px>@5h zn4^_hMX?2iTbpHIUK{f3Y}RDVL!&PAr7N|3YUXz)v*rvm^Z7J$qRTjXIG#DsWCA(P zG;?08St-ah%dDrFX6>76)@h8JXV#;I^m~z6Coy2LS>?Yq>mhP1HFHf1Jy>a0zO`m~ zb}05Uzm00 z6+Obz*VG`3-pOK7vm6$ERMeu@#Vo8 ztm|dr8c_@1c~~?LjVf6*5~pWgxW>J^r z7EN1W(Sz?T(khEOt+wdc5A3^!*lR6{{>W?VEgG@WqI17nSig?GZ?!04n?>EXb9{Di z%ywB+YA?rdA2APbd=FVv`LIRdqx9++HJqTPlhk|4qKfzv-qRNKIb+e&vliXGV9_tv zEGl^2qBh9H0i1&82G6kq2{$e3frD_~vgkM-V%a|yng1oX|1A0&W3yQKjKQh|Y(kFg zR@Nb~YD6KcrX#ViRjqLt#ox8+E7UGyl^-f=RY45Jt`DsI9%a?Us#YyPS~aUW<1EV8 zuxb(p*0gFIg0-w_hCO(@j#Yy&Hr}dCG;3g02mFOHF7`*2pjF)rs|Mf-9%5C9d@-Ss zRZrjvTeTn8usLE?m#9@=Cs=hAvy-eUoNQGL>ySN#TyPQIRIB2eShXFwnpqWU&OUgr z1${u_meiYO)wWhv9cgXV`j5!7tyM!lv8rT8`qatF^;p!8)Gk(iiT@DlYSm55=|-&X zRylDJU-z(T9y~p%;WMjV^s}mOf2(E;wyOIO`iE6Gj#5Lds__NAMlaMDPM@Y*bsJe{ zSoJYJ#X&TfN&epu4{y)1>hsxF{ea?gtXhPhFl0?_rTte=^Kcai0)sSRf12=d;mr-tZ_6}W|p_v%x1&t~+`^nrHl4<} z&dd*Y7n`1-PFI_5;3cYF%#EzQZ7Pfzc=(x3Yd*JW$JaJx8)M`9ESq+s@mQO_ z8)s9y@itvvY*XnaHud|~rk+b}8iF0D_MJ_0f3~rn3v>N~U&#@h(0!v#c{WowRw3&a zo33oNss1*b&S3I(n;Pz*cYAGmZ=X$va2{><+qCt7P5lqqGzz`{w8?bXrhP|ky7QM! zADpu3OI$od56;^3;dvYDuh=y3CcQ(~TQ<%kv?=>P9FKo(eD`eANzAxy)2{nA^?6`Z zv4=K|L77K3HG5*?S~~jn)TU`KI6hhI8VGAvJGV}-%bU%v9@*`Bkok zwrek}1?~F1uwB98b`8V%5_Zt%hr5^Z)hZNMD( zuc2LQTy|~3KN#${>j&~yEfngzUWMiDB0DnJ9vo? zx)B@qkfj&fF|V&(r%<=QT}1}iRSpI=45a2kcJ&#?z9a2wfP2U~%C3?4do*>7v8(NJ zyXNA>3Tpn|t|`c|(k}atcJ;>L^>!`z*{)SMg3QhAvz6ns&Cazkb~V~zSKi%r4cfyo z*l*YF19nwAXqV@(U5$^}b@3?MPcRNo|FUbwDLda?+SU5>|Hylm@%ZDCT@`N83(Uos zf9c`v|1tRq#~i1h{*V1x9V(m6p|d$0Dwflsg}EGBjT3JtYGQ84it|>CiX$9b4u& z^crh28H?athZfHx?tFT)#i71i9h$ezp{y4jYKZ&DcFCbpxO&;4Nmm?-|JR`bF#SiK z*nx6)9J+v_uN_JOtJ10%=HOWtrfxx6v*Rb89=9Q;qAOmoh|6p z!y-m{awNJLRe7)KJu_?vxjMQ7O);t9XDlCZ}?koqAo%sm@NPmLWafsV=yW zgoaMNKwg(q2a(h5)LMKHaw-Fb8#z@DOOYc?UdWo{lmj!9orV|UNowDL* z6zNHAcz`CooSHV=siXMnOQ)v8Gs3CArm+8Xr?Sjq+g#?I@6=1IUf|Sb_!m04eug;~ zJN4ZPr>^0f@5vqJl}?RaLt5YjBI@S6&^1?10*yU8C-A*;b z*Y~OW5p_JKjwc+~r}U~)yxO5B{y=8sc)h|ORpNC4?W)G>PBpfnUG;da#WTE9BVHe% zA0DBQDPAox)*R1ueDV4n*Ddk-)ylS-@tT8Rt#~zo#TKu{IO>Sk6+A$8XT09Uho}WF zQqTsyFdS2`2WeL#`AYeyt)O5WyEV{C|+@m7u9i+f_Y_)O5H?{TTJOWUft^j(}wRqD7@qmfIU@P1<#^Sks9R;0M( zPIW00BU`w%6Mb8{GztyUTq@Cq*vQ+~rINUaHJx3`*~O*oT^Wmq$kB~?Q07yY(owLx zOJ%VgwjM5ie{`vBKbJOOMSmB66S+7C!6nNum*R2pE5?p==`b$gyHPIw-Epb)7?*y- zUfdezQnT?c4VdB5O;nie(onQq2ms%dWv=0-WyL1pk zU$`_8wO_il9FA8m1+u!e9H+9mS@XfIKH1&ci5rOKaI+q$Tl29JFJaH=mVqD8Fqd0% zVb1MV8hTq)QSH`U}2)|L*t$(qpqFa9>p^{sVD!bLWid&O#0D-D* z9mRdTZ)Q7Q%pxX6E_7=u%KX5bXz{aK^*6Z1 zjk=T{=l8jF_5foJy43{V}fWbGZ%%e2aZ0XVOxPrJ=9;M(KR(|Z!Ni^)>(WI^({fvD*Ji3RxJv}N18xG(x zp7rslY+q`^IIP3dLBts5(JQz{GcSVUJgoKU(X4qMEyZIL|Iwqy+db-m>-#+_aDZG6 zlM9aGHcA}9QF@Ak$LTK?U>(lAal)fPCp|j;mq#z)JLgd+48yw19-YEJ*XZeWkGlTr z(G(=#@n|4gJ@jY<>`ypODEE>)QA%F_pS1(I>RsKD%I+pQj3L@3L>IJ8X z*KywJRi2t&#cF#s5>x7XSwF_BoKCOIxYp3CLN2d%2E4k1l2NZ3Vg|P2VWL;1lDz7P zIjEoNRR(^-MHFi0Rb5=>mPfYvPtBq*C%&Uo*yV|QADE)(1 z0qk1q)!rZJ=OwR9@L%<+Gaex4HTwC+b+7(_^M;qtzPu{(kC*e?yh=xJEXHpr_?X!6 zJ@KmMQ?HJ}_KbS5?6p@}IMOe2`Lv*zPbJ>-DU41SgVi{UM<`O-CkI+$0A}GAoB|)1 zt1=SM3p214|Da7ZpT?nSoKHjXw3bihYx`87o=^2~*XdKKc%Qlie7YR;sbk0|Uy@JV zFtvqGZ>9M(Dcz^{GkjXo%BRGSe9GR&r#LL_?BnkipVoBq$<^J*b)i1({miF3X#2TO zeX!t-K0dko`gF9PPmTNgGyx}3aRAS8441HSpilSk#~|Vi@#zF=4EHI=2%j#FC9h0+ zgUvXM^9axLY1tCSAj`Kt{fwkd%#Cx{xS4vl`t;sTwxQK7pXT7b-PFFvr`SFp=VMdb zA?Cx}BR=iG85BFpae(u-w65DzmZ?L68zepO5A3C&AgDH#rhawCAS`|3Ge7sa@asoB@9S5W{(jaa@T=Yc zzY_2#9uM*>&tSiHe&N?i6dUfB2_tYCb-whg`v||j$G>0s)pC?yL-8y6ea+(-KWmft zwSJsmJtq6rdOCIC9CFO?t2Dxxht0Tv<}>|j_>G^>CjHtqkJ{$@S!bC(E#S3D9Ie*(PJ6?ZJA6Bw$wO^Akc@6un^{d8@ekG$Hj{NM`#$WupgeJfG z^%b^nqF2ba*{@QliAK1(jo90Hj^jALgS>Z=59VXv8@o8ZyZzd~*ROlXv(K-N=&;|f z-WYbkughqB$gevX{)b=7a2qf1@UUN-j`%hBs9%v|)QR55{hEcBD15>%#~Ua8Is^A9 zV&nZYjK|04*dKG>IPX`33v5T`W$HrVD}I$hjlZekDmh&9tKv<+KKa+Lr)YQE&vl)C zKF6hwyZrY(KWn=BbrU5Y_*EB8@cBdXM43nAf|eMEf=}ovK78s|3OZvr=A+FszeZxu z3-ZVrP$M*hJ6Axj@&#m645%r3VrJ!lKCTi_!KwjmsTR;746Ghdxf%i4<9H2gO#$se z#2nCUOF)~g0bNJ_S^@olinRku!GCoFtO*p*Zf8Kjcw*xwO1lCo=?!pi%z)kv23T)2 zz>C}rWSR4yzJG>bIwZaIjz!uzT zO&>lEaJ^qZ<~Gca>uB39pj)WgKA;xZfsP%>37>otQ00yRz3dg>KDqcTpj~M2c|fDS z3~1lTfW8_V;Jk!@=FA9a%I1JJZKaNF0WH}Z(6nRZc$}Cg11f)p-k%MqzymAgGp9S@}Ur^cm2lWr41A=-wFsL?zf@(S>sH;PRx{u;t z1T`9`QDJycU2q94zYJ;<3XKS=ITqp(Twet>9J`P4}-dfv`6HPo9O(Qe&g*YL3P7E{PL6- z&xntV=j05>3+lrjeD{(ZU-3Rfxz|Ar#CnX7q4%;FT-$5tdR9X_vl)EvX{aJfmJC~s~*qhr>y*!5Iqd;CmpWy;h-!iltHS-yoi+uSF^~V*23m96A@Y@FKMjM<% zV`zC{LmBTF>in*u@35n&p(4eIg;B)~Jt|@7Nl8N!OBq}PU?_WOL(@_5eM3K?Wf?ZRfF%$489{X6s%|Hqxy!nW4+hlvjpl78tR4v zsBRdnL1S>PEBS^Dtw6p;hPvP&RyQ_e4*!1{QA5oW4BbbgBtvP*hEBqpV(_=6p~9(# z5^)#bHZ^2xX7D)$^EW4U3&ylGR3pt${&YhF@elT95Dz6<(FY{8CU<=Dk)iS*8+w2p zZ45p;GZaNvjKyjk!95geXQ&pMVl;N5QhSak{zUZ-hB6WNiJ{-ny(9fVp-$w4Y@L}8 z-*qt*>1t>uHsg3VL+^jeF~V_V>0zibX2ROjQ0ZQVeni&ZhKeDC6YvZ&Gzr588@he?~pXj&@R-Q&T*VUuV(VTolSk225Y&}7nGUHdwZUt$@2}py}(dB8e!&lJYUB9 z8Aq0r>-QWx>|JT7$12{JtEmTH{b1-QI;=5t487KJe14>F>-jnPnf`AuRQwl1BR5jp zZ_J5Le>Yh7lbmrB*O0V{JhqYlc0+x47#e|rI}KIc&CeN@?BRIrWgeW{XDH`>Lti8N z0Yifhkw1Pp!p|`l9X0gUF^=^Kay@0J_GyFfrVO1qL+{TTs&J0?AYS38^ZXoL;5~kc zUR>t=h0H644*yMUR}DF?8Jc#TpR*f=USsSn-b??GC+gni{r-sFJ~mVbui$yY`~4|> zd(O`zK6$~<9M}@8deYKPn@g~QVUZ^U*Qn8n?u}Rh*(&K+bCEwq;|+(J0w5u z*9*x}KcqMtuOs9LX+6q0nH!xj9FI^UKBS81iFK}!?%_3>yF=QCkSCMMBhrvDk)}ur&&)J67T{iZ>3a5r$(Yo}*rv zdGQlo!4?T|Kb(-(;vZCr(obaK6y8Y)DT*=Ji7bgB+0g^v;w%a$h2+Hm{D^;1E;*#8 z7>liVfa)p4#vB|*uGEm6=z&Ezk5WxSYJzdtfu}Gxr5BisBgo$@q#%Z21MVZPd5H5I zLt2g-_^<{2!gy@QBbZx;I1iGZ;tI;8g_MrzIE;MhA$iaT-{UIE#E65*IEZ&M=u_K} zj88))m{W5X&mF08ibfwd?*KCH>uiR=@?`U$%b zo*34$Nns71%y|5XmpC>(Ec1-8dd>>#2eg?TRxdn5(@e(A4J&;^ShEoMC9D{(z_l@~ zO238m-|n!g?;%gzM(@309o`q#i2Y$r!AU$h7*?G_)QP7U{6|=4{tRovVR~^aEE}dD z4=edZSgkPkB=h_g)^8|zihQvCbXZ%?P|Mk{T3;X^Jh@08E|CxFT&C{3)P>>qm>VVU zhxPe`u)01BYXJH@V*8UY_sj@u$17gX9#J#Al_R23n2%REBdVG^qNK_ZWv>$9-n%pcLl zKty{{J{VEqa6}2n7Kw1ZZA3HiC>qg~1je92VnjcuM&xc6(bTTQM61suT8GhnBii4O z#{m)6nv3Wb-X0jyK~x>Yc$f!AbQ$;2cSuCXhekAPSVR*iMRW+mCPy?0#ivl?)QCQq zMt*A}dWP@UMf4jyKSnffeMF6aifGl5i2lXAqYWN)Mhf?s-JBUqraiPecb^ zM>wx8sySJsTAD4YG1;T)mLsa<+)>rfA62CSQLTJCstpCB`s$siGCznaRyC@-)uOsm zJ*s0hqS_S~)k1Sr(=1Vqvqp8Rc2s}XiE4Y@sD7G4h=WP9iG#{>h?B{fxx_(l?ERJJ8_5s*koX&Q{!WdX7_%#?3z)o{x=>|LR3r9A z<=q!mq4QBik@Z4Ug)svUFEZyP`fx3(9M_{<8xqxSL~ca2{AN^5Z&CN{s9s~uohbM3 zj4F6Hs>S!1_kL8Po-h{uo<=nq1)oLL<#|*kUhtSDLCX=#nxL+DfW+(xdWpAkByc`% zf@bGTP}MvM%9b}l1q&po)Y}Paf-P_tOi-Re3A%&&MOm%6Sc2wai4s*kOQPx{9lNq6 z>OS^oPgKzyi5iqUQ6q~a>Kfd|5|vauQ4?_uWlAKfS;<7*L6K64+}9ydf0RwsIkf*E zQEkg7>HtoCn5cK#vArv?x+UsYJpMFMg+5PI`C*C5J1S9gCMRm;ltdMtPppNB>Vs=I z_HClx|1nV=vF_JI1vVzC>+d}7PE`MsiKGzM5^kLg173`fP=h7s#+m@tZ z=(Z=r!t$K#&K%GWDd zGZFhNSqXiU)nY)h`r*mIWNjamtkf~dx<5WyXQn2r^0Z`Wda|0}1X_KQEboG3Wm%Z4 zyUU6DYqD`7LYy~%Rz zOIH1($trpxSyi#-OtQW>o2;o9lC=)YFEY=iWQ}{6tl3YK<$IQ_uFsQI_(ifJn2B*Y zQZ)aq6kWm(`BK!WO^OcT8ICVa(fDON;_mVkbzG66jVQi4MagSYSo0`Fb$?3HdhFYl zBIouLrQ_U=6xG?8q9w@Om7NHUxx{wtWSLWR=#`Q)_<={n&{*EjxjO$w*$Sf6y&9GtF#L(&z(;F;+55Q)=(J#jROk!G(oft46rcwiAYL0w^VtNm!Q2EQ4+M&dVn5y6aa*T|rHAao5 z7C6Vo)E{xZTF>Ob`c`=QjALCfY zba(;vEo2`Y!8eOyYO*4xDF}QYQ&Ut}8B@-6G1dAx#yt}0*Y21)V=;RC!+xbQRPTcf z9kyqvsw0EHJu;NmCPVGpW@r&oM`q|dY{U!X8I>U?Mq>tYj?U0aH2OM2y>S$4#}I35 zhOSS@(8P%usyiuz-+MDuc}j+M<2IU2&CpOBg?(BE_q@!|G91Gt6rG--rf7?;s4^o% zwwY|h?pYb!UpPah=U`rjmgDXD8TuE47i8!;HZ06g@x>WBjaExC)NXBtIvvl@k&_v^ zfc}4F=n!rq%c%^R;lvC)LC(_|s(mIyEzV}>q$~e)U$b%7 literal 0 HcmV?d00001 diff --git a/Covance_UCO3001/browser_profile_4/Default/Code Cache/js/3613265f94813995_0 b/Covance_UCO3001/browser_profile_4/Default/Code Cache/js/3613265f94813995_0 new file mode 100644 index 0000000000000000000000000000000000000000..5fd583c014adba3cec4454819e668655e4f1587b GIT binary patch literal 19712 zcmY-1cXX817w++IriY%8Ndakrgv?}SGA(^3q4(YelqLw$M5Lo40!r__3Wy*G2#V4{ zs?v)T5swgbf z{u-47f$XYPs%O^7tX$Qf?X8}kRi$dRtg8NMmAzHGRcZwN+1XXH0^VSTHzQajE3XAJteUjq)RP% zuchY7fmZP4J6g9VbnXRrrD$KU4^XUuiZuu_hro9q!PAeS%O}v|Q&=|~Dt`vCqoD2Q z&`mPFfE99gG`u|qx=Y=$&`Pq$K@I6L0s6|2iSUKIoTPYD;rn$Ey&hcO!}=d!hb-Oz z%eE-DZLmcSO73>3E!LkQUXIIUX}Sw`@7C7I#67T3itU9u`_%`r{{l%eLw-E~=Vbap z_)20AssG1drF1?H{p7lEQoWZ268ug3C;v&&Q!q>>$o$jl?Kv?20oyM?fs0U5ev@m` z;!kLJ3EE4E%ixr`GV}_Jmzr0hrR@KoYdQyH>UCHmF*l(6-&$Ml$iLG2CcOSfdEL@@ zIU}`iD~2q%18bz)T^J-c<?2$eZ5$uwRh6p-KfAJb4 zs3hOXcF8nFFj&S)b#nyGWv`5}Mle^J+cZ~B$yLcM5J5e$6pSENzL0W7BJj&Cc_qDy zM(|dY9wj9@f-Lz)ev-cS2%_U7C@<&bwzNyo{8ABAmDf_ZbOfJBW?}@j#86&yWQ0tS zniV2AC;O8knB|DzqBDYqsS&i54bsyUK?QFF$1@{{%Zi}3jFWRxI$O_Wy7+SPO&|eGQarqX>q|XxY^) zg2)yT43xQVM{uc~YUmKbM;+Bqxgw5tBA6}TcZuNTyAgEn8o`Bb5hQh2te)!av_X+cD1r~Zj9}y92wE(SV8?+7tcM~P@IPlF*mgDo&+ic&{3C+m7b5sf zdYBEYw-_jIHBhsVfeD2T{40H94Qz@t&@#cm7s&>WR5XyEVxXR!lT$7ORXhe7N}|`m zGM|BTzk$ipxtf7LsvCGIpVct%T=HufSS_37nG~&K;3L^p*MPsCfme+U^l56KTr$9R4Ge5$!1AVYXl)>&y@CB54Lpz!IvE(z*}&+o1`2jF(D*$Ah2J+& zLVoCD;NuUpp1z?s7;50Hj}6TG#6a0$25!pfPYv7|Zs6!h1AmVt9`kryq+q@XUhAz z)|YRk)NAGUuYocqBP|LUnOE3I!6HV^6*V%Un2`liILb)VXd}C1OmQP~rFo2z&T?8x z$7-zHi!%}tZ)CF^kZ^*L5haW~lJqi0Y6xYG6qDidOF1LiiAMI7H*!X%R4}qwVv>xs zNmdL=^ce}rZFw!d{YEwfj3ft*ypv(1pQL3P$(QfsS(cHm*+w>ojQlDi!bYZvCC^Cx zd?Qa(nwYt%WY z-pLv1xJ-Ms!pI7_`;C#eR~qRqyH^=`wc1FnHQKwi>a7&`&dBT^)N2X+sJ)O|KN)GX z(a4NVM$DUyL`zfoX^WBfw<<4jZ`XMvD}yqn+LPTnkM?M<_o~KyMl$ysse4Q{ zO4bP@UrY2K+7mHeP+fBEj*(t>jeLL4NcsClyz)@8AF6+n{@BQnCq}*y`%@!d$v@9@ zuD#HH6*957u!%L2RK&#Xq9#6$GU1ChQCZf?lj0_wwC9-`kpyc}uL`$!X(iR!~7 z6Px9z6q&4k%r`M>fr$$XP1IjxqN5aCrv7|uVzeAtZ6a@ti4|*2H2%)SFY8R$*PCeb zy@{?eL0mtmU(#ZO#>w3uO>Ek1qWBgQd*zf=-)ds)HWM$zwq13|Zh2#;iG{ngmwQ#e z{It(R#r-CNlJSe`_*HetGx_^~iBShl{CC(ypQ9%Jki_FUA0+RTiO4G^&Pc6m%Ims` zI=8g{4^3PV$798lw(^5SJTX!8srEtgo~a*F?YW8lQskwHkEHE?CLTyugqb2XGanW< z>s&Q+M*fnPMa|4FW~NY-nG#Yy+Dzx-X6D40$+MfeR?*A@8J%M0h{H^)R2`SfZZq}0 zW`30Sd}apA-;x$Evp`nKlx#Ega`c#MCL&}eR%TT(Q?9Y{kWEd@IGUQVwK6k6oNt=R zkri^cwV4xb&0LZvZ=2cL-puh1W@dCU^IF!vV`hh>bvDzliZ)25sC{>V(cET3s6@RgZgrP$YIzL0M>m`VN7%t*=n$;>?Iu+dDnO=i|?HdA_w z=E%~mn!nS`H$R(sCb7HCw2;N}*B-sL*Ua1d%&eE^`^|LyMZGzs91p9uBRVeT<7PU_ z@)Ks_PMWctHPc!a{cfh{IrZy;#{X%ik*t%lm&|mzY^KH))hTl&`Y6P~wpjEJI}3I>X0vd_ZQ%oth5M4}wXjS!i_vGHW`>0wSr!UrTWBRK z<$jKZ_PG|K^DK;%1NjzmDp~MVv0$lcpdF@Lf|2Wt-{s<`$;QVyWLsW8SpTyS0TCZ7fu4YvF|~c-z9pb{1N0JxcWOY{yk=-oB%GT}{TK2NAaG>fLY~htu8LIVVo7DJ7`HoP& zBlY?y3k~IoT>adFbF_uovP_zeQJ=wF~y?y zm=-onx6omRg<>-;?4G5uvn|XN^BfD!=UJFL-$H=}7RpGDG+U_p7pX?+{jG)0YqTG0 zEsR-b;SX7`Ub+9ETsBx(zfpbJWWl=G!Z*@$i}rJe_V#BBBjlUC7Vhn{&~CqKK478o zK?^(NH|c!XLgHNu-R@cFFE_>az`~bu?vai?v5+QjJhjkORzI^)>bcf^Y2nr@3vFIo zIB2j^*=Xf+la(hDX|>YOW@VeKFKoq9#7e!QRt6Qba!86tTPZ8f;#R(sr!iJ8mbCJ^ zyp`4!tSm~hQZ(7hjEZ_q)}~n5A!!aP{hU^=$^*%EX{+Cj{F%=Zb2(=$(VF2&t+AHl`WE*X{Aq=#>gGX$^tn6!P<)n;w(@KRlR(!HdqT5<& z^_Gsy-VRpEb+qzsCo7+Jv2smPyDE1n(924CZ!1IIx3d33D~&^0!&3xW~#rSFH5CYGva! zD=F7in|vnoZ(3>gkMg*s{k?6aw7ex>KeAHlvHJf+{g)f!f2uW~Tj}w_%DR`T=arQV znf%(yf(RRbNF9TXNk$uPlZ||fjj?jfYU5e~8@_@z1{AUpTf|03SzgpeTrr!jDcIO4 z*5Wp5+HFjgv#~Y~#n~tuZ=*|sjg&WR%#c4y+4!`yjm2ebyq2ovY^;-al5PAWz7!ja z$GaK!i+vp*WWLOKW+1kblNoZ^13o*B| z(MlGyw^6u*^6g?H;$7v_)y4+-@BF29*lJ%o(H2>U&?F$?6^0^!uZ6h?sMq}wAhUv;xrp>T%cczWpS?cL*lJ4Kz7$P^t zyTQgn`CcY(wJ~s~a+2b^RF@>}RxNU5kIt6^HYT35aZCKCYw`ZCOVRg;*kuEiDa~#kWcNA?2C=0QG6sf-iRbn zDw08^Bl$~Cmx-i&*+{yT(_9&rsP(06g-9mKJh>=uCMmzP6zIAIXOeBK3VPk`9d`*&>D}%Dbh;z8T3;iER_ftqxl6 zy-3bUxgL>Bl5IUBarBC$ckf6pNKzl=@L?pcq*1>}eNT(j_q0fMNN`{zg9k^~&S>NcQ{?Nx>hL zr)>KvlG_`#7n>DJZ2Q$Ox%*2bZ~q#}$pev;IHWz41#;rB`fw_eWpYvOo{1#yTqF(T z!#^U~D8ER|`A8~A#|x2sD^oA(e3A81`_D+G$*N0{Je6lL1*mE-K>e}>m?ekgMot0z zxdr%0Liq(aDjO>opi-3rII9=nW7%D!0D+nXSYE3DO6lvvAd#}xjTx{ z`=S`WKZ-+={Yw;m4@9v|zCIYm!^2T5JQhWz6HzQX8O42Z{1(NYi%}H&GYZ?4D7}A< zB5*B=L4QZF`eqc*<(Ge=C~`ZBHzoE?6#XAWu~S+;isIwP%J*p$`=$G{D5e;rIWNl# zL^Hf#G>4>ap=cHrj^-aZUnE*TbE4@eyP~2Q5EISMVk;TV)B(|4kk7x>>p$pqiP{v+ zCNXc;F=?_dn)$N&sN$bfd|CTfG)-?svp|O5)4Ye#6n+%Vz1PvqC|sONQmSHc8pzoy z#i>xWIJJ5fr|00}{3IKP7pLUR;&c)JisH;)Tb#e7!v5lX{9AE;kqbA9v*GXJMBFUS zpgYAG@v=BaS6i0~|hL(&WwQLOi<#cik-JCIeFZEJmIN*;VHW0)8>=;5h zFKrV;CjP=EU%5 zehm2wVwkWn2J@FOG?H$MRl~{{5?872A7hxZHHPz2dV35lcgN`8hpK0942Sl`(C?QR zS{#buOF4NshTk8>kn}i)_!luu{WpdS(hxhpiao;45~H22W;^R8!)j-s&CV|IMA~^= z#7?E6b|w|GQ!L6(8z~!Y*L!3;{Uj&G&M3Q`V^Sy9&S^=Ev$IZCmDRWuJ9kp;dQWU8 z*KMannw^4vJHs>V9FkF)cD~KA^Gvqp+G!NF)2@o0Z)8VR&8=hSU|l|APL$JNqK-B!x)Z9Cm%ZZA7EdfS;S&EB_@(AUm8vbCR`%Y*H> zhuCTVv7P3_>@1Q3pV~S5nVkwF?5vTwqwQRmOJnW&KvA*f_*6S%7uh)_-Im%J^tGLB z-`I&RtwbmxZ5!)6!Gqx#?)ZcFB#~pSIJGI`=cHWj1a!Ic4wv)EU z&dz;y{ym_WN0qmXlbXNTnIgZ+m%rP&B^A!u`Qx&kidWRPtLp6?JDp|DT{{mR*(v|h z&H!VqE{VqSLedMzGEBZL63f!KSnkTWgjkln5zBpXl#1n8QY>#I$8xn|EVi^*n#wMJ zEE58;oRzV`SSn`3@_|gwjHObJUX!Y!Sk~sn@=_jGils@_SmsNSYO$277fTP>)gYEx ztz)?&8SP_f-Z7TTlGHht_hojMScbkA%RWi#8Osd0BniD@Sta4Yv3w!NK8>a2h*%a& zgHc-hbLA&{!X*t&U~4ELk5*iRqEZ0CGlP?J!RF?Shl>3#ri5%@1x@AWQ=3A#F*o# zS|E-I;x8D-=HhW!V&a(oMjRbV#j#3$Djlcy|8d-w=Vjx_E+41Q5#yLyA&zZHaYQD^ zQCU{F<9H-*`{NiIjMMeAIL^!Op*RLriDS2{tQN{D^X zpN^xEtT?BB$=&mD%z6^X6laUVc_Q!jk7u1!84!Gg#PoLini@`?mLS((6l-)jwV{**wUpA*<3#SbK~_+SFJrP^V=Ce|ZbOX7|u&{5{d zxYG%omNzbI?p2MGH8&F2@mB%`|4v}aKMB-*l)wxr`znFY3zXov^s|@XdQu5|$t8H5 zSAvpNOVCBmw=Thno+T*Vs|4qEm1F+Bazwu<$6I17n8=`*M0U&H&O{u(L_U;Ll@l3J zC6W3~5}73nJ0!CC-9#*16Dijxk(M$+z8R9pW0^8Ck>+0{vPedZPvqChiP)zo&V0>T zkVv}NRwU9?R%}VcyFHO1^5w2XzWODRd-CgvM7o_xeX*JH|4{kk5bDv%Lff$5zpQ02V}jF-d#6<8xL#6PeCe@eTt75GMa zZLYx0T@^^*U4dPvDp2BO1!j`OWeFBbqJB&gvm~o*68|J7kx@PgcZDQf6VY=S>`Ee> zmc&kP5-)v8)bJ;2~)Y&(m`WC%eYRCo@zklt^Zz>@Jy1 z(KnLmS}K{F$;qTw)LdsW4<#=(nHy3sEt#1T8&sU^WYThysgjq>-Wth7)lB9>(`5R! zN@jW0SONv6!*WcEByX3HBDv6iaH#mtHn&8kR! znI%ob60cCiz_lm`tGSn)l(I9e^*6bU8~5W8x_g_t0H6W zRMh7ndQH|os)#W%g$D9>R0_EXDU6b3zmO{PjDNMPM!a}+J zR|>A1Da@5A|D@<1uoP*!EuvrU(ap zWti-hB1Q+zOb&L*$wCf3E$m=l5eFGX9c+kq@H)Xk&k_#im2z;Uw1cK)93&^{wPXk9 zrGmr3A&E(KFhV-|9N7I1l4QF45pYm1=%8hugRYX8@4zoh<)2Cp+EjM%XKjc6J~~)g z$H8WC*LCn=JqK6ia#IHn<=bWswn|!a2mM<(xGwkGJ1}%`utg3^UPlKbJ2`kPySq8~ zO(wqQV4*~HchIVbL-#>AC^ks>3|5_T{9^|R!yJs3KEoaS^qGT{5e}Ar;n4kz4%&@z z@Z%H*|4wz#Ynp@Txei9nQ_b@ogcmq?w$MTTmkxei?4agy2NPCktQ7plK^>VQlfH8> zU(QRDb&4qqrS5ti|6Vox;Gn1+l^z>3=11+xPY&j8RGdxvdaJ(Prmweaja?3GyB### z<6yfKJg7Z5?4bJ*2j}F+V-DTR=wQ_e2XCBo;FCd;e@c0ucJM?Bo^ep^g6g^B;D@`~ zt9uS|#|!&>ZRFbkbk`k~Ei-J3c3I*-qZh zaZ;+1lk?S`RH*4>nrx`;Y?2?| zbn>dTlOAoHTx;uO;#*Emz3rq!dnc{BJ6YJnNztB8j`eX8-`B|(vU;GC?J{VPlhKkg z#L10ePM*oSPo4ZM!QoDZeCFgIc_#0SbW-jMC%?)WX))SKu`$YDHp)J!KGw;5|W?hNHJ(@EXgPOi^$;$EQm3l)EvlQPRyi@f)Z@?Pnr z-75827O!#g_gW{*H#ix;$;rvhPO5ED@3!f+?M}AraI$%)6T>d8{fm=^ziVwNan6ZT z{`u3%!7J*y%)F|cB;lIITz7I*u1TX?PTJg8PbK+*lMGodcONQ`M@~MJi_f*E|2p|x zD*xxCvFwrp5vdH8iSojd%2x$b*&y#1N@bWlknAF!KS+8?QXI+aOhQW^MrDl;FXa^YdB-fO1v#*_sXqU#7B8zI&BQ>(`3;Zz@s$rP2-;%OYIF8eF_(a#6^ zYK!p=7sX|y94zG`RN6(SvM#GM+;x8+`ri_DOVuccJJi+3uy=p(l!SjEM|nl6geanZc4i#_tY zJdqEYxY*cK@tV2FlX7j8cMsLm)5RgVEVX;PIQE%~_>nG>q{1i{-9LA6PX3bg(aLFz zi_!8>#*K3^Us{fL@vfYevJ+jboaCa`G#6jaaIsE$%+x%&Bk8kU)S2gE##b)RFLP1< zYpuCT>&v`vU96JQt6lnR-orLf#%f;l|E+X!@ z7=G79>OJkBJQ2%%7XxMc0~cuzU9@z|CjUt)QE= zh1`@a?B;rm8+WXm`BJWgo316@{QHKR>ZRQrE#ubbM{Z6fxv7!tCMm^D4~LsSTk z-85?CW``_k=H~O3Ze~f7R&F}VNh#Ud%~-i5v)Z`1*w)R9c5W(nP;DLE40+ehuC8tz z@4IzRoST^+xVg|*`YG=LZl=pOk~hdr(-CgwjC50Al$#EpyY*hg%@2||TD=+L)^$lY zH76w_zX0V){t$xjQGfCVF-F&#n%~iShwfeilt7;ricYjk}e=4s_ zZrWaT^YE3MoPSl5tp88Fz=Jiy!{>6?;33cG;cK&pI~EUbTRns#J=7O#0S|F9T8r*_GcX%k9>fv3NNB5X}h^^+~t?C{Q$%~pEU0d_;ovg0!;c){Gof~?X z*x19VCLU@u^{}L^hnsJCFt+nhr@e=k@@WT;?iu%x)k%5EiEdhZu+|>p(KR-Y-Y0a1IVWEp^6=MT53P=>~LjECD2{N2M+8S{sSW9Rky1rNh7dido}4{a}b=q8UPbj8Ce*(g1(c{nb2 zZg`0K+rt*QdCPb>xA!g68nai0~NePCwmz#LtPr@_Oc?)%RR4`_C7BMgI)%vd)c1h)$a*- z`CZCodzmalD{Fiety$H}PH9rj%kJu4`qWS^H5FT;Yb&-aZ{X!_L*?1rOPO}6qrK{o ze`I(UFNJ$~Y1UiwxiG7uCKQGRY74H)-uZDSyFX!ajHlDnc&4g z$;)CfPw~=lnwQfvyqururNV44)8xV&FG=&fOqV_jy!^D#OUfdRkqV17MjkEolDo{S zduqH?{aR~E)fHaWOQE%1ntrEs7|$9C<>PA{Hc zy!89kOYo@n;e?kjPI`GJP0o6m{kxYZ=e&f^d-+yAyXfWDKfUB!QvPz|x|g{Ryj*^$ z@sGTG^3==TXIk%HFZ-i?)GFs=Vxo`#q)>SuyOMkqsOV#`d@hM8KGLMS!^aw@k0+@< zK6U#@@%i*SAU-b2vm77!Asv@iVIK?gd=$<1VXWfg2YFRhv8wx+CV@IWD%4fHdOps{ zUvi+KkLboehRd-gKH{7CSkl}_n|3}Hx7V=_J{rlllHJiqCyDRmBUSRGLl+;tWQVxA z`UuNYv3Bz@NOrvE!`t0Q-5x%c%LduqQ#E{`8v3dRxg`hs`8XpV_V+PT@(1{6C_BYA z$j3k#C1nTuSU1GS^PxVveWdz7QJhbG43*&{eEc#}d5-eY>~rNN{YLx97~|uvEF0^i z?KmGX<9%$GeiMASC;IezB|a8R^6~FvAM2;6FH?Q&pYP-J0w3=#)T7*5q~0you_fA* zuheH*C8lNS>(|<|#X+?`@N4o8+`oqqmQZ^eKgtXWA-*5k=qq-r;pOR zd`ys;2Yp;PJolRm-Lfg)=wiTP)_4y zoSaDXQ?SvwAwD8lWrJn=Rv9(|KMEeQ8rDGlaJn!V!@5}l5rjMWdA1Gd5 zKTU@CnLX4`g^yMDI6rTX_j6c2n(AlwG|ipv=XWVL)6Zo2eU`qS<7d@eKP6Xcja8bv zM!nhMXV_N1u7zpM-G1)v@iSzfpD%v#bL3a`;((url5#2 zKR@2}Q}LeS-1k%Fq1Jw+{ytNGpZjU?!cQkzE_Gk}nes|KeeGw)zkbgDr}KdTt!29@ zfW;DEvNb@Ff&rQr3h-y)0P#@)+C>LAB7aET;sI*J1Q>4*@LCGQ1{fU|;Anh+N(lkx zmkQ9Ybbxou1Xx`*K}0mgL+5Ysb2n_dB~_YPnm z7@+N-00*Vr5XBrCAoimG4L=PqW4P-3BEX1o0S=50kUJs3u8GQJa)80|-K+r5W(Vjx zNA=7LaCLrwW(!pFq5vnq3{Y)xfD%gsboeU3F}W^=Wy6kyWf02~SM(eVI{P6X(FGC=QtH1AG;9(M!e-_w5F4-oY$~z*+ zK4Xv~<{%%-RQW?5TY^}uL3YSdsbUKmYBo4RWqski-r_rbx9;LB_rl)U~T1%LfFxJ21#A z89OM*JZUjFNEbOHWrha%<|C~+JjlS$RFhO45!Am=gY1z)qk_!*Jcw;p_ro9s9|wt-adP5Gkhh9mVY$DNSQhb7VpluakHd^(LPq_ac*l{QJ~+>of`boRAWF5q_!)aN$zxddD8hIEuAE9Iu*0^JSUxz_0x4vcRHbl>7+GDr+?FQy0uEz zJy44Cj@Imw&U-!6vGz)5f$W`{PT}e4L@Z9H))KwGLb=l9()rzzK{;Cn zt0FUqD3L*}k{O(MBZIdxGFY0K!I|s~MmEjhV6zND%`<2$YvlO*86PQ!t!+>i!Y`d=cH*(m0FNcB; zau^~rBXYT5$Ys7QmrliV`6ecp682o3?|Lkq%NQwFHkYpDa;cJ%%ZL`adY_c5`)G1$ zBzxb?Z{>1FHr>f3;$ALAWVJlLpG)Tl zxjcWKOQn~JD?iD9uX5@ATKO456gGwUNPe`2_}3PqS7eBpMM7LC8sZ|@Vp%9eY&gWNDj@>ZLM)MLHA0N78RDfBtR13Boe)3E z$a;!dUojhmXw@*p!bTyAHV(1Bi5{DU_(bM54{^DL=Clk^`>ha@-VQ;#5Nq0pc+w$6 zmyU|tB}A33A=XK^_d=}g9-?fI5cz#VjQT+1q}ad^EeEN78974hj?}uNLVQ0)^T&qh zK2E)wq+U%9@wZf+qMl3*@j~98t^Upl(SMO*E>X;-iYW!Z3bAxmh`m2(AAZz6$jF}* zd!u4+3Nc}8h~Kt_sJ=Z!o!ucO?+FpHH^hhoAr2f2as5b$r}Ev=5Id#)@eqxEQ$MBT zsSv61>*)~1e-F|6oW7PRe}p)DUcI;wqT`(qeZ_q@L|E3ylY8pPef3b9J_|ADd58ip zLTo3D#SrGQHB9OFFr5>^{3fMK>Fd(^TJDw&laUyvR{1ceDugMO9Aza3_c+-M)h(=p5f8Qm$&(RadB>a6%(6u+zD%bxCG3iS+=AiJet?=bPQ zSpI%L%o7>%L71QWhB+d`KMeCrKh+_<`iJ>pK$s6d(&O+juRaSCIUt+44JF^=Y{dl57T5}nAwZMv|1MC`_*Ayt_frK zDa<>&!>rt+9v%o&@sw&i9p?F&Fq6)QIej5a&5Nq4Jd0dhLb@OOkFOQw#YM4jgMtNM3BTe#% zZI;IthDpY)d_KCJ&uuAuFP~=j^VuzV5AzxMD4!`Z z|8YJOpXM`9&QvZuvwH6rk0SJ6RILc^)&K7FfB#I%d2d6V125Wo=f1cSdObSQ~BxEKtlW7SlGYP%-E}%3)kR~D>6%kN+?^QqqK|oNH z4pNm~q=*YWubxpYyP7wURXr=SiZ|f%Rmt*ZWd#D2eSzv(8srTGs|Pfws;_#M z-<$2LQQcRgqERsp#}=IZzgYkKJ?wA&WP_vMtJO z8*Gt-lDi#hi}hznkmGV$n(l(#yWuyPxCa(W(Y;V-zxp8dUm#g#$gcCmUrF2{ z_5K*Fl+MSYpIjGCs`s)$g1?Rf?+a2=ATw?&w=?5*nR<`Eqwvj2asY5!&Fbyy;?H=x|#T3hbOzta0Ay#7ad-O_kDBeicU zhAg-PYoyy<7$i64&;z(2vmU~7NqhtqFVp0UP#86IiWQ0tSn&l%n zC;O8lnB|DzqBDYqX%V!Q4boG8<;!~`I9@S=_^b$O%Q!hFrLy&0ri(u(f|+>{9I6t* z#HtaruNFZ<^$6asp<2XWD}tjES0{pz(zR{`tLsHjvVH_k+1Eh1Hi}@VjFw%^B8Y4e z!9bb&b_AE&sfG>_eAH3>lq=$RCxY4XeU}Jcz8gXJt`S`57C~}%#pb|He#q=(tS zdW(T_Rs%H)8kkVXz`xQr&cLR411%E`e34?{NCgA=sRruFIXUGrP{m`Qp(J??Eb|%2 z@Ee#covRu6qq>2Y@>vZ7&n3T>fz`5Eo=K5920oHqbq)CI8FuX+Z)*5(ZB=wpp$_SoehlcYM?+j1C8G^Q0RRF#pQ=S z20s2k>*}(S1`1v>Q2Dlj8+X+AyV{p~%Im3ee5SmgYkm1v zO1@Tp{~9Q5GSZ@;k$HuT6ew)uToEG^iW*rUg`$l#jWM!I#uPI$SDMEf=`5$ERGh}j zy?7%L2}U-{0SPA>8ByHGBgrUjq=rz&NKqLszmzqSon&NRIU{FeN_iuTB{tben-s;6 zB%hIh+?LnU+izq;z(`8a$UB)v`boNe!sp9(@+`|p*K8vjLq>j;5n&_K#FA&Ee!h{d zvb3_1AEb8`BcI59$*N{#xqMnvc}TrlM%v0@vDY!OsIHN!&5SgY!p&8)Op?{jJJN+}m~D$O_?Sog;E|m-b}0&Z9lr>%FRRpOK3DjnqA+8YSz5 zk*_7@5ABHq}$#`sJ$P*)9i2bRNujHR+I@exk zzY3aIT*$;4NiJ;Sb`cXFN1O1)n5Zmk1ihFx=o~b zOcd~$XyP}qE@+}zMH8>3bC!vOY!j(6Q_km@sF!P^wVcQ^vAmLrn93%4RW-4_wh4C~ z6MgF{woGndBD0~1d2+dtiM!ISv5A6Bv`$kKJLRy{YGI+<=eoGUBTbo$lMvrYx zB)(;0w?wrwF-SgaZ{p{UCLVTHKJO~mu6mRn@0mCzuI?s2=wYJa`zE%^`+ZCdle?19 z*Thm;C!PAKR}vVY{)uU*iBIIqVJ1p_YGR}G7;a*y{3E^*CSHy->3yUL%S82Il8Mc7 zR0>a4Kjxd5wZO!Mg(m7RGSN{AEK`5JH8EO_tTvIi#>9%XCK`Wd;+J(M?CVXm`QAiV znINto)GukVLF44^k0v&4Hc@PgiM?`4s&6$hcAJS8V%x4dWVgJr)5OAE+RMGFUw+zW zqQZU?LCO3@b^NM2HRW~PM4emO z|A!{7h~u&1Nn80rBA%G2`BeKLN1vIf_T0pNDg4sJN7D8`6AvUS!c1YCnGXw@b)K3z zBY#QDB4*|nHB&I!OmQg}W2SR4Gjn3i~KC$p-UDce|i$fhP{98JyGTA3Lj&Nt2E$O^gJ z+RTZzW-iH-x6N#AZ{~OhGc!7wc`a+-F|$L`JDcg(#mrTCAQQWqIscxS{@u--lF>cP z%obZuGYxtvjvSDgea)2k&`gJZW{%3>0m^TnnMqQ0keR0Pv)G0xH#t32YfV)S(qNjI zY17SmZ)7Gxmd`X3_{z+$QuJ#xU&yx`%%uHjW~5a7$;>?Iu+dDnO=i|?HdAVg=E%~m zn!nS`H$R(sCULvXw2;N}*B-sL*Ua1d%&eE^`^|LyMZGzs91p9uBRVeT<7PU_@)Ks_ zPnxluHPc!a{cfhnIrZy;#{X%ik*t$4m&|mzY^KH))hTl&`Y6P~wpjF!Itz9=X0vd_ZQ%oth5J&`Yhjse7NgHX%}fhBvMdzHw$Mse%KaP* z?Q<=}Ij1ZM=m_6D(v*v|yTK;UoEMvV|T~EP8KgVZ(F_ z9cEZ4I@7}LSsFXr!b~yGvCw>;g}L)BL@lsTT5_b>Le;)V^-1qK*!NU5D>d7Vx*3A~ak)B($mpintKU)|f-|V$;Z=Z#B`&I7&3ylw2*df13 z=ff6~?po+}&q9B>DZU35zLay1bnJJ_mvsHl}gQY^+w8F3b~@|`@5wQ{k9mDlC0v@UOD zQL>dHDOP4w&}*_b)yfV@cUbA?v~pD*NVZF3rK#IWCpj(&>B>Wx9d9nZD$M%b$Nl~yX|S*a--IeJ!n=lo4-QDc{D5PnJncTPv;J(s9|_ z!AjYVR^IJo<yFmE!WvKr61XRz4VK z<&r#+=LN4H&#B}q8cTCo0STCto(DuO5dwiHeR!mdR?{2 zXEOh$m1h4ak6YT`+g3`+Tk`cID^iudOVI zu`oxGD`;~(**+E^st3PBs5 z3>$6a$4nb%q)kN|pUChm8_T3-wv7W~2-!H9XX9bMjn$QGyjfR|@~EDTPW5fPFJH^S z2Fj(Oa&Bbfyo_vO<5xK?4Vv2cM(#DU(XP3T9`Z*E>u(3ldAKK_A!(~uE8!h|Wh#Fwid0}I;92saMZ;(wtTa}Zn zA7!KY=QeC#*hrAi<zseh?=vgvOdj+-_zW%WNcO5D~w*>cCmFA~0|y|}M^dSK(QT#i>!oUVrTzX->kvt=h)9OW?^4ka$w$UW#>idiZi?hPb0l4C zkt`_^No3JT8b(L5O-{%ic`0XNBFQWk$#cxJVi$L~`SeNCG7z8B{8g zzvOi3NXnIoq+40dm0?L*U&@q^WTMQIi}Gf&@=J*%p+Y3%Rk)-w`EuSk0Lj^u(Q_fZZXM)FD;^^4T^v`BqVi)4oc2Sze@P$Yj#g~5@GkRn4O z$(B13F*K4`$^0aesBl=MRR0xG{v_>Q)p{6KZs6ZZpq0V(Ujg9&D@`(8M`Z*nY*JIy)T;K`=dD| z*}p{7_dqn;xfo5+Kclf-iPn4PXad)w8T5BF zt8Yg0Tz>f{n!>lEc~j!!nG-`t*%ckbfY=y*7F&rJrVfbVf_(n1UjIR_OZ27~Hi>z&j!Bb! zG0d0MM-~5^;>+5?9V~XWpb1bbau`Cg*HI@#tN{ZQHiH?e;trRJu@iDP9 zlfm{_+9$-aQXIu&8CoKiv@)^um(wY+baTe?z0^yK<$ynyxIirTvttS6#Bwb+mf!MX z`J{O)ze>rsW7*s>7E7mC&dSoRvD}rn`o&VAe=LOt#Nr(k%MkffmJU{|j}_~aSjG;E z#V}lB<=f9<=`$jhEiz+dEU90_(pU1P#?pF5EMG~LnX%-~j%AcIn-j~U`LX0Lh-JdU zSj=C>(nz{3Rt+m-Nm`}4e~e|y)>zI*hYu^ieLOTS-YX>ll)FXiOn zSbl#LOY-Ab5?;hI_1{=7NJH%WD)tCFON@59n(eHYOsk!NHaok-6KUshVLO$I*qKz+ zPSI#PZKO<$UGI_Y^pl)eJEQD&j!B(3JEtWn-p)E%RYv1d?c7PT>piiZT(_O#>2?bE z?F`Sfb4W&2wDWC_ooBK&*G{9bopx31d?P!mYHl4n2kY92uV?22Y16>2f1}yi)KJeG zYmTgKV&_r|JFb>?>b6pTZ`pT(c8{sY4*OI#J+akk*)pgTpn!4J;YA?kL@%c zW@nK^eQM|IXLibuu(L+yj<$1ME{(P8gG9xa<5TU7U1aB!bX#g?(ARdhePbtbrJate z>{vJ0X(D}p)LNSqM{HZ{%-E(lQh&RhA9vU>?9_Tc+j(17$R)YD+fMo(J3IH;`S*Zg z9#!5lPHO&UXNvqPU;b|AmXtqd=a0*FDqK~xknckMiQWT)IqI|Gbyx)d76 z3&|)H$1wS}a2!kHaZCuraaP6# zPgXmuRBWy$(D8h;)55`gIP#oRl zmdrS!c~a{))p{k4ty1r197*@$=qan7#*n#gejCrLHu3cC9M2}%*)^Uv zJ>yv>3*T2hed1{>qorkkkc? za!p1pjOUnaTOQ9>E91E*7r%`s{=0ZO${ZQ~eLRO`%Z7N~+!oJLDZ3+{k$d7fD(m)Y zjeYS96aRko;6OZ=rTxKp79Eb~AL)NYNa-E$Qb?V23375@?^1z&?q|Okj@GtC+xL>6x8C|J($2O1+RC zD<@E}N&-<;6DV6(aT+C1v2lW~Q6})ZWdgNYB`~UW0>8bRK$)%yn0h6U`9T7o$|rsG zTE7Ik%M*FGe*){I%76q60~2^8C59>HXNox@foG!<=r%fm?yAw%W@;jL<|dLoPp>ab&w7hXy zbFXTgthtfMj=vHq@OL6p{z;_nqeNy%nOBK?9#x#<($8L;>&eCOr4;9NUU5oPElw9X z-?}&_dKRZtui~8BRhIep$`bRUEN_XiKoWyulh`ePJCktulK4d{BwES@`DREGk7dfpB$|Jb#3C6nK8ar^Ct;tWIP*1UK@u5aTaiRl zS+OMv@Af2y$d|j4`0AG=?#ZtwlIV6OiSMQT^&}cRN@BL0vX;YEpd3vlDzO}|N|vK$ zsd6~|<%sKAjt;VPa5?IIT#lJidTco+O)ked>9L?3{kN85rR>{Tj+mbn>sUEzpDo8U zsc^ZRuE&(4`gJ`Kj8fcxy$?R>KOqn;6=`QQrBva+BWPP5ROskH`xcVeBK-@!g{G((x$lA}6xjj}n zk4xs?Dam{`Q+Y^@*_t~yneozRUNQq0B(qD>7ba6^rQ%7??~+-(P4ng5J;{_hm`peE z9!jR}>11X|zdw>mzL?DWa{6jAKi|;&zmj=;JDJyyld1J2ne)$7+skA&%7a(QTsNiQ zGpA5ADg{@86b49(qAB!@PT?on8I!{7*c7fxC%eWbq%c&<7f)fN>@JZ)kvCH4S~7*3 zDJf)B&|GH<4<#=xg&R^YJ%yPP7gU_=6w-52sFIh$-Wn-H*G%C;(-iu(N@0hrc`Jp2 z-BM^NEBb2e$0-b!l(8ucnxyq4ZAJ>qzDnV~6xxu&=v^tCl;OW9uU}Kxcq9eW(G>cg zOrhqf6sE}2vne$FGld1R>W0SONul)J6!tt%Vapp8u$HXA#flXul2w8FGE16kWlH!6_-R|Ur0si4n5^qQ=F zQ~_gTDh=fC=u~nOQyC@8%B5oUr|PrYR6cEz%FWKHWOPZT;d`kp|2UP0;{HnGR;6-Z z=4?ylw>_zp*_+D5%XUR?m{Xl7gL#cEtPuLQ<-ujm4$NsuT)$&Q<*DM z{z=unU#Zl*oyukDc}HXKrqWJ6kZBK6b=^Fbl@C*SAah=%vhBZAOc4(H$}rh0g^doH znH=nrlLZ}oTFAk^!VWTvIM|Tj;B}&dp2Z!^E9u}$DF;nUJ4i{^Ybg%SOL>QbLlT?j zV1#t^Ik5X3B+GR9BjBK3&_T;Q2VEs8-+^D2%0HDHw5jai&)N?CeRQz0j)TqOuIu2# zdJeA2<)#iE%D2rNY?bup4*Iuna9!@VcVOt?V2d1-yp9e=c5?7oc6W2|n@oJq!9t1d z?x0ll9NK zO5OE3{=I7W!9fu@Dm^x6%#YfWpB&8Hs5qPS^;UhoO>2XyBxMLnmK1()h+s<~MP2wW(A0$2jRGo8*T#oxE!8q(>Vk z*V;On_?DAXZ#(JG-bt(OP8RlXQlzJoV||zQp2<5Sos|8;$**!oT8ws5bd2(sjj~Uwk9G3iI41+7*m%_>7vzq# zpP)J>s*Xucl4X>^ovp_?Xa4UzDT3x%QW`M zcdycD{aP{qO(XihG}_@}S%ix?gNwIJE|!{I#9CYwjd9Vkm|jnGkyXM)Z85&#qL_@7 zgC$*rO1bD%#>F>fT@+7pajl#SSF($Fl32k-`&1W4Wrx#+)#YM}+eK=Ii{6Vtm5KfO&5jhxM*J2#UA-xp2!DHTx@Kr zc+FhoN!d2ayNBxO>Ee)FmfF2t9Q({g!blg%Qht<+?w`9jCx1!CXyr7<#b|jbdbR7<0}{Em$|6_wbopv^=00- zE>=mY)h>ND@8UNxtW!Vbkeru>>oxa#7nUDX=Z~uMC)FwIHo17d*~N&hE{^O}ZM$5Q zIPIe28TIC@i*|py`0A32BJ_ciU|UoKvV^``Q=?k(*P=Zfc~sNltas!{O!+IpA~?<8m`x?xwrR z^tpBKu$#^D!0%>f*o`gU%|Llw%T3|hZuZL=sZ+bdFHz)fUBH;o#(*&$1s zx%s@Mn_1GNm79)oQcARTGgfZNtTt{gwsrHOotw%XR9itE(Hw`)=I}=Vs;y zZZ7nde#(1*o9Xh6;W^ zZgCU-)lCDj9dMH%W2EUJH}6QP!)`os=!nLia5G9Oom6k+?r+NLPvv#VP1~z(9=>vu z^RH@>_5Z0Cc(6uz_*@PfJmeWYd~Nn{$Kv5_tA|jehx%fT@(?eh{TPjxgkm02WsY2m_0ZVvVOpGrbMYSPCU{6M;i3N<9=IZ+IwgzpLX!*UU3guos_4X=%%#?YwaN(U1Rg;{ep-5ksj8_uFpM0 zjrK5Dri}G)cASUW<2}rp=;7idEXWoH%mR4t#Q(Rj)(Ko zXs(9?Qf;1xc`|;!hm#BRe4&SSi&VFaU+kgd5)UhudPw}r!w~sGMtewE5+ zJlvMx?;e)Qm_IxmJFnL-co=@s!!Lh&XnV;+H+d|fD;`$KM(J_Q!*RKD!$a)f9=6EM zTONFOw6C}o&#~Po`lahKYmCjB%CRIzPGp0;BFQj);IvdKR^Go@3il(G9q8wvrlgL(}@YB^JXxegd9DF(^-_KG5P8IS1FwuRTQ&oy50|`Q>~un*H33wi*zow zOs8Qh<E!lIr%3N~TD+gm zUO6X8ebR9bO{dRC>0FWzMx;|>WI7#3rE^@q8=X#V*_&Y$0CewT_U`klC4HBCbO3hqgcrAaj}yQ_QYQ$xAbRBVZftR}tm1lD=rQ4~F_Nqhvk>Opu6zb)r zS#QmkbA7xd^;N$8yf{BryidHm8s=r<2+bMk)z1;FJ4VOHsUG=ff*1cJFN?)I#Y@9! zUQW;Oa(6^?lQ0Lsqs?vYpp3& zS9n=31=o6M`kmI5zt?;5{@`VijNItOy-EA9*~?X#zRk-Y+qEYE)R;IqPNi?_Qpq^AbMqh_W9^XYd# zd|Z@gIX?13IxelkJ{IQrD3b5PSjEQ=@~Wz0RrfJX0(E?pud8_Ve4LZNUVOAhq&aYjDu?_;Fo5Ae}Yc8YC~kAX5u$_)0g zZitWPLw$7nNcDfBIG_3$D#J(k_+_N>9Oa|g=gLj`jrNf_#>ZV*Hr7YmaXw}@_Gw=3RGAEkErm>@F``nYh& zM}x!a+cEX@gpbv7=A@4?ziCfS`51jx=g1WwHLj_Dvj2wm_-`MdNP~ZTOuwbQ65|~o zb?*AuBr~6=hfmeBXF6|W@e3b+zx46uE4}ugk3;wgNB9XD{nQt$$xpnDmZN4rl`MXG z754LqWEb&MTQ-X!+Rq14Ji$+zT$9K0Zla&n#r>2j;U~Y0pGFc@R^w!xoJjIhwVaSy;f&7JP&cPTs5&t&<1mcE|jXVqLkC01&URhqj-z1iYt*jB%; zg=x**e(vq@Gi0BiFMjcJ6I;hy5$ z_fz_z)_$b^K2v|6`)TpQPbXO}bzl0K@=85@?Ptcne$M}=^ML@ZWxFYW#S&n$H9+A4 z0h$*K@Moa_3DE)C#RNDae@NY80cyks7;g{oTB70tjE)a*G$BBx!~pY42IyBRz`Lab ztS%FvRM`M&(nMZLm2v?h905!&#d2$YAiy^n0q$o8SR2w>`2m(y3h3VX07-QNbgLI2 zwMjtt!E5~%0qV63FtJ@gKZ}${hX9*8DPHFQ?VR%#y#FzIjr zjs*DVcz{MH0(3tap!YwTcPBuPy8-g=X+Q1~0&8Khs)Am5e>@~Cu>cgh4=n-ru)xghh)2Pu>sB)LM69;u2U zo1H-nt{@-CUayY(gM1|0GJ}}26ibSRg0u_=S(X>%c7Bjm)q^ys7i4;UjcE|1MvEZh zTL$$Rb&${B405=2kT=@~IoB>oQimW@q*|vSW8Vqt+EtL{1A^Qg803|V9Ta4qv=|(u zi=2_tLxX(tk=7g@WZ-A2Nve(r>ffh9_DI1|L1um)#5Oia!*M~j%aaK~!jn|DY?%_& z@396kP7AVC4oUv>AdBS248@(PW3z(9%3--6jbWkFs4P)s>4tyTy5eVf+Y9%TOx<+@k7>{gGS{u*dhN)o8$~`NOVdDd*!U$k|NFw-jE(r z+m*p2cLu#Y8T^o*L9#c43fX#|lflUP8M>!CgHXc^(wk(^zi9^DT4m@SD8+e4Yj(-t zy`C9Zdu6ad_D;>9(DV!<7H3dviC$l!TvsXAZ!;LYCIi!t8PxqLgUxbfV+PL68SLAl zb+&7r9T|+>tDH_`u>NEQ<$lXx(HZ4`HiMSGXHerp2Ifl{{BFsltSysOk(opk&!kp~ zOisL!$y=G3EUlQyne0qPHqGQP(c zH&^7xEfuMVBR>XC#m(n8mN2ETX+xd@A>Iv&af(v0VC8%i^c%S)|s;qGsJJCe+KKe}gR6bkE{R4~_4Y z#psW+IQnrGl|ISh;jk=nhG+4OY?sAjvbZxVi;Ov0d?lO2J~s=?{4DA($YQG;m+nim zSn_oiH?oPJ6P+t(dKQnzNZSO3y#fX2$qz8cob*=A>*so|4U; zso7*q%chQWkt#E?89g(b=km_VY*wzyro^||cxAZUT$_z=T{d6J>;2hO`&Gw|Y2J0s zyOB+;+u2NelFhlN+01#J&9#C#xC-Y`u}BUbV{@n!m!qF;Ir`a_!xCo>#nN*4Dv-mn z>>O_ACo>;0X}nwz<7k&6H1^6{-)?#QM)xkTK{rLe4)$MNLiCCZF|%-p3q?ZwBh!n9_#-+*y_gWCVnghc z!f_!!mOb$y3MPhlRyw3>9wA-l2~EsSW+6V2xy?gdZlO6XL)3mN#H6=F&@RN9_932h2+^gZ;&us9 zrE7?F((SzvYrBUi(<4NFpAe%y&^ReNFht8is$WKq(7GeF?x+yokJ0?GA-a!KuO_Ki zlSBM1Ri~&YQ$xIv_h+lWb3*iAq?k(-bE#rVfv-X=T@_;Q588(xwGT4#C&k{V*qcI3 z*c#%uZ6T^}4^d}#h{=0GMC=VQ;y{Q42SZ#x65^?RcQnLKX@5LKquP3j{gs~XH zT(*WOl@O+LVwm5gR7rhZN?*&}GGQ{4!qh4k=2ZDGB~!vIuMnnxFwEABFz(DSH7bS~ zpB1KFUYJ9*!^GANGeSPE7v^yNFnJBa7#oGD(>Tl~aWo6_e)BMY%BI#~-fA1>J!$h+ zn8k00StB>vhw*d_vp`073Uls`#>}dzgYf!z9XXDbPDif-IK5-w*Rd zhI|m_=e}W%$nX!t{L)W#NU#23ei#tu!;kbhJj|=l!bFY;>tlFqOXu z(?C9#m@#4A9IIGzN?hZV-}o@`6T_63sluc%xiU^pOb+YZ3DZd4oEm1)v@k`dtCwibhUTn@8dX5Uut?8dp+y_&C~yo@&En#KNf~R)JN#coB#ZWI;l?oRCP4(v{_JHGdR z_kMqTKF{wt%*@_vueJ8MFq}DDTl3y4OLqJDO9G%g4cj7Y%mW;iT@~Cex7$&Jr=pQDBx{OU3F7Xl|JOAOp11(V39G17m{kpVY~07Z)eZ|OmC;9?0N z*99Do0^~7_K{q@=bS0ofWuQ}CU_(8ibbX*1?V^Mvpc@4>0NhlKx+HThonf_$+i~q~ zK>O}M0Tt^5sQNS30LB^!L=FZv4+Xvs13C-`Qbz(?MgbK@1M0Cr^Kn3DiWm>9rh*Kh zmJ95o zvlM#(s7|uOKmc8)N0f8~IC>PgMpKUgIaK^OP~#-~K&n%Kj^@zmGe92AJ_{@-^*Qdr zC15SJzYL_&Gs0E&p0dex4X8|isn~U31WloZH`v=eKyn8-a1Zdg50s>9^pqMs0O~vh zT2qNffPv=IkjKDes`>;-rj!48%JYC`J_DAL@;MOvl50~w{h=POfZwl~*Bg$fn^gTR zV^DTJu#q|!00Ze2o%;aXqq!e}Riym{gwco3fanXbpUzR-S0Ir-P@8YS4mv?2zXQ`r z_=EkVjz56`&^0sI042&TLAmRe~!zq9}e^qY#55nwn)1_@A&gu$FcV`v6d4G|!Z zPU-}hs~6zDL4Z0&0h-ee>Shuk#3sPyNC7la0#v6-lt*Qv`Iu&tBSwJCI04R86kuwC z0Ie$t5KviwmQ`2_IjRY8k<>K=NT*IU1=x@%KFvjDoTjMa_3oh87`*#d~>u-0q= zZsjoFMFR9*EWqw10yJ7Cz`-*D$j%AS{~tF6$h{?i<+cE4?+D<3Pk_;sDiLCu1lC?sN4;A7!vqnO6 zqBk@nS%?9Rg^)I34o!v7wie=KiVz>DcUvLGv=<_ylMsbE3sJ9&5Jh?lQG&Mj5@J|y zuE%fcwTB4NVweyMh6@omLWoy%W26xIqlCDaF2u{pLRhB?;h}cZgwRaq_!&Z+C7+o> zbfgbdYL*a}=m~u#?OY+8^Moi*bruM5k4i5VqQO!j9#H?~LS(IA%#}i{TqVTY)k3u0 zEW|33Z(&|^pW5vd;%crC4{7TmA-)_HqWUo*mQciTAqLZW8qOb1$4(02I>py1gCZ}o zpO=J)z9B@?P3BCuNSPhF?{a;z-xs3rLm?`>722BB4kq$UlEf0L^whd{6&~g4V5CaryEp8 z&9U@OBZ446guQfzyjl^)ln~()xyy=Bg%Bu0aT-OZ%83viB*KYc5pL3q5D}J;QYS*Q zP{yDjy9iEtOTVdyLxdep5kg%ew2KfSjjWL(#M5T_79~QbXc2aML^w@jydumZX`BeP z;zig`%PNSloqALhVK}{~s7fNNqLEdZ2PIY$p*fu=RSgjq)f6G2fd~z#XhYUa)96Mc z5e_sKLD5Qt5_FZGP@~o&ENsKxrEpGX_N)uzQ+`(wPNp(OcM&vcta~^gkKp4`A`GPu zqeb{jz0&_Rdz=XMGeq#8EW-1t%zcIkrkNu2o+ZLV`Z-$!`5X~$Ws0zPE_+QI=Zkn= zvVU}wQdaz{;c5|9Q^6V$TCNqLD;-@Y!mkY?RNKfs+{7M}&t?(kZD-HPxs!WBZ+3}L zcee<0_J|2!p?fFrHLjMOaR+ zzwx~L!M!Ui#*!jpY$RP#G2RvvW05z z?g?TXs4j-Nh8TTnavhppTa1W0Vl1FXb;T&4R`tXvT%T(uiE)U||EF3bF&h5o4UgZc zXY#)WHDwO8wV4=$nv0=rA;wYiX(h%$>f2h3!zp5XY|n8WSw|-xDYc6jm&nvrjNYkY z)afb4e(Kpvj1g2o?ml8Hqb<}njeR6%fA*HdL&O+Pi${o2W~3OqDRq<>L+CZx$B6MW zUCj5NVo0a5N7KaEOBbo=boObX7<045xR)bFtwmy_P@xs<*LpEB=)wju;x>x0dXpIS zHj8m;ix{e{Vl>+(MyLNw;qf1)?d&5p+QIQuuv3gZd&ThIC&qEQPL=nIF)>$+A0$7( zdgv&XIwVHU5$^YK_JMYt5F_lQ7%qx9#d=P&9{NTv&xkShtQddKi_z<%7GS3-` zyDo;}u^2b0+EeEBOpF?Dc#eD&<1y(!Gafak?IidjM%Ay}4~qN7zWk@scQH;<(Vt=r zrRIOd_&`wt35v=k=vzd>b6SF%^n#L$NwBcE1ciMiDDj_QKMC6VOOU0MAWrqKr(qI& z_)kW-1Q+xYG&XV^RWM6%nQGZ2*hyXN5)7i3WOYiAP3vezv;>JUJjO~O@JOJhxfLZS zSC4top868#lO&KgmY_cwnn(~stEr%=1Xr3%@Q}W=lwf~ruGvO{Ic+8QO`F5+u=Kk`HEXbYlqDn#mlf_ACiz&6e;zmjnT{DpLaIatTgT@s$#cr}aA|Fz%Ef zog#Nhuz=d^mZ0+<2{!JPpv*qbp=J9y|BwW04omQj)JG*~L`&$!F+O)(f|e&F*h=3| zO3>*PdvlICo@Z?r_&P~0OOQgVu1KJ{DuMKt1WjqtZ3&9yv0wK%{(%H_X$u8Dl%T^S z393A1o&TB7<3FOGN|66ng5miRI0_`FNSo>FI|+`x=bn(|vjj8g))xt?eU+f$f3kS| z$E$A=*nUWmL+fbuALjg5f?qTgQhcOnp%klVKmDa+Vkv4$q?j(1@|Q;`RCGx$#Ranz zy)9C_r%0O=D`+o?>{3*Xkm6vJ6osOtXiRJAeT)>XW2NwmlOmnY#7hxVUJ83fDWnNf zBvz852^Fm@#bmltMT&}5r4ZC+Y>KJF*J%=o>q-$-Pl_AVwZ0UalcWf2z%dP_m`zKl zR%4EDB1Mm;Qmk$!MWyCa{GjZXQtWOeMbp+&INL~Zl^)WN6e(VirJWS_+e@MAD8($= z&`AnKXDQUQzw5t}yG!wpoB^zH(7%51SaAq*pS%OUwHh- zlW|fQGNhPCD=2Bgzal5Hr!I^C0152@E zwiIpVNKrgfilcKmex4MWB*~JZ;Q}e6u-7J_Z|P*x|==TBZX|Q6lSahX$nb!8B2Z-jif_NMFczvJ7u$$Z%km3};tzt<{W6bLh+(8T#&HjTE0N zL)bAHUO$$h&l4GTKb0Z;8Ed1_wD6S-4PG;kH{9p9GL)efwDOY-r9X2YzHlGtIXS*^ z&F?a#{*YnIPuBBGh6tMeTZU|b9CxUOP>yLLIm}`?;-zv-q)Re6p8CjPFC<6*!g8pK z%8^2=ipilVF6VU-IS!G`UyiCOIcCx=wH)U(as&p*(LpOmcquvN(4Eq9j4UI^lCpCA zri5~GY@v3ca=a#cxEzaUJ;5c1#VtoO+8H6oO==b?$8Z`ICC3V?8ZE~e5_;sg8Yjoc zcsVwd=aGUc$nl<<)Z}yYDN&BLwdCkYE9q=)=2eIJ*OlWgrPr6^G~J-uNph^AcMard z)liPq|9s-{A0rz5Yj{&Ru8_959OFsSN{+^q-CB+!ZCFPKIRqVv2)q$d8~n|%$H*+y;4RT1){&aRuu5Dv(Q8D4%}PO+N)9 z{1q6YR3L+{&`6a6C)5hm4N%~DDFvLR6&P4Xffsb6tOCJ-3Un^Vxilh(>r-He0#j)L z-KQox<`=3!K$rrP=}Nc)74-@TZ3--*v33Q{IuwX?avd_qD6l$F0ZT0f`qozP`=0`B z>MF30g!P$sGRHPi;3BD;De$HZ*XyD{9+gW~U>fCiQ$XKcfgU{+xJSBP%%QIWzo>4S zg5T>D{9dQPL2?aHV9-DXUQ*Z~1;$XZ!3soEJ_&{>prnZ53M9}Lnmtm1A5?xcV~$rK zbs}Stbg}|zRBeg^Yw7(|1zJy2pwV;%w$k?*ta+XSzbRopW04?7fo`;Qkph`Z6zH{7 zfudWO2c6!^JhmxtY`X%5b}~=O-KD_W-Q0`4j79R3>=zZBQlRB&1+Jb^pu{=uA!XB* z^X$WQ1y;~~D!8dYT%H28sqY;HcGD?R-c=xkQtm0Ro@U}bLkvCkMV&c)(1n$6YqnIw7Y^2%2)J(p|TH#(a|bCa8~ufs%kz+O7_73 zifQZvc@sXS=%zlSAw;U0}!&*!)EdGg)khdm_O%h#y>2|p~P4Hp?dkMU{K3qK^i@k2I^ddGPm{ZQnS zAKv};!<-`icu1wg{85{3RrE(lfmAFOAIw?^=Ez*<->!(DK z{z}*eDlwQI(6T{{HH@)_D=~3|62eg&OY27~(QAwn`)E$O65->O=tFTcm1sIgiRDx= zQ;FDlN{pojSxS6bs6>3W5>s-NkStcBE_GhQ8rCWiw2pP}RAR<{CGJw014<+xRr2># z)^l8mb0?HYJEcUUb4o0xtLK%t{YeSkXC(rDC^7So68ESMR5(p4feK4SDs+;lu$3ZY zDh!aTaD*%h6+RbLp?onFrWIGAxUUM$D9}&E_s}Y&QH)ZBu__fVQ4O^UHz-J>!WLQ= z$Z_E+kB^iW|sHR!2= zwvP(!Xn&dtj|Qn=9;`y^VJb8np~52a8L7gp(JF+DQDGy^&rsnRJ)EfGhoy{7muIRl zaghqwsq-=w2Ch^gcZ~{)wJM~nQ$e;vh5FQIC)e7;I3(Yv!kk>jp;`x2*m+O|;UTVf zScR6fnjX@VqbgXBsc`6o3V+Tp=0)aBlc?%76=u+BT6|lDHx!bm!ktGdggs{8p0Kz1 zDzvAp0u?@dQX%-K3jIZDUeZKOmYLp69 z<4Kqra;q9ibi|>?6sH=uXrfDvun0AJ)AUF+%E$0IO7N($DNc=_^trqm^%K-sNJT5D zQ7%!9R60^yjk!(LcuWzk)o7Ta#v{_TSEDD*>!8MvE^3@0Yd1CK&_mL8S7RM{2dOch zE{#+pd5juMsPt_-HVN9ECL4>#u=Ssln`08nh{`!8+PiM#J9=Ga*6=e@4KhPC z$kl0}2-Tnhtu|}$iCQ`|7~<0KI-Ul1>9$9MffY44N^2`=@TD5ZSJwdbH2B?6gKCX5 z_|;5<9_=;QLx(zP(5#yVD=4QY^Xa8QJ<6cue$0j14bl$NU z*C61A26bt59{WWFcQu&%MT5t*6#-bR48R*ovjyNFY3%`M?GC^R@{0&S79~ao;1P9; z4nV)y034!3504cBP`F|Md=dgst|sHu4M1eQ0A4Q*!0+S$RBIf7u}uSTtz!TJI|V@8 zJpd8C12B??_u+GC0q9C!sAInXY@v$%10Wm_fKOC%1Y?e7%rOD@HZ}mAGXk)U;wLcv z6vm&*=cfnY?3@5-GC4Pk$Ls*4(65{T99tBC;)?@NY6%}x)ujPQS{8sKVOkUo*TQDi zA}LmjY&w>pg{+bm<;hZ6i-B~giWX<8YN4*CMR%%IPm8&k;WnDU?N% zZfJ3XN9%* zpkzV`bfCLUOW;bk5-8KX1oDoQ!@_sv;P;~(T9Bwv5C$rPaFkvef}pntp)Xyp5QH%m zgHWq}5av=&n;`7%7zAmjAe8GBgk+jRYX%45GtEd3Lc{SvSVUtc2jTSeAgE?A&O*+~ z4uYHHtAmh4tM>)Lb|46YY4MRDEI$>5cXawn5IWxs!ZvFCEC{tf1z{dtmjy#!C>TlP zqYcKd(!r=&CKv`sFw~ub(T0`{3P$3vU}RF+iNTmQJs5eEnjMUO`-8ETP8xmttN(G4Rzle zf>%dE;656HBiBPv;%5jlp~E9`71yDbQir(|6{y4OARQutbufqMc&&twX^=?=uT_Ub zHXVN2b*SRdVJYRfba+MQ-8yWF;%l@tMu!?6K91vKa>nb>y}S;_3OfFL((%6m9R^m> z;eB--KGxJBw>Hc{1rd~SqC-Y#wK2(Ptv}v>s zZznS6Njm(Qp~L7*=0R2FaqfH_CR48kIt<9x;RsoCbSScx@u=Ho9hT&BK6N~%Lz%NW zbSB$59ctdtVGgC;(Lr}#hn{rfi4KRKbN&k*KEKuB_h%idebM3WH`ex3hu!qymk!Uw zp|DFrQQRjKrb40UPmPL)qML6hcF`ffP|Q+hEPa}P^8n*lA$P8Diobc zhvHReDBNM3YY4?hiZh1dIVD;{kx6P7<3xwT8WW0&aiKU~B^16@Lvb%D6lsk^aga8) z2u0z}p-86HeK>YlCJ#`VZJClo7|hvGdI*%6A2BcZrTqfRle)1laXAr#_^ zq3Clp6jiT>Vg`M^6^f(>p~$9n&pAFn6lDuSaqN32_LT~QtaKReM~0zTR2XW}TuSnW zA)8Vwgkg8{Fo;`(p=7@>)cMDfFl14mV_`_R9>#mu!tm>97(P7@L;Q;{Ovn%8=P-PZ zHhl_%ND+?O^wKvRvD$Eqr4_;9kU7Hn8FV;C)(^+4_Tg}M2uGbR;aD{+93RQNoa5Go z<2_~NhU40?a0DI?$JEQ=*nTY>xX$Nqha>M^I707-W5LsKBt8qrjOXFVp=U3`VR{vg z`84BoIPY%@N7c9CctqXuIkq4it*AH6`Vh|R>fu=XF&rN#>qj_p|As>>(4!BHpyO0j zq(=j>9!KbEVLe6`(c?r>JtB(fu_Hi_-&#GomC$2BX+0j7(Ics>9-%ru7pliy3eoFv zj+90{#!!k~50yg?9nGdYPCXJ`dL+l`(TRfM^>ENKdR<?dnOJ^D4$;~Bkgt%tCU9{cDl#ii(x-d2y#bhNV`*Jx@N zJ#xsms~(M0^}MG;kKzNF&mh)Gmxt-09ic}C^%|weuF-mgkI`e*cs=jc)T7k|J$BB} zzuwQUbNTfFu5m;U`B6RU9Mj_f z6*|j3IIl<73wq?y&P#gUr>V!fD|(c=s)wBhQv7x1eM65gROqH2mF}^gd_A@oaIfC! z5kogV>+$`E9zH+WKe|d)e(5p!H_rn~5*UyrG{8q>z$707t`ssLp|An#iW$(nxB*Lj z4g9>t!21XdxJDPs7@!U`U@XlDGT>IQ0o6kcn6Kv?>R>RSAH5)}$$)&j0h(w7TE-Yq zy1W5*D;p3})qq*Fqq+gVYZ%b2rUBb)8_>Fr0W0frd_4me);Hiul7aX97|@ya(Do(< z{Ay}IYBK|#HaB2u3j?mVG@wmu0~&WVAScy;V%-e5)XRW?J_d}Z4Fe1~Km!LFkU`;t z4R}7nfN!*AqydM?HOhd&qYZdX->6->0p-RUaGGvXqYMLzPhkGEn@&*Wi3W6;WI%uN zpUj%*9_3T(DXe2E>zHPMj>b~QIm{)~fSU6Rc(%X*b2j7WF#ZYy%C2H9)MX9xUTZ+B zb?h@O*=WGaO$MymVZh`)23*~1K&5@`T`r$HV8FhE2JAg#fba;{K4n0i+gzJUPYed-) zBW(1Feo(5;h^?VU1cw$qZH5u9iAG$RWW*E7o@~Sh>M_%Z@OeCD8F8P|7BDuIUuZ;KI!uZj zBL>nG`o4^PT5E)4y%9?`7_oM<5&Nj$7S5w@6u-@gjdYZ(dyHs)ko`Gig#Tf#MKezr zvG}|ZTPXE{5kn}S+?TjNRQ-k#({36u;I{xzZ%Ojsc>K`k_)h1i5;5)+hC6N>wpknGRrwI)QBG@&|)N}1qK z>2$WV37#@0v<)<2O*s=v1ex$O*aVZ#gaxDxGof|32^Z<0!33Gfgc)WN!rdnHh%jLY z=_5_(8D-+`r351}4N&xn|5emGyKp;T%1p>OD-jG}?rKbQ5$GGS-By<4nk-7v#=hP7_SXppP_Z zk_ihbd9n!|=@tb}HDT>E6ROQJVeuRjwoqy&=TSbn=b2DrfeCY#n{ao93AI*o&2?O# z7OXd69hKQ&;^+A$TqEHY_LI)hU8=K{bGMlw-Of69vd&$sleX+J;rm__#_TuY!Xegn z#DtPJOh~!O-rO>w)dLfjKm6C_M<(2-?~nhL{FHn7!h|2x`6c(^l?jch#v2o+zcoRS zZ^Ebo6O8Y;pY(;K?@bs$2R@i!{b)j?&+Nq)?)x|Hoy3eCQZqtjW}KCq;qPO{XzE!cGe1u<m&AeaQjJ@>1Va6e^8S;2D2GH+nW)!V%#!0$KHENhKy`~w0L^INA zo1v&rJLb1){Hje%zSTR#&!zIU~eXv zd7aXXs?!*67RSsnV-Ve%$9~N>V;Y%r%;>wwj3;z|CHuSD%+KQ4yA5V++-OGGO=eWu z!hE-y@soON=RWLUt^3UIo;IU4$+Ye@_Gm9pR& zbt`MZwm^;vvLH3gg00~e1nVsbG+NNnWa0hv7N{#((4w*h=jcaO3$L|Vu$ea0vfy)V z3)R2U~c} z&BFH&7R0Apu#t|8v%n|Af z!F&2Umpz%sanw4?g1c0Az6EEf(gF(>(By>{T+Qa=91B`4V%;=(i3KT3Em*zG0_}1O z2Ge*-Ut_`9wcLYs%z-Mew_wr+3+7SjjTW@q#D4AIp6#??KCPlEyDa#*--7SC+@pgQ zY@+=Xc8I+@!nj8*m`#O_Sy2DD1&8SZjXA;nJ;^;h#q)sjXz@7Ezc;4(x9&v9QtNK z;tva+%dGs|#ENX%71eyLkZG*=QkusyRve;Blu*`+34vDppdLY1 z>EpVNvaE-M0Jc=TGaD2`*|t@vBsiYgTuGr`LD z$5vEISoMAi{n=#2 zgUwdN@33O*PAf8Ut>|{iifxw}=L*N` z;RyL?Y#2nXO4zWXqz&p)Hk=8u!7tQ?Q8dKFab_D7F^|B$T5A#j4!7z;RhTHIKgbh>2a8A07KS#Lk1in6r_0a1n zHaMo)u!JNtY^XEKh8uHixSMH1$UGZn(Y-7ibPH^lO}(;h*p*{L_#%#>kR=>LpO)DW zyTZnMY-~ta$u%iqwGCUT@Fp9QHgjEixzz^Sb{iH^`feM{d$q*?90i5jVWqBmJ2o2Z z_+qqUq}h&eyPbdEV#j^@7Gp=ehp$s(uN^sYb`*=ZLsZd@?er^wu`1g!i<~v=2&u_< ziFV}C3p!KB4!?SKjG{~R?FeXK$I^y&G;3wYlGc2!jU9DqJw>P3(Ut<*+F_(PYSY1v z?sSk$o$T<^SCVzMV;~*uVu!7(9W_(!SVcSNXg51nc4r;ESw|n%L2u|xnjJU))3=`; z=@j4JjyiOR*9of_D_%q#(tuxr8nRc99Xvd9gJ38j@ zNN*Og_QmYw52JBCMdL{R9l^v2bc3yAcdRy&KZ?mJ<4m)=3v?F1+ z9rgFyF)!B+#R0}WWJj4Jc1)qnvv%A&XGiVx?Byk{b;XVibn~hm6RvTeuG^7ui|5T_ zJE}ZoPwC`y?)ytShEwg=cFcam{UcGn9W@H<*h86L*w3%*-#4C1wB&~!FMrz6B9H#@%TzuW_Kz_6X z?pOzwQ=51PR+V?aS&=zZXAU(Tn4IXq&w372OmbigDH}P^EZKoGl+x6}d$b*Jwcu+h z4t#Ix;NJ^6u%?#-?|U;|9|!6Wc3|ER2SSFi?nw@`ob14P8amT~qq8`7wgb1RT&4rl z>GoWHo#nu~`3{s^%Qe<KU(P$wcn)J6GaO-(Xg-+4~jSu;Oj&yKPN8G9jfW?L=~kI zlT}XqCLgsE85$=p1~^e(>%_v+PNbD_qGMSnHUv6RrkoQ-s!uBJhh6YnFO*yQ0_@lLEL@8rGxP6X9-qI04X;q{%oH=pY_aw0L=iK(re{Q1N@+BmVN zE#tL!Vp0bul--F`J)BStaH9D@C(crWp+^&M4M5-ia}joH#St ziP$Ml9GS{oraLi+HqUk9+dL;aWwD+GPCQxYM1ySByvT{Gi=C*n#EBBioM^M$iA(g1 zge#ceN+*I>J28`1k^e^4aGEuoapD$LKj*}>^G@J`6GJaMQTK`yU9URP<2C2yJCR!8 zMEpDM$9pGyzdF(Qn-eE#_YdYRaN&f=g`yG{hS5yAL!YHCNM$Y@q>EHh?m~vbg|y-> ztS{rjr?M`z3v^*qkPD51U04|6LJ^${x-b_~!x@A28e9;XT%=Sjdx*PWfy8Ex-h#I$JBPAN+TC0C%gDLwhQB$xNyFy3r(84kk`tE zpf)bdph|6BnApz6>sv0Y>hD6q02hAI#DOj>phkmS=s-8A><|~$4CR`mTo^E#HBrJC z7k_7U;TRPj>q6!@7vvLNs58lh1N3Ez3*Kq0oA%9c@$Y$E5Y2L7Kb@oa*)A-i=W`f0 zldsKnK}qN79@U-4m{~5!=DQHHz=e?uU3gDf*)BZHVZRo$*DGASM#7kMnHq0!;dU<9 zJmA8~gUt0fb2;IH^`wh`E9T;7Z|v`R*7=b6Kjs>AnY2$?6Lop!!sh2LcwV}2^rH)f zKD!V=ljzD97g~N}|7C9Mle=M3xbd^N8x{TBs6z)xs&vDjR#AbEx>01d8-gWnR9njD zS2Ndj%yqpRgEqP$-swioU2g29$GhDy>~-VBKCW|s>l}1r;&JA5#f`03-3Y$s#-f|d z|CSrcx8106&ke~#H*QNKP);6!b&3cGN<^Sq$p~C26@eBJ5m*)(ft%40NKcBu*#;5t zG>kw!+DMmsMnKy;0z(HypvIC2Okc|R%Oaqr6xy&R0-x7Lz-J@f=e!3I@IH?~R@q2A z42(p*a*?=|5Q)Ibktm!PiMZ*JNS_gjmsyeMxi=C!_eG*&ZX}+bjfClZBo-+SWbILH9rc{g;A)L9fkdLnYu2E!qSydc(p1DO;<;u2l;G_f_h67T5OHN zIeJ8&_eMc;Aqp)oM&Ud?ra{;F^-adT9ffqd{2&V2N6d@1e2BvLk5RbtBZ}u*G;Ua; z5gQrJ`<|mQZ7d&;i^iPE(WpB$8ky6gF>FROj?IjQdsZ}RPzS0wCmI=<(fCg7)<$FP zx@eSK9}OFgqF0-uVc!ys#q|4RG%B6uYnM3h8RtEZMzy!mnDr$Zd0(TE^*b6*3&+4z zGzO8yVvwSYL3woyf40T&XIl)G8e-sYjKOke3|2(P;B8C{CU{~nB_#&e+QwkpfEfH7 z7=x~ZVsL0m4CK>d@H{&PmPIkhrmmY}uw`=$dhLusQf>^g4#dFcUsO>kHs2gEJ~l zCKeN@Twp9Zm5W8i@K}s#6wCKXvAowN7Io=(lUTe-iG{OWEIxFO#kDE1C^an>lW63U zSe#rMi>PHBzakc+R&oqUH^rjX=2#To$#wH$vF&jzEKpHol6* zK8k!Di(zkKkxzT_Vjl zDf8fu+=K244>F5-aIcsLuW5F15AOJSkm%<@8Knm&sHob5VRTI6L1C>2-^zM;9mKRYjTRb>x^}u8EAk4*e+#U?35)mG>iS*zSwTks%g~tQ6 z*Mm0|J#bd?U@29q;=#nK9{i+2)jgUh4>q>;;7c11I;1de2M;QC@?Z;f?&86wt{w!YdJx~s zgR#9ij*1WPAbB9`r}QygH=XN_^Q3crazZ2iI~vsC>YK8b>{te#`^G zaSz6v@!-r^51w7{;45vu=)oasec6M$*Vs=gdEEmeoxb6L|7{PN=J9KqamRyOciD@3 z9;D=Z(1*+g9(ZXZeR;>8yk`$7>6-^x-#zg8;lTlTAr*S@NajVE0595Wy|_kYO7rV7 z{F({^y@&|%qFS&Q*F(H09qPrZFfaPKyx8yd!W`j6l}IlpM|qJL=f%0|UMOpNF^0w^ zdU3v%7jd<{5Y_dfMm;a~kiLNzJsW!Qfc7-?qD6Brx=^zgUMy+p#YTGG+6zmH7ul52 z){BenyeQwE@jEbnC&s5^UA-vW%?m9Zr9wTt2%shOvZohcXmD>Y4)^im0*&hH#i=yb zLEZa#vAw?+eTVWm%8Os4y-gRYdZ;=;`S9q~)gBL$HdLi89MZ2S3tUbmap7A2=I%~V(#rKc-(QU8o-ib%QvJrG|~-upl`Og&W6VP!o=A z8ix_BMyhrmT~=(sozH)zZ1IDB6dht6x`c)dCf;||5) zD?NJ}2lMkds9wfFTqYhh%f{n+U_4fa#v?y09xcP;(ZmpsMaFmxa>S!t`*?Kf5RaR5 zuUkBHJ>oH&s*H)p?9isAyjoW!K${GtNAu?m$g3Y%sFT8cfb4H2WE2S1Yg?^zA4f3H}P>jQ|1!w&)*8l!^tGOcnw~d#8UR{v^k+4r@8{w?jl*ApGZh_N< zpm1ThEq@k;qs3ucI{cgk)*SVf(;>*N2F0sG*G90aF_dfqZDfN~Z3;alsTpKQEqSk{ z`pSV;@YOpSvnO=!1$U)LU$75QtbvL(2r3SN?>~a4A48Ws18b>XCHFY_h+H>fWENs&|Vsf?F-r&Zf?VEO~LUx28KP(pr_YtrIR zXm|2?T5y3@g1P#+7Xe;Zbr~b;9_eF5LVg&J75!9Bka!yKRYhR|xjJyaARf%9i z)d<>Giy)zT1aH^SJS0#nf};{wCxQ{uwQdBf>P1kpegsb0*FbqTieRXWl3mRru(gO_ zpv-wYf=lg`e}@P@>Zn@E6>+>1!7TZqO9U_9ji7ti2rhJsAi29@^;BJ_MlfYs1cvFF z=llrHE>NxuBlzH}2sSQ?pv961b{vSnawviU|8pjSZD%9!{2sxT zc_eLGMAB7m$>f%i3~UvN`Ay}}I+Dcpk?ijn$piVIQzXMXM>48wBn7%f()hhd3cVjm zaryXzNE!@{>l6NLX5O5%Os>jPNt_u;a8@Lh zq~Y91E=b9*B5Afbl0Rj@*OAO#s+iwI^3AeHZZD6d)Ax}q6YE-yEf?jTpCUQAEs{&J zZf7J{_&uPr_ zk@zo0Qt(nFm2XFK2S2e$kZzQFS23iy}Ft?C_0)-8n zD`H@LQ3La(P_%)jF$Q+Y=wb%uNb^_&o#nKYic?#;7jGaU!N6uYAmKyBZ zn!Ts^a;Lk2{XG<;mx1_xn)fH#|5W?K416RHJ~!~6^ci7b+7||zj51JcoPiq?l=ox< zt|x z)LN}|Tcf&4)b|Ev{ir%i@F%T<+}dEE(MAK)HyJQ(HV`9CWy2N&?{8I3;@+-nM)+CR zh8*3cwb-reXOGr+ujaPTK*jwA>K@bFB zlVV0)uSQD885y2vFMqW$jEF%foMp9*l zoX;^*FV{$GIgw{%StTPem5ubOYGiwDBknpz`qou!nbg2YW z+Dec2j2shJcOxJ4Fw*dSBU|PDK1M#3yOPn@$P!sAo%*R(5*(oViE*frPvomljgzWQH2&VmFKdn1*BNQ^gL3}SNQ?D4CwG4`vT3uCVq1*tl~YoEtC2C= zjJy!*cI7U+<&B+27VOgc?bV!R!#*Pw_8Uo;%wLrIugYDX$=?Tzj67)Mzr#lQ95wQX zBpuf^Ahs(;&Pc6mM#f(^Qs~UmE#H+Wu$c zfn-IPC~P(HVIh;QM-yk{FKJoC#Jr*=3Pzi_R>8!mR1-%WCR(ML=q#1pChGf4{3P%B zO$?U5#Tzs+UslTGY!mfzw9PdU5i$`cGpm>=+gRhtrY0sFO-)!^nHV6>H%;Woa=F{u z#EG^hF3FR(O&srFVtOYNuVu|UCU%Iovx$CPOk9-*a{fIN{kxkuC8K(nm?hSpCK~iI zu~iPpjJ_sHd}yLWKNCk~@BrmC(8NTkI>~rHCrrejG+{n#qO~mi z-9(Xds?!Cv|IjArVZ%uF(y^+S~zyBxEc zIpQ|+fyc~!spvDaR5pvjZ>DCZnH^bX3S^sUB`f59j+yqkW@7TpjF1EQW^yW-@mDcp zu4<-UH8XEY;p%3_$%z_fs?;BeTdH!<^lQ!{0n>3DN9(`1p2VG zn(5uz%s~KB2 zGjXzDpqW>LmCI0#DdUDKw-MSOY3Aw|W}KtU%#x+je6E=}^UOreH&a@2q}c-HwNPVA z@9)fXUTtRGM&-51jAgT#Z>8rJ)pLhx`?Hzh^6g$T_x71-w_i0pV5adw)l+_x&WFt; z-8Iwgo|*n~Q~VFid?n`|>D&`DUU}oGnXa7QQfA zcp^57g@#rO+hkoK3+BQW>J_mtsHlZQQY^+o8F3b~@Vz{ZwQ#Y7h1caQv@UO9VX}oH zDHf(z&@ow)YGH?X9TxgIEnJlclI>DkY3jDnNsdc`S9!=ZiSS$KDkTCI(qy*$8B}iR z7T%K485W+)%1jGeB(0)_K3QrbcO)lA=W{K*5w_?vn1zaY7HZ0Rd6jRWdnL_D!nG~T zlnZq%)UT^K$dv{bb~dz7sgZ>}QlN>2eJw4Vl;Lk$DBs3{UzSQtTMMn;(s|k2!9v-N z7T)b-;j=Clu1Q)~=ge#e*r543R;OPY^9?tD`F+Ss8v5tTiGd=VpeL}txS=# zaaIn+TPc%ZrAwlf)Hke5mp@8c`K*+cMWwC0ma1i~td)0Cto$SXR4WVRJ0aaln+z*I zWm-8SZ7N#%M22NqSt>QNtsIcZkd>2pRvzYCd9$vSRr08wl}`1oyf5F#!3N5qp>l0x z<-Ck&V&zvkEe)Dl`Bv^Vv(m1)#%OKjge11L@}-#CS!pHn+gmBrLAiCY67jCa?`mbe zeE5Nt9b*2_NGJFslLw22I>BTl_7FdeCw?&kRN2yRx1N{DkmwnOY@TC z-I|LW*`sUYfRza+t=y8pDJx&e-QTUebxzlVSk7DNFLSP_9@o`RPD<$;T2D#+OSO|t ze_L_fw2~>S{;^Wxw))AIJ63*?@I9@?eXY#{D~IKZ{3`_>T1k0q9=t(U?VrEam1ZtV|hIrp87UE zY+%#BX*N1Evav-Xn<(#=YWt>*qY~G~#;pz-?>!smq-+lx6J=XZ8;)K!diS<*L6Z9@ zhYxMMl1BY(`uEGGf4^+(ko18z1`o3Fw^SHxW4IInd7O=YQfs`86>@)qjrJ35w3uXLojjkcInT23TB^=bEQwfPqo=G} zXk*4A8+{hrD7;pA$gk^^#}794{Ai=VPs&raZLo2Bqt;@xVu^LX>Lqu7vGMk=HclR} zQT&kBQ0B{t!>Yq68%yP)+&yC>@0^VW^5GvgHp(v&d)`KQ>3G4$cQWOot`}J+wg0p+ zRaRcI@l>A0Mp4xsMg1~S%#=fNBPWVLZWJF$C_jp$vaxa$m8wMHtRBV3vb#nU!J1Jl zs})7lmQf6poK{g--_*Wjw~oTmCW;Rwuq2v~`eR2F2&7Oy>DlO7L1VgZ_?Y)y-(0%P;>#Q}}i?Z%W*qX!<{hW~a1# z6wSwvmG9GN_DlC?(M&ePa9);0#W1Wu42Ps{!59`6is2tQUpPkZFEMnKUC}WNh>hWA zv6hHo%77Ry$QR$~_>Vd+(VJq}B&N+eCr$RnFi%z;Rs3^`FKhmaq3Nv{=F6~q>h~~) zLXTp&_d15@g^F=WN>(UF136oz80D)LqgKyi^c-A_4YF}qF-puRMi&VzFUGtz#rR9g z?=Qy3zZK&bxp1Qx>;EoB#LZ$1x>JndFN<+Re*Cu>EB`CTQ|Ux3+ahDJ8Djaz7|Xw= zSX!B5Su7SyEFEN}6tl(>9TiJkDN;o3V`6D0gYB`jPl#oOIEu$Iv_vdvWn$?sr&D6- z=8WYBsh1YZfj}&A!C3BR#}dkk{uSnizR=4EaMl%V)`nUM$&DO=CC4`q?MZYPq9qi8q0Yp zwLO-WyJPipm*%rKmP7ku>Gw-4Ee^%tY<3@tb{d84w5ww0 zTiH=nee2jcSl3Q`Jv$#rn+A6MOk`(ML+v+KA6e7H&ZQQ1TrKU?ZKeF)w$oka^s-Z< zx1CAS?0q|leeJv>Tl?9$JlKwVh@JKy+iCu(orMzhnVqwr+bKWX&T5%6%FcDUG{&wk z&J=SR#IHt=b zN$eHJN(m2+<4ZaASsX2g$FWEnjMUg)C_mXNZ;y^+xeS;b$Ih?gD7aKHR>U!ARUErz z@wzw~{}9JqF>F$8_QX+WZyco$#!>1}9NpxWOh2N2QtLO(^-3IDrQXdrlJ3RPQ&v8W zW6R4pEU)79IVzq`hIm#i;^|N_o|UqpRJ=ax$8%er zmx(94T)e(7i)Tjpc(x_SV@rvrvMhJU^GMzf#4|KKUiYHnIWND5;u%yWp53ydT0Bo` zseSEuXdKV$=JC3}8PBUW@$~K-&nDT~HJ&y-<5?;T-d8?-;%O|Sq-B5QBJT`}=j@Pp z$`6fawRHGQxk|W$!6wk+UO-3$==a_6;7SGo!;<+amzl$gS`*=Fa zY#H`LJcne<`gq>l7S9qXyCa?vd*V4NYxio5eerxMf&Hq%fp{)U`-AZ;JRHwI(*KCs z9n;+8%j5AZJ{iv)+3=fUpNc2pbUck@`8m}~?w*fl=974?$T|}EDmH;z($AN`4oUPU z&^{x9eG-$Iz-*~kF@ej{GdqF)xe4r)dLeBqCs43T0#Q{HC|g%?8YNJ%af0soCGfgs z0<~HtFtT+5zrCA4nXU;KdnJ(hK?0x2Cw+CSUjp6biM-oCfwfX)Kmw5i6L=&gK2^-m z6?1q3&qgNDZBzn3Nd9QWAFucmbbL|*2d5_xKSO0N%Mpzw@kbNsD6?hk=|oP;8<*Ahs@low8;R`rE0F?!Co=h;MCv|DWV)1j zmB<%S#W^nh?8UjBTpWK&abD*Yr$p7_bdmF|i*ur9aZ2?n&beJ>nRl-&F)zyUmKX{o zF(@{P-SW3H35P$459L(lB!*W>qJEPkX3ByNNo;;M33JyZ%Jxa3rHq$vha~Y>CXYy> z`Ikv7l;Pu&_;pee_Q{GfPkrVmks;RQNi>z^Taxf?PhyCCwJV9Qe@Wt={CXmZZfBDC zLE2wWqQRpiX2~f_IjjZB(Nv-m%kipYIckQ{NZ>87f^4#22o{Zh)*>$Qs#b1_Z2FYBO^rFesk4)Iq!<*j6W z&zMZBj>)+CBr`zVLv;S5WY)`?&y%@5Mmdj7=HJQ5d_F^YNR3(QJ13cO(r0cm1Lr5R zOS}t`DYQcIr04g^EZV02^6s8wN*zq5oA?eTQ}=W-)1}`Z$s}J)=6yMRHJP7psQ+Kd zJieXG>&MB|dXmifXPVo~WH!o!SIJyArro(FhX{hNTJ9ZDReEF!p)QvGAgLAGlhqemzKf}spm~$hQy^SPIe03 zoD{0$rLea~3eh!FxX?6(eyvj2A*OgNs(kH4kDDINbkm2($T zNx7KH+-s@SyPnGA8>uXi>wl%?`abvxtNB2@YN-I_O#4 z!Q7G#u9R}nw6ueiWF1R!a9+wg92}C^GzY__qu+r&;2>G1$sa)n_0k=*%yZCHlJXq{ zWQqJ!$w8aS4*sm|(BDS~E9yAdEbh7vKCI{9s$6dB;Guli%)wUiHh0j!g@fyIzrBOV z4i2`+LCNdrU_>Vek7ai^2fxXL_Z%#c=FC900%_}DWAcbryT#-LE@(lMoFJx z4mN!5Aa%HdWnVh<+@6DWqaFM-*}=b49Q2y%AZCt(k#jZYc@Dz!9Xwm$Apa`|zb(%Bbt;q%lb2ci@ zCcWOO*W2`ZyT;h%z`EN(!#xhROM!!0gToHGA8~L_emdsRGkXqJo^bHSNe6xzB>AV5 z_h|=Dq`(;m)h=j0cO3k9S8H|8L5`e$?BMwe2T?CoKRGEiUO5=|TGxRzjc_tM(n*xT z$=E0-Cki;JTF}YLB2L;Cb+S0xsqapldZx_DZ*ruRlejWYM#|(QCuhq!sa@X59EbWy z7pIf{@|SpBPVV@f#AiEsJI6`MN>0vKcT&Ellc}=4wv*R&ob;^g||aOCs&&~_1uV)Zn8;!eACIR)=qk~adNG#lL>D*IrX-a4(*+^>h5Gg4<|)>Iyu(I zNkU&IU&^Y1PPWUSK~6?V>JTS4K6Ua;)_&&XXGtICWXR`E{*h<$&Il)EzjX4eoRJoz zoD?0c{AHuOH&!(nr+LT)xg+hzEB6V?eWH_O87c2h*Z4D>)Sczz`dlaO`HHzfF_$_i zy-fMbd*3S86;9f%RBdI^YA1iMak6Z^lX07zoZRfB+7{Jon~rUFvSo*p%{!e$?$X%5 zIBEF1#+KseoH*s5Kb;)BqB_frtIA0duc^&-Cr9O)G`i)a&3)BTQXV+Tlx1@Fq4Id- zMY53%(ypSHrX{<|0qg;hFvShIV&qgsPBnoE&}iYb%iOrtbvHC9{M-y)5ZZ>3S9T^eI#Sf@0mNd0$oUXDmymo!Go z95MGu=_*}yM)K0dGc|aQdWsE!-n#S!>X{3)y|(AYR&dci)x}ZS z;dEhfxtQ#Bk(%M6cczP>;;882{VbQhA9ZnC?&Y|s7;^EAl+1VWP9+z8L-XnB;*eaH+Pz&I``kss2p7pxex!@; zU${6Ye@VtD+1l;TlyRqiG87Qx7xhY)R&3-u}b?Ug8RM$;JJvaRt zxUn^K)2NY~9kRHYn=e|rnJG!-->qlD+|2mE&4s?wPk9e;Gflpgyg_c74tFzqgqx_5ZaRG7)@KekKT6Ul)n>F? z_aEKVoTzwH)n>Yz!E$z%>NUsBL~$>0^Wj1_SLNb2s_$~QzBgCxR=HWd+D+*-ZmO+S zzU$n)l-@sT9oB2ETik?yb<;qs2izpcXlZ)L%{x-+up5sYI-<5G+>De;CsiA{`(fYd}H!($L!&4i-(ZSLw&JCd5D)$ zaEaahSVGp~cevH~nLNO1iGFvXidT4C-Fg4D@xp)tC6FhiJc(8x@qje8heOG_tHH2 zT;L&pgoo9#>kAK2qdW|j$zwd69qXa?I1e)?c(^!GIZe`dQ#Hmk4^L&@bPrc&c(^bB z%~VZhshzZ+?cuyMn&aVsRGaHzu8f=K;pBYnFYwTAq2?{)7J2Bn*u(NA9umLyFhstT z5#M?^xI$~NQaMQV?>vlM?DXCtn@%@Yi7vt&XUc$2?3r?jhoY zhho2ZXno4VuTuGphuf0=yN4w*`VSAs&g=LE55q2c_~lOzZ7+G~CXXd_#luS3C_S!u zI4*Z?c!>Sm!xp)D%Y*-p#+K{{9zK2O;hwyfN{>`a`S7ua%}=zZGWe;7ozFbfd*R`R z#jEc_yv&z1QC^-F@bYd!FA+t()Qa|EiTCoPq_(BJ?380twX~PfWxTwQ-br58m-F&V zc`rp%yc|i>*6XFE&&xi!5%3Zd^zvr9mxLT`!(JBVsZG9@|0;Q@QAIJUdiA;2OSO9H zU*F5j7G5s4^wO}Ea%kgaLR&8lI(k{$*~`r?URuBFrEE7ZUElL^MuvCya-fHo+@4;F z^!C!?eJ^|EoFw(};vDLw&qrP^$p^!|lo;Wq<47;Z<@-@yx{UVn-5A9l@5MjS%U9B2 zs+VQcl=E~i=Vy8;KikVx`EQPLo~Jp>%mvDGq4NAnuUB}nuJr18Xw_$pmp{MvlE2=| z$e+B7+UBL_F)u$HSDX`Sb53o}dntL<%iDLne0|r8{hpW8kGy>PSao~irQ%b~`I%}g zm0u`NDUFXV5k5}IR)Y_t$;XHCuEobHtB+DPA3^!Ku#f(+KE9C3cAx$|@v%#y;(ZL3 zcEx=xE#V{X4Ic-}`-n;LF-(TK)Xwc=x!1=%pO5x_9|zNY49xJcJ=3S><9+-tWwU)u zlA)E=zKX`I>SL!gspeyMbsv3dD3_XwEittfTb4EOakruJZ0@6UJI$lL<{|&cur59d z_43iIxBAPuK0cEAD&KxSoF6ORCq7<%>SMxi^%>#Q`-sLJt@C3wANgmzkHAD9i^Me9 zN5iQ;PEYr7euj_ovwTdI3$uMB&-F1)`poySVS$g-g=!<^7paXrTH+&jsZY<&_^A4g z#+0hdeXNs$YkV~QUgOH&>wNfr^s!JzZ1myYq;=TrtojMKAxQO5kBwZJNf*gk6-`vk#kA;%Z=+k<~;Cm`JviB^6|-2 zAA6r^ynlV{kMUEhte*)8IHj%0>E(@{>8*&s|wM#!uU^eqzV@*)ILY`*Bb3 z>-Q)8%%AAz-${PfO;#PI_}M?t&*}Mo-d&)r+*+twEz-HgT7$1uS6L~>rK;mMTBBut zOyBx-k3{3F^Aq=jpFZpTZ1~Af)s23dZ1pp1n;+YD#oOtp)Gj~cWyV227Y_Mpa9DLZ zrW&5`vr5jK^fUT5t-&cjqt5D@xZscQC2*NH58;pgv{e%^egWB>U%M1XKafRG_TeX$q=#LFl-Y6?)v9H3X>0G~*9 zkpQ)2vqVM*_&|y$1W1!>@>t$Y46v$rfKnv_8=&Ue6A&a!!B}D>TMR^F?;`>JJ*RyC2oQ5YbCwBmP7YiOa7G4S z4zTk|0RPnhc`{pmzotBHC?}aOcjW880^IsLK--%ETKyB?{W}4Ex*MRvJ;k{np!7qH z{YdqFruse)(BegaPO?nuz6>z=m1_Dr!1R9uoc~YP13_BLc4H8;ImjeSkirFmG%pzB z&q6^GqJy-H335dKkh;Z!)QAl-&K~5oM8yRe6(8hiLXb*{LFSbV(yvsIcS{FZRVGNO zvO&_MiM*65<$^>wf*4(jK%4JfJ!SemgAkSt6={j5UnH%KlydcfyYt9RU zoctmbMEx-!cSti9+YYx9^4hMpqmD-1bOgtQfBSAho z9;DHUAl**}>HUxT-3ij;Zjk(YT95ldqMrt7^(@GK+4w?vN2IgQkWOJ!Iv>jv`9mI? z(=l7p*&#=ziZz{4wsiUxP3OB(={zc(&O2q&S(B7bi*o7AE1yoG8h7U_&@ znXd1i)A{1fbPl&p=gqe1oNJd(QipUVOSMkvjCm(r_ovcXHXxn51JijWV+N%&S6U2C zr;D7C(nHhv_9KlsES-U$Yfe&ic)ETbO=pi39GT9HFVeA&NvGl1bhgWr@#%yoYTmMC za=LzRGabX!bhgSN$)A?aLb)+racAh<%yeSquw0NvvlMf7I+i)<Da^0(3_NC+9pRV6CO4s*gs_$XV^OEwv zqA}#SBwo{;y$LS=?W$%;>3Qfx(Vo?UQ7VG$O<+@V2ewV@E)fpIn%AoFs3^vP^jTtyM zXRvRJ#@ViMc4RPSuW~w(!Mc+fl>04%g=dui*$i6#o+n zJ-Z_BZ?4EsTPjjzTScxNtcdGyMdnK3KPuAvd`0%imA@+DyjhXiQs#C=-n~RQu|+IGksh(jV5F>V`4TR zPtIn~lx#AlW>ZJHNR{c?jGB?nb9rY)HY-+UQ{ua9d@@XKuF1x~Hk+^H_5N(C{i<`v z)bG0b-N>fa?QEt#$>!YCY-YdC=32oVT!nL}SR{vzu{l(V%h7vVj^5jHSnSN9SXvHW z2Xk1Oox|;%97cz77~e66-#X>+!@wL~4$7hX;2d_2&%rt|ha2;A@GQ(>zI0!c!`kn2 z=<`z!O}FJRdwUL1J8~#Yb1C?f#yywI z4_9(Iay3`?F>*<~k*iv2yuWi8)knU@Q_*9mss*fYY6lVxST8I&z5C^>>LcS0c z(lt&-h#^uuGen1qA&yDA+z?AcA>zUzZdC~ptQKOiRI3qUOwAB4r9kZvP3naBSw_@T z%=(JiAVjN%Ar>?WQKWH*{Y|uO7UC0`(>%oG7V6V7MD4diOnf^8?Lw?>AL2=e5M4Sd zZkG^Mx`tRQ-QEkarhAAoJwoL72{G~mwUeR)L$n;E`OApm8h3=o9U0<>(ds`YME9|( z)kM{5Qi#8$>SWbqN{AQo{w&pZc8LB96?3s-E>TP=@O6kKD?{x4QS0!N)^yFvRsEA)dtC_Qyjs`c3te5~o6> z$*-qF6#G3y>vMW7lm7^D_PlCwAw$ETl~aWo6_e)BMY%BI#~-fA1> zJ!$h+m_=`gSuHo(hw*d_Ghaq^3Uls`#>}dzgYf!z9XXDbPDif-I81 z-w*RdhI|m_=e}W%$gmH?{L)YJkY4@6{5T-YhaYJ>EX=FV!`Oz0@yS^!Gg5Pt(Q@pI zFqOXy(?GtEn9*V09HUrrN?c==-?%XG6T+02DZ<1sxiVHxObYAT3DZd4oDyc?)G$S- zsg`nE=1vcDN6a(B7-xm4J3Gu~*)K!pDF3-(0`tN&SrBH{!Z59thWTMtn3t==L~aQ4 z&h9WP_Nayj!c;h=xt$L4{7jgM=fj-75T@ou&F@d;a5>C6nRQ#WzoUHaDwhYU^~11! zXCX|Xr(v2sQ!OREY#u|B^2kZe!&xJbJ~i{WBvEzqXk0Iko#JYkN8d(yT#+M9@`!7e z$4F`3B9FN(^C;LVkHK%MZRG0eLtE$^6n%&Q5x8yy{XT+m?Cd<6X z`Am44&s;fExzLR2yFwUsnHr{q#RW{C|J`51;4ktpET3 literal 0 HcmV?d00001 diff --git a/Covance_UCO3001/browser_profile_4/Default/Code Cache/js/573c1d4595418dce_0 b/Covance_UCO3001/browser_profile_4/Default/Code Cache/js/573c1d4595418dce_0 new file mode 100644 index 0000000000000000000000000000000000000000..1c0c53fcde3a8ac096b63d866a6bfd59de83f6d9 GIT binary patch literal 36888 zcmWjL1$a|eAII@uleDp>O&bbD(zI!tHceaH-5th;>u`4&&T#kP?#>u6++o9Q*pT7w zHhl1YU!LdlG`;uSbN+Hd+w`V68g^Tewd3b6!IDbAZ;utBY^W-g4x@?(z zIrAEs<5Y&wS^uBw|NlnSOAY$}$Nx{h49&_(7jUnmZri1Zf8j!_ziMsi=i!NN5+NKXD$X+6O7ULy(H0NcSN1=@X<8DBmwg&-w>x z;D8{F!;nGDH9Sbaj3Pcnj1E%plpwjL2I&RX&SI|XLF#=wNDrO{>0fkw7Nqs4_dH0` zUIc0D%OD*>iC00Y`Z-9SO$Id&Ht1}mL7QC$?Z@K`1|5nrC|k5a8?igHLG`m3^hZ{M z0&atP;k?J7*0BcdEoIPOC|lZ~!(|P6RKXxiRfC#TGpGY{)ikI$_Q6rhpte|q9<`YR zJsKGFOLK#|w=n46E(ZC#8Z-toP@$VagYcm{k9!!DrKdqj_|nUuroFkgk3n;=8!>%} z4VD20HOB9FJ&<(=8I<>DgSrkjXghWcF~~O5pd8pXjGSN?VNeO|#-LGrKH8vuV+?vR zp0&_;0FzCiggT}8S{!ru_yT zL!JYShv`qooG|G58REWTkoBrTInfxyumEc@lU+VMTpm3DJT9`i4Km3f9cmV4sgEFGbXU2Rn$n~E= z{qZ*rd}R*>8MVw{)G?z`8AFWv!EDq%47V6H1-Gq6IqgQd(K^(q+F?d@LX^`eFMh#$ zRE#jH114f4E?{SrQ5WIOXw-ES%Vg9v%#SvzdS;`ZqhJ=Jdf+46S&eFpdDw}e*^C

      TwoRG>;# z4b;n;f!bf6n3@MFZ(EMFV?2InAE@~q1NFXhpwhYostpcz4b;sZ#N3VI1{|MBmy?lNwQ0LADs_nTz1ze)eu>2FK(N_ZHxEiRwIE*gW0`&^@{-yT#emzk0 zZqS39fm(SlP>o*%D&K#B8ml0UHV5fJ+ zNXPL671D$B9)q$4=?|>Q9;BQ2D_4-3b zX)F$)TCpH4g{^py8sG%(;${iruN0&eIEKi|L7Ibq5m6;bt+5(UkgFr=y~L3-Je^;!jK$eW+!2X3fL4G_%U2n{@{NVsbXK z=HtigW;KR0hgs1$fy+3Y)2wQ_%=$f#S?}_i6`zlI@u9d`Ka?;lq@-EPaT6Izne`LS zprZBtufa#GsAbmD+Ge>MnAIM4QLv#|=N~tm0?c1AkM4 zbM*MUS-US%_kS3JY?tW?He>r$>UfR4bDcejs2lVU4bcl5@cT`(4x!U6`hpL4$muS% zh5a7aU@G?EJ!;%12j~&8pa@!F0-hnuW3!SG`HH=1uqe=IksID1i{|1MDw-{NgX&g` zLTwh6M+dt_))0#pI4ydF{$ZR8w`dA%87y)|TGT3&MISxP8E?^dbWXG=Cdr~L_$ix3 zy)XbS^Kc7YR{1!!_362)9D0e}N+MySWg)MrC$|WpP z8H*ffj&o>MmNju0=drzv`?1mO)Xk<|w<|1noi=H*Ls9!USvNgA;5w7543yUhWx9C+jivqe6 z3;H8l4{G>}MYV7TBYIin>}^qvJ{Da==6=)_kNb1Y0E^ZSv?%Yd7PTH^(Q|yos=*eO z7-G>eT*6!Q7)ngTEXsjJc#W3BEt-tu_+Id4EF8xE z@fIzf!1_3eMiZ$!{>Gb0)NC^IA;T1lcH+`!Oj#5}{IK{G8HkJU(> zWzj!)h`O`+d=7D;&OD3eAoBv|z@CK`85WWIVvE+my40d7c!puiEXuXqqT*ntjZW_XQR8`PK!z(qxQ$?7cQaa z3D(DUG&o5g@C6f3S>!)U-T$^I9o^5-m-7~tx@ghAczlWdgOc~i7tJ3N_Y?NsQ+oZ3 z=MDxw=Q;AyqRlvf8<_WsI^hWHZ@B(5dl{OO9rb3;SD-RSXDZsRg0pmDxcY^aVU_L zwU88JReLyNt*Qx|$Es?$6K_>=f>oz6H_@t9IE>0(tBiieBMqBTJC9XM@>=x=PN7~t ztAg?qGe+T5A*(VJwki%qaST<8Th$h&%UCrQGqD9N%39SGb<0~7Si!0Y%&o}!xK!1u zs@1G&fUZASwI3a-Th$*g@D<&EwCe0nR`sc2Ro+_6kJ-3^jivd=RLBWAmh5X98IElyTH;A=IS+xv# z##pr%bH`eB4pYWiwR?h9Q)kd$?8Q$rt!h5os=jlqdX0H=ty+fx^XT_{@>xWT=&+T# z?Vtubty;Q^UhO8AJ?twi!1}$+jW7F&_kdMB4ieiTt5%@mpTrK|Vd{-6N2n1lBIGDF zJVvjNQ|}Y(+bitDf33XOZdEisz;uKCaLcNVx5*Wu_sHiyy?kKRKmYg8s^1<_!^hO^ zDbI&zR{7z2LA@~ZwN+={@O*g3KL5ZzMd(MX8lo+XpR5}Bh1kBbkH0Y{z@}yfo4R1X z(WcXA8feprAe#o6Z5oe5DB-XvCDbOj)238(!)^2nvuR^So3=(W4v)|@%BD_Oj`CS- zypCd>2J*X!KSlVT+^mM@V1ssEo$4e49`%au1yo>F>VnxM9szYXo*eP zmf4hVxlKQ>Adi(c^;u<8<<-=FtxXd*+B6q?H`6b|zA;~O5orIzoQ z53ct%U4r$4O*63!^FA{FC-VAi(|=#+%U7H7WU{MLX1iju*tIOHU6vTTvbpWLfM4S6 zib=HVlh>}JDRwzh?aGY&CGF~h%P3UJuJRaI!LBw{>~dGNt1^DUVw{4ru3gdCQJ?D? z*tH+8o7?prO8wA) zt_4_!OtZ)j&9Ha2T|?%OC$i78t1|}RuldZqz^;rav5*`w{{J5r*|if#QDh0V#Szq6 zX4h0K#+v1J-9fRH#DPkySOXK0d9_{1Xt;*ntR-K}TW8lzJV%E0%!Sq1j^}?+uMKt$ z!xS9aXqRadxnc_r!MBB)p$B?xWq)k5>pqHar^gtHV>`%aC;6cCE_#BgXujL7MOcr) zd#DxK?&aEjcIDh}SL6Zea>%Zt82cx2AEk!J$oV*X6>Uy1*Gb|&W!H5~K5bW{Gj?q} zOK(y2Z*o3oSKN8_5K3R5@A&niU1^u7CFcCY`O9`q!<#Gg_o`jFuM_i4yS%s9e`tV- zxQ{${*oSxNJ38H?9`~ss4nCkR57{GV|H!WDkJ-ad?D`XVo-!YbKeOwH=XM>yu^05} zm0h#n*!32r-f|6od}r7E_jbKN=?{F49mxKXJp_HChiHpai2clS2Kx~8#jdPhSqJm5 z_&=U^c!tkN_(r{8{7%hr9ltAB2Mxh`U<_7aQ?R<@x4>ZiYz|fjEDj4+hR9%bi{mkF z;W@5(_!u9o#DrjlBnGPirl5$I&y#{R6U*?;$9yTlT8IT{!OD{(Si5rt>lpIq4%SpG z!soofdXz6%?@_BjuvVgA!C+m)PlbYY8?6d+9vO=S>pNN$4c02mE*7lwHG@^RR~o4@TqmM>U0U#78LIp%+FiFI*y8cf>o+-ur?u}f3VsQ z4%XHY!3v!ktS<|K6}5=^EDlx$48|?YUmL6!_==9}g0&C6--Fc;N0GEXSZ)6Z)+IFC z7_6>anP(d{Lr?sRTHAwlU>CLCO+I^qRcJ4D*+;GSbN)cECLUzYL%|CAGgw!!@kp?; z9Szn={BVqzj#Ez*JrS(flfmkZey13RnA6nbOt9W!@!4Qy|2tTRu>BnIoDbH{3-sh- zu-0M8wP5}6Z?Gy~57uftx)H4FH|gb_U^Tu=eoulm14~ipDRDmwR&yM|dzhXFt2K7x zIP$#+)*wtk#+SiriSBra0%Oe-o@7ID(RIgEa~Bk?CEqnxZo< z!vCJRuoUlM`aoUrC(fbDN3O$Kq<^9|7=hO){yA9oFU*M9z~4wb=nyvLqc zhpNUo)C3(p4&6u9c!$p59+DFrs)wPNoaoRt+(9v~L$OK3js@tN>`)1xLyzztw^E2R zjX7aXcc^SOhrXa%cGk$@(2|@Eb;#||XH?9?<9rS^&CmD(4(%)GkiU>aV=%R_Lt#Z6 zdR^2ZdohPDz*O9!I>=jsxzMGgLx12C(n~w^4m-;@^h;TXo*=RuIl)+-b@3l;6&%Wm z9vFi4l^nW;OH~{SsOnGx8lVl1U|)6mf=>wfiFs-`RJ^7`RWJ@m(76`%t?ke%w5j9J z{JIVmuIJD?#MXDHd;^D0Ahw}H!?7NB8#xr-#G$?D*_88G-;Dk=cc@tl;%h~2*n6fV7M3H^Wa@__)2PdIhw8&L!=a5Z%yg*GEcQ5Z z%wuj;pYPB#+(f0Z6#)yw^Mg?*+E@*62mTP zy_?wgIMi|<{XfX_;t26$@iB*Lon-G|-6?u;!J#-*M8HMj!7iM>#JGQW?p$Nde~BAq zuRC~c)}chq!dYC$nw!)Y&yo8Udj@Av__RD*&N2?DG{q)hHzMohN7e15E7wYnj=YT?V-w>k8rVvdshv)J;I{NA$mK7*r$f5 z>$DIpogSj9GeUF=J!XdJ+HB&T6C&^25XH?4(eLw#b76?OZwOJq7VwAFbVQ?}p_(u} zRPRxDM5tbl3{~o=P!+(;F`@c>e5h7W;P~WFothG=#nVF7YI>;tnh~m%vqH56g=dHA z>D*9dofj$}TH;THEnuxBp{fk?(okhv5vr!xhJ7nTbrR;)ti3i=ht`Fv^M+8}z#m&f zwQd{dcZTZjo=}zB7plVtL-o(0P_6wlR1c1a>gThex_6OUTn$y7TcOJLFjO_4hw8;! za{U;pvHyi?R)AB>amDE5dt|2^Ax>q+m{6z6Ii1>o4={x}xu3a(ja22Pj|KL=qpPcGZ!>Nxoo%+3&Q*pJ4wT@F|>pS@w+^GSLxvq&* zPn)uKbEiBloO<8Vsb#I4dV=C@o!W=*DA11FupT#%+}^37xPiAFoC@gZRB9KedUbcI zWDloedpcF+7pLCf_g+r@*W0OF1DqN>$f@%~oVtZo!<)|Cdu8kFf4hdUo8YoF|>CcFL&+n0bcv z&pP!Cb*?!z;-*vWZ#iYY?Nm?nzQeHx)cK)PyB~4wV<-1eId%C7b$ZUedEwMwubi6o zj((!gN54gAMBr<{QTzBU6lRLsZ*Ht-KkIL7ZIlI_zRYdVLBWcrXx{dx`30J z!_*`uOl@Mr)G01ZUQd`F<6eB2b|r-ApTsaN@rLR5)>I@rsG>1P~7+45nUT_H?y zRfq+ps)cD2zGBUfVM_cdOf#_`FKUNrRJ}0e{5ee32ZU+#m@xe~ElkTEaBXb3cEyFO zrY~I6vxjR52ImM@?p)!@mpfdgtA(pNHdGJS=NjRvTa%CIR6AVV>xQdgy>MlzA1-H; zaNTGcuKmrz^{_>_R<;aRa%;x630Ky3;qu`uI<^njUBq+<*Eq~VyYAua>2N*zHC&fR zGS8%NwVWER=WD|?cU`#t`aN7P5WO*6PdA0@w=Lm%jg?!&RbyMYHX?L;xPHPWl-Loj zJ8ramI3$KleGa5Z`!t{FIv z@h|xNWw@?=Ctv&^mm&gO8i!dpYH+EG(WSplF8Kppx`ix3F7-0I^aW0fOP64(L^UOSLn*v=te$xHJN%k(AY?XIK;MQgOFSX|XQNfho?V=9unr zX?46ygA$NPTuCmy#ByTtJ~bE-k_B{4S*zaA_ct3vwP8;49=(fx<5Riin~vJw};g#8cd*z)~)~ zFHL@BT>M<(lB=vsqwpHF$`J#Gm3Qd{DpYW34B{%f)B$}expWdEE4x&pic1S&sOnN3 zII1xps#bS#@2g9je{yMU4c0=Hnl4qU?NYgVE?utgQjrEO?P^Huja>S(u}i=F>{7la zj=_M{LTgUkI%(tCmFz#@v(JuA{UZTQodW*Zry~m}=$hVie zV(vcjJIHw~Kjc!gzu1Eqb=0Mt$6RXq#ia$v9GO97(F?hvGVpzD2G!1#L9?=FP)wZ+ zn%*LVF5vrt40`+`gJ!(Xpv`y*UqFO5+at6!Btlc15qg2v@ex{v*To`qqC|xJWh0cW za)f677@<0KBGdt0M@Hy}aS_TjB|?TJ5&ZlS!E2on>a{0ABMwDq13sX~g$RXRi_nut z5z6#9LQS4TXbHCCFtWdhP^S_ZHK|`lRUevBrAKGf%!wIw2-Zm%xfd^^jx5cnl$#lK z0kz&_)T%ET^$@!wBe^dwQgbpzDpS2kwQ0!5#*u1>>rEn6rCFq6+D58%`$*mE7^x9G zBK32xNOc$(sULPlYVF}j8Bawj@LQy&8=}}jEs;r0N@ddfGMO~2Tqez|n@R3InUwWaCRH1rSr5);*2TXwE38LW znO0|2!F5@+;z(BQ#A$pxnpMAl&8mgpvg#9h+oJU}I9hqLM9UBz&AlPf`Vqeuh*r*m z(JF_%IDyrLqE)qUw9cSTk!T%2*J9E7fEvY_qhvJi6^Yg#rK6RrOtgw)9Bv}0Y_v|5 zi`Iq;(MqTot##;ADO%T&vkLQ~0jm5Mt$HX_Gg=k!3NM>Qt7MyK_3jw0{N19p09O#v zJz7baht55sRlQfVhF}uDqGfMlMr@yGtw)W%(K?2a{i0QOAm{Nbj-kkqXyqOnt+Zj$ zDu_2|IGo(jZe+B2VFy}`idJ`Q!sXG?dVuL;qIGR-w8AGuYYgV$HeO)b#Av;n%(*Gi z+A$4lBT3{*eW92liNAz^+ggi5%)d?%HXJ)j%z&|Tmx3F+Fy+YkN z#D}Q497F2jXiZ%bt;NW-G+JerkpmvBj@El5uH`tkW9A>x8nux;@E*~d>HD^5)kX^( zMfu&)TC_J>Gxl-a{%D;>`vdg#AT>gxL(yt|I9fgM^=PzW&PMAe{EYJ`bs<`rud*jF z4o5KLTC{c}^Yv)W#RjasK_0kuD_S3KM=Qg9_6f>8h~}QFXl;AUHBX`y@HASU7tDd) zZ;2h%-x1$?*8N0WpQ#d7}4R#|fAx6IB7)57~ zQAb=v&I&Oaj|mlHbO+fh#b{~e7-gywqtjJmbm)f|{rOXj3^ihuwl>r%{bKYKUkAi!)W8^7evOf7XpHP5Vw7!U48Mbm(cnojdWq1< zG0Hk8M!C@f{c!*p=f)^?A#35_B63<1!|%ajG#rQV1;Hy~^m=WKP8=h@zhk)9E=J2y znl77Ze_y-q$jzx$miC86gTfDa4RC!t)sYzxz*gdit#_V zH4km8yVVQXesrrPcA{?$w~V#i+%Mu*T5Y!`)^TfGUAO+jzx6oRz^%>*Xy{gD%xL6R z!JpkqY~q%osarYG4nfV_S_fBiw<^NZf^jX~x{mX$+^XB!t*uZSw~FEw0@}K@6j|H3 z)dQ395ewV9^*d}G+$xQ!xQXYe){*#d8bO`h8jXdW-MWFvU8n`hc6DnH8h3N60}kT? z=5=@L5$g1$7QeW487q3Z<>>8J7ToINR!U#Dnqz-I#`kw?HFghltLv|fN4Fu=W2jrj zhEZc=n&{T>->Abhw>IKFBB#4~t$=xF5--ALxwQs2QF}IP&2g*KT(?5!xpfa)=F?ZC zEp#hx5o2%}*2Ql9ii%6!dWm(*-1>~O%iS8en%LJ+!wqiLL@P|jd|X76jjVwy__oQd zjGNu+h~e;VajOh+ZFQ^CHpZgYcDGjI4sz|FZaB8nttz|RYKmjHgzw0|+pS@ku*a=A zh~4W}f1Jgp{p5Fm`2KY3A%^_r);V|%yLAA^jxZ0xj?xFT#5hwQG1!YTPu<+V z=GLfJjCoCs-?;Sx+uyUFKe(0o6VHR7Snl(W)t`vA#44*bRz6g>$Lf!mSk?2z>RQ2A z*^9?&7yc<7t9$TPh}Fu9vD$*Pscy%eN;QgAtq!cwIaYt; zZP!?ZcV`}y>KV(u$;|gltXzE<-#1p}`^C!GpRt2tRcA=7zKn>~kj2cuI#!pFvWEE9 z#_BYduZxxG_gLB1$7(iKVB#OKx{V_nVpVBltft^9(l^Db=9X9$-4?4}yJFSu5bK_b z)%deqi=fM~YI!$S-4JpwmU{tXwF;#l#;P-(BHyD}EyjB6e;lh~Ph+(SAD_i4&vWX4 zkNEbI9A3xj5juQ`)n5FK8Xu|g*I51hEmj?I>3gi^C{BwEaaxaDra1kHTfuRP3yo8k z@HpLv&mE`wNpTwOk5gLiIISxjrylj=RIXE;9`%ZoWlfwK9E#J`({Y+~HcrXs;^e*% zr`zavF-{lJ{t{#UiBsQ)aa!{%j<0WVYW*!vc?=$v#NYVM=+SCi#W&XDot-iztctuW?6 zwQ!F%M0oTpqepw=JiNZ((FKgm;n55f&Pi-|n#-fMxjp&?P4aj&Dz8UZ@Bo_%c(fm_ zim_gCkKSW>36D%AJqpKY+(rFT9-V=+w1@Wyc+>*N@E>ZG@n|BRmG$UcIgf54vb;xA z(6_or^MCTFP#uqY;P1K~U9Lx7DBr-Nm56Uh9UFPHwy{SKfA(lt6OZyXrFP9c>V+K5 zIgWWPJo?_!qvNeSYT4Q&LmQ9swWr=4h_@5RJ5!%7qdAq zcqBDKxlta~KtBv0?NPuuk19=~e<(hg`ocQjqf%I~fcO`BvH@HcXv^l)DXbv;G==!+HDj4!Bo z+M_!78(q$LwCk*g@6)Km-yYS)VK~px$MftJgj{4FVHrX$d6Wgsu^z3id9)OD{v|#< zN2MDcox&a1Zg~`iYe>26QSS#_^T?ygPpIcp>i>d0^O7;IJ=%w^Z#`=Go?7B(#p~CA zc-al{8iCrzc+E7$E2lZ0+wkM{)yDDQc>Umr*DDNh#j8$wy#7Jw67jkKYq@xS#~H5$ z*b9~C9QtEKg?Qel7_Vm)<5i_vygL3AuK`$BBVN1Eu~xjywc~XNnd>sHVLb2uh}Vr~ z@!Sg$FGu@$_C&l2bd1;TZp6_uUJbGGmw0VK=U(yJjCQ@_bq0O<#A_)w;2skD#w!=* zBE4U{T>axU9oJBG0I}c_{`fUs)rZHc>15)X8P7dX@!Ez@C_X!0f5I{+UMXmf{d40L zHa}i5$hd$wm&dEz%6MJGk@fL1{1LCl8{$=SBXeT-|80p^^456G-yW~4JK{BQC$-)i zuc&?TYI!7H!*CX*j>hX4b{~t^6MRJL+}F^G30ifi`P*!RD${;Bp^Zc z&&=ETOxBK!keIYOu-{;PD)U|WMV)SUxMr@jKxAUPft+GYzeBJJwg3*B&bVHa><>* z{Y%W5FG0-;Cg@_}1QjZhpczG}8x|BJ4qPstz}JlgJt>hOTS<=L5ssBg&_87ol&Nfj zOqCMU7$;Dma)OrOGip^KXLM_ppaVS<)Z-U=)0;W_CaC&g>Nt#RMPFF4dVQEh%s)N7cUBq}?8#(Kmw zP1Ia$M`*J|wZ{jHMkqcyCoIbfP+7E-s+t zj70s4Tr(3@3P<6cov7$JiM)p^Q4?`>ZlcP~OVmgl#IA*jI)+~sB`SPLq6#fbR9Bdm zC-UBpM6Fzrs2AwJig8%DCQ(VhCu+#%MD0fAt%-`wb|vcR?nLF; zL+mKJFHzf2cz>d%V(_6v?L)UenF~pOkq2I(#}Q)3)nkc#&z-1oxPXKciJF9%lZhIN zjOP{6m`;3*RRNz~oTiCS{ZSmy|Vq}Rax}K(3)Q5t?lLSG(z<|UTtpT)gMj0{2c4mD^zXkRYE&2 z??3cv%OI~_qRJ4jd_%bwt?+TUS3iyLYTqcYKBM*+uhPeQRR~*9Y@AnbFm}9GU(soT zSD7byRcW$Ud(d#ISF=%dnpcf*7bRwR^$Zo~dimPp1MDQA~a&2JFjf}+~aBlMI zM=ZlBd_vG>uZm&_Cc(JHt7_Paudr_AF|urwtL3P2*{i0Qh%8sUdW`B<=?$t~qc4d5*Q=h0yYAH*Ttc@S z)bOTPClGXtd2iEOe8G%6#DtTGzDvvxyu5G1tHzJLdid0<8_%fAb87U;tFG_8+*9t= zKgjc$>tXrgRetowcqQow5)DbR8k3X}xlBo_X--m($RxGHk*FlS%bX-bmLzpSTGk}> ziAmBnv~wq^F9Kqd)F>`VGd)RKj(0fiP13&PB;E5R$yOvurLnLmB;7*M z(n+$HNm3Mk!9_f&kR)HlBwfQ(bgjgkm6NojN|H9fRW(VYs}XPYBu&Q>T&a>dn41JKSy$_SM@JX_6Anj?gx?wfiKTFmeyhXzEWJSM7)+@xk zOxCZjlNInLS!Hk%8Q&(WF_z;PKB3cl;{1@z{m#jHja(m-`5k$(&ZFw*WKBlm7e4=% ztU~hXZv+PTcu$T`r?AoB(;c{tKGniVoJ5q#r+Qe38wd;ZsRTM>2`FyGYJQ`4o`JCr@UdvSTtjXYuKmtelVaDO;RR zV?91ik0&>LP4H=bqL04=C*_GYLE0uqkS4Up6k(K0`X3ypOfg{44;Nz?<^mG@4%-kbA6gKpMEd! zDS44kC0G0OWQ~vSkJt<7yUwSO^*;56;}4%&W7!6uyqkQQ3+HCep~P0!L(Xl?fg?!V zL2Y*XH1v{Bk8k=^;Q{la;6tA(BJ`0@(Wv#kI9H0=_6wSo@nJHQ{D@DH}VRnjUVDqvR^;nUjGuu+Q zPd`P|cBkk(M(jz^bVTo^R{O|fe~J#ANRdvaXd@1y*Qpc@M}{-Rgj4wIEHyYsY*$ls z?*_+irfB@F6g|3=qDuG3^#Ogupob|c_n3I_J8nNoQQoI1TK_ynF)vc&N8Fbbg?;67 zWci+=PVfZy^)p-szvAIG`jzJNt1E`#A0&kNl@otpNVs2D;CK1e8QX9Pl`{A>5oII% zT8txj17-9pKl)<~zM)d2U*AzF%CEW@oyo6%Q8Cf4+BkqKUcVlrZjxWE@OQFbHBv0lI()?PBohX^^mnoZH&2SC5virF&$ghuZW(!yhuV4lnuDSF{fa2)SGz)fZAOd2eibgloTyaPuNw#{=2tg- zLW|>7EpOsiKvTbL?fiO*y6ycc)!DB>$lZnca12S^{L0Xsx(xDbE()^6 zN9A#T)t}&3*2#X=`;8c<`Bi8-=kN_XX85&t9>=kMzF+%Lb^$$D=vVJWex2CK`8}M+ z`n{Y-*?pYf?^ojkeswtF*J?C6>Q_f(K1Od&@$oeM!@rnx#;=wa=@n{UqVITyikJOr zf5oppIEqEr{4!kk%X5nw;oM!nHr!{;hwQaSevNjRHrm8GH!J3q+33!^!wJE83 zf}{eBE10TF7*r@#Z(uFUd>C3TRsQm+no}uN#Ve<3&yT6{)=cF+=c&q6J5{&prD}Eq za{D<|IoqXbK5Xq%m9GOibV}9a&Z*qrk*eiAQ)T`oRb%mIZ}RMus#VC+H&qvYP1Q3L zADpV6hOjP54NcWYv>lep-<3>N#ZjqxG$vJJ#;5YT|5W`mF;&f{r7G+ERP|bz%Gb$M zmD!)Ffw*>nxeumlD<0s_BdIbTrEd5Om5-%r^udeZNHyZ>MV7omBmJHq*mf%uYDotHRrzv_&no=-mcA9n~YHpe?;5M?%OVe))(-gTVO@o(l9OGA{ z>ED%UTDdAscTju{b-*X&UYn)`*ts>0?{BCFj={A(O-=A_N1A5rB+gxF>W)8RnJc{)u#42Jt$nmQxr zCFZ@Frs24Ajow{nJl5W!UnqSqO~vjr1}mPYY0H0UdWkCE$p!o+D}@E5t3A?8>FN}g zuC@3%JYAiU!IiGjcz`n*(-jh#uKhTR9#QFff{B^Z^(i)8UE;XLm##0cq@*jkemZ}H zD_w;erE3B@H%r$=ylkDW(rwc95jESUOYPEC17*80AJ+Ct*Wlh#bpI10>7R|VvrM~n;8n4USC$3fLTDm4(6@O1x z?}Lmvl&+rttLZ+VoGQC;k3aMxAn-{SY0_a*=qUr~Ie{cosWTZ+K%`ftHxcQ*3Je_) z5s{`SO7BhS(wkJ3-rN0i*S+6bzZG+G-u>>qPlj(MIp;m-zcWr*cF_mC+#RREd*U<} zb@#?;Z5DxM?mg*d%)F-{whaVbufFUM)oP4c)!9{EkO7ceP^2WV8# z#JY|q-7I9%)S@Qc#Ye?Wx>CZVdL>Qr;tp!P&tqwmMwBrr`-g0=Xi|$xCVodSX+SlT zPT&d(#F>=aY*G5sA(snG%d|}eoDda!Zq{V1I&7|S8OiGz; zQd<=J+N73qP3phIqzRbuy-9t4FzHK}SDUo*N0X|pF{#r!lXh)0Y0^%U<{`L?{7`ha zNw@Ih0h1;kH>vyulXhR?`8}RLG-)mZk4&0{!}#HeNwc$K@-?ZI&j z&1u%vTxQ)z_S|NDil%wYT9(hO;`z<0h(A#9U9*N4G^<|`vt}3NbtD!uYbib~Zq~g@ zW*x0;)^AlASIw+3wat2kN)60JG&<1X~2E46et^Lvt6^9Gsu{Fyn?Wdc2% z$Q)=oi5zE}Ik(lU6y%y?*0W5r_Rlx#3??iv>+xdxy~M0j7`W7|3g4LZ2sxIUx&DM6 ztTHR#TC+U68HYz`zn7YD>lnQ_Y1V6ed&;cXUuNw)Pk%3&_1v&AR)V9%1<#YLG?$%VJUU92R|4)S@=UEUX=3;ky$HYlc{~x`ag+N?BwtW6@+} z!YFIem~s}@*|Kmgr-kn{ELwoZl`R^D)EXAmGFj9JxACdjqInjJBDE~~qMk)JofZvf zNPM3~r*R!q{1!b9Sd=|zQBe#)2g9PVVT*2{Wz?b^i5AuO7x@7{uUJ;NSvX>!7D5uW>M8I7&pSAe@0o9G1{WeC^m)~$6B;_ zoJE(%TXbupMF%HYRCY4`zzU>Jv1sK~i!M&HsLTxNnZ@?6EqXcEq9gMx`Zm*|q4TMA z0k5yHsLOX2%~)yC!|yH94;FP=ZPD=`*>?@G*IE=^&ubej8o9}$^S@hIPmaECvnXM^ zMLl+Ke0Floc3V_xAIES%F%NQl4_j2_h(+OJ^y)Y@oTR2x)O*^ZO867rGZytdYtgfF z7TvpO(J$96DtN=9w#dXmoQCHn&#@8-w=C+3LvY@<=mZ{N#XlCA|0TEoEczScvsn2| z!KwsoMvm-O)(Eg_WFf0&BC)VlZEys|-?Qo~)G1??A1Z5AK@7w0a#ntivTAZQs}>=x zx>cQV4i#!zH3freSv3K{+Ez8kUc6h^s=*i^Z&fCmH?*n){z4fS`=e^ms&0l=1926P z@I#1vF{!atPvHq$bpY3~C1O>Vs8wSVth$D|Nmdn3wkn2o$euzjxCC#iRdG$N+JRin ztqQeZAH3g^KA>P@q1duywXwy|o%N95Vgs-d4+Rk9;}>SX2GDe6aR7puO+e+YH8 z>K5j8BUTTqoH&KCJ*`>*PcLft%&M3Dt?DM@l5;Rl>RsbN;t{DNMiH)@Wc zPcyB$gRHZx`WW4D2n}bG|JTIByK}7ie6CeLqWCyZlltJ`bx)i97MK<_0<49und<_{84?S zz*4_~>Ig|mUuKWd=&cQ??3nl@F5v$2+uO>=M_Wlc7SDS9)8P<2RsZej`M%F$y6~-()`pl*^pWC!^tWDX*+4#=N zrd?<<-llIS*wlWaO;?uMRC<|B{lBrP*K(VNVkfG9Yt#InZLG1vT)*H~a>Qoz*kn_l zE!2%4kaep~SGU>JV7pCcF?EMcjds$zeKx(n-=@R3fOZFL+IG;U0f%iGjXr<6j%!E!%Vov+mfm z`+-e;AKFyxkxk=J=CMu9pW3+YjlMmzX~s*APZqld!J5_1Ee!1PX0xkjcDr8Yv#V}? zyQUVf>$i99+6QYvyM8ZhSFpHU!*QX6oi%0c+KZm0>{^JK7Q6mLTrImEK(+09)xfSq zn_bNsG6()^WY-#(U7PU_hWPC|iW^bpPhel%z~Mx@@+8^SKG`lu3b9(*Wy8!gyVBF` z>WInsH^Z*Vt?e4o#xB=Kc117%HxT&Pu66C~N@{Oc^A2`R!JSX-TG`RAjkt&}I#VM` zcD3s+UZGq!V&gut^kzF2^t0J6}~$UwWw!@$Nt)I8X(zQfsflwA#RA6ZA+H41-^ zp^kBOwfoMl`FOdKn!mSe8gi_%%f8;OJ~*<$u0=oF^#hI~a|`=yz>sjKj0P?3#7j&i9jcwK>DMb9Vi4*{+JW z=>g_r+`shh4#)VZU1y%zbs(!lWwSYSE{8+Kayqm)mqV*@@*Rf?<#T9yaR=)UIy9rK zL&xw{IfrJVba{vRS8yowp+n73q^d)|S97Sd&!H7a_dB?b#i0jC2s%{2aOnF)hi)S? z$)Q!Ko$S!$6o*=-GH*L_fbA29uHgZiba3!Hii7J29V*||p+kKf8u6J!Ek1YXB^vf4 zw*e0RUT3Z$#Ka9;9meyK4t;~{qa50X!+4CJMzh}-2j5>iRB@(58Q3(-q4BdF`WnAu z>pX|vU`-}t5uESP(gnm_NN=_})Nh+Z3${Cy^^!x4@BrB^J2V>Ct~fO1szdSrIy4Zb z|HuvHN4a=M*bi*g~SGElg&Q{}N7Il|4*o%(AU`_FVL%N(}NXWoTQy~656PHlmIv6Jgv zm}99^->!7(I==p%++kkj)c7BqYOva=JsauAFHUX5UPOO&YUL)U+Wbad*o}j`ooc+t zspc5_fVv-3#}n#!%5i;0uPVo@J$m5}WLAmSYy43)UKi26TDpgsk z+VCO;ZP6PeFbzwv4)-v!VZ2JY;yHIJUOsO;f1|{!TYy+byk>{u71tzQ+r#nPvmsul zY0Q<_Q1kLNQiVy4v~hAHMW;66x}`=MFr$$Q&1$4?W;c>^P9q(i+ejTU8|lsbMw+p( zk!mh(q%EagYF5Uj|H`_!4~2`*|6KYWm#et6y_!qk#<^6ru1hr=yVMCEG;uM%OaEYH zic9WPmohP`rAxceua!%q(J;-W5^af%yzN{niAz}1*`=IaT*}^+v3P_W-Ixbuy1SH) zf<0U+iyg4_bn&~QOYQo*v=J)@xcK|W#rXv;S%$k5k4s-Mc9cs;a2el@cJc3yOKrxv z^c(i!_5_!jPjqSEESGMf;#`-8q16(XW~0ecm(t)^=Hi@77w5aXUX)@}(a_KubUb_^?>ehESoz2Z!3~u$!?$$2cL^Ow+wK&~ch*fw6drr3u{D?-m z+?o$_Znx6V3$t;eq+3Tzv)>19bwj=~Zk0j!t+H zyH(BOR iQa2{~-0JFg>%*X17C2Mf`WRQ5yH#N-H6mjUF)?bfThmeIN9IJ!pWSM( z(JgL{rTnq{88FR?3ruZHo9CmBPpKkquE=SxNiZyQ?CFf(rJx85*je_Uhvb}YI zBJSRF ztLQCyj>5O8A0d2+#s9b!_pe(Ua1pET@%nwYB53oF_Xz&?$gSZ|-CB-=&)q8U!mT4O z-Fk_{H_VG{@~CPyk9Oh?&gAuIYkrT8V$_EoWvl2>4@|{jJVat8k1}x!4=a1rq6+(9 z3AW-5id6H+jv*L_iPb%-Tf?J`FxT`bjCOGzjm3K=k18YaEwe}Wu-59)q*@+rz>(S> zovrK9xq2QIuJ2JUyGP~F0a=}lNBmpy9-T)Hmq#_=h2QPbhaTd1$u;QF^c0W2PW5OD zsyFq>iBH~YM%?BerJ+_UkABBh#I^P)1=q3aV~#lfo8vk6Ur#C$6 z`maaRkbKvpL1_KRqmi&bzc($TAC$lArL8aUX~tK5CP zvZC~0uRQo~s8_{@vHeT0;&AvYFX!5LSr5sp*7zBh@%{v_-1r(hFm~K@@%idSc=2QIhP!8DbuTW=6f}IiB~@$*HZGtjBmW!gils@H5v0)d$kj# zfAlJV-D|ztx1N4p_R0kRHLp73A#z@)pKsmp>JK>NsrAsTV8Wc$I}C{W6zNi;DSF;(edO=!9`tjU#xBBBgzDpcMvU4t~LD z@Zq?sAOXEG3)}Dy+E({z0-DA7Gz`yb`&6NhPX+4xR3G=8K9!31sY}48D?y(+hJ5lR z`P2>5Tl(})nom>Gefl87r)8~uO8m&D>}`FD!}88P{%-MUO*fxhJ$zix>C?W?e7cKv zpZnAoi{9$%le?c!$NKx!WPneTa0-C$-e z%A_~gf+M(q@B*J!EMp9^eB;y4NZQQYIFC(RsCS!B@9$z8TJQF09^T(W?R$NS?e}qR zHMJdPKFmMr(@va4v11$uI8XTWG5$i{ll1kBPleC=R28Sr@f@`-aa=IvGC82o75aX| zr}%pu1MI!;(;b|9dm>{p&4e(n0guTv;C!Y>m>;tcA3=~s`DetnOBzw)cqXupQxSM(pt<2XNS zi1@W(f?qwS`qgG8b>Td6%<`)=!dQSUxQG_B{c7~JpU)xv+P#3<7W!G^m_9AywZ(op zzwxt{v0r7E`}G>_R`@v|+b=ubd`}-%v2C?qQ!sT6`>yq?=6b)9(H}>D_G{BGeqBb> zU;X+DJ2ulRWZU9bDbzw^T-#3U9X!VgT-Zt8yT}I%vHz{z9N#^Dt}FNJKJx7Mt0Oub z@T(7oAN1=AnjH4)E=K&}*9zRhOFTN_*XE;s4LRmlQ244}Wl-~PYPd!Y*Zrz=%db!W_3Ihh-|=%j zrk~GjspB61ec#U-tA5==$%lT`LsNYIh&)l|F}a`>CZOO`dWsL9`IUms7=eXo``oWl z*!z+^at72G&Ed`!(Cd5w8I=NRhF+LmC7_S122`+GKwGN^bQptb1XR9eK=wFZ!&*~7 zdl4}QG}jW)7HdE^kiT|7KcZ5dfKu>Zy#QbJ#_ksb| z0S&O`PC%=g1hff1g#)S?4X6_~U`b*?v7~_BNe-wQR$?!1piN3Zy>SrLQ<(>!-~etS zcT?h`T(f}Uk&d%?hBD0q@?&m`fPO{emW;)Ctiy>`{C7I_;wqNL0@?v@MnJ7G5-YJ4 zciYg1j{{u07m&Fv^Wz5EwGZevs(lhrOYB6)4&;PSKMkl#$ADh-4sdT;d=}7dH2gfE z(O(9%e^fwUjSp}RLO}Co1vG6-K%2Kw$M%4h?F(qeadJFC%u@kXI7{!(1ytZ7eZW_j zId(X7Eug`9gW6Ld$XXOZm9H4o59Xj!;)Aj@4Dx+VP=Q84-N0N|P^q4v-uDI-Y95rQ zMNn1S1$DDWP>->=XHdm@1r_TP)Q6u1^`w7L*#`vm526EudNwGiwu6IeHZ-Vf!-9H% z;$H+c24_%lL{MFD8LhqyYBLIr45|ed<1t)c1vLV@kv1x*6L@cQQ1kIUa*Pk^e+W+q z@_BrabsmGZ6rGb;sFNK^<5f)bb5M_4_HPk*KpNsJ{{39OPQYpmJ>qs_wR+ zy!Z}zwo^0ep)0oGIJ6_E{BUCgrXb(Wpe7*iF7iYA?x4(j*oM>a>-W;b-7lV3@Z!d8iQ13GRK;A1s^~XijyvpmS@OO}F-0AVPpa$bV zn63v|Q-Ij`_(o6*@X<}i-U@0Lir%J=cY^Bkkk=jsbscGs$s4!O`3e2TyHA7ahW+^E z88My{9~m#m8IG6KhrRgr6*<1R+1C6vfv zXdHgdX{b*wLu;@vx1suZ3@t=~yoNr*MWnuCXb)=TGc+Ih@*5g}s|Xh`v=rfY4c2is zIA6xlcZCgQ{LfJ5_Y8fDoka~5DMl=eE^g>?2}4gy8k$_n;QW3=*-IOmiAoWa(+B31-9E%TVdwhSno%A4A0u!bx}r8=8UiGlj$JNw>uYNRi3?0@OI*#6JIX>&@+Xj9YOq7{>jkUv-JL)p^E2u58^d`y1>uRMc&(& z>BSY^U&y>_=*ZvHcFmCEx}h02`1!hN=ncl-=DqX}d7|Du-tUj;?Gr+~o_go_k0o^M|+xa!4N+2x&~wkX*$=8jD4xLMl=&q&gKsdWv=*hLp8p zNEwww+FLcGdeuVOgA>(5YE&bnKXIyNNG(kveTBo=VGeOmA7bGL+(E%wA+<;TIwAS- zpngb>1|h}ScpV`}NE=Yz$=v9K5qOLe@gY@0FRXKgbRTcf!X46ngghbr4vUw$5$9)L z{Dc>92SOT!L&zE=K0072ZlH`oEKJ28C=#L`jK_Aof~|2#J+KN_P`pV<(Z=`lPn99H|5VJ$(kR$=0Y^)Eu{VJQ~YjrL(x`XsEsa1-4+gmvK4FyCc|Sr;&@ zj=jQKI3TPGm@+V|MW`|;tS<+LHGW7~C%+8KIX+^r6T_N{UC2Hute>zO z;mKjGm=e~Isf@>;c!lFL!!pkbtJj>ceni{3VfDsyG|Ob%{IJqDhBXI~U&4yvDqNew zs{C76|LqB@#$NKo9rW23){*^TjXV(6G@QcILt)iDOr3a!A%BE*_Rp{;9ibP;!?I!K ziLjDShSeJLPchG5Vf}`Zr^yE!&V;q~EVY~qtIb97!P86h;WGK4?iK33M_m|kpSe-; zL0F$Z46Ey-um+;=8A`J2@gMg@t&XGoos_BTA|gQTD14?uQ%E z8nmksQ6IcO^SFr4;4Z!}MU=aKM1DL&o(2(3#6PwO*I`9;&l8c!8_{LlM_*q=$Ndp) z3PiLI6@n2J4o8%LY>^1p%|5fP<$FSPLHVE z4DwqW(Q|yiE~4MySs&4Y4G}f@DWV^aM)WTh9E)f*>K>11>Iw2Z8BzYr5jDnZ6u1)6 zG~Bxy(XziItjiS9Dzv#7Q4f^9718zk5qmD{-`P!h-%flQEe<3)mQ(EDzjWvv1(D>s~*+W z8c`ju8P)E%s1}=}nqi4*f;Fn!b)x#SZd5z!MfGcaVm64Xls&4O*y7GsBU?q zdhL(un?O`2gHbIsqPl=7p{N$2O5>=$Y!X%Oa8#u+1jPnLm5SVhqbiO}yciPI;Gt1X z#Um`7LmW(*OB__0N1RN?%qI@|VBfDi-$Z`ckHp`o^LJ|8%$VI#UBuKq)P<^hqZ+v{ zD)0WN3SEdQimVr-DvVipbcs1H(}(L(<+u^$`j4pgAaXOR?`}oa>^61ZiRum3+>LV2 z%&3C*qFQ>Nc^^bI`YB`4|5;RHQ1E$FU0y_0;w6t+67(HnSrgP150RKXL9g&mjs(uR zP0-w&396PSLD}*qs9=Evm3lWpO|cd3f(gn~C_#78peU;+7faB5EK{OtWJy#5q+@rs zL_NTP?1?IxBT<8MCu&rYL|uowSfY}OCu%aTqfCiJH7}W{yC_mBk^3wp>W{LCI*(7v zC8}M8L>ueKN!rmoNxy%bqz~IAsbHTZIhQA?{q`gc zN4LF6D*I=WZei4sB=tI(q(`t9Oji5C$*Pc)tY1G$*4DPk+SV>vQ#&T>0G{+pR=(cJ znvK|J$x7&#td;|l)gMm>C2PmvWTlQv)`N-3Iy*gCRc0hhGn3U6C(-)rWO)}QE6d_! z-TRKXzb5Mr{@j$TUcV)4Bwk?9@5$=3C0XxnO_phUvX<^7r(NueclRVK$KGUB-Ipxa z{$w>cmaL*DlT{6C&L-=NbIF>1F)dGevcGrDz#4cc*Cbo)rCWZ;GDWO;N(V6m`#&s$%b@sy;TLYmrnfLy=;s zieU}%7EjgZ==?#dx|B~e#&1s3<}GRJyE{##j-~11g7t; z1&l0^uEy`C>%W5ODpV+)pHE(^n68t)bbakl*OYL&j`vMhts&_uI5b@$44Iv-v-8qb zGBaHVaSl`Gr>ok6bX~y%yjqwp>k{JQ0tPQlSN;_|$Bnh=a;!_2fopiNK3#De(ls0t zaRx>Dnkb7ggiXgNpUCYpXOS&GS?BR4B!mV@Zd@q?U?;~QM&SPrCO^kn*u1k3S zJYB6{q^n!Dn7&8r>@ju6dpTk{n=_`8xneqqbC{YtCTpIUHX}73+wrheOo{Ku6vH9p zEgh2w37CtMDEL84rIArSrsI`kvQ&v_MfI4HYQ|V&Bc@M1F*Qhx=|U3wB*#>@C1atC zm_}nnznD&8Xa5-Y7l~;Dc46Sam`V+bsRi;4j_G}zMwKsPYL5~lW2%aS$T2FWHW)pI zTHqWX(*VRxh$$ZVC&suBV@&<9eM(HBsWGnSi0KTrXU3FeevEs-$Fu|e7sNDiVT@xL z(~(8gx0ro!6kjiisp-m?rXlcsOwCYnRZKb8#Z>#}822WmUwdNejHT%L5BrtMQ2lZl zI%3aIHAe=2dt@lBZH7K+m!Ty{9hISPu?a7cXLN>~7=u~JIVMA|(0FWy`rsJWjw9Ci z4BeQNp~;goRBuWKzxQUS%Crpa!5uW8o}pnl2K$T*?lYO86*!K|C^|Dk&Cm|pP<2*@ zY_r*hJ##X+r*DQz&%=TYeTR1!X6RoGS(Kp{*tj@D#g}I23|cSCQ2VtR>U1JQM^9zw zA_n}Gp~JX^ET=PMh7+^!6gkgisLt68wLF)hQ?C3oechfv%pxg&#rdD}@PGeT@yXiT r??mU1-8pQq*4LbB%>Opxnb`fZr*fMbk(SY&h5!G!Z2y12|9kvDeVjHR literal 0 HcmV?d00001 diff --git a/Covance_UCO3001/browser_profile_4/Default/Code Cache/js/79fced940f0d6da1_0 b/Covance_UCO3001/browser_profile_4/Default/Code Cache/js/79fced940f0d6da1_0 new file mode 100644 index 0000000000000000000000000000000000000000..f752fa80d3496e0452eb25776523a5c89222c827 GIT binary patch literal 249 zcmXqrDOxU_`}+?o0|P@Y5DTB}`2wUE;7(iQ2w>V1A|-TTL7tUldPph0+DYKG4HCVNB#cKX)>8SyKmCBjvzKX%h zm8w)r4+gyzD^)fs#*wH3v;G(Be}C3Ab%*`$F-H7)c1`*jV86^Z!FdT+68B`71*Ti! zY(Xeg2=27@*aE)!KSM6z&c7eu~v!u?DCQgW!kH;Q8m!=?m!gC9E3?6~BV$5zu-h zbdj{LVTIfu1@DiBu2Oppw2;iPP)$0Ghu$)10(>p6Co0|)_;DRXt_RnTu>L35DT_A1 zvaQN(J8YFhlDz|JiuD(Wl@oGR8t;ZZd*HN8*b57!$UdlbKz$JVuaF?q<+p=yL8cvo zr4p^(o_!ovO2-q>M{WwI)O(pP!P8Jx{*%IIV2F&Dd1uwz3t;{Oc3gsdm!Y_vmK)OS zPn}O!psf_U3Qn0LgRj9jseT=r%Ypy7p>sf{+=RsvbqmV=t+nNz{3|_g!`pw9*By)5TeHb9Ok>+Fg}BAa#(VoLmhb}?OwnJ*)Lzd zgh^s}rGCnXuc5#A-#{fSfckOK)}%yfit*%?OtxdLnW@(@P5fD5%*YMn zaHTLNR1TwUl`vwfhVgzi)gt~HVH}g_T44;A&b7l>T_=nZb;EGV{(8!_K^TK&lrJB9K3!!Wvb4&zdnFcP{dR(JJwY8X?d zg<+hoTIYvxeu45`7{({xgt2K+7|oW1vGZUU*27`+`=4`RY(F1{=l3uU{SijdOJRH^ z-OL8oTMU%78mL~t!1#g&{*~U*1~$hSXdY+a>qG-b%Nxi`GEhe@$QhS`N*)9CCEjab zna@C~-@qj4SjE5}RSmqBuc{e%DS0&vtd=eELJHS1@R{tcZNOj0z?+5!dNnpsrio(7 zou&p_H8apz?#Sfk2Ku)!V0l+Lv@{Uc*1&=G1|G>L9SjWXXkb)l1NplcX!wzVf*%_w zCO`Eu@cAcNPk*7;8*Jdc&kfA|!a(UE25!sQFAdxqYT(##1AmV*kTStQNIsZoAZC)r zPd0E!@=Y=Dp*)gzrW!ad*X6my%`_00WuSu8pKIWfl=#L#lf?%9lzvMM%wDFL-x~OK zxq-VY40QOxz;dyzQ(kgeKKR+dsqF@?$ogFdp6xMEbFYC#lD5ylAo*Ut&=01)2Mh#% z)o~dm>BrR1;|4O%8fbh@Im>y8x}Y^L8t`2&y32;;r)g*FY(gk!A&q%q?gne<33m3L6<;#K?Rp7-6Jwq>#7c zqcv6@#25*SHL^txN=}@SVa1F*k zN>mJq_ZbPuU3n`#{YEwfj3fq)e2`|OkEEm<$&(-CMTU{inMO8+jQl3Ua*RwBORkZ+ zc}BL$l8Q!tlAe`}d?61dql%H`@?~}9A$4jPX)Q;@UdzbB+D0ljG15c|HC4?rQO-6q zvZIBO@HR$@$tk%m&Dt87*G|1_uQ^@RvyT*C?sYYCpqpa!FcQ;8b$_APL-cy6kA`C?iG38M!quE-8(~X>;VdR^c>a(nwW7IjQ z-pM&>zf60z!pI7_|DBQdR~qRmdsZ2Fv)V|FHQKwi>aFDa!N{zi)N2X+ti6ys8;vyB zWMukgBjzneBBilx+-l_GZOTjBJ9OU23gH)>BXVrF_GFLFqrKYeeX4Q4k@N#bY9CjP zl5x_=w-Wh>_C$=ARF~YiXQan{BR@VcQud({uRNB_$LgP?J~cAvnUSx>{@ln?`R9es zwO87&0wxv}G_gh!3YoZD*u>`%CVY`5D#}`UR@9{P)` z;jU$(cWuR%N%c&m)i*I$t~M}nU)nS@QJ|65X>4Mb9FZE$Of;1{@=`u-Zen0d6YE>) zv9*b~_e|`Od~Hk&kWbs1_@%vx#~qc=hsw3H9;MqyCXS1%tBFs#nW+DhCi72b)5BmonYk{HWI|^%7e6x7x2u^m zGOC-ISz_yMrd|)lk%Ka$x0&LfnrYX^%rP0*PxPb(&e9kIcl%@)>3VOU?WyMZPujwS2$9O!CiWhD-WJGjpZgCNo_&n_08POv$a9 zBTKev{w_1${bJ^YMDH=vOcu#sd-dKvGw<&=vtC{vFw^;0_2#g0Jfhl;>bRIsm}xJ| zPnwB2WyW&eOiNk#yP3il)UQh#|EHM-vQA20G1KX)nQGTmr_7Pe8)oj^HS@(iGyeN# zD#;J>{DGOh549KKd1_{goPTDf#&a`GWwzXYVaEH)%mP^@EB;lE|CxCspJCy#WEw0i zmu>Q&>@``aZMHDUV$nbBEZF6^&B9T)g-<*d9!k2`!ZO(+MxTZ1X%=>7SjeAgp@poJ zhglZdW?P8NwJ=-`=2^(9V8K_(f~B&BI#n#ZD}}0B7$+yIS*TRqLRdY;maO_ZE@vBB z=-SA_4~;F9Zld>_T9_t_q;3n1dDlYEmKIjDvQVY9g;z5FeG8k~SZLYSLZF?6Q*uQH zx3}<@cs{Ujxub=I4=qfU)txPbcd-yH+qzn4-owIz{;Fr7g*Q@Zu-2FDQtdP4J52cw z*ZU(Z)R$*+eWV5FC=0V>nKT})K8>+3Kn!CoB#*ODVZ4RZ2^LHfEqo?lO|sB!vPGXU zEo_)(q1|)~MP^voGgD({S(qW_*%q44wJ>L%g?#fZl#(oIvOx7ORE^T}dkY=cXg}6k z7`@KIA2NTva{o!WY_PC?llrpRf_009@1*-y?dMMI?JpLF$#?rKJlJoc%>mVX&_csQ z7Iw;M>3GCK{Cx{u9$4rrx5f9!!Z&i^iH<$9kRtCqx6oNuzpzl^rPh6I;m#Wit=?KV zWUx}vXl10y$}fwdA%oVldSBN6o-{QPAk{tkz~3wRvNplbdVDgo1#2qnuPhRbe7_N zE6Flj{tPI$pq2MzbgGq?vMSBWR!L5`(knw_3Fu4cXF)yd}$>;*GhHSAaC-l zbgiJ8B&Vj8nR2O?mAbW6gIud;WmkPG6&hICEBPB)+27pCDH-;zm2$1D_+*(xwzksZ zJsp>Q?W~k(Z{@=dR=(_H<%T48R_>Cohn3WxRt9}+<-n&_8uU?*`dTsfvru<$1 z#>yvStz4035;4xo-N{yVOto_8TdlQ1ab>z3{Lad!TUDdvZMRZ>ua$qUS?PV<%BCAu zl5VOt`AX*9w$kJu<#9**d)G=yc~8E5Vx`1W_5YdrFSo@1Tx-6x((RR%b+1*=8!Krt z>8+LdVK)AdS_T^vjW*mS8+jHRW8}Ei#*KV7eEDtkD_|qKkd5}Tys(X!A~s!9u(3<5 zMQv2K+n6Hfqir0Hu~9nKMyEI%N$=R0E`OA;@nuOHi%QveE0xRGSSKGO+W1F&Nj4VB z_d?KyC)GwP`8mzTIcb${;|m#@VPlz8&$Mw+3?Un*a&0`$v$48@jdyG7QJ&PX(V?!5 zkL6oAR8P6oSI!M=T$JIBZ2Tr?rCwtj-^qg}Hrh0`(M_JnkY-x5rHzvk*V@L{Vs2xj zh0JejqhLGb+sQ`Qhsvk3jSceYCpLD9qppVI?{&iYa6jLQVx%@5gKiyp>z|&H03H&r`xzc!$$T@^>miNwtg=ycy^W31^+y|n z*jOMx%A{>J`tMRsQgpZKl7u~~MUL*(`Et<4gi|)|i2sa@Z{+^(Hr~6Sb408cZS<8n z*VK=jnkT2E)Gh6=B>kn{$>zUpIBwfWlhyy&D1KM-Wa~W}ze>&n?Zrdw(<2*4fyPTAJ@>Q7;RH&A zGoWNRf63WW;gl^MPM0#8D?{S7zLYK(&IFk&m*w3A<(C*vZ254;$;qT}DmlV2c*9vF zBYfc;@`sZh&^qGI3TH)~a6EOx`LtfR{+TR0PCd-rf0J;LePGn`A3&`UXd8qOPO&?j7fr-ke9v~YGxuzxrM2ZZytlph$* zFeyAJoJ_eVVS~eolC&?vsVwVc+Lz(Hk_ulb=GWnL8>3ia85d3;sWCpBmGW>xIBh3} z(`-^W>*eKS)jTVlw^DhIVoBJ7aJtL-h2hLt6i%Dr*=kAYF7kveu-er?g(b=iD13WqH0x zhUSmtu+%OP$-;t>{390&Me1ixB<*E)L?r#9BKbvZ#Uq*0FOo|#@_W7ilirtz&5>*t z^A;VGM*Aa~C##Ps{sqOCwSPs@_)aAAW#|LVdmKr@Cy_jO8_D#7MY$p+$`_@coUc@r za+QlxqkB=h4=lO?|BCWlIuONnLloi0DE=`;@vk|G7M3U$i`5!MJ6R<~ZBazzi=wp@ zF0Ap9Q8bZ(_9)uMMzK;H#iAHoJc{JfQS_CwiBWWMM)9N6Nsi*6KZ@u;6c00_2xUca zBRh)Ixlw%4G>YG(#QRZfX&;59Lloy_N#`i;%X@vIDBm}Vg8icK4v1oq{3%NYD%R(U z^+gn8hD2c)sEDN{XI~VD_eas^*C?7D zj^Z0RbtH=4pG1-HG>X_)QB3(aic3--JHLrN%+6w?oz7-E>m|)xP;mYa7|Q(#(#lxt-cAl;8Vyy2_j$cB=KXGfA3!Y$vX_oeyMNA3IkE+HnuE z)An;aO^4W7DEYp$bN(wk<%Zc=BXdUCxhYr1*!6{?V#|pscE&8Ub4I!>u`}RXJKMjr z6TZ?;`&D+V8|*Za-al)t&59$ot#+nwR~)Ik!_Ln;?HG1xy%Asi1=0@{co>qvaQRQgnNuesyl&KR|(aaU&X7y%oGzIrXQ|eGO zB@ai_MefM-qnal*POH{y(QK1Cx1))F5KVVk^*oxbucNWPiPq<+7&;hZSS?ZJ7%JzB zVZ8YB$FQYn43?-Ero9tGyAm<1l8q%}^!Y!AyYjMh44GwP^gUt>Gs?xVJt2nh#26~d z3U>@oYsNss7~VFG(RJJy-n5FLXU7;e z%dXBbwCWziGFkAk^63>rLm4H_`zjatU_cD#2gOisa13jt-IvN$Qim(ns2Hk`j=?xS zhQOp4K9?IZVnGbYW&83NmadH9fn5GRhL|5>XfLy6=#McRmaQ9Ncz1gYOQg)s7>4hS z;h3!3r#1G+Fhu+Z)PsXDT$Q$mVpw=2hJU2*QH?vU+T`mKF)Th6!#&w}TCvZ>5PLR; z2D0LU`X%=-#xV0)4A*2mv3wI1%N^DnP$`ytm18MWTX7o1lHM>@*C}Ip+dP&UEn*qbGM3XH#!|X-ET$f@q>JBEsnjnPL;qNwNbwK+}V1ZA4_|Avmlne3u7trO)T#$(rc-{IF`msV%c3jjzURscvIqNoE^t} z*;_ddYn3=Eh^J~C17ugVI1W~iBf3T$J)~~KIA+R*1BWjh@29~y*Y7Y&ei)1 z;<&Ipj>Hvle6cc)kABn|;@lWVuV3QWDn$>*vFK17ccsb^y(iYAT1#S%#nE17%hoLi*T?aWkP9zQkg@%`Hap z%Ejm;7h4wNWcOl}>`{yhyUQ@|K^Y=nmEk=x=8tDUR6Kj+Z)ZFXUp$}6nTqiYs}xV& zM)Ay)1?}S5@?kud&heD#6;E>+FW(J{=c!B{9#7M+<5?)f#>Mm7qGdrSG<~td#w`$`bjDVjV9_ z>iMD&?=1)%BRNRK2Okh;pPwmSb9na#Z@L9OERuUpdyuEAjU)$Dh(>OgX-j9$U(B zdv`ff_mpGznQ|0+U5*(fa8-gu5~v%Mz)Z;~oxnfw38a-xz+Emu*F^MM2D%c+Nl9Rr zH-Xo_1giNHSS$;I3EY+=sR^vj&@ow@l|ZeKUgzqy1o9H-Q6YikiV6Dpl%W3x5*Sb| zfrm8{cw9Sy?e(-y!vyvE~`)mT!rOzJ;BwSA5V>x?0fnRQE{$B|^y_>+>rwP<}mcYdqs_k_Go8-}( z1a6uV@tG4Tk}nZg{zUpovm%Lfk4R*r?21feR#YO_rGs5#V-p!H<%%UTT=o=Cr0_e5 zbS{y|?ZiY<%WJMPk;jsooX9Pylaj~`i4H1GW+EwBiB!r>WM8#JBC02Hsc|BGS|qYl z*1VTUfi8(OmleG=_VYvrO5&JA229j?k~}?;WlIxzC3vB|IFZCpr<34}-v2#`3zw2eyqv_`8%fl;nZ)EfUjTy5;&v3%de!8S>0>Y#5k2RG$mTL*@A4z|i6$!+gocn1ehWlt9er)9!N z4i-p6R|hS+IdmU{gCYZz&p_2FCq8!&H^jjx={3~B#;+VC4Rf&kYlrSs5 zTBn$@Kx(ho@gG&gPYw#pG3mBJV}912Y;-VZlj3aF^KE**UC(!Djol7xdmPl?>tKiE zKcqc4;-KqM2N&e$;||@+=wQ`J2k)G6;FAH8cSd=ib?{8`pL0;VlX22THp@@%I(gI5 zNw-!`ZnSnX;XNm3-gnZjt&4~s4jC}O$tX!06 zCog2(mrj0>;7})nzH;)9ypRuuJ1O(Eli%c=G#lll$Y|v+n`FOK9pmJqu}=C)(Q&Ft zF3CM#d##h@8=Q>W?BvuICsnqpciZ*e4kuf8I@z+ziD9?a{?$qS-?g?ByWqqr|NQCX z&^7g3W?WZJ5_dymZaO(8H>ANGC#@c;r;_-{Nt!H|`;V2!6DOa_<(Jyif1Qk!ivKxj zD7z(JSTX};g1oXMvowD)8|32x$qbQ4l36I36|!9%QOR70P3Dd)i_=)?S1OrO<&yEr zZFwc#5|UY;m`vI7$z;f4S2Dk5B=fsW%}i#AL}w-QUUo8v<*E#?m`s&=$uyP1^%YYl z$+-r})M%)&a-dlJb-zT$Zbuue|NM@__U8i~SLh^o0W{vETl+DSs-l_iVN~Y*9T1%$v zPv)B=$*hxZN0S*W_aybW_D5=-O=jY`WcvS}%#26LTzZ_W&zi}+^DLPT&sBpId6i7_ z*U9XcAKoO>@~vY2n@q%i$+W@6vM?9X1{d#{Tr4rWh_bjS66vCOQN17MBBQvAnqqv% zMNt_phf25zm2}aew2SY`xF{Cy;zn5)t^^lzC9b@Swn;9I$xf#WtINe?w~M4y7d_Kl z3>HVai;pv0`u^0#U3rk@B0c2dTPcy};)4noF-jiG z*s(6=N%L_oK9uuPdV-6U6J6Ap>f)Q}F4jr68JZ{eBz2aHT60}YU+UuGG8c8f)talc zzRdmJ#VRSe+NJO2U7QxfI`vZy%SEZbUUPqRVfjgQ{;WDTs!mzA*~QB(E{1J$adekz z+wG$GSr_fksW<0cwE5G;(km`bTy=3-US3n)H?)U;xp*bk+sf;Xi%EA~gxzy7^uCMa z2iiY*CYFaT`pb?-E>a%5X!caKKhr+H&|aC{Y_PaVw7NNDb5k^*o3Erxem83ixG7!G z&CMt`?r1mjq)ah4or}Bq_Z>G?OS(B$%B}B@+?+{pQ!UX=LXw+q4mW?uL8qHYmz$w- zKgCU&&#ili-E5IZemA>v+}QHm^q03a+!U(m=75}&TD9Cvs_iDMj+;L9+=SP6)1ZNy zowB%zn~}}k%#=ng+_aZdQoN;`F>*&{wsLd1wVPLM+*E9*+S$y&3J+bxAkXCo0}l zjhXIdpq!tje$8<+QQQmMe7exhb-Dbl`n$rd@7UG5)o#|TaZ_ron=0#+?|L_{rRPuD zhYhNAtDBtP+|(1>K{v57S{fgA^MRB+;>II~k812mHzTCNDfLF~pH^OfDz7VUT3>hb z_>G&ae^ryL|4+TZgEh>WVd=hZq?p$MSoqP{2ch zf*u+d@~~U#Mrypo7WI%Mv*k*ZhlX|!Q=>gxi1AQ6)dRdtW9t$FxCR@e3Lw4R5K^*u~z=;2Hw z57iobSlrsf?e{zw+jywe)O7DO^37one;x7A;;4Fg+{2_39>Pv~D0muYY=IeZ@l;c`Bi69#+XF>2|}z3AuO6L)70M zw#w~09(?z-wq!o?Fyyg^2l7@bJW(&@)2AM`Jky@az~>%zz3@=ym4{o_6n#&U!hBhq zFNNp%Q~0nz3SmW3s1cEZH712;CG=P_gAgnW(wtIr!ZCio1>iPsb-nEKzS}yp5N&C$`ov?Qglza`m;8LKYvIeZ$kX;#dsMg zZHjqWR@_VUJ6;Z!^AefpWvC2xX`I{3iWDyoyk6S+yc`O8>7VLlN19i^C*b9GDU<1C zk_@h>@s+e@WiPv=Q57$Hs(R^FO}SK8Y>BL?*s{Eym;3dVXHzew+Nh4Uszd&fp`E-G z?BS(JPtBJLy}ZQtR=$0_I6qgsFTA`N;$^}x%^B|1&k?OVTF1w#9{Fdy7ym>ri^M$H zOZ}-{&QAAoafX+2v%E}|OS8Qs%=I!&dd>H;aeh#onOFDJc&YrY z)|ARCysVc3YrQo7LF>xj>%Dk?^0H8dZ}Q^atbN$x<+@DU?&Xgi+LK*gJimJB^P898 zG3~=iFJGVX@|Jm*4*Ml66J-%dMMU<~;Ip^|8i3@$$uU zFZ*6-y??zNi1bmTjE@QNKK_#eWqs^U@R6^)kAX5$;*)%&NLPoCHBKMTl6`#X_L1cC z>32YUT$UGEKJr33E-i9=EXegyIM0W%l8>L{O=ZQZ>SL+|YWXNvTk-1nxFCPY!TLTT z8~PY3#~b;GZQ^5bQy;C`_*m3d$J+U5Am2-7dmkMnwu6sk$(44UeDsi=;_B=pN1ltd zi;n@a^CKVLu0Cpa^RZku$e!-1;S<%+TQ$fXIoQX?Ir+4&kKvNn&qsaPCAI-R`pXC@ zJw@AkpYfqM{&$3EP z%hcCzwP(wHn7{MsT8h?L?<4w0AH6pC*!Z)L%A0&N+U8@{b|2w86mOT0lDmD3ml=nA zTsrKd-VycfxO#fh$7(ru%E#!_+LJRrMxEC=a?MAz8|t4NxTQV*+s7AD?;ju2?r5*X zc+W?z`#v_yjA!cMbM@?n&Kp_u%E#ZYeZ2cd@BQcFFn)5v{Dh2t>WbCmCq_oeF|(fv z7C$`-`T0UJ3;U@lTf`9I=MyOw>nB-m$W!?+&d=&%eo7YilULeL1IbrL<7BLyjQ3Ny zte;-VeuhfO<)@Bp7qiDtA6XFab2F&psebNd`bo|9vsBvU`B`4UPoR==sHq%k`x#fq z&+CSMDmC`APNJImY1Q1%L22L8uY02X1mDxK_I_S=@ay;G{CwBT&%;j?ueYB@gZ#`I z?5Eu4s(Y-T_s97;BA-q1vuCR2PV@7-l$qgYlKehX&u9BtHOEi!m0Dw!=B`n1w)z>e z&97@=T62$|2YdYt+VAJ5es*2+hDWG&0hKGAj_rpYd@3UsHboJO#j!<#s73Z5TK>(Fa@w!0!*?7 zD3m`y(*gnhEEpg*B0!tS07vBysa-TcwWt8&>;c|NzUTm>VgekC4NxI2z`POx`jiat zVW|MCO9v=fCP1<@lGjqHY=AIF0Fz6x+?pQ<@Lg(vhiL)UhO|~*fMpc|x_>@EeC+^T z>I6t?6wtl!TEAIBwBg9Ai=7NGu@0j3XCeP0I{Ha5V)aRIW&2iQG9xl9T$P=1&h;Ki%}ooB0_xdE=v z3(#b~YF-%N)HeaDEDBI;Nq}}s100u|Vpyj9z70@zMSv-?T#Bwy4Zo>|g8|M<&BFmE z9tptF0H2)*(BNc%uBQU@{73Wd1?YA^K;8rG$HM>-&jYl05#WGqdZoO>g6ua2DP#`v zxlEBiG^ zNik%LGl;IJFR zEXcU#L48LZWaPU+j z1A}yub5d$>kncXznnQ#1|4KDU9TxHEKYW{@a3BA2AWEXAB1#5yNP*4!Xp&I|HTX3r0D zWr6zjje5N-sOuk!DJP`G>L9;w*P1(m9N4K`_bHeCK~fF`^}ALarY zAtxm6hH8?JZU*_`R*=x&LH0ZjlK*LtSQ#rPp9OjUh5BzzWveX}S9mI~i=2l|boK!po-8pj;|DRN*qO>Z z(oJf*Qkm#ZrH3b#pHfmu@TO8eQ?Ij98D2M4_jIQcs-H?qqg47fPNhqWRNVumI3H-u zPN{s0~PFPo+}!bSewaDgX1SH2*!7YL`+mUrFV6OB!WtX{-uQBdk~& zHHxQk@|`r^OG{%(dK%|4(-_`3jYCb+2sKTkp{$V;AEy!bNgAIGOrzGKG$t+9{3U5b zOM6-UT^dhUrjc)rT-Lll)5y7%#_Uq*Tq&JS!!qfdubfWls_7J{lTPlWbcRn(=kM9+ ze7q%{pSPw{X?r?14yEHdlFnQy^hY{PFQ&6suKksc^L9G3rS#o&KD?Js;*)gxl+9pk zxeQ%%%-}aq1`*y2zLbaA8D!*Suv~go$zWsE43es4P`!2rr*hvz|<{(=&BXb0!l<==I1%wVC+VW%7-@J&;M2-*oJ_=H1l1 zTbb0jo5|E?nOu0D$?Uh8+$fNRt56o{g|lcMl|_Z)E=lkxksKZ1qy>{hiI4+u3ZD^nbGX{7yFaWb?gj!X9K(NLI_!huL&|l+DYR*;II~ zxUy0Hdy`Gix602DqM#|nXY#W(#J{!>J;FoGC=}vS;Sm4Gv?3w?hzL<9GDOL!5c{Q2 zbcoMoZ%l{+aUoum3hA0hNY^<+y3P?|h^$D`97l*L&Jf1r5W_to4yA+$c|(*BYMs;& zgQQqmh<52Aj!T>D5X(X#qH{vrsT3kmCB$N>QZ2-o>LFfB{+b~g)e7;846mb@brrK- zh!*ujENBp-aKjJ>8tJh~h%aPL(-2piX-@MHHQx&{@%<3A39+Vah-d9WbZW1-okCRV z9Acex`6$HNt|3Zy3z63=#E4HcPKxvo(R_gFm*K;-?r^O;BE*lQHGfQqu4C1!iR#s) z5PwVM$?D0J5U=FpS?cfX5PcUa=3>QMqL`9@X^17OLhSoV`|z{&L56Qs>`jWjImGyF zAx>`(QFTX%T6;oF+8ZKlUx;A`LmWI5;^xs1&*g_>A$CdI6CoO$RzIcqnGnhH+u0CB ze-F{}f}YFdKSG?ps9szO(f(eD-r~L=B1hK9vj^(QL-kM^zX&n=Wr%#QLhK+1iy?=r z)*MR4=Fl-NhtpEBgr1kwbGctShqU+{YLw04Ot~CNB<8TZd=7nsIc!VK!JU>vwe%du zW#mvNH;2PDbBL;)!!Q|HCx;_-bI7figRwylwHoHISsYDr__%2ff6C^TIlR|8hmWMy zdpRt6KZiAPt8EUR_BqU#Q5|wP_CXF6Ix2oA#qX^6vbSpv1-j=DCwnA+&m3Z9k^KE} z4$oxJCprAmJBOn(^wS)E?V~!RN8cQN>X*Z(pXqUE4sX87A$(X4UO6wNN2oR#EyqXZ zQ1R;=>d8on9G%0vV-!oyh-<9!8<#`OgdEDr6k%cx*)mp6PRh}_lS2b}cS;Tmr{+*( zntCaBW$yGG?ulh)4yIW-)SjKg7C9h;<|zNUIr!)0&}cypvliyiVp$G9uFm20nj8!p zbNFCS4lDPnhX->ge@3;P&Ee&_9421O;q0Xxs$W)pe=3KoIjomich&oQ%ICgvd8A%H z&e88S9R6c*QRqBxht3Fa`Q$m?pwLo|IWo!GLPD&@;FmEk8cz6xK}=p_mlE? z*O|w{S?uPW`Ol(v>IH9#20#@bQ>_TaQO&bbD(zI!tHceaH-5th;>u`4&&T#kP?#>u6++o9Q*pT7w zHhl2Bf7k!vx?We>bMABBU%5lu^rSf&c3Y9Pch6a~H^0rd0mirSp``pQlXO96596D^;>U zsT`%t<}FwzkC8b}WeA=1zq$VRZ%T=@p#MD%#xgW3Ctbk3@=}2c(j=&&G@mY}8 zqu%o%O?wfftuKRg2qj(xsp{t-eKr}?JlLSKkp^vc8MGgdGZ=Iz%Ajn~25rRd%m&rZ zV$dI14GOpo>V@+jgIdQLw6~N&f1zw?gASK9=uriOEL9C^Qq7fXYjf4dmu?`qH(%s_>11`Wc8?tI+Cpe#KNO2U_31~u)?wS5el zgWZVfOKh+VFsLzp$LoQtJIJ8CKO59_utD3gV~9bvp$6r^wqfK1!w7>)U^fPh;`7l4 z^&4Z*i}9?5#uJEjl0lkm&|s{XLe4le)u6Cnh#T*w5&Lw5@?j?~qU&sf;^!DtXr4i9 z=NpuJfkDGD1!~j~{mPoiw!xs&xQ51? z4KnRF=os=GU_4BJGUkLq&(9F|6@#o-4a$ke7={H{iz)vYH1mc*EpF0x6uw0~w+)KA zXV7u%dtgw*$E@?rpvBJ(TKa~3-WqfViT_fc_XdTd6xPD@k^bRlti%IYKN*w}Wj-_J zi$Sjc4C;@+ao{U^D9ET~2BVG{jmj8e)DLE(_F=fis42K@HOgr>%8k~cM%4~8suQA| zMtSiI-lJlKQ5`T58*u?Uql~%;Z$_i8qgW=RreS`xQPndW^&ADW7}WzG;m&GQW6Z-& z49#ZLXtz-VV~o0qMjoTiz#3=NX|GX}<2jCA2}Zs48I>c+sIh*dx~1}QcBAg*FzQB5 zquwENE~Dn=WgM>OGwN+YqtXf)^>bmPniMta6avMKdWGR7j9Q2LNGoa7ILt=>Qp8)@ zs9W%qKe5icd?|NQ6K6XwWFC)kMSN;o3nNca%^o> zvo=OeXlv8~yupL^MwvSpH3(syj7mfWTtM3{Mjh^IRJNY<5LbE`_3S63#`LBiedv8Z zqxuan>bpTk{WF;LhOk$L@l|HHQN7W5q)}}~8}$(0F-9GlXjGm_?3Mrdg&dG+8f)P3 zbUvP8RL40+J(_D&mU%|Cz^VDnvB;>TrAFmiWmG$ySZ!3zbL;q%t;>mSMTwr0St2t%lWMQa#)Y zGwCO%Nn@}91tUz#9BEQ2GG*Zr+wn&>leT(H%H=g_KW?FZyh%sUB!Tk?B%1ULZIVs$ z`c2B4V$wGB$zjs2Tqe!VV^W>GT$j(JsDdVqM%lt9O+)D-CQU@^q9*M|v0^42E@9H| z6-=^JG^raN;Ll22U(KYt)lJ%gE#I3|sGdn<8<#WSee zEb4-H$T{1jxi|{f9FsQ9HL2M`)6e1l8DkB>x^E2Du;5@_Lr#0JP9slfutLIun6HzraSU0i<>lrTO43;TR zuof3a>0p(v7Oa=Gg0;T^F|`O*zIGgI&v<;-Ay^AK1?ydxV5M~pR$CnI7Oa~+iMbE) zBTwI8okYui!TO8|{eu-hAXqz)J}6j4kmKiI{W3UMcTso<>tHe(59L~v8WyarNF5%m zMaVEBSflU>??wk}=)_>Tr;ra$VEfcyEtwIlOf!RZ2&r>|Wt>Z%Xn^MPf;D78uvX#* z+zW{rbr%QAza&`eehb#2jYF;{}+xEic}IE=2>g7pgZ z|DpEyc0E}0Z_tCA!CG}MSWR98EB}AN8mADAF^A|^SBQ2YC_{*nunn%L5bex}=n!?x z8lwI&AsUU%@Otqh4DyE0%9R_C)(QjCrBSbgxXYLR+%^RXm_%mOK-WOnvf+4D3C`5^c zLv*f4h#C|N(KsAH_2MB~23v^`HN*+r#m$n$UpYi8aSWNNglI1QK~&WcwZR%ZLGEfH zYKI0jLevF+;A-s)UjEJUbbS*)*%`?I7EM8??`Ggn(I(;4E2C>EHUHK#1QqH z6ryL-L-b(|dCm>d_<149xfsisdqs%yuMAQ8su0Dl4v}$9h^G7+qE4Ga)O9nt{~n^! z+d>q)i}Cx3=Pc(gaPC@&)}zsN`tpb#eF)K_P_q^~%o>oztZCSV$C#1LtmSUAmU_%O zhdHrk)r(_nyjg$ZJnki!^#;!pxz5MAB(v7zRI*vu@WpSIEyb)>0ke8wQmR?=u`SK4 zvgu}>!9SRi-K+)pK8ION;LK^38z*oXhjW=#J-1oE<~8fzd}hVxCtkcSVb*sg%?c}J z)(YH2hSFyJfO9BR#;m<%$p_=gn>7nJD-bURRW$1^x>e$1EUj!-a22z*;2<8NRaLWA zS2OD!N_}V6D^#gr)+&_#o?Ng7@3Hj zm~B?gIm9*B%>Qxhm3d}uUSL-ELbK*AH7jX3b%bN3S(VqA`FchDw@}BeW=+IO+{XBA zW*N4d6^%2Pzt^m$`_1Zw9}k$d{}46*)2x2jg`W=7yCd`y`;M`HaSOj3H*4fc_Q5IE zJZ)Bqv+RMtsKGgUeBP|x7peQ-j6wFx^aQ_S`&H_AjlFZ7J&EWW^bn2E8yoTKO|uT6 z^DX*<_jkzYF13aI9@k(R_Te3B-X{m>5wV~sT4N%fA?stal9A~Zd(&W1u+bt9d?6Oi z!!1-YTl5AstQLjaEUJKxc8jcG7A&zB?@G@t-Mc>dR z(W00ni?-m0>=yOLaLmeK(V(0bWyxjHI9$qY(Z6Vr$D#%KEwUG|C>l+1w4g#D?7&7!{FS=8fu zi@vXE(bYN@jjU_YKAgmR)Ng3fdVIs2MiymgY*8HMAzM?6o;9F{Hz_97W zJkz4Vvn-l`HAtOp(cgH8dUN=EE^(pme2eBH%R=VBo<$ZJ7L)rDi`K%r%%ZAzhT+RC z%Duv(5@>`6c#HijEjooK=&*`4S6dXd#-f7jEh>lRc#YYc*x#F(dn-9?w6*2i`G!V%ctaQ!FtFmB;1W`Ab7P-m2sTt4?EHqE)ML7*%{$83T+*8h%He zyjCsEXVq^wh5Gre3MoL$7>!eft;$fusyGzGF;p#KRXda^Yt=Z+!WOhFXH_@Ut6)`d zMXRDPuM+FyQZ=ipRkx}kx_xKWesrv1)d0M}7xehvs)wiZq`D!yi=HLc8)uGOH zt(sDgHS4n`wxD4Ht1JzzipKG#%-hVW>8-3F{rCm_HJB@Yu&9X(#NW2h#f#L23j>1g$7v__A~3^ zBp##xVAdXO)pFz=Yt>%N8)wxyOdW64?uk}Sn@NAM7eCChs>K|u`pvcKHRjK=YCQ(d zr{4?6XE8CN<5udngBt9#YS}J&wVPb_u&=NX8}>3cKJO>q16K7sNNk6!T8T=35Ig*b zsW-A7p+>lfu%p!Q7`;ADy-%=judomQvGRhuRc^e8=?44ZmQ|Z>lPkjSkJo)6Eg3c&S(dSTXUtIoXP`S36M{5|^=;UBDOgmy4~v})96V*A2A z{>qpjo0=PJ>WckFn@*!yuuUgIY#MB~X#x(Rq{F6^aGN|%n^Msox6wbsrcD`b+M0=R zc!XxrHg(1dRLE-MwQQSKWwR+R&Zf0qo3^7yyiJxwo1)MPkx9&rUidxPrUNMGw`op_ zO)C+XN{slLW>fuin_9z>!=^R(A*YSk{%jhLwA?l=%S$f#Y)Z~=(_uWs%z`#mD`ewm zUz^Gnv1v+Cn-&$bX>@U$UgB*@n+laCHk2x3(=n7TYg29fjHx(?i!hh7DGS`?ZK_$3 zxo{Zg5mDKuQBW1u$MC8)4Xj43kgd8+e_{4_Hl4+iS~mTLx3z6*S;wa3c!rYoY??Tq zaf_)TYAvBhOKr-&+@}01Z2EB}d91Rj?`oT>tfBVnY?`#mrg_-=JH12qEjE2Y$aZ4e zVN;jgHhK5i^gWuO;(nWQ9keO-uuXUH619&|$D@qJ0Jx8_4k{hDsm}?Uo}RSnBkG@` zzNc;4e1=+_x2f?3o7&?RdR$~2K3uZt@nxHK-?Yj1ka*yFL>;jWpHS+tO_Om2!=Bny z@3l>x-th5TYWXko!S&9jOR&DTX%?1a{s-p&NM4_8`tLJ+`C?Pv%yw1IVpnWdyOw9O z%MxQ(c8^^b@Kd~9F^P74^x1VZ#V$vxU0G0|lwDnM8HG#RRRM!4+SRtIU7l)oRl!eK zf>UtTv&)Sg4Y;nMUHkF6g zuc+SDuFu`=`n!i+MS9xR9X}(emt8Ff*wquBfp)zcY?pC}U44eyH4?$Y>?)3`$UfYz zqIiXG7&U@*N85E3fiZTq#wt8TjIrh%6Yv^3^M2`7(b-_UVxq!JB+LaL{7m*_-{O@tG zT|03UMVC@r96{~nc1^<)tX*N(9TZ*FFb7a`S zTv&tcc>Wvp+W3El^EefUHrZv`OupEHL-22*Zs>{LTiGMq?7EK<+vzh#;n)sx+DT3* zvx~l98d~hOYcV!p$R6s2c6+&YpIy23+m-16wK-&0F^v0z*pE`jW8{6D{ff3HnCm35 zpZY)7d7N_EuEuBV+H{s4quO8Oe$KAA^Xw&*xj_H%^F_PTE>Tm={hRZb?V64^SLpLq zyYgHo?wfY`Zm|#15R-5pdGD|v@6!MOuk$_Xa-VwQ-~;OOko|%VkL;@PnEm|3u0N3X zDRZL4GrPWfZr1@EdqLk`*)`{lU2jqPE!W`tf9+cE&aM|I^PbPK135mhpP-NQ6YX#c zv7dPUU>~AC+m-DL>tH^X{Ks<;&+rKeU#T06->5yV<5z|1pdnNbjG-!G3RMsM5*(@@ z&7tauB@v;@kSSE%Km%k{X(@FK?6e7VMwU9jto`!v`~Fs7^>*S)M!blDq;w3VZpjky}%cAS|6%? z@c$aB{y2)H4WVlHTc|Ff`KC~H+sZuKs2O_UAJpC+ssp>I_wN7Ga!;rV@1-{TsQG@z z90=8Iya;303x^p*o50juF>!YKmefLKS;5RDIC@6yp$cnwp#m)mtn% z8>$?Ch3XKtpChL8q1t(YzFZ8|dMv#bs^9(zRh8?ZT7yS7LUsKn{k#*ZCU?p4NvLLG z845oo_Gh7Lfg^Ya)ALZZ!EPK!{uiMdjETtjGE}Y50}oN~RjA72FfzZUR+xjA_=*m1 zLbU@&Q0i@{CSw6I{~M}i=z@y~ykjmb!#kMXQ(OFjbEx`(>#z>#AE^yS;x$Tq3YGmc zb7CeQ;9vCkLR`3j^8axT%TeVk^}s!YLr$YZZLt$yO%4?Zc4!ptpk|0e%kUoQW(VIV zI+WYu&@enjF{?u}kz{iy587fO!t4&!!%pN0b!aL=9S*Gtb0{X7bU4wc1ryu+SYhpNRn)D)e(4&6t!c!$p59+DFrs*hoqlIYMj+(B`l zL$OK3kA>)#>`+O+Lyzzdw^E2TjX7aXcc@%;hd!fv4%W!&(9&H0r(+(6KA}=xhdSnW zs96E7Dd^C?LJkEAJ2V#4iZ~Qe)S=hK9I_X8=mJb79IA_aC7BOhOF8r#J|ex0L;qrD zS%-cq=g<>mDoI*eI<%mkLq+O4v>vey9IDXJp%aL0L+e_hGB8~Jyq ze`6ecALGzOd_>4t;>1B{9KFOeTtepYoWl_$O&~_xLXnBYg)EaC`hqf(9h!|5$UKGm z;mCCAGQ*(;FwJym6AZH)DmW92P7hr^OEaxWu8xONnP0 zdt$jmu9d90%ApRc9r_#l*Er-|=TLUUu6JlIoWJrsz%wLlaA*jQApAG>5Psa~P{B>q zd9y>ueLx>W;2EsOwH**hQ^(6Z;;ATJ59%2YGHBA$}}5=1}dE>>aE>MK3Nm z6o*O(x=1|Oh0~W9_czaYl!)0li|bf>lltO0^4wz2;0&rhpeE2m z)_KG_2zugBQRIKdTFuF!hQK z(=7ah!kNR=5T7zx4i%f->2aOAdX)f*- z4b!1wVS3g&OrO!bU6?wy4^xv4VG8XSrka?7L!H8Ousds`ZO0w$nBTUt1hUpf1&I;4DImA0ROul(xikly% zUl$PPqA>N?7^a{tJ9HB3XVhv`&IxN0YbE2&|)@*q=>a3x>} zHe)|LJsE@Mi0Kus04`wUPvQCn&3lJy1-kYL*FePf4Obe5!PqZcPUP$#u2$%dZUe%# z0lU$8V7U6D_8{hgaWLc235|z^YvPD-y+gf`;d(hLT&bhORS>hrhU?b};aW41<5R+Q zYHGNaOb=J<8R7bKX1G?(4%ZeGnG>$3^TL&Fez^Q-g+CCnkhPYEs|w7^!j*kxxSC-b z_N@xnNtoBL_PTH#S|6@18^d)2zikcI`fZ%w8Lqo~!c~4>xDFo-*WZW2weF8_Jvbh& zAJ2yC-bHG0HC%OXg)9HVaMgMqt`~2~^+UME{THs;K~Al}6{C~ynVoWkIh6%t!<{Pc zbZR5s!xZ7cUPGw4TY8=}6 zochJ@RGt*4eA!t$pHrLibG(34*RZFcQwc?#3RH5cdu6AJRCTJxcTSc5!Kt1#o%&GA zsb6b56<3E?>pE4gfs>!lof_DL>zX?Cv>9u+aLU`#sdufMTHe~JCn(X*seSl{g6+u- z8*l^39h@458+hB%si00yrFM0ycMqpZ^>iw>ms3@La_S9!?d{ZmeVocY(5WGVojO0% zsase*+^Lk2JdPoUu}-xe=agZ*Q}-q~RcoSC%_cF=6!MztROB?L+Q2p4sd_V<$}!8S zR_Km3NT0`bc#RSBo%~*#Ja$qiJi+(7sK;)nCgC&!dz>nO;V8D3V~6P1A5OKvYHY>* zKb`7ygmsV7v*S+XI_XsPQ%*I+tTU{C)~RQxd(EklH=XKm%PI41r+T5!9gaPq&JUg1 z{fKKHJGsZosmo8O({uLC3#a~k<<#td=_mSrU_73p^GB!p!~V(1&vQ=QMY;c+I)&-q zocf6VQ4!jXKViujp~IOXbR;@L7jQC5gqp@gsBLV7I>$xG=Z(-~+>4LUu7n8vofx5| zz6kxA9HA9~2<=Oa(Cl0hnwLL9y9-39P(j8OiqO@<5sEAtp~1yi3rmZ$R>=qrFBPHK z(h(Yku(A!~M`-y2u8obAl zQ-?_1MNG#?jmK=X?-9wKj?|-{BXxNc^GuFZt7(yXzAjSp)<^2kUnBJb?oE+;x;aw6 zY>CustlAo>n%g3^3E|r#^#eAe()foFH5rl7^1NE!DdbqrljMC#2+<~$XtgXbf4=pwORiqya>kvf9VtC1>vEmAB0AqEs*}Z~t;mqorI9#| zq--ud!&XrZ|^cV20PFHSsPDPCz1YCAst(+mc<1_Pf*t*Hc_79B`>X zno9%lCnD2bYKX1bSto}}Idi)73N>=MG#@vRnwvRs0fqCrv=p}sxRhSdr9nt8#CcqR zzpzUMi@5YNqKdin7-fqSPYIWTOS|;04EdFH@pFkwu5vDo#%t6rPYf7d!KD|dSka}i zh^ypMNA#`i(n*Y};!??~E-iwgnoD)zsLp(-R>Q@;u`d1ogG=jbvKFe=a;b71m&(_7 z>2d>?iZ*m9xpm-06y@8;yu(xp>q)rweK6BkCbacS`gmr};KG#UTm z(>UUqlwd+`L=Tm z#vLv--o?JaOH|xVZ*doS_P8_!`S(&+%-ctP2RV-whg@p@Cwma1kGhoWm`lw*yR;Bl zGG$OX^hWOJ416D(L3J``(Ci!;6jL{YX0*(p3;1>*gC4)gpqcM7=y$w?KPXDS+oQBK zEJ{HA;r1QT+T7 z#cQBZ>b)mQBM(JsBi^Iug(yW_i_()vQOf){N==_cX(_hjFmk+zQstl{M| zYgWC?^7PHDY_Bq_`iLxga5jrB{*^@$J+sNQCYuVa&!&|}vS}wy-}*h^pVaRUd_G zxm6Lb@UppErP{jHr;}R+y1TUyR}j_1tt8Axm!59b=O;(k?d#SC)a>Wh zF^uZ(R=q)-$Im#1qC?%vGt8~D;cgYe8#Ee0ZfHNst=`yy)}!6(fz7x)#;pgKG1jeX z*1b3osf5? zTb;2AduF-y8G+eu-NK?d^a}On5+9=HaSW+T+?ux3ttH64%&oG^$pMenxb+T+>o|_> znDv`mqc@QU-ogDlec$F*9kj$zRM_p-;=OLo+{bnM-8zj92k7fTYJ|pz+-h^!t)BRD z)UBAaZvB8CaUP{FxRvE9djjKe1VgX6wHsNkyEP9RvF-+W;MOg-KHPRI!+rJ%%0F;( zKbBkD9&^nTw}PI!<$b{%=<}A?QR83Yd&jyTiR%-!!`3fuUdMOq@K^TEH}Z~+QA=cr zi;*inMs2YhX$dj%C&$R0BSxKY5xFYHXaXiyiqRe9s2rnZRbrI6YK%@-i_xL)V)Vxk zF*4MQQNCInuN|X4bz`)-NsP)hjnQR9G>g#_6lxx$q!uyy+B!yC+s9}@#~3y46r+Nj zV>G5qjN-b*s8#nEo$L`KM=$0a$D6y$WhGrh+LVJWX_h>y_Ej+3OZ%f9t^5{CwxAv%B z8;`a^Z9OW6R|sn7(K2Lf?@>=o!3Qkr;L)$Jb@ZqVrr{=@qk1Re!)b(c_Gk>aR`^YrI!)pc1JBxS`G25fHxQRM* zSZl6Fo#%NJKHsBz*s_4WB5jdJaf=y)%djr-=x0<~=Fv;6U+&Q-oL%A3s5QjCmKtvK zs1{md3KrlZnr>nZT*24P9%cO9qfQtB-xiO`BKKC0DsN*fdT;k=749JS4(f(uJ3Xqp z%cEvEhD-Q{0=qpLj){9bnv2-I9u2@*Y~D|P2Z-+vj~-&^pB|lq_pnC?aO?>4AmS)} zKr8%_Vas>vV7!u5E9G#0AlqA+?H5n zv&PDg8unQI789%b{#acr6f1j)Sna~!Wny&?zKXG0RVh|mkX9|0_ueudZ|lS=sBWx! zplJPARYK{;v8vsXHM+#=FTCv*tH>VAgVMcXxo?^Ieu|Z=FXQ{gszU!*83!ARt76+?)q7X0+8<)wQ?Z(GmTM7mIaaOi#;QBQ?!|JSV60Z7%)?l9!Bgaa6sslJ zfc=kSRs3nJHsiyySmk|A9q<8PUy{S?SUp0=_p#cGzfki7HU1K-AHT+`6E1y=)m+7C zu^~KYlR`|x|>)F3HNV*+tX%M+*dMdH-6L7d8Wj?<&wak8w9 zQ^P}Xx_UZJlh4K}`CObl7vgjq{V&GpB05}R%-?b9_b^UtpT+U@ElzE|#woACt5Wz2 zzZkt*gRA(8+$OIEz#HsU*$}Ui%wDBgyn2p)R<9-_)aF$s{0E2KtKX0m>Qx6E#3S5y zczG$Bxx&4Y)607`y}A{_Jg6S&)y62Vo@MlEZ=9Fc7reTFQ8~Sui6Xg(4Nr4>)h>@$ zKcQ(}uSVzd>IxoUb3w26qjhoCE8*2UtSIS~sgzfd7=ycLP}-|AaF+4%{sFIA;u!uz z?Xq4?!n1N-oh$FvO=POz)l~GW;njj4yeeGRtDg9)o>!OalNTy9^lBC28&Su`Uaf25 z)x#gX8s5~ae9fp`bFX?MXA6#FeoL>uwesqCYp+_h@ygKFtNb0PcSqvw%<(SNrz^R1 zXYL+e4ISWBn-N}qF66qAUJV&VjZl8HS2fWeBgS|YG~TPqlj$EyOrgH8F7T=}7A_?I zMP99id$CuGmUy*ul~;3Cd)0mowO+>>>%EHjl|KFE)sn5`x8JL_$G!X>+pC5rr~&>$ zu9IHw_n@w)h#&p162Id!DxLPKF8)H-GhXdF>*f12>hPCW^>7%@bM)~%dj(+^*+*E8 zuuEQLMGI^|>uX*uL*0Lf56@BghF7O>2ew;YMdKP$ZhO_|0oOe8YRVJp`IP#JE_A9L zFLRxE9YU6RjB6Cndqd)Nqj@~{Ma0X|A)Y-EuY#T8wYxiU^omy_tokWlThOI$F|iT&c08}pFfKVGf@@tT2as5X#Ta0$Qt9IqN9;?-;lam|Y7{-}6u z!$*{u6R$sDnH#SZw7~v(@rqawuNY)pNSrI;Ren{xF5<|Bco}|+SCftLs z?PR>dPca{EqVH+0N3k>Hh3R+-%h`D4J;!-0#lZ87$46|q7_Zxiyu`ZbjeqbMtFOfC zE=pdDSL$_ofOZ&qJ6>Dw#_P_#ctt&AUL-#z=4bKTYZ0%eFUb2PdE?}3>hq3XVc^Gj zwf+>Zp8v(`C>kk2{Sg+Fp!#Tyqo`^~Py-Y+Cg?oYm=g3J!NCa{f(apfj-Sj4>TF4n ztO>f0w-{tg&}4gp=ED-2pzauqA`aFGPtXShoCz9+$#6y_=t5+I?xChDLCxUFn4lIo zlqo@7q7(EpUf~pXmt0zH?(H@IY zFg8KIU?w@JBD6?P zP^;_-s*@u@19B#)Yc6uhlfb=9%$Ywy%?l;yVvz(DE}Ed3#i$z=7AFo|E|I|3jRZX@ znIKy!j^PoGl}^y#WfPRST!KuM6VwDJP_RmZmg5s@S0!h3Z=Rq7y%N;(CwkL|Ir}B3 z#t`Z_oNGrXX!`gBwVars3e#C<7Gu^VXc*;U;hU2v_uNF@-<7CIxH>OU<>x1A6b@q7 zqC_3TPm2>3xinFQmnW(lOe+$3Ur3@>txVJl3|P%LELxkWq+b&?^!G&VMwYFK%Cs#} z38;XRJIHTmqNeUj)YILG%DacyQEXqLwxP)WL`}nxLy6jl?td^BlKvzQyh6_-#Ez@S z68WAxQR8s|2`3UY88IglH4GWgC#oz4V>2Ej%Y{VlHAqxnY(~VTMBTtsB>bJIyO$HS z@JgZ@TxGp$iMoV5*Ar#Ek*L2OCMxt1J$p>eo+K&-O;P-5qIw|u896*p)H|$tLGQ5o zCC4!D4ZV4vs9OmA%JFZBIwPN|nS6Q?;!}n&pE`v5bRYIepT^@{CZGPw?9;cbKHd}J zQ|%a^TEzM^InJleUY|ViK3z)kX;`vPxxV+w_JdF5&=13E`IN7YkH6#KleeBvD;xUs zdsCl&Yv$wUSf5^@T05T-+WUBKqEA}}`}7i3hx+6n#$ngKE=#YK*%mIn$?Ss5H;V*B&1~ z3z8#3*ZP!uBXe$IEPjJ?vrpe+IZojtLVowD7=~gpj9YxFj;;6t>sCHS)@{`3xKGPY z`Lq!!r+r$F^Jjc~Kkd_86g$uQuw3vd`l3(GFZt9JX@C2)0#z^j)C`l5^@>lAQR6DT zLG^3&1@3=*>V>%LKCQ(ibiY9jZ~AlsA-9RXIN>VLzl5%EB zQhOYUPSU?wl4Qu5q^?NImZZKhN!o_?o+R}{P;8PK$0cc&H%Tk-FHZZCv@bbH_xwq+ z6-`nZEGovh;#`O6SWzlTw@|E1lI&%Z6pf#75l<>6$zLf+*YFhGDl=!5BrUC)q>XS@ zOVSyPsZPu_k~9NLaiwOGs@G5Acb7@J-ylg-8YXE0-ePN`B=u>Mq}{DpuXU0tBcx4| zjBS&69VSUjIwq-frzAN$CutrA_DNFeAl5*OpOchnNRql>&QRtXm!uoNCaL14B<(=0 z%}M%tEQxzPlk@`Lu;fINemIk)?PzeG`k=~%BsGLCCaD*)T_H~-U1N=VN!pK-8IyTG zRWWKv4F8>E<->3s#936jo6Pqk$?AA7SugM(hCN8u-iOIr^dwm~ zkoGiL-LVE8o+WE8-Xh_7vfM9{^$IaBllAlKWCguRR#}`x#<$68f)zN1kLdi4INv98 zA9S)_Blm}7epjBX^QiVISyPbsna{r_tFZj~3&BBt-nZk|DQq(Mbq5}!U$rp`ClPJ( zt3DRt1|ov}Dv2&wip#Ks_*D?yunZUBF#A;u9WfuLV6ymC7@e^U7Z76gt0?+m4X(jy z^Q#29U_F}J{pyPMsOj*lOqgHa*Gkj>WuPBWBeL4f$Pz7BJob5 zpOfj|OuvR=?`%JR6Tz=5^Zc5-fPOFZD|xYBrPlcMWUZg?lh_OBx8AR?4Sw~3<2S$B zVEIPBe4G862j}mcL&>eIhg{p314od!gWBx&YuF{f9^dq<;sfSIp@)7|Lii)U+^GH7 zuTNP0gg!lEFFa?zzTg@pyrc)O{L1^9d2t$sH-0^M?^oOhKi}`Oe?IwD13j_%n_tgS zIVeTB4Jj&t;aDD$qMImcNs--}qG((SPtj6migrY%=mXZcQnV8#Go)yKR0_YlPf=e4 zWlGUg#73v6Hb$XOmK6TJ1J`6tQN3);gOZ*U{?AU)-?1rb5SOAZuy|7xg=$!eb10FR zqDsCLUTaBFXzmoX&66TuUgAX)^e;?I=vX9017Iwgq92Q;D7AQs3Slcgpf)N^Hu&TLEJ-u)C!-<_iK7`Z1!GvMA!t@e?}{uCWJks_T; z(Iy;3?^7unfedGe38(PqS!!^O*siAN-VKi3Owoi}DSC7#MV0T7>jV0R!4FeZ{xR|3 zSKNM*qI^$NwBdP*VqT;ufVj^oiul6k$oefso#71%=tsB=0mZ{(3@FVRP&W+6-$;lE zC>MUi(8z$UAm9q93%21BDrX3263Rsdv;;@+2Fe&v0Sv%cd`0C<0ewT|=z!{BOy+?8 zL8Zii>fivb_yT&2dPxDb#$U++)k+B{G7!*fv`b|jY`{r0O$%rpcA`{zK&I>gHODpN z&Jp1LpnyKWku#t|D36J_iRT!RE1=CdkUOBvc>*eqJ+S5ts0Y^K9O~o?XfB2o2q>yh zK38+X>=0xRU0o_1Y@qoJHBU+ZAewbS_p#Mq*RID^{mJRU#UqB5j2J{U7 zR;FfE0xDCVy5l99HVEh}?jTRYfU2NbBWezNWAbSd(2Ax31vLxE);^%8sMjH&(p>@? zj67YL566(yJ)jIdsLSAh=Hb(jfNl*Ve^ePCP=kp9Wt$RE{a=W2dO(F|a1LLwV`e~m z=W`qz76h~p0j)vfqXBh7mSgnh z6pyFrAO6AQGXb@_NUu=m5`D)rRJt5chbsZ~#ZfH27Leh3K;B!_2jh^B-hAUMQf>QO_kjiTtsd|bp7-CA*jo?)NzD26m zAdfj!&r#TtDyKD7)evM$<-PQ&nt`|WR2>aXRsYCTZGkI8s?Ojaw9S;NPSL4aiQp`$ z+JVD(i(e8_W$~q|96rLDl&Xn%n#{E+sd|E>f{ZJas!JGLI8|?8EysKqRz6jM3aOe~ zIaMX9q-xLisq)oI<-O^t%3LQ^x9X>APDAqhF;%(Rr)mLg9a5FQBROSXJVymZs{M&@@da zFsNCYCL*eNn!2?}(~g#D+>@QAb+8Rg(_Wl_c~F{G;L4~pWf+~Nu4B^V9-F2V44#vw zors>7rVF@@tn<_K%c3-8TAZdK%Q=n-E7SDPsx+-you)e|v6edEBl4_E(?aarn#T7y z)C0%h+McGS_;*K|X6_`;U1{op-;iZ@nyTzc(-;)po2IHbhaCIUbPbPD{s8qnoTjnI z({vR5Pf$xlo=j8cQ^a{XO@0i4=Uke)AlD`4y_%*GxO0u(U1vPj-JxG7b1zNB?=uD~ zpQmZde`$J&s^7>3{KYFp1f{D3(oE^<9FeYd_%SkFU68?*t}%FkGa1trmMLBPaTYzJ z)AaiE)b!R@T>z%G4eYk#Fx`rcdcDmXlW=^`&@fRx0P1gt%oR_YO$TOc97o{t(I9)|i z6Ol{P^>rC>FHhG^3|m25tJAe??f==tV$4=^_Y7XH)1Y3+b6alC9L; zEGSK?G^IC@CcPuDbVNizKomvky(wLKld95t`+xbr@B3WW=ZcxkeeQG4WO;UznS0_C zS{0|h+t_D&oIXRp9dXLClRn_Zt~d?a9jC8QXHT3~>}CAEIF&g-ZGXh+!?VOaAE&o2 z#A!V;F2p4 z+(ym!cr0zw@G>T4ufX;XO=@1z#P10v^{;Buaa=}$IFoXlO)7%TsAe@OqozrjwMuAmlfHy` zwMi>}FsbSqlRB+4Y3EjxChjn4E`mGB4@GyGbQ3@9H)+B#lggbpY1c)b-{tuOljb1s z(4?6-gjJ7Cnw7<@99hkBU}ZM58sso*H;!RQPP4A$GV30)=QisTG|6Mu(tKtW&u`X; z_yYysHfvZxv-%b>YgSQSM`AIvmY_m$v+hqsTDeyhT`s%DL;W!6hntZ&v6P)(yV-I&GPJG93GqnYH&E{k>?`yN}H3h|f{(u~{EIG3)44vu?jI>&`2Bgk`U(K^DD}#iC|8Ec&RZ zMXifjSYyP(_b3+D7O`k`35(8`vdCV>qDjbvQP!d{A6QtA%fhvt7QWxGXg(TMvS<`i zt6NmlWKl!h!Y5{n=2|R@)U@b}x)$AVTGYP*@qHGZ!Zl3xTl6SkQTCukMbRG}42!-B zTXY>Qq88;yw6K;T+wo44MNP3M*`m{_%-w_qP9%#O`WQTzBTe%N`cZ?qy+}b&EQFX5ktydV;Pf(U&^=SyXrcafT2F zFR^T>MOD6F+;EHj8D&w%Xp1_d*cfX3%A!SMExI($qMH*eIxx|qvXkfsmLqktMJuLQ zbYZGRWu{ZlOtyb*(Th129iD5^x0x0VnMbYjd40J>UB0tu`U;C4d~cCfS=4E@MaO<% z-!;TuYfaGV``yC2bM$?yMG4z1>b{-hvx8%{%c4?yIfna)d4S`4$fC-J zEeao{SI4N~1T~$c-cuG;#GmkaK_(916g)S0jul9_ zX;BXxg!7g~$MF!$|FOvYFS-3^(cc)C#meUjRwZB)a%8u%et=aY3RyJ+iG{6djl(GZ zu2myZyNp$SsH{~5F%-K#u=0D9Rg>$rxDEs__WcvZ@*O;O#nA z4Z^s1t1{87fmI#w7s|NUA60@@bu+9QfGc>2RUz`l#70&hRWYnX_7rl#MR-%KifdxkcI0YiRj4`p;Jp^~0fk#qZ<js zBG0x~4f({Xk{#(&Co9)cQ9n|al4^rVK*ta{PU zs=ocLnmO32?nCGwR^d2G4YjJq7xWsvP-8fKnqk##WSwc%$M_Tn(O?$&e@#5RJ=?0! z=UDXviqExbF@D03HMN!YUp>voRg}10PhpJ4eiXh_PmM4fzv3>c-mRxLn1dt8d#|1v zqBmCH7AoGar*uri0c3knPxa9qOK}m!AJ$U}EcNQkUcbJYJL@a`qxyPpSAE^DVN>Ne z8*3ifG#lqo)?`y_Wa1Qxnr-TYjVNHTDGjTT#cER&!*Cq63>#}f+w@_`rrP)w#T(o7 z2q#i)>fF?(#~EyEW0R-7P5w`88jiXhZ3^HP=615_G{$#kez?2X^aORf+H?a?@nbie z3iV=cWbJKJVa&wC&um)rxlKF1vMJkG8{c2qv=fcT+4Svro7zpV>GBerN-wpk-#0e( zTxQb{>_D||ZJPJ9jdfU<>lge=j@X3m8*R$7nYytGS-049Wvfl~x7l4Znro%SvJ8ILNzij&8lucja;u(5y)}{*QZLFJO z)4-eb4qb2AI6u&)?Ei2){-WNT1&iA?4ChPO zS$o#5J?K%&t_7H3vFlI7)wJtARLicH_3cWu+10cGbKt**cCB&QwF&=Vu-~pDxE^Kx z1op*s97?n+Pm*2jlI?P&5UZtKHq1z~D?Qz=j+lghGwiC=%C6z9?Q(r&R|NfW9f6PS zTG!UDq;_^S>tNSp-2TL_6&>x`fD8DdGc}@QSG(@uB|hjzY}`YZUTnwwzIL5L-TrnJ z8DLjA7}zk7ng`j{XBhjAva12^A?s+nM&a)<)G^ksw%^$`4=+|w^Y?a5MUItr*?+XF zHx942YvIp!t-=vxZf2jY9G`7=u641i(GI)v?zU^t9*)6&yLKP2tJ*=kJcsRSe8jGc zN7;UYad`TdT{BPF`L5Eg)~6YF)~-J;+4bQqdVqNt`!Bt_%`tvr*XgHr?a%5^*=!D- z&EZh7oDMC@<kavI@sHx;h#Cw{Bwt1pg~`9>+j(2b>LG;WqdU*mUdnd{JNtjT07g7X|&GM~5$=*<>~`fhb- z{x*lQUUaA-?jzeJheqS-WrrqTaVY*@hX%m(A9-R2%H4730*bzNCt74doXIY$D zn$@YQIi2c&Qn{R}h96KMkCUbPoVta#^E!35pi>WvIAtp8)YxK9)hq6lrI`sm1T}~ZDPPbEQ@j=L`3>0qU zR5>g|jxc#4Ym!qA%u04DlHycL3`OTu;v>BY@o^ss&8VZfQ}1CDwzhC;Tbff>(w*9q z;Z*Lt^>5^bT{y7IsYbhjK(Ujn|!OY(u;1@mh;#c&A3ZK0rS_LLpPUT4J0zo@?;p^*gRx;`OVQ zZ8hUH7r|QbY66QbUQ2M)5w9zFfb7nAy^9K{1us(22E8yGQ?VH9a2F#Q#H*Amp7W^U z<@3h#H%h#^1&C$DYgQ;;agF1(EgaAN9pYu0%3O&JG&f&Em7my98zwbWbV@_6VQQ%U z(;KSL%!c}ARzo>wH`I|i4b>sDpY&*+FaVDre$3EudIuER=D{5&!z8i zsj^Gks=D-ToJ&>exKyK&OP%n3V;A$g^bb~~xa3ZCDHEewxU>^}Te>tF4bogH(T3Q_ z+t#I$xQI2KUCPZsck=(Hef}67k~e_ zILE*x%P^PXad9MLN4azum+Fm0bpH7~d{5(6)}^eehv zc4-hkz2cJhwoAiM`;JRKWW7r*4_(@aiO*d+h@mfBnuOXfUHT4=S1tvzy7e7SWplGG zgIj&FyR{QH5Y6Fc%}%!#U?pC{p3^M@KcHbQx8}i|+pRS8#4H>y>DH0b?DxJ~-H@-0 zTV)V_qpVy1VpB!8{zgJ2w;ok?t8*2%CgT7CRoyy@`*`2XcD%+#3vp_?xz~hSgRrt5 z^B`+|w`!rf-K``XZ9r}fiHUjGhmec9a2vhcZdLWT)eKv_)QyQgx4Qb>st|O`0%wX_ zALDW}x5`hUMr6z;CPpoCYZ}V@z?^9Dvs?8yxW$dMlpp8!xpnpcV-C921mENRLvAhq z)2%mfQ1F~vwl~gmTyW@uTMzNxMYrOSfO9B)$*tN5V;asO z>t(kRF&3S!&`+%S+pWKF7kRF_RS{lHz?~az6}?H%QTP`1BZM!p=pVP@{&j0TE@1Ut zUccv71g#(N9>F^g-5U19tz|gy%&h{?-8%fjtrtjq&AiAakE&$zXa{cNbY73Pu!)P|c${)jiq(a}AHe zXdCCzS9sUtQ6(h4VfN@Q)>=K9Skt5RI9$u4Gj%*VTi2t)^*qXD_viz3KvpN?5&uTK zN9T~kv{qcr_J~>R$DN)5PmIZ}loqO|N3Ly&8q7^}Vd|;#E$k zS7uym=v5(?S33h<-9gEyR}C=}Tk$Z_t5Qi`^~7A%PxUGTKj9(@HS?-2F17F~UrVnR zWO%g;6F>5D4=t}O9ldIbtX;gSjsrcs%H78+D@qUY%7g!gcvXBT+rRWG4u?j1Ip4<1 z+DKlt!q2#b_r`nW#@E=6DU-bX|13F7_R5ZqQ<)b9r!f|lW_cCH5*$L#IplzgnO?m$ z&#Tdky;_A_OUM(`zwv4#+AsHN66US;Y6nXH;8g&-)_S$~NBVimD---zz3Pky$a#%^ zzH!~FKj6IK<#R5tiu~i{{57xA(Hl$f8wx%qHhfRKs`=EbW3WA=UMzp@RThr)i(Eb} zEap>*_k0SY6UJgS4&xDul=jJimKcE9_ywoHhvTY@1oXm8Y{frlQ_ZLGXd36!P&}>W zQ~BCH6{zP^J=}HrR4U%5E&-n|2Yu=o^2wLvQ#VX&;nQ1bK21*d>HQ3!mbUUK@gtwI zxA7?s%R2k`yTzw9-F$L&_i=5fPkTS}=?>a{?o%Hue4~#~?!G=9?dMbD{yt5_NmLxb za~#7ZtQ_dmJ^V3Elipx64&yw+^L<*rlrhNijZZ%#X%lnf z95!yI-mN~px07vXwacfucyBkg@9`HBq`;_q?{u;-pnw{iBNPuU)^9j?bdeurio zNV3||qyI^kk*zaHa*5-91{7F;dm*WA*6oqgkdzXq1^vwoqU&n79MZd3j9P4L25x>@t_p8Sgzgo|rE}TP-nSPZ<81u0i z7tnl`Uk$(Z^EsqnyXI5d0zYdZ)2D^Jw#YB%H-6SU_N(kNzh0s3azE#0`(?-L@9D!z zwypMSGN!Cy-?e_#_|dOq^uv*#{o448UzgD2SHDJL`zCsYY@7Wmg_>xDtJ{dZo#!}? z^E=3UC;4Cj_Pw!-HRgWZL!Nzpbwr2#e)Yz%1Abjb<3oPk!SFx)T8`Uzfrp3v z+H}OP!AJdy9HUP3KJM3SyhPy>emUMa>DL*!PZ1mMpJ6;cKF9u;_r`g@8eCvIGA~mX z3SaT73~KyM4OhwGnqL)f`t`}bemzCI+kURi^z)f5b=>8@@A+AG)vuc<`M|HbXoAll zk|)YMA{Vs8cocj>Pf_8iUn%H};aGq+&-@yNJuk>3XF!e64DMV3y~-DmQ8A#V=!sdC z1Nyj1Kn1G?w53`=hcK{uK;>!#WRK%DtThF+2N82Xb1VUEwgz+^`D+FA11i=IC=d0n<(uHsH8W*y(IG`HQfI4A47AFQ2 zOA6?%~QdEK!frIwYxx&bt!@>_hC@0%t58Z z2W4pxPGjV9$`_Bpo;YjD%Lxw3ZDh_ zxL;7&`v>(8q630@Ixwgnc=NocEgJnTwSsv6&_`eJ4qZL7YiZd&N+P^xe zW$T0L`%_ROP0GMgIL|z zkU9K6GNOi>Cm6bqMoEU!k`0}NH^t!ZN<)QH4JG0(zG-U6*395D3g&K3+!l;!X{bh; zq5SEF2I3#=%^)61w4w({YE9nwXG{qR~ zM5Xo|OZ0#y$uyZ2q)kfWN0#m4>oiWg})$ISihw2qYXXAk}({cujmtQpxRhN zpW+mTj$zO-$5BVbB5lZHT2;*-h+6BpU(3$bbUPKYRH?tn(gH$^0SinHG4kGqzQI`(P72A30r(OBqFi!FO)(Bz@c`9Rh>f{8j9jT9Ine`)aUP|b zgwzD%u>((GZb~mO4@Z!{Sx7+)!v@?(T=Nj;GlujXZlFR7`h^MDjz=)J3~|0AJ;fE2 zOA9F-GjJIB(nIo~55C7$l!*}sQ*aRPX3(d$AsL^BRC)~03y0ONMOcf`v}Kt1Vf~9x zdRU5ub-i6!72AjP7jB?ihp_g466X8tFzW<{)v;$-3;Kt39+L-zwGfpDhV|v3u*MAz z>%^B~Imd-nXna_0(F1Eyc0yQFuoKxQhV>J6Av`Ip<&(o2JcaT26EAUWMp)*VVfCCH z)(>biC#+t0hNhW}n-^C4hOlNM@=I7TT!Cw2Se1SY>%ZM$Ro_FNxQ*U>!#cb#tP%Ue znu?Qnaxknqho}=zG5C+L&ionH#KZLBSXeg9I38B=iLhE>-bv>9E3Ds8@)Y@C{pql_ zoS~MpVYR+MK6rAGK3pOn)VWOEcc}}*?=d$@-Vf{Z2Vr%67}fyvdBpZ7VeV-W){a-a zo;{*wcq>OlrLX|6az<1&cSK2*Bg$SS!o71NT7$OLBkGOkXciaIY23jVrigOai^z|s z$WuR}3HZkr;d-oy?s_6Jc_X@nd+6hf=$JpEje&^vqI@u-!r_P#kS!A7I@*Y4;ZZcA zD+!E2gT#n_PL0UjE~05&iHTO9N3;%O`bMZ}ExbK2qJyY9i19EFj_5M( zqwkQ2jt`A!*szEuO^)aghE0iRGKx>7#%U3KFrEC?M)VBduZ!q6cz%p%{`!a-{}j=x zBN6?J`9~vKjXK97nsS^xPehdeQbdjL3I#4lG!=KRM6~qp2 z)`@C+-Kc)8N6h+Bm9j^516v%#az)k96V**`RImI|eG`c4L@=raMpWl9ITY1GRBja2 zmyM&!9geCr2BX-(s8W%8P*lZ{iRXi(8Z;!TDR_tlvx$SrbBKe=bBUA5n0drOZ|wb* z=Nrin`;hn>b^cC`n;5ezstcI1o4QbCPgEoJM&;cXRiX1yMUnMFRE04U4=*z3CHinJ zsvOs&Tmur-ZbWWG_1(>=n%<)B+flv7nmbYMuNhVFZd6O|G4K7TMn7RJ`aO+m3<^Gr zs>}1JO1$7POM<>bENgK%8|f%w+Wh)GeK4JBq&?n1Qjfhpi*xqs0p^f zT`)m;3MJ?c>KA1-P_wiG$HrzjogcBH7z&J-<0=B^Y?+MS|z z_N3_XofIY9P0^=$QdR8TRMo?JbS;vqr6^J?RWYnV-r}kH9G%}!RhM$93YSmSz>29F znwYBIJyI1Mo2nldrE2xARBgl1J;d0bD(mG`WvYoO(8=^#GqpQcgxc0ig&3{KOuA!%Hvm?q0O9x;1jn#xT| zQ{Aa)nma8`-kE7!SCOU_v(xnVoHX57Pn@69bZA4Ge)%O$d4Efj3*$DWY18I3_1TrC zQb*Ht;ZmBuxtFGS_tUrzEKM7-rOTH+U3GJ%>pVsjNLQn`)Ae7$bQLO;&d(>WeVDEj zzI1)2j<~mw~Hz{$sl0)~9P2Cg3!R{*PUEYVpK{+^6Jx^D+Y%zV0R@r0v6z}GU=}gX; zO6H2`0M24c?wG83V%mh%d~C;qQZXgI7gG!ek+*bA9wcB6PN3lXF_lI}xtNYsipf$r zrsdUQN~#fK&5f8o@x)X=F{blL?2{Z*ofeFRGGZEy;eBH|i5>l7+;1eN_1K9417a#Q zFsA0nHz=m}a0->bjHw+;jEJcU4j{*7;1rYTul8DH$J9#Y zg{H)~rX!})*p?YnmU%Jm7a!Ah^qU{kgat8!4Z7DIHo2mVw#G;_c1la zhbv>sxh|$!KgYO-A^qANQ)etekAK*&REFw(kfFo&3{`bx@V7^X(%NLGecKEzM(U^x zeT$8Ffjpx#>+ZP-0KgZuwxsPtUS&(L>xdqIZ& z#o&b*dX5c?GE{s?hEAi^(hRj*o1sp}Gj!x+hAyE0Ul}@to5*r1LuNQJ6Hk!ybcSl5 z$xw^489M38Kf~AU*@G;S+SPx4l868QKj-E4S$Zx$UpRcWXXgBROJ2D~rcU2E;pYVd WDx{a3I^@Zv{~MR>{|5Z;PT>arZY~DK&IZMSP97nJ z!A6y4CczQ@@!l2X#fA!8Ftd@(z2V3^-8KK$7eE5b7q zCasdJ2UhN3lbUr;^ZY!oRK8UeR_}MpPdnq-+m?KiZA*hy$?lu|Ftb7WyCPU7s6Y(> E0DDbLuK)l5 literal 0 HcmV?d00001 diff --git a/Covance_UCO3001/browser_profile_4/Default/Code Cache/js/9b059399aa5eba28_0 b/Covance_UCO3001/browser_profile_4/Default/Code Cache/js/9b059399aa5eba28_0 new file mode 100644 index 0000000000000000000000000000000000000000..3a5ac9ce5f0a463c1c72f9d448dcfeb1ec265d72 GIT binary patch literal 37268 zcmYh@1$dL^`~UqO&bbD(zL0jX^XqN!`N^g?k>X_?mpbz83TqpY`6^@GThyL z@Vs~MeU9IMJ6^}#-1jBtd0tm&liq2z`dyY~ZvW|Xprm4`lfKyn4k}YTd;Z+nv*#$8 zFHgSW*>V>zQ!0195~cIz%~qyF&XT$E@PGE)d9vr=O8$KL%H+sds#K2RrAy{4ougEl zy!o={%V%Va6X}9y{5RHr|4q%27VzJ3AeNv>8R;DEl$G+8lO{mrB?k_oUp{xSz260+K*mU=~F}cgdsJhe~_iN)Dd^PN;$eo@3D29lyQNSfU4+@b-0ZC zsIidPa0?W3Y-)m*W>^_!|EA~bu~aeZwBbz;{d%u`zHZfi#ksO zH04=D^vPsU(?Ekxha0rfWzb$cOlQ!62!paj8nhleGa6JklRtvD6AGpHec$IJfAJHVjaKO59}pg~))ZID5>!3Jf+mLcQ>!!U!2VJ8NR;PFU<`iwH@ z*;wX6!*Rqq!5~dEXdsqNB4-?!Y*5HA#ErL8h<&O-d9WSl(Rrppv9k;+Fvp-h=r>BVfl0nwX24zP>48c6C#-x7?ntsioX4hGF6udz^Hw}uoW6)9T zxo1%Qhs^WDpoLEjTKtN9UK?}^@o%WlJA*<|0;^&A!2025EXO@qKN^%Cr9RQ-vq7$Z z4eE=(vF{6eD8Q&C2BVG`jY=P6)DLE(_F$;Rs7bhKHOgr>%8i!6M%4^4sskdNMtSiI z-l2S$QSC4u>v0a-BaAu^Z+fGyqDTg#reJQQQB^Y<^%VIt8PyFR;LdDRL(IW;49;TI zNVie_ql~(a1|FkM!5U-KNv}~8V>yo=aYnsNFe+Q3QKNlEbxGmttVZ3=X4JLpM!iMG z97fH~O*>r8W7O;XMx_=o>gR$+H7ab>3HXZ|^#VhS8MOv?ky_lSF_?+IC5X4AQ8(Zz z%{92o7_}3(%2JbZMioaD)GKe)9sE+kD0@YtenV6xqlP1`vQfV8jH-;fXj_d~QSN)% z;m{98b*^DlSWTnm;}FiHW-X&;)HZ4QcMQIGR-ln8BWY)j0Hv|E;cI13ZvTK*h-_SuVMUkMjc*n)QAnN*+z2QWYp>{ zMx|^chwbEvix|0!y|tS-4zfO{nC}vOuNYP09&w;AGTvu@VB7=t*+b@fOl|NEt)3W_ z@2OG!p0WS28qMDrHQ}vME8ZDpd~eh|i%H|GCY7?8v;<4-CRGhKX(g-#&DBTkRcOCY{eg0Oxo-*DTmjjy|{t8u_hftqd2brk3Zg|C;!tb$)x{y zeJ15j{$>lu|Mbdc(vBP^&CK;pt=uO4r*0mTBJzJTlH-3$7c^-KN)|F{JX#huX(x&l zG3j72lYTE}lBK*!U2qS7R$!beCe^NL(l%`R-lPI`Od4I!r0R`KI?&jpwM|Ug4_i}{ z9wVR`wZa0VZ*J0bOlWD+B4ll4QiV1q?Pl~7-v$s$tLx| zxTz*BoJM_TP%FGe_L(Nl#$mW-nY3ZHNloT6H`**PX)Y!&G%4>Qle%ITzWh(ECDa(Z z5wz4K<8oqKO)S{H-lWesx`CWGGVbr}g-z_0-6q|_;{7JI`-9q?V4s}g9K5HA|LiyU z{x&J;ib*}LQHv)gg@5`cLV@at(S|_XHGVTBFi`)w@;}+_fjWs?!GQ`236u*ZG6ZTs zWT5tB4Ak%}feLj8Y9%^E1!@zHB9kXjkFh;EP+MXGRXjdWRWL0fP#F^gRUMuEff|p> zDS^6{HBe7*E_s z(Qq(*QDR7-HX~(dpcWwAut1H#N4y;wsKMg{<(@=7IEJm01GQ*cpfXGk)B&W-3Y2j+ zd7>Vg&I#0@d4XDvYjDpeX4GC7DBq$$t@$lbBX{%oNTAM~4pf^nfeN@loniSqP@^sd z%5gbReQ*$+uLSA^>i$FR@%3t;=3ZkBt_Nzxoj^5u7O1@c25O9gG|C*LUtK}kfq-;D zO2ihpB7(F%JtBkDK68-zMg?gkHp1)SYaGDnm>^BZeq{C14x14c7o>hkL2By@Qcs-2 zO`J#$(q$a-2k9BYQobq7u`1ReAT>xw@d)M9g7g*xvj*umtj-ps>-aNgkQ(O>(ntK6 zCrIz|F;D&=)h!UD_<}(?Qz%IFiUes4_MvLgZ#wn*`~3i*LrXWPS`D7^J_jdpI>3 zNq>|dMSb8LP5ihpK1h8g1nJ4tAibYO&a;Cwc21D8FT@h&SQezb%Y&4*B1q9IgJfJ4 zq)ER9slx{H-58|K|MT(pAeGz_q`)2Y+e>_>X>*S2SAw(_4X(0Y4_LeRL0S-O)_jLq z{W6&~1v~H%)3TVg)NR&ck6C9hE846&F|>^}>rb4;oj9{z;YmFG61bLV)>@oMGV2OH z`^>T>o7KW^RyRyYF>5Ziq?%Pa&8$=S2a~dzH4oosGpiAt+0Am}7%t*q4zsG}H0#&g zX1&Q{R%~A4#k*o=eOKJ9kP>Ds!*!%9Y1R)og94?@+FhD_Fs7_oGjP2e@nS%Evu>kH z1-{1Oie?2?GHVm|<33tcHfv=Sv)-b_cV@jnrD|raK*{gP1*`B5n}0B?Ty>6EUel~4 zwaoI=H>(|Pqd)_*%3=y0qe?^O!L3GS<^0jC{Ef}3(ZsAKxQbFusRus8+03l$&CM!; zkd|isg6wV0GPN`75#FPB2Qx2@%^HF5PG$}2LcQVdYSvTS>_%)o%!>cXtc-n_2mAU_ zj{#<-{%lsYfo3(t`a$#`%-2{0*ATPz3^U6(+^qB?%*r~-thVTh_c%J5dW>N`CYaS> zB70^s^`F9HEW>lSrkNFu<2X0dtm?CfYqptx``9aU%-T55tkC&p%~@<#;!^4e$8xhO zt}^qzjrwn*j+@OIkL9?Dv0KbCY&9zqr!aT7S&jFa)dN57Gi&bwYW}BLeXs*R9c1ke zv7Xp-g#C*f_~ocs!;iBMPB7<5vx=Q&5Bx<9&alR3&DwdMy8lfZWWC6m;CF1jOdYSV zcdoK05qXU@L<981di;9btOMwHgLT2XTjX?`+QNQ^KA3_%c#G_5& z{LrimAdBYU1}c~>dWC9Mi$ZM{l|y^GMb;3D<~uEVfPP_I3%6)8 zZ0Rg=Ww5AaMvLBi88gY&q|z2S&b)(x zf=qp>D<1ZvPk)Qn4X`NB&la^BXwg%A#>zn!6(4NT5nRA)bRR-YLoLdVg?Nb;!z`MF zqxfk!bKyOvjIgNnNQ-(PWE3^UShO5%(M%k~-fGOTz&*Ui-sKjZz$3I>rf4L%wMCkhmYQ_a3v>Pk8QNz*C+h&n@~L`*00&Ur;9;g8dc! zKeC5$179%n6Yc+HPK#C5tyVQge}vhrioyz{e}~$o7bwKe8h~AI8o55bcL*nK@l85Rj8ZNp+aBE^}fN>esW%Qs1gb9Bs_FO{|*Q!m35sgK90U zY6x>Hs|I0Q8**$*j_t@1J=$A!9=DLCgH;ERucK9^@euhtS#=)+I$LG$LSJ0zYE_|L zRy{#*;c*8+&NaQMgO_1_dN1hNQ`K|nYwMG2HUM#vV*nSNiMtCSD24=yBQmw z_7d+ttGe$ewgXlzM}T@@BqOZoGr( z8vEgfRU2-SD?;y(&t2B?o>hPU=e||HJfMaTsoP_o4^OP}!}W}MVa7|VPQBv!@P>W< zj(v*I_f|DP8yG)WHR2PoeP$njp-q5IO$|16#$KaMC($I(rei@i4K&*{4hK-&VN-Ib zO&+IBDd>uu=o@C!hV(XV&OkdnK$A$DI${~hWw!A?xlJpw*c20E(`v6xTTw06CQH0c z5om$%M8-xB{GMdfKIHe=G%MMr<%mfkMtn)NscxE0E#b&!(<=Os-NyThHjPDUPMenG zCYL-mCFQm0Ans#&ew(Tku<@GMrqYFMnpD`P1x0KcS=6TIcwOA40wswJB}&0KRkUdYREha9w6ab8t57RsscO?-nE9Per?IGp zO~2uFO`Dq6vS}%vpm-gd#?PhQLTZQ_i&&$@Hf3FEQ{H7Z{kWVwR@l^grA?JqQTsJE zP1s=59PIv`wL{lUHho6WR$|*`Q>UFadH2}#JsP3>UYm04w<-FdO}FqIH4jn8!?Z;| zxQ{RoDjc<`*D;$OAGhfP>Ykv!CvDnzidvktso^=B+TsSfou?h%U$E)nMVoeBw<+O1 z@xb+fI${exqQpa+CgKu?JhrLMOPe~p;_KJc@(ts`_12~fu)ect29{#(d&d7jULS4x z_Y>>#*{0kX?W&l`uIS8mEzM$=CCaX>9=p!rr&zn9;_dp7VAtVfyBsNYWkS9Zc6G)@ z6f9|1ISeRoSL@1ld8*h|2|r;GPQY2mE;qK-qhEcy_TptTyS}1vbGv%O+sdxGSdZ3i z=!bIc?5cr+?d_U~oE_|1*2%6fsM^`CPhIW$yPI8wy4%$iKO>-rUCsO1)g7MxcD)^F zmvN9?y$0Jg9DzgZDvHX;I@GShc!94NF^qXf+I1QJQFgV&3Oq)((aeFPXfejFE$BGT zu4xnK1It9acH$_)CfoHr-k|anyGBl>9d=A({^@qj$692ZNq%UG-Lvc(Jexd`ZLVFN z&>w%!W9<2MrAP4v>{(G|pjiYu7|6Od_@ zT}f!LnzdO&zL>k#uIqS;bn6%ktFRSMf1_UOzZuGLG7fC8%e0Yvu?Yv@+eF>a9X&U* zN4D5?7sa-+&KQ9s+sJ7lf{sidUCd=gW5Gx=P&F?Mk@8K16*?z+L3N#eTfa`u|VIJJjVa^~C;r z)aO3?1??W#RqY}B`H@|JAopX&M6oA!efQL^eK_)rb$emgtXFouM#)H~bP9tRKz6YL7)>!Ah4QSY2cI8aMFt|8d33X4pXjzEsNMATuU(visuvTJL(O{je5v)2jgLM~UY6YuP?O@sJ1Zx>S)(=+y z=D`|`53Pb#yK}HMp;(V#UV{beC@S<0R>?lW+K7OD!D=@sSeu6jD|AY*KFtqSGvxmCxrOm!zP1w)42Z9y!N3bqo!=YehJshm#`0faC9i^ryax7TU z$Ai@ieNWI1Q75U%sbIavqSL|3_E)eDVCxxTIvcF*=UA8X!CH&OSAzB1Kf$VWHCU_g z;99V*US~aT1*_3*a(oo5=~#k-kBR+Bu$tiz-oo@WSgo)VN0Ikgum)m0(mxMY3v|PM zrR5KX3+> z-_s9kkoJMvU^rf)*vDYmKQShz;~w6i+h^j!Ih6gEYgmd(U#JJ}7#wmM9cqp3_+oM> zU!X%Ha0}Ig99n{RNHaV5S<#`K7Keu5F^X6nnvO)9L%Glz^ATcqs1CLxSFl5q5$tei zRft1Tp$?tLA5Mpo!@il#(HZX00St6AMwCNA9*0U}E8b#Pv_n;59BPaXUWe|YN~}Yt za0f|o4%NjFOp14C3vQukfJYBuJ` z?$F{K-?Y!=&_`6r?NIx?4mHU~pZpH(Dd3R5phKfErI15mg&lfX#36f8ht9!N%%R%I zQ=IY8xr9T%;RDi2IrIkGOFQ&a8HXMrLs{~Iu^jW_U)ah!lmp!{80#uJbOjeGI}}jG zp*Yk>YaGI!YOD`FAmj(esqRp*8V*&)SR6v9n$);vLu(OT&!KYl z9Xf{S1`Z9wI^1sPP`4BdSijEX+=cwRvVNl+{4C?pczi(6XyU|vXbfwKDY$@)W4VSyNE}CuxPe0B zi3^z~IP@8%COR||%aCyr^~0g5)Mc7O^>>QP-l6;(sPjgLj{Z(en~53bt<)Wzw^7&a#IS=}?7oK)`w8!490fK)b(r{#;?se~24pt~z+{)}eUJ#A#f` z>g&`OPm${edj_Xa`5rZa?laE==0U(ChYBO_6XtqKEuOJQo;#HLg+u*c^Y6?X_RCxP zqvbn?et7RtpAXE1b05j)6LtB*b3h@wYY0&#Q-~&-Lv+a!qGr|*-9rm|h$4bRG&DR! zW7CCbd_;))rw`H13?b?f8KN2Z2L&^Rs5!Rb5yoc<(HKgeZUZ5EaQ0qEb0S^fz|r3Q_Ug#F&RM@`fk_TA^*e z5Us)%+(w21jDv;+Lo^$=3y0`Hkq|v;8KO^U+9pKp+lHu7yATDp4^eeY!hsGU+TWGA z(Ykwx4x-jiA+q-*&tA;mo4opjXkfn(c?OWv&-B9wj2jrD{CM2Won3)Obbz!=^?s- z?lVGkWft+y4pG9K5XH<5(XaD}b3ur@tq)PaCi2)Hq8*2*^WhMs;>8(ay&R&!S3`6n zDpWNSLzP%RRJo9$Td3kN2ph2%p6;|kQ$+O$l^^FY{HIX;f~Gw~wG5qmg{nWIdxt6& zLtyL^Dkrk{4OI(tMVEe|T8EwJ*gsT#QF8#}z&Mch=zxYpLN$I^sNSN^@K8M;5vr7t zp~{aLqeJ!UxKOPc&-qEAIx#s^i>8LE<+M=!IXzS>W`=4L3e5`D<2j+qGB;E{w7?$- zo6lT}LsbdpC85f?JXB4v1$$P6>Nw1+n0rmA4y+ATr}d$_hTk@aYV8)TZx7Y&U7;$w zCsYUbhwASGp<44tsO}vN)sLq`b>}>_xE!k5H$s*7eyD0Z4b`*P*{L@e5$)6>6pe9eHqyLK zjlw(3iFGP{oKqR%of?BS2~Pdub1GM|Qwdp_JC9Qv@^U_(Q&+Gnzf*CAo$^<3s%u53 z3RQNh+ILQs{K2X2)t!1@!>M0uIu%okSZg~~rk<16=uY)-M8C#PJ#NC>&7AT!cj|2m zrJf^yacU2~B7a+Q!#Z3;Qah)H;2K`HcPgNRQz@OD>euY#nM7Wb zoeH1gR4cfqI#p+yQ`u%X)dF3y3TbobhnE;O*U9g=$zwZp!XtdYgL>?AY64Eezssq7 z7>XjhId_2d`opPaSc%QJ`=?VK4l(ax*6gTLIgUG3^@LOPG2;~TpLXgAYF}|`_;sh+ z-Ehi$)2SZlb>NsPlcNc0Qo*LnrreId$<7b$ZIadFIrgFPxhBhV?}6_q4}jbo}5{ zU)Vo7c}?fkZIt=fsS}v`)u|8Y8xf|h_!E}&VLF&0Oot-FbPmTeg{g5=m|91Nsbfr- z61-u0h&!=i+7TC~zvIKSI3Y~GCWUF4KTLa4!Zb5SnC9dS)6RThDv+Oc1;TW>V3@)S zhiPCD=ECBl%vC&0Lra7yx@4F}Af$Ad*1}#UOg~~j%9IP!tny)ssZ1;=Sv5=>@foYX z4^#XPVVZ%xcvdS+BkP7K$B$vE);~<6Mu+M9sbN}rkG|32+7T138oqE%%NDN17?eF+ zxpIapZ?15asv53pSYIt%AFGF}P7RLeSSwuJ>V&I7-Ed{D7cOVxa9wK>uDwmeb-#JI zR2N*xIb0V#EQ+~s=g&$8xXoRTt8qVif;?oEqHc@YZ9963YT$D zxMriw-f)e^<^9Bbfc$U{S^o@I7fd?H*#A@WP`Hku)3I>9I{r=Z6XDu_He3hJ6Z3^| z^}iIZLkPYcu7X#>wfrCAy%w&4x55>4H(XO55Zl9W=~1{EJ`LA&9L2b2JboUoD__YQ z-^rzj0GGyMCJq~1>TGoBFOy6DK$mVHbC63t%`Sa{)8f(v7_2UZVgshwT#8BO(k!$~ z@6tLn&*)OEOfGFky38&O$4Mk+ap?(GyIm^gaVa(0rP(mWxYP{Oyx**fb!lK6;)yNM zrI*-}{3C$OZie=>W4oOp5{`0Y|hGD*<8w=-K7_(mcymFxQ3LR|7Rdy zpF_diE-l8*d@iNscWD5U3NSa$!B^0w{DoZl84*QXdWh0RiL01PfhApfTZ&vuyLheQ zlBY7%MuHQmUHRZ|D$|)mqsI|f=lhuyP`|SF`|-7#VfnC0EQ|q)rO-g8IGrypI)+n8E3C8y>t zoj{8g#NCn@F|3tK3x~OsJj$hsc!Q5)zKNMYjQ`V(s;!#m2)s|bE)AD_70w-{7#ov;Wl#Za%mFs?xx^J@d)|LL?~;e z2+jCDLbYp0s6D!jh|qUqBb0M;gba%#c&!q_d!`ZUxhq1$4@77^-l6-s2!&mV(4z+t z%J?usjUPp5F}C6$vOSAX$KvTVv2S`+8*;k4 zHD9II%1`NaA3HN-;QqS|nw>F&GShk$nd_oW?a-qoAAPi#ZWk#2RvMqC`_);&xc?beksZiSC`Yc%HKCZ1vH1h?Ky;@V_4_i?$k z0l~jeAI!%cq)c(EIhNoqR!pTo+|#HNa!+@wBUWJ747WbPKhv!nSTKvVLY>*fhsZgc zL&_qzrYv@A5pphZtMpQGz=Kt8y+!;Q&SNWP{N~ok4dj8haR1J_Z*i*@n&U9a?R0D5 zZnviIq2FG&PNLmD)^$HMLc;@YwL0ilcYHqVR@7;?e!!17i<0Nu%5<4Mfw4G*!B^bc ziA-1BnuGONbB#Q3m?*hoqtqHZks22zUs9CZ*`m||=aHj) zl*VCvg(%%Zwu(_&QYlIqD@W;Ml_(wfE=qs=5G6zPDCMca`I=GcRXa)>8%3#1<0xH3 zSd%C{LV>1HN^BOTFD;|Axowo@wU1K64pGYAF-oI4MJc9Blv;F+((!Ila`a#vH0c?o za=oJT5qtVX>1y97J;vw$Q5rcQN|v9aWEv7B`|v1b9TCOv_M$XsVw9dEbW)VE%#Knn zG)F(|L;5*UN?E{M*uRjR7Dw^>wI~h4L3~2+@+iGr^M8&VAb%|oX4E19$m(`?>w4|Hq|`p ziLBpy)B@Ylr@BYRnjY>+@hG*HM-ys$G`5aM|KgvzT&wRO`s1l|(^r*m(9>q8I z$k4>29B7N6rXH<@tC>d?;B8L379L&2*_IyFY30#osI^B$@B#sCJX(S*Z9VFaNqCP1 z?L7Jww)P&C!W3M`Q&jChd^m}qjvkG|f=(V?!=%pC0%f{*v8dej~VaSn64dGr9a zdr*s?Ji3VGJw0;t@+dQI^!6yZk4Me0w=eDcd9(^U2YA%wXWFCdVCpf%qoPBpF)~i@ zXxJ~*VX8+Pa2FY-d3e8pac2-O!e)B38rM;47IV$^sN)=uLg#vP2b<=xu1H`}!nv_;RY9<9JFaAdnjm3Mg51V?ZIUy*O8M?*1wmq)V^z1yRH zIE{^a$#Ea?{o&Dl4F1!jGw>etXdjLoVjP4WW-ZVHZ&3OO;~Zr#;MOr}e8QueXFbYx z&Z9%PgfSO9nt{?6$@vod7r$ZVb#l8+J@2w-?s?P-{)goDi01}IV>e1a_Hdt^M2eaoJH=TW8)JQsqZ`K&>-{(##Ott{4P`B2Rst>2=eRo54-D+QuuFBYvG z_`6iJ?jWIjv{qDz)+VG@iRLrHw8!gO(F&*?t!^k>H(C`?vSGApwr7q`(fSLoyF@Fz z8{?p4k7(|JX1t%Gh0&+JmF@X?U~-FJk;v(YlD_)x@_ZS|_n= zZM00kM$5J?TC=bm6Ml=H5r$YwlP{YHbtw*mT2|d5v{fdnD<1q#+{}w zf-Xj@#qDTyMaZ3K?m3LsN|d@EtxkB1ybq$a2^~DZldq` z7@bGE3$*z=Mt$zbX!VmAzURfL)t4CMHh5J6f8iISSF3OtUy#$}RX=zGy(%5#RifFe zREt+n(Z}l5LJhy8efyACgJX){)+S8{s!OsQ8l!Wait!@XJ` z;nkD$UhR(Y@;-%E=P)9>SJP1_2eILCPOsYJ^6Dov&h6F6JYHSGJ#5VH)n2qL%6!GV zdW&Vny)u>XDjcJ58}&+hbqdZ>UOtQ9RdXD{zo=Q-s|k2g#;Y@By}FJJ<-D4VKGnRM z_k&jjYkSolf7S8oVqNk=x%ytMKx_l**wCvrjl8=5qgO*4dzGgNwQK5CPh@Y#dCYC@ z)z=nY9c}4Vi&kD4T6>kZ9rbQcyd62;iTZRVm#&Q6&8xxvylOSf%j-w_4fkr$2x^3~ zBfYAQz8E&jtAMdyRh;#&CT*LoH9D{J_hSBo}(b8)X%t&e*7eYsclk5ME1g&fDd+*?B3Pmmw_U^#xr zCsa7;Rc-u*&ZoTEaoWqzc+}}Huj=3+oM%|)v+N~=oM)e5DMBuIl^M;j4lS>EwFI^Q zAx1n!#cN)jz%AHrcom5&NWSS+uY2@);MJr@)cY~(^Nc<9oHj4L+Ji2yy=w55TH{B> z>gRx1*$uH8j#|c8%`n9(hdGvy1H|gHjq|~=`pyxn7Z~h{RqeD`{f$n=V|5PJva$Rw zHCFSn8!E>&^uzG-v3%AtR!=I#s&ds>b@(Ax{js)stahM7%~+Xh#p(bu)uCO3SU!gm zt7}bTx&IEJBaTS ztDKmFw7#)&^^4UsTtSuo#DWX>?dMok8y2f3lZb0ZEcar?Y70J~*sNIn0n6-IC8HVk z&WTmnyjVpc{e0qF7OS!=Vs##e*2T*3TdW$bk5!EgjEQ0Y*%Yg!&9R!dHCC6m#cINK zYP~yFk$Ym*;!v!H;xtMgj@1$DJQAx%c#l>`i3fjT^08RG#gyZ*3O&JixQ^Z@>5n3( z$O}{P7?#tq%6*3GSd9K>X^#(BcRp4(5q^Pr(G&mRAy!_B)om2N604M}tO43!@Xc6l zz8$MucVZQBpK+1&keHvua!*IB8b2fN=j4s!FR9O4)(ZVU#H!`TSatt5R)^6*aq5eZ zfH>7fOB_aJL!9a%zcEf{vC0&ucL)rO(;$os;xT?Q$El+wPO`@7E?#4RElv~daheND zaGbhgAPPB{Cp1p);djPq2qwZA7N>LJak_)*t~fP;Cw-in;XsBsb&8DB&v=2aXp=Ec z(V60O3|CM&GqGYZzRMD)A8{Jju+kl;&3F(Mr_7!>HAGu1ME>YF{eneU=Z(`&1jfc` zCbGscKJMd}c*aIVLY!hT84vJ#Vx00O5d$jw;$%;zEf%0zTAW&BjZ>{`aq5>nPMvd* zORhNXnPSYmacWv1PUj27sbJwaO)o;-Fuy2q;9{{jzOTgTQSmt0N^lMjaHM3M{w^J- zjAi0vsu-t6IEMU{;LA+`=j8_YM!huHdYW-upUc%HkUfJ*? z)*-4%yyjplLYu~`9o`|TS-fiECh|0o*Q3tyitiGyL0viDEndZk$Ey$i9>G|n;?*8= za1JG=$LnY0oDr{*IE;i@@p8|O=d)z-nt;o5;#GETyhdO@b}We35&X0;Ug3-5Rd8v% zy1=w7p3k7fYsK<-Jwv~hw8Mhc@k;zPUW0#+*G^>G9Ip&p;uVK-IKGYiw#RGoj(9!Z z8L!;Ch#f`t#A^!*?TyzI3_1|6J?Q!eVTK^=MZ-+UK0^@ zJYGYP{%pKTV<0x-Au^qd=bnam^~OeoU5M8;JVxB#@w$C6Uh^--tKMbiyArPp$aOVd z)@$+l>wdg~AFyT*soA4=C8IHlK8{y6L_Q&hr}27=70*~ZtbES7|C#fO^?4Vs8wmcw zwXg9yr36(mCFohuH|atW)GjnZcVQ1t&{&+wkf6UZCg^MC1U`q7pqfz$Y8IWKi7^S< z=uMC(HbEB>6Eq|#K{>upknM+W%5d!SKSOFHC{L{f{ys&5ymb<^yncdyZ=9gtnk4Yr zH$g8@rA>n3+9vS1$OLT~n4ssVJUBtVA@oH{ydRdJABHDr&&ULQM6J;YN*j})g4l$j zV-xfWW5#{+nPbQC3Cc7vK@}$@XcrnxNzg1*nVO)6xQ*h|6Z8ZX<|Od_D1q0HiA*x+wolx}( zYXtW{3F?8Es|i|-3+Q@{I$lrEF$CRU+?%X3K4JPTV#0B_Zxi#q1U}P|phgc9bpLUJ zu05eHPpQ$11a*0v!2RwC`Wv}F(jS&j3Cf3F7^g%XLcAeSR%4>lBc~}*HOz_1o*_|f zaVRoTZ!#sykU3GEk(wn@y`vJf1#LZv>VtsjL^X^_)C_N;mf;OfCM0T4Qljqo5@jo# zs8U!^gmy*ghpAXrB2hO`q*S8pr4tp2pKu0F}fL+2CK16eMSD-y3T$DKs&#qsn>d?qYO z`EMj?1wJFk%_Mck1w4fBR+92yDE8wtD%?)u=aeM1zmueA_!mR&C29BlBrSN9q-#ih zoTRQ;g?3MpG#jrG_cTfFXGwa2sOL%g`DKy4d`q0~lDHQ; zNiUJ}eG<)A#r*)Thsg2={3gzH@O7%hLHYGQy_^c#Ej?KE27n^+=xr zGWz7r( z)VH}$e|P=naW|jxb^oSj57rlFdi_ryjwsU4ryi)>pEV!m(}&?c)f(ZGM)@>g9OI(- zc=DLQI!|O>r~5P*yJ!0NyA3{Fn&Z>#dF+GvJ|!*msl+Ou9lDu0i0QQ*E$6%hKs zCpT(7^ywp3K4Sfzut%P|xAt|x2UjbuHzm8^<)$n_rUhJp8! zRrVqA;8)yyl&n0DleO+?vZ9_P%a52($qM_-V`ToCtd8&o`1K=P2EStAG5VG2^s5Vo z;%~%-`IQ5|VQ{!#m*98#)d^d00Tt8vH34NJ{91%Vcm<{RD2EV?dVx(Vn zFe;;8|DZy=U$w9gmlFJXh&qXWwZvaZe$`0!E8OqbOSDO09<0N0G*0zv4Ys31nqQ`@ zel^7v`S7xJr6Va7zoB7R*%NKwDK;scr&qkfoO+^>I2_*JANahCS;@1kGz z%lq{NZz@u=N`959OWpAtjqCY!8n=+EzF(ElqyaUDy&?HD@@rXRzXF>4A6r|$9-~e> zze;xUYanuUW?URWVpqS?b)!B5{hEW1gZ#QNggT(oSikCx_bbaJzv})%tW*6eIE`!g zf^F0N+C7)^SU1nFJt#AuwOHU+uZ4ac+s^e}T*tcITt}HbT;J;|VHU^sC(^zk1^^7GCkoaMdsG4QhomxBXgw zmpSjV=N|Yq?x9}`p7}N774yAjPyfq0!upl9#Ze4ZipB+`=#wFZ_e4_k7@sl7l%i{a zDf|tN6s^1v zOwpuHDcp0CqGdf&Wd12dV^F7OivH+D{=HMQ5}Es?=-kgKdV*quQuM=MVnE3uDSD4K zLsR(MoGGd>GDQzYr)c!J6z)k#(ccqN)NE>svdl|S&jl%bFHKSDy(t=iEBhFGe~LEa z9{xC#BI9A|i9b>4NQzb*P0^lXDLMh)@f6*`-Lv#Nm!g>SDZIbS_{esRxN#V#uBYhh z4c7N&il*L5(f7Ag_zV@-5pyp^^|0kWb$F1X)p+rdm_E@CSw5$zCN}(=q7h$GGzAuO zs!HGwORD}tKU=DXI#M+Wfsv^ii;#?|s*lH+QZ+4es_sRlD#nwl{?Vx_5RDjE z8d90~s-&ta#x+jWF$`#us_}?unyN0%QnjslD)*A7Y7K1tQ?(n%U>=aFWwdJ55cR+jxVEOMG2U!T)%5Mexg%BG@EbDiOjV^_sTzgCyHiyeXOL}g zs;=N6%I>3{2U9irXsQmQ?=fnL@Z+iKc!D@jrpkvw@SI6iC*-)mxR+Bk47aYZc2{YS zHMdwVl)96uqIYS7EBd6N9C{N0{&{3!UEFN4ymRzbqq_>8vGcZrcOxbO4BIZ z!>ROX3dxYBy*Q2Tk!gB_2^rJ$Av#T+W9Z{c(P%rvVNz+iI&P-EVM9oT58va7L*=ZVv{BzP& z9=YZc={g{6{YW0!kNYN@r8(DGTYDK$5N0 z-7F{|Ql%-qi3mvV2rL~DX#%1sO7BhS(wlUp_x65y&-0x3yq@zpA(NT=zxPhErp){& zPUkV~JMvl@r$x)+6j~XlK3iF5Tbw>e-|cbAvV%V0#m+bl+!d#9P-l0XmhEBty>TkD zpW6P6(}!n>doE6IosZKxWL$_-rHgTzf1NyTkVk%#>;+5;;yxM{G%+`(N!JURG^wab zckoehlP;AoscuP=yts{;?{Qn&q+w-D%Kib%KQyU%MHBBMOzKzFq+_^*0&yngHk(ug zn^4VaQbtXaGHaQXT-&5W@g@y+nKTCV+-!qN9+NsXH|dj>CgwgiF$b7Q!(ok?q<$tf z!N(}j-=xR@;tn+Fn;|Bp4>hSXDt~Fx=85D#$)p8nH`%12(@jd5VNx3u`_`luvrOu{ z(4?`Ly4-)}$R%d8j3<2Gw8?&5u)S=})RRsCjt z5im2alv$Y}Vn@w7m}pkBWV39kX05~qeA2`$S2MGsXpJ3M)7-3UEzKH}Zq~RA#%N_$ zQEW!x)@B))+lKr)nKcP>(Wot#W{$Zv zD+Re`n)Ni(ti5y0I)$-w&3d$eelIlZ1o|&BtHO6?Jw%QrX3n9Z2P@3Vx5g~bPPW5C zwA)QhxN(GD95?F~zCU4B>~FL7oTa}P%zF2cSsm~N%0D*iqbFt^d1}_}7iQggMUSxL zH8sehcd}U2EQduO6}6~!F$?pfSomGW!n`OJttw&Bxl$I{%UCo4nJ~&)G^(71xx_4- zlWO7j5{u@dQ6-B;Aho(hHBA;Z#7%r^wrIA+qDW1PzN~A}b*DxB8W7)S(MepzM88Fk z0v2TtT2vJM(B81Y2{+Z!LN;%c4WGE&4vwqQP^hbuN!DwW#wC7EN7d z(Szj{X{ALSS6OuQN7h|U>@^lef8w!q77gEE(b+#N%$Y~uw^)?0)uL|O*gxCZXFDw_ zwTFGUmzew6zXvUjZgc}xh#{oERT67E#vGkTj=6}iUKa2jsm@HPlcd#k}8<8WsmAMbB z8eYh%X-F(=RcjnV@prBI8nw$<<%h~zRS-k4vz(RpQC3Z;YSnzCRkNxS&Y(gKt0rPV zO{>NtSj(zr*p0XASTzu1;;qU=vj$eR$KNR9VtrHzTGiFCsy{B{Ay$US7vmdQ^#q=< zRr_!in<7?qj#~9if>l>AE6J+D$yUX%7THtC1sC8=wJNTORojrOnN^|Ytb_Mj&<7N5 zNxf-SZEa=M;nr5I`-nW-S~d7nt4emDPaUnC|3&>s?QGRo_z$5jR^7ntuEgqQl@llM zO?Rv2!qbBqKDX*cU#t4`vugSvtGW%Qe^`lQC^f{Y8eh_D^hAwe^l6$^w~=+aRUhLs z96*B^YKUG~hMTB(zn;=D1^bchK|R$+H!Q{l6n|JxDX`S5FMIv^YVNGB z^pEQ6y`A-SzlKef<7~{=WYbKXMOl+gt&xe7C~CH;BQ~Ib#ilf@L>8+}Q4GZ~)G}<$ ze{Iu;A)9LBHxzGd(<2;DwW(86n;vJdtc^{cPi*pkYSS>(?O;;?H!-`TO{Xxn6XV0( z*`_C`)5WIic#5C8+El0~VMv~C{*6u9M%(!P%cdP@JjSN)$J*3x zoK2S&*;IP5O?|(!smBtV24g#_eQ(p8Uu?`F!&txKH*&;AblYH4o=wz^mB_l;rpsGw zs=w8y)0ni)riR<;-5#6X+iTN7oI~4vHf`B&Q@?{YjYO}%Y%(3PY3~u6?)+_2xsx`1 zg$t+Y!5N!AIA>$d7n=s$pm*qU)5h_LHf6uX{`l9%@76Y*!1UWT?YwVO?*}#&duY>W zlzC)RvnMvr-J@?$ZJPRm{gcJ60kCGZa~TM`yxHvPp53k&`RuBb->yjo?E3v}yY|3Z z(5^oU+Z8Ns*HD}*VQ1c4yLO{{DZA!jn#Hca5LeT#`%o>rUe>oO(PmfE28@CK8rrqm zW!FaB!XUq0hjA^+_zA3wYdDx_SDqxh+9liNNFi2ByKI=2W>T}kciYS!MaiMai#UCTPywI1j3WhZJx$u4%?!Aq3uN^IOi zmYyuf+&*@lMBRRN73ptRc^FtffSL!|)q5!Gjf#7WU6pJLlcl)o8n2d3V`0a5wv4pIy85 z+g0s=U7kaBH9l46Ne-<* ztz?HLq&U2^sJcRqh9r_O0M>wyJa>=2ImmP}#*P;F}{YReI zj`DXLI*+2S9ZCT+5Y(#floxwYDbA@Yc!1R=r*fE`dR@z@PEMzmB0b)z&bW_+ zhEBaeUYAn`kkjqd8k7q;m4U*IoGOnc$Pp$lWKD9)ff>n8MN*tvM z=|OFHfF?binmWv>Bl!9&r>4O(+^N4Ov;H)vvdm=J9LAmJ)Jv?I@6;yv7dSarhcOm8 z_5CuZuHxI}~&1fj+%!WEVtD)LwHq`4m4K;OML)BQ& zP@77-)U=FC|CM!dy$=`P5xTS-7c0B8wW>?s$GKFcj!QKfxzrKwH+C_;OSiBr#U*#D zOPLta!lfPP)6%7pXprVoi8jPW-nK54#09MGuK65D@1-rRa z7TaL!?&AHVOKtnQv>wa)x%iCa;`jxZEJIz2$Az!ic7#iZa1q~+bn$n`rPiZe`W<_4 zbF53v#<|pgx=T0k;VhSipyfiBW}xvRm(t)^?BbYD7sunfCz8yymBd!)vX_JGMk$@C*10t-K`zCj%W@ybCS9>4=eBz_MC1R_z?|rxitso z+-{|z2WH?{Nw*G{X1({_>WX}2+$w|c8)e=47aJ?O^$!v%x%H^BTb-)7H4*y}sOr`c z+{gQ7mg6-pScp^8%{4aM8i*D37zbJFyHyL-?QSLENCR?fNKDMZUW8oKh1=-qcB`t# zt!CKlrEZM(xz)w*)(1hiEO4f{^)W6rbF0E6YDC6NVq(Msx2B-XkBo^HzqnO@y<1#_ zO!;wcuUlvKv&{jwnqWEJKj_xdzufv0oe#M+7^~knOwLD$dxkpk3I)%)Wqacs`vnKj zyY&$7U2rQN2{?<=7u~9jFs9%vvR-m45u?%ZGX2Erf86>Tcai6cTNUBOINZ7JR?!>u z9EEREKSKBl3vRg;_pe*)a2~7f^7uWsB53`9=Lp_;=+@9DZY{z7XKodE?$)6fZoNR_ zYsN)3c~m8vN8525r}BEVIlo7TG2#P{vVG`LH%!7oJV0Vak1}xs4=Q=oyfW)xAvWVR zid6N;jzJiWan(GkQ{AKWFxT)XjJ9zeeS>#R9#ul(8)lF0VvW_K@ijeKheNeII$g)3 zGj%;GT+gFic8|)TJ+eC49`SF)dvq2#Tpm@27k;-#A9#r4CD))wQ&K$oHr1m|sMf?I zCq8+jDRG;5l!lruJ^BNe5!cG26kNrMk3BkphV4C?*u|q?u(!KM_mH=TN9AF|emusr z-X4|hLroZqwRk#^7(+dJ1=lFXMR2T#`9?jOIoG2lc#PsddDM8DN8NF4pGO7ulglA; z!4cd>iNiQTPf_p~{l$E&#o0HGdo=KbN5}s5=mmUdJ?e;|SbNE%lel%2o?i2)%fB8? zM)Dnx2B6hLkA}nkg#Co_FUb?76IB*8+uj9<<*XWS9ee{>QzHb#}+(H^r}>nS3NKr z^;5mdz|XjVLe0FYi;FG1%Gc7Xc^O{q#Q2ZATz||fO9!u-B5P-_s$+k5uX6YH%8Jqh zz4G9{!Cn;~!t$@Yio?OLy&SXSW!@*RTHzO5#Cv1Ca^qWU!=wpb{y$3&6TPyd!(_%q z!6|HuN;A9)V-XG_=PYu-g-oyBn&Z{Tghu0`aDso#0E0iP`OY69l0@@hLu|L9c! zJJ)!%=O_Ak(JK@DSG?+k2grGqe!g+dt3Tnq?&Z5MuZrCAa%`Me>F9+;_#Fiw6C1uK zUe$c+)lt}}`CC!;(%uKDYR^x~osFZa&UA^=Z%NKHWjvFMR5a z`ET_0$=%1NBYk~p+|Q@+IDv}&xsRi`h!q2Tx`#gp5@)ba$5CULPdSGBbYTp6WzrjL z!XcbPc&<-N7qbnreCN|INZQEQIExLNsCSD`@9kh2TJ7{{Hs0Gs?Yn)7?e%eNH?iV$z<^2X3K ztY6(H`PF(Fb>S>>O!uoa!kCLqIFIHt{A&2EpYJOD+Buin=J}cHnLf?uu?2oPzw=QzR|mA;=T|Qb z-S5{WG(PCp9Sr-^ucf$+7kGHcuZ@TO8g#_3$WiJNfb4NRhBc;ub|YdA zXqF|QP1b;}A%CraeniFE0j1!-x&h`P3TT%zpkO?)aRa4Y0hROyxb9~_?*;?RcN$>+ zpnz614rl{@4hK{t8c;{9!@|UXVo3qLl^jr2EW>VGL+g})dSXASr7{ja!9H9^?k2=V zxuyZdBORyl6lIzPX|ZZ5Pl@RQ)8N7TAss?a2wBei~5a4gtOF8Q>bg_&lJUXz)cqBfko0 z?}&iD9uwd=g@9&H4`}kHfHrQSj;#SL-V@N&qvUvum?r|NaGKtq38=t%`hc%5vhQ%< zNT%zoviA$>7NY%wdO9GeHUoodIyk5+LxQ@G;$H?e z3a9Ylu%J5QB3gbG)J7B<9#nHIz$3W64r&;7B5g!a$MEjRpypsXa*PS;9fZdQ`OZGb ze3n73j~dip_-1@i1*Qj83L{bUTWUqCnbeNrvx59Rqt4lEi*A|JIfrc)vd(wph6YQ5 z%Ca=5m+=1()JMyL`V6O61hsEfP)pVY)#vA+hNJd|p#DL4V~}$xgUYojs5)DM^5O^N z*-Fi*i!RuLqtLdX^23c`n23DagBpvxJID{|JA*RsVi``tvpc8+OviORMy|a<{rEpl z?hC5>{-D+!4(jz$dUZaiSNQ${`vP?@(i7yp6jWcFM~%xojtc(-IS-#cUkPd;{)6di zka-V?kB_efH5VUUXWJV=?Lg6+^zwF4y&mw`!=SDr?Gd@-20A^a=Xm=`P+hSXzdj|# zGvXuTId#GDf*P?K-@hcsS3DO{{&i3Tunxmz=)Eik=L#FTmetUXYzDuD8mfpAISh@) zFF6hM%4KLZ_T)BHFOQ*lD3I6C=Qxklw+!t<&3uODAYXn%{csuK0)`eL{Igtrp8S2nb`s=@DQ2EUsb3f439QGG+(u+D4neFF6d4RytS zR5uLfx-mE=mV85omLXpwL!EH|s~Q_JhyQ;WQA5oW4BbbgBtvP*hEBknV(=N$P~lWV ziMWgJni{e-Gx)xO9GVlq1>3YVR3pt${&YhFa0`1fh=&rb=mnBmlRrNF$WVok4L!j2 zHU{6J8H%C{#$Xi=;~omNGgJ#rF$z0S=@a%T{zCQkhB6WNsiEJ|tphzlp^oH)Y@HYn z-*+|?>0)RGHsM%TL+^jae!?+i>29boX29CRQ0bnAenQq>hKeDC`VU(x@Oh8|vHxT_N*|}eI?J$Rn&v8e>8Li?N=K*ik@rOKR?m8b-Y%7q5ta*75~-Hhz->C zJ7eOrKMdv{C1)JLRU~aBkFDgt%}}51hK6In4ntLU@mj;;-R!SDjDxd#4dvWt=o@6; zZ)o5_^2e`-c`ak%5kqesWnUjB*OP{7pECH(%FyZ4^!|*Y56|)(#4G%Kj@Qz8p63_o z#U-9!$h>Um&_C36#gOBwp{dt+tz9?t8e?wqT)IV`sC$>^`y+b$*iaq3g69d(_owvj zIj>24`hwSBz7X@-hg33uh-*)W^l^cZMimXoRV<`$FuzntMaqR#yFy4$(Ds9nvVIs+ zMx~H;R|%AW)wXTrv;We7OL)wdwC!{}M@iI2z{H%+g z@f_|zNF#6nS%bt!do02=lre~fN%#{*LezsX*ov31H43R4R^SqfHx8*0hG7Suqh6SC z@iSh*771}}o{-ky7OF()Co*vo?<9m2#c1q6mc)?k=#KAj28EMC@}fU}!oMh=98yz^ z!4^C~^%P=bHVz?IYDi9W$3mP#sU{&c!B}j^Q<$653(Ub`JfOXfrFUo_L0)nQS*Ftn~F^%|ztauwu9j*M_hv z{T|kTyTYozn>=wFz4nB4Xm41<_k}eXC-CGzSal9kC!S)^pJAQ;E3EN{=*7{nY?yW| ztmNZiwZfbejPrL`zoXhdtG{^A~Ja+x`=z|?ThHBKcWqR zi1wgDFrvcYh!T)365*WPh-TnXG@{E1Y=Z`g5&e=Hk-J?)Q@Rint-gq8Ek^Z;XkTA$ z`$w49E~1-wdq6}7P<0^N!#pUWOSq3dgCjaNB%+~1BbqQVqJtPZDWZueKA9S)L{x4n z`K^iQ8J4e&=y!O2ifHb-h#LPK(aOUS{foIrB3gwyMcHxjqnNuE=4pM zcP~e@_@4;#NJX>)t*=Ma4W(~HboE|D-#&vy8cEEiR*YE*ZtMRmD) zR7Yz>wKFcN1?H%xTA~_jjp}CYsQ#)G)wa4({Z@~d^`k0fkLo%$JBa0qs-Y*U8{Vj1 z`J?(S5Y_QuRP&6e&S7FGs`;qgD5|d-N0mDqRcQ=Du>nz~BKN?kiX#)x2Sqh-a8#4< z5c6gd2NP!z2bE_NCzEaF5C^@m=Qr+eAV2Iy;_uY?2Q_YFo1Iae$E01NQs1iE=H` zsDgK+T6B+b??*NA3EQIY)2K$F;IpVYKaZ-!3vRO{=m*5ICa4P@ATfJ_UgE7B2^^=J zpjkN+R5ee6vgJ)s!2$^?^>%`qU^CnW6O^Y=g6^PxQD%!SmY_LUtVC7MlBoJf$Ifht zx{rO?6IC=vq6X$p)QBR9x(au(L?snZ)C62bnG%U=Rx(j{P^45M*Oy4tpJfwu7N3+$ zRND%P+K-bTBZ1$!mQxg<&LwkByP zy6#R=*}sx>10xP4smJjoJ%qhrvf33+R)wTw{q|9^Hn&OEmbS^7)FD~>@VG~^^7TyC z48%T9Rzja-wdkL$zIZYqS=$CCD|K|T?vG2>=_$#oJT+OGmaHZ?j#l3$%R4_=Sr#Pg z?hnNMEm^nm*M?;E_&r&}@f-vGNLH^+$$EElvP@f(wP-sz?OaZ+D8&G^zijr5SFppA->i(Rfb=bQ# zMb2$0O2^slDXOz0MT?QSGer}2rRbgADSCV-MG1FP^jV%%6?->T^{@_Iilk~WiWEy# z46Bj1c&ffYr}tCUxqPa^6;d^zVycEDrm9!>R0T(;>Zb*%TD3D(TQOueG4`d(dMQ({ zW~OUD&S27|*vbPdHg zoI=r`(-pydjIuV zOINGs>FSy-rsZgrJ*Lm_ZjP8v=ZvXju9)`Y3?}7{$(kpojY!SMay%#%Q{sCu#c%+5 zOUL9v0%qYj3cepxX=Id->1d^xER|zgS}mre8ZqYgi0M;LO!X6EI+w&c$uZSw!M0FF zOd~O@PfRDUy>E=`s>HMoJJ7#>Or-|I)ExN+#`GReqViWUwL^*FF;&5SN&GNwM*Ix(iuq!{Ob#B>TCv7vd5UC?F^gTA<1@er{kQ1XY9XUs3=p`C`lc8QXf;FRwH6}yX z#%E~4gbdZ4n8Ewr3{{?-pYdW1V><>n!)uqGqe;(aS=tQWvD6IVhgHF&yZ~f z%dl%^2G=^yQ0dv2o1q`@_Ph-Ji$U`<^c?FKWT^O}44p!&#Tjb1CPN*MW$5sU44p^6 zzcX|YH<0CIhRkqcI-VfssSMRVouL+IGIYX~f10oBvjPE+t(yD(ce`x=yTSk5{vQq=q?7;v literal 0 HcmV?d00001 diff --git a/Covance_UCO3001/browser_profile_4/Default/Code Cache/js/9dad01a1653dc339_0 b/Covance_UCO3001/browser_profile_4/Default/Code Cache/js/9dad01a1653dc339_0 new file mode 100644 index 0000000000000000000000000000000000000000..251a8369a41b3311172dad31cabf739e2612b7c4 GIT binary patch literal 36908 zcmWjL1$a|eAII@uleDp>O&bbD(zI!tHf>tm-5th;>u`4&&T#kP?#>u6++o9Q*pT7w zHhl1YU!LdlG`;uSbN+Hd+w`V68g^Tewd3b6!IDZ~+}HBu`JjAdbLT9Rqg=_{xpS4v zS2{B_Pu^TPO6AL&t8~G;H58|6kx)An5-e2V)tUm6I;u9;+3oAWecQN)8-G;Yw0NBv+PV zsz^DpAJ?&>s2b4@MjGltcc{z107QfJ)nF6HVWeZck!QszaH57p5V8*mj5 zQEM@=;SBohk@{YiJSBp(5qohPO-cr76!w=2(tUI)9i)EfTP8>$<$@HAeieh%pmLD< zW7c;;dfz%o<~Bjvfy3~$4N?HL&)O1?gG; zAPpQ4q;VKBh`ELb>6cN&hltTZ3Z4=q*VG`rz}i{Nbv;PEZwKkY(;)qej?aR$9`&9F zY1)e*ZG9P}Ln!eoNL4=v>9fh8=D`M?jWlSp%b@*uoWY<&Q3hp;HfSSuXEvyQ7K8rC zYEY`%pk6rdF{pK{L3>LX^cTvOHt29!gC12d$WqmyCe;k;fLt{VDvo_{)H0|o7NJLN z=0J}I2L009pzbXU`nQWg{;md%!3ig9c;86mrI)sRo7pLfm*ajo7Cfln*;`5nX2+6hFtHLh}q-JKvz( z3k({LDR3?_C}pWZ(JKtPvC^RNtB8NCK?N{vok1sHTTgw_=~vc7whacI#x*qFY>;Wc zLC28i0OMi$lQAa@dVYquuNY*#YEVuz#xN|vT1@%JpqV!eYH^dkqwp=_xouF?J%f&8 z-vfghK4zU~1}%PW(9$>L^VXm{Nc@-jyf-KurLY#JkMs{eV_*+qVbqPBM!iGk zTt>~!%Q#%;f5*24jY=zI)X#;DYEsmwQ%Egt)GG`xVbnU@M_Ngv#$h)4mm=QMM%{v^ zEa%`ZXVh-oDNju*7*!J0(4eAG_wY+4qwJN9`VBEvj2embsz&+0GpZ`;qkRoxMTPGf zha*22)wPyU5w(q4h$Fa&+I5VYRoAHHxQiwAjQUXDs2$CWdW`p&+MKmpkYj73nzb=% zLR+H_;0+$MH_F_>s6hzpWK<$5-~!rqG3szvqq6m+hq%(qsAoSJHKsTH=tJ-O8P#uq zQQr+R>Yu@^H-x=1jIT1ojp~igBaLb^+Ng){jxp-cM5FRdVz2z)FXVts(^vzKr}KD* zQ61+P^=Ph9S>_ql0;lFP$0DPWmKv37l~L_*Vzp5<*D?PFqmFJgYSborwwWBa7`1kr zQGp%gu#-G-8Kd{GxAqdpVfu51^{#O3HKR&BAP)3L=7;PLOnAgTd(2u-sSVzv%`>A4 zJU42<3-&+OqUFCvO?qe4s`o}2KNz*ZV$uYwNo8y%EyHrVN!3G5S`Dkiqo+NH zib>nhCx=P9a+x$ck4bg%a$P=?q6(Tc8f6QcG!3PTm^2Zsi<-0>#fq79xP(c+S1`#^ z(WGv8fIlm7eKnKnRySz}wtR0=p?W5bZD3N(CMF$fYSQ{ADGYS_)B#{I~-ze$A$Qa_aa*`!W` zO}aGHq?N-=x`NCjh-aipmvLqkwHnP@V@!%0XOeF`^G`6T!c>#`VZwBi7SEt=v#1N+ zA?Iw9=He(^b4=Pa*Q90(Sr_dVnKU0$7n_uSiAmkD2VYTVnMr#QvfL!&O5$0|`q;VA zq%SzWi99zm-|zHx3%%cK(j6>4Xi|qii18GCKf^J2&l2}}lM4K8Qt~yEdfg!RXC_5{ zre6wHXN)xj>%K8q!-9i#4LR+>I*mM`!3qfrmJ6ja1#3`ru=ZsR*2rwZ3U>!&6RhhQz}6s&h$f|b@aSZ#5*Td;2SB<4QEk34;Y zbrLQ61?w{=^bc12fMD%F`k-JHL5`n;^~>O3-9_Octb@sDJd|ruYFMzgA}~Byi;!VN zutwn%-i;2{(22ovPaz+i!1k%ZS~4S8nPvv-5CU_8Wt>Z%Xn^MPf;D78uvX#*+zW{r zbr%QAza&`eehb#2jYF;{}+xEic}IE=2>g7pgZ|DpEy zc0E}0Z_tCA!CG}MSWR98EB}AN8mADAF^A|^SBQ2YC_{*nunn%L5bex}=n!?x8lwI& zAsUU%@OpTRLl_$uqM0~|>|VxUDQh>D^* z)*&b@M91+271KlX4ui9Y=r^p*5u%&;Gk1uZ<_*y&{FyIA?+dU-!4TCi6r#k!Av#wi zL=B3CXdDipdhrk~gRMk}8sY@*;$}(WuN$MKi(7_@43wuXWkI^A&hl*pU1)O7v7ndf6sNbXzJ)0h) z4|B+IZivRu3sKI+SjOBdLX>}Hh|*VuD0X#-jB7$P<<}5(+7zO$o5}n45S88*qTpSO z-%mVeId_3`*Fv-&jjq#^NA%}Ih!%yKwa{VKfGlQB!!A6=jBI8tcbm1;W7av$i8ZTU z9Ao3n`V;4IFTt!gc$Ua@KF%eXwH~LE&ANs!ezR;TX0=K+s|O|p%$kpFX=as8H|q@k z!IbP~Ex`9V%xVH>PP5!Nfy+3Y%dG0T&H6R3S^wrUD?UH*;(ZCTzAI@~SShns;3hJZ zHtPqRL!mNe?JY|_7+2n`S-4q&crmD=S$EN`5|6R8vRT1Z%-Vv3c!*Y2&01Z}tam8& zomsC?rG{CnQ2Kjv!5X~B)*sBOP?L{XS=+2-bXvoiN%9UK@yJqDST_On?v2AkCw8;5ZHP#$9)T*J)T zH^MCANV77IGAsKSv)ZFKKH&IR>M@RfOfsv}WcJKd>OYOou>vpQnqgKfPU6CBvue&E zuDNFZe`BxAGi&n#v%(jeHE*d|Nz17t94pPLyvEGeD(b(5I&L*hE?DBNaI1$4AqWDT=uq0^#A7!bj^NQ<+LbEE{n$DQf`a>MT0yREy!)S_q2Eb8CfqUsWKnJ0!N}egIr~^tv#&+hkflF$#p3~7Gti<9gDlGTvqfzNTl5@X zuzH9^C5Kvc443d0J%qTM)#2iW)vW2afv2{$loIx)|*Xz(nH zCSVN$vn~1?4^eLppU)*O)SYk9Tx40u9N4qSBEw>GUt-Z(SeIE;70)nyxkb5GSX2Uy z@BnYIf2BpI@B|%JvF2)vqSjbcaJ@z4&>XKZdlUP6GjnexhwT>S-$6fN+-XsnW7PgQ z{lX>mI>Gwbj)o`c13qKYDT`9iQun_sN=J`#^yR!or7v3a4<27)|De=8@ z3|8Sha@noQ7-m&GO5iZMhg&ri?{GNMDu>IeEXa>P&^3cqgYgDkqO2;D(W=GKR#nJi z)p!)l##%^L}1Rn@9n)ezmjvuZy&*05>-Uf>IQd~em+AFS$I)2e*6nICg-1D)zn=ekx+smGf2 zSrc2(uz^*UhE_%6cvI$WX4UjoRxQCk)M#y0W0>1mH3Spdkz;#u>_Cp_)zPYpxPxq+ ztU81OovkX1$0*pvs)rcV)hc^8uEn+PRu$=E)icBnpcezJ8jC`MtP1;?b#W4p(SI;& zkG5(#@{YA?FXoN2>Kvwyw`%u9tESDQzu1c(W?9u@j#d5UTJ;+9=UKHL1LxE41?01s z7}0Snb=yG=c3QP;7roj|E_>KlScnaKnH!(?6Yl}5dLAUULsqRsr9X%r{=?K8S&vX7 zTtwJWYIuxZAE(|Y*tb{MhyPf4vE3>+-otc*{cy{wO}EJv;rGbrKD~Tk)!+a3(5hb^ zQNzd7?J3WPXI7=c^@4g~)@!TIyy5xqFZ=vG`xN0HtZIaIFn+XZ)MsM*!an}Wm>`>) z8*J)|{YINkqgk*`Cqir*Y_@3v4xyyOrj&4-JWiVe=#JayA7Rs`j5ck}#5g=cvuK+- zV+AT?wedQ(O{=om6c=aHTCYvpQ6t_aOQKCtXobim=0-34o@~7Z#P1Oq7__^1nvPEo~ zQq-nJ#cUc~+@_a!ThgXNrHKut%Gh)arOVn>8$V+z4&oxrLIV=(~kW2}Qp$8G9!!ltJuZTg7%r>O5~n>L@J z7Uykhe8HynxP=}U8HW#-YQmP zeoHO?Wj?sx*>nlk_cqPKa?Jn0{2$5dlTH79rY~P?%A47)%317+&1%>3Y<5{jHj?w<{*mu8%&uj;7e<2-uYc1xne~6_-)Cv|SZ2sG?nMtJ>wMW>*#bge5oyXFa>z z*wKLN8rroVuUpvl4NY6x)fe72cGbs5v~9xngh(8xF_d>feqU0iS#DxEUTx{1)97WNk z)D}ljd%0cHumo#Y*mVcRR}lv)uVxKQLY6glC8N<=db5svF@L>XH}M=9HZT{~U^|}w zM!h!LH5^lMXp>#0&E$$LI0XL|YKETZy_Nm3&93_>v7H`c6prm6pPl4`GP~#rrlG}d zyB1>uhU}qMXt$SZ_t}+ezg?LQP?tk?6~nkci2EotJVwsP*{f)Kg1Jr-_bI!sW6Ei} z8lSOi(^-0pYJZXQIlJP{vxiXT0)5BN7wt;BL@hD*Z_Zz~YdYRsp}$w{%5$BVZ`$R% z#r{J>Ou~KSy~94dOW)D?9`(3S4RP=Rb$Q4hL5D|n)p*Pveqz@j$orJ}P~w?g-#xeM z0FJ$&SFh}v^Tw{XDE*de@cqAbEqG_w3zT`!=h%T9AJ{|CM|y~MIEC0xJZG>E(Vy+g z_JwsYA4~q@d535CgoLlu3&wBM9M|!yLUqs(st3kU6)}aX2Yv|-)sN;-b;Od0P-Vyz zs_t<-#w|R@H7_6ILzS2is<6aRHN;dD_3?R9sAgd~zWSLjB~**BFfCMhbB1bn?ob^= zfjps_hQ;`lFI126hw2?_7Yx-Z6e<*|i};~%sBWWm5zZrH(NKLu%VMEgjXA|bb-q@p z>eUX_eT=IUsxEayWvdse75LOJR0CUvYAims302*$q1u8Hy+ZkUD^$l(sc)!C_Y2i# z1PusPhasWbIx{n!T)Qh`r{~)HiW9( zZ=t$`=9@y*Z7cI^qh{!Ze^7gSs1EF+*1O4PPpAs-r7ruZ^?uGD2-T#6%y}qOA%BGG z3N{@HRraHyI*IR&5z}$%iDD;06?-yNebE0D;}CP2dYlQ>TP!&nsvLiX>JYY{BcAi2 z+IfMVTnyEEEWH-0-~I_zmFuBegGV<)b^Rv2yc4P>cggQbsAggr3O^<8XQ66=BX|eX z^H8TRedV*xV% z8>(jLf{RFf$6Q#3cQC!DuJ{AzQ1t`XVI9&xQX7oKYn1pDD*I>V#7sQEzv%IWxNrgG z|Kl8%qsmw6fqMproJNP*Vkf?u94Zj(&?wwN%@Bu{;XTsL4!$RJD7VF-VR(vSR)=OH z$>vZVw8cV%*&V8foyZgF&{Tvv99k3RP)xW(7x9PFp_B-R=E522&>;+VbA60MAs&ay zVmsbpPpm`L;v8y3Bx1)xbW3)qq~D=O zc!ygl#F@sNFsD0IF1tgYQ9TE1hgHhnf{&d_jly6>=!GutQ@p zt%ySrMICxw%prSmhc3WW!lAmzSCYBVwUk4@;Um(^IP@=emUZZ-at=K~rt;(jV+Gd5 zf3Q__C>MHSC^l4f=o&6nbttHsLkVbzwm5=)HRuaIBJ2m|sp(LOS`JmkcpO2O+SIp> zL#xrYu0spzIaH*+L+cUSz@Z8a9Xf&7Mh=a@2Hb7zP-Ihw_M%ra&SOJ!`qRRp<}Hb@ zHMwCAGPGqayz1bPucJd}QKXYY6|oeTJClDGde@blyODo)dN;*>egdaCLRB#h@-t5rv--&4}F~hu_x})n3 z>bjE{c2Voy#J!h#yOiIaK>3dk5=J(TfWX#i0^{E)oxR;q)cO{mpad z8f*ST+$eY5!E3V)C1N(t;yTveq`r8LJh#|0ID@JWs0s9tbsn(}f}S{36#1XA)^lp{ zf<5xmp}emg8u*s~U;bskyyJSbe(%r^9~|oUk+pE)6Zw3mE?;>LC`|VaVX9&Z(`0j) zu2{mTx3e&)hVY;0uOueGRGz-sV1i2P^T~*?9SR~+cQjuQRk;H*?W^`AJ*?nUj4!}ctDsugUIP;uER%6 z7#yaQq114An0k*0(+{Iq3x&ppDepLrjSo}i31K{c!n6Y66T_5_^OM3&zhAC(Zc^nMW zt|Qd>XqeLQ>Kw6N4b#x;VLBBPuG&fAN@^IcJjm1|TnQM0&Dal5PsX4*VtR!u6&En_ zr*Qp(=DowU0$uxrYan9#hAR!jVC)wzCvx@=S1WW!w*leWfZgakFkJmndl2)$IGFM1 zgvP_dHE~3^-l5*eaJ?KAuE6MU6~wHu;rew#xYkVM_>^#+ni{Sp)5FzzM!5c*8Lm~c z!?guP=7j6%yl`ckA1*&y;SWSCWUZy)ssi(}aAjW^u4dSVeXGKC66Q6my)Imb)`zRh z#&F%hZ(GB)ejDd^hU@O0aFyQ|uEPhz_4lE0t@|Tf4~~cH$Ft$Ocad6L4OiV;;mZFo zT(zEu>&07g{SdBk|AlLIkW(vg#pvXFWTzZqPG!N^aHq;Uo!W@^Fhw}IpT((VXcXzx z6g(mkyk8^4+(!EZN!F$Y$cPe9oQ<)N-8i#g1r+)D}l_$k1Uv}2c=hUYB z953M1HS8(qR6{a4Y+~i4o(fj4ZQ8>R8S|U z0$rWz-NUI;J)Mf}K0ZHcPeEhAIFfxSf|>K zbILH@se2Qgsx{H6W|Np_3VBU+Dsq}rZQz>jRJ|Ea<(TDED|E*iq|f6zyvB(6PJVYy z9y_TMp5Xgk)MK|(lW-cTdz>nO;V8D3V~6P1A5OKvYHY>*Kb`7ygmsV7v*S+XI_XsP zQ%*I+tTU{C)~RQxd(EklH=XKm%PI41r+T5!9gaPq&JUg1{fKKHJGqC-smo8O({uLC z3#a~k<<#td=_mSrU_73p^GB!p!~V(1&u>oMMY;c+I)&-qocf6VQ4!jXKViujp~IOX zbR;@L7jQC5gqp@gsBLV7I>$xG=Z(-~+>4LUu7n8vofx5|z6kxA9HAAd5!x4s(Cl0h znwLL9y9-39P(j8OiqO@<5sEAtp~1yi3rmZ$R>=qrFBPHK(h(Yku(A!~M`-y2 zu8obqM$Yy+}2x zAE~SjBIRrvsT<8AwZD0!9=43ss#cLoZo}BNk;>LSQhuC8rw)<2i+?yixbaSMB*%GPOShY1$HMd1-6T-Jg z>IZB_$sLip1JCYAO+kx2kuvU!)LfL?AE~jpdXSh8ksmG~`=62OhAD@c8?}!_>KMA5 zh}4^t%y}wO2hT_9&_!as6sdt%B6S3zS0h#UTBKI~L!37vHTX`XLheUu+9P6m94S4C zRO9E7nu+6>@Pf}@M(Wx(^2K*@DJsaN@tBRH2A8@TUHZ%9QfjbEw~#f&rQT+jKEr8o z=@JZ9m%_0L(`+uqWpHT@I%ITd16pQwsZJJ`wjx7Tmqy|=lCrt<3~SvkmGHQf7VFYn znBrV&ff-(x*2KFsI01>omE_WEY)f`2+V4^qTu*VSaH>lM(p(yVKM|SkQbTOb&N?|< z%9+!pSE!N8rTMslKyK#51r*Nf(o)fFF9ppS#9CE4opX@=5KI&4gV=guO?9xJH$&^9m&>OjNouHY!TrjgM09sZla4jpFBzC|>J~Qtv%c8hI#68}S}J zFGMNgT9lqVic;psQEK`mN=vaFhmqq&lscEpsLA~^s>ZO4Dl;adW=+bdL$FTH$h~+O zb!1sarQFP@3#k1jqgH>;sE62{DHHd_WzyWtnUuMHCbezE$0nK72-lltQq|^}6w@w~ z+H}aIdz~_AWY0|cv3DkQ9F$4l?aHKehcn4|DwBf0X3`8pwEB3Xd2JwC-^WL5G4>XW z*4!e|`mrnde_-J<7-9{F&9FKxXwRlv(9UW>(YEnf0!0W(_Z&S+nY8mZxuKWqXxb)kkE} zgR@z5@vkh3=$TEXHQ7{XeKxH;l1)2t8eflQ)30B$Y0=kg`iMR@x1NT&l`pGX2Dh7g zL)`ivzZP^WS0T5`V=qo%O<}jH6>;kf>K1kD0J;@->pg0gV2)C5-YeqPZ)M!dUDmA< z7>}C>Dd*Oy@@{Rc=vG1{x7MR?Ww)*)S5@XkLsb3Vt@xqN4{XNeF>XD;jInNA8|PN!M7PFbK5pX$rcZL~ z-zl7%>gL`nw>Ba47wUtBxQDlPNx zp;xFkm-rApk7EcdackOAx0WFHGPlYuCkH%QQMlF#gE=I2S7`4T2q$R}2pBy81 zju>^qMdYd&qY0Q;DMojYqjHRvRf$pNsxdlUEk=jFi_srH#K=%HM)_)SympNG)Q!>R zCNV14G)9*Z(JV$!P^fu~l3K**YwH+oZ6Bir9b?qEQ;Z6Bj?tJdF^cOJqgLHxbh1Z` z9KDza&3ebELZ29Y!oGeny52uVPw{17j7ATNk>%$YnTEy4J~BqxN5$|vxEKwY9HW;A zpAw^Nb7PbTEinKGka1p&0*hD+2N#pm(inaZ7NZe3jL!&N8Kc+hVszpd`TZ5cy>>BL zfudI!f1Q|b#AqJ!zKqdauSZ|tP4Fl?E+9S0qs4xY2Bvs;KY>S40gsO2BIZ^1=qe_B z=h1w$tKm^^WdGiyR@jMtH9a!c_He(5M`?9DnpD@L@%23V5C7EXTtkn#AgGZ?RWP%$ zM}>a$D6y$WhGrh+LVJWX_h>y_Ej+3OZ%f9t^5{CwxAv%B8;`a^Z9OW6R|sn7(K2Lf z?@>=o!3Qkr;L)$Jb@ZqVrr{=@qk1Re!)b(c_Gk>aR`^YrI!)pc1JBxS`G25fHxQRM*SZl6Fo#%NJKHsBz*s_4W zB5jdJaf=y)%djr-=x0<~=Fv;6U+&Q-oL%A3s5QjCmKtvKs1{md3KrlZnr>nZT*24P z9%cO9qfQtB-xiO`BKKC0DsN*fdT;k=749JS4(f(uJ3Xqp%cEvEhD-Q{0=qpLj){9b znv2-I9u2@*Y~D|P2Z-+vj~-&^pB|lq_pnC?aO?>4AmS)}Kr8%VAgVMcXxi^{leu|Z=FXQ{gszU!*83!ARt76+?)q7X0+8<)w zQ?Z(GmTM7mIaaOi#;QBQ?!|I1V60Z7%)?l9!Bgaa6sslJfc=kSRs3nJHsiyySmk|A z9q<8PUy{S?SUp0=_p#cGzfki7HU1K-AHT+`6E1y=)m+7Cu^~KYlR`|x|>)F3HNV^ZUkmM2c@i^QpCgE*D%9H&RU<78PIr-p~(boF$cCZCN{^0_#9 zF2w0J`d^IGMRd5tn7`xH?_r$QK8xe)Tb$Z_jZFL-qUqjGvR6Gd_n8=mI&s$CwhenQi{UX9M@)fGIz=7L`B zN9*FOSHi1zSW(g|Qz@?^F$Qa{9cvZNrS3U7pJ+Cg;CofcJ=+!F3H=>S>y;|4AtA{^&HN2@;`I=F?=3ezi z&K4ZU{FYvQYvtAP)?T%0Z@*Vftb)=jh{k_6ou-vX8JFVVAthiWb;_*4MmRhPwX{ zAD*M~4X;k&4s5r)ipDjh-1e%^1Fm`G)s!dH^C|Uz!Jc`^nAcwIL$|kHHF`%a@uTAP zb5OkOhIoxc9b>#^nc|hp9M5g|@%m!pcxb%7bHwWvhPvWaH$7f|qf5znU4XTGJip_N z*Fx-tDsT=1FtTDi?^BG|vr6%*T0LH!eu&pVtgjibUFcLhUgkRSI)p6s7}qGC_kYCe zM)P>?g@~7Rv{ed2Wnef!3188+e`68ps~ zH|8O|f4p1+;xz-;P;DTw;1YiOIbJnJ#H-m9;+hrDJy7x5hL0#QCtiQRGB;i+Xo3Cn z;uWzVUNOkHkT_SwtNf~XUBrlk()i`Nr;K%3*lgFi9#M7-W%+R1o@pJG1TMBmd~k78%Y z3)Arwmb3B7dyey1ih<`DkB``JFDw z#_P_#ctt&AUL-#z=4bKTV-c^WFUb2PdE?}3>hq3XVc^Gjwf+>Zp8v(`C>kk2{Sg+F zp!#Tyqo`^~Py-Y+Cg?oYm=g3J!NCa{f(apfj-Sj4>TF4ntO>f0w-{tg&}4gp=ED-2 zpzauqA`aFGPtXUXIukSuli`d=(1pkZ-9t@Rf||jTF+nYGC{u#EL?`HHyuvrM%bcLt zED1V+Yp9x)Sg{n}WlPYHIEx!t?M~2EJc>zBR!@Q&qdgX*U~GbZ!4honCTKT;;}bL+ z*%O!_5AjPPb0f-^pm zh-sFndDxEd=85Wn_lRkcsM@%Vd@U38q-&xQyCrH!caHZ+RLPNv>W9BaG1r(xb;LYe zK&hFD`Wd-rC8{)z!Z#;T?zxG)hbvK&aCKgy%Fj>KC>+GDMTt6wpB5)7a%rLpFHclA zm{uh6-j77BTA8R97_gdgShO}#Nxvp)=NprcaY!CL`~h5sHeLV zm3I%Zqu9PgZ9|d$iJFEXhZ409-Tz=NB>hPqc!i!vh#gmtCGtIYqQ>I_5>6y)GGb09 zY8Wz}PgGe9#%4T5mJ5m8YmlhE*o=rviMoNONccNZcP}Su;gv)+xXOCh5_JiAt|!WR zBT;`nOjPJ2diI!_JxNpwnxgpAMD;-QGje#IsCQWPg5F{EOO9dQ8+!9TQMVBKmE+$M zbw)l_Gx_u)#HS2lK6ME9=|1d{K8?q@Og{aU*{5$=eZ23(r`j<-wTSg;a-2__y*_#3 zeY%w7)39Wpa((ZU?FXOAp&y3T@+n^(AAhI8CvQEURyOqM_ohDm*38Gxu|B;*wRS!w zwDWuX%eVk8)u?5A)`}79mCiwIP zohSN~WwK9|r}(r7ji&iD2i2zg)EIYBa;8tuP-&izuRT6~79>Z6uJtMRM&{haSo{X( zW}m*ta-70Pg#7MPF$~3I7`OOT9b54Q)~!57)@{`3xKGPY`Lq!!r+r$F^Jjc~Kkd_8 z6g$uQuw3vd`l3(GFZt9JX@C2)0#z^j)C`l5^@>lAQR6DTLG^3&1@3=*>V>%LKCQ(i zbiY9jZ~AlsA-9RXIN>VLzl5%EBQhOYUPSU?wl4Qu5q^?NI zmZZKhN!o_?o+R}{P;8PK$0cc&H%Tk-FHZZCv@bbH_xwq+6-`nZEGovh;#`O6SWzlT zw@|E1lI&%Z6pf#75l<>6$zLf+*YFhGDl=!5BrUC)q>XS@OVSyPsZPu_k~9NLaiwOG zs@G5Acb7@J-ylg-8YXE0-ePN`B=u>Mq}{DpuXU0tBcx4|jBS&69VSUjIwq-frzAN$ zCutrA_DND;5Nn{t&q>NOBuQN`XDIWHOVW*BlT>k2l6Iih<|KVRmc%`tNqT{ASaKps zKb%R@b~HFoeNg2>k{Uu6lhg~@u8=2^uCd0wB<;t^jLE#`Dp>_@C2JMFAlL0=b;Tt- zhW}2o@?kg*;w&oNP3HTNWOclktQYtX!yY7S@55v*dXlUgNPC*B?pT8k&yqD4Z;|jk zS?(9fdWD#m$@=+qvVz_ut1M0;Skok^4h3zbjAHc~tw9 ztSLzR%;#T|Rak!gh2S7R@6GY+6gCAFj@R6jLukw3kb3LRTTZO2G`)U`Beg4upUkAes#rr)O7e& zCd{wz@mIKCUl0}P*BpH3;uuzB@N0CGUytw(F&X{(HxuWh{R+zLmp6-FIWPrXvikK? zHqOWTl|9a{abCY>#FHDoB>1%<(a+xl@~eBYUoHH^f!Wxd;@9ul8Jo{9SAM^$Vs!!P zSIAw(zTeOTYf^?$^^Eeii6R zPkZ@wt`GXrmjT2(klv2)>*Gkj>WuPBWBeL4f$Pz7BJob5pOfj|OuvR=?`%JR_rR|! z^Zc5-fPOFZD|xYBrPlcMWUZg?lh_OBx8AR?4Sw~3<2S$BVEIPBe4G862j}mcL&>eI zhg{p314od!gWBx&YuF{f9^dq<;sfSIp@)7|Lii)U+^GH7uTNP0gg!lEFFa?zzTg@p zyrc)O{L1^9d2t$sH-0^M?^oOhKi}`Oe?IwD13j_%n_tgSIVeTB4Jj&t;aDD$qMImc zNs--}qG((SPtj6migrY%=mXZcQnV8#Go)yKR0_YlPf=e4WlGUg#73v6Hb$XOmK6Sm z1J`6tQN3);gOZ*U{?AU)-?1rb5SOAZuy|7xg=$!eb10FRqDsCLUTaBFXzmoX&66Tu zUgAX)^e;?I=vX9017Iwgq92Q;C{R2_g|HQ$(62;_j+RT&?kXwzjP+Ghv6vTX{llc#7SE~3fI6wSiBSt(jPJ4L@DVNQx>;`ik# z>bWvSXSStqzkZ6Q?@rNqjNFr=8F25VR{O|fe~J#ANRdvaXcG>i_o)<(K!!8Kgj4wQ zEHyYsY*$ls?*_+irf9;g6g|3=qRRKk^#Ogu;D;$H|Co62D{enYQNE`s+VDI@F)vb- zinz}yiul6k$oefso#72i)sJu)QWX!6F;!{KRCU8}{EdW&ROP~N7#f+XD@b*vstdN^ z5-Mj%)g+XQO4Sk^!5b)JstRBL#^Ng~XG+yKRE|znJ&ehms((-^F;#VN09SmedW?EW zscMbCl2cVHB~_8Bsd|le0oK6=oJ7;KRIS5KluA#PDSN7#;~H}3Nag;ZRDFOWXQ~RJ zJSO5Mo?}F=RBgtA+^Nc(CsoC<2iCl)>VdU5hdTLEH5bDQq$;XVs@fM$)$eFoBvnO< zGAAk*OVtg86;D-nd_>C<)DLq@rs}^^sVY{QILoH;|6i&aR!r41{9BotRY_Hu`qUjS z(X>IT&f*U8G)z?$G;2i7VQ)-6O;WX@X{v&nrOMVmRZmf`L#j%5N!4KF>B@XKhNSMP z%Fu(l3{KTNd>WFfTf@j7RmP{P!NgQ$o06*fzYyc}R281VIef*AnW@@4pX1oDAXWQN zZXrEbl&U_9Q*~k|=l5_P8}@P@<@RxYf2x`sNL9xpsak`^M^n`aS&q@0Q+zy4|L_kc zpGj4#i}VV0F41>9L#4~9>To4heQ^|vucgXxJyqUY)ClM9rfTDT)_llbdz7jPk5jei zMXF}KVZFEP<^Sj(tl#J4A7M=jXd<2_b8SjMPmolQafJf9gu#UadIM`Y=EJb^0i{+5Xl~_zN>mAG&-VfO zY6W=zc|e)#1azx@Kyw<^a1UL2lyM40aY3u(4(;djhztSK7fG!o)l1v z=>cV15K!+$0lroSRCa$rgK+Hta~}+7D<0sFBLNwYQaAjGD#rp^bv&SbCjvSJ|H**v z;r@B9yAV*^#Q?9zGCy+MAZ8rJnVSK9yG0*w2Q>XoK;PdD@E#=2Bkn;!4Y2JYHFy-z zTDZ=({;>AOw(nI^QCDn>L;bCMgBBx!yhPLAWc6Z zrU>&Qyl9#{SO!D!G`^Ol=~?A8B~?k&u&TsYElt%ip=p{tGw0roA`;^Pn`Xz?D&H$}l=jUB{%!JvL1#7(6FUI}trEO&4$*S?8zemqlsH zv^Y&emUA2vR;KBnRcTtaI!$*_Vl8#RN90+TriIwKHI46as0WV0wLMKu@$Zf_&D=?x zyVBGHzah)+G*#J?rZFhGH%(P>4mtLx=^7rR`~m8DI89@Zr|BsApP-hAJej7>r-<`( zn*107&$%>pL9R>8do@iXaOWDmyUuv5yFglaiRjWiT^I4PO}fgoP1gt1YL_mxPghNp>&|>w*E?N9`f&ZU zbPY$^>~yt9%$#(k<1bX0o30TkI4@llk!LD2K ztxngnwdtz#Yx@6cx(_fX$}aBzKY9@mc%+LUD4k8Ar!1sr0!el^yVTt*C?Ha$DZPmZ zNbd+N9T5-_5JgdXZ%UWmq^k7Z{$Kv@`##t8xnd@BpZlCMS)Scw<{tIk%0Al?^eOsn zPf)fU^a0OzCTP&E1bv0NyA!lx599YHsN8;P`y)Z`pCRtK1if)SLFOSGAW3AXjIt58jmJjFJjW<;wIh32PI9qRLZ1!rA_kU7HYlCV_B1imoq8n zdu)H-q!yJ-{GMP^|7s>3!zC0-Fe$Iuq+-~F>Q<97YnhZ)+oV_>lMW@CG{j}nSk!kj z29-S~b#7tON3Be(;cH^8ER#mS8aGM(O=^k{QD}fkk%7b=WYSkdP0AQ%QWsSD+@#Hu z$bYg)3(fx)QeH|w*2ne~^<$_f!XYSzJIvzo`uvZa~zJvQK@ zre?XCn-xVH?7*59W?gG#*4PZQ#%D4|YqN@DGm5q`%fP(0 z?@DIP8EEFSXy!zharAIJbD-%2a-3=AJXf<)k!O}!PqNI~JJ+mJ7&p(XhYRWVBC}3l zz+$s1eq+`HP)(yRh&%<}AH93G(kZfe4fBlP09SugSJ3A5sVnYHIE{k>q; zTMy0Zh|f^rky#%+HtWa}vu-^%>-I}}gr%>jK^FZln?=oYS@c11i`ta1u#Sj@?@=tQ zA7as}QWl*nW0Ad_MH7()qr63<-?gyjmWAs&EquRW(L6M+Y|%)h)v&0R$)ZNMiI2?| z&9PV%sb$gU^(?yXw5WeW;`=N*iL038x9DNOqMSjCilaX|7#4jMw&)sKMlH&fY+=1Z zw&Q;(7B$1}m_?`3n7b)8AV)LyX>QT@78V_7Y0>()Mel#aym-*TqOUtzbQ>?Qv=gyA z6T7QL3Ei0sFM3!stCxj!)Gg}xsfBC2=n1-_RA1`sXHn4s#2G>yyui|-7FGS6al}h}GRHCr;q29#+kRrzbUhYSr_8R`u;~)r`Sbbss|i z@I8*9%uuUpeon8^3pIz+r|DMRLiQO}eTYwR01ao7|JTIBo3pI?Y_?TDpyV8@7U3rh zSzSlz|JBz#TtTT@^%ce_>_gGp_0<@|@hk42+MW7pi`h7g{CDfC5qe__?9K_0<5~u>==T@Ig|mS&K4_q~cQ(+ynl@EQu(7U@O|x(oV$oHtj%@u{M1>&ZhR`ZMwABrm{i3OJJ(t=v1lv*lTbt(o zY-7C@=K2M{k|Q>v`v#lxZK7^`kL;Umy1d1v23u`9jmg_=YP6l+?Xl_Yy*3@hIkekn z)0X`<^*?CSDD?i*CetCC_8zh6_Fp!=d(x&aaN#sPIAha$=WMKzV$;AI^bTEb+BiSZ zrkww9JpQ%uJ+norMs}@s*|ib>V6fk=!?+e@{v`IrH5^Q~D_@FT z?PGR1Qi;{dE*qw&+m(@FS4T|5znOMbZf)1_Hg>r_uq%T8xQ4)ocCBq^S4w-kns=~k z5^jBL*NTpIt;czM-kBOvx~pBc@dEF5BR1|LTQ9a_USGRTqF#TyiVd)<0t~DlNX>)n z>NAXeN7~g8caeRRT_f@LXzCbaSG(nQ&BgN-)cl=YQ;=(=UG^XC>WxF|>{{@%UEkv{ zvNo~L7LLzWJJ-6{)p)yI`FGhhXg9}TpIy85+g1I5U7kaBH92h8g(GY~&Nw{z%dQzG z?R-~hSDRCeJ7d=$7wvlgCOyDhjQN+|-QpNOw(HaryY^*wsC*8G&g62aL~e%`=5c5h zj=$khkpd1)E$Lt_LWic6cjySdeAl7rC|kjyeia=Gz2{If6szjc@6{aY>~m-tGW-s% zX>sTtl7bEuG93CY*`b@rN^xik?|b-_I(HFD}X^1GZmfZT4U*5KWcQ<*5**r^IwidFG~y$pDe-X+NzJLFg;Q^1Bet}3YHPYvmouE&o#|BG&QAS-{9T;- zs4M$*bE+z$uzccFH&p2ElodatSWjxheKhUm)U@GF9l@7hI5i!f5l;Ozh5e^Hm2DQ= z<}&Ymr(R&y0;e{?ztG9GFU+ynsc%;}broNKNA57MbZYGPPBmEN)UNgP;}@saV>hC| zI<;bhQ*C}DFYLtrolZ60`BQF9Qiov5a; z*b=oEM;wW|jQhyxOw?O=54GV%D%zqKhGPmAVJ+@pM8iataV2sdRib>}ME*ueRJQ=J zj6}^0B`TpwqPB(;xqm~VOjDRExuND1Xrzi08fpE+Mv6{u#5GKf)PGtd6`9dU-^^?z z=d4CLJiC!PWHr*Oxs5b!ek0Xf*hrhoy40+kOaGO3aZd^tpZ~e^9WGXJX=^o?zD;nc zYF(FVHg>5K-f7}uewY5iid2`}X)a}9WJ{NJpl>UeMxkN4OQqTp8~NM0R2mnsy0c5U zySS9ID`W8hxwf%j*-G!(5Cxik|^7Q2)V#}XIk zU%EK=-6j88mztvCk1loJ?c#4r$=rE`5oC7hU=lT`##b2%lVb$$QJC zVW@N4B_Fcip_T_O?Zt#=E*-$o=Ppe|ofj@GhvTJ7f$VNA$H^RS)@5+3PfoXX;5wqY z+^oy#)_knQ3)pkJW#9)i%H!5tnDe@oj-Hr_W2N0XT$cUbajP2&lyj>b!mpKg>tAfF zeeLeN1&QpM{p1CnAwh3xL_epEjRa)aBC1&)@L4MZ{SvK)Udmi zf+G#dtr0OX7kd$MQ5SBZm)oss9=DofvzNLt!RJ<2zgzDG-Lk-$>eh$2)ZDF#lc^Dz zvxte23*DNEaz8L9TK?=-gY|B4qbwD~xxH?k+0U2*ZZ*Ysc;}#7%l>rh4|F-?))1_I z?JzkXA?_LK#7h)D>z3`ca~u~OJnz;6ynVr~L?q!X%3gG<4#Jp&~p^MN&N`n3oQJ{t%QHwT8Hykb%)pQx)nj2`@Bc+ zzXxs&d+gRy?0@Q3p=WL#dhXV9B)?)_Ib9l5Jw{R-IN1F?JbQmMw^C-vr9(BiL z9K?MjSMn$eH*mkQM=h$b4;EoFUZGeukL(zXF&JOnqq;RbS`TwgkHTn|;L%rj%j8jI zB)?|%=nmFcJ(^IHtfeEJniFA`M%VIaafBdgNQNAqnB`vW?lrxd02DPqgnGj zT8c*~`J+cowt3V8*Y2c%JUWSguF}(M9(DcKqbZ2p_GlnlKk#S-?2kE4sPKY3QAS?*P(80#$@u6E zuU?e#s^Z&Tbu8!A6hvxx)eBA&uj8E6t9-S*ir4XKB&Ia*vc`*7xt(5_akY_GMO5ot4#ca3nW#TxjauZ@_sFxD zJTdJXuQuSLWnN9h+*Mv}N7)~|3Sj3NulD>%KQDS^g8zzFopB$zuhP%gu6gwboY%d4 z&gE6Hf4rQ(=2ZrIV=;b1;YY-V@3B|4o_KW>wx`sKWv{%-#*u!W$EO7)d@A*}PhoVz z7_7n}JVddwJ~_||127A};3W8PTvd>SUYLO`_y=vP`!o*C5_}qpC$)X5SjVSA^?j<3 zJ5HaL1P;M1j`PaQ)(`BHr9hN&%mdL!MZNf|!9lj+lv);=YF;8V`FJ|$pjXCHsJ z__Vs4PpVpNZ_3_Ew*QX=>d}`9)rwKTLN&|R~qqvBb1AV%S zKL!zJh)>5+bGT2rM)-7LEO}+o8*IWMoI`k?Ps^4t2HC#x>1U*DWNw_rhE3GF#izG- zunnzu`ZNb`@1pkIKE?O?IM15e4l*C+9`eEJZ7A^&muddjDwr+uo5 z6K8miS{FDjm~@dGP~;MQzvffo9gYEZ-}UJh&OGob$3wQm^~lHX&}>85CmcU)%;s1A z!hV_IE9O@xTqx<+BfMJ*rTyBBD`oteQ`WCDuf5~fz;b@pFZA=dC9h+y;nxp1^;*cU z{*C?0ljPU7G~zb*YX*)ZZ)-pQ{`%FvtzTo1t)pL+aq|M_}`Hq)sKXOU}$Uu6--JZ!>ww3z8vqp$sZ z4(ZpD!KqR$_1CIga7ncJkgqKA4Za zukGac?(%buxnFmYZ?9h+(P5uoy)kURUzgD2pkKE!{13mD;TE3b!6Cmk9`|OVov;m;EY-ntxNn z6>_-hSEU<%ef+OqPtg9BpKCMyd}d1>clhtSe%4#{>jp~S_p2V7;fc19*TG=F^4frV>P|avSov;pzk^_pT1oTEMplVow z-MEG}sR8xEepF9m9(;s-xQ@I{iHmoe1(b*koW>KBYaWmvvs(o8D;l?CEXHCjjy zGpHAru{a*kHh41wYK;+Cfz7zxhCX~4;5xp5%x#$;*U+wgKsQnCqkvjsJ34kCCw%;I zKvg;h^rBaQ`_$sofOewcX911+BA~q^1Nw4ofO8N6nlmGyDVqY?xP>~l2DD^PK+}$r z<1u2M2&m#|dVeOMLg(oNzP!k>!+|RS4ay(Xu0lc9r3k9R`$2tg4k|S89|l7C=~yiTG4tIwWH+h zApf3G=N!hOdlq%hWy~V>`G(xkaA{E4mId_!{^db^up+2WaC&7>`&I?DbX`z=e+p^@ z>TC$=Z-h4nxvnv&Jez{5yCo<#J%oZJ^wkNrWdI~>%jqx9)~P%rWA1&#yiU8En#e<`Sb zIFFi_c^wu14syLaJ-!muAp8f@)gbE&5E~y}3u+!dxX#!cLG3{CoAmKkP`&T-+Jm63 zBK;wG;|4lEqThJ)aZuf`7r#6q##7=W^BFnA@tpdw8{fVl$CtbhQQ=ik1F;SxWa#Z| z2G{Hwx|ZG0jvNNxaT=Ln~0Av7s(FfK^QlnZy4_X4FuN zBt!SmIK@zU%+LvVQw{#EG*mRrP%`e|n`VY=%?&=IVD1*gZONEchH9o8DwtttApXIg zOyZ$bYkGi`HsplgHWl%YphJep(k6@9{WR3BsL6P(1*vFw9Y zhV4A$yL;YFMlv}1RYizI*MLv zI6gnpw{`rC{7nDX8!GvWp^+P??KkGcC%+r4%Sp~Sf~!c`NFH0sf19Dc+YODtz#WFF z?c!$)OLlX-_An35?lqKqpP{dibHAZM2gx759Oh>ji;ft2<0!}aIJurQROghzcTk2- zpQiU`484Dr_aI*4r*r%ao#*|1kzQQl{e`T{h7SErZC4CAt{R$lji0gWhF)RpP2NlY zkSFTh;r;%Q-aax^7cb#?%=`TbeS5~wB0hf3&t8EL>$`_kx?qTVB8T*0p^!!w56M*` zq_41`Oi0Dv4XIAWkRGGmdm&|iKcvjcA?>ajQoU*+?ZUC@AvLNI(w{g{Go+TLkiNu0 zY%_fp(ob5 zLb{7rXyFcNFG8M>euu@&+(_`VFMh%^xC0@L!~tXv5+5C~7}rqFAQmR$4-^Yg55{6E zUclBkr0!UWODNeSq{bMI9e9TNVdlk8cnMo1#64+3T7!R3HA+8`g_HPSQbBmeE)Jt$^N@lVhV{6Igcc#rXAEgMuH(Iy^b6y$4G&>%72JLVCgT9!%A`;2LNY!HsqAQ;7Y(a@%di%qS*tMd!}=GYjIb0B>stG; zDt#2zU$~BL9m3l8ahUJ3!>kh+R>z)U&F>%9IZPT5)&f)+7}ghq!Wug`tm9vV*#t!715Y|uFiSWd*mQ4z4@MOm0PrSg<>0y~?gw=CaSU;fc?67*_ zDVk+5Zf;l^>%*Fb$S+~VaT%@+VO9Putp9d}Rbw}K;ud=E3G2|_utw|)YYI-_@qw`F z9;8k@!Qel_I{jx@6AsafqhZ-F{a9GB<6*VN+!M_6S6IKH^hxr;x>I3oK20rW!fJD# zeDL@JeYi+IsC$XJ?@$+p-(_x;z8BVK_rvP?AglrC^N{V2!`#avtnDv(J!eGC@kXwQ z%3wZT=8mXZ-iT7FM3l2?g!|)0v>NSdMARG4&^#fcQ@D-KO%dg-ACVtVkgq{R z73v<1X!0@gJRVWOixD-(OBA{k(G=Xd9MO`$BdpUD(Mq(r9#MCcy%EvXyAgeTKce9e zBZ@p`+Y@^5lyT1@n*BV&eRm?-|0=@yb5YI79@WwuQH{wNRkvJG#qvhgpkP#$3q`f^ z&8XHFj_S+*MV0k#RPkz2-KiecP7Wy zePT9)7ldmMf}8o~Ukkqk8F&>YG4R$AeMLH=;U+Nuj6~pi1MYzGxCv-f&c9 zF&HHVMwN!VgQ6;lEIb<=)u16!O~wPvpG6!@noS&3nM0f`#>^!SdSlP8Jl{Zm*o)-f zsPlJf+{l=nQJu%+UDSoDyQ3PhCo1pWsEVA6DvIpqqbiCScyNI^FVcsrQRTW8-s^vGLYIc*lZ$D)pSl zY)M*PwZj&@Scao~*OHz*fNh(|@NoC$lQd4Y(yKs{76-m-< zG$_t$$|aIC7fY0^8rhQ702$bsBU$&bFK4of=StR~yvZ6_ELm6KE|IL1lF6Egt0-40 zSo$s&N#?!_$@-&wvd-e8caznwVzTz*zyBy)e&odO;%t-vbz4xK9Eqv;@tCS%_34;CKNHi`^D(W(@(av!F{W`3Vw(LV zCg0PTx;~4k=<}E&n2B+@QZ@gLR9(am1ya?iZK@99DUK~o)%ayR;?D9^bzG6E4Jf%P zRk78ntYeg_dOxLV9rkWbm2+FFGH`Z#s_O1Y)e>awOx46)srujUR6V+#s-!!q`XpbP zO1zb(`dEjq#nQ9{#Y&_pj@8ItGEJYM^E+wkQXx&@ifI~HDNRF@)6~01nu24}^y9)b zt=gHUtr)tS82i#>y_BXbHC3x@P1P4q>o!#$qp9p2o2ul7rra+!U5nbMYkTK(4f`Zr z_j;$RUEg#az^DDwH4@(rNY{wL>6$tuo$D0SWf{vOW=%*}g^B5^Hzi$jrl!j~Bc1Ci z(zRk%y8fP>uIuZF^HaJGu20u5zoaYwZ|QPj?8bC$+?1|9JJVI>NV?8nOxHJe(>3>A zI@f`vYkiIk`Eq8cUY-n{!-zr|YW!w~{wtiJB1JOz`Q)|tGj!aSp|AZJniS5^(LNcf zH8?|shh!*(!80>-dQOH)XJu$V&S3J~3{{(#p-Z@j7xOb@T||7G!=S|(D!7d2xV9!k zj%RG8DlA&=NG?l%e}5e=tJ_aN|q{-%V!7 z`+yjz^N<>G9b=zl=mMTT%~0!S8S0iJuJ6z~XI!7)tz2=P&K+0jJaO&E8BER_mo;Bp z8DF}QQS2Mi7GOpZf10 zuU&C<#$xpNhyBWAs{Xr~I%LmOHAg0Ydt@rTZKghIm#IZa8=0wZu>sGKZ&aq77>yao zJvvh_(DU1nqhfiecJo^8Yse`zIY$r2ih7&XJ7`abns?O<5wLFul6Rv{Oechhk z&nB^U&ybZo{Qv)(WbfUjO&bbD(zL0jX^XqN!`N^g?k>X_?mpbz83TqpY`6^@GThyL z@PF>``JeBPa~|hz?)xp*b-mxAO?s!<>UUX|x&5clfs%@0@a^M$IVex|eA#m3EK|C8 z?p$R`<}O(>UykCXa+E2ZD{uZBC9;*wox4n~e5H!#&z?V9w&FQ*55hB`G`h;wqL^mKIl$_M=x-`qYpfQ1QSktcz}^x8x{D4a1Jnn-O9d#XOn@TMr+k3w zRSZyH%=j)q?^*`P+$uoZa1fr>0ZKs)G(lXO0R4%xIMFshY3%}31ckZ=s8_E54MW*J z0eaFmK>hm#Xbc7oV6345`eg+1A#7xT0w)E?H90`fuzCh#T@6srn*qA_I6!aE{z-t= zqR!I*O?eie&CdgL0L5MesPd-(eKHx;G|-^a;RbDV8MGG<(;0Li!k{dX2Cc`=j0V-s zWY8a(4f4AU>VdN!gIY!#w7Y~sf1z|qgASH9=s`JyER_vvRK=in$Wh&(qSymR4TD-^ z0lL*>40Nk!&@W95>e|epH=PXfbv9@erlDLHg9hMzSHA9MP^Rt%CE{}rgBtgwZ!d#p zVJD(`6B{i33~Gqq@v=Yj4lpS9&jxiKXwX({8)T4eutC|dWe7RJFwCH0*ogrncs$ae zKBEkJHkP^2a2&BtFh~;(8i-|+$QcJF8x-;japUb2VxMYI9&E>Xbe?HY>@0%{%rR*7 zT!V7XGiWF#!MVVoE;H!ba)ZXMApX?`<-?RU1|5TKE%il*UzrnG)){mXSI}^y zL8iS19YL;rw1??W+8i_J=_%sAWRUf;LD|s|Log4kG3g(Jre8Ct*>%<(1#b|~O@kut z7<3eS?ip17A@e*jXyH?X7QZ5&*9P4}{2S`?&Y)0~z-pL2uzvU%%W)6Zj|QbjsZX@| zY>?|;gZkoc?EAtV3NUJk!KfofqtXW%^@G`{Js4^+Y7%Z*jdI$Ja-(IiQ8h!1>VOER zQC|FlcPJlbR6C5vdYr@d2&2x!o8G9aD3ZabDVQ5+RMm_|Jw^UZMs>pnxHB8o5Oc5{ zgR>Yl(rr}#D5I{Ufyby*u*Mj5(reVjSk9wIoKY_mjLMd1)M%ekT~hcut5LVJ8FekY zQE!nkhf%Y0(+*ej81*{8QKXO^~xJ{2ftJ>%3jf^-w;*FsNqPfY?SXiqbj2=+Eyc0 zl>44`IP`;2oog5sR@12YIE3@4S<9#ywT)Ve+gMb`sP}b^+SbIVhj@p{O_{qHIkq&a zNh_nqwKi%WUg2I_qs;A$8i0@vM#ZBX&Y^WDqYid9Doc0P5SMxw_2eg`M)hPpda?F> zjOx?RsP6_C_0K@&8^m52!graWM)gF;;YPI@Y1DmqM;UcsyivI(uvh-`3ppUe6z0Ig zseC=nsP?mrdNA9lOmmECh7)rcV}VhLi;c>$!l*Vlw$iBTYZ!l>QHR$XHDUv6wvik+ z8MS(gQ7PNVVLN%^B1Z0FZ|x?IgRIXf=DS4SD@K*LM;z#jjQ80e825mE_K>+AQyaWP zt0zX~dumj_XY7BhM)NmDO?Ye6ig!jC-y1d0V$wLPNu_KiEx}T|NmYYQS_!Meq&m10 zV$x4elSW}3@`ss}G2EmSWXQx3Tk%I0lQw%y%HcI>FK(c2tVxH^D30s@_26&Rp4!lSbDwsd^)m4m37tZ4;CB z!`9TK#|UUft*`*;o0~Kp6IzIb(VeJmXOrr8F{xo6 z>eAPwg8iv6O8;z9hk+(t7;Mt=Atqfy#$m)W+@y;*HG+DM{3iV{M;jo%Cj4Ag(F{7-g!piUxJaG-)h0_8%9 z41pRD8K^xO12sHLphDe&T8R!(f!c(l$m9vsV{DHO)Rve)6^{>86--MARK~qH>s61^r*OvD9u3ez!bqLhk zPJv489H`bf*d{o~VbWa{@JJUZ9ra8r<`V8MPM%%C{&`YkmvV$lW|X5~wq$1J&kCpaL#XXITCY z)Tm2=a$F8n9~?yID}j1}y8lpne7zc|xz|{O>w#KvCs2)^1uE~qff}PAjWP%6S67gB zARt|k60rrYh#+lGkH{dk&m5$_Q9&AsjqrN-8V4{sCP>qIL3)O;ly3@itco=VNDb0aJVN=jAic%FtU>w>tFr~^I{wTVq{g{} z^bvpN3DUcK%#%MzbqfS3zF?5f6be$kB0(C1eW+UWnQxI;C;WlSHG}jSL+Vk_CP8}M;+ruonID4(2I(*C z9!`x$(jVnVQ6D%*6F)AD4^p2AL3%PZNbhHn^XwpvofD+&3$cVbmIW#A@*t(H2vYRQ zAQ@K$Y0|Gj>ac-)HwLNm|9t#CNF}!fDR2k<_7dM|+MMJ1l_0G}gR8991J>?+kQM}+ zHQ!-Yzf5LL!45pcv@B*Vb(^)=W7ZkWiZ-iG3~gi0`V(hyC(f)_coI*)1g<5TwH7Cm z%({ZlKC^7eX0`B})eRF;%$kcWsb-Zp<~ z&H6RBS#R=~6`PlM@vfLz-xW72q=Z?^a2@GNn)L(Dpg<|Jc9$j}j45l@3|ucqyckg4 ztlQ{Pfv>T+qFI5J%-V$gxQ`Z<&01N-thXrfomnqXshU|UQ1W|n!79AN<{!)|SDho4 z*EDNMEweoJ&1#3+DA2&HvY3L$sM3&maI2A7Ie#=Oe`B+1G%>3QuA)>^>VeO2HZv=G zbF+#dq@`KEAbVT0Ozq5ig!ky(!OV+evqm7ilUakhP;dCVn)MVnyAfLtv*Ld;D`Ow# z!M=XfV}MzyKbuu;pji#Eeh~c!^EKAMHN>nv!^|=cH!J-Jv$Bpdt1WusJ&um19%ERK z31)Se$ex)@{ipC4%kUhoX=X*^IL^&9tNJYBnr-I)KK9BSvo_8%D|EhDa~7MGxRg4= zvD~bRtIT|FqyC$y<7TtQV>xbO>=v^OTg{5ZDa_q%R^z>9^}vt&%-VZ^n*V85AMC(S z2U)vAtS9yyVgKR=emQE^@Z;=*6U=$itYW9x1AkG2GpzAhvv!`R?tjw;Sue6C_#Im> zQ^zapovZ9gL|$VJ(EvTM9=~2U>i|05U|sO;7CGIfwy@u!52j!b-lF}tn6qRVvCj5}qqMjIv8QClvklmt8IV>833pp)% zgL=6vnwQridp?UI(HMvGTa>GSMQza&#zGc7N2THxskB87G{YG*EyJ8Rh_l#Q)}oQ+ z$frCpRI>1#wCH7JVyj|N@9!+?_Ps^lSGVYLEsKWNwrCHI;~nbOw`eWCVpao-(lxXw z26K?5u|-dsSk$+vMOm9!)DV~OzPUx^+gbFYt3?6bhz0$SwL3NZ$)cLLh2cFda`v*Q zdT)!aAX8uJiiiE^)8C?X11!q(vqh~2TJ#j3v2u__#Rpq-1Q+lc-G>m

      Zr-Azq@z zFpDPPD1I8wTzHQuBP?n?(xM&+8AVMo7A;3xG!qB0cbr9w#xp;Tqu~VVj=%6~A~l=D zct|(dqMbN`dszPqZKqh&0oO2ODlt#DXy6Qs#$gpwW?J+&?xW5u9?vE&)She6Y-F0x z7}&MIBEv#*Uu4m0SeIB-8BZ{DsYN-LSyT)Sa1XDscezC;@CfZzFy~5(B34sN2vW#)(aQV;~4W}E9xI-9qwK$Jezu^Sx=Cvv)A2DMjP875%T_LMtPy|O% zxtLXLP^z?5V=x1o(7cRQT~Mc-Re|NLiol!-%#RCItg2Ggs`}{iomG3$zM572@C={P z?R%?E|6o<`>Q?2c$@rLsYv@pmI@h*pQXS^3%beJR`t_``)VC@UM;kM46RW1Suxb(Z zpju0-8p7PlszDgnh8)|HV>@z0kM>rb$1P;(VATQS>u6PJJVgFZR^7*d&Q{sG&=*&_ zT2-i*RZkGzkG1G;)o2tLU{%P^%!}iAh`s}vd!$uMk$bdNyD?{sRcA1HtW`V5TQy}m z>xb>|m{SlFKgk73O2z zZpOx^y~MlEs_y%V?SNIwQQ;3_hwmWuM&?7*2M2ot&dXgW9-{Y?8ASoyqRy6 z8}DGc#(ubA)rOnoiqJdcbCh_rD!xO9ga6O}5nDNr8Q?GbF zykVceW1k}Qy;Tj+2F4Fojrc@tpV`M>XcJ&lQ-e*NvDawRNi+$x=~$3W1I;##!vPd` z*pwV_Gk+IPOzbDzW5BYsI%}TauIbu?X5nobms+(q0OE|LGvg5>=2XPi*6>S;;RbqY&t!z{OD%1*Ds@n7yW`1YW zX)LN?({FfP)28ONY+8yZC|<{=@pEankQ$=KBGzcJO<9-Ply{j;KQ1Sa6*l!=X;Y}1XOS9NziLxuJ$F6huDb}v2c)LC%*mXGBE=P)8nUJr9 zU7c|e1xwmh4g<>D)w;4>o+@@#!cSO)6L8kC%Z+XI=vUvay?EKouCHj^+^*j6wz8`( z)}wVB`k`DqyK10dd%GqgX9v5Mb+YRVs&=;PQ&+qG?q*k^?sj#>&j{#YSMz>$b%&?F zU2g~4WgKKzufcW=N8k{I4z;T=Uf?T63}fDrc3p;llwB>c0*{exG;`o6T8y!4 z3p$RoYuW_*z%tRUoj8iH$##8@H>f7m^v9p`7<;~5=}~+EIbz&@$Axxn$6*v+Ol@%pHJ92o1&gqHnO(O~bOmvs;!5Vg z1Y}xeR}vbmW^LAxFXpbb>pGqy-8#m?Ds08m->BF6Z-#Q5i~}3&GHoPZY{CKfHc>Zp zN6*ddku7%JMX{}{Ge+RZHgeidPAIj5b-@%g+iBNAtizyP)C+BP(|3VIQ?Q zU{?{0`GeRGQ^zCZeU$x**2fs@II*Aj<|@ZYC+%u@%B~HkSz}cBi`>uH6?2xogi_~N zfBbyjuG9y=%vQSvo?@ckRR z=DoG+8A`q5F}5Mwd-fCbf%QZioIvzPoqm32+G9~zu+n7+R@WH5#tl6Ee_ZkMI5t@Eals0S z4_19lM&Se=CkATaqiVD4hRkBa8HX@*3u-Xj@*5={C3Y`+HPxFHn zxsW<73RZax!VSz@6RcZ1vK3dtS*}wXA3n$5B!6g zTZ6T42Q}aMP4ivBD!7~4?4j;^X|pd_6ZSLifnWvw5v)tta41+=4+rZwzB@u(N2w`_ z91B+T@nH2r-xIV$)JbY`Dp;?v=yb5M{S~YO*m{PT&IW7yIo9QTu-0Pnm0$OKOE#c#bb<_bOQ1a0n${2WukcA>*51H9;qwhyN{OVF}*C^p4u% z51c{e_w>UWq<`H_AyxYPmGD_xQ93B_L;bF4rTx48kVBc7wUmK28WzRhgxGh zzL*@!7wFIk+(PvrhnC000Z5O5#>;j$Dz{LinrJm?NF5%hZ>`U*P*+p z66??@+(A;DLv=9(lj0rPf?Ft>;81iT@nb%^Bso;v=gr@5 zbEr1*6lXkiF5%E`_<*!h4!yzl(hmJp#-T^ZP?o%4EXTa~7q;>aF3=sykGyhC`Jx7KhNOCN-|*&`Pwf?a;hB4i&2F&{{;- zbEsT>hmIk-fkVTv4!0XR6yDgO-RRMT>sZ&6HEQNi)8@q2lH9Nh=~^=vUbJ&4p}j+= zQK*AM<*^tSJCc7V)~_=;cOn0-tluaHKg&2Y9v=`inmDl^8pB#*3N9eySgzp^62}oE zZlKV3;zFhg4t++ci4M)gGGv@Y{cvb1b(!W+J(#9Dv;l@04i%iqUPt!1jE!pZ9GZ&j z$UC30Fb4A$kkdkkeq7{G!^On2ggvp;A=h%|T;Wi=l@9%ly{jDZu5lb%jRqrVf=W@3hUD|JWbZPax;G3=n$JBfXlLoN2O z{`+}u93p-!I^s~xb0`KC5OAJ&umdMA(C%-ZKUbLZAL2%ts}A0~btoP) zaT-^#`a1Q+Q{=kAp1~nMJ&_LzFNlL@{$i^y@t0To9se>q8WmlJs<)^!JXFs| zgeqlZsPbdR=urJSE>x?=bAD2&PD~EfqN$;3IW1IwP7l?JnW5T*LbF2kcuuIY%ng+f zE$|1z<}=sgP*s9?NvN_e4^`!;kV79TDyho+e3AG zSE$PF3Dv>bf{BholdRCJD9?p+)v}w5;O>RY7*{ecIpjAL_4(zMPrXcvoXVB#R6RQpMLY1AW_MKBDe{iaMb*J9faO&5ZPQ}zB*4j>$spsT1x>Nld(XX*nkDD-eGpD@G zoqF5CsiiHQdW2$aoZ5r0$lsRSunyOd)Xu3PxQ5s5oeJpSR7z*3dUkWFM0cm6dpK43 zC#PQF*Pc%O+smn({hb;#(5bV7ow|XQL!C+<&T$kujCQK^7^e(low_s5sT$**YBGUw zCXv@m{^?YQL(F@aH9P85j^j>MJ>gV+%s9pTr=5C&+E<(! ze%+~dH=HuxbgBn>-QwIm>U`g+oe${y(8)bqPF;LNou0C9o;mgB3#VqjVLj3NJ?-%r z9X~kL7xs@%Ueh^s8)g1=>I9~Kb?O89MucfA{)8ocm=0zL)1k;Pox|}=VQL%|rqKGHI1aFug;!bRscEpA0@Axn+P6*SlNnu*%57VBMFwM*nra5`Tv@>6r3go9a}^KM&=O&aE*Yi~2q_(=wXl~7(~sDXGUdWFt9+PZDiaGzRt?ie ze8%eU!xaBRm}X!vp4AG|$hu+5@ne{(^$*ji(P8?2YM7SZqi=M$cEp6MhA&*xvW06g z24xRduAJe@n=4$Us)nl?)>jMH$Lis#Q-dQq)(Tg*I^k+iH(Z(Ph0EDET-Ta}Yj4wV z-ESVQ6)nP*)QYyP!6&oOSsSiDe+}0&xHp9B@y2ldvMF3Iv0`($s&5I`283=6*ALi;;@iS?3!a_fnuKP% z!e!hOuGuKFH(aA}c|S29AU~W#)<4751(Oak_W#s86s{xabSzx2j(=19M7Z{!4cCG5 z#C#!K{V#><5P~m;dK9jPPs24GM=|ahkDrI@ z%2)EncXBBrz@@R6iNgk$IvZX3%jA+j(4`y59OP0@vrC`gw77Hu2CGY<*nlZEmtxYn zGz;z0yR;6?GrCkOlS`YCF0)I+aT1AHTzZ1lZkLLATuP00X*NtTE;Yk6?>DPrT^bmN zcw$R*=_R%#xfJPhsS~ayyHwEcQodA|`r%K6r@2%go3k=kHkYzzcj*PH<#1^(t|2Ao z{~5^F=TI=WON((cpG#@^T^fL-0?dtb@D+3^e<7ECMnn;p9-?$n;wt7+U`dzWmLk{E zE?%p+>=0vT*tBlE;ap=eTtEXUCMF9r6!+TnvYBw(y0u3B4=bee&$W5S{c)6X0~*S zs+~^Lny1q_eBGB$51*ye^tb8sJD$TA5TW1g5!xIQp~=n&JwvP52rb3Sq7gb)JVO35 z5z1OALNmUPQ0>|gYL6}>BJ|zZ2<4m{A;aPbUaLg#o@s=7?uyXx0})z}cj$gDLSa`T z^yoo^GCqt@<3|x%jIB6`Y|kRpv3Pn-?3-TIhNM@iQRy{fLV6v5bz*w%`Ae@uOVTU( zdU~Bh%~$EQ@>6=<$Ic8Hxc@GLW@pTxjCC`pbpwu#GN=KrHqM~RO*1H}O$N1UmqB+r zWYF;L8T4b%3~E0hgTC95L2C|XknuzY1%An(X@*Gk@<#GrLZrTrjnqQy&L64Sg(CH5 z@knJZ6RGw%+dfh)Iz;Nbj$B98PLX=wIZ`{jM5;p9NEKZg$@|NZd~b_X-3%FZEGZ+; z&y0GIhp+QyRI_{;)vG{8l_{Q4jZ0?K+tL{|v}{JrsFP8i-WiqUMMhN}mPz+cXVUq< zGAXQk7MWIMQGvBtwER#OZO2J`Ih;kme$Ju=U$W=}dfD819PCz}%x)RnZtgR2>wEl~ z->n=4+$xLRIEGaP-KtW^ty8F7*sXo&Qq-+?s9uaQO1Sx4i(9{yaw}(Pw~Apbt|O?7 zTPMo8wZ6PtaTVNJi{2I8x{4f?85i|Y`FpqOqF@cT%Hsu|H+8E-YqxrJa4TO|x8~y# zBD%Sih`H$0-K}ap-5QLE_>304h#Aqn-CBq0ecU>N5q;gNGl1*(8Anifuv@u?xRpB8 ztpa$32E)h=ZAZA(6Wh>oq+8vv5f?|fbq~`v#7&vfes7R+L;P-iyr zA#x7qkg~|FDU01&gq%yYwc4^A8?Hq}f}s)XqcJu2{{ zNAZn4GBoih2ihX2sYh$!YUWV|c$?F%g-2I$wxvgPT6we?YVA=Gyg)!3kCq@yTaUV9 z65eA$JCA;at-VL3Fa_7~6jeJAA5J2uqer8#pp!?}FsU=OK$$Kc?Lwoj9<|3ooWtC1 z9z8(q9@OF|k1k?)PmdhEJj#q4y**0q<54s0?MwT99<9R80UmYvnfB;9n0gHHsOV5? zjEoaJ8uklynCj66+(m|I9^P+Y+!@4+u$dmM#&y)1#ay#J>Nv-v(77Jn!KQhvD^eGD z6tj>vxCrYakA6mlCEq;fxOS;WA8~q_M+D+J_^D7zbg8Sqrql8$j+A)%8W|N`YwE zi$!Y({w@`*J4h%WtrZobwF#+JqWO$4?eV%+v;t~Js~ZZ}jaCJeY#6PY?U|!fwEn{D zF3}3_#yBY1Bbs}l8SkfPxq8#SPqfPQjh3+=Z3jlH_TXrJ8Xm2|ix_`Zv@RlfHSw*9 z)=4Z|8!gkX(Xy?J)+{W?gx{id6NlDEtKx=eO~z%UZH!ipP0=c{C0adqM62xq<~6Qg>GF&gEMQEILjtt}Lz?)73+wquMQ^o)^Zb&TpCh|%SfF`9TfMoDL4|Xtb#9*)5VLu+=uEWb)+Kd(Im7HEaQ|i@?FvdaE zaIe-!c=aT`SG!}pyieiPIgH5e)pQifL2P)O)2lYQy!r`^b9*&1k5`v)4;%A)wHGam zGG8&T-eOsCuS_Mp3dbniM!k|=or1HJm(L=2)f`9gFKU+dY66~=@#;)judX9QIj<(8 zPc^UR{oqx>+Fo_XUv<2?SeLv|uD(|*5Ziz{HuP#uBd_lN=+)51Ugc>*?V5Vk6WN<_ z9&?*}^|ggpM_YQ;qLo*M)?VdpN4?t&-wO)n&${POW)uPScT-@tb>!V(NU+z`?W7G(LA;)nq_m)ui6Xb_J zSdQQE2^CIyRU3by^C_=(oc8iF9(DT5t2#Ic=NZ=dEPDwd=hmGd`cs1z}^?uCyJY!Eir_D>R_MppauNu6i z*7#Ae`Z*w0c0;U&qn0sNGfc6{VUFeF0I~XP<9u+ezH`Lt1qQofRXZ(Kf1^|JSe=8l zY%IS^jn#bYhRSgb{V=?IET6TE)sqUbs$4Zz9e#*af2^$@s~zZ2GgjtWu{wZEb!gWh zmd~NY>RQuS?!SnYqg^a}CRX`7#A;_(;^+~p23YY^tTv%j&shDAw!LC?3cY*BY6;fk z4&wX7DktV3t#7Pc{bDr@S5T!tvETxJ`#DzChQ+GMB;uM8%e`2!+JX-#HY-+tz%n~l z$!LbXb7B=XFIG`VKc6_4#j5OzSe?hAb+I!17OO_YYf{Ad3#pzslobI5yD^5+|NgtMb zfw6I#iL7yqkNfx~p0N>;5T{s7#smDG7^l2R#DL1aIN6hFiv?(w7N-_j<5VkKocd*t zQ|BDyk}HmTrWiACoSGJh)A>SiDp)v9(~D3y%r8nDxL7QX?<;Y7R6I_$5}d;W94Q&6 zze~p{W0^RaD#oc1jv;@gI4#9T)T~U-=-M<+`+CHw`%kP*FUIT>r)qN=QAkrTCqG{&(Lor?XX~Vyb^zn*WlmdwG){($1B5@c*UU{j&CEs?eUtt zBVLbp#w+(OVn>lZ@!Enyd*d|)gAT-N54!%rSV;VnJn#bD4-q>qABpE@@_3EKIm8`{ z*F;1ekJk{SKO3*o7>JE{h)n0=xu+psy|EEt7vgmdj}iBGyl!8N*ZfQIs&|?BuEgsC za$Sv=^;*3Cx*xCL2dvpcYW65z$!LtCkK@%1kx$6sX}sQI#WU6pE1z@jf9AYmecr|E z27$~tWc%TpG93H-&yX4k%2O+WzfX}MZ=D1!ub-gb8z<gE0}tO$n-s&G-!KX1+$|E!6C2f|i^} z(0U}FOwd}KJ(a-E;0cVJeoDNYo7!DU~RD=|n~1C!EKl@`>_QNYoWPMwg0=St(JAD<^6_ zTvZZv3ZtqLbG1ZG!(v>jo~WvI6ZySqqVCp9)TH`}nupie+#pfC8YOCH3+8K?sEP<` z^^LK0BJbfOYEk<{mF$oxXU9a%LH}NfN*TaBX!diWG7L&oC(Ihmm}3%k?bk$=-;k(n zsIf6oUydYluW6#5;VTv$OVkgi615fe&Qc>(I+v*W(D_95K$c77io`3-aVJrGaXftz zp9xD+{u@bJfzQZsGfACs0T1E3m83iviv2i^3b&K^IVDN$?6}cN!oosNedn& z=^9cWC#fq|q1}@t&BklQJx!APS(08L>UolWewn0zS4k?3<4FHHNsX`!NALk1-xBA$ zB<{sd(o5ugpTzI#lXMnUJ|<}r;y>~DOOgu8r@s&w;N!DHKApe@gHN~MG5S;!BXAs% zCZFnJ0j?n|(5K?)gvGcBOOQ|b(FIFz9uBilMbI8|aRMfbPX*BtOK=WBR-X!^4_4s{ zoHn0|p%d1kvE8T6c!%l^pGt-J^gaFx_31Mr!hM>B?_8Y2vUEO;jPU6J-Xbc!Pj51C zJ<_Luj6QiY`IHTl&?&P|KV{*1v`<-Md>Z5RX<96~;d7i%>*9Ub_bIW2Pr1;x zv`;Hgzl=}q@Df$aQJ3e8{ndF>na++o;)2pN3rU>EU&s%HLyL6u9qG z1%y8E$&H#1efo%%k66Da?2)JJ<7f0i+;i6Eg-^L(GA>TS@XDuq?|h1R@8k6W`|6`l z)zBRqzxwnP6$6r$(~zuU7>cDq$-0ihmSowj$%@2<&}1!kCTm-Gvfg8rD_Pr7JYBNp zMkI4DL9%)yAVabqBRVo!H8BFcG9~l3C+L$oS#`274vKq{`Tsmwe@7>)UQDt&!QxF; z1gc;$&Y)O)vMMAb^WIIef^#OTb*^M3OXC~`c#LY_9bo{2Z>>(rKHK2wmasXLQ(7Q=TXYZ~0Usns6x z*qf|<$C9Pv$=ZPZ=y@Vp!;tP2G2sOMJWUPG5ZmQs-MPlO>&Y5-BUuk_C9C2ca=pj8 zVc`8_m3>G&_!T!FB`eS4WUYIetf*(n@+0O`vcf*|7@5B&t0TMte*FlS!LL|&jDDp$ z{py0D_#1Iye&xV#7#!}`CHP%_b;1^0K*e-^O+c9lzZT&TUP0;o%7=a!jW4K}!LP5V z80l9XjLPWOKd2DzS1s(rr3AkoqE4b;E%8^9Up12b3itc<5^YkL2kUSgjZ^(vgY77h z=9ej}UrliZIkWk>Z^^IsaAfzZ0Lo%KuHz|&X+X_kZ%96k{94x7uYe~1$JW-b z$EefJuaceo8i-t-85c*8*wwFe-Kft%zvkfMAir)5p$@1t)~|Zw{mL@Que!ew>r}rA zPU9NBVB2)RcF*NJ*3I*456aAEEf)CIYoTAqwsUXrEv05BaqU z4G;U(0hx}lMkhF)WF7GjCZ6)E#d+2YwJxy!c!CNS{c3l~uiiL}g;)GCT=mO)gIeLt zZNJvvWzPHTxd(oYd+67KXMW9i#eA>X)Bm!LuzqE2aTG(9qHzH!`eaDqJ&_bW#%ByN zrRZ8<3V(wmMXQj@oT8^FXi1UNnxZNQu%+;M{}fHbYkP_g2dAiSc#1Z`l`ci6@DEyN zNKuE#6fH+!rW9?%LA=H-{cfMLSlZ}75L@?$N%5Jf+>0h zYZ=DIkg_TAmrK#?iYY2qDMh=!Pfhe@s!1wketiTe}qH zZBJeuQ#7el3iq6(XjzXGnSV;r7}V*RqCa|(fA18nMCLvzI`?ymo}k#E6#X!m7*KLZ zir%Bm&=meQXNoF}OwohUDH=U4g?kcG^!J1mHJh5EEb~&-b3qEnZwrgY~_cqN%r1^!@D=K10QI#N10!J#4v89Ui1;HC}uqrcbm(md`1wi4FgzXvCKk zO@YOnsuK9alB&PZ&z7p8j#N!TU}UPsA|zv~>f>>yR87mAs(VqXit(hXe{`w}#H6Y$ z+9HoPRaY@9K2;YnCLvX`Q8zJF&GM#d3;saae5v{gQH2;6p@mcB!4epXrt-ZmRZl9W zDzQ?khEyiLDygc9ag9@T3NS_51ERPDwwm>O3k{?$N1A#=u#r+K$LMsXB+7$UHYyzbr^qhJ~pbw3PE0w>(wuC1wRj5pg-HGMmA?nqTP{Dw?BQ&nkKsz#yk?o?IA z8D!g=sw;Siviqp#!BmYtnySO-dyHBl{CKK5o*>SXsq$eEJZDnX2{|q>?&VYs!>uc< z-BsFS%`MgorS7Dv=v~@i`O{Qw`Zrb2QTZ#mfWO+Muz)nRL#ioF9mCSJ20wLLZJMg1OjpLknx1JI)QkR8(livQGt<--QM1yNhQCm5cAADE z|C}_HN3OZVxFAjbg=s2`>Ih%_{}pu~P)^iQ-^YLSA|Rl25d@^ODfEquvnNg~_OkuH zIF&g-ZGXh+!?VOaAE&o2#A!V;F2bii8-+}o zT-2mH_^7x^mrIybx1>p4+(ym!xGinc@G>T4ufXyTO=@1z#QO-7`d2mSI4+|=oJqOO zCKbVERI{3tQPZT%S|%meHtBG@Nkd#FjYT~-+n|!iq)yFE`lO|axsOfE0cO$&SYsxs zze!E-F$xSYDKe0_gG~B*s7dL=OzMovUzoII68TRyX(8H8F=^NglTv1y)CR@AF{#CD zllm<(X&k0~Z&IICCVdI>YLiy{U{cjJCUsnA($1|WP1s@590YfgAByfW=_Y>IZ_@Z< zCY3vH(yoi#zsvmxCe23Rp-D4v2&*2OG&74?IkKANz{+f9HOOJsZXCmqoMv6gW!61p z&u!MHXp+aQCHc%Mp5Lqw@dpaNZPu`YX7w#%*36KYSEk=dnX5Fo5){#nP{Z@tT zs+u*rmRT=RvA$VPklSWfS-V+rnC3LAeY{zH@J$1=mcHRK>jm<-&02@Mc;9DM4-7_C zzgeFL%*-ogR%VFUQL_#un$;}XEL*BstFRHDG%?H7%&aI{V<*-&H|u&!v&N>IH9mte zTA5W8TTr;QSqA2{A-_&$O~yPl>P%m{P)j#6@1e|^GtkU;+l-0Man&j~3GJMP{AEfW>B&|JJOB$g$MSIW+WOrCIsbn&sKW zc6f+(d#DLFkJ5`1X1&69C(VleW!Bzv^!K7!?>;iC13pK&$7X%>#H^!F&AR=RNQeX;J?M#P?Zr3fC~n zZ_%TGMcIQE6-9rvH!S)(Y|(YJh+32*(ZalpEXO-Z7B$75WQ$IxGIkScK(?l=)6Amr z%`H0E!lDf^i$45>aq+OdMc;I==nh_DX-8srB6b&x;<_^yUiPqPRxbQ;;S+ruZMHi-6RAw6W%wYL97QL8l(cw83eV1v`kh#=4kH?o;)Ooo@ z(^gpY;CqX-%A$^|EjsoC>#ia8T8pAT^4NNdMr^d`-0v3V%%ksHElSvCQTOfapB?P8 zT^5zv%Rbyk%meJ-Ll#v&Y*F|qy*fq>C#dNp^`5e*BL0N;v_*Z+SoHL)MRzY)^vgAi z3SPIU4Ki^6r{KB4eXKyjO^bTqAe^@>I*x}}_K!v8f647Xi~h#gELOgEuqpwYkR!X5 zxeu%wQOK(4NGxnsYaB-LcdhygwaZxLhss)25JR!+11s;NteRNWss%`^W>qJgMfn<5 zO~SyMR*gfjmQ~HL2XEK0Y7oZ8Ta}4s4XkR9zfi`-`lu4Ls;gnu09?UCtO}7YCN#3@ z2|Qt|_Tw5hN37}`wd(5xtFB^pl2wJ1t%_kCvZs&>F2b8?Ra_IRwj)OQd-)K{w&D4!m$hyU* zD_d=HX7thdxvo=*YZ)46En+D#bcj$7<#_@F5w4{R#- z(55jc^T?)VPi&mKN8g^>H0=fZCyQMJVa;miG7xrov)R=nyIn8x*;OaMU6Tvg_1oKa z?S-|VUB4H$D_GpFVK`sH&b+yH?Lm)HcFo6hi(P*ruBKi0p;~smtZ!GM&90^m7z6(` zv}=vau1)v{gZ*|L!SyKPC$KKA<4~eqd6MjEmu#0Kg;*`^vSE6fUFqp|b-+aYn_*X_ zR(1_j->o*SfZLCAG7wS$n%C;r6F?t>|Fa23)`wov0BdyV!LHFY!TF zV&fjN^kO;Y^|k91>h`y*$N;;_!N7)r)I7+pKEqgdq+Jbg4_QaqH4=Z1rj9XowOwx4 zT)bF8&EMNK1vysQW&hEx-Z;G8t_45awF*a&xtVpgvVXSOIq$}kauI@sHx;h#Cw{Bwt1pg~`9 z>+j$*J!1_fCa&YkQ0|X#=v!nT>Cjdj!Xx}NiuFc2_`Ter52rhnfsHd98avaWZ}2;| z%yH;7)?~6Rf^!{OJde2Z>CG00`fhb--ZqD_UUaA-?jzeJheqM*WrrqRaVY*@hX%m( zA9-R2%H4730*bzNCWvIAtp8)R0qUR5>g~jxc#4Ym!qA%uIGFlHycL3`M6@;v>BY z@o^ss&8VZfQ}1CDwzhC;Tbff>(w*9q;Z*KUPW^$rot^rm3+r`tstTg8baSdJ%5`_j zil0%WC$-@Ln)GsN+Hj|i;;S#6nhwthr~aD4`qQ1tGK*z%8F#)@FR^-oQ=8#m=;T}- z##rpscPpH_hHt(ncbHc?HFlL#^;bK!djtLW#i)*%=yKrEaQ;l{z z)eK+Xr|w78@t8WEuwS3jt4i@|ho1NYnU&-93V&3I*9Ekz8m~LmScZ1hvvqY#Oqfp%WB4J4uZAf)dUt>ycXlABVJeV0NI`KdKVQ? z3tpt44SHcXreG1);Vworh*v3BJjZUu%jb>fb4Z^G+FaVDre$3EudIvfeYp6J(53Hjsj^Gks=D-DoJ&>exKyK&OC9lkV;AGQ^bb~~ zxa3ZCDH9`GxU>^}Te>s~4bogH(T3Q_+t#I$xQI2KT*}$mrR-hU77vl5E90O{HOe{N4j(vm+;*v7k_tLYCXoK z->?_A#<|pNyh{USxO5XA&UR@iS}t;FCK@kxDGiP#E{^$haXh|D{&g-jL4zM%>b}Rt z=VF&W+UrseOx@>F%?mDlg@Kn``W0O+yEF*huDImA?b0yRzT=V)S?^NILznhp!gH4n zV(1H(CZhIBmzKlv%B4V7x0d5nHaBxlxYZ}STRU+B(Hw5(Bz0>(R^lb>Io&ew0~+RX zYc9;W-AY4G%*64MZXGGjdhff{75U1zRR-ZV%DVM0HdS=%ZzNQ5>rrL5I#qFN5)L3x z)vcqrkN3?i$7@`)5T~Y_YizhR2rKI`4zkvFs}`!;-AcmI2ISU|n3#)w2)U>Wx6#Y( zR#lH%&9KEw-I(BWtBc>Q3PHClaHhERF)lZAtNdhYM8+&)V&p=%rlQObjENRMyH$UK zTU>-p`Eh=qTW1fj%|W-C;CsA($gO36y7dP-A9ia9*1U0qoR1RsEOp`)3Z8Sz_QrYk z3l3dy>mlB|=vF)ua1Ny}xm6osOvO25z3f&Z#-QUB`iV7vyY(0DBF|N~D#DBLxO2m; zqBrR|3g4oBgzzO6{^M5MzizF^1+2cyZ{2m>_$O;~1`_QBAn2bYsfW(R(W#T3tRPv~KW!AwW zY{6?3sp^p(gE0ov~kUo=3Ut9({oJ$m(Q!#J>^m(K+OBc~l)<_}v~=@DRsKu0fBcrg-#Csz;kq zt%*lYeDX$9;x_Xr4K-VO^gFH~u9ZhAxQ3MF+j}&ri$_0WUk{J&A#YEQ%E5*M zc#LO#JSy9lnlKLQ@N^I{hI#Y~uF;H(;5ZNSje0a|o<~dZ7{!0|sPT4>df@tgj|vv{pcr^u)>R$DN z)5POAZ}loqO|N3Ly&8!r^}Wnr<5f6F%~C{V}gB9lUCatew58jsrcs%H78+ zD@qUY%7g!gcvXBT%fIw04u`(-a?FmGd7r#$g`aT=?~U`yjc>3WlP7xl|13F7^2&}5 zQy3Qor?M?7&Gaga#W;kVv&jJ$Grf9iu2-WLd9@0;7LzBYee2ame6q}|iI}_Es~sr) zgI59UTI-aS6SH8FLL>`pqNi3-t#Gpju?a0IE+UqQrag6T4DfZ;TN0& zU!bcp63`1XuoeHHO*Nm!p=q2?L-DkhPvvX-RG^+u^>EkeQ>l2LItP5Z9Q3I}$R}Tt zPhBy!g->s#`7|lrr}r~_TGGm=#E*Q+-o~dmEbZjubBj-Fy87hm?&F+OpZ0#{(;c+^ z+^0TR@J1h>+fGPY90-2Z z8{k(0{>0-!e&reL*Um5eI*DS#{W4($PNUA3esv$=*Z27ME5BNf@@pu5MZd4P9ph&% z6u;Jw^Q*^XzgkbHE}TP-8Ge;U81t|h7tnmBUk$(U^IfH1yXH~bd_QwN)29VIw$Lx< zw|?ey_N(ktzh0s3GC#+D`(?-L@9D!zmaX<{5+<)<-L-zz_|dOq^uv*#{o448UzgD2 zSHHf(_D%E(**5!C3N_IPSGN&+JNI!M=Xa3zPV&Kg?0aJu`**ir`}g{F4|(?a)dB7I z`_&u64)}E$jSu;C2gCpHYZ-3i1s)#uYts?G1|Rh+a*R6B`?z1T@Dhbj_~m%xq+e&? zK1FQ2e}?Vx@j2GV+&9kq)!+ilk$IWAQ22^pWl-a9YPd=c*Zit@)2~ne_3J6x-S%_7 zsGsk3spBsHzUOC7S-)pcMR9H^4kZ0qu4M6pSY}Zlbg+ppxDI*ZmCW-C%(E zP6Nyz6wu1X0d2%j;ecvH1L}zNSd11fNVKH#fM z>^mI18qlD;LG3OOWbTZh%6%BrDsxaN@j+P{1o=%Ts6fM@u4A?GE&7h!~4hib&(4g+4 z_!mKq#%X*wJgCmNgqB|hwF!kr1l1f1@d&Q3f*OupNE;c{alAV!sJZwaImQO{4#MMt zd}kkIKFc82M-A#vd_5tk0yBatg;6N_4Yi`xENVyb*+KrEQRf`CMfXhVoXa+gSm#@E zLxZJ3Wmy)~OZb-u_0fu;y5Y>qp!Tm0YU%o*`u-Hu2-Myf)ZYki3UV%GP`Ne-RcC8Z zUMxqRZPbjq=z^^{25k>2Kin9ONyxV&sBy@94BWtDoQx_aBs1bYc-Ai(O#d8tmUI#T0>oG!x-pgWeuCSr&Sq<&XX7F36p^7Mx z!_XM~oYPS6T!z+QZ*D{N@)(+r0(lL6h6_l2%g}Dr%x7pW^5r+wA6F1AU}!PIZyU^A zZE#$Tq2+}QWxQjk)4PVg!;YeciWDOjMin>osDz;>B@In1WpECGq3op%O-IG|4gG|c zWenvhYv??Z%NbgVyVzZxcooPK-b&ue~}#n4P_#__I(-tWdf!f|BjVW=@?!rIeN>0X9@MAqJhiXns(@C-6E3Bv~) zx`@JGkSnZT()&?{9%J!n_RrV!2{%w}jG=Bgg`s0v2dl@?r}2gs;4CzOTinEkiH5dJ zHu&5{pQqA0Buz843-zY6A7{|3nLKZ2Q(vaRe6sWfW#;nSo@Z$Cd_!+9FcgnQnE4&| zm+^eYk>%w2J^K!OR~qWEis$8O>cLk(7&?mfYYZJjueI!-AL-kAUMD}({|$zU|6*w5 zMr!+wG12XJgSkh^8AovqNt?)H8~JZH)OUxW5g54BP}SYM&ah+;`)e=b;M_h#Irkg- z8rcsR8gz*K@yiij$5?dK&|AmY*C)vJl%d+E4SugObmk1bKWpg2b36y}3O}9ab##H} z_$7LAndcWWuNXS~H?>_gEMgjBa`NV{>oT1XA6hx8{-)(EMEDWtD(2;0peu5&~ztio*+tQk@}cLoS!%Ns2h14A@aT&!Mhtvqeu@lcx zFU+|339n#_gt#tGNNe#Aszm80GI0v;B!m>j80|GO5!XD# zv5z4w#|>0yLBB8_+wlnImLZOfq^G!oa%mx@V>%8aUwTL$^uhPIiZU_cU@{Kk-3Os{=yA(Z6DVDPs9B79cF&R zusZY%YkvQ*&STPmuoj^5z_7j?6xP_mVV(FgEa%v;3XKb^EqY)r%8n0fGIk>Sgs^_X zE`%qBwQN#YgD0~+{=`chn;w>VMp!*(h4lm4%nqv;o}pN#dTh36+*|1t)ARj!rNFOed59(Z|?z_~5;rAFD zCGUsz`Gc^!JPd09`aEL!lQ7rq2y4eH9?u?8GrW}}qEeWTS2-i9nmeMT$`NI+65$%b z5v@Vn>JjzEb2N*K=rr!&3sXe7>qX?pQ{<^1(Rlo0i*RmNM0Y(AnY|ZQQ>ez3CI?SaK3ItGw~=I(UkJ7eMKt+1d7g+U|D}i;;S~y8 zj%W(*UWsVQ-x21JifAQT--xI?O5cp=+P#Rrc@WX?M-fGyuYgO??jdPK~%A-QQfT; z)s^Z|9jg)5uDGZcnxmR#iE5lRs#~?A`m;_{+v`U4YdvDtkE)bCsvFqiAeJkthMuTy zdZT*fkLue%R40N_%{QVtk4d4Z7NByYsJ?6*Rqk+9r7;-A21b>N+=HSjj!Zls9Mzy9 zQBB4}%%4RZOqxv`RGveeOtzUz9Q4NCU%9`L{ICy+zftG!)VPUlc13jolXp`Ws_cns z#NMd9`=TmzKB_3PUWlqNX5isP#=Jxyu0@sOdX)1;qS}qfji{F2jH>A^>b@P-Ypl5w zTMGs0$t-F?)hu;;kGB z9HX0{**OzbHBW-Fq*Nl;mPpheWfOG{ zpL~$0w&fFb0H-P>>fLrM??SAuiTV|fyCtg7=ZPvmEKzw!C2G#(M6H~XsKWD!wJ=eA za1F=4P1O58CaMG0{hFx2#zb}bo!i}s>VGm()hZ`xd$T0{{&A8jv`tdM-br#UO;WpU zNg9T(dy-W4&m`T%$iqqMc_K*BwJ}Fthew3^&ZIZRMZL%hJNY;Kl?wPE7 zy^=K(vCoo~&^K8v1|+K=o(xRZ_Cd)?9h0p4o)$}n5>?^C2ItpW8m+}>b*Hx?`}z!XA76>H8U>x;9=ntCBw>#+PH<6KJCxQEG_{WMv=XUXdFJXwWbBrAfM z7?&eO^WRF*CH#;tMIGCu=n$Ua_|g=OU&bx&E>BU16)DK#WyzLnz?CO)GkdsI;Ck?w=~`Fou;;Z({vD@^-t4C zd^aFXBL=5w>X0WYQ>mkAx^O8?-`-2p-1}*qGnS?e+0y09p02vN z(sdpq3Z$#i+v)nRV7dwwO6T>-V;`pLgfCs+_|r8hoUUVi(p7VCx(W_SR|tb=rt8d{ zbd}6Z*8!ZxrxROqcf|F;M#vHR1-wK26s} zJbRX|R?pMbHCs&IqgD2py5Zd%F`da7Q^{O09l%*k&K;9APfVMTnvdmpP%5Ux_hO3S zAo7-u$%6#U#t9UBKc>>iC>PVQN-iFJ}=s?&mP zp^TVDVR+w|PGU#D7}r#ZX+3sgz<`)a4UDNd@(qgVJ)A=2FJo$l5+h=&f&<7gGN#rT zHJV!B92--A#Epw79{I<|xHe@>eX(s)Orgm!&i{z%G`3~Nlx1#A>#!aD=EXFAevEw? z)8Pfww~%#k1m7%*smY3%rXcWrOil6O%9wJli>cPnF|O4}zjnve35(I=AJ!|Cp?V)= z=&(IQRUH|8_Q+6Ln+$!@HbaY$Ix<7wVIy83&!`MJF&ZW!mVJBCrP;`2RnxZYXqRNa6 z*=Di~yJux^o#PCZo`ZQAT8_8pXXsxHUXY>Z*sw4|#TRGjG+HgmP`kAm>UcauM^0ww z0{Z`zp+mTdET=MLh7&XJ1UXMr*wK$uhldk;JeO;eD$RcUoqoJd?`Tze_o-lG) t`-|n)K5AaQNw?)ss>VI<`RzOF&iCEwKU||iqn&O4ce`x=yTSk5{y%8XqYnT8 literal 0 HcmV?d00001 diff --git a/Covance_UCO3001/browser_profile_4/Default/Code Cache/js/b3bdf0e5e268fff5_0 b/Covance_UCO3001/browser_profile_4/Default/Code Cache/js/b3bdf0e5e268fff5_0 new file mode 100644 index 0000000000000000000000000000000000000000..193b1dfa45cc114d5c11bb0e56f9e5db7ddd3180 GIT binary patch literal 19700 zcmY-1cXX817w++IrYF>dObSQ~BxEKtlWFObgx-4>P?{h}6OoRJNRi%q6%auX5EP|@ zROwBM2uN3?_p0~#-L>u?m$g1?GV`9Z&))mIB*Qyz@V5Ern-V=j8g8 zdiAubzG}Wo-i)eQzVwVNUs^^+Fw+;T7N}Y|ShZ?aR%WG)N|k+81DVw-RqtH_(gb=)LQ_bSn({#l z&6R^K;j8zwW)JAp6YfcoK49;!SOXMmAY=@N?>~WOpF-!)p!?^rZWvVh0%Ar&n^DkJ z(!Ycia&I)eI|jN*ow3kTvc^Gm={y1Y$l!_Ug}j=icvInrbr7{4TtC42A7O_q-T=$C zD7S5}MGi^McBm!RUm#9S$Q5a_3wG~@-(=z*SSUsJLhb$PgV=wCM42H64#Ihveh9vn zn8WJ*aabvxPC#F|A)He0Wq|~LgKF}h6gdq;WrEB2(X<{G+^XYrLG5 zT6Yvf7Tkq3()At;lv{H6AzYMMk6^jPKZXkO@Cg{7!d5vfdC#D(Je2m&VT0_G&tJe~ zF}zei<^5MMK>V+vvaFY#QumE|A%98je_^eJ{!^_|jWG5|@31g-Nd-d~our?5jbT)j z?`6AWn8Fw&W2KrojApV|##qCcE6r@0E2rg}h>7e1-T<_<2Aoz7**tr6e<V#4u(#!nouNqd`g-ZDfP=&|mrT-Y`yNgb|w=MlBg9=cQDZp38LcXNNH}FO0*L z!F+#f331fBLFiO@7!zugfE7yi$43W{Yt7#bF z&BGWVbKec)a$D8VK8#N~sGo9G9PfoOTYl&q#;ff)Z1xcOr0Kv zafWJL5XQNM%6Cy1AAJ?Z#>HVYUmC`agJD>XsAV1kaT{$nOT?Q(93^b4guYqMg z18IH(lciHt1AkOA@Jha@Zs3LF*EFzNHp_D(Gp|3yz&oEBnD?21GD8jAk~5zhxI4_iu@MIT9&aFZqJfaSH_1TkWR0I< z;E+U2HSoSXl((iCI4;-ZnZ(aB5SVSCqBNLi;G&fL%0Sa42L6=(UmKXSOfkPP@Xc}q zcUBna_`QMUVq2%Yz<$ zGFmc@sh`IUWSue4?>#FtV}6yWU)ji8fl%R z7?R*K5|BIcMtb>;YzP=h3L1GY-AG?a%`lQL-^=q%BVDqLYz!GWAj5NwOcP6&Dv4do$qYZ_@IN5o#+$f7z%sx&pyR0=m!%`!>OG&i!n zrIGNqMvBWRxhBoq8JXW+z3ZSkUDdM>6kqOkGqS(CV)Qf;+gEjersqTTe3+3>ToSSLnt6A!^teI=nIjG*r zS?RD$d$q#I3c2^Kk#|=b=_b2Z8F{_hNX<3cyS3`AM0{^#_K)hd1b)(9$nBqvG~8%p z#wH`?%|@c6iTu39$cI~%m$nKZk*nV>JROS7%!?WxqjD3&wECGxNoG~10!B}Bw3HtKS_IHWbjiXUyA*ik+0>S=Q`J3 zYQGAaSX{`&8c8f{;!Y70pGKPSMVY81YvpM%lg?WcrDIGCk2i59!Niqh6R9aC>bOlL zc}x`WnP}`cu`Xz$X@-e6(katKT$YJsnJE{tP1MaX(MnF{nOI)YL{udcJ*$}5Udx2L zwuwG<6k8_OH<8}J#5}pu(8N7y+sH)0##*O|iJfvpYBo2~Om52y`LKnFL9I-zZ>`5R zCgR^Qv0EbAniwb_w=?le2NRDvDWCV1YZpCA_YX`Q7gskEA9Xj;;6oEz<-^`4hRQuj z>tkZ6tdov?)hh|~SO3H`#KdRv)ld_qJ~y#Zx(_okME()qa1*aanDjoUkbl6@rktg&%{H?3^P;MX6EBUW}T;I z&dOiXqKKLKMa>k9G*ev4MVaYT%*>oqsK4?XU}ln38EB@7{35o&%1zD;(OOfLgVdj9 zX4-VK-W!>TljSqb1im(NK#G22=1ci*gPD|{%#4tXpUupZ_8ZM~-DGCXW;3O>XpSu1 zs`)$3eEW-;=MuBqOmkT*f9=t0d(FJN&&+yxvENLWU)7t#%JGP5JF4SiK4GSVEI(-` z_LLdRIWw(f(eGx8oL9dtYW$yO8p=8;bJ$w^4OEU{)m8|$zIsRwnwS0nwN0Mc*uw1sv zf3nA9p^n+YWQ#@rsIy>~<2DON-4;IbSa={AUJJ`)vlx9AYNT7(k!hhomW7tGQXXVm zXqRIlD$l|QIhb!DyP^eOWeb)n7V1{D@U|4LW?{UXtZt!l4GUrQ6@p+!#%3kRs4K^9(1}g$>g! zw4Y(2=u8W{XKCzg3p2$$$3nAt7Us^k5V62QX~~wR3sw6f)hE5av(Rac_F}DtG3zY+ zAq&afz+Y2}(clq{FVN)xx0j&efcQk92HmoT4|E>gm8B}L}Q zp8@3-wDOLONwe}oR;63nA}JYGdS_~k+?DKX9nZ1yR<2d=E3IVYS*al#OD@*7Qm>9`kgN5r>}+7AVnZu?q(EaU`&w8zCBxsgQogknpDdH8Hdb1`qvNu- zy_K>Zti0dR%IBS}T$hwC%3UIQT1o3=W$=eq_J3@pVPEyApA~a|E5+s80ajdNt$Z}j z%4K;fk>jo0nPO%8G%JU`(ON4MS7yk;Z>@a1MKwzPHY*kOSo!Cwl|I+3Y`ktI`G#tf zFJ%5LD^34V9=El>cdV3>cjTMLR!Tlm|DUS=a#Q@zwB`#d-CtT+_e%A=wvsNB-&k1? zX5$a3ZLl%PXv1x?k#DgvR*qY3T#vBfD`2C4K^rlJZFG?3MQp?twdq=djh$jGW}}AP z##A{MW8-kFjWTgII>*~ce#^!T`J<$b&r8`@T-wGPsZ!R)I(aY2#y{dqwy{XQ6M{B8 zX*OERPw6(!O6v?8pUJRH8_T3dmW_jA2-!H5XX8=6jnx%xyj@3+^0=;zj`eJODBsAT z`pTt&a&Bnjf{bWv8yjDWxvh1^dK)#ut+B7e_Qe)Dbk z7uxt#b}zDFUu>hje6z&Hv!ymVeQjgqGUf7(jZ~Sr%0{*IHhz|FKiC*7x5T@_#zOf) zCU3PdV5f4DV!KqAB<@x%a&(W*mxDGYp0aUU{HJYvCHH=}@y>ajBVxT^qo2&Zs(#$i zJUJz$Z)$%f`7iZOHvMhGamz-!tp3MFi94DnTkhKURdVlZFCJ*09@;n}SLI(R@W@8e z6B}PkiDx=TWatYUr(f#adZij(Yrp@~I)u|RES$meyJQ%``NSB`7`Z3iOyPWQ4yUs% zoFzrV2`?H>gUE2U$w|2@ujFi0IO)a084?}NXgMjL+r!xx6HddpaBjX8PM~Bs151VT zmz*gbPPsDSbSgb-tt0O2a8}d}$5StykL!o)`&>Bf8-}w*42_j{3ypm{oMRHxI-J|>wcZEeoR_lQ z!>7RvDMb^pm&%=2s6~9o-FT?3RRo+D!_l`Q&ic z%Zn+hd3HE&q{>{ylCXv0^pN$7!kM`^oZd^qDZEa3$bt3BLaK4kNmvp|!da3niIMZa+<#3+K^XLew*dwS{CW2XVSZ-!V;LnNR6A9%< za7;ETTbnWr1Z{6=Kd1N*j{nG7uBvXu0T#)4vQ4A{(#bK#a zFp5QmqWDKH6pqr*oG3cTuE;3*M@R9C*h)k(wSN>BWz=_i{YSknk(;8}B<9UJCXM$+ zF<(|6Q~dLaFKhpbqRH(j7Ra#sn)fJ*LXV@k|0aqVg^F=mN>(UFeK}XT80D)Jqh^m{ z^cYl(pJn5)Vw9L!jLza;QH=R(i}9C~-(QSRe=EkXa`9#{HvCY!Sbgp9i&*FD%NMwj2#+{ zVVK6scV9%)dw4WkWX6bSlD~|mkK|2_rqzsSzLv@}qsf^a%}8lFCz{9eqsd$oW8dgS=uu66R6wQ>a(Oi&H+oNf*J6iuXR6Tp6IlM2LzQ0D({BSg1$*CjJ z{Qfwa#3#|jy^Ln+ztLQj2G}_u_Aon3jCQ)1?W~t{tDONhJG;aaZs$p1I~9xAnN-wH z(MUV3rA(Av?~(2FmF#FcBkgvMOYImtXCxuk&N^9DM&pw0+)c6TJ+Yk}x1Hjtb_)3I z3`@6jSVm^p`7YbebJ?0>r(v$0ww3LCD?6%aZf!e<>ez{`Yv&_rUEi*MquJTiK+hX# zj;w8L=W=s9t`>Icv{ZiY+UX{9d)leq%g$tJ`k|fpK6c)dt$poW8Dz&j*iO4o?KB%| zXOTpFZs*(=cFGU8vqt8QwsS)+kG1QAM8%d9Q|*jhWaqSWU213GH+HstYbSiAoerz) zSU1>dEPZ~`TALI{Y+LNi*rqsAZ@ZnJcGxlO)Ox?zc~@4*Wx2N7PU;>zJNMc7_n=}P zQ{FO8YW!wriX4!yez$X5%AdFM#}zvjuBva>)Z4puI?0@Sb{;;qQ|^_W{>B(x3XS2V zq!o%`sC-vAhNZDF+>>$fF)Vv4h6my(8N>0!7~V>X;aY_lY^gCckzM{6CIn(QCu4&# zR7j8EBbl5LL&a>pCRIW)tj&wzl{~2!L*ptj%$LGdV<=lUhVHVfehjl(#c);9+r`kV zLkw3Wu~Q5m%IwZD4EZ32eUjQEh8c2M;(NxhN^%Fq@TDC8Jcbs-V^}QpM{4a+%1`#n zyJKQlA^oSsu=DE}3NBNOl`#xl9m8%}vOb1JKg2LkjGNS(Juwv88$;CYvKiN5#_77|UvjHpfyWB9;l_FA&S- zVzF4FW10R|EbU9ivPym~6|49EvD}dtWn#%H7pu-2_y1iOs zUo1n#zh6B#7|RuDcPN%cM`HO$`W@A{`P zjiZ}9mG}F_u}&)YkHat^j>l4BsA7Jhn8V|EJ~EE3qvQBN^2aFt1jV1I*C)quXhs~d zGc|XP9v8&XL0&J6W6z>EihdQxTZ{EvYAlJP$Rfwl>ay;JDc$(zIvq1J#iN{(s zo{HkB7SBN0Sv{VEHR6e>8Bb5C*C?J@vZ8T3(M{v|O8$@v&Eok{a$3eSQYy5LXXAVE zm^#H%v}-)gy2rCfD)rF1Jr%E4ylPZDIXyIrt&GvB%=+Aai8gnRw2~TURvq zn#ReRoAK=UE1m*>$1~-hcdjOP_JWMt4mB^zy ziEOK{bs8nIw@D&p-cF>OtZ$u2<#!VGd1@jpJ0#-jok)Li57zNd64@YYzewcHSmit} zk$zjJXdY664@vZUng?Il!VWm zMA3*OTm_QoFU^Z4(IYa6pJiuM60@U|xF#L#8XK3y5Gh|gi4n59L=r{bN}@~2ByJ@o zkyb%-ok={Byp$wvO5M~XW=c#@ak7#~%}%0nUJ`q&ClOgAiHl8==-V=h9kS+~Bnoy- zqJ^yJqp_bRF-VfeCNXf5){~SONi6$1i3d_>LlUERC2>lI{i?hUB(d>m5~gEG^f{G8 zjnhd?k!R3d1+d6C4Hw<=&QS%FI#6)2KffqF7an&ehsfpo7_ zfsJh{V0xzlCHhsM!T&6-z#Qqbrvg<@SI~W36?lEU0*`N2ApfrljJaDupMmH#S^KyG z#_(k7%iod7>CG$|`yi8`>f617_9Q2W)vR4Wl9W*sL z*d?b5I{3VhgMEb^q!)3pAo_o z>ELr<_d7_G>GDUwLEWH(7I_Z3NJ72?zbuu1DmrLg$-$qs9Qym{U}bFwo5fwn!N+wS zT$3wJ96XZmnmX7jsm&bpYwqBNJZR^@(B8ooIV5=<9E|Ab;EC++>fkq-_<@6k64}i` z%kB={|KOnLK;<(?b;^lP9mEfHFj{&KbMW&Q4w8pESpKC$_c1zXJI29JQyly|)j`i` z4x;8d7&%Wh&v%f!z`^r{4)VWpaA2{68p|C_SfQ~};9Cc^Wr|Gt-obpiAdS~4rYw{? z>vjAG)$pT(B63W+Z_t>Zv?o71n7dJNHtFlF`g)tb-mW!vIk4?^&|r^)?NZ>7_TY$v zZbu!Qm!FP1bPuD0RVN+1b;^NH21@>E<$cD%Qz>xPLDh?@=dObv?`f~@JIIzZPaM2> z=^)~j`X{HP`fCT{-{?G$CSgwI7@R~Hos5fcaja zev#lXCxgFm@{c^1_eMA=`=yfua#os;c2abV@|TUWPpXY|^1(PK{iWD=)g%|?uC$w= zIwq=)Nlp@Fq`W^vxy*D@XSS0Y^PIRBDE>mlU*@Fra@8Uqe5<@yI%&H~eU`;*ocz7k z$?^?O#&2?RYO|B7ThzO4dTqOtEjyfS-s!}!OKbn?q`~i6TZ*4|;*@{>baLpbdM-1s zDJO})t}!>99FyzP@V1lI57bjhdgvrwmdm|I%Hy$=&&iQ}?Ct)sYm| zN%x~E43WE%c3k@-wa%n4>1+xEeotZM!xSz)O3{1G6yAE8LdR#SL5jXip~b5d_R06J zQ)u-@G5<{=^1l??;$m5tix`88cT6spnq5R&TojFR(W01Mk9Uz-!bL4HzU88rjF3Ym zU4%-x=vcf(;v&vua!a`BCn%y;o#MHjv0jsz>acvQnh;o2^m)p4;$ewU~6QDYYyn7v^x7w6?KNgJ)4#<&IVm&I#mY%8YEE~O+ePhpE@ph~;=(c)^}f-XtF*q%`_9EG zDYe?A&*okHCWdwDryQ0G(qO&j{@}v$qw4%gb^fe6W!)whFE+avzSYIiovLk@ixOvC zbU3TtoO99kPZwWbc5&j0i%at2s`9?BJ^ahXOR?TkUbkILzT+b7u8U#!T%_FB{>f9Z zJa92Uwm)={`p8A|C#wCa_W8N?%Is!?#Z8jc%^{ncVi9h>kgf&XtS#uKOd&TnqTRS- z+{~A<#ocr%;pX4B+*B*&=2&UBK0k7EI?+w_BsYo4Zn`_%{2>ROZlYXnhRMBDH|ajN z?j3fsSswb`?96pz%Xc$C-qdtcxR#s!a#m{Bb~Cw-o3OfW`qp<7-oQ=6hHiGqlBRA( zwQw^_8n<-QK~71DR&K`1ZJE{D&80SOUbb~psl96J;AZgqZgzEX>pEk8t>R;7rOa)k(+CB=^OQTg`6BxrQ#{|M(+Kly#7>Pm)*3v=H}6BH`)KH zCRzWVdVvRPn1@kv#NZ*%=;0f)hr1RJ?^->C!adXzYlMeb87;>Oc&J#=L%~8GniTf1 zOX@{wyu=mrkSufLa1_5JQ&-0sNK#(3;DdgNB4?*$n2;*X9ZGu zzhEk1MN_F6nTj#a_P5zs!oad`%nYB=PE>fOf>FbrL*jAN>akRMsXV1L zUOI<)IW1d_UQA{$AItkzFRN`{N`-p~$S;Mx^o#Z~N-EjC`hMbNmqf&R86<6sds$Y( zOUzqd4wm;4mE>iZ3~_0k+slenFZaD(+WEX33VIok=4E@jSHB0Mp9)KF}Rs-@VnyuO!v4U}gyFQwb6j&`a;{*hswy%g%{rD-qC zm-D^7B=k|feZ4q8RlLu*_0so%m*6q&!$~h+ zp7Qcs8lUqr`*$x-&wI(e;N?5{;*ysGe|pKjto-HX4KH&adb#pQ;~#tZ?3tIn&$Zsa zUiL@%s9Dy>!~`GzNx^bHb|w0VsNiFejFN<8AF0yK;bV={$I}!apSyh|`+WM{4M%GXi6x<1a!UvjX4kEljIhRN~9 zKH{4CSklZ#>$W}?x6`rqJ{rn*lGVXSM~Um`BSrG0ePJ1{?&o8K{Y3SDrZ}Jb7$U=l`}lQ)@*L@-=_utUeMkF9ALHYmEF0^i%{U*?<9%$Gz7u@7 zC;IgJBt8~Q^6~FvAM2;6FH?Q&pYP+$0w3=$)T7*9q~0you_fA*uhnN+C8lNS>o?l7 z#X+?^MjAx8+`oylaDGJeKg+cWA-*5;oB8&r;k#*d`ys;hkRT-?4$k> z_3gNNdeX;gIeW^-nBTM~r+th*r*q`0kLuUeKiPj%d;GVL&!ql8KBnK+UWxIpkJ|Tq zY?7Hz)x&4%*>jyYviPNszhC)y`?X&C&&Of>f`@_xLZ)y4gkD&Z%;jGu-QQC8z*oSaPXQ>C1r-YI^D zNyz1=u51&t$4_5b81Qo=sN-pV?q>N(%klHIw9ogmyrQ2#W#v#yIn?npzOJ8Fjr>$@ z;%A*iH}})Jg`b1cp_O0vL;DH7qhlTXyy)oH@5%Z3wzr=LA1PiRKaB_bnLWf$`A=2% zI6v=>_j5!(nd)cvG|ipv=XWVP)6Zo2eU`qS<7d@eKP6Ubja8bvM!nhMXXsYHu7zpM z-G1)x@iTazpD%y)bM%0EanR2r$v&+0WxG5*;-}Y9KmVRrzJK_Mx~Q6EqMVn5m;IcT zL0A0jyz0ky%}<`pk>9T?kDJO#7RX)s`Y%7X|Mt`7mYI$9{4H! zNNYb8GPCmpZTfOnI%IzVS2TUq2WA)A>MvRjSh1B|x^cq0)p0Y=9LI2IS6Vtj!4B?I&=72y5S0alj@ zP^xTz6lpB4q;k0cVU7SMmtwg!KM>&Cv;Ys%1FQ{ct^5GXDh71#e1L>H0lL-=klZ++ z`{1>H^8j^Q1en-1pr1v`qkVu)9Tl%rfN`AzME3~Lx@UkJy#m+=1ZXobz#(ZnSTTnL zi1{QygU=$-D=>pZf zD8Q+&0#scbp!m`N?Y|CiTyBVAnezK4K)DqGrpj_DwnjA^Pz?tIoReCI157#+fTICE zIT4`Y$pGC>1?csU=G_g@{a%3l``V8O0V1CTX!$(Ae%bg^d4~nrXADx<9OP4(Du2im zOAw1S$PPIsm2E*rhX?6fG{|?Qf;=uA1=`3fZ z^pGImexfyp1sU*#YLY6$gZlSrkUdgxWRRJog4o6eX)rFxc6mA>NbV%nEnB7p^?R&A zjMIW_mBW%hJ;)-tIYV)0>e#Fx(Q-sCO2gTTIVXs9ZjkJGK|Y@!-lb<1CYJe`)LW3rRyiTvmS(c#n@nyk z&!p9gOnOPgnoMHWW%ADYOb*Kxd9pc^*rS=edn}V9a#aSM*4Jkh_xDUj$caBQiNB(} zWZlC|UOdX=pTiGVb2xe}N7prS zh`*VmUTVF+b69gLhb@xvPY$2n&f%_Xx|>7T{TvF*YI*V?hfWW3c<~~Kimwz`ewP1U z=g{ko@-u`eWD4<#{A3OBuPsE+@DMW#hqzcI#6L27hzh*wgeR*1&6L;NBm>MCYE#jGEqWrGk4 z8-^&-D8&B8dTbivGnv~g#Fgfn(;`HzcS1~hHw0}%tZ5hGY5NeJJ1B1F5S6=xSSMXS z2(h+Xh%((nB+Y zl*=!Daycr)KF;OWzN$ld_RHnR{<(boi5`dL^7@Nh!iVSLm2*;Nq-v8fa(q-SmA=fS zzKoKnF}b`wRYem*w)q>Reu}$;I$Us38k;i3;sFO#dx_RsrSA#tIG|c0w9BrIOOw&9@ zO0(v9%xjTH!IpUpdRt>#tPU@~KlgpVMXX`6el!yA|?zH#wiTo%t+E z$!Cy1pR%3u>C!o$vvRRVK8d~ZnJ(3b=QDmpK5yj2%zWZ!=QCQq+nUegZTbAMBcGF} z^C^Bdp9)g_oW}pI@#6YBpFX$p87k?w^ZDdXK6j+h{d}4}$Y;0YJ<4aq<9w#b{3rQL ze3s8VIa{gF%xb+}J`U4=O_gxyyQO;gzke!bm5*-xUsTe+_V!n2ZToA>r~?P8PrH8V XPIjL=@3?oof8+nn)Blk1|NZ$t#U?=@ literal 0 HcmV?d00001 diff --git a/Covance_UCO3001/browser_profile_4/Default/Code Cache/js/b4732a7d5dc2223b_0 b/Covance_UCO3001/browser_profile_4/Default/Code Cache/js/b4732a7d5dc2223b_0 new file mode 100644 index 0000000000000000000000000000000000000000..6f6d163529e1dc07e5eeee2f5ab8826085ea3335 GIT binary patch literal 19700 zcmY-1cXX817w++IriY%8Ndakrgv?}SGA(^3p-JyuKxu*?O+-2>B1L-dRX_wmKv0wp zQk7n$h=6oOdart)-(BneaarrLCNu9j`|Q2XOESFk25*}Wzb@J1n4=&hDj-Rt#xy;U=V!SpKCv(u}lSFT*WdUjUTtU#c0_4I1#!OW_a zv#MmLXZbRNRlVs(#W);OX!ieN{qN858Lo)`J;sS&UtN*@2G}QaOmJ2rmBbyHVTIF$ zp-2(9Eq@k+qa|Ql5Pr@ATaM<+=@4XBgA#8-mxi#q5tM2St>q`F+5~z?VpG*4HRb&l znkxrd!k6!A%^uLHC)|~yeZbydu?8sCK*$^n-+c^EKY`AlLif*L-7u*9ImC{HHlv`c zWPAZDmYi)`u;tv{{eQ$;tjBD zi*nlrTjZeRZiiZ8{TbrrxLlSdyI}Wj_)RA6frV0RFVxm9wif#@kR&tY*8^})rXPf_ zB=(Sce+*Vir{mC9t_vsCds!gC-{4L8Pl}#`p)x_{pH^?rf%y;EegO(xgp%@`T$AR1 zLW4`tPD)$`r_7ZhS75x#+sutZ{RK>5G5w%n0_rPob({g3jxrSWn` zYTZ^0S#Sr|NY}eCP;Sbh2XH}VJ%r_w@CYi(gU4We0$b&fWZac1hMjklq(W}Uv9}O=~*;_ zx1;nZDbW#R$v5(o^sz?}9Unn?IWM=RZGz^PilC~zmcpeY_*60zBd95c@|q*VWs20O z5WzXwpA^9?M+6t05j04Rpp9&h9{MX^!5hKx%n0JLBB&+f}nc8 zWb+6H$lP}#xYSlPw2$E94(g{|5y!g`%$DyvNAU8!2)cEN;6m33lDa8Y5A}9h1XHI+ zV4R^^7esJ&q4Hf6!G~W)uyJt&&6h^7<3I$~LlN};|(Q9Ct z&p^80z+~xE&A=aT8h9z6S2yrn@@pDcEt}<;6s>LGW7$>5fWNMRSB(txZepNZQ^k^7 z%?z||ZlH_Yk|`|=3}|V<@|JRFWgwxQf&Co}Jdh7N8W`Tm!00Xp3U)Qn=zRl)KQK^2 ze&}uBlMl6?zM0n_V&Lsh49xq~K-r-NZp!J;4BQ!J;OGbge~&kiHqk&x-koG1ZnDNt zF>p`{Of~SHJdii088{|a<*6jhG7y+;pprD0XW)XA`qDttB?kVK{$ClGvrI9+Ht_Xw z1GiTg==hz1yyT+1`=f!A+YDTi^*aqb*=?ZK9s`RdW3Pe1@~wQTA4+@n8wmcQ z<1$(@kE)-?3}l}+(BzDAma`IbPHUbw;Jav`&?N(vZyUIAM}5DmeYvN+o+`&@%KN$2 zmv5!iYvuQ^fifl|%?lZsSJ+6wB1X;?H8P=?kp)sX%1D!FBfDfwaU*l3S&WfRa#~8q zYOLIgGZGPRWV0NQaDtKHC5$|h^fE@O3uTQIlVS2pIV0JLM)s9Aaz>_9FtS);l8m%Y zRt!n>841X3c`d#CMm7YDBnOSWn_;A{q-7e(m+$0RmXR*mMmC0w{3^r4My81+&q%#| zBU@!@Wg|aGuPR19mHU!a&B${3tcLQCx;2fok;7uIZDdg$BUPIkX(~mUsb-lZr<)tu z-qJ{9TO%dpq+FHe?TpNCuikagoUZEG`-(4jx*6HuT`_tZiR-JnKh^W0dOpm^$MWEF zBmYV75k{tuGSYaok>cZx+?c4mrxKs(> zhJ>jdYXUtBkx_ZKUQJ?cG}SRtkJ)WcCm0wFG|DUdXMVj5OS6 zWX2{V=FLW;rHTBs#mEO+m6y1;>%5T_!p}NKx7Z7CHfETi5M@aF1dEcNYA@QzQ1Rr{Cy){c_`Tr)jvspY-I2gBVUO9sgbYbpJzJP zUTD7xnOI!d#2QH|V&ZmD6Q4wx@I{-bENkUSag)wl6J=se3{Nm|I?=@C6ccHwChE9N zBzsI0^qFYvH?b~gqG_gy*U~A=M0~c16qzaKb4=9DHPK2=IzG=&$~XX^4qW<;$TaN`GczqjVo;Vu<`BzTqZbjxgzcqzTJJ^>Mb(SK?*KYf4(&_T8^wXk+;UginS&heP`mAbtdfVO|<^r zL>HMLt{>DdX}&?@$-{B zx3vEcO_oXGj((Hm}@2?WF}T-RWVbpk@ApDjmvktMWi5b}@7QeKY;KnK>n+ zyPKIUwjO5c_f#A?AT#@zDfy9^_I=G9l|lWL-vBd{r0PI3P2^{>4OVV)dWhDVsvM;L zG&9qtoAutvOuQ_gX(sTMnO~*Y*Ji$uZ#S4p{n5+_$^6O8JZZntOxI0j)@(LYdW+`B z(yf}m)66$Nn|UU&yUjG0#q!r4y|&lPJNwM6m*@M_=9 zX5vnov79y2N*4WYrsz5K>w?DrX{Mp9ld_l0biQn+`W4kFb0zzlnLD@5e0s->|E`%T z@|`@rXJ*fR?S*(Ao0%$SpO~rn)J!v(BR8L!@xCy#P*%x`f0g5ZW?sq1Sa>Me1`Eq& ztNbT>Ocv^xEljpp^p83Vb~$FVaKvrlLyv{~lIgXuOg4+rXQ4)hg&kQI3T9hqDJ$iE zj)iu)7NYYkjF1EQ7IG?C@Kv#3scNBaH4AS^kvA=jmlM@3RH>&rH&{;~2Mu6#%6 z^^q1D$P>9b%7SyWh1s%9nv7AO##%6pvyeL8LZt~7(kEIlO|tN@d_LJi_bC>=x3sWf zx`p;LEEJn*VfQSJoo!*JnCDn%HqXM``4$Q+uuw*Fr0GJ{zDV^+uWv1MTBE&KYhlbf z3xCLh^~(DP<*~uS`i<(zCJWZh7QT@lTeO!uw68x~7%t!JwQz5rg|_=u?*R*q4qDhD zze%UV7837T=z7mWKe;Ks2Nu4RbB}cFiG?(IW_^ zu(Bx0O3`F1Gb-veS({>Ihom{I^mSUfDi0*vrLoe)ZKb0em-sa0A=4$oXQhjj^jk@l zIr3*fxdpAfEo0KHJeO4&R<=lLrj_1V8Y6ckCr8I~t-KMo>V2h^%seYKWP`lQx6-YW zYLaj*E3@Q6Z7cQas0O)G-^$JgRw^~LvPTLwwz98uQtTgPa9`&1x((<-^{m4qG$LjwR^x{fWb$h( z3nFa%A+-%QCK+wGO*Zl^Hpa>^tBq>~Z1@V==wHZ2Y!MqBWO-2=am8%9mSAJ2Sc}`J zVYe|=&c@m}6lbGsyp7HYHd5ZOF+=_+W#hBbHWrt$@mi{uv$0OzO}6om_)=^vl5d5e z4Ntm_*79S9jWg0Z)5fPVEX&3+sgZ5tfEYqHPUhKom~UfsB^z(m(W5-7YolX58z0Em zaMMoW}~}2lA+DDW-A*fB%zIsFT~u|MoU@H z&PL((%D1zPi1(CF7aJSoqYrKD5X(n4`pPgF*w;pjel`m9x9PmFF=rk}0K zN!E|F(QK3r+ZQ(CWt1EmZ6h?sMkDDihUv;xrp>T%cczWpS?cL*-FdfrAqnR`Y3 zxUP9}Qp()W{z}SU>YZ%*+lJ$&jSN}+kBySIHBYwOvGI$9?`bdYYo8w2I4oD>Un%&| zM)G4DUrEWQI!9#aa~r2#=-hg#8eVC?|I<1|(la8G!ScIg8Y21F7|9s9E8R?yd}ofN zvn`S(MI(tU7DYBwk;GSwWW1b6iKL1n5`#CA#WKcyalHpQx za3tAsMy^j%k?i>)l7c@fPuccU zB)2zeFE%Td*!HVma`%@=-uX3>lLsOxaY%b83*^LM_2E<`%jBZmJrhaZxk&2EM}I`J zQGSt_^O01L4i_T%R;FIm`6BD3)}N6~lU0`@c`DCh3Q*NvfO=&MFiQ@}jhq7ba|`gX zgz^h;R5n&FK&2`LaK2f9Ph@xX0t9LlV0p~~G-*+Q0g}_Q0JgXET(Vmgz|pz@ABlfy z6d%jYpQ1?L7{!TAQ5@MEMTsp@6y6%e52BNpTXJ$o6lHcsG56;v#_oz@=I$s)?~7vC z{wNMf_AgQNIS|D*`TAfK4-ZGN@K_X;PDHWnWEA(s@mmyoE=E!8&nRqHqV(Q5iomrf z2L2tz>YGtKmtX#gqR8zi-jdimQS^Hd#ZGDQD2h)WE8nM4?3ZrOqL^Zg=DaK~5Y4cH z(HxRGg`!zhIGTUte35AV%!#Ih?23w}e@rw#i>+idQ~O7AK}LP6*MHFK616FsO=8}x zW72qEH1lQkQN=%}__Fq|Xqw!LW`PX5r+E*fDf}p!d#|IJQMfplq*TS?)R(hWic_I# zaccG`PLDyw`AIeoD^AIo#px{m6~&pqwm5%Dh5g0(~C z{AF>D$PfP(XVrhjc`6-=VVfa_NMj8Dm}23`@jnjiJ4)lH#@)q6);&Mv4~I z_~;m#${>3T?c!rtDUK2`3@I5yYS|e2$?4=6x;kU{Uh1aCaKIl!Y#@gF*)fE2Vz`zY z!*6*peA+CAU!~MLF>LM-gQa5(XJu)Z81Bm3ePgKDFNVVXWAF})VX*uuO9v^|CyMoH z3}c7JU>K&c^6lp_^d26=7MU?3hLkU2=p%VkV`w!ahOeZ`%ouWK$1qZw&WYjC{21~V z#4urD4CXImXeeD5tA>>^B(753KgKX+YYgY5^!6B9?2ggD4OP$H7!K`=q3 zmvZuO48K2$A?a}p@h@VS`fm&uqyct*6?=r8B}O}4%y!mGhSkmho1I$h@DDB z?My0Wr&yGo)>1awuJ_1x`btiWoso7s$E0?wozs#SXJ?(PDywlRcJ8Fw^`6*HuG>zD zG&=?Tc7|oxIV2-9?R=YK=b3EHwbL+cr)?EG-^h-tnp@k>!8&&0>e~5GTGzMh-)MF= zHPG`$nj>o)+qu--j;n>8IxUsoJ9fIs+@5x-_p&otntos>p^u$+WoutMmj~H#54O|p z6Fbd@+F2w8KC^T7b2}A=+gT%XN87nBm&V%lL84;I@u_ykF0yk6`Gq*&faj^%2_SZryrG?88YSSAEw zIV)p>u~f{6ID<)u8X6ief(vCNku)nX}EH!X*u8w85ELk5*qwiyxC&o?c&7N2a?~SF*!B|Qk zilwXEk{L%dPip?ATCc>iRqEc1CGlP?J!I9>Shl>3#ri5%@1x@AXpCdE#F*o#S|E-I z;x8D-=HhW!V&a(oMjY)+#j#3$Djlcy|8d-w=Vjx_E+41Q5963wA&zZHaYQD^QCU{F z<9H=mA-^TH(bsW7q#j#0t zc8Q~Pk2sde!Vi>B?>HLCXlc<;xyZW%<2XAwjtWEKSR?H}Q?8OeLa|22QDaOT#tCr* zCdcuKT$7Ot<2WYUmdEkc$~f-H#c$(?`!0?SGDn7eAIBltvLTMQw#Bhj%I%0_#GW{g z%DTN;V_zIY#lK%YI1tBWX?HM=MTg_~NBSMnxMQkKzBnGol9O@Vk)M83>{D^XpN^xU ztT?BB$=&mD%z6^X6l;ruc_Q!ii)Wow=^u|_Ks=A6wq^o7rCy^1X32`i3B)u_;7j>KDmF{t2gz-jz(}ds zI)RPvCSdB6K(Vd~H0z$gBB|U%>-JQZFo|?d&xd~*?)9VWp zIJZ23mc$)Rpo7ejaiTkVv}N zRwU9yR%}VcyFHP?^5w2XzWODRd-CgvM7o|yeX*JH}_=5;+rRUjj}0@FKIpvwCd7%z$aE3ighh<`u@{*<<3EAWl<++2a1 zyDE^ry8^pTRiMPn3d|&l%MvV>M7@|KW=U4rB>qWEBBOi~?g~k|CZgvu$dyDmEs34p zBwqTGsP0cT8`wN$hQsMA^5J=qBr1CsF0?Bz>NmM9U6IxOykiU)+Or{Np4x$lA}7 zxII=mk4xg;DM@@jQ+Y`B*_t~yiSg2VUJ?TqB(Y1<7A8@6rQ%7C?~+)&P4nfwJxP>4 zm_%3c9!jFl=_F=I-#?N_x|qZVa{6i#Ki|;&zmj--JBinilc@P5iSy4?+sh<2%7a%) zTsI}-GbdB5Kr*g^$@G`z#ggd}mCR4FGdh{sG09w&j&_ZWPiBZzD3Qzv*1dS~4>wHmEq+$)x2ZQzb8%z15S6s*%ivCdu?|namDZ z^L8?Yx+c>?R`k)>Pm&oV$zzilI7#bC>WpNTeU;38DZC+>(Yum4DZ_qIUcV-@@klbJ zqsjC+nM{pS$xM-_XOn62XEF<9)eVimlT4Yr$?SQa%$7GQVl7pXik`#H!70>G8-J8P1<0<^`TMC@g>%XUP?m`O57gLybErq(*Q2n7u!yPRD!lC;Z9kdl9NKN}csO{=I7W!9h_uD&03|%#YfWpB&8Hs5qPS^;UhoO}=4$jGs#~iwc(ZQ+{4&FHFz$XJG|CI7R?cj+NJma9+1=VxM!4G$}SN9y` z$mz!pp1*KV;HCN}C#Cu;2jgGsJdh?4PUaY#6fim&SHQ`Mf=;Rya7<|hC21}vcYIFbvYot>e~go^vPph;%gL)& zPP(^ta;=S%iEleO^^TMF?VPmi=44@aCq;WWIo8`rd>0rBPNw|@u}RBWeFN9{mZ0Mra~%S zxhXHCdr~UvlT#^QF_kP?;!5S0tWcF`lx&;ISQ*wam8nwiT^*Mr65BbIkup~--BbDSqf|bZa9@p+ z?PBSlN|$dR#cS#!Ps+7c-rZGC4;P2zvefG3;@Iad;zzhhk_sbTbQ|U3octx}qm|Pb7o+8& zj2q`-zO)$c;ypPlWhc5=Imt!MX)eB;;bNV1pQ(9rN784zs6EfcjIUgrU*@9T*IILx z)|YwTx>zNpSG)Atyo=w&uulDyLvmgktk>M{U08lloj-q*B;f4O)e)|<-fmW#=^T}0e*G3>63 z)O*@Lc_NnkE(XZ<2QJbcx@i7bwLj55Khs{B-E6S9Nw&HyYe6?_3%My< z*v<7AH||(B^QBw~H(g4)`S%SsZ*6v5lJ-ZQWFEui84e8T_7`U0vKbK5*+^ zI5#stbaSDP^i|&d-AtEnByXUbCd1v#8R4eDNH^_Ax%FPe%@2||TD=+L)^$lYH6|(E zG>w_zW{{knt$xjQGfCVF-F&pj%~iShwfeilt7;ricYjk}e=4s_ZrWUR z^YE3MoPSl5tp88Fz=Jiy!zejy@Q`Qp@U_{)9gBx|tR6y<9_op;fQL94Ek_G_s8q;9 zp~4=T6!EZ2>P2h3#25FFB6H+YjE6>c57S~joQv~NC*DI^Ne}(r@Nivvl=1L=S&d2b z(7mFE^(h|8J3N$4_3)m{qkGFe#8&h0_M09K$%`5uU0d_;ovg0s;c$U*vP}F z#vZCS@vx+ghnsJEFt+tjyPby?@>zS2?iKft)lqrMiLP3Ekk%gT(KR-Y-Y>A~vz-SMHWXf0%XUBP{HQvLli5@OaQcjb#-ZZT--NRFvKf}Y-nI7)Tf3wt+*%~M9 z=6EZkt@bcmO0Dtm?ppP0gZAu44|8R?RR77t%dH-sZ_^&_@UT|4O2wV(-7dx5 z?P0nU+~c9~UJpOZ5gEQu`@3Iz_>0a1IVWEp^6=MT4=s>~LjECD2{N2M+8S{sSW9Rky1rNh6dido}4{a`a=qisTbj8Ce*(lwwc{nb2Zg`0K z+rt*QdCPb~%B!(y+#*@uZXUT(ENvAY!c21+!duf#GnnsuR(>No;yQOiUdm6bt(kR+1 zjpiSuu~*JXV(&DZL(=H|aT=H8!{KR^9Fazck!c*4??$K5c}yDLj#calY4|3k@ujq% zmd5hw%6Uc_=Vzr+VNM#;K`#T+y=>3$>h}Y@{4V9P zy-b!Nl{LPK)~xDfr!=nSW%rw2dRJF2H56N-YbmxYukYn<1LfJwOPRK+qn+xIe`Hu^ zFNJ%0Y1&KkzsiG7rBUoXy26z@|nuZDV=I9zi^c=dBc>yFX!ajHlDnc&4g$;)Cf zPw~=VnwQfvyqururNV44)8xV&FG=&fOqbpZy!^D#OUfdRkqV17MjkEolDo{SduqH? z{aR~E)fHaWOQE%1ntZ2q7|$9C<>PA{Hcy!8Fm zOYo@n;e?kjPI`GJjn8_S{kxYZ=e&f^d-+yAzv$)HKfUB!QvPz|x|g{Ryj*^$@sGTG z`qazbXIk%HFZ-i?)GX&?Vxo`#q)>SuyOMkqsOV#mjFQ9@A8FFf;bV={$CFeapSgXc z_MD%4TDx<1ayUvi*< zkLX4|hRLzUKH{7DSklZ#>$W}?x6`rqJ{romlHI{aM~Uy~BUSRGePQQbjQtuY)*b?o@SL(B@ z64NsE^=s|fav$bze7csRb=Lcc{oY6K4L*MQ(MQ#dJ{oWJF?*Yj$nA=^(?{uDJ|@V_ zgFY@C@=^b=`gTk`J>g@uoH^-Z%x~J0Q$9wY)j4v-NA+v!pX|S(J^tIrr&9kPAJcDX zuf%xANA0^lHp$E<>fuxM?3vCRS^UDs-!FZ<^-8b(=i?B5!V!K#MnCn$YVs2&qvfdC zPbG_=o<;n8D%nN-)RN6&i1PEHl!*6}D%a$(yqDl-bqPPEOZv$#>!+a9P0QP zU)RseMt-U^@v}~1n)_+p!p{Ne(8{m-q5TBk*0BzLo_F-?_vHM1)7#Je4;8PEpT>jz z%pT&W!Y8VGoS%2b`#CHhPxZ5Vn&wXT^ShLr>1VS1K1*NE@v~~KpOP!J#wyKSquy-s zGjyw8*TS^sZa??-_!+#<&lkV=Ir6J|alp?*$vLF;WxG5%?5EceKmVRnzJK_MzMz_A zqMVZhm;9WOL6`mPyyC}q)lZ(xk>9T=j~mKK7RVj>>MuXH{`S-6rk|Go`1#MvR38n0<10@pmezasnS?pN|o{fA{+rsF2!hI%1Xvr=TKNH%RSM|d`2dM^ z0(7k#Af<6Y_rYuZ<^k%q2r#j2KtGF=NBaPqIx1eL0OL9bi0KiabO@uwo7g5c_d}2A>6(F--M+5n%YZ00+hg$ej>i*F@zqIlv(KZdQP2vjcRQqk85A zxH>;T(*>$|QGkOqJzQe2r@ORW%$4a8_y^ z3NYz#0FDIs_;`SZCjxXk8KBocns+Ba_qze|?`c2o2Z(wapyjgw`(@(`kax=lS(_N7dHEpoD+DQ=6eOu) zknSmpA)B2+46Yy_%3iOI`-6Ne+cJWfvlL5;g@UvQ2U(UENMidSQ>0qQAYe^M1<^6-)9T4P|j2#$c zo-`j6q_donGDCuV^Rd<(7G%KZs!6I259;5iLH0 zTeeII>i1ZK7^elerX*^|GL@e<-FLmzJx8{Ju?VZV$45hjQJkT=oS?+aJ{LSOxXDn)-WKbzV~b zSG0y4mxODoN#4I6AWnKPL=3% z8pw9B#H3SPmdjmxI&EXqaVMnnQHgW{Wz&f)pH9OH>FkhyrFBv|HzX=KoxO5aZb?yR zI&VmKspU#%k~^KAo^*alODD;jPQ`3J&q-%Qy>#8voldAhI%$p5>DMHkt}WAb50v7( zt2H~P^L~$XtUc3NAbY2#Q+Rqh5sTBQxkRt8P_C<#>$m9)T9c0H$8_ral+I?kvN0X! z=5+RL(K_3;&W?1(?p01F(pi5po$|k>v*?WSKbuaA-_xmnAszFjbbhyFP|lXYs>lo? zN@P&8WCkbR$l&da43=hQa3(v05lu2U*ffJsvkV%^8ae(!1_>W#@bRDwYA?=U@)FHo znnA2|kk#L0@OWhg1=h$#&HFQh@Qn=Sl*!~$*-RRh%j9g;Ov=8QNuj!#CVS+{Uzs>>W->?0-p=H`JDDUu%A{}k zEVfk0(ly5{e)VJ#<;~(Vxu2UwRyd30(z{v~KfRenO7$#i)X8E(-7Nam&tgrtES_}N z_?}se{y2-HpJY+#(<~ki%_3)57T?HrSv)3-JF~J#pOeK`vPtZ7v#`w1qTYfmw#sqo zwls?+UuSW1c^0i!WYJ3stjQvFT^4Vz&*G3=mdBg3h&z(SJ4drPELUXEDSdrLaevQZ zgdG1fi-gO{OV&Ne;`zfYPQ1v{xt7goPd2%k*}A7Wn@J<}d{j0w#%I%TVm31;W%J3D zZ1zmeCVg5qwWYIEnUT%tnb|y-cUNY!a#c1Zzs<%g!{p}LY<%mo`BGl*&!*b1I(AI+ zu4~?nY---lX4;c%&OOa$&g*Qh70SU?B!|qRIdq80p;By)ezxW4XIlFx&^4FeCgk$Qq+G_yXNz;$za*Eer5e91mtkLPj9Av@Qt!K53jL^c&*k#{ zm0XTo&DC{{ToP{Ns+U^t?_Ad0%w>yY{*%imw{p27o9^TiaW9u5vRWSB&!y9YT%JGA zrP52qm7nClSGn|ht^5oj3Y$WFEI(R9{A&x*Gcv@?A|Wmm4e^gmFBamDs1S9dLzIpQ zu}_M`hWJGG#Dyr75aL;xkgj=zbe$ul>l`75%8C@tafF!a3}H+SF~Sq#U|NWfH$=st z)=3XBSW0AsXrCG4n6%9eu`CoKHXPzsl@NhyA(lwB>LJF~2=P)1)(X+Mc8H&4L|w(K zr{4SdUFZd@6IBg}B^Yb6SL`^>&C!?}VUjh&Am(JZT@Ia|gxk z9HL5>5bLDt`ytkL3sJUvi2U9mMt-PqQfxqo76Vnkj2NzUM`+!VA-*4@`C~(L8>e1P zQm-b5_*<$@QBS6Zcp)FmR)6P&=(k8Qmnh~^#gu|yg;=^O#NHpY4?k)jWW-O3y-~3@ zg_y84#BbX|ytzF@?cE_J?+FpHH^lG*Ar2f2as5b$r}Ev=5Id#a@emDvQ$MBTsSv61 z>*)~1e-F{>oW7PRe}p)DUcI;wqQjjKeZ+k?L|E3ylY8pPef3b9JPR@Bd58ipLTo3D z#SrGQHB9OFFr5;@{3fMK>Fd(^TJDw&laUyvX8ACuDugMO9AW48l3{$&Nm`&nn8s>v$Vg8g&t-`$BCd~WN z`t2}_-wCruZnO*I=@4dtjP4lb=(}MmbyED!ir+=?Wly&-g?fZZklj+SSD1KNEPsCx z=7|jcFwD<=!W@xdABFj)uj-JV{lfgvKg>rT>v33^SD%N893I9iXQk{&)h1))*r+g- zzX(%bMoILTFmH`jEIB2vamsIen7D~yD#%n}QkYyBCnqL{b?$^|C~r*-vuIkFV$;=2 zxh?Z%gt;S@Sz%1G!_=7*X0z;( zn3a3f!vkR|o>Fb6!#qC|X43gEr!R!5aZ&aCsT?kcSueA1tM_-5&t2v6K)rq#*6%ii zDf~1{(`V|X1k2?yI5Cf$lsuf(^XOe8k4sXZP9BZw=CM;;4f5#IFpn#8q;VdxP4gHj z&6?*iuSFh(TIMn6EsbrJ$Iy0pT<)KTV_+V$Wz5Vxj?K!W^6WgyF3RJ*FY`Dp>sI9P z{F^+wuFTW5={!d5%;TwCzm|vlMjrOR^Dvdpr%suCPL<8)>*RdyRLtj{lziTD=Cdd@ zpF#e7%5}=8OXqyf$b}yHB=yQ?x>O&Y&-fAfyq4oL^GTSU&uIB}Yd(**<@3jmd`_Io zr^K0jDoXXU8vnb-i|g-v`rOQCsASyA=i}S?+?K-k@@aZMpWTx8FrN{R@|hy@ALldi zX+HDhOy$Be-|Y3`QH1_$s+E^Q>3aCTe;TzZ(qdY#8PA6wT;O_jr(d6YAMZ`hOt^p5 WYCm3oa)Sls|KB|Q4;la8pZ^0mi$IqE literal 0 HcmV?d00001 diff --git a/Covance_UCO3001/browser_profile_4/Default/Code Cache/js/d6658a29d04cbb7e_0 b/Covance_UCO3001/browser_profile_4/Default/Code Cache/js/d6658a29d04cbb7e_0 new file mode 100644 index 0000000000000000000000000000000000000000..a6274b6b145a1701b21e1059789124989a3938e2 GIT binary patch literal 36912 zcmWjL1$a|eAII@uleDp>O&bbD(zI!tHceaH-5th;>u`4&&T#kP?#>u6++o9Q*pT7w zHhl1YU!LdlG`;uSbN+Hd+w`V68g^Tewd3b6!IDbgO!f(V`Jg-nOO`BIxD)OB<}6qyPrkgROXtX6Hg~zw;H58|KCSLTG0PL4#qMxD<@sRz4B6l3eqH~qU69~6s{ySL~>;* zrizpk`*9sBs!B_%Ne9uVI@i>aK4VyI=^tdPD|N>G?ozHE(g$pxAZ1=8`A{7_u>n`{ z5VaN)8_uB59;xqT$x|Xo8?hI+(WGRMMqz)cAl*l&(n0EnzGZ?GQZ7i*=vOgF4Jrqz zKW2Rwr1!0ZWNs6r9XJe6+aRT)7MdZUU6B67d7Nq=r1TC!DuyE6gVd)_kVc?{hSHfS(bOd)3+nrcwkFT{;^(};b#LHV!~7twXLLGg18Dm2fawetAewi@NM8|6mpP@`&x8Py3f^_ol!a^FW$?+UVuLPrB`;5wwWYk!{QQcB`oZYCqIgGlI)2MgI zoXe=Wc^QZ6`HXs7(5SRRM*Upas3t{?I)y-Sqh4Wn38U8GKGI4WH4d}UzZCJ7HtH5U zWjP0TIiq&tPI+ol!Kjj`h6WXlx`$sX8D+0*)NhEXV$?{aS2fE2ol#X$AMI-pD=K`? zI2`%GsIIk)il}YWLL9+G)UIRHthz=m$6YL`XVi!KM(t>3)MLEI)aI<+f*e~L)vS$C z6WSVe0B`W1y;0^4Mh!w(C!-Qk0TMm_t0iM<06M&!~O_ zjQVbnQU45Py&>$CVSJStZd7k{9%)pY(MCOlcZ^YoCK{Dz5_{$Uejx{Bn#LM4m-&cmoa(|duuOo9Hu{KSnmqgUNfrH1L8n`WPZs0z=TKav&XFUl-l4u+B`F= zz;mMpykP%hEn5C-)TDPtt$J^i@q1U`tqiCM91psn-p1e`ZqT zXZodJb;ejjuWC3s#dC!OH(%u*NAwW6UA?)fJ*$2+9zmBy58#DnvUoB05AJvxcaD zOo&EfGrS%i;}FKig=i)YBD&Ysrg=m334i7b(fb0dQ7}aH3xz1LaEQ(o z2~mS$AsUARs9roo%U~-JqJ}tuySQ1B_$!BKC5|Cel@QIvKZvRtqBdBAC&*nbMD5U^ zMu@uL4_vJsqAwWMfI2n{(aTn>**Zi+2Z!h{>>Wu>Mspo1j-eiKjwNPXni!&flS1@t zdWb&EAYITvFYbFT4mI=P)PM zta@>bjW_F0oX5Qcv)simt@v@oJuz98ov0=vZa{SDqvO*OiDFtKDMQqRW{wM zGx!HnvYWL4-{&x^37k32a^nOp<8Usss^>QA*Su!^o6oHH{KSj*CCvJ+q*-C5%vyn) z$WYp>A8-zZ%9ypcEcswud9!BWW(DHKpo(VQMYl>k#?s1W1y?a^3l8ETT2(b`bv3iz zq11O~y+V~5X01Z$@5u#g@E%)#FsnjMK4N8UvzFB{%hS-T4!Da#jm#>KX?TiijadhG znwXXQN3#kxHLF%Lvzp;L$~31Q_yT7OvvRgHs~EysoAnEFwl~Yv!K^3vfWDo~`~Yj# zC`5KKYe+ZhjX-y^p5t~8V(VpA;!kE}?#DVfFo1dtGAr$8vuX@Bt1&hX;rgLG#yYr$ znYC|(S;moOWgKNz_AzF)M{j(<@v+on9Q~MNR;S7AnW@x&8lPhYUcxoQtXQ1Hh1q7+ zoI_l5&HNw7UYTds<^^VjFEnf3QnQklQ%5*fnpJs?nXgyWe+zZoYSu)o#BGeQ zSQ`wvm`Kh5fgUHIuRy*olbvF{lB7q{@sakECAWFMSj&C_O; zILjXRiyEAx$LG!3eUZBV%@}0AOi%DTwqK==*VsGP*^`LAK@ZUgy|EF$-ZbkFI^Uu% zcz=hS?owOW?{N*LVISV1=6!O29uW(QqBSPs8L~b$D;b$yu{RAC1sg5$z!zfCJlsMh zvqf)E!)j5u&7unEXt&53X3;{YMUOBbf^(4;O@%FkMXpR1wa#qO2QPERTl5WG5-o~J zvShbyZ@kW>MeoEb8&SMc>!7 z=xQB{M%J}xA5P*u>Nm7#J-%U1Ba1RLwkQtskgcgj&zf1(zqv)(TUgW>SMZ^wMHM?( z^s2i>K|P2C1CYHZHT=n<+PH&}y)AO~v8ZNWi>@I{f9i_I1Gr|OMH>cLl<#MY+6=bn zIlf@^5Q|CHl%6N7M;QqbXdijt1XIJV^P8N7L`MDyvFQJ?C;IYy_FocTatj0_o}>@>j7g^~3Y?|xe_51{9_Q%Gd5cP4wCEo^zQq1Pse9y$7LSSh z348A;y?(}X2ZNsT9C>Nc?>K-PnE#48;Rx(+xc(D+7`N~hvp+NbKi0HZRnux!Qw&6e z&8irz!g=JfTa_`)s(6&ZVRR3-YAD{}aHLfZmsMGiAAg{02CD|+4Z1{GRVJfVi=(Zo zkj1L;D4314kQ8H82RLJ`ss)?Zs_M8CZ&h-FRi`m8(W=!rj4D2>i~+_Y4ZovKUaOYo zv+6gTLjC+!g%luWjK-RZ#Qe6^V$b8rKl>QLvpR!ynL zn)O)|ThOq9RhEWUMdNr==51!x^j20a!9LVzZB=8K+gLRO6WWnudvfeRj_B3Vs*AXT zY@Mt+gaVzdDvQS`*u|=c7}V7&dpEAdweD6G>0{M1#15br1Fag1LW8Ud`kx?y)f&wRcGGteE64r{+@k`@DElsLOU2gS~co3v3+45e`QRN zP0bB9b;W+8O{dW;*rpR9HVro0Gy#WD(qU6dxJ@3XO{wUP+vp!*)256zZOz0uJVLW* zn>u3!DrB|sTDDEAve^_DXVY4*P1{i;-X=?;O;Kot$Ry@QFZ`Zt(*YFp+cYP|rj>|G zB}RNrv#EZ%O|9X`VbdD?kkiI%e>ROrT5g+`Zd3jhHvPDgJXYD%cePDb)=>L(Hci@O(>(0`o!+7Q7Ms2xWIM6#u&K*# zo4osM`W{VCalcKu4%!rZ*rq#piP}e~<59+90Nlq|2bGT7)aQgvPfyzP5%o_|-_tg2 zK0__e+tm1iP3>_DJuWg1A1>MS__9sAZ`$O0NIY;oqK?>xPbl@+rpdU1VNY$U_u8gT zZ+QHcTK>y?aJ{qX60GlSnuX<<|AF~GlGi7j{`*W{zSxvEvt5<5*cF@AuI1V6vc%Yx z-DB4U{1k6jOrl*MeRds9vCENaR~8f~Wmi{RM&Z(SRluN%cD1c)m#3OtRqzv*;1rzo z>~dpA1Fmam*M7WiVb?b_ZE06uc-z=j9~;rO9oL~k2fJ#aa7Vi)BX=jeR&=rJE2?+3 z>vMOz{_bH{k)C#S$Il4rWmn4qcJ+j3pk40<+hrVLSD&GFjYRM;yNaVKvJbbbC|=9TVEvhPEyQ|co=tvej=gj28akIekz>AHT`&-TE@1A3c4b7#MdXMH|NpqyuAMlF zqD!eQj-d8(yQX0Y)~>MY4vMcL4pd&v8kmGEYwSu!qqX#A9rrDJ<)qB`(vA3_fcXyJ;o>;+d)1%$p>Y2(GyHV zi`{lD#s&=8L#@zmFW2s~E7yLzG992UhwLhbaeol^QEGUMoR70t(e?y$oh0s4c3sDm z({?pJW7np$^cL0rBIk2<#hqslq09yPj-M~um3E0*V(#CZziiiZytzVuuiBO8Ix*k0 z%Xf?YhlZGh`^bBTeR!9?qw_uLai1FE-~;ONkUfG9kL;@Pm_7W&u0N3XDf6MkGrPWf zZr1@EdqJ;W*)`{lU2jqPE!W`tf9+cE&aM|I^PbPK135mhhoF!25bbaZv7dO(U>~AC z+m-DL>tH^X{KxYS&+rKeU#S<2->5mR<5z|1pdnNbjG-!G3RMsM5*(@@&7tauB@v;@ zkSSE%<9Li)c#dmcKE{VCF(Fi8iJ@wUsVM5>^Q2JC!g74|Gha%m7GYspsPg6v)$ZJ( zI)(yyLNyJG@hM-Z9_0_!JJc>1s#PddC{!2mL*Y=}M(ZM+N5-O|`i7RpLbV!miihfa ztx(mg9jf~nS0_|m>W0czFH|e=sbQ!FwhYx+d~6e{x?MxH1tofg^7B@xj-yiFP?hc% zs?7)*5ULJCLbY{dsKTd(>hr=-MK7j4OF~rd_V!R6*hQ^(lh2+|72Zo-_EGEooIen%Ne7wpP^d!w z2-OvAIufevM?-ZI-yI{Ss{tDG0Y(Gal z=R>vg0zJ7Hs`XfUEmXh#6RIlLL$wBvZiMRkO?r7JR88)Z-;+?y#4;3qO5D#v)dENG z4yNa!YJ=T4j{Gk|H5e0-@nxu5p$8tK;HyxT$6;iCO`R|YFYy%}-h^rgj-b@rP))`H zWd1i)&CmrG5qQU3ScZ2ny{E4D1Lsin1J_|4(mzrgjKph{_!KJpXXeCAJix!`@rAf> z0p+(FF{hnC?z(#;OOCv+&c#i3z%iegrW zW+KVvP#(0!LWJ2Js)wD(6Y9`ZggP8r6XsA%xI-85htr{y2#4mv8R^g=40dyUj6)$F zhst6*-eFIyL)GFOYKl%?hwh_VyhCSj56KA*)yFVQNpxr%?x48Oq1Ys1$3k>VcBrJ^ zp+|U!TPehu#+)#xJ5(;aL!VJS2W#YXXlX8oI_7cc6DsB9aejxI6<~ZphxQe6C{Wm; zv6xoGp@^amy)NdEy|_acU@GBIUF0jtT17=H7dy*3^iw&9o*+|sa)Pk} z>*7DyDms)4Juws;Dm!!ym#R7xRL!9TG(=k*!M+;w1s@Ui1M}2$s6;J?s$x8jpi6D) zTgRc*Xj|8z1@#;%Qs1HVh;86dg@z8DKx`w2MqmT(Hg+hosY83ws~P99p*j6&;ZXCI z#MheKum>61vKC%-aLCuup|dE`$)So^ip!nJzYD$VO3vNLzdOAfV<%N=s9WX)9$by)4t z-`Ky#A@4eevLkjqdmPSR+5dQkgbfZ2!4ZW2#va0t8yzaRi8^m~==kr%w3V1)-cH@o zbq96bNesKF^=@L{<4~)8^#35wizCF3CC419eUiO{^{42?1&88L2|*W$2fJ|k665~n zxpR#*{~>OayYAq%S%(ra8)tDHYj09tJV%~e>=~Rv)d$oBddNDDSO-B*94dn}`-U)8F@(SX0CdGzn|NkY2>4ZN_wNt`mN(VH!LjOrAmH^fTAt zBPI+EQ_4_kI6O?fM}+BzQLKeRW5bkp9LL6oDf5IdoNY)0%VvbB+RQNBLeE)Yx;BS+=Z48QFHCXs!}RL{;#?G_9vj0Hw1qql zhH2Lk>U=azX?S&xSg(d@==Ct2iV0Wkq;MrQ3|Agx>JhF448dmXho>iF&>S(n!WF;; zjQlBFzo2>VaIHYsKH(aO*uLRP!!Q{8h0BSY{lnD?-O+78xHe!nIu8t2f7BktJTMMs zJUXHAuy9Qr5w3TrH!@r=M};eObhrv)*4S|UIw4$ZCUSgAxK2$C*OKYsYCR)df6ffo zs@dV%f+BOm^>kjivds^dAFc2QA{MgN(r{IQd0Du!uMAf+Y{R});W`QP8rEJHu0!j? z)n#M2Zs51A;ab0q^E<x7P`K9p5v~Wv!}a6YaNWB|Ev|;E?yYd; ze;BS>&%^cNExCRO*SP<}H9N?u6}Vz_@;$OsjxeXPU~ITk<(*D##Cw<`oZQpm)G{=R zbZQD7W_9XcjEZ$?35v%#H5ch#r^ett=EXaeF~O-!iB63}JD*d(_?^m=;*>8tYv*%n zQ+|#YaOxWN6m%+~s8fMTPIa&BRFSGq)%eb-(my!Wv!+uYYB}|5ZKvYu5Nlnh$~AEE zGq_U&n{ZuIr=B)r?G{dXTRQcwl~c=GJM{!5+Bvlk-%zkUxnTotAi0B6!*By{J31BA z$*I(?PWA5LRH>d$#rATl>Q7F+!LPlY`mc{uxd%EmWUy1`hdOl&tA{(4GLnyD$YHEg zZO1uf81K}*2~O3T=v1>w%rk|&raBcl&8aqUO?Rr^45xC;a;g=&V-3>haUEV`#C#{e zyC#pF)Co`U{VwXU+o?%7jldqK3Sc;j?d8}Z`t^rXEwCC}asN-JIvru%qx9^!Q@Kt$ zRsEDx4KeEs>z{S%8R}khYUE9)I^1%~eA}sB=yQi-52*7)r*=Q$+Q&}rqjKu<6YBJw zee=SpKVLaD`(OHrz8@Hmr|A6Ass6Bka`N+=Q+HABKc`M%`ZuROqJLC`w&PD&GDhfd zrU)I0j?e|1%o3rdF%fDT8==l|5%PH>^ceTzBeW|aLVqVlXsItkza~d$MIb`^QX@1w zSA^!}kI?P{5h_%WafKpuwQz(Yi$-X0G1kJ;;;dCNLc>c%D7JKjMj@sxdG^W5!14`{@x{ z{(x&^Beg3oQnmb%nvo+?OEDy8r1IpBRQ^1XDpNgDHL$Tpq(0S*RJ~e!MCUq@>QOIJ zjp|1#YlBERn?~wJvq|e(wr!-cwU3k^XVIxcr0yc7W2DAoHrn@y zWKT!x(a({(Jc@ZHN2=AdNIhQ{sd?)o_2;jVdI9&QNIl&gsb984>NQqvja1ETk=lgt z?UDKcn^AH{r0&48J5p27Vo#)u`yw?L<@QHvEUq3T=0oI%3&{Rwq`G0sVdh5dBau3W zE+-=O<|K2TiqygLkvepdST99t;FU-nLFm;;6}}d!mH!aujYti?6RD8x$; zPa@U$d8B6II3~Q{^Oupj_Kke;om`3va%ntf(ZKdmj)*wk+_mvdW~(#E=BuY>VoSjE)@>AR3Ocz0r(S<=`J$`NhflEajy0ohiu{U<< zk0vht^rK7po04~P@@VPODYR-utgVR)BigvMc!WzSV_ceyfAMJ?aZPfm2j0wN?pf3j zZ=l&OmBC~zK$bZ!ZARC5^cNpcd_JG!Uz}d*((?6;-@ts^IR@hnmm2S4U*IJw?xwf6 zi#&T=nu7d$sVnB~Bfo>3$BIKPHUE=6h|xz~%5}`8W}jVJh%A{hs2qADcXS56kIkSu znKNj1jtq*an?W;LX3zzEJCH$-Uu4kCcNz3MUcw&~rQhvQ+8P$6sm>_9K%4j|EywHP zQ94mFN`Z1w%3dW(v%Zf~-MUfgh;E~z^xgO<<(?WP!_p{z{)pnW&M5WX6Qz-dqO=k3 z(epx-BCbX0$)hM`ejKHyPolIG+i@5p zmr+NSWmL+|jJkl@Z!&82=Zt!Y-I+3RZ(JtL&74V@>t|BiMtp3NNsVy5X(m-|o=Gw7 zGO106OuE-8lScN;q#t`{QpZ7=^xdvZT6Z{;jHfaw_-iK3Fhr}5H=5T5qV;`zv=(D; z!D!7b60JW=Mk{N%Xm!N-j?rq>DO%rk<~*u*iPnd%(c0ZDT9vv-tN8M0UKft$>s7Ss zXUeP-$(ecnW!9s7JkFn4Eed2-pF){cu4HC4EuC5K%4XK^@|iWOUS@gvW>&UWnN@v6 z7CktdMHm0dqKKZ^WLlF=h1O@&$|Kpd6Q}X@Xg2-&C7Tv~&8Cm&V{_|is9X86x@B;? zxi`eE@9}Fvw{jJ7t33AN1lAOGt6CAa&Y*5lw+^6Nakt*1W(npf<>vh&Zv9rqt=whZ zDuMC1iI8$`oht9v#)@twRB~%Q`c`)9I&xKIUNl72@7=18!nNG0h*x;o+^te=-RjfH ztpeTMT8Jx%>fu%r=A%nbw`%luYbYk;3tIIdX2kY&YXfTbbL$vJ^>?e@AkO1w97EBe zZsi%~R@!j43gHbJjUYF)ALUkW>_F?$ZuP)sTpr`r1I!rf*0phNMNV{UEau}jUSRqp zxBi{Nxv6gMy>e?4LVuw?ScrQ_o#s|cEW>@Qn$Gob&!A4oJJYSsScN^a-1>~bY`1P< z(Hwe(dUJ^n(epTl)Fp0BTk6&lIqX(Xd^ze?%vra7z>heO(ihyy za+N)S@i>B^*WB8TEZ5zdhmBZwgFJBSmRlcgyOrTS`vm15xVh)bt!T@$Hu57vc$#66(6Iv*p0M=82OW9 zn*2(04KV@cg^PpMp7**&Kqfgk^FGkn<$LJ}(42;p}K{2xY93#`P7}-b0DEp`weg_w$A(LbD z65&%~lx=Q|@}MOK-~ckti&5$#*22NXrN6~(Tgn9{q=Z>T|B4M_mxq$fGKl z+1R5(KYEnd)FVSPk8+_sLYjND9F!ZS z9L5FA@8QuS)a^wre)8xtR`&MD(Z{2#xYgIAlztwy!2bS>AK=j%>>lJ%x1Sl0?n9}^ zFpr84r^d)U$)gd!P>1OrZNhzIn&IKK0_L4Xyoi|X(OTR@ojI&E*Q3t!JPM!h(LHQg zKwpuz$fLN$jKO7Cmw5CuDlPNqCDt$Z=o8Ma@MzQ;VqZ%QH+obHtuX})a1l*6u?DW- z>t>HK{_asHjDT;8M`e+Ft4Ec$F&4eId$bC7kb4Jp!?B$nRo&%LGaSPud_#fV9u3FD zJs!

      |T!s;4C)pC%*&4_lHLhG4xN5&cS=wqXRg0gn1Bgls=#p{zchi%yXQ5fIBCs z?I-@;nHMr>s=hx~ z*9yhTULsbz@OPP5-Gi@UtX5Tu)fS{xi{<^bjK|wLu?ngis~#v?KUS4cx^b*(cVvw& zvHA;dyTvN92lJqGuUPI)X1%!KR&%ftlYWcUZ5-JctIC^VH5FHpzByL4w#2H~wpjJv6|44# zSoc({CYN+zS}1)hP2YR$cHE`5(n<2{vH=<5(4c8mrCt@GMq& zpHl~Xz}J`L@H$qH(D8k&_Tn$p{6LMr#OlYdvFe0N-(odaaawGM(+1==#pw^+3XM}- zc$~UM#_2x%o;Wo~iqn`toYL~dX?>A6^=uHQ@}1-KsCS$!Yva`LP@Jxwj??6`aY{ZH zC(ngA-A4b5ak_{Oml*SRoccYC)7ocoe0_^ko3C-oYw)TR{=zRtuh!ryz9P5Ds{!x^ zdsQ~Xt0c2mX%?@Zqo38Q$q2Q1RSEyWVfX4cB!zm_0SEC2_Z?ndie|2GujKUdeoU`! zMKBMlM|!m}%ByD?z1kb+<@E)xE?`tnuV$i1E@H#e++MZII|G^yu3%itCl#1|4_TESCjCpoLA?{dvz0; zDtI*&{c3o%;0Lb?*Y&C={;KEI<@)4>3Jtwlh4@C)v9VX{nt1i_N3VuA^(tR8YS-MW z-pJX4nY+#Kdi*> z_>4-Yy{e19(DjU0yUu#~K8-s3 zynYUfm)#Jrk*H&g*DO=Ka+%|~4L@FAY#a}b*LRM1y~0peyy~XM>u+=^8LtblmXGIm zobg(Sy-)?tVE{%}jOV?I@p@J%URA5dtJ4qh8i@5ZNBt&YTNIL@N<(Rdxh?ql(Kf)8kOoOtjjrk;q`J4`znukcgMhnwhon(I;Q z40&NXp2BiAUU|=P9!oLsJmc{Z8!pD{HX<*vE_&l1JjUuP@w$tW*W#6WogSbahTe|X z*1Pe#b1z;|51ALqkBRwNJoi|{tLY2!eo5Xq`I`E?qgNRCFG1< z1tq9HTH`3H8WPk11&s+hk2R(Qy+?3xf`(v12%qC8bAmcs5+rMa?&B>6*%CC_o}l@# zgeIsv2BV0Bb;1+$0Rd-%hG8mVib%`&@Whm4c-LpMsR$B zW+Qt7^W!0YNn~zB`4SY5sd$9nlM<9anHW&jpCEe*W3dP=(i7AwdxGlZNYH?s3F?}Q zT=FDv{}OZNPf+th3A$J$L4}JZXl60$hK0q61D8uA@O2|WPf8}pR*GYIgkz->^mo|= zWiFQ>Q{@CT!3h+slAz`IgxXcf8Qq&F=s>Ro_56w6^kL3^392!KIu7UB(FvM9K0z%f zCaA)6)|thaH3?dVk?V+QZ-Rmp75;YIo5#Bse9q=A8EfQ55w~?=9qMme3RARS84e8GD9*HVBGEx2T_bBEXlcj@B+5NEk@s*VY7(x_OH}#!i5i82*tIB8$MDnQL`5!5RN>`` z>ITz_MBe+6s8uTy^#TJ{GY*T^CMxOIL=F8tQM-|4Yoao3OH=|X;N%YS+nK1TyAt(u zccSv{A$Anom#A$hvOiJNFyv68_M!V9%!Q;s$pf#@^9Zry>aj$==T6jkTtLE!L`_D_ z$wUo9#`B3Pi^158$H;Oak$Vji)fbx)aVb$Z@DvGuC+hCyL@m6Ms0LSA?^>cRA{G7qeX{-FQ#tg*uv$LltK;KuHTdMM=hMoDKKXkzQDSb$H=;kIvw|E*(skkBIUGC>v8^!kME~_ znu}uRSs#`QK1E;jsre7r%hzTd*zDvvxe7tYMrzVemdid0*8_%fAb87U;r*7|j z+*9t;-^lxk>tXrqQvvkB1SRPR5)DbR8k3X}xlKu`WlmDgOi5~wBhg9vH%pQXS(DTi zY1xw0HzrBj(B6}zeh7+9QscNJ&GIH`1^&fpUy}AEC+VI)Nw%U%DuYGE7+0L@FdZvO zCFvH5l}VDlY?7k!6E5OO#U%MFCFvTTqFZI=tdgXqRg<(4u4+j-gE7^Kxki#^U@5ND zOj7mwN&N0IN%tEhX-dN+Ex=oBZIq-wO_H>`73;N5Qe}j+Ns_T`60gG~X-UTju)ECaXKvpu@9d&Ba?J zJWrPUMY3KY=4G;eex0nKH_0lClgRisSxvA4$M6xI-x25gWbS)T)@$Vckj(GOlXV`| zJ|$}k5mf-?ItbP?mKdiwuIBkBFKo_h>Q@dYX@g6lD zew7LH>wEka?$;MYMfx=d-?=!36&d^*9p%>}yhBVzzy8g{`Dnj_GW+Gt;#Uq#L6@w4 z{gjRKv3_Nb^J|>fuNm>=hA#p6pi(KXG6-cBlCDdv?a=^UIaruc}yG zfO;16YXT0UQxU(0BUe$sULZp;@+?vVN^X!*YIgz-v^mKwT=* zgDQSqMS695Q-dD;;8(kv)Uh@_sYC7S`L(vbUvC<4ePcfU$hfh3@zq|YOw1-~> zdeYNgex2)se)MGk@eZW7BmDX}(yuzB{L&b|22J34w46x1lj!GU`Zv?Bq1Zdy&)+@p z>&iU8<}RS$3;jx7>{qEZemz<1=ldk~0{X4@D{O;bec<@buQph|(J$X-zvjXDJLgbx zE9)WGHs-()B<`R#yZst=$*;#Z{i^tYc~R)0UzHI4$S*f)KlbYrRzIOn&)5sk*{?6S z1_>|e!7IP=zGhyWhT)B058nF~_rcHi`|O`je$_xvZ2sogb5ssWQEo$uN?m%>xD)S03kktzCsHLeuxM9B;(nje+I@9tC77eSd)^c1ntDXNW8=#wRd zzu~|&SyNOm8}p!~Cx!pBQ}lOiiWrB&Mj6FNN1yQWTmyMQ!t> z$d{LR(FFYq6B9ZXNznipi>BzuVkt^3o}xn7icjcQB1K2brD%7R6n)0}swvuo?$uHh z)*wYy@D1S&Q#1{)8Qn+6~Mbmeu=sZU5Nzn|r_fo5UeSY;Z}+s-APg9d*u3nzG3jg6qSEWJopv2pQI??(-duZo}!o+ zDGDI&bBZFq@Hw)6OHpTdg97>yE<-@^@E8M1a|YB6!|^u~A_B^V-!L>XpeqQt0_uWo zxP;0X0-A(!Q2{N%5xjvi22=n8Fcx1?Ia5I2P&qoFdKi;Apnp&)F`zm)fGfU$9;04T zK&|mtazM3G0*VX-^cw9_SqB?%5>3+rT8Et|l^&2OdqB-`4Y_j!xIZYM4{+oRs1V9y zB5vY2M&t@;GY;eqD07~GienF~c?0T!wK#`5`2w1YVFdz;Dil!r!U6q`mPG<8Qj|GS zxmZ9q5LP^(?)Zq7C8!_fmJH~>QUMh!O`K%|{QnnF!-@et!@rfOS(Sjw)Ti!viKYz# zI*U8V(=ebaXx50D!`_&Dngq0>X+S~E0G$f!~!^j_1#s}13VnErZ1XTYQVw@gO;TfF6SL~P>(BAnR$A$#~?L)bR^k7jy zeHI6FVkhVKa2^}>avtUOaejY5O%4Rq@kl^x(D-OTosi`iy*b6l)ASGjVDg!OT3w`9 zsB?+F;~6Sl4yePGfcoMn7GDdystG}<`fNz$wT)Cg#TN`QrRqj-Du2TwRcnyPoT}$2Y)O^VnyP9D zvZeBV`BcroTYIXGhNh~2WU98nl_6DU@DJK%N>!)mRINmCmQ?M)VZ6mJ38}L9QdJHg zVNFWaL_AIA+LTm1K~h1+6-w153@)6iH?WptJ`5|Lsz8NQ&8?iO5>-;Q=lfLoYNhi2 z^HgQ7ld43`x}wLs=K4ho$NR+6_VkAXR@)N>z*L zsmit>RlOIb^0hKmW%s9Q5Uw3y?t`h?iU;`PNUDrSsT=-8m1C(|bv#x3PNeD-{3la& z5BJY=-Gx-eT}q-)_;z+o_sP;H zW=YeGtZ8}>lcqRNng+(EsZd;+%A-ByNEQwj#pNz+b5&r8z<+(y>`e#*|R;^Cc9h6v09qylj)MGHuiK0kzttOYPHD6Xm)yAJ+9w*N{G3 zKP_Fukv2PB?GZC4UFrA>73QXE1PabeS4HHRPmGJw6n4V+ zAglrGYg&ZZzOWg$HiNV1i>n*{|#sx+lH5drDFE*%jO z5D-OBdT&aX-lQwNxBr*_`@YY0eXf|v+~+>$OqORinYm|KoI)$&)O#!YY>U$u=(9ae zS$5C|yx1A10lVV#Eo$$M)3QB`-y5eg`>E~EIDL4AxaZ>Z*7-QCMaG3VRk|3b`Pa$g z26^N+$zH&uAnv0(QRW$K?f=PX=nsf}8P$15v+-8%CU=ylYP0FZgQsze{CD$_PP`pWlTqcc1T{mM; z$zxK-W+r{w!o)hhCf3R_X&9_AlhoIw#`pvU`k55zPuu|}eLL8s^dTm7LglYa+B|{$ zCz`YXZ6}#DWSU7S(@koPVlzx?KFg#&3r!k>DLF({{5mvfnQ57~2@^%)xHF>7%?vx?_8>qGpBf^VBOq@Y>7i2m|2VPL20m#A3JtS88AGpnrKtT;?@n$<4etX`N= z->fBXxXgNiJZ`hr;4a?xnbi#gQPpqOmjN^DFPW7YB6ifQgNbG}O*YGxYSs#Dz^9GP zay2z8idNWx)y>Sh*21jO>1K`1V2+k%6~$&0Ze^B%xvj~sqgfL%7Y#enm(JAkxtZUU z%$nWb%xBTeiB4na;aKKC<8kCT-OPEeW~Ct4OtYS5nzeV1S*I{&u33*3(C>w2oj|`u zW>xsktcS?4#LTrQ^kBJJ`Bt0d*~vIOMBClegd0cb#c{J<;rkP2#r`&H&sq9=!K`;5 znbjU&qWojCK7L}>k*8+eeqq*~SM&%=UQ>fCdMArTO>_&d8dkDsI8v)yRMTWp1Kh-CW{YN9 zEQ-{$=&L#wU3Xg4w?6TG7M;XZOz>OuC}2_cphZQ|7wrs-z71P+4b7t#o0|m>Q6+3Hvm)Xlyf!4m7uDUCg2nKV@D#Y-iDo_7>g2ODyR??2g3l zY*AcS=EBQv7R~HoVJ&rw+J9l;8ZUZ+&M48FI{R2uxF2x_5eF}^WUxh5zGB=^i*60K zC}V_09Z_r~HGXT+f>9P-9Bt8!u@>zgXHnVl^aD$gI>Dl46D>MF$)Yk-sAn46XIS)N zmPLnVTl9UVMT6#0>s(%6YEh>jESj>+q6a@(q!ku*SZUGGpV)U5u~%CZ{h8O+S~P5f zMQ8u8u(lk1-(pe1R*SlB|MkFsifRjcMBt(sLGaRwD?STzCtYg#o1!H=wJirsj-wp9Z#I^L>GG_7w{JN%6@ zF7`*2pjBNAtNP(G9%4m^d@-(}RZrjvTeS~Yu_IrmCRlX^vy!YToNQGLYmhyK zTyO#2RIB0|TeS_jnpzcV#y)tjIekFk7Sx+&)z+3)9d2dS+Kqcj~GkhGISLqUzncYK>VqjJ)^issVap8E&HD{klrWWb8+_ z2X$2sU9lJ!Q2b$CrNC0Rp6vDNshP8$(m$@J_jcCP{Ten^jruRsO^=WK-$IHud?=rtV8@8iehr_PtGWezmdQ z3UmF2_2h_+=(@qCJe#N+E0A@wO_#UWRBx+Ir!jGxO%1lwyFE6&x7VhFIEOa-Y}&Hl zroIPl8iAgF*N5xaYhc$Zmt7li3j_Uj9mcgN^Cz$`uHj&!U3rr1YMX4A zBZXKk?6P5MnqBGXcD2WN{F`A{rIvOLZDp71W4j{gi)#pcV%M5Bb|tm7t7$vCCgApG zb}egf*E*cXR~@MlB|F=72QN{s3$bwzS$eP?b9>u$5_S68RivL?>7@LMpDNpyW0F<*Brc9M$JFkH3>PE+hzaRuAVrw)~@-#+O-0Qk-3R| zws3s5+PT)nu7=y~%Dc<10lPT{`|R4a->zy0?D8D4tI=V*E*xR|amL~4-*!zqY3I92 zyIP%M+!?$6ylB^lH|YW9VAQ|#?l#BxiCw3j+O;pMLuIo$bS8&G#d12dAeTccar`ZZ z3gvTXa&ZT15jr%btV2ieO*x0AqI7wO`c!Zz^npW7P^5}Oe^hm-qtBtGNcTIqrp2NA zNC-Mqz;NitM2Bu7Gs&Ul_$b+-@hJ{9Pi5XVO>TW1{JqXx1Br=ixICEW!yNh!*@ru{1qbm6zl>nNkq*AgcId;Y z4rO4&G>1k{cW4Iwz~8sI*%U36#! zu3U0x!exiz|8=MzO#hK5wxj$Vht8wuYll+6>aZ$?*?5-4sl{2Hs+!ZOb|{t0scQHM z1@bsqj?bx^css9CX9_y?u!vKpqE3w}=2YF{PI;<1H5eaNcgl-Bs1)ba6+FNylT$g& zPQCufsg6#kmLfggsZO|$ga%H%Kwg(q2awb4)M}IqIhBFJ4V@~FCCCvbFJw(}%7N+0 zPDN6jYJtJ%m`Z%4Hzq#rBcUmEG;``bY{Zu4PHjzd>T2ZJ6qe7O>VooJowDLr6zNWFc!0(|oSHJ!sU!I2Yp15dGt8;KC$axjr?Sjs+Z^Vd z=hREAobS{o_!l_2_JuhXIraTAr>-T*;|a(0DZQ!`ueRupKap8EUa#jMuyP03X4N6tqSU48T<%;J#s(AUl@%)VvuPy;%8S$DP zidS5tcx?^Ga}S4jnI+9n09~b8sxMUgPQamnv!`R_2 z9l}L?Kf=YoJ1(^v<r&10E`5Xk7hPJ9&X-&ofX^?xD)=QUufa8@*fvj%*fRowWtjpk5uk3E^z;#4(xLKFe zt$A3Em$2t_%fL@)kjt$(Fz0qF4c##v$4a_&xHS8{?^YM&E8|ufgx@IZ*1yXTaoVqy;VBIKej+(r+#TU9-7HN|Exbz_{*tje^DGcU5qqbk`v+K$^emDi)q`8_&};U9RE?L&{cVj>RW z0TL^El!+U7P|2famDvXiu^F#Xq^d`D48$mmt>#hf>K?6wxrRq!w2AZRTfA%Xs1g$2 zFne?ttF0c5tLf2N9Qw$k)3rT1Q^%vibv?>u_oy7&A*++|h<_vAqqE52@~Aqz@Vhk9sAp(7x10+ zr~`&z%_Wac;?`Aqdd;KG|9UhD$#*>JkCqQT8V36ljuXniBu|u*S3XqB?NuT^eaowt zrM#-}o>%S5cr^);>R$DL)5PmIXZ0#iO|N3Lyc&*4^}MX{;#E$kS7uyo;8h`)S33e; z-9gEyR}C-?TktT^t5Qi`b;oSfOZ6%Pzu*E2HT9|vE;jcnUkk71Wq7p{<39FspDeE| z?Y(M(tew27j{V)d%H7K=D@qUW%7gy~c~yKc+rRcI4hO&Sa=wk1wUNAPiC=LM?~U=w zjTzX6iQ~Qe|13F7@XC(%lb9C;Co>k6rh65}A{<1{S>%8VnO?m$$Ey(wy;^}>i^vmG zzVm7WK3(e7c+6Sp)pnHr$*TZ%uJ&rr&-C-6S0?zcc-0XPkn<}2eB+u|f5Lg)%jaBP z6}jc*{57xA(G!dCI|@D~HhfRKs`=Ebqp&@rUMzj>RThr)i(EdP+RFrI$oQ-xYS6{zb|UEFp0 zR4U%5P63}T1$}BC^2wLvQx{Bb?$cXoK21pX>HQ3!7Ps^%@nfH|xArLxOFH`ayTzwf zU3_wN^>J;dPkX-b=?>a_=~FMvf1{UA?%qBf>ElzQzCMk^2~_OIa~#D*Ebs5rJ^VR< zID>pTjv7OK$}!BR3!}*^lipwx4&fZabA4L6m@&xmoln0aX(MyvEH-SS-Yq`8w}WkH zxznfFcyAZA@AfIS*T;F*)OL{hFz2vO+i@Djj&K~{Jm%9U_#1hT)7Miz6+Z1#6`VN3 zbJV=RalwR(V z3||qyI^aTazaFDp36%6}Gp>~KYj$bB&b;xyU;WGYS-;TF=a#&VIfh?9;nW);zxp=x zD_4SF+fs?!)URncj@&K%{QK)y+tz-KLYDS^Rl?2B{VLSeuaiCe+*H)Bju?O?Z+zkB zeiMHEjOV@m>eScIngV{+?dMkl{=(w{e&reH*N(6JI)P$C{W4(~PNDYKesvw@*N^!3 z8^2nN@M|#EqtCZIj`Fjfh+k{R_|T+a|wCp(YyQ%2r};<2jDu+;;NbK|Yv=y>IN~ z`0ny^jk#a%uCdT!k7IjgBt%(!xeJ4 z>Q}`Zetq_@Ur*8Ywx4S={d{Ii9e4Tfdw$ki_3H*oKJcp!8sp1{pn_Ec+FUK5 zgXmv9pz<{Wvd8fnR+|Fajfgp*S(bn{Sp&L;{2vAM6DrmUC=d0 z8z}7xsH8W*{V4-_HyB_|&;aZ21hl+SKpXH&IG`HQfI46;7A6K1OA6?%XDmiz4UVPZ9q3s_0xcwV>{ZnBPV?JSwNNB z2lTQ>fP2;Ai-2~b{+9ub_&T7y!vp$ebbxaZ0-8N7ph=qo+PH-}wg$9#Pe4=kY<-d<=3Q&!GOox8s5;FfFK37=fZQs1+?|Qag&z3i9t6 zb09shZ{pN0r|EEH3oTikRQ@_24&vG zHk^cKcTfqKhU<8YTziB12`Bdj)op)JYYzwY`Y3%mAJi*+e}UtGIv42&@?Hw656+{; zWnM>xe}Y`^PLHnyH30v?bT!EO0>s8A*MgdhkFPWKMo>FY^d^109aPT;y!J4tt4Mo9 z-nfB|kLfqweiBp{?8R?SiSdm1$aqf9aJ-;C?8f&m$?+BMLzI6VRDZ0+Fd2F;i@`O! zhOT8bv?H6rcbtYQqC^fuqws4^Lp^gDT7^Bi4b{zKXdVjWHS`6}BlRsqyHGQqp*hHx z-%wv%M!0~XMF_ubu%@%Y`7(xnC~PR>9YY=8HS|5U7d2F*7_l&-xS>ZS3_U4nXnZMy zbNmfuFKuWlD!y;%7qlp2C{I~K=a5|9&=TCmt_sBafIQ)?MDCRhEv{ z(UKk@sTFzSvyTl`_{7iyY;SGwxtXCTI%70e;xO)^P+LPEp$SG}2P%EavBY1f-p)`a z;yyFtg8r&pAFghAiC-HNtdQyBjLq!_d#j z+S5=mgm4_50fr`E=s-gkQ1~lyh4pLtKElvrEE>tN`IbK6I;xE_^f^vq@M!kI$}#k5 ztfBch1C8SmH?VHJq0JKw{@$X`lj$9jrWo3Zx>GrZ)9BT7-m|l)FVkSHRr-Q5b9i6R zH8gRap||H7ibq3C|DNYdc`xJe59InI#}0dz8|t=#_vA|I!8bn{I)Zkq3>`&})f}In z>DyXkJkD&Cu`-)b=}b;`2WY*5xE;9Kls2Z6uGa_Z-wyLLjD<%Gy>*mheVklR8me{5;5#Tor%%)S zGlo7q%X<*7@XI-VhR*Z;zDO@F@%}>QWkZMlp|&fA99IoZxyH}fbwjT)`X=wCTjYs4 zcX_`*qPLF?)y6A$p74HuO5dLIvxv`L@UxdM#QN?bmCPUFzQ`ecQXr&}MMH8G3+Y?T zFBMXeav{~K5YiL0`5>gMABL1sDWu(1LaI|Wq+K{xEu;q3L;4FRYJ}9>6w)_1h;8N& z_xK?eR^T=Y)(ojF^4AK*FbLfn%kq}8~EDpC50Oq|3!2_Z!>3OkS`F(f;> z;X9l`;iQnf=!c*2FUlu})C8lk1rJa?h1i&lL&%jHk`vvq5a&>;aY&6Z2HWuz<|gz4 zb8r~>n}!s`5Uj&}#5D_XK4VBf;5t5NPQNe~+wchH79q}eq^G!y@@XNZV=4|IUwTL$ z^umw0f-*7UU?L9S-3I#&kCyto}o!5 z4QtrGuqNRIo*W3P_Ce~z zQw;nwtkZvmHSQ3-I2x7>Q;&s}d_1g{m~(=8{toMRlsrj3SbHk0&8Mm5OjxbXlMkL; zpbr<@_1D9#jZMR5%<_0O{4^E-~vx zRmvXKb!>JJ%N11vPgFO&QN8j<^<5yUcQ~rj7>Hv1 zqe?~Y0Z|o4CY}$BYQUhVCgLIH%_I&c%pwjd&n8YLW9ASCJ+Ws!&o_`C_9F3j>imNm zH!@~tROc~q7j>b^?x=?CiORb-szT?YiX!Xzs0w2m9$sM1i}c}YR5`9ixdtSvU5H$d z>W3RqHMvRMx1)NERd=G?Lo=%2-KZAbW8V8wjd;RX^m!W9NECb)Rj21sm3YBpmIVEP zSk?q}#sef~PtZ%el_P=kZWA;sXM(EcNl>=D2`X41L8abKP-AR{yI_Ly6iUz?)GNwr z%Eb~i2aA=c>RA$159!#MEm8NeFMFbj=1A0l+=&`qBvDu4E|#dI;)xoMt0+?JEyOO60x^iTbl_qR!&ea*1kFAyNBr@`FUZ+m`K}iPa@h>+$&WL>2lnQ5A+HD({Fy z&7PR3<&zRscpkA9B&rv#;^=pYdjID{wa1$Ei3)5;ROdf<+?A-lClXbya+0<+P0}Bq zB<2YK*NS1egva&2l*4-b7yFOXB@z;iAb^kqC!|)va|43HPP04z9bFxfZleK6& zIqhIyyuB+~Id&(j%ARDo_9m;|kz^G;o~)`^bvjvJok`Z@^T}F+A1*M@#bk|nn5>K5;u(%DNzvG)JmT&TDQdqgMH^6j zWr~tlrLc}sit7B5qP5t&HAT*CDN4uL?J26gBSnjmxidxMccti^-6?u}Cq)T&Q}lVB zR26$SRdulzor|PuF^UvRRSc_;w|J_)M9242)v0`{!WB~0zhbHeC#I@rw^Rj3rRwJe zsam-+Ra-H5H!=35%6chPnQE*SSsJT1p4D!wTt;Kr+c#G64UM^9Y?>CfP1E*{X&Ul* zn(p^ZQ=8stI)E?wrfE37@0X@w1Jg8lP#V`MrpYpzN6Z|Trt;&{RA*9}W=~F&cUl_P zRitUz%ryNoD^1te66cpR9bA{D-+oI|-rv*Y!sv}@+PEoAy>_Ol)R8ouznG@)?xktY z{WPuvOVhe+>GEYySDjqxI)`Be($(6#Eu*U?_- zsyQ%S1qY=ogn`r3b$WKXN@k{OKh9v{oOD&4o32Z^kC*e(WnD;ooWp=c>B_&9=eV{y zU5+*BGH?aYe@<82+H?)USe!!9U(yx9eB@r2t|AC+NY`RC-IT5eD0?tn2XNy|I^RvE z%lnWRsP%{%aUG+drt1QpJxf>1=jrN_Ev6sQGJ8y)5nl{9|L>mocW^*g7Gm(8L(mbi{NDTQg(I zGAG78;bYo{K67IlJ1@qujOoyP>RZ4*IE)z!V`{uCrb!6=7*i8`xICtuYhwE7*BJLI zq+h#Y>WD??c8mQ=WvFhs3>~s(sH!7_zdbUP);dF!qz=!}_t=0J$TK2CPK?Af zhFvo=xW{jXO3%jJ4E=z&=Vj<$44j{#=UBHOL&XLx)df=sf!VouPxcfh;F8WQG&d@B}$eWvJHa3^hNKp%bqBQ+-{Y zJ;);IV*Oe(c=-SSYxTvXi~GiO>iX57gdObSQ~q|9VyGA(_Q(0lI!N)rTWBGOS20j2j|1w;@81V!l} zRp~{F2uN3?_p0~#t-J0Ym$g1?GV`9Z&))mIB*Qyz@V5Qn>ry>mzA^)q#Qx=+hI%0A zuUfrIplXfms+ryz-s;}$VAZVjYFR#idZsrRtd?EXpIN!OFIX+TYF0+I%qqbQuP@zK zxw^l)w_24zcCflpF%Cx;p8daA|NHa8;12uWW32e~)fE|FfPFH@1ZO2&N!*bcRybV* ziWY_2@@H{4S`xMe;pZ%{z{yBR@&irqELonnAkMlJ{C_ zt{i9uU%sO?dqU@4a94`;Rs91LYoKBcg3KZC-AC~BW9ae;^!OCk4Ts8~LCh#<`#E%z zj4xn?+#L;XkAdz|cPzA$>~T;-x=et+GGrorAulH>-c{I8&jte2fq@3nd%e@UHxVXcJzQ>{{+F!o5FurPK>vLTGl(qFvBFe=G+ zvRyJwVGNeBQr#RzbJ;6ntYOTR<~GfhQ*u>uBf_XBmO^2~$QM$+Xc&IEC9kAcu`u3> z)T5+Cg^?xS$WPMO9!6AL7!~Ba+?ICnnqNAMs`6TjlnLV#$xH~NmKZ8%j*O5gQnO+h z=VX6k7_%HvC<9KEmu~}i%mT_`U%4F-gOc#Gn7&G(3I8-H! ziB-dBUoDKd>S4THL$!#%Rv1SmrcM|mrEA?VR@V!obp0@#vaf-1Z4|~(87;e-g%RE& zjDa%u?JzF2Qw<%$_^6}$DObetP8hT0`z~R;d^e2lUBkH0EsVtOiq%uSofgK_>0uaW zsMZBxoL#7V7lrY`mtkyN97cEb|#i z_ZyfjovRu6qq>2Y@>vZ7&!wQ2fz`5Eo=LGf20oHqbq)CI8Fw-+Z)*5(ZB=wpp$_SoehlcYM@Xz1C8G^P~?3BCFO@c z20s2k>*bGB9TU#Mj6>9V@epAE6t;gbe7XnCPriB zUaXO@I3t_ofaJv+8Bx;6BS|l7q=rz=NO2i1zmzwUonT~N1tVu~)MRs%xZbGb7EUXmiypljL*@BimaU z32$elq@0wi(xSbQ`5n}|j+)a=J$p~_DLNR%{{pSBozf2;Bm_ja8(vO@S-=ZGBLr9IiL^JtIudar8SXC!mKk-EoJqhy^h z^0h?$p*<1f1=S_j?ilHH*U0zxj8wR9#48Ua`=R5q*Jd1B-Xu|GBPmHhKe=h_SH zS78&2iohg7Qw~e57ABg@EqN~Qw=^-hwTbm@^w`!! z{97h=OGG;pgXF{ZCVuW{;$dgy^R9C3sz>SZo{3}P>TcqL9wr*TZ(^&w-^au-xhv^? zO)Qml(y5<%C4m9zpO}W4_(Z-OW}?ieCN@fs;U|nI3u;LDX;4$>fF-) zKQwVg9FG-G+R6_S_QXWZr`iWO`piVN=O*?`(U&GZlD7YucpzC}W{TR(d|1S+^VG~4 z`Ab?BGc&)qnZl7~N=k(&Go4GAnGpQphnZHXIxdynX6k#*{3!4F z%nX*lB`siPfvl1#*=FkH=rPw!SjbF_%&KChd}HMyo0^z$G&N&uWoCdl-!zjWE97o# zGbh@bxg<~CHnX+8nd2SI%;;q1wXA)|%nnKGY^GlqGgsw-Ozdjr{Cj5lcQ+VjH5|J`J@vqH%A>VE=llr5Xk&^k7nR(J-qnU1-%&ggLrpy-2k)>NT zf2Wymem3(=Vs@KpA&cd&J$h}gnYZ_uSufA`o9X(CdUHrQ9#(BfbX?5G&2*IIC(Oj2 zG-EkyrnM~k-Au7_>emI0|I#3RMGDmJcGvj?>W}&Q-75^&7|IECSkFfAivJDoN%U1bM z_LwZxHCvc$vFIOl7VL7&X5on2!UrA;_a)P7VVP_eqt8Ok3=2E5EELMN&`MUy{TvJJ zb1g*WTNo(^3M}MQvf!&?!BW*iy=oTTl%mxwjF%HNEL5p!A*_L7OHM-_m(z_cbZ=te zyQUV(HPh?OEliiiQoohPylJ6#YYQvdSg6+4!V6jOwuO!DEVOQKA<)6XNx39LJ6iZl zJnvYz*x5qjyB4O&>aG^TyIF{lt=%oO>}6r$K-DwY!YipVRO`z&sqvBW9ieh)0; z8p;#7`nd(?XbZDtnKT`vK8>|t7-u1MyoE{=ETm7gV47s%Bl&Eyg&tEZdT(iA!*mNB zW>_db)57jq8avytuCn@>h0@Qp?n?`|URh}K+QLDDmC8md zpPQ^ak#MV(hBhnPWPK4UmZDbb6|*v^xRpavBFaiRah9<1oji@UakE1CILYRU$ARbZuiCDkN( zwXMvO3w5m2ud5p5N&_o98(OK<$jTlm)WpiZmR3&6h&QcNY-7bI%Ot9;l~!-*xa{p< zrF=&#?{>2CX%{QkB(}=71vlRAB?kd zNuEgLcq_N3SlK?!%E7O-)(XXy8FJtoD<5uAjZ(19O7b2n|6H-s_o|hR*Q}&mS8ei{ z%)e=+*+0tTmiG6yl``^{eErBu>Bs8-6ZKzii2te9d~T)33oGkhs-9O?GGy{=D+|JG z{2_G=HYOQuxJ@<+EH=i-Oy)U?}} zDraMC9E!D3F3v`mcpE8i*q9-Il(z9{85@hs+ITHh%iCBd?$Z7Rk3l(1s`7 zMjQDt!^RnDlWF4<8J=Zhnbgd-aX<_q8z=K^JS?!Wx{{4I>*`S+)w9v5zK!?gYdP3J zxinPHjclBkkxgv;DyOAEQybsNy=FGrHMh}29?7s4TC=r{6B6In#us94XQP!YXm6uP z2j$zvM%cT`r>l((^5F+Ic8KLe8~tRs4C-g2Wq%tH18h1kY>bv818w9Fvgv25a+39< zY&8GehV2U*aq_tw8f_yq#ztf5A%^M7Ri@3bad)PT+*#`BY~?LA=Gs^yf6r5X^KJMS z+W1&@FS21@Y@>sGy~M`Tr8YW$Wn<+s);XOcVm)u8zs$X&eq7f) zIVojtXn!T;FZE6~{cXc>(?*7@{>MhC+nOg^?%4Q6^6qIb?rWbO*f=a#c@ z8(&GOr#eSu*mE1FUg+FvC^E3dgSEJ5o_xr*UTlzDPd-b_?}N#VpLhcjMIq=Zw&5stwd&SDwm3+JFe zoZNuc5qC~FE9!;gsUOaV4Z`((E}RaH!r3B*Cd#{|#=aTOQHg02&aDnw@4ax&N%x-M;Y3TuC*f3;bu#_aa9&8I&lK~EaC(eYEU}Car=QfC5Y9@uKQWy4lfr2+Ih^(K ze2QwG9nNd1I#;nIY+*P(W&NUXW-bn=&ysM8u2UZJ>w4w!eK>o52&d4G%2T%e6wd99 z+KbJKCAR(Qm)!j&oVR}s=j4HKN*>Z4$^toYSbaDZ&N8_uch7{Ae=eK`^5GxhY?NOl z`g}MQrQ?NgzLlvLb-u`Ysr_d-(`419aGuJu=m@IXBdA|4f?0A%ZsbJZ&yCz+nahW*{vgRw29zD@h^?!Bf0rg zB%RiA6y&cJ$5_2b#{tqJADJ>sG^6_Kk`!tgM(*0Q^Q;boZm*o*r3@;SLA*ow9 zibX}D_(#qcjndDYC_2in$S4LxNAa`RN<}esKol3`^KbR~4|-i9H$|~Y%$s#gn(T{W zzN|i~_~#T~*8UYm(_2w2km2_l$u$BF5+KNg86Gp@RwBFUxJT+E5R>v;YJBI{9S^un;(1VT&d*BAT{RteD0}Mbk_M z+oNe87tKm>l#FI*sc2HmMblqSCq>iE8O`@nFEyG2{%B$X(cI6DCX^G+wcKca%a7)h z=F$8rrQeQbbH`{bouWA_OS?vMSKjIuO>+NeiVTRxJ1CkV@~12vtXLl_)+f=79TtsY zxW>x2pGDJWL^NAu#>i+=zKEu;1&qiMN2TK_gwJ$s`$v@e=|zeLmGP&8l4$-~k7 z{wSKn$I-;Sh-T`)(Oi&**!flLVRn`n?Q}KUSuYt@I|FTYc8Mq4&f}tXDiyOcskoiu zk#^chxhT8dBirdGInj1T+3g&YIx%)mOG2!jb+W3Q#--S~lWNy{VmrBRJ0;WX6!O~{ zo?+*ZjLNk0ZH}F1vNhLEqdYt9s@VBPc2w2eI(81$wG&&<&Ii(_fnEPbv$Lt8o;TJU zS=+?Ur51KvE$!58rTpHu(_QBFvQwkCoypSdeLL}e?Ytvf``NiX*p7RMo%SEwX+F%( zB8m9a&e_lGR2*Svjm#Zw=ek@PYu5*fiY>>d+8MjZ&ME1()Xt!w0Db~``ruw&S%^?tVVwycm#a&@{?j4`?t8p8`o zFA~Er`L<{bOJifWE92s0SoTH?_r*~<582fqhFPs+xFQ+tV`$zn zhRc%JIfnOTc9$52z8AwjN$VNI47nuny<%7;d4ps4LXLeJL(35{ES3hNwD#x9Pxi{& zV`5k#1E$2V^Q#yNFH?+_F$`KA!){r!K8D8M$1qQfo79^7Rs;4n*c^QNCRgB(8#nQ$5J&SmI>l76wBrk zu~?#Gnf^vB9ZJWtN`5L6tM~u0+?MC%V#%%$tIrQ(nOQNGZHcjjC&f}(R=8t%Byam; z85)e$wX;~x%kQCB233h=x2&ud%ad9fUpp2W$MU*)tghe2@~TZNy*tOUNp^OPrA^OR zmdV2Rl~12o8p~*D*>Z^^08c# zQ43=^Cfk%?#ab(V~PDPmX0zvQ*0Nh-KuSSdPlNy;@^m zEW^aVUp+Vw%VlYQFqTD!WBEt=AJMpDs!hH)9?O!GvD}fLepBpIvBaH@rID;Sr+&%Z z^Rdi&63Z1?PaI!H$8k&gdE?k2@xD0Pr^m5RqB7!`BlR-lxGX)hncv8I5Hc@=^AAmuUp1Zt5qDMTF3F*yK$838i%P@92p_*#wh*-#h<9xC&zJcMjWv- zHFu647sSy~UM-Ac&!RYre;LOci}hS;E{UV*(l~Y{$5S*V9&cJaO>^T}AbYCDW33iX zCGk{`XOQfy5zm2|@x;`MrDi>G;ycos?Jo?5q;;`NSKjfy9yhQ;%EjMg0+Pt??S?#zuRd!Alj7|*%o@g%K? z=aZH3y!XA<5a&->_Gs#=mRa=vv* zPV_8EnO-G1x2rt!@0BO&MS0#5W1$2FMJKRZ{&ptd@Fnn}oT{9_h$;!xZ<4?)S=b?g z&F>~)>6$?KJ_)px3G&U51Rl$jkqI>aB7sFRVtfL>PENo+MRDe9&VmHe#kL}Wrm|v7 z0^aQj43RH)CGgcR3EY!kPbARoOak9a`|Albc$C0wIc2SYtxyG;N<@4GUX`vu%`z2m z`YRCAwE`Vv>EH^~`?vx#rR>-WOqyJQbJAl$1^RETz)IP-vjR~+E7q|J)IM8*X_9=o zg09C@p!#(^Mph&vsv^@nRiw&$6&WuH11hpcUWk8SMgEj_V=MBF^x9mJo4YEKzPlp3 zPF1Aj%Zkh-k;@V+o=E-ZL}p1=xkUa+NF<{|BJPTbx+bFMGT4>5|C31VLavqn+ zzf%(VY^L&%8nZQbZX)BQ&%8tiE=XjTq%BOO$V$bNp5G<1c$?sR zctjGeLP-pe7R8h38JWaSvNI})+0jW{l}>hzjZ0#vR4kdqNZDN~iDGXg(Y16EH?G21lBklO#NHZ7MAl5=LenJrwMt@#ta&Sm!rhW+ zDJ%MF?8iwAmZY&s44S0%By~m-%f3qDz7*Mz#OPf~oRs0eD6e0W*mxuf)6pdQo=l?V zsU)Vz)3Zr5{WFOLvg(G$-$|nE-6ZxrPh!g($yiG#b1^fSVp+-5ms!#@FPR0>qjEAE z+a_arE16RLlWF)ri<6lnefK0&^;EL%>q_R;wPYUMNT%SgWX9Y{)@LAkP1Zh2#u%PL z1Nl2Lh1~cQM#-`YDOmj}`s_A^Pn)E0vvUgRT~cWHUJA=UPT`@rztXr>DcqMi+fw*# zPYUJsrZDk%3P1do0;lx)?%1a9MiZ(b&5ww382H+Jh8bH&0>Z!xSFKoEIr<`!5Akn1jADO!i7qql0E92fO5C zVF#ZUaj>tbgN$MhHpDr29q*uLNeA;vJGfHDLDRAhk`nb=l7sV7(c$2bM5j6!Asu}V z?0yG{GF|=%IH(tN&@$gaS4k*v;FqQHPbCL!Dm(bIwnKj(9jvV5V6(XEI{2`jgR646 zse^~|Z8Ha3C9S!G{w*9_m;3D<7&NP$IiKXw}1^ z`yU(>AEbN+t4=xov4i+w4n|9#;SPTK%t6Ws2g|>3=srdV?Z!Cxaf*X~r#k30%|X;$ z2czbx=J^it7C3me&_ThM4t`zipyqN16IN)f6#B+N9hoANzH=~N&P$VZiYW`F?s^^n zUN!vSpqLz$9vd{~NA1Z^4(4uDoK5nIV7nALs69CBp!*RA z=j6v@4&B4(VATl+Z=7`ClR;8&N_n4l@I(roaZv4o>bc|Khr8OVdk%8s^kWClUpR<( zss71HsqxCe_}4lQq-mIwIR+;YMknJUoSZ1+q-tR&tBN^kTinT#NT)teaq1pBC%?&& zGEQR3IT_4nzPgi&HJwb8 z4Yi%TuH&Re}J)T#SpoOF{-^23`>UbS}8qm7emZJkVf z%gL#?opfmLq*Zq(3wt;z*3-$cK2GBLI{89Y4|K9!1`TpDT2h8MxiQSiGgty)` zC*wCcIl0+MwJqx1Hodmp$(9{XHt%#|*rm09ankU2tt}ypMMLn09SCx~* zU(=ZDPL9eoX>`j;oBQgiBt3AFA* zr9yHlS+c~H$}d@|{4Ue7Q&}o8IjOvro5~@%EF&wYQmsKM&81jF#gxf%rco-j8f&cV zZ;{H$w^Aw9E|sw|yi+PurT#lQE=MG$ODdyeu2_1c^1+9xd?tDQG)}gQWk4$ZWvo0I zn#%3bsRYNSa$;O6S7pKYR8~vxsi~yQ*5jO1E=s?7iY=Aqr_xA%mhgqC43Y`*e5v}h zG8OZ;sVrWd%F6Fj*&_YdX`Vcjg6~sVBfBMSQz~tDs6RVXDe<$`lBxSr`SNfo>!in# zREEkONk69jk=mzInRF(Vfxo9R^Fb;X9;WKOW-4zyNu|?M)gZ-Rq|)+bD*NQSSE;mq zt(gC&68T>$?QpRy%tegB#akv9OU*8#EiQ^jxoBBJugAN{D&?ZK7~gPFLPpBL(k?<} zTy!eu;+yg=N+!6tR>6fU(ZxK8Pj=Bh#l=zC;dEhjxtQX1k&^DBcZQ3h;>dLIewIt0 zpSrj$_i|ihhFp9tr3+lVQ^`dixh=seE*{o&QM8VW=5<}{k>BNse9*+j#-@tb%tgMG zZ=<|>sGgoK4#{Py-P^^n&s@Zfbde|(N4egJ%$O^FCMpGmhuZq^odQ?7`c>(Or9F>dBd z`I2tBmU8p&8*ZwXadWh+Tc01fIhE+9Mv|Mv6gNE_ZvK!1PB&35H^b#_nwt!tTlWsT z*(?wIZg%Fmu@$%(D6ea|DO%gjemNs`>bRL)*G*VGH~kv832*48Q6o1yWJxnOpSN@~ zOPaKD(@{=Jsn%}B$}O4I#?8gHZeFx=Q@Mj`>*!|4yKZ)Mb>n#7t$X3z%>2O3g}%~H zc@J)=a(1@* zHP_7~aW8c9;UYIz<>J@s?+Uj*V^{B1yIHfwP1&_>s;yJL>)pJR-alv`HmKGuZt{M0 z(?Dzo+{DQkX?n=bJ5uJb8;=}1qOm93jFL(x)f>6{oAUZod0leT_NtqQuiWJPtD0o} zf9eGutYIELm%|1R`9=?4n?2mIczE0DAr$VRzE~qX#L8$nTF67C!X642@zAuWhh0)X zO5-K2gohNFBbTB*G`4$~7USVutcSXB9@0vA=>LX?>(aBVhwsa2OoE3V$sX3Hc&Om; zP%hQOyDpFJE%y*p&BI&OJsgr3H9fkv=HWY8UEjmw1|B*$^f0lphf_^F)M)BqNm~y$ z-|}E==b=t}4=v@>4j$br?jfs_@{|+ZwDw@FJ;bAHY#zN|@K7+)!y4K3xrd0+9tO*l zu^!Hj^H6)dhglOnT%4qwCTqQET4TD0r!s$rhpRI^+?W4msVB2FPTJ4$a9$eC^>9F{ z&GRr%#?SX~a)F*N^w4gR>Xz|~J#<{+VZ~Ap@n3luB45bJZ#*1asXbVw9HjcU9>%Tq zFk4Em@$k-C^=pIn>_-oCWx3S&$-~R79-eR09_{e3R<=s=PW5h=;_mh^T?*~-&}6TN zpXG>**r)y7uRZ)l=YgD)FAsV6>#&DbN7Tz>9ws065O%^tiQhc5KIP$8seH!6Z3+JF zVX2Jy!^5%jdi{cj;TJvp@~4NkmppWn#}c~YVU=u@9@jh^mpeB+ME~t!i`=~B!FNY% zOZEc~!ybCLC$FW_BlS`~eC%QK6YZ%Ce(GW8GY|D%c(`Fr)8`~JLtG;F0D z+N3eDZ5j`R8aKP7(fZvq%6Chn>w9UOkrCa~IM5@F+@5I^>zzi6_tV%b=Om#| z8qT3<^!X@_OY*^pG)j$3qvNPFj>~tW)95lLjc>;)_JlNilhXK7I!sGr`E=zxBaQR3 z(x^BmjcM}VT;)7pHOs7p%5#zO{8C@9OvAP+P4|MUKWo$Y^Sd+(Hl#7?$23N7OQYwp zG`>HsI43mboW`6_qx97@-oBH@S9jB}-%I24qcny+R^Ohak@-|LKU0sT@(blDW%1G_ z%*!d+YV=|ZO0Qm(QiL-K*~>UUo@Dte3&kuB4Y`rM$$v z;pIR@FHuQehRaZw#<{($Nb_>f>!rQV%fXI^-W2-o;CiUS68@)_ghF z$4f$A<=fAT^JB&P#LKH;UM7yvoRMDr9MQUCbbOrZk$)z5@lW!ySjn6@~vcd^wCM;I{8SIeCg1|M=#kSuC6}v0``q+LKd0MxWI=a>YlDYwDluzo9+;+s7x;;2$5;Z)vZ@c*jSbyFNC_ z%qQyMQ}yhb&Kp_$!pGk)eZ2Wful?ua5PtH){Dh2t>WkInCsszwQL~>)7C*g;`uRk% zi}|T7o5c|6=L0Dj=O1UX!B3x5Kf@*D z@>5T?iP__)pDYacxgON1mDuJj((nZ^6U5H{Cv~L&;1V+udkmbL;TDh>Zjtzs(YND zx5xWAEFVqvvwNE6PWSV>l%MHmviv?vU(fNgYObGBE49Wd&0VA3Z1FQ}t6$f`wB~L< z_xAW1vd_;KzxX-wt9o(3&qK*Mr1fRHJUQ&A_Ypt;o>RVm_=&opnq{J#lLMFhoRPto z{p`Hr$9L6FzRZ!|uPKik%1IW;9r@}nKezt&)ApvHR{!{U|Bjy@@A^r;r#SchlzphR zAF033)ZgcRTDIFz?63~6{ zTE9hrdMyJ?Y!}eaBIVH`z@|=$*EztrE&-x@258eO!1dk%>;nU|9Tec8v>T$BLj%No z6rka!0cH$WeP09^F)qM?@d0ut1lToExl9f)SiYMT;Mwc|UFWEtc>%7@572CZYF-rJ zwsw0B>_i2zlQg~F5nV$!-jSbRpT#)VZWI~X1rsvVVti-K$*o1xec<)bCgY^|_k*dsuZ|QvO%8h8&mpYpO}! zyB_4b8$m*U2ig5FNTJ6;;$)nhcoO98XX?K-oh`O>T;b`wES^r4sB{|2cCkdKQ$m)@ zU3)t1V$yNPr}JUSbOPnl39pb&ql)S5kbk93Vmdb@GAW(Ca#n6hF=sk&NDry)N@tQg zonD@Fen?9v(VI?kww~vtGqQfV?&(e^)G(d2Ch7EVnohS?>AD9>ao*9IUDA24XFAqi z=`4`FQ`0FjJ)N+{>C{@H*HI^@a0Yc2XE1q*<}b}4MmoysZ!&ni zGJ}XUa#8dC%pmVZ26M`0a;aP;qPJv6>o7NbAP;^@a& zRQe=~hr_bS8J@*AvRxLB$>PqeEYjy>@s(^6``j!n^RuYGAd9VXT)HpKV#(K8++3bT z>lIn_mWVZ3#H`EWt@T+PlFRaVa~82jvUvMw7Ki1E3_hi=&nWKiS&Wq9e`XPXS$WC2 z2U$FSn8k?~SvuFUIqk_NH#1xJG-oqul%9W{&5ZHcG@6*r%t_gNJSCewQ?p5*mQ5Y$ zB2{K&GkRt=&*hz!*{ocZO{s6Q@yc+yxi%Z$x@^9b*ZZ@n_N$H^)4c1NcO#oxx3ih{ zB%5B~o+vDv-mn>>O_ACo>;0X}nwz<7k<5Q``S?~YcVyF@T*B_zq)YlwesA$o;}m{~N$g<>K8k?F-l{1F+VUQ~!O(INIp(U=e)%bwT} zh2uj!D;v@^kC3i&gmj%F#4uTrqB)KbQ=K7X(rtwC+f)J1WHYV>Ewki0*g^+KChR@;re;xH^{@-D33ag^VlSgW_i5dJdZzRQ|mn5YMaM<(&nu^7Qdax z8oALv4^PKD7RcyMc^rKwk4l{tzl-8`ReaggJ&(dY^N5$-QmA(xak5zcem{>VGUS6i ze(syc5gGnr9>4Tc9n!0R9zP7oem2#t0n~afTpXX8ei#!_0 z=Mpt0k2l9EmYfpTIOR7!kJyQMRFtX0q&#wEoSc}Pr*kKdM)Ky=JQhvMqxf|7Qf|w< z8F}0h%d9+1v-7AsCy&jtUxv(8{`2zi&(EXD!aQa#%A?h?JicF@$ICT&7=Fs*o!xn? z+@l^I$RqibYCE0B^D}u&I-kes3whMMsQUg?4wv&-FSBo}_ji=fUFGsXy?&Ud-)+dF z$kRNUJyS0wSU#U23Hjutw~Qe#8`<3|?oT8_^wAbxfMqvhMJ1w7hTz#lsbIB}|g zl4lA?mKtX@{&$TR*WU&7y;;C8$+%U(N4E>OEk*7X(CmHzyCwf&0V5w3Fh%A+E@0x* z0_Mq?%0*^Y@BQLYnEq?34kb?Mf6n^9e|kjS9+G^q%E6`m`#0RWWBR1MZ#c4hKB(Jz WM%>hsnPGoy|9|uJKVO&dy!q-oPOZECo?JB$t2;qEe=;qJrToiSjz!-m_iA;aC> z2fyd%?EA-$a~>yhU-xyr+&oeK7R?6R2&1Zj7a82c}kVaSvp_oJf+I! zEma_Qfm~(t=FO8cSI>OXe(FrfjL~rOKAgRU&_>ocT)R%#kN=sr>o#7092TyZLfv z&y&4Wz7j^}IGG`M=KtpU-@hBT(gOZ>I|xhBw5)UKr%)vpww zewg`PfZn$Xkhyh$w&M^yZ32{vnrMpnwgLJR=Ww!JfYRFss3;0|3sCRg0UC~SeFOBg zUw{Vm571Z)9>`q70`$vB;zQV|00mACkZVeSo@32S=DHT3Ubg~t|4D$}qQlbwtwY^s z0h;njWzx03kR7?dAV*BW#jwsq7O9e-s_WLpyoH|I||(-o?8Y*+%@PJ z_TD$B!6VjrYS5x*1}%9_K5q=VjfA(<=eHpW>kAjzy_ShjtHYJz?;#iYbY9N)KtuiGOAi8qn@EaW}~{}BivbxYJ|DifgxFq z8s#=>K(tXe(9mPlX;@>8I^{KLQXJ2tXS`9bd`4wYG-{0BsIIBp&t}w}>_%PBVbnWh z%4yV`JdDG&yhgn#U{qQ`qkb-ARO2E>okU78qh4ZIaiiAa9@6-qbS!3}UrFLEWzG|FDdsNWD>*{BgnuVR${JEN+g9@gQC(^p6;{ir1vrcgs8!pjnRSd>hC5hX*QgKmjN0DRs7H8@Da}~BIXSj6s%dMZ z#ME1)6{6Y?hoXQ$_G>!Yy zjp{JlsE2cm$~@Po<~TWzITjj~xWuTOD~)Q4#_=3SN`gsG(K^W_uivCR z$tG<@@9ZY+%xTiB+$Pn|!+Cj4iYQ>xD3mE=(o~cxY|;d@Dq_+u6fJ7fq2ea}Ufv{2 z1(UksKK`u8`BhD-Q_ZC9*!;ao1?!qLroKrv8k=;miAn34nsflRW+pvBKy&JVg~-^# zq#2ml%B01}*4m_sZB5$So;5pgPDhiHJDC*InYwi`sXbkWXOlV( zGU?(FlU58h=`u16C!P@|UBc;+)M^xKjW#KEtVzCc%s<|w@>5Lei}BM;S~Q)y&7>}P zha9s^nu8;7%{FP{9Fv+ZU|qCbXwp1PS!7ba#U^#bZhS@Ur6%n`&@z*ZD~M+e>tn|T zlfK~CM)KUme81D%&GdecNw=}&fJyEDAjXsQ{WQ!8K{9#f!doXP$RMiD%2gQRp=NU zsLeQr%$`6!!H$?fZH*07iG)B^#dKewG9?D82D+pKY67aH2I_jYKt09z9Dy?B4%DJT zC>5wuRRi^+W}x=fC#L3s%G;Lb+A$vAwGY(%j)8jDIZ$a`0@VhGx(4b-4`S|3{K(xW zP$$r$Z=gP7e7``&^$*l`qz?>KVPyX~P`?Zc)EyKW%sQBaMngCkC5HxT3sQ##Y9TTV z57bC}!n;v{8ZseJ?#bkXZJrDso1k4kC4Spp0|K6ZO$-ZlDIw57Y`=hkF4r zqt2p0`4arW5vY}S1J(F>pz{42sIdytXmgN$bp>fB0x|?C5nJJk2-1#>hze4NEJ5lQ z9i&m%1h0qtIEXQ^L7IUB$mV4nwjeA%Nd1$7)XpEIUO10iIGG%zD>$4Iq~{1r{ZA2Y zt6?ny(t>mhk5M5#NbfKxTabRkn(RTkfj@HvsY#w7eZrr4gY-T>>l6r5y@EkXC={f# zg@aVTXpqKYKdKcA(o)!p2dM#$;|^|=AcsmpT7jd8tQ@2{_y-YHg47zT@ff+P2B|IT zR}WHW{DCXAg7gJL>r>07L3+`WHCqK~$ecVdv9 zP7Bh9+2lDVNaN-PDaRr#W$xuc%C{m&=_`X2vnoi&)j^v4Ymho_3{sa(nvu+ zm{m8Hv2kYoiF3FcZ`Nx(P2fBq#}dt2hm%QWUBwr_S+-=eTBexQ9TQW{nuo1vW|c`d z>ooqsx z0~t!0^#jhLU}>}Vlp!CCEoatD+$c}H7+ArqJLp=G`&d%RtiZ}pSK+7s-t*UC) zJCyv+te2=<-K>=;^*y;@HQr;(4`!9G!7WzQGHYpVvpfyVYL7c8*wCzUn2IN;+K6>< zyRlihel)8<6SHbIHLEGEp>#9qfiG}2H!DXAvx*|5m07+}!}(F+^!>kYFGqSH${=?=Ap{VwNVD)!Q;+FZ5EYB2fIbq5Q`Q#EqaLlVH^v$XbNl@EOJF!)GCujAH2*NXVEuwPOvCC z(W1@xA)7_LFbp%ZTQo3-MVWJ2G!_?gS@ah5b6Ye&pGEfk7Db^6jufyccR`EVp%;vW zEqZ~9Y z=w&yH0=g3m`XgHpYWR~ywQw6FdRgS`ZBdOr7F|W=e$*9@`g6_zi`EacDDTe}wH{>A zGkn3S!4{PmV$o4t#2fS&N=(Bn%7I0Ag_grDnv7%kX#{KG1E!9&sLd#gdLm>rHN`lz z8e`Ec9Kycw7A>B@`Z$3`6RA7?!s|)YY%=p9!xW2l;VAB7!!L}TYEegA$IxlSJj0?v zGc6jA)kvLX(cgH0y0dvahqzE@o<(zzc>!}^_d<&di^zSkMQdPPYEczD#js@-th=loS+Z*jEN^LN;yN_|FS3@-OtjOa~74lV9`H#bdmjol6T1$%^wl> zWA@$?di|8w4hBBsHS)ru-?1OpG4CaH!eQ87bN(mxFmB>2W_@P-zpQDos)p67CK!M) zn^nV4lE~_#lAO1j>3|0-oYjlpVs&q!H7DZWA zKC@NhP#`O7Au-yj_Hf2nRTDO^Rn>4i&Z?w%t4?8Vf>o<<2$g+S8B-XKH2jX*d8}HJ z*Q(!e67}*~6_lTtF$yOOS(Tx%Rk0|Fqo`8csn764_(^^`!7<*B@l~s*kZf(_IjBiVh?Z~k`IihC=t1jR+ zvUarUAo6#zstg{XKxeBSU|<)k>|Hq*SG!qNxVKeL5!0Vu46tep3J$a?s%6MC#;QG-JJzbRm@>|)T@$RDI)naV4}O?wRrA?a^_^qYE6kf~)jABAN5AKj z&mv+(hb`1?J2lv0)zY2xY8SceW?x|e*6(3%eBMXA`>pD6fY=UNwE`9YAa?iAxEg;QF?uhdLL)sUS=QuW93bEtK4`G({=X4O{+HEB3FdoC7*lr^1fAn|IY)f zetAd@A5pg_ydIufl>*mu>V=uFtUCRg*TY-(`Fr*$LO)p55N%=nXw}Hi#P)@K{FN~Q zHZ?QY)CK#DHl0G#K%0&S*)+&((|8<235QL|p*DG(Hl?B)ZlPb8O&c@Xv?Y>pc!;J^ zHg&>sl+R-0{cM|7X0<6c)}}RHo3^2PoK2Pln;fc(Rp7=edX%n_9t<-KN#}A%~6k|7;qEv|KhV%|kAEZA!{#(;+;-i~=@QEokHCUz^Gl zwrO$^n-&(eX;d+rUf@j$n+ld9Hk2%F(@~TvV^b~sj43#P3ow_pDKp&VY^qU#xo`;Q z5LU^ikx*sU$FM3k4X8@3khPjke__^lHl4xZnl}B0H??ePQQM|vc#0BrZJIETaf_%S zYA&WnOKi%v%%*(HZTfKqd91Xl&nlZLucr2EZJM~zrn%VjJH11<%{F~O&^BV*Zd2!7 zHhK5j^gSA*!akdF9rO*FL;zZr3+7X<=6%cw5_54;#>?E$5+pd%J3)PzSpvAy-GcmUp)6E2?#| z>vK1|{_bv9;U0E%!_NrlX;+K>cJ+W~fL-qf*<~DTSMMQqjX>Z~yNaO-vJJDV2wvhF zMh<7)QFdKH%4oYH_qRJ%q^ zV;pu)XZ;y=Exnrl7gl2% zp8ZC>HvDH8w^ML%qg|#=)j4h92m(g*~#>u6roHjXq-}j&3KX9pr@4JLwCi zqWLbn7GXUG@1|a8yN7f4+Ld#kU6K2#%|W}0V(cHpeuO$6CGTVGSF}0KTqlVAS|bW&OfBn1{vx@*2cbd_w$J>IUOCYL9F9Rlz!72-baLunL=k)g8YC2J1(2usUFI zSg#KGjDRR7GgnKu=3;x z)~;N^I*RjcYIH(1N@sX?#?v>+^zOMJ=LEi-T1GgK-n{*9Pl3zM$i}VC{wf*I@O- z5hSh;R@>i#brH=r2CM59=GjWk&=dcl*0x~n-$~7P{int5U=`X!ZT3?4eT>;3tceGh z_h7Js{s`7(Y&;ySY)6810^c1au4B{`MUMw7=0vc1qu)u!A^H?GIUTGwSbQc}+5ZaG zL2NrqOy`2N<2-%25Uh1ray3}L{S&Op*MhYg53dL7+70@7J6MhHkmKWE&A?I=dP3|^ zgVh{|@eZbE!D@|NIEH-BgEa^fknu&ZTB181puo#umBS%qdPS`;8!zw`?Oz9LI}W4d zn_x}Cd}MkXtfuIU3rKm#Tv&>CFukX?_ycEAb zJV8;bLo<+Qb0|03U;#qx4%NjD)3}SIc!%m?C?+R3v=z5e%;!){BJpDZ zx+XbP!tc;Syu;08VohUCnA069o6VumsFs~IayYak=YKlncIXo-=5eS)K8Kp-=bQo# z?Jej~N+E~FU}|B9!iqTbs;EQuVh){$sklRRkhcW$p-V}Je#1wkmv-nac9e1Gr?L(` zMr1kig0Vd7;$PS*IFu7TFa+x>Idl~lt2h);)uDJaKpPy!-spvkb1iCI+o4rxQ^%qCbsZ{P&!KgQsqawv1`ZuZOhbo;V?FLPawxosLwnG(DaWzC z89i$5P_q`q*NWV*8yVWL7GAb@$k)N4Gbr5Ap$b@nOP$ESGyUsA&RxmB8~q#Y;CmT| zCg3B2#t~-Xr$K0qs-=S%^fqV;?3u7^VAvrB_=*PtlHCjSEOW7049CEE- z&6N(dU**u>*tgmt?^=hlA!eOJbKv}y*8!d)e!WA3aTuY$v4`;E28Rl4q|TchI`%s; zZ6Riuw^4U=*-l+|5W`Mty^Gj)JJfP7{Xf8K<1q1K@ll6ronY@^-AQ_J-l14jM8E~& z!A_jI$hg0G{aj_ue~24puQ_<{)}aK2;M9r-sx{sFj5Jd!sXjpiN#$^c6goqFg$QYtqks<0C6{4B=2Zb_) zs0Fs;F(zaV(O#T@ElUVLPlV_TtXV^}4xKz9QcQ^U{ZCSej{8GYD>+1_v=Dwj6QTk+ zLR2(oh)U-Q(cjpUJ47Y&5My5E$QPnWv_`x9AzF>CxP!=o%!5XSLNo_=iiGH3(GWdt z6{62*);2^P+J&fb`w#_p2vH48#=(vuI?#=^(WXa;4x#o>A+q-(&)%%xhrIfRXi)zU zc?Ocx&zy&k7(XaP$wR2&un_ec9-<#cvK9)C2~nQ0JU1>xnZ}3k`U%l;giZ)iI?hcD zQO!vqdWc1nL-b|}u}=+A*J&YIIz2>HXN2e`ddv*b)!D>5Cq%xvA&Q+BqF?6|=fV(m z-w>jJ&E#<)L^}^t=OZCX!^^Y8dL=|du7&7ibf{`2hAOc^sB$B+d#K_u7@M#Uo*s-r zGeq|cRSM2y#80961}4%Gm}^a)iOhQio4R8HjR7pj)%hOYfXwH~|BX+Ws@ zq1Hg=fpHMy(GiV?hHAp_P`yLl5uti9GE}LfLRA1W$As$F@u6Bhf#)ZO>g1GAEuI#t zR?|cE=ZsLToE56gC_Fn%36;(Gq_kYyoR62~}m7mxe0aicmGhR_t9FsuM7; zX6?11I=C)Woi~K)I)2*{s&!jAz9Uq3c899m-cTJn5URfqhHC8}p}K!8R6m{x)!hr! z;!3FM+zeH|2cfF@EL6|mkn4v~jr})NvjUu2j>|?T-#0tu2yrSi#)LXm&gs+!yoV{w z$#pMIEk(m{rzYb;7N_1~WQPb`9Ztj$~g;VcZI<>5oQ;$)+ty6pP4F%ef8`k4GlG-~p z6xZ>lgHr(=ol5QERIlz%mF(eEOi!n({N&VY{MyT@e|tNXYk*UO2RU_ah*LMQYM4{W zBe)$+4r82ZGuA1?IH&H8cdF(Drnp1VBJC%K=Q!UXAtC2pJ z^Y9A8=Q;V^HhJuzPI!#(cT$gCPEEuqr0jMoKZc>`9-cc$zy5HlIaXl{?)~Xh$HT09 zgq|I9D(4BOs-1MI0cM_N{WDHIMV+fojkw`d`Ii}ed_$csa+2__mPup zt(>~_m^wXU-#mBf&zDZkdP_gi=L6&M1f4!Q)erVhPJX6y>JG~O>(oh1`{vX~^ot17 zHv9=o#xNa<4AbGLFrCMV%wcL09i}!hVd@kcCZ9JmD8hUrHfK-uzPnq47Gu~mo#rK*K#6TV>0_hCx-Axtx|56^3dX;i&1<@_;B)dz%W z^q4SxKP^nl?sINTxOT>dtEN9()3b+b2?pl~SMFTl%9lG_rK^RjIyO`f*QXlcs#}v= zbgCV$?sdb}uwJ;b)DM@lNw}^z4cESA;d;;_Tq|3KE2%YO+k`7?yKwn&1|8dn>kgtj zglimTpoz>Q!ZjJqcZbWkH(Ya2c3-&0;K~7FK1hBzk8FR2t1BiS zVs6wr9Im72d^}vQPcY}na2+@ou7ekd^4udp@Ar6|8kopCMMr9vq#mtLZJPM7B4I#P4}XArmNQ7Df~OK>Z{OX&q%8i=HVtc&yT7jmgU zVV8bJL{XO>p-eGiD(+HXDVN@rCeJc1em-%@Ro10Zc!gT!hy%mQyY&43RH)$67{pd| zsRQ~{a_Iy{R(7dG6_*ymP}QY6a8zSXRITpfdRdo#|KUGtYp^D&)O4v*ZI{Z`bLmoj zmx?rSX=g)nXyno#ja~ZbN0;(7p$5&!r-e%=(Xu5mw<10aZ|%~e;VvbQc4-pc;?vmw z#7-nebjRx%tTB_i;x#nOrP7#$`N%xmrA_EEm%ifzip}FO-s02}mzJ$#{Ceiw#&a-k zcd5}%_6uI1!Y-Fq;|_A~c4;#5?V-+?yO%r8u5LawL`e1DrkwKHYVtn3*ST_=O4x5%LL__jZT9zD;X8SgUacf5c)EB9v=NgbYg}__-v4 z_eUetYj=c39E{Kgyho4o5emB+p~nv+l<84~nmmrs5^TdEWPcu^P9-vGQooF6Eo@{tdlZwEnh|*UYb$KH!|uxYQ4^=Ri88J0d_@3a$Q}d=46Ugrh1WT(~#T7 zk!px*O(IpLS)`)dMyhrDNZsuisS!OQ^<%F{br=|_?{-FN?V(5+Pev;6Yow+dqSV_P z#rpCIa8~WWDSSPWRlk18s)b*(>LYsF z+b-l;4&h*yOoG}=-k7t>b=|=f=T#-mc5A?F@4-xj~ad5I*O6~ z+^Rc}eQupX`~CFw05w9RgKo7x)SIpS9I z8Ml7Gk2r@?=iSPDg*}0BIE*1z-P(oB*W8+m4On}fJaF@-TOV$@mEj)yGS6ZONEFK*uFck9qs_RlwRkBL?bWR8uN zD=u1XunTGN(efun%bh)19dQ9UD@1ENCRB{pZDg+$t)-Qtm8nX!PF0Q8!SAB=#}Cmm z)QDEznmk`CTD|K;Yg6NBm2DEOO9*Qkt;ZQ%!8)AqE)_kv_4^P-)LRy7p*7wG9X%`21d*BbF@rDqh%iv zt!yKs`TbqA22YCC3xrONR@OPu%8eH2kNwCvH(IF+Sqldik<*fBeuoyV;W&iP2woAb zS8M-s{3tp870tDJ(OQlompSJeabJ(tT;zEXtvOzgzQ7yrQ8t`MdZI^*{2mQR_VBp` zk0Me%I)V$BTg{^@82_C|^U$`sN4=2kdyiUT2m03V$XLt6^(G#r)%Iv&9goJ<_2^&x zQ;%Z}JnD>qh8|VMj7A<6{L!O?CLS4@dXy9G5Y)`0b#OKJs3N>A7}wIHYdF`+qq?m< z+5)xls3=|{pshzsk+q#iJun#`u&}*HzrxnRqtcj)8+e9l9f=R85Y)+|(OB5oqwAR5 zg<7C&SC4k1aW{`T;1JGZUU!ckqE1h0@smfFu%eeoj@}++!OcD%CHM8HIrjBqe1DHt zW7j~By8g^~bQ?lFhI&+N7&S(wi5?CAg*r_0Xd~_+a=M525}0=;@gi)NM{95cwP&-| z9FIE9^(b_nM|ZJ#K7B>nLXTn>F$R}lUF^}%sJPUl7g)Eq<#@eTQRc{B_Yc6&4jF?&4fk2Bb`kNox%-ya@5z>q&ZIt%Y1kM`r}Vdg>D5&D3Z zc#ASendcb$0Jo1*-;*BII_FXL^Bx_>WsJS((M*)NM9!DlyZ8;WZjjp@YI%?Sa^IuY zNO?qVk9l2S4ECVR6A#zFc{J)JV_s3?*B(8`ws-93_a0^b$m<{|hR+Mc=nuFpG0JL< zkssCVG5Re!M)mwLx>_(s_Tn+xiN8z7=q`K}Vzjbij5Z^!Y7C#zWjx;0j!{6J7tba3HAc4eF`A7PnD|?aZsG8T7**OBqbaz8^i46U zxj9Bfx5lW~&KR{j$hs$EH2w_dBIr_#THc9KH-y}c;ab8NtwQMsG3tyb$oDWti?JU2 z9>u8GlNfEnho>>h^Nc#+1HQf>hgUIrhz{>#vO4l~@M;DM=Oi{f$>mks++O{J zCV9LXmDj7wxQ|T*yxNCW#aOSnSMRXAgjc4LUWH>c?x21tuTH~R+RJAQylR1?_!qUx zcr_7E%X)RToL4sxS>CHD=v&>Z`9FA7sE$`X@K;^0F4ZG1lyBhGO2jp!j*Yxp+t{lI zKYBH+iC1}>QoCke^+Jy3Jdb%Ty!zJCt7EOaYT4Q=LmRL1wWr=4h_@5ZccwmF$fX-| zclT;Yf3I2(_wsWh=Z)}c@JMQea-+Pefqoc1+N*$ZUR9d(pVi#{Pw~nBxyh|{zE`EN zU;()-^lA;wYu>!y2Gb*0)st*1_m(yPDJmckiIBN5kS9Ng+&a?FP9Qy|$ z7uZ`^hLDS1WkGYSN2{w|Ek&Jwh!4+D>AF`ZaT~UqUPa+5l5cs{`#$G9^lI{BYW#$r zJZB%hV9YD8_M+<>uNuCizW7mb`Z*v@c0-&-ptdniGfi>IX^!L4{y2TH@qBQczH`Ls zC5E`-R3|-7f1`7WIGu;JTpYg_jne|`fy#3X{V}3K9G`)V)63Xv`uBC{RqkSCvBu)i7#%WhK;^-NthFJMioHnC# zuQ>gVcD>_t8h!f2X(=|~E)x32DHrAH%%7N^D=;#6}Z zb7J`aY>rdXmN?Dd7N;xQ<1}#xwcZn_sJ(G&c{onPa0aE0#OWw@9gWjtd_e1C#DhOE z<#?RlVd{xEg`Q+S+(4gGoR6ZX$qUo)1eP;#%5#?ESb_oP7>|!we<4n{5Pp$$(F_0J z5msG}(;bw!8mH82^Z;!!6qDc#i`V(^c-=(}SG=0S zlQCY+aWFDooulIQGhX5w+GdJZOy+nU$5m9xLabPV@3O}0N1VZRta8U|3m!(tD~l&y zjnEE@P#`8=zhE)ed*ihWfpPJgg>3Q6j|ccAfw>Xki&q?`;30lbj90!SVn7vtyzI%0 z#X>Ysk5|iV@v5CYUj1{#t4mID$sN!2Pt2JwUd;-|>q6mp6)F<18AYiZ78D~6Tq+*V z*OGWWE)g$VNuI+)94!^EzstlcQ`vZ#D#fcYj-x>3crC*x)T%0ir2Jp@oF(4Ugf8;&P>Lvj@MF*SW8TM;#Kqt>pdfvxCDJ^n4mh1 z64Vl(ajh6PV1!3Ptx7v26~E+qa*9(ai! zhlw3mjwbMZc!I{^JmQZhXcD4NBxooyo=Z>}48kTnLgw=cT%VAjKG=k?iwU}pCy4($ zL3b`CXu;(K)xW}eR}*v*xvwS2dObmZJxEaSLwfdznmtZXGMb>+lLU1~)KhYJmY{c7 z`JCQi)eD~cKXYHxpZ5v6iQums`<9^7@~NuHr{_UFWeD-9eW*|OU=R0c9L`4i^j9XI zzGd<8c@m#$Mf=n|#-~ZKK5g>)eFmgo#s;`+(C&MK0QUn zxjw%B`1l!-91*<6r(7GDb0cH%8=RYb`X0-05+4!tyH7{B&t!53J!a35K= zQm11+Ej{Ve1|*;IX&ug;_VInTPjgW89P7h!-lwPwJ~g}OQx~ND?bC8px#Uw*OhlH; zK0QM9EA$4{uF@B{|M96OVz2qM1{cxoIyJoE({TjdWZql!7N0TWHZkD@+;@oizK_pi z_|*83PY<5>bp0uHc}9(1`qcHEk89O^`WtyZaXu`ceaesC7_USfMuH(xR%4jwQHUBT?1rCGtDZMBS^OsL2fyH6L%VrD39aH%`>9maNw* zQI!zX`ai}tiM&UXsKp%;RjOm6oShOi7Xx}HDs>?1p!v^od_GYPpbLrWiL95&6^U0_<8Gq% z;Y7wHKF^h;0ymSi5?_$>R+75lA|AniJ4tyl38B1^pmLR_hpevT*0vu+)ilPJN;Ur8JzY3ufmf}2utbP?i zU#!MeIBk9vM`x@<6T4qs@E$cBew7aK>wEka>em-Ug!?rc-??}W%QN^jD#EXac!%hW ze!Y$4c$8lOnf&r*_A5IkqjMI&e#*-67{9W``Zd<;*Yr4Y!!R~4+vPdy9xH691hv9Mpmkh6$i&yk@h`4#gkV{zsy;a6fw zzjC8p8NXJdL0P}r;}xovr!E!fL1n+LAiWyBsZNi6@T+YN>R5}O)TZ`z{aRDcuh;cC zzY(`TGH-Lg`nB-u?{0oQ>F!tl9`v-QUuS!xFMa7xyaVX%aKAo|@T>Mnzckvff#W$J zEhZ4}MEW_2{>|`f2=>hK^EVazx;)pfIrHiF0>6?L`BieYUys-L`F@GLfWGVe3R&-0 zZ#aJQt2LHw@XNQ!ueosk&M}nO!g|QLl{s)23EQd7F29Ce^y|?Lzbf2kUKD)bS4D(A z^vjJ}kNo{sKl|sCU)9kA zo4)z=43z?smCKN<;uwZyLCLy-B9>&?t;veQ#n5CeaVBefc(OiVwJTXWP$EOJ=0zm) zd;ethK|o}(o**VFS+y_{y)!5C_aQhZOS0-_Wge99B=i4vvi^=qR{hvyb%w>8tO!)a z5}ZZxgk)9pCG$Q^vVwCZt4;1?`SK7i8lzt!VnT<)$?6Ydk!1Z?G+C*|l2s5}@Ckj3 zC+kSrWbLY)tj}0iC0V=Ct!lDD>L;r*z9FK<7znQFux06-rF1g;PZy59- zS>+xP4}Qh1$H~h3Bw6d9B`f-QvQiNHIay&}c#JIHlGO>`fE4`*mmx)Q@EB8+=1fsn z48z}u4@*%_{DvXnDY}dlSBg4gD=wl^h7?Ui*@zS^#$mjMGNvd$`eO{fqEcjvzM)c7 zit1u?rWE~yiU}#Ijs3XnOVK0LO-xZM{FRiVn#m~&Pf5`$v`u9ltj7s7NlVdM>_Ex% z6q&N6s2Q#zSN0UHElSY`IC7+@Aj)9^Zr~Y)=S*uFvFUl^U4+~S&dr^vx@8I}uj${2Ej-%{ej_*rR za5zP)(dbBuIwJE?`g4-oQ}hu3VAAOnwY)&TQ2Qdi$5T|il%n>RQ`84Xu;^-v4A)ZR zy-A&L_D+g6++)oL?6-$08viIo3!kTG=4;k_!+!pk9>V&KzTy~$DOKYGQuW!8%KIFt zdV(()Y)aMjz*PQ5MyggLw>eeMP{@)hr!`eo5nxN@^Z2QnjyLvH9SKfVzwlIThATs= zPU9c6iA+_;s8p>$VCGb9$05AIFY&3e_)=9CA7M>Q)dW0A;@sp^Jw{>y#uZG}#s4#? zP^w4)Rg*iXa&1VemiJ7R`KMHk#UH)Nw@<28Axqy>o&PyiPf>hus(u*4+9)+N zRUgoHSSo+hGF25vrRw3BRE-&*%5?*&`g>xknomnr*7>RGwJ?>ho2e?ZFI59^bw6_- zNYxhH#~+7NWjsRt@FyxCP1VX{soHxyRVU#;k*d46caHPUrz-YBD(}%UKeAsZW*ouk z8>#wslYZVx)wJ8G`uz7p3!p477HS%k! zrov)QQ%U?`Nz-5GZ%flKN17%hFe**s5RxfP4e%s$nxr2xd)JsfL^L%OAia$^;f0}+mbYbR2XpuB|uoQ-3X?$Hv)6+_6 zO01lwp;d^lYMQEHe3LXC$H1m(nt+IAY3kZMP1{?facy^+*1|R*O?z-0=7DKij>{v{ zlwnkwx{OYfdrX>=F=%$0b|7kQn$F`Evdl}+4eDUY4#K7`mLeR;6p{nsoiYqV5CAsj~a`_>W!$ z1e7jMnW4^PKmm~|P3cWUKzi>TL_|P96h-O1DP4M#s?vMAU+(|@ z*L~OeteBJY>}T(NGQ2a%InN2LOi=Hw?6WOFpP|q81ZCMlAMku%Iv4MKN9r88RDKx&>QCyv<{gU5>)YGf)-pSj~nEX-z0khlY+R11_e#5DQVL6 zLMBZtYSL|dSlpybB}}SQ(j+f#p~gErmNsc<8I!WV&-M>YYF5F-?+hmOtzyzKTta~a zlX9C)DuPX@YBeddhDmd3niQ*L(xF6?2DwZcjk<2eprXg5j?GN^xP^%|gH5c-WzsNM z<0h%ENsaLl3iLB6(x12kO!|7TNf|>->V!&Pn6!BU`A;-yA=*wdX~;B_Qm32L8pURq z)O?mneHNKC22;K_sn<%AzJz&|Ny~pQsmf}TI;=Hm#}<>uZ8vE)f;-3$MR%HX13&CD zY3xyx%AGT5=LMeM;rV@&W+Cvvq-i*am5)rCp2e&jSn^hAHtQ2K&STb+d}bBTZ`KF+0|nnSYe+$}dKWQkdQo0Saxt?O6jy!I&*5VG{^_kTT z15w3q*5?5;>pYn?Cq(S1SqGENY8o@kmS)yUY{18j&2lw0D~eXwfi=y{y4J$1(HUlq z&18<2W);O|6mDgffqAXTucKKLF%Jzp(U;ED@~N5MnarBq-^}OJ%!y88=;2uAK;v=b zINi*7v1X+r*G#jX%rR^4T(eGL%sjImE~MX!%sPR7i_I$kjad(nW2u>ITIj(Fv+}Jm z%d?Ylc!0LMsR=iZ(2L_{y~MXC%!>bI)}FKU_kvk(KQya7K1aDnW_|eBtRqj%y7k@0xj<-@QYJ%M{i%z96cVlWmwkGV; z)S|J?EIQEKqV;i$KKPh<@t~bWGum5p8!xc51F<_2yR$_JU6~6nx>+={hlO?9Eo%Rn zg=@v=2|A-hZ|dx0QQ>~X8AKesz|z4MRsMo;LoNDexJ8*GEb542BdPIgix!Tu=;COL zZj7~P|2T`vj;9}3hO`M5EuU!7`AHU)nL<6&*gnIe=d&z2G~1$Y=U6moF160%^<@@y z`p%*$%PqS9y+vASQHNC)9sPlQR}*`UMbRI5ZJkBKHdu7_cMEIS(f2JDC2h5+>o$(h zc8=Lji%RX`815zJeva=!iz*$mD13xo9i@ij)O3P+Pg+y~f5LmpqF$#hdUD31JLfI> z<*G#muUXU@bFd#L;knLpEJxA}i@MJDmRz72}DhV5r zBfFKg2&@`b$f~JGE^JjR976H8t@;YJ%2?%x%34(rgR%2HE5AosHNJ{f3y@ybs*X5= z^3|=Hfc`bC8iQa>tD0gr-mGoa0E|wwY7Uy#x2hffLKzqPqjJ!yE{0Y8a2XGX^&_p5RbS#iggRSw1GBpj ztE*K`oWR%JteOW;cWU^|s^@*I>fP6>X#=h5I*9&ZC61xgV5_QsL9fvR)rZojsaD-W z)@fFKgimn*^{12n4C3Ltxe704K@Dm2DuBG(<>S`XYpv0}Z3S$KJq44dx zYKWou6?ahOPF=OeEF4DOyLHt7J+T}&QQ=-)WneP)BisGDs)w#vf(t1ApsrG3sasF> zdiB)ISx*@s*3&yX>*-!~n<^#PSU<_8nK+BGCYxGe4o;$|*`^NIfC3hq(yLs6%_O#$4*><%`a z!kCWC4|gY<9;0?=o37&te(YjXp&rbQtUYZijA?lAnN6!dw`u#=Hf0-S#O>=*?v8D@i{eoY~5gXBUgH3rhQ8!j1 z>t>rSZ?UP~R+~;^;x?NaY^Qg7Y(E zrd<_V+BLM5U9J!9il8s9A@Gr1YunhB($=n~?d+O>Tc6mqyuDrPaUNfEq(+qNY}akP zz0S1MB-!^8mYg4PoEmcGbsSWF2AGaQr=zI!4*m z<~zIQ;`wrF{@$)h$g#pM`;T_@#G!R|E%@24l{kz!o7iUy$7idZYh&zcxZSS2yX+dU zn`5xgu3h`>s(QdK&mp@S9k%Pj5w;&^9G?7T*R+#%zPq%m)v5oH_YC9l$3?q7xJfTC z7o+~AhqwO6#K#*ap)eBf({ih9Qr=lp_`bK z;?N4zj5#zu)uHBT%-e<>VEfpiE4YV7?Hv5x;^2Bkhst$!=s-`0hJNNyv(FuRj{3dH zt*?W>;hAe7F>wu-2lITGL*F3#aEG?wARgkU5$re8!S~$`eK6IbOl+9u(CFz7&A{*2 zJlmmHSUrca2+nnA@jT+rr#G7&>b=FGd0QRIdcmOvxQA>P9U6fvmmHdK*`dUL9qI?u zf8>enD0kbT^CyrS2dmL=yYlsG7_EY zgnLM8;M8;EbvbnaIo(dJ!FwU6GEumpQ{}J}Il|tf-#79PB z;^Q8Yno>tIr{2LvY-#S))^w*XXE?Px)2ZAYo%#cLJ2~}nXZGvjRAoeA`P8W{DA&~~ zD}F|i?$n0+Xxzi8DMOt)g0H@GYAQU#oce1L`%iT$%S^V-W#0Kty}+skPHlpJp_A)p zm}9Y1-!6CRDrS67?l7-#YV=B{>aB8W*LwQ#i&N{d8_{2#TE4-lR=<%Kc4GfdryA~Z zswuv{N8Jyp;}LZ{=D0qgR}~Z07Txg&=2S}5OZ-teQRmUNN}_I8WgFU7OVk=X#aq=A z^&a}*Aqtri)dHiTSG_ zn(!hOtRmLn2Y8 zNz9d8U$gTyQ2B8Uw0?X8MJG1kI;aNfJEegNO>3ZUrZE>?1BYZaHiO>n7lZI`Mybg2X0ZRBEpm;S-> zRF~XoF3rL4<}U3(?-nkNK>c)=O0*_6^0slQBrafeN0)MTaw&Uf#^M2TbYUKp`P8Kh z6zu9!S!{!?n~UEcU24B`(g>baCFiOa8SkHAej(UFy2q z#oxg$eYnS^ZkW8+r5fj5`U?Foy7VhLUvg;xKE3Rc_m)dTQ0ul!K4iT^Ee~AUi*e6f zI)K5?T^f&CFI@T#j+ZV4vbyyhPG)nn=7U?kvb(hd*AdO(W=&AH=3@n3z@F1B13#ca zF1O~woZGE*bjNfYE9utZ((L!HTV0T^j9X<8eyyxq|6*eWxBf;_MYkSSa;sxywnE2 z-70#6o}=(h>PHA)V&Ok-CH(8wI-JLA|EXIAp1F1C zxm(YX{EB&zO&(Rw=FxWC!l}F-ZO-q}VGMuYqii2|)D;tP5ciQ>!J|32f%_FbYF3GT zun3#+3Pq}TWXC{^!q}=F)vo5zdYG$w6h@l_kG{s+CXXs2`8Bggcd*9l(YP8Ot;3<3 z9-Xf3(V03P6|U=1F1ttXp&hb18IQ!*52++;v8tO z)cIeJCLwm)qyA|5z@uTXKjt{0+zawVDS72X)!bes z4>(P{j&oM8^3?DuUdyZDm{iZp`Y~SRbb4jR)dpS_a(T5Q;MHxEjC$1o)35~(lD#UG z;#GIdM!htzGVv2Gpion<>fmB?uky9@Ui8WY{}rz~;y!X-rJt`|^Xd;cuY39I%c~;)csak#s|@tSV*G}J zkBAN5W3OsF@#-jSPpKEnUU`*;BmF#=PYa6qRN@_NKK^d;X>}K$TwQ%!7wXfV&wRR# zHlO>{3kzQB<&(R&Pe=Or)Tpmd<8T5M`tck`aSx6i`sYl6yNLP zd~9kv$b6W4*r)9{jbcYQ4sagx=_CAwyvOP5DW3|T_Ng*XoZ&fYT;RB1!bNgGp-c4r znoo&$I0o2#*QZ-J^T4NU57`daBOkv*vkj%6aQv__i(h#Q`elZ%h+iFWp}1d<@Lma& z^lLM&l=5qKX}`|A_O4(3%lKIv(a&d@ypFksUq9f~Yaze-HuNi3l3&}>h}+b!X*iDD zE&cra>sQ;>evLww_I_2w%}@O*)YY$(J^b9%)US>hfTgc}=I34)e*K7Nz5VLc*U!2H ze%0;gR}%ijqXB;98R*xJFZ?=zVnh8hVHi%K_LqKj9p=~f`1dQnT8!{(Fn&d!uX!Bh zXKfO{){XJ2+eE)wO{FfJMUH8Hl|~rzunFhUY`R|!X88GR(yyKKsBONVwU+7A0$y9_ zm-8DxYbyIycBx-4(Po*S^SAx7EKhy2=j*sp;{{E8f{l67|C<`Fki%8KD%|kvlYjksg0{E( zT-WL6b6o1U!++oPv!<(GH&F7vUv(_?VvJ{U?5wbLT)fvLphRTgG@hVL(}4V#)hwW2(XcsVF&b-etOfs_LA|()#qof)!J8RSOANzu zY{ulb*ZT!zZq59-hBj>jx``?u2h<$f(Y_ry;ge4Ss?}df_+7!^nE!43!pe1_(nsSsJj}h}kK;=)<`!fL*I8Pt& z)kTgS4qORnK;EEs6$rAfMNs8F2x_G{sMN%uEcJtYhZ9twK~UE)%N10bC#ZM4L4}$I zdN4t z?xFY>L5;*Id@wYqPPm8`Uk0@ig@y&y3=8oPuCIa`ik(Ow9@H_sJtC;N_#Qb%2lW=h zV}g7}A7nkrAomds>Q8(|3+e^@-v#yI@}NG&=@mikTNTvObwTz1DX3wnwIQg#5#AW&`p2MhZ3?RP zmY}@&4tcgxGwPr-w%{nVEvWo(V<;vd-}a!!Any+HL&naa%)8izlkn^gDhbnY9gmP} zZ%{wrnQ(skZa}X@s*$k z;6IqI23ebc*!bvLQ1kHNb;jNZY6ptmq>s0P>Up2n9t3q2=?}>pH_-7B{l=S*gX)64 z_~i*Po)RCK&&U~$=hTPY`1S=kzT|y~a<78wk98O(L+@lUxVG2OwXBAAWHb2Q(@+JJ z$YE#{e$HvAXD&mlu_w2ox_J!EM}fSCKErvWyWj+=7cjIK;WrJ| zjW#%k#?W_#4Q0M%sN>s)zQy*UhKdv;7Df~|^st1X$0ZGoFJ*8IfT8TA4NXObcMbi7 z7G(_ODQoB)V&x1i#U1P_PrUcZ6W)sCUdhmsDhA(~8GJ`(C|K9fhxH6?!#c0QX9?6F zG}HzAQOz(|gT~-oSMm)RT8?}T4Ryi+tZHP)9RB|@qlTI#8M=ptDTdNxhEBknYVfzE zp~7i~l5q#$G%;jrYVbJ)^EV@QbH=nVR6X5L{tQF?@elT75)UO>(g&opB6oc9p`r30 z8M=?{tqndqGZaNR3M{E2Gq49!8pCx(7Q*Y@-Sg*uQE zvUOxWeA~%Tq_d&v*o0$U488j)#|X!erJJEfm=0@qL#2Bd`Vm=s8Y+emj>9v+&;$$} zXy^h8e?hLWeo5~~7{-M(Gb(W z<@qw+&p7-Yxqi>F!=4p}x~=4Wxr%!5)enY_pxtUiN6}*q$LB}-wvL~ZpXvX4L&bkF zG<*ZK{l=X5^ml`GKgk(Ka1|*V$zv<|Z!^?;yP;v|zr#?KUHqJ3$!?C<9_GQ>y@qn` zGxRmG?>98yAo=5$!~7g$(Gf#$9OYOaC)bmPYMnCpZpzT<)Aas~p%2dT9>h!hbdH~+ z^Ss9|(u+&HzcA;rp+kRD+Z98OtA?gr1!+~6;hG+LaJ3hq{nFU zen?qA2r08-NV_YCRHsTvyKt;(NDZom^e0YK52?8+q_1!g+sq;EF+?n^#4Qx85mH;^ zuN9IX_v(h^s25U#jn@%!gtQLjoXm|57>b7|kr+}1bjMm(NO$oH&DxF=3XYw!;$N9iZ#;3VEk3Mqv+F8{lZvm!$X)`gg6h9p5ijfrH7P(sW^mu86kPl3*X}k%EXC-i8z3_ zGwD;Ckc>}5Dm{|tg~MvwJgh}%(jrX!u>M6TBP_+ky4E(V3Ll5{7p|jAyRi0s66SmE zFzXG5)xLXJ^ZSN%4iox?wE&g+hxO%vutpCI>-d*pIY)<8XiQjb&<$%)c5GM^u>;x1 zh4mA5B0N5bsE36)PiY9XyH#e+|^K6reAK3pUp)V@UBcc=?P z?=m+^-V5vV`(br{5LQ3*ddT+2VeXj`*7ldYo;{+bcq2zdr7#~ab4FApcSI?bBFbJl z!u@$8T8%co-AH--GxMD!HjuZ`$8cz%p%-nxhy{S?v4!x8<9c}F5zh1y3Wns|&nk4KdMVnhw` z5(O?rGzoVuN3`Vc2OXIX>SnjCm<&Uajfv8rz8P)oNQGNARRCC^oDqbb3 zJ5{5)TrH}j)uY;(5Y<9+R8uTbjj={`vsP4p){bghov41TOU!yvm9j^59h)7*az)j^ z6V(lGR4@HeeG`c4crdE@MpWl8Ar#dDRB9O2myM#z9geCr2BKL1sM3&oKvcys2hRpZ zHDFLw6Y&7^XA%b!W)TOKW)o))W9AYEJ+bFko^K#O>_zf#)cHF#Ze+~PsLo^JF6u(% z-BAtO6P0&wRE5q(6-CzbQ5D8CJh;G|7wN;*sB&D3a&1UdyAZh^)ps|dYI2jhZ$9imCSt|lJ!T~ zWSzyw?c3ZZ0CRUeZ{fbAQCacir$tpi2S$Rh!Yxcxst(cUo!t;r> zFj>8D6-U2G*1JC@t3B5KnykQvWOe?X$6d+ldm>p?E2U^#(-i&wQHtJglcIt>Q{-Hl zqPAO8Gz49Cr>N|oDY}8-hf>u2c#0mtUNEM%g<~q864S3A#MRmzIbz2OgVPPRC!NK zuDvnUI}%gT<1tmi>eDfOaVDn8=VMxn?=CRU#hAuCh-uc7n0!xT>ijIG!p~!hU^>R+ zNY(r|QgsnO#%og zs+`+Wm4UO{Q&oFMs+M5R&Qy)xm8!RPr|Qw|R3+U>)u(yVRP60E)x|n=E|R7tC{ip< zajZt(;%WLE9p6n;r*dfumrqmw3TYagoTi@L(i9w(rXLrkY1Pg&ZN=c-#MqZ6>!mc! zQDe2p(pbImw02|VG8)U?zOjmLXw3a;)3vB=y0&*r*N{)sb+2c-+VoD>0esdsUBmHh zzjO^7n6Al#(z%W?U6#>2V&=GXl^dU~I+M~hdvdzG)6%)#B3;X8rt9xn>AJp-I6tN9 z;QDm^@=Ln%{+2EmMsG~l#!cz!wKH9%j->1S#dLjhH(hh@rE`5)y4GjQkS}|N>g3AM zISeb1p@wf}=)Zy)DpV+gpHE)je!{|I4DCQ44j^!)3Y;F za!!W!;|wOw%}|wj8M=gfcriai)_16T0u#|$N`%g_*v z#VHj1DMJw~K<@P!DuU343@t&^O&Pk6vIjGC05{HL@cm?lybp+hS`Voa*D?A@hA!ag z(+stImZ2`$;`$yfv&Z!*-p&!%>6~$u%oW#uoWaE0aar@kwGnCg*pB<9;!1uet~d@L zZ|S%^NWv@}N5OaFDviu?aUHD~m!(o%%c{neQa#Sv9C3Z(iK||6T<22QCl*)j=8T0h z;~IgXz2iE8?S10h&m^vO*nxii;wsfYu4c$LAg*_C5|zG;t1U_li>osBBggQ#T4BUU zYJqcfTz!!+Cay%}9~DichOt7 zok!olGIbC)kmY2i%y42F9wX@_*?CGA$|yh|#9}Wv z8id-aM!e8(Xk6j>Pmej1mJF;~7(R7mQ+&+%#0xytv#S6nD%~-*c%)I>=%Br^uxgyYVij7!lQoBUg);@f_Qp?_f7Lj<;GR?mBj> z!q2hpPK1VL;}ZvgYVp!H$?EH|l$1;6;h&hx3%S_wVZkHyt4KBQPX8aj3(_Cdd%{Cu zUnOB?#K{8NHgCD!!cBNSc1?{}Jy$m;AwhxZxm@7|7cqsY9B>6-DV0p7lVa|e zBRJ9psNn_ZmWG&sLLPfDXp%AF5px~gqhMF_J=29d9!(=LPbGFlFc1tp3%gGx6deX4 zA;rXWb?>QkcISZiFyRHh4yDj_jnQ85-?vC}&vDZ$FeRH32o zdn8~n@SIbbk3(E&%1(F&i9h__ZSLUl9pE1J77B58bEN~+9$YyCFImBzI%EnKA8hFn zNAW$%*36ruwc=n(A(?PMZ$gk8?BjoD`;7zbq;Y)PR82;WU>$fdZlv=Or3;T}uoV)w zVB$b8_=q5f7NV#qL^ttFQw0srO%*F!q6~c#9lHZ}P*rn`wj>$%5ceEc4VMf zE43pzRWR5C?~~6PCAdKyYYDuBz*Je$LP5v^Wx`4YTNq$|5}L5GRU-ipv+RQ;HoN;z9#Rk!UiMi8M?p4TXxWG>b(z~E?5Hfi8)6BR-l$B8;A=^ zWgMtBGMxvPK@R|D=FkR2SqA>2kU6x87%gZb;QusWx`-GKOz5Cs?J#^(W4l0IWiXdD zSMX!1)^_PbF2{smO=0zQ3!Ip9sQ23s$JC&U+I{KBG40jvYp3YwR{;)9-GmZ&*A{CK zjFo)=+MbG{h<{)g#SNWtB%N=nK}Z;j3p}P~z*ZAzV4}^jNdiLywE-~n*+Nqy4WK|V zpiKp^x>+ziLWxvV1KBoqCwRXRZ&Iuq5RdwhyjgO6V!s3()|LqHar<$X;+ya%g6E+1 z*Aa|Su$a#Gka`mmfqfvtD7~xMS8UcD7LtFEcTsD(T9><*!9{mt)$Tqj> zj-i4^q7EAHp+(vi^2C(FTQaHwCe%9E?1R_Fllk~*=*ESlkd3EOg=D&r5#zOXpS!-k z-n7blrw$JvvG87so;#0wt8P%Azu>H31&l!Z35-F58?86)Z<+8w;;P9;pI_&3)#?l# zgUGd7aa0LAjq~-hMoFF2mLe_=gz428v48>;CO8AuXJW!izL1NsgcmeN+N)4%wFh>S z&x!gBEmZkj?)c*Ra+E2bB3m=+()fy&=E=#l-m`GYtIAn<(YrdGfbDn-*I0vgU* zr<0`8YkE?xp-ZDxSgDq5?W#Ca2E$~1IpwqE>{+qr;(6C6Lrt`sGpUVK37yI)TweC; zsdL?`jrHtYR9by^F<1@f%~h-BU6r2k7iHS$w>qd@HS~7H7=@ButPgW; zu_W;I?x3M3rPWz?fE!k4ag|=6GrmlRT7^tbOJZ_XUr$vZNk+QgpVN!Be-TQTMpdpF zgX+1y$}jRmCo5>GSTj}^-1YIxZCGsP`Nn$T_wD}0l|QPR-bg9c{Yn~}4PF};YiBsu z$*V5U6dOk$7 zJQ>dirIu0_`Q~&YC5uu9P5PCZa^XvZUZZbGr0CCEv!O!Hl8qLrn{_>Ne%4M^o=uCh zR1D!kLA8PN1(ui;8`j$Nh!8rb08Nv`;&E zZBas_)4HLI8^+}`ylRD4t<}0wmmA)&bupN^NaU};hLBVrk#aIHb4uk>ubXs+SUZlV zL`XXJCh0)NN#zSddY5#rkA8G`*0!D0^|o`)A0NhK&zO5d(HOU9DEeR&__eQo_R%Nr z|MruAeLMD@d&AKOcyHg}z4NEs_kZ61=`SDgH`O`eVj>SIM ziu4s`rN<7qfAORNx0sQH=*bh!yi08OSKu;2E+gdyp^fDFFvhx%*3pt$Qnv_*QXNuBYL!%_ z(nZYTWQK%E;)LCVB#;ja%y1-2W(c1olVu1CNlY$6?hJ&$j+sq1*wK`m%?z3tAE6N z&rN&pJ#Pf8>mM2T;J5$&8@C`6!`JVG+l+9<`>(t0mQNug1ADg(t}&ngLj%(6w+wvX zslU7Rdq{8iOLn-I4A1c5eV_Vp-w5~`G6E`a@dx*R=Rn_Ga77U={OQAgdJ3LB1FNrm z{m*~xyKCS}cCgt@2=25NR-btKdv{r{95ZYIE|15TN|n9KK+D9KFI)lg(4re)>4#;dX{B+^xu)^0 zfV!qmJcb~q^#eGdL0;UuJc7uTCTnd9 zYSXGVWrZyYKr=ba+g5<9;N`7{#SDwdw9;(a3Ocsimzx2S&-X_`9?6;Wd2pF&;=s=J zE=ygg@p8VXNxY!u3ssq`2>dpZwc$3LVXP#_Q&tLdU{>0}+N~_kU^WLi_?Nxc8}v*=7c7DQw9L0FTE`THrs6u8%_`y zjjhdKIEm8~LD-4iAbTkt^ZyZ;p5CAesw&B~(9KT(U|;**wT=!vm&+fDX5>Ue<>Pgq zyA!iaSenutGypqS@Ba&+O?Pjw?Hp`tZg!rnk zZH|R~Pw3Por3+?FsR64IMck%U0J-ot6Es5-cG^yCTY+A>a}?Ndf~MYuo+I&9sa8am z^=}#z*{UjxuLh~;lb~lBHE&%3a_}zggymdV`rzGKx9-7yv8CR zhs=WNYF_ws9mg;dBgqMiBB*t_rotO^jYU#bO;9Y(JG#IKEsES=mKCYjR~pO1hEbQL zTJy7BVBX%sw-5S&;QCvmToIlPfxgSOz`Zq9P^6kDKXW4(+yyM-;{!!WZ7Prc8<>Iz za8*gDHC4D@xm{87nj$@L9%8HrU1TSI=S;rYt-~g#YW2FTGzH$`yu!lC{5WHj`265s zkRdR(a{vsUKRCK}kk|(LN5GZHA48+Y{G5Dyh){vO0k69YPcFj7KPS{&D>jI-GMBH* zDq?p1xX-*H4;zOHI|ec}P*m7jGxjjR4{l|Vy_?}t(p;)KC8vR&FZh@XFnnUe}^e+qec z(Be*k0l8VXObFu!=XT$h&6qwu-w3v!H#M+*PGqg7iN3a>(k!QdK`z`i|8qPxtZId_ zz$K@U;ks6USA|@N{|3veQn3abPM)n6^ZUNx^eh`lrU=?b5MZ-V@ZGPl7p*_q@CKf8W?GuxGD#XaNp!d;7;(+fG3JDMwOG@FD%>TnhJTK9k>F& zUFb9wmP2z!Biq#2tciA0CT-0*Y-b@u_AES zPXp_Vg?|8pW0{?>Z49fhyYSlnmyA}n?uy=Ux!#uh=YL)}zTY&!^Y9kC-qZI97qeLu zVSg0zEXSG7`|wAMsw%sFe&>Jw$?YINe(xx3GtH9BJOAtQZ~5UZ5I99><_oL}|2VMk z-Gd{ayT-N_7|QM2U0dpk)MA@L9yaLyA!ALh-TAQruF6Vt&N%?2zON0mV85E!BO*@% z4SB&Ju}H)qboLxFl$+z`zRw%s;D!9gz|J9nP~D2bAQ+~W98D=`q zw|^p;1c#=UJwCO}tOzYxdhwYj0pbRg@f#46a}pf-A$a_UdZXkw*7~3M5g34KM%Kpf z*`NrpKda6B(C3V1p(!Za(k63L(F9a8nJxhGbI)A+sA%eva)};n;JT-9};9#Mqn$ zAJotwY*pIx%RNs38C_-?aj!DN#}fO>x6Iqis*GOMKNMR1NkN6{rZr(=40DWywb~eg z5wKj3mm5=;4L$%mv4*m7viUbE+iysS3TYC<{Ux{VsN{TBGaL@X*SZJy@ z6Y_AyK!+CGX`-BqD-{%&(Uq&s7C0j9{~3DG;7bycaJgX*gHITX676bCB$}>HTJ5yh zVB4H)$`z~Az054-4YO6g6l4lH)ziX?T zY1%_rgUNJA#F%b8nHEBoSUX3y*|^oKW_h1d40~v-5$u(@I?I&E>FJi5h}IJtlPURK z{!-dMC3YQcM|RFe@Ejc|brY7|6NhhI`Rm9%?n#F=)N9wLtJ8^GeKsh`vw2Uj?jr>$ zWaSI)KwPlL9Gsh`?X9mPFI|On8k6i~RH`)Fv!PzC-JA1HcIW7NGv>uh$wEMrU2Z;E zrnC68Lk-{_ikr%^s<&8Zr9F|nm$pupiwx#wD7HB53*-}ZCY=gRR~W@zZ$%o}yb{Mk z5hW-EMQSP@#eFkncLU3%saTW{*h)G@b%Ksgy_fLydXajM^x(cq$nI`AV3+WwgY9HX ztk6WG#8a-MI9K&Yij5>xA(SUpNh@N(HO;kHZLZRr3{G0Jj5Zk%YE~YLczfwuw%T^* zZG|%9ZIv3eTBpU^Q}zsz79w0v?aWRm8)VZuJKN0Kl0Kgj%QJ4l8zosLtKlHRBMb+peBUOyc=yIOgEn9(FbyEaeNKQf5ZzMzma{+Y1F`$gk@!#SdQeD?mMXQU1s)T}RblmqS$@c#JeR3cEUXQ&emYTY$zhEkE=dB#dHS>KQcx@2dHdOyiUYb- z6bdC>RO(7m+yO#sa!@HwV+%@AeQqNQ{6brFb@!B7D{1p$ymE z0neUFEq?QDQi~J1T0HDhIHh15|HbL_;>$<%qV7PkoRMH$H;I1qs9Yo#$wdrmMJGir zmW$}0(Q6|piuDgYZw5{%7>AG1i>6C9oHexwROBV&yjp}(5ni8bNiMz}a2uODIBMk^x;uY;*vgG@FXtj!`HeJm-OM= z=1E-Aho^KX9@d8`wmC6IVq;OZd(@ps+MO7Ea(x)S7d0>PCN8PNcf2!kNgcjp9f^zN z;RD6b=00*2bRT}>{5Rx2T)rd^U;i}olKb$;RP&PiaLIl64xVU!yX4{TA6qr_x@McV zEb{si`bCUINyQze7QH=(i~P zJM@4jW#_m|y{WjlbZy%1o2HnVaJ5Wuy+pRvt0)-82Bxq|#!Hn-lcgq|i=-5B+CANh zD~0J&G~(97k&v&NJuq5iXnp^V`H(W2Vknx>r=^i{nn(8llidjCS=ar_cy&mh5yxZ}rxi@aD;zPG@W&c>)82RIC_f)ImL{63o!1S5 z?R{HEots9m-!w96YFfI1G}6S zLCDQg9#?(FJN|C1|wyWfL&67yj*(6J-K7R+-8Xl(0 zJR)s@u|TpSq~I@hXuomTIUh+ja<>s=Mi>)Nkn%kak|YY8gQgsIffWb_7ib4(6L=QR zemWS66j;##qwU~c7Sm`JAUbsSN`u8Y@>8Spd~jelG=VQM9Svq%(Qva6o|A34 zWFY4*@|B!4sm)bObiHe9hg>gUb!L?a;yHC;PMx zE}yq*_uv5!txTsdkqFh2m71sQkKs{!BTm$_!E)Q{p24dz4^H#GZW?n1k|4ca56usTlOwK`6-D<9f+g!caRCChT(@Kq0hY5FM(Nv2I`{Y+m zM7+FWlqMP4hB;1VBe))#38;r2Tn5dwQ&WR}vPMsbGIGRKr$g}a3b>RE)+2mY&B?iX z7oVC@ZE1%`h&mEd%wN_bv2K^pO5QBn!q5#XZ+>~jJp>`zD2|0;pdt+agbj&w@C97N z3#7mZoC9ZU99Do~oHW5d1Z~=BkdtvoPV`iYV!RrtQMJYtuEo-khO6hFmSzh|8U`Y! z1BA6L96YdV%G>t(N-@>Ow|azZvx{+`Lu+aQwO$p;aI@&4W_)Zzoz!B!6ear;vqY#9 zm`>$1&#X_yXOXh3(92Sm6AYJD^E0wg7`8D3+(~q>Xn7l!yzI0~)G8 zFbv6%4#rM$43E?Jyh-Zqc)Hq2x5KL4lV}zgTXWhoGn2~^LB3Rvg-dglvX*Jrl3FFL zo1`1adQ*}&60h1)$z&$d5i}`SNhukhtDTfGU4@w>vQu$)+cS-oOL!ne@u_S*FjH#I zbf=@PfF*Wt`34e$^ZAs6K6GI9$v(XUtB;svXU7|Ehgi8I27F>BQIqOiyVY&5Sq`uI z6VsW9Bu0Z>k&f}TWJL30(L~IhR)RCZa5L^r@GSa;je1kza2BU%9tQW4lpPniLP48)r3U+k{m{!RPWEZNyyB=qh~|vi!MGGr33WnDhp^8k9g}pKBw`{jc4OW+ zJ{uq#xX;#U;PF7ht7i3EPw{KG_UaBr;K=JTp?JS#A0|HMzk}&a~`7)>D+FN`}w`Ez_b{!KRd( zRHu!n=NpOxx7kRFCQsH%;QB=kWmnG8YQ;68oYoS(?o6OmnXJ?cN=$7FB3!-xz|@-`BVw+?6^ z656X!peP!4Em1d%txknIy(vdnt-2KnbA&^YHrY%xf?3`%St-E~mMmUO(y~wr>1GK_ z2_oZnX;mT__h@BKus5{?*DVL-sd~tROD?SK=3MD;L}NR}Ad_^*q;^fQO*iBgpTVaJ zmNI-6QRK;530%Lpq1ZEYf#yrLx}8Wy(;2xOXSg13^T?4|UpYP{3KdNj^w6?QPU;d_ zvNr9Rl|x0}bReikOL27fg?i6{QGz&6Qi6bqB4uaoltbWX3J$z>0_W@nn&xnuz)=ny zFF=bt;cY}ZUY?BgD7==L(U?#yIjPRNqCu+6v}}?$?=K~Ckw!$CZR_EJ^D{&G>=0(T z@!@~Q4(tN1UvEE+|KM1)rw1D!jYXP)XIgeZfU!ttL-QRL08j=%74}-yr?7+9Vv7US zErb7ZZ1~f@nb$@?!KXWvi0U&t020}t2P+9_rTW>{LKyqnOOf}D9*$d|SBM)92Q1Z~ zPV8g!B|UIe7m6nP7+jiR7A#Or>XA0^7&t729vp@dmwJ%!bq997 zNk!?pduEZMgyF#OE9NETMBh`xnfWkc-z)bCZ$MK{^j$`Ij)VqB^&sl;-DW*reJ7Nb zAODY)mdCX$+y>t#6!y@`#b#kiY`)!M^9#l$vH1=an{aMvL2Oc|=u(T`-*&x8waHrU zfU4jfAvRAw#4NVQn-rVeyglBS)_md(Xw73J#AE40o&PbWONc*gI&%pzvLqpvB*d|9 zsU-=qj{;DMjaaR0QPrLzt)iI9-ar28CAM@yshCi)7^G5?rlUaJZJn4MI(%a?I z+vVAr%GmYBrZRSK8V1MkCawYKfN=m!tN>T^nILuKa)>Y(h2rst%O#WI%NTULA&VSl+7m~9RUbMFOqh9M{d$H}xO4$p%Z_JVp+Pz6@uN@Hw| zAM*+=p(@uQR{%!NMIs*L7UTPnuxfpE?Z$<*wXMjz*R4lS zz>Gi|{r|X2cX5$8d}E>4(%qhO1T zVQerd8E)F9A7z97X9g~8)%U|lf<&$c7s4|P*htbrA@_hyaA6nifHq$Qvsm4~>2H5- z)=3s4O1}Xp3oMH{c=IJ#cvz-ki9<*Vz`%Q1WKaN;CQ|2J_~CjImhG@y49i8ZjKeZ? zn0+x6L>J%}mP=8bGh|v{n#lWg2#8D8~61uMp|5ai}~8?(48yMp}qaj=rD_m$%)jl5R3iKf-8m|F%QF5InS^_f75?F#A5bnUgE@Jg2nzi zvTF1geud5=(D@ZZDfB46!sc3r>_r|QJ|12%dKg}TK7j7fUPG@KdUD`2_zIW92#+}y zVWHYnOPbt(s1Ou0Y$yBkYQct!u!9J^co`6~4d28-{#qyAv;sAq`zo@cxd>TtY$VaTr_V)`rs3BhEB^JId1S?TC*@V_J_WA=eeAqD zzx2%4kP{*+OnErm97R@~g&?Bg1!~36Pu3rWR@|}v%%Bx8#{4}{tu7!dj>|zL2tCFe zU9ooLl2xeZ{5zgE8=Th+vc$b8px8|p-HRT}si?2iM^A{nIWtnl?Y}(&s(3^ig%_nK z9zL=U0uf++2~_dcfhv|_%m06kEhjPDj-Lur0d}MAH4`5&1Mplw0D71>viXPi|Mf&E zh>MwnCqh(=!Gqzyc|?T{_JOE0J2=3e1vZ7AduW4`b`V!_9J$O=YMNe!Qyj*ZZF!YV z;k@JZ!YOnv*n<9h9SAdnB5XZFIz_)~d{bnKw})Zod-}~X%uXl*kCG|i6ZK6~%-&4y z;XNl(f`=()N7xiPGZWU21DS!^O{Ybffw|m1a8j7rTT7@o24=QIsCX+`W*d$WD)yUx zb}w>rp4nSYsK_GoJhQV%sCboVcIJc%AdD<9Doz+;?r>uEljR^L??sJ_!*LjAwv>Rl zlz_NIGJA_iW~UX2ixLp8xG1>(?rp~>Af8Sf4lIeo*M+!U5{G9Cal0fAUkB-SNgOVT z!xQjsPoI5w*2LjS^A8t`LzsW~r`5+sq#wyY9EACY2RyphA(jzmSeWuQ(~#;x_oU+O z2tF|)g*s7BMo9%oHx&t%TOK9Zm|;@@3;}LTlySCA;sKsGJ`eAK3pea$qMQ!7)KO$1ApDruWqa z!3L-IYx6Z^rJ)S}PX#kvAQ%e!E)tX*kevv3mqCj{XF zec;(0fc=!*u-*H1rSAG#EP z9i~f%|L^vjhk@(b7VsWBVCX3C#}1kOWWI&l9UURJ&|tX_mX~4K1&sjD2fnTw15$xQu&jhtQ{feDf%g$bA0c{C>s7pQAF`gIzF(ix2vPOcUxQIuASRj8r!z-YH#e$ z?`m#rZQkD8($U$~+TGs!K^0W^ndru!Rn;!xe*ff#h9~qG%YKD&2L>xs)jI~q2FfSn zGJAD>kB$vWZB=}$yED2uh;Q=g8O1Nvan7eLdc;nA{AeOgdAt6xkN#-S_Yb}_n(^@^ zD@T_k!exJ62=Ws};!|tqP5#1L702%x4Mvq{Dyl|z=xi(+h{_Rf9G18HEbdYn9+}rc zAibDi^;+35owExmu|41Jvvfh_e_qEx)UCD@qYnM$qn4;KYSnuUE7cga>914iMwRK* z)z0{8yK;u2c3m4(PDeDNItCWJztvw<*>2U>rN3@Hr%}&nRe7G&rr%**Z&Xb@mHLay z?NTmx@Kn;xO7X2NXgIlV5sbMzpM3D+jCu=pkL5q-gQY2_(S3_Xw-qJp|J~5=13iLl zlC?(nFY5YP9gOaA#n1QX-uRXq`WW4te0-}Pz4>4iZ}#a2gM8j28N$)<{EqHt?zGX) zs7MBDhvlWEZPapIOIb9k`FBdQFD#$4ic;caJruEYLFdedE{$?Vs@iFLDkTuoR+xOHl1~AW>D); zJU4g}b8tw{U@p*-5nXLr)NFWU>Rip)VEHy1EKPs>(n}hCQ80p`&j?~zk5;SWlXo;V zot+%tGE_M|P#!8OKGpQIy4I(~@3f}qq&`O}Ic(g?ytfGDaGz_VCT>6x*hxOR-2=i}O{jbsS+-rXlKi~g6_v*^qURfSE zT{=EcEmg{W!+i}Oh+A&;&@M9a{sz*E3HE#|8>Vx1Atkow|D3MBUPsE9S@8Y^m1Wws zsKtOFmiu-c0Ere&jb@#-Db3V#ldWA7p;7rvwJw!u)gP$={Who8-=VTYD%GjGJ5-MP z0elX~0crq8Jddf#lbFsU@jcCY!azL9hv{2;)fml+$3V*b&}&7X`EuVU4Io`mIv%5n zpZsReC&;%cXld?gxUu2KehO-)M7QZk>CUFH%JEY9&WU1mYNC92VytIl%dY4amEWrd zvxYDg$D{d^F{i5)P1TYH=bQDMTXk&EJvVc%m|&mZVteNqT?0^_qfjDT^5>U*oP7Kdb5&RpdFTXJ_@bqTPkZ!!1$(^oW{6V?e7X8JHqYzc^`{FbqS!J*0o@c2|y zWnij0+R`*!92uAzt2Ui(ZX%;HQF@?w=g?TGSgsx`4fo_L1I_Id`N`&!LoKHc?ArJK z=4#ibp~`Ua*wE;}*jTZAyx4Q^j^XAr!$;dkPc;{YC-co`PmZ76Gj+H;-FL8KVo&eh zqvicawza5&(`~`6$4(XX$l;ztE$tnf$`zpqJ?#_s9?Flj^py{uEN?%tYhUv{UGLxD zGJa&wi8DKT`hyTAhZoy4Sskbrd!}0k?w&k8nZNt! zfrH17oa{dFz|L*WJF4Y;`;q&OA3T2d?uqJn+kvTKSKo>DBkh%YrkZz89qJpIQeU=A z4NgyNnjEUAMjhqS@Wz&W@zg+RO!4?cWu!D#e4V~exZG|RUbHQ`C(3DP<)T9|W>nT0 z*wW`-7DX3yY|wqPikG|O&N46*F8cVgkICcoqKJLMQy=}pT@Vgm_VHFv==2BiS)ab> zV|Vuzgvyc&rd*dE7LU(h$(>tLx5Py995|Z8hANtT5YnTX=uMjBMNL9-#+272{Ha;L zRsv8~iXKpzJ2g?qbY4_%R-ZO)=EFIJn%F*`dMEr)$8gX5E&;7bOt`_W3{u#YZZ`7}LkEsu~D{j}D>{P1{ ztDbEtvtRGBTh~Ul;0;7~=@?O+CshAFl^Rt&2X%j&>fWSxEb8u391q2P511^e*C59n z9=uVD=r#{99oW1&PVCCKy1|`!-$^~^nChEWnr~uXY?H1)QB>pHX}#w_bhq-3$KU2| z_5A_0_PE-7Qg3rYqh+Vs(yTtHs@A;T{YZ45u2bf2z4e6h$MtRp^ev0(yFT4RnRd0} z9_2Nw%#?b(Pkl0_KgMN?;z6}+Lj5rrx6HM%61TM+k4D}J5O+%LE9owm9@jk;)kIEl z!8}SsCEl!=2Lo>*CGdfGPIl>+DVvW|QFPwNA;t4xgS%iTR|q;sb(uPTD*9>7u#H-+ zdeu&l#FIMbi}0nHEp8SLD|bZiGoiQSx_y^iOb<>drxbt7oO&^@64cwHJ`11wke<0q z$J_{Vl+^RLe&nL}sBNq^tRJQLi|}?i@lkWp+kH=l?c^IY=xEkK2(R0Bs#SBX^4t$2 zgRy*8zhQm$ygWB6@SS;nGEKe<*B@%QK@EF@j#RwGw>*6Bg7QJ(U_1_Lyg`w14iea+ zzJeJElGYLW8Kr)){mk z$R_pkB+ykyd%_}x$VvuK#0*!vesMLv)hq6ss)>%jX~%tWzQsv&{P$kc@Tkxn&~c_L zD4PvyFwrD3emyhA{?em>UoljW^+cgRh{t`}sBl+m5vZUF#(ksZtQJ#@y^>mJU^qq7 zK;fdP>NUU=ON^P+C5pu^A1_k_ei4E;WkF(zVmAib7~Zp^oIzoRl|K?MR&MEph7SAJ zmRNYq?6t7a7PYLg#2UTarf=05FM)%8VP$6qin&>3SSVq@L7%q*mh6+oOtHNh2Wj&o zCekVsO_SBB;pwKqho{GcTO==h+v=1V(a4>T?6AgN1;Tx-%neczK{4cMO1Bc-lxABECV-t zCfnv9-s;m2``8|ps5Z_D+xMh$xYQ3qh1j&1<&oYF9z_UTr^ezr{V zJ`Hw7nMU2gnZw~H{Z$4pFdbUU)pttx;E>8zG{C`MU7O+&c;$Q8cd$5o|3xoT>yY`k zm}Lzv{D69#EnXOHEG+Q-Sfpn3&XUx*;CmD_?!X-Rs_^?+ z0KxHK^btGeA`7V7xMQ&db9Ah}qMpk(xMMU9=vp!`1y*zY;MqU?v#T$8w$xe7J%?Y_ zPn8P3mM&Cxc5kTWPiTU-L`M4|K2@)-HlVl{E7Vs+osy8M@M%a**|b#>h!VR z(XO4>W*k0Q0M2lt*hyF0(*K>o~BX|~>8(C~*vBq+5!j+&QanBbFfj)P z))wP%znFygig{GlLa|?qOd$qD`vh|OmA^+!Bo;UrO?k1I_KOMCrc|5W{-~HAJ9X!N zEm^RlPK)`~tGq7dt_0(-s%36ki(zlf*6SDRuU~(yVh;9-UARN(opIh#J^4N{2`gG` zx2t8{DpA&A36Pvt%V2fx6|*9*xFvqa5wULW(^3ozv80@F)%R}IwnO*rR=QW$j?~RK ztW7sKfV~{XA&jj4m_fxGwyOVk>YZTO9@Trp^2+PCQ%u5EeM@AW4(a@m-t2&SXqVn< zx4^_+^(OC~*V`V@?-_l$l9;9yu^o>HeC$z=pHx4!#yz@6eLAi5ka{I!9A=EeIg;sx zWgOaSy)ZVk)~MzVTUcy|xNQK$pe8iOo0K!6vw?V1 zXG>gPQc}&HSJtyyb^H@S^hW(b#FXQ^AVGFrslhQEcL*A=L(baTt2Mb@tJMyzEUo(O z)G7mubf-8{( z-L5_IsmKh#nuTN-Ru4cvkWU^&AS_$hx(F1(M}e8^I2^E#t^L-ng4zZ70EY_l0-08L z91sZ9;Y5+xa1$b0gBt{uaALqwwJ1LPr) zVc@OU@`R)vir;it*V5h-so%V=LwZ3lQ3KM2jtrxBA-)iVV$%>gNccpIG@cCq2mVm^ zysr(Jl+heD7~t0l&B4dI<%wUf$w@o*KYuOGw>U{wzSk)jyw*#FCK*EPQ*qR(VDLIs zP3tUp1p~{jC4!wP7`V=|1?+`h*wYr87lVRu>)%Z8l^I2C;$xLmw;@E>?0=CQ~qQ!=A-F?wf!+c6DK@Ou-;++GPp` zPT_#j}b2>&Q$z(B0fLAbJ34q78S~Pp6V2~*oWC{kEf6q3^E0SOu-;iFvt`PG6jQ-ap>?SLzAv= z#-VF#t>2K^4b!<=Hzo2Y55v^@VMgbfg27yWWC{k(ZtVh#d43Gpc(d_SP(BI(nSy~+ zq{tKuGNtCFDm62;>QFGaRb(YgI$~)bd*}C_z~aXWDHyy#Rns~PUctb!Yl&d5wt~US zUURg9hTBa(zGQ8sOA_I-KR3;|#HD$s;R5&k+IXM$=y?fihh>K8oLxwXZGpD?EL~7} z7HkYhcS}d9Q+ub*lo$F~n2%r~LzfHlVFR&7nB_Suug;X3 zO~~5DRQ^D(^_Y$gs^?L~NIDbj3s`JldPdjiiE|W6gw1|tbotm!-%td(whOQ!6&~LG z#c^iVr+nPyjiVNVc+{t7eeCXbXr`SLhwVGBytt23q_t~nus2C_G}(uw&74hBtdr+V z*)%D)wi%lyjXGz-2Ccj%aa(Kmc-UU+*D!z4Vx>1YyVblm7SA5mLAc3(2m3BtecD#4 zQJ;R$#}|D3l#ieB@l9UC%uEt>`EvD!v18Q=6d z#CuK$b`{VT4%=s>T${=g!s}_@jdBe2YZ;SFlPy6%_)R*t%K`#Mb1-zV>-{cPZl&U2mdTowm0gM1r z=fFOTZ4&ImyK`<lNHP@Cw*=CY_xDXy=v@ ztsLx~Iez+(`T&2#fO%)p4IUIcPmDW<$UpB??5^O|8uazHg(dtFxHQN zd!|TU2VuQ}f40-1wK1IP+`B@@J9p}AuVauDYM%`Nz&{%Ru=hLSGbnT@^7QR`Ou%9Q z7xSdB`x`a3d7AV80D8g3J@h}uTrq6QcK(1`0IR=Q2Oh=RS04NaaF%cU%ilQhcrEb% zxMCrkVUtda(b$e7yel_Q6=!9{A7p_L-~;!N3c@w-0@l z1pm{ZUW^RX(IqhD%Q9Zs+z1 zX%blfP~~`E$KfXa-7(%~cH6Oe4)CTVj+)vQj7O^j$_{vcIt@Gh4z49MFec_L4f&Cx;;TL0cz`(wxxhDbk zAz+sP_S@S!Tjo32>+0_6Y+c(TeV07A|HhgE`v{SMfnH6dk715eMzGur?4S44ekRh# zA~3f$T?@P{+}p=-XcFun)k265Z1(fn-N)M@p2=MZ!Mm-AVLs`M+F$&4v3`89Q2Vgh zagKsVZYPqDfN4?dAYdOyB5rS=bLYkc?~b?`f#nY^j?mv=D%eM6046`8dT<61zvnK5 z`=|pEf47-{<#k8x^L$W*R{i1v1p&i4!2Y7(E3@kLyPy5zT3~;}w>HH22KFt@J;fUv z?$`V>0sp$eep}m$Qv0`S2V%314Qgsm@$<#(H_7pzcyRxmj~~%@Bg_V|Nt7Ft*_C>s zB>9&D_Q8l(AM7t~S+ZVS7#moyD`7fk7gAz-{&FRU@z2B#Ublc6nmW#35x73ffcb)A zAz{+9ARuZ4qmUgx=m5M!r7ts9FLyZ)+>XWQn2HD$@uY6mjTjTu3&53y%;^ll;AA;l z@nt5M&vfsHdj2-noa6k04mJr1AAai%alS1xmgbuG@bjjG0v_1}Fb$46J^Z}6wgR4I z*HVUBZ3VoKee_3rP!pQ*@g-iL;1?H{h@#8>q!8rWb&G8h*x+8T3V1+jd?$D4FCS07 zR!t@N@HY7z$K6dCHuO=RgY0(v{titPxcy;&71WWi4uI86Fs3R~jOm34fK5K<$C;_k z?g2XnFbnW6O?mbckS`pLcbV(fZEDxM69UrKcD&@Z6 zz6PhuY4u!v8eXYq!HGTJE`;fvT}X-T`L!^>#kl;)Jp3&1@WT`Y&fTUXZ3<={e%yGp z;rBl4uO&{)%)^iCNBhm$NlI+}z1-;z4`)yqCb%RUL=ay%NOm}3M~wTCXG)!H1))NU zYAI$JkS~D%v}MZLQ&4-sIpIbjEQ%ngbBf!lG#IYKX>livlnS~iX7qtgEJ``!65yU4 z^WJ_rbCC*e$=&ry!$~hFZ3LZp^a*3`@g9Cy0x15lK(Q?W3k)JPRR*T2qb*It#gT!j zv1-%l<|Z;K6Qu`=cMgq}iskCD(r{0{GSJ*Uky(vjX{+(C)A!k{LBviZd+*~>PQrS9 z^5A`s&QQiXq`mp$@$P(|em^JS-wQf6=)PISU=aix$`;#@p3${h0=Bb$99{JBWgAy2 z&*?=kDErh$zi=01@t1wP)zd`%L44MyGY>zRho8*DPv+q#Gt{X?RKeEaYi-%SS!F4M zx-}cKNMw!Zz)}n$T-Ql2X6rQ{-|Ym78+4vb`%8+hKPw`@H`LQp@fP3suwM$w2ZhT# z{A9S=O5Z>((-vZAgrS)-Z9_)d+oO@U-IAj_$U+;%afSdTkFKx9C|R zRao${+2~{EbhRR?5UK5lM6S)~0Aij~yj+U#e$WGjaUYv>1$j_}=Y9THJtg=RAK&bS z^fm{vsrH$sKJ^fMH7=pwaGE};ytuDZm~d&!z_plg^X)Avsj-^t2hXmmTGTI<))db<{;b9NymraYvAQS&o82PZkFBN;9w z6FTot&=-&`Ca3vVx4mXB8(B~Lc*d7AGRNWzK0oKlnV|YBNqZk_-~GA*hau!%%#kHq zM6#U}F)@%3=ouCXHyLmJofh&qA%ogYG2?earA{el%K|jpo|k#}$vpfp7{hT`P#z3$ z>{_Bf<4kHH83Ad66-{IqhDGM0C4=0AvwMl$0`4pjr9xW=;s$a0wEB_yMSlhfTgYZ~ zZ$|XzENntXV|@cFA1LQKk^Di`j`dAM@o5>YNCu`{MsxJUT&9h!+r%!?|Jlj$EeUp? zayCsAV+K?4Sao{5*fUfaE^eBv4pfUh6Q%yiQumqGqdW6QwjJGGD(6d`$6H5QhYlS- z^zH+vclGWb+cLC*7IND{m` z0J2FgK`#(4^n7yw-L3idHSXc(pMB;-zroDhS>zZOmX8wc$v2C2d`KEBCw)J#yI z%cl!I9`*5AAD{Da2KJW+UKUybg4dI@0+f09VSL(JAA;|+e9C2Dzo{u;Or?Tl$0NiQ zFC;o(85g~n`U5OOenVhmtZ7$gff0&Z8{qIAGl$e-`52lE$we96c0TvA(d9-Nz1 zraeA=zmLa#{Gg9bZtzi`4wvUq)tT3kdH7K$DA?Ks^?0j}Ig|gHho5BsSU-j1DJ?$( z_im$gvEV*0APnHfs}5Q?jsDD0;cWTAMRx}NooOJ-V}BPFZLVVGC*9UBK;B8|V!0R4 zj^edLBCz&F%ApwS0kACzGU06f!b!mFAFW$)a38=`#@w;r|IjyUf%{_<|2{?o4BT6q zd%TAqz&%WXy1{+md0?%1_?h)!{&62?9)1`kFFd$6F#og%^Ot>mvj^7(=C}HEzmG#O zKjZTs@$syW!{s>x_qD(KE@i`zodfrohaZMw#^kR`f^6&x)$B%(&~Q6Ri46@}E|VXx zxyT+l$sg?XVflB^Q~Q8@H~?IA$bpjwA{W^sY@cJ0Go9LZTkc3GA>Raz?}PzB1gMMa za1%f%9LfREcNSpSPQbQ0-iI_s>{TO{oRx;Nbnhqs<(Ixy3;e%!;%hNlVBp`<+>>DP z!(^(zS@S&*)C>Mso5}y@9_;^xkJsPce&*qaVSnC({l_x!Pj_5do36Eoyl`(n^YBCe zh3KQL^^48VsQ#r<{TSP4|Gh=DwzIrV&PYswn<+I1mYrKZ5Cr7s5K6{CFU|nD5`Le8 zz9q5)fNW}aBFq4Ga|;OAhsFohaGrud05HFXY=IMh#{M=aN6Yg7_UFS_#@=sy|2_95@0{`@DoLU>%slsttqg-6jT41haZN02KHBKZ$IB$9Be7nLG3Tv!_TFg-W;p6(AyVum`LBB z{>_oU2OTi5Z)wVT4?ia0zXWQ(cC!MHAoWuFtL@?E#~$4OgO5!qa~6)Cg2g6UW=v*x z_1d;&&Z}VD$CB2qWp_Qzw# zK^F(Z&uH8r8|(}~JM7;%20?z;$@sFY;MvEC9J#x>lD5pCF9h=t_hbkJL0zyX=@vA0 zBsoI}32QGbGwdO<6tQQ?o+B+-9S=X-i{GfZ%)I@#ZjbYAnXxo;!+ZGIpgl!qlIO8- zWu+AG-sW|Y;yU%?74R&(mNL|8E8t}we(dASj|~S%n;e;kpBvw<(QUeVbe{L{LpI4; zqdW8PL(j}HGS`}tOWJJ6Jp9BSei-_I5+u!%&^+O-<+?Uz`i{5U(1*_GW*=|$7-oME zkNdPKH87+JKHDYq8x9wf!VArTWFCIx3RV4;GG-R^V?kvd{}of|k4?RGdA zn&I%2;q`*QIq!~WW<#Djaqn~t5JD4tu~T=W1BPyzb3*F~S?6ZNX_Mnr7Gf9jl6w$R zcOE1cN|jx0elU1G^X0y)y7w?_&fI)(Ps5E3KNfMx6asWj!KVigD35 z>p8dT*q~?J%(-HM4R?zThnUed0OdIfCBh|te%Z(Q#QagU(Pp2%Etr-M`}{|P*rsDH ziOQ;;M78mg!uDkze%uGJesQU}?`hwW>xdsbA4WbCAmYk6vga1`Os0G0;U|i0%7?MK z$2|P71TcM=Cbk4*9)7&hoWwZ0s?nV3mVvt`k5A_BK6>Eb@gpZ!+G>2};m429fajJp zjF!fCs|c=6>AumJyXL$qlQX8grs%XFZ_||$cuy)t4+uB7Q&4$K=gyDDF`W%ZJz7$z z4g6q2=aV`+sd6n6k~5OKgUbuq;EG^ zajt8o*k1;&Jyx43mWBozwQ5wN#bN&K>ib2hJg)(_*NHKcN+o9=epbZ857RdD@FQV7 z&ppdL{7gp9|4+9#yT}w^jKt-f5;Zv_3bG;&a7n+8ik${`2BDLoC+D6dgea7UFYbH^JHgHb{%^7VabC}zgmpL%)`&pt!*!rarlrZ z&>0;NR_7Fhg%WHUSZvG5jIPz%tC@wPtZ*&Y;9v9D;@8a)oR^T;?Bm?aT|HZUoO$@k zJp5!Helia~8RO8ci?$A5-;6`o)>^*?PwZNl&e?^OnDU^r)(>g$=u&XMiRh3Gs4B!r zauj7Aeh_2csqLv=A+YVyHl1x3s=Gs|Fp86%y4J31y~^zrlDka^?oJ(z`a_M_zQfhY z40^qG2)}=r&egu{O0GR0{G}eoFxnz$m|!HTSx7#pd{Jp<50ZTHoc#$z$tF$W*&a7?&3b9IhIayFd6Ic@bmK`D_M4w;XzD^rt?)0=PVYvZi15CkD7IKa6bwwFT&{DiFV?mXS&<7jcKqV49aD z%P>diS@|%2p%?b>eQZI+B0t<6w04}29cKmzDNkp&pJkLK)LkWJA;nOzGx`gEu9&)D zV-*13L2WvmY9h+Aj*EnnBK$pPF@Wc?oFmhTh7Vu_^Fb`$?N_|@@SPapwZ>fO&)@J3 zM!f}33rCi3@|>2YoILz&^86UP&6@)to2(`11+GgEKmYw}mw%I)b-~B$&k9iH;fHa4 z-iz~QR)FY@Ih6cbB;rCVK%kgOQ~!q~+lDzlU#s`(kazv;+~hT)Ahw*RJ_s(zB=&Bc z76k+rkbFoG)miCfcg^|RV-JR%7D%;l+!ZutAiY>6!4&ZJhbaMPToAnw>c<2C<^Ul3 zz$thVgfIFZxI$%Lhkc$l*beq-Vo1Ky@KsHXUh#zozh#)f1*JV#J-Wa0yWb?=Fab+* zPXg?#i7Np1=X)Ti*BroV8~^(Y5AL5_$6!D6@RNc4<$}}9!w-vQ=Gf2Bl;=ZRYcXtZT)%|T6xzDrUy3L2Me$w?&(NL4Lan9sF3vZIz&qeoW$pfu8q5NGsAJcLe zw&VF~pY>lx<@rHc8RAw&?g`m*v$4 z_ZKyP2v7U?vX5`}OnNiExYegK4?nKI!tY7C9&o=)_h%k{=GJmUyD|?yFN}vDSo(l@ z81`(DLyZHdoj+eT;vH+>nQH)K!wrBIhsGxt#9=TM{NteqgPUyXJI(s+uOg<$LnuzpZ%w`2mZ~()>9trKjY(@JhV`$%rJ;Pgr6M)S{%(x+1?OX(a0HmAxcb)Yn%FS z?QS|%8k(pKIvx162KHa?!Tqgk3hXb%)PLsThhd+A{pErEg?sy%habjM2KMQNxsaPX zt$Ai>%5pvYU<4V4eO|xpq&u(=b?%t)&TImuFxLRsXU`pq9Wd^M`?>_k!|zs5Yhm_N zhQDC}bIdj%(&sh+T>XgWBRjwzK4u?4DjYK4j6?7wwiD{0_7??T>D=4Te*Sy4!2W%2 z{BDd67}&Qo_jnIKCg5K;*k9uwei}Wv-{Rv(JXJXx#71=*lbNn0_+l=h-*8x+S6chw__^_CG`f*lv*11a zkWE&t(Vcntah+wO>FS{8`eTHp&4$dwPwe4`p${mzRfqW&I6FDMC1F0sBwbj~iM#I_97!T=LvW&y@-KnRR3^YG&|$GwLirXZNyZ93AXVCLb+ zjYk`P@3a0&Apmjia9S8oS!jJR+M?fzB(s{lAZHQ0lOL$K>|Gng3i! zaN2Wix>)*lwPR7Xh}WT!&&5o4CcAUt+AfmI)HWSA3DMGF<+90x6IQl+;PxOtf^koT zLNVV7ffn|=Ehm`oMD-Ir5VnYrQlVZWD6#efLFq`xMv-=HI%ks$E*GStGyCaAm-}7L zT;$GMa(7+T$=6jp{ICQ-|2-^FY)e4q;V1L(!?2q5jDc$z>U_!@==`#ew|YXSKZwuz z^u;70q~~0V=hmfm#N#tqax)J9A9TKL*etVzt59$eJX@Z=HeHb-M@1skejP~p5cyuJ%qx>_mLAZW#zQ*L` zXuD#V?K@@n;jrr2rZW3w%VD>!jcS=3i0;xcqB>8g{(UMns(KDa{d$9Y)EY#bhb72N zJf!v>i@{_`ZJYCSxlxPgHV-fz*u1*eOIOC#J?Cj1|4UUpe>{G3^U1U+7PWS|Ej_x* zHpAV@JFX+Iv!n9nbWo`y>X&Z4!vlKLZF=V&s;jIL?YeTGu2bf2z4e6h$MtRp^d9j3 z`g9Lv+STj#D6d&%reb>)BZ{49cZ=ddJ$pj^F{xgt_%^y2n-;_I+XLcGseL8&JnxuS zIV^{d#5oJq9SwB|L7I7vdG578VcJ`G?$wnK#OGl6Oxe7@a^A;V{lx9}@q<2Qt`frM zj4F>hek%HDAwe6X%upx2w0OZ|`%Zj+=XDX>a~{a#SJV0&WeoxK3W zhuIfkR{;THvpeQQj^X@+Y*If@0$p|9W!dJ$5?L~UB4)T+PmHQ=Y~3bA?fSyi_*Qjz z_yHYf%7#p_gqHku%@oT#{4fAQAx)Q8>(`bJyB4N%b|ED;kY0-^mKZasOH}6JXGJ{x zFl`aK9MNG^G`#G@Cs^Prdvd%|o~%r0`I@Xw4Nog>#kQj2YH_mKI8mIO8mmq!+1;9N zZ|~4aQXEr6zn-->h7Vwf6TBI0l*!KwYU(C$E z#GG2tUj_9cm{;cE=i2KBVwraw5##YbE$FZiOUlVS z{A3<}GR7f*c&#uFU0ZAY8d_`D!gS6qq{Nhm5-~J+M(4H2mP^6?#;_(El&9dynasma z=HUnOA@lHqP&`&Ou%?M^4dfw^VSp))*(})9Ln^_Mu6u(3Jp%U#zhk3_8b*&9C+3IxLjMq_&TP*i$JMA`p5^4doV{VzO4Np&|+xXF)Vx3=bO051)qM($ItjUGX&)NGhD%K zB@gpSvv-WW$mKZCS!f6-bMnI%2>Us$|I_m8{VrB-m)gSA$kQkV(sSYZ(|=m-o;03R z5x+sm2HF5+S6^y71UW!ch1BRcffa~)>hSS z-UN6$(&7mE;7OIMI1oY*5OEyr1vqoV`WE(SVqA5l;Va+vL!WxQ*D!$#O4|m_KmOjc z+sHRez|!240Q)afvi@excS5k%3<15tgZnqGW3Zn&`N<3cEf?%BGz0{@Cu!|}hnBt5 z+I$&SuJiMU%=Agt8ijC~wKXx!CtVMEa;xsA?#$}HI^jxKKVZKoz>D`iSkM4)z&@sa zoK=2MQOy1#8_PMq_Z*?`T=4+>(P&7w`VYA0UT69jW5SdMn1fazfeTsz@s3IuW`agk znp~`UIRC+@l&w72pATR8wEy8tx9+F~_IJ-VZBK%IOLLER@&mQcG^rcx2hIrU1^cV* zQQ=7Ymh-;*As2 zbdGh{2Xt<99hDD22i!xgbB2NVx<1 zTnjN3bxn~NU6RYuR}xBkM;THyYfTOW+k0Hg9P%{|`9 z58(dgO4beT1Lp(vg8L`5XECc|gWC3(Vz76DeJ+b_*w5%1+Z^X8lnBN|?h@KXFv)Yy zVTN2}&M9;nb?@WM$&c%ou%A~O++XzH?P(uh_HpLqr}p=;`4E0L()ECsUAiBJ?3_mFc;PjwGZtL zoel7Z=Euzr;N4l{M+C^gKinwH{<4*hRRYSe&5r-SblqFF1lZ{3DX{ke|A-m6?fRkk zUdKaloB3$z!hK*H0rY}1gq5^h*$`hDCVv2D`L>^X?WcFu0{=Vy;rC*+z`(zyxhKKo z$6rjnnGeA4xRmxX)#nUkNT^#AkqU98?0576puwGUpCRS92%zKXFPt9*eN4bUls!P7(M>t40UiSNJHA4EllU^LP~7UU#{dZxIQ{L;PANCVHtoTV8L;F zer~4^&tc@T1hKTRSBSGus0Nk@Yqzzhp!TxNAQ9Z5I}kuZ3kd3h1;vRdVb7Ubp)Aak r8CIsDFpw&Sy@^oK@X9YU!F;BBfAjm7YA!RMeecFN->3^qbI<<=uur /scripts/parse_emails.log 2>&1" +``` + +**Pokračování po přerušení (přeskočí už importované):** +```bash +docker exec -d python-runner bash -c \ + "python /scripts/parse_emails_tower_v1.1.py --skip-existing > /scripts/parse_emails.log 2>&1" +``` + +--- + +## Stav importu + +**Sledování průběhu (live log):** +```bash +docker exec -it python-runner tail -f /scripts/parse_emails.log +``` + +**Počet emailů v MongoDB:** +```bash +docker exec -it python-runner python -c \ + "from pymongo import MongoClient; c=MongoClient('mongodb://192.168.1.76:27017'); print(c['emaily']['vbuzalka@its.jnj.com'].count_documents({}))" +``` + +--- + +**Název:** parse_emails_tower_v1.1.py +**Verze:** 1.1 +**Datum:** 2026-06-02 +**Autor:** vladimir.buzalka + +--- + +## Účel + +Import všech `.msg` souborů do MongoDB. Z každého souboru extrahuje **všechny dostupné vlastnosti** — podobně jako EXIF u fotek. + +- **DB:** `emaily` +- **Kolekce:** `vbuzalka@its.jnj.com` +- `_id` = Internet Message-ID (nebo `filename:` jako fallback) +- Bezpečné přerušit a opakovat — upsert podle `_id` + +--- + +## Prostředí + +Běží v Docker containeru **python-runner** na **Unraid Tower**. + +| Komponenta | Umístění | +|---|---| +| Container | `python-runner` (Docker na Unraid Tower) | +| .msg soubory | `/mnt/user/JNJEMAILS` → `/mnt/JNJEMAILS` uvnitř containeru | +| Skripty | `/mnt/user/Scripts` → `/scripts` uvnitř containeru | +| MongoDB | `192.168.1.76:27017` (externí, mimo container) | + +--- + +## Spouštění (z Unraid terminálu) + +**Test na 50 emailech:** +```bash +docker exec -it python-runner python /scripts/parse_emails_tower_v1.1.py --limit 50 --no-indexes +``` + +**Kompletní import na pozadí (log do souboru):** +```bash +docker exec -d python-runner bash -c \ + "python /scripts/parse_emails_tower_v1.1.py > /scripts/parse_emails.log 2>&1" +``` + +**Pokračování po přerušení:** +```bash +docker exec -d python-runner bash -c \ + "python /scripts/parse_emails_tower_v1.1.py --skip-existing > /scripts/parse_emails.log 2>&1" +``` + +**Sledování průběhu (Ctrl+C ukončí sledování, import běží dál):** +```bash +docker exec -it python-runner tail -f /scripts/parse_emails.log +``` + +### Všechny parametry + +| Parametr | Popis | +|---|---| +| `--skip-existing` | Načte seznam hotových souborů z MongoDB a přeskočí je. Použij pro pokračování po přerušení. | +| `--limit N` | Zpracuje jen prvních N souborů. Vhodné pro test. | +| `--no-indexes` | Nevytváří indexy na konci. Použij pokud přerušíš uprostřed — indexy vytvoř ručně až je vše hotové. | +| `--msgs-dir PATH` | Přepíše výchozí cestu k .msg souborům (výchozí: `/mnt/JNJEMAILS`). | + +--- + +## Průběh na konzoli + +Každý email na jednom řádku: +``` + 1/69371 OK RE: Protocol deviation CZ10022 jan.novak@its.jnj.com + 2/69371 OK UCO3001: Draft FUL pro DD5-CZ10022 monitor@4gclinical.com + 3/69371 ERR ? ? +``` + +Každých 500 emailů oddělovač s průběhem: +``` + ──────────────────────────────────────────────────────────────────────────────── + Průběh: ok=498 err=2 0.4 msg/s ETA 47h12m + ──────────────────────────────────────────────────────────────────────────────── +``` + +Na konci souhrn: +``` +==================================================== +Vysledek: ok=69300 | skip=0 | err=71 +Celkovy cas: 47h 23m 10s +Dokumentu v kolekci: 69300 +``` + +--- + +## Zdroje dat z každého .msg + +| Pole | Popis | +|---|---| +| Předmět, normalized subject | | +| Odesílatel | email, jméno, SMTP adresa | +| Příjemci To/CC/BCC | strukturovaně `[{type, email, name}]` | +| Čas doručení a odeslání | UTC | +| Tělo | plaintext + HTML (max 2 MB) | +| Přílohy | metadata: jméno, velikost, MIME typ, inline flag | +| Internet headers | X-Originating-IP, Received, DKIM, X-Mailer, ... | +| MAPI | důležitost, citlivost, příznak, konverzační vlákno, kategorie | +| In-Reply-To, References | pro rekonstrukci vlákna | +| Raw MAPI properties | `{0xXXXX: value}` | + +--- + +## Hodnotové kódy + +| Pole | Hodnota | Význam | +|---|---|---| +| `importance` | 0 | Nízká | +| | 1 | Normální | +| | 2 | Vysoká | +| `sensitivity` | 0 | Normální | +| | 1 | Osobní | +| | 2 | Soukromé | +| | 3 | Důvěrné | +| `flag_status` | 0 | Bez příznaku | +| | 1 | Označeno (follow up) | +| | 2 | Dokončeno | + +--- + +## MongoDB indexy + +Automaticky vytvořeny na konci importu (`--no-indexes` přeskočí): + +| Index | Pole | +|---|---| +| Chronologický | `received_at`, `sent_at` | +| Odesílatel | `sender.email` | +| Soubor | `filename` (unique) | +| Konverzace | `conversation_topic` | +| Filtry | `has_attachments`, `categories`, `importance`, `flag_status` | +| Full-text | `subject` + `body_text` + `to` + `cc` (text index `text_search`) | + +--- + +## Ukázkové dotazy (MongoDB shell / MCP) + +**Emaily o UCO3001 s přílohou:** +```javascript +db["vbuzalka@its.jnj.com"].find({ + $text: { $search: "UCO3001" }, + has_attachments: true +}).sort({ received_at: -1 }) +``` + +**Emaily od konkrétního odesílatele:** +```javascript +db["vbuzalka@its.jnj.com"].find({ + "sender.email": /covance/i +}).sort({ received_at: -1 }) +``` + +**Celé konverzační vlákno:** +```javascript +db["vbuzalka@its.jnj.com"].find({ + conversation_topic: "Protocol deviation CZ10022" +}).sort({ received_at: 1 }) +``` + +**Statistiky podle odesílatele (top 20):** +```javascript +db["vbuzalka@its.jnj.com"].aggregate([ + { $group: { _id: "$sender.email", count: { $sum: 1 } } }, + { $sort: { count: -1 } }, + { $limit: 20 } +]) +``` + +--- + +## Chybový log + +Soubory které selhaly jsou zalogrovány do `parse_emails_errors.log` vedle skriptu (tj. `/scripts/parse_emails_errors.log` → `\\tower\Scripts\parse_emails_errors.log`): +``` +2026-06-02 20:14:33 | open failed [7A3F...0000.msg]: +``` + +--- + +## Výkon + +| Parametr | Hodnota | +|---|---| +| Počet souborů | ~69 000 | +| Rychlost | ~0.4 msg/s (htmlBody dekódování) | +| Odhadovaný čas | 48 hodin | +| Batch size | 200 dokumentů / bulk_write | +| Odhadovaná velikost DB | 2–5 GB | + +--- + +## Závislosti (v Docker image python-runner) + +``` +extract-msg==0.55.0 +pymongo +python-dateutil +``` + +Image sestaven z `Dockerfile` v `/mnt/user/Scripts/python-runner/`. + +--- + +## Historie verzí + +| Verze | Datum | Změna | +|---|---|---| +| 1.0 | 2026-06-01 | Iniciální verze | +| 1.1 | 2026-06-02 | Nasazení na Unraid Tower v Docker containeru python-runner; MSGS_DIR změněno z SMB share (`\\tower\JNJEMAILS`) na lokální mount (`/mnt/JNJEMAILS`); aktualizován popis spouštění pro `docker exec` | diff --git a/EmailsImport/Trash/parse_emails_tower_v1.1.py b/EmailsImport/Trash/parse_emails_tower_v1.1.py new file mode 100644 index 0000000..97118a7 --- /dev/null +++ b/EmailsImport/Trash/parse_emails_tower_v1.1.py @@ -0,0 +1,660 @@ +""" +parse_emails_tower_v1.1.py +Nazev: parse_emails_tower_v1.1.py +Verze: 1.1 +Datum: 2026-06-02 +Autor: vladimir.buzalka + +Popis: + Parsuje vsechny .msg soubory z MSGS_DIR a importuje je jako dokumenty + do MongoDB. Z kazdeho souboru extrahuje VSECHNY dostupne vlastnosti — + podobne jako EXIF u fotek: + + - predmet, odesilatel, prijemci (To/CC/BCC s typy) + - cas doruceni a odeslani (UTC) + - telo plaintext + HTML (max 2 MB) + - prilohy (metadata: jmeno, velikost, MIME typ, inline flag) + - internet headers (X-Originating-IP, Received, DKIM, ...) + - MAPI vlastnosti: dulezitost, citlivost, priznak, konverzacni vlakno, + kategorie, In-Reply-To, References, ... + - vsechny raw MAPI properties jako {0xXXXX: value} + + DB: emaily + Kolekce: vbuzalka@its.jnj.com + _id: Internet Message-ID (nebo "filename:" jako fallback) + + Bezpecne prerusit a opakovat: + - upsert podle _id — duplicity se automaticky prepisi + - --skip-existing nacte seznam hotovych souboru z MongoDB a + preskoci je => pokracovani po preruseni bez ztraty prace + +Prostredi: + Bezi v Docker containeru "python-runner" na Unraid Tower. + .msg soubory jsou dostupne jako lokalni disk (volume mount): + /mnt/user/JNJEMAILS -> /mnt/JNJEMAILS (uvnitr containeru) + MongoDB na 192.168.1.76:27017 (externi, bezi mimo container). + +Spousteni (z Unraid terminalu): + # Test na 50 emailech: + docker exec -it python-runner python /scripts/parse_emails_tower_v1.1.py --limit 50 --no-indexes + + # Kompletni import na pozadi (log do souboru): + docker exec -d python-runner bash -c \ + "python /scripts/parse_emails_tower_v1.1.py > /scripts/parse_emails.log 2>&1" + + # Pokracovani po preruseni: + docker exec -d python-runner bash -c \ + "python /scripts/parse_emails_tower_v1.1.py --skip-existing > /scripts/parse_emails.log 2>&1" + + # Sledovani prubehu: + docker exec -it python-runner tail -f /scripts/parse_emails.log + +Vystup na konzoli: + Kazdy email na jednom radku: + / OK/ERR + Kazych 500 emailu: oddelovac s prubehem, rychlosti a ETA. + Na konci: souhrn ok/skip/err, celkovy cas, pocet dokumentu v kolekci. + +Zavislosti (nainstalovane v Docker image python-runner): + extract-msg==0.55.0, pymongo, python-dateutil + Python 3.12, Linux (Docker container na Unraid Tower) + +Struktura dokumentu v MongoDB: + _id Internet Message-ID (nebo filename: fallback) + filename jmeno .msg souboru (20znakovy hex + .msg) + subject predmet zpravy + normalized_subject predmet bez RE:/FW: prefixu + importance 0=nizka 1=normalni 2=vysoka + sensitivity 0=normalni 1=osobni 2=soukrome 3=duverne + flag_status 0=bez priznaku 1=oznaceno 2=dokonceno + read_receipt_requested bool + delivery_receipt_requested bool + has_attachments bool + attachment_count int + message_size_bytes velikost .msg souboru na disku + conversation_topic tema vlakna (PR_CONVERSATION_TOPIC) + conversation_index base64 PR_CONVERSATION_INDEX + in_reply_to Message-ID predchozi zpravy + internet_references [Message-ID] — cela historia vlakna + categories [str] — MAPI kategorie / stitky + read_receipt_requested bool + delivery_receipt_requested bool + received_at datetime UTC — cas doruceni + sent_at datetime UTC — cas odeslani + sender.email emailova adresa odesilatele + sender.name zobrazovane jmeno odesilatele + sender.smtp SMTP adresa (pro interni EX adresy) + to retezec To (tak jak v Outlooku) + cc retezec CC + bcc retezec BCC + display_to PR_DISPLAY_TO (zkraceny seznam) + display_cc PR_DISPLAY_CC + recipients [{type, email, name}] — to/cc/bcc s typy + body_text plain text telo + body_html HTML telo (max 2 MB, None pokud neni) + attachments [{filename, size_bytes, mime_type, + content_id, is_inline}] + headers dict internet headers (lowercase_s_podtrzitky) + mapi dict vsech raw MAPI properties {0xXXXX: value} + parsed_at datetime UTC — cas parsovani + +Indexy (vytvoreny automaticky na konci): + received_at, sent_at, sender.email, filename (unique), + conversation_topic, has_attachments, categories, importance, + flag_status, text_search (subject + body_text + to + cc) + +Chyby: + Soubory ktere selhaly jsou zalogiovany do parse_emails_errors.log + v adresari skriptu. Radek: timestamp | open/extract failed | duvod. + +Historie verzi: + 1.0 2026-06-01 Inicialni verze + 1.1 2026-06-02 Nasazeni na Unraid Tower v Docker containeru python-runner; + MSGS_DIR zmeneno z SMB share na lokalni mount /mnt/JNJEMAILS; + aktualizovany popis spousteni pro docker exec +""" + +import sys +import re +import logging +import argparse +import base64 +from pathlib import Path +from datetime import datetime, timezone +from typing import Optional + +import extract_msg +from dateutil import parser as dtparser +from pymongo import MongoClient, UpdateOne, ASCENDING, TEXT + +if hasattr(sys.stdout, "reconfigure"): + sys.stdout.reconfigure(encoding="utf-8", errors="replace") + +# ─── KONFIGURACE ────────────────────────────────────────────────────────────── +MSGS_DIR = Path("/mnt/JNJEMAILS") +MONGO_URI = "mongodb://192.168.1.76:27017" +MONGO_DB = "emaily" +MONGO_COL = "vbuzalka@its.jnj.com" +BATCH_SIZE = 200 +LOG_FILE = Path(__file__).parent / "parse_emails_errors.log" +SCRIPT_VERSION = "1.1" +# ────────────────────────────────────────────────────────────────────────────── + +logging.basicConfig( + filename=str(LOG_FILE), + level=logging.ERROR, + format="%(asctime)s | %(message)s", + datefmt="%Y-%m-%d %H:%M:%S", + encoding="utf-8", +) + + +# ─── Pomocné funkce ─────────────────────────────────────────────────────────── + +def safe(obj, *attrs, default=None): + """Bezpecne cteni atributu — vrati prvni non-None hodnotu.""" + for attr in attrs: + try: + val = getattr(obj, attr, None) + if val is None: + continue + if isinstance(val, str) and not val.strip(): + continue + return val + except Exception: + continue + return default + + +def parse_date(raw) -> Optional[datetime]: + """Libovolny datum -> UTC datetime bez tzinfo (pro MongoDB).""" + if raw is None: + return None + if isinstance(raw, datetime): + if raw.tzinfo: + return raw.astimezone(timezone.utc).replace(tzinfo=None) + return raw + try: + dt = dtparser.parse(str(raw)) + if dt.tzinfo: + return dt.astimezone(timezone.utc).replace(tzinfo=None) + return dt + except Exception: + return None + + +def to_bson(val): + """Konvertuje hodnotu na BSON-serializovatelny typ.""" + if isinstance(val, bytes): + return val.hex() if len(val) <= 128 else f"" + if isinstance(val, datetime): + return parse_date(val) + if isinstance(val, (str, int, float, bool, type(None))): + return val + if isinstance(val, list): + return [to_bson(v) for v in val] + try: + return int(val) + except Exception: + pass + return str(val) + + +# ─── Extrakce částí zprávy ──────────────────────────────────────────────────── + +def extract_headers(msg) -> dict: + headers = {} + try: + hdr = msg.header + if not hdr: + return {} + from email.header import decode_header as _dh + + def _decode(v: str) -> str: + try: + parts = _dh(v) + out = "" + for part, enc in parts: + out += part.decode(enc or "utf-8", errors="replace") if isinstance(part, bytes) else part + return out + except Exception: + return v + + for key in set(hdr.keys()): + k = key.lower().replace("-", "_") + vals = [_decode(v) for v in hdr.get_all(key, [])] + headers[k] = vals if len(vals) > 1 else (vals[0] if vals else "") + except Exception as e: + logging.error("extract_headers: %s", e) + return headers + + +def extract_recipients(msg) -> list: + result = [] + type_map = {1: "to", 2: "cc", 3: "bcc"} + try: + for r in msg.recipients: + rtype = getattr(r, "type", 1) + try: + rtype = int(rtype) + except Exception: + try: + rtype = int(rtype.value) + except Exception: + rtype = 1 + rec = { + "type": type_map.get(rtype, "to"), + "email": safe(r, "email", default=""), + "name": safe(r, "name", default=""), + } + result.append(rec) + except Exception as e: + logging.error("extract_recipients: %s", e) + return result + + +def extract_attachments(msg) -> list: + result = [] + try: + for att in msg.attachments: + fname = safe(att, "longFilename", "shortFilename", default="") + if not fname: + continue + size = 0 + try: + d = att.data + size = len(d) if d else 0 + except Exception: + pass + result.append({ + "filename": fname, + "size_bytes": size, + "mime_type": safe(att, "mimetype", "mimeType", default="application/octet-stream"), + "content_id": safe(att, "cid", default=None), + "is_inline": bool(safe(att, "isInline", default=False)), + }) + except Exception as e: + logging.error("extract_attachments: %s", e) + return result + + +def extract_mapi_props(msg) -> dict: + """Vsechny raw MAPI properties jako {0xXXXX: value}.""" + result = {} + try: + props = msg.props + if not hasattr(props, "items"): + return {} + for key, prop in props.items(): + try: + val = to_bson(prop.value) + prop_id = f"0x{key[:4].upper()}" if len(key) >= 4 else f"0x{key.upper()}" + result[prop_id] = val + except Exception: + pass + except Exception as e: + logging.error("extract_mapi_props: %s", e) + return result + + +# ─── Hlavní extrakce ───────────────────────────────────────────────────────── + +def extract_message(msg_path: Path) -> Optional[dict]: + """Parsuje jeden .msg soubor -> MongoDB dokument.""" + try: + msg = extract_msg.Message(str(msg_path)) + except Exception as e: + logging.error("open failed [%s]: %s", msg_path.name, e) + return None + + try: + # ── Message-ID ──────────────────────────────────────────────── + mid = None + for attr in ("messageId", "message_id", "internetMessageId"): + mid = safe(msg, attr) + if mid: + break + if not mid: + mid = f"filename:{msg_path.stem}" + mid = str(mid).strip() + + # ── Předmět ─────────────────────────────────────────────────── + try: + subject = msg.subject or "" + except Exception: + subject = "" + + normalized_subject = safe(msg, "normalizedSubject", "normalized_subject", default="") + + # ── Tělo ────────────────────────────────────────────────────── + try: + body_text = msg.body or "" + except Exception: + body_text = "" + + body_html = None + try: + bh = msg.htmlBody + if isinstance(bh, bytes): + bh = bh.decode("utf-8", errors="replace") + if bh: + body_html = bh if len(bh) <= 2 * 1024 * 1024 else bh[:2 * 1024 * 1024] + except Exception: + pass + + # ── Odesílatel ──────────────────────────────────────────────── + try: + sender_email = msg.sender or "" + except Exception: + sender_email = "" + + sender_name = safe(msg, "senderName", "sender_name", default="") + sender_smtp = safe(msg, "senderSmtpAddress", "sent_representing_smtp_address", default="") + + # ── Příjemci ────────────────────────────────────────────────── + recipients = extract_recipients(msg) + + try: + to_raw = msg.to or "" + except Exception: + to_raw = "" + try: + cc_raw = msg.cc or "" + except Exception: + cc_raw = "" + try: + bcc_raw = getattr(msg, "bcc", None) or "" + except Exception: + bcc_raw = "" + + display_to = safe(msg, "displayTo", "display_to", default="") + display_cc = safe(msg, "displayCc", "display_cc", default="") + + # ── Časy ────────────────────────────────────────────────────── + try: + received_at = parse_date(msg.date) + except Exception: + received_at = None + + sent_at = None + for attr in ("clientSubmitTime", "client_submit_time", "sentOn"): + v = safe(msg, attr) + if v: + sent_at = parse_date(v) + break + + # ── MAPI vlastnosti ─────────────────────────────────────────── + importance = 1 + try: + v = msg.importance + if v is not None: + importance = int(v) + except Exception: + pass + + sensitivity = 0 + try: + v = getattr(msg, "sensitivity", None) + if v is not None: + sensitivity = int(v) + except Exception: + pass + + flag_status = 0 + try: + v = safe(msg, "flagStatus", "flag_status") + if v is not None: + flag_status = int(v) + except Exception: + pass + + conversation_topic = safe(msg, "conversationTopic", "conversation_topic", default="") + + conversation_index = "" + try: + ci = safe(msg, "conversationIndex", "conversation_index") + if isinstance(ci, bytes): + conversation_index = base64.b64encode(ci).decode() + elif ci: + conversation_index = str(ci) + except Exception: + pass + + in_reply_to = safe(msg, "inReplyTo", "in_reply_to", default="") + + internet_refs = [] + try: + refs = safe(msg, "internetReferences", "internet_references") + if isinstance(refs, list): + internet_refs = refs + elif isinstance(refs, str) and refs: + internet_refs = [r.strip() for r in refs.split() if r.strip()] + except Exception: + pass + + categories = [] + try: + cats = safe(msg, "categories") + if isinstance(cats, list): + categories = [str(c) for c in cats if c] + elif isinstance(cats, str) and cats: + categories = [c.strip() for c in re.split(r"[;,]", cats) if c.strip()] + except Exception: + pass + + read_receipt = bool(safe(msg, "readReceiptRequested", "read_receipt_requested", default=False)) + delivery_receipt = bool(safe(msg, "deliveryReceiptRequested", "delivery_receipt_requested", default=False)) + + # ── Internet headers ────────────────────────────────────────── + headers = extract_headers(msg) + + if not in_reply_to: + in_reply_to = headers.get("in_reply_to", "") + if not internet_refs: + refs_str = headers.get("references", "") + if isinstance(refs_str, str) and refs_str: + internet_refs = [r.strip() for r in refs_str.split() if r.strip()] + + # ── Přílohy ─────────────────────────────────────────────────── + attachments = extract_attachments(msg) + + # ── Raw MAPI ────────────────────────────────────────────────── + mapi_raw = extract_mapi_props(msg) + + msg.close() + + # ── Dokument ────────────────────────────────────────────────── + return { + "_id": mid, + "filename": msg_path.name, + + "subject": subject, + "normalized_subject": normalized_subject, + "importance": importance, + "sensitivity": sensitivity, + "flag_status": flag_status, + "read_receipt_requested": read_receipt, + "delivery_receipt_requested": delivery_receipt, + "has_attachments": len(attachments) > 0, + "attachment_count": len(attachments), + "message_size_bytes": msg_path.stat().st_size, + + "conversation_topic": conversation_topic, + "conversation_index": conversation_index, + "in_reply_to": in_reply_to, + "internet_references": internet_refs, + "categories": categories, + + "received_at": received_at, + "sent_at": sent_at, + + "sender": { + "email": sender_email, + "name": sender_name, + "smtp": sender_smtp, + }, + "to": to_raw, + "cc": cc_raw, + "bcc": bcc_raw, + "display_to": display_to, + "display_cc": display_cc, + "recipients": recipients, + + "body_text": body_text, + "body_html": body_html, + + "attachments": attachments, + "headers": headers, + "mapi": mapi_raw, + + "parsed_at": datetime.now(timezone.utc).replace(tzinfo=None), + } + + except Exception as e: + logging.error("extract_message failed [%s]: %s", msg_path.name, e) + return None + + +# ─── MongoDB indexy ─────────────────────────────────────────────────────────── + +def create_indexes(col): + print(" Vytvarim indexy...") + col.create_index([("received_at", ASCENDING)]) + col.create_index([("sent_at", ASCENDING)]) + col.create_index([("sender.email", ASCENDING)]) + col.create_index([("filename", ASCENDING)], unique=True, sparse=True) + col.create_index([("conversation_topic", ASCENDING)]) + col.create_index([("has_attachments", ASCENDING)]) + col.create_index([("categories", ASCENDING)]) + col.create_index([("importance", ASCENDING)]) + col.create_index([("flag_status", ASCENDING)]) + col.create_index([ + ("subject", TEXT), + ("body_text", TEXT), + ("to", TEXT), + ("cc", TEXT), + ], name="text_search", default_language="none") + print(" Indexy hotovy.") + + +# ─── MAIN ───────────────────────────────────────────────────────────────────── + +def main(): + ap = argparse.ArgumentParser(description=f"parse_emails v{SCRIPT_VERSION}") + ap.add_argument("--msgs-dir", default=str(MSGS_DIR), + help="Cesta k .msg souborum") + ap.add_argument("--limit", type=int, default=0, + help="Zpracovat max N souboru (0 = vse)") + ap.add_argument("--skip-existing", action="store_true", + help="Preskocit soubory ktere jiz jsou v MongoDB (pokracovani)") + ap.add_argument("--no-indexes", action="store_true", + help="Nevytvorit indexy na konci") + args = ap.parse_args() + + msgs_dir = Path(args.msgs_dir) + start = datetime.now() + + print(f"=== parse_emails v{SCRIPT_VERSION} ===") + print(f"Start: {start.strftime('%Y-%m-%d %H:%M:%S')}") + print(f"Zdroj: {msgs_dir}") + print(f"MongoDB: {MONGO_URI} -> {MONGO_DB}.{MONGO_COL}") + + # MongoDB + client = MongoClient(MONGO_URI, serverSelectionTimeoutMS=5000) + try: + client.admin.command("ping") + print(" MongoDB OK") + except Exception as e: + print(f" CHYBA: MongoDB neni dostupna -- {e}") + sys.exit(1) + + col = client[MONGO_DB][MONGO_COL] + + # Skip existing — nacti seznam uz importovanych souboru + existing: set = set() + if args.skip_existing: + print(" Nacitam existujici zaznamy z MongoDB...") + existing = set(col.distinct("filename")) + print(f" {len(existing)} jiz importovano") + + # Scan + print(f"\nSkenuji {msgs_dir} ...") + all_files = sorted(msgs_dir.glob("*.msg")) + if args.limit: + all_files = all_files[:args.limit] + + to_process = [f for f in all_files if f.name not in existing] + skipped = len(all_files) - len(to_process) + total = len(to_process) + + print(f" Celkem .msg: {len(all_files)}") + print(f" Preskoceno: {skipped}") + print(f" Ke zpracovani: {total}\n") + + if total == 0: + print("Neni co importovat.") + client.close() + return + + batch = [] + ok_count = 0 + err_count = 0 + + def flush(): + if not batch: + return + try: + col.bulk_write(batch, ordered=False) + except Exception as e: + logging.error("bulk_write: %s", e) + print(f" CHYBA bulk_write: {e}") + batch.clear() + + for i, msg_path in enumerate(to_process, 1): + doc = extract_message(msg_path) + + if doc is None: + err_count += 1 + else: + batch.append(UpdateOne({"_id": doc["_id"]}, {"$set": doc}, upsert=True)) + ok_count += 1 + + if len(batch) >= BATCH_SIZE: + flush() + + # Výpis každého emailu + status = "ERR " if doc is None else "OK " + subject_str = (doc.get("subject") or "")[:60] if doc else "?" + sender_str = (doc.get("sender", {}).get("email") or "")[:40] if doc else "?" + print(f" {i:>6}/{total} {status} {subject_str:<60} {sender_str}") + + if i % 500 == 0: + elapsed = (datetime.now() - start).total_seconds() + rate = i / elapsed if elapsed > 0 else 0 + eta_s = int((total - i) / rate) if rate > 0 else 0 + print(f" {'─'*80}") + print(f" Průběh: ok={ok_count} err={err_count} " + f"{rate:.1f} msg/s ETA {eta_s//3600}h{(eta_s%3600)//60}m") + print(f" {'─'*80}") + + flush() + + elapsed_total = (datetime.now() - start).total_seconds() + print(f"\n{'='*52}") + print(f"Vysledek: ok={ok_count} | skip={skipped} | err={err_count}") + print(f"Celkovy cas: {int(elapsed_total//3600)}h {int((elapsed_total%3600)//60)}m {int(elapsed_total%60)}s") + print(f"Dokumentu v kolekci: {col.count_documents({})}") + + if not args.no_indexes: + print() + create_indexes(col) + + print(f"\nKonec: {datetime.now().strftime('%Y-%m-%d %H:%M:%S')}") + if err_count: + print(f"Chyby logovany do: {LOG_FILE}") + + client.close() + + +if __name__ == "__main__": + main() diff --git a/EmailsImport/Trash/parse_emails_tower_v1.2.md b/EmailsImport/Trash/parse_emails_tower_v1.2.md new file mode 100644 index 0000000..a6a87a9 --- /dev/null +++ b/EmailsImport/Trash/parse_emails_tower_v1.2.md @@ -0,0 +1,252 @@ +# parse_emails_tower_v1.2 + +## Spuštění + +**První spuštění:** +```bash +docker exec -d python-runner bash -c \ + "python /scripts/parse_emails_tower_v1.2.py > /scripts/parse_emails_tower.log 2>&1" +``` + +**Pokračování po přerušení (přeskočí už importované):** +```bash +docker exec -d python-runner bash -c \ + "python /scripts/parse_emails_tower_v1.2.py --skip-existing > /scripts/parse_emails_tower.log 2>&1" +``` + +--- + +## Stav importu + +**Sledování průběhu (live log):** +```bash +docker exec -it python-runner tail -f /scripts/parse_emails_tower.log +``` + +**Počet emailů v MongoDB:** +```bash +docker exec -it python-runner python -c \ + "from pymongo import MongoClient; c=MongoClient('mongodb://192.168.1.76:27017'); print(c['emaily']['vbuzalka@its.jnj.com'].count_documents({}))" +``` + +--- + +**Název:** parse_emails_tower_v1.2.py +**Verze:** 1.2 +**Datum:** 2026-06-08 +**Autor:** vladimir.buzalka + +--- + +## Účel + +Import všech `.msg` souborů do MongoDB. Z každého souboru extrahuje **všechny dostupné vlastnosti** — podobně jako EXIF u fotek. + +- **DB:** `emaily` +- **Kolekce:** `vbuzalka@its.jnj.com` +- `_id` = Internet Message-ID (nebo `filename:` jako fallback) +- Bezpečné přerušit a opakovat — upsert podle `_id` + +--- + +## Prostředí + +Běží v Docker containeru **python-runner** na **Unraid Tower**. + +| Komponenta | Umístění | +|---|---| +| Container | `python-runner` (Docker na Unraid Tower) | +| .msg soubory | `/mnt/user/JNJEMAILS` → `/mnt/JNJEMAILS` uvnitř containeru | +| Skripty | `/mnt/user/Scripts` → `/scripts` uvnitř containeru | +| MongoDB | `192.168.1.76:27017` (externí, mimo container) | + +--- + +## Spouštění (z Unraid terminálu) + +**Test na 50 emailech:** +```bash +docker exec -it python-runner python /scripts/parse_emails_tower_v1.2.py --limit 50 --no-indexes +``` + +**Kompletní import na pozadí (log do souboru):** +```bash +docker exec -d python-runner bash -c \ + "python /scripts/parse_emails_tower_v1.2.py > /scripts/parse_emails_tower.log 2>&1" +``` + +**Pokračování po přerušení:** +```bash +docker exec -d python-runner bash -c \ + "python /scripts/parse_emails_tower_v1.2.py --skip-existing > /scripts/parse_emails_tower.log 2>&1" +``` + +**Sledování průběhu (Ctrl+C ukončí sledování, import běží dál):** +```bash +docker exec -it python-runner tail -f /scripts/parse_emails_tower.log +``` + +### Všechny parametry + +| Parametr | Popis | +|---|---| +| `--skip-existing` | Načte seznam hotových souborů z MongoDB a přeskočí je. Použij pro pokračování po přerušení. | +| `--limit N` | Zpracuje jen prvních N souborů. Vhodné pro test. | +| `--no-indexes` | Nevytváří indexy na konci. Použij pokud přerušíš uprostřed — indexy vytvoř ručně až je vše hotové. | +| `--msgs-dir PATH` | Přepíše výchozí cestu k .msg souborům (výchozí: `/mnt/JNJEMAILS`). | + +--- + +## Průběh na konzoli + +Každý email na jednom řádku: +``` + 1/69371 OK RE: Protocol deviation CZ10022 jan.novak@its.jnj.com + 2/69371 OK UCO3001: Draft FUL pro DD5-CZ10022 monitor@4gclinical.com + 3/69371 ERR ? ? +``` + +Každých 500 emailů oddělovač s průběhem: +``` + ──────────────────────────────────────────────────────────────────────────────── + Průběh: ok=498 err=2 0.4 msg/s ETA 47h12m + ──────────────────────────────────────────────────────────────────────────────── +``` + +Na konci souhrn: +``` +==================================================== +Vysledek: ok=69300 | skip=0 | err=71 +Celkovy cas: 47h 23m 10s +Dokumentu v kolekci: 69300 +``` + +--- + +## Zdroje dat z každého .msg + +| Pole | Popis | +|---|---| +| Předmět, normalized subject | | +| Odesílatel | email, jméno, SMTP adresa | +| Příjemci To/CC/BCC | strukturovaně `[{type, email, name}]` | +| Čas doručení a odeslání | UTC | +| Tělo | plaintext + HTML (max 2 MB) | +| Přílohy | metadata: jméno, velikost, MIME typ, inline flag | +| Internet headers | X-Originating-IP, Received, DKIM, X-Mailer, ... | +| MAPI | důležitost, citlivost, příznak, konverzační vlákno, kategorie | +| In-Reply-To, References | pro rekonstrukci vlákna | +| Raw MAPI properties | `{0xXXXX: value}` | + +--- + +## Hodnotové kódy + +| Pole | Hodnota | Význam | +|---|---|---| +| `importance` | 0 | Nízká | +| | 1 | Normální | +| | 2 | Vysoká | +| `sensitivity` | 0 | Normální | +| | 1 | Osobní | +| | 2 | Soukromé | +| | 3 | Důvěrné | +| `flag_status` | 0 | Bez příznaku | +| | 1 | Označeno (follow up) | +| | 2 | Dokončeno | + +--- + +## MongoDB indexy + +Automaticky vytvořeny na konci importu (`--no-indexes` přeskočí): + +| Index | Pole | +|---|---| +| Chronologický | `received_at`, `sent_at` | +| Odesílatel | `sender.email` | +| Soubor | `filename` (unique) | +| Konverzace | `conversation_topic` | +| Filtry | `has_attachments`, `categories`, `importance`, `flag_status` | +| Full-text | `subject` + `body_text` + `to` + `cc` (text index `text_search`) | + +--- + +## Ukázkové dotazy (MongoDB shell / MCP) + +**Emaily o UCO3001 s přílohou:** +```javascript +db["vbuzalka@its.jnj.com"].find({ + $text: { $search: "UCO3001" }, + has_attachments: true +}).sort({ received_at: -1 }) +``` + +**Emaily od konkrétního odesílatele:** +```javascript +db["vbuzalka@its.jnj.com"].find({ + "sender.email": /covance/i +}).sort({ received_at: -1 }) +``` + +**Celé konverzační vlákno:** +```javascript +db["vbuzalka@its.jnj.com"].find({ + conversation_topic: "Protocol deviation CZ10022" +}).sort({ received_at: 1 }) +``` + +**Statistiky podle odesílatele (top 20):** +```javascript +db["vbuzalka@its.jnj.com"].aggregate([ + { $group: { _id: "$sender.email", count: { $sum: 1 } } }, + { $sort: { count: -1 } }, + { $limit: 20 } +]) +``` + +--- + +## Chybový log + +Soubory které selhaly jsou zalogovány do **samostatného** `parse_emails_tower_errors.log` vedle skriptu (tj. `/scripts/parse_emails_tower_errors.log` → `\\tower\Scripts\parse_emails_tower_errors.log`). Tento log je oddělený od Graph importu, aby v něm nebyl bordel: +``` +2026-06-08 12:40:33 | open failed [7A3F...0000.msg]: +2026-06-08 12:41:02 | per-dokument selhal [_id=<...>]: +``` + +Stdout (průběh) jde do `parse_emails_tower.log` — rovněž samostatný. + +--- + +## Výkon + +| Parametr | Hodnota | +|---|---| +| Počet souborů | ~69 000 | +| Rychlost | ~0.4 msg/s (htmlBody dekódování) | +| Odhadovaný čas | 48 hodin | +| Batch size | 200 dokumentů / bulk_write | +| Odhadovaná velikost DB | 2–5 GB | + +--- + +## Závislosti (v Docker image python-runner) + +``` +extract-msg==0.55.0 +pymongo +python-dateutil +``` + +Image sestaven z `Dockerfile` v `/mnt/user/Scripts/python-runner/`. + +--- + +## Historie verzí + +| Verze | Datum | Změna | +|---|---|---| +| 1.0 | 2026-06-01 | Iniciální verze | +| 1.1 | 2026-06-02 | Nasazení na Unraid Tower v Docker containeru python-runner; MSGS_DIR změněno z SMB share (`\\tower\JNJEMAILS`) na lokální mount (`/mnt/JNJEMAILS`); aktualizován popis spouštění pro `docker exec` | +| 1.2 | 2026-06-08 | **Oprava `to_bson`:** int mimo rozsah int64 (BSON umí jen 8-byte ints) se převede na string — dřív celý `bulk_write` spadl na `MongoDB can only handle up to 8-byte ints` a zahodil celou dávku 200 dokumentů (běh v1.1 z 8.6. neuložil **nic**). `flush()` má fallback per-dokument (vadný záznam zahodí sám, ne celou dávku). `bool()` testován před `int()`. Samostatné logy `parse_emails_tower.log` + `parse_emails_tower_errors.log`. | diff --git a/EmailsImport/Trash/parse_emails_tower_v1.2.py b/EmailsImport/Trash/parse_emails_tower_v1.2.py new file mode 100644 index 0000000..aaf61b7 --- /dev/null +++ b/EmailsImport/Trash/parse_emails_tower_v1.2.py @@ -0,0 +1,701 @@ +""" +parse_emails_tower_v1.2.py +Nazev: parse_emails_tower_v1.2.py +Verze: 1.2 +Datum: 2026-06-08 +Autor: vladimir.buzalka + +Popis: + Parsuje vsechny .msg soubory z MSGS_DIR a importuje je jako dokumenty + do MongoDB. Z kazdeho souboru extrahuje VSECHNY dostupne vlastnosti — + podobne jako EXIF u fotek: + + - predmet, odesilatel, prijemci (To/CC/BCC s typy) + - cas doruceni a odeslani (UTC) + - telo plaintext + HTML (max 2 MB) + - prilohy (metadata: jmeno, velikost, MIME typ, inline flag) + - internet headers (X-Originating-IP, Received, DKIM, ...) + - MAPI vlastnosti: dulezitost, citlivost, priznak, konverzacni vlakno, + kategorie, In-Reply-To, References, ... + - vsechny raw MAPI properties jako {0xXXXX: value} + + DB: emaily + Kolekce: vbuzalka@its.jnj.com + _id: Internet Message-ID (nebo "filename:" jako fallback) + + Bezpecne prerusit a opakovat: + - upsert podle _id — duplicity se automaticky prepisi + - --skip-existing nacte seznam hotovych souboru z MongoDB a + preskoci je => pokracovani po preruseni bez ztraty prace + +Prostredi: + Bezi v Docker containeru "python-runner" na Unraid Tower. + .msg soubory jsou dostupne jako lokalni disk (volume mount): + /mnt/user/JNJEMAILS -> /mnt/JNJEMAILS (uvnitr containeru) + MongoDB na 192.168.1.76:27017 (externi, bezi mimo container). + +Spousteni (z Unraid terminalu): + # Test na 50 emailech: + docker exec -it python-runner python /scripts/parse_emails_tower_v1.2.py --limit 50 --no-indexes + + # Kompletni import na pozadi (samostatny log, ne sdileny s Graph importem): + docker exec -d python-runner bash -c \ + "python /scripts/parse_emails_tower_v1.2.py > /scripts/parse_emails_tower.log 2>&1" + + # Pokracovani po preruseni: + docker exec -d python-runner bash -c \ + "python /scripts/parse_emails_tower_v1.2.py --skip-existing > /scripts/parse_emails_tower.log 2>&1" + + # Sledovani prubehu: + docker exec -it python-runner tail -f /scripts/parse_emails_tower.log + +Vystup na konzoli: + Kazdy email na jednom radku: + / OK/ERR + Kazych 500 emailu: oddelovac s prubehem, rychlosti a ETA. + Na konci: souhrn ok/skip/err, celkovy cas, pocet dokumentu v kolekci. + +Zavislosti (nainstalovane v Docker image python-runner): + extract-msg==0.55.0, pymongo, python-dateutil + Python 3.12, Linux (Docker container na Unraid Tower) + +Struktura dokumentu v MongoDB: + _id Internet Message-ID (nebo filename: fallback) + filename jmeno .msg souboru (20znakovy hex + .msg) + subject predmet zpravy + normalized_subject predmet bez RE:/FW: prefixu + importance 0=nizka 1=normalni 2=vysoka + sensitivity 0=normalni 1=osobni 2=soukrome 3=duverne + flag_status 0=bez priznaku 1=oznaceno 2=dokonceno + read_receipt_requested bool + delivery_receipt_requested bool + has_attachments bool + attachment_count int + message_size_bytes velikost .msg souboru na disku + conversation_topic tema vlakna (PR_CONVERSATION_TOPIC) + conversation_index base64 PR_CONVERSATION_INDEX + in_reply_to Message-ID predchozi zpravy + internet_references [Message-ID] — cela historia vlakna + categories [str] — MAPI kategorie / stitky + read_receipt_requested bool + delivery_receipt_requested bool + received_at datetime UTC — cas doruceni + sent_at datetime UTC — cas odeslani + sender.email emailova adresa odesilatele + sender.name zobrazovane jmeno odesilatele + sender.smtp SMTP adresa (pro interni EX adresy) + to retezec To (tak jak v Outlooku) + cc retezec CC + bcc retezec BCC + display_to PR_DISPLAY_TO (zkraceny seznam) + display_cc PR_DISPLAY_CC + recipients [{type, email, name}] — to/cc/bcc s typy + body_text plain text telo + body_html HTML telo (max 2 MB, None pokud neni) + attachments [{filename, size_bytes, mime_type, + content_id, is_inline}] + headers dict internet headers (lowercase_s_podtrzitky) + mapi dict vsech raw MAPI properties {0xXXXX: value} + parsed_at datetime UTC — cas parsovani + +Indexy (vytvoreny automaticky na konci): + received_at, sent_at, sender.email, filename (unique), + conversation_topic, has_attachments, categories, importance, + flag_status, text_search (subject + body_text + to + cc) + +Chyby: + Soubory ktere selhaly jsou zalogovany do parse_emails_tower_errors.log + v adresari skriptu (SAMOSTATNY log, oddeleny od Graph importu). + Radek: timestamp | open/extract failed | duvod. + +Historie verzi: + 1.0 2026-06-01 Inicialni verze + 1.1 2026-06-02 Nasazeni na Unraid Tower v Docker containeru python-runner; + MSGS_DIR zmeneno z SMB share na lokalni mount /mnt/JNJEMAILS; + aktualizovany popis spousteni pro docker exec + 1.2 2026-06-08 OPRAVA: to_bson prevadi int mimo rozsah int64 na string + (BSON umi jen 8-byte ints) — drive cely bulk_write spadl na + 'MongoDB can only handle up to 8-byte ints' a zahodil celou + davku 200 dokumentu (v1.1 beh 8.6. neulozil NIC). + flush() ma fallback per-dokument: vadny zaznam zahodi sam, + ne celou davku. bool() testovan pred int(). + Samostatny error log parse_emails_tower_errors.log a + stdout log parse_emails_tower.log (drive sdilene s Graph + importem — bordel v logu). +""" + +import sys +import re +import logging +import argparse +import base64 +from pathlib import Path +from datetime import datetime, timezone +from typing import Optional + +import extract_msg +from dateutil import parser as dtparser +from pymongo import MongoClient, UpdateOne, ASCENDING, TEXT + +if hasattr(sys.stdout, "reconfigure"): + sys.stdout.reconfigure(encoding="utf-8", errors="replace") + +# ─── KONFIGURACE ────────────────────────────────────────────────────────────── +MSGS_DIR = Path("/mnt/JNJEMAILS") +MONGO_URI = "mongodb://192.168.1.76:27017" +MONGO_DB = "emaily" +MONGO_COL = "vbuzalka@its.jnj.com" +BATCH_SIZE = 200 +LOG_FILE = Path(__file__).parent / "parse_emails_tower_errors.log" +SCRIPT_VERSION = "1.2" +# ────────────────────────────────────────────────────────────────────────────── + +logging.basicConfig( + filename=str(LOG_FILE), + level=logging.ERROR, + format="%(asctime)s | %(message)s", + datefmt="%Y-%m-%d %H:%M:%S", + encoding="utf-8", +) + + +# ─── Pomocné funkce ─────────────────────────────────────────────────────────── + +def safe(obj, *attrs, default=None): + """Bezpecne cteni atributu — vrati prvni non-None hodnotu.""" + for attr in attrs: + try: + val = getattr(obj, attr, None) + if val is None: + continue + if isinstance(val, str) and not val.strip(): + continue + return val + except Exception: + continue + return default + + +def parse_date(raw) -> Optional[datetime]: + """Libovolny datum -> UTC datetime bez tzinfo (pro MongoDB).""" + if raw is None: + return None + if isinstance(raw, datetime): + if raw.tzinfo: + return raw.astimezone(timezone.utc).replace(tzinfo=None) + return raw + try: + dt = dtparser.parse(str(raw)) + if dt.tzinfo: + return dt.astimezone(timezone.utc).replace(tzinfo=None) + return dt + except Exception: + return None + + +_INT64_MIN, _INT64_MAX = -(2 ** 63), 2 ** 63 - 1 + + +def to_bson(val): + """Konvertuje hodnotu na BSON-serializovatelny typ. + + Pozor: BSON umi jen signed int64. Python ma neomezene integery, takze + velke MAPI hodnoty (PR_CHANGE_KEY, FILETIME, 64-bit handle) mimo rozsah + int64 prevadime na string — jinak cely bulk_write spadne na + 'MongoDB can only handle up to 8-byte ints'. + """ + # bool musi byt PRED int (isinstance(True, int) == True) + if isinstance(val, bool): + return val + if isinstance(val, bytes): + return val.hex() if len(val) <= 128 else f"" + if isinstance(val, datetime): + return parse_date(val) + if isinstance(val, int): + return val if _INT64_MIN <= val <= _INT64_MAX else str(val) + if isinstance(val, (str, float, type(None))): + return val + if isinstance(val, list): + return [to_bson(v) for v in val] + try: + iv = int(val) + return iv if _INT64_MIN <= iv <= _INT64_MAX else str(iv) + except Exception: + pass + return str(val) + + +# ─── Extrakce částí zprávy ──────────────────────────────────────────────────── + +def extract_headers(msg) -> dict: + headers = {} + try: + hdr = msg.header + if not hdr: + return {} + from email.header import decode_header as _dh + + def _decode(v: str) -> str: + try: + parts = _dh(v) + out = "" + for part, enc in parts: + out += part.decode(enc or "utf-8", errors="replace") if isinstance(part, bytes) else part + return out + except Exception: + return v + + for key in set(hdr.keys()): + k = key.lower().replace("-", "_") + vals = [_decode(v) for v in hdr.get_all(key, [])] + headers[k] = vals if len(vals) > 1 else (vals[0] if vals else "") + except Exception as e: + logging.error("extract_headers: %s", e) + return headers + + +def extract_recipients(msg) -> list: + result = [] + type_map = {1: "to", 2: "cc", 3: "bcc"} + try: + for r in msg.recipients: + rtype = getattr(r, "type", 1) + try: + rtype = int(rtype) + except Exception: + try: + rtype = int(rtype.value) + except Exception: + rtype = 1 + rec = { + "type": type_map.get(rtype, "to"), + "email": safe(r, "email", default=""), + "name": safe(r, "name", default=""), + } + result.append(rec) + except Exception as e: + logging.error("extract_recipients: %s", e) + return result + + +def extract_attachments(msg) -> list: + result = [] + try: + for att in msg.attachments: + fname = safe(att, "longFilename", "shortFilename", default="") + if not fname: + continue + size = 0 + try: + d = att.data + size = len(d) if d else 0 + except Exception: + pass + result.append({ + "filename": fname, + "size_bytes": size, + "mime_type": safe(att, "mimetype", "mimeType", default="application/octet-stream"), + "content_id": safe(att, "cid", default=None), + "is_inline": bool(safe(att, "isInline", default=False)), + }) + except Exception as e: + logging.error("extract_attachments: %s", e) + return result + + +def extract_mapi_props(msg) -> dict: + """Vsechny raw MAPI properties jako {0xXXXX: value}.""" + result = {} + try: + props = msg.props + if not hasattr(props, "items"): + return {} + for key, prop in props.items(): + try: + val = to_bson(prop.value) + prop_id = f"0x{key[:4].upper()}" if len(key) >= 4 else f"0x{key.upper()}" + result[prop_id] = val + except Exception: + pass + except Exception as e: + logging.error("extract_mapi_props: %s", e) + return result + + +# ─── Hlavní extrakce ───────────────────────────────────────────────────────── + +def extract_message(msg_path: Path) -> Optional[dict]: + """Parsuje jeden .msg soubor -> MongoDB dokument.""" + try: + msg = extract_msg.Message(str(msg_path)) + except Exception as e: + logging.error("open failed [%s]: %s", msg_path.name, e) + return None + + try: + # ── Message-ID ──────────────────────────────────────────────── + mid = None + for attr in ("messageId", "message_id", "internetMessageId"): + mid = safe(msg, attr) + if mid: + break + if not mid: + mid = f"filename:{msg_path.stem}" + mid = str(mid).strip() + + # ── Předmět ─────────────────────────────────────────────────── + try: + subject = msg.subject or "" + except Exception: + subject = "" + + normalized_subject = safe(msg, "normalizedSubject", "normalized_subject", default="") + + # ── Tělo ────────────────────────────────────────────────────── + try: + body_text = msg.body or "" + except Exception: + body_text = "" + + body_html = None + try: + bh = msg.htmlBody + if isinstance(bh, bytes): + bh = bh.decode("utf-8", errors="replace") + if bh: + body_html = bh if len(bh) <= 2 * 1024 * 1024 else bh[:2 * 1024 * 1024] + except Exception: + pass + + # ── Odesílatel ──────────────────────────────────────────────── + try: + sender_email = msg.sender or "" + except Exception: + sender_email = "" + + sender_name = safe(msg, "senderName", "sender_name", default="") + sender_smtp = safe(msg, "senderSmtpAddress", "sent_representing_smtp_address", default="") + + # ── Příjemci ────────────────────────────────────────────────── + recipients = extract_recipients(msg) + + try: + to_raw = msg.to or "" + except Exception: + to_raw = "" + try: + cc_raw = msg.cc or "" + except Exception: + cc_raw = "" + try: + bcc_raw = getattr(msg, "bcc", None) or "" + except Exception: + bcc_raw = "" + + display_to = safe(msg, "displayTo", "display_to", default="") + display_cc = safe(msg, "displayCc", "display_cc", default="") + + # ── Časy ────────────────────────────────────────────────────── + try: + received_at = parse_date(msg.date) + except Exception: + received_at = None + + sent_at = None + for attr in ("clientSubmitTime", "client_submit_time", "sentOn"): + v = safe(msg, attr) + if v: + sent_at = parse_date(v) + break + + # ── MAPI vlastnosti ─────────────────────────────────────────── + importance = 1 + try: + v = msg.importance + if v is not None: + importance = int(v) + except Exception: + pass + + sensitivity = 0 + try: + v = getattr(msg, "sensitivity", None) + if v is not None: + sensitivity = int(v) + except Exception: + pass + + flag_status = 0 + try: + v = safe(msg, "flagStatus", "flag_status") + if v is not None: + flag_status = int(v) + except Exception: + pass + + conversation_topic = safe(msg, "conversationTopic", "conversation_topic", default="") + + conversation_index = "" + try: + ci = safe(msg, "conversationIndex", "conversation_index") + if isinstance(ci, bytes): + conversation_index = base64.b64encode(ci).decode() + elif ci: + conversation_index = str(ci) + except Exception: + pass + + in_reply_to = safe(msg, "inReplyTo", "in_reply_to", default="") + + internet_refs = [] + try: + refs = safe(msg, "internetReferences", "internet_references") + if isinstance(refs, list): + internet_refs = refs + elif isinstance(refs, str) and refs: + internet_refs = [r.strip() for r in refs.split() if r.strip()] + except Exception: + pass + + categories = [] + try: + cats = safe(msg, "categories") + if isinstance(cats, list): + categories = [str(c) for c in cats if c] + elif isinstance(cats, str) and cats: + categories = [c.strip() for c in re.split(r"[;,]", cats) if c.strip()] + except Exception: + pass + + read_receipt = bool(safe(msg, "readReceiptRequested", "read_receipt_requested", default=False)) + delivery_receipt = bool(safe(msg, "deliveryReceiptRequested", "delivery_receipt_requested", default=False)) + + # ── Internet headers ────────────────────────────────────────── + headers = extract_headers(msg) + + if not in_reply_to: + in_reply_to = headers.get("in_reply_to", "") + if not internet_refs: + refs_str = headers.get("references", "") + if isinstance(refs_str, str) and refs_str: + internet_refs = [r.strip() for r in refs_str.split() if r.strip()] + + # ── Přílohy ─────────────────────────────────────────────────── + attachments = extract_attachments(msg) + + # ── Raw MAPI ────────────────────────────────────────────────── + mapi_raw = extract_mapi_props(msg) + + msg.close() + + # ── Dokument ────────────────────────────────────────────────── + return { + "_id": mid, + "filename": msg_path.name, + + "subject": subject, + "normalized_subject": normalized_subject, + "importance": importance, + "sensitivity": sensitivity, + "flag_status": flag_status, + "read_receipt_requested": read_receipt, + "delivery_receipt_requested": delivery_receipt, + "has_attachments": len(attachments) > 0, + "attachment_count": len(attachments), + "message_size_bytes": msg_path.stat().st_size, + + "conversation_topic": conversation_topic, + "conversation_index": conversation_index, + "in_reply_to": in_reply_to, + "internet_references": internet_refs, + "categories": categories, + + "received_at": received_at, + "sent_at": sent_at, + + "sender": { + "email": sender_email, + "name": sender_name, + "smtp": sender_smtp, + }, + "to": to_raw, + "cc": cc_raw, + "bcc": bcc_raw, + "display_to": display_to, + "display_cc": display_cc, + "recipients": recipients, + + "body_text": body_text, + "body_html": body_html, + + "attachments": attachments, + "headers": headers, + "mapi": mapi_raw, + + "parsed_at": datetime.now(timezone.utc).replace(tzinfo=None), + } + + except Exception as e: + logging.error("extract_message failed [%s]: %s", msg_path.name, e) + return None + + +# ─── MongoDB indexy ─────────────────────────────────────────────────────────── + +def create_indexes(col): + print(" Vytvarim indexy...") + col.create_index([("received_at", ASCENDING)]) + col.create_index([("sent_at", ASCENDING)]) + col.create_index([("sender.email", ASCENDING)]) + col.create_index([("filename", ASCENDING)], unique=True, sparse=True) + col.create_index([("conversation_topic", ASCENDING)]) + col.create_index([("has_attachments", ASCENDING)]) + col.create_index([("categories", ASCENDING)]) + col.create_index([("importance", ASCENDING)]) + col.create_index([("flag_status", ASCENDING)]) + col.create_index([ + ("subject", TEXT), + ("body_text", TEXT), + ("to", TEXT), + ("cc", TEXT), + ], name="text_search", default_language="none") + print(" Indexy hotovy.") + + +# ─── MAIN ───────────────────────────────────────────────────────────────────── + +def main(): + ap = argparse.ArgumentParser(description=f"parse_emails v{SCRIPT_VERSION}") + ap.add_argument("--msgs-dir", default=str(MSGS_DIR), + help="Cesta k .msg souborum") + ap.add_argument("--limit", type=int, default=0, + help="Zpracovat max N souboru (0 = vse)") + ap.add_argument("--skip-existing", action="store_true", + help="Preskocit soubory ktere jiz jsou v MongoDB (pokracovani)") + ap.add_argument("--no-indexes", action="store_true", + help="Nevytvorit indexy na konci") + args = ap.parse_args() + + msgs_dir = Path(args.msgs_dir) + start = datetime.now() + + print(f"=== parse_emails v{SCRIPT_VERSION} ===") + print(f"Start: {start.strftime('%Y-%m-%d %H:%M:%S')}") + print(f"Zdroj: {msgs_dir}") + print(f"MongoDB: {MONGO_URI} -> {MONGO_DB}.{MONGO_COL}") + + # MongoDB + client = MongoClient(MONGO_URI, serverSelectionTimeoutMS=5000) + try: + client.admin.command("ping") + print(" MongoDB OK") + except Exception as e: + print(f" CHYBA: MongoDB neni dostupna -- {e}") + sys.exit(1) + + col = client[MONGO_DB][MONGO_COL] + + # Skip existing — nacti seznam uz importovanych souboru + existing: set = set() + if args.skip_existing: + print(" Nacitam existujici zaznamy z MongoDB...") + existing = set(col.distinct("filename")) + print(f" {len(existing)} jiz importovano") + + # Scan + print(f"\nSkenuji {msgs_dir} ...") + all_files = sorted(msgs_dir.glob("*.msg")) + if args.limit: + all_files = all_files[:args.limit] + + to_process = [f for f in all_files if f.name not in existing] + skipped = len(all_files) - len(to_process) + total = len(to_process) + + print(f" Celkem .msg: {len(all_files)}") + print(f" Preskoceno: {skipped}") + print(f" Ke zpracovani: {total}\n") + + if total == 0: + print("Neni co importovat.") + client.close() + return + + batch = [] + ok_count = 0 + err_count = 0 + + def flush(): + nonlocal ok_count, err_count + if not batch: + return + try: + col.bulk_write(batch, ordered=False) + except Exception as e: + # Cely batch spadl (typicky jeden vadny dokument). Zkusime + # ho zapsat dokument po dokumentu, aby chyba zahodila jen + # skutecne vadny zaznam, ne celych BATCH_SIZE. + logging.error("bulk_write spadl (%s) -- prepinam na per-dokument", e) + print(f" CHYBA bulk_write: {e} -- zkousim per-dokument") + for op in batch: + try: + col.bulk_write([op], ordered=False) + except Exception as e2: + try: + bad_id = getattr(op, "_filter", {}).get("_id", "?") + except Exception: + bad_id = "?" + logging.error("per-dokument selhal [_id=%s]: %s", bad_id, e2) + print(f" ZAHOZEN _id={bad_id}: {e2}") + ok_count -= 1 + err_count += 1 + batch.clear() + + for i, msg_path in enumerate(to_process, 1): + doc = extract_message(msg_path) + + if doc is None: + err_count += 1 + else: + batch.append(UpdateOne({"_id": doc["_id"]}, {"$set": doc}, upsert=True)) + ok_count += 1 + + if len(batch) >= BATCH_SIZE: + flush() + + # Výpis každého emailu + status = "ERR " if doc is None else "OK " + subject_str = (doc.get("subject") or "")[:60] if doc else "?" + sender_str = (doc.get("sender", {}).get("email") or "")[:40] if doc else "?" + print(f" {i:>6}/{total} {status} {subject_str:<60} {sender_str}") + + if i % 500 == 0: + elapsed = (datetime.now() - start).total_seconds() + rate = i / elapsed if elapsed > 0 else 0 + eta_s = int((total - i) / rate) if rate > 0 else 0 + print(f" {'─'*80}") + print(f" Průběh: ok={ok_count} err={err_count} " + f"{rate:.1f} msg/s ETA {eta_s//3600}h{(eta_s%3600)//60}m") + print(f" {'─'*80}") + + flush() + + elapsed_total = (datetime.now() - start).total_seconds() + print(f"\n{'='*52}") + print(f"Vysledek: ok={ok_count} | skip={skipped} | err={err_count}") + print(f"Celkovy cas: {int(elapsed_total//3600)}h {int((elapsed_total%3600)//60)}m {int(elapsed_total%60)}s") + print(f"Dokumentu v kolekci: {col.count_documents({})}") + + if not args.no_indexes: + print() + create_indexes(col) + + print(f"\nKonec: {datetime.now().strftime('%Y-%m-%d %H:%M:%S')}") + if err_count: + print(f"Chyby logovany do: {LOG_FILE}") + + client.close() + + +if __name__ == "__main__": + main() diff --git a/EmailsImport/_test_open/ATTACH__899C0000969E661B0000.msg b/EmailsImport/_test_open/ATTACH__899C0000969E661B0000.msg new file mode 100644 index 0000000000000000000000000000000000000000..eb18ede86526c1bfc171ac832d78528b1191b587 GIT binary patch literal 680448 zcmeF430MMk`OZygsxBOrEUl4%|8V>)IG>n!+lft8%RtBv{zC1UXERQFFgToB9gp;V z2km}4{de7p_zIeemJ2_XwEPx7v%%LSut+c#yq4tpmcKn81pYhuWc}{|HN4ewtmt{O zO9dU_cQocZgFOcJI2Z~Q8v9Rxbpv}6%pVL=04)G45G)9+J6I2}r@)>Ddj_m0*t1~0 zz7{{R0P|84ib2vYik za(oCFS^Ys70_99p+UAFo;XjyvkmWn)t8Md=Bg?o5G`j7MmX$@KakFYP&Q&igKCzIlLf_l&#fh_-f*cWLlDsAx{vmejTf4&1Q z>a(b{%}23!AAdAQ>Iz2I|8HPlG}l0-Z9b{~PkH`#4!BR->F)Sw{JZxb^<^{bQH&Be*`Pr<%u z{)|dn{Vxh4K*oQ>brwghZT~z8o5}E_NuK}sLw!MD=os22JGR!rgJYK3w*S#^HsOu) zuUg=v^Bq*$ihqoqj#>bnl{~zl{2vILx`UDR|4Z1npryLD`Q-ASv+c?9zW{bGQhajp ze*)@4^H;L`&tYFO?H>bYlHO?l&wx)xe`DY*mJI(XsP7pH{(nl^|KX(gRNMa((*7rs z;v+3X{fTV*Z-9N@MS=~b?fy@0{zKLOb-<0c)7#=Fz_^bE|J~>RXQ8e>U}XJY1N*w4 ze;_`&`7c%fR|DVu`~&e(`@8kuzOKZe;QuPv*ZufIe6$AVHvih=?u-Fc?Y69hJ>2IX z#7F(lE#D^?>O<%4WZSs@5|+Lq&mhc?Dv5~x49^B)ZA=?g}d zuYrBhd&k$^1jr z|K-3X!;d95{(X8teQ1V6*8gR&FPbx<(z^d>?2$VEv2&d0UHhY~7eR9T zq4nhfU}XJ&1@?^tL!~wU9ekue?(>h+ce4DKflG!TX+QsP&quio<#V$9MI`u+l`nGn zhpPVzf$y&Uojs4t_#XuI4WZzF1?-y)hDvMg@8CO+BHXd_Lw^37>rdrS4>|wQS-4yM z_ZbNFg@KW6e{}5woim`)y8p=#Bk#kkn?PbQgv(e*GE7+L?(wV>C*P-)wL z@67*Z0~f6qqtZ5?-1tLl2@zmq{V#=m-TCiW|MAZH8@fK{ZvN-sJF<|w^M5otBPsZ= zgniLZ&J$z3Ui9mx3ah(0<09dvSh z8Sv5d0#w?He}p~vx#veiJ;TAs`j5lD{TIQ$?#}Z|U~e;s`9tiMbH zK3XqErS0}7r$6JMo-{DB{!fN|(Ha;kZS%>ke^YJ$Nx*e?{(<6;Mjra-uK$mP`ZB=C z`aco&bvOTX@X4M3QT2ZU@ZIHK2cO*hn+x@&Q}90v_9Yj8a@Rkp`kx7Wa`AWeg0|Pc zcu=1Y1^-cBAv6BNNM8S->OX2La_#S&fuPm(hZo3y_IsbvniARmkK#op|C7A_W#>9$ z@bIJj`>UwGy5pm9A3^T=J7qq~mFOG*mDchfy8qvC{nKs!q0C2I_k83(sq62Q`DE_D zbmU%A*S{(A-va;H&!H%^9)D-qVGI;*5 zPrYQr)lG*I{q@uFZuHrPzdnDG;!LW}jV+JHSHHF2ckg_3-Td$PXtmu@5Pv*86@tb7 zXZ*kNv8(?B|1*9>i}#NBqxmG7Q}_JO_>q6(J9FRT{}~^x_BslRKbp_yg55zP_>ki4 zcg{!GUH)DFi+)grYy1E5pYhR(qoW``AD*If>TmxuK3eT{6j%R0{m=Ml#qBSC4m?F` zng{+few+giKVAKQ=Rf1e|Ba8wI+C^e_1j*Z)skD|UJA zvg;3luy6O4gJ_#i zYW?{^{K@kDf&H=z|53mH!`c31`TtyhdQ|=^;EVGZTHI>$ArN$We~VVP7Jn9n`~RG5 zvi=7E+qwRU4gdI4+{7`k5q-7~-eivvSvbLfl; zozYbs8rNgN&^0b}jSu;W*1OOn8Jhz8PNlFvnL7WukKCnxq(#o{NRv=* za{i8T1jo18Bw z`^%qXzN$pTR}I19ibN7Iia=aKat88fDDr3|HkvQz3#EK9>>-6?$b^HEC>_T#W`cdY zN+=f%oy1o{1f`-OSQ4tJC6>v^m(e0<$eAK3gl#NeYDdQ>!RurA@*;R`9A79GBkuU5 zBp2?OxCy+hw7Bu(hhS-9K>=SRafBxky>*;iB?I@<_;P^SYs?(y^4?UwKm;*OknqKF zhf8r;uAA{PzC;4#OG5Ebi5U9H|DdOVI|XG55d@OQSK0|vQ5e$%aY8;i>O_%LtZ?Zt zTm@eV&Zj`{u-6ucJm*2*7UK59yaqKTl{j2TviC5tNH7~>3vrc*3Kh=&G=3~E6_cX= zG#*7ivp@`QjDv0s{T{W=xQt8`fJ_(%=$#U=0`^6RZ|}BQ{6c;KUr_+91@TLzvlLOlt(;G_r9YQ6VD4s?`oA0|F3X%@7R zG+&g;&s8vS)q~%$IAIZtT7^;$qr60fjh5po88#q!N@7YpcT944L?$mWHESSKARUz< z5{PAD=qn2JTZAZvAC?;tB@7b@BZbkCxiPF<;qctt$mpmjQFJVSXi2VP6ts1OZEthd zz!57I!)8in4in%-ZNKC1TN6cmIhLB0rWn$#OSdj#_%c};WSmm0480x_f?niFM11Hb zd19#$%N0rRQjCuQ9ZJ`WIhi##M3Sg9jk@X+xKJ0EUZTs(R1vD#qc=L1U4ZYJe;)Px&l!94 z*y2{35C81{kIG*IH0Lq232xaK0{*w>`6ouI{mJXkO7Lr0OAN^P&-h3CKWzQQnfXZc zf1l+5)llFE1K*SSv$ln;Xea%74frc4`2WxT|M2*u-0N(G|K0ji3BIqQ;C~-ze^2Yr zY6|?`r1{>_pI*RkPyKlo`0c4b=sKYX_2)tEC#ydN!2bpemDcp%o9mBxq~cFL|8D|6 zHiMD%U-XaoKRo|9GC!I8zaH3cP~Z!J?{59wG5<$%AGh-#pDitHvi@Iz{U2|HA5dCr ze=6r6uR}c>z{v93JO2wH{vDC?P}=sN-1)~ws7D7z*8g1KqqTHY+UAo#|IkBSWchs3 z{m(o1-wp!){%*+ow*2?r`Nu%uyUYKM>u+fEyFLH$sRBRNfsu_rx&H6H^Pd6WzX$cl zXIG2wWc_~`_v=<{#x^#}R=KGa9n{|ex{8-ETyxzC@!4eYll@YTRa*UV69 zJO1Rpe`Gt<^8pxH|K|Z8T^B^9b$(pS)qnT-XE)S?*r?bmb@O8`@ZI%)3iH1QY_j~> zB;t=gf1OP7^RGtmcWX-w+_-MvJc|S$efI+T1UQ-eZx4LS4>J5x;0Lwr*n0aTKB>m`0eq3)b-C}P?vKIwp82Z z!&cz8=lo*}@ZI%4hw_t~e;fpF&0u85|7PH~=lnwt{H&H1YHj>coqrsn;J*&|o}7Oi z0QO!A{EfgbcH_UJ{mIQg_CsAJ3j8;KKiMsx{QTp13!7~JdmZ@h`oA~lAL~iPpUV8B z2K?VcA^vMg@VzHGXMA#>Zt=G>;Hb>4?}P$t@FvxKh8ouRL0*v;JfSp-kg8zArXHn z^N&;D|HmycfCsl_7YV*M=N~(P@5%L#FTmqkFtYuxnne3knSXo~_J>Zy8@r3^W2K6+7k@f#J@Y_@WZvx-l`WIFGw^H!`2Jk(p|5t(i zGX;JV@I86`<5yreQsCQw@5$>QRQ2Bqe0TldoBDr^MEt4f|8_-_!bklLG%I;J4@Xk1HhN?@j%`1bo;0|ET)k z3F>p^AZP}+B?!c?J@r2j`0nmMqjLS>9(e5A5(Br+!wvz!Z%_TF1AK7HfwngPp{oDr z#y_(2AAjI`QvdG)`wt5IZonVo#(yf;AO3{8d?>X46ToM><&(eu;2e8o#9?N3Gj?*qOA1%3zM zds_cHQsDam{~0&&_vZBnUlQ^6rvCc?-!=a~s{TLK5__`wXDIO7Q~!qm-`)8S75zuw zXAnrC{|yE{{I{3Z^w+_6{B-yCU#RB)K>#1%hEG-h(RZ4VZGZGV`JU8&^nDJGQQ$uh z{3JL2Q_+9)eGce5?a2DyANWJu^1Y}3{ebVT|9eya`;v%175xu_*mtH7{}2* z4Ddav|LFTXo}s``0)B-X|EcId`aTczoknE+PXK;_TfX=7KOXq*`oA~zpG_kERP?_u z#Qtdt@qd8?-<$eB68N56|3}~FgTB*>Z2ucUqW!7pKl(nY=P2;e-|6zS{`aH6A5Ox5 zZ|Z*x3BEV=KMMG+`TtS%Ke{FMWc%Mt;J2s#i-G@~+x&~}KO}em-w^OWoI?LA06zS; zm-f*AJb+Jh!>6kMObY&sfbU8D9}H~tog!rWp8)s@H~v%6fAoDaVHEg$;7@hS_n!Xe z0N-8z_on{8L?ZrF^gjY(|2&2GPbb0mrv6U@z9-lJhl1}c3jR+e(f(BQe;BYMDe$KN z-_!aZMS(vV`0cs=KZ!*Ay{Z2bfbW|BA65U8TVhW(|1Jf7d+PtIz<<_l{w1&fFM$8? z6#CyQz=!|#(jNN%GQh=d_*C_uO~L=g!1tv7j|BE`3j77Yf7y-yRP=uYu;VE3%Yk3y zmhV0NR|DT&|M#Z;&m|FmD*B%Qv5%n;|1uJMZ|eUn;Cu4^|54yOhl2m5B-)>f{=W$9 zL<;;8;CovClPK_2z;Dm{|CJ=-?@j%e1K&0OKdSyuY>7Qt{ofA!_SFAvz;{3X$m@S9 z_@6^|Ctc`(G=ppfdt>1`oA9do?QP=1K)WR{9i|+{i*2x zcwlEy;I9R~r}cjV1^yb~ySx77&GrA)B;xN){a*=u*Zlve`k&Vld$Rg}0{HEz{~rV2 z-Tcpy|H-ZYPY3^VDfGYNz=!|#(jNMM6yWa8KdI_}HUxQQ~wW;h(8tm7eMSMQHcLu5`1s!{~q9ba{Ye> z_?|<-|J@|opNjs!1Z*J%{x0BqTK`29_&b5$p6mbBB;xN){Wk#LHUB@V{+G1Go~-^i z0KYx;-vWGh^FJ#3F9HAM6#8F1@Zo>E>Hm3vyWao#ujN&PPZ z-(?j1KTV?jsp!8H*h&igQ^5DM{;MePPXfO^^}mip{Jp9FwZM1H|BtHwFSo>=tp48z zetYVFGw?%5=`XqS|GD7*0t)@_9`NCRyXpU*0H5H7PgVcb6#Tyfd{65C9AM9)z`qTA zxf}nftpCpjb_E6gP2jiZ_y64heux|Yy{Z3AB;rp+{})2+ODV+PMuP86{kH<&-Srm- zpWNSHng_m@Q}F+H675e#|K|gH5e5D=;CovC7gON>27GtxU*25*ze*zh-qinJfbW|B zA65U?w#1&S{s;TDum1M|zPs-~p>qDe9Q6kM8VdgR z1imNre;Ke}p}>C%_^-I}pNjr31$HF`es|#GZu#C@{|^GbyZ-M@{ilJ>;D=G{KtXsZvD%f`u`Y- z__`jJ#|BD8Gd+L7_@CUllAFBGV zqu_re@I9&jZvcBe1%5d2lim1FMgLz1b`=GF81RR><$F*6S-@{k{U1gm{#5jT3&egM zh4>F4!S|;A4+g#`^?xJyuBYJtAQJ6QMgKPedn*P0K;U~?|KFm(9{~LJ)c@y6#NV6x z-yis{`TtS%e{W0d$?E?E;J2s#X92&L+x$!Z{{Q#E|D6>2UncO|Q~%R}@4EiuiR=Fc z3jXte?@9fC57=*0;ExBsC)fYq1$H$Bek$yJ|BHa{ zN&Wv2*!wB)3xV%R{XYoo8VYivAyk*zcnde<2CJH}zit zd{65CA@JQy!T($m?N3Gj4+Hxc1wJ46p4R{46!i-Pjds6?;w#1&S z{x1i9d+Pr(;JaJ@p`!m^fd8i`^uMLRZ%_Sy75J`y|G^XbUrWLNSAg$H{r?=;pHSex z4E!;q)_=%-{_itjpQONF4E*-|`#+0-@2>xQQ~wu`h(8tmKMk=zK_UL-B>3Lce>Lzu zdH?^H;Cmef|L2ove=7R_6|m1x;LiiTr}h793jDdiZ_oSx=a7iMH}!uu@Llu&qn`g? zX^A~q{oe-s_SFBkfRB;N|K#rf{{j5JK%xI_1%7+#{}$js@5Xoexe)ysa*g64%iJ8_&VUbj=zV^zanVfyZ*lk`0o0@H}(Hb67i>^{}&i-7dd-DAMNATT3!T31*-&G3APGsHP{-kwP5SO)`M*TdmZczus6Xr zf_)CA1Ji?5fo%rc0=5-wKiD>~?O<<%y#w|x*n42_gY5wO0L%bp1gi$y3APJtH`pGq zy^RuRU?;#n0s9o}Gq6)&Ux0lH z_7zwySRL3mV7U}#;IVCTTT1^XWCJFp+X(DD2TkLSVa!7N}6U>CqHf?Wd3 zhPqIj`~=T`2Kxo@L_n zux2py_af2Xi=_dpwfo=E_)nrm!FTYpXk`BW-DRi?4%=QWs=BSR)~|inf7SpWYdOHy z{P*VkZ#D3rci}(k{O?vv?8(OeW8k;v{O>sMgI)Z8xc-vA|Km6CzllQsI|h7TQhdiO zgiQZOu}7t)+BP4K0AJ#UPj&uhrQm-J@H>#=qtCyE+5ZklYYq*9zr1}F*gsR?9|k_s z6;xUqe^lmwzXH3F0{=%|1J{kPi6l1JFst1;O_)J-HrcL_5UUXel_r)A;C|kMU$C- z*ykON>`N~H8cD?8oBIC&@Llu&qw0Sr5Hl+NUj%-8>i-4cGu*U4mFqwEpzry%#Gs|x zHXj;*-=6wk5Bv#k{HLn_1cmW;9{8Tr|GU8cg985t;LF|kPeuR#1UCAc>SX6%-vNJ$ zTfX=7|6Aa@>;K-=|8pebPeuRzAojN@wEx#6_}wiZI{FA_c+D-f&{m(o4Uq>ST-qioEfbW|BA65UKYKcAB{^tkD zzdiNe7x+)PX@4sE{{;9SNTL7v03UX@m$uJ89Y^8m^M3-`-*x`?u=NkB`tMJ{|NFrA zr2cmW_G1+IcY*K8^Zzcu4xqrl1N`&p>puhduI=v${bx|{KN$G%zs>oNLx0Gv|Mvp+ zGZgr}0Pacse-_vw6!<-X-=6ya4Dj1i|9g;#KNbD&3$cHiLi__s@V%-30l@d9{`Udj zF$(_ENwhx|{SOBAa}@ag!1uKN_oKjn68P<@|J_K$-<$g175J|C|55cnx+V5x^?wxb z+w=VY1>pB|qd!#6|A&D8;S~DcNZ`ZnZR($c@167i5x^hphEMhUpGm?0Sm49|HvOlf z|AT=&fC4`T;A7nI9g!#Z`Hw-s4x_-220qg*-+Sx-QNVZC|GjzsA3-AiRP;XrV*fma z_=l0;dsF{e!1tv74+Y;@6#QqBXn!jDKMdHB6!^n{?`i#yqQD;t{PxuUAtd7OP5mDX zeAoQ{sQRDW5__`xKMDBlss9s!-`j2eC4c|l3*dh|h5k1I_^`XZw8#2?)<4?c6X*YI z3jSvTAO5%LKNbBS3GCq%_~`)mr2dZpb{qvh5BTk=|6Jg^>;K-=|1=Wur=tG}5c?Pk z@gGNm?@j$53w%%N|0wXCL&5(P675e#|6c@lA_e{!;CovClPK^<1HV1>Kbb`Qy{Z36 z!1tv7Pi%=jS^X~setYVF3Gm&W|4=#qPX+%oDD*!S@L~5h_0OB<{|exX-S8dxAKm}r z{{DN^?pzA~%YhI7+w`A`{*MFp7z%tG;OH}EsI)!*B6t2j7TD<&_(i}ka^TzGd++>T z0(^J<-<$d`CJ}!s`kx80A59_tc_jGW)PE811KhSh`TPIUz;_-6|Ai#lpNjsE2X+<( zz5w{1*8d3<__@IE;U@l${^y0?@j&B2EP0J?>zq{m;aFlpwbf7HXq&vez`OL z*(6H0E{P&+1eTB$$4tmd!?NUju~aP0$MWU4N`@8j#gbfnR<|xm(h|Jv7ud0gFBgij zuvkp^i$GMAD;Htmtgsj?Z1{+_pSe5DwdVscSFdKc8HED&J= zm0T{8DzQwlQiNqH`FVMNQDt&mAW|qsV3}DFSQ=j-$FU^29G7E5u_?Gpj`0Qd3dIUc zDiR4r!fstsie$K4$(IU{7i0J;rKnpM=fBY+sYuS3U@6i(Twdfj7I+5Erj0=RWEDU~ zg1;Rqyg>PAhhbQp0xQE+5S%hBSA_9P`4AUD0biOgQefygP?ZHhvc~|ohXJ`i^x^Jf zYcZKb#8*H~Ql(fRmhmA{c`B$vB*%mzB{YfxgSaZu@yl_EWGJpuVqz(3is8c`CTNog zD-xl%7m0>oV%Q3v%EeF{#6wxYS7M@BVucbNj{+TtLM9T3^TYys;8CTu@QGPz$pA<1bLe6%wP5>_gL<0uhfiZX>#ggOgE z3LKM*6u6`WTt$cPI3`qW5ss>a$k`jh^;l4FP?JMM_?Qfbeb5ka#E_pWX$dEI>FRA6 z#up0hdqVR#sx2)LL!9h~B*m3j8H_7?jGPAqy>1d5HLj8XPbQN?`=M@v4wJ7?K-=2K z1fFMq1$w*!9g$0ChbW_7V|UACe8@!-s0Q41^iqe%Ex$-`)O%3S%j^y3h+?J~4L;QU z3#E7|dIC{L&6+EM7@=^eq(YG#9gri6_SZ{cs6e$s0El2%I1U}!q6mgRKi}RQD2mXL zN*sv;x~vdc9YYF2w@aYntRS(Ih6mK-RAL@X|Ho+qB=7%%qxfO;3o81|+|{nIhtkWfls_#%MFuKUh(z|Vtmi3ucP zfj!W6@e^T{2|!Sam=heMAmy)K@?aj5@SvBhM7>jqOYMz{#v1AnC{Ltd`H)--L=qVq zt|^#Zk?dKg^-d86p++U4KqM%1k{7bjyQX+XzeYo$q6I@l06!& z@G3+M31^FLa>Po-u$j`C!yuu*fHIj9AJO_AFa9;i6)Kpa36vPLp~!WD)vb%eAJi~^ z6KH!2LF3t*3yHoxqbo$vfnipW%Lnh_=ulfio7j_Tw=NMau1=6iaK5lLSMBe$r(+Z# zd$mZ%AU~qUnS|yj1@MAM3W?d?`i?P)GLgMAIR_`wT9lj|Ll0&FsB<{f%if3JU{a)z z`}x8l4@ABI4h!}H^|5z)9D>m@((<4~sUYmm-%&v9c@P~`7Md-fX;n)qv-joy+3sk6 zN7sI6RukAeEmly5rcPpMVar?­3{&b z)PL!b6E2s)xf;TA^2^lQ_zvW>Q?e|p#>Z>geUl>(A85?O}^LoEn~%h5a-j!BM}Dh7fFQ{V_uUP4oN)C!Qe>^tU4P;YYV_ptiV zT+or|v0MqHB!O5ikcbANDvF@j*c%-kt7GQmh=CF-fhhwBUCYeWp|NeALOs}+@V7Gq z%BKaSPhuVb|M4Vjq)7UYmni)@@;SJ6F_%V5otmtQ+PLw_&a_TGK3#L9`C+W^yeOKG zCKt%M)jdfI@AE{Cpj)C(q)(Vaskl(kQI;zxphrDUqnjfmV(5tlPZ|T3;ly@7AyD}I?7KCvPAJy+!A)y)a~HEhr1U+>lgW$2 zX|zFIs-#o#o*b;3?b*ucAU$h%6f3eX& ztVGYdKCE83&u;F;37z;H7TU1A_qonNof}nBADZyF;xkx$Cz~)hD?Io>KT}!%T2}7! zw+HkK)jw`iHasRP!$#xX%}*MGh4;gHVNVl7tj{ufF?+N7aEagvVLn(~7#^;U&_wE@ z3`Devb=)5tOvK{PPYKN!z^&*=$5O@l1xn1nY3%V_ZZ;23S7&Hgd+$fHxf9sWbK}(m@j+_VaiZTdS*Gc=6YD2g zClh^sd%~wQmm%mo*f?CUDF3Ctwj_04eg3uKZ1I&e-L#4o9S(zpbwG%e=8s#9)N@RzYG z{3br8l_;g5=FVEtlI%V|L=!^GYlQfI=)uBYpL=q(UdkYF=GxziQ`X~J`395n{k2!` zmMq`Mj-FLtW?g%A&Yzo^hofJ`m#WuZUA|%)5&fFAUPG+Cy3+qW(`tF_>QAP9M64Z~ zkXU#p$A9oMJ9!&k+0}=5qv!5D#VLDg_kOo&^0be1-w_FkCCd*Id%qi8zco9d|C~Pw zGk5QI{TS~s6Z$V-aa_IkJ7UK(hom3uPe?TSf2JGs+4t}#b@w&>YkPl9_%M8#gYXXA zA)4M_cdGAfB_1QX_=n@YuRo#greQJt4MdEg_l7SFL7IfYJv1*e`vjPt{^o3L93#GO zFaHE}RB9cOX!_ni?hOndqf6Nm`ptQq7-xtN?MIAfrqo1ya)Fu7AmT%#t(n}E)v*O% zawp>Pp~MTC$#}|$Ks86*lZaQpM7$XBbbXR3mp$4f0Peu-k($A3LW$2*4fAI*X8DJ)XESH2h=|$=wNchdwdMXZSH3)oPoMbZ>>Gsb%`DRo+0!Qy=ZpU2+TNVXZXl*lyyQ=4)HL0>zy`*L?2ovY ztO3ho2vhbo_T#1_ny$46EXQh_G{nc&6GQ+bF!ZzR+r$^@FEzwdu%))PuKuF`DWaD( z;3o04=B$pP`NkAt2)Ow@x0y@)h@V$KuL%sYSbb~zaXa8o52+o#b9jT`Di4-&=(&=S z(|c%ztm)6@_o$Rc(IfRL5$jH5ttfn*G3w8lfauzoZ;7Z&!+oRi5$xFJSapm6T22%e zKAim-r-7r3dk410o#L<){S&@S;Kr$w67R=8Z5y*Xr7=Dz#l}85LUk+l3ESA+5lM+F z)00j=(QrFHD79{+G9qT}cs@IGe2yu8Sv+s-dvSR_RZ*LVM_CM6Vd3SSI6-{bu*L|6 zPpTq(IxC|@#?K5Wp4ZVbeYz})K3yM0Z^DEH0;MF2C!fIUpCfxUqlT{vH&5p)vUn#Z z7@M>ccS==7;gu6*9hCS)qi`lnbJ)}M(;FuQL={6F#bV{+tQ=ORdAbxYp4P|@qT_JJ znysHKEBjT_Pgc-FugunG877$26Kf~cPqwn_rW=D~LFtO7uwgcSUKE{QmsvT(d_f{K zf-(;;pLQ}^ThC9-X~;~TX31R@(I+Q&K}lXbM|eb#R5#2l6iA#gVcp+OjEi;|ns>k;V)Kzapn0n=`C#2&?48RO3`jIIBop zFwESEW9^SkwRFM?D@56{PU!{v-{R{NXTTaplb)YcSCN%dfF;9PS%&bulCKTS!8t*+ zQjslNyEG5yOd4iZ7R2|-Db3bq@n-5Jx#s80vNQ4n#bfd$vb{1)zAsn4Z@yes9jTu} zi}F$Ko<@`XDUwwyX4)dl!>jQy%y_l9uB1d#vN*S7@pN0s>bb)F(vn%WStWd4$?6g! zOEcXt!}L;Zc72XDGd-6<2$({)h?|$4pPyD&$dC*m#7dU7zib*NKDQuj=6ZggeG5|O znj=|x!Iu1r+<7!>C!W+eGegp4jH;?MXA13Lq4-?%Qhb?u`Lf|Fiq0+3NG3@2lE|FW zPCSi2u_9iZ&0oHNyD)17mfy4r$5)pWd{a{04J1-YI>8w1;-1 z@xElHtrI^gX9!Db6ra7Ozip^}YqAMry>)Z@lLx~FRS>W1b`x)!HXfaNp~*PR9LW1K z(oz?(&9>>8Yx;=m;pM~~Y`$@d{?*E3yqXI&XZG;!%eIwI)ekeL)@?J#^HOZvqWWSr z7YfSm#0ifmt<$iXwo=(~g)}HMacl?;LVP6I7Nb&InQ}s{h*L}YBXmYfVK6ZEv|7~-(F4LdiR`=ye*6+j4 zG#x*)S(dx8^2?K(PR=o^xA!X8+psI}5I?9`s93hDeSB4THIQvKB+miF10RlO5cW4r)!Ci{oaQCFWx-M zxwQS#+H-2tH=1vC-xd^yH9)nhQs(qJ~F7!i~IpkW=#tUJ~%m$!W49 z!_zvg8ke2=p#WcPQ^qFw5bTg(Vd}T+o9s6eo6?yXY$B7Jl|2EUsGg*mteaw(Y9gl9 zPOqO~eTm5N=QDDd0=8Pn6=mn)bLa=mHH)mql24V@*qpuQLMc0E-^s>Qg)CoI7$gbb zS}uvRZdJ{B`aQigjGsEe)KnOV<3Z*qJm`mRv0#n9cAxeG zdNJ=rTneuGF5PDtavp{lKlM#Mn*`{esh&Ev5LjXdAmrG#-ZoSugg`X-&Tc; z6{y1W7gFN3G@On(WQ0mMMT&rpb@H-vv(oc3YRt1#Jn4L+WMSvBg$L@?G^K0=lQ~SW z%e;qIr5|?4D3FKZ8;yC&VLWXS^Z7ZpQ`$Hhv-Gf5$RuibZ=2_yR`F`eC9JJR4ePto zW3=#w#`!@7<7!GTTvJs@N{^{39(9WjqPad%xJawfJ4mVeOvuS!-lG?LI9LcSKsTkF~|JR8dwT4O^COD62>d zIjlWko?fV(b(H`0W=q+7^y%-*WIN5tJVMJU)K>A==2RIMmG86^1~ir#bA`E@O3vvW zK2@7PMjqS8VluJS5pgM1FXs_vci`PCKryYpyjx@Zgi z^{;o(Ue+IuYhGej78yqUj6PwZfAuB$R?DuZoX^jiW71MW}XTU;f3&lqgm z#;@ENS6Sbne^d54f1&IMr&J$N7(gWR-Z3}m7h2@zl?~(dg<3*hU5ZI^-;djB9FM(o zL~bMEXl%|lK0E!CHn{w-&l1|*;EK&Pvc2?$vPE<=?d@`+>XxZ#j`?N%xSAh$AH}_& zbHB7Oz;vXNo>W(;eFx%BY;2fg+h3>iU0$iMnd)}<+&;3ZP#ae%l~*lgRa=4^YLC?g zmj~x)Dh0DDbB^@AU6d22uZ$~wZ>Kh_Pfiy|-(lO>SGLzhAJU@0;PX z%|$E@T~n!-)i0H83M!<_%{wmSjV|AGYT?V3OJ&MgxwEEkrr(zy&e_6BlkI15Y;SN@ z1l*VC_+x0=#<}{roDJB5#&z%U;x5#fOJA+bE2_@9Yql(i!{%#K<204;@i?6ODy#9B zevbJF{q>5X9CiRvY3emc}CkKiZRpCr9Fux7|r&d2_r5ufzS#eN@<*!TtW(8cIaO zE(}>HlMqJV($Eh@Z=KwLUDmIXUD2|*{CyTVOfU&(A(_;G@?}dciX8ysx!~HY+E`Ix|!@T#k zZ&}9C=W65h*em8{b~^Tn_P(0X&~!eAUt?#?4J+aq=ju5e@hdslwcc3%#p0Jkuwv~v zdPj!36Z5*}G3Mhh?6vg9mSR|RW|3?hJ(EM5TaIPvN?CGS*Z7^rS5GPwU2BOa>N~T4 z9rWYHAa-|dk8FRg`q#WJ)vuUW$=LK>wg5}!%&bOU7O%V@fU{pF8}%-xe46nLvnRY| zAa=JBdWU#!r817%`cqn&m?^D`-~CRk;Ewfcte6Iu~wZ_pKKjX_Xbh&iPc5m^-*Ndfe zqObqe>ff$$no`+m+%ZH}HgRo2oMsYt@}!HIm;5g?t}uz8*gtcBnN$>bIP90^6kSvi zG4<5%6H@8F|6;wJN}tBK`R4uXLbik}`Qu>F4?Mkk`NoQ`6VdM}+-eqn@XkuTvYAs9({% zs=N0bmpH`P*|^B`TDC@`)m0jn`fp0;!st4HULRmpjOcx|ali<;Q6qNee%c#;@A8P| zxLrBBa+cSxu)apDHLa_?yT1Njre}etvQ{B>EFc^%c>e`+4yR55Vs@5?)`Zsgr@Xwowi|T`#4|N|I z4w(+unqa*|eU-T8|2xCVw6VWPf2w1&F)}hH;?o+%?{h9_Z{e%VuiKQz^iNs#Sl_9y zuk}|nUu0bj`>slP;KtebYx?W6*s=ziu%SG&{OugZ*@UB)zUQ5dI5R?#r@Sv+Wjf8tmCUXQE-J-@!o6MFs|*>B>3eTKa)`>nS2TK(_VUrdeuSR9wd zJ!PG13Dx#yb+DBFXuc8Gn@4=153K88S?&{?ego^`(>3At0NIVu8yAM&WC!j#!aG+* zbfBHAirCFd*V6~;({pb6+|RoqyAhIZ)0hHKiXh`i5PG<9XeNoy#HgIePm2>K|=HambZ{*JCq?rVQVZ4 z^G@nB=Nh*+`B}zmUo7JJa9Q{2zS7P;Ddqp3KR5m}dhaj=qvnY12Bv23V|3Vbiq?>s zbA-dIQ|Xp*nydTx9WS3p6VGO6sP+8Io3BLN2(8KC)%B?p74le@HTBu-yoa-+d*13~Tg)8;$jTTM`cr z-rO8oQ^BW|C(4N4m3~JsKZ|S#jd3YHEbdp+IQ?<+GLAm*a(ddL(k9kv4u9-IDW0S+ zTV(-x9QW}pT`W67J(B$bclwb@cjFs%M#=a_j&V6HILCJZaU;}+_k!hP+S}oNM#6F< zl$cYkm(^4>mEEuIurf9C@&@&CT20PPT58z+8}YmEUzQM?=ov?ne8%bH0>>xO0ese2iP%~`b4d-0=v;zIA$jjkBHnRwl(H|Ja44oQuixuuz&TR~v7 zWt>f%Wp!QZrd?`^qu14M;>2TPBbq~fs!Oh4>Jvif&A~bOwl_lNRznX+p8y>K%TB#l z$G3_=>CJ={ITeqIB`t zD!=R5Gw;Ubi$f$ybj9iE-A~Fk)xr0S9kB7lb?0nl7Oc2WovDjiZ|-0wEcY_%EqJ1g z%{bj88+~$_R%eb+%1pbTHD=?14}xLF0Bd)e<2vGFgSn5uAT)_;^Xluy)o@h7T4lX< z(9)IB7tXQ@ZrAV%XrIMJ*J~^4mdDj-1wJ{8Fi}=nFsHskvAzTgJ4;_aIxo44`HXDL z3L$I7`H8Pt2cKFid0oc0$XAG1QD)gk!-s29D=UWtt=N>><>U!1o>;YzE*+Dxn&HR# zX4V+d!oan+A~a*yvkp%xpxwaM-dbW_Vvbt9?A$$lhsw+42{|muI>r@NJyGQocEGZh zcr9bh6<#uJenz=%MfMx@dewodV6DR1yXIWZ>rI<~Dr3r)RwbrSs^Kk)+qzo*R%hi~ zopY<-@+%FCd6l+wWx-1G^-t@z`{v{0>7Q}l)^A^^dOIWP?dsC87*RdAarlWzme;Dv zWcfoQH?Y32{SXKeQuXJ-^jQ1m=Eo7_>&`kpBQAcPPE>J>W&6k2Sc@=&ttTXJq^`e zeT{*}3s3m^y+RA~Gv*HSdB$*Ed)K#-Fb2`I22PbRoI?vuSX-5=)|T#iZnxE#ICNL# zUZ$bicdd_sW4!Qqb+~UgL$xKm%ab(ezD8rt0nRT5*`^NFEX=RKZz5|i_ z;Z`m-;FI(QfAy)OTlwcr7d4l3mkpE_)T;Bn(lYQsfO6A z>PAKr^LjKfKVp<|bPhLt{yL>u%`ML+TGq?o_(c8bf-iE$)2%<$EcYoW|Ma(rt2wlb zK8gJ!witcl^F)3MLH-O1XSc#@#|j~Y8aP8Pa}HLdYI?eej2MdP2e80UuZ#41)T_NT=y)C3+a1WISzn##B(QGs}5@3VF5^@z&Xm5te37|E9ZR z7Y27L8mH&@bZ7VAK9#Lz5#j!$MivKh{Ns90qs#9X;(d9xamP#Eia(mj9lu*$dL-4j zt$Y@J)?3dmOg}0i(jvwO&ge1NFl1Lh5w}O5>Z=nnB8o+GLx#)<=Z2)qh;e#(bxB=i zT~21&B3vLXwr1{|<;Pq5>|*5#)=T_K{q5ZHxjC~>7A?z|8}?4)OPlv_(Djhvv>4`a zb}ToKF%l=fG<;=3mn=?NPZ2lqA56qqnEEN}Ro3tDS-0^gpQyY zd`!Nze)S!!9SN~!rj95yNK9S1!|=ELS(>m8kmHU-SeeAb+~M!F%?_STK^8QL8NEyweBMh_~(zpEQgAB9j2KU2y>4p zHu3R8@^4KQSlD>|CQI)6#T%wIr+emlV3k*s%Em z?I4Tz0K1rd2^Veot!_cx<^7+~nyDLqM%Lyrtt7V#EoqY3e+1K#P z2ExYp>GR<2@#S*ujpFBdH)@*qn8bh7-?>a^fB*3=yj{ z6CL$h-VFQ%;}hna#Alk%b%fr3OJEgubM_W|tNJa?HXRYPq!Zp*{g|e4>Zlj`U(E0! zGK11;o^OZ`xRDbd5Wwquk~kGIAU!j5VuM9-M)S4qtijaDzn8kV<~!^6#L?Li$Ho%t ziQ}dxtlfxDtp4?MYXCv$HQkv#*iUhv&VB}u^6$?eo@WkVKR$CZCrfXsJFiRHLxd=9 zn8#J0iNJP77}L^6+lcA@8+1&67Q>&pu|C4^g^qY3dldennyq=S{(b8XxY9a@%jTs_ z;?Z_iCRB&e6mZ>9o^w;S`|Eh~BrT(%fn(akP0dcjv+xP(gKuQr%uSmtmv$&`@WCZx z>cpndu#lSO1vh0KYJRMnzYDv$rb1+?8^S2Zw7V*D!|yg^UZg3`)3AzAmZ10yUERDO zmQ}!uV>QqP9|teUJH+4>@iRjAytHp}MG?P_m{ieRKFKGJaat%^z*v-BeVb$6WuDZK zi&Y9TLTc8q-V>(hhLxSB$!}B_3ahO-#m$vNEEmJ1yLf_q1>xTpU}MYk&d~E&MKiVh zvBc@76wa=l%?k<-V4*YWFl}kJvDy~OlI*t4{I~;8u&yDXS+O=myh|@sjjpp=Xvwx4 z=3P5s_K{3e8gJ%cMU%9-yKVT-$M};fuQO!L3v%(kva773{Dit|{F92CIXf!`Fsf4G z3yX;xw3%9tx!R^GZeGCP%?sOtRd%R`+mHAeQ?M|?Qoh@Eqpl$_g)_6UY#L`bZ=l7uD53Fg&cc$6(m{d6B8F_2egWFEE#nu_MiAiX223@TGaP^=y7gTH5Yq{$?4!bHR zR_x`tTAx;?yZJ#RE7SZ7*ayP0ha=;x@1Hi{4bf#jw@%R_&_57#p!Ye3c1Zb*?(}1Z_L}{o30*>OZiq z3W9hHV*ET` zTAhv3y+;4H^Z&jGJnH>pjAf76o$5ea_F6~Uzz(r>eoyLl!{FcAHAtfs_J}EwFbXwx*ELOPlcH6)0(&jHIytHBC z;a-3?cWPtfquu=n-63X6$m#j-|b#;2tuj*5iG1bB=JADNsoc>-@#bkwlO;Sn(- zC&EWM;8xpFEst1Om?AA?w z0dIb(jq2Z}&)C6@)iai^-Zt#J<#)HNLx1kF&GOWRs@sIXe-U@t+QcQl4t@1aT1U&? zkXPD#kL$)qd^_!byr1^+*u%N5gtnjm&-bt0l-H~6_qc9Vh-D*6X5xIQw9NH>dDmUq zeC``D?$Z%bl_6u+`2O0wZOWi1^tV7Ll#*Q4Y`&zB|F7V{dF1y$g73)9M~NMJe`!=g zM4>cEJbZF~34g+bcwuyEmLh-DD71}CiFbr=2sTl|7mADE(>>G1W+Wy|#m3{(q5qG) zuK=iOS=-*5mJ$?@X4BmbqI7pkNq48DAR$Ofs3@W|QX(Nrh=L-hAOeDtCP<^C67tX5 zh$5cjfphNt@BiQLTl%oqvu5UfXWof5v*KOKOv_}}|5dszvHH?_MpCLOQd@kl zzyCPBvWAqpy5U~cevhyJ57TpNNPu^^6s6P^teTR#l8&ynl&+G# z96~``Lr)XIB5x?GB(0$+&&RK$DXXf>$}OWVp)Dt)q^TsQuB!tvemP+&UTJgnl7Je%p`w z_6zxG-wNC9@A+?O(!Tv(0>9}1mjN;Wt^iyG$OOm&$Ogy($OXs)$Ok9@xCT%N@OQue zeH)~$0jLG21E>eM1JD3)7vLU1BR~_teSil5%>WMpS^)m6ywLZ*|11nT-n%WlZ`=Oh zwtXnxYrx+CyafPv3t;a7MgT?uJ^+jXj05~TzyHmL!%@d&rm0gwHU(I6TI}h zZIIkHNFZ2@ZEZw&#Kdd`czDDF1^F$-cr7eM#6&DbElgQ~M+)#}`L>kXE~NcPY0YOX z#%n9gCuSvLD`U;@Cu7T{{;~2JiI(Sc-S)F?G@nof>Rf~Xe|c$NCDmhkWPTOUA#EGU2SZ| zkuO_I&;fq~&^z>8z?BBwwq)SFWiMMBPfj^kD>uk{kr=`fI4bc3C6WjB5JS-YNdu!p z9R7o)^AYg+xEn|$rCiL9u>O z3)~ZVI|5$>9LV;DG`<{EL`S>Lke`)7R#CJ7ep)yXDi+qB4nT#Jx}4nh@;TW<;e0z4 zDN5;S>Z*ZtKL_N>#ohwA<3U!ol#DD=pNqYPkGr?a&*~6#DxN;>pna%Wc!IJa3#6m+ zLmO1zYRD)%)2Uim*?@*9<80vodccs@J_ys|Iev_G>N0YqX?&nh@dDZ z?@_Izs&4+kS&0OnjG2mroPf0hr?Z2Dmzjj1G_urY$Xb=)6H=BClszf|WyZ-FnPO+* z)j-wQ`vd0^90*O|aR9Qi5wh)pc83i4IRRv4H7hA=@LCAems}lyBLOJQX5*7pv$6m| z{6A+NL8svbd=zj1pAf*w15_K17b%(HNgmC?PdmoS^YK+c zP}kQ5!w>LEV-GqPXb`})mIXqM3nT&q%{Loac_X9z(rR^~0YlE!72$OPjK)w3HAAR( z$bkU99kHQo>4G{2`OWq-#yg$_i7?@?i@TmzrhCuFZWb8eW{>!%4 zxXfnYPsu>BG&Kz5R8>I|DRo&T8M$v`=cXNGAdgMX-wp9?$W;WR0%%e?TNMN~DJXvk z=&B=fn9xB+;rl5e9=6V=ca?wc{|@94ay+u#7u276z|*ydyl`;p0#{d7e_Jz92wbo1 z(f8gr&A{!Bjh`4o%357Oh~2|g%?@}y@)xw#<+kxX#_gpi;-snOVyD6`&nKg`-Cv&= z!X9``z{5Vqsp;w927J@`iy?S{J3`P2#s2Kv&bM`LSKD+G#;GJLhWN+xBs^?w8*rkx z0e;MY>%o7#Y=a!|acbMRJNtu5`IpF(0auoF6G4Z+ji!NzMus_K&BJf0}p#Ron0K zt`F{ey0~+yfjK2ufdM}--M z5AXJyoG93N6%3`}konnP3;PF0{?q<{ezM>H1MBa-HldyC_r0dKlF-u;w~&z11@mDg zRdII-0|RAcO>H$KwGynUL_h}v&^c94^_CIX^6xaZOTN)c%dVlwuhX%fv z3g3+Jd;J2t(T~&%>4vu7>D>xT2Ks9OpzY7}L#5`0$?QtM3n;t&9?G8tbdzqX|E+!= znBZ>o!;b;o7JJZt7UMf9$UH@9O*GFf&kglRcC_W|#Ko zMUH)cJ^mpFo^OA?HS6F0oY`ghdH+rJj|Tb?yXb#BFxg$TKXYJv$356T3h3WW|KB|K z{I&g|XCR#Sp#StP_4C5`c2j61|J=7tKOCk3z6Edd+w;Zm0*~0MPT-LIA=5A^@TQVgTX*hXEu2jsP45kOYtdkOq(ekOhzf zkOxozPy|o{PzF!|Pz6u}PzTTe&;-x|&<4-}&;`%~&<8L8I0j${U<6=2UwkVlT> z;NAak@#&Eq85wzu>8JEKFxH>Kaln@oA^BSyDvWCf7y5}yf-wXc-&>w>B)l7r0vAVe z==+O90?#j@z>gxiBH#pq&o5EKB$1pPaHxDJa49601^Z#haA_om)^D5PGT+nBAj4&M zr00-?^h*Gk3qks{km1nxXY-I;`#T>590z8IIdH{luw(i*86hl$Xu= zut9Q`?;LWku=%~I&HQ>GIdq+%TNo;@&yMuINDdy>`zG(ij&Q#n;lW5=jI(8r5G0od z>6vAr@?hX1?GHG#;lK|4#8Kd6NDkRI7{sTBkt6vJ`%)n}RA1xBaB3v~QC=D(|509a zd`RDxO+alTxmBVC3snE8Fia%hnt!6g=#gCh+xthTFm5D=o;!s$6u8Rw_=$2*{i%NE z1xS7j$tgkHyGU;MoxcMd73PoRTlI+o&p`46ApU-N$Uf~z4(Wn6Nf^q0DDPYOMS-It zIh0><5ML68jpR5}lSfbFJcm=m1PP${ki9qSUvvkT{)wZ)LXjLgXM-dl&A|gu`mGHG zj>7|SNS})WR9*rkmj^r&$q#-H??!SWB!}K(ngkpNMuOy9c>dv=lE7g9>TmC9~EYgTqrZPaa_B+W6N*rKTtRX=z&HEP>i2LNC8&Pak^KEPd8jZl z$)EF2zJpWj;FLdcY8V}o|7hRzNPhC0erg!Qj&Q~u;XFtV&2Ki_1MdzlfaF`_FK9nI zxCoMO*@GG;isW16M}-+8IS`NBKz;4traQPVlK*IL!kXLb2L;}NSyavROWq9UL3Uq31a_!*PD%C~y)ahx%WXDpbECW{|wC@dg$4 z&<5ft0MLd4e~si&ZXSX7DDXGm`3EF_`<&3e?z&kXNE+1MPq`!c z;L95FVE9v=q=|A~X~0m--e3pD{Ml7DM{pv-7U4#|Ty92h#1 zZ!+k+>ljE5^>4^NI55ng!ck#ZKXGcD95$=;MtfaF{469-0!x}l94MvUZJ z^1=ADBm5AOZ|OsUlOj1}pA;Qvyd^{OEqhDC$dO#IMg}=vp};AS9BLm|bfNf^NNyIw ziVVkrQ6c$O{;6TqNDf`A-z+c94lWFXZ0+zpoC-O=`oSfT;gCEiJqmmu0Tllz0}R%w z54C3)k{jc1$)`ig|Ir`lkv!^KdK?(VPxCi$cu!ksBy_HYMu)$*>857gV+|po$cqB+ zF0nB})wrik&Q;HAPYHHJW;?BTdYK3n8x>jv{f!OWcoY&85JcWf{2R$(|1>>#*bMp< z5rRe5#uxg)8uXkE_#Bco^zlq-2XF9TEbDKxB?H!<>M&h!r33m4&Fc5I9RMxR4GfkZ z09#}HUrBflOnver)Ow*dss^(Ft=$>u_J((3U(@*jMB_6!V+7o$JzH*RANnP~5F^Cpa%5IS&{Ip$!H81t||Y zZBSB0+(LyRkn`>V6zB*PP9+Sbg~t7E8)zJb^FW*d0Ll||9~I)mRB+@vQWD%pg?LYA zWHeLfARG?{N2Z6`AtVt6j)LT17rB9TGm>wO+hARd37{C8f`hPlpJEaUckyhEuX4kQz7U^rA z-F?nCWBw<`-|L`*Y>mHr&F>$@-x~X&-#-ffcOU!zS^wXg_55nlt?_$H-oI-6*7^3_ z;-8M+PdCqF+sAK$;6ER~nV*(2K-Yn`#&5mn;s5sWn;V=@{$Cou(?Nc=YVbcjej~lW zq7EWYU9`x*&>3wXvQnWvI11FM^T3`I&O=x<3<3T@+tx31-46jE2>=KGklVMPP4eUK ze`t94kpZv=jTN84rN8Y61^l02yR2{fG~o9rKnMWP2M0ifRBu2wmco&T*?za+PD>&{ zF5z3xC;cmjX(0D+Y}nYi|NQ@N^a9~X!~Fd}K*E1eJ^`utqt5xOr4z~7AADlp77*w_G+ffRj`d?z7?{)yaV7rR%$A7=``}PUa zg8bVBzxp)42KJ8_^?q0Jd$Hd`|5E;D{er(B2{6=l`5DM9Cnu+=scC*5ity|98~MB% z-5~z^u`j?fn+dnq0ywfM|GSpyY4ByUo!f8ZgWPV9U0O5!J@a4(1Z|fO_CY~@EyZu- z10g`g=6_I@?ZW?1K2QM+wLME<|M&8D$lOkU&HrW*{;l$XiocXkfUqHE4FRJxjo8iY z8Q!tKng1Qqex<+KXZz_4go5_}{S*VvFW~>CqVMv5?Zw-*{H6Tukw->GK79D_y&Y~^ zV~70gJ4@S>>`6XoexMNovEMf!>brb<|4i^dG&VagH-Gd0xzzJ}k`JVT%x_n*L;m)h zPfbmcl9HjIY+dx)ZuhNypnZFi&3#Y`(9SotY?tpGnDssKZiE9Re<=UEkj))nA7Jyw z=U=X5=4~F?rSM(K|E><$9PIC2_}`GfC*gaQ4_eD#Rw$6UeFOI2)BoSMmhF=NP5VDL z)*WvkbGd`>%k4!mNDp3MKFJFu+)KKxxO-N(mGIl|Kh6KZ{f4tCrHtxP6Gfkfo>klK z5dUwdJ&!OGh+(vUThCuT{|7y*hz)=PfD3>JfDf=AfB=9H-~hm%J^x1r!pH$A04M>d z0H^_I01yDQ0Dt!U9}5U$1z-dCZ+rd^dOpt_l*G5+Qr#|(0h<7LX_=i-dWMnhrA1b5y3cl#f0fwl{e)bH~UoSs#z zmwC_bI9L&W$`R8%a8*7BykYCQ$OegbxpL@vI4Y6cNzNS`9m3@)s>`Dy8f(@KYqE32ZOg09nTTZX*M__mr8(kEZ#ujj|k1#S$&n zI9&anq`_>eiUNP)ycGS7E8Jh*Pg=`Pn!Pf`iuZ-f$+#M=XD$qb&c3mMx?>oy|LmQG z3PRq3UXBBX0W;v^!Hb&<`uo4#|9^C^|6cf#V=we<3E34IV=+sCRu&({s^~&h=4zWmot6`4h|@A@R77bG z>d}T@K4g?(5FM2f_{qM7>|ELLMe@Q8HTy3ovYz?qcLzTcSGe+_KL3nc0jc3b*&3q6 zaUEgrV0GGlet((Kg&d2xtMZ<6{OS9F5q|A6Cqk5(p^4A}=rafq1I%Z+y__AaZM?WQ zyAP7^LZ?t-})2gqY*@?v5Xr;^p4{6=`q!=bgmuwf| z^0{j)`28((Iy|0yx$iH;$%%#%CyDJ(W6r?Q&ow!H#h-RL8&m(n2r5niZdY4cv%JRv zAxEhg-?@*6swc%b-}F7|M9Jr8etA}@(SFeG8kPiuddV}UnvrVLDn!)u*d3g4CA;_d zCv?REO@dFb8P`)DKqESRW4?A#(C22m)_RflV-6P1lPkoFFU`8HT`wez*Z;`GB%FV- zO(~>Ww=?K%a^L!0bX^)$%gVd`L10Dkt34gDjK!fBJhZ^gVjA!&3S`esL%Ms~0MAg~ zNS`#{%?ZXOIGC1z1pl+QlGG>AX<2SraV>mA!b96$>YBPR7Ap<|+8b08yX0e^3HzAN z-fgMMQ_DV3-s*W>VwpOgX0rW4@-_6yh)yDAtvEt^SL`hIm{)Tx#o}?7?P|@t>@#np zMhTCPG_RmD%x697$@XBmZLi=l9qgqM{Z5c&l&(7zpFOWU=8I;3j6mGoO6*p;1cL`l z67FIjWeugu+hd&K=B}UG@Jp{CqNK*%(9B%Fh}Ct>y`wjRCzap$RKaH!xkkK{d4gLZ zk}Qp-9{CG|!V_m{JX08z-fC4v>aXF7cIS!aE%&g7Hec3p*Cukee0dI2@M4&vZIqwo z({QS+spiH6rIMb@$F8_A)~~2b&n7H9U_Cohg2=jcLb1-1TOI$Mt@>&GdmqMXDD%v) z_&#HGL63v~+UOeng9TVY2aW^tU+4)fsL}0gZc`VA60&)ST4sg&PS^+3c@W4-(yLe0 z@%BAXYa2T(iJ73BPt>Jv@L_zpN>@@iy$#h}A@J*m$rmXou^&_(JtE6xV@uNBa8TVB zUGf;mLvei4RZy8l>(ZIapOht)%QDC2=O!=6Nt7|N5L|NbW+aurCaN;7H5oAD&n7PY z=(&zwxa2@XGGq7cR7~y*Q~OVI*Bpv#NiwLA*8ISI^qtxCvK+?I;wfFr6{cu3*GbKm zZ2epIi+0(Ib+@^d%K4o&+^`pl4j9o=)jp^u?g-(}lluDjh4Rs^C z9@X?o#cJFcXK89PU|> z-dJRNlC-*ra%t+pB0g6@aT(=#9NQ%!it#JQg_7NEZBZVK`8XAit9-t=D(I-p^n$gS zD2~SciU{MizVchsEu8d1c{S%?#<8<=L+*^D3lYZI&BY{%Ayvul6i!UqLym-)pNZks~Py9e7RmS|mM!ni3L^o>{ktdFQ-^sRf26 zBg%XBhvE`rvP{6xr4IDnx(933^ay=Rohfn|_k_1fGhA6r^7K=8rCYj`nTGo{1>&Pr zYV$1bnry5;SeOZ+Jr6Cder;OREWW`e;H`yw;9CvQ!?@ed4?oTfQzqk{gSQF4UM;Fe zbv$XquCjkt=4OBUM^BTHVh&ODla`8c7(!*R%!Hx-qTsmqi%UvfuvSrTL!&3hT~rH| zQKT~A0<{!o!s%->QS-IZ1rZ+oLQ(vaXGCRkS^JZPn4>ChwbT$kB{+1O)uTt~y}Pf} z=c%aKjkSW=TGZp`umXhFU^GvArM)rdMY(%(AFe44Bw@^y8tGfXFHBh<=L^Enopf|f z&p%qm>tZVt;(Ouiw4)qOaQ>65qQ*m%s&36ueNqJZS8V)Z1$YJ#%JGqQ zOg!lP{4V_Ml>+Pj<|u9cYi0VpG`)v8zV@&8^G)_=c%rH{p63D-o(LMh>Jh5wrL4drC(zmKjV%0_OR;{oIcNe8y4@L zl46|surb3+AA>SWa>w3FOtZ87eSAzTy@wW|V2}D&tsdNH-D4Bt4so{>GG~uAVN256 z+84^!=c=+?)Rr};r(oa`t7t-xRz@*;UWv0%MeJnMrWuufUPi)M+Bx9kiPgy_Q??kN z1Sccbr|^*8G!MFJ?Zguf?_#*fhUhQ3Mc3wgDP)7GU4W`nQ>TjO>ES9t*QMxz{Qa^L z2u@6o>jW2!8#IEhe`dxce0BF8;vS1t3A&HtGeTlCDxcg;#G|pXmr|mnh?9s_`%}8> ziaHGsaqrgnA6ojXq0df0%t`-Z>LIGf)c)Ie#z!1S`mnxaHrBISR*)-~p(_;J7Q6gq z^kqmr_v!>SO?QG4_e}nwSd2x}Gg1__SIU&moIf{w*RqAFw6_3~D_J7fDUfG4Z{QB}c- zq3(R*<@fUs`szGL-eBaWEu*n|<0!+(=ajQ(-+!hyT0(hlc}A3y&B&w5^ArZrO7I~ntp*@yp!rt% zl8%ivH#~Jkn*71Ow;BW+liJDe;4w5QmhlNI*PX}^fniSQqZc9s#!75x81i9ljaY8Q zgjx0_Ig%0zqzf^z4Y@oTgQ-Qrv$0`k4}=m>QSMX1Fz|U2Iq~dzD!aP`7a0LznpRJS z%4IY*HT8X~`o30OIk(S7M>pjX4JSvOcD0i&7QJVBCx%c6?>4rd3QpR6bT$jZDh#V< z@CKt!<)?%gYb~E*DdjKYHdzxiu!VnAoqYeg#LXMaAe3CC&^1$qJ>dGemF($@+Q(Sz z4dfo8T&o~JtGZoew2zcfD@!nquZ7v1Paj3M^qPIvlyWgD%H6MXS7qsR_(F>H7W#V2 zM5)&=S-*R+w(=w-Pl2)DR;(&S0~4cd4EDmoV}v!<0W;?i>Mf~etcp|X5r?MS<(&vH zx`Rsgvq_6p^q>KgTsEvcd20L<$7vK7hbeLS^v5=Gb(9MlqI8<_Q=!jQP$tbglvm~P2i`OZ z(2ENl_=5FNFud)UtgAViEy?YC3ZpaU?D6X`-BIojdYtq1zHhla%prtH!XDU=RP|)4 zJ63b_Dsk6_-rJ|>^oXhotPkFT&!2Rg*Ymy_iSX@uHa8__90s%e*hECn<)5hkzUKHC z>oTDLBi6M0tKce`ZtwaxUoMXXoU#h(;-?LIR^@rRe^?-pc)onJb||Ke1*h_vpvgdo z`K_+!$KLO|-B&~GSD3=2Jn#|v-?S6{V&DUSxo6QyNY7->;{$)~7sXt&M#%I#SKLWl$={$B-ZIoFs<>CxHA1D|I{wO<&s)`^p}bJI<+PB#4+X^> zO(B_235V*t!+g#yF?hn22YGV1uuAt?PKp_(=8j$n7^X0?ct1=|fnqh5-bh5TLT)L8 z?)r@1TN=$MrKlTDH?n+%P1q-9zXbjX0u#a|N_7kI)S0V6{cy`55&qLLtA4SW7Qw?p zmUgTmrLQQ?J##Wy(xxz5x>>tF`qUdn7)O)6F@7qO-Mmx}k73H&@Flu3j8px`Td|UG z9|T#F+ICe%byX>aP#c7uCb)g#l17>_c}@qMqQY1j zX}w7ym&D0v{@8IXVCs!{2Gg)l?i(4V$ON?~!YsO$4~cTGc%E;lWstwf$kNT`9b?I@ zfwJ#L-odiu#4Ct}k~d+m=LXbVUy~QxA5*GP#&>RPq2W7V;C_BV(xHCX-_Sv$hKbkD z#1clQd2kR{G*j4Iz9#8by+KYW8WyH%+M|z@GzXuvwMC+E*ZCLEQ3Z;WIbC$Aq_?h6 z>d@<*3P?P^@Y!0qSXId_eZrETgA2Q9yuJ^0bj2zWrou^`)d-yJTqj_0QlWkz=f8CI=<$+3(|vC zjLr=gKBnFbjw(4dnTTJBDdlRDRl~#gN(J|Y=>vIZjPpqx6#~&R9Z@UdmP;Bdh=`F0 zsWA-fJAo&OKIh*}9A3ZYQF^cYwS;%mGc8dYnho^_c?n5mtdE6*_}=zTsjhmuGC9v% z1vj?gIv>TwWA^fTsXxF^#~#y2jN|!AZMqe24YRE|C_48EZO54K2*>c}NWv$0cgDKx zt&@dDT#|hbsk$e)4~#zHtH;s1+vNIptB=fB$ttXmozWj6-!JlbK&iF6UC*DN=Faj!;V^sI zQ&0JGe&{*0lcQ~YuS5%Q;D z^GICrM)ZL@m4kP>7ks+(*@94W3bUQLi^^|Xx~yNf8Iew4>$%HnK6T%a_N8AER(^VQ z2_iP~D}lE0iDQS|5^606@mUYFe3<2##ONeMcySxs9JzjwW=J3BY@BZC%z?sMxHrD; zEX73CU}xI3)UT)uB%vun_K5@{c?~0s=BjJY=kQLv8Ihl2yke1GJ)3vtkcid-8E4F7 z>!68(g1FRkE*eh~N~a{jD<1ThYx{02WW4>75tgwmKrPmJsmw#k`{v;!A%(7&?;4hD za@Y3>*-oudIJYJEq&v6KJbvihuvTqlMLkKO*Vj}|a%GnMVoJEzd8RXjdA8OJ`^-Pf z;cFi0IGPjxi9^^u+`fW0CH|swTd;H6sEUBN&}jL|7+Z@zhcW+rLN2-+yl_AHr13s^ zM=?YD8h_`NtKIx_bT4p6RLYR4tgV)u+ej}`vOVNpNa!z64#zw5uJu+5kC3Ix!__Vp z9+H|_vYHRKT@OUXK6sRiH_owKgf~93Vr2i~3SsX}-QZNejdtq+Z1$+n_8|4<@3Ge$c1{mIFj}4@E zhK0WiUjJ%R8KRcsr)_zt{7+~3o}DK44@?sL z+>_+A4m**0CWz;~#1)`@Lh$H<(xI-1n$$uA!gi`a?a8A4YYQ%t;{45z92J?3!*4gx zuUkc3_d1Q=c$jJKi$cWPPD3$zJLSmc=Q_QJkrUur+mi$EBA4e=LrZ^nk!|l*5cyv# zfaW3mUv34?UG)gy?Rx8K_W$HAA^N{o09``xzuXGD>=Hk2@cd8i5(58)jlm(?j27~4 z)&gEL{%OXbX5j_CHuBSqVe`CaY3o%cG<6PN)X;oui#g)ikct<4L(HLFlFJwZ&Z=0m2rN+F4pm$u?YAm?>gd>BZSC zA7fWk-p)%ZEw$?EwRSq}=ybWF)Ur!I)%lQ4_3F9uzIkKl@uOd_kMDgd^25CUle?PG ze_>Z^Lp5{B0{4AQ!Q19^e>4?A-Z9ynmh&Q;LEEvRgme+21~Z3O@bVX2q!hS0wrmK$ zo7y4r>EpvX?o8L#NF8Y{xa=d$A`^P}P$ix&#k`!p|f%ul)& zbKJ9!stmGlOP%PTv||yj<@f@qLa&D{}}R8cbz9^u^@9%8y99}8#0|-J40)v7*|`O%lWptesJJ? z`2}&m@M$kasq!L~;&uws&p4{ZbY+}YZc-0RRLTt=I*)PZ5!AkzIeB5d=3;}0r*m&32} zj3#@Z>B8cdefL~Jt2HQM->1Vgm41&Z5_OpFeW(%C6480BgJCOw`m4V|Jyl6H>O+A> z`cuLr^u@K)!YMCPpC-BZRG=s&^rzd#=jVGVe$8l$YRgFy_f$rq3HN_HNPd(_iOF8Sg0=}%K9hmrW>Ge@)$w{IO){R(GHepaUt z9Y?54tsQ-*_x1ILzW$kmwo7@`H>2be?o$OE#t`gIGmYj&bwQj*8%zJUC3*IDs}Z?RrDDO>Ipi zUqDf3&g~)28G-bu$F09-=s35DLjx- zO0J3a#5ja`G%j=Wz*GQXhcx-&!*4#KV~N(KczMOGzmI1c?Mto{k=4Qu1lJkDED>;j zhDA{oE9s^&+Z-~1JWjt86JO`PbRWGN{B>bg;tUA*8GGCG9H&lq<7SCb zwK`kEX*hIq?d9O7#vq@$Np9}doGdPlzU#&+s672|qN&o^Sy$5tQK zKEpmO!q~&%Tv#w{D!F2cye0y zhf6Qf=6oj{3kBVqSROW8-Zd(DI#bT6|3#v=Hz?F+T9deEY;eeZQ1mh{E1N-oVz<;& z>QXr$=abpb)z&Xt%37ShkztuSDkA@UF?$e?)#J|V%Km9Ig~->Jt{#1CXs7NTHIUCH zE9|ZEC420W5<_Kgs6M7f6&v@_5he0S0goh&8&Nkd5Tr&h$a=(ij3psjPJZ@RhJ8Mq zD2DA6a{@bv$#P7i?(MpH6%|3AAC-Sy1?eMQtGkz~81)jE>ON&%nW{WoDCydLeXvkw zxbfPdJ}rsX$iW_yR|^x_Lj;nt?YiT0BzH{X-akI5ZO|Mj3UX%z*mTljXnH24NP7ZN41=T#NIjO(=5x?tL;a#33@u zPan(MD#z1-)?O4QbsIdN!wyk-cU*Gw3x;K{20w_^W5mZ?XxOhLFbk7|8 z9u51E!-vcsGThbj8s;w*eW4b1IsXXu5RbgbW9ig~TA@J{fg;yl(!LO3D*6oFjQWLDfWw2G_Z{`ge3V6aNnyYJvr zL$c;vdW2!7sFjpl$?<7_@!UD)1Se6p?l;FZUx(%2;q16*9x{CHZAWYS)e-qRb-{?q zu=^dl?pX&dEL+eBkD@fzTo2DajHgLy<3aS$)iz~p9Q{_RrS9M>Cnf|KtWM^)gvfX& zs`&8e+__eqOySnsUS}M!+L7x1Dl*43F`EPDz%@}}g)?T1rg`&#v03DYVa=8h>NZ_i|LX{?i3ee!~PV{K{i z$=$?frVBh9WbKA8DwV_?$T7LjXs3#$(Oqt)RknXkKM_cpBA^@{aP%HE=Bplj4r(w~ zt=^M+rMDv7RnGjyIc>$c5sr__{qe(cG9| zqWfSgk=%kiP_#{>UOPaA)ANd@Uqzp2%*iFOo0&{WsX8V9;w_<5ZX7XUA3lnISXHF@ z@+Ee%*0WlA$!4I<^mCgRRp)ybEg=K1cLva<~$8=s;+3>lgc zAL>)9(@IF_T(IjKG-dC}Xtxb+Ao1xv>LlJdW>>7=d$H@*oTGm0)PAbE>$a`)Yla!; z;>A~ zlgDIgdUT#iyr}u`q{#hJN$)|GB#IL)q}UEumxd@z<0xOpd4-7pQ2 zQz=eC6KA_r-PhkZm9W|)(DwAYL4}ZkDc*;G8OJWyw%N9}GfpG#?^`!qZGTZVTi*U+ zT%xzq;Z$E^Hd8Tt@WOZ|Yld)MQG}JUwTH=qqjXi$$l&@t(HMuv`(6j2MISmyP{4pj zX>mR~lo@N4CSG`R5}UiPUSR3ZpUogGE_J5 z*i))r)4e(QsfC^P!iTHEgU`+8rCGF&-J`;-=eai}H1I6v?8>kry(JO4$ZeHTf;w@X z7aqogq{}B(ij>+e1r1HCFS}wHEjkvuvRSkYU?-f#E?-fjSPpq=dZ&xwT*fIf8WG>o zmKCLGU7Jx!LOj1Z%3jS6N_wNSR6SzZEa&F=CeNKsC`~xx;Z1PR9bthr+(*eYC6p0m zbLK>afL?7$g-OYPvYR$$#x-djZdI95xqDsKaIE{dJdbr=(_i9iB8v@L`iw1@%@Z0| z(ja#&qT=l5&$L<66aHtZIG>jlb{F#dTkJ2dU|l%ndb-zXUit3Lk{74^2tS=}2{t~5 z&RzU?n6yb&Tgfh6FChK+{+2X03c)rsZ|;?hPwux8`P21l?+8y3OeY;6N9cs-yuM^} z75jRlNK`(yM7;>5 z{In8SkHx!+A|g?b@jhBumYF$$ z!vR>+z7eSd7Hv&KQr#5F6!9}J=SSuX?w(v(8=swZuYLJs;Z?7$k2v|wgDqK!2S~z6 z58w;Z>uOYv(PRHlwCG(M@yZ1LU>p*MWCR!lhjuOcE8q zB=N5XUOwn5K%2oNH1K{sYCemwziX&OR2r*Q@GSm*Xw|;a1vt@}gqzCQ@}1X*vL(%& z0xutVgwM*Vp2D$+f!Ruvl#Smpz50}Pai#rwVLa!-;O2qI@%jq2@SC8?FWFi&+|6d; zi9bH-a`8pI4UShwzS;r@<2Ofdn^9I?Ez{R))IRP^-uqbUjJXe2gqxFzQAQFS`b^#ue!XJY3HgJW1NT;8fRhaB_Gl-QiNl3HHuwgvl0DBuwVj z1{x}*^gaQ*>ldGz9{m` zMQzFsK4pSPGCE&X&C5vyT2mNgOAcYCv$6fte)G~icu(9$WVu@cVGcUPVaq{`X2kVm zHN0B5&%9fs^XKL&-z53aMuL-B0{2c$MxoWU=CM9Qs7VmLbPaPSeM_n{mBbLF zPOdvLgYZPb@Wx(q2{wMN!An=Cf`%SFDz$+{IK%z||7dB@BW(PP8@9&!G+Bfj$KLhS z9%y0r4k8-X^27KA(la zwvwf1RJ;WHG#nm2Uv}8*#>h3*RZQtq zIOI#!^=)!rS7q3~($uyy)oMM}lew)TGAF(7kO+}N!Zh7m%qtc61fP{+OnUA(jDpGX zm89HzJ=a28I?fWG%nW;5me- zcM-S~R)s#BFwOm{;p^g)TV)|vGwa4IR$g4JxNb*(;;qPn`+)~6zF3iU`eQlK0sOLd zT!Yo`5Xyt99tB>lGBfwydJK+#R$vl4KE5HNRNn>j$dz~=JW5f&;!v}q z&lV-k1NC(;9g_uCl2ga>)Cs)^B%-gqETDN^8S;mNQDlKwBjngp4mi&KtHJ2o6}f3> zFk1gM7{$_LU&~atc=VPB;SydG43o>Y%38T38~7*&CAf6jV}+qEH}~Zi`wIf&XOEJo znNkl2c61U>Unt`$>gp@J&V4Ch=Ix;?lh?$Y=CY4mt($$N#9&hJ!Xcx;MyI$YurOe` z=Mxx?oD*00jw*4dm-@nTW)iz<>N;yBF14>X=M+_ibXFCe4xG#{*2Xidn>QTJ3qkSK zdm8=Wli@j%o8s4JXDS;E%VJeI)18eAjrJol*mUr|ET?BrGgmDgv3Ds52rVxzE6C+G zzNUYuR`pYH|7%DTZbJP&8d)q!! z^RvROG@HzzYIEf{diC^pXLD_F8!`DClQz@WlU+ei+b-8WQx{UTUF~z8 zUrKoCoH9r#kuH=*Z7w* zENGJ>Vj|G^m{LRdig}Md7PDdf!g)0}@(ZU}G2P^)2E)lihC1=JY46chErs|TD%My$ zh@?>tbTa1OsJn`2ER?;XkRvNgch>ofgEQ>?VN)04%JSjzk7uGABpfRC-_a44Onu|? zdYa7=(QPu&&QhRyqFT*r%>5PqQhY;-&D6nBf7B4tgZ9LCp87@i5tye%Bw!5IHGc>l zq8^XE_K3TEg8w#3qChE}p{R_g zeojv=KE81-*f`hwz_??e(CcKoqV8w&Ja}|8{zpin`~@pGPue!4+2WofG??>!1$T+vI?cQ|1=U2@IK-ABBhYp`;f!Y|e^6csPs z#Le*~{v+yhU*No7ju5T%zq9x#Z(kcl9q`HAo&!G%Zy2k6=~*VD^X1o#F9TOe;R?Z9mFtIA!@4>U08&_z{nn814`7@o%8Y-;H`a2@#S&XVf)QljHY=Lg{_|LfeBU zClbNF#`|aM*7+J%UCw;tHbv*WjPft`3)tXOblN%gN`)SzOhSv~SRk-EEQP~%fkpKI zD?O{Ut?x#sZHCi}xq781i`Fku-iRFYV{nCvg&)=yxnPiDpnmQ|7Ua_TZM3 zCWtv-ZX&sS@G?VV!T9UTs8O}oQaPU9$_S|IIp35%;klyRlBYabtW$X8q4jCCg77<; z2y~UejH~&kj^4pC*{{F_zvOgh@|;nb#&SEh+s$1C5s^4V{*-7@_hE9R3oQr9pPYRt zVE(=Z#}&`lig>w2Xgbp;W$f#_w2uUx5}ZA26QAu)=8L*j_w?a4t$&!{`4r}LRpEyC zegb3dQxC#C(J!t!_!!DD#-%24>=< zv?qj_thbF6n>niCArznn8>y#3X64dVJy{QqhLAe1O_WnARODW7~J_ug1XA{~n zdT!l2MBdQYcGqyqXx%kO@xaDLZXo7^b$?4$;r0uHPqBHX5>hkbh59h5;xgCO_5HV=NE=t?w-jLt0vq|*BI|?e2{%{v+l8z@Sq&H@>FcN(De07y?@Jh$HFH0n zsE{LMdV|sBm7XBGh3j!amB(+YYp8AT)~T$yV+n=S?5cA83zs{DHT)YcbD9NN;a69Bb#OAQ5liP#mBo!AFppeIZ%q+mr`mI>qOhbr`7iWiSqjLV4(C~yj zYZBu4>ilNetETk9-b*K+^DonXayK>;j60)M^R>K?dootO;my01Z1_cl_6y}&v{h`l zXSQ9+tq~)9`DN<6`Z8h-8Nw9 z#_=#UB$+>nEl-zy>3Jl!AcOTX`1k9&2!5FDa_kFC@RYnqo;183 z@i62it#ZCd(`h%1Q&M!4q{q+7Vt8i1#MZJ;5?LFhK=sx)sEN_KyEKf2omzdQtSeog zogJoTK4@|K%~&Y$i-4?8b>vgck#_v423$CuJ+cr#FwBQR;r`Hjv=r&`Q>R-I4dHkl-odCEYDDjNV!{fS z=VrM74|nevq+8Q%3s&u_UD##Ywr$(CZQHhO+qSvOwrv}?-Z$djbE5m}INg7HMXZ&X zYvuFjiO88V#~fo$0Hi?_zmWFCuw;_EETs_FrJ;~GJdwHUvA%M7$ zM4vrggaB6%DKD7F-eYs+6OH~=YPY~)FYE9%$Zq$Je)J<)$f=4I!8F;Fah!bm+&s89 zZf1d{jPymGE#c}S>B9aq5SpaC!A3#Fe3UNcu60c)@Nx$KpTS7i)Etu@IjFR4r0C$x*3T zRugjYIQjc$H?26Qho%5D^CqZG1%kY;jQn{JE}O%j3d;q#v4=U>=3HZ98Kn4ugGHS6 zVJ}vMO@+hY-kljAbB&_I-tTU?K~0je-=>kQdL6wcT)3_r^s`fwNjL(%_+)zLJ6kXx z%9pvjYrnhuj!JbqfVEPe?3yw+A=utU1)wwPut1Y-T9d(vkbmPDavca{3Avt0X_=e> z)8N=!#raKQN3gFFaMjGQk8+|q*>o>pTTEDqTg48}4?=Mc#N>|08=9j50{i(@jY@Bj z`er5ekTq3-mBDxJmmxi!r}%tdo~L|!hP;u}oK;G>bzwf%VFcGUMRm@A!TI?!J!%n% z=9&{V3yA`6S{M%DJ6i~14^zYDAa^)Da#);^r;sF$UJR)48{$nndG2YDOShwLnp6C$ z;c=6UI5JVUXs`g@L>1B9)<894p-tB^;2ZD{{tYF}D5W;$SAawMM>!EHrie5-A65u2 zT%RJmiZnW(_f8Yh%?)T67DX#VWk?2#FRI-^auojfp<4YGMlEL0cPo z0XgwVfEZ!MTU%o=Z7(V66HuFRCkd(#P@8in=>~JB38a%A18au}Nc$M0^T~Jl6QqV= zCy4|N)O8cE<{L`eCNwB=4rqd-w`}ef*43LrL4smruhiU(}h3|>)`Ml-bSg^E@3U*Uu@4>dYpi*le>zK77e zL>qY<$Iyq|E~GFW0hoJK2hk=HhdO`ra4pTD1Hnu1%shNwlA}el z(U|sr4lrzJywEq}mkZ!`CVbJ_0@^67&#~(P^44qBfw#b~>j9cO8v<95xGivQRF~^N zllZA^ukc(zW8bYyKEdx=K-+rTLN?aGvmz5PF^{{8$68takmV7|RYdhqM`DyCrF zAL{?Ol`aAME}A?oj{`F4EQioX0c~{x2TI|K>0MH;Tl+Y^;kPR6g^+F(e}W zO2vj^y41<6^0OWQNnPnJ0UL%H#MFh(EH1gFa}2G3(ip`O#1<;;XEW;Po^IKW-?^vh zYPK_5qMG#dOWj&*22`r8>Z%WvHnXnQuVqL>EiGb&RFI&qSGv9WK;9?&YI-`ao`Z|o zDXCx7)yIWdE|A`z#K*m-?Sk!x*7RM6JeJB_B&gT;%SG(Y6!TdXn%9SKHBmUMkmd0j7b*1oo`O@erdYr_xAIR0+hGV!tj5Lh1 zS4!bbaY|?Y3Mr^*&6fKmFjyOPCX7eAF+Gs@(`}wJ_e6Nl;y^U)Z62wrIu%h#QdpU| z(@8PJYz{kSV*HgkwytyOMy#?{BCfpm(g1YM`(Z{5PZcRe2OK&#YGQ5DwP?n17<1f% zOf^Y4DHb@i4BQ^sN}I3JN*s^8*s+eT7BrPUUrr~woAHwVQhWrkR{)mx*XQNp!PgdL zm>x-SXBzY<(gjK2DNoaY-R^IwlIR2NPOK5%k{(QbEy@iv^_TZ}U6nBv^(R%r=%D7+ z#`YZ~C9gSsUl5= zU1YxVw&>KdfwPV`yQH&yCc{&<3XSq9osarJXkbF1#wQYkA8-~?y}AwzfBTOFPJ_T9|ig=;KS!haka=iM?>W@@H(Rk=!jP(!SYzK7riFN74Ev!J~7fW zhE8p~OVVO3l!bHc376%qp;E*q)Ef*&p(oXWxk-d6XvE_kc0f!5WxGuM7erF!c@dtp zDZsDK0QyKi$W5@^OkldnI*g#PZ&I~^auG4)ftmNR)tq#%bmIWE1~G^1;m4C9do6*?nfIACw+N%eD`KNE3VL2UG@egD?HXBc^196AajEEpD0( zV&}hiOtK*#9%tuM1Cb}sl5pjReoa^SUMCyEunD>y*>Rp!7#u*qI2q)^v z512m)YKJX<$e+B=+RK;THVyMKqeyPzqW{GkcT*TZEcc91PECV5wSX32dR2i@ncseF z0tnS0hy-=J$j4wR%5k_^ef)o-kUTq%bdw)YhEwgQQX69Ps2*wU;U%zS4|lA<;6s49 zelfDi!eU1VlUdmL>l<-Ex4`qGaaAqoFG0~d zO;N5I4@k@weX=rCmbR%W!Wb99`6)S!J8Gw>*!>s(LV#~%)g{%JwfclqSdNo_ybv~ES_PSzzqN>6HKK8F+pgiR94gU&gvE41Z7B^QzWJ! zwDy6<8R^x!e7v!barZXq7N=pc+Nh>qrJ>wm3=jWvRK}LD7<<#*wJ9LyvT9ymO*I**HTlio_y9Kw1{X|(#>3Q z-xxNH=o~j4XEpBzXL4w%x-F@uLxrq{A3&~#RDaEvS*W`wi#{uh}hU3SLIJv zQ4_qNwLrdpRmslH!(9O_{gtj}Y~P^VvTG@Gn1gv(rZgPXj#r)^ol#jOelMYc!y`?@6Hr0iwOGS6qgKBAT)Az>2}X3%pv9I7nU z%<+yWH0shH>MI%rQ0MjQBeoTnKQ$y&=$GD`T1~JciCN+9VT|JfN+Am?RefREn)z&( zc=?adTS_NHLI{+_J}$!?;A}I-9{C@4;nXQ0CLFfFil&ni+pz}+FVddhk3en+$ehSJZl^vE%Wh}TE z2+JIXl0OnNWba(_Y35Pd@LBip7k> zs3u*bto_u23QWdBM)j46Lpcwz1sfBtSprQHhkG(i zb)Ti2A*M|^k!ITYkiMosqL{%C8)BtTQi@PaxqDFM5Mg1uf5;D5dgq`h`7_g@JV+~t(REjmDG6NZ4O;rlD*=;jbeWDE z$F2PqRe>ryeoJ6Ik&ZJe^K6xa@AtmpnfD*sdF2ps1600-m!jvni(KWZ;m>y%KeOQrx`pQk3C-THO3MIm!rQFsoC(;UR5_5?*^p zm*iKrY>>o7EZ|iKs%>}y@5{_1s{5NY`Q@9o`S~^ON{@DTgY)G2b=dFb(RpqSR5wmX z0cd_OaNGsu)$-^+!1#9yS0S{JtH-xN-sP+p_58xCr{!^=6;raVT0+Vij`%5dZff0| z*n$qFF6malMf|jlDW`fHgKxU+#6uyYQ8D%r<>DCq%{wa&T!fl5xZK9RZYv;zNYpoA z%7%iW@KacPIZv@CZCZ|#R+}6j!yYr&aGNnjYglF6;|+@H*UCdfaZbQM=_y)0yb&4n*)PARPF``QOw) z+JacHY^kt|Gj6{^)H#?4S(*y0rRSx!vc`(5>F;&aO=0fTM$UjsA{7L4IpQ}Y3=t}i zK1EAvs@?9Ht6`Re34%`J0^5`Z6^N` ztS6MU{-NJ_)68&yoiR|w<$ocsLJ?M}{^TMmILGvjYt_bkqZrzB#XucxTH8M$#FCF+ zZqn){wd|$AXG%w#ns~Njyx!VoY;uCNFKu@=+hdz^Ljb#dG!iQzES}KnRzwtm!8Vwz(ti$bc=R4;0EfsPe@@j zmth6DQba^E_gb=C5-6;`$M02?jP^$LE#Dn+3pHUWAG9|LvcRpT5FMkQQ<@^W7uVKA zWhHaaguF{h9Ac*XHSCFDH(hToo7X*K3XCp(s>+Nas93DW`B{3qf=YcvWD>Kw4p;t` zl|va*j(fnVuAhy=z&2(c&wZqI>mB-C2JC=%y>i`qS>R;B)*?-|nkl=vA#idCfFMHm(?jX&=|F zuNchdFnH1@%f=BP7NpjaM7%~#RHI^P&iJer>X46$mSGTrfpN{NX(~-;OD4gp)s38# zJnIxq!s_LhK)Ffrs2sRAOmFfLFy|NKP(!9pbxndldiTrd01u#nMC9`tCp?dc7`>Q&)e zA~#5n+1o=D3@z}WGc4nIa0Kpmiyyf`=;76?#~6^#6~^WkB%Dy|IoVIhZwJB^T;CJ| z4*&>9bFY?4l#Mdv5@kFS+YGzu@cuXE+UN6b|9zWgMr(o|#>8Q9(t1xieHd^oAF(Kv zJ{3||R#bI|;K(D<*euadySi=O;4PH{*Av_2?W!WyOC{|UsRO|ax-(eqj|W^7{)HQY zB!P(ZtoaTLyN{~HtKTyUs6hPi#})&@kB2F;m=HeYg}tKkpXnAg=ubg`KQ`gcS^20ywE1H8fbeR>CUh)^DBV*o_o-Va(Kt8l`d}2qPKK6p@4X!!uszI zT_88Ove^mSsmy}7txhiIDyJQN^I&f)50h%E+ivu;;vThi93EN3^(8_zod)NV*ER0j zF>jBra~hlB#f2r53&xA0-)wJYLrYK6<93Iv3QhZ18B@V=&o`DFq0wTkNG#G+D<-3x zP0-GpGpDNa>k^%=(jT>(%t$oB=G(X0Q)0k2X@PGgS`5;}>o1v>1v?0Zv$Nk+V%fsH z9-H-F307t-b^rk;IY4*j^GnLp?6ih!0%#?-0Xv$PZv)r*8<8sf@7)}l;1y*`7w`rg ze*=c3wx2+|?63p3Q>iqtTJjYr8hhERt#r={tE2003mVH;RW~&%HV+ZH7ppz{*Xcl6 zc`(amCx^I#1E4bf#jLfOD)&0_s@iH56CA}*5*UXrg&LZBWWyVB3xVZU@b-*>jflix zhrBiSLXTEpY?K;Ns>%D9XnYogb+lhX=c~&GX`wXSl%Y29p$q78=LsOP%6DkGWq?ph zP-jVrLv_#aONsft;dTJ#St$b!oKJr*SSm;LtL4&g(Pm2S56OC^S9$|XAr3JFxnMKY zm}9v_6q|$FENuG*HfboK-t0_5{`hEZB)V{+oW=rP@*&y-A3S&j4}oEL zxDcDVrGQLNO#U4;hf2gInl;leLKf>=n*+)?uCN`G(80$*Chk#s)pmclzU<@u{`9zw zl1lAPw{1G_)TPmwU?diL&nl26LW(a0pO+X6nC~YenmuH8l_JhjAcAcH8aX{b#p-#a zkBR>Iyw?`t30)b4h9csJ5*#LhoNgSop;8gLP5M#WyeGq~jom1^LyOC{Tr3Cf;N0aR zw=#LX_UiHGlv>xvoh{PK} zxZsHTBU6}j7SiuG_4WM+F=w%`u>ID$3}&G(Rh7G4xG@J;nzEFdB_*>e!DSRFFU~%i zi!h?I%CU&IGuOK-d_GV8NBXM!MoV)$&Nk%FgT=8QOzdBhf>cdLQKRoaB!&Gk{_!VM z_REH#(z!38`Ec~F3>K{<@z%@gVz(4;fUELM_;u$JCG~}bIxiQ|cVliEdN`)ldiW+x zQFggv__uAE@MadvOFT;}68GHMs%vL4?H1a#qq~}j$HBQ;>)$Xp2f)JFSt)HwB}klL z8S1|R9`j-$C?qw83hBH&X2J9F-5))cvs+BEtlx~Cmeho*ONGP796t;KPuJax0#23h zDG-W9&fQeXC?-OixU+q2m(N_vv%{Ji>v#2>-x)PJH~l7&Z=oL+I(6G`<(bO!9G*i2 zCTywysQr-3!bE#vi=!&BHZjNQ50X*dxNryCPXc?+{TV zX=L^}7&chxDzQ*9)S72;c*VCUpT!+E!6h>;C@fFG$r^oZvmharq!pml2YzL)lN&WX zfZK*L=KNrk26$N2d?YR2cOCJ=zDU7{o1ZZ;qH%k)NCm#rRt2 zyQI8MOr1{~XkQ>ohydZf z_e35Zb?}T#ohCqh0Tf{j-w!2bhVc9*qf$RO*BITsa-=PBZ9I93d4R$^+1J#S~*Lz2qF__Yh=reWxuekp(W)16h`^Nm;J;PgqNS`PbGVC+?zH)b0#0-$ zOWz1Tb+_hO*3cbT=gw#M29Iwkk4T5l0#DYk_cCP>gTi1MaQ0cBxYJ;O*-S|z#0iHM z>k({H9RTd48s>CJz9eOsZCeUKPWHd4=<@SxQDH)>on#V$Hy~* z9kR=I<9%sKqIYiw1c>+qXC{a-C;4f1Y=QIPB67BD9af>D-#yZtX`O~0J)(uT_1keM znoJ70X(BXLZITxclXtEdkTPAF@uV#a0PMjn*FL~r;erAaTnWQGNpyJ#1|E!{9hw#H zxinfth|qb$3I^|!s_;f?3G+um;b8Of5?u3S$Z|Fb)3wFa1+Jkd|KU@-ucu6ZfBIhJ z(;OKTr#WFoZGrozN$_Lm0yF^EnI7Ts*kL8ICf3pJc#9ewW+6AcZ~29UxRqFOhgMtt z`CLRV+YrtF3vu87cTB2Xz5bw&#AZ_Xu8lYxm-_T7AyMeQHs+vp8AslCx6(Q z+ac%UKWeBTJs7|IevCcf{|jUPZ;FNq)qm)*sQ-tNhDapOm%z^g4K&BBItMCC#Ex9P zPPpduU%CXj?t?k^GKGT}q4{l>!Ip7j{z5vqoORlIt*Dkzm?6`!8Q$e*VNz{qfR>JY^;8 zIbwV?T6;yd!=kxz&-12{%k23AOGU&MImB-x+>5l=zQEI(NpTkAmbsb|W9Rzp=O*`Y zw7R8|X2L6BuPH?w9S8~>j(aPcZdVT(%Wl!@uxu%s)XPpqB_`-AYc^Bz<8nl#mIc96 zyG$5;^x1kEnM;|-yio}>5Xoi$XMD(fL{MM6l;Y4@)V42^B&g4X&g1k9o^UaPnVta) zts^gvMu%H`8w-M1F_U=tP^cpF#2ox>mrqy*0PsQpP*{J`Cj#FAT02i3J9tcQW(3?3 zPA(@T289|jPkjB8sr8QmU8X8R@mu!0=CB_n)wH#qBhdn8TI;RI=E~Gv7oq|SZld{B ztw^Ej^O!Rb3SLSiA^*0WBaLM8QG6IVRjtp#e1+4#E#6Gyn4Oj zPdXry=T`|N_E)madcMssMGulX1swL86fvb@${?1V&BGUHJ7g83uRi#yp$K`^ng+g` ztvLq*E)jpy-Z+1_&Uq$DgXKd{jl?U$akDgSMYSmuE2UACJQH%cKsDGGI6&Yb>|Qbm z-cT{Heqc~N%)&hHcLfPW^&IqRcMPvqSuRm6(?oPx|G1VKMI89TgMy@RGP_T@J=h{{ zLYa!GH-}3-BLz_z6{)NyPXZR|tVgWJGvYP=G$v3b!;MM!xviY*^!btrBhu3-jeWmxM^9!Y^u zIh(l(TRvMq7sI=qL!ifz7qCO%2=je^^q)Ir5J&H0si$aX^w#sr*pAhVF=X~Y_QV|bW8pwA?2b4sjY-gd^@;cwmYu8TYu0*56KXM23vok>Ms$f~%JT>Taao>F!vvO#`i4zGgvL634Vrqak14_!xv6MY67W*(YU*HKGQ((Y$e}LuQBx8Uv(ff35y@)D~tPh8`u^<2-APOKiA5 ztVivmg+E?_B)PHdca0=;bW_E4aQx+NpkA#+9%UaXy2lP4&UYC#78qIUP^#FDqB0JO z*bPs%&>MOORD_NJkIs>;ycnYz>T7?DIvWjfAGtb)*G-}of{(Y$H&S&HqtWe}*NL28 z&&y20vXE1>A+O6>WyXe$UGgR4Y(z!5hcpR_lyPUrQa78EV z5vj54C^ebX($5KgnQ-rh?ShbJu)fh3oC11}Hpo?128nMuvr)2RkGKacA;M*#5J{!) z0!DYyE+U)>&Kx&|wf6v9mwph7i8h-Eei@7UQC|xO?1Ry~+Hv`S+EjMEZ-4;q0VJ0p zE(yh;E$k4cPho&K&uNb`HY$9l+b0s-7X&O5l1gtvJIudgXnhmJ_l#bM*0KJ4g3lbM z8D9p~7J>Sg;N22kkThG3ErD>{peB?okktMutubEr2wKkT21xwRrdNjUz-G<%dJ8Vp zDv%&on!|c>@5Dw71UuhKapzwHf+1(NI$;qTZ1lXYh@bGIX=I(lc{tRxaquL=oC?7x zIme1|M#X5P(xObQueul#3-SoOUf=~Fv>ISe*O2g@S}vh*r|A7-85%th>zTeq=iKaq zXi;E=lm&^Mz~J!PpQbC3Q80={lqXj$+W{Y&`VrovD~{2fmSn%dui<7k!G%;@h*SY! zrC_Q}|IpnpNkJU;ei zIpBE@yws#yNbN6hwa+60s0&zBjos$yLNl7uCOiDmj_bRU-h76Ruz6^b3X2SZ`ep2h zQ<31LIS;i;Ez~_nx7ZjZ1&e2A&IrJ<6T^8Q>QMr9#PhSl3?0K770X?+IxW>;q^m7> zaTyaoNl{}>t3h-G_-if{RU4@&)y2K=AU+!&{$NT&%cJafr_lS`2E<}h@D$xqTxYkJ zL`0fVcNnW_YuIsN$zTxL?;6LC2I&EZj2zvNy|-tzE##I+)=3qtzQJ}Yiy0EI%nV+z zk<=caahIaysf}dy@<`7_n&irqN(PyxI&Q>iqQ7a;|BZxL6~PzRdy{MbN)?^J64wuX z?8GpQx2sr6H;>98ZF4@HZ^--_<3N)kb|r)muBYadNK(z|CQ)@-!4$<2+($SLoqCl5 z4!+A!GU}y+v$vY0+ilyKs%(v`PS%)pJ&(7N6EuNS&nA5}%^am2mN`Lye-GzR|tf0KcsGM8qN;_Yx&{T00@BH?QEl8F!mi<{k z3*l4I3Y1{>^Hl;3Cy}g|^STV?i-2|I6iznhkIWqH5OLcf=1$T@qBNsde6LuQ+LFa- zyfM}Ff4NR4*iKuYDZG~<%)MpH8$bBQDm;?p|6VUiXl>W1fODFk#bPne#nJWh59x#!Idsk?gyEmyXTR3X~)x7JP zS*X6Axfp3rp6~ViH=yp%Pye3_4}c)5Nb8jW0N|hdf7jWtGBPyNqcOA6Gco$925D^) zCMzuh^#}c*A3=$U3d;YS^oW1@X<$FQC4fIo%G6H-=pZk`|BJWRYv^YHZY!$h@Kc>| z@Shtni2@qq=Ovn>kgB7Cjj^MPp1l!(l$n9Ojl<6fSH{@b%)rR!lF1GLfWb{nkWbNd z?Q+w^RZ%6I_~x}8=V_lC!#I00?ecQ=7cUYthddsbmfvi@^_g-z-ym;$=}1gOq=g*l6#I() z5?S5>*TerBqlLV0**!RTaGBFBH#>DJP-N-(3I7(pzoa`WamNUkpSLM;)`0w`sjWHY zcs{O3vaHIfsEVEe-Foo;D30STXFwecSwfV`~XGe6{g47fW3asJ5% z;9&mdw&=AGub4#NB~i-BD>R*-X)m;VzoT1kMPqVf`)Ct8@b>W+A4QU?z{0d>m~cs_J$d#z zG_EUMWT}t`W{#0k2HqKpK2KR@Mw;ZZbAwlP4~s66JP~qyKX{e`JfDTM5c*GfLD0hN zuQO6SA~!zwtyuSzelhCQwUOmny1w(w71uKME!ayDI`7y=ucoNWq2G5W>?kjcFB!tF z8xs=j32RwgN)o@$h=S+NQ?ZaJTwiw`d3n2vZP}H1v0RQGurj#1mUPduH+ZKLS00Gn zb%M*J>U&rOp81GjmW9q7H0N}afl~+z2V0t=_B6Q1F2c??_SW0WuX`!WTw`9ZHF=dT z5oA63Pf-CMH+CPe(%HJked8gB(Fwg6G)_v4TWD!JKKb9u(pUtx^@?HYh0O0g-HV$= zZ>-{C*APJ$f*qZS()h%z@6SM$4~(VjTkLJdFGSs7v5vs_9@7QRdeIcG|F(5ic!~Tv zO9EAJzh!klYNiu~g!?o=Af==hGJB_V2YHLj)Coui|7r_>><%p>LR4A8C2#vpWk^fG zz0JZL=D#Ma2ve=^t08Pm&!t6bjwLAIKqfC#aKe37XZ(D2fyQfm3hX`@18O{GX=V$? zwz?WBIWFwz4k!+~Op6PC15}mQU5+@$#Bh?1JiSIt)Y9CsyFlrUBYp?cR%kE}D7We{ z3VCY7%#qGhOfZ!njV3?h26HB4bDRDAbd~GN&X@_ZHMyFgN$d4ZKv3vdqwngSu_EZ@ z%{ukD|2;%-ZQt0u*iS`@-BhrSs8=3OI!xy<+%EQDX(Rvcaa|0?+@z=+)|K0iNih$n5T~UjYu+OlIyKpZwd66kGmnq z=EpG%J>z2wbsWVoLtE#wGuwM$5=B8O1LKG50G7p|u@R|gFCjKiruFfaV0bh*nO?X{ zm`2sLLCb!Xu_^+c5B-~lqBI&y9%33vzQze;@%w2iS6hts^Z42avg^j!aelS`fYHBl zYOm*`#3$%#-rk;~-oJUv&3XoEIyS09SazPfqrc?vb?4SPKJ_lCvi3;I}FYGh)(cVwTUjg(`7*EbsABN z{$EqH?Bgdo)|O~!`|3->VS3gs(P*yFGv<7oU=N)rka>~gc{velBhcgK*2i-}KiXPa zUgKwa^gji;cV!sj!J?y(Qn|sF8jI|a#P(SmlxF&VoWy_GN!m1;vv=th;$}`Wh#Ly~ zz!e)G3JQ%inXm}69Bk7diq5#{Ro#(CbJIkGo;lGB1(&Pmyb>L! zE-O^!LhOa?jbWC&fkCefo>kwoV)oo{9HWX79!l417KkhfOU-KnvDi+En3VdwFG?5|6x=# z+Is?3CcVHE@yvzkZgmGGFNe|FSBTt5#dyg+JErY4|J6|n$*Q)|A5>A^>Zk@qzI+L* z#qPhx&tvN49c5Vn`kd;{*rFovyhid8KM}1+?df;F<_){3)OR=7v)gt3O);gdJn~8- zz5D+CNb=H854@@sfr{Uvq^My;E4}F=%zPTCv>Hb{$0Q&<{fB)1;id*;h!8b=r`QW+ zS#jaEmlS$vQLQ!iIym&r>;c+&V51LJIE?G$l02k*%}TS|5pbKQ1Y&zn4{_K%URPXb za{>f}t)g@iB5?R|I@jPD$N&q=4Du=2#ZFBLY1w_(1rRjf*X+M&}OlZv9S(@~d>?nH!`tQC9vd#< z)81cy{3-2pM!l%xwUQUJQ?^!#no^8)$(@?4^e zs2tL13dqfw5?LOm^dK#7c$U2n1J%?(>j>eO(M17?vx=Xyao4;+xVQFL!RmEq^77um zvZJ;UZCHbwdWx8rY`HB3meU>c-1Qgs+%$xPc$XC4Z=Sw0^r-JQlJjwLDoqxr)I;MZ0xvBKbn8^}{6c zGg-z-G7iyW?ZX-|p<_t$c5SFvU3h0)o(0HqbQRm5Ivb;=C&9~J5UOoqvTCWok2ySi zp5+|UoJ)L~leF!^M{GiJDz{u2qK?s$xPJ#wW3E>4ayt8+prP>A)L}s0084QLYRYK= zpTD<9S`Dy$VfPbWf-hR^Y_YRGwQd$(P}jnmMxkm0ZmAqX*~cgZtRbzv41+SE>!(5~ z>5F1IqrMBwd`Aq6kL2hjt*4LVP)nko9q(i%vTd#{g1?g_Se?W%i{i`R-NcBn?!uqNIb}QSg+>~;y`fo~>m8Ijv4_s3wn~^2EuqR7!R5CdrCTy1 z!?hZz42{GU<+?`WQPw1&$pp6zs&e^LA46M|~@ z^Q493*113`C7IE7+C!t*aQPm6hRDj%`D%DV(HCguR#m_}f}+pdMhilx@s)W#L1-?~ z4}Ny2+@2~~5UM=mZmz?>nGcT=)>tDAskQnX0avpL<3}NO)tOkTXc2e6g!uHrOnKmy zSS3;t)YQVIzw8Du8XlJPZcPBFv%}abZG+7Q9oDvbK$+BR40WA9-`*#r!w z%T5LMr<6Ya@_hb@>5PcIu!+&}g!B8Dl3Q?*6Bw1S9cZHYhDy2O9^PD6$t~WGT=4&e znrgNi{6wJ1Jo?;D;(n7#p3_?CUJyvnX_vOQV@MsB-xCD82l__+hJQ;z{NO=sr zB=D|3Fv-Jc6oM=MkM>(1KeU^6dkz7n!YyZ#R>a<8FvUWkN>_=uoFcQ*Kps={)T+=q zHCzTo1+<-8rz;wGVV5CMIQjvh+;2q!k~H$f#X!U`{6qPObhjaoqA~KgMSIFqP%=y)7M74Jf@}ed zs?IV9AtEEuX-Xlww5lYQMmzyj&~HRIx1>|S->c8mcbb-e@EtJZgmGA$3tB5-;n*HY zNvZf8B`H4!_F?4~_^Znhe&=fj3J>G6l7rT%35imf37J^|<&Uv@>($*rND)MBL(18q z<;$DPYHo+g*X7sS3yS=tJ0S$|-US!M527eL7xdOcW)p_&9J9ZE!JKnt3XPKVb+KjS zPq>RySd6~dFa$na5>OOl*YPCJehcm+^3B9RGbPJMCp=Wb<1YC{mv+#4N(3fD#V=|P z_-o9n$;T7>L*HRX!ga)OfFpf;&s9$DE?d~>4*$??98TO#u#=U~b=XgPn9guo?MWT6 zM#26w-02p6IWlE(aZV(;bvQ9cP?P$DXwLzTcg;Vc7eaC(}QRrGstz*myK{#A8S<364evBw}YJJ35m7*Ef-QO`@ zdEWihP!!v*`t*wMWOQ6qUFPCO;mNs1jK zL`AzfAtlkjHN4{1Z1MFHa5-xJE0OquMPabn@gcE;n83qE{WR=A+Hht!U{b*zqVSpl z@H?2WFd{vy_#jW+fiOsubp@R+tKvd^OBN|niiMpeca<@e{sxC`obi{@?wCXO>keP^ z%fwyUHsG&oD`6JH`{yS+6mSw}6cj%?15T6hM!-Y<-^9I2{*5sjviLNta94d|oO8~< z{F@5`NsyBJ-Nb`R>^lkZ<=dK{lXnrsimt=OLu!8YltNZ-lkQK$_46F*0)~Vs5#RIr zDQ-l>K@=Zc=ocO(<5R^X_F}Ab zkoX82l|+O$t~-B}Koy@ax`41O&%}n8E5Z06jj(s1Z7>JCcIko=W-DvJO z2~ZSDM-F3HC(sb4%Gqvy86vrgbfO}3ems(q13r=d(Oj?bJfKG*F0Ofs zk751KS{8%{hr!Q09uNzJ0Y^Y5)y@O|v$re6e`H2G&A=KBfeEwv3-m5Z1S8WK-ej(= z6&F7%)>+ro->l>Vfb`VbxWIo%rZdVMH9BV`WEBpV9*P=5#Yc5+2EWpfKLP~V z${{>Bxhe!0ijt1H)>%v-!gd2evwm=wC=XVb8s2*x6V}omuO-LJ|9S>C@t9hGI@NR3 zw*Y9CgwhWuaaw{i^*N7ei~N>}D|t-=LY-i!UF?huLmPw{ zdu}KHu_RJd*Uq#fOZ z6-^oTlz^{8Pv|YGD^OGR@`=h!ckJ$H>`4OL1Sc$%OB3<+isX*B+MC87$HF?WzY4Q$ zQ7mp$j`~$M4s=|ZS}gmb3W?;_c7saQU$FQA+45OglGJAUf+lNVdc)boB)p;Cw^T7L z4Tb0ZE@J0Z+*k`vY%cc5UlqO4&={$Iy86X8QPN~cVH@CUaY#vgtRi_18gJVz6Q=f9 zDZxVsiD$a&EVzg6K<5*Nq{=TR@WZM7O&FUNBG$(#rArD<)LLxNN_h5Ze@!lOEB|jk zP2oob^*2A&DNH;XTgU@K^|h$U&7PVUqtA1`YYFZ;O+ez7o8hROa|!}Eg|;>-8j1%Y zX+m4g%>W^`P_iej+Gi(5N+W9zRFZ6{X~{UI z>4ml1COQRYZ2g*hPVJG$3->9ni1lOAk=Vw%#>wYX1my4w#GgO0yXWf3B1NFJo3?@_ zP?Hu48mdb#IObG}FPN(*Z3PtiK7-fJO{F-6VH%JQ!K^&}yiYy5^P^+tt z8m#yK@M^$6?4McNOd1p?q!awY))>j!OWZ6+v$%-(CHW{7mBWztcm8H(-hkU54+5Fo z4j?AdIzblhpi9}$y$wmUEPsT)?q5D-;bZZ0S! zL{NS|uyc7Cb@IR;NjZLH0YqTb{c<-DQG5F+A}`IBo{lajD;u8a$|FcvR8ZduHtV-V zda8xTSLfRt?+6^{^&7Y(&qd8xheIRvf>IdRZEBt4kCMQBDz>R$H!TFX9GU4=O#p2Z z;!kmPQZuZfH+hsjPtVczSyFRsyqJ!-G-bce1yV$2=r92TEFdhW(rWBp5Vwtl!^rz% zngPnfaNtEk|3zxtZXXPZ%QD$TClLV|D9)=bzTFk(ql!*jaSF%?4#Gs@4%llGNKij) zYtz8|%5IP-DuWfx3qj#Zuz`xod%6h;h+;GPlkCT#{riUK6LmD<$`k-SwM$hJyxDjn z-?TJ<;WHH5>Ho#qTY$&WEL(ytW@cu|7Be%mWU(z~W@cuVEM{hAX0n)>nVD(j|K7Lr zcJ{s5*{RCx@9XNw>Nr*1nJ1z$A_oyn83gFv%3&`3ysTnwUsw7aJlSczoFITg8C*_w z0CI9b7aneCPCx?Hoz6h2_n;xRo#F9rP{lNIfrlt^{rLq%6N}hJ8)#}VW8#S?TaL5f zM0+ju^u{LGgZ#fuB4D)F1HC=4+_2xTkKK*8ur+-Sd^v^9J)vlVmFy;>&T_e1j4< zYsOibgDFg`AxN!#Ysvwx$e`+;vGN^gp*5DZANi0?RV}&R;h?=9Fd9~vMD#uQs#XDd z2Cv!bZJvInb$A!5ma$8SbvV+e3G^RR$gY~t^s4WmMSNsU9t7`*pYQHjJ*+jpZD<~i zb&>b?a2A)<6GQZLmnv3&BoaN0@%_I4_CzgR<7Ml59MY2fBSWqns>Ft$o}VwzNS{_pJ;G}r_Op$%YW?1V0k+tes5To!zJ)v zc4Eyif;E?-`_^RSfzM(BS89sROu?(P&g2yCMzvm0LRy*Ty4XR4H*~UBV1Up=NBYBn|6Y5D3!!a|taIKen|(^_VEjT5fL!AhYu5TlsUyx=@i;l&SK;ocubSv#o@AjvKL*}0y;FdZpVB&)^6m?VX@2)BKKHZ^d5 zbtTZw)Kz{+fj|4;gQ)thLagjBKtC3%#-_S>qgPN7Ozd76__vpkTSa);AEQ4bveLQ3 zM;9-<8K_Z4Mp8n&N?{sKDW_QNMc&y7cpo0E;?Ax5XxRyN%_pm8vcNj1474$1ceQzE z1h!+O>Bm`mg%0t5e&VP5jnWJGbq@)JK&rwmLHyQ{=$BA?4AC~dJu zP@_Gzq$DHKkr|vO4O;Q$tf&*TXg3 z(+K#i9RYHBq^;0CB|bJpu46la#E+Da+g1e4K6%o8W8(gGSOjK`=}y+@*17doX1d9o z8g>+cN|mW;2f_CnaGZYX3M2Go+?f6@#qhuV>@&71ogq{~U8u&7YvDsotTFhD5R8HDtvxJI)d`(qZeU6TP5Ic%FgiXZ5z$jvBdYi7 zX%;%z3OfDbI{bu$1QQFn{&xgA!Wv)h%>+sCXdKBhp`6DCDB`-hSUl4pm{OvnEUSRJ zP>`K4_38A}AhA~9C7xD4vCI}syknvEHY8~w;_at#681rI5-t|pAOvZoOsR?ET_(s< z;@3+mA0Q~i;|S9-h@Qu)9_n^{ly%anF*rojLxlOPcW5tVdo``)mb!`+;hcWJjCn|7&*EltUN$x8 z!hvk@aoWJz8m`Kr8`8-c;PdydvC7K$Y||aHnW;pe`1qnNMS%&|Y*_S{%3(`MpNCg$ z$YJ8waQmK?sR2HMmh;<;XEBY59o z#6m$GQvgnuJbS4($ZEgrSQKmDWDi(uoX$$7Xk{BnX0jU*ixi}{I}c`BTi@2pB0X$X z&(0hmE}hwCk@R={E91-QyM)?FUUm3_NOYOh%@^7Ch#9WQ)7LsluEOw zr|?x5y@JsA&s`q&@D-=7UysYIZdAZJ4iDg!rlDOuH_P0Tz{BU=AeQMJ-{8rGfT(G} z5Lu(HEPBNic)_1)L_fv=eZ?5`v!84P0U+u!&YXJPinn6&DN)UkEg?jq*G~AD5)n z{=tb(0UbYs=ckb)YN!E@JA{-*^NFuOAke(#7L?E`?%4EDpKbG_1FQXoCf4cnPpbG~XtZvsO8m0EYk4v{>eyId7vTlFLuQrz@L+@yhR92y z^9Pb-`_&c_1_oFJd`NkrO>@Qe1a&OI2p-pK1+qFFD^FwLA>rOBaUZ{n@7(G*Vv;@p zpzm*8Abhu6^f^7ui9ihqYhT!iH zwUDh81VYTsKHGvoUe^h5l4c&)M`1u=Z5Y+n{83%4z8QI-iu{p0FajA24jhM5M97#crS?RA^@k36gYm1s1Sa#A8GV z`Hy@9^fW%|9wkQBV7aZ4l~>gFoW2Nw{(jIeZG$b0#_v@%8vK2$lr@&UJI(i%iHh?l zOxhQPF5ZYvV?cA9Z9TGgl+f$x_mfzFZn?jLDcR|)P2}BBvlL8@LZgOdz8b0G?Hd?X z&AufC6S|G8?sA06%6!I7qT3A0&}Jw^|F!j~6jDe|M2vz{(>@gj*oBa9@xVf$;fYB> z2YPo;8n(>FmIgx_{&up>Y2@0ixi&ZBS5o)HQ;1LGFv6NdhecfI*EysF*xZu*D04c* z-r7%z#0q>&ZVjYu7H*s-ubL`U`JTLzeaQf2^N75Rz|$!Pbf6*@lR_wrm$EMHXhcFS z9g-O=FJ$VfB;(^|u-2-3!7w&s+?Vi`Nj8r5<_e{szN0+PH!mThnJ^MI!i z91?$nY;rSDAMq1EzDbO{@X-Uh$){Bb;Uk@vBPX^qDef8-JBilzb-`|AyKBZpDS)d< zbBdkC|3O3BB&=$?Q3l&+f&2&Rflu1rbpuXQ%yfr;=peJ2iMF34S??SfHrbaA8|NDRePaZ&)WMU*64^sgSOjXC zv5{ZU9)A8=a4#Ms08Tr~BBOP8kzH8+r=%p#0;#sDlz-@l zJ}4eaut#9|j_MlatJ%t~XW)5fQ;uY3obzYZ2~R*=)iuvmdX#PF>$!9Ahq`lvL^UzU zU8*Lss0!O-M-b0p?d9V8h4yNOewVX-eHDS%hLcC9z23&U&d!I55z=U_H&tDSZ{V{? zxusPda2NC4<}>z>o&R`t{#V3bjlSlu!SKHp`40=?zjG1&XGhY1<3;+yepy)rH@COZxYG6h9WV{Y=jVap;V_(B zT+u8~CPf~r=0a%b=)D^oAHxkfAWn{s_Zh`99v<9+LPFXy^fYvIUH6K^0|O#YPfxg9 z$qNe$8!s!c@bJCM%g;+a^(`%-=jZ25oxCC(o**E@o}+@ zC?~I#oa4*BzP{wNH1{SyQ%BSm--oGYFT6#LUpA4n19LAxt79sCdpQ8*JQ!8ZVV2BJ2^Qu6UO4o)$(B@$K7|<_0%u<7OBXFjG6a8^@Ea=7c%hiMf&W*y)LIN13FJVQwyJgr6LZwZ!^Uo7XljfyRp?qCU}0oh8oXHp9VAbx?%;^tNF=X} za+JwPR#S7|PU*uzlJ0|&SB4o_ih8;hN3Pt296VaUE(C9z7O!l|37s>P#g%q-Jo=hK zCufeQ8eSRu)55B2zegB??L2wY>$SpR`R$GSm%94&^mLD-&C9gCzCMZe?@C&$<-0p( z3~5VCOH2ZS!^CO1Q9C=kX2)->JUj%g_;5U}m+kG`7bt|SpAQdCRvjN7AD342$D2bL z5Tey28S5K7kk5foE?1G9uobX6H%F{W%rr3~l}zgjc%^JIIyY)~UF=`vHnxdAc@FGI zYZbX`WwG}T=WCXWGSOH!swny1N&}1TSw`>}J(I@k0j>0yjLqfSq6=~Y2mvENKdg1c zM_t4*4A8iN^(~Y>_{EVY8PjBUZJ_OH#BAtA9a&oYLj#Pweo}sL@v3Z8tJoU7XY~py zLZTu9pVzOgnYN||SmQ|^jhr<<=ojVFNe~LAV8Jb9i(IeJzU12}F<`O+@|36nB9m6+1- zTJ){fVZRF{>_)jG)aZbEH*$4aT^^v~OtW&3Eo~lZxsd(vcl|HlK?&l2dA{|?*&eiG zQ4jPu?5BgQEDkqP(b#Z$LueV2SUb~C|3ri%7|_YR#G1CrA>v<*9rHROESj8lG`X76 z$z7eoiXlxta-A|{b}$K6MVDqiGVz%XDjF&xddh$$#{rr#3$CX5$*LJNgbmC*9+yh{ zNIWIs^Tf=z_Ob$BQ8ro4K-%jG2cgtH-%}qJTZ?GI11lg>!dB1XIbGM>x4v*`G2Au8 zoNOLWmGm`V`ZQol1DQK*6frP)JG6ylZay-0jrU&V>p_(|hcW``AXm>H4m=d|onJJe z*8Af0n#%Wm^qSr+P)?-?NE$2;P7v{=q|L7`ejlS{v%? zvx|z1H+6Es3Y*O1)O#W#U}>+8x^rF&M~`5ok!?0xbY@yYVKAzMq@=>>eVV#(=By|| z6-~)%r7w2u9chk^i?{Qt#^gU(H~wUNV3$5JOW9z(R)#eZM9C?FyjUL7=r2&>VLc@H@O9Vu3!3Sv&jPGDRugF(|*(|O7d#H zj$3>6jcY9|F19@S9qDtf=2#od!b?N67;t!Mhp}S6OC-(OgXZ63ckxJ!sn z8P*QvM<3r@YS3F+>*$)ndUkjoo#uhl^Kt}Uhq{(qU)m5v(oKx(n_8l%kIo*Eox(;% z=omP_o2##Wb;FhwdS)&*P4G-oOSvG{#yDlSD41uv=FIG@!3BZeVecO7q9FzkYD5}0 zzp@1{T>+Xb9PF^|Va(Ms&V*yXVJt)GPBAr!Xsj=-ULQOzFp`s_x11)rOTUiZVS+dR zy4SZb%XF{NK9LGK5ph?tdAGo1BK_^8C9tXMJ#^={M4;B`+j9pE8^0>R1Y&7o&L_aH z@P09Lx_Pg|Ss92f9FWxc`_%Z042Ocvj`DAsFT1+F>U%$rf4xV6DP)6(DeMxUpZ>a5 zVy}0n{2N9rEG$Ft?8qyK{N{5^F0%YS5S8RLM~tJ((6r$8OC9E_;? z8rFY(7IMi|#D>ojs&(uaBB)d?zUJoGGDM+l+YzJv4Q>;`BEMP-MBg8pkk|Fzd4hvI zb|c2Ij1dOSw}R&LjQyX@A&(*tLXTpTkz9NTnGHVFyNS2W`)iD~ojBea7fU|+aw7FkT3<5(!UOI3sWtrdw(+rH zqUnj#LqY-%sYIhm2!|XHhz_?1VB9aoE3NLZpHJa^X*g8fXF8)gr)_S+ef{N77dIL+ zJv1x&S#nr*SAxw^o>}ufb&?FQw5djF%0WFUOx>?MeJ>{EtO)8S!d7qJ8DfU+sk}Mf zIN#jRHL~_5r^h4;&v6aKlU#3czg1~EU^(O6J?$;kYulb<(V`DFaH!(Uct6?4oKtPI zy%u)aFZN~;sM;fVX)N3AQpVLwpyIaYwQRO9h-TL1T9Q_>olDirn7p=t-JVOV&NJ;; zN1qPm^TCLJ+QH>}QiDg;e{z#K-aw)^Ir=nP8VoiipFPDL0R0rBP5$GiDnH#6^vBmx z3EnElXb;P5$jd)yWHZP1=5bA~)a#9{7;9sDf$CD7Y?UUjKKPg5_veoEv%Fky|1n<#CTXkMrYMj_+4b3B6u7|>))dB+pNyinPuORD(pXfqxQRU-OsCz*59bW8$ZK(jJ*e@ zsjWlqN$mRTR;FUrhp{LN8T799BAI$b={s%};v zrkz&yRzfzN!sopF#U_JK4!v*QEfw1>GPoucYUx%eq{Lq(CM(<}JUU_W;bFcNavnOz z4v}eSlOIkGMF*N$QG1Lwe7C&iWCS-8%d%Y*o-D}qPB^WLd%t|3JAGyRcn9YAPmQ{JGIKXsJENJETeBS?Tz}H`UPFbhtHfddwG`b13j? zzd5MgVt=akgis&jHOKx;qe@_PHqDI`&DX*pJLRQ7T#3au_*6rS@%31l-a76Rq41~_ zuzl;G_Z6uFkPwj-t`yYqla~Sk{U4!16cEYR>tAX5{?`8@REY7v4iy6K`#K>hB=Fbk zE`9djh@pQ%g#eWkxW@nhOwvCAKU(J*ljgW1XhZ7HBx6wxsY`8X@d^G|1f&Pm5MU7k z$e01rYAVSCiNi1S!J4G#xQGTl;{CxK?4#nnNYJv?HuOut`iVW%!m$Y0>4?wuKc!+9 zQX`kcN4|3ul)k7sIxBze4Mv5Bt4D;~RU5CJa`z4$FVi>Om)g8F3YwpqftE#BbY;&sEl0fI_@V)2zWYCQIe81+K zH)GLMuLlM~1pF<6I>yGv4i2c_+)}%{udi)eLGk&#B3MElj%FH8%35@MG;wAO;^m1cLh`#^T;0O}v%*p|j%g+x0>GM_i1t7EIzKM$w z!~ILYzXD3gcs)_sU+2mo<$s{%!ul}Ke^jnzFzF!z9U??jLZ*1l5M}lc$N5%5JV@k&at$ZYD7gA9x#Qn!P&Q%S7O! zrR`bN9!EUM^~O;b%cEBej!EYka*~}m8XX*{tk&y4jf(m>NYg!pUD2LTYt%aGXg7+I zO((5K<+DK6H(AXvs2Vd*egO7)lnz)~4=BIZKbBrqM`$W*h>WBgl7e0UMv4AfWo@3k zH!j!<84u63+DUU)v%RKr)#16nK5ROXSmnW;L_~g^+;2kWZfm_D42m+9Y;b&@kRaCd z>L9fc=x~rS6v2zfia+XfXKSlFyXj3M((~?a-g;zm2Q`wRQPSJ{#l&J*so&y5EU6@O zQMr6jno6 zkvL~o(p&~DmBm+nE!5aYw?vX@T9D=yqX-;|f;P{rTl*R#b~X^V2=Ca2^CDU24Dgec zw#ffL!ZIRmfirN)xMY7++ajQLQlVtD8{z9I@s%WwX6#j2A06m_+_Zb0L|9m!YHRX% z56tIFj~-OvYqL{%=QY{v*k?x#M0t8HY?M8Pwmau}j=xo3qSg}74UrMcU=s6c%^ zf#Q_#tbXE8b_7UGoekuA;}1MmP0%*%ZyyMqf~RoD=TutpJ^qSp6=8*5Vo@bxvb@34 z?7Mm(T_eA#0KM@kCs?+>DHz2dC&9;UNXJTRdTo%7E9Gyspx;9!Z-e_zrz~1N4mOR* z!S2c-53E)pmX@gPP^?&`QH;-P-NKf}&~yT%`xSLDO0fo8n&O2W{| zkf5VoTuA#p5HRm*B0f!k_w$OJ<#L)C1d7MZn+NZ72NIAol8CZfC6+Ss?(TF4U+ZR&8uc4}5^PQ}?z|B< zMduaG)b2Q3uzm86hRjgNq%Dc%RXzgHhsF{aKB0V@9-F#aDU^9WTYD9jl8UUW>%a`y zYob;r+ef^XGTG`V?e|*RPA#d9%5K`Jn&GH&_K~rOM{1?^ z-h>S8RO5mAV3SrQ<|IQy{^HJe+fPgb>itu&%$tGN06b zQiXbd7*Wxgj$NiO8Qa}wCE2^rXS}04@KoUh^3e!s#qWpiYx#U$y!(Ti2MUl2bF$@FHi zD6AMp{k$>fEH-lO(<{z*xMMItznz;>D7aV%7Rw5;_=Cqj!%xtlKPTtCBwPhOrl@LJv?$^@qi?jS5D{hn=p`V8bNEuu{;!dJFbYCD%?%2wV zjwZ5S$k5A!RIkt$bPH%_d<+*P{ltf>l8@#Y{ZL`FXU}~~$_(N<9s>CU*{L8NCZh5b7w=R8mk>=_U!|RxP zRp{!S{2UrimRCUx#!HL5yya}kkr>0P_~w*NTi~+4M{Xw5zM7MqF&V!T))MCQ{BGz# z^w1sfQHKMwo6Tm$;=G74dV<5MTAa~mixba9`Ef|js=%g$I}GmQ?UH2CI-t#y7j6t_Fg7B4Y13lvGu^g4;JY(86qg+Dc79RbK zjc;G|``S-l)3;e|&#}bQthKQBRRo2UUYo)=&evOn<6og2n1ozY+33>6Oh;LKwpiWB ztgml+N5iG50U8yu2#E;V1Vh2utPgr@crm!@t=AV;Ax-KV$3E2*Mh8}{@iKG6YE-Zp z#gdzrWj)H$evAA|F9M!K?SwhdS@_l%4dX{DEFR^W@@cSmn>j$v^|KjCMt3zh5`@zd z3WwyJ@(f$-PX}vkf=5D<%4B-bX-dS;?8H5K?Y%>Ohmu!lvU&-`>(Vk~O2~uZP>P1a z@vYXw~DGKNk_FnEkSfNc2d+U zvICrQny&p5Jdm{bQV}VQh!x;>I=Jo_LQcO&R$q(asUAwdrSWiGe$8~6o}SXWZr6`= zVXFSKHgor5T?=-zVOUz`%ojf)pH6%xJaa0-osOkcGPNN}{UD#wG%L0`P_5zUheB?b z1(>Y3a9(h?+i5qGMI0q}X6cSfnLS!$!HU7r(s%SWp^QAzhgN2u;A5l0NX;J>qIG){ zkqC(Px3fXI@RhDdI7AUh1*r_GKX0jtU9*7yxdwuJRONk?6pV~bAVWh?_QfdZb3EI_ zpYg0*T&p~8t%6Xlp}#xd1>hr3@Zry)pN0GX{Q1-0FWgk@8wHO0{23>oQwmF zD`*1?%+N?aodW^fn+X8AsA8{9`f_r;E8OD6qacPN{)>cV5cx>vGOf9@om>^L_`E7XiY+9|UFeuT9-3AbkK({;!h#3Y8sq^ug;V_#aeD3z*&Z`+3^Q zdD;4^wS1y)_k-~%)~`HMBuGqd^M!ZzzZzWtf)R23`Q;`4wx!6?4J;;w1qtLr1o(cC zf2q**O0ewzZz{(M%uW#-N$~4G-g~3)lTB~FN1qA&O94V0UtimQ4xnl0c|+TPdP0A-~mA1v3+s8_w~hn_=Eyvy7kWq zufO>Ee`5~hUZW|EQUU;f>sR78fPuBXyq&d;{a3miM@u~`T~iBMGaEzW&!x{T0HUO* zgeU+A2ne9_wF5p^0YU%}VBo*yYXki%V31&7prByT5D?&yu+XruFwihCaPY{8aPUa* zFffSdh)5`?XlQ7#2pE{?sF=v8XsCZr0tE8a1{4em3=9et4h9bO|M&LU4M2hf!~g+6 zfQSLWNI)P+K%e~pf-fTl>`U9f3jccp0{+qw90C#w8sb0A3sYkJTWrmsku^z8hgpwTffv9QU=DZYKDWM*My zW9Q%$5*85^6PJ)wR8m$^Rr~o%-@wqw*u>P#-oeqy*~Qh(KOitDI3zSIF8+5yVp4KS zYHnVBL19sGNoj3eeM4hYb4zP)U;n`1(D2Bgnc2Ddg~g@imF=C~z5Rp3qvMn7o7=nl zhsUSqm%q6F;{1>8U%>t+Tu5KIfI&e)Kq3C(0s?masvt<9U_=by$O1ngbZt?H8GRv9 z1!Hq+dZ0*{6t2+p?53g7Ntw6FuKz;&2igA~Fu(sJWdAp?|AA`-01E>2b@M=w0DORV z#oVx)Nn{uNNtNrwGG=Y0`*HM#U4vRvr`9l1oAZG0-y#^ZOM`W1IV@lge0XHTZs5dv zIhF75C7ue(M7=heOs-FA62lGb@`NkqzTesjP=H}z4rtEY(U9fWcZBb#6u6=~pF5Sl zlv|XSsX0OG?}xBs$^)G!sfL+)K~2pZ+;CZkW6w`M1i+akX01$1G$aq9T4S!Z zQ7Qs%n_DP2NK4=N>YJxEHayg>(cUZi^~g;wrvv$DFHmVUt{-6|a9vs8UZ0-HSHt zEG#BVW*YO{MdIY+?kA5Z{P4` z>}4WhP+=Esebf*kPZz24uJIcv-pGEjB^}`X8d1b)V(A5H@=nT>llcVDx*7QLWB*n` zdAjYh-F50H4CL~%ZXn-~h2R*Xh%NzXE*jsJ0meacS(*23pfE|WLi(NV>+3)H<9P~v z9xad}s+|j3^ybtFafp=HO@gL3_xFhAG6kLhf$v=z!cGS=SFmqGB#*HeL%pSgZ$gk= zzHxES?$Q)^1zMDces;j-dqdIhVX(j%#IJmjhY`CS6mR6eFjmMKKNjjhmLE=#s$40Lm*#A} z_r7MInPG;0Jrqo0pt4xsJ&Bnhwz7M`2!ybBvE`qc9{qzK=eG*37yH%Sbtv&dxuIqc zLXu5IeGEJ%$jz0Qh9j!B%c{_J57`nCI!fl&cI5YYv-UKezvJ9*FmA!EuIPsJf#!DabR4^DQZ4$K0ku-e*@Ks z2v~bsy3FKbAjwWOj-a!_{^)?`B&d+%2eW-S@UL1wQMFs@jHws~2}VxgG3bo69X>x_dmWPQBtj%O0B8AKdhQjCCyPLK0E0`c1I zPC6W6oi=IAQK}DVG;!uICM{veXc;rkc@3~%DEI^fh$%(=*@DqT-#Pry{Fnw#kiH~tpl<*kMRs5rf?dPS}|K0X6$}>9A*L3xXVtag` zyu!HDT+SL7ipbnj@POrJ$wIRda*)mcCPvg{m)QZNI=*M+F*yiqN(br8WOAv`)gqua z_6B|%TmTO3E7ZtqBIn?P2K4YSt@u43?0m>(_JhE^jbbP13csO;Tm=oE&I-zU|Ag1=0zQ zJz8QHOn!{eWw40(0B6gs4jFyR*dqgad770GVH2l}G5EEcUS4HR210*?h9R1clnKmf{3$p?P$sx^l7b{Ei4z9`N8x+6^`%$k@z+5A`(n_!IfI%UlW z;On2(xCIZT80)!}6)0nEw3vF4AM47sn^0vGQClZI1Pd_e5yere><(0-tP29%@jVH# zMDzZ!I0_yWUoi3NZj-=y{LN(tg)e`%-HiLgcH7g*M}&<9JH|kI%3^Gy9Vnh)4e0>P{`ddtR)#y?8vZTh{5vJ z%7EhFp54CkD#0X65{dh%Z?d0uMu`~#-16+D+iVcUdxGE3M&P;C6^#B^QeuXYB>E^B zw=!^X3DXuzY_K%(6aK*7A~5~^JdYxVsy%uqIEXx8thL-r?BWyPqHn`%2mEmH)B7@q zA9E2O@fy?;W4XeE6)PiU&zu_aNe`ak7I~-&bJEM+`2+D?qLM^4Siqe{L`AgrPW}m? z4|53jMEbCY=&YHvqvZ>>K3?CXAi~ndIb17v`iMz|6gzx6TZvG>ySXD5RGCc8S+Bqm zdazQuyi(B+#jx~nI((1nn$1AtfmR9QcT4M2+{^!yTDbsgO`oU{=q4^@c+b!MyyRXE z?(`;H?d<#xak{Q0b!XA8QWg>#z(GhMZG(xMQK4G!RI+WN`!h>fIW)<}9yXc8X`{_k zyu^x^)WvJzxl}!ZH6bxf z!gB@AhV151zk2yKE;R11*JIH|sBJ6|`Z6$H#2{ndnFPVxf%->whueFoUlnvL#*$ZI z>a%rg-oayIqWya<7(v_JFanYTu$-N$+Y%5D7Fj z7Tw3W$0kS-F5FrZ_Y*6$9{LY(SB#oItN>LULzJze$o3}yQHYR%H4;?VA`bKX6R<#M zGv0JJ#D1QM@_~U70Pl3lP<<2dM}>`R5%jH#j{7@H9$P;g_ySG}EnRzHQ?da0Q`Tkr z7A!&HF{ zX?$B3)>fGMCDfDOzD|V5_6Ww=henV&vgmd_0HeA49>n)%p`)um8h%}K$PzuL(^)Lu zIG&K`2U{I(6#&*tN8#t2*pwsWmb-aTvK&PcqMA0{pNP9HkG=|keB)JO6@H-=*~bX$ zISySsUhQ|WK@cie*BAez_H@KCIS6wq;KVek#2tEH?osiF^Y??j9eTmH>0R7?1nyXs z#hs=gb-C2b^F2r%sT5)pO#>y{-+yA?H1roq7V_hFk^*yru(Z`e6;vIxV<*S5T=3Zk zxn`H3nB`zbVD0XiUKVw3`tptq~n6++t`gl7{822OBgA5mG~*3?0w zz<1>44r+3rvbI;lN5zRc8Q;r73dEOkNDW|jO9&4AWwk@Gxm@>C4Wf`&^Ou`#u5;Ky z(?KZj@uCX|IoYYV8sb!gAa`8TJR-5dXg7-R(qRC}l z;xfSEkgx;iwVSt8=!ts~3Rzk1u5*uq)p70GCvrTi?%@TCP#ph~gFFq_2P^+&9HdDM z*Y76}b+e3`PG_g;T$-r$To&gd`hfyEwRB{!QMl*LKq~T0(VD=;Plz!+jv@LheYq!$ z8Fqj(wsly=S$?-qAFi!r#9_RTtPtDipc~MA`7!c?x@&+pQmhnVvSi~!@F+hb$}EnA zmBh!(R@8a@l~WDenVp30c3~7(tX)L4I36Y}TxWoe{fl!I>!OFTZP6+AeuNipE90 z+dkp`I2Ts3f^iY0HatUSCH94yCy)BOY0HYdvJ0 zz8-Y6vy`yZ8~hG=@<`C|ff}6T=Oa>BdQ(Up9l7z~D;3&{(Ob=K8i~-i9vPCI_v+PL z+>mRGHgcyKh|N3o@)0D1lth8w3i61~k3>q~C z@stXeA_YxB?-|F&?`OIW-{A0tjDuE>pof--kV-YOe)JO-uc$`HM_~oO!F>YS?K$5B zY!QAlSBU6!;XfdEz28znFZgp^49o`hL_PC*};Hb>dz|}Feg#W>j z@cv5Lo(}sCQ9zV_Q3iKE-fu(~!k{)p9HK9NzC}9HGfcXbo@XOgd_NvOQWV9NhY&@R zV;DVBKUIW5>u?Zaam0kA+sh0W+n6w<41ArxsaP z>4r44u-90aAv}0=)K7xKm8@1`#9}YqzB?P9grtb;rLgT( zIp2LA`0SPLP-^GFb+xxDWQzVOc10_gDX|CQ?`Ov}3IBTU4*-0;;K(9)$PQrl)FIPdxQS7zO zB|)u?nC))enRWEgA4uSC3$PtN1i@8S_vCdczpylV@`qmA5ICSx@3Dkmgl8LL-D-4V zOwZDmJlVa{3Ptsul?`Lse^yr{a@r$kg=d7^u8EyMV4)cbxHB*FCf1}~5O;#?#S8+D z;>S-egkWrZNvK#{uH?4KUH^f|)B`N_+vFQT>fe!p|p% zTB=bD`m{w60`4*R`FO>Lc-BK8f64Sph_=hrK|lK4qY0{|cZ-RQ$4=BMTY2yrJZ2Tf zjMdohM0#YEFm}>{)f>As6Jkn#M3Zt2rH#V+F-px7p-9?xHY}E#AXhX^QK~^8PIRf8 zgn}D??L$Mq03d}CS|1t##KI-YlpRO(6*DNAID8lzNOAO?Z~NN}(h=wuq8ee~+_&taVF& zyuaj!Z@3nXbZr`*w;V6@4ezy5S^+@6o{ZK zS|8+x%!7#dhFQ@H_?8>?Po)}t6Y*GB8R(aCt`an0#5H}OVwSpX;);+7+AVaCqMD;h zvc8}F1T32J-7)dwDxAa(Vb^IrW!e&cuRjif#>=*1_i^TG^Ap&Lf?LJ2Wlpmp!+yv) zUZHqk^=cval^`cN9>EEKdlUj&>TcbvI!G;_29& z4~+!>;J{ztOF<39ZJfjcuk4k-snluQ;THWxp3*&+i%4^heHau7)m(6 zE!}n6@F&jnEtwxG6{6`K3}Ae=Bx$z70CVAX9(gNcd>!bWxE+yUJh{L%K4-lVs&?3g z-R>e67{E4j)w0Q zS`#KjB7Zg{NJYPMfB?X$5jgh6gw(L*{69#C;ENxxpNJ0Q$XFQ$;6|dbxCe&qdkmMm zHf^+)%h)LH_u0V5b>(C!?n(rp+vpO0l&ek%Jq9lkN|Hw2JsBBRxorKo4XQMdtFB zp4uB5@x@!dsFi@QI*Q@cjqjW|nZ3zwdfyx}^i!X>*Zh<3-a z8!c772vb3vo#d$%8G%4UN5e(sM!e#J{HnXTwIx%+iYWMp+6-*^*TD>(0CAV#pm#%4A~IO{k3o zp^hHODn&XXLkv8>#RhAe+MdZ9UojK;WkOC2dQbNt;vrua=vD;EWTU@ZtMn9`|AmpL z<<7FB%ZOfEHx?-XQh)O)$USye;_6YPHS3&7ef$tr_+WdYyBHDdFbdTe&o*^k7JY#) zG(O@ozY7@bdaqXcs1>~^ko5mz?-Gpkj+6cA#{3DJUue0@59#fC?5R z3Me2ZqJ*8#PV8=M6uT8sf%(tuy(7z&xUf9RIskapk00>rM*9(vh+RNYl!Z|bgGG{nu$ zr`_U?j~YEKtZRSmd1}F`#clc{D)GZe?~m&*bnkOzXwwy=JG{ACa9hgj&ME)b1>2Q# zKH5Hw)`r{f{nmQ*H<~87WQiR6{7`()B(KeJixz4%cIa{ zZXYtTcc4|qq&sJZ%x=A3(`;l%k<<29S}iR)Vfhit?(jh$69W;|mL)OS_DPop`H4m! zr>DEPG>e9R<=*6%hyu(k@m|4A~@ zWn`CbU!D(&5)V|58F{>5;;t|UG5^k!L!8d;^B3KA?%CengR=Tue|j@`|7B-ujqyj@ zKRPja!a}EZ!D`FL%5`vUBIcdbdD-i9dC}Kz!d&Zusp2Z}>0b6Azr!=X4cgzUzpwj} zxl50Xpf27B?3FY6Qu9eu%nK&#j(zY>t#yLO%hp$=-RpJf_AY2;NKVj{#I`RjeD8Ky zxMBaT!5`cA{_->3F@Dattw*9#)7RBcl8ZJs_IZ0Ed|Ag&ZbMhix9Hv4Rbs~KGoM?v z{xn)`{dU`}C&Gj8h)K`AG}+GaZI7WH>{lJLIN%^H(IsKG%bB)`Bh4CUlzu=KWuRZyT6V0c~^*y+Hg_2y0t%J{IrJk2`5}SK*hIxL!EVI|v`=1=s zwVg4w`KBwYWn|6UxH&YM_bhMw^TKu4uYcSU`YvRiUq7?#A zyh6_mhiengJwB5Xbu=M#hh^Osx9_QUdsk<0?=c;7>^sTsKk`!lyvF+$COe|HYVU2k z#bA4%Ed8Lo_|Khpem%IyUgz8xUCD6=nhg6G?VoqFApPR=?U!?G<@|aXFL@fVd}v00 z{Q;-X#hlyIclGD+^e#q?_U!(rW3+>r?xRAZ++opmG*>T)yJH*OZ^y7F^(4=$c~JM{ z9Yh{xzC93WXt!{AYoj$sN5X>UM&UoECl;nSocU=ohSGm8-mb&^AO-!admUC^-u%cR z1xArWz0^Z9JIL(acYo)wwxSbz?M76fsiXFmCR1Md{P6J8o)G3GyT)~gTt=^kd(L~$ z9u}M`ji~zFr5jLRTHSC;7%AN*E_cL{0mn>_J>Q_`chTW+cIz$!e|YaXKV0&`mhO=O zKcmi%ubX$Fd5-$N<@uv6>txm4f44AF)yJ$Y6?iYS*~V$38n3=#|K(w$3$8;}eVF%p z#NyT$8fI$^?$Ga1THJBTXtBu9tV}Avda}ZnZK>hIziEf(A*$K;MPZiHj!Dcjnle#+ zz%$*5zG3%H&Iz~M)b~ih+p)379S!om2TIS$IeK^3yGu)K!cIO7|8D)PfwJ3J#mL|! z?+ZG6Eaacf^8>b1r_V`s4SAtHCilRF#N+XoU*>(tZ(*^dd&JcF zg^hD2tc}qN`DWd2bkvw8nxdI^)gS*1-F{ts&ewVSKaW2*eur&L&tuVg6RbRD{^+=f zdLOjA|Jch?KfU)PPgosw!7@8cZcy@psPjg{_NB_4@X0N@K1nlTNxOJYyS7Iz>iG`L zm3LfhdnM6(-l3+~&nuZ1ti74>@$i|?!``f1Gbgmew%ZLX$9~pY5_tPSkIf3Z!+KxV zbb94BFSe_8!PyNx}j|==Z*8TxV{&{zqD;I@}k@kw;3bGcn>}K zICRYL%sM7Z?wZT&9?;5s*#P|>yK_2Djc!bNn~d+?>qNKoVV4^Fh1~7YU;Vb5M0T{u z{m*u(=aOeUTNNJqH8RC5VZgR#+ZU#Ma_OHiJSnu7&D6r&7xHIv4pF1}_KVqYVxNxeZ~x&1^RZBJH^dX#tcViUhH?RT{apKKSZHa~sKirnUxW|(x_@b17@=fl0< zFL|xdsZ*;nSsxp8_ikzQBH_aJ3+|nEdR%bWrahACtZ}5>nLP2mQkItk&Fcw*?w6Y}DLSC$$Q_ zy>{c>(T(inx6AoI4d~QTn(rf$FW{ze~eaEZmG5HZ2Ewf+lHuLeVcUAl6 z8mG^jefv83IyF_SGcP;ZW4QZ;N!I7zsHB|U?CCMd;YZ+QouQV~^M1U@)g81e%zVw+ zH4VBx%6Xb4)_rEc$7zl;6B`a6l=UP#CE@zJp6}(li_41}AWG_~o9X_gy1NqKS+!Q+~%n>q=+j4q)wOhC7-9xkJGY!thnBP8l zY-~WV@rdq)88fG^@XuN7Jk}>{rlq~sjxiIW^kNizVusf<81Hc8=q07Wk?x^a^wzhI zcw?h;Ylo$!wyVRF%-8L=XZ5%p+4JtpPg}&7#$DPd{vo~d3YpA(p_yYWebzoxfB#i{ z$@6?K3K6o3W<`eK(?S~(t^b^|Uh7R>#vuDYZl}q*Fz4X#MIQLfjyrkQbP^m}P ze@t2Y_UqwYDQT|^bzK|k%)VpQzrKQWBluvUyjv4@)ysXOUCtz3yM6G%iV=>kZB(D# zdG2<=vw!we={2XH#RqkAJK*L^Ew&oc-2b)Rll-Rzv;H$7k2Wz^=ypy%h#ss@{`_)NOu1}VWS%=ZDN58n+!L@b$1D8Mh z$7c=*@>$*IlGU^D*!wHr-dG^|W>vER-ORO>-G6R65N2rq^m(sbs>|}JcHtjXhdq3v zdh){aJ0}lb9cJn)zb^D#-7zcgO&u=%@n}mCGe6h5*9Y889vFM2X}`?JpK|Vr4YCS} z>+Cp3Y1^@>UJYb4Q!n1!t{0tu;QWPd^)0@rDZe%97&|5^)}+hwS?@+A?Ae%q_q9&c z`RE~wbNz$%!K=&rcaDtA`u@^%T7E?TTZTuL+-uRj@BE(~LlouZJhNucoO)Tz>v($K z2ls=f=ZE!6nIqoxLSVbj3ej6m`+Pbgw%_B?R;QmPmIK~B7;&TPN2@T+^%EC7Kj6@A zS+}WkFN^Jcl&p8^Qm=@`@7r76R*D(nAa>fiVWa-fyZeq1Pd#V8@S|pSuIvM;ilnl7D&>&5sjdW-ojq{$jtiFh*Pk8A& z_|5}|+<~p@oYl_N4Kz91+N`d@Tk%HQn;!|4?i+b0Gcl@-<=x}b8AsOk-Im>=#hEOf zn-&EI)9?CB+GyK2ZdU^F z9UFY=k!-dH)vj6A`g2|%M=L+sn0L{1dcv25Ev;nTz$I z8hE_T`_+CI6)r0DTJrvC=F73e20Ok_Id5`)Qs;Q}61Y+@0E}_ZXX>CuF3L8%$rQ-KeRr`>7{-4_;rS+C^p^Z}Rq; z^~n$Fb$Xgvr;QpMZQMXKy6s!ThdU&nocTJcx7g{i=RDmv`megvx$m~=8gBy6O-yRJ zK+3pl4-dWZ8>N??IqB2yL+-6_HjWmb(t4X1ZqnGVF!i4AbE?^kL6+VvMb1nL9Jyz& zs@cu2Cq*<|2NW)ytsOJbzC+Y|$;o3)zod8hFgG=>nF%Itlg-xu@^Y7unlS!z*3=fnB;yL{MG0JD_F#jVPh0ZT5&`%CL9FV(KRG><*k zIqTA4fl#mX52+_!9a)@hpe_|LEE`b~w=R!XPwAkZA_CFpBkEYYoQFT!PDGT*R75@L z4Kq^)XC3|`yQfI>D56e`-|O6Y8T@bQ7gW$SSsqbqLJxmvEm_npDqnfbOhhR+40_bR zOM&XlFuD#3ojU=CQ=)=iSh*I|or|ai88TwJAB(nRI_9aL=vCBXkA!6FXvu?ZgWd(m zZdtcGN^6tdx;qZv#>WrKyK-DUXW;;8!}H-Sd-wW4&2E*nu2=7!c@N*&?9A5f41>NU z^X(+A|FJ0ZiDc84&vC{}Rok?VjyjApZZ<{zZRc3MOX}OV9yqukb_M8{cys*TCF*k9 zHyY?)ruyi~En9o-&g*aEu1hC6tUGo1al?=A3meHGDtK$q$5wMUyet}b=wsN9b-<01 zyH%s+@GM?Gvha~pkoeD@hobJv_f2XqAGO#4oQN7w} zo=n|w>z$Q!w%HihqNayCBkJ<8hxrX*P`25`qJ|%uq}pZo&C0oC*BRecIb3|;Xjt*BlZ%8W?IekhZVNiXI z>`kwNx_Dmgdw~+n zstYFiD$H#W^-)xQO-t*rod$#VKHVSnG|}DU;L{D`Ue+Jc#@)k0x@coYQ0DY;MsNR# z@?G!jWHdH(%h*X~XU=SDKgPFiwzus~g|L@Rrb}yEP4tnmNxCd*JtuLe-}hME?K2Dx zwQT*Fb0*RS?H8viYzsc~ajh3v)_ zZto+KV(RVK8KSz+Wvbe>=EG#3Z*@-ezBpl#=bVS(9xYS*^jCAa5%l!R&Z#FKE|{6@ z`*XwNroQ`|Odt7n>b?zirf29nWS>;nF?i6HAM4y6UtCx;GbwT6$lb@zJ#L(U8V)%a z7UTGI-ti`eqHmN`?lXd#SFYKPHS!agf})r#Ly#= z=Kl=6zh1mv)Xcfo3OC*FyF2Why0t+=|J@H$#<=VId#1M>|N8O<`$V^T>pVS`7C5V~ z*(<-?{Kea^(+%%A?`yPvV*bo)vC<*WJ1u;&wBGfF$w!B$&5>HW^GNEsXA2xO#3ls{ zIpuD0^TxhSg?;4nrL*mx9-I2Id`QO?YQ#xwfi*}uQ_6S?#_PyU4HmyTjTLglAU)At$WGE z_~H?b^qqYg79E;>Xy5Zjb7i$mZYms=3=Z74_fW$Az%7qoUl`n6cKPBtuF7uyF{|$> z$$YpuN_I&0gei*^QUCc_ZUA{V&#JQT6N^2 zCcgc!KDTIH?ii^vDtVzPbwdZsZ2j?~n@i@nu?-G)>%Ve!>xj)?o0-&!(b(GgdOs)8 z9pxRgnzX~XBL?cFu& zqs6Xc?zi>xYz!AI>OXy3l=HUbi#v8u8|Rzgu9nn4V)Uk&`S*1%_K%;qMca9T@rR#- z?B>sjvRl{rnyZuHv&is6(_V<%ty+20wt=N!EKI;nq_!^^#u7%-qGUr8b+JL9bm$Afzia9a&!MVe8}I z>EP<3=`!6F3uXAFbBja=HLZL3;G=Ov?qqA$QEfkQ_}oXcbH$YYnI=BUbWPu!ocE2# znz>AB9Y1sLuKQE2T~7+>(LC?$ZndGo$zcmpCl?lWZr$OAhWm)U3!4Ubiy8jBAGrI1 zkF9Q&+t_KVH}vhj^7V}gTJLtY9;f7S)u>*Exs=}K>r3?mruuFQNceJf`7XTyYXiQ1 zPaGTCRK6e@=?6bsD66yix};6G`GdRGkLNF6YuCI%%GYI+mtXV}x!AHxvZaG#^8PRH znv`}I#$LX4r3)+!)`D-xH>K)}{8~X^<>rR3R%&e>k>0DRUvuz*oWJt7-o()Lu58oU zt9GKP&koj^px(=7lBr4f{Htr5-?bZlsHtOQr#k~=etz9QLV8|EU+EP^vE$__nzWPFQ$cwMtMMn))dUZkCqSubaU7EQkJ06X_BD>J%(OSp6uMI6NjOTo9 z-ceEFZBN5@vqnZ*$LAWj-8#Pgl-6{oqw--sEfV`L?Q<{T%P#6|j@99Diyq&f+gfVC zSu@!*ShJ0`tUb2gH0WKQJFy$H?5B+xzp#I><(2%Vm+h=WtsjQP582%HU?1%s#_z63 z?vCCx^rB7jn0d;luO0}oY`;l9V!w))SjXhfYt8K=<+Viy?4lA**`4(|BlB>=>R)eXiig9JeP45A)<2l=u%M|y5oUet-9I5tnQO;*2hY zcmMW5t+VdYujUtL8|l5JW$o%=%iUGQ50LN}L;Yj2O|u^A7Btab)yYyMw!gLXoH1=R7fc({ zzDvTpd8c++-d%ch&z=rWO43)da%X>g{WVBetwXH1<5s=)^3oYCmQXuoS6n~W)!#zr zxQIkYkCh+q*|&|686l^2=~8pU6UQbjpJ*JcDly}LvkL@;cu`BFjPsU$xRP5RN>1u^_>oShN zkX$@9cJv*C@l7;(xKBKyxwFsiFQ?A5?tgB(ao&vUmoB|H_oisu>>0hiV`Hh9o+}m@ zPHXb=-mvOWqjj|B{K1FQB_-}$$cuXLFfe87*0>w*uDR&$%(Ch7^xfFgqFodYEKc7v=G&>I zCzq|izrb>SMh7*gqXVo@J+c2_5fN}5bvOAbQsmn4L}5|Lwr1Vyir5MR5YP2}dj`wtOu(9mSUAS`EryN)?iKK|!F>a`AS*A>=lF6;&FrZEtRa1%TH!zn zHUbzwxJ1&$U}htDah-en%$n4gqK=qTR4YbupcKyH9QYSkd|857+_)0+@c<+p4p-H` zL>8~wGqTXJ@^|(2D!~%()Zj8Nuk4&Zz$b!#Rj$mOM^qu_ypF=;JY1-pWlFG7&`Fq_ z2gwSRbxESdK$0q^V`LR_mXH!A=b=L7T#^pSuEOLzsO&qbZ0Ts-O_;2Qlv!zqwNtvb z0%^{I`@1C39lJAf*0u8Vvh^q-(Y#Ytsq;)}M$TnQbX9T==^;$c!^&jiyx0`yHSn~u zY)Vl;EaNx7XDK<;4+`D|@ET9>dGXXobA}V-HybRHlKI*9s~|u6-Vn@h&6O6`qo7YP z9G+hwQ;c6r+4A$FpFD!uy^(jmpa<1chw7EgE@Ei;*~wuF1+xoH9d#5zcB;(ey_7&c8NOWXGcFl1hWg(ydiS~h9$m%GAmiT7w}d2Ul&_S z?PzHh%x+8jywG`&-B$_0>@yp(P?@q*)ePv9-Xu>muhs(R6byN0vh>}l%Ub!VaLna z%ih-678dryUxpADZw=NxBE|CiV2Z*hX|~wA@N#grwQ;Z-=m2|ULJn>&cD$=A&OvZ< zvErM4>Du3Nptl+m%t3HJg5n(3ZZ30o0zr}m2Xz^l+~HND#1OAwa=~%M;^dRF`An7^ zWfaUnaO|!)gVFbR8I%~w6HG2RhE$yV(|ulY!4W0F97>MK6sM=CrwjE=CneVn3KJ^iPcXLi@;tW7$t?D@YGtwOCT!JX*l+S zaX@|Xyq?gR5|PDz+?jx9Eu}z-)Bc5<71Ce(T@z8D>eK%2`g0caymC)OR78YMFG24e zLg5W1Xg?&Sf1N2Y+K=B2LWFKE*Av93mb9PFj85NZ z6wV8tv~+qg>PHavlb-_hljm2szizzhjz$VpK?%PYRahc^L#jx?k4pGEQ&Pb=f6Ong ze?zJ(?I-1linJVp!!dui1Ft8L^A)+q8V)YDo^lmMD>HnczPy&6)45o~p52o`gKgs5jUP6wt^8SiGQ5TIJbszjMJuo ze*+*Duo18ckOoKxki5%sck<)x7KrcSl?rNYW0?#cg3hyjj*5CXQCpA4)=g_3h%${5EW@i zr-$)bDmp9jIoK1l{X)uXNJ-N67#0isYe*^3;lz*aH=IAt@5n2h-?u5m-?Yxx9Z<)S z*iU}ge#Cxq4(vk`u7Kloriy4k?zi!-57B;7AF$`-aawH8NNov&>w7?#2VVNunR-V1 z+k%hB(d!c7V$^#9|0e}f!>i9j zIz9|t(?2*z^H2Qz)0DD-tFNsS@m1cf#`}j?m1)*PDpLys{qd?gI{l@T74=j!l~wr` zm@t+XuM}*5S-W8ls$_mqZ0#?$_2-es%KT!bzlD5$m)o{%><6~xv*o{f?Js4zI!elw zx&>;z{VH?63dXJN=LcK;%T|5}A4LBWebSjKUH_Uw0{nbu>R+jCW$Ryeh^vratbeh& zA*HzaJ<-3UJYn@O&Ts3xV*QK#Z1gV-*q6}1q&`gj8@(&EO#O@ZV69I5OUf5k|C06~ z`WKHuG4*dd@Z%rRzr@cwOM(7%fH(fws;Szq`2NvS)H5|U(Hv;)B5!1C?cnAB@5?>0 zuiPSd#e@E|_i*s^0t2>^8kDC$>1(Kx0%ff~>7uJ%e?B=?syk`1iuG63+J@v`kz1SP zvz4C``jgP~+t8e{fu^2`s!o1n~54ljHzi|HoKmW?oU+`+2 z4rl7GBb&?CU+NIwty9hm(tjKP{;8=QBZ&SYte{v)YR3H`OX=K7DMd|~w$X%C{m1pALzAL1X;U&PNlOHsx0%X<9X!USfD*$o;o z$ckhxgiELCFJ)`A^H<0SJL{i zEd5Ew`7=JxlJpM|`6IOrXo{GWi;{G4@0Il19Ord6hVNYh_R)x|~1)7Q#{?)&MQTUH_itUqnN zaKTkmL9F#B%lh+3t6JR&O*QcREw^oJvwXJlQ@#3A)kIMb-vUacX@qiXlRu#FYbi_7ePlJPpG{tV76?tcpEPdvW)=u64*Q%b3L{FIa@tp23O zW9j#yy#6QlWBpuJ{V6zpO6tSZpTWCpZv2##FRcC~a|=py@#k~#`38KK#K98<$uZMy z3Flh@S_9eu+5*}E+5?#J1dqG%!=(k{^%n4xbOYc#o>wRf7zB_53WuSRjANXa9{BYE1^`2V5x^K=0>I&Be3w}+Ikx17O<}~D z#y_@UoU>ybb{8Z*w z{QQI2XG%uKTECBfTYFhKTG?C4m71*y9R@S-U8Qmd{pxO4vVyrr*cEO%$~iH55x1VIkiC zl8k?QH$W$_6M22Q&#^SufxOk3Df>iNGsd^(15rG-HOM* z2ZI06`r`3#Ql7B(2hOi)v*Ph@I{&6sAOCIz`SI+ns?DFm??Z8VF{*avPm%T@`UhW6 zWq!r-tE^{YYHXzVyZ%u$c5tyPD^DEOUrN!*$-xsQjl%#oyu=ko?~wek{;~3eOse<* zXRCkM)}JQl*YqW2eO+>4m2fM5{#UJSgsnntmd}>|68eYG^qc-sG}hF^Z^}yl)#mk= zUL)bpvb}%V>L0f4N3N9UAJYFSOaJtN1cLf!bvgP+72+GTE7m{wc^RBitba&(!s;KK zU$k_w{=t6yei!OgrT4GRAw9mH&J<7okoqwDzgu^d-Tx)=t4seB=O^6!UD6&z|CC%u z3Kv$vuULLrzkD)=Wk{fk%w4@*?C4ji+D68zmeWUAmsf?-6P1^uWEf9>LCJ%vrodS1 zuTn3%WF5=%;jS0doz3zmA?)|sY1{Iyn;BN|^Z)<1{%qy9g#KiInHrjU_!iVR)l)CN z1=U6wDPi219DF2EuW!O5v%46to*l$MIp8+q874E~@I(m|2(0W=1 zI#Mop8MI#c%b;of&o8(t764oQ&$j+nr0y&%fEsvym)o|rS$-kBJHQLR@%rC+fG|KD zpuF|Jkq{mQ!0UgP0Ac`30m}ff0KE1Wuisq`!0Ue#0Eqy+{&yuH8L$el8i3dTt_7?E ztOt`roqv{4V7jxaR>E02cvd{V(Q^i5n1x*ZzFzjp!IfO~-Q z*8e_*aJ>FE7w{bL0`L;>3h)|$*Z;l+;Pt=n0UrQ({qH9LUjO?A@D+g9|9%7H1HJ>w zTmQ@U{;OX5OA&U1P_|Gss?;N}ChYfe?_Xh`)uqL&ZT-R4eqt*>gcD*v^?(!DJ}S$8 z8qW_G)_(GY_{{kO7T}M*TRi`clqanHg!9Aet%&`E{cPqB2#(*A`Y`P$gL2kCSNHfm zDPP$61Ef8O{e;JZD)XyG`8RN|wz6@B*>pa5BN#BdM3Ku;NfLdikC=A*UH1| zEuM+@E3J?(0kHjK>qeJc74wPx`enN4s@I>?orU>S6VKl&wQU(q{@dvqu)qGb`m>ea z5dK_{x!}%Y%nO;%IL7wRV(^CpA^?$qC_pq|2>^#L<-5#zC*(MRAC|<3vxwlgG(b8a1CR;W48Y-A`7SAk>F$BBz5MWhz}?S?dx(F01l*&H^CuX`IIq*- zKLa=mI0rZnxB$2aV3s9#e3Ku3TOi&&0Y6EHx022QJOw-h{}8H({RbOzmuvsc;DJG;3ReSz<# z^Y*_XmMe+i!-qei8TgFOMr;e?iI4n*%c+&t0Dm(7rCm>D&eitwkFEY^D}RJ5qW{VM zX=S}Xfe&N+uK&xKf4T_bKbk#n51D^L)=QH9GbvA4{g3lg@W%P^=AU4{ffN27K-K1- z2);id^h_8llw)Zb<{loJ9Aruh( z(*{o9{$*MEhs?KU_CL#;|ELOiG1uSW^$*PTcceUF^$*Su?>9&E5BB5r5Y?rBNPU?4 z=km^)(?6tqVf7Db52AmX03Vh470WN{$=BLWuKrd|PF8Y*D^UR*I!%8m?WZ;lGENQ- zyir_LRbe-w!~IW3UcpsSU#!P(+18&;-3iSV>yLl8ZELf9w)~gSU+ihp(KlDr(NV0_ zEg*#cV_z}eEmFCAlgL+jZf!q5*y>NV@`F z{MH=&(T9uYzllI$q5v^K9Y9?Go*y92cbRhy$Z-=0ljMgt1GhONZY%zA8*tk)&UauO z<9xb+UkcC_&<)TXAPwjNAmxM;3sKE!ue5v(SR`kdB9k}H~@~L$ahJ6 zrmMjZ(_+NYT69JO|ID9hSWtK&bZTVq#j5ss+$4-oM zu8d=x))V|*0B?W~z!%^L@CT5*OLK|532Q%LdE(8drZc^rvn=AP7`*t#ZPs$Tk|Kt3c9xk5$hW&VbD%7c3 z){m0bNI{~~8c4{tZCGBVZ1Vg2d( zmkzxBgN?O+Dg83iFi&Is%`2dG^f%l3>(Uwg+xtIMt!yT{{8pLXUl&H{Yk3% z+x|tm+D4`Zie+(7o7Z1forFEl_Wot7f7rGkxlUpAPhUtNsDH{Ef4~zKc>CS)=8wsM z|8iRK{zc?@FRcE-`7y`uX@9G#kKec8Uk~YjlKL?9PkH^%+SWg$J&68k2-j1YU$OkM z9wXGXxAJ!La-J?Xq!Ja-P&73#(N)xgZC7+1tnICAop_7)R8)m~2~F!SUcpsTU~K1) zv8}%|zwT^0pcOwq|J}B&&GOmuUqXMer-@e`wMyLrHPQd8(!D9nZCu;W54QS~t^5#< zi2m#dC$N4jtN%vE3z_5hC^dGon8`!HG)i&vMo;VSOj~{k5i9#qYmKd6m(hg5O`m??a)^RT}>k zeE&)6!_=SUjel0R{v_pBRews51{KmRmVX#LQc_h?{eA!T8FsetDeW1yrRJ#43v&S- zsKx()nv#%RM>;>O|40ED z?h)e{r+o_kXMkM5a{!){ieId}0^smBe3z8NbU#Db7k+pixZfCYfAEhBz%68)r|R%- zsfz87s@T6nT?DZkph{!*$_sZ(s9-)!v< zw(UnQme?O;Jh!a=JDz_Iw~)~9Uo{{ubN_z){TPFF#pBWZc+MrG(8%uQ`xe?@ImQ8?TCm$m+( zZ{4cj|K$3J{^<%Quzo2^|McdEGsln1TR)`&@eNuRe?O)l_A~SkDNk7agY%PZUaWuU z{Nej(Q0Hpt|C0JJ^-oRqe@Xem>L1b`ME{5bKb83v%P;GfPwG}4RyHnH@Fh(}7Z)oj zV=E6=ColXq)ksCd)KYHR^wR28exlM+lst#^mz5o_Qt^*^<>?ESkILR>eC;{7|w zep_VzFDXx0{g3mDo?N_t2lnIrL8_|%1^b_*KEmq%>h6D%@`cs^q&wm`xeW3`(t*8lA=)9$2{F%3C(1W+eO!Vp{+63a*O!XWf5gTYoDSbti<@ z!1KG@wyn+b+45h#`d3j+(bP;;ahOVFZh@Mx-^y)2B1ctmYy0`ZR)4aUAHo^YpHgt5 zJpEbP{HyZzk1p-~arF7(_s66>VfAP6d@jcN+1J(g{+QHbh_j!eSwv2 z|Cw$5O?Vlw`T}bW=&w>Q6I(guwXLwN_$SxDRAMS2ztyY1)fBZ9jqnE~OpFwj&41m3 z{OvDQ%a|7SC-X0?jFlCS?emX0hoBD32dE3E2M`C;2S@-K0C2oUe3zMq9Jhe5mi+M6 z;I?7JZO=dM2yQ3Fc`3#*&PN*jJpercy#T!deE@v{q@2=RIez#Mfp{YX{3PvII6n@c z08j)d0h9qM01~G(SBD?2ClJp_z)#Xnfb-@63&2FcB!DGgG62V!%6Cb8rfUab_WbY} z;5stmy6}(Pz;$Pw_hKC5y!^oL4+sFv1Ox(R0cHb8S(@<0Jv|fSf$*NF)JH)@&q((6 zUnxqr63-uUUl99`ygx4M{R!!>GsjPkY%YKNWU6(^@smfe-w7E%A>|2c|B>+$^8TKT z&s5j=38@d${;SFTPf7X0+JB@yi2VnmS*ah}=O07S@G9M z$nZhKORHF^i7Fw#*#5JDb#GAe(5eieu(ki#*8f-C|G(d#lzN#JwQXtbUD~-Cus{B_ z`j?t`w!oO{0&sfxCLus{H9czs!M)KlPO`()%Np` zt^O~S*h(O#L6d>;HHESwa1e$L=cg zE0%wl@uX~FVD$U?0iS8!0ai|qR;6aE#0%>$W#(jMmd}>|68e+S^xOP#GbK|CMICL$(wV5u>o2`V!k=Y(|FYFT zY}=1qDbYXe;RJq$mDT?w^Oc$X&+@*%h39u)mMWgVhv$zo_dh4)3ETg~`F&u_-@|@9 zpS-&IpQJt|^iMhacUJfNds4oz{ZG;!r2i=jd{pLFEWdin#-*=c^O|O5ZSP}+-~9ak zQ{siW`oJb$CZ0aFUZm@(q%M>SqTe6z3#b+S!?ON_oT}8Fuvzi*uWD^W@~_CP&GOmG zPYL})X!=e6m?$YKYnUk-mCi(MUVrH|68^4Pp&`P_AjA7**BB6q6*wcsz&B`@RN57@&`XvWR?Gm{Fil2 z!k(|~=O0`B&sP2jPelKd{!dx`&l!*a+Xu}4XK*?1Kf@sIhi%3CN8|B2{5=u!{*#m^ ztp2C-OD*0%8vCO+R(=2I=8zs=581zy)Q746%UeIznx9^bs-FGFNcqC*f6^Xs4fOhD zs7|GR7YGYNT>RoYJP3ZKEsX4UUtT;f(qo#Da zM%3xZL2Fu3QbMLGjyBD^m5C(PkjhO>$!$jAr&;BG$;L0|Hl!pd|A6tDb8Naciz(dosh+qB!1x+F3qUjm-y!v0#!OKK|t5>VA& zJ-XbwRZUJcIJRPlI8}$rnAQl1Q*Egk&re87P@l&ftT6#{t@KUG)V7e`4gNVnI%_zG>);9@YH-F1 z!aXTGMyv#9?ckg@gt$N&CrX*l(}O-PPNfN@;5|sKATMhO!!^SB;F7%Q{A{UV5ROy3 zP(BdD14>|~Cs%C(AvhODC>f{5wWjF0U>@-GVlH%P7w3SlWIX>maqhULUi1@11wwFq zYx=JZ%_FluT9B_FB?GK^!e7idlN}j4Pdg~V1!@vNm(62H29CWUPkTs*%k!YGn4+H= zxJ`{9FDu{!yO;|HnhhB5VO<_>Us6X0D9M>_Yh0!=-A=fLY@p59UKf@(io*MuW0~W% zhzp!^fU7Rayr48-c^d=iN|zffsZLNw+$w_7Yz$|4_ri!OrB{WT^6nR9TJk*U`c8*B zGo_m+f4F=zMt?@#uWTc5Eoy2 zX?c%_SXiR0==;wWy~Lfo$ir`?X!0ov`vn-dQD8PCne&v_GY zvE4F{cDqu+v_9x2v_7jZ#natK;JV?bW{_ju@O;wcW(TsV;3?-X)(I1Xiox#){g+bf zvi|kpjR6Cc4$bs`yeZOTNBy|&-7W3q)RRngV$bPC4sH?kN%70vmWnC!-ep@jHbjmm z$0^8OIH?|%|Mq2$g=oK^prLV(%`dC3NL4eO)ONH9&_Z>92cWJ5uYk(_h4j1%RyH9& zJ}%!H%$>`URm*^N`A~aN0H(PPpe~>uKpapXAOUCqXb5NoXbflqkOVXZGy^mTv;edO zv;wpSv;njQv;(vUbO3Y&bOLk+bOA^Kx&pcZx&x#EJpercy#T!deE@v{{Q&&|GJpYq zfdE;+Ab=cTFklE^C}0?1IA8=|Bw!R^G++!s9xxU#4xj)~1SkQN0V)7hfEqv@fbSJe zfEGX-paaka=mGQr1^`2V5x^K=0x$)b0mcI+0L%dvfQbNn&shQ{1Ev6`0;~Yj0M-B- zfGuD;zz$#!Z~)8zI0Bpi&HxvHE5Hrl4)6eY0=xj;03U!azz^UL2ms6k1OjFOW&?r% z!GI9J9Kc+_JU}QQ3@{(C0I(3S2(TCs4u}9m0-^xXfF*z!z*4|6KrA2*5D!=mSOG`? zBm$BED*?%XRe;riHGs8%b%6DN6u<^RDqtgE6Ce$c4#)sx0yYD-0JZ|Q0k#8n0Coa) z0d@oS0QLg*0saB(2OIz#1RMe!1{?t#1snq$2b=($1e^k70Zs$X0L}u=0nP(104@S9 z0WJfs0ImYA0j>jX0B!a4Zg}50C&f05k+N0yGAY@BcQ1WAgpq7I54WfWQCS8qfyN7SImR9?$`RbxS8e zXFz%1|LqCky#T!deE@v{{Q&&|GJpYqfdE;+Ab=cTFklE^C}0?1IA8=|Bw!R^G++!s z9zeeTs{qIN`@c#6Wq=Am6`%%C2WS8^0a^fUfDS+xpa;+g7yt|b`1`-c026>Izzi@R zfOV)jzydH4FbQA@z~BF!0+T17HTg5#R)H2DkuR0d4?y zfCs=6-~}k{`@aEjekLFgFbgmn5CjMYgaGCM<^tvcLIGib`G5t0g@8qX#ei@?1RxR+ z1&9VL0mJ~70+s<{0datMz;eI}Kms5UkOWu>NCvC|tOl$BtOcwCtOuk3HULrq8v&aD zX@GP<1|So#8L$Pg6|fDk9k2ti6R-=g8?Xnk7qAcT4`4sw0N^0t5a2N22;eB-7~nYI z1mGm#6d((58gK@17H|%59)QOm3mLcq=dJ>-0j>jX0B!5X^z& zfRh1E1~?huWPp=_vSlFuM?vuOw_k%FJpUN{Ah&efhx1Qge+kaZ|H_T>pMUi}FZgFcA;+Hpf6ROH2k?`NWw8P-Uw_C8E-WnKxGaZDCa)D7EAYd? z;eH$g90ME!90ME!90O%BaO2@yG=9!r)Y5o0U=?a*n1ovLfsb1mtwfUg$w<|E2ReBz zx2$ab+VfjZ+(&Zun^05zmB3ZX3nsT*~>2nJWF#Hy*x=q%77VN--AET+#dy z4woSjl{gwx7aT+|R$qE1+*z7|2f3e+n(q$a3*->Xo$@k2F6~G*lD1q2_FWumIUxh}c0U8$T|+XyS5TMf2T()3 z)u^so9GbT1AbQ5x%;hrt@cAdC6|f7{0lQd2cNNIuFUqSnagCb zIDpv9qQF-ZqZFPj0*~5>g-ABwCX&!jM)jco!P(5koK?dSXERp=iCh*O0~`Y!0~`bY zeFm5|b2HO4G;GcTq`BfJ*eOM5%z|9h)^Z!nJK${QvLvC{W{yLhZ2m#xBHth_u<p7dbEb;`-6PsBKY-Y^cusIKDS=5OCjt0Qky@d8k&Sn*d2L5CQIGdSW>v1+SJN}rdIh&cuMvWbFHgk{^ernc4BjOwHNMOg3uln6sH{jB2hRjscDVjscE=KbZl}W@guVoXyORKW1vq zW@fTcW5=A$Tw_#o1#t{;3~&r^4E)Iqa5gi$*5hnucKk6@b2c-RjT$@VY~~uHnk$H7 zfMbATfMeiKW`MJq*|i>LGqdB5nVPeinQYY9F=sQ^7}Z=s90ME!90ME!e=-A{&CIU# zIGdRrf6UaJ&CFz@#*R6gxyGpG3gQ^x7~mM-82FPJ;B01gt;gBS?D%7*=4@sr8#Q*! z*~~RYHCGVF0LK8w0LQ?e%m8OIvui!hW@g79Gc{*3Guf!IW6ox-F{-(OI0iTdI0iTd z{$vI?o0(nfaW*qM{+Ovbo0-W*jU96~bB$5W6~r;XF~BjvG4Lldz}d{~T931t+409r z&DqRMHfrpcvzcp*YOWxT0geHV0giz`nE}pbX4iV0&CHHJW@^r6X0lOZ$DGYvV^nhm zaSU(_a13w^{K*V(HZ!}{<7{Sj{4rB=HZzlr8aw7}<{G1#D~Mx&V}N6TW8hC_fU}v| zwH{|Pv*VAMnzNaiY}D8>XEWCr)m%Xw0~`Y!0~`Z?G6S5=%&zq~o0%Pd%+#FC%w(g+ zj%(CrE-EZQ-#+J}Pp@yFx6iWB%SZdsiwApA&h0dmb8{Vfe4U3UH`bwNw=?LlR}km@ zi?is{n;Udmgo&5b?q9c= z3k!ar&+oF)i~D=g!^;Wi_Q@c0^`I*{zk3=wyWJd}-DZliGBweu3>9=LT^XH9!>$UP z)274DZJ&TH?zKTz_Pd~4CxXz!D@o|(!~N(BpN~P;4ts(9J06`(Q$<-|51-CZ zLuWG8(b>%!=-gIKbYYt|y0Bdbod@^aRxSRq79DnWvnD#7sRrrPXnXo(x+*#cw)VBd zp6K5BXq0<*3q1y1P>^3^q;Umt3~&r^3~&tmeGFWG_#Wv5?na`jaj2PT8X6jMA89QA zfwU3|(dhZlP+QAwh*DgJMmS}nlhkJ{0e)AJ zg!W2QPc07FM;}G+zx?>S$*R7q7usenDk?&Sg@wPNpr8o-{E1LOA%bz=01M>>LC~O;K~a0@%2?y@beq`S%A=wpGBwuDpgvY zxpN#ZoD6U>z{vn71Lev<5h%4HP$mcz9KvoPy7AyO(w(^ziK>9jY*voV?3jU0UVTQV z!RhGqkXKPDI<(w6{K4_@TudH+m^&UeAH7?y&D;cRKWqcqEIx!@zWv1KkDvZ8<4;g7 ze(_1mWFdO|;uF#i*j0|roXoSCqmH0=pS}W@Fs~J-#XN#+3+B)H%jN{zzxp$8_}js8&T@UG_)Z#9ga7leLIuUm19xp`au_ZUIm_CaR$bS@%Zt% zEn094w(eG4ba@GoH(F?VuyNd~`ATXGb#BDHWxpra>Jy z(e=Z1AdC!b1f79(2*yUxBbzfep~Z12XvnlA-Z(SZ%)^-D%nNwq z%pzb<_b^XHvm@7`v@{;q8z6m3>ZZR+AEmxm(y;)WK*u*m=w8aprLX z+2+=x@xgV%{dvZUB3Zs%jBiy*={_!#4;|-z3{ijNli^f>({SGSFT)v zegVjNc-I2442MYAFL(3PBM_UuL(cu)BkBn_)uxHQV z@n9GmKAEnI{#kE~Hm#V15~8Q0i1{vPUWg}}73hlsXZj=mfB@v}8;HDoX7S*S-Py>; zcNPkOFdS$0EMF8F;)NE6xuS%~=_noY+PBUaok-WC%Qy#P*Jq*3Q!w`f*I|2-4vJqm z9?kT%M@}woP)|4H=H|)=KIXu2z{vn71Dp(SGElkl;i!SeGE`TcXEO`V&1hn{4%Nl;UbL1VDZTkL z=iLkz!f_ZHXAy|(o!k*_oBuL*g4gEZ4z?E9TV~UJkjlgWq&g`8X-)P=<0j5RZS|sQ zSuD+Fme5H8E@P3D{$iwR8Hh9?jmpHCkbWi_Z|jX*p^b1m36{tCi#c(2c1Ct~c4+(d z?ew@jj5P~wGvB;<6GcQsATMuk)3dVTPZPA3e6EODzkNs}d zK}XZ{P-fyp6uZ~~Etu<$LS}o@X}o>G9`>7seEnx4KY%}t0NOsr_A|DVG5q~8cyWCF z0+BDI!D;b1oYz9gGdA2F%CJDkHtEBB4&J;Eo~s4(L3GgeWHS^V<_Ky1k*_Z<3+D-T zItPveP6jv`;ADW4fih$uAi$s2R}&mVP$#3Mh*DhzNJb*6iD2)oKy_4>qGl$kXh`rq zq_KiGpLtZ+Q`E*{3)nDV6RO1{5w%1_sjZ~bN@~X;RjV-M;XM<^f&5TF8Rh;LbQ9L! zGl4%hxK`C^^HCF><-o&gnhR021mG_o<_yH5j??y_vEjw@nFsh?Lyh%U)BM!|jwzZy z%==2z*=PxxFk=q1i9gr}f0qu&*Nf$4vP%%^VH|}dwc}B9UFcWnEJF=6<3SdeA>7v> zbL;VZW*J|Y&#VPpgU#F!;|b>Pw!_iZ>XI4(FD;AG&xC}Ow7{nqm%_LM$BY~b{TVHbp>gsS9DMY=4KF3db4dCEe zcj}DhTd8mzkETYs`A~AK~ z2V}7>^wF9cr=sC=9`d-vYXD(AWkZ;of!6@m(^x^vp@@1i-TyOp1X;xWn!l9GinwNm z`}z4H4-bzj*~~X?-bUe(OVI3@u4sMiRIrV)eX7N?PhlR$ahQX#ImsL?T{HvDne78( zyVzF#cWqQW=8Vhm1v?s#J;%bl=xs3X`D6yHC#2_V@YW5U$TWoc(^gO~FS=eh9g`RC z`0soUaqZ5vJ0}C243sAW*j5Re6@YBrgHgZnQDDO*B0L5vp`D1NolYR-C7+Nc*nAqW z_k&v8H`LGb0&1+c3g+a(_@721>R_-G8QagL$6fy#dzsNEz;-U?*BETQ_J+&oK1W@( zI{2n)Q7$X=2#r;>i**+(R8=j2y=($X_nVk|Mf6@ z{rDY)xl;&?yTkk-bv$Oj9QttasNLipNPh84dJhuZ2N^#15o$3$jn{vJehTjIbvKDY zQ(Z!!?*ZeUe>s=J%1TvjW<2%z#?8AZA#NT@TQMHyLFm$J@aVB+uuTtbG(?HfHYgbE zRv#Gq^#OaiChbx@_Ka<3JnoF`;#D!$=H*$xsc@}?c-PB<&>R^a%y+l+W_Cf0~bvGIb^I0%=D$Bm2 zzMkj7mQDftE&=T36-d@R0@-^IdzriUFqhcYodvRF=^TQjjAOuN#{G-ssJYojG&m?5 z`ffjwTKqSdn{gR6F<3*-BdP~|w_c`8&@@+UFLQm5%G`%+Z00-Hj-!84ZD3p(_Q3#K z6tD3+2lJM9uNjYG7S4e8PGGl!t&Ha=SEf$Y8JCPZ<2gEbynD|&GkShCZ@vZ|6W2jo zk}Oadwwv)7crDhoI` zh6c^LgIZ2Vhy5Vp;GKB_l7ewSbH_O_mjK(#fA{z(mP?+k7C_HQ#$%+IBQY3@Z!>8d zJrB3H`&raTFB$eDiAVKezQG{#a5Mw#<=|P^#{2i$^-sKKh}}HdH5kT@m;SPwTUum- z9Nq?d`3l|lz_v7=3)9Oq8ri`7qS+jmm9|Z*YBT45d5P|vUW6|0Fo3P`xsM=YIx)-Qnal8x5YwvztX>&$Pz+Yv{FWb@9AW zm{ZUV-hoeY;@ivgI;-lf$Di7+cy2hJk313P({?e&b~B8}gH4C~9SwC>(sKs4)L=<67mhv)0DZu`6S__ehwIA~FbVJ^N^78r{ z!@PhKFAq0lZ0(QQ16P`-Gm{SP$RlGv$AKPYs>lZh-b@xS@mA#0~xOLSo2Bv1~>km;7QnHW7RTyv}8#%)O-2=Ro(yJ zxa8{d|0Ua8dvNW+$w2MM0Ilnm#-Qb~F=#>ba-{3N1~t%50-HGj4Ygj4{1+sm<#9_< zJcQ%8OPAJ8J^vr&gU3eT10?E%<2Xk9sd>O{>Rh-wNdEv`}%ca2g|EG;s+g!%Q#i4}@ z7yjCBQ`m84__j$f{=SJI@OJ{=KRtx5?3)bVDN#iy($vsN!2j5L&*-SKENgJq%=*@v zAM?3sSN(nMYjv;gE|b$;)!F5%(z{BZl^&7=5)bm;d*lruA@32A5OThOxYLb*Vr13YxM%!&qNF=H?cj_pe$mt-`9Jj(1%n`|5lDnsv(0t<7L zEe|2%?e_X$83;KESlS{t|S#Hbm-ZCgCD1gv43qQ;o#mrZ( zTyeZ~=@RtE<;$0`wgzaGZRjj9U~G_=sFQsKwdYXmE)Y@QqP9`F;KXrB5jt_tD`0(4Z*_O?A8`y3GTiph5?FwX*GZ;~5 zaryE^>Ylh?du?0p50bl(k&xBpOBc~En}S+9&k1-qqupD$uTaIp{q8KxKdzCV&;?=QIozC zT}_#g$rKoq$#31i{@Ew^yNqR)$&{=^I_vT|YLZ{1&iQ4o1ztyga}37E$62SRuUDN?J}g0CCY5qbD#kfK zk8R8EA?3HeT?+ZBC`+Y~<=D0?*URS4?=oWCsi`SsXJ^ zD-%(D{u9)a$52cDZ(aI3Xf8j=YaP;Y>wf)nPse{z{+8A@G?jQU-uIi-pObGQj`T0k zP;;Kwx+sU%8?tyh>h!d}i|ul6x3BFsu-yi}3vHm4^QSnz3w8N6>d@M{ExT_+?tjdA zwzaikU|;|#DJc>!L)iLll$)`zu;8drD4aXW`pt3 zE+|!6=|0{4;+d!IU>#K&$cCHIT3~QPhyIGh)$XkFrJi6!y8cbnOR1dX`g;4=mccjI z29!$WQ`l#pwlQYAyx+w5xt+&$JKJsp+il=c+W>XNAoi7FVm~aOd1-0MQLR=(t=3Ri zJ%i!Sb7;(B{Ar1kLH}%-A7QXF1FET6Uf1wGaqrW6OigK77cB-_6HuT2fyB{}d}(Cw zz-UiC>!@Y@$gkR>I;zwvDed{$B`nXcVrhP5``DJjmbL+1J6pxf^ej~B$t`Q!Th(W_ z(|vl!+wFI^{qDBgz;+vW(%OJVqru9`3JMDgADWx7xVY#zIjO=Vb;uL4esq*OpyurJ zl8(7H^)+-=d17LG2$Sk*2yFgcI8~eEzB~PREBfblnoq_U zFXmXmH&m&%W*q)5zh@ygA;0f(9lx!*iT1eNF1LP+5PPEfF<>j+wMd)#Vmyl93<)!< z#5!meBfZ6F%H2c!_#$elXKu>bjgg)LsHtO~{0@y>D%MxUHNa3;HX5@(CpUxkfb z{SO4B*kWmJbsL9l!CH7L#`QneG=&bRudfe+b2u?EAz_q1R#`l3y#=OgZ*NCWPmk2k zx7Qq-hwlW=621bOnwlhA#qD*;=E?TXb}nQq#(>t=RtWsO+3k2UFtbWMgZ`#y`jL1; z$ID259-WmgP<+R9%=&kuQcXi4A3F{!K+&KvA#W`e4+hy)E&YYw26BtLnJK zQBjervK9Oc@$QA+lM7innAXhDf1>c`xqWQ54A!n*!KKTWaPji0bgZqd>imB)e$Qs- z^~9$~S#-7cpdh~p)6?Yhe~0#rzUgseJHM@&C)dkWVCLG|TFDQT7%R82$;M&D*~oL-_dMMD&|_x(x>?xyJz1EUHh{GK8|fo2 zBX6I?%MiYcn{vOBxEgA~W8Na2>$lpL1V4kAd8DUM;-FL~zreaPt~R+TV}mvKkH{nWH}hL}V5`@PQ9 z_gQ1;F>^*nhP3DKbfB)MtCZ9zBcf*rzdHN@etGbF_)i`$ANvzTNBs)RiY#6gQ6K+! zK8*E=#>Pg;ug>FOX3dmJ(o<`QyM+&(sVUk)Q1_zb_@Lq#sy|opT*GTKGg=9wPmzzL zl=_4cQ>sb!AwH{}hUh2yXV#A~YTl#eJ)*3F%QQuOjy|7Bu34qDsV^7T)hvg|e~SJ< zrn#Rt#Xc(175Ci!jEa6k#4|He-jW_b*qJadjfQ<))PorE<~eP3MLo2L}`|rMy(U|IRXsa}{Nx zljDuCTFOK0)3XkD$wQJauT8UFqFiF1Qmf@T^O5orbrt1h{q<#Jk zTY2j5d0ZXKV_{~>LzH8BTGxK`^--~%=<6c>i+3dCFfHD%kT2WCZTH-fj(Gnn&V_o} z-QFJ7rFTP)qL1ihuVPyI_9)48-MMIExAlQ_*VfB_ecA8zeX}sLzMt#cgPQn2-^Vp< zlcHaVvWYf&w{uZ%X$)9*udaXI>i2g(H^qC!bJDwGKbGVt_O~eyDIfM{u}3D#B*p}x z<6WPRUe;=fM+hW{#)b{zfm{})R_BnkSZq!YTF;Y9_@1j5I`1Sk@6SgwpfdCJeB&3Zj90AFY=gT{`!6-o{?mH zBcJIT?OcpYVtf{57H#6TF@X2pb}r@j;Pu~=j+vL1RveX#VboRaqw~8)%q(K#^)*Lv zd=&e*LKY9M=e_RHu)j@7xckx5xL4Zie;0CIf4-6Lf}b%-T-;rEO5$foKB?(Pqnj}h z1=m@Ok+-G8F;?`!N&XjOh?oPVbN(jUpD2S$+{5Fx=hn&ZaWV51atl^2Uc|+Vi;RtV z`6loaC~)P{8m}!foa-`HuUzB#3cs)75;4>A#bqq5F7WySaCKRF?lRL7zpq_hB8 z)vMRBxVngy1NvNzpPPbxqOjnUR+}AQwCAzN929^D)U>HmiYY|kL8P(S=I%X zV+G4=*RXnNSxS42aXnX<&gDx?2Ul@PdVYy9KSkNDLDX}Z^}HmmUtfc`e|dEUYd7z| z%IA6inz;WuuIS6f>sNXI*y0k3+v-u;avsU`+4wx%4IdbM59KNE@%C{(^YxFe9#@%< zkcmiFXsmVhxJVhUP&QZBR``n!bBjEeRz)2aaP{gXEL|oa)s2)we$Ki(_6qr z-gAZbh;&w&&UL;QK8{7kI9;T?*Tj3_=Q4%1v`RmOd}f)yU1mA1F+T4q1J;Y@uJXBu z{cH+m=J+=;p~Qq@LOPVR%~Gk>W5*lcrM{trTt0!Zv2iJ;s7fj9xWvAWI8>0+7rcm> zHmOudeMsL|bbW|pKQY{dQiU|@61)damMU3}j;|h$AF;%;dp!M3KEVmpxb(sk<&AxkmW%SAh5JDnIGyCGkJ(}X`zj^%7K<81RXArrP6CEJZ? z6GBcCB90i_zaBpdY#`Qe(mUh*3g#*O#x&N~S0}$)vXR>9jrrovYwMre$am4V#QgF& zdS-#U6nvjDssD~ieM~*6(AD!s8y98K^)G!J`}(=QyrTa}_p z*d$lz+OvoWsNk5P67P)wru{az#jx@kdm$y;ZRsk)? zN9Ty6*yZvL8at{vCTrjregwPR-bHO&IcBHlrM7r8uN(D!9L#*3V5xWcBK%U5kQ{4_ zrP&Jpa!o>Ty^E{xIF}5kurE=NcL?4EY4AU14|#7a5*h!{JlYH!U z7Er03hj)?}>hmozvos3-+GbdV9>#^#Be=BO`ZZ`KFmTh{B0S?ld5;AyueM0{2y~r4 zu7!8JGinR1fi<~=mm8-SU>_F-ugD!JC^Um}&N+mhx5SDn8x7PMc*X>yB+~{0 zJ_+Agd$g81GBqu_=)2k_B@yWvmbkRqglcjvjzMk6cR5?F19mVh;~r3R-iUblD~!9l+!kS~(TednKx{2`yQ<2_Hi zqpsMMXF6;>%Zev;_8>6I5CcsC{Cx@H-rSLKSe$l4SmI~ME;$aXbe1>AoW-fdG}i!$ z?OiYlF@ovIj}e{pDSG-6k-HlUcD{<_oGpsC(kRIU%?LalA*d9`=hhXJ?63Hjc zP}5k9Sl(Bbl!!TX565wi7t|Byw<%!j6A3HxqX-UmM|4mys?*c3IyZnm)eKIYEyDpL z7uZ=Eq3--C%uVzozH$^+PCiHvvqDv41!Ch%QFAT{m*xjCHaUk=>2)|{;{|J@qlode z!Dvf9W-ra5YCwU=unaV2rf}^dL*;-H(P8OmE=os-VgQ~YIXHaC1`akxC`}H4W~>t` z4gCmlOjC2dR?llu);)^I(`jhVJBPXHVa)Np4#=nAn_P~=)-JF$I)Y?>M@;mTV`gmu z#T{da3Qk2^Q5x?bmEtJr#|be{YGyR38<4{-BpoKEwlFj{!Eq-m^cBTnVNr?v_Hjg? zI*YEd3|v~IzC*r*h_n*qp9z9?xD`_uFCnL)Pr9eK>H^0i#?uw{8^n>?InG6Wt`TwYxd5W@=EleZ1tOJ%- zK`=8hgPD~jJS>b+o*WFdqMvP$`ZC@(H#3F&<`G!<#lyhV5}sy9P;)+%ICu!N)SZpa z&mk_a5oTsSl)oALYz)znAB&p4F}Or!!TzujO3nmue(R);S|iCRvwjF>-cc|zGl!3b z0UB~*Fsm8E(BeE|lB&3Vu;t(>k=*w}}& zt`=~%G)7UhH|yAoO3~ka&hTAY!`Rde0q%B?)o`rRDABK6!0D`Jn3~(b!`%{*p?)|U z6orw2D&)2G!p1HfhDPS_ce6lmSpwU-3Z33aU-`T|QR1hlJyNNZ*z1riW{x0Mze31yhB*LauV07`@hSHPtUgY%) zAA31_$kFTPm#ENkb+jaG4KbqzoIiZl@Bm3Xr`yc-e3Trbl!#?++?XU2UpZqOK z>T}s&)p+0b7x<^o{tkIH8CaZMzUzA9aWQl0+!EfhGl%8T?_*jKNz8N&OT=`Z4ZZl4 z*~@tC$p6HCmw(1DEuX{t7JrYf3L`ib7ULz`=kWZozr!z%d=Dm0{|h}$Ziwz1z}wbu zBQoF_oa@fRi|$A9>9Oyjx%de6w_{(!V*;tAaqr<3gD>G_`va^l2%ZBWD38GQF}!a0 zOZJavs4VTm3{|ui#Wnc(v7g`_qd&nOmmlM&CcnWRyMMskkT+7frhet{=LmEAH_TkF zg>P#=-aPUj$O`{CQ{s{FZ0!(oG81#XP?R9~}HU&JWa6V*x#j*RUfg4nN=bH~7@@d-%-x zSv+I-AMo)15&0i!h-~l2>y97d*?oVGpOYJ6>HIyE)i}T;rx;%z`+MZ)?1O7nKAt`J zEd0EFh=HMG1UJ>-4g2@;!qLCN^TyxD^9Fy9n7CJ=R9E9*S|)ZL{0npx?PLCT-vf{e zdzU|tjhU%eP;!lv+}MXN_Ittq=m8Wrp5wU5HGr)>E-y5pTs{K}hgh6(a-hDW9>sNi z$V$&eTzUp`0Hk@<1k<>B)vxA~j;G33fqVZW>NTr@_F)6=zP^ zLp@N272?v|RyhnEPQk;@3>VU4;dU|sj@Bkz_e9|0{1nc$PQuv93t{e7$j;0_c|i_F zJL}Lrsz5~YEXOgM0QfjtASaV)1;oO`)(Cy2@#trntUa?3 zYH5qnG^U6S&jRR%|iqOM-Dhuaxh_bU|S&Jn+K1ob@H#yz; z+v8wnp{Eq{bxxNCCr^hV@w7kE&!;1V970zc?m?doMZK~YCT6k7@N>odB=s2NDH<9^ zAk)to^Qsn9vQHQpgd^vaJ8I<3FfoooZpd+TDOzFWkqIALYw{q&Q8?HO!=quy<9%~e z9Vk(1V00t|`KOPgwW|TCITe&aD8ikMsL#qnQj;7uCbmd8<%+z*95_a$VfP37QJLh1 zl93J=9tuWzlsD$*`f*`I34^cvQ4{Y=U2Pwnl55~(Zh*9yP~_$1p}8y%6Jw0QK%MM2 zg_*@#WL&96dCLGIxz04T_CJ=3t%DQ3kr87n=qR~$MyUEEk_*orAX6hLf<>#Wm zz63qvN<`$hAl%OlX=mbbCOZorA<+o8cZZ@oAGsZ)*lTqfVUGI|mwFa^tOH@Qb0zmpvGS0_UIDhTK+S}8q6_1t3dNm8#0=Ri~Vfz(y_llVd`&?(A|O0+;_vm{TY06@*qC3{x_6o zd`L((dKcuSV=83QC*ga?zm^A>HHngXJqYAO36JIEe9;>v$vT4Boc* z2ll(qaFX-rZ*4xpVW)q^{Ads|xIgut=~syM`88(O8gZg?2p^mM4h3;9F*PO1rWWy< zt1Z{DKgSBO`C00J-!<5Q#GvPi$2;NM(u+?`e@PwXo4j9(e8n7Ib2Pz8>XC=!IoO+) zfsal93fU=dqIS3z&V^_3@{#9pLg<<2^X^(dftgRyzr?!--b7l&8$9ch?o$#o+ZC7N z3*#T5F=q#VTSb|26+iQFz(I${Yzhjo!|eZqSY4yZ$p~`hw89u!eWTPGYCYf2CdaCn#&99Zy>( zb{(@Ny>=Xb5HUdDuF}BGuC! zD;n+%kWW)OtbmzA4AQ;0-*B-9={>X5!4T7ixuH$g4hyGbBze-FbA~$5#Wg6Xlg(-$ zgpFkwN>BNa$1{$+AuVhzLQxzQh$dMZOl%Wz#={oZw2hc0Ats@A03N2Cp9|tqOb(V6 z@pVav4|y{q$m~+W#{3kD!+f|F=*7Yk{aMdYKVI2SJ9Zx31j0RWS?}#_4zJLUB8a7f_C^CyP&83JhFNRU}G4B+Qbv|mpyb7 zGmG&;a0W)XZfNZpfvmp;SLPCt5SZ*nec0o?F1&+zjT4bEe3XiYe`ar=brzo6?X}*$fv$ zKMa+{lLw^5+{#s)sUC+3*9b+YEumfRySP9-SjKlLboCF$8A6_q zg_*_koa;JY+)FL@I)ccGk^ zSvrsK!79%e$;r#;Q^Vt!7pk+O5n0&_ZwpiEj>Gvb{JJN|Grcp>cVT}pm8R6?&?DH!HCrrXC4~K0YRnIK(EVw3F znkKJdc?FSWJqSALi2B-G_@A#si1i^1axFZ_@_D9I!)lKiI%{H(+Rz4@gFfghjKtLP zBx0-kV0Yj+21}x$UREKdvImYl@2fk5b9Eg!dVuTjv-JDLcx|GtD%NvEuHslS2=!1i zuCB~-<^p1<^FMmP4V`77h%2s#^&xjCxz?U!+w(|ia4<2o=?tb~|F|+XFE__lpG&D&1=KDQ!>l*tE%Osa|bN)2cVP^Wy zXw2S;G44&Mr*yGR^u96XXBIift*{<~Kd*%TThmp z|4z&t&mKUI@OAcso>3eKJPhxM58#n(j#r%jfRAkc857Nx7?_=e*SQo}g&e>xzmMP& z@G?gGP9cTdg7;nb;5C!K!*37&9d)`t#>J^bX^y_zA3{fDalCuq@-PBje@4u#!=3^& zpC)Gh!0J_`g%OipAAtBRu&D&Z{V=Yk0i{T$+7Q!vwev1{f&f~ zPZBeKX!acPVqfHwN>t5W!Rs#eI?Ozug=Avp_Y8MZSM-8}nf-{FKQj3h_eTY0oK10UFR8#z<7XK6W+#7Nft-|O`}}+uc)yL4XTQR+NE7_V{MQHy{WVIe!|*e2M|k-C zBdZc4vX?%JYk(~=^UH=m!HY(Ji{BsmTjZs@&ufDyRb9txC)~Mi_^74^ih0i@>|7FX{hKf7H9H^UIr=1})WOk!_x8VxBS)H9DT zEuEfOj2B{l6}*o*?pw_*EK2(9T5><^1JkLWH$hK3aa~g8{$VV7OC-+@i+uAYM*@2091)_@D;6_Z+R&$n^xe-pp z%w74^4=>2MXFJ3BZiR75YY}1Pj)9SK#8kAy!@v{04XHR&!F?VJa=I!K5Sm>9KTGPr zyRr~d&;mDO?{6J5dq;wFFH{QuY?kO@qr0UkL`zrl^G288zAMBz_Ha#PeUw8j@pTQ#M*nH zT~URAz)Ykb55V+fBi9Qv7^0npS3n`+9GIT667DB*5bNxTnV~ZDQ_t+=n}aywm2T(d2Zm!c$(s()BU-|h|60Xw4ntQVTd zxw5r8gWS`;SWvg4o;(*Tt9ayv_+nn&Az^4M%Q)nR`4Tg?z=qcfBmGe;@UvAM3b_uQ zCnl~S*TT{y0;SRZlw}Vp$s4jDwk?WaI?4`c7v@k-zO0>bB+3&`U}&rdC(hNt$l4L6 zriM6VVuFJo?m_K&t|5twtxdvFlXQ}DA3~vQ5|#!bs7&FyceDdv9XN@@yY`V2VF)8~ zoSaNd(OwcuzQ_o5o)3pd9u+g|WvdZ=n{6$vbr6n+{Lxh$i?+dGxJF!nG5I_u7ADwx z$N*M5_oBN#Uc$`why5^E76%RW$_X`ne9i~Mp!!pq<|)E()NQ_mc9p5rgq+VYlj-yO`ndew2LD--oupODWid}h4B_}MNud=!f| zwehu>z>wLlnL9c$`mJhnd5Bs#wX;lxI8&8|=e>^MfYT2#KjM!& zF>^@w5MDQV30^)wp?v}8<=#%bYPt*Fp3gEa{Ds>v^X#=w1h)2(3-Vh81pFLwbtYoE z+VGmuCkQ4c?xUW0M^XyDu=oq=CU#(AdIBM>jl`<&A}ENMdH&%r^CYpZV_6k>FaM5^ z(BDC$$|U!dG0?fkTisQUvi3aq=O^G7jvvGC2DZ+;*%(2_x&ybOK z6jlW(c=O;7keKim_iM^qwl!7d6pr~S}0)(ktxv&i&!$L0BUV#*cFER!ERq=W-`Atk|n zTtUi^JE$esITQudGuMr@z|JlKxhFkweW43;e3$7RGU}NFQJ)!!Qh6Wsv*F11ccD&l z7}@b2cGl5xh@7hO$7oG(VmTNQX&H`h)nsDEFbLnisj4(7pVOgzOm zGKKSPTpO62Kt-%SmsdlWW}b;veeg2!Mq35z-^V@Hqk+`Bd2zil1nvB)&W46-6ERMR zeRAP5qp?p3_vm~aI%IrJYwY&6FD_(oRXlo|KBM+y;?KwNF%1_d$2HS*efE?tFZP&Upu zyJLv^5y#^zV71=@WvM}^>S}_OOB_x*+CtfthXv{jdzTmC9F&6yTW9pi%HR`TgwwWe zTvJiEO+4Mcd>QV?Q<3KBi5_Bf=TmtIHn+z#uMg2i*xrkn+0lVqq-r9TsR<2ix5tQe&wE*M?}huka~H`Wk3?SBanw(=N|?EXdoRsX-LSJwLOIuz zD|3U?GtZK@5l$VvGZr-+sMIXN%rFc^><@F3ozTq9qL{p7bE8n=YG2wqbfS%R23569 zsHv+#cy0v@zqBJR_C-1E3rwkJE)Mk|2dN*0@>!T345Xep2oZ=Le6%w- zTi1qzU(z-q+!^()T*JlZ!1{aca@}`d-MTC02W(F7#lL+1f8!rM`ag-8k8io2SzzX>sw&ji*K@to zFX?$VikU?p=_qr&QGfcIJNKsKw^^;3=R4l`n&Do3ZT;_CftjghM%NO@tC%S4_IL|B zJf6evh|BCfo`GU02BBQnK4 z6L@w1`-t`V8THKV@SzU-CBy&3UdMmJF5i#wg4Iv(`>*~48IdoMAKiPMiuNwaoG7{gy!b%&0X@B^N={tDU;BW8;`ya#m#7|M%90!My?Mb+w>%o0Q>dN{$`Y|LMMn-Elj7(1;+{O}#DB-%-x_dTbaj<}t{o4tlV!4m}-x+>;t0?~1+vXcsPgG|A?KZl(oC_q*X7 z?fj<4tI#3S!XvT>?v`d~&W}O~^}^=I!x7_d2DQ8%soZz|{BtLG?f(MJ6-i8+Tn{;Y zYmj3p{E}&zW_d3;EpE}AvuJ~r9fk4!ChqOh#_P%&63Jt9usul`d%)Yy5e*q(xHL;! z!j(0|7PZ6CEdZY09`G@DM{908CZ>i_S=)`GqB1mBmtkBpi0HyrxJr8FuVZE{F{X;X zbWZ0|w|vZ5!pupf4REjzhP#Ic{OlaiSwtN=IbY+;mk^Rx2Nw??czAgtz|xJFIfXhu z!Ds$q5*NX6pjYU=hxfb8BhikFzHn z&_f&XptK6^by%P^BLqXMTG#{^!Qg|vC?rQezOt1ZdUxam(ynTu8>RtyIQ-5|6p`Z+ zM;*So0j~wyavz2EoYaxu-7m@4v7VUk#QgH8elvuhj{(ZcH@XP6hE_OFzC%w_F=nS^ zm|s{xHTNI(5+mDu@+m4aPa~K-*_{Wh5NPrNYH3#xl-&lqedcVBeyGt55zCSnLA!%o z%Gbc)1QI>%F-8t;Iel^*AhvehvkMiuvGC8}`g@NdpYx}^^9ZJ9XHYz*Am<_!Wh}$U zL zP&Z?=*5xCqq7&inKIo~*r2hVPpFQj6=zD$NEX;hCnAw(`iw^P?dq#SZb*==R&D5LF zzQ`rAn7oZ6922sT(AI}f-ldJ5^jOQ$Zh!fCH)!znmZ*u*unFIuYO(bwC7!R}rtrsSxlzUo41E_%9Z$h{kYt#>lw zt&d@tb~k>x&Din!5uEomMi$or7OpXfu{natu~P1LiM8K@?O7!p$#(yw`psA-W*%ru zrf&7!TbQ}pn|^iZr{p0qv#zbFBz!zc{;wnbO8nDj{{#MK?6w>;3qG@u@xTDN#vD5~ zf|o^k^}aFM%jq|S+!V29s7-r|n7N30<|hj?3oO*Q3UZKL;b!?0T$(v|6CU+0UB-c! z7`$ooYufewD~@>n41;wJ^s67mb$ zOEcn5of zjSw6C2`Xh-*cIx}GX0EY`T?x{f6G1k0P5l{qL^H93x6l%B<{n))jlK)$YAQX3o&Q* zz&<+$?>qhq);=s}vn%hviURJ#Tlm@%D;>i8^$~JWhGFjeIbzNpgjHq~-gkHw4go)d zvdxR7xdJ7*69HA#c;D$=9QODjIgamQufG}M<9E=6Pgm~s^%CC+jS=2UzRJOOkrVqi z&ql@1&~Q<5vYs~2-XFj<>{A>FI*gq3{m2|D!h6Rp@V3p5@t*CEa3bOjtd6JhiR+l+ z0wcJl9`D-iz+0C83XgyvqNd3g)&*raX!>JxmKstgGJ-z@(O%i-KcVP4$$YLLpsWUO zS$~9gtp5dW{?9d| zpE-?s*TJb~>efo&PWyUSUr+4bV~j*!OU(BbK{3CG407g7-Ga%R`x1WUW;mA~569?4 zy!QHTeEI%cw6iuud3_Q5!iwQ+>j@7J7lgXlBB$gW0z%Sg4-||Qt|KbA7vkfSOg{4| ztj+hJZ(S%fu zOCL8m*mcwr1_$>NOCCXo(1l*okb9woo7Wk5ao^mMypnx;kD?&L3Cr?Ej7+Z}Hn$7M zY~9J9+=bJ$+3#=6#PkAvW+ zdjJNIDQb{f(~DiZ{c(8TPUMH1V`_vvZN_0=AoroNM+4XREc!_?gwHWk4Ah)wS-w5Y z>=jjdlh3?%c>(iFmypppOYVFCvV*Lk9dE%Lxf*9myRqNa9|w;dfhFHjX1FURWi8~~ zQJ1Ej#p#S{`e$*&f!zmj#?OX*v`F%|pkY7gB_~H<=1^j0HF4nF(mW#bJFw5v6Nio* zhRuOJ^nKw)JMAv?)8C|XKn`q;ooJ)%g58I#;b*~^VU>v(Tp{N(vIHJZe$tv_*Fj5! zyBK4lC5w3pz1)K_h92WR4rZ48wP>c0H%J>?3m+7Qx?*i{m?J5mP%TSb?k4pF+`ZG_ zecTsL>?^wun9@gr4bEp}!;-!(zSw&h8G%;hW!IpIe*8Q==_l!Q80>rl@z$Gru=k_) z$t^yL!j39fSSP~6(HRadl*c|3+9({wM7Q8?({~Oz+S@DK9FzGJp< zHZ{OdaU}hW2|T&+{gNly*W9w;W^~i{SN3N&e9gUp&T{J3>BHq=`ONyhEB-IcERlyk zPXBDj5Si&qzY?=jn_GX+W_;IUTmNxv-8)c>}T^hF(&ic$IvF~8wA<0bCdenh@+ z*f8fee6Ev5uL#`#C zaeC-BJ@aMSO^waYp%P2W>;EYQ!emO7oKMUE{?oS!+j zU!tFA_2L4QOjDty9TIKnah?8|S)R$&%V;A1Vr;mEJ~}j*zr4mWE3vwy!NS^QC}$>^ zo{aE!Uc$1kZsJ&25_;cTycXf_TERI$Ntw?tjAMvA0`uH_>^1rq zbQSGqy;dJ73Fg5$g}%QovOc^h z9(myBaWV6hu!H5kY!>ym`;AUe55oDamwp7OFB%*kLq{+DMb$UbZnlTMql6DnVmt09 zx6$^buBH~9jkGb44U)&#jf2PhaLU}6KJ&8aYn6PJ5jpM0N6|qYMrTtaMn|ZV=DBQ$ zK5$gjV^W_xIH)_H;+!pf^AB?GxUPjZ2=#U7Wu9k<`3}$)Ceq%FI+T3cO-|51G<`|S z=?9hN5wSh`$#bmX-a{kp=Z3mkB>%&Lmn`Fc$1v+4>e14{G`ZKPq%L`yd(>)<4I|1a zG;{BvuA22=`Q&5NGt;+)@SQ3ALd)p8EsA>PL)0^8200Rs)k}688m8St9}6{29cW^n zW4-O1Z>XOZdD3U|@X#1J0;A*@cT&&Uj7hGaRP_0yWt#HYdBm2`zQ@`VSy4V{ZYrm5 zzcS<|r( zcbyLlUKhH=*=hPS$Ir=4NZz{wE&ZEXYXX&fp00y$D`&(lj z%lq;6D<;$jMs_;b*&#`m{vJ$I&$H*W_%YEj=UL?{DPVp%zNMThUg;-lFg? zGDiPkjcxsGGj$m4Cue}~UHD$rus`(DUy7YiCb=HAP;}-}H%$yeUV0PtZnbp{=x(mV ziW0?NR+qoaq%zmvT z?`oX>QJOpZ(A+>fJL*jZCtAcWkkhyCsDgf7=(B9!9#6!%T41azA7%8JWJP`Tg@^!j zw^yRIrIlkxH+>Ux?4TY}%|2crQ;9hfsD}MT_#GY` z9HHGk`TD%x%08+bA7I}UdNbM_@O^d-OrWlzh5eV$O$@XD3Yl(PuKM|WvoLc4v8^e2 z6df0Wxo0tsey)WZ$-@vn47xh#UvOfCWu$Kcj!i?X+W^Ojrsj6qGH{NjZ|Z(x+4{z2 z%C3>;qZ}tWCvlHTw53+sKGd`Q^|d$C2M@bLHi4o3A@0|a+sZQZQYX;R)XY9WePnwp?LXlQ5zeLNZ(ThQOt%Kjpg-o-{`F52-EjhR>097p>~=r@9K zvv1k}T0l13!ZBR<3VQgqrEg<1^wB1#>_@pTE7ExwEUQmrBmafHov?=$_dZ-6EEC_q zoVEh3`NwY90KO!}(w5Peh~96;M#`|!dmaTd&k)NV&Mv|4tbaq>vA<$`yZ?pX9Q;!} z$L}9m|2=(Eeom;Scp!FKe*@K42&ZoNb@Nvc<@3+<5m3AS@@?NImapLRq;q)A;wN~) z_;2vbLw`w|L0$fP9R3kQRY!@11+!seAAte0I3IoFUeq6UZ49sz41$9 ztoYH)EPQg{f3uD4;DdtIvh|k^J1zHQ zXQ&sVFAC-(VoZrWY2^)EDq>NIa|O?ZecUv;z6)HdEY8nU|GI)YIsIeN$7$`^SX^46 zKU~hQjl}2u9o*YiFzyM#BZtXAa7xlPKG zxK$TlOG~cdEZ2riSKy-?d}hJ<7$y!$C~k+DjW-TbuV!U*0J)(Kysrn@y((Cm`y$ob z3RCo(tKnKujDaGa%AA%yc2$e;jjw~Jy$$*+W4Q+AHR4yDe`XD;`s5NO-uKa0I1^}# zb7dD`M&89?>e$W93~=P2Av|qN$ybZVqMBHKbqQx`23Q6+&pQ=Q|O%ZJz53@%}{H)^jlhFLhvH1|e}} zNDd5vvaga@n^>A{YMy*|k=_i`6R{MvocB7HW?@OLQW$;B%?_0?#?unt`I3~LcqdX! zHMVaNk8qy$ciNd-d99brgT6lwW)^7++Z@q<3%e)a^qIEz0z8-ookIC+Br6!kK@{6l=jXuFra_9 z!Vvn)q3^{-`jXIa91;Cg#6VF~meur;=IfcvJ>M8i)5qO3_11IjD?+wXALW`y^idJx zPU=gdOf1_R<)`K~J#G=>*9_M!!me?a&x)9a`fCr8=bhId7c+~pDmj+rv<)J_ISM`H z^iQoBtd=lOk>QsOIC8`g4rYf?67NA=Ox*za$sz`!6z`dBQS=Ed->uF* zQa9F$HaRDaVI1GNrV;N*jHlvvQRW$GJY`>JnZdzJ_atgEuhqE3_Lkh~IqPQ8yq0q{|-9<)P7W^imf#*xyH< z9CZ=Y1K-&X?{_}I@nDR42)T?p4CTW;d*5^w^v^an4h7TIlAlmDtbpI?bQHyeVUb)& zrQ|d6?tX0Um+phE3EVYJ-HeQW=ORn`VQS%sBsX#yx~n8k@}tIal42KfPMYA@)J+{w zYkLQ|gYA%y^iijzq;5?u`P5X%sE-n346%m3tO6s5a~WkaHZsDPUt-O$ZocAo8RN0_ zQ-9Up+l!IGe#y_#Aa(nlU47{2=tO6G8}T+aynLVU^hFPos>DyF9#C+}M1_q9BA zda<#QVd|`?R}$rT#N$yhvy|VBvi1!Oqob=^s!w-EJ0|EKR7+nZlf)c4-z1M-K9P@* zi4==+jPj+wt$WQA0<-j!a}yF2-*K?1HnMJz7*P)7-v!DAv z?cC20c0!{AU92PZh?3s>{&ExVUFbZUxxV$H53-Vk)8z5Aa&LwEK8)`t;?LF7e@>uZ z8g21npjCDgXWYJLFR=Rr(;4Gr0HW~M7w_91J2c`W@VrJp9+sMd>zCn$tFJKI$ zI}Q^Q6Z-f(ikzGr`r*7LCTqtf5z}O}4eh10k&*bkFVgRvh-p&HH4HK1y0P&=b$#lt zvu;AaGu%sGd$+|ju^}et(5)Gs0L(1Vp;{m|g+GTXp1 z)4WVOZ;~tMvDJKg@f#gr&Uc&q~Aq*TiB*pkfF#o&ING&l0>V`FBHyJGAWI^j9$ za%P0SgIMaJ##`cLF&7GM#T4~EkBTS1HpVbr!5z^uO*M5-2qz=>akK2PY*gicB5^hEu1`X?=Qb7FiJb-R7u z)$4(T4oT>mZo`O_mniQn^<8s(k6PX%u)qv;Lvz$+iQhzi(?ZuNbn&9>d`9S>rdgIL zp~I6f_+9cOCe=zhs~gWfQoUJc>J#hg>S$+s0i&a%lAi5OncweR=!a*iAC~GO>cc}L zWVeZPnZ7>=4$gzpRZ?E#jQcF&pG)!LA5kv%tFySa8JJn5Bi3O;H>+O7?}gK>e`p2iu=TEuV`ds26+mtKGT(BsSo%XqguAN1Sf zVrG5%!q!s6j(jwGv4>wfNVr+-1>EQpGvt1$smpw*@p}v9s+WuY|2K)5%gV~&LQcJ_ zt1H~y-M@CYxw+9NlLN$kH!(9~XDi76>8Nnl@tLV>uFv?G@psaRnMGgO{PnP2HsAVx zv2Nxu*p`ZhO!B#f{a@;@%8(jtltE$; zl=QJD`F-dyb9Hq!GBPr@1T%{~E;8Qa%F6Bj05&iOJ1#CQIjYF_8)!|^`DhlHnflgt z5erb_Cp_dH>{HWbZrK0HdT2u@VgNoTtrzOfzlY)O3zE(JR_tADW9ALC%I#Y=RRY_X zd3#=alIO@f%O-4|Iy*ZhU9)6Qxyd@FJM;T4oePXCcrC*Bs=x)}_%7A&+pLR_tmzbME3u0K)NM4fmHb!JL+mHaZN(EhK;i2icui;6y4L`>|> zF0+^qWHQ;!_0vPXukG8nCGgM^SdW>-zPA{UHoIMKr>E2DZOdWvuP zB)lweb1m^>UsIUG2^7~w9uGRiUWK@4v+A{#=}eIWFEDd=t^ZA4MosE#=&L_Py962Q zO_^)~W)^;31ZGZ8PpAKC`YYc4Y)fE^B_J?!Lqh|EjquZenf2q$R`&lVIqj!q4Bbi@ z3K@v`WGnOduBQE6>_1Nmw$QiB?LPYO>$!*RZ+clj>~kBrU!=W8zXp$jnQ3F;SW26~ z(()RVWqYGC`E}aCy+X|V5@U^-qN*YfrDatpEiHZEA@(c;k7^_Le%tqyuujz#`KZf2 z#QHK`cIwNhNO=P#7fzwLw32n$ntBNPOA*^NK0aRBbJ$|Iw4MC61aS50RS7f4Fizyt z(mzE%DJdy=D#nt{8q4(c6?GSB>d!YT{iiLRKlb`RZSQL<%PX+OlQJf3x621(!Odz5 zTPbT{`!_s1EX|J(0TUbrW-ck=_)MHwU3wM`7xwEgGjVfS5@W%p`=F?}oa47{4wLQ` z_pdujOLb#>VnU*%KdrB?M`L57G*1it){}NLHa4M-Wh~BgXC2>^@UmDZwB#Q~b6qY( z%%H6-vz~AE2>kPhc(q%1tI%5tI~{?=wm%Oi0l}YIT%>=!Z}=njwnV$z%69#@X^SyK z_)91%Dv~hclRSnzZe8#8yr^$gRTT;g3sG5F`9zPQcPsz)Z%^J__q4wg{g{xDkbr`M z0tg=lPkWuV%l~Bb6X7dE*h}2-A-B;P*>QP!#ZkkUBU-^*o>ZW>Hh}z$SLj3HWyuz> ztK1Gsc|U!_FcuQ|3L5%^zw;1rv9-LGpO-KB?bvAM-{yU5D@ycMSTJ7p3$*`xiS>Pz z@qo|J&9R8~@y&e%m*#0Z1lAYv4KC5A@zYlJZ@au=k5O=QzUgv&b1nMuauVa0!1p39 z;2+~h*m8@QrpwFUOpM4sMj3C{`RS5?(9H;5**IgOY=8cL_TB=#j%3XetnTR^o*riE zp`IRIoSmK7-RbR~hDY`KQ9tMh^$J}sml*{XSj^1K%w#dMWZ4$WVrG_%b>{qemGZSL zgH*OlvO?c?6nQfv15W&L^3TY~NX5Wc%z)+S_>g5?Qzhz}t5M7ExL1{hq9)_Vs7vAe z4351vW_%y@WuB;Qtm5$+XmKUJ5$ap2czzX9(vq}sB7H4+nLBy#K;NHh-uE>Jp&|V{ zyg%R^6xOx1;1hl;s*&FgSYes@4T0BOcI{iioZBq(n-3GD+%jKCd}i_g4pZ3=LRn=F zyS#h-rrTfgd)+quD$c4tjaS7ZRWF zAoh>1nmge{Y)ZzHWPPEd#*x%l?n9;i;yWL;`hV5-r}95o*K27Hna3t$9r6xPC%^SB zK91@a2d|wDTi+2I(${B}XTE#*vs}JAXF0aq3mu~?{TLptz|E3VXvz8}*Od4pwB-CT zZZgSB}{L$qe+~FLK1%7k&Apd>wa1(=VK4{7Qjy8|EIpdq?tTe&K z^2k9h_JJy!JU`#Z{n>%4!&g-pna^@q=dr&D&P2b2AK~dJ{>gJ_slU84p#BsCiUDZj zfN~G5<|`>{H~FP!(3<@{G^T$IP3hl2d(lT&94UV)-eKDD=+S*l^k$$r z=f@md{yG{`zlPSFA7W;>g#Gf-VXBHMt71SgpcqgLCZ#NHuT#4xfMd#TO4TJye30ykBT_k$ET0ncqTRqYLhB9_+F4 zH)jqiC&hqbKrx^gPz)#r6a$KZT^M+#&n$75rdrTmb`njQoZBpZGvAfFS^PN`r&@PO z>R|6$m~6(alFzmAWtpqpNVJ!o#_C+h!7jKeonk;SpcqgLCul(hsY4fVqiUGxdVn8vV7*Gr- z2KLIp3w>ru@Zr5RjNFb!Q`Yx52l(rn@7a+4O|%uA!1Q2|=2!1EgZw0o|kM3=B)aF4vxcAlhqmuU$-%sqVx96JD-`Cb(mNn&MKE{pw_c+HS z5%=#c@0BAJUooHC0LZ3mnhws&`3fFOaaBp>wMSA(@4<4*>{f=%7cSO)%|A=cze^)Dm%*ANQ{086q`!0Ix zY_)e4<$XZ)rx;KSC{^HR?4fpRZVUx!;*CrUZU;B>ARDUkN+vlczSLN3ApEGUFS>|_Ew7DVllbbWY zslAif*Wjr6=?^)NMExlS6a$I@#eiZ!F`yVw3@8S^Bm-aCXO{fG;J38z@%=zqcdobY z8vWKkMJvA_(wg;6G^G6z*Vp)c`n7+^c^ltBN6}CC4&i&aU49YWoHxCF|U0uq_5rZ{x!{ambn}9?qGA~yYzv-&AAod<2rDEg4+c@ASC>uHa^|L?~q8G27ZgA zR_0!$`~law`x;ua=_lvDi~96$<7Uw(9OJgZWPcv+F>f_*S#J#$Dh3n-iUGxdVn8vV z7*GtnA_iWm&#ae8=2_h1yyL}*W^LTKzts&L<>&ZKlpoUHeHXX#=qJ;U7T;IiAC&j? z#1|HyS|HmpH(HL}5dWBQ#hyG?~&f%~@XXO>Nmz~2c zeyguF|Ceaa`vviHZhye_;ZC8w{5<2BYH|CUocO+BAjgw)u{zhOr73BvKgEDzKrx^g zPz)#r6a$I@#lUN3;I;eA#^ske#`4YT`x^_`TprcNh-Zh(F-2c`xIG*LoYy?a^__=r zM`-gqW=1Ocos>3gu8e8p){h?ESM!vO302#Q0mXn~Krx^gPz)#r6a#O90r8oChtPfJ zHxPbd`RL(2%ZK+?E%}XW%Z=p`%eBQm%jKDymWxxZmP^yE+VFA#r`_)ElJCjJWX8^m8F{u=SuiN8VoP2z76f1CI_#NQ?U9`W~ye?a_0 z;vW(JnD{5eKP7&X_-DjFC;kQTFNuFe{1)-AiQgvv4e@V@e@Fa#;y)1ok@!!<|3dt) z#Q#S8@5KK>{GY^sCjKwtzYza7@n4DmM*Kg-|4aOT#D6D#hxq@A-z9#J_#edY6MsPb zA@N7V*NCqZ-ypt8e2aLO_%`v!#CM4A65k`fPyB%R6XJ)&kBA==KOz2<_$l!-;^)LK zi1&zJ67Lfq5FZjB5g!wu5XXp5iQ~j)#0lba;v{j3I8B@(&JyQ{^TY+>B5{ehOk5#M z2vfq0Fek1O7K9~XMOYKp2phtdup{gV2f~qXBAf{q!j*6%+zAiDlkg(E2_M3j@FV<* z03whGB7%t!B9sUt!ifkXl87Rri5Mc5h$G^O1R{}0B9e&|B9%xZ(uoWrlgJ{ni5w!A z$RqNJ0^&MRNE8vpLI9(M|Lay+j{zhv+8;h(ThA7$!!DQDTf3CnktVVv3k1W{6p0j+iGFh(%(F zSSD78Rbq`;CpL&p;x2KIxKBJF9ukj;F9;Ct{Q5iZ{0i}_#GfI4jreuq&k}!*`18bH zApRopmx#Yi{1xIih`&nwHR7)me}nj&#NQ(RHt~0ezf1f*;_nmxfcS^RKO+7y@lS|< zO8h4A&xn6c{0rh=690<$E#hAjzfJrb;@=Ygj`;V)e<1!N@t=q4oJrN@KV4pSSOMX+Q5g zIrhABUv%t6X}{?Bi_$kf{yNh#&PUsRQ+D&R`Mg9sy@($GK)ak{gbv2n(avoHjN@eRyi9a6KPjK2)mNXx@@;{? zB@ZcYe?t!X8*>@vYR7xIzo$A&%U8-J`A8Y0>^)3N$|rFoy*{2Vzoq_q`L^p-nWpWN zG}dv?D2x z)TNtkDWTY!K(@QMucN|Xmzr&|zPGj@?J4EG$=?Q~;%1o<%2Ofb?<9JdPG4On+g17j z+nQ}U*p!C>;tt!shj!D&JUbXq%B`iVrM;CN(=zmjbj=3EM*ACcFvRmm*r&z>{C+Tc9y-ZBt;9w#>QKVFx6gau%AA*=bNyd7v<4U`|YD0ce6a56_~tLiqRWI zw6W_3ZnoN3`jYfr;mEj;>+PVoh4ksUJI%P$(}{_x8FA0viHT1}OjIOdgIp0G=!k?M z7bJ(cA~nn%=@FjDjPf!dl3}DL_jw>W)Ex=Iu80eCMy$UhVzv+);K($bkr+e-yC5mV z4Jn~+T6*$3p8MkhoHWETj16#ReD2?Zq!-71Pk_e~Shl2KNk`IiM+(c98s?!v`@OYK z+aK=1BnI~~RsJJM|%-M3fO^UyRr=&lej`33X-Lx@$HsZ7Ps97j6>CUp(`SV?5nfjMJ6;;)rh@LWklhas)UzxDll4Gnoq*^JBa z?Cn9udr=-w)N{A^dfklbBWdnD?^$IUCU+W!1~9B)a4VGGvi-WTmG2-!X~*5T)61y0 z^L9K#J)g^=&W~}pD_1X>mVU0Jr*H2y+$zg}ahY~(%duy{IN#^BvvE9adzUn|zOhyQ zr_$QuTWgmc+>7mMZN>e=(stYSqi?@%yLmzS!^Y(h+Y+$M0<9mtpzj&A$H1LF>dpw( z*H1loo=)ptq{%#wq+};V}g8n@kEw;%H(dFUMNFTdT>($h2! z4e9G;eVngxoHu4WFJq%d+~{R|K1aq}80xvYx{CYvABYxVe0*F3H{bE}bnX<~xk zDZ6_Y%gf8#SmO3h7#~;LkGa~(#ZKO~e=m{KH-#PTx3i4$d%Ijl+q=a(%KLPVUIhnw zTDyfi)88%58?&94u~8$N(aXBC4lnw>w8U>9Qg@!MOB2}K++?3wQcxTy8&EdzMr>el zaZ%Hq{p!+-bnk6BzE@p-Tk8EX^-$bA$3Nbqj=c=uZ$q3H+02*GCAkND`TIuWd&tAL zEp-)pcoCm+d}U?j$ndhhzOL2xWq6S|!r@V|nZ0szRQi+fB6WS9&Fn{)q~FcY&trIa z7`?r{xO3;uTaS^E5zNiaJ(o+J=drOdjgP**zPFy2!NEby%*?zLFT&5n#02{L`*9Sw z85kG<=O(|@^^EffAzZ%Ayhz;y!i$V$FDxuPlbikM(#FPy#&>phHe`HU;O*`G*22lj z38A5(=TRuu`?Y5|U#?3zIXQ4~aX|{_ z0P4@PclJHK|B1~AM4QBB_M7*sIPc5W|9NGot*zCxLgq#W2M25Zp>Xr6bVE_?^2#d9X1HeWwQRcnc64-T*D}#1u?L+q-KO+V(wA-FMfj2XxxME3 zYT_@j9E+^`idNReg;(2`<+>$xl=+b{F);`V3VJQNBx9GNO}c%_wNQ9{n;>-(>{XY9 z7qK<5msiQh+UnEe=`wF^h5bnKS>w$h<&_ju*!??b(Pv=cS{kNQFye+?t&(q@?r)j)xXct3z zvS0tLm*;t*p3Z)BN&24f^1Sr-dTeE78H=p{0zwb$Uy}YO*G|E+(tpwZzS%#yguskyn3!FIr}b4dUr)f&{0Mp5eH`(5<&*qG^Y-d5 z2`_T)UY;R5uN-o0S!`mfFX?e5k5%nDX0Ro((G}ro^Db@-&LA(D??X3~V*MWb49}JG z^>e>WDE&eFMtKf!&~!;S5gtZIM=>-sq=lkuVxuw!CeQcu-*SH_oJf7dx0N^&%DLhT z%5SNow4+>~(yrwtazJt8{V&w37!*$+U zR##WxMolFqhI%nWKDxX6G0@kAmd+vM7nLGEKL_>2T)&{dle~xyyxcs8XYrx$*ZF(X zx+MKYaMlD0z;E?D6PGT+}u2r7v|MNY;o=qeUOR=6+l5%6Z?RX-#9qE? zT@s#_s69hd^XO>1&3F7evAVH_;i(05-fG7k`f^PjeaOixL1A7l+Um$bZx0g6nqhX{ z0ztOss3^-rM`INhW=F9^t=HRrzu`gEC223w5_v`_{(n{;U;IOvt03peGiVuC6%-W}p}DzP(^h<2#Mc0CZqDyjL);qTbd*3vi{PZNO%}wCW@n)}}5V&8sh_>P+49w0TGA;)( z(V?)s77DW~mvON2KQHW5{H3!nV#b6A+2 zgSE8{{GA-pP@IOi;s%^M?+8Z=Glco^9sKwxoVWACnGZgK#Z^;yI$0t!J`A=l5x9Km z0xp`F!tC-n1iCoD%FYMorf2clsk5*-{UO)RN#%Wv_?mm`lLtYU)|NR=w0RFDT~n-^ z4>~i$@Q@RyEBof*=N^b44_DaxMZ)}?3H&{|u0c!)!XqPL;p~G?-}@A&Kll)qmX`3c zxQzCy6!sO)k6C{He4`iX)j`!I@l$1fhG>yI$CG+US;bEhy%1fIeKNm6o=HeN@vX#v z5?zvUe$gY*6PZgSIwRxza_;^6_qX*(uHm9#lAmZ@eSN(a%0BV0#7`67>1FQc4vH>` z4s=bgz}q(-34X5Vx>1eckztf}j=IAbWY45G@%&Im#tyy;SK9gK0{Gf z0xC+&k(!nZcb@<>BnP2oU>H|CQgHqUKZcLJ8QRLzQP$dt^Nv9{_rVA7GChfb&NAfJ zbs*5)2i;ufX=RmT(uY`=3OlFZYVC%)C^yXCT|wTBA=p?t;nK-du&}g3vabuO>neFa zPz>LoD41B;!}ZKb+%8H&>-a1z%!85YaSiKpU07Ma$Nu^B^ZXa-k$(K3>XO`BijN~Y zA!QUFN3=nF7x8&Sd&D=AXQiS+4Gj&NpCk8ea!j6I%0AI5(Iwd@x+LkzzMh^QEgkWX z#BY-4kD^`TQ;EjOJQA7DAU>4rm%If!Z@YyDNte23R^aTD1Uu6!h>r+BK~6f-N~>`B zv^C=V9FSjG4rfN+@a%%mYFlDahUmgv$t60SEP%F-OGvz$*x zKOnEV7p5OL;*7lwe)qq;i$D6t*YTY{`Z~;h{v$ZJ+aoK`m2v8D+A0K>e)41b5T+R5 z+G{NX6R`D9fccrTa5BG&%IispOe=(^jV*O4?NIB|>fL)N?wQ4<%g%5)dmM?`X|VAL zhuP`RVRrEnzW?4i{N8{2J$&=sck%fTzXvy)E4b?H3iFSTBR|>)xs5k);gmBnJgu;? z(9LnVw^Ns73`p*=L|bHhNOVJd8oBn04L1}Fwr1M zOSWbHl$Q$N8$qm*n|V_slBnyb^Kw z)G2to+95tN7#Rh*aJ2V^xz#mXva*5w)r%-AjDv4nA+DO)X^q$Y zqTX4YK4%ZhkKaQ`Tm&xIdBXho2S^QaLvUgqE}XN%RZ~-hcsL^@&=-zwUa-Dmjw_eV zaL(cyoGzb5dszZD*5^0|{^iC14ywN-wygU#a!;k-Psx3n^nba>l5uMBpY$N?(FIkoK6L@LS)qLP zJ9(&eN!nBD+*(abG(nZjjr3b(9+e5(8v@d z_oSo2~%RQ@)yzKsis!LLS>0hE9GKM4?BfgX9jgDnV&Bw8cszKq7aEPuxF4vsD@W1N0LW?38Toc%e5YY96mOXS7)V`k_UeM7^% z6yaAO{?#h|#T#Rbi1drVjnWL>$B8cO{rQqHANscBA>6#_=W#OUVSZ&5H65dH_Kb$9 z=~Xz`TB0T|2Fue!TD`UU%RRc(|IRofW72UWFA-}iGf&LN(Vw%)JPVyS<4`}Y*ZF0` zgP=<*>=R3T#?d)8hw9QwjNPoq-7oH=dwfy*J;dMZ_c))6W7!)Uo9LZfL}E$-ijyL- zIN66a-plA*$XtP!t^4!h9b{e7%PnOTeG$mEzJD*_e$U%W9tTC2^fJrbrMdY9?OA{} zpJHC#BbGTz2F*9V=aBw3Ik$|i_HK+1-_hpENqzLRzDy`K`&HF&eCKrfGTp2Q34uWQtc;u)7?=k`I+rJZGZ)^Dk=%w?LMTS9N& z0ERfnWNDuBXsGLY8$avZz3x8@x}^7aJ$#uu8pk!>ewlOk8%NJ4H#Zml{{EVOAby?R z2X;$W&XKV#X$QG~+%3+2_G!wa#w{bnT?c_Q3WE_95+s3*S&GEd~{T_<&C=gqde)u*)?>|{tS(=T> zeap-0lAJ5NyiI)QbrBnr`pLbxtS2DPBjoq<^jhp#j!XZObY$#LPw#CCg&XPPGDk(; z(Me8DeyR84bX}71&$o#Wy)NR{ieAfja8y*3_P(h+r+U@z?Mfc>CblfL!5{wFpmyhxn4jSIa#(&oa8JogkEllSN4*zeem z8^zDl{Jab=N|&DI?OAUg;9T)m}%z z29z!-J3k6`uIhNW>|E*6;c73{zf^l21shPhr0o1C*tx3X;j(k3ONXnyRR2=#brfts z>5{VZqhRN%j)%+6l`b8w_EP;zwbxOw0i{dI&X0nft2!PoJ6F1NxY|qgFV$X0!3LBr zDLX$3cCPApxa?f%(&1_^)xT7G9R(Xux}@y8GOSRWgumPn@%Fd61ovS(?E<0Dcbhz3}^)J<4N5KY^E-5=d z3U;pQc)09b>C)k9FV(+PdmRNEP`ae-{3zJDs^j6ZbEQj%tG!hJQtfpVY(VLfvh$;0 z=cUg;9T)m}%z29z!-J3k6`uIhNW z>|E*6;c73{zf^l21shPhr0o1C*tx3X;j(k3ONXnyRR2=#brfts>5{VZqhRN%j)%+6 zl`b8w_EP;zwbxOw0i{dI&X0nft2!PoJ6F1NxY|qgFV$X0!3LBrDLX$3cCPApxa?f% z(&1_^)xT7G9R(Xux}@y8GOSRWgumPn@%Fd61ovS(?E<0Dcbhz3}^)J<4N5KYOwJt3$FJXCk8B0q7gAK`V z!#-tGIwxN?)OcP|ynb08)%gdrPkwn_THMwjNo#dw3G3_YSYBDf;v(zJeQRs0Sl`&d z(()?zF}{GBWxTEbmVLWHw;%o3<1`HEXlZTfpdR;Gp`M1}oX2I+_b)9yu9H?Sy{tR- zYsXl}?emQ4wY_i0Il{@~W5UnwcComXr^J==82^@itJMFy8|&D-dvBX-Jzc{&%x6a$ zhVmNt-O0`K&ehX1K1YlH48EUC>*=x^r(;|u{XD&GcgEWpcemqe-|qHw*mx0J*xcNN z{Ed%~YvATPo}QjaPfy3h#DsQyw|cFtu3~j#lX|m)rTGPHu%ApXE~CG%AIno?Oy(ih z9({rS;VBGsw&U)~EWY60_09WOTU}$i8`xmptK8n8c75^aK92(T??1%-dw0Pd_<|>F z^7j&TZjJuI7x(XKX>8nkfR&XM+}m8^8DHQ&^N}<+*4J334J@z3S4$;|F9=p#vNdEG- zagX&~Wm@;|X}_gR8b4dU;|lfV!CgcAdk=X`%FFXt*4DSRUFUgoZH3i;02UFeEYBwM zlHc-om)UiX&Y>W`1~;lpFgH1fyX&jKBPqS1UMs8X)GcyD4&`rc;~v(fY!B|?E-SvY zvbvq;#_E!Gu5f+#!9%S)l0PGB=iU>ZnBKa^2}7o{d3Te%kOOig{K`JzS~z*Q#U-n+ z<-4i1?L)0C@3Jk8>nqnWoqLJDdG9_sxl65G#R|1oY)X$WTKwRi!B+1+e8g*@wD;rV zI(I5O{MxiHU7~#~u`e&pOksI)RO^d(*%#+lH<44(4Mztbgm^fj{(1(+#|BW?)CFfp zFT@3Up_Tn;W^4%a3kw(sH-l=NN)$$ z=cX}Df2*Nu0F4cG81K1F-C04;_$cSqY;aYJI6lI+|iHx>t(1fFU0sjC#I&SFg-bmshL@pa}py% zLt0u33v-y7oyXMJIQ!r-x(BCFR91_!!h8(2H({1}G}Q` zyXY90LV0-&dT%sfPRctmiP@qo!FQdBgHd;zcF*h}WvH3;Rk)Pt?QuMS| zp}BVewmw;KyL1wLjhUEY9yLv!D7apXTeT&apBcg6#2m`2n^9U)jEVl+n3|hI!|guw z+-l^OPnJ$p;XAPS4iP+MM%@%~P&?A47oP*+odVYb`c^rTi_ z@uTOdEzKPRC}RAY@)GoSwqas)7z^ZPZhoHE$qCF(Pf&vvu}mFrADBQzX%+g}c1vqZ z7@wLl@Td8ehrd7SHgMF#ed&_;BJ5-B&9{&r7mLx3M$FN_$*Spq$rU&J@@F66(+}T+ z_1UvXjtoIaLOhNgKab<@zYk}#OGrt?a zF+}~yDX2nqS_0M=M|j62t&_NF8;C0wCUCxd8pWyM$f<6Gt9KM^tZb1O;Eax& zH7KcSL`{A+YT9lhDWd=pKK`i8ipSJwFKXKdk)M@~+`@7Mgr&m4)(HWwc4(+bLsr=> z*f{yagy}n(oJVbT6qe>juuA`;x_1^XJ_#^6XNmwjb6hXaMOtJG+G~o~?`Ab$V}-uh z;M^iYGiqRJ<_Po8&Z8*Z56Q(PFtv2YmGc+jV`qk@$`s@_^BQp368Y&Nh|Vg7qoXgJ z?Cg*i?S+>17WgL>GYwlfT)T>!)mg|XX~I=UZxkhXU}JVj^M&T`eSzq_9$dAsA}%A4 zY1dWfAS|r{_O_mIwYOz@-stLKTbIn**sg*apv zSHjaf0#5d9w;&HRR2L#TvmO>!*OsVNvL1otnuDQp;>u+-Kd6bKoU-U^cg%Z zovLzQ2X3&lwuSw*YsgCqMSDjp;__-?cEt|kb=Bf>@Szp0fD+gGezl@|%U(^?6qidia(a8nK2=YQ^ zWhETE!eRdDXZ-DeiQ(JGXJ7L03&F7y=D2*~Bx3ztP?DX7(p#-?un9q&n=`Vj%3)z* zgY-ZfEKPM|?CwLjg%`rl)&|9S8E~f#nmIVb{^MVwB`=2ew)5NfjXAeRU~$zA*D#l&bH`jDMIhyFk0I?kw%}?;xh;2Cj=sqzSh-Crf>}Lzm3O69VW@4j{bzHf%1MhvjIzk*S8Js$}fc?ff` zL*K1(G;|LkARr2Dd9fIvPwA0b22WEf6cpsb$~zvmpS}lQFDH$^rKM@@zW%WFKULn{ zecb)((u2F}XdIZsNvmL-IPocd@!<)4@}r+3%+mr9em>|cOUL~E4Om9i;v4_<`|vpS zCs-S;M)%BJoOVpZ`(OJGtUmt;j=ml^f9fI}c|S68BUihI_s)NTNcO!@zhGRnc81A` zUm`sx3Q^$+CP*nhNdIl z*$Nd6RS1epgGFE@u>&eI8IDm zFYGRuW3)C4C9@B4=DjO8_u&V~3bMi7=`KV!O~dNrb4X8%La@6R%sl<^^KbtGj#thg zAR+{Q*PLME;f)a1eQBUc<8)vd2qGW#sbN^0n?QC$4_y31aK+UHC%^S$j5K9nh+{}T zzOlIC=Z7Et_wT{=>UsEw1R>nk5sgiyh)&HxQF0U#>u$lCe%uw)tH=wq$Mjeqg37vZ z@zc-o%Rl`D7N?IP*xv`ykFZM*VRu@P@V&8*KnBf+Uo6QkI2YCIC=!Z#>|1fk{>*6ufZeG8y74cU~}da z+(V*ZX=aMTP+RnIjH9OMHi{c+;NTaFYZtBHA07d#bC=-5zU%A}g7YU$@xjRpusHq! zGUI~aL?7wux%04gVjrh3ck#?6m|Z%L5RQ@AxcbA>(-uBXUNF6AgHsnSu#O)g*v}5u z&i-)W{a|237_OeZgq#p3EKT=en&Y{_>5Xu-v`2`K4}A?6xCZ*-_$TM!WOf0~#i^K^ z=%>%Lg37*0SlUxx92}WfD7>sM!zF5B^TJ z@CywkHy02Z8$dtM5vQ2mr=OpKE7Qv<&cu~#{^aBgEZjWcKp*z9wF9nQxqy%m`mQbk z2ywg!ch^9iKWC0pr_SQysgnrwcED8|Zv?Z=e0c9?d&L9|Iib9dn?ldTB0PihaOU$X zICJI<&Yn60J4-XI9^pQANKVegMH?@;n_fUsb_#-W3USTU4gtOau;hLpy9+$-3YRPA z(R4kH+9IT8U5AZ(2pny!k(8Op{n2onAAvjHU> z=M4yo!4*3In!yHpj%B$x!-UCtI z&K!#^WBOAFip|Gqb4Psiz3(E!&z$~JFE%*7)Hl6`$doeJ@?JE>-xW978&OtNM*WUQ zMtn5JdYY(9iP$rB6yeeZ3tTldfuA#>feZC5f#YmHKW>5de(+tC#@bUWhxn}PF2|17 zQPndE7q4iXIB$+~Km8u6vI20OK9P%O6uj*0sbln0TW;eAzp%y6zVXM*$Z{}lC^{#aS$ zSU>Z=K@ARw%!0GMGtzl4*V0mrbdKlw(KpVF3P(m>HvQ2^2=bsE4`Vu`2*|>Xm z6$?vi7@3&H;J_elWt`8=_}pb_6@#Ob7#|tHD1CxBj+=N|SmSzD97cLtu)H{n@##hM z_Yd+J-U!E1Co#-tb>qZ3j}5Fnq%M>ojpIsnHDze6tHI20ulD?BXm|`Wd=|7yo0Pc= z^1N(dXav)ot04R2nbQiNajo;1Jl|j7oPpY*DUJnsB8%7M<;6kF@>$;q$6S{AY;b{d z5h5~g;r!=Uarx3&#QHh$KBS!Es*4z&n8E1q5SBTvzR9uv*@a~c507Go_ZjOP(~^BN z^Gm4i8{=565B()q`a#{=oP`bMJ;Ud0LoC}Y<4Yfsc?A-&E<*;pbq#x+HBcHXzT1heszc%(3DH zKFgP9=Nq&wnSb=~;R9{n-wL1a%Dkcn?C*~rKE%REZ51S@FiuMTirlKV<(zQ3a~OgsO^)v zRm=1@X2`?b?2M*~68}E=TUle-nAdh1vXAAR<2->CKGR>5d9T|2j$!_&_`dha_2|+j zO0QRP9zqS)mS)K7eXXu*JXiGN*5Dj`qcULc=z!bBaoFG(k(~E{+}*qXK;wFa`QBrF z9+0CA&iPzg;=Cr>$bHV68l7K5X;~fTbX4=6i*ro4U*;%j@o6g?oA8?=cPUOQw?)&q%qkMl`chjq5M92c9BdAmxJ4!ZGT&tDS1; zQ&Tw?RLY>ur}E4241&KVluwOQsvEiW!SIe(gQ4fT3_o}QPaBR<(Y=ilh* zKR&j5d^tytqor$94=JCT?v0^V0HTc_oi| zYS$t|nRBi4A))pz5p{ojdY1mmAQon+E0VrZ9(tO_=NZ>UOJCz$(tq54o{GOCZ~eGl z&L@8FlD}RK6+Y(puyG-6yx;lW`>m_^6f%!m<_8cFbZ<<@+Ymp^xB9@78i-cIv#w*0Q0abCr5xyFcpBL3}e z>1loyeUpduzhn-&#@ik^c`|)94zwG`YM-H>d=@%@=!9c^}k# z9{VZ>yX_7tf2v$BcYXd!b?E?Vk+PeYvm3>e;^}qTfYK#pU$4`?RNBhE_G1G|mz3S? z$8OX)%5Gk#4Jchw_VqgLOQo&sYd4S zN|*L$H^SR~_*Uoak8j1>(c%(rZeY<0>rId4B)|}=08S*FV@NV#Z;D@ZYtfk9kbUEjp%K4^*mH~wEFPd*xvimCGGtO>cs@# ziM!KOid8I8V}8J=crrj=$l$ZNX)h zeO!Zejq8X_uHQ#a`3?BG2ca-A9Nk{hw~GVci(v!T0O$ zAgih$HkQr^;+nS}9=@=)uz6)u>W;p(Z+5aoE4-yWz%eb+G8Fp5QEPAnd+&uD&! ztZtuP-p6%}xCWfrX*jsrb1lnDNb_+-VNE6CB4d%0&viXwk`dzW4&P9&)9T;}UpH6e zB!y$}b}iQho5u{x6p_~i3o{pZb1jgZ_#o<64g&pxa63N%H|JNlHd-<&!aT9KHi4wN zL714j!JKPV+Fv{a-`H^YI69%4Yp5(Q3~S#nSfZBcb|Gs{wQw!Gb1qT%(RaR&Socc^ zP0!{UO^~Fy~rFXSp7MpXH|*XvwBKW$>{Y=x#-N2BEVkneUr& z&2FxfXJhV%@@PM-%?}#hTcIzf=cz)aOGnWL_M=O})BQ(}&`?+klMg?}v5!CF`njK@ zG}#}eO^xt$4Mr_}iN=mjSO%ry^e;a^n8g{4_12-0YY+zcbA9i`82TC22oDQGPGKh3 z*ojA^y(0>^j;(7<8rNq$j$~JJ6xCO8jizYoQVybGQeevUtbcj@jJ6J&hocoz!h_LO zUxo*3)9Bj#0-xK*;OF1^0o-k_AT=})AzUBG*WCqO1+i#bz6)RfIMjwXV`Os)&H>qo zw!g+TQ92PCejT5iJHhhAN2rhXqz^aEd#n3=clEJG$opLje0MB?>r44_y`b8i7~ISC$K zAqco;i4?9o?-CY=v>Y#L2T)@$t_;!N(^~;Nr25 zQ4!^V2P?zq=lG7PODcZy^&jKd$@hedoJK zbG?9Nu48s*=^oOOxqf!#b*@1&&igpE-lDO6s_mnxSNqW=8EaYRdOPi9rKs_>!zkA# zO3ZG7`x#3V<;NrMdLBBeiqJnXj%2PU=;`VUyKDBab8&&iH9LfQ*r30KYYDO6%UE(d z$6U-jlJJW^`6<5}a1pUwAJ*41koScSxNOC>X|1oq%-Ru7*UV9#9)#S2O1NGcr?H-D2y1ABX1k9}*;cs^pi3yQhJ2wKZCfv?QhD#v7r*iHJ@>4>P zQd+|`bi-lGH6i`^9gr-p73&@l1M3TB$m3eN69YH7j>r-w`CX#nfnl!kIEnVL1zZbA zf%}zHXl%{nw@^}%OKlxlmHX3Fc=>w5`n(-#5~FczWghNU{>TmWMnRo=(RI!F5R0M#dtW}j5;ZdeOwKkJ;x`eO~n<*@$f z6Z$jeu;#kU(U#U6L#pOCy~Z%bbq;5_UQpl2IC{G}ajU%(MYYYiURc2Iw$nTXaLHsjNp!YZE#7Y9GQW z|0JCI=sg5GP-D5CaCc7!$J*QZ9H4{#67S=8htU)ANp?{}U*7cF~Y~|U%%oz}0Nxnfl!}SYr7G_=X;%1d6-+8MO)7R zn)nT>>HZ!JFwgk>dU!ebp_pT8vtu3T;2N+IT!-4%&I|RtpIw|A(B?YKbG|@sV=od@ zQuqyqFrV%4>6<~5p0sC)FWM(M zxXke(UB6bDueR1D)0FeHW7N&{pj$%{1xb;y2ypJW84SXjn^oKm4&zGcC~y(Gb}-o;&na+oWifreo9{DU0}I z2Hj#g`Fn#}Bl9uE&yu;3^4w0=GuP&5ihdbA_g~|jOHF^dU(;04FQ%cOI8Zk5*ar5i zOFD;gz7Bog+ZJlNBwD$pOFQc)_oKprtck53)7QE*eDlDFZ_yye)Ad*LtCTKn^QQBs z!pAmq6uJ1ax^xsdQ*}PteMYta>u-OhORt|}WygwRWdnP&0i{cO<4f6>;!D}U>$d@= zORt|}WygwRWdnP&0i{cO<4f6>;!D}U>$d@=ORt|}WygwRWdnP&0i{cO<4f6>;!D}U z>$iay>C)8H6yKBJT9eC$x!f{WTS0N4Y(Uw->$CxxD=6#U%HQ}n*PSHz_l}Q`4^mT8 z(bw0Dsi|pD#(i%JhH~iTc`|%cWq6hOJg+|bu`qJKpFE#vE8}+C zb$g4;XWABz?{+Md`*+}3{Vtrg|2$~tJ*PiC?jO(UchYB`b?o)-m$r%y4?#^u8G5?A zF~_w@#9vBCN<~amBtm>$xpuV!g1wzI1TlO9Ui|%BIP&;Q!jtiKK_K_-9S&N#rR)J7 z_D{pz4gp*6XXxj)1Frn7!Iq&88~C|gBP6teuZC;z;XVz{)?B}raI)HhB}0J~yc{jz zDR8iWr@fA=+%|^?;cmADTQj(6Fomm)z~o6>q(c zefhw^h2_!k()E+N5Uiiz2`)9hcH#1gczPR{!i{a=W~;*t?rbA>uGzKSZfrkkM;+U3 zEbUErISObCPl2|=byqcLcC%$e&a^3k*p@48jqr1$9XFPl5f%-3VHLl0Nl{;K_7$fj|3fFmI>)qKQ#KU$Q!R|H)cE5%o9d6eU=xU7s z7c0UNeoj~6>u3%i2Qzrv3ryi{cLiRygw17maE&~HyY&UGFLxepmIk;o)L?NAu10X- zwu{Btr{K(e2ApB|BzBAM!Z-rwtAf*T5}3bvNZtnMWqCokT{lC0cdr{cvwV^_oll)# zEhOLWR>C_W{97B^!q6s{;Atbctig+GHfwFhc9Zt=wlg72;luXS;9v@0wz0sE?d`|4 z?xpSh140vL)-2m)yzfv$v`HG;Mvc4V+88`_r++M4HMgnDw##hvitK4Pc6YQM#f z39;v=A$D#A-Trq8Be?IG(EHG{LO=Gg-Qeqpm;e`4b6xG8?oRqkk98@Ax)c-QZP1fY zFT}qHA&m1(>`~J+EfYO^jHk3q*R!Ye%Y%Bgg&le&`V}2WtOH!G{w6$yB@kdR)7t*|wW@eWwqw?YFR>m>c?v^cN>H_8-Dg zv}+sGFjE5@7(M|L_RTHWQ`eq_$8p%Fue^Ea`M-3yqn>*G4WSV?TYMR~+v1XZI&Z_^ zr|G(5@E=8Yw!rpyLVq+3GWb=xk1K6w@Tm+M^w^&gUy88b(jm6Bw72F@QHQp*NY^1} zgHPqB`&Dv1+d=>}N1$uZ_U|V&h}t9ivjv0JJodewtuu_nYw433W8|mpQ*WN~=XUyc z@|*sh=u^0lJ<1DG(Zl;V-Cv4`jzwHt3^J3VxE40QUy>e+g0wgTWZM{NG2Bn2^SB^Q z;>IGM$V-huKB4W~I-bwC`DxKx=WNAIjec?;(>KK9xm#)Er7(`9mC9p8UP=rRy^VZ1 zF8h+Bk((UF{Q_=pg?ii^9?MORWITpEp2Oog{GClmD90pDb`tmTyK>oy5y)bgl@Nxk zcw#HemXOGd4@E|tAcWgn;P3R8y@L;pqb<%1+>t}!atodeJ;|>p zdG_Qzv~X^~CHglyE^F-}ZK8o1<1275fgd$S1AQES4d(QV%@H7=#s~tbF&bPfxIVq5 z0rYc%sWBSZ_R{_#?mDOs^kZaQ{3l_HF!tZ4pxw9GA)MipppVb-hn>E@{Epx?@+tUm z-yRXkdx>X)_ZyKf1n*Jg{)Fko_&cMfDD#Q?xUh(5B*e$zdR8(j3(`pB$VX{l2J;O2;>+c$4VvS@#3rm6lXq0QD!`f zGh$IleHMMqOQ8nx`*+z1)U;UonNfa73iqN`aV$>!E4gp<;&sE5HtBAK5Z9{+b~dL? z6HaCbq}>NNnh>T2uulXyT-gHmv!D12*k=s5%usLzeox>M{Oq2G%RIgtE^@8lE!Z;L z3%1VlW4L?TlHYU6WY1$pb&xt4>L&Hus_$0)g@?zyY;mP=W}Sg;KQmi%U^6~A+{1?opA5#}MdrXifymTj;Nr5z)9Um}R44rri15Jf$RV&9MQ zbwD)xq6R;PZ2K60C&chtWq>nc0|@rj$8e#Y5FCdwz?C5piX-PBFDl5%L8vU@M%m_4=W}=D58!HRYQd5A^f?O0NC!nr?`Bvql zy1Wo&qBD6($j(eg9P`gh4n|W+3aXiZdRj8IAQ*Y{c`9<^&`_319Zo|6zxkUKF6(ti zXqsG>nS>hZQbSn|8q0H0Q<8`5^kl?G1|u%ikL3?XQz`Y1`%{zS5Etf$^k^SySTwRz z;t(Gegmm8bR^}$)dTtsDGon$&?`-BV|7d=bIMUArnUU@&P7P&R^i7k)kjw9-Wbyl& z>HH2uT7)N3!rYJ?;)0|gXWESu5&|8N5a2*NG$1~}9`XJ=VTU+>g5Ru(^D~AmV*Pf& zm%n{&_KX;wqrr!vhHDI;hpl*9=j|uYSSjm{^2hP_6Lpk2OWld5cp+ChZ^B`MKN0At zA(3HXkibcU@U0=3VXzC51#E}p5LcuKLbt&7N!^A!(!xESKswt{hqPx#q?d;DtuQ0X zn|(uv4>F?&+E5lDVP>>1w}}{m-!`(jy^UCI$NKMzoH&0xjR5X@F>>Pqu`A-a|4W14 zH{$nacOr**7AA+Hqp=Kk_#MU>ev?R^#|1}cA&KKTt=GK~o0No;pPL}n`yBgeI)ZG2 zkmTph`@ax`nm8aiDhw7LE;#s(i1%39UhL4PoBnc#yNNFeI&SEMiG4$2j?(^IlJO^ zO)h-Hlkge8o08~z0iCt!=)O^do|Z~}=cEbN9#Q!DAO0~?>^{TT&Fe_7X@Uo@cPTy> z5W;y_7tL+>jgt2fA8w8Ch)|q9cUk*B=Ec9;g>)7 zCW0N0Bh23mSFT*e`A?4_k$$=fzc=9G{weSO9QgeyHyr=PC;Se~FOcGQ5smo~Xev&p zt|n6liY-}kBvK5?P$WT< z1Ob8sNP++hC{rkGXaqnMf+$4qy&n#DheIQJ@4bkTl+0xE(Ejbyqi4ZO$bY2>}vkyN%T_q?~0hNhxjn(1#YdZbcJ*MW3~)6t?) zLcg61`kg3c*hVYeT{4wECjHDiSxk2W_snj6X&&<&uC(xaUDY|59q7c=_$XFZ*A!h! z%&bHawYa5#dvZTWzx&T*c^?P=N3$b{>z2thks`2%WWP~3)2}@Zb7Df%28Z={V)QmdI z01k(T<8OcdQ(Qm&8I~>ic-qy2i=n4bar+?5hH_lLmyeI${~Xu2)_aTdfLlS-DB8in zAz_F*_XnKgK60myALn{s5Kez}9@h^X;Ja6`xWzq%YoktMZlD266Fn$xYR93Ak+^=D z`pEmue*}i(a^z)P3Ot6toI8ly(YNr)k?b}6U7JRO}bJVIxgBZjgxI8e&43#p9rP6yK!O6Yne#e2H#Jie}{rn||jQ+b@r z+gZ-?JJpNSl~L+UUxyW$3}>QC+)9Dt!hy%=s?uOPNLvWp@5WU9#D=s{4$K1Q3VJNu z_uY|vwrf7R?L0+yy$0iH(|6YwC|DZ`*bkoSkg$$M`t20buhK(Tp^0G|J#=>|qW>jm z=CLjmGw$WFGGD_T<=B|&!_34umRD3=O35rkVQw-rWe!#s7Q} zdH3%lEjkI84n-jF!WrDU`6u*NC*XfqhS4@Oh0mgH;70iGIJe5?9=92|eLfgVJ!NR_ zG9&ox*VLJCq-19zDlQ%kwAm7J%Wx#CB>R1~#=Z8?&X~N;lw-9#mgz}C-Fm)-5?-!JC?I?nE^yz^w@%{&YgT$ymqJeX^ ztVqts`0m&-*BOeaV}Ib?)5W4 zyJ5ogY8YdF7yBCU!_o+5rzWwqysFqsc~7g5nU#!77mwiU;GM z9C2p?xQ3F3Yw?fq8rVe)S0s{QWObpLzis6Rr4eaTtR$)3_N+os2kvrkZ?2-R2zoek6+9nh+ZuimJp@ zxRa8B!vTC>DEK7TcXDu_YYO>s$1!8AKzdOj*OLR#-cFVXmhhv(`GycGqIsT#aeYC8tc4nB<VK}ctHA#D-Dc$6Ew2Vz8Yqj-}T`({LjWD=B9Ubsj=Nm+u<7={P1VU zx_S`*J#T_xa1if*aS`wT>!?N@*Uodezjq1WE9$Sw!{WG!`{5 z!@HDg5aWhiRJFDv_E-Q6F~QiGG2*+mF*H(_PF{<~gP1Tp&dTzP=hX0yRuGRz;(^O`bSuP)_|1} zBbJ8@SYlol2U0-JsyqrV3j_P{Ik3P?e-&+}7>qM<5UEN7tQa|*}F+67#YTZMfnA0)O{_8+5!wL;b z+e!Pm!giImwIS{7N)zLp=x5k1>?{4Ro<*M1BLgk$qpzNMUUO@_6WE@{{LCa4`M(2X z-MgmKf|y%Txb*v{*<;k%oWx>3hh&8i4MO3cedq$nn&S?^edKK0AW- z=>crcKEn>@SlbID^bcZtPT;q9)BMh5<{AA%OdrPf{0KH?hp;|1fUTJUC2n(`zhiil zzx!cz6hr)f1`*$6;KG5!DCe`0;)fZiOHRQG>*D*B5v(pxA?0x)Zk|1b-lBW>er*_K zT;IBVh0lE+Mx&m4ZBOwz-t*aBY%i+$+u*gf<_F0THkr3A8yn24_OaDr_dP}f^TQKc>W2r_VjZt>l*}~J&Lf1%LqSu5XMJQOtn;dg#X*<5$MaSRFNCb)*Zcw3k+f4Okg!XT7#!iRE09z9xNE z>HEA7aIDO8%-G==nzvI;|1NX%&rz>DQ^_BBF;0`t5*VWck2IOtMJZUM(Nzvtz%$2H!^zgr!_*5Vji z+6>4_N#$C39@n(%&{~zx`fS91az3>~o!Q~I+@kI%+C%@gggHKUIQDm_1A?S)QM*L1 zv^Yh-M9*x$(cJa95g3f^$m6&6#=K(OLkngPz zpt-sN6?`wMt|T85O(oO}E57AiRk=Q|Bi9#1|5X2=;ukI15#1!ushvZEeQ3+e#zcJ{ ztH`Qo=lEzpo)nhgUR*Tp$3&s_NgNh?s;Nc&N}0BKUSV^(UtycNq=Z>s(Io?)wJlmJ zdA=TOP4{7QlKbw`&RZQZshTv{f#tzAyC!LUTgJgW$BQ<0cHLK{Q8LDL8YO-|G|DfX za?+(;4H7-_aUJJ8dDB@J9TJW9Pm82J-D{C(l(P;=*qs*bL64ktNOZ}o4rw~|u4|E| zgD;>*nudAOrPv32H#skd^9`=4aQv_HUcX7?p1;a9^0mo6EKwg8hRs;#Gpa2~w~a&3 zF2^8`-3wwzZScH{!zRvejGRmLDcT}7jhttltnm7)6Vxi&9$ON}G_gY#$C*FAKOo~> z(v*DJug|c=d18`jEaN)ewJ|H#vUq-7oRodKpU*J)-oWaZiTXl&i09gv?C}Ek5+CVi zo(z13XjHUFo+Yl1(oW+1&2A@AlN4KtYfQ>LRJrfU7~oit@!?CG#162J#a-J;>;=Vs z64%?|DMIoL*`C zn&efF#CCeiwvl%Im(U}hx^yod1^IcH8#2>&;5g^FT%VM&-^Y8u%(MEHd;JzQL$qO? z|8#eavgei(YJrw$Sd_pl(RK*dKC?#EU&5dLi1W9kc6pGtL9! zj3=8+mvf2UNLbh)+YE10iv&rR^N7vki_Hm(qH(KZVjs!8P4uW!SyNi(n$prUo1Mfy zXxAjJB`Wu3nCWRz4eRVD2aOWFa-&nPOryl^an&iuI4`!*8`dJvdSugoUvoA4 ze9ccA>Bp`|qD!wpljIzp?4`K-{GKa67c>1G9DCi0O|Zsw5C!}AV_5uJ{GMDBkJ}4! zExG<)j^S^WW4s;L#dG?A_RN|a)@^xF)`rC9afUXK*g=kT+H9j;`$%0&56066dZjj$t3G+1tGzRN6P76-<(>!e_!Sg)N-}#*v zyGXyDIxm4z6o0_(K1C#qX%6F4wW^hMGrJi*~Q+_@-_S)xtjR_Cw@}A7MQ)b{>{?Gr}N&9;Oi4W6|o5OEl`Au$5M=dO^)o&m9 zKKGrblKJzFndyGP@2JggsbIXHH1T&fOmt2B=GcKohV7KmFX-dMuf=D*epK2L7qoXe#vw^Dw8>r45ahkEz3-F&sbn*NUW<9A@Jn>o%0j15?w9mVX- zl>Pg-{DMNH@jKe6YvH&W7J}>Hp|6QBp4VSqS03Knd9Se^UyLvwC-{H7z0I!hm=|Ra z*HiN5&vjnMIi0S1onfu~d#N+EjC#`N z4Rfdg#H>fZttr2cO-Ze1{=u68PK?pogYu<}&m5 z3g$Zixb%PW|A7`rfYjhWErdW3Pysj>LFJ(LT$j;M|9|wgS6@GC``PQoyMJeKKshSC zx3CnFLIhw{gQE(ZwNN%VYrxf#$KN&JyBgdX5Auc3e^WmSxv^5f^=JU5x&KX(|90tD za0MIOdzs-cfaFj8Uf%BfP!lgzyHa9`8*5g|AgOF{aK)fVZYVFjNk6xRnQ-NXU6$08#)MfE+*pzzhc^fC?Z3AQK=9AR8bDAQvDHARnLr zKn*|u6ap~*R|C#kfMS3WfKq@m0A@7X0hm5s4$dn8Rs!e%NPs_k{0|-G25JT4`|F<*LKXd$N1N^S(&y4@R^=E9Ei3MHN|7TFvHU0mZ`1kKF>MwY# zd*AvqF)@yxT^mdP=S3nu}%%5MQ>UFrWokjecO{eK$pyVn1`7SLDzJqpw}<{9)q<+A=k ze~JFzyQF^@@P5I7zfb@7*p|mXgZ?K#*}nZh!|z)B^{n=P9Psx&|1tdGuISGi2kM*n z4Elcy%J%Jl8GdFBs89d%c-%c{15kCJas-s-$A1GT+xPfm zba&1FxP$tbbrM(kDNvS)R~h+Z{}%yfKiA@KCU>3;;3~fflx5;2MxM?e_PF)?ivOSV zy{r6(0Iw_j0fnk@<;98%g^}#zQ?}|)H4mhRsHvXvfeCk0P-|` z|Htuf-~7+2|1Q8A{+Rub`FmGBTpRx*L0tg=uIgV8%J$X&y_V;i{XMJxMwj`S{HxFT zpEVuSH}e_vuLEV7n30h`>VH2l_e4JSKYxDz?*zPzzhdO+{4T{mtQnx5*#NHg|L34= zU-3_`{(nvU^BLfGO@G(y-y78D^9=fLb3uQ`^7wzz`2Q5}_Z9#2^7ndyzT$r-mtt1v zT}6%>UQqzaP5H?^^uh3+jt}2K_g>z|XXN z*yH@G@A>yx=YMAIVV>DA@<;QZ;2*hf-}cWuYYzr+)&AcHWto_Xk*D+jHS6E+0bbYm zU0eSN0`<)Wa8>^eF7y92_P^d`e%IoUIiS9I&!GQ0m-(6aqi_3rR{MX~MSkAn{HyQr z7Xs=FeFpv4g0jqdIU`TAf8OKu&%XJeRsS`Bw=aHX?fuE>Q(x;3LQtOwz*YON0cHDI z|L)~ybpP}9*SpN`+Vd9-)W_tLuIgXyGXGzb|GfkFne}Q${>c6q&le1KQMuCoVW6G} z09W;24ay<_jQkOQujl(~;-9ww@3P12eew4`fAD|2lkB%2{L2YEe}BB6ECF11RsT0Z z*}n4sUi||fTYq2q2gCbB{^j=m?bkQ{2mC(368`Idy;aWz`aj`j&i|J1UoO7>C-5`* z1|xu;Se zj69v6S%2?4{)h$j-~h}$Fm?7NOz!W->Miwje&+d8-~3N>ca?uR!~fe&KArzb1i*Or ze=p4bBQf}s1i)2(#`g~Wt-7c4yY~F)S@o{~+{`m0MxMscSiURv9}ntby3xuk#ZEYL^%@p!NM;%Cr58kGIb{Q9uJzsCPZ0sg-7 zkKXoo&HpU|^(}b@{h9f)9{?jyx4*x}|1oP-uK54n)t5f!pU3YuWP&-cAKwebLq{89Te@89(9|M>Iy8Q#9^uUCJU=Ksg-{-h0|i0l=YRLsn-shq)!P#PJof&YdAI4G@1HU28vjnHwBGm5 zo}7PQhT)fkH;1&~m=4}Jde%Fb3nHI%P+m;PEr59;@^FK!u#a>yFY>U{`c?yG4l`q8RDNT zP^qiqZvZIkO8(1tZU4zX+TT@vCiZ4>U`GB(|K9f>nf2$s^G}BNB~X{E{LI|*`~2^J z`~Io+H*Qz?CxT>Qdms59`gs3?OaAAX_diVl+)w;J6N^3pbB&41o_rq!J`V;M0>H%U z%$|*50F3Ko128#^2LQ8{%&ccHHpT3PW#%?!eSvw#G!B57YbO9q1b6{}*(=NeKma@e zCIc|@$5eo60A2vo0cHR&`$}d3cmptgli6p$^c@!f1z`LDGZvZk5PtyXIb;ApAOQ1R zCKw#E44)7+aMBJmFG+&x{XM0x-UW@uf^W#f<4}fE<8afINVF zfC2!<*AM`O07U>A0LBiB0ZIT$0m=ZLaQyzf5?t2-kN_`6EJ}(p1c5gGrLHg+wI~{{#!AxriU5ad|0$0>I5=fWlU`*)03EC@s7FRtlqAWd2UXZDZl`Aw{b@4yGBO+yfc0smATO`+Jm#B~h zMe1S#nGv}-JUUby70LHY#KU8gW^&UD<|U}ovx#g~fmXwO^HT-Nc?v&)lBZJoD+Bx$ zfv7?mq)_+=2n4EtV7X6;qPRkymn;8ox8?GMCpBQ%T8(c`L5^>_n(1PfC0wm2>PD2R z0)&tks1T((SF0{k4I46SNH&sVM{+c(d?a6;juhFIvyqQgh*pi{=E;dX^=yPFQfu!1 zk^g04Z&&v}Gd9TBsH^^OJge{Zk0+6*EAby=uFRNlm46)IXM7bSPt(75?&*8}Va6Q8 z&B)_Q`#AIm{F#iC1oCwLC#?|CTln7`ne{iuU>M)vD*sr(&-i*qp3eW*JbxJj_@C>g z?}Oi^=kJgGAmamF)qk|h{qI`-&+sz-*H!*efS;LH8F^a!ySV=M58HE&`lU!~8Ie_1_@z2B_ea0WG)xUAO%Fo!J zkZ~A5{tW-W3e@uofUEo=F82Rl<^O{L|DWmqUkAFs`3(98x!nJ*`~SC|fjm`hNl7|4;gVf587|`hRBJJrQ6AeM$o0XL4{x{&@WNM!v4ZzfZWCb8oFrKS}_1 z-{X&Ac5VOtT0r+MfUEpC;P1Qt8GhH|-)Gfd4EX!<|Gn$)%>IkM{XfIM{u%U-cR~MN ze&+dq-~4L;cl9&y#{qsJD9^~#?a#IS7d4=s4FIn8e=OktE&X{4zvwsXV_M+p`Oka5 zal6XD5b*b9|IhIJ<+0ujHzVLy`jlwE&#dt?@<;72c>MgwrTy2?I#AC$0Iu>caDm?s zJUNL3?e2pAd1n110e|1)?}`8E+x{On{BH-QP5YA7fS>rS&>yuw!`|zE`sRNh)b#~` ztL^_f;70)%c{;yK>tE0O{4Wo1UmwuR&jEqcPhdeHHZ8I^4bA^S4h_jrWGjJtPEWTH znLNIL73Ox>U2e=Z27;ThMXH zWdFJ;^_;U)jFTP-UJ&pQ^ydlbvj!UnJNxP7qxJn8Mm&$Z%QR{hiA0p$_23nFQ3Dc6 z`suwQ-QdrPAWAz3FPPDw?Wg|~>2H{MUx~OUAndAWuh1nWgY>1jLrJA|GVI;b&p8l# zfkcNCv8!H&JiV$Ex%s&omYxM6NNAiiG-5$}bo>gR5|-V|z^-EH$7TljyVam$P-N~= zcGY~IK_yr6oC8UBmfl;UC45wc#YA?=yvZ{gXQ6JWk1eU3P)(kt@Z04lE1ZRvX}R9% zvt%CO^AyDp>Jv1X=kz7YfA)cp0HZ(Re=fZr?2lCkeBvh?W*;gk4=Hd%wy5R=5D4y$ zE`z9di!z6jKBM(S$Rt~B@ZJG7H_V*~kt|uk)BnIt4A{kUa-;ZD2H3Kc<;XBwk)I5e z6}1Kw4zrcaM^DYG4}9o0obbtz=exr}meI=D!K0PZhyj+tBnwhTn%q3Gef@2sT{G4^ zkE<|a>R51?i|5Utw9n)62bfU<75aD(11bfiaBT;quTWvw^ZNd%pmI=4I)(*X6f;oF zxM1>3Q!qM9HdNLR_LGG}s)1y)8=9mBJvE&QAh@`7sN0aLq3J%ajdU)VC-FczgDf!( zL+#@bZV3{umX9?onI0KF*E!gUY#UbEkW%(7$(a!{;6LDd9?a;o{>%Hq$^X7p72Jz8Q-a3s>n z>=aHacadD|!Ua>cUxxs7}SOP}kj zu+rjjLrAe1w<^slYlb6}rnA{OoLp|6Fkf6CRjZfQ(uLw8smv_5t}vz3db*0HUtzD} zyvlt|_`3KF>6_}ebk?`43DY}{A}f!K(fTbL-dPG4m*>nNN=4Iame*({hq9JId~_(e zv0-*IGL}48E{P~#!-BL_kh8e><#)2RlVfeHn&Q0N4I*n9HN9mcz8&HlG^JSa8oDBB z2C*J@hdhAhC0F`m-|wi8-K|+RJWRWyc4Zy?u7fncYg%VsZ{6T{kN$v7Z{&Q){Ydz+ zxK_HldXuoaj@FxM%wG!EIw;*P-R|l=we;S)eWtI>Ut9m?_=c{nJt)0#NWF07T)ZMT zc3*=-%%Q(k8^!0$N5#ja$JHlvC#&i2YQL}h!F0-e+Io;}F`2mZ1xJJUNAVH$PtuF( zOS;R|^xtcLuKUGgHQTIq$Ca)iJ?&oeYxUjQdvy+z)7)%raaddFVBR%$6Xy&&WvFbJ z?ds<*_oqUOD+XdakegrjB*uw;r0)o?o`rS{scbUQ*UdMqHyyX=A)H@1ZFTJ?y2Jd) z+Ue+`d)W7DAJjcG(JfCdfRPJ0Q#aN$&djYwYiV8`-{fcZw+bAzda909eKB?lo*06bY|mLi zXbW{$oTa>F7B52UjMK-~2OUzCR)v7A0b5yDWfj|?WeXBZsl2kHa(xv189(As(6Ygw zI=At6APd|yXGNXcBylyxS6Y^1^E|iPRv@}q0wW_DK0~(g11y*fxm~<%a+sSl&&{Ic zmsWAg;8IHK{0xe#DJd5^k$6?{);*s#mNsu?^{7R*g~sigPd63URFLKM^j6kFeL1M6 zOtu}G^+V7R_ib>nY)P>|;3xPtP?%I75EPsYi#F3cqr$jn(vl9%kj_;5aMQf1y=!OJ z`5Z_pO3cnI#k#b`71Y&DzLLrB_)3GDy62^egiyJ2o|zfxp5|Qn`=3Es6;wvBY$vA0 z2u%o=TbiTyU9XWDmCkalr64yKuJX;q^0`Ia7**xE&uj%((c)B?P=}KJv_dy$LFT-4 zO=lpYg0+fWzm2De&T`v!i%+IZ0x4E`Ng^u;hQNVHQjs`SAP9;N%CH4a*K86MhuC6MiyE`4-H}X1N$ECN8=95T;2%Vk zWg=MxDjB%v5LA%iEN{qfmzVjJj|wHD^vc3O54wCru&lf?5GlVOEUO?2x8B(1%(q-6 za(z;qu^z!PS!4)rdD2Q}AfkCI6$+N6Z-YYw8O65E@?u+{Pe8GZuQkk&2P(9Th9rtX42YLGzS>h8$N}$*@`MG=6GzI z&5H=YiVHqR^Dzpz{Gha)OhgR#lm#2-$z?LYEs%&5sM$~!XG(vj)y7Z6}EYzc&7^|A1Q+{~-8_lRONGn$`d z`6|G&`F!BuusQWtS$LpKD2BDfit3fMx-GGAU`AG8dVtm@&#-B0GNO1HKE;+`UNMHA zOS17RQNObWzU<7DD#u%*!hZbLO2=1$zyxWks4V%5jtcr58y z=m94kWNRSjS`O8k>W;7*%oZzs#PKbCjD4JQf_qZE`45jLHyW1mc6s$68(2J{qwjeEIca+pX*#zUsgHy$F}u`VDb>O;8%1L5s$^g zyO&j-IwL0LTGqR3uCDHhzQVmKv|qg@ZBk#?-Kf^xti4rt+jPf#DYz`V;wRoxEjewg z@KdpF3mOXx3g-|!fzJ*@CAqyaXmv3fv;!lFV3fB*Z?7QIm5Ov7Ho1Dr$8@9k?bA-q zmvuW$b!MY=n3aCy=%l;ZJsg?~3BO}I#I-+g54^S-34z9J^7h{@b0UF(f)~gn=O=Kn zfo9j5>EWEuLp*fDt4Gw1tkaD$jW&<5j&+QqC$LWqjyzIfdtn+s$PY;-e6e;k$bXWU zBb{vRV54SwifO8On$^oOou0{_#qs89W(!XhMfg-$1bP8gGG1}WAB)o4D6nydem&IJ z%60gO+0}Axm>H9rJ!wB(yG?prPTV(aa?%f2F`k3C*t(D_b0VS;K4-%Mhrdt|B??B= zngEF$zaovuR}>=y5ap+l0#AuoTw=oH#FiiFOR}}w0vv&KF#D4C;P^Q^=pT&F)eSQ} zZ(hiS9WR=eHZIFH<{RV_Z87@yWy=YlHeINA%R#+njznObL%ulqLmx#dv`PO#MsScj zJ~VofSduUYFOMu$o`}M zBXSd!AJSG!V>h+t;>MqkA8-ovr^#G2XnK%HW$T9=q$0z82E+NU5zF}HZyK@8&iTV% z51l_q`gw3!UGd=;x%3iY(Mx5*V(BmLiI@N_p=)2}&aGNxFIPW@CS`rxoa|1PUy{X~ zCX1zT`AEe76Bhb|6A1{p?-%q77Po@?8ds+#b>_IjSJ^ct-P~6-E#(Ie zO}ivJs8rby{fjXP;WiS97a%sD7_XS6gW>tQ@_LZ*U zq10Se`YL*>^mR^o`->6eZ=3BtKrdS{A7flU*&!@Ix)0=-#`M!xK5!tzo z?(=2c7KzBL7wh}U&RmJ5PUDlpWVROD={0Ad#Pp&9RSeRCx$BYp=owj7>Z!)Bji*Jy z=Wx{rgtDaAyve;V@646cqGg7BT7U>4!r8CzwEa}`Zt~o5+Pu#WRge`eAS%oK*2=4+ zPe?!KWE_fZ{9)gh=AG8~kJqHXXVGZ#EoIW>FH_ROVzpM4vH0&|I{udGLR0)udq&I& z&iB$E)CZf-hF`%e?5AbbN*I(xxTtf6PWG6dZ& z$|p`EEZI5Ubz(z>Wjh|D&+4v3a+{s4XEoC+i;7Rbl4==(dVSkDP|k&wZ&GF%%$si9 zzNSZgezW;pszu;5>(3XO_1)(UDW}&=HzGDvk#0PDrc3Ml9Ots`dEL*o0rXg!9?zb@ znaF)X$arf+ovNcJi>FA_>VkDcO#;&}Yp{b3q35#aaprS{LQE`@hN|hwoN)70;i@%f zB^K6lRML3rg0W&*;RrY<|Lj>yYmX>a-)N7j{+7FteVbmQqZgWEt#OWc8fQy53EV^> z9coSHq;MnIQce{2MJdQ3rPZ=pd7Z+PZdO`VjtttG#ZGeMs8iXiYT~>k{%f7N#W~pp z+!swmU67O}>k6xjYBhCQQ?a?kTI!(7=&afb>oP~KInSE!&{fk_)i2k+Qn$+Vs`)kR z>y9^Q`Yra`oYm@gbj!`n4=yNL2)em=4M%5wx3JtDW(HVgO{vDX#9yB-z@)raI`GJ_ag9mAg zf3%FAI##;9ZpWVPFUN>>QePrpR`0B>tNZBhV_NI(?;b#D+i(y{U*tjgsKd~JWSrr( zIlpqJri-o<=@ixA^yMQl+BVPJe#5!K1F}4~c}I^-^AkoE`?>GEpWzosXmX15uE~M-1d*=N>})!bv=`1s+A5#KY4yZ+bmEGw%^HEimj6 zG3S)see|>r#C^x9D@wt@4#e!-Z}1Pu@K+#yD*p^#ClsWN>x7h#oHIy2`AGSgktQ1G)-f}2)H~ZwO@4353;y0|I%0_M^qXY&eg|;O^uOU zIGn=glW`Sp(Le19P0EfAh@P6u^VO%8{L}^6)xJ zNE-?%Lp#~&@$js?)0uU*Q=igM)lDed@gv9qSh$CnZZ{A|x1V&JC@SJU_`X*7!6oQcByY znV2@BG#FMc)RfP}ctM3wXxidM0bvQ=ZpAPe>YWh4&v7ejCkp%%75R~&-fUwk&Wkfc z6|x|~B5~Ay_!m+Q1;i7JwP>u`&HGm(GGkF>L|LUfj4G0qsqq(WP-F$aEJ?{NhXPAd z^Zc?z<*c9Z!j$-AZgC*%yeu(TqKPgp*yAm}gc4^h78}~Br+qPZ!y(00_BBou_qxD# zl|JD)P=6@=*p&w74$Bqzn^4crdVWy4(m_M;1iHK_E__`!WnQT^5Bv|X;0vtv0Z_EEeGJ%0hFB(@IAJ5T^$LZ zv6YTQ4_msog!CY^!UHN>>C^M$9>U!~dD@O1f8euWk>m@DoroN+U!F7)-srLE%Hi~H zFz_aVVwBU-2;1SmLEl(>EW|y+jwpifkv{2x_eg^=@bX!>5y|-YoqhSDEi-m|w%KjI z&V7muUoajHp_B}IoQHultOq%2I%Ym@J>h7fzi0ozp-*v73(aDSv{8LVceeV+TKZhw zdD8{+Pu7bLCTjngBmISI722ZqNe0&x`9fOG*Sf8z2RVGGAw*bgG8`U(M^7*&Cqz^a zF}R!iS^GC3OO|k1rd>AV?vxLY1-|5GJ>+~)b3Mo3!f7a`(zq4A)}zd zvV+PCJL0xaqOl%=yYY5-zhxA;f>(vUcS!s-Hj6rh@m7s%^ylaFMDkdlgD-s97OGzF zh2GW%_-O+CO7~;CJOe`a8jQREzr27C12-yybT0&+C<+k2Y)#l2~j7WP#2IfWwumU_*q;UCQZRY-dvio&9rsz<}VZl)H z8_Rf%RvfA`eVN!W3nGmAJ;Y%Gr4`-J5oJ4wFFg++he6MLjkg_c==rf8@g0kfH|!zk z*LF)z?l2bkB$U{B>O}1gi7F}SaED(&J)EMg$F3m?H+^pAb9ghV;n;CnX)*geL|?C>wD{`v@Kq-{1ouwFG?NUzXv`7=y2 z%`ZBZ&@c7#kG;)twf=Pi6CGds_DJ8`|7?jRaPG~$LUNCidG+HAK`qg+qJ{bAl{S` z*D(t!^4(R zxnP;^6M6&tJmlO>lyZr`u|) zC3omy%3#|;Jx6HP#Y1VI0r!QgeK!y53H^i{RlE80Rx_B_9NTI7Gxq14FSuXMkGi{) zQ^z$1Kg>2>d=4+UqpyUzC|juGAiTTq5K@CIFyX1#CU|8S*}Q8+j_n|2b3RwE>E8Ec z^j`5k>0bA*bYEBht(N|#Zolb(`JnZX->f)d1a=I(kO6Ts&*bMfN4mWlt5` zS50TKvpCt@9AU0FPnxeT(9!DZB57e=k;z$i4=vG^R?}s*<#iRNW#;A96^@lO$)+ng zRos1!SHwMar=@1KMMpPQpQ$}t_mS?fskXMd<(OrEYx5w~`z8WW<8i_B5Iu%kWSbA( ztonrGRx5p<<)Gc@e(e670o;MYLE^#EA?i6pb=5hM=ZwR)-bDS7UxR`tQEiz2^Jcbn zgp~e)>nR>793>tt9itwr8&_=}Upt|0qN(~ygpXL}1>cz|<1CTK7>exJxhgNXF^LE% zQPd=1x2WAV3-jK}Ok4i>RTn%T64R#jc;wEoc_BaH5@OR&1`uWk-^O{Vm}tJyN1#X# zyaEZ%@Re|o(vJDucPfoBf&^G`6_cYs;prE=ZMz}AtD@w>SU;ZkY#$>J1?dUL$9zhz|TdY8(g!<)L+9rf@UD9yoC6f8FS9^Fo2o?-_14&Vo{9GpVHe3(4~Y_j_YBy>Qr6dxE#6JQ68Yf?WE1 zWpaS|airtSeB?a5WF>M>y0|)R`BicyeI(v7HG`gU<_3IW ztykuZu|G+s1<#z;!<$(*>+8!a;=H{##SfZYx1Qf^FrJJ&isy%XXQGkURh$gZ>J8T* zFL(xWm1HvM6!Ze7w?&3$PNjTlbV$DMOeD9ayu1mN;zLuh%ApP;b!d>U>5iL+|E1 z7b@&G%aY=4v+BJd&ts3%^W6p{zF|ghdY;GTI!c8cwU7{t+F^hFJw&iR*lx6w0n;o& ze7kdT62kYh8#Sb=6Z5~XR4gP_Pr_}w)-lIi!Cp4$GvNyEO5u7jO-ifj_f2a!Yq{?V z*NOMC%QNPLrN1Zr8}|cUPAXpNZSz5<+hb!91M!ikXlK|*1jy`tVoh6khT5x}>ily3 z{DL3p?-=|I0dl*(&=R+63nRxHm^HBtK=m+80J8((|zb?|oHH3Yn!N7*(f%#?ta^LEN| zBlCMAXV`5MX5Zgf7R^C)p4Iel_RZ^YV&&26oJieG?k%C|p45?j+kAtQI5K65{G|Mb zx7V-SyFzhpibnyy9P&s&e39^6DuS2);!dQ)9`?}kNUrTL#;m;vUv(nd4tse1Numr< zl=~oZsMYo;A+HM|zBOjTGm-D9R&q8>ch)S2&R8Uf9qF`n+OFC(S8c1E1=-VJALLOe zuX-BZ{qAa~1)m-)>a3d6<=IN6e`lNF%xwrp=H{ws&%;P8auLofUWwEqS8b;)9ap;F z?Oqf1OU_ki?%^)a9-e%<{vvWHcb4Um2qJ&6bfJP4?0n7)*&{@G5z$bROn7Al#BhUEYRU>Ub%A zUwHn}!w=gYGA{at@Hw^azVyM~l;yV_4^3_6_QvqU5pXUqBItX{zr)CTt;6_Et3MXP z4?qTm(Nmq@;?s!_*&lHzkk{{2v%lpY6&B*382#l6!NiT%fBj}eEN5=GJv97}BocGPfHFOpfh5d|b) zkj^YV9y3g*lzvTa3--k&Ho3iFC@Lw)ehK{FNnctJYr^10)PpPV4?`p?Ez!JXP}Irv=`o2eOHCHdJ5wDT1 zRqNi>t*c&NTT=TTU1n-;jH5gBiLHZMKQxU3micydosc$gHgPu#KM`+{ZdHG(+Xj{k zxI5IJ={}HdRDY=3$*JeiySTfBd&GOC`_%u8gXn|o&!wEE&MHL4QR%3yED+2%2Hi2o}<3CXoFB+O2Y-8 zrXCKd;UHjF#JR(B6fH8K~^PSIZ@krZ@sVrV~TLFBY9n19=b zFS>0@%l;7czx~EF=XHH)>^1N*jxsfmkEdip+LYu7t%M)kPn&)RN9Cz8nxeEj9twVc z+ik4B4SzQ=2GJ+chO`BP5LtANebgPR zisz;+N;^!nP{~>)-^bDfy_5MJS=@U{J5(RQa_OcTMruBYJ+3sg}a7ar|aaTAIzi%$}jZWo97_cw;Ssny-o=dJdK z7D;!5`WhC`gB})i+pc4h>%<+LL$<=Q+}K5n%X-+X8r7JAcw1oyl6=lqoL1iKn3uQ$jd!8L25@*MocC}vA-`-i(FI+Tr4RiewXB3Y)E$Cv z)VIjeZW;U*54#4J-^SWxs<5(raT_%aZ>2gnMdjVAk3Up#7rQNUVl6fgvaGfKVd;J6 zotl(({e5S%jR#@*DR^3bT1S0?u_7fWy4%=l$vFzfD&9z^8F@5xKPhx2Yw zS#}-0W8pNPByLcMJ#~%0CodQEB%}Q%Vh#`F8adK71`EFD zY=!R>a$9VZ$S$N6Q(v`INPGo1S=Z5fc(w!L`I#rP9yGs>4#wh3+eJeOQHLcUK3wEC z0E+JMpNKs|TBu33yVxVoTkzO&Rnj!s04R&3#THE9XM`4$&3yN%8VW8m&XgZNS)f{##XTFvNyCgU@%J`?!*KsH>iE3P{sA;m}XoM{ZE)|1+ z@pcS;#g^lMrYpXXl=z5!6LJSl$!ZrJY&K?ld^SSfV+krO4KQ8qhPrLaAlO%j-{;V> z!pRL;DU0se1`P=jFS_WIEzTPUcFUwS8{1HtyZgcSBiFF>BaG7+#S(78L+9G2j`a{YjLXsjW9fizwc4E3RLqo!xrR*4S?SFT4nFGlG*3n$bse8&y0CNx$PP?>Rg_)Z?v1dza%0 zt#E!fHCZ0%yLoJSK#Yf^i3+U{mt=DdZB)uh5Y+wbUKENolkSWKr-N}=!$ zH5QrN(B|(Pi{C2DZ288$WE8qU+QUn#kJL-BiHfD02H`_mRyhhKE#CyH(7b7S&I`j^ zhqvonjopoDQM^v6t{Wo87)P%eh~IYhSk{*g8gdg#Ux0>7l8Bq(i~YwUlB*UsX$#UV z=ocR=ToQFr-vkW@?&KX!+T57LDfWC#CbywSGer1k<%V9@3+|D(4ELx` z8rWmQjJ8D*!Gq>PI&<*I- zrrR|~$2JHaReDPn(8!?5w)@UoZ~(gKoW&733hUaGSXwg^BNnU@m4hBe6Cz5>$5DeO z#|6sAQZYH=0^iM-sM!5Fe1vh4Kpmi&Kq))xTfpY?u%Lc)e`>X25F&j}_O@YlrKY~c z9#vydeAOR)1XrFFjN;J-u&=XiDNkTOX(X;;wAUqS?W-?|$LrtFEERe9iF5H%Yc=)e zv}}nt)+G~r>uJC8E{Z3rIYR3b(G-d5t98k5G%V+p-9!cFlh$N;i5Kc6LHw-Ned#|H@(+$z%Yd(k22Ttn)eK|4yOoyzC7yLHyK%d%( zb>a{|Ab{ns5(SEvfg2hJKjOuy`;(!P2WXf`dyUF%L8IQuT*v$DT8G=>^30jWt6lmp z@h~*glUybn32obgv>o+ClQQdf1rBDNT=yWte>W8Bzm0X(W(ALJwohXvp%3)h_1GF& z=AOeG(MU9$XssV*TR0@V7EyjdWX2|n(swoQwJltPax@i`sQb%yo@}#4b{#uu;8*QN z=+8VI`oZY(ga>Gssk{m97Xd&t&ZSIv$)Sd?zEWPEXGCXu01L#gjJH3~PceGH!x9^q{BBIY@RELn3z7lNI# zGf^F543dHkM9<+(4c)vQJ-$INu!6N^lakLGVVW7n+rNRIiM$G})T(8M;Mn zOq)6re?(quIsV9U3=PW*&iKYcAFprSR5W6S;dn!)ah0X2jXom&R(e#OX&i%l7e?8( zA2xkQ?vsxurW!x-u#iF1oOj2=}aUk&LL^ygpDSHaYmMM8t+ z`n8G12NK7}wL;%{{oOyf6`Dl0LV^+X7iBx58-g-U!3u9OsF=U(ELyT=!AZj~N^a}M zqUo$3~RhOa1r?NM~sI@~0=``RfF`h-e${5IKtMiME?UicM0pAcQeHF063 zr4up#?saH>mFI_&eGN;U6D`dT=re}1qVl5i&1JIL?w*$H!dAZF1t=lW1VwmeODqkh zyS(wXu?;ht$01^B@vx!}_Jd^ZPS$zcIikg`(OdN`%ZN3N6QH|Wl49YN%{P9YOv_5B zGQODFgWyn)=otDneB4=&v(eq~3k0o_u%T8@?D*tdhN7j-?4Kz$_Lf-au$iYMSlxiB@XSR{hS2DL z!7qaipiLeZvBi^HGWoi%_|tS%?mBp0b39_k7WZiN&@p)G(QQ1VVam6oH_@Nq241bq z5o&_0&J%9Ck?urU`gMz?en#C))2#2DB6_X!GVE2~Jbm_~v;1|<#|;lksNnnc5f{*m zHLENf*zarj6JtSc7BO0)3hxPSFAPLNu{RANtitAvibK3XhC}-IoN^BjEXBWG7v#AN zZ>i6ed61+%1CFP`u5RiEqHQ ziBzYYgol2EW$DGCWL#Nt*wrs&axyC}?p^#B*+NTX{%vX1FnzG1ca9ci^9_+fqgrxd ze%m6?m3=SYWVdK);fSKGP&@Yi;D(fh-LkzziexxJAA{zbgl1;XQz#wI-kGpUZt*{R zSezPNx{0LUutiocsEw+NHpQ41p2^aO##wAJX>rL4C?zNiH@Ys!H3UL%TjYv3=O>uhg1!}GF}1bZ!l z!%$kGF%n5u4a&{+@1TfyaRe40x)9|hAy6*szA-#zL1IB<6ukzMspUFFb$YF`PGzz+ z)EdArSZ-VfuW}~(zwdk{DSfXoJS#VTH2hAX4$~lBSX^+lmxX@$L51f*kF%n8d0Xr( zyn+yZhj+Ieb`FI%8owh-@P|2%4BIM;MpXUW@I~QvgYYdVTk)LjV{#j{0V2vmR89KD z8$=%ykY19SU2ZItt6@na@?cZMTwZt=w8i!lRW3`99GW6Jq+hfZ$}3AvJ&;vKkrnbG zI8<0#QMmBs$tH#5D!w2KDqKugH9y{(A3CuizkY{o14JK2f)=b9UhUBYxqFU=2O58g zI-odXD`#2t3%)=;ZlDjq<<<(vGI|AjB}X@zFbGb|%62)!8<8q9IC6b#6Jcv4ywN1d zNaJh!uu3CaUy>LR@sShB4JwNBlj`NktN>$5l&D0NlL=m1c;%mOEu{Wn;9d_6$1<-P z(4=~UctMZk9+73ucI41`?0n8_&y6j(2@bzaeMp5y1W}7e$ddE+VZ))cN@LXg$ghm` zhS5g5WuCrVTe%tb%Pdb>lzEY8qb)ij7FNr|MOKYNOVcInq@Q<_FHwg)|IYiyHkag# zH|)gD%MKyaZ1RFQ-8x=}Ex+p4s&%}NkXkIB9)xni@E>8wuN={Q7tvAg@a`M8>9?U3 z{y`~jwfnIliu1CAtii^p+_#D@J~Sppzga&IR?W5Wjh4Ku#KcTEOG?H&`N`oH|743{ ziqS7QUDr$+5G>^a-Yh8K8`c%K^+Z+>bw zYFk~l1Masi$NR#(*@{AkB!t#xDb|r6kKDSV<~3HV`(`N#vBlN*$u4$QUaAfd~EDj%@J8%KjxwYzN_Z z|E(C`cAz0UE=13#KPT5hcUT8ahs-7`->Gif`?>@%5=d9OLkFpm29 z%Jt|Unj<~K)3YAGEpq|9E<=YL7Pnbq*HFU@6-f^);y7v$N}|oOxR3}hDp`&1p?)Ev zkBbW!zTrP3tYkZTeR*+Dy&J7TGvzj_nJ#Q&i+! zXHQO?M;7eRIjfs%Tk2X(O}j*q@l>Q>4!M?$m32g1(H6C1JZLI4Np{}i%vzA__lvBO zgl%UVCLDn?;pn5J-jG_N{#|Bt3Sk89d)`~aSEsPiKAcFu2yj8ip+}?&pDM8#S5h2RuS@x&-42IhrD=6 z+9u?CeBPfJq4%X9%08C&R(`7MyR-!U)m%;IgIn6~iGOzbi`B$s+13V$tDUcXltaoE zy^CMbJuGZd#651?VR9lD!b}MY$JuyPK)ZJ z=JM6@yUedtba)pNw&*Cn6m`=xo(YGUu#R1@0IrO?+cpk~EyDn%kLKCm%U;$ zp;)Sk8ic^Q8f0!(P=YVJ6ip#l#9Yk@yGz5KiDUd+3D<%AQr?^WRiW!8xbU(n3;HVX`QLMHb$yyXAK*||FI`pM*{_BePvu~j z2QV4c>>2tjJCBD4A;t$lvO0POnwYvAoOz1xLJQVGVb}0r&rjjWiyFdh5kiy`>iq7T zzCpZ4nqdv~>xjGPEq*B|Ji{-eG5XljxU%^2gvz^y*1*G(L-b2n^AeawEn+Ujc}7iT z9f|j-y3mkumJaT;CS)DK$Ah86@&NT^G=%hz3XJTGOWKLTOG>{jTUwq{*&+J7XC;B( z!7oU;Tb`v;QFIvzHQ^+i?wb+iyDTMBouw}Ty0}eHSdR1o5~x$IVBIr&ql`f2pW%1w2f8@AZS!mUvJ$H*ffYNXyV}lA>(o!h_jaAK-Ss+8ZU>uic&YYBd>a=6 zd!x!Ob54!w2k2)!E7zXFl_WHstmq95Y10o z1570tGV1|YgnDhO;-0|?1iwfn?}E$50w<~aNHxchfdzV`v|MZ+4nQ`phqfPYk1 zm6T%Ur_g}$*nZ|YwpLQWPovwt_Y!`(QwAsUIeHgg?dGu$pUz%|74&|M+}ngFBLh{@`9F*jucTt*tJhFzmhm<{`ije233t+9dcSLuHd|)hn z!FUgdujLyjP%bxXOm%d`ekOh82BwC}OUrqIZ3RLfpP2!MxL0#Ah=^;D9AReHOQqULJw;ioaP@#@fR~5Aa zS-OmXH!g!@LrZWck^*xUg(Q!^3TJ0>70~m2H4Ws zx-&4VKlCk8h`qV??hMbH$h+|7;0X0pN%128%dBA^6BN2AMxlAkOpC}|bc%J`ON6TB zZ5w0!bARJnMkmCsdRNX@hkDcbsx4`$*+p0ye ze8%gbJhaYS{66Z#5-l84#(rFpT==g!_AQb7(e2H(<)?_nTr<&iEE*J?`8uS7z5sS~ zzjf=7+tLKVy-Ct8zf89euScF(yYHshAp1pA_*xnU)shXlYfb^7xB0v5Uit#5(?t6p zkyk@$`C50Y0lr^O;2qs19|`T?f9x@GMX>h z2fYIZ9&a&~=zCOS#Y68^+MBEKccl8Vb;F#yiZZ;`aukR*!F|o7HVqh?R!y%#_q*xn z$|GzY-Aoqq&6Y8eoc(6qY59HY8Z`EZ!9*8=bNbWPvc>e1*w+;__QY>0&>aWzYgye} zgPeX_Kb?K0$Dguq@SOOu#e=54br%NJ+3#$Q?lBG*f8h}}8c$h+uH{dW2jCV`_n1*! z$c%J<%ROdz7wu!d-@O&fwyQ!8b5dpkwF9XS98sauIRT1lz7TyN?@)YQ5#6Iv9Dv_g z^n({|jkb!fiUTWAE14&(1zM++Ag#y;?trYlqWM$!&7mTj-gjxME^s znteqDWFfdhU095+MZCogZ~H0qC|rmRZ#$2LC61$_{)0T=iv8Xae%`4}+V8{L(%>~g zquT{{P`2%8`s?x|C_1(uC;`QLP+A9DyDZk7Qd}_-QSnc%#umYl*A@6%~}; zBg!*j%yC(B2kgR5sR(;FyDcNH1x*&bq7RvSCMPbLP0)NwLGhq zeub`ubDmGga<0yX;pVC_61}FcN)cz)XTU|_&VDA8#+ZA-p)P+KSmD`e^3|*1y=c+$5*s+z8eQ_M#>u$m40=Lajm$- zx;!8%aESo9I{_Bpjd?rvuhQK-0$&-^iUr?D8d&C{zRd@$8kcra9ytu(XB?tr(k4bh7?y!veQB+&$T5=IddapG|rdGmX>($^5~*=YyQDO&i!%Xz<+LIK388 z^q(CZ-fFr^PO0c=!VW7Oib5uH!IC1)VW{UMkwslcv?nz>>Pg_jiUu9^qUxz(ctPqP za`E)Rdb0^VmQjzI`BrqAn^T3)G?&2NxCrM_Z(1kh1r^6LN<3JyQ9Sk$>tlLGaNk69 zRp_ee;VDk3AY}uiq$wlPKZPay2t-xvw(>T(Sf#YCaZ#4k3M=+%hd2-_Z!%q~?^i z?rHG;qN|dx>QEfu1MHxlb^5qX9QwNLOG*!@OwILfm%fH9jP{^L?E-P3!`a?Fcng~~ z1^E7ihq#`SRIX00Y~QA3NAd1^)eq@-F*f|}{X6A{st!g`6t%8$3@`#}W@2nku$=UG zfqaVgu0d?b7-HA#)7)i1c&s`Qy$)ZbFQ=YC4~Tl?>5uCo5%5QW2a-<1{_MN50(n_o zF$v3w^OPg;Z#-8^_%*;4WNta|#3~?Tm9~97PQ-#qgMFO2W`%IIKyZJjI8gC|n^`(* zpEIQ&9QLK5rsBSJrgVs3!}^?rQfvrPOC@n&wuQhS*3zBQ1%Ss}I(ynACt7%jJK;UX z^os!@fNc)bF5ZZ+j%G zqx+iyOrwil4&-l{Cy(6r6f^x0zsGIHVCOGIxUlr{y z+HJpSlAZJ$;{(aX{7ry-z?r2LzNWzbNj;Zg6*vG6wsB!wCv$^m3pGu@I{)T++V^w5 zutI%CFMKXexNMt2e=ycDsH!7c=pO5-`oI~)C5+eRiSRJ#qX;+U8qKuHQHL#mI_Zax zc*3giIq1d8OMl-$i}#IGZHf)_OjhB`;V*FA-QCV^T1{4|_JYv{sD-rmlSdicu2xR7 z+a&o*f45G!*KptVKzQWzy>TexY2AhPT(7LHnT^Ez&{M%)8UlOP&wx{$@-dE@FFrwMBV%O}rU+92glrJ+O^P^V~psaKo4$mjO@E<_|o3o_u z+xyRlZp?I|XDMISd=MYLAg>8H@y&Gfo$s;I-eOW*MH#@HuzNh?F6hZ=wV2Gl#B((Hy7Qz0X|Y33MOm*z;JDga^^;IdGX6EiNXrrFA17 z#Jmlo*pMo6!ATXr1Ns~f8>Hyj&%aRG17QYQX>#!6BxzE53>g+3n~$|H z>38y`O6)a0rr^L^c!Wz`8k&!HqOKab?jOT2`bt6qoyH7GeJOJQS9B6x`%)uM(yO~ zrHA6F#`c=q2z+~{g-fbJH@hW;+Qw1UW&^#GRXZrs)+c-^ERMt3dUTKY4r~GUftiEf zec}Ul17;$$5&ld1#NeBUfV+}=U(i30Co7_rYc@;NQzUk0PRbF?QBrdLt@$xNmn}*! z%aUdMK+az(`JRj0O5V}L{TZL$pNKoZ9I=(;Xa}_R%oM&a|72XHu?)$p^pn4*PMC$a z9n;Klwfo2gwB~RX`c%`D$S0$)dr}x>q_=<{aU)W6haSRuh@(10-k-NcGX>jf@V%>t~ z#Wl0tu-9AjVV019sd3OhNe|5dG zQ>l7Kt~?AJ#(LJqd~dl4_-$#^(L)#$RCyi2&Ky=Lt!tyJ%_Wo{`?6Y@xkTgQUfQqTnL1VGg{ z`;8ep$!0j<7#5Ku{7ZemcZ)J!B4DYciIWg(lXq48!Wk^Z_AN+RW8s<|id<4r1{FI0 z1UkZbJ%hL?W!&F$pK368KC`=RVRj_E#Pg45L*mYV0Q7ZmPl=-b_xYj<*JbWvt;n-6K%R_P7>nDR5~L;pnW zaYB>JJ6>D2U|I1F>>_ji1*$>Bn0!*+4NMOv+rz>mdawVI#j9MdlU?`@)v<=Mck#`oDAToUO6()9+PVXFAU`s6z$fVeFa-Jfr< zz61~4UQWmC>{djqd$^3~AvdoN?;+)mObd5u{@)IASXKH4nS!Ogz%zXckJcAWNG!Yp zen6LR>r{jzL3`Z9R93U}Yz#S%ipt&#zd_<5x_5)B1<@^ROVnHglL3S5;X=jl20K%X z1q1G}Q7RgU+*^jaTJkpR<~E@e*ZHn3&4y&-;p9e>mxI z9oUDzx3m)7@){>Q0$+>Fi=KiyXmp8m{=rBxtr`CSUIGF-lRVba$}lX;mPjAky*Bbp zUDcyc*cR|HD%pmI+Oz*SE`%Hm4c{>ekmDCfmswUURAe!05;)H|u$Z$4C_I&n`?#`% zls~msjx?wi0wr#pI&YgnH_W^gabq_C{ccTM!-&V=BjK@=f*5M5jFwGfo^~~pB|s$S zHXZ2wg42`fK5}_9rVXBOQRGZZ(nWERYzGkovj#v3o0?0aif&{S+l_RDpna0e6^<6W>UByV zT+FffxUuVe1O`yhw6w<8w2&TJ|6)cR`F`MbL&3UnuAF->=***`(c}%oF!Z zY;j(1lx<&Bi4m+R&>pd-VX5U=zMfr(S;-B2#!D=N5td?cifwp5SfWvzBy6!ph`@$Q zR`4;#2WGIqs9DJRZeseNcF7eDm|iN;=BFU$of00-l2!ynq_tY+S6^rdbNDU_9AF2qE|T zZ}e&(&1-`em0aX~nE`MZ+Ow5^1<#^TmMUfb#5f?K1M5VV9aYOvt&Yilo2im`Lw2!^ zN*_&p+aZm$0Zo6Xc-2;%H--^PO)Pr8z@Twsw<4Zw@z94qaK+5;SXib-I~c5zulj^- zL*RbTEzlSwABuCotz3`9g!Y;>Y*==uciPvZ3e`*mw}+{-zFnk(a8EY*19P4-Fz>W3 z{*(AQ`vNoDe2lC`=u|}U)6rk)U&wNNKC`M#=%Bu5WJf&lb*$&bIG~fP%)%qsF8p_p zrKh9HbIhlh+`$B_nnHTY<7Hn<1)u9VxDlUof0Us~lfvs2GrcwWP_DZ%_fIygpgY!% z8_8vVsev0eQSzt>ZYl2R${R+{FU06o!zQYP*bW>eoD3EIm@`P`mCf8-l<-(v~GDuBNML5D4Gkw(ad64hc7O0PuY$wE?nHXhhF^NV{w;z z(_-n|CB>=mAJ~%FH`s&`Gck zfeW&s@Yz%v=`u@xh{-Sfrj5uXm$`&2T(BaGbB)V-<+>~;LzXQ?7pCdLSXFC5v^8yS z`T{(Q6K$lcI@32RR7vK_(!<#0SayGY7!*sV?Fo}65o_QW#4D?STCVZTO$tTg0tOY# zhFo}6diL@`OQr^D5y&qtnOB4_Qlu})2GVqCMS}Q+Z%$NhN}l?EC`bK2l~Z^({5g^Y zL(gLM(0c1UU<;9%MXso<{LFNUY{kOH($!;Ax4@O@zW*!UN;h%LM-iGdV_h0l@iV6ABn2>B<^+Rn_@qJODpe`nhuY;xM{?6>)o zE!w)pCT`0Q&0bx)yML$vq{w4xsQTc>;#NA4EcS7$F-6|HJMb_u!b9x% zPB3%6e~ zVTOkroGSb;7CAF+6c$20GKV<1J&XKcn5UVD)u6=?971;MJdxUpcn``G`GgD1L^}?( zH$Je0z@oV67>@{8PWmOv2Y5^)id9X9u~6P{F&^x~3V4jkgZu1l?kSV5vAV%3593rO z?hn47oJcFDcFCvioXbZ0&qssgH@~!W#3*aqR6#I46|M8dJD-o2y~O?`Ijg~66*WB^ucoKZ1@0>x8zF~f%-p4Vi<%-(abn6e>m5Il%{ zOT5G)b;G6mrZNxsAyw|rp-_+cVi*=4zhuWlKo zn(;|M^l>FXKRz#!okdl_VN&Y9_5PkuEq^CQxJP8n5>CKoZo z9KB*5>OBfslSb$GTO5oF=)vkC1-U|#|88iZcr^rJt^e=_Z%9AdI2|5o^Wege(eRKm z^p(Ze0~f4W@d~I)*%Xp7R-NcdC*^gE*Ke}m1I#0a-mPzLJM)a@S%T-=Sv+gmsw;i3Vm&+~sNi+t1SU1lc0=*t_%c$(Cdpt*l<%J+0-B`E#v^&c_ zZc7gN3tmv3fH!oq9cNzPwO}x(YnsuBZA;`GIHjBvU5$^~c9m?<*C8V&M@~=i&gv#~ zHI$8b#}&?5GPO`5S>9QgIn-J>PStLy^MeuLk*XHG#;<20+delDM*J<@rC&_4TI+~B#bCVdu<@KUHwC)KxQvOu6qFvU2-oZV~>ZyN#o7@DT6^mQh2Ib3R zc3nTx)24b&^A=sZ_Y2HV_t12YZKr$5ez%)|m{p>pO3^ZJF)fl=dss@vZgBVG$!oY< zf5bIBk!(ZT(FbrH3h;UdDG%JBEWiycE})+B+>w9%h#k!B5vOrAaK9T*`CJo^j}6j1 zqNGISBkCD2hPx&4!xK>dr%dI0&gWXonfID-Sp%3GK5*&Wt5CY*^@=X5=R?!X)ym)} zNRvt2VufdsiN2NmP?sCnKjzqq0T>?an5rsnmqmVNH6y#Z(S8wgx;T;5q~;H)%FGX6 zf;+Q`31au;uJ>H}BTLXz)W3gjqq7Lj){REq5ZO$QsTs9AHHYLgVoAe8cxgwsXS?!= z_z!rVa+cy}?iv1wdJ>d_;K!qS=w-V)=BZj^qH-pSOSPGSL7Mr4uz!fCLG+WD_n2H^ z%YXhC1f%YnjDi)*tVzlTMc2>~-LdM;QPb$z;_3%VBdbUkj^rCN;Y;n8nyYA#aK6C;g&H^O<$ny z4or7wPsL^kelMOK@nlcC{sHli@-J~6`X$&&KaKY48Y%PeQ_V>f52u*^q#PBYZlwI` zQE_J1bREjALqjqPl$#wMxXcw<%>ecvdMoY^ugwIgM4}BcAorU3(b$8TJL>27TMI`A zdXUg3KacNZW?)<8_qBF1Il88u))r!F!r1sp)rJNf$5~4Uuqa?PlD>t6KeHNAx(is8 z_yGR2D}hsN8z=XvdJG7ov6F<;VG`M-7>d6{lM3qUE96u^){jMc7gLW2p%~jkKBM-D zv2vTCn~$&vlL5|j8y$-8kq$yWQdhCd?;Dfp$G(~m_mUS5}B zV=NXs$vxWJbcYBE$Ow2Wwv@2PL*GNI4Dz6Md72aZ;RYQP$8Z5G3=TkD`SN%&n;%6! z^-%BQw5@3KW%!}dd+*NJMC)whZA0&C%|BFngk`Crg58b|kPDBf*>>+G?KHr)!nPkq z;>|L;lMZ`o)e_WPb1i*Y!ou2X_v!E1Za&W6I=&u^2`x~*#za$7l6L55;Y;)?{x=w; zS=9BA#(%|t?_FoQ{SOkSrv^SVywxqypG27=NiD{Z5;KBd8p=)>0E-)1N=jr&e$ehB6&b` zS!l`VZa(*vEcXQ_nws9>@K!wAC^=Ek51(lG*|z;;r&1yN<$yS`>xXS^pglPO9L;Bq zQ=LnaAsyveos2SHOa9wqc7DDmr0pJ}=x zy~#XQ-4ox^zrp{+R3J}JJmmX8F-OtAY#)Er!kVMp9hsxn09Hulv9Xleq(595z@q#h zqady&H9n$t89GP_OUQqt{+MeI_Q1sz*2ip2D^hvXde?H=Tu-J+^N{EX_@6&X!$R9k z#jK|;NfP=cI7DC2ltr#GUer61P#kO2JbzuCsJ-NT?o}p%GSNJc&Y~( z>o#=ryakt`N442~fGqRE%ipZG63)BahGdK|T1D?_R*kk)AO}@1(A(!e<`%0o&Dagc zC-@8UsCOX?oe1*qW+6L>g*;F2mOqH0vboDn!Ku@r*16Hq6Tp}=!N-}moD}GLjD_wM zKepZIOghLoi)n7gW+9>f{Eq&hxpCr@-1*6CKjK%UF+@&@re@$#dIHJd|1~vT0OwJF zE>BSuYj#=ZgTe>CZge0+tKxT_lg1HWOsebWgN#n%Kr}kWfpSp@L7LyJHQ767FrX@9Jqr?Kl9>G%-W;`>?m_o#3 z$)3N7r^TZFn5#&?xL|tWb(&tl7E3E z3BZVe=-ts`fz+fW@C4~h8xvGp%-rbM)EOzz*mOeOM43z?g~Q_fHveKn=p%9q~hg%D&-NvAH2fXf*0Zf#dPa^?4>pS zI@O-JlZ;o|$RqfKhOcau69s1{$XVvPt)QCrpd0zms%9;f2}~-VT$%E9-IRu@wrTA_ zbi`>OY>=pGe4%&|)l7BgKBBv!pp~<*w3R2$bLWZgI8WsTAbK5${a4jwvA$H+dr{S7 zA|cSMx^Eh0+w`u2+{tai%f@2Low&#)mmZgfO1#`&@Y?X4cf7DehVo@_i#V+HEdAUu zWt&_11yaJzfMfFESh5f>WrLqp%}(C43>uIe$xcGzGDK7(dBA;EH6p5+CaRh~DA&RU zgmM2>HEPVKbYYp`TaHvJ>iilmi!rfJbP~HO5l#bRJak}e+D?}JtZIsR%@Pbn+OBe< zsSf_l$;K5l<(j-h;995DctV;c04YO<{v?3)LovC(f z$dgw=oFbKe!G;`IM+3d_vcKryEyybC0XSYrbgE2pPIg`FyTmVo`GqJV!E4ufc?#tn z6ut+&+}4f{LSvPGkh`#@Yzqy3RyC_Y5!FnNa9=>H;zqLZA>4me4d$$JP4yMhqS8|` z)XQ`ynd(#-7HEG>jN9#CqJot-$v{CL>=fc0>Kf+zg`y7s0S<7lrHVPfz|kB}#O2-G zh1sCwrEEyhZgvMVwS&FFe@Pc>^{{&;|5?@iK|bM^kkjFQwU0VVP&!3B$GFP-NJ^N` z9a8+M+z*Tw>j(BjXNl*B5PLvWH3dpB=6hJEIaZ)7K~`h6+)$TR>^NZyGqp))0!ui# zh5e5H4t+188h4ld*sFDCiG#8OFWHdXtetn+*w9SNurJ|^@x0T2P0cp}aMl8978obv zJ>uMdV*u7Y?px`%j4J-6;xBqSyke0-K8||I=(j>F`z1FF2&2|Bg|b2+%oNV<(wv4W zfMQb|3)20|cgfD8Kgx?#Ta1ptX-L?BxlnD$ndjGNOZ_5tWLvqGdJ8PJepJdgvoY6d zO0O{5Bk}MdTr@TDlwdE}KrfN10V%cFyn)Vg7XH5ia3{Nk`<9Ah=8wY&B=Q))lzq*w zNDwZPGtqK>Jh%bn*ni+!a(V~u6@8Rmd6vivu9NZinFX>5a8RJexxiIl=&Oxdk+L#( z6TX=}fXmaixV%;ABHiwDfmo>TR_AT5-~0a8{;53UyRP%GnOOQ0ausgI$MP?W=0PLi z7`Tg=36VgXff7;81^gd)I$Om3o=^Lqfr^%p?+9^8MJ$x~Upd;|lzr;`t0$o!0}M=* z3%m$zlNWK<5aE>dXSP^hQo5>ab@>|cvi{|FaTruGiBNsZcz%IT6H(1PI=&n7E_gZ} z%S|D7F!ivTSPRZY(JaZ8@+4KHJb@**Cr>8|Ju0aGwI5f0u0M90@C8;41Y!~HMq!H> z#kkKchuVr5q}{tA1Yn2Cb#%QO|hK zzQt5}ku?%Hj+|ot;?8ru3y@kUvR-~p{k#5;((`4u3+4M)&jSv^9_ug=IAHC}ju=b3 zZKiOjR(7z#c1SFM|H-M$IUL9DqD#Tk0i&^RnI}}%bTVf;_wAQd-hF9+WV*P^1cmL^ z#_4hGCp@y~ORh0&GnM1#RfE0Yd?5W7#1XNr`MA>w=bv3q&d*fek_Ix}+$FovQ_@L_ zfVF9X4WCQiE1ekUv5ir`-Q&a6+-)GXo{yTrooM>J+(<+O+H-N?c(swcM21F&q*t-6 zH1rwOc(EMraYI!NWRK_4Bi5;}3Bq-!TIavTtL+YAAiBBnK=T%tQ(VxOV9pGAAbhJV z<#zd<$~y5e5~Zr3nOx9Mp5rK-nodlz(-z#voQ6XZu9rCbUsF?giC9Xt0<@Ka1K`lZ zlyx~Hq8j)Nl#kpmZ}|VZ+5M~GEmn%PErK&gREU3eio>acicF#GSyV#`r?%>s`1uu8 z5En#La|Y1Uy+BL=^s|U+?C9k_Q1lt_XA#v5u)-d2SUzvAB1KdaAGVx2g}xa{#Cx3~ z<6fq`Qoq*syeWNKc5;^TUkk|fGl6#Pe)EA?MV~U0cxP)B1m3C5x!rYI`xuZ?(%fP0 zTy%In7iJ*m<8Dhh56=WW7lxxx;FWQ<3TYQM3)Ca=DdakMGAN8g8mVP;uV{7OJAH8e z=-S)syXkg-kvV`l6I)y^n%ZunBC5&f`b&i}pu9&?X;(+@%)iP9AabUP+0ul;x+9oq zYQEzA=i>|L6)`zsGz)+7OzcP+Q8&0@h;6^V z3b?7t93lM6-o)kTH~ePa$@g>k(|Lq?q<)D)#?K=~Q^Ph@Hi2+wNi_s_D}Vg#3VNsPahN_>?cz6ZBt|o}3uk!q&OMoB3I= zvoy_fi}e(%7q=~XsO_<@-Fw=RK>o>kPB3^{{~lRHn*#N+BDNacp{a%(nQ2^{XOsiKxRJV#t5Fll2G>gx9%K<@ zHyj!YsSn~`)5vF36PKjMVPEg^d6o0)7Bu+S7WS6}MyXIUJv=(JO;L0Z3l-Lq%lXe8 z@BaFL(!jDPXyjcW9SO@hi;1R2gr*{@Nv5KXP*Ijf@q|#mfWz`kR|#PlJQX1EVmcBT zDDFg%+(-BY7o7}*r7Tj1>my2|BFj$ByoVFYBL95MTMXLVJS+AmeaoGK#1Sthq$AN& zkKijoM>ee?-IgJo$aLyNZzA!L1dQf0PHL=+IY}7t&!*-FJgS(|GqIR9q?EcKq8b#x z$~w@hXzoc?0EPVmQC#Hxvb^%j<(2t$>IS?80gW!o82miRUhEhHBwwUYvB7sCL1~K? zVx8hfIgr}Xo1N(RSG(yPxQc|eC1f`6HJUL7SJqo|RK>^!GVZVVn6+2|R}Gb*ssU{y zkBFaXYKR^cO-*~jIVjA1`=q<@x#&{oQqtAvyEBTqCz_fAva%F#3VV~ig%2lV1G7Ql zi9Ge_hSH6PR#F79=lDvKEiFE-Ve+dNcv3RtK>bMnk#!appMgXHm(YZz;Cm6()T5oy zM&=A=0zUjm2No>BzK0y3DOeI!E25fCv_N^aV-F(~aAKUZVW}-exCzi{n=15Ei5JLP zF@B#7p#+Qt<>%~f5^p=XIhzPWX2A773?|JQ)y&X5r zG$VF3yLo8I0sOu_=zrK1M)_JYAvxB#s{$#+{Brkjky*Ler=q+j?1f?uzSy#j(_#I2 zvE&~3lJp?451WFlz}7}MgA~6SJV*aU(tPOj6|u8%vS82JC(?D)5&sC8W*;+ z=iQGm71*Cl9L5;-z#opW0rDLqS6VySJz~)RO8jxKa{d~>Bj#V(h%)L{`pQ)92$Pm$ zCZag6(DU^J;Sdu5V;){-&zUGPq|g~Gq`huJ>vt22smwW|sacFR+=u6aNP8#$1S~$t zS3vEaFUSD(f7nrU?Z}(l9wN(8zSGW)S6=T^wuwWT;J(^YCTK^=bN>-;l$O?6{%dv}+yB)U>F4qA(#@-(W ztDhaq-2{dH0@D1PLUs=wYm6q86q1%7t98F(g1@J5%b1d<4=HVhbcG^~_NqH^OVhhg zb;J_X1g?Z#K?j;5g`eqiqh;Xp=p5oqyB1C*6(?a4)%X>hrtG*B;t{XYE;%fFs8*22iCRRJw^;iOkDh&C~l*nG82D-j^aDe18|no^B7s0 z%KyxU5ZR=-7W5ygx8-U#m(9&%QSyg{q49GgR{*0BE`YcoL6 zYsEp2xRc$vUZB`yd_{CDOYpz4wR8fws?x@kCjy?uZ}&SXliPK=JVWbKkWt3{U#CQGL>*8fL883lZyq~EIQrt7D!@3lJ_l$~_XieLz+{}V2;;ZVp4F7;%q4O3)H-i$eo0#)MV5POp@`})@L{rnR zZDudhS<36kCD}=1uifx8&awkJEk15AET&cWH|q+wNJ9-MinmBV>?XnzyO>_=91x#+ zor?AIcE!?Kq-n!`4C?I|@gzohj@Kz^!y^sP360;iayNsjh$7||&_@x-!?oD&icB7k zDkM!xI zyvyih{E5=RusmzdG4?9H7|nUV`P1`k_!(T=*dbeDEHi|3UUxPM_Ui#>$+Y2;L-a9a z6|oz8qRt7zOvsO1ybR=p%k2Z=Ea*`jA?@Yib-Zv9epv8Y{K*%HOCx0Mwg|U?ua3X? zd1Bpv8k}u&NhR8M6<;pO-_?CFEzoJG#;VRCE@(h;d>(U?nEW>B{EJGV^cOIoYyCcD zCg_VB;TTrbYr%%*hGPn2gB zbKxvBaU_#2{Dkj8`}KFKg@y;&k}^9}$M|SB(mlBhEJt^ML+C4B@mwWyR`wbk(Vb&w zKAXxX;=yy>%9NPm-@E!(c{j}_+TKz{=vCJJA$mJtvMkQ1NAy%6a}?7G8;!BdpBWP@ zv5dL#qN#c3W#0$#T&$c3qLvUDTDYMMyoozTw^$tg0=EG(e0Q~fadUoNkUOWuC(Cqc z;=$XF#PGo2<@FYwco{V7Th_f}-l<#lw(tJQS(;D+&9Z2LdTSoaWwM`9%@ooopj-^Wa^Z@Asas`_+bKm&5`u-l2tc#X7&Illy2Xs&H{vqMgETAlGyxL-dI z+RPV_fAd-PkdS>{DlVsdZu_tMMaj2=-R^~@=h*n%x|`!}XdX0vU^zw6tiv6U4XNei zPB&Z7;k1Vti}pT(-NMAY6dw6Ka1c6gSXq!lPAhBpp1FjarOL6A!;ur=RnAXuLrL3E zh+n-^zSKB{a=0C2h^%eJDk3wJk;XUcFtvqqMY)EH_pjavI1A4=R4;zA>-`cjt^SJOq|1OCJK)tRK<0a?#Wz z8~YpsqV#QhU7Owhk^k-ypUWDza;5%pQ4q$5A~a3du+ezf7(%OP02{!7*Ye#G{{$?W*bFR$eb zD~ZO*HsC$yLiAvsiX8p3^L-iwlUBnG| zZg|}ZJO@>3av;TAJJn6A2!l@h$ZZKJZG-MQnNztB$Ku88dJ zsE=j;zE`*D;y#Msgg?1s@CO!MG89`BP=l45$H8?OmOrthvN34Ba;5PZWNkR(8~<|6}h>0OP8z`(YW9G^M48ti)-OXQeD& zMtbkfZdpdNYeuv0Gc4Ad_nu~Zvv~HIgkX}i*_y`AMnVY4WF-l~WFrkFm>5$?nsi=P0f88^lpE;xc z$e>}2?5PeXQM&QKR?G)KmGcxq%(Zmp^^1>PGFK4Wl z&jjBx8#+WAYvVTRg||IIH}=}jJ~%d2x+-(_!6St!Y^u5F&V%sXqNi>vAKbaW_TZFe z>dJBTk>X3Y4t#ANU%PGwdul$7O*LDX%J`IVCibV`f|1f)#D972;qeC_&d>bh{yj0n z!j*&9E;MiDela_L|88umQ4Q-Gdou?v`Lg#A-T2(h|6CQ$j)xm?#`-B&8@%?&9Obz9 z^4Z}#=M%SY`o-+84> zesU(I7G{I?g5_K{=hc} zo{U{z6#bg?Zx7DQUp`w{c(O3hjektFT~~E2+*~Z}eJFEany%31Ek7JI@20MsdD4D| z_ruIT@3&7q{zcuZ@0|U1^T0pc@ArwD3TJM5=z;n__+GQ;;Z3c7oxgSO%NH8A8Sbzc z#O8s~O__mEl78f~``8~KO0w(XLu`_M==Rz9;wK(>!QkY*p=)n>m)v<}La-uAKvHr0H2=F){Rdh#WWqo4BLU*z|HZhUL; zTZY+NuA2K@_8zZ&K)GunIQv=d&b>#A2Q1VBxBNF6^#FJ6?3D+OzGe1$>Mdg7 zz&+kyncuv}mHFzy^jD^LD>wb}$9pb5aOJ>*Gx6g6?-;oJ$bW`kfA7>4XOy#CHpjhj zyzagD4fMla>1PAmcC(M_e)+Y1W8U-TO6R7xdgDh%hkmW4e!4(A|4SLTcF)7!!S@@@ z_s*&73%R;^%k6MMp7VZg;jX<~2kM{O|Iq0CdGC4E`-(?PXJj9`_tDbP(Ay&CZagq| z?kmPySN?r*Rw0fAr=jaOUNke>pJqdG1woW9HITb8-22@l z|2D&XY~-Pt;+2<7y|Q#>aekkAcJgam5Agqb&))CRAEMxp^>N>k;_t2JsAn5ra=+)7 z*Z<)MdsGKTZyleXDu48U{^`u*zFhg}q5Ca}+!*834}5TT-vA+Uw>@=_oGwy784YEXy9MiTj{U7?&z%} zubp}H&Jn{4=WcsB=9kn@whgc^qJBQ`rJ}IWH@N30OaFLJ1`axn1KPb(@wV^0j-?+v zIIMil5t|CWSWkoxvJv{@A=GW^rVY?%8-r(3{NO(p*?o^3xP9&~4_v7QA$(kT{0qA_ zeBqV{XS2J$aP@<}Z+_slyD#0Xe(Yi2*KNkxn~r>LE`0D+-slB;uAfgx#c|(l25F&a zyXVNgKR(y(K7Vh$d0FwHZwM~!kts*!J2NGJGM_(h6b%?THCKfMz!ScoiGy#FPy zKIk2s_1@21c`NtRtIk}A&pbK!{)30#qP`5cWmeS-%dy7SR1qPe2s`fpDiS@`zU`Nbb@N>(2} za`d4`cJ1D{_Xm46`fs{nqwgmVUAWQv{i$2I*vNf@h-#cXQkohbfcMpw*~{4{ezsft zqu*vW3GdJDwom=wh423Ns^;$9KYJM7S7(m@zI0%CaP&z2(uG&=`T7BV@JaE|9wSZ& zWx3SeAJLJ0N1b;*xDejAWzVCV0)zA|Uz|Vs_7WA_1ZCN=IC=CxSjg_Gvym%f?8s{8&?{3q>k7=5>s6Kr}dk1QA z-JZ>3^R9xOHtOa~hHqA0L1oo*6Upz-|Kk0-!z>)Ha#Q2uM+QuPrjsIl$6(~Z&u2%g z!kj9Y{B1(}ncYA5ghlno-yJZj9=qkjy}$DOI-0uWPgl?V?Ly@T3*Q_3Ln(12GUqfG zwOnlPr1{}lfm@)6|8ei+=dc3&`d3qiBcEnI?*G&HUISgJz5aKzkKZ31ch2oP zc!u8aAzD}v7To6z=8j%GxV89a>VEo(*&}rL+(G*2m$-NCz5ABLOmzHD`}4CL{e~?I zyGn8Ocxiula5G&v^UvdFEi`1mt0#l682|U0;+DHVspC@nM#qhM^&s)Pdi&m>>vJ>q z%MUz!E@O?}$^Uv&F?rA$y0G}!shbW;bGtsc=XPp#&;3)Ty9!ShD>nw`(#f5h^iK>0 z@7P_~xKDMiXT!e~g)ec3&uu;_{d!Ki^QPka-|IOSdiB(`poXBset|a^X>)gsL}IhsLIZ{tplGe&E2$Na_4yQ zB@6NI&E5L`gO|_wjHV5PFT2%ZIrr$sTW&gXKc^VHdGH;xZ$I#ldyk$s7dvKBh%HLl|Z@KVSWJAq`^cm%g9&T@_p-csAsJU=cxweO5 zp8CK{Nk|t5 zyoLOhm%Xtlyli{=Ix2bN0?iD2i}~a@GibVWz<9-FgTt9Y_4xmK-?wMW!WAFCG*O!> zRoFvi_Rx9Qh;!jV_7FeKK2`9d4fVkSCvDmLex>rlU!`!S zkZSwPdDw_^$K2+tL>=`IGsp~_HMqma3@9^ucDye#_OjCK*mw$9viLroJ`%CP_J9nz`^B7fqSJ zaK~J74|d`tcJ4@9$6vmA5K>aI9>9K_OHG0EXQP8>9~5oWv|(hSqL}7#oA)-a+is(` zdxKLWGnDhM4!*;DU}#%o4*PNbV`lTn%=D0TylNdE34PH~n0&!Vz`B2OgMD&C$vC;e zyVHENYQt8XQ>@xx{)*+&qV-DKdnT^8fA%Bn0rw{1!UgYCI)CAKQax+_@`a4*(zsVO zmHJU=#=BeXj$JTSm@EEx=Dh9H)-8Li131I|@yMJqI%uLbmP;KA=BtmIKV-Rd@_N@+ z_v<_(-iv*n*ZFq^3c)Kw?+IURrCcf{|z9Lhk%op~c-Xr`SAq(QM(nyXpMS?8riK_WarF4;G4^$QKMzIx!ttc=sN~A7?IN z7{!*N>WxK?{>`+mxJP^A?8OULjGs05eqK0#mM_rd@*DU+8>)@L-FsUHOEcu$k?t(oyQF`)0s(xSNM;BgH*?Fm|xP9j9RnNgjfzKp_f z<>XQGJCaYfL!aiir0&m*94*~f{$Ay+;j3%8)I;xnX!19YxC|dqnA5cn7OuYXL+`m7 z8qLj_xN-9wpS{=n2b{Eh?akL-dHuyRo{x^)aoxrH@B8?BK5_jGty|`rpL&mG!hEO8 zd&PwZKT{l7|NDOz134fT5Na-w9lpmJJroP8Zl(E|4kQsUA4Q!`KB_7XF87@m@$~jW4 zY#}f5lu#&%*QBL1scosylG4|tE25Ntlq$6H94|MSk{-=+rE>OBe4MT3&}xns(TYS9 zC*(FXg1o0f(k_rCxZi*T!kPR zPXyrpQ6XQYF24Bevo7J&!glqvj^T8SR-s8uvkDcbO(^tAnpS8CeYjjL)x;)_7tM-I!nH<9BMvTKE{pkKp~|O=4hvBc$*V|;n1Tn5K$ zr?tFBRB#MSD{z+fv_hxTGYXMbD_Ol#DTu6i+1Y2gLS}52JQlOg0*}@POKJS;;__Tl zECJamu9O3Us+BZ(>le!+S3&ExfS zp+woFLISBxQW~9(3r|rjag}r-U+$oX=6JOrGHQiV(2A(KPEhD*wN|008KqLq@3G;J4ok2O;{1pI|;8VbJBKD zHHQj-TcENS^97!22_;VEi-ZrQb5xnMh+O376Zj@4V^Yk352LX~oV@rrl64!qjmpde zVPXcE=EPRI0!Egr5_Sd-mIBU-g|dX73b38x@y-uUmvU;^fuhD4nFqF^c z3-vs%f)Q&mVT+fMuTE?_BKAxn?J}wA&Wxe%G8@uPlfy@zg;}ZUYT3!XF_^Y%>{%wo zMe5`}8aCNAt~`xaB11?MQf&MG3&4TUXs;@t=k%J1q!`xK)J=n}$po|hGTl&dp7U9w zKJ79$)6*U%*3QpuWg{Y-PdU~4l zv-UYEQW$ZXR;%-Z%;Ge6dfq!rv$U;mN&?l7=w1kXUflA)~fM5vdEkffF^YcXJ zRvKiy@L07_NyW{6G_j1kIK}2)TK=5Q?E`Dw}NAmitl#LX!wz zsPD*vh+xtYvR;qgFIFW?aoTf|RY<}pc*(K4btq1vkdQYkYS(Mlub+~J-I3F2khn<0 z@P5((*FCkUX%2F zI&PnmySkh%xomac9q%h<^muPp_naB!%d7ix<*%;7<2M7|0(dLn?*ab+cpKpDfOi1i z33wOa9|7+M{1f0kfW3fyfcFC42Y5f=1Aq?#t_FMv@L|9;fR6yK1$-269pHMv3}8Rt z2EfMv9|wE_@JYa@0G|fj2>1-(vjA)b9=HkcdBDwp1AtoqUjTd&@Fl>P0bc>!3ivAE zp8;P3+y?j;!0mvq1MUDE1l$Su2H+6jF2G^H-GF}u+yl55@J+zK0sbBEEx>;O?gPvM zaHQYB1AuP>z61C!;Cq1o1biRx1HcafKLY$1@Dsp;fQJBcfG3Y0J^CZy*M68TeD=;4nkxa^!CTtxQr09Iem&-#CaCka4B&5q=&CTt3*k4A6c2ZvI z4LPoqOy?DqLUB7i+PO&-Diutm>Cr2w9V2p5lJiKno{0kHF+#dDHY8O_a-l-HM!vvL zx1?!QmKe0tQgb_HC{_yPZS5a&+Px?UqF}`r-Dj=^U zAz-wCIYj||H$6QHD+Mx_Vs^j}3`rj+Czi z3y^DtX;NQvAyGPXJ26`kb)q+0+%fVzYsZd6N$!~ES+!xUIJCd5Uy=EF>Ck>*8+G{W zvehyxL3t=_g9cD2AG(Rmnv3bf`yuLkHqyI3Le&o4POPMdZzc)`6tlzo58c!=lpflj zKXlVFQ|aNG`)#G`{Y;E~r+%0@(91P+Vy|--P11OCj7|E`jp)vHYZ)j`02s;jxt2nb4beWY?~Sn-PBw5 zfy#g??tGpKr{^4gyLfCP^?9eFJlDvzyC6xFixpNR4}VxZyuW`<5_e=#62ghBO5XME zLQPgMDCy9RS?=(M%UQfR{@UcB8#{}WcYOq_lV_hrg%9mNynm$?%0v5?Em0CBhCBQT zqT;}SLKZ0x-AGm`+XR{x#)cNI|L|2qJITM@A=eps{X{}O45X8Ju2L{0SM{_|No|ME zldjkprBY%#nZi1rnk9ERuA%6>$GU0-sKpFLelRwK1Vf$A$A;7>NUm>Zg+&3g9FNvp zw=-`HZf7u;EAeAPt6ioh2YhhtN_GlU=@-i)*PXie?y8mxejTFXzn)3_dG^v}iG zQ^xHSO+JSuE+;P)<9?VaQzBOu6=(-VmnnwI7qB`l;RjQ$QZ=6^E6?VFE}j{c_cbUm z>r3Xhqe5H>bGi<)=wUUj(Wmo^_*{IF!^E|VWez<8EaOQhVfz7(^<6SGlvm)z(vqp7 zQnQU}!{$*c!SUD(S*Yd(Mc-_aRjaWc-1(<(PT856dpWG;3G`|^Y&C2C=&;qz>UzEL z42{!%PlF}W{3Nr>XSyCM*j`VnTRziufV-G<-V}{Q&)M2tu;Z7Je z*5<^qVFqB>ap1?S74~mPoJeKznw~jYQR1%DGb|V!ue|1+g(Uq#%-esTDSz zhaMs-5)wRly7Er1JHM->$+`*J=r2l5Yh7@alNcvGtLqLTnyG17HR!RwMZw%FtY5A( z$F-G0=i3M_PHWith8jkB#W*CmYh%D0@b1u){YT^Rnp;v zP%p?Q%Ei$hRrXP5=Zki)5q)H6r=#P$b=SMIhxQ-OdyCjY+wNPibL|)KVb6o>@Yku@ z;r(qNuEYEDFowd5>(Kt=xN#AaTE8EcY$#oHZtC~slBY3k_c7wib$F)Npf*vH!PYUT zH+IR6bh~y};SJQI)*fjt|BS1URRZD`cGtUC@(Y8hZ&i+AePqy^Q=GsjtRqxTr1f(G zqgT-kt(X?Ha9*jEaYD*JOLipeg2=%~~*MgAMsiBPQJs3wRdg(OZ_wll>B^?IJ?sWQBQg;6YF2*ioA^HOXa z+ap~{eapkm&>1(-#5J=tnZ)&Q3H>mAzPb=br3>G#-!F?f-x;j#zwvh1^m;UPQi zk;y(>2FTAz-1actm;LrI=48h`ImsG4_YUn}blrOn8=?tCEEQJIIbpiY;}M3LOb-27 zEF6ZV1PrmqpPq9yf39Ozc96O2Bg9v99f?nAX&J+31+zC%2A+#7b_IGQT6JSrZkIv> z+m=?NVrV6+((6=ejZXR8vKBrIF33dD_`m3eOxpbvU6D!BMR(+m>IIEAH8vC`J{xIK z7@`WLG+a&Kdru6QPu-YXPH|=ATe9ew$>xYr>qu2C=AccRZE76J>h84Gsf+V1A*c<7 z>k)%4Td~yj!eqIr%QCv%#&|5MG5NPvxw3JqU&Ce^X(6u)By!fR2`S=bTy(mnQ%5}$ zS`FPOXxznEg?1LUx@hZk)M{ze5_BRYMBEOewZ%4q!bnqFi%80pp_wu44!c7mRc)aj z(EG~vYJRInV=wAiQALlP4ih%3tI0ep;bbC&;cGWda&4$G}DjBdWl!tjx+L z?BkiDmzcJfTDF%PwmWw1<5_d)<>u>EY(*fm{nKZ@CXQ97#tOaYpY&9W&MPkmEXU_+ z-2b0F>sa4Dwsq_Bx^;Qc$M2c4hOgPWynOtuW)I4@-t)z(lZ(+ z!D(29I>BodDmBX~bb>goz)oBm+rbiomOG9i=BlmJ#tVCg}z(s=Au+xlMuSlr$8pX7ZRV&mwR;fsE ztjKCrLPD=2Ugd2k=~Y`dd+j>8rG0rjRFUN-33M0yJZE3O5!x5qtuYXNF@TE!*Qf?`_52w)$gPNCJ)N`=Tk z1dv_Pa0gnM%2pblT`D{IN7Ha=xBRYUKMckpoJD$zAS-O`gpIvSmJ~aiJ8^r0-JMutfoo#!&`s_Aop-&PaHIAP zPw<4^7Ei)1u*dW8hsi~EmnUI_Ib={IB`)3Q`Hl8YPx5tdt0(#$n{?V9l6{*!*XiJ? z8n4$^0G{sVG7P2@uK=7#vzL`|R;yiL(Be+n@pp+UC(A@`|<8yq?6-2aX1dGP|O2TBM`JA=NvyGHs z3+WR%ot$SpV$FKf23;Z®tPhO=3lJR7FH(J)OyNB6xe2owIgGZJnH5sCGNla(++ zNc&iQg|}I0F5)Q1kv_qy>3Bput}+eiD|`HYdIdI8_tPvD;~91c-Eat*sSRU@ZmDq2|g=W@+Vj?VgBkGzk;YcO&?s6>Zm-=v1jYSx|j|1;aN-&Xn z_@$WAUrey7zP8b6w6PqI8VkUaoL@g~I&Eyll#U`l;g6t>{b`#nv%TdC+8gemq3%IQ z6OZ{A{1jqQ;4R|!p?(Fs&0S06{ZbL-_5)T(^iCowl z&&AQV{uTmcmq9}r!D^KFyt~LNfrp%13bA^I$8R9wkGRqe^i!;oVB@)j4ebswOk%=c z^dVhBi8fmNCa2BHfR5yHd>9j))nDV-a8=G9_;N;#ObqSf*_0Hw5PAw%;}}EaJ^H#O z*c`Ql(ogcwa}z#|3xTse!4T`5ApO)RC!%3|C!y_lA5r0bmi7egN~f(+OhhC)p3|4( zwlKz|z8cHvYl68zyIVdr#&#JvO~(U_68T`6(xYsQ*@hHntr;;AXA(KJ1U$(7lCU|DzKr~`NW=H@gAUER zvk58O1b^up`#Q8I+;ZmdF0HPiPso_8qJL;->lm6%qn}Db)M$>|)L}kX@27e2G>61D znF4rPT>y{aBCcwT^;exaeJ-ApGVuUuudjA2jiT(VO#cY$qn7w|U;QGWv4|Y*XN7cr zNyx6yrek?g3V2I}qYm)o#c_5_J)(jXliZ-exWs1(e*jJNNuxMIFUhcv)W^+b(5H=|+5U@VQ8MS${CH z4B%U`tdU~*HVr%TZiWND>+2JgNgu;c1=ii->3EayN`ki~d>~rR`)%P|jEn~>sUw1u zgI5R>#+E0os|jp4O~zQlRrYRjrnh9iL}aH;$`H8}pJ0xyL!{V}`DD~h1ON4Ynso*Fy4&n)c@R_Go$=A`K6%}d zNu9ChK0ZBwuL?FSy0Yb^{UXyBcv-HT1nrl-5kGi0k^A8s_;iLd84Kjv8#o!y=*uJE zfGmR!U~@AVOTdf1YEO6b(L-KHWhWa?K}LZNRaMYP%|78*^N{l##(kU()kG5`r<3~% zyq{|lnN!!tqQ*M(fr?<$Gch(>96Euo63AZ^dPw7k-h@#M*vOy-?UeKQ_inFk}}8uCH-HIwdGUByJwxobky zfpT4t3DEZ@T(v~Y#kyr&s3F^#Y{E>&7b! zum~N{Lv$^30r@zf&-!bLAi0M8&qF^kSJ409o$dFK{gphQ(?cilRWQyFRu7@_P`7xV z&LnL5RGjEdbOU;_UJJdv1vx-;UJYck3UsQ)II4ScL@#m`+(9GDnG6-XIa}u^lErSB zME^s;d&V^pSK3W<(i1e+MN?MW(cv|&V3K^Vh5p*z zVo7@FW;wxJgx=W5OqxS=AMV4r z8rt6Uq+Kmn%dL0j{Llp|o_Lf`+F9tc5#S&v1i{-S=*QX^#u~>8O`=oAO$>NaqsC_n z8CN9Mj+7s)*Sg~qbC50{NTOe%>xA^7T%+J(j3u`+RSVM<>txH=3fhvjAgwP8En4r* z`CX7FNgB*GLg<%DJYYwEhH@mRej6XFFI}gc~?+| zS`wPRniKOIUg;~u1KFGdZHg&T7tBdehu*axJfTxA`WAeehQ6*uc@cjWZOX=?2*95U zEA45}9KpwgZ?*XFK}PqrU&>8R_==)3o`Sxaf~@P+!I={zq1RS_%a@ltL=QswbQ^yi zx=0f|TF@3tRh~;I{RQAI6=@j-=vm0a3Y`dgTpsiDKr-E%H=8iuzyX@mQ5t=Z`Lirr zQxfPv4_VQrDWa2guUAiBIWi}3%RIym86T%X1K>H6HeET9ZZy$1Zw zWRsBcM;)MfhaK~`EZWlaD!X)tc{FRa@_9#%&!#Xh!9fL4dm+(mRGkxc*by2jr!8Cb zs$rtqp;$&`vaSxoJeiC$iKj^|OCD<4#uaj431pF-D z?t9Qn8g0a!7j10CL+w5aM(`~QJ3^qIwx=6x0(Ky~*-#d8`eNKX(H4Zwo%LH1J z%pPrx5R3npWruRk?*lf8s7+#+K#k>k_eAVZ5$ zqg?Mq1~NBW3*lL1LT8OWBqw1Bx2#yjMxnaQEgGsGs4NGHKd z+PocjEXUJouRwSM_&~xIBj1y8PUP)M&j{`zm)zhVv5E`AqLT+`)s1-w$sc%&SfQgN zp(Cqd3rTs2%!n()W!_{5&t6+PjP)XTDC*K1xBX=i-VXV#D%jJoW3ZMQ=6W<|(&xZS zl!<({3fom(H0v>5VSj{9ig3J`BM^OzaezliBIZx9_uv}xH);gW@Jo&y^lCHXCOW@8 zE$PV|3GD$dk+k52(1H7OWMWgnJOpjUJW6OnS5d=GiMfQO=?=y!{;ahSjtI^`gz+Sz zu13gI$-{Qya^)CnDDTL*n4%|StCWS1Um3PFG?9rAGucX|A%oNQ35S$0(`lakl72MV zVe5qa&(P`B>CF0$?ao&bG8X7;ZqyGp+op`GYFn>XH$fX1|FHGs9Fi*%YIuT4wKG>l zAY)^SM?Jdfa1Y%@kFlU9`dl%AdSHx0pO-4oL-4(BtM?@M;6siWA93e`p%mjsd)<;0 zi)7+Byxhq7Xz1^GsT>ShO0enXz)!+{8b_CheI;M;G~t8jp0==x=n9^Qy&ex*Gp7s} z5ylnII^wR7U=9cUK2Jo7!yZ%fg!x)9=g5XwwJ)sn=Q&Fy6SBJf{6wnm%T{t8(8Q^x z4Z_Qvxv)yGwQVbyD?w*cSDcwF1D!h;kHqSy3NKDpk^)h8B^E9=17;~5oG_|gk$9aC zH9}%GtMcWFZjZ%noTQmxB9n#v(qRkatrLmUFlO3#5t^9O7x+lMnh2=Wo*=JsnNwMJ zTD_ZZ!oD7L>FxRMTpRb$@xiAsf0OO8dOOxkAYasp2<*m9d(E3^l)*nrL`Fd;#@tAv zMbJBJQz_U~S!cA^5GNcl%tLFg2u#UY_ioNC`P>Y277JtMSPAPLyo$Gia&!JDHz745 zkyIm=Lp{=M8-zVie#tz-m&W=Ju48z&y18h-oxjKX$UGZ5jT1IV@cbNE%OLtT@ImZl zDa>7&Q-=??(I09sF0-47MD$iCEkF}4dgDP~ix1H%KBuY$EEZ)ft1G#bRyP-N$HEha znwUwRW_LPX`n_qIZVpT5h0zFz=L}s?_ zmV`dt(DB`{bvPi~r7GS*Z_`)B2m@P>D-FA*j;yV~z6L!Lwn=;^Ok~NJE5w3!&>e$- z0S;wCN(BP8cq(KK`$G|{DikVa1Z4EKoQ}heOl`@by6CtbR)Q^>ng~j?KLudkaow}R#vF@P#RMCVwY<35+cAQQ`1f@R+J4x1R z4A5B9&8Gt4XtqRbq;bX{3ra;(fNnIzu+{5<9)B8WqTw+oTOJeSE9NJ$U`hfm8mEd+ zz@FEdY$es4&mz#S1xp_Xrd9xOGXZ|Gng;dCRsu9DIKbSRA}-_Asn>n)nZTp z+h&69tgp^R1(P4MKsVBy2AaUys88iFX9=H3yKENL6LcxDHhF4vjF4Lu$okDrrQ~zj zQn_HpZxcci+6x^pG zUT~cbIqD{B{bm<<16_5q)|@MY2~;L~s>X*Ewo7#&5}t6&bHhr>o#&O#mb(zPrfeZ4 z))2`WpxGUE+2VFT+h77Mfez4m>uDGtH1r1*=Ga8%gv~qFbVVRbPniyGYzRunq{|AQ z0&6iK*!(6}-kuHeH2GZMbcAbv$^=#z#H~-veJ-UkcmkdRUpVMr^=_)m;r_ z9O^KQoy6cJu0REJVRb<7tp{z^1|O+}Ps8|tp6OFVmXh(oxPllh8A}T^a%$v9M1T#w zSP$gmUSC*X++n}d9hEdbtVe|-;j9>{H=S&%ilekD0Vy>Z0uKwc+?h!Bbm*COa!gkX zIyS}!uLdUS?qC+aM5o5aoWoihE(g83-c2;I9Q*_18O3aLGj ziZhg#3g{12$i@&mg$gp%9*h)PA#>OSyG|&UQ^D8sG|adz3FbA zqVWNrEqBY22}+i_FKSeZR=>>?vU&npmD-nw{h77K;}d>|+Zwj|nN&-#7DFLA)bd+S zgMK9+Q`ayNf6BJr4cm1qo^wI>Bz{{xJ8;|ImyHZJ%Fs^JcDZ?$G82Tc-R%JmLC#@O!$;P|v2N>E!&VR9j!?%BO!lYi z_;3^71lVYE4E&VZK1lFi%)(b81^-_ujCBaXO4jAVowYk-1%7TFe=1i6{$4GAPM?7< zmmR+9*?2^iCVpS=pJ8E3&Uzzc9Se11;j<Mdf?;;-c5M2X4FrFq&d?(m|xuA4K+xKLh zHry&ST)`C9=16+XDO(*M8u-OyjT&u(e~%UZS|(l61)nA43)^lIzRW^94S8=#**zJ% z?8k%m#3#kx^$Q|C7n3Hs!Yi%z$$(+E-Rw$EHjQiyJ^|ft119(bpnjx2k>CpDTaqZh zoOET{zC)dKaep*LFE5AWf&7T?kL*V@8AQ9}Hb`Eq88lClM(xVOUr0_9$36gK(38o^ z{zWJge%{u4pyy*`sJerpxS*v6$ooPdnaI_1EOf@77VT~ln>F#t zgg;!x9hB2nh%X8JG%Dy9_=^>qZj1$#1-~sdO5I(!wKhrOK8g1v!q@tdqW zqLmu<2xZ86yC-ARyUjeF^UI!FNq@>?g81sdCj)Es;id?mAwut-e3#e2e@x=xBgMeC z0qfdnhE6CA;Ay-XYpxgv;oR}lbm?RX?(M)m@aI7Nu_p-a;G*G{Cu4w*h(QTl$$0j# zdKUeT`T@VWRFSNSBr=sAt;l|kX__W{6YapdKh_*3dUS|6zT8j8jKRe|?(-2e!#6OK zN_lMI6nr(0GY&!pXVAj9Km$$_t(1Kj14gXH_{sjR0@6dq@WpOj_#RIvti3Kl>^HIb zb0?{bOzTc_tOcAEi5x{A5+Aine_dj|dMxRKXg~eC&GMLC;&TaK%LeSrX?M~s{@foOX|?&ksVpF(ikMP zp-m{UuOml}n?@8`$Z?F*YL7NE7^m|7A>A=`cC`$$%vdrGi9eEw0WHFhlMOBM{fTgM zG5~!P{<{gXS0`A(8k+>#lYM{St1iKxS)GSo((}`UJi)#sDdUVd5Q0-8zGQ?KfG-oC zU@0EIFTr1z$aTpo!lx1CxA)HxUJc)+Wqbhmt5;T*1u>yGvA6U&#AwqI3u0|!_meOmdzKZ8ZPT5iZpcP0rut)+d? zH=z?P!x4*pfeiTVQ=<=zAn+0#m2P1{BV}jMP<3UpMfg$4W6PUX)5r4Gw(jTY$>5cA zvlP+mN_MkV_UrD+-AK>>ydvwHEZJ+;^EcPnTZWc9m`b^oz4DtYjPK>T&T+@GtY5;< zn^$)Ea&P>%_%M+vJ^4WL$n?embY7w_PBskXs|I)F&ML33e-96*v3!&b$lt zT;3MDimVmJNck=IQlD_}d-&jXb3l00BG7cV?P{Q{x z2VWDSKlbELubs!}8m^!$VofF;j~0u>-`8bQ!Nw`;C{@h5;Xexh>-PRySx0n6y1r{gBIB35TdqGk zgE9C{^vNBp0#1U4WgW;wV-3pKmWRvq*Dk)mJ0UX+n1c}CMM2xvV-2!C<0fM&P*=Ls zCmx?CsRNOrQoISifprj~A7dZqiTQ_#W<6wY!lGPn!6&{!bUL&PKAp)r@16y%SxYNc4>GG5UTd&GV?Ai9E($k&27V6MOUsoiLk(jLO0vL{CF5N-ow1 zIn~yGv7cnczQ=w8*gvo*`uKg1-9Vvoho^StAY@Mxt?AGy(f1*rQf+<#IjF{>Ex)>uI$c{5y{QP&`{XE?xBPt*MiF#ftiF9=;!huULsMGyI`3uQ^s8 zwCBYA`dp6&<+LvF+2y=3RF9jbTzpZV);NPcGM?d|7p4x9E+V#vYy$d8=1$hDs88IdD$OX-lMkE zhSN89UuyeVVa~~K#eNRVQDVftLw+$o^XV}!$tUE!zdgIrF>|S=UjgVks=QpLOaE|4htP@kOuB$JX^^<@-)ne&eL& zr=L#wp_7$QpS1kI%H{WLjw{erJkp22w+M}6nKk>)KKU41SyIy&1`XV+?vgZza z5&Sk{KU+#aam;hvCD^Bz(8O{+)XTq*u6pJ4+O}#b1ZabY|LuwV^a*W}xDxQM z!h9UDOk^KxJ=q^j{2y!BI|;oqo|kR8Atnfaq%@66jE#{<%IzaWE0BF6BBu{ zT1oRbIMFYbMXrQ6eTH(mz^AziVrQA++o`av6BU|)Fnqg(%Wzx=QfIA)Huv>Nh~Es*MBai za){!jO8b~i9BG*pX_^@>=9A+zW3n2JdS;kWni##7B|(?kr+Re`q8wJKwB)qP_9>Li zuwJ7}=hq`Mtw&~BkIaN!X5RJ4OzV-E)*~~mM`l`&%+!ls*olVpEJbF5|H*n}ruE27 z>yeq(BQq_vPOe90dX^$H`Dv?JG`q{eR@fd7)oU)siWsGQ2@!IwAw=9*kIb|lnMrsW zk(o|PU+a;XWk>K9+_!9GShlwruE27>yeq(BQq^V zs#=fCv{Dqn^~g-?k(rK(>b4%4sT-|Jy&jpV9W8V{GEW+`~$V~l_lh-3N zEsZ3-9+~MWoz$=%nQ1*T(|Tm4^~g+!zOx>gsXuDgG0_rwJDJ-%yH|<|vmTjgJu=gJ zWTtLJwe`qM>yeodF{;ZqNfe97dSs@xNA6mW%+!hSxGcKVdSs^c$V}^znGl)t*^j{W zv?3HOi^{bgnW-I#nMCYbkIb|z;?&Z;Plyt@9+`wyIc~(rVR|R;i{~t!7!JPF2t-E7$0h&FYkt zPOqeBo$54|ZBgX7w6vYt!BMG_I6XE*ZYzcDwM4bWNm*_@T`3P|@|j`2kQ<@|uEHs# zLZR3RBP6Bs*+O1w4pC`gY{(NaXqAa+t(H|QRMQNjU{oqb!O_z?#k7{u(g`htBiMx@ zikG-@S^nNotrVQdWC(G%Rw{DG2-l0*b)4W??Z+476XoJ)7isMvQX@jTM&f&&^fw_D z_$&z{CZ6!~)qYkGnsPp=N>0MX!2b(>uY1>v+s!!ZUH|mLfz7u$&pu;K%_@mSskx>U zOFzEk?6WB94dfq+8X7NDE5&LhESAdYLVjpFHN+0nL)*G3 z$P1=K(a4oWjcW1BGM^H29Qn+Z=1YZgVY)JGY49n;n-hoqq9oS1JTDF}=7FeY#X`Q^ zebjl=eY%)2UnrGCiL0P`!4gIkDFT7e#EM-QOK4PrGNGGR&;mQHP$fjQLZ{O53SB~_ zRPrJx@H+LVrBNwyJV}ofjF#gxoQ_ejBCSLUTBS%Rb-ZF)nV`jKTE{ZN^r$6YNmrWq zdRkyvtxm%$ct*o1RHB+!=vk#!kx;3pH9Rfoa9%*KrdhG+O_hL_GO41Ewi^uw!&vY2 zc%@ks$(zaUcZ(HU{D?2)D`KNUzDrdq#qA>_ZNv`edRQgwqt`**s*(h2s_i&R>7XT; z&WWK4PqJWXR;8dB1&#Azwc8oxc9n8it<|$&Kk*?#6jz*m)@4h{Y0Y;_>932G4l~KX)}i;dgI>Io;{eLt#+MbQc(+=3ljm~sb5l!1 zXugZ&pES3*?+c??uGp$#x!lVa80O0|9)ZbTAC?Q%5-;avgcL}2a~P8E%wk34D}_?9 zLp{KgSjux!Bwa~Or1O<>@ADvf)G6kZl@xkXqtSKq@0K3GNRnx@GxpI2xzhMruNh|b z8dk4vkNd@{^^+IJC|L~#kAj`1Sx6-%t>Dz6RxynrdDEKdgkGy&91P>n=CEB`O;7hg zz!+09ETbD{m1`b5B*7&^ov|Www4rT7tKn(*46N6ZPp0!?m)UO{QiIu((J^GKrX|5$ z%_YF;w-GMTts(AAG7ksC?Y-ABO8vB6R4G9Ybb?Xo`DsDJ<1A1eG!`YVQ%DKrGhYwF%MNLOEfDvPq2?6zc?+HM93V%-f+JXYeO;Q55s!M zDv@xf7)?V#i^WvP<38uvod%R@v z37oAd*S=lBYQ9ox%B*4WsX1Nd5|ZfS%Af+jh!4oO<^m6aF7pLLUa*Q>r3wzQn92%O z-T+~qZ|2G!ngcfSBqxESZ+{7qEtYDsfc6xLnB^pET9kzTj0%!esE3Mu$PBY`4vR1P zacNzA+>gk<$NjkKd%P4E_FS=0s&M&=2~rg*04cHe%mrOy)Z;DxsLSbRmgF5h{-D-w~@`FF`8swd|<&ELgz-dam0L+8?4G5R}~fg+brms6d)P(EFQ z^2tf$epjHH$e=euC25hzE!JjNkSk})ySn{ts9^GQ;S5c5NBY8}4-D-e)1S&x030RI=qtddhj<6g{UO3T*UA1euzNJr1-}<-v zZghWj!&kO$z4Fd?tW}6?-_EQx$&&B2x?vqXtkeywpISbAc}aF_zOmcKE-~57V~n2D zO!M@#f)`mR=N!)}^bDs~Bv?!dlxkWn=o6!Mb9BODFptp;&WE4GIzWQz4h);DeDRJ)ByRXM$jn+O$) z!L1&jVVunIhm-QZ5I#Fc{Xy@TIb8w`n^F*|qd}{GEC_P|Ctv_&q21ZbSE0pE9zA-L zz+3ySyU+T6|M4X6`@dbw^$mUbexmRC)40B|@BVYRzNzoNzl<+-o_`s?Ujf_-_-g0b z*E+xb-}hgCqwoD;T;JVye=n}T*}4DszUTM#U3c^PPT#Zt#P#<(_dmq%kNVy{i0g;? z?jOeWBYpQj!}ZTQ_mATDvA%bYj1M-Ln8{8Eg17)G;;WL=EXGHU%Wy?Gl2hLRM=CYaHXcZ{J& z&G?sO^z{DT%J|>@cYjQdzxAxr*S`BA+Z7uIE_p)#^5|`cJvY8`_!Td^;m~k+~-*lh7_m${{txKQ9M}P_Zb&@@WpB3iMP-9o0 zQAe_Lr$v|^u0AdKa)t8Ol)niw+%#88can_C zl|1W38{;pgzwIqnWt{r%h^6DQFuDrUxr^ z-nVJu17|$;#3y50)EK#I`FpzQS29korTq2u$F3)=1%GzBP;k|Kc~3oKuDil6Q?aV| z`^Lsrn}@Mo{5C2qaY8zmE>V{_{AN>}au@On#|4h%`s(t0*VD_(K~EWfBc3r!)HGpm z+bm9lF)-o@_3kNy*=2Xz13|wbXb)Q`o8J@iQWsfcX1mcdVP%y8uh|*gJYsT>`7I{9 z*KTnK1LRI=(Ha<|Qf+1|W|di^GHPj~S!Xn=G-|a)qci z(%K(?YW$vq#=(tW`sWu9Y#o_@bC-oa+ihD-Pdwf6_kX?p??z{Pcb+x+%Qt-NA6A3! z<=>q1=TE+B%YS^svF{UK7=4TPvX3l(f3o|#ZomFr|MUm{fc~sM$cyjr~omyHet%WveRPbRis`X}^`=c|#X7ki) z^>oY$E24F2O`o>GeCLXVoZ#WprQZ!Nlrw*!JXt*dBb)y1@6`Vi-})=ntM9q`1f?#% zdb;WV`^&1|A9>pu##_A7=N_B-YG5(v)m=T^^a0GCD0@ZBl~-5Z@~@t48S`}Iza_f; z*>1vel&O!uRI9|ov)y@5m;Rpb_201JhZhey zmvi9*_uhNWz@C9~{^vJ)2F`sDR}cTbZ7w;cS1++dgBHKr;Jl2&(SqA4SBYzJ*<(IC z?t|w${+{pr=lNd$Q_4S|<+<^32Tk9LQ`-LLf&4h7?SCHh|MPwP+P$t}HynKXNct&V z5}V1HfbMTMlktJSpvlV8fq&h7!6lFXc*FR>i^)$ouZ!nFGI(@4L@lJMe

      3PB`u4_k#!^TccSv?0rhIiAGikj><6s2{0z$Pcs-x6d}ctis`5XBvael3 z`RP@+e^upgAnhh=<*RLf3gw@N@5$eZ@XribR@43s2apdboBYX{p5&k8D)CPb7*e(hl&dbE82(mU zK9BNOM}MosKk*5X8^6l-Cs01!LDY%ppB^x;s{J2DUe~Rm{oJbiU$v_8N!!1$hVrLY z-T$kizaH*MJvwMT;m@vBw_m@S_78jvrF~)z?Z150<*$zZKZ~+IwTAL9TP6OPjubwb z{JptT_Gc9sgf5{l!;VKD|2qXU*luR$abz zRrn|U-u**2ob)fc%JP}j@xL{NMisP0VaSMU;%XVndn?Q`kr;) zE&mPRn;;+r2(RM%<>^;@pF`exKmkw$>;{woWk3Z`1=Ij_Km*VO5O2sg0Nx0IbLGIB z09OL`0G9VZq0P1S|4WdD^yA9_F9*B=@JhgWfL8%F0$vUHTfp-EC+#NvPjte+1Dp@I z0B|ATBEV+A7Qj}(Hh=4LaxE_wv5}-gNis?&<%` z{MVXVtAO9#b@r)Sx~q1bgD4pPt@@V%WwKy|*1tR$q4lo_MkO#RgHZ*HPr#@OMl~?1 zgYob64;|y6<1BQnht4<9IS)GT8iLUXj8GfM1dOI&dAXu!Su(EXU-0S-b4V`zE& z6oBd{g7H7fg9OIV?~^YGm6O8wANePP@jvp9hz`|{21aNauykQeQ$bb(tq*tr3C5Vv zBhFxe2dH3-Li3whVSGmY2g5-WVGNyLZ-k)bsq`1)3PV{3#>AkU8OFMQu^Px|KtGKC z&<4#9+(T&oe&+`c0uN)T{va^D7=Q}nh+m1!H^$QtQh*x+nqCczf7BO0jG=w^50-$j z^q+Eg02}L{%NLCe%255qqR{+e|HU0J#)0vDP(BMX8h{65P(3Wb1Nxl*QXf2E1Y>CV zLW39(0%Li1N>*ro;Q>9Ke@<@(V_&*I(!&E*Fn;g{g7tI>VT|%;{gDC}F#bn-`2}NWdvXwiwwKGl$*=yB3yY5>!vi-kF8fO#r5N;n z|7c%SF#bpTqW+tl=5KN~82`=>DZu_W=K33R|Bds)Xb;s#4#qB! z!FKBRFZH7V5Ez4ESOEJYjQ`Po;bBbvrySgGhOrmO(DFe85MlhM7?1<*!5G@VVC9E_ z^cO?Zz(J5rPySIq5B^|K z{s*JO7}|gT;D<1VHfJcqK`>wp&EJI*^!}JI{(XN^01L)Ph`+DLhVei2;lQ{T?zbHG zuj~J~A0CV){*;RW_%II3JbnTlZ%F|H7(?p-nqCYbgz<^cALE4>Km_BhN?O?X0S9>m zV`%-`=tIXtVi+^Npn%EI01_DgBmbl@2DAU?_a}of^j?4DkNj`U3qbSo=r1`5%wO<( zz9R*MVe)_I!^VK77wY}34}kG0=zxIghl8NNm?{(mFpvV&u>1X^KheNA2$cPi9u+np zKye{ku;yym$pZ5XEY5Yx$qb z^*<6n`Qu@6=2tH~*f`A1Jz4&fs{Xj%hy6c$-R~UySFihh{r_tI@qD@O0j^BS5k$Lc zZ_9wJ-+KR}zrk+&-xA;f3Rt`Ttq&f!h57N2{?z_=zuy1s_e11`rv2T|;Q=%l|DM<2 zAirSxpyS+5fzUBLKo09y;eWPxI0y+ZwBJIn*{7=m2&-JdFP_E+D`dYRCLB&LF`!L{&xh0V)wH`0)dIIVpAU zcOw{?kfF+%H$rT|TarsGx2!ZzG&6S+}8X0s{L3Ry9x_MJf5(?L<}Xk z4}c2sQUe=>dF%m4!&~Y&^EGNDQWSY~4B8JUoYdIvrpTsplh1=CiCYMID_Xz3uhM=0 zxg(aw##p~`{PNaHx4Nw1S=qzAL4JXv68-ZZ`%k^M=jLx_^=XpwUtrMX-Jm*~4B1Mk{&nzSnQOUn$T7reDzu5Oqtjk)eZS`9IPnLHM3F3xTrJP{k^@g(3MVk^m1pYlN(H{Km=3qQ<2*7e zPXspm;{pxw`_f&Sn&EN;;t|gzC3$dmC@0M!!$YlXI(qRv6Fe+*Lk*F+h#Z-6Rhl&YcDUGmwmQr( zkk3-w;KXT2fZ&;IFFp4z_7~>}HbT`QZftI%h!8`yAuU|+hbAI~$!%UB!}t2xY6p+- zfG!69%?mcAIR8UrS=qLeh&jopHX7SXmQ`yl8tS7Ray3hFCm37jJ3MkVIZJ( zW7)v9ec92nwZ%QD%Xk+UZDC9TzsVd_n8$v!g=2S&@d;kQ+Q7SlPlTe?5D8jFF9PHOz2g1uzq}s0M5(ASufJ>0fkaFDAUY%cuwVCNtN*ku5 zNqc2>COpgKFZwL8RSqh$1}Ez+M-pVQ$c%7Z$sVH!AKQAU&R;InGlj|7>#~-_I1B_k z&wHQGB4s|J#r8)QmW1p)CH(ZbpLmRut9wrJW{h;p(wsvndphz}B%*H66OkH`1v$DJa_&D=Y>_x+@sH}4G zab;mHm;0tkvMc5uMvF9wuO zC~9fpq6fhTwTX{MGXDHIJ;e1OrC&yC9KFGa_3C_|j^KW5YHHtH<32`&l$?S>c3s^E z5+YPin;S2B(3|RN9xo9xLASl! zk|xsT!Jx<8n!5#*!oq3Y-SR&L1mqNz5nH&FiHL}%bPXe@Lu(CKs$WgZI5}}{Zf=H0 zMyhLQyqVwsSYMxvP?G}Y-P*>6kdTmqit5c}y(gRogUo5mxn)9h8+e6ShC6r{z^tI-ggP*lp5%q!jv(jNuDgflSxJ_4+HVwKH*l5FbBue+F5WbaQg%`6yn$i+ljaI^zeZ;7nd6P^lc+#>dpRkbwEdSw z3wEMLJX8VrZp14=ce)P({IuQ^JdmojaKRL9aAJO{xU)EA^g4;`#+Fz34K{T>378u> za*5dKo5zlkYG+Y`v*i?R(CSM#xp8wF8i>O>Bwou3BBArdrN>0h+J4Mwj2NL&1PC5I z%4y0uhIA($SGa87VoMIt0GIe`RHDWOnvJfS9Bi{D%)8 zz;naTYNoqczke*T6=h~-Mh*}Y7l-tN=~h>VJqvJ^C%*Ugo4H#h4Ge%^+))(=k#D#W zle}mPK>{_|!Rytpk#CwlULT{5er-+`2|mZg2&ctUiH-FkA+Ui8SCz7wORTE-y$r^drb5oLIMJEX66Uj z*!gz|Y6#-NHxwoW_h@Nt6H_kV-J7xHO`@&O!j6#At#ZT#hnu%;rU6+PhK955jUff0 z-@b1k$5Mlh;GHSC{D_j_EQ;+K?m$lQE=GvFJlHY^&o*h)#9G9JS`&1P(?z$JN)1x` z@kO8ZNczqwZpUCgW$BT?KzLapXC0do&_@l-pfkDI8FY|UlbKt3KXjWlz;v=fKT%KG zTF|h;hhI1*wIe~2`DkTDW^#O*_nEQ#UZ$h&o>KjbZ_Uj*lF41)qME+AcG6s4zf(7Q z{V{I-Rq?VSFH6^Qg;}LsFhSqo>0qi^N5FlN^B8HNqi4b{ByZLqdz$>H3VAW#&e+Q- zJay$iZf&uO%cNW9NCRMFW4kvReTzX(qAe<_@VW7P7Zeo2sMgcl+uhy0Xtl3q9;O7= z+R};Ss^IG)Pq9z~?fHm5(;K($&DyD{S0t^hfNuiiKt_PuNLG>dK#Wk1h)?M1 z`QFp>ZTa+Bl^#Q~c6)3r&Cch!?k4Zo49v_lOiW=rJC8j*Jss){+_8kdeEAZcni@X8 z{xLWAt>IUXcU^b`PF*Y}FRU&rgq&H@bd^d{!!Z$r9KUb;RiDvC`>ku^1i*hj)o z{h*>E-pj}=@dlJNP~MH}Zq}P-Zg(mv>ER$!x3;q>i;2Cb=D4x7)cc3Esl9@VMKAW*`d%!s@FE4LyX*nn$!p!{Y`PVOBoK>cy#*dSPnVx=5N=Q#n7uh~1 zl(tKv9kjJsIxpqU+Jcj3iCGL`%g-7-r0m$4e~0-sApnC(76)-}&K=SB{DA4@?Qq7$ z^{Ha*%_R+vMMu4Q^F+5Bk8#`G&0tOKqTt{`!jsPn)lrW-_d_0FAaw=2%_hnQxch~_ zoJ5Xt;^cm^i}z-3q@HA!iflY{L&e=3oh`Q~W%Z{|R$v%4BcVPZm zKKNMNL2r2bUH3y$-#6=Su1Bj;2?v`lVc(UHkJ{hs?fF`tztE>M84#?i=Zae2pZ|`n zzvX^84lh)5L;ldmg@o4-S3m2bhWBv}xp2(g#i$RdPsw}B8nT7NyY-y-0Y%wSWdx<_ zhH-K4D-6=awA2%7h4nnA<1Nr8yIILoK1cud;pd=}5A6_6Iz2qk}TSjKV|K=gvJ4dF% zbm^uSd35!vc&5%2bH0AJ=fe%AwBRpV<@q|@tA1?ks7gN3z@TPVl8pJXx6{7YqSwo2 zrE2BmZ=5q8`Pn3{JM10_8O=EOm5N^8I~UdMs62nwzFk2XOgZtmdu_4Q8|Rm^#??nd zAx|GT5`w5~f=WdUX@863QI!wtFKbnq8%KuwCo2cdy8FMK*C|(ybf$aw52X`v?A?jP zc6mbv?&asR-|mD->HUy`dvhsxgD+2tT7D)8c)4tHM5HY~~l5MYm|iJNv@%7aAp_ zKTI<^*vC%uj@x+0wr%SA6M=DH?XqEzV3CdL?(hy{hev9C=NFuY8uIn37WH}HD;GNB z3v9h7tO2vA`^jd=4dvLv7_}>U9()NK9}`k`TquLFiiO)MV@XD1LgVth)>H(Dg+sPq6Vzfm zz>G22^9$L1cq*cZDUY%QId5zkYK0S3q)RE_l?jHo^R=+yga-Ta9J0OF52s7?&n*3U z4K2Nc8Ku(0SzpKlgNu$8l#yaPM3yCzXzAcX2(n!~4;a`42$#@AZ?JW{ zQOs%RRA=4azG)QSyIes<<-jVm*;tCEI{Z^q1qySf-*49` zq1(cS%uP(LUP)%C5#oBfU{Frn`W#+-;d|m9?M)UL$Hngc@~;_MxF>g*cjryw_S@Uv z13jd+QrM(XT&$40uAfP8U&+llqvbSvgkC46%ba))U0n{nlWBP-9?e`J*%mHxh_g8R zdWZ&1Jpj$j3PHbvL9}m0G=TQSGg1p2d zqE?3vN6PWn_P*Di*T$FEuj{Lw*r`0*xQ3lc#4(;{bD*d&Mfsj%Uq4qQvD*>u>(xRk z*E6qBZx0L3Sc8g*PLH4jfPLapNm2N%vBDAu{^&MAGc{TgWOeI?^_ZcPPN z*U`uT-p*6B;|j0Oy6**-dszFPESfRVet+^LRco>17sHGWyLju@vy2dU*-kzo90|54 zhy41(R(a1Y@jLUbknoS4r-xTH#GT@olqmx*zy@ z6)|U7z6?9GdtZf&aZ3cG$Qe>CzS5Ga|B9)Ettca)V8{A%l3=)6rLRDt=e)UfBkl>6 zr6tDHd~o!J=}|)SGuH1k2KqrZuV{uNRZbA_HSBiCU)%~wr97DD-FvpwY}E2J>B+%3 zFNRY^aCMEDk_x5goc@zb+vi63LSvlYa#+U>)LkBx3SAK5t>&dV+iQ+Tx9c?AG&;RI z>*wN6(T>2;YNM22#|;p|C-o}vr>iEFKvT(jf%=Z(=u|)PptzrDF!k4cO>J!rO-(K) zT5n2!F~138Uy?Sq19zdvI%R(E-#`8FS@+FjMNVO7`-$oMw+oO|o2Se5whzo6Uf@szz)LHB2EEw$^fML~PM3nxohb>NyWV zGf@wOL447!mC}rMb-jS?pPx{8NvKDL<(K+-*>6`k-&${Xd#^dj?0Ey9I^OM8>py#_ zC)Em!Rinp>TrtpQxT8+2Jz>ACly#WBC8W)`B2(YHVKIAn3m4QM>9wtFCG5Q+dlij# z{K4z;VeZ}5x(?@@e&)h#U+`@rYeT4ZZw}mW%yK(_rmGW9nj~RA$xfvv z6^2NS$yr3MQ%ulGo;@8X!V{Sq8%}sX>-2<@mA*46RiaEE^FB5eLBj&YQ-D9)O6U+= zWFM+yzso;v?EkbJ;EV4&H{IKki@K2nZoRCh4}PvC4?vQ$&)|Q%;aEpcPoMPb#fkA@3sR&qPR(cRBX=9# zU|(-FZ`YkB!=x&` zciV7heeW~eudO9MQ{`G;G#st$ab_Gd$lrQbH?Eni^}V3b#I;E zs}s7+4cfu6$b%radv%Omt@%edYnJW$=MNu&+hr{=4uL=CFf4Rc9I=)&jxNfu@V!%e zBQKEfz%9dTUw;vm;pcNdeu5jw0QgQ9sS*j30O;TUFZ^Fv0>AwWqyRe19{_a({NW$K zf-%&y2W5Bw2gXqU1vG$uUf8*Z-~I(O;MN!FGWhNPKm+bz3`-3D0R1a4zarD0AHV~Y zForrCpaFcY3C6##hlAj7LG?lXA;Y0#(Bl#RYWP3xKQuMtea>sfW5H|+z9tU(-!Yyu z^YQVsGh486b8_%=a++IkSp2IQ|MSEDF8`sMGl#2-ou|Wp)}Qx(i~sPyntx-xGOKK! zewAvgr-ae*SF!(IS^sOY-|g*Rll^Bt`|Usct?z%A|F8slFaQky(tr5q>A&qitjNs! zC;#F9?Eiy)0|)@~{~0(IJcp8#x~v3HGC;fup5+8zb_+TKjds(9U6=XpOHSY2ZR|PJ zE2m7p_b^Rz<(QnvlR`zHQ18yoAR{9)CSyICpTK{3dVGwXX4{W6i^M-`>h-+A^71LU z#)agKK?0r4dQ#CFZCvRN^HS<)+7&}N<-y|I4Z||^fhIlGgKrL(PtQUDp{z5O+(@9W zSG-QlO3h_K#f)f57N7(;GUlWoTL5@?GC-;oUYJvXeHqPbe04XBL&Gvh^=f!Gn+6Yf z_qWG}aq2)ja8xjm$OOum`9jF8iW0l#PEJKTy$W%#X8QO1ev&6YGbkuk84P!o`$t785p${#nrw7DtV!|&!dTG=ygvt{^2JZ90soJ#( zhE}#A(Fii%>SH2j%#K!Syj~>^eRzE@(@#21PRkkLy%Q@9gQ5-2{TGgfjgEqD7nw6^ zj?Uv=LzVQuf&ta|2WQ$e#55RH+ETP|s&uKbQOIH>#wivEnIb(>z}A;A;IT;pX6EgJ zG>X*jC}an}DTbK-*M+5^Uww&>z5p4yplua5nZmhvxw@RfvWpL^BtIE5kM%s}=n55B zTmo>a2-a=kO9jsMB$Tpf$v>H_m_#T6>0AZ}yDd~vBXuvFw&s-Kq>Wqsvy*U4KV~W4 zJ6{B#0WxOVk1ST+gUlu?#-I}Vb%}~Z4Aa8XDGy%f-utB_^h`O`#gtSJ_yV&OSusB? z0Y7Jerhe#s;2dcV`9^EZG2FAP-3xYkva=qGUJL!)ZQAV2(a z&F!&bI#;OQR3viFA-7N^qm~wIM0rU8=|h^D@wDx_sx0%NZ1gJ;;KL7l$V1O^R=SZh z<6XR!5lkYrWG&^TMM+xVo{@xP2jt=4&`35m)G#Nw3$l5fhXt+)!C^oqOP;q?$YUh{cisuY0dVQm$mXU;GHCU|u8L=Z43j54p=_!22mG;FiQH{_&zmnKJixX!`P*9 zUpshGN>L`;*qB@Q?o+z34X z5%rJolfE`lBk~=&RO`~0yBuJP1jv}H(K&{aW@?f@;i@31;#U|Z7#ciA5p&po%2~89 z0LPy)cCs@jqSIfv)8}E61z3Kf0w#0%xpGV5xO5EBK2=ltM^XY${POHewD|U8AL=B& zTEp~1ZXto_y&StWCguFeNF)#nmMSG+Y#e40#|sqD%BHM$%D=vS<5$Ti=gH z8|9r1``JuXDl-!T;1DXI4asAzn$ZQ0^(0ezr94-ecV@NT?|X$*N(rD5=A_BXX3Ml^ z-{Pt>+3+xZwOTk)KF>bG^n0dG$Ejy!vi+5T8J&iuLsrJmlSeQ#+GpnDO6rl}p}0o^ zbhwazoF=WqdSj>f(XJl9>Io81p@@t5(vXr{tC#xN6KgI~4uT`Bb zD=;%!PZz#`jmzaS|Fzl`vLDm7J(*>8rcHM$o&d8WLqRL0c0-Q$2H^{((Zhm=bdm8n zBaJIUDqiuG#a9nK;e`=&Orr#yKB!4!t0fJbeQ5#Y63~~$qaxBI8Ir9jF zZ`kW+Siox&`n+N);55blfof=$qvZQoU9N26T|Q%QpgWp*&Q-Swj6gK`M{s*%NHnIvrnP$*AlO`l*3hK8&S)=f-B`EhBZmZsKaAF97DgwI6C zt|1X_x2oPgC~jAr;FFg=#)p_J2XSi0(~XJ1iD3$M&&d}diwTEp0(fQF2wSy*2~y)P z?3*kQ{ARzEgflcauJyP?R(X#=h$G5g_|g>?_*o*DEG_pXgou2amI5MWCciYtX@Xry zeFWl%nTh_%Rvw$<`g|Z`)L1m-PS!hIMG~wqm3f7y1#J9Xt)HGrv#Z&=h16ETtD;Lx z4CTrKI#*jgK^#u?UQCpd9(l;D!Wm8{>PO|5QT{l7hCv@gpiQ1}CZ{130N=*m@{X1f z93%>cqK_EiRK-t$N67`qVhEWMl0Bc0#Sq8gUs`2Tf=3=vA25{OzJO#tL`ALbNmj^a z;yJ;sSyq1AsmZ@y8F3`+eMwY&p*kSJU;li6#Z(r3vn~jK1wXv@&3*01)l8kaI1%cp zB>dU~5@-}~WkU=yfc01y(C46TtKvRC7JFcuj@RT(liQoMZ}%sotG5eeq7<=!l^zrulRfGZIwFo%_Fzig2;y@d<9_yvg}w2aq7mJQ4Q} zLbpHNSYs+BU}fe)eAv^53`p|B9lTAH;Ja7%oCH#^EEC8;0wfJ?rp5#mVQYUl9c)j; zOAdJJC_UEUvyq;ai{7oCI_cU2 zzpU_iKmc`C{_)Q_wJQ|c`c8Rk3sxCS+uc60^QNYNwHGTXOC@6u409GpA@m|}jPpV{ zC|*_QeoaXHVY*XHaBQ;7VE0h9eo-q^7qTPn=f+Gk=L~dwQ^Wd1ZQlP-%iB5w(`4}} z;q^)FH>3$7nwog+FHA%zD7)kd_3}unI2GZ*DTijT&b(nwIAD%YOSPb>t?>A#h>G~A z`zgm%GgzYgp(BvT2mSKo+79{f1!!+LeO*eY-^ZinkQ4?p!KqBp*OJ}722=ubj>mau z*6>tf>2Ejt-zSlhc!T!?*UQ&Ui!Q;8gd>)Lo6`V zjIK1U-~pd0B6EgHKh_-Az%sAkCOx5gH9RHI{*mfQyxqWMW|JL>7=qt>14EAqSJ&7y zT0@G|QCTF~lbAljIBcdK>@7jKvgR{8LFbvr@nb!^O5o+rz|K)HK!B>LCcVW2+PVZC z%dXhm*YK1?iCEaHDI+m;EN`5FFC*GJg2Af_^%8t^g=xDy%Eq$ksXA(q>?SH8UL4a8 z34sG{Oy3jnlOighMYtZ3GecUMd&#v(dsA;GS+0I0E=aff{!u2KqW)=~GIiBIEK&sk9M z3-6qPO@N1A5{-_kg*KPw4RQ;%(!hjaed6)4o}Q`)JpFj@Z1CFq-P>2i!NjMdlz@#W z+MI(JKKX#hkcVxu*y`1N5|NFhtd(UYviKmX*U~eFx44UKzQkj=pDUu^SP*I8R0qR3 z$)IM?iQ%*OkH}&UeX1j)4&X|G546UlWV(y7u@ikgr<8rDzzL~;YD(VqrzvO|9brIp zT0#RPP>TBAaODr@XbAXu+)L&EoH$>TN2xO=D+BluF!RuP2!IO|Sph$R#W^E@esOE) zM$c%t>r>;9po7~SpMn9nG|Adqz{OQuUAC|kId~+76s&!M2`Q-gNm65i&=Lo(M-DOB z;1(zh1pH(Xz%I*1Ng~!bX@Hm~WHNk?Yx#K-*di|XdAJbTQHT+iPDSDuWUo+ibWc@M z8FM8ZeC`l5-lq&H3?h1_pKby|0S%16G(&+deMr%+LFE=Xw=mVNh&7$}m#u@v@UW(r zQC_2|OzRup`TMgR_mErsNm_`?t)AfqxL(+U9WjYY%n5v&@nLAZea|Csx>m7H2A6MF zRNT8`-_kET7W^YD7aqs}_=FoGq>OiaOX}ue`!y*3q;A#2Z$J>alsEhK8`D->NGaFz&o|Ub zpX6{jRF4=#9MkN6c1au2J;jkkd>CTSbXmzD;OHs~W<$tt}qt>qeSolmJpJ1$3oM23ESCga&F*i31~9T4CW5{Kj5B z>SAirP>S4(G+YA%8!Pk#FFy7xVlDd~Q`vjRgk+(qwnEA@jPWn3~VBzUG?W*94@qDxO)r)52 z7GhjP?Br?Aumh!e)Q<_ayx_|9Mc__HvEuVmO}7B(XYFo4RVmV(1&;l$*&?->&t*rYO=L zUu{@s&XRLF72H7*yY%fYZ;j8C0BJk8R^wyLb*)Op1h5O0?KlV_9B?z31h|$6R#O1^1I#8k|Tzas#JY^n{(DvoPVJ@c-O!JX0zKF zkS4~}Vzf2n$mx&)&9q}KzOFp=*f5!aX?}1oK^WYAQNa8_Ig|1n92O}U38er9w!^xL z+E-KIc#puPQ8fAjE8GA}j?&THgM?llJKzb}-?qMNw-k}~SLapo&F8~sHX}=E$-Lla zC{GoM?@}V#=h526iy!0i&5}?>1WdjSBk>Sr=&yDvn7HK{jT@KnWXoFIKd8tn6!fHwE59c&1F zQ_+*>Uv_iOLZgJ>elP__s(B!MHrxI}>bmmx5s1(? znelOtNA%AM+qbbM!7Q1?DWVqg@*>^?H|%tVxS+cdxk?Bo=rNV{BaoNs2N>|lZQ%gg z3;O^GvM?(+*~i(h)m~fl@x48Lk|HoDzAUV95%0xUr!r{kji5>2l|-h66A2EfdAVfZ8V1hV5KId?u;f1*7pU zB4-7pGR_BI-#05Z;2^A9724z6QDO+21T{K>+ZD3Ux4I$QC{U8qOjYR0Nv`(Fa!86A*Q3sdw8!M&wunyeO zh#YX1;CnF~i4d~~PJ21>?3zbe2G%DW*=Ho|(g2?79(k(7y*zkb${5hZaUX^B#e5`? z0r0@pVQwHcWbz5PrRH-VYA_%n6h!l{n=m$jmX05#Ns0|UrtHI@FJkdK2mPJj|%MwAy-Awn2G8%g!IsZ;?`2FZF_k4_aJoFC97lVRc^u%fh{f}Cx;Bd~v zflMNt02%PVZ!ulS04&r%2?Aq{o@~}Ip;v{Q%VUy^3?|lTuJs;%oSE$k(3QOI^b70| zE^K{BB#=~-I`pM*d5UKUnLd)k2E(q}42(o^OKo+XTD&#A(A-5he$vIZxYQU1H!euO zEf^ORv9IwlF@d{ARZ`M`HD83x*Wub+XQR_#4!F-0(de1qv%w9mf(TI#h3VaJz-eX_ zB4jEdul4Z=y5AL<902Zx-dv2-6o6Z(>}0o_FHwc6$f^cTc)mXpn*(ks5Adjff@Nh5 zOWwuDDxQ)8(w(c*3?e;NVoskfbkeF8scaKBWC3(yI!YkL^EGd#4nqeaL}$ZiZc)Qe zpud`#K|ZzSr>irPC~|95o7J#Dc_`p61Ddv*;3lc+VHhw*GtD2%53Y8hHV>1_XJYN}S4L)3NCvH~ot55S4g7qf-LFYe$AiE|MX z?z>1QLGRR%gyS6M9!x|@=@W(~%>ujKx^M6z(B4p8v2l~+^XS=ef$ls5+x9Y zOb_uwAKZ^9Fne8OA>gO6n8EM1CW+Yrt>+!wMQTc#f}_I^BtV%d zIGf<@ipbb&c;W6nNBE8mDBKRmV>z$LQLy6bT)t;#d~WeFQw)?s2Lqs|_p30C6@s6* z@}U;Og6I{V-_n-gDa={-|4s;i9=88;L3~H{pPnBKAp+k!0`njK$DSYj-+g`n_|w7q z`~1Lf{`bxg*nrPN{#zydfBO6Y_j5jWQ$BWHW}auy!T)1!%KMC&pOcM^nb(4s$CS;2 z=Q*3jvwth^(9i$7&JVagceORMa-mBIYW~}{;+u^*?HGlorSCGS$~RM)2~iM)`o*` zXsowd22EbSf)m3VVPxUnJ&6WNC?B*ab{e@a2I9W}j5yA~gbi}=2eIY&;AhfAet#w( z0UFGA0>RH>?k&)mK^2B^0jz|t!OM(tA^%lX2Y2D&tkau%a=SjT9PlFD*(Dt2HQ#;< zaawm+86zYX@wnGDnBIkGdsWkdMHWtaXQtS(|k-EpX<@*y3Su{iMOs_bJ|#qF45Lm49wG67pO~LU$hfC zrIB1knI6wkP3GF{i}o}S^Lhw4tffxfl{VX|U$J(PoGiwT=_UP z*UuGluJ<<@$*R#VU>&=^v&eh>)8l~P$1dOZV=}hYx_$cI*z-@8c{jH#&gjC4IiKTR zN9hc{LMyFYZgC)9Xe1GJ!CQAPepDBgtJ=un5;(YcGKI$1=|m>vO7!(t_{nFUU6E&d z4(tAAlfEZ7kq5U=97GeU@OjDZ?7m-IY*y-2m?GU%(htbI)lg$_BnU-3mu$^%RLyi? z#d)w5cJ%69_KOUHlk_jh$4fO!3n8Ot!?p%Ice7rpeBPwT%Wj!>W2+lNEavBH+;`RoLkS861wYn9LpI(p+{@zwNCdeO03WsaNV)DQG}1f?E)MK`7)zCiA+` zU$4%BtoIe?y?&jLvmE?P-MbG3v)uO*rX#oq6$U>Wq_7vXH`}nWMr7wF*YkUH%Sevk zH|Bb29A;3NJt>M;Flc|F!n_1&;=F3{a)5KZqWVS$|J>rZ z%|<#PX0}E!`C)2k?ddd@mRH*ObF+z7Y~)8mNb?iBfxLGw!?YEuW!_(^SrH23A9@{@ zYanqbU59>qIfvwC-b{*rQb;xuWCYL-{YcwF+GQqx+^U4m`U zOav0SeT!0`Zq;lmT@|17Y4y7v&g6ECN#A=4aY+^28)0_|FM^O95f>x(iO3sEx@~@W zZ6jqU`K(=Te%QMxryyk|ct^G^oh9-p%>SkHk3Au|JTGt78l0t~;;SM52ijQ+6z+|h z)O$UoEj9<~%}Z7N-p4+^R>5@cjgK4B$x3-WZv}YlKkiggKMa{6L5g~`^y!BKvB;+p z#PbzoE(^;Z_08V;HJ`mflHeyyZZdUGbB5e{I9^V@KB*5rqJA{2rGK77mSNmcopb0q z<@!CTs!+?v^Lag)&qSpc+Y`2?(owWqH4V0R=jAT*m^ro@Z^CBw0o)Sli!kLjEov^J z`LP}U_0Xzz!zp*=aePD0#X4QzkCyy%2~{X_k7s|xR}sy~hw(n+?fo8>^5*U{hf%o& z?{$4t>vUf7^1$OJ`x{mKl8ozxo*zI7al}H;I6;Y!^3K@U3mmPV%ci{|@toElW*auQs$ULYGBE~J2VO3&jCD`TWqv@Yw4|fu#!%@9T zU%nRVTHf!*Mb>^kx19LWS){nTU1sfAz}~xa@X6$cSC5psYYfhQ@6`R$>p7xk?niw_ zZKyd(>hOg{jJsV+l19e~OT}`oi?#X_{Yww=jSZZXY1UeU&a)GLN*{4dJQcZc>oiVY ztb^-6l+RNs81=?_HnG#9i}li)yz;w2kpsi%Ig=~3JmR6p;Z*YL>e5%S-ojYDB%-{n z8owme_}uC7il;3y7zoP>c=!3ktEup#FFcdYMsE5%#U+&ZN-cG_e01MOt)NSw-`xhM zHzu#TcZy7nJA?~Y#~d%IJ$^|rXDNAhVVCuz@+x3ZabnTwXxQcS+L@XA`BcghA`gr4 z)9uhs&25Kmw~wLG((S{Q6Pf1i_8Qvhti+K)zBZ93%?M=!g*!Vo2YMn6bi$n8dgnc! zCx{vIQ4t3ikKStQTKaH3qxg};-f(es5fxpYQh=T&6!@bpf4NvR`FPcQmGVQqV=TGP zE7Xhz$U!&0pYvtkbl;^QYmHNi$f$#Uy>V64nFW@7Smp!viB?5vxZ&J$gdKsE5-$dg zl~dE+IjVx6rb4957&6(Ug=D&+XAT|by;?vH=hLEWq@GQ8g!;!L`Vc7~bolQrTp zOXt`s-hx+~7S;PbGTFP-h^uAhrf|3GZ&$tT_&1M=NSmTXuTI713wuini2@lEd6x~- z+fGd%gqctI<>pj)zDL~-+nSC3*e!NEqHT_^eQx1W*Oh59gyE%?^L2bfwVX(TYO&$_ zvUM4Itgg)2-Y0RMfdu`tY!;Mj4^m4^l;f6T`Nf-+=|>&%wiX3H?yT71JmBvwVKYw4 z$``rCMssRV3>r4}i%cg(M>O6P{JKc(GAHj&7V=q_~@u3cOFhfn14WL8)TN`K}Cw8+W(b+RXpU^n030NYk*cU%WKBEW`R{0CXDo{k7%(Z z)!#j>u{`72^U*jHXLt#N(|aO=SsRugA8LB5y3%?+5+QM~eR#Aa`J?iC%yC&@L?XWL z!x~}2*U2>RU(H2aE5BZfd~DsSYwE~bjhrZz8rj{kFN3&lZZRNp8k2B!y+Vzp%M)vY z-sDx6azKz$@Cpn6!`BM?=6xFqr{c4u@@F~TS{lJhXJov{G3AWSM(+4uFFbYAS&01g z3`>e1UHOCSw=Tbu2U3%a+}$!cJyBt;uDH(#~AW=9{hOG>bxy;_E(D z=g4iS&h*ZOjGd-ww%fh8wt4v_$6aN%?bhtEDD8uyeoILjjUR5B+vn>G?2K-6UzH@) z55IbpYPZSEIW0Gh9`umC`g||L<+1k<+IQyL<)$eZHLdqm_LizrE%OHrk)q5WHgaUg#VZ@(jCopzQE_SEn9t$I z`h=rXa`g|iQuWkZUmdwxGy-$)Q5Kj}>VBZq&C*{YWSqZpJVfm4yWxmS^<8v}t;x&G zOY&eT+_AG>$b*Aya9XHIptCIRe_)kLR)6;dPvvEP!R#x__eO0>4j1h&9vjrOMF#{+ zt$a@07|C0Ss%vLylGzL@7fdUi5}WzR(qzQq8j->D6K+?Axg{n}d;j?p!|JI5v7E9b z?GMN&>edJHMu2u(47R2Gg}z!yks>4W?2{eu?+wv;m`x?)v-jVH;Anj7Th))L5;ta) z64AySacgo9dy6$>cMq?!*XQgyp{qzpGxB)Jjo=%<(^-%ASV76G0{|KvWh`ZC*Qv8k zJet<#p>e@oOZW z`7e(qBK7z?WUSxxf=f+`P*MvinJ(iN;S-W*2H8YO#`lw$)xD2hv;C@eNRjbJ6-mY- zQKO9gjADyfyn%VSw*68z-$`*BjoIR!+2NHy$Bg+!$_qGM*T>7OxhP zva4gv5RO^FDB>)>$naBLd{?U-I*gu;&3g~wVk%s?G)TAi$Z-ssz65!jM)AdDrTeii zT)C;ZjoN0S@^<}D50CP<-jn0ZaWa{Z63w^k#or<0zXNrBWlw%s14m!hWw)~lKBvkO zNgq9xvUkPR$T+nwPx5J1xBH1gRG}IuQn#7pQnYzA*0QUg9MokF954${=5KBdD3Qz_ zD-dP|vW_I4ADy!KgO~z z5jM>97E;@oEN8=0F>(wQd<(1mnKJwK#^lADQdGD%gN%h~eD*mT^}~HKS4bVRzRH#z zG+?Ij?(pKqa2t}byRxp_vK#OJ$!^}awMfMFfSeSp?84vI!P5nrBB);syI0p+LEP6k z#O`{}iSzM6X%fb_?6&6ehwHaMi}Yo-AR#|bRX$^-WkdF~VP6ma4KmglW!H@uItR~| zXlck;UI8!u-WpB%PNzCOY3-N{k|X0xwR^C;yDrrp5mNGl*yVn)L~HBXI?s0vkhAds z<5`i^_gVRk-*y0XyG_Dl`P6uDf9Cfkl4q;vSmUexcc6UBANdigbJthQ5A!5%6ThC5 zjs5gyK$AJ-*PEGYTefJCv25R6$H$ooE2)Jh)N~rnUQN}mhE&x<_^@&(bfRkAeK>h_ zoe~*qpj9^E)M6RyqXzb#(cr1>feqI)MO&D`#+6(5+k1I&y}0ej__FOd1YHO7qD=5vbo|vKeqo2{(g`1$lyK z;LWI9o=08Z><#;3>XOY@`0DDpt!Fpfm*i-XF^}Q?B7%^Cvv4dG9t>B5yfoU4oR7!y zvw_#3BJb^9D&rcRCzu&&Hv`+K9Q}Jw#cQQ_&wR$Z2YG+YS-st^m#Kqn>XYI&AxGo> z@R5pV**#mlC2Fz`E#I=&-YYR~78z@R(m!e{Ue!IYzKDq{9|3z={6b{Z_p3<-y&mm&HGGQhFA1r*<}1^{^qFDHO9DjrG%SB z#@b(#H5_G}jwF$dWE``2qnR$96jJM9L+0SA0_>^im`wGNF-L%z<)>L;e+MG}sF)>Y zVuKmr`q~$FW^0090|sKkq77!M`rn0AW&WVSxLbp7B4gffk>H^u%0u=Zse@^lb{;bB zb$2MQEQ`Bx1tLeoewey+v%Obh+$=KIAg5*szNT`LG8P%j+`+u){=B#`+?Hg#YU^&i z^Cw@%%=Im^L|$8=epeSCmyST(`tA0fQmO8L1r1uwT(OB=^O>j=8I8h$y-_GI3gz1j zLG!`WFlFfmGj-a5rI9VQENnY)7`YpCw-mYYv}k4#@=x{gbfIQEx8w45edKv7$XEkE za&6Ou4ZVDNX=NtRNciKj+lm~hvK}TG*XnX>$XLqwwLeM5G7H#bEM+XugyhIr@gg= zYGjOQ!5*-Dhzh?}r-@fB>y&Vgy_$OL!DQ4#8#SbSc5jz$Zzi22hnuU6NydMYj2&gn z^TD4+4v$-of;z4U>eEr$-Mp;J#Ur0m;4$?qc(|YP;TO)H7FVo zg{KQNL%N^&5@#j>c%*bc`QnLuP4Qc!9vC@y1uk5)$iR3hc#!MTO}p@+Y{=i&vB+2r zfo#cC$E8~j!RcgNtFDEcO~%?=WTto(nzFiZ-7XBCxzfZ@kRS4|O$V6SW$#z$X#ANo z$eCXw^Hf=nkc?~p%Vaz`1u_;i(3PW6U)-6Ul`GD}$}Rh^>N}epwdY zwI8(rvsP}!q3iVC&>&#si1~P-7>WLqT0Fl$zO2#R_+~3oTXGQTYG6;nm=>+yg(*um z8|B+GW-)>W%rM9M*zRqb4S64*XQ#1?lJzn7l5yI`ZAr%Kb{)VMmD-R9svC9c`n(FV z)M$%siM%FkB0hZNeqE~v@-!WYA|XSJOPZYj&2?`BWh}_tq6lX1 zkXSN`G^Ju?wxE)guk_b7d$0^*OuUUH8+NBU=7w;X`^vjPu@@ea%by0wWS=H6-_1ts zo$?*31&d5v5V_lFBF(j+7!I1nrkRKGqPQcgApip|=v8%UZ z!lL!)H)WX#7NtQ;HL98tt?A?%0DL@uh&hMifyhrh;|~pt|F!(ElQXAy$vAD}HY8(< zloqVph7!#O;>)V-P&T4JR&KTi>^#+|zJ&~&f;)bwO$FN!KEH{Cn~```f%)Q+IPahW z&X|KQ+fO8Q4G8A62L!pV6t|{7`}G`eSMJL^zq-HHHHOVyi3jCTk-d=>(?Ux7``Y-a zZfE1CY~k7@D*RnCR^%_uzLWh|B>9-gRoz!A#z%h*#}lx&lYKcbmrV5dy)^!Rny4j0;uW1%{23m<#_hO)y-21J`^-? zCY~*7xebl zK1>fXAM%U-tV(D6Si7eQkve1f7Gusx3NIO_ZQOojEHi{{ia2@hJoX$tfz#)0|5Cka z9;7vG`35{8#hS&>B4T6GV3#g)9eh%uCH#7gNB7AK&};HS1oWMVZ)&tR1ntVo{iUAs z1+von;=$bh7&YIrMeFPiF-pn&Sg#9@q2kWd#8TV*{(Rve%viC>?2}sj9WoYi44$zP z1%iiAEm6rS;uneS$pT@>>EGWtKKq;Z@p? z!?#rUA}!+y@fmwU3cMpPgB$_)vRW7T_nL~>_#LJPks2sSzV1`;G8A;_HIkl8A!eHN z$2`Bvi}`)?k4Q5yWW?Nfqmom?rrjjt{x%u2(U9pwJrYf~e!55m2|ffqG8Ks^6`+V@ ztEuX$2bxr&08Cl^`XYbeU^7vpM(2qL=r~rl-`*p2xKT0|@r{gKi=Tb_;ND#F z0FeFE4=HJ0}M{kqQKt+XuhL}L_ zawBUuYCZeoR`j39W|3QbqQ`-3n+U!u*DLWJC2>f#$}Pv-~Vh^4%|9Ah=6nO&%VPf2dWMedFMUwC#bB)=-9K#0Uekx;`I;3#b zn8@BgF>WJfui9>UGO{Hr*7aWY0JQ4J^#1oxkOg)MH*>P>j%_fXrkK{8g5 z`fqFFkMO}bc^xipH$ujm0HH4Ghm|@box0|H!8Ld#LYT62lX1zr7XC|Q>yue#zhDC(N*#tI{8NQr9qNh)$ZN5zgviUaoZ zGH!D+CGj~w#{Fw{o`B6H%6}SOGEUq0Pm-|%5!lq_8&IpmNCfqpgbll$dGnXC>G)X; z-Eh}QBc4kGbp_?cZvh0K)8Tb8;g*16&l7B(`@WkL`{HWwl5yI`f0~RPc-l)Z{B;RY>kr}c=q-4l`xe~SbrU`tx)qal ziFmY^rH=c}SVEGc;>pfRt7+Ch)kmJdUI}h)4z^Q8e_ewrT6SX(GS2ST344#GemR;O zA!Ehn)v6Wdg|OYazOCKUtY??Z?#bf6OvZv-+O+uUt0h~(Co>yXmeC#A1B~liRLs&; z+m4fi;uvetOhJD#WaYCbx#>APk}t$WqdS>o;Zxaj6{7P4m7Baim=yX_0p?S)Qpewg zmyFXk{^MjUMsh2k(-$wG$%5UuzsnZ5I&Ooj#}2r( zEcdma>X>kvNrSG-r15q2_HHuPfS<^?zNdTJwQ;>bSxDy|}Z(M!33=fcxx* zPZU3+cJc4+_;|<;Y&dQW>`B2i>^TAHjhTXkY|Iq(P^Q%ooI02Iw3vp?rEdvt;NTcI@@H-MCJEuz#u~qsl|Vtj1`GZ{?~E`yGudr zza|-HZe;wbg9pqs@jCtv_8dNGmMpq22cNylfn|7C_NHc8{p8%-6?0!O}q8KM5}xr)~VV$=D{a3zz>wNZdZ$?GSNq5^!&QQW=YoyX-)wQ9H2H4#Bu> z|6vjf)$WgVt%)3F0M8HML#AD^I`oW{oAJ``&5gH)HGoI*{=OFej2P_pe@+Fimy9(y zH*Udtd?GUbl0+;b_@R+momkU=Q;YvR8B-Z+l1q+8{g6?UC2VD^i4x6+%>LVCto8Ub z{rcVnGOlCDSOmQVPT$vAD}|Am>N z-LieSufsaHI&Oha&+TyavK6sW#vr!H7NI1nQ(R?Yg6g+1b=d^Kpb61lm(U%rF2+&;@Seb%P)3*|JMcRR&`coFee<5>d#ss!sabaEM&Tvnw2l8b83VoJ z_v4X{tKn)-RosJQ++!co}{@#+kuAE4Bs6I9o&9^NSx}^o905sl$zsu|i=M4IP4e>~N1d zM&1+(6q8zS3i-qKn0Wh<@#SQu`z8kkJ1-VC3=iZAJ@jDZHJn*Y# zB&NnCP|y-XTD(;GH^F*HN*S{?!B^G08gGh}))3U7V(a0tCTNp+)+9wujsB!cXS5zM z&#VM}Bk&Xn$-zs;X&e7(G9JD05T5T$B5p%f+-(zlx^9At#Ovz5jU>F?BIB+*@$!J} zSaH}Im~*1O9X)jh?MKW)@t{5k>=%O_2QAMCQ{nAOziID5b~jnEHHF&5HYOQou8UVp z!`an--3jtdLX#@{jY=(g)*3TO;93x2B%OixXo0j##%d@POh?yI z9u!bs4T>ibUA*|0iR?B%eg~TNnU2^0G;0q^QL`~s zJdMw)bs-_gV&U3d*uL*rvdUd~(9B7NM%7@gdP0i-ERswvCWQkp8K-Uh=g8QZ9XD^! zQM}cYMBIX@(|Wi%QyG(teY$NX8E>`~@^=2V4P|ET!I?`|B{oNUyx5*I*vw}A!=$hM zrp4jDJgn5lUQBf=`||g-kgH+$>khAYBV;VnQ&5;<;lr(E+eK#IHo(Jqf{~wuJYwz| z6SqQ3D=8?uh)l$yq`$Rtg(e#)P|&kQTNrz%<%b($@{%et{(=N2Lgq_(!({BN^uhCp zjJ487a%8MB&@4DbYm=ElE@hgzHad2#S)yNyn6BM^5c5{=K(`5tjUs-rcq`nYfJrP* zaX_kf9FGqwb;4aa zG+;}`Ei$D#&f?qKEa@*F=c_>^D<9|_jr$>^L*`6(QX#+cdmH3!HVDlJ%{Ia4MSffN z9%UUlYC>tMK1_()fOaDnnCa4TZ_HG)hl&1n_$qOcMaEjH|4sIuOdVsMA1x4OOeQx% z#;=NumG4Z}qOjhTKK>s5lgfAtyMf;iTm@IyQn=c$fvaOYd^&A_tBVMEBNZ~qSPHqz zRy^2qBPQ%fy+5#nOC$!r?&GL1NMH(buPARh6hgDUSurH(K;N}s$e1s<)}J%c$2`b* zNeX1FE$Z?PnYqeZtyhCcpVT%1Y}6J1xj|plp-OA3xCYZ#ViZYBM(>@*Q|1(#U-z{YQ_{Q#}6xXdeBjw${z_s zAw(4+ZS=hOD|!v;5lQW85{)4kHf+za{J*W!0|i5dnDCY5+KfR75|>tCPM8WUTRqDl zW7ej~Qm>a$-21MwkgF$T&mJ^mg_$Mza9-wB5#dx0y!Ksu2Je>dh&%xU&9y7>c~oR7 z8#xBQw-{jt{64PI#VAtK(C`=$xJ*}8&A1X9*^6k(#!Ec|(}1vSw5m%9mfiJ|aid;S z@v<6G+dQVFx>R;vGQM&AC&<{Ude*;3sRI8PMo0O}th-6iYT*%bq(bJv9&+OKm+- zP%DVI$+%AU7%bbIJQ+Js(DH$Nsq^v0eV)hPuOK#5gFfFiM8+Q*;t?v{x65@fr2Ad% zo<>!^@n<9+{xukPX+Q3ho?T=GCVzr2mBKf+9u{jx{!@a;_`P!N&FT`0&8yfCI`3$b z>-CWFsCjG6lwuQQP3PguEp;g$>ZD{W0_`_-1%4sx9};s063ZPt_6`zS zdJ(XRMd62ZB+Q4XhF>QEsXK1`d6QA@>Mbl*oR1FU@GMo{U78@G^Yh&4&3UbqfyqY% zECS@U)gyV1WuA=yzIg@O*5#!tt8Ro6s~E7p7%V%eKWE!0bB z&~pl2&~uaNhYi6)JkK92U#WI4ZVdk^WvsR8!sc&9`p|iBwOj(9cFRe)E8%LV0X!-_^nk`5L3cm{>CibiEK6S0xcB zkc~yg^-Vw-zaEpZa_e3_D0|Q3A%!g0sGxo`k)I0bO{$hVH7o2(DlI8qkyf@QNUu?U z1tixs_!5b19^{Ms0ab49#sg5R^F*VX*X=xD%o-^{Q;C0|LcKd%Q#0W~QOk1q_cMz2 zddOHobv~=s)wqLcC1y1cg@T6|^NUO=o=|?)?L34&lb4|a6=J5E-SL#x?vu*RRlBn;= z8EE1m=V;g$wb;WMK1XJ$l&4k8)S-CRifZ>@o?zUcvzciC)CA4l{yVEfS86-Py|M(!SoTgWi7q8_ zEix9Q?&SBXNe*p>&ojhYEHoOq8}&n0zuqP+V`e7JM$;<71p^18eB@{}rdrZso+IY2 zHQ^bPi#V1P8aQh|Y9VTLjzKMwmlnoUG&2o)U9j!%slnPE2btGc)a)|RoX5Av6thx= zCP!ES{jY=?9<79-Rjn1PS;Sm4WC#ib4l=!i{Pqea)kqFnB1!h`{7GR$F-mpMrN~ibx>nB5*0h~E@s}3B) zr(H?J0duK}7sIFZVz}BYg^PsjYP-Tpj>)2JJno5Hg+6PY<w(sN(}=%bj15$haqD(r)`~60LqO&Q`6p|E(s&Y~ zyhNnvWCG9#eQHTXDpesX72rlms`BW`vu6AC6s7i8*FNDqe9@H`sp6}hN5^SlP!Y3y zbJYcx%~zzPMMXF6I&5s-vddo0MJ_qWBS8afD#N`;POzaoZ0w}w+*|fxJ)hN%{fZ}i z%ItSN=BR5y_jT;lIpZm_f%l+pf9#s=n6YB3S$9uf7%P|uH2|_rtIU;$)bz%5Uy3-V z@>V&kyj6Z`e6ObgO>`dSLC;>XmGwMQYCyfXHvTnbe3TD!#>Tx^#tL^MN@x$PC*#9@<65LG4E}Y%JuQe-6 z-P14Y;ob5b(0|&BR4LVK;V-^GdQp^8>qqNF+JMB1o|_uVn@Rj$q%GW9GPb48y8Xvd zvgb@ZU3VbfXgmTPXT~SYe!JePc7Y_*Wcqq!XgnFN;8^%XEQG7Y0-KPTq>x)Lu@rJU zs^c~*ac7IA=(_y+f{Xvtn7(`qKC9l%45}!}t3W0NsUk1D@Z!IZTSmrCmvjHAGbqw! zDqMf`fU8npxXSdwV>Jh1RKgVA>!aflYj)$Yz-e$bp(+la2Ul1u)$x21GD+DGa-5}* zMaUY^3ys4!eOF=ob&h)flTcT)*QBNRU)lE7U|S|%Jp5Y-%0-T5_uDb0q!Q{aTvo$o z^&0+vK=*0gtNF$%UGx35& zcPq%)sR#P(5xWj|lf%F}byA0>zIF@qVR_ zX3DJWan}P8(O+f->;G?LY<1zyU9$`>UAky&#b(0G#fyfR67Th2APwD-ll1Rp_Aq(h z>}ARl#hPG~G5<)?INeO>x|d1DmoH!BA6_!PQQRUjwjR*IQ|FK~aspLx7r1KnN4i=A z;i^qCrb2$T@o+5Nl^PXjRVtY$YL2DStv?>Fpc!z5P#K5LCLxoE4Ixt{M=WqFWGUm| z1^BSXQmi}t&#$VGTAVm@79GYcH1^^2S{ayRd{_1W6bX&Sl%*S!oep~iR3!GhW>Jlj zMLYWMzYObsd9Q4Mj1siB9y)p)aT~W|!Md&3yzgMbAl@bZN2=zx+nqG@Ty+mtBO@F- zaT1F*ZpA!v&xcJcXF+j1OmD&Z%T9k2&S{ve59>+%*X!FqiCe0S=WpGM=j!x@t86d$ z)EvmvA3n7Q!BuSl?ycSzeHN^<_q;ZSuiAkJ8F!=RwOj-XYKpn zDwi`C&LMK}WZeHvMY!H7hD>$ZB5u87jR_HB5!9RHGjg$+&D!l8TdO7<~!WDzpeaqv7m5HTC0Hzf6k_aNE~n})DKlQDhy1~VDu{{uuZ7Qvc7 z63}DP0zC4oAD%7jkHG#DjK8pfVQ;2e_sIW2xNlnTNA#?v_?D{p-I9T*-em;V?>u0B zGdFC%KQ{|b@trz<79-{?hkuW;7&>b?_OLg1wa9T^q>Nie#;2*=e(y#VTe2fuRifZi zwGVu%^&uhKWL%~va&?%9qf~WCVO2Tn0Y@#`ga>?w!&QGYd`QMFlCe)yp4SlaRGW~g zl4Y_8olQkdLY9X`Xe`nP&PKCY3K0MAy@?9jIBeExWNX+585IBEqZ-D8;;DjRDB3*Q ztlp8jwa^mZ!?b1V@nz)*d{{OFZH7<7_WknTz6r1j-}6fXJhvqOYf5nM?f&;_`=<mdx7xdc6@EW(`CTa0PO{4TRh0vT)nD^8Spn0&a8-^CtB&9+1F{BI3W zt^F{p+PRNHA~p5bi=?<^WGs^XrPWxtN=O+;k&sEoRr`{VrH=bk8Asvskm1;LF!4HI zp4Dc-_JepMa6DYqhr!ioJbe6RGoE17v5&|&Kt$w2_}e1~ z{KrzK?vw)K5%zB)Q0;5BsB0_2(22}W9{7AvA5X_D=~3W#H^-o!lhPZT7c>Wc`yIw6kZjH}i|~ z=lmzgG^NOPnhB>_m|7M663fLJz_YGr?oZ!M@;KcU&@a}nWyT#`}(+#CO5ba22C6u0%4f)Ehokn5y%YXXwp@9Dyc`sk)JzUE&p`uny2oTreib--_a_;@SfUAD zEgg!Gq0`OO;cJ7rQyvTv%j?1}?;FU6pnG-7$*NcOxl9sCUNq;wE~vaA&k*I&rebs6 z(ob8zI;d6Wtr2%j%2qGGE7*n2ej7#BK1N9teeFE5gU z<$P<%c+0_K_^io5xQe%ftD^jjdy!cAStSbTs`i14D%n-0J1X>>g;Tamj)VOt&*0B~ zRJN7+!KdyB_%s{?R|BSoRN9R!LYB$GC}i1?n~{*Ekb^|X(+w#bg>3wgMaW9?`L_o4 zm;&bG>9&h7W&2I)+Fu2VcQBs~j)LLzp0dmYMNb-?EG5W~(~yJx@0s)GanKCfoxm_E z)wVfEI%Sh0Dx zN$Ym(H^+Lei0!;oCKu)s{Ra)pE_fFdlk<)`Pa@mRzZyvlt*3ZvpiOJ zX5Af+GDPgopP)ssnn@Tb+-UM%y4?~Ml zv(5d;8PMtY#%6k*9yK38B zEHQc6$@A?pYbS2!xsEfh4s`!I){vzkVcntbkJnQ&d+?h4{qTuXY?KdS1<$*9(=III zx#PF*!|p>#SNzbuGKVIA*12`OJStAIOpmdSojQBYnm*0bt3fcAx4)~=SD9_2s$IKt zzbQwR>5`4Rv1-d6-kVl9IboEw1KoqusA&69mZ#!pEZ@E#g_{pVhM#MrRLg;;EL3N9 zsootphP_8lS}`khthv|ZYlRnjKDUUB*X}=p4;ztii$ziecW2TJJSIcPRLIq+kSj*v z{;E;%AH4t@_#ls-y?~{=4x)75nMkkMdNqf_$8Q9c@ksa>G9FDbCLv298#gygA8UXSqz<@SJnF=*0120bP(GRs7{ z;lA#6zU)0GFG0n&!;#CsE3)}@#4imxqeyTc9zPK?R&B&-5~c&|#dND`5$pOLdogjr zN=%%;k|e&@OtcV^ySsDzO{6tp(P~7`h$8_VNO(mJ9h>`fA9?)LSxj8G2L8RqAb&s) zWUk)@-_+}hto~6b-Et_pj*TU0?PfmQdF(rNkx|AUSBpUBn7P<-_!#EJZ$<6S!;!a1 z7v5ugWaT{;Xx1BzdyU8R6&ol5+>Op9Uf#s;uu0@RRqRfd(~KqS5jk`Q%D0I|uBN?^ zxj`rV=-VFI8g@XTuwL-(Jr*Mutik@{p1$lngH7nVKdEm0r@tI*KX?>|*BM!SyP;4}Zv^+Bh}kPQB_?E@&n99A@}!v(w-zI3EyaR0n{kW{qu^XeDtRAC zc+Q%w=sIp5YIhlJ>P^mW_>53X`dLhA2kboG>hXJh z4c<{5`;mxA$VMeMlsXn6Phgs8+mNS_kZm%S+ndyJ@GSU*Xh6@IsW;C(DTGS-y>3ge zWPkFDL3+M8{}wDo>n7tx>o%iO>;CwnQVTp$peZusZiI~an&RmaVR*k{OMF^60`Ha$ z#XIFfQ7ob#=JEyg#EG*cxwv>#?JyjlRB4NsehIu`8P4-=`m*h8k7hdfZUC` zA%=NyV8}}6CbZ1{lJ(mW(tk3t)b5Bk{|v!v%-{dYhT+Y!EtuahJY6slAC?P8_4b3Y zc-5E->KLf6*@$tao-q}YB3leR*b;^$^_xva?SbK9M2UE#7o73n2)X` zsJT?3)|iE991`yJGS;!-Ydvx%3N-0~4@>j_sWMdPa$}{Oensu z+Y!E9M`HT2c$SSdAgy!gKj~s)f-zgI;PNpf(CTfY@nx0Pc%`Jy(Hw7Ah`?LrBTV_f zT{;xGeEAH9&%~M?9t#cVoX&S*;kq4coCYITqb_JMWHPqzOFW6{;E5CHF=-)+2KU7$ ztTV6h+^_OJUN6fsVR^n;CIYYX`mYpghWB{QGE};w*ti}{)UfdR9X*Q3!Bg>dl{R?s z_dwkHTSKJJ-4Kry3B~`)x5Vd_!|{HZV7$w7lQ?4s~D#+*9Cgdu;NXYWA=*PcF%4JB_e@a2~n3{v&sx!n&BIJ6*Y(gGM zLKZ2@T)|J?yX6h}n0t|)5BInSR7`lExCT}~6 z30n_i{%&^DQ)x!{r{QQT2g^5YhhNuW$XdHCUM(JoJM%Qa-M=-#E2YBlb@ev*u~sX5 zO=b9H)d;?%{jgxIn~cv;>BcNsho4Ct>3*nzNAos9cE2uY+-Dpj$IL|d@ad@7Za4`r z96p(A;Mx3*(74AKTrOfD9?jJN8GfpZPpd_u8c8l<*c7xQG1l)o23hKK#uLoj|4Id* z-{g7r@mkJlB|aeWKE^z~@OyJSS%?Hfq9_#7$4rQ5IdTRM3!Fwfx z(0^JS2{Liq66Iy&{8jj>W?N+Vu{s{f?Mp=+Wz0cc$InBL@e9y8dM2uM9EmS$w8OnQ z>*0>fRgi~jdFs-5V@`5lh}0%fb>GLccaVz;J;V3a@o4S_$l16D{QFKor}1;pV#IWm zYd;L{kSx>j_m>JcL4&9?a5Q>Ki`coM7juvlr59BFWgEbmQE+7gyqz zk@22mC-F_d0JsXaB++(;t87=eNXV}8Oci^=$0%fHP>*C>oupi|AAD*KfRC9RG7zrX zgW*$WC|q@!3?Wk``;D^g$F>dGgOH8=Sc7`ThHU#GYf?zaOe$n+>a-6PvQOAN_&9Ma zg6HA>hDqy@g$_tbC+Y(++~=_Zuq{Vmg*O&Pg=GCIoKV(^XEEvwMYQfXAEX6 z--xw4_Or`;1Y7nUM%;#77&vViiU##T#-D5Bxk6149z6{^l6btx4&FFw0v^rpk5~Q- zL)$U)u1dz+NyZ^VX5#6>L2Ly4(R=b@`xgr`%N27#XPRz_sMbV5lO|^tlv1quGwgx0T{n{H9n$Z^~qF~d9RP}>vTf+uo;-a z?tVP)aVw9P*=7ONWJl)r?cYNT;r$vAg(=H6S|$n`vK{xCwv?(o0(WJtg{;0EF?!xA zY}tFrEUPaYvh1(2@s4Hpy-v5$c(zDWWXx6@zxsE^lqK=*I+O5m8M9VwL>|9RxHnr( z{O^w-65%*Z<#SoLb3gVRK8meu_+&foHF*&V2SwqrT)t*CnN~xlVQ<3hOm{v<^V%vBgHb9xyL(H@E#Ny4n@j>M_NSC=Lz9*4(q+(sNX(u-9I>1Ku5bxoTIcD0@jR+h# z6>t0z4A-}nQLtH0%#Gh_Z2Q7F_E^?#+lxt5^xY;e#CLVsnEdRE>x5X0j$Ouj zw+y4^EaUT8gLT{YnsEdJ)9Z2P*$X#r85tkr%b6pbsC=XgnVf;W=5gGQDQF%V&EA3w2^HzztxP5dNwP3^?N+?ZF5~k>8lw}Htp;FH z!rmjtP_4soWZ+BrY~etv)EQJRDaY$rw0=Y zPpY>?*O*1dbdeHv9z2d#qhd|>_{HCYdA?=#FBUY|)?&mgyi_6>8K~OJw;Y6RQsgN# zg0fj3J$(wNJrwBZMJw@cc`Dw|D&UnO!6f`RoIIC&10j26<32HXFrPmjF4zpAgJ&ef zvJj+Z`?67buX0;F_j{0O_!L+^CG0(M3V~G0G9BIVT{YC|ILs{3<>X%EzLh=2hCRpN z&L67a>AZgIP0ZqbCx1@)?JnE48~Ocv!u3Tpd|jn2qUWwO%GwhX+0%KyN+g~t8jPBq z#&}GJwyTuE@flX`Qk_VW1;R+i?cr0pBYetqBq58K zZ9>+7o-?Rd*`638FAJ$;qm-qN2N{Lz5VBFo^+u4CsgV6_h1`fK!R>7#N!eD(#^p_f zY`MJ|KV+FK!emEw2$>|@iV9h&^Ep;dr4$AO_7yOvdrM_9J_vF7TnU%v7fX zMo@(&b>&MAo;e>%RrVT{-JRL%p+Hbytl5^_GkAj52{Au*<#J$*JBJ0u%~x5tY_o#M+EEVSGAC-T3f^{U4xUh{a7k-FncVY*N8+q zmS^#hzSvBaeKlyXx7)b+cf*lx`bM<(!yIV;09#`L@Q>MFLTy<7l&bj3<_n zjK3fmKVG;Q8uXrsjeD+s&GB*T@OjO)xHD&6{Mw|u$BaHV_8vWrQsG08K67o9Z!?4h zf9PL+6K-GJGBTE{Q`4a&J}oU?vMmXjL|mo=lL*-{S;&Sgx3?%;A=@SkO$-qk%UmIa zEHX|YWUB4DHX$361r@UApq{@qsAp#CC73HLg=`4fm@VAV-hAX`;SB1vii3}0A-7zL zj4k8PW!aUBHX8p+$g|+uWbscz-R2jIHo84FPfuBNQ8%uB6R2!JXOda zk5G~Io4&+sw;=W6cAxXSr%i{B;LlcU3^P^6FTPz6$1eFf5`-WZwGfiA282Go9x^T) zj^~q*v93FL**d&hEC6?sj2rZsKoxoYi^le!v6Ms~glCF3L*xE2?nxi!3f6yCxrpfg z!sHbjkuxv~>3*rl`y6a0PdG>*W2(+)iZn&-&LfT6pc^{Zl@!!{LL45-)eO%UYKE{O zldy|rC@6-5$ngH({CWRD=s0GsA=_(V@rGR}9zGE1sa8KF=`L9B!~nNo$hcBVl5sPV z@u(}vSj$FzB{DA96m`0d#p;9xilw1?ERo@H8%s9t!5@*)xHoSDd|9mxkKb+o;>PBE z$51R}0McivjZ!TJV%7FN#?0i!_2ZV2u`qD%YTRF}C0s>Y!}TYLxO4|9WD#;F_>_~$ z!X{*6vXD9!AzKRBie=FcJ~d>npgLyqaR&9IkVVM#Ew?v|kTt01wjmpng_)&CQnm?M z)21ylW-{S7?WxldRLCu0-@nIZ);R=M_@z8KHtYlLU=_)!hU8vom?LJXpY!-Gls zPFsQ(iU;DYa-nEBY-)m%wHg|C5=4ZPm##l(5wy9nP@&ga-8-oXP*2C*8w+S9z zC_<{pxMl}DN;0mUl#E#xRuk+l!&Te&p+>hcc)U;(d|9I{mTbCGjBMI}3`IT2c=e9G z#;oGS_2U+ivGstL@!`K(iR7C<4C(%CMM+1FbbLKxW+(hKu@G>%oYwA4~LHk*>@y-mC#e8-Tm> zH^j%a+F%+Lp##}uMLaSI7_)!}xyeS{eDE~fnWHY=t`LT(>2Ww{+nMDD95T=%<4@Qn z@BTN)_~7X?=sbQNp3Kt#FaFjLeJ3p>+1oJ|Qi92=8W8t0=r=76FHl_@G9ErHSu%F^ z78y@kvJSb~6~CKZ@(S#3d)i|Y$hh+Lk?~}n^RsHL@Bo!%ahADO`4%+zSg;xE_fNHu zy=gB@Shg`?aLl8~EqMH`$scWp&%ook{qSPJCKxtnMWS%9*GI-Hp3hmeiyo9$)c#6ot~(=&Et5i(O~99+#8^Bjxtb)Qv;KXMJ_b_+0; zWc(7z_!*fguA+=rZQY9!5rc5=Zw>H%wU(H?e1rW9!QJ$3>s3rp$o8@4Nyfngr{Iq4 zweeoXF!Z0b7>8{#)@sf{1190+--GZ;)pjJ~xKxmFEM6}YVY=yqW-PUTVI3hEcbOQA zr}Fxl;4{5r7U1ZqtB|oa|0N>1$mGzgrb92ni^b$>7mQGk*c3XC^PjV~$av!7b;#A& zO~#(yAcl;mS!Dbi3BGQ(Q3+AtbROrdI-h4QCofrxFRHh|{lEF4NEnIACS&QU#A^T7r zyKTsh*}@vo^JyAmk+G8EAyXy$n5ok;S;z-@wylsYlZAgX1fDR z9qU<1Im)BJI_}7sv+(5$oZ*M+$W*;GCM=1^$+H$=iHt+3j9>me81GezM5pm?Wvrt; zUq?Y?+?r(kMwu3Pp?DAmdXVv{3+Jgq7vZ`54e;cze&{qN)_7MWfTwZJY5p}FqJNZE zi$sKeB4bU5E)#<0p0O#c!%T9B&X6&QGiTH8xGQHpl#d*maBqU#+(gD7R&Hw=kNQ2w z7*m7!jsK~PO*!*l&-;`K=6O|K!JWD5;$!wC`b}R31@;lF zb9kQ9jkP-uqHfO#xaXI;_+P0YOj+U4kP?5#OkowIN1+fa`FjoS_c-g-*R|RuYcrM$ zWbxp>B;)P91z1+i)-b#g0qO1%Ndf5)B&55$>!zf;L8U~x8x$02X+%o8Ly_)QI&T`j zedFVa_nhy%&pH2l{onQd*FX0)_u4bF)|y;v*38~}cG_v~>iy!Gy7}T(vo9`nyOIG@ z<6n;(KHUL#WX~S=iveq;^I_|F<;)H)pJWfzP|l)j_TGxtY<2NasZm`dY_4f`%XY4o z)GBmy=uEt`^^K9~)>RuK{w|kNK+lSr9wR8gJmcSeP=Q6I#0|HBPQ}UR-#sQTC`DC| z1Z5T-yYnGj#VlkQ3LR=alu&xD;-a~DCaSO}suEB|&X*Xpj^_Q)Xs5v%s>kYnW%Otc z%>z>K;-0(Dkk^_4Ym66t^+1W^n%&e3BNDgZ&GcRd9HQXJdQ2kLyCMeXHMtgQKSLIK za$czCjNmRAKi=!FHzlkh=O%O@;lQ9Grlb9n=Z z@5gM$?|33x8jr6h=@qjjim*BNT6YKbhCg0g;o--#8CzwFtyf$hwpXpD@B3Zt?Dgm( z>0I&0GoMT}Yk%T{*g8C5=AdxV;F$Y#g7vyW2-2+&k3TJGCfIY96B=CuZ>N%Zuw~~J zOH}(^o+|$vzKuw0KX`DsQ{4V8&GP&-33!)#>`m5wh4g(0`o?6C?UMGZ7(v8iThW@C zIa>~kgL34_E-3iwKUMm0`Zey>f+&rtmo8D_)&%T{6kO~BfkH@Zxk9(Do36dXTc`Xd zVsd<5SX06XE|Dut2l;hHd#=}=o}Z1WtBBbV>Z570QmB4NpM5HwX}~@6)oC));3#Lv zE1gSW^PAi8dW(IA=>!*b!*&9pM!s*n{4svK-IOB-DGk_!y4e-PLqM-F>Xlw|W*4o! zBUygzRL8-`IeP|Q4vns4d_A-NOHa<>hgKR%Kbd%z#`B7Y<~6!bs;ABNL&!Ug`1u&J zlO9^3>A=02i~Xn2wV=MZ}ddj-qR^(W)_7Om|||kM)(!RC)jj{6muUVs?h4uq1xnSxX)gLujmVAvEl@wO>X8sOU9n?y}u7+`M!wGj;F6) zy4%6#hUWskQ34vd)mFb{Jk<(!J;ocA-F?rET1n{>KZWlbY&bp`29;;bag;VZl9l=E9yiLGx3dkGjNU^_ub&Ajmw)Zlzibl_v@j>&&oJ-JFt#l%AS1TP*rfLsf2Vsf zymvb^o!?A^ds8+|zs8)m*Mlge{@{C;55Au9ekYSemlM=AU8P(&?E_WTTT`v!0%Y4y z1baG4rpv?bN6bfQT$I!JN@9(K6w6-dtTU&C-4ot;)P$YOZ(9czd&kLsN_PvA{QH59G3!4mZS{#i7!3 zrTh^$i)ks^67~G8$xyikpd_p0`sQbaf^-eIiTFBVa#NL^yR~anZy_{dYZFp^9_}Hy|_I#9$KO8Zqd$;F+^srpaW!9gp?Bz|Fqbp5>nR!L2UoPrOW)vdINoP-@o&ng%UR=rZG{&Ez!C zv*@S3I-K89#OF#Ta4=U6xZ#db@4B{TB<_rMT*O3B_GwWL5gbe1@0lQW=q5TpG-_SqPiI+iq} z2^5`D2T3ZX9!wn+9nNF%Zh4uj7;|BF#A8TBnO*nTcWa!A24*xWPU}2yqt6l%%FMw7 zHG6WIM+I39-C}?gnw{O}%?wPQZZ{o^3J|*A2tPzf`%t~K9+Of+ywV!RhP}uUs^&0Lx;U)1n_cuN0^H+nQGg+xOEqo3m@$fM_+_N z3~Mhu<#j(}(+_!1*lnx5LKQ$>JPMXmA5UK#H)F22aPO2#e6Xj8kSF_Sk75KVQFpl! zrQ|H9MskgRTe)(Cjj@y*`NTrH#oxNx?y!aWhlJ@P{4r7^PNm%h)V2%XNp84h!K_WQ ztPjRdmB8D^v*MgCY{{$vqfjyB`a?FH30Yi6K{)<$q}bF6%yf?jzTJ4>)+pg@=TMvV zbiIhO*YOAMWXx(!jEAG%SfouIRzg-J6$cc;CEs4Jj-gO$SO+SdrWTnHo=PdadpU2~ z`ke0N&ZD0DV@ZvnU(NNI>n|Gjy+)ImsW-2Mib=wvb^Ir#ZI3@kw^qF;jcey}pARg{ zI9ZtX<6@M+5XqK7EjuZbf)}@)55R-7^l8gd-m2|Bz+7Dy30PDrkLR)=^$|Z?c?ny7EW>=~%iuOaS&Q1%#3_f8A3D zEmstp@&3cgM9d>r)RQ|ODkz_zOxjhjL6^TwO799IP`U8XKAzQky)z$NkrV4Jv9!^# zWB=vL&wIoisDb$#V_P$F9B!tYjLr71*lKp4M1Xf+hOPU3#l?rjS6=B5v2hQ&DqyPY z^KYgR|1gfmO?j|)s`pIBgn_#Sa_=KKpEpYyde-ab*YVf_p8WNthr>SSs>|oq&V3kU zC--y;Mzk|^PzzagB_QK1Z7Jopg5I6XPy19VzY2Ks@JH%B-$xxM31&UE9(}ZFG%yuD zUruP_HGdIJ)+JGYvNR|5&dNXv-oAG?sSzo4eYP`ue1w9@e8yu+wZW($GF3X~{s{`6 zYf?~Sf_cdsK?75QivDFbi$%ub$)@QvF4N4cVSL+&Zz^#l z6^>VEqI>H?n60d-Q!Q6YsBTOUwmhN^gGzrOM~~3A%HYh|&y6QFN=3v8x-M1q#M9$k ze{-k*>7F8gy?sOW!?3@x$HK;cTyooi(&nmXC8oSO0Q|CeM?x&ioB88_*151Zl2%CB z0~TvW<~g4zk%y}j8l(xBHv>W=wi!+Eq<_Q^cc04PemaN)Z;6m6+R77vHvs5R&BSW( zD^d%RX`&?VfX^v0=|Ig+zFVgh z9TB(HO$NG}?-|StM;)(gyzx6Cv5t}NIls_d5b}-{4CB*r6wW;SZ1i}?;lQ-%O7MsJ z+WXoY_b+yX7W6;o@eUc6%1>}wjz7c&WE<>#knRLu^Wk!e_!x{g=sRMv(^prA_h$a% zC#@@MVYRDGnyd7gpApez3Y`R7>vq@m{Kc1(J>ifRj&txdwBs)bb^IE;Tm(YG+z+Ti zV_xaS$LOh&A9A)}rb3ESz0>$JjVsEKj#td7;)4;7`=1*+^g$M_YlfduNm60*piFvd zKjwjeJ8#qJ;Dpj4T0t`h1HR1}&B0>3-qd3w*)sptCV@ej z9W#Mwmr^tO)#>H+cRr*kei>KWX10$lUVAWBwVNSaf%jJKEf>-~UavS}U)}y} zTw1g|+r_tDPqM|7Zj*MIp75<&5W3Gm==b;`T$cG#T|lei*e_(Z6{McdhZn><5NW{6m~`wxY# zkm7=o#0zb3!tHc-1Vxf*YFe4|VS5U*FS#g%9TS8OJc3PU;d|5(U8O`OyJzDWB*I|5 zf1U6xpL!=IP<=6GBpo{V4dM`B@rqK8Walv}CQJ2oMsGG+ewr|)=+R%^yL zMdSs_sae@UujA0c+y*u+sMkQaeW~?sJah4U@kQC7NgSVImk&jO!<2<=tN!%4%8jFN zJmu9k+-e)2QQW*lr=S_Z(%F3aV$>G5O6e%DRbe@j%9(bRX|{dv&EwE!Bi2!A&6j`b z`lw%?V;FWymwj=<68K!lny?GHO}ZO+4p}PtVCB~jP**7Xd_U!2d7*F;pV-itx8hg; zBjzZtO#o{gQs4f3C2@KoxL2nn8l<0lXa(t)49<8mq1s8S8<+AvjyqpUl*hjtcDwi? zoA}J15vSx;#^)hQxHa9^D zXmMAQX1OltSJr-CtC_!5NDt3ZExuVX9>tvv13#8I%oy(2I=3dWWo4#)D- zfX5f~TZuqye;HrjzFDKYXRSOI$q5O1Njr1ORfZ48&CiiurKL)J(j8Oj)1_-~ZY#>o zwn!VYNp&VYen9G(eEt)vnk!V}*0B9|KiY^L3Fk*>|KhhAjM9r&kOJrgeqzIZ=G zMhEUI2?RNqWXOhX}5SEb zdjd7yHK}XTu{W!gvinrMm(&$WWf$XwqFrq!+*?f=e1Xax%H)BikI?o=36)b$3ErE4 zihd%dZvx(1%Tq@?$Tm-bQ>XHXSr`K9`oiTYdG*%PXJUII6L*gc#Ss$N>Id~Yu7#Js zy_f5x)RTep!#TbWzV$_SUm?EyO+jJXT8T)h#ns+Z6~+}KnclNA9rbs%lhL?I4vaP* zdA3if=;hJM>4G2Up(MZ3W^qvM8bwm(KHPmhWB8uZ(19Q2+KfOA-G}+d!`jkza(`BE zTQ_;a(TGOJs7h=5Q|5x5-nHL5Ck}Vq1#n0DtHT-!-ZSDz%f6ZyO4nGQ4nlP4A|5=N zX)m@OAsLS6SJZyguGl$}!&@uiBwV;!aoMPkIb&49D}+fJNN1L8+B4W5TPpv^T((G7 zIvyjBSvP#IWdwXff^H-t2u}!tsEeK+jP0VeIH8f0)T}e{`2tH9Gdp;pDITl-S$HG2 zSG&V>_`S8EOrzCV87R;7T*#SGy*cmF*zVKAruYH(0RnlsiEax0^uH=3*{{o8w9?j-iIU4%@rC*eBn0{t&549OKiBIEs-C{F zCgO5qSDacDbf5*_OxY1OFZU|FqU%bvD_#-46&ob%enl^gC9A5V~; zmQ(1bZnhoUZMXlt`0QvtLSh@}ILxU%DE$1I9d)6118H2T>BkeNSg@_CNI1|-9iFu& z79=GqQ7rdPeL24@jjGw`2Wh9quITn%lRKeSxRzlH-aMkxJwRwt}d-dGV ztLCue@=&Kijq#3{C0*2LLq=q8TQhg?W_)4(oO{Z?yVL!p;t_M^9GNlRqJ7Mtg4m_m zI(dbZign(3N`(vKd5um#}ZlPo@7j1-=h8uDg*|(rjLpAf+|0_Q@9(9W{qRUC@WqHq&aBlX8P{DS z?v2oBU!TQH{>Hsh2P5BaWx`E%Ja}HzT{+H_g)hST*u2jyiswD<(&G#adHA@^uuOFN zcvdm^Ak$Pt7u85@N98Jq7tpC~E9UMgC_wSF%Oy;=b1f&Nt~l@g;2VtD2Or>U`8@Ej z%X6%fjDr?qbUM;lNGiuL8GIxNlP7(V-B@=oGrtNIp^V^k>qm0@Y_V zmSaU_)h}kqJq6Gx^evk)tW4p*t3L6Fut%Q27xh#^L#GRAo=WHtT zF?Bj^$$Fq!KWaSU*_}gjonc-<`C&s6(iI+>W4dXjR{Gj)>s@b24!e`cl182b zejbZ{pcE=nOJY4cqLRw8A93RM9~A;d5I<=Wfg4TZwi-Xr0}m8_lwjfMsEXP-k{JR> z29O>@-nfB`P{G%d?0QljKk@XXZsX?tq{^j_6JGcBeK5@WT9&~F+fwk+1iVH~wpzy! z>`CRr^pLWR3ab3`!wI%Xj6OTIR2XplbU6+o_bkHkK`LIDKRYgqb{3Oe= zg6FuuL|chc1syfbw3y|?lwR~Rs4Y^_OU-9cD#c$&~afXl|;<|vT%4G-3HNwt%z8reRL&czV)0~%3zFuFW z$o5QUdZJcv%D+!rL&95Rr*`5@*IoY6jvq8bA6ml zB{KNkNDu-qNP|y-9-ppjYOQuAO=Zf%49|e9XXnozyRJN*``AhG_ThNe#;xnYYfaS=CD~^wAmB)ac`oFL%S_iiN#-WEIa4(ZRPNDK{1rljc>SM1y7W{&pnh zB+;)+LKawsd<5l6oa3sRyhPz*6Oi7k$z=JdGEnkof0JlK2*bv$$2nmW_E?2V?INRY zm1tgR>HN6VN=vfGuxI6fE}^(m3XbO&d7Ye~FNRfz}_lemz;nB^M z8tgoA<6p*zJL^+-kNh0n;XQ;Oh}?LWJ$x)j|Mb3qMgt$m8u;8Yqj-+UIQv9XS7TgP zsbA=xY~5IcA~_y1rLBVkxu(NRFyW}ds+@LaFT=wmhpAxUmltoUi0yFs()ku#(husH*MxC> zF7Lm&w-K%h-WWeht$bxrj*UQa((0nx!FRQ9)p9=pgY=aKsYjZb;(?G)WO}G=lYx^| z6Cj|)LFQIqrA3GPL-3(y@vKEJw*eH`vQ4j(20l@)nmj$Q>=S=sd%Rgx(F&KnY5#)>*Y15fXJVI;bVYVq?X}69iw` zJvqrWy@-{h5g72{z+Ts0b4W173=^!IVy?Zvb0V3l>A4t9kUwNN*Az$*xDf>I5gxr~ zAR0y@K116voxMzO6U;bXvWjEJ;eKgms`XYsyv4K3kAZbSWO_5nY8ocnP=Vm?Sb($euuC{Y@D#-XQI~B*CRoV=rZ-hTbr8(GWfva22XCB9LYD6Iyc0W;pGl7vBrUW$cH9{l zA)<82hL=)YxQF~+6;f4xX1T)Yn=P0TK?6w)?x&U^9enpg(EkM=%d*43a4>q?=STJB z?v+nUrpj=qw-7bZ)#p{0*3aVxh z#>}oe4;%U_e4d|;m9y?&Rwhjq*;b-8IZU9IezaN4P0Mu3>Qd0fi?*D2Wo1hp?!e3Q zGAudqbLw8)zFow!x`Kns`@#w#CG!jVQ7ME%^!EpLQVZ#6nc94$2dgE~{l(G`sN57b z-6`z4kG+~~zp5o0pJWC8U^B&_V8VkiI`_e;4V+=BY9!~yc}C;ca1A|*@5;0D*|WS$ z3K$+@;}~vn6g{XV=7<03!qwh3!(+F2Jb9l~Qej0-8&fH6Saaf8`wMye(J2f|f4_Zf zqjNi3#D0(5h8f0}1fw^)~JqoXzJ*Kp?@=s3*RVZIPh^5%gM7ckaGraKJQ znUBLkbELmBCwpis(f1n#K6(OeX(r6Bl~!Bn?tD@;522<=!%VZ^ku%Rud{^3O?{vxI zOMOU~9UuPEip=geNB%fU1DWoqOQ9>(xXXqJTC!>I71d%@S{1Twzl!C6?%0xHzs6! z?l`DgcAc$>>1D67QKi|K&MIiCr?1`iahz=g+Z~=QRv*N6x^E(9f?F!&{e28Mf@aa@ zq}9y3sCjRib}sfT$2Hq`9 zHWdWB-=hcOA6fA#%`Kn^hmm?q^Wt9DY;x0iq!YKAiTsfaR5_Hpn-XX zfIiV3Q{$?zB+0AYb<+Iv;@L*!zUwl_0T(r~zaHtXmi0%%iMcEyju$IdQ`0eZh~46j zie9PhhjT64Vjmu{Ul5|0D22VgdIZG~NVJ>ZKSZ-GjMX7&9>uDX*YHq5_9$cy_GIaKiwq>^?Ug8rsD~`IXOgvO;F^?V#KQ%$$oPblGiRN^O zjz7&de(%3k3nZ9~UuGZ`pkADc`Wd9Nq9Rv8CIFuzQX6U63WL`Rm-+d33sSr@3!W7W znw#m{G=KUqsm6fKGdwdtPP4a6UxF_V-Fgxv@5WEsS~TJOYI4kJ>yl>m3rAU>2#UPD z8|By!Tc`rMt5Nv4JukF(eL{}?UBAz>ZG4l+5KhN(G?Xu37&qr1*79kOOW#A@(YF*=(&eq9Y zjl}fsN6KSLj1_m-M7W>EzV{MnETm2#`j+ya%kHvSLmHm75TZL~v zs_egh)x3-ft+EYMA48Zlz~`}_jja7nzFK3^NS9*Qvf=D+MEcYDB7Nn&oTayh*h0OK z-lBZ^>>ZxDVt^}|(8%0I=MO%nGiUIIDUS8-!=%^oD7a2xG_vvftP{_?`$_{(pYq7; zkYeHI)(+Tax7Y}1zDcc<%nlp7=OxOg?9{j;B80rET!e~WtHNPUU^T>NI?I`6Yjp(et*@XkyL~Z-EZogF2t5 zfi`?3uDnAJZLUi5YAbyYDc<#o;Xrcngt*F4Ej+SVGx3D_OsAHPXKpf_0vdz^I0d@b z&n4@|PCt1|`Re6T?=14fS}QvgE!y+Czp(!F{kgUC_fcg-d$$dZ^8T#%3!X&+n_OX6 zf=L5eG=ZTvcN-wS>7qMQ7G*CIugsd*R0*=~(IIcX_sZ&ZT}&&1YQC8S7)jkHxuh$; z)-?0SFePxRIkcqNfuFbXETo;(Bp(W+-Jen9Q0zjPPAn83wz|05I>;L$eU4nN>EVho zDnE{0iN(z`_HMAv!X(V@+n%`8L$@aIYfHt5a&bA^SaJLsy?W+)rjgqwWzRMZ$Np_Lo1{<#NLHoY|6!b%wl!jXE8)1Q=CC<`4!CT*ZM!I_p zUm6}1`_B$kN=NiD+$Ve#=fr~ZQC=W4I=fR$V)E5~%E7kO&jC)KL4(FoRa54`?pPP_ z97hHZ3fA?6+HTl^-mKQ-PDjib3}eiEeb9Mp@<-$!LZs{1lJ0 z9BooN`_z}NzgEHU=02=bO_S-!y2)AySps6XNw&jQNj(;=-6r!tk(9OClu4(^o9}=6 z4v$=Fzs?@=oHdS_>qlI0?^5&{d<5&W@2>9g-0)HO<%h2(JCi;;O;g|{Z6~ruBz)!4 zv;Mxr{&nK#4ht6KQbH}fS=w}T)PPn+w#Q-LF%h?l(ZvG2dk>*!X*}{-pX%E-3ubQj z;UgWtuS1%B4{CY7az;j~QXp4q>AqtMHZp*Bqj}N@(X(61#H+=KE|TkY&YyQOl_>G7J_cP!9Hbljase$@3n<0_If@Vq!52Fg9#TNZ&Jy(N%)ivUyjFNG{oNunjxDA((5V1IVQ4X=fGZ&GNwR)gXQGrV z^!}w@CDMJa?HW0b(Pph9lF+q%Cm zjT$;~6NyG`nb(C-gPura0_C$Rh2otXWY~<}(ciHZ(n}y2JZwFYIC~N9>$ECF+v-^* z%{De+ulxWfl3{Z-dE*?iIgyB?x9E*^nK~^sDZr~-`>Pl(^e@R@yxUWPF*dVQ9G;68>{w( zy9gx1;jAo1oyl^+W(YEJkB2TEF|lIeTxg9>o7HY-dAz!tl__58%rH^qA&M!wsyzBL z>EQi!u?2mS7;m3j#96_llj}{#UMwh!mb#x8Rvxbe!Nz#SfLh}CSIs1SywGM}GS!zlw z8Ah30ri9vx*HFjH^CerHCw|T;EdsNwtT;SXL&<1jYlwpTh3wVeJ8ab7_1Ur#DtI%H z$RqUl%Dk{JZ9G-2F`0$mG-dE18-$=>S5X;c9m+t569Sg~tuPrZ`X}$HF<=CJTv?M` zx-NV6WLfS}GN*!6lhGP26pQP0t(_)J=TlPT3pb22mCd@w4(DXj>|PbYs>~W45p)IQ z>8nGbv3+^B`m{r)8;4{YbHply)HYxLw^M^-Y%K}zB}*9kCXY4HmrYNU(ivfLpR?N@ z?3us{<$SN3LimsmExQo~Q!R2bOs8- z*Fh(FHg`|bBl;-Lp7c9gak_ryzHgn})|EK@cKwsr8f_B+L8n8mDM?gl{-?;vAg^y9 z?$N*7r6H4k6^Q=b1pZWcF0WI;W}4-MZ{A-&n`y(mA-mf;2(;(0r%kb$`s5m65|b0oBJu;6|EQrXsaM<7JII z{T9Sw=|>o6XVWFy$7wIu;?#zt;(PHcEH`_?X_)P6nS)ChV=Khy356eWb)ru8FSoVn zj(rrlhHeUkAC$G^j+Z5lE6+AGW07*qjW^=qy!RY5-<%ow{v^WSIg)3oRCuUKmQ+lU zkna!|aQb*Yu}A&nhURv{F5Dj8AF)8m*RPIiqiqTb)%lvJNUM_hl3*0?Ez5Kne5jqC zlj>F;Nlb}H`sb4h7mlB4p{aP|S}XaJY7cli&KoJLdUvs(1gx{_%PdV_Rp>J`bNPP1|nRAx23`5M0^vsE?NqO{tQ zkcgz1QM1+Abyo0mHVf-#=~M$Ls+I$LykMN^O>DfjJVI?k<8$}|$8uTUp&e&Abj57G zXl^~Iam&WQgeZnC!?PYT zw{Cy;C~{xQK9R`sgC#D-tYIe(n*x3JY4nP^UA#Hu*{-!&qyfKz7mD74Bfi0V+U!8~#my2M&)5h7W6xWsUD? ze~|qHuw!wtc6PAwf;d05v@@}`WifNG`v;`|CgKGX<-4X_EaFUiU=|Kj9qcB!=L&!| zU<;T4_P~9>7|t4S1{?qz;0olV1}FgPfHHVx2e1GxAl|PuF8~5wJq0Ymc#~Ud7QhUo z`tOVLe=>gsYg-fh`>$bb2&>$`?bH<1mH8D|)MQkZAu zfxjykEEC{=qNo3{Q2$T4-WKg2+5YL6zpLk;rus+3-}>UO@_px4Km3+YP#^rAKDh%2 z#e~ThOrD3MtY_f?e6+un-#c(Ox9P%Q`WK>{%sX(XxAY`1{GQTR6u|vk`Tw0CDu8*b z&wk4FMA{igr3u((t>1qqb#5b5eYT!8w|lKlm52=3V_GN=vzQ^zobXp0Sy z|EJ_Y!W{~6Y=G=PrXOf9z{`8L z03ARBav@kV$N)NkeV(3x319%aub4YA0Zbq};Nbu!Xhle=5lkTiFzNk!x70)mwm%AZ zRuVBiDu40R(@K^e;l|QEC@R01^;%es>=gxc4tG|9KK_PzDh)*mD1=L%eNw zn3ns`99RF69O|tW{Lko7T2r}@Kx?Mh6zv8Hv{s(2w__p$#DAKZUwMikGH?e#4^int z1(5$V-EYLRg)BbgzgS(rWB)wFyKO%JAa|o>L}5f3_fw85jr4&jC!4ytUOVLGCb3Aa4#xk=%L2q<2IECRY)cT= z4NS2IdD()P4q&OBZ?FH#O$ID4OadfsIaq^SyZ}WoH(04$z<3xhY4F+v#CriwKrcZb z2>Kw<2ZKHY^r4`?25tW^5WWU|IOrq(h>Q9I!qx`=zx%(t1U+~JA+hz9k=SYBiZ~9S^QN7RS*ld3ULN=lmoB5Kzg2k!Q-#83FBr0(%OKvfXN1EsfP`3g%@C#sHx1{4@Fd8lB4Ec!!NUSdaX(_Tu;>KSq$}@A*Ux%=y>s0~_rw zU{8NcK~4UGMj z>*N239@fjh=0(_i1*%>S^wRWng9ow7i|9dS2TZZ7Z@kl?D$(|f9*@a zB=ld=tAQo30&5IwIan!SeF8OZ%ja+99@f_|T_ysy46JQnTwpw4^YA~z zh4rEMZEt&kwT5vLyXEK({=0xV!}9!1599sI)`0ajOv}J#WLHpnV57zMc0Pt_4l6JY zwu+DeDgPOs7MK$R#IXW#e(Bxcc!@PMKElAL<`pT@7=xoAR_3#-2MZS%FAY`{Taj94b#ALqyE9W zxX}k9M}c@E?}K)xb!|{@DBo>z=6kbRT literal 0 HcmV?d00001 diff --git a/EmailsImport/create_email_indexes_v1.0.py b/EmailsImport/create_email_indexes_v1.0.py new file mode 100644 index 0000000..8712ddc --- /dev/null +++ b/EmailsImport/create_email_indexes_v1.0.py @@ -0,0 +1,70 @@ +#!/usr/bin/env python +# -*- coding: utf-8 -*- +""" +================================================================================ + Nazev: create_email_indexes_v1.0.py + Verze: 1.0 + Datum: 2026-06-08 + Autor: Vladimir Buzalka (asistovano Claude) + Popis: Vytvori slozene indexy na kolekci emailu vbuzalka@its.jnj.com + v databazi `emaily` pro rychle vyhledavani: + - { recipients.email: 1, received_at: -1 } -> prijemce + datum + - { sender.email: 1, received_at: -1 } -> odesilatel + datum + Indexy jsou v pozadi (background) a idempotentni (create_index + nic neudela, kdyz uz existuji se stejnym klicem/nazvem). + Pozn.: Pred spustenim ukazat nahled; vytvoreni indexu je nedestruktivni. +================================================================================ +""" + +import sys +from datetime import datetime + +from pymongo import MongoClient, ASCENDING, DESCENDING + +MONGO_HOST = "192.168.1.76" +DB_NAME = "emaily" +COLLECTION = "vbuzalka@its.jnj.com" + +INDEXES = [ + { + "name": "recipients.email_1_received_at_-1", + "keys": [("recipients.email", ASCENDING), ("received_at", DESCENDING)], + }, + { + "name": "sender.email_1_received_at_-1", + "keys": [("sender.email", ASCENDING), ("received_at", DESCENDING)], + }, +] + + +def log(msg: str) -> None: + print(f"[{datetime.now():%Y-%m-%d %H:%M:%S}] {msg}", flush=True) + + +def main() -> int: + log(f"Pripojuji se k MongoDB ({MONGO_HOST}) ...") + client = MongoClient(MONGO_HOST, serverSelectionTimeoutMS=5000) + client.admin.command("ping") + coll = client[DB_NAME][COLLECTION] + log(f"OK. Kolekce {DB_NAME}.{COLLECTION} ma {coll.estimated_document_count():,} dokumentu.") + + log("Stavajici indexy:") + for name, spec in coll.index_information().items(): + log(f" - {name}: {spec.get('key')}") + + for idx in INDEXES: + log(f"Vytvarim index '{idx['name']}' ...") + created = coll.create_index(idx["keys"], name=idx["name"], background=True) + log(f" -> hotovo: {created}") + + log("Indexy po vytvoreni:") + for name, spec in coll.index_information().items(): + log(f" - {name}: {spec.get('key')}") + + client.close() + log("Hotovo.") + return 0 + + +if __name__ == "__main__": + sys.exit(main()) diff --git a/EmailsImport/inbox_full_sync_v1.1.md b/EmailsImport/inbox_full_sync_v1.1.md new file mode 100644 index 0000000..bd2e0f5 --- /dev/null +++ b/EmailsImport/inbox_full_sync_v1.1.md @@ -0,0 +1,176 @@ +# inbox_full_sync_v1.1 + +**Název:** inbox_full_sync_v1.1.py +**Verze:** 1.1.0 +**Datum:** 2026-06-08 +**Autor:** vladimir.buzalka + +--- + +## Účel + +Jednorázový skript pro úplný přenos **Inboxu i Sent Items** z JNJ Outlooku (MAPI) do osobní schránky `vladimir.buzalka@buzalka.cz` přes Microsoft Graph API. + +Spouštět ručně jako záchranná síť nebo iniciální sync. Bezpečné opakovat — duplicity se automaticky přeskočí. + +--- + +## Co dělá + +1. Připojí se k Outlooku přes MAPI (`win32com`) +2. Projde rekurzivně obě výchozí složky včetně všech podsložek: + - **Inbox** — `GetDefaultFolder(6)` + - **Sent Items** — `GetDefaultFolder(5)` +3. Pro každý email zkontroluje SQLite DB — pokud už je přenesen, přeskočí ho +4. Nový email uloží jako `.msg` do temp složky, **zašifruje** (Fernet/AES) a odešle jako `.emsg` na `msgs.buzalka.cz/upload` +5. Server (`app.py`) dešifruje, parsuje `.msg`, importuje do Graph API a vrátí `graph_id` +6. Záznam se uloží do DB (`messages`, `log`) +7. Každých 100 přenesených emailů + na konci uploaduje DB na server + +Složky k synchronizaci jsou v konstantě `SYNC_FOLDERS = [(6, "Inbox"), (5, "Sent Items")]`. + +**Online Archive se nepřenáší** — `GetDefaultFolder(5/6)` vrátí pouze primární schránku. + +--- + +## Šifrování (Zscaler bypass) + +JNJ síť používá **Zscaler DLP** — blokuje upload souborů s medicínským obsahem (ECG reporty, klinická data) na externí URL. + +Řešení: soubor se před odesláním zašifruje pomocí **Fernet** (AES-128 CBC + HMAC). Zscaler vidí pouze šifrovaný bináč a nerozpozná obsah. + +- Šifrovací klíč se odvozuje z `TOKEN` přes SHA-256 — žádná extra konstanta, obě strany derivují klíč samostatně +- Soubor se odesílá s příponou `.emsg` místo `.msg` +- Server (app.py v1.6+) automaticky detekuje `.emsg`, dešifruje a dále zpracuje standardně + +--- + +## Konfigurace + +Konstanty jsou přímo v kódu: + +| Konstanta | Hodnota | +|---|---| +| `TOKEN` | Bearer token pro msgs.buzalka.cz (slouží i jako základ šifrovacího klíče) | +| `UPLOAD_URL` | `https://msgs.buzalka.cz/upload` | +| `DB_UPLOAD_URL` | `https://msgs.buzalka.cz/upload-db` | +| `DB_PATH` | `C:\Users\vbuzalka\SQLITE\jnjemails.db` | +| `LOG_PATH` | `C:\Users\vbuzalka\SQLITE\inbox_full_sync_errors.log` | +| `SYNC_FOLDERS` | `[(6, "Inbox"), (5, "Sent Items")]` | + +--- + +## Závislosti + +- Python 3.10+, Windows +- Outlook musí být spuštěn +- `pywin32`, `requests`, `cryptography` +- Server `msgs.buzalka.cz` musí běžet (app.py v1.6+) + +--- + +## SQLite DB (`jnjemails.db`) + +### Tabulka `messages` +Jeden záznam na každý přenesený email. + +| Sloupec | Popis | +|---|---| +| `message_id` | Internet Message-ID (nebo `entryid:...` jako fallback) | +| `entry_id` | Outlook EntryID — pro zpětné dohledání v MAPI | +| `graph_id` | ID zprávy v Graph API — pro sync operace | +| `is_read` | Stav přečtení při přenosu (0/1) | +| `jnj_folder` | Složka v JNJ při přenosu (Inbox i Sent Items podstrom) | +| `source` | Vždy `inbox_full_sync` | + +### Tabulka `runs` +Jeden záznam na každý běh skriptu. + +| Sloupec | Popis | +|---|---| +| `script` | `inbox_full_sync` | +| `version` | verze skriptu | +| `started_at` / `finished_at` | časy běhu | +| `transferred` | počet nově přenesených emailů | +| `skipped` | počet přeskočených (již v DB) | +| `errors` | počet chyb | + +### Tabulka `log` +Flat event log — každý console výstup i interní událost jako řádek. + +| Sloupec | Popis | +|---|---| +| `run_id` | FK na `runs.id` | +| `level` | `INFO` / `ERROR` | +| `event` | typ události (viz níže) | +| `subject` | předmět emailu (pokud relevantní) | +| `folder` | složka (pokud relevantní) | +| `graph_id` | Graph ID (pokud relevantní) | +| `detail` | pro `upload_saved`: `size=XKB`; pro `upload_error`: `error=... \| size=XKB \| body=... \| sender=... \| received=... \| entry_id=... \| message_id=...` | + +#### Události (`log.event`) + +| Event | Popis | +|---|---| +| `run_start` | start skriptu | +| `mailbox` | název schránky + kořenová složka (Inbox / Sent Items) | +| `folder_start` | vstup do složky (detail = počet položek) | +| `folder_done` | konec složky (detail = přeneseno/skip) | +| `upload_saved` | nový email úspěšně přenesen (detail = size=XKB) | +| `upload_exists` | email již v DB, přeskočen | +| `upload_error` | chyba při uploadu — detail obsahuje sender, received, entry_id, message_id pro dohledání v Outlooku | +| `progress` | každých 100 přenesených emailů | +| `db_upload` | úspěšný upload DB na server | +| `db_upload_error` | chyba uploadu DB | +| `run_done` | konec skriptu (detail = souhrn) | + +--- + +## Užitečné dotazy + +**Poslední běh — kompletní log:** +```sql +SELECT r.script, r.version, r.started_at, + l.level, l.event, l.subject, l.folder, l.detail, l.created_at +FROM log l JOIN runs r ON r.id = l.run_id +WHERE l.run_id = (SELECT MAX(id) FROM runs) +ORDER BY l.created_at +``` + +**Přehled všech běhů:** +```sql +SELECT id, script, version, started_at, finished_at, + transferred, skipped, errors +FROM runs ORDER BY started_at DESC +``` + +**Chyby z posledního běhu:** +```sql +SELECT l.event, l.subject, l.folder, l.detail, l.created_at +FROM log l +WHERE l.run_id = (SELECT MAX(id) FROM runs) + AND l.level = 'ERROR' +ORDER BY l.created_at +``` + +--- + +## Návaznost + +- Sdílí DB s `janssenpc_email_send_new_v1.5.py` — záznamy jsou kompatibilní +- Emaily přenesené tímto skriptem mají `graph_id` a jsou od té chvíle hlídány sync průchodem v1.5 +- Server endpoint: `msgs.buzalka.cz/upload` musí vracet `graph_id` (app.py v1.6+) +- nginx `client_max_body_size` nastaven na **200M** (SWAG `msgreceiver.subdomain.conf`) + +--- + +## Historie verzí + +| Verze | Datum | Změna | +|---|---|---| +| 1.0.0 | 2026-06-01 | Základní funkce: Inbox full scan, dedup přes DB, entry_id/graph_id/is_read | +| 1.0.1 | 2026-06-01 | DB upload každých 100 emailů + finální upload | +| 1.0.2 | 2026-06-01 | SQLite tabulky runs + log | +| 1.0.3 | 2026-06-01 | Kompletní konzolový výstup zrcadlen do log tabulky, skipped counter | +| 1.0.4 | 2026-06-01 | Šifrování Fernet (.emsg) pro bypass Zscaler DLP; rozšířený error detail | +| 1.1.0 | 2026-06-08 | Synchronizace i složky **Sent Items** (`GetDefaultFolder(5)`) vedle Inboxu | diff --git a/EmailsImport/inbox_full_sync_v1.1.py b/EmailsImport/inbox_full_sync_v1.1.py new file mode 100644 index 0000000..87892e1 --- /dev/null +++ b/EmailsImport/inbox_full_sync_v1.1.py @@ -0,0 +1,389 @@ +""" +inbox_full_sync v1.1 +Název: inbox_full_sync_v1.1.py +Verze: 1.1.0 +Datum: 2026-06-08 +Autor: vladimir.buzalka + +Popis: + Jednorázový skript pro úplný přenos Inboxu A Sent Items z JNJ Outlooku (MAPI) + do osobní schránky vladimir.buzalka@buzalka.cz přes Graph API. + + Prochází celý Inbox i Sent Items včetně všech podsložek. Online Archive se + nepřenáší (GetDefaultFolder(5/6) vrátí pouze primární schránku). + + Každý email se uloží jako .msg do temp složky, odešle na https://msgs.buzalka.cz/upload + a přes Graph API se importuje do odpovídající složky v osobní schránce. + Dedup zajišťuje SQLite DB — email který je v DB (message_id) se přeskočí. + +Spouštění: + Spouštět ručně jako záchranná síť nebo iniciální sync. + Bezpečné opakovat — duplicity se přeskočí. + +Závislosti: + win32com, requests, sqlite3 (stdlib) + Python 3.10+, Windows, Outlook musí být spuštěn + +Konfigurace (konstanty v kódu): + TOKEN Bearer token pro msgs.buzalka.cz + UPLOAD_URL https://msgs.buzalka.cz/upload + DB_UPLOAD_URL https://msgs.buzalka.cz/upload-db + DB_PATH C:\\Users\\vbuzalka\\SQLITE\\jnjemails.db + LOG_PATH C:\\Users\\vbuzalka\\SQLITE\\inbox_full_sync_errors.log + +SQLite DB (jnjemails.db): + messages — přenesené emaily (message_id, entry_id, graph_id, is_read, jnj_folder, ...) + runs — jeden záznam na běh (script, version, started_at, finished_at, counts) + log — flat event log per run (level, event, subject, folder, graph_id, detail) + + Dotaz pro posledn běh: + SELECT r.script, r.version, r.started_at, l.level, l.event, + l.subject, l.folder, l.detail, l.created_at + FROM log l JOIN runs r ON r.id = l.run_id + WHERE l.run_id = (SELECT MAX(id) FROM runs) + ORDER BY l.created_at + +Log události (log.event): + run_start — start skriptu + mailbox — název schránky + folder_start — vstup do složky (detail = počet položek) + folder_done — konec složky (detail = přeneseno/skip) + upload_saved — nový email přenesen + upload_exists — email již v DB, přeskočen + upload_error — chyba při uploadu (detail = chybová zpráva) + progress — každých 100 přenesených + db_upload — úspěšný upload DB na server + db_upload_error — chyba uploadu DB + run_done — konec skriptu (detail = souhrn) + +Historie verzí: + 1.0.0 2026-06-01 Základní funkce: Inbox full scan, dedup přes DB, entry_id/graph_id/is_read + 1.0.1 2026-06-01 DB upload každých 100 emailů + finální upload + 1.0.2 2026-06-01 SQLite tabulky runs + log + 1.0.3 2026-06-01 Kompletní konzolový výstup zrcadlen do log tabulky, skipped counter + 1.0.4 2026-06-01 Šifrování Fernet (.emsg) pro bypass Zscaler DLP; rozšířený error detail + 1.1.0 2026-06-08 Synchronizace i složky Sent Items (GetDefaultFolder(5)) vedle Inboxu +""" +import win32com.client +import requests +import sqlite3 +import urllib3 +import logging +import hashlib +import base64 +from pathlib import Path +from datetime import datetime +from cryptography.fernet import Fernet +import tempfile + +urllib3.disable_warnings(urllib3.exceptions.InsecureRequestWarning) + +TOKEN = "13e1bb01-9fd5-44a8-8ce9-4ee27133d340" +UPLOAD_URL = "https://msgs.buzalka.cz/upload" +DB_PATH = r"C:\Users\vbuzalka\SQLITE\jnjemails.db" +LOG_PATH = r"C:\Users\vbuzalka\SQLITE\inbox_full_sync_errors.log" +PR_INTERNET_MESSAGE_ID = "http://schemas.microsoft.com/mapi/proptag/0x1035001E" +DB_UPLOAD_URL = "https://msgs.buzalka.cz/upload-db" +SCRIPT_NAME = "inbox_full_sync" +SCRIPT_VERSION = "1.1.0" +# Výchozí složky k synchronizaci: (olFolderID, label) — Inbox=6, Sent Items=5 +SYNC_FOLDERS = [(6, "Inbox"), (5, "Sent Items")] +# Šifrovací klíč odvozený z TOKENu — stejný algoritmus jako na serveru +_FERNET = Fernet(base64.urlsafe_b64encode(hashlib.sha256(TOKEN.encode()).digest())) + +logging.basicConfig( + filename=LOG_PATH, + level=logging.ERROR, + format="%(asctime)s | %(message)s", + datefmt="%Y-%m-%d %H:%M:%S", + encoding="utf-8", +) + + +def init_db(conn): + conn.execute(""" + CREATE TABLE IF NOT EXISTS messages ( + id INTEGER PRIMARY KEY AUTOINCREMENT, + message_id TEXT NOT NULL, + subject TEXT, + sender TEXT, + received_at TEXT, + folder TEXT, + source TEXT, + uploaded_at TEXT DEFAULT (datetime('now')), + entry_id TEXT, + graph_id TEXT, + is_read INTEGER DEFAULT 0, + jnj_folder TEXT + ) + """) + conn.execute("CREATE UNIQUE INDEX IF NOT EXISTS idx_message_id ON messages(message_id)") + + conn.execute(""" + CREATE TABLE IF NOT EXISTS runs ( + id INTEGER PRIMARY KEY AUTOINCREMENT, + script TEXT NOT NULL, + version TEXT, + started_at TEXT NOT NULL, + finished_at TEXT, + transferred INTEGER DEFAULT 0, + skipped INTEGER DEFAULT 0, + sync_updated INTEGER DEFAULT 0, + sync_deleted INTEGER DEFAULT 0, + errors INTEGER DEFAULT 0 + ) + """) + + conn.execute(""" + CREATE TABLE IF NOT EXISTS log ( + id INTEGER PRIMARY KEY AUTOINCREMENT, + run_id INTEGER REFERENCES runs(id), + level TEXT NOT NULL, + event TEXT NOT NULL, + subject TEXT, + folder TEXT, + graph_id TEXT, + detail TEXT, + created_at TEXT DEFAULT (datetime('now')) + ) + """) + conn.execute("CREATE INDEX IF NOT EXISTS idx_log_run_id ON log(run_id)") + + for col, definition in [ + ("entry_id", "TEXT"), + ("graph_id", "TEXT"), + ("is_read", "INTEGER DEFAULT 0"), + ("jnj_folder", "TEXT"), + ]: + try: + conn.execute(f"ALTER TABLE messages ADD COLUMN {col} {definition}") + except Exception: + pass + conn.commit() + + +def start_run(conn): + cur = conn.execute( + "INSERT INTO runs (script, version, started_at) VALUES (?, ?, datetime('now'))", + (SCRIPT_NAME, SCRIPT_VERSION) + ) + conn.commit() + return cur.lastrowid + + +def finish_run(conn, run_id, transferred, skipped, errors): + conn.execute(""" + UPDATE runs SET finished_at=datetime('now'), transferred=?, skipped=?, errors=? + WHERE id=? + """, (transferred, skipped, errors, run_id)) + conn.commit() + + +def db_log(conn, run_id, level, event, subject=None, folder=None, graph_id=None, detail=None): + conn.execute(""" + INSERT INTO log (run_id, level, event, subject, folder, graph_id, detail) + VALUES (?, ?, ?, ?, ?, ?, ?) + """, (run_id, level, event, subject, folder, graph_id, detail)) + conn.commit() + + +def info(conn, run_id, event, **kwargs): + db_log(conn, run_id, "INFO", event, **kwargs) + + +def error(conn, run_id, event, **kwargs): + db_log(conn, run_id, "ERROR", event, **kwargs) + + +def is_uploaded(conn, message_id): + row = conn.execute( + "SELECT 1 FROM messages WHERE message_id = ? LIMIT 1", (message_id,) + ).fetchone() + return row is not None + + +def save_to_db(conn, message_id, subject, sender, received_at, folder, + entry_id=None, graph_id=None, is_read=0): + conn.execute(""" + INSERT OR IGNORE INTO messages + (message_id, subject, sender, received_at, folder, source, + entry_id, graph_id, is_read, jnj_folder) + VALUES (?, ?, ?, ?, ?, 'inbox_full_sync', ?, ?, ?, ?) + """, (message_id, subject, sender, received_at, folder, + entry_id, graph_id, is_read, folder)) + conn.commit() + + +def upload_db(conn, run_id): + timestamp = datetime.now().strftime("%Y%m%d_%H%M%S") + filename = f"jnjemails_{timestamp}.db" + try: + with open(DB_PATH, "rb") as f: + resp = requests.post( + DB_UPLOAD_URL, + headers={"Authorization": f"Bearer {TOKEN}"}, + files={"file": (filename, f, "application/octet-stream")}, + timeout=60, + ) + result = resp.json() + msg = f"DB upload: {result}" + print(f" {msg}") + info(conn, run_id, "db_upload", detail=msg) + except Exception as e: + msg = str(e) + print(f" DB upload CHYBA: {msg}") + error(conn, run_id, "db_upload_error", detail=msg) + + +def upload_msg(msg_path, filename, folder=""): + size_kb = Path(msg_path).stat().st_size // 1024 + with open(msg_path, "rb") as f: + encrypted = _FERNET.encrypt(f.read()) + enc_filename = Path(filename).stem + ".emsg" + resp = requests.post( + UPLOAD_URL, + headers={"Authorization": f"Bearer {TOKEN}"}, + files={"file": (enc_filename, encrypted, "application/octet-stream")}, + data={"folder": folder}, + timeout=60, + ) + if not resp.ok: + raise requests.HTTPError( + f"{resp.status_code} {resp.reason} | size={size_kb}KB | body={resp.text[:300]}", + response=resp, + ) + return resp.json() + + +def process_folder(conn, run_id, folder, folder_path, counter, skipped_counter, error_counter): + current_path = f"{folder_path}/{folder.Name}" + items = folder.Items + items.Sort("[ReceivedTime]", False) + + count = 0 + skipped = 0 + total = items.Count + + msg = f"Složka: {current_path} ({total} položek)" + print(f"\n {msg}") + info(conn, run_id, "folder_start", folder=current_path, detail=str(total)) + + for item in items: + subject = getattr(item, 'Subject', '?') + try: + if not item.MessageClass.upper().startswith("IPM.NOTE"): + continue + + try: + mid = item.PropertyAccessor.GetProperty(PR_INTERNET_MESSAGE_ID) + except Exception: + mid = None + if not mid: + mid = f"entryid:{item.EntryID}" + + if is_uploaded(conn, mid): + skipped += 1 + skipped_counter[0] += 1 + continue + + try: + with tempfile.TemporaryDirectory() as tmp: + safe_name = f"{item.EntryID[-20:]}.msg" + tmp_path = Path(tmp) / safe_name + item.SaveAs(str(tmp_path), 3) + size_kb = tmp_path.stat().st_size // 1024 + result = upload_msg(tmp_path, safe_name, current_path) + + status = result.get("status", "?") + graph_id = result.get("graph_id") + is_read = 0 if item.UnRead else 1 + received = item.ReceivedTime.isoformat() if item.ReceivedTime else None + + save_to_db(conn, mid, subject, item.SenderEmailAddress, + received, current_path, + entry_id=item.EntryID, graph_id=graph_id, is_read=is_read) + info(conn, run_id, f"upload_{status}", + subject=subject, folder=current_path, graph_id=graph_id, + detail=f"size={size_kb}KB") + + counter[0] += 1 + count += 1 + + if counter[0] % 100 == 0: + msg = f"celkem přeneseno: {counter[0]}" + print(f" → {msg}, uploaduji DB...") + info(conn, run_id, "progress", detail=msg) + upload_db(conn, run_id) + + print(f" {status.upper():6} | {subject[:70]}") + + except Exception as e: + sender_str = getattr(item, 'SenderEmailAddress', '?') + received_str = getattr(item, 'ReceivedTime', None) + received_str = received_str.isoformat() if received_str else '?' + entry_id_str = getattr(item, 'EntryID', '?') + detail = ( + f"error={e} | " + f"sender={sender_str} | " + f"received={received_str} | " + f"entry_id={entry_id_str} | " + f"message_id={mid}" + ) + print(f" CHYBA | {subject[:50]} | sender={sender_str} | received={received_str} | {e}") + error(conn, run_id, "upload_error", + subject=subject, folder=current_path, detail=detail) + logging.error("folder=%s | %s", current_path, detail) + error_counter[0] += 1 + + except Exception as e: + # Neočekávaná chyba mimo upload blok (MessageClass, EntryID, apod.) + print(f" CHYBA (item) | {subject[:50]} | {e}") + logging.error("folder=%s | item_error | subject=%s | error=%s", current_path, subject, e) + error_counter[0] += 1 + + msg = f"složka hotova: přeneseno {count} | skip {skipped}" + print(f" → {msg}") + info(conn, run_id, "folder_done", folder=current_path, detail=msg) + + for subfolder in folder.Folders: + process_folder(conn, run_id, subfolder, current_path, counter, skipped_counter, error_counter) + + +# --- MAIN --- +print(f"=== inbox_full_sync v{SCRIPT_VERSION} ===") +print(f"Start: {datetime.now().strftime('%Y-%m-%d %H:%M:%S')}") + +conn = sqlite3.connect(DB_PATH) +init_db(conn) +run_id = start_run(conn) +info(conn, run_id, "run_start", detail=f"script={SCRIPT_NAME} version={SCRIPT_VERSION}") + +outlook = win32com.client.Dispatch("Outlook.Application") +ns = outlook.GetNamespace("MAPI") + +counter = [0] +skipped_counter = [0] +error_counter = [0] + +for folder_id, folder_label in SYNC_FOLDERS: + root = ns.GetDefaultFolder(folder_id) # primární schránka, bez Online Archive + mailbox_name = root.Parent.Name + print(f"\nSchránka: {mailbox_name} | kořen: {folder_label}") + info(conn, run_id, "mailbox", detail=f"{mailbox_name} | {folder_label}") + process_folder(conn, run_id, root, f"/{mailbox_name}", counter, skipped_counter, error_counter) + +finish_run(conn, run_id, + transferred=counter[0], + skipped=skipped_counter[0], + errors=error_counter[0]) + +summary = f"přeneseno {counter[0]} | skip {skipped_counter[0]} | chyby {error_counter[0]}" +print(f"\n=== Hotovo: {summary} ===") +info(conn, run_id, "run_done", detail=summary) + +print("Uploaduji DB...") +upload_db(conn, run_id) + +print(f"Konec: {datetime.now().strftime('%Y-%m-%d %H:%M:%S')}") +print(f"Chyby logovány do: {LOG_PATH}") +conn.close() diff --git a/EmailsImport/parse_emails_tower_failed_20260608.txt b/EmailsImport/parse_emails_tower_failed_20260608.txt new file mode 100644 index 0000000..87544f8 --- /dev/null +++ b/EmailsImport/parse_emails_tower_failed_20260608.txt @@ -0,0 +1,126 @@ +899C0000969E661B0000.msg Attachment method missing (bug extract_msg) Attachment method missing on attachment __attach_version1.0_#00000002, and it could not be determined automatically. +899C0000987BE65C0000.msg Attachment method missing (bug extract_msg) Attachment method missing on attachment __attach_version1.0_#00000001, and it could not be determined automatically. +899C00009A2FBD760000.msg Attachment method missing (bug extract_msg) Attachment method missing on attachment __attach_version1.0_#00000002, and it could not be determined automatically. +899C00009B8A9A000000.msg Attachment method missing (bug extract_msg) Attachment method missing on attachment __attach_version1.0_#00000001, and it could not be determined automatically. +899C00009C3844690000.msg Attachment method missing (bug extract_msg) Attachment method missing on attachment __attach_version1.0_#00000001, and it could not be determined automatically. +899C00009C3844720000.msg Attachment method missing (bug extract_msg) Attachment method missing on attachment __attach_version1.0_#00000001, and it could not be determined automatically. +899C0000A4683A4B0000.msg Attachment method missing (bug extract_msg) Attachment method missing on attachment __attach_version1.0_#00000001, and it could not be determined automatically. +899C0000A5CC64F40000.msg Attachment method missing (bug extract_msg) Attachment method missing on attachment __attach_version1.0_#00000001, and it could not be determined automatically. +899C0000A5CC64FE0000.msg Attachment method missing (bug extract_msg) Attachment method missing on attachment __attach_version1.0_#00000001, and it could not be determined automatically. +899C0000B30157A10000.msg Attachment method missing (bug extract_msg) Attachment method missing on attachment __attach_version1.0_#00000001, and it could not be determined automatically. +899C0000B30157A80000.msg Attachment bez data streamu Attachments of type data MUST have a data stream. +899C0000B588253A0000.msg Attachment method missing (bug extract_msg) Attachment method missing on attachment __attach_version1.0_#00000003, and it could not be determined automatically. +899C0000BE168C140000.msg Attachment method missing (bug extract_msg) Attachment method missing on attachment __attach_version1.0_#00000001, and it could not be determined automatically. +899C0000C0CF55D50000.msg Attachment method missing (bug extract_msg) Attachment method missing on attachment __attach_version1.0_#00000001, and it could not be determined automatically. +899C0000C1CA96890000.msg Attachment method missing (bug extract_msg) Attachment method missing on attachment __attach_version1.0_#00000001, and it could not be determined automatically. +899C0000DB9693FF0000.msg Attachment method missing (bug extract_msg) Attachment method missing on attachment __attach_version1.0_#00000001, and it could not be determined automatically. +899C0000FDE653340000.msg Attachment method missing (bug extract_msg) Attachment method missing on attachment __attach_version1.0_#00000001, and it could not be determined automatically. +899C0001086D6C480000.msg Attachment method missing (bug extract_msg) Attachment method missing on attachment __attach_version1.0_#00000001, and it could not be determined automatically. +899C0001140535280000.msg Attachment method missing (bug extract_msg) Attachment method missing on attachment __attach_version1.0_#00000001, and it could not be determined automatically. +899C00012E0882410000.msg Attachment method missing (bug extract_msg) Attachment method missing on attachment __attach_version1.0_#00000001, and it could not be determined automatically. +899C0001E06482F10000.msg Attachment method missing (bug extract_msg) Attachment method missing on attachment __attach_version1.0_#00000001, and it could not be determined automatically. +899C0001ED5302060000.msg Attachment method missing (bug extract_msg) Attachment method missing on attachment __attach_version1.0_#00000001, and it could not be determined automatically. +899C0001FCC6C2910000.msg Attachment method missing (bug extract_msg) Attachment method missing on attachment __attach_version1.0_#00000002, and it could not be determined automatically. +899C0002323988230000.msg Attachment method missing (bug extract_msg) Attachment method missing on attachment __attach_version1.0_#00000002, and it could not be determined automatically. +899C000242F1A76E0000.msg olefile ale ne validni MSG (poskozeny) File was confirmed to be an olefile, but was not an MSG file. +899C00024C8DDE840000.msg olefile ale ne validni MSG (poskozeny) File was confirmed to be an olefile, but was not an MSG file. +899C000265F79E010000.msg olefile ale ne validni MSG (poskozeny) File was confirmed to be an olefile, but was not an MSG file. +899C0002A03911800000.msg Attachment method missing (bug extract_msg) Attachment method missing on attachment __attach_version1.0_#0000000A, and it could not be determined automatically. +899C0002A03911810000.msg Attachment method missing (bug extract_msg) Attachment method missing on attachment __attach_version1.0_#0000000A, and it could not be determined automatically. +899C0002A03911820000.msg Attachment method missing (bug extract_msg) Attachment method missing on attachment __attach_version1.0_#0000000A, and it could not be determined automatically. +899C0002A81D82F30000.msg Attachment method missing (bug extract_msg) Attachment method missing on attachment __attach_version1.0_#00000001, and it could not be determined automatically. +899C0002AF8653970000.msg gb2312 decode error 'gb2312' codec can't decode byte 0xe9 in position 7: illegal multibyte sequence +899C0002E47C3A1C0000.msg Attachment method missing (bug extract_msg) Attachment method missing on attachment __attach_version1.0_#00000004, and it could not be determined automatically. +899C0002E69328E00000.msg Attachment method missing (bug extract_msg) Attachment method missing on attachment __attach_version1.0_#00000004, and it could not be determined automatically. +899C0002E950197E0000.msg Attachment method missing (bug extract_msg) Attachment method missing on attachment __attach_version1.0_#00000004, and it could not be determined automatically. +899C0003073E12A00000.msg Attachment method missing (bug extract_msg) Attachment method missing on attachment __attach_version1.0_#00000001, and it could not be determined automatically. +899C0003073E12A90000.msg Attachment method missing (bug extract_msg) Attachment method missing on attachment __attach_version1.0_#00000001, and it could not be determined automatically. +899C00030F081AA20000.msg Attachment method missing (bug extract_msg) Attachment method missing on attachment __attach_version1.0_#00000001, and it could not be determined automatically. +899C0003263BA0280000.msg Attachment bez data streamu Attachments of type data MUST have a data stream. +899C00034B5587500000.msg gb2312 decode error 'gb2312' codec can't decode byte 0xe1 in position 7: illegal multibyte sequence +899C00034B5587520000.msg gb2312 decode error 'gb2312' codec can't decode byte 0xe1 in position 7: illegal multibyte sequence +899C00034B5587530000.msg gb2312 decode error 'gb2312' codec can't decode byte 0xe1 in position 7: illegal multibyte sequence +899C00034B5587550000.msg gb2312 decode error 'gb2312' codec can't decode byte 0xe1 in position 7: illegal multibyte sequence +899C0003718D82340000.msg Attachment method missing (bug extract_msg) Attachment method missing on attachment __attach_version1.0_#00000001, and it could not be determined automatically. +899C0003718D82510000.msg Attachment method missing (bug extract_msg) Attachment method missing on attachment __attach_version1.0_#00000001, and it could not be determined automatically. +899C0003821F0BBD0000.msg Attachment method missing (bug extract_msg) Attachment method missing on attachment __attach_version1.0_#00000001, and it could not be determined automatically. +899C0003821F0C190000.msg Attachment method missing (bug extract_msg) Attachment method missing on attachment __attach_version1.0_#00000001, and it could not be determined automatically. +899C0003821F0C230000.msg Attachment method missing (bug extract_msg) Attachment method missing on attachment __attach_version1.0_#00000001, and it could not be determined automatically. +899C000383EBC5AA0000.msg Attachment method missing (bug extract_msg) Attachment method missing on attachment __attach_version1.0_#00000001, and it could not be determined automatically. +899C000383EBC5B40000.msg Attachment method missing (bug extract_msg) Attachment method missing on attachment __attach_version1.0_#00000001, and it could not be determined automatically. +899C00038665FE2C0000.msg Attachment method missing (bug extract_msg) Attachment method missing on attachment __attach_version1.0_#00000001, and it could not be determined automatically. +899C00038920A2620000.msg Attachment method missing (bug extract_msg) Attachment method missing on attachment __attach_version1.0_#00000001, and it could not be determined automatically. +899C0003AF5773430000.msg Attachment method missing (bug extract_msg) Attachment method missing on attachment __attach_version1.0_#00000001, and it could not be determined automatically. +899C0003B0920A8F0000.msg Attachment method missing (bug extract_msg) Attachment method missing on attachment __attach_version1.0_#00000001, and it could not be determined automatically. +899C0003B0920A9C0000.msg Attachment method missing (bug extract_msg) Attachment method missing on attachment __attach_version1.0_#00000001, and it could not be determined automatically. +899C0003D45EACBF0000.msg Attachment method missing (bug extract_msg) Attachment method missing on attachment __attach_version1.0_#00000001, and it could not be determined automatically. +899C0003D45EACE70000.msg Attachment method missing (bug extract_msg) Attachment method missing on attachment __attach_version1.0_#00000001, and it could not be determined automatically. +899C0003D9C769EF0000.msg Attachment method missing (bug extract_msg) Attachment method missing on attachment __attach_version1.0_#00000001, and it could not be determined automatically. +899C0003D9C769FB0000.msg Attachment method missing (bug extract_msg) Attachment method missing on attachment __attach_version1.0_#00000001, and it could not be determined automatically. +899C0004C13ACDF10000.msg Attachment method missing (bug extract_msg) Attachment method missing on attachment __attach_version1.0_#00000001, and it could not be determined automatically. +899C0004C13ACE4D0000.msg Attachment method missing (bug extract_msg) Attachment method missing on attachment __attach_version1.0_#00000001, and it could not be determined automatically. +899C0004FC02CE070000.msg Attachment method missing (bug extract_msg) Attachment method missing on attachment __attach_version1.0_#00000001, and it could not be determined automatically. +899C000509346CC90000.msg Attachment method missing (bug extract_msg) Attachment method missing on attachment __attach_version1.0_#00000001, and it could not be determined automatically. +899C00052B6CED370000.msg Attachment method missing (bug extract_msg) Attachment method missing on attachment __attach_version1.0_#00000001, and it could not be determined automatically. +899C0005333450E80000.msg Attachment method missing (bug extract_msg) Attachment method missing on attachment __attach_version1.0_#00000001, and it could not be determined automatically. +899C000555088DC40000.msg Attachment method missing (bug extract_msg) Attachment method missing on attachment __attach_version1.0_#00000001, and it could not be determined automatically. +899C0005672332F80000.msg Attachment method missing (bug extract_msg) Attachment method missing on attachment __attach_version1.0_#00000001, and it could not be determined automatically. +899C0005697291740000.msg Attachment method missing (bug extract_msg) Attachment method missing on attachment __attach_version1.0_#00000001, and it could not be determined automatically. +899C000603B6EBDA0000.msg Attachment method missing (bug extract_msg) Attachment method missing on attachment __attach_version1.0_#00000001, and it could not be determined automatically. +899C0006228FF1280000.msg olefile ale ne validni MSG (poskozeny) File was confirmed to be an olefile, but was not an MSG file. +899C000633B02A850000.msg Attachment method missing (bug extract_msg) Attachment method missing on attachment __attach_version1.0_#00000001, and it could not be determined automatically. +899C000633B033310000.msg utf-16-le decode error 'utf-16-le' codec can't decode byte 0x5d in position 32: truncated data +899C000633B033350000.msg utf-16-le decode error 'utf-16-le' codec can't decode byte 0x5d in position 32: truncated data +899C00064375824C0000.msg Attachment method missing (bug extract_msg) Attachment method missing on attachment __attach_version1.0_#00000001, and it could not be determined automatically. +899C00065A149B5C0000.msg utf-16-le decode error 'utf-16-le' codec can't decode byte 0x5d in position 32: truncated data +899C00065C3470040000.msg utf-16-le decode error 'utf-16-le' codec can't decode byte 0x5d in position 32: truncated data +899C00065C3470060000.msg utf-16-le decode error 'utf-16-le' codec can't decode byte 0x5d in position 32: truncated data +899C00065C3470070000.msg utf-16-le decode error 'utf-16-le' codec can't decode byte 0x5d in position 32: truncated data +899C00065C3470090000.msg utf-16-le decode error 'utf-16-le' codec can't decode byte 0x5d in position 32: truncated data +899C00065C3470150000.msg utf-16-le decode error 'utf-16-le' codec can't decode byte 0x5d in position 32: truncated data +899C00065E02EE2A0000.msg Attachment method missing (bug extract_msg) Attachment method missing on attachment __attach_version1.0_#00000001, and it could not be determined automatically. +899C00065E02EE440000.msg Attachment method missing (bug extract_msg) Attachment method missing on attachment __attach_version1.0_#00000001, and it could not be determined automatically. +899C000679124DA10000.msg Attachment method missing (bug extract_msg) Attachment method missing on attachment __attach_version1.0_#00000001, and it could not be determined automatically. +899C0006908BA3470000.msg utf-16-le decode error 'utf-16-le' codec can't decode byte 0x5d in position 32: truncated data +899C0006908BA3660000.msg utf-16-le decode error 'utf-16-le' codec can't decode byte 0x5d in position 32: truncated data +899C0006908BA3670000.msg utf-16-le decode error 'utf-16-le' codec can't decode byte 0x5d in position 32: truncated data +899C0006908BA3680000.msg utf-16-le decode error 'utf-16-le' codec can't decode byte 0x5d in position 32: truncated data +899C0006908BA3690000.msg utf-16-le decode error 'utf-16-le' codec can't decode byte 0x5d in position 32: truncated data +899C0006908BA36E0000.msg utf-16-le decode error 'utf-16-le' codec can't decode byte 0x5d in position 32: truncated data +899C0006908BA3720000.msg utf-16-le decode error 'utf-16-le' codec can't decode byte 0x5d in position 32: truncated data +899C0006908BA3780000.msg utf-16-le decode error 'utf-16-le' codec can't decode byte 0x5d in position 32: truncated data +899C00069AC455930000.msg jiny codec decode error 'shift_jis' codec can't decode byte 0xfd in position 11: illegal multibyte sequence +899C00069AC4559A0000.msg jiny codec decode error 'shift_jis' codec can't decode byte 0xfd in position 11: illegal multibyte sequence +899C00069AC4559D0000.msg jiny codec decode error 'shift_jis' codec can't decode byte 0xe1 in position 7: illegal multibyte sequence +899C0006B783843F0000.msg Attachment method missing (bug extract_msg) Attachment method missing on attachment __attach_version1.0_#00000001, and it could not be determined automatically. +899C0006D8C513EC0000.msg gb2312 decode error 'gb2312' codec can't decode byte 0xe1 in position 7: illegal multibyte sequence +899C00073F21E17A0000.msg jiny codec decode error 'shift_jis' codec can't decode byte 0xe1 in position 17: incomplete multibyte sequence +899C00073F21E17C0000.msg jiny codec decode error 'shift_jis' codec can't decode byte 0xe1 in position 17: incomplete multibyte sequence +899C00075AED88D70000.msg olefile ale ne validni MSG (poskozeny) File was confirmed to be an olefile, but was not an MSG file. +899C00075AED8D1F0000.msg utf-16-le decode error 'utf-16-le' codec can't decode byte 0x5d in position 32: truncated data +899C00075AED8D210000.msg utf-16-le decode error 'utf-16-le' codec can't decode byte 0x5d in position 32: truncated data +899C00075AED8D260000.msg utf-16-le decode error 'utf-16-le' codec can't decode byte 0x5d in position 32: truncated data +899C00075C663C520000.msg olefile ale ne validni MSG (poskozeny) File was confirmed to be an olefile, but was not an MSG file. +899C00075C6651340000.msg utf-16-le decode error 'utf-16-le' codec can't decode byte 0x5d in position 32: truncated data +899C00075C6651360000.msg utf-16-le decode error 'utf-16-le' codec can't decode byte 0x5d in position 32: truncated data +899C00075C6651390000.msg utf-16-le decode error 'utf-16-le' codec can't decode byte 0x5d in position 32: truncated data +899C00075C66513A0000.msg utf-16-le decode error 'utf-16-le' codec can't decode byte 0x5d in position 32: truncated data +899C00075C66513B0000.msg utf-16-le decode error 'utf-16-le' codec can't decode byte 0x5d in position 32: truncated data +899C00075C66513E0000.msg utf-16-le decode error 'utf-16-le' codec can't decode byte 0x5d in position 32: truncated data +899C00075C6651500000.msg utf-16-le decode error 'utf-16-le' codec can't decode byte 0x5d in position 32: truncated data +899C00075C6651570000.msg utf-16-le decode error 'utf-16-le' codec can't decode byte 0x5d in position 32: truncated data +899C00075C66515B0000.msg utf-16-le decode error 'utf-16-le' codec can't decode byte 0x5d in position 32: truncated data +899C0007630CC2E20000.msg olefile ale ne validni MSG (poskozeny) File was confirmed to be an olefile, but was not an MSG file. +899C0007630CD81E0000.msg gb2312 decode error 'gb2312' codec can't decode byte 0xe9 in position 12: illegal multibyte sequence +899C00077582C6CB0000.msg gb2312 decode error 'gb2312' codec can't decode byte 0xe1 in position 6: illegal multibyte sequence +899C00077582C6D60000.msg gb2312 decode error 'gb2312' codec can't decode byte 0xe1 in position 6: illegal multibyte sequence +FC1300074838B0AA0000.msg gb2312 decode error 'gb2312' codec can't decode byte 0xe1 in position 1: illegal multibyte sequence +FC1300074838B84D0000.msg gb2312 decode error 'gb2312' codec can't decode byte 0xe1 in position 8: illegal multibyte sequence +FC1300074838B8580000.msg gb2312 decode error 'gb2312' codec can't decode byte 0xe1 in position 1: illegal multibyte sequence +FC1300074838B8590000.msg gb2312 decode error 'gb2312' codec can't decode byte 0xe1 in position 1: illegal multibyte sequence +FC1300074838B85A0000.msg gb2312 decode error 'gb2312' codec can't decode byte 0xe1 in position 1: illegal multibyte sequence +FC1300074838B85B0000.msg gb2312 decode error 'gb2312' codec can't decode byte 0xe1 in position 1: illegal multibyte sequence +FC1300074838B85D0000.msg gb2312 decode error 'gb2312' codec can't decode byte 0xe1 in position 1: illegal multibyte sequence +FC1300074838B8610000.msg gb2312 decode error 'gb2312' codec can't decode byte 0xe1 in position 1: illegal multibyte sequence +FC1300074838B8630000.msg gb2312 decode error 'gb2312' codec can't decode byte 0xe1 in position 1: illegal multibyte sequence +FC1300074838B8650000.msg gb2312 decode error 'gb2312' codec can't decode byte 0xe1 in position 1: illegal multibyte sequence diff --git a/EmailsImport/parse_emails_tower_v1.3.md b/EmailsImport/parse_emails_tower_v1.3.md new file mode 100644 index 0000000..c0da9db --- /dev/null +++ b/EmailsImport/parse_emails_tower_v1.3.md @@ -0,0 +1,289 @@ +# parse_emails_tower_v1.3 + +## Spuštění + +**První spuštění:** +```bash +docker exec -d python-runner bash -c \ + "python /scripts/parse_emails_tower_v1.3.py > /scripts/parse_emails_tower.log 2>&1" +``` + +**Pokračování po přerušení (přeskočí už importované):** +```bash +docker exec -d python-runner bash -c \ + "python /scripts/parse_emails_tower_v1.3.py --skip-existing > /scripts/parse_emails_tower.log 2>&1" +``` + +--- + +## Stav importu + +**Sledování průběhu (live log):** +```bash +docker exec -it python-runner tail -f /scripts/parse_emails_tower.log +``` + +**Počet emailů v MongoDB:** +```bash +docker exec -it python-runner python -c \ + "from pymongo import MongoClient; c=MongoClient('mongodb://192.168.1.76:27017'); print(c['emaily']['vbuzalka@its.jnj.com'].count_documents({}))" +``` + +--- + +**Název:** parse_emails_tower_v1.3.py +**Verze:** 1.3 +**Datum:** 2026-06-08 +**Autor:** vladimir.buzalka + +--- + +## Účel + +Import všech `.msg` souborů do MongoDB. Z každého souboru extrahuje **všechny dostupné vlastnosti** — podobně jako EXIF u fotek. + +- **DB:** `emaily` +- **Kolekce:** `vbuzalka@its.jnj.com` +- `_id` = Internet Message-ID (nebo `filename:` jako fallback) +- Bezpečné přerušit a opakovat — upsert podle `_id` + +--- + +## Prostředí + +Běží v Docker containeru **python-runner** na **Unraid Tower**. + +| Komponenta | Umístění | +|---|---| +| Container | `python-runner` (Docker na Unraid Tower) | +| .msg soubory | `/mnt/user/JNJEMAILS` → `/mnt/JNJEMAILS` uvnitř containeru | +| Skripty | `/mnt/user/Scripts` → `/scripts` uvnitř containeru | +| MongoDB | `192.168.1.76:27017` (externí, mimo container) | + +--- + +## Spouštění (z Unraid terminálu) + +**Test na 50 emailech:** +```bash +docker exec -it python-runner python /scripts/parse_emails_tower_v1.3.py --limit 50 --no-indexes +``` + +**Kompletní import na pozadí (log do souboru):** +```bash +docker exec -d python-runner bash -c \ + "python /scripts/parse_emails_tower_v1.3.py > /scripts/parse_emails_tower.log 2>&1" +``` + +**Pokračování po přerušení:** +```bash +docker exec -d python-runner bash -c \ + "python /scripts/parse_emails_tower_v1.3.py --skip-existing > /scripts/parse_emails_tower.log 2>&1" +``` + +**Sledování průběhu (Ctrl+C ukončí sledování, import běží dál):** +```bash +docker exec -it python-runner tail -f /scripts/parse_emails_tower.log +``` + +### Všechny parametry + +| Parametr | Popis | +|---|---| +| `--skip-existing` | Načte seznam hotových souborů z MongoDB a přeskočí je. Použij pro pokračování po přerušení. | +| `--limit N` | Zpracuje jen prvních N souborů. Vhodné pro test. | +| `--no-indexes` | Nevytváří indexy na konci. Použij pokud přerušíš uprostřed — indexy vytvoř ručně až je vše hotové. | +| `--msgs-dir PATH` | Přepíše výchozí cestu k .msg souborům (výchozí: `/mnt/JNJEMAILS`). | + +--- + +## Průběh na konzoli + +Každý email na jednom řádku: +``` + 1/69371 OK RE: Protocol deviation CZ10022 jan.novak@its.jnj.com + 2/69371 OK UCO3001: Draft FUL pro DD5-CZ10022 monitor@4gclinical.com + 3/69371 ERR ? ? +``` + +Každých 500 emailů oddělovač s průběhem: +``` + ──────────────────────────────────────────────────────────────────────────────── + Průběh: ok=498 err=2 0.4 msg/s ETA 47h12m + ──────────────────────────────────────────────────────────────────────────────── +``` + +Na konci souhrn: +``` +==================================================== +Vysledek: ok=69300 | skip=0 | err=71 +Celkovy cas: 47h 23m 10s +Dokumentu v kolekci: 69300 +``` + +--- + +## Zdroje dat z každého .msg + +| Pole | Popis | +|---|---| +| Předmět, normalized subject | | +| Odesílatel | email, jméno, SMTP adresa | +| Příjemci To/CC/BCC | strukturovaně `[{type, email, name}]` | +| Čas doručení a odeslání | UTC | +| Tělo | plaintext + HTML (max 2 MB) | +| Přílohy | metadata: jméno, velikost, MIME typ, inline flag | +| Internet headers | X-Originating-IP, Received, DKIM, X-Mailer, ... | +| MAPI | důležitost, citlivost, příznak, konverzační vlákno, kategorie | +| In-Reply-To, References | pro rekonstrukci vlákna | +| Raw MAPI properties | `{0xXXXX: value}` | + +--- + +## Hodnotové kódy + +| Pole | Hodnota | Význam | +|---|---|---| +| `importance` | 0 | Nízká | +| | 1 | Normální | +| | 2 | Vysoká | +| `sensitivity` | 0 | Normální | +| | 1 | Osobní | +| | 2 | Soukromé | +| | 3 | Důvěrné | +| `flag_status` | 0 | Bez příznaku | +| | 1 | Označeno (follow up) | +| | 2 | Dokončeno | + +--- + +## MongoDB indexy + +Automaticky vytvořeny na konci importu (`--no-indexes` přeskočí): + +| Index | Pole | +|---|---| +| Chronologický | `received_at`, `sent_at` | +| Odesílatel | `sender.email` | +| Soubor | `filename` (unique) | +| Konverzace | `conversation_topic` | +| Filtry | `has_attachments`, `categories`, `importance`, `flag_status` | +| Full-text | `subject` + `body_text` + `to` + `cc` (text index `text_search`) | + +--- + +## Ukázkové dotazy (MongoDB shell / MCP) + +**Emaily o UCO3001 s přílohou:** +```javascript +db["vbuzalka@its.jnj.com"].find({ + $text: { $search: "UCO3001" }, + has_attachments: true +}).sort({ received_at: -1 }) +``` + +**Emaily od konkrétního odesílatele:** +```javascript +db["vbuzalka@its.jnj.com"].find({ + "sender.email": /covance/i +}).sort({ received_at: -1 }) +``` + +**Celé konverzační vlákno:** +```javascript +db["vbuzalka@its.jnj.com"].find({ + conversation_topic: "Protocol deviation CZ10022" +}).sort({ received_at: 1 }) +``` + +**Statistiky podle odesílatele (top 20):** +```javascript +db["vbuzalka@its.jnj.com"].aggregate([ + { $group: { _id: "$sender.email", count: { $sum: 1 } } }, + { $sort: { count: -1 } }, + { $limit: 20 } +]) +``` + +--- + +## Chybový log + +Soubory které selhaly jsou zalogovány do **samostatného** `parse_emails_tower_errors.log` vedle skriptu (tj. `/scripts/parse_emails_tower_errors.log` → `\\tower\Scripts\parse_emails_tower_errors.log`). Tento log je oddělený od Graph importu, aby v něm nebyl bordel: +``` +2026-06-08 12:40:33 | open failed [7A3F...0000.msg]: +2026-06-08 12:41:02 | per-dokument selhal [_id=<...>]: +``` + +Stdout (průběh) jde do `parse_emails_tower.log` — rovněž samostatný. + +--- + +## Záchrana problémových .msg (v1.3) + +Některé `.msg` defaultní `extract_msg` neumí otevřít a celý soubor zahodí, **i když email je naprosto v pořádku** (jde otevřít v Outlooku). Tři příčiny a jejich řešení: + +| Příčina | Příklad | Řešení | +|---|---|---| +| Vadná příloha bez `PR_ATTACH_METHOD` | „Attachment method missing" | `errorBehavior=SUPPRESS_ALL` — vadnou přílohu přeskočí, zbytek (tělo, ostatní přílohy) načte | +| Tělo deklaruje codepage 1200 (UTF-16), ale bajty jsou cp1250/gb2312 | české `�` místo diakritiky | raw-OLE čtení + kaskádové dekódování | +| Vnořený email (Outlook item) | „not an MSG file", `extract_msg` vrátí prázdno | raw-OLE čtení klíčových MAPI streamů | + +**Jak to funguje:** + +1. `open_message()` — kaskádové otevření: `normal` → `SUPPRESS_ALL` → `+overrideEncoding` (dle codepage property). +2. **raw-OLE fallback** — když extract_msg vrátí prázdno/`�` nebo musel hádat kódování, klíčová pole (subject, sender, body, html) se dočtou **přímo z OLE streamů** (`__substg1.0_0037`/`0C1A`/`5D01`/`1000`/`1013`) s kaskádovým dekódováním: + ``` + utf-8 (strict) → kódování dle CPID → cp1250 → cp1252 → gb2312 → latin-1 + ``` + Hlavičkám o kódování se **nevěří** (často si protiřečí); bere se první kódování, které projde striktně bez chyby. `utf-8 strict` je silný rozlišovač. + +**Nová pole v dokumentu:** + +| Pole | Význam | +|---|---| +| `parse_mode` | `normal` / `suppress_all` / `override:` — jak byl soubor otevřen | +| `parse_degraded` | `true` = byl potřeba fallback (vadná příloha nebo hádané kódování) | + +**Ověřeno:** všech 126 dříve selhaných souborů z běhu 8.6. se obnoví čistě (74× `suppress_all`, 52× `override:cp1250`), 0 prázdných, 0 s `�`. + +Dohledání degradovaných: +```javascript +db["vbuzalka@its.jnj.com"].find({ parse_degraded: true }) +``` + +--- + +## Výkon + +| Parametr | Hodnota | +|---|---| +| Počet souborů | ~69 000 | +| Rychlost | ~0.4 msg/s (htmlBody dekódování) | +| Odhadovaný čas | 48 hodin | +| Batch size | 200 dokumentů / bulk_write | +| Odhadovaná velikost DB | 2–5 GB | + +--- + +## Závislosti (v Docker image python-runner) + +``` +extract-msg==0.55.0 +olefile +pymongo +python-dateutil +``` + +Image sestaven z `Dockerfile` v `/mnt/user/Scripts/python-runner/`. + +--- + +## Historie verzí + +| Verze | Datum | Změna | +|---|---|---| +| 1.0 | 2026-06-01 | Iniciální verze | +| 1.1 | 2026-06-02 | Nasazení na Unraid Tower v Docker containeru python-runner; MSGS_DIR změněno z SMB share (`\\tower\JNJEMAILS`) na lokální mount (`/mnt/JNJEMAILS`); aktualizován popis spouštění pro `docker exec` | +| 1.2 | 2026-06-08 | **Oprava `to_bson`:** int mimo rozsah int64 (BSON umí jen 8-byte ints) se převede na string — dřív celý `bulk_write` spadl na `MongoDB can only handle up to 8-byte ints` a zahodil celou dávku 200 dokumentů (běh v1.1 z 8.6. neuložil **nic**). `flush()` má fallback per-dokument (vadný záznam zahodí sám, ne celou dávku). `bool()` testován před `int()`. Samostatné logy `parse_emails_tower.log` + `parse_emails_tower_errors.log`. | +| 1.3 | 2026-06-08 | **Záchrana dříve selhaných .msg** (cca 126 z běhu 8.6.): `open_message()` kaskádové otevření (`normal`→`SUPPRESS_ALL`→`+overrideEncoding`) řeší vadné přílohy i „not an MSG file"; **raw-OLE fallback** dočítá subject/sender/body/html přímo z OLE streamů s kaskádovým dekódováním (utf-8 strict→CPID→cp1250…), když extract_msg vrátí prázdno/`�`. Nová pole `parse_mode`, `parse_degraded`. Nová závislost `olefile`. Ověřeno: 126/126 obnoveno čistě. | diff --git a/EmailsImport/parse_emails_tower_v1.3.py b/EmailsImport/parse_emails_tower_v1.3.py new file mode 100644 index 0000000..eb00abc --- /dev/null +++ b/EmailsImport/parse_emails_tower_v1.3.py @@ -0,0 +1,896 @@ +""" +parse_emails_tower_v1.3.py +Nazev: parse_emails_tower_v1.3.py +Verze: 1.3 +Datum: 2026-06-08 +Autor: vladimir.buzalka + +Popis: + Parsuje vsechny .msg soubory z MSGS_DIR a importuje je jako dokumenty + do MongoDB. Z kazdeho souboru extrahuje VSECHNY dostupne vlastnosti — + podobne jako EXIF u fotek: + + - predmet, odesilatel, prijemci (To/CC/BCC s typy) + - cas doruceni a odeslani (UTC) + - telo plaintext + HTML (max 2 MB) + - prilohy (metadata: jmeno, velikost, MIME typ, inline flag) + - internet headers (X-Originating-IP, Received, DKIM, ...) + - MAPI vlastnosti: dulezitost, citlivost, priznak, konverzacni vlakno, + kategorie, In-Reply-To, References, ... + - vsechny raw MAPI properties jako {0xXXXX: value} + + DB: emaily + Kolekce: vbuzalka@its.jnj.com + _id: Internet Message-ID (nebo "filename:" jako fallback) + + Bezpecne prerusit a opakovat: + - upsert podle _id — duplicity se automaticky prepisi + - --skip-existing nacte seznam hotovych souboru z MongoDB a + preskoci je => pokracovani po preruseni bez ztraty prace + +Prostredi: + Bezi v Docker containeru "python-runner" na Unraid Tower. + .msg soubory jsou dostupne jako lokalni disk (volume mount): + /mnt/user/JNJEMAILS -> /mnt/JNJEMAILS (uvnitr containeru) + MongoDB na 192.168.1.76:27017 (externi, bezi mimo container). + +Spousteni (z Unraid terminalu): + # Test na 50 emailech: + docker exec -it python-runner python /scripts/parse_emails_tower_v1.3.py --limit 50 --no-indexes + + # Kompletni import na pozadi (samostatny log, ne sdileny s Graph importem): + docker exec -d python-runner bash -c \ + "python /scripts/parse_emails_tower_v1.3.py > /scripts/parse_emails_tower.log 2>&1" + + # Pokracovani po preruseni: + docker exec -d python-runner bash -c \ + "python /scripts/parse_emails_tower_v1.3.py --skip-existing > /scripts/parse_emails_tower.log 2>&1" + + # Sledovani prubehu: + docker exec -it python-runner tail -f /scripts/parse_emails_tower.log + +Vystup na konzoli: + Kazdy email na jednom radku: + / OK/ERR + Kazych 500 emailu: oddelovac s prubehem, rychlosti a ETA. + Na konci: souhrn ok/skip/err, celkovy cas, pocet dokumentu v kolekci. + +Zavislosti (nainstalovane v Docker image python-runner): + extract-msg==0.55.0, olefile, pymongo, python-dateutil + Python 3.12, Linux (Docker container na Unraid Tower) + (olefile je tranzitivni zavislost extract-msg, raw-OLE fallback ji pouziva primo) + +Struktura dokumentu v MongoDB: + _id Internet Message-ID (nebo filename: fallback) + filename jmeno .msg souboru (20znakovy hex + .msg) + subject predmet zpravy + normalized_subject predmet bez RE:/FW: prefixu + importance 0=nizka 1=normalni 2=vysoka + sensitivity 0=normalni 1=osobni 2=soukrome 3=duverne + flag_status 0=bez priznaku 1=oznaceno 2=dokonceno + read_receipt_requested bool + delivery_receipt_requested bool + has_attachments bool + attachment_count int + message_size_bytes velikost .msg souboru na disku + conversation_topic tema vlakna (PR_CONVERSATION_TOPIC) + conversation_index base64 PR_CONVERSATION_INDEX + in_reply_to Message-ID predchozi zpravy + internet_references [Message-ID] — cela historia vlakna + categories [str] — MAPI kategorie / stitky + read_receipt_requested bool + delivery_receipt_requested bool + received_at datetime UTC — cas doruceni + sent_at datetime UTC — cas odeslani + sender.email emailova adresa odesilatele + sender.name zobrazovane jmeno odesilatele + sender.smtp SMTP adresa (pro interni EX adresy) + to retezec To (tak jak v Outlooku) + cc retezec CC + bcc retezec BCC + display_to PR_DISPLAY_TO (zkraceny seznam) + display_cc PR_DISPLAY_CC + recipients [{type, email, name}] — to/cc/bcc s typy + body_text plain text telo + body_html HTML telo (max 2 MB, None pokud neni) + attachments [{filename, size_bytes, mime_type, + content_id, is_inline}] + headers dict internet headers (lowercase_s_podtrzitky) + mapi dict vsech raw MAPI properties {0xXXXX: value} + parsed_at datetime UTC — cas parsovani + +Indexy (vytvoreny automaticky na konci): + received_at, sent_at, sender.email, filename (unique), + conversation_topic, has_attachments, categories, importance, + flag_status, text_search (subject + body_text + to + cc) + +Chyby: + Soubory ktere selhaly jsou zalogovany do parse_emails_tower_errors.log + v adresari skriptu (SAMOSTATNY log, oddeleny od Graph importu). + Radek: timestamp | open/extract failed | duvod. + +Historie verzi: + 1.0 2026-06-01 Inicialni verze + 1.1 2026-06-02 Nasazeni na Unraid Tower v Docker containeru python-runner; + MSGS_DIR zmeneno z SMB share na lokalni mount /mnt/JNJEMAILS; + aktualizovany popis spousteni pro docker exec + 1.2 2026-06-08 OPRAVA: to_bson prevadi int mimo rozsah int64 na string + (BSON umi jen 8-byte ints) — drive cely bulk_write spadl na + 'MongoDB can only handle up to 8-byte ints' a zahodil celou + davku 200 dokumentu (v1.1 beh 8.6. neulozil NIC). + flush() ma fallback per-dokument: vadny zaznam zahodi sam, + ne celou davku. bool() testovan pred int(). + Samostatny error log parse_emails_tower_errors.log a + stdout log parse_emails_tower.log (drive sdilene s Graph + importem — bordel v logu). + 1.3 2026-06-08 ZACHRANA drive selhavajicich .msg (cca 126 z behu 8.6.): + - open_message(): kaskadove otevreni + normal -> SUPPRESS_ALL (vadne prilohy) -> +overrideEncoding + Resi 'Attachment method missing' i 'not an MSG file'. + - raw-OLE fallback: kdyz extract_msg vrati prazdno/� (vnoreny + email, codepage 1200 lze byt cp1250/gb2312), klicova pole + (subject/sender/body/html) se doctou PRIMO z OLE streamu + s kaskadovym dekodovanim (utf-8 strict -> CPID -> cp1250 ...). + Hlavickam o kodovani se neveri (casto si protireci). + - nova pole: parse_mode (normal/suppress_all/override:ENC), + parse_degraded (bool). +""" + +import sys +import re +import logging +import argparse +import base64 +import struct +from pathlib import Path +from datetime import datetime, timezone +from typing import Optional + +import extract_msg +from extract_msg.enums import ErrorBehavior +import olefile +from dateutil import parser as dtparser +from pymongo import MongoClient, UpdateOne, ASCENDING, TEXT + +if hasattr(sys.stdout, "reconfigure"): + sys.stdout.reconfigure(encoding="utf-8", errors="replace") + +# ─── KONFIGURACE ────────────────────────────────────────────────────────────── +MSGS_DIR = Path("/mnt/JNJEMAILS") +MONGO_URI = "mongodb://192.168.1.76:27017" +MONGO_DB = "emaily" +MONGO_COL = "vbuzalka@its.jnj.com" +BATCH_SIZE = 200 +LOG_FILE = Path(__file__).parent / "parse_emails_tower_errors.log" +SCRIPT_VERSION = "1.2" +# ────────────────────────────────────────────────────────────────────────────── + +logging.basicConfig( + filename=str(LOG_FILE), + level=logging.ERROR, + format="%(asctime)s | %(message)s", + datefmt="%Y-%m-%d %H:%M:%S", + encoding="utf-8", +) + + +# ─── Pomocné funkce ─────────────────────────────────────────────────────────── + +def safe(obj, *attrs, default=None): + """Bezpecne cteni atributu — vrati prvni non-None hodnotu.""" + for attr in attrs: + try: + val = getattr(obj, attr, None) + if val is None: + continue + if isinstance(val, str) and not val.strip(): + continue + return val + except Exception: + continue + return default + + +def parse_date(raw) -> Optional[datetime]: + """Libovolny datum -> UTC datetime bez tzinfo (pro MongoDB).""" + if raw is None: + return None + if isinstance(raw, datetime): + if raw.tzinfo: + return raw.astimezone(timezone.utc).replace(tzinfo=None) + return raw + try: + dt = dtparser.parse(str(raw)) + if dt.tzinfo: + return dt.astimezone(timezone.utc).replace(tzinfo=None) + return dt + except Exception: + return None + + +_INT64_MIN, _INT64_MAX = -(2 ** 63), 2 ** 63 - 1 + + +def to_bson(val): + """Konvertuje hodnotu na BSON-serializovatelny typ. + + Pozor: BSON umi jen signed int64. Python ma neomezene integery, takze + velke MAPI hodnoty (PR_CHANGE_KEY, FILETIME, 64-bit handle) mimo rozsah + int64 prevadime na string — jinak cely bulk_write spadne na + 'MongoDB can only handle up to 8-byte ints'. + """ + # bool musi byt PRED int (isinstance(True, int) == True) + if isinstance(val, bool): + return val + if isinstance(val, bytes): + return val.hex() if len(val) <= 128 else f"" + if isinstance(val, datetime): + return parse_date(val) + if isinstance(val, int): + return val if _INT64_MIN <= val <= _INT64_MAX else str(val) + if isinstance(val, (str, float, type(None))): + return val + if isinstance(val, list): + return [to_bson(v) for v in val] + try: + iv = int(val) + return iv if _INT64_MIN <= iv <= _INT64_MAX else str(iv) + except Exception: + pass + return str(val) + + +# ─── Extrakce částí zprávy ──────────────────────────────────────────────────── + +def extract_headers(msg) -> dict: + headers = {} + try: + hdr = msg.header + if not hdr: + return {} + from email.header import decode_header as _dh + + def _decode(v: str) -> str: + try: + parts = _dh(v) + out = "" + for part, enc in parts: + out += part.decode(enc or "utf-8", errors="replace") if isinstance(part, bytes) else part + return out + except Exception: + return v + + for key in set(hdr.keys()): + k = key.lower().replace("-", "_") + vals = [_decode(v) for v in hdr.get_all(key, [])] + headers[k] = vals if len(vals) > 1 else (vals[0] if vals else "") + except Exception as e: + logging.error("extract_headers: %s", e) + return headers + + +def extract_recipients(msg) -> list: + result = [] + type_map = {1: "to", 2: "cc", 3: "bcc"} + try: + for r in msg.recipients: + rtype = getattr(r, "type", 1) + try: + rtype = int(rtype) + except Exception: + try: + rtype = int(rtype.value) + except Exception: + rtype = 1 + rec = { + "type": type_map.get(rtype, "to"), + "email": safe(r, "email", default=""), + "name": safe(r, "name", default=""), + } + result.append(rec) + except Exception as e: + logging.error("extract_recipients: %s", e) + return result + + +def extract_attachments(msg) -> list: + result = [] + try: + for att in msg.attachments: + fname = safe(att, "longFilename", "shortFilename", default="") + if not fname: + continue + size = 0 + try: + d = att.data + size = len(d) if d else 0 + except Exception: + pass + result.append({ + "filename": fname, + "size_bytes": size, + "mime_type": safe(att, "mimetype", "mimeType", default="application/octet-stream"), + "content_id": safe(att, "cid", default=None), + "is_inline": bool(safe(att, "isInline", default=False)), + }) + except Exception as e: + logging.error("extract_attachments: %s", e) + return result + + +def extract_mapi_props(msg) -> dict: + """Vsechny raw MAPI properties jako {0xXXXX: value}.""" + result = {} + try: + props = msg.props + if not hasattr(props, "items"): + return {} + for key, prop in props.items(): + try: + val = to_bson(prop.value) + prop_id = f"0x{key[:4].upper()}" if len(key) >= 4 else f"0x{key.upper()}" + result[prop_id] = val + except Exception: + pass + except Exception as e: + logging.error("extract_mapi_props: %s", e) + return result + + +# ─── Tolerantní otevírání a raw-OLE fallback ───────────────────────────────── +# +# Nektere .msg extract_msg neumi: (a) vadna priloha bez PR_ATTACH_METHOD, +# (b) telo deklaruje codepage 1200 (UTF-16) ale bajty jsou cp1250/gb2312, +# (c) vnoreny email ("not an MSG file") — extract_msg vrati prazdne pole. +# Data v souboru ale jsou. Otevreme tolerantne a degradovana textova pole +# docteme PRIMO z OLE streamu s kaskadovym dekodovanim (hlavickam se neveri). + +# Windows codepage -> python codec (PR_INTERNET_CPID / PR_MESSAGE_CODEPAGE) +_CPID_TO_CODEC = { + 1250: "cp1250", 1251: "cp1251", 1252: "cp1252", 1253: "cp1253", + 1254: "cp1254", 1255: "cp1255", 1256: "cp1256", 1257: "cp1257", + 1258: "cp1258", 874: "cp874", 932: "shift_jis", 936: "gb2312", + 949: "euc_kr", 950: "big5", 65001: "utf-8", 28591: "iso-8859-1", + 28592: "iso-8859-2", 20127: "ascii", +} + + +def _read_u32_prop(ole, propid): + """Precte 32-bit hodnotu MAPI property z top-level __properties_version1.0.""" + try: + data = ole.openstream("__properties_version1.0").read() + except Exception: + return None + body = data[32:] # 32-bajtova hlavicka top-level property streamu + for i in range(0, len(body) - 16 + 1, 16): + rec = body[i:i + 16] + tag = struct.unpack("> 16) & 0xFFFF) == propid: + return struct.unpack(" Optional[str]: + """Codec dle PR_INTERNET_CPID / PR_MESSAGE_CODEPAGE (jako napoveda, ne dogma).""" + for pid in (0x3FDE, 0x3FFD): # INTERNET_CPID, MESSAGE_CODEPAGE + codec = _CPID_TO_CODEC.get(_read_u32_prop(ole, pid)) + # utf-8/ascii nejsou dobry hint pro 8-bit stream (casto lzou) + if codec and codec not in ("utf-8", "ascii"): + return codec + return None + + +def _cascade_decode(raw: bytes, is_unicode: bool, cpid_codec: Optional[str]) -> str: + """Dekoduje bajty MAPI stringu. Hlavickam se neveri — zkousime striktne + v poradi priorit a vezmeme prvni, co projde bez chyby.""" + if not raw: + return "" + if is_unicode: # PT_UNICODE = utf-16-le + try: + return raw.decode("utf-16-le") + except Exception: + return raw.decode("utf-16-le", errors="replace") + order = ["utf-8"] # utf-8 strict = silny rozlisovac + if cpid_codec: + order.append(cpid_codec) + order += ["cp1250", "cp1252", "gb2312", "big5"] + for enc in order: + try: + return raw.decode(enc, errors="strict") + except Exception: + continue + return raw.decode("latin-1", errors="replace") # nikdy nespadne + + +def _raw_mapi_strings(msg_path: Path) -> dict: + """Cte klicova textova MAPI pole PRIMO z OLE (mimo extract_msg). + Pouzije se jen kdyz extract_msg vrati degradovane pole.""" + out = {"subject": "", "normalized_subject": "", "sender_name": "", + "sender_email": "", "sender_smtp": "", "body_text": "", "body_html": ""} + try: + ole = olefile.OleFileIO(str(msg_path)) + except Exception: + return out + try: + cpid = _detect_cpid(ole) + wanted = { # MAPI tag -> klic v out + "0037": "subject", "0E1D": "normalized_subject", + "0C1A": "sender_name", "5D01": "sender_smtp", + "0C1F": "sender_email", "1000": "body_text", "1013": "body_html", + } + prefix = "__substg1.0_" + found = {} # key -> (priorita_typu, hodnota) + for entry in ole.listdir(): + if len(entry) != 1: # jen top-level (ne vnorene zpravy) + continue + name = entry[0] + if not name.startswith(prefix): + continue + tag = name[len(prefix):len(prefix) + 4].upper() + key = wanted.get(tag) + if not key: + continue + typ = name[-4:].upper() + prio = {"001F": 3, "001E": 2, "0102": 1}.get(typ, 0) + if prio == 0: + continue + prev = found.get(key) + if prev and prev[0] >= prio: # preferuj unicode > ansi > binarni + continue + try: + raw = ole.openstream(entry).read() + val = _cascade_decode(raw, typ == "001F", cpid) + except Exception: + continue + found[key] = (prio, val) + for key, (_, val) in found.items(): + out[key] = val + finally: + ole.close() + return out + + +def _degraded(s) -> bool: + """Pole je degradovane: prazdne nebo obsahuje U+FFFD (nahradni znak).""" + return (not s) or ("�" in s) + + +def open_message(msg_path: Path): + """Kaskadove otevreni .msg -> (msg, mode) nebo (None, None). + normal bezna cesta + suppress_all tolerantni k vadnym prilohum + override:ENC tolerantni + vnuceny encoding dle codepage property + """ + try: + return extract_msg.Message(str(msg_path)), "normal" + except Exception: + pass + try: + return extract_msg.Message( + str(msg_path), errorBehavior=ErrorBehavior.SUPPRESS_ALL), "suppress_all" + except Exception: + pass + encs = [] + try: + ole = olefile.OleFileIO(str(msg_path)) + c = _detect_cpid(ole) + ole.close() + if c: + encs.append(c) + except Exception: + pass + for e in encs + ["cp1250", "cp1252"]: + try: + return extract_msg.Message( + str(msg_path), errorBehavior=ErrorBehavior.SUPPRESS_ALL, + overrideEncoding=e), f"override:{e}" + except Exception: + continue + return None, None + + +# ─── Hlavní extrakce ───────────────────────────────────────────────────────── + +def extract_message(msg_path: Path) -> Optional[dict]: + """Parsuje jeden .msg soubor -> MongoDB dokument.""" + msg, parse_mode = open_message(msg_path) + if msg is None: + logging.error("open failed [%s]: vsechny pokusy o otevreni selhaly", msg_path.name) + return None + + try: + # ── Message-ID ──────────────────────────────────────────────── + mid = None + for attr in ("messageId", "message_id", "internetMessageId"): + mid = safe(msg, attr) + if mid: + break + if not mid: + mid = f"filename:{msg_path.stem}" + mid = str(mid).strip() + + # ── Předmět ─────────────────────────────────────────────────── + try: + subject = msg.subject or "" + except Exception: + subject = "" + + normalized_subject = safe(msg, "normalizedSubject", "normalized_subject", default="") + + # ── Tělo ────────────────────────────────────────────────────── + try: + body_text = msg.body or "" + except Exception: + body_text = "" + + body_html = None + try: + bh = msg.htmlBody + if isinstance(bh, bytes): + bh = bh.decode("utf-8", errors="replace") + if bh: + body_html = bh if len(bh) <= 2 * 1024 * 1024 else bh[:2 * 1024 * 1024] + except Exception: + pass + + # ── Odesílatel ──────────────────────────────────────────────── + try: + sender_email = msg.sender or "" + except Exception: + sender_email = "" + + sender_name = safe(msg, "senderName", "sender_name", default="") + sender_smtp = safe(msg, "senderSmtpAddress", "sent_representing_smtp_address", default="") + + # ── Příjemci ────────────────────────────────────────────────── + recipients = extract_recipients(msg) + + try: + to_raw = msg.to or "" + except Exception: + to_raw = "" + try: + cc_raw = msg.cc or "" + except Exception: + cc_raw = "" + try: + bcc_raw = getattr(msg, "bcc", None) or "" + except Exception: + bcc_raw = "" + + display_to = safe(msg, "displayTo", "display_to", default="") + display_cc = safe(msg, "displayCc", "display_cc", default="") + + # ── Časy ────────────────────────────────────────────────────── + try: + received_at = parse_date(msg.date) + except Exception: + received_at = None + + sent_at = None + for attr in ("clientSubmitTime", "client_submit_time", "sentOn"): + v = safe(msg, attr) + if v: + sent_at = parse_date(v) + break + + # ── MAPI vlastnosti ─────────────────────────────────────────── + importance = 1 + try: + v = msg.importance + if v is not None: + importance = int(v) + except Exception: + pass + + sensitivity = 0 + try: + v = getattr(msg, "sensitivity", None) + if v is not None: + sensitivity = int(v) + except Exception: + pass + + flag_status = 0 + try: + v = safe(msg, "flagStatus", "flag_status") + if v is not None: + flag_status = int(v) + except Exception: + pass + + conversation_topic = safe(msg, "conversationTopic", "conversation_topic", default="") + + conversation_index = "" + try: + ci = safe(msg, "conversationIndex", "conversation_index") + if isinstance(ci, bytes): + conversation_index = base64.b64encode(ci).decode() + elif ci: + conversation_index = str(ci) + except Exception: + pass + + in_reply_to = safe(msg, "inReplyTo", "in_reply_to", default="") + + internet_refs = [] + try: + refs = safe(msg, "internetReferences", "internet_references") + if isinstance(refs, list): + internet_refs = refs + elif isinstance(refs, str) and refs: + internet_refs = [r.strip() for r in refs.split() if r.strip()] + except Exception: + pass + + categories = [] + try: + cats = safe(msg, "categories") + if isinstance(cats, list): + categories = [str(c) for c in cats if c] + elif isinstance(cats, str) and cats: + categories = [c.strip() for c in re.split(r"[;,]", cats) if c.strip()] + except Exception: + pass + + read_receipt = bool(safe(msg, "readReceiptRequested", "read_receipt_requested", default=False)) + delivery_receipt = bool(safe(msg, "deliveryReceiptRequested", "delivery_receipt_requested", default=False)) + + # ── Internet headers ────────────────────────────────────────── + headers = extract_headers(msg) + + if not in_reply_to: + in_reply_to = headers.get("in_reply_to", "") + if not internet_refs: + refs_str = headers.get("references", "") + if isinstance(refs_str, str) and refs_str: + internet_refs = [r.strip() for r in refs_str.split() if r.strip()] + + # ── Přílohy ─────────────────────────────────────────────────── + attachments = extract_attachments(msg) + + # ── Raw MAPI ────────────────────────────────────────────────── + mapi_raw = extract_mapi_props(msg) + + msg.close() + + # ── Raw-OLE fallback pro degradovana textova pole ───────────── + # Kdyz extract_msg vratil prazdno/� nebo musel hadat encoding + # (override/suppress), docteme klicova pole primo z OLE streamu + # kaskadovym dekodovanim — spolehlivejsi nez jeden vnuceny encoding. + parse_degraded = parse_mode != "normal" + # v non-normal modu byl encoding hadany -> raw kaskade se veri vic + forced = parse_mode != "normal" + if (forced or _degraded(subject) or _degraded(body_text) + or _degraded(sender_email) or (body_html and "�" in body_html)): + raw = _raw_mapi_strings(msg_path) + if raw["subject"] and (forced or _degraded(subject)): + subject = raw["subject"] + if raw["normalized_subject"] and (forced or _degraded(normalized_subject)): + normalized_subject = raw["normalized_subject"] + if raw["body_text"] and (forced or _degraded(body_text)): + body_text = raw["body_text"] + if raw["body_html"] and (forced or not body_html or "�" in body_html): + bh = raw["body_html"] + body_html = bh if len(bh) <= 2 * 1024 * 1024 else bh[:2 * 1024 * 1024] + if (raw["sender_smtp"] or raw["sender_email"]) and (forced or _degraded(sender_email)): + sender_email = raw["sender_smtp"] or raw["sender_email"] + if raw["sender_name"] and (forced or _degraded(sender_name)): + sender_name = raw["sender_name"] + if raw["sender_smtp"] and not sender_smtp: + sender_smtp = raw["sender_smtp"] + + # ── Dokument ────────────────────────────────────────────────── + return { + "_id": mid, + "filename": msg_path.name, + + "subject": subject, + "normalized_subject": normalized_subject, + "importance": importance, + "sensitivity": sensitivity, + "flag_status": flag_status, + "read_receipt_requested": read_receipt, + "delivery_receipt_requested": delivery_receipt, + "has_attachments": len(attachments) > 0, + "attachment_count": len(attachments), + "message_size_bytes": msg_path.stat().st_size, + + "conversation_topic": conversation_topic, + "conversation_index": conversation_index, + "in_reply_to": in_reply_to, + "internet_references": internet_refs, + "categories": categories, + + "received_at": received_at, + "sent_at": sent_at, + + "sender": { + "email": sender_email, + "name": sender_name, + "smtp": sender_smtp, + }, + "to": to_raw, + "cc": cc_raw, + "bcc": bcc_raw, + "display_to": display_to, + "display_cc": display_cc, + "recipients": recipients, + + "body_text": body_text, + "body_html": body_html, + + "attachments": attachments, + "headers": headers, + "mapi": mapi_raw, + + "parse_mode": parse_mode, # normal / suppress_all / override:ENC + "parse_degraded": parse_degraded, # True = pouzit fallback (vadna priloha/encoding) + + "parsed_at": datetime.now(timezone.utc).replace(tzinfo=None), + } + + except Exception as e: + logging.error("extract_message failed [%s]: %s", msg_path.name, e) + return None + + +# ─── MongoDB indexy ─────────────────────────────────────────────────────────── + +def create_indexes(col): + print(" Vytvarim indexy...") + col.create_index([("received_at", ASCENDING)]) + col.create_index([("sent_at", ASCENDING)]) + col.create_index([("sender.email", ASCENDING)]) + col.create_index([("filename", ASCENDING)], unique=True, sparse=True) + col.create_index([("conversation_topic", ASCENDING)]) + col.create_index([("has_attachments", ASCENDING)]) + col.create_index([("categories", ASCENDING)]) + col.create_index([("importance", ASCENDING)]) + col.create_index([("flag_status", ASCENDING)]) + col.create_index([ + ("subject", TEXT), + ("body_text", TEXT), + ("to", TEXT), + ("cc", TEXT), + ], name="text_search", default_language="none") + print(" Indexy hotovy.") + + +# ─── MAIN ───────────────────────────────────────────────────────────────────── + +def main(): + ap = argparse.ArgumentParser(description=f"parse_emails v{SCRIPT_VERSION}") + ap.add_argument("--msgs-dir", default=str(MSGS_DIR), + help="Cesta k .msg souborum") + ap.add_argument("--limit", type=int, default=0, + help="Zpracovat max N souboru (0 = vse)") + ap.add_argument("--skip-existing", action="store_true", + help="Preskocit soubory ktere jiz jsou v MongoDB (pokracovani)") + ap.add_argument("--no-indexes", action="store_true", + help="Nevytvorit indexy na konci") + args = ap.parse_args() + + msgs_dir = Path(args.msgs_dir) + start = datetime.now() + + print(f"=== parse_emails v{SCRIPT_VERSION} ===") + print(f"Start: {start.strftime('%Y-%m-%d %H:%M:%S')}") + print(f"Zdroj: {msgs_dir}") + print(f"MongoDB: {MONGO_URI} -> {MONGO_DB}.{MONGO_COL}") + + # MongoDB + client = MongoClient(MONGO_URI, serverSelectionTimeoutMS=5000) + try: + client.admin.command("ping") + print(" MongoDB OK") + except Exception as e: + print(f" CHYBA: MongoDB neni dostupna -- {e}") + sys.exit(1) + + col = client[MONGO_DB][MONGO_COL] + + # Skip existing — nacti seznam uz importovanych souboru + existing: set = set() + if args.skip_existing: + print(" Nacitam existujici zaznamy z MongoDB...") + existing = set(col.distinct("filename")) + print(f" {len(existing)} jiz importovano") + + # Scan + print(f"\nSkenuji {msgs_dir} ...") + all_files = sorted(msgs_dir.glob("*.msg")) + if args.limit: + all_files = all_files[:args.limit] + + to_process = [f for f in all_files if f.name not in existing] + skipped = len(all_files) - len(to_process) + total = len(to_process) + + print(f" Celkem .msg: {len(all_files)}") + print(f" Preskoceno: {skipped}") + print(f" Ke zpracovani: {total}\n") + + if total == 0: + print("Neni co importovat.") + client.close() + return + + batch = [] + ok_count = 0 + err_count = 0 + + def flush(): + nonlocal ok_count, err_count + if not batch: + return + try: + col.bulk_write(batch, ordered=False) + except Exception as e: + # Cely batch spadl (typicky jeden vadny dokument). Zkusime + # ho zapsat dokument po dokumentu, aby chyba zahodila jen + # skutecne vadny zaznam, ne celych BATCH_SIZE. + logging.error("bulk_write spadl (%s) -- prepinam na per-dokument", e) + print(f" CHYBA bulk_write: {e} -- zkousim per-dokument") + for op in batch: + try: + col.bulk_write([op], ordered=False) + except Exception as e2: + try: + bad_id = getattr(op, "_filter", {}).get("_id", "?") + except Exception: + bad_id = "?" + logging.error("per-dokument selhal [_id=%s]: %s", bad_id, e2) + print(f" ZAHOZEN _id={bad_id}: {e2}") + ok_count -= 1 + err_count += 1 + batch.clear() + + for i, msg_path in enumerate(to_process, 1): + doc = extract_message(msg_path) + + if doc is None: + err_count += 1 + else: + batch.append(UpdateOne({"_id": doc["_id"]}, {"$set": doc}, upsert=True)) + ok_count += 1 + + if len(batch) >= BATCH_SIZE: + flush() + + # Výpis každého emailu + status = "ERR " if doc is None else "OK " + subject_str = (doc.get("subject") or "")[:60] if doc else "?" + sender_str = (doc.get("sender", {}).get("email") or "")[:40] if doc else "?" + print(f" {i:>6}/{total} {status} {subject_str:<60} {sender_str}") + + if i % 500 == 0: + elapsed = (datetime.now() - start).total_seconds() + rate = i / elapsed if elapsed > 0 else 0 + eta_s = int((total - i) / rate) if rate > 0 else 0 + print(f" {'─'*80}") + print(f" Průběh: ok={ok_count} err={err_count} " + f"{rate:.1f} msg/s ETA {eta_s//3600}h{(eta_s%3600)//60}m") + print(f" {'─'*80}") + + flush() + + elapsed_total = (datetime.now() - start).total_seconds() + print(f"\n{'='*52}") + print(f"Vysledek: ok={ok_count} | skip={skipped} | err={err_count}") + print(f"Celkovy cas: {int(elapsed_total//3600)}h {int((elapsed_total%3600)//60)}m {int(elapsed_total%60)}s") + print(f"Dokumentu v kolekci: {col.count_documents({})}") + + if not args.no_indexes: + print() + create_indexes(col) + + print(f"\nKonec: {datetime.now().strftime('%Y-%m-%d %H:%M:%S')}") + if err_count: + print(f"Chyby logovany do: {LOG_FILE}") + + client.close() + + +if __name__ == "__main__": + main() diff --git a/JanssenScripts/FileWatchAndSend/Trash/janssenpc_file_receive.py b/JanssenScripts/FileWatchAndSend/Trash/janssenpc_file_receive.py new file mode 100644 index 0000000..bbc0789 --- /dev/null +++ b/JanssenScripts/FileWatchAndSend/Trash/janssenpc_file_receive.py @@ -0,0 +1,84 @@ +# Název: janssenpc_file_receive.py +# Verze: 1.0 +# Datum: 2026-06-05 +# Popis: Stáhne soubory čekající na serveru (msgs.buzalka.cz) do ##JNJPrenos\ZHovorcovic\. +# Spouštět ručně dle potřeby. + +import base64 +import hashlib +import requests +from pathlib import Path +from datetime import datetime +from cryptography.fernet import Fernet + +TOKEN = "13e1bb01-9fd5-44a8-8ce9-4ee27133d340" +# POKUS: neutrální názvy endpointů, aby je JNJ proxy nepráskala podle klíčových slov. +# Server musí mít stejně přejmenované routy (/status, /item), jinak vrátí 404! +PENDING_URL = "https://msgs.buzalka.cz/status" +DOWNLOAD_URL = "https://msgs.buzalka.cz/item" +RECEIVE_DIR = Path(r"C:\Users\vbuzalka\OneDrive - JNJ\##JNJPrenos\ZHovorcovic") +LOG_FILE = Path(__file__).parent / "file_send.log" +_FERNET = Fernet(base64.urlsafe_b64encode(hashlib.sha256(TOKEN.encode()).digest())) + + +def log(msg: str): + ts = datetime.now().strftime('%Y-%m-%d %H:%M:%S') + line = f"[{ts}] {msg}" + print(line) + with LOG_FILE.open("a", encoding="utf-8") as lf: + lf.write(line + "\n") + + +def resolve_dest(directory: Path, filename: str) -> Path: + """Přepíše existující soubor, pokud je zamčený → name (2), (3)...""" + dest = directory / filename + if not dest.exists(): + return dest + try: + dest.open('r+b').close() + return dest + except PermissionError: + pass + stem = Path(filename).stem + suffix = Path(filename).suffix + n = 2 + while True: + candidate = directory / f"{stem} ({n}){suffix}" + if not candidate.exists(): + return candidate + try: + candidate.open('r+b').close() + return candidate + except PermissionError: + n += 1 + + +log("=== file_receive: Spuštění ===") + +try: + resp = requests.get(PENDING_URL, headers={"Authorization": f"Bearer {TOKEN}"}, timeout=30) + resp.raise_for_status() + pending = resp.json().get("files", []) + log(f"Souborů čeká na serveru: {len(pending)}{' — ' + str(pending) if pending else ''}") +except Exception as e: + log(f"CHYBA při dotazu na server: {e}") + pending = [] + +if pending: + RECEIVE_DIR.mkdir(parents=True, exist_ok=True) + for filename in pending: + try: + r = requests.get( + f"{DOWNLOAD_URL}/{filename}", + headers={"Authorization": f"Bearer {TOKEN}"}, + timeout=120, + ) + r.raise_for_status() + decrypted = _FERNET.decrypt(r.content) + dest = resolve_dest(RECEIVE_DIR, filename) + dest.write_bytes(decrypted) + log(f" STAŽENO | {filename}{' → ' + dest.name if dest.name != filename else ''}") + except Exception as e: + log(f" CHYBA | {filename} | {e}") + +log("=== file_receive: Hotovo ===") diff --git a/JanssenScripts/FileWatchAndSend/janssenpc_file_receive_v1.1.py b/JanssenScripts/FileWatchAndSend/janssenpc_file_receive_v1.1.py new file mode 100644 index 0000000..2b871be --- /dev/null +++ b/JanssenScripts/FileWatchAndSend/janssenpc_file_receive_v1.1.py @@ -0,0 +1,95 @@ +# Název: janssenpc_file_receive_v1.1.py +# Verze: 1.1 +# Datum: 2026-06-08 +# Popis: Stáhne soubory čekající na serveru (msgs.buzalka.cz) do ##JNJPrenos\ZHovorcovic\. +# Spouštět ručně dle potřeby. +# +# Změna v1.1: +# Jména souborů ze /status jsou Fernet tokeny (zašifrované původní názvy). +# Klient je pošle beze změny jako URL token do /item/{token} — Zscaler vidí +# jen neprůhledný řetězec, ne skutečné jméno souboru (bypass DLP). +# Po stažení a dešifrování obsahu klient dešifruje i token → původní jméno → uloží. + +import base64 +import hashlib +import requests +from pathlib import Path +from datetime import datetime +from cryptography.fernet import Fernet + +TOKEN = "13e1bb01-9fd5-44a8-8ce9-4ee27133d340" +PENDING_URL = "https://msgs.buzalka.cz/status" +DOWNLOAD_URL = "https://msgs.buzalka.cz/item" +RECEIVE_DIR = Path(r"C:\Users\vbuzalka\OneDrive - JNJ\##JNJPrenos\ZHovorcovic") +LOG_FILE = Path(__file__).parent / "file_send.log" +_FERNET = Fernet(base64.urlsafe_b64encode(hashlib.sha256(TOKEN.encode()).digest())) + + +def log(msg: str): + ts = datetime.now().strftime('%Y-%m-%d %H:%M:%S') + line = f"[{ts}] {msg}" + print(line) + with LOG_FILE.open("a", encoding="utf-8") as lf: + lf.write(line + "\n") + + +def resolve_dest(directory: Path, filename: str) -> Path: + """Přepíše existující soubor, pokud je zamčený → name (2), (3)...""" + dest = directory / filename + if not dest.exists(): + return dest + try: + dest.open('r+b').close() + return dest + except PermissionError: + pass + stem = Path(filename).stem + suffix = Path(filename).suffix + n = 2 + while True: + candidate = directory / f"{stem} ({n}){suffix}" + if not candidate.exists(): + return candidate + try: + candidate.open('r+b').close() + return candidate + except PermissionError: + n += 1 + + +log("=== file_receive: Spuštění ===") + +try: + resp = requests.get(PENDING_URL, headers={"Authorization": f"Bearer {TOKEN}"}, timeout=30) + resp.raise_for_status() + pending = resp.json().get("files", []) # seznam Fernet tokenů + log(f"Souborů čeká na serveru: {len(pending)}") +except Exception as e: + log(f"CHYBA při dotazu na server: {e}") + pending = [] + +if pending: + RECEIVE_DIR.mkdir(parents=True, exist_ok=True) + for enc_token in pending: + # Dešifruj token → původní jméno souboru (pro log + uložení) + try: + orig_filename = _FERNET.decrypt(enc_token.encode()).decode() + except Exception as e: + log(f" CHYBA (dešifrování jména) | {enc_token[:20]}... | {e}") + continue + + try: + r = requests.get( + f"{DOWNLOAD_URL}/{enc_token}", + headers={"Authorization": f"Bearer {TOKEN}"}, + timeout=120, + ) + r.raise_for_status() + decrypted = _FERNET.decrypt(r.content) + dest = resolve_dest(RECEIVE_DIR, orig_filename) + dest.write_bytes(decrypted) + log(f" STAŽENO | {orig_filename}{' → ' + dest.name if dest.name != orig_filename else ''}") + except Exception as e: + log(f" CHYBA | {orig_filename} | {e}") + +log("=== file_receive: Hotovo ===") diff --git a/Soubory/enrich_files_v1.0.md b/Soubory/enrich_files_v1.0.md index 4e2718c..e8811b1 100644 --- a/Soubory/enrich_files_v1.0.md +++ b/Soubory/enrich_files_v1.0.md @@ -20,7 +20,7 @@ Spouští se **až po** [scan_files_v1.0.py](scan_files_v1.0.md). | eml | stdlib email | subject, from, to, cc, date, has_attachments, attachments[], body_head | | msg | extract_msg | totéž co eml | -Společná pole vždy: `ok` (bool), `parsed_at`, `parser_version`, `sha256_at_parse`. Při chybě `error` (název výjimky + zpráva). +S[DRY](../DRY)polečná pole vždy: `ok` (bool), `parsed_at`, `parser_version`, `sha256_at_parse`. Při chybě `error` (název výjimky + zpráva). ## Inkrementální chování Zpracují se jen dokumenty kde:

      TV9BZsauT9Wv)K zYA*jPzQ*-@M!hX)R9YdUelBcOlcGkQLZG-&uQ0rXQR{FYX(f#shuP>~ig-&Kbqk)d zoP)cZQM+-cJT<9cR7q4rgNjDo!!MPLvR5|hH^fviY9!LD8s-1asH&)s_BDtV6~1R2 zj{IO$*IGtJ)HZ4%j^H9{*D-2VU89!cE|%0Y>O*~_b~H2UG2UZpbJlJ_j;)Pq*2bs_ zZH+pBH+azAD02s+1|h7IQHiL43uxQLsKZ^2%GQ$};z}>0p8aIhnBMfG554baRKEd6 zeK*Lce+IMO5cbM2zRC&f^(I zb(~|=qq#<9nP*fBoSM%Zi;PNIYE-UOMzzC<)kf7^$NU?NI=a!QQJd)5W^&wO)Y@%E zrS2eyo#ctj7`=zRwU;;!)1Nb}cZF-O8CB{5aiBjkKV*Mk!Xx(CW7c{~ZSWp#o*7l( zxlsdNu>Y|ZE&nxY(mSJ8y*JAE!KeimlO|YADq}Ng8J62ksvc_6YFHg6)x*6olYVlV zGzJ?`Fv6tFktU@gQx-mAJO0RK(pHa2xx6Or$1T*4H|YqPByb*qM3bJOO|nT|ze#yh zOxlJ%IZWD>%cR+POsbQY>++ctRnVl-C|lU1X((O9q={%<)TG@gR?MWsB~1Fgf=QN& zCUwID{8@?XtC>`{x=A~*<$IF~)iY^q1CwetG3iiKlh!vg=^$*)O?rx;7SsWYkg=sn zGcl>PNlTEujY*Z-nY6D1Yj)(CP9~*vHYv6Xb?a(U!)_)u?nlo3O)5N)`l0O4CUqKY z(xss$tsG|36=WVkJR?oIj5DLC)o9ilV^Z8WlYHZue}YLBrkd0b6Q-NAcm{QwMP2X? zIcJ+R7f0cmW74L%CN*2gx@fn^r1_Y-*rfbROzMt3_=-BqOxlZ(1-k?qKOblRErCjHl@P8IHkwmblNGRN!xulCPQ6>jt?$Gb!>j z{ZgqhoqJ;Q~Z!7}9u*5bk_ z9jwyTg7vaiu=Y0~rWV1<*N$WD8ISKe1ZzR3V7==SthBDdYKz0&f_1YeG4~;U)hF3wL2HApi9&lmcN5F=1Q;}SA*3Lhtc&~uwJ45Khz%I zt_N%W4SH}hSgY;@tI3OC<^L~O;}oJX<`Dhr3eheEWe8Ccw!sw@qMaEL9iom|L)1Se zM5D18UJs9P2xH?yG!qAr-OD&^MMOe~1|)~5y+1^~aRIk+DkVf$aU>9;7l=p=QBhRK zIs~PK=s2FBVtR<)VQ}^k{f4zULUa><<_=NQydnC8Kl6p?eF4@e7^3=xLX=oIMCXcx zs6nw1jl%&{FCL<0u$2f=L!7`}+$>4_l|!@=$B?N?i00xSL{$w@8?3<-ZvS-<8r>)(84#pfqpyf0zacO}gVD`nOS+(d@b zX8nM3C{)I*y=BP<n^%g;xU$1HY>P_SzB-r57DZsS*xp=^$w-J zGwT(q)G%umN`Fr-ScCW2`h!^&YVr{)Yn!#Kj#-|DW_7?_6l!Evc}&AoRBOySxYNX} z+&`LCu&G(KnwixM*HNZ9^}rW6TbPxzrCG%g*4nIJkh8s6rVeI3!3Xs1WafugvqmAZ zi&;auQEvpgoAn&Gdk|YMvl4$YD|0{A!GQtPV~|;CKbuu!uvv|f8B(pkAX3tEe{?qszEASGo8D_=eBreQ0tL7Zy znrr6&H}=Xrvo$_%-Vm5n*V85KkUL!hw0rB`iXtV*uS`iUyhqK@+AA<6lM zgBn(g!fh5+Ku5bp)-a0}IxTvH0TG;wv}h`987y*TvZ!@ti#~XnGv1qW;Y-%HG1F#<+qHEiJ0p!J=2) zEeh&EEEs_7J*nYO7S+ZbjO=ZZvyVkJ`&x7jS^85~JRZO`11;Jx$fA5dThwN-MbGgC ztA|)ra;Qbea0zeGa~LrVw! zvvC;vCs?#(BJ1NM8c(9`_zQ0)Q?n_|hYV9K+Kpp)fQ`Q}cA7<oSX~;u(f7wPHa=5I@g8cXcT{BoU7;n%e%BnIMty&yyRfQ~8 zjYq+3tc9c)t2)3LYgH}SyjE4mop`H~6RbLod5Ko7#$iv??0Mn=)@RtERWIY6jnz=P-4=Rl6rzHEkyS#a{d{%c>T0tm-${s@Ir5&#LtpIG=tmAfLs= zh>lyS+YV~5)2d~==+$m=*~7lVLTuQ}-1xkocn?_B^B}PuvT7wN{Xy*TAEw^OdW0I` zBEpVR!(;UNIQ2fkzP-Xe{Kv|R?N+(*9;O@Yhg(){x=pSKzehgz>E#2f{{Fv*R{ipb z8a}3OPkBB(vnl}B3+jbgudO=shUde-?DO~RQ-pu8su9}3_|d9SpNZ`Y`}iwkf^2GT zu&FEd8*Ms`X2CX{2(f9f*`^6Ngpv-MQo?QWIBiNrcicw*2%9!#v}tQ5#^Di~McdRF zD^MY;jn}blT9wVFxHy~EdTrW{8u2z+5^ah?D?}zSH+tdsWSb74px>rBDK@P{Tq-f* zYnn~<(`{-EM-H3T;D?+xUiY(UJkoO8v@9>Vu-M85E1tHssZHG-=cH89L zXVdp+f{OcX%5~7D*uys6!AsOWLLHAX76afu#yY5U+@?M!Yk)OtHhe;<$2LvI6%2c7Q@z(Vb$Y|& zx76}q=7Z~|B<{t+4SFM`trr5yqWE)oW-u#tadHWW|t+#uIwJW zF5stlyJ8aU`slOkXo_8qRJ*dEKqztY?=S zI~s6ZL%a6lbql+`p=nFI`oi1BuKL)Bw(YnM6*|~e3xzw{H5s`(*|nmJU0+eXt6iVF z+x2%3yNdL*t2=&1P%pb$4zQ~yJOk}|H`p%Y5WD&ewQD4ThuKveRgrzTT}AN<-!N(f z>yEbTDgtBdYK>KRiX3BE1IN*7oL$?{d4gRtCUFfclkM7#f?dpPo_;UesFSIKoN-iQtO!)uD#dht)Q50QD zZE*y(m)kWBOR#o@U3XA?6>*^QYSzFcWLaZZG8(O=H|xk3^Vi#T6VH)h19M>ww&VG4 z)N7+%!!Z?yHrZv`Os?31L-22*X6T9DTiGAm?7EK<+vzbz;n)uH*-1Vqvx}Z!8d~hO zYcV!p$R28ic6+&YpIy23+m-16bva~LF^v0zxQ|l9W8{3Cy^6LcnCm2QpR(&Zrku8` z@fo`|ou#*^_7^#yvn%dAdkAGN(0BZN(XO;h)Dm<5=KN*5rsK^O`g_%`JlBc&rd_^U z>_0TbB-}^dJM6=|^c|h=QIGr75Cv2-~VgZf_HYkK$-V^jvdJHfjtC$q=#sSQ;7YAdSDDy5mTso;FsV~{b&wVM=Xg5RfbHV z>K?~q+`@BQ^YSr1REY_p3QG)CLrg_cAD<_MY8IB`tDpH&LbV7B(?XRuXQ+1P4%IOf z$P=n*Sd35kLiH$rsNSJ=!BDM2p+cd$h#v}v>NZ*z;XE=H4b?ZaEEcNOm{UAd=WB(k zUhPob$GAG7>QXmUwtAsjflm!XHLzu<#^Pg}P}S`ksx2tdE0mwNLUkOK`i81>zff&P z(11{N7!scB2)y_aveo@8|r1P)$0>oQFac@<*ty zVAGLMWj`9Kllbl!F&(F#D0U)Lu_r^-2mMbm4l$>x$C*&Q#gen3%JEmI4q^K_;yE9x zofqiI#Zaxs(rcmm?VnIpxgM%DcyuFF*Kg9xJE3ZFm;9cDY9^MU@KfS`7OECFf_E@I z4^R~o)e1fE5Cva_syq%O^K0saIe3Y$=yZAD+F&GJqr|6B**`NUX5s<hB&kg?~!hH@I9eJxh)P2!&4NqIy4hW zHiz<{Efylo?od7KM4nKGrXtkg(3&uZV!|D|h(DYTr9?P17tTnB4q>pH>th@W@iN!{=r$b9~In*(aL!VG7FOTy()T{vG3p%u~kVApO4vodM zA`V3qb?9|5hwQ~2x&TuNhw36bN;t2NDpfC7{upgMGrb8uaIaC$naRgmzQ{Orc ztw!6r4lStXP?7o$tw(GFhblC5=mcULIWz(raJR8Tkxd=ii(bt*j}6V~PYZ{dw=aXYb9&0a;U>)GRQ{>uKxGbC(qXb6rV{5SRxe%$C#!A;b8vqQ&!C#J2$4D)vCj;=eX z>rP_WMXh%e`yPi{?W6w(d0reLek?iWQ0sWh}`r2{_t^@OCS%Ka6566dD_*yyG}FK1`V>gz@|d(+Y%73{yJJPYP45$zghg#Z$uc zb}F$?3sbl0VOlmLOx0$F=@xp<3e&YY#5*@kzIkDan;)iM7ZB&7F!k6Nrl2k4aWG7~ zj!@^LVM@cRbHsWzOhd1S=~PU(YA1y&sbRSCAXATUC140PV?R7S8H47C=@qU3E@0$O z;ra#5dxvWUy7mdzK*aV9R~m-F*e_g8(>e4S~HR3Q^Iv>YPgn64_E6M;rerCxK_;$ z*A^6+6RxN8!j)})xcq2^KM=8ywU&mf3e3yGm3?KnnqeFEtqRvknAfoOx^Nv@AFeJN z!*v6{Z4KA@ZJgg3uDg4}ReoQ%4j&BH--p7r?vHRiI3BJa&xY&XMQU+1Ty<}SEC0iA z)p{PT7jMb+L%7EM7p~bsPOZQdqm%EEopOXZl?7wNoht8iY9rpm6yfB47N?e>QKVB- z@Gz@W|6)|EQ%g`h&Z)Ub_c}EO?=dglsf-CuWlD5v9NPJu`o-^5o)o8i*;zZEQ=9U0 zyns{Ju&1C?2}PX>RC20&Wv7Z%b*jd9PL=+_sh%~R`cTWMUu!!RSBF^ZI#sTLlb^wz z8rX#EnmYBg8Edz2%G=VZcdeXS-rA`rDACTTefWlg?a2)ra0AI5oEnB3c-zsbpiWMu zc6F+E52s4?bSk!&Q&oR*>J5JF?bLsLoXS1WsUd@%IzQB@TUb5Zsg#j?977IcooYMI zDZ_ZD?oDv2)d@#K9B408YAXA`Q0^n z?4(Y3g70@xkKIm9!f6EdI8^|{QEV^A4$-eaoN9s9*oymqI@Re2>mH?N$DPV`(y8jF zoN9(oj*F1b8==Rz7ayTr2@(1`F+xjy5&AVbLMs9h+Ls!k*|{P# zFMot~7l=@yf{ZH^p{s=>6j?MvgNv~imKJBNk`WqSDnhZPBQy$OWh1m6_Hq&W5eHGO zLWJg2j8I%vVnONZ5!#F|So?j15`T!$EbPaNIuROOKSH^Fj8Kh%5gIc#Lf=o1(DDad z8yl%zagnO!kJOADky?r&IU|)Pcck*?iBy^Dk*a}>H6rz?W~A!X;v+iOiBykzk!n;w zQdt{B%GoqhH=0FifAdH^Y#FIlts<4&hOuoUm92fG{5XqF9U^rXF&!f{9<$NDM;7J0f)lp52j}f);xsW!x93xhS_kQe$!TATb{zKU_feKO@x*Qw}pXY9EQzF?2Z* zsW&H?^Hih`o{!X_i^O^Ig!wMyl|&NUi*bIB!I1@SRA7+>g|>N5u3vQhE}p z#?K=)6UQ;(1)sl+)U|Kqi|^!8RFF&KF&jq>E_F4!^q0w{K(I@(X49 z;#_Kh8D5vx#Je;&0g1$wA+}~`og6OZ z%<0lA)X3%1eB3~4Zsx=V6wd3?Qrs@!QhGs`1|hi+=Wzl4!Y&mo;?mEED(2E-lr2s? zC0q(F?b5q48BrE%HNc{o0CUNmrkKoD`IU;To}>DrNtv$N*UwQWc-Uy|V*#?vacMKU&ZEEhfa3G{9RK3B>_Ln^>Qb&_E;ak?(n4g(ltJat8@Z!1@O^9s)ybSe zvvXunOx+Bc(K3TB;M;)=di)}TX1>dy-|-UupeX%rkJ8q#C{1-n=>^)vM`<};7mw13 zl2Hnji&FL~QJVFAlfSU@$*L%uXRSL_ns(?JQSskc#obJ zq7-p0N>3g|Df8nfHGLALrPz+c$nhddol9oaR6B%3ME_+BV{2lT2!a>rFGMYV%BrX_rZD zI%LwlPMI{aXD0pFJCiyN%B1ghWzxFCnPfbbNx@$;X@((MeZ0}UHW01vTZqcgLJzB+=NAtRHG+(cxRXPVw%xX~}v-%Xuta2qYt7+-XdRI2HhL_K*S@kl@(>JrSy~?cWBeLkh z*(|#FR~AL|%qG*CY$~)qn^qplrkyyAuSc`#*Du+$=xa88L?4@5Pea|xm(?wU+s(Zp zZhenm3%Zr7kXz-k7bmc$uv^uNxOE0~i@J3H-HN;Q9yLoaM=3Y&6>;mgGH&HA>sASj z$4!KkbL&)jw>DOEE1{BG>(RHeTi21RD)XWts($ZQeH52RQuUi{Xv!7eXFsi>>^#*YsKjRpR4s|Qf zFt^f%yHyBp&}am?q5UYgdSeG#k9MmEHskUbw;o`|Shuc?b1QP9TVpXFxA6kgC%N_S z6wXa`bMKW~n-Ka7^}#~iL+UiQT4EXQW7Tx7hkFKfLf)Bfb;c^}ndR1J1ZKN+3ybE^ zE7Y4ye2AXMF{CbWYuZw`mLT^sx5_Rj2RvHi);lDw<2bfs)^Bc&-b5aF2lwyveVbc# z&=N;cVYge0_qsK6AJ^@7>ohtXpsxq15gH$ItIc7zdg9Abw_?t^^#gvyd6d53R+g*m z35>@P487*oZe+Rc);w&)x*OzyTesZ$aNDg6_t_^X|G>>XS8i>4%r#Hk3VQ06_XTsH z&s$|93yv* z737A+ZMt6{-a*UQ$iBaaNF*;o>Mu)zO(H}p=$WSvz`D$^zc8vPejnU>N zF)G(IMwb!MEJjaIsCkT%TEysU>lkfqAEN~wW7N1)j0$#+(U>kVit84mR^4NCvPX;@ zy_g5hddH|jpBR0@zJ4*f-akf9@nv9)Mh}XS<>wfghQ-J}GDg`)#qc}07!8>mqn8Mu z5~FN$W0VIiF#rdUabAp47qJ!&E+(g?G5j7ZMk8<-pAot;Mz7b!=)^Jd`zwZf?P9b7 zMXxaaIx*jf(LCgR8Kb#gkG{a0;8Av5Kzfo#i~SxAO!4r30*|6nJvxeum{;AStC;Ye zNAuCHhDW`T{d(W5e$hMRbf>Ya!WrxDWGqcK?2#iJXT(v@1ETsM#Qph(FBChE*#t+^g`p65~ce2?y7%L4j} zv_&4pEoKZZ!@9(ypHXR`Wyp6Hwz1^c#xP#m~s2h&$^r-4CkDB2aF5w#r?Dl9lChqZQ zE@Jn3GyrF@c|Z9bAih65dWfNadUOun!yX;Lu_Mfbh@;v36L48ko zRQtR~IWBl~1XnQbl1H;p_A)tNVejHM%)Uu(cd6xl_R9m0+92?l+@A2fz*y`>*{2@v zU-M}6E5^L0#&0}&f$i_u&+k3T@{#93NG$jH$LbHbEwRdGjg=oY?6LYSCRX+RvAR|$ zR`wFH+J(Q%#OfY=6=SukQmnQhty(Patz|sk)`?Y6-B|TN(fYBfgwl;;Rl6f=bcxkp zc-t*jkv*6PrF+G4Z!+`!6f0L>#`lX=h5oTJ4q)uySk)aGtIs22HFOE{uZh)Vq^u>r zb+I~)73*VV`ZZRz4Y8Vom6-HftZw7T##mL}6sxJYiuBE~s(R!gt}`ya=u_|sTz#)oII%KMx; z-~+zCB!}0rdW4SeW3?B5q2>o_{3TXDevMTpT>2KPxr)myjpN&)Uxj1<) z#OXHrUyRd5bhyNrzvI;JVVu@Ji{tBCoZ5ViQ(l8trSKPiF?zKISMe3OO*B0e!mD>!QPL|@DX$_i26xe*v{z@~EaT-p0$#PmG5m+xWxbk&XXU&)SKh0e$W+0r zspwb3s|7!JRk*HKJ@HpPuP)aoFH~sg)hfg{qK=KdTGzy@hd+8Xys20Dno+yvUiC)K z797X?mR@~p<<;@lUbSlDm7%Ry`8!bWj>OxU<6WpvS90mj+&#P+I>4(oBfR`v$aN#V z8ZwF+q5NpCYN9_zjPWXHyjPVc(?67$LVaOf;8kfXTuA(jyjlzQVy_l0@oMKPujZ`w zs{I;jy^b~3dlm63efrI-C0ogFzgKOKd-?sfR}D{41N?(K*C?L%f5huX z^LXxsh?k>7JbNNu1v|xScX#6G6|Y8E^;5jIpiA#~{f_p1;&ldn`^IY-HsT%<`^76a z<{`a*yj%m~H3QdBZ6LAW5`OzRUNuI!GUVp$cH(n`df&KI1 z6|o>*G03=(I9J50{Hl0e#E}j0GW-^=CL7~bYZG%~#Q$xHSMt_)E!ZBft2^Q~X(zSb z8?Wen@oIG>Uc+$~rH{tz7G%j`LWGf#(^IkJxZAUbhi>iFMH%|KKrJUy0XUl)M(N)a&#B?J)Fqytdwr z*PVOuih9VrNPbMr&*HhqB3?~jkoQaS#>v;z=N-Mmz>o22{V85O|BKgAG*W{4BP=LE z_0bwfQPq&31}JDu(0QyeCFnhZgA+6a6GHeLKbaHM*^(ex6LcSMG02vn$@T=zhb1&Y z-7y$N9IO+bpbrQ*6EqBy;fzSog~$ZmLrqtLn!%GXK`n47Q-ZogC+KIq!Z)?Cs{RDoQy7ayXpx?vR@oC&Cr5$?V3h?-R$Cztp{eQA`ax{VXn3ZHSPNut{Rn5fq zMm|+D`Sc>hrwm~}bqM$AKJ1Y`jmNo6KK+&1r*Bz(yzj%O+A%)0i1lf5oKKs*K6&DO zx|HP8uwr@NT2qN_URMqjP)sfoKJ#^xA;^YTk!?ftvp87ZPe+wPs>jEv=J$%eOiz6XMB7=?bBQo zJJ0&CT<|ISqEF2)`P3C@fBUooRWJM043m)cicgPG<0`#D^=tG6?tgshg}CcJt;HpD zzd;Re`g8&zx0v@fy~StDyhBVl3HM!Me&FMM6FxP0?9;=iKHYdmU7k~;S3Y%n=i{Do zpZ-SPPh1bnXP*k74<;x{N04YplGT``jL2Q(!W`fWXPJNu1L$4 zq`omp+J^R?B=tj3Y?2zsC25v7Nh|O#PWzIyFF8r~{7JGEO;Q;wD#p0tT!-mcQ7TEd zP^?Un>}8V_jh}E4PbwzKUnxn~@D$xDGiQ|~Ev=fQjc`><(wOSRTO&y`uoPEnCaHS; zBz|w1r27q$G^JsZ7T_(mHcC>TCP~`einUrNsWOahlX(3lNlQ8=sdT3#IXfq59tQSF zQtBY)M~k16lxawkx?s*w<{Foz8^0#0;-)0+K&{P5`g$yhdpnc#0^hLYM3R0ulceov zaGtuL%7r8~gf1qj7qVR;KO|jajeAMjkCPdbd9PKn3f@ZADttk%+sW#ROLz?bon+<1 za2&*0RJxnY_aVvZcrRHm@E?XfNY>tm$y)RzSvQdOG+EuT1|6OyYcAd*;d!#$FOu~N zF)x$#^Xp^W!`t@%n&PV$dl-VzD7Qb>}3c6(V>!)m-kM%2i zoL}R-e$9v{H+)I(YeS-+zXRk~_hi3X_=y9vu{*`D-?K9|pI@&0epSWl0@SmhUlVW; zor?H19Jz}6^#U1+kzaAYGL~Szl71zX@+%M8m-TBE8kX~`174$g1?p0f9#rw`D$=Xd zn;P`!2fy0Yq>i=eNgZlm&#$%h{d&`Y>l^d&N9JweSO1oN{oUQKr#<{C(376_^6Ok5 z^rJ5Wh<6~p9pTrI27bezn2!jehwy`!x^F-#LepTUigewlN2e zAaMt^+3nY`OMX4R=~u-E%!@(~{i=lUM}E0c`>|i2u=)vodd6OO&VGHtHAr|#4_^6| z_cin4Gz@S2dhp(_xDS55&u9O9@~Z}VV)Hk@o}+S5igFuLR06}XJS0UoQPh$myER48 zxD=kErOp)Xh)mH3tZ}7iCrV~W(fp_serKPez6i>cqNj+BPEl=)LZ2)t{Oty=$(o{i z*_a0EQ`8_XMO|R=rYH*4uoUM|A~8jkd?~!flA_SuDQcT1MZUbmizet_ zn3&M9NQwr)STsdH7E4iT@e~!pR(wLg5-B=bE=9Ymr06r&S546#bg!18um&lrf^P_K zn4)QT-H5yz6K|UoO~uQ$DZDzPIEdb-QZxb?&JYt$;m@>V@5D`!={Dz^C0bN1B6;Ky!!zEPC5YQx) ziwbB7j^GWHF`xn%fU)?B%9#TChRV?a)x(&~0sVtYi2>EY0bKC~^ceM$0&0!Fk^`!h z5>R9ypx0=Z$~xG9lW3Y2&^qiysq}zM*#l~hYsj4=z&RH1;{7Y^umv@8-(k)q6r%Ebb@fw1BM zb;n1vEJ6J+w`4&7l?td>Y2qv!;QzmX8dePG8UC$I&8h@crapDYOEhf|&{^C;o`wNc zL9<5G9QMZK(a#eY6FWJ- zhx6F5m-8sMkMsKjYH}c;jzVz!E=*=lUo~D2J2b0eP)aoL=LY+(W9nVnd zazGuf1k@KtvG`g*hU)=&Z&4$hyBpBP`>gqpz4j=e36BF>^dg{HZ&>dwd-*^52kSR_ zisKlrR80s<)n`L0uW6*}DZXHcDOERuQ~BE!sak_P=2X6Rr^;zfRW$_JQhASjs%GG= zJyl0TQ`J8*Ra@Z7kg7BI2W>N@s#A2TRw6h{s&?Qo-r|>pR9SqfDu<7-CZ%d3o+fi` zN~)e9sUYJDrRov}7f#h1Sj#aVhLulMphBwVR!&ukDyiD@eX4x5QhCpLsxsF})vfxe zn$wWneoR%a_NiI`TZdHT???`vQ#GYaD))D!YDKS9nSV;vIQ-FvJo~05sr>FgRew)PRg3AV%C;a?y%(kO zbuv|D_or$Qt{q_RgQ?nz2l(Sis*Fde8~#LCsTC~_s?_Pg;d2| zOyxCL=0}bj#Ehdjb2C-nZqdWrshWN#Ro~xD<$Xt-N8E!{HNduq)ZkI7*5cJCV*1QD zWc!k;+Sv48sz!ZH)ihYlX)1+3ENS`+18iv;?nu)V1V^W7Ji;=ksUe>6ByJiO%oB-JWbtNq-jUXH15Mr(>mA& zrfDxuz&t2TD{y60nlg+|Q`a$Ra*s_@3I@+f(@sRsOVb71M%MXh`ejj?GA&NikmVf5 zgq3OfXH}Y3txnS&lvqn0@DX{|rD-8{ZcXF+8|r~$aBWXhQ~bLlO*3~A=dLvMz;DR1 zJ55#gq-hL_?oCrwoI{TNX}X5TD1U%@9!}HP<7qmI{wJs+aAml)0Ct;`bSYmCw_(<-at&MAdKP0{)VfB7)M@0coam zb&g2aI{X-!t}e*nO4k@Xz?qEc3d@wP{Wy!B(dl}ENtx62F*aRYG%s3=B8@|3eHPcMdX=JjEmA0Se&k+sENp>>H4~ixRdp&SXFVkt$8;O+-L? zuR}*fL)vmz--xE33RMez9_^7x^mr9sax1>p4+(ym!cr0zwurelP|B&q!Oln@y#P0|u z^{Z;qF~qaa%45jffd=zYLLUM zT{w!tInBD9%dC6Ip4+TX(Ik&qOY)gjJil2L@FxnsZPw6&X7wpz){LUOj>KYSEyjn% z&AMCBtizSe`n?L{s+u*bmRT=RvA$VPklSWfS-V+rnCdjEeY{z{F|&bLOW$yr^#Xa^ zX05?pyzeusI|iYu->feJX4YIXD>Fpws96US&1#lxmMzt+AF%P%m{P|Ig#eor!M&Hyu?KQkvf zkEMs>m;+75lj96C=eC-af?TuAdYWn0-nnL-!q|CcJz7Y=7nyYe{TG{6{#&yiBF9oQ z*PqaX6=vmIZI)*z9HAG-&3c9JPM8(@+pIlj>F))z-hE_N2Yi8YkInk% ziCIUUnsxhyS$AI1BP@MQ4YKH+EEYA(VbMoLEoxoN!rCDgzB{q7W{5>AOIUQSltuP3 z7EM4VjItJu`oO|ETNbY6wD6sVMf1?8l0_qsTHT_WCW{*4CO$P=G{<65q^3n**0t!m z)1rP2i0`xLB(7qj-=aqWi?RnTDvEw+Z&>tA*rID_5w$2sqJ=dI*^YOTENY6~$rhbT zW$q@_fNV|Kr1>~A(Tmv@9hzg&cbOIq zo=dIsczu~goxite>T-)7{9uuOw5a1si;n)pzN?76+M?*sytdY&;TtSE`-g?~S|ck zAD8hEKZeK`;~QD^1fH-}`*0PTB35;dTJ=qWRaY=O$*RK1R>iOe*;B{`7vN2`Dz1rD z+mNf7RiWnWgZEm{2NZ5ey=hi$ZDrNr)>f_kh&X(}Nm5x9UY-tNQe_YWg6nx(%j(_z}lYYKT=ezNFXa zi5kP`(=@AYBkOdlKE`J_fCe+jeNA>mI&icAv!=}n{Hr6t-X%^0+tjVU<$izt$HQUq?8&JSv zQyP9m7OPEB48<|jGHk5xY*U4hO|`Ke#T(o72**=x>eSSx#~EyEW0U6-oBW^JGz@h+ z*c8A`%;{*;DU9vJ{BU=+=?Us|vFSRV;^(e573#^{$lA-M!kCVSpWC$R3!AooV^g-# zHomj6X$KmQvFW?9HnkgP)1}2Wm0n^~-*0W|vDBu)*p6!7*);c88*8jE*Kb%)j@XE9 z8*Iw6iMsJ4vTnBN@)n!wZ?)+(CT+8+;dXkr$ENr8+H?@-&~~3qTlU-3@1RX1(d#dp zOowdRd&H(Yf7|rINt?dHh12xlj7=Y&v#~CUO#^PwJ9N2eg@Ik(Y<6|eZr6)^ zcGbym*Q5e={r)VxRv#V(X=D>dq?ONrsYa?!9kl(JuxE5vp1op)>989z;Pm*2jlI?P&5UZtKHcU&i zD?Qz=4w!&{GwiC=%C2Fp?Q(r&R|NfV4S|pCTGQ69q;_^SYj4*?-2T+A2Fs#7+5!eng`m|dno&ku&V*?A?rxH zM&O@O)G^www%^+|7cZ7m^AC1SMvfJB*?+dH7Y?npYr(H}{fNWJ+{8XxI6hnLT;F0> zqwRL(-DTIn-5i5`cJ114SG5Cnc@Ejt_^@3UjC73oDMC_<MibE|@nYS%D!1jqlS8yMV+dKFj#ldxi4wdWT(1BhK4g1`o=3hAU z0uB0*TR#VXuQS&mV&WPu58?T6hrUJj5e{v^K|I1QBiV11gYT~$sxZx=3~ZS0(3lwx z&BPzrJjbEeSe40G1m`-mcph=*)0@o>_1WUkysZvpz2Hzo+()*H4voZ>OAbxE>`?r_ z4)urWKk~$Ol)K~5c@%x^PzqQPR>d#}&$2kRB&$sn5AayqpP z>G4i=#(g9-bm|52x|}+IoNlL987SPysd89~9AWZ8)+DDKn33#MB*m$g7=liz z#7BA);^RINno&n{r{2RxY-!=t)-Qbzoca@aJ3IAB7xwGwR24*F`OK-V zDA&y?D}F_h9@K^hXwuWEsl%K)g0H`FY8pJlo%(w+`%iN!%Ph9dW#0Kty~N4|PHlpJ zp_A)fm}9Y1-z|6QDrWvb?l7-#YRr#L)nDncKNH=^sETE4-l*1wY%c4Gfd zryA{Ysu{kyPu-8G<1uwS;kZ7fSC!(`4n6QEGAqaH75=Oeuk&bEHC}hBu?_92$7?m7 z;hh@s`T%|L2!%}XYKbxCc&@vP*B`iMiPw57+iJ#Z4uZAf)dUt>ycXk#BVL#B0NI`K zdKVv}7Q9G78}!65OvWOt!Cee*5U*0Mc+Q=Qm(Lr|-zf3w8X%StuNk3u#WjxC)^I%c zY>1a>GIJ$1(42e?RepR!t((wL(Mb)tZmFUAO>L+`(;MpB84cx})li3LH&pw~hI&1> zp{CAns2U3!YEx;KnwD|tzp^gwL*e4{KbL;M#mX*it?JTuaV}M<<5G=AE_KBFja|&| z(k(1camk(PQYJ>UaA^nnv~+1C8l<^Yq7AW;x2;PhaRIA3xsjp24Y1$=0Vo_Zq-6{yIV;((tz9=5)*T=7acZgugy^99pttlw;6LX@) zuWr>}=N31|QhuD<>(-h5j5**|6a0Yp54yGNFSq_g=RLcz0c z+1@zEalyg!Zau_%7u0x;6BPTT8M3nOg;( zyLIS=TQ89Knt72;9#zTa(RSR%sk|O-&hOD-jQG%_Y!y7}hDkVx2S}{wQ6_HSK_!ox zS7sk9!e+cik*XfqF$kkEu9`=6s(Z8!<{BP_(KgPbZ}6_kqe@78!|c&rthRbIzNSZO zaj2F@r|WohrmjbY>v@#R?$HNmkE~9{BmRwekIo{8%cJV>!teIzLl1cdJ(`l@(acnj zHlbP*kDU1Aji$tG=204Iw)E%^Tt-|gk5X_ID?aw<1RA#YXkr(Se#PGI9^FIU9v+p0 z4g2vJ&w6`Qwh#4SEY{%ZKw=E_=oMU}m>0pZ9@g0OXx2QBmf|sr|LjrYZ60;UwS68H z*iSBp$OT7m8zm0o2>nFCWAqjaum)$}IPTHF6CNG=+oKooo%N_AhGNYnk51y&Rr-0& zqb~n?G#SZvJQ{#j4?P+V`xA~4%Dp5{l#*9IRLkvEB0hP`tCyv`D*v8W9m;q$8IkH< z^@P*J>o{liDo;(XVzs>*fywo~tm)!aPN!F9Ty5x8A(vM>0$$xg$*5NiF&$g*Fwv`0 zNnZ899Mn(sDg(dZ0tz+rsxB_J@G4(RujXfXwG-n%@^VisuPhzBYKp9#y{eA=-Mz}) z+bb(d5A@1|{|0+idkHHLw1J^SYPMxV$QI%gcFdUZtZK7UOpm zd`xWko_JOBsaHo~dq%xj_S&l~9O)Oid|FVshs+CCMi=Tkl0b^25)-lxt1pDqP`>JakD zm*i7dOljfMTWLN`O!w*i44;;?@+t8npR%{{DGp0J`S_c~r&V2ja&_}@EvHX=KKJPk z+J50vZ!CDDw@>aqJ{{@nQ{#R-N=Alp79DOjlDdpFk(te$J<9)vdl<~7(p`Xtzc^z{Nzkb50H$r~(Yvfn11i!YW61SOO({UWR zTlx9-*ROVM{2Glc9sH_P!Gsv$UU;1?d#fJH1!f>2Iov-}rHr%ft@bA}twH)c!5UfYvZ+IN- zXZ;Yr){gb7`y{_wPoplJMULryl|~rzunFhUe1=~QXZraJ(yyKKsBONV^^NJ%0$y9_ zm-Aac>lpi0cBx;l&~}-hbFuxh#7mzwRN=UcWk^ z{XV~XVd#FpE}`*3zwThzpMEXFZM?w4Lw;>M?AM?penpN_Cwd+8YZhLj@NvH!Z=CS! zG~6eNjrUJ89v`1&f6RU3oL>#jvmKe2s0)QJ`&9-t{-K5|%Y6N7D<29@{ z1+*Ixb3n5#0d2AdbPf4y1@sdt)($8I|J4n!UQa-~oB;*niH#d5?Fy)*H^99p19~?Y zU=7d!>+J-zqH#bQ@Jl$L8qt6{Vl5UW1{6yQ=&j^{s$w~I;~HA01k@AzQ7x5u@Co+e zI&wE5E4Z>ZldZZ0kyz(bZAdb`1I3&Dt8FzWzPWjrN!p~?L>nw z0vh>MKzm07^!1nk=N|+#XL>-BHwCnD3w3M_Xvv;{rXD57W5hfWQ2EpJ{!Bmx&eI2c zeUW2_16KkXm^Y|h1%j+Y5mdPfLH%eBDkVNBOM@Wa)dUr27}Pb)b_JE{3FP@!f) zd71}RrEO5xy9MUO|2Mc~Fo029>>EP`426AJo$ULA4neRMWvhT^SP8 zeH8yPs8KkD3d4fxjEiXbRZtsIXn0V~u@H~o`Z}m#*om|eK^?=pBZHcYACO~AQ12i- zHppl3LDqN-a?j47{=zrogDNmRs8Se-qBE%#t!7a>iq8)6?-_N@VJy03Qs-R8EMlK; z$qfyb29;%5P%q*CKB$kD2lW|FuLx@2%Al664XV#CK@CUk4MF{b@Wvq5F$R@uQ&4rb z1m(r|$g`E2Q5RjX1xKN6LFI=V!!Qx~wg)v9d3TT>(su@B-o-YYglBh937C%Sc#K?o zgZc?4_XX8`e^6@=2le_WeL5f1D|~l>dx!num|BGxkPMJ5cl{eY_o1uLr#LFsQ3Ydqm#2fliOKwjQGfSPR?+=pg!!zcQ48D74JiodmYpOti^B{dM}H?HM)kbWi_-To5A;+hAN^& z4nw2yYfeMGav55MJ-H3l%VTIh3gk8PInE>XEknCdGoPWk$d}(xKU_w*fT6_*ziqIF zv%$GChQ2RsDB~SNo!&L{9kv%WRHPWOFtWIzMyZE-LAzL$p&nB3+IWb!>rlp}8X@>Hr8ybLH*pop#lxRi$NNP>a`1B(~_DYYIF9%W)!Q4&MBJx_en+#$V z0t$aguCRVZ&qo@1jK!lkF5l26Tt~IhhCahd3>m{dSUHwHjWe_WXQ1&s;s(}DFtmA+ z!QWc+c?!Kl(o{n`QEwW@Z#uo2!TWVK^<^5Yt4d!`W-jmPd4?viyq>}kV-2XVFj|+q}s%S{AVj+El1*JkN@UZc4?q`e4vLiz(1FLNW# z&%XEt&*2V)Gy(^ZHAsB4$6{PV8G~4ugg;RvL_HXTt#}Drqma5`1umg@V=sXzu*;Ykr4Nv328NMp-Pl~A`>U^PC`ggjK&URNes!3?)VmGP&g?hFZ$zW{EKqQ zAvMJqY{3ImPa!tu;1F`9hU7$dEW$aIY7$ZtjKy|5g}Eucz+46nH?$d?|H2fgtFuAoeeIGBV3csGMS zwGGMmETqz-cwRWHb}hnMgr+US#1HFVgwn%OEUato!m9X5SbyU>y0#B%-=|@|#}2b5 zU|1b`gf+ikSm!XYe^?7pc|cfS4Ge3{psVAeSBEI zU?;*8!df;ltU;3)kH7E|N2i5lo*q_@Sz-NzHnYR(iDzh<$+)>;rLPNX79zie6~kq? zHiT8__ptuk6;}1#qXx^lNHF?sgGP=|W7j`XZt=7}Y1D zeSLZCA7M?nh;HKT0TCTQ)q#wMc~C@`a36gJM|5mRL_>#0G+|;y2QhR~L=#bbGBr+# z=!2=`w>qL{_+d>%zr*u$MDx~0)cBW(emoq}znFIP9IgnR5n zwEuO4^X8(OlQpWP*`gYqJ*uubqDsykRsH-?RVonGinpU$S1_ut--#;ogQ#Lvqq{`*I$9&DopDhuG)Fbn64h91R5xo!^;ey!w$+VleLZ5VgMI%$}f^cq>N& z=i4S|cFqJ<&6A*Pc@tEyK!QrWouDSz40pi<Tfw>bkqDZ2y!d)y;NyQU20asC`M53CNOw=6|DV4}Q783Pm*+iYi zCm$rLZTUp)$H@;9^=>=1cOh2SM6Ji;&k|MWi$s+lny9=Z6E$a2qE<{!RN?u=T9~Nb zxQe6SChGm46V(B0)+Z{kAyHla;Bi-?`khErwaQ7_)+|YXe4L~Y+a{@CuOvB_CaK-l zBn?H^-AO9@SCVdE#GxehIG&`3uop~LyTZvTpOmciA0=yZn`CWio2*G4lC=+ydn7Ag z&t%O&?DJ$L^hs8W{>kc#Cj*kTZD6ueM10a<@)T`A@s%k`UX{X{MJcNLON!QF z@75GKx1}f@XSb)Q&W;oK#WytJ-mqy})GkfiJEdvpXKA|MD@|?tr0D=Y@0X?# z_^yANh7U^9l)-6So0ulc7#=Zee45HlNK@U(X__-7P2TBgTu+gv<+IZC&+If^UrU@{ z(sXcLntuB&O?iJ$lM7=urfK7*H1*z@rcy`JbpB$RzP*>Gx%bn!{wq!EvZc$HJzaHk zrRyAq7f4s5x6}1s!E_ZWl+Mp5uT@CbabLP-`qMQroUWt2(^Yd&x(W_XR|tbZEkjMw7F$qd zdWLK>*oIxRGPs{_hDy)DybOJhx94Z*UkqB1q32k)Fhj)`XXq4KEy+;3)fwt|EJKG+ zWavEl{hgtMxPdGuGh~Jn)A0m3Pi3g~=?t|vlc5u?{L_40pFPMT>D$KdczF2V{|$J1 vPr)N^^*WQ;?#dS@%B-JJX8&Msqlts+<{P~D;HwLkTmL^U+y4*vzsLUpq7*e! literal 0 HcmV?d00001 diff --git a/Covance_UCO3001/browser_profile_4/Default/Code Cache/js/5d58225d08cb8dc6_0 b/Covance_UCO3001/browser_profile_4/Default/Code Cache/js/5d58225d08cb8dc6_0 new file mode 100644 index 0000000000000000000000000000000000000000..72cdf3d18fca0e8696790e42016224337d95cf1a GIT binary patch literal 37040 zcmXWj1$2|w|Htu9leDp>O&dy!q-oPOZECo?JB$t2;qEe=;qJrToiSjz!-m_iA;aC> z2mkl)?9Vx`lP1r7?)}OQZPF*r-k|I9EFC_736xYECnKuw687Lu*O@AZs0|6Yg~*kM7b3Y#T3SS}6HY4Lz_PSMUHe z7ZDpyqxWv9&n3xIJU|<;2e;6;M1V$OU&#R7L&s79>We<50~Ay?KvC#hAwcyj1*jip zeixwktpa3j9iZ(v1W%g)rJ^R9BED^a{=_+)Y!{&P_5mu2!rcPYyLW(wqg>wrJ?$5u z0sR9s7J~;e*RTNnGLrZZHYz}YlLO?M5}@Z;Gn2Wl1*q4p0NsBQpttDoG(hW6_gR3Z zJ`d2A7Xdnm;x7YK<#T{On+$3eXwaE(gEqMg+J{FO3_2KLP}V4eHegpKgX(2A=#MN0 zrMM01iE|!N<{kzm;!971n)Kq_-UiLaE=2bs zHdy)_)Cj-h)d1EVXi%P?4eBz;pl#Sb*dW^wgR*1mP;!D{xIx9S3j;@Tf0RLeM;r8f z9BZM`cw(JskR};42+JpvGY(EMDC8I7#=EJ+KFy%K*ntb^GRvU2*#;GyYtWi`2IZP> z&@fDfbD=@WOALxyZqW4=28~-u{A&!#kEv@7Iu6@9>WhxQvL>>wH|P|uqR}RUO#2Kv ziro7d57VEFId0Ii)5Lw*AnO%_a-b20Vm{Vj@;?U6xNcDM8}uE8ZW7NegCg!4bPRj% z8`R(t>pV4R(KCaVye6MF2Hi%&Tk7-Ppiq>=8kj!PKm3dpxDV?mgEFG@XU2Rn$n~#5 z{qQ&Te`OB^7`4=3)KQ~R8H0@a!EDrC46_(D8MmxPIqgQd(JI)eS|LVtM1<2QFMh#$ zR0uPwJtklS&SOV}Q5WFNXw)?njWlX1=0zD*Et65tP$08W-SH9bEJiiLTs2gbLG3qp|u|}Qp8Z{}7$I&z1s8>FtvL_lf#&1;DRKCt;)Sc``UC&|EJ7mgf z)SNtw!?nCdy(wT+T0x_JE@V{WB1WA=N-?8eVpwsb*5V%0N*Fa3v(T?3@s={`COl<0 z26tJbcHwq8YEs^)5~zy$6^y!zUn&}9uVmD3h^}nZ2&7jr%Kx2FRZtJ@suL^9f6q7^ z{=uj&HH`|ZWz+&3#s$=>ZPd&OuJ(WbLehq@S*wFf=K<(@`8{mH1&z34}8df(TmzWt5* zZlF>B3}U^(?3JN>mlhWyftd#JEK;D)Z8K>pmf20J7HrZgSRE$S#oZ8-esY>L z8tYLY%%n`=CZ!@WGq>1=KeC#%#bZ)VuSxrG6ZPUuI*i8g97jrmNl(!_$t17eq&&$c zZAI_wChg2=(yZJj)y~6tc}J&YSN+NCjDOCBufR8 zy5c_mtjPIQO{!DPr0v-Jy-5Y@nlz@qNi`aqbg+p@>zbN$0Jdf(JwZTo>VSpF*utb4 znApms#mLs$q>61#+S{HrJ8(`%laf1`6w{fybup5II=MeJDf~12 zQlL6vj3H3>jDZ>&7^thrVGqa^3fl-0ln<-EuvIZ*D9jI047#*n1 zIEKugKs~{Zm_Tif4OEGQKvl(bU!XE22C4?Sqy%aLs-y<$dbU74#rYh8GUX1`qCzMY zs8Uq}^`d5=_SGk*=7GxFmdDyL9^bVO)clTtde=EnXP8P@?oIs2-6v2d z(4udkK4W~pK*jYB)OMr~3{+uc|2a^<3<}g86dKGrn1n_{I2R>{25JjZhXraOG7JyY zNPNP(QGpsVAyDqgMxYKNb#|bPbI23*(QIy@2G0-F3S5VK0WqV_ zqCoi<2Wstaff}`k`$q$H_DrDKo()vMMd}R8-+>x^IZ%!(f$EDx=yEksFH!FwYL9Q% z0yXbCJ-895m3ITx_<5l6{TryU3esqEkbZRqX(s|Q1St_);fe^-j*N&3Qim)->K7fP zQP>2php%xEV`76e0|$`J%Q$R7SbUKBCk3gUKS;fB9=C8ZIY?J$NOSNHBB}(bHCE#>a#amdThy-} zq|W#QS84_63x?LGmQ927q9tp#3eu24LHY}OMo^bgoQDddsR^88h#40r1gY=DAU&NH zqz|*nb54-P%?(nHMOez*%Y&3}MUc{01}SD$kc_K?H2K#cb=(-FE}O{x_aK$p8l=FT zjNeB*XE=7AV^@Q;4h^r-n}_u2Ly#5*o3+4UR{zXqO~p<;!t|_WEpwZ-#ADW3%#Jau zZY*Qt%=#1Oa5vtp*La%1c|MLMnzarmlgzq`FMhLZ$!4`oF{?W!rkXVmThq)clWx{& z{DaBa%$kqyvzyfz&KzdBaU7R$D5qJ~a+&pO9<$!&H7hP3@#1}Pv%V`~R!B*+mg5F8 zlrrlFoJGOXX6-3MJ{VihteLn`o_H~^f?0RawIW|*NhPxaE1R_$2k-zbtC+Q_s#)() z@;kF$qH=Y!R-)ARyz}eia94*W$ijY=j{em3r%rdn%>oGo{Pe(H^V$B+f z@Xlrp?n=Fp(#@=AxYeE5dYYB+lUbSivJUq5ryc{%O8eQY>VwQ`gbjl^e+XY=EnGv* z+B@7V;|Q}djx;OVXtUa(7e3(F80s;WeoQp0<0SUX6zV^f`&f<_a7{NW1}AWSmRU7s z6W1Iw|Ie{k=9;x>zFDCQ%$mEzti)y15snpRRa$N4dlvQIOdYqFH32Jd3*)w$W!Pp` z6i#E_9CSE%Dv_Rcl-B%-dqeUM0f-IVgo2Y2E z=ryWaEef?+R307d7Fk0qTHv(kA^L}LEZm|guw}5w6=_kcOcs6cGH0Ac-_SY1qUc16 zHsgnE7WKj~%*<}lz#JB3&S}wDT+C(BThz~O(foWC+4EZzg(f&sz@pp*Eoz5eFc!Ax z1uB=YNM$T?pgGQ>Sy|S^A)Lduau$s$Pd*ihp|XYNq(!f)5L;D?`g~_m_wOzGzJ^6t zYFjj-jzxQM0`F0;fko@^4YM0sl%bJDv6zdjO)Pra)S`aPEXvm0qDHuk4=pUJ(B7h# z-7E^|PAuq;Y(1#qPZrg}ZH(w;k+Zi&HTqa|6`A`{S3K&^IRh+OKhUDQKU>s#kVVh% z1*-;IRAPulM{yBv&|@eu4YMc*7U30I4!3ABj^U>ftc4GlI?|#xqb%x)kkQl>%!dq9EZT*mxQ`9LFm|d%9dR8)rxEiEiw4cK zXgpRUb(Tec;{oc<=KdVwLY;XQ%|Ye`%z@ntEix=3_r(^ifpw`xRqzzUmRXc*xkbg% z5cly0`&L+V5|7b-C2Ov-C}Oom1=d+q7R~Sqvo^B7H!=4Xa@b~3zU}lA#vK-wK1%J6 z(Jx#?&*Q9*ZD??UKHxJZp0p_C40Zp@qI7gWOJB}eRO*67|KQO@_76(lC0{guMBIAYs3yXfoeq6`Am(&S|VSml}pV-5=iLaRTneqR!rp2lnR;!v|0K#lm zMPnt-A*bD{j3HLVp*RkqTc}k-@D7KKx_E}|2VLa0CJ8I{#YDr$J ze#1%B%V$+keqzQboGfHjhQe0Gq9~4{N^z^&qI4On#$qNmqeWS(x}t7*s{$)n6@j@G zSsxdxT2-~0RSnSfJFE7gLv^eA<2k;d`}bCz`N66_HLS{8i}^7d*U_;yb*^L8nc!UC-t$KigU97Tq6tW>w+dRy{>be|j;%sxc@y(5jH1Sr;ep2>k}J z_9&~CA{2AMx(Ds>cChJ80DkRQ!Y3;Xg#Zk>xNo z!UcpJp@v84^)c#woPB$lefW=+H{Gpr<2_8**$+3Z+IWjx5qg(=?$OKpR{i}y53Ks- zAvJtN-JbA#cxqJ&T+gW&X1=oO^lP3EZ`tSX*{2BoU{yo3h4G_RBR><{7xwX2#st{Z z%wSU&>@(VQ3QYrTIv!-xAhS*5aS$aOHYJDJ1xI$9R^x{pHs1fUX&lmW*|andx#YDeDW6S;@BlLk*i^Nkjn}_6l__k~ z%8P0R2UCFlx>+!`Ig)C;|lUvX;Yt7HdS6t?bq5gaidLhvFCSshi;o~`huWs#J1h0&bw^# z?zQQAG)9GeHsw5EQ_LZoZsP@N9j1;)7>oXJA7vd>JZ4kx<2F4xVbe#{J4t;{*|h02 zwK!)}qw_Yk!%cL*z&L!kXw#!hHto7$lkWlX!1a(iVkxPc z>o?T$E%U+k&Zdj7zPD*6mSNrp=Kn}upKSW~Gky7DQ=UwARmyBvOcuMAWwpx^ZC5sr zUFY#roL$igc762ObtKs?N2*PK%2Ilhw|<1s)<4!?3#pJ9qn4)*{-js*2S*R z-R%0iyIqBQ*wqa`BcP{UE&AKl1D*kPy&Ghgaj;#zhuAd&fkW*ohAPN5%&sDMiEkJ= zoOMUpbpSOdq>yT*{`Joy1%(iRD9P&i=d3JTi0Q@a0Eq` zP+J^Etz~vi#bT^kZr5!TTS*+Kw2Cz_5t&!pm4t?C=*?R4#k_TP-M}+sSkGKojcs`L z8}-`opJCii!NHAonKqFxHsc`to2eUmpw|}m$X2`Vq4+lXjFC9Hot$=%6H4!-FPMtv zyX;zo^%%UHdZFze&fRNQ&V6=8?x!{f?JA0~e-Qf->UfmAkFj6T<~VbmAoi30xyJ3} zQ+72vZP&&#^cYqDBKNa)#hzm?q4atBkDo8tm3EPuV$R7y5;326{$MYn zKHHV`3+rGW7XQn05Kr+5@n5MMjNhm|uHjb&>wqCx_l?0SYzkI){1OZn1ogn|SvBu6p@8E?5ci!3s$TRs&2y5g+#xgEbS&@YTI%ZOlwP7T)Q1;L71M2!{)s{#h&Cg!gV)^mJ8$92Kl3;(ad>W3pp zTpz5qzXj_enr#eL*DcJmm71X^{z0v6!P>u*dhhyAi`~I0w1?X4rRMt>vp-l94>0e+ zU$SZ}cSOt7;56|95U zc9xjV1#8E7`f?#y>#*c%uzvd|Se35@Yc(ET57xCC^z(MG8s8zu$HAI`r6}}-*q;Wg zIS%6;OwWSV8oO`|`JM-B5GEkwi(s`xcRWCWm%%EBL&)@sT46R`;49j{4%T)YM#(q9 znuPht^fp*c(HR$z@{YN%6z^bqPi^rB&Z5c(&cj-yf21}TfmbO0DOmQ;%!wJekGJUl zg}87Y<^JUumZ9=j>Vdlkhnz--+F%F1njFd>=+H>qMvWkcmf}6q%?^G}bSRg_p`mz! zqE?4yAkpSfZnVJygxDRbiyg=v?9dbhI~-aa;!t#`Ll^Le)1lfo5{qQ#+)#xJ5)BCL!VJCJ8R@{Xi3ihbja<{CsfSiP=|aDHOm@qDlS%WD4?oC@o0cHIE=m3=?^|4kw1lq4EtJI*yoz4h_e8+-c-ccoT>Apl4H#V|_Dv z)ZC$FEr_obxnValv|%m0Z10e-gF|OfxT8ZAumqPnk$-3U*M*$Bl7Bb)H`>9^F%C_@ zM+A)_P8@*7(o0OmMPwSsF&swXcw)p&6rMm_$UM=ZFDO09p;=gtOp~b}4o{;l(;cc0 z(+r0;!Z6dJLbKTG$T5$(QGLEc({Ka%7BCmaV*WyMTIA4=iydmTgm{*+Czd(nTEUtt z9csVIp}(Y5n4%Irr-od()^y0ijv8afE3&ew+ zICYV6fAjpg%9{TWH_Bdf@V>1>37Ca5xP~=1s4t!&_f7T;PNT|wY63lAorkQ0fX5CM zLB6M~^^96PXOFyaD9=lW2E5__nYZkhcbtz_?;ZN#gF}5kvKG#NBA?IH*L>=0NsB!xc1$PKh4NS(tjv+eGjkVFHM~Dug_D>^%@?cA4akk3XTa;p0PYOE<~Behw%If(Q<@N2vIuDO$<@Z zNg;ZOMUzAHW(u)S4N=!=AzC^;L{(>m=q7s14AIru#5*TMzPTZaofo2C=M(3`5Ov=W zqJYihaUeuH4^!tOAxgu`v&4EOL_@BH=wx)LY9)p$u|cSEBeHv_;xQPTun(Rdj6pL* z_Y74E&SS(+q51{QdWC8^y7Ug!0L1hORT_rE*f&&8eun1T0McsCx`0flu#|67OGa$ zL-ps3P_3L5s?8`oJ5*2RhAQj4Q2Egke;{lDYb^;?Wtf+SD%*-sHN{r!T^XtqFt29q zwV^t=E>xX2gz7qe+Y+jETRFZXRCjiVs@&dC9Xb%IzYm6L?H{4Ke=Jl#o(a|63)JFD zsOsDdRlWzIs`)Hb&)<;ihft0EH&n9%oLY{{MkhZrJLL#*Dl^7}I#tf;)CRnVDa^?= zFHS8*!*Hi2<3Sdu-eP2oQ;Sh7)~Pv2_c}Ei?=d&dsf_VXMJ6~k7Hxe_{o;2jcd}Ey zY^YnmF~ODQh=(%G<)JcP*V-*2<~JDBjkoz4(R#?Z^%5aUDtRof?Yk zc+NS4t<spJvd zjwXjOPPG~9lwq7xcgH(bbAnS%Co<1u@|xmQ_*AD_!!^yRy3?J?KGUg|=!VrupUZi8 zh2is@{9cIMp1hum$)2bgJWF);&Vc zjyaX{gj3Z{I@JI(PqY3Rr=FtDRi{SWaH{=Hr_8sU>WSXBdF(!Qe&E!uhn)M!$#qsv zU3yHNp0RJ9JN4&Fr)IsSpXl>}@pytxAD!w4`zI%_=bXBOvi~}D64Smp^%4Cd!n6&4 z!jdseha$stI4Vr%aUye=nnZ`GO-z_N#fHh}4bvmsjSJJx_%QvQ5T+%*F#VborsXMN z+M61tSvkWrH(!``gWx})$ z_OfC65eHDVe3)ie2vckoVnL~DVcLW*So3|D5`GBNOzgw++F=@1FHAXq3{&+1VH!Oq zOy5rn)3W=V8xyXbvEi!e57+eU;aY;hIl`4YSGe-!4p-@F;i`@e)x-6vM!4$MrKP8uUWVrv(WT(nG~*;Q^WOaZMf#H3)i2&hU+=p8^iTvQ@DQF9IjVbxg}gR zwuWmXLbrwM2W&!#?cur&&#rJyM)Td_GVTr69F*M`t}(cBfS3=GAI>A&pW*6?$%mL5 zwGM~tC^{bx*Xt9^c`{rF&V}pX1!BDzt^t?Bbr``{!d2*MxK{i_oY%uO=yte*?uBdW zLt=UqEExHKE>GrF`MEi$=OJF`n$kRgjpBXA0dSzUUHHEx%R zdt6G3acK@ru`V^obnkyw$GJ2p9tp&j=+Y}}O>!y9?^0)6OLnPHic9&^Tlxw?RgZ+Ls_#;f z1}^PvNDhr$`lGQ+KmF)Zz9!V58Tqtu=_FdVB<5DchvBVVS~T3Ho#_cXO z+R1*w3sl(U(rVm6?%gg;M!r4N8FTlN=K+pm`9YVO{mI_Ms3R`rJnB-@&n_)M=Ew{x zi(beTm4TmcGpKf^44RcagQDwX(DW7=bROUKXV9bP88qWv2K|l~@CQWbcYB1kghXhH zGeXbNIxa%X@TypZj+cl~O4$fys~n-3-$$rUod|V6*O3wWZd`4ITx*ts2%HdJsczM@;}(5I4H*O0Rc^P&N&eD7906sqY~1-!(I zW^R>i<5usEZsqUh)&g8cM0d9mF%O-4xK+KETSG7jU(m8QF(amrTkBDyuUkhkvY%UZ z2XY)g<0y&@aVz&wx6+2WRS>Vya5%Z4-AK23VLMula;rNw;nHZg?qm8Gx2}$LD|~`m zV=xc5@Ep@7y7hK4$ELWsUdyeG2>yloU;*wTb*ft}uoU;OavJBuJ)Jrs&kVOZVI_9Y zbn7!xX1R3}3un_S)SW|oh?>h|NL}pK)Fo~$My{o9m03m(c(~fFcSu;vb{kolThbFl$yuagIE-gN83Ew?h6dcPrlRDVm1?^ydIv3;U`*z(2Ad;D%4`pW+KM(#1uYJtqL(Q?H_ zs||J`Ek0WQq-eRbN2?<)AZLYWjmLzF(YlT7m7=w@aX|X=t?UBchdU zWHi6Ki`L*t(RzW<$CtA7D0{yWc8RteTbs=lvz#?*563y?=qBR_c@EO4?qV;O+ ze~up|$G@VvPA^)^QRFh`TqEx5(VB}qFQPTa>(Li@<2}lT^GHwhXp!He0m&Xdli*QA zsz*m~0duQ)bOqzT^JpI0R`;kEvVHGSOYA`38Xg&IdAQcZqqN!{O|0Y5xVj$wi+}2I ztbs?J5zx@1%9zo}qk=zrl+eT@LsO4(q8);od9)6$<{njqw*})`dUOrvT6t8rwMSc^ zHXaqlO9Zs_XeqL`^QZ?V;{z79_vlyHI(SqXQ*i^&P^}~J;S_>8c{CaeJ9~5;lebfNiBZz=n_`+^2pKKqb#`D$D`!F9yQ0levI$$(Q51( z=uy|78INv5sK-!`iVdU2$TZQT;lEIaX&!CFJw#6T@LmG*&Lm!h&GKjsZlLyT)|%r{ zr@0=5&hzLlHqWQ8NL%Pp>>|eC60D0o`WY3Mdh`P8mU;9EXO??3ay7B9p@thgs)<&Z zjQO~LCL37;m+^IzM;U+js3V5Mx7njI$hF0zN?RF=UfVociQCAvox0)Z4v(tr^r$J0 z;v&8w|1OV)VZv^Y<{)N|NBwaIoA#04e&YMXqX!uBr$=YuJ>=1T96iiD2s=U_&=PM^ z<|y+VV;|u5aq4^0qgv-Y%6{IX!?=vG7d@JZGMC8tGJ6-lVb%?DyF)GSv0v_c)EX&| z$n7!D3yi@YlzHOe+Bc6zy=2TQYW&)x=h*g+{ruje%pZ9k1jX=Kff)S(wiegMmzC$=@{LGuR@GgR*cbRq*aaK^SO-2o7yo7s1u{^C{iy* z6;Y~DjB0gYjm|Op3var{D7-uKpj6Kou4`t#pJL?d!}z{2D&H?g#{P^Q6r(yrV)S`L zjD{>`{?#$Mgyc2Ew>CznuzX#NOuxp+wmwF)u>uo+i_t9{-Vmco8)GyDSCGCbMm0Cb zsOZ)h_1YPub_ZGaWQ@k2;amh=ic!luG3thpyD?lx7^77v{UAo2@dWuE#%M9tW8b3~ z6?+n+P5AIMMtPo52YkTS7v%6NMi0^9eT??tFVy%zjlaa`$FDK!h>PE1G)J*oWQf&z zB#p+?NSXtJ@s=>in zT{#u2NoQh}bT(F=^Rc>xeiveO0qrj`=I>bbeGscPPhE-jBUfm319#jkWYD0uqPcwS8C)UgR4_=+e$Q)kHK;fLkh9|kaYMa}upU@(!-t)~ErCvx5huLh5#MkqJRs~YHs;iJ6@80S@`N&i{R?f(>?{GXfLTIYLJ3JVsH z%R;Z#z`e+;g^Rt~vGPB&S9$e6?N(F&wXD0&tFT|`-EUqk-a^j%ylQjI%kRFuYH*yo z;4kDn;pG|;YJHNN&=)K4J3gc0DX;3_FLXKW)y^|seukqqe|c3Ghu}O*Z_lxR5ORUN zg=Gl2=v5Xp$9lB7>eW)z`G@%M43(~XbrQE>yXjRFt|IxCSH16Z&O@&zKc>b{=*e^T z(F?}B@@g--zVWKzJL-!c6{nvA;$%0(X#{E;<22J0r<~?EF6)oe7aNZU$LTvqoL*vx zD^7LNm$2dK$7^f=L;?(hnI1RwM8gbf* zjfG z6{oHEh~l&3^am_+;*^Z$*f%#$Ve{h@jf@M3b9tP~t&GzJ99|zM!*6kFydh3CH!>%N z|Ig+)C2fh*{B3c%vOP`{cTnp+af;d-rPVc9V%O0)J;n#LK1MwF6H|`I z=^dt?h*RiE=EDv2ImP)XdYZg24NqV>6Q?|9IgTY5aE|f#i1ioZbPM4ZSr@(V4<2FF z+>t;?(3hdA}fUoOnfj-q9-z z_!y^FpW@Wx-#8sXL&d8fLIUDd53O(nRSfZ}j{?Scox^HVyxt=)FkXW(K8XAH$sDgv zmUzh;uX}idfwp)}vd3#4EWz>WhCwLoV4cu-eL#vcUPCbn&ail$50BSf)NsYCDLfhD z)f@*Sr$J`Qp{AV7x9Aj#r@~@tRSTx?w>v;=rZi@q90d z*W(iLvX$g9JjBsb@%p<=yfT%Im#I>`8sj($RF2m&d_t`%%nlLTeQk64fBrU{yhZ3u0ap!Rr==;jHkg9>3F->d@&rChlAx6<67(GXS1}F?*CZ(M*8~muJwdyWc}s#K zwv)3rzY}!l zQi2v-PEh?Ttamj*7m@o~f~?mQ^w)y~1wW)`kEq$>1SO*hiakkCcSJoUhi3_Thn3Ii z9ag>IvHv&sHT`*?pqmK(%CT<=IxU~7ntXa5B>eac(g$KQbP$y?W_ z6%Bm)y@^l1HTCiO)~A=K+SaG|c0NAS=+ovwKD|JdAwKzsaxPlo!*HK|7~#|2Q9gY_ z?J+*3kM*e#Hlx@$pI&3^c%QzY(*&O~Px7hKWS@4U;Z&byqv|xD8sQE~%<$d4WEu9=qB^tqPO^r8MlcEC*ZzA%=dkK7Q?5; zk9>OY#HZ^|smn8J^wOuU?|fXR?$h7M^NI6e`Rr4E^u~B4>M#-viLx3Kl@Ym2iK=N% zRF23*wZq}4M7_YI)K;|fB&sh0ViMITHc>OZiCT`gIOR*!-lRm` z^(V?!BvGZYuqfk-aUP~&dC5fGMA6cTvX@Cz6n?@5Jg$%^f5k*y#S?U`#GI8AwWLa- zHo#RiQKvDw8ZlQ-)O0Mt4}6XoobsJR%>J5i|vSqII3PE_RJM0LjOARE3R+ z+K!r=67}_HBG-u~>N&n)@$p3ca5_=jQ2!h?Lgn*`Y5-kGR8M5ROs+`0${KeQwGSsU zCh=LWBo(-sq?P!BoVSwH1sCxM{@Y2)i(xo`GpKkciJwc7)ZuQDp5tE(y`Q8#50bR- zagweh?MaflVKv%6P0}2^LHx5Mxt}NLC8A#>>E~BT3V5BQGB|;ZZ<5p)%W)JR(div= zzE9#B>Lk5Ft`AB4o;^wDQ1w%iCL`f9_rE5oko@`!fdPI#^W)b^Y&7_F8y=%ywJ;JV z5M}bK9v0#{!UFv&fzDWhORxm_RRCSF6c^wy`&ASjFb^kTviMa9ov;+=5oGnN2>N0* zuEJ^at2jDi9h%tv>Vo&E;qa?;h+p61uTa0fAR^qa+4#=IV_2TSuTc?xJ;XaiXY}iB zB*&xt3drP_H?v>aF&Uk+`1Mm(j>q_wE!MBGUcaWtksH3m`?Ws7&)*yJt6P#^&HcoI zS=g2A*YDXFo7XQ_KEJA9RetJOz_0N*fR2Uz8it%j{CbWIMai$2Um1%tUkSewOZt@? z?aKJI5)I1w)gG@q&RN^7o*pJ^eb{8-3|Zf8rfLZ-@K!afDyBNBX7FehnPY`DihL zcqh`&N%U`qUqi5GmY=_;;Me83e$AOrzZdwGw8*cLtNnVs#?Q}7>;?2)=U2#jzk0** zn_sQ5Y=d9EO@7UV^LLJ+#1_^=&aKRW!${apZFc!J^rBynZunKHEB1q*pZnQApZuzh9@zBF zuV<(fkgQyWWEICSEDK834HU5?%Wh3p6fTA)Yl$;i+ryLf0jpif+JO=ok~J?Pncw>- zs}BMqll25KQOT->k?5T{nZFIeIa!ibH!Jg?geRH*x0CgEOtR|7CaW_n-eg6fDwg0Z ziYFwiqA!{EVUiV`D_L!FC(Dgw9$D+wfEtaf;*n&^!TRd4u z$|h@9kU>`vBnxc5-2z2vbkS^JMC zODB@G5eLxgWU_`M!)ao|N&I<+8k{AzE6KWhoyTq@Yy8b*J-nT)N_WZiK7GTW2gxe; zh`If9s@CKylN4N|rii5|PqBLiUx?&jq zMtoR`a^g1(2~W{wq_|Sl8C!7?l`^DgBFaXjXfY1sHIy+$`OzO^@D-IJQ}hj$qEb{B zqcf%GA5=_8QElwUWnYROp>AS|TH&vx6xB>lQFuytH=jph;Sa)?x=rrl-i1 zEk(_66}hsfaBWeFKERP9MFmj~6L161Fg$09Her9R6lKbtqGH$$Yn~K!#~PeP?Yt?P zgQ59T6j3lm?FyynceE&+qQXU(6P1dl=sH4*rKlS|qD67)hdCuu^l!-&6)i=aWm5S6 zFGUS1r06N$R-$H=Q&hShb;k=dsh^@VxQ*NmQdAjD8&Y%F8<9`r6fJL(qJXCVv9(Ll z6Vz>=qEekxGzhu7Fei>8v0I8Vbf-3hQZyHz2B+xeP-=k6<5ENxx`i0sT={=sJ;-wU|znr2zID$o2Q)IZ7BJWM= zgtK>2wBa6WK48B+Owss9DO&hEMKfQs-W&Gwzw{8+Z}b(%Fifc$ACRighE(3?NYxX3 z!C+IWt_P;__c2nn8oAA>dWJ%lR5`7ws)_(xDxbwq)pWeEr|L*>s``beYBO9JQgs^t zpiN||I!2{x1p+gtYC8_$4StDFmBp8;viJyVVyY(KNfPHKr|K~h3ox!=sxJP&L4{KF z8rHJRiJ|3El~O)cb1J2(c;!^>{ytT{nyGxgJyn@%r|M?C|IBVco3nwF+7Krt199sd|dygH!dx5Y|Sip{e?S zw!>2SdzPuHI4V^S$E0e^_*AYNNY&pHQ`LN0sW4p3`Dm(E9!u5Uo2rptQ#BP9 zbDB!x4@;WgIx zG!3mnd{xs_4da`n={N>9P16KKG)q(0=4smAB8_Xi)3g@00cqNU<1i0Q({fxMnWhY* z($r;in%ra3l#D^M)3gIobJKJlw~%FCntoZBrpQHU8oZ3hF@8mw{#lu(m8;Tp8^za9 z2Yf{CwP{*_9b3})d53!7C|ujp)C6z0r)kCx;@p|0?)VLvccrQF?lg@?kv(aug0slJ zFHKkR2<7%u&qHY%b1Y3q(C;|4MEHp`bvj9$r_$udV0g}^sWWn3WZo-j8jjmn>D@KP zW9@DFh0=G^RO}vOu;N*oHvgNZ7pU@$T)QdmH`+9S=Bu1;a;T8kgU)72RnTG}*ya=Mc0r}HfUMGc~GLW7VNHUc=lK}-psx+lH5drBPfuSP;BGME^>AfjkdXuWsd%Ium|Nhr~ z*ZQoOlk@Cn?|m}7Gs!v6iBsQg?6W;ipP}E5IAz&MAMj#VoCfWV)7PlGCr&H&GJap2 z${e7!KjKvJEOF1r>8%TKT91s2ajJYNP77|3$4&CcZ<4)$NkQC4qk<;ZlQii@A(JK- zHR%pMEN;@}5+>CvX_6PWQR_V(OPe&jj7ixmu)U&5Eh?G#ox!C3)l52$%P0_MQf{+J zMX(vwttMsEGAXmRNy&9gIvj7(5SK|~QQyrNRQ8zExrIp|w=%I_u!;4!Od0`e%p~CWNnZ~&DSenpT~OrB>hpt1U&6e~q!mA!RBg3Moz|MPbE`=cc9=8=!JXuXqPtAGi68fyH2#=L z<<6V5>mtwZ^8A5Gvk`b`(hMBJ506cnnZ>LeSmIV_ zHtQ2K&12S*d}bBTZ&pS8fr4+FHLRdneT$eivna14v6xwlQK7h5cPp87q_SDRRb^Z? zvqsl8>m@2RFzX3&+srC!H!BX)oMv^1H>(f6X=v8cH(X}DKpwYQYjGFv`^@Tr!Kmgp z>+^t_HJ;4M3=unO)}chRnkSoOOEv2UY{bV+&2lw2D~dMQi8U?Ey57pHvFT=w&tQ($ zW);O26mDadfq8Aoud`W`F%ONq(3h^%@~N5Mnar9q(9Gx4%!w}J=;3(gK+_52IMd8| zv1X+p*DSN1W}3Bcu34usZk}0>7SiuUW}U=<#b%ZN)~tufvDC~pE%aceS^3tO<=MqJ zJVg6F)P$Qy>BR}NUg5iwX2t$8YwtPwd(o_SADPt=pQGGkvp#%c*3qYC-F{)#omcb- zOJ7riEP5x4Ma^?q^kGqp+7z>}R*8l0RxGShV$rG+7M(9;k-dyX6Ojp{tVN?gu&}O| zg=<7DeCJ`&JT$Is(MY7$u&9>FqDHudPs|q0u~-zTWziS)EV|*esDDG^`z$(zYnbG> z=uyC;>_Ll)qCYwq7JVJI=sH?PEy|H-VNFD~lU>|CJx{fJU4ib6-c;gQ4bu1^Oi-&@es@YvB>-{x&3F+-x!<4%4ZB#C14YBWVf;o zfmI_4Sv4Jrg{^9X!zli)RbQb_8LRwIS*r?SD0Y2d<@YG7CRVd*0n(~l)fs0|zNS@^ zFtClyR{?ss^p_@aSfXzR&|M5^>u<(S1~)us=~=u#jqCHQ^*Au;Z3zFuBlbqk*m2?p%(0e_gc~i z6mCVmX;y7(ZPk%BR;~Y#Jlk0{TZ=2 zC-HR;tLDMelNvs=>P0`R`u4YK#$ckO+t z!lyWhhBL|k8{*;ZSyp{M+o~T?e2!I%@DqltuA{X7>T4dZqQvd`3S$)Zqwt;jYK-Cd z6?akXZhf`IY#c$}d-c@_y|DtfQ0absrDG}%AlrlbYJl!of{Q5ru)b1Ysoy~M1`X80 z*+A(ZHqd*!8t8sao2tawSUbt4SvZHXCY#zI6Q@wrY*Qy}L;;IUY4`zItTsh4498L1 zu(7VRO%+2n)xobQ-o&OyIFV{o=VmrN&R|-)e$=%gs26i1Yj2whV+J06X4C4=ZQAj*P1(lS_&&>~ooF)Frtikt z)PB58mlxYqdWlW_zO||6Qk#Zg2daN()7+nJtmnd9zu;GL#3pp#Xj7ie)QumIb&E|` zw%XKSn@wjhdAm)GcF?=MHodpcrb9T7cKdDGdcdashin>!-hbL;I&9Ovqc+|7%cc)b z+4LnYo}mY4ZK`nI#`-HZ4ZKP3(Djy$^9XIq{tw6FUmM>&+jJ5$Zril$zD<1|*i`JH zO=D2zkxk8?*tnLCzCE>R+6#_P7P|(*n$^y&6YTP4v#UpTyI$n8t8RX~CKs^lx3}%u z3u{5UelKiSu((~raK40{HEiwLgC3>qnvdxgyZ%I6ExYbRwe5P@z^+7_UCkOY2mWhh z*J_ttoA3_?`|Ub{>rv)UU|(Fvp+vj#B-zzI*)B&4v0B+>!}K(}($nqgh>7?&!>-D$ z?Hb<3F4u>4MbIDD5%|ciwe9RmYHwHb4t7n#?N97l(b29AxPUJ@QzJ@twd)RE;)8C) z#yw=|#dgf=Yu72%>u*<)0d|#xfeizxd5~RwhOzHRyBgvivW~KAB>o;v9b@cjx7@C| zc(H<-zqe}&a;&t=zRs@RIK1Aj1wY&M1CAhbGy81i_-wOtZH!%wci5G8w_Stwa18d_ zwflfw)eqX`Ic!&xBX(Up%JvhC!_&X)nsLg`cb9gxIsHHKo@G4#xMWwwTl4~RG3H-- zc>8}$e!?-w>8Jl=e^!UeW^?Fl4u^{6bZB8NhgRXlTMiY<=g`#R4%R?)Xj)l^j^e8i z9GZ^O9viR-vBl;P*HWIM<=Y^N2g2-fVHG?^cKAZF4B=MTZ*UKC)eMXcVqqc4*QShvNTrXaG$AktcSb z+#QE5py+FdQoyRTDuy|Dmc^+hS)Hnu)2R+9mCLE>_z?y2I9UeJsatqEuTy6WI`y!K zQ>LO$jVb0-{o+n}syj6lwQD%##a>j7bLuJ{V71Aq9A>9p*LJG2)2U@hk9VpI?jxa* zQ!kL$<MAB3FBK;gztmBUix2$L7GCOPH6%w(q`DNeP*P;^cuKGK^KANP^a zoH|-K^&U21YfGoLr8#va-KjkpPUY_G)E~&(#i@_GvR^l+sv-)@r%rW4x$aI`@iU6_ zq&7T2(_T(Z8}8ImeD$SM)8QH6)L&EBf4WmyX0dH9^UinbB~~qPYBT%`om@Y|9E+X$ zZiQ3V@Xhz+4)aQ<#{S?`gH=xL-atQoacTqhAo{CQD>gdS<~Q=fE*#k9RO8)FHOJTY zsrwOiJf@B(9M`Axs&c&AqbL4AW|ero!XH)Rbph?G#p_OWwxNBEc&))Ryi+q?AD|x| zp^zzFtuWRc&vkt9`W@FT@%q)uwp#I;gJA7=HHF0%uf;g(h}RW7Kz3)m-bDq}h8HPl zi(VLxDOiNHxQh`D<5kKP&-qsI@_FO=yCq)T0>m=nH8T{ixF+%17LMos5%DrjVXnl6 znv<`Q%1>yd4HFwFI=KpGrA~OiiHrGN`UfjgTym$n zl!=ioUD}Dhty~&~hG{O9XiIG5ZRb)+T*T_mF6HdvQueNl#Y5!i#ylwVsY~f7*xjYF z*bZ9{7r#Hc)UKaP8?d6ki@%9noP*$!WtdCxxcC)gN4j(vm+;*v7ys_K)MkuJzhN(K zjdQ8_c$WsuaOoy0&UR@iS}k&ECYmgEDGiP#F3!_*ao)U3{HLS?_ifc z-0M;gOx@>FtqU%Fg@Kn``W0O-yEF)&UUA8L+ofTsbH^ngvfibZhc4~Igy$|D#LyQm zO+=lSE-i=Sl}mxFZY{^DY;M+kaH~&tw|3$NqB-2G2kO>*ti(&$bGl{VM>NXi)?Ao# zyOoBXn2F;h-8xd5{oZ%08}gNLs|><#ly&Q0Y^vne-$Tgp#K?tiO+}d>nG-F4cB{b#x42Q4 z^5gtIx6U45%t5!B;(NS*$gO36y7dRT9Cm96R=;tCoR1RsEOp`)3Z8Sz_QrXR3l3dy z>mlB|=vF)ua1Ny}xm5>YOvO25z3f&Z#-P&``ia$lyY(0DBF|N~D#45KxO2m;qBrR| z3g4oBgzzO6{^M5MzizF^1+2Qu>-XG>pv?o`BY5YbTf?5XwG;=QxmDn~TZdn`^#X~n znHSmQQPpf7?Z9oE&g;>Z{2m>_$O;~1tLRa8OvWKRKw>42GI0|RDtpwT3j1IYw%|32 zRP)G=!5D+_)jg_P!=nu_*Yqfic5xnkjdx8RRYu|)W{>V-jn$(GwLDsn!?is+Q`e)j z^*kzE-=kc1k3K*LWOXtg@o&U?bPhRO9@T&sez!*zJjC&mYtW;qDIR^3>d|IYZ|ac~ zAHUIzxXnFEL#e0{G*TbWG$lKGSafmv?u`>34La%3@xMHJ0pB@~I$;>rUiRn|{<%g^uY1(>Uyr6B z`Hn{e(fXlBBVd2RaYDJ5e9!ns^=O ztzPA+VW-@eQ_P@AH^HaXy8rdMyx^=i~2uYN$T#pH=;-+HwXA20K2BId60Y6nXH=v4r_ z)_Apd9sRuIl?nc919MeD z0(xNvw&EYOt?tt}G>h|TD4y2#seB!u3e@+hKJGewDi!Zjmw-=~gFbZ(`Q%ITsT-!Y z^y#fMpC+aI^nQj!5~9{1@Z{Dr(H=<8{p3ZL<*Do&o|IciU|@pm}} z*mKXP+c^8sr)-bd4%cHJzeBSPrJr*AuqlgQc?`)A5AZ7i zf8y~Vzw!+BYv&h!okX$Wewi==r&0Gyzq*g`>wEnBm0zt!`85>3qTkm%j`6cLiC^o- z`PE~xUu~vS7tSHa48KYvjCt6M3urOZuSVba`E1g!UGu1IzMplL>C*yUTj-bbTR-b5 z`&D+SU$4+^nV<8w{j%fr_w->U+gABC36oc|?;5{quJbDy{cz-Gzc&8j*CjOl)vvFx zeG|Pxw#|N(LM=4L)osMy&T|~c`5olFlYB5A``*~a@!jp${=I(PL!Nzpbwr2#e)Yz% z1AbjblS6*p!SFx)T87(rfrp3v+H}OP!AJdy9HUP3KJM2nyhPy>emUMa>DL*!PZ1mM zpJ6;cI>-K)`^I^{8eU*KGA~mX3SaT73~K&O4OhwGnqQS}`t`}bemzC|+kUR=^z%6` zb=>8@@A+BN)vuc<`M|GwXo}Atk|)YMA{Vs6I23$BPf_8iUn%H};h2xM&-@yRJuk>3 zXF!e79PV5Jy~-DmQ7NEi=!uzC0{Ww557LhcK{4K;>!%WRK%DtT6?&2N82X zvn>H_wgz+^`D+LCBP!JiC=d0n<(uHsH8W*y)grNHyB{O(E#iD z1hleAKpXK>IG~!*fI4A479|E0OA6?%33kOg=m3iKkCjnLI7|_dJ0q&EF&jQ+ohMxyC>dS!k zjST3ku>sCY2x!iXfTnB?Xwz2e*cQ-|y#Y--Mvljcc`~5#XXyRefC^lo5BTa5#|{Ut z1~e#dP`e8RS=S<{autL6!5madd{CB#LB7KYD$ppX>zM5dD%BIzd)}Zz&4co^2&!tk zpl);z>Jb+92&!1mpklp)s_uAUYtZrvrm(J1D4TLxQ?GG^qP1{zXuu zaT*ne2h|0a(CW*eHlfgnpju!d9>MihP{XkcX(NL=j(0}|H5cC_$Jn6WL3mt{&*+1! zCmG}(qCx$MuO|dmU`9}-FbYM#p;ok>MeQg)JIKFh)H#Q-=$=WPa~ZRUeZD0(G+Y`~ zmSsV`gnxNZAFc@MQ=C~D)c#dLEnOc}-=BgSfjS$5`WxX*L9TxcD%a+q>TV6ni{;3( zjhaypU9lC%pzT5Bha1B&3Hf#eH4b@qk{{A{1!dmNHk^WIPf!V%fg5;?T>FCh5vTSC z)#E@=>yHHW`WSt>5Y#Jtcah_OdY9-2@?H+AA17m(^cH=*9aQfJy!J4tYe;)U-nfa*kLfqweiBqS?87fliSdm1 z$aqf9aJ-;C?7??0$?+BMLzH_R)IhAq2pM`Wi@~+MhOTEdv@@H*_nw9-p+pWtWAJlM zL%nkuT8+KA4b{(MXg&($HS`%SAoVRnyHP8jp}EMH-%x*CLAZdS#R$J`ux_-$IW&fr z7dDjfj-k%)8u|`9iW(|Xj93^|+|Z*EhMtr(G_jPyH2{XPmo_vVmEJe>6Izuql&7qr z^GGgdXesVucX{GfAWwKJlY13IOR5=sXJ+snnW12PLmxIUv>ofc2A?HRf6!1j96$}j zU=13Bb6v?dWM~EQH8#`*2eGP&A#?cu%ZM6kkznXP8YdY_OEz>8-V}qsEe#b;HI#_E z__moLTXTcYDVV}YH7 z*_ojzx?(I=;Rx=bPCHGXv<`Szq#o1 zRC*kSKVLp^@reYuKy@YRooj-tbAL&wl-4aa94eOu4Z$=Lv>CYd^ct2%o%!r)=-?PEF!UN@Z}DFGhdfd5F7Nk8^!Bl#x_AZ86W;Gn>DzOD z9`VTwe*W@>SVumjlKDg2mpP=53WPMeXh^PNA$^Snr9vw5K}dDVhx7#PDuk4^Vn`X4 zL)ud{q9gyDFE67eBbLQkx9g>(3W{SJ$lxe@1QU;KpU za0fyfiG#=*BtAM|F|MPGK`czhA1D%{9*o5{yo9ZBNZqj#mr=Y)NR2TZJMkR#!_14H z@Cvp_i2LD$vBmeE{-67^N@lVh7GunxE3MKa|~%Y zZlFR-`i1e>jz=)J3UMAJJ;fE2OA9F-({UL2(nIo~55C7$l!*}slW`F5X3(d0AsL^B zRC+Ye3y0OdWmt>QtW}u!Vf~9xdRU5ub-jI9l|ByZFWf-44q@&8B+U2RVb&WAt7Ffw z=JyZlJSGhYYXPbZ4C~85VT~Oe)`>5}a*hqF(73SLp$FEW?D()IV<)mt28LU>|W z%O-_2crxShCtl*%^svk`!s^}nS6IKHtR1g-J$ppW@m7wAN?|@;<&3CW?ue4AM3lX1gnRQwv>NSd zMARG4(L64q)3}2#OcCX-ACVtVk*7gKfr^Aqe?~YK~WV)CY}$DYS56VCgUOI z&ms;c%_a`2%pp!DW9AYEy|MRKo^K>S>_g&j)cHF#Zeq-?s4iggZt6nSJyDI=8RKx1)NE)pw%YzcZ@f z-KZAdW8V8wje5dZ^m`iBXcT-FRhQ>cm3YBpmIN(FENgK%8|hNxCxq_ zGeOnzBq&?n1Qjfhpi*xqs42F2lxQRRmvD(|R7&6%92l~WQ`cs{WfCaMpv;n=r{ zdVgJ_I%4gwi3)5?RM+2m+?}ZYClgh@N|LrWPtxxnC8vJ z`)jgpiJu;M&LOH{+_Jfo0IkKmSmZ>C2R2xa@xthczbuUa_mV~)xF7b?MqgJ zqsc0IB3ae2`b@IEIGe1g7m~FW%P%s|rDTnJn5@}PljVDstgg?KRrp1+BAAJBIZ`zL ztrT6tkNHy6scni5;TeuEP0{#eJmT*16m?vYqKzoNDn-ewQ&{sTMfHA4(R%FLmLli& z6s6L{1VxIaDu&g_ zTRc^tqx1Wz>QXLM;qs{(SSeLQ6I0c@N2-EjQnhYjs#fhv)iw;>LyY~YvR+PArkbi% zmZs{9XLXw@m(f)Aj!jj3V^i)`o2EtW)3l>=nudLvru)6q)UI!u4&t-^X&Q;|2Bc}k z;51DglE!t6X|jyv5wj+wsocag)ti#0IaAZ*osq`%7HL{BD@}jTPScI`#Q7;rhc=|? zmtWG9_qQ~;Fm_X#Hf>H*pIvDxbu>*EE~V+)duf_`KaK0d(zGF4x_sHwRWDb%&SOM@ zbTxiEUH=tKSD`}b{Cx6S#dMwUrRy7ix+aCwb*xXiY7I_T!6E4iVerg!otcxal9}l` zfU}r9H(k}{rRy^8=P_t;y7DjMIj*lsmt$?Z3|z(Yb?J&*pRQpTkJBjn zQ@SEpfZQ9>RRp1p=~{y3o743GWe=t6Aa0&b=ljWYc^?u3bskY8ZeZ-wbX~-=XX$GF zJYC(g#q>Q|XOHPqyqhDYGdW`_nJcCPIE%@-W3uLnX%kZOu^kUe#gzD7Ofeip-qJC7 zkbv1Zfr9VHR2muOVmekiCQFr=mQ{}_sb-9|Ib!<66H|l4n9e7$PjXCkTQU~Ph-nmt z_l@Z!cJzyJKa-f&VxR~ORe|(I4LdMh=+a|>nnjGU=kC;wlTV_mI=Ek@meN5ZYZ(dB}=f^mfF&$n& zeGAzKNAS&}n3}GLX$k`0$J7iJSH_fcZA`U)j&YAf`n5Zz&RC2d|FB=F4AuW2Lx=4d zs^-YxZ;uS6waw7S?J~3osUtJ=9X8?x@{G!m6QeN$IY(#cB^rO7q24%(HDic1Hbd7Z zWN6~V4Aq;I!SB5psxl=*yKx)Mr)Fp0}IgL__PXc>;-5{gdGP&2f{R#cslA=^y0 zVfU;I?k}97(sM8`L(B2@{0#kz!3#3<92*v9sQBUxokr^=8EU^KL!FLi=*Yyl|%y41`o*?Jx4AnW4p_XSebkdc7y06=_2U#QyDqN~Q5C8Xnl}4QHGA;X8 ptyd+atef)rqoN(BnjYJaCH=do@PL=03cc?C@3?ILJK+C4{vYTJVB`P* literal 0 HcmV?d00001 diff --git a/Covance_UCO3001/browser_profile_4/Default/Code Cache/js/5f665e0d3a0246a8_0 b/Covance_UCO3001/browser_profile_4/Default/Code Cache/js/5f665e0d3a0246a8_0 new file mode 100644 index 0000000000000000000000000000000000000000..6beb2ed4233fab60cb796994fc28c1d382780e73 GIT binary patch literal 19972 zcmY-1cX(9Q7w++IriY%8Ndakrgv?}SGA(_Q(0lI!N)rTWBGN60fYN)f(gZ<3P?Qc* zm0qL@NEf8{s`vH!yMJ7s=kuJ*%-(CSwe~TYoH^0k`h%~FcYpcH3{;TZu>*VRKrk~k zkeTUE&8+H8_g1T%?oA6;O3me~&TZ*H@RNp8@vBOcR`za3yg^hFbnJ)e0vI zLZL!%TmC2lhl|0MApD#Gwk*YvlOf2g0>!FA=LWE{A(UtYt>h=E+!(q`d=p5O8uDIq z&6RyE;H!7Ec6aF51MW)U-eB*iSp5}i0HhCs?>>g7pFpQiq1$J$W(ZXL9HNIq>o1^- zql}pli2khJlzsa~=Fi(o?hFW{o2eJPG2{KiF-3Mo7%6?cZ z(Fe2#M_{>hJPLi}ns8jbm$?%B4XVmNQuqW6ma#JDqR*JmQtT2qWtMz&8OBKUE6`l_{_CpF1DSLU7E080D0@R|%N_Y!dftTBe<`n98ZW1$ z=5580xp!cdbh!%y+LWuwowi3!uYto`YD&i@lF^sfSuVVs_)eCLPp!B=6dUl2yKMPY2)7l!pf82$crDvT|s!|1A6g?lt=hDq= zV6DYKS*wBS1q_TWXy9+@9c^GkjDhBH2EI%*aHzb2yd(p4xnl|xGdacvFkZExU#e9*zb(2fR1bT*K`i-Csk87TO^fnxGQ zF9V-^p!M`kz1~L#-ulGA>`x7p9&F&IoczqdogoGe4>NFMjDeJK214@AcmpvLG=8Fi z{gQ8zfp_JByfN9p5xF8yC2qQbzzhQwr2cFJ=cU9~2AV81@Q3tUY+&XR#r)d9*GmoD zUS^=fcLtVS~_={eb z5t4pb{XAkI^Q3{sr7Y$UrZQ%MH?ZI8`(Y^o7e5#zE zsgCE$N4}L3ua)oL21=QXG%H|ac0nWg3mG|E*vQx-M&?Sv2qTRnjqH$-MUBjorcp*Z z%1J31t+8@1#zVhlxFb0hyquVMe0@`aH`Ba9RsW90fcO*L|Qnvt)jtJkt> zmQm-W`X{HP{gVGQU1nsN-2KML+sln~m7Ob$yjp3b#wzXMYV}z1eP?9G59+xDe$<}G zt)GlESZ`$N1|#N;Mk1xL{Ito)``zh|WEeIs6ZD47q{OG$lfWY7~MUyA*y zk;U@YGo5!Yw08weEGTGVl_V50al5dIPa;hCB2843)$*jMN$0SMQqd-c#+f)7Z{kvt ziIij$wcREXJtp$|Of>SFSQ9kSB;CYo>6l?6Hq%6sOp|k2ChBCHXeq~X|Fg7$iGM{_ z{7;X{Cbrfz;jU$(cWtdB6Y7~rt8ZeqTxwwAuC!@rqCg|9+1SK(Iru*{nwe<&Keu#z zF7G%0&%l<-LDsf1F|f6XxVKE~lzeSW43H1on)tcBiH99E?p@WT2SH zZYJu#Z(_5&-^;{cxhtu?O)Qc%(xH#~D1mAndjDy{GEO}jZ(^eymO>NMr#U93&oyy=o{75iO|+N%OVqD#O^lF3D^29CGO=v6 ziH6^q_+^a=`&tvNzBkeNf5z(gFV_$1qcmHm@pAV^6B{;~D7wkSZaE=UH=7u>#l#D- zZB;$8Q{LEaV%`qz_ipt;e%fQA{9Y45N&7|h{Hl87ncUcCV)%X&{~R>Y>#&L6CH|<+ z8Oc3iBK)$6Q&Quq^15cC)-9bQ4^3Pa$798l*7AddJuy-JsrEy1pQ$hZQ{}mdy;A6< ziI1iAKPDbXMwppGHZvaS)GBMLkoh%)*&4h)_M9cI_ zX38{FUb3N)8AoF?wiagkiStb}S+Y#-wls6BwV8|ZK*n`8bM8GeeY=`DAtSn(nIX3BX6p4&9N8z+dYdW!p_z7l%p8`1{ghvS zGvlT505gr{XR!@ZZgTP?tu;wGNWIBsCQmWzJ(rnSSvt*3V6mBBrO4N2zLam*nMwZ9 z%rHs+$;@nNx86*b4Q5ttG*fbu=E$PWn!nx5H$R(sCeb_1G?NAL=Po_B+sxa0%&e8? zd(CwIMZGzo91p6tLwa4zN6oaCrN_*~95-V*ZKkEnKVzowS@r9@#{Xfafvl0z7tM6K zWTx6>)%icObo^K5RWo;PoB8yP8UI}~mE=2lde6+R``Q!nJT@~)PCqeI8Z0c8&GL`zGFhl?wlKkB(Jzk{>~h3r;gH+H z2ObOeCEaUbiEI?3&qDPy3)?a*^?RH|+vte#>^R(-uLqs7#~LPkRiC#7p63*R-iP`Zi6G_^2A7D(L| z8vmw+o-HjbYh|HIYYQ)A?%NjDx3SQ&t%X243&-W6eAM2;pW=DP!iA0&65h2iSypzo z5Z=W?v~2GBpXNO*{A*r+)j04!uXL>Rk#dnOQte|4s|Kr_Rb zw3}+7$TSN(r)&HS3)93r(?ZkP7G}+{kZ-PqQj#T2=BZ!v)f1V&$il$I>f5&#IhT5(){Pdvk?xyxo@~=O^RtDa^384w_x4z5 zvsXRaXQAPK3)|#3>3GmW{9OxO?pf$7H^ukB!dG(kkzRXZAw}MJYN4~Nd}g7pTD`Wg-(aPp(aIMlD^DccYNfu-$`)B$(2Avyl{$s33@BpdfE10iQd*ovt$Zg> zqpVygZsm1ZD=o`enV(>#aH5r|<@KDbPO`F1QXE$LIIUcf2a@U1SZVCG(m{?&Y>M)b zDH7(h(pif8tt87#`6Hm*f>z#=k*QXm%ZfBBnatE=_X_Z2JauUbjErrP9lnRC-hlfRV5E$#DdD<$PE`TCKS5|6bHPqYtmUHnhA=5s6E zURYW4QuVyDk|q;gTbUbX<9DfLurc0f!)>yWXR$F#j#zD6&1b`x-$uUzHlhpJXfI0( z+lVP*({&LW+r?VcMs>T5Npd>c#(@|crDJV$inEdQhK;H6dkGt#m9(*-l#SO?xr~i9 z@=l_Szr>ehW4?SV1Z{XyZM2df(`=lQR_QiAl_426mPqwX8~el%vT;1u#=|@tD=X+I z@fB^{mp5zcIeApaMu)mK-j}ase?8?@U->t%aZZLcvhk~&lzNSAd?WXo*l5$#Mz{ZY zq~pH^H~Y`0Eo~f=xYjnl6muIJEo5$68wJ~`j!rhh-c_ERZLE_IKd`Y)EFaqFBSU0B z9~;g4+Q`?>rt`(d2szZ>M(zNce$FdDSv%ZD(=Tk;zO)f5U&w(GHbNt9G?Z>)n4-L8 z@>Cmlr`gD!u3pbj4N`5EjfHY!w(^@}!#~f)C$e+C4f_Hc?d0o)Hl8lB(Q&bj?W8bzdxMpfYuRrRyfP*gyX3j&WH8F_5ClLb`8SW zB!))HySc``8O~veZWYe0c3SVfaL!7ZZsClVE#1R$^a!VC&v4F5LNDd;VK}d(L7#Aa zuM5}rx^T8huzxrM2ZVD&$`1@@s1zO)PNv+Eu#dutlC)35sVr+`%4gxckP4qG=9l4g z8>Luc852$)sWCR3<#K;qIBmy=(`-UGYvuVw)jT7d*HU?wVoBJ%aJtLd`Qc1k5Kga! z;S^e1zd(|(w`%5@){~FHmec=>4pgoki za_pe`a3Y)~azXB%3Mcn$IQ8Vi-@{oizev=%aLP&h^Wl6elP>6dk+o9uk8mc-ii_bq zm1j};sBF(i-O~A(E(hd#RzCdM`S@5udHFaj>nrA?LZy5-tLEbq*;y?gf$I5KS|cBg zo9CmyWVOhL?M*$F%$E6Zw93ba;$IZO$8z(h2vXNaaBM>ahc-q~Y*PdUH%IV;=p^Qr z9N!i}sqGQW`Z~Z(DOb5DHM$q2`@o|7BbQ1rvqRd%cls~21 z-lBZ+TTyA_ z(ZUkNLa|z-XeTSAs4a?!d{MNP!i6ltG*eI5ZqgWIl6^|mhbQFE%WMULu zoKbu)b&{jl=Z_*f5XJq>C_-6LT+NQ+x7;W`Z5qX|QsV6>Hnxw#(jkh|vZ!+ucjc`< zQIzi+MZtbicn3r=NdAyT0~PBN#riagQG=r}4AEHm_VXxu4UJ-xOdS?Q(w9;6mfT5E zw455nVyQGOitHIt43{P|qj)qYioCf|jGY&S`Ku@zNS6hwVR;nsD^&N7QB2$%#W^Xt zHHzjtqx5^K>e(H|fjv?5`6Y^G2cq~&jvtKT%%dn09!C-TB8o|WM{!>2W9L_~huK+Z zwA0yaXRV}J?ew?V*&&{AJC6(5sZiL?_#$?SMA&I1r6cWn4{fK9WJTE-ZntwpYDL>Q zDe*CO*2s#|8kc0}PO@F^neAk|?G#I~lizP=NSd7kGCbYRw^??c$>wZ34RY+XsbuFH z*;ZL|YuVXf+fGa!J0D1^dUpMOXlFxxJ#MHuvbvF-i_Pq~n%k+}LixRIr>o5BVW(P8 zI}@bI`*z}b+j&Pe_px(npdI%hJ8eI)({!+%`I7H5JEuRlQ*Nl8RWfUYoojM&lwBW| zDz+S*WM|ZTJ13;eB0B@VwzK6MJK@Xiv|nMzy3S4`>HVYD+MqaM+hk|z7R8aeTkZU~ z&5mKa*8ADc+pwO}-Z<=aBhEQ*Qdu8fY0X2~1T+!sfQ zXpSUA^G0GcSIS3YONpkj?C?i3HW1Be85NACd|EUg$b|H0DrD(7sT_)Cb#62-<#B~* z8dZ*FjufgAO_@5;bdw$RqM6<@n#+>bHkzjGqq!sr9iw?)W^{_?qxYiOBPrdZnJO10 zu17R0BxhhWU&@isqG>)fngvpCxYqtc`N?j1dt@}rq~FA7wl9vRz!Jq+9?gK2(d?9k zYolrSeKfPhxIw+y6-~k2(UjUBP00h%bdg&!^^oRCjo(!3R>)5!WAuAL47cTZ z=@>H0#^^KB7^anrVM{^`;fXO+lx6N19?9GO7(NQd=sI2u=j2Q%h5?mg*eT1a#PFns z#@CF2hB3Tu8bgg{F}!LOL(h&eY>@4pV`$Yqh9xrZedW_DhK4din)g*M^3H%5P7jKq z+($92l6IddS4kbFSR-PnJ~9U5*cbv6V)#U^%J6wH9FZ+cV_3XAhI?}1+ZbZLi=n;D zlp){8a6mS#i{Z^JF)WfY+hQ2DD~7|eX1CVZ6T@Kf?^O@>#c)a5?vG*q!5IFMzK1mK zh-#BBkH)a@cno*sr{5I&L=3SfV`w1D&Z=K>_goCqpTuxk))LECQL)^TKHgZiNt`d1 zwyCk~k;t@IW=fs(ST0HT%vkzn$Fg1OgmkPJOMyzUaiY#qL_ShvM~&Q;muz zCkDsyc%;@H6-VTxIPT1fBXhQ%pBKm3rEw%Ki{sPfalH4v))41UarF8*j!jZ@UmOee z$8lS#9Mp4SJ*2fH=5QSCWu}Zi8OKR^NbjJy3A`A&&GG-v2>27Os{yF%UJnlP&|)i;;?v{ zei_ev89FAOUnj(4pQt!U>g`X;NxbS;kK& z%US6*w=8`(mu0!^*g6^ z_4$ITt(NZnbE9Vg0B>}5Hok-#Mh7D=FPR07i_qjUm) z#V3$fHUW3J1YIl9V;Sg5ASWe(?cM}l`Vy$-Phg?U3np+=4yGosIzz9?!mI>ph4eUA zk0p?oK#vLuBv(w(&!+_aH;}-9Y6;x0nZU!^32dpSbs8qHyKw@g-%OyZtZkJ*rMD9F z8F2zF+9%-Zl|Vmn57O%&C$LUdf1beYQObFA0)J0T;PYw9L#oZt+*t{XkzTVC=s!1s z9g;FHfr85wPr84Xz=AEBFYoS3pyd7px`_8c0<}*jFje~eopEN6yNcV_Dev<8xiOh&f zrCXK(D3aueBIEs==oiJWhoNS_voY?D=QB~qYEBF$x4Z;kyVk%5vpDv<%>wVotTO=QX9 zMD9z$b%~7Fk;riw@{98NHIem)5-}Z4r1$Yes-H+?qC7pFNaH^enJX)y<&!Cg| ztWgp-J0_9ZDT(^;C9(9ABp!-;vBs@P;=at>lEiPjk|@19iE&4h_~ExCIHBjyBysk9 z5{Va*n0+;gI@gkzcs+@Ea_!F~TsM=LB@_Qj(*12oRKK0XCFy=gWA7%>Mm~_q50Z3U zJ&ENHlXxIAUnH^RpCn9S4tmRA*)4^P4w{%8?2zLH9DG*L!Ja}6(h56R7wh14oP+Mg z9Lz4^;BrX^jY~O5Oweg4kDNP;pZRX&b+;8i^ z(9Xdo*)O^69SrN>;IZuN;@~$K_nw1!64BK`i*63x)8U}V0Od1Kb;{9C9K;QFFhY6_ zaq!dU4w8mCSo)>XwoYSy)Smq0VAguY z*`TjC>+3E0daKsh;lQ@jLH%70wo3l}+Jl1*x*l?HR(?F<(0!T?RvdHi#&HKe86bHl zl=n#oPbB{-2UX6io;wbHxU0Ro=O9Z?K6dc@g@b%A)jv5d)m}Lm^IGSDG!Anz)8HhZ z(aGq1PLAbwQn`SW6@{I&F5+Zigj1ilICUSPli%b}Nhi^zoeYMSJg?m>P{xhx|&X2*K*Rmwv!*~IcZzp$=3}u zzM+#jjhtL*?9@F!PP)hj`Qc3`uUb0k*2>A%)=tK~<>bWMPTI9~(xR)AdEJ~8?(XDB zFDJ3RoqQ=P`#aex0|q!5AxVRrTp#S@nXLKD$ zjoY0Vc4+NioYX&~wWZiuCr;s~U67$zi!F4Q@GUbzeP|#0O5& zWU1VJs5~Ay`A{xA*Pj0E9K3rjMK^Cz=T-Y<~MV0j>!g_2n& zTf`BS%-PsvZpo53jg@|-k||X#8L!-w7t$>unYD?@lr5i3hAea?^GilDXJm3_GK(ZS zE19>llQ|%lWLU*ys?6c7j86{6XO6K;6WP+oTIW{_(D>8RXGApI$ zq-2t2=r}W(3({w{VoQZN$uy9kC462o17xf`U!*=QPsaRhG7DBFv;4bcHc8(#nkUaB z@B3s{$xcbxkWA}s>d*FMivFy%WYV5wzB-u98tHZ@nUCa-q#n`!NX?VUj6ao3|1-%< zdyvfehsk=cnamqclIieNHAs;c$uxhN%pUpfRWdDKE9T$HMEsLX8(b_2a}jND@s`QO zBD0Gqi;E(WE}9qB^KmXRio2*O#y4CPm0_~Kgo{u~7adBw_@<1DV(~7nmUZDua4}or z%DZTrxoF;`v4wLpQrPv|Y9Ba8dlEi}t6~o6|1Z{NZBp#s3_=Cn+eO$N7ens4NWQ22lqX`j@1nnKec&SHp^IjZ)r%+E z_h;HWvzv7mH;Gm^`)zKD=5zD8bjj~#bpbb}3%a=$<;ETDW{#98=B9ITH-Eq3rfNwy zhfBHjd6JtG32v$-x=BcK)6L=LciHE36X|j@MDC`zN%OgNzqFf;^1$zAdyX4ho}2#i zx`vxVHQnr$Q&Ovzn+dhugw=7=r=FYe`feIDaI;MoHgWSsb2rnaQ42Ti<+v1Y>1LGN zlIgA7Txjj)MH@F2+o`tpZU(*UW=Cf?j`!WVkI&7t58RyZEq#=CKQ~k48_6BurtwfW zGl#j!H{4CTFWh=>;^qg5AEDlibn7~$o9g2gZ?eWrbu&;-&rrW+xfw6+d2T+O@8*hJ z_*(s4=GJHN>fK5=t5&%wwc1UUHOhCbo0rn_2kpZ;)w;<|&aZCjiEW>oSQ#me54d?p zN*;9MkpqV`_L!UDQsKCIBX@sOUVkXBi*8z9ar5w%o2)~-d4;|}!7}wCliAEl(HTJNuwTGK;c`&x|P^+zn=JHuP zkM586kkLVT%CRn5d!W`HEk?H z7_XcrXuZi=V~U5TGH0rXE7LsOmw%?KCo?oo+RpTFP8!VeuurPY_Apz<%<*u1t{%_x z&}P2smN5%Fv|s39*&+{di#-gIFJ;&_9`-NS9;{FfQuSL8qgQ&EAthFMcxScxwN88X zqla0tRI2^t;pJuz&$nogws}}Bo2C4A^=^ma?({H4^6&D{Xt#%-<&X^Bqy62hJ^V%I zft;1E4tV(UpobQR)XO6tCLHw;cFaT3-#oND;o(=Qc*?_V37+w=NJjqd;mA2Xf8N88 z3m$&?!$a$f9=gb530?NELe@*Ss~(QZo$DT=Zg|)vH*b0H-O<{T`M|^AhaT?9YpL)^ zy_63hd)W9ydnyB;df5KVL!B2Mu3J;|xk(ChWp%z3p5{;C-2y3u6-l8+L<-iJ6rPmO zv1AI{<%m=+mBPrnAD+Td`EEoCokphc?I^__n}TnA3SUXP$tf(IqMWCuaBg}E&R3pa>Febw*jA+IK6mwJbqarcmqOmU6o&tp!iX&?bU%{9_eT}yn8uvdm~$zV zxRS!#cT!k6iz-$Ven)1?MVvhPgV0X^;jytP@Yl>FP*}?oRG~%FDA2>59M8} zmz6dzCBwZ0?`LbGSSNr`N*Yl zZZFGHyxjA8Y3uW{Kj@`@s+X;4Ui}S(mori()5`?;sG`PK(wddMY?nq=yzH#%rB^lO zQeCknvZi9o(t2L*)>ocQy_9OBI@+oZ`Add$@=~yemnJk^ZUb2^Xb&rjg%3o_usl3d~S}CyFOXKgfuH0Db#ruPo z`7&(17xxD3!$vPxWXcvVzi-u^Z1>{%#Y>-Gy#xn{liPvMddHouX&mEz{{nF8vn@4r%%1?ex~*Q_Odt9M~yN*#>M;iM+%hn zu_M7pzVbc>$`=x!AYF_(5J(R;;Q%CQG1}k8-sYua1wi@~7;p?<2CIk0ElTk&oCWJ{C6h(W;G)1#R_O zJ0A_?Tghziql3hD@R2OJ(yo(_9Eo^}8Ret(Xdh8yd~B6IV|}>C`SiClKIV@1 z@%IEDYbUBllYH!*#wzsOMRHX z@#%Vt)?4c%`g7<>g5rw zb~Id$B}$ltV2Cwz=Jt@Gxxk7`%dQ`vi6`+md6r&8}PA5(5=|HOF5N3FX)HpsLm z>gQAS@0rdeS@6Qgjh8;&e5L39@o@k@IbnW6Mn84MYVs2!Bjm8zPX&vg9)Ji{t&j9xR0a_0TuwU8?Qp}G6M1LHh z{$~NE4pDty1{gXzz`ij7vd0G4F;2Nm2ry8-n;ziVi~yZys-D>auFMJ0WUgwSAK>^` z0jewrP;60vc8dcXk!xaDqWr!NPNwQRmu2K!Zs)l_5PD{-L0mdH;z@Y#i9}Upp zSb(m_1N8h$^X>%bb~ixYJ?+Q+01;0Ew0IU^udIKeyu*U*F$O7Q4)TdilHcXAC5Xiu zWSbn8O12;)!h`fF66D*GK^~O~@=oa>tK)+-D;s1^xgZ4-f+Um=(k)3bWTP{P!4>2K z+3nTq{vaRAmb4(|48@Wnp&-q3f-K1mayu``imE~C)d@1CuEx|0Qmt8#G0lVe96QJt zZw5KoGRT{)gPd&>B)(mciBhFQkWudhb$u(y(tbhi_7Cz(MhyruTbd0F(n(H9sgHtu z^Rd<(5~TmHs!iox$Fs&vNx!|6$|RKH}&_R>b$7@FKZ1sDsfj;le~8= z$amL+gl+`c`7lWS$3bFcv>ba9dRKKM5R(xmdagw zDs7@uamS_dVX;&KrBewnn@WRnsce(KrBy;I*Ciq`mECe$Zb@NhDsMYEFNhQIXO8HDZ&Prui-BjHJo=T{GDk+Up>DxG!E-g}ZpOoUfqcuCF@?Q5;tUXeh zE4wG9QgBKtVGB~Ju~5%1Q?4tN>$j;4T$PIH$5d+nl*&fAygn7@##Huf(mGqU&bCxW z?N(05QdxUEm9oF3GXIqFKb=bRGpSTNpNjcnDrYQdl(D6;B0P<-VrkSUp2o2^(s(N^ zjYa8coXSjNSmQMIH%TMZG>wL`N{+stM%)K!d^|9XS_{&cuu$_Cr4cRdW#u<%JYJqg zzEyHT^ZrO9=Xx45OQmzMbUF>oq;tA*I;E?oQ=m>dxf9YEHZh$WGt+s0V>&->N~hA6 zbgu4C$8|8B*;45Dbef(^XO~?5Gacv6bY@EF+v&V}C!NGc>GUa^!KQKv|$jM--^s17!IN$p-y?$&A7^m*lME_+ zn!&@t8DtH~;2YU03r1#eXL<&yGc#B$8^k^<1IwHY>dwtzvmBMKi!xaFbp|(=X3%n3 z20bO;stlsnWboG73=YU8dAu=$m_r%7eK>=Ia#;qR(ATFF_e=)E_vvowMDa!vEEXR-5M7Wp4!F-WF`Wpmz;%^X`c9g1f2 zO;k3;?Abcsbu5|9NGVe~o6cpjsg#t>&}P|spOme8ZL(<~yWh;_R{LxM?_~3!OE$la z&E}2q*^HLY7G$$`VKy0yG=51oL%!A+v8>Lf?swS~_)+Vg&F1^d*&Mo(t!o|G#9hx; zFSXu{Y*yXOW|O4L@s~^~65{uW5OpF$l#B|oM+!xU_(XQageVXf z;#sMXu7iYh?IWaXA0Y)4OY2D!=z8|Uiqe65YtzL~+uO@`JA(bbpCzC?F zkoRY(zcWMhov)Y+6?2hdO8&(m7Oe=e`v>jAkJ<+r_LE|-SL_WT#%>Pr+m;Yjw}z;- zGsJ{lA;NZt7`iXSzWpJt9SZSOzB?RZyRCd$SQeqPd&M>9!le9A!a@gk?%!_t>j=azPj zo0Ke}uS@D{xm!AiwD=rql+EEpxg1I)=CHJU4t;|;Y);L=ot8tj^c==yo_EbSD)t)J~RifoR-qVRhx{IBVXiD@yi_Q$rlni zGKV)uDVCfN*J$N8CWn}DIh2!0!uTArWwacdkfU=ahX(TIq#Wi?&Y{Q@^-^xj?5R22 z5zF)(Ofzz*Ju`=mvR4MpQvS1Z@XyJi(YzdH%+I04k{rHYnZwIfIT(J*;hmj1EZ?Ob z?#rS43DtHohv%nq7=JE@ljn1&enIv9p&TyduvTW=R`2g9pS#NCfqMNgM}Pm2L&2vx zG;B4RX0GhZ^M)-6WUc(zIDF zvzzBqphYeN-_+QaxeRWb%cXv~I0oc0Lq<-^<;e70D$dBI^!!}j{VJD}vSwK>&%eo~ z%ko@Zug>L*?YTUaYgcn|U(dyUBNtQ2JZhK9<3#B^zD~^JPWe3EPRip=XCCvD^BCyQ zqfEykB@KXaa#)B%cIHtJa$U%!#svP%44F;d7Q_%r+Lhl zQxywNtJ?F$qcHt1x_pC5f2za({a5br(iW!8BS#$wPYJY|lNWsQ$)KiTSdo1{s~Y-u_`R-vUyvy<+mWe?dKMP(=mvP5J%5CLWHy{9Yz!Nmrd zviB5JrXqV!eLlbEx}HBCuIqIrIp_PmzxREgG)+!U@xJxZH>JA0cxeJEi>1Tndb+{u z_h$!cX839Z1J%9atKzF!Jy@-JjjXJynciwS)pDw41iV$Md8-Di`@9)deF1-!>Q((U zGBUk6*%`hJgJK+tD?I&wvHth(i?itw|GP~PzwTX@zLBs;W*FhDSe3+WnPP@Nio=nT zuq6n;WGk;+jhE9Q$f*t`Ye1()u&ObXZUR3`wWg5V3^Js)e9%&JWd3{5p*!4>V!goD zS9AMmZhy!c2;Y4QPdSAKbEWuhczrLl7Td3oB2#4FemF0a55QuHKd8PR zg%#4_81xoSK=35gkpHCEDHtSUq}zEg{RUevLiF!YN>0jEY4Ha%{1e(r$xGmnnexeH z7%jD~Kug*CKUa0EW#TnhC~?=J!rxj~Zp**Y;|9F?2a4X*csV0=Zo!<}uv$9bf&Ows z4&H~0GVK8@m86Go{}C7-!)7@s`A^`-r+Ti*7tdh4L_UZ2UqCGFNY2wuD&L6=SuTlZ}OVo?O!_D5ho7(w6vITOK_vk|z@MR4G^2ufUx;7jRhiez0>Bo)k&)G8dw zm?Dw|m<&-m$s_sY{O0qYS@%~6URFCAh8j*Zi zGm>XgP&<-UQtb6eK9wDHBk|XZ|n#&aSmJwK9W3nTeM`Yw)S#uCN;CX#QK zMsjOeB=3F~$?t2m?WagiY>6aucO(PlTlris*t_;d68triIx<|cj;Q{l%IS<^JyG1J zTJM?W%ePYcm16!INm-+T7KIJWDq^5eQ3L0T85mRCz#J(OW1wlQfgLiUgn^mTJkCG| zIW1-4HCFB>7>GzTuu=9)ILW|}k_H}1Mp*+jg>nXp%V7Dnyn&o#1A8hMI3p7(8dxB4 zDF#}nDuyKc3$anHI+d!ur1M5Qu_Q{a2fk_gT zZ=imGfz7h0ih&=bM^yu#%RR}iZeXc=QA>G9z1jxel0#y9-N3xM2C6kP&`gRpSIsg` zPPZ_ywUq&D8v`Zfgj|spZ4JzBr{1;KoX+am2Z}GZyBOHpRWZ67Na(G)KiA_ydOX;` z{V$c<1Ov{A20of(;KgJE^QWnQvU;XL&j0 ze^9?9@RRx}H-9$JXuW|c8w{8>8u)pWfe$wuxGt`(I_APJI<|6ThkChF$A6cO(Qf6o z$3WIz19guoKgm9B;2VkkO}!MuMdd12ZyV@-$H4b@4OF;i;DO{kP|cF@$iTqI2EG>C z69bFopQn0$JXenk8(C1q$ZAO`YUEZiBcH_>@x>acB5UMv38S8CM#{z;8Iok=bh434 zX+}KhM(VnZq`Hk1@)>F3H?lTpq*<1cSJENdNMeqWG?^+Fa*fo>Gt#}9k*#%%xL!BX ztFB_n_y$HY8ycA%6ZVI_XxreqiLNIJ+46sH>5N9~#*#ANDjdNbX2RFC&ZO-QKES0)5pJF@9p? zbD2NLNSQB;te38XjeH{ih;N9I7ekGDZ(}5CtZEx)WTPCBqT`JmpKWB?93vO!8mT|e zNP8)?#7OM7MuyAbRYvkx8(Fr-NaOE}{JPeNZJm+U-z(oAjI{Vs`{d3~MmB6TQeu;l z-EvB5Y&J4-i;?G&x?8o$&wGqi+N(bPsvP$zN9lRQ$ZwK-%!u`}kuy^Js*y3*jJ$qR z$K`>M%VK|I1wc_t!4CgNpU zRTJeKYaQ9p#Du-62}>&zeZ}#HiCkGGciuE{{4Enx-Zk+`*1Tt8n|L~y=-tu873tH( z#3>ox)x>nMbTiSQyNS&*wU>!fADd{`+r$wW&{ymCGciu8^*7N}ei6$+tu3cNQS6B( zj!A<_CMHcb>G!aSL|Ho3L}0OreNy}z6JN`>KblDY$;42}`q{)RX}8`)=M5%SZ!}S6 zljg{x&6>a6#PVNEJe3wZO)QYVcIokM6YuOXu}+@tHPPu;)qPO;9a2q)wO>rfOthD! z$4w-hFcEdu#G5kjoQY!R)tieN|A&c2vR2CdX` zkBZWp^eAj{)Dp#ER}>$)qqrwo-YAyHMltxJsFfMTw(KYh-~FDB9*l5t|>y zP}yG)MQ-INd{v`}suo4P>QTHQMQcPcT8`I@qH3)uA{r>RPK7rcq38 z9>s}vQGC)qioeADUKGD~h$7|vD6E~McsW4xKhanjJw)+_>hZ8Bu6z}RV|WzPrTMHV zX3mZxdQKE&rT)Aq)~%1?`GzRW8>3h*-8QM#ZL0g1D2B-L-BH}#6GfZ7s&9W3jSr|+ zIVl|uMUi|biq3bV=p#48cRz~xa{i(AJ&wX7uRV#PldO6gMd@d%??n_hUq;dTRTKvz z%~Ua%`O0YKu~^M!8d}V3k#$APL=`ntub7$s#myX)60v5=iKB#>@8n6Gncqv9c~!y8 zn-$H>OEFU{)y$Mi+9qq#%xn{n-Ar$XnJbdx)HrGCGV`t+lSGelkO-fdPEyKmCS7L8 z9|7eQG&3T@%rjY;X=an8XPN1lt^M*^*sS*sX0r0l)RG_NWr3M4mCc0fn3*OQUpG^~ zu9?dX%xrIHrg9@QyQEMPGkaQ^so2`g5{Z4wOsluGO?J04Q@*{K_un=1MMpDNCB2jK zlIZScGJ2R9_@SA-ADd~^TXpv_W9n>uTEQ^)L( z&B7GifST1*)S!mPT!sl;VI4((VS@>E^Z7j5sIc+TzX=mZvjus-`SH7Jr z{3suPWMP{`eQcq(^zUtVENiYqI@L> zhg%4Zu+Uh#O5|kaCX=RExHHv4-Za%eU3p5)nHCnx-?Nn4YzzLm7Cw`m^DNjFSZF8T zEVS@sk%bP6Ev#6gT)wg3k*O;!)L3WXXX*02g@JNIygyo)E8olb%@+D?S58u5hlRnC zvQxFl;axhm`z?$;Vd19uPg$5Rcg|UO`@D{)m@io9BQr0nAJ;TbPDt777S2f8U+SA| z_}ha0hJ{kMG+s8{wh+Fn-rv))xNqT*T$X>O&;tvpk1Q;fQco-_kwMQaoO-Tf|3Z1c z)badJv9Z!U!pcB7Cs~nJJ~dbwA$O#U(aLuwD;+IX78bK&EpDY@jFl~NTyDz?ITLFo zvxJpT;;ampW&PwO#g+NUxOzGR$Y?fZs}9K(%3piY1o4>Vw?*)yg~jten_yrQ|^!8<``=52?OWR+h-`a_5Yd{PR{C$j84~ zSuejz+yyHYrTs-K-^#?_^*oSuQs)mVlVs(eR-VYyxM-@`qN!glnrU)SuIEPM&x__$ z2^Br`AZBVcf>GtXAHyl#4vbo z3B82bMm z!>SuGJdU1B!GvO!E6wNIMt ziDkB|I->aJ6<^l;6-(2bvCNUdcQx-pEJYs1a`#m%Q;L+}Pbpog1P$bD)e=;!R)X5y zO3-aU34WIKgG*3qY6&`ue_07;uPMP_QgLqyK08^0U*+QU68!jg2_kNkp#SX>40%z4 z!}7zwC0O}i37*Ki#IYqZ4yz%Ke~fYbYl@>)R2&P%Y>uOytdtU#IAWsXcuR^E)A-mp zn#llL9BmWhSRwY3aePuLj`VVI^pVr4addXX@x9bbk7K_-j`% zaeUr9j(t-4oj5kOk0a{cIL^wVPI26kw|mD?sZSh5`o`hyAICuXLlzBCtj`qd^EgHh ziX(Ec#>%%}#?f;~9Ghgy&^Xe*j-!|4PmJTuDRC^8s#D|0n;yq7X*MH{hqL1-m=njC zxpA20$I(bSFHj9D;z(Ypx_^pe!sa+GNSUp1wA>k|&l;*{cN_=z#L@fLI9eQxW4@d? z6vw%TailzoBk_406aS6lqBO+DKCwmESZJ`($z)@lWSVXCv)I@nZmW$)MQv0rW@B7& z8^vR6w3c$QHof1p(OYukYz(v6I4ZBl+c+)B2{zWs%5oZ)X5)6cP46*nb6pT@7U-fGrQZU*~7+oY4)Lwq+T}Olg+(tTpD1*HPA-e&ulaw zWMiI0e_`Y7mo_R6v9Vfa4!3bl{v2u3mk^3A$0phsInTx^>Ac8B|8Hz;S#HC+!bba* zHq1ZTXd=CS(pno7M=YCcOxdD1Qh%$BpSIbE+^+S0vGI;9lRxFkP8*(GHn#7v@$Y`c zJfgg1l+-$DV}k6H`R8ohl#1tV{C3GkrOWEu74`PEjSe#7j*a^dZB%$+qpu-er>5e0 zE*VAQ86@8pjb~9pJa=SNQanpui|3x$OUH9GC7#z(*aVhOT8QMB;Spvo2+~i&!!jgm|w>0{ZRt%8WLC~ai#>SMJF&u{Dl(O zSR#R_xCAD@mO#7G39OW#%OvQ1cLKNMS-AvqDkSK;js&JwOkhh&0@l<7s>m`|0uSXK ze*&Kb6Lg*>feUgjltBNg3G9>=)f0GJTjT2_K;r~nHBZoawgg_bPM}AJ1UAU_P6@Q` zmcSC3`=RpbnLuM1E-m{g7kRIL0%r#%Q1O!lR!h4tl&fS6RjlC&)Ebe1VN3#n@d`&m5v^|i(yh926BYh5Q+)>pgUmr_g;fVxp%g-kj`&0snrxR!-%g(D` za_2$<(;g>qS=N!r{J2DJN^fr>+a$@CNZX7=_DF1IA~U33Rw9?ATTUW<@)FrD^+LL> zl1SmIi9}aRq84N}Z66>~@;PlqMad3Yk+DTyz&B(L&IQmR@>I?9DN zOLDwhNy>CD$@v}SnSHlBvCqr%wipT}(?2emo$|LM8M`l;kL6UAWQJ5trhb!TrperP z$!vT-nW#?5l<%2LOBo}}2PX4KCJarc`Pa$JlOdy%**88J+XTg#tvPd&$q>u3WSYvd zP04t-CNogx??`6xugTn%eaDmOd?uOirR}w38azy9x|}jsz*49JO(i<10xwHfpjMd* zIQ$ie?^JgB>U~y$sZw@i1;&l9zpd14=OTRlKWOmDLNOS$1=c~LfDhSc5ezVd@0oQ zr?61w22;2phcZ%FldXNSFgJzQLwcOA#}X(=p?l>N(yOHC_fv{~22$u>GlhF~Qg~1| zg)I%VPU94IH%+138!2>=b*)pV`gV%Gmr9{k`xKl#Q|K$Mf!hCR3O~x4FH^WRQaO)G z;ok`6EADWv?K!iRGDN(#SR*ZjXycyud;SC3Mt{WygSPgUEC6xPfAmnmE`rs6ZD zQam~pXQ5R3N{iyDbc;#lXW1T`%JjHYuE@JKjZIAD6RB7-m7%h;R4T<@OQlokRBoiE zl2J)>9jQE!{Pa|=OFd62QzbsAI60|!a#N|ApUUor^Te99el?<8P-@_D(9ho~5$swMv*vSK{}qN)*ekM17eiO~aL#BVDUh zV*Oi{Fuq-hQhh4X@P8ImVutkERf%e+D(U)=O1!*UiHFxKQSetKM%=EX^Xu9sYaUj@ zU`?Ze{2h}FcepO(fKP13m0A&rcVX*B#GjisNZ@jzUQHEv}Z_hiPF zG*0eHqulN^#vV)Khm&b=O54w+asFZ&slTT&>uMVHuB9>IdKz=(+FxlnZ=^9(Cj678 z>qye5bt{ca((Sg!-btg4d?b_Zr|BGY8Y>>8abIRUPh-n}X&58y^pZicTZ$U&G&9=S zAtwsk`J#xOJw@$g7PIqXqMcVscDj|cGpn?n%Vq2|Eo&z=McY#CT#$-(I|n5$-Odnc z@3Uj`+ewkh@>{@8y`Y_z`F1)41L$mBiY&6&Pf^jft|S$)5T7! zu6BKoY^QjC(uUYs`n6rxM%igI!p=_wWoN4tI-tHDveV_To%8b3QM;~bva|BIo!3s-@kxIv zIHg=p+j%U7&e*AbQ90hW^TQqW|E`@}IsM4av*&iAU#KT?LTbLWGy0W|tu&2rFeB1I zw86osXa~m&IjC0H!OCI|-YV{3VT?oHH#l@{kAstPxQv7Nat?;cgk%S2D>$fA(ZNi+ z=150}gFfc1t*(O~8aQa%(7`v2 zG`_Ke*-ac=Y3k6m0}eXN2KnI)2QS}r(6zOLt8Y0N`?iBq?>K1J)hV7R0WbZ~u;gQv3g3kSbQaIk}cUpn|l-W%$m{MQclN%0X5 z*2@Q@)PvE=TQ16NX*))_j#aMX9K1h8>r8b}ce;aXvmChQX#QLWXO=i9yHt6~2g{Yy z3I}ags)w>*wS&LcI9U3lgV7rtoY?4~`X=>di?(fbuxXovjoTeW?$DaQI%s%KYf8!U z4jl5&9}W&&RzGFx73CsHS2gCEgClZP8r^iz`kwkFsrMaZ%2K)WKzTfL@Ui^6}kY=cX)4(pc$R zHl4B+)A7m;c`jX3(pi_9PK8S8WXnQlI=^P8b517Zq_arkbJKY{FP(#ONrqNQr+R~Q znoF^UiYepeOrvyaH`Z9$+ajG4Z>LkLO*$iG@Vn_ul=|;!zZ{nMj_C}OnG)4CosT|F z=SvCq);QTJQGL_tBO~SUC+XZ8o=$LNI>$$)b4BKiPG^<$n3zu5bluKK=XdEnOR=T$ z>~tE*FJhgWPJbCA&lagqE7CE2o6dq&>8$uJolVkbt>(#7Dfm8})v{AO8`61eoBFdo zof5xjEt$9{o%x5-Su0%+r}K&2mW-o1K2qm&I^)iy)9+k5Q}3s9@j<%Y8>aKx<8BRh(P8*yoiEt7h>EvyrlSL*caZyf+$2w_QLfey^ zWS4SMM+~nyDIr7UKxrqTGEUwt=VW<#Cnb}eT&>{5nc`%YBvo?KHqFTq+2(L!b~>5h za*~$eq(`O`dzO~KC+}5u(o=3pu&R>>wVV`v-AVJhPIk#T zc`P3_ak9RtVl{J;FXdY+->#~oo0EfbN$T`)a`a0li9?;FNX21Jx_ss2ykrb_^2rD% z!{vdD8s%iRv>ff^eK{-T#yVLs&PnY_PUcT>vR1lI)jYW^8PlD-KFi6J#ZE3PaZ>*q zt+!HZ%dBsmtdugVoOD?2dRRt$1Z8zn@+~xauRXd$>2Lq((me+$YY7R=cJ!(z3;^Hz)6co zs_n6k-Bb17Iu~-Wrm%~0MO<8qbK#12F7mW$_YTvTbN+S|m7gIlSaj}>5R^EMGOqS)6-`_>k zAueVNbrC(xMZ2$DdOzUe2T2~T-i&bR+@OnE;}ma_#!PWBK+aBAzh=4^C$70JKAz{| ziv0eK`n$}f@0ZoPRW4Sqc2RbXi|T8Y?>ZMRq{k0B4nL~aO)kRwTr?2Neiw-{LYf|Q z@t%}93Gb!H9`2;t06Ww@9x#{zon`_dotefx4X-u-4u9e)ZOLJ4f?xtM2oA;e=U6<-6 zzPg*YYq&Wm&uh7Le#^~wvZ}tDM-AL`Xy|5aV>hRoxT)FH&BC|b+<4oKp^cl@+q!8f zU$k@U8dNvg?6dN_hPqiTJHB!gJ>1OznK07L*->uljCM0^ ztefA*DW~yTZ<5xS?BGI_o$ok$J|65cT?h|n>SCn*(X)bxVa_4b8Z&Nh~L~Cy`b$E z-3%`qp+S2O3p;qY(b2=3?|UfU*+ZufJe-jsT|DgX>LIV2 zhhjZEwD{1&ZaFW>Jv}%+@zC>A4}Z!>Lp+ok>Y@EG569%Y;T}4U@bK+O#UA6qH_pR+ zX*bEk(#gtsiiZo+JXDqU=j;9o50;f4U5l#ztnu*2cOD9U z^f2rv55u>3=yue@_s10HxW=5x{jelkz!U z#>*#FG`_0Vtmb9AG^y@oXALhsYbuvoiY>8q6kC=y@N%c2@@(#!JB_zNeSuUdp$(7sqFc_qmssgS?C#qB%podJWgQBeZ{%>XCoOc=3<(vOr7| zyfmET<@6LU7p8itINi%6xj4g1$}BIFrRN+kKhO1&Hcw-u;sTA4hl{-AE%EC55HHof z(V9|inU{4^c#W5)-)UX>dz}~W4_@ZU(Dhzi8+05tdbuK#w|Mz&tB%QbFYaHx^xo$s zctpqHxR>O1nsFb$%hOyR z1tIO1R$(7=^L-R6@L{Ox;|F=VgCGAF+*n43?u!d?YsWv9P(1 z)@^(&XzQb0M<32kKEm=u%$+sDU!d<>O>zCIetcCqyL z(NES6^zrNyADur{uAgh(7g~3Sk6(xSX!ezlzZUxNELPqU_(t_E^qs>|$OV;^_ z|K3N>AAS7%laFfaeKgtZWBL{!)~!BHZ}(AVhmSEb^?;9y2Yoa+q@0iX$Up95m7F=@ zW5h|-dCJG|v+C_-A2qM~_)+#=SFir|@wqhk$H(NG>f3D}uix>pL8d-dO;3Cbd#c{c zg6BT|e&OSdm)iE9kAwILNB9XD{L~k-(NBU5mm?-Wm81N0FY4!W$tmWij%<|37(X9L z$wWWta#bG5`$>LQmGo1ll%Ilfei})1d5x1%ay;2jwF-WEru!KzA*Y{uvPDd8KfPsc zz|Xay_GkFHo#Q7X&(C6MSKw!9Wj}$c%At;OsOx8RJwGoR`>ER0&svFV;iq*=Kl`Qq zn|_wH_7i+t``Y_?_O4%lFXCr;Pe1oQQoLS%nhf+a{S!YGKU3YK{Jb;T&msAAqMx0U zGRURMm)8nw8f6pu5-~7a0RL!#gPd@`L`PqKikMD}sys9;?YkgV# zm!F$|`+4hzpH~0)`S7-%pYHgnbl1y@7= z|N6P`pN=&Fwi*LOMFkjd4p6jEfaZk*{81!8VoZQGu>lTC&A0%gZ2?}%@Pq(I5(89D z3NX8LfZk;Syk9oJs&WC!ln?Mis#XXPVGm$*2J|-o0ipu|mS+UGmljvmtFF;z8fUdg@@LP)j^;!lP+a{pbV6ELQz=n4fuS0-Q9RtL53(&fIfNMPh z*!l%{tABt4(q^Dyei9)5(*O;>2ry-^YWX_AkWm5lj}DMGCcuud%4K|j0rK6n08gg} z=rluh%nER2c7SGcROh?^C*}vJz92x!MFH9^4scYiN#qjc_f3Eb%K}W4rBY(GYS^b5 z_6ImCbq)p?cPIdd1AKZcK%?UUx||5m;~&kt9iZ!-00nmgym>D`%##4Eo(9+}>z^y{ zh#-3mL5iA!d?pj+H+d8lB+49Qn;emoS4D!_*K@Pnc>p&7v=|Viqnwelp9ER{sn#4Eq~DjSNvaJA>N8Q0T~c^hkf~nlY(rPgHkX#$UM0|MRBKU-?Sica!4*pqv?t{BZzrskla~8 zzL*{4p3ImN4u6;qB$t5reHZPA)rgY4a=Tz4y%JwZHsgZ#ZesP9wM z-$SbNPvw7EYsfK4x~iJwgKI&)yB;L;caWVAf)sibBvD4m@y9{ld8+=KGuULwz-i6k zMez)(#%9n^wn|i71|?*v+_7cQCO(6%@=S6QGjJtk@Nvlu0_8HWR>+`H#SFH|ztTD- zgX4D>tQ>BZJqZtJHC3FwT`hcXtLqcrr-wW>6_dk8?8^T0cYA<7Nuk$lfFqD~Jog>*C zlFKsSl(WuGPRU{T)Eu74dnQ{BbO5CxhxLkvLq*$Te-Q62<0-SeJ&^8&E@-kxxDC~OP2w;Y#)=0Wn3=T=j7s^ zm&+XKvL=_c-{sQtr(BwD$z{gYT%xz-QtntT?;p?Qv@AZC%gyt-toSpRzE^YEa!vEE z=d$x|E`{#rGEk;QG^0+)o+Vb>#*KL_RMo9T`d2}kDN7b}EhP24j z`<^^qOOZz-+5JWyH{0hCcrTCpo%1+3CXd&~-Fl&g1ZvJdRz>Bk6jcda3pP&SUkBJT^(zKY4t1GmqP{;dUMock?JJ ztK`wWJUZOZ2rTbpY=oftRG^KEKAcIdx(jS5Qg*+ zL){?`ctV7{Au0v6PDY4F*-irFAUtA-)wHVRR!afrQ5blWV%=Q6W-h)XRrr)7vbZ-*H7P6*nB zSlu?n<8~oBwpZMaA*yx?u~s^N5MoW25aqgtDCikt*hd;C#ruV5*>oPsMZ}8 z;`w=^=f>Gzops)^<-j*=knon^>;>yKJyfFp<*slOewTD#G;iUcK@K` z@RN>%4E>dT}vC``aOUiR(^?u&kEHch!@7>Y+4! z8e+z?5Yf*=Y$Z%oWSC3lFl7?MbVv$wQp%Lp{W7{QcglsyOb%1KLYPw(!<0@9v$Rr} zKEW`XGs3ts!_>?QGdep=z5Fl->x7A`8)k@nRWHn;`eE`LgfTP<^Lpbj8^qo$%!kdx z{2?3O4Dw1%*!vs zScio1%2_ElOf|{~Ir>$YDqn|bAh9FDyfISoyQDm}h6gjJpu#^u;i>ephXOD2Gd7*2(l+ z>i=!!b4R({SHB;Gb&Y$NB2U6Jd#Zj)uzWrPlk>?<%g0eOpPsey`BS3n=F_-dKHJ6F zFrQwH^0_RBo8%MUET3W0yhT2Xt3wRJj7a zNiE=Zr2^hbE8q=B0rS!e7~n6Ue1`%$bu8eFTFRD>*i`fTZaK z43}>=7w~XP0l#f4;P|NmN}eg8lGHq_@#i#NoPQV4>qY^CB=cqgpWZ6qmK3>LK(l)V z?3DZm1q^*yzyz87sDQCg3YaBlsuY=8qsQ}y5&ADq5*H0l*3JL@_wCK#jX9xVlafAp lS##CbJtk7BMcVesJ(tG5_+>)Ikj0<=zj^x0_5bhR{{i@pp?3fP literal 0 HcmV?d00001 diff --git a/Covance_UCO3001/browser_profile_4/Default/Code Cache/js/70d85b671f14b4a9_0 b/Covance_UCO3001/browser_profile_4/Default/Code Cache/js/70d85b671f14b4a9_0 new file mode 100644 index 0000000000000000000000000000000000000000..16d36c327a1b833d1c25b2bad93a29c5dab1e3b3 GIT binary patch literal 35356 zcmWjL1$>iN7sv5`leDoWO&f~0X;b$UcXu5duEX8k-G>i%cNs9;-DSgJIK$m#@c!O? z_WiWUbDwk1IrpYC$&>o(cUhjT{nu~)l8Rx~sJ8~bC|_}3dd}RXO6KAJTxCk;PtTVx zN2y#TOO`3+%U?2=uS}kt#mkf^Q8HhST={dADp9&*iCno$mn_4;GI>koF5$~(B*vKx zfiwRf>;M0yl}h&e|JT7-iY8^Gi+E6$xynfsq4JUgM^UhXR3GsbrSM8pI`-oxmRFXR zRFMv%cU8`*A$`TLn$kbWUR&yjf4fRKx=Ej~eY})qp%ja%=#CAzjz_4mh}>`vz4u6c zu1cO_e%gq=xQj-`{WJ>uOZe$ubSUYkzUWiRPXT58lo@@?`>9?ESa!y+`}!ep-h*FZ?w1rJuIG^3x#{ zd+n#nU;XseWKdIogU*K-wApRYemu!w(4kO+vS&7EBX(yosBTt+4rencDa@cAxZp9U zWrRU{OBnPQN|!X~Xla8Umovyx*`P*M3~GlQ)eS0&eQ?w;s5KU%TTNo1TRnq*Z)#B2 zW(K|QWKcq9gT`Pw%5^blAU<{F`)&qh?QT#UzV$GuaWBs8ZP0A&MtC1`gQdSg4e=-5 z3}D`Y2IU@PQ0Ku0ZO4uw2HA!hTR5K3STOrKdh48jULg!PL-8ByvhW4;;W{?DL(xPk-U**|_p zEj1W*!e~^+0Hb~}8?_I^Ek;eoU8_+pyHR0i8E8~Zr%@dc>N3iU-|-RUgN z*cocnC3rI$brVH088sF2G8B+P`9964`#z&?r5lwchf#BKGX^*F81*i{ zQ7HwC8dT7zMum+!gQTKHy~gljMyP{ekdGMvX*jWup>)GO9A_qHQ(uM7f_Chhx7O)wzaI!8MIq zfMd9Xnzf9YS=*>(xR1qkjQUj9s2xp=dV-Ib(v-QIQDaM^nzS-%d~2f);4L1uHOk!1 zsDW^HFe(P+a1pIL8FjR?QQ5n*ez?}dsOLS68qwvpjx?&(Xrms%JI1I(6O76=k$v)izf%J;O=S)|na20ijcPyJsK;}R$~xDm zW;ipC7z>SxTVhm>l}5F}sZ~Z*UrYQAMjhX1)Tm9Y*=B0oV$_;#MkVi{hMm-js~Ek9 zeYKZ7jBi!1%}Pu_w&+jNafQT0J)^-wUJqzhv)Y4Vu3< zYT^f@R(>?f_{pgG7L&$XO)6zGX(^W3Om*-hH&F)4@Fr2V*qx=|)Iisl%SVoZ9DR`Diz6HLmTXwo+H_L;ORhe@+?nN%w` z=j1UdG`~rsQM#Z>Q&F;zNfXerut~d7q=-pJi<$IiIg>2qP3nS&I8uT0tC&=~s!2Pr zUWm1JUChcp- zob5TMgGq@UO^WD5uR5Dlzl%u?`%-T|lL`(nsVYhjGU@VAlU58f=^C<(AeWIQUB$Uk z%rVBK$lpwg9Y@^pCY76FQeTXpX40bR^lK*lzz3wyGHDKu!#&%iO><0YvVi%}W}!** zFlCWRc^8}16?^a3^zJuEqBQoF7;%}JL;}&&3XIn3SGwI_XOSz=Uja^kxltmMzXoRZ*S;+N z8kyZ+L1F${g%08V+JckF>haez?2Pc&wn%>!kMUO(Opoi?61~1 z+QnbDyOVQof89W?KK?q5=6(J3732H)E2_W0b|7`2zY4)O$X~w?_SbzB9Kt-9goZ;o z7bS-IYb%n6`)eUGjPTbee8Gp&{u(;LUtyD}2dA)oioX_5_gAJF{yK!@+5R%lp-$98 z)4Bc{GT&b-a0_7z$QiX4`72?uzt;ZYuhDzCeZpUVpZ8arzy0NRnLfjE#b0Bt`O9(L zUwv^Dop1Q-HR}FD@A2cNzvkUy4Q~5uIZ1xNA(=wm+O z=MPZb0s)FC7@&GZ$f;t0T2&?v>QxKSUxUeQbb#8R{220rYb@vE@`M2Ook&j01C)0~ zfKpcmC}LHBCa(`rhfU1$XMjp>3y}Y=0HyB_ptk{9hXyyP`*DC42AZ|NVOIaFW=+K| zJi+wrW-SXdYl+9KzcD+)tU8g5jWX*9F5p45S#R+?hVx=M7H8HvoQXH<2EHYjWlJ=x zMUq+FFfrMzdDxa>R_Ro;&fylRUFVA*7R8L%Ps!By~0G1@3kuw;pE2^fW6=U*^Gq{`6y@St*0e zsy5iHhS)fS^M~?1*1|o^tbHTQGLAGW<0!Mz#+cO>z3>Sq$I_4ASdWQjb(qASnL_`k zavRI>3hwDjq3e%{mn zE%b4#Srf1VcQJ08S%&RqWyU$o+iO|jq32Q7?ilNdeJ9wz zxP#wMnl zSVJ^GFKop6+h!d?$2+VGKHj6I`}7v}2b_bc*oP0O{x3B^kI4mv(GnBz9NC_j6^~4> z*_#H7{EZfQ5F238T--qgvqf(aWV5Io+S@I%IxSk@vgk4T2XidMqA9Rtu*jXsqLx`K z`s5{Eltn+#DaNAkIE%L6mo$rdVK`>`EE1R{@LKq8E&XEP91X#Vt~4iyUZ%ztOY|bK)p2V0&4MMwg?O^5js-!sF4RHwP29uCUKY7}TU5P|MK_SOAAQA>{+u(w zq74Hr$}`BKR)Z~ifp1tf#G>LuEjoeAc!%!8$Z5Dm=~#p}XfeW~lju2;dGHBSM_JT* zv_(DO978`b4*SPjw0HvZ;WQdfq|f*ZZzs{C$;3d0DHiR<2|UEc-x)jAq7Jx)VbjQQ zhDC#CS~MQ3kvz+yD|m!Dv$;KoTu^(SMRSmK0Wq*=p+$y8)VkQBHLxzVs4|{o_%e%f zF1M%{8sH(`VgCw?&fqE9tz^zs7KN_1DE~T(%AhIUVAdw~@@8UhrH1Vm<=w&h!MM|+ zQYYy3N!ACK(c={JV>{}frtkQQiDxWII!~YfvM3eZ{$?F6SXAnr2`V@``z)vZ=F z#sCD{tP00UTtE)HRT-UDMWGmuqHB;C2tQw5B=oD&Isf<=F z%4}7+tX7Rf{_MdqwLz)UR{e&V*n;L|tm=X~<*f2A zZ&fJfR$zWyu3}Y{s#euUm!GWKkM`B9>W`QBhHgJwb^aHt`c$_nPfg-uHg2IqE&5#B zs>yYjvo3RD3+mUi%2MB|%sAPYxJ|5@*21dA*oSH@t!jwzZK$m+wY8%*^k{F@CEP>y z4p!ysXjN%ELHI~Kmd-2OmtD4QWs_z`D-eBHbtJYz_Jl1hOc`mZ*5ZZ60A3LaRr&UXLu?D-z zbr1Um3$S4?vGH}kRW}Y;)%_s39kOZ#Djc@zITDW2M`Sxj?YIQzae8xtH9SclPq81b zvA_PY^1`xJVfYBsE!O#tRh#ZoD}o+S&%dnEL#wX*-y^Gje@vgAST*n&`~108NpQcU zUzqvEs&jAI=kM9SAK8Bh`eaoDw1M%nRinO=+c);-cgFbH)YM>8XY4oHbQVqgZ8{ZT z(_phr<8cVZ9X2Hf+2nEAl#H&pi+;g2ZOUlV)=Z4UV>HQZQ%5XExokFGv$bhucAFw2 zZCc~CX*;S#*<^{aDHJUb5=U(Gz@PCp9YFpBn`S54v;vXIwtk78bE-bWxjL;azc? z3X~)_lqhA>36v~tQ%wxQ6dc4Qn9JCd6=7vTcQ>WcFdH31$Ga8}%ew%U}v?=1K zP51B$HILE9g>R5)ofAgc2&%3S41|umSwlg5^h(T$F7U$8D&>^j9s5&?K+-l zmm}G(tjJfwuFklMf+g)Lhk@noYF*hbPZhf=p(hsO3|w{W3d4?ioLAqj{dm*Nt{-UJ z+^#1J1Ao%sL zt9gIBy2CTTt`CFlG7hn;_fWe=!he`uMNt`P!|f`J*Z6@^BbaxzUDuH`#;%rFiD&SQ zWe%J~i{I?phK}Rynm&;MfKf|sCScfdLs1HrC zceY(a=TIkn^X%$`0XQOV%u3`jKYZ>)U%U%P-+)zf~jb>+pa~}fFXP67253O+ z&cV;`?VA6=u9qnFk=xh--zWAE^qDn88=OJJ7alX%hsJVE4Br!oml&vpSdbE^-06YZoik7;kS|xDreYDkJok_7^u5wS%~AvSU6BW(7Z^XR$+G0KwYR2s5&(R^)G&_6{t?N17)id zsO9)lKTrdj2Wl)nw+dA4&Vky3Vm$(R-V~^lsL&@+CHn?yGyM7os@;%4Z5XRKVdtUBjkhfl50bsMGlA1Ua3g zpD1!FP!XpC)f@fJFb?5o>BqT1y~E=3f%5$os6*KPH~Cx$)Xs~n$)!N8!;%|;`s1HK zRk|6d)p&d>P&aS0miGeH=sxv54b%)QMZss}{X9_3a10+{dJ(8r*o~9O`!Z02F##E0 z1*!$Q;Sut`4pdnjMV2@83A6DE-_h=EpmyLGO1ulyB+N&a_kn7HPPl}m55&S!e1PdA zeZ^t?jmn=m4{MS7nciR|-k{i*K-s?%6EpA-@6qiWdEp|;{>L#aL#6NZ0}l)ixr`3A z#!h@UIh4=ep;5Sp>H!Wd#Yd!?9sEw{P)>_O!|)76tPagUoXw$JXpIGM+8wHcoyZmF z&=dqZ99r#kC_KoaOE~OuC^6WfIdFwIbO?jPI6vH>0FOhZu^k_HTP$)Qtcr*E+L<#?1^O#xmPgfN{8C5a_9>7uXf10)}b^+tYeSEwVwTt z=ZN0m&=4F$&>!p}{JPPh{F~_WW`|DxNlshI8RqTu9i4a3*PZ0Bi(c<0_dO1^*vI-G z8oW0DrD?D~?Fy}wyjWRbKyuRvC3})dx zZeq=C`imFHb%#BJbEy1~o`sLSIyF4R zsc{*cnh@&LfQ(Mv&E!;%%udb3KPZ^Rspi;$rL_aUbjsd~I(svJAL{Ds)ZqS3c?MF`AkM>Qj34Y&;!t`x+^Jq8ocd)HbD_Xkr*i+s zedCC}zc zRV+b~5KRn$TgQf`Y5u_ws#K@jO`W;Ps1!*}t_YTqkMDz(#3WmYhH%Km| z_X|=BbVZl`LE3=b=r|xq{ZMltabO(GcyvI+VL_TOB1j)lXJn9GjS5oo=pg0C%&|dQ zKR!sSCvgAdAf1^Kq{Y*M)N*=|j?4(s%2`3$fa;OPxA4c-Ag$ZR@tr}szb8m#_XX+b!602Z z6r{C>gY@uZkbXTMqz9Mi#q}W7z7wRpkAhU=MUY;;qt;JB`t83U&GK_;Ij$L9{EqCB z!|761j16+Btjnd1_y|+5i)%StT8aiCE=|UxY%aaWs0f!9qiCc{bCBwFX$(GMZj?(I zqg~1rws^=~d2#<}!hyh}AExYT4KaVAsO6qiD#y3`8p zX)e{7?vih&OD)h9tC2dF^Y8{E=DC!Zi55rMpFZUf{ zy$-w746Cpe{~mFv!!hPP&YGQcDaUD-s-AJFK4zX{{_`$9N9`LfjlAtryE`tK@4D0j zz3*|~L;C#4rQMG?_lb+^hFrS(ls>&+-@J6`$ZMBoy=Ohq=M&@c3>`na)DQMAE}p-+ zbRT8@bLkAG{c!0s`h^B-JC4ATF<3`41?yPmU|q!Ntifs=9<0_8!Riq<>m?M7ttGR3jlo(|sXYf+6W4%9S%jd2@xR zRMikw!^UbM`cgeab!zYx9czWCTb&R!s2iee^+M!o9HLuILbShWh#oZ$(aIJfif_f( z)*;H?Hbek#$eBGQh8 zs0$_^4dFG#5S>7$Q^YtEqJtMgbm$T}T@KNJYau#@!0RC@cq2qB{vn@RAsT!yL;?SX zXzJq->1l`>z6j9_oW%H-+TGoDFOyqI{%+ktwg9(! znceydm&L8iFj(CR!X`|$xive3TkSHswE@kuxV1H_TN$#sH4JiA+K!rUt6aVsUl zt!9yKt&VbQa5Q3=KhCW;*cR_r<^;Do;bx*+1(S%CMhu@@uhZR{m&2`F7@X6sizt}e zttGgd&#lz_ZVg0y0gmG$5(>JNzmQvl5L(2oCm2`EE&q~keJJHtt9Lb>gFP z4Y$hHb?a(9w+h#HYgYsEZ0OeEMsD@|)vdgZ-AZpt&duFAgBC5wp`}|RTDi4ogjDx0)VduVD0Xw{o0ttI1cl z79eY;3@U?O$eB3gIo<0s$mM5WV{4`WcupLL?dl{;Z#WQMBzl^Fj zETc+|$*7qVGwKkmlQMGcSVkRNno)_jGwLF0zRjprUo+|vc4x}ObzGS=Crc(}shdfy z8)Q;=n@oDpA(KXS&!qMPGimM7OfsIyB>(T3G~JL{y}g-vE}mIGM`hL`?9HE9M~Y`w zwlbO39z~aB<~7#L{Or%Hx|y=*RD2d56It{)PZkX?n?*D0WRa&&7G-~(MZw*(%d|SX z3arbn700sc`|<2t=Mbi!u|9v8auf(tS?t9rtS%U)Duu#y4z&x1=>WPE4O8`EVaih? zjL!vx>5o!j%2_&0#V`)H5l|*fXUc|YWBD*eR|wNO^r;x8o5)d_n5d7+KZmI<3f2fy zdA!D}reP}4I!wJggehOwFfG6}gmw#49Oj`@_b^rK6{ew>gl}lkn|u+`Crleqy>FOK zU{t>_)fvcf48jQ%9vY@x!@`s@JWK`f77a#(=_A^X3R5raK+Dl#>W0m@IwnjHF@0>9 zZu}OekO^TLi@SJ@BqnE!_*v0@h?_R<9vior$@*= zBTOB!5_@Kb=_`_Eh3O6!&Ss5JXAZd`^IYyj^5QT}T@t3n$hkC3rI(RE9pxPX!u!<6+p`vK!{3`1{(X*aUo4AWd}#M)cbfjf7?^yzMxGW<&} z55u@#C`{X)F#c(n{GNr$`;zm~`yF|s+Iw>Qz?`4Mc#S$tN58XAeo$vbxSAttWVqZ> z;cAWDNQn+tLVUQweBtVVOUP0=TxY9<>(Ec(I{Ztx4AsMxrv~@e3|H^k;o96NTxA-E z>nehqgsVW)aK$wX*Y}p;+S)c;^V^53VTW+#?-;Hzox&B_C0s4KhU;{wLKbF$D{x7PhF1H_ox&68hBI*Ga7nS;8%}g8hd1D;!zH?ML<)J*1_G(qYCgg zXIu-9F0}NhPAiYLLajY2g4ghC*xGwk3R7_#FHp4ux#27V zI(jq)3p;sq3zIw31C;6F(H=DF>QQ?f#YN2P=Fwx+?m-WFdUO>ldU@pN?NK(|>Elsi zUyqt$e?P|e_h>bC5A>+ZAjYHXP&%S4Yx{7(JTJlceRabyPZW|Ak?%pz~p znoayU9(A1SQP4b(9w23*N0Ey-hO4kH_Gl1ZEv1LcJoskfDwq@;!$bj-0D%qZHz^)?H;YfJ>=X$e{f=_N0oPZ)C4DR z89$J3w@1SE*w`5pG?5r!V|=x=zBdUOCMju8jJ$LTj(;5|y8 zAkInF8~09mRP>BTH7|JNyXes|T*GgdJ(`KqSE>0L`xAd))@^FLPyha9Up(}v6_TD% z+f(*E#$qo@Kl5=D6ruf*#aA$K3f_l;1wei1VEXYAkz)gBt5uOlNg zbTRQ)N9ZaN*O1@Z2%W|9brCYHkC1Icgl1y}CjJqjyEwKnLKQbfXbP?)b#sJjY>7~j zZ4v6VD?)7#G4GiOjX%%12)G)d7WX6670w3{TzeLwRVei+LY?poc^^k;F*acTlL!@k z7NO1f^gKejU(g49!uMCy@Fqf!(f(tE_Tn#8|3r_!Md;V>5$b@;KO!_oky>Pk)CS}< zMd~o_1V$<{C{mq6BK0p4Jdvsw7pXBxkxI!Gsda@S)xBP%%65#@<6e=ntcg_pLy@|E zHd2$$M=JjBNO>+s>Mr_Siqs{vyUds?k?Q*>Qfr<^^6yWiT78dHZi81P@E3kJdbJwY z@f|r$UiF99->cFAUd5TcO0jtL0)4GsO+ui}s|xrJ4!c)>ATH3Wb~uQ~_}Ag(B~oGq zc_o*Z&%}9kCzv>>8sgQ)P_Le6^lERUm*>4+UBsw#uV$c74sye@oL;rbXDgrxB6O}(1e+^Zig=u>;<>F8Cf5ni6ZaNkI;hK!;P zlpXC=b@aoCF<$wNqwdLGS?7CI5(^f1d2hh0H3(be)xyPIwOvi^Yl*kctKjwY?GNVN z?^WxQUf$#Ms{Sc@kH3)Pw3qk(squ_gEzlP$@F%{a!db6s<1chR=hd$BUVfh;|G&Jd zgQIZ$O;0bdZg5^=O|cBl%U)$eGqk+n)l$^{hrI9t6>oWU2KQjQ<5gzdK;m7mdOzfx z$6if-N`IbtmFFdE_lhxZyxNB@@4Ra8fqvmvMQM;=~sk z=+rApf1+*gD4j!}K2chVjd*~VzER4Fxk&97C3pWQO~(yX89*+$j6ViNsoIDrHJMCa zGo!dRCQ94z8O3Ht=`bvFqLhec*grQ)!SkaOj*JVURCZ;QF5%dQC>j2UQlpJgsEjzwuW&ZFe3vPDSYhrk;*c z(3vRB$8GdE%lRmBj#@Ac&tN$prQCmW97{0Z0^{)+8!koZEmOH9@nC(Ol;ktxlPvH3+Zq0})xHbqY67IU6}) z34Y2RtzU5-x3DTKT3hirJX#Gs(Q1oD$R81{-?11QywTbX|EOrqLRvJj@d&@i5Er4b z(Tc(pJjS1K(aIao{HUA|Eqfwku@KEtqtzlUTD5%9>YpC1&N-+d7xD5&t7(B~T`Cl< zf`y|sqX>P$f}-SrtHq-E*&D5=#iL~_!F_m)6D6Z{rF68il!=z9Vze6J6!KS!)-rrS z&C1k@u1%wLphvX2_oVl|iP<+=)rQc!;hZ}_kud2V)U&+jA}QGQ44&+GDg)usTo{M4>vLuFU^kcMgMT}k|Zhee~{u!g)$htK~ znYP6!8s%_$2X*X>(Ue^=dbT@8x%ZGG3hj^4R17&3qkZUlm>7sVLY{by?#IXt*H6Uo zdufcu;Uc0>#b^@3PseB&GG2&LX$;0@JVDlrF}zP4qdwS-;L9<(g=dJq5~KT9W3=E} zjOtxyz8f*Rj9fQkWW5!mzaGUX@G)!hgq}Q&Q6d_n=(8AYdl91#SoxAQ!Kzm=Ja>xK zYgB0ytLV0|e9kIXTL#DK6)F#nRl=}XhsP+8nE&u?%PM83BLBstAT+5~^;A)mD6ibt~T^+qPJ3J{hZ}XJWMxiDzTA z4j0bF@;hCu=Ag(0=7!~BtTJDURnyC{>Wq{tv09GGS7X%#6Orv&te&9S^;rFlsyAXa z0Ac^css|!(#%c{Nqw6htcRN<65O9aMcVqQ0zGB8ba>8kZ-6!XVv0PIgt42>^_2^lw zZat?bFX+$fSataj%k{Rgx`NzaI3Jd;vC4n1@3Y3qkS$J~k&-=5eZu3k4Q)Mf>I=V!I5mun(@bximg7Cn#>Q!1e4HL6#K~4T zPNlH02;+)!9+sDg(;XBk6(@V?IAumpT*A}xaZ0EVryF>NE)|JaDNai&$7v(RR3*=9 zahi@LxK=$*RqMv_UQV3;trw@s_2V=j@36H&oO(Bk)9x0`(=tvKVQd}8bNo0hZXc(T z9pdEb7^k@y&^u1a1Bs7jgW{BFNSr!h_E2K|7N=Y5<5YfAoOYnb<~V&n5y$mzae9d# zSbQo@znqKHcGSB-KTzpnoa#fD;?x7#uTdM~ZZOA#IPJ&jjPZP~BwqRN#A_wKA;;Z# zb;e~pLBhRw<-u?q#CcS>AJ4zZ@oN7dUN7+ovk(#cR-;c=^4JS81F^#&_{*gylGa&*=DpJU_;B4QRaHAm^ue-ZzZb z1yuPGugQq{%I)v*DyRhg1%JN;KBthNGuUKE&^>sJ395-vIE~Dv1l7et+(NK_f{LRP zmf$KZ0SU^FE?A07aF`QR1nn^oXJE1dv2_@i>SMg%UIzISMD}B{CEtkD>|6SS&$Zizg_qM1pdmZRrH9MEx=eYKJ$dT8{k7 z)2mAKWov>4BFDA_mB2B?>>$qW1P!~KpeMHzRQ_QC@Bb#Kz@r3JK+xj^g`wt?1bxA( zr}XuCf_{F%8ocBjM86{6*9pq~hPXHj!`lQs{FtD~PYL`^M^C;as2aLs^N$3*Kt;bq z&G@t#C}&LrweM55|NCaM!G-b96>3YOq+6pKkzh1f)%qb4daXQEo? zN>pra@nbN|54u)K zl(SxL+R{-ZY?|hUD5RQB&}$bt11LCTb%tq0x*)&BTY9iCQ!(QR@*sJ5e+6 z=dwhd+m^_+w~3mzJ5d)fa!;bBBWy4I*+&ig6LsKJqI5b@n{W`l&LnCCGMpnHoWYUv z)c-emT~E}5Tika$QRD9<>hZlqReV654_PA&ew3)PPsj!9arbGW@;pn_h8Kwnf0?Kx zM1D-*4#ApV#wDrVgd}C3oTR$Hli#!?6`am7e8-L%N!mM)`>|nulJ=p@0{Xu& zNxc^(>C{e+@8LK$?BzJh?Bn?UBsDsar1r;>v>FYMC#eIno?uhc{lU86B)%Gwd7hc9XZVI8rexjnPv-OB$y$wE=4837 z$*KZBTQZ+RP1bb0vnT6#V6ys!Bx?)Y8IpAl|DbiIWOc}#tQGLjnyei-ig)-uI$4(3 zWR<~ZSmTm40ng$&H!)dHF}Pr|-ojdj7#LPISxM!RHK$^-id9P1o}ZHyTO*mzawaQF ztz^xvpRBLHCM!qVWX*@IU9$4FC+CjIn%pUw_jr@FyhpOkJ(Kkt4);!0!9K}ag=~G3 zb#YL#o}<{1Wc@OfIZ<+0vOb~B@MQjeS+XjOPS)eG$r?L8nfD%(b!B3*noUbq_W8-` zwJ=%ni;`7(f3gPR#sOj?WJ6S*OuwHkQHSJ!qe!ic~HUAt(mXhEN_ao;V{bPOHogR7a}f# z3a7|}r7#pt;oq7RJ+GLexJoG+R+;>&q^K&!H%`$h3~Z932?%YPqAtx+w4-?n*FdId zEo=i)v=^sf9+;x#xHc+98Ahk5^OzKcjZIM^2G35>PGp{&qKmkTZ1Ym|`@$4uT9l$8 z%eWuoSET5ll_^@eDn<8DYz=+DXXIL&q6OHwHHF_f=m$=~y*)*Z@qR~&X6z)-T`B5@ zKah2IiYo0%(HIooo1)728@~N1x`8Jsdw_l(P0`qsDLRgRr|2a@PN%5j8S*@vq67?q z=kFACLXOMCy`G{GxOaoKyUBR0y~lc?)Poci{g*LV@ghZA{!7s-RQ^FN;IF zkYY+z$KX`0#jhc$>VypLRE@zyoXeOhXQou`$9Z(moT{gom?c%8BU05ll5-ML^%a)H zRK?dz)i4xnn5qfr)HGF>@Tyg+O0`baC)8+@Dz!~jb(HB!Jgn`Nsv*5Oe`>0RBV|^q z+9G^*s#5V6%FRjD2;`res`AJ+j~o}KDrr%w3ZptgmZa+YQu1Dws@oX0oV-@0YU!F( zRal>@-Uk_TC{;bs=Wwe0j?f2uJDREi$5J&Gd5))Q%?ZvwnJUj|YCD&zn16_SD^>Q} zsoH`@cTyF1H&u%slgAVCaHOfAGfn027R6j?{4KFGJq}LOl#FS5g(jKPbT3Pq@@7p_ zDZE6^?0gMN(=bn(OwrsQlcqYcY5ZHBroM@3x`cahrl!f_OH(NJAt^_i8s$vWyj*Ge zC3l+sDw3u_#nUtn`ATpO;!38eU7a+wte3{$hfL$|%cN-pax_en`lhKSn!?#HO;!36 zcR-rP4o*{pA!%xl_@QaqKbiceq-il){GO&EGtyLjW}2EI)2uYros*_MOVTtR)7GY` z*ZMRKhi^lg*8GvC#EofcyE#oq4y0+~;WW)fxg+F`L(}as@^4?0*(L3CJ z&Fyz-nuD_M(=-ETvHoM4X8QT$Z}6!Q)){>&>hIGrT*RONpYEG|dIOWir`D)x^=Vn4 zPnjJ)#o!!VK|T#}`P4hqrF+q7b|-LNqEBOT`Sc%R^ZWD( zmI6LS6!a+-(+d04s)$d$FsrCfEB>#zPv2lI;nQZkMtEtTx?ms@%lOo@tdGB2;?uke z#IEYo*=j!3{>7&PHGEo+U1(X;r{cAJs*1)qf=zXNdQ{J+aSeQ$(1N`EciXYUVbh-V~ zRog#ZO){pdai(-Wx1Y}I+39>&I$hWB5R=QK>qFUe znaZUrBl@CM`E-q~oUTWxTQyz&)zbNUT-*=$&*`d#5L%LEsGZ+5rlCIg^()k;`>1xv>ozGOz z6Ldh9-qhJAT_OF5Gl)3&4=V*c#e4im zF9HIJAVsS5me5m{P0s|9>~40cn*XR1uWkL8K$nK|0cVyI<~e zug~*&LMAikJ?Biarp&x!(!3EST^ec9&Cwr5K5$)t0Cn3#`=zHc)rX}d{XcCdeTvd?y#RAe9fa6d5*vVRYmRQ`xb!DIC5I5nK4 zrc=~=+N82L4EH}KeS5~F=Vwj2f5D{Ru9=kgx=F1t69;h`t{dFPG9=wJsVn}3{gz25 z@EA*On^gS{x&3F-zZjXp%;$WwlCT+BGMhO+*Q_D=%$khk{ARVp5fu8+tf8n?+$=9t z!mPX)h}|X4ypJ+#Y(=x?BE6DX?Qs^RtC%$oeQTIC3jUgAHNjrIU)!vH7@1(!Of;!) z)|dDj#T~4V3VyRX8D{mt6+Fhz0rJI|24+2jD`?gMT*H=-SslV={g7nVRZLGYD}ThS z7}g+jD!Jey+-YW2ZDiICWNTtppegI1XfyhN{LQI1-K^~`%sSfAtaYD}XKS+td}UVQ zw)Cl;ne!H?A88%T`VRjg(9x`$n9+$?UCgrM6n^Mx)@-=CQN!0}z3OFF&)#ND>2Fq- z0rU?);{=KfG^@)0=ry{d%3%65*{r+BIK`~b(HVcD{#5e+k$8B2npxjWH|rM^nqk&_ ztjB;=wUqu}UCqW-e0;aAf*6hi$bYY{8elLs;yxG&BL%oc?)2q#d}urRl%MV|&Ns)dax)X<_QIGJWq`^FYM zjkBzkMXoO_@_uE}VAN@Akq@^pqn$uYBSoR%L^51qVI6=3_Un&QJM1=<|MGF?@fA#j<+lv z_heD#+w6}!7JmD)=oF^hwP^Q4i@tqiQNhO+jX?1y7BzWh;hYot_S~XLuh>5stm+GM zMk`ZgTjkDVRoBc`y~<@(?c7$4&tui^?_0GG=Db$@k>4tRA*%-A{Kr=2WVC88x)!l& z4knwdI*h6{ta=F5wCZ&|tCB5NHLlMX_%G3_RSv5*<2L$xtvZV9Va88lU0lbZWUF$d zSk)$Cl`WN6&8@Ova=KN~s8ww-7I)%Sm1|+u;FeZ7KC>!>-nb6m=T@z0ZB_lulK!)xt$LyX~okpGBRu$-DRVf(Q(3hI~ zvEDGN>f-@24!3F;{{5aBMp)H)sa3P^Y8mw|w`u~itgyiJJ{2ZG~b+l>l*ETi%hPXp)`U#nb*|ZIZ@C56J6Zd-? zzh~O?>13PY*fhnakyCB@5r1Io44d9!)l9a9f0j)PX4`aS4s~y}spmGEW^cDC<3*bi z@er9V*)$wiFWWTkicJZ3Z0dt*|JhU@J5lPMO&9RdTbokBOo%Fo8F-Pwu7w%xs+iTT zFHt0$U6t?)^5n2HZIxZO@P1Ca&gQl2aRIxkePq{&f_Bv{WS6UwT?0|GvR!WML%FJU zUBx4;s%BS~>UO=YX;*u@T}u#6u&VrZ5L+O--b19ruczkyw)un1X# zPIgs57^cp4bwa5wcA4=j3Us43JVK-Hc1;>=*D(zJ&aTOD4YBL*39LWa zt_;&yHj8oR*!3DK=i0Re-g$P8lV^+tb}e3J*ERgOoZL};g1+zc90Wg5Kb- z3JJP^HWd?euM*49rgDN-;{`sblAx04g(qlUEkPrzCva{|g8smDQ-U^{Sym%KGvKe8 zphhrR60`uvYzex8N62hX(1$34ns6f(ts@gC?+k*+r@tvS*6BsMGzGmb~ROvB^+Auaz;qi%_>yW74lM--;s4r(G>g}vVO`4OaD)SPxrIz~ zp$fGfs?xxrcKD>BgYg}@jb*70Inx}PiDAtg+J&CY9U6}M=?;C|irC26+M&X@h*j+! z%G$x9%pKVlkCCMla#i0_|0ZUg0@9!LH-OHg3Sk~LYXBG#)Jv(F?zC5_TknjhnkFbsLvFKZsODF4h=-}`3_A*!vzkd!?w`D z@n{Z?!*$5J#-T>2zt*8HdmVgEb?CEw4t2%E{SMW*;LuR?z2wkFbiC|PKXkt0ko&Gf zgHY?9Lmp(jPc4rf+K(|W9r_akUpX`uwO%{46t*`G`7%1S6sI#eId|EqZ!F9>3I8oTCqs3V76Q?>MS8=C`Blu1Ur|w{L zS*QL*QaPudly|Cq1*gX0Abb^_I);b%q&my-78gy#so`W!a;N%XMP0^0#(GZGL}jZ} zDL7W2+!Be2S=f(&gSv1R-JMQVbUD=oTiw)+F&?KndYvlccgh5Ns#BliaucUYkEce& zrx6pw<~cPH#eZQ;H2c-5dK;YL!YRs)^ZT7TdysAZbgB`S4aWhEpHir02+gi~143cbIqEsj7FJT89f*d7sB0I2A(6M?6RH z!DFWeJ#%Ui4!&?I&r7F{ymIOllHW2eGRdV1nOxe5yZ9%kOIvfhbQHtNxRmKrm%3m) z4&f1!%epiZH}R;POHIqO4(4Mk-l9N7m#pZI5g1*`rP`HU+JNd+TneIfRhNFiht*sv zhvavvyL2C`%`T0p;nF%Bsp-<0+Af`~<5K>*E@iX2R1#kzqn+)M@J@nD=a9wWQf0W| zb-Gl>MV@|_CZ@XdW134_P^pnic6{+pV`4UODIGPMyYvUHplS=3QgIC{K6mL962Ek5 zTt}CF#s01?JwVQGE|r1>2k{gyzICZYPwK%atikhs#2Dn#8#umaT=+-1n3K+>X|r8g zgr_L9)}@9!Thc&|A#K8k~FQq)Yuyxpd-hmtMhh z&ZTx3gf*94I*r@c=;w8pI^J<<0wVWZ>WdbST^a)GGxiZmy(Ui-ky{>A%I;P&zIe~A z*G1eaUDU0%#od~KP-VBe!(NTYao+4!jv8*oYPmHG6Y9B{1HrAVcDJhITB2L|9B%FM zxpfbP!)_&F3bx^KvRg$`-0FrIsF&te9P4or`I@*@2bY?;m8-d1bK-98#+c9CTsOrn zQ(LzhBVz}*D&t^Rx3YihmKnwRx#hxt1KcV!kmcXGRTYPZy7e5EAKYqzUvUXVN4e$1 zkJy3nW8M5emK?^pWkuTwjElSz*%sxdx)sC%975LV9q;J5lTxw|v;W+O2(S>E|W4s=<5Jt@e0?tk>x0JJ;R%3-%jszL#>V zz->3jG`ST;4=lj%$orJo@H}&?#&frh!}5Z9vE;2=8Q9aWvUxPOphq7U^(csT7=e{I zf+r|Y%p)6`qYtLxH=G7vW~)4s&>d5-4Y$#%l1HP^xT;43@w}!-rE7VVr>;kJao_Gy zkpz!A_&mDo_o!{aBTtG)oiMSPNAIP3G%o7VCvlG!w(uzVGmkR2@~A2nwfFE@#G_T6 zJaTmLa4wlg`@Z(*9$J6n(YKiU&bJ;pdwO)Nmq!hIdo%{8P__^EaU7ShqOV5}@K--X=aG!mEy$?LPi?feC%JhWga6I+!-kD`6_MH8P%^AGPnb)i8 z@D%W>9WEB~>M2TojKW@R#nmES%_!#8*>^tis&8>G^Lu&uo{`5f%kb(K{PRx0tKJQ~ z%9iBSjx^#n@oEZAB6|xje}BDd)5@z6$k5iSa=6vmt9)I&I^EsN#pS$ekA7J6&evY% zRrhKwUiS2=LvJtV9D7x_k5@@JjHms)%F*AeUH|jy6bcUZsv3siAJqQNt1d&lT8=wI zy=p$(tAW^vUO#Xm^=}&GpKPx6A3n3YM+(Y8=L|V%^nVRaxs* z1if(dSFbkx=G7%M+UV6#?AT1NkZFroMNk6`aCJMecW@skaDFFw?;;<}!Txu4vw!z^ zId|2o2gtGCtG4*^fLA>*=%81Z(eRL0_b~V`ua@90Ug7Z(uQng`s{b*sLdU5SJx+Kv z4X=^^q*u0gPI+|(&eO!kCui6mpPyrW%zEd%SM@Kj95XLd7xG{6syM3rOAS}a;hI-v zZ+i9B9j~6F&0R0&h{F>KK3S{s7*<#FX)i+6eVT6aX^YvX>&RWxr(aOEmQShpua1v7Gkn@(_sO3?Y}`aK zhfjswKCV~h(}#W^bLRP&`@*Lc4Sm{#^+BJignepMNhhxAp0D zcOTa*#MeIUM*VMm8vdP6`-k~7bfk}C27H<^#it2deA>K?I=1_?aGy_;j+5gFVxID; z^ci}8)~7rd=mUmcV&CDDQh-e$Hk0tJJ4{{aoFz)C9jw_5J+5;+HScuj`oZ z@GH&bS5dcLfhK;rn)+3twO=>7`1J(yy82bHn_saWewF#!ucy8I%G}$p+X(mZ>v>{aUonub%7u8iHDz{Q4Kc z&3?}H@+;dGziMyu%Z;VTv7MSx2OY5u$Dtj5<%Sc3F%G$Q`ZWqUcaa~WyZx%Zhh;bo z*IvJpFa+Ny+biuDTSbUNFfI64x2XbEas~0Yy$`u|* z>3{v4cT112`qdBrq1rV+=Q$G_pI`TDHa@$-wm1FSg^zC0$Gd*@c*J9m{kn$qC*+Nr zX#bRc!S7a)#{{^+44p@$l%Ykqk3FS{SB5;{E=TU=4K1u_@OzfQ?^lNWbq#%1 z&(IF6a~ph*K>dD0op2D94MU@F2f=`$WysaQPzU^pl?@G550ZP>P}3ws578jSPLzX56-%T)XQ(`t_o92e9q#Mc|HPjcku`fuzW*GWIZ35CNQo ztDm897~J2`Mdbeoa7VC5+KG}_QyoQ1}4 zi<{Um*3j1R2A{R)^F(@wlu3qmqwZw(-xPW^mFMep>YHgW4 z&h0mp^?;!tkolmYeuu~(za8cEi}}Y4y?2~_eUe;H8>;n>p_VvvhTfkw^yxXCgLs4W z=Xw2H;JJN?UR>t+g_&0j9r@Rg?V6!U*LiK-F!UB9Z}B|3O^&E@pXd4$`ufyRZM=c& z8PE0S^z0?CL45U!*Icdu^BxCOICp?+WCrwko`AmpC?H3{fPTQ-A^{aB8Bnd#0X;+O zG67}$G@y97fc91hs7}Rz_TWUNfD$VQbQq_q1k|irKtpi|JE{k`_64!`5H{c; zsx}R9++jdVaRX(V(Jzd~4m?5i<^hgNq^G!oQt1IjF&RgYD;kgs-(oqgqIirr7>_^k zVVpj-4#?;nP_gg1pFgNJ&4QYb#?6Do59$sA(V!Fy>Ux`?%6<{l-?)KJUj}vHt02ES z2er9VP;I*fHK%t_=P|BNP;*hfZ&2U$3u0C8%!Gg8BumrU%s>FVJ`<+sz6px*@1(2>ljR z3|HXT6jZt2gZghzP?h(RC+?!hzMzim4{FGPpeEoHp8XkA?L*Xw=ji`eP-hMYHRcGt zI3AP*lTQQ{IT=(7%sRz5e+O0gG`V2+*`QipAO}3VNbQ%%0ktnv>wRj$;0KI{!ViP` z=21``9|zS3-#%gavmo=j2etDJk7o|43Es;RQW4C-o2(&K%pOuo`H(VK2ywl~kXE5} z<&b*dC7M(X=^xy~|Eh(Qy>3WeJV%atA&tguONeusLb~q?shT^aOL%~9Js}2@laNBsSoWOSU$EWFkfy&1aqWqa4!#X>Oj}qp zGKRG%Q&=N1ht(-dSdr{u)yo}LxjbR5ct5NSdBYm|L0B_Oh83$A*8NIhU8x+_@hV~M zt{T?7>S0YXg*D0?)~#A$9j+bLjyhp&tV_&#VHL54bpu;%#Bzj{=nCtmJFGX}uzvD| zb$`?wWe zhZRP~3t{EQ6g(a?O zh|^_~^T zM9um{)C*D=A5oOsMQH6aGIrc|X?^r}1os6g= zR-K9He`h0_cp;)SSbC9hE=4rzaYWOfN91`CQOB1N<$o1X2vadCORDC)m#RznC0DB2 zwMx|?yugV?sT#e6Tijoos3m3doIRcC#w)?xqlRM~f=DvEPEQ&oFc zsup7A?o^H4ld2E)rt0avR3+U{Rp%UOD)?cV>S7%_7D&@V6eyUc7*-)?p)`Gi_MfDw zL#Z?cOQ)%C*)$DIPE(JrY4VRq)7p7yTDdz-+c9u2F%G23d^t@s)kw`VG*VBzsNG1} zj7GAyZKOh*8gVVebj@#*uAS}EHK=pC9`;CA>z?WQ6JPgE*Dx&Zldd8C(=~BGI_LPM z%QTW(OdFG~Qe)FqXF|GWOiY)1N;>B{q-)u|{c``>;CtFnKF(gk^4c?FHzr0c9 z%NOPK$zz{Jb!KQj(f9`+t&b{%xyZgDssadX zifSR6Y>Da-N*s#nPux5k<@d*^+>eQYT2H7EH!$*fR2T8$MN};RHScAO_8f#Ohs`T<-d!m4L%+cQw1DEmSHiq#PIK_1@@6K^+wfEF(n}P=or@~ zi>W8JkBccVKE`<#G5v$>Gh@myE5@~rW7>gUvtt@PC&s>v>BwB_o5wmhiXZ34)M!~u z6X07OQ)7I(BBrcsVygLTjO%sLuRSrf#{zV{&3Z-Rs#`LyBi6Vo+Twi9h%3ESTwk<~ zYd+G3#kCll@CrGG$7RR&n1Za|$MqTweu%3Fj$!o(VvUUJ`k1)Jj*Y9%xH#`|<0?NP zu06PmCKKZth-0u$igWF?xR&5JF5#oeaWzJ3Y(s@9aapFa411=Ga}J21%0|FZ!38|NGzK-UYrs+~VJrZO`1!mUG1C7fbHnnC(%S Zj^sHs*-DUNz?!LOacU|3mtJ`X;tnTi< z_Wiznp3g(L_uO;-a#A4Nki9|I`5GvxI7)8rKba58l`B{NQhBnM$eyQU&YU^R zOXe$8s#KZmB}$ekk+VeUviZxD&Rr^JjvTp4=gL_!2gl0f%T=;WzOuOr zyfhK2AUSXtg(^x7kX%WMsVwEd zeq6`$D$taR!49MHrMd%AgI{oynkjnGO0gi$VTq zgL>k;+n`pl2JJ0r(BCLi%Amt#40=@FAWId48do)_J#yACs2KLaQPZF{ScvYmm;>GG z8}wT`PHBq? z$#5<-C}oL3QOgawvBIEnD~W%NLHRLttwASXTStA-@psll*7XLR#x*qBWRPjULC28$ z0OMi$i!mn*dVYquuNY*#YETX|!cfe|8chDzpcyv|YJQWxqtGqlxouFyJ%f&8-vfgh zJZ7C|1}%DS(2_Ug^VXm{NPI_qJ{S~=l2`-NC;Eq9u>ucZ{cKQ1l>Wk)uLimPGpHZ_ z!GUk=p#YW*MpesX)N>TbY*crALUb0R8euMWVn|k_MnxMn zAjYVhXy`WT46JcRo%R?tDW2o#nPAjwuTj~Pj2h!Js%t8bvl(?ayHPiC81){RavC)! z594q>uTgIc7?oDgs9y^i)wqaJr{FJU)GG`tZq!=bM_LJ^#$p!wl_cI$M%{wD4CfGC z)~MaMQ;wRHH>w1xqJ9OV?%}tJM%gPF^#@`q8#MyyRgCieU{n>|2}b3f$X@xs-^c-xQ&|I#r}22YQ5|L* z^=OV!ndchS9H-_n$3ml$mKc?DrBQ8hVwF)f)-wNkqmFJcYUDt~ zVJCUwGDhuTZ|xs{g6YetoPKpg0YOb^)~82^ZU_L#MvQX70g>t{yge{NL& z7wmtmL5p`rO?+?E$`3{vKN>aPV$yi4Nu_NjEyXgsN!5Z)S_P}aq`J5lV$v^8lSX4b z3WS-IDcqz~L}unAw&TyNCT(?_l+$CD1YG%fu}O!Tn6$2`Ne5wTX3|pxG^Y+&h>R^vnt_R} zOj?X=txc-f)}(#yS+fJzbTlcYlS#3isaqG58gwL zIXDW}Y?C(5F{$YS)ir#QvQETO1@@N&l}|a%%t!y^h<&2 zgfWId-8TkmXkehOA%{Isr;$52P(dMqa-n2opaw<-YG0;6jmR3P(C9#|LdTduZNYJ5 zb_ePycE$#3TU?+@BnGM~rh5aGDJf7j(8V9938<19s2kY=^$Zts1j>{

    0q#F_MPO%9_5s?j1E|53@$DWsM=SpiGwUso6TO1fg3F#W z5acdj|yvw%4!;nZbMLr-uoUs<{lfIHtD?mS@9mdd(7-G=?Tl8jr*!?1Oe%#ZSA z`EsZGva#|psUlNV-oos zP)#b;OJvy^$8T%+5Gg$%k^5$MxQ=Br#amb;n``rIMj@MvA{*ICNg|gc56?2m1(-I+ z-TOp6Ss}Fo4w9+j=`~g07~raJPI5P(`KU}!a{XGzigldiFFDD`;`QRvc7#hSn1U-Z zi?PV!(lyB43H)bq1&W{6`0YqCeKTAGbBhGolFRgoNWL5R8gwMHM$-sXE0=4~bzgI# zbtGT}n$gp;vLFns(nu8P6QR2Y==?f#tkPZvs#CbMD)#dYj+zZR6$=jhbM?_|vU-mz z!~$rRm$~u?4$y1L;$CF&&owwuN93*$B%3{GUII`yFKoq9{%ua%c))DIrR`2;Z*-Jx z&YWASn0iU+nVOy7S`5J_L3uK#CO5UMRWj9Q(rTTlAwlC8ZEZ>(WaLH)ZVx~t96jRLAw5}jK8G@!KNn+d4K z=1>)Y*u6>+prqvS8Fk86xOUWAtC_{572O!=H zKt&LgR=~0VWz<25@xrHo`OmXdjoM}SrSCa*yvK#Cgf$Jd#cb$7zR5sJ6ippW0;f~~ z+!cQw5Vn6#6oJWj*Rm5U)ZeSipZwrqi94g`@Pc@+u_=#;(Czs$2 z``va!s4^WFE!%YOf8=+n&0=ri1S}*K=1$1XXY9JR2OABkKo82hqbdoYdO)2<)pP=e%Fy^#B2c#i1f5tCmZE3 zQ~KBCf;y{?Ix!S`;CWSf0T;u7u3Wf4%06u(;6n6pB--x)BI1Pr)J%f_bAl#f#w37+ zHV1P8VuK~xAKL8@=xTvM0EBTAj;IwH?oCJZc;e8V6@Dg5|m&>;TW7eT`;Y<^K6)YLiN`Jg@PB|(2V_{Fu7iBU;pP6fHOq735rr!t*kFk=Fp{#4}i76Q%l z5*4E1WvN+NgBG|y`8T$Nx!)ICdrHLW2uWMLT2n;G<&W;B^)xoDqi<4)jJz&7m+W97@3K< zkW6e=lTqjwq!Ls=p{2UX1t{Pr$2wUg56K8sULOo~$4*Q0zJ^y?PaxqOi%9Bb&rCy; zfWk7l7EVp;Wb;uMFqNgNm#Uer{a-}3>pW4z;V=KRi7Ftn-CA4$i@Ce;L&7I2oSrm_P#bAirSV*ZT#$0II6>LsJf0xX*> zjOB1{QA75?v&A0V^O3aDZLEt1v$!f!f1bnE1!xdKKRPa&+!UqnFR3DF zoPG-A9v7T?vIi1tsq=HCX@Y)~OZRYl!R{ZN{eX0Qh25NLGUD_z<_^NXs-gQ9nsIm# zKN%v`q(*4JTB7zXwBiIH_SK$hvN&y~0OiXJ?N+jLXsAEIK@cGbT){6qtN4%J%P4-3 zPxK^@p#Voj0n|5L)R*WB0?jty*Z}ksDGe6eEIN*eK3OBGoFQyL5>=6B^RLSh zAfa|T6N^rT3v=@EO2x1glP#{w8IF@N(8rkSFD5LEP>fY=!xAfu(UUmBEexY4v^o>ETaZT~=O$mjm)+V7RLM_)ZfyoSu*GxW zfUpub8*%Lvz1cugxHMc8&Cx$cvrJ&z^!5;IbZomeN?dlV;&kyYu4&1Kd!s({u)h=O zL~L`Kp6h$$I`Um+F`cEC8+>P|s<0&DG_VlBMkV2h;lLz#2mddI{B%dC(qkwX(l_|% zpy+G((Q7UGB`EjLvfNDLv|t_fsiqD)VQwbK6&?1?G}0$m#pWaZ+d#k|9MK7tlSx9W zc8k={^o0NG;T^BEAyJnMz<9o}n9>jPu!v&h0=_TAd4^OOwunqpeI3-?4m9zd_k>LTw-F-ey*H)f(@)`&ce;z za$;aG1kVge_pz1EEwuJI@se_&;t;tM9Rs^6;o>w2T21&q8Q^(F4r+09pqI%){f<9` ztB^3^l%$3;kEJ2N#hjHQV;cr4l@7uZ9ozU9c}JPK`yMroPmqk}-K*(e^;?r{^}>HHq$QAqddR1#jd&H-4zFw-Di^{Sz_RT`*h&c- z-Ox~tC`h(%7PEVtZDKt-u`3vaPjDmRZbPJ*=^9ly*i}Vy<&pyq|91`>GLE{Eu@TQoOuCYeR3HXn zr$`#;x8Xa--tV*~K-C-$%Mss(CTG`AgN|PX9f8oYv^@DN^53xuG$6ngVWeVyandpC zw8Mnbn9}jyM}{!^t*UiwIwjVwN|ceJ_c|5{w@}`$kOrgCXOPz+k(XQX!iHZvvyt*#6e(O)HCDF6>k z_VXbp&DY)o#EAgZ%m_eH$tBb>Kpklg^%o#IekAkSY7c@c1JqF+lrV|(1kCA=QS2U6 z&8- zv8@KS69Sv88mjB@KsDhrNyHO$+^!bvIe?wi5y8xng@E`s05v!&2c;j^# zNfsLMr~h@KQ#^o?V>KEe@Lq1B$ykX~b1td0bj)#I zMr!hXAdN%6?z1qX!9|_N#5LbNN?K^p1R*_5%7n`os^^!o~Q{vv2CPkCfA(fU|3 zT7_Mdw@FUb%b@DCjw&JThfsy{zmnCM8f;cv1GqCfIMyoFeg^LHL zVHI%e0T-o%6N+p$U^ear!}^p?>WIYDSNy%$`Ri(@RaMTcb{=|``1bp=&Wq2{&HU$` z8=hyJ40`}xN2P40Ko$PQ66dj{PDGPfQ09DT72PQ2FA1L}WXArb&Lc}1Fd6=v!u@S1 zbH1>Oy_c5cnUSDht6MgJ{@+EF&s7AcDQL+i(B5L76qWXH(9prX1GqnQqQYW?b^=6A z0P0{t) zX&Lt=%*J$G!;r$dGv;wM5}+cd$=aL(`Y1zP)`85*zghC)k(TO!ezXVR0R5?QD(NOA z(R9geO2ym1s>ChcAdRq}CxPTo*dAJ3h+Sebbq7$z73zBH6I z?KXKI9J}%ZPtZJ001bE7A9r4$RWHoU`%THc!$NLJWSW|P*xQ2lGHRc zIh@zTTK6XK@T%Y;ClXuNA$ISfH3?z(KucvGn!Ql%gG$v)vH-U%vJo!pfC^NHbuh=5 z)#!GTM^_?DGA>3~1_+Zq1(2|6{17C3Bj)lr@#t{KAp0pkYv5CMwmCcnr=mczURUR; zRZ*1?DkIK8H_kOz#+e{rm&j7VcB^3Pr_;=~Q20X*;B-rMi=}eXC4X3)F|om~Nn>T> z_V9IBN(jIiI9#OM<`RO_{J^KZa7az`U-aQDOlL>a+!*w!VX#c6v#nelNq&VY)>pgL%iX^uFVQX38WR$?L6W+VtLz9Cxv}D1VBKx^3~oOX1B%k1jWk=b@In^;bp8bUmZ*^{mi(|9~Uxm5W97~Cl8SR64# zdhB^r%15$d)W!2K-XY8`z?0tJ3@AlZ%W^*GC8%wHs1HCblTg$m2x<$U3<64==txkZ zRXCCX7ZUoED9@R6_c(LreL--{_8N6x&s4V&;5xp3x9EEypNM z%TdK?IhKW?WU&tmS!g4ReRx>FVqb3Xl(CjinzE=TjP*UfL|dSl2j7|@osCf!Amlwz z7JZPB0uz1iym<9lT<_xAimM9O&$y1w6a5448LLoI=YfF8H{VwAF|gVtR>oV_H#QlB zF@Qqwi@?#IG<70_FsA9-uD8!4b8(&*2P)+Z^cCe!$fsknynT`3wjYDXAxqwNe)+bO z5g(#A%1&TzMEQNq5R?(f&_K5w_jdUQ+e_Fxy-sMzUf)>p!~Y;w*& z^^>Z6hD#`$rm;B6$m;WR+}!mOJph5{+>dHPFSt6|J;(n{8y1UqJkxyd^jv-zbT?Q^ z=;R;j8ph?1sHPQfJz?D@7i9Ys%*uk6mko5Qm2{2<-$%dE{J@S>`f2dGfUU+$^@AdN5m;!}~mB zXgwq|oiU&7)Sxjg@?x2OiJKT*rmb1;f2OJF&zzr0i8V&r8}OKcYbpef*xlNcM}vZ% zxFvQh*>KwhVixog0zhc_Fg(zzRDYyu@1=H|ug+u}`nQdYy^&ghSWwI@8p@22XyS7E z+uSXD+ee|wAzT=ONVjkrlPq>%5Co3~8me_KOYBV@Q*P0~ezIlJ`>Vf&ub^Rfwl|<& zm^2nn><~s|@YXw}}G!0Bv%^paD0NHbIz-EZ=Zc+;pF$QCWtzkNQUVugX<}XhJp4TjU#C zn5UF3SKpkkzB^z2VEzh1(%tdejf8~v27~kaO_>rvVmBK+_$0Ll4Wrimtt6Z`Y@x*q zM9y&1IVu>{Ku!Ee6K=f4@G0ezIfMewgjIZnGnCs}!l4tak<5k=eV{xFCw_;BQ;j1x zr}#r16)os*m6CAIuq6y>Z7wpE#!hd*VJ9W@XY5lM*8 z5edhwD7R@|bj!}zNo8-9*5GKJ;&--9YjCzt@w+;%Llp6}23KcFp4Jf4CB+}xZB|-C z>~$&rxa)Bfmy+0ka}gUGzre}|$dB(`g<_d*WI9Ny65$Tkq=jDE5~^(a6ho}*gMD>+ zS&vRi1>@+)7SLQ|;7noK@WDd@bnqGA12Nf-hyg1m$B z9Y)YvT)Z#77>&uJ*68^a;QrRb(eP;wApQzKy%HJ(^);Z*Hiz;9V(k%`*Rb#)sBZvu zt~u13fVlango?2TL46CT^Ua}d2gJDm)LuTl)s}1<;4Us0V~=kk7MZ6%x7o6|Xuuh?K%)=unq0OLi0QCePj+SSg$9AMaKrjV_0j^p4hehp!3*4C$)Q}2PebFt?62PyMgbLo)9+WUkxZR_iC}A zwW$*ZUO6}8opJTS;m$q|SFDoQ&Yd2c6q|TMG5w9}mD0)TVLG}r8~?H?z^(Wfep5n2 z2aaaaXjG_|&y7#zl6rZF4{7+2iqzS*x1KE{b;cC(aIB`{p7c?D@BaUq<$HS9?1=cU zzK2@ICDrnZX`PTxDk0J+7`kBl4Nh5wRZ>0hv=IYwyf9fSvCbLFMi{nraZejDETGqs zcx{emuN|AAd@MrwIOIy6K5|?bvObJUogB1u#$uzmKnne+InzROW-N@Ccn)s9dr>nD zx|+_R5iyJB#%(df7Gx44zCan+%f#Gd)__s===EKD%qC7v^39kw1^;SCsSli0mASZ> zWYB4wa#l_#$+EE@`QIZ(sT`05Z9YJj1i*wtlmw{+$h`ujkXSDFt2UX5V;fDRJExR{tA_oKeLh4Rv(P$!xn&_v-)c6Bqx|TXbTm|Hd5pWK-m>}cTAEJf zvCTnJUGHv7BELjrhg;;^`=NE7=?>N~eM`n-8dG9eAtg)uScCk8)E5`5$ix@4Q0?&1QP{$ttZtP`fL0X>5ZAH}Js;zN;U+cu;;}3Ptt93LFUE1JW-M}WKhVMxX z$^t8puh%+v*D{?cOy+90FbKI;bst3T|A^dYX>GEZ$oXAdT-VMC1)NsX{tUQ(^;FYN zxK9DG;VRKw#&)t2#pnIbrT z7ULtpeMR7g1EE&Kya~+T=FkNNr+WY18_`Dm9u6Ux7VGO;+p zQGyvC-tv!1{qv#+RUy&c zGiX!*qoj~N6UuWy*`hhhRY12xi}J%RWxELm{`Kf#is5`Vbs7Sp4bH|pMx}u&pP@Vt zlr42Ag;f6lginV;s&xyAvr1hvm%EHgx?(J063MJad(OO04BT_unM{OadCX$$hdoL3tYe_7>qrl<8vnnriePD&%}|7!0FME&jdI+%&hze z7e@)>#Ow8WIb^9|yAi?SQNE%n@F@04RtvP0gwWOlZEHQL@uVV3fzxgyrZmOD|8%8m zX}OLiv|0Jtk0z3e+3wmSB(V*Cdv&qk5P;>93+wP}^>@0VRB3u=}XPxdOuR=NIs*=01R!%V}; zz~G?%%{dmDPE7F@XXWt7-cqpWH5KV!WZh0=Jx6p0Eb|6ryfX%w_b3f0#pAEIzFq4I zQ_}xf>-v2i-IP_hcKp|6W#m99b}G$D1Y-Iv-QZfgf%yIR2G>jfbs3H6%B3MpSHl~B8whK7U>t*L&MjjPEH+M z!rtQ#^)YmjZ^(PC6OBaZw9%sW;T!TyCZ*K)Taa2Fc+eE>07daSiiEQJ0;TvTF<9BX zyxDbWGxgAll}na7lR8nojl>C@Y87Ru$Sq#+ID#a`=xv!~R_?qJNM9>|aw@)3%Q&~i zb@C%ZS@N;#o9!-~#rWHH*Svjnvtgg>qx~+MQTcVh>v)yRYEt}Fu8QyIQ{{KAkAI~R z!jHeYUOeQA!ot=eSJ@GIv;Bx`*>Sr0@VIOFDKr>m`Jb+D|8iMqI8lNe!O^7hfVbP( zt*%91u_7sB#J7Nl+-JL7+xM_>h>E4<^1vvhcDL)_-JA{ShIZwF@!=2qTo?Dz`&ah6 zHt%N%h*z+Fmj@!TH12o3SV^CLsdW9rZeFNzeOSd3GeOYcd;WlH(*gSO!vWWMcEe`F zjQ(gsjNh+6y8ii*L7R&kI@|Lh6Z2Pf#J>V)eLcC+TBYjHKylQO@?^>Ph;s;hDRP|J|mh@nhF zE-R&xKvPie7>Gz0A$H*dg}RwfZQ)~pNGAtPTQCKDjBjJMS?B!!P=8(Mn?O@qtn&BE zB2NH}Ih4nUGt}bfXERmYYcsVmtRHPtD@NGVHkS2+$rQO8rbxDC&%)2p6Z6z!lSAxX z6)6Jm)N<4Os#L$hf<s^6cQijtX*ne<5U0jkZD6YsL~~%B zfCg@2(Qy1v-*2Wtfh-R%4VsZ$K5=2e}Sg5!)e^u7atW$%b5( zpg|oPp?u_|VDRR?xV;Cl42xcZn>=@K*FI+DJzT5?GlZFu`U|qKry;X$y3B;)@B_l% z4{dx9#{LC2A~oqRf1PXfMG}e)7hNyZ)6I^0*U#*xrrw3|w_)<4?+5fNW#J`jVpIEuo++m{RWQQw<62A!q zb{8dIB6~_Q0$cl=l~-|bxL0}1ChgoD-s6h7ibx5}vIy=Sz^ol0;XVs*W?~%%IEx;R zcQ{PVk9WLPSo1nJ$^c8j;IwgC&K>njhRS3Xq{X8eQd@jaMX?sxQjmTFKfE zwGnDE;*nM+$ujd~{_6d}qj=#8G^02-i`0N2dc-)=0@NhCPbr@4{Rm`y5g=vo!)&n) z>F}K!^+p55bvluLfHcy0d=?rhVo@d~4%!0`ul|B~yq12Sq&?C}qu5Nn8-E&o$}P{HlyHC+!GV$4=i}dbfH(lG8PhTICYz-9 z6Xd%~=B?%~3d-g#WYbfZ&1DiF3T`aKXQ~jNrm$O&B9C%hGXYD2*xEFdmTKGJw)yUp zvggB;i7$pV?LK*hyV7HP7n%tOtPUJM5~A)5W!8k7DRYL18^jk}Q+98kKrM{4EB%-! zSAvncJ>zu$&CR1VG%e4417iNcCAZtn-o_wrpc<}CaL$8sO+`k=K+z}5RZ(bqh(=$B2N73~c zb@z;(lsjb#;*ooJ_l4O#1_IrQ8OK7bS1c5~8w#XdX|_d42RtwBKQF*2L%c*_L5c{l z%(@_q7RO(|Fx5>hDWkBkpwL5c^qF;p&`)6|Uk{p9gvEZe4@1NmrwJU0?Se4i!;}{5 zZ;Zj$EjULRdV%j-HdZ9Z`fpKi78llV)hefDKZ{3cwa!ehx9oR@&|g~c4J|K`@JJbI ztHQP$dLN;<{D?dVtYH-oVWoxz9JWO<_qKfmfjOYEC0uOcE58Y=F%e=lhUbf2jFHa$ z&Zxby2xf>qJCt)>%wA_S{Y^0L$*IR?&)621q(V|>E;4wq#gmi?i6?FGe1|rgVQFTK zGKk5ItYB<2izXY&-KgL&snFFqi}*<79+F1Q$ul2lr7_^Zs($a0;`{ijmYEflZAfVg z_1k6*hqMmW(^js&(QrB~&t#p2sBW^tX)C+|l|B9?-gsCD2$=p_M55N!jf-wajXu%? z*!T<&Hm^oMHH9iT4;uC>2`=LnxE|83Kx6q0Rf`*p2M~hJpVScBfXXys5lqEKC>+^j zvVfl#E&H5S`kNqjQ--!^(9GQQt6^I}RSu{Ut!PCih~TRP(%2wa-mD$n2R5huM9CqL zS1kD+{7YjE`ZcX6DG4#4orkKV4G8r{`vD~`mRx@QN=JxNLc;%EK`H@pkApb1Zzxl@ z0X+lVnMG}!iv({_(h3aR2tB%N z64YWU99Ns>#hG{zU4E0G4)dsneAV9i_NiJ$(8PFhho$YobmE>--S0F}+cI6S>}RzQ zq9nw@Wf*BF-enluYRh}Hz)XVIq@vvNN|^E%E-oSJ=@6;x*;*3yQS_rJ0SkVOj+mrC zP6-}H0aJ8+QaY8dJ3vJFT4>7`SeB#0p&@-XhN9>QsS@1-4uCSwS|84xe*H#uRq?}qA1 z$9y@Tob>3obYsk08%cS6wlQYo>vZ$|>oGO#=ECbSv;RwPR{l5U!rM&28PW-cX%Ng; zp&@wWLOEmgfsWpyLCIaAqT0gmG2^6UIX{~d!Or&9&RO#S8zsxYm#JvqUkYH<`z73I z+bVu?wp6T>0TtaGDhd!g15h*UK~VXCvg@D*Qp4|svWb@UsERIy8F$8~1VK(DOI^BM9 z%CHh(WxqCC!jx^e)V+KTVl_wOEy7XUe+>d8dlJ16y~=-eW_yvvBeD+WJ1RBtf%Sf_nsTX?mL3 z2DOy{IWECS2FlhqCXrDO>%tQz_zHE@2wLbf;hX`SH|f~Q7M{)l-7lG7LQ<(u_5xph z90>1INI%(v^#?h!EtH+Sl%_6ISDTs=F92r%3WwAdS zBZ^IZ1d;dz;QH!F?8aQ3L(l<<*57SOCK8LW*hrcvx5Fc!C}&R{T7s0|KMaYGx}5Fk z{T4^CL&|7Xq@{1r4*HfeS`;armipSjUXGXSN3#0Oz9xA!dyGBvA4cPngC%uv-5m9 zAwc&&GW(?$TK`6^E*s(erLYp*xQAnYY=Rr8`3kyVZpweAbSl-&WI;36{oL+&Ll!K< zxR?ZIs0bn~dOmDm4 z*SiEVgO@YVa0YrhH;8)?_cn9LWTd)eFhE$}}7mD&Wp+T(=OEsFqQ;Zhc=!c#2 z2;>tD2;(J(J=GZEN->&aE22}3q45|Yhq(`o_ctWz2Er$&OfI1@Ed3sb8ko2<3{H(S z3{F@3ac(fH2JK;@pB&2Bh~${6$(K}+KCKww@PNSrofK0mh=NGknZkm&@ z16Z=B^01+#fM$c5k9Tq9#0(LOm*{CzGnQ!E+KFtlas`)YYa3ZxlQVs4Yfpo;pQJ@? z@Dgii1XbVqb90la`U==_eLki6{wGTH!?Ca5XO%o{TrtjcQ3j~L^<*cN-&XrRb;U|n zPHtW{#gxbW0IGV+D|ydQ)o0~+$<@bKIM7?{rH@4<$#P0Vjl6*xIXff~UjOW{41T`6 z@c^@1u}J^e&VYzhCVvQgh{G!9S;FbKD!-{NLJrSYF}GmSk0eH9454c|%Su7qK4Js{ zHL*HEya6R$){*+=63rS|hS%paD~E6~HezB6NsvlQ_CT`%-%rBxDj*M+bAakFUP2CA z0(UdYRr)u~0aX9yP^p0UL_(3iJ+L9IJ9WoFdVWNHmQN8V=`#u2T%a5vP>NQ~T>th0 zUz-V%l6xg3q{RtrKEMVxr=%Akya6b0Fw_D-W$2)$M$xEy5t@e(?JG-KoBEpI<&MB$ zIhc4D-}vka-O->H)b50)6T76x1r+hazl2S(lV;e8bi;u0$6-cHSSTX;tom6>o6(tQ$y4kcSy35)&n`Tb1yPDM_LqTFNfmHa}IRo z5M10Kw-VJgS#ieGQ{tGo93lQXF&VH%nYQ{#wU?vRPE8Cq^IB+fRvZyZu;aN81h7~Dn4%5C!v9gvC$ zinZE6e{@eJu4_*vZAvRw&ra@+&h(x)yKi!i={e9n!1+MW`2Ky8d-Uw(c;3*)=`cCJ zF^V@2IKCEdOyW(pV|U<mSm_`s9rV44%J@y}%}y+nG{|kJoigR)?5UJfqZP zQ`>g#f-axpTDW979FCuDQ!=L^~tX&R&e=v{iI+hbMPRQ@XSxCUhwVyKH|LQ4c)=?;u1`Y4M3kZUq856n}fAwY$aB zAK7=w29T$}(z8{UHw-ww-$7Z*pAQK50r@7ZP_$PU=73keqZMxZEMC%{|FU z!q+Q43~Hnuk1 zv#fXxT51-qJPfvv)iBeDqC)=;#uYsc{-F5g#r>1G43EMNjpqua-Gs~gJ9Yu%`7G`u zpb*cU<15JgXT_(c6ewnL2s8+0&-C zkvjfq4z?n5{)tf9=3Cy!*1H8j*w&Nofu#_i2S?iH`Lg*E4Ze#VD~NuB`L=bcg`bm3 z9k9VQBopdFG2A?Ia#-aP&vm;Nwu1b;8J>KfFT2Q7T;LfOKwm(L5o2{+is6Bg)AF}2 z$RC0G?jD>O>)}N4x!;H>%=Lr7`3uivjAk(_^m@GG(L;HPb9^2gP39Rr@D5Lox2S1Z z$Curmjlr*e{K77bX`{d$hI(|0LI}9Ka=daQjkeTmu9%6(ER#vRU@v`~>B@ruRvq zZWhtu*o=XnpG+gHej)0N&g!?F)QFDF39z=eQD3uU^}sTcm8^n-Nx433rzm=uoh)8Z z2pX#=si$vMPft<}U1?$zn;ic&m0{3`(PPx=4%jb=2oV=UXmqglUs^NAZ1jQbF75Cy z^Db+({BIafl!qSZu2{E*)2p=IQ<8`Sc%xW9Fk4?lG}H6(p;&#U&7KS9VZSFAOlg`W znW*>?^WD=B%qte_n-*)RbsSk{<)wm2Gy1CLyyitz2Y0frDW#!E8_Vb;RBL$!6Gmfh zGieM4BtA^cC>-twv(;sttnY@azeVuSs`0DzHMO#2*(&woJv0s;b$a6cWH2D#Y*D=HRI)ssk33J2y*w0UP>Iy}R&*rtGZVUu=V|Bk!>qt)2vW2;z;?t)SqV~B5-AVfkF4y`&po$qBGqMrXt>(Aj>Thtb(q`<7K#-%F`jri$D_PZq@>|;Tg)nMhYbTr#X zfZ7&-gjc_|I7HueOhdt=Qk3>nS=u?B)xn+BsSC7RZZj3;Wn7%g2$ZGe z)iOYTCZMS~oH_O(?RinKwRqCnSux4Kg&Fq2Z$`U*BgnrvyZO8jT8BI#j<>m$t+3;C7}%e)eBIbq({4@U zfNazWSo_xBE8ZmSnN5z{`K+^2NU!W_amQZLk$mSWzOpzd-I$uO_Kr~7mr|;-_OsZi zMl1895a*r(a17wiAuo)yuYT@=-oX7a(r2nJh|gNfm3~ie-Wkfu`IHYLAEEWu%M{OQ^1ZN;TaWqyoElvpyU-i zLW2i&@r{{JVkT&gUyDH#hB-qnCr?K=NUl>J>@3w}+to7?@h1u}Y|6`Hq%?670GS8i z&Cqgg z)C}DK0C#1bUqlaJ|Cn<4S>({Wl+f4MZ|i>@%EA3${s%e_4nfNshaSmOjP(aBPvk3^ zEiq&a&clHL=o`3JF;|;X!@!XROPt0rH%jTyQ0N)&&1Hj2*d2VR3+&RF=A)uy`(T8k zqS5HHyJ8<3br#@KVJ|_4eTJf#m3`whxKESW$bBm1lu?;}I$C*k0IYlL8E;SHu2zXX z)7S=zZHwxz$vJ(hwnkmoisDQWjLG6YEx)^KC*W(y+Qo^Dr(@5+*~9FvO{uknxlcK* z?wYnC5$=;ICqtv$)j)b;LiNcL_Vk)?cg+M~bW-3c!WR}(krQEXpHf_B8e3DIwx{CU zwfDv;9r&}YcG{`<^#cgKL_Rw_p}o5rKqq6*+^D!uOg!O67={RhVTkNoeKIMfI;y3+ z#u@28IiaTdq=)C%X4SknBYX`zA~-JX5<2j?dI;Gmw!Cf=Hrn(bPn_MxO zeLy06SNAC-uW>ru)j1%$y8Dibk@BOn2VuZxU~u(x*Wm7?Gsb;9x)R_9YYblEf$b10N?apwY zT9~NdBc;3@alHqz@+1ug+gmUyKu^m%P*_3pFlVdnG8d|NDi9UsuMz8z4xpH=x|>Xxevsic~Wtont19V zUaPLg*Nv&CI%dkWgxo2ZJMP3v;Ib>ZH&-HMS(cXw^<87StONi}uT(`z4f z*E+9DubttpwVf(FRcm-`H&50>lkD;I+9!Fkr)08{T`A|UpGBmczc71UM9R7A=hDNu z3-c?YoITyAY<20Up6Sro#aJFAm|wmJtAaPm19S}oza>4ge6 zxNUORvNr&~=>>O9YVA!g*=oRdh7f$Ob>7TnXHA8hFuqS1k+|<#cdea&sn8|Ag}+=+ z4dpz;a_eizqcP3IKfF!_YD*0@o$&N~!(BVC|685i)d|M5>H%*jR$oNiYNU;AtTwq% zrdAJp*LJc)V;$n#@wYYXZN~fb_F~{|Eqi<02lUo&iam2mAq;UQ_lcAfXf`M3-M+cA z`?w2u(vA<>!f+i+IX3v?wBv(6jXhJUq#Y0YJm=(z;}^elpPW>E@~aMw_1D5OEV~(&y$s9#4vm+tg=J_Jqs32HV1h@vK+CX$!19B@@)N`I3&V1# zLt_K5yn_Pt9Pe!|s zB{m+lom_Xl9r(r*4)lUY-mvDcSB@Bzlp~GzDt5yFecXMb+~z(W?miK{$$bo1yC*gxS#{(6O1$B}t=+#V<9|aAZo?Zf z?nB7okfA)>eK@@337pY;_(S}=KE!rxlkND2OulQBl$yo|lq7?@cHx6i&L@=|DoZ`e z+_D*ONKqg{`7R#e)zop)J*E4FrxRa+{Qpq)CGb%c+5bH= zJ(FV+$T>3!hv5bVL;|d2MFRpWE|-c2x@razARGxMfZ}=pA|Me=LJ|Z7IRb(TUYs5X ziYUk}m#iR)pr~AdTngm>{Z?1aOi$we_t$)y^mNyI_3G8DS5>cGy&6qsR@OAN(Aj4# zYA5e;9a5rL+q_nm)EUb}E%Hgop{$aY0aenvPPpxa`$YifoWv>|P$fV5reNc$@WFbeOj0clferKL#0w-p)>!xyv` zQG|Q7+Xw_EtY?;|wBanwshZm@wNs|blp9Pbdssw`3v6CQ8vwScL$uzI<5LldKZemp7I=zI zNYuat?G@k^V-O#m*up19DO&Q+HBVyqN@*YSZ}c5C18v&)pKFROkF99yNA{Ff;zx$6 zB(R_0S8EaMs#(LzfQFf<%}2_-r=6H-sHXW^0PG?ZX05HXxt}%v*02;MitvoK6uD}{ zsCY|}?kb8YFpF-)rmbK)(QT~c(Ci|X9pt2#5EB0E5WD_0<~|GLcYao2{{@4sO2zJ zDlON-K?2L}`>^c;TR)PXh`ESm_*9>7is7TuA#AbQ8p3p%RZpFSb5oGc8kJ@&+fTB# zq~l*y3~xAFz^_GaCuym70KQP%#LFdqiv{pI5EFC@Jli`YEY=(z;A|NYw?&IU8sY5@ zc%4og_)8c)E{SPxARUWA!(v8VW*U(m-xZul3z%IIHyj=Ma@D>k5J=1L{rPFc7IZ`t&L29?6)kaU zui>_gk(BSG3IrarSsz^DLQW19 zMoADMY6pLVOFb8*j#Z@=Mov+R-bgA-G3GByft_w5eW&8aBHXzpw4{;#tW2EW#1>JI zhPI|*)h>fX@R?Vvb|9j&O`A|1^_Rx*At=pk+{zd(7fMaWaH3RYA#xhS=bl?f+P6JvjtComW z1hh^eiY%KEF_+)?YW$yEj#A=Eg9<;PG2_*1K|!gsu*Kg%7Eia4y44CQi}b?wFn zLp(06i`JlZPzymmI2|xEiI7rm5^VBNx&!f;sqqvnV>1<+MPR$&k_z64%LAfs#jT`h zt3j!GeII zWT;pYX#@aM#4Z4_?@3}qBBQ|h=!175l`_j3ZeX@Hupd>`w19Z*^H_xozO@Zc{z4o@ z#G1LH=rV`1y3{KU1VAcrc22||54}AtJfTvT zdmoJx078j-31Jx9&scXhX*2tWnxJb z6XQ#WIG3!Uua5Oq`IhDd!|63hP6*DRBjI18(@I5MkwcUk)e`4}L-D?r_#V{t7qT^u zWsArsGNVPD3v3bofR)|3O%dzqSYE(7uyx3yRIUT7J+L|Bv$9|v*Ytv$#!;-h_=NQCSF%A#9zH2_Pog4^!*WXSy3d3#=%Cw=$06j_nhIj`~=X=#Vxd# zzKLfD2}vem04@fg$4p95a3}&hVmlfe$Lj$o#0dGHb;ma!(NQ3G4BTP+BM{Yn<1)tL zw|6%(^G;+LihZ$TUM`D2QpT;pTF4}Wkah*wBB6Q{_AFe+TLNNwOSe2(3c(naJ?QoC zTc=2fbHs1I^7y+XOi#C8YzF7i5aIsVVfJR@(a5ta7}e80=g4`cgYoQkc&Lg}m@l)dizds=QYs?>;i`fW2EPCl@nb z<;yq@KZ}`d%8kxQQek8(To-!dnD4vq8_-|#K7}k(r-3(ZvHwIw@?y)K`jYFXnJyUm zR_D1s&f`{Z%`w;#KUTBjd>zjm-`>`BFS&l4>7pxv3L*Jo0fJ9545A`>6^OoD60JgU zBCsX4jmlUwtY}0&FbCFvjv4ll=Rd;jW&F78VcA2+=PGG_5acd>2_)Y-$9FE&npv*h zvq?zaE3Rb)BzR4MYjdFsQChw%bS<7EieO!dV$R8=Ga0W>3S7HH(jx_~|A>d53S1u- ziln68XcbFTO$1888WifEvQWMdYTVGH%E3a3y6_jPgo<i zvUi}YP%7c>G3`G~?xxIo#V(?I?-XR+C3bP-&|zU$M4t`MuX zbD^tv5h+}}$o1Llf>gxHoTM#AC(y9S7v1XR*IXaJ=3=NDOR9#?Mj;L<-m=F~0`nmX z(oYs7XqVs&Q1M!UY$J5}Dtq?iSqf+0ClSwxJ)Ut=;3TkrE70_pXv~Vs-~d~Ms3GGg zISwc9ff+GxA0Exx8!{dq=l6}9I6C7#xJqXY_uf%x*Pg>|bOfqD`Ki?PN2!YrST22iA6bHFz-Y@6a zwfrJd-S{W zYlR;<8DpjD>ODH+sa~Tq#=r+Ew@+5@@uNpSn3+CqgitfNns->ST^otpprsug&%`iO z@#ag=agU@!`pI*TRwW=Bmnf*0Vr0xx)wO;Fs033FDR!o{0mQ?8sBl092KU_os6-Q# z?BX*3bJJY#kzt5@8_*7~b}d|Ew7pbFtSrH5MyzKiNp+y;*$K=IBxZA0-vwy@n6C=* zLpXX9V^{_rLgaPJiwq76Jj+#$iUT22%E@DCZ;$RMq@LMGV*t&fIGj3=W=jbQ+r$z?thc$sV%-abNc?zm92#Qgg2AQBl*znuQL1S3_VqiV^cKn7kvSCboB6MUDQewkA z{tvWbOcS#Uo7h_dzA>75h-oV;`Nb;Z)xN7!dj_}OHAL`>%{Gl6pu$gb-@CYAD}qf6 zjZ=!C;@3VTxZhNQL6oFHNGeOPFt7x^2n+CtOtlJ(7M0^`Kkny{UIa5CMF@B&+q{&?{`@16vmH4Tf_k_ znI6Ck6iBl^S*@>V6`^8dSr8aae%;F!VhdrSuqUgXC2{=l4Zx->4@=mFiAls?$DHVi zavx>cdl_ZV_m$lf5*X3GsH@@1j!ig#g!3IWK7z{Gb15@ph zE%rt1b?V(JE9ymB_B!o+V1$AwpK;#b+&TK^)x4Widmp#n!q8v-=1!64yoVRf6z_qt zX}6~ekvHZyMw34b1`RfeuIQlkO&0HIuyyw9=%P7I@r~dMH@m*x%r5%SX4h%)aAC9S zkOIh&gi$Obz4+a(P(h5-?EKdxd)EBZs5R1&30r4(f|fU55;e5??X!v07Dw z`w#FvBJl-w{(6|j`xB6bFP0K97dpU9%5i}H%T!@JUKe2AQg8+Ner1nBK{uWN z+@ry8y}TO$aeaxBzi##Nl?@0`(KurqP&b(554qvU#ie$w7j8ppH-!NzaMXn3JG3Md z)GkVGZ@)gdXHFV2kVBMPX}@Jh!Xe7K7+78_LPHMOX*^0=EIJ$A@UFiUR>z)-eqFHZ z)4chh@XqLWsdnlb$=qxj$&^OpbUTDIV-S|=3I`NRD7`PJ=&2{ZrNS6l6~=ee;;=`F z0BBAIK+_UB$lz#^a;OwiA37=&VL&)u3fnt9JhqK7WQsE-fXyi3X6xSRPLKSYptg+q zTL`(s>&>1{?MyGHw8dKD1`Op?4127!$0rEiQ-6$#q>z)tR9J0c;p=NG2c==TY7PJ> z5rz;NP3H&H(qm?c;Bd)5`->ycd%k1o*c_!*BIm7{7D$IU`xe1#CuE2n4bb>_=S^8= z*ZzT92uCj&X;4Z2kI3|KbEe#=x(ewNN|iv}69%Y2fjR}KCMJQB!|>*S`C~a+pJ@tw zVu$PNouWmDrGg@H8KT-w4aE)Rj4vq0Pr%+(V)xmGcwTnI3cEIZ4Y0Q^7GX9Z6xy;~ zu8LhQ@Z!`V*O%Y9aICauU4i$OPQ}8qz|6`HyJj6>{wt2S)`^FcM_i|l^3C<5u4~5x zY2m4|`MjvZ{GsUKH1ucClO}njX0x86#`?lgZ!V}w-C$6}c^)a+a>n)1FEqTY`^~le zoWLD=lHUR>cME@Z<^3W)$w>c&GEY@6=aHvZ=IPUL$a7Puw=eShbt5&L-x9dxlI!3l zfzPKgjWQ^FWxzK?;!{&;pqpj!RshxNkASXWaRv%2u5A^rS1ScN7D%Ej3L^0eP!2Vt zG=?`}vEB_p_{hgney~SL@ROLhx>W(d^dLY4^-hTPJ`Rvw3XHl|ji?kTn!c7%8+5hR z`yId@`9$Ve2*V0%P?i1L^Z?{EurL& z-lt2*V%iypbQ;0!+FB-TS|V-^p0Q!CZx6kn6Q;0%L)XvVk_-VuFpb=M$7f+Xbx1+D zfBViOh~H(2${&IR;v(*XBE3mBVYfEs@yMmis~LZ=7t9@zJ$`ih-PuEc%KO-6yS5g$ z(V!)lD0`~7S3#Klh=Ev-mq+u`UN>;4b;a*L+VLel8_4k2`xOvHeyWfang^oSfXJZ` zHSr??W&QX4Sdaay*cNFJrg>WdQBEMTK&q|-S%^Z`u1H^(gs>xe^uMEvQh~>Yf4rt^ zh|0%90CA|eo>FDCIjayr$d02;EePchlIO7CZ%9~Ps1<+1oE#iM$%jYcTvHJt&sl#j z;yFa`X8cKO>|VabYL2u1o@8rC{H_rQN@;cP;af!CaMs_A2oMQhGb)F*!R`zkl+~!K zHR6Wg5z<)y4DZ0do!Z9donrrD**E!*Ky_;)C&(7!U#@5yax$|CKCw)5EDk+Yv*^+t zK)3>=;yneF%}b387>tAJ?@#clnNqHLWRXWtz}=!KV4SM@9ai|r3GGGf3~wbE|Iijy zlQOEZ5{Vih9d2p?1K9!wk`7}^(XS{CKjaX=w`gQfiotqVlWve~{n{MeQX~v(YHg?) zLtj}DZ3AmUI@fy~_!W8}x@)y998VDkV!BrA^~_^=Fq8T4Iy1?sO`BX-XDSMnJ=Wiu za{S3Q!pkB2C6eIdQM(i6KFSfMa>|~mYAZx@8?`1zpS~58H8b2hXSmr+?SqUSDIo@Z zUEmo&7GP{Ht3zteTgkd407=%34`f{gl?TPbp473WWf&ghIG!Vz2QB}$Y0E>KY4~dk zwz?3A*B>*S+Sr#c3jZW{iW7xEVanEUXcAWQF@!LBDkEU34YamUqT^oyQ>!YRuiuST zm9b+-PaKquwtEN+dGkv!r6-t@eXGb_)6Tu*{&=Pv8tX^Co>Z)K!8(0C67pbG31B7ka?2^Bl_ZWiwtKv=$^sQ5eB zrOVwvEEj?jzE}v#To4wxMiL2Zqa`*eCZdlC_xCYd1I5HQX=i7WxZ#y|0FTZDX4s+Q zav*CoPy4@^aNIw%~YG4MvYO7TEMOE0^i@(*Cq?oWt07 zA3tE-+Tz$dtfD*=ns5y@p*4KZu<|PrP=RZx0&Vqn54&>75tEN)jO zP`NPr#u_Hjl@Z;v1TKOn?j2rHUe$2#=*o)f#v4F~U`Fk6@|qQp-<7!g7{(L-C>9z{ z3%MVoSYvICjhdra`IF0!q-?I3m$FP2fxRdYF|iYFK^;OJ3@RbnJF<3qoM$nWr7mXh|`dI5q>D0kg*>VQp+2{@j0W-=y5^@i-;8 zeNsQXVi1E2#IHsy0dJQ0icr$tB%`S$We>x%foXgWcCu+%9=_NdboAoN9yzT^Cf7N*g_cTHLt`HCgTuDY)Ll@)|Zx(Jt{r zk4p2g*=S^d2Q|@PShk5_#u)KXsP__>9DYbLx+LgKh#0_)HNgoVoG#4Q=&u?Tr{PC! zpR~d=hBud3PUr&s163aC^v%FkKpylkkri&T7cUNz8Tm#Qh98`!~FsqmTVzC--sLnV6#E+AWXQa`146RW|6njSPqVYv9x61J#7P3Q5 z)(ZY@oN5;@8SY^YisAY!*)ZggZa8S$fZIHzyZ)|w-FtydCm+i0c<;OiJjuxzlRY7$ zHY=dhjEtFx^^%B;$D8XVju9KSA-``FPee!c$iN~oLu359f!M^1b>;#idM95KS3}^M zpbBBk?}+Mqpb7m}vX`jpJ$1G}hcFDpDluVB=rctSRU@E!vNozFKyzClsuMe|?_~Bo zaziysprYg{su}~;Q?*gu12p4&sNi~1w&n7TaR#bde3K~onbh3?loM;Cd>QDD`%t1b z=1=TUNqzJewZTG@QYInVB%poTgjTGJJ%rD)iJT2=BEImq`u)XJjtD@|yDal9n&Psu z(;3z>=VqZL(b@W#14W5AMg2brZ9vzOEaQMTXsx^9AU|Nzj(yL#xH;4?l6PpTQ#myM(e z`15ZQe>!l2!p=eRC#)n5KV)C&o1oCKsN?f9c2VPf5KIdxGJe5X8wlE-5Et-1wX<1YuCaDmkbU9}&DkjjVvNebRuO zwn>@elE!!^azy4$!i*bd1DPS)>pv9fPdr4A<)k04S)z9(fgaV};mEKBI5Nz#qAdqx z`<+!eRoI)URxA;wo#PD*8rYj=du*;vR*Oy|ThplEeh(ksv5> zh-d$>s>(!KL;k8uZI3Fyx&hUGPjIy-!TL?Z886YDMx|@D-lL3b$!{xfgb5q*OD64WLIwTaEQcA@%5Bal5mcG&3DPHaN|c-)cp3pNVr z3xlU7Y%w8idt zcTs@Rs-QOGOGG~vT$IUm6h%3ekJ1qo2ssEs{S!hCe0e<#&Oe8{msD`FAf~MlOsj@m zYG~XN#q!ExS(+D^0*;gb-!9fDb`voEX(5)V5Yr?&%)-8b(#1=7jyI^Ofz~kE<@-j>L1#pN7I4{&<-BtfXG#-v1?1=SLWWY@AVKqPFwt_4fouZ9jM za@9+c&dbm-!hwUwB?ix<{Jr5XsM5F(VGbpdp#G4(i4rM2&JY*20yRQ!1;U?Kgd1Zm z!(rQV+^#)|Tj0}whzMF(Z4J1VCd-+aZ+7$-^pn7X`X}~?b-1LBI2u41MX`%l&K$+` zrm7PA6tu{wR&_KEU>BGEky9IjTMrBWFXiRjkLx%vq$WLW0X3yI)Wd*y(FgUYg5ngCd9?%73$>x<0Ah=R68^ciXBsi5@wpj2 zay^Y&`;deZ}y#9&8@= zC>ZsvF~TUoPL#CY0;uUGC^-}D0+@SF1;7*)u&6Pz?W>zgX%(#6mc2YSb&d2kvlcf8ge3J!}o!{FAR>|3amFOj_H%<8a=a=#n97mlE7_PMQBgpwR5NY#7AMIp?lE$HYbF-QS<*L)Cfr z4;T1w^@4lyB|f}%$-UzByUx{-~M{-&DJ&|G`h2{&W{z<(m($x<93>S6b$!(?aB z`?*Kl?;ok-{iP%ByrXrz-+t76ysr1(9&=wjrqVZ`>pQyq(tq4DzvKHo-?@Jg4?>1b zw5>Sq{^+=X4K=-=f5N@;L>=#cKH;A7y~-<~jPIRte{rgg^s|0)zw?tyA3)n{XWSdk z@cqd%?mxtX7B*1why58a)J#DRV^6qtwK0P!nyXnus{4N$o>L@iml0b`2B-&TnFBs;)KH z-M?L@tU@UUO6OPC-Dj^$>V3H${$S2a%yn$-T&E(}b~0Dx6=tj@J?rp3hfLSw7Kr8) zC>xVf!_xtqXX-43Ui%CXpNBg%%gb}0%|@h3(eW2O@6PsMgWA5?o(r#dP{^0^J>L{Cc+xKgo>vN)W@(}4 z#2h|U&hhLm5}%4Z9~bih#t###KAYsppG+)4tonYEXZB>Gz!k{CV=s8hUl8xX+SYS% zSb=fn&-9ee=ZS0pZ&09`+LRK{g;(V#L4h6}9+W9g z*VS&8nfg58C~W(X-$(V4XVTnZaYT&k#C*@O*NE@Eg`N*yH;U#f*|elzhO%U1YL{#= zGU*T`TtY;)BZI|J$OL*o5&hL-&w?caw_Mg?dpWWBgWHLGf`OdV9o1fz0r@Qwd0@Bt z7Vs7Wk0pKXxV`|Tx#FXxp0Ae@_mQQZqGc4e*Oz%NFQc?vU*>szIUhDH_mr*j*lgOY zH$88xro3!f?K!rZpDwKS6ujqg0+X|*DzGvZtngfagO#y(rRU-*LA+=jf#o{1!t?zb z%o6Q3@co{*Jf*7zNcbeSZ1RB>Ja3KX1!RV7G06{jzj}@5#dkbTCNbf;fb{Rktc}Vp zcA~NaS+yLwca*G}r3B2_lx`158oGj2*Z-FHA7#@gQn~b?6vsNCd08qB-_BP$$nHY6 z`3;eE^L$^wH+O^QWF;-FxP7g>}~Ti zIWXr{{-LM%BhtR;BhUJei2aL?Jb53B(vVz(qvPwzak9$e6XelJ=HY8T%p(E#8+1n= z<1P8o_gMZRv<_BNKk@wh39(Pw?793Ig=^;Lo|4b`X4U7O_r$~Y&pms@!_S|4E{lhk zws{J+G0mIXJjcYt#ciI2U+~QbUwFRT&WEb)o)^C&xy!%uys?9Cw(jsO-^qs^J3WPa z`S8YG&kx@+)2eShe;)VPtlI1oo{QfT>cx|uML+Y?`#*bToaLK0&U((DCDg26J>ULD zL9F=Av*R44{QGmBdF52hZQR|;}Q1-1+boKh^=%FaI#@+p({ z8iEOfxz%rljCPhX8u65B_7u{V5YVVQA*7&K<+^K1!b{Txn**>Po_za@#NNli4qo}x zZyB(6k=UjB72^iKOOmkcSHG&<$XJZ_nYm*7D>tlrTY-XpxJ47|RTw8#&jfr?}hG-L;Qu{gUP2yXx14K8g`TldpHzMNP#0{o&y`hXm(oB`Or+N ziaT=irZ5$Z#K^p%iqksfzWzrblpt>WE5Pxn9p% zwIm)k`sl8@C90%8Y~BuO^KMiT8?w)-Pfo3j*@t88D`RltsvZ`LgX&vyy(~O_LM8nA z2Q%sj*0-E)gmT6b*DY3LVoN|&Gro;zurH=@{8iL4?O_BJI013yRIBtG9ZHM*VHd1b?ftM(1B z-ye24?u*+O8$A&Y*8jH97LKa@?xhF~PNgdh?;@Yq z2714fqf)?nUSi`LmfGx5N!q)Uj14D?wa~ChH2F`$xvU-<)hI&7_GiTH5!R$~$nb2F z3`-+Sc~6Jdzn7GKNFC+^G{aC~(F#=oxL3?@+^I1X5C;_$Mej}T_;nOLI3$QT@DdGQ z5ltn~7$ixhVRPhthRRLXr37s^K+yrDp zaGPC5Hou(k!^;UQlJe8JWgZCRz=Uh>#8?fCg%YDwBEgI7lVuwZ86VAaG|-sYkVy5+ z&$*Du zIJjXbi{CC?mA@T;m$%gWq}h`eV`nPt>h`3`Tj-Q9Vd9LqSb!Nx1=nyaac(Y|hV%BK zk5Wsrc6f1h&T!O&4&Vuo7W$FF(WvxY?D7(>=?;9ig^KNxcY(#&GsXls`n(6z+atKl zU9YRv5#_4sY}p?f#SN-Bwm2lNnZ>m~HWa!hn!CWm5>hKYa)G@;S8I5qWNY{hK<#XD zAT|Q-wqj*5vKjUt)N5hvKWJqH_iB@Dt$!0N@fB32&u%`?s0(rIXJ?sAgjS@j9LIm^ZPPS_Lv&%KFMKgp`Q(b9 zuhzrSSPnz1ucFqAOtmhXy>^#Fn~GaVSKwBALR|w?u^EcziOfR!_xeZ})+Ki6t2RWi z>i{b;fqhI7!}fF~Vuu1n%(n|iZxW+NcYI5o$9H1i_}KAj4^x(N5sarF z+;qLcSOZjlszDSla=_TtILvNF2_hbTAIXis)E7Hs7aK zhNV`AHmI%=Vo5YW;s_Vpp^3zB1HsXyA@v}Fd#8s*wZRsa@aUBC@YrOlGd`u<=^jyK zttd}Ownj971X~-i{}A|KQ(>bJVRgTN`jihcbcan@e;cfQyG-9 zgLBektB0Ki->U&nEQ-#GtU*Q2HC3dPnkjcXv;(*eDxmo)VxM0KBL^JY&8=8!SAHTw zYNS`q2-%DL3RI2$snDT*o{QXjob@Bzx6JkPfOqux44|cAU=pIW0PQ>z+J8~tM&Ps5 zY4P*Z@Ix-~`5eb63MoIn^%{-bT%j}PBqTxO-lfR-)K;4ZU3s0_YN$!O8>zA>FG^D- zqc*TZ+ltcyT*Bc;gqFYtRxH(tA%Hb>9~X-Ej)wGLRn8U>)EW3S!pM>ct@m8i=egke z^uU#seGM-aPcBg3dq56(W5vt)Cf*3Y(-eS7-gFM+jjun`Tg(@Gf=06Ws3mWftkm5M z2lC>{*a%dAe^>0kb5;cpY6A7zIF#VFSE<+L2T5fd+}$pBJIkV?X~xU4p>&#mgR-rrG;CLMP!_jr5CkW>o7_`nkT9FV00c>hzcKhA8#*-5!K!`GXqKTqTcD~JIc2Clz< zP*-{!Wab*F?#xWWFQrhW$0S|4E&HZht!<3%(-x%I7;%MM<&}!EFJk$t1NKVsqgX<- zi!>;IUx=lDuasB^b)ejTlhZ=Oge}EqQa^|G32wo0ePNXB#gJUUh2Y^<6P$6lyaTyP zhAjzXSQRgAt~_yDM3rcu7kLH9igU4(XGQu8-R5$2VqQ zq4okq_u&{&_sK%%H+u9S>`c-4-Sz&Wz0t<^zT#N#+!2{$`@xSE@AUY5>A4WFCR)|s zq2&ya?CYhkp060s%-IscP?Xt6_ydh%wF841j*?3)55Vk9nGtT^#v- zD_$!Rp)*%yGOR#64;o`Kt99804)Zv>~&T4#pz1Bu}|qrsOeKUKK0W!I>e_4 zj{X3EeFHPZi>L!GI3>d`G6qxA(73&^VY`#7!(F>ZRM@Uu_8706comUoylQB?io{6I zcBQJZ@vENkD+$gKL|(rs{)=i3hl|RZyCEMUqn7exbZdURac^FXW)&aWG8q?LHpb#h zTzl@@>R{lF-yLn_+7WF*2xh*R_K8*s_88MXxoJUdUhqW}#e49bt-{zAt>d`_O+OSh zu}C$2{fqgs8PM?ZK5Fo9I0@NMJE)(}a%YO39EWvde~7S+h_k$fLj&htR02dA4y3Ou zq=p9;5#9x4YXT8I{Mkt?9+3Sb(X9$elNkQdoCxpoQaJdLE4|H#YCk7=v#Z)$nP2c_@a!wy-@I2Rl2LM>5b) z{XMacUHtv^h;rNIvS{N~$gb(3v2DKQ`;;#q(%NtCM zx~avUh~2abVe4ab+ivAo+BYb#aF!?AVmj=Jjomdpu49|8={2<@`C@$X&grhsZN4Is zlneE`2&yi)Z%yd(<;e3XDHlAqIjd4GB;4+-YGAv9Gu0AtrdorP3k_3={>$X^(QQ*M zME7u3q+E#TNjkSDpK~_(GPcnd!_S}ly?4rmMt6;X`)K9eDP@iOa$9;?|KOq0wtyW1 z!ZYiL@>R88-Ys(pZAJcjb&X|9WO z|7;n7cM%=7;KtvmEn+gHl(bR}5ojVyOwBIZ%CYl4RJ-iux-Lj#jz-AqciHR);itcs zQ-hx_AUpjn^m41D-*x-~a{**8=gQsJlY*%ZU!2ep*dW`_B~H1YvOU@h|NRje>HZ+(x~Hn9GDp1TF;bB(@&f7!}0tCZb< z7<~pF_WIn)2(1vea_a77pfovkQv)gKB4S1WVdRL2qs&0ljDT2yuDZE{9NHAzLQ2$r zawa8ceSk(vP_i`V?DadyQmAccISgyI&ZqK)f(2t@u0Qet86y?!ePWMRPR4}H3^;1G z<^YvkWhD!R>P2k~99D7v;L`+>bsVUi5!es97{irl&(6EM9Hu-Orme9ODQsx^cv01j zC&hilk*@lpuM)@$J0`{x`IFwvaf3!=WQqOW#=uHT`;2O~+%f~-)izX)cdl@}gF}|0 ztpo(l0u~cT5k7X!BLZA4@ekVf7kS| z=r%i@)hU<4W2h_RV7YSbO4cJh_#Bzo`EtY3MANIroi8ULv&g1P+9ccRHQyCme0(RcRn*Su(XHF;;QOzVFGRLUxfp}v7~NJVz}R+Q@#%}?-{WrH9vlDpv|AF- zHqd{|IQP5War^KK=g)OYx#;R5kljjnWaUmNeJ0uFxeWv*+|Hfoslu#=pNTzok+z*Y z%@G8^^Shp_C-h3uzzV7^?XH%qqvhc z(4hQ=oe`ZY?t!9@yw51n{l@zwqmaoLn>=W|A58YH2Nyf*kCa9w+nPSQE4JBA(yc#E zul4{2H}|&LNiugNSH%qJd@()cQpB)iTZ<9MrR7NeH#+4~t1L2qtbwOBdM(?f967zy zdo8e}g`Au)4gvsC5TiN=tF7W6D3rzlm8}G*gzyrZ1^CfR5eD-#r z$((I5ChXt{Hh1Wu31WV5OPJyK&6ga^MIp0gGBasK_wZQnhk-x(LFQ59^RigKI^oJ{ z?l9G~NkS9o*X9@Ji^T_E5$Iy@P-;de=Wtzt>_Oay3IP~xFjNz4=y3pBu8Qm*p$|ai` zivuqDYxv3_^O9NdGqbt@S-mN&5_lbIv5@6b!cseD6+xmhr6v<;R2A4(Z(U_K2A$+FbVOt1m1T{ zMG%a>8z_JAp~b-L&2imt=FZ(~ z#%JT$ZxkCQ0M*#q0qr^yT2V>Ef${^~fnxmH{)G4T8)7Ug2_kpq>LwTENiwxoelj~H za_y1bdYN6I&e(#yT4bu?-!ctg>{XQZ?f|e2CMrc;bOOWz1x1mWz5hu&4P80VmJAu7 zMvf94Ke1|W0lJN~(Y*mw=X~g(2CnbAi~7_E8X$4W0`WCbb;QG_+Ndle9op@(w$w)Z15ozOQq)31&opRu5lOY&iCIGjjHTy8t|n3OHQ9}r&f3=6 zs2%~Dk9?@8Zr?8&V6+`!GgR0VI@NX%9$NdXHoC8XDmy!XvK3QXxY&G2S)X(mzhMlM zl&MyYV946%wNX6}G}nEoK-uj#+uo-IRJHs&iY)~!5O3~_Swx{OMk3-GFUGD3R@ zxBkRJAzOZvQWU&JICA90*##%?Y;xQm%nG{$<@mx>4mt4dHrAm{#%;(d7&GkC9!J;> zO2!!DHS{^ye@ld_hfD>+?Pi3W7|aE#PU93hG^#bPJ@r1@i)h0FS+CKV!+nNKO`=sz zsyonrSsQJ4pzJ+fp@oc2c;tcMta5q@7#5xE9EnOvLJy$&sy3pQ(l^bQP^={~ z>P|rIFhPlcVUOXntnk%!Ryb@%!g|y%DJvCel{r9o)xjKK#EYPfRmbuLUtq_1=gW>= z4fHbZ91s0_70=v~)gVt=^hZLn{uZI-;MOyPOmQM44@=C8iwdDp9cooR*P?cs%G8Ob zL8=>BrY{1^c*e zlJf}CtbJ{wat5i~jHHsva7Cpll+`VYe#%s-Tu>rac0-;0Bd2IRo#hS5ur zZf`P&w!U)ij&Gj&>NiG zW#Xi4?Bgdmw6nO4#tybjTRCq%r3c11-z-P^qpN20440x@dZK~sTbleIntGazmwM@#{R{QUW? zoHjr~)fzR!&x1(StYQF=9x@>fZn~QSx#U+=Fa4hs)s~A9+E2La9)qb4t}Zzn2m%kA z2$ZFsjS_$0D>bZ82lDSZN#k33X08`DilCC;$>|XHcygMiY;^Yk`4JOxIRV-X#E}y* z0pdYhzFjBBE+yoZC2*4ndRH7}2551WUrKnXOc+fm9s{D2W<<1m=K;kx3JqO8jFV9n z^B)J)54E9A03!04fO@o!I>WH&$h@~$&dA7t4~ap5YSw8$^d5vt`30lJ?|=%lE>3uF<`28;UV)d_ij z2vJuXd(mY~IGFt!`vkcmtWVaU5h%7;*HGE1E`ulHotD|jc7WqMdwH89rvm2IaE?!7 zZulc1|4*SYtq>mnajf6|kudwuK#fTo+x$O|wq;}U(aoZGHQ)0)#U#OK>loIn234`n46z77vRXB32Uy_QGn_{6W+cW zT!4G8KC^~%a-5c7tgCd-%4Sq+$wy6|si>yynIPkrpaKX^-VP$>k`Qo=ZJXErs|h97 z48y!^r4W#;_KBg?<-QDMPBJ5YVtGd+qqB9?*ka^yC@7x~t|c72W|9sx!yoVZa5vi= zw&#f)B!1Nlvw;6sGk#GK-vjqG+&;~Cetyy&Y=sIBHKW9(8s}Kx`mJ`|#6R!Qw&D&H zt~akIY^gEoW>TPVoxGl~xhA-7e$Du410@H`X*gq~M@IK_^g)BN`x@>xIV6MQA|+g0 z68*idy7?YNte9jbShz0Rm^VIi?pZ^tu}``VFn?{^XxFV;e;96<#4gpCj#(}dK0R#yQjglDEtVC zJ`mB_7K<%Cq4C0l-;Ki*5`6Z!xd=ez-<-1%TsZ@-=;P&7Gd~UFX_n>%!xIIah7DHO zVX-quxb}f`dSV(SRTI1CP|{0E`1D5?d-U;(rB5%n)6{@NOY)l813D@VZBp!c- zoS2cHSenm=_wy5vi-+k2iSrBiW@SO*Iq{%{rwVHHC+f?AoZ{4UJp5he`hsTUdyy(- zCbYU#Dc=UNs+20FKM1h&H8wnS7vxY~B*jK*R~tu)P-{CJ*rp!xgJURT@iKbr6!|w; zIRxx2ScXFG!!1ZH&`&QWizqCVF|uejhz&g=@`J8LFkW#A#ASfAoGHQPl*~1OyaJFg z38Jq`!j?+71#+%Lg85f3?*{+tZr$d<+j0(lRqrY=9SO#ve~-40{Yr)*=H!4Oh&VX` z9aT?#_2i!X*uKY>&HR{^k&&KzzgP{_dU6yyY~&O5#QcwLt>ZCMlOKENFHYz|PnRJd zKEIpF*;qonGkeU~(bzr9t!3yM@Lpr0DXDklh+Yl7Bcf7gXYqUA%rTkckce{`%dG`N z;_#PDVu6_T?7zR$h*_uO0DJDEWCl;~Ht+>)>SbuN<84(Lr(5iP@av(=6D$N|D<_y)|3-wknPu88D zutZim+p-$v=YzT7vIYwcSWX$618RT|ve6QG0J$1t768gAp^61m@XAd0C262cc9gyo zvAC}wY>9C$7FOlJiHb*S9IOD$yMq~_WhLQ*(iFb_v9vihd>!CVZvS%dg*)v1GsIkJ5PyHM-4&_5>V^hsvP5c-(~HxP4K-oF=D)Z!;S@-XqBM!>C<;;b z2wC>If!zKP{95v|;&zKAQiUs?%>i7bgfmWq+eS^$$*&1A0(s`&!3#fS43_U6JV>;v zY}rJxN7$lg%!VG&k2j?>w5&N&pVHvX${Zs^85?^kt$&P*Z%WrRaR3Q62Voz1mXK_~ zbbM|z&yv^1WTWxnaEBb0*VqkpcjehaAzT^b4B5ge4P$3CSyKBLWNzWLawE8Ypma12 zA$9D>A*2a5L{qKC=}8H?anNWuQ$)}qbP+Z@U_^i&=Qw&aLEpnui|Yk_2vHxRf8HMu(a?D$(?aOF+GifJX3q3`l(q@VxN4@F@Py77nHbZN!%uv< zKS29w`TFD~`K-Lh9+=xmCScoF8W0KkApvk7*!Kk;01QPTRiJ=eG~>nkgd8drpZuof z3y}>r@T>|DJr!piElga9vWa6y)Ogxw#bMjv)d`%ui`*;-;HDKHWVljeNyo6B7lYLL zl3xXWLP)3V4L1c4;tz?fTb58{p$v>G+E~B(t42NyzV7GS#@1{jmfD zMwuFEusL;q-2|?lEC}@T?7yzCy$RwDkig0R3xVXIlDN4bFj^95(mqwQU}u`Gw9h=H zeaKpl1YZSQjHzI8^btq`M2ZgzGG%xcP$Ls+9-v|+l%eMZRBu2$1#_3jG>&8zWAkS_+j)~Xa+<11NvE9?%;^MVhY5Nmw zdm|C>20Pr#t*!LwIM8YTbi2LHzC4H3no=3!$P2aMZ&+wvxQ@Th@Vp2+{zgXR)pOu) z{d&&Il&Ywx>CrI&i3!20*x0cyjEG_{otI9Pe8h zJEykrSWnL+JQ?siK&dS~3- za1X}q#l0N&I^4T)pT>O-cRB8BxWkru^ysAla{+TqD{;(Tk(ctr-jiop$deL9CoA?f z<%(0Qy<1;_^Lsv~5T<3Fqpv5(s7 z?2r_AOPoPf6QnCvKa%jHME&3*2V8C$99{T~cF#&j za4aJhkT(UzxTipAk-`mRhbDgc;qK( zuF8}I<*Oeghf2oBBZ{c#I7{sP#OT)-WWf9yfJ=~7*wV4gM<{Y?+;&J+>gU_IJ-)h5YRC`SMy#55!N}1FRK+_*n|`@ zr6A@H6ER}qukzrS6s#~Zj1w8kADoql=xN3Qqm*@obMw`Ww+Zt76t`hGKrZ51yCQM( z8$za)NfJYo_IrNdLI%vpK5$LWBNUm-@%>LprZV~$gK0`|eIjL?BI9G5@sn(W&>KG} zQiT+$3Gp_u={_^JUnasHWep#Q&^GsChKK~-V<5d#5y|(5dOr6?;s+}OiPz88#nLxG z>s2$Yud@624tV9@r97bfuqAOSPyXqrN9kwp(9e$2t4HbAM(KT8KgT+zX5od?jYiTn ztu&JV@5i{o>a0TOH=QpmI$l^Dd|?gc3u`D|Si||k7Qq*`2)wW%1{}`!i{cAC3NQ2+ zzOct7J+=a`>~VNycNqaif(FINQ(UEOBDJS(iUenHr0RkFV_0*LyM7ttyl}zw8XDbi zZ)q5EGJ|S`mpybK4joAH{pFx4aMZU7xUQLmQ7-E4C`OCIZIFbFuiw);mMjy&M!F9j znms;ioQ!wK*X+pO1hVU9WW^ZBoCKNyC8|wK{HOGsvP-D9099jx3hw$_EK5ULbJwqi zn>g?DuZEi2+D2+8aO>?x%dTJAWdnlstFHfT^7IgM(WEU%3@&L}kOI_sSsH%GS+mb< z28j`aOGOUnzP?Vj_Vnfo$Z6g#QY$eNWE%UDFKXzIC4PxlY%sFVI zIJ^re-2^3O)m<=ZlRV8_*2H!jB1euP53P$o&5TWTCAlL`r>mF99M-l9*0M$O#PM= zyT^KSnB9|O#nJ4Y7^*-{rEi|kqf*(Nd~W#ER8Qai+(4==yziNjn>joyBgg-}R)ES* zw?t~U;|>T=8NKo@fGZ10gPICT26p#btURY!M`Roae%V49Js^A+=h4?O^TxKx>Prz~ zv%hg-$sX>yM?!ndgmP@j!!}Jv+@9DF9Qba#T;(F{9>UfD7EslfJ^M;;Fw%tXLKZmQ z$rk$c@UlyliAF?%h9&j)%qkDti-VUc8kRRI_giD~O}6_zH%DrzD3RUs{zGAguokAF zKpKYrCxYzQA_HgU_Q{fji+DPcf6A)43FsngquUBp6+Uzr50}M$H;dz8q6?}Lg_ay) z5>ojg(AG1d6$(7Sd~s=68q(HM;HP7R0*5j&u7m;BjZoo6jrc4o>g(0ck(#Ru`jlHz zj8=hxZyG-aOeaIo>`Br`AgR8IqD>v`2s=rI*#!tC-ddK1{Q7&qja(lYLru%7`9-2E=%m;Jv z>`S1B#rGgdGsh*Da9o(4jnlpc=41~=9Lt^sbI^T&FPvjgMYG5petdYeDu(X{4H)=% z&jAni=R3!pUkcA#ETFVY$DU;(EjhN+!<>5z7&K@=zsK(%NO-(I^W&pu_&1{dkIFQ7n0KtEV<)GejLs)Bz?29$KE?WD+{a;rHj(JE|Xv&}nvG-~v%SZ}N20DsBM{r8gY#C8Fq%Df=!p-6%SX+^Z z##6+;wWG&9i#5fqWJS6cr5OB35k)EdWZY|U_#pQ`30YF|A`&cZzkM8gKQUhrpZ)U0 zh)wB3p6JelH?-`mJEb7e3W16k+2@~Ajmh=U%!~;czOUfm!Xka)LfGehYp3eeQjR$@ zgvkdp$@qm1ZQ~-T5%Q(VVrRjNeixshrG6+|D#~l1E5YQ}IE=wS#+Xw;wi$>rUYE!O zW9AxrAr!Jtf$SrROnk2!9XSYeqkyWomh z(*^kpI}Yl_`zUZuQ+P{)uzn7#pGd6I>T8%{3^Zgm>_5g2HveMOvbPx6x-a=JT-*k% znon)3Jt}{hcjN_{G!zRAn+9^oO7fF3m-+Td;xr)N_=vyl=xKHiA0p$u(1hN zpzJ$Jy(@t6D}{Bg>}eF%?ZCQ4Vhym$2U-j>+WTeDdk~23TdFE(cWE8s^CeJjl_-s+ zlDK>jYS2ZKna}pe234Z(FZHGa<6MQcNSdb)Q7Rw3ebHC^HZrB|TegZmts ztv&wP_*F+zsE@}7U)%2G9foo|1}aP)7i@T|)Upt(SK`Al~#rWiAhbItr*SC6ufu4s|{N#CAW_>p@W8 z0_rOXWfYD;hXC-K4`__aid-du#{jfL0?8IjsOx~}utHTXm~CDY`VXLXnzAyMVY&lk zf)A`XP^N{1BE#kfM(cU3+Q)O#{H|KA?LPkmBM=0PU4Pl8Y?W+kp7o2X!vEiTnVleG*D) z3_|Sz#3>&XMA@)0D?$7bQ2Qm66hwphWq?_>N);?4kok(vQ-D1nVPylLr^k9gedB}l zmcl~IUQA8Qegf1t63P%P0(}R7rfS5lKe1c_v7NEXP6Ozm1d=Qv)XjkC?SmSxvQk>( z44@84sJS}M(ms?Vay&^Z>sY@*$Fd>~`N%nz&rJgUTVgu%fEe^~IPvhqk=pu4F`W_f z7w;rYPI#+{NVG963b~|n(9(Qv`aiT(;>834y^4bU!I8EFKzif~qK|-|y7_ZmYt^(ZHE2 z=_k8+9R=+bKKfJZB$OzXg;)`K5rig4LiN=~wMz?5-fA4Rv_?vHuQ|oyFi+;i0$u`K zqJ*Qe?^4|GXAZ0$=RoLj)Q`~f=->mE?#2gj(tA5F9}C1DID#t!_68Dr^tQWzSH%jL ztyvpZMYXar;DgiNbak#j%`tR6r?5eUOvaaza z4+{`@=WtbF3>hNcb*>0qhV@&l_X5_T8R@X{t0S^oSom(lX3Gn=T6c~>tjkLgfUPG| z#X9#ei@pfa*|{QSneJBL@m9E0X z$ZNJ1Ay@;RVQD+6l|8DJL#%X%h-L23Jg~4;Se|aPwhGU)>(*AzJcr%7KdMzkRIAA8 zAzH*L|!GcU!3zj3|u{_e)#n7i_B^Wd-R?!0aZ`0MGL zcY7lK*6*KpM+5v#9hld>A^!HbH}B3y_}g<(Ua!XZ+xvmMf82n-O&-d-D+z!5Je+rT z6a4+>zffkLi_PfFeIMJ)sLJJ4m(yAy9JG2DW4s&EDpJ1dmkxKW-Ff|+3ZL&QmxoOs zFrv*~k~1(9;S?+G8I@p9skrz5vGykLO;uU^_)GG#v{{-o-O@CrtYsIhAnk~jr3eZL z3MwknKns+ewjeO#RAmt>NP!j|Wd@{xAO&#*ii$fbds{_EM-*{IMFF8r9hLw0+~wsZ z#rggI|Ia`D-1OzW_dRz%_uO;OJ$Jg#lGAwGOnakXEfB&C>#e6ePtQinX^Q}hfes}} zuPcrtI9lPsgNkFQB_;pr2ulL8C}7qE(#jzGpPV=&0E2hX9{C?{>ttiV|ET5v-~Vwg zM(tbnkyp@1+@g=9s3)p(Q`9f$>nwdWSHt9BQ;O(L{iDg0(UhS&3!d{Xks zaaHb1&_wLD!K|GYWeNft^>EJf<}m-~eEcFxE=}_BmPW+n$$d@4fdK00N}Uc%S{YYh z8KxroRhsRu7&g~OdF-jp*SEV*r96!BtkL8#OPaxYB843Dm5z_+6wR=MAs;ztblPfH9;v4 zH6gNe5t+_dj?yBkYM;KUG`Rz1Q-F5_+ojWuv8HSg%)jMwVSK(*$w5%JZWh|+g`6xC zFQfo)8wg7A0zTJSX@ro#Rw99`$e5yq^I$cvzfh!zeFxV(Z&7CL5~ecRIezb+O8xnC zstxN)Jkcy2IDCC`CDZ510%=Bk86rMdNcNpa3(!)hPR?GNG4iq@#kdsPLhF~B46std zA!<2IW+PcAS=6Og3vSuSTq?#|9!us@_85BPurGBw@yJD%Q_@n3Y?)YE*5JIjQGf#*;K9x4lsa7aMj(WnnPe1hIHUPr&Fl{(Fd-s=qA?9bw#NQTG$w6x z=tp0re)>%+4k1QcGPJ8?at?|}Ir~-Wfv;)X+~eP*ZvBSspEKm*zE;}L?A_jn6f4+< zqZKo@6%4~UPB3QtqoZ^_5oVwzG$eDpf}G~BP>*FkfL z#)(d4^559HE_QU#ECcfuEWhky%P&}j!3xZ7OA*aNXt#$9a$QCLpVnTk#D+zA^?wz< z4PHZeMQr-1`91aG@2Mm;izA>b)t*~qSEq?5Ev2NOwX_ypkMyeDTLrE3jC}ZTYjb4n z5fTe2leBb8Z0bhhy~Tf9eJ}m!$4ut>X#jfGIN{}3QVfR4jGR+Ar%-_~+4`51b{FUTk5KGl7&7~i;N4=mq&G?y}pTW~i`yFHl7am0j&I*cUfEy^cwmSB^mlLRwiIQ${Kap7S{DksWGm?9Whco zsBetzs4$oLz9qVn6P)^JCqde1BjZ zS(J;u#}`0n_0y)2#>tolBgiw`R-;Ac<8^AerwXVO(#Jg15WAj^X+%etObw=%tm&y} zuWdwo)oqDEiwe$q(W2BK@IeL}wm??1n==E~RvThQ^1@`@M;*N-coMMtcSkdv-_N8r zeV=Ma#AN6hcEbGk?^Abt&pMXa5l`9R`+=!4sfSn)UAxF+u1#0RYzh7yvAn-WB(h4| zDJyX?z_k}RovvLSyCwJyQ0?~$WQ90?N8)0E>mYDkq`(eaHMk|14a7MFLmE#%jjEsh zl=|JzjFHB&`_w$>{(pZ;{p{yda+}QaOZVyX{?DnO{><_#DwdAEGoanb*zJftQ^YQW zpq1%r;g+DW)}kaLuqs&{m1f%1(lN4(fGXM&>;%M#eFC*cZ0415xq<2=P@1}1oxUab zBM_-C3ly}m~DE<>tVL(p+qmUO%Ej}GTZc!FPYh< zhx|Tfn;r`InaMfJTNSi`r>4{9c4D?VD|2aWj#?p$a^hul#RKF7TtP68klsuvmn126 zs0+8Gs81qn*aD$V-G!@t2ybkmY1;{0okaK=;p`SjdClylm}fEh!p|^6u0kYIW%z79 zehBFxY%02Vg*de$r}te`sOpPK;E$mIM`IM?NGWKz((mefgvM&V*a?|)j7_bdJtqUV z!VFsJaQU)=a}ez+T^Vr2OiS5mX!IK?aR76)z;q>fqunHE%ub1>?Jy76yxHAzumRzHU*12&`Rz@562oF=>6$4{|Ay zQmQIx0vP<>mX?g3)Z z0f{;gD^e&?=|Ei{ff8ceNMOdiM_dCtmKlGb{`%#k{&!dU*%+=Erd7-z%TuX5U+!-x z_oEC?mHV66#iGajPd`R?wms(mm|cALnE&DBbf;8(A_tE~PIU^9{$CI{`eT={3zx{QK;}l| zo$W>b1BfpUN>ncgQ2O|~0oAW1>H-kShXg85#3Z?9cVK)G?cjM5o!lr=(Nim)&8MQ| z=2HVnbRzNAFi=`gQE#Mh(;661S3!=4;LcVY#&^VBDW0pHyezL3TBC1ygvzBmbvg}e zdu(;WhWUvxe0hkSFqsRAB3U*1WND{wlJ(T3JK>Mw3!Az)dkRgEiM!FqXR2j8X6Xyc zYHXQR>m0qBEX>7%EkZq@Uy^tX*?I>7>0ud=_6t;iLvQO|)E$#kbsbL(>&VnH=)*mr z@>wzGuY6IW2TJ_A`WM-e3C`#;)d{8sQ&4qJ$m(MS0%Jd_cKXmFKu-|7K@eom zi6@S^8wvsvuDef|(vgJgiR5*ta{6H`ej>2E<{@KpQZHk> z8nNYy*sK)}&l;*_vO}fM3dNMx3;~%I2B73#YJe7kd}8E;Oa`Wi2$@axP^QU88@ep! zdM|dlnjjyWtbA8jOqOc1<57&0_R7ZL#1wO^hqir93Yi`H8`c`)MOeAX?BglFm}DdPBdm`oZy@j)-RM{oe ztr*1)Ae?xXGrZ`H-e2q6p*FMN-2;bBf;#UWE73L5{(*LM$wJfIt(NgLqowd?vsR%M z>3<9|#&J<2tJU+YMyNrthUS4=2c);V5MWv!OvL7(GZtEYBEe=Lv&kwfmi~D#!N62= z|0phv{zg5&8U-S{Sj^UZN`!PAvU zdOqI9w&Q25XDqPdxibbO0mfkUxWfZlUhpL}KRX6_(F7B>%E>r^sloR`hW{d(AWea< z|7~Vxnga9Vl(^klVR23lKlBSJ*7S{?K=yNuv~W%&$@T`>>tsL5Sg&q<5OpQ7)Rh_@ zozt0gU_~Xo9AUR6Y}?RHuRjXsWC%RfAWfV{lI{c2eFbT?*H)VPUzqXc0-E|4GV3^v zAV#$jg+HCiW~-0F=c4wIGCTg2PyLC&f$eDb2jOrt?i(G-ic>xCl+<$ciRzHpP@`bU z4j#TURm@b?`h;eaQmfiS9q^xQ-0v`A-OgNx9!F1(VdzOCYKVeJ|Ekol2Jg#NzB}`|+e^RpFh}?K2`ekatjYMg`s0kR5Wx z<2J=S8Zl>w;u6Hq+u2WdlK44_{q&^JteKT?CF|T|_emKgUQ2t_DHv@TtmL_D3w;$+ zDodT@HK>WJL}x+km(@!X<7(7iZ*(?Be+^n|}Yyu?Wo_*nm{qk-hW@OOaIC(SOPEi0ws(D=F_-(vF3bHbg0az|zS4Y6e%ik9Ovw*@}0A&xCKN(euxq@`nn=xSo!55(Qloe(f~3hG&L?ZxyN$dg%zXM8W!o7dAGi&V< z%$`ThoQiXL2u%awIqK><|4S$J{VA9FQySi-xpr~icORkMX(Fu(9b)O4)cgpERC284 z+qSy#w1kITg>tiF@0e^#D1UbrKVU}pjyYp|ZzDyts@H#dlRO=qHEY}qh^c0DW^)Fl ze`Bv0BDCtSXB(37JSSrsD+&y}8KpBbAkR|KmMB&j<{a1xxk6=!N^_S2atI`Glq^${ zE`Mcgn9{6ljK}C@Z1BRJfVFN~bEpYN|Iu$ly)TyiR{3vZz0b~mW69q{z1?KPzETW* zUl19`MmzOfsDRC`>g&a&#a*41Os`twF~3j~>%6wyrUdT8O|T4$yTKcSg9+a^!fi`o zb4c|i8ykGq?B-a1G7X^i0KOcp@a1d`6*9xNZJ{d$FCex>pDJ+Ry3Ju##7d19ko4Q0 zzl7y~8XPkaz!P3K+R7BBJElT!p=s!gu5hjB3OXY@8X_0Gk6or8h;CGgMImB|j0oEN z^}zKJxJs&zgIm?3Th;ol>WQuQQ=g#GjXpxHW@dw>g;~E?ne~f}S--?E>z7!vejzQJ z8MZGNM{T4Vi!qeP!pbCMH~Fksvo!l`(4S!nlM`~qkZvu`?u&to2dB;n1B!!*3ergmnm;5NZ&1Z{@QCp`!QztS0a& zDKJSz0V?dXxYqwvEz=wbg}7>PiqV+{e>=Sd2AhZX``2@b(4GyXK6?#riQ&2RwtRZd zC3DTY6!rVl1Am)CoO*h29$&~Q0fYhZjp6CUuD=+o)PKNsOLmIG8#qcGrks9a0u%8 zcs4xADKqhsqWRsaha*iD1#OgE*(8)4ykEK>7`;x64O;-&yFRa!;8i&huw%mc)(MmQ zMwC>#tRMXlwg_ea76OZ2?N_Sy+g8ciDpC9p3z&m}Y!!hNHFpRo%V$ElR7m0jeO`On z|NF~+i;}A-`ShF9?KXTRU!bRq5!E4}njxr)noFp{;MfWT=OS>}=u!cr{rd#F8L-w7 ziD9Vwfmp4fPPTzT0AF9HITzuE0@o%I$4BsWK<(3z^C|mWs-%`d$YDUXjX<*OOC1E2 z5-KWKS{j@%8P~x+pTlnWlq?l$NA&sZHUFj8Q7V`L(vZQkNBsQFZ|kSfZAk!?TE*-Z zC94>Y_}fJm)U(vYe+5W1@#Wj{@k2E6u!0yo9@>rN%hcvF^=uhhnCGz!yr$`Xna0-~ zt?^ZS_e#H<&;*mR*8pX&3CiBPq_S7ucaR@7#do*3?}BF&Lj%tCG}fBgJS7&i>+GT8 zP?Nz;+GPuAkl}+Z{(mv);y0Yif;YoVI#OS(?$&&(5D$n}5mUEff?WbG=p$9cW@762 zP3?jhh-6zMP`d3SYL`t7WbINMsNJxt_?9nVTaUn-Cl;OM6a+7VZ;u4I4w2-@O#Xc! zzS2;YZh?|q>{g%#2red6#f179i2rJ+Gx1TV+khGvffD`Fa@wL?_oZlo+G5ehxBbt( z<0luvSfbM{J)U^m|K))QP8*230;e5?*z!bd(iVjs4|pSDdgg1ycFmfpnJ5MNoPO7T z^gU|rXW#R$I7k=&Jm`OyU3_)W|KMTP5e%=3QcQFTYbIG9cOb4oA};A&m&H|sc)q8& zkbd?u;(GJ2|5Hv-^eT0oN4TDp^zH$@8wEYdYk2R!1Y#e3Bdaq=3DN8D?*(x1m5TT@ zFkYAsN3QQR9rafnV|kNF@!3UD>Zy(c)gh6|Ng)fbbP)WW5v|m6cl4P5yW45bayLbiyPp`uvnU+FAUx0Ih9o*(`OE)Wgw#Qdj@qOiEv*#H66ziNv(mCuT4uCIeAZWH^K!9PxH{R$JnTK62G=pzF?LVI#Iiu#?P1vNJ-`_%vlbL^vD`HL!Ew4Pj zo+KKAkc*xnGq|}2k$YxqR(B%D-^bKp7C`t-;=%QWm+zuMU>e+4lLw@JrAQ@o=8IRT z!@9tcqUQ-D4r4zb%9GVvn#qFUd5uRWLlJb*SYJICd=rah>f9!`vbo4-t4lW3n#sn& zavXxM4Ti?H*rSsgFI{vrOl@j*RS&W^SEnYMKqtlxAbTS=p2#&{OlYXi%xbnLRkwx} zg#$#KDflv^9{0K!iL|lDvrTd7_QnYHJWYkAta0!AP^+HMPlW@#DwxGu1~Nk*ng%l+ z5&ai_6o`TpDCCrw&T-3@vp||G3GVa6_t@|8Lv+`8^@M-@hx&GmHYIfPRK_IBO$Nan zJwc(=?FwRJ5g5xwI|PiHzl2Qz>@Rv)3YoG^0^n_yitr&RPk-cp<)er+G+WfbbCKkx zg4}f)xoG2cHo1La!C!A9X(w;`_(JmG&YBa+j+nMy{YF-28he6ddQ=$s2D4PE#N41# zo&OvY!PZmPIEU9o*LYChHMD*zdLs;QzTi66Xc4zU4+|e7gyh_t`t2_$T4s_Im0E>n zi&w8}_%)e7=Y~O%DOQT`Of+y@K=n8QLpV%C*>wTCHnep37;bVu)?x9tUT#v!MQP^) z3rQMwd~#N1w1pd&9F_}F3;m_q8htUoF*`((*7(B7!MQ~bJ z6mQT=u&AABM3*y=9TKxaGQtK)tu?_0NiD}hOvBV>laaDT_N0(>%(NzAu{8K%_(~U_ zpvK~+4YE#5ozKcGl3cn6n54$m`7HbaBpcRD4PD9gczEXdBFZ75AuQCaU73%hD%gKL zky;CwBkyaX&r#7(pOc#eaqR{}M4|K*O;fjXlqQ>LXRxOWfkj?{VwUnR%9dd#0(-r{ zR@?_-EKYj3La|AWEZ=MKXH!kCsdZ(lOB75r&4y0(FvkyBjOA7`&9JHEF=Uz%3kOuZ z3|1L3tf!dwdgA6}2#YizThw{E0$0w7dG=^oKU2z1>cZz>*N(6cp*6zD=b*+Ni;F^B z=;tr*qnBTj>_Ht8BL-Z`pdA0FgYwN{gcMjBZ_iuYE$R;fk@0M^zXbCGgC`yTe3OQn4aZ|leK4!E=D6Q{EN7jSvlf*!C~_gk!QuwfhyIX-5q&A+oD zohzX+u-CA$9lGZjtJPqI2D(^3$Y1GNu2akZ(L#X!_m#BNg0EL!vMA3Xurk4LpkC5i zt>oXym~nWF*$r6tMpQsM=nN($BG>de@`Jzm2a;qT`q5wWqY!CvpGQz*SsAIu z{2Pep>WQNC4z;L1BE-Ww9%K;lDFTRx0lQkrp=tdG#gi8d29$B`7t9nO*3W&gB{HDl7sL0 znaWptnRyu>fzybXlMco6d>=|0xGsH?&9$VPhY$o6zmYsUPl9?Lo}T-I>#DeE7RzI} z-5k5I>msY8eZ8ZOIPhOEm>l=oj(KB_mP5oiVs9+Qxew01SlYISaHxZ)KG{-h$AY*e z8K$C5j(B`I;nLZ4JlVn*&5|5=1$X08?hB=EPS(BVulKrHN&zrL9;+n-ySa0Ek0 zwyhW|RzCG@YcW6rB0zkSQUu644Q8;4$|fEvJIWG32Sz}N!EFKPc(aV}ghg;230ewJ zo&-TyINk1t&uKJ*kBb@PB4t)#ap`<=at{+<*7yYbdj_m8a2~xc1HF&weW-B0{g3~H zFZ^~i1RAKR6h;yB=W+!Di>f0gAKH5K9QmD`fc^j@Zf2<+4X7lsa8T_N8C105Mg2ST8Kq+D za09K-iWkTarT!&~8D1P9vHkSRBd^fpjf~7A>PeWQvzNLrNbgTCp=bXIB`UwZ2I5^E z(PD-8xk=BvrqK{{HHe5I1S|_~WiXI6%SLE6SO~4@Mso+5d$bIHyIR3}dIlfHB1_*&Fgg#R|nV_4=1l`e)Y^}B6%8Dyn ztrb@`Sk&Mw8n}vw1Zb~~ty^TbwLgxjmdO!AJ4Nk%8!tJX2Kn0+$9`XZ%x?VzlD z6z2sHqNAxPu^~C8)(xUDNQW;WyV;XW7vAjVcwaJEy?g!mN}v^t#8wSHHz=g5 zlce_YNoM#-awmGyrNQT6m~P=GDOb^xo((=1dy=KeqC!N_)^1nzC$hqZiv8DsLQvj72DOy?PxFRy6v8Sryw=t+L=Bp6mO)s8f9?o&b0Gwz)XyF zu@#dzwqoLDD<&ScViM0*OuXe*i!n1n6Kt`7;>xtRGOeymn+x{Irp#EcEfb4Z|25W^ z$5@SZQ$tM(ZDFO~u{QSGhz-Yf6^kwoY~c+#&E+m^;SI%EeGV+H#Q3~0Qnve?IiYx` zFCi!7jq`bOLJ1!IqRXY{uwnAlR4+0|yij%b@RbRl*OXyyflT8BwR94nx$Q$(!bb;& zKwp9)?0A9@uvS$Ix8n>Mb^dk;%^S9-s0R_6Av_zlL%dX-_?3vz6JZF#NQ5!lBc$qE zeuwW~1U43`c~XrSYE?ENu=q&& zX&6?YN77H>beye;|AGwNs)APjQIP2*bITz=vZ}2{UUl&a!AprW|BC zw!5;10x8o1(Rk<(Up9{FQHb!mxm0?}1N^}AannM5N>@^YZMwnSwC@s&hb^Bf{B znllk<1yJ2uqAmh4-6G2i9P^#3J?x}L9MD<}23TI3zoy^P4q@CgNILLKxNp1m1 zt&`-`OCFJQS!pYQ8WB-x%h=fQdU)*UR+Enu3%U0@8arm;r{PEa^n}>;BBx8azo#qG z3Wg6Un1evec)~&!C;Q~&1qw*aUrw^g3uZ2ut?+ruY>PG9VjW_+?@BWi{XP9`Dh90L@$U2^BNXlSt&@I9VufL_1sD0@#QM7@7N@ z0N`r31f7g_wzw6bku5;i0pRmU(8tj+JqOUOdXOl|wt#d<5GAQ?eg14?+NtU^Y9wan zX^`jqcbRkjRAM^_-=-%la^3?(-H9?iH5T{`(!+KDHcAh}=A*n|Dgf>zO3lhb3^eTX z@N;ReJjW`5OZz-6G1e%8J3(-?o?rsaOHx7X9|#;|hz9Kf==K(%X8}k`k)YYpNq+&L zJ6eD;02r=;vI(T`X#WD}&K96M0obpBhRE{O&$nI#aEt_oNK0IbV#z_E0%BU?-iIcS zCN1$G_zr+IT@jWuaGnxk$Kdw&K0kG&h42A``wbtSH&n5%C!x3Txx@_wpR2viHOo~b zG{5@ze{R6Ul3Yc?)A@wL0zs1owJJfRB zs8(%%@g27AAvc85!U$2KhacY8@ghCcc8lsCUij_-c2_QJY#ag z)ydjJB<$V~26aws@o-29OCpP#UixVJ+w@W-dHqW$i$f*zz9eyp@23?dE41*euD7ZA-izGEMdR9Q3wr(B`97ZgTT6QeR?^9+UNDKp{kcN(<$#pI;4gr6PG ziu%>uQ?rN)cR@dGT6A3OrT#wmo5^?y8+>VCj(!J4jvRf{z2CTayacPRY4a&5{lkjx zDpJ~X_|Mk%q_n{qaTBJ7X|VFuoy!br$lb)dkF=&joD9dI;de*PoH?zuh}SYy>Vq;a zF;C+YaWY+rR!?~F>goPpGF|($ImO~WPh`Wz|16+H(n1=0(0{(R&zUtG;~lS#poTM- zH{ik{GvI^@zuCiv=N-4|ABIUI&f7oVM#pndjneT8Y&SG3m>mV9-=;VtYLYc&kX0AP zt0!yJFKX1UYnTl9Ad^bAhozDsJMsY*QpseJN_ya@P{obu0{tNzfmxMYdI_>M&fs*p zlovb@PY!ZVB^c7Vy)KR{Bps!;+_0$>W)-wdxay(buA|~&&5PW$;+lHVqkrr11oZ{X z!TEVwBXH(0aUb;m;stvKlP;n_xNza-_Z|t!oxC7yDx*{IB>&O{Z$SEGiM?6fZ z^E&X*B_1Y;ht3p`b)_N!Zsph{#GXcp&Di9nf2}t;=pShX)5ng@G`4kT)RlW+ny)y& zGaZ|Tx7#48F-mPbB{fFLGI`s<;?QI|=1n-76!I!Z{HDf2s4zR|o+RQ)g7&1N?n%;7 z%D2RH4uqmCzw}E&OVH9@L`wtjX0^N$O)VeQ!6)He=>mbN8Re=_LN5QEg8%MZHXWgN zQ)Qa9F&&@%24L(@tO3hEi&H<$#Vo~;Qc##ois2rSmB3fZ!#g%ExX@OKNm*e_n0 zuAZ+6_5mhW;#O8f?uD)d>K+*@Z^=MistID_ijpr;706>Gj(jqY6*#fO3%KT*;5=X! zN!;pHk?MlAK;0`)V#_{Izt;pe0l?C zkt>vxKUb45)krK;jo6uL#KBY}PNo{cA)qiOjbo}2ce%}K%=DDU*o>L+<*_lwOmDe8 z7Ali+huxT&SnhNfGn2|)PGe?rd7R6bnNseKGiLg@LIul&*xeyCDsfDsvebiBLnW#C zatYdMZ9McL#$*-x5Gd_(LW!30B)BsRCELhIH6_-E=RQYyD*Ty+{I2pe_%jOy+~w); zXBKJ|U!DPfW}(&z1d}yd6;aAS^^!jIbP`5@8*}CWIP<-3Wba;7JT&7{X|Tu?U4V zq$*li169#t`dW^Am2|NI7hCCKH!k)g96&f)!}UZX*-$$INfXNB1NxzM9u2iLxEMwo z^csMhaO(-o{#T4(L#$?4B#sN`K%ur08IR`YKb*UIrq1kt>l)Z zr^PzQV(nzHLLmZmLA}KqwBT?t>sX6*jKx}LvG%f9`&v9}^jd-FYq^$5_vJPHkA6=+ zm;dEE|6eoVOyWW zp#1<9v;aK{K)nW5hqXwW+VO>F_%3BcL5GN!T7pmzb9)&kT7z?gOtG=@O>JRJgPdJE75 z0G@9zL50zv!vM|DgI;0FLy#~;56|A2kM1jkY0YqtwYzz%)AQHknZdRupbio5Rkb#C zUCVZyL7Fya^!ykn9ijUU4j+Al#a8UXK53hqL0J6JhYWW}4i$^YzJyx2jNIzp&1sH$ z95Q6NFJ#;7X={$bdlq{=ttLBZJ;#dQwmA0NQ;o$PtQ&i!L5^GmVR7JVB|L`THPof` zzois;a=mc^7})p=JMsJhp))u9vv6%jQ>X~|WOBKoT+BAWVKDA@D48Cjh( zYECh^ zQmd;I%EuO$(`3V{UW^wW023!+`%`kVH`RppNfu#tAHE!ZEbi4h>)N^kFvg5)bsWZ= zrqT?qiw!00Sg%Nn z1MbI)cY3@H)zER2^h|yK{ghf_LAd`e)3-#;88&=BsLpw?uw_SUsYUbD>GNnSs>g0! z<}_#Anr5W6-VL{!GfrPJcwW~RIXhV0(JMqABH(NsEi{DnQ|t~yE40kTd~CDJZmN#; zwW*&LYBt%t*t8`d#Q56RPYpH4dSP)V?%liD<;BXV{I${MORb+0a?mm@y0sNsq-|vA zVY=k5Zk0?uJtn^1=c>i5(qv0O>D!aI9Y_k2KwLs3!GR=jQZ3K<4ma~gRL5f^l=O|R zk_@ZvobQY>KJ#KTG4d44d4j$g8c+?hWHmUf=D2)n%?9_){6D(DwsZ65Q!5{pcju^n zx90VuZjsY}S1EOiA;U+E9!2kGjPRtr**3k5)L3kx9LKJYn+3Cganoi73t)%PuZ!Wz zmJ6K+4g7#Q&!FNtB~Uq$){!l-OUs3|q@5Vw@7^}_60{TS%pA7Nj>IZ z{Th47;Czde!q9(AUi%O&&ogaQ_!T?^deuZ_H>qsI>GK0`88&PVP9tT?&$UcLS@)lb zq@H5v=v3l9pDXoZ0%i)@wqT_7`sQ0k0_JsinS?>efM~FAqylrc6U^kTMwnaC8j;xw z?TB?*EM@!EH}AQVvR#0qDkn@1r<`%_uc*Jw4fmI?^$~WY2nouq9ax=a+?|0@+wNg-KN~(z+bo}<|ys9JWTJ}5BdBDJ?|A>{Kf2qNqOjE zT-9BF_O9m;c{mVnd)eEGRbBt=?c_tgRPnBlz3aC(jS19MZd1}}B|M5vB3JD5^ffMJ z;>?o`BlRNIFN=DC{QF>eH%wk-q71yejy)YK3%T|~(jD-fZ=0WViRSQ?> zEAy5#tI~kbqB5!P)9|(rbn|3o`h+fy8WseBL}tvAn4Adv6$8dJYps!NRZwf>P?4-x zghk5|jAu4x(qdZzIl<0sTI`QBB)geSiYR10Ux=0{0S9 z@s*f{ucUMu6O&my87u=SZIBCJyXszK=vQxGMmeb+s?+69fczaBylHj5G)}T}Rcv_x zqxY2Nu91VN&hcY$mP^^59oC<%UYSoN$4pqd2YPoyE46$MptH{*OQr~ zI6pOKCdX%{ER8q9JjM&p^`Qh)c_KX5hmy>`)=>0VeQlxWiSf0AqQ~wF@J#HZVVD2$y~*KUE%ztyMiuqY^d(1k!rwZ=?+A&{ z!$}Cji5*aNoZLYMGG9Ygau(qd!tV%Xyym1=5du5ujrO?ewv#;i^}?xg2ddVqMrd_s8zc}H+^y1B235xw5u2}sj%1%Sk>F~QH!L%x4npcG z{@>^#{)hhI+Rj$xdIZ+uY3-xm^K$+pr@MRXrvbXZ1?YJI zEInjQZ}8-W&6U3dXrTmQ4Q+v9PQxwX{elGC!eR{cm<`fhGWDSD&z9APpIn3u!Vr`P zk(0JzGqHd>vlzdnbjwxr`6SBC!fhct?$UQa&GQ)VW31u6y%tUbnCQ1MpuQpAUe(%k z&1$w)vQjJ=?(U#@&QM2Z;vjF;oJ(@$j-T4xK}no2xoBDeOW930t*@}a^K1$wf(axT z)nTHFv5svuf?GXINog!rtJ9Kcd{$|%wb_O*OKgMB!JawT6Ao}Sc&+TFyLvj5b$Tr9!IN=l+o{<-)C+3U$q~>Zy&OH5f7XBYc67hcFCbG{RVf!sls-oQx7rB#7b;%+YnQita6bW9(q{|2y6KGOhZxDqfGxD40n<>Rrw@4V{7{<%_xs|aR||P zz>kuUt>SCsqfE5)D2wkukpFf)#UQX&lmT@FSq9$%`=G$C{WCXl*p#RlXv0Y++BTYK zq?1fBgIsAysGLA;n^H+_n_4lqtdyz!3Nc=-wc(gua1n>lX%}ymu+3CE8G^Y;^JtlF z@(CwtfGm3Qcc76aX@qNCtuzFKKrNKWl~sJ}n9S`N;I4_p!L@gdIk*gnF2QxU@}*NXI2p*$jyKLdGfWcpU8t3Ea8 z>w|@!zaVuTD<{+57Wy=vPph~Vs)GxqhN2DyFB3<2O3qA`>y~M3q%jHv95*LBWX@ROR z22TP}cb$l>5-1hNU`W&@p#IVVwaXCv6bNfyS$a{ZMxd^1f!c2jdV#q4dVyMtGLMX{ z3Any3a8Cs90OZyI0#>ndb%ZCG5J1;QfP_3;48#XFqN1)rGny)$c$|AA@Yb>b`qHUo zfnV9hnnwe_te`t99uFLOoGxfH04scTtcUsBAr?o5T%?e0Mtmdd=?AuCMpWHGTkuQ7 zmpepe5MF-tjqwj4Z-_`KbM6vL7FIfqffy-@yE3ySw0Mqtnfm>A( z85@m-{UT7jgRKu<1<2<^Q7{p{sg67m`0|MWNu}lyEc0ua5sf|r29WG8NQ&*s%z?=d zAU1wD2xe5Wjo(x>+nx%%_Y@W8=T8MbdzzK1jhE@y?h3xGP?o3(WN#HEDmw$Cy9zXi zkD!ExU5C8zkHEq8oSdkmlkrjXETDIrpr=pf7?7$S1#$x`XY@o8Nf@}iA+V&H$h}Y< zcwrM=e6}eNViyl>4peRpz-0TMTLT-nvM6J>l@U&t&8?dQd$&-j?Rqxw;j`=|k*scR zR3zUDDKlzA!bXXNEskh9BW=Mykg{c?MP;s8#gVcJxPctdvNH36l|YQRUDhRw2q~<2 zE^zTVmKd>BP+b?V8S==~ctCS>R56j0iMv6rmXQoQnRv1$u)Bse4%ssfxP*m|B08M9D29pJ@E_Z%I56#P1NqWfS41 zUp{m245)v4rzp9~)hpRVQ9D(=m zmKfFJ0gC#EOl2xicZyUBo=%406M^_hL$!CTmKmyhp?dW1w)HzazfmQ(2sBTp%iMz8To^RsiaW&)*8{ zdYj^W=k37X>jNf}va3Gu(nkUEG36?QP_kMRNj4n{95_U2`1DYq>Ih*TITm>17)zBQ z4~!yhwYJS++53Ur@6#)ac}_0Ad73wQkY?gUvf8>K&10j=NvL8zL5kZ<6Af0aacXDc zNNjIl?-f|l{K#;o8!!bkByP5+l1~UF>RO=2MW9&YlfJ^p2zXMD?i1hww-hN=f^$LY zC4@*PQU5#{*mIJK49WFA>MqS%{}cRT23c zC2qa+v%n{xQ6ZlBEU@bH08Zd}>r`OF7p%ak!y8h8 zjUqjAAcvP7b;Aq67Z9(f1aWudJd5I9cRFzSD{2M*_&TuU8&;F72q{iVJbezI4qQ0R zD_N96RGc>;&cPy1DUTw~mBCcRmVO^%%&lTgk~R<>`8M#@cNF7i-vv(o5U`q*&<}xk zf22H}{4ucZr+^*liY<%C_1E79E`Q5XprWZ(6_NgxKC90J)}NvK|2h*m%`TeG1U7un z-lW{=b8-I1z#C^-U5fM2@}hDv0J#_4;86tEw zr0soZ^CUa18kEkQG-+C)7ByJIh=Ts988j7CN+!>|Pd;JZwqtkoyzIrZaj@)QTT({N z)Lx+Hd-8spNY)wCM1j$+pixD$1{Tf5oNY}8o{$EReSCj4lB+N5@qk572+OgsD^u&r zp`PL@CCd_cc{aw-DsErq3QV=r^>ysp?4)b*>XL1;#L@ND?Aq#~>+9LI&8zqxLL4!P zbgvJ)7n@9HO?6|}cHb2=(;{(7!|yKT+-0b(em8O+T9r?!W}0d8$w9oDt@#c$sJV&^ zTsb5y{6P!c?;cd|9kLm!!G8%xKm(jLsFvY4aRe5}nkYXaIM!IXQzChjB9tYV0>ldv zRT+gE2h^BI6yxqAjloxe`LDzg=M3x6ksYKpAK1Ghuzaq%-xjn!h+Vr6gAYc`;@^EJ z{kMnGF`Pa9aQfbd>EguV^zRp^BkRqJ)3+?4JBsxKp1;*%-?!wsLBw{qh)oXs%u1#- z+(q|Yv5N|g=GijpFY&%T$w<4l-AOda0=3g!>X;qs*d5%Jo9B5lteDda@)A~lNIgk) zO+a->?|h}l<%yp6GVn|4N2$@=fQCXwespRXQHBGr}7#1V+&M2?OCjR z#(ml1S%2-BD@!%I(ef?v4HQ*pJYdTX3H0k}?lI1q#GVb1&r;w+ge)Oq$PywpojvSA z50~0Aa99BrEgD;2p;1d+?BCHkV38VQ(#$v0IjleK$=i7zn z*`_^k8o6Cj0V$~hBJTw_m{Ykog49uF)-?!xMX>m@`u1}tvG|UZ#a`QVZe=>&G?|*g z|LFtQSzp=In&-?Z&wOdKX2%#DtMUnBh;mBNk4msBw1;88~V%QNTN!SI$&vNQr)DaNdv`2g7Dh9s3|L*x}A^e)8b8 zaWn#m{gI3j6B%@dU(bE_E-~+MoO^4#GMQ!En$v5N=^6Gxjw|K+HOCde1JjHWSdo=5 zeD{41{Z553w0~qODemr%rnaKEbvz$dkho}0*ORCVDC{W|>SB1?SxqmCo?=Drty z@n&7LCLW_9h@w9->C(ktlDS!_4?WutXiNZKv8|Yc>t1+=ITmY8EFpkj*(Q5ix=v@; zj`nojid{Q1>Dt4tU7hGUj$Oxfp=%$zc6TG&nrxHjD*ivdCp~M!o_VwAdLXW0O>0tn zwKUn5OynD!lYEy8OhoJ~jP#&QUhF$moUEd1p3(zt^8a+=;x%wib1gLqe9T9zr3j^UFmoHz2VOEp_?kR{UUqmD%dgjC6BM>t$BZ4b6-^!a;ra!of20~19Ik|<7 zC?DI?KrR?LL15(EAO-J1;0r4?2cF-oO8<0qI%e8GuTFowiqq9ccX)OB$E(?GnRw3XVL+_zQfi=UwQU@D@IXUE#~ho6XuXO0KMNThTCz2eD;g8Dt4=~U2qG=0n*P%MZnszS!=OHsmt*Drf9 zAEm9dhOgk=hJp-S-jA>Wp(j^};L#`=0y^N9SX`A-fx6Js(j-J3*?WL$?hVhn?R!^+ zcLr3hweE6262#_ib`SxmQ8mBdk5k@8z{+ht8A+j31`9z2mK-<+(46ZTVxZwiiWr;= z-h@s^yQ8@jOw8eC++nf+k(pE!*M~634oW4vz9Wd4el51&1oSeDRg-`GFmsKDG&$|o>Ep_Dz9LL>1}`ne_UNJmF=C4_HlEe0hEP#trO| ziY_P_>weG5NOrdnshK2FBNg0O-OdX-k(SX2yjsu3Md2O>ZgNB}7%Cr#A`LY^9w>d@ z7Xek&5>*PsLJjpKrBRPs4Ahhel&H-|fa$!N$_&f18vB1?Q~Ku3>7>{+mg#kp-)%~N zd@~;;%XqG~#xup2e*I+$;+iVrlI&kpb1%g7BLc@(#G_^-&l^|SOa zR$p8|?X^1}KZMpsb7O9JT5s-3r=WD~7^gJe0DgR)d6k5@>u$D(1DiRpjYIDR>C|55puMu(`iRyX6#|jZhv% zS&sZ~`G{Z=NNWez0#$L4;V~l`77c_oTnHmkrA#0E8EQH`b;VFlD>O?I+FzPdjv~6 zC;EFd(Mk|~P7=Mc!PZN+Y`U59d|Tlp+N3dPT5wW{G}z)c`kjo_0?Cd~w7}(}1%?HU z_ds9_N^(~sFXYyy_ejvl$8BQ6mQUTAi47MQLP1F9J%pnY%@g7X+@0zsrBRd02w$hN zDXW_Fvd?AcLuw6T{nV0Z3df|Eb(sU8-Y_^u1#w6D_?9pGNr7fY5+D-frlvrXkt6))E0Jz|6dR&A2hd>gtt0>s(m&2j8m2D!gPwa6XwIEBtgk2!v$g zJLc~EJ{ZM4PGc^}NPjtAY|AmiNEK)1!DyA8n}>5^6>=bpV=5P!Rhm?0nJnhRSr@EU z%q?S_2Kn1&r{D49DaPM?i5$#0vCkBSx=p5L4{Y{oW9?0u>N8ix)xpBmj%#y#9sFNA zaAnC-onCTzlZdalWTxv{2{EtMeQc@6*Xd~6_*Crc@}}inOh`|Ocwdgfky0J^0~5`Iu4_Yxa_7*w=jQ18GTSTok!xU%WZW&J97&(I{c*T z9rR>OozKah+#P<>Z7e+*C!YkvPr6T_CxvxB2g6L#%qb%edT79qw!M2;zFjLUjz?Kf zl@y`z(8rw6!@j=E%0*L%sQIZQ;4&l^YQ0=|e}_4;ji10`#>QWWvNYjl&Ub0Dtp(7D zo@AGUm2MZTH0pea$!o1jq8y!QP>VEad<@7Mfn5DJVol(b?6X2~MOrIIx!YyN%XYR2 z$-y=uIoT#87u$psrx|X>p#f)F9+94P<1=HITF8{sYKAGN%}^dgClMP+6KMQ|hEO07gtOj7O1!>GdqhFg;$j8+&*Vh9HbY7_%GNYjrxV=Iqw5 z^I6UAVBC7ha?eP4r<(^-7N(8*^Y%zY`S+cqlx6C83z9_AGEUV~)*{*hA%Sah6j`#A zf?|WDN^JAqsc*hcsG^bqGpEm*3Flms6tx-kAl0QGLS6cIkSmN3=$XI7PeCYUqevnV z`~H(3hSDHXRFXFXu3m301lwN4NzrX0g)_#Li7iQW0hy~dOHyFCHyP67XyAi`wK+H% z2@c!j@u($4l3D^iCX!EsgJOVPATV>j)6kmUYt*SBqeItsC<_0Is z=QIULlR|n|O5YBUoZ6CPH;{8~6C|+pmqW^O`v28rlM~J$TSI~0kmq&W78?B z3EX8m%_(P*)4@5YN>)-vEhW1^b9&2^EC9LG=Vazk@clolZX?FemgEcyJ)(@g0CF>~ zki<5i)mNj3z3$)KKKLt=4QI~aO+#drZV{aqL1$*mWDNv~JN0B%6nI}H=1?-Hggjl! zc0jj?%x;jG)soD;AaPJnru&qc)l|yGg(cVntTiWD@OwaJwjdMHoa#Yj>ULRS`$vgp zD08t7xZ)_>btI*BL|j5j-LNMgKg2vKd^9PFy!YV~BS%qsnobc#Yv^%eKf=a>6}t}oqcc^!WsmcN6mfxsXa7LDb17fC_~z+2#!hI^1E4# zW9AbY8t79KC>ivzckPi(|K+^O4vC6RD18MbRuWNR-%)uj0J9h6Rj)5EO;3pRP9(Nq z_VhARfK$SrMM9JAfo!?l$@P3f5uU3a;1txF1j@*gXAjRO?M!f1kwQ)c_A{~CHLUNo z#Hq2-8->e7TrT{pyZ7jJ{|k=}>W~gA_MjXFo23@KO8iy!?n_=+qDyrfpVeo)SNJ5N$g8X6) z_$UIK(B)yl59wyH5%M)4Zx%>Wt>WBKtgta-3tB@w16<6GKf%5Z>`;OA9O(g?QVsh! zN~Ree=ZwfVj@QLz7`jliLq@s-+XOmW#$?HcvK7DEsU~B?a<-)7i(*pRi=`c(5khIK|G3Wx0n-*>@^34=Wp7)W7*4KA*gXV~r~Uo0KX;dEOo95Yk!qHJJUXbi|O8GSSv$w!OH zQa7=w+15b1Y)n%^CI==uIM5r{%_etNvn5`?zv!!3)5~Nd?2MlH8G?F#4{I`7FN|`v zgo40&HWPx85ZNT@xIxM`ZTg%ev#oEAe?@azyi*QW=!P8*j-V~ZN+~9wbovQ7lw~X2 zszSGk7><`!<_cmOQ>XU%1PI0NlEg5a{`%cF2TA@Z#&IkdL}A$}NtV!BH#L1J9vuMD z`vg&GERjG&TY=zAjVQSL?Za;CizG7Q|H%0@9=GzwEkEW=FBMRdauo$Z{-RdJO&?X;b4k})A0?jyhP~`svpI=9?oJaiPVy+M``$1;Ju|_TA@Zs zQ7iWnzc+s0^fL_<{4v*3RHmEg1 z3kCn|@rq%9XQ&|ipw+D+RmOW--# zZfbZY)n`1Eb>3jWm(g^1(uMQQ=4bql!|3bQxfcw|y0j%RbxUH8zt(Jb;uSUSaQu7j z1OCfDc;1_M;k@VIcI%AI$~i;UIkR_TPS!a~;=%a${O3ac&_%B`^$hkOCeJ;iDE^D* zHe2jXRW>lzWP2kXoQd(hHR<~^7yXrkm4Nf|JMUK6-f_I^e(`|)=Z)?Cm%q|7nxi{{0^O-)yu0_@e#n9wfHO)aJem?Kb!Ikq?{f z3-t}cOoO7NY>@xo9oO9l5km+;10nNIQ&}U;J zF4`vM94bEFtXy{}`$EF?_VbKdLM{j;^*@Yk59DPw2se@kA1+T(jPFfG!To#_zdw}j z4?kS)GqC%OKaUW4f;EQ0)>E@?WmN*x;xa5ym1Wy8n`etu>lNeG#QbJIh}nMG7{!tB zIv8O-A032|4~^4Qon+=|L?`8J@dz5g0@>Tu4HyZwijjbwI97v(^YM$K&8biBg#g5N zOi{BY9)kmamA?wSoL5k*`wE~(cT3>9y{kBknmfVj0lQyDt8e6MfmydlGEnNRISHRo zWWpO17ijTY5R~a?z{NsAP~*rn!KneUU-bmh1lfI9yq-~Tm zU7cAxq3|}?7Y!;ZhO!#I`R`0^_!a63c26Z1OW}6_n56H+z;ZU z<0cg+9UINDhbLcbx?pr1TV!#yKjJv-wZ7*Mo%3J%si^UsDX#A?7d%eGVXsYh)5~re z4|`+YBO>o+8DkR z<#G*al@T)*6))U0S2ttHu%4Ponr&Uk!!Jge@TDs7p&6df;?-91f zknh49=h>8qgfM!D;XwJR1jG0ojM0~bUwcEX5XO9*0&i{RlvS{xi+M`lrTbuXd;md= zTYYQgxJAj#bsLmZNap=w5Sq~gH~CaTQE1d5@9|lfWy1Er$OL$Z)h3ARaN>E4Hm(bY z@!`r_jexmxFYCg2H65B;aKGSZ@*%^p%lx9LO8hyu+n zufC;hF(rG3HceicPw!Z#8zq~dd=31-(Zzb6a5v*#`~_&VaaEjJ-OLn8L~BvwTfoT@^8}uSJ``h(HOB_uqX7CAe5i zupzA~qL-}1o9{fV>m_dMsqqA%4~-3cN1+`>MKk&@k*y^W*=o;3(Tid3SD`Cs(><%$ znYIw*Xo4PQWzj2b^9K-nH0KgyL^1q&^05pm2JU5VNCBqpMWxV)l0}cFmYWfgYV7L% zL(@n#Rx|_Wa1_nOI|Ju%|A=^ZekNo=k9$hn&|G4hC37ZDESiV=+5#R9r*9!Xs-wyD z2sTKoJTZn5fJt_UxhaZ;bHYVNl`JJOqoSkVVVQ_4I!{owAN87#z;uzMFpKkWmeCq_ z5W>Vcqvvp8<0aJ#yUIk^RpRwz0{RH(Ct%>H*A@Y^wc^0m4A_={_E5Glracgun8wAz zooSQ3OTE`|+~CZ;&#&-#Z?|lt<0`z;lU~W9S9;ZZoy@@KT6llU#-qQ`^tLZeZ*Rbt zrynzDUPa4I@pVhR13Dp1u7Np?34@pc)8Oc?0S-i+iaxgc;*|Rr=vc72nAg1_*LrHk zP3#?}9KzZNNkPPBVQfg(iqV!&l96IeqTgV@?0$aI>k3h)-o$6fX4bn&OT09q*$LBz zq5H813W4*5O|@daMQw+;!q>n(5`h!T^rwO823=z$3t#$M`s2Svv2ZaZlnneEP+TS` z3hAnV7)>c+6pZGCz5{3soK6bfy<12Cms+V?YiDNwBlRKFXiyzc0C^2$RBmcCVm5B1 ziF(LHMrW#xsfJ?5Zi=&;`l*fvjK9u#&2dqjOIJP9?vGP47J?B#B3jY#QWp|^u)HvD zR#7o&pLm(&YIR0D+Kt=vVP@!9yL!INrqxA^;LxmG2YyWG^-n#$o@%dzGr$4N%_dTd73^s#6ouf~Xvj+aL}-gp z4op|X4C+iaGijaMB+o^YHGm5fLgezP_eSw569 z`tb7MZiXc1cZ%{k16t(~<+Gj2#}?+0iTm=22-o1~z4i`<`)KReF)(J2iJ@Anddz#jJZ)izQc0w03*(JPPvm;oImW_#RO}693jm-+38>2d)erj}4J9gvB2(MQr zOTyUAPWZ%v|KFs!O>SjlyDVc&O5NlpW2iZ`+5u@Xjb4SbE2BMw-);k!&F!*Hjt<&z z$Q9jTZPjn6=ZLp=cGT8D3!@Z62{Ci}ZKcJiA?g91=V1?`o{7y1TZvp@ zfa+T)yYsP|#^NZWA&8dW z@gGAEV{KGib_5zOen7o0kEqvD>bg}ZOTpTL`g+xPJFh&hAwu;bVRNWi$ura$ucGaC zVBOqT?FpTjqy=s!Y2b%)tylu=cr76 zmy-ZF6sK8F6(-Ot_=L+Nl6AR7{(nUNS48BWdEJ`)Rx| zc8hKZ`mxMT4S;MgFz`sZqMgX_S!DR}hztw4;*Gbh${7R}vsyt;Ik;C@V#j2i@Dq?T zq;&$HThTn_$9FJKc~{~Bv1=kxKLa&00u}9;Y{L}`*qrfZPb0C8h9k3IrX)<5Q(O$8 zc<{`UQYDX6p0`h#zK*2a0t{gjAdJwx&aXL}Y`8ZWZ_U8^p*h1~#@Oby zi~@KR_c;{YtcZdW6?MaVR%Jc{uc%Efb_#XaE6I7_W=G&yi=Kk0M2kMEFL13#TMyc; zy_~$*QId^c><*ZLnKS{XJ`xu9rX23_K9%^y@%$#0?yMfTA#+TlA1_#)=ES7hz$iDS z*h3o=yym0!rnwj0%DtOx_Qs8>{nA)SEdLL8?;a3knf-ykGn|>>&Tth}bTDPaL`B4$ zNefggO%%N5olyrE<$lp9HLbi5Spte$Yip)$YF3(-R)(6InrOPYyR~bp?ONGp1v&_o z^81|Uecxd~+3olH{`Y(JW!~pcKXTJy|1I76|D*?nooN~v<*CIkaF<~?2@ZxX=zTJ6T5-LDqAO3;Zo(%wmxi6 zBAILLCFMj?RsSQY9Q#~HNe=S1-9|Fmr`o})0ZFa>-AOG%GGDcq)J-I{?sq3uhh#E7 zZ3nAHBvt*plPW?oSKCXf2}!O0A4$2ofvpM2^f=uPR=*&r4Zk}n3zB)hy`+9cQXBtA zQY|&O1<82Swu9AgNb1Gkom3c-8P#4=w~*9J|0AguTBReIm)lF~Hj?_o|46E(fZLJG zFYP7OjHEXGkEB|#@;+mbta$I*2l+_z<=>suFeFphUQ!w)^~e8_R7(M$MKb?sFDWgO z+WfndYCtmG&bCuP48l6kDXqzFlEX`2)+_qII^h%N0w=>YX=E2w_F7RDk< zof|H{pALtzjcws#VwIBdr!`;mj6NAgNmN0n|H{E^E1UHG9|NR%yv)Pwb>ELicy?Ln z#=~6GiicT=m><1~rG>hp;ORh}ka)GEZqZdPrXFS6+Nx|Nf{V#FXqAai_dz-UmBOv! zi7ydOY~XmIEA9&uHo*ZM$zdqq6Cd83aZLBR@7I9>jW~7NZ1M~KK{Ta(8 z)ikktBuQsVf>ow18$9KSTPS9r9>R!<-qaH(2?{^J4TzamrDoc-KX8iXQG~mgp*Rr2 zWC)fhj)e$&8X-->JC|+DNTf5*=sbn2e3RabW#w5m-j8MFWw&PlyCEyzBrLHCgG|h@ z3_bshPlq07eb2;`Z+I=F*gJk2?0+g=8_@YgcGFMVE+;$Db=Wc?(-2sB^~25amS{#q zGjFUK`Z=vv>;bgZ-`6+3(!eAT|PpC2dH5vD+Ll<5hFKHgq5? z#S%*ng|T3J2kRLaj%5L&@WD9L&^m8CfE}zR5n#bX@h4(9{&XB6wy|5e+?~Yk`QdnN z=TRav25P)98Zcv!oHiAIBFCK#?jod-CRnsxC$+!1(QgirGPa^oyCmJ3J<*rD;Bl% ziXra3VlDTI5kP|W9k`QEAsQJt6}t|s6Q9-SINY6A{44De0jQ+dk@w^a%tvMRFBuDk!Kbr?wMp6v4==0iz8y@FTq0pXT$DXfH5&V@Zn3x?;M<+6`2iQv$ zK)V8XLnqS*wCn>KnJ%A`V4UKu2^Q*sDVi)qRy#2^ciK}vb%k}faE|i|Nqd?*@E_5T zPp#BY%t;@z{;bvcT(|!0VVGa{Gdi-Cd`?0*#1DV;0jDzSe)b6L=&{v_V~${Wd4}ST zSBF!pPQ-h7M|=|R;nV53z3yj<$`Lp)NVU`<_$v(6-7AQXith$WEpRSLba*a@? z6Ttqbl&!uP!)|ED`cU<~!BMAt>KD|(#F;NnpV{+zby#pW#dGFs-ahrhx8CPQwa2PE zSEJJ_91K{z7Az}IblTTib=pfjP0wp#MOL`?*%nr$+(_h>F0R#QN{IqD^mgeV zz<=uwoGo8g&X$|r=M5k84wBIeaK3|kZ{di@vply{p5``-e!jM1?V7b{ifhpn*P=65 z313Ki{nHa`4#6oALet#u#OkdBJK z0mhZW3<3KJQbkVRS1H(V1`<;KwMxJZy%7O7f;gadrB_G{`jdAkI-XAlYrRhd+I+ol zCp71J&qy@qdRfsRUY&6XF&I>MEsnsibWS?N>3cFQCwP6rO?1KPAjCOEt2k9&V&d zaY)C_MAqvatTaV0Q14G_Q>1Ml$jA4KxH)d+MCF^rC*``34?lYH6vFLC9`y~eV7Y*o zja5kt2NA1}g^7sbAGF6Ibpz>0S9ET73!g1*yQ=zeYmXWCHRSAHfDaJ52jo_ z&Oc$pG2m=ivsMcRcHn6YSb?8*qDC-R4Z%z&H!cK=Sg2k32-?u>o#@K3Z3)F()leYC zkC<1F3QLZlOiLF)JD&Jh)s$uZFgYAUcg6!*vi2VZeEX{t6Z~_pSE0%Ml`1Egy*fF5lL5RTJAluJC!v?J!Q!lia8RhrEgk+!!gyu!E(_zP|r;T5EZs7#x4RzJY) zXa$$e4e2Rlp%6{;VLIpTrg?-pbRF>?=D|+{x%hb~fXtzmudPN)i3pduRuAk7kRHbC zQX$gxJ{!aSnGI8#~{Oya{es z2(F8Io`V%lZ?IG$v5u2S_s+N$ow4O~>LZZ15ZP0dLgMOl&QFNUv=Es4;Zh-wp%Pd< zi}FXLovjG9feG~wPDAc-Q3|09C4o^ME?XB0!(K?WidKgCs?81|_JbvZI2m+3eq7y- z1%IIXNo{!^AViZ>-^vr+3{$VCy2AIy35Kt_w$}TDdVy{J5pN^cC*AK3i<&;pWC|}_q?W^4s6;>KLw+ibVt^Q0Wx&bqMXd2M5 z=6AUwP$1jMU^>67VS&^U94VR$(iix6!yY~D_2{%o#JZ;qA zuC}#N>oLEnQP+_|njd1dmL3Kk-n@8tBOfUI^TW{@wHf5xsXgXxjMTe9?UJ_C=0Oew z6%Q_~@(#;$GpNiBiAQ0T;z6KXaVyG+hBO<1N<&)gPC3`PnJjqExS-~^_M~v&@%SEj zFk&Nc^o3DbL@K-uG`u_MO*tPLHZzrn_N*Ar)M6X33$T?@$XF_y&=L$B-Y_XhZFEPf zW!-gAKNoSt2+F^_;&NL`FstS$Zf0>1KZ}6zTBcskhYF@;a@Kx7kFF=B$35&2*W-Uw5u-t)k zZY7^GvrzV9091dTKUmogI)hO^s-3KG<618e+ z-G`9I{!m`nv}K1KaHnPqI}EiF*7KQ3yoD20;%fQ-L#VGUOKb~T#Xs!fgu^MV>}3x|gqI;RbeCE6G0JQ8q@69~XBE z958UO7N){a9WDRAiPP!s6sKdUI70{b`BjzwP*-t3gBIGopoNQ*a!xJ^I?|<#2*wl- z?l8KGsfDqh+Rwd#Hp>Te0FmBoMI=R>%VI22B#YjKDr%EK67Wjo)2t4xTY_6dmMEaau%)&l;E zu@Is-8R8R560qvnlMQ?GVo;BX$rIMK*^W1P3j^Q6hU;tK0tkJGf5OMv`3)YvXJPQW z!Jj96SJ>+umfhgdWE6oxttYg9V~|i=!V!>v4>w1b2##6>t;G|TN}kN50`tm!EvYVb zI)Yelw<7-x0~3pNlqiif%AHsh8lJI_f;5`J^01X8dON564Y0}mCk9&B9CPYzywv*+ z<1P2D+yCf0j1f;>D9ICaqN^A2-JgA4oM%|DD^H7io>R1(XHQ;%%6XQypY8lSt z)RrSZ@Oo$T*regf<4_{Et4|yLZjg536=QxfB_CARrHmC1+>xl1O@Czv0Fl_x)MqYm zSVne9QP!Beg;?@460`M>Z{%V+VD(X`EyaY-{*Rw{;v4qoo3}21jHN;L1#@{Fk>SXd z{fCx{tI?GF2c7`m{h`Zxo;C7v1<-IuQI4ai$Uc`bnELPi9*jX|-h@29V8QW6HLUtv zUY3aXNplz2a_2xglEZ>#%oybsmRe|E;DE_?5!UhJgiI7r&1ZaWUf$y@RLQ76u(K?J z*HloJQ>d1S{lnr$zQjd>&|SWJk*as@tl;TE(QA$iFkpkitxA=&DEq__K1TF|nvnHE z1syM#Sm&JLM2uN_| z6_!FxGDS|r)X5P>yl~jTO-a}^msiF-$F$X@z58Xu=4vo`!@wy>5CZgLE}vjIRLP#p z#TgB)_OcWx6Xe}AqmwIQu3T1EAR~Qb#0$fe0?Ta$x895Gj}@a=igw>^e)t}S6}s^A zG9PxZ1Zk;E%y*qHB{3}OgwwS1jd>N8a!i!4oh;jF$aYHFPO&REw=aL~yjbLh9x)zw zwSc2oBXMrzH<_bMeb07++qvjWZQ^iY9{AfY+qj82aBIvx0ooYM!QXVAVPQJ30;!>; z#rCAaLL1PP$oVLx32X3My1cZLd!@LaDsG<2C0%m+Ry`+-JHigAZnTfg1q#{V(L-2z3h^13}pZcKK$jpcLY~Iq?36c@d$)4@EP8nC(N^d9!WVh{V-f82G2JxO&w% z-0!*2&u<@H73}7poV&nLn3v0{(j?lwnxl04bo2{M7icuF)S1glb(>Ak~%AOT=IyKkBSQ1vt!5GT!G_9PEDRQam>iHiOI7@4hKPIyyM=*4OcW` zh;fZL>spUEvXkphj5xBBd%}8}@{X;`WrH*tZ>z}xcp)4MEihX7a>r(+M^}*J9m;u! z3f`fTcW?!StL^rdf)^M|G^JS!{dD0{tdi;Y>PXKqNxL86u@3lN27v|II$fG$N!?DYm=u~H*_H!q#(nn zR;dm~bgk-OG}oyP7m_0yH$ST)>7K5w^ViTHiB~2tj1jma*bN|CR0JzN;s!f)wfRrn zU_sCE_Cg1mG-fN8Qc~0mPmkK-XSj@Wpk4-=Q;N8iy}2UwZPEMCwCs=DlXB6gMu(eH4sau!H*RAEH^Sn)i4#T)lKUPfJNxnaYg~MwGo~bGw!M&t z#t9f^;Ky+OM`uiBIJS5(43`xg7=JjsuxCGbk+TEbFj)XnnJE!Ab@AB&OhrzUMb||U z5iH<#?){SK$od1|g{zS~|I0;~wBUR)6P!mhF%ByW3Woc#`Vqb->K--{{R_qmUSc#G zbT>Za;XAc|Qc1C5lY_yIbo^%z&W^i0k7+}*^XAMi0@$(bVkLC?KX3B+;A~t-Vhu&? zR~Y~Hw@iF7Ne#Cz;N)lCelDA-Fxxga(_X}PLvsZcwvjG4m%z8 zXW~BVpXtMOrYgKoel&IDxa3)*lgG#fo_cmp5`%NgcL(PzNA!qg{QzRsHO?-dwX%P1 zzxW_Vg;!&fZN=(k#VfD{CaT4YV8)u(m#~@iK!iEMv zG?{Tw;BcnNV{Bd_!}SRq%Qr8jl;rW_lO9T*HDO9>@_0@YWeaMq_$N0U1rD=uzJiUM z=a@f4@`hc?$(sum5##Kcn4iS-gfe`zdxZz@_tBU&Y^M(9Z)bm8rfBg89?@&O zJQzn_Y03d|%U~QUzuJ-4l26fOo1<9FubiH?t1U^Tl?;a}hX3upvKg5ik-5+TQ%GKW z$!{;r3{d1=irP!1zEt)+B~4>SEKPX?r)s<*nLW1gC^6>qY>%;f$;rS{n6w@i_^;22b%h6TY6__zY?8tKIKqY4r9L z{{6K3eJqW>{%~-ziAeS{D74d_oqw~zXle8h60v^u5S-+m2<3nfOJhKoI|PHis__tk z;g&{Y$F_klDS@3Wje%X<1H+nch`dae#-MKQ0i5I>jhtV1OJi_!+rVW?l07YrA-$Bq zr{QO54DH=E?lVfi=vY*Ik-EsggU zwheq)2`siW_FjO%m9dY-;Gp6+t@UP~QmCJ3?E8cQ@=xGqY3#RHaegVBaZf7FzYAyo zWs37(!WsXx;=C-J1C}e!uZ1&VC7j?|dVm}Q%PfuemA7^eTHV@hd7-u2S^>AKXN5KY z=mFB*U&W+bXK5U~{w|?IHgf1omc|D*wGMsXg9H9(X?*Y%k%>PemH4WqF=?B7M9$3z z$aCaBSsI6KZySgcND;Wx(l~5a+rR`R@GVQ@@ZCz_6+w#RcNFJ0!Z~7};`~-PA9_!5 zekYs{A5ffEg>&QwaE3KQ=UL;ZgW~fMj7^W!h|iJu9DP`Pj>2ck$M{@v%+fgKI6lh9 zdZ1&Zo)E#VYDhcP+CA=cYxnpwt=$togPRF6NT4$jDrA+Ra?fk%=OMEhDn&^7d{~;p9qa-uFa(&LcBt8egch=Y9GXbCJ{}!M9@oD=;eD*-v zv%kZqt4Z+33LwR`^}VHW&JQBqRe;R>(e-Kn*&QUT`9EUJthY2~+;9)zwALzVHCP%m z8`}o1Qv!dnG-my#1l9X>6V+X*F#lecuv^M5OtWo+G(> z3UhH($epvJ0)nfG)#ab-&X%pceYJ`3w z!V;;!oZv-~;FHn-+4+@lE|mt#&VLH$GHH-V&F@VC`;=srohM+Ry|MXeX)rte0@(44 z^ne@&Edg*YmlEBbE2N?93~M%P_pjveRnl~xWdKRSsf65r7Lf;3K}G=&KQ*B7Ko?Z;jt zJ*vi@Dq^pZrmL}sB1uNILYgV(9*%WR{LSV{DP2UZl4fgEemPiP8ZV9EQlL&V7kgx8 zxoSO4%9|)@jV6ga-F}sC)t@*nL@>0jIH|H5aH?OGMm3kG@lIsRK1&h8FBB1P2J@VM zm$HA$8{L8fr_=I^{8XG&TwK2`@fb$n?FQ>ghw&9S16Q#&<F>)%ZReHl_=l5*kDWYg{Ddi^llffqq?S2j(?P;F5z1?K3fwCnjGiCk zHIO$Wg8QtT!?B|CN=kmAlG8jBeInl*5mJ&K<*m{~Y$Hq@T)#HJII*xqL6 zK^>adIUzY9v1R|_Zj8h%H^oIFpDp{h{L1Ky0I^FIWssr1Dcm6L1kPf{vcf+b&byS? zo*};J0w`>)z`&9fUoz_0O8FmMUd~&oSqlpt#ZZL@-qOgN%n3HWD=v^(al4^}sVqm3 z!$g^auAJzmLjZQ#6O+`~JH{3);W9ZghTCVCWKPJk=gP@sbou5jE)y4NmYuUv(!X6W zN8Bl2h#QNu_#8td1Toogf(R_{SI9iow7~Dxi*j`Tlu=rp#o>&MUGHEh#R>4f;x) z6N(65e`{pBj$BSbo>t^*xLkFd$p%7Nv*+!*KyGOGu-hFN zIp$P==fQ}L%uRvCQ*2hjm8b;oR}?eshmN9|2*lv5z)IUz#yqxb#h&KH<8a{R~%W5)^ZpNL?6YQ-Gp z_kj~qg0`wCU6C~~R6!UGlAMsut76)1`F6o~qTSDhsxB}eWd;OigpyCqcv^6M&{&Jr z5D{>Gs`Ura?oslV03_E(bNvD**Wy2GJ}bbk;@$4lhF|7kER~YSOp?=oJm%StxkZV_ zq*RJ1z`F}Cy)BwF(ixj?n*(()mjw%+H~ zyOi?e{`S%iF9BtjPnAS+K>N$84m%lbFw*5yCIQP(2z>d_FPpga*pwqBB}_)-sc~C` zEsY}O*diSf1(RS!#m+@sw)||{9Q#ma{3xi;TjL04rjesa_7wzu{;l0Zn4rwN630{a zg>vTIUMUvLYuN;CQg*fgDncOYXV2C9>N$^MdvW`&FS}tk?^c!Ruk6Oi`qQB|1A;IGl z5x93LHS${21BZE1a1<$VxPRbuL{!(PU%$-d(EuqZ_8Vb87tB6Em|yn1F)0{RYY&hBAxb{y-(J*7jFRx3 z1#NL?ux!3kMq=usKE7gtaTJZro#e1D%+D)i950Wsw9mhxUK) z5vJxsaLst0z^LpxC#~Ycy~4n*ojNlj@`;^1!h*jxA&aep$gNF~eP;B(yEEC512}DV zsfv%80{2ov4W@On)XD6NL3)XyN%W5!l(DE88 ztD)63RDsZ8w5|ptHaScfvoT`Rvb&zLbV0`A2xE;OMIMbXIOPWKZJ49ZG$nOvZ9-@dt6nO|OoT3g>+#yOhM3zG| zm0`^6)O3C%o%=pch?t@&2XTH!5g&;|E1`gB3`dehl@=dL zhvSZ$iFXKrRDKm8&0`@DrykP3LI~t80vRHURV?)JQA-vTN)|2Vh8tO7XtGujO%7{*z+*ofZ6QzAip_Re zyd!U_dk{_U>bXZB+EoC0aGfLd#91Kgh-eFpOpQ3=f2J+LO7V+&pI9K;XbI1{fT zZ0pI54ucV&h-_0DoY3UN%YJ@b?C7v2tprux35}B3L;3y;#z-{xH{R5$XhPtiYK~|Q zfb>M3OlesYpqf#4Wb_9mqrfCXDk88fAwRCH*v1L6`fPsVO~^NzJ4JAG?OV zcd|PDBh`4dVa@MqPX`AGEI6LPqN~*z0K2s zdcP|QC?D23&mmT4*n@Y=^EmSCa4I-lP%w#e8)kKONOmQ~6wUzUP6tP{&ha6uGh(DG z8glH|I>$$>&W zS)E;GvJ8Ivj{eu355y@*3Lp^I6aJxcidW$_)okR#rQh*qb$lp8d3J@tH|cGahuH?G$& zwmM^;bZh0kmbp3ZeY(6i=_rq_(OJU9Z@jGx+NK;Q~|9w{Hpg+2b7S?=4%LIPK z>a@JdzDY_)wzjVPZC0oCPhrhRkk0+vUC{jT5z5Xf?6f)u?{W)iZhl@N*;`iUklk(} zP0jBsFz;BM5A16d@_`cap4Iu_0k@Fm=6OnLA6T7<2U~@Z5>jJzCLMMQkqaYkZ$67C zp9T+Y-PJy3w2xVxLqBl?YHpsdBzMy49QJ8g^Cc8{I0mBT=CKH{I+Jl<>M!sc0bZHX zqr;lk3ljX<>U`)z+lu?E)%oxj44y5(NB-Td+DBbN)%nQfRw15B$iJ-4 z(O1HnUIiX0-?oaeN{MmR>KyZ*Rv~3d$Th2T>`!6Mmw|g~9mhygsyeN8KfZ2tra2j% zEC5=a<8FpEe+QWHO|4R`R8sxb>YQ+kV^@gS6Pv@De_*iYNs>kr)_hHTPnK|()rmW}Sv(J}SZRV@v2UHPlOlPLX_&&LNS`RLQR;CTE(;SjcGwh}hGlK*-a> zJ~09~?dei5pw*rjJmXU-lQXVw4i(X7N*y#(R%0`>+?~x4BC6m=&XPK5&PmUtOOcu$ zXUlE4Kh_ehOACiG_MqnTs=&`oXtg|*vOTkRB)zA4DR8L-yJo`e`bC)X-P&J?$FOQ# z$lkNzaruIwC%(fsOM3Ofp&ZW@SA`LZ++a(M<@OakhL!} zDhtqqhtfHjHkTZ+x=z&M&mXjgI$zorO!Gtia~_%sG*}W!xOf!dg|6$N!2qhEGr?M6 zSx=8!)*ha<*}Uq*{cGa;sjSLtYv=ezz5iKUNzH6%ykUeAs+*tT*wcf8d~W*OOlS&$ zj)qP*ov(VVs=dF#8Rl~%x;aquo+216t7KE}uW*Uq$C7d8Wp&w@=n|anjQf(|903n& z z!z)iS(%Yk?r^wig4Fj(XmHN8kUSBQuye|3)D;2cKH`~OK#cC5D5%=Iu3=7svumS!@ z&3^4?+!a%Ws65u=vKjGK`Y4CPgbx74)AJ{o@WHFfeY;=L;Qcp0tiM6MuEv$lLUS=F z$2+a)5+n38AXqKOEu|bSyOL}qwi0gzsKGrq%Huf}P#=m%Akc zcklHS~%K35iGwn}MmI}S;-*~d%^PS?hBhwAF zI#DjAVXi`%{)tz<{-N%KJ}xtTS!Qy({*g>EqQtx%VI*18dOwsnOS#(gFrEB}IknyD zrdoL?-%5T=aI+vu1a8-xhWLCQDVYB~9CEEJUN$lpU!#gx11y_X`KN55DV%Kp57v1~ zZ{yX3SI%YD8b9AZYuZ)b3O9&<%bifht3U8^D0orwG*(^#re?-~!qvPYeA6|(g~XqN~>=kp22AK#8< zh$aEpud}e@#9FY)*`V6;-0%)gG7tu((!WY!zcV0E%5eyBUa!p#lvAP=6I@P+ObG4>8lZ zUjNeyZhS1|IZVF%31y}8nJfR%Rp(|dL0q4HeYhE+^Rf4i-P2aFH@KI4W`x)|?ES#t z=%YMJ=4Y4SSP0&lTpaPGuAgm!Cq{emK19n8gBiCLmrT}j?kk>Iw2)c&VEqb#___EN zV!$t-H(D9UQPhGMOUw(XA2-Y+?#$o`PR_z18FOma!j$t`j1X%@|8F}yZFjGCH_gt^ zvmoAqo>bZsLyQ<%+=s=kT2E;tUU~MyV8nIlK1lQieN&Xq$lY+#zRP^QM&erqE_q(? z-wi#yXq`!Dl!Ex+w7@rdB9huGeaP$~TQ)|2kXQx_DnFs_6Y3KhpqEt(i@xYE@`W+a z^TD!mTJMf5`G@PYzWAf_KVPng{N5_uWWH%{Y9ymsCx8sl-Q4IIay~*YraqS6Q$W1J z&qo+OV@>iN+*3IR@6Pz+)8%}yFRUWVI$lk#Ua8t&NLtEF9)1!bgxODLblu)-5&Y(Q z1LsZ?QZ2Zq0qkVKZ`sN8LEBJOJaXIX!`a3Ad<{LPwusyRC384h3yHQ1#!b z)sGfiDO<%*XNXv2G(gFynl>J$O^4}~!)S(Rg(#rTbXg}BmRLv9$wPb@Q}7wxRU8-% zMyWSmL!H8B^gE2(A|BME#&7}J#``bvg39UouRI^p3{TDTKAAiAKHzA|usLuOhPmMC zd5*04d?8uk>nhP{NXVPR1C>?*Tvr9l&OrrcA9&6$_B+#804ojw%dX?6PQ zBfOwo+B3o%yfNjnA<)>Vp|MkQgHPienI#jas18*dr_CG(#ta24P!JuL5Ju8Ae(DztcI zD$^WE=XBiEZ1h8(kKjFrvqE`E*~kmA#}G@i-+f8h9X=mnIr+;QXnKeFo+Ym#u^ij3 z$9#sxBrh-P#0v8YOm*rF$Ml9T^oCn{!!A856w(~}Me`)YaufI7JYg|7q9eE`tJ;T>F^(~q;q^Wr7bpDr;5pI$Qk zO?<4lY^u75dxLW*aNI3G2gcncrl+NO1TJmVa&!(MGwL7DbFnWoM zrOu#KDp!J<;4?_Di<;ma+N^jH-v5QvI2H?FBUvy$19f$Ix#R4acG1j>Q=iZ;S^M`) zgin8>=Y!ViMGwaGoHn!1^r9ILD)*HZ+2o5ri=fyJ3z#I?6*IjL;w_q9)OSX&7#VOn zTo1x?@r-*HO`G1gXvV!UF%K$1eL3ML;ucR|EUryFaO{UPATAZncR-ef&Gx};)ZjVDUb4?*z<|ZyyCoA zY-%t;aRC}GEc=KH(DT8lelb0{Y{(LFB0F@SCh+KplEzTM5%&ewTb`bh#Y^oc8Usu& zs-5c)#>+vVX;-B&&|(FWZ*3WrTX11W76X_jWUW|fa3jV_gO(k!O-8E2)$wD!($EO~ zTb;cvNZX{Oz20!xSJRJ|$Gmjm82tMXujpof|568DC8Xv-Rs*-G=46SA#fy=vk0 z;aut`CbHbO z)~=}#1CCnQ`%%~^rLgh>S!_B~lz7?B>mKN=mu#JY&K|s?lZp~5)Z-CMO)wD&c2g1* zapYZhwOieAE5n?Eb3suz+<>`mb|0~wM(WQ*a-rqoaFKt0)pTr^$y-YNVVCLU_e};$ zlsuQhU(=x*&=@#R+fsYGYt8LO?dizw z1g1ny?<&!Fc$Ihbpy}T=CJ#;G>O-clk8n#9H4C(=#H5HQQgw}KUyVQtlVay8S1oKk zWV!?pOqQq}xA>JuOuLWB@e@TMDii~%Dur1fvxi!MrKwB)GXIAdG&pH+QNAtLG$-3u zR5YZUeDf`q4a7qHaBeJ?sE#>&1Ff5>h(*SRbeofxomXf@*!`vq42ZG9+v>m_V8@*M zyO}U0aICZvv}ViPPwB{msEg_7?)fZ~z#Hl3elRusz!ZJzn(3z- zCJ##d?S|>pFI+93|6=;|Hx9b;o9V;b{IROpRMRZT?D^vBTmvmr?3+KBZu}rOBlNB6 z3~s7i+f~<0=YQnd{_#iC*`MXAbBAlbW~%*>`yS%DFMqE8WZLkvnx5Ml;UlN%NF)1~ zH<^z7A|fcQp#_)!{9-!!n+ofO(ELYf{TMrLR=a)sj27g^5yWQe%e>!R_{4thcVCpR|vbaLNT@m%`$|zLkyJb=D zJZ(}R z&UiITZLo(yfy7au!XPx*Y)t6l+4FqV+BH#VFfXr(+FpTs*NH1Cqh76Itd3VjeY94f z=lx+Xj@<5ewh(y6xL3>_Q_?K8lE(mpzvC5YiRlJIi~Dr62x;|lPb>V6u@N^m-Be;I zGm#UC#*F7mmd8D=%y+A!KHetk1pXM`)CFv9b=2W)?u4&wGrlbb68EY|+=bbO)kN;K zsmFOWA$Z2>+6rzk+^Fm@TLN2s80<8vI4pC|?wp3`i;uxSs{%KoN{ltXF@y6p;H@5* ze4LK-6h8cD-u`uiQ`Tq3{7YUVa1$K-C!;iAJGOr?Qi@@uJuc2gP)!zS3qT~n#gUyT z>wo3q1RhC83<;W!c@_2Lw?R9&+(K}$Rk`o|J*wJa57KwNNKX?!YA(+wZ6C6|$!7$L z74X4Kl%9yA9!?xhX8`$dqLl`)?}rb0SX78O&>L3*bCx-FM5XQaOrG|6FV9Z|GtLy9 zO+q~3h8DDN^0X>Fh1|!aQ{GBNTIjmnipJnK`fwBpvfNIb7is z9(yP7(!=mkIfblL?IzfTFfASpTObkI=$pR6h!~6$0>LH^?b&CD*x+w`lTOE`E)B5R z>jhiCiW~ag;STz=Qp79E1CGTN3brLkRhd_~g*iF6s zsl}&J{`A0Skofdzh`#9~G28#u&d@3y4sMHY$Fm{utL6K|r?YUVdA&2_-r}A9UGOKs zbT-&n8+J2Tl7qUb(qmX~tU zN{>UYaG!kD9RjygoHe;K{J0f|kDbeFabDrIV)?x>!BYwpJ6DW%uC9M&d(;a%+`B%y zpE7MR%G@BCz4H_@i&fC6{GA-YQ#*{(H+XRpmd^YT$nv-5|2;%?hsk+3@LU@vU68`0 z^JtGrSFYD-&A}@T7-WNC6#9mj=1j2n>0qBvvrsAZ9@Yk5UAZ4vb`Ac9@&E&Vjb1(t zX6-$JJ}jw-n)Exv2Bw^v05h!&3WVamU{Ayf2`Ufu!f#kec?WO&hKB)4w=yCe5jy&C zgoyG^z8ugA0s7$1X8+(wbHK_jk%-XMk0W#`H~Hf?%v2r~z!6~zz-)Bo+pW8jZ?rjZ z8!{#s?8jbl<@bi*w|6`<8eUWqhqGMw-VAmlpBhtlukr|}tiWEuX(A;@xs-N{Fm;_r};SL3ha<8UhZcsaga`Ir;f4fny1 zIs7udB8~#)Xd;9*kecYb+q67zH)4)bkL#3yyXDy2i4nqxksvBc<#AesGPw=FSyQHQ z=W;#@ui{-sDfer1FR(Si)5M`On42kSsc6^+pwY+#=14CnNQ#d<@E-f&fK zNYfi;=nVzTFg3*L1K(!Fp@;DDuljPQSHIi)b%$~PZZE#O|941Veck=tztuDu7x%Y4 z=B)pto{|->SdT#tfpU&AbJm^3`5fBPPfA-7bsNG~_-@Vv(0m23T3J7-tiO)|^79=a z^AP=06=Xd?c*Ipfjsm3a4v-6oJ|;)WWeq@7o)RAs9|K7J9UzY)`oIDOMBTWmxf}<` zb$1Z4zKG@)CyTXjy8HSOesSx z8?*m%lBYCavVu}FZ5Jfw1p_~<6n_=adiSrwDT&33yi`$a!LL0J?W;abW-TA(yr(R~ z#Ug|uI4Y-9A;`(!oZ?EPc*DJ*A?v%K&)AZI#y2V|Rn@ZTL{5f*o&}JzEzoYg?J59n zsz7T2B?|j0Wwthj*tt!-es+gNng^Z80r9JMyPEvn%gsKlS@`oQzzclNbRPY z+IBxRF&t{xRs-gY3b!6~mKkFz^3MaZQGskBJ_ZKcIRL#eMInFX8gAe2#Ahv7O|1Yc zx?nJ|y#)~GR0VA98u<)g&20^UerXE?C6|o=@Smmtt!o2R1)yJ5Ah0bmDrR=)bqg-H zfxVlHyGu}OcL(#5#ZhioPF}!s3OFmp%8f8Z+0Wc0X1t{1l{jLrwDbQA$G2j<66)bN zS#VF%O2AbqE(IGJi}=^JM-Js(fP4#Q7<8`9wz2vojj?(*r^FAhnK|y3brZw|Bs(;y zwZueNo4BMoCX*f1JFK@Y1`!%nLR6r(TGMYWNb#FW3Kw4hgSPEg0DUlBB|9!+$_m99 zC2phD0KDZ6C=_TfU}WVU9CIw4%cl+VGQ^=sdFQG@jV*p zv#`bhX}|WY-`q3VFv$zC9af|KSxBQ1MxA_aM&mcqO>cSCTpo7hp#lOGD$-xbvMN>U z(m7XgJB0UxJQ(OvbNpM0Zpv`-fUp5b-gc)O4+zKfHUmmFN-Z6aUJND=KTPfy0oLpe zCdmC5XC;$+;(sBxSxQ7i8H*o5>ZKpFkh_{E<&%2yQ(BEYQf>w&H7YjAWV?gbe*iuc z6LX0+!IeAs$UC zGoVfQ<{l+_6^>rst@HfM0JkkaU+7kq`{mG$(^))^kB5|QD*~l8RBKtoow0xQxF@*d z^2rcRFPMo5<|udE^|RqE9yNPW$Drn;| z+T>Q%Sc%y(W_n5+@QSqu59n<>)+S^L?GNIS`($+&tlw-e0cg`K1+WqaB<{oc%K*~0 z1uD_oHUl6wT>+|U1N27#K~YERoJ#e!egGJ(0`XCddrq4HL~Vgy(c2ybK$Z%$t_{#D z0MfMuO4i%v1K_v{R1F|L;o^sT;T8btTLE!*!P?b!79jC9*We`6&>hKF0cub|QIl5N z#beAS$&r;JSgrZ;DVR)Oj0v@R+ZZHRrzTp3(-pa`%eZVsf}U!EV&n$U0liH>+f$l= zSJY;*awMY`U^{@k+5jcnCL;RU_CR(3#QP4Ab%;J>PCL200T7=yAXwMik^qpc0*NL2hey=@mj2%?SxjOSPGJiIzq^Lq!N##W$fx?n$JGXSVa1zcNM)e2}Y zfCAeBrRZ%70B}?VS_dHaCbkbiL2ZGq>TRC_;G7Cn4IuYs^e%vc-GN5)hLKrh%EXd% zJe`ZumeV(Z_k|dzu?a@|!29l}Mrmj*#_7vqU$|XJztrjHzK$@Si+M++zA7V69m!n_ zk7V0zAi6n2ZCI3YTpf%&kp{Db_5^y78`x$kLeh)c>xRWHL3Y&*lfz;!!%;(w@Jj74Ro0E#G_9Z7AuMxm z2>qB3&S~(mpZ@A2piLO{MS>jqabKf9$H_3~qsK1;EZst=zS>*xL zZX$o>mboM{jn%B}lCH;MLgTqEk~S(?u8;D_Uz0unfFd>1W_cOuzOFfa)+mjJf@+rg zL&Q#Fhu2{e7 zE#t2xWq*4o*1gXer3}3PZ?XOeSdUY&-gJyPLJq;t0Ut@`^MH2*J`dPF=X^w&#OW27 zKDJ-7Jf$8EWlUI0+gxJ;laae$4bmR3q`fvUP?HaTPi5ZjQHLN}q`an;?lobw+*l`LrH|lhH`SYfwPVXsy z-mugeyyeg9sAW$}otLldY~;1|ELKu=+rZU#I5P1%=gzNc#g$ zh1JJM`;8}Iaxx^W9;!$K;d76)Kj>sweRpYp@QJW`FKK_sCt>x`(*DrnVfEdl{b9!( zbwBIEu!oT(SbEfGPX%{45uyDgtM2EYehe=U*J@9N)ZGek1GE69KgRs#J&Lo{$q}`6>^*`jEF_FGPM-V-#j^lC_ z^2nKlsvDzLU-Fu2JNFiKI6nlaR0Zm>ej-zzQLupUFq<%vN5#X5?E-q#D*3Vz_bk}+ z=wO0aH_W@;L*8eDb!Q^(6*nh*En2;Qxk1vN5B5A4(d%rv7c7`{^0?_>5pEW}Ry!k` z32c$Pe(sD>+6+oyjFmg9OCE|>@diI=q>$yI0@!&GlGn16DT!kV_3(oSL3hdPHRTxPLPNfPhdCAdo&dym2#AJo! zyq5fL$1qz_0aw*Z;KP=dWxiS!hmm9lCGR!A^RQ*b=SFD@Uc*HBumx7IS{=5iXDwyg zL?DRr;xA9ty*uATcQcw{7*(05d44tWe2>xG-DvJ%G)EiF zW}~^M(HtYrb$SWm>wAUpb#Ebj9V^atw7zDKa)VxLrgBe%)~pNmGV3D@IHd5F&X)Ul zYAg-D+HyZHt=Y5O-&u`+XS03W0HT#!` z`fJSr{$^u&Sb)|XSl+>?H3#{cgUiDMwdRnO5eCn*{?>+$p7_(r8-F_c;!mVM{&X=S zmC*98L0WTIxhYs{?ob{TqBVz?cMH{;Bg*dy)0#V$ckiGzcPj4@t~GZKjy6Y@o1x&L zON91pdC!ho9N%=()|U6`tUX!vkFm&e_sHJi)(ch{PGmdE!%N&}*`XC%MxJj8X%5Od7RgfJWr4eWs9q5I4@ z78(>D(F^y?J4W=zZSu|$vA9d#rF?KtgbXq9fzboqIyE%;pMz}rJr8!rSy5s%{v`E0 z6FgKL81=&7IqaN}OdqZu7!5mz1Eb{LXMGwI8v5YCNcrrCx){+P2S&-g&mhP-00%@P z2J(SX)1c~@dmggF{qW$k@l7KiTvi)AD)GhxwLXo@_$T-g{>xfGlGHPzoTHjGhD(9Z z4MS^;!K>@tFCxAFAt94a#(ri#DB|}H+4MtN?k;G@@^O&-mxn|4k^k|UTzzF9o#MkT z4&i@%0ziZvozucrW0+i1*4-J_fpmuh3(N z7Ri5l9K(SS-jR6I@Y?adf_FRK-FOe+J&gAx-g9^_9^*r$EBLy`;7-PyFlmfYBc+2os98FAT{SM0@ zY$UcZ>eXZ&iaSslhUk@GstBP2A#@>xoFNn%N|B)y6G|gP$q`Bgp|m)Z)`il(P&yb& zwV`w|l$@cotvl`OPTP9Z!QOPCH|b(&WGvZYsWg^S`q1Hiv^tKq#Zhe>U5TS>aTL*? zqWV)pe;U%C*2UAlc)Au(P4QGPfDR9!x&gFl5KXaCftAXv^oo_7R*D%+NrP#|V0vXR zZF`Uc6DcB*5)#RtNXrvxQzGq4q=SicA(1pm(SBH|{FiIFkQKKkf6b%_g_EA(Yib_Y(rbj4rG?k8~b)#wDXu6d`x-k?w zhHA%9(-_i?rO2_=V=N6BOC_mPkxJWA>0l~dNTpk;q)Q{eGzv|ls5FX6qqsD(q)}2D zjZCAoG_s|UBaI5uXn7j#N}~g5bU2MprqQ`HvX7&JakOt79UMm&#?h5=bZs0t$I-2E z6gr-w##79AiW^Us@su>4MvkZ233OosU7SEyCeXDBG-M);oJgxDlHVi>oJ=v3DQ+?i znM|dVY1d>rFqw``rrOE0Yzl3kLNU|GF^y`c(bZ`bH=QigY07jenNF*x)2``sayp%x zPG3wX=XAO?og!yYj~Ns@gHmSD#2GYW2H9s&&I~G%;Yf$7vEoffCl@^q?5r;X`Un@(S()8%x!noeFe3bav#ji%VhW}_S%mD#Am zMjLIkeKuX2O--|D(;V70hYrl4!*l5596E>ZxpZ^EUL(&jal?c7H!X>-C1-Xi;iVcZ5Ca~qKjE{EsL76NaG+c2VI#**XEIP z9^INpy7}ZcpF-zT)O?DWPjU0fGM|#?Q`&r*GM{YoDQ7;F&Zp(`>0mZ}kxiHJKZhc7 zsV5BA>40Q(Zna<&&m>yb36=fFcSgs(@k&D6W7k1(aMsDFrmKfMyhsy?}BG zXjuW36;MS1Z7iTy3TS%)9W0__MO0fv7mCPPM7N5_tC&hlsH}w6mC%6&bZ!BCv4H9p zP}2g6SV%n`F>rNhvF7@hUpG3Z_@-i&b=a6zuZ$wfXjd8SE2Cp& zR9i+D%jjwu)s<0G8EKv+uV*RpS?Wt%5PC3uf?&s+0bL4!E;#O1H zYN}XG8&^})^OUxR9BXLf8oIiMyecTPg5oO4Qb|dblu}9OD(M=ulU7kO^mSIz>MFWg zMfSB+u$FdL(}8MASx*zeWnNFK*VD%Jq}xDI8z^}LP252C4OFs$c5R>o8|c^uy0w7{ zUZiy|(zeaCdo!KfOewF^#Mf!Y>tuhON?xbMuT$U-+P8xa?x15k=)w-Vyo0XoAmiFxQ`Q!* zKnWjG%7--ZLn{4{A`fatrxrZkYv@mjnA4Jm4uiJIhaMg|>XFeYW5%YYjT=8<;-txs zPMK<(JqHHSGP4}>=4a>R=H(X@78RE)Som1!@3`+ZSaJiMLx#h zWi)Rmcy|KxPf(Fs7F=b}`4}`lSb#$qtFl!T*vfjwOJl5@jp*WGI50&5J3sJA+-2s9 zj2b@+Du&}`jTt*@*w~bmv14Y98ZSeESH0u&jy)Kn1sfS-S*ONZsJ z^d$NBQljEc)c7h}qVPwA&|yCWnDBDy{BSszO%whI80sinatK9)kR_DaOx@Cty}~;z z8ymJ7DlE!CsxWv2oeU-$RtUj-m&SYbq9+&X3Eh2w6*uL#mmbbmXJ4A2O4z z2r4JRPQuk>7<_ryR+I%5tZth8Opm1V$ujnpt(5sqIS8$pw>0DzMzLXZxjX4X4N<;y ztvC6_Qfw?AF)c8>y^uF`P&itc=a_3!uK!4eSG>8LW27R;6hd)A-eY!bsQJ!NxEEiL zWlBwY?1_Jg1MR#yC9JuCHAeEqsn?3$xXvmTXZB3VdwkJC`|SCS;zeT@laD5L-dFVk?-E3+Aj2U`j%n^W3~bD4xx5JSGB$zI9qO#+LFG!S){@ zs=xdD<6J;jIf@_?!kA=KZG%D=SA|L#Ir|7}f%PXw%;C&)iX8UgZZ%dxLzY%>^X$|3 z%`N7|6csuoY_K=u)!H=`6bX1V#SuU6`IVWf4jA>BjeE=!i|mC-iY5UO;md!#_pTga zn4m(kYBL8w6>I2lY$aWZt)lIp(5_Et_b0UP6QD*1KGB5_{kJEhKB~H7E)#LQEyD&J zM6Ev`v9>$=$w`8+LzZ&!w@i=R?8V6B7TYtSZksL8=}bo|g&v@TpHQF)1rYd?t`AB; zu~?9QLdQO#gg!K+59e0@gku{MD!(ufw^j0l^g~cuSZ}UkK5)&0C+?`Ak<1b7=RVQb zEL=x&m>j@#d2_^Xr+943DlX11vi9wZGu}QTP9H}eqZ)0Qw}|29%*}1_hwMi6=|8_3 z27jTAp>H9yf7pubMSc7CiSIv9f&a|SNlwOJ1>hV2vmD;q1?(4A3*BW==1<7xyCX?T&9l3e@n7YxE@OiN0f?S4Q!5twwRm>4Tp7 zC9VsuYc=FEAzzys9>s_Zw`XKSH@JkR9aTeKCph<~Mo$qZ&a+XrfdfipE1Yf8xO;{t z`?bxB7RRlxqA77?kE5J8Iu@r3FTCn$Nb;q?{uJ9E&8XCi>?U1!x5vH6)*mBmRDc*3 zacQS4V76Z3u~%j{KKgL_OfBe8V0=ja$T5ycU&1~mMnkfH`sW(Z-`CJ1z;@(yjkI>B zMtVjv*tF9$!>dtzw{#3TqwRAf3Q!3xPJDB7)tQ!Qgo8(ToheXuaEDzxjgtG5qd!&j zr;YvTih?Hx{a^589B=P(;W=pSY*qH0+ry*ocw&BX;YqjpyU?thM#uWowf^J;Ew?Q8 zB1=4md;CtsFEkp^kd1~iZ^LqLs8c1&MhcCWNz9G^|APAauy+x*$Ax-vC8k9tn^INo zs0(enEy(wXcOfq@7A~fwz+1Su=LzhE3#<+aWf0$DATE_tV7}>^X|y<=H1QM}PciY7 z98b1*a$t8JPn+T?X#hWQkU(h(GAY85&i{oJ4N!^L z<*17k&sEO$7N?$fAqABrh+=SSqjmDPSWfJdznKhlPX1;h&^7s+NkD!BTSyQqe=`Zl zA;;kwrCstj4^iCoX-EQ1Nub3Ev?+lOCeRlNK@fs` zPW+HpV`4;|RcxCL4dP-+xnjsO>v*=21LP~=6GSj@hsu@|6NN_Ii2<}xX^d5^$F{%$ z7_veKR8s`r63aTOu&k%;vIx$LU+oqu!{ux;3T-)dV1Qb_vj<+J87i)ie zCaef8?>#s-Jpx8d4n$C&LSRr zN8?*5d$-LgW@>vuyk-r0WT~)k02>VX$=R?pgUtdj&|NU@^o4Qa_Hv2MZZ~KnkZuRJ zx)<6Fid*3daz`QNiMvyP<*TQLf3vd#Dgpu=uqaVH36_2{_*OgincTHerm8zA$8hJ5 zeqdn%ZWT_p#;QVb8@me}MvsQ*Z@2Mu0sSTrxD;93H7;F2G4D(Q8p`hG?ec3|kq6&! z1-Vni@!?&)>t@~6I{{=>P-&Asw}w4|+xGGfMr>en9K}{vtq5!IE*Q6rx#>UuAMw6&2)vB7ZM%fs4R}`-eY@ntw~5G%j!F_|FpJi zyR;wMY}a;mS9k5R)bD-fxfj7pZNE?Z{eFEpJkOoy%*>fHXU?3NIdeu2lN|IOcdD`2 zUVDE3D@=HXRUvyXj!_(VedIf=Etz50V`jVDuH3&T4ag9&w`!12k2K$p54FAaJsgR` z7v}wAk)RK&I#UbuCAf)Xg2hmjhs-s1)@R}2CUD*L385`RQ?b9-fRzey(R~A5c#>8< ziIcdPNS*ITSD&N-6RBzv1x;oGeIdvEhE;>iSlpd5H#0F4?-VqJKV=kEr}B_zD#~@< zj}(HHkoIz**Ah-Vc9+b zJ{G8XGM$)A#Z&0S6wKv+t1%2AS1gAbY71q|^_J;H#`iL?) zh}9iuEUsh^N2S~52;=HOzt8H+YfVti5=5eSlgWzTHH_)K6%+G$?CrYQrW;5N`Hd1e zTnjx8_pS`2esy{GsiBbY8ru1Oqn-A?Pc84)(t-EMFC2Hc+`g#loch{(=%ZYrYl(*8 ztk%JDZ6T{+UYES-a5%KXPq0|Fy#s$f=Rbq~(2q`rYo3kuUHNTC_;U-90{5zL2df58 zh!ZB&dP`MFPBptN%EPLUMZED9LDejr%%&nsHCBZU=4u>EVLy$z)dj{}+*DPKE12}9 z)o?ddT3yUnX_Xcks!dRXtNF?pQ%O-3UR0+V)i}>miasrtEE*O(&O6E;scDsCMyFZR z%xNWQc{n5~8rQ>qmuTET{05aXe!i=i$2s=Rl$M&7tJmd)>!znK3VC$wV)l=8M9O>d zA$*@)jn5g*tl-kALYH2hn&F{Kt9&9aJ!qtdCN|c*P&qT3`AGPH3JeUC14XXE08C4h z(}P9?$<+bf;{rG?AgH=~TwqXYT6%gl6-P3zYn{n>^u1qEd}wL^*{Ic7%&^f~teK+~M&@ z7V#{8L|VF7iMkOLl*)4=;9ng)A}9@D9&m)@b=s3pLN@p15ok>K$S-*08Y$|RA*hfp zXp3-;ehD}3H3ys9a3xeN_Mlv9T&uHY-$HRA}aQ(7PrXn#*GMm=@ktIlp z!H{d2%42P%RX{GZ|I&wRp7C&?M}sK%kyAG~X$HK0)o{e>kjDlwCK=pDK=^(CZTImk zsXBE8R++KzSX;*~7|YGmmV`3cgh0W%c}8r0RP*_&>Jn=K2Oa+i(gng#R8elVDNkpu zDmAFggmk>Deecmn2Jy1?h(H6@X{$}Sxu9+8Nbn*%%^DF@f@To%@au2#xp_u_0iEAP z{P`27hO!79A=cQdg9NJp<&3<#nT+xX(U2hM$-b~1j?Eqz+wVS6SLDOLC#-05a8-lQ zT;%%!bJ@b#n!84EQnhs^+``OIR-KOus@1zyTW5usdv{&f9mpMZ1a|;kT5ix}t^}%z zZ%c;U?8BqBK#3RaGf>M%f;?#O2TbJQPha{wV>~l4dJd5B(2R~PlqR?D3cz~?ax<3T zG8?A^s^-Ro!!~_&wzv(DvFAKKJM^>uoJU4MTCT_gOnc+Ouk(1lAtN=OtJWT{&JH5n+n!t zd9&fOuYS+tkDIVT99O$K#^5sw84cMJk|*R( zb%qX<3&P_O?q#>W=+bP{@sANggIx$G^y*{#9!6nP zIXb!3>j|c}(K0W34xXf+%FO!lQ8|T~6&JC&HU&J$KAje8sd+lBfi1~&Pi_1I5*?mS z(TQ|oI))!Cub!Sx7pHUj35Um&vEpPaF~Sf$LEKhGm#33olKWuI@ZWxX_hVe1xBzU9 zp(Nj0;E{zoiXJk({_RaH2h@APVl4(+u8EzsZU0+8?D$4#e0mO)7zE*!`?g4~>x0)b zzhJ3_MRmbEn$h+i4&uE0`f9ZH9=mVd8lkw)RIi=b;Ij9iaW{a|p5K!?;7-Xg)yvQ8 zd(z@F4W3a8wEr9RiJOU5Yx+Rc&fV7!WM&=YCHAxtu1_cb85B7KsWsyq**s)2&4mKw z87Ty90}?bKK?4#rkP+^hXVA_W)H;JYW{3hcAF=Y0g=C|hNrjB*^Xbo6z?MMu!MdF9 z9oY0iYm5D$_)n@sxc3x6$+UZ|8Gut=Vfg&{b?gZ>rP%3Qq@51Tw9^HIPE^KIs~>{x z`KVg2=sRj@Ra7nQ#Cvg{TJrO+C4FKo7x>_wuljPPEJ8)Z=F&O;U<@Emu^d(9joJ+E zS4W<3-Tndj&IC&2HN+^0Xu4qqSGJH$tXJa0iBKlCUhYRsGyz5 zdj_L^@UM5^#%a(BEDN_vpl0`m0N?rge6?0C;!bAP=VC_*yH+AL`TiZ{%#K1e%QjU` z<=h&qS1vIj^01XAI%rIA&0iU+6z|B5i1_`N5$bC>00 z(+pO=)-RXZX0ZzLZT~M%u{7s_v>F!;=2aIMjQIuD>I!2nNQf2bS#%M*4YRy1pUvvG;%mxCh5t z?wke+o#UYBIWPv9Q$xjb>~w67`_e7Ee1q*4huM+Bj!BT6QnYsHHFmm)R3R`oSsYDk zqRAfZaM$4}1uNRrgiqLX>CO=Xg=N_d)E3=9R}gL@?2bmKVf&TnI=UKNPku2J9z!WH zq>rJh7}^^{2V&?#3=IpUq`8znm)6bI6fmzn3Q{mNMT_sn{xPy|q#?0FfjT(lQ>~EV zeDNcDyu{I%Mjr99|7sn@BOWF>PYI{db4=>;1>zdTVsj(4)x$_8rjhIjO$clFIhXd% zCC^wC0JlUGg#WPsq|jJ^QY7sEVkjvV;ADtJ0&0_~Dvox>(SkOn zeB)_IJo(2{P&|diuvkl5?cVR6Lc!;wdVglHw^n zo)*W`s(4x#PbcE3EuJpMyEDGmD&eeT4SPS~%mQ?edvj(Ha}#Is@4Vm3|INR%O;*?d zj`A{)y2ik9nnz}5u_mY)7hCkrgb{0))%2;{W78*KU=?c5v<=S#2qzODdoCux7!KiP zLanFv+Ip#$d=v4Oy#;T6qwr?-!<%gm4CfMS$qnJXPQW7W~ z=2%dws5pUa2`G(LC6GM<#nH|L6i9~?P$ab_piJsWK&f;!0p(I>f+(51;a)3|1}BQr z$v=^T@QUIo1h%?~6qktNDFuIVG9;185`h3MPNb$psKx(*-TK7seLTL|*{5r_p4DXL z@ZR=McP8H2KW$Op#i)8reP?-q9q~1Z)SO7W6X^gngha0^1IRl`#Z}0zpI}+=?A|^e zefM|an$`#l1!kCDaD}M9g{xnZcxPN)76*(gg{bj77~|lLfZ= z1tn2vlI8_wvuXIsGd96ytFUqDscj7w7Y+9x|Ie+Qr+R*p@5F%11J*4*8+cQ!vtc-y z%5Golzzucajymv$0O)_ZPS}C~Ai|Ve#a_|I+|YFWS9;IAll{@kA;*okSOs=u#40PomBw@=WeUfA>#DHw#IwgUYqoyN-q= z*V3?L44}yro=i!}l%7n6WGYT3TQV(9rZvgrNT%jwI*?4qlIdhJT}q~#$(onBrRJal z!x2PF`Ddy-zhB>bZiUeEifopGh$_`AEa1ijPcd3@q&V`*_F^FL#~Yu%hm+^=2iUdc zEKtANSxcCHbH2E1M|>1EUB(<|Vl~^Za~o@zAp}5zvB-pxOr)Ie^Rl?%{E++7X0^pF>#kg&>K%+9B<6hrD8it}%B00k#$&?L?ffUN{8v}mbD(-+#1$XzEjjkr zt`9)h3?ne{q5SRvQ+T08#TE`R@GflQZoK%-OeR^jS_Br%U0YwN)SBVi8-N{1*X{}g zK(}|@YC8>h3dirY?`iFG$L+bpHG;QSB2E56;jRv%lZyV`WljbR; zac2-HsX~XVr@`~;>D*J)@f2Nus)6F>sp3ToJb#KQ$*X_ur^Pgo=xgIFVNFY^_`VsYEj>r z7wDM!&Ke+{RNwg^D4kQ^AK>>6^_?&B7Un0z=26N#($6E~JhIKB#q(&@JhIQD=6SSx z9vzrRt@EgD9$lEnbBFUcm!4uQZ6$DZVpUn0G$|@&nF>FJvJZUM$0J@M*B}#HlkMp| z1kAI;9;Q~V8nIlzML!l*xElNxWwm2=NnMm}NTo~j$UBAnabhKfqEjd-g?rNRlW7%9 zF=2_K6I;VNUY*ym=TjWgch?CiDw7i~d93t1-i%ZeVuwqYZ_Ly2T{Jc`&nXH12>~{I z-n>*^G47s!cR-2~V8`F>^CUN-GdBp;p4m})DleASzIb2WkS;J`<7mw33F)EH*7TUj z3cvlQR=0n~jMN^%6!%%;j0U(Q?xFA@h7tH?=2sQ1cCp2!G>HhmkuFxA{-t#i#QeoWKiFk0N8+f+FN{KGP#&th=B_!B3_7r zV`>T^2Ck^_LJa8Ccp(OcsqaDz3`rGfg%}v7zITa%lPNS{K1I!^xcQVmpN#XVY(7=Z zr`_}E#C*CqpRUg*-&FET}Kv>7s3H z-4BR@?-jDQ1cRWjQ}8i;?Wv^6ApZ;s%Ak-88lOSu{zHgA9Z4R4oqY@O`X502Qif;_ zcNr$u55zZtxPPX2XT+g6@6Di#8FV>=yfeu+la^)D;Y=Em1-e6_5ljU*!76cC*leQc zEU&@+X=fI<+sB{h=J6-zodT+?vs#5T`~2F;r&&z(_*N_|(sck4J2f$3PBOACfH`^_E*mkJRRGALL4OPUjCtP$FhjVkh9+w)wW>h#YI|;K z53UjMFf~)3d*4%^SDsd%$6isN#y8bxtMmKe1M2TK_1Vja;LO=B;A+L+I`OyLYQVVJ zS==Szo*oF$-uGapMy>DB;RDomfG)OCM;l#gqmb-gvR{_X%k}%_LE&x6uA`j@W!bbU zTf~t)yPle}9lfx?$$4(ahA`XsJmB}Im{XwI!R!Xc8@C-TqLyqroJ}XP-Bv^|0uQVb z*3jwfM(W7ssmqb`@*-Zdf%ijPorb2ve7yE*>92Tti0$qw3Y$lo9P-ZTWi!)1jCJ`O zJ4GQFaxfv6R^Uk5GW@b5RL#c1&5)d03eBmb=$v{o<_HL~2xk@?XSM`%TJlFx?OLai(7wm#h9;kYtGo&;zn1v#-z^vsI~8%U&a3MYv$g9F)A58 z|1>5={C-UR9lUM&TJigF_4oSGoezuO*g<8oZQeQ}O#B`ze*50p|H$L3n2vly2VK|E zHlo2^8uaTDJHBizi zI+0hS(Xu-+V1OV5&*1z$9m#FfPAn$=Y7q)NoSYsCtGks;42puTu`LIKwkUiAvl zj2`4?bniplvfDS#+`ui1gM8sha}qPBhQ~)HX3m{HJs~ntb%z9fZPNMd4XoBh%uR}! z79O9H866%!BPu2{K5E9yM8s?EOw^}6|MvC3w7&@Bn^X4|^y5r#ho2KUJ&|D--Sg^< zj)nD;xzXMpvd5PvO7kJm6Gv?Nn=cNVX-FlG@Qt-{L9m-F7Ax%D)%X)wV*3E^se>U*Q&U8<>-rY zYr|}f zaCg8FvHTi3moIFqKCOG}Z6>Gyj1a9Z;6#OXX?_#glRUQort&RABDc%PtrNkwpoWGa zv_cA;qLZhn?G&9pMdwb@g;R9#6t(1|U^G}7F>JZz~yrS5d0>Cx94COB!7fZgs4K~l3rLt zWra1G$72^{T=JPP965p0V3!Anz|K4@PnmH>&5#>aG97y)u1Kc;DkKD>f9~+!#f*-G z@umv34mGq5IUfK3xbBMs>t9fDbf%suOva*0oXSxRodj?PfYIc`f7ZH}boCUq z8bJs;2VVq6x@-h7sM82?kZ&OfLc)ai5K#P%l6t+su68=Ptf)(BZI=z7WifDWh#TAjU zh;|ma?*>ClP*>^R-Z1!09&}tcj|sD;?bE-?WXY0bH5N7E$`BFx^#dOTu*jSBR3i57 zZaX7Km-aVeZR@tfcWA3G`W_YAV`wW^5nvI&cJgl51Uh;MZElPk7ndF8{+H`K0III1 zvXpgt_1o3&1rtx&dIE4Kb^>f~l-6?&C{X2bmvG=5XjnT1wUe%$2DF2fxVvyYSy>R> z1yXqEv`0Hw3L`z&l)FY~JNdTLDhEOn!rqcb?uQY3 zR!s~D7ku^?i2NxSHmYxiOcqqy+*P7BQ-A;|B2uWX-l&{YKwjv3Za3g}pjunfV0u$u{d z!UUr$lbuDx_QMYu8EGJjO(5>f;bxI0EaVj%`=CsNLs#B8*bf*I*5S~t&KzeFH zDJGDY4z$zZb~@Hht?jJ(umAa>S9lm=TVlRWI6SwU&u!)QGNV1QjQifbL;wCZcPUo3 zE!Jsj$1>!y+t_f7xY!<9CYpKfJ5k)sDwujA%mqZP0wiF7pWp=Hk;GN5Gat?9#vU^) zy3Pw4VPW;;kFYGPz84cCPjkIkwW+6JW^7xU>tTh8L~&*Z=@E*}4sjS83mo`mM`$S{ zPcscL(-1R~P>>mkXuO%C%t%B@W+Wqn840P(ERxbB6OIk*-YEa0HVESfYC`a0O_0=pwwXoFkM0BX1Zxc0#q4yHbG^0 z9JFNSb}1$6r~S>Fr;&VS4SbF1-)&B8pt!7m`H>4eCpJ`;@=c;{Ff`x^?we)x+^(B_ z6Q38eJYFqy`t6V8gsQ;t$nv;Yj3st+gaCe{XcjX84ip(+>YNMnJF7uG+as7Dg8O4b zn%@(wr?`OTfW?Hm&3q>0G-kHUE9bY}8_HS(^I)$4N0vPJ6^|NS08ae4tO#mrkD${C z=h`Fc9GckLY%M^UP8@KOUh=M|kO|-l3!WC#ILrbAJA|aM4jc$_kf%jJ(EtnJ$j<^u z3c|aELeT&g3bz29;w(r&DHd>FFWPe%XS@pL1x*NtEp<$#{wuROoD=65n3OYXqrdP; zmPB#&UmfW!uyO%fYkD*R2! zK3+b^={7=;|3_ZM-Wb-b>b`;Co1bF)5$olV_>`Ax3o)(k`)xlc+}gGLPP!QJ&Qg_< z)OfM7A<7c;1o0{=r}?jki*ym7=YbVx=-GEw<7cE7`5oVx_}YYPHfOXRUtf z#%OXDJmO||)hf2(2R0SHuU5{Qh*~*o!i@p187HlD#Y)$$)M=%`HX3jH&ol)i{B~{^ z(rNbpGfmNmJt-T7+bGILaW+b^QJIbQI_vOL3BO^9m&dbDch%ts3Gdv|=P4Mq+HSE^ zoBA#Y-(u)uClG$8jauLW&qgO~blOHYok+9%{3-jAjPP5}bs_zNJ^Kz1)+2f|Q0UGr zgUfFrtyA9x(&6ema|=bQ?_yUnMSbTk>*_x&{is-tzlYzQT*u21cc~e=J!x3@puI^zwO7NGLE>UAcI#@5_pk_BvbqlhikQcedJVhz*RM|#L`7kB?sY^k%xMYgH#5>B;ew!wC} ztO9y?1*O9=VMVQ`prMBuF|NHrAHr}bo+vdTYv$J^eP6H}oJIIH~c{;Cg z#=^Aeg?=!p*JvAiWC7m^JppkB%N64@TVw%~Z?>uTy)!TUAC-NOr?EKS zc*!$sr*SU&A}huy*tY-Mtf;B-7E<@j&f@+s1H1U#7~j-RN#;di*AdDn)ks$?Z;w6u zhhH34FX#9fvUiVC0hb55j|32e@@o(qfp0VqE#s5BIkRf^WZ_O-4x?{{N@xRWL zY!!5}f~7>swtu|AQbM&lG3J+;%m&tf7TVALgX^Nk>*05>3a-g4Iu!za^mIiRFF5@g zMv~za8Bd9glKor!na7KWpwz;Na=~!-&r%&Fu8PV=CSCvNLIrhH&}Ed| z6OfBs7Y(o{6^1G7Zg|1f6&0dp@`FylEw4Gx$7je2C$$BeC`t^-CR?LfW z{NzU^7#r&++(KFkjCqV&&l22LEz!%MjcO|E$+wb*RMKuZ7pkPPg;ceWnif*WLRArA zsqjss^E$423snC4itu44)lv^L%r#&w6- z1=eECwbX>I2d&5<7$$8VbeKzry*Ur^Kc&rLAMWQ7_yq2b5~_mcxw;?l*LAX5=q=o0 zbWVL|mJyR|@r6|fjNDzS7hP4MgchT}N5pe;cy;y>?<{{@mfZUa2WG-*pILWC2by3SPKj)CoprZeq?1( zw=N<$gu95C2mW#6M4lq5-6u0&be*=vbYU@FT1;0K)8HlKw}i$oq3|UXwSRd*i z%W1%J8oZqRmQ&Dj3RzC$ms8|&ie663mXl*S?OaY5mUDp-uZR4C8A+T{vA_*wv8mi3 zT$Oxibn%IE!*1tph0?NQV_M)E<9P6xKvmQWD&5uO!1tDqcxd zD{0xvUY0tVR|4e&D{&rSE5b4j{vdfBtyzilv%vK5N@`unAL!&tjhnVEN^~XJy^-~V z`43+6=hY*;tYntva!_=?EL0>BA!>T1O9v|pZ8vR!r<0N zC>#d%QR~c)G|y;8*Y;Rn6fzCfT9)mA9hd`lU?9;mH24|vdxnNRLrKrj&S!b-8L?#l z+bj^(bxjDyE6?<{6!|Rk!Lzm0`g|=#;%RucmU(yI#`2eiE^0|;#>gdZqX1fXIM>ML8b*sN1C{;7$4QS(DCLjX+ENYn5>2su z61SGFKSQ3+)`82O#nRWa4YcNCTK6#-pGDU0f|XJRdu`sJaFvIxk*DGWn|IBqA}Yhdng=RDMVS^=t4 zm4D8|_nw0neV%3E#&XlSQRu-WJxE7hV{zb)0GNX3pXZO33nQ95ILl!>O0hHgiZYFt zCfyV1TwoqJh0UPL>(A}`9?$|9atX^!uH^fl7wT9ER!N}Nl9{qRY=uGFdr?kmskOxU zv#}CW^v2s~{>7twFSuEa)*=J5$>yg+3zQb3 zr-uk;n!jpUIj0x!vGGx`Axq(odF}GI;-t*OW5UNweJoVKuD#Z8CF>}v2dLPnnAvK+ z{k`trFY=u}{qb>6j1{owi;s_ECQXbCpOXpewAqpIV)`5$7racsj(%+H<6|EauwPx> zA?hGtyWuc@{nIHb?C5bJ<3@}0-z>j>1~1eLjpB;fd8o#nH?4IE>&XY+u? zxVq@F@QJa0+{6({iHYz!KQq#4B$qXvGXdc~`()-!2ACNc&emzS04f;(Ep~0)hyTTt zik>?SRZ_oao!6+Tm;d^!GhCGVF>!9J%UJJG20-fC@_;@}4;A34sA-8aJ+l5A>OEWD zAs+w!KAHT^Fe-U#54^;vOrJZKTdxZh&gYwp9Ulq4frVCJ$mr3-v^p)*ps&|a;dr35 z5)nwtiy~uAypzXMhtf*bFHQ0rFV->+5p$=dxN_AbX<~ijG@m~3c-c&#I?+;|udOUD zDzStGus>_Kv#zM92(EZ6*ksNhH3mk0qW}>A^~+EJm+)Z$qqU>8A!8p84jJQo1WcL; zrNuI7qG0t&!8t`1UC1InyglLJyu7?87f&3eewjE*g%iDS5@!45un(O$O8q%8Uu(<_ z3z(y?GMF>R1ZahcYYEIGoN?MQD5pD2h^{xN5I~ihimLKWCE6Tpcc4}Rp8&0x5#Z;z zF~Ot9q7I|A>YMvtQM<>~+CAoka>lt5jSd(!Y2v7SX8?gFd9`@b&X2iaZd@ICl1I1+ z1<ng0TY4NGPIGvc0U z2bUC)_us!~##WU~r$LB-#>YLLhn9+w)@n5rms%4|bHwQ9;h^R<4vJa>{qYQyogv#9 zsyai9*N9`I%M(K1;2c$Tc%~RZ#Qq&9|MBF1{)xqcI;9P=X&*c{f zaSnQ$wSX-wo%?ehQ{ii8j3iv-?3?kZFUt}bFrZaT3ydI+`0$ne)jN3*t<>pDjk*QA z#(@v0OYNT)gmPUfG5(n=^zagp%Wr&6DK_tI&-b2Ttp&c^E30%p%N5yf{>{-&&XyG| zy;VJb5}774pZNG z7EDpEww6NIQutbm zUP~!!$*`8n*3z=Iv~Ddmt)<;->A+e#xt1=jrORvS`dZQ`q(UcjjyII`)QOu1wl|{U8{q9U&EZ_IS1~ty+&=-Ir15x_29B-AfImd(P=D()e5h zC;$AN93Q8V8Z>0s3w5&xgmcMv#3Ii5wBUB`Wnx|*&hv8h$_5;Y!<_c+&N>!g;-h+2 z(*riLuQrhP#s-$553aoU1`qlLQ0%#PH_)+GK0Di2_&%BN(zp!n6$x1AiL(jO1=l9p zkPG7LkuA@D%8Vqg09I{iEpU8tZJxLId~N34cW~lFQ*pM%YAQk3hA|n++>_$Yq-w3Xgo@u~8nJaZg8NE0)3CGPz1xp?(&b}fKDcYecZ0cDQ6R6DPRA;f z$y`-So^RDUNOzW*)_p018(>26OLg1;;DK-p#uA>U3UBRsIVZ+5|GPdU;g$^XVRdO* zf9Hp3daK?!uLX1Nn_DiFiiF7cWGL2{jfS43@n7yQn03VgrP&5UDW=-xAQe0z#pZq%wlr8B z8cTB3bNl!}QD-UoEXAFrODGw=2A$@1WkOs(BE-+y3yZv%xz!s&B1>{`dMN?N_V}!j zgW`?~&7uF`;62W1xM~nDEYVo405vk|%Hz1R2{XG2CuVEU54AD14VD~zDJ*dEVSVGE zl(Th|ewOrS$p9RW_D+wFS3ESGYn&862WM*LWzLC=nE`d(BWo*AApf^O7tHeBjkG?^ zBTHn=)Vb4es5CM;GA6Mbd|fS-ou$iX$lgktbu?t%?Ym=;<#iC{SQA@E+t$$q0PtYU zwD>85@qZuc?=kCFU4wB!BkUVk4eD($zP#?%V0=@37lX0$7_bnVJ_S|uKse@d0OI`5q7s*<$<5{~igtxDZb zFt1b56;5J5C7t+0jq!I3Z}SC%xUF@fOzW)hJ;Sf+%&B9SOJL`!R%b z_IlR0XZ@-9J=V8b`op$UJ!&!6X0>4VUx*=mtA`se47KN#_MAx5x|#6!HPB+s& zkn0qU06H?d^F>}FQ>}0X&Q2^;uzCt_1=6R~Ui$ej(;K+lQs>bpA+k+4#iSm|f`mC) z=)j2&2Mw+jlBPD~_(0}w)$BC_^D*3uR?0#JG>G`i?_U(Micc?b-7M2_-Pf#yxiJiY z8tnSVH+5Vb@1=F2Cf3)SKsZ?<1m^~yQ43hKcT-D%%f&OIm>UxoJiw&p0fA4e!XDIR zn+wY}9mbi?d2&>Eu~z!-$J<=Pdcv0zJBL7GncEx4rqn4Xz{B$-4X+fKhz!|5lUHDWtjBpb<-G z*gCgB@rTUB+AMA*sime`YQf4s7FtnI9r@Q0?hXq@?}0naV|4QvmDSO*I_f+|n&aeo z-0RpK)P&2$U@llkC+g^Q9bKrSj=ElYXBd=6?pPbfUyERWz7gD-7;hqYYw0L%+^RhQ6ERB_%hv3{2u*)H(_;lQZ%-hV&$!psF#~<`7q3&Sdh`Io8B+mJOP4|M zvvl<=UB_6CyDV{97#kOG$l~s@5QmX&^y_A*^T6yZ7T4Sn$38pn6IQkb@34mqY;kh| zJYb(1zeuPQk(D_`wp@ewLb_LY7@crpgL*fNdcH+0t&N~N|A#g2skofXj3@3m?An2M zT5!;SbL4xD(r0u9gH8+vP0Mb zFY3o&w5FbGzy0~a6M2}#Nr|GWL=&#N#1u<>`Q}PWBp09O?CR7~@2=oclH=CCIjk-l z7$YR|NabeVel~VI%MAl--dN^>|D_TOX7Q}RcL7pIJ%s1d<_4y5N9 zOZSCjI?2%I9JSPe5QPwp5Qos}uv41@T?^SKv+kIR^kEL0<&`^T{RD9F%?8NWW4Rv&}fi8g%$o@LAciVlN!Bh?2J@q4| zD$8^>0frBpXj2Jq3!{j09Tk(LE>F7?X7>w_KInPO~DUK>iw<>NWQ__BixMAx&tCvL>EZ`})i} zGAK@TX3W-2nK`-CgbZ2l{i)`p{ny>;;j`gR*CNyl^*>-v+FeO>Du#>`c3IyN%C1m+ z4>a9Ud^H=yyHI=wsPBTyuc$E0h2*cs^T17U>N^h_)S<#~2NRm);wIYGM6FG9vWZSN z(ak3E+(5n?C}aagZJ?wL-GsVRl6qYy><}hM)UvRb;mmoKqXEr_&KRaCsPAFqNi7?u zQQPc7(|k>t#-9BeqUIrpB%U|`a&d!$E^lyPvN^FI^r?*wI)TuM*cLo5Z3Guw-Pk~$ zn;OU$!5=|~FdiWiA!!o;^qX*m5@9jI8UzPIoEf*V;dz(=LRQyM+ol@2fY7`V=ZEpU ziQw5>LxYF`G2PA4}4dpfrf_|wIWr~zHxh$_(aji>~9Z$dR_@FrA*hHXMsC}a~VLt&dx9g5n7 z3Q@`?)QAk5P$w$egj&(EO{f>G+k~1?(wO=(y&>PjKas4ayxqrMc?j2cr?GwMwGX4IM%H>2LP zrWq9{M>DEU+nQ1NUOWpLxrsVAzbfFnJ(oOu`OrD#OEBS3kz7(_>IaBy%O4*F8 z$+j7J)4I*bopx_V{&WDqn^6E=*i4r)X9$LHU>BVT-Trur}6ASxQft;;Jej9!?pq-WGmb?Z*HI{JZ)gwb$B*y z<(1Dq;My%HhQ@C}ITXGHC6Rs$%A(>eD2;4eP#!JYf)Z)X7IJJsk+gFQ%A~_vP%5=< zLAi8p3reO-TTnJ#--6OfvlZpj;H|)bf*1t~-3lZqY%9>9=&eA6R$(C)EDV3sTd8>~ zqeGX@(YdYeLW7bFlx`q{p%)dxDKely;{tUaKziC4)8%$Iulg8M_9=}WVoa&bF_iL5 zg0+|1z3&Iwdn|t9NEohc-CjpFgkjq$d^>vM_FDH*hV0ux_PyI{sA@a9{dT)X%hPk!?()_E!*qq^!DC0Bh8eWo|??11sb24p3?0y?isp0${p(Ff(YtFhzgA0vuW-^ zG7N(y(@*18;~jN07@=x5JbZ75;mZzOEV-kX8tbsahWs7mzk@<{H2jE>o%U{wU=6?F zYTSD~fpXagxQuZa)ow$1EK7E+lYT->m(9a44SX<|3mY9UG+Ylh&^E;FMK}gSmZ%*R zw*#%TgA6;!zJr=};4|&q0RU>*;l5->tvgVU#XB%-LpY42Cs6yg9ay~R=_ZdZ;`?QU zkO@d|ZU;O>0Qkxd(!AJ>eO=QEN0HDNsd!f}3=E#V&6}Q3z-zKlSr0h8<+cffp1dp! zGmD;X_vrF2xP;o(8w;L#+eYtthSb|IFzo+@0&UhobgS+#X8bLxw$6yvO~drSR`K_VORf zS<#+0H(IPuxHep=Y8c4ty;1DG1c$yekTq_&v&SNc1-l$ovvIl{iomKp0$|XFKfl3i zzUrnGZ-W@4#Uyg*DQ%;e@$uRMAF2fq{9&Aeo0R#DXbUJW=s>}5z9ifY3#%U0EKJ<$ z3M8oMJlXc39BMvK+s@OPJ+yld4fr`-`nfyr!^~)j)P3R?3Fnt}Jtg3(=Xs`3c;Bp0 zo+&sDH!aZR#llCI@f8H@grD8q$t)tQ9dND@6B;pT|9p?Kkk?TukU^B0t z2%B|0;q06VI_c1TV>udLvq~%R)P5h4Y%{Px1El_t2QF&@93|^QSqj2be9L73YI#w`z)bw&R%oC)`tkci2}O z7}rlJd5h?KMm?7H00SBi-K5>bvmnt}IqcA>YspWwdNB9x=gli$-2l|vKoG};4D_*m z#f5}~mR52P9dpn4r7Zlq!B?;|B?|e3`EMK#Z9LUt<`+X-+!^MF&%XRsG|#%s`Purw zF`=Q4YH$4s2@c~s2!1)CW|G@Z#z=FzRLhEZEju8J4$N0Sc%Q1Qu zTWT5|A9=E|Y+>B@CH~hVeee#{xiNixPW^G(Y;Mg`2z%bhVyZQy>CD`X#-V_aF{mVZ z@B771L~;diCyY+LxDXk_6U(<7`hEgrJ-{DY4k4}=QLT{iqaW4Y`ZGE>lwn1|4O`xH zh`#E)pdstq@4ox44jkLqLnigsS#RHGRmE1u9c2f*i7l1^x>9UC!-Gv}0ZPTCY>hqC zE2r@JXRPnvhsLcq{b#`R|FKqO{k8ZfS~)BrWORU5Wf1k9Ey%(GO0Yv8Ai&t2-~yO~ z0gCC z_5Bu^!a=4m&D$Fup7_}R6EeYp!~X>$Rk{dtI|G4_x-rl=W+3MMTa3o6rScoYG201# zyTxcQyzbejS)SY&8QQ?|!~kDwMcDJ^t7X*H#!vhI<_@7J6rcw=zX;o!YkprPvBa>M z)dUTit+BqF4n`X+^@z>D1&0|ECy8q@)6#+;eR4vYWlBK$$iTGVUgP;j%D{l&kpV$L zQvw6iQd39k#`ATak1a-mfBT-!mvN@*bqm9F^V4(;J`$Hzj&#PPFB5gGT7ABf;&h@rH#Vvg|K) zI93pHbZQ7_ULAs#8k3HzFrB|sL&l_w#;blTb#w@S2pL~JW^_?3u=vZINdX@p+VMs5I1|NJgHI5c$(%}OzECE!^(C-l%Vfp> z)2-vCcT@aT`(cAwXTjbgZe1xMCEwy52(m z`&dCcRr%&2UK8np7KdJPJy2e&|P~V8PwbwCZfN0yN zztqG;gJql(F4qM(8zBJ?`$qyCSe>OMpsHtj9%cwo&}o{t|!06yE*g z{8=e`SaFBPiyoha9mVo*`YjM@Jb#=Dvs5@m>XALIdYuluPOY!k(~w`2->=F4*EHAG0oRG34`1ae9$H-y$+W9Nj#iuBO4T+2Wjv@@;^wrgEami zMINNMgOqZR3JTLzBK;vU9-;$>=-44TafnVIqKk*<@*x`XhDtp~?Wa(W%I@-* zRo+FtA9VloJzJlodE*xK2B_~$J-Gi#dV{VWBL6o?_Xb73K_Q1}l@o6!%TK|(1~|XF zq6_cmYJcGLe0RKes`!akcT!)p`lVZVllNg!AJOV5>K!7Y)&13Y(dwNlyl8cu8qcjR zTG99ht$Txxy+J45pwn;Al{d)uFohka^uuI>Q48N2#e<`!W_H#zenS3!^-9d=+{N=v zrhMUI1A}P)S}!xh;l9LthFQOB*GD|oR_O~&CQb(>Z~3|QQ8ll_oBu3Jc7v-Sa>_^vV|+UVhMr2Ae0(=JX|4$<2W=F2{ZR+n8T6 zP6Z|_e6FkI4|?azc21Ameim4YVF1tRL7#im{wI**^Nsm%=m5Qi&P&sgPN~;K=;Agl`vR!#bJ%iS--DdxOj#8lnRTh zud%AY!=yC)<`7<5>K?xkzxmt2XFm9x`L_EvEdS>6FgN_ZRsW+7bF4q9`Bms~jRdE~ z_b>iY^H;a;CUa4)^ZQrFc5LT$(e8N{!cj7x4B_;9%gWc8iq;AvPJfvN z+=vdpAcn)#d4U0|Xv_(Hhr~?f);02h3#|O05e0_~%--`Y$Ctv*hXD$Oi$gO0^~(Xw zWme+?t7(B+e)8`M#B#Q!L|+OIAy(0{|NJUez@dC5AIE*6A1~stQjlxp7DQa|v_t94 zEoC;GcH^=U_gVFXFGX5gadwfj$84|M^bN=Ht;GwRaZ5H>6GV?OVu9V9>p{aVaPpE@ zZTVcy3ZPy)PLDhnxMbNu zkEUSJ>IS$-KV>hW~?%DIfzT%FrW|TS8BleJ`m!#;s3m2B2(C`qA1`- z)SY;o;Y7dH=NY*E^WO=t;`)~xOa+|oi)-OO=lrvA)&>lrmU%k0lJO`v=2qdXo`{=} za!AklS3r&#(bQbu8zZwPalg(MH%jE-D4m*qUtqymF1N6PSN;uVF6Xn)w;$p>7r^@!Q1w`kU6{rGpe38%qXZ4TsD7Q@pOcUX)v z?_QYG$s^EI5Za>aqOLQI_mOV;j;jRlb4H)je$3CYpqn;9OyZp>1|vnIib*&4n0XVP zxCL*@!S<08-oID)Blm=f3*bfm$)dYB;dSotsKt#b&41)tsQ7@vF&yOMcNT&NjdxE2 zD$V*Xp&v7`)03FwzTRqaKWOAl4B2Aa(>7p!3+7+q)1J~SDl9O1@R5qll>Dd}c^Ys%u=CWqt zN|WFuSQg?uXqkH&P;36ijl%mvB(prgRM>Uyu%K4$*a!D9wZikTO<`1b;#K%2cX)`G zU2R_oN01583C?_Xy2C*$`F!h>L9BJe;vQRVcem;gHERAXZs}m<@>h-e@tE63mSyEy z(^3}U@wkV}Y}Oa4uqOfQMs9|F=65z8M4UX}EcV-_>bEb<&NOP3NAEk9i>BLdGc$BUmrOu<| z_a>cwQ>`-R{Zp#EaNk`XuOH~D^0ZorLLQXYoau(6E|H9Q`EQA$C5kcXk9T&N7E{@%Hp1+IDpHORAj zxX>DYyE%^=1>PqNIMypxSjEcOFNc1_)OFc#C5W4=K^^p+Q|%#N(YY~c!;TyiEUc1ZGFk^M}`qz=e#ub!s(i-$fE#k*4o7RFbi8^ zK$HlNJ9z0zu61P%$ziRUpcVTwPG2M?rNxC7)?P=I;&2vxPK=r&j2A}XwZ!_cD;Hh) zW4bQZ%RIg?!DYTF$-%2g~@t7iYilW4*ZJ+Bqik(O@W4ER+D~p?PFhKJ(BI{bSF& z{Qbwkl5rU&t!M5WbnOo}IA>Q?M^%``+5zpw8I9r8@s{t&Ghaf;k@L!WkM$6TlE(u{ zop$zF<= zrzH1N`t_A$Z^he7lKU(D`$_U0${pU4e5Z0}e@Pyo47fv*2Py;aM1IYk%3TBS+|;S~ z43y-%6yLif*+&`VBgwwX-M;v;u~WHckR%UM2H!2ocPsbaBgyyp$b)_4dzJeJOY(in z{r5`p{mPL0BzcIBJX9Haza;<6M}ELZ_EUZ~M3Ns=9vCXg4=H{>lVq)r?C&E7_{b0Y z$dCBQ!+hl7KC71taJVE-^pV4S zvpk~~crrIX}HA9=cuJi|wx z=_5xeqk|=RmXAE!N1o#&M=K$tBsoSIGg^}8DvyOAgSt-T@iCGdtAsu#$#Kfq#}QZC zsXP%X$??j#v67sijDG@g_D&x;(ML}5k&~4P<0Sbh<;n4qJWrW8L6TFHuqP#XzA|Z| zB&RBq!z4LPnKDU|)0ObalANJLOp)YFWokIGsp(XvMd0~-rxH0;lCzZQ(sfZ@oR0Tl9V9H3zXzUNiI^JN|NMaWnQu*mnbPuNwP_q zKTncNl~i1SIdn~@k~UwG%ars~Nj57PX_9PFGSem5s$^wIvQ5!vN^-f9oh8W?N{(KV zE0x@ANv={1Ig-3k$;*}GMM}OwlB<=1JV{=x81p50iBeb~$xD?5MoE5JDJqoYWlHe^ zNnWm$6iM<5#Z)ZGE0xj`NnWLtnIw6&VlI{BXB11BBtNTI&62!Eu~{T}tx|54WJRg4 zN%C__Ww|7;Q>rQ?dA+i*Qj(un7F9`djZ(c(lI_akMUq^rEUA{{I%Vl%Nv>C(ULwg3 zW!X|mZcvs#Ey<0_ie-}gg0gbCBsVFmR!H&&W%Wu)-l#mYN|HAz&#so_W@XJYlDt`2 z`>Z5y@sYPG${I=DraZS+lD8}C6iMEptbb0DUsRr7C&@dNn)Q;rOR+yM$uB9jHIn?Y zQfHUs-Aa9}B=1oib&~vZrJ-JuUr`zzlDt=Wp+S;gRhk+l`4`HD7bN*LWn+^hw`faa_hozYM#+7}-m*z@U$wVxmfY9u zZCfPwb$k0($$i7#u}yN{w0CZo+_&sqJ0$mQd-qPseaGIjOLG5h@7*oA@7nwJNbY;~ z{=Jg>zI|YyB2Gh~$2j z$oP9WO<{sWm%v>!i$ zOe7)`iADR#zaU9O`{`pymuNqG0-02_pFf36CfYBaK_(aNm(L+ni1w=&kSRs`HGTuv zZHo4rSCE!yzkLlED%$VfK&BGy_irIni}r_ikZDBw<9o=oqW$RuWIECQ{1Gy}Xn*+x znSnBsk^W>7?XRB^l3BFBeSyp(+TXuIx<%Xb4Kk}}M}CLQCfZ&PWOh-o1u+s+q&o+o zD0&IvyK%N83L;=GKp87Iz}$d}C=tv9sEU|T1$SORO+>ih&IhQAD#84KhNuz55i1)X z8z5K^Fs^72ECd*Wj}QPB28<`hC0GP7z8FIA2fzekJc3056N>Q(76VKqCLmZGFtM1B zUr5FeP3`11t|{iYW+I z0JOxE1S|V3DyA2 zAf_W&6ELHgo?tD&OkxItwE;7W841<_%pztYSQpTZGk$L^*aR@In44fzz60fMan3yTE_wgxOB79!XN@CUIl!M1=!#UcdT0TvT~AowF- zaj__%HOeE{CB$MB+8&`L#o`1z0G1L<5bOw8S}aMh6JQy!6v57bWyR72y8xCG%Mk1e zSY9kkup3|nu^hqffEC5^1b+goBvv5U1F*7Kk>JmORm4gJdjeJ!D--MmSWT=#us2|J zu`0nnfHlNw1p5Nk6sr^L2Utt2L9jnyZLuc70f2SHS_B6I))i|L90V99)*(0;FkGxl za0p;MF^u3)!1`i1!C`<6#CimW12)7r6ahy7HWC{U90}N1Y)EhvU=y(s!O?(C#l{53 z05%hw5F88GTx?1(0lEOeJ{3LcGH~_GR*qs#S zLE&fdCxY_E&%L>_e%kP0qiaIB)AZ;kJyXgBFgDv`tvIS`-;6Oa0y^Pu@AxD zC~7JFS%$#=VqXeePJ9LU0I?tOmBd$p4;1?oUkx}&96<1Qz`^1`f@=VWh=U0J0XS3~ zOmHpWFmVXMKLLk}LkX@UkL$rlh{K3)030a}C%6%ClsJOmCcx3+NP?RI$B3f{ZXw&P z;A6$n#J2%Ph+_zD2OKAkCAb4{JifIIxD#-KIF8^hKwBJ7a5vyYaRR|TfRjX<;9kJV z;zWY`0H=tP2<``*Do!SN0C1W(h2TNJ>Ecv^hX7}Y(+D00oGDHxcm!~kID_C(%Jeb% za~y%Q#hDa%0&tEvi{MF$It4ygoK5^R;5=~-!7~(vGiHJt?->g2bBLKQ&ZU_1fD6QV z1TO&oBF-mx5pbcnfZ!#-MdB|6F9R+X7ZSVz_^Y^x;8nmS;$ni=0DlvIC3qchsknsT z4ZvmMZv<~r>bL06Z3HeCmr~#zz!i8S4e)QkmEv-OcL7(4D+t~LTrI97cpvb0aTUP_ zfNR9n1RnzaA^uMAAHcQZ8iJ1i{}lfq_%Gl(aV^2efa}FS2|fYbAg&|$6mX-sp5QaU zP2vWE&jB}!8v(6;xQw=ln+Wy=+$wG+g%?oRCT=145^%e?mEbGD9pW~Euc@qW=+9dO z?i9CE;5)!w;tqoE0e6c#34Q?FBkm&j5pb`#o8TwFec~R1p8@xadkKC4JRt5P_!aP= zxS!xRz(e?nUcm2whsA>gJ%C5VLj)rMkBWy0dI67#M+jo|V;>if62yP|gm{dg1b9+B zPEZCsC7vLt0G<|45>x@th^Gi@fM>l3(bK+Tw zP5^jb{EJ{hzzgCzf{6exisuPpTfx30ULcqR@UnQ3po`ojr9a8&PjbXu5ie0p3c#!4 zWr8UIuZdR(nt<2Es{}2;8{##Bp@28V>jYB)-V$#RObvKjyh$((IZsP}($Syv^d|%T z$q1c0;w{q21o*djn_y|2L!$nUm(!x=>acFfyEH`T6{^G#R1=luLza^ zd@H^tSQ7A^_=aF9!1v-?f~5gJi0=rN0sJVwCs-EnllXxkwj}J&;zvO1XH?1;@e{!w zfM3PW1b+hjCVnB^^3eS*ex=av2=$2H2zCRE6u*-~1t@q$55bCnf)q)x5}+t~Nw+I> z(Vy|p>Ow`UOhv0gf2u-BmPEw3vFAa1WCW`Ns*+5w2B0P(9LrWfT~Z0wBHP;Z2m2qk zA!!s?7ch>b6U07<9al04h69F3aR}A}j3>nDY)#JFfTxg> z5pN5aQc6y+9iSsU(YZdJ^vio>~ee-WxEDl!{;{jN(K3; zC#B;l+V!RKk|-1n_cV|)#H!Fxs=yT*Ntt3*Xe?Fa3QeReu_#cYyqG*uV7sYQ2`1Fw zMZ-MJq^xL6!r`9gQuhBx7cHd90T(T$oPHOrq};K%!0nw>g=e#kgf3vWm8w#gMRjxz z_v9B&hkO#2xrC5+LQ!gYR3xO0!PvR!r5pEx0iHqMhh*B)e8z)L@!* z%hau#reWPM<5<_txYji@#JXz6v#toEyGUhuqtgRpGro1%OkiCSLKk{2dWFzmJQuuX zLhHPl$U0{xw*C@A7kJKk%_P9S6nNv%`3dzETAK2iHMm;x>Vj1AbT zPbRpqRiE5UVVyKnS|?1?I*z+pskS7!Ei=?QhWlBm4!1Vb`4X(CH5(UySM_HK06Ebrh)U=_@tl=4l11 zj)zjNjiT1};MFohUFvvhdzu2*!6-&mSI5&_5SFUK*p`&X_@YoK%+rc_;C0sqi%nrv zKdGI7(T*w$<6(aZPc_je$vaZ*T-Ss1HiVpUu@ly&f#&0v@&Ks|(!rSH&SYltUEc$x zZdkA;aAy%l4U&FBA7G7wp_YCx%mXQ(t7N;NTHS=FhYtZE*iV@*#DPjyc<&rlX66sYMLCJpDl z+Sl^b^o(RUMUa!xOq1-ZBRy_ERuIb6@(jR&U6_rLabs=ItPR3ASS`h+?ZN^9g+|#1 zhkM2g!U|mIt`QP+T_b~HY(ZF_R-lwnau?PNWx_p^ke1JKvM`crOK@Qg;SZb|#Ry9Z z7)=i{nn6bMJSKkLa``5V03BuiC=S%!r>c!IPX zI(hzw&Pw>_wzjldU^8rR#wSW^xPm=N3Ztt#aA~YX#9WUMF4G2( z4)a`M_DiHIL0yY?nBSypu;c!eAb(4x8wd}KWw)4zrP3Y2G^6TsKg*=MJpC>-_T6XN z%cO^>>g7^>Uezn4M=_G;4T|LLl~Mz0&_IfhnU7V{Qz7I7m43DK9BmTral5fcBsGLG zW=lG!ihUxf5vN!%p@#5$F{|Lh^Tlj}3(ps`3oblg%pth&d@-ls!t=#kEF`z!!c)dP zf@>4for8A5bH=>b29g?MrpYIa+A6&iL^d^Hun^4r)*&I|Ht7|L$$Mx$>5U(6mv9gW z`Joq>gr!)M**l~rJWnhrVyE;0OGa!ANlmGke7N5&eRMqdRuh5#{25E%JDvd(K}UU0qdX;aX^wq;~e&uq-MeS zQ80W`={{j~qwy7*Gm;ph5OGL~EApjyuma0Z2$X&Kp)r`_!%{+#+U~HF*qSA!|Rjv7}Z!I3ooYw)UAtti9$B)*j!0bUOM- z$GbO`=$-e3+3-sjHJU`>E88Aj)h%le!bcQpbKS{X`I}Ci{idgJ4y_m(tG!tN7|C zbT(!KUQ6hPPA$#y2qF02bC%}|295%vyOdel+K!DvsVBz3GGo(b_R_r%Y@8GB+EGj!<%<|S|R$;h96B1L+VFalM zdZpn6sWk+71VL&IQ65QoQdO3z_#wgTyXweV z6U>S6<(keMWG9d(A`6&a63TSYAdx(Y)5LNe&?NF?PF->sXi|9!r}5-^{<)|qWps9Z zx}it@iJ8@eqVK#3$mMXct{CC_351)cuL+mZi9e%<|8^cFZEr;;Fjjp2$R2 zc{Zon&0x2w? zCQ?Km12O^2a*!Y72vGk{ z-j+o3wj_$Tr2%g$_g2C2R#9Fai?dJ>=@pd?x zH=Mi(s<)#7Z_afZ=6DO2kH_NeL^N+FqIf$M@D`uvt)AnpzI-Own{$<)jbe>68@{VN z0k>}8ST~d}1Y3XLV+4+H1eN4+z&atfZsb@umaoQQjguTf);9vyScOxqHgT+*%C};% z#^H`2>%RlmiMe$%$GW+EFBa?jQLJ&c!&h$XH&WUy9P5_yqgbr}jbi;IVC~}8tsLvt z^0Qd1apEH==Qz{hOFJpIZsSLVy^oc8cp zC+F7f9qSJA*I2A^_#?;~hdzAPDY$h<$GVg34Yqb>7(t3U!w6EaH_VqlZ&;L38+3NO zb&(Y*=6t0_^QK1erU$(7og!CP$6Gf!PAuNyM)MXoinn+HZx+v6cgNdLa)MxQ&Q*nD zCPDR-IA9&ht$R4uKg+IQYp0%)M$1dmDBf@m#aB;wgh2Jw)A80zP8o|gGnzL%2@A?w zXuw-)?ya}ut&f~K7H?^ySf>kE<7oxurLSY%PtFjFb;f9U$r#03=72Xm-5_sxb(F1G z2FQ5E9%IFlHJUdZcL^$4_JFr^+}l9M+aNh-EZ%ZO^Oh@$H=Km=)p~mFZLs5Qh@3AL zZ~3En!$Fy#yy2LP&szrWZK&gIm|Qp(Z$+Y57Y$fvk)GCSgcD#u`U&`#zsEX z@<_*elw2kj>#|X-%LlB{AY?t-u^uB=jK#WA6zeJhYdpyy>#>e?gj_8aYn+h@sx_RA z@zol?O>>QNtjEi>gRPyb5XWYMtZ`h%XPuR&J;AZI<$A%^&Q*xhGeOo31J>Akq?}_v zh4syea^qO6n?!4W9Iy%U)-2#HJNGup$;)K9MJ(QM&L+sZb-+3Yx1QoyPnFxoV%;u^ zb^CyIPHsKTv7Rn>47PS^u~QUloXGLjVlHky!?B(zcZmgCB zal*%EosU~DaIAm9E=fxGHBSBbtP61K#g6r_ z*yxC9jgvn?<;IC0pLIcQy~MHp4Z905t*1q?o)NGv#I2V)*2{4J9AxdZ_v|Rva|70e zx%G0#dWAec*xI=U7x;RQQ;T?p6;zUies8{~4CUz#yDsyL-HzSTVzy~DE_erL3EMrY zKzHvEE9IqG8g8Ai9#h2<3vnjo!mP(k^3WC1%L*dnP&KCsKceBmye zo;9wP|6u+rMT;}TXfu5srNfJg}>S+xg9$ z*?-6jkWm_WI`X3fbv#@D+bOa~b;2CkYvo^}n{Jo>yo6JnxPbC@`8Q5$ z6LsxiN!DReJJH6>ZCw_%i$#U8sNM219))Mdg4xhoiL=r2avoHlf*M&X%*NJovx&9L zY-%mVd1-VB=BxolH?w{-n_ElF7S^w3OKUOCP|GVNY{U4r(VRZ9U*0dB3G93xlwj*r zU4Q8iuR2y=@4ZJPw)6R3a2{9iXRD~@F0{>cj3wO==0fOH&mtVJnc`XKHCtJ~n60e^ zc$y}kkoX4MsDtuJY$s7KJ|v%#LKYD^ET54=77{ul|0S8N2pyHrOJ-|A$K;EW*@n<@ z`7#dEosd_dsGuihJgIQHd?PA$8*9GV)|w|ooRY6g#yR%1%eQUVg)-+ljf)!BL&h^Q z9!yYCdxo*CeLR{NiboPSg>Zuv1<$%zZ(>$tfh%Z$beF|-LsUHK4&8m=C(`ab*>j)8 z_i)%l#(s7fo?O7Br^6mI*2`f}8N=BSbeOa9YLpJDeZVk2@U;JupR>Teq%-!VbW$kr z#(PeF#RB_LAozLt4deZz@c|CMAirbr1Bu%gF<>w{h^Xrl>wbe7zRd6thOh7%b6tf* zeW3@j@G@bZ54;9l*JJ_gBR1AieV=%*aa~7XxaYIOZp1MD;uzm##$Oo=c~6e$p#l4@344*rOZ9!qlL`!Zx$oP$dl~E-(~TNe3pu!A`orh zx`)7UkH%^Shi-6;^1iI|IA7+N^9Rg0j^pYfBnBPoq&;cik%YL+!?36xT>o%=pC?p9 zJjcT$<}ZGX_ykV;zbrnX!(yhFh^06Df2Nnj@$i`WbHzw6sT2Q%#V6y;UoKHd&e9q2 zKhsI+_<73wm@(3^ocL!fJ~T#rDkq-jBQPl(Wfvws$%e_5W8esp}zU zbv@Y`7F<**bv-#aqo*hszUpGLBd1K`;cGd!?CX}~;Z2Z-yiq*li{T+Z^YB(K7{$Z8 zAP_s0faDL?qo30U}l`m4wMiAsYg{&;N%2I;z@ErnHfQpyo7r5jz?Xi(=gEjH)iYdRT+dcBwxuncC?GwI+EZBnHN&nAk&rfE9# zQJ^+%7@Vy%gwy(iJ!~&f%acs$4ShO5N{88MdHTvHsr9)EH{~k89ciq1gA;cB<$w-P zmg{hwTp1_}h2D4v^Ni55Sp|DQvzzg?;iNE6O4KwCq-G22_Sh0w{KSzfb)HPh^9 z%@9H-d8T{KPS!LbbfRY}7M8YWir4IHO*Y$8Ca^$4`nZ8frHqAJV7P6J`r*-d-$vPh z<))*QM!~j>qlDu4mC`C314`+X34W!vK}zYBO;AEo8I*~#&wWN^GY`z9O!fz6R<`iK zEXq`Wpj+9>1G6gA{ejt(Z9Fi$GSeTJL)p#)?@6=$fjN~OJTR9s*B_W$*@-}>aCwyZ z{(LtL>ZAOdjCXXD z-JC|s%Rmb&dpP|huRwBWNBAhBtb&gpl;3?miYj}#)(3eFjEX7yIDIRx1ud@Z=k%kz z4zz@FfYV5M187O*Ag71fw7PPF(;CWY8P9GglT&f^on;d| z!<1{F;mT=F>nS%t>nmqCZJ^u&ZK#~(w2^}KuiaSri_<0w7PWR$4B~mGhjo zP%tRkEtLzPEK5_6&qpjvt(3=zYOP!hj(WeS zQSB8hAnXpxmEfq4EUKgO8Bv{-tHDuUSyX4`JEFQM*Mg%WSyWg0AfM9_yD6CG=mN)O z+Fik%$Pi0iAYAT!rj^QZS=L^iUEg*@QK?9~_R+ z+Bw`mM#l3{G~L?zQ4aTyk%iSogi`_M7?&|dcT>nY9gg~0xlZ}ViKs3$Ja4@T6`^=7 z$ixbryccHC7J&TOL5kb2)DlXR z9hw%{42=nr-QQCaVs5PXvw)<7vgD)Uc z4Cd}3N9XYG;7-=u(yb)j3((u%M&9Xi@5o-KQ{ za@Vo%ItkGy(e<_dl1m$5=>*@+ESAut9Y^A0`6a5U-jjtn3RQ^Hpqvj?lwG}#ETuZ8pOq)yr zesOB8mK4rA#q9J^Hh0JcX@q-hr9Rj2pWmihqu19OvIJ*RYalZ?B+OSs7%$i{Ggi@) zl}Ap_(UMFx%4TR|=3*8zrFNO3{L6DZRcXqqJPqVuh+_k@Awa$lW?Nn^*zCh=Y_&4dS7W~`@5x^s&pc(6V)iApMj3-F{Goi{5o;A(7xtgZM^4u%<3ZOe zpE%usFH;8UZW61n1;~Nf+Zt*1u|}AEt>O4Khw>Tf$lXH9oxMrJ|GG88K)xd^wkm3oKjU^OPB=*8_^eqYo;x z6chmwhm<)?kyQ@(VPzf^k0|&QC`IR!7qDnnv*1USg@`_;XgvD3vKaJ)qH}suSps@W zF*rS~ECoHI#NqU;vfST~{zS&jA@~51*BmNX{k`Ted_~1;4#x*nyyghO>f<#>3RZ8g zISL=f@M3=trCkRbexa-<6oyrzxsK6uTEg4Nk;P74oL0fDI|+YBO2b=ajf8IOrBIbE;sqN6Vg9LU`a-3Y;cb zKYGpSg4NDz&Je7&UUQ~kwegy>1gkZ})TkGfc(}{P_`5+_qfitDUR2^E&>5IFC~Mi( z+MH6`#uC4zB;e_6XY{g?kkcKEUQrTpx|7kXN@7lTF?vl&!s%{CuPZK2_b_@xNy_P7 zMsF&~INitSEhRap`-w)}R@R|!B3B1k>>VWqk3Gof-%3hO4>5XIF*!ZV=sm^a^a!Xq zTd-Pr%{lmB0&4NT63U~FGR+4{Do&3v`cO&D>2Wfgi!UO0&3S^=9ESfWX?WBLruj%o z%jrqdoG)0-p!2Vijt8Eizy*TU)GI_hR@U=^oTk8E1gnYHTqszLz2+i(xxi~K7OaLi zy8A@gpx|LDpNfVk8=cOA-%_T@#OW-X75A^^61?T=HGdPV`d)LXVAb=Q%h0l3b2+TN z<_hQ|)o039XTXnmu56>LoJQ#vN_u1vqx4HN!wV&CRK%UI5kAJe(erFM%3rUQXkvS3u*c z`8ZvmTmubJ^K+V2xd9qaEx>7f^%iIXwIHYMlslja)k2&mQtyH$Rts~QM7lg&D_(OI*5O`rH8STle@DK&<{D%PWl9xXrZj3vUzt)nWlF1- z@|7u_TH05p^lBNWOm+sfEJ1o-C8Ju7Al_FAdh^NfzabRiG5>&~*IWx7ulXllXZg=% zm)V0aA2O+LsH5W!0hL3GBU&|NR^PIDh^;@sv#9SGXV*WtTm8s58-&2Ks-GEW0~+{O zZ1^uXe2hFZl;PkT+$+T&_py(W`pkf9A%BkX8A;z!i zuOi${)svF*)`BLh6ASf)d$AXCN`w>s;C&%mz_^S1k#1}h0qt%VQY)g!7?1y=4BLg( zN}Qf!w1`@n)ANk}pjP4Z0;5IMs+?YAw3u3r(@UV{I=r5Q0js#0Mn&V%3{^s{j(A*8 zCDpV@xs+Oi)6!~s&@yUGPH##XQ8zF^rYP|Qo}jDMRaUtm6E&7qAIKPc+?$6tElxk{hQIMY6DL1GFnY- z$mu;stE-JTz0YV3wK1m;h(>F~z}x3F)h192nh>(E>^vl+u~`}Zhv94tKVmpL!~X({ z@%LX6*{=Izu=t6nC{IWyepj9FQ>Ftwrt^$q>{@D5p0nqS)>fNw`hsXg9W{rF{S!1o zv^>{UbE?#YVQTIeozfQ~J!o5|_Yi<>+vR-qWV3qNj+Xbt%m#yDl zldFg}YE56~ZmYK73C>Y!A^mo0OHSu0bwGbqTXEW64fAK`4f&YZA$aiZq_&10n@~DB zgKuZG4F%DJ(nW1ckS3I_Dm@2cFAH{4e=a5p){<|j8tq|fZ&`Bh!dEy{_iiC#gxWyO=H4Sjj8q!}>=hzLsf_^k;h3xH-Y>Yu zsO|&f+y~8r)XUA?ESnKy)yCAGcr$G`?NdjnO;mFip>b+6G#eId#cAYh5u@w-&VHGD z_$pw$+J}mPVb_13-%54T+RM_ytwV&`2GxQG4STuUc0P@L0gd)tV;|S(=+oHG^E*N9 z?BsVp&u^EYTz2y*AK=Qi`jex4fGhV1Qtqh=u8FKV-=Q|mLxNSxYaSM?l2{&03U1UX zYF{cDHR@!iQKzc?D2N($n%bWrHR^PA06}Wh8R|fS)I(>gg9uU&ouv*YNIi76I)otg z&^hW*g49Fjs>29U51pqDCrCYXzB+;+_0R?CNP^Tue^EyfjJ1d2_3bg}H~8Ok4C^<& zRre9WwU8C}D;4*sV3qKi#{{dmH=g^rc|x#?dCil8Rn%*q609G*=4rty;x*3*R$;Gs zRH7^KOKCgLEu=0A%OM;chYhD(t++OpFVCC|fR|PAl z*SscJIlSg|!OHG6ZwOX4uX$6jvU<&1g5~y_w*@PU*SsTGnZ4%Uf|bc@-W9BjUh|${ zW$>E!1uMPRd>~lq&?bw5+vHbuG!>rOWU;HCPN>UgrH^j0|Otx_jY5T&=Q8(r6!ewf5XiZ8XQQ^*I>WjnKdSp$Bj27Dq|sl4V> z!3y=7&jib2Yf6gYD~~_bsr-g{s)7+}>_BGdq3E%L7>)#FO9w9nMyyi@W2|^?z7QNLs^vWDH}A?;tD#`->%N) z6kqOu^Bw9OPUDdI7r~0}HNOg0JUnt9?FsRk-vleJ*ZeM6aj*#7sg6Q@V()a9IvOBS zh}f-;0l@w79(AmmnSQK5NP&8>4DbIq^&7zo7?<+kuLg7o45z*^STNy?)>8IfbuRK4 zWfUH-(q=s~M;8krHxc{rJ2%b}b-y|f7Faf{Q7{_X2h{nT9#k>d*@x5xoE}!Ef*w(S z;q<6F-9M?vBbO$c)zVS$W9m%Rpw66xf*}(?Vv`3b5rx>t)rIf@iVvEAo=_KYitn6& zo>Uieid`;b^prZwm(kPeuRQHD>TG1?th$8Lsmfe`R`7WeBu1M;npZH<2`m+T@Gn+@ zNh!{SpE^d;_;3mEd4`h{wlAo^@pMx%dQn}ncVj`-ZxL)0^rN&|B(CPH(GALGP%mIQ?72aAV(9S95w#T?u+$ z{hiaP%4&ZRElS)(hqe?Hk-jh^L!!f4_;QVjo@(Le8ccLiOMpbPTi!?>kBfFJerXh& zXb;psRIW>5e>!37kmN&k4U%-OZ+`9Kb1X;@{RW}q$ojI13(yG=#%^KO|EOC7VfG{S z4?g&uSGNZR|EsR`jY&I$f*-4Y^57@x?x5hO>N+0$Ox+t4{9IkngI}oogMweG8+h<5 z^&k&MGpC}gTahR~`l#iJ#P>JUje+tVX6>Jvm5<);`wm6)R_hxidZYCf5`EVC5{Z*? zD*dvDV4_!BpAk+U!ubS=US)lZ6h^;QkK&?6nrX;g#5?tvuiw5`H}O{dpdLrg(7(`i zKB^~C+n?0UJnFN0+TXzV5Dn@ZJ=FRD|LC38dr0&->m4M_t+yCWzNlw?34B$za4+9f z^mG$F772V;(Yu{n%5=;l!mT&(fDUB6Mpby!tuRB5(^GV`ktI^Sh(Q*;1K}*5Mi*!6 z?lP;k49qDyhxH0hQPb8-NK~fv0ur@gJ%>bLtY?wz{vjh7*j{xTPc;)L3(w5L1#LSI z&*BSrvv5({!NapMDrq}8%|_Hj$*iYH23fS8pp|5e3Y4AVTnfWE7*-k1$*{(7E{1i6 za}zdEAnP$|*3hnE0K+e*2oZ6#Yp7)Weu@wgSG(@iw}~90fYsks8W>DdIX6QTK_4o%ORj4k&`jDvPBUv>&@9>^PVv(~ z8or~U9p*HfhMr|-*N$+SLqmtMb81I9&849q*}1i2oaWKufacYXbDB>J0nM+S;Ix2- z-~TpCvn&$7wk&HE4P5Jf{`3w4fEW3!GNc(j!ZySe7bl84*=QyU3%eYMBvL zmPJ+5+=!~KUE)zSv}~X?wac8=(sDqv9Mi0=y?DfA5VKV-u?i*`f}S!W>8c-Co1zMEP$IN;4<8Vxpvy83wr%*IFB`yvCo&N3_){XjoZded?c4ct!B7G8~@LDx$>^ zj{)wcT3N$~ezmHO2_;Z0%+p@0=2z*U)qqMztrl0ob4)07(rRmXmI>5ZtE=IG7*H22 z+;7xXtFO_bw=yzK>2%W?!bx|naUg4KC(3D~c}f$FT>PXp^SkJwwE)Hhh?YkeaTT-7BxV7$fE{ooufq!(*EI5gSD>FqK0UXc+^m>d$g!w+P^$% zxYh$#@(ArQ?-jTf(JR8y3wEG4)PvlP-Y`<@N%f4nvqx!9potb3t@Xk+-+*27W3)cN z4H+J*^#g9iaD+Ah&c|s_xyg8K5awSm@GsgN;GPUG)aC(qWO$Lb0Jt&3i?xNoT^RmVTMXQl z;U(G<;NA@XrY!~T!|+mVIdFf5muV}JrRCado~0EUe&N>~$f8ziYY??cd&8qvYimJ& z*WPlvMq3B^hxU%swb};IKehLquG2QbPfO-!y|x9o9m5;6ZNSYK-l**W{*mEL+AiSc z3~$!<0C#41i?$EA7sFe%1HgkA-liQwa@(~JJh>g(5zw95M^1NX$3S;$pE%v4odDgd zedctZb_#UA_Jz{}+8NM;+E-2wX@7wp*1mCiL_3c}yR$@(Y8Mf8O#9BGj%$|@^%ILa zpdRUO*#h!UNYuBr7P1xOACRpf*Fd&`{2j6_y{X~bE<|r>FF|i>3a59p z*PwrEDyMg~x1jel{G>1`-`C!QKG1YdA8H@{bIw27XG~L%w6DIr|En2X>#_C?Mo+Xj zoIce&pwG0poIcmQpf9u#PG4%GjuR1DJWgM0GUyvEKBsRr74)5!fYbMy4*Ee$$mvHd zj_#YCKWQPl5b;@yuVZfK6FO@v6yl4PK&J_wwHNqTEs@{svYG^D-?XGUUkBLVwM5*x zM@xpZBDKVvdbJdwf}Vs^Q8z&)-NmV_hk`14QchJpHK?X1<5btvf*N{qPUGn5LF4Kv zINcy;^k*kT&#co)hELd=il@6NQ#3Qh*He-%?$PwDFiohNoF>wrFSjaJvfdvuYybC-FO|GYc z`=C4Q{OlPfR-|wm0prndG7fSSePBVg0xeeMo&+Wo>rvQGZ6f*!we%m?4BKqWISqp&yE6Op^TMc zIz1!oaLr-~2bx~b#3`1Fpc(YcoMOcYno-ZfDV7ePnRNQuEZAZN0h(FQ$|*)$JT1%; zT)M1!HpH>gxt-Ew)3Z|$l`gxUgCLbIhn|xll`f~Ai{O9l!?Ry8oR}*(l{|WGvYQ4pn4MlVi~QYovKAV{f{(@PSh!j{)d5v0dk74*^s>G4)Yy$nHmyj4jr zOOPIKRo2T9q{mxT^zsDpcq{0sXMF!t&*AvgV^zJ7o|!U+$MWdLrj0tH?f+`XCARUsrofn4J0jnI=`Z<7R6R7pCb{(~ML>M#o#iMWyMAy~0M9PB6#P0@1%i$j(8?BuA) z)o_xlsaK4dT&aK=Ki=lgWi7|7wq7ZwSsA~X5Q3ui9F9k+4lGU7%D2ZJ<}>w4q*I z4?Oj)sSEK1HZov!B*ZU67dF;MnAaQWwRQGc1T2$qoj2C2!5*<#EuqA7kl#MY_gu){ z$nii=FZ>4~s;2>aQQ=!zj!$^nt+vZ4JV(T<^gBaz+EUXkb)p*Hk8Y*cqdr=f{pto)S!=x}%uCXDPwMOO(ak8Zjb1A#5dDh++v>Fgf$T{;`?O6% z)^W*qJH2sK-#_Yg6zMc~-o)>`y!`Pk%~`8x&cLHMYZcWQ>Xe*y(%Z!5tZg)B;8C2ljpEEV zDPu8>PS;ug(KqLJ(Zf*VnDe{p?fp|XmfC3bZhAPP(9BqIgLc>Jaf*d^jE$b3^p3bx zF!5sn#MEghi9gOo&6+s)$z*5Nt*~Z?#~ylp?h%W2boTk^&^^$h7eM|5`3q!s$c2#I zAQwS)#qQJ3dIN5TH9oxb)Ejb&r9Nmcy%8vWdRCa&J9tR%t2ahC)u^ivzpCwidJ_u5 zr4cmV;%H@Rlmn*)`lCbk*PD_G0`P1X$EfJnY)$+pKX}+UK=1A^wnE8MFLn(?7_Pby zIOy4*eQmdglj0z~8M%X!|3FAjU2qL%m4aIo)WQ-t?}F0)2H6><9ilgf=c1h>hw3N~ z3r242VR{P+4)+Y#`v!tXkI?&5XYtJsAs8Up5I(>+^pgW$2y%i}vPbGIkttswIuQkq z(pv=u@^RcAt+x&e#KREM9HX}h3gjDm_E^1bP@q%#2)$h((D%aO19cF_&2jpVh(ce( z{TUi@yxyKu+@^s}&^vI7yERZ-@5m``+G6y?iTV)UB=#h|6V#B$_;I6F`7l=9xYLVa zJXs&Xjr|*SXeu0^Oe1{*YreiU-oppD=8w0jx=Uc^%L0S>5&<7C2iYVx^jORaQ#(p8%T!~C}#FBrdKHXR1Rr)~Kp~SyRGyFxweLEhh z(T_-*t6|asCad*XK9k?|K|Yh&eiPi{qbk?vbA4KW=!1P)s4M681{(mlT7QSn_PAQt zK>i5%2V^_QwUBL*)>?gm&&!|s5T6&+pyLJG2k`PIwA;XH9b{`*t*F~c&FBGr0;jkKMeIS{<`lQ0$j=s}&$jL67UxIK|2x^n^a0 zQ{4Q3p44Y>ihCf?Q~FF!aVvxj>_mc%knk?ZhLF1<8$j-XtPi;tvL1i1jHNQ{PwTU| zJyy)1XY|>eV#y48R-eNuR?VP)>2o>7;u-XuK95tZp+V2<^Et&58d=$gq{5Npe#kJ$ z1CVu57Z>yeTn#H%HoC?mi5`L#EX)o zJWyE8x*V1RP&opXnlV=GfqjF^`XZRpSm`{O|D73Q4FTh$Fs_0Ad{a3 z4ai;SFzO$ym>A~ZsBeX6+ zs}d^fB4kC@qAZ*SC;O?sfh@!E*6v2EkDjr@VU&c~C8$?`*=5M`kXInfL0*L{3waH) zOpFfVzpZ0-=pF1`35<2rQzD-0TWKVvJCGOpMr5*B9c+zmL!Mvin>c-??*M(RZ|3xk zz6f1Q|q#pqNtZ(P^i+%|7tGULnPVp5#P}$hasbX9JRgHa|YQ`nD z`-h*D@Go2VayC#)RI9#P!qviRNjI)h!nDm`82iarZBHEII$Xy!4saS`+ysqh9ON{< zaT_#&afs7|#^0ccjKiEJHtvBYF^+KhU4H=TGLCW@ss96-)HudzGUH#+GMQy5QB zhBsa`ne!G4`pAElhWduDG%uXeq%>anN@E%)xYszwYb0VBCpir<-hzf2r#Ovoya!EX zoaQv4@ewq&afZ{x#%Itp##v6k>t8|B8h>#bseg}_-$<5U_L3KdN6h?KJkUUi`4~f< zz>W)I{uP>2ASO#p_~{JMaJFjG8|TO|KC5Hk6OndC<2pN5_bRXEXGAn z-G%|0)wslIq#oDsEkrQUA_vz|QKfMa-GD3wc@wfE79`n>cuvaE>e% zaglmLe=?ZI*_wn&_bv8IEC0PdNsKc`w=qstS>qXu3Ku8q+^B1$Y-NG`0GS!`BV;B>W|WYDNWQ5jBs+8+uE1qavqR!-3W?DshUn8b7Dus>$md1>#|R zD6M5wF@$nqC=gB5wT)^96**v4=fAD+UAY=O)>YS_ugt}sLT#fKi*-D?!We@E(hE1h zT=iH_!D^BpH973ha(#c|tdP#=-@t$Yl55~3-jFf;rS^(wWHh3tL+MZsRvEM+z}tc%fjt&FbZk1mSV#$Dbo+Zf%@$uu@wv^9QWxn`Au&e+cQ8FBn1 zz>h{RV3FyyH~OG!cQEd87afg${=SJdH2P*F`cf+NDKBIwB!2qCvLIn@nUMJSg_RN# zuB{Z1@M9&1R3Vc=B0E-6Nc^ma<-&>_WpNu4&S--t0q+cspX`X}Vhlim+#wQvcuz8gRJrj$kRk5ypFhC8O+tB=c`g z_Q9i{1c*-@DTDy`?8Bbd3^dMSH_!M0OI+Q!Az>2?ldMaOGCuNE^=M--o2>&;V~kHc zYOFC7*Hr|&u5gPKG)19P;Z5{$#&8yg+ol+C}* z+@kZ@##nT+iN4J=h0d2A| z!5Qi!rWiIQgkFG!N^IxZrWz9sd_n|+@-$V|mM2d^uDA=`S)?2AT?dv9TKY`PEoMC8kkpiSY+zjr#j<##hQ( zUC&ZuEi!~4WNw+U&Y!vE#s(O#FgE!Lv(os+3$x1D?AIzNZ$-PTHoj9-xaW6cyMYg& z0Ie~0!u$_occ6+>Q$tbWxSv{U?7=7%2Dy)AIXLc5;{c2M(>UZ$XPt3`>9NL!`}M{# zxZhx$2)Jh(6>z!HIEh-tiU4?%aoX=`dHwTPce)B!X9hmPm?s9W{n+6K|jC+PTg3x~B zfq`$=039&?F|fD+I%xdsH$P-NVXm7p*Z8E4@r*TnQKzYo7%vQS2UYY@<5i#&IJcs8o*w1CL2cq2@5Vc1ybv;uue=){nD;7`8P`mW~8Or2o z;FBv~^P&f_*Gl+SI=eWc?0+YWL-v=A#Bt2R zgsvE_IA&==SB+%;j9xQRAXC>3)5#Q)qF3Qb?S^5or0FGi;x~;{ezRLf8eoiX?xd11 zHeDRSolHt1xbeeGW(o{3AsA{>LdJ!}k1bhoAT3CPt^UhW{aUCfEJ=rI>Ep23*LB;O zg6uZQjm%U? zWEwTk)X_Y)ktGg}RT*A>Vo{?ahWgc5(@B>u{XLqU}IYa=c}O8kuxLXZ-FYs4c+ ziN7=A6Qso78wm)~Wd6ZONDz~GjC{oP&#b+X8~pFto6V@%O$&AYT+EQBoIW;P6hf0X(OZojM?X6o7s&=S!lTPvCYwN7h>b! zAmE>|X@GylUcvD1*j9jn*s2WwiERTIjE!e#iFTn@{!sS~m*`-tFL#Rs=86&>A>9ZVT|Ys7%OTp6yjI9Lpy|q@Kh#wbH2VWvoEV6rLAvM)F&OkfO;;5|K)2U)ych<$gQgS22+$oh zT}@mAy0WILi_zMxmJx0Z_KwkR4fc-HWi2AguJlgOWi>?3C2~W&xw>qKH}8_NVcsda zY?wD6)u<_wxEhIKI$TNCt|W;WpnGY$mM8*UNz=8(tV`4l_m*gN!@aY?*G}`*5pzMC zfqXt_#2TTxQd|#{bww>UnJgAwQmfkD8??IG-o+5Zq!42D#F9{#z&a_07koS|>2LJF zCP@E6+7#)ZNSh(O5U4bXx;fVTFl}3=yZk4bUao1ZsN$sjD)ji~*aPY##mCdi8;II) z3Sys8ad|^ghar}Z08_-346%X)=ofVveyL%qNM`tzhK)o$hFH%5b7OH8LoDmS^)$G6 z9Qdg(SRWqeIVRSG-QaiAHe1!g&~%J09yz@!{Y=K@e#MAKcKob z(zANXs7)qeNGeYgsnL1~`mlF}4tl5vM-^R3oQ1X&D=#V2HAY!0QSK}&Z!H?J$~I!P zvj{4+gAi*gZoQ;TR}E$D#M(>BbUjhlUaS*V{SIP1AA#`Q40?6!2DDZij8knPS8!XAhH9< zt3?_!Vet&dr*v_bJqDp}x(}jXb{BVR|Mfru+(X=}aa|Gt&Jg!$toK^rOtDF0>}0yU zr+6ULudz0Vx4{<&e#4RXH@x>~E7!ZcmuSgB?k%wij*+=4KxjR zKW_UnP_$-)gT#~AIWNaDShQi5aqg$XEah3EEoToA&te1^D%x>yvEm2shKc9l9hoa1 zF4}X+&s2h#jSw#gy0`aCP~VJ7!*%&c(E&^}kyHp*@o%_ZEa+@fyiVyLmUPy6g?Rhi4Os1ie3z7iH`w`MQ?^B;?t19bKcKk zuvC0$49*sPz=iz-OLTfRIY)d2;klwO3(phZgoIVh5#1iYlwogi9&n`?#;~vW6FnMrg`S(m-=RJCELlsu8g={$u}DYyBj$M+ED=zw zZQ@w7O4C^1jF<#-jKUXsSBv2=Lt(NPegDxySPX^o?kG70tJ@EsU4!1yg#3IiwbJ0ox$d6~#NW|!d^<|}F05o5EoR;&?jX-8_U z7|FH0O+-mNaj9#&PDD#{VFjzPa0vNHN1>}1(j%}?5U9ZK^uRZ8=yq`p?duhR^&$q! z?+`-j-OF0BK}fPgJJp?H6xkUXsPHO@H{poU3`e?gcT;G`r~>)B#T7>A9&s&m-7Bg> zXrmaz@IH|c5<2It4x#%+O(V2PjAgFPA~D3JVroemRi^3l4ZS!*ZlTxmc_})LzN4g$ zwEVp>N@AS$_rZjIi-=gF+a|_AGs(r%XpN>T-!8^e7R~A(6cdP~S^YyIn@F0~KP+;H zq*?tVVj__=tAAAF5=pcA9byuZv_$uq$Rm=L=pGl7iKHdEC&UyY|Lv~od<=@%iu3jH zvM&7Zi_yIwB)-PYmrsg%Qs3%|#dI_yzF(U3Rp2J-Jy=!8KJ%2g$~4x~qP_{?Gh!-C zqOlHp8zAn_ihPF8i4?%+#WaR5h*ZEA#dL-XJ&gfh5(Nxj7EJ+P5i=ORDw+enCJGt8 zF4E-1r_y{apTfFR6oC!rnshB6!42I<)=H9FyF?r4+AU_Xt~W$Gz&FJ#hHr@ufNzUp zhVO_@fO|vs7d;m4vM;3wjGhM$T7fS-v43_llx0KX6m8Gb3U0KXE8>{9Pgz^}y( z48IY>0V_lq!y{rO;8C%d;i9NffXBp*43CRz0Z)h}48Ij)0lyPV8GbLu1D+Ji82%u# z0Z)nL41W|80e=!J82&6K0sbOxV)(0=40u|sWcZty3V24`%lwZ-mH;Yw2ScA+23SdMU|3nM0IVYK zWEdw`0$w5SVpvs{1IEj{879cpfYszZ488JJ!0Pf|hBf3`z?yO+!$i3bFiGCWu$Ej8 zSXs(U|qSHVY0jju%3K?;X$zx@G7~5VSRZ&U<0|8VMDnYFhy=- z=$BgnQ{{GsUwXHNVs_5^AY#@?K5SyvSU$*HP2?jGYAPRM*i7yKY%U*W*g`%Im?j@# z*it?T*h)Uiu(f;|u#Mcou&sO+u$_F2VSD*JU2J9@KWY|T% z3fNUX#ju-v9q?-TG{bbc3$VLlLTIvli{TXcb4ci%_g4r_mA@IGeEBwWO_OIJG+n;K zut1&-38|QKy52YqSTRFhFzy%1KaG|mxrfDO%DPDC+eafB}&6kyo2iM7cY_hkg3=giC`x!2faexcu0fr;pRRI^t4;a1? zod9@)Jjk%ZTOF`W9%8sy)&#s!9%i^iCIK#$|6$lUwsxp)C%ji8Aj@R3ac8;wkhxaK zdJwuve#CI4tPgmz{Fq_6Y#7pU&g+McRkD%Mv08q@T(`)^5V}=<%5aTr3b zcgPOLlMV7qwsoiM7_xQ3+Zq1eCA%7~yX9BRl`p!%!F%M_4DXfcA)#~L9uV3nGmX%F z@*C#5U-k@fshHln8k4b8Zju#Xu&dEm?ZK5U*`K88{Nw?7grw>GWB^QVkw+OW7lRaD z!J&(`$}FwyC+zt{py@O0@hD096zMRepCBEM^kbwWkbZ=8B+?K6{lu(%n>?Fnt|qckI9piMN{X;)#1 zf$jpN@1U9A#F@wp42L-2`U{c1jkE|N@5t-zVQ|SFxj=F7-<1oMwPdfn!N%{>`^+ zjW*sVmvEf?GofO?TxL`pkjrhB59A7n9F!|m@(efD=kgA;-52tAhF{7%0l$)G8GbGA2K+|;!Elba7qCK} zV|YZ~2Y6JTXLw9*3bnh^?Ou$qy^XLPN0>^m@12krz-qVS18ACDwAZ)t&v52eWKKlp zck-`r=5}P}AoF|qcR2GQWM=b2-njh)JMBpsKq>kh?m_|lLH@%KtM7oPWRM~5UjW2$ z9e2Bc8MiS2{v=%taW@0M?5(OHa6bd*;4&o6Eq|7eAchdEMzH)B>1IJ(mjwJ(Mlr-C zO2E_7!w^?00e_Rx3~|8{@Qm~_#C1!+-(?KLS{j~}u?%r}5KpH*t{+sbqv?0`&HGn^ zuB0Dw#}z{CWTlAgTZqyhQm`Pd-9ha+DH-BQ8Q^)T7~+B%;05Vpi0fw1F&jGG#500e zdqNd)9Sw*3KlQNFP?yg^`5V|D<|5sVhQ%BOe7LR#zP~k%t7=dikd;_1uB1WjJh1PA z*nFfrkzR-Nb-4PEtjuh<5&{jF(?A=phH$`fIfMyZ58+Sr;8F+JEIsDoatD{5WLAxAQUFl)F`& zS6^^g6!R#CKVnDr(kS&9j@%ge`H63J1D-aeI{+S6xWq&U0^&3|kU>a^M8_uF zzV=1*lPbhvKi=n2SD+3?%znHtT2+n6v>)&Ds`zlGp3`9&>{#^E*d1e30tcd%j!Uen z#t@fN5GJ9jGsN`=K&fgl#H9#8rD`(76$wC}qFchyB)F=8m@Yv@p1b5Y9D17=DyVJf z<6tF~1X0Iv_*va-xGDk7l~pa)jKzDvDylX^tl1KF>ND)FVGY%QVGj*!s)h`)@Cdt!Dup4|908M*pJ7je zi5L#($dARgZL!Z|EMj_V?293KOYF;_(Ou%d;AUGZsjjn7&dqA}*Rzy@9r^s~R(0F5c49s8g6mErlb`qQ@;m`V7+LNS{W!0_jsQ zo{Zz=O*mFz>WiktVi~R{zN2ZJdhsoqIQL=#Ctn!ju2Or91NBuC5xfrg|f zF&~-`cmg$mj-xUE{_0}o-U)=WiA z)mo_L@KjILFhSQ{G)=XjESjpdRB1%gRIQb2NhD3xTB}w>(p0UDYE2}qa<)}%i0lip zooY)Yt#Yp_DMO_bNp;Fp-HD_+ z^;A8Gq&oFd8AMW@daFz#sZM=VPa>&KeN`_asZRY=Zz8Eq{Z$_#sZIk_Um~ea164mF zQKyKC*dHXo1Ki`Vw2Q5HoL<`fR3)9XR^j|0T&*nCpX8}pgY9Y!Q3EK8sx?#%B$BE% zObsHEsx@26a$ogHEwT|47_0yNNeul08>acFmrPj~F z`rWAWRCSK5-g8;2$PHP&a9OK=vDNbqs|H1-FLXV4Q9v3xn zlutKt&|%G>OReEMGX9N-@O`MpcJ!h9k!}k__AZ?BQSS=fNaD*ggsRXA)u^MY6syQXFUywwJs^OFKx( z*pbBbs=iZVfyyxw4V)5K*CUCAD#aqow_rxP z9)sOhq*#IQZ^NN@L*$|OE>#G5(jAW_2|Z)GTNP0j9g6Q!Gl`@_@x5vmk#s2DsEUcC zL-Bp8gh)CR->*uEq(kv0HJeB}6mM2@h{T~d;`obY6Z<_g*J9AaR(!2K{`T`FeQPCd z2mclflMf<&0O>Nb>(dbsdrL zKf)1j$dS=-1Y7ZF?Z^OM(g~~9sKEV!L^LiA*0?w_$d_~kOPK0`Pd`_f>QA-epNPoM;ru54CRRL7hAC8< zKbP~H`kUgbED`y6oZrmf3}0x8$e+Ub&Hc^s#g&Nse9mv=Z)C;eL#WDIk6AI8crM{%2$PA)#wJL&G2dH(Fo{!Goh`>ZybKpu{-0yN+mmiBL zzgL&fL-~dnRbgRW%xYZ`d_i4@oMkbIeytz(wLR=!0K?nT$uJz#e8+IHm%Km0`R2!A>E6$j^XgsHy;e{d!_n2yzutD$=j z%Z0x4vh-DT6ORX2kW~w)XQI}jHTjhYEndG1X?iju>6q2}SnzdKZhNeaNR}ayB+dpgX=FU$Eh|&$Cf`A+;CC(n~w4`!MiRh z$K8k#^1lb~xu|@e!@pmH8!sw<%c1|5;QbeszwIcW64-oEInM4Q>`xAC@g?HB&DsVnz+s<3%nZx$5|%0o z=U}D-Ep%sBS6VNF6u+BF6^3}i%UKcMep&ji+HqN59}D?fU~51Q`>JMybJ#a{Uz^t8 zv~BRQe;3v1ljtYxI)TIX7b`$U#`br5NO#y@e3!;ppuqYj{uX z1W)9CxLfOCeztR)=S|k5Jy{xf+hi<4K)rFq92)p6oDV!H@Pz~C2EKCOiGgn%I45w#fwKe0 z9Qai5gaiK&{LX<-22VQh_rX(PJZ*g7Cq&42`b)S3o_-fR9mc4wzLPV=dnQ~4-fx3v z9r#4>9LA1{;68PMj#H{cU$o1zNA}Af5%xQJ>R&j{oW*izN~pDt1_PvPtDnCAPA%B_ zXt25`=(FYy3*dp_?Nunh?a`pSl68m2x(TdsI`SaG-%^8M;#E*;x+@(vJ(a92E%ia? zvaV@a68ChE5p=nB~bU@XjL!r}Vd^wIHlpjzF?W5Lo zdf%H5EMe7^D_M2$!LS#s?0hXjQn{&Yv=x2O9cx{cWqH6K z9k(Vv*>$HSc6m_djjT zAa+)d*m`mHcF^i$#q}^-Y&}mp;@HET5?6JXWwtezH`$YBX&FkH?qm7(b@Z1&wghpf zw(}&E;Y022nq@K>tq|U*|L8U!fOu=4`dYrYU6x0;Gx~z2k*3+3DT_#bRL2CgS(&R< zY1K4qwB_dMJm~Z61Nw*Yr>rCAk#E{R>O-!S zlIrPJNo0RD{zayCyhFZ6mZ5&p3Dj??pY^p$4vY@hF@jIqpnVUvqR@s>32D~4#jX^e z4>65R^RGi4vk!C>rtcD8sC^Mz_W;DAtWhZDo_*B!QP0IB$NRy>{zb@holV`HsoaJB zLh;NV`dU@=K7g3(c6FzC z_I0dVvG{^@MsIudK0^D6J2tH@_X$0Y#p-%3-iw&?M&lrjb#C;zNLytX6LcJTEHQP# z_!f>a#~%Hde4x1L{zLnQ-4E>ea(khY*-q&q?3T;kup*Y$35&c`2>$cQ&;aG9($ybc+B;%+DY+>9r_0_2!hhfX) zN2b|>cudAVAhGD!3*F(!wf202A@D+I_ z2Riz>Uv^BSnDIuj!iI8;XVKZ+vMjeb#!+81{lxGLpz%Kq{R%OAgT_Wd$L(Y~Rw7L~ zvlz#}egDIz?V&H)eH*eQj}6BSDnlQSu8Dq5$80kWhj?&2O-QS|smva)Xb z&*-(w%iLGRYW=W*NwPcQKMFY>i+GhMQzKkK^tI zCT~ohsTu1uQXD6)KeZL*hc%J!tc7bqzvM61f%*%#Ft-PLZ8Sz9G6MXRvPR~j9OmQ* zaNH=DJ!3zK!}!DbVGb%I6pkp%@E*t9+-tZ#mvVAG{j#L_HBsUA;BwQ4*&1^g&rGz~ zpNsWTJ;?&K08x=OH<&FOKBLFv5+-@pV)U~t>!osz49Cw%5)c1}bBHoNu~tS#A4fc_ zm&XHcW3s{jMlbn9{fq3<{=}5g!SQF!>^;%!i}92(|2p&7Pp+AAas9kyET9Pj2Wvko=cpo>>VNPxvlBNI1GG|}m+OUr%Vx*g-%>Ezg zZ6wWc3`?1Q#gU~_qlf)A-mnfXW14u`NA}xjARev{=a4P7%Iz7pZTKiB+>1C$EWvuh z_Ka>*Bi2P@AKNmVR4djV&T(>38&wz6k0Zjim=6D%n2`TOlU6D<`KI2C>DQE9j)S;af+H5jVeW9BGEoV~ z&3I~RZL}G?Myug7Da9}{G8AF{Cy5xlj4g9JnVv`%=y*UpykAlMXrneU{&Sr;o~9=3 z8hGI1~|OK`1-CoE@b9_BP$%tyRbW+eVCH9Y@s z&dY0H`S7oy*g7HePx6taR0E@vd5q`Amqm%bt;!=H=W;YiisQz) zY@MypEXj;Ztlj7fOBkuh9JWQ4S&A&M72dCym+iB6Mw)6H?sMS?P&sQLe&RBmf~^h4Fc`&&R@oh5Hq05xngO_`zRvvMVY&`AGD%WB@Wlf45q$+80!m z-(3!Mhp?V}uzr;LgM#zt{_tRB*s|A#Q(Xyba05iC*3sRQ`I zpR2DsCebyKE>qnCh*HaQGQm|dYtjSOy?DymvSt<+O`4rsnqO3iqK{HCJ*QJ#wX^bi z&Dk&vtIyV?oYI`;GxG{36*bQlQq-5bMG5nE^&!%HEY+ZU8^=}EnBy4 z-@a8^ht{qB#X-;h#+jb8jWb=TSyKmXjyjYCecI>lg*gTDQL&QlGxPfvPRT3bxMp~s zdY*g%8)DWVYs%3bvO#qcDkvzLn^9a;QZl$WAJOYooHHX2&S!cWHp=ikwjjfmoHe;} zX4j~yV9w2%SvtEoFQcfiq^KZoK+zOpByH8FEh`{xHp8I2(z!*&(}(8GnhgiEwi78m zJ(c{Kp1zGTJuBh+2&6gK5|P&s+w9a#&%h>`o~KZ@5%f==XL{DcgN@H+dRn5qJIWqT zjc9n!OR2i{e^!Z3rgsA7%`43-EI}vA$}29(FDV^Rl$%p9j9WKT_ow$)x1#3 zer{>++4+;GqNwTUCK;X)uo3+hY7Cq6{XIR~8u#?LC=Wh1dihJB@7w@&n*;rDk~QIecyOlB*`|1-v9-?*(^_&ZOPok!lIJhGkjBh*o}a zUZ3H^vxa4OTB3I7+7JBIb3b+M;=Gcg*~Phe89BLA(Z#I{&u1euJb4JzENl%CoXw50 z!Do36rS|ZAlp3>%RKIs*saGI#PEl@FQE_Qb0q6|RwiH)d*0ieC>&OPc|4ZlgxK>@p z|Mg|M0e()q`4lz4_|(#ziTQ<-^5!kbEhB>$XY^Y|bfJqz zK>91kc4&pm@*P~_cH!Q6e1v%V`E#Cfyd?I}wDVqiM*-5#Qd zz0!uBMStp7){K91=YHa$zeXK;JzY9`VgDULS6qu}?tZ)9eE;>XKd75$tXj8c?`Cg3 LBNxT&q2K=lo{0;z literal 0 HcmV?d00001 diff --git a/Covance_UCO3001/browser_profile/Default/Code Cache/js/6c52ef606329e72f_0 b/Covance_UCO3001/browser_profile/Default/Code Cache/js/6c52ef606329e72f_0 new file mode 100644 index 0000000000000000000000000000000000000000..e2c55372ac455328a887ca1d019055f29c186fa0 GIT binary patch literal 37308 zcmXus1yq%3+lJwr4ih9zL_oSb46s|VyJPI`u>-riySux)yE{G;yLJBi@_PPR>sY76 ze&44+2R9gAzsvGG?SKBV5s_l*%Rnh>VVnh)+$6jfqc4Em0~pDk05EuW`;L>r7k=|F!8H zXo0$`Nc|N&Ry{36jvKSAMc}64po4mAOtTY#2RZ3NZV}iQO^4z|z&??BYT z+$E`X6%klhmGV^+si$_Rv~-d7%DcKqj4Gr4sYN}tFrW@CY%T&0?Wsiv5y&)hbQJ;D zp47UR-dC;bO>uoiU}Jy!`mYGI96;>`iNL18RD6gCxDBWJBSfH$5j#=@R;tVlk%ptF ztrp6UrrKIa7(=DB&~hAg)%G1vBen2z0=1j0V^Ui-k@IGe;4LDXx6%RaqHQ7{)!pqP z&bvjH?a}qwM|-qz#z@*P0(OVULkpLTM_NcfOh=B0z*S@XQ4yGLw5NXlg%9w*nf{4?~6bl(8Z{q?K;?(jSPQuyQJ@xP8~q-Oz*wX76A`Fo zoY4ODRI6?plb?yeV#DRR2o!oj(OP(G{Lw~Jyg;mB5 zZIN8GPzw$&R9_35jjpa1;_N|%v~bsWqlHGE6q!%QtkR6%TF924252G9o62axvJg3I zVW=@ld)tRj_*%$}0J^Wgr9tH&s;`A@s(mo|gj)z)iX-=U3xTp~jJj>)PteyHQ?)R? z2z5=hkh8`E?f5imT*5-Yqa-yfWg+m|h%BS)pe`70<#fN*Fr#&O3xRbNC|^Yjf#a1Z zTNPa|)z8S#!r|(=M>Q>^modAco<;Sr5ydspbyfYF(kLxFHUgSk2+TCLw6qZT*^1h> zwh*}2#zK7C>KNKnZtdePde*yH$mBs5@^XlUc#Y6AJ%uJu)z>SlX_QmDUR_Z((=BAu zJi0mGLZIvds;Px83oT^lA|2aeeR&Br({^2HA)#w^j_Uq;3z@&cLSi>rNUP1d{#z{M z&Nd4fvBN^z?9uh!XCciGSjhf^I={nuhK}lfAG46!$1UW*X|g+OA<*;x-OyjFeK#re zmflY#sWW#hB-cF)8Dg}vu@u;BONHz#1;UNTS}2{B#$~e<_+xZ+vlQ6nPPIHO1)3X! za$CyAe3tS-6?4)Fr*ZH*Fw=Uv`z~-%29vq;qsOeS%H34wG`-_P6ex53M?~T*RT|*SCd+6 z;kBAni+a_z6tJyB73%8z)NbRu7HZa`hg!%|pAKl@vhhp{o{h;*3%!iArj`OH)CZ$W zGfRP?EhwY4r9hT8mQwW}OUc%WUX0asRAJ*OSqsf4ko!bSfd-T4j20XxQ!6ceF!D~Z z6u4+S(ZW~5bB3iv&7@*ls659~?iu+OS_)KOOb@isb1BVQrsG;p%U4(myje-jHd+eY z-$c!~>-(uI`{VNhwBq=gD)sJ<4?8Ls851QwL1wCYv@)s5^mtOW8K6SQ!>Chf0nCE(DAa%NWPVxYcVWgko*hFA$K znMA>ptpvJEp`TN&1QyPqPg+QvrQ?`wCF_kn+QJL0^z#Ot*1`={Vm61CRd&*}T~-1%yUAG#>Bf#dRsx;& z(sM0@?58CLFF%634BoTm#t*E;e1EOq4pY9 z_pAiE7*F3?33SM$E$^%Z3caU~T1favE3^>vnfiXQ5*TT?e${iUma13Z^mED&s-M+b zU{N+&uLa-i^d^V3z`sru;cP8X+}NP~lFM2@$58<{Yk{Gjbluxp;E_Lt1z8J}40R`^#Djgp{MM<*fxC z851j63&d8YIa+vBg)+6!s48WxW-U-HoepZ@oGMe3YG_{@-?h-GmbLV$OPlLi3-qZ^ zo(-%8jwr`Q*3#SP*4SF$P*eKY!dl>NE2`dF*Gb(q+WliKaM1{EYc0^F9aZjREwI<< z)LF-+1{#@Ki0Mj8w6IAv>rQX95Y>|wX<@yx?neW(uy7#dA7m}C(`YwX$Eo@mue1;` zlztAg7HBz+Y{y#*RG2`!wQ#}6KG9m>@?4rR&syN#e5$y>TA-JK(xfDPSy?2Ln-*rIQo*V=0^N*V)ocU;(#gKIjX+N$u#SyDqOnp7 znRV%MeH;CM78{w?jDBljLvuQyg|HUXy`_!76Qf648-Z&^Mmt?6HPf(fuj5gbI?!G% zOz%p0y4eUc=}s54(5EN4_0svP2}W9P8-aA=kk-Dh&eyo!&qg3@GF{R_r71LJs*Qlv zH1g2Gis=-!)JEWxk#o6?z(`~5HXDJU?KDgaaXV;^7Mkp&HoI&D*6*hLdu#-vj3s+* z1XdiRRflW@z8N)-*a$2#{&!T*s`_?}ypG#QLu0cRzMr7hCv5~W&r;esT|1R=p1x_p z<`Om4!ivk}e#J(>_9oTU!h&0rzi>=2hl@^h*o<#rCg{ zT1c>@6PicR$!tniJh(f1%|D-8W-(t17tZa%vK;Gm2A^&1uB%FI$FqHlE!K; zm$H@A(qvJ|R$!TtSXr;9u2-eD)ocYerqk3KwgQWcinVP8>eQi*b!`P!)}y+OZ3Uv5 z*vb{-p|)RB`kxj;o74RkwgSGb$f1p`z^^`(+E2%=HX37x+6r7AMybQ~?dr)03e2z- zm}%6QV=FLwE;-J#6)0d-T%hw&n|IQWUA6*tyJ?jc+V7$B2lN~$*F!W^3#*RNyW_S3 zjZRRO)4JcP>KQtqg{wx3bG8EBnbhW;tw0asr4}MS&_XTT{zTqi^l>W8$oth+ptZ5? zo2@{;@3icvt-StaEA@WU8B05X;#M@m+D_n$;b3PcP}!dLX<>6VvdwNMP$38P&S@ub z*2v{-C*WlS=CTvmXnb|C6S$v;eiyP6sOv)ueC-5s_)%W%w8HdT3mg3DfEL06sC%HD zz!M`O*iK-9kse|v(9F1`1&=Tqp#_TwYORGlkrbqbS;m7XJAum4G%ChU;JdLV)=prL z5frD7SDoYOffn+n&`>SJ6`|5v*k=4HYA4XP7^Rf86PRJ#D`zKAu{=GlWG8U2G8L<0 zCveorQq4}_crCi3g`suGr=Fcagt1Hu&h@Ew13Q7^#<3=L0tK5=t7dirgIdy4Ed;fu zSz2)HKrtQd1p0QO6W#0ts&uDmJ@gzXo1T;%p%C+C$qFEz-RriIh1sM{Vpf$ys5K07IVlwLiy6X^Pcc0RQe@P9@rS{P!?eQ769 z{T0o6t?Qs1-cWumG%%KbvJ=SnnVNmkGpsHd&$STwmEL^U`Kfk4Xwy$Sfr7s%Rtpn< z(>x1%fjdSyOM8I{Rup1wFHqE$Mr+}s9X)ll7l_D0J+s;ixMioNT3C^T+;iFsba0}B zTCmGSrCsd>CL1^1>;=xclb46RKub^Z&ucF*&A5|K=b{GXr$q(q1%4Z81?>ek8O{Cd z1zxELe|uSA)G2Q-u+I2Y!Cs(QMe3x5<;Iyx_5%KusY4Z=pSo)dt7b27%BYlXFR;pZ zSKVHqQ4JbU*IwYV;aT5aV5DKw$X=kfF|V=iqsrEV*0!`4uxLf4TkE>2ZAP~)_5ueC z+ivy(-HqPe?FDM}Ajh8e0=bP0Eu8N~MS9x{q#GTyuz5Ju7-279KaxDOFv2*Sq5G?n zM^RNRv@UGdw;H;7Bu)V-w!}o~2K!$PtsP2mzeVWE!u@`u4L|)T*tA$49EnP>|;5Hr9g56!} zp@rFxsrNHIA1cGRqJ;v_>4p~k|3}@lumbm<&p|v2(^&0ge+NkoAj@zEfknpf2nT^Pk(3nWAW+2!NpuicS%E?; zItX;DM31%5qzdiPf@L+@S4-DeCDow|T5zjJubVgsjQ@vjYoTB}nxKV!?J1yxgLLfZ zAomR4&JF?{y3sE!ROwFBdN}BxX&m&=G;}}<(Y>foZwG-FM&UjV0z-`)eH{c6jJH~_ z=tnMEh#f#_TG(Vv9poVJ!zebyLEzU&YB$zsdL8G1 zJN41Rz8&;tr-MM$Zd#-T`xCTM3z;XW;VB1!E2k;749Rw;F-R|hQRXdH7T5!2bK3ZsckJf5o@_kyYh0R9U2Mz*Lj5QA(1il*ITpR_` zT&bd$qreQ~tQMXpQe={&Kz}2-sH4CIV`p(kfnuo?Skh78U*kwAM}er)w4#ioKzc3e zrG>=WWM9WoAl*o)>nIRVkGg3ga*5Ml{k8CN2gU4k61cpJ&hK^-$i0WM?R65^YUn3i zeR8ssyf&^Ja1tnRkY*op5*U4$rXO(<$T&`ePdEvjH4;ub33NS8`?Rq941GN3BryLX z6}#*tuqhMXDz8@!Dz*(9ahn<`Sdb-ddE!gLw$vvF~?inN2It%pNN{6)Iw2O9W!Dctz(?Yf5G*=7j zF3{lHI(~K5*ziARf%MljPYZ+J(V>reKb7qhz5DGfFfCiIzaDBKUty}Gg`275la@=M zOnYkICzrquW9Q&p0(quWOD#mMq`4b%3H;CSIic56|6Zk&TDbR|w!O$DVDXZAzs)5u z^e3Iy!qz{u=D%D5UyWwsBCyYr9IRXfURl#08yA7vwzOCac6QW63u}yA_AUZWj#OU@ zIdYJLvtD0SH~P4`2sHMf)mjM1P5tt?2n2ai4=r5xqc(vq0$Ypu%tC*YN0`QD%`_GAX`rg@9iSc*La|X zC4K1qzdA0JJb*?IbP=!|ObxWKb_jJI>LRemm^REsz<(rl)k2ZURCk(-z)~Z1x{E;4 zOd76*>a*z6To-|&^Jv_B7Xh1vR7DGI7SZ+9x(~{G4b|VS`>iJJrMp_lzn^LyaS>Q# zxE<5|QD=`+_meIHHP6yQEnGQAw?4TD_Z)HerS4itbfMv{t^ya0 za&E2y*9~uXSAk8&8ZTFYK!180K6>zUWU9?cI5-rohuFBMQNsG>FX-c_+P3q&{bf8;W)@u z;N}qW8R{yq-k6=C_gBx1hog1eO2$)pEnJ#RqZhaeTr=7%aTVyjoc6796>wNhP1m>z z*lnX~TIjl+n(xxNsr82a9#?^B`{I7 zx(a;wM1_933iPyc`|FSvei$*?+yn+1YqPrvEODnyEsXJ`WqI8M-Wvh=+ypNAQeHnd zfhUE@KFm!Z-8dZSCNM6FZfaq4G!>3@6X;@0jB^txmPn(ukd{mvins~GLpj;hvBTBL9_!w! zy+(zXZUWx#sJ#}}e5E}<-307@Q3nfm{rZ!;G_#_0T5z$UG)H%VaYkeocY)ox$kxSO zU}|1!lFwaWjj@Ltdm5yj(bqV@X#$BLzS(2*m0>5ienVRnU+&g#qRgXHha2MER z9Bl0_P_I2L)582tWZPNSM^!a4v{0)DEz&~s-gL9CyMRwWTCasBgJ_KwVusPL3>}v$ zJ<xxeG*1q<^*W)EGYBUErdzZ-uV2TDqFvY2p4_a^L7K(A1cvg~40stQPicqdNQC z1(p~E54Z~qJ4zR{u<01Z9M^fMfkxyBJzr}2X?moE#%E~3Id_3qMvwFE0-G++S+ojFq?be5p@H=3RGz8DHqJ7B-8=UkhD41YR56!#xBJ z7@iRx0*zznxE7paX_gi$#L*)yv`?TONge_RjS9*7e(GRx%9`pS;Fv}Q%X31y;fiksecwG;HtF6eZwTFOp2a4_DAuz}o(A7i0t2?#T!WW}e4-bJ&MruzF z0n1+WNeg)f((55QP8Bzlz76*fXp=!(v`};u{T`>|S7pZ2w~6}x>dZ89pY9=$I*Z)r z>C39A@oT<^z|jSibD@Vo-bM6F3#AuR`VtR;!-YNn%I@ze5FSS9NuC1pjH79u0(K>+ zm=;1yQg1CBEJdeFdkVOfp$=N8Se0gIVP!RPsqQJT(72<8!Zm2C7Lsbya4i(BM?0H) z3Rt(GoNYV>YP6#TS}5M0vUkw=Dz}bg*~?S+QpaXo8|W$Uc@z~Jt@BmRlj-ejPl1Fv zbZx%Azq-AG{8oAj3|LM7Z1EJ>Y6R}^6zF`2_Gls3Xeau?t@xj zxL@!TXll&T!kFuHT?=_1QRgRmU$w_r|J+mH!2c-A3r~Sbuc-VdPl0KM*Dp_j5stb4 zx}=5fuJp_|w?Kp+{VtMQAWs^#)WY4mbh&+Qf&3ll_Thp8bKjBkkAeaX467{O0=-@6 zh!$Q1Qb2^aKsV!Bac_a4sZ_C=x4;ZzeiLtj-L1&BwYNaQ&Qwba%EK3sm|p}uej3s>v>DO8c zNriuDx)utIrU?@Z3EVc?%_}6(V=t}N!tsOTe5jCs{Y5H!vyi|Pqwu3b0Be351p@qm^^gs)ZM$;-Sbl6QV5Bmtj9HGP4d<1g; zr0L=-@W_bH=_^ptg=T0W-iuy&`wGMsq7WZnfd&5bN(+60DJ9HT;9xlYjPMmG6-kS= zFh81JYT;ZAZHV_3_-QOo)c05Al4(N`eY^T;L>2WF=unJ;iu(#wOQX<|zWRHCukrMCU`@oJl~ zVTg`jy%|mMV|1O>pGh=iy05@Fqtr}YHn9Ku$*r&f+J~)2Nx#PoTXM?a;zOXPW8aC-B5* z=ISR9;X(bh;FFt%Y2ip7%8}Pkpmjca>E|a9Q<&NZ>V4HmqezgSz;mNQn4iFO!!6oR z;7J07CHe`Z7NKLM`~;jz)4g;*f$p{GfELy_psa2D1Zo*8yZQ-){Y!nc;5V9jPw*2s zVgya|6IiyC-fJP-Hp)2cCve3We9}+A=M?Qc?Ev~p3$y&VS%0X$+|&dfjm8^ zvi7em-WC?vm`T61u;CL~Irs}yGF~|O3nY2c za4jq=M0Sz>0@aK`)%*oswxF1n{sNW%p%wr73w$&}mih}UTSM=)Fl!%OJ?byub&SSe z@)y{8mE@Ygz^q$z`<}mm-+h|%)L)>&Gn(|=UtqrR?0^0O!7pjH7AC!-8?XKKXV3Uc z={NL93+>-hg-pG!YGicL!juoRPz$R+(g!Wf`a%2t^B1tT2>7e376ux}w2<8@K&o2@ z$YJA3)&PM)+30xo0D;&Xw9O+x;I}8W&mABzCm%h|A0Uukfc$&|1ls%2T`l+o&{-|G z1kq3}G>stF$N&LfW2*K}RDe{7rdmY;1X>&3MFRvPjV0Pw#R8;Wae7cTK;XTxx?F(3 zZX=|8fOM-6AWw`(=>Y;CjkVPS1oj$XH3FnZ%>a33yl<@6R+dd@j~31tMVbc4ux0`B z**MZBK;Wt|{+|GSu1Wb0(_inW(uegv z%KivdJ{lmf-^g-C-%t6RqqgS*1a2GKF9ry-xI}9%2MFZ7LJ?Z%Z4|wx^HjsH(-$pd zxj`lF1qgI_OItGo1bp97q86@yrtd!j1RQ_T5iMLXO8p8D82g)kYa!ht@UK~xfdYi0VY>d#A}t6DgppWM6x1%?}wyaNSp7NW8~ zfdaDwXpI(H22u|#{Lcsr4itDBLGB5G0u2)>U$H=eyCun|bfCZ#V_Vrkf#2n*efdCv zt(B;8&D9WeZY5X%LP$1V>^3lRQ z#fCtE729a+u0Xl6J5WmOp(*?H{HPWCY0rT`f!znm@^GNQy^~b=R-iy*Blqn{b^>6R9zB+wEq zxFu49q#%K_#v?5ZD^4XU1qswJa#RiyC}2#~!i_3arfQHt1LH)^Ab~3lC{Lpxfzig` zW~}`(dvys0(*=en{;k!xbaO3MYqs;EgUhzb_EI4KR}BQ>iJQ*4w1hW zCLgDT=Yj+_8ST#Nc~t$3w_1p~NK3U)_Bu_t5hT#-7ES*UByjH|Rr(a9U;hh|ykDr< z*C2t*M$R8W0=0h9aV>28MRk7%2`v0WPX7f7G?L)ImRSS~xLHyI>tKN;HsoR(ERfTg zYUK(RaPy@2Ji!8G4XeDt0=bM~S~!!BlJf@(H1ncW1%m~0d(+cG!2-d)G)D`bg{iTB zu)qc5Kwz+dT`)}w2^R2=p^mY^0s(Qf$=UeSRgK$mTMtjQEFZ+SfI1*-RST9(>t)1>e`(Qb1Jkmnhj&yNI zuz<%f^3{URaB4duSm3r1lMyV?Zxm%{;iEBTOt8RQqt;m6XVuEMsRgg`w0c6YK$$7D za9XgyCZpZ-V1a(dTP?)Qq;hkD1*R>fyUT(FDlVssYjl3SfJ)-n)^lf zP7V7;9c@Acw%L-OU5LOLd&=b)A~3{glO;r8Lss(279#M>g+kmy1m+qAbB74D&O?9l zh6t3*PZtV=2#oikYrY`@rToa(KSZEi0Nv5T=|FN04iOk^WQK(Z#759EE$lWvM1}|) zObHSDq9M}D_+2JMAbVLlp@kbpxpE-_6U&oDg%E-6mB^uTh*YT(A_t7c)k6eE)S?+$ zs8*YrYT=5Jr*4SAXydgOX4Iqm^+N=HG@{~7LIlnE+GQ< zx*FZJ%C{#?)xs*HNbeB+KE@D9A4;=^g$OtfrzRsp1Xhfsty=KTpf;oQoG2Mjr6+_4 z9G*gs)ATy3k8yKmh=A8@nxKV{`61G6L5Mst?l0GMP<|_Enig8GqxI`U1PW}R5}QH< zMsKE{TIjfywr$gMue$G{lv5!Bl??mSdQOywF-i;RXQ{as@}HwnEu1}1-7o8P)o`QO zl@Ng{M&?yLuSy>1`aBGg`cLTNuMmO6KeS21+r$N^z5MmhmDHPdM(w^@W>S^;BU;*!b2CT z>KZCA#f@&ehYFPUps+ll0zLB5GcB|)KwG>*1*&>eyTYLYoBgR!K&XIM5VZ;p)t~1| zZY4qm8kD57TKG|#ikA)5=T?QvMq^#YP=U{ts72*af$>#CxT-wY(Q3x zLIuh-rdnDU)Pznn4b`8Y8Y=P4sG=4wx1siZbgpVkU-Ib}s?V_sm2X3+=&(?M^~T{5 zx*y6hgZgM;(rCIlCRCv8Seh|DRN(#usytEGM~$CCFQ@7})K_Efv`~R3)9Jky{+mHr zXX(*Q7En7aj9o-c7l+EqC86TEl=^C6 zq#Cx0&a4g`jae5eFw@AlK2)Ij1}d~o&xk6ron~ucg;8pU?yLH_m%i@{ z6)1LqHfUk5QTSk}K=H#g@`#RCO*OI{4Hc+%j1FnR{RA~UsUJV;oU!n1s6KB$RQ`94 zYM&1kD0h)2UJ4bkxJcZMyIq;{06d+=;GZ_f#UaQ@cmGMlMkr= z!%%@X#%C=gKc+QWc=?(l-i8V+G!j093Jm;6@3ipSDE3L$Rh>4veGV1a{e@0wq0d)3 z_$^eR!Vh|G7bXzuK=ZV)!I8dZ2@`0Ql`L|G36yanJNGbwFZswWzrL&v8W**YR)9u% zg$evHI(ml*Y%4@3eZmBC`qBBIFoB$5R4Y78;JEQTGEAJKs7`d4fJY+LNzs?pf+Cc& zs9r<;SBy%fh6!9uqu=Gi^y`~pQlbK#uc-G{GiuWPT44f}Yg3tex&~@|eX7(nOki;f zdf75epl&NF*d|P%^*?k&3q#w|>2_fPN$n{|$1s7Ko#>brZX4d6!vq5Rg-PfBVe-)E zGBive&oF8_JWSw{u`we|pyeo9J336@CV8vAOn5OHi?#>{eSz!WG zjQ?iq`l?cMX`2>i%-8i>pli2~W~|oNDf>0_Yh9TBOjkW88|cBtFoB}mX!!OpfsB3B z{$iNGmP_PwS;wJ%-KMm=dL5PT2{n8hCQCEJ#PuCr{}d)L@G~9%qUTD*eWgm@bU)P( zqxg?7fsIB12^VN-LD#gf*NUud!Ueh+t?a@D*4a~jhj4)?<52c+fgUb2LJP%Rsj3zZ z8;b-i;R5+f(`hX@m!-j4 zSW$^GD~AiLt3d@C>3*n|jp>>eUKxX1>f=?m4phBkxWEzPcIR*b@2=$7UDsCy{!5() z==jvHfi!+-xWKhx)MP}s{`p?#I*J^}=;Ku%QrA+&8`@M(Fp>MM%+PTCauLDKx)Ggg}m>WR)5ru+{jL79lXAB>9w&5NKP0 zZfoImWpb_>Au!muSS>=pqdG0F5g|~o5iM#QA<(2H1-Fh6NHM-@!LAMU*1~~*XhpjS z0sk)4v8&Es-8W8m*Kw(CJ!qH~iuR<+S~zIf_l^+gWo+sjA>aE&NSprjZGf()>Ntq{ zX$KFblfxnes*j-mEshWfTT1h_5Vf58tk6AGHmj)7rU-#$o5^iUgh1zQv}1dOK-x~K zwl_jx=00-RA0cr4Amu+CAu!IEekMZT-dU=2E<)hzMJjSRLSUV7<4T0UsH=4Gn(n2_ zxJmy#*7K@LJ*910IPsivywEeH1{jrI>HXBy*JSlJLds=E$S!007agA}`jv)%ixBu? zEc&5mMZNe*b$&$%4F8YLN~A!F1tnWW3RE=gtRn^7jSTGtn@A~UOC7RD3Jfq3azqN0 zHFj$)og$@+k=r9uAjo*Ch0jJS&q!I9J5uuJp`u=q0#yvhf{_BbjWOEG-jR}4h&l&F z3Jf-qgLOWtg0W9)6B;SqjrmcL0?(ppaEv}yy-lE)q)36KMw6nE0xOD9RBEKa?y_WA zUgxXER-m6%BLz~^X_FRQYEr#gkpicUrgb9)R@S5F29W}rn$q`Xkpe?o(5lXn0`I#} zldd{GRjn`0>=!BE^DnuNiIj$8BjudYe{!V2ktq~CRqv;683m_D3QRO^&Cs{0g0pDN z>_~w;tEuT49l!EfPYHYUJg9+tDa-yyeO`;s?FhX)8Y$5CIE_3RDRBN26+Nx{uRa=y zXCnnx8T+;H1t$F> z%insY)U-cz_rFMiiW2qLe(NX!TU(lF7bTEA3)RRPCGa2{c{oK0G;*f%S}5g0V_l;J zej6F?Q34k{sF-Jzz}$S)J%5xys{*vnD@q`LLHenM)Iwwt5G7z8OyxtO^xqnY62~Z7 z6%!@!K9)8lM+r14O3R8x2}GolcljuRHWkRfT9m-l8g!>-lt6`AG`>-kz_rFys)^29 z?P^9AEp&WpOiOZUA0<$)13l{)CE(hN>i3QkIAb*GtK(G5`jK1zD1pj@XxiW?ff^%e z=$I&h(_<-VT$I4!@#HvB*G2U)HqM9=_%@ST&x#V5JBOakjS{FnkH#+0{Zv;LQi(-T z0=bt^lciAt7ma6Huv|uWmh1YdLMv&q7FHO!)<+3=pQ1LWbsyACqwLuzfeGhG&PNIK zzeH6oM+vmOLLFa42^4xu?J}bTioT<|@1q2qzEbUPQ35B7oj;-kDqBSVb=)diAiE9y ztA)wN9W8veC0n~_fdj?`Eu`90hC{SK_nfpgf3(1-0@U0qT3~}W)hrY(FxQ8&`9=%) z7N&Oo(E@jj-GR{pmci6T3&+AKTckc-^*8p#Mhn=)Q+F-oOr}~X(E`hg(3_&s0&7ZA zr3%q9wW2<@5|yeMEikqg{no;WI&`jXv_PHubh}ZsfOiv`q=gdAXms;v0k@X4qGz-~ zW-t1sh0(ofjuvY6p_W>>VHD^WEwHLT)f%kxQ@w^zh8EI>Qo0t78d--&3rrtD_M@W( zDvzQ4TKF=KQYJ(TtTpybiWc}VnXINn3+y${YN6;xDNVd!LJgbV!X|EP88MW6%3*6dAYxnD1 z)rkYt>zJ;q+JBtFPDBg5I8EVaqxE}9^vs^4Uk`OZRoY{!qJ>L_=hJ9?-k9!@@z1kp zfsM~8`9-wAk&l$+bF_emF-8lQzfi+((E{D=V*c7=A0rU#KtFTF2&6hwWi9MCY+YjX z`|V>Sm$5<%nXc5xEk+>3le*=O5s304he9y|Reb1x7XBFZd}9Qj8%};P0>_M-T6k^b z2#gWPYqZls*jNSoT!L+jO$iZ#>mHm9hTx(@1}_S92r*MVHL^NiKn9i1qotFEOw zYP9SgBM{pwMiP6+$p8Ar$id+;(qy8p(`3pvHAbNIGzy&=BQV^!H7`cMViA>D93!y9 z_@agMC3Ig44ohjD7A_i3v|zWAT(mILsJU9t$r{RBt81$ot&5R9>uH1*R&1hdn`6X! zJC)xNBe2^zp@qjgDR6g;z%1kVo*02EM$q0E0h|3aObcfYQ1U_DL)FK)u7zfYXsi}e z4^s^-v^GW`ixHS%B%X}Xf7hAboz}fNM=!Nk&QrU~dQR2mD^%!ej6k?i^tz7GSa2go z;Q39ebt^`o)IG9!sPj^{Y-9f_Xdf%E#(^wy#|o6mLznZ$3N(nNC2_F=F7dH)BY~c3 zuO-IHkIJz!ES=6&j}=I+K~=S|-ni5$R=~3h-RK!BAA7}0|2{NId!&D?{=H+Y{Fxpr zU1!Eh@!7HRL`|O)E05;Iir0czDYu9wE{+wjSVC@EXlkrm6)W(0HMLk1D+AZYisO26 z*Pc;9n_~4`#Y*?hu@bi>Rz_}(m5lANvUO*yG}#?1=l8@)`F*ise=t`6QEy$76R}d` zRIKzqt?PL!R=(efl|Fa%n)j*d1D&_Z`7Bmao>MvP-Z!xlpQ+b>7b|%`#mY~|IC-8W zPNH+fiM>;tSm%n9beA}Bca4)PdE#VN0ea{aCs4H@HPoIc6emS}^|6KH1VN0)veAN$~>lDYQZholDS;lJNrm zrKoiIc!6;hs7IxEf%R?aOS^c1K^-Wgf4snjf2r7jc!7$>$AR$ziGyjC7WNy9M#T%f zok20P;sur(yR_gsn{4OC3sjs(d$n-MXuBj{VDWN#xguVm?n>&Y1;_Q|wkckq!Dc$E zg-6Ec-SGnM=c(a^c!6`qV=eT#M(1wm+m!1q8m5Iw#-#^3R^|DKGPJPi1AYG(FL3z> zO$bTQ-(M5tdMK3+OORpek?IhhATw0Ohy?xnngr>prbQ>n#+U?2ilZ{x>_rpw?_Ltb zw?u-3lueN2atYF}e1hDnm>^fGB*>!L3G%c-g6wUaAgh}uNZvLHGQC5BTmz8|SiPUBGM=VS(8sBNC(+T#2?8-wsGJsB8mZF~1Tv=6cP%tuO{>@F zcvPOX6t0EA#>))}0uh^Np%#9hpc1DN1i~*;>NCBc%6Lv?-XsW2`9in9CJ4;>O;58X zN^tf>iOWGvT@nR~xlx9DqJAABQ5FX#O0FPU8kH!pEP>u6CJKy7rg2RZ1+F%uExi&2 ze)gueeG&x@jwAaCi2~2(QRsq1fq6#T4f_6S(?;sNJy9TiAI;jIDByU2ye=gQw7N{! zwXpOSy}q3&u=*kOe3~e*?-_+Y*ZZp@?bc-Z`dzLiUK1rZiE?VW1B#_&c zF6T|s-z)Xk`Dv6E3VKoNf=L3Y{xq~^lECR&lvF!Oe-=uTR56a#NfLP7l%kp^34CZn zSH~p@IL_tlMesZJn>$@;FJ(KS`2H zPs#Inl0b&h`i0I*t$#^-v=H}-{(YS!@YdM%Hc7zZ9c9484yVG=$pRf>sIL}s$5NBHWPyuDqoibkWy$20k}U8#m7+={3oJHDlu8yDU7CJs zAxl}RRxVlKkTI-+j#HhfNXeCSoT_$ZnqMVZAV*a?Q7u^@M|B#Yh1oUeQO#t5YPG0r zgJgjT4M`d$3#@NUUz#Kfv}{U0Tk3dKYHQl0g*N}thPKH9UhSx8=VXE5UFeGza`vKH zy>;)6VMBGU>dY`o9U!MU=N3y_v zN%_mxGDYB#9p(2(5oqB_SGABoAGOG@uUA)%Os^DySZ^v*C`I6!59RYq5m-@}dPJuP z?2Vz2*c5?MaWpnQMW8|vI$JhHz@K6lPZ79gbm);Hu(c<3>z^X9 zbuj%Jk|N+Rl)|-e)9@OeA`oJX(!#|NRD5KLKqX^@)_D}w8J!|<(zvFD;4!*pW66Dd zihz$XSqn0OlC&_!xI8gMAZ-#=(L$Zcv|vh#K+dU@PYZ91Inz=E-Ws+u^y5KU&!qCR zQUrDz|5r1;g+vuaVI2Ru;KR_+LpSQdG^jDNAc-D|vvwlsgGMHnnq365D`g>cQ6z)x z238beLnGNsQPKof;0418gP@0~z!}rbj1t9}G$+hVXf4ojKKKsC4oc)F?%I~UI zKAt;Eu2Y69vhOKxy#tZ=KoxVvbHAE=>Oi!-a4@?`&F6}Rt$fZlUJE!l(4iV$I}k_T zDo>{aaU!UCxf3B3)5T|DSGxI~9=><%=4Tb`bs*Bes2r~N*QZkZd7kW<QpLsB(|IcN>GVu1aT@|edP*QhT4%y z5CJP`J3*9Ysc&5IE?X_mA&5)XZLZk4OZjpMVqTsq%O{AyZdF-G5dCKetIrX<*0ox~ z`#XdbuZpWD9J)^kT8)ng6ORc;8q{fSf}b$S8k-3*EresNpp|fzZE07R0|YT{{rFB0 zYX{V#L4ueYYo=u^HxQk1>ftH_5%H*f2?ioR(V%{fL0PhjFE$W|52_GX^d2`@Sz=IQ zrCl_rt}>XiKGYg4^%`8Yp0pW==u6epZXiB(s%0Sq;jz-X3`F%OHN_RKZk04>AWDZ+ zC0A@5Ruy3b5w_eT1|nxvb#MiZsj8@fxMkJ-HV`+)m5(bzDel^>C4Zx{03^AF)^Vnv rnx=x2g%r7d-cu3p5AI*GXWNC;&5`w)3t~sRhF#@FGyCSuY_RVPAf>!iA5j&gf)ynv_TdJW zR+1Kx{fh#%rH**eRZ8k6eZsaeQoi|8cdWxdc!XZNrQTPizzi2{ zz#iN|qf8eK!@evRJwS(S7xh8!92a?%c9B2&lygzN3NGr4=|8*ZV@nqqTe)aEjv%nL zi{elNO%T?`MTc<_r`x(Hp`DA;k=oToy?VLmPn7B7qUU{G)W4sLMq$wJ#QMWUlZKHW ze1^NoeS(W}O?1&qteQ@&8!qa3$3+jHx#&IGKX=g@)Oq2eEw5a35E-vsROyS0zPP!n zsk^Jr`MPRTE?4ctliaR4=;x{e{;t}9UHM#9H@~Y6{p70H09WeE*dtt5Ns@9l~ZZ(O4ZuML>si~{FHgnbcPOggX z?5Yu%in3i?^*cUw<$gC;VI(+sjomu?q!zlN(I^T-6YN;Z1+W{oPeX z2Dqy8Kv!+U_Cc=l8tf_uwhm!VaQ)L&8Q6v2hw*s0tNM&^)yvV0g@$9ub)2g--cE$Zu?wy9EJD0>LlC_vnD59_2MjfU2~P^KdzdK%kRkf zBQ^Z&ssZr)k8w-}O@Q5OPyqbw28Cb}KBAnDLG3UWJNyi~jF3DA-9UO?gC=8+zdHL1#h?8Xw9wI3f)i8EsIPIPNDJ zbkAYXO{YQmk_?(v#Gp60!C!}WB@BvBHfTVKL5A8dSC# zZE*A#gF4qR$fu@3^KcZGQL~mo(`y^F1oyD8jzOR58nnHMK~L}z6Pq$-Gv?FMpeC&h z8q?aKw=lLd=y$a4WYCe$1{LT|-EpmlLC=3PXhctgTJ|xh<4}WI4L9f!LPi)=c$`5U z{%;a_An#=QZ+@Hd6IqSbSQ zioYO(D^4+L`30x<%cTo$98sXqo1wT}V%N(~%4}{Z-aYrgCoT zg3Z<3w5Exh4#2Cao1S4zGdImgp5|_vhH)+3v=E7{+*H1eoA$ONR(slaa8pc2HwASf z=gw}b-^EQ0`;b##H>LD5SQ3g)Q##u(>NMueIC9-8*p zL-Q?0&9fTSFTYWfu@g@)wSZAe0*qP|Xw(JF3^J-tFl|GPI*g0BA7<2BJP$YO3wB1Z zKhmf*I2~owb$pFB$}7gG7O_Tk!?-x3=3r~QQKb@$I*WfXA9|#v9PxWOqwb+g zdG5o#qEVZ10FTh3l2I!v8}$KMKO40duTin8Q9ZF7+11D&EAbIqele!N`j;qlUq^lTm}ZP;10?HR=WKbR)+eMuq=oRK7lp zf&Klc&F@CV4=}3gK%*LB!yx((<~~*<*AVLPr%{HXM&%i1RNE2M0-tbVBsCeuI*c=_ z!+4IDiPU{EkFgZ5kZY<@K{$m=GmNS}lbmK5d2Vrx%r?q8+G85Oz2DC;t#Dy%eW z;U?B#Gj-cy)L1OT9gN;;lwcs59i+yGjp~D)`0WU5ca$~7 z-s2pzxQ$6Cj2e21u;D3{K zLId=~2CThh)IoH-P5n{f9`%FyKJ76Xd+`C)ACNQjn6Z(DmKclY`00sJQONt6Q03!|SdlxpX53l>LpEJx#LrGO2oR zlddCwU+RM={b=mmGB&YEHSCjQj;>! z01vTmnMtSd6z!HX-U^faR+>~|jY*}^6mKwNBgfe$;%*`TZ6+1lPVHgXVN%X<>UYAV zez<}jCm9>tQ2!LQ#21V^ZBpzxYIxqH1a!MVjW3#%eVOACPp+`m$hyy5(d-F1Kjk=i z#(F*HIL7ZUI9^|w^cVKyCg!}RMmP%dTl)XU@rK*@ju~HQ|BW$Co~rKYsmACJA1_bk zv3V*K890Kj-kuta4>;oMDQhlI(Z$cOjk?7= z_1`Q+}9T-cwg9d#Z93 zPj&g(Q~S`qs;BzlC5qPcREJvBtG1^m)FD<~Vqr7t*YlLAzNh?gqA`7&cxp-uPc6h= zRBh?0F>T1VE%~-1U-W42smmzd(NjVFs8N4UCI9Xz+W`9D6rP~(Ku;Nmduj=ajP%qV z%pT>b3z#_CQ@h4`YVtH{jy?Egx~H1W^i-c&o_d2hvpuy2{pYX-bIE0arw*e17Us2` z{C9Y2@lNWui=1||)|iKNdpHiRv9AAma>Bz?0r&{Fo7DHVr#9XpPh5E5sY#DLRq(l| zVv*}5^Ff18)E$P;o@(mqrF{l3HF5XSNe?d#GrFAak#dMOH~ zN?!T{{VOvM6sY2*^O*6om(F2f4KJ<7yP95VUdu~M@EjXzdnvPym&VSa?E>b#+Dqd$ zdTGyJUaGd&ON~%&pO=yjcq!0Yj z>WN&BnGd$&KV&`e(s*3MkY`@1^TtaZ-g5sPb9(Qk+sO67OII-cBROKuCog^a%)I~e z(zh?v=Bt;Ao@G{N zTt!N@S!Gc)$E>KbW?pxi)w+^dftAgwh~Kafr(v&SRsgowqkny~_Tf!4vwom)bF+FQ zq?K89u>q~y&<|zXnN0X9R&*R=*3@zIfoZ&1yKn+N6V0lI_oy`4tl?8=hn-Uyf0|kIum<^NFh4ZKo|$G1 zp2a-jm}6Ea^vB`3#GYqX9%RmEju`X*+XZIrz%isPqP94SnoG=@jD=XW)U3NGxtu&u zVFhDg9P+PZ-OykaYqOg9V$K?~Zs7%TuOk*#VjEtpr(PS(`U4YjaHCmno0uy$;~=6p zQ!{i&&n+A$Tg`fajBTtjhT-^j=CgzOAZI6Qg2`yM%d7=hhe5lk7252f?_RT#_L-G; zKXo~1Rysx0Cy8~6yic2T0~5}e)$puY8_%(}sC=F|Uob29BF7MN zF0t+yaM`T*E7TIR{$~GGv!>wfHP-hZvkKoJ=UZk)+~)X0eT>5c6uHZBc#m~Q$NSXd z0X4*dht%Z}#|YXzHmm9rj^U?f9YT?3#6!k&vwnVI)_xp+$y&WOYvx#4=3wDBo_BbT{}A?_dcp96 zn&Sr6%Ay0V7CkgrlKe>_+{O!B58*b{qVO<_Y~dEw z$3&z>@Ho<<=~#mA(Zq|fXg=n}TU5kp(XK)k9Y^uP7EQ(i{8!YX$HgrAfSM&NT8`vo zi!S4r6pQYlWh(oTC(WWCXr6A-3d}5N(Zw1T)v0OG1B|L=QK#A#dDXFKDgLW(QUB%^ zjl}0x7S---(Pm`yu<%;iq7x|J+oJ3~7Hxt{Ka1K8vS`ati@YaW^ktq!{tKwjLW{~_ z5N>1cYKvatD>|&PXfLAITGSWE5V_8xHtQ|Af~FfS>avA6Td5g(;9u0-X3_qg)Or{5 z*=zh zq2L+nan_=DSa{AN$9anmV%r7sxoFXjORULdi`HP#b&J;jYf;4;7OlkNn-<-;#aiCA zsL?&<_tc_kSd5fsDW;luuaC>1WV|SfJ&d}ht){